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7Endoscopic Diagnosis of Early Gastrointestinal Graft-Versus-Host Disease
William Ross, Alexander A. Dekovich, Karen R. Cleary, Shubra Ghosh, Jeffrey H. Lee,
Daniel R. Couriel
BACKGROUND: Gastrointestinal (GI) graft-versus-host disease (GVHD) is a major cause of
morbidity and mortality following allogenic hematopoeitic stem cell transplantation (HSCT).
Diagnostic yield of endoscopic biopsy of various GI tract segments as well as the correlation
between endoscopic findings and histology are currently debated. METHODS: All allogenic
HSCT patients from July 2002 to Dec. 2004 who underwent same day esophagogastroduod-
enoscopy (EGD) and flexible sigmoidoscopy (FS) in the first 100 days post-transplant were
studied. All patients were on prophylaxis for GVHD. There were 72 patients with same day
biopsies from the stomach, duodenum and rectosigmoid. Endoscopic findings were recorded.
Pathological specimens were reviewed by a single pathologist for possible GVHD. RESULTS:
Fifty-four patients had histologic evidence for GHVD and 18 did not. Rectosigmoid biopsies
were the most sensitive and had the highest negative predictive value (NPV) at 92.5% and
81.8% respectively. Gastric biopsies were the least sensitive with the lowest NPV at 57.4%
and 43.9% respectively. Duodenal biopsies were intermediate at 66.7% and 50% respectively.
Agreement between gastric and duodenal biopsy findings was good with a kappa score of
.665. However, agreement between UGI sites and rectosigmoid biopsies was only fair with
kappa score of .402 for stomach and .471 for duodenum. Correlation between endoscopic
findings and histology were poor in the stomach and rectum, p values of .404 and .267
respectively. However, the degree of duodenal injury was correlated with histologic evidence
for GVHD with p=.008. However, 12 of 35 patients with duodenal GVHD had an endoscop-
ically normal duodenum. Symptoms were not help in selecting those patients most likely
to have GHVD. Of the 49 patients with nausea, vomiting and diarrhea 77.5% had GI GVHD.
Of the 14 with diarrhea only, 78.6% had GVHD. Of the nine with vomiting only, 62.5%
had GVHD. Presenting symptoms did not alter the enhanced sensitivity of the rectosigmoid
biopsies. CONCLUSIONS: Rectosigmoid biopsies was the most sensitive and had the highest
negative predictive value for the diagnosis of GVHD in the first 100 days post-HSCT compared
to upper GI sites. Presenting symptoms were not helpful in determining which portion of
GI tract was most likely to yield a diagnosis. The degree of endoscopic injury was poorly
correlated with presence of GVHD except in the duodenum.
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Impact of Double-Balloon Endoscopy On Clinical Management of Obscure
Gastrointestinal Bleeding
Keigo Mitsui, Shu Tanaka, Akihito Ehara, Tsuyoshi Kobayashi, Yoshihisa Sekita,
Tsuguhiko Seo, Masaoki Yonezawa, Kazuhiro Nagata, Yoshiaki Shibata, Atsushi
Tatsuguchi, Shunji Fujimori, Teruyuki Kishida, Katya Gudis, Choitsu Sakamoto
Background: Obscure gastrointestinal bleeding (OGIB) has several difficulties in clinical
management. Recently, capsule endoscopy (CE) is exertive tool in the diagnosis of OGIB.
However, its diagnostic yields are often equivocal, and the reliability of a definitive diagnosis
depends a lot on further diagnostic procedures, including push or intraoperative enteroscopy
and laparotomy. Double-balloon endoscopy (DBE) enables us to observe the entire small
intestine without laparotomy. DBE is a promising tool for diagnoses and treatments of OGIB
and may complement a diagnosis of CE. However, there have been a few reports concerning
its clinical benefits and safety in OGIB. In addition, a favorable management of the enteroscop-
ically negative OGIB (EN-OGIB) patients is still unknown. Aims: To determine the value
of DBE in diagnosis and therapy of OGIB and analyze the management of EN-OGIB. Patients
& Methods: 59 consecutive patients of OGIB underwent DBEs between June 2003 and
November 2005 at Nippon Medical School Hospital, Tokyo, Japan. We used EN-450 P5
and T5 double-balloon endoscopes (Fujinon, Japan). We evaluated patient characteristics,
clinical manifestation, a positive finding rate, diagnostic yields, therapeutic procedures,
complications, outcomes, and outcomes of EN-OGIB in 1 year follow-up. Results: Patients
were 24 females and 35 males. Mean age was 58.6 (19-82) years old. Mean follow-up term
was 371 (21-862) days. Hematochezia, melena, and iron deficiency anemia were in 22, 22,
15 cases, respectively. Positive findings were observed in 39 (66.1%) of 59 cases. In positive
finding rate, ongoing bleedings (100%; all of 10 cases) were higher than discontinuation of
bleedings (55.1%; 27 of 49 cases). Diagnostic yields were tumor, ulcer, angiodysplasia,
stenosis, and miscellaneous in 14, 13, 6, 3, and 3 cases. 7 (58.3%) of 12 cases of tumor
were confirmed pathologically diagnoses before surgical treatments. One case underwent
polypectomy. All the 6 patients (100%) of angiodysplasia were performed the cauterization.
DBE was a well-tolerated and no complication was encountered. 37 (94.9%) of 39 patients
had no recurrence of bleeding for one year. In 2 cases of malignancies, their bleedings was
continued. In EN-OGIB cases for one year follow-up, only one patient underwent a push
enteroscopy at another hospital a month later, and a bleeding angiodysplasia was detected.
The other patients of EN-OGIB have been still in hemostasis. Conclusions: DBE enables
scrutiny of the entire small bowel, tissue sampling, and therapeutic intervention in OGIB
patients. Diagnoses using DBE lead patients to desirable outcomes. A rebleeding risk of EN-
OGIB patients is low.
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Extensive Gut Mucosal Involvement in Diarrhea-Prone IBS Patients Disclosed
By Jejunal Mast Cell Infiltration
Mar Guilarte, Javier Santos, Ines de Torres, Carmen Alonso, Laura Ramos, Maria Vicario,
Francesc Casellas, Cristina Martinez, Esteve Saperas, Juan Ramon Malagelada
Background: Stress-induced mast cell activation has been associated with both symptom onset
and severity in irritable bowel syndrome (IBS). Furthermore, IBS patients show increased mast
cells numbers in distal ileum/colonic mucosa. Upper gut symptoms are common in IBS.
However, mast cells have not been thoroughly evaluated in the proximal gut of these patients.
Methods: Jejunal biopsies by Watson’s capsule, aspiration of intestinal fluid and a blood
sample were obtained in 20 diarrhea-prone-IBS (D-IBS), 12 of them suffering also from
dyspepsia (Rome II), and 14 healthy volunteers (H). Psychological stress (Holmes-Rahe
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Scale) and depression (Beck’s questionnaire) were evaluated at baseline in all participants.
Biopsies were processed for H&E staining and scored for mucosal inflammation (1: normal-
to- 3: criptitis & PMNs). In addition, immunohistochemistry with CD117 (c-kit) was used
to evaluate mast cells in the lamina propria. Mast cells were blindly counted in 8 non-
contiguous high power fields (HPF)/sample and tryptase levels measured in both intestinal
fluid and serum. Food and respiratory allergy was excluded in all participants. Results: D-
IBS patients showed higher psychological stress (D-IBS:205±113 vs. H:112±99; p=0.007) and
depression levels (D-IBS:8.3±7.4 vs. H:2.8±3.7; p=0.007) at the time of biopsies, compared to
healthy. Jejunal mucosa of both H and D-IBS appeared normal on H&E staining with no
additional differences on histological inflammatory score (D-IBS:1.3±0.47 vs. H:1.2±0.43).
In contrast, D-IBS showed a marked increase in jejunal mast cell numbers (D-IBS: 34±9.3
mast cells/HPF; H:14.3± 4.4 mast cells/HPF; p<0.0001), a finding paralleled by higher
tryptase levels in jejunal fluid (D-IBS: 0.41 ± 0.38 µg/L; H: 0.09 ± 0.11 µg/L; p=0.014)
although not in serum (D-IBS: 5.91 ± 1.31 µg/L; H: 5.49 ± 2.32 µg/L; p=ns). Tryptase
release correlated with depression scores (r=0.51; p=0.025) and mast cell numbers with
stress (r=0.35; p=0.05). However, upper gut symptoms were not associated to gender, mast
cell numbers, tryptase release, stress or depression. Conclusion: Psychologically-related mast
cell hyperplasia and activation, a heretofore unravelled profile in the upper gut mucosa of
IBS, may be a helpful diagnostic tool for D-IBS patients.
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Effect of Nitazoxanide in Treating Rotavirus Gastroenteritis in Hospitalized
Pediatric Patients
Jean-Francois Rossignol, Mona Abu Zekry
Rotavirus is a leading cause of severe, dehydrating gastroenteritis among children worldwide.
It is estimated to be responsible for 500,000 deaths each year accompanied by enormous
morbidity, medical and social costs. There is no effective treatment for rotavirus infection.
Renewed efforts to develop a safe and effective rotavirus vaccine are ongoing. Nitazoxanide
is a gastro-intestinal anti-infective approved in the United States for treating diarrhea caused
by Cryptosporidium parvum and Giardia lamblia in patients down to 12 months of age.
Nitazoxanide is active in vitro against a broad range of viruses. With this background, we
evaluated the activity of nitazoxanide against rotavirus in vitro and in a randomized, double-
blind, placebo-controlled clinical study. Methods: Nitazoxanide and its circulating active
metabolite, tizoxanide, were evaluated for activity against rotavirus (Simian rotavirus SA-
11) in MA104 cell cultures. A randomized, double-blind, placebo-controlled clinical study
was conducted in 50 pediatric patients hospitalized with rotavirus gastroenteritis at the
Cairo University Children’s Hospital. Rotavirus was diagnosed by stool test using ELISA
(Ridascreen®, R-Biopharm AG). Patients were randomized to receive nitazoxanide suspen-
sion (100 mg/5 mL) 7.5 mg/kg BID for three days or an equivalent quantity of a matching
placebo suspension. All patients received optimal supportive care including oral or intraven-
ous rehydration therapy. Administration of the study medication, food intake, adverse events,
and number and consistency of stools were monitored and recorded daily. The time from
first dose to resolution of illness was recorded for each patient and compared by treatment
group using a survival analysis and Wilcoxon test. Results: In vitro, nitazoxanide and tizoxan-
ide inhibited replication of Simian rotavirus SA-11 with IC50s of 0.5 µg/mL and selectivity
indices >100. Phase contrast microscopy images showed that the compounds were cytopro-
tective. Further mechanistic studies indicated that the drug has a selective effect on the
synthesis of rotavirus protein VP7. The clinical trial enrolled 50 pediatric patients from 4
months to 7 years of age (median age = 10 months). The median time from first dose to
resolution of illness was 31 hours for the nitazoxanide-treated patients compared to 75
hours for patients randomized to the placebo group (P=0.0137). There were no significant
adverse events. Conclusion: Our study indicates that nitazoxanide therapy reduces the duration
of rotavirus diarrhea in hospitalized pediatric patients. Further studies are warranted to
confirm our findings.
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HLA Typing in Patients with Whipple’s Disease
Federico Biagi, Myriam Martinetti, Carla Badulli, Michele Di Stefano, Jonia Campanella,
Gino R. Corazza
Introduction. Whipple’s disease (WD) is a systemic chronic-relapsing disorder due to both
environmental and host factors. Although Tropheryma Whipplei is known to be the enviro-
mental factor, the host factors are still unknown. Probably due to the rarity of this condition,
the association between HLA and WD was studied in only small samples of patients. The
few papers that have been published so far have given conflicting results [1,2]. The EU
funded European Study Group on WD (QRLT-2001-01049) collected DNA and tissue
samples from sixty western European WD patients. Methods. HLA class I and II alleles were
identified, at low resolution level, with sequence specific primers and PCR using commercial
kits (Pel Freez,Wi,USA). Gene frequencies obtained in patients were compared with those
published in German healthy population using EPI5 statistical package. Results. DRB1*13,
B*44 and Cw*05 alleles were shown to be significantly more frequent in WD patients.
Cw*02 allele was shown to be significantly more frequent in controls. Moreover, odd’s ratio
was 2.22 for B*44 allele alone (p=0.04) and was 2.8 for DRB1*13 allele alone (p=0.01).
However, odd’s ratio incresed to 12.4 (p=0.000017) if we consider the presence of both
B*44 and DRB1*13 versus none of them. Conclusions. This is the largest HLA study ever
performed in WD patients. B*44 and DRB1*13 alleles may act as risk factors related to the
disease. B*44 and DRB1*13 are independent to each other but if they are present together
they enhance the risk factor. The Cw*02 allele could be a protection factor towards the



















Homozygote Mutations of Neurogenin-3 in Children with Congenital
Generalized Malabsorptive Diarrhea and Dysgenesis of Enteroendocrine Cells
Jiafang Wang, Galen Cortina, Vincent Wu, Bob Tran, Ming-Jer Tsai, Jang-Hyeon Cho,
Marvin Ament, William Treem, Ivor Hill, Jorge Vargas, Douglas Farmer, Laurie Reyen,
Martin Martin
Background: The neurogenin family of proteins are basic-helix-loop-helix transcription fac-
tors that play instrumental roles in cell fate determination of neuronal and endocrine cells.
Neurogenin-3 (ngn-3) is expressed in endocrine progenitor cells and is essential for endocrine
cell development in the pancreas and intestine. A novel autosomal recessive disorder charac-
terized by severe generalized malabsorption and a paucity of enteroendocrine cells is
described. Methods: Genomic DNA from three unrelated patients with rare enteroendocrine
cells were screened for mutations of the ngn-3 gene, and then assessed for their ability to
alter ngn-3 function using in vitro and in vivo assays. Results: The clinical characteristics
of three patients were remarkably similar and characterized by severe generalized malabsorp-
tion that required prolonged parental nutrition. In all patients, multiple intestinal biopsies
showed that the number of chromogranin A-positive enteroendocrine cells was dramatically
reduced, while the Paneth, goblet and absorptive cells were of normal appearance and
number. Molecular analysis identified two homozygous mutations in the ngn-3 gene. Each
alters a strictly conserved arginine residue at position 93 or 107 in the DNA-binding domain
of all neurogenins in species ranging from human to C. elegans. Transient transfection
studies in non-ngn-3 expressing HeLa cells revealed that both mutant-ngn-3 proteins failed
to augment promoter activity of NeuroD, a downstream target of ngn-3. DNA binding assays
confirmed that both mutations markedly decreased the ability of ngn-3 to bind to an E-
box element located in the NeuroD promoter. Ectopic injection of wild-type ngn-3 mRNA
in Xenopus embryos induced endogenous NeuroD expression, while mutant ngn-3 tran-
scripts failed to change NeuroD levels. Conclusions: A novel disorder characterized by
malabsorptive diarrhea and lack of intestinal enteroendocrine cells is presented that represents
the first description of a loss-of-function mutation in humans of any member of the neurog-
enin family of proteins. We propose to name this disorder enteric dyspinetic anendocrinosis.
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Colorectal Cancer Survival in Ulcerative Colitis Is Associated with Prior Use
of 5-Aminosalicylic Acid But Not Surveillance Colonoscopy
Fernando Velayos, Edward V. Loftus, Tine Jess, William J. Tremaine, William J. Sandborn
Background: Colorectal cancer is a serious consequence of long standing ulcerative colitis
(UC). Unlike in sporadic cancer, prognostic factors are not well-described and the mortality
benefit of surveillance colonoscopy is debated. In sporadic colorectal cancer, decreased
tumor expression of COX-2 is associated with improved survival. These data suggest chronic
5-aminosalicylate use may be a rational and novel prognostic factor in colitis-associated
cancer. Aim: To test if prior 5-ASA use and surveillance colonoscopy are associated with
improved cancer survival in UC. Methods: The study population consisted of all patients
with a minimum of 10 years of ulcerative colitis who had colorectal cancer diagnosed
between 1976-1999 and were evaluated at least 1 year prior to the diagnosis of cancer (n=
76). 5-ASA use for two years prior to the diagnosis of colorectal cancer was categorized as
regular (>75% use), intermittent (25-75%), or infrequent (<25%). Performance of a dysplasia-
free surveillance colonoscopy during this same time period was recorded. Five-year colorectal
cancer mortality using the Kaplan-Meier method was derived using medical records and
death certificates routinely obtained by our institution. The hazard ratio (HR) between the
exposures of interest and cancer mortality were determined using Cox proportional hazards
regression adjusted for disease extent, duration, age, year of diagnosis, primary sclerosing
cholangitis, family history of cancer, and immunomodulator or prednisone use. Results:
Increasing 5-year colorectal cancer mortality was associated with decreasing 5-ASA use (10%
regular vs. 35% intermittent vs. 63% infrequent) (log rank p=0.002) and the absence of a
surveillance exam (11% vs. 34%) (log rank p=0.2). In the adjusted model, both regular
(HR=0.1; 95%CI:0.01-0.4) and intermittent 5-ASA users (HR=0.3; 95%CI:0.1-0.8) had lower
cancer mortality compared to infrequent users. The HR associated with a normal surveillance
exam was 0.8 (95% CI: 0.1-6.7). Regularity of 5-ASA use did not correlate with cancer
stage, but both variables were independent predictors of mortality. Conclusion: This is the
first study in UC patients to suggest a dose-dependent reduction in 5-year colorectal cancer
mortality associated with prior 5-ASA use. Regularity of use did not correlate with cancer
stage. Given that prognostic factors in colitis-related cancer are not well described, further
research may help to identify novel patient and biologic characteristics to explain our findings.
The lack of mortality benefit associated with a dysplasia-free surveillance colonoscopy within
2 years is notable, but likely due to wide variation in technique.
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Increased Inflammatory Activity Is An Independent Risk Factor for Dysplasia
and Colorectal Cancer in Ulcerative Colitis: A Case-Control Analysis with
Blinded Prospective Pathology Review
David T. Rubin, Dezheng Huo, Jami A. Rothe, Jeremy Hetzel, Mina Sedrak, Nicole
Yadron, Alana Bunnag, John Hart, Jerrold R. Turner
Patients with ulcerative colitis (UC) are at risk for dysplasia and colorectal cancer (D-CRC).
Some risk factors, including duration and extent of disease, presence of primary sclerosing
cholangitis (PSC), and FH of CRC are known but have no potential for therapeutic interven-
tion. A recent report of increased D-CRC risk with active inflammation in UC was based
primarily on patients with pan-UC. To evaluate the risk of D-CRC conferred by inflammatory
activity in UC of various extents, we performed a blinded case-control prospective review
of biopsies obtained from 1994 to 2005. METHODS: The University of Chicago IBD
Endoscopy Database was used to identify all UC patients with D-CRC. Controls were all
database patients who matched D-CRC patients by disease extent, disease duration, and
age. All biopsies (4742) were scored independently by at least 1 of 2 GI pathologists blinded
to patient outcome using a 6 point inflammatory activity scale ranging from uninvolved to
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erosions; interobserver reproducibility was 86% (k=0.52). Detailed information was collected
for 5-ASA and immunomodulator adjusted dose; steroid and folic acid use; smoking status;
PSC; and FH of CRC. Relationship between inflammatory activity and risk of D-CRC was
assessed by conditional logistic regression in univariate and multivariate models, expressed
as odds ratios (OR) with 95% confidence intervals (CI). RESULTS: 146 UC patients (56
cases, 90 controls) were matched for extent of disease (84% pancolitis), disease duration
(mean 20.2 yrs), and age (mean 47.5 yrs, range 19-70). Cases and controls were similar in
numbers of procedures (2.1 vs 2.4) and biopsies (30 vs 34), steroid exposure, 5-ASA
exposure (cumulative and daily dose), smoking status, and FH of CRC, but differed in
immunomodulator exposure (14% vs 33% p=0.02) and PSC prevalence (12.5% vs 3.4%
p=0.09). Mean inflammatory activity differed significantly between cases (2.0) and controls
(1.6, p=0.013). This corresponded to an OR of 1.71 (95% CI 1.15-3.18) in univariate
analysis. Multivariate analysis, adjusting for FH of CRC, smoking status, and 5-ASA and
immunomodulator use also showed increased D-CRC risk with increased inflammatory
activity (OR 2.73, CI 1.44-5.18; p=0.002). Multivariate subset analysis of pancolitis patients
was similar (OR 2.79, CI 1.35-5.78; p=0.006). CONCLUSIONS: These data confirm an
association between inflammatory activity and D-CRC risk in pan-UC. They also establish
that inflammatory activity is an independent risk factor for the development of D-CRC in
patients with UC of various extents. This has profound implications for therapeutic goals
and endpoints as well as future prevention strategies.
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Risk Factors for Colorectal Cancer in Crohn’s Colitis: A Case-Control Study
Corey A. Siegel, Ifat Kamin, Bruce E. Sands
Background and Aims: Exposures associated with increased risk or protection for colorectal
cancer (CRC) have been well described in the setting of ulcerative colitis. Few data exist
regarding exposures associated with CRC in patients with Crohn’s colitis. The aim of this
study was to identify exposures that alter risk of CRC in patients with Crohn’s colitis.
Methods: This was a retrospective matched case-control study. The Research Patient Database
Registry (RPDR) at Massachusetts General Hospital (MGH) was searched to identify cases
and controls. The RPDR is a database of all patients seen at MGH since 1990. Cases had a
confirmed diagnosis of Crohn’s colitis involving at least 1/3rd of the colon and a confirmed
diagnosis of colorectal adenocarcinoma. Controls were randomly chosen from the same
source population and matched 1:1 for gender, age of diagnosis of Crohn’s disease and age
of diagnosis of cancer. Information extracted from the medical record included details of
their history of Crohn’s disease, medication use, indication for colonoscopy, family history
and smoking history. Paired univariate analysis was performed to develop an odds ratio for
each exposure. Results: Twenty-seven patients were found to have Crohn’s colitis and CRC.
The median age at diagnosis of cancer was 56. The median duration of Crohn’s disease
before the diagnosis of CRC was 25 years. Prior small bowel resection had an odds ratio of
0.18 (95% CI: 0.02-0.83, p = 0.03). Having had a colonoscopy for an indication of screening
or surveillance was associated with an odds ratio of 0.21 (95% CI: 0.04-0.77, p = 0.02),
as opposed to having had a colonoscopy for a change in symptoms that yielded an odds
ratio of 4.67 (95% CI: 1.30-25.33, p = 0.02). Non-significant trends for a protective effect
included prior appendectomy (OR 0.30, 95% CI: 0.05-1.17, p = 0.10) and regular 5-ASA
use (OR 0.30, 95% CI 0.05-1.17, p = 0.10). Smoking history was associated with a 4-fold
increased risk for colorectal cancer, but this was not statistically significant (OR 4.00, 95%
CI 0.80-38.67, p = 0.11). Prior immunomodulator, oral corticosteroid, folate or calcium
use were neither protective nor risk factors for developing colorectal cancer. Conclusions:
We found that both ileal resection and having colonoscopy for an indication of surveillance
or screening are protective factors against developing colorectal cancer in the setting of
Crohn’s colitis. These data underscore the importance of CRC surveillance for Crohn’s colitis
in addition to ulcerative colitis, and should prompt further study in this area.
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Use of Immunosuppressants Results in a Higher Incidence of Abnormal PAP
Smears in Women with Inflammatory Bowel Disease (IBD)
Sunanda V. Kane, Bahareh Khatibi, Deepa Reddy
Background and Aims: Many women with IBD require immunosuppression for management
of their disease. Previous work has shown that immunosuppression leads to an increased
prevalence of cervical dysplasia as compared to healthy controls. We aimed to examine the
relationship between immunomodulator use and the presence of abnormal cervical histology
in women with IBD. Methods: Women with a detailed history of serial Pap smears followed
at a tertiary IBD center were recruited. Results of Pap smears were recorded in relation to
exposure to immunomodulatory agents including prednisone, azathioprine/6MP, methotrex-
ate and infliximab. Abnormal cytology was stratified by degree of dysplasia and lesions were
categorized as “low risk” or “high risk” for cancer according to accepted definitions. Variables
of interest included disease, type and duration of immunosuppressant use, smoking status,
family history for gynecologic neoplasia, marital status and OCP use. Results from the IBD
patients were compared to a published historical control population of similar socioeconomic
background. Results: Thirty-five patients with a total of 101 Pap smears were included.
There were 5 UC patients and 30 CD patients. The prevalence of an abnormal Pap in a
woman with IBD was 35.5%, compared to 14.6% of controls (Odds ratio 3.1, 1.4-6.5, p=
0.005). Table 1 shows the cytomorphology of the groups: there was an increased risk for
low risk lesions (OR 4.6, 3.8-6.8, p < 0.001) but not for high risk lesions (OR 1.8, 0.6-
4.8, p = 0.2) as compared to controls. Of those Paps done with at least six months exposure
to an immunomodulator, 44.6% vs. 22% in the non-exposed patients were abnormal (OR
2.9, 1.2-4.1, p = 0.02). The cytopathology of all abnormal lesions were consistent with HPV
16, 18 infection. Multivariate analysis did not reveal any differences between the groups
when controlled for other variables. Conclusions: Women with IBD have a higher risk of
an abnormal Pap smear as compared to healthy controls. Patients with immunomodulator
use have a higher risk of an abnormal Pap smear than those not exposed, and is associated
with HPV infection. Women with IBD should be included in the American College of
Obstetrics and Gynecology screening guidelines for immunocompromised individuals.
Table 1
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Abnormal PAP Smear, Cervical Dysplasia and Immunomodulator Therapy in
Women with Inflammatory Bowel Disease (IBD)
Thangam Venkatesan, Dawn B. Beaulieu, Vladimir Ferrer, Lydia R. Weber, Judy Podoll,
Josh F. Knox, Jeanne Emmons, Mazen Issa, Kathy A. King, David G. Binion
Background: Immunosuppressive therapy in organ transplantation is associated with
increased risk of neoplasia including cervical cancer. The relationship between cervical
dysplasia (cervical intraepithelial neoplasia (CIN)) and cervical carcinoma with immunomod-
ulators in the treatment of IBD has not been defined. Given that 5-7% of U.S. women have
had abnormal cervical cells detected on Pap smear, we characterized the spectrum of cervical
dysplasia in women with IBD and its relationship with immunomodulator therapy. Methods:
This was a retrospective observational study of female pts treated at an IBD center between
2003-2005. Pts with a history of abnormal Pap smear were identified and data regarding
specific IBD diagnosis (Crohn’s Disease (CD), Ulcerative Colitis (UC)), disease duration,
immunomodulator therapy and duration, smoking history and gynecologic procedures for
diagnosis/management of cervical dysplasia were recorded. Results: Among 534 women with
IBD (74% CD, 26% UC) there were 25 pts (mean age 38±10 y (SD), IBD duration 12y)
with a history of abnormal Pap smear (5% of total; 22 CD, 3 UC), 8 of whom required
more extensive evaluation with cervical conization and loop electrosurgical excision proced-
ure (LEEP). Among IBD women with abnormal Pap, history of tobacco use was 68%
compared with 25% in the total IBD female cohort (p=0.001). Immunomodulators used in
treatment of IBD women with abnormal Pap included azathioprine/6MP (40%), methotrexate
(28%), infliximab alone or in combination with other agents (44%), and the mean duration
of use was 35±19 months (SD). In women with abnormal Pap, 20% had received no
immunomodulators. Among women requiring more extensive cervical diagnosis/treatment,
75% were active smokers and 86% were receiving immunomodulators for a mean duration
of 55±22 months (SD). The majority of women (75%) had abnormal Pap detected prior to
initiation of immunomodulators, while 25% developed CIN after start of these agents. There
were 4 pts who had CIN grades I-III detected and treated with LEEP. All of these pts were
active smokers and half had severe dysplasia emerge after immunomodulator initiation.
There were no cervical cancers and no hysterectomies during a mean follow-up of 5 y.
Conclusion: Abnormal Pap smears and CIN occur in female IBD pts at rates similar to those
described in the general population. Smoking is significantly increased among IBD women
with abnormal Pap. Although no cervical cancer was detected, close gynecologic surveillance
and smoking cessation, particularly for those IBD women on immunomodulators, is war-
ranted to prevent disease progression.
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Serum P53 Antibodies (ABS) in Patients with Ulcerative Colitis (UC) Are
Associated with the Development of Colorectal Cancer and Screening of P53
ABS By ELISA Is Useful in Cancer Surveillance Program for UC Patients
Nagamu Inoue, Shigeo Yoshizawa, Katusyoshi Matsuoka, Hiromasa Takaishi, Haruhiko
Ogata, Yasushi Iwao, Makio Mukai, Tomonobu Fujita, Yutaka Kawakami, Toshifumi Hibi
Purpose: Although molecular mechanisms underlying ulcerative colitis (UC)-associated col-
orectal cancer (CRC) remains incomplete, mutation of p53 gene and cellular accumulation
of p53 protein are frequently detected early in the progression of UC-associated CRC and
considered to play an important role in carcinogenesis. For early detection of UC-associated
CRC, surveillance program using colonoscopy is recommended in UC patients at high risk.
However, poor acceptability for surveillance colonoscopy deteriorates the effectiveness of
surveillance program and suitable marker for selecting patients at high risk for the developing
neoplasms is needed. Here, we attempted to evaluate the usefulness for measurement of
anti-p53 antibodies (Abs) by enzyme-linked immunosorbent assay (ELISA) using sera samples
from UC patients with or without CRC. Experimental Design: Sera from 286 patients with
UC and 63 healthy controls (HC) were obtained. Serum anti-p53 Abs were detected in
duplicate with ELISA method. Immunohistochemical detection of p53 protein overexpression
was performed in 13 UC patients who developed dysplasia or CRC. Results: Serum p53 Ab
was positive in 15.0% (43/286) of UC patients while only one subjects (1.6%) was positive
for p53 Ab (p=0.0014). Even if 8 patients with CRC were excluded, the positivity of serum
p53 Abs in UC group (13.3%) was still significantly higher than that in HC group (p=
0.0063). In UC patients, 20.8% (30/144) of patients with disease duration ≧ 8 years were
positive for serum p53 Abs while 9.2% (13/142) of patients with duration < 8 years were
positive (p=0.0076). Six (75.0%) of 8 patients with UC-associated CRC were positive for
serum p53 Abs, which was significantly higher than that in UC patients without CRC
(p<0.0001). All the UC patients with CRC positive for serum p53 Ab were also positive for
p53 staining. The percentage of CRC patients was 2.8% in whole UC group, 5.1% in the
group of patients with extensive disease and longer disease duration, however, it was 20.0%
in the group of patients positive for serum p53 Ab with longer disease duration while the
number of the patients with CRC missed in the group were similar. Conclusions: Serological
detection of p53 Abs by ELISA is easy to perform and it can be applied as routine clinical
procedure. The present study revealed that serum p53 Abs are associated with the progression
of CRC in patients with UC and that utilization of serum p53 Ab positivity improved the
positive rate of CRCs in the group, suggesting that serological detection of p53 Abs by
ELISA is a complementary method for surveillance colonoscopy by selecting patients at high
risk for the development of CRC.
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Tumour Necrosis Factor α Promoter Polymorphisms: Influence On Phenotype
and Severity in Childhood IBD and Regression Analysis of the Relative
Contribution to Crohn’s Disease Phenotype
Johan van Limbergen, Richard K. Russell, Elaine R. Nimmo, Hazel E. Drummond, Linda
Smith, Niall Anderson, David C. Wilson, Peter M. Gillett, Paraic McGrogan, Kamal
Hassan, Laurence T. Weaver, Michael W. Bisset, Gamal Mahdi, Jack Satsangi
Background & Aims: The incidence of childhood IBD in Scotland is rising and is among
the highest worldwide. The tumour necrosis factor α (TNF) gene lies within the HLA class
III region of chromosome 6, a region identified as containing an IBD susceptibility gene in
genome wide scans. Our aims were to assess the contribution of polymorphisms -1031T/
C,-863C/A, -857 C/T, -806 C/T in the TNF promoter region to disease susceptibility and
phenotype in childhood IBD. Methods: 277 patients (male/female 148/129, mean age (±SD)
10.46 (± 3.26) years at diagnosis) (174 CD/77UC/26IC) were enrolled. TNF promoter
polymorphisms were assessed using direct sequencing. Transmission disequilibrium testing
(TDT), case-control analysis with 256 controls, detailed genotype - phenotype analysis and
multifactorial analysis were performed. Logistic regression was used to assess the relative
contribution of NOD2, OCTN, DLG5 and TNF promoter polymorphisms to CD phenotype.
Results: By case-control analysis, an association was found between TNF -863A and UC/IC
(p=0.04 OR 1.77 CI 1.01-3.11) and the CACC haplotype and IC (p=0.01 OR 2.46 CI 1.22-
4.97). TDT analysis was negative. Haplotype analysis showed a negative association of the
CCCC-haplotype with small bowel disease and ileal disease in CD patients (p=0.0003 OR
0.24 CI 0.10-0.59 and p=0.003 OR 0.31 CI 0.13-0.77), irrespective of NOD2 carriage.
Negative associations were found between the TCCC- haplotype and BMI<50thcentile (p=
0.03 OR 0.59 CI 0.35-1.00) and inflammatory disease behaviour (p=0.03 OR 0.50 CI 0.25-
1.04). Raised CRP (p=0.01 OR 0.33 CI 0.12-0.93) and hypoalbuminaemia (p=0.04 OR 0.47
CI 0.19-1.15) were negatively associated with the CCCC-haplotype. Granuloma formation
was negatively associated with the CACC-haplotype (p=0.04 OR 0.53 CI 0.26-1.08). Multifac-
torial analysis controlling for factors implicated on univariate analysis confirmed the negative
association of TNF-1031CC with small bowel disease (p=0.009 OR 0.02 CI 0.00-0.38).
Regression analysis controlling for other susceptibility genes (NOD2, OCTN, DLG5) replic-
ated the protective effect of TNF-1031C on small bowel disease (p=0.006 OR 0.02 CI
0.00-0.33). Conclusion: These variant alleles of the TNF promoter polymorphisms have a
significant effect on disease location, severity and behaviour in the Scottish early onset CD
population. The significant negative association of TNF-1031CC with small bowel disease
might explain the milder disease phenotype. The protective effect of TNF-1031CC on small
bowel disease persists when controlling for other genes known to be involved in CD
susceptibility and severity.
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NOD1/CARD4 Insertion/Deletion Polymorphism +32656 and IBD: Influence
On Susceptibility and Disease Phenotype in the Scottish Childhood Onset
Inflammatory Bowel Disease (IBD) Population and Regression Analysis of the
Relative Contribution to Crohn’s Disease
Johan van Limbergen, Richard K. Russell, Elaine R. Nimmo, Hazel E. Drummond, Niall
Anderson, Linda Smith, David C. Wilson, Peter M. Gillett, Paraic McGrogan, Kamal
Hassan, Laurence T. Weaver, Michael W. Bisset, Gamal Mahdi, Jack Satsangi
Background & Aims NOD proteins are intracellular pattern-recognition receptors that influ-
ence Toll-like receptor responses and NF-κB activation. NOD2/CARD15 is a known determin-
ant of susceptibility and need for surgery in CD. The NOD1 gene lies within the 7p14 IBD
locus. Recently, an association was found between the NOD1+32656*1 deletion variant of
a complex del*1/ins*2 polymorphism and an earlier age of onset of IBD. The aim of this
study was to assess the influence of NOD1+32656 on IBD susceptibility and phenotype at
diagnosis and follow-up. Patients and Methods 290 children with IBD aged <16years at
diagnosis (192CD/74UC/22IC), their parents and 318 healthy controls were genotyped using
TaqMan. Case-control, transmission disequilibrium testing (TDT) and detailed genotype-
phenotype analyses were performed. The effect of NOD1+32656 genotype on age of onset
was assessed with the Mann-Whitney test. Regression analysis was used to assess the relative
contribution of NOD1, NOD2, OCTN & DLG5 variants to CD. Results By case-control
analysis, a protective association was found between carriage of NOD1+32656*2 and IBD
(43.8% v 53.1%, p=0.01, OR 0.69 CI 0.50-0.95) and IC (26.1% v 53.1%, p=0.006, OR
0.31 CI 0.12-0.81), but not CD/UC. TDT analysis was negative. The calculated Population
Attributable Risk to IBD for NOD1+32656*1 was 10.6%. NOD1+32656 genotype did not
influence age at diagnosis in IBD, CD or UC. In CD, on unifactorial analysis of allelic
frequency, NOD1+32656*2 was associated with gastric body disease at diagnosis (38.7%
v 24.2% p=0.02 OR1.98 CI 1.10-3.55) and with perianal disease at follow-up(58.3% v
21.1% p=0.004 OR 5.23 CI 1.54-17.80). These findings were confirmed on multivariate
analysis (p=0.004 OR 3.42 CI 1.47-7.93 and p=0.02 OR 7.31 CI 1.31-40.86, respectively).
NOD1+32656*1 carriage was protective against IBD surgery (84.0% v 95.7% p=0.002 OR
0.23 CI 0.08-0.71), with a stronger effect on drainage than resection. In CD, NOD1+32656*1
carriage was lower in NOD2 variant carriers cf. NOD2 wild type (85.0% v 94.9%, p=0.01)
providing evidence for epistasis. After stratification, significant protection against IBD surgery
only persisted for NOD2 variant carriers (70.6 v 95.7%, p=0.008 OR 0.11 CI 0.01-1.04).
On regression analysis, only NOD2 (1007fs) and OCTN2 contributed to CD susceptibility
(p=0.02 OR 9.99 CI 1.30-77.08 and p=0.01 OR 2.73 CI 1.18-6.33, respectively). Conclusion
NOD1+32656 variants are weak determinants of susceptibility to early onset IBD.
NOD1+32656 influences CD phenotype at presentation and at follow-up and interacts with


















Substantial Differences in Lansoprazole Pharmacokinetics Between Older and
Younger Infants and Neonates
Weijiang Zhang, Michael J. Kukulka, Galen Witt, Debra Sutkowski-Markmann, Janine
North, Stuart Atkinson
Background: Pharmacokinetic studies were conducted in infants and neonates to establish
an appropriate lansoprazole dose to study safety and efficacy in GERD management in
pediatric patients up to 1 year of age. Purpose: Five-day studies were conducted to characterize
the pharmacokinetic, pharmacodynamic, and safety profiles of lansoprazole in neonates and
infants with clinically evident GERD. Pharmacokinetic data are presented here. Methods:
Two phase 1, multicenter, randomized, parallel, open-label, repeated-dose studies were
conducted in the United States and Poland. The doses of an investigational formulation of
lansoprazole (a microgranule suspension) were 0.5 mg/kg/day or 1.0 mg/kg/day in neonates
and 1.0 mg/kg/day or 2.0 mg/kg/day in infants. Pediatric patients, including 24 infants and
24 neonates (ages were corrected for premature births), received lansoprazole once daily
for 5 days. Blood samples (0.2 mL each) were collected on day 1 (hrs 0, 1, 2, 3, 4, 6, 8,
and 12 relative to dosing) and day 5 (hrs 0, 2, and 6 relative to dosing). Results: More than
a 5-fold higher dose-normalized lansoprazole plasma total exposure (AUC) was observed
in infants with uncorrected age ≤10 weeks compared with infants with uncorrected age
>10 weeks (Table). The pharmacokinetic parameters from infants ≤10 weeks were similar
to those observed in neonates. Conclusions: Lansoprazole pharmacokinetics in pediatric
patients older than 10 weeks were substantially different from those in pediatric patients
10 weeks and younger. Additional safety and efficacy studies are necessary to determine
appropriate dosing of lansoprazole for infants and neonates.
Mean (CV%) Preliminary Pharmacokinetic Estimates
(a) Normalized to 1.0 mg/kg/day. (b) Harmonic means are presented.
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Evaluation of the Utility of Magnetic Resonance Cholangio-Pancreatography
(MRCP) in Children Using Endoscopic Retrograde (ERCP), Intra-Operative Or
Percutaneous Cholangio-Pancreatography As Gold Standards
Neelesh A. Tipnis, Kulwinder S. Dua, John R. Sty, Steven L. Werlin
INTRODUCTION: ERCP is an invasive, highly specialized procedure not available at all
pediatric centers. Although MRCP is rapidly replacing diagnostic ERCP in adults, there is
little published information on its use in children. AIMS: To evaluate the accuracy of MRCP
in children using ERCP, percutaneous fluoroscopic and intra-operative assessment of the
pancreatico-hepato-biliary tree as gold standards. METHODS: Records of 32 children (age
0-18 y, 17 male) who underwent MRCP between Jan 2001-July 2005 were reviewed. Results
of MRCP, ERCP, percutaneous fluoroscopic or intra-operative studies of the pancreatico-
hepato-biliary tree and clinical outcomes were evaluated. RESULTS: Of the 32 children,
17 (52%) had MRCP alone, 11 (36%) MRCP and ERCP, 3 (9%) MRCP and intra-operative,
and 1 MRCP and percutaneous fluoroscopic evaluation. MRCP results correlated with other
evaluative methods in 14/15 cases. There was 1 false positive (anomalous pancreatic duct
union) and no false negatives for anatomic abnormalities. 2 children with normal anatomy
by MRCPs and ERCP were diagnosed with sphincter of Oddi dysfunction (SOD). MRCP
had 100% sensitivity, 89% specificity and 86% PPV for the identification of anatomic
abnormalities. In 10 children, MRCP preceded ERCP, intra-operative or percutaneous evalu-
ation (MRCP diagnosis: 5 normal, 2 choledocholithiasis, 1 cong absence of gallbladder, 1
choledochal cyst, 1 anomalous pancreatic duct union). 4 children initially evaluated by
MRCP (2 SOD, 2 choledocholithiasis) underwent endoscopic or surgical intervention (stent/
sphincterotomy 3, cholecystectomy 1). In 5 children where MRCP followed other imaging,
only 1 (PSC) had an intervention (sphincterotomy and dilatation). 10/17 children evaluated
by MRCP alone had normal findings and all were well with a follow up period of 198-1266
days (median 866 d). 7 children evaluated by MRCP alone had the following diagnoses and
abnormal findings: 4 recurrent pancreatitis (3 pancreatic parenchymal changes alone, 1
tortuous main pancreatic duct), 2 refractory cholestasis (intrahepatic duct dilation and
contracted gallbladder), and 1 ulcerative colitis with autoimmune hepatitis (irregular
intrahepatic bile ducts). 5/7 children improved clinically, the child with autoimmune hepatitis
is unchanged and 1 child with chronic pancreatitis died from status epilepticus; none of
these children had further pancreatico-hepato-biliary interventions. CONCLUSIONS: In
this retrospective pilot study, MRCP was sensitive and specific in identifying anatomic
abnormalities in the pancreatico-hepato-biliary tree in children. Prospective studies with
large cohorts will be required to confirm these findings.
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Effects of Osmolality, Volume, and Nutrient Density On Gastric Emptying
(GE) in Preterm Infants
Robert J. Shulman, Alex Ramirez, William Wong
Background: Impaired GE is an important component of feeding intolerance in preterm
infants. However, the factors regulating GE are unclear. We sought to clarify the independent
as well as the interactive effects of osmolality, volume, and nutrient density on GE. Design/
Methods: In Study I, 10 infants (birth gestational age: 29 ± 1 wk; postnatal age: 28 ± 15
d; mean ± SD) received in random order one of four feedings (A,B,C,D; i.e., one per day)
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to test a single variable on GE (Table). Infants received their usual feeding (human milk or
preterm infant formula). Sorbitol was used to increase osmolarity because it does not add
energy and has similar effects on GE as glucose (J. Physiol 1960;154:254). In Study II, 7
infants (birth gestational age: 27 ± 1 wk; postnatal age: 34 ± 14 d) received in random
order one of two feedings (D, E; i.e., one per day) to test the combined effects of altering
osmolality and volume on GE (Table). GE was determined by measuring 13C breath (over
4 h) after adding 10 µL/kg 13C-octanoic acid (99 % 13C) to the feedings to obtain the time
it took to empty half of the stomach contents (T1/2). Results: Cumulative percent dose
recovered was similar among feedings for both studies (Study I: 50 ± 20, 59 ± 15, 45 ± 9,
57 ± 22, A,B,C,D, respectively; Study II: 37 ± 5, 33 ± 6, D,E, respectively). Study I: T1/2
was similar among feedings (90 ± 24, 93 ± 13, 85 ± 22, 97 ± 35; A,B,C,D, respectively).
Study II: T1/2 was significantly faster with feeding E vs D (102 ± 15 vs 125 ± 35, respectively;
P = 0.035). Using results from all infants (n=17) for feeding D (i.e., full strength human
milk or formula), T1/2 was inversely related to gestational age at birth (P = 0.026, r2 = 0.24)
but did not correlate with birthweight, postnatal age, study weight, or type of feeding (human
milk vs formula). Conclusions: 1) In contrast to adults, individual alterations in osmolality,
volume, and nutrient density do not differ in their effects on GE in preterm infants; 2)
Simultaneously decreasing osmolality and increasing volume enhances GE by 25% and we
speculate, may account, in part, for reduced feeding intolerance seen clinically with this
regimen (Am J Dis Child 1988;142:730 and Indian Pediatr 1990;27:829); 3) Birth gestational
age still exerts an influence on GE even at one month postnatal age.
24
Corticotropin-Releasing Factor (CRF) Levels Are Elevated During Episodes of
Cyclic Vomiting Syndrome
Seth B. Marcus, M Agjabe-Williams, De Grigoriadis, Y Tache, Don Zimmerman, B U. Li
Background: Cyclic vomiting syndrome (CVS) is a severe, recurrent, functional vomiting
disorder affecting children and adults. Although the relationship to migraine headaches is
well established, no specific pathophysiologic cascade has been elucidated. Based upon
animal data demonstrating that CRF alters gastric motility, CRF has been proposed as a
potential mediator of vomiting in CVS (Taché, Dig Dis Sci 1999;44(8S):79S). We hypothes-
ized that CRF levels in asymptomatic CVS patients would be similar to control values but
elevated during symptomatic vomiting. Methods: We studied three groups of children ages
5-19 years: healthy controls (n=8), asymptomatic (n=14) and symptomatic CVS patients
(n=10) during vomiting episodes. We evaluated the hypothalamic-pituitary-adrenal (HPA)
axis at 8 am and 4 pm in controls and asymptomatic CVS patients, and, within the first four
hours of an CVS episode. Plasma CRF, ACTH and cortisol were assayed by radioimmunoassay.
Results: Diurnal 8 am cortisol levels were significantly higher than at 4 pm in both controls
and CVS patients. There were no significant differences between CRF, ACTH and cortisol
levels between controls and asymptomatic CVS patients at either 8 am or 4 pm. During
vomiting episodes, CRF was significantly (p < 0.01) elevated when compared to 8 am
baseline values in controls (†). Conclusions: There is heightened HPA axis activation in
children with CVS during active vomiting episodes. Our study provides the first evidence
of elevated peripheral CRF values in episodes of CVS and supports the concept that CRF
may trigger or mediate vomiting in cyclic vomiting syndrome. Supported by NINS 44187
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Cholinergic Contractile Responses and Signal Transduction Mechanisms of
Gastric Smooth Muscle in M2 and M3 Muscarinic Receptor Subtype Knockout
Mice
Alan S. Braverman, Henry P. Parkman, Jurgen Wess, Michael R. Ruggieri
Atropine slows gastric emptying indicating involvement of muscarinic cholinergic pathways.
Although the majority of muscarinic receptors in the GI tract are M2 receptors, cholinergic
contractions of GI smooth muscle are primarily mediated through the M3 subtype. AIMS:
1) to explore the subtypes of muscarinic receptors mediating cholinergic contractions of the
stomach using M2 and M3 receptor knockout (KO) mice; 2) to determine contractile signal
transduction cascades activated by M2 and M3 receptors. METHODS: Gastric body smooth
muscle strips from M2 and M3 KO mice and their wildtype (WT) strains were studied in vitro.
The maximal contractile response was determined using KCl. After rinsing, a concentration
response curve (CRC) to carbachol was performed in absence or presence of the M3 receptor-
preferring antagonist darifenacin or signal transduction pathway enzyme inhibitors.
RESULTS: Contractile responses to 120 mM KCl between strains were similar (0.35±0.07,
0.36±0.09, 0.38±0.07, and 0.44±0.09 g for M2 WT, M3 WT, M2 KO, and M3 KO respect-
ively). The maximal contraction to carbachol was decreased in M3 KO mice (75% decrease;
p=0.0005) and M2 KO mice (29% decrease; p=0.060) compared to their WT controls. 10
nM darifenacin shifted the carbachol CRC to the right for M2 KO, M2 WT and M3 WT
strains (Kb=2.0±1.5, 0.8±0.4 and 4.0±0.4 nM respectively) with no shift for the M3 KO
strain (Kb>10 nM). This suggests carbachol contractions in WT controls and M2 KO mice
were mediated by M3 receptors but by M2 receptors in M3 KO mice. Y27632, an inhibitor
of rho kinase (ROCK), reduced carbachol contractions in WT and M2 KO but not in the
M3 KO. ET-18-OCH3, an inhibitor of phosphoinositide specific phospholipase C, had no
effect on the carbachol response in any strain. D609, an inhibitor of phosphatidyl choline
specific phospholipase C (PC-PLC), attenuated contractions in M3 WT and M2 KO. Chelery-
therine, an inhibitor of protein kinase C (PKC), inhibited contraction only in the M2 KO.
H89, an inhibitor of protein kinase A, ROCK and protein kinase G, suppressed contractions
in the M2 WT. CONCLUSIONS: Cholinergic contractions of the gastric body are primarily
mediated by the M3 receptor subtype with a smaller component mediated by the M2 subtype.
The M3 subtype activates ROCK, PKC and PC-PLC pathways to mediate gastric smooth
muscle contraction. Because M2 mediated contractions in M3 KO mice were unaffected by
the enzyme inhibitors, either none of these enzymes are essential for M2 signaling or
redundant pathways are activated by gastric smooth muscle M2 receptors. These studies
suggest several parallel pathways mediate cholinergic contractions in gastric smooth muscle.
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Physiological Dependence of Gastric Emptying and Intestinal Motility On 5-
HT4 Receptors: Analyses in Wild-Type and 5-HT4 Knockout Mice
Abigail Cuenca, Min-Tsai Liu, Kerri Holick, Rene Hen, Michael D. Gershon
The 5-HT4 receptor is expressed by neurons in both plexuses of the mammalian enteric
nervous system (ENS). These receptors are presynaptic and increase the amplitude of excitat-
ory postsynaptic currents. We have thus proposed that 5-HT4 agonists strengthen neuro-
transmission in prokinetic pathways. Despite the ability of 5-HT4 agonists to accelerate
intestinal motility and gastric emptying, 5-HT4 antagonists do not, by themselves, block the
peristaltic reflex. To test the hypothesis that 5-HT4 receptors are necessary for normal
motility, we studied gastric emptying, small and large intestinal transit in 3 month-old 5-
HT4 knockout (KO) mice and their wild-type (WT) littermates. Gastric emptying was assessed
by instilling 250 µl of rhodamine-B-dextran (RD; 10 mg/ml) into the stomach and measuring
the retained RD fluorescence and that emptied into the small intestine (to obtain the % of
dose emptied). Small bowel transit was determined from the distribution of RD in the small
intestine and from video images of small bowel propulsion in vitro. Colonic motility was
estimated by measuring the time required to expel a glass bead pushed a distance of 2 cm
up the rectum. Numbers of myenteric neurons (visualized with antibodies to Hu) were
counted in KO and WT animals at 10, 15, and 20 weeks of age. The rate of gastric emptying
in KO mice (38.0 ± 10.2 % emptied; n = 5) was significantly slower than that of WT animals
(75.6 ± 10.2 % emptied; n = 5; p < 0.05). Small bowel transit was slower in KO (geometric
center = 2.2/10; n = 5) than in WT mice (4.1/10; n = 5; p< 0.05) and the time to eject a
bead from the colon was also longer in KO mice (139.4 ± 15.1 sec; n = 4) than in their
WT littermates (74.1 ± 21.7 sec; n = 4; p < 0.05). The numbers of myenteric neurons in
the colon were consistently less in KO mice than in their WT littermates (the ratios of WT/
KO were 1.9 at 10 wks, 1.5 at 15 wks, and 1.7 at 20 wks mean = 1.7; p < 0.02). The 5-
HT4 agonist, tegaserod, reversibly increased in vitro intestinal propulsion by 27% (n = 6;
p < 0.001); this effect was abolished by the 5-HT4 antagonist, GR113808. These observations
suggest that 5-HT4 receptors are physiologically prokinetic and required for normal gastric
emptying, small, and large intestinal motility. Because the number of colonic myenteric
neurons is reduced in KO mice, it is possible that the receptors also exert a neuroprotective
effect on enteric neurons; alternatively, the loss of neurons in animals lacking 5-HT4 receptors
may be an indirect effect of constitutive slow transit. Supported by Novartis and NIH grants
NS12969 and NS15547.
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Identification of New Variant of Corticotropin Releasing Factor (CRF)
Receptor Type 2α(Crf2α): Differential Distribution and Regulation in the
Gastrointestinal (GI) Tract in Rats
Pu-Qing Yuan, S Vincent Wu, Lixin Wang, Yvette Tache
Background: Two types of CRF receptors, CRF1 and CRF2 differentially modulate GI func-
tions. In rodents, CRF2α is the major splice variant expressed in brain, whereas CRF2β is
found in peripheral tissues with high levels in the GI tract and heart where it is subject to
down regulation by endotoxin. Aims: 1. To determine whether CRF2α mRNA is also
expressed in rat GI tract and compares its gene expression pattern with those of CRF1 and
CRF2β. 2. To examine the regulation of CRF2α mRNA by endotoxin in rat stomach and
colon. Methods: Esophagus, lower esophageal sphincter (LES), gastric corpus, antrum,
pylorus, duodenum, jejunum, ileum, cecum, proximal colon, distal colon and rectum were
collected from 4 SD male naïve rats and total RNA was processed for RT-PCR using specific
primers for rat CRF1, CRF2α and CRF2β. Rats (5/group) were injected intraperitoneally
(ip) with saline (0.3 ml) or lipopolysaccharide (LPS, 100 μg/kg) and gastric corpus and
proximal colon were harvested 6 h later. Mucosa and submucosa plus muscle layers (S+M)
were separated. Total RNA was processed for RT-PCR of CRF2α. RT-PCR for acidic ribosome
protein (ARP) served as a control for RNA quality and normalization. The intensity of bands
was quantitatively analyzed using Scion imaging software. Results: CRF2α mRNA was
detected within the whole GI tract and expressed more abundantly at two ends of the GI
tract with the highest level in the esophagus and LES, which is similar to that found for
CRF2β. In addition, a novel splice variant named CRF2α-I3 was identified and confirmed
by sequencing, which contains an unspliced intron 3 and is predominantly expressed in
the mid GI tract with the highest level in the jejunum. The CRF2α distribution pattern
differs from that of CRF1 which is expressed at highest levels in the ileum and colon while
very low to undetectable levels are found in the esophagus and gastric corpus. CRF2α is
decreased by 84% and 82% in mucosa and 90% and 52% in S+M of gastric corpus and
proximal colon respectively after LPS injection. By contrast, CRF2α-I3 is significantly
increased by 40% and 179% in mucosa and 118% and 143% in M+S of gastric corpus and
proximal colon respectively after LPS injection. Conclusion: CRF2α and CRF2α-I3, a newly
identified splice variant, are expressed in rat GI tract with a distribution pattern distinct
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from that of CRF1 and CRF2β. The regulation of CRF2α mRNA expression by LPS suggests
that CRF2α, like CRF2β, may play important roles in LPS-induced alterations of gastric and
colonic function. Supported by NIHDDK 57238.
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Ghrelin Agonist Activity in a Rat Model of Postoperative Ileus and Opioid-
Delayed Gastrointestinal Motility
Kalina Venkova, Graeme Fraser, Hamid Hoveyda, Beverley Greenwood-van Meerveld
Acute postoperative ileus (POI) is the product of two main mechanisms: (1) disruption of
spinal and supraspinal signaling pathways as a consequence of surgical injury and (2)
reduction in propulsive gastrointestinal (GI) motility as a side effect of opioid analgesics
administered for post-surgical pain. Although opioid antagonists may be used to treat the
latter mechanism, no single agent has been reported to potently address both aspects of
POI. TZP-101 is a novel ghrelin receptor agonist with selective gastroprokinetic activity.
The aim of this study was to determine whether TZP-101 could effectively treat both the
individual and combined components of acute POI in a rat model. Methods: Delayed GI
motility was induced by surgery [i.e. laparotomy and manipulation of the bowel, model 1],
pretreatment with morphine (3 mg/kg, s.c.) [model 2] or a combination of both [model 3].
In all three models, gastric retention was measured 15-min after co-incident, intragastric
administration of 99mTc labeled methylcellulose and i.v. administration of TZP-101 (30-
1000 µg/kg) in fasted rats. Results: As expected, gastric emptying of the radiolabeled meal
was delayed in all three models in vehicle-treated subjects (Table 1) in comparison to non-
operated, morphine-naive controls (30.4±4.7%, n=8). TZP-101 dose-dependently normal-
ized gastric emptying with similar efficacy and potency in all three models (Table 1).
Summary: Selective activation of ghrelin receptors resulted in a complete recovery of impaired
gastric emptying induced by surgery alone, morphine alone or a combination of surgery
and morphine. The unique finding that there was no diminution of TZP-101 potency in
the combination model suggests that TZP-101 activates a common prokinetic pathway to
counteract the delay in GI transit consequent to morphine treatment and surgery.
Table 1
One-way ANOVA with Bonferroni’s MCT. *p<0.05, **p<0.01, ***p<0.001 compared to
vehicle
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The New CRF1 Selective Agonist Cortagine Injected Peripherally and
Centrally Stimulates Colonic Motor Function and Induces Diarrhea in Rats: A
Relevant Tool for Stress-Related Gastrointestinal Disease Studies
Muriel H. Larauche, Karina Pambukchian, Armen Karapetyan, Mulugeta Million, Jean
Rivier, Yvette Tache
Background: Corticotropin releasing factor (CRF) binds to two subtypes of receptors: CRF
receptor type 1 (CRF1) and type 2 (CRF2). Stress via the release of CRF and the activation
of peripheral and central CRF1 induces alterations of colonic motility and secretion and may
be relevant for Irritable Bowel Syndrome (IBS) (Br J Pharmacol. 2004, 141:1321-30). Whereas
highly selective agonists for CRF2 exist, no agonist with a similar selectivity for CRF1 was
available until the recent development of the new CRF1 agonist: cortagine (binding affinities:
2.6 nM for rCRF1 vs 540 nM for mCRF2β) (PNAS 2004;101:9468-73). Aim: To characterize
the properties of cortagine on colonic and gastric motor functions in rats and establish its
relevance in the study of stress-related gastrointestinal diseases. Methods: Studies were
performed in conscious male Sprague-Dawley rats (250-300g). The fecal pellet output (FPO)
and diarrhea incidence were monitored for 2 h after intraperitoneal (IP) injection of cortagine
(3 and 10 μg/kg). The central effect of cortagine (3 and 5 μg/rat, 10 μl) was evaluated on
FPO and diarrhea incidence after its intracerebroventricular (ICV) injection. The selectivity
of IP cortagine (10 μg/kg) for CRF1 was tested on the FPO by injecting the specific CRF1
antagonist, CP154,526 (20 mg/kg) subcutaneously (SC) 30 min before cortagine, and by
evaluating its effects on gastric emptying of solid food. Results: Cortagine at the dose of
10 μg/kg, but not 3 μg/kg, IP, significantly increased the FPO in rats (6.9±1.9 vs 0.3±0.3
pellet/hour in vehicle IP) and induced diarrhea in 43% of rats within 30-45 min post-
injection. Cortagine IP had no effect on gastric emptying of a chow meal compared to
vehicle-treated rats. The increase in FPO induced by cortagine (10 μg/kg IP) was significantly
reduced by CP154,526 pretreatment (3.1±1.0 vs 6.9±1.9 in cortagine IP). Central cortagine
(3 and 5 μg/rat ICV) significantly increased the FPO for both doses and induced diarrhea
after 60 min in 14% and 40% of responders respectively. Conclusions: The data using the
new selective CRF1 agonist cortagine, confirm the involvement of CRF1 at both peripheral
and central levels in the stimulation of colonic secretory motor functions leading to diarrhea
in rats. They also support the selectivity of cortagine for CRF1 since the solid food gastric
emptying known to be CRF2 mediated (AJP 2002;282:G34-40) is not modified and the
increased FPO is abolished by a selective CRF1 antagonist. All together, those data highlight
the potential of cortagine as a useful tool in the study of stress-related gastrointestinal


















Activation of the RHo-INteracting PRotein P116RIP By Src Kinase Inhibits
RHOA and Enhances Mlc Phosphatase Activity: A Mechanism for Inhibition of
Acetylcholine-Induced Muscle Contraction By Internalized Cannabinoid Cb1
Receptors
Sunila Mahavadi, Jiean Huang, Karnam S. Murthy
Sustained MLC20 phosphorylation and contraction in smooth muscle are mediated by a
Ca2+-independent MLC kinase (ZIP kinase) and concurrent inhibition of MLC phosphatase.
The latter is mediated by dual Rho-dependent pathways involving phosphorylation of the
regulatory subunit of MLC phosphatase, MYPT1 by Rho kinase, and phosphorylation CPI-
17, an endogenous inhibitor of MLC phosphatase, by PKC. The endocannabinoid, anandam-
ide, acting via CB1 receptors inhibits sustained contraction. The inhibitory mechanism is
not known, since our previous studies have shown that CB1 receptors are coupled to an
atypical G protein (Gαi2/Gβ5/RGS6) and signal only after internalization via a G protein-
independent GRK5/β-arrestin/c-Src pathway. Aim: To determine whether inhibition of Rho-
mediated smooth muscle contraction is dependent on internalization of CB1 receptors by
GRK5/c-Src pathway. Methods. Acetylcholine (ACh)-stimulated Rho kinase activity was
determined by immunokinase assay in cultured gastric smooth muscle cells in the presence
or absence of the CB1 antagonist AM251, or the c-Src inhibitor PP2, and in cells expressing
dominant negative GRK5 (K215R). Association of the Rho-Interacting Protein p116Rip with
RhoA and MYPT1 was determined by co-immunoprecipitation. MLC phosphatase activity
was measured using [γ-32P]ATP-labeled myosin. Results. Anandamide stimulated c-Src
activity, which was blocked by the CB1 receptor antagonist AM251 and the Src-kinase
inhibitor PP2, and in cells expressing dominant negative GRK5 (K215R). Acetylcholine
stimulated Rho kinase activity and sustained smooth muscle contraction (determined by
scanning microscopy); contraction and Rho kinase activity were inhibited by anandamide,
and the inhibition was reversed by AM251 and PP2. Anandamide increased the association
of p116Rip with RhoA and MYPT1, and stimulated MLC phosphatase activity; the increase
in association and MLC phosphatase activity were blocked by AM251 and PP2. The associ-
ation of p116Rip with RhoA inhibits RhoA activity and thus blocks the inhibition of MLC
phosphatase via Rho kinase, whereas its association with MYPT1 stabilizes the binding of
MYPT1 to the catalytic subunit and thus enhances MLC phosphatase activity. Conclusion.
Internalization of CB1 receptors via GRK5 leads to activation of c-Src, which increases the
association of p116Rip with RhoA and MYPT1, thereby enhancing MLC phosphatase activity
and causing inhibition of sustained muscle contraction. The study provides the first evidence
for regulation of p116Rip upon receptor internalization by G protein-independent GRK5.
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Effect of Inflammation On the Intestinal Nhe8 Gene Expression
Hua Xu, Jennifer K. Uno, Rongji Chen, Huacong Chen, Fayez K. Ghishan
Introduction: NHE8 transporter is a newly identified NHE isoform from kidney and intestine.
This transporter protein is expressed at the apical membrane of the epithelial cells of the
renal and intestine, suggesting the possible role of NHE8 in vectorial Na+ transport in both
tissues. Although other work has been shown that the NaCl absorption in the gastrointestinal
tract of patients with inflammatory bowel disease (IBD) and in animal models of chronic
enteritis is reduced, little is known about the role of Na+/H+ exchange and the involvement
of NHE isoforms in the pathogenesis of inflammatory disorders and the mechanism of
inflammation-associated diarrhea. Thus, the current study was performed to investigate the
involvement of NHE8 in inflammatory disorders. Methods: Rats were injected interaperitone-
ally with one dose of LPS at 10 µg/g body weight or with equal volumes of vehicle. Twenty
hours after injection, rats were sacrificed and jejunal mucosa was harvested. RNA and BBM
protein purification were performed from collected jejunal mucosa samples. Semiquantitative
PCR analysis was used to detect NHE8 mRNA abundance in control and LPS injected rats.
Western blotting was used to detect NHE8 protein expression levels. The NHE8 gene
promoter region was subcloned into pGL3 basic vector and used to study the effect of TNF-
α (100 ng/ml) on NHE8 gene promoter activity in Caco-2 cells. The endogenous NHE8
gene expression in Caco-2 cells was measured by Real time PCR method. Results: Western
blotting indicated a significantly reduction of NHE8 protein by LPS treatment, with phospho-
image units from 0.36 +/- 0.01 in control rats to 0.20 +/- 0.058 in LPS treated rats. Semi-
quantitative PCR with rat NHE8 specific primers and β-actin primers showed that the rat
NHE8 mRNA expression was reduced by ~ 40% in LPS injected rats. Promoter assay indicated
that the human NHE8 (hNHE8) promoter construct is active in Caco-2 cells, and TNF-α
treatment inhibits the hNHE8 promoter activity by 44%. A similar reduction in endogenous
NHE8 gene expression was also observed in TNF-α treated Caco-2 cells. Conclusion: We
conclude that the novel NHE isoform, NHE8, is altered by inflammation. The NHE8 expres-
sion is inhibited by endotoxemia introduced by LPS or by proinflammatory cytokine TNF-
α treatment. The mechanism of this inhibition may involve inactivation of the NHE8
promoter. This investigation was supported by NIH grant R37-DK33209.
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The Role of Ctla-4 On Regulatory T Cell Function in a Mouse Model of
Microbially-Driven Inflammatory Bowel Disease
Koichiro Watanabe, Rao P. Varada, Shilu Xu, Theofilos Poutahidis, Masahiro Ohtani,
Kristen Clapp, Juri Miyamae, Arlin B. Rogers, Zhongming Ge, Toshio Fujioka, Susan E.
Erdman, James G. Fox
Background: We have shown that transfer of CD4+CD25+CD45RBlow regulatory T (Treg)
cells inhibits colitis and cancer induced by Helicobacter hepaticus infection in Rag2-/- mice.
Regulatory function is mediated by cytokines such as IL-10 and CTLA-4. The latter is a
costimulatory molecule, expressed highly on Treg cells, and binds B7 on the antigen pre-
senting cells resulting in the regulation of T cell proliferation, and is known to be important
in inflammatory modulation. Aim: We examined the cell contact-mediated function of Treg
cells through CTLA-4 signaling in an H. hepaticus-induced colitis model. Materials and
Methods: CD4+CD25+CD45RBlow cells were isolated from donor spleens and mesenteric
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lymph nodes of H. hepaticus-free 129 SvEv wild type mice, as described previously. Rag2-/-
129 SvEv mice received the donor cells i.v. at 3.0 × 105 cells/animal 3 days before infection.
H. hepaticus (ATCC 51449) was administered per os every other day for three doses (2.0 ×
107 bacteria/animal). The recipient mice underwent 2-week administration with either ham-
ster anti-mouse CTLA-4 Mab or control Ig ip, starting at one day before or 6 weeks after
H. hepaticus infection. Inflammation and epithelial dysplasia were evaluated histologically
and scored 0 to 4 as described previously. The mice were euthanized 6 weeks after the last
dose of anti-CTLA-4 treatment. Results: H. hepaticus infection induced moderate to severe
inflammation (pathology score, median[range]: 4 [2-4]) , with mononuculear cells and
neutrophils, and moderate dysplasia (2 [2-3]) in the transverse colon. Adaptive transfer of
Treg cells led to the inhibition of inflammation (1 [0-4]) and dysplasia (0 [0-4]), matching
earlier findings in this model. However, the recipients of Treg cells treated with anti-CTLA-
4 showed significant weight loss and blood in feces, and developed transmural inflammation
(4 [4-4]) with deep ulcerations and severe dysplasia (3 [3-4]) in the colon. This effect was
independent of time interval of administration of anti-CTLA-4. Inflammation was not
observed in the stomach, ileum, and liver of anti-CTLA-4 treated mice. Conclusion: In vivo
administration of anti-CTLA-4 eliminated the inhibitory effect of Treg cells on H. hepaticus-
induced colitis and epithelial dysplasia. These data suggest that CTLA-4 signaling is involved
in the immune-suppressive function of Treg cells.
Pathology scores of transverse colon
median [range]
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TNF and Light Cause Epithelial Barrier Dysfunction in Vivo, But Only TNF
Induces Diarrhea: Role of NHE3
Daniel R. Clayburgh, Mark W. Musch, Yang-Xin Fu, Jerrold R. Turner
Acute T cell-mediated diarrhea is associated with increased mucosal expression of proinflam-
matory cytokines, including the TNF superfamily members TNF and LIGHT. Either TNF
neutralization or myosin light chain (MLC) kinase inhibition prevented T cell-mediated
epithelial barrier dysfunction and diarrhea, i.e. net water secretion. We therefore asked
whether in vivo administration of either purified TNF or LIGHT was sufficient to induce
acute barrier dysfunction and diarrhea. METHODS: C57BL/6 mice were injected i.p. with
5μg of recombinant murine TNF or LIGHT. In vivo jejunal perfusions were used to determine
net water flux and paracellular permeability. Bidirectional 22Na+ flux was assessed in Üssing
chambers. 10 μM S3226-sensitivity defined the NHE3 component. Immunofluorescent
morphometry on frozen jejunal tissue used antisera against occludin, phosphorylated MLC,
NHE3, or PKCα. RESULTS: TNF injection resulted in acute diarrhea within 2 hrs. This
was accompanied by epithelial barrier dysfunction and water secretion. The loss of barrier
function was characterized by increased epithelial MLC phosphorylation and occludin
internalization. Both barrier loss and water secretion could be prevented by MLC kinase
(MLCK) inhibition, although water absorption was not fully restored. LIGHT injection caused
similar MLCK-dependent barrier dysfunction and occludin internalization, but was not
associated with either water secretion or reduced water absorption. Thus, despite quantitat-
ively and qualitatively similar effects on barrier function, TNF and LIGHT had markedly
different effects on water flux. TNF, but not LIGHT, blocked Na+ absorption due to NHE3
downregulation. This was associated with NHE3 translocation from the brush border to a
subapical cytoplasmic pool. In contrast, LIGHT did not cause NHE3 internalization. TNF,
but not LIGHT, treatment also caused PKCα translocation to the apical membrane, suggesting
that TNF might downregulate NHE3 via PKCα-mediated internalization. CONCLUSIONS:
These data suggest that both TNF and LIGHT are able to induce in vivo MLCK-dependent
epithelial barrier dysfunction and that this barrier dysfunction is necessary for diarrhea.
However, only TNF caused diarrhea and only TNF inhibited NHE3-dependent Na+ absorp-
tion. This suggests that NHE3 downregulation is also required for acute cytokine-meditated
diarrhea to occur. These observations explain previous studies showing that neither barrier
dysfunction nor Na+ malabsorption alone are sufficient to cause diarrhea. TNF may cause
diarrhea by both increasing paracellular permeability and reducing the driving force for
water absorption, i.e. Na+ absorption.
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Bifidobacterium Animalis Causes Extensive Duodenitis and Mild Colonic
Inflammation in Interleukin-10 Knockout Mice
James P. Moran, Susan L. Tonkonogy, J.N. Walter, Gerald W. Tannock, Balfour R. Sartor
Backgound/aims. The interleukin-10 knockout (IL-10 KO) mouse has been studied extens-
ively as a genetically susceptible model for IBD. When housed under germ-free (sterile)
conditions these mice remain healthy, however, when housed under specific pathogen free
(SPF) conditions IL-10 KO mice develop chronic TH1-mediated colitis. We have previously
shown that the bacterial species Bifidobacterium animalis is more prevalent in the colons of
IL-10 KO mice than in wild type (WT) animals colonized with the same SPF fecal microbiota.
In the present study we tested this organism for its ability to cause disease by selectively
introducing it into germ-free IL-10 KO and WT mice. Methods. Germ-free IL-10 KO and
WT 129S6/SvEv mice ages 10-26 wks were monoassociated with Bifidobacterium animalis
subsp. animalis (ATCC# 25527). Mice were killed at 11, 17 and 23 weeks after colonization.
Inflammation was measured by blinded histologic scores (0-4+ range) of the duodenum,
cecum and colon and by spontaneous secretion of IL-12p40 by colonic strips cultured for
24 hrs. Bacterial specific T cell responses were measured by IFNγ secretion by CD4+ cells
isolated from the mesenteric lymph nodes (MLN) of monoassociated mice co-cultured for
72 hrs. with T cell-depleted splenic antigen presenting cells (APC) pulsed with lysates of
several bacteria. Results. B. animalis was found to colonize the intestines of germ-free WT
and IL-10 KO mice to similar levels after 23 weeks (WT duodenum=6.7±1.3 vs. KO=6.6±1.4;
WT distal colon 9.3±0.5 vs. KO=9.4±0.3 log colony forming units/g tissue). B. animalis
caused marked duodenal inflammation in monoassociated IL-10 KO mice characterized
by extensive mononuclear cell infiltration, architectural distortion and thickening. Mild
inflammation was detected in the cecum and colon of IL-10 KO animals by histological
analysis and by spontaneous release of IL-12p40 from colon explants (WT=0.4±0.3 vs. IL-
10 KO=1.0±0.5 ng/ml p<0.005). Disease was associated with immune cell activation in IL-
10 KO mice as measured by IFNγ release from CD4+ MLN cells co-cultured with bacterial
lysate pulsed APC (17.9±7.4 ng/ml IFNγ for B. animalis vs. 4.5±2.4 for B. infantis vs. 7.0±3.6
for B. bifidum). No disease or immune activation was detected in WT animals. Conclusions.
Bifidobacteria are considered beneficial members of the gut microbiota and are often included
in probiotic products. We show that B. animalis induces marked duodenal and mild colonic
inflammation when introduced alone into germ-free IL-10 KO mice, demonstrating a patho-
genic role for a bacterial species previously shown to form an increased proportion of the
gut microbiota of colitic mice.
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Leukotriene D4 Modulates Na-Neutral Amino Acid Co-Transport During
Chronic Intestinal Inflammation
Jamil Talukder, Ramesh Kekuda, Uma Sundaram
Background: Na-neutral amino acid (e.g. alanine) co-transport is present on the brush border
membrane (BBM) of the absorptive villus cells in the rabbit small intestine. This co-transport
process is inhibited in the chronically inflamed small intestine secondary to a reduction in
the affinity of the co-transporter for alanine. Leukotriene D4 (LTD4) is markedly increased
in the mucosa during chronic enteritis. Whether the inhibition of Na-alanine co-transport
during chronic enteritis is mediated by LTD4 is unknown. Aim: Determine the effect of
LTD4 on Na-alanine co-transport in enterocytes. Methods: Rat small intestinal epithelial
cells (IEC-18) were grown on transwell plates and confluent monolayers were used for
transport experiments at the 10th day post confluence. 3H-alanine was utilized to determine
Na-dependent alanine uptake in IEC-18 cells. Na+/K+-ATPase activity was determined by
measuring the inorganic phosphate formation. Total RNA was isolated from IEC-18 cells
using Trizol reagent. ASCT1 mRNA from both groups was quantified by real-time PCR.
Results: Na-dependent 3H-alanine uptake in IEC-18 cells was significantly inhibited by
LTD4 (6.4±0.1 nmol/mg protein/2 min in control and 2.6±0.1 in LTD4 treated cells, p<0.01,
n=3). Since Na+/K+-ATPase provides the favorable Na+-gradient for this co-transporter, it
was measured and found not to be altered (26±6 nmol/mg protein/min in control and 25±3
in treated cells, n=6). The effect of LTD4 was reversed by cysteinyl leukotriene receptor
antagonist REV5901. Kinetic studies revealed that the mechanism of inhibition of Na-alanine
co-transport by LTD4 in IEC-18 cells was secondary to a decrease in the affinity for alanine
without a significant alteration in the maximal rate of uptake. Real-time PCR demonstrated
that Na-dependent neutral amino acid co-transporter (ASCT1) mRNA was not significantly
altered by LTD4 treatment. Conclusions: These studies demonstrate that LTD4 inhibits Na-
neutral amino acid co-transport in intestinal epithelial cells. This inhibition is not secondary
to an alteration in the Na extruding capacity of the cells. The mechanism of inhibition of
Na-alanine co-transport in IEC-18 cells by LTD4 is secondary to a decrease in the affinity
of the co-transporter for amino acid without a significant change in co-transporter numbers.
This mechanism of inhibition of Na-neutral amino acid co-transport is similar to that seen
in the rabbit model of inflammatory bowel disease where mucosal levels of LTD4 are known
to be elevated. Thus, these results indicate that proinflammatory leukotrienes inhibit Na-
dependent neutral amino acid co-transport during chronic intestinal inflammation.
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Essential Roles for P53 and Puma in T Cell Induced Stem Cell Activation,
Proliferation and Crypt Cell Apoptosis
Navdha Mittal, Ramanarao Dirisina, Jennet Manjali, Yueming Tang, Gery R. Grimm, Goo
Lee, Navdeep S. Chandel, Terrence A. Barrett
INTRO/AIMS: p53 is linked to oxidative DNA damage and tumor formation in humans
with ulcerative colitis. To investigate the effect of inflammation on p53 activation and
examine its role in epithelial proliferation and cell death,we utilized the anti-CD3 model of
inducing systemic T cell activation. METHODS:Apoptosis was assessed by TUNEL and
activated caspase-3(casp-3)staining and Western blot. The induction of apoptosis in cells
undergoing proliferation was examined by double staining for casp-3 and BrdU incorpora-
tion(8h pulse). p53 levels were assessed by Western blot on isolated epithelial cells,localized
by IHC and its requirement was tested in p53-/- mice. The induction of BH3-only proteins
were detected using RT-PCR and Western blot for Bim, Bid, Bax, Bak and PUMA and their
requirements for mediating apoptosis were examined using gene knockout mice. Intestinal
stem cells (ISC) were identified by BrdU labeling x 48h after radiation. Label retaining
cells(LRC) were detected as BrdU+ cells 21 days after radiation. RESULTS: Evaluation of
TUNEL and Western blot for casp-3 revealed that T cell activation increased apoptosis by
17 and 35-fold respectively with >85% lower levels of both markers in p53-/- mice. Notably,
apoptosis was unaffected in all BH3-only gene knockout mice except for PUMA-/- mice
where it was abrogated (Table).Double staining for BrdU and casp-3 revealed that all apoptosis
in the crypt was restricted to proliferating cells. IHC staining revealed high levels of p53 in
epithelial cells localized to the lower and mid-crypt areas. To determine whether this
population included stem cells, p53 levels were examined in mice 21d after radiation and
BrdU labeling of stems (Methods). Results show that 3h after anti-CD3, p53 staining localized
to two populations: 1) label retaining stem cells at position 4, and 2) proliferating cells in
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the mid-crypt. Examination of proliferation-associated phospho-cMyc and cyclin D1 revealed
that levels increased 3-fold in B6 mice without induction in p53-/- mice. CONCLUSION:
These data suggest that T cell-induced crypt cell apoptosis occurs via a p53-dependent
pathway that requires the BH3-only p53 target protein, PUMA to execute rapidly proliferating
cells. To our knowledge, this is the first report linking a role for p53 in ISC division to
apoptosis. We suspect that this explains the p53-dependent crypt cell proliferation due to
T cell activation which may provide clues to the role of p53 in mediating neoplastic
transformation in colitis-induced cancer.
37
Comparison of Digital Image Analysis (DIA) and Fluorescent in Situ
Hybridization (FISH) in the Detection of Neoplasia Barrett’s Esophagus
Kenneth K. Wang, Ganapathy Prasad, Navtej S. Buttar, Michel Wongkeesong, Lynn S.
Borkenhagen, Sheila Krishnadath, Marlys Anderson, Sarah Papenfuss, Kevin Halling,
Thomas Smyrk, Catherine Demars, Lori Lutzke
Biomarkers such as LOH of p53, p16, and DNA ploidy have been shown to be of value in
determining cancer risk in Barrett’s esophagus. However, they have not previously been
used as a tool to detect high-grade dysplasia or cancer in Barrett’s esophagus. Aim: To
compare the ability of DIA and FISH to detect high-grade dysplasia or cancer in Barrett’s
esophagus. Methods: Patients referred to the Barrett’s Esophagus Unit were prospectively
assessed with both DIA and FISH performed on brush cytology prior to surveillance biopsies
that were taken in 4 quadrants every centimeter and assessed by two expert pathologists.
The brush cytology specimens were processed by placing the specimens in PreservCyt
solution (Cytyc Corp., Boxborough, MA). These were then collected using a ThinPrep 2000
Processor and stained with Feulgen dye and assessed with a CAS 200 digital imaging system.
A DNA index was calculated by comparing the intensity of the nuclear staining of the
Barrett’s cells obtained by brush cytology to that of morphologically benign appearing
epithelial cells within the specimen. A DNA index between 0.90 and 1.10 is considered
diploid. Values between 1.1 and 1.9 are considered aneuploid. Values between 1.9 to 2.1
are considered tetraploid. FISH was performed using a twelve probe set including 12-probe
set; p15, 5q21-22, CEP7, 7p12, 8q24.12-13, CEP 9, 9p21, CEP 17, 17p13.1, 17q11.2-12,
CEP Y, and 20q13. In order to compare results, we dichotomized the results of DIA and
FISH as positive or negative based on the presence of any abnormalities (excluding loss of
Y on FISH since this is almost ubiquitous in Barrett’s mucosa and excluding nuclear morpho-
metry on DIA). Using DIA, abnormalities such as increased tetraploidy or aneuploidy would
be considered as a positive DIA test Results: A total of 92 patients were assessed of whom
8 had adenocarcinoma, 61 had high-grade dysplasia, 13 had low-grade dysplasia, and 11
patients had no dysplasia on biopsy. patients with high-grade dysplasia or cancer had DIA
abnormalities in 47/69 (68%). This same group of patients had FISH abnormalities in 57/
69 (82%) of patients indicating that FISH abnormalities appear to be superior to DIA for
predicting the presence of high-grade or cancer (p<0.05) Conclusions: FISH detected genetic
abnormalities in cytological specimens correlated significantly better than DIA with the
presence of neoplasia in Barrett’s esophagus. This test has the potential to improve surveillance
in Barrett’s esophagus.
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Cyclin a Immunocytology As a Risk Stratification Tool in Barrett’s Esophagus
Surveillance
Pierre Lao-Sirieix, Laurence Lovat, Rebecca C. Fitzgerald
Background The incidence of esophageal adenocarcinoma (AC) is increasing rapidly. Endos-
copic surveillance of patients with Barrett’s esophagus (BE) using biopsies for histopatholog-
ical assessment is prone to sampling bias, is not cost effective and interpretation of dysplasia
is subjective. Alternative methods for surveillance are direly needed. We have previously
demonstrated that surface expression of a proliferative marker, Mcm2, is a marker of progres-
sion. However, the detection of patients at risk of progression through detection of Mcm2
positive cells in cytological specimens lacked specificity. Aims To determine whether cyclin
A, which detects proliferating cells in the S and G2 phases of the cell cycle, would be more
specific than Mcm2 for the detection of patients at risk of progression to AC. Methods
Archival specimens (30 squamous esophagus (SE), 12 gastric antrum (GA) and 9 duodenum
(D2), 62 BE +/- dysplasia, 16 AC) were stained for cyclin A. In addition, 9 patients with
3-13 years follow-up who developed AC were compared with 18 controls matched for age
and length of follow-up who did not progress. Endoscopic cytological brushings were taken
from a prospective cohort (24 SE, 93 BE +/- dysplasia and 36 AC) and scored blind as
cyclin A positive or negative. Results There was no surface expression of cyclin A in control
samples (NE, GA, D2) and its expression at the surface of BE samples correlated with the
degree of dysplasia (p=0.016). In the case-control cohort, patient with biopsies expressing
cyclin A at the surface were more likely to progress to AC than those who did not (OR
10.0, 95% CI 1.5-64.2). The sensitivity and specificity of cyclin A expression in brushings
for the detection of high-grade dysplasia (HGD) and AC were 97.9% and 61.2% respectively.
The associated negative predictive value (NPV) was 98.2%. Comparatively, the sensitivity,
specificity and NPV of Mcm2 for detection of AC and HGD patients, in a previous cohort,
were 100%, 35.6% and 100%. Using cyclin A nearly doubled the specificity with little
impact on the sensitivity or NPV. Conclusions Expression of cyclin A at the luminal surface
is a marker of progression to AC. Detection of cyclin A positivity in immunocytology could
be used as a first step to stratify BE patients according to their risk of progression. A large


















Pathologic Distinction of Barrett S Esophagus from Carditis with Intestinal
Metaplasia: A Blinded Interobserver Variability Study
Amitabh Srivastava, Mark Redston, Gregory Y. Lauwers, Donald A. Antonioli, Robert D.
Odze, Jonathan N. Glickman
Background: Barrett s esophagus (BE) and carditis with intestinal metaplasia (CIM) have
different etiologies, natural history and risk of malignancy. We have previously identified
several morphological parameters, listed below, that are useful in distinguishing these two
conditions in mucosal biopsies from the gastro-esophageal junction (GEJ) region. The purpose
of this study was to evaluate the level of interobserver agreement among expert GI pathologists
in recognizing the various morphological parameters and in distinguishing BE from CIM in
GEJ biopsies. Design: Routinely processed H&E stained biopsies from the GEJ region,
representing 10 of distal esophagus in BE and 10 of proximal stomach in CIM, were evaluated
by four GI pathologists in a blinded manner without knowledge of the clinical or endoscopic
findings. Each pathologist was asked to categorize cases as either BE or CIM, and to score
the presence or absence of the following previously reported BE-associated features: crypt
atrophy, crypt disarray, incomplete or complete IM, extensive incomplete IM (>50% crypts),
squamous epithelium over metaplastic crypts (Sq/IM), hybrid glands, multilayered epithelium
(ME) and esophageal gland/ducts (EG/ED). Interobserver agreement was calculated for
each morphological parameter and for the overall diagnosis, using kappa (k) statistics for
concordance between multiple raters. Interobserver agreement was rated as excellent (k >
0.80), good (0.6-0.8), fair (0.4-0.6) and poor (<0.4). Result: Interobserver agreement was
good for the overall diagnosis of BE vs. CIM (k=0.6). Three or more observers correctly
diagnosed BE or CIM in 15/20 (75%) cases. The interobserver agreement for each individual
morphological parameter ranged from excellent to good for some features (EG/ED: k= 0.83,
Sq/IM: 0.65, incomplete IM: 0.56, crypt atrophy: 0.53), fair for extensive IM (0.47), and
poor for the others (complete IM: 0.25, crypt disarray: 0.21, and ME: 0.17). Interestingly,
when none of the BE-associated features were present (5/20 cases), agreement for a diagnosis
of CIM was excellent (3 or more observers agreed in all five cases). Similarly, when four or
more BE-associated parameters were present in the same biopsy specimen (10/20 cases),
three or more observers agreed on the diagnosis of BE in all cases. Conclusion: There is
good agreement among expert GI pathologists for distinguishing BE from CIM in GEJ
biopsies when using the morphological features outlined above. In fact, a correct diagnosis
of BE is more often reproducible when a combination of these features (>4) are present
together in the same biopsy specimen.
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Biomarkers in the Therapy of Barrett’s Esophagus with High-Grade Dysplasia
Ganapathy A. Prasad, Kenneth K. Wang, Halling C. Kevin, Shannon Brankley, Navtej S.
Buttar, Louis M. Wongkeesong, Lori S. Lutzke, Sarah M. Papenfuss, K K. Krishanadath
Rationale: Photodynamic therapy (PDT) has been shown to be effective in the treatment of
high-grade dysplasia (HGD) in Barrett’s esophagus (BE), however a substantial proportion
of patients do not respond. Aims: To determine if biomarkers known to be important in
Barrett’s neoplasia can predict response to PDT in BE and HGD/mucosal cancer. Methods:
Patients with BE and HGD/mucosal cancer referred for endoscopic therapy to the Mayo
Clinic were prospectively studied from 2002-2005. All patients underwent a protocol assess-
ment with EGD, 4 quadrant biopsies every cm, EMR of visible nodules and EUS. Biomarkers
were assessed using FISH for region specific and centromeric probes. Biomarkers assessed
included:loss of 9p21 (site of p16 gene) and 17p13.1 (site of p53 gene) loci; gains of 8q24(c-
myc), 17q (HER2-neu) and 20q13 loci. Respective centromeric probes were used to assess
chromosomes 9, 17, 20, and 8. Cells were also assessed for loss or gain of chromosomes
(aneusomy and polysomy). Patients were treated with PDT 48 hours following administration
of sodium porfimer.Demographic and clinical variables were prospectively collected. Logistic
regression was performed to determine predictors of response to PDT (defined as the absence
of dysplasia at surveillance biopsies 3 months following PDT). Results: 58 patients have
been entered with a mean age 67.6 years (SEM1.38). 54 (93%) were males. 41 (82%) had
HGD and the remainder had cancer. The mean BE segment length was 5.5 cm (SEM 0.44).
46 (80%) patients had EMR done before PDT. 31 (53%) of patients was responders at 3
months following PDT. On univariate analysis, BE segment length (OR 0.67 [0.53,0.85] p=
0.001), 9p21(p16) loss (OR 0.15 [0.05,0.52] p=0.003), were significant predictors of lack
of response to PDT. Loss of the 17p13.1(p 53) locus (OR 0.25 [0.06,1.15] p= 0.08) was a
marginally significant predictor. Age, gender, EMR, and other biomarkers were not significant
predictors on univariate analysis. On multivariable analysis, BE segment length and loss of
p16 locus were independent predictors of response to PDT. The presence of polysomy and/
or gain at 8q24/17q/20q13 loci was a marginally significant predictor of response to PDT.(see
table) Conclusion: This is the first prospective study which identifies a biomarker, p16, as
predicting response to PDT in BE and HGD/cancer. Identification of biomarkers may help
in the selection of appropriate therapy for patients and improve treatment outcomes.
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DNA Methylation in the Esophageal Mucosa of Patients 5 Or More Years After
a Fundoplication for Barrett’s Esophagus
John J. Kelly, Eric Smith, Paul A. Drew, Stuart R. Phillis, Andrew R. Ruszkiewicz, Glyn G.
Jamieson
Introduction: Barrett’s esophagus results from reflux and is a major risk factor for adenocarcin-
oma of the distal esophagus. Aberrant DNA methylation is frequent in Barrett’s esophagus
and adenocarcinoma and is thought to contribute to the disease progression. Fundoplication
protects the oesophagus from reflux and may result in regression of the Barrett’s mucosa,
but it is not known what effect it has on methylation in the esophagus. Aim: To test the
hypothesis that reflux control by fundoplication in patients with Barrett’s esophagus will
reduce DNA methylation in the esophageal mucosa. Method: We studied 23 patients with
histologically proven Barrett’s esophagus preoperatively who had a laparoscopic fundoplic-
ation more than 5 years ago. Reflux was measured by 24 hour pH monitoring. Biopsies at
2 cm intervals from any columnar epithelium and squamous epithelium were obtained at
endoscopy. Methylation was measured in the promoter region of 9 genes - APC, CDKN2A,
ID4, TEMMF2, MGMT, RBP1, RUNX3, SFRP1 and TIMP3. Results: The median follow up
was 8 years (60 - 127 months). Of the 18 patients with no reflux, 17 had an apparent
regression of the columnar mucosa. This regression was complete in 9 patients (5 long
segment and 4 short segment) and partial in 8 patients. Five patients had reflux and persistent
Barrett’s esophagus. There was significantly less methylation in the columnar epithelium of
patients without reflux compared to those with reflux (p<0.0001). The squamous biopsies
from patients without reflux but continuing Barrett’s had more methylation than either
squamous epithelium proximal to the Barrett’s in patients with reflux (p=0.005), or from
patients with complete regression (p<0.001). This may reflect the squamous biospies coming
from areas in which metaplastic changes are reversing. Conclusions: We observed complete
regression to squamous mucosa in 50% of patients with a fundoplication and no acid reflux.
In patients with complete regression the regenerated squamous had minimal methylation
which did not differ from the squamous proximal to Barrett’s. In patients with partial
regression there was significantly less methylation in the columnar lining compared to the
patients with continuing reflux, but more methylation in the squamous regenerating region
than in the normal esophagus. The significance of the methylation in the partially regressed
esophagus warrants further investigation.
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CDX2 Expression Predicts the Presence of Specialized Intestinal Metaplasia in
Columnar Epithelium of the Esophagus Even in the Absence of Goblet Cells
Marjon Kerkhof, Dorine A. Bax, Leon M. Moons, Anneke J. van Vuuren, Herman van
Dekken, Ernst J. Kuipers, Johannes G. Kusters, Peter D. Siersema
Background: Barrett’s esophagus (BE) is a premalignant condition characterized by the
presence of specialized intestinal metaplasia (IM) in columnar epithelium. In some patients,
patchy areas of IM and cardia-type mucosa (CM) are present in the columnar-lined esophagus,
whereas in other patients only CM is detected, which is generally not regarded as premalig-
nant. In contrast to patients with IM, patients with only CM are currently not advised to
undergo endoscopic surveillance. As IM and CM are endoscopically indiscernible, sampling
error during endoscopy may result in false-negative diagnoses of IM. Aim: To investigate
whether intestinal markers for IM, such as CDX2 (early intestinal marker), MUC2 (goblet
cell marker) and villin (late intestinal marker), in the absence of a histological diagnosis of
IM (characterized by goblet cells), are predictive for the presence of IM in another part of
the columnar-lined esophagus. Methods: A total of 122 sets of biopsies from columnar
epithelium of the esophagus from 61 patients (42 males, mean age at first endoscopy 56
years) were collected at two different gastroscopies with a medium interval of 24 (range 4-
156) months. Patients were divided into three groups: 15 patients with IM in both biopsy
sets (group 1), 25 patients with in one biopsy set only CM and in the other IM (group 2),
and 21 patients with only CM in both biopsy sets (group 3). Haematoxylin and eosin, alcian
blue, and periodic acid-Schiff staining was performed to identify the type of epithelium.
CDX2, MUC2 and villin expression was determined by immunohistochemistry. Results: IM
was present in 55/122 (45%) samples, which were all positive for CDX2 and MUC2. Villin
expression was present in 32/55 (58%) IM samples. In addition, CDX2 expression was
detected in 23/67 (34%) samples with only CM. CDX2 in CM was more often (p<0,05)
observed in patients of group 2, in which the other biopsy set was positive for IM (13/25;
52%), compared to patients of group 3, in which IM was absent in both biopsy sets (10/
42; 24%). The detection of CDX2 in CM significantly increased the chance of finding IM
in another biopsy sample of the columnar segment (OR 3.5 (95% CI=1.2-10). Thirteen of
these 23 (57%) CDX2 positive CM samples were also positive for MUC2, whereas villin
expression was detected in 7/23 (30%). Conclusion: CDX2 expression in CM, in the absence
of goblet cells suggestive for IM, predicts the presence of IM in another part of the columnar-
lined esophagus. Our results suggest that CDX2 staining should be used as an additional
histological marker to determine if endoscopic surveillance is indicated.
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H. Pylori Accelerates the Progression of Dysplasia of the PYLORIC Antrum in
Tff2-/- C57bl X Sv129 Infected Mice
James G. Fox, Arlin B. Rogers, Evelyn Kurt-Jones, Timothy C. Wang
Trefoil facter 2 (TFF2) also referred to as spasmolytic polypeptide is upregulated in Helicob-
acter spp infected gastric tissues of both humans and mice. Recent studies (Kurt Jones et al
submitted) demonstrated that this peptide plays a role in regulation of innate immunity
similar in some respects to that of IL10. To ascertain TFF2’s biological effects in vivo, TFF-/-
C57BL x Sv129 (n=20) and C57 BL6 x Sv129 mice (n=20) were orally dosed with H. pylori
SS1 (109 CFU) every other day for a total of 3 doses. Two other control groups of TFF-/-
and WT mice were sham dosed. Gastric lesions were scored in blinded fashion by a
comparative patholgist at 6 and 19 months post inoculation (pi). At 6 mos pi, there was
not a statistically significant difference in corpus inflammation between H. pylori TFF2-/-
and WT mice, but their was a significant difference (p<0.05) for some epithelial criteria
(mucosal defects, oxyntic atrophy, hyperplasia and intestinal metaplasia) in the corpus of
TFF2-/- vs WT mice. At 19 mos pi, a similar statistical difference in epithelial parameters
was noted in the antrum of TFF2-/- vs WT mice (p<0.01) (See figure below). However,
corpus lesions at 19 mos pi did not differ significantly in infected TFF2-/- and WT mice.
Importantly, 2 of 9 TFF2-/- H. pylori infected mice developed gastric intraepithelial neoplasia
(GIN) of the pyloric antrum and the remaining had high grade dysplasia whereas only one
of 11 WT infected mice developed antral GIN and the remaining had only low grade
dysplasia (P<0.01). A gender effect was not noted. In conclusion, TFF2 provides a protective
gastric epithelial effect against the progression of premalignant lesions of the pyloric antrum
in H. pylori infected mice.
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Cobra1: A Novel Regulator of TFF1 Transcription in Upper Gastrointestinal
Adenocarcinomas
Patricia McChesney, Mohammad Razvi, Rong Li, Chrsitopher Moskaluk, Alexander Zaika,
Wael El-Rifai
We and others have shown that TFF1 mRNA and protein expression is frequently downregul-
ated in upper gastrointestinal adenocarcinoma (stomach, GEJ, and lower esophageal).
Although promotor hypermethylation and LOH have been suggested as mechanisms for
downregulation of TFF1 in gastric cancers, the majority of gastric tumors lack these changes.
In this work, we demonstrate that Cofactor of BRCA1 (COBRA1), a newly characterized
member of the Negative Elongation Factor (NELF) complex, is overexpressed in the majority
of primary upper UGCs, and its overexpression correlates with downregulation of TFF1.
We have detected overexpression of COBRA1 mRNA using quantitative real time RT PCR
in twenty-eight primary UGCs (79%). Immunohistochemical analysis of UGC tissue arrays
that contained 70 tumor samples demonstrated moderate-strong staining for COBRA1 in
60 tumors (84%). Simultaneous loss of TFF1 expression and overexpression of COBRA1
was observed in 42/70 (60%) tumors. Using siRNA technology, with gastric cancer cells,
we demonstrate that COBRA1 inhibition leads to increased TFF1 promoter activity and gene
expression. Promoter analysis of TFF1 indicates that regulation of TFF1 by COBRA1 is
estrogen independent, and that COBRA1 can negatively regulate the AP-1 complex at the
TFF1 promoter, and thus , downregulate TFF1 expression in gastric cancer cell lines.
Electrophoretic mobility shift assay (EMSA) verifies that COBRA1 attenuates AP-1 binding
to DNA. In conclusion, our results demonstrate a novel transcriptional mechanism that may
explain the loss of TFF1 expression in the majority of upper gastrointestinal carcinomas.
COBRA1 acts as a transcription factor binding protein that regulates the activity of AP-1,
thus inhibiting expression of TFF1 in gastrointestinal cells. These findings suggest that
COBRA1/AP1 is a novel transcription regulatory mechanism with oncogenic potential in
UGCs.
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Effects of Peroxisome Proliferator-Activated Receptor-Gamma Agonist,
Rosiglitazone, On Chemoprevention of Gastric Cancer in Rat
Wai K. Leung, Shanying Liao, Zhi-Rong Zeng, Christine Y. Wong, Wai-Kit Chu, Victoria
Y. Cheng, Ka-Fai To, Jun Yu, Pin-Jin Hu, Joseph J. Sung
Background: Peroxisome proliferators-activated receptor-gamma (PPARγ) is a nuclear hor-
mone receptor that regulates gene expression and cellular differentiation. We have previously
shown that PPARγ suppresses the growth and induces apoptosis of gastric cancer cells
[Leung, Gut 2004]. Aim: To evaluate the in vivo chemopreventive effects of PPARγ agonist
in an animal model of gastric carcinogenesis. Methods: Gastric tumors were induced in
Wistar rats with N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) as described previously
[Hu et al, Gut 2004]. MNNG (100μg/ml) were given in drinking water ad libitum. Four-
week-old male rats were divided into 4 groups (20 in each group) to receive rosiglitazone
at 0.2 (Group A), 0.8 (B), 3.2 (C) mg/kg/d or distilled water (positive control; D) by oral
gavage for 40 weeks. Rats treated with vehicle alone without MNNG were used as negative
control (E). All animals were sacrificed at the end of study. Stomach was harvested and
gastric carcinoma was verified by histology. Gene expression profiles of rat gastric tumors
treated with rosiglitazone or MNNG alone were analyzed by oligonucleotide microarrays
(CodeLink UniSet Rat I Bioarray) that contains 10,000 rat gene targets. Microarray data was
processed by the Significance Analysis of Microarrays (SAM) and fold-difference filtering.
Results: 70% of MNNG treated (Group D) rats developed gastric adenocarcinoma and none
of the control rats fed with vehicle alone (Group E) had stomach cancer. Treatment with
rosiglitazone significantly reduced the incidence of gastric cancer development in rats (Group
A: 15%; B: 20%; C: 25%, P = 0.0005). The mean tumor volume was also lower in rosiglitazone
treated rats (Group A, B and C: 0±0, 1.6±1.6 and 16.1±15.7 mm3) as compared to MNNG
group (50.4±30.5 mm3, P=0.004). The best chemopreventive effect was obtained in rats
treated with rosiglitazone 0.2mg/kg/d. Oligonucleotide array showed that 79 genes were
differentially upregulated in rosiglitazone treated gastric tumors when compared to MNNG-
induced tumor. These genes were involved in transcription factors (e.g. Stat5A and TGFBR1),
signal transduction (LHCGR, NPY5R), metabolism (MET1a), cell cycle (bcl2) and biosynthesis
(HMBS) by Gene Ontology annotation. 54 genes had yet unknown biological function.
Notably, no gene was found to be significantly downregulated in rosiglitazone treated gastric
tumors. Conclusion: Our results showed that the PPARγ ligand rosiglitazone has a potent
chemopreventive effect against gastric cancer development in rat. Gene activation appears
to play a major role underlying the chemopreventive effects of PPARγ ligands.
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Chemoprevention of Gastric Cancer By Celecoxib in H. Pylori-Infected
Mongolian Gerbils
Seiji Futagami, Kenji Suzuki, Tetsuro Hiratsuka, Tomotaka Shindo, Tatsuhiko Hamamoto,
Atsushi Tatsuguchi, Nobue Ueki, Shinji Yoko, Masafumi Kusunoki, Ken Wada, Kazumasa
Miyake, Katya Gudis, Taku Tsukui, Choitsu Sakamoto
Aims/Background: A number of studies have shown that the cyclooxygenase(COX)-2/PGE2
pathway plays a crucial role in cancer development and progression. Although, elevated
expression of COX-2 had been clearly shown in gastric cancer, it was not clear whether the
inhibition of COX-2 in turn lead to the inhibition of gastric cancer occurrence or to the
inhibition of pre-cancerous lesions that culminate in gastric carcinoma. Therefore, in this
study, we evaluated whether administration of celecoxib, a selective COX-2 inhibitor, contrib-
utes to the prevention of not only gastric cancer but also of intestinal metaplasia in MNU-
pretreated H. pylori-infected Mongolian gerbils. Methods: Fifty-two male Mongolian gerbils
were given MNU (N-Methyl-N-nitrosourea) (30ppm) every second week for 10 weeks and
divided into three groups: group 1 (n=10) received Brucella broth without H. pylori; group
2 (n=20) received H. pylori inoculation at week 7; group 3 (n=22) given a daily CRF-1 diet
containing celecoxib (1500 ppm) after H. pylori inoculation. At experimental week 54, all
animals were sacrificed. The incidence of gastric adenocarcinoma was determined by histolog-
ical analysis. COX activity in the gastric tissue was measured by the production of prosta-
glandin E2 using ELISA methods. Apoptotic index was determined by terminal deoxynucleot-
idyl transferase-mediated nick end labeling assay. The extent of intestinal metaplasia (Alcian-
blue PAS), CdX2, and MUC2 expression in the stomach were evaluated semi-quantitatively
immunohistochemically. Results: The incidence of gastric adenocarcinoma at sacrifice was
0% (0/10) in group 1, 65% (13/20) in group 2, and 23% (5/22) in group 3. Celecoxib
significantly prevented gastric cancer development induced in MNU-pretreated H. pylori-
infected Mongolian gerbils. Overall intensity of COX-2 expression measured by immuno-
histochemistry in intestinal metaplasia, dysplasia, and gastric adenocarcinoma was nearly
the same in group 2 and 3 gerbils. However, celecoxib administration significantly reduced
COX activity and provoked apoptotic activity in group 3 gerbils. CdX2 was also expressed
in intestinal metaplasia, dysplasia, and gastric adenocarcinoma in H. pylori-infected gerbils,
while celecoxib also significantly reduced extent of CdX2 as well as MUC2 expression and
AB-PAS-positive intestinal metaplasia in H. pylori-infected gerbils. Conclusions: The data
presented here suggests that the selective COX-2 inhibitor celecoxib prevents gastric cancer
occurrence by disrupting the progression of intestinal metaplasia into gastric carcinoma,
through its inhibition of CdX2 expression in MNU-pretreated H. pylori-infected Mon-
golian gerbils.
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Female Hormones Provide a Protective Effect in Helicobacter Pylori Induced
Gastric Disease in Ins-Gas Mice
Masahiro Ohtani, Zhongming Ge, Alexis Garcia, Arlin B. Rogers, Nancy S. Taylor, Sandy
Xu, Koichiro Watanabe, Kristen Clapp, Juri Miyamae, Robert P. Marini, Takeshi Azuma,
Timothy C. Wang, James G. Fox
Background: The incidence rate of human gastric cancer in males is approximately 2 times
the rate recorded in females. Although some epidemiological studies indicate that female

















the role of female hormones in gastric carcinogenesis caused by infection with H. pylori has
not been evaluated in rodent models. We previously demonstrated that gastric cancer caused
by infection with H. pylori is male-predominant in INS-GAS transgenic mice (Fox et al,
2003) Aim: The aim of our study was to investigate the effect of female hormones on gastritis
and cancer caused by infection with H. pylori in INS-GAS mice. Methods: Forty-six (16
males, 30 females) specific pathogen free INS-GAS mice on a FVB background were used
in this study. Ovariectomy or sham ovariectomy were performed on female mice at the age
of 8 weeks. Eight to 10 week old mice were inoculated three times by oral gavages with
108 cfu of H. pylori SS1 or broth alone. Mice were euthanized at 16 weeks post-infection.
Histological evaluation (inflammation, atrophy, hyperplasia, intestinal metaplasia and dyspla-
sia) were graded on a blinded basis, on a scale from 0 to 4, by a comparative pathologist
. Quantitative cultures of H. pylori were performed on gastric tissue (antrum and corpus).
Statistical analyses were performed using Mann-Whitney U test. Results: Male mice infected
with H. pylori developed corpus gastritis with atrophy, intestinal metaplasia, foveolar hyper-
plasia and dysplasia. Intact female mice infected with H. pylori developed attenuated gastric
pathology compared to infected male mice (P<0.05). In contrast, ovariectomized mice
infected with H. pylori developed corpus gastritis with atrophy and dysplasia comparable
to infected male mice. All lesion scores in ovariectomized mice infected with H. pylori were
significantly higher than those in infected female mice (P< 0.05). Ovariectomy didn’t affect
colonization levels of H. pylori when compared to other infected groups of mice. Conclusion:
Ovariectomy in female INS-GAS mice statistically increased severity of gastric disease caused
by infection with H. pylori. This finding suggests that female hormones have a suppressive
role in development of gastritis and premalignant lesions. A long-term study to investigate
the molecular mechanisms responsible for the protective effect of female hormones on
development of gastric cancer is in progress.
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Reciprocal Fundic and Antral Changes in Sonic Hedgehog (SHH) During the
Progression from Atrophic Gastritis to Gastric Cancer
Meghna Waghray, Weiqun Kang, Yana Zavros, Juanita Merchant
Objective: Previously we have shown that loss of gastrin results in impaired gastric acid
secretion and the development of antral cancer within one year (Oncogene 2005). Prior
studies by Beachy and co-workers have shown that sonic hedgehog (Shh) levels are elevated
in human gastric cancer cells (Nature, 2003). Therefore, we examined the expression of
Shh and relevant signaling molecules in gastrin deficient (G-/-) mice during progression to
gastric cancer. Methods: RNA isolated from the antral tissues of G-/- and wild type (WT)
mice was subjected to microarray analysis. Stomachs from the 15 month old G-/- and WT
mice were separated into fundus and antrum then further compartmentalized into epithelium
and mesenchyme via EDTA chelation. The purity of the separation was documented using
HK-ATPase and gastrin RT-PCR as fundic and antral epithelial specific markers respectively,
with Actg2 and Madcam1 as mesenchymal markers. RT-PCR was used to analyze the
abundance of Shh and its target genes in specific compartments. Protein prepared from WT
and G-/- mice was analyzed for Shh and its target gene patched (Ptc) by western blot.
Results: Atrophic changes were detected in the fundus of the G-/- mice, with a subsequent
progression of hyperplasia in the antrum. Accordingly, western blot analysis showed reduc-
tion of Shh (15-fold) and Ptc (7.5-fold) in the G-/- fundus, but significant elevation of Shh
(4-fold) and Ptc (3.2 fold) in the neoplastic antrum. RT-PCR results confirmed reduction
of Shh and Ptc in the fundus, and induction in the mesenchymal compartment of G-/-
antrum. In addition, Shh target genes BMP7 and sFRP1 also increased in the antral mesen-
chyme. Microarray analysis consistently revealed prominent upregulation of the genes
belonging to TGFbeta and Wnt signaling pathways in antral tumors. Conclusion: Atrophic
gastritis results in the reduction of hedgehog signaling in the fundus. In the antrum, an
elevation in the hedgehog signaling pathway is seen, which may contribute to antral trans-
formation. Thus, the G-/- mouse model may be used to study how spatial and temporal
changes in hedgehog signaling and its target genes predispose the stomach to atrophy leading
to gastric cancer.
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Elevated Iron Absorption in the Neonatal Rat Reflects High Expression of Iron
Transport Genes in the Distal Small Intestine and Colon
David M. Frazer, Sarah J. Wilkins, Therese L. Murphy, Gregory J. Anderson
Background: Neonatal mammals have a very high rate of intestinal iron absorption to ensure
an adequate supply of iron to the growing infant. They may absorb up to 100% of a test
dose of radioactive iron during the suckling period, but absorption drops rapidly to adult
levels (approximately 10%) at the time of weaning. Aim: To investigate the molecular basis
of this dramatic change in absorption by determining the expression of iron transport genes
in the gastrointestinal tract of neonatal rats before and after weaning and correlating gene
expression with iron absorption. Methods: All studies were carried out using Sprague-Dawley
rats which were weaned when they were 21 days old. Suckling rats were maintained with
their mothers. Samples from the duodenum, jejunum, ileum and colon were taken at 10,
15, 20 and 25 days after birth. Tissue was also taken from adult rats (10 months old)
maintained on normal pellet diet. The expression of iron transport genes was determined
by ribonuclease protection assay. Intestinal iron absorption was determined by measuring
the retention of an oral dose of 59Fe in whole animals, or by measuring iron transported
to the body using cannulated intestinal loops. Results: Iron absorption measurements showed
that 10 and 15 day old rats absorbed 87.0±2.2% and 84.1±4.2% of a test dose respectively,
but this reduced dramatically around weaning with 20 day old rats absorbing 50.6±4.9%
and 25 day old animals absorbing 7.8±1.7%. The expression of the brush border iron
transporter DMT1 and reductase Dcytb increased during suckling in the duodenum to reach
a maximum just before weaning. After weaning, expression declined to adult levels. Duodenal
expression of the basolateral transport components hephaestin and ferroportin remained
relatively constant throughout suckling and weaning. Neither of these expression patterns
correlates well with iron absorption. However, during the suckling period, all genes studied
were expressed at high levels in the colon and to a lesser extent in the ileum. After weaning,
only hephaestin was expressed in the distal alimentary tract. Iron absorption by duodenal
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loops was similar in 15 and 25 day old rats, but absorption by ileal and colon loops was
increased 6.6 fold and 3.3 fold respectively in the younger animals relative to their older
counterparts. Conclusions: These results suggest that the entire length of the small intestine
and the colon may be involved in iron absorption in the neonate and that following weaning
the absorption of iron becomes restricted to the duodenum and upper jejunum.
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Protein Composition of the Pre-Chylomicron Transport Vesicle (PCTV)-CIS
Golgi Fusion Complex
Shadab Siddiqi, James Mahan, Charles Mansbach
Vesicle fusion with its target membrane is mediated by specific membrane proteins, soluble
NSF attachment protein receptors (SNAREs). SNARE complexes are composed of 1 vesicle
SNARE (v-SNARE) and 3 target membrane SNAREs (t-SNAREs) which form a 4 component
α-helical bundle which by itself can induce membrane fusion. SNAREs select cargo for
inclusion in the transport vesicle, attract coatomer proteins (COPII), and target the vesicle
to specific acceptor membranes. We have identified vesicle associated membrane protein 7
(VAMP7), a post Golgi SNARE protein, to be uniquely localized to the endoplasmic reticulum
(ER) in the intestine (Siddiqi, S, et al. J. Cell Sci., 2005, in press) and have shown that
VAMP7 is both concentrated on PCTV and functional in transporting chylomicrons to the
cis Golgi. We postulated that VAMP7 functions as a v-SNARE for PCTV and forms a unique
SNARE complex with t-SNAREs on the cis Golgi enabling fusion. We have made an anti-
rat VAMP7 specific antibody (Siddiqi, S. J. Cell Sci., 2005) that we used for immuno-
precipitation of its binding partners. PCTV were generated from rat ER (Siddiqi et al. J. Cell
Sci., 2003). We were able to dock PCTV with cis Golgi, thus stabilizing the SNARE complex,
by incubation with cytosol at 4 C in the absence of ATP and Mg2+ as identified by
PCTV becoming iso-dense with the cis Golgi indicating association and the lack of PCTV-
chylomicron acquisition of apolipoprotein-AI (apo-I). Apo-AI is present in the Golgi but
not in PCTV-chylomicrons. Bead-bound VAMP7 antibodies immuno-precipitated the t-
SNAREs syntaxin5, vti1a, and rBet1 in a 112 kDa complex disassociated by boiling. Bead
bound rBet1 antibodies immuno-precipitated VAMP7, syntaxin5, and vti1a also in a 112
kDa complex. Antibodies to membrin, GOS28, and Sec22b, ykt6, other v- and t-SNAREs,
identified each to be present in docked PCTV-cis Golgi, but at their monomer Mr indicating
they were not part of the SNARE complex. Antibodies to each SNARE inhibited fusion of
PCTV with cis Golgi. Incubation of PCTV with cis Golgi, cytosol, ATP and Mg2+ at 37 C
resulted in chylomicron acquisition of apo-AI as determined by isolating chylomicrons from
post-fusion Golgi membranes indicating a fusion event. PCTV were shown not to fuse with
liver or kidney cis Golgi indicating the specificity of the fusion process. We conclude that
the protein composition of the PCTV-cis Golgi fusion complex is composed of VAMP7,
syntaxin5, vti1a, and rBet1. We propose that this unique system facilitates the transport of
chylomicrons to the cis Golgi which occurs intermittently with fat feeding as compared to
the constant transport of newly synthesized proteins.
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Intestinal Threonine Metabolism in Wild Type and MUC2 Deficient Mice
Maria Van der Sluis, Maaike Schaart, Barbara de Koning, Henk Schierbeek, Anna Velcich,
Ingrid Renes, Johannes van Goudoever
Mucin 2 (Muc2) is the major secretory mucin of the mucus layer covering the intestinal
epithelium. Muc2 is a large glycoprotein rich in threonine-proline-serine tandem repeats.
Previous studies in neonatal pigs showed that the intestine utilizes 60-90% of the dietary
threonine intake. We therefore hypothesized that dietary threonine is mainly used for
intestinal Muc2 synthesis. Our aim was to determine the threonine utilization in the intestine
of Muc2 knockout (Muc2-/-) mice and wild type (Muc2+/+) mice. Muc2-/- and Muc2+/+ mice
received a U-13C- threonine bolus. Mice were sacrificed 1, 3 and 6 hours after threonine
administration. The concentration and isotopic enrichment of threonine was measured in
small intestine, colon and faeces by GC-(IR)MS. In the gastrointestinal tract 41.5% of the
dietary [13C] threonine administered was recovered after 6 hours in Muc2+/+ mice [33.7%
[13C] threonine and 7.7% as [13C] glycine] vs. 44.8% in the Muc2-/- mice [34.3% [13C]
threonine and 10.5% as [13C] glycine]. In the Muc2+/+ mice, 27.5% was recovered as protein
bound [13C] threonine in the intestine vs. 25.2% in the Muc2-/- mice (non significant),
when the threonine tracer was given as free amino acid. There were no significant differences
in the percentage of [13C] threonine recovered in small intestinal tissue proteins between
Muc2+/+ and Muc2-/- mice after 6 hours [14.1% vs. 8.0%, respectively]. The percentage of
[13C] threonine recovered in colonic tissue proteins was significantly higher in Muc2-/- mice
compared to Muc2+/+ mice at 6 hours [0.4% vs. 0.2%, respectively p=0.02]. 27.5% of
the [13C] threonine in the faeces was derived from Muc2. Conclusions: Dietary threonine
metabolised by the intestine of mice was used for synthesizing constitutive proteins, as well
as Muc2. Thus, secretory protein synthesis is an important pathway of intestinally utilized
dietary threonine.
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Conditional Intestinal Lipotoxicity: Functional Superiority of APOB48 and a
Survival Advantage for APOB mRNA Editing
Yan Xie, Jianyang Luo, Zhouji Chen, Nicholas O. Davidson
Microsomal triglyceride transfer protein (MTTP) and apolipoprotein B (apoB) expression
are dominant genetic restriction points in hepatic and intestinal lipoprotein secretion. Homo-
zygous germ-line deletion of either Apob or Mttp in mice results in embryonic lethality.
Earlier studies suggested a subtle functional advantage in lipid export of apoB48 over
apoB100, but Apobec-1-/- mice (apoB100-only) appear to grow normally and intestinal
enterocytes appear indistinguishable from wild-type (apoB48) controls. We have bypassed
the embryonic lethality associated with targeted Mttp deletion by creating conditional,
tamoxifen inducible intestine specific Mttp deletor mice (Mttp-IKO), which demonstrate
intestinal triglyceride (TG) and free fatty acid (FFA) accumulation when fed a chow diet.
We then generated Mttp-IKO mice on an apoB100 (ie Apobec-1-/-) background (AMttp-
IKO) and examined their response to high fat intake. On a chow diet AMttp-IKO mice
manifest dramatic TG and FFA accumulation, similar to Mttp-IKO mice. However, when
challenged with a high fat diet 100% AMttp-IKO mice (n=7) died by two weeks, while
100% of the Mttp-IKO mice survived for at least 1 month. There was gross distortion of
the villus architecture and altered enterocyte proliferation, suggesting that there is greater
conditional intestinal lipotoxicity with Mttp deletion in the background of apoB100 compared
to apoB48. To address the relevance of this observation in the perinatal setting, when apoB
mRNA editing occurs, and to examine the survival advantage of apoB48, we generated
compound heterozygous mice containing one apoB38.9 hypomorphic allele (apoB38.9hypo)
and either an apoB48-only allele (apoB38.9hypo/48) or an apoB100-only allele
(apoB38.9hypo/100). The apo38.9 hypomorphic allele is functionally equivalent to an apoB
null. All animals expressing the apoB38.9hypo/48allele survived the neonatal period while
90% animals expressing the apoB38.9hypo/100died within 4 days. These findings further
confirm a survival advantage for neonatal intestinal apoB48 expression. In summary, the
data demonstrate that intestinal Mttp expression is necessary for surviving the high fat
challenge encountered during suckling. In addition, our findings of lethal intestinal lipotox-
icity in AMttp-IKO mice and perinatal death of the compound apoB38.9hypo/100 mice
imply a survival advantage for apoB48. These are the first conclusive data to demonstrate
a plausible physiological role for mammalian intestinal apoB mRNA editing.
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Intestinal Epithelial Cell-Derived IL-7 Contributes to the Alternation in
Intraepithelial Lymphocytes After Total Parenteral Nutrition
Hua Yang, Xiaoyi Sun, Daniel H. Teitelbaum
Background: Total parenteral nutrition (TPN) results in profound changes to both intestinal
epithelial cells (EC), as well as adjacent intraepithelial lymphocytes (IEL). Such changes may
result in alterations in the mucosal immune system and a loss of mucosal barrier function.
IL-7 is vital for IEL development and maintenance. Because EC are a rich source of IL-7,
and TPN results in marked EC changes, it was hypothesized that TPN would diminish EC-
derived IL-7 expression, and contribute to the observed IEL changes. Methods: Adult C57BL/
6J mice received 1) TPN; 2) ad lib feeding (Control); 3) TPN supplemented with exogenous
IL-7; or 4) enterally fed mice treated with anti-IL-7 receptor (IL-7R) antibody (Ab). Mice
were sacrificed at 7 days after TPN administration. EC-derived IL-7 expression was measured
by RT-PCR and Western immunoblot. IEL phenotype, proliferation rate (S/G2+M phase),
and IL-7R expression in sub-populations were detected with flow cytometry. Antibodies to
IL-7 and CD3 (T cell marker) were used for confocal microscopy to observe for co-localization
of EC-derived IL-7 to IEL. Results: TPN administration significantly decreased EC-derived
IL-7 expression. IL-7R expression was observed in CD4+, CD8+, TCR-αβ+, as well as TCR-
γδ+ IEL. Significant changes in IEL phenotype and a marked decrease in IEL numbers were
noted after TPN administration (See Table). IEL proliferation decreased 1.6-fold with TPN.
Further, maturation of the IEL (as measured by the CD44+ IEL) declined with TPN. Blocking
IL-7R with anti IL-7R Ab on normal health mice, resulted in several similar changes in the
IEL as those observed with TPN administration. To further address the contribution of IL-
7 to these changes, TPN mice received exogenous IL-7, which significantly attenuated TPN-
associated IEL changes, including reducing the decline in IEL proliferation, and significantly
prevented the development of TPN-associated IEL phenotypic changes. Finally, confocal
microscopy showed a close IEL-EC cross-communication mediated by EC-derived IL-7
expression. Conclusion: TPN leads to a significant decrease in EC-derived IL-7 expression.
This decrease in EC-derived IL-7 may be a contributing mechanism accounting for the
observed changes of neighboring IEL after TPN administration.
Data are expressed as mean±SD. Each group n=6. *p<0.05 compared with TPN
group,†p<0.05 compared with Control
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Novel Differentially Expressed Genes Revealed By Microarray Analysis of
Duodenum in Patients with Disorders of Iron Homeostasis
James F. Collins, Zihua Hu, Stuart Rakka, Ellen Kilcourse, Kris V. Kowdley
Background/Aim: Previous studies have demonstrated that genes which encode proteins
related to iron transport are induced in the human duodenum by iron-deficiency. We thus
performed microarray analyses to identify changes in duodenal gene expression patterns in
patients with altered iron homeostasis. Methods: Duodenal tissue was obtained via endoscopy
from 2 patients with iron-deficiency (“ID”), 2 patients with iron-overload (“IO”; one with
HFE-associated iron-overload {HFE+/+} and one with non-HFE related iron-overload), and
2 patients that had the HFE genotype associated with hemochromatosis (C282Y+/+) but
that did not have iron-overload {“NE”; non-expressers}. Total RNA was purified from duo-
denal biopsies and microarray analyses were performed utilizing Affymetrix human genome
gene chips (U133A and U133B or U133 Plus 2.0; representing >40,000 human genes). All
resulting data were within the quality control parameters established by the manufacturer
(Affymetrix). Microarray data were processed by 3 different probe set algorithms (RMA,
dChip, MAS 5.0) and analyzed using regularized t-test. Only differentially expressed genes
(DEGs) which were common to all three probe set algorithms were considered for further
analysis. Results: The following numbers of genes were identified by the different compar-
isons: 77 (IO vs. ID), 49 (NE vs. ID), and 38 (NE vs. IO). Several genes known to be
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involved in intestinal iron transport showed increased expression in the ID patients versus
the NE and IO groups, including Divalent Metal Transporter 1 (DMT1), Iron-Regulated
Gene 1 (IREG1; also called ferroportin), Hephaestin (HP) and Transferrin Receptor 1 (TfR1).
Furthermore, many novel genes were induced in the ID group, including genes that encode
proteins involved in intestinal copper and ascorbic acid transport and in regulating gene
transcription. Conclusions: This pilot study has identified several novel DEGs in the duo-
denum of iron-deficient patients. Further research is indicated to more precisely characterize
the expression of these novel genes and to decipher their physiological roles during disturb-
ances of iron homeostasis. These studies were supported by NIH Grants 1 R21 DK068349
(JFC) and DK002957 (KVK).
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Early Immunomodulator Use Improves 18 Month Outcomes in Pediatric
Crohn’s Disease
Jaya B. Punati, James Markowitz, Trudy Lerer, Jeffrey Hyams, Subra Kugathasan, Anne
Griffiths, Anthony Otley, Joel Rosh, Marian Pfefferkorn, David Mack, Jonathan Evans,
Athos Bousvaros, Susan Moyer, Robert Rothbaum, Robert Wyllie, Vasundhara Tolia, Maria
Oliva-Hemker, Adam Mezoff, Neal Lelieko, J Fernando- Del Rosario, David Keljo, Wallace
Crandall
BACKGROUND AND AIM: 6-mercaptopurine (6-MP)/Azathioprine (AZA) have been shown
to have steroid sparing effects and to maintain remission in pediatric Crohn disease (CD).
We sought to describe 6-MP/AZA use in children with newly diagnosed CD, comparing
outcomes following early vs. late initiation of therapy. METHODS: Patients ≤16 years of
age with newly diagnosed CD were enrolled in a prospective, multicenter (20 site) observa-
tional study (The Pediatric IBD Registry). All patients were managed according to the dictates
of their individual physicians. Patients who received 6MP/AZA and had ≥ 2 yrs follow-up
were identified. Early use of 6MP/AZA was defined as the initiation of therapy within 3
months of diagnosis and late use was defined as initiation of therapy between 3 and 12
months. Moderate to severe disease was defined by physician global assessment or a Pediatric
Crohn Disease Activity Index > 30. RESULTS: Of the 482 children with CD enrolled in the
database, 185 (60% male, mean age 11.6 years) had ≥ 2 years of follow up. Of those 185
children, 94 (51%) started 6-MP/AZA within 3 months of diagnosis, 43 (23%) began between
3 and 12 months, 17 (9%) were started after 12 months and 31 (17%) did not receive
6MP/AZA. Sixty eight percent of patients were categorized as moderate to severe disease at
diagnosis. Eighty six percent of those with moderate to severe disease and 49% with mild
disease at initial presentation received 6MP/AZA within the first year. More severe disease
activity was predictive of 6MP use within the first year (p< .01, OR= 4.6, 95%CI=1.7-12.4)
and showed a trend toward predicting early use (p<.06, OR= 2.5, 95%CI=1.0-6.5). Age,
gender, Tanner stage, disease extent and initial laboratory values were not predictive of
6MP/AZA use. Patients with moderate to severe disease treated with early (n=81) and late
(n=27) 6MP/AZA were compared for the outcomes of corticosteroid use, infliximab treatment,
hospitalizations and surgery. No differences were noted in the rates of infliximab use or
surgery between groups. However at 18 months from diagnosis, the number of patients
who received steroids in the previous 3 month period (12% vs. 33%, p<.05) and the
cumulative rate of patients with at least one hospitalization (26% vs. 48%, p=.05) were
lower in the early group as compared to the late group. CONCLUSIONS: Seventy-four
percent of a large inception cohort of children newly diagnosed with CD were treated with
6MP/AZA within the first year and 81% by the end of 2 years. Early use of 6MP/AZA was
associated with lower rates of corticosteroid use and number of patients hospitalized 18
months after diagnosis.
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Infliximab As a First Choice Therapy in Children with Newly Diagnosed
Crohn’s Disease (CD) Promotes Long-Term Sustained Remission and Alters
the Course of the Disease
Erminia Romeo, Franca Viola, Gianluigi De Angelis, Alessia Vernuccio, Veronica Pannone,
Barbara Bizzarri, Osvaldo Borrelli, Salvatore Cucchiara
Background. Infliximab (IFX), the monoclonal antibody anti-TNF-alpha, is currently indic-
ated for children with CD unresponsive to traditional regimens such as corticosteroids (CS),
immunosuppressors, antibiotics, nutritional therapy. IFX has never been used as a first line
choice in pediatric patients (pts) with a recent diagnosis of CD. Aim. To compare clinical
outcome between pts receiving IFX as initial therapy (group A) and pts treated with a
traditional therapeutic approach (group B). All had an active CD recently diagnosed. Methods.
13 pts of group A (range age 5.9-18.0 years) had a baseline i.v. IFX schedule (5 mg/kg/
dose, 0-2-6 weeks) and 9 of them also underwent IFX retreatment for 12 months every 8
weeks; all also had long term azathioprine (AZA) or methotrexate (MTX). Of 19 pts of group
B (range age: 5-17 years), initial therapy consisted of a nutritional course alone in 5, CS in
14; all received a long term maintenance therapy with AZA (or MTX). At diagnosis all group
A and B pts had an ileo-colonic mucosal disease, 9 of group A and 3 of group B also had
perianal disease (fistulae and/or ulcers). At baseline all underwent ileocolonoscopy with
histology and clinical assessment with the PCDAI, that was also measured after remission
and thereafter. Results (mean±SD): following initial therapy, remission (PCDAI <15) was
achieved in all pts of both groups (A: 9.3 ± 2.4: B: 9.6 ± 2.1 p< 0.01); during the following
12 months, disease relapses (PCDAI > 15) were seen in 1 of group A and in 17 of group
B pts (Fisher’s Exact test: p<0.01); number of relapses was significantly lower in group A
(0.1±0.2.9) than in group B (1.93 ±0.9, p<0.01); 4 group B pts also underwent surgery for
intestinal resection. At the end of the 12 month maintenance treatment, the PCDAI was
markedly higher in group B (22.3± 8.9) than in group A (11.3±1.89, p<0.01) and the ileo-
colon endoscopic score (CDEIS) was markedly lower in group A 6.5 ± 2.8 than in group
B 12.4 ± 4.1. Conclusions. In children with a recently diagnosed CD, the initial therapy
either with IFX or traditional regimens induce clinical remission; however, only use of IFX
suppresses intestinal inflammation and promotes a more prolonged and stable remission.
Our data support the immunological view that the use of a potent immunomodulator in



















Maintenance Therapy with Infliximab Every 8 Weeks Is Superior to Every 12
Weeks in Maintaining Response and Remission in Pediatric Patients with
Moderately to Severely Active Crohn’s Disease
Jeffrey Hyams, Wallace Crandall, Subra Kugathasan, Anne Griffiths, Allan Olson, Jewel
Johanns, Grace Liu, Suzanne Travers, Robert Heuschkel, James Markowitz, Stanley
Cohen, Harland Winter, Gigi Veereman-Wauters, George Ferry, Robert Baldassano
Background & Aims: The REACH study was a multicenter, randomized, open-label study
that evaluated infliximab therapy in children with moderately-to-severely active Crohn’s
disease (CD). Methods: Patients (n=112) with a Pediatric Crohn’s Disease Activity Index
(PCDAI) score >30 received infliximab 5 mg/kg at weeks 0, 2, and 6. Patients responding
to treatment at week 10 were randomized to receive infliximab 5 mg/kg every 8 weeks or
every 12 weeks through week 46 and followed through week 54. The primary endpoint
was clinical response at week 10 (decrease from baseline in the PCDAI score > 15 points,
and a total score < 30, at week 10). Clinical remission was defined as a PCDAI score < 10
points. The median age was 13 years, the median duration of disease was 1.6 years. Results:
At week 10, 99 of 112 (88.4%) patients responded to infliximab (95% confidence interval:
82.5%, 94.3%) and 66 of 112 (58.9%) patients achieved clinical remission (95% confidence
interval: 49.8%, 68.0%). At week 54, 33 of 52 (63.5%) and 29 of 52 (55.8%) patients
receiving infliximab every 8 weeks were in clinical response and clinical remission, respect-
ively, compared with 17 of 51 (33.3%) and 12 of 51 (23.5%) patients receiving treatment
every 12 weeks (p=0.002 and p<0.001, respectively). The clinical response rates of patients
with age < 13 yrs and > 13 yrs, with disease duration < equal to 1 yr and >1 yr and with
disease in the colon and in the small intestine were similar at week 10. Adverse events, and
serious adverse events including serious infections were comparable among patients treated
with infliximab every 8 weeks vs patients treated every 12 weeks. Safety findings in children
were also comparable to those observed in adults. Conclusions: Response to infliximab
approached 90% at week 10 and was similar regardless of age, disease duration, and location
of disease. Maintenance dosing with infliximab every 8 weeks was superior to every 12
weeks dosing in maintaining response and remission.
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Natural History of Crohn’s Disease in Children : A Population-Based Cohort
Study in Northern France
Mamadou Balde, Gwenola Vernier-Massouille, Corinne Gower-Rousseau, Dominique
Turck, Jean-Louis Dupas, Olivier Mouterde, Jean-Louis Salomez, Eric Lerebours, Antoine
Cortot, Jean F. Colombel
Background and methods : The natural history of Crohn’s disease (CD) in children is poorly
described and a limited number of population-based studies is available. In a geographically
derived incidence cohort diagnosed from 1988 to 2002 we identified all patients with onset
of CD before the age of 17 years to describe their clinical course and morbidity. Results
[median (range)] : 424 cases of childhood CD were recorded (8 % of all CD cases in Northern
France). The mean standardized incidence was 2.3/105. Follow-up information is available
to date in 304 children (72%) (167 M and 137 F) for a median follow-up of 69 mos (41-
107). CD location at diagnosis and last follow-up was both small bowel and colon (65%
and 83% respectively), colon only (18.5% and 8.5%), small bowel only (15% and 8%).
Upper gastrointestinal tract lesions were present in 18% of patients at diagnosis and in 30%
at follow-up. Anoperineal lesions were present in 30% of patients at diagnosis and in 52%
at follow-up. 84% of children required treatment with corticosteroids within the first year
after diagnosis. Corticosteroid resistance occurred in 9.5% and corticosteroid dependence
in 51%, 11 mos (4-24) after corticosteroids were started. Immunomodulators were prescribed
in 173 children (57 %) after 18 mos (9-33)(all received azathioprine and 42 azathioprine
followed by methotrexate) with a response in 68%, intolerance in 13% and failure in 9%.
Sixty-five children (21%) received infliximab with a response in 81%. The cumulative
probability of resection surgery was 8.1% at 1 year, 19.5% at 3 years and 32.2% at 5 years.
Time between diagnosis and surgery was significantly longer in children who received
immunomodulators than in those who did not [44(24-181) vs 11.5(4-43); p<0.01]. In these
two groups, the cumulative probabilities of surgery were 2.4 % and 16.7 % at 1 year
(p<0.01), 16.7 % and 23.7 % at 3 years (ns) and 31.8 % and 32.9 % at 5 years (ns)
respectively. No death occurred in this cohort. Conclusion : In one of the largest available
population-based cohorts, childhood-onset CD was characterized by an extensive disease,
frequent anoperineal lesions, a high percentage of patients treated early with steroids followed
by a dependence in more than half. Immunomodulators seemed to prolong time to surgery
but this effect was not sustained at 5-year follow-up.
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Height of Growth Delayed Children with Active Crohn’s Disease Improves
During Treatment with Infliximab
Anne Griffiths, Jeffrey Hyams, Wallace Crandall, Subra Kugathasan, Allan Olson, Jewell
Johanns, Grace Liu, Aparna Raychaudhuri, Suzanne Travers, Robert Heuschkel, James
Markowitz, Stanley Cohen, Harland Winter, Gigi Veereman-Wauters, George Ferry, Robert
Baldassano
Background & Objectives: Delayed linear growth is a common problem in children with
moderately to severely active Crohn’s disease. The effect of infliximab on growth was
examined in children with growth delay at the time of entry into the REACH study (a
multicenter, randomized, open-label study that evaluated infliximab therapy in children
with moderately to severely active Crohn’s disease). Methods: Children (n=112) with a
Pediatric Crohn’s Disease Activity Index score >30 received infliximab 5 mg/kg induction
treatment at weeks 0, 2, and 6. Patients responding to induction treatment assessed by the
principal investigators at week 10 (n=103) were randomized to receive infliximab 5 mg/kg
every 8 weeks or every 12 weeks through week 46 and followed through week 54. Height
status z scores, which adjust for age and gender, were calculated using the SEER database
at baseline, and Weeks 30 and 54 for the subgroup of children with at least a 1 year delay
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in bone age (as measured by a wrist radiograph) at the time of study entry (n=38). Results:
At week 0, the median height status z score was -1.6 and the mean height status z score
was -1.5. The mean height status z scores were significantly improved from baseline at both
Week 30 (mean = 0.3, p<0.001) and Week 54 (mean = 0.5, p<0.001), in the combined
infliximab dose groups. At Week 54, the improvement in height status was greater in patients
in the every 8 week maintenance treatment group with 43.5% improving their z score by
at least 0.5 standard deviation and 13.0% improving their z score by at least 1 standard
deviation in contrast to 20.0% and 6.7% respectively in the q12 week maintenance treatment
group. Conclusions: Infliximab significantly improved the height status of children with
moderately to severely active Crohn’s disease who had a 1 year delay in bone age.
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Inter-Center Variation in the Initial Management of Children with Crohn’s
Disease
M Kappelman, A Bousvaros, J Hyams, J Markowitz, M Pfefferkorn, S Kugathasan, J Rosh,
A Otley, D Mack, A Griffiths, J Evans, R Grand, C Langton, J Finkelstein
Background and Aims: Recent data suggest that early use of immunomodulators and
biologics may prolong remission in children with Crohn disease (CD). Because there are
no practice guidelines for the management of pediatric IBD, considerable variation in the
timing and usage of available therapies may exist. We performed this study to determine
the extent of inter-center variation in the initial treatment of children with CD. Methods:
Since 2002, newly diagnosed children with IBD at 20 North American pediatric centers
have been prospectively followed and comprise the Pediatric IBD Collaborative Group
Registry. Patients are managed according to the usual practices of their physicians, and not
by protocol. All patients with CD and at least 3 months of follow-up were eligible to be
included in this study; final analysis was based only on patients from centers contributing
≥ 20 such patients. Using logistic regression to control for disease severity (Physician Global
Assessment), age, gender, and race, we compared initial utilization (within 3 months of
diagnosis) of systemic steroids, immunomodulators (6 MP, azathioprine, and methotrexate),
5-aminosalicylates, antibiotics, and infliximab among our study centers. Results: Data from
321 patients (10 centers) were analyzed. 72% of patients presented with moderate/severe
disease; severity did not differ by center. Initial treatment, however, varied greatly. Variation
was statistically significant for treatment with prednisone, immunomodulators, 5-aminosal-
icylates, and antibiotics, and remained significant after adjusting for disease severity and
demographic factors. For infliximab, inter-center variation after adjustment approached
statistical significance. Table 1 provides the overall proportion of patients receiving each
treatment, the range among the centers, and adjusted p values obtained from logistic regres-
sion. Conclusions: Considerable inter-center variation exists for the initial management of
children with CD, even after adjusting for demographic factors and disease severity at
presentation. Efforts to reduce this variation, such as the implementation of clinical practice
guidelines, may be an important step in improving the care for these children.
Table 1: Proportion of Patients Receiving each Treatment by Center
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Endoscopic Ultrasonography and MRI-Pancreatography in the Evaluation of
Patients with Suspected Chronic Pancreatitis: Are Both Imaging Techniques
Required?
Julio Iglesias-Garcia, Carmen Villalba, Jose Larino-Noia, Enrique Dominguez-Munoz
Endoscopic ultrasonography (EUS) and magnetic resonance (MRI) plus MRI-pancreatography
(MRP) are becoming the methods of choice for the diagnosis of chronic pancreatitis (CP)
in clinical practice. Whether the information provided by EUS and MRI-MRP is superimpos-
ible or complementary is unknown. Aim: To compare and correlate EUS and MRI-MRP
findings in patients with clinical suspicion of CP. Methods: 26 consecutive patients (mean
age 48 years, range 28-70, 14 male) with clinical suspicion of CP were prospectively evaluated.
EUS and MRI-MRP were performed 2 to 7 days apart. EUS was performed under conscious
sedation by an endoscopist blinded to MRI findings. Parenchymal and ductal EUS criteria
for CP were evaluated. CP was defined by the presence of ≥3 criteria. Pancreas MRI with
gadolinium i.v. and MRP with secretin i.v. were performed by a radiologist blinded to EUS
findings. Parenchymal enhancement after gadolinium and ductal changes before and after
secretin injection were evaluated. CP was defined by the presence of at least one parenchymal
and one ductal change at MRI-MRP. Data are shown as median and 95%CI. Concordance
and correlation studies (Kappa score, Spearman correlation, chi-square, and Wilcoxon test
for paired data) were performed. Results: CP was diagnosed by both EUS and MRI-MRP in
17 patients (65.4%), whereas the disease was consistently excluded in 4 patients (15.4%).
Therefore, EUS and MRI-MRP provided with the same diagnosis in 21 patients (80.8%).
The MRI-MRP finding was considered as equivocal in the remaining 5 patients, three of
them with normal EUS and two with EUS criteria of CP. Diagnostic concordance was highly
significant (kappa score 0.60; 95%CI 0.36-0.84) (p<0.00001). The number of parenchymal
criteria at EUS correlated with the signal intensity ratio at MRI (p=0.008). Patients with ≥3
parenchymal EUS criteria have a lower signal intensity ratio at MRI than patients with ≤2
EUS criteria (1.24 [IC95% 1.07-1.41] vs 1.69 [IC95% 1.38-2.0]; p=0.063), and maximal
MRI enhancement occurred at the venous phase and the arterial phase, respectively (p<0.05).
Patients with abnormal pancreatic duct at MRP before secretin injection is associated with
more EUS ductal criteria (4.5; 95%CI 3.9-5.0) than patients with abnormal pancreatic duct
only after secretin injection (3.0; 95%CI 1.7-4.3), and these in turn more than patients with
normal duct at MRP (1.5; 95%CI 0.3-2.6) (p<0.05). Conclusion: Both EUS and MRI-MRP
are accurate methods to evaluate pancreatic changes in the context of CP. The information
provided by both imaging techniques is highly concordant, so only one of them is enough
to establish the diagnosis of CP in most cases.
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Combined Pancreatic Juice IL-8 Concentration and EUS Are Highly Predictive
to Diagnose Chronic Pancreatitis
Surakit Pungpapong, Kyung W. Noh, Mohammed Al-Haddad, Michael B. Wallace,
Timothy A. Woodward, Massimo Raimondo
Background: The diagnosis of chronic pancreatitis (CP) remains challenging. EUS seems to
be highly sensitive, but not specific enough to diagnose CP. Pancreatic juice IL-8 concentra-
tion has been proposed as a specific marker for pancreatic diseases. In this study, we aim
to compare the diagnostic accuracy of pancreatic juice IL-8 concentration and EUS to
diagnose CP. Methods: Seventy-nine patients presenting at our pancreas clinic with abdominal
pain suspicious for CP were prospectively enrolled in the study from January 2003 to
December 2004. EUS was performed with Olympus radial and linear echoendoscopes. The
diagnosis of CP by EUS was established when 4 or more of the previously established criteria
were present. After intravenous secretin (0.2 μg/kg) was administered, pancreatic juice
emptied into the duodenum was collected and immediately frozen in liquid nitrogen until
IL-8 concentration was measured by a modified ELISA assay. The diagnosis of CP was made
when pancreatic juice IL-8 concentration was 20 pg/mL or higher. Final diagnosis of CP
was made by the referring gastroenterologist using the composite gold standard: ERCP,
histology, CT or MRI, and clinical follow-up (mean 18 months). Results: Thirty-eight patients
(mean age 56 years; male 42%) were diagnosed with CP, whereas 41 patients were found
to have no pancreatic diseases and therefore considered as controls (mean age 49 years;
male 29%). No significant differences were demonstrated in age and gender distribution.
The accuracy of EUS to diagnose CP was 80% with sensitivity and specificity of 71% and 88%,
respectively. The accuracy of pancreatic juice IL-8 concentration was 71% with sensitivity and
specificity of 47% and 93%, respectively. EUS was significantly more sensitive, but equally
accurate and specific to diagnose CP compared to pancreatic juice IL-8 concentration.
Combining the findings of EUS and pancreatic juice IL-8 concentration, the sensitivity and
specificity significantly increased to 82% (either EUS or IL-8 positive) and 100% (both
EUS and IL-8 positive), respectively. Conclusions: Both EUS and pancreatic juice IL-8
concentration are accurate diagnostic modalities for the diagnosis of CP. Pancreatic juice
collection can be performed at the time of EUS. EUS and pancreatic juice IL-8 concentration
are complementary with higher sensitivity and specificity when both are used together. If
confirmed in larger series, the combination of EUS with pancreatic juice IL-8 will be highly
predictive of CP.
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Stopping Smoking At the Clinical Onset of Chronic Pancreatitis Reduces the
Risk of Developing Pancreatic Calcifications
Talamini Giorgio, Massimo Falconi, Nora Sartori, Marina Mastromauro, Claudio Bassi,
Paolo Pederzoli, Italo Vantini
Cigarette smoking is associated with a higher risk of developing chronic pancreatitis and
increases the likelihood of developing pancreatic calcifications. It is not known whether
stopping smoking is capable of modifying the course of this disease. Methods. We reviewed
701 chronic pancreatitis patients with well known smoking and drinking habits and selected
a subgroup of patients with follow-up longer than 6 years and with no calcifications by the
end of the 5th year. A total of 360 patients with the above-mentioned characteristics were
identified. Three groups of patients were studied: smokers, non-smokers and patients who
stopped smoking within 5 years of onset of symptoms of chronic pancreatitis. In the actuarial
analysis the 6th year from onset of symptoms was taken as time 0. Results. The 360 patients
selected comprised 43 females (11.9%) and 317 males (88.1%) with a mean age of 38.7
years (SD 11.4). The median follow-up was 19.0 years (25th percentile 13.0; 75th percentile
24.0). The chronic pancreatitis was alcohol-associated in 255 patients, familial in 10, obstruct-
ive in 54, and idiopathic in 41. At the end of follow-up 212 patients (59.8%) developed
calcifications. Thirty-seven patients stopped smoking. Smokers were 317 (88.1%) with a
mean total of 23.4 cigarettes smoked daily. Drinkers drank a mean amount of 147 grams
of alcohol daily. As regards the risk of calcifications, non-smokers and ex-smokers had
similar actuarial survival curves and these were significantly different from the curve for
smokers (p<0.003). Cox multivariate actuarial analysis supported these data. Considering
non-smokers as the reference class, ex-smokers had an Odds Ratio (OR) of 0.56 (0.2-1.4;
p=ns), patients smoking 1-10 cig/day an OR of 1.95 (1.1-3.4; p<0.019), patients smoking
11-20 cig/day an OR of 1.76 (1.1-2.8; p<0.018), and those smoking > 20 cig/day an OR
of 1.79 (1.1-2.9; p<0.019). Conclusion. Stopping smoking within 5 years of clinical onset
of chronic pancreatitis reduces the subsequent risk of developing pancreatic calcifications.
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Abnormal Pancreatic Duct Morphology Is Highly Suggestive of Pancreatic
Acinar Cell Dysfunction
Mansour A. Parsi, Darwin L. Conwell, Gregory Zuccaro, John A. Dumot, John J. Vargo
Background: Chronic pancreatitis is characterized by morphological ductal and parenchymal
changes that typically lead to loss of function. The correlation of pancreatic ductal changes
and acinar cell function has not been well studied and is poorly understood. Hormone
stimulated pancreatic function testing allows comparison of secretory function to radiologic
imaging. Aim: To assess whether pancreatic ductal morphology by endoscopic retrograde
pancreatography (ERP) can predict pancreatic acinar cell function. Methods: 35 patients
with chronic abdominal pain and suspected chronic pancreatitis prospectively underwent
an ERP and an endoscopic pancreatic function test (ePFT). The pancreatograms obtained
at ERP were scored by 3 experienced endoscopists in a blinded fashion based on the
Cambridge classification. The final score was based on consensus among at least 2 endoscop-
ists or if no consensus, based on the average of the 3 scores. The ePFT was performed after
continuous intravenous infusion of synthetic CCK (Sincalide 40 ng/kg/h) as previously
described. Duodenal fluid was collected with an upper endoscope during endoscopy at
30,40,50, and 60 minutes during infusion and the peak lipase concentration was determined
(Normal > 800,000 IU/L). Results: In 18 patients the pancreatogram showed morphological
changes consistent with chronic pancreatitis. The median and interquartile range (IQR)
Cambridge score in this group was 3 (2-3) and the median (IQR) peak lipase concentration
was 268,700 (148,000-425,350). Seventeen patients had normal pancreatograms with
median (IQR) peak lipase of 435,000 (328,400-628,000). The correlation between the
Cambridge score and the peak lipase concentration was 0.42 using the Spearman correlation
test (p=0.01). The sensitivity, specificity, and the positive and negative predictive values of
ERP for detecting patients with pancreatic insufficiency was 57%, 80%, 94% and 24%
respectively. Conclusion: There is a poor correlation between the pancreatic duct morphology
by ERP and pancreatic acinar cell function by ePFT. However, an abnormal pancreatogram
is highly suggestive of pancreatic acinar cell dysfunction with presence of pancreatic insuffi-
ciency. For practical purposes, in patients with pancreatic duct abnormality by ERP, pancre-
atic insufficiency can be assumed. In patients with normal pancreatic duct morphology, a
dedicated pancreatic function test is necessary to assess for presence or absence of pancre-
atic insufficiency.
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Clinical Aspects of Chronic Pancreatitis Associated with Gene Mutations
Luca Frulloni, Chiara Scattolini, Giulia Martina Cavestro, Cecilia Pravadelli, Laura
Bernardoni, Anna Katsotourchi, Paolo Bovo, Riccardo Manfredi, Rossella Graziani, Giorgio
Cavallini
Background: Mutations of CFTR gene, SPINK1 gene, and K8 gene have been associated
with chronic pancreatitis (CP). The clinical outcome of CP associated with gene mutations
(CPgm) seems to be different from CP secondary to other aetiologies. Aim of this study was
to compare clinical and radiological findings between CPgm and CP with negative genetic
tests (CPwt). Patients and Methods: We collected clinical and radiological data from all CP
patients referred to our Dpt between 2000 and 2005. All patients underwent genetic tests
for 18 CFTR gene mutations, N34S mutation on the SPINK1 gene and G61C gene mutation
on the K8 gene. We study 400 unrelated partners of cystic fibrosis pts as control group for
CFTR gene mutations, and 200 blood donors as control subjects for K8 and SPINK1 gene
mutations. Results: We found 39 out of 143 (27.3%) pts with CPgm, of whom 23 (16.1%)
with CFTR gene mutations, 11 (7.7%) with SPINK1 gene mutation and 7 (4.9%) with K8
gene mutation. The relative risk to develop CP was 5.29 (CI 2.64 - 10.6) for CFTR, 16.6
(CI 2.2 - 129.9) for SPINK1 and 10.24 (CI 1.25 - 84.2) for K8. The mean age at the onset
of the disease was younger in CPgm (37.3 ± 17.3 yrs) than in CPwt (44.4 ± 12.3 yrs) (p=
0.007). Female sex was significantly more frequent in CFTR pts (59%) than in SPINK1
(30%), K8 (17%) and CPwt (27%) (p= 0.025). Heavy drinkers were more frequently found
in CPwt (40%) than in CPgm (8%) (p<0.0001), as well as smokers (78% vs 34%; p<0.0001).
Pancreatic calcifications were less frequent in CFTR (50%) pts than in SPINK1 (90%) and
K8 (83%) groups (p=0.053). Exocrine and endocrine pancreatic insufficiency appeared less
frequently and later in pts with CFTR and SPINK1 than in K8 gene mutations and in CPwt.
Conclusions: Clinical and radiological findings and the evolution of the disease are different


















Glucidic Homeostasis Improvement After Endoscopic Ductal Drainage in
Chronic Pancreatitis
Pierre Deprez, Helene Devroye, Jean-Paul Thissen, Yves Horsmans, Jean-Francois Gigot,
Michel Hermans
Chronic pancreatitis is characterized by progressive parenchymal fibrosis, ductal obstruction
and calcification of the pancreas. One of the common complications of the disease is the
onset of “secondary” diabetes, which is the result of the progressive destruction of the
Langerhans islets. The influence of medical, endoscopic and surgical therapy in chronic
pancreatitis on endocrine function has received little attention in clinical research. The aim
of our study was to evaluate the impact of endoscopic drainage on endocrine function in
chronic pancreatitis. Our hypothesis was that an efficient drainage of the obstructed ducts
might improve endocrine pancreatic insufficiency and/or secondary diabetes of these patients.
Patients and methods: prospective study including patients with chronic pancreatitis (CT-
EUS-MRI or ERCP proven) and an indication for endoscopic drainage (pain, duct dilation,
pseudocyst). Endocrine function was evaluated by glycosylated hemoglobin levels and HOMA
test before and after (1 and 3 months) ductal decompression. Inflammatory (WBC and CRP)
and nutritional (weight, BMI, fat mass, IGF-1, prealbumin, Cu, Zn, Se levels) parameters
were recorded. Results: 34 pts were included between, mean age 54 y ± 12; mean BMI was
21.2 ± 3.1 kg/m2. Etiology was alcohol in 19 and obstructive or genetic or idiopathic in
15. Smoking was present in 56%, calcifying pancreatitis in 73.5%, exocrine insufficiency
in 65% and diabetes in 35%. At the first visit, we observed a significantly worse endocrine
function in patients with pancreatitis caused by alcohol and smoking, with calcifying pancreat-
itis and when exocrine insufficiency was present (P<0.01). After endoscopic drainage (suc-
cessful in 81% of pts), increase in the β cell function was significant in the group of patients
with less severe (non calcifying) pancreatitis (76% before vs. 101.2% after drainage, P<0.05)
and reduction in glycosylated hemoglobin was significant in the diabetic subgroup (7.1%
before vs. 6.1% after drainage, P<0.05) Conclusion: patients with non calcifying pancreatitis
appear to be the favorite candidates for endoscopic drainage which seems to be more efficient
on endocrine functional recovery when it is carried out early in the course of the ductal
obstruction. However, glucidic homeostasis was also improved in the more severe pancreatitis
group with a reduction in glycosylated hemoglobin levels, suggesting that endoscopic drain-
age might also be a valuable option.
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Effect of Acid Inhibition On Reflux Symptoms Depends On Symptom
Association Probability
Marissa C. Aanen, Bas L. Weusten, Mattijs E. Numans, Niek J. de Wit, Melvin Samsom
Introduction In patients with heartburn the symptomatic response to a proton pump inhibitor
(PPI) is variable. We hypothesized that the highest response to PPI treatment can be expected
in patients in whom a proven relationship exists between symptoms and reflux events.
Methods Seventy-four heartburn patients were categorized into 4 groups according to pres-
ence or absence of pathological reflux, defined as pH<4 >6% of the time (pH+/pH-) and
positive and negative SAP (SAP+/SAP-). During 7 days off and 13 days on esomeprazole 40
mg daily subjects kept a diary in which overall symptoms (O) and heartburn (H) were
scored from 0 [absent] to 5 [very bad]. Data are presented as mean (7 days off PPI vs. last
7 days on PPI) and analysis was performed with Kruskal-Wallis tests. Results The 4 groups
(SAP+pH+ (n=40); SAP+pH- (n=12); SAP-pH+ (n=10); SAP-pH- (n=10)) were similar in
age and gender. Pre-treatment scores were highest in the SAP+pH+ and SAP+pH- subgroups.
In all subgroups of patients a reduction in reflux symptoms was seen. The greatest reduction
was achieved in SAP+pH+ subjects (ΔO p<0.01,ΔH p<0.02). The residual symptom scores
on treatment were lowest in SAP+pH+ and SAP-pH+ subjects (O p<0.01, H ns) and relatively
high in the SAP+pH- subjects. Conclusion The best response to PPI treatment was found
in patients with positive SAP and pathological reflux. Subjects with a positive SAP and
physiological reflux responded less favorably, presumably reflecting the element of visceral
hypersensitivity in these patients.
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Adherence and Persistence to Proton Pump Inhibitors in Daily Clinical
Practice
Eva van Soest, Peter D. Siersema, Jeanne P. Dieleman, Miriam C. Sturkenboom, Ernst J.
Kuipers
Purpose: The worldwide expenditure on proton pump inhibitors (PPIs) is high and further
increasing. The adherence to daily prescriptions is thought to be high, but it is currently
not well known how PPIs are actually being used under everyday circumstances. We therefore
aimed to analyse the PPI usage pattern by indication in the general population. Methods:
We conducted a cohort study using the IPCI database, a general practice research database
containing the complete, longitudinal electronic medical records of 600,000 persons through-
out the Netherlands. For all persons who had started PPI treatment between 1996 and 2003,
persistence (treatment duration) and adherence (medication possession ratio) with treatment
were calculated. Potential predictors of persistence and adherence were identified. Results:
During the 8-year study period, 17,813 persons started PPI treatment. Persistent use was
seen in 25% of patients after 1 year and in 19.5% after 2 years. One-year persistence was
highest in patients using PPIs for gastroprotection with aspirin (42%), and if taken for
gastro-esophageal reflux symptoms (30.6%). Fifteen percent of patients with non-reflux
dyspepsia or Helicobacter pylori-associated disease used PPIs for at least 1 year. A specialist
visit in the year prior to PPI treatment, presence of co-morbidity, increasing age and use of
co-medication were associated with longer persistence. Overall, 55% of patients had an
adherence level ≧80%, meaning that they were at least 80% of time on treatment. Patients
using PPIs in combination with aspirin were most adherent (61.5% with adherence level
≧80%). Adherence increased with age and use of co-medication. Subgroup analysis showed
that patients with Barrett’s esophagus (BE) were not only more persistent (66% after 1 year),
but also more adherent (64% with adherence level ≧80%) compared to the whole group
of PPI users. Conclusions: The majority of patients (75%) stop PPI use within one year,
however at least 15% of patients with an indication for short-term treatment used PPIs
longer than 1 year. Almost half of the patients use PPIs on a non-continuous basis (adherence
level <80%), indicating intermittent or on-demand use. The consequences of these usage
patterns are probably minor in patients treated for symptom control only. However, infre-
quent use of PPIs may have a more serious impact if prescribed for other purposes, such
as treatment of BE or gastroprotection with non-steroidal anti-inflammatory drugs or aspirin.
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Positive Association Between Intragastric and Intraesophageal Acid Control
and Healing of Los Angeles Grade C and D Erosive Esophagitis: Results of a
Prospective, Controlled Clinical Trial
Philip O. Katz, Gregory G. Ginsberg, Paul Hoyle, Mark B. Sostek, John Monyak, Debra
G. Silberg
BACKGROUND & AIM: Acid control has been considered to be a surrogate marker for
clinical efficacy (EE [erosive esophagitis] healing and symptom control). However, the
relationship between efficacy for EE healing and acid control has not been prospectively
established. This study’s aim was to assess the relationship between the percentage of time
intragastric pH is >4 and the healing of EE, using an acid suppression drug. Also assessed
was the relationship between intragastric acid control and gastroesophageal reflux disease
(GERD) symptom control. METHODS: In this 28-site, double-blind, exploratory study
(D9612L00062), adult patients with endoscopically verified Los Angeles grade C or D EE
were randomly assigned to oral esomeprazole 10 or 40 mg once daily for 4 weeks. At
treatment day 5, patients underwent a dual-electrode, intraesophageal and intragastric,
catheter-based, 24-hour pH study. The electrodes were placed 5 cm above and 10 cm below
the proximal border of the lower esophageal sphincter (15 cm apart). At 4 weeks, an
endoscopist blinded to the pH study results assessed EE healing status. Investigators scored
GERD symptoms before treatment and at 4 weeks, before the final endoscopy, as none (0),
mild (1), moderate (2), or severe (3). Analyses included patients who satisfactorily completed
the pH study and final endoscopy, and met predetermined protocol criteria. A t-test was
used to compare the percentage of time pH was >4 for healed vs unhealed patients. Spearman
rank correlations (r) and tests of significance were done for percentage of time pH was >4
and investigator-assessed symptom scores. RESULTS: Of 103 patients who had evaluable
data (mean age, 48.7 years; 65% men), EE was healed in 69.9% at 4 weeks. Mean percentages
of time intragastric pH was >4 at day 5 in patients with healed and unhealed EE were 61.3%
and 42.1%, respectively (P = .0002). EE healing rates were positively related to the percentage
of time intragastric pH was >4. A post hoc analysis showed a significant difference in the
percentages of time intraesophageal pH was >4 between healed and unhealed patients (95.2%
and 88.9%, respectively; P = .0059). Better control of gastric acid was also correlated with
lower final heartburn and acid regurgitation symptom scores (r = -29% and -21%; P = .003
and .032, respectively). CONCLUSION: This is the first prospective study to show a positive
relationship between intragastric and intraesophageal acid control and the clinical outcomes
of EE healing and symptom control. These data support the importance of intragastric pH
as a surrogate marker for drug efficacy. Supported by AstraZeneca LP
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The Effect of Baclofen On Esophago-Gastric Motility and Gastroesophageal
Reflux in Children with GER Disease
Taher Omari, Marc Benninga, Ross N. Butler, Lloyd Sansom, John Dent, Geoffrey P.
Davidson
INTRODUCTION: The GABA(B) agonist baclofen has been shown to inhibit transient LES
relaxation (TLESR) and thereby diminishing gastroesophageal reflux (GER) in adults and
animal models. The aim of this study was to evaluate the effect of baclofen on the rate of
TLESRs, GER and gastric emptying (GE) in neurologically normal children with GER disease
(GERD). METHODS: The efficacy of 0.5mg/kg baclofen was evaluated in a randomised
double blind placebo controlled trial. Thirty children with GERD ranging from 2-17 years
were enrolled. Patients were intubated with a manometric/pH assembly and positioned
recumbently. Patients were given a milk drink consisting of 250ml of full cream cow’s milk
and then esophageal motility and pH were measured for two hours (Control period). Baclofen/
placebo was then administered via the assembly and after a one hour a second identical
drink was given and esophageal motility and pH measured for a further two hours (Test
period). 13C Na-octanoate (100mg) was added to the second meal for breath test measure-
ment of gastric half emptying time (GEt1/2). TLESRs and GER occurring during the control
and test periods were analysed using standard criteria and compared. RESULTS: Baclofen
produced a significant reduction in the number of TLESRs (mean 7.3±1.5 vs 3.6±1.2 TLESR/
2h, p<0.05) and acid GER (mean 4.2±0.7 vs 1.7±1.0 TLESR+GER/2h, p<0.05) during the
Test period compared to Control. GE rate was significantly faster in children receiving
baclofen compared to placebo (median [IQR] GEt1/2 61 [39, 81] vs 114 [67, 170] min,
p<0.05). In children who received baclofen, GEt1/2 was also less frequently ‘delayed’ com-
pared to age matched controls (29% vs 64%% in placebo group, p=0.066) and 13CO2
excretion curves used in for the estimation of GE were less frequently multi-peaked (29%,
vs 86% in placebo group, p<0.01). Baclofen did not significantly alter swallowing rate, the
patterning of esopageal peristalsis, or LES pressure. CONCLUSION: We conclude that
baclofen inhibits TLESR and GER and accelerates GE in children with reflux disease. An
acceleration of GE may explain the improvement in symptoms of emesis previously reported
in the children with neurological disease and GER who were given baclofen. This trial was
supported by the Women’s & Children’s Hospital Research Foundation, the JH & JD Gunn
Medical Research Foundation and AstraZeneca R&D.
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Influence of Gastric Motility Modifying Drugs On the Postprandial Acid and
Bile Pockets At the Gastro-Esophageal Junction
Raf Bisschops, Daniel Sifrim, Rita Vos, Jozef Janssens, Jan Tack
Gastro-oesophageal reflux (GOR)occurs mainly postprandially and is more pronounced in
the distal oesophagus. Fletcher et al (2001) have previously established that a pocket of
highly acidic gastric juice is present at the gastro-oesophageal junction (GOJ) after intake
of a solid meal in healthy volunteers. Bilitec® studies have shown that a “bile pocket” is
also present at the GOJ in some subjects. Factors that determine the location and the extent
of the acid and bile pockets have not been identified, but gastric motility is likely to play
a role. The aim of the current study was to investigate whether altering gastric motility
would affect the location and the extent of postprandial acid and bile pockets in healthy
volunteers. Methods: 16 healthy volunteers underwent acid and bile pocket studies on 3
different occasions, at least one week apart. LES position was determined preprandially with
pull-through manometry. Dual pH electrode and Bilitec® probe stepwise pull-through (1cm/
min, LES-10 to +5cm) was performed before and 10, 30 and 50 min after a liquid meal (200
ml Nutridrink®, 300 Kcal). At the start of the meal, saline, the gastrokinetic erythromycin 200
mg i.v. or the gastric relaxant sumatriptan 6 mg s.c. were administered in a randomized
fashion. Results: After saline pre-treatment, a significant pH drop of on average 2.26±0.56
units to a nadir pH of 2.71±0.68 (p< 0.05), was present between LES-2 and +2cm, 10
minutes after the meal. A similar pattern was found after 30 and 50 min with pH drops of
1.59±0.40 and 1.68±0.42 units to nadir pHs of 2.02±0.45 and 1.74±0.47. Erythromycin
significantly suppressed the pH drop at the GOJ at 10 min to 0.66±0.17 units and a nadir
pH of 3.43±0.89 (p<0.05 compared to saline), with comparable patterns at 30 and 50 min
(nadir pH resp. 4.20±1.08 and 4.13±1.07, p<0.05). Intragastric pH at 50 min was higher
after erythromycin (4.19±1.05 vs. 5.40±1.39, p<0.05). Sumatriptan was associated with a
pH drop of 2.04±0.54 and nadir pH 2.16±0.58 at 10 min (NS). The position of the acid
pocket relative to the LES was not altered by sumatriptan. However, at 30 and 50 min the
nadir pH after sumatriptan was significantly lower (resp. 2.02±0.54 and 1.74±0.47, p<0.05).
A “bile pocket” (segmentary rise in Bilitec® absorbance>0.14) was seen in 49% of pull-
throughs after saline, compared to 76% after erythromycin (p<0.05) and 24% after sumatrip-
tan (p<0.05). Conclusion: Gastric motility modifying drugs have a major influence on the
presence of postprandial acid and bile pockets at the GOJ in health. Enhanced motility
disrupts the acid pocket but increases occurrence of a bile pocket, while motor inhibition
has the opposite effect.
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Intestine Specific Deletion of Math1 Reveals Its Roles in Epithelial Cell Fate
Determination and Homeostasis
Noah F. Shroyer, Vincent Y. Wang, Huda Y. Zoghbi
Background: Math1 (Mouse atonal homolog 1; Atoh1) is a basic helix-loop-helix transcription
factor essential for formation of Paneth, goblet, and enteroendocrine cells. The aims of this
study were to generate and characterize mice that lack Math1 in the intestinal epithelium.
Methods: We used homologous recombination in ES cells to generate mice bearing a
conditional Math1 allele flanked by loxP sites (Math1 flox). Math1 flox mice were crossed to
Fabpl4x at -132-cre mice to generate intestine-specific Math1-ablated mice (Math1 Δintestine).
Histological, immunochemical, and gene expression analysis was performed on small and
large intestine of Math1 Δintestine and wild type littermates. Results: Math1 Δintestine mice
were viable and fertile. Their growth and adult weight was not significantly different than
wild type littermates. Analysis of cre-mediated recombination showed a mosaic pattern with
75-80% deletion of Math1 in the distal ileum, and 80-90% deletion in the cecum and colon.
Due to their clonal nature, crypts were either wild type or Math1-ablated, whereas villi were
polyclonal showing mixed wild type and Math1-ablated epithelium. Math1-ablated crypts
lack all secretory lineages (Paneth, goblet and enteroendocrine cells). Immunostaining
revealed loss of transcription factors important for differentiation of the secretory lineages
(e.g., Gfi1, Ngn3, GATA5, GATA6) We found increased proliferation but unchanged
apoptosis in Math1-ablated crypts. Fate mapping with the Math1 lacZ allele suggests that
cells fated to become secretory cells undergo a fate switch and differentiate as absorptive
enterocytes. Abnormal mucosal architecture was observed in adult Math1 Δintestine mice,
with branched villi in the ileum and branched and cystic crypts in the colon; this phenotype
became more prominent in older animals, but survival of animals up to one year was not
compromised. Conclusions: Our results confirm that Math1 is required for intestinal secret-
ory cell specification, and that Math1 functions upstream of genes involved in differentiation
of the secretory lineages. We further demonstrate that in the absence of Math1, progeny
from the intestinal crypt adopt an absorptive fate. We find abnormal proliferation in crypts
lacking Math1, and suggest that this aberrant proliferation leads to the abnormal mucosal
morphology seen in adult Math1 Δintestine mice. Math1 Δintestine mice will serve as a useful
model to study the effects of loss of secretory lineages in a normal physiologic milieu.
This work was supported by HHMI, FDHN, and NIH (DK56338, DK7664, DK63747,
and DK71686).
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Identification of Sonic and Indian Hedgehog Activity During Small Intestine
Morphogenesis
William Zacharias, Blair B. Madison, Xing Li, Asa Kolterud, Deborah L. Gumucio
Sonic (Shh) and Indian (Ihh) hedgehog are secreted signaling molecules that are expressed
in the small intestinal epithelium during intestinal organogenesis; lack of either Shh or Ihh
results in marked developmental abnormalities involving both the epithelial and mesenchy-
mal compartments of the intestine. Recent work in our laboratory utilizing animals expressing
a secreted form of the pan-Hh inhibitor Hhip (Villin-Hhip) demonstrates that inhibition of
the combined Shh and Ihh signal leads to disorganized villus formation, mislocalization of
myofibroblasts, and perturbed smooth muscle development. We recently developed two
additional mouse models to further examine phenotypes resulting from Hh inhibition and
identify crucial Hh target genes. A Villin-flox-βgal-flox-Hhip X Villin-Cre double transgenic
model recapitulates the Hhip phenotype previously reported, with a significant decrease in
differentiated smooth muscle in the cores of the villi and a mislocalization of myofibroblasts
in adults. A complementary transgenic Villin-Ihh model exhibits a reciprocal phenotype:
significant increase in villus smooth muscle at several adult stages examined. Our results
suggest that Hh signaling is crucial not only for the patterning of muscularis externa, as
previously demonstrated, but also for the development of smooth muscles within the villus
cores and muscularis mucosa. These models, in combination with microarray experiments
performed on tissue derived from Hhip mice or on cultured, Hh-treated embryonic small
intestinal mesenchyme, are now being used to identify specific mesenchymal targets of
Hh signaling.
80
Specification and Terminal Differentiation of Small Intestinal Endocrine Cells
Occurs Independently of Wnt Signaling
Yang Wang, Andrew B. Leiter
Wnt signaling is required for the maintenance of intestinal stem cells and their proliferating
descendents in the crypts. Wnt loss of function studies indicate that differentiation of the
three secretory lineages depends on Wnt signals. Because these studies examined loss of
Wnt signals in relatively immature proliferating cells in the intestinal crypts, it is not known
at what stage of development Wnt is required for endocrine differentiation in the intestine.
Prior cell lineage tracing studies indicate that most enteroendocrine cells arise from precursor
cells expressing the basic helix loop helix transcription factor, neurogenin 3 (Ngn3). In
addition, Ngn3 null mice fail to develop enteroendocrine cells, suggesting that Ngn3 is
necessary for their differentiation and that Ngn3 expression is a very early event in endocrine
specification. To determine whether Ngn3+ cells require Wnt for further differentiation, we
knocked out the β-catenin gene in Ngn3+ cells by crossing Ngn3-Cre recombinase transgenic
mice to mice with one null and one conditional allele for β- catenin. Examination of the
small intestine revealed normal morphology and normal enteroendocrine cells, suggesting
that Wnt signaling is not required for endocrine precursor cells to terminally differentiate.
To further examine the role of Wnt in intestinal differentiation, we took advantage of our
previous observations that small numbers of secretory progenitors that give rise goblet and
Paneth cells and rare pluripotent cells express Ngn3 yet do not become endocrine cells. We
generated mice with conditional deletion of the β-catenin gene in Ngn3 expressing cells in

















cells expressing Cre recombinase by staining for β galactosidase activity. The number of β-
gal positive enteroendocrine cells was the same in control and transgenic mice confirming
that Wnt was not required for terminal differentiation of enteroendocrine cells. Likewise,
the number of β-gal+ goblet cells was normal, suggesting that secretory progenitors committed
to become either goblet or enteroendocrine cells do not require Wnt for terminal differenti-
ation. However, the numbers of β-gal+ Paneth cells and crypt-villus strips with all cells β-
gal labeled were reduced by 80% and 74%, indicating that Wnt was required for Paneth
cell differentiation as well as for maintenance of pluripotent cells. We conclude that enteroen-
docrine and goblet cells, unlike Paneth cells, differentiate independently of Wnt and comprise
a distinct subpopulation arising from intestinal secretory progenitor cells.
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β1 Integrins Regulate Wnt Signaling in the Intestinal Epithelium
Scott K. Kuwada, Brett Doxey, Phillip Gray, Xiufen Li
We recently reported that conditional deletion of β1 integrins in the intestinal epithelial
cells (IEC) of mice (β1 KO) disrupted intestinal homeostasis through a loss of Hedgehog
expression and signaling. We report now that the β1 KO mice demonstrate striking similarities
to mice in which Apc was conditionally deleted in the IEC’s. Both KO mice demonstrated
dysplastic crypts, increased Paneth cell markers, defective enterocyte differentiation, early
neonatal malnutrition, and expansion of intestinal stem cells. AIM: To determine the role
of β1 integrins in the regulation of Wnt signaling in the intestinal epithelium. METHODS:
Villin-Cre mice were crossed with β1 integrin(lox/+) mice, and, the offspring were
backcrossed to generate villin-Cre/β1 integrin(lox/lox) mice. The loss of β1 integrin expres-
sion was determined by immunoblot (IB) and immunohistochemistry (IHC). Quantitative
reverse transcription-polymerase chain reaction (qRT-PCR), IHC, and IB were used to deter-
mine the expression levels of Wnt signaling pathway members. RESULTS: The mRNA
expression of the Wnt signaling pathway targets Matrix Metalloproteinase-10 and Defensin/
Cryptdin 5, in the IECs of the β1 KO mice was increased by 3-10-fold compared with
control littermates. Cryptdin 5 protein was localized to Paneth cells in the control mice but
was expressed along the entire crypt-villous axis in the β1 KO mice, however, electron
microscopy and expression of enterocyte markers showed that the villous IECs were
enterocytes and not Paneth cells. These results demonstrated increased and mislocalized
Wnt signaling in the IEC’s of the β1 KO mice. Nuclear β-catenin was seen in similar numbers
of Paneth cells in the crypts of the β1 KO mice and control littermates indicating that Wnt
signaling was not increased proximal to β-catenin. IHC and IB demonstrated nuclear Tcf-
4 in a few IECs in the crypt bases of the control mice, but increased nuclear Tcf-4 expression
in IECs along the entire crypt-villous axis in the β1 KO mice. Normal mouse pups were
treated every other day with the Hedgehog inhibitor cyclopamine or vehicle for 10 days.
Cyclopamine caused increased nuclear Tcf-4 expression along the entire crypt-villous axis.
CONCLUSIONS: β1 integrins mediate Wnt signaling at the level of Tcf-4 in a Hedgehog-
dependent fashion. These studies demonstrate the signaling pathways by which the extracellu-
lar matrix regulates IEC proliferation.
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P53-Activated Ndrg1 Expression Plays An Important Role in Inhibition of
Normal Intestinal Epithelial Cell Proliferation Following Polyamine Depletion
Ai-Hong Zhang, Jaladanki N. Rao, Tongtong Zou, Lan Liu, Bernard S. Marasa, Lan Xiao,
Jie Chen, Jian-Ying Wang
Normal intestinal mucosal growth requires polyamines that regulate expression of various
genes involved in cell proliferation, growth arrest, and apoptosis. Our previous studies have
shown that polyamine depletion stabilizes p53 resulting in inhibition of intestinal epithelial
cell proliferation, but the exact down-stream targets of induced p53 are still unclear. The
NDRG1 (N-Myc down-regulated gene 1) gene encodes a growth inhibiting protein, which
is primarily regulated at the transcriptional level. The current study tests the hypothesis that
induced p53 causes inhibition of normal intestinal epithelial cell proliferation by activating
NDRG1 transcription following polyamine depletion. Method: Studies were conducted in
IEC-6 cells, derived from rat normal intestinal crypts. The NDRG1 gene transcription was
examined by its promoter luciferase reporter gene assays, and levels of NDRG1 mRNA and
protein were measured by RT-PCR and Western blot analysis. p53 was knockdown by
specific siRNA, and ectopic expression of the NDRG1 gene was induced by infection with
the recombinant adenoviral vector containing wild-type NDRG1 cDNA (AdNDRG1). Results:
Polyamine depletion by DFMO, the specific inhibitor of polyamine synthesis, not only
activated NDRG1 promoter but also increased levels of NDRG1 mRNA and protein. The
NDRG1 promoter activity was increased by 5-folds on day 6 after treatment with DFMO,
while levels of NDRG1 mRNA and protein were increased by ~4-folds, which were completely
prevented by exogenous polyamine putrescine. Decreased p53 expression by specific p53
siRNA in polyamine-deficient cells prevented the increased expression of NDRG1. Ectopic
expression of the NDRG1 gene by AdNDRG1 infection dramatically inhibited IEC-6 cell
proliferation, but had no effect on apoptosis. Cell number was decreased by ~50% 48 h
after infection with AdNDRG1. In contrast, there were no significant differences in rates of
apoptotic cell death between cells overexpressing NDRG1 and cells infected with the adenovi-
ral vector lacking NDRG1 cDNA after exposure to TNFα plus cycloheximide. Conclusions:
These results indicate that decreasing cellular polyamines increases NDRG1 transcription
through a p53-dependent mechanism and that p53-induced NDRG1 following polyamine
depletion plays a critical role in inhibition of normal intestinal epithelial cell proliferation.
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Critical Interactions Between Elf and Cdk4 in Regulation of Gastrointestinal
Cell Proliferation in TGF-β Signaling Pathway
Sang Soo Kim, Hye Jung Baek, Anthony Kang, Yi Tang, Varalakshmi Katuri, M. Blair
Marshall, Bibhuti Mishra, E. Premkumar Reddy, Lopa Mishra
TGF-β is an important regulator of G1/S cell cycle progression. Inactivation of TGF-β
signaling frequently occurs in gastrointestinal cancer. We have shown that disruption of
ELF disrupts TGF-β signaling through Smad3 and Smad4. Interestingly, our previous analysis
of elf-/- and elf+/- mice showed developmental defects with embryonic lethality and a
prominent increase in spontaneous gastrointestinal cancer, respectively. In addition, ELF
functions as a Smad3 and Smad4 adaptor. Recently, Smad3 has been shown to be a CDK4
substrate indicating that suppression of Smad3 by CDK4 could represent a mechanism by
which tumorigenesis occurs. However, there is no clear evidence for tumorigenic contribu-
tions from Smad3 mutations in human and knockout mice. Aim; To gain further insight
into the potential regulatory role of ELF in CDK4 function, cell cycle progression, and
neoplasia formation, we carried out detailed biochemical analyses and genetic studies.
Methods and Results; Here we show that CDK4 is activated in cancers from elf+/- mutant
mice and ELF interacts with CDK4 by forming a complex containing Smad3 in COS-7 cells.
Our further mapping analysis identified the N-terminal actin-binding domain of ELF to be
responsible for interactions with CDK4. Interestingly, CDK4 also interacts Smad3 in the
presence of ELF upon TGF-β stimulation. To ascertain interactions between CDK4 and
ELF in tumor formation, we intercrossed elf+/- and CDK+/R24C mice where CDK4-R24C
mutations abolish the ability of CDK4 to bind to p16(INK4a) thus rendering CDK4 constitu-
tively active. Surprisingly, most of the compound heterozygote elf and CDK4-R24Cmice
showed embryonic lethality resembling homozygote phenotypes of elf-/- mice with CNS
and GI defects. Conclusion; These results show the molecular interactions between ELF and
CDK4 are essentially for cell cycle regulation, cell proliferation, and differentiation. This
study also suggests that ELF, a major dynamic scaffolding protein, is a key molecule by
modulating the interaction of regulatory proteins such as CDK4 and also for transmitting the
TGF-β signaling pathway, which is essential for cell cycle regulation and tumor suppression.
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The Basic Helix-Loop-Helix Transcription Factor Mist1 Regulates
Differentiation of Gastric Zymogenic (Chief) Cells from Their Mucous Neck
Cell Precursors
Victoria G. Ramsey, Christopher C. Chen, Jason M. Doherty, Thaddeus S. Stappenbeck,
Jason C. Mills
Digestive enzyme secreting zymogenic (chief) cells (ZCs) reside in the bottom of gastric
units of mammalian stomachs. The ZC arises from its precursor, the mucous neck cell (NC),
which has its own distinct, specialized functions. Loss of differentiated ZCs is a hallmark
of precancerous lesions such as atrophic gastritis and intestinal metaplasia. However, the
genes that coordinate the trans-differentiation from the NCs to ZCs are not known. To
identify candidate genes, we used laser-capture microdissection (LCM) to purify individual
ZCs, parietal cells, and surface pit cells from stomach frozen sections. RNA was extracted,
amplified, converted to cRNA and hybridized to Affymetrix MOE430v2.0 GeneChips. Using
commercially available as well as in-house bioinformatic software, we identified ~30 transcrip-
tion factor (TF) transcripts enriched in ZCs vs the other cells. One gene, the basic helix-
loop-helix TF Mist1, had been previously shown to be expressed in ZCs. In normal mice,
NCs and ZCs are thought to differentiate as they migrate. To examine whether Mist1 affected
this process, we obtained Mist1 knockout mice and examined well-oriented gastric units
with immunofluorescent markers of NC and ZC differentiation. In control mice, we observed,
as expected, that mean fluorescent intensity/cell (MFI) of the NC marker increased linearly
with distance from the stem cell compartment. At the bottom of the neck region of the
gastric unit, there was a brief transition where 3-4 cells/gastric unit co-expressed NC and
ZC markers. Thereafter, cells shut off the NC marker, expressing only the ZC marker. In Mist1
knockouts, neck cell differentiation was normal, but the numbers of NC->ZC transitional cells
were doubled. There was a ten-fold increase specifically in the numbers of transitional cells
co-expressing high levels of the ZC marker while retaining GSII (NC) expression. MFIs of
the ZC marker then decreased as cells migrated out of the transition zone, contrasting with
control mice whose ZCs increase zymogenic markers as they migrate to the base. Electron
microscopic studies corroborated that, in knockouts, the mature zymogenic granules charac-
teristic of terminally differentiated ZCs occurred aberrantly in transitional cells and were
then lost as ZCs migrated toward the base. Immunofluorescence showed that Mist1 is
expressed only in the cells that are aberrant in the knockout: ZCs and late transitional cells.
Thus, we propose that Mist1 regulates the emergence and maintenance of the ZC lineage.
Experiments are underway to determine whether Mist1 expression is lost in mouse models
of atrophy and in human carcinomas and pre-cancerous lesions.
85
The Risk of Gastric Cancer Correlates with Serum Pepsinogen I / Pepsinogen
II Ratio Both in Longitudinal Settings As Well As Cross-Sectional
Hirotsugu Watabe, Yutaka Yamaji, Makoto Okamoto, Ryoichi Wada, Hidetaka Doi,
Haruhiko Yoshida, Takao Kawabe, Toru Mitsushima, Masao Omata
INTRODUCTION: Serum pepsinogen (PG) is related to gastric atrophy. PG I /PG II ration
is a useful marker for gastric cancer. However, the evidence supporting this usefulness is
mainly based on the cross-sectional studies. It is unclear that PG is also helpful to predict
development of gastric cancer during follow-up. We previously conducted a prospective
endoscopic follow-up study to evaluate efficacy of the combination of H. pylori antibody
and serum pepsinogen (Watabe H, et al. GUT 2005; 54: 764). We reanalyzed this cohort
to evaluate the efficacy of PG as a predictive marker for gastric cancer in cross-sectional
and longitudinal settings in the present study. METHOD: Between March 1995 and February
1997, 10234 subjects (male/female; 7021/3213, mean age; 49.1±8.8) participated in the
endoscopic mass screening program. PG I and II levels were simultaneously assayed. We
reclassified the subjects into 3 groups according to PG I / PG II ratio (PGR); Low PGR group
(PGR < 3.0; n=2863), Medium PGR group (3.0 ≦ PGR < 4.0; n=1819), and High PGR
group (PGR ≧ 4.0; n=5552). In the cross-sectional analysis, the prevalence of gastric cancer
was investigated according to PGR groups in the population at the entry. In the longitudinal
analysis, we analyzed the cohort of 6983 followed-up subjects for 4.7 years, and investigated
the incidence rates of newly development of gastric cancer. Risk ratios adjusted by age and
gender were calculated for PGR status. RESULT: At the initial endoscopy, 32 (0.3%) had
gastric cancer. Odds ratios compared with High PGR group were 5.8 (95% CI; 1.5-22.5, p=
0.01) in Medium PGR group, and 10.3 (3.0-35.0, p=0.0002) in Low PGR group, respectively.
Among the 6983 subjects with endoscopic follow-up, 43 subjects (0.6%) developed gastric
cancer. The annual incidence rates of gastric cancer were 0.02%, 0.12%, and 0.35% in
groups of High, Medium, and Low PGR, respectively. Hazard ratios compared with High
PGR were 4.1 (95% CI; 1.2-14.1, p=0.02) in Medium PGR group, and 10.0 (3.5-28.6,
p<0.0001) in Low PGR group. Older age and male gender were also independent risk factors
for both the prevalence and the incidence of gastric cancer. We could establish a super
high-risk group, male older than 60 with Low PGR. They had the prevalence of 1.46% and
annual incidence of 0.71%. CONCLUSION: Serum pepsinogen I / pepsinogen II ratio was
a correlated marker for the risk of gastric cancer.
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Gastrin-Induced Pepsinogen Regulates Sonic Hedgehog Processing and
Prevents Gastric Atrophy
Yana Zavros, Meghna Waghray, Linda Zhang, Arthur Tessier, Deborah Gumucio, Linda C.
Samuelson, Andrea Todisco, Juanita L. Merchant
Objective: Sonic hedgehog (Shh) has been reported to regulate epithelial cell differentiation
and maturation in the adult stomach. Shh is highly expressed in the acid-secreting parietal
cells. During progression from gastritis to gastric cancer, the parietal cells fail to produce
acid and are eventually replaced by mucous secreting cells (atrophy). Gastrin regulates acid
production in the parietal cell. Gastrin-deficient (G-/-) mice have impaired acid secretion
and over time develop parietal cell atrophy that eventually results in gastric cancer. Since
loss of Shh correlates with atrophic gastritis, the hypothesis that gastrin regulates Shh
production within the parietal cell was tested. Methods: Shh expression was analyzed by
qRT-PCR and western blot using RNA and protein extracted from mucosal scrapings of wild
type, G-/- and gastrin-infused G-/- mice. Shh protein expression was analyzed using whole cell
extracts (WCE) prepared from canine parietal cells treated with vehicle, gastrin, omeprazole or
both. Shh processing was assessed by incubating WCE prepared from treated parietal cells
with in vitro translated Shh 45kDa peptide. To directly test the digestion of Shh protein
with pepsin A, the activated enzyme was incubated with in vitro translated Shh protein.
Results: Both the 45kDa precursor and 19kDa biologically active Shh proteins were absent
in the G-/- mice. Restoration of acid secretion after gastrin infusion resulted in Shh processing
of the precursor to the 19kDa form and increased Shh mRNA abundance. Gastrin-treated
canine parietal cells showed processing of the 45kDa precursor in WCE to the secreted
19kDa biologically active peptide in the media. When acid secretion from the parietal cells
was blocked with omeprazole, the effect of gastrin on Shh processing was abolished. WCE
collected from gastrin treated parietal cells processed the 45kDa to 19kDa fragment, and
this processing was blocked with the protease inhibitor pepstatin. Pepsinogen I (PGI) expres-
sion was induced by gastrin and inhibited by omeprazole treatment of parietal cells. Digestion
of pepsin A clearly showed cleavage of the precursor 45kDa peptide to a 19kDa protein
within 20 min. Conclusion: Gastrin induces the expression of PGI that under acidic condi-
tions converts to the active protease pepsin A. Pepsin A cleaves the 45kDa Shh peptide to
the soluble secreted biologically active protein. Therefore, the current study links the loss
of Shh during atrophic gastritis to the loss of PGI expression. Specifically, low levels of PGI
are predictive of the presence of atrophic gastritis, which is the most important predictor
of susceptibility to gastric cancer.
87
Activation of Hedghog Signaling in GI Cancers
Jingwu Xie, J.N. He, Tao Sheng, Arwen Stelter, Laura Westerberg, Shuhong Huang, Xiaoli
Ma, Hongwei Zhang, Robert Whitehead, Patrick Adegboyega, Stan Lemon, Mark Evers
GI cancers are the major causes of cancer-related death worldwide. Patients with GI cancers
usually present at late stages and have a poor prognosis. Thus, identification of specific drug
targets in the tumor is an essential step to reduce the mortality. Recent studies indicate that
abnormal activation of the sonic hedgehog pathway is aasociated with pancreatic cancer,
gastric cancer and esophageal cancer. To determine if hedgehog signaling activation can be
utilized for diagnosis and treatment for GI cancers, we performed a comprehensive study
to assess hedgehog pathway activation in over 200 primary GI cancer specimens, including
gastric cancer, esophageal cancer, pancreatic cancer, colon cancer and heptocellular carcin-
omas. Through analyses of hedgehog target gene expression, we discovered that hedgehog
signaling is frequently activated in gastric cancer, esophageal cancer, hepatocellular carcinoma
and pancreatic cancers, but rarely in colon cancers. Our studies further indicate that hedgehog
signaling activation is associated with tumor stage, differentiation and tumor subtype of
gastric cancer. Over-expression of sonic hedgehog (shh) was observed for tumors with
activation of the hedgehog pathway, suggesting that elevated Shh expression may be respons-
ible for hedgehog signaling activation in the tumor. Furthermore, activated shh expression
was also observed in the mouse HCC derived from HCV-transgenic mice. The significance
of hedgehog signaling in GI cancers was demonstrated by the fact that targeted inhibition
of hedgehog signaling by either cyclopamine or Shh neutralizing antibodies reduced cell
growth of cells with activated hedgehog signaling. Our data indicate that hedgehog signaling
is an important abnormality in GI cancers. These data predict that targeted inhibition of
the hedgehog pathway may be effective in the prevention and treatment of GI cancers.
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Evidence That Integrin-Linked Kinase Is Involved in Murine Colitis-Associated
Carcinogenesis
Baljinder Salh, Kiran Assi, David Owen, Shoukat Dedhar
Integrins are transmembrane cell surface receptors that mediate cell-cell and cell-matrix
contacts. The recently identified integrin-linked kinase (ILK) is a binding partner of integrins
and has been ascribed essential roles in development and angiogenesis. It also imparts
tumorigenic properties to cells when overexpressed. As we had previously shown dysregul-
ation of this molecule in human colon cancer, we were interested to explore its role in
murine tumorigenesis, using a recently described colitis-associated cancer model dependent
upon azoxymethane and DSS. To create intestinal ILK knockout animals (ILK-iko), we used
Fabp/Cre mice (Cre recombinase expressed under the control of a modified Fabp promoter),
and mated them with mice carrying a LoxP-flanked (floxed) ILK gene (ILKflox/flox). (These
mice have been used to demonstrate ILK’s effects on chondrocytes as well as its role in
vascular development). Expression of Cre and excision of ILK were determined in the
offspring using PCR. We have previously observed that mice with intestinal epithelial cell
ILK knockout develop normally upto 1 year. They exhibited partial reduction in the size
of the cecum (approximately 70-80% of littermate size). They did not exhibit any macroscopic
signs of basally increased inflammation. Immunohistochemical analysis revealed that there
was diminished ILK expression in ILK-iko animals. Evaluation of BrDU staining in the
knockout animals revealed a significant reduction in cells positive for this parameter as
compared to the wild-type animals in both the cecum and colon (p<0.001 for both),
confirming ILK’s effects on cell proliferation. Following azoxymethane and DSS treatment,
we observed fewer total tumors in the ILK knockout animals, especially those > 5mm in
diameter (wt:7.9 +/- 3.4/animal, ko:2.7 +/- 1.8/animal, p< 0.05, n=14 and 10 animals for
the two groups respectively, data represent mean +/- SEM). Histology revealed that there
were fewer invasive tumors in knockout animals (only 1 compared with 4 in the wild-type
group), and this correlated with a reduction in MMP9 expression. We conclude that ILK
has a role in intestinal epithelial cell proliferation and provide the first evidence that it
influences the development of colitis-associated neoplasia.
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Annexin II Binds Progastrin and Gastrin Like Peptides, and Is Required for
Mediating Growth Factor Effects of Autocrine and Exogenous Gastrins On
Colon Cancer and Intestinal Epithelial Cells
Pomila Singh, Hai Wu, Azar Owlia
BACKGROUND. We and others have reported the presence of novel progastrin (PG) prefer-
ring receptors on normal and cancerous intestinal cells (AJP 2003). We had earlier identified
~34 KDa proteins on cellular membranes of colon cancer (CA) cells, that were specifically
cross-linked to radio-labeled gastrins. It is not known if the ~34 KDa proteins represent the
novel PG preferring receptor proteins. AIM. To identify the binding proteins in the ~34
KDa band, and analyze the functional significance of the protein(s) thus identified.
METHODS. 125I-rhPG and 125G-17 were used for cross-linking the membrane proteins
from CA cells, followed by solubilization of the native binding proteins and enrichment by
>1,000-fold by several steps of purification. The purified 32-36 KDa proteins, specifically
cross-linked to 125I-Gastrins, by carbodiimide cross-linker, were subjected to SELDI-TOF-
MS analysis (using the protein chip system from Ciphergen) and the MALDI-TOF-MS analysis
(in the UTMB Biomolecular Research Facility). Peptide masses were researched against the
NCBInr database using the ProFound search engine to identify the proteins in the punched
out bands of interest. RESULTS. Annexin II was identified as the major protein in the ~34
KDa cross-linked band from CA cells. Since HCT-116 cells express autocrine PG, the in
situ association of autocrine PG with Annexin II was confirmed in pull down assays. The
binding of PG peptides with Annexin II, was further confirmed in vitro solution binding
assays with purified Annexin II and rhPG. Annexin II/rhPG in solution were immunoprecipit-
ated with either anti-PG or anti-Annexin II Antibodies (Abs), followed by Immunoblot
analysis with either of the Abs. The results provided the first direct evidence that rhPG and
Annexin II bind in solution. Annexin II also functions as a membrane receptor for Tenascin-
C (Ten-C). Therefore, the relative binding affinity (RBA) of Ten-C for displacing the binding
of 125I-rhPG to IEC-18 and CA cells was examined. The RBA of Ten-C was similar to that
of rhPG, suggesting that the 2 proteins may share binding sites on Annexin molecules. In
order to confirm the functional importance of these observations, sense(S) and anti-sense
(AS) clones of IEC-18 and HCT-116 cells were generated for the expression of Annexin II;
the AS clones demonstrated a significant loss in the growth response of the cells to exogenous
(IEC-18) or autocrine (HCT-116) PG. CONCLUSIONS. The membrane associated protein,
Annexin II, specifically binds PG and gastrin-like peptides, and its expression is required
for mediating growth factor effects of exogenous and autocrine PG on normal and cancerous
intestinal cells.
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Cd4+Cd45rbLoCd25+ Regulatory Lymphocytes Protect Against Induction of
Helicobacter Pylori Gastritis in C57bl/6 Mice Through An Il10 Dependent
Mechanism
Chung-Wei Lee, Varada P. Rao, Susan E. Erdman, Arlin B. Rogers, James G. Fox
Mouse models of Helicobacter pylori (Hp)-induced gastritis and associated lesions are valuable
for the study of immunopathogenesis of gastric cancer in humans. Gastritis due to Hp
involves CD4+CD45RBhi effector T cells both in mice and humans, whereas T cell populations
of CD4+CD45RBlo CD25+ phenotype are known to be protective against Hp-induced gastritis.
Interestingly, IL10-deficient C57BL/6 mice develop more severe Hp-induced gastritis than
wild-type (WT) mice. We hypothesized that IL-10, a potent immunosuppressive cytokine
of regulatory T cells, is critical for the control of gastritis in the host. In the present study,
we assessed regulatory function of CD4+CD45RBloCD25+ T cells from WT or IL10-deficient
donors in Hp-infected C57BL/6 Rag2-/- mice that have received CD4+CD45RBhi effector T

















weeks post transfer with effector T cells (inflammatory score 2.7+/-0.11). In contrast, Hp-
induced gastritis was ameliorated in mice that received co-transfer of effector T cells and
regulatory T cells from WT donors (1.0+/-0.15, p<0.001). Suppression of gastritis, however,
was not observed when regulatory T cells from IL10-/- donors were used (inflammatory
score 2.0+/-0.35, p=0.146), suggesting that IL10 is critical for regulatory T cell function of
CD25+ cells in this model. Similarly, adoptive transfer of WT regulatory T cells was effective
in ameliorating pan-gastritis observed in mice that have received effector T cells in the
absence of Hp infection. We observed a significant decrease in Hp colonization in mice
reconstituted with effector T cells compared to non-transferred control animals. Compared
to the non-transferred group, mice that have received co-transfer of effector and regulatory
T cells also had lower levels of Hp colonization. These data support previous studies
demonstrating that mounting an immune response against Hp reduces Hp colonization in
the gastric compartment. These findings highlight the important protective role of IL10-
competent CD4+CD45RBloCD25+ regulatory T cells in Hp pathogenesis, and suggest that
approaches aimed at selectively enhancing regulatory T cell function in humans may prevent
Hp-induced gastritis and gastric cancer.
Table 1
†p<0.001 when compared to Hp+TE group, #p<0.05 when compared to Hp+TE+IL10-/-TR
group *p<0.001 when compared to Hp group
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H. Pylori-Induced Phosphorylation of C-Fos Is the Key Regulatory Step in the
Activation of Macrophage Apoptosis
Mohammad Asim, Rupesh Chaturvedi, Francoise I. Bussiere, Kshipra Singh, Keith T.
Wilson
Background: Inhibition of innate immune response to H. pylori (Hp) is inhibited by induction
of macrophage apoptosis. We have reported that: this apoptosis is dependent on generation
of polyamines by ornithine decarboxylase (ODC), ODC induction requires binding of c-
Myc to the ODC promoter, and c-Myc expression is mediated by phosphorylation of extracel-
lular signal regulated kinase (ERK) 1/2 and translocation of phospho-ERK1/2 to the nucleus.
Our aim was to determine how phospho-ERK1/2 activates c-Myc. Because c-Myc transcription
can be regulated by the AP-1 complex, we assessed the involvement of AP-1 member proteins
c-Fos, c-Jun, and Jun-D in the response to Hp. Methods: RAW 264.7 macrophages were
stimulated with lysates of Hp SS1. We assessed c-Myc, ODC, and c-Fos mRNA expression
by real-time PCR, c-Myc and Jun-D protein levels by Western blotting, and c-Fos and c-
Jun phosphorylation by phosphoblotting. Oligonucleotide pull-down assays were performed
using an AP-1 consensus binding sequence as a probe. Apoptosis was quantified by flow
cytometry (annexin V/PI staining). Results: Hp induced c-Fos mRNA expression that peaked
at 20 min. with a 5.8 ± 1.2 fold increase (p < 0.01) and c-Fos phosphorylation that peaked
at 40 min. To determine if c-Fos is a downstream target of phospho-ERK1/2, we tested the
effect of inhibition of ERK1/2 with PD98059, and found that while there was no effect on
c-Fos expression, this completely blocked Hp-stimulated c-Fos phosphorylation. Inhibition
of p38 MAP kinase or c-Jun N-terminal kinase (JNK), with SB203580 and SP600125,
respectively, had no effect on c-Fos expression or phosphorylation. Hp also induced c-Jun
and Jun-D, and c-Jun phosphorylation. SP600125 blocked c-Jun phosphorylation and Jun-
D protein expression, but did not affect Hp-stimulated c-Myc and ODC levels or apoptosis,
indicating that phosphorylation of c-Jun or the expression of Jun-D is not involved, and
phosphorylation of c-Fos is the major event in the AP-1 complex formation and the induction
of c-Myc. Pull-down assay confirmed the presence of phospho-c-Fos in the AP-1 complex
formed in nuclear extracts of Hp-stimulated cells. When cells were transfected with a
dominant negative form of c-Fos (Fos-A) there was significant attenuation of Hp-induced
c-Myc and ODC expression. In parallel, Fos-A inhibited Hp-stimulated apoptosis by 76.5
± 12.6% (p < 0.01). Conclusions: We have identified that phosphorylation of c-Fos in the
nucleus by phospho-ERK1/2 is a critical event in c-Myc/ODC-dependent apoptosis in Hp-
stimulated macrophages. Activation of early stress response genes of the AP-1 complex is
an important part of the dysregulated immune response to Hp.
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Site Specific Activation of Focal Adhesion Kinase (FAK) Is a Key Regulator of
Helicobacter Pylori Mediated Intracellular Signaling
Fazal H. Tabassam, Yoshio Yamaoka
Background: CagA containing Helicobacter pylori induce cytoskeletal organization, motility
and elongation of gastric epithelial cells (e.g., AGS cells). These changes have been related
to CagA which following injection into the cell undergoes tyrosine phosphorylation in EPIYA
motifs. The initial signaling events resulting in these phenotypic changes remain unknown.
There are a number of potential phosphorylation sites on FAK that result in activation of
different pathways. Aim: To examine the effect H. pylori on site specific activation of
FAK. Methods: AGC cells were co-cultured with H. pylori (wild type and its isogenic
cag pathogenicity island (PAI) or oipA mutants) in various dose and time courses and
phosphorylation status of FAK, Src, Erk1/2 and paxillin was evaluated by immunoblot and
fluorescence microscopy analyses. Results: H. pylori caused rapid, transient phosphorylation
of FAK at residue Y397 and Src at Y418 followed by tyrosine phosphorylation of FAK at
Y407, Y576, Y577, Y861 and Y925 in a dose- and time-dependent manner. Activation of
FAK and Src induced tyrosine phosphorylation of Erk1/2 at sites T202/Y204 and paxillin
at Y31 and Y118. Chemical inhibitors of PI3 kinase and Src blocked the H. pylori mediated
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tyrosine phosphorylation of FAK, Src, Erk1/2 and paxillin. These results suggest that complete
activation of FAK through interactions and activation of Src and paxillin are likely responsible
for the regulation of intracellular signaling leading ultimately to cytoskeletal reorganization,
motility and phenotypic changes associated with CagA positive H. pylori. Interestingly, use
of cag PAI or oipA isogenic mutants showed that phosphorylation of FAK at Y397, Y576,
Y577 and Y925 was mediated by OipA. In contrast, phosphorylation of FAK at Y407 and
Y861 was induced by the cag PAI, while phosphorylation of Src,Erk 1/2 and paxillin were
both virulent factors dependent. These results are consistent with the notion that different
upstream effectors and downstream signaling pathways are mediated by different virulent
factors. Conclusion: These findings suggest that the virulence factors, cag PAI or OipA,
control the phosphorylation of FAK, Src, Erk1/2 and paxillin and thus contribute to actin
remodeling, enhanced inflammatory responses and various pathological outcomes from H.
pylori infection. Inhibition of site specific proteins should provide novel therapeutic strategies
for interfering signaling at multiple phosphorylation stages and inhibition of various down
stream signaling. Supported in part by the Gulf Coast Digestive Disease Center.
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Interleukin-1β Antagonizes Helicobacter Pylori-Mediated Down-Regulation of
H,K-ATPase α Subunit Gene Transcription
Arindam Saha, Charles E. Hammond, Monika Gooz, Maria Trojanowska, Adam J. Smolka
H. pylori infection of human gastric fundic mucosa perturbs normal acid secretory mechan-
isms, inducing hypochlorhydria, fundic atrophy, and increasing risk of gastric carcinoma.
Gastric acid secretion is mediated by H,K-ATPase, a K+-stimulated, H+-translocating ATPase
in parietal cell apical membranes. We showed previously that H. pylori down-regulates H,K-
ATPase α subunit (HKα) gene transcription in vitro and also decreases parietal cell proton
pump expression, providing a partial mechanistic basis for clinical hypochlorhydria. Given
that H. pylori infection up-regulates gastric mucosal IL-1β expression and that IL-1β inhibits
secretagogue-stimulated acid secretion, we sought to determine the role of IL-1β in H. pylori-
mediated down-regulation of HKα transcription. Human gastric adenocarcinoma cells (AGS)
were transfected with luciferase reporter gene plasmids containing deletion fragments of
human HKα 5'-flanking sequence. Maximal transcriptional activity of HKα sequences was
induced by 100 nM phorbol myristate acetate, the cells were treated (24 hr) with H. pylori
(ATCC 49503) and/or IL-1β, and relative light units were normalized against co-transfected
H. pylori-insensitive GFP plasmids. H. pylori dose-dependently inhibited transcriptional
activity of 2199 bp, 207 bp, 195 bp, and 132 bp HKα deletion fragments. H. pylori-mediated
inhibition of 2199 bp HKα activity (29%) was antagonized by IL-1β (10 ng/ml). The activity
of the smaller deletion fragments was significantly stimulated by IL-1β (100%, 46%, and
35% respectively), and co-treatment of these transfected AGS cells with H. pylori and IL-
1β did not further decrease HKα activity. Pre-treatment of AGS cells with PD 98059 (a
MEK-1 inhibitor) prevented the IL-1βmediated stimulation, but SB203580 (a p38 inhibitor)
and SP600125 (a JNK inhibitor) did not. IL-1β mRNA levels in AGS cells were very low
and unaffected by H. pylori treatment, and ELISAs of H. pylori-treated and control AGS cell
culture supernatants showed no measurable IL-1β secretion in either case. These data indicate
that 1) an IL-1β-dependent positive cis-response element is located between -177 and -64
nt in the HKα 5’-flanking region; 2) IL-1β antagonizes H. pylori-induced down-regulation
of HKα transcription by up-regulating HKα transcription through an ERK-1 kinase pathway;
and 3) neither endogenous AGS cell IL-1β nor exogenous IL-1β mediate H. pylori-induced
HKα inhibition at the transcriptional level in vitro. We conclude that IL-1β exerts direct
positive regulatory effects on HKα gene transcription, and that any contribution made by
IL-1β in H. pylori-mediated hypochlorhydria occurs by indirect, alternative mechanisms.
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Gastrin and Helicobacter-Infection Synergistically Up-Regulate Expression and
Secretion of Interleukin-8 in Gastric Cells Through Distinct Signaling
Pathways
Shigeo Takaishi, Alexander Dubeikovskiy, Zinaida Dubeikovskaya, Iva Smirnova,
Wandong Ai, Shuiping Tu, Tomoyuki Okumura, An V. Tran, Kelly S. Betz, Timothy C.
Wang
Background & Aims: We have previously described synergistic interaction between Helicob-
acter felis (H.felis) infection and gastrin in a gastric cancer (INS-GAS) mouse model. The
chemokine interleukin-8 (IL-8) has previously been implicated in both inflammation and
carcinogenesis. In this study, we investigated the regulation of IL-8 expression in gastric
cells by gastrin stimulation and Helicobacter pylori (H.pylori) coculture in vitro, as well as in
vivo expression of two chemokines, Cxcl1 and Cxcl2, both IL-8 family members. Methods:
AGS-E gastric cancer cell line stably transfected with gastrin/CCK-2 receptor was stimulated
in vitro with amidated gastrin G-17 (1-100nM) and/or cocultured with H.pylori strain 60190
(MOI:1-100) for 24 hrs. IL-8 gene expression was analyzed by quantitative realtime RT-
PCR (Q-PCR), and IL-8 secretion was measured by ELISA. Human IL-8 2kb promoter-
reporter construct was analyzed by luciferase assay. In vivo, male INS-GAS mice were
infected with H.felis for 6 months, and the expression of Cxcl1 and Cxcl2 in stomach was
analyzed by Q-PCR. Results: Gastrin stimulation and H.pylori coculture of AGS-E cells up-
regulated IL-8 gene expression in dose-dependent manner, with a maximum 3- and 2.5-
fold increase, respectively (100nM and MOI:100). Gastrin plus H.pylori synergistically up-
regulated IL-8 gene expression 10-fold. In addition, gastrin and H.pylori increased IL-8
secretion from AGS-E cells in dose-dependent manner, with a maximum 15- and 5-fold
increase, respectively. Gastrin plus H.pylori increased IL-8 secretion 20-fold. In IL-8 promoter-
luciferase assay, either transfection with a dominant-negative IκB-α plasmid or treatment
with a NF-κB inhibitor (pyrolidine-dithiocarbamate) resulted in near-complete inhibition
of gastrin-induced IL-8 up-regulation, whereas H.pylori-induced up-regulation was not sup-
pressed by these treatments. Murine chemokine Cxcl1 was up-regulated in stomachs of
hypergastrinemic (INS-GAS) mice and H.felis-infected non-transgenic FVB/N mice 2- and
20-fold, respectively, compared with non-infected FVB/N mice, and the expression was
synergistically up-regulated 40-fold in H.felis-infected INS-GAS mice. A closely related
chemokines Cxcl2 also showed a similar expression pattern. Conclusions: Gastrin stimula-
tion and H.pylori infection synergistically up-regulated expression and secretion of IL-8
through distinct signaling pathways in human gastric cells, and the expression of related
chemokines Cxcl1 and Cxcl2 was markedly increased in H.felis-infected hypergastrinemic
mice stomach, a mouse model of gastric cancer. The results suggest a significant role for
these chemokines in gastric carcinogenesis.
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Do Intrinsic Sensory Neurons Show Directional Stretch-Sensitivity in Guinea
Pig Distal Colon?
Eamonn J. Dickson, Terence K. Smith, Grant Hennig, Nick J. Spencer
Background: We have recently identified that a class of mechanosensory S-interneurons are
strongly activated by maintained circumferential stretch and are likely responsible for the
activation of a maintained discharge of ascending excitatory and descending inhibitory nerve
pathways in the guinea pig distal colon. Aim: Since extrinsic afferent nerve endings have
been recently shown to be activated by either circumferential or longitudinal stretch i.e. no
directional sensitivity, we sought to determine whether intrinsic sensory neurons (myenteric
S-interneurons) that underlie the peristaltic reflex would show a similar phenomenon.
Methods: Animals were euthanized humanely and a segment of distal colon excised (~3cm
length). The mucosa and submucosa were removed by fine dissection and the colon was
mounted (serosal side uppermost) in a Sylgard-lined organ bath containing oxygenated
Krebs solution at 37oC. Simultaneous intracellular recordings were made from pairs of CM
cells at either cut end (20mm apart) under alternating conditions of maintained circumferen-
tial or longitudinal muscle stretch. Results: Under slack conditions (i.e. no circumferential
or longitudinal stretch) no spontaneous activity was ever observed in CM. Interestingly,
under these conditions, transmural stimuli evoked IJPs at both the oral and anal cut ends
(3 of 3 animals). In 9 of 13 animals, longitudinal stretch (2 times slack diameter) evoked
IJPs simultaneously at both the oral and anal cut ends in response to transmural stimulation.
No synchronized spontaneous activity was ever observed in response to longitudinal axis
stretch, although in 4 animals transmural stimulation produced small amplitude (<5mV)
oral EJPs and anal IJPs at the anal cut end. Upon removal of longitudinal stretch in these
same animals, the application of circumferential stretch now revealed (in 8 out of the
13 animals) synchronized large amplitude oral EJPs (ascending excitation) and anal IJPs
(descending inhibition). In all these 8 animals transmural stimulation now produced robust
oral EJPs and anal IJPs at the oral and anal recording sites. Conclusions. In the absence
of circumferential stretch, spontaneous or electrical activation of enteric nerve pathways
preferentially activates ascending inhibitory and descending inhibitory nerve pathways to
the CM layer. Activation of ascending excitatory nerve pathways is only revealed in response
to circumferential stretch. Unlike extrinsic afferents, the activation intrinsic sensory neurons
that underlies ascending and descending inhibitory pathways shows a high degree directional
stretch-sensitivity Supported by NIH RO1 DK45713
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Co-Transmission from Sympathetic Vasoconstrictor Neurons in Mouse Colonic
Submucosal Arterioles and the Effect of Colitis
Alan Lomax, Stephen J. Vanner
Maintenance of tissue oxygenation is vital for repairing inflammatory damage and maintaining
normal function in the gastrointestinal (GI) tract. The GI microvasculature delivers oxygen
to GI tissues and is subject to complex neural control mechanisms. Recent studies have
suggested that altered neural control of the microvasculature may contribute to the pathogen-
esis of inflammatory bowel disease. Therefore, we wished to determine the effects of nerve
stimulation on the submucosal microvasculature in the mouse colon and to examine the
effect of colitis. Videomicroscopy techniques were employed to measure submucosal arteriolar
diameter changes in response to nerve stimulation at 5, 10 and 20 Hz. In arterioles that
were preconstricted by superfusion of prostaglandin F2α (400 nM), nerve stimulation
resulted in frequency-dependent vasoconstrictor responses. The neurally mediated constric-
tions were abolished by tetrodotoxin (1μM; n = 4) and guanethidine (10 μM; n = 6),
indicating that they were due to action potentials in sympathetic nerve terminals. ATP or
a related purine is the neurotransmitter at sympathetic neuroeffector junctions in submucosal
arterioles in guinea-pig ileum, as sympathetic vasoconstrictions can be abolished by a P2
purinoceptor antagonist. In contrast, superfusion of mouse colon submucosa with two potent
P2 receptor antagonists (Suramin at 100 μM and PPADs at 30 μM; n = 18 combined)
reduced but did not abolish the vasoconstriction. The residual vasoconstriction was not
affected by the alpha adrenergic receptor antagonist phentolamine (1 μM; n = 8). However,
the alpha 1 receptor antagonist prazosin (100 nM; n = 5) abolished the non-purinergic
vasoconstriction. We have also examined the effect of TNBS colitis on arteriolar responses
to nerve stimulation. Nerve-evoked constrictions of submucosal arterioles from mice with
TNBS colitis had a slower onset and offset than arterioles from naive controls and were not
reduced by suramin (in 6 of 8 preparations). This appeared to be due to a lack of arteriolar
responsiveness to purines, as superfusion of ATP (10 µM) resulted in a large vasoconstrictions
in control mice (n = 5/5 arterioles tested) but had no effect in mice with colitis (n = 9/9
arterioles tested). These data identify co-transmission from sympathetic vasoconstrictor neu-
rons in mouse colon. Moreover, in colitis the sympathetic vasoconstriction is mediated only
by the non purinergic component. The lack of a purinergic vasoconstriction may be due to
the absence of a post-junctional response to purines during colitis.
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Enteric Glia (EGC) Support Barrier Functions of Intestinal Epithelial Cells
(IEC) Under Physiological and Inflammatory Conditions
Christiane Hank, Sebastian Hoff, Michael Pfaffl, Michael Schemann, Anne Ruhl
Glial ablation causes epithelial barrier dysfunction in the gut, resulting in fulminant tissue
inflammation (Bush e.a., Cell 1998). As alterations of the epithelial barrier contribute to
intestinal inflammation, it was our aim to analyse the influence of EGC on epithelial functions
during inflammatory conditions. Using a coculture model in which IEC (T84) are grown
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as mature monolayers in the apical compartment of a transwell filter system with or without
EGC in the basolateral compartment, we mimicked inflammatory conditions by application
of the proinflammatory cytokine tumor necrosis factor (TNF) α. Tightness of the IEC
monolayers was monitored by assessing transepithelial electrical resistances (TER). Full
differentiation of IEC was accomplished when TER had reached a stable plateau which
usually occurred after 14 days. At this time, IEC were treated for 24hrs with human
recombinant TNFα (10ng/mL) in the presence or absence of EGC. Subsequently, media
were changed and epithelial barrier functions were monitored for another week. To detect
major cytokine-induced alterations of paracellular pathways, macromolecular permeability
was measured with fluorescein sulfonic acid (478Da) and fluorescein dextran (7kD). Cocul-
turing IEC with EGC significantly enhanced TER within 48hrs (p<0.001). In the absence
of EGC, a marked drop in TER was observed after TNFα stimulation (p<0.02), most
likely reflecting tight-junctional alterations because there were no detectable increases in
macromolecular permeability at any time-point. The drop in TER was prevented when EGC
were present during cytokine exposure (p<0.001). Forty-eight hrs after cytokine-exposure,
all treated IEC showed a significant rise in TER (p<0.005). This was potentiated in the
presence of cytokine-stimulated EGC in the basolateral compartment (p<0.001). Addition
of EGC to IEC after cytokine-treatment significantly augmented TER values after at least
48hrs of coculture (p<0.001). Neurotrophin production was measured by qPCR and revealed
NGF and NT-3 production by basolateral EGC. We conclude that under physiological
conditions, epithelial tightness is enhanced by EGC. Acute inflammation diminishes epithelial
tightness which is restored within 48 hrs. The presence of EGC during an acute inflammatory
insult prevents disruption of the epithelial barrier and appears to accelerate and potentiate
epithelial restoration, suggesting that EGC modulate epithelial barrier functions not only
under physiological conditions but also during acute inflammation, potentially via neurotro-
phins. Supported by Broad Medical Research Program IBD-0105R.
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An Alpha-7 Selective Nicotinergic Agonist Ameliorates Postoperative Ileus By
Inhibiting Activation of Intestinal Macrophages
Wouter de Jonge, Frans O. The, Esmerij P. van der Zanden, Dennis C. van der Coelen,
Rene M. van den Wijngaard, Guy E. Boeckxstaens
Background. Post-operative ileus (POI) results from activation of intestinal macrophages
due to bowel manipulation during surgical procedures. Vagus nerve-derived acetylcholine
inhibits macrophage cytokine production by activating alpha-7 nicotinic receptors present
on these cells. This anti-inflammatory pathway is mediated by transcription factor STAT31.
Here, we evaluated the efficacy of nicotinergic agonists to ameliorate POI, and the cellular
mechanism behind this effect. Methods. Mice were treated with 1)vehicle, 2)nicotine (0.4
mg/kg), 3)AR-R1779 (a specific alpha-7 nicotinic agonist; 10 mg/kg) by i.p. injection. Thirty
min thereafter mice underwent either control laparotomy (L) or intestinal manipulation
(IM). Gastric emptying of a semi-liquid meal was determined by scintigraphic imaging 24
hrs after surgery. Myeloperoxidase (MPO) positive mononuclear cells were quantified in
ileal muscularis of the manipulated region. Peritoneal macrophages were pre-treated in vitro
with nicotine (0-10 uM), or AR-R1779 (0-10 uM) prior to challenge with LPS (10 ng/mL)
and cell lysates were immunoblotted. Results. In mice treated with vehicle, post-surgical
(24hrs) gastric emptying (an indicator of POI) was significantly delayed in IM-mice compared
to L control (gastric retention (%) at 80 min: 13.3 ± 2.7 (L) and 38.9 ± 9.7 (IM); p<0.05;
n=8). Treatment with AR-R1779, but not nicotine, accelerated post-operative gastric emptying
after IM, compared to saline (gastric retention (%) at 80 min: 30.7 ± 8.6 (nicotine), ns,
19.6 ± 4.4 (AR-R1779), p<0.05 ;n=8). Nicotine or AR-R17779 treatment did not affect
gastric emptying after control L. In saline treated mice, IM was associated with a significant
increase in MPO-positive cells in intestinal muscularis (50 ± 11 (L) vs 572 ± 112 (IM)
cells/mm2, p<0.05). In mice pretreated with AR-R179, but not nicotine, the number of
inflammatory cells recruited after IM surgery was reduced (cells/mm2: 231 ± 33 (AR-R1779)
p<0.05, and 395 ± 50 (nicotine) ns, n=8). In LPS-stimulated peritoneal macrophages, nicotine
and AR-R1779 dose-dependently activated the anti-inflammatory transcription factor STAT3.
Conclusion. The alpha-7 nicotinergic receptor agonist AR-R17779 activates STAT3 in intest-
inal macrophages and reduces manipulation-induced inflammation thereby ameliorating
POI. Nicotine at the dose tested fails to reduce inflammation but higher doses may be
required. 1. de Jonge,W.J. et al. Stimulation of the vagus nerve attenuates macrophage
activation by activating the Jak2-STAT3 signaling pathway. Nat. Immunol. 6, 844-851 (2005).
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Intestinal Handling During Abdominal Surgery Induces Mast Cell
Degranulation and Intestinal Inflammation in Man
Frans O. The, Roelof J. Bennink, Willem M. Ankum, Marrije R. Buist, Matthe P. Burger,
Sicco van der Heide, Rene M. van den Wijngaard, Wouter J. de Jonge, Guy E.
Boeckxstaens
Introduction: Intestinal handling during surgery is increasingly recognized as an important
factor involved in the pathogenesis of postoperative ileus. In mice, we previously showed that
mast cell degranulation triggered by intestinal handling results in the release of inflammatory
mediators and the influx of inflammatory cells leading to postoperative ileus. To what extent
this sequence of events also occurs in man is currently unknown. Aim: 1. To assess if
intestinal handling results in mast cell activation and inflammatory mediator release during
abdominal surgery and 2. to evaluate whether intestinal handling leads to intestinal leukocyte
recruitment. Methods: 1. In patients undergoing an abdominal hysterectomy, peritoneal
lavage fluid was obtained during surgery at three different time points: 1. immediately after
opening of the peritoneum (basal), 2. after initial inspection and gentle handling of the
intestine (early) and 3. at the end of the surgical procedure, immediately before closure of
the peritoneum (late). Tryptase, IL1β, IL6, TNFα and IL8 release were determined in the
different samples. 2. Another series of patients undergoing an abdominal or a vaginal
hysterectomy were invited to have an abdominal 99mTc-labelled leukocyte SPECT-CT scan
24 hours before (basal) and after surgery. Clinical recovery (i.e. flatus, defecation and hospital
stay) was evaluated in both groups. Results: 1. Gentle intestinal handling resulted in a

















to basal levels (6.4 ± 1.7 μg/l vs. 28.4 ± 6.2 μg/l, p=0.02, n=6). In the late samples, tryptase
(55.9 ± 12.8 μg/l, p=0.002, n=6), IL6 and IL8 were increased (increase compared to basal
IL6= 1756 ± 1648 pg/ml, p=0.046 and IL8= 2128 ± 2079 pg/ml, p=0.046, n=6), but not
IL1β and TNFα. 2. Leukocyte scanning 24 h after surgery showed an increase of intestinal
activity compared to basal in abdominal hysterectomy patients (Δ=132.2 ± 8% of preoperative
scan, p=0.01, n=8) but not in vaginal hysterectomy patients (Δ = 99.4 ± 12% of preoperative
scan, n=8). Clinical recovery was prolonged after abdominal hysterectomy in comparison
to vaginal hysterectomy and correlated with the leukocyte activity (r=0.58, p=0.018) Conclu-
sion: The current study demonstrates that intestinal handling during surgery activates mast
cells resulting in the release of inflammatory mediators (IL-6, IL-8) leading to an influx of
inflammatory cells. These results identify mast cells as an important therapeutic target to
shorten postoperative ileus.
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Role of Adaptive Immune Cells in the Functional Response to Intestinal
Nematode Infection
Justin E. Elfrey, Aiping Zhao, Kathleen B. Madden, Thomas L. Sutton, Joseph F. Urban,
Terez Shea-Donohue
Nematode infection induces stereotypic changes in gut function that are dependent on IL-
13 activation of STAT6 signaling pathways. Recently we showed that smooth muscle and
epithelial cells exhibit a constitutive expression of receptors for IL-13 indicating that these
cells can respond directly to IL-13. Aim: To determine the contribution of adaptive immune
cells to infection-induced changes of intestinal smooth muscle and epithelial cell function.
Methods: BALB/c (WT) and SCID mice received IL-13 (10 mg iv) or VEH daily for 6 days
prior to study, or were inoculated with Nippostrongylus brasiliensis (Nb) and studied 9 days
later. Segments of jejunum were suspended longitudinally in organ baths and stretched to 9.9
mN. Spontaneous contractions (SC) of smooth muscle and responses to 5-HT or acetylcholine
(ACH) were recorded. Muscle-free segments of jejunum were mounted in Ussing chambers
to measure tissue resistance and changes in Isc in response to serosal addition of ACH or
5-HT. IL-13 gene expression was measured by real-time PCR. Results: Nb significantly
increased IL-13 mRNA expression in WT mice(200 fold) and to a lesser extent in SCID
mice(18 fold). Exogenous administration of IL-13 had no effect on IL-13 gene expression
in WT or SCID mice. In WT mice, both Nb infection and IL-13 significantly decreased
mucosal resistance, inhibited epithelial cell secretion to ACH and 5-HT, enhanced small
intestinal smooth muscle responses to 5-HT and ACH and increased the amplitude of SC
(Table). Nb-induced hyposecretion and hypercontractility were not observed in SCID mice.
In contrast, these functional changes were observed in SCID mice given exogenous IL-13.
Mucosal resistance was unaltered by Nb or IL-13 in SCID mice. Conclusion: The small
upregulation of IL-13 in Nb infected SCID mice is insufficient to impact gut function, but
supports an endogenous source of IL-13 such as NK cells. The ability of exogenous IL-13
to alter function in both WT and SCID mice indicates that smooth muscle and epithelial
cells respond directly to IL-13.
Epithelial cell function = μA/cm2; *p<0.05 vs. WT VEH, Φp<0.05 vs.SCID VEH; [ACH],
[5-HT] = 100μM; n≥4
101
At Motif Binding Factor 1 (ATBF1) Negatively Regulates Transcription of the
Muc5ac Gene in Gastric Cancer
Yoshinori Mori, Hiromi Kataoka, Makoto Sasaki, Satoshi Tanida, Tadayuki Oshima,
Naotaka Ogasawara, Yutaka Miura, Takashi Joh
Background and aims: MUC5AC belongs to the family of secreted mucins and is expressed
in foveolar cells of the stomach. Alterations of mucin expression take place in gastric cancer
cells and MUC5AC expression is known to correlate with poor prognosis. However, the
mechanism of MUC5AC transcriptional regulation has not been elucidated. AT motif binding
factor 1 (ATBF1) is a homeotic transcription factor which was originally found to binds to
AT motif in AFP promoter region and negatively regulates it. We reported that the absence
of ATBF1 is a distinct feature of AFP-producing gastric cancer cells which are characterized
by extremely high malignancy (Oncogene 2001). Furthermore, we recently showed that
ATBF1 is a new candidate of tumor suppressor (Nat. Genet. 2005). In this study, we
investigated the transcriptional regulation of MUC5AC by ATBF1. Materials and Methods:
1. We analyzed ATBF1 and MUC5AC expression in 123 area of 41 gastric cancer specimen
by immunohistochemistry. 2. We explored AT motif like element which ATBF1 might bind
to in MUC5AC promoter region by computer search. 3. To analyze the transcriptional
regulation of MUC5AC by ATBF1, we performed dual luciferase-reporter assay using MKN45
cells. 4. To analyze the transcriptional regulation of MUC5AC by ATBF1 in protein level,
we examined MUC5AC protein expression in MKN45 cells by transfectiing ATBF1 using
confocal microscopy. 5. We performed chromatin immunoprecipitation (ChIP) assay to
assess the binding of ATBF1 to the AT motif like element in MUC5AC promoter region.
Results: 1. Inverse correlation between ATBF1 nuclear staining and MUC5AC staining was
detected (p<.0001) (Table 1). 2. We detected the AT motif like element (-1646~-1634) in
MUC5AC promoter region. 3. Dual luciferase-reporter assay demonstrated that ATBF1
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suppressed the MUC5AC promoter activity to 35% (p<.0001). 4. Overexpressed ATBF1
suppressed endogeneous MUC5AC protein expression in gastric cancer cells. 5. Chromatin
immunoprecipitation (ChIP) revealed that ATBF1 binds to the AT motif like element in
MUC5AC promoter region. Conclusion: ATBF1 binds to the AT motif like element in
MUC5AC promoter region and negatively regulates its transcription in gastric cancer cells.
The negative correlation between ATBF1 and MUC5AC
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Kras and Hypoxia Can Induce VEGF Through C-Myc in Colon Cancer
Yusuke Mizukami, Eva-Maria Duerr, Manish Gala, Won-Seok Jo, Xiaobo Zhang, Yutaka
Kohgo, Daniel C. Chung
BACKGROUND: The induction of VEGF is an essential feature of tumor angiogenesis.
Hypoxia is a potent stimulator of VEGF, and hypoxia inducible factor-1 (HIF-1) is considered
to be critical for its induction. However, we have previously demonstrated that induction
of VEGF by hypoxia both in vitro or in vivo was preserved in the absence of HIF-1alpha
when KRAS signaling was activated. The aim of this study was to clarify the mechanism by
which KRAS and hypoxia can upregulate VEGF independently of HIF-1. METHODS: The
effect of hypoxia on KRAS effector pathways was determined through Western blotting.
Specific inhibitors of ERK, PI3K, Akt, Rho, and ROCK were tested. 5’ VEGF promoter
deletion constructs were designed in order to localize the region of the promoter responsive
to hypoxia. Gel electrophoretic mobility shift assays and site-directed mutagenesis were
performed to characterize the novel response element. Silencing of c-Myc was accomplished
with siRNA duplex oligonucleotides. RESULTS: In colon cancer cells, hypoxia stimulated
multiple KRAS effector pathways including PI3K. Inhibition of Akt did not block the hypoxic
induction of VEGF promoter, but the induction was completely abrogated when the PI3K
targets Rho and ROCK were inhibited. 5’ deletions of the VEGF promoter revealed a region
between -418 bp and -223 bp from the transcriptional start site that was responsive to
hypoxia. Electrophoretic mobility shift assays further defined a fragment between -300 bp
and -251 bp that demonstrated a unique shift only in hypoxic conditions. A binding site
for c-Myc, a target of ROCK, was identified at -271 bp. Activation of both Rho and c-Myc
was demonstrated when colon cancer cells were stimulated by hypoxia, and these effects
were enhanced by KRASV12. Finally, the role of c-Myc in the hypoxic induction of VEGF
was verified by site-directed mutagenesis of the VEGF promoter and silencing of c-Myc by
siRNA. CONCLUSIONS: In colon cancer, VEGF can be synergistically induced by hypoxia
and KRAS. A binding site for c-Myc located at -271 bp of the VEGF promoter can mediate
this effect in a PI3K/Rho/ROCK-dependent and HIF-independent manner. These findings
emphasize the interplay between oncogenic signaling pathways and hypoxia, and highlight
the pivotal role of KRAS in angiogenesis in colon cancer.
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KLF4 Promoter Activity Is Inhibited By the Notch Signaling Pathway
Walden Ai, Adolfo Ferrando, Timothy C. Wang
Introduction: Kruppel like factor 4 (KLF4), a transcription factor and tumor suppressor in
gastrointestinal tract, is required for goblet cell differentiation in colon. Notch regulates the
cell fate decisions of proliferating cells in development and in adult life, including the
development of goblet cells. We hypothesized that KLF4 could be regulated by the Notch
signaling pathway in goblet cell differentiation. Aim: To examine the regulation of KLF4
promoter by the Notch signaling pathway. Methods: Construction of KLF4 promoter
reporters, transient cotransfection and promoter activity assays. Results: 2kb human and
mouse KLF4 promoters were generated by PCR and cloned into the pGL3-basic vector.
Transient cotransfection assays in a human gastric cancer cell line (AGSE cells) and a human
colon cancer cell line (HCT 116 cells) with a constitutively active Notch receptor (ICN1)
construct and a human Hes1 (hHes1) construct showed that the human KLF4 promoter
activity was inhibited by ICN1 and hHes1 (50% inhibition). The mouse KLF4 promoter
activity was also inhibited by overexpression of ICN1 and hHes1 in AGSE cells by the same
assay. A series of 5’ truncation reporters from the full length 2.0kb human KLF4 promoter
were further generated to identify ICN1 and hHes1 responsive elements in the promoter.
While a KLF4 promoter reporter, containing 495bp nucleotide sequence upstream of the
transcription start site (-495bp), showed a similar inhibition by hHes1 as did the full length
KLF4 promoter, further truncation of the promoter to -181bp position totally abrogated the
inhibition of the promoter by hHes1, suggesting that the hHes1-responsive element was
located between -495bp and -181bp upstream of KLF4 promoter. Since hHes1 is a down-
stream target of Notch, we tested the possibility that ICN1 inhibits KLF4 promoter through
hHes1. Surprisingly, an element responsive to ICN1 was identified between -151bp and -
108bp upstream of KLF4 promoter by the same cotransfection assays. Conclusions: KLF4
promoter activity was repressed by constitutively active ICN1 and hHes1. In the human
KLF4 promoter, the responsive element of ICN1 is different from that of hHes1, suggesting
that Notch inhibits KLF4 gene expression by Hes1 dependent and independent mechanisms.
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Krüppel-Like Factor (KLF5) Mediates the Proliferative Effect of Oncogenic K-
RAS in Intestinal Epithelial Cells IEC6 Containing An Inducible K-RAS (IEC-
iK-Ras)
Mandayam O. Nandan, Hongmiao Sheng, Jinyi Shao, Vincent W. Yang
BACKGROUND: Krüppel-like factor 5 (KLF5) is a member of the Krüppel-like family of
transcription factors. Studies indicate that KLF5 expression is enriched in the proliferating
crypt cells of the intestinal epithelium. We previously showed that KLF5 is essential for
mediating the transforming effect of activated H-Ras in H-Ras-transformed NIH3T3
fibroblasts by accelerating cell cycle progression [Nandan et al. (2004) Oncogene 23, 3404;
Nandan et al. (2005) FEBS Lett. 579, 4757]. AIM: To determine the role of KLF5 in K-Ras-
mediated transformation of intestinal epithelial cells IEC6. METHODS: IEC-iK-Ras cells were
established by stable transfection of IEC6 cells with an IPTG-inducible oncogenic K-RasV12G
[Sheng et al. (2001) Cancer Res. 61, 2670]. PD98059 was used to inhibit MEK/ERK activities.
Small interfering RNA (siRNA) specific for KLF5 was used to inhibit KLF5 expression.
Several clonal derivatives of IEC-iK-Ras cells were established from colonies that formed in
soft agar due to K-Ras induction. Cells were examined for KLF5 expression, MEK/ERK
activity, rate of proliferation and transforming potential. RESULTS: The level of KLF5 in
IEC-iK-Ras was increased with the induction of oncogenic K-Ras from IPTG treatment and
was correlated with both accelerated proliferation and anchorage-independent growth in
soft agar. In addition, MEK/ERK activity was significantly elevated in IPTG-treated IEC-iK-
Ras cells. Upon treatment of IPTG-induced IEC-iK-Ras cells with either PD98059 or KLF5-
specific siRNA, the level of KLF5 protein was significantly reduced. This reduction in KLF5
expression abrogated the increased rate of proliferation of IEC-iK-Ras cells from IPTG
induction. Clonal derivatives of IEC-iK-Ras cells, selected from soft agar after prolonged (14
days) IPTG treatment, showed significantly increased basal levels of both K-Ras and KLF5.
These cells exhibited an increased rate of proliferation when compared to the unselected
parental IEC-iK-Ras cells. The levels of KLF5 were further increased in selected clones after
IPTG treatment and were correlated with a further increase in the rate of proliferation.
CONCLUSIONS: Induction of K-Ras in IEC-iK-Ras results in elevated KLF5 expression that
is accompanied by an increase in cell proliferation and MEK/ERK activities. Inhibition
of KLF5 expression by MEK inhibitor or KLF5-speicific siRNA reduces K-Ras-mediated
proliferation. Moreover, stably transformed clones of IEC-iK-Ras cells have an even higher
rate of proliferation that correlates with further increased levels of K-Ras and KLF5. These
results suggest that KLF5 mediates the proliferative effect of K-Ras in intestinal epithelial cells.
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CDX2 Promotes Tumorigenicity in the Human Colon Cancer Cell Line Lovo
Long H. Dang, Fang Chen, Chi Ying, Sang Y. Chun, Stephanie A. Knock, Henry D.
Appelman, Duyen Dang
BACKGROUND: CDX2 is a Drosophila caudal-related homeobox transcription factor that
is important for the establishment and maintenance of intestinal epithelial cells (JBC 1994;
269:15229-37). CDX2 is a marker of colon cancer, with strong staining in up to 90% of
colonic adenocarcinomas (Mod Pathol 2004; 17:1392-9). CDX2 heterozygous-null mice
develop colonic hamartomas, which have suggested that CDX2 is a tumor suppressor (Nature
1997; 386:84-7). However, several lines of evidence have suggested that CDX2 may not be
a tumor suppressor. First, CDX2 does not affect colon cancer xenograft growth (JBC 1998;
273:14030-6). Second, CDX2 is rarely mutated in colon cancer (Br J Cancer 1999; 79: 440-
4). Third, CDX2 has been identified as the transforming event in a mouse model of leukemia
(PNAS USA 2004;101: 817-22). AIM: To determine the functional contributions of CDX2
to colon cancer. METHODS: The CDX2 gene in LOVO cells was sequenced and found to
be not mutated. The CDX2 gene in LOVO cells was disrupted using targeted homologous
recombination (Nature 2004; 416:1). The resulting CDX2-/- cells are isogenic with their
parental cells, with the exception of CDX2 ablation, as confirmed by western blot analyses.
In vitro and in vivo assays were used to assess the effects of CDX2 disruption on tumorigenic-
ity. Four independent clones were analyzed. RESULTS: Consistent with its role as a putative
tumor suppressor, loss of CDX2 led to a 20-30% increase in anchorage-DEpendent colony
formation on plastic culture plates. In contrast, loss of CDX2 led to a fourfold decrease in
anchorage-INdependent colony formation in soft agar. Cell cycle analyses revealed that
CDX2 promotes anchorage-INdependent G1 to S progression and prevents anoikis (pro-
grammed cell death caused by loss of adhesion). CDX2 promotion of anchorage-independent
cell survival was associated with phosphorylation of the anchorage-independent growth
kinases ERK and FAK; increased expression of the anti-apoptotic factor Bcl-2; and decreased
cleavage of caspase-3 and PARP. In vivo xenograft studies confirmed that loss of CDX2 led
to a 5-fold decrease in LOVO xenograft growth. There were no microscopic alterations in
tumor histology. CONCLUSIONS: These data directly demonstrate, for the first time, that
CDX2 mediates anchorage-independent growth and survival in colon cancer cells. This is
consistent with CDX2 mediation of anchorage-independent growth in leukemia cells (PNAS
USA 2004;101: 817-22). These data suggest that CDX2 may have a tumorigenic role in a
subset of colon cancers in which it is expressed.
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ZBP-89 Is Essential for Butyrate-Induced P53 Acetylation At Lys320
Longchuan Bai, Juanita Merchant
BACKGROUND: The zinc finger protein ZBP-89 stabilizes p53 protein and enhances its
transcriptional activity. Studies using ZBP-89 haploinsufficient mice demonstrated that ZBP-
89 is required for p53 phosphorylation at Ser15, the same site targeted by ATM. Ser15
phosphorylation of p53 usually precedes its acetylation at C-terminal lysines by acetyltrans-
ferases (HATs), including K320. Acetylation of p53 at lysine 320 stabilizes p53, enhancing
activation of p53-responsive genes. Since phosphorylation of p53 at Ser15 promotes its
association with CBP/p300 HATs , we tested whether ZBP-89 facilitates p53 acetylation at
K320. METHODS: Human cell lines HCT116 and ataxia telangiectasia (A-T, ATM defective)
fibroblasts were used. Point mutations of p53 and ZBP-89 were generated by site-directed
mutagenesis. The p21waf1 reporter containing 2.4 kb of the human p21waf1 promoter was
used. RESULTS: In ATM-defective A-T cells, we found that basal and trichostatin A (TSA)-
induced p53Ser15 phosphorylation was attenuated as expected since ATM is the kinase
phosphorylating p53Ser15. Moreover, basal and TSA-induced levels of acetylated p53 were
reduced. To assess whether this result was due to the absence of TSA-induced ZBP-89
protein, an immunoblot was performed. TSA significantly increased ZBP-89 protein levels
in the normal but not the A-T fibroblasts, confirming that regulation of ZBP-89 was proximal
to p53 regulation and suggesting a possible role for ATM in ZBP-89 regulation of p53. Next,
we tested whether ATM phosphorylated ZBP-89. Indeed, we found that ATM phosphorylated
ZBP-89 and through a series of truncating mutants mapped the ZBP-89 phosphorylation
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site to Ser202 within the second zinc finger. As ZBP-89 is required for p53Ser15 phosphoryl-
ation, we further tested whether it is also essential for p53 acetylation. We found that reduction
of ZBP-89 with specific siRNA not only blocked butyrate-induced p53 phosphorylation at
Ser15 but also the p53K320 and subsequently diminished butyrate-induction of p21waf1,
a p53 target gene. Examining further the significance of the ATM phosphorylation of ZBP-
89 on p53-dependent transcription, Ser202 in ZBP-89 was disrupted by a point mutation.
We found that the ZBP-89Ser202 mutation reduced p53 induction of p21waf1 expression
by ~30%; whereas a zinc finger deletion completely abolished induction. This suggested
that additional residues within the ZBP-89 zinc finger domain is likely to cooperate with ATM
to regulate p53. CONCLUSIONS: ZBP-89 is essential for butyrate-induced p53 acetylation
at Lys320. ATM phosphorylates ZBP-89 at Ser202, which contributes to p53 induction
of p21waf1.
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Moderate Alcohol Drinking May Not Be the Risk Factor for Fatty Liver in
Health Checkup of Middle-Aged Japanese
Tamaki Yamada, Mitsuru Fukatsu, Sadao Suzuki
(Background/Aim) Fatty liver (FL) associated with multiple metabolic disorders was reported
to be caused by obesity and alcohol drinking, while alcohol consumption is associated with
a lower prevalence of metabolic syndrome (Diabetes Care 2004:27;2954-59. Obes Res
2004:12;1375-85). Therefore, we aimed to determine whether alcohol drinking may be the
risk factor for FL by cross-sectional and longitudinal manners in health checkup of the
apparently healthy middle-aged Japanese. (Methods) 1) Cross-sectional study: 55,615 parti-
cipants without hepatitis virus who received health checkup from 1999 to 2003 (men:
29,101. 49.3±11.8, y.o., women: 26,514. 48.7±11.4 y.o.) were enrolled and data at the first
visit during this period were used to determine characteristics of drinking habits and the
related factors of FL diagnosed by ultrasonography. 2) Longitudinal study: 9,156 participants
of both 1998 and 2003 without hepatitis virus (men: 4,750. 49.1±9.6 y.o., women: 4,406.
48.7±8.9 y.o.) were enrolled to determine the risk factors for newly diagnosed FL by
ultrasonography in 2003. Multiple logistic regression analyses were performed to determine
alcohol drinking as the risk factor for FL in men and women, adjusted for age, body mass
index (BMI), and smoking in the cross-sectional study and these factors and BMI increase
for 5 years in the longitudinal study. (Results) 1) The overall percentages of occasional and
daily drinkers were 33.6 and 45.3% in men and 31.3 and 8.9% in women, respectively.
The average alcohol consumptions in the occasional and daily drinkers were 53.8 and 218.7
g/week in overall, 58.3 and 222.9 g/week in men, and 48.1 and 194.2 g/week in women,
respectively. The prevalence of FL were 17.2, 23.5, and 10.3% in overall, men, and women.
The prevalence of FL in non-, occasional, and daily drinkers were 27.9, 27.3, and 18.6%
in men and 12.2, 7.9, and 5.3% in women, respectively (p<0.01 for both). Occasional and
daily drinking were negatively associated with FL in both sexes (men: occasional, OR:0.86,
95%CI:0.80-0.94. daily, OR:0.56, 95%CI:0.51-0.60. women: occasional, OR:0.78,
95%CI:0.71-0.87. daily, OR:0.57, 95%CI:0.46-0.69). 2) FL was newly developed in 13.3,
17.2, and 9.1% of overall, male, and female participants in 5 years, respectively. Daily
drinking was negatively associated with FL in men (daily, OR:0.77, 95%CI:0.62-0.96).
(Conclusions) In health checkup of middle-aged Japanese, the prevalence of FL was signific-
antly lower in the alcohol drinkers of both sexes and daily alcohol drinking was negatively
associated with FL in men. Our findings suggested that moderate alcohol drinking may not
be the risk factor for FL in these participants.
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Role of Uncoupling Protein-2 in Fasting-Induced Metabolic Response and
Hepatic Steatosis
Anthony Sheets, Peter Fulop, Zoltan Derdak, Edmond Sabo, Jack R. Wands, Gyorgy Baffy
Background: Uncoupling proteins are mitochondrial inner membrane constituents that
mediate regulated proton leak. UCP2 is heavily upregulated in genetically determined and
diet-induced fatty liver, but its biological role remains debated. While UCP3, a muscle
homologue, is implicated in fatty acid metabolism, a similar function for UCP2 has not been
established. Aim: To assess the effect of UCP2 on lipid utilization and disposal in the acute
model of fasting-induced steatosis, which avoids potential confounding effects of insulin
resistance. This work is an extension of previous findings (Hepatology 36(S1): 486A).
Methods: UCP2-/- mice and wild type littermates were fasted up to 72 h with controls fed
on regular diet (n = 5 to 12). We assessed the time course of steatosis (oil-red-O staining
and tissue lipid extraction), serum metabolic parameters, and expression of key genes in
lipid metabolism. Results: While fasting-induced steatosis was prominent in wild type livers
at 24 h and mostly resolved by 72 h, UCP2-/- livers showed delayed but persistent hepatic
fat accumulation (p = 0.017). Hepatic UCP2 mRNA increased in fasted wild type mice to
3-fold by 72 h (p < 0.001). Higher baseline insulin levels typical of UCP2-/- mice plummeted
to same levels as wild type mice after fasting. Serum fatty acid levels showed no genotype
difference. However, fasting-induced decrease of serum triglycerides was delayed in UCP2-/-
mice (24 h, p = 0.024). In addition, fasting-induced increase in expression of carnitine
palmitoyl transferase I, acyl-CoA carboxylase (alpha), acyl-CoA oxidase, D-bifunctional pro-
tein, CYP2E1, and microsomal triglyceride transfer protein was blunted in UCP2-/- mice
(72 h, p = 0.005 to 0.048). Conclusion: Our findings indicate that lack of UCP2 impairs
the effects of fasting on lipid utilization, fatty acid oxidation and VLDL formation, and may
cause prolonged fat accumulation in the fasting liver. Accordingly, the role of UCP2 in lipid


















Low Circulating Dhea Levels in Severe Non-Alcoholic Fatty Liver Disease - A
Potential Metabolic Basis of Disease Progression
Michael R. Charlton, Paul Angulo Hernandez, Phunchai Charatcharoenwitthaya, Lawrence
Burgart, Samer Gawrieh, Keith Lindor, Kimberly Viker, Anuradha Krishnan
Background: The biological basis of variability in histological progression of NAFLD is not
known. More severe non-alcoholic fatty liver disease (NAFLD) is characterized by oxidative
stress, insulin resistance and progressive fibrosis, phenomena which can be modulated by
dehydroepiandrosterone (DHEA). Aim: We evaluated whether circulating DHEA levels vary
between and/or can be used to identify and differentiate patients with mild (simple steatosis
and NASH with fibrosis stage 0-2) and more severe (NASH with fibrosis stage 3-4) NAFLD.
Methods: Serum samples were obtained prospectively at the time of liver biopsy in 78
patients with NAFLD and 44 controls with other forms of liver disease. Serum levels of
DHEA were measured by ELISA. Model building was carried out using logistic regression
techniques. Results: DHEA levels in patients with NAFLD are shown in figure 1. All patients
with more severe NASH (n=25) had low plasma levels of DHEA (<0.45microg/dl). A model
incorporating DHEA (stratified into <0.45 microg/dl >0.45 microg/dl), patient age (<45 vs.
>45) and gender (M vs. F) was found to exhibit the greatest area under the receiver
operator curve (AUC=0.87). A DHEA level of >0.45 microg/dl alone (a level associated with
hypoadrenalism) had both sensitivity and negative predictive value of 100% in distinguishing
between mild and severe NAFLD. Specificity was 58.5%, and positive predictive value was
47.8%. A relationship between histological severity of NAFLD and DHEA levels was not
seen in the control group with cholestatic liver diseases. Conclusions: Patients with more
severe NAFLD, as indicated by the presence of NASH with advanced fibrosis stage, can be
identified with a high degree of accuracy using a simple model. These data provide novel
evidence for relative DHEA deficiency in patients with histologically progressive NASH.
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Increased Sensitivity to Carbon Tetrachloride Hepatotoxicity in the AP2DTA
Mouse Model of Acquired Lipodystropy and Insulin Resistance
Shazia Rafiq, Valerie Andersen, Sateesh K. Satchidanand, Reed Graves, Michael D. Sitrin
Introduction: Non-alcoholic fatty liver disease (NAFLD) most commonly occurs in patients
with the “metabolic syndrome” characterized by insulin resistance. It is currently hypothesized
that progression from NAFLD to nonalcoholic steatohepatitis (NASH) and cirrhosis occurs
because hepatitic steatosis or insulin resistance sensitizes the liver to a “second hit” such as
an oxidant stress, toxin, virus, etc. Testing of this hypothesis and investigation of the
pathogenesis and treatment of NASH has been hampered by lack of appropriate animal
models. The aP2DTA transgenic mouse was developed by linking the diptheria toxin A gene
to the aP2 promoter that directs adipocyte-specific gene expression. These mice develop
adipocyte necrosis and become essentially devoid of fat by 8-9 months, a model of acquired
lipodystrophy. The mice have insulin resistance, dyslipidemia, and in some strains fatty
liver. Methods: In the present studies, adult aP2DTA mice and wild-type littermates in CD1
and C57B1/6J backgrounds (7-10 per group) were given i.p. injections of 0.8 mg/kg body
weight carbon tetrachloride (CCl4) diluted 1:4 in corn oil. After 48 hrs., the mice were
sacrificed, blood collected for measurement of blood glucose, insulin, and serum alanine
aminotransferase (ALT), and liver tissue obtained for histology. Results: As shown in the
Table [mean (SD)], aP2DTA males and females from both strains were insulin resistant,
with elevated glucose and insulin levels. aP2DTA CD1 mice, but not aP2DTA C57B1/6J
mice, had hepatomegaly due to fatty liver. Transgenic mice from both strains had a signific-
antly greater rise in ALT after CCl4 treatment than wild-type controls. Conclusions: aP2DTA
transgenic mice demonstrate greater sensitivity to CCl4-induced hepatoxicity than wild-type
controls. This was observed in mouse strains that differ with respect to hepatic steatosis,
but have similar degrees of insulin resistance, suggesting that insulin resistance rather than
fatty liver is responsible for susceptibility to a hepatotoxin.
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Vitamin D and Parathyroid Hormone (PTH) Status in Adults with Non-
Cholestatic Chronic Liver Disease
Leon Fisher, Alexander A. Fisher
Background: Liver plays a central role in the metabolism of vitamin D resulting in formation
of 25-hydroxyvitamin D [25(OH)D]. In addition to calcium homeostasis, vitamin D affects
immune and epithelial cell functions. In chronic liver disease (CLD) vitamin D status has
mainly been studied in relation to cholestatic diseases and hepatic osteodystrophy. Objective:
To investigate the vitamin D-PTH status in a cohort of patients with non-cholestatic CLD
and its relation to the aetiology and severity of underlying disease. Methods: In a tertiary
referral center (Canberra, latitude 33’15”S) we studied 94 consecutive outpatients [58 males,
36 females, mean age 48.9 +/- 12.2 (SD)] with non-cholestatic CLD due to alcohol use (n=
36), hepatitis C (n=36), hepatitis B (n=12), autoimmune hepatitis (n=4), hemochromatosis
(n=41), NASH (n=2); 45 patients had cirrhosis. The diagnosis was confirmed by biopsy (n=
35), clinical and biochemical features. Serum concentrations of 25(OH)D, immunoreactive
intact PTH (iPTH), calcium, phosphate, magnesium, creatinine and LFT’s were determined
in each subject. Results: Serum 25(OH)D concentration was inadequate in 90.2% of patients,
including severe or moderate deficiency (<25 nmol/L) in 28.3%, mild deficiency (25-49
nmol/L) in 39.1% and hypovitaminosis D (50-80 nmol/L) in 22.8%. Secondary hyperparathy-
roidism (serum iPTH>6.8 pmol/L) was present in 16.1% of patients. The prevalence of low
25(OH)D concentrations (<50 nmol/L) was significantly higher in cirrhotic vs non-cirrhotic
patients (87.5% vs 46.8%, p=0.0001), in subjects with alcohol related CLD compared to
other causes (87.1% vs 53.6%; p=0.004) and in patients with hyperbilirubinemia (>60
mmol/L; 100% vs 56.5%; p=0.0001). Serum 25(OH)D concentration in patients with Child-
Pugh class C was significantly lower than in patients with class A (22.2 +/- 10.5 vs 42.1
+/- 13.5 nmol/L; p=0.0014). Of 54 patients with preserved liver function only 9 (16.7%)
had a desirable level of 25(OH)D (>80 nmol/L). Serum 25(OH)D positively correlated with
serum albumin (r=0.4835; p<0.0001) and negatively with INR (r=-0.4382; p<0.0001),
bilirubin (r=-0.4057; p=0.0001) and ALP (r=-0.3346; p=0.0015). Conclusions: Most patients
with non-cholestatic CLD (90%) have inadequate serum 25(OH)D concentrations and 1/6
have secondary hyperparathyroidism. Hypovitaminosis D is common even in patients with
preserved liver function, and the 25(OH)D level further decreases in parallel with liver
damage. Since vitamin D exerts important calciotropic and non-calciotropic functions, correc-
tion of vitamin D-PTH status may prevent osteoporosis, fractures and improve the course
of CLD. This requires further investigation.
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Protection Against Fatty Liver But Normal Adipogenesis in Mice Lacking
Adipose Differentiation Related Protein (ADFP)
Benny H. Chang, Lan Li, Antoni Paul, Vijayalakshmi Nannegari, William C. Heird, Pradip
Saha, Lawrence Chan
Adipose differentiation related protein (ADFP or ADRP), also known as adipophilin or ADPH,
is a lipid droplet (LD) protein found in most cells and tissues. ADFP expression is strongly
induced in cells with increased lipid load. We have inactivated the Adfp gene in mice to
better understand its role in lipid accumulation. The Adfp-deficient mice have unaltered
adipose differentiation or lipolysis in vitro or in vivo. Importantly, they display a 60%
reduction in hepatic triglyceride (TG), and are resistant to diet-induced fatty liver. To
determine the mechanism for the reduced hepatic TG content, we measured hepatic lipogen-
esis, VLDL secretion, lipid uptake and utilization, all of which parameters were shown to
be similar between mutant and wild-type mice. The finding of similar VLDL output in the
presence of a reduction in total TG in the Adfp-deficient liver is explained by the retention
of TG in the microsomes where VLDL is assembled. Given that lipid droplets are thought
to form from the outer leaflet of the microsomal membrane, the reduction of TG in the
cytosol with concomitant accumulation of TG in the microsome of Adfp-/- suggests that
ADFP may facilitate the formation of new LDs. In the absence of ADFP, impairment of LD
formation is associated with the accumulation of microsomal TG but a reduction in TG in
other subcellular compartments. We crossed Adfp-deficient mice with the leptin deficient
(ob/ob) mice. The double deficient mice maintained similar body weight and adipocity as
those of the leptin deficient alone. They, however, have reduced fatty liver and improved
insulin sensitivity. Adfp, therefore, plays an important role in liver TG storage and is a key
determinant in the development of fatty liver disease.
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Altered Gastrointestinal Motility and Enteric Neuronal Apoptosis in Diabetes
Is Due to Increased Oxidative Stress
Shareen Iqbal, Andrew Gewirtz, Dean Jones, Shanthi Srinivasan
Background and Significance: Chronic diabetes causes complications such as gastroparesis
and altered colonic motility which lead to significant morbidity. These motility related
effects have been attributed to decreased intestinal inhibitory neuronal innervation. We have
previously demonstrated hyperglycemia-induced apoptosis in enteric neurons. We examined
the role of oxidative stress in hyperglycemia-induced apoptosis of enteric neurons and the
ability of Glial Derived Neurotrophic factor (GDNF), on modulating this oxidative stress.
Methods: In vitro experiments were performed in primary enteric neurons isolated by
immunoselection from digested E14 rat embryonic intestines. Apoptosis was assessed using
the Hoechst method. Oxidative stress was assessed by dichlorodihydrofluorescein staining
intensity. Diabetes was induced using intraperitoneal injection of streptozotocin in C57BL6
mice in WT and GFAP-GDNF overexpressing mice. Gastrointestinal motility was measured
by assessing gastric emptying (methylene blue) and intestinal transit. Results: Primary enteric
neurons exposed to 20mM (24 h) glucose have a significantly higher level of apoptosis
(TUNEL method) and levels of reactive oxygen species (dichlorodihydrofluorescein staining
intensity) compared to exposure to 5mM glucose (P <0.001). GDNF reduced this increased
oxidative stress and apoptosis (P <0.001). 8 weeks after inducing diabetes in C57BL6 mice
we find evidence of enhanced enteric neuronal degeneration and apoptosis by electron
microscopy in diabetic mice compared to controls. Diabetic mice had loss of NADPH-
diaphorase staining myenteric neurons, delayed gastric emptying and increased intestinal
transit time. The pathophysiological effects of hyperglycemia (apoptosis, loss of inhibitory
neurons, motility changes) were reversed in diabetic GFAP-GDNF transgenic mice. Conclu-
sions: Hyperglycemia induces enteric neuronal cell apoptosis through increased oxidative
stress. GDNF ameliorates these effects. These studies may provide novel therapeutic strategies
to prevent the neuronal injury that occurs in patients with diabetes.
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Catalase Overexpression in Transgenic Mice Improves Motor Dysfunction in
Dextran Sulfate Sodium (DSS)-Induced Colitis
Weibiao Cao, Zhongmao Guo, Karen M. Harnett, Claudio Fiocchi
We have previously shown that H2O2 is elevated in the circular muscle layer of ulcerative
colitis (UC) patients, and sigmoid circular muscle cells exhibit reduced contraction and Ca2+
signaling in response to the endogenous neurotransmitter neurokinin A (NKA). The H2O2
scavenger catalase reduces H2O2 levels and restores the decreased Ca2+ signal and cell
shortening to normal levels. These observations suggest that H2O2 contributes to the motor
dysfunction of the sigmoid muscle layer in UC. In the present study we investigated whether
overexpression of catalase in transgenic mice could improve motor dysfunction in the model
of dextran sulfate sodium (DSS)-induced colitis. Colitis was induced by feeding mice (C57Bl/
6, 20-22 week old) 1%, 1.5%, 2% or 3% DSS (molecular weight 36000-50000) for 7 days
and the animals were sacrificed on the eighth day. Disease activity index (DAI) was determined
by scoring changes of weight loss, stool consistency and occult/gross blood in the stools
according to well established criteria. In wild-type mice, 2% and 3% DSS caused severe
bloody diarrhea and a >15% weight loss. 1.5% DSS caused moderate bloody diarrhea and
weight loss with good tolerance. 1% DSS caused neither diarrhea nor weight loss. Therefore,
1.5% DSS was used in our study. 1.5% DSS-induced colitis significantly increased the levels
of H2O2 in the distal colonic circular muscle layer of wild-type mice, and significantly
decreased NKA-induced contraction and intracellular Ca2+ increase in circular muscle cells.
In contrast, in catalase-overexpressing transgenic mice, the DAI of 1.5% DSS-induced colitis
was significantly lower, infiltration of inflammatory cells and mucosal ulceration in the distal
colon were less severe, and production of H2O2 in distal circular muscle layer was significantly
lower than in DSS-treated wild-type littermates. In addition, in catalase over-expressing
transgenic mice, the reduction in NKA-induced cell shortening and Ca2+ signal in the distal
colonic circular muscle cells was significantly lower than wild-type littermates. We conclude
that in vivo reduction in H2O2 levels by endogenously overexpressed catalase improves
inflammation and distal colonic motor dysfunction of DSS-induced colitis, confirming a role
of H2O2 in colitis-associated motor dysfunction. Supported by NIDDK R21 DK62775-01
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Hydrogen Peroxide (H2O2) Contributes to Decreased Spontaneous Phasic
Contractions of Human Sigmoid Circular Smooth Muscle in Ulcerative Colitis
Weibiao Cao, Karen M. Harnett, Victor E. Pricolo
We have previously shown that in normal sigmoid circular muscle strips, electrical field
stimulation (EFS)-induced contraction is blocked by the NK-2 antagonist Bz-Ala-Ala-D-Trp-
Phe-D-Pro-Pro-Nle-NH2 (NK-2ra), but not by the NK-1 antagonist FK888, indicating that
NK-2 receptors mediate neurally induced contraction of human sigmoid circular smooth
muscle. In addition, in vitro spontaneous phasic contractions of normal sigmoid circular
smooth muscle are significantly reduced by the NK2 receptor antagonists NK-2ra and
MEN10376, but not by atropine or by the NK1 antagonist FK888, suggesting that NK-2
receptors are involved in development of spontaneous contractions in human sigmoid colon.
In the present study we explored a possible mechanism for reduction of spontaneous phasic
contraction in UC. To confirm that neurokinin A (NKA) is an excitatory neurotransmitter
in normal sigmoid colon, we measured NKA release before and after electircal field stimula-
tion. In basal condition, normal sigmoid circular muscle released 11.8±3.1 pg NKA/g protein/
min. Electrical stimulation significantly increased the NKA release to 128.3±29.7 pg/g protein/
min. Tetrodotoxin (10-5M, 90 min) significantly decreased basal NKA release as well as
EFS-induced NKA release and reduced both spontaneous and EFS-induced contraction.
In addition, spontaneous phasic contractions were abolished by Ca2+-ATPase inhibitors
thapsigargin and cyclopiazonic acid and significantly decreased by the PKC inhibitor cheler-
ythrine and by the calmodulin inhibitor CGS9343B, suggesting that spontaneous phasic
contractions may be mediated by Ca2+ release from intracellular stores and by a PKC- and
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calmodulin-dependent pathway. These inhibitors had no effect on spontaneous NKA release.
In strips from patients with ulcerative colitis, H2O2 levels were significantly higher than in
normal muscle and EFS-induced and spontaneous contractions were significantly lower than
in normal muscle. The reduced contraction was partially restored by the H2O2 scavenger
catalase. NKA release, however, was not affected. In addition , H2O2 significantly affected
NKA-induced release of Ca2+ from intracellular stores. We conclude that spontaneous phasic
contractions of human sigmoid circular smooth muscle are mediated by NKA-induced
calcium release from intracellular stores and activation of calmodulin and PKC. In UC
patients, spontaneous phasic contractions are decreased and this decrease is not related to
decreased release of NKA but rather to overproduction of H2O2 affecting sigmoid circular
muscle, most likely through depletion of releasable calcium stores. Supported by NIDDK
R21 DK62775-01.
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Beta-3 Adrenoceptor Agonism Decreases Motility and Induces Anti-
Hyperalgesia: A Novel Target for IBS
Selim Cellek, Ramkumar Thangiah, Anna K. Bassil, Colin A. Campbell, Kelly H.
Donaldson, Karen M. Gray, Celestine T. O'Shaughnessy, Jennifer L. Stretton, David E.
Uehling, Shanmugam Vivekanandan, Wendy J. Winchester, Gareth J. Sanger, Kevin Lee
Beta-3 adrenoceptor (AR) agonists have previously been shown to relax colonic smooth
muscle and to induce the release of somatostatin (SST), a known endogenous analgesic
substance. Here we demonstrate that a selective beta-3 AR agonist GW427353 (pEC50 =
8.4 in stimulating cAMP accumulation in CHO cells expressing human beta-3 AR; Uehling
et al., J. Med. Chem. Submitted) decreased electrical field stimulation (50 V, 0.5 ms pulse
duration, 5 Hz, for 10 s, every 1 min)-induced cholinergic contractions in human isolated
colon circular muscle. The inhibitory effect of GW427353 on cholinergic contractions
was reversible with beta-3 AR antagonist SR-59230A (1 µM). SST-2 receptor antagonist
CYN154806 or desensitisation to SST did not alter the inhibitory effect of GW427353 on
cholinergic contractions. GW427353 elicited neurogenic release of SST from human colon
strips measured using ELISA; an effect completely inhibited by tetrodotoxin (1 µM) or SR-
59230A (1 µM). GW427353 had no effect on carbachol-induced contractions of the human
colon. Furthermore, immunofluorescence studies demonstrated that beta-3 AR was co-
localised in cholinergic nerve fibres in the human colon with SST. In conscious rats, another
beta-3 AR agonist (CL-316243; 0.3-1 mg/kg po) decreased wet weight of faecal matter
following oral castor oil administration. Similarly, in a model of hyperalgesia, CL-316243
(0.03-0.1 mg/kg, po) decreased the number of arches induced by intrarectal administration
of mustard oil; an effect reversed by a SST-2 receptor antagonist CYN154806 (10 mg/kg,
sc). These results suggest that beta-3 AR agonism inhibits cholinergic contractions in human
colon, an effect consistent with an ability to reduce intestinal motility via SST-independent
mechanisms, while inducing anti-hyperalgesia by releasing SST from enteric nerves. These
dual actions of beta-3 AR agonism represent a novel therapeutic target for diarrhoea-predom-
inant IBS.
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FG7142, a Benzodiazepine Inverse Agonist, Acts Peripherally to Stimulate
Colonic Motor Functions in Rats
Muriel H. Larauche, Lixin Wang, Mulugeta Million, Yvette Tache
Background: Stress induces alterations of colonic motility and secretion via the release of
corticotropin releasing factor (CRF) and activation of CRF1 receptors (CRF1) in rodents and
may have relevance to Irritable Bowel Syndrome (IBS) (Br J Pharmacol 2004;141:1321-30).
The benzodiazepine inverse agonist FG7142 is an anxiogenic drug acting on GABAA receptors.
It suppresses the inhibitory tone of the GABAergic system on the release of CRF in vivo and
in vitro in the paraventricular nucleus of the hypothalamus, a nucleus known to be involved
in the colonic motor alterations induced by stress (AJP 2001;280:G173-7). Aim: To determine
whether FG7142 administered intraperitoneally (IP) in rats alters colonic motor functions
and involves the CRF/CRF1 system as shown in other stress models. Methods: Male and
ovariectomized (OVX) female SD rats (250-300g) were used in 4 experiments to monitor:
1) the colonic and hypothalamo-pituitary-adrenal (HPA) axis responses to FG7142 (2, 10
and 20 mg/kg IP); 2) the role of CRF1 in the effects of FG7142 (10 mg/kg IP) by pretreating
rats subcutaneously (SC) with the CRF1 antagonist NBI-35965 (30 mg/kg) or intracerebroven-
tricularly (ICV) with the CRF1/2 antagonist astressin (10 μg/kg, 10μl); 3) the influence of
estrogen on FG7142 (10 mg/kg IP) effect by pretreating OVX females acutely with 17β-
estradiol (400 μg/rat SC, 18 h before) and 4) the central/peripheral site of action of FG7142
on the modulation of colonic functions by injecting it centrally (30, 100 and 300 μg/rat
ICV). In each experiment, the fecal pellet output (FPO) and corticosterone plasma levels
(CORT) were determined. Results: FG7142 (2, 10 and 20 mg/kg) induced a dose-related
increase in FPO in males (2.3±0.5, 5.0±0.7, 5.8±1.0 pellet/h respectively vs 0 in IP vehicle)
and at 10 mg/kg, 20% had diarrhea. FG7142 (20 mg/kg) induced a 3-fold increase in CORT
(342±24 ng/ml vs 96±15 ng/ml in vehicle). Peripheral NBI-35965, central astressin or 17β-
estradiol did not modify FG7142-induced increased FPO in rats. FG7142 injected centrally
did not reproduce the effects of the peripheral administration on colonic functions. Conclu-
sions: The data show that acute systemic administration of FG7142 in male and female rats
leads to an increase in defecation and an activation of the HPA axis similar to the well
described stress response. The data did not show the CRF1 receptor system involvement,
centrally and/or peripherally in the action of FG7142. Estrogen does not seem to influence
the effect of FG7142. The absence of effect of centrally-injected FG7142 suggests a primary



















Serotonin-Transporter (SERT) Polymorphism Genotype and SERT Expression
in Mucosal Biopsies of Patients with Irritable Bowel Syndrome
Christopher Andrews, Michael Camilleri, Adil E. Bharucha, Paula J. Carlson, Irene Ferber,
Debra Stephens, Raul Urrutia, Jeroen Aerssens, Leen Thielemans, Hinrich Goehlmann,
Ilse van den Wyngaert, Bernard Coulie
Background: A previous study has suggested that irritable bowel syndrome (IBS) with diarrhea
(IBS-D) or constipation (IBS-C) is associated with low mucosal levels of serotonin transporter
(SERT, encoded by the SLC6A4 gene) mRNA and immunoreactivity. Aims: To compare the
mucosal biopsy levels of SLC6A4 mRNA in IBS-C or IBS-D and controls, and to study
whether differences in mucosal SLC6A4 mRNA were associated with polymorphisms of the
SLC6A4 promoter (SERT-P). Methods: Validated bowel symptom questionnaires character-
ized the phenotype in 14 patients with IBS-D, 16 IBS-C and 15 healthy asymptomatic
controls. Subjects underwent SLC6A4 promoter genotyping and rectal and sigmoid colon
mucosal biopsies. Mucosal SLC6A4 mRNA was characterized using RTQ-PCR and compared
between groups using ANOVA. Concordance and reproducibility of sigmoid mucosal SLC6A4
mRNA was assessed on duplicates on same day and median 82 days apart. Fishers’ exact
test compared the proportion of SLC6A4 genotypes in the three groups; the relationship
between tissue SLC6A4 mRNA and genotype was explored. Results: Results from sigmoid
biopsies taken on the same day and median 82 days apart were highly concordant and
reproducible. There were no differences in SLC6A4 mRNA in rectal or sigmoid biopsies
between controls and IBS-C; in contrast, IBS-D was associated with significantly decreased
SLC6A4 mRNA in the sigmoid, but not in rectal biopsies (Fig.). The proportions of SLC6A4
promoter genotypes were unrelated to the SLC6A4 mRNA levels in the sigmoid mucosal
samples. Conclusion: Relative to control tissues, expression of SLC6A4 mRNA in sigmoid
mucosal biopsies is decreased in patients with IBS-D and unchanged in IBS-C; the observed
differences do not appear to be related to SLC6A4 promoter genotype.
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Identification and Validation of Serological IBD Biomarkers By a Novel High
Throughput Proteomic Approach Using High Density Protein Chip Technology
Sean Sullivan, Heng Zhu, Carmen Cuffari, Steve Brant, Shengce Tao, Yueping Chen,
Xuhang Li
Background: Anti-microbial or anti-human (autoantibodies), are present in the sera of patients
with inflammatory bowel disease (IBD), and may be used as serological biomarkers to
enable classification, and may predict disease progression. Herein, we describe a novel high-
throughput and highly sensitive proteomic approach to screen and identify new serological
biomarkers for IBD. Methods: We developed highly reproducible high-density protein chips,
each containing 5800 unique yeast proteins that cover essentially the entire yeast proteome.
Each protein was robotically spotted in duplicate on a 75X25X1 mm glass slides coated
with specific polymer. Each protein chip was used for serological IBD biomarkers screening
using individual sera from normal pediatric subjects and IBD patients. Pediatric patients
were utilized as this population tends to experience less concomitant disease, and is at
relatively earlier stages compared with adult patients. Positive identification was achieved
with a GenePix array scanner using goat anti-human antibodies covalently conjugated with
fluorescent dyes Cy3 or Cy5. The intensity of antibody-protein recognition was quantitatively
measured by fluorescent intensity with automatic subtraction of background surrounding
each protein spot. Results: 45 protein chips were screened against serum from healthy
children and children with IBD. Serum was analyzed from 15 children with active Crohn’s
ileocolitis, and 15 from patients with active pan-ulcerative colitis (UC), and was compared
to healthy controls. Disease activity was defined histologically as moderate to severe for the
majority of patients. More than 220 IBD-specific antibodies, which were defined as antibodies
that were not present in sera of any normal subject, were identified from serum of patients
with UC and Crohn’s disease (CD) patients, suggesting a hyper-inflammatory immune
response. ~20% of the 220 unique yeast proteins recognized by IBD-specific antibodies have
human homologues that can be grouped into 5 major functional classes: ubiquitination,
nucleotide-binding/transcription regulation, signal transduction, cell division, cytoskeleton/
vesicular trafficking. > 40 additional antibodies in CD/UC patients were also present in at
least one of the normal subjects. Among IBD-specific antibodies, ~ 130 were CD-specific
and 40 were UC-specific. Additional 50 antibodies were identified to be present in at least
one of the CD or UC patients studied. A newly designed protein chip, on which all proteins
recognized specifically by IBD sera are robotically spotted, is being tested for its accuracy
and specificity in diagnosis of IBD and differentiation between CD and UC.
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Gastrointestinal Diseases in Chronic Granulomatous Disease
Sushil Ahlawat, Jordan Feld, Nadeem Hussain, David Kleiner, Victoria Anderson, Dianne
Hilligoss, John Gallin, Harry Malech, Steven Holland, Theo Heller, T. Jake Liang, Jay
Hoofnagle
Background: Chronic granulomatous disease (CGD) is a group of hereditary disorders
characterized by the impaired intracellular destruction of certain bacteria and fungi. CGD
affects multiple organ systems. However, a comprehensive clinical picture of gastrointestinal
(GI) tract involvement is lacking. Our aim was to describe the spectrum of GI disease and
its predictors among patients with CGD. Methods: 194 patients with CGD have been followed
at the clinical center of the NIH for a median of 7.8 years. A retrospective chart review was
carried out focusing on the GI tract abnormalities and their treatment. Results: Initial mean
age was 12 years. The genetic defect was identified as gp 91 phox in 110, p22phox in 4,
p47phox in 55, p67phox in 3, and was unknown in 22 patients. Inflammatory conditions
including the obstructive lesions of the GI tract, colitis or enteritis were seen in 42% of
patients. Colitis or enteritis was the most common GI disease in the present series, occurring
in 28% (n=54) of patients. Patients with colitis or enteritis were managed with steroids
(78%), antibiotics such as a combination of ciprofloxacin and metronidazole (30%), and 5-
ASA compounds (21%). Azathioprine or infliximab were used only in 3 patients. Five
patients underwent partial bowel resection or fistula repair. Obstructive lesions of the upper
GI tract were found in 13 % (n=26) of patients. Gastric outlet obstruction was the most
common lesion involving the upper GI tract (n=20). Four patients were noted to have
esophageal dysmotility described as achalasia like abnormalities. Steroids were used to
manage upper GI tract obstructive lesions in 38% (n=20) of patients. Three patients had
endoscopic dilatation and 1 patient required partial bowel resection. Age and gender were
not associated with GI disease; however, Caucasian race including Hispanics was found risk
factor for GI disease (OR = 2.4; CI, 1.1-5.2; p<0.02). p47 phox genotype had significantly
less upper GI disease(OR = 0.38; CI, 0.20-0.72; p<0.003). No significant association was
found between GI disease and mortality. Conclusions: Inflammatory colitis or enteritis and
the gastric or esophageal outlet obstruction are the most common GI diseases in patients
with CGD. Caucasian race appears to be a risk factor for developing GI disease. However,
p47 phox genotype appears to be associated with less upper GI disease, though lower GI
manifestations of colitis and enteritis are seen in a significant number of these patients and
in some cases is the main morbidity associated with their CGD. Mortality was not influenced
by GI disease.
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The Relationship Between Abnormal Innate and Adaptive Immune Function
and Fibrostenosis in Crohn’s Disease Patients
Andrew F. Ippoliti, S Devlin, H Yang, L Mei, K Papadakis, E Vasiliauskas, G Melmed, O
Shaye, P Enyati, G Chen, J Choi, I Nastaskin, Y Patel, E Mehdikhani, K D. Taylor, C
Landers, J I. Rotter, S Targan
Bkgd: Allelic variants of NOD2 have been associated in some studies with fibrostenosing
(FS) phenotype of Crohn’s disease (CD), (Abreu Gastro 2002, Mow Gastro 2004). Multiple
antibodies (ab) to commensual gut microorganisms, ASCA, I2, OmpC, and CBir, are positive
and at high levels in patients with FS, (Mow Gastro 2002, Targan Gastro 2005).The purpose
of this study was to analyze the relationship between NOD2 variants and abs to ASCA, I2,
OmpC, and CBir in CD patients with FS. Methods: Serologic, genetic and phenotypic data
were examined in 745 CD patients. ASCA and abs to I2, OmpC, and CBir were measured
by ELISA. Quartile scores and overall quartile sums (range 4-16) of levels for all abs were
calculated as previously described, (Mow Gastro 2004). Genotyping (TaqmanMGB) was
performed for 3 Crohn’s-associated variants of the NOD2 gene, single nucleotide polymorph-
isms 8, 12, and 13. Phenotypes were determined by chart review by pairs of observers
blinded to serologic and genetic data. Results: FS phenotype was present in 44% of CD
patients. ASCA was present in 51%, I2 in 58%, OmpC in 38%, and CBir in 56% of patients.
NOD2 variants were found in 33% of patients, 27% had one allelic variant and 6% had
two. Among the subgroup with FS phenotype 41% had at least one allelic variant vs 27%
in those without FS, p<.0001 by ChiSquare).There was an increasing prevalence of FS in
patients with 0->4 positive abs; 0=14%, 1=31%, 2=49%, 3=54%, 4=63% (p<.0001).There
was a similar increase in this phenotype when patients were grouped by antibody quartile;
4-6=21%, 7-9=31%, 10-13=55%, and 14-16=60% (p<.0001). These results confirm the
association of FS with NOD2 variants and ab seropositivity in this cohort. Further, NOD2
variants were more common patients with multiple positive abs and high ab levels. Among
the 325 patients with FS the prevalence of NOD2 variants was only 19% in patients without
ab positivity and increased to 60% when all 4 abs were positive. Similarly, in the lowest
quartile group only 19% had NOD2 variants as compared to 64% in the highest quartile
group. NOD2 variants were independently associated with FS when compared to individual
abs; OmpC p<.002, I2 p<.03, CBir p<.0003, ASCA p<.023. However NOD2 variants were
not independently associated with FS when compared to multiple positive abs (p=.97) or
when compared to quartile sums (p=.46). Concl:While both NOD2 variants and antibody
seropositivity are strongly associated with the FS phenotype, it is not an independent
association.This suggests that a patient with defects of innate immunity as well as hyperres-
ponsiveness to commensual microbial antigens (adaptive immunity) will frequently
develop FS.
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Immune-Mediated Inflammatory Disorder Co-Occurrence Among
Inflammatory Bowel Disease Patients in US Healthcare Datasets Between
2001-2002
Don Robinson, Jr, Monica Hackett, Kevin Renahan, Clark Paramore, Kathy Fraeman,
Ning Zhao, Stephen Xu, Mohan Bala
Background: In 2005, Bernstein et al and Gupta et al independently reported a higher risk
for certain other immune-mediated inflammatory disorders (I.M.I.D.s) among inflammatory
bowel disease (IBD) patients in Canadian (Manitoba) and UK healthcare datasets. We report
on similar work conducted in two large US healthcare datasets. Methods: Adult patients
continuously enrolled from 2001-2002 were identified in two US healthcare claim data sets
with initial populations of about 6 and 11 million covered lives, respectively. Patients with
ulcerative colitis (UC) and Crohn’s disease (CD) were identified based on the presence of
one claim with ICD-9 codes corresponding to these diseases. Controls for each disease were
matched 3:1 based on age, gender, US Census region and pre-baseline insurance coverage.
Odds ratios (OR) for the risk of selected I.M.I.D.s were computed between IBD cohorts and
controls; confidence intervals (CI) were estimated using the Mantel-Haenszel method. A
sensitivity analysis was conducted that required at least one inpatient or two ambulatory
face-to-face medical visits to identify patients with UC and CD. Results: The OR for the risk
of selected I.M.I.D.s were consistent across US data sets and IBD sub-types (see Table). CD
and UC patients had risks for these I.M.I.D.s that were similar to the UK and Canadian
findings. The highest OR was for ankylosing spondylitis; an OR of about 2.00 was seen for
rheumatoid arthritis, scleroderma and systemic lupus. These findings persisted in the sensitiv-
ity analysis. Conclusion: This US study confirms previous UK and Canadian reports, sug-
gesting a notably higher likelihood for certain other immune disorders among IBD patients.
Prospective research is needed to confirm these findings and clarify the relationship between
these diseases.
Table: Risk for Selected I.M.I.D.s Among CD and UC Patients*
* I.M.I.D.s reported in either the Canadian or UK study and reported as OR (95%CI)
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A Panel of Serological Antibodies (gASCA, OMP, ACCA, ALCA and AMCA)
Predicts Complicated Disease Course and Surgery in Crohn’s Disease
Marc Ferrante, Marie Pierik, Liesbet Henckaerts, Nir Dotan, Gary L. Norman, Rom T.
Altstock, Iris Dotan, Karolien Claes, Nele van Schuerbeek, Zakera Shums, Benjamin
Schooler, Gert van Assche, Paul Rutgeerts, Severine Vermeire
BACKGROUND & AIMS: Crohn’s disease (CD) presents heterogeneously and may often
lead to complications needing surgery. Several serological markers (ASCA, pANCA, anti-
OmpC, anti-I2) have been identified in IBD and are associated with distinct clinical pheno-
types. We tested if a panel of new serological markers could predict complicated disease
course (as fistulas or strictures) or the need for surgery in Crohn’s disease. METHODS: A
total of 913 CD patients (mean age 42.3 years, 58% female) were tested for Anti Saccharo-
myces cerevisiae Antibodies (gASCA), Outer Membrane Porin antibodies (*Omp), Anti-
Chitobioside Carbohydrate Antibodies (ACCA), Anti-Laminaribioside Carbohydrate Anti-
bodies (ALCA) and Anti-Mannobioside Carbohydrate Antibodies (AMCA) by commercially
available ELISA-assays (Glycominds Ltd, Israel and *INOVA Diagnostics Inc., USA) in a
blinded way. Based on the cut-off values and the number of positive markers a score ranging
from 0 (no serological markers) to 5 (positive for all markers) was developed. Clinical
characteristics on smoking, disease location, complications (strictures or fistulas) and the
need for surgery, were obtained and analyzed using SPSS. RESULTS: Multivariate analysis
using each serological marker separately showed that ACCA, AMCA and Omp were independ-
ently associated with need for surgery (all p<0.01). gASCA also showed a trend for association
with the need for surgery (p=0.06) and was independently associated with a non-inflammat-
ory behavior (p=0.02). Assessing the data from a clinical perspective, a complicated disease
course (strictures or fistulas) needing surgery was independently associated with gASCA (p=
0.002), ACCA (p=0.011), Omp (p=0.008), and ileal (p=0.043) as well as anal (p=0.002)
involvement. Combining the different markers, 126 patients had a score lower than 1 (group
A), 591 had a score between 1 and 3 (group B) and the remaining 196 had a score higher
than 3 (group C). A more complicated disease course (presence of strictures or fistulas) was
noted with an increasing score (from 35% to 60% to 83% respectively; group A vs. B OR
2.80 (1.73-4.53); group A vs. C OR 9.10 (5.01-16.55)). Very similar findings were found
using the need for surgery as outcome (from 33% to 51% to 79% respectively; group A vs.
B OR 2.19 (1.35-3.56); group A vs. C OR 7.95 (4.46-14.17)). DISCUSSION: Our results
illustrate that serological markers directed against glycan-epitopes (gASCA, ACCA, AMCA)
and the outher membrane porins (Omp) are all associated with severe and complicated
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Crohn’s disease and with the need for surgery. Furthermore, a panel of serological markers
may define CD patients with different disease outcome.
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Both Preoperative pANCA and CBIR1 Flagellin Expression in Ulcerative
Colitis (UC) Patients Influence Pouchitis Development After Ileal Pouch-Anal
Anastomosis (IPAA)
Phillip Fleshner, Eric Vasiliauskas, Marla Dubinsky, Ling Mei, Carol Landers, Andrew
Ippoliti, Konstantinos Papadakis, Stephan Targan
PURPOSE: Although most studies of pouchitis after IPAA for UC consider acute pouchitis
(AP) and chronic pouchitis (CP) to be a single entity, several lines of evidence suggest that
they are distinct disease processes. Antibody responses to microbial antigens define different
groups of patients with IBD. Preoperative high-level pANCA (perinuclear antineutrophil
cytoplasmic antibody) expression is associated with CP but not AP development (Fleshner
et al., Gut 2001;49:671). The association of serum responses to CBir1 flagellin with AP or
CP is unknown. AIM: The aim of this study was to assess the association of preoperative
CBir1 flagellin and pANCA expression on AP or CP development after IPAA for UC.
METHODS: Patients were prospectively assessed for the development of clinically and
endoscopically proven AP (antibiotic responsive) or CP (antibiotic dependent or refractory
to antibiotic therapy). Sera obtained at time of colectomy in 238 colitis patients were analyzed
for ANCA and CBir using ELISA. pANCA+ patients were substratified into high-level (>100
EU/ml) and lower-level (<100 EU/ml) groups. RESULTS: There were 171 pANCA+ patients
(72%) and 46 CBir1+ patients (19%). After a median followup of 47 months (range, 3-153
mos), 72 patients (30%) developed pouchitis. Median time to diagnosis of pouchitis was 7
months (range, 1-116 mos). Pouchitis developed in 36% of pANCA+ patients vs. 16% of
pANCA- patients (p=0.005), 46% of CBir1+ patients vs. 26% of CBir1- patients (p=0.02),
and 54% of 35 pANCA+/CBir1+ patients vs. 31% of 136 pANCA+/CBir1- patients (p=0.02).
AP was seen in 43 patients (18%) and CP seen in 29 patients (12%). AP developed in 37
pANCA+ patients (22%) vs. 6 pANCA- patients (9%) (p=0.02), and 12 CBir1+ patients
(26%) vs. 31 CBir1- patients (16%) (p=0.1). Overall pANCA and CBir1 were not associated
with CP development. Twenty-one patients (12%) were high-level (HL) pANCA+ and 150
patients (88%) were lower-level (LL) pANCA+. Although AP was not influenced by pANCA
level, AP was seen in 38% of LL pANCA+/CBir1+ patients vs. 18% LL pANCA+/CBir-
patients (p=0.03). CP was seen in 29% of HL pANCA+ patients vs. 11% of LL pANCA+
patients (p=0.03). There was no significant difference in CP incidence between HL pANCA+/
CBir1+ patients (50%) and LL pANCA+/CBir- patients (20%) (p=0.3). CONCLUSION: Both
pANCA and CBir1 expression are associated with pouchitis after IPAA. AP is influenced by
both lower-level pANCA+ expression and CBir1, whereas CP appears to be linked solely to
high-level pANCA+ expression. These unique serologic patterns suggest that changes in
reactivity to microbial antigens may manifest as different forms of pouchitis after IPAA.
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A Dose-Ranging, Double-Blind, Placebo-Controlled Study of Lubiprostone in
Subjects with Irritable Bowel Syndrome and Constipation (c-IBS)
John F. Johanson, Raymond Panas, P. Christopher Holland, Ryuji Ueno
IBS is a condition that affects nearly 30 million individuals in North America and accounts
for 25-50% of the referrals to gastroenterologists. Lubiprostone is a novel type-2 chloride
channel (ClC-2) activator that has been shown to be efficacious and well tolerated in a
number of well-controlled clinical trials in subjects with chronic constipation. We present
the results from a 12-week dose-ranging study where lubiprostone was tested, for the first
time, exclusively in subjects with IBS with constipation (c-IBS), as defined by the Rome II
Criteria. Methods: Approximately 50 subjects were randomized in a double-blind fashion
to each of the four treatment groups: placebo (0 µg) or 16, 32, or 48 µg lubiprostone daily
(8, 16, or 24 µg BID). In an electronic diary, subjects recorded data relating to dosing,
abdominal symptoms (bloating and discomfort/pain), bowel movements (BMs; frequency
and straining and consistency ratings), and rescue medication use. Weekly diary questions
queried subjects on their assessment of the treatment effectiveness. Trend-tests were used
to detect dose-dependent efficacy relationships and a step-down testing procedure was used
to make pairwise comparisons between the active lubiprostone and placebo groups in the
case of a dose-dependent trend. Safety was assessed by adverse event (AE) incidence rates.
Results: Significant dose-dependent trends were observed during at least 2 of the 3 months
for abdominal discomfort/pain, abdominal bloating, spontaneous BM frequency (SBM), stool
consistency, bowel straining, and assessments of constipation severity. Pairwise comparisons
revealed many significant differences between the active groups and placebo. During months
1 and 2, improvements in abdominal discomfort/pain and SBM frequency rates were more
than doubled in all lubiprostone groups as compared to placebo. Specifically, at Month 1,
decreases from baseline in abdominal discomfort (based on a 5-point scale) were 0.19, 0.45,
0.40, and 0.46 points in the placebo, 16, 32, and 48 µg groups, respectively; at Month 2,
decreases from baseline were 0.23, 0.52, 0.53, and 0.54 points, respectively; and, at Month
3, decreases from baseline were 0.34, 0.56, 0.59, and 0.53 points, respectively. Overall,
improvements were typically highest in the 48 µg group. With respect to safety, dose-
dependent trends were also observed. AE incidence and drop-out rates typically increased
with increasing dose. Conclusion: Lubiprostone is an efficacious and well-tolerated treatment


















Effects of Multidose Administration of MD-1100 On Safety, Tolerability,
Exposure, and Pharmacodynamics in Healthy Subjects
Caroline Kurtz, Don Fitch, Robert W. Busby, Angelika Fretzen, G. Steven Geis, Mark G.
Currie
MD-1100 acetate (MD-1100), a guanylate cyclase-C (GC-C) agonist, is a novel agent that
acts in animal models to promote intestinal secretion and transit and to reduce visceral
pain. These pharmacological actions are ideal attributes for the treatment of constipation-
predominant irritable bowel syndrome (IBS-C) and chronic idiopathic constipation (CIC).
Aim: In an effort to better understand the potential utility of MD-1100 for treating gastrointes-
tinal (GI) disorders, we have begun to characterize its safety, tolerability, exposure, and
pharmacodynamics in healthy male and female subjects. Methods: A placebo-controlled,
double-blind, randomized, multiple dose level study was performed with 48 healthy subjects.
Oral doses of 30, 100, 300 or 1000 μg of MD-1100 or placebo were administered once
daily for 7 days. Subjects were assessed for safety, tolerability, MD-1100 systemic exposure,
and GI pharmacodynamics using the Bristol Stool Form Scale (BSFS). Subjects recorded
stool characteristics including stool frequency, consistency, and ease of passage in diaries
for 7 days preceding dosing and for the duration of the 7 day treatment period. Additionally,
stool weight was measured during the 7 day treatment period. Results: MD-1100 was well
tolerated at all dose levels. There was no detectable systemic exposure to MD-1100 or any
evidence of metabolites at any dose level. All subjects completed the study and there were
no serious adverse events. Subjects who received MD-1100 reported a loosening of stools
during treatment as measured by a statistically significant increase from the baseline in the
mean BSFS stool consistency scores at the 30 μg (p=0.050), 300 μg (p=0.001) and 1000
μg dose levels (p=0.001). Mean ease of stool passage scores showed a statistically significant
increase from baseline at the 1000 μg dose level (p<0.001). Other dose-related indications
of GI pharmacodynamic activity in subjects receiving MD-1100 included increases in stool
frequency and stool weight. Conclusion: In this multiple-dose Phase 1 study, MD-1100 was
well tolerated across the dose range studied (30-1000 μg). There was no detectable systemic
exposure to MD-1100. MD-1100 demonstrated dose-related effects on GI pharmacodynamics
including stool consistency, ease of passage, stool frequency and stool weight. To date, the
preclinical and clinical data in healthy subjects support the potential of MD-1100 for the
treatment of GI disorders, including IBS-C and CIC.
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Predictors of Premature Antidepressant Discontinuation in Functional
Gastrointestinal Disorders (FGIDs): A Survival Analysis Approach
Gregory S. Sayuk, Jill E. Elwing, Patrick J. Lustman, Ray E. Clouse
Antidepressants (AD) are a mainstay in the management of moderate to severe FGID, but
patient adherence to AD regimens can be poor. Preliminary data from a placebo-controlled
trial of a tricyclic antidepressant (TCA) in women with functional bowel disorders suggest
that high degrees of somatic complaints (somatization, SOM) predict subsequent side effects.
Other potential risk factors for premature discontinuation have not been determined nor
have the preliminary findings been confirmed in open-label treatment of broader subject
groups. Methods: 173 consecutive patients (45.9±1.2 yr; 70% female) with FGID (29.6%
IBS) treated with AD specifically for management of the FGID and followed by an academic
gastroenterology practice were studied. Clinical features, AD type, duration of Rx, side effect
type and severity, global AD treatment response (GTR), presence of psychiatric disorder
(PSY: anxiety disorder or depression), and degree of SOM were based on systematic chart
review. High degree of SOM was present if subjects endorsed >7 recent symptoms from the
PHQ-15 or scored >median on # of historical functional GI and non-GI disorders. Survival
analysis methods with Cox proportional hazards models were used to determine independent
predictors of Rx discontinuation with 12 mo of AD initiation. Logistic regression models
were used to determine predictors of maximal GTR as well as side effect severity. Results:
Subjects were followed for 12.4±1.4 mo after AD initiation. At time of discontinuation or
censoring, 94.2% were receiving TCAs with the remainder receiving other agents. High
degree of SOM was present in 41.9% by PHQ-15 threshold; 34.1% had history of PSY. In
Cox models that included age, sex, FGID dx, PSY, and SOM, both high degree of SOM (by
PHQ-15: OR 2.9, 95%CI 1.4-6.3; by medical history: OR 2.5, 95%CI 1.3-4.8; p<0.01 for
each) and male sex (OR 2.8, 95%CI 1.1-6.8; p=0.02) predicted early discontinuation. The
logistic regression models showed that only high degree of SOM predicted poor GTR (OR
3.0, 95%CI 1.3-6.9; p=0.005), whereas both high degree of SOM and male sex predicted
high side effect severity (OR 3.4, 95%CI 1.4-8.7; and OR 2.7, 95%CI 1.03-7.3, respectively;
p<0.05 for each). Conclusions: A high degree of SOM, manifested either by recent symptoms
or a medical hx of functional disorders, is a strong predictor of poor treatment outcome,
side effect severity, and premature Rx discontinuation when AD are used for FGIDs in
clinical practice. Male subjects without high degrees of SOM also tolerate AD poorly. Designs
for clinical trials and treatment algorithms should consider these observations to optimize
adherence to AD maintenance regimens.
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A 10-Day Course of Rifaximin, a Non-Absorbable Antibiotic, Produces a
Durable Improvement in All Symptoms of Irritable Bowel Syndrome: A
Double-Blind Randomized Controlled Study
Mark Pimentel, Sandy Park, Yuthana Kong, Kimberly Low, Soumya Chatterjee, Hyo-Rang
Lee
Recent data suggest a relationship between gut bacteria and IBS symptoms such that improve-
ment in IBS is observed after antibiotic treatment. We have recently reported the beneficial
effects of rifaximin, a non-absorbed antibiotic, on global improvement in IBS. In this sub-
analysis, the component symptoms of IBS and their response to rifaximin are determined.
Methods: Rome I criteria positive IBS patients were enrolled in a double-blind randomized
placebo-controlled study. After a 1-week run in, subjects were asked to complete a symptom
questionnaire with diarrhea, constipation, bloating and abdominal pain rated on a VAS score
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from 0-100mm after which a lactulose breath test was conducted. Subjects were then
randomized to rifaximin 400mg or placebo tid for 10-days. One week after completion of
treatment, subjects repeated their questions. Thereafter, for an additional 9 weeks, subjects
completed a weekly symptom questionnaire. The number of subjects with > 50% improve-
ment in each of the symptom categories was determined over the 10-week follow-up time
period. Two endpoints were examined. The first endpoint was one week after completing
treatment. The second was the overall 10-week period. Results: 87 subjects were randomized
in the study (44 placebo, 43 rifaximin). One week after rifaximin, 48.6% of subjects demon-
strated a clinical response with diarrhea (>50% improved) compared to 23.5% for placebo
(p<0.05). For bloating, 34.9% of subjects demonstrated relief compared to 18.6% for placebo
(p=0.07). At this first endpoint, constipation and abdominal pain were not improved. When
the proportion of patients with clinical improvement (>50% improvement) was determined
for the entire 10-week follow-up period for each symptom, all four symptoms were statistically
improved including bloating (49.2±6.8 vs. 22.6±3.5%, p<0.0000001), diarrhea (50.6±5.7 vs
35.3±6.3%, p<0.00001), abdominal pain (39.7±7.4 vs 28.9±7.2%, p<0.01) and constipation
(35.1±7.0 vs 28.1±5.0%, p<0.05). Conclusions: Rifaximin treatment results in a significant
improvement in the four major symptoms of IBS for 10 weeks after completion of treatment.
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Tegaserod Improves Multiple Symptoms in Women with Mixed/Alternating
Bowel Habits As Well As Those with IBS-C
William D. Chey, Pierre Pare, Andrea Viegas, Gregory Ligozio, Michael A. Shetzline
BACKGROUND: Tegaserod, a promotility agent, is safe and effective in the treatment of
irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. IBS
patients with a mixed or alternating bowel pattern (IBS-M), although clinically distinct,
share clinical characteristics with the IBS-C group. At present, no medical therapy has been
demonstrated to be effective in IBS-M patients. METHODS: A randomized, double-blind,
placebo-controlled, multicenter study was performed in women with IBS-C (Rome II criteria)
and IBS-M (not IBS-C or IBS-D by Rome II). The primary efficacy variable was patients’
assessment of satisfactory relief over 4 weeks’ treatment with tegaserod (T) 6 mg b.i.d. or
placebo (P). The proportion of patients reporting satisfactory relief for≥3 out of 4 treatment
weeks (75% rule) and improvement during each of the 4 weeks in individual IBS symptoms
were also assessed. Treatments were compared using a generalized linear model with logit
link. RESULTS: 661 women were randomized (IBS-C 337; IBS-M 324). Baseline symptom
assessment clearly distinguished between the IBS-C and the IBS-M cohorts. Statistically
significant differences were found between the two cohorts in bowel movement (BM) fre-
quency, stool consistency and straining. Overall, T provided statistically significant improve-
ment in satisfactory relief of IBS symptoms over a 4-week treatment (OR=1.75; 95% CI:
1.35-2.25; p<0.001) for the IBS-C and IBS-M cohorts. In the two cohorts, the percentage
of patients experiencing satisfactory relief of IBS symptoms (75% rule) was significantly
higher for T when compared to P (IBS-C: 43.3% vs 28.9%, p=0.008 and IBS-M: 52.3% vs
36.3%, p=0.010). T was significantly superior (p<0.05) to P at improving weekly BM
frequency (IBS-C: T 6.88, P 6.06 and IBS-M: T 9.78, P 8.34), stool consistency score using
a 7-point scale (IBS-C: T 3.53, P 2.89 and IBS-M: T 3.95, P 3.49) and days/week with
straining (IBS-C: T 3.08, P 3.55 and IBS-M: T 2.42, P 2.87). Adverse event discontinuations
were low (IBS-C: T 1.2% vs P 2.4% and IBS-M: T 2.5% vs P 3.6%). The most frequent
adverse events with discontinuation of study medication were diarrhea (1.1%) and headache
(0.6%). No cases of ischemic colitis were reported. CONCLUSION: This study demonstrates
that T is effective and safe in treating the overall symptoms of IBS in patients with a mixed/
alternating bowel habit. Efficacy in this subgroup was similar to that demonstrated in IBS-
C patients. This is the first study to identify an efficacious medical therapy for patients with
IBS and a mixed bowel pattern.
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Human Visceral Pain Hypersensitivity Is Not Attenuated By a Selective Oral
Neurokinin-1 (NK-1) Receptor Antagonist. A Randomized Double Blind
Placebo Controlled Pharmacodynamic Study in Healthy Volunteers
Robert P. Willert, Claire Delaney, Anthony R. Hobson, Kirsty J. Hicks, Odile E. Dewit,
Qasim Aziz
Introduction: In animal models, use of NK-1 receptor antagonists (NK1RA) and of NK-1
knock-out mice have demonstrated a role of Substance-P (SP) in the development of visceral
hypersensitivity. Aims: To determine whether SP is involved in the development of human
visceral pain hypersensitivity, using a selective NK1RA, in a validated model of acid induced
esophageal hypersensitivity [Willert et al, 2004]. Methods: In 13 healthy subjects (6 male;
mean age 26 years), sensory and pain thresholds to electrical stimulation (mA) were measured
in the proximal esophagus (secondary allodynia) and the foot (somatic control) in a double-
blind randomized 2-period crossover study, pre- and for 4 hours post distal-esophageal acid
infusion. These measurements were taken on the 3rd day of dosing with either an oral
NK1RA or matching placebo, with 2 weeks wash-out between periods. Plasma drug concen-
trations were measured concomitantly to the threshold measurements. The study was
powered to detect an 18mA between treatment difference in post-acid infusion area under
the curve compared to baseline (AUCΔ[PT]PO) in the proximal esophageal pain threshold,
as observed in a previous study of an EP-1 antagonist [Sarkar et al,2003]. Results: Pre-acid
infusion sensory and pain thresholds did not differ between treatments: mean (SD) for the
NK1RA and placebo treatment groups respectively: sensory thresholds: proximal esophagus
7.1 (2.9) and 6.0 (2.3); foot 1.6 (0.6) and 1.7 (0.7); pain thresholds: proximal esophagus
37.2 (12.3) and 37.9 (16.7); foot 39.5 (25.3) and 37.8 (23.7). The reduction in pain
threshold in the the proximal esophagus post acid infusion was similar between treatments
(mean (SD) change from pre- to 4 hours post-acid infusion: -6.1 (6.2) and -5.9 (8.5), NK1RA
and placebo respectively); and for AUCΔ[PT]PO: 95% confidence interval [-18,15]. Plasma
concentrations of the NK1RA overlapped the target exposure range. No serious adverse
events occurred. Conclusions: The results in this study are in keeping with data in human
somatic pain where NK1RA’s did not attenuate hyperalgesia, despite convincing data in
animal somatic and visceral models. The lack of effect of this NK1RA on baseline sensory
or pain thresholds in the esophagus or foot is consistent with published data, where NK-
1 receptor antagonists were anti-hyperalgesic but not analgesic, in non-inflamed states.
References: Willert et al Gastroenterology 2004;126(3):683-692 Sarkar et al Gastroenterol-
ogy 2003;124(1):18-25
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Cost of Illness of Gastroesophageal Reflux Disease (GERD): Comparison of
Medical, Pharmacy, Sick Leave, short- and Long-Term Disability, and Workers’
Compensation Claims and Medical Claims By Place of Service Between
Employees with and Without GERD
Richard A. Brook, Sara Campbell, Peter Wahlqvist, Mari-Ann Wallander, Nathan L.
Kleinman, Ingela Wiklund, James E. Smeeding
OBJECTIVE: To assess the Annual Cost of Illness (CoI) of GERD in an employed population.
METHODS: A retrospective analysis was conducted using the Human Capital Management
Services Research Reference database of multiple large geographically diverse US based
employees with data from 2001 through 2004. Data included medical, pharmacy, payroll
and demographic data. The analysis compared the direct medical costs by Place of Service
(PoS) for a subset of employees where this data was available. ICD-9 Codes were used to
distinguish employees with GERD from the non-GERD cohort. The index date in the GERD
cohort was defined as the date of first diagnosis during 2001 or later, while the average
GERD index date was used in the non-GERD cohort. Regression modeling was used to
measure the cost differences between employees with GERD and employees without GERD
while controlling for age, job tenure, gender, salary, region, and comorbidities. RESULTS:
Data were available for 267,269 employees (4.3% with GERD). The mean age of employees
with GERD was 43 years, and 94% were full time employees. All of the annual CoI and
PoS comparisons (Tables 1 and 2) were statistically different (all P<0.001). GERD was
associated with an annual mean incremental cost of $3,355, of which direct medical costs
accounted for 65%, prescription drug costs for 17%, and indirect costs in terms of sick
leave, short- and long-term disability, and workers’ compensation for 19%. The largest PoS
component (47%) was in the category “Outpatient Hospital or Clinic”. CONCLUSIONS:
GERD is associated with substantial direct and indirect costs, of which direct medical costs
excluding prescription medications contributed to 65% of total incremental costs in this study.
Table 1. Cost of Illness
Table 2. Mean Direct Medical Costs by Place of Service
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Nighttime GERD and More Severe GERD Symptomatology Are Associated
with Greater Work Productivity Loss
Adam B. Elfant, Stephen M. Lange, Quan V. Doan, Lynda S. Welage, Stephen Brunton,
Richard B. Lynn, Robert W. Dubois
OBJECTIVE: To assess the relationship between work productivity loss and GERD-related
severity among daytime (DG) and nighttime GERD (NG) cases. METHODS: A survey was
conducted among adults. A screening questionnaire assessed frequency and severity of GERD
symptoms during the past 12 months and past 7 days and identified GERD cases and controls.
GERD was assessed using the validated GERD Symptom & Medication Questionnaire (GERD-
SMQ). Symptomatic GERD was defined as GERD-SMQ score >9 and =>1 episode of heartburn
or acid reflux during the past 7 days. Symptomatic NG was defined as individuals with
GERD reporting =>2 nights with symptoms (whether or not daytime symptoms are present)
or 1 night with symptoms (in absence of daytime symptoms). A maximum value from 4
severity ratings of heartburn and acid regurgitation (each based on a 10-point Likert scale)
was used as the severity score to stratify patients into the following severity groups: mild
(1-4), moderate (5-7) and severe (8-10). Among the DG and NG cases, the severity score
was based solely on the 2 nighttime severity ratings and solely on the 2 daytime severity
ratings, respectively. GERD-specific productivity losses were assessed using the validated
Worker Productivity & Activity Impairment Questionnaire (WPAI), which measures work
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time absenteeism and impairment while working. Mean percent reductions in Work Produc-
tivity Scores (WPS) were calculated for all GERD, NG and DG cases and differences were
assessed using statistical test. RESULTS: 13,231 (21.4%) of 65,001 invited to participate
responded; 1,515 satisfied the study criteria (mean age 44.3 years; 57% women). Of these,
1002 were symptomatic GERD cases (475 NG vs 469 DG) and 513 were non-GERD controls.
More severe symptoms were associated with statistically greater work productivity loss among
GERD, DG, and NG cases. Overall, patients with NG suffered significantly greater work
productivity loss compared with DG cases (P<0.05). Patients with NG in moderate or severe
strata had statistically greater work impairment than DG cases. CONCLUSIONS: GERD-
related symptom severity is strongly associated with work impairment. Patients with NG
reported substantially greater work impairment in every severity stratum compared with
DG cases.
GERD-specific Work Productivity Loss
* P<0.05 Φ 58 cases w/missing data excluded ψ P<0.05, comparison of DG and NG
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Gastroesophageal Reflux Disease As a Cause of Death Is Increasing: A
Population Based Analysis of Fatal Cases After Conservative and Operative
Treatment
Jarmo A. Salo, Tuomo K. Rantanen, Jari V. Rasanen, Eero I. Sihvo
Background: Only few population based analyses of fatal outcome of gastroesophageal reflux
disease (GERD) exist. Therefore, we evaluated, using unselected population based data, the
mortality of GERD and compared this to the use of health resources. Methods: All death
certificates in which esophagitis, esophageal ulcer, stricture, or hiatus hernia were mentioned
between January 1st 1987 and December 31st 2000 in Finland were obtained. The medical
records of these 306 patients were analyzed. Objective findings and symptoms were recorded
to ascertain the diagnosis of GERD and 93 patients had to be excluded due to uncertain
diagnosis of GERD. National use of antireflux medication and rate of antireflux surgery
(obligatory annual report given by all Finnish hospitals to the Central Registry of National
Research and Development Center for Welfare and Health) were assessed by using Finland’s
administrative databases. Results: From 1987 to 2000 the annual mortality of GERD increased
(p<0.001) from 0.18/100 000 to 0.46/100 000. The increase was seen in patients under
conservative treatment. Annual mortality of antireflux surgery stayed around 1.9/1000 opera-
tions. At the same time, use of H2-blockers, proton pump inhibitors, and annual rate of
antireflux surgery increased significantly (p<0.001). Of 213 patients whose cause of death
was GERD, 185 (87%) had undergone conservative treatment, 24 (11%) antireflux surgery,
and 4 (2%) diagnostic or therapeutic endoscopy. The most common cause of death in the
conservative group was hemorrhagic esophagitis (85/185, 46%) followed by aspiration
pneumonia (46/185, 25%), esophageal ulcer perforation (25/185, 14%), spontaneous eso-
phageal rupture (15/185, 8%)and esophageal stricture (14/185, 8%), and at the interventional
group gastric or esophageal perforation (14/28, 50%). Conclusions: Regardless of the
increased usage of health resources the mortality of GERD, especially under conservative
treatment, has increased. The mortality of antireflux surgery seems, however, to be 5 to 10
times greater than estimated mortality of symptomatic erosive esophagitis under conservat-
ive treatment.
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Association Between Erosive Esophagitis and Visceral Fat Accumulation
Quantified By Abdominal CT Scan: A Case Control Study
Hang Lak Lee, Oh Young Lee, Yong Chul Jeon, Dong Soo Han, Byung Chul Yoon, Ho
Soon Choi, Soon Young Song, Jin Bae Kim
Backgroud & Aims: To date, many studies have reported on the association between obesity
and reflux esophagitis, although none of these were conducted systematically. There was
no objective data between erosive esophagitis and abdominal fat mass. BMI and other classical
anthropometric measure are imperfect estimates of adiposity, particularly in male, mainly
because of greater muscle mass. Computed tomography quantifies subcutaneous and internal
abdominal fat, allowing measurement of visceral fat (VF) and determination of its relation with
disease risk. Under these backgrounds, we conducted this study to examine the association of
abdominal obesity and reflux esophagitis. Methods: Between May 2004 and October 2005, a
total of 100 erosive esophagitis diagnosed by upper endoscopy were included in a prospective
manner. Control subjects, age and sex matched, without erosive esophagitis and any reflux
symptoms, were included. All of patients and control groups conducted abdominal CT scan.
Body fat distribution was assessed by CT with 10-mm-thick slice at the level of the fourth
lumbar vertebra. VF area was defined all of the pixels with attenuation coefficients of adipose
tissue. Subcutaneous fat (SF) area was defined as the adipose area between the two defined
contours and total fat (TF) area was defined as the sum of VF and SF. Results: Erosive
esophagitis patients presented with a significantly higher mean visceral fat area (104.68 ±
39.47 vs. 75.90 ± 49.10 cm2, p=0.014) than control group. However, there was no association
between erosive esophagitis and subcutaneous fat areas (109.72 ± 49.09 vs. 98.66 ± 52.43
cm2, p=0.379) and total fat areas (214.41 ± 78.78 vs. 172.59 ± 90.49 cm2, p=0.054).
Multivariate logistic regression analysis demonstrated that hiatal hernia (p=0.0001), high
body mass index (p=0.047), high visceral fat areas (p=0.0035), and smoking (p=0.005) are
independent factors associated with erosive esophagitis. Conclusions: These results suggest


















Characteristics of Patients with Gastroesophageal Reflux Disease (GERD)
Who Respond Incompletely to Therapy with Proton Pump Inhibitors
Roger Jones, Harley Liker, Phillippe Ducrotte
Objective: Proton pump inhibitors (PPIs) are useful in the treatment of GERD, although a
number of patients receiving PPI treatment still experience symptoms. In addition to assessing
the frequency and severity of GERD symptoms in the general population, one objective of
this large survey was to characterize patients who have incomplete responses to PPI therapy.
Methods: People suffering from symptoms of GERD were identified by random telephone
screening of >200,000 households in the USA, UK, Germany and France. Those who agreed
to participate in the survey had face-to-face interviews. Patients diagnosed with GERD who
were receiving PPIs were defined as complete responders (no symptoms), well controlled
(used a PPI compliantly, experienced an improvement in or decrease in frequency of symp-
toms, and suffered key GERD symptoms on ≤1 of the past 7 days), incomplete responders
(the same definition as well controlled but with symptoms on ≥2 of the past 7 days), or
non responders (no improvement or symptoms worsened). Results: Of the 537 PPI users,
23% were complete responders, 12% well controlled, 46% incomplete responders, 9% non
responders, and 10% other (e.g. responded but were non-compliant). Incomplete responders
and non responders had suffered GERD symptoms for significantly more days of the past
week (table). Incomplete responders were significantly more likely than more responsive
patients to have concomitant anxiety (25%), migraine (24%), irritable bowel syndrome
(22%), or chest pain (13%). They had been receiving their current PPI for significantly
longer than well controlled patients (2.4 vs 1.6 years). Incomplete responders were more
likely than complete responders or well controlled patients to experience sleep disturbed
by GERD symptoms (49% vs 0% and 30%). Their symptoms were more likely to impact
quality-of-life (QOL) measures (tired or worn out, generally unwell, having worries or fears,
difficulty socializing, eating less than usual), they thought about their condition significantly
more often, and their perceived seriousness of the condition was significantly higher. Conclu-
sions: Despite good compliance, a large proportion of patients receiving PPIs have incom-
pletely controlled GERD. Interestingly, these incomplete responders are more likely to
experience concomitant conditions and to have impaired QOL than responsive patients.
Frequency of GERD symptoms (days) in the past week in patients receiving PPIs
148
The Extracellular Matrix Component Hyaluronan (HA) Is Increased Over Time
in the DSS Model of Colitis, and Precedes Leukocyte Influx. Monocyte
Interaction with HA Affects Migration and Gene Expression
Carol A. de la Motte, Sudip K. Bandyopadhyay, Sean Kessler, Scott A. Strong
Background: Hyaluronan (HA) levels are increased in human colonic mucosa involved in
active inflammatory bowel disease (IBD), as compared to non-inflamed tissues. HA appears
to emanate largely from the muscularis mucosae. Additionally, we have shown the generation
of leukocyte adhesive hyaluronan structures in vitro from colonic mucosal smooth muscle
cells (M-SMC) treated with virus or stimulated with a viral mimetic, poly I:C (synthetic
double stranded RNA), among other cell stressors, but not cytokines. The question of whether
hyaluronan accumulation is promoting leukocyte infiltration or is a result of the inflammation
has not previously been determined, and a mouse model of colitis was chosen to follow the
course of hyaluronan deposition and inflammation in vivo. The impact of monocyte binding
to HA in vitro was also assessed. Methods: 8wk old C57Bl/6 mice were treated with or
without 2.5% dextran sulfate sodium (DSS) via their drinking water. Individuals were
sacrificed periodically over the two-week duration of treatment and the colon tissue fixed,
sectioned and stained for histologic analysis and HA detection. HA leukocyte binding struc-
tures were generated in M-SMC cultures from surgically resected human colon by treating
with or without poly I:C for 18 hours. Isolated peripheral blood monocytes were used to
assess the effect of HA on RANTES-driven migration across a M-SMC monolayer. Additionally,
gene expression was compared between HA-bound and non-bound monocytes in HA produ-
cing M-SMC cultures by Affymetrix gene array. Results and Discussion: DSS-induced colitis
mice showed a time dependent change in HA deposition, especially pronounced in the distal
colon, which preceded the mucosal influx of leukocytes. In vitro, smooth muscle cultures
producing leukocyte adhesive HA impeded monocyte transmigration across M-SMC mono-
layers in response to RANTES compared to non-producing cultures, suggesting that HA
contributes to leukocyte retention in tissue. Additionally, monocyte binding to HA induced
the expression of greater than 8 fold increases in the expression of over 100 genes, many
of which are growth factor related and could contribute to the smooth muscle cell hyperplasia
typical of IBD pathology. Significance: We have previously reported HA accumulation in
the mucosa of inflamed IBD colon, and demonstrated that M-SMC generate HA-based
leukocyte adhesive structures in response to viral, as well as endoplasmic reticulum stress
inducing agents. The findings that HA deposition precedes inflammation, has an impact on
monocyte migration and triggers gene expression supports the idea that HA is an active
participant in the pathological process.
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The Role of the Pro-Inflammatory Mediator S100a12 in IBD
D.R. Foell, Helmut Wittkowski, Dorothee Viemann, Jan Heidemann, Pia Lebiez, Torsten
Kucharzik, Johannes Roth
Objectives: S100A12 is a pro-inflammatory protein expressed and secreted by neutrophils.
S100A12 lacks a leader sequence necessary for trafficking via the endoplasmatic reticulum
or the Golgi complex. Binding of released S100A12 to the receptor for advanced glycosylation
end products (RAGE) activates endothelium and leukocytes. Blocking S100A12 activity
revealed promising therapeutic effects in various murine models of colitis. In previous studies
we found that IBD patients in remission who have residual inflammation not leading to
clinically apparent signs of disease activity nevertheless had elevated S100A12 serum levels.
Methods: We investigated mechanisms involved in S100a12 secretion. S100A12-induced
effects on human endothelial cells (HMECs and HUVECs) and human intestinal microvascular
endothelial cells (HIMECs) were analyzed. Signaling pathways leading to pro-inflammatory
activation of target cells have been investigated. Sensitivity of S100A12 serum measurements
for the detection of relapsing disease activity was analyzed by ELISA serum samples from
IBD patients who were followed up prospectively. Results: S100A12 secretion follows an
alternative pathway bypassing the classical Golgi-route. Secretion depends upon intact micro-
tubules and protein kinase C (PKC). Erk1/Erk2 and Syk signaling are involved. Stimulation
of HMECs and HIMECs with S100A12 increased surface expression of VCAM-1 and ICAM-
1, decreased endothelial resistance and promoted transendothelial migration of phagocytes.
After S100A12-stimulation, pro-inflammatory genes were upregulated in endothelial cells.
S100A12 serum levels were significantly elevated in patients with inactive IBD prior relapses
compared to patients in stable remission. Conclusions: Released S100A12 is a mediator
which activates immune cells critical to pathogenesis of colitis. Activation of intestinal
endothelium by S100A12 leads to enhanced extravasation of neutrophils, thus promoting
infiltration of intestinal tissue. The pro-inflammatory properties of S100A12 make this
neutrophilic protein an attractive target for anti-inflammatory therapies. S100A12 may pro-
vide an ecellent serum marker for the early detection of relapsing colitis.
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Enhanced Platelet Adhesion Induces Angiogenesis in the IBD Microcirculation
Silvio Danese, Franco Scaldaferri, Cristina Graziani, Carol de la Motte, Alessandro
Sgambato, Alfredo Papa, Achille Cittadini, Antonio Gasbarrini, Claudio Fiocchi
Platelet (PLT) dysfunction is a prominent feature of inflammatory bowel disease (IBD) and
PLTs actively contribute to gut inflammation. We recently reported that angiogenesis is a
novel component of IBD pathogenesis, but the cell type(s) promoting angiogenesis in the
inflamed mucosa are still undefined. We investigated whether PLTs contribute to induction
of angiogenesis in IBD. Unstimulated or thrombin-activated human PLT were overlaid on
resting or TNF-α-treated human intestinal microvascular endothelial cells (HIMEC), in the
presence and absence of VCAM-1, -ICAM-1 or -integrinαvβ3 blocking antibodies. Expression
of VCAM-1, ICAM-1 and αvβ3 was analyzed by flow cytometry, adhesion of PLTs to
endothelium was measured by fluorescence microscopy, and presence of angiogenic factors
(VEGF, bFGF and sCD40L) in culture supernatants was checked by ELISA. A matrigel
tubule formation assay was used to evaluate the capacity of PLTs to induce HIMEC angiogen-
esis. TNF-α strongly up-regulated VCAM-1, ICAM-1 and αvβ3 expression on HIMEC (all
p<0.01). Unstimulated HIMEC bound few PLT, but adhesion increased significantly (p<0.05)
in TNF-α pre-treated HIMEC, reflecting the greater capacity of inflamed endothelium to
recruit cells. When activated PLT were co-cultured with unstimulated HIMEC, a significant
(p<0.01) increase in PLT adhesion was observed, and adhesion further increased when
HIMEC and PLTs were concomitantly activated. Adhesion was ICAM-1- and integrin αvβ3-
(both at p<0.05), but not VCAM-1, -dependent. VEGF, bFGF and sCD40L were not detected
in HIMEC cultures either before or after TNF-α stimulation. In contrast, co-cultures of
resting HIMEC with resting PLT contained small amounts of PLT-derived VEGF and sCD40L,
which significantly (p<0.05) increased when resting or activated PLT were placed on TNF-
α-pre-treated HIMEC. bFGF was not detected in any of the co-cultures. Finally, activated
PLT significantly induced HIMEC tubule formation. PLT adhesion is maximal with TNF-
α-pre-treated HIMEC, a process mediated by ICAM-1 and αvβ3, and accompanied by the
release of PLT-derived VEGF and sCD40L. This indicates that, in inflammatory conditions
like IBD, the mucosal microcirculation displays an enhanced capacity to recruit PLT which,
upon contact, actively release angiogenic factors able to promote angiogenesis in the inflamed
mucosal microvasculature.
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PD-L1/PD-1-Mediated Interaction Between Normal and Ulcerative Colitis-
Derived Colonic Myofibroblasts and T Cells
Irina V. Pinchuk, Jamal I. Saada, Ellen J. Beswick, Julia Brenmoehl, Giovanni Suarez,
Patrick A. Adegboyega, Randy C. Mifflin, Victor E. Reyes, Gerhard Rogler, Don W. Powell
BACKGROUND: Current theories regarding the pathogenesis of ulcerative colitis (UC) sug-
gest that UC represents a disruption of tolerance to intestinal microflora, leading to dysregul-
ation of mucosal CD4+T cell responses and chronic inflammation. Recent evidence indicates
that regulation of this response involves, at least in part, PD-1/PD-L1 negative co-stimulator
interactions between T cells and antigen presenting cells (APC). Moreover, strong upregul-
ation of these molecules has been observed in the inflamed colon of with inflammatory
bowel disease patients. However, the nature and spectrum of PD-L1-expressing APCs in
normal and inflamed colon are poorly characterized. We recently reported that normal
human colonic myofibroblasts (CMFs), which are located in the lamina propria just beneath
the epithelial layer, are novel non professional APCs that constitutively express negative
(PD-L1 and PD-L2) and positive (ICOSL and B7-H3) costimulators and can suppress prolif-
eration of CD3-activated CD4+T cells. We thus hypothesize that PD-L1+ CMFs are novel,
local negative regulator of T cells in the colon and that abnormalities in CMF-mediated
immune inhibitory signals may contribute to UC pathogenesis. METHODS: We have analyzed
expression of PD-L1 by using FACS analysis of acutely isolated and cultured CMFs and
evaluated PD-L1 involvement in CMF mediated suppression of CD3-activated CD4+ T cells
using lymphoproliferation assays and IL-2 ELISA. A combination of real time RT-PCR,
Western Blot and FACS analysis was used to compare PD-L1 expression by CMFs from UC
patients versus the control group. RESULTS: We demonstrated that ~ 15% of freshly isolated
lamina propria mononuclear cells from normal mucosa constitutively express PD-L1. CMFs
represented ~ 80 % of this PD-L1-expressing population. In vitro functional analyses demon-
strated that CMFs suppress proliferation of CD3-activated CD45RA+CD4+T cells via cell-
contact-dependent mechanisms. Blockade of PD-L1 on CMFs enhanced T cell proliferation
and IL-2 production. When compared to normal colon, a significant increase in PD-L1, but
not PD-L2, was observed on CMFs isolated from UC patients. CONCLUSIONS: These results
are consistent with the hypothesis that CMFs expression of negative co-stimulators may
favor their suppressive function on the response of activated CD4+ T cells in the colonic
mucosa. Our data also indicate that PD-L1 contributes to the CMF-mediated suppressive
capacity and suggest that abnormalities in expression of this molecule on CMFs may play
a role in UC associated immunopathogenesis. Supported by NIDDK, GRIP and the Gulf
Coast DDC, James W McLaughlin Endowment.
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Enteric Glia (EGC) Are Activated By Bacterial Products Via Nod and Nuclear
Factor-Kappab (Nf-κB) Signaling
Eike Hollenbach, Manfred Neumann, Michael Vieth, Bruce Vallance, Peter Malfertheiner,
Anne Ruhl
We have previously shown that EGC may participate in intestinal immune responses via
phagocytosis, upregulation of MHC II and ICAM-1 in response to proinflammatory signals,
MHC-II restricted and antigen-specific stimulation of syngeneic T-cells, and production of
cytokines. Here, we have investigated if EGC can be activated by bacterial products like
peptidoglycans (PGN), employing an H. pylori based model of intracellular translocation of
PGN. Sixty min post infection (p.i.) of EGC with a wild type (wt) H. pylori strain possessing
a type IV secretion system for PGN translocation, immunoblot analysis revealed a strong
peak of IκBα-degradation while no significant IκBα-degradation could be detected after
infection with a mutant strain without secretion system. Nuclear translocation of p65 peaked
with expected delay at 60-90 min p.i. only in EGC previously infected with wt H. pylori. These
findings were confirmed by EMSA revealing active p65/p50 and p65/c-Rel heterodimeric NF-
κB complexes in EGC infected with wt H. pylori only. To further analyse the signaling
pathways induced by immune-activation of EGC, we studied upregulation of NOD, MAP
kinases p38 and ERK in EGC upon PGN challenge. Because Rip-like interacting caspase-
like apoptosis-regulatory protein kinase (RICK) is a critical downstream kinase of NOD and
as such key component of a pathway leading to NF-κB activation, we assessed RICK activation
after intracellular PGN translocation by in vitro kinase assays. We found that RICK activity
is dramatically upregulated after delivery of PGNs into EGC peaking at 60 min p.i. While
the mutant H. pylori strain did not activate RICK, p38 and ERK were activated by both H.
pylori strains with a maximum at 30 min p.i. Of note, only ERK but not p38 activation was
completely independent of intracellular PGN delivery. Finally, we validated these data in
salmonella typhimurium infected mice. Immunohistochemical analysis of murine ceca
revealed enhanced nuclear translocation of the transcriptionally active phosphorylated p65
in EGC 24hrs p.i., while NF-κB activation in macrophages peaked at 48hrs p.i. Overall,
bacterial products induce strong and early responses in EGC with activation of the RICK/
NF-κB signaling cascade as well as the MAP-kinase pathway. These data implicate EGC as
a supplementary immunoregulatory cell-type in the intestine which supports the innate
immune system. Supported by Broad Medical Research Program IBD-0105R.
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Mesenteric Adipose Tissue Is An Important Source of C-Reactive Protein in
Crohn’s Disease
Florent Gonzalez, Christel Rousseaux, Laurent Dubuquoy, Xavier Thuru, Cecilia
Decourcelle, Luc Gambiez, Alain Saudemont, Christel Neut, Luc Penicaud, Jean-Frederic
Colombel, Pierre Desreumaux
Background: C-reactive protein (CRP) is an important biomarker in Crohn’s disease. Its
production is believed to mainly occur in the liver by the hepatocytes as part of the
acute phase response upon stimulation by inflammatory cytokines originating at the site of
inflammation. Mesenteric adipose tissue (MAT) hypertrophy is a characteristic feature of
CD. There is accumulating evidence that adipocytes from the mesentery may participate in
the immune response in CD. We hypothesize that adipocytes from MAT constitute an
important extra-hepatic source of CRP in CD. Aim: A)to study in vitro expression and
regulation of CRP in adipocytes; B)to quantify the expression of CRP in the MAT and the
intestine of patients with CD and ulcerative colitis (UC) and of controls. Methods: A) Primary
cultures of human adipocytes, murine 3T3-L1 preadipocytes and mature adipocytes, and
HepG2 human hepatocytes were used. CRP mRNA levels were quantified in resting cells
and after activation by inflammatory cytokines and bacterial components. B) Ex vivo, CRP
expression was quantified in paired biopsy specimens of MAT, subcutaneous adipose tissue,
healthy and inflamed ileal and colonic tissues of 29 CD patients, 17 UC patients and 13
controls. CRP was assessed by real-time polymerase chain reaction and immunochemistry.
Results: A) CRP mRNA levels were similar in resting mature adipocytes and hepatocytes.
Adipocyte differentiation as estimated by morphological features and expression of adipocyte
fatty acid binding protein (aP2) was associated with a 21±2.5 fold increase of CRP mRNA
levels. CRP mRNA expression increased 2290±350 fold the resting cell level after stimulation
with E. coli (p<0.01), 50±5 fold with LPS (p<0.01) and 20±3 fold with TNFα (p<0.01). B)
Low and similar CRP mRNA levels were detected in the healthy and inflamed small bowel
and colon of CD, UC and controls. CRP mRNA levels were 150±90 times higher in MAT
and 145 ± 87 times higher in the subcutaneous adipose tissues than in the intestine of UC
and controls. Patients with CD were characterized by a dramatic over-expression of CRP
mRNA levels in MAT, which were 80±40 (p<0.05) and 1450±750 (p<0.01) times higher
compared to CRP levels detected in MAT of UC and controls respectively. No difference
was observed between the subcutaneous tissues of CD, UC and controls. These results were
confirmed and extended using immunohistochemistry. Conclusion: CRP is expressed by
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adipocytes and is induced by specific stimuli such as E. coli, LPS and TNFα. Healthy and
inflamed intestine is a minor source of CRP. MAT in CD is characterized by an increased
production of CRP which may participate to the elevated plasma levels.
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Activation of the Cholecystokinin-1 Receptor Subtype Attenuates Development
of Desensitization of Opioid Receptors in Morphologically-Identified
Myenteric S-Type Neurons in Guinea-Pig Small Intestine
Yun Xia, Guo-Du Wang, Xiyu Wang, Sumei Liu, Na Gao, Gui-Jun Fie, Hong-Zhen Hu,
Jackie D. Wood
Cholecystokinin (CCK) and opioid peptides are well recognized as important signaling
molecules in enteric neural control of gastrointestinal motility and secretion. We used
intracellular electrophysiological recording methods to investigate how the two neuropeptides
interact in the small intestinal myenteric plexus. Bath application of the μ-opioid receptor
agonist [Tyr-D-Ala-Gly-MePhe-Gly-ol]enkphalin (DAMGO, 10-500 nM) evoked slowly-
activating hyperpolarization of the membrane potential ranging from 6 to 18 mV in 22 of
38 S-Type neurons in 31 whole-mount myenteric plexus preparations. The hyperpolarizing
responses, evoked by DAMGO, were suppressed by the selective mu-opioid receptor antagon-
ist cyprodime (10 μM). Desensitization occurred in 16 of 22 S-Type neurons when 200-
nM DAMGO was applied 4 or 6 times in 10-min exposures within a 2-hour period.
Application of the CCK-1 receptor agonist, CCK octapeptide sulphate (CCK-8, 10 -500
nM), evoked slowly-activating depolarization of the membrane potential ranging from 8 to
25 mV and augmented excitability reflected by elevated spike discharge in 26 of 32 S-Type
myenteric neurons. Pretreatment with the CCK-1 receptor antagonist proglumide (5-10 μM)
or lorglumide (5-10 μM) or the CCK-2 antagonist YM022 (5-10 μM) reversed the excitatory
responses to CCK8 in 17 of 26 S-Type neurons. Pretreatment with DAMGO suppressed the
depolarizing responses to CCK-8. CCK-8 (20 nM) acted in converse manner to attenuate the
inhibitory action of DAMGO. Co-application of DAMGO and relatively high concentrations of
CCK-8 (0.5-2 μM ) attenuated development of desensitization to DAMGO in 7 of 22 neurons.
This action of CCK-8 was reversed by co-application of the CCK-1 receptor antagonists,
proglumide or lorglumide, but not by CCK-2 receptor antagonist,YM022. Neuronal labeling
confirmed that each S-Type neuron in this study expressed the characteristic morphology
of uniaxonal Dogiel Type-I neurons. The results show co-expression of CCK and μ-opioid
receptors by S-Type neurons in the myenteric plexus and suggest that stimulation of the
CCK-1 receptor attenuates development of opioid tolerance in the neurons. Consequently,
treatment with a CCK-1 receptor antagonist might facilitate desensitization of the neurons
to endogenously-released opioid peptides and thereby enhance propulsive motility and
secretion by suppressing some of the known inhibitory action of endogenous opioid peptides
on enteric neuronal excitability. (Supported by NIH RO1 DK37238 and KO8 DK060468)
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Endogenous Adenosine Acts At A1 Or A3 Inhibitory Receptors to Modulate
the Stereotype Neural-Motor Behavior of the Gut Triggered By Histamine Or
Distension
Andrey Bozarov, Yu-Zhong Wang, Jun-Ge Yu, Helen J. Cooke, Fievos L. Christofi
Background: Endogenous adenosine acts at high affinity A1 adenosine receptors (A1R) on
enteric neurons to inhibit synaptic transmission and enteric reflexes. However, the function
of low affinity A3R expressed in gut neurons remains unknown. Aim: The aim was to
elucidate the role of A3R in gut neural circuits and reflexes. Methods: The histamine H2
receptor agonist dimaprit was used to elicit a stereotype cyclical increase in short circuit
current (Isc=chloride secretion) in coordination with motility. Isc was recorded in guinea pig
distal colon (in flux chambers under voltage clamp) simultaneously with muscle length in
the circular orientation (by sonomicrometry with 1mm piezoelectric crystals fixed on serosa
5mm apart). Distension reflexes were evoked by serosal removal of 10µl of fluid for 10 sec.
Results: Dimaprit (10µM) caused cyclical increases in Isc of 40±2.3 µA/cm2 at frequencies
of 2.4±0.3 cycles/5min coordinated with contractions measured as intercrystal distance (ICD)
of 260±22.5µm (n=6). A1R selective antagonists 8-cyclopentyltheophylline (CPT) or 1,3-
dipropyl-8-(2-amino-4-chlorophenyl)xanthine (PACPX) caused a concentration dependent
augmentation of coordinated responses (1nM-10µM,n=3); 100nM antagonist caused max-
imum blockade of A1R and enhanced Isc 133% (p=0.0001) and ICD 64% (p=0.0006, n=
6) with ED50 values of 30-50nM. In 100nM CPT (or PACPX), the selective A3R agonist N6-
(3-iodobenzyl)-adenosine-5'-N-methyluronamide (IB-MECA,10µM) abolished coordinated
responses (IC50-Isc=2.1µM;IC50-ICD=7.1µM,n=6). In mucosa-submucosa, dimaprit Isc
responses were abolished by 10nM A1R agonist 2-chloro-N6 -cyclopentyladenosine and
reversed by 100nM PACPX (p<0.001). In PACPX, 5µM IB-MECA abolished the Isc response
that was reversed by MRS 1191 (5µM-30µM, p<0.001). In a parallel study, coordinated
responses to dimaprit displayed the same sensitivity to A1R and A3R ligands (n=5). The
coordinated response to dimaprit was blocked by TTX (0.1µM,n=4), and remaining myogenic
activity (254.4µm±24) was reduced 48.4% by IB-MECA in CPT-treated tissues (n=
3,p<0.0001). MRS 1191 (1µM) enhanced the TTX-sensitive distension-evoked Isc response
from 50±8.6 to 95±9.6µA/cm2 (p=.003,n=3). A3R immunoreactivity occurs in myenteric
and submucous neurons of guinea-pig, mouse, rat and human colon (n=4 each species).
Conclusions: Endogenous adenosine acts at inhibitory A1R and A3R to modulate the stereo-
type neural-motor behavior triggered by the mast cell mediator histamine or a distension
reflex. Recent availability of A1/A3R KO mice should provide unequivocal proof of function


















Endothelin Receptors and Actions in Adult Guinea-Pig Enteric Nervous
System
Sumei Liu, Xiyu Wang, Xiucai Fang, Na Gao, Chuanyun Gao, Hong-Zhen Hu, Guo-Du
Wang, Yun Xia, Jackie D. Wood
The endothelin receptor-B (ETB) and its ligand endothelin-3 (ET-3) have a key role in the
development of the enteric nervous system (ENS). Loss of signaling through the ETB receptor
leads to failure of colonization of the developing gut by neural crest precursors and results in
aganglionic megacolon, which resembles human Hirchsprung’s disease. The three endothelin
peptides (ET-1, ET-2, and ET-3) and their receptors (ETA and ETB) are known to be
expressed in adult rat, guinea-pig and human ENS. However, a functional role for ET
receptors and their ligands in the mature ENS has not been examined. We used indirect
immunofluorescence, Western blot analysis, intracellular “sharp” microelectrode recording
followed by intraneuronal injection of biocytin to study the expression of ET receptors and
actions of ETs on morphologically-identified myenteric neurons in the adult guinea-pig
small intestine. Exposure of myenteric neurons to ETs depolarized the membrane potential
and elevated neuronal excitability in 63% (59/93) for ET-1, 54% (21/39) for ET-2, and 53%
(18/34) for ET-3. Both Dogiel Type I neurons with S-type electrophysiological behavior and
Dogiel Type II neurons with AH-type electrophysiological behavior responded to ETs.
Depolarizing responses to ETs were concentration-dependent with an EC50 of 37.25 nM
for ET-1, 43.04 nM for ET-2, and 41.74 nM for ET-3. The selective ETB receptor antagonist
IRL 1038, but not a selective ETA receptor antagonist BQ-123, suppressed the actions of
ETs. The selective ETB receptor agonist safarotoxin S6c mimicked the excitatory actions of
ETs on myenteric neurons. Pre-incubation with U-73122, a phospholipase C inhibitor,
suppressed the depolarizing responses to ET exposure. Western blot analysis confirmed
expression of ETB receptor protein in the adult guinea-pig and human ENS. Immunoreactivity
for the ETB receptor was expressed by the majority of neurons in adult guinea-pig and
human small intestine. The results suggest that ETs might act as neuromodulators within
the mature ENS to increase neuronal excitability and thereby influence intestinal physiology.
Actions of ETs on myenteric neurons were mediated by the ETB receptor subtype coupled
with a phospholipase C intraneuronal signaling pathway (Supported by NIH RO1 DK37238).
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Adenosinergic A3 Receptor Regulation in the Human Enteric Nervous System
Jacqueline E. Wunderlich, Helen J. Cooke, Zhixiong Chen, Jun Ge Yu, Iveta Grants,
Kristen Hinshaw, Scott Melvin, Fievos L. Christofi
Background & Aim: Little information exists on mechanisms of synaptic transmission and
modulation in the human enteric nervous system (ENS). Optical Ca2+ recordings revealed
excitatory P2Y1 purinergic synaptic transmission in human submucous neurons. Other
purinergic receptors including adenosine A1 or A3 receptors (A3R) are negatively coupled
to synaptic transmission in rodent gut. Our aim was to test the hypothesis that A3R contribute
to inhibitory purinergic transmission in the human ENS. A3R immunoreactivity is abundant
in human submucous neurons. Methods: Microdissected submucosa (SMP) from jejunum
of Roux-en-Y patients was loaded with 30μM Fluo-4/AM Ca2+. Time-series Ca2+ analysis of
intracellular Ca2+ levels was done using a Zeiss LSM/REN 410 laser-scanning confocal imaging
system. A 3 s fiber tract electrical stimulation (EFS) (0.1Hz, 0.5Hz, 1Hz 5Hz, 10Hz, 25Hz
50Hz, 75Hz, 100Hz) was applied by a 25μm tip titanium electrode placed 0.3 mm away
from the recording ganglion. Drug effects were assessed after 30min superfusion in Krebs
at 36°C. Short-circuit current (Isc=chloride secretion) was recorded in flat sheets of mucosa-
SMP in flux chambers under voltage clamp. Distension evoked a reflex Isc response by
serosal removal of 150µl fluid for 30 s. Results: Data analysis included 319 neurons from
39 SMP from 10 patients. EFS elicited a Ca2+ response in 319 of 531 neurons responsive
to high K+-depolarization (3s, 25Hz; ↑ of 66.0 ± 6.0 intensity units) that was blocked by
TTX (to 7.0±1.3) or high Mg2+/low Ca2+ solutions. The selective A3R agonist Cl-N6-(3-
iodobenzyl)-adenosine-5'-N-methyluronamide (Cl-IB-MECA) caused a concentration-
dependent inhibition of synaptic Ca2+ responses (0.1µM-5µM; n=79; p=.0001). The human
A3 antagonist MRS 1220 caused a 50-70% augmentation of the synaptic Ca2+ response (1,
10µM; 3s, 25Hz; n=62; p=0.0001). In contrast, the rodent A3 antagonist MRS 1191 had
no effect (n=67, p>0.05). EFS caused a frequency-dependent synaptic Ca2+ response peaking
at 25Hz and declining at 50Hz-100Hz. At 5µM, Cl-IB-MECA nearly abolished synaptic Ca2+
responses from 0.1Hz-10Hz (p<0.001) and reduced by 70% responses between 25Hz-100Hz
(p<0.001). The distension-evoked Isc response was reduced 29.3±7.1% (p=0.006) by 10µM
capsaicin and 1µM TTX reduced it by 63.7±7.0% (p=0.002, n=7). MRS 1220 (2µM) enhanced
the distension response by 30.7±1.5% (p=0.0025, n=3) and enhancement was blocked by
TTX (p=0.002). Conclusions: Endogenous adenosine may act at low affinity neural A3Rs
to inhibit both synaptic transmission and distension reflexes in the human submucosa
(DK44179, DK37240, NCRR 1S10RR11434).
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Extrinsic Primary Afferent Neurons Stimulate Enteric Mast Cells to Release
Histamine As a Paracrine Modulator in the Enteric Nervous System in the
Guinea-Pig Intestine
Guo-Du Wang, Xi-Yu Wang, Sumei Liu, Na Gao, Gui-Jun Fei, Hong-Zhen Hu, Yun Xia,
Jackie D. Wood
Release of substance P (SP) or calcitonin gene-related peptide (CGRP) from primary afferents
evokes excitatory responses in enteric neurons. We tested a hypothesis that SP and CGRP,
released from primary afferents, stimulate release of paracrine neuromodulators (e.g., histam-
ine) from mast cells. Mast cells were identified by immuno-reactivity (IR) for tryptase or
chymase. A subset of the tryptase-IR cells expressed IR for the neurokinin-1 (NK-1) receptor.
Application of SP, CGRP, capsaicin or compound 48/80 increased the concentration of
histamine in the bathing medium in a range of 855±103 to 979±114 ng.gtissue-1 from basal
levels of 684±82 ng.gtissue-1 determined by ELISA for intestinal preparations from 8 animals.
Stimulation of histamine release by SP was reversed by the selective NK-1 receptor antagonist,
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RP6758. The selective CGRP antagonist, CGRP8-37 reversed the histamine-releasing action
of CGRP and the selective VR-1 receptor antagonist, SB366791, reversed the action of
capsaicin. Electrical stimulation of nerve trunks containing primary afferent fibers in the
intestinal mesentery stimulated release of histamine from 684±82 to 1100±142 ng.gtissue-
1 in preparations from 8 animals. Pretreatment with an NK-1 or CGRP receptor antagonist,
but not a VR-1 antagonist, partially suppressed histamine release evoked by mesenteric
nerve stimulation to 826±96 ng.gtissue-1(n=6). Pre-incubation with the mast cell stabilizing
drugs, cromolyn or ketotifen decreased basal release of histamine from 684±82 to 313±73
and 162±41 ng.gtissue-1 respectively. Either of the mast cell stabilizing drugs significantly
reduced the stimulating action of SP, CGRP, capsaicin and electrical stimulation on histamine
release. Application of SP, CGRP or histamine evoked membrane depolarization and pro-
longed discharge of action potentials reminiscent of slow synaptic excitation in submucosal
and myenteric neurons. Neither cromolyn nor ketotifen suppressed the neuronal responses
to SP, CGRP or histamine. Pretreatment with cromolyn or ketotifen suppressed the slow
EPSP-like responses in myenteric neurons that were evoked by electrical stimulation of
primary afferents in the mesentery. The results are consistent with the hypothesis that firing
of intramural primary afferents releases SP and CGRP at junctions with enteric mast cells.
SP and CGRP both act at their receptors on the mast cells to stimulate the release of
histamine. Once released, histamine “blankets” the enteric nervous system as a paracrine
neuromodulator. (Supported by NIH RO1 DK37238, RO1 DK57075 and KO8 060468)
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Perturbing NMDA Receptor - PSD-95 Protein Interactions Prevents Selective
Loss of Nitric Oxide Synthase (NOS) Containing Neuron in Rat Gastric
Myenteric Plexus
Chun Hsu, Shi-Yi Zhou, Yuanxu Lu, Kwang-Deok Moon, Il Song, Chung Owyang
Defective accommodation and gastroparesis are serious complications of diabetes. We previ-
ously showed that in diabetic rats, gastric myenteric NOS containing neurons were selectively
damaged through chronic NMDA receptors activation, and that this damage was prevented
by NMDA antagonist. We hypothesize that glutamate activation and nitric oxide release are
important in damage of NOS containing neurons, and that dissociating NMDA receptor from
down stream neurotoxic signal may prevent this deleterious effect. To test this hypothesis, we
demonstrated via immunocytochemistry (ICH) studies of whole mount preparations of gastric
corpus that glutamate containing neurons were abundant and frequently co-localized with
NOS or CHAT containing neurons. Glia cells containing glutamate synthetase were present
in close proximity with enteric neurons. These findings suggest that the glutamate system
in the stomach enteric nervous system is similar to that in the central nervous system (CNS).
In diabetic animals, whole mount gastric corpus ICH of streptozotocin (STZ)-induced diabetic
and age matched control rats demonstrated that diabetic animals had a 37.5% reduction of
NOS containing neurons but no reduction of the CHAT and glutamate containing neurons.
Glutamine containing glia cells also appeared intact in diabetic animals. To demonstrate
that NOS containing gastric neurons are selectively damaged by the Glut-NMDA-PSD-
95-NOS signal pathway, we first demonstrated via rtPCR that exposure of whole mount
preparations of gastric corpus to L-glutamate 1.5 X 10 -3 M for 20 minutes resulted in 17%
increased NOS mRNA expression. We then constructed Tat-NR2B9c, a peptide that readily
transduces cellular cytoplasm and perturbs the NMDA receptor-PSD-95 protein interactions,
thereby selectively decreasing glutamate mediated downstream neurotoxic signaling without
affecting other glutatmate mediated neuronal activities. Exposure of whole mount prepara-
tions of gastric corpus to L-glutamate 1.5 X10 -3 M for 2 hours resulted in 55% loss of
NOS containing neurons. This loss was prevented by Tat-NR2B9c peptide transduction, but
not by exposure to Tat38-48, a peptide that does not transduce cell membrane. In conclusion,
we showed that the gastric myenteric glutamate system is similar to that in CNS and that
glutamate leads to increased NOS mRNA expression. We also showed that Tat-NR2B9c, a
peptide that selectively interrupts the Glut-NMDA-PSD 95-NOS signal pathway, can prevent
loss of glutamate induced NOS containing neurons. This approach to prevent the loss of
gastric myenteric NOS neurons may have important therapeutic implications for gastric
motility complications of diabetes.
160
Feedback Inhibition of GαI Function By GβγI Subunits: A Novel Mechanism
Involving Phosphorylation of GαI By Gβγ-Dependent Src Kinase, Recruitment
to Rgs12, and Inactivation of GTP-Bound GαI
Jiean Huang, Sunila Mahavadi, Karnam S. Murthy
Regulators of G protein signaling (RGS) accelerate the intrinsic GTPase activity of activated
Gα subunits, and thus determine the intensity of G protein signaling. RGS12, in addition
to its RGS domain, contains other domains including a phospho-tyrosine binding (PTB)
domain that binds to phospho-tyrosine residues in other proteins. Tyrosine phosphorylation
of Gα subunits could promote their association with and inactivation via RGS12. Agonist-
stimulated dissociation of Gβγi induces activation of PI 3-kinase and c-Src raising the
possibility of Src-mediated phosphorylation of Gαi subunits. Aim. To examine whether
tyrosine phosphorylation of Gαi2 via a Gβγi/PI 3-kinase/Src kinase pathway increases RGS12
binding to and inactivation of Gαi2. Methods. Gαi2 activity was measured as inhibition of
forskolin-stimulated cAMP formation in response to the δ-opioid receptor agonist, DPDPE.
Tyrosine phosphorylation of Gαi2 was determined by immunoblot analysis and the association
of RGS12:Gαi2 by immunoprecipitation. Results. Previous studies have shown that δ-opioid
receptors are coupled to Gi2 in smooth muscle. DPDPE inhibited forskolin-stimulated cAMP
formation in cultured gastric muscle cells and increased tyrosine phosphorylation of Gαi2.
Treatment of the cells with the PI 3 kinase inhibitor LY294002, the Src kinase inhibitor
PP2, or expression of a Gβγ-scavenging peptide blocked tyrosine phosphorylation of Gαi2
and caused further inhibition of cAMP, implying that tyrosine phosphorylation of Gαi2
attenuated Gαi2 activity. DPDPE also increased RGS12:Gαi2 binding; the binding was inhib-
ited by LY294002 or PP2, and in cells expressing Gβγ-scavenging peptide. The results
suggest tyrosine phosphorylation of Gαi2 by Src kinase facilitated binding of phosphorylated
Gαi2 to the PTB domain of RGS12, thereby accelerating inactivation of Gαi2. This notion
was examined by mutation of putative tyrosine phosphorylation sites in Gαi2 to phenylalanine
(Y69F, Y231F and Y321F). Expression of Gαi2 mutants, (i) blocked DPDPE-induced tyrosine
phosphorylation of Gαi2, (ii) inhibited the increase in RGS12:Gαi2 binding, and (iii) caused
a further decrease in forskolin-stimulated cAMP, providing additional evidence that tyrosine
phosphorylation of Gαi2 increases RGS12 binding and augments Gαi2 inactivation. Conclu-
sion. This study shows that effectors downstream of Gβγi promote inactivation of Gαi. This
novel inhibitory feedback mechanism involves activation of Src kinase via Gβγi and tyrosine
phosphorylation of Gαi, which enhances the binding of phosphorylated Gαi to the PTB
domain of RGS12 and accelerates inactivation of Gαi.
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Substance P (SP) Induces Ubiquitination and Degradation of the Neurokinin 1
Receptor (NK1R)
Graeme S. Cottrell, Benjamin E. Padilla, D.R. Roosterman, Stella Pikios, Martin Steinhoff,
Nigel Bunnett
Little is known about the post-endocytic trafficking of receptors back to the plasma mem-
brane, which mediates receptor resensitization, or to late endosomes and lysosomes, which
mediates receptor down-regulation. Low concentrations of SP (1-10 nM) promote NK1R
endocytosis and recycling, but the effects of sustained stimulation of cells with high concentra-
tions of SP, which may occur during chronic inflammation and pain, on trafficking of the
NK1R are unknown. We hypothesized that sustained stimulation with high concentrations
of SP causes ubiquitination and degradation of the NK1R . To examine down-regulation of
NK1R signaling, we exposed KNRK cells expressing NK1R to SP (100 nM, 3 h) or vehicle
(control), washed the cells, and then examined SP-induced Ca2+ signaling. Immediately
after washing, there was complete desensitization and full resensitization took 16 h. This
resensitization was abolished by cyclohexamide, suggesting resensitization requires synthesis
of new receptors. To examine the importance of ubiquitination in degradation, lysine-
deficient mutants of NK1R were made (NK1RΔ5K/R, C-terminal tail lysines and NK1RΔ10K/
R, all intracellular facing lysines). Both mutants were expressed at the plasma membrane,
and responded normally to SP by Ca2+ mobilization. NK1R , NK1RΔ5K/R and NK1RΔ10K/
R were completely desensitized after exposure to SP, but the mutants resensitized 4-fold
more rapidly than NK1R. In contrast, NK1RΔ324, which corresponds to a naturally occurring
truncated variant of the NK1R, showed diminished desensitization and enhanced resensitiza-
tion. SP (100 nM, 3 h) induced ubiquitination of NK1R, determined by immunoprecipitation
of the NK1R under both native and denaturing conditions and probing Western blots for
ubiquitin. In contrast, NK1RΔ10K/R was completely resistant to ubiquitination. Moreover,
whereas SP induced degradation of NK1R , determined by Western blotting in the presence
of cyclohexamide (41±9% reduction after 16 h with SP), NK1RΔ10K/R showed diminished
degradation (25±9% reduction). To determine the fate of activated NK1R, we labeled living
cells with an antibody to the extracellular epitope tag of the NK1R, exposed cells to SP (100
nM, 3 h), washed them, and at various times localized the antibody by immunofluorescence.
SP induced similar endocytosis of NK1R, NK1RΔ5K/R and NK1RΔ10K/R. However, whereas
NK1R remained internalized even after 4 h recovery, NK1RΔ5K/R and NK1RΔ10K/R recycled
to the plasma membrane. Thus, chronic exposure to SP induces ubiquitination of the NK1R,
which is not required for endocytosis, but is necessary for degradation and down-regulation
of the NK1R. Supported by NIH grant DK39957.
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Up-Regulation of Rgs4 Expression By Interleukin-1β in Colonic Smooth
Muscle Is Enhanced By Erk1/2 and P38 Mapk and Inhibited By PI 3-Kinase/
Akt/Gsk3β
Wenhui Hu, Fang Li, Sunila Mahavadi, Karnam S. Murthy
Initial Ca2+-dependent contraction of intestinal smooth muscle is inhibited upon exposure
of muscle cells to the pro-inflammatory cytokine, interleukin-1β (IL-1β). We have recently
shown that the decrease in contraction reflects up-regulation of RGS4 via a canonical NF-
κB pathway resulting in rapid deactivation of Gαq. Exposure of other cell types to IL-1β
results also in activation of various protein kinases, including extracellular signal-regulated
kinases (ERK1/2) and p38 MAP kinase that could influence directly or indirectly activation
of NF-κB and RGS4 expression. Aim. To characterize the role of ERK1/2, p38 MAP kinase,
and the PI 3-kinase/Akt/GSK3β pathway in the up-regulation of RGS4 expression in muscle
cells by IL-1β. Methods. Cultured rabbit colonic smooth muscle cells in first passage were
treated with IL-1β for various time periods with or without various kinase inhibitors and
RGS4 mRNA expression was determined by real-time RT-PCR. Activities of various kinases
and NF-κB were determined by Western blotting with phospho-specific antibodies. Results.
IL-1β caused a transient, rapid phosphorylation (activation) of ERK1/2 and p38 MAPK. IL-
1β also caused phosphorylation of Akt and GSK3β, sequential downstream effectors of PI
3-kinase. Phosphorylation of GSK3β inactivates GSK3β. PD98059 (a MEK inhibitor) and
SB203580 (a p38 MAP kinase inhibitor) strongly inhibited IL-1β-induced RGS4 mRNA
expression. In contrast, LY294002 (a PI 3-kinase inhibitor) augmented IL-1β-induced RGS4
expression. PD98059 blocked IL-1β-induced IKK2 phosphorylation, IκBα degradation, and
p65 phosphorylation, whereas SB203580 had no effect, implying that effect of ERK1/2 is
exerted on IKK2 or on upstream components of NF-κB signaling, whereas the effect of p38
MAP kinase is not exerted directly on NF-κB. The increase in RGS4 expression caused by
LY294002 was accompanied by increase in IKK2 phosphorylation, implying that GSK3β,
the terminal effector of the PI 3-kinase pathway, which is inhibited upon phosphorylation
by Akt acts normally to augment activation of NF-κB. Conclusion. ERK1/2, p38 MAP
kinase, and PI 3-kinase/Akt are activated in muscle cells treated with IL-1β. ERK1/2 and
p38 MAP kinase enhance IL-1β-induced increase in RGS4 expression; the effect of ERK1/
2 reflects its ability to phosphorylate IKK2 and increase NF-κB activity. The PI 3-kinase/Akt/
GSK3β pathway attenuates IL-1β-induced up-regulation of RGS4 expression by inhibiting
activation of NF-κB.
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Agonist Induced Trafficking of the Motilin Receptor
Anna Mitselos, Inge Depoortere, Pieter Vanden Berghe, Theo Peeters
The motilin receptor (MTLR) is a potential therapeutic target for the treatment of hypomotility
syndromes. However the MTLR is subject to rapid desensitization (Thielemans et al., 2005)
and this may limit the effectiveness of motilin agonists as therapeutic agents. We studied
the mechanisms underlying the desensitization process in CHO-cells expressing the motilin
receptor. Methods. Agonist induced Ca2+ luminescence was measured in CHO-cells
expressing the Ca2+ indicator apoaequorin (Euroscreen, Belgium) and the MTLR C-terminally
tagged with EGFP (MTLR-EGFP) or the C-terminally truncated MTLR C-terminally tagged
with EGFP (MTLRΔ358-EGFP). Cells were desensitized by incubation for 2 h with different
concentrations (10-4-10-12M) of motilin prior to a second stimulation with motilin. Receptor
phosphorylation was evaluated after preincubation of CHO-MTLR-EGFP cells with inorganic
32P followed by motilin stimulation and receptor immunoprecipitation with anti-EGFP
antibody. Internalization of the MTLR-EGFP was visualized by fluorescence microscopy and
analyzed with ImagePro software. Organelles were identified using the endosomal marker
transferrin Alexa-Fluor 594 and the lysosomal marker cathepsin D. Results. The potency
(pEC50) of motilin to induce Ca2+ fluxes and to desensitize (pDC50) was 10.02±0.09 and
7.82±0.04 resp. Motilin induced a rapid (T1/2<1 min.) and dose-dependent phosphorylation
(pEC50:8.33±0.13) of the MTLR. With fluorescence microscopy maximal internalization in
the cytosol was observed after approximately 50 min of constant exposure to 10-7M motilin.
Colocalization of the receptor with the endosomal marker transferrin was already observed
20 min after stimulation with motilin. During the timecourse of internalization, colocalization
with the lysosomal marker cathepsin D was never observed. Following stimulation with
motilin (10-7M) for 2h, cells were washed and receptor fluorescence was monitored at 0,
2, 4 and 8 h. Complete recycling of the internalized MTLR-EGFP to the plasma membrane
was observed 8h after removal of motilin. C-terminal truncation of the MTLR remarkable
reduced the potency of the MTLR (pEC50:8.26 ± 0.20) but motilin was still able to desensitize
the receptor (pDC50:7.48±0.32). Conclusion. Desensitization of the motilin receptor after
stimulation with motilin involves receptor phosphorylation followed by sequestration of the
MTLR in the endosomal compartiment from where it is recycled back to the plasma mem-
brane. The C-terminus of the receptor is not critical for desensitization.
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Motilin Receptor Antagonism Attenuates Naturally Occurring Mmcs and
Reverses Motilin-Impaired Gastric Accomodation in Concious Dogs
Graeme Fraser, Eric Marsault, Bernard Coulie, Luc Ver Donck
Background: Motilin has been postulated to have a role as an interdigestive hormone
regulating antral migrating motor complex (MMC) in various species, including dog and
man. A potent and selective antagonist is required to establish motilin’s physiological role,
but no such antagonist has yet been described. The aim of this study was to investigate the
role of motilin in the interdigestive and post-prandial periods in conscious dogs using a
novel, potent and selective motilin antagonist (JTZ-2002). Methods: Gastrointestinal motility
was measured for 24h by telemetry in freely moving Beagle dogs (F) instrumented with
strain gauges on antrum and duodenum. In a second series of experiments, fundic accom-
modation in response to a 200ml milk meal was measured using a barostat. Results:
Following an overnight fast, JTZ-2002 (0.1, 0.3, 1 mg/kg, i.v.) suppressed the regular
occurrence of phase III activity of the MMC in a dose-dependent manner. Baseline MMC-
interval during the 4h period before drug was 86±5 min and contraction amplitude (CA)
was 276.7±66.0 mN (mean±SEM, n=6). After JTZ-2002 (1 mg/kg), time to first MMC was
225±31 min vs. 99±15 min in controls (p<0.01, n=4) and CA was reduced to 5±2% of
baseline CA over the first hour and recovered to 52±21% after 4h. The 0.1 and 0.3 mg/kg
doses also suppressed MMC activity where CA returned to baseline levels after 3h (n=2).
After a standard 75g meal, JTZ-2002 (0.3 mg/kg, i.v., dosed 2h after meal) suppressed post-
prandial CA during the first hour to 58±4% of pre-drug baseline (n=2) whereas vehicle
treatment maintained CA at 106±10% (n=4). While JTZ-2002 (1 mg/kg, i.v.) did not influence
normal fundic accommodation in response to a milk meal (AUC1h 296±39 vs. 365±26 ml.h
in control, p>0.05, n=5), JTZ-2002 (0.3 mg/kg) did antagonize the fundic contraction
induced by infusion of exogenous motilin (0.01 mg/kg/h, i.v.); AUC5min of fundic relaxation
for vehicle administration was 18.7±3.3 vs. 27.3±3.5 ml.h after JTZ-2002 (p<0.05, n=4).
Conclusions: These data provide the first pharmacological evidence that motilin is an
endocrine regulator of the phase III contraction of the MMC and further suggest that motilin
also has a role in stimulating post-prandial antral and duodenal contractions. Thus, motilin
antagonists may have a role in the treatment of gut motility disorders characterized by
increased spontaneous activity in the upper gut and/or poor gastric accommodation.
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The Orphan Nuclear Receptor Lrh-1 Regulates Intestinal Inflammation
Laurent Dubuquoy, Pierre Desreumaux, Johan Auwerx, Kristina Schoonjans
Background: Liver receptor homolog 1 (LRH-1: NR5A2) is an orphan nuclear receptor that
controls many metabolic pathways. In the gut, LRH-1 was shown to stimulate intestinal
crypt cell renewal and to enhance intestinal tumorigenesis (1-2), but its effect during intestinal
inflammation remains unknown. Aim: To investigate the role of LRH-1 in the regulation of
intestinal inflammation in mice and to quantify its expression in patients with inflammatory
bowel diseases. Methods: Acute or chronic colitis was induced by administration of TNBS
or DSS in Lrh-1+/- mice and their wild type littermates. The intensity of colitis was assessed
by macroscopic and histologic inflammatory scores and quantification of colonic myeloperox-
ydase and inflammatory cytokines. In parallel, LRH-1 mRNA and protein levels were quanti-
fied in paired healthy and inflamed small bowel and colon biopsies of untreated IBD patients
(7 CD, 7 UC) and controls (n=9) using real-time PCR and western blot. Results: LRH-1
expression was induced by inflammation in the colon of WT animals. LRH-1 haplo-insuffi-
ciency predisposes Lrh-1+/- mice to the development of acute and chronic intestinal inflam-

















and histological scores and by an induction of local inflammatory parameters. In human
intestinal biopsies, LRH-1 levels were similar in healthy mucosa of IBD patients compared
to controls. However, a dramatic and similar decrease of LRH-1 mRNA and protein levels
was observed in inflamed mucosa of CD and UC patients compared to healthy areas of IBD
patients or controls. Conclusions: LRH-1 is an important nuclear receptor to control colon
inflammation in mice. Impaired expression of LRH-1 in inflamed mucosa of IBD patients
may participate through a defect of epithelium renewal to the pathophysiology of the diseases.
1: Botrugno OA, et al. Mol Cell. 2004 Aug 27;15(4):499-509 2: Schoonjans K, Dubuquoy
L, et al. Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):2058-62.
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Low Serum Adiponectin Levels in a Transgenic Mouse Model of Hepatitis C
Infection
Aymin Delgado, Yoshitaka Kamegaya, Sergio H. Jordan, Saurabh Agrawal, Yoichi Hiasa,
Raymond T. Chung
Background and Aims: Recent studies have demonstrated an association between HCV
infection and insulin resistance. However, the underlying mechanisms for this association
remain unclear. We sought to evaluate whether HCV decreases in vivo levels of adiponectin,
an anti-inflammatory adipokine known to induce insulin sensitivity. Methods: Transgenic
(Tg) mouse models expressing HCV core and HCV core-E1-E2 proteins under the control
of the HBV enhancer and albumin promoter, respectively, were created on a hybrid C57BL/
6/FVB background as previously described (Kamegaya Y., Hepatology 41: 660-7, 2005).
On this background, mice do not develop significant liver pathology. Twenty-eight Tg (18
core, 10 core-E1-E2) and 12 littermate controls were evaluated. All mice were 16 to 18
months old. Serum samples were collected following an overnight fast, and immediately
frozen at -80C. Adiponectin levels were measured using Luminex ELISA technology. Results:
Mean adiponectin levels were 16.45 μg/ml for non-Tg vs. 13.79 μg/ml for Tg mice (p =
0.2). There were no differences in adiponectin levels observed between the core and core-
E1-E2 Tg animals. The greatest difference in frequencies was observed for the group of
adiponectin levels <10 μg/ml (36% Tg vs. 9% non-Tg). Thus, adiponectin was dichotomized
at the critical value of 10 μg/ml, and low adiponectin was defined as any value below 10
μg/ml. Logistic regression was used to compare the probability of having a low adiponectin
level between the Tg and non-Tg groups. The odds of having a low adiponectin level were
30.4 (1.6 - 583.8) times greater (p=0.02) for the Tg than the non-Tg group. Conclusions:
HCV Tg mice were significantly more likely to have low adiponectin levels as compared
with non-Tg mice. These data demonstrate an in vivo association between HCV and low
adiponectin levels, and suggest that HCV structural protein expression alone may suffice to
decrease adiponectin levels. These results provide a plausible mechanism for HCV-associated
insulin resistance.
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The Prevalence of Metabolic Syndrome in Veterans with Chronic Hepatitis C
Virus
Prashant K. Pandya, Sharad C. Mathur, Peggy Callahan, Priyank Shah, Dean Reker
Background: In addition to traditional predictors of poor response to antiviral therapy for
chronic hepatitis C such as viral load, genotype, race, and advanced fibrosis, recent evidence
has implicated obesity related factors such as insulin resistance and hepatic steatosis. The
prevalence of insulin resistance and related MS in veteran population with chronic hepatitis
C has not been systematically studied. Methods: We performed a cross-sectional analysis
of the prevalence of the metabolic syndrome in chronic hepatitis C infection. We evaluated
38 consecutive veterans referred for evaluation of chronic hepatitis C, who were drinking
less than 20 g alcohol per day (by standard questionnaire). We hypothesized that the
metabolic syndrome (MS) would be associated with worse hepatic histology than HCV
infection alone. We collected detailed demographic, anthropometric, serologic, histologic
and metabolic parameters in order to compare metabolic, virologic and histologic status
between subjects with and without the MS. Insulin resistance was defined as a HOMA-R
(fasting insulin (mU/L) x fasting glucose (mmol/L)/22.5) greater than 2.5. MS was defined
by the presence of 3 or more ATP III criteria. Additional data included determination of
hs-CRP, TNF-α, IL-6, adiponectin and leptin. Groups were compared using t-test and/or
Fisher’s exact analysis. Results: The average age, BMI, viral load, ALT and HOMA were
53.3±7.0, 28.0±6.3, 2.57x106, 59.4±38.3 and 4.7±7.4 respectively. All but one of the
patients were male. Caucasians and African Americans comprised 71% and 18.4% of the
cohort. The predominant genotype in the cohort was Type 1 (81%). Twenty of the 38
veterans studied met the ATP III criteria for the MS. Veterans with the MS had higher BMI
(p=0.001), HOMA-R (p=0.012), and leptin (p=0.008), while no differences were seen (p=
ns) in age, race, ALT, TNF-α, Il-6, adiponectin, hs-CRP, viral load, or genotype. Patients
with MS had significantly higher prevalence of steatosis (p=0.001) and fibrosis on biopsy
(p=0.001). Conclusion: Metabolic syndrome was present in 53% of veterans referred with
chronic hepatitis C. Leptin but not adiponectin was significantly associated with the metabolic
syndrome. Veterans with metabolic syndrome have more steatosis and advanced fibrosis.
The high prevalence of metabolic syndrome may adversely impact outcomes with antiviral
therapy in veterans.
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Immunohistochemical Expression of Junctional Proteins and Intestinal
Permeability Are Altered in Hepatitis C Virus (HCV) Related Chronic
Hepatitis (HCV-CH)
Luigi Martorelli, Sapone Anna, Pasquale Esposito, Laura Demagistris, Michele Russo,
Maddalena Generoso, Maridela Carteni', Gabriele Riegler, Franca Ferraraccio, Alessio
Fasano
Background/rationale: Altered intestinal permeability values (IP) and intestinal ultra-struc-
tural abnormalities have been shown in cirrhotic patients as well as other liver diseases.
Aims: To study the IP, serum levels of the intestinal tight junction (tj) modulator zonulin
(Z), and the immunohystochemical expression of junctional proteins occludin, claudin,
desmoglein and intracellular actin in duodenal mucosa of HCV-CH patients. Methods: The
IP was evaluated by the Lactulose/Mannitol (LA/MA) test. Serum Z levels were determined
by sandwich-ELISA. Distal duodenum biopsies were obtained by EGD and processed for
immunohystochemistry. Staining was obtained with antibodies specific for occludin, claudin-
4, desmoglein-3, and actin. Twenty-five consecutive naïve HCV-CH patients were enrolled
(12 males, 13 females, mean age 59,9 ±10,5, range 35-72); none of them was on interferon
treatment. All enrolled patients underwent IP and Z investigation; 9 of them gave informed
consent to perform an EGD with duodenal biopsies. Results: The LA/MA mean ± SD value
in the 25 patients studies was 0.025±0.020, with 8 patients (32%) having LA/MA values
higher than the normal cut off (< 0.028). The mean ± SD value of Z in the 25 patients
resulted 1.27±1.64 ng/mg protein, with 10 of them (40%) having Z values higher than the
normal cut off (< 0.6 ng/mg protein). There was a correlation between elevated LA/MA and
serum zonulin levels. Occludin immunoreactivity at the cell membrane surface resulted
diminished in all cases but one (decrement ranging between 50-90% as compared to normal
controls). These changes were paralleled by an increased cytoplasmatic occludin immunore-
activity (2-50%), suggesting a displacement of the tj protein from the membrane boundary
to the cytoplasm. Claudin-4 expression resulted diminished by 30-60% in all cases and was
associated to a decrease in actin immunoreactivity (45-85%). Desmoglein immunoreactivity
also decreased by 45-70%. Conclusions: Alteration in IP was detected in a one third of the
HCV-CH patients studied and was associated to elevated serum Z values. These changes
were associated to modification of tj proteins expression and localization. Our data suggest
that a subgroup of HCV-CH patients has increased serum Z and changes in tj proteins
distribution compatible with altered IP. These changes may lead to increased non-self antigens
access that may influence the course of the liver disease.
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Novel Defective HCV Clones Influence a Resistance to Antiviral Therapy in
Recurrent Hepatitis C After Living-Donor Liver Transplantation
Akio Iwai, Hiroyuki Marusawa, Yasutsugu Takada, Hiroto Egawa, Motoshige Nabeshima,
Tsutomu Chiba
Background: Interferon (IFN)-α2b plus ribavirin (RBV) combination therapy is widely used
for recurrent hepatitis C following liver transplantation; however, the rate of sustained
virological response (SVR) in transplant patients has been limited. Recurrent hepatitis C in
transplant patients differs from that in immunocompetent individuals in several ways such
as immunosuppressive condition and extremely high viral loads. However, it remains unclear
whether viral and host factors determine the effectiveness of combination therapy in those
patients. Aim: The aim of this study was to identify the host and viral factors associated
with a SVR to antiviral therapy in patients with recurrent hepatitis C after living-donor liver
transplantation (LDLT). Methods: Twenty-three patients receiving the IFN-α2b plus RBV
combination therapy for recurrent hepatitis C after LDLT were enrolled. The hepatitis C
virus (HCV) genome clones circulating in sera of those recipients were cloned by reverse
transcription-polymerase chain reaction. Results: Twenty of the 23 patients (87%) were
infected with HCV genotype 1b. Before treatment, all patients had serum HCV RNA levels
over 100 KIU/mL by the Amplicor HCV 2.0 assay. Moreover, HCV RNA levels were greater
than 850 KIU/mL (ranging from 850 to 21,200 KIU/mL) in 17 cases (74%), which is
equivalent to 8.5 × 105 to 2.12 × 107 copies/mL HCV RNA, indicating that a majority of
the patients in this study had high baseline viral loads before treatment. SVR was achieved
in seven of 23 patients (30%). Predictive factors for SVR included; (1) 2log10 decline in
HCV RNA at two weeks after the start of therapy, (2) disappearance of HCV RNA at four
or 24 weeks after the start of therapy, (3) frequency of positivity for HLA-B51, and (4)
frequency of negativity for HLA-A26. Since the pretreatment high viral load showed no
association with SVR, we asked whether other viral factors played roles in determining
response to the combination therapy in transplant recipients. We found several novel defective
HCV clones in four (33%) of twelve recipients’ sera with genotype 1b and extremely high
HCV RNA loads (over 850 KIU/ml). All defective HCV clones had deletions in the envelope
region of HCV genome. Interestingly, no patients with defective clones showed a 2log10
decline in HCV RNA at two weeks after the start of therapy. Conclusions: Early decline in
serum HCV RNA after treatment was closely associated with SVR. The circulating defective
HCV clones are present and might be responsible for resistance to the combination therapy
in patients with recurrent hepatitis after liver transplantation.
176
Reliable Early Prediction of Viral Relapse By Detection of Minimal Residual
Hepatitis C Viremia At Treatment Week 12
Alexandra Bergk, Christoph Sarrazin, Michael von Wagner, Gerlinde Teuber, Peter
Buggisch, Viola Weich, Bertram Wiedenmann, Thomas Berg
Introduction: Current treatment guidelines for the therapeutic management of chronic hepat-
itis C virus (HCV) genotype 1 infected patients include a week 12 stopping rule for nonrespon-
ders defined by a drop of viral load less than 2 log10 in patients treated with pegylated
interferon and ribavirin. Nevertheless there has been no convincing prognostic tool to easily
and reliably predict viral relapse after the end of 48 weeks of treatment. Aims: Aim of the
present study was to evaluate the predictive value of a minimal residual HCV viremia for
a relapse in genotype 1 infected patients with early virologic response to therapy. Patients
and methods:We retrospectively analyzed viral kinetics at week 12 and response of 773
treatment naive HCV genotype 1-infected patients using PegIFNα-2a/b and ribavirin treated
at our outpatient clinics. For the detection of residual viremia at week 12 a quantitative
real-time PCR with a lower limit of detection of 10IU/mL (TaqMan) was used. Results: Using
standard quantitative HCV-RNA assays at week 12 75% (430/773) of the patients treated
with PegIFNα-2a/b and ribavirin showed an early virologic response defined by week 12
viral load drop ≥2 log10. By re-analyzing 222 available serum samples of early virologic
responders by TaqMan a residual viremia could be detected in 84 out of 222 patients (38%).
The presence of viremia highly correlated with a viral relapse after the end of 48 weeks of
treatment (p<0,001). Residual viremia was detectable by real-time PCR at week 12 in only
19 out of 126 sustained responders (15%) as compared to 69 out of the 96 relapse patients
(72%) (p<0,001). A relapse occurred in 78% of the patients who had detectable HCV viremia
at week 12 (68/88) as compared to only 19% (25 out of 134 patients) if HCV RNA was
undetectable at week 12. The relative risk to suffer from a relapse was 3.5 and 0.26 in
patients with and without residual hepatitis C viremia at week 12, respectively (p<0,001).
Discussion:Using a highly sensitive real-time PCR the detection of minimal residual hepatitis
C viremia at treatment week 12 was in 78% associated with a viral relapse after the end of
therapy and is therefore a valuable prognostic tool for the prediction of individual treatment
outcome. Treatment of patients with detectable viremia at week 12 should be individually
intensified by either prolonging treatment duration or preventing dose reductions by the
application of erythropoetin or GM-CSF.
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JC Virus Is Present in Adenomatous Polyps and Associated with Microsatellite
Instability
Woontae Jung, Meishu Li, Ajay Goel, C. Richard Boland
Background: JC virus (JCV), a human polyomavirus, has been implicated in the pathogenesis
of colorectal cancer (CRC), but its role in premalignant lesions is unknown. We have shown
that JCV induces chromosomal instability when introduced into diploid cells in vitro, but
it is not known how it participates in the early stages of colorectal carcinogenesis. Aims:
We tested the hypothesis that JCV is present and expresses T antigen (T-Ag) in adenomatous
polyps, and sought associations with specific forms of genomic instability in those lesions.
Methods: DNA was extracted from 32 paraffin-embedded adenomatous polyps. JCV gene
sequences were amplified by PCR using primers specific for T-Ag, and confirmed by sequenc-
ing. Immunohistochemical (IHC) staining was performed using an anti-T-Ag monoclonal
antibody. To test for microsatellite instability (MSI), five mononucleotide repeats (BAT-25,
BAT-26, NR-21, NR-24, and NR-27) were coamplified in a pentaplex PCR and analyzed
for mutations (change in allele length) in an automated DNA sequencer. Results: JCV T-Ag
DNA sequences were found in 91% (29/32) and T-Ag was expressed in 16% (5/32) of the
polyps. The T-Ag staining was localized exclusively in the nuclei of adenoma cells, but not
in the cytoplasm nor in adjacent non-neoplastic cells. The prevalence of MSI-H (≧3 muta-
tions), MSI-L (1-2 mutations), and MSS (no mutations) was 3% (1/32), 38% (12/32), and
59% (19/32), respectively. Among 29 specimens in which JCV DNA was detected, MSI was
found in 45% (13/29), however, all specimens negative for JCV DNA were MSS. Conclusions:
This study demonstrates that JCV DNA is detectable in 91% of colorectal adenomas, expresses
T-Ag in 16%, and unexpectedly, is associated with MSI in these lesions.
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Double RNA Interference of Dnmt1 and Dnmt3b Induces Promoter
Demethylation and Reactivation of Tumor Suppressor Genes and Apoptosis in
Human hepatocellular carcinoma Cells
Satoshi Kurita, Yoshimasa Saito, Hajime Higuchi, Nobuhiro Nakamoto, Hitomi Horikawa,
Hideaki Kanamori, Shinichiro Tada, Hidetsugu Saito, Toshifumi Hibi
[Background & Aims] DNA methylation plays critical roles in chromatin remodeling and
regulation of gene expression in mammalian development and human disease, such as
cancer. We have reported that several tumor-suppressor genes are silenced by aberrant
DNA methylation of their promoter CpG islands in the tumor tissues from patients with
hepatocellular carcinoma (HCC), and that expression levels of DNA methyltransferases
(DNMTs) were increased during the progression from chronic hepatitis or liver cirrhosis to
HCC. Although both DNMT1 and DNMT3b are required to maintain genomic DNA methyl-
ation patterns in mammalian cells, their roles in human hepatocarcinogenesis have not been
fully understood. To clarify the correlation between DNA methylation and hepatocarcinogen-
esis, we depleted DNMT1 and DNMT3b in human HCC cells. [Methods] Human HCC cell
lines (PLC/PRF/5 and Huh7) were transfected with short interfering RNAs (siRNAs) to
specifically downregulate the expression levels of DNMT1 and DNMT3b. Expression levels
of mRNAs and proteins were examined by real-time RT-PCR and western blotting, respect-
ively. DNA methylation status of the promoter CpG islands in tumor suppressor genes
(p16, RASSF1A and E-cadherin) was examined by methylation-specific PCR after bisulfite
modification. Cell proliferation was measured by MTS assay and the cell nuclei were stained
with DAPI. Caspase-3, -8, and -9 activities were measured by EIA. [Results] Trasnfection
of specific siRNA to each DNMT significantly reduced mRNA and protein expression levels
of each enzyme, but did not affect DNA methylation status of promoter CpG islands in
p16, RASSF1A and E-cadherin genes. On the other hand, trasnfection of both siRNAs
successfully induced demethylation of promoter CpG islands and reactivation of these
genes. Moreover, knockdown of both DNMTs resulted in the significant reduction of cell
proliferation, and DAPI staining of the transfected cells showed nuclear condensation and/
or cleavage. Caspase-3, -8, and -9 activities were increased in the cells transfected with both
siRNAs, indicating that apoptosis was induced by double knockdown of DNMT1 and
DNMT3b. [Conclusion] These data suggest that DNA methylation of specific genomic regions
maintained by DNMT1 and DNMT3b plays a critical role in survival of HCC cells, and a
simultaneous knockdown of both DNMT1 and DNMT3b may be a novel anti-cancer strategy
for the treatment of HCC.
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Role of Braf Mutation in HNPCC Screening Strategies
Xavier Bessa, Belen Balleste, Beatriz Bellosillo, Montserrat Andreu, Spanish
Gastroenterological Association GI Oncology Group
The selection of patients according to Bethesda guidelines and further genetic testing, is the
most efficient strategy for detection of MSH2 or MLH1 gene carriers in patients with newly
diagnosed colorectal cancers (CRC)(Piñol V. JAMA 2005). Recently, an oncogenic mutation
in BRAF gene has been found in colorectal tumours showing DNA mismatch repair gene
deficiency without germinal mutations in the mismatch repair genes. MSI in these patients
are due to hypermethylation of MLH1. It has been suggested that BRAF analysis could
simply and improve the cost-effectiveness of the genetic testing reducing the number of
DNA repair genes sequencing. Objective: To know the prevalence of BRAF mutation in
a population sample with CCR and microsatellite instability. To evaluate the differential
characteristics according to BRAF mutation. To analyse the costs of BRAF mutation analysis
compared to traditional strategies. Methods: Study sample was the 1222 patients with
colorectal cancer belonging to EPICOLON study (Piñol V. JAMA 2005). We determine the
BRAF mutation in 91 cases with deficiencies in DNA mismatch repair genes (MSI and/or
lack of MLH1 or MSH2 inmmunostaging). The BRAF mutation was evaluated by automatic
sequencing. Results: BRAF mutations were found in 20 patients (21.4%) with colon cancer
showing deficiencies in DNA mismatch repair genes. None of them showed unambiguous
germline mutations in MLH1 and MLH2 genes. Only 2 patients (4.8%) with MSI-L had
BRAF mutation. Variables associated with mutation of BRAF were: older age (78+6 vs.
67+15, p<0.002) and right tumour location (OR: 4.69; IC 95%: 1.01-21.94). In patients
fulfilling revised Bethesda guidelines, performing BRAF analysis allowed a small reduction
in costs (saving of 700 or 322 euros per detected mutation based on the presence of MSI
or abnormal inmunostaging, respectively.) However, if we performed BRAF analysis in
patients without previous selection according to these clinical criteria, we achieved a signific-
ant minimisation of costs (a saving of 3970 or 1867 euros per detected mutation based on
the presence of MSI or abnormal inmunostaging, respectively) Conclusions: Detection of
BRAF mutation could simplify and improve the cost-effectiveness of genetic testing for
HNPCC, especially in patients whose family history is incomplete or unknown.
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Loss of Imprinting of the Insulin Growth Factor 2 (IGF2) Gene in Buccal
Cells: Correlation with Risk of Colorectal Cancer
Enrique Quintero, Daniel Deniz, Cristina Paz-Cabrera, Alejandro Jimenez, Antonio Z
Gimeno, Adolfo Parra-Blanco, David Nicolas, Eduardo Salido
Introduction: Loss of imprinting at the IGF2 gene (IGF2-LOI) is an epigenetic change present
in colonic tissue of about 40% of colorectal cancer (CRC) patients. Aim: to investigate
whether IGF2-LOI in the epithelial cells of buccal samples is a surrogate marker that could
predict the risk of CRC. Methods: 34 patients with CRC, 60 with colonic adenomas and
62 controls (colonoscopy without pathological findings) were included. LOI was assessed
by studying the methylation status of a key CpG island at the IGF2 promoter, using PCR-
RFLP after bisulfite treatment of DNA (COBRA method). Hypomethylation was taken as a
surrogate marker for LOI, which was investigated in DNA from buccal cells, tumor samples,
non-neoplastic adjacent mucosal samples, and peripheral blood cells. Results: In buccal
cells, IGF2-LOI was detected in 5/62 (8%) controls, 10/60 (17%) patients with colonic
adenoma and 12/34 (35%) patients with colorectal carcinoma. In neoplastic tissue, IGF2
LOI was observed in 9/43 (21%) samples of carcinoma and 13/50 (26%) samples of adenomas.
No differences in IGF2-LOI were observed in the DNA from peripheral blood cells among
the various study groups. Buccal samples of patients with colorectal carcinoma presented a
higher relative risk to show IGF2-LOI than the controls (OR 6,21; IC 1,96-19,70, p<0.01).
Conclusion: IGF2-LOI in the DNA from buccal cells could be a non-invasive surrogate
marker useful for the screening of colorectal cancer in the average-risk population.
181
Disruption of Activin Signaling Components in Microsatellite Stable (MSS)
Colon Cancers
Barbara Jung, Jessica Gomez, Christine M. Caro, Eddy Chau, Temitope Keku, Robert S.
Sandler, John M. Carethers
BACKGROUND: Mutations in TGF[beta] receptor 2 (TGFBR2) have been identified in both
microsatellite unstable (MSI) and MSS colon cancers. Activin, a growth-suppressive ligand
from the transforming growth factor beta superfamily, binds to activin receptor 2 (ACVR2),
which in turn phosphorylates activin receptor 1 (ACVR1), causing SMAD2 phosphorylation,
association with SMAD4, and translocation to the nucleus affecting gene transcription. We
have previously shown that ACVR2 is mutated in one of its two coding polyadenine tracts
in more than 80% of MSI primary colon cancers, leading to loss of expression and increased
local tumor growth. Here, we examined if activin signaling is also abrogated in MSS colon
cancers. METHODS: Fifty MSS population-based colon cancers were tested for presence of
ACVR1 and ACVR2 protein by immunohistochemistry. Loss of ACVR1 or ACVR2 was
correlated with levels of pSMAD2. Markers flanking the ACVR2 gene locus were used to
assess for loss of heterozygosity (LOH) in tumors with protein loss and coding polyadenine
tracts of ACVR2, which is the prime site of inactivation in MSI colon cancers, were sequenced.
RESULTS: Of 50 primary MSS colon cancer specimens, 5 lost ACVR2, 2 lost ACVR1 and
1 lost expression in both. This correlated with decreased pSMAD2 in 2 cases. One case
showed a decrease in pSMAD2 in tumor tissue without concomitant loss of ACVR2 or
ACVR1 or TGFBR2. We found no cases with LOH at ACVR2, nor mutation in the polyadenine
tract of the tumors tested, implicating different mechanisms for loss of expression. CONCLU-
SIONS: Both ACVR2 as well as ACVR1 loss occurs in MSS colon cancers and correlates
with decrease in downstream pSMAD2 activation, implicating disruption of activin signaling
regardless of the type of genomic instability in colon cancers. The mechanism for ACVR2/


















The Role of the Bone Morphogenetic Protein Pathway in Sporadic Colorectal
Cancers with Different Microsatellite Instability Status
Liudmila L. Kodach, Sylvia A. Bleuming, Alex R. Musler, Maikel P. Peppelenbosch, Gijs R.
van den Brink, Johan A. Offerhaus, James C. Hardwick
Transforming Growth Factor b (TGFb) is thought to play a central role in colorectal cancer
(CRC). TGFb receptor 2 (TGFbR2) is the most frequently mutated gene in MSI (microsatellite
unstable) cancers, but quite how this leads to cancer is unclear with TGFbR2 knockout
mice showing no CRC phenotype. The TGFb superfamily consists of TGFb, Activin and
Bone Morphogenetic Protein (BMP) subfamilies. Recently Activin receptor 2 (ACVR2) has
been found to be mutated in the majority of MSI cancers. The finding of BMP Receptor 1a
mutations in Juvenile Polyposis suggests that BMPs also play a role in CRC carcinogenesis.
Our aim was to investigate the role of BMPs in sporadic CRC. We assessed the expression
of BMP receptors and SMADs 1 and 4 in 72 sporadic CRCs (56 Mismatch repair (MMR)-
proficient and 16 MMR-deficient tumors), using a Tissue Microarray and immunohistochem-
istry. We also investigated whether BMP receptor type 2 was normally expressed in 4 MSI
cell lines and 3 microsatellite stable (MSS) cell lines using immunoblotting. Colon cancer
cell lines were further analyzed for mutations in a coding sequence microsatellite (A7) of
BMPR2, as well as the known A8 tract in ACVR2 and A10 tract in TGFbR2. MMR-deficient
CRCs show frequent loss of expression of BMP receptors 1A, 1B and 2 compared with
MMR-proficient cancers. The expression of BMPR2 is altered in 75% of MMR-deficient and
in 25% (p<0.001) MMR-proficient colorectal cancers. Loss of BMPR2 expression is only
seen in SMAD4 expressing cancers and not in SMAD4 negative cancers. BMPR2 is mutated
at A7 microsatellite sequence in 2 out of 4 MSI colon cancer cell lines and in none of the
MSS cell lines. BMPR2 is not expressed at protein level in MSI cell lines, but is normally
expressed in MSS cell lines. Our data provide evidence that the BMP pathway is important
in sporadic colon cancer. The mutually exclusive nature of BMPR2 and SMAD4 expression
loss is as would be biologically expected and strongly suggests that we are not looking at
an artefact of immunohistochemistry. This is further supported by our cell line data where
we see the same expression pattern. Furthermore, in two cell lines we find a mutation at a
microsatellite in BMPR2. The loss of BMPR2 expression in MSI cancer ties up neatly with
the known defects in TGFbR2 and ACVR2 expression in MSI cancers and confirms the
importance of the TGFb superfamily in the carcinogenesis of CRC. The mouse knockout
data would support the hypothesis that while a mutation in one of the SMADs is sufficient
to cause neoplasia, mutations at the receptor level in the same pathway must occur in com-
bination.
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Proteomic Analysis of Immunoisolated H/K-ATPase Containing Tubulovesicles
from Human Parietal Cells
Lynne A. Lapierre, Kenya Avant, Catherine M. Caldwell, Janice A. Williams, Amy-Joan L.
Ham, Salisha Hill, Adam Smolka, James R. Goldenring
Gastric parietal cells possess an amplified apical membrane dedicated to regulated recycling
of the H/K-ATPase to the luminal surface of the stomach. While apical recycling is amplified
in parietal cells, this process is critical to polarized secretory processes in most epithelial
cells. To understand better the regulation of apical recycling in polarized cells, we used a
proteomic approach to characterize the components of H/K-ATPase-containing recycling
vesicles in human parietal cells. Using a monoclonal antibody specific to the a-subunit of the
gastric H/K-ATPase, we immunoisolated vesicles from an enriched tubulovesicle preparation
derived from resting fundic mucosa of 4 organ donor stomachs obtained under IRB approval.
Proteins were eluted from the immunoisolated vesicle preparations with CHAPS and analyzed
by multidimensional-LC-MS-MS mass spectrometry. We identified and validated by western
blots many of the components previously identified on immunoisolated rabbit tubulovesicles
including Rab11 and Rab25 as well as two previously unrecognized small GTPases, Rab4
and Rab10. Similarly, we confirmed the presence of several proteins involved in vesicle
docking and fusion, including syntaxin 3, SCAMPs and VAMP2, previously identified on
rabbit tubulovesicles. In addition, we detected several previously unrecognized proteins
including VAMP8, syntaxins 7 and 12/13, pantophysin, DP1/TB2 (the human homolog of
YOP1p) and Annexins. We also identified the potassium channel component, KCNE2.
Immunostaining of human gastric mucosal sections confirmed the presence of each of these
proteins in parietal cells and their co-localization with H/K-ATPase on the tubulovesicles.
To investigate the role of these proteins in apical recycling, we transfected them as DSRed2
fusions into a GFP-Rab11a expressing MDCK cell line. Both VAMP8 and pantophysin caused
a collapse of the GFP-Rab11a compartment, while a less dramatic effect was observed in
cells transfected with syntaxin 7 or VAMP2. Interestingly, while overexpression of DsRed2-
pantophysin altered the GFP-Rab11a compartment, it did not co-localize with the GFP-
Rab11a, but was localized to an adjacent tubular compartment. This study, which represents
the first proteomics analysis of an immunoisolated vesicle population from native human
tissue, not only identified previously unrecognized proteins present in parietal cell H/
K-ATPase recycling membranes, but also revealed common regulators of epithelial cell
apical recycling.
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Identification of a Novel Negative Feedback Regulation of the ECL Cell
During Acid Secretion By the Parietal Cell Using Subtractive Hybridization
Microarray Gene Expression Profiling
Nils Lambrecht, Iskandar Yakubov, Cindy Zer, George Sachs
Background: The identification of novel cell-specific genes from gastrointestinal epithelial
cells will lead to new therapies for diseases of the gastrointestinal tract. Although much data
have been accumulated as to the function of some of the most prevalent proteins expressed
in the major epithelial cell types of the gastric mucosa, others have not been suspected or
identified. Here we present specific microarray expression profiles of parietal cells and ECL
cells of the rat gastric mucosa obtained by a novel microarray based technique - subtractive
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hybridization. These profiles suggest proteins involved in novel functions in both cell types,
which can be further studied by classical physiological model systems. Methods: Rat ECL
and parietal cells were purified to more than 95% homogeneity using a physical separation
approach (density centrifugation and counterflow elutriation) followed by FACS based on
unique properties of each cell type. RNA from the purified cells was compared to RNA from
the whole gastric mucosa using Agilent 22K whole genomic expression oligonucleotide
microarray. Only genes specific to ECL or parietal cells are present in high amounts with
equal abundance of “house keeping” genes present in all cells of the gastric mucosa. This
approach is the subtractive hybridization method. Here, we report on proteins involved in
regulation of acid secretion and targets were tested by immunohistochemical localization in
rat gastric mucosa and by intracellular calcium imaging and aminopyrine uptake in gastrin
stimulated intact rabbit gastric glands. Results: 1) Comparison of ECL cell specific and
parietal specific genes identified apelin expressed specifically in parietal cells and the apelin
binding APJ receptor expressed specifically in ECL cells, confirmed by immunohistochemical
localization. 2) Gastrin stimulated intracellular calcium signals in ECL and parietal cells in
the gastric glands are abolished in the presence of apelin. 3) Gastrin stimulated aminopyrine
uptake in the glands is significantly inhibited in the presence of apelin. Conclusion: Expression
of apelin in parietal cells and the inhibitory APJ receptor in ECL cells suggests a novel
negative feedback loop between these two cell types during acid secretion. Although we did
not study the release of apelin from parietal cells, the fact that apelin abolishes gastrin
stimulated ECL cell calcium signals, the hallmark of histamine release in these cells, and
inhibits acid secretion in the rabbit gastric gland model, strongly supports the hypothesis,
that apelin is released during stimulation of parietal cells and directly down regulates
histamine release from ECL cells.
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MIRP1 (kcne2) Is Essential for Gastric Acid Secretion
Torsten K. Roepke, Arun Anantharam, Stephanie M. Busque, Jeffrey B. Young, John P.
Geibel, Daniel J. Lerner, Geoffrey W. Abbott, Philipp Kirchhoff
Background: Gastric acid secretion via H+/K+-ATPase is coupled to luminal K+ uptake and
therefore requires a K+ recycling mechanism across the apical membrane. Several different
K+ channels are proposed to contribute to this mechanism. One of them, KCNQ1, is
postulated to form functional complexes in parietal cells with the voltage-gated potassium
(Kv) channel β subunit MiRP1 (encoded by kcne2), converting it into a constitutively open
‘leak’ channel. Mice lacking the KCNQ1 gene exhibit hypochlorhydria and gastric hyperplasia.
Here, we directly studied the role of the Kv β subunit MiRP1 in gastric acid secretion.
Methods: To investigate the role of MiRP1 in acid secretion we created kcne2 (+/-) and (-/-
) mice by replacing the entire kcne2 coding region with the E.coli lacZ gene and a neomycin
resistance cassette (neor) flanked by loxP sites using homologous recombination. The effects
of kcne2 knockout on gastric acid secretion were characterized using intracellular pH (pHi)
measurements of individual parietal cells in freshly isolated murine gastric glands under
stimulation with histamine (100 mM) or carbachol (100 mM); and pH measurements in ex
vivo whole stomach preparations. Results: Comparing pHi in isolated gastric glands, kcne2
(-/-) mice have a 90 % reduction in gastric acid secretion (n = 70 parietal cells from 5
glands), and kcne2 (+/-) mice show a 50% reduction (n = 140 cells, 15 glands). Mean ex
vivo whole stomach pH was raised from pH 3.75 ± 0.01 in wild-type mice to pH 4.12 ±
0.28 (+/- mice) and pH 5.65 ± 0.84 (-/- mice) (n = 2-3 whole stomach preparations per
group). Further, kcne2 (-/-) mice displayed fivefold enlargement by weight of the stomach,
significant glandular hyperplasia due to lengthening of the neck and fundus portions, parietal
cell atrophy and hypergastrinemia (317.38 pg/ml ± 103.87 (-/-) vs. 62.78 pg/ml ± 29.8 (+/
+)). Nevertheless, kcne2 (-/-) mice appear healthy at 12 weeks, and show no significant
difference in bodyweight compared to wild-type (27.19 g ± 1.09 vs. 26.14 g ± 1.42 (male);
20.15 g ± 1.87 vs. 21.76 ± 0.47 (female), respectively (n = 5-10 per group). Conclusions:
Our findings provide first genetic evidence that MiRP1, encoded by kcne2, is required for
gastric acid secretion. The data suggest that conversion of KCNQ1 to a leak channel by
MiRP1 is essential for this process. Furthermore, MiRP1 appears important for normal
development and structure of mouse gastric parietal cells.
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Intracellular Signal Transduction Pathways Activated By Growth Factors in
Isolated Parietal Cells
Nonthalee Pausawasdi, Mahdi Sareban, Maria Y. Mao, Andrea Todisco
BACKGROUND: EGF and IGF-I exert important regulatory actions on gastric epithelial cell
growth and differentiation. We previously reported that while incubation of purified (>95%)
canine parietal cells with EGF for 16 h induces H+/K+-ATP-ase gene expression through
the activation of Akt, prolonged exposure (>72h) of the cells to EGF leads to parietal cell
morphological transformation and to inhibition of H+/K+-ATP-ase gene expression through
MAPK-dependent mechanisms. We also observed that BMP-4, a peptide known to promote
gastric epithelial cell differentiation, induces H+/K+-ATP-ase gene expression in the parietal
cells. AIM: We explored the effects of prolonged exposure (72 h) of the parietal cells to
IGF-I and we compared them to those observed in the presence of EGF. Moreover, we
investigated if BMP-4 modulates the actions of EGF and IGF-I in the parietal cells. METHODS:
H+/K+-ATP-ase gene expression was examined by Northern blots with a canine H+/K+-
ATP-ase alpha-subunit cDNA probe. MEK1, MAPK and Akt activation were measured by
western blots with anti-phospho-MEK1, -MAPK and -Akt antibodies. Parietal cell morphology
was examined by immunohistochemical staining of the cells with anti-H+/K+-ATP-ase alpha-
subunit antibodies. RESULTS: Both IGF-I (10 nM) and EGF (10 nM) changed the morphology
of the parietal cells that acquired the appearance of fusiform cells. IGF-I induced the activation
of both MEK1 and MAPK and this effect was less then that seen in the presence of EGF.
IGF-I induced Akt while EGF had no effect. EGF inhibited H+/K+-ATP-ase gene expression,
while IGF-I had a modest stimulatory effect. BMP-4 (20 ng/ml) potentiated the effect of
IGF-I on H+/K+-ATP-ase gene expression and it blocked the inhibitory actions of EGF.
BMP-4 inhibited EGF and IGF-I stimulation of both MEK1 and MAPK, but it had no
significant effect on IGF-I induction of Akt. CONCLUSIONS: In contrast to EGF, IGF-I
does not inhibit H+/K+-ATP-ase gene expression, it induces a sustained activation of Akt
and it only weakly activates the MAPK signal transduction pathway. BMP-4 appears to
potentiate the actions of IGF-1 and to inhibit those of EGF. Thus, IGF-I and EGF regulate
different programs of parietal cell activation. These results underscore the importance of
the Akt signal transduction pathway in the regulation of parietal cell differentiation and they
suggest that complex networks of growth factors and regulatory peptides might be needed
for the regulation of the biological functions of the gastric parietal cells.
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Transgenic Expression of Hedgehog Interacting Protein (HIP) in Parietal Cells
Blocks Sonic Hedgehog Activity and Acid Secretion
Yana Zavros, Meghna Waghray, Michael J. Smith, Andrea Todisco, Deborah Gumucio,
Juanita L. Merchant
Objective: The hedgehog signaling pathway is critical to normal gastrointestinal development
and function. The stomach is the largest source of sonic hedgehog (Shh). In particular, Shh
is highly expressed in the acid-secreting parietal cells where it induces H+,K+-ATPase gene
expression and enhances histamine-stimulated acid secretion. Chronic gastritis and parietal
cell atrophy associated with an increased risk for the development of gastric cancer. Hedgehog
interacting protein (HIP) binds to and sequesters Shh by preventing the interaction with its
receptor patched (Ptc). Therefore, we test the hypothesis that loss of the Shh signaling
pathway within parietal cells is crucial for the development of parietal cell atrophy. Methods:
The parietal cell-specific H+,K+-ATPase β subunit promoter (HK) was used to drive expression
of mouse HIP (mHIP) lacking the transmembrane domain which allows HIP to be secreted.
HK/mHIP mice were sacrificed at 2 months of age and examined for tissue morophology
and gastric acid content. Total RNA was prepared from stomachs of HK/mHIP mice and
their age matched non-transgenic (Ntg) litter mates. RT-PCR was used to analyze H+,K+-
ATPase, Shh, Ptc1 and Gli1 mRNA abundance. Protein was also prepared and analyzed by
western blotting for Shh expression. Results: Histology revealed that there was a decrease
in parietal cell numbers. Gastric acidity was significantly lower in the HK/mHIP (3.07 ±
0.92 μEq, *P<0.05 versus Ntg, n=3) compared to the Ntg (36.4 ± 2.35 μEq, n=3) mice.
Reduced gastric acidity in the HK/mHIP mice was consistent with reduced H+,K+-ATPase
mRNA abundance. Western blots revealed no differences in the 45kDa precursor Shh protein
in the stomachs of Ntg and HK/mHIP mice that was consistent with no change in Shh
mRNA abundance. Interestingly, the processed biologically active 19kDa Shh peptide was
significantly reduced in the HK/mHIP animals. RT-PCR data revealed a loss of the Shh
downstream gene targets Ptc1 and Gli1 mRNA in the HK/mHIP animals. Conclusion:
Secreted HIP binds to the 19kDa biologically active Shh peptide that subsequently blocks
the hedgehog signaling pathway within the gastric parietal cells. As a consequence there is
loss of acid secretion and the development of parietal cell atrophy within 2 months. The
HK/mHIP mouse model may be used to study how loss of Shh predisposes the stomach to
atrophy and the development of gastric cancer.
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Glycosylation-Mediated Apical Sorting of the Na,K- and Gastric H,K-ATPase β
Subunits in Polarized Cells
Olga Vagin, Shahlo Turdikulova, George Sachs
Background: The gastric H,K-ATPase is located in tubulovesicles in the resting parietal cell
and relocates to the canalicular (apical) membrane upon stimulation of acid secretion. The
homologous Na,K-ATPase resides in the basolateral plasma membranes in most polarized
cells. The present work was aimed at identifying the role of N-glycosylation in apical sorting
of the gastric H,K-ATPase. Methods: Stable cell lines expressing YFP-linked β-subunits of
the H,K- or Na,K-ATPase were developed. Cellular localization of the subunits was examined
using confocal microscopy. Apical and basolateral content of the β-subunit and the rate of
endocytosis was determined using surface-selective biotinylation. Results: The YFP-linked
H,K-ATPase monomeric β subunit was expressed on the apical membranes in three types
of polarized cells: kidney-derived LLC-PK1 and MDCK cells and parietal cell-derived HGT-
1 cells. Mutagenic removal of any of the seven N-glycosylation sites from the H,K-ATPase
β subunit impaired delivery of the protein from TGN to the apical membrane and enhanced
endocytosis from the apical membrane in all three cell types. Deletion of sites at N1, N3,
N5 and N7 had the most significant effect, suggesting a critical role for these sites in
apical sorting of the H,K-ATPase. HGT-1 cells express the endogenous H,K-ATPase and the
homologous Na,K-ATPase β subunits on the apical membrane in contrast to MDCK and
LLC-PK1 cells that lack H,K-ATPase and express the Na,K-ATPase only on the basolateral
membrane. HGT-1 cells express the Na,K-ATPase β2 , but not the β1 isoform, while the
β1 is the major isoform in MDCK and LLC-PK1 cells. When expressed in HGT-1 cells, the
YFP-linked β1 subunit was localized to the lateral surface. The human β2 subunit has eight
N-glycosylation sites, while the β1 isoform has only three. We tested whether the greater
number of glycosylation sites in the β2 subunit as compared to the β1 is responsible for
the apical localization of the Na,K-ATPase subunit in HGT-1 cells. Hence, up to five additional
N-glycosylation sites homologous to the ones present in the β2 subunit were successively
introduced in the β1 subunit by site-directed mutagenesis. The mutated β1 subunits were
detected on both apical and basolateral membranes but the fraction of the mutant β1 subunit
present on the apical membrane increased in proportion to the number of glycosylation
sites inserted and reached 80% of the total surface amount for the β1 mutant with five
additional sites. Conclusion: The N-glycans linked to the β subunit isoforms of P2-type
ATPases contain apical sorting information and may be essential for parietal cell sorting of
the H,K-ATPase.
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Expression of Oncogenic Kras in Developing Zebrafish Pancreas: A New
Vertebrate Model of Exocrine Pancreatic Cancer
Seungwoo Park, Jon Davison, Steven Leach
The zebrafish has emerged as a powerful vertebrate system for the study of cancer biology.
In an effort to generate the first zebrafish model of exocrine pancreatic cancer, we created
transgenic zebrafish in which ptf1a regulatory elements were utilized to target oncogenic
Kras to developing zebrafish pancreas. Materials and Methods: Two different BAC transgenes
were generated by recombineering a genomic BAC spanning the zebrafish ptf1a locus
(CH211-142H2). Ptf1a coding sequences were replaced by either GFP alone (ptf1a:GFP) or
by a GFP-Kras(G12V) fusion construct (ptf1a:GFP-Kras(G12V)), in order to enable real-time
visualization of transgene expression. Transgenic lines were established following injection of
modified BACs at the single cell stage. Results: Ptf1a:GFP transgene expression faithfully
recapitulated the normal developmental pattern of ptf1a expression. GFP expression became
apparent at 32 hours post fertilization and persisted in virtually all exocrine pancreatic cells
through adulthood. In contrast, expression of the ptf1a:GFP-Kras(G12V) transgene gradually
diminished during development, becoming restricted to an abnormal population of undiffer-
entiated precursor cells. However, widespread expression of the ptf1a:GFP-Kras(G12V)
transgene reappeared at adulthood, as evidenced by external examination of transcutaneous
green fluorescence (Tc-GFP), immunohistochemistry, and RT-PCR. Selective sacrifice of fish
with Tc-GFP revealed pancreatic carcinoma with occasional invasion and metastasis into
bowel wall, liver, and ovary. Proportions of fish with detectable Tc-GFP increased with
advancing age of the fish: 20% (6/30) at 3 months, 41% (31/75) at 6 months, and 67%
(30/45) at 9 months. The extent of detectable Tc-GFP was highly concordant with tumor
burden. Tumors displayed a mixed pattern of differentiation, with areas of ductal or squamoid
differentiation intermixed with areas of undifferentiated and acinar cell carcinoma. Immuno-
staining for pan-Ras and GFP showed robust transgene expression confined to tumor cells.
Tumor cells also stained positively with Alcian blue, PAS, and mucicarmine, confirming the
production of mucin. Similar to human pancreatic cancer, components of the Hedgehog
signaling pathway, including Ptc2, Smoothened and Gli1, were upregulated in tumor cells.
Conclusion: We have generated the first zebrafish model of exocrine pancreatic cancer, in
which use of a GFP-Kras fusion protein allows for the non-invasive determination of tumor
burden. This model offers a novel platform for high-throughput, in vivo screening for new
pancreatic cancer drugs, in a manner not currently achievable in mouse or human.
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Reconstitution of P16ink4a in An Orthotopic Pancreatic Mouse Model Inhibits
Tumor Growth and Angiogenesis
Petra Schulz, Arne Scholz, Annett Rexin, Peter Hauff, Michael Schirner, Bertram
Wiedenmann, Katharina Detjen, Stefan Rosewicz
Introduction: The tumor suppressor gene p16INK4a is inactivated in more than 90% of
patients with pancreatic cancer. The biological relevance of p16 inactivation is well character-
ized at the cellular level and represents an essential step in the transformation process.
However, less information is available about effects on cancer progression, metastasis and
angiogenesis. We used an in vivo inducible system to reexpress p16 in an orthotopic model
of pancreatic cancer and examined the impact on these clinically relevant aspects of pancreatic
cancer tumor biology. Methods: The vectors pcDNA6/TR and pcDNA4/TO-p16 were sequen-
tially transfected into p16 deficient MiaPaCa-2 cells and clones with inducible expression
of p16 were selected (MiaPaca-2-TREx-p16). After in vitro characterization of proliferation
(Alamar blue assay), colony formation (Human Tumor Clonogenic Assay) and cell cycle
analysis (Flow Cytometry) the cells were orthotopically implantated into the pancreas of
nude mice. Mice were randomly assigned to treatment and control groups (11 each). Animals
in the treatment group received doxycycline (Dox) in the drinking water. Tumor growth,
vascularization and metastasis were determined at the time of autopsy. Micro vessel density
(MVD) and lymph vessel density (LVD) were determined by IHC based on CD31 and Lyve-
1 staining, respectively. IHC detection of Human Cytokeratin was used to confirm metastatic
cells. Results: Induction of p16 in MiaPaCa-2 cells in vitro led to a small reduction of
proliferation (13% of the control) and colony formation (40% of the control) as well as to
an accumulation of cells in the G1-phase. In vivo, Dox-induced expression of p16 was
confirmed in 6/11 mice with Mia PaCa-2-TREx-p16 orthotopic tumors. In these animals,
tumor size was reduced to 60% of the respective controls. In contrast, Dox treatment had
no significant effect on tumor size in mice inoculated with MiaPaCa-2-TREx control cells.
Induction of p16 expression led to a significant reduction of MVD (34% of the control).
Similarly lymph-angiogenesis was decreased in the presence of p16 (36% of the control).
In addition to the decrease in vascularization, tumor cells with reexpression of p16 were
less frequently found in lymph nodes (27% of lymph nodes positive as compared to 90%
in controls). Conclusions: In extension to previous reports on antiproliferative effects of
p16, we demonstrate that reexpression of the tumor suppressor in an orthotopic model of
pancreatic cancer reduced both primary tumor growth and metastasis. Furthermore this is
the first study to show an anti-(hem/lymph)-angiogenic effect of p16 in a clinically relevant
model of pancreatic cancer.
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Dissemination of Human Pancreatic Tumor Cells Is Mediated By Caveolae
Lidiya Orlichenko, Muyiwa Awoniyi, Mark A. McNiven
BACKGROUND: Pancreatic cancer is a lethal disease with an exceptionally poor prognosis,
as pancreatic neoplasms have a marked tendency to invade and metastasize to distal organs.
Currently, the molecular mechanisms that make these tumors so aggressive are poorly
defined. Recently we have demonstrated that EGF stimulation induces both normal epithelial
cells and human pancreatic tumor cells (PANC-1) to form large numbers of endocytic
structures termed caveolae at cell borders. Caveolae formation precedes internalization of
the cell adherens junction protein E-cadherin (E-Cad), loss of cell-cell contacts, and sub-

















pancreatic ductular cell-cell integrity during metastasis is mediated by EGF-stimulated caveo-
lae formation. RESULTS: We find that the endogenous levels of both caveolin 1 (Cav1), a
coat protein for caveolae, and E-Cad differ among normal epithelial cell lines (MDCK, NRK)
and neoplastic pancreatic tumor cell lines (BxPC3, PANC-1, HPAF). Furthermore, cells with
decreased Cav1 levels, either endogenously or by siRNA knockdown, form few caveolae
and maintain the integrity of cell-cell contacts. In contrast, cells over-expressing Cav1 initiate
an active internalization of E-Cad-containing caveolae vesicles from the cell borders upon
EGF stimulation, leading to cell dissemination. Interestingly, these internalized vesicles
coalesce into large endocytic structures at the cell center, reminiscent of “caveosomes,” and
this may facilitate E-Cad degradation. Indeed, SDS-PAGE analysis of E-Cad in cells over-
expressing Cav1 shows substantial proteolysis of E-Cad. EGF stimulation induces phos-
phorylation of Tyr14 of Cav1 and, interestingly, expression of a Tyr14 phosphorylation
mutant form of Cav1 greatly reduces cell separation, internalization of E-Cad, and subsequent
E-Cad proteolysis. Thus, this suggests that phosphorylation of Cav1 via the EGF signaling
pathway contributes to these processes. CONCLUSION: We find that there is a relationship
between the cellular levels of Cav1 protein and the capacity of cells to form caveolae,
internalize E-Cad, and maintain cell-cell integrity. Cells that express high levels of endogenous
or exogenous Cav1 protein internalize and subsequently sequester E-Cad into large endocytic
structures upon EGF stimulation, whereas cells expressing low Cav1 levels, either endogen-
ously or by siRNA knockdown, form few caveolae in response to EGF stimulation and
maintain E-Cad-based cell-cell contacts. This study provides new molecular insights into
pancreatic tumor cell dissemination and metastasis and the role of caveolae in these processes.
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The Kinase Mirk/Dyrk1b Is Activated Through the Rac1-Mkk3 Pathway and
Mediates Survival in Pancreatic Ductal Adenocarcinoma
Xiaobing Deng, Kideok Jin, Daina Z. Ewton, Sheena Li, Asghar Naqvi, Stephen E. Mercer,
Eileen A. Friedman
Ductal adenocarcinoma of the pancreas is highly resistant to apoptosis induced by chemother-
apeutic drugs or by radiation. Mirk/dyrk1B is a stress-activated kinase which facilitates the
survival of regenerating skeletal muscle cells after injury, and mediates survival in pancreatic
ductal adenocarcinoma where it is upregulated. Increased expression of Mirk was seen in
pancreatic carcinomas compared with primary cultures of normal ductal epithelium by serial
analysis of gene expression. Mirk was detected in the majority of cases of pancreatic ductal
adenocarcinoma by immunohistochemistry with elevated expression in 39%, and in fetal
pancreatic ductal epithelium, so Mirk may be an oncofetal protein. Mirk was detected in 7
of 8 pancreatic cancer cell lines and was an active kinase in each cell line where it was
detected. Mirk was activated as a kinase by signaling from Rac1 to the MAP kinase kinase
MKK3, which in turn phosphorylates Mirk. Rac is a Ras superfamily GTPase which, when
activated, functions downstream of Ras oncoproteins to promote cell survival, transformation
and membrane ruffling. The constitutively active mutant Rac1QL activated Mirk through
MKK3, which in turn activated Mirk by phosphorylation. Dominant negative Rac1, dominant
negative MKK3 and knockdown of MKK3 by RNA interference inhibited the kinase activity
of co-expressed Mirk. Mirk knockdown by RNA interference reduced the viability of Panc1
cells several-fold and in a dose-dependent manner, demonstrating that Mirk is a major
survival-mediating kinase in these cancer cells. Mirk initiated survival signals which inhibited
apoptosis in Panc1 cells, while Mirk knockdown increased the apoptosis induced by gemcitib-
ine and nocodazole in these cells. Mirk kinase activity in pancreatic cancer cell lines was
inversely related to the activity of the survival kinase Akt, which suggested that pancreatic
cancer cells relied primarily on either Mirk or Akt for anti-apoptotic signaling. Mirk does
not appear to have wide-spread effects on cell viability as others have found that knock-
out of Mirk/dyrk1B was not lethal to the embryo. It is believed by many investigators that
carcinoma cells depend on a few dominant survival signals, while normal cells rely on many
survival signals, so there might be a therapeutic window which would allow the targeting
of a survival kinase such as Mirk in cancers. Because of its properties and expression pattern,
Mirk may represent a novel therapeutic target for pancreatic ductal adenocarcinoma.
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Pancreas-Specific Inactivation of Relap65 in Two Mouse Models of Pancreatic
Tumor
Maryna Lesina, Hana Alguel, Nakhai Hassan, Paxian Stephan, Matthias Treiber, Roland
M. Schmid
NF-kB/Rel has been shown to be activated during oncogenesis of the pancreas in several
murine tumor models. Its activation has been associated with antiapoptotic and proliferative
functions. Therefore inhibition of NF-kB/Rel has been evaluated as therapeutic agents in
the treatment of pancreatic cancer. Here we present a mouse in which RelAp65 has been
specifically inactivated in the pancreas using the Cre/lox-system. Tissue-specific deletion of
RelAp65 in the pancreas enabled us to examine the role of NF-kB/Rel in the development
of preneoplastic lesions or pancreatic oncogenesis in two mouse models. The floxed RelAp65
mouse was crossed with the TGFα transgenic model of pancreatic tumor and with the
KRASG12D mice representing a model for PanIN lesions. Tissue-specific deletion of RelAp65
was directed to the pancreas by using a p48 Cre mouse which expressed the Cre recombinase
in progenitor cells of the exocrine compartment. This resulted in a truncated RelAp65 protein
which is incapable of translocating into the nucleus, binding DNA or even forming dimers
as it has been analysed in electromobility shift assays (EMSA). In both mouse models,
pancreas-specific inactivation of RelAp65 did not prevent progression of preneoplastic lesions,
but promoted development of metaplastic ductal structures. RelAp65 deficient mice overex-
pressing TGFα under the control of the elastase promoter exerted an accelerated progression
to duct-like metaplastic formation and successive loss of acinar cells. Pancreas-specific
deletion of NF-kB/Rel and activation of heterozygous KRASG12D displayed lesions similar
to intraductal papillary mucinous neoplasms (IPMN) with strong expression of MUC5 in
mice at the age of 18 weeks. IPMN-similar formations were numerous with nearly no acinar
cells in-between. Acinar cell death in both models was probably due to pronounced apoptosis
with higher proliferation rates in duct-like structures. These data suggest that RelAp65 did
not prevent pancreatic oncogenesis, but promoted early metaplastic lesions in two mouse
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models of pancreatic tumor. Moreover, we suggest a distinct role of RelAp65 during pancreatic
oncogenesis. While deletion of NF-kB/Rel induced apoptosis in acinar cells, it did promote
metaplastic lesions arising from duct like structures with IPMN-like features.
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Spectral Markers of the Duodenum Can Detect Pancreatic Cancer
Randall Brand, Yang Liu, Young Kim, Alexy Kromine, Hemant Roy, Nahla Hasabou,
Dhiren Shah, Vadim Backman
Introduction: Due to limitations in pancreatic imaging modalities and lack of good tumor
markers, it is not possible to diagnose individuals with pancreatic adenocarcinoma (PC) at
an early stage. Our group has developed a novel optics technology, four-dimensional elastic
light-scattering fingerprinting (4D-ELF), which allows quantitative assessment of the nanos-
cale cellular architecture. We have demonstrated that 4D-ELF has unprecedented sensitivity
for assessment of the genetic/epigenetic changes of the field effect field of colon carcinogenesis,
whereby, uninvolved mucosa accurately predicted the presence of colonic neoplasia. Assess-
ment of the duodenal mucosa by 4D-ELF represents an attractive approach given the
profound genetic/epigenetic alterations in the histologically normal duodenal mucosa of PC
patients(pts) (Clin Cancer Res 2005:11:573). We, therefore, investigated in this pilot study
whether 4D-ELF derived spectral markers from normal appearing duodenal mucosa could
detect the presence of PC. Methods: Periampullary biopsies from 28 control pts obtained
by endoscopy and 19 PC pts, obtained by pancreatic resection(7) or endoscopy(12), were
analyzed for the 4D-ELF derived markers of spectral slope and fractal dimension. The spectral
slope evaluates size distribution of intracellular components ranging from macromolecules to
small organelles. The fractal dimension reflects the tissue organization at larger length scale,
ranging from large organelles to groups of cells. Results: The median age of PC pts and
controls were 74(51-87) and 57(27-84), respectively. 26% of PC pts and 25% controls were
male. PC stage was I-2, II-8, III-2, and IV-7. There were statistically significant differences
in the spectral slope (p=0.02) and the fractal dimension (p =0.003) between the controls
and PC pts. Diagnostic accuracies are shown in Table. Conclusions: We demonstrate for
the first time that 4D-ELF of periampullary biopsies can identify PC. This study provides
compelling data to further investigate 4D-ELF’s ability to discriminate PC from not only
normal pts but pts with other pancreatic diseases. The use of additional spectral markers
may increase both our sensitivity and specificity. A probe is currently under development,
which would alleviate the need to obtain biopsies, and thereby, allow for an even less
invasive manner to predict the presence of PC.
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Hemochromatosis Is Associated with Increased Colorectal Cancer Prevalence
in a National Sample of US Veterans: A Case-Control Study
Alastair D. Smith, Deborah A. Fisher
Introduction: Iron is a pro-oxidant and may promote carcinogenesis. However, studies of
patients with iron overload syndromes (genetic susceptibility, dietary iron intake) vary in
their conclusion of the potential relationship between iron and colorectal cancer (CRC).
Our aim was to determine whether patients with hemochromatosis (HC) were at increased
risk of developing CRC compared to subjects without HC. Methods: We examined the
national VA inpatient and outpatient databases (October 2003 - September 2005) for a
random cross-sectional sample of 118,999 unique patients, aged ≥ 50. The diagnoses were
identified by ICD9 codes: 153, 154 for CRC and 275 for HC. Using logistic regression, we
assessed the relationship between CRC and HC, and calculated the adjusted odds ratio
(aOR) with 95% confidence intervals (CI). Models were adjusted for age, gender and race.
Results: The study population was 96% male, and its mean (SD) age was 67 (11) years.
The prevalence of CRC was 1% (1246 patients) and of HC 0.6% (724 patients). Eighteen
patients carried both diagnoses (0.02%). There was a significantly increased likelihood of
CRC among patients with HC, with aOR of 2.4 (95% CI 1.5-3.8; p=0.0004). Other predictors
of CRC included African American race (versus Caucasian) with an aOR of 1.4 (1.2-1.7; p=
0.0002), male gender with an aOR of 2 (1.4-3.3; p=0.0005), and age with an aOR of 1.5
(1.5-1.6; p<0.0001) per 10 years. Conclusions: Our results suggest that HC increases the
risk of CRC even when other risk factors, such as age, are considered. Longitudinal analysis
of a younger patient sample may support earlier CRC screening for patients with known HC.
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Patients with Coronary Artery Disease Are At High Risk for Developing
Colorectal Cancer and Adenoma: An Interim Analysis of a Prospective Study
Annie On On Chan, Man Hong Jim, Kwok Fai Lam, David Cw Siu, Teresa Sm Tong,
Fook Hong Ng, Wai Mo Hui, Chi Kuen Chan, Kam Chuen Lai, Wayne Hc Hu, Man
Fung Yuen, Yuk Kong Lau, Stephen Lee, Shiu Kum Lam, Benjamin Cy Wong
Background: Identifying high risks groups for developing colorectal neoplasia (cancer and
adenoma) (CN) allows early detection and hence prevention. We observed in our retrospective
study that there was a strong association between patients with CN and coronary artery
disease (CAD), probably due to common risk factors. Aim: To investigate the prevalence of
CN in patients with and without CAD in those aged ≥ 50 years in a prospective study
and to identify the underlying risk factors. Methods: Patients were recruited for screening
colonoscopy after undergoing coronary angiogram, and was defined as CAD+ if there was
greater than 50% stenosis of one of the main arteries, and CAD- if not. Advanced colonic
lesion was defined as the presence of cancer, or adenomas with villous component, or with
moderate to severe dysplasia, or ≥1cm, or >2 adenomas. Underlying risk factors were
recorded. The calculated sample size was 200 in each arm. An interim analysis was carried
out at a sample size of 150 at each arm. Pearson chi-square test was carried out to test for
the association between CN and CAD. To adjust for the factors of age, sex and other risk
factors, a random-effects bivariate logistic regression analysis was used. Bayesian analysis
was carried out using the software WinBUGS. Intracluster correlation (ICC) is a side product
of the model that gives an idea of the strength of the association after adjusting for the
explanatory variables. Results: There were 307 patients (68.7% male) recruited, 46.3% of
them were CAD+. The prevalence of CN was 30.3% vs 19.4% (p=0.027), and advanced
lesions was (16.9% vs 6.7%, P=0.005) in patients with and without CAD. There were 5
colorectal cancers (3.5%) detected in the CAD+ arm but none in CAD- (p=0.015). All the
cancers were asymptomatic except anemia was found incidentally in one patient. Using
logistic regression analysis, the variance of the random effects σ2 =1.7 (95% CI: 0.42, 4.59),
and ICC = 0.32 (95% CI: 0.11, 0.58), both indicates a strong association between CN and
CAD after adjusting for the risk factors. Male sex and smoking were risk factors for predicting
the occurrence of the two diseases. Conclusion: Patients with CAD+ are at high risk for
developing colorectal cancer and adenomas, screening by colonoscopy for these patients
is mandatory.
209
A Prospective Evaluation and Classification of Extra-Colonic Abnormalities
Identified with Computed Tomographic Colonography Screening in
Asymptomatic, Average Risk Individuals
Patrick E. Young, Cecilia H. Kim, Priscilla A. Cullen, Duncan S. Barlow, Donald W.
Jensen, James W. Kikendall, Peter W. Soballe, Brooks D. Cash
Background: Computed tomographic colonography (CTC) uses CT technology to detect
colorectal polyps. While CTC technique differs from dedicated abdominal CT technique,
CTC can detect extra-colonic (EC) abnormalities. The nature and outcomes of these findings
have not been fully investigated in a proscribed manner. We report herein the prevalence
and characteristics of EC findings in patients undergoing CTC for colorectal cancer (CRC)
screening over a 12 month period. Methods: 979 asymptomatic, average risk patients under-
went CTC for CRC screening from October 2004 to October 2005 using a Phillips 40 slice
CT scanner EC and colonic abnormalities were recorded. EC abnormalities were categorized
as critical, moderate, or incidental. Critical findings were those that required further thera-
peutic intervention whereas moderate findings only required additional diagnostic interven-
tion (serial CT scans, etc.). Incidental findings required no further action. The likelihood
of detecting EC abnormalities was compared to that of detecting colonic abnormalities
using a 2-sided t-test for two percentages. Results: 15.9% (156/979) patients had 188 EC
abnormalities which required further evaluation. The most common of these were coronary
artery calcifications (n=41) and non-calcified pulmonary nodules (n=33). A variety of other
abnormalities were noted and are delineated in the chart below. 83.3% (133/188) had a
single EC abnormality whereas 2.6 % had 3 or more abnormalities. 51.6% were classified
as incidental abnormalities, 33% were moderate and 15.6% were critical. The likelihood of
detecting EC abnormalities paralleled that of colonic abnormalities (15.9% vs. 13.5%, p=
0.13). Location and number of findings (n=188) Pulmonary 42 Coronary 41 Renal 41
Hepatic 16 GU (non-renal) 12 Aortic 10 GI (non-polyp) 7 Biliary 6 Bone 4 Pancreatic 3
Other 6 Conclusions: Extra-colonic abnormalities are detected in approximately 16% of
screening CTC. The majority of these abnormalities are incidental in nature and do not require
additional evaluation but more significant abnormalities are encountered and represent nearly
50% of all EC abnormalities. While early detection of potentially morbid conditions may
benefit select individual patients, EC abnormalities identified by CTC may substantially
increase the indirect cost of the exam. Future cost-benefit analyses using this type of real-
world data and outcomes are needed before routine use of this technology can be endorsed.
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Colonoscopy (C-scope) in Ambulatory Outpatients in the Va: Should We
Protect Elderly Veterans from Unbeneficial Procedures
Andy Fan, Stephen J. Sontag, Thomas G. Schnell, Jack Leya
Introduction: Requests for C-scope in elderly Pts with co-morbid diseases are becoming
more frequent with the aging of the population. The reasons both for and against performing
a C-scope are numerous, and few data are available to justify either approach. In July
2001, the Hines VA GI Section adopted a strictly regulated policy in which inappropriate,
unnecessary, or unlikely-to-benefit C-scopes were denied. No published mortality data on
this subset of Pts is available. Aim: To determine whether our rigid policy has resulted in
adverse outcomes in elderly VA Pts in whom elective C-scopes were requested and denied.
Methods: During the program’s first 3 years of existence (Sep 2001-Dec 2004), 279 elective
outpt requests for C-scope in Pts 80 yrs or older were received and reviewed by the GI
fellow. C-scope requests for these Pts were approved ONLY IF the requestor was willing to
explicitly document in a separate progress note that the pt was (1) healthy enough to undergo
the procedure (ASA class 2 or less) and (2) was expected to live more than 5 years. All
consults were reviewed by a GI fellow using pre-determined criteria and, when appropriate,
template responses. The fellow’s responses were reviewed by a senior GI attending, and the
fellow’s decision was supported. Results: In the group of 279 Pts, the mean age was 83
years and the mean follow-up was 26 months. 67 of the 279 Pts died (all-cause mortality
rate: 24%).The mean time to death from the initial C-scope request date was 15 months.
Of the 279 requests, 167 (60%) were approved for C-scope and 112 were denied. Of the
167 approved, 44 (26%) died; of the 112 denied, 23 (21%) died. Kaplan Meier survival
curves showed no statistical difference between the groups (p=0.39) Fig 1. Thus, within a
mean of 15 months of the request for elective outpt C-scope in octogenarian Pts, regardless
of whether the request was approved or denied, 24% were dead, and none died from CRC.
There was no difference in overall mortality between those who were approved for C-scope
and those who were denied. Conclusion: Without even considering the potential for C-
scope complications, our data clearly show that the decision to perform or not perform
elective C-scope in veterans 80 years or older does not positively influence overall mortality.
T : 89386$$CH2
05-04-06 23:18:24 Page 37Layout: 89386B : o
A-37 AGA Abstracts
With nearly a quarter of the total group dying within 2 years, careful scrutiny must be given
to C-scope requests in this group of patients.
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Risk for Adenoma Recurrence At the Second Surveillance Exam
Douglas Robertson, Carol A. Burke, Leila A. Mott, John A. Baron
Background: Current guidelines for post-polypectomy colonoscopic surveillance are based
only on the most recent exam findings. Aim: We determined adenoma recurrence risk over
time in the context of an individual’s entire lifetime adenoma history. Methods: Subjects
were drawn from 2 adenoma chemoprevention trials. At enrollment, all subjects had one
or more adenoma and had undergone clearing colonoscopy. For this analysis, we only
included subjects whose qualifying adenoma(s) were their first lifetime adenoma(s). ‘First
follow up exam’ was defined as the protocol exam occurring either three or four years after
the baseline exam (varied by trial). Any exam ≥ 2 years after the ‘first follow up exam’ was
defined as the ‘second follow up exam’. The main outcome of interest was development of
an advanced adenoma (tubulovillous or villous histology, high grade dysplasia, or ≥ 1cm)
or multiple (>2) adenomas (AdvMult) at the second follow up exam after baseline. Statistical
significance was assessed by χ2. Results: 793 subjects (mean age, 58 years) were identified;
62% were male. Mean time from baseline to first follow up exam was 3.4 years, and from
first to second follow up exam, 4.2 years. 82 (10%) subjects developed AdvMult at the
second follow up exam. When separately considering high and low risk populations at
baseline, outcomes at second follow up exam were significantly influenced by both prior
colonoscopy results (see table). For example, those with high risk findings (AdvMult) at
both baseline and first follow up exams had a 30% risk of AdvMult on the second follow
up exam. This was significantly higher than the 15% risk of AdvMult at 2nd follow-up in
those with high risk findings at baseline but no adenomas on the first follow up exam(p=
.03). Similarly, in a low risk group at baseline (< 3 small tubular adenomas), findings at
the second follow up exam were significantly influenced by the first follow up exam. In the
low risk group at baseline,those with AdvMult at the first follow-up exam were at much
higher risk for AdvMult at 2nd follow-up (15%) compared to those with no adenomas at
the first follow-up (3.6%) (p=.01). Conclusion: An individual’s entire adenoma history is
useful in determining adenoma recurrence risk. Based on findings from both colonoscopies,
high and low risk groups can be identified that may lead to more effective surveillance
recommendations.
Subjects (%) With Advanced or Multiple Adenomas on 2nd Follow Up Exam
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Comorbidity and Colorectal Cancer Screening Utilization in a National
Sample of Veterans Health Administration Patients
Deborah A. Fisher, Joseph Galanko, Tara K. Dudley, Nicholas J. Shaheen
Objectives: Quality assessment of colorectal cancer (CRC) screening in the Veteran Health
Administration (VHA) system relies on reporting the proportion of patients aged 52-80 years
screened. This approach does not assess for comorbid illnesses that may impact a patient’s
suitability for screening. The Charlson-Deyo score, which can be calculated from administrat-
ive data, is a predictor of mortality. Our primary aim was to determine the relationship
between comorbidity, as measured by the Charles-Deyo score, and fecal occult blood testing
(FOBT) in the national VHA database. Our secondary aim was to test the validity of the
Charlson-Deyo score as a predictor of 1-year mortality in VHA. Methods: We examined the
national VHA administrative databases (October 2003- February 2005) for a random sample
of 86,785 primary care patients, aged ≧50. Charlson-Deyo score was calculated. The associ-
ation between Charlson-Deyo score and mortality was assessed using chi squared analysis.
Using logistic regression, we also assessed the relationship between comorbidity, and the
likelihood of receiving CRC screening. Models were adjusted for age and sex. Results: The
sample was 97% men; mean age was 67 years. Charlson-Deyo score was 45%=0, 24%=1,
14%=2, 7%=3, 3%=4, 2%=5, 1%=6, 3%≧7. Overall there was no significant association
between Charlson-Deyo score and whether or not an FOBT was performed. There was a
strong and incremental relationship between Charlson-Deyo score and 1-year mortality.
There was no association between FOBT status (performed or not) and 1-year mortality
within any of the Charlson-Deyo score categories. Conclusions: In the VHA system, patients
with severe comorbidity undergo FOBT screening as frequently as healthy patients. Substan-
tial effort is being directed toward screening patients with an increased likelihood of dying
from competing causes. Further, there was no evidence providers selectively screened the
healthiest patients within each Charlson-Deyo score category. The current “one-size-fits-all”
quality measurement for CRC screening in the VHA may promote inappropriate screening
in ill patients, and does not emphasize screening in those with the most life-years at stake.
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Effect of Helicobacter Pylori (HP) Screening and Treatment in a Population -
Questionnaire Data for 10,433 Individuals At 5-Years Follow-Up
J.N. M. Hansen, Mette Wildner-Christensen, Ove B. Schaffalitzky de Muckadell
Aim: to evaluate the long term effect of screening and treatment of Hp in a population.
Methods: 20,000 individuals aged 40-65 years were identified and randomised to screening

















including the “Gastrointestinal Symptom Rating Scale” (GSRS), and SF36 at year (yr) 0, 1,
and 5. The primary endpoint was dyspepsia (an aps-score >= 2 in GSRS). Results: 12,530
individuals were included. 11,098 were alive and had not moved at yr 5 and 94% answered
the questionnaire (84% of included individuals). At inclusion 17.5% were Hp-positive and
received Hp-eradication. Dyspepsia decreased more in group 1 than in group 2 in the 5 yr
follow-up (24.9% to 20.4% and 21.0% to 19.6%, respectively (p<0.01)). Multiple logistic
regression analyses were applied in order to evaluate the effect of the intervention adjusting
for baseline imbalances (dyspepsia, ASA/NSAID use, and smoking): the effect was significant
at yr 1 (OR 1.25 (1.12-1.40)) but not at yr 5 (OR 1.04 (0.93-1.16)). A subgroup analysis
showed a larger decrease in dyspepsia in Hp-positive (27.8% at yr 0 to 24.5% at yr 1 and
22.5% at yr 5) than in Hp-negative individuals (23.6%, 19.7% and 20.0% at yr 0, 1, and
5, respectively). Prevalence of reflux symptoms decreased in both groups during follow-up.
The frequency of dyspepsia related visits at GP and sick leave days, and upper endoscopy
was lower in group 1 than in group 2 at yr 5 (table). The use of ulcer drugs, NSAID/ASA
increased in both groups (table). Conclusion: In this low Hp prevalence area, screening and
treatment for Hp only had a modest long term effect on dyspepsia and dyspepsia related
health care use.
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Determinants of Symptom Severity and Weight Loss in Functional Dyspepsia
Lukas van Oudenhove, Vandenberghe Joris, Brecht Geeraerts, Rita Vos, Phillippe
Persoons, Sebastien Kindt, Koen Demyttenaere, Jan Tack
Background: Both gastric sensorimotor dysfunction and psychosocial factors have been
implicated in symptom generation in functional dyspepsia (FD). The aim of this study is
to determine the relative influence of gastric pathophysiological mechanisms and psychosocial
factors on symptom severity and weight loss in FD. Methods: In 139 consecutive FD patients
(mean age 39.5±12 years) from a tertiary referral center, gastric sensorimotor function was
studied with a barostat (sensitivity, compliance & accommodation) and gastric emptying
test. Psychosocial factors (depression, anxiety, fatigue, alexithymia, perceived stress and
abuse history) and somatic symptom severity/somatization (SSS) were assessed using self-
report questionnaires. Gastric pathophysiological mechanisms, psychosocial factors and SSS
were correlated with a dyspepsia severity score (DSS) (obtained from a 10-item symptom
questionnaire) and with weight loss. Furthermore, gastric pathophysiological mechanisms
and psychosocial factors were correlated with SSS (obtained from a 15-item symptom
questionnaire). Multiple linear regression was used to identify independent determinants of
DSS, weight loss and SSS. Results: DSS was higher in women and in hypersensitive patients
and correlated with age, perception threshold, gastric emptying coefficient, SSS, fatigue,
positive affect and the lack of joy factor of the perceived stress questionnaire. Multiple linear
regression identified three independent determinants of DSS: age (β=-.05,p=.06), SSS (β=
.41,p<.0001) and lack of joy (β=-.21,p=.04) (model R2=.28,p<.0001). Weight loss was higher
in women and correlated with DSS, SSS, depression, momentary and chronic fatigue and
positive affect. In multiple linear regression, gender (β=.76,p=.01) and a composite depres-
sion-SSS index (β=.60,p<.0001) were determinants of weight loss (model R2=.24,p<.0001).
SSS was higher in women, in patients with panic disorder and in patients with chronic fatigue
symptoms. SSS correlated with DSS, weight loss, perception threshold, gastric emptying,
depression, panic, momentary fatigue, positive & negative affect and perceived stress. Gastric
emptying (β=-1.71,p=.08), DSS (β=.35,p=.02), presence of chronic fatigue (β=4.1,p<.0001)
and a composite depression-negative affect-stress index (β=1.52,p<.0001) were independent
determinants of SSS in multiple linear regression (model R2=.64,p<.0001). In conclusion,
symptom severity in FD is determined by psychosocial factors (especially somatization),
rather than gastric pathophysiological mechanisms.
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H.pylori Eradication V Empirical Acid Suppression in Uninvestigated H.pylori
Positive Dyspepsia: A Cochrane Collaboration Individual Patient Data Meta-
Analysis
Brendan C. Delaney, Michelle Qume, Paul Moayyedi
Introduction: The Dyspepsia Trials Collaborator’s Group has been conducting a series of
prospective, individual patient data meta-analyses of initial management strategies for dyspep-
sia for the Cochrane Collaboration. H.pylori test and treat has been shown to be marginally
less effective, but more cost-effective than endoscopy-based management, whilst empirical
acid-suppression is as effective as endoscopy but less costly. The question has remained
over the cost-effectiveness of eradication therapy compared with empirical acid suppression.
Methods: Prospective, individual patient data meta-analysis of RCTs comparing H.pylori
eradication therapy v placebo eradication plus PPI in the first-line management of H.pylori
positive adult patients with dyspepsia in the primary care setting. Original datasets were
obtained and costs re-calculated using US healthcare costs for 2004. Patient level net benefits
were calculated using the formula, Net Monetary Benefit (NMB) = Effect x willingness to
pay(WTP) - cost. Relative risk of remaining dyspeptic was pooled using a fixed-effect model
and NMB using weighted mean difference. A sensitivity analysis on WTP was conducted.
Results: Two studies including a total of 571 subjects, met the inclusion criteria, one
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published and one unpublished. Costs and effects were reported after one year of follow-
up. Eradication therapy was significantly more effective than in preventing epigastric pain
(RR 0.83, 95% CI 0.69-0.89), but not heartburn (RR 0.93, 95% CI 0.78-1.10). At a wtp
of zero, the pooled difference in NMB was $6.12 (95% CI -13.30 to 25.53), at a wtp of
$1000 per patient symptom free the difference was $79.07 (95% CI 0.84 to 157.31) in
favour of eradication therapy. Conclusions: The analysis provides support for recent guide-
lines promoting first line use of H.pylori test and treat for dyspepsia in patients with
predominant epigastric pain. Eradication therapy was more effective than placebo plus
PPI for the management of uninvestigated epigastric pain, but not heartburn symptoms.
Eradication therapy was also more cost-effective than PPI at reasonable willingness to pay.
Existing RCTs are not able to exclude a small residual benefit in heartburn, and data is
awaited from ongoing studies.
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Who Consults with Dyspepsia? A Ten-Year Cross-Sectional Survey
Alexander C. Ford, Alastair G. Bailey, David Forman, Anthony T. Axon, Paul Moayyedi
Introduction: Dyspepsia is a chronic relapsing, remitting disorder, the natural history of
which has been studied extensively. However, there are few studies examining factors that
influence the likelihood of consulting a family practitioner with symptoms in those who are
symptomatic, particularly over a long time period. Methods: The authors performed a ten-
year follow-up cross-sectional survey of individuals previously recruited into a community
screening and treatment program for Helicobacter pylori. All surviving, traceable participants
were contacted, using a validated postal dyspepsia questionnaire. Baseline demographic data,
quality of life at study entry (assessed via the psychological and general well-being index),
and dyspepsia and irritable bowel syndrome (IBS) symptom data were already on file.
Written informed consent was sought to examine primary care records, and data on the
use of non-steroidal anti-inflammatory drugs (NSAIDs) and aspirin, and the number of
consultations as a result of dyspepsia over the ten-year period were extracted from these
by two individuals. Results: Of 8407 individuals originally involved, 4003 (48%) responded
to the questionnaire, and 3266 (39%) gave consent to examination of primary care records.
The mean age of included individuals was 55 years, and 1799 (55%) were female. 1738
(53%) individuals had dyspepsia at any point during ten-year follow-up, when dichotomized
according to questionnaire data. Of these, 729 (42%) consulted their family practitioner.
The mean number of consultations in these individuals was 3.5 (range 1 to 23). Univariate
analysis revealed that H. pylori infection, female gender, tobacco use, Asian ethnicity, lower
socioeconomic status, lower quality of life at study entry, irritable bowel syndrome, and
NSAID or aspirin use significantly increased the likelihood of consultation, whilst the opposite
applied to regular alcohol use. Following logistic regression analysis, H. pylori infection,
lower socioeconomic status, lower quality of life at study entry, and aspirin use remained
independent risk factors for consultation. Conclusions: The reasons for consulting a family
practitioner with dyspepsia are multi-factorial, but H. pylori status, aspirin use, low socioecon-
omic status, and poor quality of life are independent predictors of consultation.
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Score & Scope Versus Test & Treat Strategies for the Management of
Dyspepsia: A Randomised Controlled Trial
Merce Barenys, Rosa Rota, Anna Garcia -Altes, Agueda Abad, Josep Maria Lopez Balaguer,
Sergi Romero, Margarita Admetlla
INTRODUCTION .Many studies have tried to address the issue of the best initial work-up
in patients with uninvestigated dyspepsia. There are few randomised clinical trials in this
field, so recomendations are generally based on decision analysis and favor empirical approach
in young patients(1). AIM:To compare the effectiveness and cost of 2 strategies: Score &
Scope and test& treat METHODS : Randomised controlled trial in a Catalan regional Hospital.
Subjects : Uninvestigated young dyspeptic subjects, without alarm symptoms or isolated
reflux disease, between 18 - 55 years old. INTERVENTION: Randomisation to: Group
SCORE & SCOPE (S&S) A previously locally validated scoring system(2) is performed and
classifies patients in high or low risk for organic dyspepsia. Group TEST & TREAT (T&T)
A UB Test C13 for H. Pylori classifies patients in infected or not. Infected patients eradication
and non infected treatment with PPI during 1 month. In both groups: Lack of improvement
or relapse during follow-up prompted a second breath test in infected patients or an
endoscopy in patients with PPI. According to those antisecretory drugs, antibiotics or proci-
netics were prescribed. A follow-up of 18 months was established. OUTCOME MEASURES
Efectiveness. Complete: Rate of assymptomatic patients at the end of follow-up orpartial:
Rate of patients with a reduction of symptoms > 50% on a LiKert scale. Costs. Direct costs
only. Drugs, tests and Visits costs considering tariffs (2005)from the Catalan Health Service.
RESULTS (See table below) CONCLUSIONS 1.Costs were significantly * lower in the score
and scope group than in the test and treat group. 2. Clinical effectiveness (>80%) was similar
in both groups although complete resolution of symptoms was superior in the T& T group.
3. Empirical approaches in dyspepsia can avoid endoscopic procedures in 56% of young
dyspeptic patients. REFERENCES 1.García Altés A, Rota R, Barenys M. Cost-effectiveness
of a “score and scope” strategy for the management of dyspepsia. A decision analysis. Eur
J Gastroenterol & Hepatol 2005; 2.Barenys M, Abad A, Pons JMV. Scoring system has better
discriminative value than H. Pylori testing in patients with dyspepsia in a setting with high
prevalence of infection. Eur J Gastroenterol & Hepatol 2000.
Comparison between Score and H.pylori selection
53%patients in the T& T were infected by h.pylori and 23% in the S&S were classified as
hirgh risk dyspepti
218
Three-Fold Increased Risk of Infertility: A Meta-Analysis of Infertility After
Pouch Surgery in Ulcerative Colitis
Akbar Waljee, Jennifer . Waljee, Arden Morris, Peter D. Higgins
Background: Increased rates of infertility in females have been reported post ileal pouch-
anal anastomosis (IPAA) for ulcerative colitis. The reported infertility rates vary substantially.
Aims: 1) To perform a systematic review and meta-analysis of the relative risk of infertility
post-IPAA to better inform patients. 2) To estimate the rate of infertility post-IPAA. 3) To
identify any modifiable risk factors which contribute to infertility. Methods: Medline,
EMBASE, Current Contents, meeting abstracts, and bibliographies were searched independ-
ently by two investigators. Study selection criteria included the following: 1) publication in
full manuscript form in English; 2) data provided from both patients with medically treated
colitis and patients post-IPAA for ulcerative colitis; 3) raw data provided on infertility,
defined as lack of conception despite trying to conceive for at least 12 months; and 4) data
not duplicated in another manuscript. Twenty-eight eligible articles were reviewed, eight
studies met criteria, and data from these studies were extracted independently. Consensus
was achieved on each data point, and a meta-analysis was performed with the metan
command in Stata 9.0. Funnel plots and sensitivity analysis were performed. Results: The
initial meta-analysis of eight studies had significant heterogeneity (p=0.003) due to one
study with a very high baseline infertility rate (38%) in medically treated UC patients. When
this study was excluded, the relative risk of infertility shifted from 2.42 (1.99-2.95) to 3.17
(2.41-4.18) with a heterogeneity chi-squared = 8.00, p = 0.238. The weighted average
infertility rate in medically treated UC was 15% for all 7 studies, and the weighted average
infertility rate was 49% post IPAA (51% if the high-baseline study is included). We were
unable to identify any technical factors that consistently affected the risk of infertility,
including the number of abdominal surgeries, the use of an adhesion barrier, intraoperative
lysis of adhesions, the pouch type (S vs. J), or the use of pouch anti-adhesives. One study
did report increased risk of infertility in cases with intra-operative transfusion, which may
be a marker of surgical complexity. Conclusions: IPAA increases the risk of infertility in
females with ulcerative colitis by at least three fold, raising the baseline infertility rate in
medically treated UC patients from 15% to 49%. Approximately half of females post-IPAA
for UC who attempt conception will fail to conceive in the first 12 months. This provides
a basis for counseling patients considering colectomy with IPAA. Further studies to identify
modifiable risk factors are needed.
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Disease Activity During Pregnancy in Women with Inflammatory Bowel
Disease (IBD): A Population Based Cohort Study
Uma Mahadevan, Douglas Corley
Introduction: Referral center studies suggest IBD activity during pregnancy is associated
with adverse outcomes. Using a sample that approximated the population of Northern
California, we evaluated the association between disease activity per trimester and adverse
maternal/fetal outcomes. Methods: We conducted a cohort study among members of Northern
California Kaiser Permanente. 461 pregnant women with a pre-birth diagnosis of IBD were
frequency matched to 495 non-IBD pregnant women for age and hospital of delivery.
Maternal demographics, potential confounders (e.g. smoking, alcohol, etc.), IBD activity,
medication use, pregnancy outcome and maternal/fetal complications were abstracted from
electronic and written prenatal and birth records. Univariate analyses included chi-square
and t-tests; multivariate analyses used unconditional logistic regression. All analyses were
two tailed. Results: The table outlines disease activity per trimester (T). The majority of
patients were inactive throughout pregnancy. Disease activity during conception/T1 had an
odds ratio(OR) of 1.23 (0.93, 1.63) for an adverse conception outcome (spontaneous (SAB)
or therapeutic (TAB) abortion). If TAB is not included, OR = 0.81 (0.53, 1.24). Disease
activity in a particular T was not associated with adverse pregnancy outcome (preterm
birth, low birth weight, intrauterine growth retardation, small for gestational age, congenital
anomalies, APGAR score <7, stillbirth). OR for T1 = 1.02 (0.69, 1.51); T2 = 1.20 (0.85,
1.69); T3 = 1.41 (1.00, 1.97). Disease activity in T3 was not associated with adverse labor
outcome, OR 0.85 (0.58, 1.25). A flare in a particular T was not associated with adverse
neonatal outcome (NICU admission, jaundice, seizure, mortality). Conclusions: Active disease
during conception and T1 is not associated with a higher rate of spontaneous abortion.
Though there is a trend towards an increase in adverse pregnancy outcomes with disease
activity in T3, overall and per trimester, there is no significant association with disease
activity and adverse pregnancy, labor or neonatal outcome. Few women with IBD experience
significant disease activity during pregnancy in a population based setting. While this is
reassuring, it may explain the lack of association between disease activity and adverse
outcomes in this study.
Disease Activity per Trimester (T)
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Risk Factors for Pregnancy Outcome in Patients with Inflammatory Bowel
Disease (IBD)
Clemens Dejaco, Sieglinde Angelberger, Thomas Waldhoer, Thomas Haas, Heimo Wenzl,
Peter Knoflach, Wolfgang Miehsler, Gottfried Novacek, Harald Vogelsang, Walter Reinisch
Active disease and immunosuppressive treatment during pregnancy in IBD have been critic-
ally discussed. We have recently shown that maintenance therapy with azathioprine/6-
mercaptopurine may be safe throughout pregnancy, whereas the impact of disease activity
has not yet been evaluated prospectively. Aim: This prospective study has been performed
to assess risk factors for pregnancy outcome in patients with IBD. Patients & Methods:
Eighty pregnancies from 58 women with IBD were prospectively followed till birth. For
statistical reasons in women with multiple pregnancies one index pregnancy was selected,
based on the occurrence of an adverse event (referring to abortion, malformation, or perinatal
complication) and/or prematurity, defined by birth before the 37 gestational week or by a
birth weight of less than 2500g. If all pregnancies were uneventful, the most recent one
was chosen. The impact of the potential risk factors maternal age, nicotine abuse and disease
activity on unfavorable pregnancy outcome subsuming adverse events and prematurity, was
assessed by using the exact Fisher test as well as by a multivariate logistic regression model.
Disease activity was defined by the physician’s overall assessment based on stool frequency
and/or abdominal pain. Results: After exclusion of two patients with voluntary abortion 56
index pregnancies from 43 women with Crohn’s disease and 13 with ulcerative colitis were
evaluated. Median maternal age was 29 years (21-39), body mass index was 22.8, (16.6.-
32.9), 13 women (23%) were smokers. Seventeen patients (30%) had active disease at
some time during pregnancy. There were 13 abortions, 2 cases with malformation (Turner
Syndrome, Fallot’s tetralogy) and one serious perinatal complication. Prematurity was found
in 10 children. Unfavorable pregnancy outcome and prematurity as independent variables
were significantly related to active disease (46% vs 19% inactive, p< 0.04 and 70% vs 18%,
p < 0.004, respectively), but neither to maternal age nor nicotine abuse. Abortion as a single
outcome parameter was not associated with any of the investigated potential risk factors.
Conclusion: This first prospective study clearly demonstrates that active disease during
pregnancy represents a significant risk factor for unfavorable birth outcome and supports
the current treatment guidelines that maintenance of remission during gestation is essential.
221
Rising Hospitalization Rates for Crohn’s Disease But Not Ulcerative Colitis in
the United States
Meenakshi Bewtra, Chinyu Su, James D. Lewis
Background: Over the last two decades, medical therapy for inflammatory bowel diseases
(IBD) has witnessed increased use of immunomodulator and biologic therapies. We hypothes-
ized that increasing use of these therapies would result in fewer hospitalizations and surgeries
for IBD. This study examines trends in hospitalization and surgery rates for IBD in the
United States over a 14-year period. Methods: We performed an analysis of secular trends
of hospitalization and surgery rates from Crohn’s disease (CD) and ulcerative colitis (UC)
using 1990 to 2003 National Hospital Discharge Survey data. Rates were based on the total
US population, including patients with and without IBD. We used Spearman’s correlation
coefficient to examine the association between calendar year and rates of hospitalization or
bowel resection surgery. Analyses for hospitalizations required CD or UC to be listed as the
primary diagnosis. Results: From 1990 to 2003, hospitalization rates per 100,000 people
ranged from 9.3 to 17.1 for CD and 8.2 to 12.4 for UC (Figure). Over this period, there
was a significant trend for increasing hospitalization rates for CD (rho=0.83, p=.0002) but
not UC (rho=0.06, p=.83). Over the same period, the annual rates of bowel resection
surgeries per 100,000 population ranged from 2.8 to 5.0 for CD and from 1.6 to 3.4 for
UC. We did not observe a significant trend in surgery rates over the study period for CD
(rho=0.30, p=.30) or UC (rho= -0.31, p=.28). As expected, there was a significant trend for
shorter hospitalizations for both CD (rho= -0.98, p<.0001) and UC (rho= -0.87, p<.0001).
Conclusions: Despite advances in therapy, IBD hospitalization and surgery rates in the US
have not declined since 1990. Rather, there has been a significant increase in hospitalizations



















Steroid Dependency and Steroid Resistance in Crohn’s Disease (CD): Is There
Any Predictable Risk Factor?
Manuel Barreiro-Acosta, Aurelio Lorenzo, Enrique Dominguez-Munoz
Background: Steroid dependency (SD) and steroid resistance (SR) develop frequently in the
context of CD patients. Risk factors for the development of SD and SR in CD are unknown.
We hypothesized that some of the known risk factors for CD may be helpful to predict the
development of SD and SR in these patients. Aim: We aimed at evaluating the potential
association between different known factors related to CD and the development of SD or
SR. Methods: 188 consecutive patients with CD (111 female, 77 male, mean age 36 years,
range 17-76 years) were included. SD was defined as a relapse within 30 days after the end
of steroid treatment or after at least two attempts of tapering the steroid dose within the
last 12 months. SR was defined as the absence of respond to steroid therapy (minimum
50 mg of prednisolone daily) for more than 7 days. Gender, smoking habits, previous
appendectomy, family history of CD, extraintestinal manifestations of the disease, presence
of at least one mutant allele in any of the three considered variants of CARD15 gene (R702W,
G908R and 1007fs) and presence of TLR4+299 or the CD14-260 sequences variants were
analyzed as potential risk factors for SD and SR. Results are shown as percentages and 95%
confidence intervals (95CI). Association is shown as odds ratio (OR) and 95CI and analyzed
by the Fisher’s exact test. Results: Forty patients (21.3%, 95CI: 15.4-27.1%) developed SD,
whereas SR was observed in 29 (15.4%, 95CI: 10.3-20.6%). SD was associated to smoking
(OR 3.2; 1.4-7.4) (p<0.005) and to the presence of extraintestinal manifestations of the
disease (OR 3.7; 1.7-7.6) (p<0.001). In addition, although SD was not related to any of the
evaluated gene mutations, it tended to be more frequent among patients with a positive
family history of CD (OR 2.3; 0.9-5.6) (p=0.07). None of the analyzed factors, except
previous appendectomy (OR 3.7; 1.5-9.1) (p<0.01), were associated to SR. Conclusion:
Smoking habit, presence of extraintestinal manifestations and, probably, family history of
CD, appear to be associated to steroid dependency. Only a previous appendectomy is related
to the development of steroid resistance. Genetic variants of CARD15, TLR4 and CD14 play
not role in the development of SD and SR.
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Aminosalicylate (ASA) Use During Pregnancy Is Not Associated with
Increased Adverse Events Or Congenital Malformations (CM) in Women with
Inflammatory Bowel Disease (IBD)
Uma Mahadevan, Douglas Corley
Introduction: ASA’s are FDA pregnancy category B. Using a sample that approximated the
population of Northern California, we evaluated the association between ASA exposure and
adverse pregnancy outcomes (AO). Methods: A cohort study among members of Northern
California Kaiser Permanente identified 461 pregnant women with a pre-birth diagnosis of
IBD frequency matched to 495 non-IBD pregnant women for age and hospital of delivery.
Maternal demographics, potential confounders (e.g. smoking, alcohol, etc.), IBD activity,
medication use, pregnancy outcome and maternal/fetal complications were abstracted from
electronic and written prenatal and birth records. Sulfasalazine (SAS) use was evaluated
independently of other ASA’s. Bivariate analyses were conducted of ASA and SAS use during
conception/trimester 1 (T) and T2/T3 versus AO in all patients and by IBD diagnosis (Crohn’s
Disease - CD, Ulcerative colitis-UC). A multivariate analysis was done of the risk of CM
taking into account maternal age, current alcohol, ever smoking and race. Results: During
conception/T1, 158 women had ASA exposure, 58 SAS and 570 had no exposure. During
T2/T3, 137 women had ASA exposure, 47 SAS and 684 had no exposure. Table 1 summarizes
the rate of AO in all patients exposed to ASA/SAS and by IBD diagnosis versus unexposed
patients. UC Patients who used ASA’s in T2/T3 (n=94) had lower rates of AO than UC
patients who did not (n=197) (67% vs. 82% p = 0.004). This same effect was not seen with
SAS alone, but was seen with either ASA or SAS use in T2/T3 (70% vs. 83%, p = 0.008).
Overall, there was no association between ASA or SAS use and CM. (Table 2). There was
a trend towards increased CM with SAS exposure during conception/T1, but this was not
statistically significant. Conclusions: The use of ASA and SAS during pregnancy is not
associated with an increase in AO. The increase in AO in UC patients not on ASA in T2/
T3 and the fewer patients on ASA in T2/T3 versus T1 suggests that continuing ASA into
T2/T3 may be protective. There is no risk of CM with the use of ASA during pregnancy.
There is a trend towards an increased risk in patients on SAS during conception/T1.
Table 1: Risk of Adverse Outcome with ASA use
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Table 2: Risk of CM with ASA use
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Ctla4-IG Abrogates TNBS Colitis By Inducing the Expression of Indoleamine-
2,3-Dioxygenase
William Stenson, Gregory J. Gurtner, Suzanne Schloemann, Filipe Muhale, Keely G.
McDonald, Rodney D. Newberry
Background: CTLA4-Ig is a biological agent consisting of the extracellular domain of Cytotoxic
T cell Late Antigen-4 (CTLA-4) fused to the Fc region of IgG. CTLA4-Ig potentially promotes
tolerance both via costimulatory blockade as well as through the induction of indoleamine
2,3-dioxygenase (IDO) in professional antigen presenting cells (APCs) including dendritic
cells. Objectives: We had previously demonstrated that IDO was induced in trinitrobenzene
sulfonic acid (TNBS) colitis and that inhibition of IDO with 1-methyltryptophan(1-mT)
resulted in worsening of TNBS colitis. We sought to determine if induction of IDO by
administration of CTLA4-Ig could abrogate TNBS colitis, and if so, to determine if IDO
played a role in this process. Methods: Intrarectal TNBS and intraperitoneal CTLA4-Ig were
administered to SJL/J mice along with 1-methyltryptophan(1-mT),a specific IDO inhibitor.
Clinical and histological criteria were assessed to determine colitis severity. IDO protein and
mRNA expression were assessed by Western blotting and real time PCR respectively. Results:
We found that CTLA4-Ig induced IDO in cultured lamina propria mononuclear cells
(LPMNCs) as well as in the murine colon after systemic administration. Immunohistochem-
istry for IDO in mice given CTLA4-Ig showed staining of pericryptal mesenchymal cells
that appeared to be a subset of CD11c+ cells. Intraperitoneal CTLA4-Ig administration prior
to and at the time of TNBS administration significantly abrogated colitis both clinically and
by histological criteria. At 6 days mice treated with TNBS had a 25% survival,those receiving
CTLA4-Ig+TNBS had a 68% survival while those receiving CTLA4-Ig+TNBS+1-mT had a
25% survival (p=.02). Similarly treatment with TNBS was associated with a 17% weight
loss at day 2, treatment with CTLA4-Ig+TNBS was associated with an 8% weight loss and
CTLA4-Ig+TNBS+1-mT was associated with a 16% weight loss (p=.05). The results of
morphologic and histologic scoring followed the same pattern as survival and weight loss.
Colonic IFNα and IFNγ mRNA were measured by RT-PCR. Treatment with TNBS resulted
in a 2-fold increase in IFNα and a 5-fold increase in IFNγ,whereas treatment with CTLA4-
Ig+TNBS resulted in a 2-fold increase in IFNα but no increase in IFNγ. Conclusion: This
study demonstrates that CTLA4-Ig improves the clinical outcome in TNBS colitis via IDO
induction, and suggests a potential therapeutic role for CTLA4-Ig in the treatment of IBD.
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An Anti-Inflammatory Role for the Heme Oxygenase-1 Pathway in Chronic
Th2-Mediated Murine Colitis
Refaat Hegazi, Arthur Barrie, Antonia Sepulveda, Leo Otterbein, Scott Plevy
Introduction: The products of the heme oxygenase-1 (HO-1) pathway, namely, carbon
monoxide (CO), biliverdin (BV), and iron, exert immunomodulatory effects in tissue injury
and acute inflammation. Our laboratory has recently demonstrated for the first time that CO
also suppresses chronic inflammation utilizing a Th1-mediated mouse model of inflammatory
bowel disease (Hegazi R, J.Exp.Med., 2005, In Press). Up to now, we had not yet determined
if this novel protective role for the HO-1 pathway in chronic disease is unique to Th1
specific disorders. Aim: To determine if the HO-1 pathway also suppresses Th2 mediated
chronic inflammation, we assessed the therapeutic potential of CO and BV in the T cell
receptor- alpha (TCRα)deficient (-/-) murine model of colitis. Methods: TCRα -/- mice at
16 weeks of age were exposed to CO (250 ppm) (n = 9) and compared to air exposed mice
(n = 9). In other experiments, TCRα-/- mice were injected IP with BV (30 mg/kg twice
weekly) for two weeks (n = 10) and compared to a vehicle-injected group (n = 6). At the
end of the study period, mice were sacrificed and colonic tissue sections assessed for
inflammatory changes by a single pathologist blinded to treatment group. Colonic mucosal
explants were cultured for 24 hours, and IL-10, IL-1β, IL-5, IL-6, IL-12 p40, IL-23 and IL-
17 protein secretion determined by multiplex ELISA. Results: Significant amelioration of
colitis is demonstrated in both the CO-exposed and BV-treated groups compared to their
respective controls (CO vs. air colitis scores = 0.39 ± 0.2 vs. 1.68 ± 1.02, p<0.05; BV vs.
vehicle colitis scores = 0.79 ± 0.43 vs. 1.54 ± 0.37, p<0.05). Consistent with the observed
histologic improvement, both CO and BV repress numerous Th2 pro-inflammatory cytokines
including IL-1β, IL-5, and IL-6 in colonic mucosal explant cultures, while intestinal IL-10
is induced in CO- exposed but not BV-treated mice. In addition, IL-12 p40, IL-23 and IL-
17 are overexpressed in TCRα-/- intestinal tissue and are inhibited by BV. Conclusions: The
heme metabolites CO and BV suppress pro-inflammatory cytokine expression and Th2
mediated colitis in TCRα-/- mice. This observation in combination with previous investi-
gations suggests that HO-1 products are ubiquitous anti-inflammatory factors in both acute
and chronic inflammation. CO and BV may act via alternative mechanisms based on the
divergent IL-10 levels in these two treatment groups. Lastly, independent of these findings,
the observed expression pattern of IL-23 and IL-17 implicates a novel role for this cytokine
axis in this disease model.
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Innate Cell-Targeting Therapeutic Effect of IL-22 On Experimental Colitis
Ken Sugimoto, Atsuhiro Ogawa, Yasuyo Shimomura, Akira Andoh, Atul K. Bhan, Atsushi
Mizoguchi
BACKGROUND & AIMS: Dysregulated host/microbial interactions result in the develop-
ment of IBD. Activation of signal transducer and activator of transcription (STAT) 3 has
previously been shown to activate innate responses against enteric bacteria to avoid the
development of colitis (Immunity 1999,10:39; Nat Med 2002,8:1089). Recently, IL-22 has
been identified as a strong activator of STAT3 in innate cells (such as epithelial cells) but
not acquired cells (such as T and B cells) (Immunity 2004,21:241). However, the role of
IL-22 in the pathogenesis of colitis has not yet been defined. METHODS: In vitro and ex
vivo studies using human epithelial cancer cell lines and freshly isolated colonic epithelial
cells (CEC) from mice were performed to test the effect of IL-22 on the CEC activation. In
addition, in vivo studies using experimental models of colitis were carried out to define the
role of IL-22 in the pathogenesis of colitis. RESULTS: IL-22 expression was specifically
elicited in the colon under inflammatory conditions observed in experimental colitis models
as well as human IBD patients. Interestingly, the receptor specific for IL-22 was constitutively
expressed on CEC but not acquired cells. IL-22 efficiently induced the activation of STAT3
and subsequently enhanced the expression of suppressors of cytokine signaling (SOCS) 3
in human colonic cancer cell lines and freshly isolated CEC from mice. Inactivation of
STAT3 using siRNA approach abolished the IL-22-mediated upregulation of SOCS3. To test
the role of IL-22 in the pathogenesis of colitis, IL-22 activity was neutralized in DSS-induced
colitis model by administration of anti-IL-22 antibodies. Neutralization of IL-22 activity
significantly delayed the recovery from DSS-induced acute colitis. To explore the therapeutic
potential of IL-22 for IBD, we established a new lipid complex-based, pressurized local gene
delivery approach to induce the overexpression of IL-22 into the colonic lamina propria
(LP). Of note, this approach efficiently delivered the gene encoding IL-22 with GFP as
indicated by massive accumulations of GFP+ cells in the colonic LP. Importantly, the
overexpression of IL-22 in the colon led to a rapid suppression of colitis in T cell receptor
α knockout (TCRαKO) mice that have developed severe colitis. This rapid attenuation of
colitis was associated with restoration of CEC homeostasis as indicated by a significant
increase in goblet cells. CONCLUSION: We here demonstrate that IL-22 contributes to
the suppression of colitis by specifically restoring the CEC homeostasis presumably through
the activation of STAT3.
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Nemo Binding Domain Peptide Ameliorates Chronic T-Helper-1 (Th1)-
Mediated Murine Colitis
Shaival H. Dave, Jeremy S. Tilstra, Khaja K. Rehman, Paul D. Robbins, Albert S. Baldwin,
Scott E. Plevy
BACKGROUND: The NF-κB family of transcription factors is a central regulator of chronic
inflammation. The phosphorylation of IκB proteins by a specific IκB kinase (IKK) is a key
step in NF-κB activation. IKK is a complex of two catalytic subunits, IKKα and IKKβ, and
a regulatory subunit, “NF-κB essential modulator” (NEMO). An N-terminal region of NEMO
associates with a hexapeptide sequence within the C-terminus of both IKKα and IKKβ,
named the NEMO binding domain (NBD). A cell permeable peptide containing a cationic
protein transduction domain (PTD) coupled to NBD (PTD-NBD) disrupts the association
of NEMO with IKKs in vitro and blocks NF-κB activation in vivo. As a therapeutic modality,
PTD-NBD has the theoretic advantage of selectively inhibiting activated NF-κB, and the
potential for local and systemic administration. OBJECTIVES: The purpose of this study
is to determine efficacy and mechanism of a novel cell permeable peptide NF-κB inhibitor
(PTD-NBD) in murine colitis. METHODS: To determine transduction efficiency, murine
bone-marrow (BM) derived macrophages were incubated with two PTDs (8K and HIV-TAT).
NF-κB activity was evaluated using an NF-κB luciferase reporter plasmid transfected into
RAW264.7 cells. IL-10 deficient (-/-) mice at 10 weeks of age were injected i.p. with PTD-
NBD (1, 5, or 10 mg/kg and vehicle) daily for two weeks. Colitis severity was scored by a
pathologist blinded to treatment group. TNF and IL-12 p40 production were determined
by ELISA (mean±SD) in supernatants from intestinal explant cultures and LPS (100 ng/ml)
plus IFN-γ (10 ng/ml) activated splenocytes. RESULTS: The PTD peptides transduce BM-
derived macrophages with close to 100% efficiency. In RAW264.7 cells, PTD-NBD dose-
dependently inhibits LPS-induced NF-κB activity. In vivo, IL-10-/- mice treated i.p. with
PTD-NBD demonstrate amelioration of colitis (colitis score 1.6±0.4 vs. 5.4±0.9) compared
to IL-10-/- mice treated with vehicle. Intestinal explants of treated mice express less TNF
(71±43 pg/ml vs. 219±34 pg/ml) and IL-12 p40 (270±11 pg/ml vs. 650 ±56 pg/ml) than
controls. Decreased LPS plus IFN-γ activated IL-12 p40 is demonstrated in splenocytes
cultured ex vivo from PTD-NBD treated IL-10-/- mice. CONCLUSIONS: A cell permeable
peptide inhibitor of IKK, PTD-NBD, ameliorates colitis in IL-10-/- mice. Mechanistically,
mucosal explants and splenocytes cultured ex vivo for 24 hours demonstrate decreased
cytokine expression, suggesting that inhibition is not related to the continued presence of
the short-lived PTD-NBD peptide. These results demonstrate that inhibitors of IKK, in
particular a PTD-NBD peptide, could be therapeutic in the treatment of colitis.
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Cannabinoid Receptor 2 Activation Prevents and Reduces Intestinal
Inflammation
Xavier Thuru, Mathias Chamaillard, Meliha Karsak, Emilie Gantier, Edmone Erdual,
Caroline Dubuquoy, David Philippe, Claudio Schteingart, Jacek Stalewski, Andreas
Zimmer, Pierre Riviere, Pierre Desreumaux
Background: The G protein coupled cannabinoid receptor 2 (CB2) is specifically expressed
on immune cells, mediating analgesia and regulation of the immune response. However,
the potential regulatory role(s) of CB2 and its ligands during intestinal inflammation remain
unknown. Aim: Evaluation of the potential therapeutic effect and the underlying mechanisms
of CB2 function in preventing/treating acute and chronic intestinal inflammation using
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different experimental models of colitis in mice. Methods: Colitis was induced by intra-
rectal administration of TNBS (150mg/kg, 5 days) in CB2-/- mice and their respective wild
type littermates (WT). Effects of CB2 ligands were also investigated using a known selective
CB2 agonist (JWH-133), a new CB2 ligand (FE 200859) and/or a specific CB2 receptor
antagonist (SR144528), given preventively or in a treatment mode in C57/Bl6 mice with
acute or chronic colitis induced either by TNBS or DSS. The intensity of colitis was assessed
by mortality rates, macroscopic and histologic inflammatory scores and quantification of
myeloperoxydase activity. Results: Mutant mice lacking CB2 were highly susceptible to
colitis. Consistently, we found suggestive anti-inflammatory properties of the known CB2
agonist JWH-133 (0.1 mg/kg/day) during TNBS-induced colitis. The novel specific CB2
ligand FE 200859 administered preventively or in treatment mode was effective at optimal
dosages ranging from 0.1-1 mg/kg/day, reducing the mortality and the intensity of colitis
in mice with acute and chronic inflammation. Consistently, this effect was CB2-dependent
and reversed by the administration of the CB2 receptor antagonist SR144528 (1 mg/kg/
day). Finally, we showed in vivo that activation of CB2 reduces neutrophil recruitment in
the mouse colon, providing an explanation for the anti-inflammatory role of CB2 in the
gut. Conclusion: Modulation of CB2 function and the particular efficacy of the new CB2 ligand
FE 200859 open a novel therapeutic strategy for the treatment of intestinal inflammation.
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Intestinal Colonization with the Helminth Heligmosomoides Polygyrus
Abrogates Il17a Production By Mesenteric Lymph Node Cells
Ahmed Metwali, John Leung, M. Nedim Ince, Sarah Winkler, Arthur Blum, Tommy
Setiawan, Joseph F. Urban, Joel V. Weinstock, David E. Elliott
Interleukin 17A (IL17, CTLA-8) is a pro-inflammatory cytokine required for autoimmune
pathology. IL17A is made by a distinct linage of T cells separate from classical Th1 and
Th2 cells. IL17A expression is increased in active Crohn’s disease and ulcerative colitis.
Exposure to intestinal helminths inhibits aberrant inflammation in several mouse models of
colitis. Colonization with the helminth Trichuris suis decreases disease activity in patients
with Crohn’s disease or ulcerative colitis. Because elevated IL17A expression is associated
with active IBD, we tested if helminth exposure affects gut-associated T cell IL17A expression.
Wild-type C57Bl/6 mice were colonized with the helminth Heligmosomoides polygryrus by
gastric gavage containing 150 larvae. Controls received no larvae. H. polygyrus is a nematode
that resides in the duodenum of mice and inhibits TNBS or IL10-deficient colitis. Two
weeks after gavage, mice were euthanized and mesenteric lymph node (MLN) cells isolated
for RNA extraction or cell culture. As determined by real-time PCR, freshly isolated MLN
cells from H. polygyrus-colonized mice expressed 16 fold fewer IL17A mRNA transcripts
than MLN cells from control mice (p<0.05). MLN cells from either group produced no
ELISA detectable IL17A when cultured without stimulation or stimulated with LPS (100ng/
ml) or CpG oligonucleotide (0.6μg/ml). When stimulated with anti-CD3, MLN cells from
worm-free control mice produced copious IL17A (1.40 ± 0.23 ng/ml). Identically simulated
MLN cells from H. polygyrus-colonized mice produced much less IL17A (0.20 ± 0.10,
p<0.01). Results are from three separate experiments each with 3 to 4 mice per group.
Conclusion: Helminth colonization inhibits IL17A mRNA expression and TCR-stimulated
production by gut-associated lymphocytes. IL17A is a critical cytokine that promotes inflam-
mation. The inhibition of IL17A may explain how helminth exposure can limit colitis.
(DK58755, DK49382, and VAMC)
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Antrum Mucosal Protein (AMP)-18 Activates Multiple Pathways to Assemble
and Stabilize Tight Junctions
Margaret M. Walsh-Reitz, Sreedharan Kartha, Marc Bissonnette, Bogdan Goc, F G. Toback
AMP-18 (gastrokine-1), a novel 18 kDa protein, is cell protective, mitogenic, and motogenic
for intestinal epithelial cells. Both recombinant human (rh)AMP-18 and a synthetic 21-mer
AMP peptide stimulate accumulation of specific tight junction (TJ) proteins and stabilize
perijunctional actin. These actions triggered by AMP-18 suggest that it could not only protect
the mucosal barrier, but also speed its recovery after injury in inflammatory bowel disease
as we observed in mice with dextran sulfate sodium-induced colitis. To determine if AMP-
18 is a molecular regulator of TJ protein assembly after TJ disruption, we asked if it activates
protein kinase C-zeta (PKCζ) and generates the multimeric phospho (p)-PKCζ/Par6/ Cdc42/
ECT2-GTP/Par3 protein complex known to associate with JAM-A and ZO-1 proteins needed
to form mature TJs. By utilizing immunoblotting, confocal microscopy (CF), and measure-
ments of transepithelial electrical resistance we showed that addition of rhAMP-18 to Caco2/
bbe (C2) cell monolayers induced phosphorylation of PKCζ by 10 minutes, followed by
the appearance of p-PKCζ in the detergent-insoluble, cytoskeletal fraction. Furthermore,
CF revealed that cytosolic p-PKCζ colocalized with perijunctional actin, suggesting its
translocation to the TJ. AMP-18 also promoted the translocation of Par6, Cdc42, and the
GTP-GDP exchange factor ECT2 into the detergent-insoluble fraction of cell monolayers
exposed to low-calcium medium (LCM) to disrupt their TJs. ZO-1, ZO-2, and JAM-A also
accumulated in TJs after treatment with rhAMP-18. We then asked if the capacity of AMP-
18 to stabilize the actin cytoskeleton following exposure to the actin-disrupting agent cyto-
chalasin D could be mediated via activation of the p38 MAP kinase (MAPK)/heat shock
protein (hsp) 27/actin pathway. Immunoblotting demonstrated that AMP peptide rapidly
stimulated phosphorylation of p38 MAPK and hsp27, whereas the specific p38 MAPK
inhibitor SB202190 prevented phosphorylation of hsp27 suggesting that p38 MAPK activa-
tion is required for hsp27 phosphorylation. CF showed that treatment with AMP peptide
increased accumulation of p-hsp27 at 30 minutes and its translocation to perijunctional
actin. After TJs in C2 cell monolayers were disrupted by LCM, treatment with AMP peptide
resulted in rapid phosphorylation of hsp27 and its translocation along with ZO-1 and ZO-
2 to actin. These observations suggest that AMP-18 stimulates phosphorylation of both
hsp27 and PKCζ, and that translocation of these phosphoproteins promotes assembly of TJ
proteins and stabilizes the actin filament network to protect mucosal barrier structure and


















GTPase Activation in Polarity Complexes Initiates Intestinal Epithelial
Defense Responses
Atsuko Fukazawa, Kiyotaka Kurachi, Xiubin Gu, Ben Margolis, Karl Matter, Hans C.
Reinecker
Background and aim: The coordination of two evolutionarily conserved multiprotein com-
plexes, Cdc42-Par6-Par3-aPKC and Crumbs-PALS1-PATJ, has been implicated in the regula-
tion of tight junction integrity. GEF-H1 has been identified as a tight junction-associated
guanine nucleotide exchange factor for RhoA. The aim of this study was to identify the
protein interaction of GEF-H1 in junctional complexes and determine its function as a
coordinator for Rho-GTPase dependent signaling pathways in polarized epithelial cells.
Materials and Methods: Interaction of GEF-H1 with polarity and tight junctional proteins
was assessed by immunoprecipitations and live cell imaging using spinning disc confocal
microscopy. Subcellular redistribution of polarity and junctional proteins was assessed in
Triton X-soluble and -insoluble protein fractions. Expression vectors were generated for
GFP tagged GEF-H1, mRFP-tagged RhoA, Rac1, Cdc42 and their dominant negative or
constitutive active mutants. Additional constructs included non-tagged and VSV-tagged GEF-
H1, HA-tagged PAR3, PAR6 and 14-3-3ζ. Transcriptional activation was assessed by dual-
luciferase assays using reporter constructs containing NF-κB consensus binding motifs or
the human IL-8 promoter. HEK293, Caco-2 and MDCK cell lines were used for the analysis
of GEF-H1 functions. Results: We originally identified GEF-H1 as a serine phosphorylated
protein in claudin-2 containing tight junctional complexes of human intestinal epithelial
cells. The protein interactions responsible for the subcellular recruitment of GEF-H1 changed
with epithelial cell differentiation. In nonpolarized epithelial cells, GEF-H1 associated with
microtubules but shifted into junctional complexes upon polarization and establishment of
functional tight junctions. GEF-H1 was found to bind to partition defective (PAR) 3 in a
complex with the adaptor 14-3-3ζ. Formation of this complex inactivated GEF-H1. Increases
in cytoplasmic GEF-H1 resulted in the activation of RhoA with subsequent enhanced recruit-
ment of Cdc42 but not RhoA or Rac1 into junctional complexes. Interestingly, release of
GEF-H1 let to the RhoA dependent activation of NF-κB and the induction of IL-8 promoter
activity in epithelial cells. Conclusion: We show that GEF-H1 is recruited during epithelial
differentiation to become part of the apical polarity complexes. There GEF-H1 may serve
as a trigger in tight junction responses to challenges to the intestinal barrier for the induction
of epithelial repair and defense signals.
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The Tumor Necrosis Factor (TNF) Family Member Light Causes Actomyosin-
Dependent Occludin Endocytosis and Barrier Dysfunction
Brad T. Schwarz, Fengjun Wang, Yingmin Wang, Yang-Xin Fu, Jerrold R. Turner
LIGHT (Lymphotoxin-like Inducible protein that competes with Glycoprotein-D for binding
to Herpes virus entry mediator on T cells) is a member of the TNF superfamily involved
in T cell regulation during innate and adaptive immune responses. Although related, it is
notable that LIGHT and TNF utilize distinct, non-overlapping surface receptors to trigger
differing intracellular signals. Mucosal LIGHT expression is increased in human Crohn’s
disease and, in mice, transgenic LIGHT expression induces Crohn’s-like disease. Effects of
TNF on intestinal epithelial cells have been linked to barrier dysfunction in Crohn’s disease.
However, no studies have examined the effects of LIGHT on the epithelial barrier. The aim
of this study was to determine if LIGHT is able to disrupt the intestinal epithelial barrier
and, if so, to determine the mechanisms involved. METHODS: Caco-2BBe monolayers were
treated with basolateral cytokines (IFNγ, 10ng/ml, and/or LIGHT, 50ng/ml) as indicated.
Barrier function was measured as transepithelial resistance (TER). Myosin light chain (MLC)
phosphorylation and MLC kinase (MLCK) expression were determined by immunoblot. Tight
junction protein localization was assessed by deconvolution immunofluorescent microscopy.
RESULTS: LIGHT did not affect TER in the absence of IFNγ. In monolayers primed with
IFNγ (24hrs), expression of the LIGHT receptor LTβR was upregulated and LIGHT treatment
caused TER to fall within 4hrs, with maximal TER loss of 31±7% after 8hrs. LIGHT-induced
barrier dysfunction was not accompanied by apoptosis, but was associated with markedly
increased MLCK expression and MLC phosphorylation. TER loss correlated with internaliz-
ation of the tight junction protein occludin. Both TER loss and occludin distribution were
restored by specific MLCK inhibition. Occludin endocytosis occurred via a caveolae-mediated
pathway based on increased occludin:caveolin-1 colocalization and inhibition by MβCD,
which blocks caveolae-dependent endocytosis. CONCLUSIONS: LIGHT disrupts intestinal
epithelial barrier function. This process is distinct from TNF-induced barrier dysfunction,
as LIGHT and TNF do not share cell surface receptors. LIGHT-induced tight junction
disruption occurs as a result of caveolae-mediated occludin internalization. These data are
the first to suggest a role for LIGHT in epithelial barrier loss in Crohn’s disease. Moreover,
these data imply that MLCK inhibition may be an effective strategy to correct LIGHT-induced
barrier dysfunction.
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Role of Keratin-8 in Intestinal Barrier Function
Lixin Wang, Didier Merlin, Shanthi V. Sitaraman
Background and Significance: Keratin 8 (K-8) and keratin-18 (K-18) are the predominant
intermediate filament proteins in the small and large intestinal epithelia. Recent studies
have shown that Keratin-8 null mice develop spontaneous diarrhea and colitis. Moreover,
mutations of keratin-8 may be associated with inflammatory bowel disease. The regulation
and function of keratin in the intestinal epithelia is largely unknown. We recently demon-
strated that IL-6 induces a transcriptionally-mediated synthesis of K8 and K18. In this study
we addressed the role of IL-6-induced K8 expression in barrier function. Methods: Caco2-
BBE cell line was used to study the effect of IL-6 (100ng/ml) on keratin expression. Paracellular
permeability was assessed by apical-to-basal transport of a dextran probe (MW4000) conjug-
ated to fluorescein (percentage of apical flux per cm2/h) and expressed as % of vehicle
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treated cells. Keratin expression was studied by Northern blot and Western blot. Caco2-
bbe cells were transiently transfected with scrambled or K8 siRNA and silencing of K8
expression was confirmed by Western blot. Results: IL-6 decreased paracellular flux of FITC
dextran compared to vehicle treated monolayer by 31±2% compared to vehicle treated cells.
K8 siRNA abolished the decrease in paracellular permeability induced by IL-6 (scrambled
siRNA+1L-6 43±8% and K8 siRNA+IL-6 120±18 of vehicle treated cells). IL-6 significantly
upregulated mRNA and protein levels of K8, K18 and K19. Confocal microscopy showed a
reticular pattern of intracellular keratin localized to the sub-apical region after IL-6 treatment.
Keratin was localized to the triton-insoluble fraction after IL-6 treatment. Interestingly, in IL-
6 treated cells, immunoprecipitation studies showed that K8 associated with apcial junctional
proteins, E-cadherin and occludin. Conclusions: Collectively, our data demonstrate that IL-
6 induces K8, which mediates permeability changes induced by IL-6. We show that K8
regulates barrier function and the effect of K8 on barrier function may be related to its
direct interaction with apical junctional proteins.
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WIP1 Protects Hydrogen Peroxide-Induced Colonic Epithelial Barrier
Dysfunction By Targeting Claudin-4
Tadayuki Oshima, Takaya Shimura, Fumitaka Fujita, Yoshinori Mori, E.J. Kubota,
Tomonori Yamada, Tsuneya Wada, Naotaka Ogasawara, Satoshi Tanida, Hiromi Kataoka,
Makoto Sasaki, Toshiyuki Takeuchi, Takashi Joh
Background and Aim: Tight junctions create a paracellular permeability barrier, and though
reactive oxygen species (ROS) have been implicated as mediators of inflammation in inflam-
matory bowel diseases their effect on the function of colonic epithelial tight junctions remains
unknown. In this study, we examined the effect of hydrogen peroxide (H2O2) on colonic
mucosal barrier properties and tight junction organization and investigated the role of Wip1,
a serine/threonine phosphatase. Methods: Human colonic epithelial cells, Caco2, were used
in this study. Epithelial barrier integrity was determined by assessing trans-epithelial electrical
resistance (TEER) using a volt-ohm meter with ‘chopstick’ electrodes and by measuring the
paracellular permeability of dextran molecules. To examine the effects of H2O2 on junctional
proteins, immunoblotting and immunofluorescent staining were performed with specific
antibodies (claudins-1, -3, -4, and -7). In some experiments, cells were dual stained and
samples were analyzed with a confocal laser scanning microscope. The mRNA level was
analyzed by real-time PCR. The activation of p38 MAP kinase was detected by a phosphospec-
ific antibody. SB203580 and PD98059 were used as a p38 MAP kinase inhibitor and a MAP
kinase kinase (MEK) 1 inhibitor, respectively. Wip1-expressing Caco2 were produced by
transfection with adenovirus vector containing the Wip1 gene. Results: H2O2 (500 μM)
treatment of colonic epithelial monolayers caused a significant decrease in TEER and a
significant increase in dextran permeability. Oxidant-mediated permeability and phosphoryl-
ation of p38 MAP kinase were significantly attenuated by SB203580 (1 μM), but not by
PD98059 (10 μM). Although the amount of tight junction proteins was not altered with
H2O2 stimulation, H2O2 changed the localization of claudin-4 protein from an NP-40
insoluble fraction to a soluble fraction. Interestingly, levels of claudin-4 mRNA were increased
by H2O2 stimulation. Wip1 transfection significantly attenuated phosphorylation of p38
MAP kinase, oxidant-mediated permeability, and levels of claudin-4 mRNA. H2O2-induced
changes in claudin-4 localization were abolished by SB203580 pretreatment as well as Wip1
transfection. Conclusions: This is the first study able to demonstrate that the change in
claudin-4 localization is important for H2O2-induced colonic permeability and that Wip1
functions to protect colonic mucosal integrity by targeting claudin-4.
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Mechanism of Prednisolone Modulation of the Intestinal Epithelial Tight
Junction Barrier: Role of the Glucocorticoid Receptor Pathway in Promoter
Regulation
Michel Boivin, John C. Kennedy, Dongmei Ye, Thomas Y. Ma
Background: Glucocorticoids are the first-line therapeutic agents for inflammatory bowel
disease. Glucocorticoid treatment results in the restoration of the intestinal epithelial tight
junction (TJ) barrier in patients with active Crohn’s disease. Previously we have shown that
prednisolone prevents the TNF-α induced increase in Caco-2 TJ permeability. Prednisolone
prevented the TNF-α induced opening of the TJ barrier by inhibiting the TNF-α induced
increase in expression and activity of the enzyme myosin light chain kinase (MLCK). Gluco-
corticoids exert anti-inflammatory effects by binding to cytoplasmic glucocorticoid recep-
tor(GR) which then translocates to the nucleus to bind its transcription factor motif: the
glucocorticoid receptor element(GRE). The aim of this study was to examine the intracellular
mechanisms of prednisolone inhibition of the TNF-α induced increase of Caco-2 TJ permeab-
ility. Methods: Filter grown Caco-2 intestinal epithelial monolayers were used as an in-vitro
model of the intestinal epithelial barrier. Results: TNF-α treatment resulted in a significant
increase in Caco-2 TJ permeability. Prednisolone had no effect on baseline TJ permeability
but prevented the TNF-α induced increase in permeability. Prednisolone caused a rapid
cytoplasmic to nuclear translocation of Caco-2 GR as determined by immunostaining. Predni-
solone also caused an increase in binding of activated GR to a DNA oligonucleiotide containing
a consensus GRE. The known GRE binding antagonist RU-486 inhibited the prednisolone
induced increase in GRE binding. TNF-α caused a significant increase in MLCK promoter
activity and expression; and prednisolone inhibited the TNF-α induced increase in MLCK
promoter activity and expression. Moreover, RU-486 prevented prednisolone inhibition of
MLCK activation. A GRE binding motif was identified on the MLCK promoter and an MLCK
promoter construct was created with a mutation of the GRE binding site using site-directed
mutagenesis. TNF-α also caused an increase in the promoter activity of the GRE-mutated
MLCK promoter. However, in the absence of the GRE binding motif, prednisolone no longer
prevented the TNF-α increase in MLCK promoter activity. Conclusion: Prednisolone protects
against the TNF-α induced increase in Caco-2 TJ permeability by preventing the TNF-α
induced activation of MLCK promoter activity and subsequent increase in MLCK expression.
Our results show that the prednisolone inhibition of MLCK promoter activity is mediated
by prednisolone activation of GR which translocates to the nucleus and binds to the GRE
site on the MLCK promoter. GR binding to the GRE on the MLCK promoter inhibited
MLCK promoter activity.
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Slow Wave Circus Movements and Reentry in the Canine Stomach in Vivo
Wim Lammers, Luc Ver Donck, Betty Stephen, Jan A. Schuurkes, Bernard Coulie
The mechanisms underlying gastroparesis have not been well elucidated but could be based
on gastric tachy- or brady- dysrhythmias. Such arrhythmias could be due to focal or reentrant
activations. We analyzed the pattern of slow wave propagation in the stomach in an in vivo
canine model. Five fasted dogs were anesthetized and after a median laparotomy, the ventral
surface of the stomach was exposed in situ. A multi-electrode assembly of 240 electrodes
(covering a 4 by 4 cm area with 2.5 mm interelectrode distance) was positioned on the
serosal surface of the stomach. After a 5-minute stabilization period, electrical activity was
recorded for 5 min from all 240 electrodes simultaneously. The timings of slow waves at each
recording site were determined off-line and slow wave propagation maps were constructed. In
the majority of cases, slow wave behavior was regular, homogeneous and uniform (4.8
cycles/min). They propagated from corpus to antrum at increasing speed until the impulses
terminated in the pyloric region. Occasionally (n = 5), the regular slow waves were followed
by a burst of 2-3 extra slow waves, occurring at much shorter intervals (5.5 sec) than the
regular interval (12.4 sec). Reconstruction of the propagation of these extra slow waves
revealed inhomogeneous conduction and propagation blocks, mainly in the transitional area
between corpus and antrum. Around these blocks, the slow waves propagated in elliptical
loops (long and short diameter 22 and 7 mm respectively) with an interval of 5-6 seconds.
After two to three revolutions, lasting a total of approximately 20 seconds, the slow waves were
blocked in the corpus area and the bursts thereby terminated. This is the first demonstration of
reentry and circus movement of the slow wave in the stomach. The fact that these fasted
and anaesthetized animals were otherwise normal, seems to indicate that reentrant activity
in the stomach could be more common than previously recognized.
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Diabetes Induces Gender Dependent Changes in Gastric Neuronal Nitric
Oxide Synthase (nNOS) Expression, Dimerization and Function
Pandu R. Gangula, Maria-Adelaide Micci, John Winston, Raj Kumar, Xiemin Cao, Pankaj
J. Pasricha
Introduction: Both idiopathic and diabetic forms of gastroparesis, like many other disorders
of gastrointestinal motility, predominantly affect women. However, the biological basis of
this gender bias remains completely unknown. Based on the importance of neuronal nitric
oxide synthase (nNOS) in the regulation of gastric motility, we explored the effect of gender
on its expression and function in healthy and diabetic rats. Methods: Age-matched male
and female Sprague-Dawley rats were used. Diabetic animals were studied 12 weeks after
streptozotocin (55 mg/kg body weight, i.p.)-induced sustained hyperglycemia. Changes in
gastric nNOS mRNA and protein levels were analyzed using real-time PCR and Western
immunoblotting respectively. Both COOH- and NH2-terminal nNOS antibodies were used
to measure changes in expression of both total nNOS protein and the alpha homodimer in
normal and diabetic gastric tissues. nNOS dimerization studies were performed using low-
temperature SDS-PAGE. Nitrinergic relaxation (AUC/mg tissue weight) was studied after the
application of electric field stimulation (EFS) to fundal, antral and pyloric tissues in an
organ bath. Results: As compared with males controls (MC), gastric nNOS mRNA, protein
expression and nitrinergic relaxation were significantly (P<0.05) elevated in healthy female
control rats (FC) in all regions of the stomach. The active dimeric form and dimer: monomer
ratio (DMR) of nNOS alpha were also higher in females compared to male rats (P<0.05).
Interestingly, diabetic females (FD), but not males, showed significant (P<0.05) impairment
in both nNOS alpha dimerization (Fundus FD 7.97± 0.02 vs. FC 22.31±5.88; Antrum FD
15.6±1.29 vs. FC 41.6±3.02; Pylorus FD 3.4±1.17 vs. FC 8.98±0.82) and nitrinergic relaxa-
tion (Fundus FD -0.26±0.06 vs. FC -0.55±0.16; Antrum FD -0.07±0.02 vs. FC -0.49±0.19;
Pylorus FD -0.22±0.07 vs. FC -0.46±0.09). Conclusions: This study demonstrates significant
gender differences in gastric nitrinergic expression, and function in both health and disease.
Nitrinergic relaxation is more pronounced in healthy females accounted, in part, by an
increased expression of the active dimeric form of nNOS alpha. On the other hand, chronic
hyperglycemia causes a greater reduction in active forms of nNOS in females associated
with significantly more impairment of nitrinergic relaxation. This study also illustrates for
the first time the importance of nNOS dimerization in gastric physiology. While we are still
exploring the underlying mechanisms, these findings may provide a biological explanation
for the greater vulnerability of females to develop diabetic gastroparesis.
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Gender Influences Effect of Cannabinoid Receptor Agonist, Dronabinol, On
Human Gastrointestinal Motor Functions
Tuba Esfandyari, Irene Ferber, Duane Burton, Kari Baxter, Alan R. Zinsmeister, Michael
Camilleri
Cannabinoid receptors (CBR) are located on cholinergic neurons in the brain stem, stomach
and colon. CBR stimulation inhibits motility and increases food intake in rodents. Effects
in humans are unclear. Hypothesis: Dronabinol (DRO), a non-selective CBR agonist, retards
gastric emptying and colonic transit, and enhances gastric accommodation. Aims: To compare
the effects of DRO and placebo (PLA) on gastric emptying, small bowel and colonic transit,
gastric volume, satiation and postprandial symptoms in healthy volunteers. Methods: In a
double-blind, parallel-group study, 30 volunteers were randomly assigned to DRO 5 mg
b.i.d. or PLA, each given for 3 doses. Using validated tests, we measured: on day 1,
scintigraphic transit (111In-egg meal) and fasting and postprandial gastric volume by 99mTc-
SPECT; on day 2, maximum tolerated volume (MTV) and 30-minute post-Ensure® symp-
toms. ANCOVA was used to assess treatment effects, with gender and age as covariates.
Planned sample size had sufficient power to detect 25-30% differences in primary endpoints.
T : 89386$$CH2
05-04-06 23:18:24 Page 43Layout: 89386B : o
A-43 AGA Abstracts
Results (see table): There was an overall significant (p=0.018) retardation of gastric emptying
(GE) with DRO; this was most pronounced in females (PLA 158±10 min vs. DRO 200±13,
p=0.011), but less so in males (p=0.18). A significant (p=0.04) interaction of gender by
treatment was detected for fasting gastric volume; DRO increased the volume in males
(185±16 on PLA vs. 238±17 on DRO, p<0.05), but slightly decreased it in females. MTV
and postprandial symptoms, small bowel and colonic transit were not significantly different
with DRO and PLA. Conclusion: A non-selective cannabinoid agonist retards gastric emptying
in humans; effects are gender related. Effects on satiation of changes in fasting gastric volume
with DRO require further study. These data are consistent with the observation that gonadal
sex steroids influence neuronal responses to cannabinoids (Neuroendocrinol 2001;74:185).
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Neuropathological and Genomic Changes in the Stomach of Patients with
Human Diabetic Gastroparesis
Harsha Vittal, Gianrico Farrugia, Nonko D. Pehlivanov, Matt S. Lurken, Pankaj J. Pasricha
Background: The pathophysiological basis of diabetic gastroparesis is unknown, with almost
no data on neuropathological and molecular changes in the stomachs of patients. The aim
of this study is to use modern analytical methods to determine morphological and molecular
changes in the gastric wall in patients with diabetic gastroparesis. Methods: Full thickness
gastric biopsies were obtained laparoscopically from gastroparetic patients undergoing sur-
gical intervention and from comparable disease-free areas of control subjects undergoing other
forms of gastric surgery. Samples were processed for histological and immunohistochemical
examination as well as mRNA preparation and gene expression analysis using Affymetrix
Gene Chips. Results: As part of an ongoing study, specimens have been obtained from two
patients with diabetic gastroparesis and two control subjects. Although both patients had
severe refractory symptoms with malnutrition, requiring the placement of a gastric stimulator,
one of them had no detectable abnormalities as compared with controls. This patient had
an abrupt onset of symptoms with a short duration of well controlled diabetes and no
significant episodes of ketoacidosis or hypoglycemia. By contrast, the other patient had long
standing poorly controlled diabetes with numerous episodes of diabetic ketoacidosis and
frequent hypoglycemic episodes. Histological examination in this patient revealed increased
fibrosis in the muscle layers as well as significantly fewer nerve fibers and myenteric neurons
as assessed by PGP9.5 staining. Further, significant reduction was seen in staining for nNOS,
VIP and tyrosine hydroxylase as well as for c-KIT. By contrast, staining for substance P
appeared to be increased. Analysis of mRNA expression confirmed some of these changes
including a 1.9 fold decrease in Kit and 2.2 fold increase in tachykinin precursor 1 and
indicated changes in several other potentially relevant genes such as a 1.5-fold reduction
in tryptophan hydroxylase I, a 3.2-fold reduction in heme oxygenase 2 and a nearly 12-
fold reduction in the muscarinic M3 receptor. Conclusion: Poor metabolic control in diabetes
is associated with significant pathological changes in the gastric wall that affect all major
components including muscle, neurons and ICC. However, severe symptoms can also occur
in the absence of these changes and may reflect vagal, central or hormonal influences.
Gastroparesis is therefore likely to be a heterogenous disorder. Careful molecular and patholo-
gical analysis may allow more precise phenotypic differentiation and shed insight into the
underlying mechanisms as well as identify novel therapeutic targets
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Predictive Factors for Clinical Improvement with Enterra Gastric Electric
Stimulation Treatment for Refractory Gastroparesis
Jennifer L. Maranki, Vanessa Lytes, John E. Meilahn, Sean Harbison, Frank Friedenberg,
Robert S. Fisher, Henry P. Parkman
Gastric electrical stimulation (GES) treatment for refractory gastroparesis has been available
for 5 years. Although studies have investigated the clinical effectiveness of this therapy, the
clinical factors that predict a favorable response have not been addressed. The AIMS of this
study were to: 1) to analyze the clinical response to GES in patients with refractory gastropar-
esis; and 2) to determine factors associated with a favorable response to Enterra GES
treatment. METHODS: This clinical protocol was conducted prospectively at our institution
in patients undergoing Enterra GES (Medtronic, Inc) for refractory gastroparesis under the
FDA’s Humanitarian Device Exemption program. Symptoms associated with gastroparesis
were scored before and at regular intervals after GES implantation using the validated
Gastroparesis Cardinal Symptom Index (GCSI) questionnaire with additional questions about
abdominal pain and global clinical response. RESULTS: During an 18 month study period
from 3/2004 to 9/2005, 29 patients (25 female, 4 male; mean age: 40 years) underwent
implantation of Enterra GES. Follow-up data were available for 28 patients, with average
follow-up of 148 days. At follow-up, 14 of 28 patients felt improved; 8 remained the same;

















2.7±0.2; p<0.05) with improvement in the nausea/vomiting subscore (30±7%; p<0.01) and
the postprandial subscore (10±10%; p<0.05), but no improvement in the bloating subscore
or abdominal pain. The decrease in the GCSI was greater for the 12 diabetic patients
(18±11%; p<0.05) than the 16 idiopathic patients (7±9%; p=NS). The subgroup of 22
patients with a chief complaint of nausea/vomiting had a greater improvement (16±9%;
p<0.05) than the 6 patients with a chief complaint of abdominal pain (3±11%; p=NS). The
13 patients taking narcotic analgesics at the time of implant had a poorer response with
the GCSI slightly increasing by 9±10% (p=NS) compared to the 15 patients who were not,
whose GCSI scores decreased by 30±8% (p<0.01). There was no effect of gender, BMI, or
hemoglobin A1c in diabetics on the clinical response. CONCLUSIONS: Gastric electric
stimulation resulted in clinical improvement in 50% of patients with refractory gastroparesis.
Three clinical parameters were identified to be associated with a favorable clinical response:
1) diabetic rather than idiopathic gastroparesis, 2) nausea/vomiting rather than abdominal
pain as the primary symptom, and 3) independence from narcotic analgesics prior to
stimulator implantation. Knowledge of these three factors may allow improved patient
selection for gastric electric stimulation.
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Multi-Channel Electrogastrography and Autonomic Nervous System Function
in Different Subtypes of Patients with Functional Dyspepsia
Xiaohong Xu, Zhiqiang Song, Zhaolu Ding, Zhifeng Wang, Xiaoyan Chen, Meiyun Ke
Previous studies have shown that patients with functional dyspepsia(FD) had significantly
lower percentage of slow wave coupling (%SWC) in fasting state. However, the effects of
test meal on multi-channel Electrogastrography(MEGG) and autonomic nervous system
(ANS) in FD patients with different subtypes were not conclusive. The aim of this study
was to utilize MEGG and ANS test to investigate the difference of MEGG parameters and
ANS parameters between FD patients and healthy subjects(HS). Methods: 62 patients with
the diagnosis of FD were enrolled in this study (16M, 46F, mean age: 43yrs) and divided
into dysmotility-like FD group(15M, 35F, mean age: 42yrs) and ulcer-like FD
group(1M,11F,mean age:46yrs) based on Rome II criteria. 50 HS were recruited as control
(25M, 25F, mean age: 44yrs). MEGG were recorded simultaneously with the electrocardio-
gram (ECG) recording for 30 min in the fasting state and 60 min after a standard 450Kcal
test meal. MEGG parameters included dominant frequency (DF), normal percentage of 2-
4cpm gastric slow waves (%N) and %SWC. ANS was determined by power spectra analysis
of HRV and parameters included sympathovagal balance LF/HF Ratio, mainly sympathetic
activity LF and vagal activity HF. Results: 1) Compared with HS, %SWC was significantly
lower in ulcer-like FD group in fasting state(P<0.05) but not in fed state. No significant
difference of %SWC was shown between dysmotility-like FD group and HS either in fasting
state or in fed state. 2) Compared with HS, LF/HF ratio and LF were significantly lower
and HF was significantly higher in fasting state in dysmotility-like FD group (P<0.05), this
difference was abolished by test meal in the 1st 30min fed state and the lower LF and higher
HF were present in the 2nd 30min fed state again in dysmotility-like FD group. There was
no significant difference between ulcer-like FD group and HS in any of those ANS parameters
either in fasting state or in fed state. 3) Compared with fasting state, test meal significantly
increased the DF in the 3 groups but decreased the %N and %SWC in both dysmotility-
like FD group and HS in fed state(P<0.05),%N only significantly decreased in 1st 30min
fed state and %SWC had no change in fed state in ulcer-like FD group. Test meal significantly
increased the LF/HF ratio and LF but decreased the HF in all 3 groups in fed state (P<0.05).
Conclusions: Gastric slow wave coupling was abnormal in patients with ulcer-like FD.
Patients with dysmotility-like FD had abnormal ANS function in fasting state and test meal
could only correct the abnormal ANS for short time which suggest that different subtypes
of FD may have different patterns in ANS test.
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Flexible Sigmoidoscopy is Associated with a Reduced Incidence of Distal But
Not Proximal Colorectal Cancer (CRC): a Population-Based Cohort Study
Linda Rabeneck, James D. Lewis, Lawrence Paszat, Refik Saskin, Therese A. Stukel
Background: Flexible sigmoidoscopy (FS) is used to triage those with distal colon polyps
to colonoscopy and those without polyps to repeat FS screening in 5 yr. However, it is
unclear whether those with a negative FS (without polyps) have a reduced incidence of
cancer proximal to the rectosigmoid colon. Objectives: In a population-based cohort study
of persons with a negative FS to: 1) estimate the annual incidence of CRC; and (2) identify
factors associated with incident CRC. Methods: We identified all individuals 50-80 yr who
had a negative FS between 1/1/1996 and 12/31/1998 in Ontario and followed them through
12/31/2002. We computed the annual age- and sex- standardized incidence rates (SIRs) for
colon (ICD-9 codes 153.0-153.4, 153.6-153.9) and rectum or rectosigmoid (154.0-154.1)
cancers for the study cohort and for the remaining Ontario population. We compared the
annual incidence of CRC between the study cohort and the remaining Ontario population.
Cox proportional hazards models were used to examine patient (age, sex), physician (type,
procedure volume) and procedure setting (office, hospital) factors associated with incident
cancers among those with a negative FS. Data were obtained from the: 1) Ontario Cancer
Registry; 2) Canadian Institute for Health Information database, which has information on
all patients discharged from hospitals; 3) Ontario Health Insurance Plan (OHIP), which has
information on all claims for physician services; and 4) Registered Persons Database, which
is a roster of all permanent residents who are covered under OHIP. Results: Between 1996
and 1998 we identified 45,304 persons who had a negative FS, of whom 58.3% were
women. During follow-up 324 cancers (269 colon, 58 rectum/rectosigmoid) were observed
in these patients. For rectum/rectosigmoid cancers the annual SIRs following negative FS
were significantly lower than in the Ontario population. For example, at 4 yr, the SIR
following negative FS was 0.24 cancers/1000 persons (95% CI: 0.11-0.45) vs 0.54/1000
(0.51-0.57) in the Ontario population (RR=0.44, 95% CI: 0.16-0.73). For colon cancers,
the annual SIRs following negative FS were not significantly different than in the Ontario
population. For example, at 4 yr, the SIR following negative FS was 1.32 cancers/1000
persons (1.00-1.72) compared with 1.34/1000 (1.29-1.39) in the Ontario population (RR=
0.99, 95% CI: 0.72-1.25). Only age was significantly associated with incident CRC following
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negative FS. Conclusions: Following negative FS the incidence of rectum/rectosigmoid can-
cers - but not colon cancers - is reduced for up to 4 years. Age, but not sex, is associated
with incident CRC following negative FS.
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A One Year, Randomised, Double-Blind, Placebo Controlled Trial of a
Lactobacillus Or a Bidifobacterium Probiotic for Maintenance of Steroid-
Induced Remission of Ulcerative Colitis
Fergus Shanahan, Francisco Guarner, Atte Von Wright, Terttu Vilpponen-Salmela,
Diarmuid O'Donoghue, Barry Kiely, Progid Investigators
Background: Probiotics have been shown to have modest but consistently significant efficacy
in attenuating disease severity in animal models of inflammatory bowel disease (IBD).
However, the role of probiotics in human IBD is less clear. Aim: to compare two different
probiotics vs. placebo in the maintenance of remission of ulcerative colitis following steroid-
induced remission. Design: a prospective, balanced, randomised, parallel group, double
blind, placebo-controlled trial of (109 daily for one year) Lactobacillus salivarius subsp.
Salivarius UCC118 or Bifidobacterium infantis 35624 versus placebo, each administered as a
rehydrated blended yoghurt powder. Patients were entered within one month of achieving
clinical remission of ulcerative colitis following a documented relapse that required steroids
to induce remission. Remission was defined as <3 bowel movements/day (without frank/
gross blood) out of 7, while off all steroids. A stable dose of aminosalicylate was the only
concomitant medication for colitis permitted. The number of patients in remission at study
end was the primary efficacy variable with time to relapse being a secondary criterion. A
total of 157 patients were recruited with similar numbers (52-53) per group. Results:
Patients’ demographic characteristics were similar across the three treatment groups. The
extent of colitis which was similar across the groups was left-sided in about one third,
limited (proctitis) in one third and pan-colitis in one third. About half of all patients were
still in remission at end of the study with no difference across the three study groups. The
risk of relapse was not significantly different across the groups. Patient age was the only
prognostic factor with a significant (p = 0.04) influence on risk of relapse, with odds for
an older patient decreasing over that of younger patients by 2.8%/year of age. Mean times
to relapse were also similar for each study group. Adverse events were uncommon, unrelated
to the treatment, and similar across the groups. Conclusions: Prolonged feeding with live
probiotics is safe in patients with ulcerative colitis. However, in contrast to studies in animal
models using the same probiotics, there was no significant benefit with either probiotic over
placebo. Differences in probiotic efficacy between animal and human IBD may reflect the
timing of administration and might indicate the importance of manipulating the enteric flora
prior to the onset of disease, and/or may relate to differences in disease severity or effective
probiotic dose/body weight.
250
Can Aspirin be Reintroduced with Proton Pump Inhibitor Infusion After
Endoscopic Hemostasis? A Double Blinded Randomized Controlled Trial
Joseph Sung, James Lau, Jessica Ching, Wai-Keung Leung, Yuk-Tong Lee, Justin Wu,
Vincent Leung, Francis Chan
Background: Among patients with aspirin-induced bleeding ulcers who received pantoprazole
infusion after endoscopic hemostasis, it is uncertain whether aspirin can be reintroduced
immediately. Aim: This study aims to investigate whether early reintroduction of aspirin is
safe in patients who received intravenous pantoprazole for peptic ulcer bleeding. Method:
This double-blind, placebo-controlled, randomized trial included patients who required
aspirin for cerebrovascular (CNS) or cardiovascular (CVS) diseases but developed ulcer
bleeding. After confirmation of peptic ulcer bleeding (active bleeding, visible vessel or
adherent clot), endoscopic hemostasis was applied using epinephrine injection and thermal
coagulation. Patients were randomized to receive aspirin 80mg daily or placebo aspirin daily.
All patients received intravenous pantoprazole (80mg bolus injection followed by 8mg/hour)
for 72 hours and then oral pantoprazole 40 mg daily until end of follow up at 8 weeks. The
primary endpoint was recurrent upper gastrointestinal bleeding within 30 days. Secondary
endpoints included blood transfusion, requirement for surgery, hospital stay, 1-month and
2-month mortality, and cardiovascular/cerebrovascular event. Results: In this interim analysis,
113 patients were randomized (58 to aspirin and 55 to placebo). The aspirin and placebo
groups were comparable in age (74.2yr vs 73yr), gender (men: 62% vs 69%), indications
for aspirin (CVS:CNS:both 33:19:6 vs 30:19:6), previous history of ulcer (6.9% vs 3.7%)
and concomitant use of NSAID (12% vs 11%). Patients randomized to aspirin and placebo
also have comparable ulcer location (GU:DU 28:30 vs 33:22), size (1.13cm vs 1.20cm) and
ulcer appearance (bleeding: visible vessel: adherent clot 16:24:18 vs 17:21:17). Recurrent
bleeding within 30 days was documented in 11 (18.9%) who received aspirin and 6 (10.9%)
who received placebo (Log rank test P=0.25). There was no difference in requirement for
blood transfusion, surgery and hospital stay. The aspirin-treated patients have lower 1-
month (1.7% vs 9.1%, P=0.08) and 2-month (1.7% vs 14.5%, P=0.012) mortality compared
to those who received placebo. Conclusion: In the presence of intravenous and oral pantopra-
zole, immediate reintroduction of aspirin has not substantially increased the risk of recurrent
bleeding from peptic ulcers. There is, however, an associated increased mortality with
discontinuation of aspirin.
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The Degree of COX-2 Selectivity and Risk of Cardio and Cerebrovascular
Events
Neena Abraham, Christine Hartman, Hashem El-Serag, Anita Deswal
Background: To determine if the degree of Cox-2 selectivity of an NSAID influences risk
of cardio and cerebrovascular events, we assessed the association between Cox-2 selectivity
and myocardial infarction (MI) or non-hemorrhagic stroke (CVA). Methods: A retrospective
cohort study of veterans ≥65 years prescribed NSAIDs at the VA from 01/01/00 to 12/31/
02. VA pharmacy, inpatient and outpatient data was linked to inpatient Medicare claims
files. NSAIDs were categorized as poorly (naproxen, ibuprofen), moderately (celecoxib,
etodolac, meloxicam, nabumetone) or highly (rofecoxib, valdecoxib) Cox-2 selective. Each
day of observation was assessed for presence of NSAID and degree of selectivity. Validated
ICD-9-CM codes were used to define MI and CVA. The incidence of MI and CVA over
180 days was assessed using Cox-Proportional Hazards Models adjusted for gender, race,
cardiovascular risk factors, the daily presence of low dose ASA, anticoagulant or antiplatelets,
and the propensity score for prescribing a highly Cox-2 selective NSAID. Patients were
censored at event, end of follow-up period, last day of exposure or death. Hazard Ratios
(HR) with 95% confidence intervals were calculated. Results: Of 384,322 patients (97.5%
men; 85.4% white), 79.4% were prescribed a poorly selective NSAID, 16.4% were prescribed
a moderately selective NSAID and 4.2% were prescribed a highly selective NSAID. There
were 985 cases of MI and 586 cases of CVA in over 145,870 person years of follow-up.
Exposure to highly selective agents was associated with the highest rate of MI (12.3 per
1000 person-years) and CVA (8.1 per 1000 person-years). The incidence rates were lower
among veterans prescribed a moderately (7.6 MI and 5.4 CVA per 1000 person-years) or
poorly selective agent (7.4 MI and 4.2 CVA per 1000 person-years). Periods without NSAID
exposure were associated with the lowest risk (3.9 MI per 1000 person-years; 2.2 CVA per
1000 person-years). The prescription of highly selective NSAIDs was associated with a 61%
increase in CVA and a 47% increase in MI, when compared to poorly selective NSAIDs. In
all adjusted models, no NSAID exposure was protective for both MI(HR=0.66; 95% CI:
0.55-0.80) and CVA (HR= 0.58; 95% CI: 0.45-0.74). Similar results were observed among
lower risk patients (those without a prior MI or CVA, a history of revascularization procedures,
atrial fibrillation, or evidence of anticoagulant or antiplatelet agents at index NSAID prescrip-
tion). Conclusions: Among older veterans, the risk of MI and CVA increases with exposure
to any NSAID. Highly Cox-2 selective NSAIDs confer the greatest risk of MI and CVA.
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Notch 1 Acts At Multiple Stages of Endocrine Differentiation to Regulate
Endocrine Cell Fate in the Pancreas
Maryann Giel-Moloney, Andrew B. Leiter
Notch signaling enables individual cells to adopt cell fates that are distinct from neighboring
cells. When Notch receptors on the cell surface bind to cell surface ligands like delta or
jagged, expressed by adjacent cells, the receptor is cleaved, releasing the notch-intracellular
domain fragment which migrates to the nucleus where it associates with RBP-Jk as a coactiv-
ator, resulting in expression of downstream Notch effectors including the transcriptional
repressor, Hes1. Notch appears to block endocrine differentiation in the pancreas by inhibit-
ing bHLH transcription factors, including neurogenin3 (Ngn3) which initiates the earliest
stages of endocrine specification. A downstream bHLH protein, BETA2/NeuroD is required
for normal islet morphogenesis and terminal differentiation of β cells. Others have shown
that conditional activation of Notch during early pancreagenesis when Ngn3 is first expressed
arrested epithelial differentiation, whereas Notch had no effect on the adult pancreas. To
further determine at what stage of endocrine differentiation precursor cells still respond to
Notch, we used the Cre-loxP system to activate Notch signaling at the onset of BETA2
expression in developing islets. We generated transgenic mice expressing Cre inserted into
a BAC containing 115kb of 5’ and 78kb of 3’ flanking sequence from the BETA2 locus to
ensure its expression would recapitulate that of the endogenous BETA2 gene. BETA2-Cre
mice were crossed with ROSA-Notch mice, a line containing a bicistronic transgene with
the Notch 1 intracellular domain (NICD) and EGFP inserted into the constitutively expressed
ROSA26 locus. Transcription read through of the transgene was prevented by an upstream
stop sequence flanked by loxP sites. Expression of Cre recombinase results in excision of
the stop sequence leading to permanent, constitutive expression of NICD and EGFP. BETA2-
Cre X ROSA-Notch mice showed disrupted islet morphogenesis with a marked reduction
in insulin staining in the islet core. The cells in the islet center showed staining for EGFP,
suggesting that these were BETA2 expressing cells destined to become β cells. In addition,
many of the EGFP expressing cells formed large aggregates of mixed cell lineages expressing
glucagon, somatostatin, and PYY. The present study is the first to show that Notch functions
at later stages of pancreatic development. Thus the effects of Notch on the endocrine pancreas
depend on both the context and the stage of differentiation much like other organs. We
conclude that activation of Notch 1 in BETA2-expressing precursors in the pancreas inhibits
β cell maturation resulting in cells adopting a non-β cell fate.
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Acetylcholine Stimulation of the Nkcc1 Transporter Is Calcium-Dependent and
Is Rapidly Desensitised By Endocytosis in Human Colonic Crypts: Major
Implications for Intestinal Fluid Secretion
Amy Reynolds, Alyson Parris, Richard Tighe, Michael Lewis, Denise Westgarth, Duncan
Bell, Crawford Jamieson, Jamie Dearlymple, Joanne Southgate, Kevin Sargen, Martin
Philips, Mark Williams
Intestinal fluid secretion is driven by transcellular active transport of chloride. NKCC1
mediates basolateral uptake of chloride and is emerging as a master controller of fluid
secretion. Acetylcholine (ACh) stimulates a calcium dependent secretory response that is
transient in nature. Recent observations in T84 cells point to the importance of NKCC1
internalisation as a regulatory mechanism (Del Castillo et al., AJP 2005; 289: C1132-42).
AIM: To characterise NKCC1 expression along the intact human colonic crypt axis and
study its cellular location in response to cholinergic calcium signals. METHODS: Crypts
were isolated from tissue biopsies obtained at sigmoidoscopy from healthy-subjects (Ethical
approval). Isolated crypts were attached to collagen-coated coverslips and cultured for 24
hours - 7 days in serum-free DMEM (5%CO2/37oC). Total NKCC1 expression was probed
for using a panel of polyclonal antibodies. Labelling was visualised using a FITC conjugated
secondary antibody in conjunction with confocal microscopy. For calcium imaging experi-
ments colonic crypts were loaded with the calcium-sensitive dye Fura2-AM. RESULTS:
NKCC1 exhibited an expression gradient along the crypt-axis; all cells were NKCC1 positive
and labelling predominated at the crypt-base. A dichotomy was evident for NKCC1 labelling
at the cellular level: one population of cells (approx. 25%) exhibited labelling on both basal
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and basolateral membranes, the remaining cells expressed NKCC1 on basolateral membranes
only. These characteristics were also evident in crypts stimulated with ACh (10 μM) for up
to 3 mins. After stimulation for 10 mins, vesicular cytosolic NKCC1 labelling juxta lateral
membranes was apparent. Prolonged exposure (30 mins) led to a striking accumulation at
the apical pole of NKCC1 labelled cytosolic vesicles, with the concomitant loss of membranous
NKCC1. Ionomycin mimicked ACh-induced calcium mobilisation from intracellular stores
and was sufficient to induce internalisation of NKCC1. Accordingly, inhibition of ACh-
induced calcium mobilisation by TMB-8 (100 μM) abolished NKCC1 internalisation. In
contrast, chronic stimulation with the cAMP secretagogue forskolin (100 μM) did not lead
to internalisation of membranous NKCC1. CONCLUSIONS: For the first time we have
demonstrated the dynamic regulation of membrane transporter trafficking in the intact
human intestinal epithelium. NKCC1 internalisation explains the transient nature of the
cholinergic secretory response and identification of the underlying molecular mechanisms
may be exploited in the development of therapies for secretory diarrhoea. (Supported by
the BBSRC)
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An Essential Role of Farnesoid X-Receptor in Regulating Intestinal Fibrosis in
Murine Model of Chronic Colitis
Piero Vavassori, Andrea Mencarelli, Barbara Renga, Giovanni Rizzo, Antonio Morelli,
Mark Pruzanski, Roberto Pellicciari, Stefano Fiorucci
Backgound. The Farnesoid X Receptor (FXR) is a member of the nuclear receptor superfamily
involved in cholesterol and bile acid homeostasis and expressed in the liver and gastrointesti-
nal tract. INT-747, a potent FXR ligand, has been demonstrated to reduce α1 (I) collagen
and TGFβ1 in hepatic stellate cells and to be beneficial in the treatment of liver fibrosis.Aim.
Because Crohn’s disease if often characterized by excessive extracellular matrix deposition
that can lead to intestinal obstruction, in this atusy we have investigated whether INT-747
may represent a therapeutic option to prevent the intestinal fibrosis in a murine model of
chronic colitis. Methods. Chronic colitis was induced in mice with an 8-week administration
of increasing amounts of TNBS enemas (0.5 to 1.25 mg/mouse). In the first in vivo experiment,
Balb/c mice were treated with daily intragastric administration of 5 mg/kg of INT-747 or
saline solution. In an second in vivo experiment, chronic colitis was induced in wild-type
and FXR knockout mice (C57Bl/6 background). All mice were weekly examined for signs
of colitis and systemic inflammation. Each colon was scored regarding macroscopic signs
of inflammation and/or fibrosis. Serial paraffin sections of each colon were stained with
H&E to asses the degree of inflammation and with Sirius Red to detect the connective tissue.
Colonic expression of α1 (I) collagen, fibronectin, αSMA, MMPs and TIMP-1, TNF-α and
TGFβ1 was examined by quantitative RT-PCR. Results. Eight-week administration of TNBS
induced in Balb/c mice a chronic colitis predominantly characterized - at macro- and
microscopic level - by fibrosis and collagen deposition into the intestinal wall, and increased
colonic expression of α1 (I) collagen (10 folds when compared to the naïve mice), fibronectin,
αSMA, TNF-α and TGFβ1 mRNAs. INT-747 treatment resulted in an almost complete
prevention of the intestinal fibrosis, at macro- and microscopic level. In mice treated with
the FXR ligand, the colonic expression of α1(I)collagen, fibronectin, αSMA, TNF-α and
TGFβ1 mRNAs was similar to that of naïve mice. Differently than Balb/c mice, C57Bl/6
wild-type mice resulted to be insensitive to the chronic administration of TNBS. In contrast,
C57Bl/6 FXR knockout mice developed a severe chronic colitis similar to those observed
in Balb/c mice. In vitro experiments on intestinal fibroblast cell line confirmed the inhibitory
effect of INT-747 on the TGFβ1-induced collagen production. Conclusion. This study
provides evidence that FXR ligands might represent a novel therapeutic option to treat
intestinal fibrosis.
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Role of the mRNA Stability Factor HuR in Inflammatory Bowel Disease and
Colon Carcinogenesis
Kristi Bemis-Standoli, Lisa Cox, Vimala Kasa, Melinda Lynch, Hyllaerye Ford, Robert J.
Coffey, Dan A. Dixon
Aberrant overexpression of many growth-related immediate-early response genes, including
proto-oncogenes, cytokines, and angiogenic growth factors, is commonly observed in inflam-
matory bowel disease (IBD) and colorectal cancer. A central point in the regulation of these
factors occurs through post-transcriptional mechanisms controlling rapid mRNA decay.
However, recent evidence reveals that the loss of post-transcriptional regulation is a character-
istic feature found in cancer and chronically inflamed cells. To better understand the mechan-
isms regulating these factors in IBD and colon cancer, we have identified the RNA-binding
protein HuR as a potential link. This protein binds to the AU-rich element (ARE) located
within the 3’-untranslated region (3'UTR) of many tightly regulated mRNAs and functions
as a nuclear-cytoplasmic shuttling protein, yet when overexpressed in cells, HuR interferes
with rapid mRNA degradation. Normally expressed at low levels and located in the nucleus,
HuR cytoplasmic overexpression was observed in tissues obtained from ulcerative colitis,
colon adenomas, adenocarcinomas, and metastases. Overexpression of the HuR target gene
COX-2 colocalized with elevated HuR expression. Similarly, HuR levels are elevated in
colonic epithelium and correlate with increased COX-2 expression in a murine model of
IBD. Elevated cytoplasmic HuR levels are observed in colon cancer cells and promote cancer-
associated gene expression. Down-regulation of HuR by siRNA leads to respective down-
regulation of the HuR targets COX-2, IL-6, IL-8, VEGF, and c-fos. To determine the functional
significance of HuR overexpression in vivo, a HuR-transgenic mouse (HuR-Tg) was created
to overexpress HuR in GI epithelium. This transgenic utilizes the intestinal-specific A33
promoter to drive expression of a HuR/GFP bicistronic transgene restricted to the small
intestine and colon. HuR-Tg mice display normal growth and breeding characteristics. Gross
and histological analysis did not reveal any morphological changes in the GI tract of the
HuR-Tg mice, however elevated endogenous COX-2 and VEGF mRNA were observed in
the colon and small intestine of all HuR-Tg lines. The impact of HuR overexpression on
tumorigenesis was further examined through breeding with the APCMin/+ mouse. At 15
weeks of age, HuR-Tg/APCMin/+lines display approximately 2-fold increased tumor burden

















HuR functions in tumorigenesis downstream of a tumor-initiating event and identify this
mRNA stability factor as a new molecular target for therapeutic intervention in controlling
pathogenic gene expression.
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Accuracy of Computed Tomographic Colonography for Colorectal Cancer
(CRC) Screening in Asymptomatic Individuals
Brooks D. Cash, Cecilia Kim, Priscilla Cullen, Myra Kim, Cathy A. Dykes, Donald W.
Jensen, Duncan S. Barlow, Mark H. Johnston, James W. Kikendall, Peter W. Soballe
Background: Pickhardt demonstrated that computed tomographic colonography (CTC) was
comparable to optical colonoscopy (OC) for the accurate detection of adenomas. Our study
seeks to validate Pickhardt’s findings using the same technique for CTC. Methods: Participants
are asymptomatic, average-risk patients referred for colorectal cancer screening who undergo
CTC with subsequent care based on CTC interpretation. Patients with polyps >10 mm or
>3 polyps exceeding 6 mm proceed to same day OC in which all polyps identified by CTC
or OC are removed (Category A). Patients with 1 or 2 polyps measuring 6-9 mm undergo
CTC and clearing OC at 1 year (Category B) and patients without any polyps >6 mm have
OC in 5 years (Category C). Fleets Phosphosoda prep is used with oral contrast to tag fluid
and stool for digital subtraction. CO2 is used for colon insufflation and a 3-D flythrough
serves as the primary mode of assessment by an experienced (>500 CTC) radiologist.
Polyp matching adheres to Pickhardt’s method of segmental unblinding during OC. Data
is presented on a per patient basis and is not histology specific. Results: 666 patients have
undergone CTC since inception (mean age 56.0 years; 33.6% female; 78.5% Caucasian).
16.1% (107/666) patients have proceeded to OC; 35.5% (38/107) for significant CTC
findings (category A) and 44.9% (48/107) randomly selected (categories B/C). For lesions
>10 mm, CTC polyp detection sensitivity and specificity are 94.1% (95% CI: 80.3% to
99.3%) and 93.2% (95% CI: 84.7% to 97.7%), respectively, with positive predictive value
(PPV) and negative predictive value (NPV) of 86.5% (95% CI: 71.2% to 95.5%) and 97.1%
(95% CI: 90.1% to 99.7%). The 93.6% accuracy of CTC is comparable to OC (p= 0.10,
McNemar’s Test). For 6-9 mm polyps, the sensitivity, specificity, PPV and NPV of CTC are
65.6% (95% CI: 46.8% to 81.4%), 92% (95% CI: 83.4% to 97%), 77.8% (95% CI: 57.7%
to 91.4%), 86.3% (95% CI: 76.7% to 92.9%), respectively, with an accuracy of 84.1% (p=
0.001). There are too few patients in group B with evaluable outcomes to comment on the
observational history of intermediate sized polyps at this time. Conclusions: These results
indicate that CTC and OC have similar accuracy for the detection of polyps > 10 mm and
validate the previous findings of Pickhardt. CTC accuracy is significantly less than OC for
polyps 6-9 mm, however the observed accuracy of CTC for these polyps is superior to
previous studies. The natural history of intermediate sized polyps remains unclear, but CTC
may be a valuable tool in elaborating this information in future longitudinal outcomes ana-
lyses.
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The Management of Small (6-9mm) Polyps Found By Virtual Colonoscopy:
Results of a Decision Analysis
Chin Hur, Daniel C. Chung, Robert E. Schoen, Amy B. Knudsen, G. Scott Gazelle
Background: Although there is a firm consensus that larger (>9mm) colonic polyps should
be removed, the necessity of polypectomy for smaller polyps is controversial. The majority
of polypoid lesions found by VC will be less than 9mm in size. Furthermore, recently
published VC reporting guidelines suggest that it may be reasonable to manage a 6-9mm
polypoid lesion discovered on VC with another VC study 3 years later. The aim of this
study was to compare the outcomes of two management strategies for smaller polyps
discovered by VC. Methods: A Markov decision-analytic model was constructed to analyze
the outcomes of patients with a small polyp on a screening VC. These hypothetical patients
were simulated to either: 1) undergo immediate colonoscopy for polypectomy (COLO); or
2) wait 3 years for a repeat VC examination (VC). The time horizon (f/u period) for the
model analysis was 3 years and endpoints compared included # of deaths, # of cancers
(CAs) and CA stage (SEER Summary Staging). Model input (parameter estimates) values
were derived from and calibrated to SEER data and published estimates and included: VC
false positive rate=31.9%; POLYPS- Hyperplastic=39.3%, Adenomas (Low Risk=94.1%, High
Risk=5.0%, Cancer=0.9%); ANNUAL CANCER MORTALITY RATES- Local=2%, Regional=
7.5%, Distant (metastatic)=37%; COLONOSCOPY- Complication rate=0.1%, Complication
Death Rate=0.01%, Inability to find polyp=5%. Results: The results (see Table 1) are 3 years
after the initial VC and the #s presented are out of 100,000 patients in each strategy. The
overall number of CAs in the VC group was 1168 (1.168%) compared to 58 (0.058%) in
the COLO group (polypectomy cured the majority of CAs in the polyp). All the deaths in
the VC group were from CA (111) vs 6 CA and 10 colonoscopy complications deaths in
the COLO group. The stage distribution of the CAs is also presented as they significantly
impact both prognosis and treatment. Conclusions: Following a small polyp found on VC
for 3 years will result in a greater number of CAs and more deaths than immediate COLO.
Table 1. Results (# out of 100,000 pts)
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*Neg value=VC greater **CC=COLO complication
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MR Colonography Without Bowel Purgation for the Assessment of
Adenomatous Colon Polyps: Preliminary Results of a Prospective Cohort
Study
Jost Langhorst, Christiane Kuehle, Thomas Zoepf, Michael Nuefer, Waleed Ajaj,
Barkhausen Joerg, Guido Gerken, Gustav J. Dobos, Thomas Lauenstein
Background: Colorectal cancer, which arises mostly from preexisting adenomatous polyps,
continues to be the second most common cancer. Colonoscopy (in conjunction with histopa-
thological biopsy) is considered the gold standard for the detection of adenomatous polyps.
The impact of existing colonic screening techniques strongly depends on the according
patients’ acceptance. Recently developed MRC techniques based on the tagging of fecal
material allow for the visualization of colorectal lesions without prior bowel cleansing. Aim:
To compare virtual MR colonography (MRC) to colonoscopy (CC) regarding the detection
of adenomatous polyps > 5 mm and patients’ acceptance in a screening population. Methods:
284 asymptomatic patients (150 female, 134 male, average age 59 years) underwent MRC.
Preparation for MRC included the ingestion of 200ml of a contrast solution containing 5%
gastrografin, 1% barium and 0.2% locust bean gum with every main meal starting two days
before the MR examination. MRC was performed on a 1.5 T MR system (Magnetom Sonata,
Siemens Medical Solutions, Erlangen, Germany) in patients’ prone position. After the place-
ment of a rectal tube, the colon was filled with approximately 2500ml of warm tap water.
CC was performed with a maximum time lag of 4 weeks between both procedures. The
overall acceptance was evaluated using a 10-point scale (1=excellent, 10=poor acceptance).
Results: Colorectal adenomatous polyps > 5mm were found in 33 patients by CC. MRC
revealed these lesions with a sensitivity of 78% and a specificity of 93%. In addition, one
inflammatory pseudotumor due to sigmoid diverticulitis and one adenocarcinoma of the
sigmoid were detected by both methods. No significant difference was detected between
the overall rating for MRC (mean value: 3.4) and CC (mean value: 3.0). Most unpleasant
aspects of the examinations were bowel cleansing for CC and the placement of the rectal
tube for MRC. No significant difference was found as for the preference of future examinations:
46% of the patients would choose MRC, while 43% preferred CC. Conclusion: Fecal tagging
MRC provides a satisfactory accuracy for the detection of relevant colorectal lesions in a
screening population. Both MRC and CC have comparable general acceptance levels in a
screening population. However, in patients with positive findings, conventional endoscopy
is required for polypectomy.
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CT Enterography in Crohn’s Disease: A Prospective Study Demonstrating
Inter-Observer Agreement and Correlation with Disease Activity
Taft Bhuket, Elaine M. Caoili, Peter D. Higgins, Beth Manoogian, Joel Platt, Paul Sonda,
Tahira Khan, Ellen M. Zimmermann
Background: CT Enterography (CTE) yields high resolution images of the bowel and is
effective in assessing Crohn’s Disease. Performance characteristics including inter-observer
variability have not been determined. Correlation of CTE findings with measures of disease
activity including the Crohn’s Disease Activity Index (CDAI) is lacking. Questions exist as
to what CTE adds to standard clinical activity assessment. Aims: 1) To prospectively determine
the inter-observer agreement for 10 findings on CTE; 2) To determine the Spearman correla-
tion between CTE findings, CRP, ESR and CDAI; 3) To use CTE findings and lab markers
to predict CDAI, and determine whether CTE findings add predictive power to the assessment
of disease activity. Methods: 41 patients with Crohn’s disease were enrolled for prospective
assessment of the CTE, CRP, ESR, and CDAI. CTE was performed per standard protocol
with intravenous contrast, oral ingestion of 1500 cc of a low-density barium sulfate contrast,
and the use of a multi-detector CT. Two expert radiologists blinded to clinical data independ-
ently rated 10 CTE findings, including 5 scaled items (rated 0-3): mucosal enhancement,
mesenteric vascularity, bowel wall thickening, stranding, and global assessment. An additional
5 dichotomous findings were rated 0 if absent or 1 if present: extraluminal gas, fistula, fluid,
lymphadenopathy, and bowel fat. Agreement analysis was performed with a weighted kappa
for scaled variables, and a simple kappa for dichotomous variables. Spearman correlations
were calculated for each comparison, and linear regression modeling was used to determine
whether lab or radiologic findings could predict the CDAI. Results: 7 findings had substantial
inter-observer agreement (0.6-0.8); fluid had an almost perfect kappa of 0.88, and extralu-
minal gas and stranding had only moderate agreement (0.4-0.6). The scaled CTE findings
correlated well (0.30-0.39) with the CDAI, in comparison to the ESR (0.23) and the CRP
(0.35). Extraluminal fluid (0.50) correlated well with CDAI, the only one of the dichotomous
variables to do so. A model with ESR and CRP predicted only 17% of the variance of CDAI,
while a model that added bowel thickening and extraluminal fluid to CRP predicted 39%
of the variance (p=0.001 for the model). Conclusions: CTE findings in Crohn’s disease have
good inter-observer agreement, the scaled CTE findings correlate better with CDAI than
laboratory measures of inflammation, and these findings add to the ability to predict disease
activity. These finding are consistent with an important role for CTE in assessing Crohn’s
disease activity and identifying complications.
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Complete Versus Incomplete Optical Colonoscopy: Predictive Factors Based
On Clinical and Virtual Colonoscopy Findings
Meghan Hanson, Perry J. Pickhardt, David H. Kim, Andrew J. Taylor, Patrick R. Pfau,
Deepak V. Gopal
Background & Aims: The purpose of the study was to compare clinical and CT virtual
colonoscopy (VC) findings in patients who underwent either complete OC (COC) or incom-
plete OC (IOC). Methods: Clinical data and VC examinations were reviewed in 100 consecut-
ive patients who underwent COC immediately after VC and in 85 patients with IOC who
were subsequently evaluated by VC. The 3D colon map with automated centerline and 2D
MPR images from VC were independently reviewed by two experienced GI radiologists for
colonic lengths (total, sigmoid, and transverse), number of acute angle flexures or bends,
and presence of advanced diverticular disease. Discrepancies were resolved by consensus.
Results: From the clinical perspective, there were significant differences between COC and
IOC groups for age (mean, 58.2 vs. 64.2 years; p<0.0001), gender (M/F: 60/40 vs. 35/50;
p<0.05), and history of prior surgery (26.0% vs. 44.7%; p<0.01). Significant differences
were also seen for several evaluated VC factors between COC and IOC groups, including
total colorectal length (mean, 167.0 vs. 209.0 cm; p<0.0001), sigmoid length (mean, 48.7
vs. 66.4 cm; p<0.0001), transverse length (mean, 49.2 vs. 65.3 cm; p<0.0001), number of
flexures (mean, 9.4 vs. 11.9; p<0.0001), and advanced diverticular disease (22.0% vs. 34.1%;
p<0.05). Conclusions: In addition to patient age, gender, and surgical history, certain
anatomic features seen at VC, such as colonic length, number of colonic flexures, and
presence of advanced diverticular disease are associated with failure to reach the cecum at
OC. These predictive factors may have implications for patients who are sent to OC for
polyps detected at VC.
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Colon Cancer Screening According to Polyp Characteristics: Cost-Effectiveness
Analysis with CT Colonography and Endoscopy
Cesare Hassan, Angelo Zullo, Andrea Laghi, Paola Cerro, Franco Iafrate, Sergio Morini
Background & Aims: The relationship between the natural history of each of the different
types of adenomatous polyps and the cost-effectiveness of colon cancer (CRC) screening is
unknown. A high accurateness of computerized tomographic colonography (CTC) for large
polyps has been shown in two meta-analysis, which also confirmed a low sensitivity for <5
mm polyps. Aim of this analysis was to assess the impact of avoiding the removal of
diminutive polyps on the cost-effectiveness of CTC in comparison with that of colonoscopy
and flexible sigmoidoscopy (FS). Methods: Cost-effectiveness of screening strategies was
compared by using computer models of a Markov process, in which a hypothetical population
of 100 000 persons 50 years of age undergoes CTC, colonoscopy or FS every decade or
once in life-time. Outcomes were projected to US national level. Results: Incremental cost-
effectiveness as compared to no screening (ICER) of CTC, colonoscopy and FS was 7.138$,
7.407$, and 9.180$, respectively. CTC ICER improved to 4.362$ when avoiding <5 mm
polyp removal. As compared to such a policy the ICER of CTC and colonoscopy was
118.440$ and 63.900$, whilst FS was dominated. To avoid polypectomy for diminutive
lesions in the US population allowed an earning of 60.437.106$ and 433.584.633$ in the
one-time and in the once every 10 year schedule, respectively. Conclusions: To avoid removal
of diminutive lesion appears as the most cost-effective and safe option when simulating a
general population screening with CTC. If a high accuracy for large polyps is confirmed,
such technique could also be a convenient alternative to colonoscopy.
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Neoplasia Yield of FOBT Following a Negative Screening FS
Senore Carlo, Segnan Nereo, Andreoni Bruno, Bisanti Luigi, Castiglione Guido, Ferrari
Arnaldo, Foco Alberto, Gasperoni Stefano, Malfitana Giuseppe, Pera Angelo, Recchia
Serafino, Saracco Giorgio, Zappa Marco
Aims: To estimate the additional yield of neoplasia achievable offering fecal occult blood
test (FOBT) to subjects with negative screening sigmoidoscopy (FS). Methods: We conducted
a population based multicenter randomized trial comparing four screening protocols: 1)
Biennial immunological FOBT, 2) “Once-only” FS, 3) FS followed by biennial FOBT for
screenees with negative FS; 4) Patient’s choice between FS and FOBT. A random sample of
men and women, aged 55 to 64, was drawn from general practitioners (GP) rosters. GPs
were asked to exclude patients with a history of colorectal cancer (CRC), adenomas, inflam-
matory bowel disease, recent (≤ 2 years) colorectal endoscopy or FOBT, or two first degree
relatives with CRC. Eligible subjects were randomized, within GP, and were mailed a personal
invitation. The aim of FS was to advance the scope beyond the sigmoid-descending colon
junction. Screenees with “high risk” distal polyps (villous component, high-grade dysplasia
or cancer, size ≥ 10 mm, or > 2 adenomas), and those with positive FOBT, were referred
for colonoscopy (TC). Only subjects allocated to group 3 are included in this analysis. The
most advanced lesion was considered to estimate the detection rate (DR) of the tests and
the cumulative DR per persons invited. Results: Out of 20142 people allocated to group 3,
5569 (27.3%) had a FS and 3218 (61.0%) of those with negative exam attended the invitation
for a FOBT two years later. The DR at the initial FS was 0.42% for CRC (0.38% distal
0.04% proximal) and 4.85% for advanced adenoma (4.72% distal; 0.13% proximal). Of
3218 subjects performing FOBT, 115 (3.6%) were positive and 103 (89.6%) of them
underwent colonoscopy. The DR was 0.15% (5/3218) for CRC (0.02% distal; 0.13% prox-
imal) and 0.53% (17/3218) for advanced adenoma (0.22% distal; 0.31% proximal). The
cumulative DR per invited persons increased from 011% to 0.14% for CRC and from 1.32%
to 1.40% for advanced adenomas, when considering also the results of FOBT. Conclusions.
Among people with negative FS the positive predictive value of FOBT is low. FOBT may
lead to some increase in the DR of advanced neoplasia in the proximal colon only. The DR
for advanced proximal neoplasia (0.44%) is about twice as high as among people undergoing
a second FOBT screening following a previous negative test in group 1 (DR=0.24%). Cost-
effectiveness of this strategy should be evaluated over several screening rounds.
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Prevalence of a First Degree Family History of Colorectal Cancer in Persons
with a Screen-Detected Colorectal Adenoma in the Prostate, Lung, Colorectal,
and Ovarian (PLCO) Cancer Screening Trial
Ajay Pabby, Robert E. Schoen, Paul F. Pinsky, Richard B. Hayes, Joel L. Weissfeld
Objective: To estimate colorectal cancer (CRC) risk in families with an index case of colorectal
adenoma, we measured the association between screen-detected distal adenoma and a family
history of CRC, as reported by participants in a community-based cancer screening trial.
Methods: We selected 55-74 year-old participants in the Prostate, Lung, Colorectal, and
Ovarian (PLCO) cancer screening trial who did not report a personal history of cancer,
colon polyp, diverticular disease, or recent fecal occult blood testing or lower gastrointestinal
procedure. Among persons with an adequate 50 cm screening flexible sigmoidoscopy exam-
ination, we contrasted the self-reported CRC family histories of 2257 persons with distal
adenoma(s) against the CRC family histories of 19,790 persons without a distal polyp.
Results: Relative to persons without a distal polyp, a family history of CRC was more
prevalent among persons with distal adenoma(s) (adjusted odds ratio (adj OR) 1.43, 95%
confidence interval (CI) 1.25-1.63). The association of adenomas and family history was
not any stronger among persons with distal advanced adenoma(s) (adj OR 1.53, 95% CI
1.26-1.86), among persons with more than one distal adenoma (adj OR 1.62, 95% CI 1.27-
2.07), or among younger persons with adenoma(s)(age 55-59) (adj OR 1.52, 95% CI 1.20-
1.92). Similarly, the risk for having multiple affected first degree relative with CRC (adj OR
1.56, 95% CI 1.00-2.42), or having a younger onset affected first degree relative (< 50 years)
(adj OR 1.42, 95% CI 1.01-1.98), was of a similar magnitude as the risk for any affected
relatives. Conclusions: We observed a 40% increased risk of CRC in first degree family
members of subjects with a screen-detected distal colorectal adenoma. However, the usual
indicators of increased risk for CRC (presence of advanced or multiple adenomas and younger
age of adenoma detection) and enhanced genetic susceptibility to disease (adenoma associated
with multiply affected relatives or younger age of relative with CRC) did not magnify the
degree of association.
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A Prediction Model Based On Age, Gender and Distal Findings Accurately
Identifies Black and Hispanic Patients At Low-Risk for Advanced Proximal
Colorectal Neoplasia (APN) But Underestimates Absolute Risk
Benjamin E. Levitsky, Colin C. Brown, Heeren C. Tim, Paul C. Schroy
Background: Tailoring the use of screening colonoscopy based on the risk of APN has been
advocated as a strategy for reducing demand and optimizing cost-effectiveness. A simple,
7-point scoring system has been proposed that stratifies individuals into low, intermediate
and high risk categories (Imperiale et al. Ann Intern Med, 2003:139:959-65). The aim of
this study was to determine the validity of this clinical index, which was derived and validated
among a mostly White patient population, for Black and Hispanic patients. Methods: Data,
including age, gender, colonoscopic findings and any pathology results, were collected
retrospectively from 1094 consecutive White, 1119 Black and 388 Hispanic asymptomatic,
average-risk patients undergoing first-time screening colonoscopy. Scores ranging from 0
to 7 were derived for each subject using Imperiale’s system, which assigns points for each
category of age (<55y=0, 55-59y=1, 60-64y=2, >65y=3), gender (female=0, male=1) and
distal findings (no polyps=0; hyperplastic polyps=1; tubular adenoma < 1 cm=2; advanced
neoplasia =3). ‘Advanced’ was defined as an adenoma ≥ 1 cm in size or one with villous

















group (low, intermediate, and high) after stratification by race and compared using χ2
analyses. Results: For Whites, 33% were classified as low risk (score 0-1), 43% as intermediate
risk (score 2-3) and 24% as high risk (score 4-7); corresponding rates of APN for each
group were 0.8%, 3.0% and 3.8%, respectively. For Blacks, 37% were categorized as low
risk, 47% as intermediate risk, and 16% as high risk; corresponding rates of APN were
1.2%, 2.5% and 5.0%, respectively. For Hispanics, 44% were categorized as low risk, 38%
as intermediate risk, and 18% as high risk; corresponding rates of APN were 0.6%, 2.1%
and 4.5%, respectively. If colonoscopy was performed on everyone, regardless of risk group,
the number needed to endoscope (NNE) to detect one patient with APN ranges from 38
for Whites to 41 for Blacks to 55 for Hispanics; conversely, if colonoscopy is performed
only for patients in the intermediate and high risk groups, the NNE falls to 31 for Whites,
32 for Blacks and 36 for Hispanics. Restricting the use of colonoscopy for the intermediate
and high risk groups only would detect 89% of APN in Whites, 82% in Blacks and 86%
in Hispanics but miss 11%, 18% and 14%, respectively (P=0.774). Conclusions: A prediction
model based on age, gender and distal findings accurately identifies Blacks and Hispanics
at low risk of APN. Miss rates of up to 18%, however, may limit dissemination of the model
into clinical practice.
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Risk Stratification for Colonic Neoplasia Through Enhanced Backscattering
Spectroscopy Analysis of the Endocopically-Normal Rectal Mucosa
Hemant Roy, Young Kim, Yang Liu, Michael Goldberg, Nahla Hasabou, Vladimir
Turzhitsky, Mohammed Jameel, Eric Elton, Vadim Backman
Background: Risk stratification is critical for designing an efficacious, cost-effective colon
cancer screening program. Examination of the rectal mucosa for markers of the “field effect”
(e.g. aberrant crypt foci, epithelial proliferation, apoptosis etc.) can reliably predict the
occurrence of proximal neoplasia; however, their performance characteristics have been
suboptimal for clinical practice. Working with some of the pioneers of light scattering
technology (Nature 2000, Nature Med 2001, Gastroenterology 2004, Gut 2005), our group
has developed a new generation of optics technology, enhanced backscattering spectroscopy
(EBS). EBS can provide heretofore unattainable depth-selective quantitative assessment of
the nanoscale architecture of the cell (reflecting subtle genetic/epigenetic events). We have
previously reported outstanding sensitivity for the “field effect” in the azoxymethane-treated
rat and MIN mouse models of colon carcinogensis (Clin Cancer Res in press). In this study,
we assess the ability of novel EBS markers obtained from the rectum to predict colonic
neoplasia in humans. Methods: Two rectal biopsies from endoscopically normal mucosa
were taken from 88 patients undergoing colonoscopic evaluation at our institution. The
fresh tissue was subjected to EBS analysis using an advanced light scattering apparatus. Five
spectral markers were chosen that span the spectrum of EBS parameters and values were
calculated by an investigator blinded to colonoscopic findings. Results: Spectral markers
from histologically normal rectum are detailed in the table below. In general, there were
highly significant differences between the values from patients harboring neoplasia when
compared to those who were neoplasia free. Importantly, the magnitude of alteration progress-
ively increased with importance of colonoscopic findings (i.e. advanced adenomas> aden-
omas). With this panel of 5 markers, it was possible to approach 100% sensitivity for
predicting advanced adenomas. Conclusions: We report, for the first time, that novel EBS
markers assessed from the rectum were able to accurately predict neoplasia throughout the
colon. Our long term goals would be to develop a rectal probe that could be used by the
primary care physicians to decide upon timing of colonoscopic screening.
Correlation of EBS Markers from normal rectal mucosa to findings on colonoscopy
p values compare control versus adenoma or control versus advanced adenoma, respectively
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A Population Based Study of Effectiveness of a Negative Colonoscopy
Harminder Singh, Donna Turner, Lin Xue, Laura E. Targownik, Charles N. Bernstein
Background: There is limited evidence to guide the optimal frequency of repeat endoscopic
examination for colorectal cancer (CRC) screening after a negative colonoscopic evaluation.
We have established a population based cohort of individuals who had colonoscopic evalu-
ation that did not result in a diagnosis of colorectal neoplasia i.e. a negative colonoscopic
evaluation. Methods: Manitoba Health’s (the province’s single insurer) physician billing
claims database was utilized to identify individuals who had a negative colonoscopy between
April 1, 1989 and December 31, 2003. Individuals with a history of CRC prior to the
index endoscopic evaluation, IBD, resective colorectal surgery, and those with a lower
gastrointestinal endoscopic examination of any type within 5 years prior to the index
colonoscopy were excluded. The cohort was followed until diagnosis of CRC in the provincial
cancer registry, death or migration, whichever came first. Standardized incidence ratios
(SIRs) were calculated to compare observed cancer incidence to that expected in the general
population. Stratified analysis was performed to determine the duration of the protective
effect of negative colonoscopy. Results: There were 35,975 individuals with an initial negative
colonoscopy and with 164,733 person- years of follow-up. A negative colonoscopy was
associated with statistically significant SIRs of 0.69 at six months, 0.66 at one year, 0.59 at
two years, 0.55 at five years and 0.28 at ten years. A subgroup analysis limited to individuals
who did not have a repeat lower gastrointestinal endoscopy until they were diagnosed to
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have CRC was associated with significant SIRs of 0.49 at six months, 0.43 at one year, 0.36
at two years, 0.24 at five years and 0.00 at ten years. There were more right sided cancers
(defined as cancers arising from caecum, ascending colon or hepatic flexure) in the colonos-
copy cohort compared to all CRC cases diagnosed in the general population (76 out of 163
vs. 2884 out of 10197; p<0.001). Conclusions: This is the first study to demonstrate the
lower likelihood of developing CRC beyond ten years after a negative colonoscopy. There
is a need to improve the early detection rate of right sided colorectal neoplasia in the usual
clinical practice.
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Chromoendoscopic Colonoscopy Detects More Adenomas Than Conventional
Colonoscopy: A Randomized Trial of Back-to-Back Colonoscopies
Elena M. Stoffel, David H. Stockwell, Daniel P. Normolle, Missy Tuck, Norman Marcon,
D. Kim Turgeon, John Baron, Nadir Arber, Robert Bresalier, Sapna Syngal, Dean E.
Brenner
Background: Conventional colonoscopy, currently the gold standard for the detection of
colorectal neoplasia, misses some neoplastic lesions. Application of contrast dye (chromoen-
doscopy) may help increase the sensitivity of polyp detection during colonoscopy. Aim: To
compare the efficacy of chromoendoscopy vs. standard colonoscopy for detecting adenomas,
taking into account the prolonged inspection time of chromoendoscopy. Methods: Fifty
subjects with a personal history of sporadic colorectal cancer or adenomatous polyps under-
went tandem colonoscopies at one of 5 study centers of the Great-Lakes New England
Consortium of the Early Detection Research Network. The first exam for each subject was
a “standard” colonoscopy with removal of all polyps found. The second exam was randomly
allocated to be either pan-colonic indigocarmine chromoendoscopy or conventional standard
colonoscopy with intensive inspection lasting >20minutes. Size, histology, and numbers of
polyps detected on each exam were recorded. Results: Seventeen of 50 (34%) subjects had
a total of 40 adenomas detected on the initial conventional colonoscopy; 19 (48%) adenomas
were found in subjects in the chromoendoscopy arm and 21(52%) in those assigned to
intensive inspection. Of the 27 subjects randomized to chromoendoscopy, 12 (44%) were
found to have additional adenomas on second exam, 7 of these did not have adenomas on
the initial exam. Among the 23 subjects randomized to intensive inspection, 4 (6%) had
adenomas found on the second exam (p =0.07), yielding a total of 5 additional adenomas.
In the chromoendoscopy group 38 adenomas in total were detected; 19/38 (50%) adenomas
were found on the second exam, as compared with 5/26 (19%) adenomas in the intensive
inspection group (p <0.01). Ten of the 24 adenomas missed on first colonoscopy were
characterized as “flat”. Of the 19 additional adenomas found during chromoendoscopy, 16
were located in the right colon vs. 2 of 5 for intensive colonoscopy. On average, polyps
found on first colonoscopy were larger (3.74+3.12mm) than on second colonoscopy
(2.39+1.25mm). Average inspection time was 29.7 minutes in the chromoendoscopy group,
as compared with 20.4 minutes for the intensive inspection group. In multivariable analysis,
the use of chromoendoscopy remained a significant predictor for detecting greater numbers
of adenomas. Conclusions: Chromoendoscopy detects more adenomas missed by standard
colonoscopy than intensive inspection. Because as many as half of colonic adenomas may
be missed by conventional colonoscopy, pan-colon chromoendoscopy may increase the yield
for neoplastic lesions. Supported by NCI grant CA86400
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Toll-Like Receptor (TLR) 2 Maintains Tight Junctional-Associated Intestinal
Epithelium Barrier Integrity Against Stress-Induced Damage in Vivo
Elke Cario, Guido Gerken, Daniel K. Podolsky
Background: Stress stimuli such as toxic injury, inflammation or spontaneous apoptosis
induce functional and structural damage of the intestinal epithelial barrier by degradation
of morphological integrity of tight (TJ) and adherens (AJ) -junctional proteins. We have
recently demonstrated that TLR2 enhances intestinal epithelial barrier integrity through
translocation of zonula occludens-1 (ZO-1) via protein kinase C in vitro. The aim of this
study was to determine the functional relevance of TLR2-induced modulatory effects on
structural intestinal epithelial barrier integrity against apoptotic or chemical stress-induced
damage in vivo. Materials & Methods: Mice (TLR2 knockouts (TLR2KO; F10), wildtype
(WT; C57BL/6J)) were maintained under strict SPF conditions. DSS-colitis was induced by
standard protocol (4%; 5 days). Subcellular distribution of TJ/AJ-associated proteins was
assessed by laser confocal microscopy of primary intestinal epithelial cells (IEC) in situ or
cultured short-term ex-vivo with or without PCSK (synthetic Pam3Cys-SK4), a known TLR2
ligand. Spontaneous apoptosis was assessed by TUNEL. Results: DSS-induced colitis in
TLR2KO was paralleled by dissociation of ZO-1 from the lateral TJ membrane, loss of apical
symplekin and disorganization of E-cadherin in IEC. Compromised intestinal epithelial
barrier integrity in TLR2KO resulted clinically in significantly more severe intestinal bleeding
and diarrhea than in DSS-WT mice which did not show any significant changes in subcellular
TJ structure. Ex-vivo short-term culture of IEC from TLR2KO induced dramatic disruption
and depolarization of the epithelial barrier. Membrane-associated ZO-1 was internalized and
redistributed to the cytoplasmic center. However, TLR2 stimulation with PCSK preserved
intestinal epithelial integrity which correlated with inhibition of apoptosis. PCSK significantly
prevented stress-induced injury maintaining consolidated lateral cell-cell contacts in distinct
TJ/AJ areas of ex-vivo IEC monolayers from WT, but not in the absence of TLR2. Conclusions:
The results of the present study suggest an essential physiological role for TLR2 in preservation
of intestinal epithelial integrity against exogenous stress-induced TJ/AJ damage, thus exerting
important protective effects on mucosal homeostasis between commensals and host in vivo.
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Protection from Lethal Septic Peritonitis By Neutralizing the Biological
Function of Interleukin-27
Stefan J. Wirtz, Ingrid Tubbe, Mark P. Birkenbach, Peter R. Galle, Richard S. Blumberg,
Markus F. Neurath
Sepsis represents a significant health problem worldwide. At present, there are only a few
effective therapeutic approaches for the treatment of septic patients and mortality rates still
remain high. Once the host fails to restrict microbes to a local area, they may enter the
circulation and trigger an inflammatory response that can be overwhelming and as a con-
sequence fatal to the host. In the present study, we analyzed the contribution of the recently
discovered heterodimeric cytokine Interleukin-27 (IL-27) to the development of severe septic
peritonitis. First, we analyzed C57BL/6 mice in the clinically relevant cecal ligation and
puncture model (CLP) of polymicrobial sepsis. Interestingly, we detected a strong upregul-
ation of IL-27 protein in serum and peritoneal lavage fluid shortly after surgery. Interestingly,
IL-27 mRNA is apparently upregulated earlier than that of the subunits of the related IL-
12 family members IL-12 and IL-23 consistent to in vitro data leading to the suggestion that
the biological function of IL-27 precedes IL-12/IL-23 action. Further studies demonstrated
that mice deficient for the EBI3 subunit of IL-27 displayed improved long-term survival
compared to WT mice, which almost all died within 72 h post CLP. We observed a similar
outcome, when EBI3-/- or WT mice were intraperitoneally injected with 4x108 live gram
negative bacteria. However, after systemic administration of recombinant single chain IL-
27 into EBI3-/- mice immediately post CLP, these mice died within 2 days after treatment
suggesting that IL-27 is critically involved in sepsis pathophysiology. The reduced mortality
in EBI3-/- mice was accompanied by an attenuated proinflammatory cytokine response as
indicated by decreased expression of proinflammatory cytokines including IL-6, IL-1 and
IL-17. To determine the cellular targets for the early biological functions of IL-27 during
sepsis, we analyzed the expression of the IL-27 receptor in cells, which have been implicated
in the pathogenesis of the disease. As a result, we determined that not only T and NK cells,
but also mast cells, neutrophils and resident peritoneal macrophages co-expressed both
receptor chains. Moreover, in the latter cells IL-27 can induce high amounts of proinflammat-
ory mediators. Finally, we evaluated whether neutralizing of IL-27 can be beneficial for CLP
subjected mice. A single i.p treatment with a soluble IL-27 receptor fusion protein immediately
post CLP resulted in significantly improved survival. Conclusion : Our results indicate that
high IL-27 expression is harmful for the septic host and that IL-27 is a novel potential
therapeutic target for treatment of sepsis.
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T-Cell Induced Colitis Is Associated with Enhanced Myelopoiesis and
Remarkable Neutrophil Infiltration Into Secondary Lymphoid Tissue
Dmitry V. Ostanin, Dwain Dsouza, Kathryn L. Furr, Jason Hoffman, Carla M. Brown,
Laura Gray, Stephen Pruett, Matthew B. Grisham
Introduction: Numerous studies have focused on the role that the adaptive immune system
plays in the pathogenesis of chronic colitis in vivo. However, virtually nothing is known
about the role that granulocytes (neutrophils) may play in promoting (or regulating) colonic
inflammation in immune-based models of colitis. The objective of this study was to determine
how the induction of chronic colitis affects myelopoiesis and the infiltration of neutrophils
into secondary lymphoid tissue and the intestinal interstitium. Methods: Adoptive transfer
of 5x105 C57Bl/6 CD4+CD45RBhigh T-cells mice into syngeneic recombinase activating gene-
1-deficient (RAG-1-/-) recipients was used to induce chronic colitis whereas transfer of
CD4+CD45RBlow T-cells into RAG-1-/- mice was used to generate healthy controls. Histo-
pathology and flow cytometry were used to assess inflammation and leukocyte numbers in
different tissues. Serum protein levels of IL-17 and granulocyte colony stimulating factor
(G-CSF) were measured using ELISAs. Results: We found that at 8 weeks following transfer
of CD45RBhigh T-cells, mice developed chronic colitis characterized by massive leukocyte
infiltration, crypt abscesses, bowel wall thickening, goblet cell loss and epithelial breaks and
erosions. Co-incident with disease was a dramatic leukocytosis in which total circulating
leukocytes increased 5-6 fold compared to unmanipulated RAG-1-/- mice. Differential count-
ing of the peripheral blood revealed that neutrophils comprised approximately 50% of the
total circulating leukocyte pool in the CD45RBhigh→RAG-1-/- with mononuclear cells (i.e.
monocytes, lymphocytes) accounting for the other 50% of circulating leukocytes. In addition,
we found that serum levels of the granulopoietic cytokines IL-17 and G-CSF increased
by 4- and 9-fold, respectively compared to the healthy CD45RBlow→RAG-1-/- controls.
Corresponding to these dramatic increases in systemic neutrophil production in the
CD45RBhigh→RAG-1-/- mice, we observed large and significant increases (30-50-fold) in
GR-1 and Mac-1 double positive cells in the spleen, MLNs and colonic lamina propria.
Cytospin preparation and differential staining of single cell suspensions prepared from these
three tissues confirmed the presence of large numbers of mature neutrophils. Conclusions:
T-cell-induced chronic colitis is associated with a remarkable myelopoiesis and infiltration
of large numbers of neutrophils into the MLNs, spleen and colonic lamina propria. The role
that these granulocytes play in modulating the onset and/or severity of colonic inflammation
is currently under investigation. (Supported by DK64023, DK43785 and Yamouchi USA
Foundation).
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A20 Is Critical for Restricting Basal TLR Signal
Osamu Hitotsumatsu, Emre Turer, Ruslan Medzhitov, Averil Ma
A20 is a novel protein that is induced by pro-inflammatory NFkB signals in multiple cell
types. Prior work from our lab suggested that A20 is required for preventing spontaneous
inflammation and that A20 is critical for terminating TNF induced NFkB signals. More
recently, we have found that A20 is also critical for terminating heterologous Toll-like
receptor (TLR) induced NFkB signals and limiting the production of inflammatory cytokines
by macrophages. We have also acquired provocative data suggesting that A20 is a novel
enzyme with two independent ubiquitin modifying functions - including the ability to modify
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the uibiquitylation status of TRAF6, a key TLR signaling protein. As recent studies suggest
that intestinal luminal microbes may tonically stimulate TLR dependent signals in unmanipul-
ated mice living in specific-pathogen free conditions, we are now investigating whether such
basal signaling may contribute to the inflammation seen in A20 deficient (A20-/-) mice. We
will present preliminary studies suggesting that A20 is indeed required for restricting basal
TLR responses in vivo. Specifically, mice that lack both A20 and the common TLR-adapter,
MyD88 (A20-/- MyD88-/- double mutant mice), show a dramatic amelioration in the cachexia
and spontaneous inflammation when compared to A20-/- MyD88+/- mice. These findings
contrast with the A20-/- RAG-1-/-, A20-/- TNF-/- and A20-/- TNFR1-/- double mutant mice,
all of which develop spontaneous colitis similarly to A20-/- mice. They also highlight the
critical role of TLR signals at the apex of physiological inflammation. We will also present
studies using radiation chimera generated from A20-/- MyD88-/- hematopoietic stem cells
that will help dissect the role of MyD88 dependent TLR signals on intestinal hematopoietic
cells versus stromal cells in this process. We will also present complementary studies using
a published cocktail of broad spectrum antibiotics to reduce luminal bacteria and TLR signals
in the intestine. These findings emphasize the importance of restricting basal TLR responses
in vivo and highlight the critical role of A20 in this process, as well as the importance of
TLR signaling in regulating physiologically downstream inflammatory events.
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Association Between Serum IgG Antibody to C. Difficile Toxin A and
Polymorphism of the Interleukin-8 Gene
Zhi-Dong Jiang, Herbert L. Dupont, Kevin Garey, Margaret Price, Gail Granham, Pablo C.
Okhuysen, Thanh Dao-Tran, Mark Larocco
Previous studies have shown that defective humoral immune response to C. difficile (CD)
toxin A is associated with the development of more severe C. difficile diarrhea (CDD) and
relapse. We have previously shown that single nucleotide polymorphism (AA) in the IL-8
gene promoter region (-251 position) (SNP) is associated with increased susceptibility to
CDD in hospitalized patients. The present study was to look at the relationship of serum
antibodies to CD toxin A, presence or absence of SNP and levels of fecal IL-8 in a group
of hospitalized patients with toxin-B positive CDD (n = 24) and CD toxin-A & B negative
asymptomatic controls (n = 20) matched by age, length of hospital stay, comorbidity and
receipt of antibiotics. At enrollment, serum and stool samples were collected from each
participate. Serum IgG antibody levels against CD toxin A were measured by an enzyme-
linked immunosorbent assay (ELISA). CD toxin A antigen was obtained from Remel Inc
(Lenexa, KS). Fecal samples were collected from all subjects and studied for level of IL-8
by commercial ELISA. The results are given in the table. In the study, we found an association
between C. difficile diarrhea, absence of IgG antitoxin A antibody, presence of AA SNP
genotype and fecal IL-8. The IgG antitoxin negative CDD patients with AA IL-8 genotype
more commonly had detectable IL-8 in stool samples (70% verses 40%, p<0.001) and with
significantly higher levels of fecal IL-8 (820.23pg/mL vs. 0pg/mL, p = 0.001) than the CDD
cases who were IL-8 genotypes AT or TT. The non-diarrhea controls without IgG antitoxin
less frequently showed the AA IL-8 genotype than the CDD cases (29% verses 67%, p =
0.035). The study provides evidence that host susceptibly to C. difficile diarrhea is related
both to IL-8 genetics and to absence of a humoral immune response to CD toxin A. Both
factors were associated with higher levels of fecal IL-8. Future studies will focus on the
relationship between host genotype and immune responsiveness to CD and its toxins. The
study suggests that host genetics, immune responsiveness to toxin A and presence of the
fecal inflammatory markers IL-8 may help to define populations at risk for C. difficile or
provide important information about disease pathogenesis.
Median for fecal IL-8 Concentration (pg/mL)
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Molecular Characterization of NOD2 and Grim-19 Interactions By Ligand
Activation
Jose E. Aguirre, Jesus Yamamoto-Furusho, Nicolas Barnich, Daniel K. Podolsky
Background: The protein product of NOD2/CARD15, the first susceptibility locus linked to
Crohn’s disease, activates NF-KB and serves an antibacterial function in intestinal epithelial
cells following MDP stimulation. Mutations of the LRR regions, including the frameshift
mutation 3020insC, results in susceptibility to Crohn’s disease due to loss of the defensive
function in IECs. Grim-19 (Gene Associated with Retinoid-IFN induced Mortality 19), a
binding partner of NOD2, reduces the ability of Salmonella typhimurium to invade intestinal
epithelial cells. Aim: To define the interacting regions and binding characteristics of NOD2,
the mutant NOD2 proteins associated in Crohn’s, and Grim-19 and examine these interactions
in response to MDP. Methods: NOD2 and Grim-19 mutants were generated by PCR using
Quick Change Site Directed Mutagenesis Kit. The proteins were expressed in COS-7 cells
transiently co-transfected with Flag-tagged NOD2 or Flag-tagged truncations of NOD2 and
Xpress-tagged Grim-19; protein interactions and expression were checked by immunoprecip-
itation and western blot analysis. Results: The binding region of NOD2 for Grim-19 is
contained within the LRR region and binds to a specific region of Grim-19. Interestingly,

















analysis may disrupt but not eliminate binding to Grim-19. Blau syndrome NOD2 mutations
elicit a similar relationship. MDP stimulation of NOD2 and Grim-19 co-transfectants appears
to affect binding ability. Conclusion: NOD2 and Grim-19 interactions could be affected by
molecular mutations resulting in a lack of ligand activation.
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Functional Characterization of the Serotonin Transporter (SERT) in Human
Intestine
Ravinder K. Gill, Seema Saksena, Sangeeta Tyagi, Ayesha Zaheer, Amika Singla, Waddah
A. Alrefai, Pradeep K. Dudeja
Serotonin is an endogenous amine that exerts a wide range of biological effects on mammalian
physiology. About 90% of the whole body content of serotonin is present in the gastro-
intestinal tract. In the gut, serotonin plays an important role in the regulation of both the
gut motility and electrolyte and fluid transport. Since serotonin plays an important role as
a signaling molecule, a means for its inactivation must exist in the cells. However, the
enzymes that catabolize serotonin are located intracellularly and require serotonin to be
internalized before being inactivated enzymatically. Emerging evidence suggests that sero-
tonergic transmission is under the regulation of serotonin transporter (SERT) that serves to
inactivate mucosal serotonin by reuptake into epithelial cells through a Na+ and Cl- coupled
mechanism. Recently, the presence of a functional SERT was established in Caco-2 cells at
both the apical and basolateral membrane domains. However, the mechanism of inactivation
of serotonin has not been characterized in the native human intestine. Therefore, the objective
of the present studies was to characterize SERT function and expression along the length
of the human intestine. Purified apical (AMV) and basolateral membranes (BLM) were
isolated from human small intestinal and colonic mucosa obtained form organ donor intestine.
Uptake of 3[H]-serotonin and immunoblotting studies were performed in the purified
apical and basolateral membrane vesicles utilizing SERT antibodies. Immunoblotting studies
detected a protein band (~70 kDa) most prominently in the ileal plasma membranes. The
expression of SERT was found to be substantially higher in the ileal basolateral membranes
compared to apical membranes. Functional studies suggested that uptake of 3[H]-serotonin
(150 nM) was significantly increased in the presence of both Na+ and Cl- in human ileal
BBM and BLM vesicles. The uptake was found to be linear with time for up to atleast 1
min in AMVs and BLMs at 30°C. The 3[H]-serotonin uptake was inhibited (~50%) by the
neuronal SERT inhibitor, fluoxetine (10-50μM) in apical and basolateral membranes. The
uptake of 3[H]-serotonin exhibited saturation kinetics indicating the presence of carrier-
mediated process for transport of serotonin in ileal AMVs and BLMs. In conclusion, our
data suggest that in the human ileum, SERT is functionally expressed at both apical and
basolateral membranes. Knowledge of the detailed characterization of SERT-mediated trans-
port of serotonin might have major implications in understanding the pathophysiology of
inflammatory bowel disease associated with altered serotonin availability.
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MAPKAPK2 Is a Critical Signaling Intermediate in NHE3 Activation Following
Na+-Glucose Cotransport
Zhihong Hu, Yingmin Wang, Mark W. Musch, Liping Su, Jerrold R. Turner
Villus enterocyte nutrient absorption occurs via precisely-orchestrated interactions among
multiple transporters. For example, transport by the apical Na+-glucose cotransporter, SGLT1,
triggers a cascade that leads to increased Na+-H+ exchange as a consequence of NHE3
translocation to the apical plasma membrane. This NHE3 translocation requires sequential
activation of p38 MAP kinase (MAPK), Akt2, and ezrin. Akt2 directly phosphorylates ezrin,
but the precise role of p38 MAPK in this process remains unknown. The aim of this study
was to identify the mechanism by which p38 MAPK effects downstream Akt2 activation.
METHODS: Caco-2BBe cell monolayers stably transfected with wild type ezrin or dominant
negative (N-terminal truncation mutant) ezrin were initially equilibrated in media with
mannose in place of glucose. SGLT1-mediated transport was initiated by iso-osmotic replace-
ment with glucose-containing media. Protein phosphorylation was detected by immunoblot.
siRNA knockdown was performed by standard approaches. Surface NHE3 expression was
quantified by modified whole-cell ELISA. RESULTS: In silico analysis suggested that p38
MAPK could not phosphorylate Akt2 Ser473. However, MAPKAPK2, a direct p38 MAPK
effector may phosphorylate Akt2 Ser473 in human neutrophils. We therefore hypothesized
that MAPKAPK2 might link p38 MAPK and Akt to effect ezrin-dependent NHE3 translocation.
MAPKAPK2 was rapidly phosphorylated at Thr334, an indicator of activation, after initiation
of Na+-glucose cotransport. This occurred with kinetics that paralleled activation of p38
MAPK, Akt2, and ezrin. p38 MAPK inhibition attenuated MAPKAPK2, Akt2, and ezrin
phosphorylation. Dominant negative ezrin expression had no effect on p38 MAPK, MAP-
KAPK2, or Akt2 phosphorylation. In contrast Akt2 inhibition blocked ezrin, but not p38
MAPK or MAPKAPK2 phosphorylation, suggesting that MAPKAPK2 could be an intermediate
in p38 MAPK-dependent Akt2 activation. siRNA-mediated MAPKAPK2 knockdown inhibited
Akt2 and ezrin phosphorylation but did not affect p38 MAPK phosphorylation. MAPKAPK2
knockdown also blocked NHE3 translocation to the apical surface. CONCLUSIONS: These
studies show that MAPKAPK2 is a critical intermediate in the signal transduction pathway
that causes NHE3 translocation after SGLT1-mediated transport. Moreover, the data show
that the role of MAPKAPK2 is to phosphorylate Akt2, thereby linking upstream p38 MAPK
to downstream Akt2 and ezrin activation. As p38 MAPK and NHE3 are both activated under
hypo-osmotic conditions, these data may also provide a mechanistic basis for understanding
NHE3 responses to osmotic stimuli.
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Distinct Isofroms Encode Apical and Basolateral Intermediate Conductance K
(IK) Channels
Christoph Rahner, Christian Barmeyer, Youshan Yang, Frederick J. Sigworth, Henry J.
Binder, Vazhaikkurichi M. Rajendran
Basolateral IK channels are generally thought to provide the driving force for agonist (cAMP/
Ca2+)-induced Cl secretion, while apical IK channels mediate Ca2+-activated K secretion
in rat colon (Am J Physiol 285:G185-G196, 2003). Although IK channel-like functions and
proteins have been demonstrated in both apical (Ap) and basolateral (Bl) membranes, only
a single IK cDNA (designated as IK1) has previously been cloned. In these studies we sought
to establish whether both Ap and Bl IK channels are encoded by IK1 or by two (or more)
distinct isoforms. Two distinct transcripts (1423 bp and 1336 bp) were identified by RT-
PCR analyses using mRNA from rat colon and oligos that were designed from the 5’ and
3’ untranslated regions flanking the coding sequence of IK1. The larger one (1423 bp) was
identical as IK1, while the second RT-PCR product (1336 bp) was designated as IK2. IK2
differs from IK1 by lacking the entire second exon that encodes a continuous 29 aa domain
that also represents entire predicted 2nd membrane spanning domain in IK1. Immunofluores-
ence studies using an antibody (anti-IK1-2) raised against C-terminal region of IK1 localized
IK-like proteins in both Ap and Bl membranes of rat colon. Western blot analyses established
that anti-IK1-2 antibody recognized 37 and 40 kDa proteins, while immunoprecipitation
studies indicate that anti-IK1-2 antibody also precipitated 37 and 40 kDa proteins from rat
colonic epithelial cell homogenate. In addition, immuno-EM studies with human colon
indicated the IK1-2 antibody also localized IK-like proteins in both Ap and Bl membranes.
In contrast, an antibody (anti-IK1) raised against a peptide from the 29 aa motif (that is
deleted in IK2) localizes IK-like proteins only in Ap membranes of rat colon. In transiently
transfected HEK293 cells, IK2 exhibits Ca2+-dependent K current with intermediate conduct-
ance (16 ps). IK-proteins are expressed in surface membrane of IK1-cRNA injected oocytes,
but in IK2-cRNA injected oocytes no surface membrane expression was seen. In contrast,
surface membrane expression of IK-protein was present in oocytes co-injected with IK2 and
MaxiK β-subunit cRNAs. We conclude that apical and basolateral IK channels are encoded
by IK1 and IK2 isoforms, respectively. We speculate that a β-subunit-like accessory protein
is necessary for surface membrane expression of IK2 (but not IK1) proteins. Thus, these
studies establish that IK1 channel is an Ap membrane protein associated with agonist-
induced K secretion, while IK2 channel is localized to Bl membrane and provides the driving
force for agonist-induced Cl secretion.
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Regulation of Kcnq1/Kcne3 By Basolateral Sphingomyelinase (SMase)
David Saslowsky, Nori Tanaka, Wayne Lencer
The environment of the human intestine contains a variety of SMases contributed by both
host cells as well as the intestinal microbial flora. SMases cleave the phosphorylcholine head
group of sphingomyelin (SM) leaving the ceramide component intact in the lipid bilayer.
These enzymes are implicated in physiologic processes including cell differentiation, prolifera-
tion, apoptosis, and atherosclerosis. Through our studies on the biology lipid rafts, we
discovered that conversion of SM to ceramide by SMase on the basolateral membrane of
intestinal T84 cells attenuates (by >50%) the cAMP-induced Cl- secretory response. In
contrast, apically applied SMase has no effect on Cl- secretion. Our Aim is to explain the
mechanism of SMase action. Methods: Cl- secretion is measured as a short circuit current
(Isc) on intact and semi-permeabilized T84 cell monolayers by standard electrophysiology.
Phosphorylation of ERK1/2,JNK, and c-Jun is measured in cell lysates by SDS-PAGE and
immunoblot. Results: Basolateral SMase acts rapidly and inhibits the Isc induced by the cAMP-
agonists vasoactive intestinal peptide, forskolin, and 8-Br-cAMP. In T84 cells permeabilized to
monovalent ions by amphotericin B, incubation with basolateral SMase causes inhibition of
the cAMP-gated and Ba2+-sensitive K+ conductance, presumably KCNQ1/KCNE3. The
Ca2+-gated K+ conductance, presumably KCNN4, is only marginally affected. ERK1/2 is
not involved as assessed using the chemical inhibitor PD98059 and by assay for phospho-
ERK1/2. However, SMase induced the phosphorylation of both JNK and the chemical
inhibitor of JNK SP600125 dose-dependently reverses the SMase induced block of cAMP-
induced Isc. Pharmacological induction of membrane ceramide levels recapitulates the SMase-
induced inhibition of the forskolin secretory response. Similarly, this effect was rescued by
inhibition of JNK. Conclusion: Conversion of SM to ceramide by SMase in the basolateral
membrane of T84 cells blocks Cl- secretion by inhibiting the cAMP-gated basolateral K+
channel, presumably KCNQ1/KCNE3. Signal transduction likely occurs by ceramide-induced
activation of JNK. This mechanism may allow control of transepithelial Cl- secretion by
adjacent eukaryotic and perhaps prokaryotic cell types.
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Enac Expression By Aldosterone Is Paralleled By Upregulation of Claudin-8
and Increased Barrier Function in Human Colon
Salah Amasheh, Maike Bergs, Maren M. Amasheh, Alexander G. Markov, Anton J.
Kroesen, Michael Fromm, Joerg D. Schulzke
Background & Aims: In colon sigmoideum, the limiting factor for sodium absorption is
induction of the epithelial sodium channel (ENaC) by aldosterone. In order to investigate
the functional interplay between transport and barrier, we analyzed the regulation of the
tight junction in human sigmoid colon during ENaC induction by aldosterone in vitro.
Material and Methods: Epithelial preparations from surgically removed sigmoid colon were
mounted in Ussing chambers. Colonic ENaC induction was performed by incubation with
aldosterone (3 nM) in vitro. Short circuit current (ISC) and transepithelial resistance (Rt) of
the tissues was reported and ENaC induction was determined by final addition of amiloride
(10-4 M). Subsequently, tissues were removed from the chambers and used for Western
blotting and laser-confocal microscopy of immunofluorescent stainings of ENaC and tight
junction proteins. Results: Aldosterone stimulated JNa by inducing ENaC in the apical
membrane of epithelial cells within 8 h. After subsequent blockade of ENaC by addition of
amiloride, Rt values were higher after aldosterone-treatment compared to respective controls,
indicating an additional mechanism tightening the epithelium. Analyses of the tight junction
by means of Western blot and immunofluorescence analyses revealed a differential regulation
of tight junction molecules. An increase of occludin and claudin-8 during aldosterone
incubation was observed, whereas claudin-1, -4, and -5 remained constant. Confocal laser
scanning microscopy revealed that the increase of occludin was limited to subjunctional
regions, whereas claudin-8 was induced within the tight junctional complex. A separate
approach adding amiloride prior to aldosterone in the Ussing chamber experiment revealed
no increase of Rt, occludin, and claudin-8 indicating ENaC action being part of the signaling
pathway. Conclusion: Aldosterone enhances Na+ absorption by two independent mechan-
isms acting in concert, namely increased ENaC-mediated sodium transport and an increase
of barrier function. On molecular level of the tight junction, expression of the sealing tight
junction protein claudin-8 is enhanced, which is one of the “tightening” tight junction
proteins. In this manner, paracellular back-leak of actively absorbed sodium is diminished
by selectively sealing the tight junction for cations. This process may enable a pronounced
electrochemical gradient from lumen to plasma and thus contribute to Na+ absorption
efficiency. Prerequisite for this mechanism is a functional ENaC.
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Elevated Intracellular Calcium ([Ca2+]i) Inhibits NHE3 Activity By a PDZK1
(NHERF3) Dependent Process in Which NHE3 and PDZK1 Bind Basally and
Dissociate with Elevated [Ca2+]i
Nicholas C. Zachos, Xuhang Li, Olga Kovbasnjuk, Rafiq Sarkar, Boris Hogema, Hugo de
Jonge, Mark Donowitz
The NHERF family (NF) of PDZ proteins is known to play a role in acute regulation of
NHE3 activity, including inhibition of NHE3 activity by cAMP, cGMP, and elevated [Ca2+]i.
Calcium regulation of NHE3 activity occurs through specific NHERF interactions with NHE3
(NHERF1 = no effect; NHERF2 = inhibition; NHERF4 = stimulation), which involve formation
of multi-protein complexes and affect NHE3 trafficking. While specificity of calcium regula-
tion has been demonstrated for NHERFs 1, 2 and 4, the role of NHERF3 is not defined.
The current study tested the hypothesis that PDZK1 had a role in calcium regulation of
NHE3 activity. NHE3 activity was measured using the pH-sensitive dye, BCECF in PS120
cells stably expressing NHE3 alone or with NHERF3. Treatment of PS120/NHE3 cells with
the calcium ionophore, 4-Br-A23187 (0.5μM), had no effect on NHE3 activity. However,
in PS120/NHE3/NHERF3 cells, elevated [Ca2+]i decreased NHE3 activity by ~50%. This
decrease correlated with a similar decrease in NHE3 surface expression (Ctl = 12 ± 2%)
after treatment with A23187 (7 ± 1%). Confocal microscopy demonstrated NHE3 and
NHERF3 co-localize in PS120 cells under basal conditions but dissociate after treatment
with A23187. While the pattern of NHE3 localization did not appear to be different than
control with elevated [Ca2+]i, NHERF3 formed distinct intracellular clusters which were
spatially separate from NHE3. Acceptor photobleaching FRET showed direct NHE3/NHERF3
interaction basally and a complete loss of NHE3 and NHERF3 interaction 15 min after
A23187. NHERF3 clusters were also observed with elevated [Ca2+]i in the brush border
(BB) of Caco2/bbe cells treated with carbachol (10μM). Under basal conditions, NHE3 and
NHERF3 co-localize in the BB of Caco2/bbe cells. However, in Caco2/bbe cells treated with
carbachol, NHERF3 formed clusters in the BB while NHE3 appeared to localize to a subapical
region immediately below the BB. Thus, the current study demonstrated that (1) Elevated
[Ca2+]i decreased NHE3 activity in PS120/NHE3/NHERF3 cells. (2) Calcium inhibition of
NHE3 mediated by NHERF3 involves reduced NHE3 surface expression. (3) Elevated [Ca2+]i
results in NHERF3 clustering and dissociation from NHE3 in fibroblasts and polarized
intestinal epithelial cells. Taken together these results suggest that (1) NHERF3 may anchor
NHE3 in the plasma membrane under basal conditions and this interaction is disrupted
with elevated [Ca2+]i . (2) NHERF3 clustering is associated with NHE3 removal from the
plasma membrane thereby decreasing NHE3 activity. (3) NHERF3 does not traffic with
NHE3 from the plasma membrane to the recycling endosome.
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Altered Immunologic Function Determines Symptom Pattern and Severity in
Patients with Irritable Bowel Syndrome
Tobias Liebregts, Birgit Adam, Christoph Bredack, Susan Lester, Sarah Downie-Doyle,
Alexander Roth, L. Ashley Blackshaw, Gerald Holtmann
Background: There is increasing evidence that immunologic mechanisms play a role for the
manifestation of functional gastrointestinal disorders (FGID). Altered immunologic responses
may determine the manifestation and severity of symptoms in patients with FGID. We
hypothesized that the release of pro-inflammatory cytokines from peripheral blood mononu-
clear cells (PBMC) is linked to the severity of symptoms in patients with Irritable Bowel
Syndrome (IBS). Thus, we aimed (1) to characterize systemic cytokine production, (2) the
cellular response to LPS stimulation and (3) to correlate symptom pattern and severity with
immunologic function. Methods: PBMC from 15 (alternating-) IBS patients and 20 matched
controls were isolated by density gradient centrifugation and cultured for 24 hours in RPMI
1640 supplemented with 10% FCS. Basal and E. coli LPS (lipopolysacharide)(1-100ng/ml)
stimulated cytokine production (TNF-α, IL-1β, IL-6) of PBMC was measured by enzyme-
linked immunosorbent assay (ELISA). Abdominal symptoms and psychological co-morbidit-
ies were assessed utilizing the standardized Bowel Disease Questionnaire (BDQ) and Hospital
Anxiety and Depression Scale (HADS). Results: At baseline TNF-α (69.2±4.8pg/ml vs.
35.4±18.2pg/ml), IL-1β (86.4±21.7pg/ml vs. 147.8±41.3pg/ml), but not IL-6 release were
significantly higher (p<0.05) in IBS patients compared to healthy subjects. LPS stimulation
caused a dose dependent increase of all cytokines. Interestingly, the LPS induced increase
of TNF-α and IL-1βwas significantly attenuated in IBS patients compared to healthy controls.
In IBS patients baseline TNF-α level was correlated with pain frequency (r=.618, p<0.01),
intensity (r=.494, p<0.05) and loose (r=.630, p<0.01) and watery stools (r=.445, p<0.05)
while IL-1β level were linked to constipation (r=.440, p<0.05) and lumpy stool (r=.614,
p<0.01). LPS stimulated IL-1β production was inversely correlated with symptom frequency
(r=-.618, p<0.01), intensity (r=-.599, p<0.05) and pain severity (r=-.524, p<0.05). Depression
was correlated with the LPS induced TNF-α production (r=.503, p<0.05). Summary and
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Conclusion: PBMC of IBS patients are characterized by an increased baseline and impaired
LPS- induced release of pro-inflammatory cytokines in-vitro. These alterations of cytokine
production are closely linked to symptom severity. Since low-grade inflammation is believed
to play a role in IBS patients, the altered cytokine release may reflect an abnormality in the
regulation of immune responses of IBS patients.
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Markers of Inflammation in IBS: Increased Permeability and Cytokine
Production in Diarrhoea-Predominant Subgroups
Eugene Campbell, Marguerite Richards, Stephen Foley, Maggie Hastings, Peter Whorwell,
Yashwant Mahida, Ian Hall, Keith Neal, Robin Spiller
BACKGROUND: We have previously described increased mucosal lymphocytes in post-
infective IBS (PI-IBS) and others have demonstrated low-grade mucosal inflammation and
immune activation. It is uncertain if subgroups of IBS differ in their degree, type or site of
inflammation. AIMS: To assess evidence of inflammation between IBS subgroups and healthy
controls by measuring small bowel (SB) and colonic (C) permeability, stool cytokines, urine
neopterin and peripheral blood mononuclear cell (PBMC) cytokine production. METHODS:
Fifty-five IBS patients satisfied Rome II criteria for IBS. Twenty-one normal healthy controls
were also recruited. Gut permeability was measured by Cr51-EDTA method, with timed
urine collection for small and large bowel permeability; Stool supernatants and medium
from PBMCs after incubation for 24 hours were assayed for cytokines by cytometric bead
array. Anxiety and depression were measured by Hospital Anxiety and Depression scale.
RESULTS: (Mean±SEM) Small bowel permeability was significantly increased in D-IBS,
whereas colonic permeability was unchanged. PBMC incubations from D-IBS and PI-IBS
had significantly elevated IL-1, IL-10 and TNF levels compared to healthy controls. High
sensitivity CRP, urine neopterin and stool cytokines showed no significant differences between
patient groups and controls CONCLUSION: Subgroups of IBS have evidence of immune
activation and altered gut permeability. IBS patients with diarrhoea show evidence of systemic
immune and altered small bowel but not colonic permeability. The increased cytokine profile
suggests systemic monocyte activation which may be due to bacterial products absorbed




Decreased Number of IGA+ Plasma Cells in the Ascending Colon Mucosa of
Patients with Irritable Bowel Syndrome (IBS)
Johan Forshammar, Stefan Isaksson, P-O Stotzer, Hans Strid, Henrik Sjovall, Magnus
Simren, Lena Ohman
AIM: Irritable bowel syndrome (IBS) has been suggested be associated with a low grade
inflammation in the intestinal mucosa. Food reactions may contribute to the immune activa-
tion, since some patients with IBS symptoms benefit from specific elimination diets. Moreover,
one of the most frequently recognised immunological features of IBS is increased numbers
of mast cells in colonic lamina propria and muscularis propria. However, the profile of
plasma cells in the colonic mucosa of patients with IBS has not been investigated previously.
METHOD: 11 healthy controls subjects and 11 patients with IBS, defined by the Rome II
criteria, participated in the study. Biopsies were taken during colonoscopy and were then
frozen, sectioned and mounted on slides whereupon they were saturated with antibodies
with affinity for human IgM, IgG, IgA and IgE conjugated with horse radish peroxidase
(HRP). Positive cells were detected by light microscopy. RESULTS: The number of mucosal
IgA+ plasma cells of the ascending colon (201 cells/mm2) was significantly lower in IBS
patients than in healthy controls (462 cells/mm2) (p=0.039). Furthermore, IBS patients had
a significantly lower number of IgA+ plasma cells in the ascending colon (201 cells/mm2)
as compared to the sigmoid colon (430 cells/mm2) (p=0.04). The IgG+ plasma cell populations
did not significantly differ between IBS patients and controls in the ascending colon (166
cells/mm2 vs 291 cells/mm2) or in the sigmoid colon (285 cells/mm2 vs 174 cells/mm2).
The IgM+ plasma cell populations were comparable in IBS patients and controls in the
ascending colon (180 cells/mm2 vs 240 cells/mm2) and in the sigmoid colon (219 cells/
mm2 vs 264 cells/mm2). Very few IgE+ cells were detected in the colonic mucosa and there
was no difference between the two subject groups. CONCLUSION: The reduced number
of IgA+ plasma cells in the ascending colon mucosa of IBS patients suggests that IBS patients
may have an impaired IgA mediated mucosal immune defence. Whether this phenomenon


















Intestinal Immune Activation in Post-Infectious Functional Dyspepsia
Sebastien Kindt, Alexander Terychnyy, Karel Geboes, Jan Tack
Background: Recent studies have shown that, similar to post-infectious (PI-) irritable bowel
syndrome (IBS), functional dyspepsia (FD) symptoms may develop acutely and persist after
a gastrointestinal infection. Biopsy studies in PI-IBS have shown signs of persisting low-
grade colonic inflammation and increased counts of enterochromaffine cells (EC). It is
unclear whether PI-FD is similarly characterized by low-grade intestinal inflammation. The
aim of the present study was to compare signs of inflammation and EC hyperplasia on
duodenal biopsies in PI-FD and unspecified-onset (U-)FD. Methods: Duodenal biopsy speci-
mens were obtained at upper g.i. endoscopy in 12 U-FD and 12 PI-FD patients (15 women,
mean age 38.8±3.2, onset of symptoms on average 10±3 months earlier). The mean number
of intra-epithelial lymphocytes (IEL) and Chromogranine C (CC) positive cells per villus,
presence of focal aggregates of T-cells, increased number of T-cells at the base of the villi,
lymphoid aggregates and focal IEL aggregates were compared between both groups with
Student t-test, Wilcoxon test and Fisher exact test. Data are shown as mean±SEM. Results:
The mean numbers of IEL (20.6±1.7 vs. 23.5±2.3) and the mean number of EC cells (3.6±0.3
vs. 3.5±0.2) per villus did not differ between PI-FD and U-FD. Focal aggregates of T-cells,
reminiscent of cryptopatches (CP) in mice, were found in 6/12 PI-FD patients, and in none
of 12 U-FD patients (p=0.01). In mice, CP are inducible and have been shown to play a
major role in gut immune defense (Eberl 2005). No significant differences were reached
when comparing in PI-FD and U-FD the presence of increased numbers of T-cells at the
base of the villi (respectively 7/12 and 3/12), focal aggregates of IEL (respectively 6/12 and
2/12) or lymphoid aggregates (1/12 in each group). Conclusion: PI-FD is not associated
with increased lymphocyte or EC cells counts in villi, but is characterized by the presence
of focal T-cell aggregates which persist several months after the acute insult. We speculate
that, similar to murine CP, these aggregates indicate ongoing low-grade intestinal immune
activation in PI-FD.
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Pathogenic Mechanisms of Post-Infectious Functional Gastrointestinal
Disorders: Results After 3 Years
Antonia Perello, Monica Perona, Agustin Balboa, Miquel Sans, Ruth Benasayag, Antonio
Salas, Marc Perez-Oliveras, Jordi Coderch, Asuncion Garcia, Fermin Mearin
We have previously shown that one year after a Salmonella infectious outbreak, which
affected more than one thousand people, 17% developed functional dyspepsia (FD) and
12% irritable bowel syndrome (IBS) (Gastroenterology 2005;129:98-104). Aims: To evaluate
possible mechanisms related to the development and persistence of post-infectious functional
gastrointestinal disorders (PI-FGID) 3 years after the outbreak. These include mucosal
inflammation, visceral hypersensitivity and psychological factors. Methods: Participants were
recruited from our previous prospective study: 16 patients (cases) suffered PI-FGID (7 FD,
3 IBS and 6 overlap between the two) and 8 control subjects without PI-FGID. We performed
upper and lower digestive endoscopy obtaining multiple biopsies in gastric fundus, antrum,
right and left colon. Samples were processed for histological study, mast cell quantification
and interleukin-1β production (IL-1β). Genomic DNA was typed for the IL-10 gene poly-
morphisms. Visceral sensitivity was assessed by the satiety drinking test and rectal barostat.
Psychological aspects were evaluated by the SCL-90 and vital events questionnaires. All
studies were conducted under blind test conditions for the investigators. Results: Biopsies
did not show significant inflammatory signs in the stomach. In the colon 3 cases and 2
controls had an increase cellularity in the lamina propria, also without evident acute inflam-
matory changes. Mast cell count in the stomach was similar between the two groups (188±16
vs 155±13) so was the level of IL-1β (2.9±0.9 vs 4.9±1.8). In the colon the number of mast
cells was also similar between the two groups (198±25/mm2 vs 176±25/mm2) so was the
level of IL-1β (2.6±0.3 vs 2.8±0.9). No differences in carriage, genotype and allele frequencies
of the IL-10 gene polymorphisms were found. Gastric sensitivity was similar between the
groups (maximal volume intake: 676±87 vs 605±118 kcal). Cases showed a lower pain
threshold to rectal distension (29±2 vs 37±2 mmHg; p<0.05). Scores for anxiety (0.63±0.11
vs 0.28±0.14; p<0.05) and somatization (1.01±0.15 vs 0.45±0.15; p<0.05) were higher in
cases than controls. The number of stressful events (7.2±1.7 vs 5.4±0.8) and stress scores
for events did not differ between groups (15.5±3.1 vs 11.7±2.6). Conclusion: Three years
after salmonellosis there is no evidence of inflammatory changes in the stomach or the colon
in patients who developed PI-FGID. Rectal sensitivity is higher than in control subjects
whereas gastric sensitivity is normal. Anxiety and somatization levels are increased.
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Prognosis of Post-Infectious Irritable Bowel Syndrome (PI-IBS) Four Years
After the Walkerton Outbreak of Waterborne Gastroenteritis (GE)
John K. Marshall, Marroon Thabane, Amit X. Garg, William F. Clark, Stephen M. Collins
Background and Aim: In May 2000, municipal water contamination by E. coli 0157:H7
and Campylobacter species led to a large outbreak of acute GE in Walkerton, Ontario. A
prospective cohort study was undertaken to determine the incidence and natural history of
PI-IBS in this population. Methods: Local residents who attended study clinics in 2002 and
2003 were invited for follow up in 2004. Standardized interviews included a modified Bowel
Disease Questionnaire to diagnose IBS by Rome I criteria. Subjects who were age > 16 and
permanent residents of Walkerton in May 2000 with no prior diagnosis of IBS or inflammatory
bowel disease were included. The prevalence and incidence of IBS among participants with
and without GE were estimated. Risk factors for IBS in 2004 were assessed by multiple
logistic regression. Results: 3280 of 4315 participants enrolled in 2002/2003 returned in
2004. Of 1587 who were eligible for study cohort (57.2% female; mean age 48.1±16.5),
1012 (63.8%) reported exposure to GE in May 2000 and 273 (17.2%) fulfilled Rome I
criteria in 2004 (38.1% IBS-D, 12.1% IBS-C). Among 302 subjects with GE in 2000 and
IBS in 2002/2003, 153 (50.7%) still fulfilled Rome I criteria in 2004. Among 1226 subjects
with no IBS in 2002/2003, IBS was detected in 2004 in 80 of 710 (11.3%) with GE in
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2000 versus 23 of 516 (4.5%) with no exposure to GE (p<0.001)(see Table). Among subjects
exposed to GE, independent predictors of IBS in 2004 included female gender, weight loss,
abdominal pain and duration of diarrhea during the outbreak. Conclusion: The prognosis
of PI-IBS appears favorable, with spontaneous resolution in half of patients. A diarrhea-
predominant phenotype of PI-IBS remains common. Funded by the Ontario Ministry of
Health and Long-Term Care
Prognosis of PI-IBS After Waterborne GE Outbreak
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Analysis of the IBD2 Locus: Inherited Variants in Gli-1, the Major Effector of
the Hedgehog Signalling Pathway, Are Strongly Implicated in Susceptibility to
Ulcerative Colitis
Charlie Lees, Elaine R. Nimmo, Gwo-Tzer Ho, Hazel E. Drummond, Albert Tenesa,
Malcolm G. Dunlop, Sarah E. Howie, Jack Satsangi
Introduction. The Hedgehog (Hh) signalling pathway is critical to GI tract development,
homeostasis and disease1. Recapitulation of embryonic Hh signals play vital roles in tissue
response to injury and repair, and regulation of T cells & macrophages. Expression of
pathway components is dysregulated in IBD2-3. Gli-1, the major transcriptional target of the
Hh signalling pathway, is located in the IBD2 susceptibility locus (12q13.3)4. Aim. To
determine whether inherited variants in Gli-1 contribute to IBD susceptibility, using a gene-
wide haplotype-tagging approach. Methods. Initial mutation screening of the Gli-1 gene
was performed in 32 IBD cases. Of 8 SNPs present, 4 tagging SNPs (rs3817474 [tSNP1],
rs2228225 [tSNP2], rs2228224 [tSNP3], & rs2228226 [tSNP4]) were identified which defined
Gli-1 variation. Five haplotypes (A-E, see table) were present in the Scottish healthy control
population (HC, n=362). SNPs were assayed by Taqman in HC, Crohn’s disease (CD, n=
335) & ulcerative colitis (UC, n=474). Taqman failures were assayed by direct sequencing.
Haplotype & variant analysis was performed using chi2 analysis. Log-likelihood testing
assessed the overall contribution of Gli-1 variation to disease susceptibility. Results. Log-
likelihood testing demonstrated a highly significant association of the Gli-1 gene with UC
(p<0.00001), but only a modest effect in CD (p<0.05). In UC, the rare haplotypes D & E
were significantly associated with susceptibility (p<0.0001), whilst haplotypes A & C were
protective (see table). In CD, haplotype B had a protective effect of borderline significance
(p<0.05). Analysis of individual SNPs revealed significant associations for tSNP2&4, but not
tSNP1&3. Carriage of the ‘2’ allele on tSNP2 was associated with IBD (OR=1.30, p=0.049).
Allelic frequency and carriage of the ‘2’ allele on tSNP4 was also associated with IBD (OR=
1.22, p=0.043 and OR=1.41, p=0.0086). Conclusion. Inherited variants in Gli-1 are strongly
associated with UC. The data presented suggest that rs2228225 (tSNP2) may be in LD with
the causal variant. Further detailed analyses of the gene are in progress. References. 1. Lees
et al Gastroenterology 2005;129(5):1696-710; 2. Nielson et al Lab Invest. 84(12);1631-42;
3. Lees et al Gastroenterology 2005;128(4):A504; 4. Satsangi et al Nat Genet
1996;14(2):199-202.
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IBDChip: A New Strategy to Predict Clinical Course and Development of
Complications in Patients with Inflammatory Bowel Disease (IBD)
Miquel Sans, Marta Artieda, Tejedor Diego, Carlos Cara, Luis Rodrigo, Manuel Barreiro,
Maria Teresa Arroyo, Montserrat Aceituno, Manuel Alvarez-Lobos, Jordi Yague, Juan I.
Arostegui, Llorenc Quinto, Laureano Simon, Josep M. Pique, Antonio Martinez, Julian
Panes
Background: Accurate prediction of clinical behaviour and response to therapy in IBD
patients is, at present, not available. Previous studies have failed to identify single genes as
clinically relevant predictive factors, probably because both Crohn’s disease (CD) and ulcerat-
ive colitis (UC) are polygenic conditions. The IBDchip is a DNA array, allowing the simultan-
eous study of 61 single nucleotide polymorphisms (SNPs) of 40 genes, which have been
selected by their potential impact on IBD, according to the published literature. Aim:
To evaluate the usefulness of the IBDchip to predict clinical course and development of
complications in IBD patients. Methods: The genetic profile of 579 patients (335 CD and
244 UC), with >5 years of follow-up, was assessed by the IBDchip. The following clinical
outcomes were considered: 1) In CD patients: Extension, fistulizing phenotype, perianal
disease, stenosing phenotype, extraintestinal manifestations and bowel resection. 2) In UC
patients: Extension, extraintestinal manifestations and need for colectomy. Relationship
between clinical outcomes and the patient’s pattern of SNPs and other clinical characteristics,
including gender, age at disease onset and smoking habit, was analyzed by logistic regression.
For each clinical outcome the optimal predictive model, based on a weighted combination
of IBDchip SNPs and clinical characteristics and aimed at resulting in a very high (95%)
specificity, was identified. Results: At abstract submission we have completed the analysis
of the IBDchip predictive value for 4 clinical outcomes. The IBDchip was able to discriminate
between fistulizing and inflammatory phenotype in CD patients with a specificity (Sp) 95%,
sensitivity (Se) 58%, positive predictive value (PPV) 92%, negative predictive value (NPV)
65%, overall accuracy (OA) 74%, and likelihood ratio (LR) 11.7. Need for colectomy in UC
patients was predicted with a Sp 95%, Se 70%, PPV 66%, NPV 96%, OA 93% and LR 15.3.
The IBDchip was also able to identify extraintestinal manifestations in CD patients with a
Sp 95%, Se 31%, PPV 82%, NPV 65%, OA 68% and LR 6.7; and in UC patients with a Sp
95%, Se 60%, PPV 79%, NPV 89%, OA 87%, and LR 12.4. Conclusions: The IBDchip is
able to discriminate between fistulizing and inflammatory phenotype in CD patients and to
identify a significant proportion of UC patients requiring colectomy or presenting extraintest-
inal manifestations, with a very high specificity. The IBDchip could be useful in the clinical
setting, selecting a subgroup of higher risk IBD patients, who might benefit from specific treat-
ment.
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Socio-Economic Status Critically Influences Penetrance of the DLG5 113A
Variant in Early-Onset IBD: A Novel Gene-Environmental Interaction
Richard K. Russell, Hazel E. Drummond, Elaine R. Nimmo, Niall Anderson, Linda Smith,
David C. Wilson, Peter M. Gillett, Paraic McGrogan, Kamal Hassan, Lawrence T. Weaver,
Michael W. Bisset, Gamal Mahdi, Jack Satsangi
Introduction: The 113 G→A mutation within the discs, large homolog 5 Drosophila (DLG5)
gene located on chromosome 10q22 has been associated with susceptibility to Inflammatory
Bowel Disease (IBD) in adults, although data are inconsistent across populations. No paediat-
ric studies are described. We studied the contribution of this mutation in detail in a cohort
of Scottish patients with early-onset IBD. Patients and methods: 296 patients (197 Crohn’s
Disease (CD), 73 Ulcerative Colitis (UC), 26 Indeterminate Colitis) with IBD diagnosed at
<16 years of age were analysed. Parental DNA was collected for Transmission Disequilibrium
Testing (TDT) analysis. Clinical, anthropometric and socio-economic data (assessed using
a standardised deprivation category DepCat score) were collected for each patient. Results:
TDT demonstrated an association of DLG5 113A variants with IBD (p = 0.045), but case-
control analysis was negative (p=0.92). Correlations were seen with socio-economic and
nutritional status. On unifactorial analysis carriage of 113A variants was seen with: 1) higher
social class (DepCat score 1 compared to 2-7 and DepCat 1-2 combined compared to 3-7)
(66.7% vs. 22.6% p=0.0005 OR 6.84[1.99-23.55] and 37.2% vs. 22.2% p=0.03, OR
2.08[1.04-4.17] respectively) 2) higher (75-91st) weight and height centile (56.2% vs. 23.4%
p=0.004, OR 4.20[1.49-11.81] and 48% vs. 22.4% p=0.006 OR 3.19[1.36-7.47] respectively)
3) males with CD (29.3% vs. 16.9%, p=0.04 OR 2.04[1.01-4.11]. Multifactorial analysis
demonstrated that higher social class was independently associated with carriage of variants of
113A (p=0.001, OR=6.92[2.24-21.33]). Conclusions: The DLG5 113A mutation is associated
with susceptibility to IBD in Scottish children living in relative affluence but not in socio-
economically deprived children, a novel gene-environmental interaction. We suggest socio-
economic status critically influences the expression of disease in children carrying this variant.
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TLR5 Polymorphisms Are Associated with OmpC and CBIR1 Expression and
with Severity of Crohn’s Disease in Ashkenazi Jews
Jerome I. Rotter, Kent D. Taylor, Huiying Yang, Ling Mei, Yoanna Picornell, Thomas R.
Hawn, Maria T. Abreu, Alan Aderem, Kostas A. Papadakis, Eric A. Vasiliauskas, Alan
Ipolitti, Stephan R. Targan
Background. Increasing evidence supports the paradigm that genetic variation contributes
to the pathophysiology of CD by altering the response of the innate immune system to gut
microflora. We have reported that serum expression of antibodies to OmpC (E. coli outer
membrane porin C) is heritable and associated with more severe CD, and that expression
of antibodies to CBir1 (bacterial flagellin) identifies a CD subgroup. Since members of the
Toll-like receptor (TLR) gene family play roles in pathogen recognition and in activation of
the innate immune response, and that TLR5 is activated by flagellin, TLR5 is a candidate
gene for CD and for serum expression of microbial antibodies. Aim: To investigate the
association of TLR5 SNPs and serum expression of antibodies to microbial antigens in CD
using a case/control design. Methods: In 889 CD patients & 236 controls, serum expression
of OmpC & CBir1 was measured by ELISA, and 3 TLR5 SNPs (R392X, N592S, F616L)
were genotyped by TaqMan MGB. Chi-square was used to test for the association of allele
with disease, clinical characteristics, & antibody combinations, and Wilcoxon and logistic
regression for antibody expression levels and disease severity. Results: the F616L F allele
was associated with the presence of OmpC expression in Jewish cases (the F allele was
present in 93.3% of OmpC+, Jewish, CD cases and in 81.2% OmpC-, p=0.0025; p=0.0005
for trend through 3 genotypes). By multivariate analysis, the F/F genotype contributed to
a higher level of OmpC expression in both ethnic groups (presence of F/F p=0.019; OR of
F/F versus L/L, 2.02 95%CI 1.15-3.58). Similarly, the N592S S allele was associated with
the presence of OmpC expression in Jewish cases (30.8% of OmpC+, Jewish, CD cases had
the S allele compared with 19.5% OmpC-, p=0.02). In contrast, the N allele was associated
with higher levels of CBir1 flagellin expression (278 for N/N & N/S genotype & 190 for S/
S, p=0.05 with logistic regression). On multivariate analysis, the N/N allele was associated with
CD severity as defined by internal penetrating, perianal perforating and severe fibrostenosis
combined (OR 6.88, 95%CI 1.65-28.6, p=0.0059). Conclusion: TLR5 SNPs are associated
with the level of OmpC expression, particularly in Jews. The observation that the opposite
allele of one of the TLR5 SNPs is associated with CBir1 flagellin, a TLR5 ligand, supports
the concept that specific variation in genes of innate immune pathways govern variations
between individuals in expression of specific antibodies to microbial antigens. The combina-
tion of these immune signals then leads to increasing severity of disease.
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The Familial Mediterranean Fever (FMF) Gene (MEFV) As a Disease
Susceptibility Gene in Inflammatory Bowel Disease (IBD)
Alexandra-Chloe Villani, Mathieu Lemire, Edouard Louis, Mark Silverberg, Yannick
Renaud, Sebastien Brunet, Catherine Collette, Genevieve Fortin, Cecile Libioulle, Jacques
Belaiche, Alain Bitton, Daniel Gaudet, Albert Cohen, Diane Langelier, John Rioux, Paul
Rutgeerts, Gary Wild, Severine Vermeire, Thomas J. Hudson, Denis Franchimont
Familial Mediterranean fever (FMF) is a hereditary auto-inflammatory disease caused by
mutations in the MEFV gene (Chr.16p13), which encodes pyrin/marenostrin that, like
NOD proteins, belongs to a structural super-family of death domain proteins. Moreover,
epidemiological studies have revealed a higher prevalence of Crohn’s disease (CD) in FMF
non Sepharadic Jewish patients. We therefore sought to evaluate MEFV as a susceptibility
gene for IBD. Methods: Phase 1: MEFV expression was examined in human biopsies collected
from CD patients (n=7), UC patients (n=6), and controls (n=4), using the ABI PRISM 7900HT
Taqman system. Phase 2: DNA samples were obtained from 4 centers: Liege (190TRIOS:
156CD, 34UC; 96 UC, 106 controls), Leuven (435TRIOS: 356CD, 79UC), Quebec (125
TRIOS: 95CD; 30UC), and Toronto (190 TRIOS: 131CD, 59UC). The haplotype structure
and fine-mapping of MEFV was done by genotyping 65 SNPs over 96.5kb using SNPstream
UHT, FP-TDI, and sequencing technologies. Standard measures of linkage disequilibrium
(LD) were estimated using EM algorithm, and association testing was done using FBAT
v1.4.2. and Armitage test for trend. Results: Phase1: CD colonic biopsies showed a significant
increase in MEFV expression (p<0.024) compared to controls. No significant difference in
expression level was observed in UC. Phase 2:LD analysis of MEFV gene showed 2 regions
of high LD. Association analysis revealed that the minor alleles of SNPs in exon 2 of MEFV,
and SNPs in high LD with them, are significantly associated with UC (p=0.0002) in Belgium
families (Leuven and Liege), even after correcting for the number of SNPs being tested.
Moreover, these associations are consistent across both Belgium centers (Liege: p=0.00047;
Leuven: p=0.018). In addition, the minor alleles of SNPs located in exon 5, and SNPs in
high LD with them, were also found to be significantly associated in both Quebec trios (p=
0.0060) and Liege case-control (p=0.025), indicating possible allelic heterogeneity for this
gene. No significant associations were observed with the Toronto UC trios. Furthermore,
weak associations with the major alleles of SNPs located around exon 2 were observed in
the CD Belgium families (p=0.0138). Other associations were also observed with SNPs
located in exon 5 in the Toronto CD trios (p=0.0338). These associations were not replicated
in Quebec CD trios. Conclusion: The MEFV gene appears to be a disease susceptibility gene
for IBD. Interestingly, this study suggests that a gene associated with a rare inflammatory
disorder could be implicated in the susceptibility of more common inflammatory diseases,
such as IBD.
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Genotype/Phenotype Analysis of a Panel of Genes in Pediatric Patients with
IBD. A Study of the Italian Society for Pediatric Gastroenterology (SIGENP)
A Latiano, S Cucchiara, G Vieni, G Guariso, R Berni Canani, E Miele, D de Venuto, S
Accomando, C Romano, A Campanozzi, C Bascietto, F Bossa, O Palmieri, Mr Valvano,
Vito Annese
Background: The identification of CARD15, OCTN and DLG5 as susceptibility genes for
inflammatory bowel disease (IBD), as well other candidate genes like TNF-alpha and MDR1,
have suggested that these genes may influence both the predisposition and the clinical course
of these disorders. Approximately 10% and 30% of patients with IBD are diagnosed under
the age of 18 and 21 years, respectively. However, it unclear whether the impact of these
genes is of relevance in pediatric onset Crohn’s disease (CD) and ulcerative colitis (UC).
Aim: To investigate the frequency of a panel of genes variants in an Italian population of
pediatric onset IBD and to analyse genotype-phenotype correlations. Patients and Methods:
A panel of 11 SNPs of CARD15 (R702W, G908R and L1007fsinsC), IBD5 locus (IGR2198a_
1, IGR2096a_1), OCTN (SLC22A4 and SLC22A5), DLG5 (R30Q), TNF-alpha (-308 and -
857), and MDR1 (C3435T) genes was assessed in 228 children with IBD (115 with CD and
113 with UC), and 254 unrelated healthy controls. Transmission disequilibrium testing
(TDT) on 177 available trios was also performed. Accurate information on clinical sub-
phenotypes (age at diagnosis, disease localization and behaviour, presence of perianal fistulae
or extra-intestinal manifestations, need of surgery), response to medical therapy, and sub-
clinical markers (ASCA, ANCA) was available. Results: A significant correlation in CD patients
was found with CARD15 (one variant, p<0.001, OR=4.3; two variants OR=6.3), IBD5 locus
(homozygotes p=0.028, OR 1.86), OCTN (SLC22A4, p<0.006, OR=2.17; SLC22A5, p<0.003,
OR=1.91), DLG5 (p=0.015 at TDT), and TNF-alpha-308 (p=0.003, OR=2.3). At genotype/
phenotype analysis, an excess of OCTN and DLG5 variants was found only in patients with
fistulizing behaviour (p<0.04 and p<0.05, respectively). A trend towards a growth delay at
diagnosis was found in CD patients with TNF-alpha-308 variant (p=0.05). No significant
correlation in UC patients was found. Conclusions: Variants of CARD15, OCTN, DLG5 and
TNF-alpha genes are significantly involved in predisposition to CD with pediatric onset;
however, only a weak influence on clinical features and response to medical therapy was
found.
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Absence of Functional Peroxisome Proliferator Activated Receptor-α (Ppar-α)
Increases Tumour Formation in APC Min/+ Mice
Anthony Shonde, David R. Bell, Andrew J. Bennett, Christopher J. Hawkey
Background: Peroxisome proliferator-activated receptor-alpha (PPAR-alpha) is expressed at
reduced levels in murine and human colon tumours relative to normal mucosa1. Apc Min/
+ mice dosed with methylclofenapate (a PPAR-alpha ligand) have significantly less polyp
area in the small intestine and colon compared to control animals1. It is not certain that
this response is PPAR-alpha specific. We investigated the hypothesis that the absence of
functional PPAR-alpha would incease tumour formation in Apc MIN/+ mice. Before studying

















examined the role of PPAR-alpha in colon carcinogenesis using Apc Min/+ PPAR-alpha-/-
mice. Aim: To establish if PPAR-alpha has a tumour suppressive function in Apc(Min)/+
mice. Method: Once weaned C57BL/6J Apc Min/+ mice and C57BL/6J Apc Min/+ PPAR-
α-/- mice were fed standard chow (Rat & mouse standard diet, BEEKAY, Humberside)
throughout the study. Mice were weighed weekly and until mice showed signs of anaemia
or lost >20% of weight at which time they were sacrificed by cervical dislocation. The
primary endpoints to be compared brtween groups were the number and location of tumours.
Result: Apc Min/+ PPAR-α-/- mice have significantly greater number of tumours in the
colon. They also tend to have more tumours in the small intestine but this increase failed
to reach significance (p>o.o5). The mean number of polyps in the colon was 2.43 (SE 0.31)
in Apc Min/+ PPAR-α-/- mice and 0.75 (0.25) in Apc Min/+ (Min) p<0001. In the small
intestine the mean numbers of tumours were 18.00 (2.26) and 15.92 (1.7) respectively (p=
ns). Conclusions: PPAR-α has a role in the formation of tumours in Apc Min/+ mice. Deletion
of PPAR-α leads to increased polyp number inthe colon. This data allied to the tumour
suppressive effects of MCP indicate a tumour suppressive role for PPAR-α in colon cancer
which may be clinically exploitable. 1. Potential role for peroxisome proliferator activated
receptor-α (PPAR-α) in preventing colon cancer. Jackson L, Wahli W, Michalik L, Watson
SA, Morris T, Anderton K, Bell DR, Smith JA, Hawkey CJ, Bennett AJ. Gut. 2003
Sep;52(9):1317-22.
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Mitochondrial DNA (mtDNA) Mutations in Helicobacter Pylori Chronic
Gastritis and Gastric Carcinoma
Ceu Figueiredo, Valdemar Maximo, Paula Soares, Jose C. Machado, Raquel Seruca,
Fatima Carneiro, Manuel Sobrinho-Simoes
Mitochondrial DNA (mtDNA) is a likely hot spot for mutations in cancer as it is preferentially
modified by many carcinogens. mtDNA alterations have been observed in various types of
tumors, including gastric carcinoma. Gastric carcinoma is considered a long-term con-
sequence of H. pylori chronic gastritis. Therefore, we aimed at elucidating the significance
of mtDNA mutations in the context of H. pylori chronic gastritis and gastric carcinoma. A
total of 150 H. pylori infected patients (99 with chronic gastritis and 61 with gastric carcinoma)
were included in this study. DNA isolated from gastric samples and matched blood or
adjacent normal tissue, was screened for mutations in mitochondrial genes encoding NADH
dehydrogenase 1, 3, 4, and 5 (ND1, ND3, ND4, and ND5), cytochrome c oxidase subunit
I (COI), ATP synthase (ATPase6), and two regions of the displacement loop (D-Loop; D310,
corresponding to a mononucleotide C repeat, and D514, corresponding to a dinucleotide
CA repeat). H. pylori vacA and cagA genotypes were determined by multiplex PCR and
reverse hybridization (LiPA). Overall, mtDNA mutations were more frequent in gastric
carcinoma (28/61; 46%) than in chronic gastritis patients (20/99; 20%) (p<0.0001). D-Loop
mutations were more frequently detected in gastric carcinoma (22/61; 36%) than in chronic
gastritis patients (17/99; 17%) (p=0.008). Both gastric carcinoma and chronic gastritis
patients harbored D310 mutations (19/61; 31% vs. 17/99; 17%, respectively), whereas D-
Loop D514 mutations were restricted to gastric carcinoma cases (9/61; 15%). In coding
genes, mutations preferentially affected complex I genes, and were more frequent in gastric
carcinoma (13/61; 21%) than in chronic gastritis (5/99; 5%) (p=0.003). ND1 mutations
were present in both groups of patients, whereas ND3, ND5, COI, and ATPase6 mutations
were gastric carcinoma specific. Mutations in coding genes were frequently transitions,
preferred targets for oxidative DNA damage. Unconditional logistic regression was performed,
with both mtDNA mutations and H. pylori genotypes being tested in the model. In the final
model, both the term for mutations in the D-Loop region, and the term for H. pylori vacA
m-region were statistically significant. The threshold of statistical significance was not attained
for H. pylori vacA s-region, H. pylori cagA, as well as for mutations in coding genes, probably
due to lack of statistical power. Altogether, these results suggest that mtDNA mutations
are frequent events in gastric carcinoma, and that these mutations are independent of H.
pylori genotypes.
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Genome Scanning Analysis Identifies Alx4 Gene Methylation As a Potential
Marker for Colorectal and Other Gastrointestinal Adenocarcinomas
Matthias Ebert, Fabian Model, Christoph Rocken, Hans-Ulrich Schulz, Peter
Malfertheiner, Cathy Lofton-Day
Background & Aims: The identification of novel genetic and epigenetic markers indicative
of changes in the pathogenesis of colon cancer along with easier to use, more sensitive assay
methods may improve the detection, treatment and overall prognosis of this malignancy.
Methods: Using Methylation Specific Arbitrarily Primed PCR a fragment of the ALX4 gene
that was highly methylated in colon adenomas and cancer was identified. Methylation of
ALX4 was analysed in colorectal cancers (n=47) and matched normal colon mucosa (n=
21), as well as in the liver metastasis of 24 patients with colorectal cancer and 61 other
neoplasias, including gastric, esophageal, hepatocellular cancer and cholangiocarcinoma.
ALX4 methylation was also analysed in the serum of 30 colon cancer patients. Results: ALX4
was more frequently methylated in primary colorectal cancers (30/47) compared to the
normal colon mucosa (0/21) (p<0.0001). In 16 of 24 colon cancer metastasis methylation
of ALX4 was also observed. In addition, ALX4 methylation was frequently observed in
adenocarcinomas of the esophagus (12/14), stomach (11/15) and bile ducts (4/5), compared
to all other cancers (p<0.001). ALX4 gene methylation was also more frequently found in
sera of colon cancer patients compared to non-cancer controls (p<0.0001) and using a cut-
off of 41.4 pg/ml sensitivity and specificity were 83.3% and 70%, respectively. Conclusions:
Apart from primary and metastatic colorectal cancers, ALX4 is frequently methylated in
adenocarcinomas of the gastrointestinal tract. ALX4 gene methylation in sera of cancer
patients may, thus, serve as a methylation-specific test for colon and other gastrointesti-
nal cancers.
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JC Virus T-Antigen Expression Is Associated the Methylator Phenotype in
Sporadic Colorectal Cancers
Ajay Goel, Meishu Li, Takeshi Nagasaka, Sung Kwan Shin, Florentine Fuerst, Luigi
Ricciardiello, C. Richard Boland
JC virus (JCV) is a polyomavirus which ubiquitously infects the human gastrointestinal tract,
where it has been implicated in carcinogenesis. JCV encodes a “transforming” antigen, T-
antigen (T-Ag), which mediates the oncogenic potential of the virus. Previous in vitro data
indicate that JCV can induce chromosomal instability (CIN) in diploid colorectal cancer
(CRC) cells. However, JCV can be found in CRCs regardless of whether or not they have
CIN. Aim: This study was designed to test the hypothesis that JCV may associate with
multiple forms of genomic instability in CRC. Methods: We characterized a cohort of 100
primary unselected sporadic CRCs for microsatellite instability (MSI) and CIN using a panel
of microsatellite markers. PCR amplifications were performed for T-Ag DNA sequences and
immunohistochemical (IHC) staining was performed to detect T-Ag expression in tissue
sections. De novo methylation of the promoter regions of nine tumor suppressor genes
implicated in CRC (hMLH1, APC, p16, p14, PTEN, TIMP3, RUNX3, HIC1 and RARβ) were
studied by a methylation-specific PCR (MSP) assay. Results: JCV T-Ag DNA sequences were
found in 77% (77/100) of the CRCs, and 56% (43/77) of these cancers (or 43% of the total)
expressed T-Ag by IHC. A significant association was observed between T-Ag expression
and CIN in the CRCs (p=0.017). Unexpectedly, T-Ag expression was slightly more frequent
in CRCs with MSI (8/15; 53%) than those without MSI (35/85; 41%, p=0.55). However,
we observed a significant association between T-Ag expression and promoter methylation
of multiple genes, including hMLH1 (p=0.01). Conclusions: The significant association
between T-Ag expression and promoter methylation in CRC suggests that the methylator
phenotype may directly contribute to genomic instability through dysregulation of methyl-
ation, or indirectly influence the MSI and CIN pathways. Taken in the context of our prior
work, the association between JCV T-Ag expression and multiple pathways of genomic
instability in CRC suggests that JCV may be involved in neoplastic transformation through
all of the mechanisms that lead to genomic instability in the colon.
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Activated Neutrophils Cause An Hmlh1-Independent G2-M Arrest and
P53ser15 Phosphorylation in Colorectal Cells
Christoph Campregher, Gloria Luciani, Christoph Gasche
Background: Chronic inflammation in the GI tract is associated with increased risk of cancer
development. This is particularly evident in ulcerative colitis (UC). Exposure of colon
epithelial cells to reactive oxygen species generated by activated polymorphonuclear neutro-
phils (PMNs) and macrophages has been implicated in carcinogenesis. DNA mutations may
occur during replication; however, the mismatch repair (MMR) system is thought to detect
replication errors and maintain DNA fidelity. Since microsatellite instability is a common
finding in colitis tissue (even without dysplasia), a relaxation of the MMR system has been
proposed. Because the molecular mechanism of the underlying pathway is incompletely
understood, we intended to simulate inflammation-driven mutagenesis in a cell culture
model. Methods: A co-culture system was developed using HCT116 (hMLH1 mutated
colorectal cancer cells) as target cells and freshly isolated human PMNs as effector cells in
6-well plates separated by a semipermeable membrane (Transwell, Costar). PMNs were
activated with PMA for 30min, ROS was measured by lucigenin-amplified chemilumines-
cence, and cells were co-cultured at various ratios (1:1 to 1:10) for 24 hours. Cell cycle
progression of HCT116 was analyzed by flow cytometry. Changes in levels of MMR proteins
(MSH2, MSH3, and MSH6), cell cycle-related protein p21Waf1 and phosphorylation of
p53Ser15,Chk1Ser345, Chk2Thr68 were detected by Western blotting. Results: PMA activa-
tion of PMNs caused an increase in extracellular ROS (about 100-fold). Co-cultivation with
PMA-activated PMNs at all ratios caused HCT116 cells to accumulate in the G2-M phase
(table). No changes in hMSH2, hMSH3, or hMSH6 were found. However, p53Ser15 was
phosphorylated and the expression of p21Waf1, a p53 target gene, was increased. Discussion:
In our co-culture model, activated PMNs induced an increase in the G2-M cell cycle phase
indicating that the production of ROS caused DNA damage. The G2-M arrest in hMLH1-
deficient cells points to the activation of an MMR-independent G2-M checkpoint. This seems
to involve p53Ser15, a site targeted by ATM or ATR kinases, that might induce expression
of p21waf1, which is an inhibitor of cyclin dependent kinases. Our system will serve as a tool
to study the molecular processes that are involved in inflammation-associated carcinogenesis
Cell cycle distribution of HCT116 cells
*P<0.05 compared to w/o PMNs
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IL-6, TNF-A and CRP Gene Polymorphisms Are Associated with Increased
Colon Cancer Risk in African Americans Compared to Whites in the North
Carolina Colon Cancer Study
Temitope O. Keku, Joseph Galanko, Seun Omofoye, Rachel Holston, Janie Peacock,
Jeffrey Barnes, Chris Martin, Robert S. Sandler
Background: Among major US ethnic groups, African Americans have the highest incidence
and mortality of colon cancer. However, critical questions remain unanswered about genetic
susceptibility to colon cancer in African Americans. Cytokines mediate immune and inflam-
matory responses, which may act in neoplastic pathways. Genetic variants that influence
cytokines levels may thus affect colon cancer risk. Aim: To evaluate IL-6 (G -174 C), TNF-
a (G -308 A), CRP (G -1081 A) genetic polymorphisms among African Americans and
Caucasian Whites in relation to the risk of colon cancer and assess interactions with lifestyle-
dietary factors. Methods: We analyzed 528 incident colon cancer cases (231 African Amer-
icans, 297 Whites) and 836 controls (306 African Americans, 530 Whites) from a large
population-based case control study in North Carolina. Controls were frequency matched
to cases on age, race and sex. Consenting subjects provided blood specimens, information
about lifestyle and diet histories, and anthropometric measurements. IL-6, TNF-a, CRP
genotypes were determined by the TaqMan assay. Logistic regression was used to calculate
odds ratio (OR) and 95% confidence intervals (CI) for variant genotypes while controlling
for potential confounders such as age, sex, non-steroidal anti inflammatory drugs (NSAIDs),
and body mass index (BMI). Results: IL-6 and TNF-a variant genotypes were significantly
associated with increased risk of colon cancer among African Americans, compared to
wildtype genotypes (IL-6 GC+CC, OR 1.7, 95% CI 1.0-2.8; TNF-a GA+AA, OR 1.6, 95%
CI 1.0-2.4), but not in Whites. However, the CRP GA+AA variant genotype showed a modest
association with colon cancer in Whites compared to wildtype (OR 1.3, 95% CI 1.0-1.8).
Interestingly, in a combined analysis with all three genes, using common wildtypes as
referent, having one or more variants was significantly related to colon cancer risk in both
African Americans and Whites (OR 1.3, 95% CI 1.0-1.6) but this association was stronger
for African Americans (OR 1.4, 95% CI 0.9-2.0; Whites OR 1.2, 95% CI 0.9-1.7). No
interactions were observed with BMI and NSAIDs use. However, the risk of variant genotypes
was greater among persons with elevated waist-to-hip ratios (WHRs). The OR for having
greater-than-median WHR plus 1 or more variants was 2.2 (95% CI 1.6-3.2), compared to
persons below median WHR having no variants. Conclusion: These results suggest that
genetic polymorphisms in IL-6, TNF and CRP strongly contribute to colon cancer susceptibil-
ity, particularly in African Americans. Supported by grants from NIH K01CA093654,
P30DK34987 and P50CA106991
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Gender Effects in Nutrient-Stimulated PYY and Ghrelin Secretion
Lukas Degen, Stefanie Graf, Sibylle Oesch, Christoph Beglinger
Background: Ghrelin and peptide YY (PYY) appear to play an important role in appetite
regulation, and their release is modulated by food ingestion. Ghrelin increases hunger and
food intake, and its levels decrease after eating. PYY decreases food intake and appetite, and
its levels increase proportionally to the amount of ingested calories. The aim of the present
study was therefore to investigate whether nutrient stimulated responses of ghrelin (suppres-
sion) and PYY (release) were modulated by gender. Methods: 20 healthy subjects (10 males,
10 females, aged 20-25 years) with normal BMI were studied on two different occasions in
a randomised order. After fasting for at least 10 hours, participants ingested the following
meals on two different days: 1) 500 kcal meal and 2) 1500 kcal meal. The meals were
identical in content (orange juice, ham sandwiches, chocolate mousse, water), but differed
in size and calories. Blood was drawn in regular intervals over 240 min for plasma ghrelin and
PYY concentrations. Hormone concentrations were determined by specific radioimmunoassay
systems. Results:(Mean ± SEM) Data were analysed using ANOVA followed by multiple
paired t-test with Bonferroni’s correction. * indicates significant difference males vs females
(p<0.05). Summary: 1) The two test meals induced a calorie-dependent, significant decrease
in ghrelin levels (p<0.01), and this decrease was modulated by sex. 2) PYY levels were
calorie-dependently increased by the two test meals; gender did not affect these responses.
Conclusion: 1) The calorie content of a test meal determines the degree of postprandial
suppression of ghrelin levels, both in males and females. 2) Healthy normal weight females
exhibit a higher ghrelin suppression after meal intake than males. We infer from these data
that ghrelin concentrations (unlike PYY) are subject to modulation according to gender.
Hormone responses to two test meals
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Alterations in Gut PDK4 and Calpain-9 Are Associated with Improved Insulin
Sensitivity Following Roux-en-Y Gastric Bypass Surgery
Edward Lin, Ih-Ping Huang, Leena Khaitan, Li Gu, Thomas R. Ziegler, C. Daniel Smith,
Nana Gletsu
BACKGROUND: Pyruvate dehyrogenase kinase-4 (PDK4) and Calpains (CAPN) are novel
hormones that affect insulin resistance. Skeletal muscle PDK4 downregulates pyruvate dehy-
drogenase activity which inhibits glucose utilization. CAPN have been shown to improve
peripheral glucose transport by facilitating GLUT4 translocation. Insulin resistance is associ-
ated with inappropriate levels of PDK4 and CAPN, and restoration of normal expression
improves insulin sensitivity. We studied the effects of roux-en-Y gastric bypass surgery
(RYGB) on gut PDK4 and CAPN-9 (gut specific) expression and its association with insulin
resistance. METHOD: Five severely obese women (BMI 49.7±1.1) were admitted to the
General Clinical Research Center for IVGTT studies at baseline and at 6 months following
RYGB. Gastric and jejunal mucosa were biopsied from identical sites at baseline and at 6
months. PDK4 and CAPN-9 gene expressions were determined using microarray analysis
and independently confirmed using RT-PCR. Results are reported as means±SEM. RESULTS:
BMI at 6 months was 36.3±1.6. Overall gastric and jejunal PDK4 expression was downregul-
ated at 6 months, while CAPN-9 was upregulated. The most significant change was seen
in a reduction in gastric PDK4 (densitometry 1.0±0.1 to 0.64±0.06, p=0.01, and an 8.7
fold decrease by microarray analysis). There was an overall 50% increase in insulin sensitivity
(Si) at 6 months. CONCLUSIONS: This is the first documentation of alterations in gut PDK4
and CAPN-9 expression following RYGB, which are associated with significantly improved
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insulin sensitivity. These changes in hormone expression may provide an additional mechan-
ism for the resolution of type-2 diabetes observed following RYGB.
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Markov Economic Model for Surgery in the Morbidly Obese
Donald Garrow, Kit Simpson, Joe Romagnuolo
Introduction: Gastric bypass surgery appears to be an effective tool for weight loss in the
morbidly obese, but is an expensive procedure. Some insurance companies and government
payers have been reluctant to fully fund this procedure. We sought to determine the cost-
effectiveness of gastric bypass surgery in the morbidly obese. Methods: We used a Markov
process to model progression of weight loss and associated costs for both surgical and non-
surgical interventions. The base-case was a 50 year old patient with a body mass index
(BMI) >40. A third-party payer perspective was used, using direct health care costs and
indirect costs related to recovery from surgery. We included literature-derived data con-
cerning BMI-specific direct costs (including physician visits, medication costs, hospitaliza-
tions, etc), transition probabilities, and quality of life (utilities), as well as competing age-
specific death rates, for both laparoscopic and open gastric bypass surgeries versus diet and
exercise with a decision tree. Indirect costs related to time lost recovering from surgery were
considered. Transitions between BMI states were modeled in 1-year transitions, over a
lifelong time horizon. Downstream health care costs and utilities were discounted at 3%
per year. Incremental cost-effectiveness ratio (ICER) calculations were planned for non-
dominant strategies. Results: Surgical therapy for obesity was dominant (less costly and
higher quality of life), therefore an ICER is not calculable (no tradeoff). The discounted
health care cost savings per patient over an expected lifetime for surgery vs. non-surgical
therapy was $21,248. However, the total procedure cost, ancillary services and hospital stay
for the initial surgery took 13 years to recoup. Over the expected lifetime, 1.5 years (dis-
counted) quality-adjusted-life-years (QALYs) were gained per patient for surgery vs. non-
surgical therapy. Sensitivity analyses revealed the model conclusions to be robust. Conclu-
sions: Surgery for the morbidly obese is a cost-effective (in fact dominant) choice for morbidly
obese subjects when lifetime healthcare costs are considered.
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Six Months Supplementation with Conjugated Linoleic Acid Decreases Fat
Mass Region-Specifically in Overweight and Obese
Jean-Michel Gaullier, Christian Syvertsen, Jo Halse, Hans O. Hoivik, Marianne O Shea,
Alexandra W. Einerhand, Ola Gudmundsen
Conjugated linoleic acid (CLA) isomers are normal constituents of fats derived from ruminant
animals and dairy products. Animal studies have demonstrated CLA to positively affect
diabetes, osteoporosis, immune function, carcinogenesis, atherosclerosis, and body composi-
tion. In humans the effects of CLA are not well established, because thus far only limited
amount of long term clinical trials with high numbers of participants have been conducted.
The present study aimed to assess the regional effects of CLA on body composition. Addition-
ally, the safety of CLA was evaluated by monitoring adverse events and all changes in blood
safety parameters, and insulin sensitivity using means of euglycemic CLAMP. In a randomized
double-blind placebo controlled trial 118 overweight and obese subjects (BMI 28-32 kg/
m2) received either 3.4g/d CLA or placebo-olive oil for 6 months. Results obtained on the
PP population demonstrate a significant reduction in body fat mass by -5.6 % (P=0.004)
for the CLA group when compared to the placebo group. Reduction of the fat mass was
already observed after 3 months (-0.7 kg, P=0.034) in the CLA supplemented group, and
the reduction was located in the legs and the abdomen of women whereas changes in men
occurred essentially in the abdomen. Waist (-3.1 cm, P<0.001) and Waist/Hip ratio (-0.024,
P=0.017) also decreased in the CLA supplemented group. Body weight and BMI reduced
relative to placebo (-1.5 kg, P=0.05 and -0.6, P=0.05 respectively). Individuals with the
highest BMI responded best to CLA. Insulin sensitivity was unaffected. In conclusion: this
study shows that CLA supplementation for 6 months in healthy, overweight and obese
adults affected body fat mass in specific regions of the body and was well tolerated.
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Regulation of Glucose-Dependent Insulinotropic Polypeptide (GIP) Expression
in Cells of Pancreatic and Intestinal Lineage
Lisa I. Jepeal, Michael O. Boylan, M. M. Wolfe
Background: GIP, a potent stimulator of insulin secretion, has been implicated in the
regulation of fat metabolism and in the pathogenesis of obesity. Because GIP appears to link
nutrient intake with adipocyte function, the regulation of GIP expression may have potential
applications in treating obesity. However, a thorough examination of GIP expression has
been hampered by difficulty in isolating GIP-producing enteroendocrine K-cells, widely
dispersed within the small intestinal mucosa. The identification of suitable surrogate cell
lines would thus be invaluable to facilitate studies examining the regulation of GIP expression.
Purpose: To elucidate the molecular mechanisms governing the regulation of GIP expression
and to identify GIP-producing cell lines to perform such studies. Methods: In addition to
the mouse intestinal cell line STC-1, which we and others have shown previously to express
GIP, 13 intestinal and pancreatic cell lines were assessed for their suitability for studies
examining GIP expression. A bioassay measuring bioactive GIP only was used to screen
cells for their ability to secrete intact GIP. RNA encoding GIP and relevant transcription
factors were detected by RT-PCR and Northern analysis, and Western analysis was employed
to measure the transcription factors. Transient transfection of GIP promoter constructs was
performed to examine GIP promoter activity, and transient transfection of a GATA-4 expres-
sion plasmid was done to assess the effects of exogenous GATA-4 expression on GIP mRNA
and secreted peptide. Results: Both STC-1 and the pancreatic cell line βTC-3 were found
to express GIP mRNA and secrete biologically active GIP. However, levels of GIP mRNA
and bioactive peptide and the activity of transfected GIP reporter constructs were significantly

















known to be important for GIP expression, PDX-1 and ISL-1, but not GATA-4, were detected.
Consistent with this result, transient transfection analysis of a GIP promoter construct lacking
the GATA-4 binding site did not appear to affect GIP promoter activity in βTC-3 cells,
although an intact binding site was necessary for high promoter activity in STC-1 cells.
Finally, exogenous expression of GATA-4 in βTC-3 cells led to marked increases in both
GIP transcription and secretion. Conclusion: Both STC-1 and βTC-3 cells synthesize and
secrete biologically active GIP and thus represent excellent cell lines to characterize GIP
expression. Moreover, our data support the hypothesis that GATA-4 may not be requisite
for GIP expression, but rather may act as an enhancer that upregulates GIP expression.
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Nutrient Stimulation of Stomach Apelin Secretion
George H. Greeley, Jason T. Reed, Ella W. Englander
Apelin is the endogenous ligand for the APJ receptor. Apelin is produced in the GI tract
and brain, the stomach is a primary production site for enteric apelin. Apelin has been
shown to influence food and water intake and cholecystokinin and insulin secretion. The
aim of these experiments was to examine the effect of different nutrient types, given directly
into the stomach, on apelin levels in the systemic circulation and in the gastric lumen.
Methods. Fasted adult SD rats were either given intragastric (IG) 5 ml dextrose (30%),
casein (5%), peptone (2%), a fatty acid (corn oil) or a triglyceride mixture. Thirty minutes after
IG administration of secretagogues, plasma was collected for extraction and concentration of
apelin with C18 Sep Paks. In a separate experiment, the gastric contents were harvested
after giving the above IG secretagogues. The solid gastric contents and supernatant were
separated by centrifugation. Apelin levels in the supernatants and plasma extracts were
measured by an apelin immunoassay. Results. IG administration of all nutrient types
increased plasma apelin levels significantly (Table). Plasma apelin levels increased 3- to 14-
fold when compared to basal levels. The order of magnitude of potency for stimulation of
apelin secretion by the various nutrients was triglycerides > casein > amino acids/fatty acid/
peptone > dextrose. IG administration of nutrients also resulted in an elevation of apelin
levels in the stomach lumen. In the gastric lumen, apelin levels increased 2- to 3-fold.
Conclusions and Discussion. Secretion of gastric apelin into the systemic circulation is
activated by all nutrient types. Triglycerides and intact protein (casein) are the most potent
secretagogues for stimulation of gastric apelin secretion. Gastric apelin is released into the
gastric lumen as well as the systemic circulation. These findings indicate that gastric apelin
may influence target tissues by systemic and luminal routes.
1 = mean ± SEM * = P<0.05 vs basal, N=5-6 rats/group.
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Hypnotic Medications Impair Nocturnal Esophageal Acid Clearance: A Double-
Blind, Placebo-Controlled Study Using Simultaneous pH Testing and
Polysomnography
Ashish P. Shah, Sidney Cohen, Karl Kwok, Susie Rivera, Nikroo Hashemi, Karl
Doghramji, Anthony J. Dimarino
BACKGROUND: Nocturnal gastroesophageal reflux (GER) can induce sleep arousals and
awakenings, which initiate protective mechanisms to clear acid from the esophagus. Pro-
longed acid contact with the esophageal mucosa is implicated in the pathogenesis of reflux-
related complications. The effect of hypnotic medications on nocturnal spontaneous acid
reflux, acid clearance time (ACT), and simultaneous sleep architecture has not been studied.
Hypnotics may impair reflux-induced arousals and awakenings, and delay esophageal acid
clearance during sleep. AIM: To evaluate the effects of the hypnotic, zolpidem, on ACT,
reflux-induced sleep arousals and awakenings, and other sleep architectural parameters.
METHODS: A total of 16 subjects were entered into the study; 8 had GER and 8 did not,
based on previous 24-hour pH testing. Subjects were randomized to zolpidem 10 mg or
placebo in a double-blind, placebo-controlled fashion and underwent simultaneous nocturnal
pH testing and polysomnography. Each subject received zolpidem and placebo on two
separate sleep study nights. Entry criteria included normal esophageal manometry, no prior
use of zolpidem or other hypnotics, and no reported history of a sleep disorder, such as
sleep apnea syndrome, periodic limb movement disorder or narcolepsy. Subjects with GER
stopped acid suppressive therapy five days prior to the study. RESULTS: The mean age
was 47.0 ± 3.9 years (mean ± SEM); 9 female, 7 male; mean BMI was 26.6 ± 1.0. In all
subjects, mean ACT increased significantly from 60.4 ± 37.0 seconds (s) with placebo, to
148.2 ± 76.2 s with zolpidem (p < 0.05). In non-GER subjects, mean ACT increased from
1.1 ± 0.3 s with placebo, to 15.7 ± 13.4 s with zolpidem. Likewise, in GER subjects, mean
ACT increased from 247.0 ± 66.4 s with placebo, to 394.0 ± 102.7 s with zolpidem. A
reflux-associated sleep awakening occurred more often with placebo (82%) than with zolpi-
dem (25%). Similarly, the reflux-induced arousal index was lower with zolpidem (18/hour)
than with placebo (22/hour). Sleep efficiency (total sleep time/time in bed) and sleep latency
(time to fall asleep) improved in 10 out of 16 subjects with zolpidem. CONCLUSIONS:
1) Hypnotic medications significantly increase nocturnal esophageal acid exposure by
impairing acid clearance in GER and non-GER subjects. 2) Hypnotic medications suppress
reflux-induced arousals and awakenings while improving sleep efficiency and latency. These
results suggest that hypnotic use may lead to, or worsen damage to the esophagus and may
cause false positive results with esophageal pH testing.
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Obesity and GERD: Is Increased Intragastric Pressure the Mechanism of
Linkage?
Sudip K. Ghosh, James G. Brasseur, John E. Pandolfino, Peter J. Kahrilas
AIM: Obesity (BMI>30) is epidemiologically linked to GERD, but the causal mechanism is
argued. Recent data show that intragastric pressure and, particularly, the median gastroeso-
phageal pressure gradient (GEPG) at inspiration, when reflux events are most likely to
occur, are significantly greater in the obese than in the non-obese (Pandolfino JE et al.
Gastroenterology; In Press). Reflux volume is also increasingly recognized as a key determinant
of GERD. Our aim was to use computer simulations to explore the mechanical significance
of the increased GEPG observed in obesity (15 vs 10 mmHg) on reflux events and reflux
volume. METHODS: Anatomic and physiologic properties of the esophagogastric junction
(EGJ) were obtained from physiological data and, along with Newton’s laws, used to develop
a computer model of the EGJ. Simulations were done to examine the sensitivities of: 1) EGJ
opening (reflux) to changes in EGJ stiffness and GEPG, and 2) reflux volume to changes in
GEPG, assuming stiffness constant. Refluxate volume was calculated for 0.5 seconds of flow.
GEPG was varied between the median values of non-obese (n=129) and obese subjects (n=
75). RESULTS: Opening of the relaxed EGJ occurred almost instantaneously (0.02-0.19 sec),
strongly driven by increases in GEPG but relatively insensitive to changes in EGJ stiffness
(Figure I). EGJ radius as well as the refluxate volume showed a strong dependency on
changes in GEPG. As GEPG increased from 10 to 15 mmHg, reflux volume increased more
than two-fold, from 6.7 to 14.1 ml (Figure II). CONCLUSION: Our computer simulations
suggest that: 1) opening of the relaxed EGJ is primarily driven by the GEPJ rather than EGJ
stiffness, 2) an increased GEPG of the magnitude observed with obesity doubles the volume
of reflux and halves the time to initiate reflux, all other variables held constant. These
findings suggest that the increased GEPG with obesity may be a key mediator in the causal
pathway linking obesity with GERD.
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Obesity: A Challenge to Esophagogastric Junction Integrity
Nimeesh Shah, John E. Pandolfino, Hashem B. El-Serag, Sudip K. Ghosh, Zhang Qing,
Peter J. Kahrilas
Background and Aims: The aim of the current study was to analyze the relationship between
obesity and the morphology of the esophagogastric junction (EGJ) pressure segment using
high-resolution manometry. Methods: 285 patients (108 males, ages 18-87) were studied.
A solid-state manometric assembly with 36 circumferential sensors spaced 1 cm apart was
placed trans-nasally and simultaneous intra-esophageal and intra-gastric pressures were
measured over 6 to 8 respiratory cycles. Separation of the LES and crural diaphragm was
quantified by measuring the distance between the two EGJ elements during inspiration. The
association between anthropometric variables and pressure values were examined using
univariate and multivariate analysis. Results: There was a significant correlation of BMI and
waist circumference (WC) with intra-gastric pressure (Inspiration, BMI (r=0.57), WC (r=
0.62) P<0.0001; Expiration, BMI (r=0.58), WC (r=0.64), p<0.0001) and gastroesophageal
pressure gradient (GEPG) (Inspiration, BMI (r=0.37), WC (r=0.43),P<0.0001; Expiration,
BMI (r=0.24), WC (r=0.26), p<0.0001). Multivariate analysis adjusting for age, gender and
the patient type did not alter the direction or magnitude of this relationship. In addition,
obesity was associated with separation of the EGJ pressure components (BMI, r = 0.17,
p<0.005; WC, r= 0.21, p < 0.001). Conclusions: Obese subjects are more likely to have
EGJ disruption (leading to hiatus hernia) and an augmented GEPG providing a perfect
scenario for reflux to occur. Whether or not weight loss can reverse these abnormalities
is unknown.
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Critical Role of Stress in Increased Esophageal Mucosal Permeability Induced
by Acid and Pepsin
Ricard Farre Marti, Pieter Vanden Berghe, Kathleen Blondeau, Jan Tack, Jozef Janssens,
Daniel Sifrim
In patients with non-erosive reflux disease (NERD), heartburn is thought to occur when
acid reaches sensory nerve endings through mucosal dilated intercellular spaces (DIS)(Bar-
low&Orlando 2005). Stress or anxiety may increase heartburn perception, and this is
attributed to central or peripheral hypersensitivity. In the rabbit esophagus, perfusion of
acid and pepsin induces DIS and increases mucosa permeability. In the rat, acute stress
increases gastric and intestinal mucosa permeability. We hypothesized that stress might also
increase esophageal mucosa permeability and thereby, enhances acid induced esophageal
symptoms. Aim: To evaluate the effect of acute immobilization stress (AIS) on esophageal
mucosa permeability in rats. Methods: Male Sprague-Dawley rats were handled daily for
one-week prior to study. Stressed rats were placed in a harness for 2h, followed by 2h of
free movements in their home cage. Control rats were maintained in their home cage for
4h. Rats were euthanized and segments from esophagus and ileum (15x8mm) were removed
and mounted in diffusion chambers. Mucosal permeability was assessed by measuring the
mucosa-to-serosa passage of FITC-dextran 4 KDa (FD4) and 20 KDa (FD20). The tissue
was pre-incubated for 30 min with Krebs pH 7.2 or HCl pH 2.0 + pepsin 1 mg/mL in the
mucosal side. Permeability was expressed in mmols of FD obtained at the serosal side after
incubation for 30, 60, 90 and 120 min. Results: The stress protocol was effective: AIS
increased the fecal output for 4 hr (4.14±0.7 vs 10±1.7, N=7 P<0.01); increased glucose
concentration by 24±5.4 %, (N=7, P<0.01) and increased small intestinal permeability to
FD 20 (ANOVA P<0.0001). Esophageal mucosa permeability increased in stressed rats only
when the tissue was pre-incubated in HCl + pepsin solution both to FD4 (ANOVA P=0.004,
N=5, n=10) and to FD20 (ANOVA P<0.0001, N=5, n=10), reaching significant differences
at 60, 90 and 120 min. The increase at 120 min was from 0.70±0.27 to 3.80±1.35 pmols,
(P<0.01). Esophageal mucosa from stressed rats did not show changes in permeability when
the tissue was preincubated in normal Krebs solution and esophageal mucosa permeability
was not increased by HCl+pepsin in control rats. Conclusions: In rats, acid-pepsine alone
or stress alone do not induce significant changes in esophageal mucosa permeability. In
contrast, esophageal acid-pepsin exposure in stressed animals has a dramatic effect on
mucosal permeability. These results suggest that stress plays a critical role in the acid-pepsin-
induced increase in esophageal mucosa permeability. We propose that this mechanism may
contribute to stress-influences on heartburn symptoms in man.
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Production of IL-6 and IL-1β in GERD-Associated Human Esophagitis: Impact
On Esophageal Motility
Florian Rieder, Ling Cheng, Manijeh H. Phillips, Gail A. West, Weibiao Cao, Michael V.
Sivak, Piero Biancani, Claudio Fiocchi
Introduction: Gastroesophageal reflux disease (GERD) is associated with abnormal eso-
phageal motility, and the presence of active esophagitis may contribute to motor disturbances.
Various inflammatory mediators can alter esophageal muscle contraction in vitro, including
the proinflammatory cytokines IL-6 and IL-1β. However, essentially no information is
available on the production of such cytokines in inflamed human esophageal tissue and
their cellular sources. Therefore, we investigated the presence of these cytokines in esophageal
biopsies, their cellular sources, and impact on esophageal motility in vitro. Methods: Endos-
copic mucosal biopsies were obtained from the upper, middle and lower third of the
esophagus of patients with and without endoscopic evidence of esophagitis. Biopsies were
organ-cultured overnight and undernatants recovered for measurement of cytokines. The
profile of cytokine production by esophageal epithelial and mesenchymal cells was assessed
in supernatants of the human esophageal squamous epithelial cell line HET-1A and primary
human esophageal mesenchymal cells isolated from surgical specimens. Cytokines were
measured by ELISA and mRNA determined by rtPCR. Super- and undernatants were used
for in vitro esophageal muscle contraction assays. Results: IL-6 was present in all control
and inflamed biopsy undernatants. IL-1β was detected exclusively in biopsies with severe
esophagitis. In esophagitis patients the amount of IL-6 found in the lower third was ten
times as high as that of control subjects (*p<0.01), and also higher (*p<0.01) than that
found in the upper and middle thirds of the same patients. HET-1A cells and primary
esophageal mesenchymal cells spontaneously secreted IL-6 in low amounts, which increased
remarkably after stimulation with IL-1β or IFN-γ+PMA. IL-1β was only detected at the
mRNA level. Both the undernatants of esophageal biopsies and supernatants of primary
cell cultures reduced in vitro esophageal muscle contraction in response to electrical field
stimulation. Conclusion: Production of IL-6 and IL-1β is significantly elevated in the
inflamed esophagus of GERD patients, and esophageal epithelial as well as mesenchymal
cells are sources for IL-6. IL-6 directly influences esophageal motor function inducing changes
that mimic those found in experimental cat esophagitis. These results suggest a direct
link between the inflammatory mediators produced in reflux esophagitis and the motor
disturbances associated with this condition.
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Body Mass Index Is Associated with Gastroesophageal Reflux Symptoms in
Both Normal Weight and Overweight Women
Brian C. Jacobson, Samuel C. Somers, Charles S. Fuchs, Ciaran P. Kelly, Carlos A.
Camargo
Background: Overweight and obese individuals are at increased risk for gastroesophageal
reflux disease (GERD). An association between body mass index (BMI) and reflux symptoms
among normal weight individuals has not been demonstrated. Methods: In 2000, a supple-
mental questionnaire was used to determine the frequency, severity, and duration of GERD
symptoms among randomly-selected participants of the Nurses’ Health Study, a cohort study
of 121,700 registered nurses begun in 1976. After categorizing women by BMI as measured
in 1998, we used age- and multivariate-adjusted logistic regression models to study the
association between BMI and GERD symptoms (heartburn and/or acid regurgitation). Heart-
burn was defined as “a burning pain or discomfort behind the breast bone in your chest”
and acid regurgitation was defined as “a bitter or sour-tasting fluid coming into your throat
or mouth.” Results: Among 10,545 women who completed the questionnaire (86% response
rate), 6,215 (59%) reported experiencing at least one episode of GERD symptoms in the
previous year and 2,310 (22%) reported symptoms at least once a week (frequent reflux).
The majority (55%) described their symptoms as moderate in severity, while 303 (4.5%)
thought their symptoms were sufficiently severe to affect their lifestyle. We observed a dose-
dependent relationship between increasing BMI and frequent reflux symptoms (multivariate
P for trend <0.001). Compared to women with BMI 20-22.49 kg/m2, the multivariate odds
ratios (OR) were 1.38 (95% CI 1.13-1.67) for a BMI of 22.5-24.9; 2.20 (95% CI 1.81-2.66)
for a BMI of 25-27.4; 2.43 (95% CI 1.96-3.01) for a BMI of 27.5-29.9; 2.92 (95% CI 2.35-
3.62) for a BMI of 30-34.9 and 2.93 (95% CI 2.24-3.85) for a BMI of 35 or greater. Women
in the lowest BMI category (<20) had less risk for frequent GERD symptoms than those
with BMI 20-22.49 (multivariate OR 0.67; 95% CI 0.48-0.93). A similar trend was seen
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across all degrees of symptom severity and duration and for the association between waist-
to-hip ratio and GERD. Among women who experienced a gain in weight over the previous
14 years, a dose-dependent increase in risk of symptoms was observed. However risks were
significantly decreased among women who lost weight during the same time period, with
a nearly 40% reduction in risk of frequent GERD symptoms among those with a decrease
in BMI of more than 3.5 kg/m2 (OR 0.64; 95% CI 0.42-0.97 compared to women without
a change in BMI). Conclusion: BMI is directly associated with GERD symptoms in both
normal weight and overweight individuals. This suggests that even modest weight gain
among normal weight individuals may cause or exacerbate reflux symptoms.
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Chemicals Formed from the Gastric Acidification of Salivary Nitrite Influence
Oesophageal and Gastric Function
Jonathan J. Manning, Angela Wirz, Kenneth E. McColl
Introduction: Saliva contains high concentrations of nitrite derived from the enterosalivary
recirculation of dietary nitrate and its reduction by buccal bacteria. Acidic gastric juice
converts the nitrite in saliva to varying proportions of nitrous acid and nitric oxide, determined
by vitamin C availability. In vitro nitric oxide (NO) and nitrous acid relax the smooth muscle
of the stomach, lower oesophageal sphincter (LOS) and oesophageal body. Neuronally
generated NO plays a major role in upper gastrointestinal motility and contributes to the
pathophysiology of GORD. Aim: To determine whether luminal administration of NO or
nitrous acid alters oesophageal or gastric function. Method: 15 Helicobacter Pylori negative
healthy volunteers were studied on 3 separate days. A water-perfused manometry catheter
was placed across the lower oesophageal sphincter (LOS) after a meal, to record oesophageal,
LOS and gastric pressure and transient lower oesophageal sphincter relaxations (TLOSRs).
Two pH probes were placed in the oesophagus to record reflux events. A submental swallow
sensor was also positioned. On each day, one of three solutions was infused, for one hour,
into the region of the LOS. These were 1) Control solution of hydrochloric acid pH1.0
(HCl), 2) HCl pH1.0 plus nitrite 1.6mM ie: nitrous acid and 3) HCl pH1.0 plus nitrite
1.6mM, plus ascorbic acid 5mM to generate NO. The manometry catheter channels were
used as both a delivery system for the test solutions and also as a recording system for the
manometry data. Solutions were randomised and double-blinded. Duration of pH<4 was
assessed for each pH probe. TLOSR frequency was also quantified as well as the effect on
intragastric pressure during the infusion. Results: The NO solution gave a significantly
increased oesophageal acid exposure, 62.2%, compared to both control 37.5% (p<0.03)
and nitrous acid, 36.6% (p<0.002). The frequency of TLOSRs was also significantly increased
by the NO solution (5.2/hour) compared to both control (3.5, p<0.01) and nitrous acid
(3.1, p<0.0001). There was also evidence of impaired oesophageal clearance of acid refluxate
following the NO infusion. During the nitrous acid infusion the intragastric pressure was
3.4mmHg lower than the control (p<0.03) indicating loss of gastric smooth muscle tone.
Conclusion: Luminal chemicals formed from the acidification of salivary nitrite influence
both oesophageal and gastric motility and may contribute to the aetiology of disorders
associated with disturbed gastric and/or oesophageal motility.
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Cardiovascular Outcomes from a Long-Term Randomized Colorectal Adenoma
Chemoprevention Trial of a Once-Daily Dose of Celecoxib
Nadir Arber, Scott Solomon, Janet Wittes, Maria Lechuga, Paola Gerletti, Katie
MacDonald, Craig Eagle, Marc Pfeffer, John McMurray, Robert Fowler, Peter Finn, Ann
Zauber, Frank Ruschitzka, Bernard Levin
Background: The cardiovascular safety of specific cyclooxygenase-2 (COX-2) inhibitors is
currently of concern, with only limited data available from placebo-controlled clinical trials.
Methods: The PreSAP study is an international (32 countries), multi-center (106), placebo-
controlled, randomized, double-blind trial designed to measure the effect of three years of
treatment with celecoxib on the risk of recurrent adenomatous polyps in individuals with
a prior history of polyps. Patients (n=1,561) with a history of colorectal adenomas were
randomized in a 3:2 ratio, 933 to receive celecoxib (400 mg once a day) and 628 to receive
placebo. An external adjudication committee reviewed all serious adverse events and deaths
in a blinded fashion, categorizing each event as cardiovascular or non-cardiovascular. Non-
fatal cardiovascular events were categorized according to a pre-specified scheme. An external
statistician analyzed the data in an intent-to-treat framework. Results: During a mean of
32 months of observation (83 percent and 54 percent of patients had at least 24 or 36
months of safety data, respectively), a composite cardiovascular end point of death from
cardiovascular causes, myocardial infarction, stroke, or heart failure occurred in 12 (1.9
percent) and 22 (2.4 percent) of patients in the placebo and celecoxib group, respectively
(hazard ratio 1.2; 95 percent confidence interval 0.6 to 2.5). Conclusion: Celecoxib at a
dose of 400 mg once a day did not significantly increase either the short- or long-term risk
of serious cardiovascular events (cardiovascular death, myocardial infarction, stroke, or heart
failure) in patients with a history of colorectal adenomas; however, the small number of
events limits our ability to exclude a hazard of the magnitude reported for other randomized
trials of this class of drugs.
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Comorbidity and Colorectal Cancer Screening Utilization in a National
Sample of Veterans Health Administration Patients
Deborah A. Fisher, Joseph Galanko, Tara K. Dudley, Nicholas J. Shaheen
Objectives: Quality assessment of colorectal cancer (CRC) screening in the Veteran Health
Administration (VHA) system relies on reporting the proportion of patients aged 52-80 years
screened. This approach does not assess for comorbid illnesses that may impact a patient’s
suitability for screening. The Charlson-Deyo score, which can be calculated from administrat-
ive data, is a predictor of mortality. Our primary aim was to determine the relationship

















(FOBT) in the national VHA database. Our secondary aim was to test the validity of the
Charlson-Deyo score as a predictor of 1-year mortality in VHA. Methods: We examined the
national VHA administrative databases (October 2003- February 2005) for a random sample
of 86,785 primary care patients, aged ≧50. Charlson-Deyo score was calculated. The associ-
ation between Charlson-Deyo score and mortality was assessed using chi squared analysis.
Using logistic regression, we also assessed the relationship between comorbidity, and the
likelihood of receiving CRC screening. Models were adjusted for age and sex. Results: The
sample was 97% men; mean age was 67 years. Charlson-Deyo score was 45%=0, 24%=1,
14%=2, 7%=3, 3%=4, 2%=5, 1%=6, 3%≧7. Overall there was no significant association
between Charlson-Deyo score and whether or not an FOBT was performed. There was a
strong and incremental relationship between Charlson-Deyo score and 1-year mortality.
There was no association between FOBT status (performed or not) and 1-year mortality
within any of the Charlson-Deyo score categories. Conclusions: In the VHA system, patients
with severe comorbidity undergo FOBT screening as frequently as healthy patients. Substan-
tial effort is being directed toward screening patients with an increased likelihood of dying
from competing causes. Further, there was no evidence providers selectively screened the
healthiest patients within each Charlson-Deyo score category. The current “one-size-fits-all”
quality measurement for CRC screening in the VHA may promote inappropriate screening
in ill patients, and does not emphasize screening in those with the most life-years at stake.
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The Impact of Literacy On Colonoscopy
Rony Ghaoui, Arthur T. Evans, Bashar M. Attar
Background and Aims Approximately 20-30% of attempted colonoscopies are incomplete
because of poor bowel preparation. This problem is not only costly and wasteful, but
increases risks and delays diagnosis and treatment. Although literacy skills are necessary for
patients to successfully follow home bowel preparation instructions, they are nearly imposs-
ible to assess informally. Our aim was to evaluate the impact of literacy on bowel preparation
and completion of colonoscopy, with the ultimate objective of redesigning instructions to
be more effective, regardless of patients’ literacy skills. Methods We performed a prospective
cohort study at a large urban public hospital during the summer of 2005 among patients
who presented for outpatient colonoscopy. Before the colonoscopy, literacy was assessed
using the 7-minute test of functional health literacy. Using structured interviews, we also
gathered information on patients’ past history, beliefs, and self-reported behaviors on bowel
preparation. Results of the colonoscopy were obtained from the procedure reports. Results
The sample of 195 subjects included 64% women, 49% African Americans, and 40% with
low literacy skills. 25% of colonoscopies were not completed, primarily (90%) because of
poor bowel preparation. Low literacy increased the risk of an incomplete exam 4-fold: 12
% incomplete exams among patients with adequate literacy skills compared to 45% with
low literacy skills (p<0.001). Other important predictors of an incomplete exam were: eating
lunch or dinner the previous day, not taking the bisacodyl (p=0.001), and not finishing the
1-gallon polyethylene glycol solution (p=0.01). Patients with a past history of colonoscopy
(p=0.03) and those who received additional oral instructions from a physician or nurse (p=
0.05) were more likely to have a complete colonoscopy. Low literacy remained the strongest
independent predictor of incomplete colonoscopy after controlling for the contribution of
all other factors (OR=8.7; 95% CI: 3.4-22.1; p<0.001). Discussion/Conclusion Low literacy
accounts for 30% of all incomplete colonoscopies. This important effect is independent of
age, gender, ethnicity, and even whether oral instructions supplemented the written instruc-
tions. In light of these findings, we must redesign our methods of instructing patients about
bowel preparation in order to improve the efficiency and effectiveness of colonoscopy.
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Vertebral Fracture Prevalence in Crohn’s Disease: Patients with or Without
Decreased Bone Mineral Density
Jesse S. Siffledeen, Kerry Siminoski, Ho Jen, Richard N. Fedorak
Introduction: Vertebral fracture prevalence in patients with Crohn’s disease (CD) suggests
a frequency of between 14 and 22%. However, most studies have limited the patient
population to those with low bone mineral density (BMD) and have not examined the
occurrence of vertebral fractures in CD patients with normal BMD. Objective: Our primary
objective identified the prevalence of vertebral fractures in a representative cohort of CD
patients. Our secondary objective identified clinical and biochemical factors associated with
these fractures as risk predictors of vertebral fractures in CD patients. Patients & Methods:
225 patients with active or quiescent CD were recruited and underwent BMD analysis, as
well as thoracic and lumbar spine radiographs. Vertebral fractures were identified by two
methods of radiographic assessment: First, quantitative height reduction morphometry on
vertebrae T2-L2, (six points on each vertebra), was recorded as the lowest ratio of these
measures compared to the greatest posterior vertebral height. Second, spinal fracture index
(SFI) assessed vertebral fracture severity by visual estimation of vertebral height reduction
and morphologic change. Vertebrae were graded as normal, mildly deformed (Grade 1:
reduction of 20-25% vertebral height and 10-20% of projected vertebral area), moderately
deformed (Grade 2: 26-40% height reduction and 21-40% of projected vertebral area), or
severely deformed (Grade 3: >40 % reduction in height and area). Results: 44/225 (19.6%)
patients demonstrated 84 vertebral fractures (SFI ≥ 1), with a mean age of 40.6 ± 11.0
years. Sixty percent reported corticosteroid (CS) use in the preceding year. 16/44 patients
with vertebral fractures had normal BMD (19.0% of all patients with normal BMD). Comparat-
ive analysis between patients with or without vertebral fractures did not demonstrate any
significant differences in BMD of the lumbar spine or hip, or in reported CS use. Linear
regression analysis demonstrated that elevations in body mass index, C-reactive and parathy-
roid hormone significantly predicted vertebral fractures (SFI grades I-III, r = 0.415, p <
0.05 and height reduction > 20%, r = 0.417, p < 0.05). Conclusion: This study is the first
to demonstrate that vertebral fractures in CD patients occurs with an equal frequency in
those with low and normal BMD. The mean age of CD patients with vertebral fractures was
much lower than that reported in the general population. The ability of elevations in BMI,
CRP and PTH to predict vertebral fractures in CD patients suggests that sedentary lifestyle,
inflammatory activity and metabolic bone disease play an important role in their pathogenesis.
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Risk of Pancreatic Adenocarcinoma and Hereditaty Pancreatitis: The First
National Cohort in France
Vinciane Rebours, Marie Christine Boutron-Ruault, Claude Ferec, Dermot O'Toole,
Matthieu Schnee, Frederique Maire, Pascal Hammel, Philippe Ruszniewski, Philippe Levy
Hereditary pancreatitis (HP) is an autosomal dominant disease caused by a mutation in the
cationic trypsinogene gene (PRSS1). Chronic pancreatitis (CP) is a known risk factor of
pancreatic adenocarcinoma (PA) with a standardized incidence ratio (SIR) of 27. The fre-
quency of pancreatic cancer in the inherited type of pancreatitis is uncertain. Aims: To
evaluate the incidence of the PA in extensive French national series of patients with HP and
to search for risk factors. Patients (pts) and methods: A cohort comprising all French HP
pts was constituted by contacting all French gastroenterologists and pediatricians (response
rate: 84 %) and genetics laboratories (response rate: 100 %). Inclusion criteria were the
presence of PRSS1 gene mutation, or CP in at least 2 first-degree relatives, or 3 second-
degree relatives, in the absence of another cause of CP (notably, alcohol). CFTR and SPINK
1 gene mutations were also systematically examined. Diagnosis of PA was based on histological
examination. Results: The historical cohort included 78 families and 200 pts of whom 181
were alive. It represented 6673 person-years (median number of generation: 3, males: 53%,
chronic alcoholism: 5%, tobacco intoxication: 34%). At time of inclusion, the median age
was 30 y (range: 1-84). PRSS1 mutations were present in 68% (R122H: 78%, N29I: 12%,
others: 10%). SPINK1 and CFTR mutations were present in 13% and 2%, respectively.
PRSS1 inheritance was maternal for 65%. 10 PA were diagnosed (6 males) at a median age
of 55 y (range: 39-78). The SIR of PA for the cohort, the males, and the females was 87
(42-113), 69 (25-150) and 142 (38-225), respectively. At 50, 60 and 75 y, the cumulated
risk of PA was 11%, 16% and 49% for males and 8%, 22% and 55% for females, respectively.
The risk of PA for smokers at age 75 y was 61% and 70% for males and females, respectively.
19 patients died, 8 from PA (42%). The cause of death was known for all the patients except
one. Conclusions: Patients with HP have a markedly increased risk of pancreatic cancer
(SIR: 87) compared with the general French population. This may be explained in part by
the long exposure time to CP. There is no correlation between this risk and the PRSS1
genetic status but the PA is highly linked with the tobacco intoxication. PA is the first cause
of death in patients with HP.
386
Risk Factors for Esophageal and Gastric Adenocarcinoma
Crane J. Sarah, G R. Locke, Yvonne Romero, William S. Harmsen, Diehl N. Nancy, Alan
R. Zinsmeister, Lee J. Melton, Nicholas J. Talley
Background: Some have suggested that increased use of acid suppressing drugs explains the
increasing incidence of distal esophageal cancer. Database studies are flawed because the
esophagogastric junction (EGJ) and the proximal stomach cannot be discriminated. Hence
it is unclear whether these two sites share similar risk factors or reflect different at-risk
populations. Aim: To evaluate risk-factors associated with esophageal and gastric adenocarci-
noma in a population-based, case-control study. Methods: The data resources of the Rochester
Epidemiology Project were used to identify all cases of gastric and esophageal adenocarcinoma
in Olmsted County, Minnesota between 1971 and 2000. Cases were categorized as eso-
phageal, EGJ, proximal stomach, distal stomach and diffuse. An age and sex matched control
group was identified from Olmsted patients seen for evaluation during the same time period.
A complete medical record review was conducted, including histology, radiology, endoscopic,
autopsy, operative, inpatient and outpatient records and reports. Risk factors, including a
history of gastroesophageal reflux disease (GERD), duodenal or gastric ulcer, acid-suppressing
medication use, BMI>30, tobacco, alcohol abuse, other cancer diagnosis, family history of
esophageal or gastric cancer, previous cholecystectomy and blood type were assessed using
a conditional logistic regression analysis, reported as (OR [95% CI]). Results: A total of 186
cases of esophageal and gastric adenocarcinoma were identified. Of these, 29 were esophageal,
36 were EGJ, 27 were proximal gastric, 75 were distal and 19 were diffuse. Incidence rates
in this population demonstrated a significant increase in esophageal adenocarcinoma from
0.4 to 2.5 per 100,000 py over this time period. A history of GERD was significantly
associated with esophageal (OR=5.5 [1.2,24.8]) and EGJ (OR=13[1.7,99.3]) cancer but not
with proximal gastric cancer. PPI use was not associated with esophagus and EGJ cancer
combined (OR = 5.0, 95% CI [0.6,42.8]). No significant risk factors for proximal or diffuse
gastric cancer could be detected, though sample sizes were small. A history of gastric ulcer
and a BMI>30 were associated with distal gastric cancer (OR=12.0[1.6,92.3]) and (OR=
2.7[1.0,6.8], respectively). Conclusions: Esophageal and EGJ adenocarcinoma are signific-
antly associated with GERD. Proximal gastric adenocarcinoma appears to have a different
risk factor profile suggesting a different disease pathogenesis. Supported in part by an ACG
research award.
406
Co-Localization of Lysosomal Hydrolases with Digestive Enzyme Zymogens in
Acinar Cells During Pancreatitis Is Not Dependent Upon Digestive Zymogen
Activation
Gijs J. Van Acker, Eric R. Weiss, Michael L. Steer, George Perides
Background: Digestive enzyme zymogens become co-localized with lysosomal hydrolases
within acinar cell cytoplasmic vacuoles and digestive zymogens become activated within
acinar cells during the early stages of experimental pancreatitis. We have previously hypothes-
ized that the co-localization phenomenon leads to zymogen activation by facilitating cathepsin
B-catalyzed activation of trypsinogen but others have argued that the co-localization phenom-
enon might be the result, rather than the cause, of zymogen activation. The current studies
were designed to resolve this controversy. Methods: Mice were given tail-vein injections of
CA-074 me (5 mg/kg) 1 hour prior to induction of pancreatitis to inhibit cathepsin B activity
and then acute pancreatitis was induced by administration of hourly i.p. caerulein injections
(50 µg/kg). The co-localization phenomenon was monitored using the techniques of both
sub-cellular fractionation and immunohistochemistry. For the former, pancreas samples were
subjected to differential centrifugation while the activities of amylase and aryl sulfatase (a
lysosomal hydrolase) were tracked using specific substrates. In vivo immunohistochemistry
studies were accomplished using confocal microscopy and antibodies directed against amylase
and the lysosomal membrane protein LAMP-1. F-actin distribution was determined by
phalloidin staining. JNK activation was evaluated by immunoblot and AP-1 activation by
EMSA. Results: In vivo cathepsin B activity was completely inhibited by administration of
CA-074 me and, under these conditions, supramaximal stimulation with caerulein did not
lead to intrapancreatic activation of trypsinogen. In contrast, inhibition of cathepsin B activity
and prevention of caerulein-induced trypsinogen activation did not interfere with either the
caerulein-induced co-localization phenomenon or with other caerulein-induced responses
including redistribution of sub-apical f-actin, activation of JNK, and activation of AP-1.
Conclusion: Our results indicate that trypsinogen activation is not a pre-requisite for induc-
tion of the co-localization phenomenon or for either f-actin redistribution or pro-inflammat-
ory factor activation. Our studies exclude the possibility that the co-localization phenomenon,
f-actin redistribution, and pro-inflammatory factor generation are the result of digestive
zymogen activation and they support the hypothesis that the co-localization phenomenon
leads to zymogen activation during pancreatitis. Supported by NIH grant R01-31396
407
Transgenically Elevated Basal Levels of Nf-κB Increase Pancreatic Sensitivity
to Injury and Pancreatitis Severity
Baoan Ji, Jian Song, Craig D. Logsdon
Background & Aims: NFκB activation in pancreatic acinar cells is an early event in experi-
mental pancreatitis models. However, the role of NFκB in this disease is still uncertain.
Pharmacological inhibition has not been able to differentiate the specific effects of NFκB
because the inhibitors have non-specific actions. Adenoviral mediated gene transfer of the
p65 subunit of NFκB was previously found to induce pancreatic inflammation, but suffers
from the potential non-specific effects of viral infection. Therefore, in the current study, we
utilized a transgenic approach to investigate the role of NFκB activation in pancreatitis.
Methods: A transgenic mouse line was created with the CMV-chicken beta actin chimeric
promoter followed by loxP sites flanking GFP-Stop and p65 (Floxed-p65). This construct
expresses GFP throughout the animal but activation of Cre leads to removal of the GFP-
Stop cassette and allows expression of p65. These animals were crossed with a Pdx1-Cre
mouse, to drive the expression of p65 specifically in the pancreas. Pancreatitis was induced
by twelve hourly injections of caerulein (50ug/kg) or JMV180 (1mg/kg). Serum amylase,
pancreatic edema and histology were evaluated. Results: GFP was expressed throughout
the floxed-p65 mice and this expression was greatly diminished in the acinar cells of double
transgenic floxed-p65/Pdx1-cre mice indicating efficient recombination. The p65 subunit
was expressed in the pancreas from double transgenics as shown by Western blot. Despite
obvious over-expression of p65 in acinar cells there were no changes in pancreas size, weight
or histology in double transgenic animals. This was likely due to a compensatory negative
feedback mechanism involving p65 mediated increases in IκB-α that was observed in these
animals. However, animals with high levels of p65 responded to treatments with caerulein
with much greater severity of pancreatitis as indicated by higher levels of edema, inflammatory
cell infiltration and acinar cell damage than controls. Furthermore, JMV180, a CCK analog
that does not cause pancreatitis in wild type mice, caused pancreatitis in double transgenic
mice. Conclusions: Developmental alterations in p65 expression lead to compensatory
changes in other pathway regulators. However, elevated levels of basal NFκB determine the
sensitivity and severity of the proinflammatory response in acute pancreatitis.
408
Double-Edged Role for Relap65 in Acute Experimental Pancreatitis: Relap65
Protects Local Tissue Damage, But Promotes Systemic Complications
Following Acute Pancreatitis
Hana Alguel, Hassan Nakhai, Dieter Saur, Stephan Paxian, Marina Lesina, Matthias
Treiber, Roland M. Schmid
NF-kB/Rel activation has been shown to be activated during acute experimental pancreatitis.
In several studies the inhibition of NF-kB/Rel activation has been associated with attenuated
inflammatory response and severity of pancreatitis. Although previous studies suggest a
deleterious effects of activated NF-kB/Rel in acute experimental pancreatitis, there is still
disagreement about its effect in acinar and infiltrating cells. RelAp65 knockout mice have
been shown to be embryonic lethal due to pronounced apoptosis of hepatocytes. Therefore
we used the Cre/lox-system to inactivate RelAp65 (floxed RelAp65) specific in the pancreas
and infiltrating cells analysing its role in acute inflammation. Crossing the floxed RelAp65
mouse with the p48Cre and Lysozyme-Cre mice we were able to generate a mouse producing
truncated RelAp65 either in the pancreas or pancreas and myeloid cells. This truncated
RelAp65 is incapable of translocating into the nucleus, binding DNA or even forming dimers
as it has been analysed in electromobility shift assays. Following cerulein challenge mice
lacking functional RelAp65 in the exocrine part of the pancreas develop severe necrotizing
pancreatitis which is associated with enhanced necrosis and apoptosis compared to floxed
control animals. Severe inflammation in the pancreas lead to systemic complications involving
liver as well as lung. Impaired upregulation of Bcl-xL and PAP I were responsible for
apoptosis and necrosis in the pancreas. Lentiviral mediated transfer of PAP I into the pancreas
protected acinar cells from necrosis, but not from apoptosis. Moreover, additional deletion
of RelAp65 in macrophages and granuloyctes rescued systemic complications, but did not
alter local damage. These data suggest that activation of RelAp65 in acinar cells is a critical
event involved in a cascade of mechanisms following acute pancreatitis. Its inactivation
increases acinis susceptibility to inflammation-associated apoptosis and necrosis. Therefore
RelAp65 in the pancreas protects apoptosis via upregulation of Bcl-xL and necrosis via
induction of the acute phase protein pancreatitis-associated-protein I (PAP I) during acute
inflammation, but promotes systemic inflammation and lung failure when activated in
myeloid cells. Therefore we suggest a double-edged role for NF-kB/Rel during acute pancreat-
itis.
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Proteolytic Cleavage and Inactivation of Human Pancreatic Secretory Trypsin
Inhibitor (SPINK1) By Cathepsin B
Thomas Wartmann, Thilo Kaehne, Hans-Ulrich Schulz, Miklos Sahin-Toth, Markus M.
Lerch, Walter Halangk
Trypsinogen activation represents an early event in the pathogenesis of acute pancreatitis.
We and others have shown that cathepsin B can act as a trypsinogen activating enzyme via
limited proteolysis of the trypsinogen activation peptide. Here we have studied whether
cathepsin B can also affect the inhibition of activated trypsin by its physiological inhibitor
SPINK1 (PSTI). The human SPINK1 gene was cloned into the pET SUMO vector and
expressed in the E. coli strain BL21 (DE3). Molecular masses of native and cleaved SPINK1
were determined by MALDI-TOF mass spectrometry. Cleavage was followed by SDS-PAGE
and staining of purified SPINK1 protein. Western blotting was used to demonstrate degrada-
tion of SPINK1 in homogenates of pancreatic tissue incubated with cathepsin B. Activity of
SPINK1 was measured by inhibition of trypsin in a fluorometric assay. Recombinantly
expressed SPINK1 had a M.W. of 6,247 Da, and inhibited human cationic as well as anionic
trypsin. Incubation of homogenates from human pancreas with cathepsin B resulted in a
rapid decrease of the SPINK1 protein band on Western blots. This cleavage was insensitive
to a benzamidine-type protease inhibitor indicating that SPINK1 degradation was not cata-
lyzed by trypsin generated from trypsinogen activation by cathepsin B. Rather, SDS-PAGE
demonstrated that the incubation of SPINK1 with human cathepsin B led to rapid degradation
of the SPINK1 protein band. MALDI-TOF mass spectrometry of SPINK1 incubated with
cathepsin B at pH 5.5 demonstrated a reduction of the 6.25 kDa peak. The intermediate
appearance of peaks at 4.99 and 4.03 kDa indicated cleavage sites at positions R67-Q68
and C32-Y33 of SPINK1. Our results show that cathepsin B can affect trypsinogen activation
via two independent mechanisms in pancreatic acinar cells: i) as shown previously via limited
proteolysis of the trypsinogen activation peptide and ii) as shown here via inactivation of
the physiological trypsin inhibitor SPINK1. The latter of the two mechanisms has the potential
to be of much greater consequence since it would promote, unlike the first mechanism,
trypsinogen autoactivation in a cascade-like manner.
410
Ethanol Sensitizes Pancreatic Acinar Cells to Nf-κB Activation Through
Activation of Protein Kinase C Epsilon
Akihiko Satoh, Anna S. Gukovskaya, Joseph R. Reeve, Ilya Gukovsky, Stephen J. Pandol
Background & Aims: Although alcohol abuse is the most common cause of pancreatitis,
the mechanisms of alcohol’s effects on pancreas are poorly understood. Previously we
demonstrated that both in vitro and in vivo, ethanol treatment augments the cholecystokinin-
8 (CCK) induced activation of the transcription factor NF-κB, a key signaling system mediat-
ing the inflammatory response of pancreatitis. We further determined that protein kinase
C (PKC) novel isoforms δ and ε are involved in NF-κB activation by CCK in pancreatic
acinar cells. The aim of the present study was to determine the role for individual PKC
isoforms in the sensitizing effect of ethanol on CCK-induced NF-κB activation in pancreatic
acinar cells. Methods: Dispersed rat pancreatic acini were treated for 3 h with and without
100 mM ethanol (EtOH), and then stimulated with CCK for 30 min. We determined PKC
activation and translocation by isoform-specific kinase assays and by measuring the levels
of PKC isoforms in membrane and cytosolic fractions with Western blot. NF-κB binding
activity was measured by electrophoretic mobility shift assay. To evaluate the roles of
individual PKC isoforms in NF-κB activation, we applied PKC isoform-specific peptide
inhibitors and activator. Results: As we showed before, NF-κB activation by a supraphysiol-
ogic concentration of CCK (100 nM) was mediated in acinar cells by activation of novel
PKC isoforms, δ and ε. We found that a physiologic dose of CCK (0.1 nM), which did not
activate NF-κB, only activated PKC-δ but not other PKC isoforms. Acini stimulation with
0.1 nM CCK in combination with a specific peptide activator of PKC-ε resulted in NF-κB
activation, although PKC-ε activator alone had no effect on NF-κB. These data indicate that
activation of both PKC-δ and PKC-ε is required for the CCK-induced NF-κB activation in
pancreatic acinar cells. We found that ethanol alone activated PKC-ε in acinar cells without
affecting other PKC isoforms. Ethanol by itself did not cause NF-κB activation; however,
combined stimulation of acini with ethanol and 0.1 nM CCK resulted in activation of NF-
κB, as well as of both PKC-δ and PKC-ε. The NF-κB activation induced by the combined
treatment with ethanol and 0.1 nM CCK was inhibited by specific inhibitors of either PKC-
δ or PKC-ε. Conclusion: Taken together, the results demonstrate that activation of both
PKC-δ and PKC-ε is required for NF-κB activation. They suggest that ethanol enhances the
CCK-induced NF-κB activation at least in part through activation of PKC-ε.
411
Lack of the Chemokine Receptor Ccr5 Exacerbates Acute Pancreatitis in Mice
Christophe Moreno, Charles Nicaise, Thierry Gustot, Eric Quertinmont, Nathalie Nagy,
Hubert Louis, Jacques Deviere
Background: Acute pancreatitis (AP) is an inflammatory disease involving the production
of different cytokines and chemokines, and is characterized by leukocyte infiltration. CCR5
is a chemokine receptor for the CC chemokines CCL3/MIP-1α, CCL4/MIP-1β and CCL5/
RANTES. Aims: To investigate the expression of CCR5 ligands and the role of CCR5 in
experimental AP in mice. Methods: AP was induced by hourly intraperitoneal injections of
caerulein (50 μg/kg) in CCR5-deficient (CCR5-/-) or WT mice. Anti-mouse CC chemokines
(CCL2/MCP-1, CCL3/MIP-1α, CCL4/MIP-1β and CCL5/RANTES) monoclonal antibodies
were administered 30 minutes before starting caerulein injections. Severity of AP was deter-
mined by measuring serum amylases, lipases and IL-6 levels, and by histopathological
changes analysis, 6 and 10 hours after starting caerulein injection. Pancreatic gene expression
of CCR5 ligands during experimental AP was determined by RT-PCR. Serum levels of CC
chemokines and IL-6 were measured by ELISA. Results: Induction of AP resulted in an early
significant increase of pancreatic CCL3/MIP-1α and CCL4/MIP-1β mRNA expression, while

















pancreatic injury in comparison with WT mice, as assessed by a more pronounced increase
in serum amylases, lipases and IL-6 levels and by more severe pancreatic edema, inflammatory
infiltrates and necrosis. CCR5-/- mice also exhibited increased production of CCL2/MCP-1
and CCL4/MIP-1β. In vivo neutralization of CCL2/MCP-1 reduced pancreatic damage during
AP in CCR5-/- mice, suggesting that increased production of CCL2/MCP-1 is partially
responsible for the exacerbation of AP observed in CCR5-/- mice. Conclusions: Lack of the
chemokine receptor CCR5 exacerbates experimental acute pancreatitis and leads to increased
levels of CC chemokines. This suggests that CCR5 expression can modulate severity of AP.
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Influence of Polymorphisms in the NOD1/CARD4 and NOD2/CARD15 Genes
On the Clinical Outcome of H.pylori Infection
Philip C. Rosenstiel, Stephan Hellmig, Jochen Hampe, Wolfgang Fischbach, Hany Sahly,
Ralph Lucius, Dana Philpott, Stefan Schreiber
Background:Host immune response influences the clinical outcome of H.pylori infection
leading to ulcer disease, gastric carcinoma and MALT-lymphoma. A genetic risk profile for
gastric cancer has been identified, but genetic susceptibility to develop MALT-lymphoma is
still unclear. We investigated the role of NOD1 and NOD2 as intracellular recognition
molecules for pathogen-associated molecules in H.pylori infection in vitro and analysed the
influence of single nucleotide polymorphisms on susceptibility to ulcer disease and MALT-
lymphoma. Methods: The influence of NOD1 and NOD2 expression on H.pylori-induced
NF-κB activation was assessed using luciferase reporter gene assays. Expression of NOD1
and NOD2 protein in the gastric mucosa was investigated using Western Blot of isolated
gastric epithelial cells and by immunohistochemistry of biopsy material. 534 healthy blood
donors, 440 H.pylori infected patients with chronic gastritis and gastric ulcer and 153 patients
with gastric MALT-lymphoma were genotyped for NOD1 and NOD2 polymorphisms by
Taqman technology. Associations were tested in a case-control setting. Results: Expression
of NOD1 and NOD2 significantly sensitized HEK293 cells to H. pylori- induced NF-κB
activation in a cagPAI-dependent manner. In cells carrying the Crohn-associated NOD2
variant R702W the NF-κB response was significantly diminished. NOD1/NOD2 expression
levels were induced in the gastric epithelium in H.pylori-positive patients. No mutations
were found to be associated with gastritis or gastric ulcer development. However, the R702W
mutation in the NOD2/CARD15 gene was significantly associated with gastric lymphoma.
Carrier of the rare allele T had a more than doubled risk to develop lymphoma than controls
(OR: 2.4, 95CI: 1.2-4.6; p< 0.044). Conclusions: H.pylori-induced upregulation of NOD 1
and NOD2 in vivo may play a critical role in the recognition of this common pathogen. A
missense mutation in the leucine-rich region of CARD15 is associated with gastric lymphoma.
414
Global Analysis of the Human Gastric Epithelial Transcriptome Altered By H.
Pylori Eradication in Vivo
Murray B. Resnick, Edmond Sabo, Sung Soo Kim, Young S. Cho, Patricia Meitner, Hyunk
K. Kim, Rose Tavares, Steven F. Moss
Analysis of gastric epithelial genes regulated by H. pylori (HP) is important in the elucidation
of HP molecular pathogenesis. The transcriptional profile of gastric epithelial cell lines co-
cultured with laboratory HP strains has been investigated previously, as has the global gene
expression of whole gastric mucosa in vivo. We aimed to overcome limitations of both prior
types of study by determining the effects of HP eradication in vivo on the transcriptional
profile of purified gastric epithelial cells extracted from intact human tissue samples (exclud-
ing contaminating stromal and inflammatory cells that add noise to gene expression signals),
and using each patient as their own control. Methods: Laser capture microdissection
(Arcturus) was employed to extract mRNA from formalin-fixed, paraffin-embedded gastric
antral foveolar epithelial cells from 12 patients with peptic ulcer disease, before and 1 month
after HP eradication. mRNA was reverse transcribed and applied onto Affymetrix cDNA
microarray chips customized for mRNA from paraffin and formalin-exposed tissue. Differenti-
ally expressed genes were statistically identified, annotated with GeneMapp and MAPPFinder
bioinformatics tools and validated by real-time PCR. Results: After removing the concordantly
absent microarray signals, 13,817 transcripts decreased and 9,680 increased following HP
eradication. Applying cutoff criteria (p<0.02, fold-change threshold 2.5) reduced the sample
to 112 significantly differentially expressed genes. Multiple gene function categories were
represented including immune response, transcriptional regulation, signal transduction, cell
cycle regulation, apoptosis, cell adhesion, growth factors, metabolism, ion channels and
structural genes. So far PCR has confirmed results for 10 selected transcripts examined. For
specific examples of highly differentially regulated genes see table. Conclusions: This is the
first report of the transcriptome of purified gastric antral epithelial cells from HP-infected
patients. Studying paired biopsy samples from the same patients before and after HP eradica-
tion has confirmed some previous studies while highlighting novel candidate genes involved
in HP pathogenesis.
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Helicobacter Pylori Induces Gastric Epithelial Cell Invasion in a Cag Pai
Dependent Manner
Maria J. Oliveira, Ana C. Costa, Lara Henriques, Gianpaolo Suriano, John Atherton, Jose
C. Machado, Raquel Seruca, Marc Mareel, Ancy Leroy, Ceu Figueiredo
Numerous studies have shown that H. pylori is able to interact with gastric epithelial cells,
activating signaling pathways, modifying host cellular functions, and inducing cell phenotypes
important for carcinogenesis. One of the less explored cell phenotypes induced by H. pylori
is cellular invasion, and little is known about the mechanisms involved in this process. Our
aim was to investigate the role of H. pylori on gastric epithelial cancer cell invasion, and the
mechanisms underlying this process. We also examined whether there were differences
between strains in their ability to stimulate cell invasion, especially to assess the role of cag
pathogenicity island (cag PAI), CagA, and VacA in cell invasion. We found that H. pylori
induced in vitro AGS cell invasion in two well established invasion assays, collagen type I
gels and Matrigel filters. H. pylori mediated cell invasion was blocked by the c-Met receptor
inhibitor NK4, and by silencing c-Met expression with small interference RNA. Supernatants
of cells cultured with H. pylori showed increased MMP-2 and MMP-9 activity, which was
also suppressed by silencing the c-Met receptor. Studies with different H. pylori strains
revealed that cell invasion, c-Met tyrosine phosphorylation, and increased MMP-2 and MMP-
9 activity, were all dependent on the presence of an intact cag PAI. Our findings suggest
that H. pylori strains with an intact cag PAI activate c-Met and induce high levels of MMP-
2 and MMP-9 activity, possibly increasing extracellular matrix degradation and leading to
subsequent invasion of cancer cells.
416
Spermine Oxidase As the Link Between H. Pylori Caga and Gastric
Carcinogenesis
Rupesh Chaturvedi, Mohammad Asim, Francoise I. Bussiere, Kshipra Singh, Robert A.
Casero, Richard M. Peek, Keith T. Wilson
Background: We have reported that oxidation of polyamines, specifically spermine, by the
enzyme spermine oxidase [(SMO) also known as polyamine oxidase 1] is induced by H.
pylori (Hp) in gastric epithelial cancer cell lines and in the epithelium of gastritis tissues.
This causes H2O2 generation, and the resulting oxidative stress causes apoptosis at MOI
200 and DNA damage at MOI 800. A rodent-adapted strain of Hp, 7.13, has been reported
to cause gastric cancer in gerbils, while its parental strain, B128 does not; this has been
related to increased translocation of CagA into gastric epithelial cells with 7.13. Our Aim
was to determine if the effects of this carcinogenic strain of Hp are mediated by SMO.
Methods: We utilized conditionally immortalized mouse gastric epithelial cells (MGECs)
for these studies. Cells were exposed to live Hp strains B128, 7.13, and 7.13 cagA- isogenic
mutant at MOI 200 and the following were assessed: SMO mRNA by real-time PCR, intracellu-
lar H2O2 levels by flow cytometry using CM-H2DCFDA dye, and apoptosis by flow cytometry
using annexin V/PI staining. DNA damage was studied in MGECs stimulated with Hp at
MOI 200-800, by measuring FITC-8-oxoguanosine binding using flow cytometry. Results:
Hp 7.13 induced significantly more SMO mRNA expression than B128, and this induction
was prevented by cagA deletion (Table 1). Similarly, 7.13 induced more H2O2 generation,
apoptosis, and DNA damage than B128, and these responses were markedly attenuated with
the cagA- strain of 7.13 (Table 1). Notably, significant DNA damage was detected even at
MOI of 200 when 7.13 was used. Consistent with the high, low, and absent levels of SMO
induced by strains 7.13, B128, and 7.13 cagA-, respectively (Table 1), transfection of MGECs
with SMO small interfering RNA inhibited apoptosis induced by 7.13 by 80%, but with
B128 stimulation apoptosis was only inhibited by 50%, and with 7.13 cagA- there was no
inhibition. Conclusions: The increased levels of apoptosis and DNA damage induced by a
carcinogenic strain of H. pylori appear to be mediated by CagA-dependent SMO expression
and associated H2O2 generation. Polyamine oxidation may be an important cause of CagA-
induced dysregulation of gastric epithelial cell integrity and risk for neoplastic transformation.
Table 1
*p < 0.05, **p < 0.01 vs. control; †p < 0.05, ††p < 0.01 vs. B128; §p < 0.05, §§p < 0.01
vs. 7.13.
417
Innate Immune Response Gene Polymorphisms and Their Role in H. Pylori-
Induced Gastric Cancer
Georgina L. Hold, Malcolm G. Smith, Mairi H. McLean, Susan Berry, Kenneth E. McColl,
Ashley Mowat, Emad M. El-Omar
Background: The nature of the immune response to H. pylori infection is determined initially
by the innate immune system. This response is orchestrated by a variety of pattern-recognition
receptors, most notably Toll-like receptors (TLRs). The family of human TLRs currently
comprises 11 members, with at least 5 TLRs namely TLR2, 4, 5, 9 and 11 involved in
recognising bacterially derived pathogen-associated molecular patterns. The majority of these
TLRs and other innate immune response genes have been shown to contain functional single
nucleotide polymorphisms. However, other than TLR4, there has been little data on innate
immune response genes in the context of H. pylori pathogenesis. Aim: We examined whether
SNPs in TLR2 (TLR2 Arg753Gln), TLR5 (TLR5392Stop), TLR9 (TLR9-1237 T/C) and CD14
(CD14-159 C/T, which is part of the TLR4 signalling complex) influenced the risk of
developing gastric atrophy and hypochlorhydria (ATR/HC), the most important precursors
of gastric cancer. Subjects & Methods: We used PCR-RFLP and 5' nuclease assays to
genotype the 4 SNP’s in 149 healthy gastric cancer relatives (GCR) and 100 population
controls. The GCR had detailed assessment of gastric morphology and physiology and were
divided on the basis of these measurements into three groups: (1) H. pylori-infected subjects
with ATR/HC, (2) H. pylori-infected subjects without these abnormalities (No ATR/HC), and
(3) H. pylori negative subjects with normal physiology and morphology. Results: An associ-
ation between carriage of TLR9-1237T/C and CD14-159C/T SNPs and presence of hypoch-
lorhydria and gastric atrophy was identified. Compared to infected subjects who did not
develop ATR/HC, the odds ratio for H. pylori-induced ATR and HC in subjects with the
TLR9-1237T/C was 3.9 (95% confidence interval 1.7 - 8.6) and CD14-159 C/T was 3.8
(95% confidence interval 1.4 - 9.8). Although the functional consequences of the TLR9
promoter polymorphism are unknown, in silico analysis indicates that the SNP disrupts a
putative NF-κB binding site. In contrast, the CD14 polymorphism is functional and affects
binding of the promoter GC box and also Sp3 proteins. No association was detected between
functional polymorphisms in TLR2 and 5 and the presence of premalignant gastric changes.
Conclusions: Our results indicate that carriage of the TLR9-1237T/C and CD14-159 C/T
mutations predispose H. pylori infected subjects to a severe phenotype characterised by
hypochlorhydria and gastric atrophy, the two most important precursor lesions of GC. These
novel findings call for further evaluation of innate immune gene polymorphisms as important
host genetic factors in H. pylori-induced gastric cancer.
418
Chemokine Receptors Regulate Intestinal Dendritic Cell Subspecifications in
Mucosal Defense
Jan Hendrik Niess, Rosa Maria Salazar-Gonzalez, Xiubin Gu, Mike Pazos, Beth A.
McCormick, Ifor R. Williams, Stephen J. McSorley, Hans-Christian Reinecker
Aim and Methods: Dendritic cells (DCs) play an important role in innate and adaptive
mucosal immune responses to intestinal entero-invasive pathogens. To define the intestinal
DC subsets responsible for the recognition of intestinal pathogens, we utilized mice in which
one or both copies of the gene encoding the chemokine receptors CCR6 or CX3CR1 were
replaced with a Green Fluorescent Protein (GFP) reporter. The distribution of DC subsets
and the interaction of DC subsets with pathogen-specific CD4+ T cells in living intestinal
tissues was assessed by 3D reconstructive confocal microscopy. T cell activation by DC
subsets was determined by the analysis of CD25 and CD69 expression on T cells after
adoptive transfer of congenic Salmonella-specific CD4+ T cells (SM1) during S. typhimurium
infection. Results: An extensive CX3CR1+ myeloid-derived mucosal DC system populates
the lamina propria of the intestine and Peyer’s patches (PPs). Lamina propria DCs depend
on CX3CR1 to form transepithelial dendrites, which enables the luminal sampling and
transport of commensal and pathogenic microbiota to mesenteric lymphnodes (MLN). In
contrast, CCR6+ DCs are confined to PPs and absent from the lamina propria of the small
intestine. CCR6+ DC were recruited into the dome regions of PPs in response to invasion
of the follicle associated epithelium (FAE) by entero-invasive pathogens. Twelve hours after
oral S. typhimurium infection CCR6+ DCs formed aggregates with pathogen-specific T cells
in PPs leading to the rapid activation and expansion of Salmonella-specific T cells. CCR6
deficient DCs were unable to enter the dome regions of infected PPs and consequently failed
to initiate pathogen-specific T cell activation resulting in enhanced susceptibility to oral S.
typhimurium infection. Conclusion: PPs contain a DC subset, which can be distinguished
from lamina propria DCs by CCR6 expression. CCR6-dependent regulation of this PP specific
DC subset is responsible for localized T cell dependent defense activation against entero-
invasive pathogens.
419
Isolated Lymphoid Follicles Contain a Heterogenous T-Lymphocyte Population
and Support the Development of IL-10 Producing Cd4+ T-Lymphocytes
Keely G. McDonald, Jacquelyn S. McDonough, Caihong Wang, Rodney Newberry
Background: Isolated lymphoid follicles (ILFs) are inducible organized intestinal lymphoid
structures that function as inductive sites for mucosal immune responses. The role these
structures play in mediating beneficial or harmful intestinal immune responses is unclear.
To better understand the function of ILFs within the mucosal immune system, we examined
phenotypic and functional characteristics of T-lymphocytes within ILFs. Methods: Splenic,
Peyer’s patch (PP), lamina propria, and ILF cellular populations were isolated from 3A9
transgenic mice which express a T-cell receptor specific for a peptide of hen egg-white
lysozyme presented in the context of I-AK and from C57BL/6 mice receiving LTβR-Ig in
utero to block Peyer’s patch formation. Cellular populations were examined by flow cytome-
try. Cytokine production was measured following in vitro culture with antigen using ELISA
and ELISPOT assays. Antigen specific T-lymphocyte proliferative responses were examined
T : 89386$$CH2
05-04-06 23:18:24 Page 61Layout: 89386B : o
A-61 AGA Abstracts
using CFDA incorporation. Results: ILF T-lymphocytes were predominantly, if not exclus-
ively, TCRβ+ CD103- and either CD4 or CD8α single positive. CD4+ T-lymphocytes outnum-
bered CD8+ T-lymphocytes by a ratio of greater than 2:1. Similar to the spleen and Peyer’s
patch, 20% of the CD4+ T-lymphocytes expressed Foxp3, however in contrast to other
organs, the majority of the Foxp3+ T-lymphocytes in the ILFs were CD25-. ILF CD4+ T-
lymphocytes had lower levels of CD62L expression when compared with CD4+ T-lympho-
cytes from the spleen and Peyer’s patch. The majority of ILF T-lymphocytes expressed CCR7,
while a minority of the ILF T-lymphocyte population expressed CXCR5. Following in vitro
culture with antigen T-lymphocytes from ILFs displayed a proliferative capacity equivalent
to that of splenic and PP T-lymphocytes. Following in vitro culture with antigen ILF T-
lymphocytes produced less IL-4 and IFNγ, and more IL-10 when compared with splenic
and PP T-lymphocytes. Conclusions: ILFs contain a heterogeneous T-lymphocyte population
most consistent with the presence of naïve T-lymphocytes that have been recently activated,
a population of T follicular helper cells, and a population of Foxp3 expressing regulatory
T-lymphocytes. When compared with the spleen and PP, ILFs preferentially support the
development of IL-10 producing CD4+ T-lymphocytes. These findings suggest that ILFs
propagate homeostatic mucosal immune responses in unchallenged animals.
420
Cd1d-Dependent Regulation of Bacterial Colonization in the Intestine
Edward E. Nieuwenhuis, Tetsuya Matsumoto, Mark Exley, Ytje Simons-Oosterhuis,
Margaretha Lambers, Janneke Samsom, Dicky Lindenbergh, Sean Colgan, Andrew
Onderdonk, Richard S. Blumberg
The host mechanisms involved in controlling intestinal colonization with commensal bacteria
are poorly understood. The cellular locations of CD1d expression in the intestine and the
known role of CD1d in microbial host defense prompted us to examine the role of CD1d
in regulating the normal colonization of the intestine. In a murine intestinal colonization
model under specific pathogen free or gnotobiotic conditions, established by intragastric
application of Pseudomonas aeruginosa or Escherichia Coli, CD1d-/- mice exhibited markedly
reduced intestinal eradication and enhanced translocation of these microorganisms compared
with wild-type mice. Furthermore, treatment of mice with α-galactosylceramide, a lipid that
activates CD1d-restricted T cells, was associated with rapid clearance and prevention of
colonization. When raised in germ-free conditions, CD1d-/- mice showed a strongly enhanced
colonization rate with various bacteria (E coli, Staph. aureus) in comparison to wild-type
mice, particularly at early time points (109 CFU vs. 103 CFU at t=24h for E coli). The
differences in colonization were present throughout the entire intestine, but remained over
time (t=4 days) within the jejunum. The small intestine was identified as the main site of
CD1d-restricted anti-microbial regulation that was further confirmed by applying a small
intestinal overgrowth model. These data indicate a role for CD1d in regulating mucosal
colonization of the intestine with commensal bacteria.
421
Subclinical Helicobacter Hepaticus Infection Alters Immune Response to
Soluble Luminal Antigen
Megan Mcbee, Onyinye I. Iweala, Cathryn Nagler-Anderson, David B. Schauer
Development of mucosal immunity and ease of delivery make oral vaccines desirable.
However, oral delivery of soluble antigen can lead to tolerance, rather than immunity, which
complicates the design and development of oral vaccines. In order to better understand the
relationship between oral delivery of antigen and tolerogenic versus immunogenic responses,
we investigated subclinical bacterial infection in the intestinal tract of C57BL/6 mice. Previous
studies demonstrated that enteric helminth infection acts as an adjuvant, priming for a Th2-
biased response to soluble ovalbumin (OVA), a tolerogenic form of dietary antigen. A
comparable Th1-biased adjuvant effect was found to be mediated by infection with enter-
ohepatic Helicobacter species by feeding OVA to C57BL/6 mice infected with Helicobacter
hepaticus. An 8-week chronic infection with H. hepaticus primed for a systemic IFN-γ response
to intragastrically administered OVA, even though infection of C57BL/6 mice did not lead
to overt intestinal inflammation. H. hepaticus infection also influences systemic T cell responses
at distant sites, as increased T-cell proliferation in response to OVA was detected in draining
lymph nodes following subcutaneous immunization. Using quantitative RT-PCR, MHC class
II expression in mesenteric lymph nodes (MLN) from mice infected with H. hepaticus was
found to be 2 to 4-fold lower than in the MLN of uninfected mice between 6 and 48 hours
post-inoculation. The apparent decrease in MHC class II expression may be due to an influx
of polymorphonuclear leukocytes early in infection. Dendritic cells isolated from MLN
immediately prior to and within hours of H. hepaticus inoculation were analyzed by flow
cytometry for co-stimulatory molecule expression. Despite immune activation and adjuvant
effects, subclinical H. hepaticus infection of C57BL/6 mice did not alter OVA-specific IgG2c
or IgG1 antibody titers. Thus, the ability of enteric pathogens to influence immunologic
responses to a model dietary antigen is common to both Th1 and Th2 polarizing infections,
and does not appear to depend on the establishment of an inflammatory cell infiltrate at
the site of antigen uptake. These findings have implications for understanding the basic
mechanism of oral tolerance as well as for possible immunomodulatory consequences of
subclinical infections with enterohepatic Helicobacter species.
422
Food Hyposensitization Differs in Milk Proteins Belonging to Different
Protein-Families
Franziska Roth-Walter, Cecilia Berin, Stephanie Dahan, Giulia Roda, Xian Yang Yio, Hugh
Sampson, Lloyd Mayer
Background: Despite the abundance of protein present in food, most allergens belong to a
limited number of protein families and the factors that determine allergenicity are not known.
We investigated the allergenicity of food allergens belonging to different protein families.

















and casein (CAS) to compare their allergenicity by oral sensitization. Methods: Allergenicity
in vivo was tested by orally sensitizing C3H/HeJ mice with 1 mg ALA, BLG or CAS plus
cholera toxin as mucosal adjuvant once a week for a six-week period (n = 12 mice/group).
Subsequently, mice underwent a graded oral food challenge. Anaphylactic symptoms and
mean body temperature (MBT - negatively correlating with anaphylaxis severity) were
recorded. Plasma was analyzed for histamine and serum for IgE and IgA. Splenocytes were
re-stimulated with allergen in vitro and their supernatants collected for analysis of interleukin
IL-4, IL-5, IL-10 and IFN-γ. We compared antigen-uptake using polarized Caco-2 cells in
vitro. Antigen-uptake was also compared in vivo by feeding C3H/HeJ mice with FITC-
labeled ALA, BLG and CAS and assessing uptake by microscopy. Results: Allergenicity was
clearly different between the 3 allergens, with ALA inducing the most severe anaphylaxis
(MBT 33.5 °C) at the lowest dose of antigen (median oral dose 10 mg). BLG next, inducing
anaphylaxis (MBT 34.2 °C) at a median dose of 20 mg. Casein induced mild anaphylaxis
(36.3 °C) only at doses of 50 mg orally or 50 mg administered systemically. Allergenicity
correlated with antigen binding of serum IgE (800, 200 and 120 ng/ml antigen in ALA,
BLG, and CAS sensitized mice, respectively) but was not equivalent to immunogenicity
however, as CAS induced significantly (p < 0.05) higher levels of IL-5, IL-10, IFN-g, and
IgA compared to BLG and ALA. IL-4 was undetectable in all cases. To test if allergenicity
was related to uptake across the epithelial barrier, transcytosis studies were performed on
polarized Caco-2 cells and in vivo in mice. Transcytosis of BLG was 3-fold higher than ALA
or CAS, despite their similar molecular weights (14-25 kDa. In mice, there was abundant
uptake of BLG, detectable uptake of ALA, and sparse uptake of CAS into the lamina propria.
Conclusions: Food proteins of different families elicit significantly different immune responses
when given orally with cholera toxin, with a spectrum of allergenic or immunogenic
responses. Factors intrinsic to the protein, not related to uptake, are likely to determine the
nature of the immune response in the GI tract.
423
The Ccr6-Ccl20 Chemokine Axis Is Necessary for Food Allergen-Induced
Diarrhea
Adina K. Knight, Shu Zhang, Sergio Lira, Lloyd Mayer, Hugh A. Sampson, Cecilia Berin
Allergic inflammation of the gastrointestinal tract is associated with a Th2 cytokine profile
that supports the development and survival of effector cells including mast cells and IgE-
producing plasma cells in the lamina propria. CCR6 is present on B cells, memory T cells,
and dendritic cells and its ligand CCL20 (MIP3α) is highly expressed by intestinal epithelial
cells. We hypothesized that the CCR6-CCL20 chemokine axis is critical for the development
of gastrointestinal allergic symptoms. Methods: Balb/c mice or CCR6 -/- mice (Balb/c back-
ground) were sensitized to ovalbumin (OVA/alum i.p., day 0, 14), followed by feedings of
OVA (50 mg, days 28, 30, 32, 34). mRNA was isolated from full-thickness jejunum and
real time RT-PCR was performed to assess cytokine and chemokine gene expression. Results:
Wild-type mice developed severe acute diarrhea beginning 20-30 min after the 3rd feed,
and diarrhea recurred at the next feed (53.9% with diarrhea after feed 3, 82.4% after feed
4, n = 17). CCR6 -/- mice were significantly protected (p = 0.001 by survival curve analysis)
from development of allergic diarrhea (9.5% after feed 3, 34.0% after feed 4, n = 21). OVA-
specific serum IgE was boosted after feeding in CCR6 +/+ mice, whereas no boosting of
OVA-specific IgE was observed after feeding in CCR6 -/- mice. Expression of the Th2
cytokines IL-4 and IL-10 were significantly upregulated in the lamina propria of wild-type
mice after 4 OVA feeds in comparison to unfed OVA-sensitized mice (p < 0.05), and this
upregulation was significantly suppressed in CCR6-/- mice. The absence of CCR6 also
impaired the upregulation of the Th2 chemokine/receptor pair CCL1(TCA-3)/CCR8 in the
lamina propria (p < 0.05). Flow cytometric analysis demonstrated that CCR6 was constitu-
tively expressed on B cells and dendritic cells in the MLN, and upregulated on CD4+ T
cells after activation in vitro. Therefore the absence of CCR6 could be playing a role in the
trafficking of multiple cell types from the MLN to the lamina propria in this model. CCR6
did not influence the initial systemic sensitization, as baseline IgE and cytokine levels prior
to feeding were not significantly different between wild-type and CCR6 knockout mice.
Conclusions: The CCL20/CCR6 chemokine/receptor pair is necessary for the full development
of allergic diarrhea. Absence of CCR6 inhibited not only antigen-specific IgE and development
of a local Th2 cytokine milieu, but also chemoattractants known to recruit Th2 cells,
demonstrating that CCR6 may function at an early stage in the generation of allergic inflamma-
tion of the gastrointestinal tract.
424
Arachidonic Acid Metabolites Uniquely Regulate Anion: HCO3 Exchangers in
the Chronically Inflamed Rabbit Small Intestine
Steven Coon, Uma Sundaram
Background: There are two anion exchangers in rabbit intestinal villus cell brush border
membrane (BBM) both of which are inhibited during chronic intestinal inflammation.
Cl:HCO3 exchange is inhibited secondary to an alteration in the affinity for Cl. In contrast,
short chain fatty acid (SCFA):HCO3 exchange is inhibited secondary to a decrease in Vmax.
Arachidonic acid metabolites (AAM), known to be elevated in the chronically inflamed
intestinal mucosa, may regulate these two anion exchangers. Aims: Determine whether AAM
mediate the inhibition of villus cell anion exchangers during chronic enteritis. Methods: A
rabbit model of chronic enteritis induced by Emeria magna was utilized. Villus cells were
isolated from the intestine by a Ca++ chelation technique. BBM vesicles (BBMV) were
prepared from villus cells by Ca++ precipitation and differential centrifugation. Rabbits were
treated with arachidonyl trifluoromethyl ketone (ATMK), an inhibitor of Phospholipase A2,
to prevent the release of arachidonic acid from plasma membrane phospholipids. Results:
ATMK treatment stimulated Cl:HCO3 exchange in villus cell BBMV from the normal intestine
(540±60 pmol/mg protein/15 sec in control and 938±89 in ATMK treated, p<0.05,n=5)
while SCFA:HCO3 exchange was unaffected. ATMK treatment of rabbits with chronic enteritis
alleviated the inhibition of Cl:HCO3 exchange (535 ±73 pmol/mg protein/15 sec in control,
172±24 in inflamed, and 607±53 in inflamed treated with ATMK, p <0.01, n=4). ATMK
treatment also alleviated the inhibition of SCFA:HCO3 exchange in the chronically inflamed
intestine (700±80 pmol/mg protein/9 sec in normal, 650±50 in normal treated with ATMK,
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100±30 in inflamed, and 730±30 in inflamed treated with ATMK, p<0.01,n=4). Kinetic
studies demonstrated that the mechanism of ATMK mediated stimulation of Cl:HCO3
exchange in the normal intestine was secondary to a significant increase in the Vmax without
an alteration in the affinity for Cl. During chronic intestinal inflammation, the mechanism
of reversal of Cl:HCO3 exchange by ATMK treatment was secondary to a restoration in the
affinity without a change in Vmax. In contrast, the mechanism of reversal of SCFA:HCO3
exchange by ATMK treatment during chronic enteritis was secondary to a restoration of the
Vmax without a change in Km. Conclusions: These data indicate that AAM inhibit Cl:HCO3
exchange in the normal intestine while SCFA:HCO3 exchange is not affected. Further, AAM
mediate the inhibition of Cl:HCO3 and SCFA:HCO3 exchange during chronic enteritis.
However the mechanisms of inhibition of Cl:HCO3 and SCFA:HCO3 exchange by AAM
during chronic intestinal inflammation are uniquely different.
425
Vav Proteins Maintain the Colonic Epithelial Barrier
Thaddeus S. Stappenbeck, John Liu, Wojciech Swat, Jason Mills
The mammalian intestine performs its primary function, the absorption of water and nutri-
ents, while maintaining a physiochemical barrier directed against luminal microbes. The
physical barrier is a single layer of polarized, terminally differentiated epithelial cells at the
luminal surface that undergo continuous replacement from a population of proliferative
stem cells in underlying crypts. The apical cytoplasm of the surface epithelial cells is highly
enriched in cytoskeletal elements that are linked to cell-cell junctions. This transcellular
network has long been assumed to be critical for maintaining barrier function. However,
testing the components of this barrier in adult animals is difficult as cytoskeletal genes are
typically expressed in many tissues and function in cell division. Here we show that expression
of Vavs, a protein family of Rho GTPase guanine nucleotide exchange factors that are capable
of functionally regulating the cytoskeleton is restricted to the surface barrier cells in a limited
region of the intestine. The surface epithelial cells of mice deficient for all three Vavs
(Vav1/2/3null) contain an abnormal apical microtubule cytoskeleton that is associated with
abnormalities in cell size and cell polarity. Surprisingly, these defects occurred in an absence
of any perceptible defects in the actin cytoskeleton and its associated structures (microvilli,
apical junctions). Also, the underlying colonic crypts of Vav1/2/3/null mice are normal in
appearance, proliferation rate and are not surrounded by excess inflammatory cells in the
lamina propria. The surface epithelial defects, in combination with an adaptive immunodefici-
ency of Vav1/2/3null mice, predispose to mucosal injury of the intestinal lining in the form
of numerous focal ulcers. As demonstration that ulcer formation requires an absence of Vav
expression in both the epithelium and hematopoietic cellular compartments, bone marrow
chimeras of irradiated Vav1/2/3null mice with bone marrow transplants from wild type mice
contain abnormal polarity of the surface colonic epithelium but do not develop ulcers. We
anticipate these findings will stimulate further discovery into the interactions between the
actin and microtubule cytoskeletal networks in epithelial barrier cells and will lead to the
recognition of new molecular targets for diseases such as inflammatory bowel disease where
gut injury is a fundamental feature of the pathology. This work further demonstrates the
interplay of the immune system and surface epithelial cells is required to maintain barrier
function.
426
Distribution of and Alterations in Na-Glutamine Co-Transporters SN1 and
SN2 During Chronic Intestinal Inflammation in Rabbits
Jamil Talukder, Ramesh Kekuda, Vadivel Ganapathy, Steven Coon, Uma Sundaram
Background: Glutamine, the primary metabolic fuel for enterocytes, is absorbed by Na-
glutamine co-transporters in the small intestine. System N1 and N2 are two candidates for
Na-glutamine co-transport in the rabbit small intestine. However, the distribution of SN1
and SN2 in the normal small intestine is not known. Further, how SN1 and SN2 may be
altered during chronic intestinal inflammation is also not known. Aim: Determine the
distribution of SN1 and SN2 along the crypt-villus axis of the normal rabbit small intestine
and alterations during chronic enteritis. Methods: A rabbit model of inflammatory bowel
disease induced by Eimeria magna was utilized. Villus and crypt cells were isolated from
the rabbit intestine by a Ca++ chelation technique. Uptake studies were done by rapid
filtration technique using 3H-glutamine. Total RNA was isolated from enterocytes using
Trizol reagent. Real-time quantitative PCR was performed to determine the levels of SN1
and SN2 message using total RNA. Results: Both SN1 and SN2 mRNA are present in villus
and crypt cells. SN2 message is about 2-fold higher in crypt than in villus cells while
preliminary studies indicate that SN1 message is greater in villus than in crypt cells. Na-
dependent glutamine uptake is found in both villus and crypt cells in normal intestine,
albeit higher in villus as compared to crypt cells (1551±101 nmol/mg protein/2 min in villus
and 507±43 nmol/mg protein/2 min in crypt cells, n=3, p<0.01). Na-dependent glutamine
uptake was decreased in villus cells from chronically inflamed intestine (557±44 nmol/mg
protein/2 min in inflamed villus cells, n = 3, p<0.01). The message for SN1 decreased about
3-fold in villus cells from inflamed rabbit small intestine. In contrast, Na-dependent glutamine
uptake increased in crypt cells from chronically inflamed rabbit small intestine (1238±93
nmol/mg protein/2 min in inflamed crypt cells, n = 3, p<0.01). Message for SN2 increased
about 3-fold in crypt cells from chronically inflamed rabbit small intestine. Conclusions:
These data indicate that SN1 is most likely the Na-glutamine transporter in villus cells and
it is inhibited during chronic enteritis. In contrast, SN2 is most likely the Na-glutamine co-
transporter in crypt cells and it is stimulated during chronic enteritis. Thus, these results
indicate that SN1 and SN2 are differentially distributed in the normal rabbit small intestine.
Further, SN1 and SN2 are uniquely regulated in the chronically inflamed rabbit small
intestine.
427
Epithelial Calcium-Sensing Receptor Activation By Eosinophil Granule Protein
Analogs Stimulates Collagen Matrix Contraction
Peter Ngo, R. John MacLeod, Punitha Ramalingam, Sean P. Colgan, Glenn T. Furuta
Background: Eosinophils reside directly adjacent to basolateral surfaces of epithelial cells
in eosinophilic gastrointestinal diseases and inflammatory bowel diseases. Recent evidence
demonstrates that highly cationic molecules, similar to eosinophil granule proteins, bind
the epithelial extracellular calcium-sensing receptor (CaR). We hypothesized that CaR ligation
by eosinophil granule proteins leads to collagen matrix contraction. Aim: To define the
molecular mechanisms of CaR activation by eosinophil granule proteins and its influence
on collagen contraction Methods: Caco2 intestinal epithelial cells, AML14.3D10 eosinophils,
HEK293 cells not expressing CaR (HEK-wt) or HEK cells stably over-expressing CaR (HEK-
CaR) were suspended in type 1 collagen gels (1mg/ml) and stimulated with the analog of
eosinophil major basic protein, poly-L-arginine (PA, 1µM). Contraction was measured as
percent reduction of initial gel surface area. Western blot and electrochemiluminescence
(Meso Scale Diagnostics) was performed to quantify phosphorylated ERK 1/2 (pERK) and
total ERK 1/2 on lysates of Caco2, Hela, HEK-wt and HEK-CaR cells stimulated with PA,
Ca2+ (20mM) or Epidermal Growth Factor (EGF 100ng/ml). To assess loss of CaR function,
Hela cells were transduced with CaR dominant negative adenovirus (R185Q) or control
virus. Results: Caco2 cells co-cultured with 3D10 eosinophils stimulated greater contraction
(51.5±1.0%) than Caco2 cells alone (34.3± 2.2%) or 3D10 cells alone (0.7 ± 3.6%). Similarly,
Caco2 populated collagen gels treated with PA augmented contraction compared to untreated
Caco2 gels (53.4±6.1 vs. 44.0±2.5, p<0.02). Mechanistic studies revealed that PA induced
pERK in Caco2 and Hela cells within 5 min. Transduction of Hela cells with CaR dominant
negative virus attenuated this response compared to control virus. HEK-CaR cells stimulated
with PA or Ca2+ resulted in 9.0 and 11.1 fold increases in pERK respectively, compared
to only 1.4 and 2.0 fold in HEK-wt. Response to EGF (CaR independent pERK activation)
was similar between HEK-CaR and HEK-wt cells (12.4 and 9.0 fold increase respectively).
Similar results were obtained in transiently CaR transfected HEK cells. HEK-CaR populated
gels treated with PA displayed augmented contraction compared to control (41.2%±2.9 vs.
29.0%±3.9, p<0.001), while PA treated HEK-wt gels displayed no difference in contraction
(28.2% ±1.9 vs. 30.3%±0.9). Conclusion: These results indicate that CaR activation by
eosinophil granule protein analogs stimulates collagen matrix contraction. We speculate
that eosinophils activate CaR to produce the dysmotility and fibrosis seen in intestinal
inflammatory conditions.
428
PI3-Kinase Regulates Immune-Mediated Induction of Intestinal Goblet Cell
Gene Expression
Mei-Lun Wang, Sue A. Keilbaugh, Xi C. He, Rao Dirisina, Tanesha Cash-Mason, Terrence
A. Barrett, Linheng Li, Gary D. Wu
Background and Aims: Th2 adaptive immune responses, typified by mammalian host
responses to intestinal nematode infection, lead to intestinal goblet cell hyperplasia and the
induction of goblet cell-specific genes, including TFF3 as well as the α and β members of
the RELM family of secreted proteins. Although it has been established that TFF3 and
RELMα are regulated by STAT6 through an IL4Rα-dependent pathway, the immune-medi-
ated mechanisms by which RELMβ is activated are unknown. In the current study, we use
both in vivo and in vitro model systems to elucidate the signaling pathways responsible for
the regulation of RELMβ gene expression. Methods and Results: Goblet cell morphology
and RELMβ expression were studied in mice with conditional inactivation of PTEN, a tumor
suppressor gene that inactivates PI3-kinase. Whereas RELMβ was essentially undetectable
in the small intestine of wild-type mice, inactivation of PTEN led to a dramatic induction
of RELMβ expression concurrent with the development of goblet cell hypertrophy. Consistent
with this observation, we noted a significant decrease in RELMβ expression in the LS174T
intestinal goblet cell line following treatment with the PI3-kinase inhibitor LY-294002. To
investigate the divergent signaling pathways by which RELM α and β may be regulated in
vivo, we studied their expression in both classic Th2 and generalized T-cell mediated models
of intestinal inflammation. Wild-type BALB/c, STAT6-/-, and IL4Rα-/- mice were either
infected with the intestinal nematode Heligmosomoides polygyrus or received intraperitoneal
injections of anti-CD3 monoclonal antibody. As predicted, RELMα induction occurred in
an IL4Rα and STAT6-dependent fashion in both model systems. In contrast, RELMβ expres-
sion was induced through IL4Rα and STAT6-independent pathways. Conclusions: Using
RELMβ as a model, we demonstrate that PI3-kinase pathways are important regulators of
goblet cell-specific gene expression. This observation is consistent with the role of PI3-
kinase signaling in the pathogenesis of goblet cell hyperplasia observed in many juvenile
polyposis syndromes as well as recent evidence implicating the role of RELMβ in insulin-
dependent signaling pathways.
429
Inability to Regulate Ileal Bile Acid Transporters in a Novel Mouse Model of
Necrotizing Enterocolitis
Melissa Halpern, Nazzareno Ballatori, Sarah Doelle, Tara Saunders, Dania Molla Hosseini,
Anna Stagner, Jessica Clark, Bohuslav Dvorak
Background: Necrotizing enterocolitis (NEC) is the most common gastrointestinal disease
of prematurely born infants. In a neonatal rat model of NEC, we have shown that the
accumulation of bile acids (BA) in the distal ileum contributes to the development of NEC,
and may be a result of an inability to regulate BA homeostasis. We have recently developed
a neonatal mouse model of NEC to further examine the pathophysiology of this disease,
but the regulation of ileal BA transporters in this model are unknown. Aims: To examine
the regulation of ileal BA transporters in a newly developed neonatal mouse model of NEC.
Methods: Newborn, never suckled C57BL/6 mice were fed cow’s milk-based formula every
4 hours for 3 days and exposed to asphyxia and cold stress twice daily to develop NEC
(NEC, n = 24). Dam-fed littermates, also exposed to asphyxia and cold stress, were used
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as controls (DF, n = 12). Using this method, approximately 70% of the formula-fed group
develop ileal damage consistent with NEC, while none of the DF animals develop disease.
Ileal tissue from each animal was used for immunohistology and Western Blot techniques
to evaluate the apical sodium-dependent bile acid transporter (Asbt), ileal bile acid binding
protein (Ibabp) and the heteromeric organic solute transporter Ostα-Ostβ. Results: Asbt,
Ostα and Ostβ were up-regulated in the distal ileum of neonatal mice with NEC compared
to DF controls, but were significantly lower than in adults. In contrast, Ibabp was significantly
lower in mice with NEC compared to DF mice. Further, animals in the formula fed group
that did not develop NEC had significantly greater Ibabp protein levels than those that
developed disease. Conclusions: The inability to adequately up-regulate ileal BA transporters
may lead to accumulation of BA in the terminal ileum and may contribute to the development
of experimental NEC in the neonatal mouse model. Supported by NIH Grants HD-39657
and DK-067954
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Enteroendocrine Precursor Cells Develop Small Intestinal Tumors in Response
to Wnt Signaling and Lose This Response During Further Differentiation
Yang Wang, Maryann Giel-Moloney, Andrew B. Leiter
Wnt signaling is required to maintain cell proliferation in intestinal crypts. Mutations resulting
in increased Wnt signaling are associated with the development of intestinal neoplasms. It
has not been established which intestinal cell lineages differentiating from pluripotent cells
are capable of responding to abnormal Wnt signals. Two basic helix loop helix (bHLH)
transcription factors, Neurogenin 3 (Ngn3) and BETA2/NeuroD, play an important role in
cell fate determination and differentiation of enteroendocrine cells. Ngn3 is transiently
expressed in the earliest enteroendocrine cell progenitors and required for the specification
of intestinal endocrine cells. BETA2 is a factor downstream of Ngn3, which coordinates
enteroendocrine cell differentiation at later stage. In the present study, we sought to determine
when during differentiation intestinal endocrine cell precursors are capable of responding
to Wnt signaling. We used site specific recombination to conditionally activate Wnt signaling
in enteroendocrine progenitor cells at either Ngn3 or BETA2 expressing stage. We crossed
transgenic mice expressing Cre recombinase under control of bacterial artificial chromosomes
(BAC) containing the Ngn3 or BETA2 genes with Catnb mice. Catnb mice have a conditional
β-catenin allele with loxP sites on either side of exon3, which encodes all GSK3β phosphoryl-
ation sites in β-catenin. Deletion of this exon prevents β-catenin from forming complexes
with APC that target it for degradation. As a result, the stabilized β-catenin localizes to the
nucleus to function as a coactivator of Wnt target genes. Ngn3-Cre X Catnb mice were born
with the expected frequency and appeared normal until 4 weeks of age. After 4 weeks,
adenomatous polyps appeared with increasing frequency in the small intestine with the
eventual development of widespread small intestinal adenocarcinoma, resulting in death by
the age of 6-9 months. Tumor cells frequently expressed serotonin and PGP9.5, confirming
their neuroendocrine origin, as well as a number of Wnt target genes. In contrast, Wnt
signaling initiated at a later stage of differentiation in BETA2-Cre X Catnb mice, failed to
induce neoplasms or to alter intestinal differentiation. Our results are the first to demonstrate
that precursor cells committed to a specific intestinal cell lineage continue to respond to
Wnt signals much like more immature and pluripotent cells in the crypts. In addition we
have defined a specific stage later in endocrine differentiation where this response is lost.
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Effect of Helicobacter Pylori Infection in Experimental Gastric Carcinogenesis
of Mongolian Gerbils
Koji Nozaki, Xueyuan Cao, Harunari Tanaka, Yuzuru Ikehara, Tetsuya Tsukamoto, Hayao
Nakanishi, Nobuyuki Shimizu, Sachiyo Nomura, Hirokazu Yamaguchi, Yoshio Yamaoka,
Michio Kaminishi, Masae Tatematsu
Helicobacter pylori (Hp) infection facilitates gastric disorders and gastric cancer development.
As for in vivo experimental animal models, Mongolian gerbils can be used to study the
virulence of Hp infection because of their high susceptibility to infection with Hp, and the
resultant gastritis and gastric cancers. To explore the causal link between Hp infection and
gastric carcinogenesis, we studied following experiments, I: Eradication after long-term Hp
infection model; II: Hp infection and 10% w/w high-salt diet administration model; III:
Eradication model at early, middle, or late period after Hp infection; and IV: Establishment
of gastric cancer cell lines from Mongolian gerbil. I: Long-term Hp infection frequently
developed proliferative glands with dysplastic change of constituent cells, and finally with
intestinal phenotype with Paneth cells. After eradication, proliferative glands were reduced,
and gastric lesions in mucosa improved with few remnants of the former injury. These
proliferative glands are induced solely by Hp infection and are related to severe gastritis
and intestinal metaplasia. II: The interaction of Hp infection and a high salt diet on gastric
carcinogenesis was investigated using gerbils with a combination of N-methyl-N-nitrosourea,
inoculation with Hp, and a 10% high salt diet. A high-salt diet significantly enhanced the
effects of Hp infection on gastric carcinogenesis, and these two factors acted synergistically
to promote the development of gastric cancers. III: The timing effect of eradication in gastric
carcinogenesis (eradication at the early, middle or late period) was investigated using gerbils
with a combination of Hp-infection, eradication and N-methyl-N-nitrosourea-treatment. The
tumor incidence at week 75 was significantly higher in animals treated with Hp, and was
related to the period of inflammatory status. Eradication at an early stage of inflammation
was effective in preventing Hp-enhanced gastric carcinogenesis. IV: Gastric cancer cell lines
with different invasive activities, designated MGC1 and MGC2, were established from one
original cancer tissue induced in the Mongolian gerbil. The derived cells can be stably
attached with Hp, and easily transplanted to the nude mice. Rapid phosphorylation of IkB,
Erk1/2, and AKT of these cells was observed by IL-1 beta stimulation, and luciferase reporter
gene assay revealed the Hp-dependent NF-kB transcriptional activation. Long-term Hp
infection strongly enhances gastric carcinogenesis, and eradication of Hp at an early timing
resulted in lower incidence of gastric carcinogenesis, showing that eradication of Hp can


















Aspirin for the Prevention of Recurrent Colorectal Adenomas - Results of the
UKCAP Trial
Richard F. Logan, Kenneth R. Muir, Matthew J. Grainge, Nicholas C. Armitage, Vic C.
Shepherd, Ukcap Trial Group And
Background: Many observational studies have found regular aspirin use is associated with
a reduced risk of colorectal (CR) cancer and 2 randomised trials have shown that aspirin
reduces risk of recurrent CR adenomas, although results were not wholly consistent (Baron
et al., N Engl J Med, 2003; Benamouzig et al., Gastroenterology, 2003). We report the
preliminary aspirin results of a large factorial trial of aspirin (enteric 300 mg/day) and folate
supplements in patients under surveillance for recurrent CR adenomas. Methods: A double-
blind, placebo-controlled randomised trial was carried out in 10 centres (9 in the UK and
1 in Denmark). Patients who had one or more adenomas (>0.5cm) removed by colonoscopy
in the 6 months prior to enrolment were randomised to receive either aspirin (enteric 300
mg/day) or placebo. All participants were followed-up at intervals of 4 months to assess
compliance, with a second colonoscopy arranged for 3 years after the date of trial entry.
The primary outcome measure was a histologically confirmed CR adenoma or cancer either
at the end examination or during the course of the trial. Results: 945 patients were recruited
into the study, of which 853 (434 receiving aspirin and 419 placebo) underwent a second
colonoscopy and were included in an intention to treat analysis. 56.9% of randomised
patients were male and the mean age at recruitment was 57.8 years. Full compliance with
trial medication was reported by 700 patients . In total, 101 (23.3%) patients receiving
aspirin had a recurrent adenoma compared with 120 (28.6%) patients who received placebo
(Relative Risk = 0.81; 95% CI, 0.65 to 1.02). 103 advanced CR adenomas were observed
(on the basis of villous/tubulovillous features, size >1cm, evidence of severe dysplasia, or
CR cancer diagnosis); 39 (9.0%) of these were in the aspirin group and 64 (15.3%) in the
placebo group (Relative Risk = 0.59; 95% CI, 0.40 to 0.86). This advanced group included
11 patients with CR cancers (3 aspirin and 8 placebo). Conclusion: Aspirin use (300 mg/
day) resulted in a 19% reduction in risk of any colorectal adenoma recurrence and a marked,
statistically significant, 41% reduction in risk of advanced adenoma development.
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Association of a Complex Insertion/Deletion Polymorphism of NOD1/CARD4
with Susceptibility to Inflammatory Bowel Disease in the Scottish Population
Johan van Limbergen, Charles W. Lees, Elaine R. Nimmo, Richard K. Russell, Hazel E.
Drummond, David C. Wilson, Ian D. Arnott, Jack Satsangi
Background & Aims NOD1/CARD4 and NOD2/CARD15 are intracellular pattern-recognition
receptors that influence Toll-like receptor responses and NF-kB activation1. The NOD1/
CARD4 gene lies within the 7p14.3 IBD locus2. Recently, the deletion allele NOD1+32656*1
of a complex deletion*1/insertion*2 polymorphism was found to be associated with IBD
and CD3. On haplotype analysis, the presence of the NOD1+32656*2 allele was shown to
have a strong protective effect on IBD susceptibility. The aim of this study was to assess
the influence of NOD1+32656 on IBD susceptibility in a Caucasian population with a low
NOD2/CARD15 contribution. Patients and Methods 991 patients with IBD (476 CD, 491
UC, 24 IC) and 318 healthy controls were genotyped for NOD1+32656A/C using TaqMan.
We performed a case-control analysis using χ2(Yates). The Population Attributable Risk
(PAR) for the NOD1+32656*1 allele was calculated. The effect of NOD1+32656 genotype
on age of onset was assessed using the Mann-Whitney test. Results By case-control analysis,
the NOD1+32656*1 deletion allele was associated with susceptibility to IBD (allelic frequency
74% v 70% p=0.04 OR 1.23 CI 1.01-1.49 and *1*1 genotype frequency 54% v 46% p=
0.02 OR 1.35 CI 1.05-1.74) and CD (*1*1 genotype frequency 54% v 46% p=0.03 OR
1.37 CI 1.03-1.82), but not UC. These data suggest the possibility that NOD1+32656*1 is
a recessive risk allele. Indeed, the NOD1+32656*2 insertion allele has a protective effect
on IBD susceptibility (allelic frequency 25% v 30% p=0.03 OR 0.82 CI 0.67-0.99). Carriage
of the NOD1+32656*2 insertion allele is protective against IBD (45% v 53% p=0.01 OR
0.74 CI 0.58-0.96) and CD (45% v 53% p=0.02 OR 0.73 CI 0.55-0.97). The heterozygous
genotype is associated with protection against IBD and CD (39% v 46% p=0.03 OR 0.76
CI 0.59-0.98 and 39% v 46% p=0.03 OR 0.75 CI 0.56-0.99, respectively). The PAR to IBD
of NOD1+32656*1 is 13.6% to IBD and 13.9% to CD cf. 11% for NOD2/CARD154. In
contrast with a previous report, no effect was seen of NOD1+32656 genotype on age of
diagnosis of IBD, CD or UC. Conclusion In our population, NOD1+32656 variants are weak
determinants of susceptibility to IBD and CD, but not UC. We were unable to replicate the
previously reported association with age at diagnosis. Our data suggest that the
NOD1+32656*1 deletion allele is a recessive risk allele for IBD, although we can not exclude
a direct protective effect of the NOD1+32656*2 insertion allele. References 1. van Heel et
al. Eur J Immunol 2005;35:2471-2476 2. Satsangi et al. Nat Genet 1996;14(2):199-202 3.
McGovern et al. Hum Mol Genet 2005;14(10):1245-50 4. Arnott et al. Genes Immun
2004;5:417-25
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NOD2 Variants Are Significantly Associated with Sero-Reactivity to Microbial
Antigens in Crohn’s Disease (CD)
Shane M. Devlin, Andrew Ippoliti, Huiying Yang, Konstantinos Papadakis, Eric
Vasiliauskas, Maria T. Abreu, Gil Y. Melmed, Phillip Fleshner, Kent D. Taylor, Ling Mei,
Carol J. Landers, Jerome I. Rotter, Stephan R. Targan
Background: Recently a locus on chromosome 3 of the C3Bir mouse (Cdcs1) was identified
to confer severe colitis associated with a decrease in innate immune function and an increase
in adaptive T-cell responses to commensal bacterial antigens, a link between innate and
adaptive immunity. We have previously shown in CD that the number and magnitude of
antibody responses to microbial antigens are associated with a more severe disease course.
Since functional mutations in the innate immune gene NOD2 are associated with CD, the
aim of our study was to determine the relationship of NOD2 variants to the magnitude of
CD associated antibody responses to microbial antigens. Methods: Serologic and genetic
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data were examined in 748 CD patients. ASCA and antibodies to I2, OmpC, and CBir were
measured by ELISA. Antibody sums (AS) and overall quartile sums (QS) (ranging from 4-
16) of levels for all four antibodies were calculated as previously described (Mow et al Gastro
2004;126:414). Genotyping (TaqmanMGB) was performed for 3 CD-associated variants of
the NOD2 gene, R702W, G908R, and 1007fs. Results: 1] ASCA was detected in 51%, anti-
I2 in 58%, anti-OmpC in 38%, and anti-CBir1 in 56%. 2] 250 of 748 CD patients (33.4%)
had at least one NOD2 variant;206 (27.5%) having one and 44 (5.9%) having two. 3]
NOD2 variants were present at increasing frequency in patients with reactivity to increasing
numbers of antigens. Variants were present in those with 0, 1, 2, 3 or 4 positive antibodies
in 24%, 25%, 36%, 36%, and 46%, respectively (p for trend < 0.0001). 4] NOD2 variants
were present at increasing frequency in patients with increasing cumulative quantitative
immune response as reflected by individual QS (p for trend <0.0001). QS were also clustered
into four groups by increasing cumulative quantitative immune response (group 1=4-6,
group 2=7-9, group 3=10-13, and group 4=14-16). The frequency of having at least one
NOD2 variant in each of the four groups was 22%, 29%, 35%, and 49% in groups 1,2,3,
and 4, respectively (p for trend <0.0001). 5] The mean AS (number of positive antibodies)
and QS was higher for patients with at least one NOD2 variant versus those with no variant
(2.28 +/- 1.21 & 10.70 +/- 2.99 vs. 1.90 +/- 1.23 & 9.68 +/- 2.97, respectively. p<0.0001).
Conclusions: Individuals with CD who have variants of the NOD2 gene as a marker of
abnormal innate immunity are more likely to have an increased adaptive immune response
to multiple enteric organisms. These data provide a potential pathophysiologic link to similar
findings in rodent mucosal inflammation. This should allow disease relevant crossover genetic
and functional studies.
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Detection of Muramyl Dipeptide Sensing Pathway Defects in Patients with
Crohn’s Disease
David A. van Heel, Karen A. Hunt, Subrata Ghosh, Kathy King, Simon Gabe, Christopher
Mathew, Alastair Forbes, Raymond J. Playford
Background & Aims: Crohn’s disease is strongly associated with double mutations in NOD2/
CARD15. Three common mutations (Arg702Trp, Gly908Arg, Leu1007fs) impair innate
immune responses to bacterial muramyl dipeptide. Rare NOD2 variants occur, but it is
difficult to both identify them and assess their functional effect. We assessed the true
frequency of defective muramyl dipeptide sensing in Crohn’s disease and developed a rapid
diagnostic assay. Methods: An ex-vivo assay was established and validated based on muramyl
dipeptide stimulation of peripheral blood mononuclear cell cytokine production. Muramyl
dipeptide induced enhancement of IL-8 secretion, and synergistic increase in lipopolysacchar-
ide induced IL-1β secretion were studied. Assay results were compared with NOD2 genotype
status (three common mutations and rare variants) in 91 individuals including a prospective
cohort of 49 Crohn’s disease patients. Results: The assay was highly sensitive and specific
for detection of profound defects in muramyl dipeptide sensing caused by double NOD2
mutations (IL-8 P=0.0002; IL-1β P=0.0002). Disease state, active inflammation or concurrent
use of immunosuppressive medication did not influence results. Healthy NOD2 heterozygotes
had modest impairment of muramyl dipeptide induced IL-8 secretion (p=0.003). Only 1
of 7 Crohn’s disease patients with both a common mutation and a rare variant had a profound
muramyl dipeptide sensing defect. Conclusions: Profound defects in muramyl dipeptide
sensing were found in 10% of Crohn’s disease patients. Defects were due exclusively to
inherited mutations in NOD2. This is the first demonstration of impaired function in NOD2
heterozygotes. The ex-vivo assay has multiple potential applications as a clinical diagnostic
tool to distinguish patients with muramyl dipeptide sensing defects, and for research investi-
gation.
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Genes Regulating the Expression of Antibody to CBIR1 Flagellin in Humans
Are Located Within a Syntenic Region to the Major Mouse Colitogenic Locus
Cdcs1
Kent D. Taylor, Huiying Yang, Ling Mei, Carol J. Landers, Yingzi Cong, Kostas A.
Papadakis, Eric A. Vasiliauskas, Andrew Ippolitti, Charles O. Elson, Jerome I. Rotter,
Stephan R. Targan
Background: CBir1 flagellin has been identified as an antigen capable of inducing severe
colitis in the C3H/HeJBir substrain (Lodes et al 2004, J Clinical Investigation 113: 1296).
Recently, a 7.6 Mb region from the C3Bir strain spanning the NfkbI gene on mouse chromo-
some 3 has been identified as a major modifier of colitis in IL-10 deficient mice (Beckwith
et al 2005, Gastroenterology, 2005: 129; 1473). Bone marrow derived cells from C3Bir.il-
10-/- mice had diminished responses to the TLR5 ligand, CBir1 flagellin, but showed
increased CD4 T-cell responsiveness to this antigen. We have recently shown that antibodies
to CBir1 flagellin are also expressed in the serum of a subset of patients with severe Crohns
disease (CD) as characterized by small-bowel, internal-penetrating, and fibrostenosing disease
features. Aim: To investigate the genetic determinants of CBir1 response in human CD by
linkage analysis of CBir1 expression as a quantitative trait (QTL). Methods: Measurement
of CBir1 serum levels in 968 individuals in 80 CD-only (no UC affecteds) and 57 Mixed
(both CD and UC affected) families was performed by ELISA and a 10cM genome scan was
performed with microsatellite markers. QTL analysis was performed using the SOLAR
program. Results: The heritability of expression of serum antibodies to CBir1 antigen in this
study was 0.19 (p=0.0005). A peak multipoint LOD score for CBir1 expression was observed
for human chromosome 4 at 91 cM (LOD=1.82, marker ATA2A03). This LOD increased
with bivariate linkage analysis of expression of both ASCA and CBir1 antibodies (LOD=
1.99). This region is syntenic to the mouse chromosome 3 Cdcs1 region containing the
NfkbI gene. Conclusions: This observation supports the role of genetic variation that deter-
mines response to CBir1 flagellin in this region in both mouse and human and raises the
possibility that genetic variation in the NF-kappa-B gene creates an abnormal innate response
to enteric bacterial antigens that results in severe CD. For CD, these studies will allow
crossover studies of human and mouse models to determine whether the same genes regulate
similar responses in these species.
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The Characterisation of Distinct Intestinal Gene Expression Profiles in
Inflammatory Bowel Disease (IBD) By Microarray Analysis
Colin L. Noble, Alex Abbas, Jennine Cornelius, Ian D. Penman, Ian D. Arnott, Zora
Modrusan, Toy Karen, Jack Satsangi, Lauri Diehl
Introduction: Gene expression technology using microarray allows a comprehensive picture
of gene expression at the tissue and cellular level. The aim of this study was to investigate
differential gene expression in endoscopic colonic biopsies of a well phenotyped cohort of
IBD patients and controls. Patients and methods: 67 Ulcerative colitis (UC), 53 Crohn’s
disease (CD), and 31 normal and ‘inflamed non-IBD’ controls (HC) were studied. Paired
endoscopic biopsies were taken from specific anatomical locations for RNA extraction and
histology. Patients symptoms were scored at the time of endoscopy (simple clinical colitis
activity index for UC, Harvey-Bradshaw score for CD), medication was noted and phenotypic
data were collected by patient questionnaire and case note review. Whole genome arrays
were used to analyze 230 biopsies using the agilent platform. Conformation of results was
carried out by RTPCR and immunohistochemistry. Results: Comparing 95 UC biopsies to
67 HC biopsies, 1099 genes were up-regulated and 1203 genes were down regulated in the
UC samples (1x10-35 < p< 0.001, Fold change (FC) -1.8- +5.0). When these genes were
grouped by molecular function there were a preponderance of genes associated with deamin-
ase activity (p =0.0007 OR 7.3) and protein binding (p =0.01 OR 1.3). When histologically
inflamed (18) and non-inflamed (19) UC sigmoid biopsies were examined, 1438 genes were
up regulated and 1393 genes were down regulated (2.0x10-41 < p < 0.001, FC, -11.2-
+8.4). Comparing acutely inflamed (11), chronically inflamed (8) and non-inflamed (11)
sigmoid colon UC biopsies, a greater number of differentially expressed genes were associated
with organic acid transporter activity (p =0.006 OR 4.3) and had protein functions in the
extracellular region (p = 2.5x10-5 OR 2.3). A subset of 2309 genes were up regulated and
1860 genes were down regulated in CD biopsies (69) when compared to HC biopsies
(67)(1x10-45< p <0.001, FC -2.3- +7.2). Differentially regulated genes were associated
with immune function when biological processes were considered (p =5.1x10-9 OR 1.72),
hydrogen ion transporter activity when molecular function was considered (p =1.7x10-9
OR 2.15), ribosomal (p =1.2x10-8 OR 7.7) and mitochondrial (p= 1.8x10-8 OR 1.79)
locations of function. Conclusions: In this large, rigorously phenotyped IBD microarray
study, a number of novel gene families have been identified and implicated in the pathogenesis
of CD and UC. These findings have led to the identification of novel potential thera-
peutic targets.
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Safety and Efficacy of Pravastatin 80mg/Day in 320 Hypercholesterolemic
Patients with Compensated Chronic Liver Disease (CLD): Results of a
Prospective, Randomized, Double-Blind, Placebo-Controlled Study
James H. Lewis, Mary Jean Fusco, Jeffrey R. Medoff, Mary Ellen Mortensen, Steven Zweig
HMG-CoA reductase inhibitors are associated with mild elevations in liver-associated enzymes
(LAEs). In pts in clinical trials of cholesterol reduction using pravastatin (Prava)with ALT
values up to 1.5X ULN at entry, no significant hepatic events were reported (Circulation
2002;105:2341), and retrospective studies suggest the safe use of statins in pts with elevated
LAEs (Gastroenterology 2004;126:1287). Herein we present the first prospective study of
a statin in hypercholesterolemic pts with known CLD. METHODS: Screened adult pts with
>6mo of well-compensated CLD of any type and LDL cholesterol >100mg were eligible for
statin treatment. The primary efficacy endpoint was the percentage (%) chnage from baseline
to wk 12 of LDL-C and the primary safety endpoint was the % of pts with at least one ALT
>2X for those with a normal baseline or a doubling of ALT for those with elevated baseline
ALT (up to 5X)within 36wk of once daily dosing with Prava 80mg. Several CLD were
represented, the most common being NAFLD (64%)and chronic hepatitis C (24%). Other
CLD included PBC, PSC, Wilson dis., autoimmune hepatitis, and hemochromatosis. IRB
approval and permission was obtained for all subjects. Enrollment was in a ratio of 1:1
Prava vs placebo (PBO). RESULTS:Prava pts had a clinically significant reduction in total
cholesterol (20%), LDL-C (31%) and TGs(9%) compared to PBO by wk 12 (3%,3%, and
6% increase respectively; p<0.0001 for all 3 comparisons). The % fall in LDL from baseline
at wk 12 for Prava-treated pts was similar for those with mild (100-130mg/dL), moderate(130-
160mg/dL) and severe LDL(>160mg/dL) at baseline (29.1%,32.3% and 33% respectively).
Among 160 pts on Prava , only 12(7.5%)met the ALT safety endpoint vs 20(12.5%) of 160
PBO recipients (p=NS). There was no statistically difference in ALT endpoints at any of the
cumulative visits from wk 1 to 36 vs PBO, and the # pts having sustained ALT elevations
for at least 2 consequtive wks was comparable (5% vs 7% PBO, p=NS). The time to onset
of elevated ALT was also not different between groups (median for both >36wk log rank
p=NS). The cumulative # of events in the Prava group regardless of ALT at baseline also
was not different from PBO. One pt with NAFLD in the PBO group had transient bilirubin
>2X ULN w/o ALT elevation that resolved. CONCLUSIONS:This prospective RCT of Prava
80mg/day was not associated with any excess of ALT or bilirubin elevations compared to
PBO in a variety of CLDs in hypercholesterolemic pts over 36 wks and produced a significant
reduction in total cholesterol, LDL-C and TGs, thereby supporting its safety and efficacy in
this setting.
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Phosphatidylcholine Transfer Protein (PC-TP) Is Regulated By Peroxisome
Proliferator Activated Receptor α (PPARα) and Participates in Pparα-Mediated
Hepatic Triglyceride Metabolism
Keishi Kanno, Erez F. Scapa, Wen-Jun Wang, Gabriela Orasanu, Jorge Plutzky, David
Cohen
Background: We have demonstrated a regulatory role for PC-TP in hepatic triglyceride
metabolism. We have also shown that the Pctp gene promoter contains a binding site for
PPARα, a liver enriched ligand-activated transcription factor that regulates hepatic triglyceride
homeostasis. Aim: To investigate regulation of PC-TP by PPARα in vivo and to determine
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a role for PC-TP in PPARα-mediated regulation of hepatic triglyceride metabolism. Methods:
To elucidate regulation of PC-TP by PPARα, eight week old male wild type and Pctp-/-
C57BL/6J (n=6/group) and FVB/NJ (n=8/group) mice, as well as PPARα-/- (n=6) and wild
type (n=4) 129S3/SvImJ mice were fed 7d chow or chow supplemented with 0.2% fenofibrate,
a known PPARα ligand. Hepatic PC-TP expression was analyzed by quantitative real-time
PCR, as well as Northern and Western blot analysis. To identify potential downstream
hepatic targets of PC-TP, gene expression profiling was performed using eight week male
Pctp-/- and wild type FVB/NJ mice fed 7d fenofibrate-supplemented chow. Total RNA was
extracted from liver and used to hybridize Affymetrix Mouse Genome Array GeneChips (one
chip per mouse, n=6/group), each containing 14,000 mouse genes. Differentially regulated
genes were identified using Bayesian Analysis of Differential Gene Expression (BADGE)
software (Adv Dent Res. 17:104, 2003). Metabolic pathways regulated by PC-TP were
identified using Ingenuity Pathways Analysis software (www.ingenuity.com). Results: In
chow-fed wild type mice, hepatic PC-TP protein, as well as mRNA levels, were lower in
FVB/NJ compared with the C57BL/6J strain. Fenofibrate feeding increased PC-TP mRNA
expression and protein levels in both genetic strains. Quantitative real-time PCR revealed a
22-fold increase of PC-TP mRNA in FVB/NJ mice compared with a 3-fold increase in C57BL/
6J mice, and a 6-fold increase in wild type 129S3/SvImJ mice. Fenofibrate did not induce
hepatic PC-TP mRNA in PPARα-/- mice, indicating that this response was PPARα-dependent.
Based on the potent induction of PC-TP by fenofibrate, FVB/NJ mice were utilized for gene
expression analysis. Consistent with a key role in PPARα-mediated triglyceride metabolism,
BADGE followed by pathway analysis identified that both fatty acid metabolism (14 genes)
and biosynthesis (5 genes) were highly regulated by PC-TP expression. Conclusions: PC-
TP is regulated by PPARα and plays a key role in coordinating PPARα-mediated hepatic
triglyceride metabolism. Because it binds phosphatidylcholines containing polyunsaturated
acyl chains, we speculate that PC-TP may provide a link between triglyceride metabolism
and hepatocellular membrane composition.
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Probiotics Reduce Inflammation in Nonalcoholic Steatohepatitis in An Animal
Model of Sedentary Lifestyle
Stephanie H. Abrams, Chantal A. Rivera, Anita Mantri, James Versalovic, Milton J.
Finegold, C. Wayne Smith
Nonalcoholic steatohepatitis (NASH), which includes steatosis; inflammation; and fibrosis,
currently affects up to 3% of the world’s population. We have previously reported that
male rodents exposed to hindlimb unloading (HU) have pathology resembling NASH. This
phenomenon was associated with elevated levels of portal endotoxin and was not found in
endotoxin-resistant rodent strains. In a genetic model of NASH, probiotics have been used
to modify intestinal flora and have shown a decrease in injury. This study was designed to
assess if NASH secondary to sedentary lifestyle (modeled by HU) and a high fat/high sucrose
(HF/HS) diet is alleviated by colonization with probiotics. It was hypothesized that, as in other
models of steatohepatitis, animals receiving probiotic would have decreased inflammation. To
test this hypothesis, male Wistar rats were fed a HF/HS diet (15% of calories from casein,
32% from corn oil, and 48% from sucrose) for 3 weeks. Subsequently, half of each group
underwent 3 weeks of HU, with the remaining animals housed separately to control for
thermoregulation. VSL#3, a mixture of lyophilized bifidobacteria, lactobacilli, and Streptococ-
cus thermophilus, was given to half of each of the aforementioned groups at a dose of 1.5
X 10^9 colonies/rat/day for 5 days. Colonization of stool was confirmed at the end of 5
days, prior to HU, and at the end of 6 weeks. Upon sacrifice, Oil-red O stained liver sections
demonstrated that the combination of HF/HS diet and HU caused hepatic fat accumulation
and focal necro-inflammatory foci. While treatment with VSL#3 improved necosis and
inflammation, it did not affect steatosis. Consistent with these histological findings, serum
ALT levels of VSL#3 treated HU animals were decreased by more than 3-fold (p=0.009).
Total circulating leukocyte counts were similar among all of the treatment groups; however,
circulating neutrophil counts were significantly decreased in VSL#3, HU animals when
compared to control, HU animals (p<0.001). As expected, adiponectin levels were signific-
antly increased in the VSL#3, HU group (p=0.02), indicating improved insulin resistance
in these animals. It was concluded that the combination of high fat diet and sedentary
behavior due to HU causes steatosis and inflammation consistent with NASH in male
adolescent rats. Consistent with our hypothesis, probiotic treated animals had a decreased
inflammatory response.
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The Gene Encoding the Nuclear Bile Salt Receptor FXR Is Associated with
Cholesterol Gallstone Susceptibility in a Murine Model and in a Mexican
Population
Rahel Kress, Jacqueline Rocha, Peter Kovacs, Nahum Mendez-Sanchez, Michael Stumvoll,
Joachim Mossner, Henning Wittenburg
Cholesterol gallstone susceptibility includes the combination of predisposing alleles of
lithogenic (LITH) genes and environmental factors. Employing quantitative trait locus map-
ping in a previous intercross of gallstone susceptible PERA/EiJ and gallstone resistant I/LnJ
mice, we detected a Lith locus on chromosome 10 named Lith7. The gene encoding the
nuclear bile salt receptor FXR (Nr1h4) is a positional candidate gene for the Lith7 region.
To investigate further an association of Nr1h4 alleles and gallstone susceptibility in mice,
we employed real-time PCR to determine mRNA expression levels of Nr1h4 and its down-
stream genes Cyp7a1 and Cyp8b1 in gallstone susceptible and resistant mice after feeding
chow or a cholic acid enriched diet for four weeks. Furthermore, the Nr1h4 gene was
sequenced in inbred mouse strains with susceptible and resistant Lith7 alleles. To identify
polymorphisms in the orthologous human gene, the 11 exons, the intron-exon boundaries
and 1,5 kb of the 5’ region of NR1H4 were sequenced in 24 subjects. Subsequently, 80
gallstone carriers and 80 age- and sex matched subjects were genotyped for the polymorph-
isms detected by sequencing employing the TaqMan method. Significance levels were deter-
mined by logistic regression. After feeding chow, the expression of Nr1h4 or its downstream
genes Cyp7a1 and Cyp8b1 did not differ between mice carrying the susceptible or resistant

















coding region that lead to amino acid changes. Following activation of FXR by feeding cholic
acid, mice carrying the susceptible Nr1h4 allele displayed significantly lower expression
levels of Cyp7a1 and Cyp8b1 compared with animals carrying the wild type allele suggesting
an association of impaired cholesterol degradation into bile salts and cholesterol gallstone
formation. To translate our findings from inbred mice to men we aimed to identify an
association of genetic variation of NR1H4 and gallstone prevalence in a Mexican population.
Sequencing detected 7 single nucleotide polymorphisms in the screened population that
were all in Hardy-Weinberg equilibrium. Three polymorphisms were associated with choleli-
thiasis: 5’ region -20647T>G, p=0,06, RR 2,38 (95% confidence interval 0,95 - 5,9); exon3 -
1G>T, p=0,04, RR 4,0 (1,05 - 15,2) and IVS7 -31T>A, p=0,05, RR 2,11 (0,99 - 4,50). In
conclusion, our results indicate a primary role of FXR in the genetic susceptibility and
pathogenesis of cholesterol gallstones. Therefore, the bile salt receptor is an attractive target
for the development of new means of prevention and non-surgical management of choles-
terol cholelithiasis.
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Characterisation of the Intrahepatic Immune Response in C5 Bac-Transgenic
Mice During Liver Fibrogenesis
Sonja Hillebrandt, Hermann E. Wasmuth, Judith Dahmen, Christian Trautwein, Tilman
Sauerbruch, Frank Lammert
Background: BAC transgenesis of the gene for complement factor C5 in C5-deficient FVB/
N mice leads to increased susceptibility to liver fibrosis and confirms the identity of C5 as
the fibrogenic modifier gene identified on chromosome 2 (Hillebrandt et al. Nat Genet
2005;37:835-43). Recently it has been postulated that the fibrosis phenotype in different
organs is tightly regulated by the quality of the T-helper (Th)-cell response (Wynn Nat Rev
Immunol 2004;4:583-94). The aim of the present study was to characterize the intrahepatic
immune regulation related to fibrogenesis in C5 BAC-transgenic mice. Methods: Liver fibrosis
in C5 BAC-transgenic mice and in the FVB/N (C5-/-) background was induced by CCl4
challenge for 6 weeks (2 ml/kg/wk i.p.). For quantification of liver fibrosis, hepatic collagen
concentrations and histological stages of fibrosis were determined. The hepatic mRNA
expression of regulatory type 1 cytokines IL-12p35, IL-23p19 and IL-27p28 as well as the
expression levels of the cytokines IL-6 and TNF-α were measured by quantitative RT-PCR
(Taqman). Results: After challenge with CCl4, C5 BAC-transgenic mice displayed significantly
(P < 0.01) higher hepatic fibrosis stages (2.00 ± 0.10) and collagen concentrations (352 ±
12μg/g) compared to non-transgenic FVB/NJ mice (1.46 ± 0.14 and 227 ± 10 μg/g, respect-
ively). Interestingly, the expression levels of the regulatory cytokines IL-12p35, IL-23p19
and IL-27p28 were significantly lower in C5-sufficient BAC-transgenic mice in comparison
to the C5-deficient FVB/N background (all P < 0.05). The reduced expression of these type
1 cytokines was correlated to the severity of liver fibrosis. In contrast, the expression of IL-
6 and TNF-α did not differ significantly between the strains, indicating that immune activation
was not generally suppressed by C5 BAC transgenesis. Conclusions: The reduced expression
of regulatory type 1 cytokines of the IL-12 family in fibrosis prone C5-sufficient mice is in
line with the paradigm that polarized Th cells regulate organ fibrosis and that a shift from
Th1 to Th2 cytokine subsets promotes fibrogenesis.
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Efficacy of Leukocyte Esterase Dipstick Test As a Screening Test for
Spontaneous Bacterial Peritonitis (SBP)
Worawut Rungsangmanoon, Pradermchai Kongkam, Rungsun Rerknimitr
Introduction: The diagnosis of spontaneous bacterial peritonitis (SBP) is established by a
positive ascitic fluid bacterial culture and/or more than 250 cell/mm3 of polymorphonuclear
leukocyte (PMN) in ascitic fluid. One of rapid tests for detecting PMN is leukocyte esterase
(LE) strip test. Aims: To evaluate efficacy of the LE test as a screening method for SBP.
Methods: There were 200 ascitic fluid samples from patients whom SBP was suspected.
Urine dipstick (Combur10 Test ®M from Roche, Mannheim, Germany) was used as a
screening test. And then manual PMN count was referred as a gold standard. Number of
PMN more than 250 cells / mm3 by manual count was used as a cut off values. One to
three plus LE strip test results were used as a positive result. Results from both tests were
compared to determine the efficacy of LE strip test. Results are shown in the table. Results:
Prevalence of SBP diagnosed by manual cell count was 21.0 %. The sensitivity and specificity
of LE test were 88.1 % and 81.0 % respectively. Positive and negative predictive values
were 55.2 % and 96.2 % respectively. The likelihood ratio was 4.6 times. Conclusion: LE
strip test can be used as a screening test to exclude SBP since it has a high negative
predictive value.
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VIP Induces L-Type Calcium Channel Gene Expression in Human Colonic
Circular Smooth Muscle Cells: A Novel Role in Regulation of Motility
Function
Xuan-Zheng Shi, Barun K. Choudhury, Sheng Yan, Bal M. Mishra, Sushil K. Sarna
Vasoactive Intestinal Polypeptide (VIP) is an established inhibitory neurotransmitter of the
NANC neurons. The aim of the present study was to determine whether VIP also mediates
gene expression in human colonic circular smooth muscle cells (HCCSMC), and if so what
are the molecular mechanisms of this novel function of VIP. Our findings show that VIP
induces gene expression of the pore-forming α1C subunit of L-type Ca2+ channels. Methods:
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The experiments were performed on primary cultures of HCCSMC and on freshly isolated
human colonic circular smooth muscle strips. Results:Incubation of HCCSMC with 10-8 to
10-6 M VIP for 24 hours concentration-dependently increased α1C mRNA and protein levels
when compared with medium control. The maximal increase of α1C mRNA and protein levels
at 24 hours were 45 ± 4% and 42 ± 5%, respectively. None of the other neurotransmitters
(Acetylcholine, Nitric oxide, ATP, Substance P) at same concentrations produced this effect.
VIP (10-7 M) time-dependently enhanced cellular cAMP and phosphorylated protein kinase
A (PKA). VIP also transiently phosphorylated cAMP response element binding (CREB)-
transcription factor for about one hour. Sequence analyzer identified two variant cAMP
response elements, CRE1 (5’-TGACGTCA-3’, -563 to -556 from the transcription start site)
and CRE2 (5’-TGACAGCA-3’, -176 to -169) on the promoter of human α1C gene of L-type
Ca2+ channels (hα1C1b). Agarose nucleotide pull down assay showed increased binding of
CREB to both response elements in response to 10-7 M VIP (CRE1>CRE2). The inhibition
of CREB by siRNAs blocked VIP-induced binding to CRE1 and CRE2 as well as the increase
in expression ofα1C. PKA inhibitor H-89, which blocked VIP-induced CREB phosphorylation
also inhibited the enhanced gene expression of α1C. VIP 10-7 M increased α1C1b promoter
activity by 43 ± 7% in HCCSMC. Studies with progressive 5' deletions of promoter hα1C1b
showed that CRE1 motif, rather than the CRE2 motif, plays a predominant role in regulating
VIP-enhanced expression of α1C. Incubation of fresh circular muscle strips for 24 h with
10-7 M VIP enhanced their response to 10-6 to 10-2 M ACh in organ bath, when compared
with those incubated with medium only and it also increased the expression of α1C in tissue.
Conclusion: VIP, one of the neurotransmitters of NANC neurons, also regulates gene
expression of the pore-forming subunit α1C of L-type Ca2+ channels that maintains normal
human colonic smooth muscle function. This novel function of VIP is PKA-dependent and
is mediated by transcription factor CREB.
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A Novel Innervation of the Crural Diaphragm By the Vagus
Richard L. Young, Nicole J. Cooper, L Ashley Blackshaw
The gastroesophageal reflux barrier is secured by both the inner lower oesophageal sphincter
(LES) and the external crural diaphragm (CD). During gastroesophageal reflux both transient
LES relaxation and CD inhibition occur concomitantly, permitting esophageal common
cavity, and acid reflux. Our group has characterised how the LES is controlled by the vagus
nerve during reflux events [1] but the neural mechanism that controls relaxation of the CD
has not been fully investigated. Recent evidence suggests a novel inhibitory nerve pathway
may act on the CD independent of the phrenic nerve [2]. Understanding this pathway and
its relation to LES control may provide new insights into the mechanisms of gastroesophageal
reflux. The aims of this study were to determine if the vagus provides a motor and/or sensory
innervation of the CD in ferrets. METHODS: Restricted volumes of retrograde nerve tracers
CTB-FITC and CTB-HRP were injected into the CD, costal diaphragm and LES of 8 ferrets.
Brainstem, spinal and vagal tissues were removed after 5 days recovery. RESULTS: CD
tracing labeled spinal sensory neurons in dorsal root ganglia and motor neurons in phrenic
motor nucleus (C5-7) as expected. In addition we labeled a unique population of vagal
sensory (nodose ganglion) and motor neurons (rostral dorsal motor nucleus of vagus).
Innervation of the CD by the vagus was specific for this portion of the diaphragm as tracing
from the costal diaphragm did not label vagal structures. Dual-tracing studies from LES and
CD also revealed rare co labeled vagal afferents in the nodose ganglion. CONCLUSIONS:
These findings indicate that the CD is uniquely and specifically innervated by vagal afferents
and efferents in the ferret. Moreover, the finding of co-innervation from LES and CD suggests
that a single vagal afferent may provide sensory input from both structures. The function
and phenotype of vagal afferent and efferent neurons innervating the CD is the subject of
ongoing studies in our laboratory. 1. Blackshaw L.A. et al J Auton Nerv Syst 1997 66:179-88
2. Liu J. et al Am J Physiol Gastrointest Liver Physiol 2000 278:G281-8 Supported by: AstraZeneca
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Chemical Hypersensitivity in Patients with Functional Dyspepsia
Johannes Matiasek, Lorenz Pipal, Johann Hammer
Background: The pathophysiology of functional dyspepsia (FD) is unclear; chemical hyper-
sensitivity might be a causing factor. Capsaicin stimulates the vanilloid receptors (VR1) on
afferent neurons, that are involved in chemical nociception in the upper GI tract. Aim: To
evaluate the sensitivity for gastric capsaicin in healthy controls and in patients with FD or
other GI disorders. Methods: N=25 healthy controls, n=30 patients with functional dyspepsia
(FD), n=17 with inflammatory bowel disease (IBD), n=10 with gastric ulcers or erosions,
and n=19 with other GI symptoms swallowed a capsule after an overnight fast containing
0.75 mg capsaicin. Subjects filled out a graded questionnaire evaluating the severity of 9
different upper abdominal symptoms before and 30 minutes after capsule ingestion; an
aggregate symptom score was calculated by adding all symptom scores. Data are expressed
as mean ± SEM; p-values <0.05 were considered significant. Results: Healthy controls had
an aggregate symptom score of 6.3±2.9; the median was 6.5 (25% confidence interval: 4).
The 75% confidence interval was 9 and was considered as the upper limit of normal. The
FD group had a mean symptom score of 12.2±5.6 (p<0.001 vs. controls). The aggregate
symptom scores in the IBD group was 3.9±4.4 (NS vs. controls, p<0.001 vs. FD), in the
ulcer group was 3.3±4.3 (NS vs. controls, p<0.001 vs. FD), and in the group with other
GI symptoms was 6.1±6.3 (NS vs. controls, p<0.001 vs. FD). 60.0% of the FD group had
a positive capsaicin test (aggregate symptom score >9), 40.0% were negative. Among the
FD group testing positive, 38.9% had pain-predominant FD, 50% discomfort-predominant
dyspepsia; in 2 subjects data were missing. 33.3% of the patients with a negative capsaicin
test had pain predominant FD, 50% discomfort predominant FD, in 2 subjects data were
missing. Summary: 60% of patients with FD were hypersensitive against gastric capsaicin,
independent whether the predominant symptom was pain or discomfort. Conclusion:
Chemical hypersensitivity discriminates functional disorders from healthy controls and
patients with other upper GI disorders. The capsaicin test is a simple and non invasive
method to detect the subgroup of functional dyspepsia with chemical hypersensitivity.
Targeting the VR1 receptor might be a therapeutic option in a large subgroup of patients
with functional dyspepsia.
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Alternatively Activated Macrophages Contribute to Enteric Nematode
Infection-Induced Intestinal Smooth Muscle Hypercontractility in Mice
Aiping Zhao, Robert M. Anthony, Justin E. Elfrey, Kathleen B. Madden, Rex Sun, William
C. Gause, Joseph F. Urban, Terez Shea-Donohue
We showed previously that nematode infection induced an intestinal smooth muscle hyper-
contractility that depends on IL-13 activating STAT6. Macrophages orchestrate inflammatory
responses and have been implicated in nematode infection. Depending on the cytokine
environment, macrophages can differentiate into distinct subsets: classically activated macro-
phages (caMΦ) that are activated by IFNγ and are characterized by the secretion of nitric
oxide via NOS-2; or alternatively activated macrophages (aaMΦ) that are induced by Th2
cytokines, IL-4 and IL-13, and are characterized by the upregulation of arginase-I. Aim: To
determine the contribution of aaMΦ to H. polygyrus (Hp) infection-induced changes in
murine intestinal smooth muscle function. Methods: BALB/c mice were infected with Hp,
cured, re-infected (Hp2), and studied 14 days later. Groups of infected mice were injected
with 0.2 ml of PBS- or clodronate-liposomes to deplete macrophages. Segments of jejunum
from mice were suspended longitudinally in organ baths. After equilibration, the amplitude
of the spontaneous contractions (SC) was measured over a 2-min period. Responses to
acetylcholine (ACH), electric field stimulation (EFS), and 5-HT were determined. Real-time
quantitative PCR was used to measure the mRNA expression of the molecular markers for
caMΦ and aaMΦ from intestine. Results: Hp2 infection increased F4/80 mRNA expression
(4-fold), a macrophage molecular marker. In addition, infection upregulated the mRNA
expressions for aaMΦmarkers including arginase I (144-fold), macrophage mannose receptor
(13-fold), MGL1 (5-fold), MGL2 (59-fold), and FIZZ1 (498-fold), but did not affect the
expression of NOS-2, a caMΦ marker, indicating specific accumulation and activation of
aaMΦ. Hp2 infection induced an intestinal smooth muscle hypercontractility (Table), includ-
ing elevated responses to ACH, EFS, and 5-HT, and increased amplitude of SC. However,
depleting macrophages with clodronate prevented Hp2-infected mice from developing this
hypercontractility. Conclusions: Hp2 infection induces the recruitment and activation of
aaMΦ that are required for the induction of intestinal smooth muscle hypercontractility.
Thus, aaMΦ play a major role in IL-13-induced alterations in smooth muscle function that
contribute to host defense against intestinal nematode infection.
Values=Tensions in N/cm2; *p<0.05 vs Control; Φp<0.05 vs Hp2-PBS; n≧4
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Timed Feeding Alters Clock Gene Expression in the Murine Stomach and
Colon
Willemijntje A. Hoogerwerf, Joshua R. Scott, Tor C. Savidge, Helen Hellmich
Background. Disruption of biological rhythms, such as occurs with shift work or time zone
traveling, has been associated with gastrointestinal symptoms. These observations suggest a
functional correlation between biological rhythms and gastrointestinal physiology. Biological
rhythms are controlled by clock genes. A central clock is located in the suprachiasmatic
nucleus of the brain. Clock genes have been identified in peripheral organs as well. Within
a peripheral organ, clock genes can control the expression of a subset of tissue-specific
genes, which may impact directly on its physiological function. Clock genes synchronize
themselves to external time cues such as the light/dark cycle and feeding. We previously
reported circadian expression of clock genes in the murine proximal colon. The aim of this
study was to determine (1) whether circadian clock gene expression occurs in other parts
of the gastrointestinal tract and if so, whether they are synchronized and (2) whether clock
genes in the murine intestine can shift their expression patterns in response to a restricted
daytime feeding schedule. Methods. Adult male C57BL/6J mice were kept under a 12 hr
light/dark cycle (lights on at 7 AM). Group 1 was fed ad lib for one week. Group 2 and 3
were fed for the first 4 hours of the light cycle for 48 hrs and 1 week respectively. Total
RNA was isolated from the stomach body, proximal- mid- and distal colon every 4 hrs
starting at 4 AM (n=3 mice per time-point). A real-time multiplex PCR assay was developed
for the detection of the clock genes period (PER2, PER3), cryptochrome (CRY1) and PAS
helix-loop-helix transcription factor (Bmal1). PCR data were normalized against 18S. Statist-
ical analysis was performed using a 2 way-ANOVA followed by a Tukey test. Results. Peak/
trough ratios for PER2, PER3, CRY1 and Bmal1 in the proximal colon changed from 20.1,
23.3, 2.3 and 10 at baseline to 5.9, 3.2, 5.4 and 5.6 following 48 hrs of restricted feeding,
respectively (P<0.05). Peak expression shifted from 8 PM to 4 PM, 8 PM to 8 AM, 4AM to
12 PM and 4 AM to 4 PM, respectively. This pattern persisted following 1 week of restricted
feeding. Similar observations were made in the stomach body, mid- and distal colon.
Conclusion. Restricted feeding can shift clock gene expression in the murine stomach and
colon. The data suggest that the stomach and colon may have a time-keeping capability
that allows for the physiological adaptation to environmental stimuli. We speculate that
gastrointestinal symptoms may result from the inability of clock genes to make timely
adjustments to changes in environmental cues, such as occurs with time zone traveling and
shift-work.
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Fecal Serine-Protease Activity: A Pathophysiological Marker and Possible
Therapeutical Target in Diarrhea-Predominant Irritable Bowel Syndrome
Richard Roka, Andras Rosztoczy, Mathilde Leveque, Ferenc Nagy, Janos Lonovics, Rafael
Garcia-Villar, Jean Fioramonti, Tibor Wittmann, Lionel Bueno
Background: The pathogenesis of irritable bowel syndrome (IBS) remains only partially
understood, and no specific or universally effective patient management procedure has been
developed so far. Activation of receptors for proteases located on colonocytes may participate
in immune mucosal stimulation. Consequently, our study was designed to evaluate if colonic
luminal serine-proteases may be altered in IBS. Methods: Fecal samples of 38 IBS patients
(IBS-D:17; IBS-C:14; IBS-A:7), 15 patients with ulcerative colitis (UC) and 15 healthy controls
were studied. Fecal serine-protease activity was determined photometrically using azocasein
as a proteolytic substrate; fecal pancreatic elastase-1 and mast cell tryptase content were
measured by ELISA. Fecal secretory leukocyte protease inhibitor (SLPI) concentration was
determined by ELISA in control subjects and in patients with diarrhea-predominant IBS.
Results: Fecal serine-protease activity was 3-fold higher (p<0.001) in patients with diarrhea-
predominant IBS (67.9±10.8 U/mg protein), than in both controls (16.4±5.0 U/mg protein)
and IBS patients with either constipation (16.0±7.0 U/mg protein) or alternating bowel
habits (16.4±7.1 U/mg protein). Fecal serine-protease activity was not correlated with the
frequency of bowel movements in all groups. Elevated serine-protease activity was also
detected in stools of UC patients (67.4±15.3 U/mg protein). No significant difference was
observed in fecal mast cell tryptase and pancreatic elastase concentrations between all groups,
and in fecal SLPI concentration between controls and diarrhea-predominant IBS patients.
Conclusions: Fecal serine-protease activity is markedly elevated in patients with diarrhea-
predominant IBS. This increase, however is not coupled with changes in either mast cell
tryptase or pancreatic elastase concentrations, and may participate in the mucosal immune
stimulation described in such patients and subsequently in the genesis of their symptoms.
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Inhibition of the Putative Anion Transporter (PAT-1, SLC26A6) Impairs the
Ability of Upper Villous Epithelial Cells to Regulate Intracellular pH During
H+-Dipeptide Transport
Janet E. Simpson, Nancy M. Walker, Manoocher Soleimani, Lane L. Clarke
Carrier-mediated transport of di- and tripeptides via the small intestinal oligopeptide trans-
porter PEPT1 accounts for the majority of dietary amino acids absorbed after protein digestion.
Proton influx during PEPT1 di-/tripeptide uptake by intestinal epithelium requires mainten-
ance of intracellular pH (pHi) to sustain the driving force for peptide absorption. Studies
performed in the absence of CO2/HCO3- in the medium have demonstrated that the apical
membrane Na+/H+ exchangers NHE3 and NHE2 can effectively minimize pHi acidification
during proton di-/tripeptide transport. However, the contributions of acid-base transport
proteins in the regulation of pHi during H+-peptide transport have not been fully investigated
under physiologic conditions (i.e., in the presence of CO2/HCO3-). Therefore, we used
BCECF microfluorimetry to measure pHi and to investigate the role of acid-base transporters
during exposure of the epithelium to the dipeptide glycyl-sarcosine (gly-sar) in Kreb’s HCO3-
Ringers. Measurements were made in the upper villous epithelium of the murine duodenum
because this is a major site of PEPT1 activity. Surprisingly, we found that inhibition of
luminal Cl-/HCO3- exchange with either 100 µM niflumic acid or application of bilateral
Cl- free conditions resulted in a greater proton influx during gly-sar exposure (NFA = -
7.05± 0.89; Cl- free = -15.93 ± 0.21 mM/min; control = -0.83 ± 0.94 mM/min; n = 3;
p<0.05). Since PAT-1 is the major apical membrane Cl-/HCO3- exchanger in the upper
duodenal villous epithelium, we measured the effect of gly-sar transport on pHi in wild-
type (WT) and PAT-1 knockout (KO) duodena. Exposure to gly-sar resulted in a greater
proton influx in the PAT-1 KO as compared to WT (-9.54 ± 3.40 vs. -0.07 ± 0.79 mM/
min, n = 3, p<0.05). The effect of gly-sar on pHi was also compared between WT and
carbonic anhydrase II (CAII) knockout intestine because previous studies have shown that
CAII interacts with PAT-1 and plays a role in facilitating peptide transport in physiological
solutions. Gly-sar-induced acidification was significantly greater in the CAII KO intestine (-
14.37 ± 1.71 vs. - 1.68 ± 1.03 mM/min, n =4, p<0.05). We conclude that PAT-1 Cl-/
HCO3- exchanger in conjunction with CAII contributes to protection against intracellular
acidification during H+-dipeptide absorption in the upper villous epithelium, perhaps by
operating in Cl-out/HCO3-in mode as a base-loading mechanism for the epithelial cell. Sup-
ported by NIH.
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Glucose-Dependent Insulinotropic Polypeptide (GIP) Stimulates
Transepithelial Glucose Transport in Mouse Jejunum in Vitro
Selvi Krishnan, M.michael Wolfe, John H. Schwartz, Satish K. Singh
Background: Recent reports have suggested a key role for GIP, a regulatory peptide synthe-
sized by intestinal enteroendocrine K-cells, in the pathogenesis of obesity. Previous studies
from our group have demonstrated effects of GIP on nutrient deposition. Thus, we hypothes-
ized that GIP may regulate intestinal glucose transport directly and thereby influence systemic
glucose homeostasis. Objective: To characterize the effects of GIP on jejunal glucose transport
in vitro. Methods: Stripped proximal jejunal epithelium from fasted mice was mounted in
Ussing chambers: The serosal side was bathed with a bicarbonate-Ringer solution containing
5mM glucose, and the mucosal side, with a solution containing 10mM 3-O-methyl glucose
(3OMG), a non-metabolizable glucose analog. Mucosa-to-serosa fluxes of 3OMG (Jms3OMG)
and short circuit current (Isc) were determined in the presence and absence of 1µM and
10nM GIP, with and without the inhibitors of glucose transport, phlorizin (20µM) and
phloretin (250µM). To examine whether GIP stimulates epithelial cells directly, viable
enterocytes isolated by Ca2+-chelation were incubated with GIP for 4h after which cAMP
was measured by RIA. Results: GIP increased both Isc and Jms3OMG significantly. The
increase in Jms3OMG was greater than the change in Isc (68% vs. 53%). As such, the

















component. The stimulatory effect of GIP on Jms3OMG was concentration-dependent: 1µM
and 10 nM GIP increased Jms3OMG by 70% and 30% over control, respectively, consistent
with receptor activiation. Phlorizin, an inhibitor of SGLT1, abolished the increase in Isc and
decreased Jms3OMG by ~65%. These results indicate that stimulation of SGLT1 by GIP only
partially accounts for the increase in Jms30MG. Phloretin further inhibited GIP-stimulated
Jms3OMG, suggesting that GLUT2 contributes to the effects of GIP on glucose transport.
Finally, cAMP, a previously described second messenger of GIP in pancreatic islet beta-cells,
was increased 2.5-fold in isolated enterocytes, consistent with a direct effect on these epithelial
cells. Conclusion: The present studies are the first to demonstrate direct stimulation of
intestinal glucose transport by GIP independent of its insulinotropic properties. GIP stimulates
epithelial cAMP and thereby upregulates glucose transport. The GIP-induced increase in
glucose transport is mediated primarily by SGLT1 and, to a lesser extent, by GLUT2. The
stimulation of multiple jejunal glucose transport processes further supports the hypothesis
that GIP plays an important role in glucose homeostasis and the pathogenesis of obesity.
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Role of Peptide YY in Ileal Brake Induced Satiety and Proximal Gastric
Function
My K. Vu, Jeroen W. Maljaars, Izak Biemond, Banafsche Mearadji, Ad Masclee
Activation of the ileal brake with ileal fat perfusion induces satiety and reduces food intake.
Peptide YY (PYY) is considered as mediator of the ileal brake. Recent studies indicate that
PYY influences satiety but the role of PYY as physiological mediator is under debate. The
present study was undertaken to compare the effects of ileal brake activation with ileal fat
(endogenous PYY release) versus exogenous PYY infusion on satiety and proximal gastric
motor function. Two protocols were performed in 16 healthy volunteers (8 per protocol;
7M, 9F; age 22-53 yr). Study A: ileal fat perfusion (Intralipid 20%, 2 kcal/min for 3 hrs)
versus saline (control) on two separate occasions. Study B: PYY 3-36 infusion at low and
high doses of 15 and 30 pmol/kg/hr vs. placebo, on three separate occasions. Studies were
performed in the fasting state and in response to a 200 ml, 300 Kcal liquid meal. Parameters
studied were: plasma PYY (RIA), satiety (hunger, fullness, wish to eat, nausea) by visual
analog scale (range 0-100mm) and proximal gastric motility (volume by barostat). Results:
Ileal fat significantly (p<0.05) increased plasma PYY from 15 ± 1 to 26 ± 2 pM. During PYY
infusion plasma levels of 28 ± 3 pM (with the dose of 15 pmol/kg/hr) and 55 ± 10 pM
(with the dose of 30 pmol/kg/hr) were reached. Ileal fat significantly (p<0.01) increased
satiety (fullness increment 15 ± 3 mm) in contrast to PYY (fullness increment 2 ± 1 mm).
In the postprandial state, ileal fat also significantly (p<0.01) increased satiety (meal+ileal fat
vs meal+placebo: fullness increment 25 ± 3 vs 12 ± 3 mm) while exogenous PYY did not
further increase satiety (meal + PYY vs. meal with placebo : fullness increment 11 ±2 vs.
10 ±2 mm). The same was true with respect to hunger scores. Fasting gastric volume
(barostat) increased significantly (p<0.01) in response to ileal fat (from 150 ± 14 ml to 433
± 54 ml) but not in response to PYY 3-36 infusion (from 162 ± 18 ml to 180 ±19 ml; n.s.).
In all experiments ingestion of the meal resulted in an identical increase in proximal gastric
volume to a volume of 400-450 ml at 15 min postprandially. Postprandial proximal gastric
volume at 90 min after meal ingestion was significantly (p<0.01) higher during ileal fat vs.
control (410 ± 42 ml vs 183 ± 20 ml) while PYY infusion did not affect volume over control
(230 ± 19 ml vs 187 ± 15 ml). It is concluded that ileal fat induces satiety and results in
proximal gastric relaxation, in contrast to exogenous PYY 3-36 at identical plasma levels.
These data do not support a role for PYY as physiological mediator in ileal brake induced
satiety or ileal brake induced proximal gastric relaxation.
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A Comparison of Nasogastric, Nasojejunal and Parenteral Feeding in Acute
Stroke Patients with Lower Esophageal Sphincter Dysfunction
Richa Dewan, Nitin Gupta, Rahul Anand, Pankaj Mehta, V V. Mittal, Divey Manocha,
Ravi Nehru, Kuldeep Kumar
In acute ischemic stroke, aspiration is the 2nd most common cause of mortality (after brain
herniation). Lower Esophageal Sphincter (LES) dysfunction may predispose to aspiration in
this setting, and there is no prospective trial in acute stroke comparing the various modes
of feeding. OBJECTIVE: To compare the effect of Nasogastric (NG), Nasojejunal (NJ) and
Total Parenteral Nutrition (TPN) on aspiration and mortality in acute stroke with LES
dysfunction. METHOD: 71 patients of Cerebral Infarction with GCS score ≤ 7, and who
failed the Water Swallow Test at 72-96 hours of onset of cerebral infarction were studied.
Those with diabetes, known esophageal/jejunal disease, and known aspiration were excluded.
Esophageal manometry was performed on entry at 72 hrs post stroke, and patients with
resting LES tone of ≤ 4.5 mmHg were included in the study. Baseline parameters included
age, sex, site and size of infarct, and NIH stroke scale and GCS scores. At 72-96 hours post-
stroke, they were randomly divided into 3 groups receiving NG, NJ and TPN feeds respectively
for next 7 days while being monitored for outcomes of aspiration and death. RESULTS: Of
71 patients, 18 (25%) developed aspiration pneumonia. 11 of 25 (48%) on NG feeds, 4 of
23 (17%) on NJ feeds and 3 of 23 (13%) on TPN aspirated. All patients who developed
aspiration pneumonia died. Aspiration was comparable in patients on NJ feeds and TPN
(p= 1). The patients on NG feeds had significantly higher aspiration pneumonia and related
mortality as compared to the other 2 groups (p= 0.027). There was significantly more gastric
residual volume in the NG feeds group. Diarrhea was more in the NJ group as compared
to the TPN group, but this difference was not significant. Metabolic complications were
more common with TPN but not significant. A total 29 patients died, 16 of 25 (64%)in the
NG group, 7 of 23 (30%) in NJ group and 6 of 23 (26%) in the TPN group. Of these 29
patients, 18 patients died of aspiration pneumonia. Mortality was significantly higher in NG
feeds group (p= 0.013 by Pearson chi square test), as compared to the NJ feeds and TPN
groups which were comparable to each other (p=1). CONCLUSION: In patients of acute
stroke with LES dysfunction, Nasojejunal feeding significantly reduces the risk of aspiration
pneumonia and mortality as compared to Nasogastric feeding, and is comparable to TPN
in terms of reducing aspiration risk.
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Effects of Modified Oral Diet and Human Growth Hormone On Nutrient
Absorption and Parenteral Nutrition Needs in Adults with Severe short Bowel
Syndrome: Results of a Randomized, Double-Blind, Placebo-Controlled
Clinical Trial
Concepcion Fernandez-Estivariz, Menghua Luo, Niloofar Bazargan, Li H. Gu, Shanthi V.
Sitaraman, Jan-Michael Klapproth, Dean P. Jones, John R. Galloway, Lorraine M. Leader,
Thomas R. Ziegler
Background: Limited data exist on gut rehabilitation with dietary changes alone versus diet
+ growth factors in patients with SBS. We evaluated gut nutrient absorption and PN needs
in response to diet change ± growth hormone (GH) over a 12-week period in adults with
severe SBS. Methods: Stable adults with PN-dependent SBS were admitted to the GCRC for
28 days. Subjects underwent 7-day baseline studies with usual oral diet and PN. Gut
absorption (% of intake) of nitrogen (N), fluid, sodium (Na), potassium (K) and magnesium
(Mag) and stool wet weight (WW) was determined in pooled 4-day studies. Body composition
was determined by DEXA. During the subsequent 21 days, subjects continued usual PN,
but were placed on individualized oral diets, modified daily based on tolerance and stool
output. Dietary principles included small frequent feeds, use of oral rehydration solutions and
limited simple sugars, lactose, and fat. During this 21-day period, subjects were randomized to
receive, in a double-blind manner, sc saline (control; n=9) or hGH (0.1 mg/kg/day; n=14)
daily. Nutrient absorption and DEXA studies were repeated during week 4 (days 25-28).
Subjects were discharged home on a 3X/week study drug regimen for 8 subsequent weeks
with close outpatient dietary and clinical monitoring. PN was weaned as appropriate, based
on serial clinical and biochemical data, diet responses and daily urine and stool output. At
week 12, subjects were readmitted to the GCRC and the studies above were repeated.
Results: Control and hGH groups were similar in gender, age, residual gut length and chronic
daily PN needs. Both diet modification and hGH were well tolerated. Nutrient absorption
and PN weaning were similar over time in the diet + hGH and the diet + placebo patients
(not shown). However, % change in nutrient absorption from baseline to weeks 4 and 12
markedly improved in the entire study group for N (week 4 +10 and week 12 +10 %,
respectively), fluid (+13 and +22%), Na (+36 and +43%), K (+22 and + 24%), Mag (+3
and 22%) and stool wet weight fell (-710 ±207 and -489±180 mL); all P<0.01 vs baseline.
Weekly PN needs in the entire study group at week 12 were markedly decreased from baseline
(-7.5±1.0/L; P<0.001). The change in lean body mass (LBM) by DEXA was significantly greater
in the hGH group at week 4 (control +0.7±0.6 vs hGH +2.1±0.4 kg; p<0.04) and week 12
(control -0.8±0.7 vs hGH +1.8±0.1 kg; p<0.04). Conclusion: Use of hGH did not add to
the effects of diet alone to enhance nutrient absorption and PN weaning but maintained
LBM. Individualized modified diet is an effective approach to improve nutrient absorption
and facilitate PN weaning in adult SBS patients.
463
in Vitro and in Vivo Characterization of the Minimal Promoter of the Human
Intestinal Biotin Transporter HSMVT: Adaptive Regulation of the Biotin
Uptake Process
Jack C. Reidling, Hamid M. Said
Background: The molecular mechanisms involved in the regulation of biotin transport in
mammalian cells are poorly understood. Previous studies established that the human sodium
dependant multivitamin transporter, SMVT, is the predominant system involved in biotin
uptake in the human intestine. Little is known about the basal transcription activity of the
SMVT gene or about possible adaptive regulation of the human intestinal biotin uptake
process by dietary substrate levels or the mechanism(s) involved in such a regulation. Our
aim in this study was to address these issues. Methods: In vitro characterization of the
minimal promoter region of the SMVT gene was performed using human-derived intestinal
epithelial Caco-2 cells, mutational analysis and electrophoretic mobility shift assays (EMSA);
in vivo characterization was achieved using transgenic mice that express the human SMVT
promoter (fused to the luciferase reporter gene). Adaptive regulation was studied by compar-
ing carrier-mediated biotin uptake, SMVT protein and mRNA levels as well as SMVT promoter
activity in Caco-2 cells under biotin deficient and control conditions. Results: In vitro studies
demonstrated that mutation of specific cis-elements in the SMVT minimal promoter (GKLF,
AP2) led to a decrease in activity. Using EMSA specific DNA/protein complexes are being
identified and interacting factors determined by oligonucleotide competition and antibody
super-shift analysis. In vivo studies using transgenic mice established the physiological
relevance of in vitro data by demonstrating activity of the cloned full-length SMVT promoter.
In addition, the in vivo studies showed that the pattern of expression of the SMVT promoter-
luciferase constructs in transgenic mice were similar to our observed RNA expression pattern
in native human tissues. Our studies on possible adaptive regulation of biotin in Caco-2
cells showed that maintaining these cells in a biotin deficient condition leads to a significant
and specific up-regulation in carrier-mediated biotin uptake which is associated with an
induction in protein and mRNA levels of SMVT. In addition, an increase in the activity of
the human SMVT promoter was observed in Caco-2 cells maintained under biotin deficient
conditions. Conclusions: 1) GKLF and AP2 play roles in driving the basal transcription of
the SMVT promoter, 2) the cloned promoter is functional in vivo in transgenic mice, and
3) biotin uptake by Caco-2 cells and expression of SMVT is adaptively up-regulated during
biotin deficiency, and this up-regulation is mediated via transcriptional regulatory mechan-
ism(s). [Support:DK58057, DK56061 Jack Reidling NIH NRSA award 1 F32 DK062629].
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Night-Time Working Increases the Ulcerogenic Potential of H. Pylori Infection
Antonio Pietroiusti, Andrea Magrini, Antonio Forlini, Alberto Galante, Luca Coppeta,
Umberto Iannaccone, Antonio Bergamaschi
Backgroung. Night-time working has been found to be associated with an increased risk of
peptic ulcer disease. Since most peptic ulcers are due to H. pylori infection, it is possible
that night-time working potentiates the ulcerogenic effect of infection; alternatively, the link
between peptic ulcer and night-time working might be due to an increased prevalence of
infection in these workers. This subject has never been explored until now. Aim of this
study was to evaluate the interaction between night-time working and H. pylori infection.
Patients and Methods. All subjects were selected for endoscopy by a pool of primary care
physicians involved in an educational program with our Institution. Entry criteria were:
being active worker,persistent dyspeptic symptoms during the last year, presence of H.
pylori infection according to urea 13C breath test or stool testing, no previous endoscopic
examination, no treatment with gastric antisecretory drugs or antibiotics during the previous
month. Regular NSAIDs users were excluded. Before endoscopy, work characteristics of the
patients were analyzed by an occupational physician. On this basis, subjects were divided
into two broad categories: night-time workers (those performing work at night for at least
six times per month from at least one year) and day-time workers ( those working during
day-time only). 101 consecutive night-time workers, and 247 consecutive day-time workers
were enrolled during one year. At endoscopy, three biopsies were taken from the gastric
antrum, and three from the body. At each site, H. pylori infection was diagnosed if culture
was positive and/or if the organism was concomitantly detected at histology (Giemsa staining)
and urease testing. H. pylori cagPAI status was determined by PCR cagA amplification on
isolated strains. Results. The prevalence of duodenal ulcer was higher in night-time workers
than in day-time workers (29 out of 101, 28.7% vs 23 out of 247, 9.3%; p<0.0001), and
persisted after multivariate analysis taking into account age, sex, smoking, familial history
of peptic ulcer disease, length of work, and social status as possible confounders: odds ratio
4.51, 95% confidence interval 2.08 to 7.23). Among day-time workers, duodenal ulcers
were strongly related to cagA status (18 out of 99 cagA positive (18.2%) vs 5 out of 148
cagA negative (3.4%); p<0.05), whereas among shift workers they were not: 16 out of 43
cagA positive (37.2%) vs 13 out of 48, (27.1%); p=NS). Conclusions Shift working increases
the ulcerogenic potential of H. pylori. Application of a test and treat strategy in these workers
may have strong health and economic implications.
465
Effect of Intravenous Application of Esomeprazole 40 Mg Vs Pantoprazole 40
Mg On 24 Hour Intragastric pH in Healthy Adults
Dieter Schilling, D.R. Hartmann, Juergen F. Riemann
Background: Intravenous infusion of proton pump inhibitors (ppi) represents an alternative
administration route in patients for whom the oral administration is inappropriate. Recently
an intravenous (i.v.) formulation of esomeprazole has been developed. There are only
rare data about the equal doses of intravenous administration of esomeprazole (ESO) and
pantoprazole (PAN). This study compared the effect on intragastric pH of ESO and PAN .
Methods: We performed a single center three way cross over study comparing three intraven-
ous - single - shot - treatments (A: esomeprazole 40 mg as a 15-minute infusion; B:
pantoprazole 40 mg as a 15-minute infusion; C: pantoprazole 40 mg as a 3- minute injection)
separated by a wash out interval of at least 13 days. Subjects were required to be Helicobacter
pylori negative or positive as determined by 13C Urea Breath test. 24-hour intragastric pH
was recorded using a microelectrode (Inggold-bipolar glass) linked to a Digitrapper pH 100.
6 hours after injection or end of infusion a standardized meal was given to the subjects.
The time for intragastric pH> 6, > 5 and > 4 within the examination time of 24 hours as
well as the time of intragastric pH> 6, > 5 and > 4 within the first 6 hours after application
were analysed. The differences between the three treatments were assesed using the signed-
rank-test. Results: 28 people (mean age 33.7 +/- 7.65 years were enroled into the study. 15
persons were men. 21 Volonteers were H-pylori negative. All treatments were equally well
tolerated. For results see table below. Conclusion: Esomeprazole 40 mg i.v. provides a
statistically significant better acid suppresion than pantoprazole 40 mg intravenously.
Effect of the three treatments on intragastric pH
* p<0.05 versus PAN INJ (treatment C) # p<0,05 versus PAN INF (treatment B)
466
Ulcer Healing Properties of Pioglitazone Are Inhibited in Diabetic Rats
Peter C. Konturek, Tomasz Brzozowski, Grzegorz Burnat, Stanislaw Konturek
Experimental diabetes mellitus (DM) is associated with a significant increase in the vulnerabil-
ity of gastric mucosa against different irritants and delay in ulcer healing. Our previous
studies demonstrated that PPARγ ligands, which are used in the therapy of DM as insulin
sensitizer, accelerate ulcer healing. However, there is no information whether PPARγ ligands
influence ulcer healing in diabetic rats. The aim of the present study was 1) to compare the
effect of treatment with PPARγ ligand, pioglitazone, on ulcer healing in normal rats and those
with streptozotocin (STZ)-induced diabetes mellitus; 2) to assess the effect of pioglitazone on
the mRNA expression of cyclooxygenase-2 (COX-2) and interleukin 1β; 3) to investigate
the role of endogenous nitric oxide in the healing effect of pioglitazone. Methods: STZ (70
mg/kg i.p.) was used to induce DM in rats. 4 weeks after induction of DM, experimental
gastric ulcers were induced, and 10 days later, the healing rate and the gastric blood flow
(GBF) were measured by planimetry and hydrogen (H2)-gas clearance method, respectively.
Following major groups of rats with gastric ulcers were used: (1) vehicle (saline), (2) STZ
alone; (3) pioglitazone (40 mg/kg i.g.); 4) pioglitazone (40 mg/kg i.g.) in diabetic rats; 5)
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pioglitazone (40 mg/kg i.g.) in combination with L-NNA (20 mg/kg i.p.) and 6) pioglitazone
(40 mg/kg i.g.) in combination with L-NNA (20 mg/kg i.p.) in diabetic rats. The expression
of IL-1β and COX-2 was assessed by RT-PCR. Results: In the diabetic rats, ulcer healing
was significantly delayed and accompanied by a reduction in the gastric mucosal blood
flow. This prolongation of ulcer healing in diabetic rats was associated with an increase in
gastric mucosal expression of IL-1β. Administration of pioglitazone significantly accelerated
the ulcer healing in normal rats, but this effect was significantly attenuated in diabetic
animals. Pioglitazone significantly inhibited the expression of IL-1β and COX-2 mRNA at
the ulcer margin of normal rats, but this effect was significantly attenuated in diabetic rats
and the expression of these two genes was significantly upregulated. Pretreatment with L-
NNA abolished the healing effect of pioglitazone and led to a significant delay in ulcer
healing. The inhibitory effect of L-NNA on ulcer healing was significantly more pronounced
in diabetic rats than in normal animals. Conclusion: Experimental DM dramatically impairs
ulcer healing, depending upon the increased release of proinflammatory cytokines. The ulcer
healing effect of pioglitazone, which is mediated, at least in part, by endogenous NO is
significantly attenuated in diabetic rats.
467
Proton Pump Inhibitor Use Is Associated with the Development of Sporadic
Fundic Gland Polyps
Mathilde Jalving, Jan J. Koornstra, Jelle Wesseling, Jan H. Kleibeuker
Background: Fundic gland polyps (FGPs) are the most common gastric polyps, occurring
in approximately 2 % of the general population (termed sporadic FGPs) and in up to 84%
of FAP patients. Proton pump inhibitors (PPIs) are widely used to inhibit gastric acid
secretion. There is conflicting evidence regarding the association between the development
of sporadic FGPs and use of proton-pump inhibitors (PPIs) and the influence of PPIs on
the development of dysplasia in FGPs. FGPs are relatively rare making a case-control study
the most feasible method to determine whether there is a relationship. Methods: In this
case-control study, the prevalence and duration of PPI use in a consecutive group of patients
undergoing esophagogastroduodenoscopy were assessed. For each patient, sex and age were
recorded as well as the duration of PPI use. For each patient with FGPs, the number,
localization and size of FGPs were assessed. Biopsies were taken from FGPs and normal
gastric mucosa. The biopsies were fixed in formalin, embedded in paraffin and stained for
hematoxylin and eosin (H&E) for routine histology. The presence of dysplasia was evaluated
and graded as negative, low-grade or high-grade. Results: Data were obtained from 599
patients, of whom 324 were on PPI therapy. Patients on PPI-therapy were older than patients
not using PPIs (56 ± 13 vs 51 ± 17; mean age ± SD). There was no difference in sex
distribution between the groups. Histologically confirmed FGPs were identified in 107
patients. Patients with FGPs were older than patients without FGPs (60 ± 12 vs 52 ± 16,
p < 0.001). PPI therapy was associated with an increased risk of FGPs (OR 2.3, 95% CI
1.5 - 3.6). Subgroup analysis showed that long term PPI use was associated with an increased
risk of FGPs (1 - 4.9 years use: OR 2.2, 95% CI 1.3 - 3.8 and > 5 years use: OR 3.8, 95%
CI 2.2 - 6.7) while short-term PPI therapy (< 1 year use) was not (OR 1.0, 95% CI 0.5 -
1.8). Linear regression analysis showed that both age and PPI use were independent predictors
of having FGPs (p < 0.001 for both). There were no differences in the localization, size or
number of FGPs found in patients with and without PPI use. None of the FGPs showed
dysplasia. Conclusion: Long-term use of proton-pump inhibitors is associated with an up
to 4-fold increase in the risk of sporadic fundic gland polyps. The risk of dysplasia in these
polyps is, however, negligible.
468
Increased Plasma Ghrelin Levels in Patients with Peptic Ulcer
Hidekazu Suzuki, Tatsuhiro Masaoka, Hiroshi Hosoda, Toshihiro Nishizawa, Yuriko
Minegishi, Eisuke Iwasaki, Kenji Kangawa, Toshifumi Hibi
Ghrelin is a novel appetite-promoting peptide secreted primarily from the A-like cells of
the gastric fundic mucosa. As gastric inflammation caused by H. pylori infection increases
in extent, the number of ghrelin-producing A-like cells in the gastric fundus decreases as
does the gastric ghrelin content (Gut 53:187, 2004). We previously reported that plasma
levels of ghrelin, which correlated well with serum pepsinogen (PG) I and the PG I/II ratio,
but not with H. pylori seropositivity, decreased with increasing severity of gastric mucosal
atrophy in non-ulcerogenic conditions (Hepatogastroenterol. 51:1249, 2004), and that
plasma ghrelin levels increased in rats with cysteamine-induced duodenal ulcers (Am. J.
Physiol., Gastrointest. Liver Physiol. 289:G138, 2005). The present study was designed
to investigate the plasma levels of ghrelin in patients with peptic ulcer disease. Patients
and Methods. Two hundred and eighty-six patients with epigastric symptoms who under-
went upper GI endoscopy were enrolled for the study. Fasting blood samples were collected
prior to the endoscopy after a 12 hr fast. The patients were grouped as follows: chronic
gastritis with high PG (n=197), chronic gastritis with low PG (n=58), duodenal ulcer (n=
14), and gastric ulcer (n=17). Plasma levels of total and active ghrelin, as well as serum
levels of PG I and PG II were measured by radioimmunoassay. Six patients with duodenal
ulcer and 7 patients with gastric ulcer were also assessed after ulcer healing. Results. Plasma
gherlin levels were significantly lower in patients with low PG-gastritis than in patients with
high PG-gastritis, and were significantly higher in patients with duodenal ulcers (p<0.05)
and gastric ulcers (p<0.05) compared to those without peptic ulcers (chronic gastritis with
high PG; 169±12 fmol/ml, chronic gastritis with low PG; 144±19, duodenal ulcers; 232±62,
gastric ulcers; 212±51). Similar elevations of plasma ghrelin were found in peptic ulcer
patients with and without H. pylori colonization. Elevated plasma total ghrelin levels did
not change significantly after the ulcer healing. Conclusions. Plasma ghrelin levels were
significantly higher in patients with peptic ulcers irrespective of H. pylori colonization when
compared to patients with chronic gastritis only. Since elevated levels of plasma ghrelin did
not decrease after the ulcer healing, the increase in plasma ghrelin was not the results of


















Polymorphisms of TLR-4/TLR-2 and Risk of Helicobacter Pylori Infection and
Duodenal Ulcer Disease in Children
Dulciene M. Queiroz, Andreia M. Rocha, Silvia B. Moura, Gifone A. Rocha, Juliana B.
Guerra, Paulo Bittencourt, Taciana F. Soares, Ludmila M. Godoi, Luciana R. Almeida
Although host factors linked to the outcome of Helicobacter pylori (HP) infection have been
investigated, no study has evaluated yet the role of single nucleotide polymorphisms (SNPs)
in genes that encode mediators of the innate immune response such as Toll-like receptor
(TLR)-4 and TLR-2 in the risk of HP infection and HP associated diseases in children. The
SNPs of genes encoding TLR-2 and TLR-4 are thought to impair the efficiency of bacterial
ligant signaling and the capacity to elicit the host defense against microorganisms. Considering
that the infection is mainly acquired in childhood, we evaluated 432 children (193 boys,
mean age 9.4 years (SD 3.8), range 1-18). Among them, 207 were HP+ (72 with DU). cagA
status was investigated by PCR. TLR-4 (Asp299Gly) and TLR-2 (Arg753Gln, Arg677Trp)
polymorphisms were investigated by PCR-RFLP and confirmed by sequencing. The allele
Arg677Trp was not seen in this population. The other alleles were in Hardy-Weinberg
equilibrium. No association was seen between the polymorphic alleles and DU (p=0.71,
OR=0.78, 95%CI=0.33-1.94 for TLR-4 and p=0.32, OR=1.68, 95%CI=0.45-5.65 for TLR-
2). In addition, these polymorphisms did not associate with HP status (p=0.34, OR=0.63,
95% CI=0.26-1.49 for TLR-4 and p=0.69, OR=0.75, 95%CI=0.27-2.02 for TLR-2). However,
the polymorphic G allele of TLR-4 was significantly associated with infection with cagA+
strains (p=0.02, OR=9.08, 95%CI=1.21-18.8). Our results show that SNPs in TLR-2 and
TLR-4 were neither associated with the susceptibility to HP infection nor with the outcome
of the infection in childhood. However, TLR-4 SNP was associated with susceptibility to
more virulent HP strains. Grants: CNPq/FAPEMIG.
483
Anti-Tissue Transglutaminase Autoantibodies are Deposited in the Small
Intestinal Mucosa of Patients with Type 1 Diabetes
Mariantonia Maglio, Francesco Paparo, Adriana Franzese, Raffaella Spadaro, Maria Vittoria
Barone, Luciano Rapacciuolo, Virginia Vitale, Linda Cosenza, Riccardo Troncone
Backgroung Anti-tissue transglutaminase (anti-tTg) IgA are coeliac disease (CD) associated
autoantibodies. Most evidences suggest that the primary site of their production is the small
intestine.The association between CD and type 1 diabetes (T1D) has long been established.
Signs of gluten sensitivity (organ culture and rectal gluten challenge studies) have been
reported also in T1D patients with absence of anti-tTg antibodies in their serum. Aim To
investigate the deposition of anti-tTg autoantibodies in the jejunal mucosa of T1D patients
irrespective of their presence in the serum. Methods By double immunofluorescence staining,
anti-tTg IgA deposits were evaluated in jejunal biopsies from 29 T1D patients (median age
11 years, range 3-22) with normal mucosa; only in 12 of them serum anti-tTg autoantibodies
were present. Ten untreated coeliac patients (median age 8 years, range 1.5-15.5) and 29
patients (median age 5.6 years, range 0.7-18) with normal mucosa and absence of serum
anti-tTg served as controls. IgA deposits were detected in green by FITC-labelled rabbit
antibodies against human IgA, while tissue transglutaminase was revealed in red by RPE-
labelled rabbit anti-mouse secondary antibodies, primary antibodies being monoclonal mouse
anti-Guinea pig Tg (CUB 7402). The anti-tTg IgA deposits stained yellow; colocalization
was further assessed at confocal microscopy. Results Jejunal mucosa from all 10 untreated
coeliac patients presented evident anti-tTg IgA deposits in the subepithelial region. 11/17
T1D patients without serum anti-tTg antibodies, as well as 10/12 T1D patients with positive
serum anti-tTg antibodies showed intestinal anti-tTg IgA deposits, like classical CD patients,
but with a patchy distribution. In the control group only 4/29 patients presented a positive
IgA deposit pattern. Conclusion In most of T1D patients with absent anti-tTg antibodies in
the serum, anti-tTg IgA are deposited at the level of the small intestinal mucosa. This finding
confirms recent experimental data obtained by phage display libraries (Florian et al. J Pediatric
Gastroenterol Nutr vol 40, 2005: 617). It remains to be estabilished if this phenomenon is
related to dietary gluten.
484
Novel Antibody Tests Based On Synthetic Gliadin-Related Peptides Have a
Great Yield for Celiac Disease
Emilia Sugai, Horacio Vazquez, Fabio Nachman, Maria L. Moreno, A Czech, Silvia
Pedreira, Sonia Niveloni, Roberto Mazure, Zulema Kogan, Juan C. Gomez, Eduardo
Maurino, Julio C. Bai
Background/aim: Celiac disease (CD) serology has a key role for screening, diagnosis and
follow-up of patients. Although antigliadin antibodies (AGA) were recognized more of 30
yr ago, they have lost enthusiasm by a disappointing low specificity and the identification
of more reliable autoantibodies. We aimed to explore the diagnostic value of newly developed
peptide antibody assay addressing specific synthetic gliadin-derived deamidated peptides.
Materials: We studied serum samples prospectively obtained from a selected population of
92 consecutive patients with newly diagnosed CD and 113 controls (84 with non CD-related
disorders and 29 with Crohn’s disease). Diagnosis of CD was based on histological criteria
(Marsh II enteropathy or greater), CD-related serology and/or response to a gluten-free diet.
Patients were re-evaluated after 6-mo (n=56) and 1-yr (n=20) on treatment. Methods: All
patients and controls underwent intestinal biopsy and a set of CD-related serology tests. A
newly developed enzyme-linked immunosorbent assay (ELISA) to detect IgA and IgG antibod-
ies against synthetic deamidated gliadin epitopes (AGA II IgA and AGA II IgG) was used
(QUANTA Lite Gliadin IgA and IgG II- Inova Diagnostic Inc.; San Diego, CA). Results: At
diagnosis, sensitivity and specificity for AGA II IgA were 94.6% and 99.1% and for AGA II
IgG 92.4% and 100%, respectively. Interestingly, the only control subject with a positive
AGA II IgA test had other evidences of gluten sensitivity. When patients were assessed at
6-mo and 1-yr after starting on a gluten-free diet, mean absolute values were reduced
significantly (p<0.0000 and p<0.001, respectively). Furthermore, the proportion of patients
with positive samples was also significantly reduced at the same periods. Compared with
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the conventional AGA, peptide antibodies had greater sensitivity, specificity, positive and
negative predictive values, diagnostic accuracy and likelihood ratios. Compared with anti-
tissue transglutaminase antibodies, AGA II had a similar sensitivity but a greater specificity,
predictive values and better likelihood ratios. Considering the IgA isotype, an excellent
agreement (κ statistics: 0.92) was shown between AGA II and a-tTG. Conclusions: In our
knowledge, this is the first study assessing the value of an ELISA assay to detect antibodies
against specific gliadin-related peptides in CD patients. Our data evidenced that the new
AGA II tests are reliable tools for diagnosis of CD and suggests a promising diagnostic
accuracy that might be very useful in practice.
485
Epidermal Transglutaminase Antibody Differentiates Dermatitis Herpetiformis
from Celiac Disease
Federico Biagi, Jonia Campanella, Paola I. Bianchi, Olga Ciocca, Camilla Vassallo, Clara
Piccolo, Giovanni Borroni, Gino R. Corazza
Introduction: Dermatitis herpetiformis (DH), the cutaneous counterpart of celiac disease
(CD), is a blistering itchy skin disease characterized by IgA granular deposits localized either
in the dermal papillae or along the dermo-epidermal junction. These immunocomplexes
allow differential diagnosis between DH and other skin bullous diseases [1]. It has recently
been shown that DH immunocomplexes contain epidermal transglutaminase (eTG) and that
sera from patients with DH contain antibodies specifically directed against eTG [2]. We
studied whether serum eTG ab discriminates between DH, CD, and other gastrointestinal
and dermathological diseases. Patients and methods: eTG ab were tested in sera from 34
patients with untreated DH (UDH) (18 males, mean age 34, range 18-70 years), 19 patients
with treated DH (TDH) (all from UDH group: 9 males, mean age 35, range 22-65 years),
54 patients with untreated CD (14 males, mean age 34, range 4-64 years), 52 gastrointestinal
pathologic controls (18 males, mean age 40, range 18-75 years), and 31 dermathological
pathologic controls (all affected by skin bollous disease; 12 males, mean age 53, range 10-
85 years). Samples were tested for eTG ab with an ELISA kit (Immunodiagnostik). Based
on the cut off provided by the producer, results were considered positive when optical
density was ≥ 18 arbitrary unit (AU). Results: Average eTG ab levels were 62.9±37.3 AU
in UDH, 14.9±7.0 in TDH, 25.7±30.1 in untreated CD, 9.8±4.7 in gastrointestinal controls,
and 6.5±3.7 in dermathological controls. So, sensitivity was 97.1% and specificity was
96.2%. Statistical analysis showed that in UDH eTG levels were significantly higher than in
both TDH (t test, p<0.0001), untreated CD (p<0.0001), gastrointestinal controls (p<0.0001),
and dermathological controls (p<0.0001). Conclusions: eTG ab can almost perfectly discrim-
inate between DH and other skin bullous diseases; eTG ab levels decrease in DH patients
on a gluten free diet. Moreover, eTG ab levels are significatively higher in UDH patients
than in untreated CD patients. Detection of serum eTG ab is therefore a new tool for the
diagnosis of patients with skin bullous diseases. 1. Fry L. Bailliere’s Clin Gastroenterol
1995;9:371-93. 2. Sardy M, et al. J Exp Med 2002;195:747-57.
486
Involvement of Systemic Serum Cytokine Levels in the Pathophysiology of
Celiac Disease
Lincoln Hernandez, Sindhura Kunduvaram, Anne Lee Roland, Edward Ciaccio, Naiyer
Afzal, Govind Bhagat, John Manavalan, Green H. Peter
Celiac disease (CD) is an autoimmune disorder that occurs in genetically predisposed
individuals as the result of an immune response to gluten. Although considered to be a
local upper GI autoimmune disease it is now known to have widespread systemic implications.
We tried to define the nature and role of systemic cytokine levels in the pathophysiology
of disease. We preformed a multi-plex cytokine assay on 4 different groups of adult patients;
Patients with Active CD, patients on a Gluten Free Diet (GFD) with positive TTG IgA
Antibodies, patients on a GFD with negative antibodies and those with Refractory Disease
(RF). We individually compared all groups with normal controls, and we found those
patients with active disease and those on GFD that had positive antibodies had significantly
higherlevels of proinflammatory cytokines, such as INF-gamma IL1-B, TNF Alfa, IL-6 and
IL-8 and also Th-2 Cytokines such as, IL-4 and IL-10, as compared to normal controls and
patients on GFD without antibodies. Interestingly patients on GFD for less than 1 year had
significantly higher levels of both proinflamniatory cytokines and Th2 cytokines as compared
to the patients on GFD for more than 1 year. Within the group on GFD for less than a
year, at least 75% had positive TTG antibodies, while those on a GFD for more than 1 year,
only 25% had positive TTG Ig A antibodies. Based on a linear regression analysis there was
a statistically significant correlation between the serum levels of TTG Ig A and the levels of
Th-1 Cytokines as IL-4 (p<0.025) (fig. 1) , IL-10 (p<0.03) and Inflammatory cytokines such as
TNF alpha (p<0.006), IL (p<0.02) and IL-8 (p<0.000l). This is the first study to demonstrate a
significant correlation between the levels of TTG Ig A Antibodies and the presence of
proinflammatory and Th2 Cytokines in patients with CD.
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Association Studies of Myo9b Genetic Variants in a British Celiac Disease
Cohort
Karen Hunt, Alienke J. Monsuur, Parveen J. Kumar, Simon P. Travis, Julian R. Walters,
Derek P. Jewell, Raymond J. Playford, Cisca Wijmenga, David A. van Heel
Background and Aims: Development of celiac disease involves an interaction between envir-
onmental factors (especially dietary wheat, rye and barley antigens) and genetic factors (there
is a strong inherited disease susceptibility). The known HLA-DQ2 and -DQ8 association
explains only a minority of disease heritability. A recent study in the Dutch population
suggested that genetic variation in the 3’ region of myosin IXB (MYO9B) predisposes to
celiac disease (Monsuur et al. Nature Genetics 2005 doi:10.1038/ng1680). MYO9B is a Rho-
family GTPase-activating protein involved in epithelial cell cytoskeletal organisation. MYO9B
is hypothesised to influence intestinal permeability, and hence intestinal antigen presentation.
Methods: Four single nucleotide polymorphisms (rs2305767, rs2305765, rs2305764,
rs1457092) were chosen to tag all common haplotypes of the MYO9B 3’ haplotype block
(exons 15-27). We genotyped 375 celiac disease cases and 1346 controls (371 healthy and
975 population-based). All individuals were white UK Caucasian ethnicity. Results: UK
healthy control and population control allele frequencies were similar for all MYO9B variants.
Case-control analysis showed no significant association of any variant or haplotype with
celiac disease. Frequencies of rs2305764 were 38.7% in celiac disease and 41.5% in controls.
Conclusions: Genetic variation in MYO9B does not have a major effect on celiac disease
susceptibility in the UK population. Differences between populations, a weaker effect size
than originally described, or possibly a type I error in the Dutch study, might explain
these findings.
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Long Term Histological Follow-Up of People with Coeliac Disease
Gerry Robins, Thomas Fitzgerald, Peter Howdle
Background: Increasing numbers of people are being diagnosed with celiac disease (CD) for
which the only treatment is a gluten-free diet [GFD]. There are few studies looking at the
long-term histological follow-up of people with CD. Methods: All CD patients, with an
index small bowel biopsy and one or more sets of follow-up biopsies and attending a CD
clinic in either of two large UK teaching hospitals have their details entered into a Celiac
Patient Database [CPD]. Clinical information is entered prospectively where possible and
relevant retrospective data extracted from notes, including histological score [HS] (classified
as normal, increased intraepithelial lymphocytes [IELs] only, partial villous blunting [PVB],
subtotal villous atrophy [SVA] or total villous atrophy [TVA]) and overall compliance with
GFD (good, partial, poor). The primary aim of this study is to look at the length of time
to histological remission [HR] in CD patients. Correlation between HS, gender, age and
compliance was examined by Kendall’s rank, Mann-Whitney U or Chi square tests, as
appropriate Results: Of the 169 patients (125 female, 44 male) mean age at diagnosis was
42.8 (range 0.73-80.32) years with a mean follow up of 6.03 (range 0.13-26.21) years.
Median number of sets of biopsies taken was 3 (range 2-12). Nine (all female) patients in
the CPD had an initial biopsy reported as normal (i.e. they had latent CD), 12 with IELs,
31 with PVB, 56 with PVA and 61 with TVA. Of the 160 patients with an initial histological
abnormality, 58 (43 female, 15 male) patients had a documented complete HR. Only 28
(48%) remissions occurred within 2 years, 41 (71%) within 5 years and the remaining 17
took greater than 5 years to achieve HR. Overall 129 (81%) of these 160 patients showed
either HR or some improvement in their HS at least once, but 26 (16%) showed no change
and 5 (3%) a deterioration. There was no association between either gender or age and HR,
although there was a significant trend towards faster HR as patients got older (P<0.01).
There was a strong correlation (P<0.001) between good compliance with a GFD and better
HS, but not between age and HS, gender and HS or age and compliance. Conclusion: Time
taken to histological remission even for CD patients with good compliance for GFD may
take longer than many clinicians realise, especially in younger patients.
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Risk Factors for Opportunistic Infections in Inflammatory Bowel Diseases: A
Case-Control Study
Murat Toruner, Edward V. Loftus, Jean F. Colombel, Robert Orenstein, W S. Harmsen,
Alan R. Zinsmeister, William J. Sandborn, Laurence J. Egan
BACKGROUND: Numerous case series have reported opportunistic infections in patients
with inflammatory bowel disease (IBD). However, risk factors that predispose IBD patients
to opportunistic infections have not been defined. AIMS: We sought to identify clinical
factors that were associated with opportunistic infections in IBD patients. METHODS: We
conducted a case-control study to identify risk factors for opportunistic infections in IBD
patents seen at Mayo Clinic Rochester between 1998 and 2003. Opportunistic infections
were defined as infections caused by an organism that does not ordinarily cause disease but
that under certain circumstances becomes pathogenic. Liver transplant patients were
excluded. Cases were identified by searching the diagnostic index and were only accepted
with laboratory confirmation of opportunistic infection, or a pathognomonic clinical presenta-
tion. For each case, 2 controls that did not have a history of opportunistic infection were
selected, and matched on type of IBD, gender, date and residence. Conditional logistic
regression was used to assess associations between putative risk factors and opportunistic
infections. RESULTS: One hundred verified cases were identified. Cases and controls were
similar with respect to age, disease duration and extent. Corticosteroid, AZA/6MP or inflixi-
mab use within 3 months before the infection was associated with a significantly elevated
risk of opportunistic infection, odds ratios (OR) 3.4 (95% CI 1.8-6.2), 3.1 (95% CI 1.7-
5.5) and 4.4 (95% CI 1.2-17.1) respectively. The OR for opportunistic infection associated
with the use of any 1 of these drugs (relative to none) was 2.6 (95% CI 1.4-4.7), and increased
when 2 or more drugs were used to 12.9 (95% CI 4.5-37.0). The use of corticosteroids alone
or AZA/6MP alone was associated with OR of 2.2 (95% CI 1.1-4.8) and 2.5 (95% CI 1.2-
5.1) respectively, while their use in combination increased the OR to 15.7 (95% CI 4.1-
59.5). The combination of infliximab with AZA/6MP did not significantly increase the risk.
The number of subjects receiving infliximab, corticosteroids and AZA/6MP was insufficient
for assessment. The most common opportunistic infection with corticosteroids was candidi-
asis, with AZA/6MP was viral (e.g. cytomegalovirus and Epstein-Barr virus) and with inflixi-
mab was histoplasmosis. No patient died from any opportunistic infection. CONCLUSION:
Corticosteroids, AZA/6MP and infliximab were all independently associated with an increased
risk of opportunistic infections, a risk that increased when they were used in combination.
The absolute risk remains to be determined, as does any potential benefit of antimicro-
bial prophylaxis.
490
Safety of Infliximab and Other Crohn’s Disease Therapies - Treat™ Registry
Data with Nearly 15,000 Patient-Years of Follow-Up
Gary R. Lichtenstein, Russell D. Cohen, Brian G. Feagan, William J. Sandborn, Bruce A.
Salzberg, Donny M. Chen, Michelle L. Pritchard, Delma L. Broussard, Robert H.
Diamond
Background and Methods: TREAT, a prospective patient registry, was established to study
the long-term safety of infliximab (IFX) and other therapies in Crohn’s disease (CD). Results:
6273 patients (pts) were enrolled as of 8/05, of whom 3272 received IFX (8314 pt-yrs (py))
(88% ≥2 infusions) and 3001 received other therapies only (6596 py) with a mean follow-
up of 2.7 yrs. More IFX-treated pts had moderate-to-severe (31.5% vs 10.7%, p<0.0001)
or severe-fulminant (2.6% vs 0.6%, p<0.0001) CD, more had been hospitalized (27.4% vs.
19.1%, p<0.0001) in the prior year, and more were taking prednisone (27.2% vs. 15.9%,
p<0.0001) or immunomodulators (49.4% vs. 31.9%, p<0.0001). Infusion reactions occurred
in 4.0% of 28,281 infusions; severe reactions in 0.10%. Mortality was identical for both
IFX and non-IFX-treated pts (0.47 per 100 py vs 0.47; RR=1.0, 95% CI=0.64-1.56). In Cox
proportional hazards analysis, only the use of prednisone (HR=2.24, CI=1.37-3.66, p=0.001)
and narcotics (HR=2.63, CI=1.60-4.32, p<0.001) were associated with increased risk of
mortality. The incidence of malignancies in the two groups was similar (0.58 per 100 py
in IFX pts vs 0.53 in non-IFX pts; RR=1.1, 95% CI=0.71-1.63), as was the incidence of
lymphoma (0.06 per 100 py in IFX pts vs 0.05 in non-IFX pts; RR=1.3, 95% CI=0.36-
5.03). The incidence of serious infections (SI) was 1.29 per 100 py within 3 months of an
IFX infusion and 0.68 not within 3 months of an IFX infusion (RR=1.9, 95% CI =1.34-
2.70, p=<0.001). However, Cox analysis showed IFX was not an independent predictor of
SI (HR=1.40, 95% CI=0.95-2.07). The only medications independently associated with SI
were prednisone (HR=2.01, CI=1.40-2.90, p<0.0001) and narcotics (HR=2.72, 95% CI=
1.87-3.96, p<0.0001). One IFX treated patient with known latent TB, who did not receive
adequate prophylaxis, developed active TB. Conclusions: IFX safety is similar to that of
conventional immunomodulators. Despite having more severe CD, IFX pts had similar rates
of mortality, neoplasm and lymphoma as pts not treated with IFX. IFX-treated pts have an
increased risk of serious infection but Cox proportional hazard analysis suggests that this
increased risk is independently associated with prednisone and narcotic use, and not inflixi-
mab therapy.
491
Risks and Benefits of Infliximab for the Treatment of Crohn’s Disease
Corey A. Siegel, Chin Hur, Joshua R. Korzenik, Bruce E. Sands
Background & Purpose: Infliximab is effective for the treatment of active Crohn’s disease
(CD). However, serious potential complications related to infliximab therapy including
lymphoma, sepsis and death have been reported. The purpose of this study was to analyze
the risks and benefits of infliximab for the treatment of CD with the goal of providing data
to aid both physicians and patients in the decision making process. Methods: A decision
tree analysis model was constructed to determine the risks and benefits of infliximab when
compared to standard therapy in a 35 year old patient with active CD. The analysis simulated
two cohorts of 100,000 patients each with one arm receiving infliximab while the other

















a systematic review was performed of all published manuscripts specifically reporting inflixi-
mab-related adverse effects and with a minimum of 48-weeks of follow-up. Compiling data
from the 6 manuscripts meeting our criteria, at 1 year there were 1.6 lymphomas/1000
patients and 4.0 non-lymphoma related deaths/1000 patients in the infliximab arm. 46%
of these patients were concomitantly taking either 6-MP or azathioprine. The benefits of
infliximab were based on data from the ACCENT 1 trial (Hanauer, Lancet 2002). The clinical
course of the standard therapy strategy (no infliximab) and quality of life adjustment factors
were based on previously published literature (Silverstein et al. Gastroenterology 1999,
Lewis et al. Gastroenterology 2000). Results: Model results show that in 100,000 patients
at 1 year, infliximab will lead to 12,216 more patients in remission, 4255 fewer surgeries
and 33 fewer deaths from flares of disease. This is at the cost of 201 more lymphomas and
249 more deaths related to complications from infliximab. Overall, the infliximab strategy
resulted in more quality-adjusted life years (QALYs) than the standard therapy strategy (0.77
QALYs/patient vs 0.75 QALYs/patient). Sensitivity analysis demonstrated that the model
results are robust with changes in endpoints occurring only with large changes (or unlikely
values) of model input estimates. Conclusions: Despite an increased risk of lymphoma and
death associated with use of infliximab, the substantial clinical improvement and saved
surgeries due to infliximab results in an increase in quality-adjusted life years. In properly
selected patients, the benefits of infliximab could outweigh its risks. These data should help
guide decision making and the informed consent process when considering the use of
infliximab for the treatment of Crohn’s disease.
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A Safety Evaluation for Progressive Multifocal Leukoencephalopathy (PML) in
Greater Than 3,500 Patients with Crohn’s Disease (CD), Multiple Sclerosis
(MS), and Rheumatoid Arthritis (RA) Previously Treated with Natalizumab in
Clinical Trials
William Sandborn, Stephan Targan
Introduction: Natalizumab is a humanized IgG4 monoclonal antibody against α4 integrins.
It was approved by the FDA in November 2004 for the treatment of MS. Phase 3 trials for
CD, had completed enrollment, and a Phase 2 trial in RA was ongoing. Clinical trials and
marketing were voluntarily suspended in February 2005 based on the reports of 2 patients
receiving combination therapy with natalizumab and interferon beta-1a in a MS clinical trial
who developed PML. Subsequently, a previously diagnosed malignant astrocytoma in a
natalizumab-treated patient with previous exposure to azathioprine was reclassified as PML.
Thereafter, a safety evaluation was performed in all patients who had recently been treated
with natalizumab in clinical trials to screen for PML. Methods: The safety evaluation protocol
included informed consent and an urgent additional follow-up visit(s) to include a physical
exam, referral to a neurologist, brain MRI, polymerase chain reaction (PCR) analysis of
cerebral spinal fluid (CSF) and serum for JC virus. MRI scans of the brain were performed
and interpreted at each center. MRI images were also sent to a core laboratory facility for
central interpretation by a neuroradiologist with expertise in white matter disease. An
independent adjudication committee (IAC) consisting of experts in JC virology, neurological
and clinical manifestations of PML, and MRI imaging of neuroinflammation was created to
adjudicate all suspected cases of PML and make a final determination of whether the patient
had PML. In addition to patients from clinical trials, 4 post-marketing MedWatch reports
of suspected PML were also referred to the IAC. Results: Enrollment in the safety evaluation
included 87% (1,275), 91% (2,248) and 92% (296) of all eligible CD, MS, and RA patients,
respectively. Neurological exams and MRIs were completed in >97% of CD, MS, and RA
patients. CSF was analyzed for JC virus in 6% of CD, 16% of MS, and 4% of RA patients,
and plasma in 88% of CD, 56% of MS, and 95% of RA patients. No additional cases were
judged by the IAC to have PML. The 4 post-marketing cases referred to the IAC were also
judged not to have PML. Conclusions: Results of this analysis suggest that the absolute
risk of developing PML during therapy with natalizumab is low (approximately 0.1%). It
is not yet clear whether any screening strategy for the early detection of PML will be effective.
The potential clinical benefit of natalizumab in selected patients with moderate to severe
CD needs to be carefully weighed against the small risk of PML.
493
Incidence of Benign Infections in Inflammatory Bowel Disease (IBD) Patients
Treated with Azathioprine (AZA)
Philippe Seksik, Jacques Cosnes, Isabelle Nion-Larmurier, Jean-Pierre Gendre, Laurent
Beaugerie
Introduction: It is well established that serious infections may occur in IBD patients treated
by immunomodulators and/or biologics. However, there is no data concerning the incidence
of benign infections during exposure to AZA. The aims of our study were: 1) to determine
the incidence of benign infections (upper respiratory tract infections (ear nose throat infections
and bronchitis), herpes lesions and viral warts) in a prospective cohort of IBD patients
receiving A (AZA+); 2) to compare this incidence with that observed in IBD patients receiving
neither immunomodulators nor biologics (AZA-); 3) in the AZA+ group, to test the role of
neutrophil and lymphocyte blood counts in the development of benign infections. Patients
and Methods: Between September 2003 and November 2004, 230 outpatients were included
in a prospective cohort followed up to July 2005. Total observation time was 207 patient-
years and mean observation time per patient was 0.9±0.4 patient-years (range: 0.2-1.7).
Episodes of upper respiratory tract infections, herpes flare ups and viral warts arising or
worsening were prospectively noted using a standardized form filled at each visit. In parallel,
neutrophil and lymphocyte blood counts were collected. In each individual, the number of
benign infections was expressed as the number of events per observation-year (mean±SD).
In the AZA+ group, neutrophil and lymphocyte blood counts were dichotomized around
the median values. Results:The incidence of upper respiratory tract infections in the cohort
was 2.1±2.2 per observation-year. There was no difference between the AZA+ (n=169) and
AZA- (n=61) groups (2.2±2.3 vs. 2.1±2.1, p=0.77). The incidence of herpes flare-ups was
significantly increased in the AZA+ group compared with the AZA- group (1.0±2.6 vs.
0.2±0.8 per year, p=0.04). Similarly, there was significantly more patients with arising or
worsening viral warts in the AZA+ group (17.2% (AZA+) vs. 3.3% (AZA-), p=0.004). In
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the AZA+ group, there was a trend towards an increased incidence of herpes flare-ups in
the subset of patients with low lymphocyte count (p=0.06). Conclusion: This study suggests
that the incidence of herpes flare-ups and the appearance or worsening of viral warts are
increased in IBD patients receiving AZA. The increased risk of herpes flare-ups seems to be
more pronounced in the subset of patients with low lymphocyte count.
494
Increasing Incidence of Clostridium Difficile Infection in Patients with
Inflammatory Bowel Disease
Joseph F. Rodemann, Kimberly A. Reske, Erik R. Dubberke, Christian D. Stone
BACKGROUND: In the past decade, rates of nosocomial Clostridium difficile-associated disease
(CDAD) have been increasing for all diagnoses. The incidence of CDAD in patients with
inflammatory bowel disease (IBD) has not been examined, however. We analyzed a seven-
year database of inpatient admissions to determine if the incidence of CDAD has also been
increasing in Crohn’s disease (CD) and ulcerative colitis (UC). Because CD in particular is
often treated with outpatient antibiotics effective against C. difficile, we hypothesized that
the CDAD rate would be lower in CD than in UC. Based on the observation that CDAD is
sometimes the cause for admission in IBD, we also hypothesized that C. difficile toxin
positivity would, on average, occur within 48 hours of admission, which suggests the
infection was acquired in the outpatient setting. METHODS: An informatics database of
345,808 adult inpatient admissions from 1998 to 2004 at a large tertiary hospital was
analyzed for demographic data, length of stay (LOS), presence of a C. difficile infection, and
time from admission to a positive C. difficile test. Incidence of CDAD was calculated per
year for all admissions combined and separately for the primary ICD-9 discharge diagnoses
of CD and UC. Cases with insufficient data or indeterminate colitis were excluded. Descriptive
statistics and Chi-square testing were used to determine the risk for CDAD in IBD. RESULTS:
For all years combined, the rates of CDAD for CD and UC were 16 and 39 cases/1000
admissions respectively, compared to 13 cases/1000 for all admissions. The incidence of
CDAD increased in all three groups over the time period studied. Comparing 1998 and
2004 data, CDAD incidence doubled for all admissions (8.8 to 16.9/1000 admissions) and
CD (9.5 to 22.2/1000 admissions), and tripled in UC (18.4 to 57.3/1000 admissions; Chi-
square test for trend in UC = 3.8, p=0.05). LOS did not differ significantly between the
three groups. Compared to CD, the odds ratio (OR) for CDAD in UC was 2.3 (95% CI:
1.5, 3.6). Compared to non-IBD admissions, the ORs for CDAD in CD and UC were 1.5
(1.1, 2.1) and 3.5 (2.5, 4.7) respectively. The median times in days from admission to a
positive C. difficile test for CD, UC and all admissions were 0.8, 0.9 and 4.0 respectively.
CONCLUSIONS: Over the seven years studied, the incidence of CDAD in IBD has increased
and is higher in UC than CD. IBD patients are more likely to be admitted to the hospital
with a C. difficile infection compared to non-IBD patients. In both CD and UC, C. difficile
toxin assays were predominantly positive within 48 hours of admission, suggesting infection
was acquired prior to hospitalization.
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Munc18b Controls Zymogen Granule Exocytosis in Pancreatic Acinar Cells
Patrick Lam, Maria Kauppi, Laura Cosen-Binker, Vesa Olkkonen, Herbert Y. Gaisano
Background: The Sec1/Munc18 (SM) proteins are essential accessory components of molecu-
lar machineries required for membrane fusion. SM proteins serve to induce conformational
changes to Syntaxins (Syn) to enable Syns to bind their cognate SNARE partners to form
secretory-competent SNARE complexes. Pancreatic acinar cells express non-neuronal SM
isoforms Munc18b and Munc18c, which regulate apical and basolateral exocytosis, respect-
ively. Aim: In the present study, we examined Munc18b interactions with Syn-2 and Syn-
3 in mediating specific apical exocytotic events in rat pancreatic acinar cells. We employed
adenoviral over-expression of Munc18b mutants with altered affinity and specificity to Syn-
2 and Syn-3. Results: Wildtype (WT)-Munc18b, which binds both Syn-2 and Syn-3 with
high affinity, and S48D which binds only Syn-2, both inhibited CCK-stimulated amylase
secretion, supporting a role for Syn-2 in apical exocytosis. K314L/R315L mutant, with
reduced affinity to both Syns, had no inhibitory effect. E59K mutant, which has no detectable
binding to either Syn, caused major inhibition in secretion. Electron microscopic examination
revealed that WT-Munc18b induced formation of abnormal multi-leaflet membrane struc-
tures at sites of contact between ZGs, which was not observed with the other Munc18b
mutants, which taken together with the secretion results suggest a role for Syn-3 in ZG-
ZG fusion. Subcellular fractionation detected endogenous Munc18b on ZGs and plasma
membranes (PM), and on CCK stimulation, Munc18b was released from the ZGs while
remaining in the PM. Acini over-expressing WT and S48D mutants showed no changes in
Munc18b levels in the ZGs or PM. In E59K transfected acinar cells, CCK stimulation caused
a paradoxical increase in this mutant Munc18b association with ZGs and PM fractions. Syn-
2, Syn-3 and SNAP23 were all found on the ZG and PM fractions, and the level of Syn-3
decreased in the ZG fraction upon CCK stimulation. Conclusion: Our findings support a
role for Munc18b interaction with Syn-2 in apical exocytosis, and Syn-3 in ZG-ZG homotypic
fusion, which seems to require Munc18b displacement from ZGs, likely as a mechanism to
activate cognate Syn-3. (Funded by National Institutes of Health, Alcohol Beverage Medical
Research Foundation, and Finnish Cultural Foundation).
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Diverse Roles of Class I PI3K Isoforms δ and γ in Cerulein-Induced
Pancreatitis
Lars Fischer, Aurelia Lugea, Mohammad Shahsahebi, Bart Vanhaesebroeck, Josef M.
Penninger, Helmut Friess, Anna S. Gukovskaya, Stephen J. Pandol, Ilya Gukovsky
Background & Aims: Phosphoinositide 3-kinase (PI3K) is a key signaling molecule; however,
its function in pancreatitis is poorly understood. Class I PI3K isoforms are critical mediators
of immunoinflammatory responses. Furthermore, we recently showed that PI3Kγ regulates
key pathologic responses of the pancreatic acinar cell. In this study, using genetic approaches,
we sought to determine the roles of PI3K δ and γ in various responses of acute pancreatitis
in the cerulein (CR) model. Methods: To inactivate PI3K we used mice deficient in PI3Kg
catalytic subunit, p110g, or homozygous for loss-of-function p110dD910A mutant of PI3Kδ.
Pancreatitis was induced by hourly injections of 50 μg/kg CR. We measured both early and
late responses of pancreatitis at, respectively, 30 min and 7 h after the 1st CR injection.
Results: Genetic inactivation of PI3K d or γ reduced neutrophil infiltration in pancreatitis
by 50-60%. Pancreatic necrosis was also inhibited ~2-fold. However, serum amylase and
lipase levels, and acinar cell vacuolization were unaffected in PI3K mutant mice. PI3K d or
γ inactivation stimulated apoptosis in pancreatitis by up to 2-fold. Caspase-3 activity did
not increase, suggesting that PI3K regulates apoptosis via a caspase-independent mechanism.
The lysosomal marker hexosaminidase was activated in pancreatitis, which was inhibited
by PI3K d or γ inactivation by 85 and 65%, respectively. Cathepsin B activity was also
inhibited in PI3K mutant mice. These results suggest important roles for both PI3K isoforms
in lysosomal activation in CR pancreatitis. In both mutants, premature trypsinogen activation
was markedly reduced at both early (30 min) and late (7 h) time points, with the late phase
completely inhibited in PI3Kδ mutant mice. In pancreatic acini isolated from PI3K mutant
mice, trypsinogen activation by CR was only partially reduced (compared with wild type),
suggesting that non-acinar cells may regulate trypsinogen activation in pancreatitis via PI3K.
We previously showed that neutrophils regulate trypsinogen activation. Neutrophils isolated
from PI3K mutant mice displayed impaired oxidative burst, which might contribute to the
observed inhibition of trypsinogen activation. Conclusions: PI3K d and g regulate key
responses of pancreatitis, i.e., inflammatory infiltration, trypsinogen activation, and multiple
pathways of parenchymal cell death (necrosis, apoptosis, and lysosomal activation), but are
not involved in other responses, i.e., hyperamylasemia. The results further indicate the role
of inflammatory cells in trypsinogen activation in pancreatitis.
503
Impaired Pancreatic Regeneration in Notch Signaling Ablated Mice During
Acute Experimental Pancreatitis
J.N. T. Siveke, Marcel Lee, Clara Lubeseder-Martellato, Christine Koehler, Roland M.
Schmid
Introduction: The adult mammalian pancreas has a strong regenerative capacity after severe
cell damage such as in acute pancreatitis. The mechanisms for this process, however, are
not well known but involve reactivation of pathways activated in undifferentiated pancreatic
cells such as Notch, beta-Catenin or expression of Pdx1. Thus, we were interested what
effect ablation of Notch signaling may have during the course of acute pancreatitis and what
members of the Notch signaling pathway are involved. Ablation of Notch signaling and its
effect during the course of acute pancreatitis was studied in two models, in genetically
engineered mice with pancreas-specific inactivation of Notch1 or Notch2 and in wildtype
mice by using the gamma-secretase inhibitor DBZ which inhibits cleavage of active Notch-
IC. Methods: Conditional pancreas-specific Notch1 and Notch2 knockout mice were gener-
ated by crossing p48+/Cre mice with floxed Notch1 and Notch2 mice. These mice are alive
and show no obvious organ pathology. Notch1 and Notch2 knockout and control mice as
well as wildtype mice treated with either DBZ or vehicle as control were followed during
caerulein-induced acute pancreatitis. Histological examination, mRNA and protein analysis
and ChIP assays were performed before, 8 and 72 hours after induction of acute pancreatitis.
Results: During the course of acute pancreatitis, we found only modest morphological
differences between Notch knockout, DBZ treated and respective control mice 8h after
caerulein induction. However, 72h after induction we found a significant increase in acinar
cell death as well as a change in acinar differentiation status in DBZ treated compared
to control mice. Interestingly, Notch1 but not Notch2 knockout mice revealed similar
morphological alterations as DBZ treated mice providing evidence for a pivotal role of
Notch1 in acinar cell regeneration. The higher rate in apoptosis together with no change
in proliferation rate resulted in a significantly smaller pancreas in DBZ treated and Notch1
ablated mice. Histomorphologically, an increase in undifferentiated pancreatic cells,
expressing Pdx1, beat-Catenin and Clusterin and most likely of acinar origin, was notable.
Conclusion: These data suggest that inhibition of Notch signaling during pancreatic regenera-
tion after cellular damage results in an altered regulation of acinar differentiation processes. By
comparing Notch1 to Notch2 knockout mice, regenerative processes during acute pancreatitis
seem to be regulated by Notch1. The observable shift in acinar differentiation status points
to an important role for Notch signaling in differentiation processes in the adult mamma-
lian pancreas.
504
Pancreatic Stellate Cells Are Involved in Pancreatic Regeneration Following
Caerulein-Induced Acute Pancreatitis in Rats
Filip Sermon, Veronique Andriessen, Daniel Urbain, Albert Geerts
Background and Aims: Pancreatic stellate cells (PSC) play a major role in the fibrogenesis
associated with chronic pancreatitis and are responsible for the desmoplastic reaction sur-
rounding pancreatic tumours. The role of these cells in acute pancreatitis has not been
investigated until now. Material and Methods: Acute pancreatitis was induced in rats by six
(50µg/kg) intraperitoneal injections of caerulein at hourly interval. Animals were sacrified
at different time points between 1 hour and 14 days after the first injection. The severity
of acute pancreatitis was assessed by hydrolase serum levels, histology, and water content.
Immunostaining for desmin, vimentin, GFAP, α-SMA, and Ki-67 were performed at all time
points. Results: In normal pancreatic tissue, PSC were easily identified as desmin or vimentin-
positive cells with a typical morphology and a periacinar and periductular distribution. After
induction of acute pancreatitis, immunostaining for desmin and vimentin showed lack of
immunoreactivity in large areas of the pancreatic parenchyma as soon as 1 hour after the
first caerulein injection and a complete absence of immunoreactivity 1 hour after the third
caerulein injection whereas blood vessels still showed positive staining (internal positive
controls). Some PSC could be detected again after 20 hours. From that time point onward,
the density of PSC in the pancreatic parenchyma increased gradually exceeding the density
of PSC in normal pancreas with a peak (2.7 X normal) at day 2-3. The density of PSC then
decreased gradually to the normal value over the next five days. PSC were not only more
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numerous during the regeneration phase, they also looked bigger with more cytoplasmic
processes as compared to controls. The mean increase in cell surface at day 2 was 67%.
Dual immunostainings for Ki67 and desmin allowed us to study simultaneously cell prolifera-
tion and reinvasion of the pancreas by PSC. The sequence was as follow: 1) 20 hours: re-
appearance of PSC (desmin+) around the ductuli 2) 23 hours: presence of Ki67+ cells in
and around the ductuli 3) 29 hours: increasing number of ductular Ki67+ cells and invasion
of the pancreatic parenchyma by desmin+/Ki67- PSC 4) 48 hours: regeneration phase with
numerous Ki67+ acinar cells. Taken together, these results suggest that PSC originate from
a periductular reservoir. Conclusion: During an episode of acute pancreatitis, PSC proliferate
and reinvade the injured pancreatic tissue before acinar proliferation. This reinvasion seems
to originate from a periductular reservoir.
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Nuclear Factor of Activated T-Cells (NFATs) Function As a Downstream
Effector of Calcineurin in CCK-Induced Pancreatic Growth
Grzegorz T. Gurda, John A. Williams
Proliferation of pancreatic acinar cells has been shown to be regulated by several GI hormones,
most notably cholecystokinin (CCK). Studies in our lab have determined that the Ca2+-
activated phosphatase calcineurin is one of the key mediators of the trophic effects of CCK,
but the mechanism by which calcineurin regulates pancreatic growth are not well understood.
The present study aims to evaluate whether the Nuclear Factor of Activated T-cells (NFAT)
family of transcription factors act as a transcriptional effector of calcineurin. Feeding camostat,
a synthetic trypsin inhibitor that induces endogenous CCK release, to mice was used to
study the effects of this hormone in vivo, whereas isolated acinar cells directly stimulated
with CCK served as an in vitro model. Western blots showed that NFATc1, c2 and c3 were
present in exocrine portion of the pancreas and that acute camostat feeding activated these
transcription factors, as indicated by increased nuclear abundance of NFATc1 and c2.
Administration of camostat also induced a transient increase in nuclear NFAT DNA binding
activity with a peak at 1 hour, as shown by EMSA. This effect was dependent on calcineurin,
as it was blocked by injection of a calcineurin inhibitor FK506. Supershift analysis suggested
that NFATc1 and c2 in cooperation with AP-1 family members c-jun and c-fos were the
primary components of this transcriptional complex. Camostat also increased mRNA levels
of NFAT-dependent MCIP1, but not NFAT-independent homologous genes MCIP2 and
MCIP3. More directly, the transcriptional activity of NFAT, as measured by adenovirally
delivered NFAT-luciferase reporter, was induced in vitro in a dose-dependent fashion by
10pM to 1nM of CCK as well as by 0.5μM to 2μM of a calcium ionophore A23187 (serving
as a positive control). NFAT-luciferase activity shows a small, but significant 2.5-fold increase
with 10pM CCK and peaks at nearly 600-fold increase with 100pM CCK. This increase in
activity was nearly completely abolished (>95% inhibition) by addition of low doses of
calcineurin inhibitors FK506 (1nM) and CsA (10nM). CCK also increased NFAT DNA
binding activity in isolated acini, as shown by western blotting and EMSA. Lastly, both
CCK and A23187 induced nuclear translocation of a NFATc1-GFP protein delivered by an
adenoviral vector into acinar cells, which points to functional activation of this transcription
factor. Thus, both in an in vivo physiological model and in isolated acini, CCK is able to
induce nuclear translocation and DNA binding of NFATs, indicating that NFATs act as a
downstream effector of calcineurin in CCK-induced pancreatic growth.
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Impact of Purinergic Signaling On Fibrosis and Angiogenesis in Chronic
Pancreatitis
Beat M. Kunzli, Pascal O. Berberat, Eva Csizmadia, Elzbieta Kaczmarek, Keiichi Enjyoji,
Helmut Friess, Simon C. Robson
Introduction: Extracellular nucleotides are released from injured cells, bind specific pur-
inergic-type 2 receptors (P2-R) and modulate inflammation and immunity. Ectonucleotidases
hydrolyze extracellular nucleotides to regulate P2-R signaling. Studies in null mice show
that Cd39/NTPDase1 is the dominant ectonucleotidase of the vasculature and immune cells
and has a regulatory role in inflammation, vascular thrombosis, tissue remodeling and
angiogenesis. Persistent inflammation, venous thrombotic disease, and progressive fibrosis
with parenchymal atrophy and angiogenesis characterize chronic pancreatitis (CP). Manifesta-
tions of CP might be therefore linked to disordered purinergic signaling in vivo. Aim: We
have explored the impact of deletion of Cd39 on the development of fibrosis and angiogenesis
in experimental CP and examined expression of CD39 and P2-R in human pancreatic disease.
Methods: Experimental pancreatitis was induced by intraperitoneal injections of cerulein in
wild type (wt) mice and Cd39 null mice, both pretreated with Cyclosporin A. Morphological
and immunohistochemical analyses were performed at 3 and 6 weeks to score inflammation,
fibrosis and angiogenesis. Expression of CD39, P2X7, P2Y2, metalloproteinases (MMP-2,
MMP-9, MMP-13) and inhibitors (TIMP1), TGF-β, smooth muscle actin (SMA), CD45,
procollagen-α and CD31 was determined by immunohistology, validated at RNA and protein
level. Comparable studies were done on human CP specimens. Results: Wt mice (n=19, 2
died) developed morphological features in keeping with CP with parenchymal atrophy with
fibrosis and neo-angiogenesis. Cd39, P2X7, P2Y2 and MMP-9 were upregulated and markedly
overexpressed at 6 weeks. Cd39 expression was on vascular endothelium and infiltrated
fibrocytes co-expressing Cd45. Cd39 null mice (n=16) exhibited no mortality and had
preservation of pancreatic weights at 6 weeks (wt 0.10g ± 0.01 vs. null 0.15g ± 0.01; p=
0.002). Immunopathology revealed minimal fibrotic changes and blunted angiogenesis.
Upregulation of P2-R was observed at all time points as for wt, but substantial early induction
of MMP-2, MMP-13, TIMP1 and TGF-β was noted specifically within Cd39 null tissues.
Analysis of human CP samples (n=11) also confirmed high level expression of CD39, P2Y2
and P2X7 within fibrotic tissues and vasculature. Conclusions: High expression of CD39
and P2-R is observed in both murine models of pancreatic inflammation and human CP.
Cd39 deletion with alterations in purinergic signaling impact experimental pancreatitis,
impeding both fibrogenesis and angiogenesis. Our data implicate purinergic signaling in CP


















Nodose Ganglia Neurons Demonstrate Gluco-Responsiveness Mediated Via
Voltage-Dependent Potassium Channels
Gintautas Grabauskas, Shi-Yi Zhou, Il Song, Chung Owyang
We have shown that hyperglycemia inhibits gastric motility. In rats, the inhibitory action
is abolished following perivagal capsaicin treatment. Vagal afferent fibers receive and convey
the sensory signals that elicit vago-vagal gastric reflexes, and are strategically positioned to
mediate rapid changes in gastric motility in response to systemic glucose. Our hypothesis:
a subset of vagal nodose neurons is glucoresponsive and expresses ATP-sensitive K+ channels.
Immunocytochemistry studies were performed on neurons isolated from rat nodose ganglia.
Immunoreactivities of glucotransporters (Glut 1,2,3,4) were detected in a subgroup of
neurons which also demonstrated immunoreactivities of the inwardly rectifying K+ channel
6.2 and the sulfonylurea receptor, as well as glucokinase immunoreactivities. Similar findings
on gene message were obtained from RT-PCR. Whole-cell patch clamp recordings were
done to determine if the excitability of vagal afferent neurons is modulated directly in response
to changes in glucose concentration. In 9/15 (60%) neurons, substitution of mannitol for
glucose (15mM) in the perfusing medium elicited an outward current (50±5pA) associated
with an increase in membrane conductance (from 1/368±66 MΩ to 1/223±37MΩ). Responses
were fully reversible, and increased in a concentration-dependent manner as external glucose
concentration was reduced in 5mM increments over the range of 15 to 0mM. The current
responses to reductions in external glucose concentration were abolished reversibly by
tolbutamide (0.5mM,n=3), a specific blocker of the KATP channels. Responses were also
prevented when neurons were dialyzed with a high concentration of ATP (1 mM in recording
pipette solution). By contrast, disruption of glycolytic activity either by 1) substitution of
2-deoxyglucose for glucose in the perfusion medium,(n=3); 2) administration of the glucose
transporter blocker phloretin 40µM,(n=3); 3) inhibition of glucokinase with glucosamine
5mM (n=6), blocked voltage-dependent K+ currents and produced an inward shift in
membrane holding current. These results provide the first demonstration that vagal afferent
neurons process glucotransporters and KATP channels. These neurons respond in a specific
manner to changes in extracellular glucose concentration. The data suggest that glucose
induced modifications of neuronal excitability involve modulation of voltage-dependent K+
channels, including the ATP-sensitive K+ channel. These results provide a functional basis
for our previous in vivo findings that nodose neurons play a critical role in mediating
alterations in gastric motility in response to changes in systemic glucose levels.
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Stimulation of CCK-1 Receptors Activates a TRPC Like Inward Current in GI
Vagal Afferent Neurons
Michael Beyak, Annemarie Surprenant, David Grundy
CCK is one of the most important GI hormones regulating short term food intake via an
action on vagal afferents. The ionic mechanism by which CCK stimulates gastrointestinal
vagal afferents is unclear. TRPC channels are receptor operated cation channels and are thus
potential candidates for mediating CCK induced responses. Methods: NGNs innervating the
GI tract were labelled by an i.p. injection of fast blue (4%, 10µL). 2-7 days later cells were
isolated and whole cell patch clamp recordings were performed on labelled neurons 12-48
hours later. Cells were voltage clamped at -60mV and drugs applied using a fast flow solution
switching system. Antagonists were applied 2-5 min prior to agonists. Extracellular recordings
were made from mouse gastric vagal afferents in vitro. Responses to drug superfusion
and ramp distension were examined. Results: CCK-8S (1-100nM) induced a concentration
dependent, slowly developing inward current in 38/72 (53%) of labelled nodose ganglion
neurons. The amplitude of this current ranged from 10 - 150 pA (mean 38±4.5 pA), and
the reversal potential was approximately +10mV. CCK induced currents were blocked
completely and reversibly by the CCK-1 receptor antagonist lorglumide (1µM n=5). The
effect of a number of putative TRP channel blockers on the CCK induced current was
examined. Ruthenium red (3µM) (n=5) 2-APB (100µM) (n=5), blocked the CCK induced
current. Furthermore, in all CCK sensitive NGNs (n=12), and in 24/29 NGNs tested in total
GdCl3 (100µM ) activated a large transient inward current. This current was completely
and reversibly blocked by 100uM 2-APB (n=5). Prolonged application (3-5 min) of Gd
desensitized the Gd sensitive response as well as the CCK induced current (n=10). In vagal
afferent recordings, CCK also stimulated gastric vagal afferents (mean increase 55±9.5spikes/
s) and resulted in a marked shift of the tension / response relationship to the left. These
effects were prevented with 100µM 2-APB. 2-APB also significantly attenuated stretch induced
responses (66% inhibition, p<0.05). Conclusions: CCK-1 receptors activate a TRP - like
cation conductance in GI - projecting nodose ganglion neurons. All of these cells also express
a GdCl3 activated TRPC4/5 - like current. We speculate that CCK-1 receptors are coupled
to the activation of TRPC channels, as has been described for other Gq coupled receptors.
TRPC4/5 appear be candidates. This appears to be a major mechanism by which CCK
activates gastrointestinal vagal afferents. Antagonism by 2-APB of both stretch and CCK
induced responses in gastric vagal afferents suggests a potential common mechanism by
which CCK and mechanical stimuli may interact.
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Serotonin Differentially Activates C- and A- Type Vagal Primary Afferent
Neurons Which Contain Vanilliod (VR1) and Puringenic (P2X) Receptors
Xiaoyin Wu, Chung Owyang, Ying Li
It is well known that serotonin (5-HT) released from intestinal EC cells mediates motility,
secretion, and visceral sensation through activation of vagal afferent C-fibers. These C-fibers
contain VR1 and are capsaicin sensitive. We have also shown that lower intensity electrical
vagal stimulation which activates capsaicin-insensitive A-fibers regulates CNS cortical activit-
ies stimulated by noxious colorectal sensation. P2X receptors have been reported to be
present on vagal nodose neurons and afferent fibers. In this study we investigate whether
5-HT activates both C- and A- type vagal afferent fibers and examine whether 5-HT sensitive
vagal afferents contain VR1 and P2X receptors. Single neuronal discharges of nodose ganglia
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neurons innervating the duodenum were recorded in vivo in rats, followed by juxtacellular
neurobiotin labeling to characterize VR1 and P2X receptor expression. Vagal A- and C- type
neurons were identified based on conduction velocities. Luminal perfusion of 5-HT (10-
5M) elicited an increase in vagal C- and A- type neuronal discharges in 17/30 and 11/36
neurons recorded respectively (from basal 0.7±1 to 29±5 and 33±4 impusles/20 sec). Double
labeling immunocytochemistry showed that all of the 9 C-type neurons labeled by neurobiotin
contained VR1 receptors. In contrast, while 7 labeled A-type neurons activated by 5-HT
contained P2X receptors, none of them expressed VR1 receptors. In separate studies using
perivagal capsaicin-treated rats, luminal 5-HT (10-5M) stimulated A-type vagal afferent
discharges in 8/33 neurons tested. Intra-arterial injection of ATP (2 and 10 mg/kg) and the
selective P2X receptor agonist α,β-methylene-ATP (5 and 20 μg/kg) increased neuronal
firing in a dose dependent manner. Further, α,β-methylene-ATP augmented the neuronal
responses to luminal 5-HT (10-5M) by 30%. In capsaicin-treated rats, immunohistochemistry
studies showed luminal 5-HT significantly increased the number of fos-positive neurons in
nodose ganglia and that 94% of these neurons contain P2X but not VR1 receptors. We
conclude that intestinal 5-HT differentially activates subpopulations of both A- and C- type
vagal primary afferent neurons. Most of 5-HT activated vagal A-type neurons also contain
P2X receptors. The synergistic interaction between 5-HT and ATP in the A-type neurons
may enhance vagal responses to noxious stimulation. Hence, in contrast to DRG neurons,
where P2X and VR1 receptors frequently co-localize, these receptors are found on distinct
myelinated A-fibers and unmyelinated C-fibers respectively. This suggests that P2X and VR1
receptors are involved in mediating distinct 5-HT activated autonomic reflex functions.
510
Acid Exposure Increase TRPV1 Channel Expression in Spinal Afferents
Innervating the Esophagus of Cats
Banani Banerjee, Bidyut K. Medda, Jyoti N. Sengupta, Reza Shaker
Background: It is a general notion that proton-gated ion channels play a key role in visceral
hypersensitivity. Gastroesophageal reflux disease (GERD) may contribute to esophageal
hypersensitivity by acid-induced activation of these channels and one of the potent molecules
involved in sensitization could be transient receptor potential vanilloid 1 (TRPV1). The aim
of this study was to evaluate the expression of TRPV1 and co-expression with substance P
(SP) in the dorsal root ganglia (DRG) and spinal cord receiving input from the esophagus.
Method: 4 groups of cats (n=3 in each group) were used in this study. The group 1 (acute-
acid) received 0.1N HCl (pH 1.2, 30 mins @1 ml/min) under awake condition via a
chronically implanted catheter in the mid-esophagus. Group 2 (acute-PBS) received 0.1M
PBS (pH 7.4) in similar fashion and; group 3 (chronic-acid) and group 4 (chronic -PBS)
received infusion same way for 5 consecutive days. Tissue samples from thoracic (T2-T4)
spinal cord and respective dorsal root ganglia (DRG) and esophagi were collected for TRPV1
immunoreactivity (ir), mRNA expression and measurement of protein level. Myeloperoxidase
(MPO) content in the esophageal tissue was measured as marker for neutrophil infiltration
in inflammation. Result: ELISA absorbance (OD at 460 nm) as measured for MPO indicated
a 6- and 10-fold increase in MPO in acute-acid (0.25 ± 0.05) and chronic-acid (0.51 ±
0.10) compared to PBS-treated cats (0.05 ± 0.04). There was no significant difference in
TRPV1 mRNA expression in the spinal cord from acute and 5 days acid-treated and PBS
infused groups. However, in DRGs TRPV1 gene expression was significantly higher in 5
days acid-treated cats, but not in acute treated cats, compared to PBS-treated cats. TRPV1-
ir cells significantly increased in acute and 5 days acid-treated cats. In addition, it indicated
that in acute acid-treated cats 80-90% TRPV1-ir DRG cells colocalize with substance P (SP)
compared to 38-40% cells in PBS-treated cats. Similarly, a majority of TRPV1-ir cells in
chronic-acid exhibited a high level of colocalization with SP (55-65%) compared to PBS-
treated cats (25-30%). Conclusions: The result indicates that acid exposure in the esophagus
increases TRPV1-ir cells in the spinal afferents innervating the esophagus. The study provides
a strong evidence of involvement of TRPV1 channels in esophageal inflammation.
511
TRPV1 Expression and Function in Chronic Pancreatitis and Its Role in
Nociceptive Sensitization and Pain
Guang-Yin Xu, John H. Winston, Mohan M. Shenoy, Huaizhi Yin, Pankaj J. Pasricha
Background and Aims: The mechanism of pain in chronic pancreatitis (CP) is poorly
understood. We have previously developed a model of trinitrobenzene sulphonic acid
(TNBS)-induced chronic pancreatitis that results in nociceptive sensitization in rats mani-
fested by pancreatic hyperalgesia and referred somatic allodynia. The aim of this study was
to investigate the molecular substrate of these changes, specifically focusing on the role of
the transient receptor potential vanilloid subfamily 1 (TRPV1). Methods: CP was induced
in adult rats by a single intraductal injection of TNBS and dorsal root ganglion (DRG)
neurons innervating the pancreas were identified by DiI fluorescence labeling. Whole cell
patch-clamp recordings were made from acutely dissociated DRG neurons from rats on day
21-26 post treatment with TNBS or vehicle. In separate experiments, cholera B toxin was
used to label pancreatic neurons for subsequent laser capture microdissection (LCM) and
quantitative PCR as well as immunohistochemistry. In vivo responses to pancreatic electrical
stimulation were recorded at baseline and 30 minutes after i.p. injection of SB-366791 (1.3
mg/kg in 0.5 ml), a highly specific small molecule competitive antagonist of TRPV1. Results:
Application of capsaicin produced an inward current with an amplitude of 7.0±2.8 pA/pF
(n=6) in DRG neurons from the control group. TNBS treatment caused a nearly five-fold
increase in capsaicin-induced current density (n=12, P<0.02). Further, capsaicin-induced
responses were observed in 46.2% (n=13) of all recorded DRG neurons from control and
70.6% (n=17) of all recorded neurons from rats with CP (P<0.05). As measured by LCM
and subsequent RT-PCR, the expression of TRPV1 mRNA in pancreas specific DRG neurons
increased by 40% in the neurons of rats with CP as compared with controls (P<0.05).
Furthermore, the percentage of TRPV1 positive DRG neurons innervating pancreas was
significantly enhanced after TNBS treatment (control: 59.9±4.5%, n=4; TNBS: 82.1±5.9%,
n=3, P=0.01). Systemic administration of the TRPV1 antagonist SB-366791 markedly reduced
the pain behavioral response to electrical stimulation in rats with CP to levels similar to
that seen in control rats. This was not a non-specific analgesic effect since the compound
had no effect on pain behavior in control rats. Conclusions: Thus, these experiments suggest
that TRPV1 sensitization is a specific mechanism contributing to the hyperalgesia of chronic
pancreatitis and that TRPV1 is a useful target for treatment of pain in this condition (supported
by R01 DK62330-01 to P.J.P.).
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Identification of Mechanically-Activated Pain Pathways from the Gut Wall
Xin-Yung Song, Bao-Nan Chen, Marcello Costa, Simon Brookes
Pain is an important symptom of many gastrointestinal disorders, mediated via spinal afferent
pathways, but the peripheral endings responsible have not been specifically identified. Intense
distension is the most widely used stimulus to elicit pain from naïve (non-inflamed) intestines,
in animals and humans. Sensory axons in the serosa and mesentery comprise the great
majority of spinal afferent endings in small and large intestines (Lynn & Blackshaw 1999,
Brierley et al 2004) and are leading candidates for mechanonociceptors. We identified
transduction sites of serosal/mesenteric endings with in vitro electrophysiology, anterograde
labelling and immunohistochemistry in guinea pig ileum. Afferent axons in mesenteric nerve
trunks responded to strong focal compression (300-1000mg) with blunt probes at punctate
“hotspots”, as reported in many previous studies. Anterograde tracing labelled many smooth
axons-of-passage throughout the mesentery but the only specialised endings were varicose
branching axons (“VBAs”) on mesenteric arteries. There was a significant association between
mechanosensitive “hotspots” and VBAs on mesenteric arteries (p<0.01). Serosal mechanore-
ceptors were also investigated. In preparations where both mucosa and submucosa had been
removed, few hotspots could be detected using blunt probes (5.9 ± 2.8% of tested sites, n=
6). However, in preparations with submucosa attached, but with muscularis externa and
serosa removed, numerous hotspots were identified (51.3 ± 8% of tested sites, n=10), always
located on submucosal blood vessels. Our results suggest that mechanosensitive hotspots
for “serosal” receptors comprise some of these sensory endings on submucous arteries.
Circumferential stretch (10-20g) of the submucosa alone, or of the mesenteries without any
of the gut wall, powerfully activated mechanonociceptors, with high thresholds (10 - 20g).
The majority of submucous (85%) or mesenteric hotspots (68%) could also be activated by
locally applied capsaicin (1µM). We conclude that serosal/mesenteric primary afferents to
the gut wall have mechanotransduction sites comprising varicose branching axons on blood
vessels in the submucosa or mesentery. They are powerfully activated by strong distension,
consistent with a role as mechanonociceptors, in addition to their well established role in
vasodilation. 1. Brierley SM et al Gastroenterology. 127(1):166-78, 2004. 2. Lynn PA &
Blackshaw LA J Physiol (Lond). 518.1:271-82, 1999 This work was supported by R01-
DK56986 from NIH (USA) and by #275530 from NHMRC Australia.
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Dietary Sulfur Amino Acid Supplementation Improves Plasma, Jejunal and
Ileal Mucosal Thiol/Disulfide Redox Status and Increases Indices of Intestinal
Adaptation After Massive Small Bowel Resection in Rats
Yvonne S. Nkabyo, Li H. Gu, Yancy 0. Mannery, Junqiang Tian, Dean P. Jones, Thomas R.
Ziegler
Background: Thiol/disulfide redox status is determined by the glutathione (GSH)/glutathione
disulfide (GSSG) and cysteine (Cys)/cystine (CySS) redox couples. This study in a rat model
of short bowel syndrome (SBS) determined whether dietary supplementation with the sulfur
amino acids (SAA) methionine (Met) and Cys: 1) results in a more reducing thiol/disulfide
redox state in plasma and gut mucosa; and 2) enhances adaptive small intestinal growth.
Methods: Adult rats underwent mid-small bowel transection (TX) or 80% mid-jejunoileal
resection (RX). After operation, rats in the TX and RX groups were pair-fed complete
diets containing adequate SAA (Con; control for diet) or isonitrogenous, isocaloric diets
supplemented with SAA (SAA; 300% of Cys and 180% of Met content of control diet,
respectively). Four groups of animals were studied: TX-Con (n=7), TX-SAA (n=9), RX-Con
(n=9), and RX-SAA (n=10). Jejunal and ileal mucosal samples were obtained 7 days after
surgery and wet weight, DNA and protein content, crypt depth (CD) and villus height (VH)
determined. Mucosal and plasma concentrations of thiols (Cys, CySS, GSH and GSSG) were
measured by HPLC. Redox potential (Eh in mV) of the Cys/CySS and GSH/GSSG couples
was calculated using the Nernst equation. Results: Mean daily food intake was not different
between groups. Dietary SAA supplementation resulted in a significantly more reducing
plasma Cys/CySS redox potential in RX rats (TX-Con -92±2, TX-SAA -95±3, RX-Con -93±4,
and RX-SAA -105±2 mV; P<0.05 RX-SAA vs all other groups). Jejunal and ileal Cys/CySS
Eh became significantly more reducing by SAA supplementation in RX rats; jejunum: TX-
Con -197±9, TX-SAA -202±6, RX-Con -203±5, and RX-SAA -212±2 mV (P<0.05 RX-SAA
vs all other groups); ileum: TX-Con -199±8, TX-SAA -199±4, RX-Con -200±4, and RX-
SAA -210±3 mV (P<0.05 RX-SAA vs all other groups). A significant increase in adaptive
ileal CD (+20%) and VH (+21%) occurred in the RX-SAA group vs the RX-Con group
(P<0.05). SAA also significantly increased ileal wet weight (+20%), DNA content (+34%)
and protein content (+22%); each P<0.05 RX-Con vs RX-SAA. Ileal mucosal GSH/GSSG Eh
in RX-SAA was positively correlated with ileal wet weight (r2=-0.48), DNA (r2 =-0.48) and
protein content (r2=-0.38); all P <0.05. Conclusion: Dietary SAA supplementation after
massive small bowel resection improves plasma, jenunal and ileal thiol/disulfide redox status
in rats. Increased Ileal adaptive growth with dietary SAA appears to be partially dependent
on mucosal GSH/GSSG redox status. These data may have translational significance for
nutritional approaches to enhance small bowel redox status and adaptive growth in SBS.
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Subcutaneous Glucagon-Like Peptide 2 (GLP-2) Alone and in Combination
with Oral Cholylsarcosine in the Treatment of short Bowel Syndrome (SBS)
Patients
Palle B. Jeppesen, Peter Hoeyerup, Per B. Mortensen
Background: GLP-2 given subcutaneous has been shown to improve intestinal wet weight
absorption short bowel syndrome patients, but the effect on macronutrient and energy
absorption seems limited. Cholylsarcosine is a synthetic conjugated bile salt that has been
shown to increase fat absorption in SBS patients. The combined effect of these two novel
treatment modalities has not been evaluated. Methods: 8 short bowel IBD patients received
400 mg TID GLP-2 s.c. for 26 weeks (2F, 6M; 49±10 years; small bowel 178±62 cm; 1
with a colon; 4 on parenteral nutrition or fluids). 72-hour balance studies were performed
at baseline, week 13 and at week 26. At week 26, the patients were given 2 gram TID
cholylsarcosine perorally in addition to GLP-2 given subcutaneously in relation to the three
main meals. The intake of cholylsarcosine capsules was initiated 48 hours prior to initiation
of the balance studies. Access to food and beverages was free, collecting double portions
for analysis. Wet weight, energy (bombcalorimetry) and fat (Van de Kamer) absorption were
the difference between diet intake and fecal excretion. Results: The results are presented in
the table. Conclusions: Subcutaneous administration of GLP-2 significantly decreases fecal
wet weight excretion by 906±597 gram/day thereby improving the relative wet weight
absorption by 16±14%. A decrease in fecal energy excretion was also observed, but due to
the trend towards a lower dietary energy intake in relation to GLP-2 treatment, neither the
relative or absolute energy absorption changed. The addition of oral cholylsarcosine did not
jeopardize the GLP-2 effect wet weight absorption. Although a significant increase in the
fat absorption of 27±27 gram/day was observed in relation to the combined treatment with
GLP-2 and cholylsarcosine compared to baseline, this effect did not translate into an overall
improvement in energy absoption.
Results from 72-hour balance studies
515
Gut Decontamination and Dietary Glutamine Each Improve Thiol/Disulfide
Redox in Rat Jejunal Mucosa Following Combined Partial Small Bowel-
Colonic Resection
Junqiang Tian, Li Gu, Prakash Chandra, Menghua Luo, Andrew T. Gewirtz, Ifor R.
Williams, Dean P. Jones, Thomas R. Ziegler
Background: Thiol/disulfide redox status is important for cytoprotection and may regulate
cell turnover and function. The thiols glutathione (GSH) and cysteine (Cys) are major
mediators of cellular and extracellular redox. We studied the effects of luminal bacterial
decontamination and dietary L-glutamine (GLN) supplementation on GSH and Cys levels
and GSH redox state in residual jejunal mucosa in a rat model of short bowel syndrome.
Methods: Adult rats underwent small bowel transection (TX; n=10), resection of the distal
60 cm of small bowel + left colon with jejuno-colonic anastomosis (RX; n=9); RX with oral
antibiotics (RX-ABX; n=5); or RX with dietary GLN supplementation (RX-GLN; n=6). After
operation, TX, RX and RX-ABX rats were pair-fed complete, semi-purified diets; the RX-
GLN group was pair-fed an isocaloric, isonitrogenous semi-purified diet supplemented with
GLN (4% w/w). RX-ABX rats received an established antibiotic regimen for gut decontamina-
tion (neomycin, metronidazole and polymyxin) in drinking water from 3 days preoperatively
until tissue collection on day 21. Mucosa of defined segments of jejunum was analyzed for
thiol content by HPLC [GSH, glutathione disulfide (GSSG) and Cys concentrations]. Mucosal
GSH/GSSG redox potential (Eh; in mV) was calculated by the Nernst equation. Results:
Daily food intake was not different between groups. Jejunal GSH in TX rats was 14.3 ± 0.7
nmol/mg protein and was unchanged by RX alone (RX 12.8 ± 0.6 nmol/mg protein). Jejunal
GSH was markedly increased by both oral antibiotics (RX-ABX 39.3 ± 3.2 nmol/mg protein;
P < 0.001 vs TX and RX groups) and dietary GLN (RX-GLN 39.7 ± 14.3; P < 0.001 vs TX
and RX groups). Jejunal GSH redox potential (Eh) was unaltered by bowel resection (TX; -
243 ± 2 vs RX -242 ± 2 mV; NS), but became significantly more reducing with both oral
anti- biotics and GLN supplementation (RX ABX -263 ± 4 and RX-GLN -259 ± 5 mV; each
P < 0.001 vs TX and RX groups). Jejunal Cys levels were similar in TX and RX groups (TX
0.9 ±0.1 vs RX 0.9 ± 0.2 nmol/mg protein; NS), but were significantly increased by oral
antibiotics (RX-ABX 6.2 ± 1.5 nmol/mg protein; P < 0.01 vs the other 3 groups) and dietary
GLN (RX-GLN 2.9 ± 1.1 nmol/mg protein; P <0.05 vs TX and RX). Conclusions: Both oral
antibiotics and dietary GLN improve important indices of thiol/disulfide redox status in the
residual jejunal mucosa of rats following massive small bowel-colonic resection. Our results
suggest that: 1) these agents each may have redox-mediated cytoprotective effects in this



















The Effect of Severe Malnutrition and Subsequent Refeeding On Gut Mucosal
Protein Fractional Synthesis in Human Subjects
Trevor A. Winter, Steven J. O'Keefe, Marie Callanan, Tessa Marks
Objective: Malnutrition has been associated with gut mucosal atrophy, impaired absorption,
and increased permeability. This study investigated the effect of severe malnutrition, and
subsequent re-feeding, on duodenal mucosal architecture, and gastric, and duodenal mucosal
protein fractional synthesis (mucosal turnover). Research Methods and Procedures: 23
severely malnourished patients were studied. Endoscopic biopsies were taken from the
duodenum for assessment of mucosal architecture. In vivo mucosal turnover was investigated
in the gastric body, antrum and duodenum by means of 14C-leucine incorporation into
tissue protein following a 4 hour primed/constant IV infusion. The studies were repeated
following a period of re-feeding. Results were evaluated in comparison with a group of 22
healthy controls, and illustrated as the mean (standard error of the mean). Statistical analysis
was by the Statistica package using analysis of variance (ANOVA), Students t-test and Mann-
Whitney U test as appropriate. Results: The mean body mass index (BMI) of the malnourished
patients was 13.29±0.33 kg/m2, compared to 22.67±0.63 kg/m2 in the controls (P< 0.001).
Various degrees of villous atrophy were evident in 8 patients (35%). Mucosal turnover in
the controls and malnourished patients were similar (gastric body 36.49±2.88 %/d vs.
33.41±3.08 %/d; gastric antrum 25.51±2.20 %/d vs. 24.95±2.32 %/d; duodenum 25.90±2.58
%/d vs. 25.49±1.99 %/d). Following re-feeding, the BMI of the malnourished patients
increased to 15.87±0.44 kg/m2 (P<0.001). Villous atrophy was still evident in 3 patients.
Mucosal turnover increased significantly (gastric body 51.80±8.12 %/d; P= 0.02, gastric
antrum 33.44±3.66 %/d; P<0.05, and duodenum 46.27±80.2 %/d; P<0.01), with the mucosal
turnover of the gastric body and duodenum now significantly greater than the control values
(P<0.05). Conclusions: Despite severe malnutrition, and evidence of villous atrophy, mucosal
turnover of the gastric body, antrum and duodenum remained similar to control values.
Enteral feeding resulted in a significant increase in mucosal turnover, with improvement in
villous atrophy, indicating a trophic response to topical nutrients.
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Continuous Enteral Feeding Improves Intestinal Absorption in short Bowel
Syndrome Patients
Francisca Joly, Xavier Dray, Sophie Rousseau, Laurence Barbot, Kouroche Vahedi, Nathalie
Kapel, Bernard Messing
Background: Continuous enteral feeding (CEF) in the post-operative period may help short
bowel syndrome patients (SBS) to be weaned off parenteral nutrition. Past this period, CEF
has not been tested either exclusive (ECEF) or partial, i.e. oral + CEF (OCEF) compared to
usual oral feeding (OF). It was postulated that absorption could be better with CEF than
OF due to motor disturbances in SBS, the latter inducing a decreased contact time between
gut and nutrients. Methods: In 16 patients (7M/9F, mean age 53 yr), with SBS constitution
> 3 months and a mean remnant small bowel length of 76 cm (4 jejunostomy, 12 jejuno-
colic anastomosis), intestinal absorption were compared on 3 different 7-d regimen periods:
ECEF vs OF (n=16) vs OCEF (including 1000 Kcal with CEF, n=9). During the last 3-d of
each regimen period, caloric intake and fecal output were measured. Intestinal absorption
rates of lipids (Van de Kamers’ method), proteins (Kjeldahls’ method) and glucids [bomb
calorimetry-(proteins + lipids)] were calculated. The study was performed in a median time
lag of 33 months after the last surgery. Wilcoxon matched-pairs signed-ranks tests were
used for statistical analysis. Results: Total intake were significantly greater with OCEF (3106
kcal/d) than with CEF (2407 kcal/d) and OF (1993 kcal/d) (p<0.0001). No significant
change was seen in stool output between the 3 periods. The caloric absorption rate was
significantly greater with ECEF (82%) and OCEF (75%) than with OF (65%) (p<0.001).
Similar significant improvements were observed for both lipids (69% and 59% vs 40%
respectively, p<0.001) and proteins (72% and 67% vs 57% respectively, p<0.001). Absolute
gain (g per kg body weight) for protein was 1.0 in ECEF and 1.1 in OCEF vs OF (both
p<0.0001). For lipids, gain (g/Kg) was 0.55 in ECEF and 0.72 in OCEF vs OF (p<0.005).
Conclusions: in SBS patients, CEF (whether exclusive or not) induces a significant 10-20%
increase in intestinal absorption rates compared to OF alone, total energy gain being equiva-
lent to 35% of resting energy expenditure.
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Evolution of the Quality of Life of Malnourished Patients Treated with Home
Enteral Nutrition
Xavier Hebuterne, Pierre Senesse, Nicole Gaconnet, Patrick Bachmann, Alain Burde,
Kamel Arab, Corinne Bouteloup, Erick Beaujard, Laurence Beck, Franck Arnaud-
Battandier, Stephane M. Schneider
Quality of life (QOL) is lower in home enteral nutrition (HEN) patients than in the general
population. As HEN aims at improving QOL, the aim of this study was to assess prospectively
the evolution of QOL after the onset of HEN. Methods. All patients able to read, understand,
and fill QOL forms and treated with HEN in 23 centers during one year were included in
this study. QOL was evaluated at home the day of discharge from hospital (M0) and after
one (M1) and three months (M3) of HEN. Two validated generic auto-questionnaires (SF-
36 and EuroQOL) were used. SF-36 explores eight domains: physical functioning (PF), role
physical (RP), bodily pain (BP), social functioning (SF), mental health (MH), role emotional
(RE), vitality (VT) and general health (GH), ranging from 0 (worst) to 100 (best). EQ-5D
includes five questions that permit to calculate a score (0 to 1), and a visual analogue scale
(VAS) (0 to 100). A subjective assessment questionnaire with 33 questions on HEN daily
experience for the patient and his/her relatives, impact on current activities, physical and
mental wellbeing and the role of HEN in their evolution was also used. A multivariate
analysis was performed to determine discriminating factors associated with the evolution of
QOL. Results. 193 patients (132M, 61F; 59±13 yrs ; BMI:19.9±4.4, loss of BW: 13.9±10.6%)
treated with HEN for head and neck or esophagus cancer (66.3%), digestive disease (12.4%),
neurological disease (8.8%) or others, were included. The mean energy input was 1585±512
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kcal/d, 78% of patients had a gastrostomy tube, and a pump was used in 70% of patients.
EQ5D (0.56 ± 0.38 vs 0.61 ± 0.30) and VAS (49.5 ± 19.3 vs. 55,2 ± 18,4) improved
significantly (P<0.05) at M3 but not at M1. The evolution of SF-36 domains at M1 and M3
is presented in the table. In multivariate analysis age > 45yr, low performance status and
cancer were associated with a lower improvement of QOL. Subjective questionnaires sug-
gested that many burdens were associated with HEN. However, HEN was felt very (49%),
rather (37%) or quite (7%) beneficial by patients and 92% of patients felt secure vis a vis
HEN. Conclusion. Despite burdens due to HEN, health-related quality of life is improved
during the first weeks of HEN. This is indicated both by validated QOL markers and by
patients’ subjective assessment. Discriminating factors associated with a somewhat less effect
of HEN on QOL are age, low performance status and cancer.
Net improvement (95% CI) compared with M0. *significantly different from M0
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Bone Morphogenetic Protein (BMP)-4-Mediated Transformation of Inflamed
Squamous Esophageal Mucosa Into Barrett’s Esophagus
Jantine van Baal, Francesca Milano, Navtej S. Buttar, Agnieszka M. Rygiel, Floor de Kort,
Jacques J. Bergman, Kenneth K. Wang, Maikel P. Peppelenbosch, Kausilia K. Krishnadath
BACKGROUND: To identify genes specifically involved in the transformation of squamous
epithelium into Barrett’s esophagus (BE), we previously used SAGE to compare the expression
profile of BE with normal squamous esophagus (SQ) and gastric cardia mucosa. BMP4 was
found to be uniquely expressed in BE. The aim of this study was to investigate the potential
role of BMP4 in the metaplastic development of BE. MATERIAL AND METHOD: Immunob-
lotting was performed on patient biopsies of BE, SQ and inflamed SQ mucosa for the
presence of BMP4 and protein members of the BMP pathway i.e. BMP Receptor IA and II,
Smad 4, P-Smad 1/5/8 and ID2. Furthermore, primary cell cultures of biopsy specimens of
SQ and BE were established. The primary cell cultures of SQ cells were treated with rec.
h. BMP4 and the BMP4 pathway was investigated by immunoblotting. Immunohistochemistry
was performed for analysis of the Cytokeratin (CK) expression pattern and microarray
analysis was done to analyze and compare the gene expression profiles. RESULTS: Immunob-
lotting revealed BMP4 expression and activation of associated signaling in BE and inflamed
SQ mucosa but not in normal SQ (see Fig). Upon treatment of SQ cells with BMP4 the
level of P-Smad 1/5/8 was increased, this was blocked through addition of the BMP antagonist
Noggin. Phenotipically, a shift of the CK expression pattern, of the BMP4 treated SQ cells
towards that of columnar cell type was found with upregulation of CK7 and CK20 and
downregulation of CK10/13. Finally analysis by microarrays demonstrated a shift of the
gene expression profile of the BMP4 treated SQ cells towards that of BE cells. CONCLUSION:
BMP4 is a keyplayer in the transformation of inflamed esophageal mucosa into BE. We
propose that the premalignant metaplasic development of BE is mediated by BMP4 and that
inhibition of BMP4 signaling offers a novel avenue for the therapeutic management of
this disease.
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A Pro-Inflammatory IL-10/IL-12 Gene Profile Is Associated with An Increased
Risk for Developing Barrett’s Esophagus
L.M.G. Moons, J.G. Kusters, J van Delft, E.J. Kuipers, R. Gottschalk, W.A. Bode, H.
Geldof, A.H.M. van Vliet, J.C.S. Kleinjans, P.D. Siersema
Introduction: The development of a Barrett’s esophagus (BE) is paralleled by a shift towards
a Th2 type immune response, suggesting a causal relationship. A strong pro-inflammatory
response is associated with this shift towards a Th2 response, both in a TNF-α knockout
mouse, and in Helicobacter pylori induced gastric carcinoma. Increased expression of pro-
inflammatory cytokines has also been associated with esophageal carcinogenesis, and it is
conceivable that this is at least partially based on genetic differences. As patients homozygous
for the CCG-haplotype of the anti-inflammatory cytokine IL-10 produce higher IL-10 levels,
and the IL-12 C-allele is associated with increased levels of pro-inflammatory cytokine IL-
12, the distribution of both genotypes was determined in patients with BE to test whether
a genetic based increased pro-inflammatory response is involved in the development of BE
. Methods: DNA was obtained from 258 patients with histologically confirmed BE (100%
Caucasian; mean age 62±13; 68% male) with a mean BE-segment length of 4.2 ± 2.3 cm,
and 247 patients with endoscopically confirmed reflux esophagitis (RE) (100% Caucasian;
mean age 56±14; 54% male). Gene polymorphisms of IL-12 (A1188C) and IL-10 (C-592A;
C-819T, A-1082G) were determined by multiplex SNaP-shot™ methods. Results: BE patients
were less frequent homozygous for the IL-10 CCG-haplotype (21% CCG versus 79% A-
carriers) as compared to RE patients (30% CCG versus 70% A-carrier; p<0.015), correspond-
ing to a reduced risk for BE in IL-10 CCG homozygotes [OR 0.61 (95% CI 0.41-0.91); p=
0.016). The IL-12 C-allele was more frequently detected in BE patients (35% C-carrier
versus 65% AA) as compared to RE patients (27% C-carrier versus 73% AA, p=0.061),
corresponding to an increased risk for BE in the C-allele carriers [OR 1.4 (95%CI 0.98-
2.10); p=0.062). Combining IL-10 and IL-12 allele data revealed that BE patients more
frequently had the pro-inflammatory combination IL-12 C-carrier and IL-10 A-carrier [BE
27% versus RE 18%;OR 2.5 (95%CI 1.40-4.44); p=0.002], and less frequently the anti-
inflammatory combination IL-12 AA and IL-10GG [BE 12% versus RE 21%; OR 0.40
(95%CI 0.23-0.72) ; p=0.002). Conclusion: Based on the polymorphic IL-10 and IL-12
allele distribution of patients with BE and RE, BE patients are more likely to have an increased
pro-inflammatory response than RE patients in the presence of the same stimulus. This may
be an important drive for the inflammatory shift towards the observed Th2 type response
in BE, and eventually the development of specialised intestinal metaplasia. Treatment of the
inflammatory response may therefore decrease the incidence of BE.
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Origin of Barrett’s Epithelium: Development of Columnar Characteristics and
Increased Expression of Anti-Apoptotic Proteins in Het-1A Squamous
Esophageal Cells Made Resistant to Low pH and Bile Acids
Katerina Dvorak, Melissa Chavarria, Claire M. Payne, Harris Bernstein, Carol Bernstein,
Harinder Garewal
Background: Barrett’s esophagus (BE) is characterized by the replacement of squamous
epithelial cells by metaplastic intestinal-like columnar epithelium. The cell of BE origin
remains unclear. We favor the hypothesis that BE originates from esophageal stem cells as
a result of reflux with gastric and bile acids, two components of refluxate potentially important
to the pathogenesis of BE. To test this hypothesis we developed esophageal squamous cells
lines resistant to low pH and/or bile acids as in vitro model systems and evaluated them
for expression of columnar characteristics and anti-apoptotic proteins. Methods: Normal
squamous Het-1A cells were gradually exposed to low pH (pH 6 or 5) and/or 0.5mM bile
acid cocktail (BA), consisting of equimolar concentrations of glycodeoxycholic, glycocholic,
taurocholic, glycochenodeoxycholic and deoxycholic acid. This BA incorporates known bile
acids present in the refluxate. Our goal was to develop cell lines able to survive exposure
to pH 5 or 6 and/or BA for 3 hours. The resistant cells have thus far been evaluated
(1) morphologically using electron microscopy and Giemsa staining in conjunction with
brightfield microscopy, (2) for expression of columnar markers, Cdx-2 and villin, by western
blot, and (3) for expression of anti-apoptotic proteins, Mcl-1, Bcl-xL, aven and survivin,
using western blot and fluorescence microscopy. Results: Over 85 weeks, we have gradually
developed several cell lines resistant to different conditions for up to 3 hours, including
low pH alone (pH 6, 5), 0.5mM BA, and 0.5 mM BA plus low pH (pH 6, 5). An untreated
long-passage sensitive cell line was also maintained, as a control, to compare with the
resistant cells. The resistant lines displayed changes with the most significant altered pattern
observed in the cells resistant to pH 5 and pH 5 and BA. These cells were morphologically
different in appearance and showed enlarged nuclei, condensed mitochondria and lipid
droplets by EM. Increased expression relative to control cells, was observed for columnar
differentiation markers, villin and Cdx-2, as well as anti-apoptotic proteins, including Mcl-
1, survivin, aven and Bcl-xL. Conclusion: Chronic, repeated reflux with gastric acids and
bile acids is the major clinical factor for the development of BE. Our studies show for the
first time that squamous cells may show characteristics of transdifferentiation after repeated
exposures to low pH and bile acids. These cells also express markers of columnar differenti-
ation and increased levels of antiapoptotic proteins.
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Pge2 Regulation By Cytosolic Pla2α, a Potential Non-COX-2 Chemopreventive
Target, During Carcinogenesis in Barrett’s Mucosa
Malini Madhavan, Cathrine Demars, Sarah Papenfuss, Ganapathy Prasad, Lori Lutzke,
Marlys Anderson, Louis Wong Kee Song, Kenneth Wang, Navtej Buttar
INTRODUCTION Reflux of gastroduodenal contents into the esophagus increases PGE2
production, which is closely associated with esophageal adenocarcinoma. Cytosolic phospho-
lipase A 2α (cPLA2α) catalyzes the release of arachidonic acid (AA), the substrate for
PGE2 production, from peri-nuclear membrane phospholipids. Pharmaceutical inhibitors
of cPLA2α are under development to be used as an anti-inflammatory agent in patients.
The AIM of this study was to examine the expression of cPLA2α during carcinogenesis in
Barrett’s esophagus and its effect on Barrett’s epithelial (BE) cell survival. METHODS Endos-
copic mucosal resections from 10 patients that contained squamous, non-dysplastic and
dysplastic Barrett’s mucosa as well as esophageal adenocarcinoma were selected and stained
with anti-cPLA2α antibody. Semi-quantitative immunohistochemistry was used to assess
cPLA2α expression in the mucosa. BE cell lines were treated with 20 or 40 μM of the
selective cPLA2α inhibitor, AACOCF3, with and without AA (30 μM) and PGE2 (20 ng/
ml). Total cell count, apoptotic cells (Caspase 3 and 7 Immunoassay) and potentially
proliferating cells (Ki-67) were counted. RESULTS Dysplastic Barrett’s epithelium had higher
expression of cPLA2α than non-dysplastic Barrett’s and squamous epithelium. Adenocarcin-
oma arising in a background of Barrett’s mucosa had the highest expression of cPLA2α.
The expression was both epithelial and stromal. Compared with control- treated cells,
treatment with 40 μM AACOCF3 decreased the proliferation of Barrett’s epithelial cells by
34 ± 6.6 % (p<0.05). Treatment with 40 μM AACOCF3 also increased the percentage of
apoptotic Barrett’s cells by 69 ± 4.4 % (p<0.05). Exogenous AA, as well as PGE2 treatment,
reversed the effect of inhibition of cPLA2α by AACOCF3) on BE cell proliferation and
apoptosis. CONCLUSION Expression of cPLA2α increases progressively and appears to be
functionally relevant to the process of carcinogenesis in BE. Inhibition of cytosolic PLA2α
appears to be an important chemopreventive approach as it decreases arachidonic acid,
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which is the substrate on which the COX-2 enzyme acts to generate PGE2. The inhibition
of PGE2 synthesis by decreasing the release of arachidonic acid rather than inhibiting COX-
2 may avoid the thrombo-embolic effects of COX-2 inhibition. With this approach, the
supply of arachidonic acid will be decreased to both pro and anticoagulation cascades.
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P53 Mediates An Anti-Proliferative Effect of Acid in Non-Neoplastic Barrett’s
Epithelial Cells
Hui Ying Zhang, Linda A. Feagins, Ruben D. Ramirez, Stuart J. Spechler, Rhonda F. Souza
Introduction: The observation that acid has pro-proliferative effects on Barrett’s cancer cells
and on Barrett’s mucosal explants is a basis for the common clinical practice of prescribing
high-dose antisecretory therapy routinely for patients with Barrett’s esophagus. However,
we have found that acid exposure causes an increase in p53 expression that is associated
with an anti-proliferative effect in benign, non-neoplastic Barrett’s epithelial cells. Therefore,
we hypothesized that p53 mediates the anti-proliferative effect of acid, and we tested this
hypothesis by observing the effects of p53 inhibition with RNAi on Barrett’s cell proliferation
after acid exposure. Methods: The retroviral vector pSUPER-siRNA-p53 was generated by
digesting the p53 siRNA sequence from the pSUPER.p53 plasmid and cloning the DNA
fragment into the pSUPER.retro.neo mammalian expression vector; pSUPER.retro.neo with-
out the insert served as a control. Supernatants containing pSUPER-siRNA-p53 or pSUPER.re-
tro.neo viral particles were used to infect telomerase-immortalized, metaplastic Barrett’s cells.
Expression levels of p53 were determined by Western blotting using β-actin as a loading
control. Equally seeded wells of infected, uninfected, and empty-vector infected cells were
placed in acidic media (pH 4.0) for two 3-minute exposures, 60 minutes apart. Cell counts
were performed 24 hours later. Results: Infection with pSUPER-siRNA-p53 decreased p53
expression levels to 17% of those found in uninfected cells; p53 expression in cells infected
with the empty vector did not differ from uninfected cells. Uninfected and empty vector-
infected cells both exhibited a significant decrease in cell number following acid exposure
(1374 ± 24 to 1159 ± 29 SEM and 1400.5 ± 55 to 1237 ± 55 SEM, respectively, p<0.05).
In contrast, cells containing p53 siRNA exhibited no significant change in cell number
after acid exposure. Conclusions: In non-neoplastic Barrett’s epithelial cells, multiple acid
exposures have an anti-proliferative effect that can be blocked by inhibiting p53 expression.
This study elucidates a molecular pathway whereby acid exposure has potentially beneficial,
anti-proliferative effects on benign Barrett’s epithelial cells and suggests that the common
clinical practice of prescribing antisecretory therapy in dosages beyond those required to
heal esophagitis could be detrimental.
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Acid Exerts An Anti-Proliferative Effect in Non-Neoplastic Barrett’s Epithelial
Cells By Delaying Cell Cycle Progression
Linda A. Feagins, Hui Ying Zhang, Mizael Quinones, Deena Thomas, Stuart J. Spechler,
Ruben D. Ramirez, Rhonda F. Souza
Introduction: Acid has been shown to exert pro-proliferative and anti-apoptotic effects on
Barrett’s cancer cells and on explants of Barrett’s epithelium. In a benign, non-neoplastic
Barrett’s epithelial cell line, in contrast, we have found that multiple acid exposures cause
a significant decrease in cell numbers that is not due to a decrease in cell viability or to an
increase in apoptosis. To further explore the mechanisms underlying the acid-induced
decrease in Barrett’s cell numbers, we studied whether our cell line maintains the ability to
undergo apoptosis and to express p53 and p21 (proteins that may mediate apoptosis and
cell cycle arrest), and we studied whether acid induces a decrease in cell proliferation.
Methods: Following irradiation of telomerase-immortalized, metaplastic Barrett’s cells with
varying dosages of UV-B, we determined cell numbers (by cell counting), apoptosis (by
immunofluorescence with TUNEL), and expression levels of p53 and p21 (by Western
blotting using β-actin as a loading control). In other experiments, cells were synchronized
with a double thymidine block (which arrests them at the G1/S boundary of the cell cycle)
and then placed in acidic media (pH 4.0) for two 3-minute exposures, 60 minutes apart.
Cells were collected at various time intervals following the second acid exposure, fixed in
70% ethanol, and stained with propidium iodide for analysis by flow cytometry. Results:
Irradiation with 100-400 J/m2 of UV-B significantly decreased cell numbers at 24 hours
(p<0.05). Marked TUNEL staining (indicating apoptosis) was found in cells irradiated with
200 and 400 J/m2. p53 expression increased in a UV-B dose-dependent manner, whereas
p21 expression increased following 50-300 J/m2, but not 400 J/m2 of UV-B irradiation. In
control cells that were not exposed to acid, the peak fraction of cells in G2/M was seen at
6 hours. In contrast, acid exposure delayed the G2/M peak to 12 hours. Conclusions: Acid
decreases proliferation in a benign, non-neoplastic Barrett’s epithelial cell line by delaying
cell cycle progression. Although acid exposure does not induce apoptosis in these cells, the
cells do retain the ability to undergo apoptosis and to express p53 and p21. Our finding
of a potentially beneficial effect of acid on Barrett’s epithelial cells suggests that the common
clinical practice of prescribing antisecretory therapy in dosages beyond those required to
heal esophagitis could conceivably be detrimental for patients with Barrett’s esophagus.
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Association Between Central Activation and Pain Reports in Women with IBS
Yehuda Ringel, Douglas A. Drossman, J.N. Leserman, Weili Lin, Kathy Wilber, Brandall Y.
Suyenobu, Steve Berman, Whitehead E. William, Emeran Mayer
Background: Greater pain reporting in response to rectal distention in patients with IBS
(“visceral hypersensitivity”) may relate to alterations in peripheral (intestinal) and central
pain modulatory mechanisms. In previous studies we found that IBS patients with a history
of abuse report more pain despite higher (not lower) rectal sensation thresholds, suggesting
altered central pain modulation (Ringel, Gut 2004). Aim: 1) To investigate the association
between subjective pain reports and regional brain activation using fMRI. 2) To assess the

















Methods: Twenty female subjects were studied. Brain fMRI images (BOLD responses) and
pain ratings (on a 0-5 pain scale) were obtained during barostat-mediated baseline and
painful (50mmHg) rectal distension. Statistical parametric mapping (SPM2) analysis was
used to identify activation differences in 8 predetermined regions of interest (ROI). Correla-
tions between the activation at a specific region and the subjects’ reports of pain were
assessed by covariate analyses. Results: 1. Pain scores during rectal distention for all 20
subjects strongly correlated with midcingulate cortex (MCC) activation [corrected p family
wise error (pFWE) =0.045]. 2. Abused (n=10) patients had significantly greater MCC (pFWE=
0.02) and posterior cingulate cortex (PCC) (pFWE=0.04) activation than non-abused (n=
9) patients. 3. IBS (n=9) patients showed greater PCC activation compared with non-IBS
(n=10) patients (p<0.05 by spatial extent and pFDR=0.06). 4. The subgroup of patients
with IBS and abuse (n=5) scored significantly higher on pain during distention compared
to all others (4.5 vs. 3.35 p<0.04 respectively) and showed significantly greater activation
in the PCC (pFWE=0.02) and MCC (pFWE=0.05) and less activation in the perigenual
anterior cingulate cortex (pACC) (pFWE=0.01). Conclusions: We demonstrated a strong
correlation between visceral pain reporting and specific regional brain activation, and an
enhancing effect of psychosocial trauma on cingulate activation. The greater activation of
the MCC, a region activated in response to internal or external perturbation of homeostasis,
together with a reduced activation of pACC in the abuse-IBS group explain the greater
subjective pain reports in these patients. Supported by DK48351, R24 AT002681, P50
DK64539 (EAM),
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Non Genomic Transmission of Visceral Hypersensitivity Across Generations
After Maternal Separation
Rene M. van den Wijngaard, Olaf Welting, Pieter H. Looijmans, Wouter J. de Jonge, Guy
E. Boeckxstaens
INTRODUCTION: Adverse parent-child interactions are associated with an increased risk
to develop IBS later in life. Changes in maternal care induced by neonatal maternal separation
(MS) in rats lead to altered stress responsiveness in the separated offspring, which can
be transmitted across generations in a non-genomic fashion. Earlier, we showed visceral
hypersensitivity to colorectal distension (CRD) in response to water avoidance (WA) stress
in adult MS rats. Whether this hypersensitivity is also subject to non-genomic transmission
is unknown. METHODS: Female rats that underwent MS or were left undisturbed as a
pup, were allowed to mate with non-handled (NH) male rats. The subsequent offspring was
not subjected to MS. At the age of 3 months the offspring was equipped with EMG electrodes
in the abdominal muscles to record the visceromotor response (VMR) to CRD. Visceral
sensitivity was assessed by intermittent distention (1, 1.5, 2 ml) before and 24 hours after
WA in male animals only. Post-WA VMR to CRD was expressed as % of the pre-WA response
to 2 ml distension, and the area under the volume/%VMR curve (AUC) was calculated.
P<0.05 is considered statistically significant, pre-WA vs post-WA, Wilcoxon signed rank
test. RESULTS: 4 MS female rats yielded 12 non-separated male pups. Nine of these pups
became hypersensitive to CRD after WA (AUC>77). As a group, the post-WA AUC was
significantly increased compared to pre WA (fig 1,*P=0.004), indicating visceral hypersensit-
ivity to CRD. The male offspring (n=6) of the NH females did not develop visceral hypersensit-
ivity after WA (fig 1). CONCLUSION: We showed that the NH offspring of MS, but not
of NH female rats, develops visceral hypersensitivity to CRD after WA later in life. These
data suggest that the feature to develop stress-induced visceral hypersensitivity is transferred
in a non-genomic behavioral fashion. At present, cross fostering experiments are being
carried out to further confirm this hypothesis.
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Identification of Brain Networks Associated with Visceral Perception and
Hypervigilance in Patients with Irritable Bowel Syndrome (IBS)
Jennifer S. Labus, Emeran A. Mayer, Steve M. Berman, Brandall Suyenobu, Lin Chang,
Bruce D. Naliboff
Background:IBS patients show evidence of hypervigilance and hyperresponsiveness to visceral
stimuli. This hypervigilance may play a role in the enhanced perception of visceral stimuli
and in the cardinal IBS symptom of abdominal pain. Aims: To identify functional brain
networks underlying these responses and especially changes in brain responses associated
with perceptual changes over repeated sessions of stimulation. Methods:12 IBS patients(8
females) underwent barostat controlled rectal distension assessments 6 times over a 12-
month period. During the first and last session, PET(H215O)images were obtained during
2 trials each of resting baseline(BL), aversive rectal distension (INF), and anticipation of an
aversive distension(ANT). Multivariate task partial least squares(PLS) was tested for patterns
of brain activity related to changing task demands and distributed systems of brain activity
operating in IBS patients(seed PLS). Results: IBS symptom severity did not change over the
12 months, but perceptual ratings of the distensions significantly decreased (p<.01). Task
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PLS revealed a pattern of regions that separated BL from ANT across days and included
supragenual anterior cingulate cortex(ACC),[Brodmann Area 24], dorsal[46] and ventrolater-
alprefrontal cortex(PFC)[44/ 47], midbrain, posterior cingulate [31], posterior parietal [40],
anterior/mid insula, and hippocampus(p<.001). Seed PLS identified distributed patterns of
activity that were functionally connected with the rostral ACC, an area commonly activated
in IBS distension and other experimental pain procedures. Seed PLS revealed two significant
networks: one functioning similarly across days and conditions and another that evidenced
day-specific functioning. The common network included typical pain regions (thalamus,
posterior insula, rostral ACC[24], midcingulate[24/23]), and medial and lateral prefrontal
regions (medial PFC[32/10], dorsolateral PFC[46/9]). The day-specific network included
somatosensory [2/1/3/4/40], limbic and paralimbic (infragenual[25], amygdala), pre-
frontal(ventrolateral/medial PFC [11/47]) and midbrain/ brainstem regions. Conclusions:
These findings highlight activation of specific networks during actual and anticipated visceral
distension. In contrast to the stable neural network which includes the typical pain regions,
the day-specific network contains cortico-limbic-pontine circuits. The activity in these circuits
may be associated with IBS hypervigilance given that the strength of the functional connec-
tions within this circuitry changes following repeated exposure to an aversive visceral stimulus
and in conjunction with a decline in perceptual ratings.
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Abnormal CNS Response to Anticipation of Visceral Distention in Female
Patients with Irritable Bowel Syndrome (IBS) an FMRI Study
Steven M. Berman, Bruce D. Naliboff, Brandall Suyenobu, Lin Chang, Joshua Bueller,
Kim Ruby, Michael Minnema, Jean Stains, Emeran A. Mayer
BACKGROUND: Expectation of aversive somatic stimuli results in distinct patterns of brain
activation, which can amplify or attenuate afferent signals (Porro et al, 2002). In IBS patients,
abnormal brain responses to anticipated visceral discomfort (visceral anxiety) may contribute
to altered perceptual and autonomic responses. AIMS: To determine if female IBS patients
with constipation-predominant bowel habit (IBS) differ from healthy control subjects (Ctrls)
in their brain response to expected visceral discomfort. METHODS: Functional MRI com-
pared brain responses of IBS (n=14) and Ctrls (n=12) to a cue-light which signaled aversive
rectal distension in 3-5 s. Subjects received 60-90 15-s distentions. Trials pseudorandomly
varied between moderate (45 mm Hg), mild (25 mm Hg) and sham (5 mm Hg) distention.
Each trial began with a 15-s baseline (BL). Data were normalized to a standardized brain image
space. SPM2 software generated contrast images contrasting activity during cue (expectation
condition) and each level of rectal inflation (inflation condition) to BL for each subject.
Within 7 bilateral regions of interest (ROIs) comprising subregions of anterior cingulate
gyrus (ACC;3 ROIs), insula (2), amygdala and dorsal brainstem, random effects analyses
assessed CNS response to the cue and distensions. RESULTS: Expectation condition: Across
all subjects, there were no ROIs significantly activated by the cue light. However, there were
BOLD signal decreases, interpreted as deactivations, in insula, amygdala and brainstem. The
deactivations were consistent in Ctrls, but not in IBS, producing group differences in right
(R) anterior insula (p=.009), posterior insula (L: p=.098. R: p=.016), L amygdala (p=.044)
and dorsal pons (L: p=.005. R: p=.050). Whole brain exploratory analyses at p<.01 (uncorrec-
ted) found the cue activated 291 voxels in IBS but none in Ctrls. In contrast, there were
362 deactivated voxels in IBS compared to 8,251 in Ctrls (p<.001). Inflation condition:
Both groups showed the expected pain matrix activations during distention, with no signific-
ant group differences. CONCLUSIONS: 1. As compared to healthy controls, female IBS
patients respond to cued anticipation of uncomfortable visceral distention through less
consistent deactivation of brain regions involved in modulation of visceral pain. 2. In contrast,
they do not show significant group differences during actual aversive distension. This altered
anticipatory response may be related to visceral anxiety. Supported by DK48351, R24
AT002681, P50DK64539 (EAM), NR04881 (BN).
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A Randomized Controlled Trial of Therapist-Administered vs Minimal-
Therapist-Contact Cognitive Behavioral Treatment for Moderate to Severe IBS
Jeffrey M. Lackner, Kenneth A. Holroyd, Gregory D. Gudleski, Susan S. Krasner, Leonard
A. Katz, Catherine D. Powell, Praveen K. Sampath, Rebecca S. Firth, Brian T. Yates
BACKGROUND. While cognitive behavioral therapy (CBT) is regarded as an efficacious
treatment for IBS (Gastroenterology, 2003;125(1):19-31), it has not shown a commensurate
level of clinical utility because of its cost, limited availability, and labor-intensive demands.
Given the prevalence of IBS, the absence of a consistently satisfactory medical option, and
a chronic course whose trajectory is subject to strong psychosocial influences, there is an
unmet need for a behavioral self management treatment that is less costly to deliver and
more transportable yet retains the efficacy of standard, therapist administered CBT. AIMS.
To develop and test the feasibility of a largely self administered version of CBT. METHOD.
59 Rome II diagnosed IBS patients (80% female) were stratified by symptom severity and,
after a 4 week baseline, randomized (1:1:1) to 1 of 3, 10-week conditions: (a) 10 session
manualized Standard-CBT (S-CBT; n = 20); (b) 4 session manualized Minimal Contact CBT
(MC-CBT, n = 22); or (c) wait list (WL, n = 17). MC-CBT covered the same range of
procedures featured in S-CBT but they were taught through a self-study workbook (Breaking
Free of IBS: A Step by Step Guide, Lackner & Holroyd, 2005) developed expressly for the
trial. WL patients’ data were obtained before they crossed over (1:1) to an active condition.
Primary endpoints were adequate relief from pain and GI symptoms (2 Yes/No items) and
global ratings of IBS symptom improvement. Secondary endpoints were distress (BSI), quality
of life (IBS-QOL), coping (CSQ, IBS-SEQ), IBS symptom severity (IBS-SS), and cost-efficiency.
RESULTS. In intent-to-treat analyses, both CBT versions were significantly (p < .0001)
superior to WL at post-treatment in the percentage of participants reporting moderate-to-
substantial improvement in IBS symptoms (MC-CBT = 72.8%, S-CBT = 73.7%, WL = 0.0%).
A similar pattern was found for the percentage of patients reporting adequate relief of pain
(MC-CBT = 72.7%, S-CBT = 73.7%, WL = 11.8%) and GI symptoms (MC-CBT = 63.6%,
S-CBT = 68.4%, WL = 0.0%). MC-CBT patients achieved significant improvements in QOL,
IBS symptom severity, distress, and coping (e.g., catastrophizing, self-efficacy to control IBS
symptoms), with all pre-post therapy difference p values < .01. Cost effectiveness analyses
indicated that MC-CBT achieved symptom relief about 5 times as efficiently as S-CBT. 16%
of MC-CBT (vs 15% of S-CBT) patients dropped out. CONCLUSIONS. Data suggest that a
4-session CBT regimen is a well tolerated, efficient, and clinically effective treatment that
provides significant relief from the range of problems of more severe IBS. Supported by
NIDDK grant 67878.
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Pain and Depression Predict Improved Health-Related Quality of Life in
Severe IBS Treated with Psychotherapy of Antidepressant
Francis Creed, Elspeth Guthrie, Joy Ratcliffe, Lakshmi Fernandes, Barbara Tomenson,
Nicholas Read, David Thompson
Objective We have reported previously long-term improved health-related quality of life in
patients with severe irritable bowel syndrome (IBS) following treatment with an antidepress-
ant or psychotherapy (1). In this study we assessed the relative importance of improved
pain or depression in this finding. Method We assessed 257 patients with severe IBS before
treatment and 239 one year after the end of treatment (75 psychotherapy, 85 Paroxetine
and 79 treatment as usual) using a visual analogue scale (VAS) of abdominal pain and the
Hamilton Depression Rating Scale (HDRS). Linear regression was used to predict change in
SF36 physical component score. Structural equations modelling using AMOS tested whether
baseline depression (HRSD) score predicted follow-up VAS pain score and vice versa. Results.
Preliminary analyses confirmed that VAS pain and HDRS depression scores represented well
the dimensions of pain and depression experienced by participants in our sample. Linear
regression analysis to predict 1 year follow-up SF36 physical component score (health-
related quality of life) indicated that pre-treatment VAS pain (p<0.001) and HDRS depression
scores (p=0.005) and change (follow-up minus baseline) of VAS pain (p<0.001) and HDRS
depression scores (p=0.006) were all significant independent predictors. Structural equation
modelling including baseline and follow-up scores of VAS pain and HDRS depression showed
that the overall fit of the model was excellent, chi2=2.06, df=3, p=0.56, chi2/df=0.69,
RMSEA<0.0005 and CFI=1.000. The standardised regression coefficients for baseline to
follow up depression score and VAS pain were 0.36 (p<0.005) and 0.38 (p<0.005), respect-
ively, demonstrating that each follow up variable is predicted by its own baseline value.
The standardised regression coefficient for baseline VAS pain predicting follow-up HRSD
was also significant (chi2=0.15, p=0.02), but that for baseline HRSD predicting follow-up
VAS pain today was not (chi2=0.09, p=0.16). Addition to the model of psychotherapy and
SSRI antidepressant treatments as additional variables did not change the model and the
same model fits the data in each of the 3 treatment groups, when these were analysed
separately. The model held when only patients who also had a psychiatric disorder were
included. Conclusion: In patients with severe IBS receiving psychological treatments, both
improved pain and depression influences later health-related quality of life but change in
depression is not primarily responsible for this result. Other aspects (eg coping with pain
and its attribution) are likely to be involved. (1) Gastroenterology 2003; 124 :303-17.
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Laboratory Parameters in the Diagnosis of Choledocholithiasis: A Meta-
Analysis
Jack Braha, Anita Turok, Jian Jun Li, Scott Tenner
The presence of a common bile duct stone warrants intervention to prevent cholangitis and/
or pancreatitis. Due to complications from laparoscopic cholecystectomy including bile leaks,
the need for preoperative diagnosis of common bile duct stones has led to increased utilization
of imaging, including magnetic resonance cholangiopancreotography (MRCP) and endos-
copic retrograde cholangiopancreotography (ERCP). Clinicans often are considering particu-
lar laboratory tests in the decision to evaluate the common bile duct in patients with biliary
disease. Although several laboratory parameters have been proposed to assist the clinician
in determining the risk of a common bile duct stone, there is considerable controversy. The
purpose of this study is to determine which laboratory parameters are helpful in predicting
the presence of common bile duct stones. In order to overcome the complexity and number
of studies that have addressed this issue, a meta-analysis was performed. After a Medline
search identified all studies since 1974 that described the role of laboratory parameters in
predicting the presence of a common bile duct stone, the papers were analyzed. Only studies
that allowed a relative risk calculation were included. Thus, the paper had to include
individual data points for the laboratory parameters to be studied. There had to be a group
of patients with common bile duct stones and a group of patients without common bile
duct stones. The following laboratory parameters were studied: aspartate transaminase (AST),
alanine transaminase (ALT), alkaline phosphatase (AP), bilirubin, and amylase. Twenty
studies were used in the final analysis. 687 patients with common bile duct stones were
compared to 574 patients without common bile duct stones. A weighted mean was calculated
with confidence intervals for the results from the combined analysis. The relative risk (RR)
for the presence of a common bile duct stone was 3.3 (1.2 - 4.4) for AST, 2.1 (1.1 - 3.5)
for ALT, 1.4 (0.8 - 3.3) for alkaline phosphatase, and 4.4 (2.2 - 7.7) for bilirubin. An
amylase of greater than 3 times normal had a RR of 2.2 (0.9 - 3.3). Abnormal liver function
tests increase the relative risk of having a common bile duct stone. However, the increased
risk appears more significant for the AST, ALT and bilirubin. An elevated alkaline phosphatase
and/or amylase is not significantly associated with the presence of a common bile duct stone.
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Efficacy of Non-Invasive Hepatic Fibrosis Quantification By Liver Elasticity
Measurement in Nonalcoholic Steatohepatitis (NASH) -Comparison of
Ultrasonic TRANSIENT ELASTOGRAPHY and Histopathological Diagnosis
Yoshitaka Fukuzawa, Tomohiko Ohashi, E.J. Matsumoto, Ken Sato, Minoru Ayada, Naoki
Hotta, Akihiko Okumura, Tetsuya Ishikawa, Shinichi Kakumu
[Background and Aim] The global & golden standard for NASH progression still relies on
histopathological diagnosis by liver biopsy, but since this is an invasive test, it causes a large
amount of physical and mental stress for patients (particularly elderly patients) and assessment
of progression over time (treatment) is difficult. The aim of this study was to compare NASH
patients’ hepatic fibrosis evaluation using an elastometer to measure elasticity score (ES),
with a histopathological diagnosis using a liver biopsy, and examine the efficacy of both
methods. [Subjects and Methods] We measured the ES of all NASH patients (n=38) using
an elastometer (Fibroscan, ver.3 EchoSens, Paris, France) applying a low-frequency shear
wave-elastography. The patients laid on a bed on their backs and the location of measurement
was determined with B-mode ultrasound. The elasticity was automatically calculated in the
apparatus and the data were shown as Kilo Pascal (KPa). Measurements were taken 5-10
times for each case and we obtained the average value. We comparatively examined the
correlation between the measurement values and hepatic fibrosis progression (Fibrotic Sta-
ging, by Brunt classifications) including the control group (n=6). [Results] Normal control
group (group C, n=6) (Mean±SD, 3.5±1.3), group S0 (n=8) (3.9±1.5), group S1(n=9)
(6.8±2.3), group S2 (n=8) (8.4±3.5), group S3 (n=7) (35.4±7.8), group S4 (n=6) (59.1±18.8).
No significant difference was shown between group C and group S0, but together with the
progression of fibrosis, clear significant differences were evident between groups (P< 0.05).
This was particularly notable in the shift in progression from S1-S2 to S3-S4. Further, the
average measurement time for each case was (7.8±2.8) minutes, a significantly shorter time
than that with liver biopsy (P< 0.05). [Conclusion] We have shown that using ES obtained
by an elastometer, it is possible to assess the progression of hepatic fibrosis in NASH non-
invasively, simply, quickly and quantitatively, and it is extremely effective for long-term
monitoring, including therapy. It is considered effective (promising) as an alternative test
for NASH patients for whom a liver biopsy is not possible, periodically or frequently.
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What Are the Best Cut Offs for the APRI ?
Ned Snyder, Rami Hawari, Shu-Yuan Xiao, Daryl Lau, Roger Soloway, John Petersen
Background: The AST/platelet ratio (APRI) is a simple biochemical index for hepatic fibrosis.
We have found it accurate in retrospective and prospective studies at at our institution.(Gas-
troenterol 126:A-304, Am J Gastroenterol 99: S100). When first proposed by Wai et al
(Hepatology 38:518), the cut offs proposed were <0.5 for mild fibrosis, >1.5 for significant
fibrosis, and > 2 for cirrhosis. While most investigators have used these cut offs, there is
little published data on the accuracy of other cut offs. The ideal cut-off would have a negative
or positive predictive value > 90%, and result in a small indeterminate zone. Purpose: We
wanted to determine the best cut offs for mild and significant fibrosis and cirrhosis for the
APRI in a group of patients enrolled in a prospective study of multiple hepatic fibrosis
markers.Methods : We prospectively collected blood from 208 patients with chronic HCV
on the same day they underwent pre treatment staging liver biopsy. The liver biopsies were
read blindly by one pathologist using the Ludwig Batts criteria for the staging of fibrosis
(F0-F4). APRI was calculated as below.* Results: There were 91 patients (43.8%) with mild
fibrosis (F0-F1), and 117 (56.2%) patients with significant fibrosis (F2-F4). The ROC curve
for the APRI resulted in an AUC of 0.878 (95% confidence interval 0.822-0.921). The results
of cut offs for mild and significant fibrosis are shown in the table below.Utilizing cut offs
of 0.42 and 1.2 led to high predictive values and an intermediate zone of 43.3%. The
originally proposed cutoffs of 0.5 and 1.5 resulted in a lower negative predictive value, and
a similar indeterminate zone (42.3%).The APRI was not accurate in our patients in predicting
cirrhosis. There were 40 patients with Stage 4 disease. At >1.75, 22/38 (57.9%) had cirrhosis
while at >2.00, 19/32 (59.4%) had cirrhosis. Conclusion: Our study confirms that the APRI
is an accurate method to predict the presence or absence of significant fibrosis in patients
with chronic HCV. In our patients, 0.42 for mild fibrosis and 1.2 for significant fibrosis
appear to be the best cut offs.The use of these cut offs could improve the accuracy of the
APRI. The APRI is not as useful in predicting cirrhosis. * APRI = AST/ULN X 100/platelets
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Protective Factors for Severe Recurrence of Hepatitis C After Liver
Transplantation
Speranta Iacob, Susanne Beckebaum, Vito Cicinnati, Razvan Iacob, Christian Klein, Liana
Gheorghe, Cristian Gheorghe, Irinel Popescu, Andrea Frilling, Massimo Malago, Guido
Gerken, Christoph Broelsch
INTRODUCTION: Although reinfection of liver grafts is virtually universal, factors influen-
cing disease progression in HCV infected liver transplant (LT) recipients remain controversial
and are poorly understood. AIM & METHODS: The aim of this study was to identify
predictive factors for absence of fibrosis at the first liver biopsy showing recurrent hepatitis

















year protocol biopsies. We retrospectively assessed the liver biopsies from 109 patients with
recurrent hepatitis C and the virus, host (pre and posttransplant), donor and iatrogenic
related variables. Univariate and multivariate logistic regression analysis have been conducted.
RESULTS: We identified 31 (28.44%) patients without fibrosis at first liver biopsy. There
were 71% and 69.2% male respectively in the group without and with fibrosis, respectively.
The mean age at LT was 53.4+/-9.5 years and respectively 51.8+/-8.7 years in the group
without and with fibrosis. The following factors were associated with no fibrosis at first
biopsy: absence of pretransplant portal vein thrombosis (p=0.03), cold ischemia time < 400
minutes (p=0.009), absence of steatosis at first liver biopsy showing histologic recurrence
(p=0.04), female donor (p=0.006), hemoglobin serum level of the donor > 10 g/dl (p=0.02)
and absence of de novo diabetes mellitus (p=0.05). Multivariate analysis has identified the
following independent predictors for absence of fibrosis in transplanted patients: cold isch-
emia time less than 400 minutes (p=0.02) and female gender as donor regardless of the
recipient gender (p=0.03). CONCLUSION: A shorter cold ischemia time and female gender
as donor are associated with a less aggressive recurrent HCV disease.
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Novel Markers of Cirrhosis and Hepatocellular carcinoma in Hepatitis C
Kuntal M. Thaker, Bridget Seymour, Divya Gupta, Kuldip S. Banwait, Mark A. Feitelson,
Steven K. Herrine, Victor Navarro
Background and Aim: Previous work has shown that hepatitis B x antigen triggers up-
regulation of two novel genes (URG& and URG11), both of which contribute to tumor
development in patients with chronic hepatitis B virus (HBV) infection. Anti-URG7 and
anti-URG11 have been detected in most patients who develop HBV associated hepatocellular
carcinoma (HCC). Since the pathogenesis of HBV and hepatitis C virus (HCV) associated
HCC has some similarities, experiments were designed to test the hypothesis that these
antibodies would also be triggered in patients with HCV related diseases. Methods: Consecut-
ive HCV infected patients seen at the liver clinic from October 2004 to March 2005 were
prospectively recruited into four groups: chronic HCV without cirrhosis (Group 1, n=30),
HCV with cirrhosis (Group 2, n=29), HCV with HCC (Group 3, n=13), and uninfected
controls (n=8). Sera were tested for anti-URG7 and anti-URG11 by specific ELISAs. Results:
For anti-URG7, 21/30 (70%) of group 1; 29/29 (100%) of group 2; and 11/13 (84.6%) of
group 3 patients were positive (p<0.05 for group 1 vs. 2, group 2 vs. 3). For anti-URG 11,
14/30 (46.7%) of group 1; 19/29 (65.5%) of group 2; and 6/13 (46.2%) of group 3 patients
were positive (p<0.05 for group 1 vs. 2, group 2 vs. 3). Both antibodies were detected in
36.67% of group 1; 65.52% of group 2; and 54.55% of group 3 patients (p<0.05 for group
1 vs. 2, group 2 vs. 3). No antibodies were detected in the uninfected controls. Mean ELISA
OD values were lower for group 1 (0.0904) as compared to group 2 (0.1191) with p=
0.0039. Mean ELISA OD values were not statistically significant for group 1 versus group
3, or group 2 versus group 3. There was no relationship between presence and absence of
antibodies and amino alanine transferase, alpha-fetoprotein, and hepatitis C viral levels.
Conclusions: 1)Anti-URG7 and anti-URG11 are detectable in HCV infected patients, as they
are in HBV patients. 2)Up-regulation of anti-URG7 and anti-URG11 is not an unique effect
of HBxAg as previously believed. 3)No antibodies are present in uninfected controls. 4)Up-
regulated expression of these two genes in HBV and HCV may have a similar pathogenic
mechanism in causing HCC. 5)These antibodies may serve as surrogate markers for cirrhosis
and HCC in HCV patients, and may be identified by a simple blood test.
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Colonoscopic Screening of First Degree Relatives of Patients with Colorectal
Cancer: A Concurrent Case-Control Comparison to First Degree Relatives of
Asymptomatic Individuals with Normal Colonoscopic Findings
James Y. Lau, Wai-Keung Leung, Priscilla L. Siu, Simon S. Ng, Janet F. Lee, Sara Fung,
Raymond Y. Yiu, Joseph J. Sung
Background: First-degree relatives to patients with sporadic colorectal cancer have a higher
risk of developing colonic adenomas and cancer. The evidence has been based mostly on
cohort studies. There has been controversy over methodology in choosing control subjects.
Methods: We invited first degree relatives (aged 40-70) of patients with sporadic colorectal
cancers to undergo colonoscopy. In the same period, we also invited control subjects,
who were first degree relatives of subjects with normal colonoscopic findings from our
asymptomatic screening cohort [Sung Gastroenterology 2003; 124:608-14]. We excluded
subjects with known inflammatory bowel disease, suspected FAP or HNPCC, subjects who
had undergone colonoscopy in the past 5 years or severe comorbid illnesses that precluded
safe colonoscopy. Endoscopists were blinded to family history of subjects. In both studied
and control subjects, colonoscopies were performed concurrently. To each examined relative,
one control matched for sex, age (+/- 3 yrs), and possible symptom was selected. Results:
Between Sep 04 and Nov 05, 163 case and 163 control subjects (mean age of 53, men %
33) from 128 and 125 families respectively underwent colonoscopies. Prevalence of adenomas
in first-degree relatives of patients with colorectal cancer and their matched controls is listed
in table 1. Conclusions: Subjects with affected first degree relatives are at increased risk of
advanced colonic lesions.
Table 1. Prevalence of adenomas in first-degree relatives of patients with colorectal cancer
and their matched controls
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Temporal Trend in Relative Risk of Second Primary Colorectal Cancer (CRC):
An Impact of Surveillance?
Ananya Das, Amitabh Chak, Gregory S. Cooper
Patients with CRC are at a higher risk for developing a second primary CRC. A number of
factors that have potential impact on the risk of second primary CRC such as, survival rate,
rate of receipt of surveillance procedures and the overall incidence of colorectal cancers in
the western population have changed over the last three decades. However, currently no
information is available on the temporal trend in the risk of second primary CRC in patients
who survived initial CRC. Objectives: In this study, our aim was to use the Surveillance,
Epidemiology and End Results Public-use database to assess whether the relative risks of
second primary CRC has changed in patients with initial primary CRC, and also to compare
clinical characteristics of the second primary CRC in patients diagnosed with first primary
CRC during two different periods of time. Methods: The database was analyzed to assess
the temporal trend in the standardized incidence ratio (SIR) and excess risk of cancer (beyond
the expected amount) per 100,000 persons per year for a second primary CRC in these
patients. Also, the demographic and clinical features of the second primary CRC was com-
pared in two subgroups based on the year of diagnosis of the first primary CRC: Group A
(1973-1977) and Group B (1988-1992). Results: During the period of 1973 to 2002, 216,751
patients developed a primary CRC and over a follow up period of 11,250,687 person-years,
5,595 of these patients developed a second primary CRC with an SIR of 1.41 (95%CI, 1.37-
1.44). While the overall age-adjusted incidence rate of first primary CRC declined from 204
per 100,000 in 1992 to 177 in 2002, the excess risk of second primary CRC increased from
85 per 100000 in 1992 to 173 in 2002. Patients in Group A had more advanced disease
at diagnosis of the second primary CRC compared to those in Group B. In a Cox proportional
hazards model, the period of diagnosis of the first primary CRC was an independent risk
factor for a subsequent primary CRC; the relative hazard of second colon cancer in Group
B compared to Group A was 1.18 [ 95% CI, 1.05-1.31], after controlling for age at diagnosis,
gender, race, site and stage of first primary colon cancer. Conclusion: The relative risk of
the second primary CRC has increased since early nineties and these subsequent cancers
are being diagnosed at an earlier stage. Among other factors, this probably reflects impact
of increasing receipt of surveillance procedures.
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Stated Preferences for Colorectal Cancer Screening Using a Discrete Choice
Experiment
Seija K. Kromm, Steven J. Heitman, Robert J. Hilsden, Deborah A. Marshall, S. Elizabeth
McGregor, Gillian R. Currie
Background: Uptake of colorectal cancer (CRC) screening may be influenced by the attributes
of available screening tests. The purpose of this discrete choice experiment (DCE) was to
determine the attributes of CRC screening tests that are most important to the general public
and how these attributes might affect uptake. Methods: 218 subjects aged 50-70 (115 men)
recruited from the general population participated in a DCE administered as a face-to-face
interview involving a series of 8 choices between two hypothetical screening tests and not
being screened. Each test was described by 7 attributes: accuracy, need to travel for test,
waiting time, test procedure, ability to find polyps, need for follow-up test and testing
interval. A series of four focus groups and pilot testing informed the choices of DCE attributes.
Responses were analyzed using multinomial logit regression. Results: Respondents preferred
to be screened over not being screened (p<0.001). Test accuracy (p<0.001), ability to find
polyps (p<0.001) and not having to travel out of the community for the test (p<0.01) were
determinants of test choice, in order of importance. Those who had not been screened
(56%) preferred a procedure whose description matched a virtual colonoscopy, all else
equal. Respondents who had been screened preferred a procedure whose description matched
a colonoscopy, all else equal. The regression coefficients were used to estimate the uptake
of existing screening tests. Preference for accuracy and prevention drive uptake when the
tests are offered as part of a menu of options. Given a choice between FOBT and colonoscopy
at current local wait times for colonoscopy (15 months) and single test FOBT accuracy (50%
of cancers missed), 95% would choose colonoscopy. With higher FOBT accuracy, as that
for annual testing for 10 years (25% of cancers missed), 73% would choose colonoscopy.
Given a choice between colonoscopy and virtual colonoscopy (assuming zero wait time in
both cases), 60% of people would choose colonoscopy. Conclusion: The most important
characteristics influencing preferences for screening were test accuracy, ability to find polyps,
and the need to travel out of the community for the test. Preferences about the nature of
the procedure depended upon screening experience. Predicted uptake of screening was
much higher than seen currently. This may be due to the hypothetical nature of the choices,
prior screening experience, and the influence of other test features not included in the set
of attributes used in the DCE. These findings may be useful in developing education initiatives
and a population-based CRC screening program most acceptable to the public.
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Colorectal Cancer Screening in Chinese Immigrants: Who Can Deliver the
Message?
Karen E. Kim, Stacy Tong, Eva Lu-Bonn
Background: Colorectal cancer (CRC) ranks third in cancer incidence and mortality in Asian
Americans. Studies on colorectal cancer in Asian Americans suggest that screening rates are
among the lowest reported. Barriers to colorectal cancer screening (CRS) in immigrants
include language, access and absence of routine health care. The effectiveness of ethnic and
culturally specific community outreach on colorectal screening in Chinese immigrants has
not been previously reported. This study compares the effectiveness of physician directed
compared to lay health educator directed CRS programs in Chinese immigrant communities.
Methods: Chinese community based organizations were asked to randomize their clients
aged 50 and above into two CRS programs. Physician directed programs used Asian, non-
Chinese speaking physicians coupled with a trained medical interpreter for CRC education
and fecal occult blood testing (FOBT), while lay educator programs (LHE) used peer educators
for education on CRC and FOBT. All participants completed a translated survey on CRS
compliance, CRC risk perception and knowledge gained. The effectiveness of each educational
program on CRS behavior was assessed by compliance with fecal occult blood testing (FOBT).
Results: 260 participants attended CRC programs. The average age was 54; 55% were women,
the average years in the US was 10. 80% of participants reported speaking Chinese at home
and were of limited English proficiency. 5% of participants in the MD group (n=135)
completed the FOBT, compared to 76% in the LHE group (n=125). Overall, 30% were
found to have a positive FOBT. 75% in the MD group and 85% in the LHE group reported
a gain in knowledge about CRC and CRS. Conclusions: In this study, Chinese immigrants
were significantly less likely to comply with FOBT when education was delivered by Asian,
non-Chinese speaking physicians. In stark contrast, the same program delivered by a peer
educator (a respected member of their community) resulted in an extremely high FOBT
compliance. Since no significant difference in knowledge gained between the two groups
were reported, these differences cannot be attributed to language barriers. Given the high
rates of positive FOBT in this population, this study highlights the importance of community
based and community directed education in hard to reach populations.
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Variation in Polyp Detection Rates At Screening Colonoscopy
Thomas F. Imperiale, Elizabeth A. Glowinski, Ching L. Cooper, Gregory N. Larkin,
Faouzi Azzouz, David F. Ransohoff
Background: Wide variation in adenoma detection rates has been found in the U.K. Flexible
Sigmoidoscopy Screening Trial. This variation, attributed to endoscopist performance, has
been used to justify the need for establishing quality standards for performance of colonos-
copy. Purpose: The objectives of this study were to measure, in a program of screening
colonoscopy, variation in polyp detection rates (PDRs) and to identify factors associated
with PDRs. Methods: We reviewed summary-level data from endoscopists who performed
at least 40 first time screening colonoscopies for the Lilly Colorectal Cancer Prevention
Program between 9/1995 and 6/2001. Summary-level data include mean age, mean procedure
time (MPT), gender distribution, and % persons with any polyp, any adenoma, any polyp
>= 1.0 cm, and multiple polyps. We described the variation in PDRs and used boxplot
analysis to identify outliers. Multivariable regression modeling identified factors associated
with PDRs and that accounted for some of the variability in PDRs. Results: 2664 screening
colonoscopies (1108 [42%] in women, 1556 in men) were performed by 25 endoscopists,
whose number of procedures ranged from 40 to 207. Overall mean patient age was 59 years
(mean age range, 56 to 62 yr), the mean % women was 42% (range, 29-52%), and MPT
was 17.1 minutes (range, 9.7-31 min). Mean PDRs, ranges, number of outliers, and outlier
values are in the Table. Regression models that included procedure N, mean age, % women,
and MPT accounted for 42% of the variation in PDRs for any polyp, 56% of the variation
in PDRs for any adenoma, 37% for large polyps, 36% for > 1 polyp, and 46% for >1 adenoma.
In all models, only MPT was significantly associated with PDRs. For the endoscopists with
the shortest (9.7 minutes; N=80) vs. longest (31 min; N=56) MPTs, respective PDRs for
any polyp, any adenoma, polyps >= 1 cm, > 1 polyp, and > 1 adenoma were 20% vs. 82%,
15% vs. 43%, 0% vs. 12.5%, 7.5% vs. 50%, and 6.3% vs. 25% (all P-values < 0.003).
Conclusion: PDRs vary widely among screening colonoscopists, though only a few (high)
outliers were identified. Variation in PDRs was significantly associated with MPT, but not
with age, gender, or the number of procedures. Further research is needed to understand
the reasons for variation, and requires attention to patient risk factors, scope withdrawal
time, and quality of the prep.
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The Impact of Literacy On Colonoscopy
Rony Ghaoui, Arthur T. Evans, Bashar M. Attar
Background and Aims Approximately 20-30% of attempted colonoscopies are incomplete
because of poor bowel preparation. This problem is not only costly and wasteful, but
increases risks and delays diagnosis and treatment. Although literacy skills are necessary for
patients to successfully follow home bowel preparation instructions, they are nearly imposs-
ible to assess informally. Our aim was to evaluate the impact of literacy on bowel preparation
and completion of colonoscopy, with the ultimate objective of redesigning instructions to
be more effective, regardless of patients’ literacy skills. Methods We performed a prospective
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cohort study at a large urban public hospital during the summer of 2005 among patients
who presented for outpatient colonoscopy. Before the colonoscopy, literacy was assessed
using the 7-minute test of functional health literacy. Using structured interviews, we also
gathered information on patients’ past history, beliefs, and self-reported behaviors on bowel
preparation. Results of the colonoscopy were obtained from the procedure reports. Results
The sample of 195 subjects included 64% women, 49% African Americans, and 40% with
low literacy skills. 25% of colonoscopies were not completed, primarily (90%) because of
poor bowel preparation. Low literacy increased the risk of an incomplete exam 4-fold: 12
% incomplete exams among patients with adequate literacy skills compared to 45% with
low literacy skills (p<0.001). Other important predictors of an incomplete exam were: eating
lunch or dinner the previous day, not taking the bisacodyl (p=0.001), and not finishing the
1-gallon polyethylene glycol solution (p=0.01). Patients with a past history of colonoscopy
(p=0.03) and those who received additional oral instructions from a physician or nurse (p=
0.05) were more likely to have a complete colonoscopy. Low literacy remained the strongest
independent predictor of incomplete colonoscopy after controlling for the contribution of
all other factors (OR=8.7; 95% CI: 3.4-22.1; p<0.001). Discussion/Conclusion Low literacy
accounts for 30% of all incomplete colonoscopies. This important effect is independent of
age, gender, ethnicity, and even whether oral instructions supplemented the written instruc-
tions. In light of these findings, we must redesign our methods of instructing patients about
bowel preparation in order to improve the efficiency and effectiveness of colonoscopy.
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Prevention of Low Dose Aspirin-Associated Gastroduodenal Ulcers and Upper
Gastrointestinal Symptoms in Patients Receiving Esomeprazole 20 Mg Per Day
Neville D. Yeomans, Angel Lanas, Joachim Labenz, Sander Veldhuyzen van Zanten,
Christo van Rensburg, Istvan Racz, Emma Naucler, Lars-Erik Svedberg
OBJECTIVE: To assess whether esomeprazole reduces the incidence of ulcers in patients
taking low dose (75-325 mg daily) aspirin (acetylsalicylic acid). METHODS: Male or female
Helicobacter pylori-negative patients ≥60 years with a condition requiring daily low dose
aspirin, at risk of developing gastroduodenal ulcers were included in this randomized,
double-blind, multicenter, placebo-controlled trial. Patients were excluded if they had upper
gastrointestinal symptoms, including heartburn, that required treatment, or if they had
erosive esophagitis. Patients with Los Angeles Grade A lesions and without reflux symptoms
requiring treatment could be included. Patients were randomized to receive either esomepra-
zole 20 mg or placebo once daily (qd) for 26 weeks. Patients continued to receive the aspirin
dose they were taking when enrolled into the study. The primary outcome variable was the
presence of gastric and/or duodenal ulcers at endoscopy over the 26-week period. We
present data from endoscopy taken at 26 weeks. RESULTS: A total of 991 patients (57.1%
male, mean age 69.3 years, median aspirin dose 100.0 mg, 89.0% taking aspirin for >4
weeks) were included in the intent-to-treat population. Eight patients (1.6%) had developed
a gastroduodenal ulcer in the esomeprazole group by 6 months, compared with 27 patients
(5.4%) in the placebo group (p=0.0007). This corresponded to a relative reduction of
developing an ulcer of 70% when taking esomeprazole rather than placebo. The related life
table estimates were 1.8% for esomeprazole and 6.2% for placebo. In patients with Grade
A esophageal lesions at baseline and with pre- and post-baseline data, 13 patients (28.3%)
in the esomeprazole group had Grade A lesions at week 26, compared with 37 patients
(71.2%) in the placebo group (p<0.0001). Resolution of investigator-assessed aspirin-associ-
ated upper gastrointestinal symptoms (rated as none to severe) was significantly higher with
esomeprazole than with placebo for epigastric pain, burning and discomfort, as well as
heartburn and bloating (p<0.05 for all symptoms). Esomeprazole was safe and well-tolerated.
CONCLUSIONS: Esomeprazole 20 mg qd is more effective than placebo and is well-tolerated
in reducing the risk of developing gastroduodenal ulcers and resolving upper gastrointestinal
symptoms associated with low dose aspirin use in patients at moderate-to-high risk of
developing ulcers. At risk patients taking low dose aspirin may therefore benefit from co-
administration of esomeprazole.
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Effects of Concomitant Aspirin (81 mg qd) On Incidence of Gastric and/Or
Duodenal Ulcers in Healthy Subjects Taking Celecoxib Or Naproxen: A
Randomized, Placebo-Controlled Trial
Jay L. Goldstein, James Aisenberg, Manuela Berger, William E. Dodge
Background: Patients who use nonselective nonsteroidal anti-inflammatory drugs (NSAIDs)
or cyclooxygenase-2 (COX-2) selective inhibitors often require concomitant low-dose aspirin
(ASA) for cardiovascular (CV) prophylaxis. The impact of the most common prophylactic
ASA dose (81 mg qd) on the gastrointestinal (GI) safety profile of COX-2 selective inhibitors
remains controversial. Methods: In this multicenter, double-blind, placebo-controlled study,
healthy subjects (seronegative for Helicobacter pylori) aged 50-75 y were randomized to
receive celecoxib 200 mg qd + ASA 81mg qd, naproxen 500 mg bid + ASA 81 mg qd, or
placebo + ASA 81 mg qd for 1 week. The primary end point was incidence of gastric and/
or duodenal ulcers in subjects treated with celecoxib + ASA compared with naproxen +
ASA. Upper GI (UGI) endoscopy was performed at baseline and Day 7 (or early termination).
Subjects were excluded if baseline endoscopy revealed >5 erosions in the stomach or
duodenum; any gastric, pyloric channel, or duodenal ulcer (≥3 mm diameter); or any
esophageal ulcers/erosions. In addition, subjects with any NSAID use within 2 weeks of
enrollment were excluded. Results: A total of 662 subjects (mean age, 58 y) were randomized
in a 2:2:1 fashion (celecoxib + ASA, n=267; naproxen + ASA, n=264; placebo + ASA, n=
131). There were no significant differences in baseline demographics between groups. A
total of 7% (18/257) of evaluable subjects randomized to celecoxib had gastric and/or
duodenal ulcers compared with 25.3% (65/257) of those on naproxen and 1.6% (2/129)
of those on placebo. Statistical pairwise comparisons by Cochran-Mantel-Haenszel test are
shown in the Table. For secondary end points, significantly fewer celecoxib-treated subjects
had gastric ulcers (GU) or duodenal ulcers (DU) vs naproxen (GU: 5.8% vs 22.6%; DU:
1.2% vs 7%; P<0.001 both comparisons). More celecoxib-treated subjects had GUs vs
placebo (P=0.016) but there was no significant difference in the incidence of DUs (1.2% vs

















results in more gastric and/or duodenal ulcers than aspirin alone but fewer compared with
naproxen. In parallel with a similarly designed trial (but with 325 mg qd ASA), these data
suggest that daily ASA doses commonly used for CV prophylaxis do not completely negate
the UGI benefit of celecoxib compared with naproxen, as measured by endoscopic ulcer rates.
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Effects of Antisecretory Drugs and Nitrates On the Risk of Ulcer Bleeding
Associated with NSAIDs and Anti-Platelet Agents
Angel Lanas, Luis A. Garcia-Rodriguez, Maria T. Arroyo, Fernando Gomollon, Faust Feu,
Montse Forne, Sofia Aleman, Enrique Garcia, Luis Bujanda, David Nicolas, On Behalf of
AEG Investigators
Background and Aims: After the withdrawal of rofecoxib, an increased prescription rate of
some non-selective NSAIDs has been observed, but, according to recent reports, additional
prevention strategies are not being followed. In this study we report the effect of antisectory
drugs (proton pump inhibitors-PPI; H2-receptors antagonists- H2-RA) and nitrates on the
risk of upper gastrointestinal ulcer bleeding (UGIB) associated with NSAID use in clinical
practice Methods: Type of Study: hospital-based case-control study with prospective data
collection. Setting: A network of 40 general hospitals integrated within the Spanish Associ-
ation of Gastroenterology. Cases were consecutive patients with UGIB confirmed by endos-
copy. Controls matched 2:1 to cases by age (5 years range), hospital and month of interview
were individuals with an outpatient visit or hospitalised with a primary diagnosis that was
neither an indication nor a known contraindication of NSAID or low dose aspirin treatment.
The same structured questionnaire was used in all sites. Relative risk (RR) of UGIB was
estimated using logistic regression analysis. Results: 2,777 cases and 5,532 controls have
been included. Overall, current use of PPI (RR:0.33; 95%CI:0.27-0.39), H2-RA (RR:0.65;
0.50-0.85) and nitrates (RR:0.52; 0.38-0.70) reduced the risk of developing an UGIB event.
The risk reduction was stronger with PPI use among both non-aspirin NSAID (RR: 0.13;
0.09-0.19; vs 0.30; 0.17-0.53 with H2-RA and 0.48; 0.19-1.24 with nitrates) and aspirin
users (RR: 0.30; 0.20-0.40 vs. 0.40; 0.24-0.68 with H2-RA and 0.66; 0.44-0.98 with nitrates).
Among individual NSAIDs, a similar risk reduction effect with PPI was observed for the 3
most widely used (diclofenac, ibuprofen and naproxen). Among low-dose aspirin users, PPI
(RR:0.32; 0.22-0.51) and H2-RA (RR: 0.40; 0.19-0.73)use were associated with risk reduc-
tion, while nitrates had a weaker effect (RR: 0.69; 0.36-1.04). In patients taking clopidogrel,
only PPI use was associated with a significant risk reduction (RR: 0.19; 0.07-0.49). However,
among patients taking anticoagulants neither nitrates (0.67; 0.33-1.34), nor H2-RA (0.88;
0.32-2.45) or PPI use (0.67; 0.37-1.21) were associated with a significant effect on the risk
of UGIB event. Conclusion: Treatment with nitrates, H2-RA or PPI is associated with a
reduction of the risk of developing UGIB events in patients taking NSAID or aspirin. However,
only PPI therapy was associated with a marked and consistent risk reduction among patients
receiving all types of agents including non-aspirin anti-platelet agents. Protection was much
less apparent in patients on anticoagulant therapy.
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Gastroprotection Gap: A Rising and Dangerous Omission for Elderly Users of
NSAIDs with Arthritis
Gurkirpal Singh, Huijian Wang, Eiichi Tanaka, Alka Mithal, Lauren Gerson, George
Triadafilopoulos
Background: GI complications from NSAIDs have been well-recognized since early 1990s,
and were significantly reduced by the use of selective cox-2 inhibitors, concomitant proton
pump inhibitors (PPIs) or misoprostol in the early 2000s. Recent media attention on the
potential association of cardiovascular events with selective cox-2 inhibitors and market
withdrawals resulted in a large decline in the use of these drugs. We report change in
prescription patterns in a large cohort of elderly arthritis patients from January 1, 1995 to
June 30, 2005. Methods: MediCal, the Medicaid program for California, is the largest
Medicaid program in the US, with over 7 million participants per year. All study drugs
were available without formulary restrictions or copayments. We studied individuals with
physician-diagnosed arthritis who were over 65 years of age and treated with NSAIDs for
at least 30 days. Results: Of the total 5,194,765 prescriptions for NSAIDs, 2,634,345 (50.7%)
were for selective cox-2 inhibitors. Among the 2,560,420 prescriptions for non-selective
NSAIDs, only 1,215,762 (47.5%) had concomitant use of PPI or misoprostol. Figure shows
the use of selective cox-2 inhibitors and concomitant PPIs or misoprostol, as a percentage
of all NSAID use. The increasing implementation of gastroprotection strategies over the past
several years reached a peak in 2004 when the percent of patients not receiving gastroprotec-
tion (Gastroprotection Gap) decreased to 14% from 91% in 1995. However, this gap more
than doubled to 35% in 2005, following a decline in selective cox-2 inhibitor use, without
a commensurate increase in other gastroprotective therapies. Conclusions: An increasing
number of elderly users of NSAIDs are again left without gastroprotection. This trend, if
left unchanged, will undoubtedly increase morbidity and mortality from NSAID-related
complications to levels unacceptable for optimal medical care and deserves immediate
public attention.
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Gastroprotection (GP) gap in elderly patients 1995-2005. PPI=proton-pump inhibitors,
miso=misoprostol, cox-2=selective cox-2 inhibitors
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Improved Gastrointestinal Safety Profile with Lumiracoxib Compared with
Naproxen and Ibuprofen in Patients At Least 65 Years Old At Increased Risk
of Gastrointestinal Events
Christopher Hawkey, Wilfred Weinstein, Walter Smalley, Gerhard Krammer, Bernhard
Mellein, Dominik Richard, Xavier Gitton
Background: Increasing age is a risk factor for nonsteroidal anti-inflammatory drug (NSAID)-
related gastrointestinal (GI) ulcers and associated ulcer complications. Selective COX-2
inhibitors such as lumiracoxib were developed to reduce the risk of GI events. The Therapeutic
Arthritis Research and Gastrointestinal Event Trial (TARGET), the largest published GI
outcomes study to date, showed a 79% reduction in GI ulcer complications (perforation,
obstruction or bleeding) for lumiracoxib compared with naproxen and ibuprofen in the
non-aspirin population. Here we report additional analyses on the sub-group of TARGET
patients ≥65 years of age. Methods: Patients (n=18 325) aged ≥50 years with OA were
randomized to receive lumiracoxib 400 mg once daily (od) (4 times the recommended dose
for treatment of OA), naproxen 500 mg twice daily (bid) or ibuprofen 800 mg three times
daily (tid) for 1 year. Randomization was stratified by age (50-64, 65-74, ≥75 years)
and low-dose aspirin use. The primary endpoint was definite or probable upper GI ulcer
complications. Secondary GI endpoints included all definite or probable ulcers (complicated
and uncomplicated symptomatic ulcers) and clinically evident major bleeds. Results: In
total, 7939 of the TARGET population were ≥65 years (lumiracoxib [n=3980] and NSAIDs
[n=3959]), approximately 31% of whom took low-dose aspirin. In patients ≥65 years not
taking aspirin (n=5484), there was a significant reduction in ulcer complications in the
lumiracoxib group compared with the NSAID group (0.29% vs 1.42% respectively; p<0.0001)
and significantly fewer ulcers (complicated and uncomplicated) (0.69% vs 2.62%; p<0.0001).
In addition the incidence of clinically evident major bleeds was significantly lower in the
lumiracoxib group than in the NSAID group (0.26% vs 0.98%; p=0.0012). In patients ≥65
taking low-dose aspirin, there were no statistically significant differences between treatments.
Conclusion: Lumiracoxib 400 mg (od) delivers a consistent GI safety profile that is superior
to the NSAIDs naproxen or ibuprofen in patients ≥65 years not taking aspirin.
566
A Prospective, Randomized, Controlled Trial of Clear Liquids Vs. Low-Fat
Solid Diet as the Initial Meal After Mild Pancreatitis
Brian C. Jacobson, Martha B. Vandervliet, Michael Hughes, Rie Maurer, Katherine D.
McManus, Peter A. Banks
Background: Patients recovering from mild acute pancreatitis typically receive a clear liquid
diet (CLD) when ready to initiate oral nutrition. The timing of patient discharge frequently
depends upon successful advancement to solid food. We hypothesized that initiating feeding
with a low-fat solid diet (LFSD) after mild pancreatitis would be well tolerated and would
result in a shorter hospital length of stay (LOS). Methods: A sample size of 120 subjects
was calculated to have 90% power to detect a one day difference in LOS between two study
arms. Exclusion criteria included narcotic use within 6 hours prior to refeeding, an underlying
condition that could itself cause poor oral intake or prolonged LOS, inability to monitor
the patient post-discharge, pregnancy, and supervision of a patient’s care by a study team
member. Patients with mild pancreatitis, defined in accordance with the Atlanta symposium,
were randomized to receive either a CLD or a LFSD when the responsible medical team
determined refeeding was appropriate. The decision to advance a patient’s diet and the
timing of discharge were determined by the medical team. Patients were monitored daily
for dietary intake, recurrence of pain, need to stop feeding, post-refeeding LOS, and for a
total of 28 days post-refeeding to capture symptoms or readmission. Post-refeeding LOS
(primary outcome) was compared using a t test and need to stop feeding (secondary outcome)
was compared with Fisher’s Exact test. Results: We randomized 121 patients: 66 to CLD,
55 to LFSD. Baseline characteristics including age, gender, and cause of pancreatitis were
similar in both groups. The number of patients requiring cessation of feeding because of
pain, nausea or vomiting was similar in both groups (5% for CLD and 9% for LFSD; p=
0.47). There was no difference in 28 day re-admission rates between the two arms. By
intention-to-treat, the mean LOS after refeeding was similar in both groups (1.7 +/- 1.9
days for CLD and 1.7 +/- 2.0 days for LFSD; p=0.94). Calorie counts for the first meal
consumed were available for 69% of patients and showed significantly lower calories and
grams of fat consumed in the CLD arm than in the LFSD arm (mean 177 +/- 106 cal vs
394 +/- 250 cal; 2 +/- 4 gm fat vs 8 +/- 7 gm fat; p<0.001 for both comparisons). Per-
protocol analyses and analyses restricted to those with calorie counts provided similar results
for both diet tolerability and post-refeeding LOS. Conclusions: Initiating feeding with a
LFSD was as well tolerated as a CLD, but did not result in a shorter LOS.
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Randomized, Double-Blind, Placebo-Controlled, Trial of High-Dose
Intravenous Anti-Oxidant Therapy in Severe Acute Pancreatitis
Ajith K. Siriwardena, James M. Mason, Srinivasan Balachandra, Anil Bagul, Simon
Galloway, Laura Formela, Jonathon Hardman, Saurabh Jamdar, David Schofield, Pauline
Kay, Ioannis T. Virlos
Introduction: Oxygen free-radicals (oxidative stress) mediate acinar injury in acute pancreat-
itis (AP). In clinical AP, inhibitors of oxidative stress (anti-oxidants) are depleted with
extent corresponding to severity. Small studies suggest that anti-oxidant supplementation
ameliorates AP but there is no substantive evidence. This study undertakes the first ran-
domised, double-blind, placebo-controlled trial of anti-oxidant therapy in human severe
AP. Methods: Patients with a clinical diagnosis of AP were eligible if their admission APACHE
II score was >8. Principal inclusion criteria were: ability to give informed consent, disease
duration <72hours and not on anti-oxidants. Patients were randomised to receive intravenous
n-acetylcysteine, selenium and ascorbic acid or three equivalent-volume placebos. All com-
plications were characterized by Atlanta conference criteria. Principal end-point was daily
organ dysfunction scores during the first 7 days. A study population of 110 was predicted
as sufficient to detect a 25% improvement in primary end-point at 85% power. Hospital
pharmacy allocated arm by random number generation. Independent monitoring of recruit-
ment/complications was undertaken and stopping criteria were met in 2005 (under-recruit-
ment). Results: 44 patients were randomized (23 anti-oxidants vs 21 placebo). Groups were
statistically similar in terms of age, gender, etiology, APACHE and organ dysfunction score.
Duration of anti-oxidant therapy was median 4 days in both. Anti-oxidant levels fell from
admission in placebo but not in the treatment group. Analysis of primary endpoint showed
7 patients to have triggered organ dysfunction during the first 7 days in the anti-oxidant
group (7/22 [31%]) compared to 4 of 21 (19%) in placebo. This difference was not statistically
significant (P=0.49 Fisher’s exact 2-sided). There was no difference in the incidence of
individual organ dysfunction, complications or mortality. Overall 4 patients died (all in the
anti-oxidant group) [P=0.11; Fisher’s]. Although underpowered to detect change: with 43
patients the original power calculation has a 60% risk of type II error, further recruitment
is unjustified as the probability of detection of any major effect of therapy is exceedingly
low. Conclusion: This is the first study to examine the effect of anti-oxidant therapy in a
well-characterized population of severe AP using contemporary disease descriptors in a
double-blind, placebo-controlled fashion. The results show no evidence of benefit from
treatment. Although underpowered, the final analysis suggests that there is unlikely even
to be a trend towards benefit from treatment.
568
Hereditary Pancreatitis Amlodipine Trial (H-PAT): A Phase I Study of a
Calcium Channel Blocker in Hereditary Pancreatitis
Veronique D. Morinville, Mark E. Lowe, Beth D. Elinoff, David C. Whitcomb
Background: Hereditary Pancreatitis (HP) is a cationic trypsinogen (PRSS1) mutation-medi-
ated form of recurrent acute pancreatitis (AP) with variable complications of fibrosis (i.e.
chronic pancreatitis), recurrent and chronic visceral pain, diabetes and pancreatic cancer.
Since trypsinogen mutations cluster in the calcium-associated regulator regions, it follows
that increased trypsinogen activation in acinar cells during calcium influx after stimulation
predisposes these patients to AP attacks. In rats, calcium channel blockers prevent hyper-
stimulation-associated AP. Thus, a phase 1 study was designed to determine the safety of
giving calcium channel blockers to subjects with PRSS1 mutations. Methods: Recruited
subjects ≥ 6 years (y) old had a PRSS1 mutation, recurrent AP and recurrent abdominal
pain. Pancreatic enzymes, acid-blockers and antioxidants had to have been used for ≥ 3
months. Exclusion criteria included exocrine (elastase < 100μg/g stool) or endocrine (diabetes
mellitus) insufficiency or antihypertensive use. Total study duration was 16 weeks. Weeks -
4 to 0 were observational; Weeks 0-12 were interventional. Amlodipine was given for Weeks
0-11, including dose escalation and weaning. Dose (2.5, 5 or 10 mg daily) was based on
weight (range 0.08-0.17 mg/kg/day). Subjects filled a daily symptom diary including pain
level (0-10 scale) and automated blood pressure value. Subjects were clinically assessed at
Weeks -4, 0, 1, 2, 6, 10, 11 and 12 and telephoned weekly. Laboratory testing was obtained
at all visits except Week 11. Subjects filled an SF-36v2™ (SF-10™ for Children < 14 y) at
Weeks -4, 0, 6 and 10. Data were compared for Weeks -4 to 0 and 6 to 10. Results: Nine
subjects signed informed consent (4 males; 12-52 y). Four were excluded during the screening
period. Drug was discontinued in one due to development of unilateral lower extremity
numbness within 1 day of initiation. Four subjects (12-30 y) completed the study, all with
good drug tolerability. Mean blood pressure, standard laboratory tests, physical examination
findings and daily pain scores did not clinically significantly differ before and during drug
therapy overall, although all subjects reported reduced symptoms. Three subjects reduced
pain medication use. Three had slightly improved SF-36v2™ and SF-10™ for Children
scores. Conclusion: This pilot study suggests amlodipine is generally safe in subjects with
HP and does not increase pain or episodes of acute pancreatitis. Amlodipine’s potential
benefit must be validated through a larger, blinded, longer-duration study. Supported by
NIH/NCRR/GCRC Grant #M01 RR00056 and the National Pancreas Foundation.
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Novel Radiotherapeutic Management of Painful Flare Ups in Chronic
Pancreatitis
Luisa Guarner, Xavier Molero, Begona Navalpotro, Jordi Giralt, Juan-Ramon Malagelada
Patients with chronic pancreatitis may present repeated painful flare-ups of pancreatitis and
even unrelenting pain. Current management options are limited to analgesics and surgery,
in selected cases. We reasoned that anti-inflammatory radiotherapy, which appears to be
effective in other inflammation based painful disorders of the body, might prove valuable
to severely symptomatic patients with chronic pancreatitis. PATIENTS AND METHODS:
We studied prospectively over a 4-year period till Nov. 05, the efficacy of single dose anti-
inflammatory radiotherapy in 12 consecutive patients with chronic pancreatitis (ethanol
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related in 7, idiopathic in 4 and cystic fibrosis in one) who fulfilled the following criteria:
either 2 flare ups of pancreatitis in the previous 6 months (all 12 patients) and/or continuous
pain for more than 3 months (2 of the 12). Median age was 41 years (range 32-80), there
were 9 males and 3 females; diagnosis of chronic pancreatitis (6 months to 16 years, median
5 years) and number of prior attacks (2 to >15, median 6). Treatment consisted in a single
dose of radiation of 8 Gy. Before and after radiation we assessed: exocrine function by fecal
elastase, endocrine function by c peptide, quality of life (EuroQol) and clinical outcomes.
Response was defined as no further pain or flare-ups of pancreatitis. RESULTS: During
follow up (median 33 months, range 1 to 48 months) 10/12 patients had no further pain
or flare-ups. One patient required a second radiation dose after 1 year and has been well
since (26 months), 1 patient did not respond and had a pancreaticojejunostomy at 1
month. Before radiation 4 patients had exocrine (fecal elastase<100 μg/g) and 2 endocrine
(c peptide<0.50 ng/ml) dysfunction. Post treatment 1 additional patient developed exocrine
(at 25 months) and endocrine (at 13 months) insufficiency. The responder group (11/12)
gained 4 to 20 Kg in weight during follow up (median 6 Kg) and EuroQol improved
significantly from 0.572 before till 0.817 after treatment (p<0.01). CONCLUSION: Radiation
treatment of severely symptomatic chronic pancreatitis is effective and could potentially
substitute or delay surgery.
570
Correlation Between Coefficients of Fat Absorption and Nitrogen Absorption
in Subjects with Cystic Fibrosis-Related Pancreatic Insufficiency Treated with
Altu-135
Drucy Borowitz, Christopher Goss, Stacey E. Limauro, Susan Casey, Frederick T. Murray
Background: The largest randomized double-blind parallel dose study of subjects with
malabsorption due to cystic fibrosis (CF)-related pancreatic insufficiency (PI) was conducted
with ALTU-135, a microbially-produced (bacterial lipase and fungal protease and amylase)
pancreatic enzyme replacement therapy, in order to identify the most effective dose to
increase oral fat and nitrogen absorption. In this study, one hundred twenty-nine (129)
subjects with CF and PI were randomized to one of three treatment arms: Lipase / Protease /
Amylase (Units USP/meal or snack): - Arm 1: 5,000 / 5,000 / 750 - Arm 2: 25,000 / 25,000 /
3,750 - Arm 3: 100,000 / 100,000 / 15,000 One hundred twenty-five (125) subjects between
the ages of 11 and 55 years of age received study drug. Objective: To identify the relationship
between the coefficient of fat absorption (CFA) and the coefficient of nitrogen absorption
(CNA) in subjects with CF-related PI using a dose response of pancreatic enzymes with a
fixed ratio of 1:1 lipase:protease. Methods: Controlled marker-to-marker stool collections
for fecal fat (modified Van de Kamer Method) and fecal nitrogen (Dumas combustion
methodology) were conducted. The CFA and CNA were each determined by calculating the
mean of two independent fecal fat or nitrogen results from one stool collection. In order to
evaluate the relationship between CFA and CNA, Pearson product moment correlations
were conducted for the relationships of baseline CFA with baseline CNA, treatment CFA
with treatment CNA, and change in CFA with change in CNA. Results: There were statistically
significant positive correlations between CFA and CNA (baseline, treatment, and change)
for all three treatment arms as well as for all subjects combined. For all subjects combined,
correlations between CFA and CNA for baseline (r = 0.8323), treatment (r = 0.8642), and
change from baseline (r = 0.8442) were statistically significant (p < 0.0001). Conclusions:
For subjects with CF-related PI in this study, baseline CFA correlates significantly with
baseline CNA, and treatment CFA correlates significantly with treatment CNA. These findings
support the efficacy of the 1:1 ratio of lipase:protease in ALTU-135, which is significantly
less protease than is present in porcine-derived pancreatic enzyme products.
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Resection vs. Extended Drainage in Chronic Pancreatitis: Long-Term Follow
Up of a Randomized Trial
Tim Strate, Philipp Busch, Jens-Peter Bruhn, Oliver Mann, Paulus Schurr, Christian
Bloechle, Claus Schneider, Emre Yekebas, Jakob R. Izbicki
Objective: To report on the long term follow-up of the randomized trial comparing the
pylorus-preserving Whipple’s procedure (PPPD) and the organ sparing extended drainage
procedure (Frey) in patients suffering from chronic pancreatitis. Background: PPPD has
been the standart of operative care in patients suffering from chronic pancreatitis for decades.
Organ sparing procedures (like the Frey procedure featuring a limited pancreatic head
excision and extended drainage of the pancreatic body and tail) have been proposed to bear
significant advantages especially regarding pancreatic functioning and quality of life. These
two procedures have been evaluated and published in a randomized controlled trial by our
group, however long term results have not been published so far. Methods: 61 patients
suffering from chronic pancreatitis were initially allocated to PPPD (n=30) or Frey (n=31).
One patient died immediately postoperatively (Frey). This postoperative follow-up included
following parameters: Mortality, quality of life (QL), pain (validated pain score), and exocrine
and endocrine function. Results: Median follow-up was 7 years. Six patients were not
available for follow-up (PPPD=2; Frey=4). There was no significant difference in late mortality
(14% (4/28) vs. 15% (4/26)). No significant differences were found regarding QL (global
QL 54,17 (0-100) vs. 50 (16,7-83,4)), pain score (12,5 (0-75) vs. 6,25 (0-100)), exocrine-
(96% vs. 85%) or endocrine insufficiency (67% vs. 77%). Conclusion: After 7 yrs long term
follow-up there was no difference regarding mortality, quality of life, pain, exocrine or


















Curcumin, a Promising Drug for Long-Term Maintenance Therapy in Patients
with Ulcerative Colitis: Results from a Multicenter, Randomized Double-Blind
Placebo-Controlled Clinical Trial
Hiroyuki Hanai, Takayuki Iida, Ken Takeuchi, Masami Yamada, Yasushi Iwaoka, Akira
Andoh, Tomoyuki Tujikawa, Yoshihide Fujiyama, Fumitoshi Watanabe, Yasuhiko
Maruyama, Keiichi Mitsuyama, Michio Sata, Kazunari Kanke, Hideyuki Hiraishi, Kazuhisa
Hirayama, Hajime Arai, Shigehito Yoshii, Masato Uchijima, Toshi Nagata, Yukio Koide
Background and Objective: Curcumin is a plant-derived natural substance present in tur-
meric. Curcumin is known to have a variety of pharmacological effects including tumor
suppressing action, anti-inflammatory and anti-mirobial activities. The pleiotropic effects of
curcumin are attributable at least in part to the inhibition of the transcriptional nuclear
factor-κB (NF-κB). Further, recently we found that treatment with curcumin resulted in the
prevention as well as improvement of experimental murine colitis, actions which were
associated with the suppression of NF-κB signaling and CD4+ T-cell infiltration in the
colonic mucosa. The principal objectives of this clinical trial were to investigate whether,
or not curcumin suppresses colitis and maintains remission of quiescent ulcerative colitis
(UC) in man. Methods: This report is on the clinical efficacy of curcumin in combination
therapy with sulphasalazine (SASP) or 5-aminosalicylic acid (5-ASA). A total of 89 patients
with UC in quiescent state were recruited to participate in a double blind, multi-center,
randomized trial. Forty-five patients received curcumin plus SASP or 5-ASA (curucumin
group) and 44 patients received placebo plus SASP or 5-ASA (placebo group) for 6 months.
Results: Seven patients were excluded according to patients’ requests to be treated with a
steroid or immuno-modulators. Therefore, 43 patients in the curcumin group and 39 patients
in the placebo group were eligible for the efficacy analyses. Of the 43 patients who received
curcumin, 2 patients (4.55%) relapsed during 6 months of therapy, while 8 of 39 patients
(20.51%) in the placebo group relapsed (P=0.04). Recurrent rates evaluated in all patients
(intention to treat) also showed a significant difference in favor of the curcumin group (P=
0.049). Of particular interest was that curcumin treatment, but not placebo significantly
improved the clinical activity index (CAI; P=0.038) and endoscopic index (EI, P=0.0001)
after 6 months, indicating that curcumin improves the quality of life of patients with UC.
Among cytokine mRNA levels examined in the colonic mucosa from patients in remission,
IL-8 was well correlated with EI, suggesting that EI score is valuable for assessing intestinal
inflammation without biopsy. Conclusions: The results of this study indicate that curcumin
may prove to be a promising agent for maintaining remission in patients with UC. Future
studies are essential to fully assess the clinical value of curcumin for patients with inflammat-
ory bowel disease.
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Prediction of Azathioprine Responsiveness in Crohn’s Disease By 6-
Thioguanosine Di- and Triphosphate Levels in Red Blood Cells: A Prospective
Study
Markus F. Neurath, Ralf Kiesslich, Ute Teichgraeber, Claudia Fischer, Uta Hofmann,
Michael Eichelbaum, Peter Galle, Mathias Schwab
Background and Aims: The mechanism of action of azathioprine is based on the metabolite
6-thioguanosine triphosphate (TGTP) that blocks the guanosine exchange activity of Vav
on the small GTPase Rac1. Here, we assessed the impact of TGTP levels for monitoring of
azathioprine therapy in a prospective study. Methods: Following our initial retrospective
study on azathioprine metabolites in 50 patients, we designed a subsequent prospective
study. In 79 patients with Crohns disease under long-term azathioprine therapy levels of
TGTP and its precursors 6-thioguanosine mono- and di-phosphates (TGMP, TGDP) in red
blood cells were determined. Clinical parameters were monitored over time to determine
clinical outcome. Results: TGTP levels could be quantified in all patients taking azathioprine
and a subgroup of the latter patients showed significant high levels of TGDP. 6-TGN levels
showed a significant correlation with TGDP (p<0.0001), TGTP (p<0.0001), and TGDP plus
TGTP concentrations, suggesting that active TGTP and its inactive precursor TGDP are the
main metabolites within 6-TGN. No TGMP levels could be detected. Patients with high 6-
TGN and TGTP levels showed on average better response rates than patients with lower 6-
TGN levels. A subgroup of patients with higher 6-TGN and elevated TGDP levels showed
a worse outcome with lower response and more flares. Finally, patients with low TGTP
levels showed more frequently flares and a refractory course of the disease. Conclusions:
This is the first prospective study on the azathioprine metabolites TGDP and TGTP in Crohns
disease. The data show for the first time that quantification of TGTP can be used to monitor
azathioprine therapy in IBD patients. The analysis of TGDP and TGTP levels as well as
the metabolite ratio can by used to predict poor response in a subgroup of azathioprine
treated patients.
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Medical Decision Analysis for Unifocal Low-Grade Dysplasia (LGD) in
Ulcerative Colitis (UC)
Geoffrey Nguyen, Kevin D. Frick, Themistocles Dassopoulos
Background Unifocal LGD detected on surveillance of long-standing UC remains a manage-
ment dilemma between proctocolectomy and continued intense surveillance. Proctocolec-
tomy eliminates the risk of colorectal cancer, and is associated with good health-related
quality of life. However, a recent survey of gastroenterologists revealed that only one fifth
would refer patients with LGD for colectomy. There are no clinical trials comparing the
effectiveness of the two approaches. We therefore used the tools of medical decision analysis
to compare the expected costs and effectiveness (measured in quality-adjusted life years,
QALY) of total proctocolectomy with ileal pouch-anal anastomosis (TPC-IPAA) and continued
surveillance colonoscopy. Methods We developed a larger model that included small Markov
models to represent the expected experience of a hypothetical 45 year old male with UC
for ten years and with unifocal LGD detected on a surveillance colonoscopy. Initial states
in the model include: false positive (no dysplasia) (5%), true positive with LGD (77%), or
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true positive with synchronous but missed colon cancer (18%). Options for management
were TPC-IPAA or continued colonoscopic surveillance. A 3% annual discount rate was
applied and the time horizon was 40 years. The patient was assumed to have a utility value
of 0.95 during surveillance and 0.90 after TPC-IPAA. Transition probabilities, including the
onset and stage of colon cancer for patients undergoing surveillance, were derived from
previous observational studies, and cost estimates were derived from Medicare reimbursement
values and those previously reported in the literature. Results For immediate TPC-IPAA,
the present value of lifetime expected QALYs was 19.3 and the present value of lifetime
expected expenses was $36,726. For surveillance colonoscopy, the expected utility was 18.9
QALYs and total expenses were $51,187. These results suggest that immediate TPC-IPAA
dominates surveillance colonoscopy. A sensitivity analysis showed that for the expected
utility states of the interventions to be equal, the utility post-colectomy would have to be
as low as 0.72. At that level, immediate TPC-IPAA would still dominate surveillance as it
costs less. Conclusion TPC-IPAA is dominant over surveillance colonoscopy with higher
expected QALYs and lower expected lifetime expense. Based on our model, the post-
colectomy health utility state would have to be 20% lower, for colonoscopic surveillance
to be considered possibly worthwhile. TPC-IPAA warrants serious consideration in the
management of unifocal LGD.
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Acute Severe Ulcerative Colitis: A Study of Predictors of Outcome and
Efficacy for Cyclosporin and Infliximab
Alissa Walsh, Rebecca Cooley, Di Templeton, Tim Florin, Graham Radford-Smith
Background: Acute severe ulcerative colitis (ASUC) is a life threatening complication of
ulcerative colitis which occurs in approximately 15% of patients with UC. Intensive treatment
and early recognition of severe disease have improved outcomes. Several prognostic factors,
specifically CRP>45 and bowel actions >8 on day 3 help to decide further treatment.
This may include Cyclosporin (CyA) or Infliximab (INF), or colectomy. CyA and INF are
increasingly used for ASUC however there are limited data on efficacy and safety in this
setting. Methods: Data were collected prospectively on patients presenting with ASUC from
1996 to 2004. All patients included in the study had ASUC as defined by the Truelove and
Witts criteria and received intravenous hydrocortisone. From 2001, intravenous CyA or INF
were given to steroid refractory patients. Colectomy was performed in all those not responding
to medical therapy. Aims: To determine: 1. Clinical features of patients with ASUC compared
to the remainder of the UC cohort. 2. Significant markers of response to therapy 3. Significant
predictors of colectomy. 4. Efficacy and safety of CyA and INF in ASUC. Results: There
were 63 patients with 80 episodes of ASUC. The proportion of ASUC in our UC cohort
was 14.4% (63/439). Significant differences in those with ASUC were younger age of initial
diagnosis (24.3 y.o vs 31.7 y.0, p=0.005) and shorter duration of disease (8.2 years vs 11.9
years, p=0.008). Significant predictors of response to IV hydrocortisone were number of
bowel actions on day 3 of admission (responders(r)/non responders(nr),5/9, p<0.0001), Hb
on admission (r/nr, 129/118, p=0.03) and albumin on admission (r/nr,35/31, p=0.01). There
was a trend for increased CRP at day 3 in the non responders group (r/nr, 28.7/50.9, p=
0.077). The only significant predictor of colectomy was CRP on day 3 (56.6 vs 32.7, p=
0.04). CyA and INF delayed colectomy at discharge compared to those that only received
IV hydrocortisone (28% vs 43%, p=NS), however there was no difference at 12 months
(46% vs 47%). Comparison of CyA and INF data (colectomy at discharge 48% vs 14%
respectively) indicate a better response to INF. Adverse event profiles were very similar
(18.5% vs 14%) and there were no fatalities in either group. Conclusions: CRP and bowel
actions remain the most important predictors of outcome in ASUC. CyA and INF delay
colectomy however long term follow up data are disappointing. Other factors are implicated
in the risk of developing ASUC, including genetic susceptibility and host intestinal bacteria,
which are currently being investigated as cofactors in the development of ASUC.
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Intravenous Iron Sucrose: A Simple, Safe, and Quick Method to Treat Anemia
Secondary to Digestive Diseases
Santiago Garcia Lopez, Fernando Gomollon, Jose Antonio Garcia Erce, Roberto
Aramendiz, Beatriz Sicilia, Raquel Vicente
Chronic bleeding from gastrointestinal lesions is the most important cause of Iron Deficiency
Anaemia (IDA) in developed countries. IDA cause significant lose of quality of life in our
patients. Iron restitution is the main therapy, usually by oral route. However, oral iron faces
2 clinical problems: low adherence due to gastrointestinal upset and slow clinical response.
These limitations can be especially relevant in inflammatory bowel disease (IBD) patients.
Intravenous (IV) iron can be a goof alternative to improve tolerance and hasten response
but concerns about safety persists in many clinicians OBJETIVE: To evaluate safety of IV
iron sucrose therapy in gastrointestinal patients PATIENTS AND METHODS: IV iron sucrose
in an “outpatient regimen” was used for patients with IDA due to digestive disorders with
at least 1 of the following criteria: 1) no response or intolerance to oral iron; 2) IBD with
severe anaemia (haemoglobin (Hb) <10.5 g/dl) and/or 3) clinical need of quick recovery of
anaemia. Therapeutic approach in all cases follows a predefined protocol: total iron deficiency
is calculated according to an accepted formula and it is administered in several sessions of
200 mgr each, once to three times a week. Evaluation of safety is our main objective. Efficacy
of every course is evaluated by complete blood count and iron metabolism determinations
15 days after the last session. Hb increase (pre and post-course) is used as main indicator
of efficacy. Descriptive data are given and 95% CI when appropriate RESULTS: We have
treated 70 (54 IBD, 27 Crohn`s Disease, 18 Ulcerative Colitis, 9 Pouchitis) patients to whom
we have administered 148 courses of IV iron (some patients have received > 1 course), in
> 700 sessions. Security profile is evaluated in all treatments in our series. No severe adverse
event happened in our patients. Apart from metallic taste, only 1 isolated mild blood pressure
decrease and 1 unexplained fever occurred: two mild side effects in > 700 treatment sessions
(0.0028%; 95% CI 0-0.01%). Mean total amount dose of IV iron per course was 920 mgr.
Average Hb pre-course was 9.8 g/dl (+/- 1.7), and post-course 11.7 gr/dl (+/- 1.5), with an
average increase of 1.89 g/dl (range -2 + 5’5). In 47% (95% CI 36-59%) of courses Hb
increase exceded 2 g/dL CONCLUSIONS: IV iron sucrose has shown to be a simple to use,
very safe and effective alternative to oral iron in our patients. No significant side-effects
were seen. Efficacy appeared to be good, and anaemia could be improved and many times
controlled rendering a better quality of life in our patients. IV iron sucrose should become
standard treatment in IBD patients with iron deficiency
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Clinical Course in Crohn’s Disease: A Prospective Population Based Follow-Up
Study in Southeastern Norway from January 1990 to December 2004 (The
IBSEN study)
Inger C. Solberg, Jorgen Jahnsen, Morten Vatn, Bjorn Moum, Idar Lygren
Background: Few prospective studies have described the long-term clinical course in unselec-
ted and well-defined Crohn`s disease (CD) populations. Aim: To assess the disease outcome
in a population based CD cohort followed prospectively during the first 10 years after
diagnosis Methods: A population based inception cohort of CD patients was recorded in
southeastern Norway from 1990 to 1994. This cohort has since inclusion been followed by
the same senior gastroenterologists in a standardized way.Statistics: Kaplan-Meier survival
plot, Pearson Chi-Square tests and Cox multiple regressions were applied. Results: A complete
10-year dataset was achieved in 197 of overall 237 CD patients (83%). Twenty-two patients
(9%) were lost to follow up and 18 patients (8%) had died. The cumulative probability of
at least one bowel resection was 38% (95% CI: 31%-44%) after 10 years. Initial location
in terminal ileum, age below 40 years, as well as stenosing or penetrating disease behavior
at diagnosis were predictive factors concerning the risk of surgery, while smoking habits,
familial occurrence of IBD and gender had no influence. Only 10% of the patients (n =20)
stayed relapse-free during the whole study period. There was however, a significant increase
in the number of patients with non-relapsing disease in the last 5-year compared to the first
5-year period (p<0.001). Still, a chronic intermittent or a chronic continuous course of
disease during the entire follow-up were observed in 32% (n=63) and 19% (n = 37) of the
patients, respectively. Furthermore immune-modulating therapy was required in 44% (n =
87) during the last 5 years. Conclusion: The cumulative risk of a bowel resection (38%)
was lower than previously reported (55-70%). This may reflect differences in study design,
but also changes in medical treatment and attitudes toward surgery. A significant increase
in the number of patients in remission was observed in the last 5-year, which may indicate
a decrease in disease activity over time.
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Increased Activity of Microsomal Triglyceride Transfer Protein, Bile Acid and
Cholesterol Synthesis and Trafficking in the Liver of Chilean Hispanics with
Gallstones
Juan Francisco Miquel, Juan Castro, Cecilia Galman, Ludwig Amigo, Luz Carreno, Silvana
Zanlungo, Mats Rudling, Flavio Nervi
Aim/Background - Gallstone disease is an important, costly health-care problem in Western
societies, particularly in the Hispanic population. Bile acids (BA) have long been known to
affect triglyceride homeostasis. For example, BA-binding resins induce the production of
VLDL triglyceride. We recently showed that BA synthesis was increased in gallstone patients
(GS) (Gastroenterology 2004; 126: 741. The aim was now to investigate whether the produc-
tion of hepatic VLDL, a function associated to BA and cholesterol synthesis, was increased
in the liver of GS compared to GS-free patients. Methods - A total of 27 voluntaries subjected
to elective surgery, 9 (6F/3M) without GS and 18 (13F/5M) with GS agreed to give a liver
biopsy after informed consent. Fasting blood plasma samples were assayed for fatty acids,
7α-hydroxy-4-cholesten-3-one (C4) and lathosterol, two indicators of hepatic BA and total
body cholesterol synthesis, respectively. We quantified the activity and mRNA content of
hepatic Microsomal Triglyceride Transfer Protein (MTTP), a rate limiting protein in VLDL
synthesis, as a surrogate of VLDL production. Hepatic lipid levels and mRNA expression of
genes responsible for uptake, synthesis, intrahepatic transport of lipids and sterol secretion
into bile were determined. Results - Age, body mass index and serum albumin, lipids and
fatty acids were similar in both groups. Hepatic histology was normal in all samples. Hepatic
cholesterol levels were similar in GS and GS-free patients, whereas hepatic triglycerides were
increased by 200% in GS. MTTP activity increased 70% (p<0.02) and mRNA expression
50% (p<0.01) in GS. Serum C4 levels were 75% higher and hepatic CYP7A1 mRNA
expression was increased by 250% (p<0.01) in GS compared to GS-free patients, while
CYP27A1 was unchanged. Serum lathostherol levels were similar, but hepatic hydroxy-
methyl-glutaryl-CoA reductase mRNA expression increased by 90% (p<0.01) in GS. Expres-
sions of Fatty Acid Binding Protein, Sterol Carrier Protein-2, SR-BI and ABCG8 mRNAs
were significantly increased in GS, while LDLR and ABCG5 mRNA were in normal range
in GS. Correlation between MTTP mRNA and CYP7A1 mRNA was r=0.52 (p, 0.005) and
between serum C4 and CYP7A1 mRNA was r=0.57 (p, 0.002). Conclusions - The data show
that hepatic MTTP activity and mRNA expression are concomitantly induced, suggesting
that VLDL production is increased in GS and further confirm that BA synthesis is induced
in GS. Hepatic cholesterogenesis, but not total body cholesterol synthesis is enhanced in
GS. The results indicate that hepatic trafficking of cholesterol is increased in GS disease.
(Supported by FONDECYT 1030744 and 1040820)
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Prevention of Cholesterol (Ch) Gallstones By the Potent Ch Absorption
Inhibitor Ezetimibe in Gallstone-Susceptible Mice
Helen H. Wang, Piero Portincasa, David Q. Wang
Since biliary Ch hypersecretion is an important prerequisite for Ch gallstone formation,
considerable interest has been focused on identifying genetic and physical-chemical determin-
ants of intestinal Ch absorption. Aims: We explored whether Ch gallstones could be prevented
by ezetimibe in doses of 0, 2, 10, 20 μg/day in male C57L mice (n=20 per group) fed a
lithogenic diet containing 1 or 2% Ch plus 0.5% cholic acid for 8 or 12 wk. Methods:
Gallbladder biles and gallstones were examined by microscopy. Gallbladder emptying in
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response to CCK-8 was measured gravimetrically. Biliary lipid outputs were analyzed by
HPLC. Expression levels of the genes for hepatic and intestinal lipid transporters were
investigated by real-time PCR. Ch absorption efficiency was determined by mass balance
methods. Results: There was a dose-dependent decrease in gallstone prevalence rates from
80%, 40%, 10%, to 0% in mice at 8 wk on the lithogenic (1% Ch) diet, coupled to a
significant dose-dependent decrease in intestinal Ch absorption efficiency from 50±7%,
36±5%, 15±4%, to 7±2%. On ezetimibe at 20 μg/day, gallstones were prevented in mice
fed the lithogenic diet with even higher (2%) amounts of Ch for a longer (12 wk) period.
Gallbladder emptying studies showed that fasting gallbladder volumes were larger (56±18
μl) on the lithogenic diet than those (22±9 μl) on chow, and that high dietary Ch induced
a 3-fold increase of residual gallbladder volumes. These lithogenic effects on gallbladder
dynamics were fully blocked by ezetimibe at ≥10 μg/day. Also, biliary Ch outputs and Ch
saturation indices of pooled gallbladder biles were significantly decreased in a dose-dependent
fashion from 30±8 to 7±2 μmol/h/kg and from 1.5 to 0.6, respectively. Outputs of biliary
phospholipid (from 59±17 to 27±14 μmol/h/kg) but not bile salts (from 219±83 to 187±65
μmol/h/kg) were significantly reduced. Expression levels of Npc1l1 in the small intestine
and of Abcg5/g8 and Abcb4 in the liver were significantly and dose-dependently reduced
from 7±2 to 0.5±0.1, from 5±2 to 2±1, and from 5±2 to 3±1, respectively. However, there
were not significant changes in mRNA levels of Abcg5/g8, Abca1, Sr-b1 and Slc10a2 in the
small intestine and of Abcb11 and Sr-b1 in the liver. Conclusions: High efficiency of intestinal
Ch absorption is an independent risk factor for Ch gallstones. By effectively inhibiting
intestinal Ch absorption, ezetimibe can prevent not only Ch gallstone formation but also
the deranged gallbladder motility, mostly due to increased biliary Ch content. Our findings
point to an efficacious novel approach for the prevention of Ch gallstones by inhibiting
intestinal Ch absorption in humans.
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The Adaptive Immune Response Appears Critical in Promoting Cholesterol
Gallstone Formation in a BALB/C Murine Model
Kirk Maurer, Martin C. Carey, James G. Fox
In C57L/J mice, coinfection with Helicobacter hepaticus and H. rodentium contributes signific-
antly to cholesterol gallstone formation. One possible explanation for this is modulation of
the adaptive immune response by these organisms. To test this hypothesis we studied
cholesterol cholelithogenesis in male BALB/c (WT) mice and coisogenic male BALB/c Rag2-/-
(Rag2) mice which lack functional lymphocytes and are unable to mount an adaptive immune
response. Mice were divided into 4 groups: uninfected WT (n=18) and Rag2 (n=17) mice
and infected WT (n=10) and Rag2 mice (n=17). Infected groups were inoculated at 4-5
weeks of age with both H. hepaticus and H. rodentium. All groups were fed a lithogenic diet
(containing 1.0% cholesterol and 0.5% cholic acid) for 8 weeks beginning at 8-9 weeks of
age. At the completion of the study gallbladder bile was analyzed by microscopy. WT mice
of either group displayed significant increases in mucin gel, the prevalence of cholesterol
monohydrate crystals, sandy stones, and cholesterol gallstones when compared to Rag2 mice
(Table 1). Cholesterol gallstone formation in BALB/c mice appears to be less dependent on
infection status than in C57L mice. However, infected WT mice demonstrate a nearly
significant (P=0.055) increase in cholesterol gallstone formation when compared to their
uninfected counterparts (Table 1). These data rigorously demonstrate that the adaptive
immune response plays a role in the pathogenesis of cholesterol gallstone formation. It is
likely that infection with Helicobacter spp. act to modulate this response leading to an
increased prevalence of cholesterol gallstones. Based upon the near absence of mucin gel in
Rag2 mice it is likely that the adaptive immune response stimulates excess mucin production
creating a pronucleating gel matrix for phase separation of solid crystals leading to cholesterol
gallstone formation.
*P<0.005 and ‡P<0.05 when compared to Rag2 mice †P=0.055 when compared to WT
uninfected mice
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Anti-Oxidant Mechanism of Ursodeoxycholic Acid On Gallbladder Muscle
Cells from Symptomatic Gallstone Patients
Michele P. Guarino, Ping Cong, Simone Carotti, Rossana Alloni, Michele Cicala, Jose
Behar
Bile acids may be involved in the pathogenesis of acute cholecystitis since the hydrophobic
chenodeoxycholic acid (CDCA) reproduces in vitro the muscle dysfunction observed in this
condition. Gallbladder muscle cells exposed to CDCA show poor contractility in response
to agonists caused by oxidative stress as cells generate reactive oxygen species and display
lipid peroxidation of plasma membranes. The hydrophilic ursodeoxycholic acid (UDCA)
prevents these deleterious effects of CDCA in the animal model of acute cholecystitis. In
symptomatic gallstone patients, UDCA reduces the risk of biliary pain and acute cholecystitis
and restores muscle cell contractility. These studies were aimed at determining the mechanism
of UDCA on gallbladder muscle cells in symptomatic patients with cholesterol gallstones.
Methods: A double blind study was performed in 15 patients, 7 were randomized to UDCA
and 8 to placebo and treated for 4 weeks prior to cholecystectomy. In the preliminary study,
muscle cell contractility resulted to be improved following UDCA and this effect was related
to a lower cholesterol content in the plasma membranes. H2O2, lipid peroxidation, PAF-
like lipids, PGE2 and catalase activity were now determined as biochemical markers of

















UDCA treatment decreased the levels of H2O2 from 13.6 ± 2.4 in the placebo treated
patients to 4.9 ± 0.2 mmol/L per mg protein (p<0.001). Compared to placebo, UDCA
strongly reduced the levels of lipid peroxidation (2.52 ± 0.39 vs 1.29 ± 0.28 nmol/100 mg
of protein), of PAF-like lipids (29.2 ± 1.6 vs 8.6 ± 1.0 pg/mg of protein), and the production
of PGE2 (363 ± 36 vs 156 ± 14 pg/mg protein), p<0.001. UDCA treatment decreased the
activity of catalase, a scavenger of free radicals, from 35.8 ± 6.4 to 14.6 ± 4.6 units/mg
protein (p<0.001). Conclusions: UDCA significantly reduces the biochemical markers of
oxidative stress and inflammation in gallbladder muscle cells from symptomatic gallstone
patients. It is conceivable that UDCA reduces the oxidative stress by “inactivating” hydro-
phobic bile acids and this may also explain the prophylactic effects of UDCA on biliary pain
and acute cholecystitis in patients with symptomatic gallstones.
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Sustained Potential of Soybean Lecithin to Counteract the Progression of Liver
Disease and the Premature Mortality Induced By ABCB4 Deficiency in Mice
Majorie Martel, Veronique St-Hilaire, Beatriz Tuchweber, Marie-Eve Bourbonnais,
Guylaine Bouchard
Mutations in ABCB4 can lead to progressive familial intrahepatic cholestasis type 3 (PFIC-
3), characterized by severe portal hepatic fibrosis and ductular proliferation. Although some
therapies limiting the progression of the disease are available, transplantation often remains
necessary to avoid mortality. Using a murine Abcb4-/- model, we previously established that
a diet enriched in soybean lecithin could exert beneficial effects against PFIC-3 in a short-
term experiment. We now tested whether lecithin could provide a sustained protective
action against ABCB4 deficiency-induced liver disease in mice supplemented or not with
cholic acid (CA). Methodology: Post-weaning Abcb4-/- mice and wild-type (FVB/J) controls
were fed diets containing 0 or 0.025% w/w CA that were supplemented or not with soybean
lecithin (4.0% w/w phosphatidylcholine). Mice were sacrificed after 4 months of dietary
intervention as Abcb4-/- mice receiving CA exhibited advanced health complications and
mortality (3/10 mice within 2 weeks). Selected end points were body and liver weights,
hepatic serum enzymes and liver histology at sacrifice. A group of Abcb4-/- mice was also
sacrificed at time 0 to establish the extent of the liver disease at the initiation of treatment.
Results: Abcb4-/- mice fed CA exhibited a very severe hepatic disease as evidenced by portal
inflammation, extensive ductular proliferation, and marked portal fibrosis. Serum ALT, ALP,
AST, bilirubin, BS and GGT were also highly elevated. Abcb4-/- mice not receiving CA
also displayed significant hepatic disease but in much less advanced stage. Of note, CA
administration in Abcb4+/+ mice did not impact adversely any of the parameters followed.
Treatment with lecithin abrogated the progression of the liver disease in Abcb4-/- mice,
whether they were fed CA or not. In fact, histological features were maintained at a level
virtually similar to the one observed in the pre-treatment group. The same was true for
serum liver enzymes, except for AST and ALT where lecithin treatment in Abcb4-/- mice
not receiving CA only reduced their level of elevation. Lecithin also normalized the body
weight gain and the liver to body weight ratio in Abcb4-/- mice fed CA. Conclusion/Specula-
tion: Soybean lecithin is extremely effective to counteract the severely progressing liver
disease induced by the absence of ABCB4 in mice. As lecithin safety is well established in
human, rapid confirmation of its potential as an anti-cholestatic and anti-fibrogenic agent
in PFIC-3 patients but also in other human chronic progressive cholestatic conditions may
enable to improve survival and minimize the need for liver transplantation.
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Regulation of Fatty Acid Fluxes and Synthesis in the Liver By
Phosphatidylcholine Transfer Protein (PC-TP)
Erez F. Scapa, Keishi Kanno, Wen-Jun Wang, David Cohen
Background: PC-TP is a highly specific phosphatidylcholine binding protein that is enriched
in liver. We recently showed (Hepatology 42:509A, 2005) that chow fed mice with homozy-
gous disruption of the gene encoding PC-TP (Pctp-/-) develop hepatic steatosis, despite
increased hepatic triglyceride secretion rates. Taken together with unchanged plasma concen-
trations of β-hydroxybutyrate, which reflect rates of hepatic fatty acid oxidation, these
findings suggest that PC-TP expression might limit de novo lipogenesis or the supply of
plasma-derived fatty acids. Aim: To explore the molecular basis for hepatic steatosis in
Pctp-/- mice by quantifying mRNA expression levels of key genes that control triglyceride
and fatty acid metabolism in the liver. Methods: Eight week-old male wild type (n=5) and
Pctp-/- (n=6) FVB/NJ mice were maintained on chow. Mice were sacrificed, and liver RNA
was extracted and utilized to prepare cDNA for quantitative real-time PCR. Gene amplification
was quantified using SYBR green and normalized to ribosomal protein L32 mRNA expression,
which was not influenced by genotype. Results: In chow fed mice, the absence of PC-TP
expression was associated with a 51% reduction in mRNA levels of sterol regulatory element
binding protein-1c, a transcription factor that promotes hepatic lipogenesis. Accordingly in
livers of Pctp-/- mice, we observed significant downregulation of lipogenic target genes:
acetyl CoA carboxylase by 41%, fatty acid synthase by 66% and stearoyl CoA desaturase 1
by 68%. Consistent with our prior observation that plasma β-hydroxybutyrate concentrations
were unchanged in Pctp-/- mice, the absence of PC-TP did not influence hepatic mRNA
levels for carnitine palmitoyl transferase I or II, which regulate fatty acid oxidation. In Pctp-/-
mice, there was a modest 19% reduction in mRNA of HMG CoA synthase, which promotes
ketone body formation. Suggestive of the likelihood that steatosis and increased hepatic
triglyceride secretion were primarily attributable to increased uptake of plasma fatty acids
by the liver, we observed a 43% increase in mRNA for fatty acid transport protein 2.
Moreover, there was no change in mRNA for microsomal triglyceride transfer protein,
the upregulation of which could alone increase the rate of hepatic triglyceride secretion.
Conclusions: In Pctp-/- mice, increased uptake of plasma-derived fatty acids, as opposed
to de novo lipogenesis or decreased fatty acid oxidation, appears to account for the overproduc-
tion of triglycerides for both storage and secretion. These findings suggest that a key function
of PC-TP is the regulation of fatty acid fluxes, as well as de novo synthesis in liver.
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Generation of Bacterial-Reactive T Regulatory Cells Able to Inhibit Colitogenic
T Cells
Brian G. Morris, Langfang Wang, Yingzi Cong, Charles O. Elson
Background and Aims: A set of immunodominant antigens of the bacterial flora has been
identified that stimulate pathogenic immune reactions in C3H/HejBir mice, a strain that
spontaneously develops colitis. We have previously shown that ovalbumin-specific T-regu-
latory cells can be generated using immature, NF-κB blocked dendritic cells(DCs). The
purpose of this study was to generate bacterial antigen-specific Tregs and test their ability
to inhibit proliferation of memory T cells reactive to the same antigen (direct inhibition) or
whether such Tregs could inhibit colitogenic Th1 cells broadly reactive to the entire cecal
bacterial flora (bystander inhibition). Methods: Splenic CD4+ T cells were isolated from C3H/
HeJBir mice immunized with CBir1, an immunodominant bacterial flagellin, and CBir19, an
immunodominant bacterial non-flagellin antigen. Primed CD4+ T cells were cultured in the
presence of antigen-specific DCs to generate memory T cells(Tmem) or NF-κB blocked DCs
to generate regulatory T cells(Tregs). The DCs were blocked by Curcumin, a specific inhibitor
of the NF-κB cascade. CBir1- and CBir19-specific Tregs were placed in culture along with
Tmem or a cecal bacterial antigen(CBA)-specific Th1 cell line. T cell proliferation was
measured by 3H-TdR incorporation. Results: CBir1- and CBir19-specific Tregs both blocked
the CBir1 Tmem response by 50-75%, demonstrating the ability to generate bacteria-specific
Tregs using curcumin induced NF-κB blockade. These assays also demonstrate direct, antigen
specific inhibition as well as bystander, non-antigen specific inhibition. The same CBir1-
and CBir19-specific Tregs also blocked proliferation of CBA-specific Th1 cells, a cell line
that causes colitis when adoptively transferred into C3H.SCID mice. Both Tregs inhibited
proliferation of this Th1 line by 75-90%, demonstrating the ability of two immunodominant
antigen-specific Tregs, one flagellin and one non-flagellin, to inhibit a colitogenic T cell line
in a bystander fashion. Furthermore, the addition of both anti-IL-10R1 and anti-TGFβ
together, but neither alone abrogated the inhibition. Conclusions: Bacterial antigen-specific
Treg cells can be generated in vitro using NF-kB blocked immature DCs. Furthermore, such
Tregs are able to inhibit Tmem and colitogenic Th1 cell responses by direct and bystander
inhibition in vitro. This inhibition appears dependent on the presence of both IL-10 or TGF-
β. We postulate that these Tregs will inhibit colitigenic T cells in vivo as well.
597
The Cd28 Homolog, B and T Lymphocyte Attenuator (BTLA), Is An Important
New Target for Immunoregulation in Experimental Colitis
Edwin F. De Zoeten, Kenneth Murphy, Jonathan Kaye, Wayne W. Hancock
Many costimulatory receptors and their ligands are now recognized but little is known of
their functions in disease, including inflammatory bowel disease (IBD). BTLA, a CD28
homolog induced on activated CD4 and CD8 cells and also expressed by B cells, macrophages
and dendritic cells, has two ITIM motifs in its cytoplasmic tail, consistent with an inhibitory
function of this surface protein. The ligand for BTLA was recently identified as herpes virus
entry mediator (HVEM). We investigated whether BTLA expression contributed to regulation
of host immune responses during experimental IBD. Chronic colitis was induced using 3%
dextran sulfate sodium in wild-type and BTLA-/- C57BL/6 mice, and mice were scored daily
for weight, bleeding and stool consistency over the next 4 weeks. Colons were evaluated
by histology, immunoperoxidase and quantitative real-time PCR (qPCR) for cytokine and
costimulatory molecule expression. Spleens, mesenteric lymph nodes, lamina propria cells
and intraepithelial lymphocytes were studied by flow cytometry and qPCR. Normal colons
contained only low-level BTLA expression, but qPCR analysis of colonic samples from mice
treated with DSS showed a marked increase in BTLA expression, and BTLA was localized
by immunoperoxidase to infiltrating mononuclear cells. Concomitant flow cytometry studies
showed induction of BTLA by T cells and B cells, especially in mesenteric lymph nodes
versus spleens, as well as by colonic intraepithelial lymphocytes and lamina propria cells.
BTLA-/- mice developed colitis at the same rate but had significantly enhanced and persistent
diarrhea (p<0.01) and bleeding (p<0.01), compared to WT mice. Moreover, whereas controls
regained their weight in 12-14 days, weight loss in BTLA-/- mice persisted over the 28 day
period of follow-up (p<0.01), and comparable findings were noted in wild-type mice treated
with DSS and a neutralizing anti-BTLA mAb (but not control IgG). At 28 days, colons of
BTLA-/- mice were grossly thickened, hemorrhagic, stiff and adherent to surrounding tissues,
whereas wild-type mice had only mildly thickened colons. Compared to controls, colons
from BTLA-/- mice had increased expression of multiple costimulatory molecules (ICOS,
LIGHT, PD-1, PD-L1) and pro-inflammatory cytokines (IFN-g, TNF-a). Our data show BTLA
has an important role in regulation of immune responses during experimental IBD, and
suggest that BTLA molecule may be a useful target for IBD therapy. To that end, we are
currently testing whether ligation of BTLA, using HVEM-Ig or an agonistic anti-BTLA mAb,
can enhance the inhibitory effects of BTLA signaling on activated T cells and thereby regulate
IBD in wild-type mice.
598
Centaurin Beta 1 Protein Down-Regulates Nuclear Factor Kappa B (NF-kB)
Activation By NOD2 and NOD1 Pathways
Jesus K. Yamamoto-Furusho, Ramnik Xavier, Tadakazu Hisamatsu, Daniel K. Podolsky
Background: Centaurin Beta 1 (CENTB1) is a GTPase-activating protein belonging to the
ADP ribosylation factor family. A yeast two-hybrid screen showed that CENTB1 binds
NOD2. Nucleotide-binding oligomerization domain (NOD) proteins have been implicated
in intracellular recognition of bacterial components such as peptidoglycan containing γ-D-
glutamyl-meso-diaminopimelic acid (iE-DAP) and muramyl dipeptide (MDP) can activate
NF-κB. Aims: To study the interaction between CENTB1, NOD2 and NOD1 proteins and
its functional role on NF-kB activation. Material and Methods: Yeast two hybrid screening
was performed by MATHCMAKER GAL4 Two-Hybrid System 3. Construction of expression
plasmids: Xpress-tagged CENTB1 mammalian expression vector (pCDNA4/HisMAX-
CENTB1) was generated by PCR from cDNA of SW480 cells. Real-time RT-PCR was done
in an ABI Prism 7000 sequence detector using SYBR Green JumpStart detection system.
Immunoprecipitation and Western blot: COS7 cells lysate were immunoprecipitated with
anti-Flag anti-HA or anti-Xpress monoclonal antibodies and protein A/G sepharose beads. NF-
kB activation assay: HEK293 cells were transfected with CENTB1 at different concentrations,
NOD2 (1ng), NOD1 (10ng), pIV luciferase reporter, renilla plasmid, MDP and iE-DAP.
Immunostaining was performed in COS-7 cells using Texas-Red-conjugated anti-mouse IgG
or FITC-conjugated anti-rabbit IgG antibodies. Invasion assay: Gentamicin protection assay
using Salmonella typhimurium was performed in Caco-2 cells. Results: CENTB1 is expressed
in several cells from immune system such as Jurkat, THP-1, lymphocytes B and monocytes.
Interestingly, colonic epithelial cells lines showed an increased expression of this protein
after stimulation with TNF-α, MDP and iE-DAP. Expression was also increased in mucosa
from Ulcerative Colitis and Crohn’s disease patients as compared to normal individuals.
Interaction between CENTB1 and NOD2 as well as NOD1 proteins was confirmed by
immunoprecipitation. CENTB1 partially colocalized with NOD2 and NOD1 in the cytoplasm
of COS-7 cells. CENTB1 decreases NF-kB activation in a concentration dependent manner
in HEK293 cells co-transfected with NOD2 and NOD1 proteins and stimulated with MDP
and iE-DAP respectively. Transfection with CENTB1 siRNA significantly increased the MDP
and iE-DAP driven response to NOD2 and NOD1. Conclusion: CENTB1 is a down-regulator
of NF-κB activation through NOD2 and NOD1 pathways, suggesting that this protein could
play a role in the innate immune response in inflammatory bowel disease.
599
Characterization of Foxp3+Cd4+Cd25+ Regulatory T Cells from Mesenteric
Lymph Nodes in Human Ulcerative Colitis (UC)
Masayuki Saruta, Qi T. Yu, Allison H. Banham, Konstantinos A. Papadakis
Background: CD4+CD25+ regulatory (Treg) cells can control the development of experi-
mental colitis by regulating effector T cells and innate immune responses in mucosal lymphoid
tissues. However, little is known about the presence and/or potential functional impairment
of these cells in human inflammatory bowel disease (IBD). We sought to determine the
presence and functional characteristics of Treg cells isolated from Mesenteric lymph nodes
(MLN) (one of the inductive sites of the mucosal immune system) in human UC. Methods:
Colonic MLN were isolated from patients with severe UC that were undergoing surgical
resection and lymphocytes were isolated using standard techniques. Phenotypic analysis of
CD25+CD4+ T cells isolated from colonic MLN was performed by flow cytometry. Analysis
of FoxP3 expression among CD25- and CD25+ subsets was performed by RT-PCR and flow
cytometry. Localization of FoxP3+ cells in MLN was performed by immunohistochemistry
(IHC). Functional characterization of CD4+CD25+ T cells was performed with proliferation
assays following allogeneic (dendritic cells) or polyclonal T cell activation (anti-CD3 plus
autologous APC). The effect of CD4+CD25+ T cells on cytokine production by effector
CD4+CD25- T cells was performed using the 22-plex Luminex assay. Results: MLN from
human UC colon contain a subset of CD4+CD25+ T cells with phenotypic characteristics
of Treg cells (expression of CCR4, CD122, HLA-DR, GITR and intracellular CTLA4). FoxP3+
Cells were detected by IHC in the MLN medulla dispersed in the T cell rich areas and
occasional FoxP3+cells were present in the follicles. CD4+CD25+ cells express FoxP3 mRNA
and protein and potently suppress the proliferation of autologous MLN CD4+ T cells. In
contrast to peripheral blood Treg from healthy donors, the CD4+CD25hi and CD4+CD25int
MLN T cell subsets exhibit potent suppressor activity in vitro. The suppressor function of
CD4+CD25+FoxP3+ cells is not mediated through TGF-beta or IL-10, whereas addition of
exogenous IL-2 restores the proliferation of responder CD4+CD25- MLN T cells. In addition
to their ability to suppress the proliferation of CD4+CD25- cells, CD4+CD25+ cells potently
suppressed the secretion of IL-2, IL-5, IL-13 and IFN-gamma by CD4+CD25- effector T
cells. Conclusions: CD4+CD25+ T cells isolated from human colonic MLN in UC display
typical features of Treg cells and possess potent suppressor activity in vitro in spite of
persistent mucosal inflammation. These data suggest that their suppressor activity is likely
compromised in vivo and finding ways to restore their suppressive activity is desirable in
order to achieve long-term tolerance in the gut.
600
IL-23 Cross Regulates IL-12 Production in T Cell Dependent Experimental
Colitis
Christoph Becker, Heike Dornhoff, Clemens Neufert, Massimo C. Fantini, Stefan Wirtz,
Alexei Nikolaev, Hans A. Lehr, A J. Murphy, D M. Valenzuela, G D. Yancopoulos, M
Karow, Peter R. Galle, Markus F. Neurath
IL-12 related cytokines are important mediators of cell-mediated immune responses and
are implicated in the pathogenesis of chronic inflammatory and autoimmune diseases. We
describe a novel mechanism by which crossregulation of IL-12 by IL-23 controls colitis. IL-
23 was found highly expressed in the lamina propria of animals suffering from colitis.
Immunohistochemical analysis demonstrated expression of IL-23p19 by infiltrating dendritic
cells that had taken up bacteria. To investigate the functional role of IL-23 in experimental
colitis, we generated mice in which the coding region for IL-23 was replaced with the
reporter gene beta-galactosidase. In unchallenged mice, constitutive reporter gene activity
was significantly present only in the ileum and the colon implicating constitutive activity
of the IL-23p19 promoter in the latter organs. When mice were challenged with TNBS,
unexpectedly, IL-23p19 knockout mice developed more severe colitis than wildtype mice
as defined by weight loss, in vivo endoscopy and histology. We next challenged mice with
orally administered dextrane sulfate to verify our previous findings. Again, mice deficient
for IL-23p19 developed a very severe colitis when compared to wildtype mice. Mice hetero-
zygous for IL-23p19 showed an intermediate course of disease. Colon lysates of heterozygous
and knockout mice contained high levels of beta-galactiosidase and reporter gene activity
correlated well with the disease severity as determined by the weight loss of the animals.
Interestingly, bone marrow derived dendritic cells from knockout mice expressed significantly
higher levels of IL-12p35 as compared to wildtype animals. Furthermore, exogenous IL-23
suppressed IL-12p35 mRNA expression in BMDC derived from knockout mice, implicating
that mice lacking IL-23p19 may overproduce IL-12. To investigate whether the overproduc-
tion of IL-12 may be responsible for the severe colitis observed in IL-23p19 knockout mice,
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we induced colitis in IL-23p19 knockout mice and subsequently injected a weekly dose of
an antibody neutralizing IL-12p40. While in the control group, mice continuously lost
weight and finally died, in contrast, mice that received anti-IL-12p40 antibody were protected
from colitis and survived. This finding was furthermore confirmed by endoscopic examina-
tions of the colon, demonstrating a high colitis score in control mice as compared to antibody
IL-12p40 treated animals. Therefore our data strongly suggest a cross regulation of IL-23
and IL-12 in dendritic cells in the regulation of colitis. Our findings question the use of
neutrolizing IL-23p19 antibodies in the treatment of colitis.
601
Essential Counter-Regulatory Role of Farnesoid-X-Receptor (FXR) for
Intestinal Innate Immunity
Stefano Fiorucci, Barbara Renga, Giovanni Rizzo, Andrea Mencarelli, Moses Disante, Mark
Pruzanski, Roberto Pellicciari, Antonio Morelli
Background. The farnesoid X receptor (FXR) is a member of the nuclear receptor superfamily
of ligand-activated transcription factors involved in cholesterol and bile acid homeostasis
and expressed in the liver and gastrointestinal tract. A growing body of evidence suggests
that certain nuclear receptors exerts counter-regulatory function in inflammation. INT-747
(6-Ethyl chenodeoxycholic acid) is a semi-synthetic FXR ligand. Aims. To investigate whether
FXR is expressed by cells of innate immunity and regulates inflammation in animal models
of colitis. Methods. Human peripheral blood monocytic cells (PBMC) were prepared from
healthy volunteers. Endoscopic samples from intact and macroscopically inflamed colons
from obtained from patients with Crohn’s disease. Colitis was induced in wild type and
FXR-/- deficient mice (C57BL6 background) by intrarectal administration of TNBS or by 7-
day administration of 5% DSS in drinking water. Animals were administered with 1, 3 or
10 mg/kg INT747 by gavage for 7 days. Results. FXR is expressed by and exerts counter-
regulatory effects on cell of innate immunity. Microarray analysis of LPS-induced PBMC-
derived macrophages reveals that FXR ligands function as negative regulators of NF-κB
dependent-genes resulting in a reciprocal regulation of genes involved in innate and adaptive
immune response (TNF, IL-1, IL-6, approximately 50-70% inhibition of mRNA expression)
as well as bile acid/cholesterol homeostasis as demonstrated by induction of the FXR regulated
gene, SHP. Using two rodent models of colon inflammation, we show that progression of
these immune-mediated disorders is severely exacerbated in FXR-/- mice resulting in a
reduction of disease activity score of 50-60% (p<0.01 versus wild type mice). Colon inflamma-
tion in Crohn’s disease patients and in rodent models of colitis associates with a significant
reduction (70-80%) of FXR mRNA expression in the colon. In vivo treatment with INT-
747 attenuates organ injury and immune cell activation in the TNBS and DSS colitis. At
the dose of 3 mg/kg, INT747 significantly increased the colon expression of IBABP, FXR,
SHP while reduced IL-1, IL-2, IL-6, TNF-α and IFNγ mRNA expression and attenuated the
disease activity score of 50-60%. FXR is expressed by lamina propria-derived CD11b+ cells.
Exposure of these cells to INT-747 significantly reduced cytokine release induced by LPS.
Conclusions. These findings identify FXR as a bile acid-dependent regulator of inflammatory
gene expression in macrophages, possibly establishing a link between cholesterol/bile acid
homeostasis and innate and adaptive immunity in the gastrointestinal tract.
602
Colon Cancer Specific Antigen-3 and -4 (CCSA-3 and CCSA-4): Novel Serum
Based Markers for Detection of Colorectal Cancer (CRC)
Eddy Lehman, Robert E. Schoen, Grant W. Cannon, Robert H. Getzenberg
A blood test for CRC screening would represent a major advance because of the relative
ease of implementation and potential to markedly increase patient participation. Using a
proteomic approach focused on nuclear matrix proteins specific to colorectal cancer, we
developed an ELISA based assay to CCSA-3 and CCSA-4, two novel proteins. Aim: To assess
the sensitivity and specificity of these markers. Methods: Serum samples were collected
prospectively from patients undergoing colonoscopy, and from subjects with CRC and benign
colon conditions prior to surgery. Based on histologic results, subjects were classified into
the following categories: normal colonoscopy (N=30), hyperplastic polyp (N=23), benign
surgical condition (N=9), and cancer (N=28). A pilot study was performed to establish cut
off points for test positivity (CCSA-3 (2 μg/ml) and CCSA-4 (0.3 μg/ml)). Results: Mean
levels for both CCSA-3 and CCSA-4, respectively, were higher in colorectal cancer (3.2 ±
1.1; .72 ± .29) than in the benign conditions: normal colon (.66 ± .3; .13 ± .05); hyperplastic
polyps (1.08 ± .48; .13 ± .76); pre-surgical benign (.58 ±.13; .26 ± .10). At the specified
cut off points, CCSA-3 and CCSA-4 each detected 100% (95%CI 88-100) of the cancers.
The specificity for normal colon, hyperplastic polyps, and benign colon was 98% (95%CI
88-100) for CCSA-3 and 97% (95%CI 86-99) for CCSA-4. Conclusions: This is the first
report of a serum based assay able to distinguish subjects with cancer from subjects with
a benign colon. Studies in subjects with advanced and non-advanced adenoma are ongoing.
If substantiated, this would represent a major advance in colorectal cancer screening.
603
Apoptosis in Normal Rectal Mucosa Predicts Adenoma Recurrence
Ahmad Amin, Joseph Galanko, Christopher Martin, Barbara Schliebe, Robert S. Sandler,
Temitope O. Keku
Background Lower levels of apoptosis in the normal rectal mucosa have been shown to be
strongly associated with the presence of adenomas elsewhere in the colon (a field effect) in
cross sectional studies. It is not known whether apoptosis can predict subsequent adenomas.
We evaluated whether apoptosis and other factors at baseline colonoscopy could predict
recurrent adenomas. Methods: We evaluated subjects initially enrolled in the Diet and Health
Study III (DHS3), a cross sectional study of adenoma risk factors. There were 489 participants
enrolled in the original study. The present study was limited to 257 men and women
(baseline adenoma status; 129 had adenomas and 128 adenoma free) who returned for

















normal mucosa to evaluate apoptosis by morphology on H &E stained sections. The number
of adenomas, the size, type and degree of atypia at baseline colonoscopy and the level of
apoptosis in normal rectal mucosa were evaluated as predictors of recurrence. T-tests were
used to assess relationships between continuous variables and adenoma recurrence. Multiple
logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CI).
Results: Of the subjects who had adenoma at baseline, 41% had at least one adenoma at
follow-up compared to 15% of individuals who were adenoma free at baseline. After adjusting
for age, race and sex, individuals in the highest tertile of rectal mucosal apoptosis were
substantially less likely to have an adenoma at follow-up (OR 0.28; 95% CI, 0.10-0.75)
compared to the lowest tertile. The inverse relationship between apoptosis and adenoma
status at follow-up was strongest in individuals who were free of adenoma at baseline.
Having more than one adenoma at baseline also increased the risk for recurrence (OR 1.61;
95% CI, 1.29, 1.87). Consistent with the results of previous studies, the presence of an
advanced adenoma at baseline also predicted recurrence, but was not statistically significant.
No association was observed between adenoma location and recurrence. Conclusion: The
results of the study provide new evidence that low apoptosis is strongly associated with
increased risk of recurrent adenomas. Apoptosis could potentially be used to identify patients
at higher risk for recurrent adenomas. Work was supported by grants from NIH R01
CA44684 and P30 DK 34987
604
Increased Level and Freqency of Methylation Correlates with a Poor Response
to Chemotherapy and Radiation in Esophageal Cancer
James P. Hamilton, Fumiaki Sato, Bruce D. Greenwald, Mohan Suntharalingham, Mark J.
Krasna, Martin J. Edelman, Yuriko Mori, Takatsugu Kan, Suna Wang, Bogdan C. Paun,
Tetsuo Ito, Yulan Cheng, John M. Abraham, Stephen J. Meltzer
Background and Aims: Multiple studies have shown that promoter methylation of tumor
suppressor genes underlies esophageal carcinogenesis. Hypothetically, methylation resulting
in tumor suppressor gene inactivation may result in tumors that are unresponsive to chemo-
therapy and radiation. Accordingly, our aim was to find methylation markers that could be
used to predict response to chemoradiation. Materials and Methods: Tumor specimens
were obtained prior to treatment from 35 patients enrolled in a uniform chemo-radiation
treatment protocol. Methylation-specific quantitative PCR for eleven genes was performed
on all samples using the ABI 7700 (Taqman) system. Esophagectomy specimens were used
to define response to treatment. Results: 13 (37%) of 35 patients were responders, and 22
(63%) of 35 patients were non-responders. The number of methylated genes per patient
was significantly lower in responders than in non-responders (1.4 vs. 2.4 genes per patient;
Student’s t-test, p=0.026). The combined mean level of promoter methylation of p16, Reprimo,
p57, p73, RUNX-3, CHFR, MGMT, TIMP-3, and HPP1 was also lower in responders than in
non-responders (Student’s t-test, p=0.003; Mann-Whitney test, p=0.001). Of particular
interest, both the frequency (2, or 15%, of 13 responders vs. 14, or 64% of 22 non-
responders; Fisher’s exact test, p= 0.01); and level (0.078 in responders vs. 0.313 in non-
responders; Mann-Whitney test, p=0.037) of Reprimo methylation was significantly lower
in responders than in non-responders. Conclusions: Reprimo methylation occurred at signi-
ficantly lower levels and frequency in chemoradioresponsive than in non-responsive eso-
phageal cancer patients, suggesting potential clinical application of this single-gene biomarker
in defining prognosis and management. In addition, increased methylation of a 9-gene panel
correlated significantly with poor responsiveness to chemoradiation.
605
Selection and Suitability of Microsatellite Markers for Colorectal Cancer
Classification According to Microsatellite Instability Degree
Rosa M Xicola, Xavier Llor, Elisenda Pons, Anna Giros, Miquel A Gassull, Gi Oncology
Group Spanish Gastroenterology Association
Introduction: The first set of recommended markers for the identification of microsatellite
instability (MSI) in colorectal cancer (CRC) tumors was published in 1998 (Bethesda panel)
This included 5 markers, 2 of them mononucleotide repeats (BAT25, BAT26) and 3 dinucleot-
ide repeats. Recently it has been suggested that the use of 5 mononucleotide repeats (NR21,
NR22, NR24, BAT25, BAT26) or even just BAT26, could be as effective to detect high
degree MSI (MSI-H). A major advantage of using those markers is that they are quasi-
monomorphic in most populations and there is no need for uninvolved tissue examination.
Regarding the Bethesda panel, it has also been suggested that when only dinucleotide markers
are unstable, it is necessary to check more mononucleotide markers in order to exclude low
degree MSI (MSI-L). Objectives:1)To establish if the use of the 5-mononucleotide panel is
at least as sensitive as the Bethesda panel for the identification of MSI-H tumors. 2)To
establish if it is necessary to study more mononucleotide markers when tumors are MSI-H
exclusively due to dinucleotide instability. 3)To establish which are the most useful markers
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for the identification of MSI-L and MSI-H tumors. Methods: Out of the 1,309 newly diagnosed
CRC from the EPICOLON project, 753 were analyzed with the Bethesda panel and 556
with the 5-mononucleotide set. All MSI-L, 100 stable tumors (MSS) and all MSI-H classified
as such exclusively through dinucleotide instability with the first panel, were subsequently
studied with the 5-mononucleotide set. Results: 1,156 CRC were initially classified as MSS,
105 MSI-H and 44 MSI-L. The series studied with the 5-mononucleotide set identified a
percentage of 9,9% of tumors as MSI-H while the series studied with the Bethesda markers
identified 6,6% of tumors as MSI-H. Sensibility for MSI-H identification for specific markers
was: 91.4% for BAT26, 93.3% for BAT25, 94.5% for NR21 and NR24, and 89% for NR22.
Specificity was 100% for BAT25, NR22 and NR24. Only 2/105 tumors were MSI-H only
for dinucleotide markers and one of them was reclassified as MSI-L with the 5-mononucleo-
tide set. None of the tumors identified as MSI-L with the Bethesda panel was reclassified
as MSI-H when adding the study of NR markers. 14 MSI-L tumors were unstable only for
NR21 Conclusions: The set of 5-mononucleotide markers (NR21, NR22, NR24, BAT25,
BAT26) is the most sensitive and specific for MSI-H identification. Analyzing BAT25, NR21
and NR24 only from tumor tissue we can identify all MSI-H and a significant proportion
of MSI-L tumors. If tumors are MSI-H only for dinucleotides, it is necessary to study more
mononucleotides to correctly classify them
606
Expression of Multiple Simultaneous Biomarkers in Tissues of Patients with
Colitis-Associated Neoplasia
Steven Itzkowitz, Lina Jandorf, Noam Harpaz, Joel Skoletsky, Anthony Shuber
Background: Molecular genetic alterations that are important for sporadic colorectal carcino-
genesis have also been implicated in colitis-associated neoplasms (CANs). Few studies have
simultaneously analyzed multiple markers in the same tissues of IBD pts. In anticipation of
developing a fecal DNA-based assay for detecting CANs, we have begun to analyze tissues
from pts with longstanding ulcerative colitis (UC) for expression of the 22 DNA mutations
(MuMu-22) currently included in a commercially available fecal DNA test. Aim: To compare
the expression of MuMu-22 in cancerous and non-neoplastic tissues of IBD pts and compare
this with normal controls (NL). Methods: From the Mount Sinai GI Pathology Database,
we identified surgical specimens from 15 UC pts with CRC (one pt had two cancers), and
37 NLs who underwent surgical resection for diverticular disease or volvulus. Average (+/-
S.D.) duration of UC was 19.8 (+/- 11.7) years. Neoplastic and non-neoplastic tissues were
microdissected by an expert GI pathologist and analyzed for MuMu-22 (3 kras, 8 p53, 10
APC, and 1 Bat-26 mutations) using PCR technology as previously described. Results: Among
the 37 NLs, only one case was positive for a k-ras mutation (Table). In contrast, 7/16 (44%)
UC-cancer specimens had a mutation. Cancers did not have more than one mutation, and,
confirming previous observations, APC mutations were rare. Four samples of non-neoplastic
tissue had a mutation. Conclusions: Even in a limited sample set, sensitivity of 44% using
this marker panel suggests that a refined marker panel targeting more alterations involved
in UC carcinogenesis could lead to a fecal DNA test for pts with UC.
607
Expression of Galectin-3 and Its Binding Protein (MAC-2BP) Correlate with
Progression and Metastasis of Colorectal Adenocarcinoma
Kai-Feng Liu, James C. Byrd, Shumei Song, Robert S. Bresalier
Background: Mac-2 BP (90K) is a large oligomeric glycoprotein composed of subunits of
approximately 90 kDa, identified as a ligand for the carbohydrate binding protein, galectin-
3 (Gal-3). Immunohistochemical studies of Mac-2 BP expression in colon cancer have not
been reported, although previous studies have indicated that serum levels of this protein
may have prognostic value in patients with several types of cancer. We have reported that
other ligands for Gal-3 such as colon cancer mucin and a 40 kDa aberrantly glycosylated
form of haptoglobin may play a role in tumor progression and have diagnostic value in
patients with colorectal neoplasia. This study examined the expression of Mac-2BP in colorec-
tal cancers using immunohistochemistry, and correlated its expression and distribution in
these tissues with expression of Gal-3 and mucin sub-types. Methods: 33 sporadic colorectal
cancers with 11 associated metastases as well as specimens of normal (n=10) and transitional
(n=28) mucosa and colorectal adenomas (n=10) were examined immunohistochemically for
expression of Mac-2BP and Gal-3, then scored semiquantitatively to take into account
distribution and intensity of staining (0-3). Genetically related colon cancer cells with different
metastatic potential were compared by Western blot analysis. Results: Colorectal cancers
expressed Mac-2BP in 32 of 33 (97%) cases (mean score ±SE, 1.71±0.14). Expression of
this protein in cancers was significantly higher than that in normal mucosa (0.75±0.11,
p<0.001), colorectal adenomas (0.30±0.21, p<0.001) and transitional mucosa (0.54±0.14,
p<0.001). Metastases expressed higher amounts of Mac-2 BP than the primary tumors from
which they were derived (2.32 ± 0.24; p<0.05). Mac-2BP was expressed in the cytoplasm
of neoplastic tissues and in secreted material, with levels of the ligand paralleling that of
Gal-3. In keeping with previous reports, normal tissue expressed predominately nuclear
galectin-3. Most colorectal carcinomas (85%) lost nuclear localization of Gal-3 and expressed
the protein only in the cytoplasm (co-localized with Mac-2BP). Some cancers (15%) expressed
both nuclear and cytoplasmic Gal-3. Highly metastatic colon cancer cell line Lim6 expressed
higher levels of both galectin-3 and Mac-2BP compared to low metastatic cell line LM12.
Mac-2 BP was expressed in mucinous tumors, which strongly expressed MUC2 and MUC5AC,
and also in non-mucinous carcinomas. Conclusion: The galectin-3 binding protein Mac-2BP
is highly expressed in colorectal cancers and may serve as a marker of neoplastic progression.
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Early Weaning Stress Predisposes Adult Pigs to Stress-Induced Colonic Barrier
Dysfunction: A Novel Model for Stress-Induced Gastrointestinal Disorders in
Humans
Adam J. Moeser, Duncan X. Lascelles, Anthony T. Blikslager
Adverse early life experiences may predispose individuals to development of stress-induced
gastrointestinal (GI) disorders as adults, often associated with pain. In the neonatal pig,
early weaning (less than 21 days) involves multiple psychosocial stressors such as early
maternal and sibling separation, abrupt changes in environment and diet, and establishment
of a dominance hierarchy with non-littermate pigs. We sought to determine whether early
weaning stress predisposes piglets to stress-induced GI dysfunction in adult life. Neonatal
piglets were subjected to one of 2 weaning conditions: 1) early weaning at 19 days of age
(EW), or 2) weaning at 28 days of age (control). At 63 days of age, the pigs were subjected
to a 6-hour period of social stress involving mixing the pigs with unfamiliar pigs (social
stress). Colonic tissue and spinal cord was then removed for evaluation. Transepithelial
electrical resistance [TER] and mucosal-to-serosal fluxes of 3H-mannitol were measured in
colonic tissues mounted on Ussing chambers. Ion secretion was determined by measuring
short circuit current [Isc]. Western blot analyses of corticotrophin releasing factor (CRF)
receptor 1 and mucosal mast cell staining were performed on colonic tissue. Western blot
analyses of COX-1 and 2 on spinal cord segments T12, L2 and L6 were performed. Data
were analyzed using a standard 1-way ANOVA. Social stress in EW pigs decreased colonic
TER by 41% and induced a 2-fold increase in mucosal permeability to 3H-mannitol (P<0.01).
Social stress did not effect TER and 3H-mannitol flux in control pigs. Colon from EW pigs,
but not control, exhibited significant elevations in baseline secretory activity following social
stress (ΔIsc = 11±3µA/cm2). EW, but not control pigs, showed diarrhea following social
stress. Western blot analysis revealed enhanced expression of CRF receptor 1 in colonic
mucosal homogenates of EW pigs but no change in CRF expression in control pigs. Addition-
ally, mast cells numbers were markedly increased in colonic mucosa of EW pigs following
social stress compared with control pigs (cell numbers = 6.6±0.7/10µm2 and 2.8±1.7/10µm2
in stressed EW and control pigs, respectively). Spinal cord levels of COX-2, but not COX-
1, were elevated in EW pigs compared to control pigs. Results from these studies provide
supporting evidence for the validity of this novel porcine model to study human functional
GI disorders such as irritable bowel syndrome.
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Acupuncture Induces Gastric Phase III-Like Contractions Via Ghrelin Release
in Conscious Rats
Cindy Chen, Kiyoshi Tsukamoto, Yukiomi Nakade, Theodore N. Pappas, Toku Takahashi
Background; The mechanism(s) of the beneficial effects of acupuncture on GI symptoms
still remains unclear. We have previously showed that acupuncture on the hind limb (ST-
36) changed the fasting gastric motor patterns and elicited strong cyclic contractions (phase
III-like contractions) in conscious rats. Acupuncture-induced phase III-like contractions
were abolished by atropine, hexamethonium and vagotomy, suggesting the mediation of
vagal cholinergic pathways (Am J Physiol 285, R862-72, 2003). Ghrelin is a newly discovered
orexigenic peptide originating from the stomach. Peripheral administration of ghrelin induces
phase III-like fasting motor activity of the rat stomach (J Physiol 550.1, 227-240, 2003).
We hypothesize that acupuncture-induced phase III-like contractions of the rat stomach is
mediated via an endogenous ghrelin release. Methods; A strain gage transducer was implanted
on the serosal surface of the stomach to record circular muscle contractions. One week after
the surgery, the rats were fasted for 24 hrs. After the recording of basal gastric motility for
2 hrs, ghrelin (1, 4 and 10 µg/kg) was administered subcutaneously (sc). Acupuncture
needles were inserted to a depth of 5 mm into the skin and underlying muscles at ST-36
bilaterally. Needles were stimulated by electricity (0.1 msec, 1 mA and 1 Hz) for 1 min.
Fasting gastric motility was recorded before, during and after EA in a conscious state. To
investigate whether an endogenous ghrelin is involved in mediating acupuncture-induced
phase III-like contractions, growth hormone secretagogue receptor (GHS-R) antagonist (400
nmol/kg) was administered 10 min before EA. It has been demonstrated that ghrelin receptors
are located on the vagal afferent. To investigate whether ghrelin- and acupuncture-induced
phase III-like contractions are mediated via vagal afferent pathways, we utilized perivagal
capsaicin-treated rats. Results; Ghrelin (1-10 µg/kg, sc) significantly provoked phase III-like
contractions in a dose dependent manner in conscious rats. EA at ST-36 also elicited strong
phase III-like contractions, which mimicked with ghrelin-induced phase III-like contractions.
GHS-R antagonist significantly attenuated the incidence of acupuncture-induced phase III-
like contractions. Ghrelin (4 µg/kg, sc) and EA causes no more phase III-like contractions
in perivagal capsaicin-treated rats. Conclusions; Acupuncture-induced gastric phase III-like
contractions is mediated via an endogenous ghrelin release in conscious rats. Released ghrelin
from the gastric mucosa induced by acupuncture primarily acts on vagal afferents to induce
phase III-like contractions.
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Peripherally Administered CRF Stimulates Colonic Motility Via Central CRF
Receptors and Vagal Pathways in Conscious Rats
Kiyoshi Tsukamoto, Yukiomi Nakade, Christopher Mantyh, Kirk Ludwig, Theodore N.
Pappas, Toku Takahashi
Background: CRF (corticotropin releasing factor) is one of the most important factors to the
mechanism of stress-induced stimulation of colonic motility. However, it is controversial
whether stress-induced stimulation of colonic motility is mediated via central or peripheral
CRF receptors. We investigated the hypothesis that peripherally injected CRF accelerate
colonic motility through central CRF receptor, but not peripheral CRF receptor. Methods:
A strain gauge transducer was sutured on the serosal surface of the proximal colon. Colonic
motility was monitored before and after the peripheral injection of CRF (3, 10, 30 and 100
µg/kg; sc). To study the influence of peripherally administered hexamethonium, atropine,
or intracisternal (IC) injection of astressin (a CRF receptor antagonist) on CRF-induced
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stimulation of colonic motility, these drugs were injected 20 min before the injection of
CRF (30 µg/kg, sc). To study whether vagus nerve is related to the alteration of colonic
motility evoked by CRF, subdiaphragmatic bilateral truncal vagotomy was performed during
the operation to install the strain gauge transducers and five days after the operation, the
colonic motility was recorded before and after CRF injection (30 µg/kg, sc). In vitro muscle
strip study was also performed to investigate the peripheral effects of CRF. Results: Subcutane-
ous injection of CRF (30-100 µg/kg) stimulated colonic motility in a dose-dependent manner.
The stimulatory effect of peripherally administered CRF (30 µg/kg, sc) on colonic motility
was abolished by truncal vagotomy, hexamethonium and atropine. IC-injection of astressin
also abolished the stimulatory effect of CRF (30 µg/kg, sc) on colonic motility. No contractile
responses were observed to CRF (10-9 M -10-7 M) of the muscle strips of the proximal
colon in vitro. Conclusions: These results suggested that the stimulatory effect of colonic
motility in response to peripheral administration of CRF is mediated by vagus nerve, nicotinic
receptors, muscarinic receptors and CRF receptors of the brain stem. It is suggested that
peripherally administered CRF reaches area postrema and activates dorsal nucleus of vagi
(DMV) via central CRF receptors, resulting in stimulation of vagal efferent and cholinergic
transmission of the proximal colon.
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Pathways Involved in Gut Mucosal Barrier Dysfunction Induced in Adult Rats
By Neonatal Maternal Deprivation: CRF and NGF Interplay
Frederick Barreau, Christel Salvador-Cartier, Laurent Ferrier, Jean Fioramonti, Lionel
Bueno
Background and aim: The increase in gut paracellular permeability (PP) observed in adult
rats submitted to neonatal maternal deprivation involves nerve growth factor (NGF) and
mast cell activation. Maternal deprivation triggers an overexpression of NGF at both brain
and colonic levels. It also increases hypothalamic corticotropin releasing factor (CRF) expres-
sion, but its effect on colonic CRF remains unknown. This study was aimed to determine
whether maternal deprivation induces colonic CRF overexpression and whether CRF, NGF
and mast cells play an interactive role in alterations of PP induced by maternal deprivation.
Methods: Male Wistar pups were either separated, 3 h per day, from postnatal days 2 to
14 (deprived animals), or left undisturbed with their dam (non-deprived). At 12 weeks of
age, adult deprived rats were treated i.p. with a non specific CRF receptor antagonist, alpha-
helical(9-41)CRF (250 µg/kg), or a specific CRF-R1 receptor antagonist, SSR-125543 (10
mg/kg). Furthermore, adult non-deprived rats were treated by CRF (50 µg/kg), or BrX-537A
(a mast cell activator, 2 mg/kg) and anti-NGF antibodies (15 µg/kg). PP was assessed by
oral administration of 51Cr-EDTA (1 µCi/rat), and expressed as the percentage of radioactivity
collected in the urine during 24 hours. In addition, rats were sacrificed and colonic strips
used for staining of mucosal CRF expression, which was analysed and graded from 0 to 3,
according to the degree of immunostaining. Results: Neonatal maternal deprivation increased
colonic CRF expression in adult rats, mainly at the bottom of the crypts (1.5±0.2 vs 0.6±0.4;
P<0.05). Alpha-helical CRF(9-41) or SSR-125543 treatment suppressed the increase in PP
induced by MD (P<0.05). In adult non-deprived rats, CRF increased PP (3.9±0.3 % vs
1.8±0.2 %; P<0.05). This increase in PP was reduced by anti-NGF antibodies treatment
(2.8±0.3 % vs 3.9±0.3 %; P<0.05). Similarly, mast cell activation by BrX-537A increased
PP (4.1±0.4 % vs 1.8±0.2 %; P<0.05). Anti-NGF antibodies treatment also reduced this
increase (3.1±0.4 % vs 4.8±0.4 %; P<0.05). Conclusions: Maternal deprivation induces
CRF overexpression in the colon. Since anti-NGF antibodies inhibit the increase in PP
induced by both CRF and mast cell activation, it can be concluded that CRF may acts at
CRF-R1 receptors to stimulate NGF release from mast cells, which in turn participates
to the increase in colonic in PP observed in adult rats that were submitted to neonatal
maternal deprivation.
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Imaging Glutamate in Human Swallowing Motor Cortex: Implications for
Mechanisms of Neuroplasticity
Salil Singh, Satish Mistry, Samantha Jefferson, Karen E. Davies, Steve R. Williams,
Shaheen Hamdy
Background: Activity in the swallowing motor cortex (SMC) can be facilitated by an interven-
tion termed paired associative stimulation (PAS). This technique involves delivery of an
electrical stimulus to the pharyngeal muscles followed by a transcranial magnetic stimulus
to the SMC. The resultant changes have been termed neuroplasticity but the molecular
mechanism remains uncertain. Glutamate, the most abundant excitatory neurotransmitter,
has been implicated. Aims: To identify the neurotransmitter changes associated with PAS
using proton magnetic resonance spectroscopy to measure cortical glutamate concentrations
in vivo. Methods: Seven healthy volunteers were studied on two occasions, receiving either
real or sham intervention. An electrical pharyngeal stimulus was followed 100ms later by
a transcranial magnetic stimulus to the SMC. These paired stimuli were repeated every 20s
for 30mins. Post intervention, serial magnetic resonance spectroscopy was undertaken at
the stimulated SMC as well as an occipital control site. Data were analysed using jMRUI
software with metabolite peaks compared across real and sham visits. Results: All subjects
showed a reduction in glutamate 1 peak (the most prominent glutamate peak) at the SMC
following real stimulation compared to the same site following sham stimulation. Group
mean data showed a 27±6% reduction in glutamate concentration (p<0.004). A similar
24±12% decrease was confirmed at the glutamate 2 peak (p<0.05) but no significant changes
were seen with any other metabolites at the SMC or control sites. Conclusions: Neuroplastic
changes induced by PAS are associated with a focal decrease in cortical glutamate. Our data
suggest a role for glutamate in the induction of neuroplasticity and give important insights
into the molecular basis for plasticity in the human brain. These findings also identify a


















Central Glucagon Like Peptide-1 Accelerates Colonic Transit Via a Central
CRF and Peripheral Parasympathetic Pathway in Conscious Rats
Yukiomi Nakade, Kiyoshi Tsukamoto, Constant Masere, Kirk Ludwig, Christopher R.
Mantyh, Theodore N. Pappas, Toku Takahashi
Background: Glucagon like peptide-1 (GLP-1) is a gastrointestinal (GI) regulatory peptide
secreted from the small and large intestine in response to absorbed nutrients. Peripheral
GLP-1 stimulates insulin secretion on the islet beta cell to decrease blood glucose level.
Apart from the role of incretine, GLP-1 is also known to act as a neurotransmitter mediating
GI function in the brain. Central administration of GLP-1 inhibits gastric emptying (Am J
Physiol 273, G920-927, 1997). However, little is known about the effect of central GLP-1
on colonic motor function. We examined the effects of intracerebroventricular (ICV)-injection
of GLP-1 on colonic transit in conscious rats. Methods: Using male SD rats, indwelling
silastic cannula was inserted into the cecum and positioned to the proximal colon. ICV-
cannula was inserted into the right lateral ventricle. One week after the operation, immediately
after ICV-injection of GLP-1, radioactive material (51Cr) was applied via the catheter onto
the proximal colon. Ninety minutes after 51Cr injection, rats were sacrificed and the entire
colon was removed and divided into 10 equal segments. The radioactivity of each segment
was counted and the geometric center (GC) was calculated as a distribution of 51Cr. To
examine the pathway through which central GLP-1 mediates colonic transit, atropine (50
µg/kg, IP), hexamethonium (20 mg/kg, IP), and guanethidine (5 mg/kg, IP) were administered
20 minutes before ICV-injection of GLP-1. Truncal vagotomy was performed 1 week before
the colonic transit study. To study the relationship between corticotropin releasing factor
(CRF) and GLP-1 in the brain, CRF antagonist, astressin (2.8 nmol), was administered by
ICV 10 minutes before ICV-injection of GLP-1. Results: GC in vehicle-treated rats was
4.4±0.3 (n=6). ICV-injection of GLP-1 (0.3-3.0 nmol) dose-dependently accelerated colonic
transit. Maximum effect was observed by 3 nmol of GLP-1 (GC; 7.8 +/- 0.5, n=6). In contrast,
intraperitoneal-injection of GLP-1 (3 nmol) did not accelerate colonic transit (5.2 +/- 0.5
n=6). ICV-injection of GLP-1 (3 nmol)-induced acceleration of colonic transit was abolished
by truncal vagotomy, atropine and hexamethonium, but not by guanethidine. ICV-injection
of GLP-1 (3 nmol)-induced acceleration of colonic transit was also abolished by the pretreat-
memt with astressin (2.8 nmol; ICV). Conclusions: These results indicate that the central
administration of GLP-1 accelerates colonic transit via central CRF and peripheral parasym-
pathetic pathways in conscious rats.
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Dual Actions of Neurotensin and Localization of NTS1 Receptors Relative to
SK3 Channels and Interstitial Cells of Cajal in Human Ileum
Yael Azriel, Fei Shang, Lu Liu, Elizabeth Burcher
Purpose: Neurotensin (NT) is a brain-gut peptide from the ileum, released in response to
ingested fats. We studied the mechanisms of action of NT in isolated muscle strips and
localized its receptors in relation to various cell types and markers in the human ileum.
Methods: Isometric tension recordings were made from longitudinal or circular muscle strip
preparations from normal terminal ileum. Discrete concentration responses curves to NT
were obtained in the absence and presence of various inhibitors. Inhibitory responses were
expressed as a percentage of the height of spontaneous contractions before addition of NT.
Ileal sections were incubated with primary antibodies against the NTS1 receptor, SK3 (marker
for Ca2+-activated K+ channels) and c-kit (marker for interstitial cells of Cajal), then processed
for confocal microscopy. Results: In longitudinal muscle, biphasic effects were seen: an
initial relaxation and inhibition of spontaneous rhythmic contractions (EC50 2.5 nM, n=15),
usually followed by a weak delayed contraction (EC50 1.6 µM), with maximum tension only
6.8% compared to acetylcholine. NT-induced inhibition was unaffected by tetrodotoxin,
indomethacin, hexamethonium and L-NAME, but was almost abolished by apamin (100
µM). In ileal circular muscle, NT had weak contractile effects (EC50 126 nM, n=14), unaffected
by inhibitors. Thus, NT is a substantially more potent inhibitory agent compared to contractile
agent in the human ileum. Using RT-PCR, mRNA transcripts were detected for the NTS1
receptor, but not for NTS2. NTS1 immunoreactivity (IR) was observed in myenteric and
submucosal ganglia, on mast cells and also as punctate immunoreactivity in longitudinal
and circular muscle. There was negligible colocalization of NTS1-IR with c-kit-IR. SK3-IR
occurred within and around myenteric ganglia, within muscle and on submucosal arterial
blood vessels. Substantial colocalization of NTS1-IR with SK3-IR was seen in the myenteric
plexus; approximately 20% of NTS1-IR in muscle was colocalized with SK3-IR. However
the presence of NTS1 receptors in ganglia may be at variance with the functional data
showing tetrodotoxin-independent mechanisms. Conclusions: Neurotensin has potent, apa-
min-sensitive inhibitory actions on ileal longitudinal muscle. Its receptors (NTS1) are found
on myenteric and submucosal ganglia as well as the muscularis; colocalization with SK3
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was seen. Neurotensin may represent a novel pharmacological target for motility disorders.
Supported by NHMRC of Australia.
615
ICC Networks Coordinate Propagation of Longitudinal Muscle Activity and
Movements in the Murine Small Intestine
Grant W. Hennig, Peter Bayguinov, Laura Ritchie, Kyu Joo Park, Hyun Tai Lee, Nick J.
Spencer, Kent M. Sanders, Terence K. Smith
Background: Rhythmic longitudinal muscle (LM) activity persists in the small intestine of
WWv mice that lack slow waves due to the absence of myenteric interstitial cells of Cajal
(ICC-MY). The overall frequency of LM activity in WWv mice appears to be similar to wild-
type mice, however the coordination of this activity has not been investigated. Aim: We
hypothesized that the lack of a pacemaker network in WWv mice would alter the stability
and coherence of propagating waves of LM activity and associated motor patterns. Methods:
Segments (3-5 cm long) of small intestine were removed, opened along the mesenteric
border and pinned mucosa side down in an organ bath maintained at 36°C and perfused
with Krebs solution. The preparation was loaded with fluo-4 and LM activity was visualized
using an upright microscope and CCD camera. In separate experiments to monitor LM
movements, the mucosa was removed and small surface markers were applied to the circular
muscle (pinned serosal side down) to track the relative movements of the LM using video
imaging. Results: The LM of wild-type mice (n=7) displayed cyclic Ca2+ waves (muscle
action potentials) that propagated in a coherent fashion across the field of view (1 Ca2+
wave per cycle). In contrast, Ca2+ waves in the LM of WWv mice (n=4) propagated
at varying velocities across the field of view and changed direction from wave-to-wave.
Occasionally, a bursting pattern was observed consisting of up to 10 rapid Ca2+ waves per
cycle in WWv mice. Ca2+ waves were blocked with nifedipine (2µM) or nicardipine (1µM),
but were unaffected by atropine (1µM). LM motor activity reconstructed from videos of
surface markers in wild-type mice often showed regular propagating waves of contraction
that traveled for considerable distances along the preparation. LM motor activity in WWv mice
was highly erratic and unstable, consisting of “jerk-like” contractions at random locations.
Conclusion: While LM in the small intestine remains active in mice lacking ICC-MY, there
is little spatio-temporal coordination of this activity. Pacemaker activity in the ICC-MY
network promotes regular, ongoing waves of LM activity/contraction that propagate in an
orderly fashion. Supported by grants from NIH (NIDDK): R01 DK45713 (TKS), DK41315
(KMS) and Core laboratory Cobre grant P20 RR-18751.
616
Kit-Like Immunoreactivity Localizes in the Myenteric Plexus Region of the
Zebrafish Gastrointestinal Tract
Adam Rich, Scott Leddon, Simon Gibbons, Xu Xiaolei, Gianrico Farrugia
Background: Gastrointestinal (GI) motility results from the coordinated actions of enteric
neurons, interstitial cells of Cajal (ICC), and smooth muscle cells. The GI tract of the
zebrafish has a cellular anatomy that is essentially similar to humans. Previous work by our
lab has shown the presence of Kit-like immunoreactivity in the zebrafish GI tract. Kit-like
immunoreactivity has been used extensively to identify ICC in the GI tract of other organisms.
Characterization of the anatomical location of Kit-positive cells within the tunica muscularis
of the GI tract and their relation to enteric nerves and smooth muscle is necessary to classify
these cells as ICC subserving similar functions as ICC in other species. Aims: To determine
the localization of cells displaying Kit-like immunoreactivity and the relationship to enteric
nerves and smooth muscle within the tunica muscularis of the zebrafish GI tract. Methods:
Kit protein expression within the zebrafish tunica muscularis was assessed by immunohisto-
chemistry using the anti c-Kit polyclonal antibody, ab16832 (abcam). GI tissues dissected
from larvae (7 days post fertilization) and from adult zebrafish were fixed in 4% paraformal-
dehyde overnight. Transverse sections (4-8 mm) were cut from paraffin-embedded tissues.
Enteric neurons and smooth muscle cells were specifically identified using anti a tubulin
and anti Hu C/D (Molecular Probes), and SM22 (abcam), respectively. Results: Immunhisto-
chemistry performed on tissue sections with anti a tubulin revealed a population of enteric
neurons between the outer longitudinal layer and the inner circular layer of smooth muscle
cells consistent with the enteric myenteric plexus. Kit immunolabeling showed a cell popula-
tion with Kit-like immunoreactivity in the same region. . Double labeling experiments
revealed Kit positive cells adjacent to enteric neurons and smooth muscle within this layer.
Intramuscular Kit immunoreactive cellswere not observed, and no Kit immunoreactive cells
were observed between the circular layer of smooth muscle cells and the mucosa. Kit-like
immunoreactivity did not co-localize with smooth muscle or neural cell markers. Conclusion:
These data establish the presence of a cell population with Kit-like immunoreactivity in the
myenteric plexus region within the zebrafish GI tract. Cells with Kit-like immunoreactivity
were adjacent to enteric neurons, intercalated between enteric neurons and smooth muscle
cells within the zebrafish GI tract. The anatomical arrangement of these Kit-positive cells
strongly suggest that they are ICC. Supported by NIH DK07158801, NIH-NCRR 12546,
and DK52766, DK57061
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Involvement of Interstitial Cells of Cajal in Gastrointestinal Dysmotility of
Diabetic Db/Db Mice
Takahiro Yamamoto, Kenji Watabe, Masanori Nakahara, Koji Isozaki, Tatsuya Kiyohara,
Syusaku Tsutsui, Shinji Tamura, Yasuhisa Shinomura, Norio Hayashi
[Background] Diabetes mellitus often causes gastrointestinal dysmotility. Neuropathy has
been long considered to be a major cause of the diabetic gastroenteropathy. We examined
the colon from the patients of diabetes mellitus type 2 and found that the number of ganglion
cells did not vary. In contrast, we found that the number of interstitial cells of Cajal (ICCs)
decreased. ICCs are considered to be pacemaker cells for the gastrointestinal movement.
We recently demonstrated that db/db mice (obese due to deficiency for leptin receptor and
develop diabetic mellitus type 2) could be used as a model of diabetic gastroenteropathy.
[Aims] We investigated involvement of ICCs in gastroenteropathy of diabetic db/db mice.
[Methods] 1) Isometric tension was recorded by tension transducer in intestine. 2) ICCs
were detected by fluorescent immunohistochemistry using KIT antibody. The fluorescent
image from circular muscle layer and myenteric plexus region in gastrointestinal tract was
captured on computer and the area of KIT-positive cells for each region was calculated. 3)
Apoptotic cells in gastrointestinal tract were examined by TUNEL assay. 4) mRNA expression
of stem cell factor (SCF) in gastrointestinal tract was examined by quantitative real-time
PCR. [Results] 1) Isometric tension of intestine was irregular in db/db mice when compared
with that of db/+m mice. Since the parameter reflects the autonomic motility, the result
suggests malfunction of ICCs. 2) The area of KIT-positive cells both in circular muscle layer
and myenteric plexus region from stomach, intestine, and colon decreased in db/db mice.
3) There were no apoptotic cells both in circular muscle layer and myenteric plexus region
from stomach, intestine and colon in both db/db and db/+m mice. As control, apoptotic
immunocytes in submucosal layer were observed in these mice. 4) mRNA expression of
SCF from intestine and colon decreased in db/db mice. [Conclusions] Irregular isometric
tension and decreased number of ICCs suggest involvement of ICCs in gastroenteropathy
of diabetic db/db mice. Decrease in the number of ICCs may be attributable to the decrease
in the supply of SCF from the surrounding tissue.
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Jejunal Afferent Hypersensitivity to Mechanical Stimulation in W/Wv Mice
Infected with Trichinella Spiralis
Chris D. Keating, Johanna Wheatcroft, Steve Foley, Gulzar Singh, Arleta Reiff.marganiec,
Chapman Victoria, Andrew Bennett, Charles Marsden, Robin Spiller, David Grundy
Background: Visceral hypersensitivity is one of the hallmarks of post-infectious IBS. Following
Trichinella spiralis infection in mice, there is augmented sensitivity of jejunal afferents
responding at low threshold (LT) and high threshold (HT) levels of distension1. Here, we
investigate the role of mast cells in the mechanisms underlying afferent hypersensitivity
using mast cell deficient W/Wv mice. Methods: Multiunit recordings from mesenteric afferent
bundles supplying in vitro segments of mouse jejunum were made from T. spiralis infected
W/Wv and wild type (WT) littermates (=>25 days post infection), and from uninfected
controls. Data presented as mean±SEM (N≥8) and analysed by one-way ANOVA. Tissue
was also processed for immunocytochemistry to determine enterochromaffin (EC) cell num-
bers. This data is presented as median (n=>3) and compared using Mann Whitney. P<0.05
was taken as significant. Results: The WT response to ramp distension of the jejunum
consisted of a biphasic increase in afferent firing. The WT increase at LT (0-10mmHg) levels
of distension was comparable in the W/Wv animals (42.19±2 imp/s and 35.44±1.7 imp/s
respectively, p>0.05) but was significantly attenuated at HT (30-50mmHg) levels of distension
(11.2±1.4 and 3.4±1.7 imp/s, p<0.01), despite similar pressure-volume curves indicative of
compliance. Following infection in the WT there was significant augmentation at both the
LT (58.0±4.0 imp/s, p<0.05) and HT (17.1±1.3 imp/s, p<0.05) levels of distension, indicating
afferent hypersensitivity. This was associated with an increase in compliance (287.5±22μl
required for a 50mmHg distension pressure in infected WT compared to 200±13μl in
uninfected WT, p<0.05). In contrast, following infection in the W/Wv animals, the hypersens-
itivity to LT distension was absent (36.0±2.75 imp/s, p>0.05) while hypersensitivity in the
HT response while present, was significantly blunted (9.9±1.3 imp/s, p<0.05). Compliance
remained unchanged in the W/Wv animals. EC cell number was elevated in infected WT
animals (151 cells/mm2) compared to the W/Wv (21 cells/mm2, p<0.0001). Conclusion:
Enteric infection with T.spiralis produces a mast cell dependent EC cell hyperplasia, and a
sensitization of mechanosensitive afferent neurons. The LT component of this sensitization
is mast cell dependent, possibly as a consequence of reduced EC cell number, whilst the
HT component appears to be independent of mast cells since it persists, albeit blunted, in
the W/Wv animals. The altered baseline sensitivity in the W/Wv mice may indicate a role
for interstitial cells of Cajal (ICC) in jejunal mechano-transduction. Funded by the BBSRC
1Keating et al., DDW 2005.
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Reduction of Interstitial Cells of Cajal (ICC) in Auerbach’s Plexus in Patients
with Achalasia: New Insights in Pathogenesis
Ines Gockel, Juergen R. Bohl, Volker F. Eckardt, Theodor Junginger
Background. Interstitial cells of cajal (ICC) form neuronal networks which are spread in
submuscular, intramuscular and intermuscular layers of the gastrointestinal tract. They
generate pacemaker potentials determinating the spontaneously electrical and mechanical
activity of smooth muscle cells. There is a close relationship between the c-kit positive cajal
cells and the nitrogen monoxide (NO)-synthetasis as a neurotransmitter of nerve fibres. The
aim of our study was to investigate the significance of interstitial cells of cajal in the plexus
myentericus in patients with primary achalasia. Patients and methods. In 35 patients with
a median age of 55 (14-78) years undergoing surgery for achalasia, staining of the cells of
Auerbach’s plexus was carried out. In 19 patients, biopsies were taken from the high pressure
zone of the lower esophageal sphincter (LES) in the context of a Heller myotomy, whereas
in 11 patients the complete esophagus was resected in patients with end-stage achalasia and
a decompensated megaesophagus. The tissue samples were fixed in formalin, embedded
in paraffin, and investigated microscopically. Apart from conventional staining methods,
immunohistochemical examinations were carried out (n-NOS (=neuronal nitrogen monoxide
synthetasis), neurofilament, smooth muscle antigen, Desmin, CD 117, S 100, B- and T-
lymphocytes, and CD 68). Autopsy samples from patients with normal esophageal function
served as controls. Results. The median duration of symptoms was 10 (0.5-63) years. 14
patients had undergone a pneumatic dilation previously, and 10 patients had had previous
surgery at the lower esophageal sphincter. The preoperative Eckardt score was 6 (3-10).
With a maximum diameter of the esophageal body of 45 (25-60) mm, the radiologically
measured narrowest point at the cardia was 4.5 (1-15) mm. Esophageal manometry displayed
a median LES resting pressure of 24.4 (12-115) mmHg. The present histopathological
examination showed a marked reduction up to a complete absence of the ICC in the area
of the high pressure zone of the esophagus. Staining with the antibody n-NOS points at a
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reduced neurotransmission in the LES. Conclusion. The present results suggest that in the
pathogenesis of achalasia, especially in the development of the high pressure zone, the
deficient or missing function of the cells of cajal play an important role. The associated
reduction of the NO-synthetasis, therefore, is possibly responsible for the lack of relaxation
of the LES, on account of the missing inhibitory neurotransmission. The reduction of the
cajal cell-function also seems to be of relevance even if the cells of Auerbach’s plexus
are unscathed.
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Natural Orifice Transluminal Endoscopic Surgery (NOTES) Cholecystectomy:
A Transcolonic Survival Study in a Porcine Model
Reina D. Pai, Derek G. Fong, Douglas S. Fishman, David W. Rattner, Christopher C.
Thompson
Background and Aim: Transgastric cholecystectomy has been reported in two non-survival
studies which detail substantial technical limitations and only a 33% success rate when
limited to one gastric exit site despite the use of a multiple channel locking endoscope. The
aim of this study was to demonstrate feasibility and evaluate technical limitations of a
transcolonic approach to cholecystectomy. Methods: Under general anesthesia, adult York-
shire pigs were prepped with multiple tap water enemas, per-anal instillation of an antibiotic
and betadine rinse, and external betadine scrub. A sterile dual-channel endoscope
(Olympus™) was introduced through the anus and advanced through a 2 cm, anterior,
trans-colonic incision created by a needle knife approximately 15 - 20 cm from the anal
verge. Upon completion of intra-abdominal exploration and identification of all major upper
abdominal organs, the cystic duct and artery were dissected and ligated with endoclips.
Dissection of the gallbladder away from the liver was achieved using hot biopsy forceps,
snare tip, prototype endoscopic scissors and an insulated-tip needle knife. The gallbladder
was successfully removed with hot snare cautery. The gallbladder fossa was then lavaged with
sterile water, re-examined and additional cautery or endoclips were applied for hemostatsis or
closing of defects. At the conclusion of each procedure, the colonic incision was closed
using endoloops and/or endoclips. Results: The animals were survived for two weeks
followed by elective termination and necropsy. Four of the five animals flourished in the
post-operative period demonstrating appropriate feeding and activity patterns as well as
stable weights or weight gains. The colonic incision site in all 4 animals healed completely,
however external adhesions were appreciated. In the last animal complete closure of the
colonic incision site was not possible and a small 4mm residual defect remained. The animal
was survived for 48 hours but then sacrificed due to concerns of peritonitis. Pathology from
all 5 subjects subsequently confirmed the resected organs as gallbladders. Conclusions:
The transcolonic approach provides improved visual exposure of the gallbladder and scope
stability when compared to the transgastric approach. This study demonstrates the technical
feasibility of transcolonic organ resection via a single incision. The one complication appeared
secondary to inadequate incision closure and not related to the organ resection. For this
approach to be translated to humans, a sterile conduit, secure closure device and better
instruments for triangulation are necessary.
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Endoscopic Anastomotic Reduction After Roux-en-Y Gastric Bypass Surgery: A
Potential Treatment for Weight Regain
Derek G. Fong, David B. Lautz, Christopher C. Thompson
Background and Aims: The mechanisms leading to weight regain after Roux-en-Y Gastric
Bypass (RYGB) are not clearly understood. Dilation of the gastrojejunal (GJ) anastomosis is
a structural complication of the surgical pouch that may contribute to weight regain. The
aim of this study was to examine our experience with endoscopic anastomotic reduction to
effect weight loss after RYGB surgery. Methods: Between November 2003 and June 2005,
thirty-eight endoscopic anastomotic reductions were performed at our institution. These
procedures were performed using a Bard EndoCinch suturing device in conjunction with
argon plasma coagulation, fibrin sealant, and tissue excoriation with a cytology brush. Fifteen
patients with six month follow-up data were identified and included in this analysis. Patients
with other upper GI pathology and early iterations of technique were excluded. Results:
The GJ anastomotic size prior to reduction ranged from 15 to 30 mm in diameter (mean
size 23.4 mm) with the post procedure size ranging from 2 to 15 mm in diameter (mean
size 6.57 mm). Eleven of the patients lost weight following the procedure while four of the
patients did not experience any weight change and one patient experienced weight gain.
Mean percent excess weight loss at six months ranged from a gain of 9.6% to a loss of
56.8% (percent mean excess weight loss 14.2%). Three of the patient’s who did not lose
weight were found to have dilation of their GJ anastomosis at follow-up endoscopy and a
second reduction was performed within eight months of the initial procedure. Two of the
patient’s who did not lose weight were known to be noncompliant with dietary restrictions.
There were no serious complications from the procedure. Symptomatic complaints from
the procedure were self limited and included sore throat, abdominal discomfort, and nausea.
Conclusions: Endoscopic anastomotic reduction may be a useful treatment option for weight
regain in selected patients after RYGB. Endoscopic anastomotic reduction appears feasible
and safe, and is associated with variable weight loss. The durability of weight loss and
the need for subsequent anastomotic reductions will need to be explored with additional
prospective randomized studies.
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Transcolonic Endoscopic Abdominal Exploration
Derek G. Fong, Reina D. Pai, Christopher C. Thompson
Background and Aims: Although a transcolonic endoscopic approach to access the peritoneal
cavity has been previously described by our group, the ability to systematically identify
abdominal organs with animal survival has not been reported. The aim of this study was

















in a survival study design. Methods: Six female Yorkshire pigs weighing 25 to 30 kg were
used in this study. Under general anesthesia, the rectum was lavaged with multiple tap
water enemas. After endoscopic confirmation that the distal colon was free of particulate
matter, a cefazolin suspension was instilled for 10 minutes followed by a betadine lavage.
Colonic incision was performed over the anterior colonic wall at a distance of 15 cm to 20
cm from the anus. A sterilized Olympus upper endoscope was then passed through the
incision and endoscopic abdominal exploration was performed. The incisions site was closed
using endoscopic clips, endo-loops, as well as a novel closure device. Results: The peritoneal
cavity was accessed through the colonic incision without difficulty. The stomach, liver,
gallbladder, spleen, small bowel, and colon were identified in all of the animals in under
3 minutes. The lower pelvic organs were not consistently visualized. All of the animals
survived 14 days without apparent sequelae before elective sacrifice. At necropsy, the colonic
incision sites were completely closed and well healed from the luminal surface. From the
serosal aspect, salpingocolonic and cystocolonic adhesions were identified in 5 of 6 animals.
The develpment of adhesions are in contrast to our previous findings with transgastric
endoscopy. There was no evidence of organ injury or peritonitis. Conclusions: This study
demonstrates the ability of transcolonic abdominal exploration to successfully evaluate major
organs in the upper abdomen. In contrast to the transgastric route, a transcolonic approach
provides en face orientation to organs in the upper abdomen and allows for better visualization
and scope stability. Therapeutic interventions in the upper abdomen including organ resec-
tion may therefore be technically easier using a transcolonic approach.
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Usefullnes of Endoscopic Mucosal Resection As a Final Diagnostic Method in
Gastroesophageal Dysplasias and Carcinomas
Mario Rey
Objective: comparing initial biopsies taken from mucosal tumor lesions with the final result
of pathology in mucosectomy. Materials and Methods: 66 patients aged 53.3 old on average,
seen to be suffering from 69 mucous lesions by endoscope, were prospectively analyzed;
15 lesions in the esophagus and 54 gastric lesions having an average diameter of 12.7 mm
were found. A minimum of 5 biopsies were taken of each lesion; once histological diagnosis
had been made, they were removed by endoscope with submucosal infiltration, using
endoscopic snare, plastic cap, overtube or IT endoscopic knife. Biopsies and mucosectomies
were pathologically classified into being benign, low or high dysplasia and carcinoma and
compared to a Spearman’s correlation index. Esophageal lesions were type IIa and IIb,
around 5 to 20 mms in diameter, half of them being associated with Barrett’s esophagus;
76.4% were localized in the antral part of the stomach. Results: 12 benign lesions were
confirmed as were 26 low grade dysplasias, 17 high grade dysplasias and 14 carcinomas;
biopsies had 65.2% correlation (p<0.001) with 18.4% over-diagnosis and 15.9% under-
diagnosis with a 72.4 Spearman coefficient of correlation. Biopsy in esophageal lesions
revealed a moderate 69.6% correlation (p<0.01) with 33.3% over-diagnosis. Better correlation
was obtained in the stomach (87.1%, p<0.001) with 14.8% over-diagnosis and 14.8% under-
diagnosis. Discussion: as serious intra-mucous dysplasias and carcinomas continue to be
surgically treated in our area, then establishing that biopsies do not have 100% correlation
with final pathology having greater over-diagnosis could lead to esophagectomies or gastrec-
tomies being practiced on lesser lesions having secondary surgical morbidity-mortality.
Conclusions: this article shows that esophageal biopsies in premalign and malign mucosal
lesions are only slightly correlated with final pathology, their scores improving in the stomach.
Mucosectomy has been shown to be an extremely useful diagnostic tool for surgical decision-
taking regarding this type of lesion.
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Anxiety and Depression Predict the Likelihood of a Functional GI Disorder
(FGID) Separately from Their Relationship to Somatization
Gregory S. Sayuk, Jill E. Elwing, Patrick J. Lustman, Ray E. Clouse
Psychiatric disorders (PSY), particularly anxiety and depression, are common comorbidities
among patients with FGID. Recent studies have shown that somatization (SOM), the reporting
of multiple unexplained somatic symptoms, may be responsible for the high rates of PSY
in FGID patients via symptom-reporting tendencies, reducing their primary importance. We
examined an outpatient clinic sample to determine if PSY and SOM had independent ability
to predict FGID diagnoses or whether these features shared a common pathophysiology.
Methods: 417 consecutive new outpatient referrals (age 45.9±1.4 yr, 98% caucasian, 62%
female) to an academic gastroenterology practice from January 2003 to January 2005 were
evaluated. Systematic record review was used to determine diagnosis, presence of PSY
(recorded anxiety or affective disorder), and degree of SOM; degree of SOM was determined
from recent (2 wk) symptom endorsement on a review-of-systems check-list and number
of GI and non-GI functional diagnoses recorded in the medical history. High degree of SOM
was present if >7 key SOM symptoms (based on the PHQ-15) were endorsed on the check-
list. Subjects were categorized by primary diagnosis (FGID or structural) after having been
followed for 3.5 ±0.2 mo to confirm correct categorization. Logistic regression analysis was
used to determine independent predictors of primary diagnosis controlling for potential
clinical/demographic confounders. Results: 270 (64.7%) had a FGID primary dx and 147
(35.3%) a structural GI illness. IBS was the most common FGID dx (29.6%). FGID pts were
more likely female (70.4% vs. 46.9%; p=0.002) but were of similar age as structural GI
illness pts (46.2±1.2 vs. 45.6±1.2 yr; p=0.74). Both PSY and high degrees of SOM were
more common in FGID patients (34.1% vs. 13.6%, p=<0.001; and 41.9% vs. 12.7%, p<0.001,
respectively). The logistic regression analysis revealed that both PSY (OR 2.8; 95%CI 1.3-
5.7; p<0.01) and high degree of SOM (OR 3.7; 95%CI 1.9-7.0; p<0.001) independently
predicted the presence of a FGID over a structural GI illness. A similar analysis using number
of GI and non-GI functional illnesses for the SOM measure confirmed the independent
contribution of PSY and SOM to a FGID diagnosis (p<0.01 for each). In each model, female
sex had predictive value for FGID independent of PSY and SOM effects. Conclusions: Both
PSY (anxiety and depression) and SOM are common in patients with FGID, and each
independently predicts the likelihood of a functional over structural GI disorder in the
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outpatient setting. Anxiety and depression thus share a relationship with FGID that is not
solely dependent on their linkage to SOM.
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Pain and Depression Predict Improved Health-Related Quality of Life in
Severe IBS Treated with Psychotherapy of Antidepressant
Francis Creed, Elspeth Guthrie, Joy Ratcliffe, Lakshmi Fernandes, Barbara Tomenson,
Nicholas Read, David Thompson
Objective We have reported previously long-term improved health-related quality of life in
patients with severe irritable bowel syndrome (IBS) following treatment with an antidepress-
ant or psychotherapy (1). In this study we assessed the relative importance of improved
pain or depression in this finding. Method We assessed 257 patients with severe IBS before
treatment and 239 one year after the end of treatment (75 psychotherapy, 85 Paroxetine
and 79 treatment as usual) using a visual analogue scale (VAS) of abdominal pain and the
Hamilton Depression Rating Scale (HDRS). Linear regression was used to predict change in
SF36 physical component score. Structural equations modelling using AMOS tested whether
baseline depression (HRSD) score predicted follow-up VAS pain score and vice versa. Results.
Preliminary analyses confirmed that VAS pain and HDRS depression scores represented well
the dimensions of pain and depression experienced by participants in our sample. Linear
regression analysis to predict 1 year follow-up SF36 physical component score (health-
related quality of life) indicated that pre-treatment VAS pain (p<0.001) and HDRS depression
scores (p=0.005) and change (follow-up minus baseline) of VAS pain (p<0.001) and HDRS
depression scores (p=0.006) were all significant independent predictors. Structural equation
modelling including baseline and follow-up scores of VAS pain and HDRS depression showed
that the overall fit of the model was excellent, chi2=2.06, df=3, p=0.56, chi2/df=0.69,
RMSEA<0.0005 and CFI=1.000. The standardised regression coefficients for baseline to
follow up depression score and VAS pain were 0.36 (p<0.005) and 0.38 (p<0.005), respect-
ively, demonstrating that each follow up variable is predicted by its own baseline value.
The standardised regression coefficient for baseline VAS pain predicting follow-up HRSD
was also significant (chi2=0.15, p=0.02), but that for baseline HRSD predicting follow-up
VAS pain today was not (chi2=0.09, p=0.16). Addition to the model of psychotherapy and
SSRI antidepressant treatments as additional variables did not change the model and the
same model fits the data in each of the 3 treatment groups, when these were analysed
separately. The model held when only patients who also had a psychiatric disorder were
included. Conclusion: In patients with severe IBS receiving psychological treatments, both
improved pain and depression influences later health-related quality of life but change in
depression is not primarily responsible for this result. Other aspects (eg coping with pain
and its attribution) are likely to be involved. (1) Gastroenterology 2003; 124 :303-17.
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Effect of Corticotropin-Releasing Hormone Receptor Antagonist On the Brain
Activation By Colonic Distention in Healthy Subjects and Patients with
Irritable Bowel Syndrome
Shin Fukudo, Toyohiro Hamaguchi, Michiko Kano, Yasuhiro Sagami, Tomotaka Shoji,
Yuka Endo, Masatoshi Itoh, Kazuhiko Yanai, Michio Hongo, Motoyori Kanazawa
Background & Aims: Determining substance that plays a key role in brain-gut interactions is
a crucial step for clarifying pathophysiology of irritable bowel syndrome (IBS). We previously
reported that peripheral administration of CRH antagonist, alpha-helical CRH (ahCRH),
improves visceral stimulation-induced increase in colonic motility, abdominal pain, and
anxiety in IBS patients (Gut 2004;53:958-64) and that peripheral administration of CRH
receptor-1 antagonist selectively induces similar phenomena in IBS model rats (Gastroenterol-
ogy 2005;129:1533-43). We tested our hypothesis that peripheral administration of ahCRH
modifies brain activation to the colonic distention in normal subjects and IBS patients.
Methods: Subjects were 20 healthy subjects and 10 IBS patients. This study was approved
by the Ethics Committee and all subjects gave the written informed consent. Barostat bag
was inserted to the descending colon with colonoscope. The intracolonic bag was intermit-
tently inflated for 3 min with no (0 mmHg), mild (20 mmHg), or intense (40 mmHg)
stimulation with random order. The same procedure was repeated after the intravenous
injection of either placebo in a control subjects (n = 10) or ahCRH (10 microg/Kg) in the
other control subjects (n = 10) and IBS patinets (n=10). Radioactive H2[15-O] saline was
injected at the bag inflation and positron emission tomography was performed. Changes in
rCBF were analyzed using statistical parametric mapping 2. Results: In controls with
20mmHg-colonic distention, administration of ahCRH significantly inhibited increase in
rCBF at the anterior cingulate cortex (BA32), mid cingulate cortex (BA24), and prefrontal
cortex (PFC) compared with that of placebo (p<0.0001). In controls, the rCBF with 40
mmHg-colonic distention after the administration of ahCRH was significantly less in the
right PFC (BA9) than that after the administration of placebo (p<0.0001). IBS patients
showed significantly greater activation in the brain stem to the 20 mmHg and 40 mmHg-
distention than controls (p<0.0001). Significantly more activated brain regions with 40
mmHg-distention between placebo and ahCRH treatments in IBS patients than that (placebo
vs ahCRH treatments) in controls were right anterior insula, right PFC (BA11), and left
parahippocampal gyrus. Conclusion: These data suggest functionally crucial role of CRH in
limbic and prefrontal cortices during normal and abnormal visceral perception. Moreover,
they may provide rationale of therapeutic challenge for IBS using agents that modify CRH tone.
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Effects of Hypnotherapy On IBS in Different Clinical Settings - Results from
Two Randomized, Controlled Trials
Perjohan Lindfors, Peter Unge, Einar S. Bjornsson, Annika Stenman, Patrik Arvidsson,
Hasse Abrahamsson, Magnus Simren
Hypnotherapy is considered to be effective in patients with irritable bowel syndrome (IBS).
Few randomized, controlled trials exist, and most of the data originate from centers highly
specialized in this kind of treatment (Whorwell et al 1984). To be more widely spread the
effects of this costly treatment alternative need to be further evaluated in clinical practice.
Here we report the results from two randomized, controlled trials on hypnotherapy in IBS
in different clinical settings. METHODS: We included 135 patients with IBS refractory to
standard management (107 females; mean age 41 (21-68) years). Study 1 was performed
in a university hospital specialized in functional GI disorders (n=87) and study 2 in a
county hospital (n=48). In both studies patients were randomized to receive gut-directed
hypnotherapy 1 h/week for 12 weeks performed by specially trained psychologists, or to
serve as control group. At baseline, immediately after the treatment period and after 6 and/
or 12 months the treatment effect was evaluated with questionnaires assessing quality of
life (IBSQOL / SF-36), anxiety and depression (Hospital Anxiety and Depression (HAD)
scale) and GI symptoms (Gastrointestinal Symptom Rating Scale (GSRS)-IBS / GI symptom
questionnaire). RESULTS: GI symptoms severity improved after the treatment period in the
hypnotherapy group in both study 1 (Cumulative GI symptom score 29±6.9 vs. 26±7.3
(mean±SD); p=0.002) and study 2 (GSRS Total score 4.0±0.9 vs. 3.4±0.9; p=0.03), but not
in the control groups, respectively. The improvement was more pronounced for abdominal
pain, distension and bloating than for the bowel habits. At the one year assessment the
improvement was sustained or even enhanced. Anxiety and depression was improved at
one year in study 2 compared with baseline (HAD anxiety 8.5±4.7 vs. 6.3±4.5; p=0.009;
HAD depression 6.0±3.1 vs. 4.2±2.8; p=0.005), but no such effect was noted in the hypno-
therapy group in study 1 or in the control groups. In both studies we observed clear
tendencies towards a better quality of life in the hypnotherapy groups, but not in the control
subjects. The total responder rate, in terms of significant improvement of GI symptoms,
was higher in the hypnotherapy groups vs. the control groups (52% vs. 32%; p=0.03)
CONCLUSION: In these two randomized controlled trials we have demonstrated that hypno-
therapy is a useful treatment alternative with long-term effect in IBS patients refractory to
standard management. Hypnotherapy can successfully be conducted in different clinical
settings, also outside the highly specialized gastroenterology centers focused on functional
GI disorders.
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Sex-Specific Differences in a Brain Network Functioning During Anticipation
of Rectal Discomfort in Irritable Bowel Syndrome Patients (IBS)
Jen Labus, Emeran A. Mayer, Steve Berman, Brandall Suyenobu, Lin Chang, Bruce D.
Naliboff
Background: IBS is a chronic functional disorder characterized by abdominal pain associated
with altered bowel habits. Evidence supports significant sex-related differences in the auto-
nomic and perceptual response to aversive visceral stimuli in IBS patients. This study aimed
to identify and characterize a functional brain network consistent with sex-related differences
in general arousal and enhanced threat responsiveness. Methods: 48 IBS patients (24 females)
received H215O PET scans during three conditions: resting baseline (BL), rectal distension
and ANT. Multivariate task partial least squares (PLS) tested for distributed patterns of brain
activity associated with changing condition demands. Seed PLS was used to identify sex-
related and unrelated distributed patterns of activity that were functionally connected with
the amygdala, an area that previously has shown sex-dependent activation during anticipation
and experience of rectal distension. Based on apriori hypotheses, known neuroanatomical
connectivity, and seed PLS results, we specified an amygdala mediated general arousal circuit
and tested the effective connectivity of this network using a stacked structural equation
modeling approach. Results: Task PLS revealed a significant functional pattern of
regions(p<.001)that optimally separated baseline from anticipation and included bilateral
amygdala, prefrontal cortex (PFC) and anterior cingulate cortex (ACC). Seed PLS identified
2 significant networks: one functioning similarly across sex, and another that evidenced sex-
specific functioning. The sex-common amygdala network included the thalamus, dorsolateral
PFC[Brodmann Area 9/46], rostral ACC[32/24], hippocampus, and mid/posterior insula.
The sex-dependent amygdala network included ventro/dorsomedial PFC[10], perigenual
ACC subregions[32/24/25] and pontine regions. Significant differences in the strength of
the functional connections (effective connectivity) were found in well-characterized amygdala
modulatory circuits, including amygdala efferents to the pons, midbrain, and infragenual
ACC and afferent input to the amygdala from the supragenual ACC. Conclusions: During
anticipation of rectal discomfort, male patients show normal feedback inhibition within a
network circuit involving infra- and supra-genual ACC, and amygdala resulting in a suppres-
sion of limbic activity. In contrast, female patients show strong connectivity between amygdala
and infragenual ACC, but not in feedback inhibition, resulting in stronger infragenual ACC
activation. These results are consistent with a greater female responsiveness of a circuit
regulating amygdala reactivity to emotionally salient stimuli.
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Is Abdominal Distension Related to Delayed Small and Large Bowel Transit in
Patients with Constipation Predominant Irritable Bowel Syndrome (IBS-C)?
Anurag Agrawal, Peter J. Whorwell, Lesley A. Houghton
Background and Aim: Patients with IBS-C often have slow gastrointestinal (GI) transit (1)
and exhibit a diurnal increase in abdominal girth (i.e. abdominal distension) that is related
to a feeling of progressive bloating (2). The aim of this study was to investigate whether
IBS-C patients with delayed GI transit exhibit greater abdominal distension and more severe
bloating than do patients with normal transit. Methods: Abdominal girth was recorded for
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24 hours using the validated technique of Ambulatory Abdominal Inductance Plethysmogra-
phy (3) in 27 IBS-C (Rome II) patients, aged 18-68 years (3 male) and 24 healthy volunteers
(HV), aged 21-58 years (3 male). Within 2 weeks of this recording, both small (SBT) and
large (LBT) bowel transit were assessed. SBT was determined from the rise in breath hydrogen
after a standard meal (4), and LBT from the number of 3 differently shaped radio-opaque
markers (24 of each ingested on 3 consecutive days) identified on plain abdominal X-ray
72 hours after ingestion (5). The severity of abdominal bloating was also assessed on a scale
of 0-3, where 3 = severe. Results: As anticipated, IBS-C patients reported more severe
abdominal bloating (IBS: 2.00 (1.73, 2.26), mean (95% CI) v HV: 0.33 (0.07, 0.59); p<0.001),
and exhibited greater abdominal distension (change in girth from the beginning to end of
day: 3.8cm (2.2, 5.5)cm v 0.46cm (-1.1, 2.0) cm; p=0.007) and slower LBT (52 markers
(45, 58) markers v 35 markers (28, 42) markers; p=0.003) but not SBT (330 min (291,
368) min v 293 min (262, 325) min; p=0.35) compared with HV. Using the 97.5 percentile
for LBT in HVs (i.e. > 59 markers), 48% of IBS-C patients had delayed LBT and these
patients exhibited greater abdominal distension (5.3cm (3.7, 6.9) cm) than those with normal
LBT (2.4cm (-0.1, 5.0) cm; p=0.03). Furthermore, there was a direct relationship between
LBT and the degree of abdominal distension in IBS-C patients (r=0.51, p=0.006). There was
no difference in bloating severity between patients with (2.00 (1.60, 2.39) and without
(2.00 (1.61, 2.38): p=0.63) delayed LBT. Conclusion: IBS-C patients with delayed large
bowel transit have greater abdominal distension than those with normal transit. Drugs that
accelerate transit may therefore be expected to alleviate this often troublesome problem.
Refs: (1) Gut 1983; 24: 404-11; (2) Gut 2004; 53 (Suppl III): A114; (3) Gut 2001; 48:
216-20; (4) N Engl J Med 1969; 28: 122-7; (5) Gastroenterol 1987; 92: 40-7.
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Effect of 2 Weeks Furazolidone- Or 2 Weeks Metronidazole- Or Combination
of 1week Furazolidone+ 1 Week Metronidazole-Based Anti Helicobacter Pylori
Regimens in Peptic Ulcer: A Randomized-Controlled Multicenter Trial
Y Ajvadi, R Malekzadeh, S Nasseri-Moghaddam, N E Daryani, H Vahedi, N Zendehdel, R
Sotoudehmanesh, S Agah, J Mikaeli, A Pourshams, M Khatibian, A Ali Asgari, Sadegh
Massarrat
Background:Metronidazole or Clarithromycin combined with Amoxicillin, a Bismuth com-
pound and Omeprazole are commonly used to treat Helicobacter pylori (HP). There is a high
bacterial resistance to Metronidazole and high cost for Clarithromycin. Iranian studies show
that Furazolidone is effective against HP, with no resistance, but intolerable side-effects are
common in 2weeks therapy. We compared efficacy and side-effects profile of three different
anti-HP regimens with 1 or 2 weeks Furazolidone administration. Materials and Methods:
Consenting, HP positive peptic ulcer patients were randomly allocated in three groups.
Group 1 received Omeprazole 20mg BID+ Amoxicillin 1 g BID + Furazolidone 200 mg BID
+ Bismuth-subcitrate 240 mg BID for 2 weeks. Group 2 received the same but Furazolidone
was replaced with Metronidazole 500 mg BID. Group 3 received regimen 1 for the first
week and regimen 2 for the 2nd week. Patients were followed at weeks 2 and 10. Compliance
and side-effects were checked at week 2. 13C Urea breath test (UBT) at week 10 verified
HP eradication. Results: 314 patients were enrolled, 299 followed at week 2 and 276 took
the UBT. There were 100, 102, and 97 patients in groups 1-3 respectively. Seven, 3, and
6 patients discontinued medication prematurely in groups 1-3 respectively. Side-effects were
more common in group 1 (7 patient with high fever, 10 vomiting and 19 weakness) than
group 2 (4 with fatigue) and group 3 (1with fever, 7 fatigue, and 4 vomiting) (p<0.05). Per
protocol eradication rates were 95.2%, 83.1% and 95.3% in groups 1 to 3 respectively (p=
0.005). Intention to treat eradication rates were 87.0%, 74.5%, and 86.6% in groups 1-3
respectively (p=0.02). Conclusion: Furazolidone given for one week followed by Metronida-
zole has the same efficacy for HP eradication as Furazolidone for 2 weeks with fewer side
effects. Furazolidone-based regimens are superior to Metronidazole based ones.
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One-Week Once-Daily Triple Therapy with Esomeprazole, Moxifloxacin and
Rifabutin Is Effective in the Treatment of Helicobacter Pylori Resistant to Both
Metronidazole and Clarithromycin
Stephan Miehlke, Wulf Schneider-Brachert, Andrea Morgner, Ahmed Madisch, Christian
Kirsch, Elke Baestlein, Christian Haferland, Claus Jebens, Holger Knoth, Manfred Stolte,
Norbert Lehn
Objectives: Failure of standard triple therapy aiming at eradication of H. pylori often leads to
post-treatment resistance to metronidazole (MET) and/or clarithromycin (CLA). Subsequent
treatment of these patients remains a clinical challenge. We evaluated the efficacy and
tolerability of a convenient triple therapy using esomeprazole, moxifloxacin and rifabutin
for eradication of H. pylori resistant to both MET and CLA in a prospective open-label study.
Methods: Consecutive patients with H. pylori infection resistant to both MET & CLA (Etestâ)
were treated with esomeprazole 40 mg, moxifloxacin 400 mg and rifabutin 300 mg, each
given orally once daily in the morning for 7 days. Follow-up endoscopy including histology
and H. pylori culture was performed 6 to 8 weeks after treatment. Results: Between January
2004 and October 2005, 86 patients were enrolled (56 female, 30 male, median age 52
years. 62 patients (72.1%) had a history of two or more previous treatment failures. Three
patients (3.5%) discontinued treatment prematurely due to adverse events). 73 patients
(85%) are currently available for per protocol efficacy analysis. Successful eradication was
confirmed in 58 patients (79.5 %). In the patients with clinical failure (n=15), post-treatment
resistance to the test drugs rifampicin and ciprofloxacin were detected in 5 and in 3
patients, respectively. Conclusion: One-week once-daily triple therapy with esomeprazole,
moxifloxacin and rifabutin is effective and safe for eradication of H. pylori resistant to both


















Three and Seven Days Levofloxacin/Azithromycin-Based Triple Therapies As
First-Line Treatment for Helicobacter Pylori Eradication
Rosalba Finizio, Enrico C. Nista, Marcello Candelli, Giovanni Cammarota, Giovanni
Gasbarrini, Antonio Gasbarrini
Background and aim: The failure of first-line anti-H.pylori therapies is due to primary
antibiotic resistance and poor compliance. For this reason it is essential to investigate new
antibiotic associations and simple therapeutic schemes. Levofloxacin and azithromycin are
broad spectrum antibiotics with long half life administrable in single daily dose that could
increase patients compliance. Aim of the study is to compare the efficacy of a 3- and 7-
days levofloxacin/azithromycin based H. pylori eradication regimen against standard 7-days
triple therapy. Material and methods: Ninenty Hp-positive patients (infection was assessed
by histology and 13-C UBT) were randomized to receive: Group A (30 pts): levofloxacin
(500 mg od), azithromycin (500 mg od) and esomeprazole (20 mg bid) for 3 days; Group
B (30 pts): levofloxacin (500 mg od), azithromycin (500 mg od) and esomeprazole (20 mg
bid) for 7 days; Group C (30 pts) clarythromicin (500 mg bid), amoxicillin (1 gr bid) and
esomeprazole (20 mg bid). Hp status was re-checked by 13-C UBT six weeks after end of
therapies. Results: H. pylori eradication rate in Group A was 86.7% (26/30 pts), in Group
B was 93.3% (28/30 pts), in Group C was 70% (21/30) in either ITT or PP analysis.
Eradication rate of 7-days levofloxacin/azithromycin-based triple therapy was significantly
higher than that observed using standard triple therapy (93.3% vs 70%; p<0.05). Eradication
rate of 3-days levofloxacin/azithromycin-based triple therapy was higher even if not signific-
antly than that showed by standard therapy (86.7% vs 70% p=0.06). Incidence of side
effects were lower in groups A and B than in group C. Moreover, prevalence of side effects
resulted higher in the group B than in group A. Conclusions: According to the present data
a 7-days levofloxacin/azithromycin-based triple therapy may be considered a high effective
therapy for H. pylori eradication.
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Analysis of Effects and Costs of Gatifloxacin, rabeprazole Or Lansoprazole-
Based Triple Therapies in Eradication of Helicobecter Pylori Infection in China
Yingqiang Zhong, Zhongsheng Xia, Qikui Chen, Zhiyong Zeng
OBJECTIVE: The resistance of H. pyroli to antibiotis is more and more severe. Clinically,
it is an essential problem of soluting the resistance of H. pyroli to antibiotics to find
newer and more effective antibiotic agent. Gatifloxacin is a new and fourth- generation
fluoroquinolone, and has comfirmed broad spectum and activity of antimicrobial agent, and
lower adverse drug reactions. The present study investigates the effects and costs, adverse drug
reactions of gatifloxacin, rabeprazole or lansoprazole-based triple therapies on eradicating
Helicobacter pyroli (H. pyroli), so as to find the best one of the schemes. METHODS:
Grouping and contrast study were used in present study, and pharmaco- economics was
analysed in the ratio of cost and effect (C/E) of the schemes. 175 patients of primary
eradication of H. pyroli were randomized into group A,B,C,D, and 17 patients of second
eradication of H. pyroli were into group E. The drugs of group A were gatifloxacin (200mg,
bid), metronidazole (0.4g, bid) and lansoprazole (30mg, bid); Group B were gatifloxacin
(400mg, qd), metronidazole (0.4g, bid) and lansoprazole (30mg, bid); Group C were gatiflox-
acin (400mg, qd), metronidazole (0.4g, bid) and rabeprazole (10mg, qd); Group D was a
control of clarithromycin (0.5g, bid), metronida-zole (0.4g, bid) and lansoprazole (30mg,
bid); and scheme of group E was similar as group A. RESULTS: Eradication rate of H. pyroli
was 90%, 91.4%, 91.7%, 84.4% in group A, B, C, D respectively. There were not significant
differences among group A, B, C and D (P>0.05). Eradication rate of H. pyroli was 82.4%
in group E. The primary total eradication rate and total eradication rate of H. pyroli with
gatifloxacin was 90.1% and 89.8% respectively. The mainly adverse drug reactions were
nausea, poor appetite, abnormal taste and dizzy of head. A few of reactions were mild
diarrhea and lumbago, and few was some rash. There was not phototoxicity, hepatotoxicity
and renal toxicity in the objects, but there was transient mildly hyperglycemia. The rate of
adverse drug reaction was 12.5%, 22.9%, 27.8%, 39.1%, and 25% in the group A+E, B,
C, D and total population respectively. The lowest rate was in group A+E. There were
significances among group A+E, C and D (P<0.001), and there was not significance between
group B and C (P>0.05). The ratio of C/E was 3.44, 3.38, 2.77, 4.39, 3.75 and 3.45 in
group A, B, C, D, E and all groups of gatifloxacin respectively. CONCLUSIONS: Gatifloxacin
is a most effective drug of eradicating H. pyroli infection, and has lower adverse drug
reactions. Among these schemes, group A and B were better, and group C is best.
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In Children Eradication of Helicobacter Pylori Does Not Promote
Gastroespophageal Reflux Disease: A Multichannel pH-Impedance Study
Osvaldo Borrelli, Caterina Anania, Letizia Cordischi, Felicia Galos, Marina Aloi, Manuela
Cirulli, Valeria Labalestra, Valentina Mancini, Salvatore Cucchiara
Background. Conflicting data on the relationship between Helicobacter Pylori (H. pylori)
infection and gastroesophageal reflux disease (GERD) have been reported, and only few
studies on this issue have been performed in children. Aim. We aimed at assessing the effect
of eradication of H. pylori on both acid and non-acid esophageal exposure, as measured
with 24-hr multichannel intraluminal impedance and pH (MMI-pH) monitoring in children
without reflux esophagitis. Patients and Methods. 17 consecutive patients (pts) (median
age:10.2 years; range: 4-15) with H.Pylori infection and no reflux esophagitis were enrolled
into the study. Diagnosis was performed by endoscopy with histology and 13C-urea breath
test. MMI-pH monitoring was performed before and 8 weeks after eradication of H.Pylori,
which was achieved using standard triple therapy (omeprazole, amoxicillin and clarithromy-
cin for 14 days) and confirmed by 13C-urea breath test. The MII-pH parameters evaluated
were: total numbers of reflux episodes (TN), numbers of acid reflux episodes (AR), numbers
of non-acid reflux episodes (NAR), % of time with esophageal pH < 4 (ARI), numbers of
long-lasting (> 5 min) acid reflux episodes (LAR) and acid clearance time (ACT)(sec).
Esophageal acid exposure was considered abnormal when 24-hour ARI was > 5%. Results
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(mean±SD). At baseline ARI was abnormal only in 8 pts; MII-pH TN, AR, NAR, ARI,
LAR and ACT were 62.59±31.92, 41.2±21.3, 20.9±19.8, 4.9±3.1, 2.0±2.3 and 87.1±48.9
respectively. After H. Pylori eradication, there was no significant change in all MII-pH
parameters evaluated (TN: 61.7±35.5; AR: 43.7±27.8; NAR: 17.9±14.6; ARI: 5.2±4.1; LAR:
2.6±2.4; ACT: 101.9±35.1; NS). Of the 8 pts with abnormal ARI, the latter became normal
in 4 and persisted abnormal in 4 (in 2 with a reduction of the acid exposure); of the 9 pts
with normal baseline ARI the latter became abnormal only in 2. Conclusions. In children
with H.Pylori infection, eradication of the organism is not associated with significant change
in the pattern of gastroesophageal reflux. Our results fail to show a positive association
between anti-H. Pylori therapy and occurrence of de novo GERD
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Signs of H Pylori Infection in Autoimmune Atrophic Gastritis Patients By
Immunoblotting
Edith Lahner, Annalisa Santucci, Dino Vaira, Amelia Pasquali, Roberta Mini, Natale
Figura, Gianfranco Delle Fave, Bruno Annibale
Background: Two mechanisms are generally considered able to induce atrophic body gastritis
(ABG): autoimmunity and H pylori infection. The most characteristic clinical presentation
of autoimmune ABG is pernicious anemia (PA). No sign of H pylori infection is detectable
in about 30% of ABG patients, who are thus considered having autoimmune ABG. Western
blotting permits an accurate exposure classification to H pylori infection. Aim: to assess the
strength of H pylori-ABG relationship by using immunoblotting against specific H pylori
antigens to detect past H pylori exposure in patients with autoimmune ABG. Methods: Case-
series consisted of 138 ABG outpatients, classified as autoimmune when histology and ELISA
serology were negative, and as H pylori-related, when histology and ELISA serology were
positive (active infection) or only serology was positive (past infection). Immunoblotting
against H pylori-specific antigens (CagA, VacA, HspB, UreA and UreB) was performed.
Results: 22.5% of patients had autoimmune ABG, 21% had H pylori-related ABG with
active infection and 56.5% with past infection. All autoimmune ABG patients showed
immunoblotting seroreactivity against at least one of the H pylori-specific antigens. The
number of mean seroreactive antigens of autoimmune ABG patients was similar to those of
patients with past H pylori infection (3.6±0.2 vs 3.5±0.1 ns), but lower than that of patients
with active infection (4.3±0.2, p<0.001). Seroreactivity against CagA and VacA antigens was
not different between the three groups (80.6% and 93.5% of autoimmune patients; 86.2%
and 96.6% in active and 67.9% and 89.7% in past H pylori infection, respectively). Some
classic features of gastric autoimmunity, as PA and corpus-restricted atrophy were observed
more frequently among patients with autoimmune ABG, whereas others as positivity to
autoantibodies against parietal cells and intrinsic factor and the association of other autoim-
mune diseses were similarly distributed among patients with autoimmune and H pylori-
related ABG. Conclusions: H pylori immunoblotting reveals a close relationship between H
pylori and autimmune ABG, suggesting a misclassification of exposure and an underestimation
of infection in this condition.
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Intestinal T-Cell Responses to Gluten-Derived Peptides Reveal a Large
Repertoire and a Hierarchy of Gluten Epitopes in Adult HLA-Dq2-Positive
Celiac Patients
Alessandra Camarca, Robert P. Anderson, Gianfranco Mamone, Mauro Rossi, Gaetano
Iaquinto, Nicola Giardullo, Salvatore Auricchio, Riccardo Troncone, Carmen Gianfrani
Background: The identification of gluten peptides eliciting intestinal mucosa lesions in coeliac
patients has crucial importance for the design of immunological therapies that may augment
or replace gluten-exclusion. Methods: We have analysed intestinal T cell responses from 10
adult, HLA-DQ2+ celiac patients (3 untreated, mean age 29.3 years range 30-34; 7 treated,
mean age 29.1 range 18-36) to a panel of 21 gliadin (glia) and glutenin (glt) synthetic
peptides including: the known alfa-glia 33-mer (57-89)[1], its truncated peptides 13-mer
(56-68)[2], 17-mer (57-73)[3] and 3 related polymorphysms, 18-mer (71-89[4] and 25-
mer (64-89)[4], the glia20[5], glu-5[5], the gamma-glia peptides: DQ2-gamma-I[5], DQ2-
gamma-II[5] and an elongated 14-mer analogue (105-118)[4], DQ2-gamma-III[6], DQ2-
gamma-IV[6] DQ2-gamma-V[6], 14-mer (173-186)[4] and glt-1565 peptides. Furthermore,
immune responses against two novel peptides, DQ2-omega-1 and glt19-23, and the innate
immunity eliciting alfa-glia 31-49 were also assessed. Gliadin-specific, long-term T cell lines
(TCL) were obtained by cyclic stimulation of intestinal mononuclear cells with a peptic-
tryptic digest (PT) of gliadin and IL-15 as growth factor. Both proliferation and gamma-
IFN production were analyzed in response to either native or tTG-deamidated peptides
(30ug/ml). Autologous or HLA-DQ2-matched allogeneic EBV transformed-B cell lines were
used as APC. Results: Each patient recognized a different set of peptides. Only 5 out of 10
(50 %) of patients recognized 33-mer and all its truncated peptides; 4 of them responded
also to DQ2-omega-1, which was recognized by an overall of 5/10 patients, gamma-peptides
were recognized by no more than 3 individuals. No response was found to glia20, glu-5,
glt19-23, glt-156 and 31-49. The TCL from one patient was unresponsive to all peptides,
although it responded very well to PT-gliadin. Interestingly dose curve responses indicate
that both 17-mer and 25-mer were as potent as 33-mer in stimulating T-cells. Conclusion:
iTCLs from adult HLA-DQ2+ CD patients have diverse specificities for gluten peptides, as
previously reported for children patients and confirmed that repertoire of active gluten
peptides is larger than previously appreciated. Focusing the exact repertoire of peptides
relevant for CD pathogenesis and their hierarchy would be of great impact for CD therapy.
[1]Shan L. et al. Science 2002; 297:2275 [2]Arentz-Hansen H. et al. J. Exp. Med 2000;
191:603 [3]Anderson RP. et al. Nat Med 2000; 6:337 [4]Mamone G. et al. FEBS Letters
2004; 562:177 [5]Vader W. et al. Gastroenterology 2002;122:1729 [6]Arentz-Hansen H. et
al. Gastroenterology 2002; 123:803
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Role of CXCR3 in Gliadin-Mediated Zonulin Release and Increased Intestinal
Permeability
Julie Brownley, Ruiliang Lu, Anna Sapone, Bao Lu, Craig Gerard, Stefanie N. Vogel,
Alessio Fasano
Background/rationale: The autoimmune process of Celiac Disease (CD) is triggered by gliadin
ingestion. Our previous studies have shown that gliadin triggers release of an intestinal tight
junction regulator, zonulin, which is associated with an increase in intestinal permeability.
These effects are observed only when gliadin was added to the mucosal side of the intestine,
suggesting that the protein exerts its effects by interaction with an intestinal luminal receptor.
Aims: To establish whether the effect of gliadin on intestinal permeability and zonulin release
is mediated by interaction of gliadin with an intestinal luminal receptor and to investigate
the identity of this receptor. Methods: Soluble membrane preparations obtained from rabbit
small intestine were loaded on an Affi-gel 15-α-gliadin affinity column, incubated for 90
min, washed with PBS containing 0.1% Triton X-100, and eluted with PBS containing 0.1%
Triton X-100 with increasing NaCl concentrations. Fractions were collected and subjected
to SDS-PAGE and mass spectroscopy analysis. Ex vivo experiments to measure zonulin
release and intestinal transepithelial electrical resistance (TEER) changes in response to
gliadin exposure were performed using mouse small intestine mounted in microsnapwell
chambers. Results: Three main proteins with estimated molecular weights of 93, 100, and
107 kDa, were eluted from the gliadin affinity column following adsorption of solubilized
intestinal plasma membrane preparations. The bands were subjected to MALDI mass spec
fingerprint analysis and the 100 kDa band was identified as the chemokine receptor CXCR3.
To determine if CXCR3 plays a role in gliadin-induced increase in intestinal permeability,
ex vivo animal studies were conducted on both CXCR3 knock out (KO) and C57BL/6 wild-
type (WT) mouse intestinal tissues mounted in microsnapwells. When exposed to gliadin,
intestinal segments obtained from WT mice (n=8) released zonulin (0.34±0.06 vs. 0.61±0.13
ng/mg protein, baseline vs. post-gliadin exposure, respectively; p<0.04) and showed a
significant TEER decrement (130.9±24.7 Ω.cm2 vs. 80.1±17.6, baseline vs post-gliadin
exposure, respectively; p<0.02). Conversely, intestinal segments obtained from CXCR3 KO
mice (n=18) exposed to gliadin failed to release zonulin (0.36±0.14 vs. 0.18±0.04 ng/mg
protein, baseline vs. post-gliadin exposure, respectively; p = N.S.) and showed no TEER
changes (129.1±25.8Ω.cm2 vs. 109.2±27.1, baseline vs. post-gliadin exposure, respectively;
p N.S.). Conclusions: Our data suggest that CXCR3 is a component of the intestinal gliadin
receptor and is responsible for zonulin release and increased intestinal permeability.
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Enteric Glial Protein S100-Beta Modulates Intestinal Mucosa Inflammation in
Celiac Disease
Esposito Giuseppe, Carla Cirillo, Daniele De Filippis, Giovanni Sarnelli, Alessandro
Iacono, Francesco Paolo D'Armiento, Teresa Iuvone, Rosario Cuomo
The enteric nervous system (ENS) is involved in the homeostasis of the whole gastrointestinal
tract. Enteric glia, as part of the ENS, controls the physiological release of neurotrophic
factors and participates to the inflammatory responses in animals. In the central nervous
system increased expression of astroglial derived S100β protein has been recently associated
with the onset and maintaining of inflammation. The role of enteric glial-S100β protein in
the gastrointestinal inflammation has never been investigated in humans. We aimed to
evaluate the role of S100β protein in patients with celiac disease that is a well characterized
gut chronic inflammation. Duodenal biopsies from 30 patients with celiac disease (15
untreated and 15 on gluten-free diet) and 10 controls were evaluated for S100β protein
expression, the iNOS expression and nitrite production. To further test whether S100β was
able to modulate the inflammation, biopsies deriving from controls were stimulated for 3-
6-24 hours with exogenous purified S100β (0.005-5 μM) and iNOS protein expression and
nitrite were measured. Also, lipid peroxidation and p38-MAPkinase activation were evaluated
by adding S100β alone or in the presence of specific inhibitor of p38-MAPkinase and NF-
kappa B transcription factor, SB203580 and TLCK, respectively. Results. In untreated celiac
patients the S100β protein expression, the iNOS protein expression and nitrites were signific-
antly increased respectively by 399±7.1%, 2537±20% and 247±7.3% as compared to celiacs
on gluten-free diet and controls. In cultured duodenal biopsies derived from healthy subjects,
incubation with S100β induced a 40 fold increase of iNOS expression and a concentration-
dependent increase of the nitrite production [65.5±2.5, 213.8±4.8, 397.4±9.0, 749±12.6%].
The effect of S100β (5 μM) on lipid peroxidation was significantly inhibited by increasing
concentration of both SB203580 (0.03; 0.3; 3 μM) [29.7±4.1, 49.3±3.5, 72.6±5.8%] and
TLCK (0.01; 0.1; 1 μM) [49.3±4.8, 66.0±5.1, 80±4.4%]. We found for the first time that
S100β is increased in the duodenum of patients with celiac disease. This protein seems to
modulate duodenal inflammation through induction of iNOS protein expression and nitrite
production via p38-MAPkinase activation. Finally, our data highlight the importance of glial
cell activation in pathophysiology of celiac disease and more extensively of gastrointesti-
nal inflammation.
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Challenge of HLA-Dr4, -Dq8, Human CD4 Triple Transgenic NOD Mice with
Gliadin in Complete Freund’s Adjuvant, Followed By Oral Gluten
Tobias Freitag, Grete Sonderstrup, Detlef Schuppan
Introduction: Celiac disease (CD) is a malabsorptive syndrome caused by an uncontrolled
immune reaction to ingested gluten proteins. Untreated, CD patients can develop serious
secondary morbidity, such as T cell lymphoma and autoimmune diseases. We aim to develop
an in vivo animal model in which non-dietary therapies can be tested. CD is strongly
associated with HLA-DQ2 and -DQ8, suggestive of a connection to the CD4 T cell compart-
ment of the immune system. The design of our model is therefore based on HLA-DQ8,
associated -DR4 alleles and human CD4 (huCD4). Methods: 4 groups of mice (n=7-8; 16-
24 weeks) transgenic for HLA-DR*0405/DQ8/huCD4, HLA-DQ8/huCD4, HLA-DR*0401/
DQ8/huCD4 or HLA-DR*0401/huCD4 were kept on a gluten-free diet from birth. 4 mice/
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group were immunized with 100μg gliadin/CFA i.d. and with 50μg gliadin/IFA on day 14.
From day 14, all mice were fed a diet containing 3g of crude gluten/kg. On days 56-60,
organs and serum were collected. Splenocytes of individual mice were submitted to red cell
lysis and re-suspended at 5x106 cells/ml in complete RPMI 1640 containing 10μg/ml gliadin,
ovalbumine or 3μg/ml anti-mouse CD3 antibody. After 48 and 72h of culture, supernatants
were harvested. Results: Mice remained normal over the course of the study. All groups of
immunized mice developed high anti-gliadin IgG serum titers, without significant differences
between the groups with the highest (serum dilution 20,931-fold; HLA-DQ8/huCD4) and
lowest (15,810-fold; HLA-DR*0401/huCD4) levels, while titers in non-immunized mice as
well as anti-gliadin IgA levels remained low. IgG2c and IgG1 serum titers did not show
significant differences between groups. Production of IgG2c was greater than IgG1 in all
groups. Interferon γ production in response to gliadin reached high levels, from 12,670
(HLA-DR*0401/DQ8/huCD4) to 24,315 pg/ml (HLA-DR*0401/huCD4) at 48h, in all
immunized mice. IL-10 levels ranged from 816 (HLA-DQ8/huCD4) to 1882 pg/ml (HLA-
DR*0401/huCD4), and IL-2 from 177 (HLA-DQ8/huCD4) to 745 pg/ml (HLA-DR*0401/
DQ8/huCD4). There was no significant production of IL-4. Cytokine levels at 72h were
invariably lower. While histological analysis of various organs is ongoing, the small intestine
was normal. Conclusions: Splenocytes of mice transgenic for HLA-DQ8, HLA-DR*0401,
HLA-DR*0401/DQ8 and HLA-DR*0405/DQ8 respond with a Th1 pattern to gliadin re-
challenge after immunization with gliadin/CFA and oral gluten challenge. The mice do not
develop small intestinal lesions. In order to further develop this humanized animal model
of celiac disease, modifications of antigen challenge or the depletion of regulatory T cells
may have to be tested.
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A 35mer Peptide with T Cell Stimulatory Activity Comparable to Whole
Gliadin: A Lead Compound for Peptide Immunotherapy in Celiac Disease?
Jason A. Tye-Din, Tim Beissbarth, Robert P. Anderson
Celiac disease (CD) is an HLA-associated enteropathy driven by dietary gluten that is mediated
by CD4+ T cells specific for diverse gluten peptides. Studies in other human immune and
infectious diseases indicate that antigen-specific immunotherapy and T-cell diagnostics for
CD are likely to utilize peptides that are efficiently and consistently recognized by the
majority of gluten-specific T cells in CD. Using comprehensive gluten peptide libraries we
have established a hierarchy of gluten peptides with T cell stimulatory activity. AIM: To
compare the T cell stimulatory activity of peptides encompassing strings of epitopes (“combi-
topes”) with prolamin fractions from grains toxic in CD. METHODS: Subjects with biopsy
proven HLA-DQ2 CD on a gluten free diet consumed either wheat bread 200 g/d (n=17),
rye bread 100g/d (n=17) or barley grains 150g/d (n=17) for three days. Peripheral blood
mononuclear cells (PBMC) collected six days after commencing gluten challenge were incub-
ated in interferon-γ ELISPOT assays with deamidated prolamins (100mcg/ml), the immuno-
dominant wheat α-gliadin peptide QLQPFPQPELPYPQPQP, (which includes two overlap-
ping T-cell epitopes PFPQPELPY and PQPELPYPQ) (50mcg/ml), the relatedω-gliadin peptide
immunodominant after rye or barley ingestion (QPEQPFPQPEQPFPWQP) (50mcg/ml), and
a 35mer peptide (20mcg/ml) encompassing these α- and ω-gliadin sequences as well as a
γ/ω-gliadin sequence occasionally dominant in HLA-DQ2 CD. RESULTS: PBMC ELISPOT
responses to peptides were expressed as a percent of an individual’s response to whole
deamidated prolamins. Subjects who had a significant response (>3x medium alone & >10
spots/well) to gliadin after wheat challenge (15/17), hordein after barley (13/17) or secalin
after rye (13/17) responded to the 35mer combitope. Following wheat gluten challenge
respective responses to the combitope, p57-73 and DQ2-ω-I were 87±11% (mean±SEM),
51±5% and 63±6%. Following barley challenge they were: 88±11%, 16±10%, 73±5%, and
following rye: 80±11%, 20±6% and 70±12%. CONCLUSIONS: The number of peripheral
blood T cells that recognize a 35mer combitope is equivalent to over 80% of the total T
cell response to deamidated prolamins after in vivo exposure to wheat, rye or barley. This
finding indicates substantial redundancy of gluten peptides with T cell stimulatory activity,
and simplifies design of peptide immunotherapy and diagnostics.
662
Intestinal Dendritic Cells in Celiac Disease
Antonio Di Sabatino, Karen M. Pickard, John N. Gordon, M R. Beattie, Giovanni
Monteleone, Tom T. MacDonald
“Background & Aims”: T-cell activation largely depends on the delivery of costimulatory
signals from intestinal dendritic cells (DC) which act as sentinels for incoming food or
bacterial antigens. To identify the changes in DC that may underlie the dysregulated T-cell
response to gluten in celiac disease (CD), we examined coeliac lamina propria DC in terms
of phenotype, activation/maturation state and cytokine production, and investigated the in
vitro effects exerted on DC by the immunodominant (p57-68) and the non-immunodominant
(p31-43) gliadin epitopes, the latter of which is supposed to activate the innate immune
system. “Methods”: DC were identified in lamina propria mononuclear cells isolated from
untreated CD patients and controls by multicolor flow cytometry as an HLA-DR+ lineage-
population. Plasmacytoid (CD123) and myeloid (CD11c) receptors, together with activation
(CD80/CD86) and maturation (CD83) markers were assessed by flow cytometry. In situ
distribution of DC was investigated by confocal microscopy. IFN-γ, IL-5, IL-12p40, IL-18,
IL-23p19 and TGF-β transcripts were analysed by RT-PCR in sorted DC. After 24-h culture
with p31-43 or p57-68 or TNF-α, CD83 and HLA-DR expression on DC and COX-2 levels
in duodenal biopsies were respectively assessed by flow cytometry and immunoblotting.
“Results”: A significantly higher number of plasmacytoid DC were found in active CD than
in controls. DC from untreated CD patients expressed significantly higher levels of maturation/
activation molecules, and expressed greater IL-18 and IL-23 transcripts. CD83 and HLA-
DR expression on coeliac DC were increased after incubation with TNF-α, but not p31-43
or p57-68. Organ culture experiments failed to show an increase in mucosal COX-2 levels
after treatment with either p31-43 or p57-68. “Conclusions”: In active CD, lamina propria
DC are activated and express higher number of transcripts of pathologically relevant cyto-
kines. The non-immunodominant gliadin epitope appears to have no effects on DC matura-


















ELF Phosphorylation By TβRi and Cyclin Dependent Kinases in Cos-7 and
Hepg2 Tumor Cell Lines
Nady Golestaneh, Eugene A. Volpe, Jyotshna Kanungo, Stephen R. Evans, Bibhuti Mishra,
Harish Pant, Lopa Mishra
TGF-β can induce growth inhibition responses during cell cycle progression and escape
from this response is a hallmark of many cancer cells. Previously, we demonstrated that
TGF-β induces phosphorylation and association of ELF (embryonic liver fodrin) with Smad3
and Smad4 resulting in nuclear translocation. However the precise kinases and receptors
by which ELF is phosphorylated remain to be determined. Upon phosphorylation, ELF
binds to Smad3 and Smad4, the complex translocates to the nucleus and induces the
transcription of downstream genes. Strong evidence implicates the TGF-β signal transduction
in suppression of gastric carcinogenesis. Mice that carry a heterozygous disruption of Smad4
or elf/Smad4 present increased gastric tumors. Aims: 1. To determine the TβRs involved in
ELF phosphorylation. 2. To study the role of CDKs in ELF phosphorylation and identify
the specific CDK that preferentially phosphorylates ELF. Methods and Results: 1. Cotransfec-
tion of Cos-7 cells with ELF and TBR constructs followed by immunoprecipitation, using
specific p-ELF antibody raised against S804 revealed that constitutively active TbRI and
TbRI receptors significantly phosphorylate ELF, whereas dominant negative TbRII and TβRII
do not phosphorylate ELF. Coimmunoprcipitation of ELF and TβRs revealed a robust band
confirming the interaction of TbRI with ELF. A weak interaction was also observed between
ELF and TβRII. However this interaction does not result in ELF phosphorylation 2. Co-
transfection of HepG2 tumor cells with ELF/(SBE)4-Lux and TβRI/ (SBE)4-Lux constructs
in the presence or absence of TGF-b and TbRI kinase inhibitor (SB 431542) was followed
by Luciferase reporter assay. The results revealed that TGF-β-induced transcriptional activity
of ELF and TβRI was inhibited up to 3-fold and 6-fold respectively in the presence of 1mM
of inhibitor and further increase in inhibitor concentration did not significantly affect this
inhibition. 3. Cotransfection of the COS-7 cells with ELF/CDK4 or CDK5 followed by
immunoprecipitation revealed that CDK4 and CDK5 both phosphorylate ELF. However,
immuoprecipitation results confirmed direct interaction of CDK4 with ELF whereas CDK5
did not show an interaction. Conclusion: 1.Our results suggest that TβRI is required for
ELF phosphorylation and this phosphorylation occurs through direct protein interaction.
Furthermore, TGF-β downstream transcriptional activity requires an active TbRI kinase.
2.CDK4 and CDK5 phosphorylate ELF. The phosphorylation of ELF by CDK4 occurs through
direct protein interaction. Further studies are required to fully understand the role of CDK
phosphorylation of ELF mediating TGF-β signaling pathway
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Insulin-Like Growth Factor Binding Protein-3 Regulates Esophageal Epithelial
Cell Homeostasis Through Negative Regulation of Insulin-Like Growth Factor
Signaling
Munenori Takaoka, Takaomi Okawa, Claudia D. Andl, Carmen Z. Michaylira, Meenhard
Herlyn, Hiroshi Nakagawa
Introduction: Esophageal epithelial homeostasis is thought to be regulated by multiple
growth factor-mediated signaling pathways. We have recently found that growth factor
deprivation induces insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) and that
IGFBP-3 is subject to negative regulation by EGF in the esophageal epithelial cells (Takaoka
M et al. Am J Physiol. In press). However, the regulatory role of IGFBP-3 in esophageal
epithelial proliferation remains to be elucidated. Methods: Human esophageal cells were
grown in serum free medium containing bovine pituitary extract, insulin, and EGF. IGFBP-
3 was stably transduced with a retroviral vector. To reconstitute the stratified squamous
epithelium in vitro (organotypic culture), esophageal cells were seeded upon a type I collagen
matrix containing human skin fibroblasts, and exposed to the liquid-air interface. Gene
expression was determined by enzyme-linked immunosorbent assay and Western blotting.
Western ligand blotting with 125I-IGFs was performed to determine the IGFBP-3 binding
affinity. Cell proliferation was assessed by 3H-thymidine incorporation assay. Cell cycle was
analyzed by flow cytometry. The glucose level was measured by colometric glucose oxidiza-
tion reaction. Results: IGFBP-3 was highly secreted in conditioned media of wild-type or
mutant (I56G/L80G/L81G) IGFBP-3 transduced cells (1.5-2 µg/ml) compared with control
cells (2-10 ng/ml). Ectopically expressed wild-type IGFBP-3, but neither the mutant IGFBP-
3 lacking the binding affinity to IGF, nor empty vector greatly suppressed activation of IGF
receptor and AKT by IGF-I, resulting in the impaired G1/S progression with concomitant
failure of induction of pRB phosphorylation, 60-70% reduction in cell proliferation, and
decreased cellular glucose uptake by 30%. By contrast, insulin fully activated IGF receptor
and stimulated cell proliferation regardless of the IGFBP-3 level, implying the lack of negative
regulation by IGFBP-3. In organotypic culture, wild-type IGFBP-3 severely impaired epithelial
formation of the esophageal cells induced by IGF-I, which was rescued by physiologically
exceeding level of insulin. Apoptosis did not occur in IGFBP-3 overexpressing esophageal
cells for at least 24 hours even in growth factor deprived condition as cleavage of Caspase-
3, a sub-G1 fraction and nuclear chromatin condensation were not observed. Conclusions:
These results suggest that IGFBP-3 plays a critical role in the regulation of esophageal
epithelial formation through inhibition of IGF-I-mediated mitogenic effects and glucose
metabolism, and underscore the role of IGF, rather than insulin, in esophageal epithelial
homeostasis.
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Prostaglandin E2 Stimulates Intestinal Epithelial Proliferation and Migration
Through Activation of Intestinal Subepithelial Myofibroblasts
George G. Sheng, Jinyi Shao, Randy C. Mifflin, Don W. Powell, Hongmiao Sheng
Cyclooxygenase-2 (COX-2) and its derived prostaglandins (PGs) play critical roles in intestinal
inflammation and neoplasia. It has been shown that PGE2 stimulates intestinal epithelial
proliferation and neoangiogenesis. Intestinal subepithelial myofibroblasts (ISEMF) are the
major stromal cell type in both hyperplastic and neoplastic colonic polyps which express
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COX-2 and generate PGE2. In the present study, we show that PGE2 activated ISEMF
through Gs protein-coupled EP receptors and the cAMP/PKA pathway. Both primary colonic
myofibroblast (CMF) isolates and an established myofibroblast cell line (18Co) expressed a
number of growth factors including amphiregulin (AR) and hepatocyte growth factor (HGF).
PGE2 exposure robustly increased the expression of AR mRNA in 18Co cells and CMF
cultures which normally did not express AR. Levels of AR protein were increased > 10-fold
in PGE2-stimulated 18Co and CMF conditioned media. As a result, 18Co cells stimulated
the proliferation of intestinal epithelial cells (RIE) in a co-culture system in which RIE cells
were grown in Transwell and 18Co cells were grown in the bottom chamber. Neither PGE2
nor 18Co cells stimulated the proliferation of RIE cells; however, PGE2-activated 18Co cells
increased DNA synthesis of RIE cells by ~ 100%. Addition of anti-AR neutralizing antibody
significantly attenuated the growth advantage of RIE cells that were stimulated by PGE2-
treated 18Co conditioned media, indicating the mitogenic effect of 18Co cell-generated AR.
Furthermore, PGE2 robustly induced the expression of HGF. HGF protein was detected in
18Co culture media at a concentration of ~ 0.4 ng/ml. Addition of PGE2 increased the levels
of HGF protein ~ 5-fold by 24 h. In a modified Boyden Chamber Assay, PGE2 did not
stimulate the migration of RIE cells and the cells which migrated through the polycarbonate
membrane retained a cuboidal appearance. Placing 18Co cells in the bottom chamber
significantly increased the motility of RIE cells. However, when activated by PGE2, 18Co
cells strongly stimulated the migration of RIE cells; the number of migrating cells increased
by ~100%. It was noted that the migrating RIE cells acquired a widely stretched morphology
when co-cultured with PGE2-activated 18Co cells. Addition of anti-HGF neutralizing anti-
body completely blocked the PGE2/18Co-induced RIE cell migration. These results suggest
that autocrine or paracrine PGE2 may stimulate intestinal myofibroblasts to release growth
factors which provide a pro-neoplastic microenvironment for the transformation of intestinal
epithelial cells.
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Azoxymethane Protects Intestinal Stem Cells and Reduces Crypt Epithelial
Mitosis Through a COX-1 Dependent Mechanism
Courtney W. Houchen, Terrence Riehl, Robert George, Mark Sturmoski, Brian
Dieckgraefe, Shrikant Anant
Colorectal cancer is characterized by distinct genetic, morphological, and cellular events.
The transformation of a normal mucosal epithelial cell to an invasive colorectal carcinoma
occurs via a well-coordinated accumulation of mutations in a series of critical genes. In the
gut, tumorigenesis is thought to arise specifically in the stem cell population located at or
near the base of intestinal and colonic crypts. Azoxymethane (AOM) is a potent DNA
damaging agent and carcinogen that induces intestinal and colonic tumors in rodents. The
present study examined the role of cyclooxygenase 1 and 2 in the early response of intestinal
stem cells to treatment with AOM. Methods: Wild type (WT ) 10-wk old (C57BL/6J) mice
COX-1-/- and COX 2-/- mice on the C57BL/6J background, were treated with AOM (10
mg /kg body weight I.P.) . Changes in COX-1, COX-2 mRNA and protein as well as
prostaglandin E2 (PGE2) were determined at 8 hours after AOM. AOM induced apoptosis
and changes in crypt epithelial mitosis were also assessed. The ability of intestinal crypt
stem cells to survive 12 Gy whole body g-irradiation (IR) in treated mice was assessed using
a modification of the clonogenic microcolony assay 3.5 days after IR. AOM was administered
8 h prior to irradiation. Identification of apoptotic cell death, 8h after AOM, was assessed
using morphologic criteria on hematoxylin and eosin stained sections and confirmed by
TUNEL methods. Results: AOM elicited a COX-1 dependent (2.5 fold) increase in intestinal
stem cell survival. Mice treated 2h before AOM with indomethacin (1.5 mg/kg) but not the
COX-2 specific inhibitor NS-398 (1mg/kg), failed to exhibit increased stem cell survival.
Furthermore, AOM treatment increased stem cell survival (4-fold) in COX-2 -/- mice but
not COX-1 -/- mice confirming an essential role for COX-1 in AOM induced radioprotection.
COX-1 mRNA, protein and COX-1 derived PGE2 were increased 8h after AOM treatment.
WT mice receiving AOM exhibited increased intestinal crypt apoptosis and a simultaneous
reduction in crypt mitotic figures compared to untreated controls. There were no significant
differences in baseline or AOM induced intestinal crypt epithelial apoptosis between WT
and COX-1-/- mice but there was a complete reversal of the AOM mediated reduction in
mitotic figures in COX-1-/- mice. Conclusions: These data suggest that alteration of the cell
cycle is an important component of the PGE2 dependent stem cell survival response.
Demonstration that AOM elicits a COX-1 dependent stem cell survival response may provide
insight into the role of prostaglandins in the early phase of intestinal tumorigenesis in
response to DNA damage.
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The Colorectal Cancer Tumor Suppressor Krüppel-Like Factor 4 Is Anti-
Apoptotic in Response to γ Radiation-Induced DNA Damage
Amr M. Ghaleb, Vincent W. Yang
BACKGROUND: Studies indicate that the tumor suppressor p53 is crucial in mediating
either cell cycle arrest or apoptosis in response to DNA damage. How a cell decides which
of the two pathways to follow is not well understood. We previously demonstrated that the
putative colorectal cancer tumor suppressor, Krüppel-like factor 4 (KLF4), is a critical
mediator for the cell cycle checkpoint functions of p53 after γ radiation-induced DNA
damage at both the G1/S and G2/M transitions [Yoon et al. (2003) JBC 278, 2101; Yoon
and Yang (2004) JBC 279, 5035]. AIM: To determine whether KLF4 plays a role in modulating
apoptosis following DNA damage caused by γ irradiation. METHODS: We examined the
responses of the following derivatives of two human colon cancer cell lines and of mouse
embryonic fibroblasts (MEFs) to γ irradiation: RKO (wild type for p53 and containing
negligible endogenous KLF4 levels), EcR/RKO-KLF4 (containing an inducible exogenous
KLF4 under the control of the insect hormone, ecdysone); HCT116 KLF4/sh2-2 (with
significantly reduced KLF4 levels due to interference by small hairpin (sh) RNA), HCT116
KLF4/sh-vector control; MEF KLF4+/+ (wild-type for KLF4 alleles) and MEF KLF4-/- (null
for KLF4 alleles). Cells were irradiated with 12 Gy of γ ray, or not, and maintained in
culture for 3 days before analyses. TUNEL staining, cell cycle profile analysis, Western
blot, luciferase reporter and chromatin immunoprecipitation (ChIP) assays were conducted.
RESULTS: Following γ irradiation, apoptosis was evident in RKO and uninduced EcR/RKO-
KLF4 cells but was significantly reduced in EcR/RKO-KLF4 cells treated with ecdysone to
induce KLF4. Western blot analyses showed that while levels of p53 and Bax were increased
in RKO and uninduced RKO-KLF4 cells by irradiation, those of KLF4 and p21 didn’t.
Treatment of EcR/RKO-KLF4 cells with ecdysone resulted in increased KLF4 and p21 levels
that were accompanied by a reduction in both Bax levels and in apoptosis following irradi-
ation. Similarly, in response to γ irradiation, high levels of apoptosis were noted in HCT116
KLF4/sh2-2 cells and MEF KLF4-/-, but not in HCT116 KLF4/sh-vector and MEF KLF4+/
+ controls, respectively. ChIP and reporter assays showed that KLF4 bound to the Bax
promoter and inhibited the ability of p53 to transactivate the promoter. CONCLUSION:
Results of this study suggest that KLF4 exhibits a surprising and unexpected anti-apoptotic
function following DNA damage and may therefore be involved in cell fate decision. Potential
mechanisms by which KLF4 accomplishes this task are by inducing expression of p21,
known to be an inhibitor of apoptosis, and by suppressing Bax expression.
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Galectin-3 Loss Leads to Pten Down-Regulation and Acquisition of Trail-
Resistance in Human Colon Cancer Cells
Nachman Mazurek, Yun Jie Sun, Kai-Feng Liu, Robert S. Bresalier
Background: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) plays an
important role in immune surveillance, suggesting a potential role in cancer therapy. Resist-
ance to TRAIL-mediated apoptosis in cancer cells may, however, limit the success of TRAIL-
therapy. We have reported that galectin-3 (GAL3), a beta-galactoside binding lectin, plays
a key role in rendering TRAIL-sensitivity to breast carcinoma cells through induction of
PTEN and deactivation of the PI3K/Akt survival pathway. AIM: Identify the molecular
mechanisms responsible for TRAIL-resistance in human colon cancer cells. Methods: Human
colon cancer cell lines LS174T and LiM6 were used as model systems. TRAIL-induced
apoptosis was assessed using a flow cytometry based TUNEL assay and PARP cleavage. The
effects of GAL3 and PTEN on TRAIL signaling were examined by transient tranfection of
GAL3, and knockdown experiments using GAL3- and PTEN- specific short interfering RNAs
and pharmacological inhibitors of PI3K. Results: Exposure of LS174T or LiM6 to TRAIL
resulted in 90% apoptotic cell death. The residual TRAIL-resistant cells (LS-R, LiM6-R) were
propagated and maintained under TRAIL selective pressure. Exposure of resistant cells to
TRAIL failed to activate caspase-8, indicating that the acquisition of TRAIL-resistance occurred
upstream to caspase-8, at the assembly of the death-induced signaling complex (DISC).
Western blot analysis, immunohistochemistry and confocal microscopy revealed a marked
decrease in GAL3 protein expression accompanied by PTEN-loss and concomitant Akt
phosphorylation in LS-R and LiM6-R cells compared to the parental TRAIL-sensitive cells.
Silencing of GAL3 in parental LST147 and LiM6 cells resulted in a decrease in PTEN
expression, increased Akt phosphorylation, and conferred TRAIL-resistance. Silencing of
PTEN in parental cells elicited responses similar to those observed in GAL3 knockdown
cells without decreasing GAL3 protein expression, suggesting that GAL3 acts upstream to
PTEN. Overexpression of GAL3 in LS-R and LiM6-R cells increased PTEN expression,
decreased Akt phosphorylation, and induced TRAIL sensitivity. TRAIL sensitivity was also
induced by PI3K inhibitors. TRAIL resistance associated with GAL3 and PTEN loss was not
mediated by an increase in intracellular levels of members of the DISC nor by caspase-8 or
its inhibitors. Conclusions: These results further identify GAL3 as a novel regulator of PTEN,
and suggest that the acquisition of TRAIL-resistance in human colon cancer cells may be
due to nonfunctional assembly of the DISC mediated by loss of GAL3. This may have
implications for treatment of TRAIL-resistant tumors.
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Substance P Mediates Anti-Apoptotic Pathways Through Akt/Protein Kinase B
Activation in Human Colonic Epithelial Cells
Hon Wai Koon, Dezheng Zhao, Yanai Zhan, Mary P. Moyer, Charalabos Pothoulakis
Background and Objectives: Substance P (SP) participates in intestinal inflammation via
binding to the G-protein coupled neurokinin-1 receptor (NK-1R). Previous reports showed
that apoptosis is evident in the colonic mucosal epithelium of rats with dextran sulfate-
induced colitis. Here we determined whether SP stimulates anti-apoptotic pathways in
colonic epithelial cells. Methods: Human non-transformed NCM460 colonocytes stably
transfected with the human NK-1R (NCM460-NK-1R cells) were used for this purpose.
MTS assay, TUNEL assay, and PARP cleavage were used to detect apoptosis. Results: SP
(10-7M) exposure, time-dependently induced Akt phosphorylation that was evident at 10
min. Pretreatment with the PI3K inhibitor LY294002 (10 μM) or the Jak2 inhibitor AG490
(100 μM) blocked SP-induced Akt phosphorylation. However, blockade of ERK1/2 and p38
by PD98059 (25 μM) and SB203580 (20 μM), respectively, did not affect SP-stimulated
Akt phosphorylation. Tamoxifen is a well-established inducer of apoptosis, and its effect is
mediated by mitochondrial damage and oxidative stress. We found that tamoxifen (10 uM)
exposure induced loss of cell viability (MTS assay) and PARP cleavage (Western blot analysis)
in colonocytes, while co-administration of SP (10-7M - 10-9M) rescued tamoxifen-induced
loss of cell viability and PARP cleavage. SP also reduced tamoxifen-induced nuclear DNA
fragmentation evaluated by TUNEL assays in situ. Pharmacological inhibition of PI3K and
Akt reversed SP-mediated anti-apoptotic responses on tamoxifen-induced PARP cleavage
and reduced cell viability. Conclusion: These are the first results to demonstrate that SP
induces Akt phosphorylation and prevents apoptosis in colonocytes. We speculate that SP-
associated Akt activation pathways might participate in colonic inflammation and prevention
of apoptosis. Supported by grant DK 47343 from the National Institutes of Health.
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CREB-Dependent COX-2 Expression By Ang II and EGF in Intestinal
Epithelial Cells
Hung Pham, Lee W. Slice
Background. Cyclooxygenase-2 (COX-2) expression plays a major role in a broad range of
physiological processes and diseases including human colorectal cancer. Previously, we
demonstrated synergistic COX-2 expression by Angiotensin (Ang) II and EGF through
distinct signaling pathways requiring small GTPase activity that led to COX-2 promoter
activation. The aim of this study is to further define the signaling pathways used by Ang II
and EGF to express COX-2 that result in prostaglandin (PG) production in intestinal epithelial
cells. Methods. IEC-18 cells are a non-transformed epithelial cell line derived from rat ileum
that expresses endogenous EGF receptors and type I Ang receptors. COX-2 and GAPDH
mRNA was measured using real time RT-PCR. Western blot analysis was used to determine
COX-2 expression and the phosphorylation state of signaling proteins. Transient transfection
with COX-2 promoter luciferase reporter vectors was used to measure COX-2 promoter
activation. Protein-DNA binding was measured using electrophoresis mobility shift assay
(EMSA). Immunoassays were used to measure PG levels. Results. Co-stimulation with Ang
II and EGF promoted synergistic induction of COX-2 mRNA and protein and resulted in
a high level of PGI2 production. The specific COX-2 inhibitor NS-398 blocked Ang II and
EGF-induced PGI2 production. Ang II and EGF induced a transient phosphorylation of ERK,
p38MAPK and CREB. Co-stimulation with Ang II and EGF prolonged the phosphorylation of
ERK, p38MAPK and CREB. The selective p38MAPK inhibitor SB202190 blocked Ang II-
dependent CREB phosphorylation and COX-2 expression. The selective MEK inhibitor
PD98059 blocked EGF-dependent CREB phosphorylation and COX-2 expression. Inhibition
of CREB expression using CREB specific siRNA attenuated COX-2 expression by Ang II,
EGF and Ang II & EGF. Expression of the dominant mutant CREB S133A inhibited COX-
2 promoter activation by Ang II and EGF. EMSA showed CREB binding to a specific site
on the proximal COX-2 promoter. Conclusions. Ang II and EGF synergistically induce both
COX-2 mRNA and protein expression in IEC-18 cells that result in PGI2 production.
Signaling by either Ang II or EGF resulted in transcriptional activation of the COX-2
promoter by phosphorylation of the promoter bound CREB. In addition to Ca2+ signaling,
phosphorylation of CREB was mediated by p38MAPK for Ang II and by ERK for EGF. The
synergistic increase in COX-2 expression by Ang II & EGF correlates with the prolonged
phosphorylation of CREB. This suggests that the distinct signaling pathways used by Ang
II and EGF in COX-2 expression converge onto the CREB transcription factor. DK061485
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RNA Interference Reveals a Differential Role of FAK and Pyk2 in Cell
Migration, Leading Edge Formation and Increase in Focal Adhesions Induced
By LPA in Intestinal Epithelial Cells
Xiaohua Jiang, Rodrigo Jacamo, Elena Zhukova, James Sinnett-Smith, Enrique Rozengurt
Background: In the gastrointestinal mucosa, cell migration plays a crucial role in the organiza-
tion and maintenance of tissue integrity but the mechanisms involved remain incompletely
understood. Immortalized cell lines derived from FAK-/- mice show decreased rate of migra-
tion but these cells have accumulated abnormalities and are fibroblastic rather than epithelial
cells. Consequently, the precise role of FAK in cell migration and morphology of intestinal
epithelial cells remains poorly understood. Materials and Methods: We used siRNA-mediated
depletion of focal adhesion kinase (FAK) protein to determine the role of FAK in wound-
induced migration and cytoskeletal organization in the non-transformed intestinal epithelial
cells IEC-6 and IEC-18 stimulated with the G protein-coupled receptors (GPCR) agonist
lysophosphatidic acid (LPA). Results: Treatment of these cells with FAK siRNA reduced FAK
expression by 85%, but did not affect the expression of Pyk2. Knockdown of FAK protein
significantly inhibited LPA-induced migration of both IEC-18 and IEC-6 cells. LPA induced
reorganization of actin and microtubule cytoskeleton in the leading edge was inhibited in
FAK siRNA-transfected cells. Interestingly, in contrast to the FAK-/- cells, which exhibit an
increased number of prominent focal adhesions when plated on fibronectin, FAK knockdown
IEC-18 cells exhibited dramatically decreased number of focal adhesions in response to both
LPA and fibronectin as compared with the control cells. We also used siRNAs to knockdown
Pyk2 expression without reducing FAK expression. Depletion of Pyk2 did not prevent LPA-
induced migration or cytoskeletal reorganization in IEC-18 cells. Conclusion: Our study
shows that FAK plays a critical role in LPA-induced migration, cytoskeletal reorganization
and assembly of focal adhesions in intestinal epithelial cells whereas depletion of Pyk2 did
not interfere with any of these responses elicited by LPA.
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Localization of Protein Kinase D2 in Endoplasmic Reticulum and Regulation
of Neurotensin Secretion in the Human Bon Endocrine Cell Line
J.N. Li, Kathleen L. O'Connor, Srinivasan Rajaraman, Courtney M. Townsend, B. Mark
Evers
Protein kinase D2 (PKD2), a novel serine-threonine kinase and member of the PKD family,
has been implicated in the secretion of neurotensin (NT), an important gut hormone which
regulates intestinal motility, secretion and growth. The purpose of this study was to determine
the mechanisms for PKD2-mediated NT release in the human endocrine cell line BON,
which produces and secretes NT peptide. METHODS. Stable BON cell clones expressing
wild type (BON/PKD2WT), kinase dead PKD2 (BON/PKD2KD) or empty vector (BON/
pcDNA3) were established. (i) To further determine the role of PKD2 in NT secretion, BON/
PKD2KD cells were treated with vehicle or PMA and NT release was measured by a NT
EIA kit. (ii) To examine the expression of PKD2, BON/PKD2WT and BON/PKD2KD cells
were treated with either vehicle or PMA and single or double immunofluorescent staining
and confocal microscopic analysis performed. In addition, electron microscopy (EM) was
utilized to assess ultrastructural changes. RESULTS. (i) NT release was significantly increased
in BON/pcDNA3 cells stimulated with PMA. In contrast, PMA-mediated NT release was

















significant increase in NT secretion from BON/PKD2WT cells. (ii) PKD2 localized in the
cytosol of BON/PKD2WT cells; translocation to the membrane and large cytosolic vesicles
occurred after PMA treatment. Similar vesicles were noted constitutively in BON/PKD2KD
cells; these vesicles were not affected by PMA treatment. PKD2 was colocalized with the
trans-Golgi network (TGN) as well as the endoplasmic reticulum (ER) in BON/PKD2WT
cells. PKD2 disassociated with TGN but associated with the vesicles, which were positively
stained by ER markers (PDI and calnexin). In BON/PKD2KD cells, kinase dead PKD2 also
colocalized with PDI-stained vesicles which were identified as dilated ER by EM. Decreased
secretory granules in BON/PKD2KD cells compared with BON/PKD2WT cells were also
noted. CONCLUSIONS. PKD2 plays a crucial role in regulating NT secretion. We also
found, for the first time, the unique colocalization of PKD2 with vesicles containing ER
components, suggesting the association of PKD2 with ER functions related to NT protein
synthesis and transport. Importantly, we identify a significant contribution for the PKD2
isoform in stimulated gut peptide secretion.
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Pkd3 in Intestinal Epithelial Cells: Activation By Phorbol Esters and G Protein
Coupled Receptor Agonists Through Pkc
Jingzhen Yuan, Enrique Rozengurt
BACKGROUND: Protein kinase D (PKD) is the founding member of a novel protein kinase
family that also includes PKD2 and PKD3. PKD and PKD2 have been the focus of most
studies to date, but very little is known regarding the regulation mechanisms of PKD3 in
intestinal epithelial cells. Here, using nontransformed IEC-18 cells, derived from fetal rat
intestinal crypt cells, as a model system, we examined whether PKD3 is endogenously
expressed and regulated in intestinal epithelial cells through PKC and G protein-coupled
receptor (GPCR) signaling. RESULTS: Our results demonstrated that abundant PKD3 was
expressed in IEC-18 cells. Treatment of IEC-18 cells with biologically active phorbol ester,
phorbol 12,13-dibutyrate (PDBu) led to striking activation of PKD3. PKD3 was also rapidly
activated in these cells by GPCR agonists including lysophosphatidic acid (LPA), angiotensin,
and vasopressin in a concentration-dependent fashion. Either PDB- or the GPCR agonists-
induced PKD3 activation was abrogated by treatment of IEC-18 cells with PKC inhibitors
GF-1 and Ro 31-8220. Downregulation of PKCs α, δ, and ε by chronic stimulation of the
cells with PDBu led to complete inhibition of PKD3 activation induced by LPA, angiotensin,
and vasopressin, suggesting that the classic and novel PKCs are involved in the GPCR-
induced PKD3 activation. To clarify the G protein pathways leading to PKD3 activation
induced by the GPCR agonists, we examined the effect of pertussis toxin (PTx, an inhibitor of
the Gi) on PKD3 activation comparing with PKD. The results showed that LPA-, angiotensin-,
and vasopressin-induced PKD3 activation were not prevented by treatment with PTx, sug-
gesting that all the three GPCR agonists induced PKD3 activation via PTx-insensitive Gq
pathway. In contrast, exposure of parallel cultures to PTx completely blocked LPA-induced
PKD activation but did not affect PKD activation stimulated by angiotensin or vasopressin,
indicating that LPA induced PKD activation through a PTx-sensitive pathway involving
Gi, whereas angiotensin or vasopressin promoted PKD activation via PTx-insensitive Gq.
CONCLUSION: Our results demonstrate that PKD3 is activated in intact IEC-18 cells by
biologically active phorbol esters and by the GPCR agonists LPA, angiotensin, and vasopressin
through a PKC-dependent signal transduction pathway. These findings reveal a link between
PKCs and PKD3, and implied that PKD3, like PKD, also lies downstream of PKCs in a novel
signal transduction pathway. In addition, the finding that LPA-induced PKD3 activation is
PTx-insensitive suggests an important difference between PKD3 and PKD in the regulation
through heterotrimeric G protein pathways.
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Protein Kinase D2 Potentiates DNA Synthesis Induced By Gq-Coupled
Receptors By Increasing the Duration of ERK Signaling in Swiss 3T3 Cells
James Sinnett-Smith, Elena Zhukova, Gabriel Kleinman, Xiaohua Jiang, Enrique
Rozengurt
Background: Protein kinase D (PKD)/protein kinase Cµ and two recently identified serine
protein kinases termed PKD2 and PKCη /PKD3, which are similar in overall structure and
primary amino acid sequence to PKD, constitute a new protein kinase subfamily separate
from the previously identified PKCs. PKD has been implicated in the regulation of multiple
cellular responses but much less is known about the function of PKD2 and PKD3. In
particular, the precise role of PKD2 in neuropeptide-induced DNA synthesis and cell prolifera-
tion has not been elucidated. One of the major signaling pathways involved in the mitogenic
response induced by both receptor tyrosine kinases and G protein coupled receptors (GPCRs)
is the ERK cascade. The duration and intensity of ERK pathway activation in response
agonists of these receptors is of critical importance for determining specific biological out-
comes, including proliferation, differentiation and transformation. The protein products of
immediate early genes (e.g. c-Fos) have been proposed to function as molecular sensors of
ERK1/2 signal duration. Aim: To examine the role PKD2 plays in DNA synthesis, kinetics
of ERK activation and the induction of c-Fos induced by GPCRs in Swiss 3T3 cells. Methods:
In order to generate Swiss 3T3 cells stably overexpressing PKD2, cultures of these cells were
transduced with retrovirus encoding either wild type PKD2 (Swiss 3T3-PKD2.GFP) or GFP
alone (Swiss 3T3-GFP) as control, in which PKD2 and GFP were translated from the same
bicistronic mRNA and expressed as two separate proteins. After transduction, cells expressing
higher levels of GFP were sorted by FACS, collected and propagated for further studies.Re-
sults: Addition of bombesin to Swiss 3T3 cells overexpressing PKD2 potentiated DNA
synthesis and induced a striking increase in the duration of ERK1/2 activation as compared
with cultures of either control Swiss 3T3 cells. In contrast, the DNA synthesis and the
duration of ERK activation in response to epidermal growth factor, which acts via protein
kinase C/PKD-independent pathways, were not increased. Furthermore, bombesin promoted
a striking increase in phosphorylation (at Ser-374) and accumulation of c-Fos (the c-fos
proto-oncogene product) in Swiss 3T3 cells overexpressing wild type PKD2. Inhibition of
the sustained phase of ERK/RSK activation abrogated the increase in c-Fos accumulation
and DNA synthesis induced by bombesin in PKD2 overexpressing cells. Conclusion: PKD2
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facilitates bombesin induced DNA synthesis by increasing the duration of ERK signaling
leading to the phosphorylation and accumulation of c-Fos.
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Induction of Mu Opioid and Cannabinoid Receptors By Probiotics: A New
Mechanisms of Actions
Christel Rousseaux, Thuru Xavier, Laurent Dubuquoy, Christel Neut, Caroline Dubuquoy,
Arthur Ouwehand, Didier Carcano, Pierre Desreumaux
µ opioid receptor (MOR) and receptors for cannabinoids (CB1 and CB2), which belong to
the G protein coupled receptor family, are expressed in the central nervous system where
they exert analgesic effect. In the gut, they are expressed by epithelial cells and mediate
anti-inflammatory effects. Aim: To evaluate the ability of different strains of probiotics to
induce MOR, CB1 and CB2 expression. Methods: In vitro, colonic epithelial cells HT-29
were incubated for 0 to 6h with different strains of probiotics or bacteria (100 CFU/cell):
L. acidophilus (NCFM), L. salivarius (UCC118), L. paracasei (Lpc 37), a commensal E. coli,
and an enteropathogenic E. coli (LF82) strain. To preclude an unspecific effect of bacteria
on MOR and CB induction by epithelial cells, the retinoid X receptor (RXR) was quantified.
The involvement of NF-κB activation on MOR and CB expression was assessed by a pre-
treatment of HT-29 cells with a specific inhibitor of NF-κB (CAPE). In vivo, Balb/c mice
were orally fed with L. acidophilus NCFM (10e9 CFU) during 15 days. MOR and CB
expression was evaluated in the colon of mice at mRNA and protein levels by real time PCR
and immunohistochemistry together with a quantification of inflammatory cytokines such
as TNFα, KC and IL-1β mRNA. Results: By comparison with resting cells, NCFM (1±1 vs
145±65, p<0.01) and UCC118 (1±1 vs 28±8, p<0.01) were the most effective strains to
induce rapidly a strong expression of MOR in epithelial cells. This induction was similar
to HT-29 cells stimulated by optimal dosage of TNFα. Induction of CB1 (1±1 vs 3.7±0.8,
p<0.05) and CB2 (1±1 vs 4.4±0.98, p<0.01) expression was limited to the NCFM strain.
Other probiotic strains or bacteria did not affect MOR or CB expression. RXR mRNA
expression remained unchanged in stimulated cells. CAPE did not modify MOR expression
level in epithelial cells stimulated by NCFM. In vivo, NCFM administration in mice strongly
enhanced colonic levels of MOR mRNA compared to control animals (24±0.75 fold, p<0.01).
Induction of MOR, CB1 and CB2 expression by colonic epithelial cells was confirmed by
immunohistochemistry in mice receiving NCFM and was inversely correlated with a signific-
ant 50% reduction of inflammatory cytokine levels. Conclusion: L. acidophilus NCFM is
the most effective strain to induce expression of MOR and CB in colonic epithelial cells.
These findings suggest that modulation of the gut microbiota may regulate intestinal inflam-
mation and analgesia through the induction of MOR and CB expression, which may be
used as new markers to screen functional bacterial strains with anti-inflammatory and
analgesic properties(patent applications FR04/09966-PCT EP05/010880).
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Activation of Pkc-β1 Isoform - A Novel Mechanism for the Beneficial Effects of
Lactobacillus Gg (LGG) On Monolayers of Intestinal Epithelial Cells
Ali Banan, Lijuan Zhang, Maliha Shaikh, Christopher B. Forsyth, Jeremy Z. Fields,
Ashkan Farhadi, Ali Keshavarzian
Despite a large number of studies of probiotics, major gaps in our knowledge still exist, not
the least of which are the interactions of probiotics with gut epithelium and the molecular
processes that orchestrate their beneficial effects on the gut barrier. In particular, their
mechanisms have not been well-documented in in vitro models of IBD. Because the β1
isoform of PKC is key to maintenance of healthy GI epithelial cells, we hypothesized that
PKC-β1 activation is necessary for LGG-induced protection of the intestinal epithelial barrier
function under conditions of oxidative stress. Methods: Cells were transfected to stably over-
express PKC-β1 or to under-express it. These clones were preincubated with LGG (10 3 -
10 12 CFU/mL) or a PKC activator (DAG analog, OAG, 0.01-1 uM) before exposure to
oxidant (H2O2, 10-500 uM). Naive (un-transfected) cells were treated similarly. We mon-
itored barrier function {fluorometry}, tight-junction integrity {laser confocal microscopy},
PKC-β1 subcellular distribution {membrane, cytoskeletal, cytosolic}, PKC-β1 subcellular
activity {in vitro kinase assay}; ZO-1/ZO-2 (immunofluorescence, SDS-PAGE fractionation),
n=3/grp. Results: {I} Cells stably overexpressing PKC-β1, but not naive cells, were protected
from H2O2-induced injury by low doses of LGG or OAG. In oxidant-exposed transfected
cells, but not naive cells, pretreatment with a low dose of LGG or OAG was protective: 1)
increasing ZO-1/ -2 membrane distribution while decreasing ZO cytosolic distribution; 2)
enhancing the architectural integrity of ZO; 3) maintaining barrier permeability (FSA, FD
clearances). These effects were prevented by a PKC inhibitor. {II} Pretreatment of transfected
cells with LGG or OAG caused a large change in subcellular distribution of PKC-β1, increasing
membrane and cytoskeletal fractions of PKC-β1 several fold while decreasing cytosolic
fractions, indicating PKC-β1 activation. {III} In LGG treated cells, PKC-β1 was active and
complexed with ZO. {IV} Anti-sense inhibition of endogenous PKC-β1 expression abolished
LGG-induced protection, and was associated with less membranous ZO and more cytosolic
ZO, unstable ZO cytoarchitecture, and barrier hyperpermeability. Conclusions: We demon-
strate a new biologic mechanism that LGG-induced protection against oxidative injury
requires PKC-β1 activation. The ability of bacteria to promote the normal dynamics of tight
junctions and barrier function is a novel mechanism not previously attributed to this PKC
isoform. This mechanism suggests a potential target for development of novel therapies for
the treatment of a variety of inflammatory GI disorders, including inflammatory bowel
disease (IBD).
677
Estrogen Modulates Bacterial Colonization in the Gut and Responses to
Probiotic Therapy
Brendan Diederichs, Dave Thiel, Francis Cheung, Julia Ewaschuk, Hugo Diaz, Karen
Madsen
The pathogenesis of inflammatory bowel disease (IBD) involves a complex interaction between
genetic and environmental factors. There is evidence that the magnitude of immune responses
in autoimmune diseases are gender-dependent and stronger in females compared with males.
Live probiotic bacteria are effective in reducing gut permeability and inflammation; it is
unknown how gender affects gut responses to probiotics. We have shown that Bifidobacterium
strains release peptide bioactive factors that modulate epithelial resistance in vitro. Aim:
The aims of this study were to determine if peptides released from Bifidobacteria retain their
bioactivity when administered orally and also if a gender-bias exists in the gut response to
these bioactive factors. Methods: B. infantis was incubated overnight in RPMI-1640 media
and media centrifuged and filtered to remove live bacteria (CM). Adult 129/SvEv mice
received CM (30 µl) and were sacrificed 6 hrs later for assessment of intestinal permeability
in Ussing chambers. Controls received RPMI alone. A separate group of 8 wk old IL-10
deficient mice were treated with CM for 4 wks (30 µl/ 2x day). At sacrifice, ileal and colonic
tissue were assessed for mRNA levels of TNFα, IFNγ, and TGFβ by RT-PCR and permeability
measured in Ussing chambers. Bacteria adherent to the mucosa were analyzed by culture
and DGGE. A separate group of female IL-10 deficient mice were treated with the estrogen
receptor antagonist ICI-182780 (1 mg/kg/day sc) ± CM. Results: CM administration acutely
reduced colonic permeability in wild-type mice within 6 hrs of administration. Long-term
CM treatment normalized colonic permeability in both male and female IL-10 deficient mice.
However, gender differences were evident in the gut immune responses to CM treatment. In
males, CM treatment resulted in a significant decrease in intestinal secretion of IFN and TNF
and decreased mRNA levels. However, in females, CM treatment resulted in an upregulation of
secretion and mRNA levels of IFN and TNF. Furthermore, females demonstrated significantly
greater levels of colonic adherent bacteria compared with males, and also exhibited major
differences in bacterial strains colonizing the mucosa as compared with males. Blocking
estrogen receptors with ICI-182780 partially attenuated the enhanced cytokine response in
females. Conclusion: Estrogen appears to have a significant role in modulating bacterial
colonization of the gut and in the gut response to probiotic-based therapies. Peptide bioactive
factors from B. infantis retain their biological activity in vivo and are effective in normalizing
gut permeability in animal models of colitis.
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The Probiotic Bacterium E. Coli Nissle 1917 (EcN) Ameliorates Experimental
Colitis Via TLR-Dependent Pathways
Anja Grabig, Daniela Paclik, Claudia Guzy, Anja Dankof, Daniel C. Baumgart, Baerbel
Raupach, Bertram Wiedenmann, Ulrich Sonnenborn, Axel Dignass, Andreas Sturm
BACKGROUND: Recent studies demonstrated that bacterial products activate T cells via
Toll-like receptors (TLRs), suggesting a link between the luminal bacterial flora and the
immune system. We previously demonstrated that EcN inhibits activation and proliferation
of T-cells through a TLR-2-dependent pathway. We therefore aimed to explore the effects
of EcN in an experimental colitis induced in TLR-2 ko and TLR-4 ko mice. METHODS:
Acute experimental colitis was induced in wildtype (wt), TLR-2 ko and -4 ko mice by adding
5% DSS to the drinking water. Mice were treated with either NaCl or EcN twice daily
rectally or orally until they were sacrificed on day 8. Disease activity was quantified macro-
scopically using an established disease activity index (DAI) and microscopically using the
Dieleman score. PBT were isolated, stimulated with CD3 for 3 days and cytokine secretion
was determined by CBA analysis. Mucosal recruitment of granulocytes was assessed by MPO
activity. Using flow cytometric analysis, IFN-γ and TNF-α expression in splenic T cells was
determined after stimulation for 6h with PMA/Ionomycin. RESULTS: Wt and TLR-2 ko mice
exposed to DSS developed acute colitis, whereas TLR-4 ko mice developed significantly less
inflammation. In wt animals, EcN significantly reduced macroscopic and microscopic disease
activity as well as MPO activity compared to controls (p<0.01). Furthermore, secretion of
pro-inflammatory and chemotactic cytokines was significantly reduced by EcN treatment.
EcN significantly reduced intracellular expression of TNF-α and IFN-γ in splenic T cells.
In contrast, in TLR-2 ko and -4 ko mice, DAI, microscopic damage and MPO activity were
not significantly modulated by EcN. In TLR-4 ko mice, TNF-α, IFN-γ, IL-6 and IL-10
secretion was nearly abolished and no differences between EcN or control treated mice were
observed, whereas MCP-1 secretion was comparable to wt, but not different in control or
EcN treated mice. In TLR-2 ko mice, IFN-γ secretion was reduced by EcN. MCP-1 secretion
was nearly completely abolished and TNF-α and IL-10 secretion were not modulated by
EcN. CONCLUSION: EcN significantly ameliorated experimental colitis and reduced pro-
inflammatory and chemotactic cytokine secretion in wt mice. This effect was not observed
in TLR-2 or TLR-4 deficient mice, suggesting that both TLR are required to mediate the
effects of EcN on cytokine secretion and modulation of disease activity in experimental
colitis. Furthermore, we demonstrated, that TLR-2 and -4 are needed to efficiently secrete
pro-inflammatory and chemotactic cytokines in intestinal inflammation.
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Lactobacillus Rhamnosus GG (LGG) Soluble Proteins Prevent Tumor Necrosis
Factor (TNF)-Induced Epithelial Injury in Colonic Organ Culture
Fang Yan, Hanwei Cao, Robert Whitehead, D. Brent Polk
Background. The intestinal epithelial monolayer integrity is essential for maintenance of
normal gut function. An increased inflammatory cytokine levels is one of the factors known
to disrupt this monolayer in several diseases, such as inflammatory bowel disease (IBD).
We reported that the probiotic bacterium, Lactobacillus rhamnosus GG (LGG) prevents
cytokine-induced apoptosis in mouse and human colon epithelial cell lines through regulating
epithelial cell signaling pathways. Furthermore, we have purified two proteins (p75 and
p40) secreted by LGG, which exert anti-apoptotic functions. Therefore, the purpose of this
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study is to determine the roles of LGG and these soluble proteins on TNF-induced colonic
epithelial cell injury. Methods: Colon explants were isolated from 6-8-week old C57BL/6
mice and cultured on the top of inserts in DMEM medium containing 0.5 % FBS. After 6
or 24 hours treatment with LGG, LGG-conditioned-media (LGG-CM), or purified proteins
in the absence or presence of TNF (100 ng/ml), paraffin-embedded sections were prepared
to determine tissue injury by H&E staining, and apoptosis by in situ oligo ligation (ISOL)
and active caspase-3 staining. Polyclonal antibodies against p75 or p40 were generated and
used for immuno-depletion of the respective proteins from LGG-CM. Young adult mouse
colon (YAMC) epithelial cells were treated with TNF in the presence or absence of LGG for
24 hours. Culture media were collected and cytokine production detected using a cytokine
protein array. Results. Co-culture of colon tissue explants with p75, p40, LGG-CM, or LGG
with TNF significantly decreased TNF-induced ulcerative lesions, including mucosal necrosis,
and disruption of epithelial integrity. TNF induced colon epithelial apoptosis with 75% of
crypts containing more than 10 apoptotic cells, which was decreased 3-fold by p75 or p40
co-treatment (p<0.005). p75 or p40 also inhibited TNF-stimulated caspase-3 activation by
4-fold (p<0.005). Importantly, LGG-CM inhibitory effects on TNF-induced colon injury
and apoptosis were blocked by immuno-depletion of p75 and p40. Furthermore, LGG
blocked TNF-induced RANTES and MIP-3b secretion from YAMC cells. Both of these
chemokines are known to attract mononuclear inflammatory cells. Conclusion. These studies
are the first to identify probiotic bacterial soluble proteins’ effects on regulating intestinal
epithelial homeostasis by inhibiting cytokine-induced apoptosis and chemoattractant produc-
tion. Importantly, this novel mechanism of probiotic action suggests the potential for applica-
tion of native bacterial components to prevent TNF-mediated gastrointestinal epithelial injury.
680
Suppression of Experimental Autoimmune Encephalomyelitis (EAE) By Oral
Administration of Lactobacillus Paracasei DSM 13434
Shahram Lavasani, Frida Fak, Balik Dzhambazov, Jan Alenfall, Bjorn Westrom
Background & Aims: Probiotics has been shown to exert beneficial health effects in intestinal
infection and mucosal inflammation by modulating the immune system. In the case of chronic
autoimmune diseases, like multiple sclerosis (MS), which is associated with inflammation in
the central nervous system, a major goal of treatment is to reduce inflammation. The aim
of our study was to investigate whether oral administration of Lactobacillus paracasei DSM
13434 could affect the systemic immune response by suppressing a T cell-mediated chronic
inflammation in CNS. To assess this effect we used an animal model for multiple sclerosis,
experimental autoimmune encephalomyelitis (EAE). Methods: Female C57BL/6 mice, from
9 to 10 weeks old, were treated daily with L. paracasei DSM 13434 dissolved in the drinking
water, at a dosage of 109 cfu/mouse/day throughout the whole experiment. A control group
received only water. After 12 days of treatment EAE was induced by immunisation with a
myelin oligodendrocyte glycoprotein peptide (MOG35-55). Animals were daily scored for the
clinical signs of EAE and sacrificed at day 25 post immunisation. Results: Oral administration
of L. paracasei DSM 13434 significantly inhibited EAE in mice. This was confirmed by
histopathology, demonstrating a decrease of CD4+/CD8+ T cell infiltration in CNS. Autoan-
tigen re-challenge in vitro revealed similar T cell proliferation in L. paracasei DSM 13434
treated and control mice but reduced cytokine response in L. paracasei DSM 13434 treated
mice as measured by both IFN-γ and TNF-α. Investigation of lymphocytes in the mesenteric
lymph nodes showed a significantly increased of CD4+CD25+ T lymphocytes. An increase
of plasma IgA was also observed in L. paracasei DSM 13434 treated animals. Moreover, anti
CD3 stimulation of spleen cells prior to immunisation showed an increased production of
IL-10 and IL-4 cytokines in L. paracasei DSM 13434 treated animals. Conclusions: These
experiments showed that oral exposure to L. paracasei DSM 13434 can modulate systemic
immune responses and therefore represent a promising approach in the management of
autoimmune diseases.
681
Differential Effects of Pdz-Adapterprotein NHERF1, E3karp and Pdzk1
Knockout On the Regulation of NHE3 Transport Activity in Native Murine
Colonic Epithelium
Ayhan Cinar, Mingmin Chen, Brigitte Riederer, Boris Hogema, Hugo de Jonge, Mark
Donowitz, Edward J. Weinman, Olivier Kocher, Ursula Seidler
Backround & Aims: The PDZ-adapter proteins NHERF1, E3KARP and PDZK1 have all
been shown to bind to the sodium hydrogen exchanger NHE3, and all three proteins are
ex-pressed in the brush border membrane (BBM) of murine intestine. In PS120 fibroblasts,
NHERF1 or E3KARP coexpression with NHE3 is required for cAMP-mediated inhibition of
NHE3 transport activity. We therefore investigated, whether the three NHE3 binding PDZ-
proteins show functional redundancy, or have differential roles in the native intestinal epithe-
lium. Methods: NHERF1, E3KARP, PDZK1, and NHERF1/PDZK1- deficient mice and their
wild type NHE3 transport rates were assessed fluorometrically in the NHE3-expressing sur-
face cell region of BCECF-loaded murine colonic crypts isolated from (wt) littermates. NHE3
BBM abudance was measured by Western analysis of isolated BBM, NHE3 localization was
assessed immunohistochemically, and NHE3 mRNA levels were determined by RT-PCR.
Results: In NHERF1-deficient surface enterocytes, acid-activated NHE3 transport rate was
significantly reduced to 65% of the rate in wt enterocytes. Significant inhibition of NHE3
transport activity by forskolin was observed in NHERF1-deficient surface enterocytes, but
this inhibition was significantly less pronouned than in wt enterocytes (56% vs. 75%,
p<0.01). A similar reduction in the efficacy of inhibition by 8-Br-cGMP and ionomycin was
also seen. In E3KARP-deficient colonic enterocytes, acid-activated NHE3 transport rate, as
well as in-hibition by forskolin and 8-Br-cGMP was identical to wt enterocytes, but the
inhibition by ionomycin was completely abolished. In PDZK1-deficient surface enterocytes,
acid-activated NHE3 transport rate was strongly reduced to 35% of that in wt enterocytes,
and no significant inhibition of transport rate was seen by any of the above second messengers.
Surprisingly, the changes observed in the NHERF1/PDZK1-deficient enterocytes were ident-
ical to those in the PDZK1-deficient enterocytes. In NHERF1 and E3KARP-deficient intestine,
NHE3 BBM abundance was unchanged, whereas it was significantly decreased in PDZK1-

















The results demonstrate that the PDZ-Proteins NHERF1, E3KARP and PDZK1 are important
regulators of NHE3 transport activity in native murine intestinal epithelium and appear to
serve differ-ent, and partly signal-specific functions.
682
Modulation of Niemann-Pick C1 Like 1 (NPC1L1) Protein By Cholesterol in
Caco2 Cells
Fadi Annaba, Zaheer Sarwar, Ravinder K. Gill, Seema Saksena, Dudeja K. Pradeep,
Waddah A. Alrefai
Niemann-Pick C1-like 1 (NPC1L1) is a novel intestinal cholesterol transporter localized to
the brush border membrane of the enterocytes. Studies in knockout mice demonstrated that
NPC1L1 is an essential intestinal component of cholesterol absorption. Also, NPC1L1 was
shown to be the molecular target of Ezetimibe, the cholesterol absorption blocker used for
treatment of hypercholesteremia. Recently, NPC1L1 expression in mice has been shown to
be reduced by cholesterol feeding. However, it is not clear whether the decrease in NPC1L1
expression by cholesterol occurs via changes in the rate of gene transcription. Therefore,
the current studies were designed to investigate the molecular regulation of human NPC1L1
expression and promoter activity by cholesterol in human intestinal Caco2 cell line. The
relative abundance of NPC1L1 mRNA was evaluated by real time PCR. NPC1L1 gene
fragment (-1741/+56) was amplified from human genomic DNA and cloned into pGL2
vector upstream of luciferase reporter gene. Transient transfection and luciferase assay
techniques were employed to assess NPC1L1 promoter activity. Our results revealed that
24 h incubation with 5 micro g/ml concentration of 25-hydroxycholseterol significantly
decreased the relative abundance of NPC1L1 mRNA in Caco2 cells by 56.4 ± 0.5 % compared
to cells treated with vehicle alone. The inhibitory effect of 25-hydroxycholesterol may be
mediated by inactivating Sterol Regulatory Element-Binding Protein (SREBP) transcription
factor. Therefore, we examined the effect of SREBP activation by depletion of cellular
cholesterol on NPC1L1 expression. Activation of SREBP by incubation with 40 micro M
Mevinolin (inhibitor of HMG-CoA reductase) for 24 h led to a significant increase (~ 2 fold)
in the relative level of NPC1L1 mRNA compared to vehicle treated control. Similarly, NPC1L1
promoter activity (-1741/+56) was significantly inhibited (40.5 ± 4.5 %) by incubation with
25-hydroxycholesterol and significantly stimulated (~ 2 fold) in response to Mevinolin.
Sequence analysis of the promoter region revealed a potential binding site for SREBP in a
region between nucleotide -506 and -512. Interestingly, the activity of NPC1L1 promoter
fragment (-291/+56) lacking SREBP potential biding site was unaffected by 25-hydroxycholes-
terol or Mevinolin treatment. Conclusion: Our studies, for the first time, demonstrate the
modulation of human NPC1L1 expression and promoter activity by cholesterol in human
intestinal Caco2 cells. Our findings suggest that NPC1L1 regulation by cholesterol is mediated
by SREBP-dependent mechanism.
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Evidence for the Association of Apical Ileal Bile Acid Transporter (ASBT) with
Lipid Rafts
Waddah A. Alrefai, Zaheer Sarwar, Fadi Annaba, Seema Saksena, Alka Dwivedi, Pradeep
K. Dudeja, Ravinder K. Gill
Apical Sodium-Dependent Bile Acid Transporter (ASBT) is responsible for active intestinal
absorption of bile acids in distal ileum. Earlier studies demonstrated the involvement of
membrane trafficking in the acute modulation of ASBT function. Recent evidence suggests
that targeting of membrane transporters to specialized membrane domains such as lipid
rafts is crucial for their optimal function. Lipid rafts are cholesterol and sphingolipids rich
and resistant to solubilization by detergents. Whether ASBT is present in lipid rafts of plasma
membrane is not known. Therefore, the current studies were undertaken to examine the
association of ASBT with lipid rafts utilizing Western blotting and Immuno-fluorescent
studies. Purified apical membranes (BBMs) were isolated from human ileal mucosa obtained
form organ donor intestine. Lipid rats were isolated from Triton-X 100 treated human ileal
BBMs based on their low buoyancy and floatation on a discontinuous Optiprep density
gradient. Our data showed that ASBT in ileal BBM was detected in the low buoyancy
fractions, which were also enriched with alkaline phosphatase, a marker for lipid rafts.
hASBT was also detected to some extent in all other fractions of the gradient indicating that
only a subpopulation of the transporter on the BBM is associated with lipid rafts. We further
investigated the co-localization of ASBT with ganglioside GM1 a marker for lipid rafts, in
human intestinal Caco2 cell line, utilizing fluorescent CtxB which binds to GM1. Confocal
microscopy studies showed hASBT protein was primarily localized in the apical membrane
and was colocalized with ganglioside GM1-bound to CtxB. Interestingly, depletion of plasma
membrane cholesterol by incubation with Methyl ≤-cyclodextrin (M≤CD) disrupted the
association of ASBT with GM1-bound CtxB. Furthermore, treatment with M≤CD decreased
Na+-dependent 3H-TC uptake in Caco2 cells and HEK 293 cells expressing ASBT. The
inhibition of ASBT function by M≤CD was blocked in the presence of cholesterol and
appears to be mediated by a decrease in the Vmax of the transporter. Conclusion: Our
studies provide direct evidence for the association of ileal hASBT with multiple pools of
BBM of intestinal epithelial cells including lipid rafts and demonstrate that cholesterol content
of lipid rafts is essential for the optimal activity of hASBT. Since the luminal bile acid content
constantly varies between meals, it is expected that ileal ASBT undergoes rapid adaptive
changes to the varying intestinal milieu. These findings suggest a novel mechanism by which
hASBT activity is rapidly modulated by alterations in cholesterol content of plasma membrane
lipid rafts.
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NHE3 Has Restricted Brush Border (BB) Mobility Due to Cytoskeletal
Association Which Is Dynamic As Part of Acute Stimulation and Inhibition
Boyoung Cha, Anne Kenworthy, Ming Tse, Mark Donowitz
The epithelial BB Na/H exchanger NHE3 is associated with the actin cytoskeleton by binding
separately directly to ezrin and indirectly to ezrin via attachment to NHERF family proteins.
NHE3 point mutants can separately eliminate the direct (F1) and indirect (F2) ezrin binding.
NHE3 mobility in polarized epithelial cell BB is restricted by cytoskeleton binding such that
only 30% of NHE3 in the renal proximal tubule OK cell line is mobile as judged by
fluorescence recovery after photobleaching (FRAP) using confocal microscopy to examine
the BB. Given that acute NHE3 regulation is partially by changes in trafficking, the hypothesis
tested in this study was that the cytoskeleton association of NHE3 was dynamic and changed
as part of acute regulation. OK cells stably expressing NHERF2 (to mimic the small intestinal
and proximal tubule distribution of NHERF family proteins) had NHE3 acutely stimulated
by exposure to LPA(100uM) or inhibited by exposure to serotonin (5HT)(30 M) (both
partially act by altering the amount of BB NHE3, with 5HT acting by elevating Ca2+). With
both LPA and 5HT, the BB NHE3 mobile fraction (measured by FRAP/confocal microscopy)
rapidly increased to 70% in a time dependent manner, with maximum mobility 30 min
after ligand exposure and returned to basal mobile fraction by 45 min. Neither LPA nor
5HT altered NHE3 activity in OK/NHERF2/F2mutant NHE3 (which does not associate with
NHERF proteins). Under these conditions, there were no LPA or 5HT induced changes in
NHE3 mobility. In contrast, LPA caused a normal increase and recovery of NHE3 mobility
in the OK/NHERF2/F1 mutant NHE3 (which does not directly bind ezrin). In conclusion:
1) Restricted BB mobility of NHE3 due to cytoskeleton association is dynamic and is increased
as part of both acute stimulation and inhibition, which change the amount of BB NHE3.
2) We suggest that acute stimulation of NHE3 by LPA occurs via addition of NHE3 to the
BB and that this addition of NHE3 precedes binding of NHE3 to the actin cytoskeleton via
NHERF/ezrin. 3) Acute inhibition of NHE3 by 5HT, which is associated with acute Ca2+
dependent removal of NHE3 from the BB, is associated with an increase in BB mobility of
NHE3, although it is not known whether the changes in mobility proceed or follow changes
in NHE3 complex formation . These results identify dynamic steps in cytoskeleton involve-
ment with NHE3 regulation which could be manipulated to stimulate or inhibit Na absorp-
tion.
685
Enteropathogenic E. Coli (EPEC) Infection Reduces Surface Expression of
down regulated in adenoma (DRA) Protein in Caco-2 Cells
Ravinder K. Gill, Alip Borthakur, Kim Hodges, Jerrold R. Turner, Seema Saksena,
Krishnamurthy Ramaswamy, Gail A. Hecht, Pradeep K. Dudeja
Enteropathogenic E. coli (EPEC), an important food-borne enteric pathogen is a common
cause of infantile diarrhea. EPEC is neither invasive nor toxigenic but expresses a type III
secretion system (TTSS) that allows it to deliver virulence proteins (E. coli secreted proteins;
Esp) directly into host cells. We previously demonstrated that alterations in luminal ion
absorptive transport processes contribute to the pathophysiology of EPEC-induced diarrhea.
Specifically, EPEC infection decreased apical Cl-/OH- exchange activity in human intestinal
epithelial cells via the involvement of TTSS and the effector molecules, EspG and Orf3
(EspG homolog). However, the direct effect of EPEC on anion exchangers responsible for
intestinal apical Cl-/OH-(HCO3-) exchange process is not known. Increasing evidence sug-
gests the involvement of both SLC26A3 (DRA), (mutated in Congenital Chloride Diarrhea)
and SLC26A6 (Putative anion transporter, PAT-1) in mediating luminal Cl-/HCO3-(OH-)
exchange in the intestine. Therefore, the current studies were undertaken to ascertain the
role of DRA and PAT-1 in the effects of EPEC. Human colonic adenocarcinoma Caco-2
monolayers were infected with EPEC or specific mutants for 30 min and DRA or PAT-1
protein expression was analyzed by biochemical and confocal microscopic studies. Cell
surface biotinylation studies demonstrated that the surface expression of PAT-1 did not
change in response to EPEC infection. However, expression of DRA on the plasma membrane
was considerably reduced (~70%) in EPEC-infected cells, corresponding with decreased Cl-/
OH- exchange activity. Total cellular DRA was not altered by EPEC infection. Neither non-
pathogenic E. coli nor an escN mutant (non-functional TTSS) altered the surface expression
of DRA. Confocal immunofluorescence studies showed that DRA protein was predominantly
localized to the apical surface of cells infected with non-pathogenic E. coli, however, infection
with EPEC caused a marked re-distribution of DRA from the apical membrane to intracellular
compartments. Interestingly, deletion of espG, involved in disruption of microtubules, signi-
ficantly attenuated the removal of DRA protein from the apical membrane as compared to wild
type EPEC (~40%). Conclusion: Our data demonstrate that reduction in surface expression of
DRA is TTSS-dependent and involves EspG. Alteration in the level of DRA expression at
the apical membrane by EPEC demonstrates a novel mechanism for acute modulation of
DRA and indicates its regulation by membrane recycling events.
686
Ileal Apical Sodium-Dependent Bile Acid Transporter Activity Is Inhibited By
Enteropathogenic E. Coli (EPEC) Infection
Zaheer Sarwar, Ravinder K. Gill, Alip Borthakur, Krishnamurthy Ramaswamy, Pradeep K.
Dudeja, Gail A. Hecht, Waddah A. Alrefai
EPEC is a food-borne enteric pathogen and a major cause of diarrhea worldwide. EPEC is
non-invasive and non-toxigenic but expresses a type III secretion system (TTSS) through
which bacterial virulence proteins are translocated into host cells. The pathophysiology of
EPEC-induced diarrhea is multi-factorial. Recent studies showed that EPEC infection modu-
lates intestinal Na+, Cl- and short chain fatty acid ion transport processes in human intestinal
epithelial cells. In this regard, Apical Sodium-Dependent Bile Acid Transporter (ASBT),
responsible for the absorption of the majority of bile acids from the intestinal lumen, has
been implicated in diarrhea associated with inflammatory diseases. However, the effect of
pathogenic microorganisms that induce diarrhea, such as EPEC, on ASBT activity is not
known. Therefore, current studies were undertaken to investigate the short-term effects of
EPEC infection on ileal ASBT function utilizing the human intestinal Caco2 cell line as a
model epithelia. ASBT activity was assessed by the measurement of Na+-dependent 3H-
taurocholic (TC) luminal uptake. ASBT protein expression was evaluated by immunofluoresc-
ence studies. Sodium-dependent 3H-TC uptake in Caco2 cells was significantly inhibited
(64 ± 1.5 %) following 30 min infection with EPEC but not with non-pathogenic E. coli.
Mutation of escN, the gene that encodes the ATPase for TTSS rendering it ineffective, ablated
the inhibitory effect on 3H-TC uptake. Also, mutations in genes (espA, espB and espD)
encoding proteins of TTSS terminal structure abrogated the observed inhibitory effect of
the infection. The inhibition by EPEC was associated with a significant decrease in the Vmax
(135 ± 23 versus 74 ± 17 pmol/mg protein/5 min) with no changes in Km, suggesting a
potential reduction in the luminal membrane ASBT content. Immunofluorescence confocal
microscopic studies showed that ASBT localized predominantly to the apical membrane of
uninfected cells. EPEC infection, however, significantly decreased the level of ASBT on the
apical surface by internalization into intracellular compartments. Conclusion: Our study
provides novel evidence that EPEC infection inhibits ASBT activity in a TTSS-dependent
manner that results in the removal of ASBT from the luminal surface of intestinal epithe-
lial cells.
687
ACE Inhibitor Therapy Is Associated with a Decreased Incidence of Colorectal
Cancer
George Makar, James D. Lewis, Yu-Xiao Yang
BACKGROUND Laboratory data suggest that increased angiotensin II may promote the
growth of colorectal cancer (CRC) by inducing neovascularization and IGF-1 receptor expres-
sion, while angiotensin converting enzyme inhibitors (ACE-I) enhance the antitumor effect
of COX-2 inhibition through inhibition of the IGF-1 pathway. Based on these observations,
we sought to determine whether ACE-I therapy reduced the risk of CRC in a population-
based cohort. METHODS We conducted a nested case-control study within a cohort of
hypertensive patients in the General Practice Research Database (United Kingdom). Cases
were subjects with a new diagnosis of CRC. Using incidence density sampling, up to 10
controls per case were selected, matched on age, sex, calendar year and duration of follow-
up. Patients with <1 yr of CRC-free follow-up after diagnosis of hypertension and CRC
patients with <1 yr of ACE-I therapy before their cancer diagnosis were excluded. Conditional
logistic regression was used to calculate Odds Ratio’s (ORs) for CRC associated with exposure
to ACE-I therapy. The primary exposure duration of interest was≥3 years. We also assessed
the effect of escalating durations of exposure. A priori potential confounders adjusted in the
model included duration of follow-up after hypertension, number of physician visits within
1 year of index date, BMI, smoking, aspirin/NSAIDs, hormone replacement therapy, folate,
calcium, statins, and insulin. A priori testing for effect modification among diabetics was
performed, since hyperinsulinemia among diabetics has been shown to increase the risk of
colorectal cancer primarily via the IGF-1 system. RESULTS(Table) 1,988 cases were matched
with 18,131 controls. Greater than 3 years of ACE-I therapy was associated with a reduction
in CRC risk (OR 0.79 (95% CI, 0.64 -0.96)); a significant duration-response effect was
present (Test for trend: p=0.02). Larger effects were observed among patients with diabetes
(LR test for interaction: p=0.06). CONCLUSION Long-term ACE-I therapy was associated
with a decreased risk of CRC in this cohort. The magnitude of this effect was greater
in diabetics.
Duration of ACE-I Therapy and OR of CRC
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Long-Term Aspirin Use and Mortality: Implications for Chemoprevention
Andrew T. Chan, Joann E. Manson, Diane Feskanich, Meir J. Stampfer, Graham A.
Colditz, Charles S. Fuchs
Randomized trials have shown that aspirin reduces risk of colorectal adenoma. However,
the use of aspirin for widespread chemoprevention has been hindered by uncertainty over
its risk-benefit profile. One measure of the overall benefit of aspirin is the relation between
long-term aspirin use and total mortality. Methods: We conducted a prospective, nested
case-control study of 75,816 women enrolled in the Nurses’ Health Study to determine the
association between aspirin use and mortality. Women provided data biennially since 1980
and were followed through 2004. Each participant who died was matched with 7 controls
alive at the time of her death. For each death, aspirin use was assessed prior to initial
diagnosis of cardiovascular disease (CVD) or cancer and during the corresponding time
period for matched controls. Results: Over 24 years, we documented 9,477 total deaths.
Among women who reported current use of aspirin, the multivariate relative risk (RR) of
death from all causes was 0.75 (95% CI, 0.71-0.81) compared to women who never used.
The risk reduction was more apparent for CVD death (RR 0.62; CI, 0.54-0.71) than for
cancer death (RR 0.88; CI, 0.81-0.96). The lower risk of cancer death among current users
was significant only for colorectal cancer death (RR 0.72; CI, 0.56-0.92). We observed a
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significant linear relationship between increasing duration of use and decreasing all-cause
mortality (Ptrend<.0001). However, for CVD death, much of the benefit was achieved within
the first 5 years of use (Ptrend=0.14). In contrast, for all cancer-related mortality, significant
risk reduction was not apparent until at least 10 years of use (Ptrend=0.005). The strongest
effect of long-term use was observed with colorectal cancer death, with a RR of 0.60 (CI,
0.41-0.90) for >20 years (Ptrend=0.02). The benefit associated with aspirin was confined
to low and moderate doses. However, we did observe a relationship between increasing
dose and lower risk of colorectal cancer death among women who used aspirin >10 years
(P trend = 0.02). Of note, we documented only 41 cases of death related primarily to
gastrointestinal bleeding or peptic ulcer disease over the 24 years of follow-up. Conclusions:
Aspirin use, at low to moderate doses, is associated with a reduced risk of all-cause mortality,
largely due to death from cardiovascular disease. Although aspirin did appear to have a
modest benefit against death from cancer, the effect was primarily confined to death from
colorectal cancer, and required at least 10 years of use. These data support a need for
continued study into long-term use of aspirin in prevention of chronic diseases.
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Daily Soluble Aspirin and Prevention of Colorectal Adenoma Recurrence :
Four Years Results of the APACC Trial
Robert Benamouzig, Jacques Deyra, Antoine Martin, Baktiar Bejou, Jean-Jacques Raynaud,
Bernard Girard, Stanislas Chaussade
Aspirin is one of the most promising candidate drugs for colorectal cancer chemoprevention.
Many case control, cohort and two prospective studies suggested an aspirin protective effect.
To clarify this effect, we conducted a prospective, randomized, double-blind, placebo-
controlled, multicenter trial (the APACC Study) involving 49 centers in France to compare
the efficacy of aspirin as lysine acetylsalicylate 160 or 300 mg/d vs. placebo on the recurrence
of the colorectal adenomas at one and 4 years. A protective effect was previously showed
at one year. However the optimal dose and the duration of this chemoprevention remain
discussed. We report here the final results at 4 years. Subjects were aged between 18 to 75
years and had undergone a complete colonoscopy with removal of at least one adenoma of
more than 6 mm or at least 3 adenomas irrespective of size. Patients with an history of
colorectal cancer, FAP, inflammatory bowel disease and the women likely to be pregnant
were excluded. In order to evaluate the tolerance and compliance with the treatment, the
291 eligible patients received 300 mg of lysine acetylsalicylate daily during a 4-week run-
in period. After this period, 272 patients were randomized: 188 men and 84 women, 58
years, with at least one adenoma of more than 10 mm in 180 cases and more than 3
adenomas in 90 cases, a personal history of adenoma in 64 cases and a family history of
colorectal cancer in 94 cases. After one and 4 years of treatment, 238 and 176 subjects (90
and 65% of randomized) underwent colonoscopy respectively. The presence of at least one
recurrent adenoma at 1 or 4 years was noted in 94 (53%) of the 176 patients. Aspirin was
associated with a reduction in the risk of recurrent adenomas at one year in term of subjects
with at least one adenoma of more than 5 mm or multiple adenomas (>3) (p<0,005). Aspirin
was associated only with lower multiplicity (RR of 0,28, p<0,02) at 4 years. This lower
effect observed at 4 years was not related to a lower statistical power related to lost of follow-
up. The effect at one year seems more important with the 300-mg dose while the effect at
4 years seems more important with the lower dose suggesting different transduction pathways
according to the aspirin dose. One possible hypothesis could be that the high dose had a
direct anti-tumor effect, observed on the polyps left in place, and that low dose would be
the “preventive” dose associated with an observed after several years of treatment as suggested
by observational studies.
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All Trans-Retinoic Acid (ATRA) Induces Apoptosis Via P38 and Caspase
Pathways in Barrett’s Esophagus
Kathy Hormi-Carver, Linda A. Feagins, Stuart J. Spechler, Rhonda F. Souza
Introduction: Retinoids have been used as chemopreventive agents for a number of premalig-
nant conditions. Data suggest that all trans--retinoic acid (ATRA) is one of the safest and
best tolerated retinoids and that it exerts pro-apoptotic effects. To explore a potential role
for ATRA as a chemopreventive agent for Barrett’s esophagus, we studied the effects of ATRA
on apoptosis in a non-neoplastic, telomerase-immortalized, metaplastic, Barrett’s epithelial
cell line. Methods: Telomerase-immortalized metaplastic Barrett’s epithelial cells, which are
not transformed and which express intact p53, were grown to 70% confluence and placed
in minimal media overnight. Cells were treated with 1 or 5 μM ATRA in the presence and
absence of inhibitors to p53 (pSRZ-siRNA-p53), p38 (SB-203580), and the caspase cascade
(z-Val-Ala-Asp-fluoromethyl ketone). Twenty-four hours later, apoptosis was determined
quantitatively by Annexin V and qualitatively by immunofluoresence with TUNEL and
caspase-3. p53, p38, total p38, and caspase-3 expression were determined by Western
blotting using β-actin as a loading control. Results: Treatment with ATRA significantly
increased apoptosis as assessed by Annexin V in a dose dependent fashion (0.27 ± .06 to
21.60 ± 1.83 % SEM and 46.12 ± 6.74 % SEM, respectively, p<0.01). This finding was
confirmed by the finding of abundant apoptotic cells by TUNEL and caspase-3 staining.
ATRA increased the expression of p53 protein in a dose-dependent fashion, and also increased
the phosphorylation of p38 and the expression of cleaved caspase-3. The apoptotic effect
of ATRA was abolished by treatment with inhibitors of both p38 and the caspase cascade,
but not by p53 RNAi. Inhibition of p38 also prevented expression of cleaved caspase-3,
suggesting that ATRA activates p38 upstream of the caspase cascade. Conclusions: ATRA
induces apoptosis in Barrett’s epithelial cells via activation of p38 and the caspase cascade,
but not through p53. This study elucidates molecular pathways whereby ATRA treatment
might prevent carcinogenesis in Barrett’s metaplasia, and provides the rationale for a clinical


















A Randomized Controlled Trial of Long Term Rofecoxib On Changes of
Gastric Intestinal Metaplasia
Wai K. Leung, Enders K. Ng, Francis K. Chan, Wing Y. Chan, Kui-Fat Chan, Alex C.
Auyeung, Candice C. Lam, James Y. Lau, Joseph J. Sung
Background & Aim: Gastric cancer and its precursor lesion, intestinal metaplasia (IM),
frequently express cyclooxygenase-2 (COX-2) at high levels. We tested whether gastric IM
would regress with long term use of specific COX-2 inhibitor. Methods: This was a double-
blind, randomized, placebo controlled trial. Individuals with histologically confirmed IM
were randomized to receive rofecoxib 25mg daily or placebo for 2 years. H. pylori infection
was eradicated in all patients prior to randomization. None of these patients took NSAID
and aspirin. Endoscopy was performed at baseline, end of Year 1 and Year 2 with multiple
biopsies taken from the antrum and corpus according to a standard protocol. The severity
of histological changes was graded by the updated Sydney Classification (score 0-3). The
primary endpoint was the proportion of patients with regression of IM (ie. score lower than
baseline by 1 or more). The severity of IM and the proportion of subjects with complete
regression of IM were regarded as secondary endpoints. Results: 213 subjects (mean age 51
years, 64% male) with confirmed IM were randomized: 107 to receive rofecoxib and 106
to placebo. The baseline characteristics and histological results of the two groups were
comparable. At Year 2, the COX-2 expression level in the gastric epithelium was significantly
lower in patients treated with rofecoxib (P = 0.027). The proportion of subjects with
regression of IM did not differ significantly between rofecoxib and placebo groups (antrum:
24.5% vs 26.9%, P = 0.74; corpus: 4.3% vs 2.2%, P = 0.68). 19.1% of patients on rofecoxib
and 16.1% of patients on placebo had no IM detectable at the end of 2-year (P = 0.59).
There was no significant difference in the severity of IM (Table), acute or chronic inflammation
and atrophy between the two groups. Conclusions: Gastric IM failed to regress after two
years of treatment with rofecoxib. Our findings may cast doubt on the reversibility of gastric
IM by COX-2 inhibition.
IM Scoring at Year 1 and 2
*P > 0.25 (rofecoxib vs placebo)
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Polyphenon E Inhibits Growth of Malignant Human Esophageal Epithelial
Cells By Downregulation of CREB and Cyclin D1
Shumei Song, Koyamangalath Krishnan, Kai-Feng Liu, Robert S. Bresalier
BACKGROUND: Green tea polyphenols including epigallocatechin gallate (EGCG) inhibit
tumor formation induced by multiple carcinogens in rodent cancer models. Polyphenon E
(Poly E) is a decaffeinated well-defined green tea catechin mixture that contains 50% EGCG
and is rapidly prepared. AIM: This study was designed to determine the effects of Poly E
on growth of human esophageal epithelial cells and the mechanisms involved in growth
regulation by this agent. METHODS: Human esophageal adenocarcinoma cell lines (SEG-
1, SKGT-4, BIC-1 and BE3) were used as model systems. MTT uptake assays and cell counts
were used to monitor cell proliferation, and flow cytometry for cell cycle analyses. Western
blots and immunocytochemistry were performed to determine protein expression and activa-
tion status (phosphorylation). Transient transfection of CREB and Cyclin D1 promoter
constructs were used for promoter activation analyses. RESULTS: Treatment with Poly E
potently inhibited the growth of four EA cells in a dose-dependent manner regardless of
their p53 status and increased the percentage of cells in the G1 phase of the cell cycle. Poly
E blocked transactivation of CREB promoter and phosphorylation of CREB induced by
tumor promoters including the bile acids chenodeoxycholic acid and deoxycholic acid. In
addition, Poly E significantly decreased cyclin D1 expression and induced hypophosphoryl-
ation of pRB in a dose-dependent manner, changes associated with G1 cell cycle arrest. Poly
E also inhibited transcriptional activity of the cyclin D1 promoter. Furthermore, Poly E-
induced down-regulation of cyclin D1 was blocked by lactacystin, an inhibitor of the 26S
proteosome, suggesting that Poly E also downregulates cyclin D1 expression by promoting
proteolysis. CONCLUSIONS: The phytochemical polyphenon E inhibits growth of trans-
formed human esophageal cells by deactivation of CREB transcription factor, and down-
regulation of cyclin D1 via both transcriptional and post-transcriptional mechanisms. These
findings have implications for use of this compound in the prevention and treatment of
esophageal adenocarcinoma.
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Prospective Comparison of Routine Cytology (RC), Digital Image Analysis
(DIA), and Fluorescence in Situ Hybridization (FISH) in Patients Undergoing
Endoscopic Ultrasound Guided Fine Needle Aspiration (EUS FNA)
Michael J. Levy, Jonathan E. Clain, Amy C. Clayton, Kevin C. Halling, Gavin C.
Harewood, Benjamin R. Kipp, Elizabeth Rajan, Lewis R. Roberts, Thomas J. Sebo, Mark
D. Topazian, Kenneth K. Wang, Maurits J. Wiersema, Gregory J. Gores
Background: Prior studies indicate enhanced diagnostic accuracy for DIA and FISH versus
RC when evaluating biliary strictures. These tumor markers have never been applied to EUS
FNA specimens. We hypothesize that these molecular markers incorporate generic targets
capable of identifying a broad spectrum of malignancy. Aim: To compare the diagnostic
accuracy of DIA and FISH to RC for a broad spectrum of pathologies sampled during EUS
FNA. Methods: We prospectively evaluated pts with known or suspected malignancy by
RC, DIA, and FISH. For clinical purposes, presence of malignancy by either DIA or FISH
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(DIA/FISH) was considered diagnostic. However for study purposes separate confirmation
of malignancy was required for diagnosis. Pts with benign disease were followed at least 12
months and charts were reviewed to determine the accuracy. Results: 39 pts were enrolled
and each diagnostic test performed upon samples collected from 42 sites to evaluate lymphad-
enopathy (n=19), solid pancreatic mass (n=12), cystic pancreatic lesion (n=7), esophageal
or gastric wall mass (n=3), and thyroid mass (n=1). Malignancy was detected in 30/42
pts, including esophageal squamous cell carcinoma, esophageal adenocarcinoma, gastric
adenocarcinoma, pancreatic adenocarcinoma, pancreatic mucinous cystic neoplasia, intrad-
uctal papillary mucinous neoplasia, metastatic forearm sarcoma, small cell lung cancer, non
small cell lung cancer, thyroid follicular carcinoma, malignant gastrointestinal stromal tumor,
melanoma, adenocarcinoma of unknown primary, and lymphoma. The sensitivity, specificity,
and accuracy of DIA/FISH versus RC for detection of malignancy were 97%, 100%, 98%
versus 87%, 100%, 90% respectively. (Table 1) No false positive results occurred for DIA or
FISH. The one failed diagnosis for DIA/FISH was in a patient with a malignant gastrointestinal
stromal tumor. DIA/FISH correctly identified dysplasia or malignancy in 5 pts with cytology
interpreted as benign, atypical, or suspicious. The final diagnosis in these pts was pancreatic
adenocarcinoma (n=3), esophageal squamous cell carcinoma (n=1), and IPMN (n=1). No
complications were identified. Conclusion: Our findings suggest that in pts undergoing
EUS FNA that DIA and FISH have a higher diagnostic accuracy than RC. These data suggest
that these tumor markers incorporate generic targets as suggested by the high diagnostic
sensitivity in this cohort of pts with diverse pathologies.
Table 1:
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Screening Colonoscopy with Confocal Laser Endomicroscopy (CLE) for in
Vivo Diagnosis of Colorectal Neoplasias
Ralf Kiesslich, Martin Goetz, Arthur Hoffman, Katharina Lammersdorf, Constantin
Schneider, Michael Vieth, Manfred Stolte, Peter R. Galle, Markus F. Neurath
Introduction: Confocal laser endomicroscopy (CLE) allows subsurface, microscopic imaging
of living cells in colonic tissue in vivo. The aim of the present study was to assess the
potential of in vivo confocal laser colonoscopy for prediction of histology during screening
colonoscopy for colorectal cancer. Methods: Patients with informed consent designated for
screening colonoscopy were enrolled in the study and underwent total colonoscopy with
CLE (Optiscan, Australia; Pentax, Japan; excitation of 488nm argon ion laser; detection
>515 nm; optical slice thickness 7μm; lateral resolution 0.7μm; frame rate 0.8 or 1.6 frames/
sec with 1024x1024 or 1024x512 pixels). After reaching the cecum, a fluorescent contrast
agent (fluorescein) was administered intravenously. During withdrawal of the endoscope,
standardized locations (right, transverse colon, rectum) and every circumscript lesion was
examined by using the confocal microscope (fluorescence technique), afterwards biopsies
were taken. Confocal images were graded according to the confocal pattern classification
for the presence of neoplastic changes and compared with final histology. Results: 280
patients were included in the study. 112 colonic lesions (34 non-neoplastic, 65 adenomas,
9 adenomas with high-grade dysplasia, 4 cancers) larger than 5mm could be endoscopically
diagnosed. By the use of CLE, different cellular structures, capillaries and connective tissue
limited to the mucosal layer could be identified. Neoplasia could be prospectively predicted
by the use of confocal pattern classification with high accuracy (Sensitivity 98.7%; Specificity;
94.1%; Accuracy: 97.3%). All patients developed a transient discoloration of the skin after
fluorescein application. However, no further side effects were noted. Conclusions: In this
largest prospective study on CLE carried out so far, confocal laser endomicroscopy (CLE)
emerged as a safe and well tolerated additional diagnostic option for screening colonoscopy.
Endoscopically identified colonic lesions can be microscopically graduated during ongoing
colonoscopy and neoplasias can be predicted with high accuracy. Thus, in vivo histology
can be used to target endoscopic therapy or biopsies.
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Spectroscopic Microvascular Assessment from the Endoscopically Normal
Mucosa for Colon Adenoma Identification
Hemant Roy, Yang Liu, Young Kim, Michael Goldberg, Nahla Hasabou, Vladimir
Turzhitsky, Mohammed Jameel, Eric Elton, Vadim Backman
Developing technology to decrease polyp miss rate(estimated to be 15% in expert hands)is
of great importance from both a clinical and medicolegal perspective. Members of our group
have been pioneered light scattering technologies for diagnosis of dysplastic lesions (Nature
2000, Nature Med 2001). We have recently developed four dimensional elastic light scattering
fingerprinting (4D-ELF)(Gastro 2004), which allows unprecedented ability to quantitatively
probe the mucosal micro-circulation. Using 4D-ELF, we have reported that microvascular
blood content was increased in the histologically normal colonic mucosa in experimental
CRC models(Gut 2005). In the present study, we assessed whether increased microvascular
blood could aid in localization of colonic neoplasia. METHODS One hundred subjects
undergoing colonoscopy were recruited and had two biopsies taken from the in the endoscop-
ically-normal mucosa (at least 5 cm from any adenomas) cecum, mid-transverse colon and
rectum. Fresh biopsies were subjected to 4D-ELF analysis Microvascular (within 50 μM of
tissue surface) were analyzed by an investigator blinded to colonoscopic findings. RESULTS
As demonstrated in the figure, microvascular blood content was demonstrated to be markedly
elevated in the endoscopically normal mucosa of patients who harbored adenomas in the
respective colonic segment (right colon, transverse or left colon). The sensitivity, specificity,
positive and negative predictive value of increased microvascular blood was 89%, 100%,
100% and 75%, respectively. CONCLUSIONS: We demonstrate, for the first time, that
microvascular blood content in the endoscopically normal mucosa could identify patients
at risk for colonic neoplasia and aid in localization. In the future, we envision that this
approach (with a probe) could determine which colonic segments warrant extra endoscopic
scrutiny (including possibly chromoendoscopy).
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Image Registered Gastroscopic Ultrasound (IRGUS): 3D Registration of
Endoscopic Ultrasound and CT Improves Efficiency and Structure
Identification Over Standard Endoscopic Ultrasound
Christopher C. Thompson, Nicholas Stylopoulos, Raul San-Jose Estepar, Eigil Samset,
Randy Ellis, William Brugge, Kirby G. Vosburgh
INTRODUCTION Although Endoscopic Ultrasound (EUS) is a useful tool for the diagnosis
and staging of abdominal and thoracic diseases, it has not been maximally adopted by
gastroenterologists. This is due in part to the long learning curve and the lack of confidence
in ultrasound interpretation. To overcome these hurdles, we have designed and implemented
IRGUS, a novel system that links preprocedure CT with real-time EUS imaging. MATERIAL
AND METHODS IRGUS aligns preprocedure CT images with real time EUS imaging so that
the CT image corresponds to the oblique EUS plane. The operators are also provided with
a novel 3D display and important spatial cues that show them how the plane of the EUS
is oriented relative to the patient’s anatomy. In this study, novice and expert gastroenterolog-
ists were asked to perform an in vivo EUS examination of anesthetized pigs, identifying 8
key anatomic structures in a 5-minute period using traditional EUS and IRGUS. A sensor
that was mounted on the echoendoscope allowed the tracking and recording of the motion
of the scope during the task. These recordings were then used to calculate the efficiency of
performing the exam, which is based on a set of kinematic parameters that we have used
and validated in previous studies. At the conclusion of the tasks, participants completed a
questionnaire. RESULTS Using conventional EUS, novices identified 29% of the structures
and experts 50%, within the allotted time. Using IRGUS these rates increased significantly
to 71% and 80% respectively (P<0.0001). IRGUS had the largest impact on the localization
and identification of the right lobe of the liver and the right kidney. IRGUS also had a
statistically significant benefit in assisting novices to identify the pancreatic body and tail.
In the questionnaire, all participants rated IRGUS as superior to EUS. The analysis of
kinematic data showed that IRGUS increased efficiency of conventional EUS by improving
the economy of movements (path length), the smoothness of motion and the response
orientation of the operator. CONCLUSIONS IRGUS is superior to conventional EUS in the
localization and identification of anatomic structures and in various kinematic measures. It
enhances procedural efficiency of both experts and novices and allows direct CT confirmation
of structures and lesions. This novel technology has the capability of expanding the applica-
tions of conventional EUS and may allow for broader adoption beyond its current use.
Portions of this work are sponsored by the US Department of the Army. The information
does not necessarily reflect the position of the government and no official endorsement
should be inferred.
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Comprehensive Three-dimensional Microscopy of the Porcine and Human
Esophagus in Vivo Using Optical Frequency Domain Imaging
Melissa Suter, Benjamin J. Vakoc, Norman S. Nishioka, Jerry Evans, Seok H. Yun,
Seyedmohammadreza Motaghiannezam, Adrien Desjardins, Brett E. Bouma, Guillermo J.
Tearney
Current assessment and diagnosis of patients with Barrett’s esophagus involves endoscopy
accompanied by the collection of multiple random biopsies. This form of assessment is
however invasive and susceptible to sampling errors highlighting the need for improved
evaluation techniques. Optical coherence tomography (OCT) has been shown to provide
high-resolution cross-sectional images of the esophageal microstructure allowing for accurate
differentiation of dysplasia and SIM in patients with Barrett’s esophagus. One drawback to
traditional OCT is that it is generally restricted to point sampling techniques due to limitations
in imaging speed and catheter design. Optical frequency domain imaging (OFDI) is a new
imaging technology that is based on frequency domain interferometry and is capable of
improving imaging speed over traditional OCT techniques by orders of magnitude without
sacrificing image quality. We have developed a catheter based OFDI system that acquires
comprehensive three-dimensional microscopic images of the entire distal esophagus. Both
porcine and human in vivo studies were performed with the developed OFDI catheter based
system. Complete volumetric imaging was performed in 5cm longitudinal segments and
was consequently analyzed and correlated with histopathology. We anticipate that the
introduction of comprehensive volumetric microscopy of the distal esophagus into clinical
practice will significantly improve the accuracy of current screening and surveillance methods
in patients with Barrett’s esophagus and will in turn lead to earlier detection of malignancy.
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As the survival rate of esophageal adenocarcinoma is stage dependent, earlier detection may
help to significantly reduce the current mortality rate associated with the disease.
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The Aer-O-Scope™ Omnivision System, a 3600 Panoramic View of the Colon
Douglas Rex, Thomas Roesch, Bernard Levin, Jorje Pfefer, Nadir Arber
The Aer-O-Scope™ (GI View, Ramat Gan, Israel) is a disposable, miniaturized, self-propel-
ling, self-navigating, endoscope. In a recent human study the cecum was reached in 10 of
12 patients (Vucelic et al, Gastro 2006). The Aer-O-Scope™ includes an advanced vision
system with two simultaneous scanning views that provide complete coverage of the entire
surface of the colon. A standard front view system (900 forward view) is similar to a
conventional endoscope, while a novel and unique imaging system provides a 3600 panoramic
view of the colonic surface, both in front and behind the scanner device (the OmniView)
[Fig. 1]. The OmniView mechanism enables detailed inspection of the entire colon surface
area, including those areas behind mucosal folds where polyps may be missed. The electro-
optical capsule size is 15 mm OD x 1.5mm long containing a CMOS based digital camera.
Its spatial resolution is greater than 1mm within the FOV and the depth of view is from
contact up to ~100mm which is adequate for all segments of the insufflated colon. The tip
is embedded within a low pressure hydrophilic coated vehicle balloon. This balloon has
two functions: it is the moving part of the Aer-O-scope, propelled by gas pressure and it
also serves as the imaging center of the device. The capsule is covered by a transparent
dome containing the optical lenses protruding from the balloon’s front end. White LED’s
with automatic intensity control provide illumination. The OmniVision system was tested
in thirty young female pigs. In all of the Aer-O-scope examinations clear and sharp visualiza-
tion of the colonic mucosa, similar to that obtained during conventional colonoscopy, was
achieved. High resolution images from the digital video camera were received, processed
and displayed in real time on a PC screen and digitally recorded.
Fig. 1: Simultaneous Frontal and OmniVision Fields of View [FOV]
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Endothelin-Converting Enzyme 1 (ECE1) Degrades Substance P (SP) and
Calcitonin Gene-Related Peptide (CGRP) in Early Endosomes and Thereby
Determines the Rate of Receptor Recycling and Resensitization
Graeme S. Cottrell, D.R. Roosterman, Benjamin E. Padilla, Stella Pikios, Laurent Muller,
Martin Steinhoff, Nigel W. Bunnett
β-arrestins interact with G-protein coupled receptors at the plasma membrane to mediate
desensitization of G-protein signaling and clathrin-dependent receptor endocytosis. However,
little is known about the mechanisms that control receptor recycling and resensitization.
Although neprilysin degrades peptides at the cell-surface to terminate signaling, the role of
intracellular peptidases in controlling receptor signaling has not been studied. We hypothes-
ized that ECE1 degrades peptides in endosomes and thereby accelerates dissociation of β-
arrestins from receptors to promote recycling and resensitization. We expressed ECE1a-d-
GFP in KNRK cells expressing the neurokinin 1 receptor (NK1R), the receptor for SP, and
in HEK cells expressing calcitonin receptor like receptor (CLR) and receptor activity modifying
protein 1 (RAMP1), the receptor for CGRP. ECE1 isozymes were detected in vesicles that
colocalized with early endosomal antigen 1. When KNRK-NK1R-ECE1 cells were incubated
with Alexa-SP for 30 min at 37°C, both NK1R and SP were detected in early endosomes
containing ECE1. Similarly, when HEK-CLR-RAMP1-ECE1 cells were incubated with CGRP
for 30 min, CLR and RAMP1 were detected in endosomes containing ECE1. To determine
if ECE1 degrades SP and CGRP in endosomes, we incubated membranes (5-20 µg protein)
with SP and CGRP (25 µM) at the pH of early endosomes (5.5), and analyzed metabolites
by high-pressure liquid chromatography. Membranes from cells expressing ECE1 rapidly
degraded SP and CGRP, whereas membranes from cells expressing control vector only slowly
cleaved these peptides. We exposed cells to SP or CGRP (10 nmol, 10 min), washed and
then examined the rate of resensitization of Ca2+ signaling to a second challenge with the
same agonist. In KNRK-NK1R cells, resensitization to SP after 30 min was greater in ECE1
cells compared to control cells. Similarly, expression of ECE1 in HEK-CLR-RAMP1 cells also
accelerated resensitization to second challenge of CGRP. To determine if peptide degradation
promoted dissociation of β-arrestins, which would release receptors for recycling, we localized
receptors and β-arrestins. In vector control cells, SP and CGRP induced the prolonged
sequestration of β-arrestin 1 and 2 in endosomes containing NK1R or CLR-RAMP1. Overexpr-
ession of ECE1 accelerated the dissociation of β-arrestins from receptors, thereby promoting
recycling. Thus, we report a new role for ECE1. ECE1 can degrade SP and CGRP in early
endosomes to promote the dissociation of the NK1R and CLR-RAMP1 from β-arrestins and
thereby accelerate recycling and resensitization of the receptors for SP and CGRP. Supported


















P53 Downregulates Tff2 Expression in Gastric Cancer Cells Through An AP-1
Binding Site
Shuiping Tu, Wandong Ai, Alfred L Chi, Shigeo Takaishi, Zinaida Dubeykovskaya,
Timothy Cragin Wang
Background: Spasmolytic polypeptide (SP/TFF2) is a member of the trefoil peptide family,
abundantly expressed and secreted by neck cells of stomach. It plays an important role in
maintaining mucosal integrity. Expression of TFF2 is upregulated in chronic gastritis, and
overexpression of TFF2 is associated with cell migration, resistance of apoptosis, angiogenesis
and possibly gastric cancer invasion. Deregulation of p53 is also frequently observed in
preneoplastic conditions of the stomach. However, the relationship between p53 and TFF2
remains unknown. In this study, we investigated the effect of p53 on the expression of
TFF2 in gastric epithelial cells. Methods: Endogenous mRNA expression of TFF2 was detected
by semi-quantitative RT-PCR and quantitative RT-PCR. A series of truncated promoters of
human TFF2 gene were generated using a pGL3 luciferase reporter vector (TFF2-Luc
reporters). Cells were cotransfected with either wild type p53 or dominant negative mutant
p53 (p53Mut) expression plasmids with TFF2-Luc reporters. Reporter activities were meas-
ured by Dual-Luciferase Reporter assay system. Results: TFF2 mRNA was detected in all 5
gastric cancer cell lines tested. Overexpression of p53 inhibited the level of endogenous
TFF2 mRNA and p53Mut increased the level of TFF2 mRNA in gastric cell lines. P53 dose-
dependently inhibited the activity of TFF2 promoter. The temperature-sensitive p53 mutant
at the permissive temperature also inhibited the expression of TFF2 mRNA and the activity
of TFF2 promoter. Reporter assays showed that p53-depedent inhibition of TFF2 promoter
occurred through an upstream -175~-219bp region contains an AP-1-like cis-element.
Ectopic expression of c-jun/c-fos activated the TFF2 promoter and p53 inhibited this effect.
Furthermore, mutation of AP-1 binding site abrogated c-jun/c-fos-mediated activation and
p53-mediated inhibition of TFF2 promoter activity. PMA, a tumor promoter and activator
of AP-1, stimulated endogenous mRNA expression and the promoter activity of TFF2, and
p53 inhibited the effect of PMA on TFF2. Conclusions: p53 downregulates the expression
of TFF2 at the transcriptional level through an AP-1-like cis-acting site. The p53-depedent
inhibition of PMA- and c-jun/c-fos-mediated TFF2 activation supports the hypothesis that
deregulation of p53 allows oncogenic or inflammation-stimulated upregulation of TFF2.
The data suggest the possibility that TFF2 may be a downstream target of p53. The inhibition
of TFF2 by p53 may facilitate damage cells to undergo apoptosis and to inhibit cell invasion
and angiogenesis in the chronic inflammation and development of cancer.
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Rap1 Regulates Neurotensin Secretion Downstream of cAMP/PKA and cAMP/
Epac Pathways in the Human Endocrine Cell Line Bon
J.N. Li, Kathleen L. O'Connor, Courtney M. Townsend, B. Mark Evers
Neurotensin (NT) is a gut peptide localized predominantly to the small bowel that plays
an important role in gastrointestinal growth. We have reported that both cAMP/PKA and
cAMP/Epac pathways are involved in forskolin (FSK)-stimulated NT secretion, in a novel
human endocrine cell line BON; however, the mechanisms regulating cAMP-mediated NT
secretion are not known. cAMP regulates secretion of certain hormones via Epac or PKA,
but it is not clear if Rap1 is involved in their effects. Rap1, a small GTPase, is phosphorylated
by PKA; Epac, a guanine nucleotide-exchange protein activated by cAMP, catalyzes the
exchange of GTP for GDP and activates Rap1. In the present study, we determined: i)
whether Rap1 regulates cAMP-stimulated NT secretion, and ii) whether Rap1 is a downstream
effector of Epac or PKA. METHODS. (i) To determine the role of Rap1 in NT secretion,
stable BON cell lines expressing constitutively active Rap1 (BON/Rap1V12) were established.
Parental BON cells were transfected with either Rap1 siRNA or Rap1GAPII plasmid to
suppress endogenous Rap1 expression or inactivate Rap1 activity, respectively. (ii) To deter-
mine the cellular localization of Rap1, GFP-tagged Rap1 was analyzed by confocal microscopy.
(iii) To determine whether Rap1 activation was regulated by upstream PKA or Epac, BON cells
were treated with PKA or Epac activators (6-Phe-cAMP or 8-pMeOPT-cAMP, respectively) or
transfected with wild type Epac or a cAMP binding mutant EpacR279E; in vitro Rap1
activity assays were performed. RESULTS. We found that FSK-stimulated NT secretion was
significantly enhanced in BON/Rap1V12 cells but reduced in BON cells transfected with
either Rap1 siRNA or Rap1GAPII. GFP-tagged, wild type Rap1 was expressed in the cytosol
and nucleus of BON cells, whereas the constitutively active Rap1V12 was predominantly
localized to the membrane in addition to the cytosol. The dominant negative Rap1N17 was
localized in the cytosol associated with granule-like structures. Rap1 activity was significantly
induced by overexpression of wild-type Epac and Epac activators which increased NT release.
In contrast, Rap1 activity was inhibited in BON cells stably transfected with EpacR279E,
which decreased NT release. Rap1 activity was significantly up-regulated by the PKA activator,
which also increased NT secretion. CONCLUSIONS. Rap1 plays a critical role in cAMP-
regulated NT secretion. Importantly, we demonstrate, for the first time, that Rap1, acting
downstream of both cAMP/PKA and cAMP/Epac pathways, is involved in the regulation of
NT hormone secretion, thus identifying these pathways as critical components for stimulated
intestinal hormone release.
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Mechanisms of Stimulation of Intracellular Calcium in Enteroendocrine STC-1
Cells By Bitter Tastants
Monica C. Chen, Shuping V. Wu, Enrique Rozengurt
Background: We recently demonstrated the expression of bitter taste receptors of the T2R
family and the a subunits of the G protein gustducin (Gαgust) and transducins in the rodent
GI tract and in GI endocrine cells. However, the intracellular signal transduction cascades
initiated by bitter tastants in the enteroendocrine cells have not been explored. Aims: This
study was designed to determine calcium signaling pathways initiated by bitter tastants in
the enteroendocrine cells. Specifically, we characterized mechanisms of Ca2+ fluxes and
mobilization induced by two distinct T2R bitter ligands: denatonium benzoate (DB) and
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phenylthiocarbamide (PTC), in mouse enteroendocrine cell line STC-1. Methods: Expression
of bitter taste signal transducers was determined by RT-PCR and immunocytochemistry.
Calcium responses of STC-1 treated with various concentrations of DB or PTC in the presence
of ion channel blockers or openers were measured by calcium fluorometry. Results: In
addition to previously identified mT2Rs, we detected the expression of Gαgust, PLCβ2,
TRPM 5 and L-type calcium channel (Cav1.2 and 1.3) in STC-1 cells. About 95% of these
cells were gustducin-positive, as shown by immunocytochemistry. Both DB and PTC induced
a marked increase in intracellular calcium concentration ([Ca2+]i) in dose- and time-depend-
ent fashion. Depolarization by KCl and L-type calcium channel opener Bay-K8644 mimicked
the increase in [Ca2+]i induced by DB and PTC. Chelating extracellular Ca2+ with EGTA
blocked the increase in [Ca2+]i induced by DB and PTC but did not prevent the effect
induced by bombesin. Tharpsgargin at 50 nM blocked the transient increase in [Ca2+]i
induced by bombesin, but did not attenuate the [Ca2+]i increase activated by DB or PTC.
These results indicate that Ca2+ influx mediates a substantial component of the increase in
[Ca2+]i induced by DB and PTC in STC-1 cells. Preincubation with the L-type Ca2+ channel
blockers nitrendipine or diltiazem inhibited the increase in [Ca2+]i elicited by tastants and
KCl, indicating that the opening of L-type Ca2+ channels play a major role in mediating the
increase in [Ca2+]i in response to DB or PTC in STC-1 cells. Tastants also induced a marked
increase in the release of CCK from STC-1 cells, an effect prevented by L-type Ca2+ channel
blockers. Conclusion: Our results demonstrated that bitter tastants increase [Ca2+]i through
Ca2+ influx mediated by the opening of L-type Ca2+ channels in the STC-1 cells. Our data
suggest that STC-1 cells provide a model system to study intracellular signal transduction
pathways and secretory responses initiated by tastants in enteroendocrine GI cells.
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Agonists of Protease-Activated Receptor 2 (PAR2) Sensitize Transient Receptor
Potential Vanilloid 4 (TRPV4) to Induce Mechanical Hyperalgesia
Andrew Grant, Graeme Cottrell, Elizabeth Joseph, Nicola Lissi, Marcello Trevisani,
Pierangelo Geppetti, Nicole Alessandri-Haber, Jon D. Levine, Nigel W. Bunnett
Proteases that are generated during injury and inflammation, such as trypsins and tryptase,
cleave PAR2 on primary spinal afferent neurons to induce hyperalgesia to thermal and
mechanical stimuli. Thermal hyperalgesia depends on protein kinase A (PKA) and PKCε-
mediated sensitization of the ion channel TRPV1, but the mechanisms of PAR2-induced
mechanical hyperalgesia are unknown. We hypothesized that PAR2 induces mechanical
hyperalgesia by sensitizing TRPV4, which mediates pain responses to mechanical and osmotic
stimuli. Since TRPV4 shows preference for Ca2+ ions, we examined sensitization of TRPV4-
dependent changes in [Ca2+]i in human bronchial epithelial cells (HBE), which naturally
express PAR2 and TRPV4, and HEK cells, which express PAR2 and were transiently trans-
fected with human TRPV4. The TRPV4 agonist 4α phorbol 12,13-didecanoate (4αPDD,
0.1-10 µM) and hypotonic stimuli (-10-20%) increased [Ca2+]i in HBE and HEK-TRPV4
cells, but not in untransfected HEK cells, suggesting activation of TRPV4. Preincubation
with PAR2 activating peptide (AP, SLIGRL-NH2, corresponding to the tethered ligand domain
of PAR2, 100 µM, 5 min) enhanced the effect of 4αPDD by 124±14% in HBE and 55±17%
in HEK-TRPV4 cells, and enhanced the effect of a hypotonic stimulus by 38±16% in HBE
and 149±19% in HEK-TRPV4 cells, indicating TRPV4 sensitization. Inhibitors of PKA (H89,
10 µM) and PKC isozymes (GF109203X, 10 µM and Gö6976, 0.1 µM) inhibited sensitization
by >50%. The inactive reverse peptide sequence (PAR2-RP), and PAR1-AP (TFLLRN-NH2),
which do not cause hyperalgesia, had no effect, confirming specificity. Superfusion of slices
of rat spinal cord with 4αPDD or hypotonic solution stimulated the release of the nociceptive
peptides substance P by >4-fold and calcitonin gene-related peptide by >9-fold. Preincubation
with PAR2AP (100 µM, 20 min) enhanced the effects of 4αPDD on release of SP and CGRP
by 3-fold and 2-fold, and enhanced the effects of hypotonic solution of release of both SP
and CGRP by 1.5-fold, compared to PAR2-RP. In wild type mice, intraplantar injection of
PAR2-AP increased the frequency of paw withdrawal to mechanical stimulation with a von
Frey hair (0.174 mN) by 222±20%, and enhanced the response to hypotonic stimulus by
189±23%, indicative of sensitization. These effects were absent from TRPV4-/- mice. Thus,
activation of PAR2 sensitizes TRPV4 by PKA and PKC-dependent mechanisms to potentiate
the release of nociceptive peptides from primary spinal afferent neurons and cause hyperalge-
sia to mechanical stimulation. Supported by NIH grants DK57480, DK43207, DK39957.
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Altered Gastrointestinal Function and Energy Balance in Obestatin Receptor
(GPR39) Knockout Mice
Inge Depoortere, Dieder Moechars, Betty de Smet, Benoit Moreaux, Peter King, Kim
Cryns, I Goris, Luc Verdonck, Theo Peeters, Bernard Coulie
Obestatin has recently been discovered as the ligand of the orphan GPR39 receptor. Obestatin
is encoded by the ghrelin gene and is part of what was known as the ghrelin associated
peptide. Functionally obestatin opposes the effects of ghrelin and decreases food intake,
body weight gain, gastric emptying and intestinal motility (Zhang et al., Science 310: 996-
999, 2005). To gain insight into the functional role of the obestatin receptor we generated
GPR39-/- mice. Methods. Energy balance was investigated by comparing food intake and
respiratory quotient (RQ) between wildtype (GPR39+/+) and GPR39 knockout (GPR39-/-)
mice. For gastrointestinal function gastric emptying (measured by the 14C octanoic breath
test), fecal pellet propulsion and gastric secretion were compared between the two genotypes.
Results. Development, growth, immune function and fertility were identical in GPR39-/- and
GPR39+/+ littermates. The mature body weight of GPR39-/- mice (42.3±1.8 g) was significantly
(P<0.05) higher than that of GRP39+/+ mice (35.7±1.9 g) although the growth rate parameters
were the same. Under normal ad libitum feeding, both genotypes consumed the same amount
of food with normal circadian patterns of spontaneous 24h food intake. In contrast, deficiency
of the GPR39 receptor led to reduced hyperphagia after fasting. Six hours cumulated food
intake after 19h fasting was 2.20±0.29 g in GPR39+/+ but only 0.96±0.29 g in GPR39-/-
mice (P<0.05). The RQ was significantly higher in the GPR39-/- mice and this was mainly due
to increased RQ values during the light period. Cholesterol levels (mg/dl) were significantly
increased in both male (142.2±29.0) and female (118.7±16.2) mutants, compared to wildtype
male (107.3±37.8) and female (83.5±24.2) littermates. Gastric emptying of a solid meal was
significantly (P<0.005) accelerated with a gastric half emptying time of 49.5±2.2 min com-
pared to 86.9±8.4 min in GPR39+/+ mice. A more effective expulsion of distally located
pellets (30-75% of length) was observed in the colon of GPR39-/- mice. Four hour after
pylorus ligation, volume of gastric secretion was significantly increased (GPR39-/-: 638±336
μl, GPR39+/+: 225±170 μl), but gastric acid secretion was unchanged. No changes in anxiety
were observed between both genotypes but open field test indicated a significant decreased
general activity in GPR39-/- mice. Conclusion. Our data are mostly in agreement with the
described effects of obestatin and suggest that this peptide plays a functional role in the
regulation of energy balance and gastrointestinal function through interaction with the
GPR39 receptor, probably by counteracting the effects of ghrelin.
732
Proton Pump Inhibitor Plus a COX-2 Inhibitor for the Prevention of Recurrent
Ulcer Bleeding in Patients with Arthritis: A Double Blinded, Randomized Trial
Francis Chan, Vincent W. Wong, Bing Y. Suen, Justin C. Wu, Wai K. Leung, Yuk T. Lee,
James Y. Lau, Joseph J. Sung
BACKGROUND Among patients with a history of NSAID-induced ulcer bleeding, neither
NSAIDs plus a proton pump inhibitor (PPI) nor a COX-2 inhibitor is adequate to prevent
recurrent ulcer bleeding. AIM To investigate whether PPI plus a COX-2 inhibitor is superior
to COX-2 inhibitor alone for the prevention of recurrent ulcer bleeding in patients with
previous ulcer bleeding. METHODS Patients with arthritis who presented with NSAID-
induced ulcer bleeding confirmed by endoscopy were eligible if they: 1. had healed ulcers
on follow-up endoscopy, 2. were H. pylori negative or eradicated, and 3. required regular
NSAIDs. The exclusion criteria were renal failure (creatinine >2.2 mg/dl), concomitant use
of low-dose aspirin, steroids or anticoagulants, malignancy and terminal illnesses. The use
of prohibited drugs (low-dose aspirin, NSAIDs, steroids, anticoagulants, or other anti-ulcer
drugs) during the study period was a protocol violation. RANDOMIZATION After the ulcers
had healed, all patients received celecoxib 200 mg b.i.d. They were randomly assigned to
esomeprazole 20 mg b.i.d. or its placebo for 12 months. PRIMARY ENDPOINT Recurrent
ulcer bleeding determined by an adjudication committee using pre-specified criteria.
RESULTS In the intention-to-treat analysis, which included 273 patients (137 receiving
celecoxib plus esomeprazole and 136 receiving celecoxib plus placebo). The probability of
recurrent ulcer bleeding during the 12-month period was 0% in the esomeprazole group
and 8.9% (95% CI, 4.1 to 13.7) in the placebo group (log rank test, P=0.0004). During
the study period, 16.1% of patients in the esomeprazole group and 15.4% in the placebo
group used low-dose aspirin. Among patients who did not use concomitant aspirin, the
probability of recurrent ulcer bleeding was 0% in the esomeprazole group and 7.1% (95%
CI, 2.4 to 11.8) in the placebo group (P=0.004). CONCLUSION Among patients with a
history of NSAID-induced ulcer bleeding, esomeprazole plus celecoxib was superior to




In Vivo Diagnosing of Helicobacter Pylori with Confocal Laser
Endomicroscopy - Prospective Evaluation in Comparison with Conventional
Histology and Urease Testing
Ralf Kiesslich, Martin Goetz, Arthur Hoffman, Constantin Schneider, Katharina
Lammersdorf, Michael Vieth, Manfred Stolte, Peter R. Galle, Markus F. Neurath
Abstract: Confocal laser endomicroscopy (CLE) enables surface and subsurface imaging of
living tissue during ongoing endoscopy. Currently, in vivo diagnosis of Helicobacter pylori
with acriflavine aided CLE was described. The aim of the current prospective study was the
in vivo detection of Helicobacter pylori in patients with dyspepsia and the correlation with
histologic findings and urease testing. Methods: Endomicroscopy (Pentax, Tokyo, EC-
3870CIFK) of the stomach was performed by using two different contrast stains. Fluorescein
was applied intravenously to enable confocal endomicroscopy of the gastric mucosa. Confocal
image data were collected at a scan rate of 1.6 sec/frames (1024x1024 pixels) using an optical
slice thickness of 7µm (lateral resolution≤1µm). Subsequently, acriflavine hydrochloride was
applied topically onto the surface of the gastric mucosa with the help of a spraying catheter.
Acriflavine netted the surface and allowed identification of focal accumulation of Helicobacter
pylori at the surface and in deeper layer of the gastric epithelium. Targeted biopsies of the
examined areas were performed at the antrum and corpus for urease testing and histology
(Warthin-Starry silver). Results: In 11 out of 30 patients Helicobacter pylori infection could
be diagnosed by CLE. Accumulated as well as single bacteria with bright contrast could be
observed including the distinct shape and flagella of Helicobacter pylori. In addition gastritis
could be graduated due to visible vessel and cell alterations. Helicobacter pylori infection
was proven in all except one case by histology and urease testing (Sensitivity 90.9%,
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Specificity 96.7%). The single false positive result was seen in a patient with extremely
few germs detected by endomicroscopy. Furthermore, 4 patients were re-examined after
eradication. CLE correctly proved the absence of Helicobacter pylori. Conclusions: Endomicro-
scopy allows simultaneously endoscopic images of the stomach, in vivo histology of gastritis
and immediate diagnosis of Helicobacter pylori infection during ongoing upper endoscopy.
The diagnostic accuracy is comparable with conventional histology and urease testing.
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Acidification of Distal Esophagus Increases Cough Reflex Sensitivity in
Patients with Gastroesophageal Reflux Disease (GERD) and Chronic Cough
Nikoleta Javorkova, Renata Pecova, Silvia Varechova, Michal Demeter, Rudolf Hyrdel,
Dusan Balaz, Milos Tatar, Marian Kollarik
BACKGROUND & AIMS: Gastroesophageal reflux ranks among the most important causes
of chronic cough, however, the mechanisms by which gastroesophageal reflux initiates
coughing are incompletely understood. It is generally accepted that hyperexcitability of the
cough reflex (increased cough reflex sensitivity) results in coughing. Here we address the
hypothesis that acidification of distal esophagus increases the cough reflex sensitivity in
patients with GERD and chronic cough. METHODS: Eight consecutive patients with GERD
complaining of chronic cough (cough persisting for >8 weeks) and 18 gender- and age-
matched patients with GERD without cough were recruited. GERD was confirmed by positive
fibroscopy and/or pH monitoring. In a randomized double blind study, saline and acid (HCl
0.1M) were separately infused into distal esophagus via nasoesophageal catheter (10ml/min,
15 min). The infusions were separated by at least 20 min. Cough reflex sensitivity was
determined immediately after completion of each infusion using standard capsaicin inhalation
challenge (single-breath inhalation of the aerosols of capsaicin solutions with doubling
concentrations, from 0.49μM to 500μM). The cough reflex sensitivity was expressed as the
lowest concentration of capsaicin evoking 2 coughs (C2). Group data were expressed as
median (interquartile range). RESULTS: Infusion of acid but not saline into distal esophagus
induced mild heartburn and/or chest discomfort in 7/26 patients. In patients with GERD
and chronic cough, infusion of acid into distal esophagus increased cough reflex sensitivity
[1.95 (0.98-15.6) μM after saline vs. 0.98 (0.49-1.95) μM after acid, p<0.05]. In contrast,
infusion of acid into distal esophagus in patients with GERD without cough had no effect
on the cough reflex sensitivity [15.6 (7.81-46.88) μM after saline vs. 31.25 (4.88-125) μM
after acid, p>0.5]. CONCLUSIONS: We conclude that acidification of distal esophagus
induces the cough reflex hyperexcitability in patients with GERD and chronic cough. We
speculate that this phenomenon (likely mediated by vagal nerves) underlies chronic cough
due to gastroesophageal reflux. Absence of this phenomenon in patients with GERD who
do not complain of cough further supports this notion. Supported by Slovak National
Research Grant VEGA 1/2273/05.
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Accelerate Healing of Penetrating Ulcer Using Bone Marrow Cell
Transplantation
Tsutomu Nishida, Shingo Tsuji, Masahiko Tsujii, Syuji Ishii, Toshiyuki Yoshio, Shinichiro
Shinzaki, Satoshi Egawa, Takanobu Irie, Yoshimi Kakiuchi, Masakazu Yasumaru, Hideki
Iijima, Hiroaki Murata, Sunao Kawano, Norio Hayashi
Background and Aim: Bone marrow (BM) has been found to be a source of multipotent
stem cells that could distribute into various organs including gut. We have reported that
BM-derived adult somatic stem cells have a potential to differentiate to myofibroblasts and
other types of stromal cells. However, therapeutic potential of BM-derived cells in intractable
ulcers has not yet demonstrated. The aim of this study was whether dish attached cultured
bone marrow cells promote ulcer healing in mice. Methods: BM cells and gastric myofibrob-
lasts were prepared from GFP-transgenic mice (TgN(β-act-EGFP)Osb). In certain experi-
ments, BM-cells were incubated in plastic dishes and the cells attaching the dishes were
collected and designated as cultured BM cells. Gastric ulcers were induced by serosal
application of acetic acid on anterior wall of the stomach in C57/B6 mice. Then, the ulcers
were implanted with the cultured BM cells (4×105 cells), myofibroblasts (4×105 cells), and
PBS as the control in the serosal surface where gastric ulcers were induced. The animals
were sacrificed on day 3, or 7. The samples were fixed in 4% paraformaldehyde/phosphate-
buffered saline for 3 h and mounted in Tissue-Tek OCT compound and frozen in liquid
nitrogen. The products of the long and short diameter of ulcer area were represented as
ulcer index. The origin and phenotypes of implanted cells were examined by fluorescence
immnohistochemistry for GFP, α-smooth muscle actin (SMA), vimentine, and other surface
marker antigens for stromal cells. Results: Healing of the acetic acid ulcer was significantly
promoted by injection of cultured BM cells than the control on day 7, but not on day 3
(ulcer index 4.4±1.5 vs 11.1±2.8 mm2 , p=0.0140). In healing ulcers, GFP+ cultured BM
cells were observed in submucosal layers. These cells were positive for GFP, α-SMA, and
vimentine, have spindle shape, and considered to be differentiated mesenchymal cells. On
the other hand, healing of the acetic acid ulcer was prolonged in mice implanted with
myofibroblasts as compared to the control. GFP+ stromal cells were not seen in ulcered area
in mice transplanted with myofibroblast. Conclusions: Cultered BM cells were transplantable
to penetrating ulcers. Cultured BM cells could be a new source of mesenchymal cells


















Evidence from Linkage Analysis for Susceptibility Genes in Familial Barrett’s
Esophagus and Esophageal Adenocarcinoma
Yvonne Romero, Joshua P. Slusser, Mariza De Andrade, Julie M. Cunningham, Teresa G.
Zais, Debra M. Geno, Gloria M. Petersen, Barrett’s esophagus genomic study group
Background: The Barrett’s Esophagus Genomic Study Group comprises 156 physicians from
varying practice environments who collaborate to identify Barrett’s esophagus (BE) families
for genomic analysis. Aim: To map susceptibility genes in familial BE pedigrees by genome-
wide linkage analysis using BE and esophageal adenocarcinoma (ACA) phenotypes. Methods:
Study Group members refer families in which more than two persons are suspected of
having long segment BE, with or without ACA. Following informed consent, pathology
slides and endoscopy and surgical reports of potential index patients are reviewed. Confirmed
index patients provide contact information of living first-degree relatives, or next of kin of
deceased relatives. Pathology slides and records on relatives are reviewed to confirm pheno-
type. To augment phenotype characterization, a separate research project screened family
members who had not previously had an upper endoscopy. All available living members
of documented BE families were asked to complete a validated symptom questionnaire, and
to provide a blood sample. Genotyping of lymphocyte DNA was performed using the ABI
PRISM® Linkage Mapping Set version 2.5 using 403 markers equally distributed along the
entire autosome at ~10 cM resolution. Two-point and multi-point linkage analyses were
performed. Results: 466 families were evaluated for eligibility, and 94 were documented to
have multiple affected family members: 2 families had 5 affecteds, 4 families had 4 affecteds,
29 families had 3 affecteds, and 59 had 2 affecteds. Linkage analysis was performed on 278
persons in the 31 most informative families. Under a dominant model with decreased
penetrance, the phenotype of BE yielded a multipoint heterogeneity LOD (HLOD) score of
3.07 at 66.9 cM, near D2S2259; 2.51 at 79.43 cM between markers D2S391 and D2S337;
and 1.57 at 8.64 cM at D2S2211, all on the short arm of chromosome 2. Other promising
HLOD scores include: 1.52 on chromosome 12p at 73.55 cM at D12S368; 1.41 at 43.59
cM near D19S414, and 1.47 at 71.06 cM at D19S902. Linkage remained consistent on
chromosomes 2, 12, and 19 when a combined phenotype of BE or ACA was used, with
the highest HLOD score being 2.78 at 66.94 cM at D2S2259. Linkage was not identified
for either phenotype on chromosome 13 (maximum HLOD= 0.56). Conclusion: These
results provide strong evidence for major susceptibility genes for familial Barrett’s esophagus
and esophageal adenocarcinoma.
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TRPV-1 Knockout Paradoxically Protects Mouse Gastric Mucosa from Acid/
Ethanol-Induced Injury By Upregulating Compensatory Protective Mechanisms
Yasutada Akiba, Tetsu Takeuchi, Misa Mizumori, Paul H. Guth, Eli Engel, Jonathan D.
Kaunitz
Capsaicin-sensitive afferent nerves (CSAN) coordinate upper gastrointestinal tract mucosal
protective mechanisms through the release of calcitonin gene-related peptide (CGRP) and
increasing prostaglandin (PG) synthesis. The acid-sensitive cation channel TRPV-1 may serve
as a primary acid sensor that activates CSAN in response to luminal acidity. Acute disruption
of components of this protective system increases mucosal injury susceptibility. Other
putative acid sensors, such as acid-sensing ion channels (ASICs) have been implicated in
luminal acid sensing, and PG type E (EP1) receptors are also involved. To evaluate the role
of TRPV-1 and effector molecules in gastric mucosal protection, we examined their role in
gastric mucosal injury using TRPV-1 knockout (KO) mice, hypothesizing that KO would
increase injury susceptibility in a standard gastric injury model. Wild type C57BL/6 (WT)
and KO mice were gavaged with 150 mM HCl/60 % ethanol (0.3 ml) in order to produce
gastric injury. Pretreatment with the CGRP receptor antagonist hCGRP8-37 (0.3 mg/kg, iv),
the nonselective cyclooxygenase (COX) inhibitor indomethacin (Indo, 5 mg/kg, sc), the
nitric oxide (NO) synthase inhibitor L-NAME (20 mg/kg, sc), the TRPV-1 antagonist capsa-
zepine (CPZ, 10 mg/kg, sc), or the TRPV-1 ligand capsaicin (10 mg/kg, i.g.) were given to
evaluate the role of these components of the capsaicin pathway. Expression of acid-sensing
ion channel (ASIC) 1 and ASIC3, and COX-1, COX-2, EP1 receptor, and calca (pro-CGRPα
gene) in the stomach, dorsal root ganglion (DRG) and nodose ganglion (NG) were analyzed
by real-time RT-PCR. Unexpectedly, acid/ethanol treatment injured the gastric mucosa of
KO significantly less than it did WT. In WT, Indo, hCGRP8-37, L-NAME and CPZ aggravated
whereas capsaicin reduced gastric lesions, confirming the role of afferent nerves in coordinat-
ing mucosal protection. In KO, Indo and hCGRP8-37 reversed the protective effect of TRPV-
1 deletion, producing injury to a degree not different from similarly treated WT. COX-1
mRNA expression increased 4-fold in KO stomach compared with WT. COX-2 and calca
mRNA expression were induced and ASIC3 was up-regulated 10-fold in DRG of KO, whereas
calca was induced and ASIC1 was increased 25-fold in NG of KO. EP1 was expressed in
wild type and KO stomach, but was down-regulated in DRG of KO. The unexpected
decrement in mucosal injury observed in TRPV-1 KO can be explained by compensatory
upregulation of CGRP release and COX-2 function. In KO stomach, up-regulation of ASIC1
in NG and ASIC3 in DRG may serve as compensatory, alternative acid sensors in afferent
neurons that may coordinate CGRP release and PG synthesis.
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ErbB-4 Expression Is Increased in Experimental Colitis and Is Required for
Intestinal Epithelial Wound Closure
Mark R. Frey, D. Brent Polk
ErbB-4 is the most recently described member of the epidermal growth factor (EGF) receptor-
related receptor tyrosine kinase family. It is expressed in epithelial cells in membrane-bound
full-length as well as cytosolic and nuclear cleavage product forms. Studies in other tissues
suggest that ErbB-4 regulates cell division and survival; however, only limited data are
available on expression and function in the intestine. This study tests a role for ErbB-4 in
intestinal epithelial wound healing and response to inflammation. METHODS: Colitis was
induced in C57BL/6 mice with 3% dextran sulfate sodium (DSS) in drinking water for 4
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days, followed by 3 days recovery. ErbB-4 expression was assayed by immunohistochemistry
on paraffin-embedded tissue or Western blot of colon mucosal scrapings, using antisera
specific for total receptor or the cleavable isoform. For wound healing assays, young adult
mouse colon (YAMC) cells plated on fibronectin were transfected with ErbB-4 siRNA,
subjected to multiple wounds with a rotating silicone tip, and monitored by time-lapse
photography. Western blot analysis of cell lysates was performed using phospho-specific
and total antibodies for EGF receptor, ErbB-4, FAK, AKT, p38, and ERK. RESULTS: ErbB-
4 protein expression in mouse colon demonstrated two distinct patterns. Membrane staining
for full-length receptor was detected in the upper crypts and surface epithelium of the
postmitotic compartment, while nuclear ErbB-4 cleavage product was observed only in the
lower crypt. Western blot of mucosal scrapings confirmed the presence of both full-length
and cleaved receptor. DSS colitis induced a modest induction of ErbB-4 protein, with staining
expanded along the entire length of crypts. During recovery, ErbB-4 expression increased
dramatically throughout the renewing epithelial compartment. We therefore asked whether
ErbB-4 was required for wound healing in cell culture. In YAMC cells, ErbB-4 siRNA
significantly impaired restitution over a 24 h period. Furthermore, analysis of growth factor-
induced signaling showed that loss of ErbB-4 attenuated EGF-stimulated phosphorylation
of the adhesion regulator FAK and the anti-apoptotic kinase AKT. CONCLUSIONS: These
data represent the first demonstration of spatially segregated expression of different ErbB-
4 forms in the intestinal epithelium, implying distinct functions for cleaved versus full-
length receptor in this tissue. Our results argue that ErbB-4 plays a role in wound healing
and remodeling after inflammation, possibly by regulating growth factor-induced cell survival
and migration signals.
739
Gata4 Is Essential for the Maintenance of Jejunal-Ileal Identities in the Adult
Mouse Small Intestine
Tjalling Bosse, Christina M. Piaseckyj, Ellen Burghard, John J. Fialkovich, Satish
Rajagopal, William T. Pu, Stephen D. Krasinski
The mammalian small intestine is lined by a highly specialized epithelium that displays a
wide-ranging, yet tightly regulated functional diversity along its cephalo-caudal axis. Gata4,
a member of the zinc finger family of GATA transcription factors, is highly expressed in the
mammalian small intestine in proliferating crypt epithelium and mature absorptive
enterocytes of the duodenum and jejunum, but is undetectable in distal ileum of adult mice.
We confirmed that this pattern is conserved in humans by immunofluorescence analysis on
adult intestinal sections. In the present study, we established an inducible, intestine-specific
knockout model for Gata4 to test the hypothesis that Gata4 is necessary for the maintenance
of jejunal-ileal identities in adult mouse small intestine. An inducible Villin-CreERT2 mouse
line was crossed with a mouse line containing Gata4 alleles flanked by loxP sites (Gata4flox).
Treatment with Tamoxifen™ for 5 consecutive days resulted in the inactivation of Gata4
in the jejunum 2 weeks after the last injection. We analyzed the expression of enterocyte
genes that are normally expressed in jejunum but not in ileum and found that lactase-phlorizin
hydrolase (LPH) and liver fatty acid binding protein (Fabp1) were strongly attenuated as
shown by immunostaining for Fabp1 and real-time RT-PCR for LPH and Fabp1 (P<0.05,
n=4). In contrast, absorptive enterocyte genes not normally expressed in jejunum, but highly
expressed in ileum, such as the apical sodium-dependent bile acid transporter (Asbt) and
ileal lipid binding protein (Ilbp), were both markedly induced in the mutant jejunum as
indicated by Asbt immunostaining and Asbt and Ilbp real-time RT-PCR (P<0.01, n=4).
Moreover, the goblet cell population was increased 50% as determined by unbiased counting
(P<0.05, n=4) and the enteroendocrine cell fate as determined by peptide YY and cholesystoki-
nin mRNA levels were redistributed, all to an ileal-like composition. Consistent with an
expansion of secretory cells, Math1, a known activator of the secretory cell fate, was induced
in the jejunum of Gata4 mutant mice (P<0.05, n=4). Conclusion: These data demonstrate
that Gata4 is a major and essential positional signal that is required for the maintenance of
jejunal-ileal identities in the adult mouse small intestine.
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Sumoylation Modulates Transcriptional Activity of Cdx1 By Direct Interaction
Fang Xiao, Eunran Suh
Background: Cdx1 plays significant roles in multiple cellular pathways including cell growth,
intestinal differentiation, and apoptosis. However, little information is available on how the
Cdx1 protein is modulated by intracellular and nuclear signaling processes to achieve such
a broad range of functions. Sumoylation is one of post-translational modifications, which
modulates functions of target protein by regulating protein-protein interactions, translocaliz-
ation, DNA-protein interactions, and/or protein stability. In the present study, we examined
interactions between the Cdx1 protein and Sumo-1, Ubc-9, or PIAS-1, which are members
of sumoylation machinery, and determined whether sumoylation modulated biological func-
tions. Methods: GST pull-down assay and co-immunoprecipitation (co-IP) were performed
to demonstrate protein-protein interaction in vitro and in vivo, respectively. A series of point
mutations, K69R, K69A, K263R, or K263A was generated by using the QuickChange site-
directed mutagenesis kit. Results: The Cdx1 protein interacts with Sumo-1 conjugating
enzyme Ubc9 and E3 ligase PIAS1 in vitro and in vivo. Furthermore, in vitro sumoylation
assays has demonstrated that the Cdx1 protein is sumoylated by Sumo-1 in Caco2 cells
following cotransfection of Cdx1 with Sumo-1. Alignment of the primary amino acid sequence
of Cdx1 orthologs from a variety of species demonstrates that there is one evolutionarily
conserved somoylation consensus sequence (ΨKXE/D), which is located at the amino acid
residue K263 of the murine Cdx1 protein. A sumoylated form of Cdx1 following co-IP with
Sumo-1 was detected on wild type Cdx1, but not on K263A/R. This result has indicated
that the sumoylation site is at the lysine residue 263 of the Cdx1 protein. To assess the
potential functional role of the conjugation of Sumo-1 to Cdx1, we carried out transfection
assays in Caco2 cells where sucrase-isomaltase promoter-reporter construct was cotransfected
with Cdx1 in the presence or absence of Sumo-1. The results demonstrate that overexpression
of Sumo-1 represses its transcriptional activity in a dose-dependent manner, suggesting that
SUMO-mediated transcriptional repression modulates Cdx1 function. Conclusion: Cdx1 is
a new target for Sumo-1 modification and that lysine residue 263 is a sumoylation site of
Cdx1. In addition, sumoylation represses transcriptional activity of Cdx1, suggesting that
sumoylation plays a significant role on modulating Cdx1 functions.
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A Cell Culture System Modelling the Entire Small Intestinal Crypt Villus Axis
Katri Lindfors, Essi Myrsky, Heikki Kainulainen, Markku Maki
Introduction: Epithelial cells lining the small intestine represent a highly organised system
built up by multipotent stem cells. A process of asymmetric mitosis produces a population
of transit amplifying cells that rapidly proliferate and migrate along the crypt villus axis,
differentiating into functional mature cells before dying and exfoliating into the intestinal
lumen. At present the primary culture of isolated crypts or epithelial cells retaining high
viability - not to mention the culture of stem/progenitor cells - is still extremely difficult.
The culture of stem/progenitor cells is in part challenging due to the lack of definitive stem
cell markers. In addition, long-term cultures (more than 10 days) of small intestinal epithelial
cells has proved to be almost impossible. We have developed a long-term cell culture which
recapitulates the entire small intestinal crypt villus axis with regard to progenitor cell
proliferation as well as terminal differentiation and apoptosis. Methods: Single crypt epithelial
cells and small organoids were isolated from mouse small intestine and cultured under
specific conditions on collagen with a feeder layer and a specific medium. Immunohistochem-
ical stainings with antibodies against specific proteins involved in either proliferation or
differentiation were performed on formalin fixed sections. Results: The isolated small intest-
inal epithelial cells formed organized clusters that remained viable for at least 10 weeks-
the longest period ever published. The clusters were characterized by a large central lumen
and a well-deposited basement membrane. Furthermore there were small villus-like structures
that protruded into this lumen. A portion of the cells were proliferative as evinced by Ki-
67 positivity. In addition, the clusters also harbored polarized columnar cells that had
differentiated either into absorptive enterocytes as indicated by alkaline phosphatase activity,
or goblet cells based on Alcian blue positivity. Additionally, on the basis of EphB3 staining,
Paneth cells were also present in these clusters. When these parental clusters were broken
into single cells that were cultured under identical conditions, they formed daughter clusters
with similar characteristics as the parental ones. Conclusions: We have developed a long-
term cell culture system that models the in vivo small intestinal crypt villus axis in terms
of epithelial cell proliferation and differentiation. This culture system eases the study of
small intestinal progenitor cells, and also research concerning proliferation and differentiation
as well as the development of stem cell based therapies for severe small intestinal disorders.
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Differences in the Appetite-Stimulating Effect of Orexin, NPY, and Ghrelin
Among Young, Adult, and Old Rats
Saeko Akimoto-Takano, Chihiro Sakurai, Setsuko Kanai, Hiroko Hosoya, Minoru Ohta,
Kyoko Miyasaka
Aging is associated with a progressive decrease in appetite and food intake. The appetite-
stimulating peptides orexin-A, NPY (neuropeptide Y), and ghrelin are known to play a
critical role in food intake. In this study, the stimulatory effect of intracerebroventricular
administration of these peptides on food intake was compared among young (4-month-
old), adult (11-month-old) and old (24-27-month-old) male Wistar rats. A stainless steel
cannula was implanted stereotactically into the left lateral ventricle. After a 7-day recovery
period, different doses of orexin-A (0 to 3 nmol), NPY and ghrelin (0 to 1 nmol) were
injected into the left lateral ventricle without anesthesia. Food consumption was measured
at 1, 2, and 4 hr after injection. We also examined the plasma levels of acylated and desacyl
ghrelin in young and old rats by ELISA. Intracerebroventricular administration of orexin-A
and NPY stimulated food intake in young and adult rats, but no effects were observed at
any dose in old rats. Ghrelin increased food intake in a dose-dependent manner in all
groups, and the effect of ghrelin was reduced with advancing age. Neither the acylated nor
the desacyl plasma ghrelin level differed significantly between young and old rats. In conclu-
sion, we observed a decrease in the orexigenic effect of the peptides orexin-A, NPY and
ghrelin in old rats, and this reduction may have been responsible for the age-related decrease
in food intake.
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Controlled Polymeric Delivery of VEGF Enhances Angiogenesis in Developing
Intestine
Flavio G. Rocha, Cathryn Sundback, Nicholas Krebs, Kent Leach, David J. Mooney,
Stanley W. Ashley, Joseph P. Vacanti, Edward E. Whang
Background: Intestinal ischemia is a common cause of massive bowel resection leading to
short bowel syndrome in both children and adults. Our laboratories have previously created
a functional neointestine capable of restoring absorptive function. However, the amount of
vascular endothelial growth factor (VEGF), a key mediator of angiogenesis, is markedly
reduced in the maturing construct compared to native bowel. Therefore, we wanted to
deliver VEGF to the neointestine in order to enhance its development. Methods: Rat recombin-
ant VEGF was encapsulated in polymer microspheres by a double emulsion method. Incorp-
oration and release kinetics were determined in vitro using radiolabeled growth factor. Tissue
engineered intestine was generated by seeding donor neonatal rat intestinal organoid units
onto a cylindrical polymer scaffold. VEGF or empty microspheres were loaded in the lumen
of the polymer along with the organoid units and the construct wrapped in the omentum
of recipient rats (6 animals per group). After four weeks, the animals were sacrificed and the
neointestinal cysts harvested for morphometry, VEGF levels, epithelial cellular proliferation,
apoptosis and capillary density by ELISA and immunohistochemistry. Results: VEGF was
encapsulated in microspheres with 30% efficiency. Sustained release of VEGF into simulated
body fluid occurred over a period of four weeks. Intestinal constructs with encapsulated
VEGF were significantly larger (99.3 + 0.4 cm3 vs 25.8 + 0.2 cm3) and (10.2 + 3.8 g vs
3.5 + 0.5 g) (p<0.05) than those containing empty microspheres. Tissue VEGF levels were
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significantly higher in neointestine loaded with VEGF compared to those without growth
factor (106 + 33 pg/mg vs 28 + 34 pg/mg)(p<0.05) and approached the levels of juvenile
native intestine. Epithelial cellular proliferation and angiogenesis were significantly increased
in the VEGF-loaded neointestinal constructs (84.9 + 7.1% vs 53.8 + 13.8% BrDU staining
crypt cells) and (29.8 + 4.5 vs 10.3 + 1.1 capillaries/hpf)(p<0.05); however, apoptosis
remained unchanged (5.0 + 2.4% vs 3.8 + 3.1% TUNEL staining crypt cells). Conclusion:
Tissue-engineered intestine responds to sustained delivery of VEGF by increasing microvascu-
lature and epithelial proliferation. This strategy may be used to enhance neointestinal con-
structs in order to stimulate small bowel development. In addition, these optimized constructs
may be able to preserve critical intestinal function after injury.
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Neonatal FC Receptor for IgG in Intestinal Epithelial Cells Contributes to the
Protection Against Epithelium-Associated Pathogen, C. Rodentium Infection
Masaru Yoshida, Timothy T. Kuo, Lynn Bry, Jonathan N. Glickman, Steven M. Claypool,
Arthur Kaser, Takashi Nagaishi, Darren Higgins, Emiko Mizoguchi, Takeshi Azuma,
Atsushi Mizoguchi, Wayne I. Lencer, Richard S. Blumberg
Background: Citorobacter rodentium is a bacterial pathogen that causes a murine infectious
colitis equivalent to enterohemorrhagic and enteropathogenic E.coli infection in humans.
Importantly, CD4+ T cells, B cells and IgG, but not secretory IgA or IgM, have been shown
to play a critical role in the prevention against this infection. The neonatal Fc receptor for
IgG (FcRn) plays a major role in regulating host IgG levels and transporting IgG and
associated antigens across polarized epithelial barriers (Immunity 2004; 20;769). Aim: We
sought to test the possibility that FcRn-mediated transport of IgG and bacterial antigen/IgG
complexes may be involved in the mucosal immune response to an epithelium-associated
pathogen, C. rodentium. Methods and Results: FcRn-/- and littermate FcRn-/+ mice were
orally inoculated with C. rodentium. FcRn-/- mice exhibited more body-weight loss, higher
bacterial concentrations in the feces, and severer mucosal inflammation in the distal colon.
Murine (m)FcRn and mβ2m double transgenic mice under the control of the intestinal fatty
acid binding protein on a mFcRn-/- mouse background (IFABP-mFcRnTg/mβ2mTg/mFcRn-/-
mice) were developed. As expected, these mice expressed FcRn only in the epithelium and
were capable of secreting IgG into the lumen in comparison to FcRn-/- mice which were
not. To test whether specific IgG for bacteria is required for the regulation of C. rodentium
infection through FcRn-mediated transport of IgG, C. rodentium was orally inoculated
into IFABP-mFcRnTg/mβ2mTg/mFcRn-/- and FcRn-/- mice that had or had not received a
polyclonal anti-C. rodentium IgG antibody. Whereas the nonimmune control antibody had
no effect on C. rodentium eradication in FcRn-/- mice or transgenic mice, the pre-administra-
tion of specific antibody resulted in less body-weight loss and lower bacterial concentrations
in the feces of IFABP-mFcRnTg/mβ2mTg/mFcRn-/- mice. This was associated with induction
of proliferation of CSFE-labeled OT-II transgenic T cells when mice were infected with C.
rodentium expressing OVA. These results indicate that FcRn expression in intestinal epithelial
cells contributes to the protection against C. rodentium infection but only in the presence
of specific IgG antibodies. Conclusion: Selective expression of FcRn in the epithelium is
shown here to be associated with secretion of IgG into the lumen that allows for defense
against an epithelium-associated pathogen. Epithelial-associated FcRn integrates luminal
antigen encounters with systemic immune compartments and, as such, provides essential
host defense and immunoregulatory functions at the mucosal surfaces.
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Certolizumab Pegol Administered Subcutaneously Is Effective and Well
Tolerated in Patients with Active Crohn’s Disease: Results from a 26-Week,
Placebo-Controlled Phase III Study (PRECiSE 1)
William J. Sandborn, Brian G. Feagan, Simeon Stoinov, Pieter J. Honiball, Paul Rutgeerts,
Juliet A. McColm, Alison Innes, Stefan Schreiber
Background: Certolizumab pegol (CDP870) is a PEGylated Fab’ fragment of a humanized
monoclonal antibody that neutralizes tumor necrosis factor-α. A Phase III, randomized,
double-blind, multicenter study assessed efficacy and tolerability of certolizumab pegol in
active Crohn’s disease (CD). This is the largest long-term induction study of a biologic agent
performed to date in CD. Methods: Adult patients (pts) with moderate-severe CD (CD
Activity Index [CDAI] 220-450 points) were randomized to receive subcutaneous (sc) certoli-
zumab pegol 400mg or placebo (PBO) at Weeks (Wks) 0, 2, 4, then 4-weekly up to Wk
24. Pts were stratified at baseline according to C-reactive protein (CRP) level (<10mg/L or
≥10mg/L) and immunosuppressant/corticosteroid use. Safety and efficacy were determined
at Wks 0, 2, 4, 6, 8, 12, 16, 20, 24 and 26/withdrawal. The co-primary endpoints were
the percentages of pts with a clinical response (decrease in CDAI ≥100) at Wk 6, and at
Wks 6 & 26, in pts with baseline CRP ≥10mg/L. Secondary endpoints included 70-point
response (decrease in CDAI ≥70, post-hoc analysis), and remission (CDAI ≤150) in the
CRP≥10mg/L stratum, response and remission in the overall intention-to-treat (ITT) popula-
tion, and CRP levels (last observation carried forward; LOCF, post-hoc analysis) in both
populations. Results: Both primary endpoints showed a significant advantage for certoli-
zumab pegol over PBO. Responses (70- and 100-point) at Wks 4, 6 and Wks 6 & 26 were
significantly higher (p<0.05) for certolizumab pegol vs PBO in the CRP ≥10mg/L stratum
and the overall ITT population (n=659) (Table). Remission at Wk 4 was significantly higher
for certolizumab pegol vs PBO; there were positive trends at Wk 6 and Wks 6 & 26. Median
CRP levels were significantly lower for certolizumab pegol vs PBO at Wks 6 and 26 (p≤0.01,
changes from baseline) (Table). Overall, no safety signals of concern were observed. Conclu-
sions: Monthly certolizumab pegol 400mg sc demonstrated significant efficacy and was well

















*p≤0.05, **p≤0.01 vs PBO an is decreasing over time
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Critical Role of Toll-Like Receptors in Modulating GM-CSF Activity in Rodent
Models of Colitis
Stefano Fiorucci, Andrea Mencarelli, Barbara Renga, Eleonora Distrutti, Antonio Morelli,
Ed Croze, Sharlene Velicko, Brent Larsen, John Parkinson
Background. Toll-like receptors (TLRs) sense extracellular pathogens and regulate innate
immune responses in the intestinal mucosa. Evolving research suggests that Crohn’s disease
may be caused by a deficiency in cells of the immune system within the mucosal barrier
and that this precedes reactive inflammatory processes. GM-CSF (granulocyte macrophage
colony-stimulating factor) is a naturally occurring growth factor and part of the innate
defense system, which increases the number and activity of white blood cells (neutrophils,
monocytes/macrophages, and dendritic cells). Aim. To test the efficacy and immunomodula-
tory actions of GM-CSF in TNBS and DSS-induced colitis, using wild type and TLR deficient
mice. Methods. TNBS-colitis was induced by intrarectal administration of 0.5, 1 or 2 mg/
mouse TNBS in 50% ethanol; DSS-colitis by 5% DSS in the drinking water. Mice were
administered 5 μg/mouse/day recombinant yeast-derived pegylated murine GM-CSF (PEG-
mGM-CSF). Mucosal cytokine content cytokines was assessed by quantitative (q)RT-PCR.
Isolated lamina propria (LP) mononuclear cells composition was assessed by flow cytometry.
The protective effects of PEG-mGM-CSF were also examined in TNBS-colitis induced in
TLR2-/-, TLR4-/-, TLR9-/- and myd88-/-mice. Results. In wild-type mice, PEG-mGM-CSF
prevented TNBS- and DSS-induced colitis by all disease endpoints measured: weight loss,
inflammation, disease activity/diarrhoea scores and macroscopic/microscopic scores (p <
0.05). PEG-mGM-CSF reversed established DSS colitis when dosed from days 5-14, attenuat-
ing mucosal increases of IL-6 and IL-1β. In TNBS colitis, PEG-mGM-CSF did not alter
mucosal TNF-α or COX-2 mRNAs, but increased mucosal levels of IFN-γ, IL-1β and IL-6
mRNAs (P<0.05 versus TNBS). Moreover, PEG-mGM-CSF reduced LP CD4+ and CD8+ T
lymphocytes, while increasing the number of CD11b+ myeloid cells and CD19+ B lympho-
cytes. In TNBS-colitis PEG-mGM-CSF enhanced the antibacterial effector functions of
mucosal CD14+ myeloid cells and significantly inhibited bacterial translocation to spleen
and lymph nodes. Mucosal protection by PEG-mGM-CSF in TNBS-colitis was preserved in
TLR2-/- and TLR4-/- mice, but lost in myd88-/- mice and TLR9-/- mice Conclusions. PEG-
mGM-CSF prevents DSS- and TNBS-colitis and treats DSS-colitis in mice. Protection by
PEG-mGM-CSF in TNBS-colitis is associated with enhanced myeloid antibacterial effector
functions, is independent of TLR2 and TLR4, but dependent on the TLR adaptor protein
myd88 and the bacterial double-standed DNA (CpG)-sensing TLR9. The findings are consist-
ent with the innate immune activating functions of GM-CSF and its use to enhance host-
protective immunity.
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Natalizumab Induces Sustained Response and Remission in Patients with
Active Crohn’s Disease: Results from the Encore Trial
Stephan R. Targan, Brian Feagan, Richard Fedorak, Bret Lashner, Remo Panacionne,
Daniel Present, Andreas Raedler, Paul Rutgeerts, Zsolt Tulassay, Miroslava Volfova,
Douglas C. Wolf, William Sandborn
Purpose: ENCORE (Efficacy of Natalizumab in Crohn’s Disease Response and Remission)
was a phase 3, international, randomized, double-blind, placebo (pbo)-controlled trial that
evaluated the efficacy and safety of natalizumab induction therapy in Crohn’s patients with
moderately to severely active disease and objective evidence of active inflammation (elevated
C-reactive protein [CRP] levels). Methods: Patients (N=509) with Crohn’s Disease Activity
Index (CDAI) scores between 220 and 450 (inclusive) and CRP levels greater than the upper
limit of normal (2.87 mg/L) were randomized 1:1 and received natalizumab (300 mg; n=
259) or pbo (n=250) infusions at weeks 0, 4, and 8. Efficacy and safety were assessed at
weeks 4, 8 and 12. The primary endpoint examined the ability of natalizumab to induce a
clinical response (≥ 70 point decrease in baseline CDAI score) by week 8 that was sustained
through week 12. Additional efficacy endpoints included the proportion of patients achieving
a clinical remission (CDAI < 150) by week 8 and through week 12, and the proportion of
patients in response or remission at any assessment. Results: A significantly higher proportion
of patients in the natalizumab group were in response at both weeks 8 and 12 compared
to patients in the pbo group (48% [124/259] vs. 32% [81/250], p < 0.001). Response at
week 4 (following the first infusion) was 51% [133/259] for natalizumab vs. 37% [92/250]
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for placebo, p = 0.001), and remained significantly higher in the natalizumab group at all
subsequent assessments (p < 0.001 for all comparisons with pbo). Remission at both weeks
8 and 12 was also achieved by a higher proportion of patients in the natalizumab group
compared with pbo (26% [68/259] vs. 16% [40/250], p=0.002). Patients receiving
natalizumab also had superior remission rates at all assessments (p ≤ 0.009 for all compar-
isons with pbo). The incidence and types of adverse events were similar between groups.
Conclusions: Natalizumab induced response and remission by week 8 that was sustained
through week 12. The response and remission rates for natalizumab were superior to placebo
at all timepoints beginning at week 4, thus confirming the efficacy of natalizumab as induction
therapy. Natalizumab was well tolerated, with adverse events not significantly different
than pbo.
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GM-CSF Efficacy in Murine DSS Colitis Is Mediated By Changes in the
Function of Plasmacytoid Dendritic Cells
Eyad Hanna, Satheesh K. Sainathan, Kumar S. Bishnupuri, Qizhi Luo, Rodney D.
Newberry, Courtney W. Houchen, Shrikant Anant, Brian K. Dieckgraefe
Crohn’s disease (CD) is a chronic inflammatory condition of the gastrointestinal tract. It is
associated with a loss of tolerance to commensal gut flora and an overactive adaptive
immune response. Recent knowledge has implicated impaired innate immune clearance in
the pathogenesis of CD. A recent clinical trial showed efficacy of GM-CSF, a hematopoietic
growth factor, in human CD. To understand the mechanism this effect, we studied a murine
model of colitis. DSS colitis is a model of impaired mucosal integrity and, therefore, may
be ideal to understand the effects of GM-CSF. Administration of pegylated recombinant
murine GM-CSF (Peg-rmGM-CSF) significantly ameliorated disease activity in DSS colitis
as assessed by weight loss, colon length, histopathological score, stool consistency, and
stool hemoccult. In addition, GM-CSF altered the number and function of dendritic cell
populations. The therapeutic effect of Peg-rmGM-CSF in DSS colitis was blocked by adminis-
tration of a monoclonal antibody (Ab), 440c, which recognizes a cell surface molecule
selectively expressed on plasmacytoid dendritic cells (pDCs). The pDCs are the main inter-
feron (IFN)-producing cell in the intestine. They express toll-like receptor-9, which recognizes
bacterial DNA motifs, specifically cytosin-guanosin dinucleotide (CpG). Type-I IFNs (IFN-
α and β) are produced in response to stimulation with CpG. Addition of monoclonal Ab
440c, both in vitro and in vivo, blocks IFN-α production in pDCs stimulated with CpG
but does not deplete cell numbers. Furthermore, we demonstrated that GM-CSF augments
expression of Type-I IFNs, IDO, and IL-10 in the mouse ileum and spleen after stimulation
with CpG. Therefore, we hypothesized that the pDC is involved in the mechanism of
therapeutic response of DSS colitis to Peg-rmGM-CSF. Fms-like tyrosine kinase 3 (Flt-3)
ligand, another hematopoietic growth factor, is a potent DC growth factor that significantly
expands pDC numbers. Accordingly, we examined the effects of Flt-3 treatment on DSS
colitis. Flow cytometry data showed that both GM-CSF and, more impressively, Flt-3 expand
dendritic cell (CD11c and MHCII positive) populations in the spleen. However, disease
activity in animals treated with DSS worsened rather than improved with Flt-3 treatment.
Conclusions: The pDC is implicated in the response of DSS colitis to Peg-rmGM-CSF.
Expansion of pDC numbers alone is unlikely to explain the therapeutic effects of Peg-rmGM-
CSF based on the data from Flt-3 treated animals. The data suggests that the response to
Peg-rmGM-CSF is mediated through a functional change in pDC response to bacteria or
bacterial products.
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The Ideal Management of Crohn’s Disease: Top Down Versus Step Up
Strategies, a Randomized Controlled Trial
Daniel Hommes, Filip Baert, Gert van Assche, Filip Caenepeel, Philippe Vergauwe, Hans
Tuynman, Martine de Vos, Sander van Deventer, Larry Stitt, Paul Rutgeerts, Brian Feagan,
Geert Dhaens
Current management of moderate-severe Crohn’s disease (CD) consists of glucocorticostero-
ids (GCS), leading to a 26% 1-year remission rate, steroid dependency and significant
toxicity. This study examined if more aggressive induction therapy with infliximab (IFX)
and azathioprine (AZA) would lead to higher remission rates, lower toxicity and fewer
complications. Methods. 133 CD pts with CDAI > 220, diagnosed < 4years ago and never
treated with GCS/immunomodulators/IFX were randomized to (1) top-down (TD) treatment
with 3 infusions of IFX (w 0, 2 and 6) and AZA 2-2.5 mg/kg/day or (2) step-up (SU) therapy
with topical (budesonide 9/mg/day) or systemic (prednisone 40 mg/day) GCS. In the TD
group, relapse was treated with repeat IFX infusions and GCS when they failed to respond
to IFX. In the SU group, AZA was added in case of repeated need for GCS or dependency
and IFX was only given after failure of immunosuppression. Patients were examined at week
0, 2, 6, 10 and 14 and every 3 months thereafter until month 24. The primary endpoint
was remission (CDAI <150 without GCS and no resection) at month 6 and 12; secondary
endpoints included overall treatment success (remission at week 14 and beyond, no resection,
no GCS or IFX after week 14), mean CDAI scores, toxicity and prolonged remission up to
month 24. Results. Baseline characteristics were similar in both groups (mean CDAI at
inclusion 331 TD vs. 306 SU), 19 pts dropped out before month 12. Induction therapy
was successful in 81% and 73% of TD and in 60% and 67% of SU pts at week 10 and 14.
Remission without GCS and without resection was attained in 60 % (TD) vs. 41 % (SU)
(p=0.03) at 6 months and in 61 % (TD) vs. 50 % (SU) at 12 months (p= 0.19). At 6 months,
31 % of patients in he SU group were still receiving GCS (median dose 26 mg/day) compared
with 0 % for TD; at 12 months, 17 % of pts in SU were remained on GCS (median dose
23 mg) compared with 0% for TD (p< 0.001). At 6 and 12 months 84% and 93 % of pts
were using immunomodulators in the TD group, versus 41% and 65 % in the SU group
(both p< 0.001). Overall treatment success was seen in 29% TD and 5% SU pts (p<0.001).
During the first 12 months, 13% of patients in the SU group needed IFX infusions to induce
remission and 41% of patients in the TD group required at least one further IFX infusion.
Serious adverse events were observed in 49% of TD and 41% of SU pts (NS). Conclusion.
Aggressive induction with IFX + AZA is superior to sequential SU therapy for reducing
exposure to GCS and attaining overall treatment success. 41% of TD patients needed further
IFX infusions after induction. Complete results until month 24 will be available at DDW.
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Van Gogh-Like Protein1 (Vangl1) Mediates Spatial Organization of Signaling
from Itf and EGF Leading to a Polarized Migratory Response of Intestinal
Epithelial Cells
Jiri Kalabis, Ian Rosenberg, Hans-Christian Reinecker, Vijay Yajnik, Daniel K. Podolsky
Background: The intestinal trefoil factor (ITF/TFF3) protects intestinal epithelia from a range
of insults and contributes to mucosal repair. However, the signaling events that mediate
ITF dependent mucosal protection are not well understood. We recently demonstrated that
Vangl1, a Dlg1 binding partner and a member of the planar polarity complex in Drosophila,
was phosphorylated in response to ITF signaling and was required for the ITF induced
migratory response. The aim of this study was to define mechanisms resulting in directed
migration by ITF. Material and methods: GST-Pac and GST-Rhotekin pull down assays were
used to demonstrate effects of ITF and EGF on small GTP-ases in HEK293 cells. GFP- or
flag-Vangl1 constructs were used for up-regulation and siRNA for silencing of Vangl1. Effects
were confirmed by RT-PCR. Western blotting, immunoprecipitation and pull down assay
were used to quantitate effects of Vangl1 on phosphorylation of EGFR or CDC42 activation.
Confocal microscopy with anti-phospho EGFR and GFP-Vangl were used to determine
spatial organization of ITF signaling. siRNA mediated silencing was used to study effects of
small GTP-ases on the ITF induced migratory response in a wound healing assay of HT29
colonic epithelial cells. Results: Vangl1 is not localized to the leading edge of wound, and
contributed to the polarization of migratory response by modulating spatial activation of
two signaling pathways. While ITF and EGF stimulated cells increased phosphorylation of
EGFR on Y992, overexpression of Vangl1 decreased Y992 phosphorylation by ITF. The
Vangl1 transfected cells decreased Y992 phosphorylation of EGFR to 50% of maximal
intensity during the initial 10 min of stimulation. siRNA mediated Vangl1 downregulation
increased Y992 phosphorylation of EGFR following stimulation by both ITF and EGF in
intestinal epithelial cells. Spatial interaction between EGFR and Vangl1 was demonstrated
using confocal microscopy. ITF was also found to activate CDC42 as demonstrated by pull
down assays, siRNA silencing of CDC42 expression inhibited the ITF induced migratory
response of intestinal cells. However overexpression of Vangl1 inhibited CDC42 activation.
Conclusions: ITF induced activation of EGFR and CDC42 signaling is required for ITF
dependent migration. Vangl1 did not associate with the leading edge of migrating cells and
had inhibitory activity on EGFR and CDC42. We hypothesize that polarized expression of
Vangl1 together with its inhibitory activity leads to inhibition of the pathways in the posterior
compartment of migrating cells and promotes directional migration.
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Chitinase 3-Like-1 (CHI3L1) Enhances Potentially Pathogenic Bacterial
Adhesion to Colonic Epithelial Cells in Vitro and in Vivo
Mayumi Kawada, Yuriko Hachiya, Atsuhiro Ogawa, Ken Sugimoto, Emiko Mizoguchi
Background & Aims: Dysregulated host /microbial interactions play a key role in the develop-
ment of intestinal disorder. However, the exact mechanisms leading to this dysregulation
have not been fully defined. We have recently proposed that Chitinase 3-like-1 (CHI3L1/
YKL40/HC-gp39) molecule, which is induced on colonic epithelial cells (CECs) and lamina
proprial macrophages during inflammatory condition, may play a key role in host/microbial
interaction. Studies were performed to further characterize the functional role of CHI3L1
on CECs/bacterial interaction. Methods: Gentamicin protection assay by using S. typhimur-
ium and three different types of (pathogenic, potentially pathogenic and non-pathogenic)
Escherichia coli was performed in CMT93 colonic epithelial cell line that was transfected
with full-length mouse CHI3L1 expression vector. To examine the functional role of CHI3L1
in vivo, anti-CHI3L1 Ab was administrated in S. typhimurium infection model. Results:
CHI3L1, one of mammalian chitinases, has a chitin-binding domain and may efficiently
bind to chitin-containing organisms but completely lacks glycohydrolase enzymatic activity.
Enhanced CHI3L1 expression by transiently transfection in CMT93 cells significantly facilit-
ated S. typhimurium adhesion (4.3 fold) and internalization (6.3 fold) one hour after infection
compared to mock transfection. Blockade of CHI3L1 activity by anti-CHI3L1 Ab (100 μg/
ml) or CHI3L1 siRNA significantly reduced the S. typhimurium adhesion and invasion. This
blockade also inhibited the adhesion/invasion of two pathogenic E. coli strains (adherent
invasive E. coli, and entero-pathogenic E. coli) but not non-pathogenic E. coli strains.
CHI3L1 expression in CECs was significantly upregulated in C57BL/6 mice two days after
oral inoculation of S. typhimurium. Rabbit anti-CHI3L1 antibody treated C57BL/6 mice
exhibited a significantly lower load of the S. typhimurium in mesenteric lymph nodes,
spleen, liver and colon. In addition, the typhimurium-induced mortality was significantly
reduced by the treatment with anti-CHI3L1 antibody compared to control rabbit IgG: all
mice with control rabbit IgG treatment died, whereas about 50% of mice treated with anti-
CHI3L1 antibody still survive at 12 days after infection. Conclusions: CHI3L1 plays a
pathogenic role in intestinal inflammation by enhancing the adhesion and invasion of
intracellular bacteria on CECs. Since neutralization of CHI3L1 activity significantly reduced
the bacterial loads in lymphoid organs. Inhibition of CHI3L1 activity would be considered
a novel therapeutic strategy for infectious colitis and IBD. Support: NIH DK 64289 and
Broad Foundation.
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PIAS1 (Protein Inhibitor of Activated Stat1) Interacts with and Up-Regulates
Levels and Activities of the Pro-Proliferative Transcription Factor KrüPpel-Like
Factor 5 (KLF5)
James X. Du, C Chris Yun, Vincent W. Yang
BACKGROUND: Krüppel-like factor 5 (KLF5) is a zinc finger-containing transcription factor
that regulates growth and differentiation of intestinal epithelial cells and fibroblasts, and
have been implicated in epithelial cancers. Studies demonstrate that KLF5 promotes prolifera-
tion by transcriptionally activating the genes encoding cyclin D1 and Cdc2. AIM: To identify
proteins that interact with and regulate the activity of KLF5. METHODS: Yeast two-hybrid
screen of a day 17 mouse embryo cDNA library with KLF5 as a bait was conducted to
identify KLF5-interacting proteins. Interactions between candidate proteins and KLF5 were
verified by co-immunoprecipitation and indirect immunofluorescence microscopy. The
effects of the interacting proteins on KLF5’s activity were determined by transient co-
transfection and dual luciferase assays. RESULTS: Several candidate proteins were identified
by the screen. One was protein inhibitor of activated Stat1 (PIAS1), which was further
characterized. PIAS1 is an E3 SUMO (small ubiquitin-like modifier) ligase for a number of
transcription regulators, such as p53, Sp3, Stat1, and Smad4. KLF5 contains two potential
SUMOylation motifs ΨKXE, suggesting that it is potentially regulated by SUMOylation.
The interaction between PIAS1 and KLF5 was first verified by co-immunoprecipitation in
transfected cells. Consistent with this finding, indirect immunofluorescence demonstrated
that FLAG-tagged PIAS1 and HA-tagged KLF5 co-localized to the nucleus and were enriched
in subnuclear speckles. Although we obtained no evidence that KLF5 was SUMOylated by
PIAS1, we showed that KLF5 physically interacted with SUMO. Transient transfection of
PIAS1 and KLF5 in COS-7 cells significantly increased the steady-state levels of each other
in co-transfected cells when compared to cells transfected with the individual construct,
suggesting that the two proteins stabilize each other. Consistent with the increased level of
KLF5, dual luciferase assays with cyclin D1 and Cdc2 luciferase reporters showed that co-
expression of PIAS1 and KLF5 led to a significant and synergistic increase in the activities
of the cyclin D1 and Cdc2 promoters when compared to cells transfected with PIAS1 or
KLF5 alone. Furthermore, cells co-transfected with KLF5 and PIAS1 exhibited enhanced cell
proliferation when compared to singly-transfected cells as measured by BrdU incorporation.
CONCLUSION: The results demonstrate for the first time that PIAS1 is an interacting
partner of KLF5. Interaction between the two proteins significantly increases the levels, and
transcriptional and pro-proliferative activities of KLF5. PIAS1 is therefore a biological modifier
of KLF5.
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Intestinal Barrier Repair Is Impaired Following Ischemic Injury in NHE2-
Deficient Mice
Adam J. Moeser, Prashant K. Knighot, Lane L. Clarke, Anthony T. Blikslager
The intestinal brush border Na+/H+ exchanger isoforms NHE3 and NHE2 mediate most of
the Na+ absorption occurring between meals. Although NHE3 appears to be the predominant
NHE isoform mediating Na+/H+ exchange in the mammalian intestine, little is known
regarding the functional importance of NHE2. We have previously demonstrated an effect
of pharmacological blockade of NHE2 in recovery of mucosal barrier function in the ischemia-
injured porcine ileum associated with recovery of tight junction structure. To definitively
explore the importance of NHE2 in mucosal barrier repair, we studied mice with targeted
disruption of the NHE2 gene (NHE2-/-). Ileum from NHE2-/- mice and their heterozygote
(NHE2+/-) and wild-type (WT) siblings was subjected to a 1-hour period of acute mesenteric
ischemia in vivo. Ischemic intestinal segments were then allowed to reperfuse/recover for 3
hours after which in vivo plasma-to-lumen clearances of 3H-mannitol were performed, as a
measure of intestinal permeability. After the 3-hour post-ischemic recovery period, intestinal
loops of WT mice exhibited increased permeability compared with non-ischemic control
loops (3H-mannitol plasma-to-lumen clearance = 0.646±0.2 vs. 1.08±0.3 ml/hr x 100g in
control and ischemic intestinal loops, respectively, P<0.05), indicating a modest residual
permeability defect . Similar findings were observed in NHE2+/- mice. However, in NHE2-/-
mice, plasma-to-lumen clearances were dramatically elevated following the 3 hour recovery
period (by approximately 6-fold) compared with clearances observed in non-ischemic control
loops (0.722 ± 0.19 vs. 4.52 ± 1.53 ml/hr x 100g in control and ischemic intestinal loops,
respectively, P<0.01) and compared with WT and NHE2+/- ischemic intestinal loops (P<0.01).
Western blot analysis of the tight junction proteins occludin and claudin-1 showed increased
expression of both occludin and claudin-1 in Triton-X soluble fractions in NHE2-/- mice
following the 3 hour recovery period as compared to WT and NHE2+/-mice, suggesting
evidence of increases in cytoplasmic expression of these junctional proteins and loss of tight
junction integrity. For claudin-1, there was a corresponding decrease in the Triton-X insoluble
fraction. Overall, in vivo permeability data and western analyses of tight junctional proteins
suggest that NHE2-/- mice have impaired mucosal barrier recovery that is characterized by
delayed recruitment and assembly of interepithelial tight junctions following ischemic injury.
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Protective Role of MMP-2 in the Development of Colitis
Pallavi Garg, Anupama Ravi, Vijay K. Matam, Steve Epstein, Andrew Gewirtz, Didier
Merlin, Shanthi Sitaraman
Introduction: Matrix metalloproteinases (MMPs) represent a family of proteases that regulate
diverse cellular functions. The two known gelatinases, MMP-2 and MMP-9, are upregulated
during human as well as animal models of inflammatory bowel disease. We recently demon-
strated that epithelial-derived MMP-9 is an important mediator of colitis and targeted deletion
of MMP-9 attenuates colitis. In this study we examined the role of MMP-2 in the development
of colitis. Methods: 6-8 week old female and male MMP2-/- mice and age- and sex-matched
wild type (WT) mice were obtained from Jackson Laboratories. Colitis was induced by oral
administration of 3% dextran sodium sulfate (DSS) in drinking water. Inflammation was

















(inflammatory infiltrate, ulceration and crypt damage-total score 11) scores. Another set of
mice were administered Salmonella typhimurium (ST) SL 3201 by gavage (25 X 104 cfu/
mice) with or without pretreatment with streptomycin (n=10 per group). Mice were followed
for signs of colitis (streptomycin pretreated mice) weight loss and mortality. Results: We
observed that total MMP-2 protein as well as MMP-2 activity was upregulated in WT mice
treated with DSS or ST compared to WT water using zymography (pro form: 2.5+0.5 fold
and active form 10+3 fold), Western blotting (5.2+ .07 fold). Interestingly, MMP-2 -/- mice
were highly susceptible to the development of colitis induced by DSS or ST compared to
WT. This was reflected by rapid weight loss, diarrhea, rectal bleeding and death in MMP-
2-/- mice compared to WT mice (clinical score: MMP-2-/-: 11.0±1, WT: 8.0± 1). All MMP-
2 -/- mice given DSS died compared to 20% mortality in WT. Histological assessment
suggested massive inflammation and extensive tissue damage among MMP-2 -/- compared
to WT mice (Histological score: MMP-2-/-: 10.2±1 WT: 7.4±0.5). Conclusions: In contrast
to MMP-9, MMP-2 plays a protective role in the development of colitis in two murine
models of colitis. Although MMP-2 and MMP-9 belong to the family of gelatinases and share
common substrates, the lack of collagen V domain in MMP-2 likely alters the substrate
specificity of this gelatinase leading to its protective role in the development of mucosal inflam-
mation.
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Metalloprotease Cleavage of TGF-α Mediates Oxidant-Induced Intestinal
Permeability While Paracrine Hb-EGF/EGFR Signaling Regulates Baseline
Intestinal Permeability
Christopher B. Forsyth, Ali Banan, Ashkan Farhadi, Ali Keshavarzian
We have previously identified a novel TNF-α convertase (TACE)-epidermal growth factor
receptor (EGFR) dependent pathway regulating intestinal permeability in response to oxidant
stress. In this model, oxidant induces activation of TACE resulting in cleavage of surface
EGFR ligand precursors such as EGF, HB-EGF,TGF-α,and amphiregulin. The ligand then
binds to the EGFR initiating ERK1/2 signaling required for increased permeability. Aim: In
this study our principal aim was to identify the specific EGFR ligand cleaved by TACE
resulting in EGFR-dependent ERK1/2 activation and increased permeability. In addition we
sought to identify possible EGFR ligands mediating baseline impermeability and identify
mechanisms for regulation of TACE ligand cleavage. Methods: The human Caco-2 cell in
vitro model of tissue culture inserts was used for the permeability (FSA dye movement,
18h) as well as cell signaling studies. Confluent cells on glass coverslips were used for
microscopy studies. For oxidative stress, cells were exposed to H2O2 (500uM). Cells
remained viable. Western blotting of cell lysates from oxidant treated cells was used for
phosphoprotein analysis of mitogen activated protein kinases (MAPK) ERK1/2 as well as
EGFR phosphorylation. Some cells were pre-treated with specific chemical inhibitors of
EGFR and TACE as well as blocking protein (CRM197) to HB-EGF, and blocking antibodies
to EGFR, TGF-α,and amphiregulin. Immunofluorescent microscopy was used to stain for
TACE, EGFR, HB-EGF, and TGF-α. Results: Oxidant-induced permeability (5-fold/h) as
well as increased EGFR and ERK1/2 phosphorylation. These were blocked >90% by EGFR
and TACE inhibitors as well as blocking Abs to the EGFR and TGF-α. Blocking protein to
HB-EGF or Abs to amphiregulin had little effect on oxidant-induced permeability. However,
treatment of resting cells with HB-EGF blocker (but not other blockers) increased permeability
five-fold. Immunofluorescence images reveal EGFR and HB-EGF localize to the cell periphery
in resting monolayers, while TACE and TGF-α stain diffusely. However, oxidant induces
translocation of both TACE and TGF-α to the cell-cell contact zones. Conclusions: These
data support a significant and new TACE-EGFR model for regulation of intestinal permeabil-
ity. Our data strongly support TGF-α as the principal EGFR ligand cleaved by TACE to
initiate permeability induced by oxidant stress. In addition they support a role for paracrine
HB-EGF/EGFR signaling in maintaining baseline impermeability. Co-translocation of TACE-
TGF-α to cell-cell contact zones probably facilitates TACE cleavage of TGF-α to induce per-
meability.
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A Combined Regimen of Infliximab and Azathioprine Induces Better
Endoscopic Healing Than Classic Step-Up Therapy in Newly Diagnosed
Crohn’s Disease
Geert R. D'Haens, Daan Hommes, Filip Baert, Martine de Vos, Filip Caenepeel, Gert van
Assche, Guy Lambrecht, Jean Claude Coche, Severine Vermeire, Marijke van Camp
Current guidelines for treatment of moderate-severe Crohn’s disease (CD) recommend
corticosteroids and at a later stage immunosuppressives (IS)such as azathioprine. Often, CD
complications develop during the period prior to the initiation of IS, probably because of
insufficient mucosal healing with steroid regimens. We examined if a strong induction
regimen with anti-TNF therapy in combination with IS given in an early phase of the disease
induced better mucosal healing than ‘classic’ step-up treatment with corticosteroids. Methods:
133 patients with recently diagnosed CD were enrolled in a prospective trial and randomised
to receive treatment with 3 infusions of 5 mg/kg infliximab (IFX) + azathioprine 2-2.5 mg/
kg/day (TD or ‘top-down’ treatment) or corticosteroids at standard dosage (SU or ‘step-up’
treatment). In the latter group, IS was added in case of relapse and need for further steroids;
IFX was given if IS failed. Patients enrolled at 8 centers participated in this substudy and
had ileocolonoscopy 2 years after enrollment. Results were compared by a blinded investigator
with the endoscopy reports at diagnosis. In 5 ileal and colonic segments lesions were scored
as follows: 0=no ulcers, 1= aphthoid ulcers, 2=larger ulcers, 3= ulcerated stenosis. The
primary endpoint was disappearance of all ulcers; the secondary endpoint was percentage
of reduction of all CD lesions. Results: 44 pts have reached year 2 and underwent repeat
endoscopy. 24 pts received TD therapy and 20 classic SU therapy. The characteristics of
the pts and the baseline endoscopies in both groups were comparable. At year 2, all pts in
the TD group received IFX and IS vs 45% IFX and 60 % IS in the SU group. The interval
between the last IFX infusion and the second endoscopy was 15.8±8.7 months in TD vs
7.44±4.4 months in SU (p=0.001) and the mean duration of IS was 24 months in TD vs
19 months in the SU group. Complete ulcer disappearance was seen in 17/24 TD pts (71%)
vs in 6/20 SU pts (30%)(p<0.001). Mucosal healing was significantly more pronounced in
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TD patients (ulcer reduction 88 % versus 47 %, p<0.001; in TD the score went from 5.75
± 2.47 to 0.75 ± 1.60, in SU from 5.40 ± 2.41 to 3.25 ± 2.97, p<0.001). Conclusion: the
‘top-down’ strategy with IFX+IS is superior to induce mucosal healing two years after the
start of therapy. This superiority vs classic ‘step-up’-therapy is maintained even in patients
who receive IFX and IS later on. Since persisting lesions lead to development of complications
and healing is associated with a reduction in surgery and hospitalisations, this strategy
should be considered in all patients with severe newly diagnosed Crohn’s disease.
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The Treatment with An Oral Spherical Adsorptive Carbon (AST-120) Improves
Anal Fistula, PDAI and CDAI Scores - A Randomized Double-Blind Placebo-
Controlled Trial
Yoshihiro Fukuda, Masakazu Takazoe, Akira Sugita, Tadashi Kosaka, Toshihiko Tomita,
Kazutoshi Hori, Ken Fukunaga, Hiroto Miwa, Takayuki Matsumoto, Hiromasa Koizuka,
Takashi Sakagami, Takashi Shimoyama
BACKGROUND Crohn’s disease (CD) patients are often suffering from anal fistulas, leading
difficult lives. The current therapies with various drugs including anti-TNF-α antibodies are
effective in most of fistulizing CD, but anal fistulas are still remaining unhealed in some
patients. Surgical treatment including fecal diversion and stoma is indicated, however, not
all of patients can accept it. We conducted a randomized, double-blind, placebo-controlled
multi-center clinical trial of an oral spherical adsorptive carbon (AST-120). METHODS CD
patients with active fistula under medical treatments were randomly assigned to receive
either AST-120 or placebo for 8 weeks. The number and status of draining fistulas were
evaluated by the investigators at 0, 4 and 8 weeks. The improvement was a reduction of
50% or more from base line in the number of draining fistulas observed both at 4 and at
8 weeks. The fistula remission was defined by closure of all draining anal fistulas both at
4 and 8 weeks. Severities of symptoms related to CD were graded referring to a patient
diary. Also, Crohn’s Disease Activity Index (CDAI) and Perianal Disease Activity Index
(PDAI) were evaluated. RESULTS Sixty-two patients were evenly assigned to both group
and were given AST-120(n=27) or placebo(n=30). The fistula improvement rate in the AST-
120 group (37.0 % ) was significantly greater than that in the placebo group (10.0 % ) (p=
0.025). The fistula remission rate in the AST-120 group (29.6 %) was significantly greater
than that in the placebo group (6.7 % ) (p=0.035). Symptomatic scores such as drainage
amount, perianal pain and fecal consistency were significantly improved in the AST-120
group but not in the placebo group. PDAI scores significantly improved both at 4 weeks
and at 8 weeks in the AST-120 group compared with those in the placebo group (p=0.004
and p=0.005, respectively). Also CDAI scores significantly improved both at 4 weeks and
at 8 weeks in the AST-120 group compared with those in the placebo group (p=0.007 and
p=0.001, respectively). The AST-120 treatment was generally well tolerated and was observed
no life threatening adverse events. CONCLUSIONS The AST-120 treatment is safe and
effective for the control of intractable anal fistulizing CD.
766
A Meta-Analysis of the Placebo Outcomes in Clinical Trials Evaluating
Maintenance Therapy for Patients with Crohn’s Disease
Monina F. Pascua, Gary R. Lichtenstein, James D. Lewis, Colleen Brensinger, Chinyu Su
Background: Placebo-controlled RCTs (PC-RCTs) are the gold standard for evaluating efficacy
of maintenance therapy in patients with Crohn’s disease (CD). There has been no formal
systematic analysis in the literature on the outcome of placebo therapy in maintenance
clinical trials for CD patients in remission. Aim: To estimate the proportion of CD patients
treated with placebo who maintain remission for the duration of the PC-RCTs and to identify
factors influencing this rate. Methods: PC-RCTs evaluating CD maintenance therapy were
identified from MEDLINE from 1966 through September 2005. Studies evaluating surgically-
induced remission were excluded. Outcomes were dichotomized into remission vs. active
disease at the primary endpoint of the study. Pooled estimate of the proportion remaining
in remission was calculated using logistic regression analysis after applying sample weights
according to the placebo size. The influence of study design features on this rate was
estimated using univariate logistic regression models clustering on study. Results: Of 23
studies fulfilling the inclusion criteria, the pooled estimate of the proportion of placebo-
treated patients remaining in remission was 0.45 (95% CI 0.38-0.52), with significant
heterogeneity among studies (p<0.001). These rates were similar if analyses were limited to
20 studies using CDAI and 12 studies using CDAI>150 plus a minimum point increase as
remission definition (0.44 and 0.46, respectively). Factors associated with the placebo
remission rate are shown in the Table. The placebo remission rate was independent of the
following features: publication years, sample size ratio, drug administration route, number/
frequency of study visits, and age, disease duration/distribution, prior surgery and smoking
status of placebo patients. Conclusions: The placebo rate of maintaining remission was 45%
in prior CD trials for maintenance therapy. Study features that influence the placebo remission
rate include study duration, trial location, length of remission prior to study, and steroid-
induced remission. These factors should be considered when designing future studies to
optimize study efficiency.
*OR >1 indicates the factor was positively associated with a higher proportion of patients
in the placebo arm remaining in remission
767
Validation of the Crohn’s Disease Activity Index As a Measure of Post-
Operative Disease Recurrence
Thomas D. Walters, A H. Steinhart, C Bernstein, W Tremaine, B Wolff, S Ross, R Parkes,
M McKenzie, R S. McLeod
BACKGROUND/AIMS: Objective measures of disease activity are important as endpoints
in randomized controlled trials (RCT). The Crohn Disease Activity Index (CDAI) has been
used in medical trials with scores <150 indicative of remission. Its value in assessing post-
operative recurrence is unknown. Taking advantage of an international, prospective, RCT
investigating post-operative disease recurrence, we examined the association between a
combined clinical/endoscopic assessment of disease activity and the CDAI. We desired to
determine the suitability of the CDAI as a single post-operative outcome measure. METHOD/
PATIENTS: 120 patients [38% male] from 16 surgical units were included in an RCT
comparing surgical techniques. All underwent clinical and colonoscopic evaluation 12
months post ileocolic resection, at a mean age of 39.7 yrs [+/- 13.5]. Outcomes were
adjudicated by a three person committee and consensus reached. Endoscopic appearance
was assessed using the Rutgeerts score [i0-i4]. Symptomatic disease recurrence was defined
by the composite of symptom severity warranting therapy and an endoscopic score >/=
i2. Eighty eight [73%] subjects had CDAIs calculated according to established criteria.
Comparisons were made using both non-parametric methods and the Receiver Operator
Curve (ROC). RESULTS: Thirty five [40%] patients had evidence of recurrent disease [23%
symptomatic, 17% endoscopic only] by 12 months. Seven percent had endoscopy scores
>i2 in the absence of symptoms. Median CDAI for symptomatic recurrence was 215 [Inter-
quartile Range (IQR): 116 to 280]; significantly different from asymptomatic subjects [median
70, IQR 40 to 125, p<0.001]. The area under the ROC for symptomatic disease and CDAI
was 0.80 [95% CI 0.67 to 0.93, p<0.001]. Recurrence was best predicted by a CDAI of >/=
148 [sensitivity 70%, specificity 85%, PPV 58% and NPV 91%]. CDAI did not differentiate
between endoscopic scores >/= or < i2 in the absence of significant symptoms [median 64
vs 88, p=0.99]. CONCULSIONS: This study confirms that a CDAI of 150 is the best
cutpoint for assessing disease activity. CDAI is useful in assessing outcome in postoperative
RCTs. However, given a PPV < 60%, it does not replace combined clinical/endoscopic
evaluation as a single outcome measure in the assessment of post-operative disease recurrence.
Supported, in part, by Research Grants from the Canadian Institutes of Health Research (CIHR)
and the Crohn’s & Colitis Foundation of America (CCFA).
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Natalizumab Maintains Remission in Patients with Moderately to Severely
Active Crohn’s Disease for Up to 2-Years: Results from An Open-Label
Extension Study
Remo Panaccione, Jean-Frederic Colombel, Robert Enns, Brian Feagan, Stephen Hanauer,
Ian Lawrance, Paul Rutgeerts, William Sandborn, Stefan Schreiber, Stephan Targan,
Sander van Deventer
Introduction: Phase 3, randomized, controlled, trials have demonstrated that natalizumab
is effective as both induction and long-term maintenance therapy for Crohn’s patients with
moderately to severely active disease. Patients who responded to 3 monthly natalizumab
(300 mg) infusions in the ENACT-1 induction trial were re-randomized to maintenance
therapy with 12 monthly infusions of either natalizumab or placebo in the ENACT-2 trial.
A significantly higher proportion of patients in the natalizumab group maintained a sustained
remission (defined as a Crohn’s Disease Activity Index [CDAI] score <150) through 12
months of continuous therapy compared with the placebo group (39% [51/130] vs. 15%
[18/120], p < 0.001). This analysis was undertaken to assess the ability of natalizumab to
maintain remission for up to an additional year in natalizumab-treated patients who were
in remission at month 12 of the ENACT-2 trial. Methods: Patients who completed month
12 of the ENACT-2 trial were eligible to enroll in a phase 3, long-term, open-label, extension
(OLE) study. The primary objective of this 2-year study was to examine the long-term safety
and tolerability of natalizumab. Secondary efficacy endpoints included evaluation of the
ability of natalizumab to maintain remission. The population for this analysis included 146
natalizumab-treated patients who had maintained remission at month 12 of ENACT-2, and
subsequently enrolled in the OLE study and received an additional 12 months of natalizumab
therapy. Remission rates were calculated using last observation carried forward. Results:
Ninety-eight percent (143/146) of patients who had maintained remission at month 12 of
ENACT-2 were in remission at baseline of the OLE study. The proportion of these patients
in remission following 6 additional infusions of natalizumab in the OLE study was 89%
(130/146) at 24 weeks, and 84% (122/146) following a total of 12 additional natalizumab
infusions (48 weeks). Conclusions: Maintenance therapy with monthly infusions of
natalizumab has previously been shown to achieve a sustained remission through 12 months
in a significant number of Crohn’s disease patients. Patients in this analysis who were in
remission after 12 months of natalizumab therapy were highly likely to remain in remission
through an additional 12 months of treatment.
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A Phase I Study: Visilizumab Therapy in Crohn’s Disease (CD) Patients
Refractory to Infliximab Treatment
Daan Hommes, Stephen Targan, Daniel C. Baumgart, Axel U. Dignass, Lloyd Mayer,
James N. Lowder
Purpose: Studies of visilizumab, a humanized anti-CD3 antibody, in ulcerative colitis (UC)
patients, show its tolerability and clinical activity at doses ranging from 5 to 15mg/kg
administered on 2 consecutive days. The current open-label study was designed to evaluate
the safety and clinical activity of 10 μg/kg visilizumab doses in patients with moderate-to-
severe inflammatory non-penetrating Crohn’s disease. Methods: Subjects with a diagnosis
of CD, a Crohn’s Disease Activity Index (CDAI) > 250, a C-Reactive Protein (CRP) > 4 mg/
L (above normal), and endoscopic evidence of active inflammatory disease were treated with
bolus intravenous visilizumab on days (D) 0 and 1. A clinical response was defined as a
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decrease of CDAI at D59 of more than 100 points below the baseline value. Results: The
protocol will enroll a total of 18 subjects. To date, a total of 12 subjects have enrolled, 8
of them have been followed for at least 59 days and are discussed below. The median
baseline CDAI was 386.5 (308-516). The median baseline CRP was 30.5 mg/L (2.0-69). All
subjects were steroid refractory (n=3) or dependent (n=5) with a median dose of 20 mg/D
prednisone. All subjects had received infliximab; 2 were primary non-responders, 1 had an
intolerable infusion reaction and 5 had lost activity after an initial response. Six of the 8
subjects had a day 59 clinical response. The median D59 CDAI was 218 (150-366). Three
complete remissions (CDAI<150) at any time and 1 at D59 were observed. Both primary
infliximab failures responded to visilizumab. In visilizumab responders, the CRP decreased
quickly after drug administration and it remained low in 2 subjects who achieved clinical
remission. Mild to moderate cytokine release syndrome occurred in the majority of subjects.
The adverse event (AE) profile of severity, incidence and drug relatedness was similar to
that seen in those UC subjects who received 10 μg/kg visilizumab. No lymphoproliferative,
malignant or life-threatening AEs were reported. Transient elevations of transaminases were
observed in 4 of 8 subjects. Conclusion: Two 10 μg/kg visilizumab doses administered as
an IV bolus on consecutive days were tolerated and produced a rapid and sustained improve-
ment in 6/8 steroid and infliximab resistant CD subjects.
770
Is Irritable Bowel Syndrome (IBS) a Diagnosis of Exclusion? A Survey of
Primary Care Providers, Gastroenterologists, and IBS Experts
Brennan M. Spiegel, Mary Farid, Eric Esrailian, Jennifer Talley, Lin Chang
Background: Published guidelines state that IBS is not a diagnosis of exclusion, and encourage
clinicians to make a positive diagnosis using the Rome criteria alone. Yet many clinicians
remain unsettled by the prospect of overlooking alternative diagnoses, and instead approach
IBS as a diagnosis of exclusion by conducting a series of tests prior to “settling” on a diagnosis
of IBS. We measured provider beliefs about whether IBS is a diagnosis of exclusion, and
measured testing proclivity in IBS between nurse practitioners (NPs), primary care physicians
(PCPs), GIs, and IBS experts. Methods: We developed an online survey consisting of 2
clinical vignettes: 1) Rome-II IBS-D patient, and 2) Rome-II IBS-C patient, both without
alarm features. We developed the vignettes with IBS experts to ensure face validity and
comprehensiveness, and subjected the survey to iterative revisions by experts in survey
design to ensure acceptable psychometric properties. The survey elicited provider knowledge,
attitudes, and beliefs in IBS, including items about testing proclivity and beliefs regarding
IBS as a diagnosis of exclusion. We surveyed a random sample of 300 VA NPs, 300 VA
PCPs, 300 GIs from the AGA membership rolls, and 45 internationally-recognized IBS
experts. Results: The response rate was 31% (102 NPs, 89 PCPs, 90 GIs, 27 experts). IBS
experts were less likely than non-experts to endorse IBS as a diagnosis of exclusion (8% vs
72%; p<0.0001). Among non-experts, 42% of GIs and 76% of both NPs and PCPs shared
this belief (p<0.01 for GI vs NP+PCP). In the IBS-D vignette, experts were more likely than
non-experts to make a positive diagnosis of IBS (67% vs. 38%; p<0.001), to perform fewer
diagnostic tests (2 vs 4.1; p<0.01), and to expend less cost on testing ($297 vs $658;
p<0.01). These trends were repeated in the IBS-C vignette (+IBS=67% vs 20%, p<0.01;
tests=1.4 vs 2.2, p=0.06; cost=$298 vs $550, p=0.03). In regression analysis adjusting for
provider group, expert status, age, and gender, providers who believed IBS is a diagnosis
of exclusion ordered 1.6 more tests and consumed $364 more than those who did not
(p<0.0001). Conclusions: Most (72%) community providers in this sample believe that IBS
is a diagnosis of exclusion, and this belief is associated with increased diagnostic testing
and resource utilization. In contrast, “IBS experts” comply more closely with published
guidelines to make a positive diagnosis with minimal diagnostic testing. This disconnect
between experts and community practice indicates that better dissemination and implementa-
tion of IBS guidelines is warranted in order to minimize variation and improve cost-effect-
iveness of care.
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Yield of Diagnostic Testing in Patients with Suspected Irritable Bowel
Syndrome (IBS): A Prospective, Us Multi-Center Trial
Brooks D. Cash, Allan H. Andrews, Dong H. Lee, John H. Smith, Cecilia H. Kim, Richard
Saad, Jennifer K. Rai, William D. Chey
Background: A recent systematic review examining the yield of frequently recommended
tests concluded that there was little evidence to support exhaustive testing in suspected
irritable bowel syndrome (IBS) pts without alarm symptoms. We report preliminary results
from a prospective, multi-center US trial intended to validate these findings. Methods:
Consecutive adult pts with suspected non-constipation IBS (Rome II) were invited to particip-
ate. Exclusion criteria included alarm symptoms such as hematochezia or weight loss, a
family history of organic gastrointestinal (GI) disease, a previous evaluation for IBS, or
conditions precluding evaluation. Patients underwent colonoscopy with random biopsies
and the following: CBC, metabolic panel, thyroid function testing (TFT), antibodies for
celiac disease (CD-ab) and inflammatory bowel disease (IBD-ab), and lactase genomics.
These latter 3 “non-standard tests” were also collected from asymptomatic pts undergoing
screening colonoscopy. Positive CD-ab were confirmed with EGD and small bowel biopsy
and IBS symptoms were reassessed 3 months after initiation of a gluten-free diet in confirmed
CD. Results: 250 IBS pts (mean age 44.8 years, 66.0% female) and 201 controls (mean age
53.7 years, 41.8% female) have been enrolled. 3.2% (8/250) IBS pts were identified with
organic disease felt to be responsible for their symptoms. One pt each was diagnosed with
IBD, peritoneal carcinomatosis, and sigmoid volvulus. The prevalence of abnormal TFT was
15 (6%) in IBS pts, consistent with the population norm. CD was confirmed in 4 (1.6%)
IBS pts and 2 (1%) controls (p=0.07), however the prevalence of abnormal CD-ab was
significantly greater in IBS pts. Conclusions: There does not appear to be a significant
difference between IBS pts and asymptomatic controls in organic GI disease diagnosed via
colonoscopy and random biopsies or blood tests for thyroid disease, IBD, and lactose
intolerance, suggesting that such testing should not be routinely obtained as part of an initial

















are more common in IBS pts, perhaps indicative of gluten hypersensitivity. Whether dietary




Screening for Celiac Disease (CD) in Patients Fulfilling the Rome II Criteria
for Irritable Bowel Disease (IBS) in a Secondary Care Hospital in the
Netherlands: A Prospective Observational Study
Egbert-Jan Van der Wouden, G. F. Nelis, J. Vecht
Introduction. A few studies showed that screening for CD in patients with symptoms
suggestive of IBS is cost effective, while other studies suggested no benefit. We, therefore,
started to screen routinely patients with typical IBS symptoms for celiac disease using anti-
endomysial antibodies. Methods. Patients attending the outpatient department of our hospital
and fulfilling the ROME II criteria for IBS were eligible. All patients received standard care
including an interview, physical examination, routine laboratory tests and an endoscopy of
the lower gastrointestinal tract. Apart from these tests the treating physician could order
any other diagnostic test as considered necessary. Furthermore, in all patients anti-endomysial
antibodies were measured according to the instructions of the manufacturer. Results. Between
november 2002 and november 2005 161 patients (53 males, median age 33 years (range:
16-75)) fulfilling the ROME II criteria were included. 153 patients were finally diagnosed
with IBS, 3 with Crohns disease, 2 with hyperthyroidism, 1 with endometriosis, 1 with
lactase deficiency and 1 with idiopathic bile salt malabsorbtion. 15 patients were not screened
with anti-endomysial antibodies although in 4 of them duodenal biopsies showed normal
mucosa. In none of the 146 evaluable patients fulfilling the ROME II criteria (0%, 95%
confidence interval: 0-2.6%) anti-endomysial antibodies were positive. In 32 patients the
treating physian ordered duodenal biopsies as well, mostly because of predominant diarrheal
symptoms. In two of them MARSH 1 was found, in the the other 30 patients duodenal
biopsies were normal. Conclusion: Screening for CD with anti-endomysial antibodies in IBS
patients in a secondary care hospital in the Netherlands seems to be ineffective.
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The Effectiveness of a Model Physician-Patient Relationship Versus Usual Care
in Irritable Bowel Syndrome (IBS): A Randomized Controlled Trial
Brennan M. Spiegel, Bruce Naliboff, Emeran Mayer, Roger Bolus, Ian Gralnek, Paul
Shekelle
Background: Practice guidelines emphasize that the physician-patient relationship is the
fundamental cornerstone of treatment in IBS, and that an effective relationship may improve
health related quality of life (HRQOL) more than any alternative therapy currently available.
However, the components of this relationship have not been operationally defined or pro-
spectively tested, and data suggest that the physician-patient relationship is often sub-optimal
in IBS. We performed a study to compare the effect of an intervention aimed at improving the
physician-patient relationship in IBS vs. usual care. Methods: We performed a prospective,
randomized controlled trial comparing a multi-factorial intervention vs. usual care (i.e. no
intervention) in patients with Rome II positive IBS evaluated in the West Los Angeles
VA between Jan-Sep 2005. The intervention included 4 components: (1) point-of-care
questionnaire designed to rapidly capture patients’ agenda, concerns, and HRQOL; (2) MD
prompt card outlining a checklist of key components of effective communication in IBS;
(3) multi-media patient educational kit, including info pamphlets, dietary card, website
listings, and a self-empowerment video; and (4) patient home educational mailings. The
intervention did not include specific diagnostic or treatment suggestions. The primary
outcome was 3-month change scores on the IBS-QOL - a validated measure of disease-
targeted HRQOL. Secondary outcomes included global symptom relief (percentage scoring
>4 on 6-point Likert scale), satisfaction with care (7-point scale), and patient assessment of
MD interpersonal (IP) skills (IP Skills Rating Form). Results: 63 patients were enrolled (31
intervention, 32 control). The average age was 52, and 33% were women. There were no
significant baseline differences in key covariates between groups. The mean 3-month change
scores on the overall IBS-QOL were +2.4 and +12.2 for the control and intervention groups,
respectively (Δ=9.8, 95% CI=5.2, 12.4; p=0.01; effect size [ES]=0.7). The % with global
symptom relief was 15% and 56% in the control and intervention groups, respectively (p=
0.001). Satisfaction with care and assessment of MD interpersonal skills were higher in the
intervention group (p<0.03 for both). Conclusions: These data indicate that a standardized
physician-patient relationship improves global outcomes in IBS over and above routine care.
The HRQOL impact observed in this study (ES=0.7) exceeds the HRQOL impact of the
most effective pharmaceutical agents in IBS (ES range=0.1-0.5), suggesting that medical
therapy alone is sub-optimal if not delivered in the context of a supportive physician-
patient interaction.
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Chronic Treatment-Resistant Constipation in Children: Experience with
Radioisotope Transit Studies, Colonic Manometry and Transcutaneous
Electrical Stimulation
Bridget R. Southwell, Sebastian K. King, Jonathan R. Sutcliffe, Janet Chase, Susie Gibb,
Val J. Robertson, David Cook, Anthony G. Catto-Smith, John M. Hutson
Chronic constipation can be due to dietary defects, avoidance of defecation, withholding,
abnormal anal sphincter responses or defects in transit through the colon. New clinical
methods (radioisotope transit studies, manometry) should allow different subgroups and
etiologies to be separated. This study reports our experience using these methods to analyze
300 children with chronic treatment-resistant constipation presenting to a surgeon at a
major tertiary children’s hospital in Australia. Methods: Metabolic and genetic disorders
were excluded by blood tests and Hirschsprung disease by rectal biopsy. Whole gut transit
was measured using gamma camera scintigraphy at 0,2,6,24,30 & 48 hrs. 24hr colonic
manometry using 8 channel water-perfused catheter was performed via established appendix
stomas. For transcutaneous electrical stimulation using interferential current (IFT), 2 surface
electrodes were placed anterior & 2 posterior at the level of the umbilicus with current
crossed and applied 3 times/wk for 4 weeks. Results: Children with palpable fecaloma were
classified as having anal retention and not sent for nuclear transit studies or biopsies. 120
nuclear transit studies have been performed since 1995. 48hr transit studies clearly separated
patients with normal transit (16%) or anal retention (11%) from patients with slow transit
in the proximal colon. Slow colonic transit (SCT) consisted of pancolonic slowing (44%),
isolated holdup at the splenic flexure (16%) and combined small bowel/large bowel slowing
(13%). Colonic manometry was performed on 26 children who had transit studies (18
SCT, 8 non-SCT). SCT children had significantly (p<0.05) reduced frequency of anterior
propagating contractions and no increase in activity post-waking or post-meal compared to
non-SCT children with anal retention or normal transit. IFT was applied to 16 children. 8/
16 were followed by daily diaries. 13/16 increased defecation and 15/16 stopped soiling.
The effects lasted more than 3 months post-stimulation. Two patients had colonic manometry
before and 6 months after electrical stimulation. Both showed normalized defecation and
increased frequency of antegrade propagating contractions into the normal range. Conclu-
sions: Many children with chronic constipation have slow colonic transit independent of
outlet obstruction. Clinical assessment using radioisotope transit studies can separate these
two groups. SCT is associated with reduced propagating contractions and lack of postprandial
increase in activity. Transcutaneous electrical stimulation can increase propagating contrac-
tions into the normal range and the effects last months after the stimulation.
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Prolonged Measurement of Colonic Motility in Slow Transit Constipation
Eduard A. Van Hoboken, Hilde Slingerland, Ad A. Masclee
Slow Transit Constipation (STC) is characterized by delayed transit over all colonic segments.
Recent studies indicate that decreased phasic colonic motility may be involved in the
pathophysiology of STC. Colonic motility is best evaluated by ambulatory colonic manometry.
However, using this method the repeatability between two measurement days has been
shown to be poor. Therefore ambulatory colonic manometry should be performed over at
least several days. Our aim was to investigate colonic motility in STC-patients compared
with healthy volunteers (HV) by recording over a prolonged period. Thirteen STC-patients
(12F,47±4 yrs; colonic transit time 115±13 hrs (ref:<69hrs)) and 12 HV (10F,40±3 yrs)
underwent 24-hr colonic manometry on two consecutive days. A catheter with 6 solid-state
pressure sensors (s1-2 hepatic flexure, s3-4 splenic flexure, s5-6 sigmoid; 10 cm distance)
was positioned endoscopically and clipped to the mucosa. Subjects were ambulatory with
standardized resting and eating conditions. Data were averaged over two measurement days.
Colonic motility was evaluated by motility index (MI=wave frequency*duration*amplitude;
10^3 sec*mmHg) per hour with MI-values averaged per period (evening-night-daytime).
Furthermore several distinct pressure patterns were analyzed, i.e. High-Amplitude Propagated
Contractions (HAPC’s;≥3 sensors;≥80 mmHg), propagated pressure waves (≥2 sensors)
and retrograde pressure waves (≥2 sensors;directed orally). MI per hour was sign. (p<0.05)
reduced in STC-patients compared to controls during daytime (14±2 vs.22±2) and evening
(11±2 vs.19±4). During the night MI was 7±1 in both STC and controls. HAPC-frequency
per 24-hr in STC-patients was significantly reduced (2.2±0.7 vs. 5.3±0.7;p<0.05). In STC-
patients HAPC’s predominantly (44.2%) originated at the splenic flexure (s4). In controls
HAPC’s originated more often (51.5%) at the proximal colon (s1;p<0.05). HAPC’s propagated
over more than three sensors in 30% of cases in STC-patients versus 52.3% in HV (p<0.05).
Propagated pressure waves occurred less frequently in STC-patients during daytime (10±1
vs 17±2/hr;p<0.05). Retrograde pressure waves occurred less frequently (p<0.05) in STC-
patients during night (2±0 vs 5±1/hr) daytime (4±1 vs 8±2/hr) and evening (3±1 vs 7±1/
hr). Conclusions. Overall phasic colonic motility is sign. reduced in patients with STC during
daytime, but not during nighttime. Furthermore, in STC-patients HAPC-frequency is reduced,
HAPC’s originate more distally and propagate over a shorter distance. Propagated and
retrograde pressure waves occur less frequently in STC-patiens. All of these features may
contribute to delayed colonic transit in STC.
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Overlapping Gene Expression Profiles of Experimental Colitis and IBD
Anje Te Velde, Floor de Kort, Ellen Sterrenburg, Inge Pronk, Fiebo Ten Kate, Daniel
Hommes, Sander van Deventer
Background: The pathogenesis of Crohn’s disease and Ulcerative Colitis is directly related
to a dysfunction of innate responses to bacterial products. Mouse models of inflammatory
bowel diseases (IBD) are used to unravel the pathophysiology of IBD and to study new
treatment modalities, but their relationship to Crohn’s disease or Ulcerative Colitis is unclear.
Aim: This study was set up to investigate the gene expression profile of the colon of mice
with an established colitis and compare this with the expression of genes known to be
associated with IBD. Methods: We analyzed the gene expression in three widely used models
of experimental colitis with microarrays. In two of the models exogenous agents induce the
colitis: intrarectal application of TNBS and oral administration of DSS. In the third model
the colitis is induced after transfer of a T cell population (CD4+CD45RBhigh T cells) that
lacks regulatory cells into an immunodeficient host. Agilent mouse TOX oligonucleotide
microarrays were hybridised with amplified and labelled cRNA, generated from isolated
total colon mRNA. Results: Of 19 genes that are known to be upregulated in IBD: TNF,
IFN-gamma, IL-22, Socs3, CCL2, 5, 7 and 20, CXCL5 and 10, MMP3, 7 and 14, Timp1,
Reg3gamma and PAP, S100A8, S100A9 and Ptgs2: 2/19 are upregulated in TNBS, 11/19
are upregulated in DSS and 18/19 are upregulated in the CD45RB transfer colitis. Conclusion:
Our gene expression profiles indicate that the CD45RB transfer model best resembles human
IBD, and this is the only model that is characterized by chronic inflammation. In contrast,
the DSS and TNBS model reflect a more acute insult to the intestinal mucosa, either by
inflicting epithelial damage (DSS colitis) or by causing a hapten-dependent DTH reaction
(TNBS colitis).
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Combination of QTL and Expression Analyses Revealed Cd14 As a Candidate
Gene for IBD in Il10-Deficient Mice
Maike F. De Buhr, Robert Geffers, Wiebke Hansen, Astrid M. Westendorf, Joerg Lauber,
Jan Buer, Hans J. Hedrich, Michael Maehler, Andre Bleich
Background & Aim: Interleukin-10-deficient, Il10tm1Cgn (Il10-/-), mice serve as a model for
inflammatory bowel disease (IBD). The severity of colitis depends on the inbred strain
carrying the disrupted Il10 gene: C3H/HeJBir (C3) mice develop severe colitis, whereas
C57BL/6J (B6) mice are colitis resistant. Genetic dissection of this susceptibility revealed
ten colitogenic quantitative trait loci (QTL). The aim of this study was to identify valuable
candidate genes by a combination of QTL mapping and expression analyses. Methods:
Affymetrix GeneChips were used to detect gene expression in the colon of C3- and B6-
Il10-/- mice and their wildtype (WT) controls. Cd14 gene and CD14 protein expression was
determined by real-time RT PCR and western blot analysis in the mouse strains indicated
below. Naive peritoneal macrophages were harvested from mice of both Il10-/- strains,
cultured, stimulated with cecal bacterial antigens or left unstimulated, and stained with
FITC-labeled CD14 antibody for FACS analysis. Results: Microarray analysis revealed that
sixteen genes were differentially expressed between B6- and C3-Il10-/- mice and were located
within the QTL intervals. Cd14 showed prominent expression differences between B6- and
C3-Il10-/- as well as between B6 and C3 WT mice, which was confirmed by real-time RT
PCR. Western blot analysis revealed strain differences also at the protein level. Cd14 expression
rates determined by real-time RT PCR in animals with defective and intact TLR4 signalling
(C3, C3H/HeN, B6) made the TLR4 defect of C3 mice unlikely as the reason for higher
Cd14 expression. Lower Cd14 mRNA expression in germfree mice indicates a contribution
of the microflora to Cd14 expression. Stimulation of naive peritoneal macrophages with
bacterial antigens showed that B6 mice responded with a lower CD14 surface expression
than C3 mice. Conclusions: The ultimate goal of QTL mapping is to identify genes underlying
a complex trait, which is complicated by large QTL intervals containing multiple candidate
genes. By combination of QTL and expression analyses, the number of candidate genes was
reduced and Cd14 identified as a promising candidate. Studies are underway to investigate
a possible contribution of Cd14, which plays an important role in innate immunity, to
colitis susceptibility.
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Wasp-Deficiency in Mice Leads to Global Regulatory T Cell Dysfunction with
IL-10 Deficiency and Aberrant IL-2 Signaling Independent of Immune Synapse
Formation
Michel Maillard, Vinicius Cotta-De-Almeida, Pierre Michetti, Cathryn Nagler-Anderson,
Scott B. Snapper
Background: Naturally occurring CD4+CD25+Foxp3+ regulatory T cells (Tregs) play a critical
role in the prevention of autoimmunity. An imbalance between effector T cells and regulatory
T cells has been implicated in many murine models of Inflammatory Bowel Disease (IBD).
The Wiskott-Aldrich Syndrome (WAS), a primary human immunodeficiency, results from
a mutation in the gene encoding the Wiskott-Aldrich Syndrome Protein (WASP), and is
associated with autoimmunity including an IBD-like illness. The majority of WASP-deficient
(WKO) mice develop colitis; lymphocytes are required and CD4+ T-cells sufficient for colitis
induction. In mature T cells, WASP is recruited to the immune synapse where it induces
actin polymerization following T-cell receptor signaling. We have recently demonstrated
that WKO mice have decreased percentages of CD4+CD25+ Tregs and therefore hypothesized
that Treg dysfunction may be central to the pathogenesis of colitis. Using the CD45RB
transfer model, we observed a severe dysfunction of WKO Tregs in vivo. The aim of this
study was to dissect the molecular mechanisms responsible for Treg dysfunction in WKO
mice. Results: We looked at Foxp3 expression in WKO Tregs, a transcription factor that is
critical for Treg lineage specification and function. The percentage of CD4+Foxp3+ Tregs
in WKO mice was reduced in comparison to WT mice, similar to the reduction in
CD4+CD25+ Tregs previously observed. The vast majority (>90%) of CD4+CD25+ cells
were also Foxp3+ in both WKO and WT mice. Correlating with our in vivo findings, we
observed a marked reduction in suppression by WKO Tregs employing an in vitro suppression
assay. This defect was also observed when using WKO CD4+CD25- cells as responder cells.
In vitro pre-activation of WKO Tregs with IL-2 and plate-bound anti-CD3 partially rescued
this defect. Finally, we observed a marked decrease in IL-10 secretion by WKO Tregs. We
next analyzed actin polarization at the immune synapse by incubating T regs with anti-
CD3/anti-CD28 coated beads. Surprisingly, the percentage of WT Tregs with polarized actin
was reduced in comparison to WT CD4+CD25- cells. Further, there was no difference in
percentage of polarized WKO Tregs in comparison to WT Tregs. Similar findings were
observed when spreading of WT or WKO Tregs was analyzed. Conclusion: Treg dysfunction
likely plays a role in colitis development in WKO mice. IL-2 and IL-10 deficiency may play
a critical role in WKO Treg dysfunction. Our data suggest that WT Tregs do not form an
immune synapse and that aberrant synapse formation is not a mechanism accounting for
the observed defects in WKO Tregs.
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IL-23-Dependent Cd4+ ThIL-17 Cells Mediate Chronic Colitis
Charles O. Elson, Yingzi Cong, Terrill McClanahan, Robert Fick, Robert Kastelein
Purpose: IL-23 is increased in IBD lesions but its role is unclear. IL-23 supports a distinct
lineage of T cells producing IL-17 (ThIL-17) that can mediate chronic inflammation. This
study was done to define the role of Th1 and of ThIL-17 cells in chronic colitis in mice.
Methods: Colitis was induced by transfer of a cecal bacterial antigen (CBA)-specific C3H/
HeJBir (C3Bir) CD4+ T cell line to C3H/HeSnJ SCID mice. Anti-CD3 activated polyclonal
CD4+ T cells were transferred as a negative control. Cytokines were measured by flow
cytometry, ELISA, and real time PCR. Monoclonal anti-IL-23p19 was administered at the
same time as or 4 wks after CD4 T cell transfer. Histopathology colitis score was assessed
in a blinded fashion. Results: IL-12p40, IFNγ, IL23p19, and IL-17 mRNA were all elevated
in colitic lesions. The pathogenic C3Bir CD4 T cell line contained more cells producing
only IL-17 (38%) than those producing only IFNγ (11%). A similar high frequency of ThIL-
17 cells was observed in CBA-reactive CD4+ T cells from IL-10-/- and mdr1α-/- mice. C3Bir
CD4+ cell lines producing only IL-17 or only IFNγ were generated. After transfer to SCID
mice, the ThIL-17 cells induced marked inflammation in a dose dependent manner (Table).
Even at a dose as low as 104 cells/mouse, ThIL-17 cells induced more severe disease than
did Th1 cells at 106 cells/mouse. Anti-IL-23p19 mAb given from the time of pathogenic T
cell transfer abrogated colitis and the associated inflammatory cytokines and chemokines
(IL-17, TNFα, IL-6, IFNγ, etc.) compared to mice receiving control antibody. Anti-IL-23p19
mAb given to mice 4 wks after Bir14 T cell transfer was effective at treating active chronic
colitis, with virtually complete resolution by 8 wks, with concomitant downregulation of
cytokines and chemokines in the colon, including IL-17, TNFα, IL-6, MIP, and IP-10 among
others. Conclusion: Bacterial-reactive CD4+ ThIL-17 cells are potent effector cells in chronic
colitis. Inhibition of IL-23p19 is effective in both prevention and treatment of active colitis
mediated by ThIL-17 cells. The IL-23-IL-17 axis is an attractive therapeutic target.
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Colitis in Wild-Type Mice Following Neonatal Bone Marrow Transfer with
Mdr1a -/- Hematopoietic Stem Cells
Reed A. Dimmitt, Camalla Kimbrough, Robin G. Lorenz
Background: Mice lacking the mdr1a gene (p-glycoprotein) develop spontaneous colitis,
which is dependent upon the presence of a conventional luminal microbiota. One reported
mechanism for this phenomenon is that mdr1a-/- intestinal epithelia have a barrier defect,
which increases the access of bacterial products to the mucosal immune system. To test this
hypothesis, we reconstituted FVB wild-type (FVB) neonatal pups, which should not have
this barrier defect, with mdr1a-/- hematopoietic stem cells. Methods and Materials: Five day
old FVB pups were lethally irradiated in preparation for stem cell transfer. Adult FVB
(control) or mdr1a-/- mice were used as bone marrow stem cell donors. Following euthanasia,
the femoral bone marrow was enriched for stem cells using anti-Thy1.2 monoclonal antibody
and rabbit complement. Each pup received 106 enriched cells via intraperitoneal injection.
The nursing dams were treated with sulfamethoxazole and trimethoprim in the drinking
water for 10 days post-transfer. The pups were weaned at 1 month and weighed weekly
until sacrifice at 20 weeks. Colonic tissue was harvested for histological analysis and colitis
scoring (0-19) and RNA extraction. The expression of various inflammatory mediators was
determined using real-time RT-PCR, normalized to 18S ribosomal RNA. Results: All the
FVB + FVB (n=7) and FVB + mdr1a-/- (n=6) mice survived until 20 weeks. There was no
significant difference in body weight changes between groups. None of the FVB + FVB mice
developed diarrhea and the median colitis score was 0. In contrast, 4 of the 6 FVB + mdr1a-/-
had diarrhea. The median colitis score of the 6 FVB + mdr1a-/- mice was 11.5 (25-75
percentile; 2-14). The inflammatory mediators with the greatest increase in expression in
the FVB + mdr1a-/- colons were MIP-2, LIX, IL-17, and IFN-gamma. Conclusions: FVB
mice reconstituted with mdr1a-/- stem cells develop colitis, which appears to be a TH1 and
TH17 mediated process. Thus, FVB mice that have normal intestinal epithelial p-glycoprotein
activity still develop disease in the presence of mdr1a-/- hematopoietic cells. We believe
this model of reconstitution permits the study of the role of p-glycoprotein during the
development of mucosal immune function and will provide insight into the mechanism of
colitis in the mdr1a-/- mouse. Additional reconstitutions (mdr1a-/- + FVB and mdr1a-/- +
mdr1a-/-) are underway to further define the disease process. This work was supported by
NIH PO1 DK071176 and R24 DK064400.
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The Pro- and Anti-Inflammatory Roles of TLRS in a Model of Experimental
Colitis
Kyoko Katakura, Sean Fine, Jongdae Lee, Carol Shen, Lars Eckmann, Yukio Sato, Eyal
Raz
IL-10 plays an essential role in colonic homeostasis. We explored the protective role of
different Toll-like receptors (TLRs), in the absence of IL-10, against colitis induction by
dextran sulfate sodium (DSS). While TLR9-/-/IL-10-/- double knock-out (DKO) mice
developed much more severe colitis than IL-10-/- mice, TLR2-/-/IL-10-/- or TLR4-/-/IL-10-/-

















DKO mice, TLR9-deficiency caused higher production of inflammatory cytokine such as
TNF-α but lower production of type-1 IFN and TGF-β compared to TLR2 or TLR4 deficiency.
Furthermore, TLR9-/-/IL-10-/- bone marrow-derived dendritic cells (BMDC) exhibited sus-
tained NF-κB activation in response to mouse colonic microbial extracts and an uncontrolled
secretion of TNF-α compared to BMDC from TLR2-/-/IL-10-/- or TLR4-/-/IL-10-/- mice. These
effects were associated with induction of A20, a negative regulator of NF-κB activation. In
response to colonic microbial extracts, A20 was strongly induced in TLR2-/-/IL-10-/-, TLR4-/-/
IL-10-/- BMDC, but not in TLR9-/-/IL-10-/- BMDC. These results suggest that TLR9 triggering
by microbial DNA suppresses colonic inflammation via the induction of A20 while TLR2
or TLR4 triggering causes inflammation. (Katakura, K and Fine, S are cntributed equally.)
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Meal Induced Rectal Sensitivity in Patients with Irritable Bowel Syndrome
(IBS) May Be Related to a 5-Hydroxytryptamine Mediated Reduction in Rectal
Compliance
Lesley A. Houghton, Wendy Atkinson, Catherine Fell, Peter J. Whorwell, Stephen
Lockhart, Brian Keevil
Patients with IBS perceive rectal distension, particularly following meal ingestion, more than
healthy volunteers (HV) (1). Both distension and the presence of nutrients within the gut
releases 5-hydroxytryptamine (5-HT) from the enterochromaffin cells (2), which in the case
of the latter, as measured by the concentration found in platelet depleted plasma (PDP), is
abnormal in patients with IBS (3,4). As the concentration of PDP 5-HT directly correlates
with colonic motility (5), it was the aim of this study to determine whether the increase in
perception of rectal distension seen following meal ingestion in IBS patients compared with
HV, is related to an abnormal 5-HT mediated reduction in rectal compliance. Methods:
Isobaric phasic distension of the rectum was performed one hour after ingestion of a standard
meal (12g protein, 65.5g carbohydrate, 46g fat) in 18 IBS (Rome II) patients, aged 20-51
years (6 male) and 12 HVs, aged 19-41 years (3 male). Post-prandial PDP 5-HT concentrations
were measured at 30 minutes intervals both 1 hour before (period A) and for 3 hours after
the start of the distensions (period B). Results: IBS patients reported pain at lower volume
(mean difference from HV (95% CI) -58.3ml (-109.5, -7.0)ml; p=0.027) and pressure (-
7.8mmHg (-16.5, 0.9)mmHg; p=0.075) thresholds than HVs. The difference in pressure
threshold between the two groups however, was smaller than that for volume, and thus
probably explains the slightly lower rectal compliance seen in IBS patients (-1.3 ml/mmHg
(-3.7, 1.1)ml/mmHg; p=0.264). In addition, distension was associated with an increase in
PDP 5-HT concentration in IBS patients (ratio B:A 1.48 (1.02, 2.09); p=0.04) but not in
HVs (1.09 (0.86, 1.40); p=0.464), with this 5-HT increase in IBS patients negatively correlat-
ing with volume threshold (r = -0.476; p=0.046) and compliance (r = -0.337; p=0.171) but
not with pressure threshold (r= -0.014; p=0.955). No such correlations were seen in HV
(volume threshold r = - 0.049; p=0.88, pressure threshold r = - 0.007; p = 0.983, compliance
r = -0.028; p=0.931). Conclusion: These data are the first to suggest that the increase in
rectal sensitivity seen following meal ingestion in IBS patients compared with HV, may be
in part related to a 5-HT mediated reduction in rectal compliance. Furthermore, they support
the use of 5-HT modulating drugs which increase gut compliance in the treatment of IBS
patients with excessive concentrations of PDP 5-HT. Refs (1) Simren et al 2001, (2) Sanger
1996, (3) Houghton et al 2003, (4) Atkinson et al 2006 (in press), (5) Atkinson et al
2005 (DDW).
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A New Form of Hypervigilance in Irritable Bowel Syndrome (IBS) Patients
Monica Garcia Alonso, Enrique Rey, Manuel Diaz-Rubio
Hypersensitivity is well described in IBS. With random protocols, it disappears in some
patients, considered as hypervigilant. Some patients show a lower threshold in random than
in ascending protocols, and therefore, would be classified as hypersensitive. However, its
meaning is unknown. We aim to deep in this perceptual response. MATERIAL AND
METHODS: Consecutive patients with IBS (Rome II criteria) were studied with rectal barostat.
They underwent a slow ramp distension (16 mmHg/min) and thresholds was obtained by
ascending methods of limits (AML) using a phasic distension protocol. Only patients with
disomfort threshold (DT) in AML below the lower limit of the 95%CI of control subjects
were included. A tracking (T) procedure was performed, providing an initial distension
equal to DT in AML followed by random distension phases driven by the report of discomfort
to achieve 6 phases after discomfort was reported. DT in T was defined as the mean pressure
of discomfort-rated phases. Patients were classified as: Truly Hypersensitivity: DT in T keeps
below normal limit; Hypervigilance: DT in T rises above normal limit. We called ‘Precipitators’
to patients whose discomfort threshold in T was more than 4 mmHg lower than DT in
AML. Compliance in AML protocol, DT in ramp distension, AML and T and maximum
tolerated distension (MTD) in ramp and AML were compared. Correlation between DT in
T and DT in ramp was done to evaluate the impact of the exclusion of “precipitators”.
RESULTS: We included 49 consecutive IBS patients hypersensitive in AML protocol (39
women; mean age 49). Table summarizes the results. Precipitators were similar to hypervigil-
ant patients except for defining variables, while both share several differences with truly
hypersensitive. DT in ramp and DT in T were not correlated(r=0.26; p=ns). When precipit-
ators were excluded, DT in ramp correlates to DT in T (r=0.48; p=0.001). CONCLUSION:
Subjects with significant decrease of discomfort threshold in random distension (“precipit-
ators”) are closer to hypervigilant subjects than to truly hypersensitive subjects. This per-
ceptual abnormality may have implications in the interpretation of sensitivity studies in IBS.
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Relationship Between Symptoms and Abnormalities in Rectal Sensitivity and
Compliance to Distension in Patients with Irritable Bowel Syndrome
Kwang Jae Lee, Bo Heon Meong, Jin Hong Kim, Ki Baik Hahm, Sung Won Cho
Background/Aims: Abnormalities in rectal sensitivity and compliance to distension are fre-
quently observed in patients with irritable bowel syndrome (IBS), which is considered to
play an important role in the genesis of symptoms. However, their relationship to symptoms
is unclear yet. Our aim was to investigate associations between symptoms and the presence
of abnormalities in rectal sensitivity and compliance to distension in patients with irritable
bowel syndrome. Methods: Twenty-four patients with diarrhea predominant IBS (D-IBS),
twenty patients with constipation predominant IBS (C-IBS) and fourteen healthy controls
participated in this study. The intensities of the symptoms in the past 4 weeks were scored
on a 5-graded Likert scale with descriptive anchors, and the presence of symptoms was
determined as the scores ≥3 (moderate). Using a barostat, sequential isobaric rectal disten-
sions were performed before and 30 min after a meal. Abnormalities in rectal sensitivity
and compliance were defined using control means ± 2SD. Results: No patients had hyposensi-
tive or hypercompliant rectum to distension, both in the fasting period and in the postprandial
period. Hypersensitive rectum to distension was observed in 16 D-IBS patients (67%) and
9 C-IBS patients (45%) in the fasting period (NS), and in 17 D-IBS patients (71%) and 9
C-IBS patients (45%) in the postprandial period (NS). Hypocompliant rectum to distension
was observed in 13 D-IBS patients (54%) and 8 C-IBS patients (40%) in the fasting period
(NS), and in 15 D-IBS patients (63%) and 8 C-IBS patients (40%) in the postprandial period
(NS). Bloating was more frequent in hypersensitive rectum in the postprandial period
compared to normosensitive rectum (50% vs. 11%). Decreased bowel movements were
more frequent in normosensitive rectum in the postprandial period compared to hypersensit-
ive rectum (61% vs. 31%). Increased bowel movements were more frequent in hypocompliant
rectum in the postprandial period compared to normocompliant rectum (52% vs. 24%).
The other symptoms, including loose stools, incomplete evacuation sense, hard stools,
straining, and urgency, did not differ according to abnormalities in rectal sensitivity and
compliance to distension. Conclusions: Abnormal sensitivity or compliance of the rectum
to distension in the postprandial period is associated with bloating or increased bowel
movements. However, most of IBS symptoms do not reflect underlying abnormalities in
rectal sensitivity and compliance to distension.
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Puborectalis Muscle in Nulliparous Women: Functional Assessment Using 3-D
Ultrasound Imaging
Milena M. Weinstein, Sung-Ae Jung, Dolores H. Pretorius, Charles W. Nager, Ravinder K.
Mittal
Objective: The levator ani and puborectalis muscles have been imaged with 3D ultrasound
(US) and measured during rest and with straining, but not with contraction in normal
subjects. Our study aim was to determine if measurements of the puborectalis muscle (PRM)
are reliable, and if so, do they shorten during pelvic floor contraction when measured with
3-D US. Material and Methods: In a prospective study, 16 nulliparous volunteers with a
mean age of 32 (19 - 54yrs) were imaged with a 3D US system (Voluson 730, GE Medical
Systems, Milwaukee, WI) using a 5-9 MHz transvaginal transducer probe placed on the
perineum. The images were obtained at rest as well as during an anal sphincter squeeze
(pelvic muscle contraction). The images were analyzed with the 4D View software program
and displayed in a standard, symmetrical orientation in axial, coronal and sagittal planes.
The technique used to rotate the 3D image included: 1)rotation of the coronal image into
the plane of the PRM, 2)identification and marking of the symphysis pubis in the axial
image, 3) rotation of the sagittal image to align symphysis pubis and anorectal angle.
Measurements were then made of the anterior-posterior (AP) length, the PRM length, area
inside PRM (inner area) and including the PRM (outer area), and PRM area (subtracting
outer from inner area) (see Fig. 1). All rotations and measurements were then repeated by
a second blinded observer to determine interobserver reliability. Results: see Table 1. Observer
2 data demonstrated the same differences between rest and squeeze. Best interobserver
correlation was noted for AP length (r= 0.70 for rest and 0.88 for squeeze). Conclusion: 3-
D ultrasound imaging technique can be used reliably to measure PRM length and functional
shortening with squeeze.
Table 1: Data from one observer
Fig 1: PRM measurements
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Changes of Rectal Motor and Sensory Response to Distension After Longo’s
Haemorrhoidectomy: A Barostat Study
Antonio Gianluca Castellaneta, Maura Corsetti, Simone Squillante, Nadine Osman, Pier
Alberto Testoni, Sandro Passaretti, Paola de Nardi
The occurrence of faecal urgency, pain and/or increased stool frequency has been reported
in up to 31% of patients treated with Longo’s procedure for third and fourth degree
hemorroids (Cheetham MJ, 2000). The mechanisms underlying these symptoms are unclear.
A previous study using anorectal manometry has demonstrated no changes of rectal function
after Longo’s procedure but, as stated by the authors, rectal distensibility should have been
assessed using the electronic barostat (Fantin AC, 2002). Aim of the study was to assess
the rectal motor and sensory response to distension before and after Longo’s haemorrhoidec-
tomy using the electronic barostat. Methods: Six patients (4 males, mean age 47±9 ys) with
third and fourth degree haemorroids underwent rectal distensions controlled by an electronic
barostat one week before and six months after Longo’s procedure. After a conditioning
distension, three distensions (a pressure-controlled stepwise (4 mm Hg/2 min), a volume-
controlled stepwise (20 ml/2 min) and a ramp at 100 ml/min) were performed in each
patient. Data (mean±SD) of rectal distensibility as well as volume and pressure thresholds
for sensations of desire to defecate and discomfort were compared before and after surgery
by means of the Wilcoxon test. Results: Rectal distensibility was significantly lower after
than before surgery during pressure stepwise (4±1 ml/mm Hg vs 10±4 ml/mm Hg, P= 0.02),
during volume stepwise (0.17±0.06 mm Hg/ml vs 0.09±0.03 mm Hg/ml, P= 0.04) and
during volume ramp distension (0.17±0.02 mm Hg/ml vs 0.07±0.02 mm Hg/ml, P= 0.009).
Discomfort occurred at a significantly lower volume after than before surgery during pressure
stepwise (106±11 ml vs 199±79 ml, P= 0.02), during volume stepwise (100±40 ml vs
206±82 ml, P= 0.03) and during volume ramp (113±45 ml vs 220±80 ml, P= 0.04). Volume
threshold for desire to defecate was lower after than before surgery during pressure stepwise
(47±19 ml vs 139±55 ml, P= 0.02) while it did not differ during volume stepwise and ramp
(NS). Pressure thresholds for desire to defecate and discomfort did not differ before and
after surgery during any distensions (NS). Conclusions: Rectal distensibility and volume
thresholds for desire to defecate and discomfort decrease after Longo’s haemorrhoidectomy.
These modifications of rectal function could explain the occurrence of rectal urgency, pain
and/or increased stool frequency in some of the patients subjected to Longo’s procedure.
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Investigation of Sensori-Motor, Recto Anal Inhibitory and Contractile Reflexes
in Rectal Hyposensitivity
Jose M. Remes-Troche, Sherrie de Ocampo, Megan Miller, Jessica Paulson, Satish Sc Rao
Background/Aim: Ano-rectal sensations play an important role in maintaining normal contin-
ence and defecation. Recently, we showed that a desire to defecate was associated with a
reflex contraction of the anal sphincter -sensori-motor reflex (SMR) (Gastroenterology 2005;
128(2): A38). Whether SMR is altered in patients with rectal hyposensitivity is not known.
Our aim was to examine the characteristics of SMR, as well as the recto-anal inhibitory
(RAIR) and recto-anal contractile reflexes (RACR) in patients with rectal hyposensitivity
(RH). Methods: Rectal sensation and recto-anal reflexes were assessed by performing stepwise
balloon distensions in 10-30 cc increments, in 30 RH patients (M/F=7/23, mean age=45 yr)
and 23 healthy subjects (M/F=8/15, mean age=48 yrs) after placing a 6 sensor probe with
a 4 cm long latex balloon in the rectum. Thresholds for first sensation, desire and urgency
to defecate were recorded. Patients were defined as hyposensitive (RH) if at least two of
sensory thresholds were greater than 2 SD of normal values. The lowest volume of balloon
distension that evoked RAIR, RACR and SMR were recorded. Onset, duration, amplitude,
and area under the curve (AUC) for SMR were also analyzed. Results: All subjects showed
all 3 reflexes. Unlike healthy controls where a SMR was associated with a desire to defecate,
in RH patients, the onset of SMR was not associated with any sensation in 13 (43%) and
with a blunted sensation (first perception or fullness) in 17 (57%). Threshold for SMR was
similar between patients and controls, but the amplitude, duration and AUC were higher
(p<0.05) in RH patients (Table). Also, the onset of SMR was prolonged in RH patients who
reported no sensation with SMR when compared to patients with blunted sensation during
SMR (13±9 vs. 7±3, p<0.05). The minimum balloon volumes that induce RAIR and RACR
were significantly higher (p<0.001) in RH patients (20±10 cc and 56.1±19 cc) compared
to controls (12±6 cc and 32.8±10 cc). Conclusions: Recto-anal reflexes are altered and may
play an important role in the pathogenesis of rectal hyposensitivity. The absent or blunted
sensory perception in spite of an intact SMR in patients with rectal hyposensitivity suggests
that this reflex is mediated by both the ENS and CNS, and that the afferent rectal-brain
pathway may be dysfunctional in these patients.
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DX-pH Measurement System: A Sensitive Device for Detecting Liquid and
Aerosolized Supraesophageal Gastric Reflux (SEGR)
Gregory J. Wiener, Ross Tsukashima, Colleen Kelly, Erich Wolf, Molly Schmeltzer, Charles
Bankert, Lauren Fisk
PURPOSE: Clinical and animal data have documented deleterious effects of acid pH < 4
(AGR) and weakly acid pH 4-7 (WAGR) gastroesophageal reflux, even in small amounts,
when above UES. Despite recognition of multiple manifestations of SEGR, characterization,
identification and response to therapy have evaded understanding due to lack of a suitable
detection device. AIM: Evaluate the Dx minimally invasive catheter (Restech) with ionic
flow sensor, able to measure pH in liquid or aerosolized droplets at posterior oropharynx,
for SEGR detection, using standard 24hr triple sensor pH catheter (24pH) for verification.
METHODS: Pts in a GI practice (GW) with chronic symptoms likely due to SEGR, off reflux
meds 4-7days, underwent 24pH with 2 esophageal (E) and 1 pharyngeal (P) sensor (Sandhill
PHI10-V) positioned with LES Indicator at 5 cm > LES, 5 cm < UES and 1 cm > UES. The
1.5 mm nasopharyngeal catheter placed at oropharynx behind uvula, above pts discomfort
position. Tracings from all 4 synchronized pH inputs & pt diary were analyzed graphically
on single screen, excluding meals +5 min. SEGR event definition: rapid pH drops at the
Dx sensor, >3 S.D. from 60 sec baseline, sequential to drops in pH<4 in 24 pH sensors,
then classified as AGR/WAGR. S.I. <50%:+. RESULTS: 15 Patients, 5M, 10F, avg. age 57.5
(25-75): 11 cough, 1 loss enamel, 1 sleep apnea, 2 asthma. 4 had normal 24pH. There
were 48 Dx SEGR events in 10 pts, being near vertical with gradual return to baseline &
synchronous to E pH drops. SEE TABLE 1. Increase in pH was 46% from E to P, 6% from
P to Dx. These 48 SEGR events were 7.8% of 616 episodes with pH<4 at lower E. All 5
Dx negative pts had normal 24pH at E. CLINICAL FOLLOW UP (f/u): 11 pts took PPIs
BID (f/u 3-8 mo., avg 6.5) or fundoplication (f/u 4 & 6 wks). 9 Dx + pts had 60%
Chief Complaint Improvement (CCI), no worsening. 7 of these on PPI had CCI 48.6%
(0,0,20,50,70,100,100), 2 had fundoplication with 100% CCI, post-op Dx without pharyn-
geal events. 2 Dx negative pts, 1 with CCI 0% on PPIs, the other 100% CCI on NO meds.
CONCLUSIONS: (A) SEGR exists in oropharynx, detectable by Dx. (B) There is a gradient
of increasing pH from E to oropharynx, the latter rarely <4. (C) Redefinition of significant
pH events above UES as % or >3 S.D. pH drops merits consideration. (D) Clinical management
may be influenced by Dx results, further studies should aid understanding of SEGR.
Table 1: Characteristics of Synchronous pH Drops - SEGR
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The Measurement of Oesophageal Cross-Section Diameter and Volume Using a
Novel Multi-Channel Intra-Luminal Impedance Catheter: In Vitro and in Vivo
Validation
Mark Fox, Donald MacLachlan, Amir Thakur, Roy Anggiansah, Terry Wong, Angela
Anggiansah
Introduction: Multi-channel intra-luminal impedance (MII) measures fluid movement in
the oesophagus and detects non-acid reflux. Larger reflux volumes that cause significant
oesophageal distension are more likely to trigger symptoms. A novel MII technique designed
to detect variation in volume (vMII) is described. The multi-sensor catheter monitors pressure,
pH and impedance (Gaeltec Ltd, Scotland). Three impedance electrodes are placed at 50mm
intervals, another is placed 5mm from the middle electrode. Impedance measured by closely
spaced sensors depends primarily on the conductance of fluid in the lumen; measurements
from sensors placed further apart also vary with luminal cross-section diameter (CSD). This
data allows the volume of an unknown fluid bolus to be estimated. Aims: (1) To assess the
sensitivity of vMII to variation of CSD in vitro. (2) To validate the sensitivity of vMII to
variation of bolus volume in vivo. Method: (1) Measurements with the vMII catheter were
obtained in cylinders (0.5-5cm CSD) containing water, saline, orange juice (OJ), milk and
gastric secretions obtained at endoscopy. (2) Stationary studies were performed in nine
healthy volunteers (6M:3F, age 21-40) in the upright position. The vMII catheter was
placed such that the closely spaced impedance electrodes were 5cm proximal to the lower
oesophageal sphincter. Measurements were obtained for 5 swallows each of 5, 10 and 20ml
for water, OJ and milk. Results: (1) For each fluid, impedance measurements varied inversely
with CSD in a logarithmic relationship. The effect was greater for widely spaced than closely
spaced electrodes (p<0.01). Impedance was greater for water than other fluids (p<0.01),
measurements for OJ, milk and gastric secretions were similar. (2) For each test fluid,
impedance significantly decreased as bolus volume increased from 5 to 20ml (p<0.05).
Again, the relationship was logarithmic and was greater for widely spaced than closely spaced
electrodes (p<0.01). Impedance was less in the distal than proximal oesophagus (p<0.01),
suggesting greater distension of the distal oesophagus after fluid ingestion. Oesophageal

















widely spaced electrodes by correcting for (1) bolus conductivity as assessed by the closely
spaced electrodes (2) reference values from the in vitro measurements. Conclusion: The novel
vMII catheter with closely and widely spaced impedance electrodes provides measurements of
oesophageal CSD and volume in vivo. Future studies will assess the sensitivity of vMII
catheter for the measurement of reflux volume.
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Characterisation of Intraluminal Impedance Patterns Associated with Gas
Reflux (Belching) in Healthy Volunteers
Michiel P. Van Wijk, Daniel Sifrim, Nathalie Rommel, Marc A. Benninga, Geoffrey P.
Davidson, Taher Omari
BACKGROUND: Multichannel Intraluminal Impedance (MII) recording allows assessment
of flow through the esophagus and differentiation between liquid and gas contents. MII
criteria have been developed for recognition of gas but these have not been validated during
known gas reflux in humans. AIMS: To characterize patterns of impedance change associated
with gas reflux and to examine the interrelationships between the magnitude of impedance
change, luminal diameter and electrode-mucosa contact. METHODS: 10 healthy volunteers
(6M:4F, 21-37yrs) were studied using an esophageal MII-manometry catheter. After catheter
placement, subjects were asked to drink up to 600ml of carbonated soft drink. Belching
episodes were then recorded for 20min and the protocol was repeated. Only belches con-
firmed manometrically as being triggered by transient LES relaxation and associated with
an esophageal common cavity episode were included for analysis. A further 5 subjects (3M:2F,
26-52yrs underwent simultaneous MII and videofluoroscopy(VF) during performance of
the same protocol. ‘Standard’ MII criteria for recognition of gas reflux were an antegrade or
synchronous impedance rise of ≥50% in ≥2 channels that exceeded 5kΩ in ≥ 1 channel.
VF was analysed blinded from MII results and vice versa. RESULTS: All analysed belches
(n=88) were associated with a pattern of impedance rise which was either retrograde(62.5%),
synchronous(19.3%) or antegrade(18.2%). Median (IQR) intraluminal impedance at the
onset and peak of gas reflux was 2.0(1.6, 2.7)kΩ and 4.4(2.8, 7.5)kΩ respectively and the
median % increase was 106.6%(50.2, 200.3). Of all belches 31(35.2%) did not meet the
‘standard’ MII criteria because the impedance rise was antegrade(18.2%), did not increase
by ≥50% in ≥2 channels (9.1%) or did not exceed 5kΩ in any channel(23.8%). During
MII-VF 15 belches were recorded. The magnitude of impedance change increased with
increasing luminal diameter during gas reflux (r=0.718, p<0.0001). The magnitude of imped-
ance change was greater when impedance electrodes were not in direct contact with the
esophageal mucosa (7.0(5.4, 7.8)kΩ) compared to when one (2.4 (1.1, 5.2)kΩ, p<0.001)
or two (1.8 (0.8, 2.6)kΩ, p<0.001) electrodes were. CONCLUSIONS: A significant number
of gas reflux episodes do not meet current standard impedance-based criteria for their
recognition. Factors including the degree of esophageal distension as well as the extent of
direct contact between the esophageal mucosa and MII-electrodes influence the magnitude
and patterning of impedance change recorded.
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Effects of Feeding On Esophageal Exposure to Acid Gastroesophageal Reflux
During Esophageal Emptying and During Subsequent Mucosal Acid
Neutralization in Infants
Frederick W. Woodley, Namhee Kim, Soledad Fernandez, Melissa Metheney, Hayat Mousa
Background: Esophageal pH monitoring (EPM) is limited in its ability to identify mechanisms
of esophageal acid exposure; whether due to gastroesophageal reflux (GER) bolus contact or
the subsequent neutralization of mucosal acid. Combined EPM and multichannel intraluminal
impedance (pH/MII) can measure durations of volume clearance (VC) and chemical clearance
(CC). The effects of feeding on VC and CC of AGER during each stage of the feeding cycle
have not been reported. Aims: 1) To assess the extents to which VC and CC influence total
esophageal acid exposure. 2) To assess the effects of feeding on VC and CC in infants.
Methods: We analyzed EPM/MII tracings from 14 infants (9 males, median age 3.5 months)
who were referred to our facility for symptoms suggestive of GER. Individual AGER episodes
were identified as having occurred during feeding, the first post-prandial hr (1stPP), the
second post-prandial hr (2ndPP), or fasting. We measured the duration of VC and CC for
each AGER episode using pH/MII. Each outcome variable was expressed as the mean ±
standard error. The study protocol was approved by the Institutional Review Board at
Columbus Children’s Hospital and all patients were enrolled following parental consent.
Results: In nearly 329 hr of combined recording time (median study duration 23.5 hr/pt),
331 AGER episodes (median 23/pt) were detected. pH/MII registered 14.9 hr of total acid
contact time (median 52.8 min/pt); 2.3 hr (15%) was spent during VC and 12.7 hr (85%)
were spent during CC. CC duration was more prolonged than VC during all phases of
feeding and was significantly longer than VC during 2ndPP (156.1 ± 22.3 vs 26.5 ± 4.4s,
p = .003) and fasting (169.7 ± 19.4 vs 26.9 ± 3.9s, p = .0005). Duration of CC contributed
to greater than half of the total acid exposure time and significantly dominated during 2ndPP
(65 ± 5.2% vs 35 ± 5.1%, p = .004) and fasting (76 ± 3.2% vs 24 ± 3.2%, p = .0002).
Neither the durations nor the proportion of VC and CC was significantly different during
feeding or 1stPP. Conclusions: In our infant population, the vast majority of esophageal
acid exposure occurred during CC. While esophageal acid exposure during feeding and
1stPP phases was comparably attributable to both VC and CC, a significant proportion of
the acid exposure during 2ndPP and fasting occured during CC. We speculate that prolonged
neutralization of mucosal acid during 2ndPP and fasting is due to reduced primary and
secondary peristalsis related to decreased frequency of swallowing during these periods. The
shorter duration of CC during feeding is likely due to the buffering effects of swallowed
saliva and milk-based formulas during feeds.
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Four-Day BRAVO pH Recording Combining 48-Hour Periods On and Off
Proton Pump Inhibitor Therapy
Pai-Wain C. Lo, Qing Zhang, Nirmala Gonsalves, Ikuo Hirano
Background & Aims: Bravo monitoring increases the sensitivity of pH testing by allowing
for 48 rather than 24 hour recordings. Controversy exists as to whether pH studies are
optimally done off or on proton pump inhibitor (PPI) therapy. The aim of this study was
to determine the feasibility of 4-day pH recordings using the Bravo pH system to encompass
2 day periods both before and during PPI therapy. Methods: 16 patients underwent 4-day
pH recordings (2 day off; 2 day on) using 2 separate receivers calibrated to a single Bravo
capsule. Indications for pH testing were refractory heartburn, chest pain, and chronic cough.
Patients were off PPI therapy for days 1 & 2. Rabeprazole 20mg orally twice a day was
administered on days 3 & 4. Results: 13 patients completed the 4 day study and were
included in the analysis. Off therapy, 5 patients (38%) had esophageal acid exposure values
exceeding 5.3%. On therapy, all patients showed significant and progressive acid reduction
(Fig). By day 4, esophageal acid exposure value was 0% in 8 patients and < 1% in 5 patients.
The symptom index was significantly higher off (median 50%) than on (median 0%) PPI
therapy (p<0.001). 2 patients with capsule detachment on day 3 and one on day 2 were
excluded. Of the excluded patients, two had normal off PPI acid exposure and the lack of
day 4 data did not change the overall test interpretation. Conclusions: Prolonged recordings
using the Bravo pH system are feasible and allow for combined testing both off and on
therapeutic trial of PPI. The initial 2 day off PPI allows for increased sensitivity and symptom
association for the diagnosis of GERD compared with on PPI testing. Such combined studies
may allow for acquisition of information useful in the evaluation of refractory and atypical
reflux symptoms.
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Light Microscopy Analisys of Intercellular Space Diameters of Esophageal
Epithelium in Nerd Patients: Comparison with Electron Microscopy
Mentore Ribolsi, Giuseppe Perrone, Renato Caviglia, Massimo Gentile, Sara Emerenziani,
Michele Guarino, Rabbitti Carla, Michele Cicala
Background: Dilation of intercellular space diameters (ISD) of esophageal epithelium detected
at transmission electron microscopy (EM) has been shown to represent an objective, sensitive
ultrastructural marker of non-erosive reflux disease (NERD). ISD evaluation using the less
demanding and more available light microscopy (LM) seems to provide interesting results
in GERD patients. Aim/Methods: to compare the gold standard EM against LM in detecting
dilation of ISD, two adjacent biopsy specimens, at 5 cm above Z line, obtained from 12
NERD patients (F8, mean age 43 yrs) and from 7 asymptomatic controls (F4, mean age 32
yrs) were assessed for ISD measure. Computer assisted morphometry was performed on
photographs obtained by EM and LM, according to published methods. 100 ISD measures
were obtained from each subject. ISD size was also assessed by LM according to a published
semi-quantitative score (grade 0: absence of dilated ISD, 1: small size dilation, 2: mild and
3: marked dilation). Results: Mean ISD values and ISD score from patients and controls are
shown in the Table. Confidence intervals of mean ISD in patients did not overlap with those
in controls both at EM and at LM. A significant correlation between intra-subject mean ISD
at EM and at LM was found when considering the study population (r: 0.83, p<0.01) and
the patient group; no correlation was found in the control group. Out of 12 patients, 3
presented an ISD score within the normal range (0-1). Conclusions: ISD measures obtained
by LM morphometry significantly correlate with those by EM. ISD semi-quantitative score
evaluated at LM seems not to be accurate. Light microscopy morphometry seems to be a
promising method for assessing ISD of esophageal epithelium in non-erosive gastroesophageal
reflux disease.
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A Novel Selective Gene Targeting Approach to Selectively Kill Cancer Cells, in
Vitro and in Vivo, with Hyperactive β-Catenin
Hadas Dvory-Sobol, Diana Kazanov, Eyal Sagiv, Dana Yona, Nadir Arber
Background: The APC or β-catenin genes are frequently mutated in gastrointestsinal cancers
resulting in oncogenic activation of β-catenin signaling. Recently, we have shown that
recombinant adenovirus, that carries the PUMA gene under the control of β-catenin/Tcf -
responsive promoter (AdTOP-PUMA), suppressed the growth of human HCT116 and SW480
colon cancer cells. Replacement of AT by GC bases created the negative control adenovirus
(AdFOP-PUMA). The PUMA protein (p53 up-regulated modulator of apoptosis) interacts
with Bcl-XL and Bcl-2 to induce the release of cytochrome c from the mitochondria and to
induce apoptosis Objective: To further evaluate the efficacy of this model in vitro and in
vivo for selective killing of human cancer cells with an activated β-catenin pathway. Methods:
The AdEasy system was used to generate the AdTOP-PUMA and AdFOP-PUMA adenoviruses.
In vitro: SW480, HCT116, DLD-1, LS174T and HT29 (colon), HepG2, SK-Hep-1 (liver),
AGS (gastric) and Colo357, Panc-1 (pancreas) human cancer cells were infected with the
AdTOP-PUMA adenovirus and the vector control AdFOP-PUMA. The combined effect of
AdTOP-PUMA and several chemotherapeutic agents (5-FU, doxorubicin, paclitaxel) was
also evaluated. Cell viability was measured by methylene blue assay. Protein expression was
analyzed by Western blot. Cell cycle and apoptosis were evaluated by FACS analysis. In
vivo: 3x103 SW480 cells were infected with the AdTOP-PUMA and AdFOP-PUMA, harvested
after 24h, and then inoculated subcutaneously into nude mice. Results: In vitro: The TOP-
PUMA adenovirus inhibited cells growth in a dose dependent fashion, depending on the
level and activity of β-catenin. The growth of cells with high β-catenin activity (SW480,
DLD-1, HCT116, LS174T, AGS and HepG2 cells) was inhibited, but that of cells expressing
low activity levels (HT-29, SK-Hep-1, Panc-1 and Colo357) was not. Growth inhibition was
associated with induction of apoptosis. Hepatocellular carcinoma cell line (HepG2) and
gastric cancer cell line (AGS), in which β -catenin is mutated, were very sensitive to AdTOP-
PUMA therapy. Chemotherapy synergistically enhanced the effect of AdTOP-PUMA. In
vivo: AdTOP-PUMA treated mice did not develop tumors (0/8), while AdFOP-PUMA and
adenoviral vector control developed (3/8) and (4/7) tumors respectively. Conclusions: This
selective gene therapy may be used in cancer therapy. A combination of the adenovirus system
with standard therapy may improve the efficacy and reduce the toxicity of chemotherapy in
humans.
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Sox4 Is a β-Catenin-Interacting, Tumor-Promoting Modulator of Wnt Signaling
That Is Upregulated in Colorectal Cancer
Jeffrey Franklin, Emilios Tahinci, Ethan Lee, Loice Jayekumar, Galina Bogatcheva, Tim
Yeatman, Bruce Aronow, Robert J. Coffey
Wnt signaling provides essential functions in embryonic development and in epithelial
homeostasis. It is tightly regulated by various effectors to provide stereotypic control of
patterning and differentiation of tissues and is often misregulated in colorectal cancer (CRC).
We have found that Sox4 is a unique regulator of Wnt signaling that down-regulates overall
Wnt patterning cues in Xenopus embryonic development and in rat intestinal epithelial cells
(RIE-1 cells). At the same time, it increases the stability of β-catenin in an in vitro proteosomal
degradation assay and alters β-catenin levels in Sox4- overexpressing APC-mutant SW480
cells. In SW480 cells overexpressing Sox4, there is enhanced invasion in a Boyden chamber
assay and altered cell morphology. Consistent with these effects, we see four-fold increased
Sox4 expression in adenomas compared to normal colonic mucosa, and this increased
expression persists during CRC progression in 300 CRC tumors. SiRNA directed to Sox4
in SW480 cells regulates some Wnt effectors but has a greater influence on other signaling
pathways (e.g. the Stat pathway, cytoskeletal regulation). Similarly, morpholino knock-
down of endogenous Sox4 in Xenopus embryos upregulates Wnt signaling in the embryo
phenotypically, by affecting axis formation, without inducing well-known Wnt Sox4 target
genes (like Xnr3). These results imply that Sox4 is not simply a negative regulator of Wnt
signaling but can modulate tumor-promoting pathways. Our view of canonical Wnt signaling
in cancer needs to be refined to reflect the increasing complexity of interacting transcription
factors and their interacting effects. In a single cell, β-catenin can interact with multiple
transcription factors simultaneously. Depending on their relative abundance and activity
state, these shifting β-catenin complexes can influence cell growth in a combinatorial way
affecting multiple signaling pathways instead of a binary addition or subtraction of β-catenin/
TCF-driven expression of targets.
796
Novel Crosstalk of KrüPpel-Like Factor 4 and Beta-Catenin Regulates Normal
Intestinal Homeostasis and Tumor Repression
Wen Zhang, Xi Chen, Yoichi Kato, Paul M. Evans, Subo Yuan, Jun Yang, Piotr G.
Rychahou, Vincent W. Yang, Xi He, Mark B. Evers, Chunming Liu
Epithelial cells of the intestinal mucosa undergo a continual process of proliferation, differenti-
ation and apoptosis which is regulated by multiple signaling pathways. The Wnt/beta-catenin
pathway plays a critical role in this process. Mutations in the Wnt pathway, however, are
associated with colorectal cancers. Krüppel-like factor 4 (KLF4) is an epithelial transcriptional
factor which is down-regulated in many colorectal cancers. The interplay between Wnt/
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beta-catenin signaling and KLF4 in the normal intestine and colon cancers were analyzed
in this study. We found that KLF4 interacts with beta-catenin and represses beta-catenin-
mediated gene expression. Moreover, KLF4 inhibits axis formation of Xenopus embryos.
KLF4 also inhibits Wnt/beta-catenin target gene expression in Xenopus embryos and in
colon cancer cells. We have established a stable colon cancer cell line that expresses inducible
KLF4. We found that KLF4 inhibits xenograft tumor growth in athymic nude mice. Our
findings suggest that the crosstalk of KLF4 and beta-catenin plays a critical role in homeostasis
of the normal intestine as well as in tumorigenesis of colorectal cancers.
797
β-Catenin and Nf-κB Differentially Regulate Proliferation in Native Epithelia
Shahid Umar, Yu Wang, Joseph H. Sellin
Background: Both β-catenin and NF-κB have been implicated in our lab as candidate factors
in driving proliferation in an in vivo model of hyperproliferation, transmissible murine colonic
hyperplasia (TMCH). Although the signaling pathways controlled by these proteins are
independent, both inhibitor of NF-κB, IκBα, and β-catenin are regulated by phosphorylation
at similar consensus N-terminal serines leading to targeted ubiquitination through SCFβ-
TRCP and proteasomal degradation. Aim: To determine whether blocking proteasomal
activity in vivo affects β-catenin and NF-κB-mediated changes in cell census during TMCH.
Methods: TMCH was induced by Citrobacter rodentium inoculation. Proteasomal activity was
blocked in vivo with intra-peritoneal injections of proteasomal inhibitor PS-341 (VelcadeR).
Westerns, immunohistochemistry (IHC) and gel shift assays were performed in distal colonic
crypts isolated from normal, days 6 and 12 (peak hyperproliferation /hyperplasia) post-
infected mice. Results: The characteristic findings of TMCH were invariably present: a grossly
thickened distal colon, elongated crypts without obvious increases in epithelial/submucosal
inflammatory cell numbers. VelcadeR treatment to Citrobacter-infected mice led to significant
decrease in chymotrypsin-like activity and marked increases in accumulation of polyubiquiti-
nated proteins both at days 6 and 12 TMCH, compared to control. VelcadeR however, did
not abrogate hyperplasia despite significant inhibition of NF-κB activity due to accumulation
of Ser32,36-phosphorylated IκBα in treated samples. VelcadeR also blocked nuclear transloca-
tion of activated p65 as IHC failed to detect any nuclear staining for Ser536-phosphorylated
p65 at either time points. In contrast, proteasomal blockade in vivo did not affect Casein
kinase I-mediated phosphorylation of β-catenin at Ser45 (β-cat45). The primary GSK-3β
phosphorylation site for degradation (Ser33,37/Thr41) in β-catenin however, did not show
accumulation of β-cat33,37 in either untreated or treated samples suggesting a lack of GSK-
3β action on β-cat45. Indeed, activity assays confirmed temporal inhibition of GSK-3β at these
time points. Impairment in linking β-cat45 to subsequent GSK-3β-mediated phosphorylation/
degradation stabilized β-cat45 which translocated to the nucleus, interacted with CREB
binding protein (CBP) and T-cell factor-4 (Tcf-4) and the complex bound the DNA. Conclu-
sions: 1. Proteasomal inhibition in vivo blocked NF-κB activity but did not abrogate hyperprol-
iferation/hyperplasia. 2. β-Cat45, which forms transcriptionally active complexes with CBP
and Tcf-4, rather than NF-κB, drives proliferation during TMCH.
798
Expression of CDX Proteins Interfere with the Formation of Beta-Catenin/Tcf
Complex
Rong J. Guo, Toshihiko Ezaki, Eunran Suh, John P. Lynch
INTRODUCTION: Cdx1 and Cdx2 are intestine-specific transcription factors known to
regulate proliferation and differentiation. We previously have reported that Cdx1 and Cdx2
inhibit the proliferation of human colon cancer cells by inhibiting beta -catenin/Tcf transcrip-
tional activity. Herein we describe studies that further elucidate this mechanism. METHODS:
Coimmunoprecipitation (CoIP) was performed using anti-c-myc and anti flag tagged tech-
niques to analyze the interaction between beta-catenin/Tcf complex and Cdx1 and Cdx2 in
293T and DLD1 cells. GST-beta-catenin pull-down with in vitro-translated Cdx1 or Cdx2.
RESULTS: We previously found that Cdx1/Cdx2 expression dramatically reduced the beta-
catenin/ TCF transcriptional activity in DLD1 and 293T cells. To clarify the mechanism
involved, c-myc tagged Tcf4 was transfected with a S33Y beta-catenin and a Cdx1 or Cdx2
expression vectors into 293T or DLD1 cells, then immunoprecipitated using an anti c-
myc antibody. Western blotting of the IP products showed that beta-catenin could not be
coimmunoprecipited with TCF4 in the presence of Cdx1 or Cdx2 expression. This effect
of Cdx proteins was dose-dependent and consistent with the corresponding inhibitory effect
of Cdx proteins on b-catenin/TCF transcriptional activity. Moreover, expression of a Cdx2
mutant in which a classically characterized transactivation domain (delta 55-134 Cdx2) is
deleted still had significant effect on inhibiting Topflash activity and interfereing correspond-
ingly with the formation of b-catenin/TCF complex. To explore the possibity of direct protein-
protein interactions between Cdx and beta-catenin, we performed immunoprecipitations in
vivo and GST-pull down studies. Immunoprecipitating Flag-tagged Cdx1 or Cdx2 or beta-
catenin demonstrated a reliable specific interaction between the Cdx proteins and beta-
catenin. In the reverse experiment, IP of b-catenin also pulls down Cdx1 or Cdx2. In
contrast, GST-b-catenin could not pull down in vitro translated Cdx proteins, nor could in
vitro translated Cdx2 protein disrupt a GST-beta-catenin/TCF4 interaction. This observation
suggests that Cdx1 and Cdx2 proteins’ disruption of the beta-catenin/TCF complex is not
a direct effect but is instead mediated by a protein binding both Cdx and beta-catenin. In
summary, we conclude that Cdx1 and Cdx2 expression reduces b-catenin/TCF transcriptional
activity through the disruption of the beta-catenin/TCF complex. Considering the pivotal
role of beta-catenin/TCF activity in regulating cell proliferation and carcinogenesis, our



















Overexpression of Human IGFBP-3 Inhibits the Development of Intestinal
Tumors in An APC/Min Mouse Model
Irena Kirman, Suvinit Jain, Avraham Belizon, Richard L. Whelan
Deficiency in circulating IGFBP-3 has been linked to the development of various types of
tumors in humans. The effect of systemic IGFBP-3 over-expression as a means of overcoming
or preventing tumor growth has not been investigated so far. The goal of the current study
was to evaluate the development of intestinal tumors in APC/min mice carrying the human
IGFBP-3 transgene. Materials and Methods: 24 wild-type (WT) CD1 APC/min mice and 16
CD1 APC/min mice, males and females, carrying IGFBP- 3 cDNA (IGFBP-3 TG) were
maintained until 8 months of age. Genotyping for the min mutation was performed using
a PCR reaction, while the presence of human IGFBP-3 in serum from the IGFBP-3 TG mice
was confirmed in ELISA. At the end of experiment, the animals were sacrificed, their colons
excised, open longitudinally, and then fixed and stained with methylene blue. Tumors and
ACF (aberrant crypt foci) were assessed using inverted microscopy and confirmed hitolog-
ically. Results: The mean body weight of CD1 males, 36.3±5.6g was comparable to the
mean body weight of IGFBP3-TG males, 31.3±4.5g (p=0.2). Similarly, the mean body weight
of CD1 females, 32.3±4.7g was comparable to the mean body weight of IGFBP-3 TG females,
29.9±2.8g (p=0.1). Visible tumors were found in 1/3 (8 out of 24) wild-type min mice, but
in none of the IGFBP-3 TG mice. The number of ACF per intestine was significantly smaller
in IGFBP-3 TG males, 4.1±4.9, compared to WT min males, 10.7±7.5 (p<0.002). Similarly,
significantly less intestinal ACF were found in IGFBP-3 TG min females, 1.7±2.4 compared
to WT min females, 7.0±4.4 (p<0.002). Conclusions Over-expression of human IGFBP-3
was associated with a significantly decreased rate of formation of colonic aberrant crypt foci,
a forerunner of intestinal malignancies in a min mouse model. Over-expression of human
IGFBP-3 may become a strategy to inhibit the development or growth of colonic tumors
806
Molecular Characterization of the Chemopreventive Activity of Pentacylic
Triterpene Ursolic Acid
Sandra Ulrich, Bettina Jung, Stefan Buettner, Juergen Stein
Background: Previous studies could demonstrate that ursolic acid (UA), a pentacyclic
triterpene found in berries and plants has antiproliferative, antiangiogenic as well as proapop-
totic activities on cancer cells. The objective of this study was to elucidate the underlying
molecular mechanisms of these chemopreventive effects of UA. Materials and Methods:
Caco-2 cells were cultured under standard conditions and were treated with increasing
concentrations of ursolic acid [10-30µM] for different time intervalls. Hypoxia was induced
by stimulating Caco-2 cells with CoCl2 [100µM]. Cell growth was determined by BrdU
incorporation and crystal-violet staining. Apoptosis induction was detected by measuring
DNA fragmentation. The cell cycle regulating proteins p21WAF1 and p27KIP1, the apoptosis
related proteins BAX, Bcl-2 and TRAIL, as well as the proangiogenic vascular endothelial
growth factor (VEGF) were determined by western blot analysis. The VEGF content of the
culture supernatants was measured using ELISA. Caspase-3 induction was determined via
an activity assay. Results: UA [10-30µM] leads to a significant time and dose-dependent
decrease both of cell counts and cell proliferation (Means ± SE, n=8; ***p<0.001 at 30µM),
coincident with the upregulation of the cell cycle inhibitors p21WAF1 and p27Kip1. In addition,
ursolic acid leads to a significant induction of apoptosis after 24h of incubation (Means ±
SE, n=4, ***p<0.001 at 10µM), which is mediated by an increase of BAX/Bcl-2-protein-
ratio as well as an upregulation of TRAIL protein which meets in an induction of caspase-
3 activity. VEGF expression and release induced by CoCl2 [100µM] could be significantly
counteracted by the treatment with ursolic acid in a time and dose-dependent manner
(Means ± SE, n=2, **p<0.01). Conclusions: These data demonstrate that ursolic acid
mediates its antiproliferative effects via the induction of the cell cycle inhibitory proteins
p21WAF1 and p27KIP1. Cell death was induced by activating both intrinsic and extrinsic
pathways, leading to activation of proapoptotic caspase-3. Moreover ursolic acid seems to
exhibit potent antiangiogenic properties as it counteracts hypoxia-induced VEGF production
in colorectal cancer cells.
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Novel Curcumin Analog Diphenyl Difluoroketone (L-2395) Mediates Anti-
Colon Cancer Activity Through Epidermal Growth Factor Receptor Signaling
Inhibition
Katherine B. Lee, Dharmalingam Subramaniam, Sripathi M. Sureban, Rama P.
Ramanujam, Hideg Kalman, Periannan Kuppusamy, Courtney W. Houchen, Brian K.
Dieckgraefe, Shrikant Anant
Curcumin is a chemopreventive agent that has been shown to reduce intestinal tumors in
murine models. Previously, the water-soluble curcumin analog, diphenyl difluoroketone (L-
2395, also known as EF24), was shown to induce apoptosis of cancer cells. We have also
determined that L-2395 induces apoptosis and inhibits proliferation of HCT-116 and HT-
29 colon cancer cells. The mechanism, however, of L-2395 anti-cancer activity has not been
characterized. This study demonstrates that L-2395 mediates the anti-cancer activity by
blocking activation of the epidermal growth factor receptor (EGFR) and subsequent signaling
through its downstream cytoplasmic and nuclear targets. HCT-116 human colon cancer
cells were treated with EGF (100 ng/ml) alone, or in the presence of L-2395 (10 µM). EGF
rapidly induces phosphorylation of EGFR, whereas L-2395 decreases baseline and EGF-
stimulated EGFR phosphorylation. We next determined the effect of L-2395 on EGFR
downstream targets, ERK and AKT. L-2395 suppressed both baseline and EGF-stimulated
ERK and AKT phosphorylation in a dose dependent manner. Transcription factor NFkappaB
is a downstream target of ERK and AKT activation. Phosphorylation of IkappaB promotes
the nuclear translocation of the normally cytoplasmically sequestered NFkappaB subunits
p50 (NFKB1) and p65 (RelA). Western blot analyses demonstrated that L-2395 inhibited
both baseline and EGF-mediated IkappaB phosphorylation. Moreover, nuclear extracts of
L-2395-treated cells show decreased levels of both p50 and p65 proteins, suggesting that
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L-2395 blocked NFkappaB translocation to the nucleas. EGF-mediated signaling induces
the expression of colorectal cancer promoting genes cyclooxygenase-2 (COX-2), interleukin-
8 (IL-8), and anti-apoptotic mitochondrial gene Bcl-XL, as well as altering the Bcl-2/Bax
ratio. Real time PCR analyses of L-2395-treated cells exhibit reduced baseline and EGF-
stimulated expression of COX-2 and IL-8. Additionally, EGF-stimulated expression of Bcl-
XL was significantly reduced by L-2395 treatment. Finally, L-2395 suppressed EGF-mediated
increase of the anti-apoptotic Bcl-2/apoptotic Bax ratio. These results imply that L-2395
inhibits activation of EGFR and its downstream targets in HCT-116 cells. This L-2395-
mediated EGFR signaling blockade may account for the growth inhibitory and pro-apoptotic
anti-cancer effects of the novel molecule.
808
Red Meat & Colon Cancer: Dietary Heme Injures Surface Epithelium and
Thus Inhibits Apoptosis and Stimulates Cell Proliferation Leading to Crypt
Hyperplasia in Rat Colon
Johan de Vogel, Wytske Boersma-van Eck, Aloys Sesink, Denise Jonker-Termont, Jan
Kleibeuker, Roelof van der Meer
Background & Aim: Epidemiologic and animal model studies show that a high intake of
heme, present in red meat, is associated with an increased risk of colon cancer. The aim of
this study was to elucidate the effects of dietary heme on colonic cell homeostasis in rats.
Methods: Rats were fed a purified, Western control diet, or this diet supplemented with 0.5
mmol heme/kg for 14 days. Fecal water cytotoxicity was determined with a bioassay.
Exfoliation of colonocytes was measured as the amount of rat DNA in feces. At day 14
colons were excised and examined histologically after staining with hematoxilin-eosin to
score intercryptal colonic surface epithelial damage. In addition to measurement of DNA in
feces, caspase-3 expression and activity were measured in colonic mucosa to determine the
rate of apoptosis. Colonic epithelial cell proliferative activity was evaluated with 3H-thymidine
or 5-bromo-2’-deoxyuridine (BrdU) incorporation into DNA, both administered 2 h before
sacrifice, or by Ki-67 immunohistochemistry. Results: Dietary heme induced a more than
ten-fold increased cytotoxicity of the fecal water and a hundred-fold lower fecal excretion
of rat DNA. Colons of heme fed rats showed injured surface epithelium and an approximately
25% increase in crypt length indicating crypt hyperplasia. Dietary heme inhibited colonic
mucosal apoptosis almost completely, whereas at the same time it doubled crypt cell prolifer-
ative activity, as shown by all three markers. Conclusions: Our results clearly show that
dietary heme causes injury of the colonic surface epithelium, which is overcompensated by
inhibition of apoptosis and by hyperproliferation of crypt cells, resulting in crypt hyperplasia.
This disturbed epithelial cell homeostasis might explain why a high intake of dietary heme
(i.e. red meat) is associated with an increased risk of colon cancer.
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3,3'-Diindolylmethane (DIM) Induces Apoptosis and Cell Cycle Arrest in
Human Colon Cancer Cells
J.N. H. Park, Eun Ji Kim, Dae Young Kwon, Hyun J Choi, So Young Park, Hyun-Kyung
Shin, Young-Joon Surh
DIM is a major in vivo derivative of the putative anticancer agent indole-3-carbinol, which
is present in cruciferous vegetables and has been reported to have anti-carcinogenic proper-
ties. The present study examined the mechanisms by which DIM inhibits human colon
cancer cells. To examine the effects of DIM on the growth of HT-29 and HCT116 human
colon cancer cells, the cells were cultured with various concentrations (0-30 μmol/L) of
DIM. Treatment of cells with increasing concentration of DIM led to a dose-dependent
decrease in viable cell numbers in both HCT116 and HT-29 cells. The decrease in cell
growth was due to a decrease in cell cycle progression and an increase in apoptosis. Results
from DNA flow cytometric analysis revealed that DIM induced G1 and G2/M phase arrests
at 12 h of culture. Western blot analyses of total cell lysates revealed that DIM decreased
phosphorylated retinoblastoma proteins (Rb) and E2F-1 and increased hypophosphorylated
Rb levels. DIM decreased cyclin A and D1 and increased cyclin-dependent kinase (CDK) 4
levels in a time-related manner. DIM also increased the protein levels of the CDK inhibitors
p21 and p27. In addition, DIM decreased the levels of cell division cycle 2 and cyclin B1.
DIM increased annexin-5-stained cells in both HT-29 and HCT116 cells in a dose-dependent
manner. Western blot analysis of total cell lysates revealed that DIM induced cleavage of
caspase-8, caspase-9, caspase-7, caspase-3, and poly (ADP-ribose) polymerase in both
HCT116 and HT-29 cells. In addition, DIM increased the translocation of cytochrome c
and Smac/Diablo from the mitochondria to the cytosol in both HCT116 and HT-29 cells.
In HCT116 cells, DIM increased truncated Bid levels but did not affect the protein levels
of p53, Bcl-2, or Bax. In HT-29 cells, DIM decreased Bcl-2 and increased truncated Bid
levels. We have demonstrated that DIM inhibits cell cycle progression and induces apoptosis
in human colon cancer cells. These results suggest that DIM inhibits G1 and G2/M phase
cell cycle progression by inhibiting CDK activities. The induction of apoptosis by DIM in
colon cancer cells may be mediated through changes in mitochondrial events which are
associated with the release of cytochrome c and Smac/Diablo and the activation the caspase
pathway through p53-independent pathway.
810
Scutellaria Baicalensis Extract and Constituent Flavonoids Inhibit Proliferation
in Pancreatic Cancer Cell Lines
Alexandra Berger, Yantao Niu, Guido Eibl, Vay Liang Go, Diane Harris
Extracts of Scutellaria baicalensis (SB; Chinese Skullcap or Huang Qin) root have traditionally
been used to treat inflammation, suggesting inhibition of arachidonic acid (AA) metabolism.
Regulation of AA flux through the cyclooxygenase (COX) and lipoxygenase (LOX) pathways
modulate pancreatic cell proliferation. Therefore we chose to study the effect of an extract
of SB on 6 different human pancreatic cancer cell lines that differ in COX and LOX phenotype;
AsPc-1, PANC-1, MiaPaCa-2 are COX-2 negative, while BxPc-3, HPAF2, and CAPAN-2 are
COX-2 positive. 75% ethanol extracts of SB (Botanica Biosciences, Ojai, CA) were used (224
mg baicalin/g SB). Pancreatic cancer cell lines (initial 3-5,000 cells) were treated with
increasing concentrations (12.5-200 µM) of SB extract or selected flavonoids: baicalin,
baicalein, wongonin, as well as indomethacin (non-specific COX inhibitor) and nordihydrog-
uaiaretic acid (NDGA; non-specific LOX inhibitor) for 48 h. Levels of SB were matched to
baicalin content. Cell viability was assayed using an ATP based cell proliferation assay
(CellTiter-Glo, Promega). Expression of 5-lipoxygenase (5-LOX) was assayed by RT-PCR.
The SB whole extract was most potent in inhibiting proliferation in the lines positive for 5-
LOX expression (AsPC-1, BxPC-3, Capan-2, and HPAF-2; IC50 46.8-89.8 µM baicalin
equivalent) and was least effective in the other lines. The whole extract was also generally
more potent than baicalin itself. NDGA showed inhibitory activity in most lines (IC50 23.8-
109.0 µM), while indomethacin showed little to no activity in all lines. The results demonstrate
that natural compounds with LOX inhibitory activity inhibit proliferation in pancreatic cell
lines. These effects appear to be mediated through the 5-LOX and not the COX-2 pathway,
as COX-2 negative cells were also responsive to SB. These data suggest that SB extracts may
have pancreatic cancer-preventive activity. Supported by NIH AT1535, CA4271, and the AGA
Foundation for Digestive Health and Nutrition.
IC50’s for SB in Pancreatic Cell Lines
--- = 50% inhibition is not reached. * SB is on μM baicalin basis
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Bile Acids Activate Epidermal Growth Factor Receptor (EGFR) Kinase-
Dependent Phosphatidylinositol 3-Kinase (PI3K)/AKT Proliferative Signaling
in Colon Cancer Cells
Chang Guo, Jean-Pierre Raufman
Recently, we demonstrated that conjugated secondary bile acids transactivate EGFR, activate
p44/42 MAP kinase (MAPK) signaling and stimulate colon cancer cell proliferation (Biochem.
Pharmacol. 2005;70:1035). In the present study, we used HT-29 and H508 human colon
cancer cells to determine the role of EGFR kinase activity and stimulation of PI3K/Akt
signaling in mediating the proliferative actions of bile acids. Immunoblotting (IB) of colon
cancer cell lysates with specific polyclonal antibodies for phospho-Akt(Ser473) revealed that
deoxycholyltaurine (DCT, 10-300 μM) caused dose- and time-dependent Akt phosphoryl-
ation without altering total cellular Akt. Akt phosphorylation was maximal with 300 μM
DCT, the highest concentration examined. The time course for DCT-induced Akt phosphoryl-
ation was biphasic; initial rapid phosphorylation was maximal at 5 min with a second
increase in phosphorylation observed from 20-60 min. Adding either EGFR kinase inhibitors
(0.1 μM AG1478 and 2 μM PD168393) or PI3K activation inhibitors (30 μM LY294002
and 100 nM wortmannin) abolished DCT-induced Akt phosphorylation. Transfection of
HT-29 cells with a dominant negative EGFR mutant (K721M that inactivates EGFR kinase
by removing the ATP-binding site) markedly reduced DCT-induced Akt phosphorylation.
In contrast, EGFR overexpression by transfection with a wildtype clone increased DCT-
induced Akt phosphorylation. These findings provide evidence that in human colon cancer
cells, bile acid-induced phosphorylation (activation) of Akt is EGFR kinase- and PI3K-
dependent. EGFR kinase (PD168393) and PI3K (LY294002 and wortmannin) inhibitors
also reduced DCT-induced proliferation of both HT-29 and H508 cells. Compared to control,
incubation with LY294002 (50 μM) and wortmannin (50 nM) reduced DCT (50 μM)-
induced proliferation of HT-29 cells by 86.1 ± 4.6% and 28.4 ± 5.0% (mean ± SD; n=4;
p<0.01), respectively, and of H508 cells by 97.6 ± 1.6% and 31.9 ± 9.0% (mean ± SD; n=
4;p<0.01), respectively. In contrast to Akt phosphorylation, DCT-induced p44/42 MAPK
phosphorylation was not reduced by transfection of HT-29 cells with the K721M EGFR
dominant negative mutant or by incubation with an EGFR kinase inhibitor. These findings
indicate that DCT-induced activation of p44/42 MAPK is EGFR kinase-independent. Bile
acid-induced activation of EGFR kinase-dependent (PI3K/Akt) and kinase-independent (p44/
42 MAPK) signaling may augment human colon cancer cell proliferation by activation
of both anti-apoptotic and pro-proliferative mechanisms, respectively. Collectively, these
observations provide mechanisms to explain the in vivo actions of bile acids in promoting
colon cancer growth.
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Treatment of Mild to Moderate Acute Attacks of Distal Ulcerative Colitis with
Rectally-Administered E. Coli Nissle 1917: Dose-Dependent Efficacy
Harald Matthes, Thomas Krummenerl, Manfred Giensch, Corinna Wolff, Juergen Schulze
Introduction: Distal ulcerative colitis (UC) is commonly treated with anti-inflammatory
medication , with rectal formulations being particularly successful. Anecdotal clinical observa-
tion point to the successful use of enemas containing stool suspensions or probiotic suspen-
sions. Efficacy of oral therapy with probiotic E. coli Nissle 1917 (EcN) for remission mainten-
ance in UC patients has been shown in several studies. Subsequent to a documented phase-
I study of EcN enemas which were well tolerated in 80 patients, clinical effectiveness as
compared to a placebo was investigated at various dosages to test for efficacy and dose-
dependency. Study design: A total of 90 patients were enrolled. In a double-blinded study
patients were randomly treated with either 40, 20 or 10 ml enema containing 10exp8 EcN
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per ml (n = 24, 23 or 23) or a placebo (n = 20). Patients received the study medication
once daily over at least 4 weeks. Admission criterion was UC proctitis or proctosigmoiditis
with mild to moderate activity (DAI according to Sutherland 4 - 9). After 2 and 4 weeks
the clinical DAI (primary objective) as well as data on tolerance were determined. Patients
reaching clinical DAI ≤2 within the therapy phase were regarded as responders. Results:
According to the (Jonckheere-Terpstra) test for rank correlation evaluating dose-dependent
efficacy, 57/90 per-protocol patients (no concomitant acute-phase therapy with aminosalicyl-
ates or glucocorticoids, no abrupt stop of acute-phase therapy prior to study commencement,
maximal spread of inflammation 45 cm from anus) were assessed: the responder rates
significantly correspond to the applied EcN doses by increase in ranking (p = 0.04). Remission
was achieved by 2/11 patients (18.2%) receiving a placebo, 3/11 (27.3 %) receiving EcN
10 ml, 8/18 (44.4 %) receiving EcN 20 ml, and 9/17 (52.9 %) receiving EcN 40 ml. Time
to remission was the shortest in the EcN-40-group, followed by the EcN-20-ml group.
Assessment of tolerance by patients and by the physician as well as the number of patients
with suspected side effects did not reveal significant differences between the treatment
groups. Conclusion: Rectal application of 20 or 40 ml EcN enemas (10exp8 EcN/ml) for
the therapy of mild to moderate distal UC represents an effective and well tolerated alternative
to topical use of aminosalicylates or glucocorticoids.
813
Combined Data from Two Pivotal, Randomized, Placebo-Controlled, Phase III
Studies Show That SPD476, a Novel mesalamine Formulation Given Once Or
Twice-Daily, Is Effective for the Induction of Remission of Mild-to-Moderate
Ulcerative Colitis
William J. Sandborn, Michael A. Kamm, Gary R. Lichtenstein, Miguel Gassull, Stefan
Schreiber, Lechoslaw Jackowski, Prabhakar Boddu, Natalya Gubergrits
Background: Mesalamine (5-ASA) is a first-line treatment for mild-to-moderate ulcerative
colitis (UC). Presently available formulations are associated with inconvenient multiple-daily
dosing, which can lead to patient non-compliance, thus reducing drug effectiveness and
overall treatment success. Here we report an analysis of combined efficacy and safety data
from two, prospective, randomized, multicenter, double-blind, placebo-controlled, phase
III studies (SPD476-301 [Study 301] and SPD476-302 [Study 302]) investigating SPD476,
a novel, high-strength (1.2g/tablet), once-daily formulation of mesalamine. SPD476 uniquely
combines a gastro-resistant polymer film, delaying release of the active drug until the terminal
ileum, and MMX Multi Matrix System™ (MMX) technology, extending consistent delivery
of 5-ASA throughout the entire colon. Methods: Eligible subjects had mild-to-moderate
UC. Data were combined for subjects receiving SPD476 2.4g/day (given once daily [QD;
Study 302] or twice daily [BID; Study 301] combined n=172), SPD476 4.8g/day (given QD
[Studies 301 and 302] combined n=174) or placebo (combined n=171). The proportion of
subjects in remission (primary endpoint: UC disease activity index of ≤1, with a rectal
bleeding and stool frequency score of 0 and ≥1 point reduction in sigmoidoscopy score
from baseline) at week 8, was compared for the SPD476 groups vs the placebo group.
Results: A statistically significantly greater percentage of subjects achieved remission in the
SPD476 2.4g/day group compared with the placebo group (37.2 vs 17.5% [p<0.001]).
Similarly, a statistically significantly greater percentage of subjects in the SPD476 4.8g/day
QD group achieved remission compared with the placebo group (35.1 vs 17.5% [p<0.001]).
A total of 10 subjects reported 13 serious adverse events (7 with placebo, 4 with SPD476
2.4g/day BID [aggravated UC=1; pancreatitis=1; perianal abscess=1; urinary retention=1]
and 2 with SPD476 4.8g/day QD [viral gastroenteritis=1; pancreatitis=1]). Only pancreatitis
was considered to be possibly and probably related to study medication. Both cases were
resolved following discontinuation of the study drug. Conclusions: These data show that
this unique formulation of SPD476, combining a high dose of 5-ASA per tablet and MMX
technology, was well tolerated and effective for the induction of remission of mild-to-
moderate UC at doses of 2.4g/day and 4.8g/day given once or twice daily. The efficacy and
convenience of SPD476 is anticipated to improve patient compliance and enhance overall
treatment success.
814
Similar Clinical Remission Rates with mesalazine Foam and Enema in Patients
with Active Left-Sided Ulcerative Colitis (UC): Results of a Multicentre,
Prospective, Randomized, Investigator-Blinded, Comparative Study
Antoine Cortot, Denis Maetz, Eric Degoutte, Olivier Delette, Pierre Meunier, Tg Tan,
Jean-Brice Cazals, Olivier Dewit, Xavier Hebuterne, Sylvain Beorchia, Bernard Grunberg,
Eric Leprince, Geert D'Haens, Sylvie Forestier, Marc Lemann
Aim: To demonstrate that mesalazine foam was at least as effective as mesalazine enema for
inducing clinical remission defined as modified Rachmilewitz score (CAI 1-4) inferior or
equal to 2 in patients with left-sided active ulcerative colitis treated for 4 weeks. Methods:
375 patients with mild to moderate UC received mesalazine foam 1g/100ml /d or liquid
mesalazine enema 1g/100ml /d for 4 weeks. Inclusion criteria were: newly diagnosed or
relapsing active UC, disease extension superior or equal to 5 cm from anorectal junction to
the splenic flexure, CAI1-4 superior or equal to 4, age superior or equal to 18 years. Oral
maintenance treatment at stable doses with mesalazine, azathioprine or methotrexate was
permitted. Oral steroids treatment was not allowed. The primary endpoint was clinical
remission at week 4. Secondary objectives included rate of endoscopic remission (endoscopic
Rachmilewitz score inferior to 4) at week 4, acceptability assessed with VAS, safety and
compliance to the treatment. For this non-inferiority study, the equivalence limit was 15%.
Results: Patients were comparable in foam and enema groups as far as : duration of UC (60
and 64.4 months) duration of the current episode (2.1 months in both groups), % of
relapsing (68% and 69%) ,% of proctitis (43% and 46%) , % of proctosigmoiditis (51% in
both) and % of left-sided colitis (6% and 3%). Remission rates at 4 weeks in foam and
enema groups were 68% and 73% in per protocol (PP) analysis (95% CI: -15.1%;4.4%)
and 67% and 70.5% in intent-to-treat (ITT) analysis (95% CI: -13.4%;5.8%). In PP analysis,
CAI1-4 was 6.23 and 6.17 at baseline, 2.65 and 2.57 at week 2, 1.87 and 1.67 at week 4
(NS). Endoscopic remission rates were 67.5 and 80% in PP (p=0.012) and 67% and 77%

















were similar in foam and enema groups: 82% and 84%, 96% and 97% (NS). The enema
retention score was better in foam group (p<0.001). 11% and 13% patients withdrew from
the study (NS), 4% and 3% due to non-serious AE (abdominal pain and flatulence), 2% in
both groups for worsening. Conclusion: A 4 weeks treatment of 1g mesalazine foam was
equivalent for inducing a clinical remission to 1g enema in patients with mildly to moderately
active left-sided UC. Retention was better with foam. Mesalazine foam is a therapeutic
alternative to mesalazine enema for controlling symptoms in such patients.
815
Four-Week Results of Adalimumab Treatment in Subjects with Fistulizing
Crohn’s Disease Who Have Failed Response Or Showed Intolerance to
Infliximab
J Hinojosa, F Gomollon, P Nos, M Penate, D Ceballos, Ma Gassull
PURPOSE To assess the efficacy and safety of adalimumab, a fully human monoclonal
antibody targeting TNF-α, for inducing fistula closure in subjects with fistulizing Crohn’s
disease (CD). METHODS In this open-label multi-center study for the induction of clinical
remission and perianal fistula closure, subjects with failed response or intolerance to inflixi-
mab and a diagnosis of fistulizing CD (CDAI<220) or both luminal (mucosal) and fistulizing
CD (CDAI>220) were treated with subcutaneous adalimumab: 160 mg at Week 0, 80 mg
at Week 2, then 40 mg every other week (eow) for 52 weeks. Subjects were routinely
assessed for complete or partial (≥50% decrease in number of draining fistula compared
to baseline) fistulae closure, PDAI score, and adverse events (AE). RESULTS Of 22 subjects
treated with adalimumab, all had been treated previously with infliximab: 5 (23%) had
failed response to infliximab, 17 (77%) were infliximab-intolerant. Subjects had luminal
and fistulizing CD (45%) or fistulizing CD only (55%). At baseline, the mean PDAI score
overall (n=22) was 10.5 ±2.8; the mean number of fistulae was 2.5±1.2 in subjects with
fistulizing CD only and 3.8±5.5 in subjects with both luminal and fistulizing CD. Week 4
results are shown in the table. Treatment-related AE were mild to moderate in severity and
similar to those observed in studies of ADA in subjects with rheumatoid arthritis. The most
common AE were erythema, nausea/dizziness, weakness, and myalgia. One patient dropped
out due to non-pruritic erythema. No serious AE’s were reported. CONCLUSIONS Adalimu-
mab induced complete or partial fistula closure in these subjects and was well-tolerated.
No new safety concerns were found in subjects with fistulizing CD compared to other
adalimumab-treated populations.
PDAI Scores and Fistula Closure at Week 4 of Adalimumab Treatment
Intention to treat analysis
816
Autologous Hematopoietic Stem Cell Transplantation (HSCT) for Refractory
Crohn’s Disease (CD), 4 Year Follow Up
Robert M. Craig, Yu Oyama, Larissa Verda, Laisvyde Statkute, Krosnjar Nela, Kathleen
Quigley, Richard Burt
Purpose: HSCT is being studied in an effort to ascertain its value in inducing a clinical
remission in severe CD Methods. Patients with severe CD who have failed standard therapy
(5-ASA, antibiotics, corticosteroids, immunosuppression, and infliximab), whose CDAI was
> 250, were accessed for therapy. Stem cells were mobilized from the peripheral blood using
cyclophosphamide (2.0 g/m2) and G-CSF (10 ug/kg/day), enriched ex vivo by CD34+
selection, and reinfused after immune conditioning with cyclophosphamide (200 mg/kg)
and anti-thymocyte globulin (90 mg/kg). Clinical variables, small bowel radiography, colon-
oscopy and T-cell subsets were followed annually following the HSCT. Results: 19 subjects
have undergone the therapy successfully. HSCT had no in-patient mortality, and was complic-
ated only by 24-48 hours of culture negative fever. Usually, diarrhea and abdominal pain
resolved prior to hospital discharge. Perianal fistulae and perianal disease were slower to
resolve, but gradually improved over months to years. Abdominal masses and colonic
strictures have resolved. Two patients had progression of their small intestinal strictures
following the transplantation and required surgical resection, but their post-operative courses
have been uneventful, and they continue to do well off all Crohn’s disease medications.
Three patients have had major relapses, 2 at one year and 1 at 2 years, requiring re-institution
of immunotherapy. One had a minor relapse at 1 year requiring re-institution of infliximab,
promoting remission (which was ineffective pre-transplant). Following HSCT, a robust rise
in CD4+CD25+(bright) T-cells was observed. There was a smaller rise in these T-cells in
those who eventually relapsed. In most subjects, serum albumins, hemoglobins, weights,
sedimentation rates, and CRPs have improved or normalized. The patient with the longest
follow up, at 4 1/2 years post HSCT, remains in remission off all CD medication. Conclusion:
This preliminary experience in the first 19 patients who have received this unique therapy
continues to be encouraging, although 3 have had major recurrences of the disease. Induction
of regulatory T-cells may be partially responsible for the salutary effect. A randomized study
is in progress.
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Atorvastatin Decreases Seo Index in Patients with short Duration of Disease
in Ulcerative Colitis: A Randomized Placebo-Controlled Clinical Trial
Peter D. Higgins, Tahira Khan, John Mapili, Ellen M. Zimmermann
Background: Statin medications have systemic anti-inflammatory effects. Studies in animal
models and a case series in humans have shown improvement in colitis with statins. Aims:
1) To determine whether the Seo Index is improved in a randomized controlled 24-week
pilot study of daily oral atorvastatin 40 mg in patients with mild to moderate ulcerative
colitis; 2) To identify any subgroups of patients most likely to respond to atorvastatin.
Methods: Thirty-six patients 18 to 70 years of age with mild to moderately active ulcerative
colitis despite a variety of stable medications were randomized to placebo or 40 mg daily
oral atorvastatin for 24 weeks. Subjects were allowed to leave the study after a final evaluation
if a symptomatic flare occurred. In an intention-to-treat analysis, the final Seo Index when
controlled for baseline Seo Index was the primary outcome. A decrease in the Seo Index of
>30 points was considered clinically significant improvement, and a Seo score of less than
120 points was considered remission. Six pre-specified covariates of disease duration, disease
extent, baseline CRP, thiopurine use, steroid use, and pANCA titer were evaluated in a
multivariate model to identify subsets of subjects with improved responses. Similar assess-
ments with the IBDQ (>205 for remission, >20 change for improvement) were performed
to evaluate effects on quality of life. Results: The final Seo Index was 132.1 points in patients
randomized to atorvastatin, and 157.6 points in patients on placebo (p=0.06). The disease
duration covariate had a significant interaction with therapy, with longer duration of disease
leading to less response. After controlling for this interaction, the final Seo Index was 46
points lower in patients randomized to atorvastatin vs. placebo (p=0.02). Clinically significant
improvement was seen in 40% of patients on atorvastatin, compared to 25% with placebo.
Clinical remission was achieved in 45% of patients on atorvastatin, compared to 25% with
placebo. With the IBDQ endpoints, 50% of patients had clinically significant improvement
on atorvastatin vs. 19% on placebo, and 35% of patients achieved remission on atorvastatin
vs. 31% on placebo. The atorvastatin group had one significant adverse event: a fall with
head injury probably unrelated to drug. No significant elevations in liver tests or creatine
kinase occurred. Conclusions: Daily oral atorvastatin 40 mg appears to be moderately
beneficial in a subset of patients with shorter duration of disease in this pilot study of
atorvastatin for ulcerative colitis. The anti-inflammatory effects of atorvastatin in ulcerative
colitis warrant further study.
818
The Seattle Protocol for High-Grade Dysplasia in Barrett’s Esophagus-It May
Not Be As Good As We Think
Revital Kariv, Thomas P. Plesec, Mary P. Bronner, John R. Goldblum, Mary Oldenburgh,
Thomas W. Rice, Gary W. Falk
Background: The optimal management of high-grade dyplasia (HGD) in Barrett’s esophagus
(BE) remains controversial. A biopsy protocol consisting of 4 quadrant jumbo biopsies at
1 cm intervals plus biopsies of any mucosal abnormalities no matter how trivial (Seattle
protocol) is thought to be a reliable method to detect early cancers in HGD patients. However,
this protocol has never been validated outside of Seattle. Aim: To validate the Seattle protocol
in a cohort of BE patients who underwent esophagectomy for a diagnosis of HGD. Patients
and Methods: This is a single center study of 32 consecutive BE patients with a biopsy
diagnosis of HGD who underwent esophagectomy between 1999-2005. None had mass
lesions suggestive of obvious malignancy at the time of preoperative endoscopy. All biopsies
were confirmed by expert GI pathologists prior to surgery. Patients were divided into 2
groups: Group 1 had preoperative surveillance biopsies done according to the Seattle protocol
as described above; Group 2 had 4 quadrant biopsies every 2 cm. Postoperative pathology
findings confirmed by expert GI pathologists were compared to preoperative findings in
both groups. Results: There were 21 patients in Group 1 and 11 patients in Group 2. Age
and hiatal hernia size were not significantly different between the 2 groups. Median [IQR]BE
length was greater in Group 2 (10.0 cm [4.0,10.0] vs 4.0 cm [2.0,5.0](P= 0.01)). Postoperat-
ively, unsuspected intramucosal cancer was found in 7/21(33.3%) Group 1 vs 3/11(27.3%)in
Group 2 (P=0.99). No patients in either group had a postoperative diagnosis of submucosal
cancer or lymph node metastases. Conclusions: Intensive preoperative surveillance biopsies
using the Seattle protocol does not reliably predict the presence of intramucosal carcinoma
at the time of esophagectomy any better than a less intensive surveillance biopsy protocol.
This calls into question the concept that the Seattle protocol consistently detects early cancer
arising in BE patients with HGD.
819
Natural History of High Grade Dysplasia in a Regional Veterans
Administration Barrett’s Cohort
Gareth S. Dulai, Dennis M. Jensen, Fasiha Kanwal, Brennan M. Speigel, Ian M. Gralnek,
Paul G. Shekelle
OBJECTIVES: Published data on the natural history of high grade dysplasia (HGD) in Barrett’s
esophagus (BE) give widely varying estimates of risk for esophageal cancer. The risk of
cancer and related mortality may be greater in prevalent than incident cases due to detection
of early stage disease in surveillance or bias. Our primary aim was to describe the natural
history of prevalent and incident HGD in a large cohort of BE patients. A secondary aim was
to compare outcomes in those with prevalent vs. incident cancer. METHODS: Consecutive BE
cases from 1988-2002 were identified via pathology databases in a regional VA healthcare
system and medical record data were abstracted. The risk of progression to cancer as well
as mortality was measured and compared in cases with prevalent vs. incident HGD/cancer
using survival analysis. RESULTS: There were 30 cases of prevalent HGD, six of whom
developed cancer over 70 patient-years of follow-up. Three of thirteen cases with incident
HGD developed cancer over 136 years of follow-up. The crude rate of cancer was 1 in 12
years for those with prevalent vs. 1 in 45 years with incident HGD (p=0. 085). Ten cases
with prevalent and five cases with incident HGD died, but only 20% were due to cancer.
Mortality was 1 in 7 years for those with prevalent vs. 1 in 27 years with incident HGD
(p=0.005). There were 45 prevalent and 11 incident cancers. Cancer was early stage in 16%
of prevalent vs. 45% of incident cases (p=0.03). Twenty-eight cases with prevalent and six
with incident cancer died. Death was due to cancer in 96% of prevalent vs. 50% of incident
cases (p=0.01). Mortality rates were 1 in 4 years for those with prevalent vs. 1 in 16 years
for incident cancers (p=0.02). CONCLUSIONS: In a large cohort study of Barrett’s, high-
grade dysplasia was associated with a high rate of progression to cancer. The risk of overall
mortality was significantly higher in those with prevalent vs. incident high-grade dysplasia
and cancer. The reduction in risk may be an effect of surveillance and/or other factors
including bias.
820
The Development and Validation of An Endoscopic Grading System for
Barrett’s Esophagus-the Prague C and M Criteria
Prateek Sharma, David Armstrong, Jacques JGHM Bergman, John Dent, Liebwin Gossner,
Yoshio Hoshihara, Janusz A. Jankowski, Ola Junghard, Lars Lundell, Guido Nj Tytgat,
Michael Veith
Background and Aims Barrett’s esophagus (BE) is a pre-malignant condition for esophageal
adenocarcinoma, and its diagnosis relies initially on the endoscopic recognition of a columnar
lined distal esophagus (i.e. suspected or endoscopic BE). The accuracy of this endoscopic
assessment is hampered by a lack of consensus-developed, explicit criteria for the endoscopic
diagnosis and grading of its extent. In this study we have developed and validated such
criteria. Methods Over several meetings, an international working group agreed on endoscopic
diagnosis and grading criteria and developed materials for their formal evaluation by use of
video-endoscopic recordings (of the distal esophagus, the gastroesophageal junction (GEJ)
and proximal stomach) gathered in a standardized manner in 29 patients. The criteria
included assessment of the Circumferential (C) and Maximum (M) extent of the endoscop-
ically visualized BE segment as well as landmarks such as the diaphragmatic hiatus, the GEJ
and the proximally displaced squamo-columnar junction. The recordings were scored for
multiple criteria by an international panel of 29 endoscopists especially interested in BE (22
of those endoscopists scored C and M for all 29 patients). Results The criteria, now named
the Prague C&M Criteria, give explicit guidance on the endoscopic recognition of BE and
grading of its extent. Among the 29 patients, the means of the values for ‘C’ ranged from
0 to12 cm and for ‘M’, the range was 0 to 14 cm. The overall reliability coefficients (RC)
were excellent for the assessments by the 22 endoscopists of both Circumferential and
Maximum extent of the endoscopic BE segment above the GEJ (RC for C value 0.95 and
for M value 0.94). For C and M measures, the rates of exact agreement for pair-wise
comparisons of individual patient values were 53% and 38% respectively whereas the
agreement within a 2 cm interval was 72% and 76% respectively. The overall RC for
endoscopic recognition of BE > 1 cm was 0.72, but for < 1 cm, the RC was poor at 0.22.
The RC for recognizing the location of GEJ and the diaphragmatic hiatus was 0.88 and
0.85 respectively. Conclusions The Prague C&M criteria have high overall validity for the
endoscopic assessment of visualized BE lengths, when used by endoscopists especially
interested in BE. For less than 1 cm however, use of the criteria did not result in acceptable
levels of diagnostic reliability and the causes for this need further research. The reliability
of recognizing endoscopic landmarks is excellent. The criteria represent a useful advance
in the endoscopic assessment of BE for clinical practice and research.
821
Squamous Overgrowth in a 5-Year Randomized Phase III Trial of
Photodynamic Therapy Using Porfimer Sodium in Ablation of High-Grade
Dysplasia in Barrett’s Esophagus
Mary Bronner, Shari Taylor, Bergein Overholt, Kenneth Wang, Steven Burdick, Charles
Lightdale, Michael Kimmey, Hector Nava, Michael Sivak, Norman Nishioka, Hugh Barr,
Chad Davis, Norman Marcon, Marcos Pedrosa, Michelle Depot
PURPOSE: Squamous overgrowth may obscure the endoscopic extent of Barrett’s epithelium.
Although squamous overgrowth has never been rigorously studied, it has been speculated
that photodynamic therapy (PDT) increased the risk of subsquamous metaplastic glands.
Consequently, its true diagnostic significance was assessed following PDT with porfimer
sodium plus 20 mg omeprazole BID [PORPDT] versus 20 mg omeprazole BID [O alone]
in patients with high-grade dysplasia (HGD) in Barrett’s esophagus (BE) in a large randomized
trial. METHODS: Patients were randomized (2:1) to PORPDT or to O alone. Patients on
PDT received 2 mg/kg i.v. of POR followed by endoscopic laser light exposure of Barrett’s
mucosa at a wavelength of 630 nm within 40-50 hours up to a maximum of 3 courses
administered at least 90 days apart. Starting at baseline, every 3 months patients underwent
4-quadrant jumbo biopsies of their pre-treatment Barrett’s length until four consecutive
quarterly follow-up results were negative for HGD and then biannually up to 5 years or
treatment failure. Biopsies were taken at 2-cm intervals and centrally processed for standard-
ized histologic interpretation by GI pathologists blinded to treatment assignment and patient
identity. RESULTS: There were 138 patients and 23,473 total biopsies in PORPDT and 70
patients with 10,160 total biopsies in O alone. Occurrence of squamous overgrowth was
similar for PORPDT relative to O alone both per patient (31% vs. 33%) and per biopsy
(1.2% vs. 2.2%). In no patient was the highest grade of neoplasia per endoscopy found
exclusively beneath squamous mucosa. CONCLUSIONS: This 5-year large randomized trial
with a rigorous surveillance biopsy program documents that squamous overgrowth occur-
rence is similar following either PORPDT or O alone. This trial confirms that squamous
overgrowth is not detrimental to the longer-term safety of PORPDT.
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New Barrett’s Epithelium After the Healing of Erosive Oesophagitis -
Prospective Endoscopic and Histological Assessments
Ali S. Taha, Margaret Balsitis, Wilson J. Angerson, Frances Gallagher, Christopher G.
Morran
BACKGROUND Epidemiological studies have considered a number of risk factors for Barrett’s
oesophagus including oesophagitis. However, prospective assessments have been lacking.
We, therefore, aimed at studying the possible development of new Barrett’s epithelium in
patients with a history of oesophagitis while considering other risk factors including gastro-
duodenal disease and H pylori. PATIENTS & METHODS After the endoscopic healing of
oesophagitis in 120 patients, 15 (12.5%) found to have Barrett’s oesophagus were excluded.
The remaining 105 patients were followed-up for the development of new Barrett’s epithelium
for a median (range) of 52 (38-77) months. They included 67 men (64%), 38 women (36%),
39 smokers (37%), 67 alcohol drinkers (64%), and had a median (range) age of 52 (19-
83) years. Baseline endoscopic findings included 41 patients (39%) with non-erosive and
64 (61%) with erosive oesophagitis, 9 (9%) with gastric ulcers or erosions, 25 (24%) with
duodenal ulcers or erosions, and 66 (63%) with H pylori gastritis. Eradication therapy was
given to 43 patients. Using recent criteria (Coad RA, Shepherd NA. Current Diagnostic
Pathology 2003; 9: 218-227), histological features diagnostic of Barrett’s oesophagus (category
1) included the presence of native oesophageal structures such as oesophageal gland ducts
with juxtaposition to glandular mucosa. Less diagnostic or normal categories (2-4) were also
noted. The endoscopist and pathologist were not aware of patient’s baseline characteristics.
RESULTS Diagnostic features (category1) of newly developed Barrett’s oesophagus were
found in 9 patients (8.6%) after a median (range) of 52 (35-83) months, with a median
(interquartile range) length of 3 (1-3.5) cm. There was a negative correlation between the
length of Barrett’s epithelium and the histological categories (r = - 0.28; p = 0.004). Six of
the new Barrett’s cases developed in those with baseline erosive oesophagitis (6/64, 9.4%)
and 3 in non-erosive disease (3/41, 7.3%). Five of 43 patients (12%) given H pylori eradication
therapy developed Barrett’s epithelium, compared with 3/23, 13% whose infection was not
treated. Taking all histological categories into account, males had greater tendency to develop
Barrett’s oesophagus (X2 = 5.69; df = 1; p = 0.017). No significant tendency was seen with
other risk factors including gastro-duodenal abnormalities H pylori, or eradication therapy.
CONCLUSIONS New Barrett’s epithelium can develop after the exclusion of baseline cases
in patients with oesophagitis. It is more likely to develop in men, and does not seem to be
influenced by baseline gastro-duodenal disease, H pylori or its eradication.
823
The Effect of Scheduled Second Endoscopy Against Intravenous High Dose
OMEPRAZOLE Infusion As An Adjunct to Therapeutic Endoscopy in
Prevention of Peptic Ulcer Rebleeding - A Prospective Randomized Study
Philip W. Chiu, Henry Joeng, Catherine Choi, Kwok Hung Kwong, Siu Ho Lam
Background From our randomized study, scheduled second endoscopy reduces rebleeding
in bleeding peptic ulcers [GUT 2003.52: 1403-7]. Intravenous high dose omeprazole infusion
is another strategy established to reduce rebleeding. This study aimed to compare second
endoscopy against intravenous omeprazole infusion in prevention of ulcer rebleeding. Patients
and Method We recruited patients who had bleeding peptic ulcer with endoscopic stigmata
of acute bleeding, visible vessel or adherent clot and hemostasis achieved on primary
endoscopy. One group (2nd OGD) received scheduled second endoscopy 16-24 hours after
initial haemostasis, and further therapy applied if endoscopic stigmata persisted as above.
Another group (PPI) received high dose adjunctive omeprazole infusion. Those patients that
developed rebleeding would receive operation if further endoscopic therapy failed. The
outcome measures included rebleeding, transfusion, length of stay, and mortality. Results
From 2003 to 2005, 335 patients presented with bleeding peptic ulcers. After endoscopic
haemostasis, 164 eligible patients were randomized, 84 to PPI group and 80 to 2nd OGD
group. 8 (9.4%) in the PPI group and 5 (6.3%) in the 2nd OGD group sustained rebleeding
(Chi square test p = 0.43; RR = 0.63, 95% CI 0.19 - 2.03). There is no difference in the
probably of rebleeding within 30 days upon Kaplan Meier statistics (Log rank test p = 0.54)
(Fig 1). The number of patients that required surgery for rebleeding was 4 (4.8%) in PPI
group and 1 (1.3%) in 2nd OGD group (p = 0.36; RR = 0.25, 95%CI 0.03-2.32). There
was no difference in the hospital stay, ICU stay, transfusion or mortality between the two
groups. Conclusion Both scheduled second endoscopy and adjunctive high dose omeprazole




















Proton Pump Inhibitor Treatment Initiated Prior to Endoscopic Diagnosis in
Unselected Upper Gastrointestinal Bleeding: A Cochrane Systematic Review
and Meta-Analysis
Stephanie Dorward, Aravamuthan Sreedharan, Grigoris I. Leontiadis, Colin W. Howden,
Paul Moayyedi, David Forman
Background The clinical effectiveness of proton pump inhibitors (PPI) in patients with upper
gastrointestinal (UGI) bleeding has been evaluated in recent meta-analyses. However, none
of these has addressed the role of PPI treatment initiated prior to endoscopic diagnosis in
unselected patients with UGI bleeding. Objectives We aimed to systematically review evidence
from randomized controlled trials (RCTs) that studied PPI treatment initiated before endos-
copy, in UGI bleeding. Methods We performed a search of CCTR, MEDLINE, EMBASE,
CINAHL databases and major conference proceedings up to September 2005. RCTs compar-
ing intravenous or oral PPIs with either placebo or H2-receptor antagonists in patients with
unselected UGI bleeding were included. Two reviewers independently assessed the eligibility
criteria of each study and extracted data regarding outcomes and factors affecting methodolo-
gical quality. The primary outcome was 30-day mortality; secondary outcomes included 30-
day re-bleeding and surgical intervention rates, stigmata of recent hemorrhage (SRH) seen
at endoscopy, length of hospital stay and blood transfusion requirement. Sub-group analyses
were performed for the outcomes in patients with peptic ulcer bleeding. Results Five RCTs
were included for review. Four RCTs comprising 1512 patients reported data for all random-
ized patients. Four RCTs were published in full; one was presented in abstract form. Two
RCTs reported adequate concealment of allocation. Meta-analyses were performed for all
dichotomous outcomes. Adequate data were not available to perform meta-analyses for
continuous outcome measures such as blood transfusion requirements and length of hospital
stay. Sensitivity analyses were performed as appropriate and sources of heterogeneity were
explored. The main results are presented in the Table. Conclusions PPI treatment initiated
prior to endoscopy in unselected UGI bleeding significantly reduced the proportion of
patients with SRH at index endoscopy. However, there was no evidence that PPI treatment
improved clinically important outcomes such as mortality, re-bleeding or need for surgery.
Results
825
7 Or 10fr, with Low Or High Volume Epinephrine? A Single Center
Prospective Randomized Control Trial in Acute Non-Variceal Upper
Gastrointestinal Bleeding (AUGIB)
Subbaramiah Sridhar, Sherman Chamberlain, Sreeram Parupudi, Sankar Sethuraman,
Dharma Thiruvaiyaru, Urias Cuartas, Lynda Roach, Robert Schade
Background: Endoscopic injection of epinephrine (1:10,000) together with thermocoagul-
ation is considered highly effective for AUGIB. We compared the efficacy of low (10 ml)
or high volume (35ml) epinephrine followed by 7 or 10Fr BICAP probe. Methods: A
total of 197 pts., mean age 63.4(SD+16.6) who shared common demographic details with
endoscopically confirmed AUGIB (Forrest I & II) were prospectively randomized to one of
4 effective treatment groups; high vol epi +10Fr (A, n=58), high vol epi +7Fr (B, n=47),
low vol epi +10Fr (C, n=36), & low vol epi + 7 Fr (D, n=56). All endoscopic procedures
were performed within 6- hr. of admission by a single endoscopist (S, S). The outcome
variables of interest were: rebleeding incidence, need for surgery, no. of hospital days &
no. & duration of coagulations. Results: 113 DUs, 77GUs & 7 MW tears noted. 67 pts.
took NSAIDs: 18, 17, 15 & 17 in A, B, C & D. The no. of rebleeding incidences (<48hrs)
were 2,3,4 &13 in gps. A, B, C & D respectively. Only 1 pt in A required surgery for
rebleeding when compared to 6 in D. The mean no. of coag. & duration (5.4, 7.7sec SD
+ 1.1, 2.1) were also low in A when compared to other groups. Using logistic regression
analysis, the odds of rebleeding was significantly lower in A when compared to D (ref. to
table). Using multivariate ANOVA, ICU & ward days in non-NSAID users were sig. lower
in A than in D (P<0.01), but there was no difference between the two groups in NSAID
users & among C, B & A for all pts. No. of coag. & duration in sec. were sig. fewer in A
when compared to other groups(P< 0.01) in all pts. Conclusion: In our study 10Fr coagulation
probe with high vol. epinephrine was associated with significantly reduced rebleeding risk
and lower no. of coag. & duration. However, there was no sig. difference between the
groups with respect to need for surgery for rebleeding. This therapy, when compared to
7Fr coagulation with low vol. epinephrine, was also superior in reducing hospital stay in
non-NSAID users. Use of large probe with high volume epinephrine should be standard
therapy when dealing with AUGIB for minimizing morbidity and costs.
Rebleeding Risk (Logistic regression)
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Early Is Good; Is Very Early Better? Does Endoscopy Within 6 Hours of
Presentation Improve Outcomes in High-Risk Patients Presenting with Acute
Non-Variceal Upper Gastrointestinal Bleeding (ANVUGIB)
Leila Keyvani, Laura E. Targownik, Sanjay K. Murthy, Shanua Leeson
Background: ANVUGIB is a serious cause of morbidity and mortality and is associated with
a 5-10% case-fatality rate. The evidence to date suggests that performance of endoscopy
within 24 hours of presentation reduces the risk of rebleeding and mortality in patients
presenting with ANVUGIB. However, it is unclear whether performing endoscopy very early
within this 24 hour window provides any additional benefit. The benefits of performing
very early endoscopy would likely be most pronounced in high-risk patients, including the
elderly, those with evidence of shock on presentation, and patients with a history of severe
co-morbid illness. Therefore, we sought to determine if there were significant differences
in outcomes between high-risk ANVUGIB patients who undergo endoscopies within 6h of
presentation (“very early”) or between 6h and 24h from presentation. (“early”). Methods:
We performed a retrospective review of all patients with ANVUGIB who presented to one
of our two tertiary care medical centers in Winnipeg, Manitoba between 1999-2004.We
selected the patients who were high risk based on their having a clinical Rockall score >=
3. We separated subjects into two comparator groups based on whether they received
endoscopy “very early” (<=6 hrs) or “early” (6-24 hrs). The primary outcome measure was
any adverse outcomes (re-bleeding, need for surgery, mortality, readmission within 30 days
of ANVUGIB). The secondary outcomes include the length of hospital stay, and receiving
a blood transfusion more than 24h following the initial endoscopy. Results: 221 patients
with a clinical Rockall score >=3 underwent endoscopy within 24 hours of presentation.
Of these high risk patients, 79 had “very early” endoscopy whereas 142 underwent “early”
endoscopy. There were no significant differences in the baseline characteristics between the
comparator groups. Patients receiving “very early” endoscopy were significantly more likely
to have undergone endoscopic hemostasis (50% “very early” vs. 36% “early, p=0.01). There
were no differences in the incidence of adverse outcomes (25% vs. 22%, p>.0.2). Patients
undergoing “very early” endoscopy were significantly more like to have a hospital stay
exceeding 5 days (64% “very early” vs. 49%, p=.032). Conclusion: There is no difference
in the rate of adverse outcomes in high risk ANVUGIB patients who undergo “very early”
endoscopy and “early’ endoscopy, though patients receiving “very early” endoscopy are more
likely to require both endoscopic hemostasis and longer stays in hospital. The optimal timing
of endoscopy within first 24 hours should be confirmed in well designed randomized
controlled trial setting.
827
The Predictive Value of Admission Hematocrit in Patients Hospitalized with
Acute Upper and Lower Gastrointestinal Bleeding (GIB)
Richard A. Del Rio, Richard C. Wong, Layla Hajjafar, Gregory S. Cooper
Background: The ability of admission hematocrit (HCT) to help identify those patients at
risk of death from acute GIB is unclear. Aims: 1) To compare the in-hospital mortality rate
of patients with different admission HCT values; and 2) To determine if admission HCT is
an independent predictor of mortality. Methods: A retrospective cohort study was performed
using 7,909 patients hospitalized with the primary diagnosis of acute GIB. In-hospital
mortality rates were compared for patients with lower versus higher admission HCT for
specific values: 10, 15, 20, 25, 30, 35, and 40%. A multivariate logistic regression model
was performed to determine if admission HCT was an independent predictor of mortality
after adjusting for: age, sex, race, admission pulse and blood pressure, admission platelet
count and prothrombin time, history of GIB, and comorbidities (diabetes, CAD, cirrhosis
and chronic renal failure). Results: In-hospital mortality rate was 3.3% for all GIB, 3.7%
for upper GIB, and 1.8% for lower GIB. For all GI bleed, low HCT was an independent
predictor of mortality for values less than 25%, with the risk of death ranging from 19%
higher for HCT < 25% to 69% higher for HCT < 10% (Table). HCT values of 30, 35 and
40% were not significant predictors of mortality (data not shown). Similar results were
found when evaluating upper and lower GI bleed separately (Table). Other predictors of
mortality were age, gender, admission pulse and blood pressure, prothrombin time and
comorbidities. Conclusion: An admission hematocrit value of less than 25% appears to be
an independent predictor of in-hospital mortality and can be used with other known
predictors to help identify patients at risk for poor outcomes.
In-Hospital Patient Mortality Rate for Different Admission HCT Values
HCT = admission hematocrit; NP = no patients in group; OR = odds ratio; CI = confid-
ence interval
828
Characterization and Regulation of the 5'-Flanking Region of the Human
Anion Exchanger SLC26A6
Seema Saksena, Alka Dwivedi, Ravinder K. Gill, Ayesha Zaheer, Atul Goel, Jaleh
Malakooti, Waddah A. Alrefai, Krishnamurthy Ramaswamy, Pradeep K. Dudeja
SLC26A6 (Putative Anion Transporter 1), a member of the SLC26 anion transport gene
family, is one of the candidate proteins for the luminal Cl-/HCO3- (OH-) exchange process
in the human intestine. However, almost nothing is known about the molecular mechanisms
involved in the transcriptional regulation of SLC26A6 gene expression in the intestine.
Current studies were, therefore, undertaken to clone and characterize the 5'-regulatory region
of the human SLC26A6 gene as well as determine the mechanisms involved in its regulation.
The SLC26A6 promoter region was cloned by PCR method utilizing human genomic DNA
as a template and specific primers designed from the Human Genome sequence. A 1,095
bp (-964/+156) SLC26A6 promoter fragment was cloned upstream to the luciferase reporter
gene in pGL2-Basic and luciferase reporter gene assays were performed in transiently trans-
fected Caco2 cells. This promoter fragment (-964/+156) exhibited high promoter activity
when transfected in Caco2 cells. Progressive deletions of the 5'-flanking region from p-714/
+156 to p-214/+156 did not alter the promoter activity. However, further deletion to p-44/
+156 resulted in a drastic decrease in promoter activity, indicating that -214/-44 region of
the promoter harbors cis-acting elements important for maximal SL26A6 promoter activity.
Sequence analysis of this region revealed the presence of a number of cis-regulatory elements
including Sp1, AP2, MZF1, NF-Y (nuclear factor Y), GC box elements, CCAAT motif and
ATF (activating transcription factor). Since, diarrhea associated with inflammatory bowel
disease is attributed to increased secretion of pro-inflammatory cytokines, we next examined
the effects of IFNg on SLC26A6 promoter activity. Transiently transfected Caco2 cells were
treated with IFNg (30 ng/ml) for 24 h and luciferase assays were performed 48h post-
transfection. IFNg significantly repressed SLC26A6 promoter activity by 52±1.8%. In parallel,
real time PCR studies showed that the relative abundance of SLC26A6 mRNA was also
decreased (47±0.1%) in response to IFNg treatment. Conclusion: Our studies for the first
time report the characterization of the human SLC26A6 promoter region and the importance
of cis-regulatory elements in -214/-44 promoter region required for maximal SLC26A6
promoter activity. Our results also demonstrate the inhibitory role of IFNg on SLC26A6
expression. These findings are of significant importance for an understanding of the transcrip-
tional regulation of SLC26A6 with respect to its expression in the human intestine.
829
Down-Regulated in Adenoma (DRA, SLC26A3) Cl-/HCO3- Exchanger Is a
Major Contributor to Basal and cAMP-Stimulated HCO3- Secretion Across
Murine Duodenum
Nancy M. Walker, Janet E. Simpson, Clifford W. Schweinfest, Lane L. Clarke
Previous pH stat studies measuring HCO3- secretion across murine duodenum have proposed
that basal secretion results from the activity of apical membrane Cl-/HCO3- exchangers
whereas most (> 80%) cAMP-stimulated secretion is mediated by a CFTR-dependent HCO3-
conductance (Clarke and Harline, Am. J. Physiol., 1998, Spiegel, et al., Am. J. Physiol., 2003).
The latter conclusion was primarily drawn from experiments showing that cAMP-stimulated
HCO3- secretion is unaffected by removal of luminal Cl- to inhibit apical membrane Cl-/
HCO3- exchange. However, recent studies of recombinant CFTR indicate that CFTR anion
permeability may be altered by changes in extracellular Cl- concentration (Shcheynikov, et
al., J. Biol. Chem., 2004). Therefore, in pH stat studies, we investigated the role of the
apical membrane anion exchange during basal and cAMP-stimulated HCO3- secretion in
physiological (Cl- containing) solutions using duodena from mice with gene-targeted deletion
of DRA (Slc26a3). Under basal conditions, the rate of HCO3- secretion (Jsm) across DRA(-
) duodenum was reduced 82% relative to that in DRA(+) littermate duodenum [Jsm DRA(-
) = 0.4 ± 0.1 vs. DRA(+) = 2.2 ± 0.2 µeq/cm>2-h, p < 0.05, n = 7-10) whereas the short-
circuit current (Isc) in DRA(-) duodenum was significantly greater than in DRA(+) duodenum
[Isc DRA(-) = -2.2 ± 0.3 vs. DRA(+) = -0.5 ± 0.1 µeq/cm>2-h, p < 0.05]. During cAMP
stimulation with 10 µM forskolin, Jsm across the DRA(-) duodenum was reduced by 42%
relative to the DRA(+) duodenum [cAMP ΔJsm DRA(-) = 0.8 ± 0.1 vs. DRA(+) = 1.4 ± 0.1
µeq/cm>2-h, p < 0.05, n = 7 - 10] whereas the ΔIsc was not different [cAMP ΔIsc DRA(-
) = 6.6 ± 0.7 vs. DRA(+) = 7.0 ± 0.4 µeq/cm>2-h, ns, n = 7 - 10]. In experiments where
T : 89386$$CH2
05-04-06 23:18:25 Page 123Layout: 89386B : o
A-123 AGA Abstracts
luminal Cl- was removed, the magnitude of cAMP-stimulated HCO3- secretion increased in
the DRA(-) duodenum to a level equivalent with the DRA(+) duodenum [cAMP ΔJsm DRA(-
) = 1.2 ± 0.1 vs. DRA(+) = 1.2 ± 0.1 µeq/cm>2-h, ns; cAMP ΔIsc DRA(-) = 15.0 ± 2.1 vs.
DRA(+) = 13.6 ± 1.0 µeq/cm>2-h, ns, n = 3]. It was concluded from these data that under
physiological conditions, Slc26a3 (DRA) contributes ~80% of basal HCO3- secretion and
~40% of cAMP-stimulated HCO3- secretion. The remaining 60% of cAMP-stimulated HCO3-
secretion is apparently mediated by a CFTR-dependent HCO3- conductance which carries
a HCO3- current that is ~12% of the Isc, i.e., approximately equal to HCO3-:Cl- permeability
ratio of CFTR. Removal of luminal Cl- apparently normalizes the rate of cAMP-stimulated
HCO3- secretion across the DRA(-) duodenum by increasing the contribution of the CFTR-
dependent HCO3- conductance. Supported by NIDDK and CFF.
830
Intestinal Impactions and Altered cAMP-Stimulated Anion Secretion Across
Murine Proximal Colon of Nbc1 Na+-HCO3- Cotransporter Knockout Mice
Lara R. Gawenis, Gary E. Shull
Cyclic AMP-stimulated anion secretion in the colon is dependent on apical CFTR and
basolateral anion uptake proteins. The NKCC1 Na+-K+-2Cl- cotransporter mediates bulk
basolateral Cl- uptake, and anion exchanger 2 (AE2) is required for normal transepithelial
Cl- and HCO3- secretion. Along with other Na+-HCO3- cotransporters, basolateral NBC1 is
believed to participate in HCO3- uptake during cAMP-stimulated secretion. To test the
hypothesis that NBC1 supports transepithelial anion secretion, mice lacking NBC1 were
prepared and short-circuit current (Isc) responses to cAMPi were measured in muscle-stripped
proximal colon mounted in Ussing chambers. NBC1 null mutant [NBC1(-)] mice exhibited
high mortality with no survival beyond 25 days, severe growth retardation, splenomegaly, and
intestinal impactions. Surprisingly, the cAMP-induced increase in Isc was sharply increased in
NBC1(-) proximal colon (ΔIsc WT = -187.3 ± 58.3 vs. NBC1(-) = -396.4 ± 27.3 μA/cm2;
n = 5; p<0.005). In addition, similar to findings in AE2(-) proximal colon, the Isc response
to cAMP in NBC1(-) proximal colon exhibited increased bumetanide sensitivity (increased
NKCC1 activity; ΔIsc WT = 45.5 ± 11.0 vs. NBC1(-) = 117.2 ± 6.7 μA/cm2; n = 5; p<0.0006).
There were no significant changes in Isc response to the distilbene derivative SITS or the
residual (post-bumetanide and SITS) cAMP-stimulated Isc in NBC1(-) proximal colon. How-
ever, the Isc response to amiloride [epithelial Na+-channel (ENaC) activity] was enhanced
in NBC1(-) proximal colon (ΔIsc WT = 4.3 ± 2.6 vs. NBC1(-) = 20.2 ± 3.3 μA/cm2; n = 5;
p<0.007) and distal colon (ΔIsc WT = 47.4 ± 6.6 vs. NBC1(-) = 124.6 ± 11.8 μA/cm2; n =
5; p<0.0004). We conclude that the intestinal impactions in mice lacking NBC1 may
result from increased Na+ absorption via ENaC, while anion secretion may be enhanced to
compensate for the imbalance between absorption and secretion by increased NKCC1 activity.
Current studies are focused on anion substitution experiments and measurement of HCO3-
secretion to determine if disruption of NBC1 specifically alters net transepithelial HCO3-
secretion. Supported by NIDDK.
831
Differential Activation of the CFTR Hco3- Conductance By Forskolin and
Genistein in Murine Duodenum
Biguang Tuo, Ursula Seidler
Background & Aims: It has been shown that the Cl- and HCO3- conductance of the CFTR
anion channel can be selectively activated (Reddy et al, Nature 2004), and that severe forms
of cystic fibrosis have mutations that affects their HCO3- conductance, whereas mutations
which only have a reduced Cl- conductance have a milder phenotype (Choi, et al. Nature
20001). Targeting the CFTR HCO3- conductance, if possible, may therefore be of great
therapeutic benefit. The flavonoid genistein is known to activate normal and mutant CFTR
and has been evaluated in clinical trials. In the present study, we examined the effects of
genistein on duodenal HCO3- and Cl- secretion. Methods: Murine duodenal mucosal HCO3-
and Cl- secretions were examined in vitro in Ussing chambers by the pH stat and short
circuit current (Isc) techniques. Results: Genistein markedly stimulated duodenal HCO3-
secretion and Isc in a dose-dependent manner. Neither cAMP-dependent inhibitors,
MDL12330A and H89, nor Ca2+ channel blocker, verapamil, and nor cGMP-dependent
inhibitor NS2028 had effect on the action of genistein in duodenum. But, in the CFTR null
mice, genistein had no effects on duodenal HCO3- secretion and Isc. After addition of
genistein, HCO3- secretion increased 157.79%, and Isc increased 224.09%, whereas, after
addition of forskolin, an activator of adenylate cyclase, HCO3- secretion increased 196.00%,
and Isc increased 604.65%. In Cl--free solutions, HCO3--free solutions, and both HCO3--
and Cl-- free solutions, genistein-induced Iscs were reduced by 41.86%, 48.27%, and
89.75%, respectively, whereas forskolin-induced Isc was reduced by 69.23%, 18.75%, and
90.89%, respectively. Conclusion: Genistein-stimulated duodenal HCO3- and Cl- secretion
occurs via an activation of the CFTR anion channel, but at equipotent concentrations, the
relative percentage of HCO3- in the anion secretory response is much larger for genistein
than the cAMP-dependent agonist forskolin. This opens the potential for selective drug
targeting of the CFTR HCO3- conductance response is much larger. Genistein has a relatively
high selectivity to CFTR HCO3- conductance.
832
Epithelial Extracellular Carbonic Anhydrases Facilitate Disposal of Luminal
Acid As CO2 in Rat Duodenal Mucosa
Misa Mizumori, Yasutada Akiba, Tetsu Takeuchi, Caudiu T. Supuran, Paul H. Guth, Eli
Engel, Jonathan D. Kaunitz
In the duodenum, large amounts of concentrated HCl mix with secreted HCO3-. The
subsequent neutralization of H+ generates CO2 > 500 Torr, which dissipates in the jejunum,
implying that the duodenum absorbs almost all secreted gastric acid and its neutralization
products. The mechanism of this high throughput acid disposal, though essential for body

















is facilitated by extracellular ecto-CA isoforms. We thus examined the effect of novel cell-
impermeant, specific ecto-CA inhibitors on CO2 diffusion and HCO3- secretion in rat duo-
denum. Rat duodena were perfused with different pH and p CO2 solutions with or without
the cell-impermeant benzene sulfonamide CA inhibitors (CAI6a and CAI14v, 0.1μ M), or
cell-permeant CA inhibitor methazolamide (MTZ, 1 mM). Flow-through pH and p CO2
electrodes simultaneously and continuously measured perfusate and effluent pH and p CO2.
Portal venous (PV) pCO2 and pH were analyzed at the end of the luminal challenge.
Furthermore, a 13C-labeled high CO2 solution (pH 6.4, pCO2 260 Torr) was perfused
through duodenal loop, with measurement of PV 13C/12C. Luminal perfusion with a high
CO2 solution (pCO2 = 260 Torr) increased net CO2 loss from the perfusate compared with
controls (pH 6.4 saline, pCO2 ≈ 0) accompanied by portal venous (PV) acidification and
pCO2 increase, but with no change of PV total [CO2]. Impermeant CA inhibitors abolished
perfusate net CO2 loss, but increased apparent HCO3- secretion, whereas all inhibitors
inhibited PV acidification and pCO2 increase. Furthermore, net CO2 loss during perfusion
of a buffer equilibrated with 30% CO2 (pH 6.5) was delayed by impermeant CA inhibitors
and was abolished by MTZ. Perfused 13CO2 was significantly increased in PV 10 min after
the challenge with the increased pCO2 and decreased pH in PV, inhibited by all inhibitors.
H+ and CO2 loss from the perfusate were accompanied by increases of PV H+ and tracer
CO2, but unchanged PV total CO2, consistent with transmucosal net H+ and tracer CO2
movement, which was inhibited by impermeant CA inhibitors. Inhibition of extracellular
CA augments HCO3- secretion, normally obscured by high luminal [CO2]. The duodenum
absorbs luminal acid by neutralization with secreted HCO3- to CO2, absorption of CO2,
cytosolic conversion of CO2 to H+ and transport of cellular H+ to the subepithelium and to
the PV. Thus, the duodenum, like red cell, absorbs H+ as CO2 with constant CA-mediated
interconversions between CO2 and HCO3-.
833
Role of Intracellular Ca2+ in 5-Hydroxytryptamine (5-HT)-Mediated Duodenal
Mucosal Bicarbonate Secretion
Hui Dong, Anders Smith, Alfred Chappell, Kim E. Barrett
Background & Aim: In previous studies, we have shown that 5-HT likely regulates duodenal
mucosal bicarbonate secretion (DMBS) via Ca2+-and cAMP-dependent pathways. However,
little is currently known about whether and whereby 5-HT is involved in acid-stimulated
DMBS. Thus, the aims of the present study were to demonstrate the physiological relevance
of 5-HT in acid-induced DMBS, and to further elucidate the role of the Ca2+ signaling
pathway in this process. Methods: short-circuit current (Isc) and bicarbonate secretion across
the murine duodenal mucosa were measured. Acid-stimulated 5-HT release from duodenum
in vitro was assessed by immunoassay, and acid-stimulated DMBS in vivo was measured
using a CO2-sensitive electrode. Cytosolic Ca2+ measurements and siRNA knockdown were
also applied to study the 5-HT-mediated Ca2+ signaling pathway further. Results: Acid
significantly increased duodenal mucosal release of 5-HT from the basal level of 6.4 ± 0.8
pmol/mg tissue (pH 7.4) to 16.8 ± 1.6, 14.9 ± 1.4 and 16.1 ± 2.2 pmol/mg tissue (pH 3,
4, 5; n=5, P<0.01). SB204070, a selective 5-HT4 receptor antagonist, reduced luminal acid-
stimulated net peak HCO3- secretion in vivo from the control group of 14.8 ± 3.1 μmol/
cm.h to 7.0 ± 2.4 or 1.5 ± 0.5 μmol/cm.h in mice treated with 5 or 10 mg/kg SB204070
(n=5, P<0.05 or P<0.01), respectively. 5-HT-inducded Isc and DMBS in vitro were abolished
by removal of extracellular Ca2+,and significantly attenuated by KB-R7943 (10 μM, a selective
inhibitor for the reversed mode of Na+/Ca2+ exchanger (NCX)), thapsigargin (10 μM, a
selective inhibitor of the endoplasmic reticulum (ER) Ca2+ ATPase), 2-APB(100 μM, a
permeable inhibitor of IP3 receptors), TRAM-34 (10 μM, a selective inhibitor of intermediate
Ca2+-activated K+ channels (IKCa)) or glybenclamide (300 μM, an inhibitor of the cystic
fibrosis transmembrane conductance regulator (CFTR)). The expression and function of
NCX proteins in SCBN cells, a well-characterized nontransformed duodenal epithelial crypt
cell line, were confirmed by Western blot analysis and digital Ca2+ imaging. 5-HT directly
increased intracellular Ca2+ concentration in SCBN cells and knockdown of NCX1 proteins
with a specific siRNA greatly decreased 5-HT-mediated Ca2+ signaling. Conclusions: 5-HT
released from the duodenal mucosa in response to acid stimulation may act on 5-HT4
receptors located on epithelial cells. Activation of 5-HT4 receptors induces both intracellular
Ca2+ release from the ER and extracellular Ca2+ entry via the reversed mode of plasma
membrane NCX. An increase in intracellular Ca2+ may activate basolateral IKCa and thereby
stimulate DMBS through apical CFTR channels.
834
The P38 Mitogen-Activated Protein Kinase Regulates Epidermal Growth Factor
Receptor Down Regulation
Mark R. Frey, Rebecca S. Dise, Karen L. Edelblum, D. Brent Polk
We have previously shown that epidermal growth factor (EGF)-stimulated young adult
mouse colon (YAMC) cell restitution requires p38 mitogen-activated protein kinase (MAPK),
and we have proposed that p38 acts as a molecular switch determining whether EGF receptor
(R) ligand exposure leads to cell migration or proliferation. Interestingly, p38 alters activation
of other EGF-stimulated signaling modules such as ERK MAPK. Therefore, this study tests
the hypothesis that p38 influences EGFR expression or activation. METHODS: YAMC cells
were given EGF with or without p38-directed pharmacological inhibitors or siRNA. EGFR
and the EGFR-directed ubiquitin ligase Cbl were immunoprecipitated from cell lysates
and subjected to Western blot analysis with antibodies specific for EGFR, Cbl, ubiquitin,
phosphotyrosine, and individual EGFR phosphosites. Subcellular EGFR localization was
determined by laser scanning confocal microscopy. Site specific EGFR mutants were
expressed in EGFR-/- mouse colon epithelial cells. RESULTS: The typical near-complete
(>90%) down regulation of EGFR from YAMC cells after 4 h EGF exposure was blocked
by p38 inhibition. Preserved EGFR retained elevated tyrosine phosphorylation, indicating
sustained activity. In addition, depletion of p38 from the cells led to accumulation of EGFR
over a 72 h period. Pretreatment with cycloheximide showed that p38 does not regulate
EGFR downregulation by altering new receptor synthesis. Instead, EGF-induced activation
of the ubiquitin ligase Cbl and subsequent ubiquitination of EGFR were impaired by p38
blockade. Pretreatment of cells with p38 kinase inhibitor completely blocked EGF-induced
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Cbl phosphorylation despite robust activation of EGFR and other targets such as ERK MAPK.
EGF-driven phosphorylation of EGFR on Tyr 1045, a regulatory site for Cbl activation, was
also prevented by p38 blockade, while phosphorylation of other specific tyrosines was not.
Mutation of EGFR to Y1045F recapitulated the effects of p38 inhibition in that EGF-
stimulated migration but not proliferation was lost, identifying this tyrosine on EGFR as a
key target of p38 signaling. Finally, immunolocalization of preserved EGFR revealed that
in the absence of p38 activity, ligand-stimulated EGFR internalizes properly but accumulates
in intracellular vesicles which stain for caveolin-1 and the early endosome marker EEA1.
CONCLUSIONS: Our data show that p38 regulates Cbl-mediated EGFR down regulation
and vesicular sorting after ligand binding. These novel results position p38 as a modulator
of ligand-stimulated EGFR processing and demonstrate that this processing has a profound
impact on the cellular outcome of EGFR signaling.
835
Adaptation Following Massive Small Bowel Resection Requires Math1
Dependent Intestinal Secretory Lineages
Noah F. Shroyer, Michael A. Helmrath, Vincent Y. Wang, Susan J. Henning, Huda Y.
Zoghbi
Background: Small bowel resection (SBR) is a frequent surgical therapy for inflammatory
bowel disease and necrotizing enterocolitis. Following SBR, the intestine adapts by increasing
villus height and crypt depth. We hypothesized that intestinal secretory cells mediate this
adaptive response. Math1 (Mouse atonal homolog 1; Atoh1) is a basic helix-loop-helix
transcription factor essential for formation of Paneth, goblet, and enteroendocrine cells.
Thus, we studied the adaptive response to SBR in mice that lack Math1 in the intestinal
epithelium. Methods: We used the cre/loxP system to generate intestine-specific Math1-
ablated mice (Math1Δintestine, a cross between Math1 flox and Fabpl4xat-132-cre mice). 50%
SBR (N=38) or transection and re-anastamosis (sham operation, N=25) was performed on
Math1Δintestine and wild type littermate male mice. Following a BrdU pulse, distal ileum
and proximal jejunum were collected for histology 12 hours, 36 hours, 7 days, and 28 days
following surgery. Proliferation, apoptosis, cell number, and linear depth of crypts were
measured on tissue sections. Results: Math1Δintestine mice showed 75-90% deletion of
Math1 in the distal ileum, cecum, and colon. Due to their clonal nature, crypts in Math1Δintes-
tine mice were either wild type or Math1-ablated (lacking secretory cells), whereas villi were
polyclonal showing mixed wild type and Math1-ablated epithelium. Math1Δintestine mice
tolerated the surgery well, with no significant increased mortality after 28 days. Adaptation
following SBR, as measured by crypt depth and changes in proliferation, was significantly
blunted in Math1-ablated crypts compared to adjacent wild type crypts or to crypts from
wild type littermates (p<0.01). Higher than normal proliferation was observed in unoperated
and sham operated Math1-ablated crypts. However, increased proliferation following SBR
(as seen in wild type crypts) was not observed in Math1-ablated crypts. Apoptosis was
unchanged between genotypes. Conclusions: We observed defective adaptation following
SBR in crypts deficient for Math1. Following SBR, Math1-ablated crypts did not increase
linear depth whereas adjacent wild type crypts lengthened, indicating the adaptive signal
was present in SBR treated Math1Δintestine mice. Baseline proliferation in untreated Math1-
ablated crypts was somewhat increased, but this level of proliferation did not increase after
SBR as in wild type crypts. Thus, we conclude that the blunted response to SBR in Math1-
ablated crypts is due to lack of increased proliferation. Our results implicate Math1-dependent
secretory lineages in modulating intestinal homeostasis.
836
Epidermal Growth Factor Stimulates Rac1 Activation in Intestinal Epithelial
Cells Through SRC and PI 3-Kinase to Promote Cell Migration
Rebecca S. Dise, D. Brent Polk
Disruption of the epithelial lining of the gastrointestinal tract initiates rapid epithelial cell
migration from the wound margins to restore epithelial integrity. We have shown that
treatment of young adult mouse colon (YAMC) epithelial cells with epidermal growth factor
(EGF) stimulates wound closure. This study tests the hypothesis that EGF activates Rac, a
member of the Rho family of small GTPases which regulate migration and differentiation
in vivo, to stimulate increased lamellipodia formation and cell migration. Circular wounds
were made in confluent monolayers of YAMC cells and the percent wound closure was
measured by time-lapse microscopy. Lamellipodia formation and Rac membrane translocation
were analyzed in wounded cells using Rac immunofluorescence staining and phase-contrast
microscopy. Rac activation was assessed using a GST fusion protein that recognizes only
active, GTP-bound Rac followed by Western blot analysis for Rac. EGF treatment of wounded
YAMC cells stimulated an increase in lamellipodial extensions and Rac membrane transloca-
tion at the wound margin (p<0.001). EGF stimulated wound closure in YAMC cells was
completely inhibited by both a Rac inhibitor and Rac1 siRNA, confirming that Rac activation
is required for EGF stimulated wound closure. Active, GTP-bound Rac was detected in
YAMC cell lysates within 30 seconds after EGF treatment until 6 minutes after treatment.
EGF receptor (EGFR)-/- mouse colon epithelial (MCE) cells derived from the EGFR knockout
mouse failed to activate Rac or stimulate migration in response to EGF treatment. Stable
transfection of EGFR-/- MCE cells with wild type EGFR restored EGF stimulated Rac activation
and wound closure in these cells, but kinase dead EGFR expression did not, demonstrating
a requirement for EGFR kinase activity. A MEK 1/2 inhibitor, U0126, had no effect on
Rac activation or migration, while two different PI 3-Kinase inhibitors, LY294002 and
Wortmannin, inhibited EGF stimulated Rac activation, lamellipodia formation, and migration.
Expression of dominant negative Akt in YAMC cells did not inhibit Rac activation, demonstrat-
ing that activation of Akt by PI 3-Kinase is not required. Three different Src inhibitors,
CGP77675, PP1, and PP2, inhibited EGF stimulated Rac activation, wound closure, and
lamellipodia formation. Treatment of YAMC cells with both LY294002 and CGP77675
ablated Rac activation, suggesting that these kinases work in parallel to activate Rac. These
data demonstrate a novel pathway in which EGF activates the small GTPase Rac through
two different kinase cascades to promote wound closure in intestinal epithelial cells.
837
Insulin-Like Growth Factor-1 Is Essential for Intestinal Growth in Response to
Glucagon-Like Peptide-2 in Mice
Philip E. Dube, Catherine L. Forse, Patricia L. Brubaker
BACKGROUND & AIMS: Glucagon-like peptide-2 (GLP-2) is an intestinal hormone that
stimulates intestinal growth through unknown paracrine pathways. We have previously
demonstrated that GLP-2 regulates intestinal insulin-like growth factor-1 (IGF-1) secretion
in vitro and IGF-1 mRNA transcript expression in vivo. We therefore investigated the role
of IGF-1 and the related hormone, IGF-2, as mediators of GLP-2-enhanced mucosal growth
in the murine small and large intestine. METHODS: Intestinal growth was assessed in wild-
type (Igf1+/+ and Igf2+), heterozygous (Igf1+/-) and null (Igf1-/- and Igf2-P) mice treated with
saline (control, n=6-12), GLP-2 (n=7-13) or IGF-1 (n=3-6) for 10 days, followed by measure-
ments of intestinal weight, crypt depth, villus height, mucosal cross-sectional area, prolifera-
tion and mRNA expression. RESULTS: Igf1+/+ mice responded to GLP-2 treatment with
increased small and large intestinal weight (131±7% and 138±12% of control, P<.001 and
.01, respectively), with concomitant increases in crypt depth in the jejunum and colon
(P<.05 - .001), villus height in the jejunum and ileum (P<.001) and proliferative indices in
the jejunum (P<.05 - .001). In contrast, Igf1-/- mice did not respond to GLP-2 with respect
to either small or large intestinal weights (110±9% and 108±8% of control, P>.05) or the
other measures of intestinal growth, while Igf1+/- mice demonstrated an intermediate response.
Expression of jejunal mRNA transcripts for the GLP-2 receptor and proglucagon were
unaffected by genotype or treatment with GLP-2. Igf2+ mice responded to GLP-2 with
increased small intestinal weight (128±8% of control, P<.05), crypt depth in the jejunum
and colon (P<.05), and villus height (P<.01), mucosal area (P<0.05) and proliferative indices
(P<.05 - .01) in the jejunum. Igf2-P mice responded to GLP-2 with increased small intestinal
weight (115±5% of control, P<.05), crypt depth in the colon (P<.01), and villus height in
the jejunum (P<0.05), but did not respond with increased mucosal cross-sectional area or
proliferative indices. Furthermore, the increase in small intestinal weight in Igf2-P mice was
significantly smaller than that observed in Igf2+ mice when normalized for body weight
(P<.05). Both Igf1-/- and Igf2-P mice demonstrated normal to enhanced intestinal growth in
response to chronic administration of IGF-1, compared to wild-type controls. CONCLU-
SIONS: IGF-1 is essential for small and large intestinal growth in response to GLP-2, while
IGF-2 may be partially involved in the small intestinal growth responses. These findings
identify the IGF’s as important mediators of the intestinotropic actions of GLP-2.
838
Lack of P21 (WAF1/CIP1) Enhances Intestinal Stem Cell Survival Following
Radiation Injury
Courtney W. Houchen, Mark A. Sturmoski, Randal May, Robert George, Brian
Dieckgraefe, Shrikant Anant
The transformation of a normal mucosal epithelial cell to an invasive colorectal carcinoma
occurs via a well-coordinated accumulation of mutations in a series of critical genes. The
time span between initiation and gross development of tumors creates an enormous challenge
in dissecting the critical molecular mechanisms that regulate neoplastic change. In the gut,
tumorigenesis arises specifically in the stem cell population located near the base of intestinal
and colonic crypts. Identifying and assaying resident intestinal stem cells is quite difficult,
because no definitive specific gut stem cell markers have been identified. However, the
microcolony assay following g-irradiation (IR) is by definition a functional assay of intestinal
stem cell fate and can provide a mechanism for examining the early events of tumorigenesis.
The cyclin-dependent kinase inhibitor p21 (Waf1/Cip1) plays an essential role in cell cycle
arrest following DNA damage. While the gene encoding p21 is rarely mutated in human
cancers, a variety of recent studies suggest a tumor suppressor function for p21. To explore
the role of p21 in the regulation of stem cell fate, we have examined the effects of p21
deletion on intestinal stem cell survival following IR and correlated these findings with
expression of the putative intestinal stem cell marker Msi-1. METHODS: Adult wild type(WT)
and p21-/- mice were exposed to 13 Gy g-IR. Crypt survival was measured 3.5 days later
using the microcolony assay. Crypt viability was confirmed by the presence of >5 S-phase
cells as measured by immunohistochemical detection of BrdUrd incorporation. Msi-1 and
p21 mRNA levels were determined by real time PCR. Cell specific expression Msi-1 and
p21 protein were determined by immunohistochemical analysis. RESULTS: Higher numbers
of surviving crypts (3.5 fold) were detected in p21-/- mice compared to WT littermates.
Msi-1 mRNA levels measured prior to IR in the small intestines of p21 -/- mice were elevated
2.1 fold compared to WT. Immunohistochemical analysis demonstrated increased Msi-1
protein expression in crypt epithelial cells in both wild type and p21-/- mice 3.5 days after
irradiation. CONCLUSIONS: Deletion of p21 in adult mice results in a 3.25 fold increase
in stem cell survival following radiation injury compared to WT littermates. These data
suggest that functional p21 promotes apoptosis in the stem cell population in response to
lethal doses of whole body IR. Furthermore p21 deletion results in a 2-fold increase in Msi-
1 expression in the crypt. These data provide additional evidence for a potential tumor
suppressor function of p21 on intestinal stem cells.
839
Small Intestinal Adaptation After Partial Enterectomy Is Impaired in Pparδ+/-
Mice
Lihua Wang, Qun Zheng, Deborah C. Rubin, Marc S. Levin
We have shown that retinoic acid (RA) stimulates intestinal adaptation following partial
small bowel resection (SBR) by stimulating crypt cell proliferation and by inhibiting apoptosis.
RA has been identified as a high affinity agonist of PPARδ. PPARs are nuclear receptors that
serve as sensors of nutritional stimuli and modulators of gene expression. Of the 3 mammalian
subtypes, PPARδ which is involved in peripheral lipid metabolism, is the most highly
expressed in the murine gut. Administration of a PPARδ agonist to APC +/min mice increased
small intestinal polyp size by inhibiting apoptosis (Nat Med 2004 10:245). These observations
suggest that the proadaptive effects of RA may be mediated via PPARδ. To address the role
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of PPARδ in adaptation, the response after SBR was compared in PPARδ+/- and PPARδ+/+
(WT) mice. PPARδ+/- mice were used due to the reduced viability of PPARδ-/- mice. Methods:
C57BL/6 WT (n=26) and PPARδ+/- mice (n=24 gift of R. Evans, Salk Inst.) underwent 50%
SBR or shamresection. At 7 d post-op the adaptive response was assessed in the remnant
gut by quantitation of crypt depths, villus lengths, crypt cell apoptosis (detection of activated
caspase 3) and proliferation (5BrdU incorporation). Results: There were no significant
differences between shamresected PPARδ+/- and WT mice. After SBR, PPARδ+/- mice compared
to WT mice tended to have reduced crypt depths and villi length in the jejunum and ileum,
though the differences were not significant. However, the relative adaptive changes (i.e.,
resected versus shamresected) were significantly increased in the ileum and jejunum of WT
mice, whereas the only significant increase in PPARδ+/- mice occurred in jejunal crypt
depths. Following SBR, PPARδ+/- compared to WT mice had significantly reduced crypt cell
proliferation in the jejunum and ileum and an increased apoptotic index in the ileum (p<
0.05). The fold-changes (resected vs shamresected) were also significantly different. After
SBR, enterocyte proliferation in the jejunum increased by 1.08 fold in resected PPARδ+/-
mice vs 1.32 fold in WT mice. In the ileum the changes were 1.15 fold vs 1.45 fold.
Apoptotic indices in jejunum increased by 2.13 fold in resected PPARδ+/- mice vs 1.83 fold
(p<0.05) for WT mice and in the ileum the changes were 4.25 fold vs 2.45 fold. Conclusion:
After partial enterectomy, PPARδ+/- mice exhibit increased crypt apoptosis and reduced
proliferation which result in a blunted morphologic adaptive response. These data suggest
that regulation of PPARδ target genes contributes to adaptation and are consistent with the
hypothesis that the proadaptive effects of RA may partly be mediated via this receptor.
840
Regulation of Macrophage TNF Production By MNK Kinases
Mark T. Worthington, Carol A. Chrestensen, Mary G. Harp, Robert Rowlett, Xiao Ming
Wang, Fabio Cominelli, Theresa T. Pizarro, Thomas W. Sturgill
Background: Tumor necrosis factor (TNF) is a pathogenic factor in inflammatory bowel
disease. In studies of TNF mRNA stability, we found that polyA tail binding PABP1 protein
blocked tristetraprolin-mediated TNF mRNA degradation and that PABP1 is a substrate for
the MNK1 kinase. Because MNK phosphorylation of the cap-protein eIF4E increases transla-
tion and nucleocytoplasmic transport of another AU-rich element containing mRNA (cyclin
D1), we explored the regulation of TNF by MNK in macrophages. Hypothesis: Both the
p38 and p42/ERK MAP kinase cascades are required for maximal TNF production. The
inducible MNK1 and the constitutive MNK2 kinases integrate p38 and ERK signals, although
whether the MNKs mediate TNF effects is unknown. We used the RAW264.7 macrophage
cell line and bone marrow-derived macrophages from wild-type and SAMPYit/Fc mice to
test this hypothesis. SAMPYit/Fc mice are a model of human Crohn’s Disease with spontan-
eous ileitis, perianal disease, and arthritis. Both MNK1 and MNK2 are inhibited by the drug
CGP57380 (CGP). Results: Using phosphospecific Western blotting, we found that eIF4E-
phosphorylation increases in response to LPS stimulation in RAW264.7 macrophages and
is completely suppressed by CGP, without changes in total eIF4E. CGP to 50 uM inhibited
RAW264.7 cell TNF production by ELISA in a dose-dependent fashion. Use of a commercial
panel of TLR pathway agonists with CGP to 50 uM revealed dose-dependent suppression
of TNF by ELISA induced by agonists for TLR2, TLR7, TLR9, TLR6/2, as well as TLR4
(LPS). At 50 uM, the drug repressed TNF by ELISA to 0.4% to 5.7% of that of control.
Mechanistic studies reveal that MNK inhibition sharply limits the pulse of TNF mRNA
production after LPS (by 18S rRNA-normalized real-time PCR) and that MNK inhibition
accelerates TNF mRNA decay (by actinomycin-inhibited 18S rRNA-normalized real-time
PCR), suggesting both nuclear and cytoplasmic effects of MNK. We were interested if this
is TNF-specific, or whether this extends to other IBD-relevant cytokines. Using a cytometric
bead array, CGP inhibits IL6, MCP1/CCL2, and IFNg after LPS stimulation. Interestingly,
we saw no IL-10 production with control or unstimulated CPG-treated cells, but elevation
of IL-10 in the 4 hour stimulated CPG-treated cells suggests that the overall effect of MNK
inhibition may be an anti-inflammatory, Th1-inhibited state. Finally, bone marrow-derived
macrophages from wild-type and SAMPYit/FC mice confirm that MNK inhibition has the
same effects on TNF production in native cells. Conclusion: MNK inhibitors are promising
agents for treating inflammatory diseases like IBD by targeting inflammatory cytokines.
841
Differential Chromatin Remodeling in Mucosal Diseases Modifies IFNG
Expression
Rivkah Gonsky, Richard L. Deem, Stephan R. Targan
IFN-γ plays an important role in the generation and perpetuation of mucosal inflammation
of inflammatory bowel disease. The goal of our studies is to identify mucosa-specific molecular
mechanisms involved in regulation of IFNG expression that represent potential targets for
selective attenuation of mucosal IFN-γ production. Previously, we identified mucosa-specific
CD2 cis-elements within the IFNG promoter. Differential IFNG expression may be controlled
epigenetically by chromatin remodeling through alterations in histone acetylation and DNA
methylation patterns. Histone hyperacetylation of cytokine promoters precedes transcrip-
tional activation and correlates with the hypomethylated status of the promoter. We hypothes-
ized that because LP T cells are inherently activated and poised in-vivo to secrete IFN-γ,
they would display a hyperacetylated and more hypomethylated profile than their PBL
counterparts. We evaluated the histone acetylation status of IFNG locus from -7.6 kb
upstream to +7.7 kb downstream using chromatin immunoprecipitation analysis. Selective
hyperacetylated histone H3 and H4 was revealed following CD2 signaling, in LPMC but
not in PBL, with a preference to regions surrounding the coding and downstream regions.
Likewise, a more pronounced augmentation of histone acetylation was seen in LPMC com-
pared to PBL following PMA/ionomycin activation. Pyrosequencing was used to examine
the CpG methylation status of the -295 to +171 bp IFNG sites in rested CD3+ PB or CD3+
LP T cells. LP T cells displayed a hypomethylated profile within the proximal promoter
region compared to PB T cells. No differences were detected in the downstream regions. The
hypomethylated profile was reflected in the disease phenotype with decreased methylation in
LP T cells from normal or Crohn’s mucosa compared with those of UC or PBL. These results

















acetylation and methylation of the IFNG promoter. Furthermore, the data suggests that
epigenetic modulation of IFNG may play a mechanistic role in disease phenotype and
enhanced secretion of IFN-γ in the mucosa.
Differential Hypomethylated Profile of IFNG Locus in IBD (p value)
ns, not significant
842
Ceacam1 N-Domain Mutation Found in An Ulcerative Colitis (UC) Patient
Affects Il2 Secretion
Mee Sook Park, Giulia Roda, Okebugwu Kamalu, Lloyd Mayer
Background - CEACAM1 (BGP) is a member of the CEA family of glycoproteins characterized
by its expression as a transmembrane molecule. This CEACAM family member is the only
one known to be expressed by lymphocytes and has been found on both LPLs and IELs.
The presence of a cytoplasmic ITIM and its ability to recruit the phosphatase SHP1 suggests
that this molecule might play a regulatory role in T cell activation. Previous studies from our
lab support the concept that CEACAM family members are important in immunoregulation in
the gut. Defects in expression or function could result in aberrant mucosal immune responses.
Methods - CEACAM1 specific primers were used to amplify cDNA derived from normal
and inflammatory bowel disease (IBD) LPL. The N domain of each PCR product was
sequenced and compared to the known sequence in the database. The mutation containing
PCR product was put into a plasmid vector. To separate out the mutation containing allelic
form, sequencing was carried out using DNA preparations of separate colonies from plasmid
transformed bacteria. The wild type (WT) and mutant DNAs were transfected into Jurkat
T cells. These cells were stimulated with Daudi cells and Staphylococcus enterotoxin E (SEE
25 ng/ml) with subsequent measurement of IL2 production by ELISA. Results - CEACAM1
was expressed equivalently on normal and IBD LPL, and minimally on peripheral blood T
cells. Three mutations (Q1->K1, A49->V49, Q89->H89) were found in a PCR product of
cDNA from a UC patient. This was verified by sequencing the PCR product of another
cDNA sample from the same patient. Sequencing DNA preparations of separate bacterial
colonies revealed that the three mutations were all on one allele. We then stably transfected
Jurkat cells with the mutant or wild type DNA. Cell growth (3H-thymidine uptake for 6
hours) of mutant and WT transfected cells were 15-25% and 120-150% of the vector
transfected cells, respectively. Upon stimulation with Daudi cells and SEE for 6 hours, IL-
2 production by the mutant transfectant was only 10-20% of the vector transfected control.
IL-2 production by WT transfected cells was similar to mutant transfectant despite 5-fold
higher CEACAM1 expression. Conclusion - LPL T cells are unique in their constitutive
CEACAM1 expression. The CEACAM1 mutation found in a UC patient results in markedly
reduced IL-2 production. Considering importance of IL-2 for regulatory T cell development
as well as immune activation, the relevance of this observation to the disease process remains
to be determined.
843
The Vegf-Vegf Receptor (VEGF-R) Pathway Is Up-Regulated and Mediates
Mucosal Angiogenesis in Human and Experimental Inflammatory Bowel
Disease (IBD)
Silvio Danese, Franco Scaldaferri, Cristina Graziani, Carol de la Motte, Egidio Stigliano,
Alessandro Sgambato, Riccardo Ricci, Achille Cittadini, Antonio Gasbarrini, Claudio
Fiocchi
A crucial component of several inflammatory conditions is pathological angiogenesis, a
process where the VEGF-VEGF-R pathway plays a key mediator role. We recently reported
that pathological angiogenesis occurs in IBD and represents a novel component of its
pathogenesis. Because essentially no information exists on the VEGF-VEGF-R pathway in
gut inflammation, we investigated its expression and activity in both human and experimental
IBD. The expression of VEGF-R1 and -R2 in colonic sections of control, Crohn’s disease
(CD) and ulcerative colitis (UC) mucosa was assessed by immunohistochemestry, and during
induction of dextran sodium sulfate (DSS) murine colitis (at day 3, 5, 7 and 10). VEGF
levels were quantified by immunoblotting in the same tissues. Using human intestinal
microvascular endothelial cell (HIMEC), the capacity of VEGF to induce cell migration was
tested in a transwell chemotaxis system, and to induce angiogenesis in a matrigel tubule
formation assay. VEGF-R1 expression levels were low and essentially equal in control, CD
and UC mucosa. Control healthy mice also displayed very low levels of VEGF-R1 and
expression did not change with the induction of DSS colitis. In contrast, VEGF-R2 was very
strongly up-regulated in both forms of IBD, and the same was true during the course of
DSS colitis, being particularly evident in newly formed submucosal small vessels. VEGF was
detected in normal human mucosa, and was significantly (p<0.05) higher in CD and UC.
Moreover, actively inflamed CD and UC contained significantly (p<0.05) more VEGF com-
pared to non-inflamed CD and UC tissues. Colitic mice also expressed higher (p<0.05)
VEGF mucosal content. Finally, VEGF contained in mucosal extracts was able to induce
HIMEC migration, a process specifically blocked by an anti-VEGF antibody. Recombinant
VEGF was a potent inducer of HIMEC tubule formation. The up-regulated expression of
VEGF-R2, the inducible form of VEGF-R, in both human and experimental IBD strongly
suggests the occurrence of active angiogenesis in the intestinal mucosa during inflammation.
In addition, VEGF is aberrantly over-expressed in the inflamed mucosa of IBD patients and
colitic mice. Taken together, these results point to a crucial contribution of the VEGF/VEGF-
R pathway to the pathological angiogenesis of IBD, and this pathway may represent a novel
target for therapeutic intervention.
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Intestinal Microsomal Triglyceride Transfer Protein (MTP) Regulates Cd1d
Function On the Intestinal Epithelium and Protects from Mortality in the
Oxazolone Model
Arthur Kaser, Masaru Yoshida, Glenn T. Furuta, Feilin A. Zhu, Nicholas O. Davidson,
Sean P. Colgan, Richard S. Blumberg
Introduction. CD1d is a MHC class I homolog expressed on myeloid cells, hepatocytes and
intestinal epithelial cells, and presents lipid antigens to natural killer T (NKT) cells. This
laboratory has previously shown that MTP regulates CD1d function. The in vivo function
of CD1d on the intestinal epithelium is not yet understood. Aim. To assess the role of MTP
and CD1d in the intestinal epithelium in vivo. Methods & Results. We crossed Mttpflox/
flox mice with a transgenic mouse expressing a tamoxifen-dependent Cre-recombinase
expressed under the control of the villin promotor. Administration of tamoxifen resulted in
efficient deletion of Mttp in the intestinal epithelium in the small and large bowel. Deletion
of Mttp resulted in decreased CD1d immunostaining in the epithelium, suggesting that in
the absence of ER-based lipid loading of CD1d by MTP, CD1d molecules are impaired in
their trafficking to the cell surface. Rectal administration of the colitis-inducing hapten
oxazolone resulted in 62.5% mortality within 48h in the MTP-deleted mice, while none of
the mice in the control groups died within an observation period of 5 days. Severe inflamma-
tion with prominent neutrophilic infiltration was observed at early time-points. Microarray
gene expression profiling at baseline and 6h after oxazolone administration showed upregul-
ation of neutrophil-chemotactic factors and mRNAs primarily expressed in neutrophils in
MTP-deleted mice compared to non-deleted littermates. Altogether, these data suggest that
MTP regulates a barrier-protective CD1d pathway in the intestinal epithelium. To investigate
the mechanistic basis of this protective function, we devised an in vitro reductionist system
using the mouse intestinal epithelial cell line MODE-K. Co-culture of the CD1d-restricted
NKT cell hybridoma 24.7 with MODE-K resulted in release of barrier-protective IL-10, but
no IL-12, into the supernatant in the presence of the model glycolipid alpha-galactosylceram-
ide, while replacing MODE-K with CD11c+ dendritic cells resulted in IL-12 induction, but
no IL-10 release. IL-10 and IL-12 release from MODE-K and dendritic cell co-cultures,
respectively, was abrogated by anti-CD1d antibody. Furthermore, silencing of IL-10 expres-
sion in MODE-K confirmed MODE-K cells as the source of IL-10 in the co-culture system.
Conclusions. In summary, these latter data implicate that a NKT cell is capable of inducing
retrograde signalling of CD1d in intestinal epithelial cells, specifically inducing a barrier-
protective transcriptional programme. These data propose a model whereby NKT cells
regulate a protective role of the intestinal epithelium via a CD1d/MTP pathway.
845
Identification of Inducible Intestinal B Cell Development Pathway Under
Inflammatory Condition
Yasuyo Shimomura, Atsuhiro Ogawa, Ken Sugimoto, Mayumi Kawada, Emiko Mizoguchi,
Atul K. Bhan, Atsushi Mizoguchi
Background: Intestinal inflammation elicits B cell lymphopoiesis that is often associated
with ectopic neolymphoid follicle formation. However, the pathway of intestinal B cell
development through this inducible lymphopoiesis has not yet been defined. Methods: For
the study of intestinal inflammation-induced B cell development in the colon, 4% dextran
sulfate sodium (DSS) in drinking water was administrated for 4 days and the treatment was
terminated by changing DSS water to normal water. Results: DSS-induced inflammation
elicits a polyclonal expansion of B cells in the colonic lamina propria (LP) during the recovery
(4 days after termination of DSS-treatment) but not acute (on-going DSS treatment) phase
of inflammation. Interestingly, the expanded B cells shares several functional and phenotypical
similarities with splenic immature transitional type B cells (T1/T2) and do not produced
immunoglobulins. Studies utilizing IL-7R knockout (KO) (absence of B2 but not B1 cells),
Rac2 KO (absence of marginal zone B cells) and Lyn KO (absence of follicular B cells) mice
suggest that the inducible intestinal B cells do not originate from B1 or mature follicular or
marginal zone B cells. In addition, B cell receptor (BCR) signaling cascade and T cell help
are not required for the inflammation-induced intestinal B cell expansion as indicated by a
marked expansion of intestinal B cells during the recovery but not acute phase of DSS-
inflammation in Btk KO mice (absence of a key molecule in BCR signaling cascade) and
monoclonal BCR mice (RAG KO mice crossed with hen egg-lysozome-specific BCR transgenic
mice) as well as TCRβδ double knockout mice (absence of T cells). Of note, inflammation-
induced intestinal B cell expansion can be induced even in the absence of both spleen and
gut-associated lymphoid tissues (splenectomized LTα KO mice). In addition, the inducible
B cell expansion unexpectedly results in formation of LTα-independent aberrant lymphoid
clusters that are anatomically and phenotypically distinguishable from resident lymphoid
follicle structures (such as colonic patches and isolated lymphoid follicles) within the intestinal
LP. The expanded B cells are subsequently maintained through BAFF-R (receptor of B-cell-
activating factor of the TNF family) signaling cascade capable of preventing the apoptosis.
Conclusion: We herein identify a novel pathway for inducible intestinal B cell development
associated with colitis. Importantly, the inducible B cells are characterized by BCR-independ-
ent “innate type” B2 (but not B1) phenotype.
846
Directed Expression of Salmonella Avra in Drosophila Melanogaster Reveals
Mechanistic Conservation of Innate Immune Repression
Rheinallt Jones, Andrew Neish
Background: Enteric pathogens such as Salmonella are important causes of food-borne
disease. Many bacterial pathogens influence host cell biology by utilization of preformed
effector proteins that are translocated into the cytoplasm of host cells during the initial
stages of infection. These effector proteins are thought to function by usurping eukaryotic
cellular processes for the benefit of the bacterial life cycle. We have shown S. typhimurium
effector AvrA has potent negative effects on the NF-kappaB/Rel pathway in mammalian
epithelial cell culture in vitro. Purpose: To evaluate cellular effects of this protein an intact
eukaryotic organism in vivo, we have employed a genetic model system in Drosophila. Flies
possess a well-studied anti-bacterial response exhibiting striking functional and structural
homology to human innate immune signaling systems, including NF-kappaB/Rel. Methods:
We generated transgenic Drosophila harboring the wild type AvrA gene from S. typhimurium,
as well as a version with point mutations in the AvrA catalytic core. The bacterial gene is
under transcriptional control of the yeast UAS promoter and can be expressed in a regulated
fashion in fly tissue using the bipartite Gal4/UAS expression system. Flies were routinely
challenged by microbial infection, which normally results in Rel protein translocation,
transcription of antimicrobial effectors and clearance of infection. Nuclear translocation of
Rel was detected by immunohistochemistry, anti-microbial gene activation assayed by qRT
PCR or reporter gene assay, and immune response determined by survival analysis. Apoptosis
was detected by an anti-caspase-3 antibody and by TUNEL staining. Results: We find that
expression of AvrA, while having no cytotoxic or pro-apoptotic effects, is a potent inhibitor
of NF-kappaB/Rel translocation and transcription of anti-microbial peptides. Expression of
AvrA also reduced the ability of bacterially challenged flies to carry out clearance of infection.
The catalytically inactive mutant AvrA had no effect in any of there assays, indicating
conservation of biochemical function. In further studies, no effects were found on the
MAPK pathways as determined using flies harboring lacZ under a MAPK specific promoter.
Conclusions: This data reveals that AvrA mediates a highly conserved and specific repression
of NF-kappaB/Rel without direct effects on cell survival. This system will allow future
forward genetic approaches to elucidate the biochemical function of this and potentially
other bacterial proteins.
847
Helicobacter Pylori Persistence and Disease Severity Is Modulated By the
Induction of Regulatory T-Cells
Rupert M. Kenefeck, Karen Robinson, John C. Atherton
Introduction: Helicobacter pylori (Hp), the major cause of peptic ulcer disease, provokes a
vigorous immune response. Despite this, however, most infections are persistent and show
highly variable levels of pathology. Regulatory T-cells (Tregs) are found in the Hp infected
human gastric mucosa and have been shown to reduce inflammation in animal models. We
hypothesize that regulatory T-cells are important in mediating the persistence of Hp infection
and modulating disease severity. Methods: Gastric antral biopsies were collected from sixty-
three consenting patients attending the Queen’s Medical Centre, Nottingham for an upper
GI tract endoscopy. Flow cytometry was used to quantify Tregs by staining for the markers
CD4 and CD25 and also interleukin-10 (IL-10). Expression of the natural Treg-specific gene
FOXP3 was quantified by real-time PCR. Results: Elevated frequencies of CD4+CD25hi
regulatory T-cells were detected in the gastric mucosa of Hp-infected compared with uninfec-
ted donors (p=0.04). A 12-fold higher frequency of CD4+CD25hiIL-10+ cells was found
amongst gastric cells from infected compared to uninfected donors (p=0.002). Up to 95%
of the gastric CD4+CD25hi cells from infected donors were IL-10+ (median 61.3%; IQR
32.2-83.3%), and the proportion of IL10+ Tregs was 18-fold greater than that obtained
with cells from uninfected donors (median 3.5%; IQR 0.0-24.3%; p=0.002), suggesting that
suppression of the normal T-cell response may be IL-10-mediated. Real-time PCR revealed
a 7-fold increase in FOXP3 expression in gastric tissues from infected compared to uninfected
donors (p=0.003), indicating the presence of natural Tregs during infection. Infected patients
were further divided into two groups, according to whether peptic ulcer disease (PUD) was
present or absent. The frequency of gastric CD4+CD25hiIL-10+ Tregs was significantly
elevated in those patients with a normal gastric mucosa (median 2263; IQR 1766-3636) as
compared to patients with PUD (median 946; IQR 524-2365; p=0.05). In addition FOXP3
transcript levels were also elevated 5 fold in patients without PUD indicating that natural Tregs
play an important role in the modulation of inflammatory disease (p=0.006). Conclusion: We
show that IL-10-secreting natural Tregs are present in the gastric mucosa of Hp-infected
patients and are inversely associated with disease severity. We propose that Tregs not only
impede the ability of the immune system to clear infection, but also modulate inflammation
and protect against peptic ulcer disease.
848
Salmonella Flagellin Acts As An Avirulence Factor and Limits Disease During
Enteric Infection in Vivo
Matam Vijay-Kumar, Huixia Wu, Andrew T. Gewirtz, Andrew Neish
Background: Flagellin, the primary component of bacterial flagella, is a potent activator of
inflammatory signaling. We had previously demonstrated that viable aflagellate Salmonella
were unable to induce proinflammatory signaling pathways or gene expression in in vitro
models, suggesting flagellin is a major proinflammatory determinant of enteropathogenic
Salmonella. Purpose: The goal of this study was to evaluate the role of flagellin as a pathogenic
determinant in in vivo infection. Methods: We utilized the recently developed streptomycin
pretreatment murine model of enteric Salmonellosis. Mice were pretreated with 7.5 mg of
streptomycin orally and 24 h later were orally inoculated with 108 CFU of Salmonella
typhimurium (SL3201), an isogenic aflagellate mutant (fliC-/fliB-), or left uninfected. Blood
was collected at 6, 12, 24, and 48 hr and assayed by ELISA for serum IL-1 and IL-6.
Intestinal tissues were harvested at the same times and evaluated by morphology (H and
E), histochemistry (myeloperoxidase) and immunohistochemistry (active caspase 3). Rat
IEC-6 cells were cocultured with the same bacterial strains and apoptosis quantified with
fluorescent caspase staining and TUNEL. Transcript levels of anti-apoptotic proteins (IAPs)
were measured by qRT-PCR. Results: Consistent with previous in vitro data, aflagellate
Salmonella mutants were initially impaired (6-12 hrs) in their ability to upregulate mucosal
and systemic inflammatory marker molecules and elicited markedly reduced mucosal inflam-
mation relative to the isogenic WT parent strain. However, these aflagellate bacteria caused
markedly exacerbated mucosal inflammation at the later stages of infection (24 and 48
hours) and ultimately a more severe clinical course. These phenomena correlated with
increased activation of epithelial caspases and subsequent apoptosis. The aflagellate Salmon-
ella also induced strikingly more intense and rapid caspase and apoptotic activation in
cultured IEC-6 cells relative to the wild type strain. Aflagellate Salmonella induced signific-
antly less IAP gene expression both in vivo and in vitro. Conclusions: These observations
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indicate that in Salmonella infection, flagellin plays a dominant role in activation of not
only innate immunity but also anti-apoptotic/survival pathways in epithelial cells, controlling
caspase activation and thus protecting the host from greater damage. In this situation,
flagellin intriguingly acts as an avirulence factor. This notion is consistent with the emerging
paradigm that specific TLR ligands may have a fundamental cytoprotective effect during
inflammatory stress.
849
Gp96 Is a Colonocyte Plasma Membrane Binding Protein for Clostridium
Difficile Toxin A
Xi Na, Ho Kim, Charalabos Pothoulakis, J. Thomas Lamont
Background & Aims: Clostridium difficile (C. difficile) Toxin A (TxA) is a key mediator of
antibiotic-associated colitis in human, causing fluid secretion, epithelial necrosis, and acute
inflammation. TxA requires binding to a cell surface receptor prior to internalization, but
the human receptor for TxA has not been identified. The aim of this study was to identify
novel plasma membrane binding proteins for TxA and to characterize their role in the TxA-
mediated inflammatory cascade in colonocytes. Methods: TxA was coupled with biotin and
cross-linked to the surface of HT29 human colon cancer cells. The main colonocyte binding
protein for TxA was identified as glycoprotein 96 (Gp96) by co-immunoprecipitation and
mass spectrum analysis. The interaction between Gp96 and TxA was further confirmed by
fluorescence immunostaining and in vitro co-immunoprecipitation. Cell binding and round-
ing assays were used to access Gp96 antibody and silencer Gp96 effects on TxA-mediated
attachment and cytotoxicity to human colonocytes. Gp96-deficient B cells (E4.126), generated
by a frameshift mutagen and wild-type parental cells were used to further delineate the role
of Gp96 in TxA mediated signaling. Results: The major TxA binding protein on HT29 cells
was Gp96, a member of the heat shock protein family. In resting HT29 cells, this protein
is expressed on the cell surfaces as well as in the cytoplasm. Following TxA binding, the
TxA- Gp96 complex was translocated from the cell membrane to the cytoplasm. Pretreatment
with Gp96 antibody decreased TxA binding to colonocytes and inhibited TxA-induced cell
rounding. SiRNA directed against Gp96 reduced Gp96 expression and cytotoxicity in HT29
cells. TxA-induced inflammatory signaling via P38 and apoptosis as measured by activation
of caspase 3 and DNA fragmentation were decreased in Gp96 deficient cells. Conclusions:
Human colonocyte Gp96 serves as a plasma membrane binding protein that facilitates cellular
entry of the toxin, and participates in cellular signaling events in the inflammatory cascade.
Heat shock proteins are chaperone proteins expressed in the endoplasmic reticulum and
plasma membrane that bind to proteins, preserve their correct folding. Our data indicate
that C. difficile TxA exploits Gp96 as a membrane receptor/co-receptor that facilitates its
entry to the cytoplasm.
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Decay Accelerating Factor (DAF) Is a Cellular Receptor for Helicobacter Pylori
Daniel P. O'Brien, Uma Krishna, Judith Romero-Gallo, John Nedrud, M E. Medof, Feng
Lin, Raymond Redline, Douglas M. Lublin, Bogdan J. Nowicki, Dawn Israel, Aime T.
Franco, Richard M. Peek
Persistent gastritis induced by Helicobacter pylori is the strongest known risk factor for peptic
ulcer disease and distal gastric adenocarcinoma. H. pylori induces the activation of NF-κB,
and a downstream effect of NF-κB activation is up-regulation of the gene encoding decay-
accelerating factor (DAF). DAF exhibits at least two distinct roles within epithelial cells;
protecting cells from complement-mediated lysis, and functioning as a receptor for several
microbial pathogens. Adherence of H. pylori to gastric epithelial cells is critical for induction
of inflammation and injury. We therefore, hypothesized that H. pylori uses DAF as a receptor
which contributes to pathogenesis. Methods: Chinese hamster ovary (CHO) cells stably
transfected with full-length human DAF, individual complement control protein (CCP)
domain deletion constructs, or vector control were co-cultured with H. pylori, and adherence
was assessed by quantitative culture and immunofluorescence. MKN28 gastric epithelial
cells were co-cultured with H. pylori strain J166 and isogenic mutants. DAF expression was
measured by quantitative real-time RT-PCR, Western immunoblotting, and immunofluoresc-
ence. C57/BL6 wild-type (WT) (n=14) and DAF knockout mice (n=13) were infected with
the rodent-adapted H. pylori strain SS1 or broth alone and sacrificed 8 weeks post-challenge.
Colonization density was determined by quantitative culture and inflammation was scored
from 0-4. Results: H. pylori adhered more efficiently to CHO cells expressing DAF (12 fold)
versus vector alone. Adherence to DAF by a population of clinical H. pylori isolates indicated
that affinity varies between strains. Studies performed using DAF domain deletion constructs
indicated that DAF CCP domains 1, 2, and 3 are essential for H. pylori adherence and
deletion of CCP-4 reduced binding by 70%. Co-culture of H. pylori with gastric epithelial
cells induced the expression of DAF, and induction was dependant upon a functional cag
PAI. In a mouse model of DAF deficiency, H. pylori colonized WT (n=10) and Daf1-/- (n=
9) mice equally; however, the intensity of inflammation was significantly attenuated in H.
pylori-infected Daf1-/- versus WT mice (p=0.013). Conclusion: These results indicate that
H. pylori uses DAF as a cellular receptor. Co-culture of H. pylori with gastric epithelial cells
induces the expression of DAF in a cag PAI-dependent manner, indicating that cag+ bacteria
may have increased pathogenicity due in part to the induction of DAF as a receptor. H.
pylori-induced inflammation is significantly attenuated in Daf1-/- mice, indicating that DAF


















Viable Bacteria Versus DNA Extracts As Anti-Inflammatory Agents in Crohn’s
Disease
Monica Carol, Marta Llopis, Maria Antolin, Cristina Martinez, Natalia Borruel, Francesc
Casellas, Francisco Guarner, Juan-Ramon Malagelada
Background: Other investigators described an immunomodulatory effect of DNA extracts
from probiotic bacteria via TLR-9 in animal models and cellular lines. Our group reported
a potent anti-inflammatory effect of viable Lactobacillus casei DN-114 001 in ileal tissue from
Crohn’s disease patients. Aim: To compare the effect of viable L. casei versus bacterial DNA
in inflamed ileal mucosa from Crohn’s disease patients. Material and methods: Explants of
ileal mucosa (20-30 mg) from 4 patients with Crohn’s disease were incubated for 18h with
viable Lactobacillus casei (L. casei, 10E6 CFU/mL), DNA extracts from specific bacterial strains
(5 µg/mL), including L. casei (Lc-DNA), Bifidobacterium longum (Bl-DNA), and Bifidobacterium
brevis (Bb-DNA), or medium alone (blank). Each condition was run in triplicate (n=12).
Tissue viability (LDH) and pH of the culture media were monitored; TNF-a levels and
recovery of bacteria were assessed in the supernatant at the end of the incubation period.
The following additional cytokines: IL-1b, IL-2, IL-6, IFN-g, IL-13, IL-4, IL-5, IL-10 were
analyzed in L. casei, Lc-DNA and blank conditions. Results: Tissue incubation with viable
L. casei and Bl-DNA significantly decreased TNF-a concentration in the supernatant, but
Lc-DNA and Bb-DNA did not induce significant changes (blank: 194.7±43.5; L. casei:
27.9±15.7*; Lc-DNA: 69.4±16.1; Bl-DNA: 32.6±8.2*; Bb-DNA: 71.8±40.6; results are mean
± sem in ng/mL, *p<0.05 v.s. blank). Likewise, levels of IL-1b, IL-2, IL-6, and IFN-g were
significantly decreased by viable L. casei but not by Lc-DNA. On the other hand, IL-13, IL-
4, IL-5 and IL-10 were significantly stimulated by both viable L. casei and Lc-DNA. Conclu-
sion: DNA extract form Lactobacillus casei increases the level of antiinflammatory cytokines
in Crohn’s disease mucosa, but the inhibitory effect of the viable bacteria on Th1 cytokines
is not reproduced by the DNA extract.
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Inhibition of Telomerase By Mutant Template Telomerase RNA and Anti-
Telomerase Sirna Induces ALT in Immortalized Human Esophageal Epithelial
Cells
Michaela Doebele, Alexander von Werder, Christine Fulda, Steffen Heeg, Gitta Goessel,
Michael Quante, Hideki Harada, Yasir Suliman, Shang Li, Elizabeth H. Blackburn, Hubert
E. Blum, Oliver G. Opitz
Introduction: Immortalization is an important step in the malignant transformation of human
cells. Telomere maintenance is essential for immortalization. Immortalized cells maintain
their telomeres either through activation of the ribonucleoprotein enzyme telomerase, which
contains an intrinsic template RNA moiety (human telomerase RNA; hTER) and the core
protein (human telomerase reverse transcriptase) or through utilization of a recombination
based alternative mechanism (ALT). Little is known about the regulation and coexistence
of these two mechanisms in a single cell. Previously, we could demonstrate that the induction
of the respective telomere maintenance mechanism is dependent on cell-cycle kinetics. Now
we investigated, whether immortalized cells can switch from one mechanism to the other
applying specific genetic telomerase inhibitors. Methods: Cyclin-D1 (EPC-D1) or hTERT
(EPC-hTERT) overexpressing cells were generated by retroviral transduction of normal
human esophageal epithelial cells (EPC). Furthermore, these cells were transduced with
mutated versions of hTER (MT-hTER/AU5, MT-hTER/47A), anti-hTER siRNA or a combina-
tion of both using lentiviral gene transfer. Transduced cells were sorted by GFP-coexpression
and their growth characteristics, telomerase activity (TRAP-assay), telomere length (PFGE-
TRF) and indirect immunofluorescence (APBs) were assayed. Results: Overexpression of
MT-hTER, siRNA and the combination of both rapidly inhibits cell growth in immortalized
human esophageal epithelial cells, in contrast to cells transduced with control vectors. A
reduction in telomerase activity could be observed whereas the control cells showed a robust
activity. TRF analysis revealed heterogeneous telomeres in MT-hTER, siRNA- and MT-hTER
plus siRNA-cells, which is characteristic for ALT. In contrast, the control cells displayed
stable and homogeneous telomeres correlating with a high level of telomerase activity. In
indirect immunofluorescence ALT-associated PML bodies (APBs) could be observed in a
higher frequency in telomerase(hTER)-inhibited cells. Summary: Genetically defined immor-
talized human esophageal epithelial cells are capable to elongate their telomeres using both
telomere maintenance mechanisms, namely ALT or telomerase activation. In our telomerase-
positive cell populations ALT could be induced by the inhibition of telomerase using a
lentiviral delivery system of mutant template telomerase RNA and anti-telomerase short-
interfering RNA. These findings suggest that immortalized cells like cancer cells treated with
telomerase inhibitors as potential anti-cancer strategy might find alternative ways to maintain
their telomeres.
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Hypoxia Inducible Factor 1α Regulates Insulin-Like Growth Factor Binding
Protein-3 Function in Esophageal Epithelial Cells
Munenori Takaoka, Mangatt P. Biju, Claudia D. Andl, Takaomi Okawa, Carmen Z.
Michaylira, Daniel C. Chung, Volker H. Haase, Hiroshi Nakagawa
Introduction: Insulin-like growth factor (IGF) binding protein-3 (IGFBP-3), a key regulator
of IGF bioactivity, is induced by cellular stresses such as growth factor deprivation and
hypoxia. In normoxia, epidermal growth factor (EGF) potently represses IGFBP-3 mRNA
transcription through the Ras-MAPK signaling pathway, while IGFBP-3 protein translation
depends upon the PI3K-AKT-mTOR pathway (Takaoka M et al. Am J Physiol. In press).
However, it remains unclear how IGFBP-3 is regulated by hypoxia in esophageal epithelial
cells. Methods: Immortalized human esophageal cells were exposed to hypoxia (0.2-1%
O2). Cells were retrovirally transduced with wild-type (WT) and dominant-negative (DN)
hypoxia inducible factor (HIF) 1α. Small interfering RNA (siRNA) directed against HIF1α
was stably transfected. Gene expression was determined by real-time RT-PCR and Western
blotting. Pharmacological inhibitors were used to dissect the signaling pathways involved.
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The eukaryotic initiation factor complex was analyzed by the m7GTP Cap-binding assay.
Results: IGFBP-3 mRNA and protein were robustly induced by hypoxia as well as cobalt
chloride (CoCl2), an inhibitor of oxygen-dependent proteasomal degradation of HIFs, with
concomitant induction of HIF1α in esophageal cells. When WT-HIF1α was ectopically
expressed and stabilized by hypoxia or CoCl2 in normoxia, induction of mRNA and protein
for IGFBP-3 and carbonic anhydrase 9 (CA9), a HIF1α specific target gene, were enhanced
(2 to 5-fold) compared with control cells. By contrast, DN-HIF1α and HIF1α siRNA inhibited
IGFBP-3 and CA9 expression by 80-90%. Interestingly, EGF failed to fully inhibit HIF1α-
mediated induction of IGFBP-3. Hypoxia suppressed p44/42 MAPK activity. Moreover,
inhibition of MAPK by U0126 (MEK1/2 inhibitor) or growth factor deprivation greatly
enhanced hypoxia-dependent induction of IGFBP-3. While LY294002 (PI3K inhibitor) inhib-
ited IGFBP-3 in both hypoxia and normoxia, rapamycin (mTOR inhibitor) appeared to be
less efficient to inhibit IGFBP-3 in hypoxia. In concert with this, the m7GTP pull-down
assay revealed an increased physical association of eukaryotic initiation factor 4E with its
inhibitor 4E-BP1 in hypoxia compared with normoxia, implying a reduction in rapamycin-
sensitive (i.e. cap-dependent) translation under a hypoxic condition. Conclusions: In hyp-
oxia, HIF1α plays a critical role in IGFBP-3 induction. Unlike growth factor deprivation,
hypoxia may employ cap-independent translation. These novel findings have important
implications in how epithelial cells respond to cellular stress during infection, injury and
transformation.
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Reprimo Methylation Is a Potential Early Biomarker of Barrett’s-Associated
Neoplastic Progression
James P. Hamilton, Fumiaki Sato, Bruce D. Greenwald, Tetsuo Ito, Yuriko Mori, Bogdan
C. Paun, Takatsugu Kan, Yulan Cheng, Suna Wang, Carmite Mantzur, John M. Abraham,
Stephen J. Meltzer
Background: Reprimo, a novel tumor suppressor gene, regulates p53-mediated cell cylce
arrest at the G2 phase of the cell cycle. Accordingly, our aim was to determine the level of
Reprimo methylation in normal, premalignant, and malignant human esophageal tissues.
Methods: 161 tissue specimens were obtained during endoscopy. Real-time methylation-
specific PCR (MSP) for Reprimo was performed using an ABI7700 (Taqman) system. Eso-
phageal cancer cell lines were incubated per protocol. 5 mM 5-Aza-deoxycytidine (5-Aza-
dC) was added every 24 hours for 6 days. Cells were harvested for DNA/RNA extraction
on days 0,2,4, and 6. RT-PCR and MSP was performed using a Taqman. Results: In both
Barrett’s (BE) and esophageal adenocarcinoma (ADCA), the level and frequency of Reprimo
methylation were significantly greater than in normal esophagus (NE) or esophageal squam-
ous cell cancer (SCCA). There was no statistically significant difference between BE and
ADCA. In addition, in vitro demethylation with 5-Aza-dC resulted in enhanced mRNA
expression of Reprimo. Reprimo methylation was seen in 0 of 19 NE samples (mean MSP:
0.004), 6 (14%) of 44 SCCA (mean: 0.092; SCCA vs. NE, p=0.157), 8 (32%) of 25 cases
of BE (mean: 0.111; BE vs. NE, p=0.019), and 44 (60%) of 73 ADCA (mean: 0.214; ADCA
vs. NE, p=0.002; BE vs. ADCA, p = 0.09). 5-Aza-dC treatment of ADCA cell line OE33
resulted in reduced methylation of Reprimo (day 0 MSP: 1.2, day 6: 0.34), as well as increased
expression of Reprimo (day 0 mRNA: 0.0002, day 6: 0.002). ROC curve analysis of Reprimo
methylation in ADCA vs. NE revealed an area under the curve (AUROC) of 0.812. Conclu-
sions: Reprimo methylation occurs significantly more often in ADCA and BE than in NE or
SCCA, suggesting that this is a cell type-specific early event that shows potential as a
biomarker for early disease detection.
Reprimo Methylation
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Induction of COX-2 By Unconjugated Bile Acids Involves AP-1, CREB and
Reactive Oxygen Species-Mediated Signaling Pathways in Esophageal
Adenocarcinoma Cells
Shumei Song, Robert S. Bresalier
BACKGROUND: Bile reflux is thought to contribute to esophageal injury and neoplasia.
COX-2 is involved in both inflammation and carcinogenesis, and bile acids can increase
COX-2 expression. However, the mechanisms by which bile acids enhance COX-2 expression
are largely unknown. AIMS: Determine the molecular mechanisms that govern COX-2
regulation by bile acids in esophageal adenocarcinoma (EA) cells. METHODS: Immunoblot-
ting and transient transfection were used to assess the effects of bile acids on COX-2
expression and transcription in SEG-1 EA cells. Specific pharmacological inhibitors, dominant
negative (DN) mutant constructs and SiRNA inhibition techniques were used to identify the
signaling pathways involved. Flow cytometry and reactive oxygen species (ROS) scavengers
N-acetyl cystene and sodium formate were used to examine ROS involvement. RESULTS:
Chenodeoxycholic acid (CD) and deoxycholic acid (DC), but not conjugated bile acids,
were strong activators of COX-2 expression. Increased phosphorylation of AKT and mitogen-
activated protein kinase1/2 occurred in unconjugated bile acid-treated cells but not in
conjugated bile acid- treated cells. A DN AKT mutant, LY294002 a PI3K inhibitor, and
UO126, an inhibitor of MAPK blocked induction of COX-2 by CD and DC. Furthermore,
AP-1 protein and activity were increased by CD and DC, and a CMV-driven DN AP-1 vector
decreased COX-2 transcription. Phosphorylation of CREB was strongly increased by CD
and DC, and inhibitors of AKT and MAKP blocked CREB phosphorylation induced by CD
and DC. Silencing of CREB by SiRNA inhibited COX-2 expression. Induction of COX-2
and phosphorylation of CERB were also blocked by reactive oxygen species scanvengers
N-acetyl cystene and sodium formate. CONCLUSION: These data suggest that dihydoxy
unconjugated bile acids in GE refluxate contribute to COX-2 induction via pathways involving
AP-1 and CREB and ROS-mediated activation of phosphatidylinositol 3-kinase and mitogen-
activated protein kinase1/2. This may explain, in part, the mechanisms by which bile acids
contribute to tumorigenesis in the esophagus.
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Stepwise Endoscopic Resection of the Whole Barrett’s Esophagus in Patients
with Early Neoplasia Effectively Removes All Genetic Alterations from the
Esophageal Epithelium
Femke P. Peters, Jantine W. van Baal, Agnieszka M. Rygiel, Wouter L. Curvers, Wilda D.
Rosmolen, Paul Fockens, Fiebo J. Ten Kate, Kausilia K. Krishnadath, Jacques J. Bergman
Background & Aims Malignant transformation of Barrett’s esophagus (BE) is associated with
several genetic events that accumulate as the mucosa becomes dysplastic and develops into
adenocarcinoma. Stepwise radical endoscopic resection (SRER) of BE with high grade intra-
epithelial neoplasia (HGIN) or early cancer (EC) is a promising new treatment for BE, which
results in complete re-epithelialization of the resected area with neo-squamous epithelium.
However, it is not known whether SRER eradicates pre-existing genetic abnormalities. The
aim of this study was to prospectively evaluate whether genetic abnormalities as found
before SRER are effectively eradicated and absent in the neo-squamous epithelium. Patients
& Methods Nine consecutive BE patients with HGIN or EC who underwent SRER were
included in this study. Immunohistochemistry (IHC) for assessing proliferation (Ki-67) and
p53 over-expression, and DNA Fluorescent In Situ Hybridization (FISH) were performed
on endoscopic resection (ER) specimens of the BE and on biopsies of the neo-squamous
epithelium taken during follow up. DNA-FISH was performed to determine aneusomy with
centromeric probes for chromosomes 1 and 9 , and with locus specific probes for assessing
loss of the tumor suppressor genes p16 and p53. FISH results were blindly scored by two
experts. A minimum of 100 nuclei were scored for each DNA-FISH probe. Lymphocytes in
the ER-specimens were used as controls. Results Nine pts were included (3 HGIN, 6 EC).
FISH results showed that all pts had genetic alterations in their ER specimens. All pts showed
hyperploidy for chromosome 1 and 5 pts for chromosome 9. Four had loss of chromosome
9. Loss of p16 was seen in 7 patients, while 8 patients proved to have loss of p53. IHC
results showed that 7 pts had intense p53 nuclear staining in 100% of cells, indicating p53
mutations, while 2 pts were negative for p53. All pts had Ki-67 positive surface epithelium,
indicating an increased proliferation index. In contrary to these pre-treatment findings, all
post-treatment biopsy specimens showed a normal diploid signal count for all DNA-FISH
probes. Furthermore, in all neo-squamous cases normal IHC staining for Ki-67 and negative
staining for P53 was seen. Conclusions Stepwise radical endoscopic resection of the complete
Barrett’s esophagus with early neoplasia successfully eradicates pre-existing genetic abnormal-
ities such as aneusomy and loss of p16 and p53 and results in neo-squamous epithelium
without these genetic abnormalities. This research is financially supported by AstraZeneca
BV The Netherlands.
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New Establishment of Diagnostic Algorithm of Esophageal Cancer and High
Sensitivity Oligo Chip
Yutaka Shimada, Tetsuo Ito, E.J. Tanaka, Motoshige Higashiyama, Atsushi Itami, Go
Watanabe, Takatsugu Kan, Fumiaki Sato, Shigemi Matsumoto, Shin'ichi Miyamoto,
Michihide Mitsumori, Masashi Kadowaki, Gozoh Tsujimoto, Hideo Akiyama, Akira
Myomoto, Osamu Nomura, Hitoshi Nobumasa
Purpose: We have reported that microarray can detect the difference between squamous
cell carcinoma and adenocarcinoma (BBRC 2001), prognosis of esophageal cancer (BBRC
2001) and prediction of lymph-node metastasis (Ann Surge Oncol 2004). However, in order
to perform tailor-made therapy, the sensitivity of the microarray was inadequate for a biopsy
sample. Here we established the algorithm of diagnosis of esophageal cancer, prediction of
lymph-node metastasis and prediction of chemo-radiation sensitivity using an ultra sensitive
oligo chip. Material and Method: First, we identified esophageal cancer related genes from
about 30,000 genes using 100 selected esophageal cancer samples. Secondly, gene expression
was normalized by locally weighted scatter plot smooth (LOWESS) and evaluated by support
vector machine (SVM) and several bio-informatic analyses. Thirdly, we evaluated 39 biopsy
samples by these machines. Fourthly, we tried to predict lymph- node metastasis and chemo-
radiation sensitivity using the samples which were diagnosed by cancer detection machine.
Finally, we successfully established an ultra sensitive oligo chip by nanotechnology, and re-
evaluated the samples. Results: We selected 22 genes for diagnosis esophageal cancer and
17 genes were newly identified. Accuracy for cancer diagnosis of conventional oligo-chip
was 95% and ultra sensitive oligo-chip was 100% in learning samples. We also selected 95
genes for prediction of lymph- node metastasis and the accuracy for prediction of lymph-
node was 86% in learning samples and 68% in biopsy samples. Preliminary evaluation of
the accuracy for chemo-radiation was 71%. The sensitivity of our new chip is 100 times
more than previous chips and the minimum sample requirement for examination was 0.1μg
of total RNA. Conclusion: This technology is able to diagnose esophageal cancer, prediction
of lymph-node metastasis and prediction of chemo-radiation-sensitivity using biopsy samples
without gene amplification. Thus, this technology may be useful for performing tailor-made
therapy to esophageal cancer patients.
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Regional Differences in Serotonergic Activity in the Mucosa of the Human
Stomach and Duodenum
Niels Van Lelyveld, Jose Ter Linde, Marguerite Schipper, Melvin Samsom
Background & Aims: The serotonergic system plays an essential role in gastrointestinal
motility and sensitivity. In the current study, enteroendocrine (EE) cells, enterochromaffin
(EC) cells, and the mRNA levels of several genes encoding components of the serotonergic
system were determined in the fundus, antrum, and duodenum. We anticipated that this
would elucidate the molecular basis and understanding of the role of serotonin (5-HT) in
normal gastroduodenal function. Methods: Mucosal biopsy specimens were collected from
the fundus, antrum, and duodenum of 11 healthy subjects. EE cells (chromogranin immuno-
reactive) and EC cells (5-HT immunoreactive) were counted and the mRNA levels of TPH-
1 (rate-limiting enzyme of 5-HT synthesis), SERT (5-HT transporter), the 5-HT4 receptor,
and the 5-HT3(C) and 5-HT3(E) receptor subunits were quantified by real time RT-PCR.
Results: The number of EE and EC cells was larger in the duodenum compared to the
stomach (all P < 0.001), however comparable between the antrum and the fundus. The
percentage of enteroendocrine cells that were EC cells was larger in the duodenum compared
to the fundus (P = 0.008), however comparable between duodenum and antrum and between
antrum and fundus. In spite of a larger number of EC cells and a larger fraction of EC cells
in the duodenum, TPH-1 expression in the duodenum was lower compared to the antrum
and fundus (P = 0.017 and P < 0.001 respectively). The expression of SERT was higher in
the duodenum compared to the antrum (P < 0.001), and higher in the antrum compared
to the fundus (P < 0.001). The relative differences of TPH-1 expression (duodenum versus
antrum and fundus: -2.3 and -3.6 respectively) were, although significant, much smaller
than the relative differences in SERT expression (duodenum vs antrum and fundus: 19.1
and 457 respectively). The 5-HT4 receptor, the 5-HT3(C), and 5-HT3(E) receptor subunits
were more abundantly expressed in the duodenum compared to the stomach (all P < 0.001),
whereas no differences were found between antrum and fundus. Conclusions: 5-HT synthesis
(TPH-1 expression) and 5-HT uptake capacity (SERT expression) do not coincide. 5-HT
synthesis varies only marginally between the three regions, whereas the uptake capacity of
5-HT differs tremendously. The higher expression of 5-HT3 and 5-HT4 receptors, and in
particularly the higher uptake capacity of 5-HT, suggests a larger 5-HT release in the
duodenum, and consequently points to a more prominent role of serotonergic signalling at
the mucosal level in the duodenum compared to the stomach.
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Role of PYLORIC Pressures and Botulinum Toxin (BT) Injection in the
Treatment of Diabetic (DM) and Idiopathic Gastroparesis (IG)
Katerina Shetler, Linda Anh B. Nguyen, Stephen Bunker, Shelly Parker, William J. Snape
Background: Pylorospasm (basal pyloric pressures >10mmHg; Mearin et al. Gastro 1986)
has been implicated in gastroparesis. BT injection into the pylorus has been suggested to
reduce symptoms and improve gastric emptying in patients with gastroparesis. It is unclear
whether pyloric pressures correlate with gastric emptying. Aims: 1)Correlate baseline pyloric
pressures with gastric scintigraphy(GET) in patients with DM and IG. 2)Determine the effect
of BT injection on GET in patients with DM and IG. Patients and Methods: 35 patients [(19
DM, age 41.3±10.3 years) and (16 IG, age 48.8±13.1)] had pyloric manometry and GET.
17 of these patients were treated with BT injection into the pylorus and had follow up GET.
Delayed gastric emptying was defined as gastric retention > 60% at 2 hours or > 10% at 4
hours. Pyloric manometry was done during upper endoscopy by marking the pylorus with
a hemoclip. A Dent Sleeve was placed across the pylorus using fluoroscopic guidance. The
amplitude of the tonic and phasic contractions were measured using the intragastric pressure
as a zero point. 100 U of BT was injected into the pyloric sphincter in patients with elevated
pyloric pressures. Results: The 4hr GET was higher for DM (49.9±21.0 %) than for IG
(33.9±24.6%), p <0.05. The mean basal pyloric pressure was similar in patients with DM
(15.4±13.5 mmHg) and IG (13.8±7.7 mmHg). Baseline pyloric pressures were elevated
above a normal pressure of >10 mmHg in 11(57.9%) patients with DM and in 10(62.5%)
patients with IG. Correlation between baseline pyloric pressure and 4 hour GET was assessed
using a linear regression analysis. The baseline pyloric pressure correlated poorly with 4
hour GET in both groups (DM: r=-0.012, p=0.48 and IG: r= 0.07, p=0.4). Of the patients
who received BT, there was no difference in basal pyloric pressures (DM=20.4±5.1 mmHg
vs. IG=13.8±2.6 mmHg, p=0.26) Repeat GET was done after a mean follow up period of
31.4±7.2days (range: 2-120 d). GET did not change after BT injection in the DM group(4hr:
66.8±8.4% to 76.8±11.5% ,p= 0.48 and 2hr: 44.6±7.6% to 53.6±12.2%, p=0.054). There
was a trend toward improved GET in the IG group but it was not statistically significant
(60.3±6.1% to 50.5±7.8% at 2 hours,p=0.34; 27.8±5.9% to 14.3±7.7% at 4 hours, p=0.18).
Conclusions: 1)Pylorospasm is present in approximately 60% of patients with gastroparesis.
2)There is no correlation between basal pyloric pressures and gastric emptying. This suggests
that other factors affect gastric emptying, especially in the DM group. It would be important
to correlate antral activity, pyloric pressures and GET, especially in those patients who do
not respond to BT.
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The Role of the Dopamine-3 Receptor in the Regulation of Gastric Motility
Purna C. Kashyap, Maria-Adelaide Micci, Pankaj Jay Pasricha
Background: Enteric neuronal dopamine (DA) inhibits acetylcholine release and gastric
motility; this effect has traditionally been thought to be mediated via neuronal D2 receptors
(D2R) and the role of newly discovered dopamine receptors such as D3 and D4 has not
been explored. The aim of this study was to investigate the modulation of gastric motility
by the D3 receptor (D3R). Methods: Adult rat Sprague-Dawley rats were used in the study.
D3R expression was measured in pyloric protein extracts by Western blotting. Pyloric
relaxation in response to electrical field stimulation (EFS) was assessed in an organ bath in
the presence of varying concentrations of a selective D3R agonist (PD 128907 hydrochloride

















after feeding a non-nutrient methylcellulose meal to rats treated with varying doses of PD
128907 hydrochloride (0.2, 0.5 or 1 mg/kg i.p.) or DA (1 mg/kg) with and without a
selective D3R antagonist (nafadotride 0.1 or 1 mg/kg i.p.). Control rats were treated with
vehicle only (PBS). Results: Western blot analysis confirmed the presence of D3R in the
rat pylorus. The D3R agonist PD 128907 significantly (P=0.01) reduced EFS-induced relaxa-
tion of pyloric strips in an organ bath. This effect was dose dependent, showing a greater
decrease in relaxation with increasing doses of D3R agonists (1 μM vs control, P<0.05; 10
μM vs control, P=0.001). Gastric emptying was also significantly delayed in rats injected
with the D3R agonist in a dose-dependent fashion as compared to vehicle (D3R agonist 0.5
mg/kg vs vehicle, P<0.05; 1 mg/kg vs vehicle, P<0.001 by one-way ANOVA). The D3R
antagonist nafadotride partially reversed the effect of DA on gastric emptying. Conclusions:
Our data suggest a novel and important role for D3R in the regulation of gastric emptying.
D3R activation delays gastric emptying, an effect that may be due to impairment of pyloric
relaxation. D3R antagonists therefore hold the promise for being useful agents for the
treatment of gastric motility disorders.
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Slow and Rapid Liquid Nutrient Load Tests in Assessment of Proximal
Stomach Function in Healthy Subjects
Ke Zheng, Meiyun Ke, Zhifeng Wang
BACKGROUND: Liquid nutrient load test (LNLT) is a simple and convenient method to
evaluate the function of proximal stomach. However, there is no uniform standard for it,
especially in the intake rate. AIMS: To compare the rapid (intake rate 100ml/min) and slow
(intake rate 15ml/min) LNLT in order to find the most reasonable LNLT. METHODS: Forty
Healthy Subjects (HS M:F=1:1, average age 32.2±2.1yr, BMI 22.7±0.49kg/m2) received both
the rapid and slow intake rate of LNLT on two separate days. The caloric density of the
nutrient meal was 1kcal/ml (Carbohydrate 48%, Fat 39%, Protein 13%). The TVDRI (thresh-
old volume of drink) and MVDRI (maximal volume of drink) were recorded, and the
corresponding proximal stomach volume TVPS (threshold volume of proximal stomach) and
MVPS (maximal volume of proximal stomach) were measured by B-ultrasound. RESULTS: (1)
The results of two different LNLT were shown in table 1. (2) There were correlations between
TVDRI and TVPS (r=0.387, p<0.01; r=0.464, p<0.01), and between MVDR and MVPS (r=
0.645, p<0.01; r=0.782, p<0.01) in both slow and rapid LNLTs. (3) TVDRI and MVPS in
slow LNLT was significantly smaller than those in rapid LNLT (p<0.01), but MVDRI was
significantly bigger in slow LNLT than that in rapid LNLT (p<0.01). There was no difference
in TVPS between two different LNLTs (NS). (4) TVDRI was much closer to TVPS in slow
LNLT than in rapid LNLT. But MVDRI was much closer to MVPS in rapid LNLT than in
slow LNLT. (5) All the subjects completed the study and no severe side effects were presented.
CONCLUSIONS: Both slow and rapid LNLTs could be used to evaluate the accommodation
to a meal and visceral sensitivity of proximal stomach. The visceral sensitivity is related to
the accommodation function. TVDRI of slow LNLT is more sensitive in estimating the
visceral sensitivity of proximal stomach; MVDRI of rapid LNLT is more accurate in estimating
the accommodation of proximal stomach.
Table 1. Slow and rapid intake rate of LNLT
VS the rapid LNLT, *:P<0.01.
862
Gastroduodenal Motility Measured in Health and Disease During Transit of
An Ambulatory Capsule- Smartpill
Mihaela Podovei, Marek Majewski, Annabel N. Yuen, Braden Kuo, Irene Sarosiek, John
Kuhn, Laura Negron, Jack R. Semler, Connor Semler, Richard W. McCallum
Introduction: Differences in GI luminal pressure patterns between healthy normals (N) and
patients with gastroparesis (GP)could give insight into pathophysiology. Pressure measure-
ments in the antrum and duodenum have traditionally been performed with invasive
indwelling manometry catheters. SmartPill is a wireless ambulatory capsule that measures
luminal pH and pressure as it courses throughout the GI tract after being swallowed. Passage
of the indigestible solid SmartPill from the stomach into the duodenum appears to occur
near the end or soon after the gastric emptying of a solid meal or during the fasting state
when MMCs occur. Aims: To compare pressure patterns between normal subjects and
patients with gastroparesis as defined by a previously abnormal gastric scintigraphy. Methods:
In 2 centers, healthy subjects and patients swallowed the SmartPill (SP) after an overnight
fast together with a standardized meal of 120 g Eggbeaters,2 pieces of bread with jam;255
kcal,2% fat) and 120 cc water. The rapid pH change from acidic to alkaline (>3 unit rise
from baseline gastric pH) marked the emptying of the ingested SmartPill from the stomach
into the duodenum. The frequency and amplitude of contractions recorded by the capsule
were counted in 30 minute intervals from 60 min before gastric emptying (GE) to 60 min
after the capsule left the stomach. These parameters for Ns and GPs were then compared
for each time interval by two-sample unequal variance T test. Results: 21 Ns (13M/8F, mean
age 30.8) and 16 GPs((4M/12F, mean age 40.9 (9 diabetic/7 idiopathic)) were studied. Mean
contraction frequency and pressure amplitudes in both groups for 30 min intervals are
summarized in the table below. Gastroparetics had lower gastric contraction frequencies in
the time period -60 to -30 min (preceding gastric emptying) compared to normals, p<0.02.
There were no differences in contraction amplitudes between the 2 groups. Conclusion: 1.
This new ambulatory technology represented by SmartPill detected impaired gastric (antral)
motility in GP compared to normals. 2. Decreases in frequency in gastroparetics prior to
emptying of an indigestible solid may reflect neurogenic abnormalities in Phase II fasting
response. 3. Contraction patterns in health and disease throughout the gut can be measured
with the SmartPill Capsule.
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Relationship Between Proximal and Distal Gastric Motor Activity in Humans
Nam Q. Nguyen, Richard H. Holloway, Laura Bryant, Carly Burdstag, Robert Fraser
Normal gastric emptying involves not only intact proximal and distal gastric motility but
also a coordination of motor activity between the 2 regions. In dogs, fundic volume waves
may play a role in transferring contents to the antrum for subsequent emptying. However,
data on this relationship in humans are limited to scintigraphic studies. Aim. To determine
the relationship between proximal and distal gastric motor activity during fasting and in
response to duodenal nutrient stimulation in healthy humans. Methods. Concurrent proximal
(barostat) and distal gastric motility (perfused antro-pyloro-duodenal (APD) manometry)
were recorded in 10 healthy volunteers (5M:5F; age= 28+2yrs). Studies were performed
during fasting and two 60-min duodenal infusions of Ensure (1 kcal/min and 2 kcal/min),
administered in random order separated by a 2h “washout” period. Proximal gastric volume
(PGV), fundic wave (FW) activity, and number, length and direction of propagation of APD
waves were determined. The association between these variables were also assessed. Results.
During fasting, approximately 32% FWs were followed by a distally propagated antral wave
(PAW) (Table). Associated PAWs were almost all ante-grade (96+3%), propagated at least
6cm and traversed the pylorus into the duodenum on 57+7% of occasions. Duodenal
nutrients increased PGV in a dose-dependent fashion. Total FWs and PAWs significantly
reduced during 2kcal/min but not 1kcal/min infusion. The proportion of FWs followed by
a distally PAWs was similar during 1kcal/min (P=0.89) and 2kcal/min (P=0.43) infusions.
Although associated PAW during nutrient infusion remained ante-grade (96+2%) and over
6cm, they were less likely to traverse the pylorus (36+7%; P=0.04). Conclusions. In health,
proximal and distal gastric motor activities are coordinated during both fasting and after
duodenal nutrients. Changes in FWs during duodenal nutrient feedback may influence the
rate of gastric emptying of nutrients. These data suggest a close relationship between proximal
and distal gastric motility.
864
Signaling Pathways in TGF-β Induced Tumorigenesis in Elf+/-/Smad4+/-
Mutant Mice Cell Lines and Human Gastric Tumors
Nady Golestaneh, Yi Tang, Varalakshmi Katuri, Bibhuti Mishra, Lopa Mishra
TGF-β induces antiproliferative gene responses during cell cycle and escape from this
response is a hallmark of tumorigenesis. ELF deficiency in mice results in mislocalization of
Smad3 and Smad4 truncating TGF-β signaling and transcriptional response. Elf+/-/Smad4+/-
mutant mice develop gastric tumors and present an ideal model for further analyses of
signaling pathways involved in TGF-β induced growth inhibition and/or tumorigenesis.
Aims: To study the role of TGF-β on MAPK signaling pathways in elf+/-/Smad4+/- gastric
cell lines and gastric tumors. Methods and Results: 1.Western Blot analysis of ERK pathway
members revealed a 15-fold increased expression of activated ERK (P-ERK) in gastric tumors.
In the elf+/-/Smad4+/- cells, the basal level of P-ERK (P-p42) expression was 15 fold lower
than the wild type control, whereas P-p42 was completely absent in Smad4+/- and elf+/-/
Smad4+/- cells. These mutant cells were not responsive to TGF-b unlike the wild type cells
showing an eight-fold decrease in P-p44 and 12-fold decrease in P-p42 expression in the
presence of TGF-b induction. 2. Activated JNK (P-JNK) expression was 10 fold higher in
Smad4+/- cells compared to the wild type and this expression was responsive to TGF-β
induction. 3. Activated p38 (P-p38) expression was approximately 10 fold higher in the
polyposis and five different human gastric tumors as well as in elf+/-/Samd4+/- mutant cells
compared to the wild type control. The P-p38 expression was responsive to TGF-β and
increased by 10-fold in elf+/-/Smad4+/- cells. 4. We have also observed a 10-fold increase
in CDK4 expression in Smad4+/- cell lines and this expression was not responsive to TGF-
β induction. Conclusion: 1. Our results suggest that TGF-β may regulate MAPK signaling
pathways either directly through elf/Smad4 interaction or indirectly through other down-
stream protein interactions. 2. Increased level of P-p38 in gastric tumors as well as in elf+/-/
Smad4+/- mutant cells, and higher level of P-JNK expression in Smad4+/- mutant cell lines
indicate that disruption of TGF-β signaling pathway may induce tumorigenesis through
induction of p38 and/or JNK activation. Further studies are needed to delineate TGF-β -
induced signaling pathways during growth inhibition and tumorigenesis.
865
Gastrin-Stimulated Colorectal Cancer Cell Proliferation Is Mediated in Part
Through Phosphorylation and Subsequent Degradation of PPARγ
Albert J. Chang, Diane H. Song, M. M. Wolfe
Background: We have previously reported that the trophic properties of gastrin in colorectal
cancer (CRC) may be mediated in part through a decrease in peroxisome proliferator activated
receptor gamma (PPARγ) activation. Purpose: To elucidate the precise molecular and cellular
mechanisms by which gastrin decreases PPARγ activation. Methods and Results: DLD-1
cells, human CRC cells that express high levels of functional CCK-2 (gastrin) receptors,
were incubated in the presence of 200 nM amidated gastrin-17 (G-17) for 60 min, after
which Western analysis was performed using a phospho-specific antibody recognizing Ser84
phosphorylated PPARγ. Gastrin promoted PPARγ phosphorylation starting at 5 min and
persisting up to 60 min, which coincided with gastrin-induced activation of ERK1/2. We
next examined the possibility that ERK1/2 activation might also play a role in gastrin-
stimulated PPARγ phosphorylation. DLD-1 cells were pre-incubated with the ERK1/2 inhib-
itor PD98059 for 45 min prior to the addition of 200 nM G-17. Both gastrin-induced ERK1/
2 activation and PPARγ phosphorylation at Ser84 were abolished by co-incubation with
PD98059, suggesting that gastrin enhanced PPARγ phosphorylation at Ser84 is mediated,
in part, through ERK1/2 activation. We then examined the possibility that gastrin might
attenuate ligand-dependent PPARγ activation by enhancing PPARγ phosphorylation at Ser84.
A phosphorylation mutant of PPARγ was generated by altering the Ser84 residue into an
alanine residue, and stable DLD-1 cell lines expressing wild type (wt) and mutant PPARγwere
created. While co-incubation with G-17 markedly attenuated PPARγ activation stimulated by
the PPARγ agonist rosiglitazone (ROS) in cells overexpressing wtPPARγ, gastrin had no effect
on PPARγ activation in cells overexpressing mutant PPARγ. The mutation of PPARγ at Ser84
also abrogated gastrin-induced degradation of PPARγ in DLD-1 cells. Finally, in the presence
of 200 nM G-17, ROS-induced growth suppression was diminished by ~64% (p<0.001 vs.
5 μM ROS alone) in wtPPARγ overexpressing cells, whereas in the presence of gastrin,
PPARγ growth suppression was minimally affected in cells overexpressing mutant PPARγ.
Conclusion: The results of these studies demonstrate that the trophic properties of gastrin
may be mediated in part by phosphorylation of ERK1/2, which, in turn, phosphorylates
PPARγ at the Ser84 residue. The phosphorylation of PPARγ at Ser84 decreases PPARγ
transactivational activity and appears to signal PPARγ for proteasomal degradation. As a
result, PPARγ protein levels are diminished, which attenuates the tumor suppressive effects
of PPARγ, resulting in enhanced cellular proliferation.
866
Cross Talk Between TGF-β-IL-6 Pathways Is Important for Suppression of
Hepatocellular Cancer
Varalakshmi Katuri, Yi Tang, Wilma Jogunoori, Anton Sidawy, Bibhuti Mishra, Lopa
Mishra
Inter-α-trypsin inhibitor-4 (Itih-4) is a liver-restricted member of the serine protease inhibitor
family with diverse functions as an anti-apoptotic and matrix stabilizing molecule that are
important throughout development and cancer. We first isolated Itih-4 together with ELF,
a TGF-β adaptor from fore-gut endodermal stem cells. Itih-4 is expressed in early hepatoblasts,
is regulated by IL-6 and levels rise eightfold in GADD45 (a P53 target) mutants that develop
multiple cancers. The adaptor protein ELF, a beta-spectrin, demonstrated a pivotal role in
carcinogenesis through regulation of the TGF-beta pathway. Interestingly, elf+/- mutant mice
had increased incidence of hepatocellular cancers (HCC) in elf+/- mutant mice. Aim: To
determine the role of TGF-β/ELF as well as IL-6/Itih4 in regulating HCC. Methods and
Results: 1. We generated Itih4 deficient mice by targeting exon 2 and part of exon 3 (1.8kb),
which is replaced by Neo gene. 2. Genetic studies showed Itih4 deficient mice appear to
be normal without any tumor development over the past four years. 3. Elf +/- mice, known
to develop HCC, were crossbred with Itih4-/- mice. The elf +/- and elf +/- / Itih4-/- offspring
were autopsied to determine the development of any abnormalities. Interestingly, hepatocel-
lular cancer incidence is dramatically decreased in elf +/- / Itih4-/- mice. Only one out of
twenty elf +/-/ Itih4-/- mice developed a small liver tumor at two years compared with nearly
two thirds of elf +/- developing tumors at this age spontaneously. Conclusions: 1. Loss of
IL-6/Itih4 plays critical role in suppression of HCC induced by inactivation of TGF-β /ELF
pathway. 2. Our results suggest that TGF-β-IL-6 cross talk is important for suppression of
HCC, and this model may be important in the development of future therapeutics for
hepatocellular cancers.
867
Posttranscriptional Regulation of COX-2 Gene Expression in Intestinal
Tumorigenesis: Role of Novel Protooncogene RBM3
Sripathi M. Sureban, Dharmalingam Subramaniam, Katherine B. Lee, Satish Ramalingam,
Aubrey R. Morrison, Courtney W. Houchen, Brian K. Dieckgraefe, Shrikant Anant
RBM3 is a ubiquitously expressed glycine-rich protein that can bind to both RNA and DNA
via an amino-terminal RNA binding domain. RBM3 was observed to bind 60S ribosomal
subunits, and enhance global protein synthesis. Furthermore, RBM3 was identified as a
member of a complex of proteins along with RNA stabilizing protein HuR, that bound to
AU-rich sequences (ARE) located in the 3’untranslated region (3’UTR) of cyclooxygenase-
2 (COX-2) mRNA. However, the functional significance of RBM3 in the complex is not
known. We have now identified RBM3 in a yeast two-hybrid screening using HuR as bait.
We confirmed RBM3 interactions with HuR and CUGBP2, another RNA stabilizing but
translational inhibitor protein using ectopically expressed tagged proteins in HeLa cells.
Immunocytochemistry demonstrated that RBM3 colocalized with both HuR and CUGBP2
in the nucleus of transfected cells. Furthermore, bacterially expressed recombinant GST-
RBM3 bound to in vitro translated 35S-labeled HuR and CUGBP2. Since COX-2 levels are
elevated in cancer, we next determined the expression patterns of RBM3, HuR and CUGBP2
in human and murine tumors. Real time PCR analyses of total RNA from human colon cancer
tissues demonstrated increased expression of RBM3 and HuR, while decreased expression of
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CUGBP2. Likewise, RBM3 and HuR levels were significantly higher, while CUGBP2 was
lower in intestinal adenomas of APCmin/+ mice compared to the surrounding uninvolved
tissues. Finally, HuR and RBM3 expression was significantly induced in HCT116 human
colon cancer cell nude mice xenografts. In HCT116 cells in culture, ectopic overexpression
of RBM3, HuR and CUGBP2 by transient transfections results in increased COX-2 mRNA
expression by at least 2-fold when transfected alone. In addition, coexpression of RBM3
and HuR further induced COX-2 mRNA levels to greater than 4-fold. In order to determine
the mechanism by which RBM3 increased COX-2 mRNA levels, we determined the effect
of RBM3 on COX-2 mRNA stability using actinomycin D. The half-life of COX-2 mRNA
significantly increased from 1 h to greater than 4 h in the presence of RBM3, which
was further increased to 8 h when cotransfected with HuR. These data support a novel
protooncogene function for RBM3 whose overexpression results in increased stability of
COX-2 mRNA in tumorigenesis.
868
Rack1 Induces Apoptosis of Human Colon Cells By Suppressing SRC Tyrosine
Kinase Activity in the Intrinsic and Akt Pathways
Vidya Mamidipudi, Chris Cartwright
Previously we showed that Src tyrosine kinases are activated early in the development of
human colon cancer, and are suppressed during intestinal cell differentiation. We identified
RACK1 as an endogenous substrate, binding partner and inhibitor of Src. We demonstrated
that RACK1 regulates colonic cell growth in part by suppressing Src activity at the G1
checkpoint. Here we show that overexpression of RACK1 induces apoptosis of HT-29 colon
carcinoma cells, in part via its inhibitory influence on Src. Depletion of Src has a similar
effect. We defined mechanisms whereby RACK1 functions in apoptosis. RACK1 induces
cleavage of caspases 10, 9, 6 and 3, and the death substrate PARP. In the intrinsic pathway,
RACK1 overexpression decreases expression of anti-apoptotic Bcl-2, increases expression of
pro-apoptotic Bim, and induces translocation of Bim and another pro-apoptotic protein,
Bax, from the cytosol to mitochondria. Moreover, RACK1 overexpression or Src depletion
inhibits Src-mediated cytochrome c oxidase activity, depolarizes the inner mitochondrial
membrane and releases cytochrome c. We show that RACK1 also induces apoptosis by
blocking the Akt cell survival pathway in a Src-dependent manner, and consequently activat-
ing caspase 9, the pro-apoptotic factor Bad and the transcription factor FOX03 (which is a
potent inducer of apoptosis and G1 arrest). Collectively, our results suggest that RACK1 is
a tumor suppressor because it inhibits growth and induces death of colon cells. Exploitation
of these dual functions could be used to develop new and more powerful and selective
strategies for treatment of human colon cancer.
869
Direct Interaction Between RNA Binding Proteins Hur and CUGBP2:
Functional Antagonism in Intestinal Epithelial Cells
Sripathi M. Sureban, Jacquelyn M. Means, Pavel Rodriguez, Nabendu Murmu, Courtney
Houchen, Brian K. Dieckgraefe, Shrikant Anant
Cyclooxygenase- 2 (COX-2), a critical enzyme in prostaglandin synthesis is overexpressed
at an early stage in the pathogenesis of colorectal cancer. In addition to transcriptional
controls, COX-2 expression is tightly regulated at the post-transcriptional level of mRNA
stability and translation by AU-rich sequence elements (ARE) located in the COX-2 3’-
untranslated region (3’UTR). RNA binding protein HuR binds to the COX-2 ARE and
increases mRNA stability and translation, suggesting that HuR plays a role in carcinogenesis
in part through induction of COX-2 expression. On the other hand, RNA binding protein
CUGBP2 binds to the same COX-2 ARE and also stabilizes the RNA but inhibits its translation,
thereby leading to cell apoptosis. HuR and CUGBP2 have high structural similarity consisting
of two N-terminal RNA recognition motifs (RRM1 and RRM2), a hinge region, and a C-
terminal RRM (RRM3). The hinge region in CUGBP2 is longer than that observed in HuR
and is rich in alanine and glutamine residues. Nitrocellulose filter binding assays showed
that HuR and CUGBP2 bind to the ARE sequences with similar affinities (KD of 27 ± 4 nM
and 34 ± 4 nM for HuR and CUGBP2, respectively). In in vitro translation assays, HuR
increased, while CUGBP2 inhibited COX-2 mRNA translation in a dose dependent manner.
Furthermore, when both proteins were included in the reaction, COX-2 mRNA translation
was inhibited suggesting that CUGBP2 overrides HuR in the translation process. In a yeast
two-hybrid screening, with CUGBP2 as bait, HuR was identified as an interacting partner
in a cDNA library from human liver cells. This interaction was also observed when the
two proteins, expressed in a rabbit reticulocyte lysate cell-free translation system formed
heterodimers in vitro. Immunofluorescence studies also showed that HuR and CUGBP2 co-
localized in the nucleus of transfected cells. In addition, heterokaryon shuttling assays with
HeLa human cells transfected with either FLAG-HuR or FLAG-CUGBP2 and NIH3T3 mouse
cells revealed that both proteins shuttled from HeLa to NIH3T3 cell nuclei with similar
frequencies. Moreover, immunoprecipitation coupled with RT-PCR demonstrated that both
proteins together were associated with COX-2 mRNA, when the two proteins were co-
expressed in HeLa cells. These data, taken together suggest a functional antagonism exists
between RNA binding proteins HuR and CUGBP2, wherein CUGBP2 interacts with HuR
and COX-2 3’UTR to suppress HuR-mediated COX-2 mRNA translation.
870
Inhibition of C-Met As a Therapeutic Strategy for Esophageal Adenocarcinoma
Gregory A. Watson, Xinglu Zhang, Michael T. Stang, Steven J. Hughes
Introduction: We have previously demonstrated universal over-expression of the hepatocyte
growth factor (HGF) receptor c-Met in esophageal adenocarcinoma (EA), yet the therapeutic
potential of c-Met inhibition in EA remains unknown. We hypothesized that inhibition of
c-Met signaling in EA would reduce cell proliferation, inhibit motility and invasion, and
induce apoptosis. Methods: Three EA cell lines (Seg-1, Bic-1, and Flo-1) previously shown

















HGF and the small-molecule, c-Met-specific inhibitor PHA665752. Inhibition of c-Met and
known downstream mediators of c-Met signaling (ERK1/ERK2 and PI3K/Akt) were analyzed
by immunoblotting. Cell viability over time was assessed by MTT assay and apoptosis was
analyzed by FACScan analysis following Annexin V/PI labeling. Motility was evaluated by
cell wounding assay and invasion was quantified using the QCM cell invasion assay. Results:
c-Met was constitutively phosphorylated in 2 EA cell lines (Bic-1 and Seg-1) known to
express HGF, and HGF induced further phosphorylation of c-Met in all 3 EA cell lines.
PHA665752 decreased constitutive and HGF-induced phosphorylation of c-Met in a dose-
dependent fashion, resulting in inhibition of ERK1/ERK2 activity and a 50% reduction in
cell viability (p < 0.01) in all 3 EA cell lines. HGF induced PI3K/Akt activity and stimulated
motility and invasion only in Flo-1 cells. PHA665752 abolished PI3K/Akt activity, inhibited
motility and invasion, and induced apoptosis in this same cell line; inhibition of PI3K activity
with LY294002 reproduced the effects of c-Met inhibition. Conclusions: Inhibition of c-Met
reduced the proliferation of all 3 EA cell lines but inhibited motility and invasion and
induced apoptosis only in a subset of EA cells. Our data suggests that the clinical response
of EA to c-Met inhibition may be dependent upon factors other than over-expression of c-
Met, such as involvement of the PI3K/Akt pathway in c-Met signal transduction.
871
Reversal of Early Stages of Colorectal Cancer with EGF-Receptor Related
Protein (ERRP)
Eva M. Schmelz, Hu Xu, Jianhua Du, Arun K. Rishi, Fazlul H. Sarkar, Adhip P. N.
Majumdar
Inactivation of EGFR family members (EGFRs) represents a promising strategy for the
development of novel and selective anticancer therapies. Current anti-EGFR therapies target
EGFR or HER-2 but not both. Since most solid tumors express several members of EGFRs,
identification of inhibitor(s), targeting multiple members of the EGFR family may provide
a therapeutic benefit to a broader patient population. EGF-Receptor Related Protein (ERRP),
a 53-55 kDa secretory protein, which we have isolated and characterized as a pan-erbB
inhibitor that targets multiple members of EGFRs, is a potential therapeutic agent for several
epithelial cancers, including colorectal cancer. We have repeatedly observed that ERRP is
highly effective in inhibiting growth of SCID mice xenografts of colon cancer cells. However,
it remains to be determined whether ERRP can inhibit/regress growth of chemically-induced
colonic neoplasia/tumors in immunocompetent mice. As a first step in achieving this goal,
we studied the effect of recombinant ERRP on inhibition/regression of aberrant crypt foci
(ACF) formed in the colon of mice after dimethylhydrazine (DMH) treatment. ACF are
considered to be the precursor of colorectal adenomas and subsequently carcinoma. CF1
mice were injected (i.p.) once a wk for 6 wks with DMH (30 mg/kg bodyweight) to induce
ACF formation, subsequently divided into two groups and injected (i.p.) once a day for 10
days with recombinant ERRP (50 µg/mouse) or vehicle. Administration of ERRP significantly
decreased (40-50%) the number of ACF per animal (P<0.05). The number of ACF per focus
was also reduced by 30-40% after ERRP treatment, compared to the controls (P<0.01). This
was associated with a marked inhibition (50-60%) of proliferation (PCNA immunoreactivity)
and stimulation (60-70%) of apoptosis (TUNEL assay) in the colonic mucosa. These changes
were also accompanied by marked reduction in activation (tyrosine phopshorylation) of
EGFR, HER-2 and HER-3 in the colonic mucosa leading to attenuation of NF-kappa-B
activity and a marked reduction in COX-2 expression. In contrast, the levels of alkaline
phosphatase, a marker of intestinal differentiation, was greatly elevated in the colonic mucosa
following ERRP treatment. Taken together, the results suggest that ERRP is effective in
regressing the number and the size of existing ACF, which are precursors of colorectal
adenomas and colorectal carcinoma. This could partly be attributed to inhibition of EGFRs
signaling and induction of differentiation of the colonic mucosa.
872
Specific Targeting of Tumor Endothelial Cells By a Shiga-Like Toxin-VEGF
Fusion Protein As a Novel Treatment Strategy for Pancreatic Cancer
Hubert G. Hotz, Joseph M. Backer, Marina V. Backer, Birgit Hotz, Sarah Bhargava, Heinz
J. Buhr
Background: Inhibition of angiogenesis is a novel treatment strategy for pancreatic cancer,
which is almost resistant against radiochemotherapy. Activated endothelial cells of the tumor
vasculature abundantly express receptors for vascular endothelial growth factor (VEGF), a
key mediator of tumor neoangiogenesis. The aim of the present study was to specifically
target and damage the vasculature of pancreatic cancer by fusing the VEGF isoform VEGF121
to the A-subunit of Shiga-like Toxin 1 (SLT-VEGF), which inhibits the protein synthesis of
target cells. Methods: SLT-VEGF fusion protein containing fragments of the SLT-1 A-subunit
fused to human VEGF121 was expressed in E. coli strain Origami(DE3)pLysS and purified
to homogeneity. In vivo: 5 million cells of 2 human pancreatic cancer cell lines (AsPC-1 /
poorly differentiated, HPAF-2 / moderately differentiated) were injected subcutaneously into
nude mice. 1 cmm fragments of the resulting subcutaneous tumors were implanted into
the pancreas of 72 other mice. Animals were randomized into control and treatment groups:
application of the SLT-VEGF fusion protein (200 µg/kg, every other day ip.) began either
3 days (prophylaxis) or 6 weeks (therapy) after tumor induction. Treatment was continued
for 14 weeks or until death of the mice. Volume of the primary tumor (TU-Vol), local
infiltration and metastatic spread (dissemination score: D-Score) were determined at autopsy.
Microvessel density (MVD) was analyzed in CD31-stained tumor sections. Results: All control
animals developed extensive primary tumor growth, local infiltration, and distant metastasis.
The effects of SLT-VEGF therapy after delayed onset (therapy) and early begin (prophylaxis)
are summarized in the table. Conclusions: SLT-VEGF fusion protein reduces tumor growth
and metastatic spread of experimental pancreatic cancer, resulting in increased 14-week
survival of the animals. Reduced microvessel density indicates that this effect is mainly due
to the toxic effect of SLT-VEGF on endothelial cells of the tumor vasculature. SLT-VEGF
therapy was not associated with systemic side effects such as weight loss.
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Evaluation of Dendritic Cell-Based Vaccination Used in Combination with
Gemcitabine in a Murine Model of Pancreatic Carcinoma
Marc Dauer, Christian Bauer, Franz Bauernfeind, Max Schnurr, Stefan Endres, Andreas
Eigler
Background: Tumorantigen-specific cytotoxic T lymphocytes (CTL) can be induced in vivo
by vaccination with dendritic cells (DC). However, relevant clinical responses are rarely
seen in patients with solid cancer after DC-based vaccination. Chemotherapy can sensitize
tumor cells to CTL responses and may thus improve the clinical efficacy of DC-based
vaccination (Dauer et al., J of Immunotherapy 2005). Here, we evaluated the combined use
of a DC-based vaccine and chemotherapy with gemcitabine in a murine model of pancreatic
carcinoma. Material and Methods: DC were derived from bone marrow of C57BL/6 mice
by in vitro culture with GM-CSF and IL-4. On day 6 of culture, DC were loaded with
syngeneic, apoptotic Panc-02 pancreatic carcinoma cells and stimulated with LPS and IFN-
γ. For tumor induction, 1 x 10E6 Panc-02 cells were injected s.c. into the flanks of C57BL/
6 mice. Therapeutic vaccination was started when tumor size reached 8 to 17mm2. For
vaccination, 0.3 x 10E6 antigen-loaded DC were administered s.c. into the contralateral
flank in weekly intervals. Gemcitabine (50mg/kg) was given twice weekly. For prophylactic
immunization, mice were vaccinated three times prior to tumor challenge. Results: Prophy-
lactic immunization completely prevented tumor development. At day 35 after challenge,
tumor size was 79 ± 10 mm2 in the control group vs. 0 mm2 in the DC vaccination group.
In the therapeutic setting, combination of DC-based vaccination and chemotherapy improved
outcome compared to immunotherapy or chemotherapy alone. Survival at day 58 after
tumor challenge was 0 % in the control group, 13 % in the DC vaccination group, 17 %
in the gemcitabine group and 50 % in the DC plus gemcitabine group. Discussion: DC-
based vaccination showed therapeutic efficacy in a murine model of pancreatic carcinoma.
The efficacy of the vaccination could be enhanced by combination with gemcitabine. At
present, we analyze whether the combined treatment affects tumor environment and the
induced CTL response by histopathological analysis and in vitro-analysis of CTL activity.
874
15d-Pgj2 Down-Regulates Microsomal Prostaglandin E2 Synthase Type 2 in
Colon Cancer Cells
Oliver Schroeder, Yulyana Yudina, Nadine Zahn, Alan Sabirsh, Jesper Haeggstroem,
Juergen Stein
Introduction: Clinical, genetic, and biochemical evidence indicates that Prostaglandin (PG)
E2 plays a central role in colorectal tumorigenesis. The terminal step in the biosynthesis of
PGE2 from arachidonic acid is accomplished by several PGE2 synthases (PGES). Overexpre-
sion of microsomal PGES type 1 and type 2 (mPGES-1 and mPGES-2, respectively) has
been observed in colorectal cancer, whereas the expression of cytosolic PGES remains
unchanged in this tumor entity. The cyclopentenone prostaglandin (CyPG) 15d-PGJ2 acts
both, as a key regulator of negative feedback of the COX pathway in an inflammatory setting
and as a potent anti-tumoral agent. We therefore aimed to further determine the potential
implication of this CyPG in PGE2 mediated colorectal cancer promotion. Material and
Methods: The human colon cancer cell lines Caco-2 and HCT 116 were challenged with
15d-PGJ2 (0.1-10 µM) and expression of PGES on mRNA and protein level was analysed
by semi-quantitative RT-PCR with the fluorescent dye Pico-Green or immunoblot, respect-
ively. PGES synthase activity after treatment of cells with 15d-PGJ2 was determined by RP-
HPLC. In additional experiments, Caco-2 cells, transfected with a mutant receptor to inhibit
wild type PPARγ action, were also treated with 15d-PGJ2. Finally, HCT 116 cells were also
treated with arsenite (1-50 µM) alone and in combination with the antioxidants DTT (2
mM) and N-acetylcysteine (30 mM) and subjected to immunobloting for evaluation of
mPGES-2 protein expression. Results: Whereas mRNA expression of cPGES, mPGES-1,
COX-1 (expressed in HCT 116) and COX-2 (expressed in Caco-2) remained unchanged
following treatment with 15d-PGJ2, mPGES-2 was transiently down-regulated time- and
dose-dependently on the mRNA and protein level in both cell lines. Reduced mPGES-2
expression was followed by diminished PGES activity in the microsomal fraction. Comparable
effects on the expression of mPGES-2 were observed in PPARγ dominant-negative Caco-2
cells, excluding an involvement of this transcription factor in 15d-PGJ2 induced suppression
of mPGES-2. Chemically induced oxidative stress by arsenite resulted in a similar down-
regulation of mPGES-2 protein, which could be completely abolished by the antioxidants
DTT and N-acetylcysteine. Conclusion: Our data clearly indicate, that 15d-PGJ2 down-
regulates mPGES-2 expression in Caco-2 and HCT 116 cells without affecting the expression
of mPGES-1 or cPGES. The action of 15d-PGJ2 occurs to be related to a redox-dependent
mechanism. The results obtained may preclude a novel mechanism for the anti-proliferative
effects of CyPG and point to mPGES-2 as a promising drug target in colorectal cancer.
875
The Oral Multi-Target Tumor Growth InhibitorTm, Zk 304709, Inhibits
Growth of Pancreatic Neuroendocrine Tumors in An Orthotopic Mouse Model
Arne Scholz, Karola Wagner, Martina Welzel, Bertram Wiedenmann, Stefan Rosewicz,
Gerhard Siemeister, Katharina M. Detjen
Background: Neuroendocrine tumors of the gastroenteropancreatic system (GEP-NETs) rep-
resent a molecularly heterogeneous group of tumors that share a well vascularized phenotype.
While biotherapies such as somatostatin analogues and interferon-alpha are well suited to
control the hypersecretion syndrome associated with functional NETs, these therapeutic
modalities do not provide sufficient control of tumor growth. ZK-304709 is a first in class,
oral Multi-target Tumor Growth InhibitorTM (MTGI) that induces tumor cell death via
inhibition of cell cycle progression and tumor-induced angiogenesis. ZK-304709 is a nanomo-
lar inhibitor of CDKs 1, 2, 4 and 7, VEGF-RTKs1-3 and PDGF-RTKβ, undergoing phase I
clinical trials. The multi-targeted profile recommends ZK-304709 as an attractive treatment
option in GEP-NETs. Methods: BON and QGP-1 human NET-cell lines were used for in
vitro studies. Direct effects of ZK-304709 on NET cell proliferation, survival and cell cycle
distribution were determined based on cell numbers, flow cytometry and immunoblotting.
For induction of orthotopic NETs in vivo, BON cells were injected into the pancreas of
immunodeficient mice. Two weeks after injection, animals were randomly assigned to control-
or treatment groups. Animals were sacrificed after nine weeks and primary tumor growth,
vascularization and metastatic spread were determined. Apoptosis fraction and micro vessel
density (MVD) were examined in situ using TUNEL and immunohistochemical detection
of CD34, respectively. Results: ZK 304709 dose dependently inhibited anchorage dependent
and anchorage independent growth of NET cell lines. Cell cycle analyses revealed a blockade
of cell cycle progression that was consistent with CDK inhibition. In addition, a prominent
pre-G1 fraction suggested apoptosis induction, which was confirmed based on detection of
the apoptosis specific 85 kDa PARP cleavage product. Oral treatment of mice bearing
orthotopic BON human pancreatic NETs with ZK-304709 achieved approx. 80% reduction
of primary tumor growth and reduced the incidence of liver metastases. Tumor samples
from ZK-304709 treated animals revealed both an increase in the apoptosis fraction as well
as a reduction of MVD when compared to control animals, suggesting that proapototic and
antiangiogenic mechanisms contributed to tumor growth inhibition. Conclusion: The multi-
target mechanism of action of ZK-304709 attacking tumor cells via inhibition of cell cycle
progression and attacking tumor neovascularization via inhibition of VEGF- and PDGF-
RTKs results in highly efficacious inhibition of growth and metastasis formation of human
pancreatic NETs.
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Life Expectancy, Complications and Causes of Death in Patients with
Achalasia: Results of a 33-Year Prospective Follow-Up Investigation
Volker F. Eckardt, Tom Hoischen, Gudrun Bernhard
Background and aims: Patients with achalasia often require repeated invasive therapies and
may experience multiple complications related to the natural course of this disease and/or
its therapy. This study determines the incidence of such complications and causes of death.
In addition, survival rates were determined and compared with those obtained in an average
population. Material and methods: From 1972 to 2002, 178 consecutive patients (mean
age: 47.0±18.9 [mean±1SD] years, 105 males and 73 females) with newly diagnosed achalasia
were admitted to this prospective investigation and followed until 2005 in two-year intervals.
The diagnosis of primary achalasia was based on manometric, radiographic and endoscopic
findings. Patients regularly underwent structured interviews with regard to their symptoms
using a previously described symptom score (Gastroenterology 1992;103:1732) and were
reinvestigated if significant changes in health status occurred. Survival rates were determined
by Kaplan Meier estimates. We also generated survival data for an average but age and sex
matched German population (Bundesamt für Statistik) and compared these findings with
those obtained in patients with achalasia. Causes of death were determined from hospital
records, informations supplied by private physicians and from death certificates. Results:
Complete follow-up was obtained in 98.9% of all patients. The mean observation period
was 10.5±6.5 years with a range from 2 to 33 years (in surviving patients). Within this time
period, 175 patients underwent a mean of 2.2±1.8 invasive procedures (range 1 to 13). The
mean symptom score was 6.0±2.2 at first presentation and 1.5±1.5 at last follow-up. Disease-
and therapy-related complications occurred in 18.5% of all patients, the most common of
which were megaesophagus (7.3%) followed by reflux esophagitis (3.3%), peptic stenosis
(2.2%) and large esophageal diverticula (2.2%). A total of 24 patients (13.5%) had died.
Causes of death were comparable to those of the control population with the exception of
a higher incidence of pulmonary causes in patients with achalasia (12.5 vs. 2.6%). The
estimated 10 and 20 year survival rates were similar in patients with achalasia (88% [95%
CI:82-94%] and 76% [95% CI:66-85%]) and in sex and age matched controls (92% [95%
CI: 87-97%] and 78% [95% CI:67-90%]). Conclusions: During the course of many years,
most patients with achalasia require repeated therapies and experience a significant number
of complications. However, causes of death and life expectancy do not differ significantly
from those of the average population.
877
Sensory and Biomechanical Properties of the Esophagus After Nissen
Fundoplication
Jose M. Remes-Troche, Ranjit Mudipalli, James Maher, Satish Sc Rao
Introduction/Aim: Previously, we have shown that prolonged acid reflux can induce signific-
ant sensory-motor changes in the esophageal wall in patients with GERD (Am J Gastroenterol
2001; 96(1):S24).Whether these changes are reversible with definitive therapy for GERD is
not known. Our aim was to prospectively assess sensory and biomechanical properties of
the esophagus before and after Nissen Fundoplication (NF). Methods: Graded balloon
distensions were performed using impedance planimetry to assess sensory and biomechanical
properties of the esophageal wall in 6 patients with refractory symptoms and with endoscopic
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+ 24-hr pH study evidence of GERD (M/F= 3/3, mean age=43 years), and in 12 matched
healthy volunteers (M/F= 6/6, mean age=43 years). GERD patients underwent a baseline
evaluation and a repeat evaluation, at least 12 months after surgery (range 13-44 months).
Sensory thresholds were evaluated using a 4 point Likert scale. Data were analyzed with
ANOVA and paired t test. Results: Before NF, the cross sectional area (CSA) of the esophageal
wall was higher (p<0.05*, Table) and the circumferential wall tension/strain relationship
was decreased in patients with GERD compared to healthy controls. After NF, when compared
to baseline, CSA and esophageal wall reactivity decreased (p<0.05) and the wall tension/
strain relationship increased. The biomechanical parameters after NF were similar to healthy
controls. Before NF, sensory thresholds were lower in GERD patients compared to controls;
first perception (mean ± SE, cm H20; 13±2 vs 30±3, p<0.01), discomfort (34±4 vs 54±4,
p<0.01) and pain (49±7 vs 62±2, p<0.01). After NF, there were no changes in these thresholds
(first perception =13±3, discomfort =37±7, and pain =53±6, p= NS) Conclusions: The
esophagus has a larger lumen and the esophageal wall is stiffer and less deformable and is
hypersensitive in patients with GERD. After NF, the biomechanical abnormalities improved
but sensory thresholds were unchanged. Thus, antireflux surgery appears to correct the
esophageal biomechanical dysfunction(s) in patients with GERD, but not the underlying
hypersensitivity. This finding may explain persistent symptoms in some patients, after
Nissen fundoplication.
Changes in biomechanical properties in GERD patients and controls
mean±SD *p≤0.05 vs after and controls
878
TRPV1 and P2x3 Expression in Vagal and Spinal Pathways Following Acid-
Induced Esophagitis in Rats
Banani Banerjee, Bidyut K. Medda, Reza Shaker, Jyoti N. Sengupta
Background: Esophageal hypersensitivity is one of the common findings in gastro-esophageal
reflux disease (GERD). Transient receptor potential vanilloid 1 (TRPV1)and P2X3 purine
receptors contribute significantly in hypersensitivity. The aim of this study was to evaluate
the altered expression and co-expression of these two receptor molecules in the spinal and
vagal afferents in esophagitis. Method: Four groups of rats (n=3/group) were used in this
study. In group 1, 2 and 3, fundus was ligated by suturing the limiting ridge between the
fundus and corpus and placing a nalaton ring 2cm below the pyloric sphincter to restrict
gastric emptying. Group 4 rats (sham control) received a midline abdominal incision, but
no fundus ligation. Forty eight hours following surgery group 1 rats were deeply anesthetized
and perfused with fixative (4% paraformaldehyde). Group 2 (7 days ligated), 3 (ligated +
PPI) and 4 (sham control) were perfused in similar fashion after 7 days. Bilateral nodose
ganglia (NG), spinal cord (T2-T4) and respective dorsal root ganglia (DRG) were collected
for examining TRPV1, P2X3 and IB4 immunoreactivity (ir). The Group 3 rats received
proton pump inhibitors (PPI, omeprazole 20mg/kg, p.o. Qday) for 7 days starting on the
day of surgery. In addition, esophagi were collected from non-perfused rats (n=2) for
myeloperoxidase (MPO) assay as a marker of neutrophil infiltration in inflammation. Results:
Fundus ligation produced severe inflammation of the distal esophagus. In DRGs, P2X3-ir
cells were significantly high (p<0.001) in 48 hrs (90.0±3.2) and 7days (183.0±3.2) ligated
rats compared to sham operated (47.67±2.9) and PPI-treated (62.0±2.9) rats. Interestingly,
the number of IB4-positive cells in DRGs also increased in ligated rats (101.67±3.0 in 48hrs
and 127.33±3.8 in 7 days vs 49.0±1.7 in sham, p<0.001). In NG, TRPV1-ir cells in 7 days
ligated rats were significantly higher (206.67±5.4 vs 102.0±3.8 in sham, p<0.001). Similarly,
P2X3-ir cells were significantly higher in ligated rats (228.6±3.2 vs 37.67±2.60 in sham).
Like in DRG, IB4-positive cells in NG were significantly higher in ligated rats (127.67±2.8
in 48hrs, 178.33±3.8 in 7 days) compared to sham (59.0±1.2) and PPI-treated (84.3±3.8)
groups. Conclusions: This study provides a strong evidence for the involvement of TRPV1
and P2X3 channels in reflux-induced changes in vagal and spinal afferents. Results indicate
that following inflammation there is a phenotypic change in number of IB4-positive cells
in DRG and NG. These changes can be attenuated by PPI. Therefore, it can be speculated
that acid can contribute to peripheral sensitization by upregulating ionotropic channels.
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Reduced Pain Perception in Barrett’s Esophagus (BE) Patients Is Likely Due to
Downregulation of TRPV1 Receptors in the Squamous Epithelium Rather
Than in the Barrett’s Mucosa Itself
Ram Dickman, Pankaj J. Pasricha, John Winston, Mohan Shenoy, Diley Hernandez,
Harinder S. Garewal, Ronnie Fass
Background: Patients with BE demonstrate reduced pain perception. It is currently assumed
that this is due to the presence of columnar, metaplastic epithelium that is less sensitive to
acid. Aims: To compare the distal esophageal expression of TRPV1, a receptor that is gated
by protons and is suspected to mediate heartburn sensation, in the squamous and columnar
metaplastic epithelium of BE patients to erosive esophagitis (EE) patients and normal controls.
Methods: Five normal, healthy controls, 5 patients with EE and 5 with BE were recruited
into the study. All participants underwent an upper endoscopy to ascertain their diagnosis.
BE was defined as any columnar-like extension into the tubular esophagus that is positive
on biopsy for intestinal metaplasia. In all groups, 2 biopsies were obtained from normal
appearing mucosa in the distal esophagus, 6 cm > esophagogastric junction. Two additional
biopsies were taken from the Barrett’s tissue in BE patients. TRPV1 expression was analyzed

















controls, 52.0 ± 3.5, 3/2 for EE and 62 ± 4.3, 5/0 for BE, respectively. The mean length of
the Barrett’s mucosa was 5.9 ± 0.5 cm (4.5-7.0 cm). The distribution of erosive esophagitis
grading as Grade A - 1, Grade B - 3 and Grade C - 1. Patients with BE had the lowest
expression of TRPV1 receptors in the squamous epithelium (0.3771) as compared with EE
(0.4167) and healthy controls (0.5151) (p <0.05). In contrast, the TRPV1 receptors expression
within the Barrett’s tissue was the highest (0.9652) when compared to the TRPV1 expression
in the squamous epithelium of all other groups (p <0.05). Conclusions: Patients with BE
have the lowest TRPV1 receptors expression in the distal esophageal squamous epithelium,
but at the same time the highest TRPV1 receptors expression within the Barrett’s tissue
when compared to EE patients and healthy controls. It is likely that the observed reduction
in pain perception of BE patients is due to downregulation of TRPV1 within the esophageal
squamous epithelium and not within the Barrett’s mucosa.
880
The Magnitude of Visceral Pain Hypersensitivity After Distal Oesophageal
Acidification Correlates with Pre-Study Anxiety State Scores
Abhishek Sharma, Qasim Aziz, Claire Delaney, Anthony Hobson
Patients with stress or anxiety at the time of gastrointestinal injury/inflammation (eg gastro-
enteritis) have a higher risk of developing subsequent Irritable Bowel Syndrome. Anxiety is
common in functional chest pain of presumed esophageal origin, where previous injury
from acid/bile may play a role, but how they interact is unknown. We have previously
shown that oesophageal pain thresholds (PT) are inversely correlated with anxiety scores
(1). In addition, we have shown that distal oesophageal acidification induces sensitisation
of spinal dorsal horn neurones leading to the development of pain hypersensitivity in the
non-acid exposed proximal oesophagus (PO) and chest wall (CW) (2). The effect of anxiety
in modulating the magnitude of sensitisation to oesophageal acid has not been studied. Aim:
To determine whether the magnitude of pain hypersensitivity after oesophageal acidification
correlates with pre-study anxiety state. Methods: In 14 healthy volunteers (7 male, 7 female,
and age 20-50, mean 34.2yrs) the Spielberger State Anxiety Inventory (SAI), a validated
measure of state anxiety, was completed. PT to electrical stimulation (in milliamperes, mA)
were determined in the PO, CW and foot pre and post a 30-minute distal oesophageal
infusion of 0.15M HCl. Results: Mean SAI score was 30.8 (SD 8.7, range 20-51). Acid
infusion resulted in a reduction in PT in the PO [35.3 mA (SD 5.8mA) Vs 25.8 mA (SD
7.7mA), p<0.0001] and CW [31.3 mA (SD 13.5mA) Vs 27.5 mA (SD 8.7mA), p=0.04] but
not the foot [22.6 mA (SD 11.1mA) Vs 22.3mA (SD 9.7mA), p=0.8). There was a group
correlation between baseline spielberger score and maximum decrease in PT post acid
(magnitude of sensitisation) in the PO (r = -0.572, 95% CI -0.845 to -0.059; p=0.03) but
not the CW (r = 0.333, 95% CI -0.240 to 0.734). Subgroup analysis suggested the strength
of this correlation was proportional to the baseline Spielberger score. If the SAI score was
< 30 then r= -0.001, 95% CI -0.665 to 0.663; p=0.99. If the SAI score was > 30 then r= -
0.953, 95% CI = -0.997 to -0.448; p=0.01 Vs. Furthermore, if > 35 then r= -0.999, 95%
CI -0.999 to -0.956; p=0.0009. Conclusions: Increased baseline anxiety state is associated
with a greater reduction of oesophageal pain threshold after acid infusion. There may be a
role for anxiety in modulating the sensory responses to injurious stimuli in the gut. Future
studies with larger numbers and more objective physiological measures of stress and anxiety
may further help to understand the mechanism by which anxiety influences post injury gut
sensitisation. References: [1] Worthen S et al. Gut 2005; 54(suppl 2): A19. [2] Sarkar et al
Lancet 2000; 356(9236): 1154-9.
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Neural and Non-Neural Pathways in Vanilloid Receptor (TRPV1) -Mediated,
Acid-Induced Esophageal Inflammation in the Cat
Ling Cheng, Karen M. Harnett, Weibiao Cao, Claudio Fiocchi, Jose Behar, Piero Biancani
The transient receptor potential channel vanilloid subfamily member-1 (TRPV1), originally
described in primary sensory neurons as a receptor for capsaicin and related natural irritants
(referred to as vanilloids) such as heat and acids, has recently been demonstrated in non-
neural cells. To test whether this acid-sensitive receptor may be the initial mediator of acid-
induced inflammation in the cat esophagus, a tubular segment of normal esophageal mucosa
was removed and tied at both ends to form a mucosal sac (AJP-GI 289:860-869, 2005).
The sac was filled with 0.01N HCl (or normal Krebs’ solution for control) and kept in
oxygenated Krebs’ solution at 37° C. The medium around the HCl-filled sac (supernatant) was
collected after 3 hr incubation and examined for inflammatory mediator content. Compared to
control, substance P levels in mucosal tissue and in supernatant increased six-fold in response
to HCl, while CGRP levels increased 200 times in the mucosa and 10 times in the supernatant.
The HCl-induced increases in substance P and CGRP in mucosa and in supernatant were
abolished when the TRPV1 receptor antagonist IRTX was added inside the mucosal sac, or
when tetrodotoxin (TTX) was added inside the sac and to the supernatant, suggesting that
TRPV1-induced production of substance P and CGRP was neurally mediated. PAF levels
increased more than three-fold in mucosa and in supernatant in response to HCl , and the
increase was blocked by IRTX. The increase in PAF levels in mucosa and supernatant,
however, were not affected by neural block with TTX, suggesting that production of PAF
may arise from non neural pathways. We then examined the presence of TRPV1 receptor
mRNA in esophageal mucosa by RT-PCR. We derived primers from conserved regions of
mRNA sequences of humans, rat, dog, mouse guinea pig and rabbit and confirmed, through
the BLAST database, that the primers were specific for TRPV1. The band produced using
these primers was sequenced, obtaining the sequence of cat TRPV1 with 95% homology to
human TRPV1. RT-PCR of mucosa exposed to HCl for 3 hours showed upregulation of
TRPV1 cat receptor mRNA. To demonstrate the expression of TRPV1 receptor mRNA in
non-neural cells, esophageal epithelial cells were enzymatically isolated, sorted by flow
cytometry, and a 90-95% pure cell preparation was obtained. RT-PCR confirmed the presence
of TRPV1 receptor mRNA in these cat esophageal epithelial cells. We conclude that HCl-
induced activation of TRPV1 receptors in esophageal mucosa results in upregulation of
receptor mRNA, neurally mediated release of substance P and CGRP, and non-neurally
mediated release of PAF from epithelial cells.
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Distinct Clinical Characteristics of Patients with Non-Erosive Reflux Disease
(NERD) and Reflux Esophagitis (RE)
Justin Wu, Carrian Cheung, Vincent Wong, Joseph Sung
BACKGROUND: It has been postulated that NERD and RE are two distinct entities of GERD
instead of a continuous spectrum. AIM: To compare the clinical characteristics, quality of
life, prevalence of concomitant functional GI and psychological disorders between NERD
and RE patients. METHODS: We prospectively recruited consecutive patients presenting
with weekly attacks of heartburn or acid regurgitation. Exclusion criteria included previous
gastric surgery, recent use of NSAID or PPI, and peptic ulcer. All patients completed a self-
administered GI symptom standard questionnaire and a validated, 18-item disease specific
quality of life (QoL) questionnaire (HK GERD-QOL: 0-72 points, high marks indicated poor
QoL). Concomitant functional dyspepsia (FD) and irritable bowel syndrome (IBS) were
diagnosed by Rome II criteria. Psychological disorders (PD) including depression and panic
disorder were documented by standard questionnaires. RE and hiatus hernia (HH) were
assessed by EGD. Esophageal manometry (EM), Bernstein test (BT) and 24-hour pH metry
were performed for all patients. NERD and RE patients were compared for QoL and prevalence
of co-morbidities. RESULTS: 214 patients (NERD: 113, RE: 111; mean age: 53.2+/-19.6;
male: 49%) were studied. Although both groups of patients had comparable age, gender,
duration and ratings of symptom severity, NERD patients had significantly higher QoL scores
(54.8+/-16.6 Vs 42.5+/-13.8, p=0.02) than RE patients. Compared with RE patients, NERD
patients also had higher prevalence of FD (65 Vs 42%, p=0.003), IBS (44 Vs 15%, p<0.001),
PD (9 Vs 1%, p=0.04) and positive BT (41 Vs 20%, p=0.004). However, RE patients had
more HH (35 Vs 18%, p=0.009), higher esophageal acid exposure (Mean DeMeester score:
12.6+/-8.5 Vs 8.2+/-9.1, p=0.01) and more severe esophageal dysmotility (Ineffective eso-
phageal motility: 26 Vs 13%, p=0.03; lower esophageal sphincter pressure <10 mmHg: 29
Vs 11%, p=0.002). CONCLUSION: NERD and RE patients have distinct difference in clinical
characteristics. Despite similar severity of reflux symptoms, NERD patients have poorer QoL
related to GERD, higher prevalence of other functional GI and psychological disorders, and
more sensitive esophagus. These observations suggest visceral hypersensitivity predominates
in the mechanism of NERD, while esophageal dysmotility and defective anti-reflux mechanism
plays a more important role in RE.
889
The Functional Lumen Imaging Probe (FLIP) for the Evaluation of the
Esophagogastric Junction (EGJ)
Barry P. McMahon, J.N. B. Frokaer, Peter Kunwald, Donghua Liao, Peter Funch-Jensen,
Hans Gregersen, Asbjorn M. Drewes
Despite being one of the most dynamic structures in the human body, knowledge about
the esophagogastric junction (EGJ) behaviour is very limited. A functional lumen imaging
probe (FLIP) using impedance planimetry technology was used to quantify the competence
of the EGJ. The aims of the study were; to verify the efficacy and usefulness of the FLIP
for the evaluation of the EGJ in healthy controls (HC); to confirm the location of the FLIP
with ultrasound imaging of the EGJ and to compare the ability of FLIP in determining EGJ
characteristics in HCs with data on a classical achalasia patient. 8(6 m) mean age 25.5 (21-
35) were recruited for the study. Inclusion criteria ≤ 35yrs, non-smokers, no history of
reflux, heartburn or regurgitation. FLIP consisted of a catheter with a 10cm long cylindrical
bag which could be infused with saline to a diameter of 3.2cm. After calibration the probe
was inserted orally and using manometry the respiratory inversion point was located and
used to place the FLIP bag straddling the EGJ. A radial scanning ultrasound miniprobe
(UM-3R, Olympus Corp. Tokyo, Japan) was inserted into the balloon to confirm FLIP
position. Stepwise distentions allowed ultrasound and FLIP measurements to be made. Then
volume controlled distensions to 60ml at a rate of 45ml/min were performed before and
after the administration of butylscopolamine and data on 8 CSAs at 4mm intervals in the
cylindrical bag were recorded along with bag pressure. The ultrasound images verified the
probe was actually placed in the EGJ. A variation on the geometry for all 8 HCs was observed
across the 8 CSA measurements. Pressure-volume data for the HCs indicated that pressure
rose from on average from 0 to 35 cm H20 but for the achalasia patient from 0 to 50 cm
H20 when the bag is filled to a volume of 60ml. However, pressure-CSA data indicated
that the minimum CSA measured remained at the lowest measurable CSA for the achalasia
patient as the pressure increased while the volunteer CSAs reached 250mm2 on average.
In all the HCs the narrowest point measured moved proximally during distension. Three
dimensional lumen imaging with the FLIP indicated visually the difference between the
pattern of the HC distensions and the pattern of the achalasia patient. FLIP represents a
new technique for measuring EGJ competence. The FLIP can be placed successfully in the
EGJ using manometry. It can distinguish between normal subjects and an achalasia patient
suggesting it may have a use in determining EGJ function in different diseased states. It has
the potential to monitor patients before, during after endoscopic and surgical treatments
for gastroesophageal reflux disease.
890
Characteristics and Determinants of Long-Term Outcome in Acute Onset
Functional Dyspepsia Patients
Sebastien Kindt, Philippe Caenepeel, Joris Arts, Jozef Janssens, Jan Tack
Background: Recent studies have shown that functional dyspepsia (FD) may persist after an
acute gastroenteritis, and that post-infectious (PI) origin may be present in up to 20% of
FD patients. The aim of this study was to evaluate the long-term prognosis of PI-FD and
to identify factors influencing outcome. Methods: FD patients of presumed PI origin (acute
onset with symptoms suggestive of infection) were prospectively followed and evaluated by
telephone interview and mailed questionnaires. Patients underwent a full pathophysiological
investigation (gastric emptying, barostat, H.pylori status) at inclusion, and follow-up data
included FD symptom status, changes in body weight, quality of life (using NDI question-
naire) and trait and state anxiety and depression (using STAI and HADS). Correlation of
these characteristics to FD status was assessed using Chi-square, parametrical or non-
parametrical tests, and logistic regression. Results: Ninety-four PI-FD patients (mean age
46.1±1.4 y, 66 women), with a mean weight loss at presentation of 7.0±0.8 kg were recruited.
After a mean follow-up of 63±3 months, FD symptoms had resolved in 30% of the patients.
There was an increase in weight of 3.0±1.1 kg during follow-up, resulting in a residual net
loss of 3.5±1.1 kg compared to symptom onset. Persisting FD symptoms during long-term
follow-up were not influenced by any of the pathophysiological variables assessed, but were
significantly associated with body weight at presentation and STAI scores. FD symptom
status was also significantly associated with the NDI and the HADS-depression and -anxiety
scores. In multivariate logistic regression, only STAI-trait was significantly associated with
long-term FD outcome. Conclusion: Five years after the onset PI-FD, the majority of patients
are still symptomatic and body weight has not fully recovered. Persisting symptoms are
highly associated with a decreased quality of life, anxiety and depression. Trait anxiety is
the main determinant of outcome of long-term prognosis in PI-FD.
891
Comparison of Outcomes of Gastric Electrical Stimulation (GES) in Diabetic,
Postsurgical and Idiopathic Gastroparesis By Applying Intention-to-Treat
Analysis
Zhiyue Lin, Irene Sarosiek, Jameson Forster, Richard W. McCallum
Previous reports of GES therapy for refractory gastroparesis were based on perprotocol
analysis and did not compare outcomes in different etiologies of gastroparesis. The aims of
this study were to compare outcomes of GES therapy among patients with diabetic, idiopathic
and postsurgical gastroparesis by applying intention-to-treat (ITT) analysis and to identify
possible predictors associated with symptom improvement. Methods: 130 gastroparetic
patients (81 diabetic, 29 idiopathic, 20 postsurgical) with GES implantation (Enterra™
System, Medtronic) for at least 1 year from 4/1998 to 10/2004 were retrospectively assessed.
Total symptom scores (TSS) derived from 7 symptom sub-scores, a low-fat 4-hour gastric
emptying test (GET), electrogastrogram (EGG), quality of life (QOL) using SF-36 Health
Status Survey questionnaire including physical composite score (PCS) and mental composite
score (MCS) and weight were compared between baseline and 1-year follow-up among the
three etiologies. ITT analysis was performed where the missing data from those who died
(6 diabetic and 1 idiopathic patients from non-device related complications.), had device
removed (N=7), had partial data sets (N=8) within 1 year of GES therapy or lost to follow-
up (N=9) were imputed using the last observation carried forward method. Results: The
median reduction in TSS in the postsurgical and diabetic groups was substantially greater
than in idiopathic patients (59% vs. 52% vs. 34%). Mean baseline vomiting score in diabetics
was significantly higher (P<0.05) than for postsurgical but similar to the idiopathic group
(3.2 vs.2.2 vs. 2.9). PCS and MCS were significantly improved to similar degrees among
the 3 groups. Idiopathic patients reported more abdominal pain than diabetic and postsurgical
groups both at baseline and after GES. Diabetic and postsurgical patients gained more weight
than idiopathics (2.4 vs. 1.5 vs. 0.2 kg). 82% idiopathic patients had an abnormal baseline
EGG (dysrhythmia >30% or decrease in postprandial power) which was substantially more
than the diabetic (56%) and postsurgical groups (50%). No significant improvement in GET
occurred in any of the 3 groups. 5 patients (4%) had devices removed within 12 months
of GES due to infections in the pulse generator pocket. Conclusions: High-frequency GES
is more effective in symptomatically improving gastroparesis in diabetic and postsurgical
patients than the idiopathic group who had the poorest response (35% reduction in symp-
toms). Idiopathic patients comprise a population presenting with prominent abdominal pain
and more EGG abnormalities and require a more thorough evaluation prior to considering
GES therapy.
892
Natural History of Functional GI Disorders: A 15 Year Longitudinal
Population-Based Study
Smita Halder, G Richard Locke, Cathy D. Schleck, Alan R. Zinsmeister, L Joseph Melton,
Nicholas J. Talley
Background: Functional Gl disorders (FGID) fluctuate and transition, yet the long term
natural history of FGID is unknown. Aim: To describe the 15 year natural history of FGID
in a US population. Methods: This prospective cohort study collected symptom data by
mailing multiple validated surveys to random samples of Olmsted County, MN residents
over a 15-year period. Each subject received a minimum of 2 surveys. Survey responses
were utilized to categorize subjects into 10 mutually exclusive FGID subgroups (see below).
Point prevalence (per 100), onset and disappearance rates and transition probabilities were
calculated for each FGID. A generalized logits logistic model for transitions among FGID
subgroups was used to assess the association (Odds Ratios (OR) [95%CI]) with age, gender,
length of time in the study, education, alcohol use and smoking (at first survey). Results:Over-
all,14,070 separate surveys were mailed over the 15 year period with several people receiving
more than 2 mailings; 8673 responded (68%).Over the 15 year period the prevalence was
stable for IBS-any and AP, but increased four-fold for Dysp.The number of people reporting
onset was greater than disappearance for each of the nine disorders. Although the proportions
varied by group, in general, one third had resolution of symptoms, one third had symptom
stability and one third transitioned to a new group (table). Women had greater odds for
maintaining (2.0 [1.2,3.4]), developing (1.8 [1.2,2.6]) and gaining symptoms (2.0 [1.2,3.3])
over time than men, smokers had decreased odds (0.4 [0.3,0.96]) for symptom stability;
high alcohol consumption was associated with increased odds (2.4[1.2,5.0]) for symptom
stability. Conclusions: Most people with FGID in the community continue to have symptoms
for more than a decade but specific symptoms change over time. Gender, smoking and
alcohol use were associated with symptom transition. Supported by an unrestricted grant
from Novartis.
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C=Constipation; D=Diarrhea; AP=Abdominal pain only; Dysp=Dyspepsia
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The Epidemiology of Episodic Crampy Abdominal Pain: A Population Based
Study
Meredythe A. Mcnally, Smita L. Halder, G. Richard Locke, Alan R. Zinsmeister, Cathy D.
Schleck, Nicholas J. Talley
Background: Frequent abdominal pain is reported by up to 25% of the U.S. population.
Much is known about IBS and dyspepsia yet detailed epidemiologic data about frequent
abdominal pain, in general, and episodic crampy abdominal pain (ECAP), in particular, is
lacking. Aim: To describe the epidemiology of ECAP in a population based study. Methods:
A valid GI symptom survey was sent in 2003 to 4196 randomly selected residents of Olmsted
County, MN, who were previously surveyed between 1988 and 1993. Subjects were asked
to report episodes of abdominal pain separate from menstrual cramps and to characterize
the pain in detail. After adjusting for age, gender, and education level, separate logistic
regression models were used to estimate the odds ratios (OR[95%CI]) for ECAP (versus
frequent non-crampy abdominal pain) of several reported abdominal pain related symptoms.
Results: Of those mailed, 2300 responded (55% response rate) and 2255 had sufficient data
available for analysis. Twenty-two percent of the population reported frequent abdominal
pain (> 6 episodes per year) and 31.7% (6% overall, [5%, 7%]) described their pain as
crampy. Increased odds for ECAP were observed in subjects who reported their pain as
moderate (OR 2.3, [1.3, 4.0]) or severe (OR 3.1, [1.4, 6.5]). The odds for ECAP were
smaller in subjects who experienced daily (OR 0.37, [0.2, 0.7]) or multiple weekly episodes
of pain (OR 0.3, [0.1, 0.8]) and smaller in subjects who reported pain that lasted more
than 2 hours (OR 0.5, [0.3, 0.9]). The odds for ECAP were significantly increased in subjects
reporting pain below the navel (OR 7.7, [4.3, 13.8]) or both above and below the navel
(OR 7.9, [4.2, 14.9]). A decreased odds for ECAP was observed in subjects who experienced
improvement in pain with a bowel movement (OR 0.14, [0.1, 0.2]), had bowel movements
triggered by pain onset (OR 0.16, [0.1, 0.3]), or experienced loose bowel movements with
pain onset (OR 0.12, [0.1, 0.2]). While the odds for ECAP were decreased in those experien-
cing pain relief with H2 blockers or proton pump inhibitors (OR 0.5, [0.3, 0.9]), the odds
were increased in those reporting pain relief with antispasmodics (OR 5.4, [1.1, 25.9]). Of
those with ECAP, 76% met Rome II criteria for IBS yet only 8% of ECAP patients had seen
a physician specifically for this pain. Conclusion: ECAP affects 6% of the population. The
multiple predictors of ECAP, when compared to frequent, non-crampy abdominal pain,
suggest that ECAP may represent a distinct symptomatic entity in the community and should
be recognized clinically.
895
Factors Related to Lymph Node Metastasis and Feasibility of Endoscopic
Mucosal Resection in Poorly Differentiated Early Gastric Cancer
Young Dae Park, Yun Jin Chung, Chang-Min Cho, Wan Sik Yu, Won Young Tak, Seong
Woo Jeon
Background: Although most of poorly differentiated early gastric cancer (EGC) have not
accompanied with lymph node metastasis (LNM), endoscopic mucosal resection (EMR) is
currently not accepted as an alternative treatment to surgery. If patients with low-risk of
LNM were defined in this type of EGC, application of EMR would be possible instead of
surgery. This study was performed to determine the factors related to LNM in poorly
differentiated EGC and the feasibility of EMR. Methods: We investigated 234 patients with
poorly differentiated EGC confined to mucosal and submucosal layer who underwent radical
gastrectomy with lymph node dissection from January 1999 to September 2005. Several
clinicopathological factors were investigated to identify predictive factors for LNM: age, sex,
tumor location, type of operation, tumor size, gross type, ulcer findings, depth of invasion
and lymphatic invasion. Results: Lymph node metastases were found in 29 patients (12.4%).
In univariate analysis, tumor size (P=0.039), gross type (P=0.008), depth of invasion
(P<0.001) and lymphatic invasion (P<0.001) were significantly related with LNM in EGC
patients. In multivariate analysis, tumor size (>30mm vs. ≤15mm, odds ratio = 4.1, P=
0.05), depth of invasion (≥ SM2 vs. ≤ SM1, odds ratio = 6.23, P=0.01) and lymphatic
invasion (odds ratio = 9.14, P<0.001) were associated with LNM. Using tumor size (>15
mm) and depth of invasion (> SM1) as the predictive factors, no LNM was observed in
patients who had neither of these factors. In contrast, the LNM rate was calculated to be

















confined to mucosa or SM1 layer in depth and less than 15mm in size, is good candidate
for EMR, given the null possibility of LNM. Feasibility of EMR in poorly differentiated EGC
should be evaluated in order to avoid extensive radical gastrectomy.
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Non-Cardia Gastric Cancer Remains An Important and Deadly Cancer in the
United States: Secular Trends in Incidence and Survival
Melvin K. Lau, Anne Le, Hashem B. El-Serag
Background: Non-cardia gastric cancer is not frequently mentioned in the United States.
However, it is unclear if previously reported decline in non-cardia gastric cancer has con-
tinued, and if detection and management has affected overall survival outside the setting of
clinical trial. The recent temporal trends in incidence and survival of this malignancy have
not been well examined. Methods: We utilized Surveillance, Epidemiology, and End Results
registry (SEER) to identify all cases of non-cardia gastric cancer diagnosed between 1973
and 2002. The yearly age-adjusted incidence rates and the relative survival rates were
calculated. Cox proportional hazards (PH) models were used to examine temporal trends
(yearly from 1983 to 2003) in mortality risk while controlling for changes in age, race, sex,
geographic region (9 SEER regions), cancer stage (localized, regional, distant), and treatment
(gastrectomy, gastrectomy and radiation). Results: The age-adjusted yearly incidence rate
has declined by 23% between 1973 and 2002 from 4.3 to 3.3/100,000 (esophageal adenocar-
cinoma was 2.4 per 100,000 in 2002). However, the incidence of localized non-cardia
gastric cancer (invasive neoplasm confined to the organ of origin) remained without change
between 0.9 and 1.0 per 100,000, and has increased slightly for persons 85 and older. The
incidence rates in men were double those in women, and 1.6-fold and 2.6-fold higher in
Blacks and Other races (mostly Asians), respectively compared to Whites. These differences
have remained relatively unchanged during 1973-2002. The 3-year survival was 34% (95%
CI, 32%-35%) in patients diagnosed during 1995-99. The Cox PH analysis shows no
significant change in mortality risk for patients diagnosed between 1983 and 2002, both in
unadjusted as well as adjusted analyses for all the variables listed above. However, there
were significant independent regional and racial variations in survival. For example, compared
to Hawaii, the mortality risk for Utah and New Mexico were 19% and 16% higher, respect-
ively. Asians had a 17% lower mortality risk compared to Whites. Conclusions: Despite
the overall decline in non-cardia gastric carcinoma, the incidence of local stage disease have
remained stable in most ages and even increased in old ages. Unfortunately, there has been
no significant improvement in survival during the past 20 years. Moreover, there remain
considerable regional as well as racial variations in mortality.
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Risk Factors for Pancreatic Cancer in Younger and Older Patients
Sara H. Olson, Jennifer Simon, Emmy Ludwig, Robert C. Kurtz
Pancreatic cancer (PC) is generally thought of as a disease of aging. The purpose of this
analysis is to investigate patterns of weight in adulthood, smoking, family history of cancer,
and risk of pancreatic cancer PC in individuals according to age (<60 vs >=60 years).
Methods. Our Familial Pancreatic Cancer Registry is tied to an epidemiologic case-control
study of environmental risk, which includes both familial and sporadic PC cases. Data are
from this hospital-based case-control study including PC patients as cases (n=241) and
controls consisting of well spouses or visitors accompanying patients to an endoscopy clinic
(n=122). All participants were questioned on several potential risk factors for PC, including
maximum weight, lifetime smoking habits, family history of cancer, and demographic charac-
teristics. Logistic regression was used to determine adjusted odds ratios (OR) and 95%
confidence intervals (CI). Results. We analyzed data from 241 patients (97 aged <60 years
and 144 aged >=60) and 122 controls (61 aged <60 years and 61 aged >=60). In the total
sample, increased risk was associated with obesity (BMI >=30) (OR=2.21, 95% CI 1.20-
4.04); heavy smoking (>=15 pack years) (OR 1.51 95% CI 0.88-2.62) and history of PC in
first or second degree relatives (OR 1.91, 95% CI 0.93-3.92). Results for obesity and smoking
were stronger among the younger respondents: adjusted ORs were 3.42 (95% CI 1.33-8.79)
for obesity and 3.62 (95% CI 1.24-10.6) for heavy smoking; compared to 1.71 (95% CI
0.73-4.01) for obesity and 1.16 (95% CI 0.58-2.34) for heavy smoking among older respond-
ents. For family history, there was less difference in risk according to age group, with
adjusted OR of 2.02 (95% CI 0.66-6.17) among younger respondents and 1.54 (95% CI
0.57-4.16) among older ones. Family history of other cancers that are found in some families
with PC (breast, ovarian, melanoma, colon, and endometrium) were not different between
cases and controls overall or when stratified by age group. Conclusions. Our study shows
that smoking and obesity, independent risk factors for PC development, appear to be more
important in younger PC patients than in older ones. It is possible that in older people
variables related to aging, such as weakening of immune function or DNA repair capacity,
could be more important. While, as expected, family history also increased PC risk, the age
related differences were smaller. This study emphasizes the need for aggressive population-
based smoking cessation and weight control programs, especially among younger people.
898
Detereminant and Outcomes of Curative Internt Surgery (CIS)for Pancreatic
Cancer in the United States
Yasser H. Shaib, Jessica A. Davila, Chris R. Nauman, Hashem B. El-Serag
Background: Pancreatic cancer is the fourth leading cause of cancer death in the United
States. Curative intent surgery (CIS) is presumed to be the only curative option in the
treatment of pancreatic cancer. The determinants and the outcomes of surgical resection are
not clear at the population level. Methods: Using data from 9 registries of the Surveillance
Epidemiology and End Results (SEER) program we examined the predictors of receiving
CIS as well as the survival of patient receiving CIS between 1987-2001. The definition of
CIS in SEER has been previously validated and found to be highly accurate. Cox proportional
hazard model was used to examine the effect of potential determinants on survival. Results:
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We identified 32,348 cases of pancreatic cancer. Of those 3,545 (10.9%) received CIS. The
proportion of patients receiving CIS decreased significantly with age (p <0.0001), was similar
across all racial groups (10.8% in Whites, 11.4 % in Blacks, 11.5 % in Asians and 11.2 %
in Hispanics, p= 0.5), was slightly higher in males (11.3% vs. 10.5 %, p = 0.02), decreased
with advanced disease stage (p <0.0001) and progressively increased over time (7.5 % in
1987-89, 9.1% in 1990-92, 10.4% in 1993-95, 12.4 % in 1996-98 and 13.4 % in 1999-
2001, p < 0.0001) and differed significantly across different SEER registries (9.7% in San
Francisco, 11.8 in Connecticut, 12.5 % in Detroit, 11.7% in Hawaii, 9.3 % in Iowa, 10.1
in New Mexico, 9.5% in Seattle, 13.2 % in Utah, 11.4% in Atlanta, p<0.0001). In the
multivariable logistic regression analysis, more recent time periods, younger age, early disease
stage and geographic location, but not race or gender were independent predictors of
receiving CIS (Table). In the Cox survival analysis, younger age, early disease stage, more
recent time period, geographic location and receipt of CIS were independent predictors of
improved survival and Black race was an independent predictor of shorter survival Conclu-
sions: Early stage disease, female gender, younger age, geographic location and more recent
time periods are predictors of receiving CIS. Early disease stage and receipt of CIS are the
strongest predictors of improved survival among patients with pancreatic cancer. Black race
is an independent predictor of shorter survival.
Predictors of Recieving CIS
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Risk of Pancreatic Adenocarcinoma and Hereditaty Pancreatitis: The First
National Cohort in France
Vinciane Rebours, Marie Christine Boutron-Ruault, Claude Ferec, Dermot O'Toole,
Matthieu Schnee, Frederique Maire, Pascal Hammel, Philippe Ruszniewski, Philippe Levy
Hereditary pancreatitis (HP) is an autosomal dominant disease caused by a mutation in the
cationic trypsinogene gene (PRSS1). Chronic pancreatitis (CP) is a known risk factor of
pancreatic adenocarcinoma (PA) with a standardized incidence ratio (SIR) of 27. The fre-
quency of pancreatic cancer in the inherited type of pancreatitis is uncertain. Aims: To
evaluate the incidence of the PA in extensive French national series of patients with HP and
to search for risk factors. Patients (pts) and methods: A cohort comprising all French HP
pts was constituted by contacting all French gastroenterologists and pediatricians (response
rate: 84 %) and genetics laboratories (response rate: 100 %). Inclusion criteria were the
presence of PRSS1 gene mutation, or CP in at least 2 first-degree relatives, or 3 second-
degree relatives, in the absence of another cause of CP (notably, alcohol). CFTR and SPINK
1 gene mutations were also systematically examined. Diagnosis of PA was based on histological
examination. Results: The historical cohort included 78 families and 200 pts of whom 181
were alive. It represented 6673 person-years (median number of generation: 3, males: 53%,
chronic alcoholism: 5%, tobacco intoxication: 34%). At time of inclusion, the median age
was 30 y (range: 1-84). PRSS1 mutations were present in 68% (R122H: 78%, N29I: 12%,
others: 10%). SPINK1 and CFTR mutations were present in 13% and 2%, respectively.
PRSS1 inheritance was maternal for 65%. 10 PA were diagnosed (6 males) at a median age
of 55 y (range: 39-78). The SIR of PA for the cohort, the males, and the females was 87
(42-113), 69 (25-150) and 142 (38-225), respectively. At 50, 60 and 75 y, the cumulated
risk of PA was 11%, 16% and 49% for males and 8%, 22% and 55% for females, respectively.
The risk of PA for smokers at age 75 y was 61% and 70% for males and females, respectively.
19 patients died, 8 from PA (42%). The cause of death was known for all the patients except
one. Conclusions: Patients with HP have a markedly increased risk of pancreatic cancer
(SIR: 87) compared with the general French population. This may be explained in part by
the long exposure time to CP. There is no correlation between this risk and the PRSS1
genetic status but the PA is highly linked with the tobacco intoxication. PA is the first cause
of death in patients with HP.
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The Short Health Scale - A Valid and Easy to Use HRQOL Instrument in
Crohn’s Disease
Henrik Stjernman, Christer Granno, Leif Ockander, Gunnar Jarnerot, Curt Tysk, Bjorn
Blomberg, Magnus Strom, Henrik Hjortswang
Background: Health related quality of life (HRQoL) is an essential part of IBD health
assessment not only in clinical trials but also in quality assurance of routine management.
HRQoL can be divided into four aspects: symptoms, function, worry and general well-being.
We have developed the Short Health Scale (SHS), a HRQoL questionnaire in which the
patients score the disease impact on each of these four aspects on visual analogue scales.
The SHS has in a previous study shown to be valid, reliable and sensitive for change
(responsive) on patients with ulcerative colitis. Aim: To evaluate the SHS on patients with
Crohn’s disease (CD). Methods: 367 patients with CD completed the SHS and four other
HRQoL questionnaires (IBDQ, SF-36, RFIPC, and PGWB) and a symptom diary at their
regular outpatient visits. 330 patients completed the questionnaires at a second visit after
6 months or earlier in case of deterioration. In addition, reliability data was obtained with
replicate measurements after four weeks from the first visit in 38 patients stable in remission.
Results: Patients in remission scored better on all four questions than patients with active
disease (p<0.001) and all four questions correlated strongly with the corresponding dimen-
sions of the other HRQoL questionnaires (rs=0.74-0.83) in keeping with a good validity.
Reliability was confirmed with high correlations (rs=0.66-0.80) and intraclass correlation
coefficients (0.65-0.77) between test and retest measurements in stable patients. Patients
who changed from remission to active disease or vice versa had a significant change in SHS
score for all four questions (p<0.01). Conclusion: SHS is a valid, reliable and responsive
HRQoL instrument also in patients with CD. It is easily completed by the patient and
demands no further calculation by the investigator. SHS gives a comprehensive overview
of the main aspects of the patient’s subjective health perception to broaden the basis of
clinical decision and to deepen the insights of disease impact on daily life.
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Differences in Health Care Resource Consumption in a European
Multinational Population-Based Inflammatory Bowel Disease Inception Cohort
with 10 Years Follow-Up
Selwyn H. Odes, Michael Friger, Hillel Vardi, Frank Wolters, Maurice Russel, Bjorn
Moum, Ebbe Langholz, Paolo Bodini, Kostas Katsanos, Juan Clofent, Joao Freitas,
Giuseppe D'Albasio, Severine Vermeire, Colm O'Morain, Reinhold Stockbrugger
BACKGROUND/AIMS: Consumption of health care resources in inflammatory bowel disease
(IBD) may vary by country and during the time course of disease. The prospectively-incepted,
uniformly-diagnosed, population-based cohort of the European Collaborative Study on IBD
presents an ideal setting for examining this hypothesis. METHODS: We studied 1321 IBD
patients from 9 countries diagnosed during the 2 year inception period October 1, 1991 to
September 30, 1993 and followed for 10 years. Data on resource use were obtained retrospect-
ively from medical records in hospitals and community clinics. Resources were grouped for
analysis as: diagnostics (consultations with gastroenterologists, general practitioners and
surgeons; radiology, endoscopy, pathology), medical and surgical hospitalizations, 5-aminos-
alicylates (5-ASA), other drugs. Data are means per patient-year (p-y). RESULTS: Resource
consumption by IBD patients varied significantly by country (Table), but not in terms of
any geographical gradient. Denmark had the highest and Norway the lowest total hospitaliza-
tion days and diagnostic events. 5-ASA treatment events exceeded those of other drugs in
all countries. Rates of medical hospitalization, surgical hospitalization and diagnostics were
higher in the 1st follow-up year (7.84 days/p-y, 1.58 days/p-y, 7.84 events/p-y) than the
next 9 years (2.56 days/p-y, 1.15 days/p-y, 2.56 events/p-y). Treatment events for 5-ASA
and other drugs were fairly constant over all 10 years. Associations were noted for medical
hospitalization days with diagnostics (r = 0.93), and surgical hospitalization days with 5-
ASA events (r = - 0.70). Compared with Crohn’s disease (set at 100%), consumption in
ulcerative colitis of medical hospitalization was 54%, surgical hospitalization 26%, diagnostics
73%, 5-ASA 107% and other drugs 53%. CONCLUSIONS: This study is the first multina-
tional, population-based, time-dependent characterization of the use of resources in IBD
patients. Increased use was predicted largely by country, hospitalization, follow-up year and
disease diagnosis.
Mean resource consumption by IBD patients per country
* days/patient-year, ^ events/patient-year
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Environmental Factors Associated with Ulcerative Colitis: A Large Population-
Based Case-Control Study
Richard B. Gearry, Ann Richardson, Christopher M. Frampton, Judith A. Collett, Andrew
Dodgshun, Bruce A. Chapman, Michael J. Burt, Murray L. Barclay
Introduction: The increase in the incidence of ulcerative colitis (UC) in developed countries
is likely to be due to exposure to environmental factors in genetically susceptible individuals.
Aim:. To identify environmental factors associated with UC in a large population-based
cohort. Methods: 1421 IBD patients (668 UC, 715 Crohn’s disease (CD)) were recruited,
representing over 91% of people with inflammatory bowel disease in Canterbury, New
Zealand (population 464,800). This is part of the Canterbury IBD Project, a population-
based study of genetic and environmental factors associated with IBD. Sex and age frequency-
matched controls (599) were recruited at random from the electoral roll. Cases and controls
completed a self-administered questionnaire which was posted back to the investigators.
Univariate and multivariate analysis was performed. Subjects were encouraged to corroborate
answers with family members or child health books. Results: Response rates were 95.2%,
94.4% and 84% for UC, CD subjects and controls, respectively. Age, sex, current and
childhood socioeconomic status (SES) and smoking status were included in the multivariate
model. Statistically significant adjusted odds ratios with 95% confidence intervals included:
one relative with IBD 2.48 (1.79-3.47), two relatives with IBD 6.80 (3.18-14.58), smoker
at diagnosis 0.67 (0.49-0.91), ex-smoker at diagnosis 1.82 (1.40-2.37), appendicectomy
0.45 (0.30-0.67), breastfed as infant 0.71 (0.52-0.96), antibiotic use in adolescence 1.71
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(1.04-2.81), and having a household vegetable garden in childhood 0.62 (0.40-0.87). Fur-
thermore, a duration-response effect was observed for breast-feeding (p=0.002), high child-
hood SES was associated with later development of UC (p=0.007) and there was a significant
relation between increased household crowding early in life and reduced risk of later
development of UC (p=0.01). Over sixty additional factors were not significantly associated
with UC. Conclusions: In addition to previously recognised factors associated with UC, we
report some further environmental factors. The protective effect of breast-feeding suggests
that the risk of later developing UC may be influenced by the composition of the faecal
flora. The protective effect of increased household crowding suggests that hygiene-related
factors may be important early in life. The association with having a vegetable garden suggests
that diet early in life may play an important role in CD aetiology.
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Mortality in the Kaiser Permanente Northern California Inflammatory Bowel
Disease Registry, 1996-2003
Susan Hutfless, Xiaoping Weng, Liyan Liu, James E. Allison, Lisa J. Herrinton
Background & Aims: We sought to describe the causes of death in a community-based
cohort of 9,076 patients with incident and prevalent inflammatory bowel disease (IBD)
within the Kaiser Permanente Northern California (KPNC) IBD Registry for the period 1996
through 2003. Methods: The 9,076 IBD patients included persons with at least one inpatient
or two outpatient diagnoses recorded in computerized data during 1996-2002 from among
the average annual 3.2 million membership of KPNC. Deaths were ascertained from the
2003 California Death Master File, which uses a probability algorithm to assign a single
cause of death from all contributing causes listed on the death certificate. To determine the
validity of the Master File’s classification, chart review was performed on 32 patients whose
cause was attributed to IBD (ICD codes 555 and 556). Standardized mortality ratios (SMR)
were calculated as a measure of the association between IBD and risk of mortality with exact
Poisson 95% confidence intervals. Results: A total of 545 IBD patients died compared with
470 expected, resulting in 75 excess deaths. All-cause mortality was increased by 15%
among IBD patients (95% CI, 6-26%), with most of the increase being focused on Crohn’s
disease (CD) (40% increase, CI, 10-70%). The number of excess deaths was greatest for
respiratory disease (N=29), followed by septicemia and other infections (N=15), colorectal
cancer (N=14), digestive diseases other than IBD (N=11), and small bowel cancer (N=2).
The relative excesses in risk were as follows: respiratory disease, 50% excess (95% CI, 20-
90%); septicemia, 380% (130-780); other infections, 180% (50-370); colorectal cancer,
100% (30-190); and digestive disease other than IBD, 50% (0-100). Two deaths from small
bowel cancer occurred among CD patients, compared with 0.04 expected (p<0.001). The
risk of death from colorectal cancer did not differ appreciably between ulcerative colitis and
CD. Conclusions: IBD, especially CD, is related to a substantial increase in mortality. The
role of IBD and its treatment in death from respiratory disease is underappreciated and
merits greater attention. Ulcerative colitis and CD were similarly related to death from
colorectal cancer.
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Lifetime Utilization of Health Care Resources by Patients with IBD in
Manitoba: A Profile of Time Since Diagnosis
Teresa Longobardi, Charles Bernstein
Keywords: Lifetime costs, case-control studies, inflammatory bowel disease Objectives: We
tested the hypothesis of non-linear longitudinal trends for health-care resource utilization
by individuals with inflammatory bowel disease (IBD) in Manitoba. Methods: Administrative
databases were used to examine utilization of health-care resources by persons with IBD.
5756 cases of IBD in the 2000-2001 fiscal year were separated into incident cases (0-5 years
of disease), cases with long-standing disease (6-15 years of disease), and cases with very
long-standing disease (16 or more years of disease). A pooled group of 66,406 matched
controls represented the general population against which the likelihood of utilization for
a number of services was estimated. Odds ratios indicating the likelihood of resource-use
within each category of disease duration were computed using logistic regression analysis,
controlling for age and gender. Excess demand was inferred for outpatient visits and overnight
hospital stays including visits with a specialist, gastroenterologist or surgical visits. IBD cases
were stratified by whether they had an IBD-specific diagnosis (a primary or secondary ICD-
9-CM diagnosis code) IBD or non-IBD-specific diagnoses. IBD cases were also stratified by
the type of IBD, namely Crohn’s disease (CD) or ulcerative colitis (UC). Results: Compared
with the general population, in the first five years of disease IBD cases were over five times
as likely (OR=5.51; 95% CI=(4.92-6.18) to have had a gastroenterology visit; over three
times as likely to have had an outpatient surgical visit (OR=3.53; 95% CI=(3.15-3.95)); and
over three times as likely to have had an overnight hospital stay and an overnight stay
attended by a specialist (OR=3.28; 95% CI=(2.85-3.77); and OR=3.37; 95% CI=(2.88-3.95)
respectively). IBD patients that had a longer duration of disease had significantly lower odds
of utilization compared with the incidence cases. Utilization rates appeared to be constant
across disease duration categories. There were few differences found in the odds of resource-
use of CD cases compared to UC cases. Conclusions: Our results suggest within the first
five years from disease diagnosis were when the greatest increase in costly resources were
used by cases with IBD. We can likely measure the greatest proportion of treatment effects
on resource use within a relatively short period.
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The Impact of Negative Affectivity & Conscientiousness On Quality of Life &
Symptom Severity in Patients with Inflammatory Bowel Disease
Robert Rahimi, Laurie Keefer, Shahriar Sedghi, Ece Mutlu, Ali Keshavarzian
Individual psychological variables can substantially mediate the effects of chronic illness.
Less is known about psychological factors influencing Inflammatory bowel disease (IBD), a

















symptoms. Early identification of such factors may influence disease management. The aim
of this study was to understand the role that positive & negative attributes, including
conscientiousness (C), neuroticism (N) and hostility (H) may play in symptom severity &
QOL in IBD. Methods: 72 patients w/biopsy-confirmed inactive IBD (37 CD, 35 UC) were
studied [mean age 42.29 (19-75); 9.84 (9.54) yrs w/disease]. Psychological questionnaires
included the NEO-FFI personality inventory, Buss-Perry Aggression Questionnaire, SF-12
health-related QOL measure & a global measure of symptom severity. Data was analyzed
using SPSS v.12. Multivariate analyses of variance & regression were performed to identify
possible relations between the aforementioned psychological characteristics, QOL & symp-
tom severity. Results: C alone predicted better physical QOL & accounted for as much as
30% of the variance (R2= .32, t= 2.70, p= .008). There was an interaction effect for N and
H such that patients w/high levels of both traits exhibited the lowest QOL. There was also
an interaction effect of diagnosis such that patients w/CD who had higher levels of N and
H had the lowest mental health QOL (F= 3.20, p= .048). While N and H have some degree
of overlap (r2= .41, p < .001) they were independent constructs. C positively mediated the
effects of abdominal pain [F= 2.98, p= .04] but not overall symptom severity. None of the
other personality constructs were significantly linked to QOL or symptom severity. Conclu-
sion: Identifying baseline personality constructs relevant to IBD is important for disease
management. Our data supported our hypothesis that the presence of high levels of N and
H negatively impacted QOL & symptom severity in IBD. This seemed to be most notable
in patients w/CD. Previous research has linked negative affect to poor health outcomes in
a variety of conditions including cardiovascular disease and cancer. As expected, C accounted
for 30% of the variance in predicting general physical well being & improved symptoms
of abdominal pain. C has also been linked to improved disease management & adherence
to medical regimens in other diseases including diabetes and HIV. C may also be a positive
attribute in IBD where adherence is critical in reducing flares. Future studies are needed to
determine whether psychosocial interventions can positively affect IBD course and disease
outcome.
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Rapid Reorganisation of the Human Swallowing Motor Cortex to a Virtual
Lesion Induced By 1hz Repetitive Cortical Stimulation
Satish Mistry, John Rothwell, David G. Thompson, Shaheen Hamdy
Background: The cortical control of swallowing is bilaterally innervated but displays inter-
hemispheric asymmetry, with dominant (D) and non-dominant (ND) projections. However,
the precise relationship between these pathways remains unclear. 1Hz repetitive transcranial
magnetic stimulation (rTMS) can transiently suppress brain excitability non-invasively (a
virtual lesion) with effects on peripheral function. Until now, virtual lesions have not been
applied to bilateral systems such as swallowing. Aims: We assessed the effects of a 1Hz
rTMS-induced virtual lesion on the excitability of D and ND swallowing motor cortex (SMC)
and compared this to hand MC. Methods: 7 healthy adult volunteers (4 male, age range
25-46) had EMG excitability measurements from the pharynx and the hand in response to
TMS before and up to 60 minutes post 1Hz rTMS. Real and sham rTMS paradigms (600
pulses over D SMC) were applied at 120% of pharyngeal resting motor threshold and
randomised to separate days. Data were analysed using a non-parametric ANOVA. Results:
Real 1Hz rTMS dramatically suppressed D SMC by 36±6% (*p<0.006) immediately and for
up to 45 minutes afterwards (Figure 1). Hand MC was similarly suppressed by 41±13%
(†p<0.01) up to 30 minutes whereas ND SMC showed a transient increase in activity. In
contrast, sham rTMS had no effect. Conclusions: An rTMS-induced virtual lesion can induce
differential inter-hemispheric suppression and excitation of SMC. These compensatory
changes may be relevant to mechanisms of recovery after dysphagic stroke, a likely con-
sequence of the bilateral innervation pattern for swallowing.
Figure 1: Changes in excitability in swallowing and hand motor cortex following real
1Hz rTMS
907
Regional Brain Activation During Gastric Nutrient Infusion in Healthy
Volunteers
Brecht Geeraerts, Lukas van Oudenhove, Patrick Dupont, Stijn Dirix, Dominique
Vanderghinste, Guy Bormans, Koen van Laere, Jan Tack
Background: Brain regions processing gastrointestinal (GI) sensory information are classically
studied using balloon distension of the GI tract, but it is unknown whether more physiological
stimuli, including ingestion of a meal, activate similar brain regions. The aim of the present
study was to identify brain regions which are activated by gastric nutrient infusion in healthy
volunteers. Methods: Brain 15O-water PET imaging was performed on a Siemens BGO HR+
in 15 healthy volunteers (22.8±2.1 years, 11 women) during administration of a standardized
liquid meal (Nutridrink®, 150kcal/100ml) through a nasogastric tube. A liquid nutrient
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bolus was injected 60 seconds prior to each image acquisition. Satiety and abdominal
sensation were scored on separate 0-6 graded scales (0=no sensation, 6=maximal sensation)
immediately after each acquisition. Measurements were stopped when abdominal discomfort
(score≥5) was reached. To determine maximal activation, baseline activity was subtracted
from activity at discomfort intragastric volume. To detect activations correlating with total
injected nutrient volume, satiety or upper abdominal sensation, analyses were performed
using total volume, satiety score and sensation score as covariate. Data were analysed
using Statistical Parametric Mapping (SPM2) software. Results: Subtraction analysis showed
significant activation (Pcorrected <.05) of the right superior temporal gyrus and the left
cerebellum at discomfort nutrient volume (783±65 ml). Several key regions of the “visceral
sensory network” (including insula, anterior cingulate cortex and somatosensory cortex (SI/
SII), which are activated by intragastric balloon distension (Vandenberghe 2005), were not
significantly activated in this study, even at a low threshold (Puncorrected <.05). Several brain
regions were found to covary significantly (Pcorrected <.05) with nutrient volume as well as
satiety score and upper abdominal sensation score: bilateral gyrus frontalis medius/inferior
and a small part of the right gyrus frontalis superior and gyrus orbitalis (orbitofrontal cortex,
BA10/11), left cerebellum and a small part of the gyrus frontalis medialis/gyrus frontalis
superior bilaterally (dorsomedial prefrontal cortex, BA8/9). Conclusion: The results of
the subtraction analysis question the generalizability of balloon distension studies towards
physiological stimuli like food ingestion. The covariate analyses confirm the role of the
orbitofrontal cortex in multimodal processing of food-related information (Price 2003).
908
Regional Cerebral Cortical Fmri Activity Volume Is Directly Related to the
Intensity of Subliminal Proximal and Distal Esophageal Distension
Mark Kern, Adeyemi Lawal, Arthi Sanjeevi, Tanya Rittmann, Candy Hofmann, Reza
Shaker
FMRI studies have documented brain activation in response to subliminal stimulation of
the esophagus. At perceived levels, cortical activity response was significantly more than at
subliminal levels. Presence or absence of a dose response to subliminal stimulations in
specific regions of the brain has not been studied. AIM: Determine the fMRI response to a
range of subliminal proximal and distal esophageal distensions in the cingulate gyrus and
insular cortex. Methods: We studied 12 healthy subjects (age: 18-35) during fMRI of the
insula (n=6) or cingulate (n=6). Paradigm-driven scans were performed during intervals of
randomly timed rest and 15-seconds of esophageal distension before and after 30 min of
distal esophageal acid perfusion (0.1 N HCl, 1ml/min). Correlation analysis was used to
test the relationship between subliminal stimulus intensity and fMRI activity. Results: For both
proximal and distal esophagus, there was always a positive correlation between subliminal
distension and the amount of fMRI activity in both the cingulate and insula. The positive
correlation between stimulus intensity and fMRI activity was preserved after acid in the
distal esophagus (figure). Correlation coefficients were always positive for distal (pre-acid
coefficient range:0.44 to0.99 post-acid:0.77 to 0.99) and proximal (pre-acid: 0.76 to 0.99,
post-acid: 0.74 to 0.99) esophageal distensions. Conclusions: In the subliminal domain of
distal and proximal esophageal distension, the magnitude of recruitment in the cingulate
and insula is directly related to the intensity of esophageal distension. This dose-dependent
response esophagus is preserved after distal esophageal acid exposure.
909
Attentional Modulation of Visceral and Somatic Pain
Paul Dunckley, Qasim Aziz, Richard G. Wise, Jonathon Brooks, Irene Tracey, Lin Chang
Background/Introduction. Hypervigilance, an increased state of guardedness, watchfulness
or attention, has been proposed as a possible underlying aetiology in irritable bowel syndrome
(IBS) and fibromyalgia (FM). As hypervigilance must be a centrally mediated process,
functional magnetic resonance imaging of the brain can be used to test this hypothesis.
However, a better understanding of the normal attentional mechanisms during visceral pain
in health is initially required. The aim of this experiment was to identify the neural correlates
underlying the attentional modulation of visceral and matched somatic pain. Methods.12
healthy, pain-free, right-handed subjects were recruited for the study. Simultaneous electrical
pulses and auditory tones lasting 6 seconds were delivered to the subjects during a whole-
brain functional scan acquisition. The electrical catheter was placed into the rectum for the
visceral scan and onto the lower abdomen for the somatic scan. Subjects were instructed
to attend to and count either the auditory tones or electrical pulses. Electrical pulses and
auditory tones were delivered at either 2, 3.5 or 4.3Hz thereby varying the cognitive demand
of the tasks. Pain intensity, unpleasantness and tone/pulse count were recorded after each
stimulus. Results. During the 3.5Hz and 4.3Hz conditions alone, distraction by the auditory
tones resulted in a significant reduction in pain report (p<0.05) in both sensory modalities.
There was a marked spatial overlap in the group statistical activation maps during somatic
and visceral pain. The typical “pain matrix” was activated. Using pain intensity values as
regressors in a group level regression analysis, the left primary somatosensory cortex (SI)
increased in activity with increasing pain report, during attention to visceral pain. Bilateral
anterior insula cortex activity increased with somatic pain report independent of the direction
of attention. Conversely, the primary auditory cortex (AI) increased in activation with
decreased pain report. Right dorsolateral prefrontal cortex (DLPFC) activity correlated posit-
ively with pain intensity during somatic pain. Conclusions. Pain perception during attentional
modulation is reflected in the primary sensory cortex and anterior insula cortex activity and
may be influenced in a top-down manner by the right DLPFC during somatic pain. A
positive correlation of the right DLPFC, a region more commonly activated in IBS and FM
patients than controls in functional imaging studies, with somatic pain intensity suggests
that this region biases incoming sensory inputs (nociceptive and auditory) towards nocicep-
tive processing.
910
Structural Brainstem Alterations in Patients with Irritable Bowel Syndrome
(IBS)
Joshua Bueller, Steven M. Berman, Brandall Y. Suyenobu, Bruce D. Naliboff, Kashyap
Trivedi, Jean Stains, Emeran A. Mayer
BACKGROUND: The periaqueductal gray (PAG) plays a major role in descending pain
modulation and central autonomic control. Patients with IBS have enhanced perception of
visceral stimuli and alterations in autonomic regulation of gut function. We have reported
altered activation of the PAG in IBS patients during aversive visceral stimulation as well
autonomic dysregulation due to this stimulus. Thus, IBS, and perhaps other functional
disorders, may be partially mediated by altered structure/function of the PAG. AIMS: Compare
the amount of gray matter in the PAG between IBS patients and healthy control subjects
using voxel-based morphometry (VBM). METHODS: 11 female constipation-predominant
(IBS-C) patients and 11 healthy age and sex matched control subjects were scanned on a
1.5T Siemens Sonata camera using a 3D T1-weighted MPRAGE sequence (0.5 x 0.5 x 1
mm). VBM was conducted on segmented normalized images after modulation to correct for
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volume changes. Statistical Parametric Mapping software (SPM2; p<.01) made voxelwise
group comparisons. Differences in the amount of gray matter were assessed for normality
and significance with SPSS. RESULTS: Gray matter volume in a region including the PAG
was significantly larger in IBS patients compared to controls (t = 3.07, p = 0.007). In patients,
the size of the PAG positively correlated with the duration of symptom flare-up (p = 0.043,
r = 0.617). CONCLUSIONS: This is the first demonstration that functional abnormalities
of IBS patients in brainstem regions involved in central autonomic control and endogenous
pain modulation may be accompanied by structural abnormalities.
911
The Effect of Esophageal Acidification On Airway Mucociliary Function
Ivan M. Lang, Steve T. Haworth, Bidyut K. Medda, Reza Shaker
Gastroesophageal reflux disease (GERD) is associated with symptoms of asthma, i.e. nar-
rowing of the airways and increased airway resistance; but asthma is also characterized by
increased airway mucus secretion. However, the effect of esophageal acidification on airway
mucociliary function is unknown. AIM: Our aim was to determine the effects of esophageal
acidification on measures of airway mucociliary function. METHODS: Cats (N=18) were
anesthetized with alpha-chloralose (50mg/kg, IP) and the effects of esophageal acidification on
three measures of airway mucociliary function: tracheal mucus secretion, tracheal mucociliary
transport, and lung clearance, were determined. In all studies the esophagus was cannulated
just below the cricopharyngeus and just above the lower esophageal sphincter and the
esophagus was perfused with 0.1N HCl or 0.1MPBS at 1ml/min. Tracheal mucociliary
transport was quantified (N=7) by determining the rate of orad movement of a tantalum
puck (1mm diameter, 0.3ug) using a micro-focal x-ray system. Tracheal mucus secretion
was quantified (N=6) by measuring the hexosamine content of tracheal perfusate (0.9%
NaCl at 0.25ml/min) taken every 10 min. Lung clearance was quantified (N=5) by measuring
the clearance of Tc99 sulfur colloid from the lungs using gamma camera. RESULTS: We
found that esophageal acidification significantly decreased tracheal mucociliary transport by
about 50%, increased tracheal mucus secretion by about 350%, and stopped lung clearance
(Table). CONCLUSIONS: Esophageal acidification causes a significant increase in mucus
secretion that results in a significant decrease in tracheal mucociliary transport and lung
clearance. In prior studies it was found that esophageal acidification caused a small increase
in airway resistance or small decrease in airway diameters. Therefore, we conclude that the
primary airway response to esophageal acidification is increased mucus secretion and given
the buffering ability of mucus this physiological response acts to protect the airways from
subsequent H+ aspiration that may occur during GERD. Supported in part by DK-25731
Table. Effect of esophageal acidification on airway mucociliary function
Values are mean ± SE (N). *, P<0.05 for a difference between PBS and HCl.
912
Non-Acid Reflux Events Reaching the Pharynx Are Important Factors
Associated with Cough
Robert N. Patterson, Inder Mainie, Gerard Rafferty, Lorcan P. McGarvey, Liam G. Heaney,
Radu Tutuian, Donald O. Castell, Brian T. Johnston
Gastroesophageal reflux has been suggested as an aggravating factor in patients with asthma
and chronic persistent cough. To date most studies have focused on acid reflux and measured
pH below the UES. The aim of this study was to assess the relationship between cough and
reflux both above and below the UES. Patients: 37 respiratory patients were recruited from
the respiratory clinic (18 with chronic persistent cough and 19 with stable asthma). Methods.
Impedance: A combined multichannel intraluminal impedance and pH probe with impedance
measuring segments at 3,5,7 and 9cm above the LES and 1 and 2.5 cm above the UES and
pH sensors 5cm above the LES and 1 cm above the UES was used to monitor patients with

















SAP for cough: Symptom association probability (SAP) was calculated as described by
Weusten et al. using a 2-minute association window between symptoms and bolus entry
5cm above the LES. SAP was considered positive if >95%. Results (median (IQR)): On
average 13% of impedance episodes reached above the UES. In total only 1-2% of all these
episodes registered on the pharyngeal pH probe. 26 of 37 patients recorded cough. 7 of
these 26 (27%) had a positive cough SAP. The +ve SAP group recorded more impedance
episodes crossing the UES compared with -ve SAP patients. This was true for both the total
number reaching the pharynx (5(2.5-8.5) v. 2(1-4) p=0.05) and when expressed as a % of
all esophageal impedance episodes (14%(12.5-28%) v. 6%(2-12.5), p<0.02). There was no
difference between patients with a +ve SAP and those with a -ve SAP in the total number
esophageal impedance episodes (37(24-57) v. 31(16.5-48.5)), acidic esophageal impedance
episodes (12(7.5-18.5) v. 10(2.5-17)) or esophageal acid exposure time (%total < pH4)
(1.7(1.2-4.5) v. 3.8(1.1-10.2)). Conclusion: A positive cough SAP did not correlate with
any parameter of esophageal reflux. By contrast, it was significantly associated with reflux
reaching the pharynx. These episodes were not detected by pharyngeal pH monitoring.
Pharyngeal non-acid reflux is an important measurement in patients with cough. Weusten
BL et al. Gastro 1994;107:1741-5.
913
The Role of Gastroesophageal Reflux (GER) in Exercise-Triggered Asthma
Kathryn Peterson, John Fang, Chistopher Canale, Darin Ryujin, David Young, Wayne
Samuelson
Background: Exercise-triggered asthma develops when vigorous physical activity triggers
symptoms of cough, wheezing, dyspnea, and/or chest tightness during or directly after
exercise. ETA can occur both in people with chronic asthma and in otherwise healthy
individuals.In patients prone to symptoms of supra-esophageal reflux, exercise may trigger
GER, resulting in shortness of breath and cough. Aims: (1)To determine the prevalence of
abnormal pH in patients with exercise-triggered asthma, (2)To determine whether acid
suppression improves respiratory symptoms during exercise in ETA patients. Methods :We
performed a randomized, double blind trial of rabeprazole versus placebo in the treatment
of patients (both asthmatic and non-asthmatic) with exercise-triggered asthma. Patients
reported “heartburn” less than 2x/week. Upon enrollment, subjects underwent underwent
24 hour pH testing while undergoing 30 minute treadmill program exercising them at pre-
determined 60-65% of their VO2max. They were subsequently randomized to rabeprazole
20mg Qam and placebo QPM, rabeprazole 20 mg po BID, or placebo BID for 12 weeks.
At the end of 12 weeks, exercise testing was repeated. Subjects reported whether their
treadmill symptoms improved or did not improve at the end of the study. Results: 37 total
patients were recruited. A total of 30 patients completed the study in it’s entirety (20
asthmatics, 10 non-asthmatics). 22/30 (73%) subjects had abnormal pH studies. For all
subjects, rabeprazole improved symptoms more often than placebo(p=0.04). In the pH+
group, rabeprazole resulted in even greater improvement(p=.02). Discussion: Acid reflux is
common in ETA patients. Many patients with exercise-related respiratory symptoms are
under-diagnosed (or misdiagnosed) as chronic asthmatics. In addition, exercise related
symptoms improve with the use of acid suppression. Such patients may benefit from an
empiric trial of high dose acid suppression.
914
What Is the Optimal Initial Therapy Duration for Patients with Suspected
GERD-Related Laryngitis?
Michael F. Vaezi, Rocio Lopez, Douglas Hicks, Thomas Abelson, Claudio Milstein
Objective: ENT and GI literatures currently recommend initial PPI therapy of at least 3-4
months in pts suspected with GERD-related laryngitis. However, there are currently no well
designed studies in support of such recommendations. Thus, the aim of our study was to
assess the optimal treatment response duration for this group of patients. Methods: Pts with
suspected GERD-related laryngitis based on chronic throat symptoms and laryngoscopic
findings were enrolled. Questionnaire assessed the presence/severity of throat symptoms
and heartburn. Symptom severity scored using a scale of 1 to 4 [1=rare (once a month or
less); 2=occasional (once a week or less); 3=frequent (several times a week); 4=all the time
(several times daily)]. Subjects kept daily symptom diaries of the primary throat symptom
and heartburn during 4-months of BID PPI therapy. Greater than 50% primary symptom
improvement from baseline defined symptom response. Results: 47 Patients enrolled (median
age: 49 yrs, IQR: 44.0 - 65.0; 76% Caucasian; 34% male). Daily symptom diaries were
complete in 43 (91%) patients. 34/43 (79%) patients responded to therapy. The most
common presenting throat symptoms (prevalence, median severity score) included: throat
clearing (84%, 2.8), hoarseness (80%, 3.0), and cough (71%, 2.3). Heartburn (65%, 2.4)
and regurgitation (55%, 2.1)were present in nearly half of pts. Maximum (92%) symptom
response to therapy was achieved by 30 days for the primary throat symptoms (Figure) and
by 18 days for heartburn (Figure 2). Conclusions: 1) In patients with suspected GERD-
related laryngitis one month of therapy is adequate to assess response to therapy. 2) In
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those unresponsive to PPI therapy after one month the likelihood of symptomatic response
with continued PPI therapy does not justify the cost.
915
Effects of High Dose PPI (rabeprazole) On Laryngopharyngeal Reflux Disease:
A Prospective, Double Blind, Randomized Controlled Study
Apichart Suramethakul, Permsarp Isipradit, Supinda Saengpanich, Sutep Gonlachanvit
Background : The role of high dose PPI on laryngopharyngeal reflux disease has not been
well established. We performed a randomized, placebo-controlled, double blind, single
center study to evaluate the effect of high dose PPI in patients with chronic laryngopharyngeal
reflux symptoms. Methods: Thirty patients(8M, age 45±2 yrs, mean±SEM) with suspected
of having laryngopharyngeal reflux disease for >12 weeks(median durations 15 mo(3-120)
by ENT doctors were included. Each patient underwent a video laryngoscopy and a dual
channel(15 cm apart), 24 hr esophageal pH testing before receiving either rabeprazole(R)
20 mg bid or placebo(P) for 12 wks. Each laryngopharyngeal reflux symptom including,
hoarseness, lump in the throat, cough, clearing throat, sore throat, burning throat, breathing
difficulties or chocking, and mucous in the throat was scored 0-5 using modified visual
analog scales before and at the end of treatments. Positive pH monitoring results for lower
and upper esophagus were defined as %time pH<4 at lower esophagus >4 % and upper
esophagus >1%, respectively. A positive pH test was defined as a positive result in either
lower or upper esophagus. Results: The main symptoms were lump in the throat(n=20),
sore throat(4), burning throat(5), and hoarseness(1). 16 patients had weekly typical GERD
symptoms. 15, 15, and 18 patients had positive esophageal pH tests at lower, upper, and
either lower or upper esophagus, respectively. The baseline symptom score for R(12.7±1.8)
was similar to P(13.5±1.3, p>0.05). At the end of the 12th week, the symptom score for R
was 4.2±1.6, significantly improved compared to P(8.7±1.3, p<0.05). Baseline symptom
scores for patients with positive pH test in R and P group were similar(11.4±1.9 vs 14.2±1.9,
p>0.05). R significantly improved the symptom scores compared to P at the end of the 12th
wk(2.9±1.2 vs 9.7±1.7, p<0.01) in patients with positive pH tests. In contrast, the symptom
scores for R and P group in patients with negative pH tests were similar at both baseline
(14.5±3.4 vs 12.3±1.7, p>0.05) and the 12th wk(6.0±3.4 vs 7.2±2.4, p>0.05). Reflux finding
scores(RFS) evaluated by video endoscopies were improved similarly in both R and P(p>0.05).
There was no significant different of RFS improvements after R or P irrespective of the pH
results (p>0.05). Conclusions: High dose rabeprazole is superior to placebo for relieving
ENT symptoms in patients with laryngopharyngeal reflux disease especially in patients with
positive pH tests, but not in patients with negative pH tests. The dual channel, 24-hour
esophageal pH monitoring is helpful for identifying patients who will have benefits from
high dose PPI therapy.
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Reg IV Increases Apoptotic Resistance and Crypt Stem Cell Survival in a
Radiation-Induced Intestinal Injury Model
Kumar S. Bishnupuri, Qizhi Luo, Satheesh K. Sainathan, Eyad M. Hanna, Courtney W.
Houchen, Shrikant Anant, Brian K. Dieckgraefe
Background: The human Regenerating (Reg) gene family encodes four small-secreted proteins.
Reg IV, a recently identified member of the family is expressed at highest levels in the
colonic mucosa and is significantly upregulated in malignancies of the gastrointestinal (GI)
tract. Overexpression of Reg IV is also associated with increased resistance of colon tumor
cells to chemotherapy. The present study tests the hypothesis that Reg IV increases resistance
of GI tumor cells to apoptosis and enhances crypt stem cell survival following radiation-
induced intestinal injury. Methods: 6-wk old female C57BL/6J mice were injected IP with
vehicle or HPLC purified recombinant human Reg IV (rhR4) (4mg/kg body weight) either
once at 1 d or daily for 5 d prior to 6- or 12 Gy whole body γ-irradiation (IR). To assess
apoptotic cell death, mice were sacrificed 6 h following IR, and tissue from distal jejunum
was stained by Hematoxilin/Eosin and TUNEL methods. To identify GI crypt stem cell
survival, a microcolony assay was performed where the mice were administered bromodeox-
yuridine (BrdU) at 82 h following IR and sacrificed 2 h later. Proliferating crypts in the
distal jejunal sections were identified by immunostaining for BrdU. Surviving crypts were
counted as those with at least 6 BrdU positive cells. Results: Mice treated with rhR4 1 d
prior to IR exhibited a significant reduction in the number of apoptotic cells per crypt
compared to controls (1.4 ± 0.03 vs. 3.3 ± 0.12 in controls, and 1.4 ± 0.05 vs. 3.7 ± 0.11
in controls for 6- and 12 Gy, respectively). Moreover, the number of cells undergoing
apoptosis at crypt cell positions 3 to 6 counted from the base (corresponding to the location
of the putative stem cell) was less in rhR4-treated mice than in controls. Further, in the
microcolony assay, the rhR4-treated mice had significantly higher numbers of surviving
crypts than controls (25.0 ± 1.2 vs. 15.7 ± 1.2). These data suggest that rhR4 may protect
GI tumor cells including the crypt stem cell population against IR-mediated apoptosis.
Similar results for both apoptosis and stem cell survival were observed when Reg IV was
administered for 5 d before IR. Immunostaining of sections and real-time RT-PCR analyses
of total RNA isolated from distal jejunum 6h following IR demonstrated significantly increased
expression of the anti-apoptotic genes, survivin, Bcl-2 and Bcl-XL in rhR4-treated mice.
Conclusion: Reg IV appears to serve as an anti-apoptotic mediator in GI tumor cells. Since,
Reg IV is significantly upregulated in GI cancers, therapeutic strategies designed to interfere
with its activity may enhance the effect of radiation.
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Hif-1α Promotes Non-Hypoxic Proliferation in Colon Cancer Cells and
Xenografts
Duyen Dang, Fang Chen, Lawrence Gardner, Jordan Cummins, Carlo Rago, Fred Bunz,
Sergey V. Kantsevoy, Long H. Dang
BACKGROUND: The hypoxia-induced transcription factor HIF-1α is overexpressed in cancer
and its level of expression is correlated with patient mortality (Nat Rev Can 2003;3:721-
32). HIF-1α mediates cancer cell adaptation to hypoxia by directly transactivating genes
important for growth, metabolism, angiogenesis, and metastasis. More recently, cancer genetic
alterations have been shown to induce the expression of HIF-1α under non-hypoxic condi-
tions (Embo J 1998;17:5085-94). The role of HIF-1α expression in non-hypoxic cancer
cells remains unknown. AIM: We hypothesized that HIF-1α mediates colon cancer cell
proliferation under non-hypoxic conditions. METHODS: HIF-1α was genetically disrupted
by targeted homologous recombination in HCT116 human colon cancer cells (Nature 2004;
416:1). The resulting HIF-1α-/- cells are isogenic with their parental cells, with the exception
of HIF-1α ablation, as confirmed by western blot analyses. The effects of HIF-1α disruption
on cell proliferation, glycolysis, and downstream gene expression were determined in vitro.
In vivo, the effects of HIF-1α disruption on xenograft growth, microvessel density, blood
flow, hypoxia, and proliferation were measured. Two independent clones were analyzed.
RESULTS: In vitro, loss of HIF-1α significantly reduced glycolysis, G1 to S cell cycle
progression, cell proliferation, and the expression of known downstream genes under both
normoxic and hypoxic conditions. In vivo, loss of HIF-1α led to a ~40% decrease in xenograft
growth. Surprisingly, there were no alterations in tumor microvessel density as determined
by CD31 endothelial staining, or tumor blood flow as determined by Hoescht 33342 diffusion.
Moreover, there were no alterations in the extent of the hypoxic tumor compartments as
measured by incorporation of the hypoxia marker pimonidazole. Most significantly, loss of
HIF-1α led to ~50% less incorporation of BrdU in the non-hypoxic tumor compartments
(BrdU positive, pimonidazole negative regions). Thus, loss of HIF-1α affected cell prolifera-
tion within the non-hypoxic tumor compartments; rather than cell survival in the hypoxic
compartments, or tumor angiogenesis. CONCLUSIONS: These data provide the first evidence
that HIF-1α promotes cell proliferation in non-hypoxic cells in vitro and in vivo, through
induction of aerobic glycolysis and G1 to S cell cycle progression. Surprisingly, while HIF-
1α promoted cell proliferation and survival under hypoxic conditions in vitro, its expression
did not grossly contribute to the tumor hypoxic compartments in vivo. These data suggest
that HIF-1α-targeted therapy may be potentially valid in smaller, non-hypoxic tumors.
918
Expression of the Pro-Proliferative KrüPpel-Like Factor 5 (KLF5) in Intestinal
Epithelial Cells Is Induced By Bacterial Infection in Vitro and Correlates with
Colonic Crypt Cell Hyperplasia Caused By Citrobacter Rodentium in Vivo
Beth B. Mcconnell, Jan-Michael A. Klapproth, Maiko Sasaki, Sengthong Chanchevalap,
Jonathan P. Katz, Vincent W. Yang
BACKGROUND: Krüppel-Like Factor 5 (KLF5) is a pro-proliferative transcription factor
that is highly expressed in the intestinal tract and is localized to the base of the crypt epithelium
where active proliferation occurs. Citrobacter rodentium is a gram-negative bacterium that
colonizes the mouse colon, resulting in transmissible murine colonic hyperplasia (TMCH).
Previously, we reported that KLF5 expression is increased in intestinal epithelial cells in
response to the bacterial component lipopolysaccharide (LPS) [S. Chanchevalap and V.W.
Yang (2005) Gastroenterology 128, A33]. Here, we address whether KLF5 expression is
induced by bacterial infection in cultured intestinal epithelial cells and whether KLF5 levels
are increased in the mouse colon in response to C. rodentium infection. METHODS: Confluent
rat intestinal epithelial cells, IEC6, were infected with C. rodentium over a 5 hr time course.
KLF5 transcript and protein levels were determined by Northern and Western blot analyses,
respectively. Mice were infected by oral gavage with 5 x 108 colony-forming-units C. rodentium
or phosphate-buffered saline (PBS) control. Five infected and control animals were sacrificed
at 8, 15 or 21 days post-infection and the distal colon harvested and examined by immunocy-
tochemistry using polyclonal antibodies against KLF5 or the proliferative marker, Ki67.
RESULTS: In IEC6 cells infected with C. rodentium, KLF5 mRNA expression was induced
acutely and transiently, with maximal induction of 2-fold at 1.5 hrs post-infection. The
increase in KLF5 transcript levels was followed by a corresponding increase in KLF5 protein
levels. In a mouse model of bacterial infection, animals colonized with C. rodentium showed
a significant increase in colonic crypt epithelial cell proliferation by day 8, with crypt height
increasing up to 3-fold by day 21 when compared to controls. Expression of KLF5 was
correspondingly increased by 3-fold in the colon of infected animals at day 21, as measured
by the height of KLF5 immunofluorescence signals within the crypt compared to its height
in control tissues. The pattern of KLF5 staining in the expanding crypts of infected mice
correlated with that of the proliferation marker, Ki67. CONCLUSION: Our study demon-
strates that expression of KLF5 is induced in both rat intestinal epithelial cells in vitro and
in mouse colon tissues following infection with C. rodentium in vivo. This induction correlates
with an expansion of the crypt epithelium, and higher levels of KLF5 are found in the
proliferating cells of the crypt. Thus, KLF5 may potentially mediate crypt cell proliferation
in mouse colon in response to pathogenic bacterial infection.
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Protein Kinase C-ε Regulates the Apoptosis and Survival of Intestinal
Epithelial Cells
Yuning Zhou,, Qingding Wang, B. Mark Evers, Dai H. Chung
Free oxygen radicals are thought to be involved in the pathogenesis of necrotizing enterocolitis
(NEC) in premature infants. We have recently found that multiple intracellular signaling
pathways, including protein kinase C (PKC), are activated during oxidative stress-induced
intestinal epithelial cell injury. In particular, PKC-ε isoform has recently been implicated
during cellular response to ischemic stress in intestinal epithelia; however, its potential role
in NEC is unknown. Therefore, the purpose of this study was to determine the role of PKC-
ε in the apoptosis and survival of intestinal epithelial cells during oxidative stress. METHODS:
Rat intestinal epithelial (RIE)-1 cells were maintained in DMEM with 10% fetal bovine
serum. Cells were plated for 24 h and then treated with either H2O2 (500 µM) or vehicle.
To knockdown the expression of PKC-ε, RIE-1 cells were transfected with small interfering
RNAs (siRNA) directed against the PKC-ε or control siRNA. Treated cells were harvested
over a time course and protein extracted. Cell apoptosis was quantitated using a DNA
fragmentation ELISA assay. Western blotting was performed to determine PKC-ε, caspase-
3 activation, cleavage of poly (ADP-ribose) polymerase (PARP), total and phosphorylated
protein kinase D (PKD), a novel protein kinase which mediates important cell survival
signals during oxidative stress. RESULTS: Treatment with H2O2 resulted in the rapid
induction of phosphorylation of PKC-ε phosphorylation without affecting total PKC-ε expres-
sion. H2O2 significantly increased DNA fragmentation, caspase-3 activation and PARP cleav-
age in RIE-1 cells; siRNA directed against PKC-ε significantly enhanced H2O2-induced RIE-
1 cell apoptosis. To delineate the molecular mechanisms involved in the enhanced apoptosis
noted by PKC-ε silencing, we determined the phosphorylation status of PKD, which can be
regulated by PKC-ε. Treatment with H2O2 increased the expression of phosphorylated PKD
and PKC-ε siRNA completely blocked this induction. CONCLUSIONS: Our results suggest
that PKC-ε plays an anti-apoptotic role in the oxidative stress-induced intestinal cell injury.
Moreover, PKC-ε regulates PKD activity and may be essential for the survival of intestinal
cells. Delineating the signaling pathways regulating oxidative stress-induced intestinal cell
injury will provide a better understanding of the molecular mechanisms contributing to
NEC and potentially lead to novel treatment strategies.
920
Basic Fibroblast Growth Factor-Induced Multidrug Resistance 1 Expression
Plays An Important Role in the Protective Effect On Intestinal Epithelial
Injury
Minoru Matsuura, Hiroshi Nakase, Satohiro Masuda, Masanori Asada, Satoru Ueno,
Hiroshi Kitamura, Satoko Inoue, Norimitsu Uza, Katsuhiro Kasahara, Yasuhiko Tabata,
Ken-Ichi Inui, Tsutomu Chiba
Background and aims: Multidrug resistance (MDR) 1 gene product is highly expressed in
the epithelial surfaces of intestine, where it constitutes a barrier against luminal antigens
and bacteria. We previously reported that rectal administration of basic fibroblast growth
factor (bFGF) ameliorated experimental murine colitis (Gastroenterology, 2005). However,
it remains unclear whether MDR1 expression plays an important role in the protective effect
of bFGF on intestinal epithelial injury. The aim of this study is to investigate whether bFGF-
induced MDR1 expression is involved in the protective effect on intestinal epithelial injury
in vitro and in vivo. Materials and Methods: 1) Gene expression of MDR1a and MDR1b in
IEC-6 cells stimulated with and without human recombinant bFGF (HrbFGF; 100 ng/ml)
was determined by semiquantitative RT-PCR and western blot analysis. We also examined
the signaling pathway associated with bFGF-induced MDR1 expression. 2) MDR1 expression
in the small intestine of FVB/N normal mice treated with HrbFGF (5.0 mg/kg, i.p.) was
determined by western blot analysis. 3) We investigated the protective effects of bFGF on
intestinal epithelial injury using both mdr1 knockout mice and FVB/N control mice. Intestinal
epithelial injury was induced by X-ray irradiation (12Gy). Mice received HrbFGF (5.0 mg/
kg/day, i.p.) daily for 5 days just before and after irradiation. Mice were killed at 5 days
after irradiation, and histologic findings of small intestine were examined. Results: 1) Gene
expression of MDR1a and MDR1b in bFGF-treated cells was significantly higher than in
non-treated cells (MDR1a/GAPDH ratio: 1.21±0.08 vs 0.80±0.08; p<0.05, MDR1b/GAPDH
ratio: 1.38±0.11 vs 0.71±0.05; p<0.05). bFGF-induced MDR1 expression was inhibited by
pretreatment with ERK1/2 inhibitor and p38 inhibitor. Similar results were confirmed by
western blot analysis. 2) MDR1 expression in the small intestine of FVB/N normal mice
treated with HrbFGF was higher than in the non-treated mice. 3) Histologic findings of
small intestine in X-ray-irradiated FVB/N mice revealed shortening of small intestinal villus
height and destruction of intestinal crypt. In contrast, in FVB/N control mice treated with
HrbFGF, an obvious increase of villus height and restoration of intestinal mucosa were
observed. However, histologic findings of mdr1 knockout mice treated with HrbFGF revealed
severe distortion of regenerative crypt and less restoration of goblet cells, compared with
bFGF-treated FVB/N control mice. Conclusion: The present study strongly suggests that
bFGF-induced MDR1 expression plays an important role in the protective effect on intestinal
epithelial injury.
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Toll-Like Receptor (TLR)4 Is Involved in the Epithelial to Mesenchymal
Transition (EMT): Implications for Colitis-Associated Cancer
Masayuki Fukata, Anli Chen, Suneeta Krishnareddy, Junsuke Maki, Moshe Arditi, Maria
Abreu
Background: We have recently demonstrated that mice deficient in TLR4 or its downstream
adapter molecule MyD88 have decreased epithelial cell proliferation following DSS induced
colitis, resulting in defective epithelial repair. During repair or carcinogenesis, epithelial cells
may undergo an EMT characterized by morphological changes, increased expression of
fibroblast markers, and increased cell motility. We hypothesized that TLR4 signaling mediates

















stimulated with LPS (2μg/ml) for 24 hours. EMT was assessed by morphology and wound
closure assay. Alterations in expression of epithelial and mesenchymal markers were deter-
mined by immunofluorescent staining of E-cadherin and vimentin or integrin αvβ6, respect-
ively. Carcinogenic phenotype was examined by epidermal growth factor receptor (EGFR)
phosphorylation and expression of EGF like amphiregulin (AR) using Western blot and
real-time PCR, respectively. Transforming growth factor (TGF-β1), tumor necrosis factor
(TNF-α), and secreted AR were measured by ELISA. Small interfering RNA (siRNA) against
MyD88 was used to confirm the downstream signal involved in this process. Results:
Treatment of IEC with LPS resulted in a spindle cell morphology. LPS stimulation significantly
increased cell migration rate into a wounded area, and this effect was abolished by MyD88
siRNA. Punctate expression of the epithelial marker E-cadherin decreased after LPS stimula-
tion. By contrast, the fibroblast marker integrin αvβ6 was detected in the cytoplasm of LPS
treated cells but not in untreated cells. Vimentin increased with LPS stimulation. EGFR
phosphorylation was observed within 30 min after LPS stimulation and was abolished by
MyD88 siRNA. Expression of AR peaked 24 hours after LPS stimulation. TGF-β1, a potent
inducer of EMT, was significantly induced after 24 hours of LPS treatment. Induction of
TNF-α was also observed after 24 hours but was not temporally associated with EGFR
phosphorylation. Conclusion: TLR4 signaling results in EMT in IEC in a MyD88-dependent
fashion. TLR signaling is critical for epithelial repair but activation of the same pathways
may lower the cancer threshold in the setting of chronic injury. Because dysregulated immune
responses to commensal bacteria are observed in patients with IBD, our results may provide
novel insights into the pathogenesis of colitis-associated cancer in IBD.
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Optimization of 6-Thioguanine Production By Allopurinol in Inflammatory
Bowel Disease Patients Not Responding to Azathioprine/ 6-Mercaptopurine
Leads to Improved Disease Activity, Reduced Corticosteroid Requirements and
Normalization of Liver Enzymes
Miles Sparrow, Scott A. Hande, Sonia Friedman, Dingcai Cao, Stephen B. Hanauer
Background: At least 40% of IBD patients do not respond to the immunomodulators azathiop-
rine(AZA) or 6-mercaptopurine(6-MP). Many non-responders have high/normal thiopurine
methyltransferase (TPMT) activity and preferentially metabolize 6-MP to 6-methylmercaptop-
urine(6-MMP). Aim: We describe the clinical response to adjunctive allopurinol, used to
shunt 6-MP metabolism towards the active metabolites 6-thioguanine nucleotides (6-TGN),
in 6-MP/AZA non-responders. Methods: 21 outpatients (13 CD, 6 UC, 2 IC) from 2 IBD clinics
who were clinical non-responders to AZA/6-MP and whose metabolite profiles demonstrated
preferential metabolism towards 6-MMP>6-TGN were included. Subjects were commenced
on allopurinol 100 mg daily and the current dose of 6-MP/AZA was reduced by 50-75%.
Patients were followed clinically with weekly CBCs and serial 6-TGN and 6-MMP levels.
Partial Harvey Bradshaw Index scores (pHBI-Number of bowel movements, pain, well being))
were used to assess response in CD patients, Mayo Scores (without endoscopy) were used
to assess patients with UC & IC. Results: Median doses of AZA(6 patients) pre- and post
allopurinol were 200 mg(50-250) and 92 mg(50-100) respectively; and median doses of 6-
MP(15 patients) pre-and post allopurinol were 87 mg(0-125) and 51 mg(25-100) respect-
ively. After initiating allopurinol, 6-TGN levels increased from a mean of 187.2 (± SEM)
±16.7 to 387.3±37.4 pmol/ 8 x 108 RBCs(p < 0.001) while 6- MMP levels decreased from
a mean of 10517.1±1212.3 to 1919.3±423.6 pmol/ 8 x 108 RBCs(p < 0.001). The addition
of allopurinol led to a decrease in WBC from a mean of 8.6±1.0 to 6.1±0.6 x 108/L(p =
0.003). Analysis of disease activity indices showed that the addition of allopurinol led to a
reduction in the pHBI in CD patients from a mean of 4.9±1.0 to 1.5±0.3 points(p=0.001)
and in UC patients the Mayo Score decreased from a mean of 4.1±0.7 to 2.9±0.7 points(p=
0.13). The addition of allopurinol enabled a reduction in prednisone dosage from a mean
daily dose of 17.6±3.9 to 1.8±0.7 mg (p<0.001) and led to normalization of transaminases
with mean ALT levels reducing from 101.6±26.9 to 33.9±5.2 IU(p=0.01), and mean AST
levels reducing from 42.5±8.1 to 23.5±1.6 IU(p=0.12). Conclusions: The addition of allopuri-
nol to thiopurine non-responders with high/normal TPMT activity and preferential shunting
to 6-MMP appears to be an effective and safe means of optimizing 6-TGN production, leading
to improved disease activity scores, reduced corticosteroid requirements and normalization of
hepatic transaminases. Long-term efficacy and safety related to potential nodular regenerative
hepatic changes will be monitored.
923
Continuation of Immunomodulators Is Not Required to Maintain Adequate
Infliximab Efficacy in Patients with Crohn’s Disease But May Improve
Pharmacokinetics
Gert A. van Assche, Gilles Paintaud, Geert D'Haens, Filip Baert, Severine Vermeire, Maja
Noman, Herve Watier, Charlotte Magdelaine, Paul Rutgeerts
Background. Concomitant immunomodulators at the start of infliximab treatment improve
long-term duration of response in parallel with sustained infliximab serum levels. Aims: to
investigate the role of immunomodulators in maintaining adequate infliximab trough levels
and long-term efficacy in patients beyond 6 months of combined therapy. Methods. 80
patients were randomized to continue (CON, n=40) or to interrupt (DIS, n=40) immunomod-
ulators (azathioprine or methotrexate)≥6 months after the start of infliximab (5 mg/kg IV)
in combination therapy. All patients were in clinical remission at baseline. Infliximab serum
levels were determined q8 wks. (before every infusion) and efficacy and adverse events were
assessed at the same time-points. Patients requiring a change in IFX dosing strategy due to
a disease flare (increase in CDAI ≥ 70) or to a de novo fistula, were considered failures
but were followed for efficacy and safety. Results. Patients in the 2 treatment groups had
comparable overall IFX trough levels (median CON: 3.2 (percentile 25-75: 1.4-5.4), DIS
2.4 (0.9-5.3) µg/mL (CON) (median follow up: 83 wks.), but high inter-individual variations
were observed. For the change of IFX levels over time we observed a trend towards decrease
in the discontinuation group (median change baseline to Wk 24: +0.32 (0.005-1.8) (CON), -
0.647 µg/mL (-2.0-1.28) (DIS, p=0.05), baseline to Wk48: +1.29 (0.9-3.0) (CON), -0.57
(-2.2-3.1) µg/mL (DIS, p=0.18). Fourteen/40 (35%) (CON) and 13/40 (32%, p=0.81) (DIS)
patients required a change in dosing interval. Two more patients in each group failed because
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of tolerability or lack of compliance. The median time to failure was: CON 17 wks. (25-75
perc.:8-25) , and DIS 8 wks. (6.5-25.5) (CON) respectively (p=0.82). A ≥50% decrease in
infliximab trough levels preceded clinical relapse in only 1/13 (CON) and 4/13 (DIS, p=
0.18) patients respectively. IFX was interrupted due to complete loss of response or tolerability
in 2/40 (C0N) and 4/40 (DIS, p=0.40) patients respectively. All others regained clinical
response with changes in IFX treatment schedule. Conclusion. Discontinuation of immuno-
modulators after at least 6 months of combined treatment with systematic IFX maintenance
does not affect long term efficacy but may lead to lower trough levels.
924
Adjustment in Infliximab Dose Or Dosing Interval in Crohn’s Disease (CD):
Experience from the University of Pittsburgh
Benjamin Siemanowski, Kevin Kip, Scott Plevy, Miguel Regueiro
BACKGROUND: Infliximab is effective therapy (tx) for CD. Standard dosing includes 3 dose
induction (0,2,6 wks) at 5mg/kg followed by q8wk maintenance. Pts who lose response
often require a dose increase or interval decrease. Up to 62% of Rheumatoid arthritis pts
require a change in infliximab dosing (JMCP2005;11:383-93). The proportion of CD pts
requiring a dose adjustment is unknown. OBJECTIVE: To determine the frequency of
infliximab dose adjustment in CD pts. METHODS: Using our infliximab infusion database
we identified all CD pts who received >8 doses (46 wks) of infliximab. Data collected
included infliximab dose and dosing interval, concomitant immunomodulators (6MP/AZA/
MTX) at the onset, and presence of a lapse in tx (defined as a >6mos interval between doses
at any point). Subgroup comparison of infliximab dosing adjustments was made between
pts with and without lapses in tx. RESULTS: There were 293 pts who received infliximab
for CD and 108 who had received >8 doses. All 108 pts had an initial response to infliximab
and none were primary nonresponders. 51/108 (47.2%, 95% confidence interval (CI):
37.5%-57.1%) had an increase from 5 mg/kg to 10 mg/kg; median number of doses before
change was 5 (range 2-17). 28/108 (25.9%, 95% CI: 18.0%-35.3%) had a decrease in
interval from q8 wks to every 4-6 wks; median number of doses before interval decrease
was 7 (range 3-18). 25/108 (23.1%, 95% CI: 15.6%-32.3%) had a change in both dosage
and interval, while 3/108 had a change in interval only. Overall, 54/108 (50.0%, 95% CI:
40.2%-59.8%) had a dosage increase and/or an interval decrease. Although the reason for
dose adjustment was not available, our practice is to adjust infliximab dosing in pts experien-
cing sx’s and signs (endoscopic recurrence) of CD. The majority of pts (91/108, 84.3%)
were on concomitant immunomodulators; of the 17 not, 9 required a dose adjustment. 58
pts (57%) had no lapse in infliximab and 43 (43%) pts had at least one >6mos lapse between
doses (no data available in 7 pts). The proportion of pts requiring an increase in infliximab
dose or decrease in dosing interval was similar between pts with and without a lapse in tx
(48.9% vs. 53.4%, respectively: p=0.69). Of the 58 pts without a lapse in therapy, 29 (50%)
were on concomitant immunomodulators at the time of 0,2,6wk infliximab induction and
q8wk maintenance; 14/29 (48.3%) of these pts still required infliximab dosing adjustment.
CONCLUSIONS: 50% of CD pts receiving long-term infliximab require an increase in dose
or decrease in dosing interval. Concomitant immunomodulators and a q8wk schedule did
not prevent the need for infliximab dosing change.
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Is Infliximab a Durable Therapy for Crohn’s Disease?
Stephen J. Rudolph, David I. Weinberg, Robert P. McCabe
Background: Long-term use of maintenance infliximab (IFX) therapy for Crohn’s disease
(CD) is becoming increasingly common. Maintenance infliximab has been shown to be safe
and effective up to 12 months. However, evaluation of maintenance treatment beyond 12
months is limited. Many IFX treated patients eventually experience a loss of benefit or an
adverse event that results in discontinuation of IFX therapy. The aim of this study was to
determine if maintenance of response (MOR) to IFX therapy is durable beyond 12 months,
and to examine factors affecting this durability. Methods: A retrospective chart review was
performed on 198 CD patients who started IFX with maintenance dosing planned and had
at least 30 months follow-up. MOR was defined as continued IFX therapy, without loss of
response or adverse event requiring discontinuation. MOR rates were estimated using Kaplan-
Meier analysis. The effect of specific variables on MOR rates was calculated using multivariate
Cox proportional hazard regression analysis. Results: An initial response was seen in 174/
198 (88%) patients. MOR rates at 72 months were estimated to be 66.4% for initial responders
and 58.2% for all patients. Analysis of the 174 initial responders revealed smoking decreased
MOR (HR=2.63, p=0.005), immunomodulators initiated >3 months prior to IFX tended to
increase MOR (HR=0.50, p=0.088) and immunomodulators initiated <3 months prior to
IFX had no effect on MOR (HR=0.80, p=0.55). Analysis of all 198 patients failed to show
an impact of smoking on MOR (HR = 1.63 P=0.087), while immunomodulators started >3
months prior to IFX increased MOR (HR=0.50, p=0.027), and those started <3 months
prior to IFX had no effect (HR = 0.66 P=0.17) (figure). Conclusions: Long-term maintenance
IFX treatment of CD was durable for most patients. Concurrent immunomodulators may
increase the durability of maintenance IFX treatment. Smoking appears to decrease the
durability of maintenance IFX treatment.
Effect of Immunomodulators on Maintenance of Response in All 198 Patients Treated
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Long-Term Infliximab Mainteance Infusion Regimens and Rates of
Hospitalization, Surgery and Disability in Crohn’s Disease
John B. Williams, L:ydia R. Weber, Dawn B. Beaulieu, Mazen Issa, Joshua F. Knox, Jeanne
Emmons, Mary F. Otterson, Ossama A. Hatoum, David G. Binion
Introduction: Although infliximab is effective in the management of moderate to severe
Crohn’s disease (CD), there is no consensus regarding optimal infusion schedules and the
need/benefit of maintenance treatment. Concerns regarding cost, and lack of long-term
efficacy data beyond 1 yr have diminished enthusiasm for ongoing maintenance treatment.
We reviewed our center’s database, focusing on rates and incidence of hospitalization, surgery
and disability in a cohort of CD pts, before and after specific long-term infliximab regimens
followed beyond 2 years. Methods: This was a retrospective, observational study of CD
patients who were treated with maintenance infliximab beyond 2 yrs. Maintenance infliximab
infusion regimens were categorized as SCHEDULED (loading and maintenance infusions q
≤8 weeks) or EPISODIC (all other infusion schedules; i.e. no loading regimen and/or any
maintenance infusion interval delayed beyond 8 wks). Histories of hospitalizations, surgeries
and permanent disability were recorded before and after the initiation of infliximab. Results:
56 pts met criteria for long-term maintenance infliximab treatment (31-SCHEDULED main-
tenance; 25-EPISODIC maintenance). Rates of hospitalization (39% vs 48%; p=NS) and
surgery (55% vs 48%; p=NS) between the SCHEDULED and EPISODIC pts were identical
prior to infliximab initiation. The number of hospitalizations per pt between the SCHEDULED
and EPISODIC groups (0.548 vs 0.6; p=NS) were identical. Similar relationships were evident
in surgical events prior to initiation of therapy (mean1.839 vs. 1.8; p=NS). After long-term
infliximab maintenance treatment, rates of hospitalization between the SCHEDULED and
EPISODIC infusion regimens differed significantly (16% vs 64%; p≤0.001). Surgical rates
favored SHEDULED over EPISODIC as well (3% vs 48%; p≤0.01). The cumulative number
of hospitalizations after infliximab in SCHEDULED was 5 and EPISODIC was 29. Following
infliximab initiation the cumulative number of surgeries in SCHEDULED was 3 and in
EPISODIC was 20 in the >2 year followup period. Finally, rates of permanent disability
were significantly lower in the CD pts treated with long-term SCHEDULED infusions com-
pared with the EPISODIC regimen (3% vs 25%; p≤0.03). Conclusions: Significant differences
in clinical outcome emerge in CD pts treated with specific infliximab infusion regimens
beyond 2 yrs. Scheduled maintenance infusions are superior to episodic infusions schedules,
when rates of hospitalization, surgery and disability are used to assess long-term clinical out-
come.
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Predictive Factors of Response to Cyclosporine (CsA) in Severe Steroid-
Refractory Ulcerative Colitis (SSRUC)
Cacheux Wulfran, Lemann Marc, Marteau Philippe, Seksik Philippe, Nion-Larmurier
Isabelle, Afchain Pauline, Allez Mathieu, Daniel Fady, Beaugerie Laurent, Gendre Jean-
Pierre, Cosnes Jacques
CsA is an effective rescue therapy in SSRUC and may avoid immediate colectomy in more
than fifty per cent of patients. However, the individual response to CsA is poorly predictable.
The aim of this study was to identify predictive factors of response to CsA in SSRUC.
Methods : 135 patients with SSRUC admitted consecutively in three Paris IBD centers
between 1992 and 2004 were included in this retrospective analysis. Data collected on the
1st day of CsA therapy were age, gender, smoking habit, UC characteristics, duration
of steroid treatment, Truelove and Witts criteria, weight loss, polynuclear neutrophils,
lymphocytes and platelets counts, C-reactive protein, serum magnesium, and serum choles-
terol. Colonoscopy was performed within two days preceding or following CsA treatment
in 118 patients and presence of severe endoscopic lesions (extensive deep ulceration, mucosal
detachment, well-like ulcerations, and large mucosal abrasion) was searched for. In order
to identify independent predictive factors of colectomy, the variables selected at the 0.20
level by the log-rank test were introduced into a regression Cox model, successively for the
whole population and for the patients who have had colonoscopy. Results : The actuarial
rate of colectomy was 0.45 at 6 months. Cox analysis in the whole population selected three
predictive criteria of colectomy : body temperature > 37,5°C [adjusted hazard ratio 1.94
(CI 95% 1.51-2.49)], heart rate > 90 bpm [adjusted HR 1.86 (1.45-2.38)], and CRP > 45
mg/L [adjusted HR 1.70 (1.34-2.16)]. The 6-mo. colectomy rates were 22, 47, 55 and 92%
when 0, 1, 2 and 3 of these criteria, respectively, were present. In the 118 patients who
underwent colonoscopy, the presence of at least one severe lesion was an independent
predictive factor of colectomy (adjusted HR 2.38 [1.80-3.14]). Colonoscopy findings did
not change the therapeutic decision in patients without severe clinical or biological criteria
(n=42) nor in those with 3 criteria (n=12). However, colonoscopy was decisive in patients
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with 1 or 2 criteria [among 35 patients with severe endoscopic lesions, 25 colectomized
(71%) vs. 5 among 29 without severe endoscopic lesion (17%), p<0,001]. In total, the
clinical, biological and endoscopic criteria allowed the classification of patients into 2 groups,
those with a high risk of colectomy (80% at 6 months) and those with a low risk of colectomy
(20% at 6 months). Conclusion : In patients with SSRUC the combination of simple criteria
(fever, tachycardia and elevated CRP) is useful to predict the response to CsA. Colonoscopy
is crucial in patients with intermediate clinical and biological severity.
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Colonic Irritation in the Rat Sensitizes Urinary Bladder Afferents to PAR-2
and Capsaicin: Role of Neuropeptides in the Overlap of Chronic Pelvic Pain
Disorders
Elena E. Ustinova, Michael A. Pezzone
Background: Chronic pelvic pain (CPP) disorders frequently overlap, but the mechanism
underlying this phenomenon is still unclear. Proteinase activated receptors (PARs), important
mediators of pain and inflammation (Steinhoff 2000; Fiorucci 2002), can sensitize the
capsaicin receptor to induce hyperalgesia (Amadesi 2004). In the bladder, PAR-2 receptors
are co-localized in nerve fibers with capsaicin receptors, and upregulation of PAR-2 receptors
was shown in cyclophosphamide-induced cystitis (Dattilio 2005). Some data suggest that
activation of PAR-2 receptors is mediated by neuropeptide-dependent mechanisms (Su
2005). Recently we demonstrated that colonic irritation with trinitrobenzenesulfonic acid
(TNBS) lead to the development of neurogenic cystitis (Pezzone 2005)as evidenced by the
activation of bladder mast cells and increased sensitivity of bladder afferents to capsaicin,
substance P, and bradykinin. We hypothesize that colonic irritation causes cross-organ
bladder sensitization by way of neuropeptide release from sensory afferents and upregulation
of PAR-2 receptors in the bladder. Methods: Single unit afferent activity was recorded from
fine filaments of the pelvic nerve in urethane-anesthetized SD female rats 10 days after intra-
colonic administration of TNBS. Only spontaneously active capsaicin sensitive afferents with
receptive fields in the bladder and conduction velocities <2.5 m/s (unmyelinated C-fibers)
were studied. Afferents were tested with iv capsaicin and the PAR-2 agonist, SLIGRL. Results:
In the control group, 37% of capsaicin-sensitive afferents were activated with the PAR-2
agonist. In the TNBS group, the number of PAR-2 activated afferents increased to 58%
(p<0.01). The magnitude of afferent responses to capsaicin and SLIGRL was increased by
270% and 190%, respectively, in TNBS group as compared to controls. Colonic irritation
also significantly increased the responses of bladder afferents to bladder distension. Pretreat-
ment of the animals with capsaicin (100 mg/kg, 3 days before TNBS administration) abolished
these effects. Conclusions: In rats, colonic irritation sensitizes urinary bladder afferents to
capsaicin, PAR-2 agonist and bladder distension. Systemic depletion of sensory afferents
abolished these effects suggesting that neuropeptides facilitate the release of endogenous
PAR-2 agonists such as mast cell tryptase to upregulate PAR-2 and to produce cross-organ
sensitization. These findings add further support to the role of mast cells and their mediators
in pelvic afferent cross-sensitization and the overlap of CPP disorders. Supported by NIH
grant DK066658 to M.A.P.
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TRPV4 Is Implicated in PAR2 -Induced Visceral Hyperalgesia and Allodynia
Nicolas Cenac, Christophe Altier, Nathalie Vergnolle
Background and aim: PAR2 activation induces somatic and visceral hyperalgesia and allody-
nia by sensitizing TRPV1 (Transient Receptor Potential Vanilloid) in response to thermal
but not mechanical stimuli. The TRPV4 ion channel transduces osmotic and mechanical
stimuli. In trpv4 null mice, TRPV4 was found to be necessary for normal thresholds in
response to noxious mechanical stimuli. We hypothesize that TRPV4 is implicated in PAR2-
induced visceral hyperalgesia and allodynia in response to a mechanical stimulus. Methods:
In a first set of experiments, neurons from mice dorsal root ganglia (DRG) were isolated to
perform immunostaining of PAR2 and TRPV4. In a second set of experiments, three groups
of 8 mice were intrathecally injected with TRPV4 SiRNA and 3 other groups with a control
SiRNA. Three days after the SiRNA treatment, mice were treated with the TRPV4 agonist
4αPDD (100μM, 10μl per mouse), or with a non inflammatory dose of PAR2 agonist (10μg
per mouse), SLIGRL. To evaluate visceral nociception in mice, we performed colorectal
distention (CRD) 30 min after TRPV4 agonist or 6 hours after PAR2 agonist treatment. CRD
was performed by insertion of a balloon catheter into the colon, 5 mm proximal to the
rectum and was increasingly inflated in stepwise 15mmHg gradation of pressure, from 0 to
60 mmHg. The external abdominal oblique muscle contraction is recorded and used as an
index of pain sensation. Results: 90% of the DRG neurons express TRPV4 and 60 % PAR2,
PAR2 and TRPV4 coexpress on the same neurons. Intrathecal administration of TRPV4
SiRNA significantly decreases pain sensation in response to CRD compared to control SiRNA
groups, for all volumes of distension 3 days after its administration. Intrathecal injection of
4αPDD caused hyperalgesia and allodynia 30 minutes after its administration in response
to CRD. Intracolonic administration of SLIGRL caused hyperalgesia and allodynia 6 hours
after its administration in response to CRD. Hyperalgesia and allodynia induced by the
treatment with 4αPDD or with SLIGRL were both significantly inhibited by the pretreatment
with TRPV4 SiRNA. Conclusions: Our study shows that treatment with TRPV4 or PAR2
agonist increased visceral hyperalgesia and allodynia by a TRPV4-related mechanism. More-



















Dexamethasone Prevents Visceral Hyperalgesia Induced By Proteinase-
Activated Receptor-2 Agonist Through Modulation of Colonic Mast Cell
Activation in Rats
Richard Roka, Afifa Ait-Belgnaoui, Christel Salvador-Cartier, Aurelie Waget, Jean
Fioramonti, Lionel Bueno
Background. Recent clinical data suggest that low-grade inflammation plays a role in the
genesis of irritable bowel syndrome (IBS). Intracolonic infusion of proteinase-activated recep-
tor-2 (PAR-2) agonist induces a delayed colonic hypersensitivity resulting from alterd gut
permeability and mast cell degranulation. The aim of this study was to evaluate if a corticoïd
such as dexamethasone may prevent PAR-2 activation induced visceral hyperalgesia in rats,
and to determine its level of action. Methods. Abdominal contractions provoked by rectal
distension were recorded in rats equipped with abdominal intramuscular electrodes. Changes
in sensitivity to rectal distension following intracolonic administration of PAR-2 activating
peptide (SLIGRL), changes in colonic mucosal rat mast cell proteinase-II (RMCP-II) content,
mast cell number and PAR-2 expression were measured after 4 days treatment with dexame-
thasone (1mg/day/rat ip) or its vehicle (water). Effect of short term dexamethasone administra-
tion (3x during 24 hours) on mast cell degranulator (BRX537A)-induced visceral hyperalgesia
was also determined. In vitro, the effects of SLIGRL and mast cell degranulator (C48/80)
on permeability of colonic strips from vehicle or dexamethasone treated rats were investigated
in Ussing chambers. Effect of short term dexamethasone administration (3x during 24 hours)
on mast cell degranulator (BrX537A) provoked visceral hyperalgesia was also determined.
Results. Dexamethasone (4 days) diminished the SLIGRL-induced hyperalgesia for all vol-
umes of distension from 0.4 to 1.2mL while it had no effect per se on rectal sensitivity. This
effect was coupled with reduced in vitro colonic permeability response to C48/80 (0.03±0.32
vs. 1.86±0.46 nmol/h/cm2, p<0.05), decreased RMCP-II content (0.17±0.01 vs. 0.25±0.02
ng/mg of total proteins, p<0.05) and mast cell number (15.02±2.77 vs. 147.30±14.38 mast
cell/mm2, p<0.01). Dexamethasone did not influence colonic mucosal PAR-2 expression
and permeability response to SLIGRL. Short term dexamethasone administration prevented
BrX 537A induced visceral hypersensitivity (4.7±1.9 vs. 11.8±2.0 contractions/5 min, p<0.01
a 0.4mL). Conclusions. Dexamethasone attenuates PAR-2 agonist induced visceral hyper-
sensitivity in rats by reducing colonic mast cell activation but does not prevent the action
of PAR-2 agonist on colonic permeability.
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Agonists of Protease-Activated Receptor 2 (PAR2) Activate Protein Kinases D
(PKD) 1-3 Expressed in Primary Afferent Neurons to Sensitize Transient
Receptor Potential Vanilloid (TRPV) 1 and 4
Andrew Grant, Lorna Divino, Osvaldo Rey, Enrique Rozengurt, Nigel Bunnett, Silvia
Amadesi
Agonists of many G-protein coupled receptors activate PKD, a family of 3 Ser/Thr kinases, by
protein kinase C- (PKC) dependent phosphorylation. PKC isozymes mediate the hyperalgesic
effects of agonists of certain receptors, including PAR2, by sensitizing TRPV channels in
primary spinal afferent neurons. We investigated if agonists of PAR2 activate PKD in nocicep-
tive neurons and sensitize TRPV1 and -4 to cause hyperalgesia. We localized PKDs in rat
dorsal root ganglia (DRG) using immunofluorescence and confocal microscopy. Immunoreac-
tive PKD1/2 and PKD3 were detected at the membrane, cytosol and nucleus of neurons
and in nerve fibers. Small diameter neurons expressing PKDs expressed calcitonin gene-
related peptide and bound isolectin B4, markers of nociceptive C fibers. Large diameter
neurons expressing PKDs expressed neurofilament 200 kDa, a marker of Ad fibers. Neurons
expressing PKDs coexpressed PAR2 and PKC epsilon, potential upstream regulators of PKD,
and TRPV1, a potential downstream target of PKD. We examined trafficking of PKD in
HEK293 cells using PKD-GFPs, and in cultured rat DRG using PKD antibodies. In unstimu-
lated cells, PKD1-3 were cytosolic. PAR2 activating peptide (AP, 100 µM) and the phorbol
ester PMA (positive control, 1 µM) induced membrane translocation of PKDs within 5 min.
To confirm enzyme activation, we used antibodies to phospho-PKD-S744/748 and S916. In
unstimulated cells, there was minimal detectable PKD phosphorylation. PAR2-AP and PMA
increased PKD-S744/748 and S916 at the plasma membrane in HEK293 cells and neurons.
PKD phosphorylation in HEK293 cells was confirmed by western blotting. To determine if
PKD contributes to sensitization of ion channels, we examined PAR2-induced sensitization
of TRPV-mediated Ca2+ signals in HEK293 cells. Pretreatment with PAR2-AP (100 µM, 5
min) sensitized responses to the TRPV1 agonist capsaicin (10 nM) and the TRPV4 agonist
4a-phorbol 12,13-didecanoate (0.1 µM). The PKD inhibitor, Gö6976 (0.1 µM) prevented
sensitization of both channels. To assess the role of PKD in hyperalgesia, we measured the
latency of paw withdrawal (LPW) of mice to radiant heat. Mice received intraplantar injections
of Gö6976 (1 µg) or vehicle, and 30 min later, PAR2-AP (1 ng) plus capsaicin (1 µg) or
vehicles. 3 h later, the LPW was 12.05s in mice receiving Gö6976/vehicle vs. 8.51s in mice
receiving vehicle/PAR2-AP-capsaicin. This hyperalgesic effect was not observed in mice
receiving Gö6976/PAR2-AP-capsaicin, whose LPW was 12.31s. Thus, PAR2 agonists activate
PKD1-3 in nociceptive neurons, where PKD may sensitize TRPV channels to mediate hyperal-
gesia. Supported by NIH grants DK57480, DK43207.
932
Effects of Proteinase-Activated Receptor-2 (PAR2) Deficiency in Ischemia and
Inflammatory Responses in Mouse Intestine
Eric Hyun, Patricia Andrade-Gordon, Nathalie Vergnolle
PAR2 is a member of a G-protein coupled receptor family that is activated by various
proteinases including trypsin, coagulation factor VIIa/Xa, and human mast cell tryptase.
Considering that the activation of PAR2 elicits pro-inflammatory responses in various tissues
including mouse colon, together with the fact that high levels of trypsin and tryptase are
present in the colon of inflammatory bowel disease (IBD) patients, it is reasonable to assume
that PAR2 plays a significant role in the pathogenesis of colitis. Therefore, we investigated
the effects of PAR2 deficiency in mice models of intestinal inflammation using PAR2-deficient
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(PAR2KO) mice. Colitis was induced in C57BL6 wildtype and PAR2KO mice by administration
of 2.5% DSS (in drinking water) or TNBS (1 mg or 2 mg in 100 μl of ethanol, intracolonically).
Seven days after colitis induction, intravital microscopy was performed on selected colonic
venules to assess the role of PAR2 on leukocyte rolling, adherence and recruitment. Intestinal
inflammation was also induced by ischemia/reperfusion via clamping of the superior mesen-
teric artery for 30 minutes, where immediately after intravital microscopy was performed
on selected intestinal venules. Various inflammatory parameters including maximum bowel
thickness, myeloperoxidase (MPO) activity, and macroscopic damage score were measured.
Lastly, the survival rate and weight loss of the animals were also assessed. PAR2KO with
ischemia/reperfusion-, DSS-, or TNBS-induced intestinal inflammation displayed significant
lower numbers of adherent leukocytes to the vessel wall, and vessel dilation compared to
wildtype animals. Concurrently, MPO activity in PAR2KO was significantly lower compared
to wildtype mice in all three models of intestinal inflammation. Colitis induced by DSS or
TNBS elicited higher damage score and bowel thickness in wildtype mice than PAR2KO.
We observed a rate of 64% mortality in wildtype mice, whereas only 8% was observed in
PAR2KO animals. Lastly, severe weight loss commonly associated with the TNBS-induced
colitis was more readily seen in wildtype mice than PAR2KO. In conclusion, deficiency in
PAR2 modulated the recruitment of leukocytes in the intestinal tissues and attenuated the
inflammatory responses in the mouse colon. Furthermore, reduction in numerous inflammat-
ory parameters, weight loss and mortality rates in PAR2KO compared to wildtype animals
indicate a pro-inflammatory role of PAR2 in the intestine. Thus, this study shows PAR2
activity and PAR2 activating proteases as possible therapeutic targets in the treatment of
inflammatory diseases in the intestine.
933
Signaling By Protease-Activated Receptors PAR1 and PAR2 in Smooth Muscle
Reflects Differential Activation of G Proteins: GQ, GI and G12 By PAR1 and
GQ, GI and G13 By PAR2
Wimolpak Sriwai, Jiean Huang, Karnam S. Murthy
Extracellular proteases generate intracellular signals by activating a family of four cloned G
protein-coupled protease-activated receptors (PAR1-PAR4). PAR receptors couple variously
to pertussis toxin (PTx)-sensitive and -insensitive G proteins. Their expression, G protein
coupling, and signaling in smooth muscle are not known. Aim. To determine the expression
of PARs and characterize their signaling pathways in rabbit gastric muscle cells. Methods.
PAR protein expression was determined by immunoblot and G protein activation by
[35S]GTPγS binding to activated Gα subunits. PI hydrolysis, cAMP formation, and Rho
kinase activity were measured in freshly dispersed muscle cells and in cultured muscle cells
transfected with various Gα minigenes. Muscle contraction was measured by scanning
micrometry. Results. Immunoblot analysis demonstrated expression of PAR1 and PAR2 but
not PAR3 or PAR4 in smooth muscle. The PAR1 agonist SFLLR activated Gq, G12, and Gi3,
but not Gi1, Gi2, G13 Gs or Gz, whereas the PAR2 agonist SLIGRL activated Gq, G13, Gi1,
and Gi2, but not Gi3, G12, Gs or Gz. Both PAR1 and PAR2 agonists stimulated PI hydrolysis
and Rho kinase activity and inhibited cAMP formation in a concentration-dependent fashion.
PAR1-stimulated PI hydrolysis was abolished in cells expressing Gαq minigene, but was not
affected in cells expressing Gαi minigene or in cells treated with PTx. PAR2-stimulated PI
hydrolysis was partly inhibited in cells expressing Gαq (62%) or Gαi (35%) minigene and
in cells treated with PTx (30%). Thus, although it activated Gi3, PAR1 stimulated PI hydrolysis
exclusively via Gαq, whereas PAR2 stimulated PI hydrolysis via both Gαq and Gβγi. PAR1-
stimulated Rho kinase activity was abolished in cells expressing Gα12 minigene, whereas
PAR2-stimulated Rho kinase activity was abolished in cells expressing Gα13 minigene. Both
PAR1 and PAR2 agonists induced a transient initial contraction that was selectively blocked
by inhibition of PI hydrolysis with U73122 and MLC kinase activity with ML-9. The
sustained contraction by the PAR1 agonist was preferentially inhibited by the PKC inhibitor
bisindolylmaleimide (78%) and to minor extent by the Rho kinase inhibitor Y27632 (18%),
whereas sustained contraction by the PAR2 agonist was preferentially inhibited by Y27632
(80%) and to a minor extent by bisindolylmaleimide (14%). Conclusion. PAR1 and PAR2
are differentially coupled to G proteins. PAR1 stimulate PI hydrolysis via Gq and PAR2 via
Gq and Gi. Both receptors activate RhoA, PAR1 via G12 and PAR2 via G13, but this distinctive
coupling results in different effects on Rho-dependent sustained contraction.
934
Induction of Autophagy, a Novel Effect of H. Pylori Vacuolating Toxin Vaca
Mauricio R. Terebiznik, Cristina L. Vazquez, Karl Torbicki, Noboru Mizushima, Tamotsu
Yoshimori, Maria I. Colombo, Nicola L. Jones
Autophagy is an evolutionarily conserved mechanism for the degradation of cellular compon-
ents in the cytoplasm. It has multiple physiological functions including protein degradation,
organelle turnover and autophagic type II cell death. In addition disruption of autophagy
has also been implicated in carcinogenesis. Although bacteria and viruses are vulnerable to
autophagy, several intracellular pathogens have developed strategies to utilize this pathway
for their own benefit. Current evidence indicates that H. pylori can invade epithelial cells
in the gastric mucosa and survive inside large vacuolar compartments. However, relatively
little is known about the biology of H. pylori invasion and survival in host cells. In AGS
cells invaded with H. pylori, bacteria containing vacuoles originate through the fusion of
late endosomal-lysosomal organelles by a mechanism based on the ability of the VacA toxin
to hijack the small GTPase Rab7 at the membrane of the bacterial compartment. Since the
scission of Rab7 from its functional locations disrupts the host’s endocytic pathway, we
hypothesized that H. pylori could induce a nutritional stress that triggers autophagy. To
assess this possibility, we monitored the outcome of autophagy by expressing the autophagic
protein markers Rab24 and LC3 in AGS cells. H. pylori infection caused the recruitment of
GFP-LC3 and Rab24 to a sub-population of intracellular compartments where H. pylori
resides. To further confirm this observation, we utilized embryonic fibroblast cells defective
for autophagy (atg5-/- MEFs). In atg5-/- MEFs H. pylori-containing vacuoles were not labeled
with LC3 indicating that autophagy is responsible for the recruitment of LC3 to the H. pylori
vacuolar membrane. Importantly, the engagement of the autophagic pathway was totally
dependent on the presence of the bacterial toxin VacA since autophagy was not detected
when isogenic VacA mutant bacteria were utilized. Furthermore, our findings indicate that
autophagy contributes to vacuolation since the vacuolating phenotype was impaired in
autophagy deficient mutant cells infected with H. pylori or exposed to VacA positive bacterial
supernatants. Our results describe a novel interaction of H. pylori with the host cell. Since
modulation of autophagy has been linked with carcinogenesis these findings may have
relevance for the development of H. pylori associated pathologies.
935
Regulation of Urease Activity in Helicobacter Pylori Acid Acclimation
David Scott, Elizabeth A. Marcus, Hong Wu, George Sachs
Background: Helicobacter pylori, a neutralophile, is dependent on urease for gastric habitation
by a process now defined as acid acclimation. The urease gene cluster consists of soluble
intrabacterial urease apoenzyme (UreA + UreB =~15% of bacterial protein), UreI, a proton
gated inner membrane located urea channel and the cytoplasmic Ni2+ insertion proteins,
UreE/G and UreF/H that are essential for activation of the UreA/UreB apoenzyme. Only
about 30% of the soluble urease is active at neutral pH. When H. pylori encounters an acidic
environment that decreases periplasmic pH to 6.1 or less, UreI opens, permitting urea entry
to the cytoplasm where it is hydrolyzed by urease to 2NH3 and CO2 for cytoplasmic buffering.
NH3 and CO2 diffuse into the periplasm where NH3 consumes entering H+ by conversion
to NH4+ and CO2 is converted to HCO3-, effectively buffering the periplasmic pH to 6.1.
Perhaps, under continued or greater acid stress, the inactive urease apoenzyme is activated
to enhance acid acclimation. Aims: This study investigated the mechanism of activation of
the urease apoenzyme and its possible role in acid acclimation under acidic conditions.
Methods: Urease activity, synthesis and cellular location were determined after incubation
at pH 5.5 and 7.4 in the absence or presence of urea, chloramphenicol, dimethylglyoxime
and UreI for up to 4 hours. Urease location was observed by post-sectioning immuno-
electron microscopy. UreI mutants were constructed by homologous recombination. Results:
Total bacterial urease activity increased 3 to 5 fold at pH 5.5 in the presence of the protein
synthesis inhibitor, chloramphenicol, but not in the absence of Ni2+ or UreI. There was an
accompanying 3 fold increase in survival to acid shock (pH 2.5). Urease shifted from a
predominately cytoplasmic localization at neutral pH to the inner membrane at pH 5.5,
dependent on the presence of UreI. Native gel electrophoresis showed UreB and UreI
association in the membrane fraction. Conclusions: The data suggest that at neutral pH only
about 1/3 of the total bacterial urease contains the Ni2+ required for enzyme activity. A
decrease in medium pH increases the amount of active urease by Ni2+ insertion into apoen-
zyme, independent of de novo urease synthesis. Ni2+ insertion and urease pH dependent
redistribution was UreI dependent. Therefore, UreI in addition to its urea channel activity
appears to play a role in acid acclimation by serving as a membrane anchor for urease and
its Ni2+ insertion accessory proteins to increase the amount of active urease, thus increasing
acid survival likely at more extreme conditions of acidity.
936
Dupa-Positive H. Pylori Strains Are Highly Prevalent in Brazil and Are Not
Associated with Duodenal Ulcer in Brazilian Adults and Children
Dulciene M. Queiroz, Luciana I. Gomes, Gifone A. Rocha, Taciana F. Soares, Andreia M.
Rocha, Ludmila M. Godoi
Helicobacter pylori (HP) infection is associated with clinical outcomes as different as distal
gastric carcinoma (GC) and duodenal ulcer (DU). Although HP virulence factors have been
associated with clinical complications of the infection, they do not distinguish between DU
and GC. Recently, Lu et al. (2005) described a new putative HP virulence marker (dupA)
associated with an increased risk for DU and reduced risk for GC in Japan and Korea, and
with a reduced risk for GC in Colombia. Since differences between the association among
HP virulence markers and HP-associated diseases have been demonstrated around the world,
we investigated the presence of dupA in a large number of HP strains isolated from Brazilian
patients. We evaluated 487 HP strains from children (38 DU, 100 gastritis) and adults (125
DU, 143 gastritis, 81 GC). Bacterial DNA was PCR amplified for cagA (Peek et al., 1995)
and jhp0917-0918 (Lu et al., 2005). We constructed primers located at the jhp0917 3’ region
(sense primer) and jhp0918 5’ region (antisense primer) to test again jhp0917-0918-negative
strains and for sequencing 30 jhp0917-0918-positive strains (10 randomly selected from each
group of disease) in order to detect the insertion of C or T (after position 1385) in the
jhp0917 3’ region that characterizes dupA. Data were analyzed with the SPSS statistical
package. Both genes were present in 422(86.7%) and absent in 37(7.6%) strains. jhp0917
or jhp0918 was present in 22(4.5%) and 6(1.2%) strains, respectively. Since an insertion of
T or C was observed in 90% of the jhp0917-0918 positive strains, the presence of the two
genes was considered to be dupA+. Strains with only one gene were not included in the
analysis. Almost all samples from children with (38/38, 100%) or without (98/100, 98.0%)
DU were dupA+, without any difference between the disorders (p=1.0). No association was
also observed among the strains from adults with gastritis (89.8%), DU (86.6%, p=0.6) and
GC (89.0%, p=0.9). Conversely, cagA+ status was independently associated with DU (in
adults and children) and with GC in logistic analysis. Curiously, dupA- and cagA-positive
status were associated with each other (p=0.02). When children and adults were compared,
the presence of dupA was significant higher in children, even when only the group of gastritis
was analyzed (p=0.003) which may indicate that the bacteria lost 1 or 2 genes along the
adult life. In conclusion, in Brazil, dupA was not associated with GC or DU in both adults
and children. Similarly to that seen with other HP virulence markers, there are wide regional
differences in the distribution of dupA that is highly frequent in Brazilian strains.
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Phase Variations of Helicobacter Pylori Outer Membrane Protein Expression in
Infected Mongolian Gerbils
Tomoyuki Ohno, Saori Fujimoto, Hiroaki Ogiwara, Stefan Odenbreit, Rainer Haas, David
Y. Graham, Yoshio Yamaoka
Background: The outer membrane proteins (OMPs) of Helicobacter pylori (H.pylori) are
thought to play important roles in colonization, adherence, resistance to the gastric milieu
and protection from the host immune response. BabA, SabA and OipA are OMPs putative
virulence factors that undergo phase variations. Phase variations have been observed both
in vitro laboratory passages and rhesus monkey models. However, it remains unknown
whether the phase variations were limited to monkeys or whether phase variations played
a role in gastric damage. Methods: Six week male Mongolian gerbils were inoculated with
strain TN2GF4 and sacrificed after 1, 3 and 18 months. At least five infected gerbils were
used in each time period. At least 10 single colonies were picked up from each gerbil and
the expression of BabA, BabB, SabA and OipA was determined by immunoblot. The ability
to induce interleukin-8 from gastric epithelial cells (MKN45 cells) co-cultured with H.
pylori obtained by expansion of each single colony were determined by an enzyme linked
immunosorbent assay. Results: Challenged strain TN2GF4 expressed functional BabA, BabB
and OipA and did not express SabA. All isolates recovered from challenged gerbils at 1
month expressed BabA, BabB and OipA proteins. At 3 months BabA/BabB expression was
absent from one gerbil and was present in less than 25% of recovered colonies from the
other 4 gerbils. By 18 months, BabA/BabB expression was mostly absent except for two
colonies from one gerbil. OipA was expressed in all isolates at all time periods. SabA
expression was not observed in any isolate from challenged gerbils. In vitro IL-8 levels were
independent of the expression of BabA and BabB. Conclusions: We confirmed that phase
variations of BabA and BabB occurred in infected gerbils. BabA and BabB may be important
for colonization but continued expression is either not required or possibly confers a disad-
vantage for survival possibly as the gastric milieu changes. Supported in part by the Gulf
Coast Digestive Disease Center.
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Role of H. Pylori Adhesins in Colonization of the Primate Stomach
Andre Dubois, Hui Liu, Cristina Semino-Mora, Steven Mog, Thomas Boren
H. pylori adherence to gastric epithelial cells is critical for gastric colonization and life-long
persistence in the primate stomach. Adherence depends on the ABO/Leb blood group antigen
binding BabA adhesin and on the sialic acid binding SabA adhesin that binds to the host’s
sialyl-Lewis glycosphingolipid. To explore the role of these adhesins, we inoculated 11 H.
pylori negative rhesus monkeys with 107 CFU of either a J99babA::cam sabA::kan double
mutant (N=5; DM; Science 2002;297:573) or wild type (WT) H. pylori (N=6). Videogastro-
scopies were performed at regular intervals for 6 months after inoculation and biopsies were
cultured and analyzed by RT-PCR. The mRNA expression of H. pylori-specific 16S rRNA
and monkey IL-1β and IL-8 (copies/100 ng RNA) were determined using an absolute
real-time quantitative RT-PCR(TaqMan) method, standard curves of cloned cRNA, and
normalization with monkey 18S rRNA. In situ hybridization (FISH) was used to detect sabA
and babA expression in WT and DM strains and in the gastric mucosa. All WT-infected
monkeys were culture+ and RT-PCR+. The DM inoculate and all post-inoculation biopsies
were negative for both sabA and babA. Culture of all DM post-inoculation biopsies were
negative and RT-PCR detected the DM strain in only two monkeys and only at 7 days after
inoculation. Gastritis scores and IL-1β and IL-8 expression were lower than in WT controls
but increased significantly in the corpus of the stomach (figure) but not in the antrum.
These observations suggest that either SabA or BabA or both adhesins are required for
successful establishment of colonization and persistent H. pylori infection. Ongoing experi-
ments with babA and sabA single mutants explore whether the presence of one of the two


















Helicobacter Pylori Vaculating Cytotoxin Inhibits Duodenal Bicarbonate
Secretion By a Histamine-Dependent Mechanism
Biguang Tuo, Bettina Gebert, Rainer Haas, Michael P. Manns, Ursula Seidler
Background&Aims: Helicobacter pylori (HP) infection reduces the secretory capacity of the
duodenal mucosa for bicarbonate (Hogan et al. 1996), and CagA/VacA positive HP water
extract strongly decreases murine duodenal HCO3- secretion in vitro within one hour (Tuo
et al 2004). In this study, we investigated the effect of HP vacuolating cytotoxin (VacA) on
duodenal mucosal bicarbonate secretion, and the underlying mechanisms for the VacA-
induced reduction in HCO3- secretion. Methods: Bicarbonate secretion by murine duodenal
mucosa was examined in vitro in Ussing chambers. HP extracts from a VacA producing
strain (P12) and an isogenic mutants lacking VacA (P12ΔvacA) were used (Gebert et al
2003). Results: VacA-positive extract reduced PGE2-stimulated duodenal HCO3- secretion by
48.9% (P<0.0001), whereas the VacA-negative extract only slightly reduced PGE2-stimulated
bicarbonate secretion by 17.% (P>0.05). Preincubation with the H2-receptor antagonist
ranitidine, but not with the H1 receptor antagonist diphenhydramine or the H3 receptor
antagonist thioperamide, significantly attenuated the inhibitory effect of VacA-positive extract
on PGE2-induced bicarbonate secretion partially. The VacA-positive HP extract stimulated
duodenal mucosal histamine release concentration-dependently. After incubating 15min
with VacA-positive HP extract, duodenal mucosal histamine release markedly increased, it
reached maximal levels at 45min, and this corresponded to the development of the reduction
in PGE2-mediated HCO3- secretion. Conclusion: Hp VacA inhibits PGE2-stimulated duo-
denal epithelial bicarbonate secretion in part via the release of mucosal histamine, which
in turn inhibits HCO3- secretion in an H2-receptor dependent mechanism. HP VacA inhibi-
tion of duodenal bicarbonate secretion might therefore be an important pathogenic factor
contributing to HP related duodenal mucosal injury.
940
Single Screening Colonoscopy in Octogenarians: A Markov Decision Analysis
Grace Shih, Yu Xiao Yang
BACKGROUND: The benefits of a single colorectal cancer screening colonoscopy (SC) in
previously unscreened patients over 75 years old are unknown. AIMS: (1) To determine
the effect of single SC on the life expectancy of octogenarians versus no SC. (2) To determine
the cost effectiveness of single SC in octogenarians versus no SC. METHODS: We constructed
a lifetime Markov cost-effectiveness model with one year cycle length. Patients cycled between
no neoplasia, polyp, unresectable cancer, resected cancer, and death. Age adjusted mortality
from the US census was used. Transition probabilities, quality of life measurements, and
costs were obtained from systematic literature review. Costs of differing colonoscopies were
obtained from Medicare data. We assumed that all patients undergoing SC had 100%
adherence rate to follow up colonoscopies and/or surgeries if polyps or neoplasia were
found. Otherwise, all other patients received no further colonoscopies. Success rate in
completed SC was 90% (Lukens et al., Am J Gastro 2002). Cancer rates were based on
SEER data. Mortality rate from colonoscopy was 0.01% (Winawer et al, Gastro 1997). We
analyzed the model for the starting ages of 75, 80, 85, and 90. Sensitivity analysis was also
performed. RESULTS: SC provides marginal benefit in quality adjusted life years (QALY)
for all age groups (75yrs, 0.03 yrs; 80yrs, 0.03 yrs; 85yrs, 0.02yrs; 90yrs, 0.006yrs). The
incremental cost-effectiveness ratios are $3006, $3576, $14787, and $59631 respectively.
Sensitivity analysis shows no threshold values for success rate for all ages. Threshold values
for cost of colonoscopy ranged from $497 in 75 year olds to $156 in 90 year olds. Cost of
colonoscopy accounted for at least 99% of model uncertainty. SC sensitivity and success
rate account for < 1%. CONCLUSIONS: A single SC in octogenarians provided marginal
benefit of QALY. Success rate in this population did not greatly affect the benefit of single
SC. The younger octogenarian is the most ideal candidate in this population, while single
SC in older octogenarians became less cost effective.
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Isolated Lymphoid Follicle Formation Is Augmented and Aberrant with Aging
Keely G. Mcdonald, Jacquelyn S. Mcdonough, Caihong Wang, Rodney Newberry
Background: Isolated lymphoid follicles (ILFs) are organized lymphoid structures in the
murine intestine that act as inductive sites for the generation of adaptive mucosal immune
responses. Intestinal lymphoid aggregates, the human counterpart to ILFs, are increased
with inflammation and have been proposed to be the sites for the initiation or propagation
of the inappropriate immune responses seen in IBD. With aging,the mucosal immune system
undergoes immunosenesce resulting in a decrease in protective immunity and a predisposition
toward inappropriate immune responses. Given these associations we examined the presence,
composition, and function of ILFs in aged mice. Methods: Two month old (young) and
twenty month old (old) Balb/c mice from the national institute of aging colony were examine
for the presence of isolated lymphoid follicles using whole mount and immunohistochemical
techniques. Cellular populations from ILFs, spleens, and Peyer’s patches were examined
using flow cytometry. Immunoglobulin production by ILF cellular populations was examined
using ELISA. Results: Old mice had a greater than three fold increase in the numbers of
ILFs per small intestine when compared with young mice. The cellular composition of ILFs
from old mice was also altered when compared with young mice. ILFs from old mice had
a decreased population of B-lymphocytes, 30% of the cellular population, and an increased
population of T-lymphocytes, 50% of the cellular population, when compared with young
mice. No differences were observed in the ILF dendritic cell population between the two
groups. In addition the ILF cellular population from old mice contained CD4+ CD8α+
(double positive) TCRβ+ T-lymphocytes, which comprised up to 30% of the ILF T-lympho-
cyte population. This double positive T-lymphocyte population was not observed in the
spleen or Peyer’s patches of old mice. ILFs from old mice had a smaller population of Foxp3
expressing T-lymphocytes when compared with young mice. ILF cellular populations from
young and old mice produced predominantly IgA. IgG production was observed in ILF
populations from old mice, but not from ILF populations from young mice. Conclusions:
ILF formation is increased with aging and ILFs from aged mice have an abnormal cellular
composition which includes a substantial population of CD4+ CD8α+ (double positive)
TCRβ+ T-lymphocytes. In contrast to young mice, ILFs from old mice produce IgG. These
findings suggest that aberrant ILF formation, composition, and function may contribute to
immunosenescence of the mucosal immune system.
942
Age and the Risk of Failure of Medical Therapy in Inflammatory Bowel
Disease (IBD): A Case-Control Study
William J. Tremaine, Lawrence J. Timmons, Edward V. Loftus, Darrell S. Pardi, William J.
Sandborn, William S. Harmsen, Prabin Thapa, Alan R. Zinsmeister
Background & Aims: There are few data on the response to medical therapy for Crohn’s
disease and ulcerative colitis with respect to the patient’s age. We examined age as a risk
factor for failure of medical therapy, as defined by the need for surgery for control of
symptoms of IBD. Materials and Methods: This was a single center case-control study of
patients seen at a tertiary referral center from 1994-2001. Case subjects were all patients
seen at our institution from MN and the surrounding 5 states (WI, IA, ND, SD, IL) with
ulcerative colitis or Crohn’s disease who required an initial operation for disease refractory
to medical therapy. Controls were matched 1:1 based on gender, IBD subtype, date of first
visit to our center (±2 yr) , time interval from IBD diagnosis elsewhere prior to visit to our
facility (±3 yr), and duration of follow-up based on the time from diagnosis to surgery for
case subjects. Cases and controls were excluded if the indication for surgery was dysplasia
or malignancy, or if IBD was not diagnosed until surgery. The association with age, disease
extent, smoking history, and medication use vs. case/control status was assessed using
multiple variable conditional logistic regression to estimate the Odds Ratios (OR [95%CI])
for being a case (undergoing surgery). Results: Among 132 Crohn’s patients, the median
age was 30.6 yr (range, 8.9 -88.5). Older patients had smaller odds for surgery (OR per 5
years = 0.86 [0.75, 0.98]). Alternatively, patients ≥ 50 yr had smaller odds than patients
< 50 yr to fail medical therapy (OR 0.13 [0.02, 0.69]). The failure rate of medical therapy
was not significantly associated with disease distribution (ileitis, ileocolitis, colitis), use of
5-ASA, or use of thiopurines. Among 234 ulcerative colitis patients, the median age was
37.5 yr (4.5- 82.9). Patients ≥ 50 yr had smaller odds than patients < 50 yr to fail medical
therapy (OR 0.49 [0.26, 0.92]). The failure rate of medical therapy was not related to disease
extent or cigarette smoking. Ulcerative colitis patients who had taken 5-ASA were at increased
odds for surgery (OR 10.4 [1.1, 99.1]), as were patients who had taken azathioprine (OR
5.0 [2.2,11.5]), or 6-MP (OR 3.0 [1.1,8.1]). Conclusions: Failure of medical therapy for
Crohn’s disease and for ulcerative colitis was more common in those younger than age 50,
irrespective of disease distribution. There was a suggestion that among current smokers with
Crohn’s disease, older age was associated with increased odds for failed medical therapy,
but this interaction was not stable across different age break points. This study was supported
by research funds from P&G Pharmaceuticals.
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Incidence, Risk Factors, and Mortality Associated with Fecal Incontinence in
Older Individuals
Carline Quander, Martha C. Morris, Julia Bienias, Jocelyn Carter, Denis Evans
OBJECTIVE: In a large, biracial community study of older persons, we estimated the mortality
risk associated with fecal incontinence and investigated risk factors associated with newly
acquired symptoms of fecal incontinence. METHODS: As part of a 1993-2004 longitudinal
study of community residents aged 65 years and older, study participants were administered
comprehensive in-home interviews at baseline and at 3-year follow-up. The interviews
included a wide range of questions regarding demographics, medical history, medication
use, the presence of fecal incontinence, and assessments of physical disability, cognitive
function, and depressive symptoms. RESULTS: Fecal Incontinence was reported by 585 of
6,099 participants (9.6%) at the baseline. The prevalence of fecal incontinence was associated
with increased mortality (hazard ratio=1.8 for a person of average age (75), 95%CI: 1.6,
2.1) in a Weibull hazards model. Among 3976 participants unaffected by fecal incontinence
at the baseline and who participated in the 3-year follow-up, fecal incontinence was reported
by 336 (8.5%). We examined risk factors for developing these symptoms over 3 years in
multiple logistic models that included terms for age, sex and race and their interactions.
There were statistically significant interactions between race and sex and also between race
and age, such that the risk of incident fecal incontinence was higher with older age and
black race and was highest among older black women. In addition, higher incidence of fecal
incontinence was associated with diabetes (OR=1.6; 95% CI; 1.2, 2.1), stroke (OR=2.3;
95% CI; 1.7,3.2), use of anti-psychotic (OR=3.6; 95%CI; 1.6, 8.0) and anti-parkinsonian
medications (OR=5.2; 95%CI; 2.2, 12), physical disability (OR= 1.6; 95% CI: 1.4,1.7), and
number of depressive symptoms (OR=1.1; 95% CI; 1.1,1.2). Lower incidence of fecal
incontinence was associated with higher cognitive scores (OR=0.6; 95% CI; 0.5, 0.7).
CONCLUSION: Fecal incontinence among older persons is associated with increased mortal-
ity, probably at least partially because of its association with multiple markers of poor health.
The risk of developing this condition may be associated with a history of diabetes or stroke,
certain medications, symptoms of depression, and physical or cognitive impairment.
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Colorectal Cancer Screening Colonoscopy in Elderly Patients with Dementia: a
Decision Analysis
Grace Shih, Keith Obstein, Jerry Johnson, Yu-Xiao Yang
BACKGROUND: The benefits of colorectal cancer screening colonoscopy (SC) in the elderly
population with varying degrees of dementia are unknown. AIM: (1) To determine the effect
of SC on the life expectancy of patients with varying degrees of dementia. (2) To determine
the cost effectiveness of SC in patients with dementia. METHODS: We constructed a lifetime
Markov cost-effectiveness model with one year cycle length. Patients cycled between no
neoplasia, polyp, unresectable cancer, resected cancer, and death. Age adjusted mortality
rates based on mini-mental status in dementia patients (score of 18-21 was mild/moderate;
<18 severe) were used (Larson et al, Ann of Int Med 2004). Transition probabilities, quality
of life measurements, and costs were obtained from systematic literature review. Costs of
differing colonoscopies were obtained from Medicare data. We assumed that all patients
undergoing SC had 100% adherence to follow-up colonoscopies and/or surgeries. Cancer
rates were based on SEER data. Mortality rate from colonoscopy was 0.01% (Winawer et
al, Gastro 1997). We analyzed the model for the starting ages of 65, 70, 75, and 80.
Sensitivity analysis was also performed. RESULTS: SC provides marginal benefit in quality
adjusted life years (QALY) for all age groups of patients with varying degrees of dementia
(Table). The incremental cost-effectiveness ratios (ICER) are shown in the Table. Sensitivity
analysis shows a threshold value of $364 for the cost of colonoscopy in patients aged 65
but $200 for age 80. Age and severity of dementia accounted for 58% and 41% of model
uncertainty, respectively. Sensitivity and cost of colonoscopy accounted for the other 1%.
CONCLUSIONS: Colorectal cancer SC in patients with varying degrees of dementia provided
a marginal benefit of survival although at relatively low costs. Age is slightly more important
than dementia severity in choosing whether to undergo SC.
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Age-Related Rise in Colorectal Adenomas Is Associated with Increased EGF-
Receptor Expression
Sudha Reddy, Sabeena Misra, Richard Jaszewski, Hu Xu, Edi Levi, Nadeem Ullah, Adhip
P. N. Majumdar
Although the incidence of colorectal and other gastrointestinal cancers increases with advan-
cing age, reason for this increase is poorly understood. Earlier studies from this and other
laboratories have demonstrated that at least in Fischer-344 rats, aging is associated with
increased proliferative activity and decreased apoptosis in the colonic mucosa (Mech. Ageing
Dev. 122: 1849-1864, 2001). Morphological studies of the colonic mucosa of human volun-
teers have also revealed that cell proliferation in the young is confined to the lower two-
thirds of the crypt, while with aging there is a major shift from the base to the middle and
upper-third of the gland, a pattern that is commonly seen in colorectal cancer. Although
the regulatory mechanisms for the age-related rise in mucosal proliferation and reduction
in apoptosis have not been fully delineated, we have reported that these events are associated
with increased expression and activation of EGF-Receptor (EGFR) and reduction in EGF-
Receptor Related Protein (ERRP), a negative regulator of EGFR (Dig. Dis. Sci. 48: 856-864,
2003). An inverse relationship of EGFR and ERRP has been observed in colorectal cancer
(Cancer Lett. 213: 249-255, 2004). To determine whether aging predisposes the colon to
the processes of carcinogenesis, we examined the relationship between aging and formation
of colonic adenomas, the most frequent premalignant colorectal lesion. In our study there
were 177 patients with colorectal adenomas in different age groups. Our data show that
the number of polyps formed increase with advancing age (age in years: 1 polyps in <51
yrs; 2 polyps in 51-60; 3 polyps in 61-70 yrs; 4 polyps in 71-80; 5 polys in 80 yrs = 0.95).
The age-related rise in polyp formation was associated with a concomitant increase in EGFR
expression in the macroscopically normal rectal mucosa. The levels of phosphorylated (active)
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form of EGFR was also higher in macroscopically normal rectal mucosa from 60-70 years
old patients with colonic adenomas, when compared with their younger counterparts. On
the other hand, levels of ERRP, a recently identified pan-erbB antagonist (Mol. Cancer Ther.
4: 435-442, 2005), were found to decrease with advancing age in patients with colorectal
adenomas. We also observed that the expression of cyclooxygenase-2 (COX-2) increases
with aging in patients with adenomas. In conclusion, there is a positive relationship between
advancing age and polyp formation. This is associated with increased expression of EGFR
and COX-2 and downregulation of ERRP.
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The Effects of Obesity and Weight Loss Surgery On Symptoms of
Gastroesophageal Reflux (GER)
Milan E. Folkers, Tom Cloward, Ted Adams, John Fang, Mae Go, Kathryn Peterson
Background: Obesity is an increasing epidemic in developed countries and has been associated
with an increased risk of hypertension, hyperlipidemia, diabetes, coronary artery disease,
stroke and gastroesophageal reflux disease. The use of bariatric surgery as an option to treat
obesity has increased dramatically in the past several years and has been shown to be effective
in treating obesity and its co-morbidities. To our knowledge, no one has assessed the effects
of Roux En Y gastric bypass surgery for morbidly obese patients on GER in a prospective,
controlled manner. Aim: To assess the effects of Roux En Y gastric bypass on reported
“heartburn” and acid regurgitation in morbidly obese patients. Methods: In conjunction
with the Utah Obesity Study, 1159 participants were recruited into three groups: a surgical
group of 415 patients who underwent bariatric surgery, a nonsurgical group of 420 patients
who were denied or refused surgery, and a community group consisting of 321 morbidly
obese patients randomly selected from the community. These patients were administered a
GER questionnaire upon initial enrollment and at their 2 year follow-up period. The question-
naire assessed severity and frequency of heartburn and acid regurgitation as well as the
presence of supra-esophageal manifestations of reflux. Results: General linear model analysis
was used to compare changes in reported reflux and heartburn among subjects within the
surgical treatment (n=144), non-surgical treatment (n=22) and community control (n=263)
groups, controlling for age, sex, smoking status, BMI, apnea, apnea score, use of PPI drugs,
use of antacids and baseline reflux and heartburn respectively. Significant differences were
observed for both reflux (p = 0.005) and heartburn (p < 0.002), with paired analyses showing
significant differences between surgery and control groups (p = 0.001 for reflux and p
< 0.001 for heartburn). Discussion: From this analysis, gastric bypass surgery provides
symptomatic relief of heartburn and reflux up to 2 years post-operatively. This finding
remains significant even after controlling for BMI, suggesting reduction of reflux symptoms
related to the surgical procedure rather than the associated weight loss. Future analysis will
include extra-esophageal symptoms of reflux in these patients.
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The Tantalus™ System for Obesity: Effect On Gastric Emptying of Solids
Claudia P. Sanmiguel, Scott A. Cunneen, Edward H. Phillips, Edy E. Soffer
Background: Gastric electrical stimulation (GES) is currently investigated for the treatment
of obesity. The TANTALUS System delivers gastric contractility modulation (GCM) signals
in synchrony with gastric slow waves, resulting in significant augmentation of gastric contrac-
tions during food intake. We hypothesized that such modulation of contractile activity may
affect gastric emptying and plasma ghrelin levels. Aim: To test the effect of GCM of the
gastric antrum on gastric emptying of solids and ghrelin levels. Methods: 12 obese subjects
were implanted with 2 pairs of antral electrodes and an implantable pulse generator (IPG,
TANTALUS TM).Gastric emptying test (GE) for solids was performed twice, on separate
days, in each subject, starting few weeks after implantation: 1) control, before the start of
stimulation, and 2) with stimulation, after device was turned on. Blood samples for ghrelin,
were taken at baseline, and at 15, 30, 60 and 120 min after the test meal. Results as mean
+SD, analysis by t-test and p<0.05. Results: 11 females, 1 male, age: 39.1±8.9 years, BMI:41.6
± 3.4, 3 subjects with type 2 diabetes. One diabetic patient did not complete GE test because
of technical issues. GCM significantly accelerated gastric emptying: retention at 2 hours
18.7±12.2% vs. 31.9±16.4%, stimulation vs. control respectively, p=0.008. T 1/2 78.3±23.5
vs. 95±31.7min, stimulation vs. control respectively, p=0.04. Mean results for gastric empty-
ing were within normal at both baseline and stimulation. Meal ingestion induced only
minimal, insignificant reduction in ghrelin levels. There was no significant difference in
AUC of ghrelin between control and stimulation. Conclusions: 1) After GCM stimulation,
there is significant acceleration of gastric emptying of solids in obese patients, without affect



















Endoscopic Management of Upper Gastrointestinal Hemorrhage Following
Laparoscopic Roux-en-Y Gastric Bypass
Laith H. Jamil, Clara Jackson, Kevin Krause, David Chengelis, Michael C. Duffy
Laparoscopic Roux-en-Y Gastric Bypass (LRYGBP) is increasingly being used for the manage-
ment of morbid obesity. Upper gastrointestinal hemorrhage (UGIH) has been reported as
an infrequent complication, ranging from 1%-3.8%, and previous publications addressing
management have been small case series, with reluctance to perform upper endoscopy (EGD)
in the immediate postoperative period for fear of complications. We sought to determine how
frequently UGIH complicates LRYGBP and whether endoscopic management is successful in
controlling hemorrhage. Methods A retrospective chart review of all patients (pts) who
underwent LRYGBP from 11/2001 to 7/2005 at William Beaumont Hospital was conducted
with hemorrhage as a complication identified by standard coding criteria. UGI hemorrhage
was defined as bleeding from the surgical site, and/or hematemesis and/or melena, and/or
hematochezia with significant hemodynamic changes (increase in heart rate >20 BPM,
decrease in systolic blood pressure >20 mmHg), and/or significant drop in hemoglobin (>2
gm/dl). Results Of 933 pts who underwent LRYGBP, 30 pts (3.2%) developed postoperative
UGIH. EGD was performed in 27/30 pts (90%). Almost all patients (25/27, 93%) were
found to be bleeding from the gastrojejunostomy (GJ) staple line. The other 2 pts had an
adherent clot on the GJ site. All pts had endoscopic signs of recent bleeding, including 13
pts with blood oozing from the GJ site, 7 pts with a bleeding vessel, 1 pt with a visible
vessel in a cratered ulcer on repeat endoscopy, and the remainder with adherent clots at
the GJ site. Endoscopic intervention was performed in 24/30 (80%) with epinephrine
injection and heater probe cautery being used most commonly. Endoclips were used in 2
patients. Endoscopic therapy was successful in controlling all hemorrhage, with 5 patients
(17%) requiring a second EGD for rebleeding. No patient required surgery to control
hemorrhage. Blood transfusions were given in 14/30 (47%) with an average of 2.6 units
PRBC/pt among those requiring transfusion. One patient aspirated during the endoscopic
procedure with respiratory compromise and subsequent anoxic encephalopathy and died 5
days postoperatively. Twenty-one patients (70%) developed UGIH in the intraoperative or
immediate postoperative period (<4 hrs postop). Conclusions: 1. UGIH complicates LRYGBP
in a small but significant number of patients. 2. Bleeding usually occurs at the GJ site. 3.
EGD is safe and effective in controlling hemorrhage with standard techniques. 4. UGIH
occurs most commonly in the immediate postoperative period and is best managed in the
operating room with the patient intubated to prevent aspiration.
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Pilot Study of Preoperative Weight Loss in Super Morbid Obese Patients: The
Additional Effect of Endoscopic Intragastric Balloon Placement
Gianluca Bonanomi, Simona Di Caro, Mario Traina, Ilaria Tarantino, Giselle G. Hamad,
Madelyn H. Fernstrom
Background: Preoperative weight loss is often needed to reduce operative risk. Furthermore,
adherence to dietetic and behavioral instructions is a determinant of patient compliance and
outcome for bariatric surgery. Methods: Twenty consecutive patients suffering from super
morbid obesity (BMI ≥ 50 kg/m2) were randomized for a 6-month balanced hypocaloric
diet, either alone (group A) or associated with endoscopic intragastric balloon placement
(group B). Mean age was 37.2 years (range: 21-55) in Group A and 38.9 (range: 24-58) in
group B. Mean BMI was 56.5 kg/m2 (range: 51-61) in group A and 58.4 (range: 50-69) in
group B. There was no significant difference in age, BMI, gender, and comorbidities between
the 2 groups. All patients received counseling and follow-up by a dietitian and were evaluated
for possible bariatric surgery after 6 months. Results: Total mean weight loss after 6 months
was 7 kg (range: 0-21) in group A and 19 kg (range: 8-32) in group B (p < 0.05). Mean
% excess weight loss was 12% in group A and 32% in group B. Five patients in group A
and no patients in group B experienced less than 5 kg weight loss after 6 months. One
patient in group B developed pulmonary embolism that required early balloon removal.
Nine out of ten patients with intragastric balloon and five out of ten patients on diet alone
experienced a significant improvement of comorbidities and have undergone uneventful
bariatric surgery. Patients who failed preoperative weight loss were submitted to additional
dietetic and behavioral counseling or were referred for intragastric balloon placement. Conclu-
sion: The results of this pilot prospective randomized study suggest that preoperative intra-
gastric balloon placement in super morbid obese patients results in significant short term
weight loss and comorbidities improvement as compared to diet alone.
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Pre-Operative Endoscopic Screening Is Not Cost-Effective in Patients
Undergoing Bariatric Surgery
Cindy Mong, Jacques van Dam, Lauren B. Gerson, John M. Morton, Myriam J. Curet,
Subhas Banerjee
Background: Bariatric surgery patients undergo pre-operative screening endoscopy. EGD in
morbidly obese patients carries an increased risk due to high rates of sleep apnea. The yield
of EGD in detecting clinically significant lesions in this patient population has not been well
studied. The purpose of this study was to examine the yield of screening EGD in the bariatric
patient population and to determine its cost effectiveness. Methods: Patients undergoing
bariatric surgery between Aug ‘02 and July ‘05 at our institution were identified from a
database. Clinical, endoscopic and pathological data were analyzed. The prevalence of
endoscopic findings of moderate (erosive esophagitis, Barrett’s esophagus, erosive gastritis,
peptic ulceration, benign upper GI neoplasms) and high (UGI cancer/lymphoma) clinical
importance were determined. The cost of endoscopy and biopsy/pathology were determined
by Medicare reimbursement and institutional billing records. Results: A total of 270 patient
records were examined. At the time of analysis, complete records were available for 217.
188 (87%) of these were female and 167 (75%) were Caucasian. The median age was 43
yrs (range 20-64 yrs) & the median BMI 47 (range 35-75). 71 (33%) patients had sleep
apnea documented by a sleep study. Only 26 (12%) patients had endoscopic findings of
moderate clinical importance [see table], leading to alteration in surgical technique (subtotal
gastrectomy) in a single patient.* 17 of these patients (65%) had a prior history of GERD
or dyspepsia. The cost of detection per clinically important lesion was $7343. Conclusions:
1. Lesions of moderate significance were found in only 26 (12%) of 217 patients, leading
to alteration of surgical technique in only a single patient. No findings of high clinical
significance were noted in any patient. 2. The detection cost per significant lesion with
screening EGD is high at $7343. As acid reflux is essentially cured by Roux-en-Y gastric
bypass and most cases of peptic ulcer disease are caused by H. pylori, a more cost effective
approach might be to perform H.pylori stool antigen testing in all patients (with eradication




Vagal Blocking for Obesity Control (VBLOC): Concordance of Effects of Very
High Frequency Blocking Current At the Neural and Organ Levels Using Two
Preclinical Models
Katherine S. Tweden, Mehran Anvari, Michael D. Bierk, Charles J. Billington, Michael
Camilleri, Christopher N. Honda, Mark B. Knudson, David E. Larson, Richard R. Wilson,
James W. Freston
BACKGROUND: Vagal blocking using intermittent, very high frequency current is being
studied for obesity management. The targeted physiologic effects are to: (1) inhibit gastric
accommodation leading to early satiation and reduced food consumption; (2) inhibit gastric
contractile activity leading to prolonged satiety; and, (3) inhibit pancreatic exocrine secretion
(PES) leading to reduced calorie absorption. Historically, surgical vagotomy for refractory
ulcers caused transient anorexia and weight loss by mechanisms that are unclear. AIM: To
evaluate the effects of vagal blocking using intermittent, very high frequency current on
pancreatic function and neural activity as measured by inhibition of PES and compound
action potential (CAP) propagation, respectively. METHODS: In an acute porcine model
using non-vagolytic (chloralose) anesthesia, electrodes were placed on the anterior and
posterior vagal trunks at the esophagogastric junction. PES was measured by direct can-
nulation of the pancreatic duct. PES, as well as heart rate (HR), blood pressure (BP) and
blood glucose, were measured before, during and after very high frequency vagal blocking
at 5000 Hz. In an acute rat model, three pairs of bipolar hook electrodes were placed in
series for stimulation, blocking and recording, respectively, on either the cervical vagus or
sciatic nerves. The effect of block at 5000 Hz on the amplitude of electrically evoked fast
and slow CAP waves was measured following 5 minutes of blocking at times 0, 1, 2, 3, 4,
5, 10 and 15 min post-block. Data are expressed as relative response (post-amplitude/pre-
amplitude) x 100. RESULTS: Vagal blockade decreased PES >80% (0.35±0.06 vs.
0.06±0.01ml/h, n=6, p=.005). PES returned to baseline values within 19±8 min post-block.
Immediately after block, CAP amplitude (fast and slow waves) was reduced to 3±2% of
baseline. CAP recovered to 50% by 2 min and 90% by 10 min (n=9). HR, BP and glucose
remained unchanged. CONCLUSIONS: 1. Vagal blocking reversibly inhibits pancreatic
exocrine secretion and compound action potential propagation. 2. The effectiveness of vagal
blocking using very high frequency current was corroborated at the neural and organ levels
in two preclinical models. 3. Physiologic changes caused by intermittent vagal blocking may
offer potential for treating obesity without long-term loss of efficacy.
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Resectability of Pre-Symptomatic Pancreatic Cancer and Its Relationship to
Onset of Diabetes: A Retrospective Review of CT Scans and Fasting Glucose
Values Prior to Diagnosis
Mario Pelaez-Luna, Naoki Takahashi, Joel G. Fletcher, Suresh T. Chari
Background/Aim: Pancreatic cancer (PaC) is frequently unresectable at diagnosis. The timeline
of progression of PaC from resectable to unresectable disease is unknown. Glucose intolerance
and diabetes (DM) occur in up to 80% of PaC and new-onset DM may be a marker of early
PaC. Our purpose was to determine the resectability of PaC on CTs done prior to clinical
diagnosis and correlate resectability with onset of DM. Methods: 20 PaC patients with DM
who had≥1abdominal CT scans prior to diagnosis of PaC (total 45 CT scans) were included
in the study. Most CTs were performed for non specific abdominal pain or for other reasons
different from PaC related symptoms. CTs were reviewed by one radiologist and pancreatic
changes characterized as negative for pancreatic mass, pancreatic ductal changes (dilatation,
abrupt termination), resectable, relative unresectable or unresectable PaC. Fasting blood
glucose (FBG) values obtained at and prior to diagnosis were available in 14 patients. Date
of onset of DM was defined as date of first FBG ≥126 mg/dl with a prior normal FBG.
Interval between onset of DM and diagnosis of PaC was noted. Results: At diagnosis of PaC,
8 (57%) patients were deemed resectable; however, successful surgical resection was possible
only in 3 (21%) cases. 23 CTs in 20 patients were done >6 months prior to diagnosis; 18
were normal and 5 had pancreatic ductal changes or resectable mass. At the onset of DM,
7 patients had normal pancreas, 5 had resectable and 2 had unresectable PaC. By the time
of PaC diagnosis 3/7 cases with previous normal pancreas had unresectable disease after a
median interval of 13 months. Among those with resectable PaC on previous scans, 4 were
still resectable at diagnosis of PaC and 1 was unresectable. Conclusions: Resectability of PaC
can be significantly improved if detected >6 months prior to clinical diagnosis. Onset of
PaCDM predates clinical diagnosis of PaC by >12 months. Detecting asymptomatic PaC in
subjects with new-onset diabetes can lead to improved resectability.
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Ductal Pancreatic Cancer Development of the Pancreas Among Intraductal
Papillary Mucinous Neoplasm
Minoru Tada, Takashi Sasaki, Natsuyo Yamamoto, Yosuke Nakai, Takeshi Tsujino, Naoki
Sasahira, Hiroyuki Isayama, Takao Kawabe, Masao Omata
Background Intraductal papillary mucinous neoplasm of the pancreas (IPMN) is a benign
or low-grade malignant tumor. Branch duct type IPMN is expected to have more favorable
clinical course than main duct type. Therefore, some of them are closely and carefully
followed-up without resection. In this study, we prospectively examined incidence and types
of neoplasm developing in the pancreas by follow-up of the patients with IPMN. Methods
Eighty patients (50-87 years old, average 67), who were diagnosed as asymptomatic branch
duct type IPMN without characteristics of malignant features that mural nodules were not
observed within the cystic lesion, were followed-up as outpatients up to 8 (average 4) years.
Clinical examinations, blood tests and imaging diagnosis (US, EUS, CT or MRCP) were
performed twice a year. In addition, incidence of pancreatic cancer was compared with
expected number of pancreatic cancer death that was calculated with age-gender matched
population. Results Malignant pancreatic neoplasms were detected in 4 patients. Two arose
from the cystic wall that was previously detected. These cases were consistent with malignant
IPMN. In the other two patients, ductal pancreatic carcinoma developed. In one patient
whose tumor was found smaller than 2 cm, it was arising in the apparently different site
from the cystic lesions. The other patient who was found at advanced stage died with
extremely rapid tumor progression accompanying liver metastasis. Overall incidence of
malignancy was 1.25 % per year. The relative risk for pancreatic cancer was 30 times higher
compared with the expected incidence of pancreatic cancer death in general population
according to Japanese statistics. Conclusion Pancreatic cancer may develop in two different
manners in patients with IPMN: One originated from cystic wall, and the other was conven-
tional ductal pancreatic cancer that developed apart from cystic lesion.
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Discovery of Novel Diagnostic Approach for Pancreatic Cancer
Joo Kyung Park, Yong Bum Yoon, Yong Tae Kim, Ji Kon Ryu, Jun Kyu Lee, Won Jae
Yoon, Sang Hyub Lee
Introduction Pancreatic cancer remains one of the most deadly human cancers. The imaging
studies, fine needle aspiration cytology (FNAC) or biopsy (FNAB), and ERCP guided brush
cytology are usually performed as a method of diagnosis. However, the reliability of cytologic
analyses of fine needle aspirates remains unsatisfactory, with a diagnostic accuracy of≤80%,
and even worse in brush cytology. The purpose of this study was to develop a novel
diagnostic approach based on genetic and epigenetic characteristics of pancreatic cancers.
Especially, aberrant methylated genes have been identified in surgical specimen, and NPTX2
were found more than 90%. Therefore, we tried to prove NPTX2 as a useful diagnostic
marker. Methods The 50 patients with pancreatic cancer were enrolled prospectively between
2004 and 2005. They underwent computed tomography, FNAC or FNAB, and ERCP guided
bile and pancreatic duct brush cytology. Genomic DNA was extracted using phenol-chloro-
form extraction method in cytology samles. DNA methylation patterns in the CpG islands
of the target genes were determined by chemical modification of unmethylated, but not
methylated, cytosines to uracils, and subsequent PCR amplification using primers specific
for either methylated or modified unmethylated DNA. The bisulfite-modification was per-
formed. The NPTX2 CpG island was examined by real-time PCR amplification using oligonu-
cleotide primers and a TaqMan probe specific for a fully methylated bisulfite converted
portion of the NPTX2 gene. The β-actin primers and probe set, designed specifically for
bisulfite-converted DNA, were used as a reference gene. Results The fifty patients were all
pathologically confirmed with definite diagnosis of pancreatic cancer. In brush cytology,
the 5 out of 31 patients (16%) had the pathologic reports of positive for malignant cells,
and another 5 patients had atypical cells. The rest of 21 patients had the negative for
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malignant cells. In real-time PCR, aberrant methylation of NPTX2 was detected in 27 out
of 31 patients (87%). In FNAC, the 9 out of 19 patients (47%) had the pathologic reports
of positive for malignant cells, and 3 patients had the atypical cells. The rest of 7 patients
had the negative for malignant cells. In real-time PCR, aberrant methylation of NPTX2 was
detected in 19 patients (100%). Conclusion Our diagnostic approach resulted in 87%
accuracy in brush cytology and 100% in FNAC. The aberrant methylation of NPTX2 gene
can be expected to become a valuable new tool to improve the reliability in conjunction
with conventional diagnostic procedures in pancreatic cancer.
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Tumour-M2-Pyruvate Kinase (Tu-M2-PK): A Novel Biomarker of Adverse
Prognosis in Pancreatic Cancer
Priyantha Siriwardana, James M. Mason, Kolitha Goonetilleke, Nicolas K. King, Michael
W. France, Ajith K. Siriwardena
Introduction A wide range of human tumours express the enzyme pyruvate kinase, a
component of aerobic glycolysis pathways. Of the four different isoforms found in mammalian
tissue, the M2 isoenzyme is strongly over-expressed in cancer states. A commercially available
enzyme-linked immunosorbent assay (ELISA) kit has allowed for the reliable detection and
quantification of the enzyme tumour-M2-pyruvate kinase (Tu-M2-PK) in blood. This study
tests the hypothesis that Tu-M2-PK is a prognostic marker in pancreatic cancer. Methods
Between July 2002 and March 2004, 104 patients were admitted to the hepato-pancreatico-
biliary service of a University Hospital with suspected pancreatic cancer and gave informed
consent for participation. CA 19-9 and Tu-M2-PK levels in blood were assayed prior to
resection or pancreatic biopsy. 23 Jaundiced control patients had evidence of the absence
of cancer at ERCP and 44 non-jaundiced controls underwent elective cholecystectomy. The
principal outcome measures were estimation of the sensitivity and specificity of Tu-M2-PK
and CA 19-9 individually and in combination for the pre-operative diagnosis of peri-
ampullary cancer and for prediction of survival. Of the 104 pts, 49 had jaundice. Subsequent
Histopathologic findings confirmed pancreatic/peri-ampullary malignancy in 76. Survival
data (up to 3 years follow-up with a median of 271 [2-1129] days) in patients with confirmed
cancer were used to gain further understanding of the test findings. Results The mean plasma
Tu-M2-PK level for patients with histologically-proven malignancy was 40.5 (26.4) U/ml
and for all non-cancer patients was 29.9 (20.9) U/ml. This difference was statistically
significant (Mann-Whitney U=1163, P = 0.006). However, Tu-M2-PK with an AOC of 0.623
is unlikely to provide a useful discriminant test for pancreatic cancer although Tu-M2-PK
test findings were unaffected by the presence of jaundice. Tu-M2-PK correlated with poor
differentiation and metastatic disease. Multivariate Cox regressions modelling determinants
of survival with Tu-M2-PK dichotomised at the optimal cut-off (27 ml/U) and fitted as a
binary variable in the model revealed that patients with values above the cut-off were dying
2.6 times faster than those with values below (95%CI: 1.3 to 5.3). THis difference was
statistically significant at the P<0.01 level and was sustained throughout the 3-yr follow-up
on Kaplan-Meier survival analysis. Conclusion In a tertiary referral practice setting an elevated
Tu-M2-PK over 27 units/ml was a strong independent predictor of poor survival and this
is worthy of incorporation into future management algorithms
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Evaluation of Hedgehog (HH) Pathway Expression in Cell Lines and
Endoscopic Ultrasound-Guided Fine-Needle Aspirate (EUS-FNA) Biopsies of
Pancreatic Adenocarcinoma
Adam Steg, Selwyn Vickers, Mohamad Eloubeidi, Amy Petersen, Wenqan Wang, Andra
Frost, Martin Johnson
INTRODUCTION: Pancreatic adenocarcinoma is characterized by an unusual resistance to
radiation and chemotherapy. Recent studies suggest that activation of the HH signaling
pathway is involved in the initiation, maintenance and progression of pancreatic adenocarcin-
oma and that targeting this pathway could potentially be used as a novel therapeutic strategy.
OBJECTIVE: The goals of this study were to: 1) examine HH expression in EUS-FNA biopsies
obtained from patients diagnosed with pancreatic adenocarcinoma; and 2) determine the
molecular basis of response to the HH pathway antagonist cyclopamine in pancreatic cancer
cell lines. METHODS: The expression of 46 HH pathway-associated genes was examined
in 11 EUS-FNA biopsies and 11 pancreatic cancer cell lines (AsPC-1, BxPC-3, CFPAC1,
HPAF-2, MiaPaCa-2, Panc-1, Panc 2.03, Panc 6.03, Panc 8.13, Panc 10.05 and S2013)
using Taqman Low Density Array (TLDA). To test for response to cyclopamine, cells were
cultured in medium containing different concentrations (1, 2, 3.5, 5, 7.5, 10, 12.5, 15,
17.5, 20, 22.5, 25, 27.5 or 30 µM) of cyclopamine. After 96 hours of treatment, cell viability
was calculated using an MTS colorimetric assay relative to vehicle control. Linear regression
analysis was performed to determine the dosage at which 50% inhibition of cell growth was
achieved (IC50). RESULTS: Among the HH ligands examined, Sonic and Indian demonstrated
the highest average mRNA levels in tumor compared to uninvolved pancreas (336 and 162-
fold respectively). Among the HH receptors, Patched 1 and 2, expressed 1.48- and 5.38-
fold higher, respectively, while Smoothened, the target of cyclopamine, demonstrated a
1.67-fold decrease in expression in tumor. The glioma-associated oncogenes, GLI-1, -2 and -
3, transcription factors which have been correlated with HH pathway activity, expressed
4.18-, 10.18- and 3.34-fold higher in tumor, respectively. The response to cyclopamine
varied among the cell lines with IC50’s ranging from a low of 7.62 µM for BxPC-3 cells to
a high of 42.91 µM for S2013 cells with a trend toward low Smoothened and high Glycogen
Synthase Kinase 3-beta (GSK3B) mRNA levels in sensitive cell lines as compared to resistant
cell lines. CONCLUSION: These data suggest HH pathway expression varies among both
pancreatic tumor samples and cell lines and that Smoothened and GSK3B may be indicators
of response to cyclopamine. This characterization could, ultimately, be used to develop a



















Prevalence of Pancreatic Cancer Risk Factors and Perceptions of Cancer Risk
Among Individuals with An Inherited Predisposition to Pancreatic Cancer
Kerry B. Dunbar, Marcia I. Canto
BACKGROUND: Individuals with a family history of pancreatic cancer (PC) have increased
risk for developing the disease. Little is known about the prevalence of risk factors for sporadic
PC in high risk individuals and their perceptions of their cancer risk. This information is
important for possible future intervention trials. AIM: To identify potentially modifiable risk
factors, such as smoking, obesity and physical inactivity and to study perceptions of cancer
risk among high risk individuals with a genetic predisposition for PC. METHODS: Cancer
of the Pancreas Screening (CAPS) Studies 1&2 (1998-2002) prospectively screened adult
high risk patients from familial PC kindreds with at least 2 affected first-degree relatives for
early pancreatic neoplasia using CT and EUS. Adult control subjects without a personal or
family history of PC and without suspicion of pancreatic disease were concurrently enrolled.
Risk factor information was prospectively obtained through a standardized questionnaire,
including race, weight, height, personal and family history of neoplasia, medical history,
tobacco use, medication use, alcohol use, physical activity and perception of cancer risk.
RESULTS: Age, race and gender were comparable among the 113 high patients and 129
normal risk controls studied. However, high risk individuals were more likely be overweight
or obese (BMI>25) compared to controls (64.6% vs. 43.9%, p=0.008) but not more likely
to be inactive (i.e. total physical activity <4 hours/week) (61.5 vs. 85.7%). Exposure to
cigarette smoke was similar in high risk and control subjects; 46% had ever smoked cigarettes,
86% had passive smoke exposure, but only 8.9% were current smokers. High risk subjects
were also more likely to be current regular alcohol drinkers than controls (31% vs. 19%,
p=0.03) but their exposure to aspirin, folic acid and HMG-CoA reductase inhibitors, which
have been associated with a potential protective effect for PC development, were similar to
controls. High risk individuals were more likely to be moderately to extremely worried
about PC (86%) and to perceive their lifetime risk for PC as moderately to extremely high
(91%), but their perceived risk for other cancers was no different from controls (p=0.09).
CONCLUSIONS: Individuals with a family history of PC possessed other potentially modifi-
able risk factors of PC (overweight, inactivity, smoking). They were significantly more worried
about their PC risk compared to controls. This high level of concern presents an opportunity
to encourage lifestyle modifications and study interventions that could potentially modify
their risk for PC.
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P130cas and CRK May Regulate Human CACO-2 Intestinal Epithelial Cell
Migration Via the Small GTP Binding Protein Rac1 and the Guanine-
Nucleotide Exchange Factors Dock180 and C3g
Matthew A. Sanders, Marc D. Basson
We have previously observed that Caco-2 intestinal epithelial cell spreading, migration and
lamellipodial extension on the extracellular matrix protein collagen IV requires Src-dependent
phosphorylation of the adaptor protein p130Cas and also requires the adaptor protein Crk,
which binds to phosphorylated p130Cas. We hypothesized that focal adhesion kinase (FAK),
which contains a potential binding site for the p130Cas SH3 domain, may also be required
for collagen IV-dependent phosphorylation of p130Cas and its subsequent interaction with
Crk. Additionally, we hypothesized that Caco-2 spreading and migration may require the
guanine-nucleotide exchange factors DOCK180 and C3G, which bind to Crk in some cell
types. Transfection of Caco-2 cells with a FAK-specific small interfering RNA (siRNA) reduced
FAK protein by more than 90% and strongly inhibited (47±4% inhibition, n=3, p<0.01)
phosphorylation of p130Cas Tyr(P) 249, which is an important Crk binding site in some
cell types. siRNAs specific to DOCK180 or C3G reduced levels of each protein by more
than 80%. DOCK180 siRNA inhibited Caco-2 spreading on collagen IV by 17±3% (n=3,
p<0.05). C3G siRNA did not significantly inhibit Caco-2 spreading by itself. However,
combined C3G and DOCK180 siRNA inhibited cell spreading by 38±5% (n=3, p<0.05
compared to control siRNA or individual DOCK180 and C3G siRNAs). Additionally, com-
bined C3G and DOCK180 siRNA transfection significantly inhibited Caco-2 migration on
collagen IV (32±5% inhibition, n=4, p<0.01) and similarly to p130Cas or Crk siRNA
transfection noticeably inhibited lamellipodial extension. Since DOCK180 can serve as a
guanine-nucleotide exchange factor for the small GTP-binding protein Rac1 in some cell
types, we therefore next examined the role of this protein in Caco-2 spreading and migration
on collagen IV. The Rac1 specific inhibitor NSC23766 strongly inhibited Caco-2 migration
(66±5% inhibition, n=3, p<0.01) and lamellipodial extension on collagen IV, as well as cell
spreading (42±9% inhibition, n=6, p<0.01). We confirmed the specificity of this result using
siRNA specific for Rac1. Transfection with siRNA to Rac1 reduced Rac1 protein by more
than 80% and similarly to NSC23766 Rac1 siRNA inhibited Caco-2 spreading on collagen
IV by 39±3%(n=6, p<0.001). Taken together, these results suggest that collagen IV may
regulate Caco-2 migration via FAK and Src-dependent p130Cas phosphorylation and binding
to Crk and subsequent signaling through the guanine-nucleotide exchange factors DOCK180
and C3G to the small GTP-binding protein Rac1.
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Novel Roles of IGF-1 in Gastric Ulcer Healing: Activates G-Actin
Polymerization and RE-Epithelialization Via Cross-Talk Between COX2 and
PI3K Signaling Pathways
Thomas Nguyen, Jianyuan Chai, Tetsuya Tanigawa, Andrzej S. Tarnawski
Background & Aims: Insulin-like growth factor-1 (IGF-1) promotes cell survival in a variety
of cells and may play a role in gastric ulcer healing. It is unknown whether IGF-1 regulates
re-epithelialization during gastric ulcer healing, and if so, what are the molecular mechanisms
and signaling pathways of this action. We examined effect of gastric ulceration on expression
and cellular localization of IGF-1 in gastric mucosa in vivo, and determined in in vitro studies
in gastric epithelial RGM1 cells the effects of exogenous IGF-1 on G-actin polymerization into
F-actin, epithelial cell migration and Cox2 expression. We also examined dependence of
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these processes on PI3K and MAPK signal transduction pathways. Methods: Gastric ulcers
were induced in rats by focal serosal application of acetic acid. Specimens of ulcerated and
non-ulcerated mucosa were obtained sequentially following ulcer induction for analysis of
IGF-1 and Cox-2 mRNA and protein expression by RT-PCR, ELISA and immunohistochem-
istry, respectively. To evaluate the signaling pathways mediating IGF-1 actions and the role
COX-2, we used specific inhibitors of PI3- kinase, MEK1 kinase and Cox2. IGF-1-induced
RGM1 cell migration was evaluated using standard “scratch wound assay” in the presence
IGF-1 with or without PI3-kinase inhibitor (LY294002), MEK1 kinase inhibitor (PD98059)
or COX-2 inhibitor (NS-398). Results: Gastric ulceration increased tissue IGF-1 concentra-
tion by 226%, 305% and 254%, respectively, at 4, 6 and 12 days (all p < 0.001). Immunohisto-
chemical staining demonstrated increased IGF-1 expression in epithelial cells at the ulcer
margin base, and later in the cells re-epithelializing granulation tissue. Treatment of RGM1
cells with exogenous IGF-1 (10-50 µg/ml) produced a dramatic increase in G-actin polymeriz-
ation into F-actin, ~800% increase in cell migration (p<0.001), > 200% increase in cell
proliferation (p <0.05), and a significant increase in COX-2 expression. Inhibition of PI3-
kinase activity abolished IGF-1-induced actin polymerization, RGM1 cell migration and
proliferation and COX-2 protein expression. MEK/MAPK inhibitor reduced IGF-1-induced
activation of all above processes by 30-50%. Conclusions: 1) Gastric ulceration activates
IGF-1 gene in epithelial cells of the ulcer margin. 2) In vitro, IGF-1 stimulates in gastric
RGMI cells, in a PI3-kinase dependent manner: G-actin polymerization into F-actin, cell
migration and proliferation and induces COX-2 expression. 3) A strong IGF-1 expression
in the cells migrating onto granulation tissue and re-epithelializing gastric ulcer indicates
its critical role in autocrine regulation of this process.
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Role of 15-Deoxy Prostaglandin J2 and NRF2 in Protection of Gastric Mucosa
Against Oxidative Stress During H.pylori Infection in Mice
Akinori Yanaka, Ken Itoh, Masafumi Tauchi, Hideo Suzuki, Takeshi Shibahara, Hirofumi
Matsui, Akira Nakahara, Ichinosuke Hyodo, Masayuki Yamamoto
Background: Persistent H.pylori (Hp) infection causes gastritis, ulcers, and gastric cancer.
However, cells can withstand stresses by inducing a variety of antioxidant enzymes, thereby
prevents gastric mucosa from oxidative injury. 15-deoxy PGJ2 (15-DPGJ2), which is endogen-
ously generated by COX-2 in inflamed tissues, affords strong cytoprotective activity against
oxidative stress (Ann N Y Acad Sci. 2003;993:208-16). Although PGJ2 family has been
shown to exert anti-inflammatory action by activating PPARγ and/or by inhibiting NF-kB,
the exact mechanisms by which15-DPGJ2 protects cells against oxidative stress remains
unclear. We have previously reported that nrf2 (NF-E2 p45-related factor-2), a transcription
factor, which regulates cellular response against oxidative stress, plays an important role in
induction of antioxidant enzymes in gastric mucosa during Hp infection (AGA 2003). In
the present study, we aimed to determine if endogenously generated 15-DPGJ2 contributes to
gastric mucosal protection via up-regulating nrf2-dependent antioxidant enzymes. Methods:
Standardized mice model of Hp infection were set up by inoculating C57/BL6 female mice
(nrf2+/+ and nrf2-/-) with Hp Sydney Strain; SS1. Mice were maintained with high salt diet
(7.5% NaCl). Some mice were treated with either NS-398 and/or 15-DPGJ2. Mice were
sacrificed at 4, 8, and 16 wks later. Degree of gastritis was evaluated by updated Sydney
system. DNA damage was estimated by measuring mucosal level of 8-OHdG. Expressions
of TNF-α, IL-1β, COX-2, and antioxidant enzymes (GST, and HO-1) were analyzed by real
time RT-PCR. Mucosal level of 15-DPGJ2 was evaluated using ELISA. Results: 1. In nrf2+/
+ mice, 4w treatment with Hp + high salt diet caused severe inflammation in corpus mucosa,
accompanied by marked elevation of TNF-α, IL-1β, COX-2 and 8-OHdG, while expressions
of 15-DPGJ2, GST and HO-1 were not prominent. 2. During 8-16 w treatment, mucosal
inflammation improved over time, accompanied by a gradual decrease in levels of TNF-α,
IL-1β, COX-2, and 8-OHdG. In contrast, 15-DPGJ2, GST and HO-1 were more up-regulated
than those at 4 w. 3. Treatment with NS-398 exacerbated the corpus gastritis at 4 w, and
inhibited subsequent improvement of gastritis, whereas administration of exogenous 15-
DPGJ2 in combination with NS-398 rescued the worsening effect of NS-398 on gastric
mucosa. 4. The effects of NS-398 and 15-DPGJ2 were completely abolished in nrf2-/- mice
treated with Hp and high salt. Conclusion: These results suggest that endogenous 15-DPGJ2
protects gastric mucosa against oxidative stress during Hp infection, at least in part by up-
regulating nrf2-dependent antioxidant enzymes.
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Protein Kinase C-Delta (Pkc-δ) Isoform Is a Key Regulator of NF-kB and Its
Endogenous Modulator I-kb During Oxidative Stress Injury: A Crucial Pro-
Inflammatory Mechanism in Gut Epithelium
Ali Banan, Lijuan Zhang, Maliha Shaikh, Jeremy Z. Fields, Ashkan Farhadi, Christopher
B. Forsyth, Ali Keshavarzian
NF-kB activation & gut barrier injury are required factors in the pathogenesis of inflammatory
GI disorders. Using GI cells, we found that oxidative stress activates NF-kB (by degrading
its modulator IkBα) & leads to disruption of the intestinal barrier. But, the underlying
molecular mechanisms are unclear. Since PKC-δ,a member of the novel family of PKC
isoforms, is key in cellular injury, we investigated whether inhibition of PKC-δ expression
is required for protection against oxidant-induced IkB-α degradation, NF-kB activation &
barrier disruption. Methods: We used GI cell clones transfected to either overexpress or
underexpress PKC-δ. Monolayers of these unique GI clones were then incubated with PKC
activators or inhibitors ± oxidant (H2O2). Naive, wild type (WT) cells were treated similarly.
We then assessed cell survival {LIVE/DEAD assay}, monolayer barrier permeability
{fluorometry}, tight junction integrity & assembly {laser confocal microscopy, PAGE
fractionation}, PKC-δ subcellular activity & distribution {immunoprecipitation, in vitro
kinase}, IkBα levels {PAGE}, NF-kB (p50/p65) subunit activities {ELISA, EMSA}, n=6/grp.
Results: {A} Cells transfected to underexpress PKC-δ or WT cells pretreated with the PKC-
δ inhibitor (rottlerin) were protected against oxidative damage as indicated by: PKC-δ
inactivation, IkBα stabilization, NF-kB (p50/p65 subunits) inactivation, occludin assembly
(increased membrane fraction, decreased cytosolic fraction), occludin cytoarchitectural integ-
rity, & monolayer barrier stability. All measures of protection against NF-kB induced by
inhibition of PKC-δ were synergistic with protection by growth factor (EGF). {B} Sense
transfection to induce expression of full-length endogenous PKC-δ caused IkBα degradation
& NF-kB activation, and led to occludin & barrier hyperpermeability, paralleling oxidant-
like affects in WT cells. {C} Most of the overexpressed PKC-δ resided in membrane &
cytoskeletal fractions, indicating constitutive activation. In both transfected clones & oxidant-
treated WT cells, PKC-δ (75 kDa) was active and found with IkB (37 kDa), forming novel
endogenous PKC-δ:IkB complexes. {D} PKC-δ expression & activation prevented all measures
of EGF protection against oxidant-induced IkB/NF-kB activation & monolayer barrier instab-
ility. Conclusions: Our findings support novel pathophysiologic mechanisms in GI cells
that: 1) Activation of PKC-δ is necessary for cellular & barrier injury due to the stress of
I-kB/ NF-kB activation; 2) PKC-δ appears to be a unique intracellular modulator of I-kB;
3) Protection of barrier integrity can occur through inactivation of PKC-δ and of I-kB/NF-kB.
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Telomere Shortening and Senescence Differentially Affect Gastric Acid and
Duodenal Bicarbonate Secretory Capacity in Aging Mice
Biguang Tuo, Zhenyu Ju, Brigitte Riederer, Regina Engelhardt, Michael P. Manns, Lenhard
Rudolph, Ursula Seidler
Background&Aims: The incidence of non-H.pylori-related duodenal ulcers strongly increases
with age, but the study of its pathophysiology has been hampered by the lack of suitable
animal models. There is a growing evidence that telomere shortening and senescence influence
human aging. We therefore wondered how telomere shortening may affect the aggressive
and protective ion secretory processes in the gastroduodenal mucosa of late generation
telomerase deficient (mTERC-/-) mice with shortened telomeres. Methods: Murine duodenal
mucosal bicarbonate secretion and gastric acid secretion were examined in vitro in Ussing
chambers. Duodenal mucosal CFTR and Slc26a6 expression levels were analyzed by quantit-
ative RT-PCR. Results: In aged late generation mTERC-/- mice with shortened telomeres,
forskolin-stimulated bicarbonate secretion and Isc were reduced by 43% and 47% respect-
ively, compared with age-matched wt mice with long telomere reserves (P<0.0001). In
contrast, forskolin-stimulated gastric acid secretion was not significantly altered (P>0.05).
Correspondingly, duodenal mucosa of mTERC-/- showed villous atrophy in the duodenum,
whereas gastric mucosal histology was not altered compared to wt controls. Interestingly,
the ratio of CFTR and Slc26a6 mRNA expression in relation to cytokeratin 18 was not
altered, demonstrating a balanced atrophy along the whole crypt length with no shift in
the expression of villous (SLC26A6) vs crypt-predominant (CFTR) transporters. p21 is a
downstream effector of senescence signaling resulting in cell cycle arrest. In order to investig-
ate whether the defect in bicarbonate secretion in mTERC -/- mice was due to p21 dependent
senescence induced by telomere shortening, we analyzed duodenal mucosal bicarbonate
secretion in late generation mTERC-/-/p21-/- double knockout mice. In mTERC-/-/p21-/-
mice duodenal atrophy was rescued compared to mTERC-/- single knockout mice and
forskolin-stimulated bicarbonate secretion and Isc were not different from wt controls
(P>0.05). Conclusion: Telomere shortening and senescence results in mucosal atrophy and
reduced bicarbonate secretory capacity in the duodenum of aging TERC-/- mice. In contrast,
the stomach with its longlived glandular cells displays normal histology and acid secretory
function. This suggests that telomere shortening and senescence has a differential effect on
gastroduodenal ion transport functions, resulting in an imbalance between aggressive and
protective secretions and thus predisposing to duodenal ulcer formation.
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Short Food Deprivation Abolishes Orexin-a Induced Intracellular Calcium
Signaling in Acutely Isolated Duodenal Enterocytes
Gunnar Flemstrom, Magnus Bengtsson, Kari Makela, Gunilla Jedstedt, Markus Sjoblom,
Karl-Heinz Herzig
BACKGROUND & AIM: Neural pathways including reflexes within the enteric nervous
system as well as stimuli elicited within the central nervous system and transmitted to the
intestine by autonomic nerves are key elements in the control of small intestinal secretion.
Some appetite regulating hormones, including orexin-A and orexin-B are produced in the
hypothalamus but also expressed in the intestinal submucosa. Interactions between central
nervous and intestinal actions of these hormones would seem of particular interest. We
have compared effects of Orexin-A on enterocyte intracellular calcium [Ca2+]i signaling in
enterocytes acutely isolated from duodenum in continuously fed and overnight food deprived
animals. METHODS: Rats had continuous access to their regular food supply, or were
overnight deprived of food (but not water). Animals were sacrificed at 8 am and the duodenal
mucosa was cut into 0.5-1.0 mm pieces followed by mild digestion (collagenase/dispase)
to yield clusters (10-100 cells) of duodenal enterocytes. Clusters were loaded with fura-2,
mounted in a perfusion chamber and [Ca2+]i was measured with fluororescence imaging.
RESULTS: Orexin-A (1-100 nanomol/L) in a dose-dependent manner induced [Ca2+]i sig-
naling in duodenal enterocytes isolated from continuously fed animals. There was a rise in
[Ca2+]i to a peak level, and the response was similar to those observed with carbachol or
cholecystokinin. In contrast, there were no responses to orexin-A in enterocytes from over-
night food deprived animals. Even at a high concentration (1 micromol/L), the muscarinic
agonist atropine did not affect [Ca2+]i signaling induced by orexin-A.The orexin (OX1)
receptor antagonist SB-33487 was used at concentrations of 1-100 nanomol/L). The highest
concentration of SB-33487 alone induced [Ca2+]i signaling, similar to that observed with
orexin-A suggesting that the compound is a partial agonist. At the lower concentration of
10 nanomol/L, SB-33487 inhibited the response to 10 nanomol/L of orexin-A but did not
abolish that to 100 nanomol/L of the peptide. CONCLUSION: The orexogenic peptide
orexin-A induces [Ca2+]i signaling in duodenal enterocytes from fed animals and short
fasting abolishes the response. These findings are in line with absence of an electrolyte
secretory response to orexin-A in fasted animals and strongly suggest that enterocyte OX1
receptors are involved in regulating intestinal secretion. Supported by the Swedish Research
Council and the Finnish Academy
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Increased Life-Time Risk for Colorectal Cancer in Patients with Loss of
Genomic Imprinting of Insulin-Like Growth Factor 2: A Survival Analysis
Marcia Cruz-Correa, Ronghua Zhao, Dana Sands, Eric Weiss, Juan Nogueras, Steven
Wexner, Francis M. Giardiello
Background: Loss of genomic imprinting (LOI) of the IGF2 gene is independently associated
with colorectal cancer (CRC), but underlying carcinogenic mechanisms remain unclear.
Whether LOI-positive individuals have a higher life-time risk for CRC than LOI-negative
individuals is unknown. This study investigated the incidence rate and life-time risk of
developing CRC in patients whose LOI-status was known. Methods: We performed PCR
on gDNA and RT-PCR on RNA extracted from normal peripheral blood lymphocytes (PBL)
of prospectively recruited individuals. After digestion by Apa I, the PCR and RT-PCR products
were run on 2% agarose gel and the gel photos were quantitatively analyzed to determine
the informative status and IGF2 imprinting status, respectively. Incidence rates of CRC were
calculated by person-year analysis using Kaplan-Meier survival estimates and cox regression
as appropriate. Results: A total of 245 informative patients were recruited including 130
normal individuals (73 males; mean age 60.0 ± 12.6 years), 71 patients with colorectal
polyps (33 males; age 62.8 ± 7.7 years) and 44 with CRC (18 males; age 61.9 ± 12.3 years).
The incidence rates for CRC were 2.3 and 6.0 per 1000 person-years for LOI-negative and
LOI-positive patients, respectively (Hazard Risk 3.03, 95% CI 1.62-5.7). Using age-at-
diagnosis as a time variable in a gender-adjusted cox regression model, LOI-positive patients
presented with CRC at earlier age compared to LOI-negative patients (p = 0.001). Conclusion:
Individuals with LOI of IGF2 as noted in PBL had an increased life-time risk for and earlier
age of diagnosis of CRC, compared to LOI-negative patients. These findings suggest a distinct
carcinogenic pathway for LOI-positive patients, which may have implications in screening
and risk assessment. Support: NIH grants K07 CA092445 and P50 CA-62924-10, The John
G. Rangos, Sr. Charitable Foundation, The Cancer Research and Prevention Foundation,
The Clayton Fund.
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Risk of Colorectal Cancer in Juvenile Polyposis
Lodewijk A. Brosens, Anne C. Tersmette, Linda M. Hylind, Christine Iacobuzio-Donahue,
Katharine Romans, Jennifer Axilbund, Arnout van Hattem, G. Johan A. Offerhaus, Francis
M. Giardiello
Background: Juvenile polyposis is an autosomal dominant disorder characterized by the
development in childhood of juvenile polyps primarily in the colorectum but also elsewhere
in the gastrointestinal tract. Juvenile polyposis is associated with colorectal cancer, but the
risk is unclear. Therefore, we determined the relative and absolute risk of colorectal cancer
in juvenile polyposis patients. Methods: The study population consisted of 73 patients with
juvenile polyposis from the Johns Hopkins Polyposis Registry contributing 1625.2 person
years of follow-up. This included 35 males (738.9 person-years) and 38 females (886.3
person-years). The incidence rates of colorectal cancer in these patients with juvenile
polyposis were compared with the general U.S. population through person-year analysis
using SEER data with adjustment for population. Results: In juvenile polyposis patients the
relative risk (RR) of colorectal cancer was 34.5 times (95% confidence limits [CL], 15.0-
68.5) the general population. Similar risks were noted in both males (RR 36.2; CL, 13.0-
76.8) and females (RR 30.1; CL, 3.5-103). The cumulative lifetime risk for colorectal cancer
was 39.4%. The mean age of diagnosis of colorectal cancer was 40.4+/-10.7 (SD). Other
gastrointestinal tumors were not observed in this cohort. Conclusion: Patients with juvenile
polyposis are at high relative and absolute risk for colorectal cancer. Vigilant colorectal
cancer surveillance of these patients starting at young age is imperative. Supported by The
John G. Rangos, Sr. Charitable Foundation, The Clayton Fund, The Netherlands Digestive
Disease Foundation, NIH grants K07 CA092445, CA 53801, and P50 CA 62924-10.
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Prospective Results of Surveillance Colonoscopy in Autosomal Dominant
Familial Colorectal Cancer Families with and Without Lynch Syndrome
Isis Dove-Edwin, Andrea de Jong, Joanna Adams, Lara Lipton, Peter Sasieni, Hans Vasen,
Huw Thomas
Background & Aims: Lynch syndrome is an autosomal dominant predisposition to colorectal
cancer caused by mutations in DNA mismatch repair genes; colorectal cancer risk is high.
Few studies have addressed colorectal cancer risk in individuals from dominant families
without mismatch repair deficiency. We sought to establish whether they are also at increased
risk by examining the incidence of advanced neoplasia during surveillance Methods: In this
prospective cohort study, carried out at two tertiary centres, 126 individuals from 98 families

















them as Lynch syndrome (microsatellite unstable) or non-Lynch syndrome (microsatellite
stable). Results of colonoscopy in 291 at-risk family members were compared. Results: 29
families were classified as Lynch syndrome and 69 as non-Lynch syndrome. 785 colonoscop-
ies were undertaken. High risk adenomas ocurred in 7/91 (7.7%) of Lynch syndrome
individuals and 17/200 (8.5%) of non-Lynch syndrome individuals chi-sq= 0.01, p=0.92.
Cancer was observed in 4/91 (4.4%) of Lynch syndrome individuals, none occurred in non-
Lynch syndrome Fisher’s exact chi-sq= 7.0460 p=0.017. Multiple adenomas were only seen
in non-Lynch syndrome 9/200 (4.5%) Fisher’s exact chi-sq=4.2257, p=0.040. Forty percent
(6/15) of individuals with multiple adenomas developed a high risk adenoma at some point
during surveillance OR=12.0 (95% CI (2.4, 59.4)) p-value=0.002, adjusting for age, sex
and extent and centre solely within the non-Lynch group. Conclusions: Individuals with an
autosomal dominant family history of colorectal cancer with and without evidence of Lynch
syndrome are at equal risk for the development of high risk adenomas during surveillance,
but colorectal cancer was only seen in Lynch syndrome. Therefore non-Lynch syndrome
individuals do require colonoscopic surveillance, but the interval could be lengthened because
risk of (interval) cancer is low. Lynch syndrome individuals require short surveillance
intervals as is the recommended practice.
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The Genotype-Phenotype Relationship of Polyposis Families Reveals Clinically
Distinct Subgroups
Kevin J. Monahan, Volikos Emmanouil, Robin K. Phillips, Thomas J. Huw, Andrew R.
Silver, Ian P. Tomlinson
Background: Familial adenomatous polyposis (FAP) is an autosomal dominant condition
predisposing to multiple polyps of the large bowel. However, not all patients with polyposis
carry germline mutations in the APC (adenomatous polyposis coli) gene or other known
genes which predispose to this condition. Aims: The genotype-phenotype relationship of
polyposis kindreds without identified mutations in known genes was determined in order
to characterise features of a previously undescribed polyposis syndrome. The yield using
stringent mutation detection methods was also determined. Patients: A cohort of sixty-two
unrelated patients recorded at St Mark’s Hospital did not have mutations in the APC or
MYH genes identified using standard techniques in diagnostic genetics laboratories. Methods:
The coding and splice site regions of the APC gene were directly sequenced. Exon copy
number changes were detected using a relatively new technique called multiplex-ligation
probe amplification (MLPA). Haplotype analysis was performed using six flanking microsa-
tellite markers, and two intronic single-nucleotide polymorphisms (SNPs) within APC. The
MYH gene was screened for mutations using single-stranded conformational polymorphism
(SSCP) analysis and sequencing. Results: Nineteen kindreds were found to have either
previously undetected APC mutations or exon copy-number changes. Four patients were
found to carry a biallelic MYH mutation. Therefore approximately 37% of patients had
mutations found not previously identified by diagnostic genetics laboratories. Five novel
mutations of APC were identified, including a duplication of exon 4 of APC found using
MLPA. Duplication mutations have not previously been identified. Genotype-phenotype
analysis revealed a difference in polyp number between mutation positive (no.=23) and
mutation negative (no.=39) groups (p<0.003, t test). A subgroup analysis of the mutation
negative group (based on family history) shows that there is a less penetrant condition
among those with evidence of recessive inheritance of the trait. There is a later age of
diagnosis of polyposis (41 years versus 31.8 years, p=0.007, t test), lower rate of colorectal
and extra-colonic cancers (p=0.002 and 0.017 respectively, Fisher’s exact), and lower rate
of duodenal polyposis (p<0.0001, Fisher’s exact). Conclusions: The mutation negative group
is likely to consist of a heterogeneous group of patients with mutations in different predisposi-
tion genes for polyposis. A subgroup analysis indicates that those kindreds with a recessive
type of inheritance pattern have a less severe phenotype and may represent a distinct syn-
drome.
968
Association of Y Chromosome Haplotypes with Barrett’s Esophagus and
Esophageal Adenocarcinoma in the Dutch Caucasian Population
Agnieszka M. Rygiel, Sjoerd Repping, Leon M. Moons, Sander Ouburg, Franceska Milano,
Jantine W. van Baal, Jacques G. Bergman, Servaas A. Morre, Peter Siersema, Cornelis L.
Mulder, Johannes G. Kusters, Maikel P. Peppelenbosch, Jan M. Hoovers, Kausilia K.
Krishnadath
BACGROUND: Barrett’s esophagus (BE) is a metaplastic condition of the distal esophagus,
which predisposes for the highly malignant esophageal adenocaricoma (EAC). It is known
that BE and EAC have a 3-7 times increased incidence in males especially in the Caucasian
population. Interestingly the loss of Y chromosome is one of the most consistent aberration
in BE and occurs already in the stage of metaplasia and has a high frequency in dysplasia.
HYPOTHESIS: We hypothesized that certain Y chromosome haplotypes may be associated
with increased or decreased susceptibility for BE and EAC development. MATERIAL and
METHODS: To test this hypothesis, we have analyzed a set of 6 Y chromosome linked
polymorphisms to define 7 major Y chromosome haplotypes (A,B-C, DE, F(xJ,xK), K(xP),
J, P(xR1a), R1a ) in the Dutch Caucasian patients presenting with BE (n=286), EAC (n=
116) and esophagitis without BE(n=109). Their Y haplotype profile was subsequently com-
pared with matched for age (>50 years old), BE free Control population (n=90). RESULTS:
The frequency of Y haplotypes in the investigated populations is shown in the table below.
We found significant difference in frequencies of the P(xR1a) and DE haplotypes between
the patient groups and the control population. The P(xR1a)haplotype had a significantly
higher frequency in BE patients (62%) vs. Control (44%) (OR- 2.0, p<0.001). In contrast
the frequency of the DE haplotype was significantly lower in patients with BE (3%) and
EAC (1,7%) vs. Control (14,5%)(OR- 0.19, p<0.001 and OR-0.10, p<0.0001, respectively).
Also the DE haplotype was underrepresented in esophagitis (7,3%) vs. EAC (1.7%) (OR-
0.22, p<0.05). CONCLUSIONS: Our results suggest that the P(xR1a) haplotype is associated
with increased susceptibility for BE. In contrast the DE haplotype is associated with decreased
predisposition to both BE and EAC. We postulate that haplotypes P(xR1a) and DE might
be linked to the variants of genes which predispose and protect against BE /EAC development,
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respectively. Together with other markers, this may help identify those patients who are at
risk for BE or might benefit from surveillance.
Y chromosome haplotypes frequency (%) in BE, Esophagitis, EAC and Contol population.
969
Biallelic and Monoallelic Germline Myh Mutations and Colorectal Cancer
(CRC): Correlation with Family History of CRC and Related Cancers
Francesc Balaguer, Sergi Castellvi-Bel, Victoria Gonzalo, Antoni Castells, . GI Oncology
Group of the Spanish Gast. Association
Background: Germline mutations in the base-excision-repair MYH gene have been associated
with the development of multiple colorectal adenomas and CRC with an autosomal recessive
inheritance. In that sense, different studies have shown that biallelic germline mutations
account for less than 1% of the total of CRC. However, the risk of CRC among monoallelic
MYH gene mutation carriers is controversial, with a suggested weakly penetrant autosomal
dominant inheritance pattern. Aims: 1. To establish the prevalence of germline MYH gene
mutations in newly diagnosed CRC patients. 2. To evaluate the association of monoallelic
MYH mutations with family history of CRC and related cancers (endometrial, gastric, ovarian,
hepatobiliary, small bowel, or transitional cell carcinoma of the renal pelvis or ureter).
Patients and methods: Between November 2000 and October 2001, all newly diagnosed
CRC patients in 20 hospitals were included in the EPICOLON study, a prospective, multic-
enter, nation-wide survey aimed at establishing the incidence and characteristics of familial
forms of CRC in Spain. Mutational analysis of the MYH gene was performed in two steps:
1. screening for the recurrent missense mutations Y165C (494A>G; exon 7) and G382D
(1145G>A; exon 13) by allelic discrimination using TaqMan technology; 2. in heterozygotes
for any of these variants, PCR-based single strand conformation polymorphism analysis of
the 16 exons of the MYH gene. Abnormal migration shifts on SSCP were then sequenced.
Results: Pathogenic biallelic MYH germline mutations were detected in 2 out of 518 (0.4%)
evaluated patients, one patient being homozygote for Y165C and the other compound
heterozygote (Y165C/G382D). Eleven additional patients (2.1%) were heterozygotes for
either Y165C or G382D. In 4 out of these 11 patients, two known MYH gene polymorphisms
(Q324H in three and V22M in one) were identified. On the other hand, compared with
non-carriers, carrying a germline Y165C or G382D mutation was neither associated with
family history of CRC (9.1% vs. 18.7%, respectively; p=0.36) nor other related cancers
(27.3% vs. 31.6%, respectively; p=0.52). Conclusions: Biallelic MYH gene mutations account
for less than 1% of all CRC cases. Moreover, monoallelic MYH gene mutations seem not to
be associated with family history of CRC or other related neoplasms.
S1097
Are Women Choosing Careers in Academic Gastroenterology?
Lauren B. Gerson, Dayna Early, Gail Hecht, Linda Lee, Kenneth McQuaid, Theresa
Pizarro, Sarah Street, Cynthia Yoshida, Kay Twomey
Background: Representation of women in the AGA and in Gastroenterology leadership
positions has not increased significantly in the past decade. We performed a national survey
in order to determine factors that influence women to pursue academic or practice careers.
Methods: An on-line survey was administered to all AGA members between 2004-2005
including physicians in private practice, academic centers, and GI fellows. The survey
inquired about career satisfaction, the effects of gender on career advancement, and integra-
tion of family and career. Results: There were a total of 424 (14.8%) responders from 2856
invited physicians. 92 (22%) were in private practice, 233 (55%) in academic careers, and
99 (23%) trainees. There were 237 (56%) women and 187 (44%) men; equal numbers of
women (157/237) and men (108/187) were in academic careers (p=0.07) Significantly more
women (45%) compared to men (8%) stated that gender affected their career advancement
(p<0.0001) regardless of the practice setting. There was no significant difference between
the number of men or women who had obtained the rank of associate or full professor (p=
NS). Men were more likely to have held leadership positions. (p<0.001) Sixty-three (58%)
men and 63 (40%) women in academics responded to questions regarding career satisfaction:
there were no significant differences regarding satisfaction of salary levels, work load expecta-
tions, academic lifestyle, or balance between work and family. Men in academics tended to
report higher overall career satisfaction (p=0.06). Women were more likely to describe the
tenure process as difficult (p=0.01) and the promotional process as unfair (p<0.001). There
were no difference between genders regarding mentorship, however both men and women
were more likely to have had male mentors (p<0.001). When asked when fellows decide
to enter private practice, men were more likely to make this decision during residency
(p=0.02). Women in private practice were as satisfied as men regarding their financial
compensation, balance between work and family, and ability to be a shareholder in a group
practice (p=NS). Significantly more men compared to women had children and were married
(p<0.001). There was no significant difference between the genders for hours worked per
week. All respondents perceived that women in internal medicine residency programs were
less likely to choose GI as a career option because of lack of role models and difficulty with
family life issues. Conclusions: Compared to their male counterparts, female gastroenterolog-
ists perceived that gender affected their career advancement and were less likely to hold
leadership positions.
S1098
A Survey Assessing Attitudes Towards Privacy and Research
Subhas C. Ganguli, Yousra Al-Rweli, Christine Vanderkooy, Karen Miranda, Lehana
Thabane
INTRODUCTION: Legislation has recently been passed in Canada and Ontario to increase
the privacy of patients and their health records. However, patient views on privacy and its
applications to health research are poorly known. It was the aim of this study to assess
patient views towards privacy and health research. METHODS: A convenience sample of
450 outpatients in waiting areas at an Ontario teaching hospital (St Joseph’s Hospital,
Hamilton, ON) were asked to complete a paper-based survey to assess their views on privacy
and health research. RESULTS:The average age of respondents was 51, and 61% were female.
Purpose of visit was to see a doctor in 76.5%, for a test in 14.6% and for another reason
in 6.2%. Patient were more willing to be contacted about studies into the cause of their
disease if they had previously given explicit consent to be contacted (52.7% vs 45.9%;
P<0.01). Patients were more likely (P<0.01) to want to be contacted about adverse side-
effects of drugs (AEs) which they were currently taking (93.8%) than to be asked to be
involved in studies of their disease causation (45.9%) or new therapies (49.6%). Most also
felt that a computerized database could be kept for notification about drug side-effects
without their explicit permission (53.4%) but not for studies assessing disease causation
(36.0%) or new therapies (37.9%)(P<0.01). When asked about Ethics Board (REB) approved
access to their charts for retrospective review of drug AEs, 50.8% of patients felt they did
not have to be notified, while 37.1% preferred to be contacted and 12.1% felt this was
essential. When asked about future possible uses of their chart for REB approved studies,
42.2% of patients agreed that notification by letter (with option to not be involved) was
acceptable, while 30.1% felt they should be contacted to give blanket consent for any future
studies and 17.3% wanted to be contacted for each access to their chart. Opinions on this
question correlated with degree of skepticism towards healthcare providers (P<0.01). 90.3%
of patients agreed that medical research is beneficial; this was weakly correlated with their
satisfaction with the amount of time their physician spent explaining their medical condition
to them (r=0.14; P<0.01). CONCLUSIONS: Most patients want to be contacted about new
side-effects of their drug therapy and are willing to have their charts used for retrospective
reviews of this; many also want to be contacted about studies looking at the cause or new
therapies for their disease
S1099
Three Month Nutritional Supplementation Improves Both Muscle Function
and Quality of Life in Malnourished GI Patients - A Prospective Randomised
Controlled Trial
Kristina Norman, Henriette Kirchner, Manuela Freudenreich, Herbert Lochs, Matthias
Pirlich
Introduction: Malnutrition is a common problem in hospitalized GI patients and is generally
associated with higher morbidity and mortality. Nutritional status frequently worsens during
hospitalization and both weight loss and muscle dysfunction cause higher risk of readmission
and loss of general functionality. Aim: We therefore investigated the effect of a three month
post hospital nutritional intervention with a high protein oral supplementation on body
composition, muscle function and quality of life in malnourished GI patients. Methods:
Seventy-seven malnourished patients with benign gastrointestinal disease were randomized
to receive either a high protein supplement (400 ml, 150 kcal and 10 g protein/100ml) in
addition to their normal food or dietary counselling for 3 months. Nutritional status was
determined with the Subjective Global Assessment, body composition by bioelectrical imped-
ance, muscle function with hand grip strength and peak flow. Quality of life (QoL) was
assessed by the validated Medical Outcomes Study 36-item Short-Form Questionnaire (SF
36). All measurements were made at baseline and after 3 months. Results: Age, body cell
mass (BCM), muscle function (hand grip and peak flow), gender distribution and QoL
did not differ between intervention (n=37) and control group (n=40) at baseline. Oral
supplementation increased nutritional intake by 706±127 kcal/d and 46±9g protein/d in
the intervention group. Body weight and BCM improved significantly in all patients after 3
months, but to a slightly greater extent in the intervention patients. However, both hand
grip strength, peak flow as well as the physical component of SF 36 improved significantly
only in the intervention patients and remained unchanged in the controls. Conclusion: A
three month intervention with high protein oral supplements improves nutritional status
and functional parameters in malnourished GI patients. This leads to an improvement of
quality of life. Oral supplements should therefore be included in the standard therapy of
malnourished GI patients.
Abbr.: BCM= Body cell mass; SF 36 PCS= Physical Component Summary of Quality of Life
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S1100
Overweight and Obesity Protect Against Inguinal Hernia in the United States
Population
Constance E. Ruhl, James E. Everhart
Inguinal hernias are common, but few studies have investigated their risk factors. Therefore,
we examined the relationship of potential risk factors with the occurrence of inguinal hernia
in a large national population-based prospective study. Methods. In the first National Health
and Nutrition Examination Survey, 1971-75, interview and examination data were collected
on possible risk factors for inguinal hernia. Participants were followed through 1992-93 for
inguinal hernia as identified by a hospital diagnosis (ICD-9-CM 550) or physician diagnosis.
Ninety-six percent of the baseline cohort was recontacted. Hazard rate ratios for inguinal
hernia according to levels of potential risk factors were calculated using Cox proportional
hazards analysis. Results. A total of 5,316 men and 8,136 women were followed for a
median of 18.2 years (range 0.02-22.1). Because of the much higher cumulative incidence
at 20 years, and hence number of cases, in men (14%, 500 cases) than women (2.1%, 120
cases), further analysis was restricted to men. In both age-adjusted and multivariate analysis
(Table), factors associated with a higher incidence (p<0.05) of inguinal hernia among men
included middle and older age, white race, lower BMI, and doctor-diagnosed hiatal hernia.
Factors unrelated to inguinal hernia included smoking, physical activity, constipation, body
fat distribution, chronic cough, chronic obstructive pulmonary disease, and alcohol intake.
Conclusion. In the U.S. population, inguinal hernia is a common condition among men
that increases substantially with aging. The lower risk among overweight and obese men
was an unexpected finding that bears further study.
S1101
Obesity, Physical Activity, and the Long-Term Risk of Peptic Ulcers
Edward Lew, Nancy R. Cook, Martin J. Blaser, Guillermo Perez-Perez, J. Michael Gaziano
Background: Recent studies report that the incidence of peptic ulcers unrelated to Helicobacter
pylori or the use of nonsteriodal anti-inflammatory drugs (NSAIDs) is rising, suggesting that
other factors are likely involved. To date, it remains unclear whether obesity and physical
activity affect ulcer formation. Methods: We prospectively examined the associations of
increasing body mass index, physical activity and the development of peptic ulcers among
21,426 men in the Physicians’ Health Study. Information about these factors as well as other
atherosclerotic risk factors and NSAID use were assessed at baseline and periodically updated
during follow-up. Proportional hazards models with time-varying predictors were used to
calculate relative risks (RR). In a separate nested case-control study within the cohort, we
also examined case subjects who developed ulcers and controls (1:4) matched by age and
follow-up interval. Stored blood samples obtained at study entry were assayed for antibodies
against H. pylori. NSAID use was determined up to date of the ulcer for cases or to the
respective follow-up date for controls. Odds ratios (OR) with 95% confidence intervals (95%
CI) were calculated by conditional logistic regression analysis. Results: The mean age of the
participants was 53.7 +/- (standard deviation) 9.5 years. During a 12.5-year follow-up, we
identified 562 new peptic ulcers. Increasing body mass index (RR, 1.033 per unit kg/m2
increase; 95% CI, 1.006 - 1.060) elevated the risk of developing peptic ulcers, while
controlling for NSAID use, older age, cigarette smoking, and other atherosclerotic risk factors.
In contrast, regular exercise at least once a week (RR, 0.798; 95% CI, 0.662 - 0.961) was
inversely related to ulcers. In the nested case-control study, we examined 183 case subjects
who developed peptic ulcers and 730 matched controls. As expected, H. pylori infection
(OR, 2.160; 95% CI, 1.511 - 3.088) and increasing NSAID use (OR, 1.663 per month of
NSAID use during the year; 95% CI, 1.274 - 2.171) were associated with an elevated risk
of peptic ulcers. Increasing body mass index (OR, 1.061 per unit kg/m2 increase; 95% CI,
1.002 - 1.124) also elevated ulcer risk, whereas regular exercise at least once a week (OR,
0.677; 95% CI, 0.460 - 0.995) was inversely related to ulcers while controlling for H. pylori,
NSAID use, and other atherosclerotic risk factors. Conclusions: Obesity increases ulcer risk
whereas regular exercise at least once a week is associated with a decreased risk of peptic
ulcers, independent of H. pylori and NSAID use. Further studies are needed to confirm
these findings.
S1102
Alcohol and Symptomatic Gallstone Disease: A Swedish Twin Study
Despina Katsika, Catherine Tuvblad, Curt Einarsson, Hanns-Ulrich Marschall
Background and aim: With data from the Swedish Twin Registry, we recently estimated the
overall contributions of genetic and environmental factors for the development of sympto-

















consumption on the development of GD. Materials and Methods: The risk of alcohol con-
sumption as a specific environmental factor can be estimated from associations within twin
pairs discordant for disease in which the influence of genetic and early environmental factors
is substantially reduced. For this purpose, the Swedish Twin Registry was linked to the
Swedish Inpatients and Causes of Death Registries for GD and GD-surgery related diagnoses
for twins born between 1888 and 1958 to identify twins with GD. Data of alcohol consump-
tions, as evaluated from self-reports, were provided by the Registry. Consumption was
defined as moderate, 600-1.800 g/month for females and 900-2.400 g/month for males, or
high, >1.800 g/month for females and >2.400 g/month for males. The follow-up time was
1970-2002. The cohort analyses were based on 23.636 twins of the same gender and with
known zygosity. The within-pair analyses then included 1.411 twin pairs discordant for
GD. Odds ratios (OR) and 95% confidence intervals (CI) were calculated by logistic regres-
sion. Results: In the twin cohort analyzed, both moderate and high alcohol consumption
was associated with a lower prevalence of GD as compared to no alcohol consumption (OR:
0.83; 95% CI: 0.66-1.04, and OR: 0.83; 95% CI: 0.66-1.03, respectively). These negative
associations remained consistent in within-pair analyses and reached statistical significance
for high alcohol consumption: Moderate alcohol consumption, MZ: OR: 1.39; 95% CI: 0.99-
1.95, DZ: OR, 1.00; 95% CI, 0.80-1.25; high alcohol consumption: MZ: OR, 0.68; 95%
CI, 0.48-0.95; DZ: OR: 0.96; 95% CI: 076-1.20. There were no differences between monozyg-
otic (MZ) and dizygotic (DZ) twins. Conclusion: The data from the Swedish Twin registry are
consistent with data from some epidemiological studies that alcohol consumption “protects”
against symptomatic GD.
S1103
Differential Time Trends in the Incidence of Cancer of the Esophagus in the
Netherlands 1989-2001
Mark Van Blankenstein, Caspar W. Looman, Peter D. Siersema, Ernst J. Kuipers, Jan W.
Coebergh
Background: In common with other industrialized countries, The Netherlands has been
experiencing a rising incidence of esophageal adenocarcinoma since the 80’s. The country
of 16 million inhabitants is well served by a comprehensive system of Regional Cancer
Registries to which both hospital medical record departments and histology departments
report all malignancies. The Netherlands Cancer Registry in turn collates these data from
all 9 Regional Cancer Registries. Aims: To investigate whether similar time trends were present
in the annual incidence rates of the two types of esophageal cancer, i.e. adenocarcinoma of
the esophagus (ACE) and the gastric cardia (AGC) and in addition, to compare them with
those of squamous cell carcinoma of the esophagus (SCC), which is considered to have
another etiology. Methods: We analyzed the annual European Standardized Rates (ESR) for
AGC, ACE and SCC in The Netherlands over the 13 year period 1989 to 2001, as provided
by the Netherlands Cancer Registry. Results: In contrast to the highly significant annual
rises in the ACE incidence rates of 6.5% for males and 2.6% for females, the annual incidence
rates of SCC and AGC remained stable, with the exception of an actual significant decline
in the annual AGC incidence rates for men. Conclusions: The etiological factors driving the
rising incidence of ACE in The Netherlands appear to have been absent in both AGC and
SCC. This finding provides confirmation for their differing etiologies, expected in SCC, but
unexpected in AGC. Some of the decline in AGC incidence rates in men may be explained
by diagnostic drift on the part of clinicians from AGC to ACE. In view of the recently
reported 20 year delay in the age of onset of Barrett’s esophagus (the precursor for ACE)
in females as compared to males (1), the current far lower female ACE incidence may well
be mirroring the male ACE incidence rates 20 years ago. (1) van Blankenstein et al, Am J
Gastroenterol 2005;100:568-576.
S1104
Eosinophilic Esophagitis in Adolescence
Juan F. Villalona, Thomas M. Rossi, Marilyn R. Brown, Ashok Shah, Phillip Katzman,
Carol French
INTRODUCTION A large number of adolescent patients undergo endoscopic evaluation for
esophageal symptoms by pediatric and adult gastroenterologists. Eosinophilic esophagitis
(EE) should be included in the differential diagnosis of adolescents with esophageal symp-
toms. METHODS Forty-eight charts were selected for review from the Division of Pediatric
Gastroenterology and Nutrition at the Golisano Children’s Hospital at Strong, Rochester,
NY. Inclusion criteria were age (12-18 years) and the diagnosis of EE. Sex, age at presentation,
age at onset of symptoms, specific symptoms, pH probe test results, RAST tests, biopsy
results and endoscopic findings were observed. RESULTS Thirty patients met the current
diagnostic criteria for EE (15-20 eosinophils/HPF in the esophagus). The 18 excluded had
fewer than 15 eosinophils/HPF. Of the 30 with EE, 22 (73%) were male and 8 (27%) were
female. The mean age was 16.5 ± 2.5 years. The mean age at onset of symptoms was 11.8
± 3 years. The mean age at presentation was 12.5 ± 3 years. Predominant symptoms were
dysphagia 22 (73%), food impaction 10 (33%), abdominal pain 9 (30%), and heartburn 8
(27%). A pH probe study was done in 22 (73%) patients, of which 6 (20%) demonstrated
gastroesophageal reflux. Nineteen (63%) reported food, medications or environmental aller-
gies. Radioallergosorbent test (RAST) was done in 22 (74%) of cases and of those, 14 (64%)
were positive. Milk was the most common allergen. The most common endoscopic findings
were linear grooves (50%), white spots (27%) and rings (17%). Five (17%) patients had
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mid-esophageal strictures. One patient had normal an appearing esophagus. Biopsies from
the mid- and proximal esophagus revealed greater than 20 eosinophils/HPF in 26 (87%)
cases. Aggressive acid-blockage therapy alone did not improve the symptoms of EE. All
patients responded clinically to elimination of the food allergen and fluticasone. Mast cell
stabilizers and leukotriene receptor antagonists and proton-pump inhibitors were used for
maintenance. CONCLUSION Pediatric and adult gastroenterologists should be aware of this
disorder, as they will be treating many adolescents with esophageal symptoms. Dysphagia
and food impaction were common presenting symptoms. Interestingly, food impaction was
associated with mid-esophageal strictures in five patients. The characteristic endoscopic
(furrowing, white spots and trachealization) and biopsy (>15 eosinophils/HPF, especially at
the mid- and proximal esophagus) findings are diagnostic of EE. It is important to recognize
this disorder early so that proper treatment may be started and complications can be avoided.
Treatment is easy and usually effective.
S1105
The Natural Course of Acute Idiopathic Pancreatitis
Paul G. Lankisch, Nils Breuer, Anja Bruns, Bettina Weber-Dany, Patrick Maisonneuve,
Albert B. Lowenfels
The natural course of acute idiopathic pancreatitis is unknown. The aim of our study was
to determine the incidence of relapses and to identify any factors associated with these
recurrences. Patients and Methods: We identified 106 patients with a first attack of acute
idiopathic pancreatitis admitted to our hospital from 1987 - 2004. Alcohol consumption
was less than 40 g of pure alcohol/day in all patients, and in none of them could biliary
disease or other causes of acute pancreatitis be identified as the underlying etiology. All
living patients were interviewed by telephone and questionnaire to obtain information on
their health status, lifestyle, and family health history. For patients who died after the first
acute pancreatitis the cause of death was obtained from their general practitioners. Results:
1. Diagnosis: The etiology proved to be different than originally thought (idiopathic) in two
patients in whom a pancreatic carcinoma diagnosed during follow-up was responsible for
the first attack. 2. Mortality: 38 (37%) patients died, 9 (9%) during the first attack and 29
(28%) from unrelated causes. None of the latter group experienced any relapse. 3. Follow-
up: Of the 66 living patients 64 could be contacted, and 8 of these had had recurrent attacks
(4 patients: 1 attack, 3 patients: 2 attacks, 1 patient: 3 attacks). The etiology of these relapses
was again unknown with the exception of one attack which occurred following alcohol
abuse. In none of the patients did relapsing pancreatitis progress to chronic pancreatitis.
One patient developed pancreatic cancer 15 years after a single attack of acute pancreatitis.
4. Recurrence risk: Among living patients, recurrence was more frequent in those with a
family history of pancreatic disease (acute pancreatitis, pancreatic cancer, or diabetes mellitus;
p=0.047) and in smokers, although the latter association was not statistically significant (p=
0.17). However, 3 of the 4 patients, who had multiple relapses, were smokers. Neither the
APACHE II score on admission for the first attack, nor the Imrie and Ranson score after 72
hours, nor the result of a contrast-enhanced computed tomography (Balthazar score) correl-
ated with the recurrence rate. Conclusion: The relapse rate in patients with acute idiopathic
pancreatitis is low.In the case of recurrence, a change of etiology is very unlikely. There is
no progression from acute to chronic pancreatitis in this etiological subgroup. Patients who
have experienced acute idiopathic pancreatitis are advised to stop smoking and to undergo
appropriate imaging procedures 3 months after the attack in order to identify the eventual
presence of an pancreatic carcinoma.
S1106
Prospective Study of Time-Related Morphological Changes in Patients with
Intraductal Papillary Mucinous Tumours of the Pancreas (IPMT) Confined to
the Branch Ducts (BD)
Pierre Emmanuel Rautou, Anne Couvelard, Marie Pierre Vullierme, Dermot O'Toole,
Laurent Palazzo, Alain Sauvanet, Frederique Maire, Olivia Hentic, Pascal Hammel,
Philippe Ruszniewski, Philippe Levy
Compared to main pancreatic duct (MPD) involvement, IPMT involving exclusively the BDs
bears a low risk of malignancy that may allow patients follow-up (FU) without surgery.
However to date the long-term safety of conservative management has poorly been evaluated.
Aim of the study: Assess time-related morphological changes and risk of malignancy inpatients
with BD-IPMT. Patients (pts) and methods: All consecutive pts seen for BD-IPMT were
prospectively followed from 1999 to 2005. IPMT diagnosis relied on histological confirmation
or was highly probable on radiological findings (cystic lesions communicating with MPD
on a least 2 imaging procedures). Pts with at least 1 criterion of malignancy (BD diameter
>30mm, cyst wall thickening >2mm or mural nodule, n=13) or with FU <1yr (n=65) were
excluded. Surveillance included CT, MRI and EUS, at least annually. Results: 102 pts (M:
22, median age at diagnosis: 64 (30-82 years) were included (histological confirmation in
20 pts and highly probable diagnosis in 82). Diagnosis was incidental, due to pancreatic
pain, acute pancreatitis or others in 63, 23, 13 and 3 pts, respectively. Median number of
dilated BD was 2; with a median size of the largest BD of 15 (3-30) mm. Diffuse BD
involvement was present in 12 pts. Median follow-up was 28 (12-80) months from diagnosis
with 3 (1-15) imaging procedures/pt. Morphological changes occurred in 12 pts after 26
(5-61) months: size >30mm, cyst-wall thickening >2mm, involvement of the MPD in 3, 7
and 2 pts, respectively. Surgery, performed in 3/12 pts found 1 invasive carcinoma, 1 high-
grade dysplasia (HGD) and 1 low-grade dysplasia (LGD). The 9 remaining pts were not
operated on due to minor BD changes, associated severe co-morbid conditions or refusal.
Close follow-up during 0-24 months (EUS every 6 months) revealed no further modifications.
Among the 90 pts without morphological changes, 10 underwent surgery (7 for recurrent
acute pancreatitis, 3 for miscellaneous raisons). At pathological examination, hyperplasia,
LGD and HGD were found in 3, 6 and 1 pts, respectively. Uneventful follow-up was 28
(12-80) months in the remaining 80 pts. Conclusion: In the absence of criteria suggestive
of malignancy at diagnosis, BD-IPMT exhibit a low rate (12%) of morphological changes
during a more than 2 years FU period. These data support conservative management of
BD-IMPT in those without criteria of malignancy. However, careful monitoring is mandatory,
since malignancy cannot be excluded and should be assessed in long-term studies.
S1107
Prevalence of High-Intensity Proton Pump Inhibitor Use in Manitoba: A
Population Based Analysis
Laura E. Targownik, Colleen J. Metge, Stella Leung
Proton pump inhibitors (PPIs) are among the most commonly prescribed drugs in North
America. While PPIs are often recommended to be used at standard doses, PPIs are often
prescribed at higer doses when standard doses are ineffective, though the incremental benefit
of increasing the PPI dose in limited. We therefore sought to determine the prevalence of
high intensity PPI use and to describe the characteristics of high-intensity users. Methods:
We chose to determine the prevalence of high-dose chronic PPI use on July 1st, 2003. We
categorized individuals as being chronic PPI if they had been using PPIs for more than 80%
of the ninety days before July 1st, 2003. A chronic user was considered high dose if he was
using on average more than 1.5 standard doses of PPIs daily for at least one-half of the
ninety days before July 1st, 2003. We compared age, gender, burden of comorbid illness,
socioeconomic status, history of upper GI events and of endoscopic investigations between
high-intensity and standard intensity PPI users. The burden of comorbid illness was deter-
mined by enumerating the number of unique aggregated diagnostic groups (ADGs) for
which the enrollee received care in the year prior to July 1st, 2003. Results. Out of 825,429
enrollees, we identified 117,201 individuals who had filled at least one prescription for a
PPI, of whom 26,943 (22.9%) had were chronic users as of July 1st, 2003. 3.394 (12.6%)
of chronic PPI users could be classified as high-intensity users by our definition High intensity
PPI users were of similar age to standard intensity users (both groups = 63.5 yrs.) and the
groups had a similar percentage of females (62.5 “high dose” % vs 60.2% “standard dose”).
Other differences between high-dose and standard dose users are summarized in Table 1.
Conclusions. Approximately 12% of PPI users are using these medications at higher than
standard doses. High-intensity PPI use is associated with a greater burden of comnorbid
illness and use of other medications known to promote GI complications. We intend to
perform further analyses with this comprehensive database to characterize the population
of high-intensity PPI users and to gain further insights into the clinical and economic
outcomes associated with high-intensity PPI use.
Comparison of High Dose vs. Standard Dose PPI Users
S1108
Relevance of Phase Angle Percentiles in Hospitalized Patients
Tatjana Schuetz, Matthias Pirlich, Kristina Norman, Hebert Lochs
Rationale: Evaluation of prognostically relevant changes of nutritional status is still controver-
sial. Phase angle (PhA) is calculated from resistance and reactance measured by bioelectric
impedance analysis (BIA) and is an indicator for membrane integrity. We hypothesized that
PhA <10th percentile (U. Kyle et al., Clin Nutr 2004; 23: 758) reflects clinically relevant
malnutrition. Methods: In 1313 patients (697 m, 616 f; age 20-75) consecutively admitted
to hospital (n=861 medical, n=452 surgical) PhA was measured by BIA (Nutrigard-2000M,
Data Input, Germany). BMI, Subjective Global Assessment (SGA), the number of drugs and
length of hospital stay (LOS) were assessed. Results: In 665/1313 (50.6%) patients PhA was
below the age- and gender-matched 10th percentile. These patients were older, more fre-
quently malnourished and took more drugs as surrogate parameter for severity of disease
than patients with PhA >10th perc (table). In 627/1265 (49.6%) patients with a BMI >18.5
kg/m2 PhA was <10th percentile. Patients with a low PhA had a significantly longer LOS.
In all patients significant (p<0.001) correlations between PhA and age (r=-0.427), BMI (r=
0.162), number of drugs (r=-0.313) and LOS (r=-0.182) were calculated. Conclusions:
Measurement of PhA with the 10th percentile as cut-off might be a simple tool to detect
patients with clinically relevant malnutrition.
PhA: phase angle; SGA: Subjective Global Assessment; LOS: lengsth of stay **p<0.001;
*p<0.05
S1109
Rectal Bleeding in Children: Findings of Pancolonoscopy
Lissy D. Ridder, Anna V. Lingen, Jan Taminiau, Marc A. Benninga
Introduction Limited reports are available evaluating the value of endoscopy and histopatho-
logy in children referred to a tertiary hospital for rectal bleeding. In our hospital, it is policy
to perform pancolonoscopy under general anaesthesia in children presenting with severe
and/or prolonged rectal bleeding. In case of suspicion of inflammatory bowel disease (IBD)
gastroscopy is performed and intubation of the terminal ileum is attempted. In all cases
biopsies are taken for histopathological examination. We have conducted a retrospective
cohort study of this policy to obtain information on endoscopic diagnosis and complications.
Methods All records of children undergoing a colonoscopy because of prolonged and/or
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severe rectal bleeding over an 8-year period (January, 1998 - November 2005) were reviewed.
Results 151 Colonoscopies were performed in 140 paediatric patients (66 boys). Ten patients
underwent two and one patient three colonoscopies because of persistent, unexplained
bleeding. The mean age at time of the first colonoscopy was 9.3 years (range 10 days-17.8
years). Diagnoses after the first colonoscopy were; normal (n=29), lymphonodular hyperplasia
(n=7), infectious (n=5), anal fissure or haemorrhoid (n=10), aspecific proctitis (n=10), IBD
(n=49), polyps (n=25), polyposis coli (n=1), allergic colitis (n=2), neutropenic colitis (n=
1), enterocolitis (n=1), ulcus (n=5), Meckel’s diverticulum (n=2), sarcoidosis (n=1) and
amyloidosis (n=1). The ileum was intubated in 76% of the procedures performed. In all
but 3 patients who were diagnosed IBD the ileum was intubated (93 %). In 70 out of 140
patients gastroscopy was performed, in these patients IBD was part of the differential dia-
gnosis. In 25 patients 27 polyps were found. All but one were juvenile polyps, one patient
had an inflammatory polyp. One patient had 3 polyps, all other patients had one polyp.
The polyps were located in the rectum (n=11 ), sigmoid (n=10 ), descending colon (n=5)
or transverse colon (n= 1). Therefore, in case a sigmoidoscopy was performed as first
procedure, 22 % of the polyps would have been missed. No complications occurred either
during or after colonoscopy or anaesthesia. Conclusions Colonoscopy under general anaesthe-
sia is a safe and important tool in diagnosing rectal bleeding in children. However, in
approximately 20% of the patients no macroscopic or microscopic cause could be identified
to explain rectal bleeding. In case of persistent bleeding diagnostic procedures such as
Meckel’s scan and/or video capsule endoscopy should be considered. Pancolonoscopy as first
diagnostic procedure in children with prolonged and/or severe rectal bleeding is advisable.
S1110
Prevalence of Celiac Disease Among Blood Donors in Sao Paulo City - The
Most Populated and Multi-Ethnic Center of Brazil
Marilia L. Alencar, Carmen L. Ortiz-Agostinho, Ieda Nishitokukado, Aderson Omar M.
Damiao, Clarice P. Lemos, Andre Z. Leite, Thales Brito, Dalton A. Chamone, Aytan M.
Sipahi
Background: Celiac disease is a permanent enteropathy caused by the ingestion of gluten
and leads to an immunologically mediated inflammation of the small intestine mucosa. The
prevalence of celiac disease varies among different nations and ethnic backgrounds, and its
diversity is determined by genetic and environmental factors. More recently, several serolo-
gical population screenings have shown that the prevalence of the disease is more common
than previously imagined. Sao Paulo city is one of the biggest cities in the world, with a
large population and with an important history of migratory flow from other countries,
mainly European ones, and from other Brazilian cities, also with an important miscegenation.
Since Sao Paulo city can be thought as a reflection of ethnic and social characters of the
Brazilian population, we have decided to study the prevalence of celiac disease in Sao Paulo
city. The aim of the present study was to assess the prevalence of unrecognized adult celiac
disease in Sao Paulo and correlate it with further information about ancestry of the population
studied. Methods: We have measured the prevalence of celiac disease by means of a survey
of serum markers (IgA transglutaminase antibody-guinea pig and IgA endomysium antibody-
human umbilical cord) in 4,000 volunteers donors in the central Blood Bank in Sao Paulo,
“Pro-Sangue Foundation”. The antibody-positive subjects were asked to undergo small-
bowel biopsy. Results: There were 1896 female and 2104 male with mean age of 33 years.
In the ancestry evaluation of the 4,000 volunteers, we had 68% subjects with Brazilian
origin and the remaining from other countries, mainly Italy, Portugal, Spain and Germany.
Of the 4,000 subjects, fourteen subjects had positive tests, with results of the two antibody
tests concordant. Eight subjects were positive for IgA-class tissue transglutaminase only. The
prevalence of serum markers positivity for celiac disease is at least 1 case in 286 healthy
blood donors. Most donors diagnosed with celiac disease were asymptomatic and when
symptomatic the most common symptoms were flatulence and constipation. So far, in 8
positive patients, duodenal biopsies were performed and in all the patients the diagnosis of
celiac disease was confirmed (Marsh criteria). Conclusion: Among apparently healthy blood
donors, the prevalence of serum markers positivity for celiac disease was similar to that
seen in the United States and Europe.
S1111
Intrafamilial Clustering of Atrophic Gastritis
Yoshihisa Urita, Susumu Ishihara, Kenichiro Arai, Jun Kondo, Tatsuo Akimoto, Hiroto
Kato, Noriko Hara, Hideyuki Koshino, Yoshiko Honda, Yoko Nagai, Kazushige Nakanishi,
Nagato Shimada, Motonobu Sugimoto, Kazumasa Miki
Background: Many previous papers desclibed marked intrafamilial clustering of Helicobacter
pylori (H.pylori) infection. Although H.pylori is an important cause of atrophic gastritis, it
has been unknown whether all family members with H.pylori infection have advanced
atrophic gastritis. Only a part of infected patients go on to develop atrophic gastritis,
suggesting that factors other than H.pylori, such as environmental and host genetic factors,
may contribute to the progression of atrophic gastritis. Serum pepsinogen (PG) is a known
marker of gastric mucosal status, including mucosal atrophy. We therefore investigate the
intrafamilial clustering of atrophic gastritis using serum PG method. Patients and Methods:
Forty-six H.pylori-infected men (40-59 years) whose both parents had a positive serology
for H.pylori were studied. Venous blood samples were obtained after overnight fasting and
serum PG1 and PG2 concentrations were measured. If PG1/2 ratio was less than 3, the
patient was defined to have atrophic gastritis. Results: Atrophic gastritis was found in 20
patients (43%). The PG1/2 ratio of their fathers and mothers were significantly lower (2.0
+/- 1.1, 2.1 +/- 1.0, respectively), compared with patients without atrophic gastritis (3.2 +/-
1.8, 2.6 +/- 1.0, respectively). When the PG1/2 ratio of patients is lower than that of their
parents, atrophic gastritis is considered to progress more markedly than their parents. This
marked progression was found in 17 patients (37%) although atrophic gastritis progress
with age. These results suggest that 37% of H.pylori-infected patients had more progressive
atrophic gastritis than expected from the PG1/2 ratio of their parents. There may be other
factors affecting the progression of atrophic gastritis in H.pylori-infected patients. Conclusions:

















H.pylori-infected patients, whereas one third of H.pylori-infected patients were more influ-
enced by environmental factors than genetic factors.
S1112
Effective Management of Pancreatic Cancer Is Dependent On the First
Symptoms
Marek Benes, Julius Spicak
Introduction: The prognosis of pancreatic cancer is dismal, and effective treatment is depend-
ent on correct and early diagnosis and staging. Aims and methods: The aim of our multicentric
study was to analyze the effectiveness of the diagnostic process reflected in adequate treatment.
We prospectively analyzed the initial symptoms, length of the diagnostic process, and use
of imaging methods with consequent application of adequate therapy. Results: A total of
110 patients with pancreatic cancer being managed within the last 12 months were enrolled.
The most frequent first symptom was dyspepsia (43 patients), followed by pain (38) and
jaundice (29). While, overall, hyperglycemia was documented at the beginning of the
diagnostic period in 30 patients (27.2%), it was present in 23 (77%) of those with dyspepsia.
Radical resection was performed in 26 (23.6%) patients, exploratory laparotomy in 16
(14.5%), palliative surgery in 38, and chemotherapy in 21 patients. Mean time from the
onset of the first symptoms to presentation (time I) was 38±30 days. Mean time of the
diagnostic process to specific treatment (time II) was 3.5 ±3.4 months (1-24 months). Mean
time I in patients presenting with dyspepsia was 44.8±25.1 days, in patients presenting with
jaundice or pain 30.2±28.9, and in those who underwent resection 26.1±24.3 days. Mean
time II in these groups was 3.9±4.5, 2.7±2.1, and 2.1±1.4 months, respectively. Ultrasound
was the most frequently used imaging method (180 examinations) followed by CT (127),
ERCP (110), endosonography (35), and MR (7). The mean number of imaging methods
used per patient was 4.6±1.5 (2-11). Fine needle biopsy was performed in 18 patients. The
most frequent algorithm of use of imaging methods was ultrasound followed by CT and
ERCP. Conclusion: The decision-making process undertaken preoperatively is not sufficiently
effective, as reflected by the inadequately high rates of exploratory laparotomy. The length
of the process of diagnosis is dependent on the first symptoms, which can influence resectabil-
ity. The diagnostic process was significantly shorter in resected patients. Dyspepsia with
hyperglycemia have been shown to serve as a warning sign, and when this combination
appears at an adequate age, intensive search for pancreatic cancer should be initiated.
S1113
Gastrointestinal Carcinoid Tumors: A Problem of Increased Magnitude and
Diminished Support
Irvin M. Modlin, Geeta N. Eick, Mark Kidd, Manish C. Champaneria
A major medical misconception is that carcinoid tumors (CTs) of the GI tract are rare,
indolent neoplasms. On the contrary, the diagnosis of GI CTs is increasing rapidly and
many exhibit aggressive behavior with metastasis at presentation. To clarify the magnitude
of the problem, we initially analyzed the NCI SEER registry (1973-1999) and the earlier
ERG and TNCS series (Cancer 2003, 15:934-59). The greatest incidence of CTs is in the
GI tract (67.5%) and the bronchopulmonary system (25.3%). Within the GI tract, most
CTs occur in the small intestine (39.3%). Evaluation of SEER 2005 showed that small
intestinal CTs have increased 740% over a 3-decade period from 27/yr to 273/yr (same as
ovarian carcinoma). Iowa and Connecticut have the highest incidences of all continental US
states (0.82/100,000) and the North-Eastern seaboard harbors ~20% of all GI CTs. SEER
2005 recorded 562 gastric carcinoids (GCs) over the last 50 yrs, comprising 4.61% of all
CTs. In the endoscopic era, the incidence of GCs has risen from 3.5% of all CTs to 6%, a
~75% increase over the last decade with the greatest increase (800%) in white females.
Overall GCs increased 2,700% over a 3-decade period from 4/yr to 86/yr. These marked
increases reflect varying rules of registration among databases, improvements in diagnosis
and increased awareness. Nevertheless, physicians are increasingly faced with lesions they
know little of, and for which limited therapeutic options are available. A major reason is
the limited visibility afforded CT disease and the lack of funding for its study. Thus, only
3-5 CT meetings are held annually compared to between 30-40 to discuss GERD and Barrett’s
esophagus and its relationship to esophageal adenocarcinoma. Analysis of SEER 2005 reveals
that the latter has increased 12-fold since 1973 yet been declared an “epidemic” in contrast
to CT, which is labeled an orphan disease. A review of Federal research funding in 2005
demonstrates that almost 600 grants have been awarded to study carcinoma in contrast to
only 2 for CT or neuroendocrine tumor disease. Thus $110 million is spent annually on
carcinomas vs <$300,000 for CTs. Research dollars for carcinoma range from $189/ patient/
yr (pancreas) to $85 (colorectal) while carcinoids receive only $34. Current epidemiological
data indicate the prevalence of GI CTs is far higher than previously thought (>0.82/100,000
vs 0.05/100,000) and the incidence is rising (700-2700% depending on organ site since
1973). The lack of awareness, knowledge and research in the area of CT is fundamentally
different to that of other GI cancers and merits more attention by the medical and scient-
ific community.
S1114
Assessment of ACGME Core Competencies in Gastroenterology Trainees:
Results of a National Survey
Derek Patel
Background: In 2003, the Accreditation Council for Graduate Medical Education (ACGME)
established a competency-based standard for medical training. Training programs must
demonstrate that their graduates are competent in six “core” areas. The current state of
trainee competency evaluation in Gastroenterology (GI) fellowship programs is not known.
Aims: To assess the current practices and opinions regarding the evaluation of ACGME core
competencies in GI trainees. Methods: A web-based survey was emailed to the program
directors of all United States (including Puerto Rico) adult GI fellowship programs. The
survey consisted of 14 questions about program demographics, evaluation methods and
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program directors’ attitudes toward the core competencies and competency assessment tools.
Results: 155 GI fellowship training programs were identified. Valid email addresses were
obtained for the directors of 147 programs. 72 (49%) of the contacted program directors
completed the survey. 81% of the respondents administer university-based training programs.
89% report having at least 5 total trainees in their program. 92% of responding fellowship
directors describe themselves as “very familiar” with the six ACGME core competencies.
However, only 44% feel that the trainee evaluation methods currently used in their program
are “adequate.” The assessment tools used most widely are procedure logs (used by 97%
of programs), standardized evaluation forms (96%), written examinations (67%) and trainee
portfolios (47%). A majority (56%) of the responding program directors favor the required
use by all programs of a set of standardized assessment tools. 72% of respondents believe
that professional organizations or the ACGME should be responsible for developing such
tools. Conclusions: GI fellowship program directors are knowledgeable about ACGME core
competencies and the assessment tools used to evaluate trainee competency. Yet, only a
minority of program directors rate their programs’ current evaluation methodology as being
adequate. Potential solutions include greater leadership by professional societies and the
ACGME in developing assessment tools, and the mandatory use of a set of standardized
assessment tools.
S1115
Development of a For-Profit Free Standing Endoscopy Center (EASC) As Part
of An Academic Gastroenterology Division
Ann Ouyang, Lisa S. Poritz, Abraham Mathew, Thomas J. McGarrity, Thomas R. Riley
We describe a successful for-profit EASC venture within an academic medical center. The
project was developed with voluntary participation by faculty in the Divisons of GI and
colorectal surgery. Start-up costs were financed 60% by physicians (controlling group) who
formed an LLC (limited liability company), 20% by a management LLC formed by a private
practitioner with expertise in EASC development and management with key members of
his organization, and 20% by Nittany Healthcare Systems, Inc. (Nitt Health), a for-profit
corporation affiliated with Penn State University. A win-win arrangement recognizing expert-
ise, contribution and needs of all partners was achieved. The management group provided
expertise and time instead of money and developed the budget, negotiated leases and
contracts with third-party payers, and hired the architect, contractors and staff. Nitt Health
provided “name recognition” as most patients are directly referred, and agreed to take over
the EASC if physicians were to leave without sufficient replacement investors. Nitt Health
would then become controlling partner. Physicians were able to design and control a facility
providing efficient and pleasant service to patients for routine procedures, generate wRVU’s
efficiently while at the EASC, and have opportunity for financial gain with clearly defined
and limited risk. Buy-in and buy-out terms are relatively cheap with all profit being paid
to investors quarterly. The Dept of Medicine gained increased professional income and
contributed by loaning the cost of the physician legal fees to Nitt Health who agreed to pay
back from profit when available. The Dept recognized that the EASC would help in recruiting
faculty. The EASC has existed for 2 yrs and is now profitable. The GI Division increased
the number of procedures/clinical FTE by 30% during the first year and by an additional
10% during the second year. The hospital unit decreased its total number of procedures by
only 3% while the total number of endoscopic procedures (both EASC and inpatient)
increased by 30% by the second year of EASC operation. While the adult GI service decreased
its activity in the hospital unit, the unit has accommodated an increase in activity by other
services. The colorectal surgeon doubled her colonoscopy numbers with the same time
commitment. There is a negative impact on fellows’ procedure with a decrease in available
colonoscopies by 1/3, however the numbers still allow fellows to perform over twice guideline
numbers. We conclude that it is feasible to develop a for-profit enterprise within the
Department of Medicine if a win-win situation can be developed for all parties involved.
S1116
Patients with IBS Have Greater Treatment Satisfaction with Tegaserod
Compared with Placebo
Pierre Pare, Carlos Francisconi, Andrea Viegas, Christopher R. McBurney
BACKGROUND: Irritable bowel syndrome (IBS) is a chronic medical disorder that signific-
antly impacts on patients’ lives. However, the impact of medical treatment of IBS is often
not clear. Tegaserod, a promotility agent approved for use in patients with irritable bowel
syndrome with constipation (IBS-C) and chronic constipation, has demonstrated clinical
efficacy in multiple studies. In this study, we investigated the use of tegaserod in patients
with IBS and how this therapy impacts on patients’ perception of treatment satisfaction.
METHODS: Women (≤65 years) meeting Rome II criteria for IBS, excluding those with
IBS with diarrhea (IBS-D) and/or a recent episode of diarrhea, were randomized in a double-
blind, placebo-controlled, multicenter study. After a 2-week baseline, patients were treated
with tegaserod (6 mg b.i.d.) or placebo for 4 weeks. After the treatment period, a questionnaire
assessed patients’ expectations including satisfaction with treatment, symptom relief, and
willingness to re-use and recommend treatment with tegaserod at the end of the study. Data
were analyzed using Cochran-Mantel-Haenszel tests. RESULTS: 661 women with IBS were
randomized (tegaserod [n = 339], placebo [n = 322]), and satisfaction data were available
for 329 tegaserod and 322 placebo patients. Patients who received tegaserod were more
likely to be satisfied (tegaserod 76%, placebo 65.3%, p=0.021) compared with placebo.
More tegaserod users reported their treatment expectations were met or exceeded (tegaserod
61.2% vs placebo 47.8%, p<0.001). When satisfaction was compared with prior IBS medical
therapy, 60% (vs placebo 45%, p=0.032) of tegaserod patients reported greater relief of
symptoms with tegaserod. In addition, the majority of patients treated with tegaserod would
recommend it to others with IBS (tegaserod 71% vs placebo 61%, p=0.007). There was not
a statistically significant difference for greater future utilization of study medication between
treatment groups. CONCLUSIONS: In this controlled study of IBS subjects, patients were
more satisfied with tegaserod as a treatment for their symptoms related to IBS-C than placebo,
and the majority of IBS patients who received tegaserod would continue to use this promotility
agent and recommend the therapy to others with IBS.
S1117
High Prevalence of Abnormal Endoscopic Findings in Patients with Non-
GERD Dyspepsia
Nimish Vakil, Sander Veldhuyzen van Zanten, Nigel Flook, Nicholas J. Talley, Karsten
Lauritsen, Torre Persson, Johan Brun, Tore Lind, Elisabeth Bolling-Sternevald, Ewa Bjorck
OBJECTIVE: To determine the prevalence and nature of abnormal endoscopic findings in
patients with non-GERD dyspepsia. METHODS: Patients aged 18-70 years with pain or
burning centered in the upper abdomen were enrolled for possible inclusion in an interna-
tional, multicenter trial (Study SD-NED-0021) of acid suppression. Patients with predominant
symptoms or with a diagnosis of gastroesophageal reflux disease (GERD) were excluded
(heartburn >once a week), as were patients taking proton pump inhibitors (PPIs) or H2-
blockers as maintenance therapy within the preceding 6 months. Patients with alarm symp-
toms or with a history of non-steroidal anti-inflammatory drug use were also excluded.
Helicobacter pylori status was determined using a 13C urea breath test. We present data from
patients who were not randomized because of abnormal findings at baseline esophagogastrod-
uodenoscopy (EGD). RESULTS: 2868 patients were enrolled, of which 2741 were eligible
for study entry and underwent an EGD. The most frequent endoscopic findings, plus
malignancies, are presented in the table. Three patients had an esophageal malignancy
(aged 30, 53 and 65 years) and 3 had a gastric malignancy (aged 50, 51 and 58 years).
CONCLUSIONS: 1. Abnormal endoscopic findings are common in patients with non-
GERD dyspeptic symptoms. 2. Most lesions are treatable with H. pylori eradication or acid
suppressive therapy, supporting recent guidelines for the empirical medical management of
dyspeptic patients. 3. Although uncommon, upper gastrointestinal malignancies will be
missed despite a careful evaluation of alarm features. 4. Empirical age cutoffs for early
endoscopy e.g. 60 years in the AGA guideline will detect some but not all of these patients.
S1118
Tegaserod Significantly Reduces Work Productivity Loss and Daily Activity
Impairment in Patients with IBS Versus Non-Tegaserod-Treated Patients
Pierre Pare, Robert Balshaw, Shideh Khorasheh, Martin Barbeau, Suzanne Kelly,
Christopher R. McBurney
BACKGROUND: Abdominal pain/discomfort, bloating and altered bowel function are gastro-
intestinal (GI) dysmotility and sensory symptoms related to irritable bowel syndrome (IBS).
Dysmotility symptoms are associated with impaired quality of life (QoL) and work productiv-
ity. LOGIC (Longitudinal Outcomes study of GI symptoms in Canada) is an ongoing,
prospective, observational study designed to evaluate the treatment patterns and health
outcomes of patients with IBS symptoms in Canada. METHODS: 1,555 subjects with IBS-
type symptoms were enrolled from 147 community and specialist medical sites across
Canada. Clinical data and patient-reported outcomes were collected at baseline and at Months
1, 3, 6, 9 and 12. Work productivity and daily activity impairment were assessed using the
WPAI:IBS. Tegaserod (T) subjects were defined as those taking ≥7 days of therapy or ≥7
tablets, non-tegaserod (Non-T) subjects did not report T use; all other subjects were excluded
from the analysis. RESULTS: Baseline data were obtained from 1,555 patients of whom
1,372 could be identified as T subjects (n=360) or Non-T subjects (n=1,012). These patients
had a mean age of 46 years and mean disorder duration of 12 years and 86% (1,182) were
women. Self-reported bowel patterns were predominantly constipation (40%) and mixed/
alternating (38%). Of the T patients, 216 (60.5%) were working, as were 598 (59.4%) of
the Non-T patients. There was no improvement in any item of the WPAI for the Non-T
group between baseline and Month 6 for the work productivity components (there was a
decrease in daily activity impairment). In the T group, there was an improvement in all WPAI
items between baseline and Month 6. In addition, the T group had a bigger improvement than
the Non-T group in all items of the WPAI: absenteeism (2.8%), presenteeism (8%), overall
productivity impairment (8.2%) and daily activity impairment (12.4%, p<0.001). Averaged
over a 40-hour working week, the T group reduced work productivity loss by 3.28 hours
more than the Non-T group. CONCLUSIONS: In this study, after 6 months, T users had
3.28 hours of increased productivity per week when compared to Non-T users. Furthermore,
the T users had a significant improvement in daily activity compared to the Non-T users.
This is the first prospective observational study to show that T has a positive impact on
work productivity as well as daily activities in the setting of usual care.
S1119
Canadian IBS Observational Study Shows Tegaserod Patients Have Greater
Improvements in QOL As Compared to the Control Group
Pierre Pare, Robert Balshaw, Shideh Khorasheh, Martin Barbeau, Suzanne Kelly,
Christopher R. McBurney
BACKGROUND: Abdominal pain/discomfort, bloating and constipation are gastrointestinal
(GI) symptoms related to irritable bowel syndrome (IBS). These symptoms are associated
with impaired quality of life (QoL) and work productivity. LOGIC (Longitudinal Outcomes
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Study of GI Symptoms in Canada) is an ongoing, prospective, observational study designed
to evaluate the treatment patterns and health outcomes of patients with IBS symptoms in
Canada. AIMS AND METHODS: LOGIC enrolled 1,555 patients at 147 community and
specialist physician sites across Canada. Clinical data and patient-reported outcomes were
collected at baseline and at Months 1, 3, 6, 9 and 12. QoL was assessed with the IBS-
QOL. Tegaserod treated subjects (T) at baseline and non-tegaserod subjects (Non-T) were
compared. Unadjusted mean QoL at baseline (BL) and Month 6 were compared between
groups using the Wilcoxon rank-sum test. The within-subject slope of the QoL scores was
compared using a mixed model analysis of variance. The model compared the average slope
of the T and Non-T subjects after adjusting for IBS severity (measured by the Total Symptom
Severity score, TSS), usual bowel pattern (normal, constipated, diarrhea, alternating), dura-
tion of symptoms, gender, history of tegaserod use, and baseline IBS-QOL. RESULTS: Of
the 1,555 subjects enrolled, 1,372 were identified as either T-users (n=360) or Non-T-users
(n=1012). At baseline, T subjects had a mean IBS-QOL score of 61.38 compared to Non-
T subjects with a mean of 68.39 (p<0.001). By Month 6, the unadjusted mean scores were
67.30 for T and 71.43 for Non-T patients, p=0.037. After adjusting for baseline covariates,
T subjects showed significantly greater improvement in IBS-QOL scores over the first 6
months of the study (mean improvement of 1.04 vs. 0.42 points per month, p=0.004).
CONCLUSIONS: The LOGIC study is an ongoing, prospective, observational study that will
follow patients for 1 year. This analysis of the LOGIC study followed treatment in a real
world setting with physicians treating patients on an individual basis. Subjects using T at
baseline showed more improvement in their IBS-QOL scores than the Non-T users at 6
months. This is the first prospective observational study to show that T has a positive impact
on health-related quality of life in the setting of usual care.
S1120
Longitudinal Outcomes Study of GI Symptoms in Canada (LOGIC): Tegaserod
Versus Usual Care Comparison At Baseline
Pierre Pare, Robert Balshaw, Shideh Khorasheh, Martin Barbeau, Suzanne Kelly,
Christopher R. McBurney
BACKGROUND: Some GI motility disorders may be chronic and episodic, such as irritable
bowel syndrome (IBS), and can be characterized by recurrent abdominal pain and altered
bowel habit. Tegaserod, a selective 5-HT4 receptor agonist, is effective and well tolerated
in patients with symptoms of abdominal pain, bloating and constipation, associated with
IBS. LOGIC is an ongoing prospective observational study designed to evaluate treatment
patterns and health outcomes in patients with IBS symptoms in Canada. AIMS AND
METHODS: The study is designed to characterize quality of life (QoL), healthcare resource
utilization and productivity of patients with symptoms associated with IBS over a 1-year
period. A total of 1,555 subjects were enrolled at 147 centers. The present analysis compares
the characteristics of patients receiving tegaserod at baseline with those not receiving tegaserod
(Non-tegaserod). RESULTS: Baseline data were obtained from 1,555 patients, of which 1,372
could be identified as tegaserod (n=360) or Non-tegaserod (n=1,012). The mean age in both
groups was 46 years. The majority of the patients were female (86%) and Caucasian (88.3%).
Significant but minor differences between the groups were noted for gender, ethnicity and
the mean duration of IBS. The patients’ self-reported bowel habits indicated that IBS-C was
more common in the tegaserod group (38.6%), and IBS-A (30.3%) in the Non-tegaserod
group (p<0.0001). The group receiving tegaserod had a significantly (p<0.01) higher percent-
age of subjects reporting more severe bowel movement-related symptoms at baseline based
on frequency, intensity and resulting distress when compared with Non-tegaserod. In addi-
tion, the group receiving tegaserod reported significantly more physician visits in the month
prior to the baseline visit. DISCUSSION: Baseline data from this ongoing, prospective,
observational study indicate that the severity of symptoms influences the choice of treatment.
This study will follow patients for 1 year, providing insight into the assessment, treatment
and outcomes of IBS symptoms. However, future analyses of data gathered in this study
will need to take into account the baseline differences presented here.
S1121
Tegaserod Significantly Reduces Work Productivity Loss and Daily Activity
Impairment in Colombian Patients with IBS with Constipation
Maria T. Galiano, Jairo A. Martinez, Ciro Crispin, Giovanny de Vuono, Ramon J.
Espinoza, Jacobo Feris, Carlos Gomez, Belen Mendoza, Jaime Obregon, Federico Pelaez,
Adriana Varon, Maria C. Eslava, Claudia Deaza, Claudia J. Ramirez, Amparo Castro
BACKGROUND: Irritable bowel syndrome with constipation (IBS-C) symptoms are respons-
ible for a negative impact on patients’ quality of life as well as affecting aspects like work
and personal daily activities. Tegaserod (T) is a selective, serotonin type 4 (5-HT4) receptor
agonist with proven efficacy and safety in patients with IBS-C. AIMS: One of the objectives
of this study was to assess the impact of T 6 mg b.i.d. on work-related productivity and
daily activity impairment in a working population of patients (pts) with IBS-C. METHODS:
Pts (men and women <65 years old who met Rome II criteria for IBS-C) were assessed
during this open-label trial, with a 2-week baseline period and a 12-week treatment period
with T 6 mg b.i.d. Absenteeism, presenteeism, and overall work productivity loss (combined
absenteeism plus presenteeism) and daily activities due to IBS symptoms during the previous
7 days were measured with the validated Work Productivity and Activity Impairment Ques-
tionnaire for IBS (WPAI-IBS). The questionnaire was performed on days -7 and at baseline
as well as during days 14, 28, 56 and 84 of the treatment period. Results are presented as
a comparison between the baseline period (no treatment), and the end of T treatment (after
12 weeks of therapy). Analysis was by intention to treat. RESULTS: 120 pts with IBS-C
were included in the trial. Mean age was 37 years (range 19-62) and 97.5% of pts were
women. At the end of T treatment, and in comparison with baseline, T significantly reduced
absenteeism by 6.26% (p<0.01), presenteeism by 10.9% (p<0.03), overall work productivity
loss by 9.33% (p<0.02), and daily activity impairment by 12.69% (p<0.005). Assuming a
40-hour workweek, T reduced work productivity loss by 2.1 hours. In comparison with
baseline, T treatment was superior, providing relief from every symptom, such as abdominal

















(p values <0.05). CONCLUSIONS: T treatment significantly improved work-related produc-
tivity and reduced the number of daily activity hours lost due to IBS-C. These benefits were
maintained at 12 weeks. This is the first Latin American study to show that one IBS therapy
has a significant positive impact on work productivity as well as on daily activities.
S1122
Impact of 0.5 Mg Qd, 1 Mg Qd and 1 Mg Bid Alosetron Hydrochloride On
Quality of Life (QOL) and Productivity in Women with Chronic, Severe
Diarrhea-Predominant IBS (D-IBS)
Susan Gordon, Vanessa Ameen, Marquita West, Amy Heath, Teresa Perschy, Eric Carter
Objective: IBS negatively impacts physical, social, and psychological well-being and results
in lost social activity and work time. The 5HT3 receptor antagonist alosetron at a dose of
1mgBID is indicated for women with chronic, severe D-IBS who have not responded
adequately to conventional therapy. This dose regimen improves IBS-related QoL and lost
productivity in women with severe D-IBS but is associated with constipation. The objective
of this study was to determine the effect of lower alosetron doses on IBSQoL and productivity
in patients with chronic, severe D-IBS (protocol S3B30040). Methods: 705 women with
severe D-IBS were equally randomized to 12wks of placebo, 0.5mgQD, 1mgQD, or 1mgBID
alosetron, followed by a 4wk follow-up period. IBSQoL and workplace/household/leisure
activity time questionnaires were administered at Randomization and wk12/Final Visit.
Changes from baseline in scale-specific scores were computed for 9 QoL domains: emotional,
mental health, sleep, energy, physical functioning, food, social functioning, physical role,
sexual relations. Pairwise treatment comparisons were adjusted for the 9 QOL domains
using the general multiple Simes procedure described by Hommel. To assess productivity,
changes from baseline in the amount of time prevented from doing normal activities due
to IBS symptoms were compared. Results: With regard to IBSQoL, all alosetron regimens
showed improvement on multiple domains vs. placebo on the IBSQoL questionnaire. Treat-
ment differences for the alosetron groups were statistically significant compared with placebo
(p<0.038) on all domains, with the exception of: sexual relations for all three alosetron
doses, physical functioning in the 1mg QD and 1mg BID groups, and emotional and sleep
in the 1 mg QD group. With regard to productivity, lost workplace activity(hrs), social/
leisure and household activity(days) were reduced from baseline in all three alosetron
treatment groups. Significant treatment differences (p<0.05) over placebo were seen in the
0.5mgQD and 1mgBID regimens in lost workplace and social/leisure activities. Conclusion:
Lower doses of alosetron also show improvement in multiple IBS specific QoL measures
and productivity in women with chronic, severe D-IBS.
S1123
The Clinical Characteristics of Patients with Idiopathic Constipation with a
Positive Family History
Annie On On Chan, Wai Mo Hui, Kwok Fai Lam, Gigi Leung, Wayne Hc Hu, Chi Kuen
Chan, Man Fung Yuen, Shiu Kum Lam, Benjamin Cy Wong
Background: We observed that there is familial aggregation in patients with idiopathic
constipation, which may be due to underlying genetic factors or intrafamilial environment.
The clinical characteristics between those with and without a positive family history of
constipation have not been studied. Aim: To investigate the clinical characteristics of patients
with idiopathic constipation with and without a positive family history. Methods: 230
consecutive patients with idiopathic constipation satisfying Rome II criteria were recruited.
A Rome II questionnaire on constipation was given to the patients’ families to identify if
there was any family members with idiopathic constipation. Results: There were 104 and
126 patients with (at least one 1st degree relative) and without a positive family history,
respectively. The patients in the two groups were comparable in mean age (p=0.3), and sex
distribution (p=0.98). Using the method of Analysis of Interval-Censored/Grouped Failure
Time Data, patients with positive family history had a younger age of onset (median: 11-
20 years vs 21-30 years, p=0.0042). Moreover, patients with positive family history were
less likely to be married (60.6% vs 75.4%, P=0.016), had longer duration of constipation
(19.8 ± 14 vs 16.3 ± 13, p=0.042), more often associated with digital evacuation (26% vs
13.5%, p=0.017), more complications eg symptomatic hemorrhoids, anal fissure and rectal
prolapse (44.2% vs 31%, p=0.038), less precipitating factors leading to the onset of constipa-
tion (17.3% vs 30.2%, p=0.024), and fewer associated psychological disorders (2.9% vs
11.9%, p 0.011) Conclusions: Patients with idiopathic constipation and with a positive
family history showed different clinical characteristics. This may be related to the early age
of onset of the symptoms, which may in turn, gives clues to the underlying etiology.
S1124
The Impact of Non-GERD Dyspepsia On Productivity While At Work and in
Regular Daily Activities - Results from One Study in Endoscoped (STARS I)
and One Study in Uninvestigated (STARS II) Dyspeptic Patients
Peter Wahlqvist, Tore Persson, Johan Brun, Nigel Flook, Karsten Lauritsen, Nimish Vakil,
Sander Veldhuyzen van Zanten, Katarina Halling, Nicholas Talley
OBJECTIVE: To assess the impact of dyspepsia on productivity while at work and in regular
daily activities in endoscoped (STARS I study) and in uninvestigated (STARS II study)
dyspeptic patients. METHODS: Dyspeptic patients (with symptoms of pain or burning
centered in the upper abdomen) were enrolled into 2 randomized, placebo-controlled,
double-blind, multinational studies of similar design. During the week before start of treat-
ment, patients rated dyspeptic symptoms daily using a 4 grade scale (0=none to 3=severe)
and only those with a sum symptom score of 5 or more during the last 7 days of the run-
in period were included in the study. In STARS I, all patients underwent an endoscopy at
baseline, and those with abnormal findings were excluded. Before start of treatment, patients
completed the Reflux Disease Questionnaire (RDQ) to assess symptom severity in three
dimensions (heartburn, regurgitation, dyspepsia), and the Work Productivity and Activity
Impairment (WPAI) questionnaire to assess disease-specific absence from work, reduced
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productivity while at work, and reduced productivity while carrying out regular daily
activities. Both questionnaires use a recall period of 1 week. RESULTS: Productivity results
were obtained from 568 and 452 patients (of which 372 and 344 were employed) in the
STARS I and II studies, respectively. Overall, patients reported that dyspeptic symptoms
had a substantial impact on productivity (Table). This impact was slightly more pronounced
in the endoscoped than in the uninvestigated patients. However, because these were two
different populations the reasons for this difference are unclear. Mean number of work-
hours lost per employed patient and week due to absence from work and reduced productivity
while at work was 11.1 hours (1.9 + 9.2) in endoscoped patients and 8.7 hours (2.0 + 6.7)
in uninvestigated patients. Results on reduced productivity were more strongly correlated
with the RDQ dyspepsia dimension (r = 0.2 to 0.4) than with the other dimensions (r =
0.1 to 0.2), which lends support to the observed productivity loss mainly being related to
non-GERD dyspepsia. CONCLUSION: Non-GERD dyspepsia has a substantial impact on
productivity while at work and in regular daily activities in both endoscoped and uninvesti-
gated patients.
Productivity results, mean values and 95% confidence intervals (CI)
S1125
Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Famotidine
in Patients with Functional Dyspepsia
Mototsugu Kato, Takeshi Yoshida, Tamotsu Hata, Yuji Ono, Shouko Ono, Manabu
Nakagawa, Souichi Nakagawa, Yuichi Shimizu, Masahiro Asaka
Background: histamine 2-receptor antagonists were used as a first therapy against functional
dyspepsia (FD). Meta-analyses on the treatment of FD have demonstrated the effectiveness
of H2RAs. Most reports to date have examined reflux-like FD, and few FD studies have
been conducted based on the Rome II criteria. Reflux-like FD includes endoscopy-negative
GERD and tends to respond better to antisecretory drugs. Also few clinical studies with
famotidine for FD have been reported. Aim: To evaluate the effectiveness of famotidine
for FD patients. Methods: A multi-center, randomized, double-blind, placebo-controlled
crossover trail was conducted. Patients diagnosed with FD by the Roma II criteria were
included. Subjects were randomized into two groups, and received either famotidine or
placebo as the first four weeks medication. After a one-week washout period, they were
switched to the other regimen for another four weeks. Evaluation was made prior to the
start of study, upon completion of the first drug cycle, and the second drug cycle, by
GSRS(Japanese version) for the seriousness of abdominal symptoms, and by SF-36(Japanese
version) for the level of QOL. Results: Nineteen patients out of 21 enrolled patients success-
fully completed this study. Significant improvement in GSRS scores was observed in abdom-
inal pain (P=0.007), indigestion, and reflux syndrome after famotidine treatment. GSRS
abdominal pain scores were lowest following the administration of famotidine in both
treatments. In patients treated first with famotidine, there was a rebound in increase of
abdominal pain scores in the following period of placebo administration. Also QOL scores
showed significant improvement in body pain, vitality, and general health perceptions
after famotidine treatment. There was no improvement of symptoms and QOL scores after
administration of placebo. Conclusions: Famotidine was effective for improving symptoms
and QOL in FD patients. In the situation of high placebo response, crossover design is
advantageous to identify true drug responders and nonresponders.
S1126
Association of Perfectionism with Psychophysiological Background of
Functional Dyspepsia and Gastroesophageal Reflux Disease Compared to
Anorexia Nervosa
Masahiro Ochi, Kazunari Tominaga, Toshiya Iketani, Kaori Kadouchi, E.J. Sasaki,
Masatsugu Shiba, Toshio Watanabe, Yasuhiro Fujiwara, Nobuhide Oshitani, Kazuhide
Higuchi, Nobuo Kiriike, Tetsuo Arakawa
Background and Aims: Anorexia, early satiety, bloating, and belching were common com-
plaints for patients with functional dyspepsia (FD), gastroesophageal reflux disease (GERD),
and anorexia nervosa (AN). Although showing similar abdominal symptoms, the difference
in psychophysiological background among these diseases remains unknown. Perfectionism
has been associated with the pathogenesis of eating disorder and identified as a predisposing
factor in patients with AN. In this study, we analyzed the relationship of perfectionism as
the psychophysiological background in patients with FD and GERD, compared to that in
patients with AN. Methods: FD patients according to Rome II criteria (N=154, 59% female,
mean age 49.2 years), GERD patients (N=21, 48% female, mean age 53 years), AN patients
according to DSM-IV criteria (N=101, 100% female, mean age 23 years) were recruited in
this study. Number of healthy controls was 130; 81% female, mean age 26.2 years. We
used the Frost’s Multidimensional Perfectionism Scale (FMPS) to explore the association of
perfectionism, which comprises 35 items in the form of statements with a Lickert-type 5-
point response format from strongly disagree (1) to strongly agree (5). These 35 items are
divided into 6 sub-scales tapping 6 dimensions of perfectionism: concern over mistake (CO);
personal standards (PS); parental expectations (PE); parental criticism (PC); doubts about
actions (DA); organization (OR). Results: Scores of all sub-scales expect for OR in AN patients
were higher than those of controls (p < 0.05). PC scores of FD patients were also significantly
higher than that of controls, but lower than those of AN patients as well as all other sub-
scales expect for OR. On the other hand, CO and PC scores of GERD patients were significantly
higher than those of both controls and FD patients, whereas CO and DA scores of GERD
patients were lower than those of AN patients. Conclusion: Continuous long-term mental
stress such as parental criticism (PC) was suggested to be critical for some eating disorders.
But perfectionism identified as a predisposing factor in AN was not closely related to the
psychological background of FD, but might be in part involved in the psychophysiological
background of GERD.
S1127
Outcomes of Recurrent Abdominal Pain (RAP) in Children and Responses to a
Multidimensional Measure for RAP (MM-RAP): A 2 Years Follow-Up Study
Hoda M. Malaty, Michael Takenticho, Kennard J. Fraley, Suhiab Abudayyeh, David Y.
Graham, Kimberley Omalley, Mark A. Gilger
Background: Recurrent abdominal pain (RAP) is a common problem in children and adoles-
cents. Evaluation of children with RAP continues to challenge investigators due the lack of
a psychometrically sound measure for RAP. Aims: 1) to characterize the course of children
with RAP 2) to evaluate the diagnostic outcomes of RAP, 3) to compare responses of a
newly developed measure for RAP across the different diagnostic categories of RAP. Methods:
We conducted a prospective 2 year study of children diagnosed with RAP during their first
visit to the Pediatric Gastroenterology Clinic at Texas Children’s Hospital and who were
followed-up. At their initial visit, the eligible child/ parent completed a multi-dimensional
measure for RAP (MM-RAP) consisting of 4 scales (pain intensity scale, symptoms scale,
disability scale, and satisfaction scale). The final diagnosis was defined as the diagnosis at
their last visit. Outcomes were classified into 3 categories: functional RAP, organic RAP,
and Gastroesophgeal Reflux Disease (GERD). The responses of the MM-RAP were analyzed
by One-Way ANOVA analysis among the 3 RAP outcome groups. Results: One hundred
and forty one children ages 4 to 18 years (44% boys) participated. The follow-up ranged
from 4-130 weeks (mean = 50 weeks). The final diagnoses were functional RAP in 46%,
organic RAP in 24%.and GERD in 30%. Neither age nor sex predicted the outcome. The
total scores for the pain intensity scale were significantly higher among children with
functional RAP than organic RAP or GERD (19.7 (+3.5) vs. 14.2 (+4.7) and 13.1 (+4.2);
respectively, p=001). Although the non-pain symptoms total score did not differ between
the three outcome groups, independent items within the scale, i.e. diarrhea, vomiting, and
heartburn were significantly higher among children with organic RAP and GERD compared
to functional RAP. The scores for pain disability and health satisfaction scales were similar
among the three outcome groups. Conclusions: The MM-RAP discriminated between func-
tional and organic RAP across the studied population. Children with functional RAP report
more intense pain than children with organic RAP or GERD. Neither the disability scale
nor the satisfaction scale differentiated between the functional and organic RAP.
S1128
Rikkunshito Improves Induction Therapy for Depression with SSRI
Takakazu Oka
Background: Gastrointestinal (GI) symptoms such as nausea and vomiting by serotonin-
specific reuptake inhibitors (SSRI) are critical issues that impair QOL of patients with
depressive disorder and that may result in discontinuation of drug use. Rikkunshito, a
Japanese Kampo medicine, has been reported to improve gastric emptying by functioning
as a serotonin-3 receptor antagonist and improve GI symptoms in patients with functional
dyspepsia. Aim: To assess if Rikkunshito reduces GI symptoms when treating depressed
patients with SSRI by a randomized controlled study. Methods: Forty-three patients who
met DSM-IV criteria for major depressive disorder (19 to 75 years; mean age 40.2 years)
were randomly allocated to one of the following two groups: SSRI alone (fluvoxamine 50
to 150 mg) group (n=21) or SSRI plus Rikkunshito 7.5 g combination group (n=23). The
treatment period was 8 weeks. The following parameters were compared between the two
groups. (1) GI symptoms were compared by GSRS (Japanese edition). (2) Depressive symp-
toms were compared by self-rating depression scale (SDS). (3) The number of patients who
required discontinuation of SSRI treatment because of adverse reactions. Results:(1) In
the SSRI alone group, GI symptoms significantly worsened. In the SSRI plus Rikkunshito
combination group, no significant changes were observed in the GSRS scores including
total GI symptoms, reflux symptoms, abdominal pain and dyspepsia symptoms. Scores of
dyspepsia symptoms in the SSRI plus Rikkunshito combination group were significantly
lower than those in the SSRI alone group (p < 0.05). (2) In the SSRI alone group, SDS
scores significantly improved in the 8th week. In the SSRI plus Rikkunshito combination
group, the scores improved significantly in the 4th and 8th weeks (p < 0.05). There
were no differences in antidepressive effect between the groups. (3) SSRI treatment was
discontinued because of adverse reactions in 47.6% (10/21) in the SSRI alone group and
in 19.4% (4/22) in the SSRI plus Rikkunshito combination group (p < 0.05). Conclusions:
In the SSRI plus Rikkunshito combination group, the number of patients who discontinued
SSRI was less than that in the SSRI alone group. This study suggests that Rikkunshito is
beneficial for reducing SSRI-induced GI symptoms.
S1129
Blood-, Breath- Or Gene-Test for Detection of Lactose Malabsorption? A
Comparison of Three Methods
Per G. Farup, Oistein Hovde
Introduction: Genetic testing for lactose malabsorption (LM) is a new diagnostic method
that supplements commonly used blood- and breath- tests. Aims and Methods: The study
compares blood- breath- and gene-tests for detection of LM. Patients with suspected LM
were included. LM was assessed with a combined blood- and breath- test. A gas chromato-
graph (Model SC MicroLyzer, Quintron Instrument) was used for the breath tests. Samples
for H2 and CH4 were measured before and 30, 60, 120 and 180 min after intake of 25g
lactose, and samples for blood glucose were taken before and after 15, 30, 60 and 90
minutes. Peak values of H2 breath excretion > 20 ppm above the lowest preceding value,
peak CH4 excretion > 12 ppm above baseline, and/or combined H2 and CH4 increase >15
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ppm were considered a positive breath test for LM, and increase in blood glucose < 1.0
mmol/l as a positive blood test. The combined test was repeated 10-18 months later and
supplemented with a gene test in patients with a discrepancy between the results of the
first blood- and breath- tests. The “correct” diagnosis was based on an overall evaluation of
all the tests. Results: 60 patients (men/women: 17/43) with a mean age of 39 years (range
18 - 71), most of them with symptoms of functional gastrointestinal disorders, were included.
46 out of 49 patients with a normal breath test had a normal blood test, and 5 out of 11
patients with a pathological breath test had a pathological blood test (agreement 85%, kappa
0.44, p=0.004). LM was considered to be “correct” in 7 (12%) of the patients. Referring to
the “correct” diagnosis, 4 false positive breath tests normalised when repeated, 2 out of 3
false positive blood tests normalised, 2 false negative blood tests became positive when
repeated, and one gene test was false negative. The table gives the relation between correct
diagnosis and the first breath- and blood-tests and the gene test. The sensitivity and specificity
of the breath-, blood-, and gene- test were 100% and 92%; 71% and 94%; and 50% and
100% respectively. Conclusion: All the tests are suitable for identifying patients with LM,
but none of them are perfect. The breath test seems to be best suited for daily practice, but
positive tests should be repeated. There were no false negative breath tests, and all false
positive tests normalised when the test was repeated.
The relation between the “correct” diagnosis and the first breath- and blood- tests and the
gene test (number of patients).
S1130
Sacral Neurostimulation in Fecal Incontinence - Is Clinical Response
Associated with Improved Anal Sphincter Pressures Or Anorectal Perception?
Heiko Fruehauf, Daniel Pohl, Oliver Goetze, Franc H. Hetzer, Dieter Hahnloser, Werner
Schwizer, Michael Fried, Radu Tutuian
BACKGROUND: Sacral Neurostimulation (SNS) is a promising emerging treatment option
for patients with fecal incontinence (FI). However, the mode of action is insufficiently
understood and the effects on anal sphincter pressures and anorectal perception remain
controversial. AIMS: To evaluate the effect of SNS on anorectal sphincter pressures and
rectal sensation in patients with FI. METHODS: 15 consecutive patients (12 F; mean age
64, range 38-86 years) with idiopathic (n=2), neurogenic (n=2) or structural (n=11) FI
refractory to conservative therapy, underwent anorectal manometry and sensory testing
before and 6 months after definitive neurostimulator implantation in our institution. The
Wexner score (Dis Colon Rectum 36:77-97; 1993), bowel habit diaries, anal resting pressure
(RP), squeeze pressure above RP, initial sensation, urgency to defecate and maximal tolerated
volume to balloon distention before and 6 months after neurostimulator implantation were
compared using paired t-test. Data are presented as mean ± SEM. RESULTS: During SNS,
FI improved in all 15 patients (Table). Six months after SNS implantation we found a
decrease (p < 0.001) in the Wexner score of 9 ± 1 points, a 55% reduction in urgency
episodes (p < 0.02) and a 77% reduction in uncontrolled bowel movements (p = 0.087)
per day. Anal manometry revealed an increase of 14 ± 4 mmHg (p < 0.01) in the squeeze
pressure even though the latter remained below the lower limit of normal in 10/15 patients.
SUMMARY: Clinical improvement after SNS implantation is associated with an increase in
external anal sphincter pressure, whereas internal sphincter pressures and anorectal percep-
tion remain unchanged. CONCLUSION: SNS is an effective treatment option in patients
with fecal incontince.
S1131
Familial Aggregation in Constipated Subjects in a Tertiary Referral Center
Annie On On Chan, Wai Mo Hui, Wayne Hc Hu, Gigi Leung, Chi Kuen Chan, Man
Fung Yuen, Shiu Kum Lam, Benjamin Cy Wong
Background: Clinical observation showed that there is family aggregation in constipated
subjects, but formal data are lacking. This prompted us to conduct a formal family study
in constipated subjects Methods: Constipated subjects (probands) were identified according
to the Rome II and Chinese constipation questionnaire criteria, healthy subjects were chosen
as controls. Living first degree relatives (parents, siblings and children) and spouses from
both groups were identified. The questionnaire on Rome II criteria was given to the relatives
either through the index subjects or by mail. The questionnaire was received by mailing
back or through the index subjects. Any non-responders were chased. Results: There were
132 probands with constipation and 114 controls identified. The Rome II questionnaire
was sent to a total of 677 relatives of the probands and 591 of the controls. The respond
rate was 100%. Relatives were comparable in mean age, sex distribution, family size and

















versus 9.1% in controls’ relatives (p < 0.001). Among them, only 6% vs 9.3% of the relatives
reporting constipation were spouses of the probands and controls (p=0.5). Probands’ relatives
were at increase risk to have constipation than controls’ (odds ratio 1.86 for at least one
member with constipation ((CI) 1.11, 3.14), odds ratio 3.54 for two or more member with
constipation (CI: 1.71, 7.36)). Conclusions: Familial aggregation of constipation occurs,
supporting a genetic or intrafamilial environment component.
S1132
The Epidemiology of Irritable Bowel Syndrome and Its Relationship with
Gastroesophageal Reflux Disease in the General Population: Results from the
Loiano-Monghidoro Study
Rocco Maurizio Zagari, Paolo Pozzato, Silvia Damian, Maria Luisa Bianchi, Liza Ceroni,
Lorenzo Fuccio, Maria Eugenia Minardi, Mari-Ann Wallander, Saga Johansson, Bahman
Farahmand, Enrico Roda, Franco Bazzoli
Purpose: We aimed to study the relationship between irritable bowel syndrome (IBS),
gastroesophageal reflux disease (GERD) and esophagitis in the general population. Methods:
A representative sample of 1533 adults from two Italian villages was approached between
2000 and 2004 to undergo gastrointestinal symptom assessment and endoscopy (Savary-
Miller classification). We recorded the frequency of 18 different gastrointestinal symptoms
during the previous 12 months using a validated questionnaire. Based on the Rome II
criteria, IBS was defined as abdominal pain or discomfort associated with at least two of
the three following features: abnormal stool frequency; urgency or feeling of incomplete
evacuation; relief of abdominal pain by defecation. GERD was defined as reflux symptoms
at least monthly with or without esophagitis. Odds ratios (OR) and 95% confidence intervals
(CI) were calculated by unconditional logistic regression models. The odds ratio estimates
were adjusted for age and gender and for other variables included in the models. Results:
Data were obtained from 1069 individuals representative of the general population (a response
rate of 70%). The overall prevalence of IBS and GERD was 39.6% and 45.3%, respectively.
Female gender (OR: 2.8; CI: 2.0-3.9) and the presence of dyspepsia (OR: 2.7; CI: 2.0-3.7)
increased the risk of IBS. The risk of IBS was also significantly increased in individuals with
GERD. This association between IBS and GERD was stronger in individuals who had GERD
without esophagitis (OR: 2.5; CI: 1.8-3.4) than in those who had GERD with esophagitis
(OR: 1.8; CI: 1.1-2.8). Individuals with both IBS and GERD were more likely to be younger,
have a higher body mass index, and have a prior history of peptic ulcer disease than those
with IBS but no GERD. In the subgroup of individuals with IBS and GERD, those with
esophagitis were more likely to have a hiatus hernia (OR: 3.8; CI: 1.6-9.0), but less likely
to have dyspeptic symptoms (OR: 0.04; CI: 0.01-0.12), than those without. Conclusion:
Our results show an association between IBS and GERD, especially in young, overweight
individuals with a prior history of peptic ulcer disease. The association between IBS and
GERD was stronger in individuals with GERD who did not have esophagitis than in those
who had esophagitis. An increased awareness of the comorbid occurrence of different
gastrointestinal conditions may result in better diagnosis and treatment for individuals
affected by both IBS and GERD.
S1133
The Community Prevalence of Abdominal Pain and Cramps: A Multi-National
Survey
Guido N. Tytgat, Luiz G. Paulo, Stefan Mueller-Lissner, Eamonn M. Quigley, Richard G.
Locke, Eckhard Schaefer, Iris Helfrich
Background: Abdominal pain and cramps are common symptoms of functional disorders
of the gastrointestinal tract. These ailments are widespread in the general population in
various countries worldwide. Aim: To describe the demographics, clinical features and
management of abdominal pain and cramps in the community. Methods: Interviews were
carried out in Argentina, Belgium, Brazil, Germany, Italy, Japan, Mexico, UK, and USA in
two phases. In the first phase approximately 1,000 people in each country were randomly
selected from the general population. The second phase consisted of interviews with a sub-
sample of approximately 200 subjects in each country. Acid-related complaints and menstrual
pain were excluded. Data were analysed using descriptive statistics and logistic regression.
Results: In the first phase, 10,005 respondents (55.5% women) were interviewed. Females
were more likely to suffer from abdominal pain and cramps than males (OR: 1.25, C.I.
1.21-1.30). Those aged less than 60 years were also more likely to complain of these symptoms
(OR: 1.40, C.I. 1.27-1.53). South American countries reported the highest prevalence of
symptoms (39.9%; OR: 2.32, C.I. 2.13-2.53) and Japan (10.5%) the lowest. A total of 1,717
subjects (65% females) were included in the second phase, carried out in all countries except
Japan. The frequency of episodes of abdominal cramps and pain differed from country to
country, being by far the highest in the US, followed by Brazil, Belgium and the UK. The
average age at onset of symptoms was similar in all countries (27-31 years). Frequency of
drug usage was highest in the US and lowest in Germany and Italy. In most countries, the
intensity of different episodes was considered similar. The incidence of consultation of a
physician for these symptoms varied considerably across countries, from 74% in Italy to
less than 50% in Mexico and the UK. The use of medication was higher in the US and in
Latin America (87-91% of all sufferers) than in Europe (68-77%). With the exception of
Mexico, OTC products dominated. Antispasmodics were most popular in Latin America
and Italy, and antacids in Germany and the UK. Conclusions: Although prevalence and
severity of abdominal symptoms seemed similar and common in the general population
especially among young to middle-aged females throughout the world, the rates of health
care seeking and medication usage were quite different between the countries. These findings
have important implications for multi-national studies of functional disorders. This research
was funded by Boehringer Ingelheim, Ingelheim am Rhein, Germany.
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S1134
Provider Beliefs Regarding Diagnostic Testing in IBS Exhibit Extreme
Variation and Diverge from Guidelines
Brennan M. Spiegel, Mary Farid, Eric Esrailian, Jennifer Talley, Lin Chang
Background: Data indicate that diagnostic testing is generally low yield in IBS, yet many
clinicians remain unsettled by the prospect of overlooking alternative diagnoses. We measured
provider beliefs about the appropriateness and yield of common tests in IBS. Methods: We
developed an online vignette survey that elicited provider beliefs about the appropriateness
(using 9-point RAND Appropriateness Scale [RAS], where 1-3=inappropriate, 4-6=unsure,
7-9=appropriate) and diagnostic yield of common tests in IBS. We calculated the RAND
Disagreement Index (DI) for each set of ratings. The DI is a validated measure of provider
variation, where DI>1.0=extreme variation, and DI<1.0=acceptable variation. We surveyed
a random sample of 300 VA NPs, 300 VA PCPs, 300 GIs from the AGA membership, and
45 recognized IBS experts. Results: The response rate was 31% (102 NPs, 89 PCPs, 90
GIs, 27 experts). Table 1 shows the RAS and DI results of the IBS-D vignette. Experts only
rated celiac sprue testing and CBC as appropriate (mean RAS>6), and breath testing as
inappropriate. Non-experts rated most tests as appropriate. Experts were consistent in their
disfavor of breath testing and favor of CBC and sprue testing (DI<1.0), but exhibited extreme
variation for all other tests. Non-experts revealed a mix of extreme and acceptable variation
across tests. Compared to published data, 45% of experts vs. 69% of non-experts over-
estimated the yield of diagnostic testing (p<0.004). There were similar results in the IBS-C
vignette (data not shown). Conclusions: Despite the dissemination of guidelines regarding
diagnostic testing in IBS, there remains extreme variation in beliefs among both experts and
non-experts. Compared to experts, non-experts consistently over-estimate the appropri-
ateness and yield of testing. This suggests that better dissemination of IBS diagnostic guidelines
is warranted in order to minimize extreme variation and improve cost-effectiveness of care.
Table RAS and DI Results. Mean RAS>6=“Appropriate,” and DI>1=“Extreme Variation.”
S1135
Does the Use of Complementary and Alternative Medicines (CAM) Predict a
Non-Organic Gastrointestinal Disorder?
Shital Amin, Subhadip Ghosh-Ray, Niall van Someren, Kalpesh Besherdas, Steven Mann
Background: Many studies have highlighted the increase in use of CAM in adults in the
developed world. Adults with gastroenterological complaints are also known to be frequent
users of CAM. Reports suggest that up to 50% of patients with IBS or inflammatory bowel
disease use some form of CAM. Aim: To review the use of CAM in consecutive new patients
seen in a general gastroenterology outpatient setting in one National Health Service Hospital
Trust. Method: Consecutive new patients referred to our clinics (NVS, KB, SM) completed
a questionnaire in the waiting room before the consultation. The questionnaire was in the
form of a tick box enquiry looking at demographic data, use of CAM (15 options) and
symptoms at presentation (19 options). Data were collected prospectively and re-analysed
after appropriate diagnostic work-up. Patients were divided into two groups according to
the final diagnosis: organic (O) or non-organic (NO) disease (functional dyspepsia, functional
abdominal pain, or functional colonic pain). Non-parametric analysis was used to evaluate
any correlations. Results: 154 patients (F:78 [51%]) completed the questionnaire. The
distribution of diagnoses was O:75/154 (49%; F:43 [57%]), NO:79/154 (51%; F:35 [44%]).
22 patients had used CAM (14%; F:9 [63%]). The distribution of diagnoses amongst CAM
users was O:10/22 (45%; F:3 [30%]), NO:12/22 (55%; F: 6 [50%]). Use of CAM was not
associated with a diagnosis of non-organic disease (p=0.67). The age distribution of CAM
users was 15-29 years:13.6%, 30-49 years:32%, 50-69 years: 41%, 70+ years:13.6%. The
commonest therapies used were herbal or dietary supplements. 50% of CAM users reported
a ‘modest’ or ‘significant’ improvement in symptoms. Conclusion: There is a perception in
gastroenterology that most CAM users will have a non-organic underlying disorder. Our
data has failed to support this notion. CAM users are a heterogeneous group, with an equal
distribution of organic and non-organic conditions represented.
S1136
Making a Diagnosis of Gastroparesis Reduces Diagnostic Cost and
Unnecessary Surgeries in Patients with Recurrent Nausea and Vomiting
Chadwick W. Hatfield, William D. Chey, David Barthel, Jack Semler, Steve Harrell, John
Wo
Gastroparesis (GP) is a disorder defined by delayed gastric emptying. Symptoms of GP are
non-specific and the diagnosis is often overlooked. Extensive medical resources may be
spent for its diagnostic workup. AIM: To determine the extent of medical utilization in
diagnosing GP in subjects with recurrent nausea and vomiting. METHODS: Potential subjects
were identified at University of Louisville and University of Michigan from Jan 2001 through
Dec 2003 using ICD billing codes for GP, miscellaneous gastric, nausea, vomiting, and
nausea with vomiting. Outpatient records were reviewed in chronological order. Study
criteria were nausea and vomiting ≥3 months and documented gastroparesis by delayed
gastric scintigraphy or residual solid food by EGD despite overnight fast. Those <18 years
old and non-ambulatory individuals were excluded. Diagnostic tests were separated into 3
categories: endoscopic, radiographic (including scintigraphy), and motility. Type and number
of each diagnostic test and surgical procedure was obtained before and after making the
diagnosis of GP. Cost of diagnosis was calculated using Medicare 2005 physician and hospital
outpatient payment schedule for Kentucky and Michigan. Mann-Whitney U, Wilcoxon
signed-rank and paired McNemar’s tests were utilized. RESULTS: 240 charts were reviewed.
141 subjects (median age 46 yrs, 79% female) met study criteria. Results are shown in table.
There was a high variability in total diagnostic cost among the subjects. Gender, age, and
etiology of GP did not significantly affect the total diagnostic cost. Cost associated with
endoscopies was significantly greater than radiographic and motility testing (p<0.01). Total
diagnostic cost decreased significantly after the diagnosis of GP was made. Prior to diagnosis
of GP, 56 subjects (40%) had cholecystectomy, compared to only 1 of the remaining 85
subjects (1%) after diagnosis. 23 subjects (16%) had laparoscopy/laparotomy before diagnosis
of GP, compared to 3 subjects (2%) after diagnosis. CONCLUSIONS: Diagnostic cost of GP
in patients with chronic nausea and vomiting was quite variable. Establishing a diagnosis
of GP significantly reduced the cost associated with testing and number of unnecessary
surgeries unrelated to GP.
†Median (range); *p< 0.01
S1137
Quality of Life Survey in Patients with Functional Gastrointestinal Disorders:
An Asian Study
Daphne Ang, Hock-Foong Lui, Widjaja Luman
Aim: Health-related quality of life (HRQoL) is an increasingly important outcome in patient
care. Data on HRQoL in Asians with functional gastrointestinal disorders are lacking. Func-
tional dyspepsia (FD) and irritable bowel syndrome (IBS) are commonly encountered func-
tional gastrointestinal disorders. This study quantified and compared the impact of FD and
IBS on HRQoL in subjects seen at a tertiary referral hospital; and compared patients’ scores
against previously published normative United States(US) data, using the well validated,
generic Medical Outcomes Study 36-item Short-Form Health Survey (SF-36)form.
Methods:185 patients seen at a tertiary referral centre in Singapore who fulfilled Rome II
criteria for FD or IBS were invited to participate. Patients completed a baseline questionnaire
at clinic visits that included demographics; duration and severity of symptoms and the SF-
36 questionnaire forms. The mean scores for each of the 8 domains of the SF-36 questionnaire
for the FD group were compared against the IBS group; scores for both groups were compared
against previously published US data of normal controls. Unpaired student’s t-test was used
for statistical analysis. Results:Completed questionnaire forms were obtained in 62 FD
patients (45 females; mean age 34.2 +/-8.5 years; Chinese 83.9%)and 42 IBS patients (26
females; mean age 38.0 +/- 11.2 years; Chinese 83.3%). Patient demographics; symptom
duration and severity did not differ between the 2 groups. Mean scores (standard deviation
SD in parentheses) are presented in Table 1. No significant differences in mean scores for
all 8 individual SF-36 domains occurred between FD and IBS groups. Differences between
FD group and US norms were significant in all domains (p<0.05) except for physical
functioning and role function (emotional). Differences between IBS group and US norms
were significant for all domains (p<0.05) except role function (physical) and vitality. Conclu-
sion: The baseline HRQoL in both FD and IBS groups were significantly lower in most
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S1138
The Impact of Sleep Disruption On Quality of Life (QOL) in IBD & IBS
Laurie Keefer, Ali Keshavarzian, Ranjbaran Ziba, Laura Benson, Edward J. Stepanski
Chronic sleep disruption is a risk factor for disease & linked to inflammation & altered
immune function. Sleep c/o are common in IBS; less is known about sleep in IBD. We
examined sleep patterns in IBD & IBS & relations w/QOL. Meth: 16 biopsy-proven inactive
IBD(8CD,8UC), 9 IBS & 7 controls (C) completed the Pittsburgh Sleep Quality Index (PSQI),
Epworth Sleepiness Scale (ESS), IBDQ, SF-12 & overnight polysomnography (PSG). Mean
ages of IBD,IBS & C were 41.4(13.3), 52.7(12.1) & 34.3(9.4). PSGs were scored manually
in 30s epochs w/standard criteria. One-way ANOVAs w/post-hoc tests were performed for
b/w group comparisons; linear regression identified assoc b/w sleep & QOL. Res: IBS &
IBD groups did not differ from each other on subjective parameters but differed from C on
impaired sleep quality, duration, efficiency, disruption & global PSQI scores. IBS reported
the most sleep disruption, followed by IBD, followed by C (Table 1). IBS & IBD did not
differ on objective sleep parameters but both differed from C; IBS exhibited less total sleep
time and reduced sleep efficiency. IBD fell numerically between IBS & C on most parameters
(Table 2). PSQI global linked to IBDQ (R2 = .63, p = .00), SF12-physical (R2 = .25, p =
.01) & mental health (R2 = .43, p = .00). IBD & IBS share similar sleep c/o, objectively &
subjectively; c/o are linked to QOL. IBS reported the most disturbance followed by IBD and
C. CNS hyperarousal & cognitive attributions may contribute to sleep c/o in IBS; sleep may
affect IBD in additional ways ie. immuno-inflammatory pathways or increased risk to flare.
if share letter p < .05
if share letter p < .05
S1139
Targeted Esophageal Biopsies: What You See Is What You Get (WYSIWYG) -
Or Not?
Robert H. Riddell, Vijay Mann, Paul Moayyedi, Sjo Veldhuyzen van Zanten, Janusz
Jankowski, Marc Bradette, Jacob Louw, Garth Noad, Robert J. White, David Armstrong
Background: Evaluation of esophageal epithelial histology for features of gastroesophageal
reflux disease (GERD) has shown regional variations related to the distance from the Z-line,
anterior or posterior location and proximity to mucosal breaks (MB). Discrepancies between
histological and endoscopic findings for MB and Barrett’s esophagus (BE) have been attributed
to deficits in endoscopic recognition of lesions but discrepancies may also indicate the

















of biopsies from the Z-line (readily recognized at endoscopy) and MB should be equivalent.
Aim: To assess the accuracy of biopsy acquisition from the esophagus in GERD patients.
Methods: An ongoing 6-month, open-label, multicentre trial planned to recruit patients from
tertiary care with heartburn and erosive esophagitis (EE: n=50), nonerosive reflux disease
(NERD: n=150) and heartburn non-dominant dyspepsia (HND: n= 150). At baseline endos-
copy, biopsies were obtained from 7 sites, including 1 each from the Z-line anterior &
posterior locations, and, in EE patients, from the edge of an MB. Histological assessment
evaluated the accuracy of acquisition of biopsies by determining the proportions of (a) Z-
line biopsies that contained both columnar mucosa (CM) and squamous epithelium (SE)
and (b) MB biopsies that showed features of an erosion or MB. Results: To date, 145 patients
have been enrolled - EE: 50, NERD: 50, HND: 45. Evaluable Z-line biopsies are available
from 145 patents (290 biopsies) and MB biopsies from 49 patients (49 biopsies). In 26/145
patients (18%), both Z-line biopsies showed both CM and SE and in another 45 (31%),
one Z-line biopsy showed CM and SE; overall, 97/290 (33%) of biopsies were acquired
accurately from the Z-line. In 3/49 (6%) patients, histology showed fibrinopurulent exudates
consistent with an erosion and in another 12 (24%), there were features of regeneration;
overall, 15/49 (31%) were acquired accurately from an MB. Conclusions: “WYSINotWYG”
Although the accuracy of biopsy acquisition from the Z-line and MB was comparable,
acquisition of targeted biopsies in the esophagus was accurate in only about one-third of
cases; this appears to be related to technical difficulties in targeting specific lesions rather
than failure to recognize the lesions although a true mismatch between the endoscopic and
histological features or mucosal breaks cannot be excluded. These results have implications
for the conduct of clinical studies, for accurate biopsy acquisition from the lower esophagus
and cardia, for endoscopic surveillance in patients with BE and, possibly, for endoscopy
training.
S1140
The Clinical Impact of Prolonged (48 and 96-hour) Oesophageal pH
Monitoring By the BRAVO™ System
Mark Fox, Amir Thakur, Roy Anggiansah, Angela Anggiansah, Terry Wong
Introduction & Aims: The day-to-day variability of pH recordings is high; thus prolonging
the duration of pH studies is likely to improve the reliability and diagnostic yield of the
investigation. The optimal duration of pH monitoring is unknown. The catheter-free Bravo™
system is designed to record intra-oesophageal pH over 48 hours; however the capsule
remains in place for an average 5-6 days. This provides an opportunity to examine variability
in pH recordings over extended periods, and the impact of prolonged recordings on the
diagnostic yield of gastro-oesophageal reflux disease (GORD). Methods: 56 consecutive
patients (22M:34F; 48 (35-61) years) with reflux symptoms referred for pH monitoring
were studied. 43 patients were monitored for 2 days and 13 patients over 4 days (returning
after 48-hrs to download pH data and replace batteries). The day-to-day variability of pH
measurements was assessed. Patients were classified with normal or abnormal acid exposure
(>4.2% pH<4/24hr) during each test period. The increase in diagnostic yield for GORD by
prolonging pH recording from 24 to 48 and 96-hours was calculated. Kappa (k) values
assess diagnostic agreement between test periods. Results: Two-day recordings were available
for 47/56 patients (incomplete recording (n=8), early detachment (n=1)). Four-day pH
studies were available for 12/13 patients (day 3 detachment (n=1)). There was no difference
in mean acid exposure day 1-4 (8.2%, 7.8%, 7.9%, 7.3% respectively, p=0.61); however
within patient day-to-day variability was high, ±30% relative to the mean. Pathological acid
exposure was present in 29/46 day 1 and 27/46 day 2 (12 patients changed diagnostic
classification). Cumulative diagnostic yield increased from 29/46 (48%) day 1 to 34/46
(74%) day 2. Diagnostic reproducibility of 24-hr pH recording was fair (k = 0.45). Within
patient variability between 48-hr test periods was lower than that for 24-hr test periods
±16% vs. ±30% relative to the mean (p<0.01). Only 1/12 patients changed diagnostic
classification from the first to the second 48-hr test period. Diagnostic reproducibility of
48-hr pH recording was very good (k = 0.76). Similar results were obtained for alternative
diagnostic ‘pH values’ for GORD and the DeMeester score. Conclusions: Increasing the
duration of pH monitoring from 24- to 48-hrs significantly improves the reliability of clinical
measurement and raises the diagnostic yield of GORD by 25%. Preliminary evidence suggests
that prolonging pH studies to 96-hrs provides little further improvement in diagnostic yield.
48-hr pH monitoring provides important advantages for the investigation of reflux symptoms
in clinical practice.
S1141
Multichannel Intraluminal Impedance and pH (MII-pH) Is Accurate in
Assessing Esophageal Transit Abnormalities
Amine Hila, Amit Agrawal, Wojciech Blonski, Inder Mainie, Janice Freeman, Donald O.
Castell
BACKGROUND: 24-hr MII-pH esophageal monitoring allows detection of both acid and
non-acid gastroesophageal reflux (GER) episodes. The MII-pH catheter is 2 mm in diameter
and contains 6 impedance segments placed 3, 5, 7, 9, 15 and 17cm above LES, plus a pH
electrode at 5 cm. MII and esophageal manometry (MII-EM) allows both functional and
manometric evaluation of the esophagus. MII-EM catheter is 4.5 mm in diameter and contains
4 impedance segments (5, 10, 15 and 20cm above LES) and 5 pressure transducers (at LES
and 5, 10, 15 and 20cm above LES). 5 cc saline boluses are given in the recumbent position
when performing an MII-EM study. In our laboratory, all patients have an MII-EM study
performed prior to MII-pH study. However, this is not true everywhere. AIM: To assess
accuracy of swallows given prior to ambulatory MII-pH monitoring in detecting esophageal
transit abnormalities. METHODS: 37 consecutive patients (27 females; mean age=53yrs)
presenting for MII-EM and 24-hr MII-pH study, also received 10 saline swallows in the
recumbent position at the beginning of the MII-pH study. Impedance for these swallows
was assessed for the presence of complete or incomplete transit, defined as bolus entry at
17cm and bolus exit at 15, 9 and 5 cm, defined by a rise in impedance above 50% between
baseline and the nadir, and remaining above this value for at least 5 seconds. Out of 10
swallows, presence of 8 or more complete swallows satisfies MII-EM criteria for diagnosis
of complete transit. These findings were blindly compared to those of the 10 saline swallows
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on the MII-EM study. RESULTS: The MII-pH swallows gave identical transit diagnosis to
the MII-EM in 35 patients (95%). In 1 patient, diagnosis changed from incomplete transit
(7 complete swallows) on MII-EM to complete (8 complete swallows) on MII-pH, and from
complete transit (10 complete swallows) on MII-EM to incomplete (7 complete swallows)
on MII-pH in the other patient. With both methods there were 27 patients with complete
transit and 10 with incomplete transit. Thus, MII-pH swallows had a sensitivity of 90% and
a specificity of 97% for detection of esophageal transit abnormalities. Comparing swallow
diagnosis for each patient, we found that there was a highly significant correlation (p<0.0001)
for the number swallows with of complete (Pearson r=0.9) and incomplete bolus transits
(r=0.9). CONCLUSION: Use of 10 saline swallows at the beginning of MII-pH studies is
both accurate and highly sensitive and specific for detection of esophageal transit abnormalit-
ies. This may provide a method for assessment of esophageal function when an MII-EM
study is not planned prior to MII-pH monitoring.
S1142
The Diagnostic Value of the Proton Pump Inhibitor Test for Gastroesophageal
Reflux Disease: A Population-Based Study
Marissa C. Aanen, Bas L. Weusten, Mattijs E. Numans, Niek J. de Wit, Andre J. Smout
Introduction General practice guidelines often suggest as diagnostic tool for GERD the
symptomatic response to a short course of proton pump inhibitor (PPI test). Our aim was
to re-determine the diagnostic abilities of the PPI test by using the most relevant reference
test, the symptom association probability (SAP), in a primary care population. Methods
Subjects suspected of GERD who had heartburn complaints for at least twice a week during
at least 3 months were recruited from primary care, either during consultation or by
advertisement. After a 24h pH recording with calculation of the SAP, subjects started using
40 mg esomeprazole once daily for 13 days. The PPI test was considered positive when the
subjects reported that their symptoms were adequately suppressed. Sensitivity, specificity
and positive likelihood ratios (LR) were determined daily for each PPI test day. Results A
total of 90 subjects were included (1/3 consultation, 2/3 advertisement). Successful 24h pH
recording was accomplished in 84 subjects and the SAP was calculable in 74. The median
age was 51 yr (IQR 41- 62), and 62% was male. The SAP was positive in 70% of the
subjects. The sensitivity of the PPI test was 92.2% (87.4-93.5) and the specificity was 28.6%
(19-33.3). The LR was low (1.3 (1.2-1.4)) and fairly constant during the 13 days (figure).
Conclusion The sensitivity of the PPI test for diagnosing GERD is high, but its specificity
low. The low LRs observed from day 1 to day 13 indicate that the PPI test does not change
the high pre-test probability (70%) of GERD found in primary care patients with heartburn.
Thus the additional value of short term treatment with a PPI for diagnosing GERD in primary
care is relatively poor even with the most adequate reference test SAP.
S1143
Non Acid Reflux in Children By Long Term pH-Impedance Study, - An
Analysis of Practice Based Data
Sudipta Misra, Zahangir Khaled, Amy Lee
Introduction: Due to lack of control population, no pediatric norms are available for non-
acid refluxes detected by Multichannel intraluminal impedance (MII). We present data from
our practice. Method: Prospective data collection, automated and manual analysis of study
data in children undergoing MII (Sandhill Scientific, USA) for clinical indications. The pH
port of the impedance catheter was placed, under fluoroscopy, at 3 and 5 cm above the
diaphragm in young (< 2 years) and older children respectively. Informed consent was
obtained from the caregivers. All frequency data were normalized for occurence/24 hours.
Mann-Whitney U and Aspin Welch tests, percentiles and correlations were used for data
analysis. Results: - Three of the 142 children (Table) in the study were excluded from acid
reflux analysis for probe failure. Percentile norms of the refluxes were calculated (Table).
Numbers of liquid, mixed and gas MII refluxes and numbers of those of respective refluxes
migrating to the proximal esophagus (PM) had excellent correlations (r= 0.81 to 0.93, r2=
0.79 to 0.86). Good correlation was found between number of acid reflux episodes and
percentage of acid reflux (r = 0.74, r2 = 0.55). No correlation could be established between
non-acid refluxes (total and PM) and acid reflux indices. 2-18 years group had fewer
incidences of some non-acid refluxes (Table), less episodes of long pH refluxes than the
other two groups (p < .05) and less number of liquid (total and PM) refluxes on antacids.
Though children on antacids (n=82) had less liquid refluxes, their acid reflux indices did
not differ from those who were not (n=57). Conclusion: Older children had fewer non-acid
refluxes with or without antacids, Number of non-acid refluxes migrating to the proximal
esophagus appears to be a function of total number of respective types of refluxes. Acid
reflux indices were independent of numbers of non-acid refluxes, suggesting a possible role
of pH only (without detectable refluxate in the esophagus) refluxes in acid exposure.
Non Acid Reflux in Children (Episodes/ 24 hours)
IQ range = Interquartile range; Prox Migr = Proximal Migration. * and ++ p = < .01; ** ,
@ and + p = < .05
S1144
Differentiating Laryngopharyngeal Reflux and Gastroesophageal Reflux
Utilizing Impedance Characteristics
Kevin D. Halsey, Eric A. Gaumnitz
Background: Laryngopharyngeal reflux (LPR) has been recognized as a distinct entity from
gastroesophageal reflux disease (GERD). Correlating gastric refluxate, responsible for LPR
pathophysiology, remains elusive. 24-hour pH testing is the gold standard for diagnosing
classic GERD, however less sensitive and specific for LPR. A new tool of esophageal perform-
ance, impedance-pH testing, is useful in furthering the diagnosis of LPR. Our aim was to
compare the impedance characteristics of the proximal esophagus in patients with LPR
symptoms to those with classic GERD symptoms. Methods: Patients referred for 24 hour
pH-impedance during a 6 month interval were enrolled in this study: 20 patients with
classic GERD symptoms of heartburn and/or regurgitation, and 24 patients referred for
laryngopharyngeal symptoms including hoarse voice, sore throat, or chronic cough. Both
groups were tested off of acid suppression medication and were similar in age and gender
make up. The Sandhill Impedance-pH system was used and the following measures obtained:
proximal bolus contact time, number and % proximal total, liquid, and gaseous reflux
events; total, acid, and non-acid reflux events; total, upright, and supine percentage of acid
reflux exposure; symptom correlation to proximal reflux, and % discordance between pH
and impedance. Results: LPR patients had a 33% increase in duration of proximal bolus
contact time when compared to those with GERD(27.28 vs 18.27 sec p=0.04). There was
a trend towards a greater number of proximal events in the LPR group (ave. 21 vs 16 events)
with percent total events reaching proximal esophagus of 40.7 vs 34.6%. LPR patients had
a 21% increase in total liquid reflux events reaching the proximal esophagus, but gaseous
reflux events were not increased. Patients with LPR had a 30% increase in symptom-
correlation to gaseous events compared to GERD. The PPV in diagnosing LPR is three fold
for impedance when compared to 24 hour pH. pH testing had a 4 fold sensitivity for
diagnosing GERD in patients with typical symptoms. Conclusion: Impedance testing reveals
that patients with LPR symptoms have a significant increase in proximal esophageal reflux
contact time with a trend towards increased number of total and proximal esophageal reflux
events compared to patients with GERD. Impedance was useful in reconsidering the diagnosis
of LPR in patients with normal pH studies. We conclude that impedance-pH monitoring is
a promising complimentary analytical tool which aids our ability to more confidently diagnose
LPR through evaluation of proximal esophageal reflux characteristics.
S1145
MII-pH Monitoring in Infants and Children: What We Can Get from the
Autoscan?
Silvia Salvatore, Bruno Hauser, C Luini, S Arrigo, Yvan Vandenplas
Multichannel esophageal intraluminal impedance (MII-pH) is an emerging pH-independent
diagnostic tool for gastroesophageal reflux (GER) in both pediatric and adult subjects. The
MII may detect any kind of reflux episodes: acid and non-acid and with fluid, gas or mixed
content and thus offering the possibility of a more precise correlation between episodes of
reflux and symptoms. The new software versions provide automatic analysis that offers wide-
ranging data and a considerable advantage in the trace reading time. Patients and Methods:
40 pediatric patients (20F-20M, mean age(±SD) 72±66 months, range 1-161 months) with
suspected GER were submitted to prolonged MII-pH study (Sandhill Scientific, MII-pH).
Automatic reading through Autoscan measurements analysis (Bioview Analysis software
version 4.9) was used twice for each patients: once, as suggested by the manufacturer, for
episodes associated with bolus movements (meal excluded) (Autoscan) and then for bolus-
independent episodes with falls of pH below threshold of 4 (meal included) (pH-Autoscan:
a reading more similar to normal pH-study). All traces with artefacts were previously excluded
from the study. Acid beverages were not allowed during the registration time. Results: The
mean duration of MII-pH was 21±1 hours. Total episodes of reflux detected by Autoscan
were 2358 (mean 59±37): 853 (36%) episodes were acid (mean 21±16) and 1505 (64%)
non acid (mean 38±29): 1045 (44%)(mean 26±26) liquid, 549 (23%)(mean 14±12) mixed
and 765 (32%)(mean 19±23) gas refluxes. PH-Autoscan analysis detected 1519 acid episodes
(mean 38±27) representing 64% of total episodes reported by Autoscan. Conversely, Autoscan
detected 56% of acid episodes reported by pH-Autoscan analysis. Thirty-six (90%) among
40 subjects presented symptoms during the registration. In 15/36 (42%) subjects only non-
acid symptom correlation was present. In 4/36 (11%) subjects only (acid) pH-Autoscan
showed a correlation with symptoms. In 17/36 (47%) both acid and non-acid reflux episodes
were associated with symptoms. Conclusion: Using Autoscan analysis we found that non
acid reflux prevails on acid reflux episodes although a more complete automatic analysis
(including all acid esophageal exposure, pH-Autoscan) provides nearly 1/3 further acid
episodes. The new MII-pH software automatic analysis is useful and time-sparing but might
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still be improved by considering also meal time and acid exposure on just the most distal
channel. Gas reflux episodes are common in pediatric patients although their clinical signific-
ance need to be further clarified. Symptom correlation with reflux episodes highly benefits
from MII-pH analysis.
S1146
Symptoms of Both Acid and Non-Acid Reflux Occur Almost Exclusively in the
Upright Position
Amit Agrawal, Amine Hila, Wojciech Blonski, Radu Tutuian, Inder Mainie, Marcelo Vela,
Donald O. Castell
Background: 24 hour multichannel intraluminal impedance and pH (MII-pH) esophageal
monitoring allows detection of both acid and non-acid gastroesophageal reflux (GER) epis-
odes. The MII-pH catheter contains 6 impedance segments placed 3, 5, 7, 9, 15, and 17
cm above the LES, plus a pH electrode at 5 cm allowing detection of cephalad progression
of refluxate. Symptom index (ratio of times the symptom occurs when the pH is less than
4 to the total # symptoms) documents the relationship between patient’s symptoms and
actual reflux episodes during the study. A positive symptom index can define an abnormal
study even with normal esophageal acid exposure or normal number of non-acid reflux
episodes. Aim: To assess symptom index in the upright versus recumbent position for acid
and non-acid reflux using 24 hour MII-pH. Method: 75 consecutive MII-pH studies (49
females; mean age 47 years; range 8 months - 85 years) on PPI therapy (qd or bid) performed
in our laboratory were analyzed. The total number of symptoms reported and positive
symptom index (Positive symptom index with reflux is defined as positive > 50%) was
calculated in the upright and recumbent positions. We analyzed the data for typical GERD
symptoms (heartburn, regurgitation and chest pain) and atypical symptoms (cough and
throat clearing). Results: There were 47 (63%) negative and 28 (37%) positive MII-pH
studies. The total number of symptoms events reported in the 75 MII-pH studies were 1139;
247 (22%) were positive for non-acid reflux and only 34 (3%) positive for acid reflux. 990
(87%) events occurred in the upright position and 149 (13%) in the recumbent position.
Upright symptoms accounted for 33 (97%) positive with acid reflux episodes and 230 (93%)
positive non-acid reflux episodes versus only (p<0.05) 1 (3%) symptom event positive with
acid reflux episode and 17 (7%) symptom events with non-acid reflux episodes in the
recumbent position. Thus, 95% of reflux-positive symptoms occur in the upright position.
Conclusions: Many patients experience symptoms associated with acid and non-acid reflux
despite PPI therapy. Almost all symptoms with either acid or non-acid reflux occur in the
upright position versus the recumbent position.
S1147
Typical and Atypical GERD Symptoms Refactory to PPI Therapy Are Produced
By Different Mechanisms
Inder Mainie, Radu Tutuian, Amine Hila, Amit Agrawal, Wojciech Blonski, Donald O.
Castell
Background: Refluxate with a pH > 4 (‘non-acid’ reflux, NAR) cannot be accurately detected
on standard esophageal pH monitoring. Combined multichannel intraluminal impedance
and pH (MII-pH) detects gastroesophageal reflux (GER) at multiple levels of the esophagus
independent of pH. Aim: To clarify the relationship of typical and atypical GERD symptoms
to reflux episodes (acid and NAR). Methods: All patients with persistent symptoms despite
proton pump inhibitor (PPI) therapy referred to the esophageal laboratory underwent com-
bined MII-pH monitoring. Prior to the study, patients and/or the referring physician were
contacted to ensure the patient had been on at least twice daily PPI for at least a month or
more prior to testing. Upon completion of the manometry a 2.1 mm MII-pH cathteter was
passed transnasally and the esophageal pH sensor was positioned 5cm above the LES. The
configuration of the catheter allowed monitoring changes in intraluminal impedance at 3,
5, 7, 9, 15 and 17cm above the LES. The pH was monitored at 5cm above and 10cm below
the LES. A positive SI (+SI) was declared if ≥ 50% (i.e. at least half of symptoms associated
with reflux). Typical GERD symptoms were heartburn, regurgitation or chest pain. Atypical
symptoms were cough, hoarseness, abdominal discomfort, nausea, dysphagia, throat clearing,
mucous, globus, and wheeze. Results: From a total of 200 patients (Female: 98; mean age
44; range 3 months to 85 years); 172 patients had symptoms during test day; typical GERD
symptoms (n=99), atypical symptoms (n=73). Table shows MII-pH SI for the primary typical
and atypical symptoms (p < 0.01). Conclusion: MII-pH monitoring separates types of reflux
causing symptoms. Typical GERD symptoms on PPI therapy are more likely to be associated
with a positive symptom index, primarily non-acid, whereas atypical symptoms are more
likely to be associated with no reflux.
S1148
Interobserver Variation in the Magnification Endoscopy Findings of Non
Erosive Reflux Disease
Rupa Banerjee, Nalini M. Guda, Santosh Darisetty, Manu Tandan, Sandeep Lakhtakia,
Rajesh Gupta, Venkat G. Rao, Nageshwar D. Reddy
Background: Magnification endoscopy after contrast enhancement with acetic acid or staining
with methylene blue has been able to detect minimal mucosal changes in patients with non
erosive reflux disease (NERD). However the interobserver variability of this new technology
in the assessment of NERD has not been studied. Patients and methods: 10 patients with reflux
symptoms and 10 healthy volunteers with a normal standard endoscopy were prospectively
evaluated. High resolution magnification endoscopy was undertaken and data collected as

















specially on the tops of the folds. The evaluation criteria used followed the published pilot
observations: a) pinpoint/ comma shaped capillaries above the Z line b) punctuate erythema
proximal to the Z line c) increased vascular markings distal to the Z line d) loss of palisade
pattern of blood vessels above Z line e) triangular indentations into squalmo-columnar
mucosa by villiform columnar mucosa and f) islands of squamous epithelium distal to the
Z line. Examples of magnification endoscopic examinations were shown and agreed upon
by 5 experienced endoscopists. The recordings were then evaluated by them in a mixed
and blinded fashion and results obtained as per the criteria above. Levels of agreement were
evaluated and expressed with kappa statistics using the SPSS software. Results: With regard
to the criteria selected for evaluation, pin point blood vessels, loss of palisade pattern of
vessels and triangular indentations of villiform mucosa were seen more frequently in reflux
patients than in healthy controls (p<0.05). Interobserver variability was also low with a
kappa value of 0.71and 0.63 for presence of pinpoint vessels and the villiform triangular
indentations respectively. However the variability was high (all kappa < 0.4) for the presence
of punctuate erythema, increased or decreased vascular markings and presence of islands
of squamous mucosa just distal to the Z line. Conclusion: There are some magnification
endoscopic features seen more frequently in patients with reflux with low interobserver
variability. These criteria may be used as prospective markers for NERD on magnification
endoscopy.
S1149
Correlating Impedance (Imp) Falls from Above to Below 1000 Ohms with
Barium Presence and Amount At the Impedance Site: Findings from
Simultaneous Videoesophagram, Impedance Monitoring, and Manometry
Francisco J. Marrero, Hala Imam, Steven Shay
Videoesophagram is the gold standard for bolus transit evaluation. Imp is a new method
that measures bolus transit. Aim. 1) Correlate Imp falls from above to below 1000 ohms
with barium presence and amount at the Imp site by concurrent videoesophagram. 2)
Compare Imp falls due to failed clearing of a swallowed bolus vs Imp falls between swallows
after successful bolus clearance, e.g., gastroesophageal reflux. Method. 17 normal volunteers
and 63 patients with a variety of esophageal disorders were the study population. A catheter
with both an Imp electrode pair (2.5 cm between the electrodes) and a pressure transducer
at four sites (5,10,15,and 20 cm above LES) was passed per nares. Six 10 cc boluses of 45%
barium mixed with 0.9% NaCl were swallowed at about 20 sec intervals while recumbent. A
timing device accurate to .03 sec displayed a simultaneous signal on the impedance waveform
monitor and the fluoroscopy screen. For each Imp fall from above to below 1000 ohms,
the lowest Imp value (Imp nadir) was determined. This Imp nadir value was correlated with
simultaneous fluoroscopy screen findings. If barium was present, barium area was calculated
in square millimeters (mm2). Results. 38 subjects had 169 Imp falls from above to below
1000 ohms. Mean (SEM) Imp fall was 1107±50 ohms and mean Imp nadir was 565±17
ohms. 97% (164/169) of Imp falls had barium present. There was good correlation (r=.82,
p<.001) between Imp nadir and barium area (see table). The Imp nadir value of 600 ohms
best distinguished minimal and small barium areas from moderate and large barium areas.
Imp values of <400 ohms were nearly always associated with a large barium area. Barium
area and Imp nadir were similar for 85 Imp falls due to noncleared swallowed boluses
compared to 84 Imp falls between swallows after successful bolus clearance. Barium area
and Imp nadir were also similar in the 38 Imp falls in 8 normal subjects compared to 131
Imp falls in 30 symptomatic patients. Conclusions. 1) This study validates that impedance
falls from above to below 1000 ohms denote bolus presence, whether the Imp fall is from
a noncleared swallowed bolus or occurs between swallows. 2) The lowest impedance value
reached during the impedance fall has a good correlation with bolus volume.




Evaluation of Cyp2c19 Genetic Polymorphism On the Accuracy of Proton-
Pump Inhibitor (PPI) Test in the Diagnosis of Gastroesophageal Reflux
Disease (GERD)
Jaw-Town Lin, Yi-Chia Lee, Hsiu-Po Wang, Han-Mo Chiu, Shih-Pei Huang, Ming-Shiang
Wu
Background: Although the PPI test can provide diagnostic value in patients with symptoms
suggestive of GERD, the role of cytochrome (CYP) 2C19 genetic polymorphism and optimal
dosage of PPI are unclear in a population with low prevalence of extensive metabolizers.
Aim: To evaluate whether the CYP2C19 genotype can alter the diagnostic accuracy of
rabeprazole-based PPI testing in a Chinese population. Patients & Methods: Patients pre-
senting with symptoms suggestive of GERD were randomized to receive 20mg or 40mg
rabeprazole after a diagnostic endoscopy. Their symptom responses were assessed with a
daily, five-graded scale during a two-week treatment. The PPI test was considered positive
if the symptom score improved more that 50% from the first baseline score after treatment.
DNA from peripheral blood leukocytes were was genotyped with PCR-RFLP technique with
allele-specific primers. Results: Of the 97 patients (56 female, 41 male; mean age: 49.1 yrs;
range: 83-25 yrs.) who completed the study, 50 (51.6%) were classified as erosive and 47
(48.4%) as non-erosive. Their demographics and outcomes are tabulated and stratified. The
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20mg testing provided a sensitivity of 73.1% and a specificity of 66.7%, which were similar
with those of the 40mg testing (85.7% and 73.1%, respectively). In a multiple logistic
regression with GERD diagnosis as a dependent variable, the presence of variant CYP2C19
alleles did not show any significant effect (P=0.28). Conclusions: Both PPI regimens were
sensitive and specific for diagnosing GERD and the accuracies were unrelated to the CYP2C19
genotypic status.
S1151
Minimal Change Esophagitis Symptomatically Resembles Functional
Dyspepsia, But Is Pathophysiologically Similar to GERD
Yasuyuki Shimoyama, Motoyasu Kusano, Osamu Kawamura, Shiko Kuribayashi, Masaki
Maeda, Atsuto Nagoshi, Hiroaki Zai, Tatsuya Higuchi, Fumitaka Moki, Tsutomu
Horikoshi, Munetoshi Toki, Masatomo Mori
BACKGROUND AND AIMS: Minimal change (MC) esophagitis is endoscopically character-
ized by prominent erythema that does not show clear demarcation from whitish cloudiness
of the lower esophageal mucosa obscuring the longitudinal blood vessels. These findings
do not fit the criteria for mucosal breaks in the Los Angeles classification (LA) of esophagitis.
We characterized the symptoms and pathophysiology of patients with MC esophagitis.
SUBJECTS AND METHODS. The subjects were 347 patients who attended the Gastroenterol-
ogy Outpatient Department of Gunma University Hospital. All patients underwent upper
GI endoscopy to rule out organic disorders. The diagnosis was as follows: 39 patients with
MC esophagitis, 85 with GERD (LA ≧ grade A), 195 with functional dyspepsia (FD) who
had no abnormalities apart from endoscopic gastritis, and 28 with other conditions. A 50-
item questionnaire requiring only “yes” or “no” answers was completed before endoscopic
examination, which consisted of 10 questions relating to reflux-like symptoms, 12 to dysmot-
ility-like symptoms, six to ulcer-like symptoms, and 11 to psychosomatic symptoms. The
chi-square test was used to compare the percentage of positive replies to each question
among the patients with MC esophagitis, GERD, and FD. We performed 24-hour pH
monitoring (μDigitrapper, Sweden) at 5 cm above the LES in 7 patients with MC esophagitis,
14 patients with GERD, and 7 normal controls (C). RESULTS. An affirmative answer to
the questions about “nausea” and “heavy stomach” was given in the order of FD>MC
esophagitis>GERD. There was a significant (p<0.05) differences between FD and MC esophag-
itis, and between MC esophagitis and GERD. “Heartburn” and “regurgitation” were signific-
antly more common in GERD patients than in MC or FD patients. “Fatigue” and “anxiety”
were significantly more common in FD patients than in those with GERD, but not than in
those with MC esophagitis. By pH monitoring, the total number of GER episodes in MC
patients (61.9 ± 16.4/24 hour, mean ± SE) was significantly greater than in the C group
(11.7 ± 4.6), and was similar to that in LA grade A+B (79.0 ± 23.2). The % time at pH<4
for MC esophagitis patients (3.8 ± 1.1) was significantly larger than that in the C group
(0.53 ± 0.27), while it was similar to that in the LA A+B group (3.3 ± 1.2), and smaller
than that in LA grades C (15.9 ± 4.3) and D (58.4 ± 10.5). CONCLUSIONS: Patients with
MC esophagitis can be pathophysiologically classified as GERD. Therefore, proton pump
inhibitors should be administered as the initial treatment, although the symptoms of MC
patients mimic those of patients with functional dyspepsia.
S1152
Association Between Non Acid Reflux and Symptoms. Multicenter Ambulatory
24-Hour pH-Impedance Study in 150 Patients Off and On Proton Pump
Inhibitors (PPI) Therapy
Frank Zerbib, Sabine Roman, Alain Ropert, Stanislas Bruley des Varannes, Philippe
Pouderoux, Ulriikka Chaput, Francois Mion, Jean Paul Galmiche, Daniel Sifrim
Combined ambulatory pH-impedance studies allow detection of both acid and non acid
gastro-esophageal reflux (GER). However, the clinical relevance of nonacid reflux remains
to be determined in clinical practice. The aim of this study was to evaluate the diagnostic
yield of this technique in patients with suspected GER symptoms on and off PPI therapy.
Patients and methods. Patients from 7 academic centers with symptoms possibly related to
GERD have been included in this retrospective study. Reflux events were detected visually
using impedance (Sandhill, CO, USA) and then characterized by pHmetry as acid (AR), or
nonacid (NAR) reflux, i.e. weakly acidic, or weakly alkaline (Gut 2004;53:1024-31). A
symptom index (SI) ≥ 50% was considered indicative of a positive association. Results. A
total of 150 patients was included, 103 females (mean age 52±14 years, range 16-84). In
the group of patients off PPI (n=79, 57 females, mean age 53±12 years), 4 had no symptoms
during the study, SI was ≥ 50% in 44 (58.7%), for AR in 25 (33.3%), for NAR in 9
(12.0%), and for both 10 (13.3%). The most frequently associated symptoms with GER
were regurgitation (n=15 patients for AR, n=4 for NAR), heartburn (n=10 for AR, n= 3 for
NAR) and cough (n= 8 for AR, n= 3 for NAR). In the group of patients on PPI (n= 71, 46
females, mean age 51±15 years), 10 had no symptoms during the study, SI was ≥ 50% in
26 (42.6%), for AR in 3 (4.9%), for NAR in 20 (32.7%), and for both 3 (4.9%). The most
frequently associated symptoms with GER were regurgitation (n=4 for AR, n= 13 for NAR),
heartburn (n=1 for AR, n= 5 for NAR) and cough (n= 8 for AR, n= 3 for NAR). Conclusion.
By the means of 24-hour pH-impedance studies, NAR can be associated with symptoms
(mainly regurgitation and heartburn) in 25% and 38% of patients off and on PPI respectively.
S1153
The Relevance of Duodenogastroesophageal Reflux and Its Diagnosis
Ulrich Muller, Patrick Darb-Esfahani, Thomas Fiedler, Sarah Johanssen, Daniel Kottler,
Heike Muller, Herbert Lochs, Winfried A. Voderholzer
Introduction: Duodenogastroesophageal reflux (DGER) is a common finding in patients
suffering from gastroesophageal reflux (GER) symptoms and has been accused to be an
important factor in the pathogenesis of Barrett’s esophagus. However, data on large samples
are rare. Aim: To elucidate whether or not DGER results in specific symptoms or Barrett`s
esophagus. Methods: We conducted a retrospective analysis of patients undergoing semiquan-
titative esophageal 24h-bilirubin measurement (Bilitec™) for evaluation of GERD between
2000 and 2005. All patients were evaluated by a standardized reflux symptom questionnaire
(which included heartburn, regurgitation, dysphagia, odynophagia, nausea, vomiting, cough,
asthma, sore throat, thoracic pain, problems with nose and ears, abdominal pain, and other
problems) and underwent esophageal manometry, 24hour pH-metry (partially double probe
measuring), and esophagogastroduodenoscopy (EGD). Pathologic DGER was defined as the
percentage time with bilirubin absorption > 0.2 exceeding 10.7%. Results: We included
217 patients (54.4±12.9 years; 95 female, 139 male). Sixty-three of them had isolated acid
reflux, 20 isolated biliary reflux, 70 combined reflux, and 64 had no reflux at all. There
was no significant difference between patients in each group with regard to the development
of erosive esophagitis (ERD)or Barrett`s esophagus. In 42% of patients a pathologic DGER
was found (mean DGER 31.0±17.6 %). On EGD, DGER positive and negative patients did
not differ with respect to ERD (37.8% of all patients with DGER vs. 26.5% without, p=
0.056) nor with respect to short segment Barrett (10.9% with DGER vs. 9.8 % without
DGER, p=0.68) or long segment Barrett (13.9% with DGER vs. 8.3% without DGER, p=
0.13). As expected, patients with ERD (n=122) had a significantly higher DeMeester Score
than patients without esophageal erosions (65.3±60.0 for ERD vs. 30.6±36.7 for NERD, p=
0.0001). However, ERD-patients suffered from significantly more DGER than NERD-patients
(17.6±18.4% for ERD vs. 10.1±15.5% for NERD, p=0.004). DGER correlated with distal
esophageal acid exposure time (r=0.432;p<0.0001) but not with proximal reflux (r=0.206;p=
0.07 Spearman-rho test). Symptom evaluation did not find any association of DGER with
reflux symptoms. Conclusions: Our data confirm the positive correlation of DGER with acid
GER. Although DGER can be found in almost half of the patients with reflux symptoms
there is no symptom indicative of DGER. Our study does not support the hypothesis that
DGER is a relevant factor in the development of Barrett`s esophagus.
S1155
Esophageal Manometry Findings in Patients with GERD-Like Symptoms
Unresponsive to Proton Pump Inhibitors Obtained By 24-Hour pH and
Motility Recordings
Susan N. Ramdhaney, Venkat Pavan R. Kancharla, Manojkumar Singh, Vijaya Boyella,
Yatin Zhang, Hulya Levendoglu
Many patients (pts) with GERD-like symptoms have neither significant acid reflux nor
respond to proton pump inhibitor (PPI) treatment. The cause of these symptoms is not
known. We performed 24-hour esophageal manometry and pH testing in a total of 247 pts
with GERD-like symptoms unresponsive to PPIs (176 female, 81 male), age ranging from
21 to 96 years, to evaluate if changes in motility and pH parameters may explain these
symptoms. Testing was performed with specially designed manometry and pH probes after
the location of LES was established by a stationary manometry. Composite acid and alkaline
reflux scores were calculated. We found in the 52 pts with no reflux (A), 69 pts with
increased acid reflux (B), 20 pts with both increased acid and alkaline reflux (C) and 106
pts with increased alkaline reflux (D) that baseline mean gastric pH was appropriately high
in D>C>A>B and overall 24hr wave activity was higher in A>B>C>D. Contribution of
peristaltic activity to overall esophageal contractions was decreased to <66 percent in all
groups (no significant difference) and the % of simultaneous and isolated waves correspond-
ingly increased in all groups. However, C and D pts had significantly increased simultaneous
waves in the distal 13cm of esophagus compared to B (p=0.006, p=0.06) and A (p=0.04,
p=0.02) respectively. In addition, isolated contractions in the distal esophagus were increased
in D pts (p=0.08) and the % repetitive contractions were increased in the distal esophagus
in C and D pts (p=0.04, p=0.02) when compared to A. Although B pts had increased
repetitive waves more than A pts, this was not significant (p=0.08). In addition median
amplitude of waves in the distal esophagus in D pts was significantly increased compared
to A (p=0.009) and B (p=0.008) and the duration of waves also was somewhat prolonged.
Based on these findings, we may conclude that GERD pts unresponsive to PPIs are a
heterogenous group of pts having no reflux, acid, alkaline or combined acid and alkaline
reflux. Irrespective of reflux scores all patients have decreased primary peristalsis and
increased simultaneous and isolated contractions. Overall, total esophageal contractions were
significantly decreased in alkaline reflux patients when compared to normal. In addition,
patients with alkaline reflux or combined reflux show more disturbed motility in the distal
esophagus regarding the increased repetitive waves and the amplitude of contractions.
Therefore, in GERD patients unresponsive to PPIs, symptoms are most likely related to
motility abnormalities rather than the presence or absence of acid or alkaline reflux or both.
S1156
Ambulatory Esophageal Impedance-pH Monitoring in GERD Suspected
Patients: A Visual Analysis of Recording Segments Preceding the Occurrence
of Symptoms Is Needed
Sabine Roman, Stanislas Bruley des Varannes, Philippe Pouderoux, Ulriikka Chaput,
Francois Mion, Jean-Paul Galmiche, Frank Zerbib
Esophageal impedance-pH monitoring allows the detection of acid and non acid reflux.
Direct visual analysis of impedance recordings is however time consuming and represents
the main limitation to the diffusion of this technique. The aim of this tudy was to compare
“visual” results with those provided by the automatic analysis (autoscan) of the BioviewR
software (Sandhill, CO, USA) for the diagnosis of GERD. Subjects and methods. 73 suspected
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GERD patients (52 females, mean age 50.4 years, range 16-84) underwent ambulatory 24-
hour esophageal impedance-pH monitoring in 5 academic centers. Reflux episodes were
detected and characterized as acidic (pH<4), weakly acidic (4 ≤ pH < 6.5) and weakly
alkaline (pH ≥ 6.5) (Gut 2004;53:1024-31). Each recording was analysed twice i.e. visual
analysis (V) using the BioviewR software system and automatic analysis using the autoscan
(AS) function of that software. Symptoms were considered as associated with acid or non
acid reflux provided that the symptom index (SI) was ≥ 50%. Results were expressed as
median and compared using the Wilcoxon test. Agreement between both analyses was
evaluated with Kendall’s coefficient (W). Results. Autoscan analysis detected more reflux
episodes than visual analysis (50 vs 44, p<0.001). Weakly acidic (13 vs 9, p<0.001), weakly
alkaline (3 vs 2, p=0.011), liquid (19 vs 15, p=0.049), pure gas (14 vs 7 p<0.001) and
proximal reflux events (20 vs 9, p<0.001) were also significantly more often detected by
AS analysis. Agreement between V and AS analysis was good (p<0.01) for all parameters (W
> 0.72). During impedance-pH monitoring, 65/73 patients reported symptoms. Agreement
between V and AS analysis to detect a positive symptom-reflux association was good in 48
patients (73.8%). In the 17 remaining patients, AS analysis over estimated SI in 11 cases
(64.7%). Conclusion. Despite good agreement with visual analysis, automatic analysis over-
estimates the occurrence of reflux episodes, especially weakly acidic, pure gas and the
proximal extension of reflux episodes. Automatic analysis allows a correct assessment of
symptom-reflux association in 75% of GERD suspected patients. Visual analysis of recording
periods that precede marker event activation is mandatory to avoid overestimation of symp-
tom index.
S1157
Clinical Impact of Esophageal Impedance-pH Measurement in Children -
Results from the German Pediatric Impedance Group (G-PIG)
Tobias G. Wenzl, Denisa Pilic, Thorsten Frohlich, Ulf Pfeifer, Michael Welter, Henrik
Kohler, Anjona Schmidt-Choudhury, Heino Skopnik
Gastroesophageal reflux (GER) is frequent in children. Pathology arises from associated
symptoms, e.g. dysphagia and esophagitis, but also extraesophageal symptoms such as
chronic cough, bronchitis and apnea. The old diagnostic standard, pH monitoring, can only
detect acidic (pH < 4) episodes. Non-acidic GER and laryngopharyngeal reflux (LPR) is
concealed. In 2005 the German Pediatric Impedance Group (G-PIG) was formed to standard-
ize and further advance the use of intraluminal impedance (IMP) combined with pH measure-
ments in children. Methods: All four G-PIG centers perform combined 24-hour esophageal
impedance-pH measurements in children presenting with symptoms suggestive of reflux
and an indication for a long-term reflux study. We use a single catheter with 6 impedance
channels and 1 distal pH sensor, with the impedance channels spanning from the pharynx
to the distal esophagus. Data is recorded with a portable device (Sleuth, Sandhill Scientific,
USA). Results: So far, combined routine studies were performed in 201 children (median
age 3.5 years, range 0-16 years). Patient age varied remarkably depending on the presenting
symptoms: gastrointestinal symptoms, n = 89, median age 6.5 (range 0-16 years); pulmonary
symptoms, n = 93, median age 2.3 (range 0-15 years); neurological symptoms, n = 19,
median age 1,1 (range 0-8 years). In 152 patients (75%) pH-data showed normal findings.
However, in 92 patients with non-acidic GER/LPR documented by IMP an association with
the individual symptoms could be demonstrated. Conclusions: This is the largest pediatric
series and represents first data on the collaborative use of multiple intraesophageal impedance-
pH measurements in clinical routine in children. Overall, combined studies have significant
clinical impact in all participating centers. They improve the detection of reflux and symptom
association, and allow specific assignment of treatment options . The role of extraesophageal
reflux symptoms is being increasingly recognized, especially in infants and young children.
With a portable recording device the combined measurement of pH and impedance will
replace isolated pH monitoring and become the new standard for complete GER / LPR
detection. Normative data and validated automated analysis are the most important tasks
for the near future.
S1158
Effects of Test Meal On Multi-Channel Electrogastrography and Autonomic
Nervous System Function in Patients with Gastroesophageal Reflux Diseases
Xiaohong Xu, Zhaolu Ding, Zhifeng Wang, Xiaoyan Chen, Meiyun Ke
Most previous studies applied single channel electrogastrography in patients with gastroeso-
phageal reflux diseases(GERD) and spatial information of gastric myoelectrical activity was
missing in those studies. The aims of this study were to utilize multi-channel electrogastrogra-
phy(MEGG) and power spectra analysis of Heart Rate Variability(HRV) to investigate the
responses of gastric myoelectrical activity and autonomic nervous system(ANS) to test meal
in patients with GERD and study whether there is any correlation between MEGG parameters
and ANS parameters in patients with GERD. Methods: 16 patients with the diagnosis of
GERD were enrolled in this study (11M, 5F, mean age: 47yrs) and 16 healthy subjects (HS)
matched for age and gender were recruited as control (11M, 5F, mean age: 47yrs). MEGG
was recorded simultaneously with the electrocardiogram (ECG) recording for 30 min in the
fasting state and 60 min after a standard test meal (450Kcal). MEGG parameters included
dominant frequency (DF), dominant power (DP), the normal percentage of 2-4cpm gastric
slow waves (%N) and the percentage of slow wave coupling (%SWC). ANS was determined
according to the parameters of power spectra analysis of HRV which was derived from the
ECG recording and the parameters included sympathovagal balance LF/HF Ratio, mainly
sympathetic activity LF and vagal activity HF. Results: 1)Compared with fasting state, test
meal significantly increased the DF but decreased the %N and %SWC in both GERD patients
and HS in the 1st 30min and 2nd 30min fed state(P<0.05),DP was not significantly altered
by test meal in both groups in fed state. However, there is no significant difference between
1st 30min and 2nd 30min fed state for DF, %N and %SWC. 2) Compared with fasting
state, test meal significantly increased the LF/HF ratio and LF but decreased the HF in both
groups in the 1st 30min after meal (P<0.05); however, the increase of LF/HF ratio and LF
but decrease of HF were still present in HS whereas absent in patients with GERD in the
2nd 30min fed state. There is no significant difference between 1st 30min and 2nd 30min

















patients and HS in any of those MEGG and ANS parameters neither in fasting nor in fed
state. 4) There was no significant correlation between MEGG parameters and ANS parameters
neither in fasting nor in fed state in both groups. Conclusions: Both patients with GERD
and HS may have similar response to test meal in MEGG test. GERD patients could not
maintain the response to test meal longer in ANS test suggests GERD patients may have
impaired ANS regulation to test meal.
S1159
Multichannel Intraluminal Esophageal Impedance Predicts Early Persistent
Symptoms Following Fundoplication
Matthew Shane, Julia P. Shane, Morgenthal B. Craig, C Dan Smith, Edward Lin, Vickie
Swafford, Leena Khaitan
Background: Esophagogastric fundoplication (EGF) is now considered the procedure of
choice in the surgical management of patients suffering from gastroesophageal reflux disease
(GERD). Up to 20% of patients will have worsening of their symptoms after surgical therapy,
yet preoperative manometric findings alone are not predictive of poor symptomatic outcomes.
Combined multichannel intraluminal impedance and esophageal manometry (MII-EM) is a
technique that allows simultaneous evaluation of esophageal bolus transit in relation to
manometric changes. This study evaluates the use of preoperative MII-EM in predicting
which patients will have persistent symptoms following EGF. Methods: From 12/02 - 11/
05, all patients referred for reflux disease who did not have outside manometry underwent
MII-EM. Reflux symptoms were scored pre-operatively and post-operatively using a standard
questionnaire that has been used in our institution for over 12 years. Data was analyzed
using an ordered probit logistical model using STATA- 9 statistical software (Stata Corpora-
tion, College Station, Texas). Results: We retrospectively identified 71 patients who had
undergone MII-EM at our institution prior to fundoplication. Of those, 55 (77%) had both
pre-operative and post-operative symptom score data available for review, with a mean
follow-up of 3 months. Though fundoplication was associated with a significant overall
improvement in symptom scores (p < 0.001), 9 patients (16%) had either no effect or
worsening of their total symptom scores. Manometry alone was not a statistically significantly
factor in determining outcome (t= -0.88). However, abnormal MII was found to be an
independent, statistically significant factor in determining worsening post-operative symp-
toms (t = 1.86). The predicted probability of having undesirable post-op symptoms is
strongest when both the impedance and manometry demonstrate abnormal findings
(60.64%). Conclusion: Esophageal manometry is an independently significant factor in
predicting persistent postoperative symptoms. Combined MII-EM is able to predict which
patients will have persistent symptoms in the early postoperative period following EGF.
Further investigation is needed to determine its value in predicting long- term results
after fundoplication.
S1160
Accuracy of a Comprehensive Histopathological Score for the Diagnosis of
Patients with Gastroesophageal Reflux Disease
Sharad Mathur, Ajay Bansal, Srinivas R. Puli, Amit Rastogi, Prateek Sharma
Background: The role of histology in the diagnosis of GERD remains controversial, in part
due to the conflicting results in recent publications after the initial promising studies. Besides
the evaluation of traditional features such as basal cell hyperplasia and papillary elongation,
recently, evaluation of dilated intercellular spaces (DIS) has also been proposed to be a
marker for GERD. Aim: To compare the accuracy of a comprehensive histopathological
score in patients with GERD (both erosive esophagitis- EE and non erosive reflux disease-
NERD) and control subjects. Methods: Subjects with and without GERD symptoms as
documented by 2 validated GERD questionnaires (GERQ and RDQ) were enrolled in the
study. Upper endoscopy was then performed and the distal esophagus was carefully examined
for the presence of erosive esophagitis. Two biopsies were obtained from the distal esophagus,
1 cm above the normal SCJ and in case of patients with EE, away from the areas of erosions.
All biopsies were stained with H&E and were evaluated by a single blinded pathologist for
basal cell hyperplasia, length of papillae, DIS, eosinophils, neutrophils and necrosis and an
overall histopathological score was calculated (range: 0-12). The scores between EE/NERD
group and controls were compared by an unpaired t test. Sensitivities and specificities of
this score were calculated by plotting ROC curves. Results: A total of 72 subjects were
enrolled in the study- 36 GERD patients (23 EE, 13 NERD) and 36 controls. The mean age
was 60 yrs and included 67 males. The mean histologic scores (including all the above
mentioned parameters) were as follows: EE patients: 5.4±2.3 (p=0.009 vs. controls), NERD
patients: 6.5±1.8 (p=0.0002 vs. controls) and controls: 3.9±1.9. Based on ROC curves, in
the NERD group, a cutoff score of 5.3 gave a sensitivity of 75% and specificity of 87% for
the diagnosis whereas in the EE group, a cutoff value of 4.5 had a sensitivity of 74% and
specificity of 70% for the diagnosis. Conclusion: Using a comprehensive histopathological
scoring system based on a combination of multiple histological findings, GERD patients
(NERD and EE) can be accurately discriminated from non-GERD subjects. The objectivity
of this score may prove to be a useful tool in clinical practice and research studies to further
improve the diagnosis of GERD.
S1161
Esophageal and Intragastric pH Monitoring Using a Wireless System (BRAVO)
to Evaluate Esophageal Acid Exposure and Gastric Acid Secretion
Ayaka Seza, Takeo Odaka, Michiko Kobayashi, Taketo Yamaguchi, Syunn Genn, Takuto
Suzuki, Hiromitsu Saisho
Background Recently, a new catheter-free pH monitoring system (Bravo) has become avail-
able. However, only a few reports on normal values for esophageal exposure using wireless
system have been seen. The aims of this study were to establish the cut off level for the
diagnosis of GERD patients, to discriminate the patients with reflux from those with non-
erosive reflux disease (NERD) and to examine the differences in gastric acid secretion between
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with and without reflux. Methods Fifteen patients with non-erosive reflux disease and fifteen
healthy volunteers underwent 48-hr esophageal and gastric pH monitoring using the Bravo
system. Two pH capsules were positioned under direct endoscopic visualization. One was
positioned at 5cm above the squamocolumner junction, and the other at the posterior wall
of lower gastric body. The signals from both capsules were recorded by separate receivers
synchronized for time and pH data was analyzed in Excel spreadsheets. We used % time
pH<3, % time pH<3.5, % time pH<4, % time pH<4.5 to assess esophageal acid exposure
and mean gastric pH to assess intragastric acidity. Results The cut-off level (mean+2SD) for
the diagnosis of GERD as calculated from the esophageal pH of controls were as follows:
1.49% for % time pH<3, 2.30 % for % time pH<3.5, 3.44 % for % time pH<4, 7.89 % for
% time pH<4.5. The cut-off levels for the diagnosis of GERD were lower than those previously
reported. In all parameters, the detection rates of the patients with reflux to those with
NERD were 53.3 % (8/15). The mean gastric pH did not differ between NERD patients
with and without reflux or between them and controls. Conclusions Normal values for
esophageal acid exposure were lower with the Bravo wireless system than with conventional
catheter pH system in healthy volunteers. The detection rates of the patients with reflux
from those with non-erosive gastritis disease using the Bravo wireless system were higher
than those by conventional methods. Intragastric acidity did not differ between NERD
patients with and without reflux or between them and controls.
S1162
Use of BRAVO Wireless pH Monitoring Placed in the Columnar Segment of
Barrett’s Esophagus to Assess Antisecretory Therapy
Jorge Uribe, Marianna Dejongh, Matthew Gideon, Philip O. Katz
INTRODUCTION: Normalization of esophageal acid acid exposure is felt by many to be
desirable in patients with Barrett’s esophagus(BE). Documentation of esophageal acid control
with catheter-based pH monitoring is limited to a 24 hour period and may not be reflective
of consistency of control of intraesophageal pH day to day. The electrode is placed 5 cm
above the lower esophageal sphincter which may not accurately reflect acid exposure in the
most distal columnar segment in patients with BE. BRAVO capsule allows for 48-hour
monitoring, provides a better estimate of normal daily activities and most importantly, can
be placed closer to the gastroesophageal junction, providing information on esophageal acid
exposure in the distal esophagus. The reliability of BRAVO pH recordings placed in the
columnar segment in BE while on antisecretory therapy is unknown. AIM: Determine if the
BRAVO capsule will provide reliable information on esophageal acid exposure when placed
in the columnar epithelium, and to assess variability in esophageal acid exposure over 2
days in esophageal pH on esomeprazole 40 mg twice daily in patients with BE. METHODS:
Data was prospectively collected on patients with known BE of at least 2cm. Bravo capsule
was placed one cm above the top of the gastric folds in columnar mucosa during scheduled
surveillance upper endoscopy. All patients were on antisecretory therapy with esomeprazole
40 mg BID for at least 7 days prior. Studies reviewed for number of hours of recorded data
and time esophageal pH<4 (normal <4.2% total) Analysis was performed as normal vs.
abnormal acid exposure on days 1 and 2 separately, both days combined and for worst day
when only one day was abnormal. RESULTS: 25 studies were performed, of which only
one provided less than 48 hours of data (damaged external recorder due to patient non
compliance), 24 studies analyzed for pH control (table) No statistically significant differences
(Fisher exact test) between different analytic methods. CONCLUSIONS:1)The BRAVO cap-
sule records consistent and reliable data when placed 1 cm above the top of the gastric
folds in the columnar segment of patients with Barrett’s 2)Esomeprazole 40 mg BID resulted
in consistent acid control over 2 days using normal/abnormal as endpoint 3)While more
data are required 24 hours of pH monitoring may be sufficient to determine the adequacy
of esophageal acid control in Barrett’s patients on high dose antisecretory therapy. This
study was supported by a grant from ISS program of Astra Zeneca.
S1163
Lower Esophageal Recording of Acid Exposure Better Explains Symptoms in
Patients with Non-Erosive Reflux Disease
Ram Dickman, Jimmy M. Bautista, Wai-Man Wong, Rajan Bhatt, Joy N. Beeler, Isaac B.
Malagon, Sara Risner-Adler, Ronnie Fass
Background: Patients with non-erosive reflux disease (NERD) demonstrate the lowest eso-
phageal acid exposure profile and percent symptoms associated reflux as compared to the
other gastroesophageal reflux disease (GERD) groups. Aim: To determine if lower esophageal
acid exposure recordings at 1 cm >lower esophageal sphincter (LES) is greater and better
explaining symptoms in NERD patients than recording at 6 cm >LES as compared to the
other GERD groups. Methods: Consecutive patients with classic heartburn symptoms were
enrolled into the study. Patients were evaluated by a demographics questionnaire and the
validated GERD Symptom Checklist. Upper endoscopy was performed to evaluate the
presence of esophageal erosions and Barrett’s esophagus. Ambulatory pH testing was per-
formed using a commercially available 4-sensor pH probe located 5cm apart. The distal
sensor was placed 1 cm above the lower esophageal sphincter. Results: A total of 64 patients
completed the study. Of those, 21 patients had non-erosive reflux disease (55.7 ± 15 yrs,
M/F 16/5), 20 erosive esophagitis (52.1 ± 12 yrs, M/F 14/6) and 23 Barrett’s esophagus
(64.0 ± 14 yrs, M/F 18/5). All patient groups demonstrated a significant increase in mean
% total time pH <4 (NERD - 10.4 ± 1.4 vs. 7.9 ± 1.1, EE - 15.4 ± 3.0 vs. 11.7 ± 2.5 and
BE - 26.0 ± 2.9 vs. 17.3 ± 2.4, p = 0.009) and mean % upright time pH <4 (NERD 15.4
± 2.0 vs. 11.4 ± 4.9, EE - 19.5 ± 4.2 vs. 13.1 ± 2.7 and BE - 23.9 ± 2.9 vs. 15.8 ± 2.2,
p = 0.016) at the 1 cm >LES versus 6 cm >LES sensor. Mean % supine time pH <4 was
significantly increased only in BE patients (29.2 ± 4.3 vs. 19.3 ± 3.4, p <0.001) at the 1
cm >LES versus 6 cm >LES sensor. There was a twofold increase in the number of NERD
patients with a positive symptoms associated reflux and only NERD patients demonstrated
a significant increase in the % symptoms associated reflux from 6 cm to 1 cm >LES (NERD -
50 ± 14 vs. 75 ± 16, p = 0.01, EE 84 ± 7.9 vs. 94 ± 4.1, p = NS, BE - 64 ± 10 vs. 68 ±
10, p = NS). Conclusions: All GERD groups demonstrated a significant increase in esophageal
acid exposure at the lower pH sensor (1 cm >LES), primarily due to short upright reflux
events. Only in NERD patients the lower pH measurements explained better GERD-
related symptoms.
S1164
Multichannel Intraluminal Impedance (MII-pH) for the Evaluation of
Heartburn in Subjects Both On and Off PPI Therapy
Ellen Stein, Sharmila Anandasabapathy, Barry W. Jaffin
BACKGROUND: Patients with persistent heartburn symptoms on maximal doses of PPI
(proton pump inhibitor) therapy are a therapeutic and diagnostic challenge. Through better
characterization of reflux composition and patterns in these individuals, MII-pH may better
guide therapy. We used 24 hour MII-pH in symptomatic individuals both on and off PPI
therapy to determine what reflux characteristics are associated with heartburn episodes.
METHODS: Subjects with frequent, daily symptoms of heartburn both OFF (n=23) and ON
(n=20) twice-daily PPI therapy underwent 24-hr MII-pH study. In all individuals, upper
endoscopies revealed no Barrett’s or esophagitis, and manometries revealed no functional
abnormalities. Symptom indices (SI)were calculated in all patients. Patients with positive SI
both OFF(n=13) and ON(n=5)PPI therapy were further evaluated to determine which reflux
characteristics were associated with heartburn sensation. RESULTS: Subjects both OFF and
ON therapy were well matched in terms of age, study duration, and bolus clearance time.
Both mean % acid exposure and total number of reflux events were lower in subjects ON
PPI therapy (Table 1). Among patients with a positive SI, 59% had heartburn symptoms
related to acid reflux. Full column reflux was more likely to occur in subjects OFF PPI therapy
and was a significant predictor of heartburn sensation. (P value=0.015) CONCLUSION: In
individuals with chronic, daily heartburn, reflux-symptom correlation was higher in indi-
viduals OFF PPI therapy and was associated with both acidity and height of refluxate. In
patients ON PPI therapy, overall acid exposure was low and the total number of reflux
events was markedly reduced. Although a majority of patients with a positive SI had symptoms
associated with acid reflux,approximately 41% of individuals has a positive non-acid SI and
all these subjects were on PPI therapy. In this subset of patients, escalating PPI dosage may
be ineffective and alternate therapies need to be considered.
Table 1: Mean Characteristics in Subjects OFF and ON PPI therapy
S1165
Prolonged Wireless pH-Metry in Community Practice: Does the Longer
Sampling Time Improve the Yield of pH Testing?
Saeid Goshtasbi, Nimish Vakil, David Carron, Michael Molloy, Steven Lipscomb
Introduction: It has been suggested that wireless pH metry improves the yield of pH testing
by prolonging the sampling duration but the available studies are small in size and are from
expert centers. The aim of this study was to determine if the yield of pH testing was increased
by a 48 hour sampling period in 135 consecutive patients in a community setting. Methods:
(Mean+SEM; comparisons by Wilcoxon test). The records of 135 consecutive patients who
underwent wireless pH-metry (Bravo, Medtronics) between 2003 and 2006 were analyzed
using a pre-determined data abstraction tool. Results: The principal indications were non-
cardiac chest pain=(n=18), atypical ENT presentations (n=28) and symptoms refractory to
PPI therapy (n=37). 116 of 135 (86%) patients had received a trial of PPI therapy before
pH metry and 55 (41%)had received double dose PPI therapy. The wireless capsule failed
to attach in 2 cases (1.5%). This was recognized endoscopically and a second capsule was
successfully attached in both cases. Day 1 recordings were obtained in all 135 patients and
day 2 recordings were obtained in 134 patients. Receiver error resulted in incomplete
recordings in 1 patient (1%) in whom day 2 data were lost. The mean number of reflux
episodes on day 1 was 37+4 and on day 2 (median 27, IQR=35) was 35+4 (median 21,
IQR=46; p=0.025). The total time pH was < 4 was 54+9 min (median=21, IQR=55) on day
1 and 52+10 (median=21, IQR=58; p=0.07) on day 2 and the fraction of time pH was <4
on day 1 was 3.9+0.6% (median=1.5, IQR=4) on day 1 and 4.2+0.8 (median=1.6, IQR=
3.8) on day 2 (p=0.39). Assuming a normal acid exposure of 4.4% (Scand J Gastroenterol.
2005 Jul;40(7):768-74), 48 patients (35%) had an abnormal recording (either day 1 or day
2, or both days). 28 patients had an abnormal recording on only one of the days (day 1=
17/28 (61%), day 2 11/28 (39%)). Most procedures were performed in the morning.
Conclusions: 1. In routine US practice, wireless pH-metry is generally performed in patients
who have failed acid suppressive therapy. Normal values for this population are lacking and
are an important need. 2. Distal acid exposure is not greater on day 2 as has been claimed
in some smaller studies. 3. Many patients are diagnosed by abnormalities on only one of
the study days suggesting that the longer sampling time improves the yield with wireless
pH-metry.
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S1166
Reproducibility of pH Profiles in 48hour Wire Free Capsule Esophageal pH
Monitoring
Joanna Gray, Aileen Sutherland, Grant M. Fullarton
The wire-free capsule (WFC) is a recognised alternative to conventional wire-based catheter
systems in esophageal pH monitoring. Although WFC has improved patient acceptability
in terms of comfort, the benefit and reproducibility of a 48hr recording period remains
unclear. In addition,the presence of an esophageal implant may affect oesophageal motility
which could alter pH profiles over a prolonged period. The aim of this study was to assess
the reproducibility of esophageal pH profiles on day 1 and day 2 of WFC esophageal pH
monitoring. Methods 48 patients undergoing WFC esophageal pH monitoring as part of
their GERD assessment were studied. The WFC (BRAVO, Medtronic) were all secured by
a single endoscopist under sedation with propofol. The WFC was secured 6 cm above the
endoscopically identified squamocolumnar junction. For each patient 48hr esophageal pH
profiles were recorded and the parameters assessed were: percentage of total time esophageal
pH < 4, number of long refluxes and the duration of long refluxes for day 1 and 2. Results
All patients had successful endoscopic placement of the WFC with only 2/48 patients having
dislodgement of their electrode prior to completion of the recording period. The percentage
of total time esophageal pH<4 was 5.5 (0.1-41.5)(median, range) on day 1 and 5.1 (0-43)
on day 2. Rank correlation coefficient R=0.7(p<0.001)(Figure). The number of long refluxes
on day one was 3 (0-9) and 3 (0-21) on day2 (R=0.7,p<0.003).The duration(sec) of these
refluxes was 12(0-115) on day 1 and 12(0-250)on day 2 (R=0.6,p<0.002). Conclusions
Esophageal pH profiles demonstrate close correlation between day 1 and 2 of the 48hr
recording period with the WFC system. This suggests that the WFC system does not induce
capsule related reflux changes, at least during the initial 48hr recording period.
S1167
Magnification Endoscopy Changes of Minimal Change Esophagitis: Effect of
Rabeprazole Therapy
Rupa Banerjee, Manu Tandan, Rajesh Gupta, Santosh Darisetty, Sandeep Lakhtakia,
Venkat G. Rao, Nageshwar D. Reddy
Introduction: More than 60% of patients suffering with gastroesophageal reflux disease show
no or minimal changes on standard endoscopy (NERD). Magnification endoscopy after
contrast enhancement with acetic acid is able to detect subtle mucosal alterations. The
primary aim of this study was to identify and evaluate these changes before and after oral
Rabeprazole therapy as possible predictors of NERD. Methods: Consecutive patients with
GERD as identified by a questionnaire and normal standard endoscopy were included in the
study after informed consent. These patients were examined by high resolution magnification
endoscopes (Olympus GIF Q 160Z ). Subsequently these patients were treated 20mg Rabepra-
zole/day for four weeks and re-examined by magnification endoscopy. Data was collected
as still images and digital videotapes concentrating on the tops of the folds. Potential criteria
for minimal change esophagitis were identified according to pilot observations in prior
studies: a) comma shaped dilated intrapapillary capillary loop (IPCL) above the Z line b)
increased vascular markings distal to the Z line c) loss of palisade pattern of blood vessels
above Z line d) triangular indentations into squalmo-columnar mucosa by villiform columnar
mucosa and e) islands of squamous epithelium distal to the Z line. Images and videos were
coded and examined by the investigator and results validated by two independent observers.
Results: 18 patients with reflux symptoms and normal standard endoscopy were included
in the study. Frequency of these changes and response to PPI are shown (Table 1). Conclu-
sions: Some of the changes of minimal change esophagitis on magnification endoscopy may
resolve with Rabeprazole therapy. These reversible changes may represent true endoscopic




















Gastrin-17 (G-17) As a Sensitive Serological Bio-Marker for Diagnosis of
Gastro-Esophageal Reflux Disease (GERD) Independently of H. Pylori Status
Lucas G. Cavallaro, Antonio Nouvenne, Andrea Maini, Roberta Merli, Libera Fanigliulo,
Daniela Basso, Mario Plebani, Veronica Iori, Giulia Martina Cavestro, Marta Maino,
Giorgio Nervi, Angelo Franze', Francesco Di Mario
Background: The prevalence of GERD is 25% of the general population and is due to an
excess of acid into the oesophagus. High basal acid output (BAO) can determine very low
Gastrin 17 (G-17) levels due to the negative feedback relating antrum and corpus mucosa.
Serum Pepsinogens I and II (sPGI and sPGII) are surrogate markers of maximal acid output
(MAO) and gastric inflammation respectively. Aim: To evaluate G-17, sPGI and II levels in
patients with GERD compared to patients with other acid-related disorders.. Patients and
Methods: 124 consecutive outpatients (60 M, mean age: 39 ± 9.4 years, range 21-59) with
upper GI symptoms and not under PPI treatment were enrolled. This population was divided,
on the basis of upper GI endoscopy and gastric histology, predominant symptoms and
medical history, into: 84 with GERD 42 (17 Hp+ve) with Esophagitis (ERD); 42 (19 Hp+ve)
with Non Erosive Disease (NERD), 42 with Other Acid-related Disorders 6 (5 Hp+ve) with
Duodenal Ulcer (DU), 28 (14 Hp+ve) with Gastritis (GAS) and 6 (3Hp+ve) with Gastric
Ulcer (GU). In all patients H. pylori status was assessed and ,a blood sample was taken to
evaluate serum G-17 and sPGs levels (EIA, Biohit, Helsinki, Finland). Mann-Whitney U test
was used to compare the means of serological parameters into the different clinical subgroups.
Results: The mean of G-17 levels showed a marked decrease in group GERD vs Other acid-
related disorders (GERD: 2±2, Other: 5±3 pmol/l, p<0.001). No difference was found between
ERD and NERD according to G-17 and sPGs. Notably all Hp+ve patients showed significantly
increased sPGII levels (Hp+ve15±4; Hp-ve 9±3 pmol/l, p<0.001). GERD patients confirmed
significant lower G-17 levels also in this Hp+ve subcohort (GERD 2.3±2; Other 5±2 pmol/
l, p<0.001). Decreasing levels of sPGI were observed from DU (124±33 pmol/l ), to GAS
(109±36 pmol/l), to GERD patients (93±35 pmol/l), to GU (82±35 pmol/l). Conclusion: G-
17 could be useful, in the first approach, to the management and diagnosis of GERD,
independently of H. pylori status, highlighting a new risk factor of acid exposure. On the
other hand, Pepsinogens are good serological biomarkers to assess gastric hypersecretion
and mucosal inflammation.
S1169
Evaluating the Day to Day Variability Detected in the 48 Hour Ambulatory
BRAVO pH Data
M. Babitha Reddy, Gregory Haber
Introduction: The ambulatory Bravo pH test offers extended esophageal acid exposure
recording time with improved patient comfort and compliance in esophageal pH testing.
However, the initial reports of data obtained from the two day ambulatory Bravo pH test
illustrate significant day to day variability in the results. Aim: To retrospectively review all
consecutive Bravo pH studies from a single institution from January 2003 through August
2005 and to calculate the discordance in positive studies. We also assessed the possible
impact of sedation, studied while on and off proton pump inhibitors (PPI), and time of day
the study commenced. Methods: Bravo pH results from January 2003 through August 2005
were obtained from the computerized records of the endoscopy unit from a single institution.
Sixty nine studies were excluded due to insufficient recording time (less than 36 hours) or
insufficient collected data due to patient diary violations. Of 175 included studies, 57 were
performed on PPI and 118 off PPI. Discordance was defined as a positive study in only one
of the two days recorded and concordance defined as positive studies in both days recorded.
Early morning studies were defined as studies completed between 8am and 10am and late
afternoon studies were defined as studies completed between 2pm and 5pm. A positive
study was defined as pH < 4, > 5.3% of the recorded time in each 24h time interval. Results:
Two hundred forty four Bravo pH results were reviewed and 175 studies were included.
Of these, 100 (mean age 50) were female. Among the 118 patients off PPI, 50% of studies
were positive, 16 only on Day 1, 9 only on Day 2, and 34 on both days with a discordance
rate of 42%. Discordance rates were similar in all groups with the exception of the supine,
74%, vs. upright, 34% position. Among the 57 patients on PPI, 19% of studies were positive,
4 only on Day 1, 3 only on Day 2, and 4 on both days with a discordance rate of 63%.
This was similar in all groups. The overall discordance rates were higher in patients on PPI
(63%) versus off PPI (43%) and this was true for all subgroups. The overall discordance
rates among all groups were higher than previously reported. Conclusions: This large study
of Bravo pH data collected from a single institution demonstrates day to day variability
greater than with previously published data. Percentage of positive studies was similar in
all groups. The discordance rates are higher on PPI vs. off PPI. The discordance rates were
higher in the supine position on PPI than the other subgroup analysis.
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S1170
Time Esophageal pH<4 Significantly Overestimates the Prevalence of
Pathologic Esophageal Reflux in GERD Subjects Treated with Proton Pump
Inhibitors (PPIs)
Lauren B. Gerson, Peyman Sahbaie, George Triadafilopoulos, Winston Young, Jerry D.
Gardner
Background: A recent study concluded that 50% of GERD patients have pathologic esophageal
acid exposure despite PPI treatment that abolished all GERD symptoms (Am J Gastroenterol
2004; 99:991-96). We considered the possibility that this high prevalence of pathologic
esophageal acidity occurred because data were analyzed in terms of time esophageal pH<4.
Aim: To compare the prevalence of pathologic esophageal reflux assessed by calculating
time pH<4 and integrated acidity from the same records. Methods: Raw data from 49
esophageal pH recordings in GERD patients from the study cited above were analyzed.
Three records were omitted for technical inadequacies. The postprandial and nocturnal
periods were 900-2200 and 2200-900, respectively. Receiver operator characteristic (ROC)
analyses of results for integrated esophageal acidity based on 24-hour ambulatory esophageal
pH recordings from 26 normal subjects and 57 GERD subjects who reported heartburn at
least 4 times/week for at least 6 months (Aliment Pharmacol Ther 2003; 17:955-964)
were used to determine cut-off points that defined pathologic integrated esophageal acidity
(mmol.hr/L) as 24-hour >8.1; postprandial >1.85, and nocturnal >6.8. Similar analyses
showed that pathologic time pH<4 (%) was defined as 24-hour >4.3; postprandial >6.8,
and nocturnal >2.35. Results: For the 24-hour period, the prevalence of pathologic esophageal
reflux measured as time pH<4 was 43% [95% CI; 29%, 57%] and was significantly higher
(P=0.006; Fisher’s Exact Test) than that measured as integrated acidity (15% [5%, 25%]).
For the nocturnal period, the prevalence of pathologic esophageal reflux measured as time
pH<4 (35% [21%, 49%]) was also significantly higher (P=0.012) than that measured as
integrated acidity (11% [2%, 20%]). For the postprandial period, the prevalence of pathologic
esophageal reflux measured as time pH <4 (28% [15%, 41%]) was not significantly different
(P=0.821) from that measured as integrated acidity (33% [19%, 47%]). Conclusion: The
present results indicate that in GERD subjects treated with a PPI until they are asymptomatic,
assessing esophageal acidity with time pH<4 significantly overestimates the prevalence of
pathologic esophageal acid exposure compared to integrated acidity. The 3-fold overestimate
of the prevalence of pathologic nocturnal but not postprandial esophageal reflux occurs
because time pH<4 fails to fully quantify effects of PPIs on esophageal acidity and as a
result, gives artificially high values for esophageal acid exposure.
S1171
Endoscopic Placement Under Sedation Does Not Affect pH Monitoring By the
BRAVO™ System
Amir Thakur, Mark Fox, Roy Anggiansah, Wong Terry, Angela Anggiansah
INTRODUCTION & AIMS: The Bravo™ system is designed to provide catheter-free, intra-
oesophageal pH measurements over 48 hours. Early observations have suggested that oeso-
phageal acid exposure is less during the first than the second 24 hour period.[Pandolfino
AmJG 2003] This study examined whether endoscopic placement under sedation has effects
on pH measurement, and if present whether these effects are a direct consequence of the
procedure or caused by a reduction in oral intake. METHODS: 56 consecutive patients
(median age 48 (35-61) yrs) referred for pH monitoring were studied. The Bravo™ capsule
was placed using a standard gastroscope under moderate sedation (midazolam 3-5mg,
fentanyl 0-50 mcg) on an afternoon list and measurements began one hour after the proced-
ure. ‘Refluxogenic’ test meals (1000kcal) were provided to 12/56 patients for lunch and
dinner throughout the study. Acid exposure during the 3, 6 and 24 hours after endoscopy
on the first day were compared to the same time periods on the second test day. Data is
presented as the median±SEM. RESULTS: Complete 48-hour pH data was available for 47/
56 (85%) patients (incomplete recording (n=8), early detachment (n=1)). Pathological acid
exposure (>4.2%pH<4/24hr) was recorded on at least one day in 34/47 (74%) patients.
Acid exposure was similar after endoscopic placement on day 1 than the same period on
day 2 at 3-hrs 8.7±1.4% vs. 7.3±1.6% (p=0.28), at 6-hrs 8.8%±1.8% vs. 8.0%±1.5% (p=
0.71) and over 24-hr 8.2±1.4% vs. 7.8±1.3%(p=0.61). Moreover pH measurements during
the first 3 hours after endoscopy were not significantly different to those during any other
time period (p=0.58 by repeated measures ANOVA). Acid exposure was also comparable
in the postprandial periods (11.5±1.6% vs. 11.2±1.5%, p=ns) and during the first and
second nights / supine periods (7.5±1.4% vs. 6.9±1.5%, p=ns). Similar results were found
in the subset of patients that received set meals. Moreover the reproducibility of pH measure-
ments between day 1 and day 2 over 3, 6 and 24 hours was not significantly improved by
the provision of set meals. CONCLUSIONS: Endoscopic placement of the Bravo™ capsule
under moderate sedation had no impact on pH recordings. Providing patients with set meals
did not alter the reproducibility of pH measurements. The interpretation of pH recordings
obtained by the Bravo™ system need not take the effects of endoscopy on acid reflux
into account.
S1172
Wireless Vs Traditional pH Monitoring: Better Tolerability and Lower Impact
On Daily Activities and Food Intake
Ausilia Grigolon, Ivana Bravi, Paolo Cantu', Roberto Penagini
Background and aim Catheter-based esophageal pH monitoring is traditionally considered
the gold standard for the diagnosis of gastroesophageal reflux disease (GERD). Patients often
report discomfort and limitations of daily habits during the test, however few objective data
are available. The new wireless technique may overcome these limitations. Aim of our study
was to evaluate the tolerability and impact on daily activities and food intake of traditional
catheter based and of the new wireless pH monitoring. Methods One-hundred and twenty-
five consecutive patients with suspected GERD, referred for ambulatory esophageal pH
monitoring were enrolled. Seventy-height patients (36 M, 53+2 yr) underwent 24 h traditional
pH monitoring (Slimline; Medtronic) and 47 patients (21 M, 45+3 yr) 48 h wireless (Bravo;
Medtronic) pH monitoring. The traditional pH catheter was passed transnasally and posi-
tioned in the oesophagus with the pH step-up method, whereas the pH capsule was positioned
transorally during endoscopy. Discomfort during placement of the pH electrodes and during
the whole pH monitoring were evaluated by two 100 mm visual analogue scales. Limitations
of food intake and of daily activities were evaluated by two standardized questionnaires
(score 0-3: 0 = no limitation; 3 = food intake limited during all meals/activities severely
limited). Results (means + SEM). See table. Successful pH study was completed in all patients
except one in the Bravo group for early detachment of the capsule. pH data were captured
by the receivers for 98.0% +1.5 and 94.5+1.0 of time during traditional and wireless
monitoring respectively. Fewer patients reported discomfort (p<0.01), limitation of food
intake and of daily activities during wireless compared to traditional monitoring (21% vs
46% p<0.05, 17% vs 65% p<0.01 respectively). Twenty-six % of the patients had chest
complaints during wireless monitoring. Conclusions Traditional catheter-based pH mon-
itoring is reasonably well tolerated; it induces, however, important limitations of food intake
and daily activities, which may impair diagnostic accuracy. The Bravo wireless pH monitoring
is technically successful, better tolerated and, above all, has minor impact on food intake
and daily living. Whether this translates in better diagnostic accuracy remains to be evaluated.
* p<0.01, † p<0.05 vs traditional technique (unpaired Student’s t test)
S1173
Esophageal pH Testing in Patients Symptomatic On PPI Therapy
Barbara Ann M. Mackalski, Alexandra Ilnyckyj
Background: The clinical utility of 24 hr pH testing in the setting of PPI therapy is unclear.
Pivotal data reports pH tests are predictably normal in 92% of patients *(1). Aim: To describe
24 hr pH findings in patients undergoing testing for the indication of GERD unresponsive
to PPI therapy. Methods: The St. Boniface General Hospital is a tertiary care centre located
in the province of Manitoba, Canada. Our laboratory performs approximately 100 pH tests
yearly. Requests are limited to specialists; gastroenterologists or GI/thoracic surgeons. Clinical
indication and medical therapy are documented by the referring specialist on a standardized
form. All patients are contacted prior to the test by a dedicated GI nurse to confirm medical
regimen and reinforce importance of drug compliance prior to and during the pH study.
pH tests are performed using standardized technique and analyzed using Esophagogram
software (Medtronic, Inc). Charts were reviewed and data extracted by a GI fellow. Results:
A retrospective review of 415 consecutive patients referred over a 3 1/2 yr period, January
2002- June 05 inclusive identified 107 patients (35% male) meeting study criteria. 61 /107
had typical symptoms and 61/107 were on BID dosing. Test results were classified as
abnormal by applying 3 different criteria for abnormal reflux parameters: #1) DeMeester
score >14.7 #2) % time pH < 4 : total >5.5 %, upright > 8.3%, supine >3.0% and # 3) %
total time pH <4: >1.6 %. Results are tabulated below. Conclusion: A significant number
of patients in a specialty practice who remain symptomatic on PPI therapy, including BID
dosing, will have abnormal pH parameters. Therefore the role of acid in their symptoms
cannot be excluded. *1. Charbel S, Khandwala F, Vaezi M. The Role of Esophageal pH
Monitoring in Symptomatic Patients on PPI Therapy. Am J Gastroenterol 2005;100:283-89.
Abnormal pH tests by criteria/dose
S1174
Multichannel Intraluminal Impedance and pH (MII-pH) Esophageal Testing Is
More Specific Than pH Alone for Diagnosing Acid Gastroesophageal Reflux
Amine Hila, Amit Agrawal, Wojciech Blonski, Janice Freeman, Donald O. Castell
BACKGROUND: 24-hr multichannel intraluminal impedance and pH (MII-pH) esophageal
monitoring allows detection of both acid and non-acid gastroesophageal reflux (GER). The
MII-pH catheter contains 6 impedance segments placed 3, 5, 7, 9, 15 and 17 cm above the
LES, plus a pH electrode at 5 cm allowing detection of cephalad progression of refluxate.
Standard 24-hour pH monitoring detects changes in pH, and defines reflux as drops in pH
below 4. The new MII-pH technology has shown that some of these pH detected episodes
are actually due to swallowing acid foods. AIM: To assess accuracy of pH monitoring
alone in detecting acid reflux compared to MII-pH. METHODS: Review of 60 consecutive
ambulatory MII-pH studies recorded off acid suppressing therapy performed from 6/03 to
8/05 (36 females; mean age = 52.7 yrs; range: 16 - 77 yrs). All studies were initially read
by exclusively analyzing the pH tracing for acid reflux episodes (pH drop <4), excluding
the meal periods. Symptom association with acid reflux was also evaluated. Subsequently,
all studies were blindly read again analyzing MII-pH detected acid reflux episodes (pH drop
<4 and an MII detected reflux episode), excluding the meal periods. Symptom association
with MII-pH acid reflux was also evaluated. A symptom was positively associated with acid
reflux if ≥ 50% of symptoms occurred within 5 minutes of the start of an acid reflux
episode. Normal values for % time pH < 4 were: total < 4.2%; upright < 6.3%; recumbent
< 1.2%. RESULTS: The table below shows the sensitivity and specificity of pH alone compared
to MII-pH for detection of acid GER using either % time pH<4 alone or symptom association
alone, and including both as diagnostic criteria. The upright, recumbent and total % time
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pH<4 was significantly higher when using pH alone compared to MII-pH (Wilcoxon signed
ranked test; p<0.0001). In these 60 patients, MII-pH detected 1133 acid reflux episodes
while pH alone detected 2307 episodes (Wilcoxon signed ranked test; p<0.0001). 81% of
the acid GER episodes exclusively detected by pH were associated with a swallow as demon-
strated by MII. Of the 60 patients, 13 (22%) were diagnosed as having an abnormal 24-
hour pH test, that proved to be negative for acid GER when the MII was included in the
evaluation. CONCLUSION: Use of pH alone for detection of acid reflux is very sensitive
but lacks specificity compared to MII-pH. pH alone may over diagnose abnormal acid reflux
in up to 22% of tested patients.
S1175
Diagnostic Value of Oesophageal Physiology Studies - An Eight Year
Prospective Study
Samir Mehta, Alexander P. Boddy, Richard Lowndes, Michael Rhodes
Introduction Physiology studies are an aid in the diagnosis and management of patients
who suffer from gastro-oesophageal symptoms. The purpose of this study was to evaluate
the diagnostic value of oesophageal pH and manometry studies at a university hospital
physiology unit over a nine-year period. Methods Between July 1996 and October 2004
there were 1116 referrals for 24 hr oesophageal pH / manometry to investigate four cardinal
symptoms. These were symptomatic gastro-oesophageal reflux (n=802), atypical chest pain
(n=137), dysphagia (n=153), and achalasia (n=74). Results Studies were successfully com-
pleted in 92.4%. Reasons for failure were patient intolerance (3.3%) and recording malfunc-
tion (4.3%). Results are shown in the table: Conclusion Symptoms alone are a poor predictor
of abnormal oesophageal function. 24 hour pH and manometry studies are valuable in
defining the physiological abnormality in order to allow appropriate treatment.
S1176
Heartburn and Regurgitation - Does That Mean I Have GERD?
Inder Mainie, Radu Tutuian, Amine Hila, Amit Agrawal, Donald O. Castell
Background: Typical symptoms such as heartburn and regurgitation are believed to be
associated with gastroesophageal reflux (GERD). Aim: To clarify if patients presenting with
heartburn or regurgitation have abnormal reflux. Method: Patients were evaluated for typical
symptoms of heartburn and regurgitation. All were studied off therapy with PPIs discontinued
for a minimum of 5 days prior to the study. The 2.1 mm dual electrode antimony pH
catheters were placed after an overnight fast 5 and 20cm above the manometrically located
proximal border of the lower esophageal sphincter (LES). Each study was analyzed for
percent time pH < 4 in the distal (normal values: upright < 6.3%; recumbent < 1.2%) and
proximal (normal values: upright < 1.3%; recumbent = 0). The symptom index was calculated
by dividing the number of symptoms preceded by a reflux episode within a 5 minute
window by the total number of symptoms (postive if ≥ 50%). Results: pH studies from
450 patients off therapy (303 female; mean age 53; range 11-88) between July 2002 and
October 2004 were analyzed. The mean duration of ambulatory studies was 22 hours and
34 minutes; range 20 - 24 hours. 220 patients had abnormal reflux (121 upright; 156
recumbent and 57 both). 127 patients recorded heartburn, 14 patients recorded regurgitation
and 14 recorded both. See table below. Conclusion: These results indicate that typical


















Delayed Esophageal Clearance in Patients with Barrett’s Esophagus As
Assessed By Pillcam EsoTm
Daniel Wolfson, Jamie Barkin, Shosh Friedman, Ron Nitzan, Hagit Ephrath, Inna
Dolnikov
Backround: Esophageal capsule endoscopy (PillCam ESO tm, Given Imaging, Israel) is utilized
for detection of esophageal structural pathology. Efficient esophageal clearance is an important
defense role in the prevention of gastroesophageal reflux disease (GERD). One of the mechan-
isms for (GERD) is felt to be poor esophageal clearance. The aim of our study was to compare
esophageal transit time of the PillCam ESO in patients with esophageal pathology and
normals. Methods: A group of 166 patients consisting of Barrett’s esophagus (45), Erosive
esophagitis (52), Non-erosive reflux disease-NERD (60), and normal cohorts (9) were studied.
The groups were divided based on pathology detected by capsule endoscopy or EGD. Each
patient ingested the capsule in the supine position. Esophageal transit time was measured
and compared in each group. Measurements were made of the time from the initial esophageal
image to the first stomach image as well as the measurements of time from the first gastroeso-
phageal junction image (first Z line image) to the first stomach image. Statistical analysis
using multiple variance analysis (MANOVA) was used between multiple groups and a T-
test analysis was used between two groups. Results: There was no significant difference
(p>0.05) between any of the groups in total esophageal transit time. (See Table 1) There
was a significant difference (p<0.05) in the time the capsule took to pass from the GE
Junction into to the stomach in the Barrett’s esophagus group vs. the other groups. (See
Table 2) Conclusions: Total esophageal transit time of the PillCam ESO tm was the same in
patients with Barrett’s esophagus, reflux esophagitis, and NERD compared with normals.
However, patients with Barrett’s esophagus had significantly slower transit times of the
PillCam ESO tm from the first GE Junction image to the first image of the stomach. This
suggests that there may be a motility disorder predisposing to the formation of barrett’s eso-
phagus.
Table 1: Total Esophageal Transit Time (min)
*p>0.05
Transit Time From 1st GE Junction Image→First Stomach Image (min)
‡p<0.05
S1178
Acid Gastroesophageal Reflux Reports in Infants: A Comparison of Esophageal
pH Monitoring and Multichannel Intraluminal Impedance Measurement
Techniques
Frederick W. Woodley, Hayat M. Mousa
Background: Over the past decade, several groups have reported successful use of the
combined esophageal pH monitoring (EPM) and multichannel intraluminal impedance (MII)
for measuring gastroesophageal reflux (GER) frequency and duration. While previous studies
have compared the sensitivity of these two techniques in detecting the frequency of GER,
the variable abilities of these two techniques to assess distal esophageal acid GER (AGER)
exposure has not been reported. Aim: To test the differences between EPM and pH/MII in
detecting acid reflux. Methods: We reviewed parallel EPM and pH/MII reports from 14
infants (9 males, median age 3.5 months) who were evaluated over a 24 hr period. Results:
Significantly fewer AGER were detected by pH/MII (25.1 ± 4.0/patient) compared to EPM
(99.9 ± 18.3/patient, p = .001). Significantly more time was spent in AGER when determined
by EPM (156.6 ± 30.4 min/patient versus 66.6 ± 15.9 min/patient, p = .002). The mean
percentage of total study time spent below pH 4 was 9.7 ± 1.7% using EPM and 4.7 ± 1.1%
using pH/MII (p = .002). The mean duration of an individual AGER event was 154.8 ±
20.0s using pH/MII and 94.6 ± 15.6s using EPM (p < .0001). Of the total AGER episodes
detected by EPM, 71.8% could not be confirmed by pH/MII. Conclusions: Compared to
pH/MII, EPM detects acid exposure that is significantly greater in AGER frequency and
duration. Detection of significant numbers of “EPM-only” AGER episodes raises concerns
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regarding possible over estimations of acid exposure that may occur when estimates are
based solely on EPM.
S1179
Gastroesophageal Reflux Disease in Tehran
Mehdi Nouraie, Maryam Asadi, Hadi Razjouyan, Siavosh Nasseri-Moghaddam
Introduction: GERD is a common, chronic and relapsing disorder with a rising incidence
in the western world. The prevalence of gastro-oesophageal reflux disease (GERD) in Asian
populations is reported to be lower than that in the west. Population-based data on the
prevalence and symptom profile of gastroesophageal reflux disease (GERD) in developing
Caucasian countries is lacking. Aim: Our aim was to determine the prevalence of gastrointesti-
nal symptoms and clinical spectrum of GERD in Tehran, Iran and their association with
patient characteristics. Methods: A two step screening telephone survey of 1700 simple
random Tehran household telephone number using a validated questionnaire was performed.
In each answered call a second rapid survey was done to select a random subject aged 18-
65. Several patient characteristics (age, education, sex) and history of acid regurgitation and
heartburn during the last week and three months were questioned. Results: Of the 1700
selected numbers 278 did not answer nor had eligible case, and 220 refused to participate.
A total number of 1202 subjects (42% males, mean age: 36 years, range: 18-65 yr) were
surveyed. The prevalence of heartburn occurring monthly, weekly, and daily was 4.7 %
(95% CI: 3.5-6.0), 1.6 % (95% CI, 1.0-2.5), and 0.05 % (95% CI: 0.02-1.2), respectively.
The corresponding figures for acid regurgitation were 15.6 % (95% CI, 13.6-17.7), 5.7 %
(95% CI, 4.4-7.1) and 1.5 (95% CI,0.9-2.4) respectively. The prevalence of GERD, defined
as heartburn and/or acid regurgitation experienced daily, weekly and monthly was 1.9 %(
95%CI,1.2-2.9), 6.8% (95% CI,5.4-8.3) and 18.4% (95% CI,16.2-20.6). There was no
relationship between the prevalence of GERD and either sex, age or education. CONCLU-
SIONS: Monthly GERD symptoms occur in 18.5% of the general population in Tehran.
Acid regurgitation is more common (4-5 times) than heartburn. Sex, age and level of
education do not affect the prevalence of GERD symptoms.
S1180
Validation of Structured Scoring Using the La Classification for Esophagitis
and Barrett’s Esophagus in Asian Patients
Reuben Km Wong, Khay Guan Yeoh, Kok Ann Gwee, Khek Yu Ho
Background The Los Angeles (LA) classification is commonly used to grade reflux esophagitis.
Aim To determine the inter-observer agreement and validity of the LA Classification in
scoring the severity of esophagitis in Asian patients. Methods Video endoscopy clips were
selected from 44 consecutive patients who participated in reflux esophagitis studies. The
videos were randomly arranged and annonymised, and viewed by 3 experienced endoscopists
blinded to the diagnoses. The endoscopists were required to independently complete a
worksheet to score the presence, severity and distribution of esophagitis, including Barrett’s
esophagus. Each video was subsequently replayed, discussed and a consensus reached on
the findings. Statistical analysis was performed using kappa correlation for inter-observer
agreement as well as for individual endoscopists against the final consensus grade. Results
10 video clips were excluded for poor image quality or inadequate visualization of the
esophageal-gastric junction. 34 clips were scored and analyzed (final consensus LA classifica-
tion: no esophagitis 5 (15%), grade A 21 (62%), grade B 7 (21%), grade C 1 (3%),
respectively). Twelve patients (35%) had endoscopic Barrett’s esophagus. There was good
agreement on the presence of esophagitis (mean k 0.79, range 0.72 to 0.82). Observer
agreement on the LA grade against the consensus grade was moderate to strong (mean k
0.76, range 0.72 to 0.79). Evaluation of the extent of esophagitis showed good k values
using the alternative approach of grouping by circumferential extent (mean k 0.86, range
0.64 to 0.97) at the lower categories of severity. There was good agreement on the presence
of Barrett’s esophagus for individual endoscopists versus consensus (mean k 0.74, range
0.75 to 0.80) while between endoscopists the mean k was 0.52 (range 0.46 to 0.62). There
was a clear trend of increasing inter-observer agreement as viewings progressed, with superior
kappa correlation after 15 cases. Conclusions Scoring using the LA classification for esophag-
itis and the concurrence on the presence of Barrett’s esophagus showed moderate to strong
agreement amongst Asian endoscopists. Our results also suggested that an alternative method
of scoring esophagitis based on proportion of circumferential involvement was reliable. A
learning effect was observed and reliable scoring was achieved after 15 patients.
S1181
One Week rabeprazole Trial Is Not Enough to Diagnose Patients with GERD-
Related NCCP
Jeong Hwan Kim, Poong-Lyul Rhee, Hee Jung Son, Jae J. Kim, Jong Chul Rhee
Background: Noncardiac chest pain (NCCP) presents as a frequent diagnostic challenge,
with patients tending to use a disproportionate level of health care resources. Gastroeso-
phageal reflux disease (GERD) is the most frequent cause of NCCP. Empirical trial with
high-dose proton pump inhibitor (PPI) has been shown to be a sensitive tool for diagnosing
patients with GERD-related NCCP. However, the optimal duration of PPI trial is defined
poorly. Therefore, we aimed to determine the optimal duration of an empirical trial of high-
dose rabeprazole in detecting patients with GERD-related NCCP Methods: Patients who
were referred by a cardiologist after a comprehensive evaluation, with at least two episodes
per month of unexplained chest pain as the predominant symptom, were enrolled into this
study. Patients completed a daily diary assessing severity and frequency of chest pain as the
predominant symptom during 14 days for a baseline symptom assessment. Then, the follow-
ing evaluations were undergone: upper endoscopy to determine esophageal mucosal disease
followed by 24-h esophageal pH monitoring to assess acid exposure. Patients were then
assigned to rabeprazole 20 mg orally twice daily during 14 days. Patients completed the
same daily diary throughout the PPI treatment. The rabeprazole empirical trial was considered
diagnostic if chest pain score improved ≧ 50% than baseline. The assessment of chest pain
score was performed by day 7 and by day 14. Results: Of the 28 patients with NCCP that
were enrolled, 12 (43%) had erosive esophagitis and/or pathologic acid exposure (GERD-
positive) and 16 (57%) had both tests negative (GERD-negative). The rabeprazole empirical
trial was considered significantly higher diagnostic in patients with GERD-positive NCCP
(n=9, 75%) than in patients with GERD-negative NCCP (n=6, 38%) on two weeks PPI trial
(P < 0.05). However, there was no significant difference between the two groups on one
week PPI trial (GERD-positive vs. GERD-negative = 58% vs. 38%, P = 0.24). Conclusions:
The rabeprazole empirical trial was highly diagnostic in detecting patients with GERD-related
NCCP. The optimal duration of the rabeprazole empirical trial in diagnosing patients with
GERD-related NCCP was determined as two weeks in this study.
S1182
Reflux Episodes Are Similar in Asymptomatic African Americans and Non
Hispanic Whites
Kenneth Vega, Christina Lambiase, Louis Lambiase
African Americans develop Barrett esophagus at a much lower rate than non Hispanic Whites.
This suggests there may be less esophageal acid reflux in African Americans (AA) as opposed
to Non Hispanic Whites (W). Very little is known about the prevalence of acid reflux in
AA. Further, 24hr pH testing has only been validated in W. There is no data establishing
normal ranges for 24 hr pH testing AA. AIM: To determine the normal parameters for 24
hr esophageal pH probe measurements in AA. Further to compare those values to those
obtained from W to determine any differences. Methods: 24 hr pH probes were performed
in asymptomatic AA and W patients who were classified based on self reported ethnicity.
Values for Number of reflux episodes, number of reflux episodes longer than 5 minutes,
length of time (minutes) of the longest reflux episode and the total time (minutes) the pH
was less than 4 was recorded. Data was recorded in two channels the distal placed 5 cm
from a manometrically determined lower esophageal sphincter (LES) and the proximal,
which was 15 cm above the LES. Means were compared using an Independent Sample t
test. Results: See Tables. 33 AA and 29 W patients were studied. There were no significant
differences between AA and W for all parameters. Conclusion: Normal 24 hr pH probe
values for AA are reported. There appears to be no difference from those values found in
W. This would suggest, that if the racial difference in Barrett esophagus incidence is due





Ginger-Ale Swallow Test to Locate the BRAVO pH Capsule in the Esophagus
Kozhikot Kumaran
BACKGROUND AND AIM: Bravo capsule ambulatory esophageal pH testing has become
the standard procedure in evaluating symptoms related to gastroesophageal reflux disease.
Aim of this study is to use ginger-ale swallow to verify the location of Bravo pH capsule in
the esophagus. Occasionally the pH capsule may become detached from the wall of the
esophagus soon after it is implanted, making the test invalid. A sustained acidic pH below
3 will suggest the capsule is in the stomach, requiring the need to implant a second capsule
to continue with the test. However, if there is no acid in the stomach due to the use of PPI,
bile reflux or other conditions, the pH measurement alone will cause incorrect localization.
To circumvent this problem, we come up with the “ginger ale swallow test”. METHOD:
Standard EGD procedures established for the Bravo pH tests were followed in all patients.
Prior to the implantation of the pH capsule in the esophagus, we routinely aspirated the gastric
juice using the endoscope for pH determination. Ginger-ale swallow test was performed soon
after the patient recovered from sedation and was able to swallow liquids. While observing
the pH reading in the Bravo monitor, each patient was allowed to swallow about two ounces
of room temperature ginger-ale (pH 2.8) followed by a swallow of water, or the patient’s
own saliva. If the capsule was located in the esophagus, a transient drop in the pH reading
below 4 was observed as the bolus of ginger-ale passed through the distal esophagus, followed
by the rise in pH to the esophageal pH level of about 6. A sustained low pH below 4
indicated the capsule location in the stomach, requiring the need for the implantation of a
second capsule for the successful completion of the study. RESULTS: Out of the 40 consecut-
ive tests performed, six patients (15%) had no acidic pH in the stomach and the ginger-ale
swallow test helped to verify the location of the capsule in all 5 patients. In one patient
(3%), a second capsule had to be placed in the esophagus as the first capsule fell off the
esophagus because the pH reading after the placement of the first capsule was indicative of
its dislodgement into the stomach. This was confirmed by direct endoscopy. In one case
(3%) the capsule did not slough off the esophageal wall even after 30 days as verified by
radiology, and was retrieved safely by the endoscope. No complications occurred in any of
these patients with ginger- ale test. CONCLUSION: Ginger-ale swallow test is very simple,
safe and useful in testing the proper location of the pH capsule after endoscopic placement
and prior to the patient discharge.
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S1184
Normal Values for Ambulatory 24-H Combined Impedance-pH Monitoring On
Acid Suppressive Therapy
Radu Tutuian, Inder Mainie, Amit Agrawal, Janice Freeman, Donald O. Castell
Background: Combined multichannel intraluminal impedance and pH (MII-pH) is increas-
ingly used to monitor patients with persistent reflux symptoms on proton pump inhibitor
(PPI) therapy. The normal range of the number of reflux episodes “on therapy” (<73) was
determined by extrapolating data from healthy volunteers “off therapy” (Shay et al. Am J
Gastro 2004) and by assuming that PPI primarily change the pH of the refluxate without
affecting the total number of reflux episodes as seen during post-prandial studies (Vela et
al. Gastroenterology 2001). Aim: Evaluate the effects of twice daily PPI on reflux 24-h
parameters during combined MII-pH monitoring and define normal values “on therapy”.
Methods: Healthy volunteers underwent combined MII-pH monitoring before and after
dosing with esomeprazole 40mg bid AC for 5 days. The 8 channel combined MII-pH probe
recorded impedance data at 3, 5, 7, 9, 15 and 17 cm above the LES and pH data 5cm
above and 10cm below the LES. In each subject we counted the total number of MII-
detected reflux episodes, the number of acid reflux episodes (MII-detected reflux episodes
with intraesophageal pH <4) and the number of non-acid reflux episodes (MII-detected
reflux episodes with intraesophageal pH >4). Results: Twenty healthy volunteers (12F, age
mean 32y, range 18-67y) completed baseline and “on therapy” impedance-pH monitoring.
There was a statistically significant decrease in the total number of reflux episodes and the
number of acid reflux episodes at 5 and 15cm above the LES during dosing with esomeprazole
compared to baseline. The number of non-acid reflux episodes was unchanged during dosing
with PPI compared to baseline. Conclusions: Acid suppressive therapy reduces the number
of acid reflux episodes but not the number of non-acid reflux episodes. The revised upper
limit of normal for reflux episodes on PPI therapy (<48) should improve the sensitivity of
identifying patients with an abnormal number of reflux episodes on acid suppressive therapy.
Data are presented as mean ± SD; p-value for paired Student T-test
S1185
Discontinuation of Proton Pump Inhibitors in Patients On Long-Term
Therapy: A Double-Blind, Placebo-Controlled Trial
Einar Bjornsson, Hasse Abrahamsson, Magnus Simren, Niklas Mattsson, Pia Agerforz,
Anders Kilander
Background: The proportion of PPI users on long-term therapy who could discontinue PPIs
without developing symptoms is unknown. It has been suggested that acid rebound following
treatment with PPIs can make it more difficult to stop PPIs due to exacerbation of symptoms.
We aimed to study what proportion of long-term PPI users is able to discontinue their
medication and whether tapering down the PPIs makes it easier to stop PPIs. Method:
Patients buying PPIs on prescription at the pharmacy were asked to complete a questionnaire
concerning the indication for the medication and their symptomatology. Patients using PPIs
for at least two months, without a history of peptic ulcer or esophagitis were asked to
participate and examined with upper endoscopy. If an ulcer or esophagitis was observed
the patient was excluded. Remaining patients were randomized double-blindly to taper
down or continue with a constant dosage of omeprazole for three weeks. Thereafter, all
patients discontinued PPI therapy. Results: A total of 115 patients underwent endoscopy,
19 patients were excluded due to organic GI disease (16 had esophagitis). Of the 96 enrolled
(median age 63 years, 52 females), who had used PPI for a median time of 48 months (IQR
22-87; range 4-180 months), 23 (24%) had helicobacter pylori, 75 (78%) had GERD and
21 (22%) other indications. A total of 26 patients (27%) did not use PPIs during the year
after discontinuation. A total of 31% randomized to tapering discontinued PPIs whereas
22% of those who did not taper PPIs could discontinue therapy (NS). Sex, age, duration
of PPI therapy or HP status did not predict PPI requirement. GERD patients were more
prone to resume PPI therapy than those with other indications. Only 16 (21%) of GERD
patients were off PPIs compared with 48% of patients without GERD (p<0.05). GERD
patients resumed their PPI therapy after a median time of 18 days (4-34; range 4-193)
whereas the non-GERD patients resumed therapy 95 days (17-114; range 22-203) after the
three week study drug period (p<0.0001). Serum gastrin was higher at baseline in GERD
patients who resumed PPIs vs. those who did not (59pmol/L (36-81) vs. 38 (25-57); p=0.03).
GERD and serum gastrin were independent predictors of PPI requirement. Conclusions:
Discontinuation of PPIs was successful in 27% of long-term PPI users. Patients with GERD
were less likely to discontinue PPIs than those with non-GERD. Tapering down the PPIs did
not significantly increase the possibility of a successful discontinuation. Hypergastrinaemia


















Predictors for Treatment Failure of On-Demand Proton Pump Inhibitor (PPI)
Therapy in Gastroesophageal Reflux Disease (GERD)
Justin Wu, Carrian Cheung, Vincent Wong, Joseph Sung
BACKGROUND: It is unclear whether on-demand PPI is equally effective as step-down
therapy in patients with non-erosive reflux disease (NERD) and reflux esophagitis (RE).
AIM: To compare the efficacy of on-demand PPI therapy in NERD and RE patients and
identify the predictors for treatment failure. METHODS: We prospectively recruited consecut-
ive patients with weekly attacks of heartburn or acid regurgitation. HP eradication was
completed before recruitment. Exclusion criteria included high grade (B or above) RE,
previous gastric surgery, recent use of NSAID or PPI, and peptic ulcer. All patients completed
a self-administered questionnaire for baseline assessment of reflux symptom. Diagnosis of
concomitant functional dyspepsia (FD), irritable bowel syndrome (IBS) and psychological
disorders (PD) were recorded. RE and hiatus hernia (HH) were assessed by EGD. Esophageal
manometry (EM), Bernstein test (BT) and 24-hour pH metry were performed for all patients.
Esomeprazole 20 mg daily were given for 8 weeks after baseline assessment. Patients with
complete symptom resolution were then enrolled to open-label, on-demand Esomeprazole
20 mg for 26 weeks. Treatment failure was defined as need of Esomprazole in >/= 75% of
time for satisfactory symptom control at 26 weeks. NERD and RE patients were compared
for treatment failure rates after 26-week on-demand PPI therapy. Potential predictors (age,
gender, RE, HH, baseline reflux severity, FD, IBS, PD, positive BT, abnormal pH study,
ineffective esophageal motility (IEM: failed peristalsis >/=30%) and weak lower esophageal
sphincter (LESP<10 mmHg)) were determined using multivariate logistic regression model.
RESULTS: 182 patients (NERD: 113, RE: 69; mean age 52+/-16.8, male: 48%) were studied.
NERD patients had significantly higher prevalence of FD (65 Vs 42%, p=0.003) and positive
BT (41 Vs 20%, p=0.004) than RE patients. Both groups had comparable symptom resolution
rate after 8-week daily PPI (NERD Vs RE: 92.0 Vs 97.1%, p=0.16). However, NERD patients
had significantly higher treatment failure rates after 26-week on-demand PPI therapy (36.3%
Vs 20.3%, p=0.023) than RE patients. Multivariate analysis showed that daily reflux symptom
(OR: 2.1, p=0.001), FD (OR: 1.7, p=0.02) and positive BT (OR: 1.6, p=0.03) were the
significant predictors for treatment failure of on-demand PPI. NERD was not a predictor
(OR: 1.1, p=0.73). CONCLUSION: Daily reflux symptom, concomitant FD and positive BT
are associated with failure of on-demand PPI therapy in GERD patients. Although NERD
apparently has higher treatment failure rate, it is actually confounded by higher prevalence
of FD and esophageal sensitivity.
S1187
Proton Pump Inhibitor Therapy for Suspected GERD - Related Chronic
Laryngitis: Is It Effective? A Meta-Analysis
Mohammed A. Qadeer, Rocio Lopez, J. Pieter Noordzij, David L. Steward, Maria Suurna,
Thomas Havas, Wo John, Colin W. Howden, Michael F. Vaezi
Background: Chronic laryngitis (CL) suspected to be GERD-related is increasingly diagnosed
and usually treated with proton pump inhibitors (PPIs). Since placebo-controlled trials have
reported mixed results, we performed and report the first meta-analysis of the randomized
controlled trials (RCTs). Methods: Literature search was conducted using Medline, Cochrane
database and Embase. Individual authors were contacted if only abstracts were available
without published manuscripts. RCTs were included if they used PPIs, and enrolled patients
with chronic laryngeal symptoms but excluded if patients with only chronic cough or chest
pain were enrolled and if the model suggested significant study heterogeneity. The primary
endpoint was at least 50% reduction in the primary symptom or overall symptom score.
Each study was assessed for quality and subjected to sensitivity analysis. Heterogeneity was
evaluated by Q statistic and a random-effects model was used was used to calculate the
summary odds ratio (OR). Results: Overall, seven RCTs qualified and included 325 patients
(186 in the PPI group and 139 in placebo group). There was no significant heterogeneity
(Χ2 =7.63; p = 0.27) and the quality scores ranged from moderate to high. None of the
individual RCTs achieved statistical significance. The summary OR in favor of PPIs was 1.49
(95% CI 0.82-2.69) (Figure 1; Forest plot). Sensitivity analysis did not change the summary
OR significantly suggesting that the result was robust to the exclusion of individual RCTs.
Conclusion: 1) This meta-analysis of RCTs suggests that there is no significant difference
between PPIs and placebo for the treatment of suspected GERD-related CL. 2) The dichotomy
between clinical practice and the results of this meta-analysis suggests over diagnosis of
GERD-related CL.
Forest plot displaying individual and summary odds ratio.
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S1188
Involvement of Cannabinoid Receptors in the Triggering of TLESRs in Healthy
Subjects
Hanneke Beaumont, Magnus Ruth, Jorgen Jensen, Anders Lehmann, Guy Boeckxstaens
Background/ Aims: Transient Lower Esophageal Sphincter Relaxations (TLESRs) are the
main mechanism underlying gastroesophageal reflux and are a potential target in the treatment
of gastroesophageal reflux disease. Previous animal experiments have showed that activation
of cannabinoid (CB1) receptors reduces the occurrence of TLESRs. To determine whether
these receptors also control TLESRs in humans, we evaluated the effect of the CB receptor
agonist delta-9-tetra-hydrocannabinol (THC) on meal induced triggering of TLESRs in healthy
volunteers. Methods: The effect of THC (marinol ® 10 and 20 mg, p.o.) was evaluated on
the occurrence of postprandial TLESRs in a randomized double blind placebo controlled
study. On 3 different study days, 18 healthy volunteers (19-51, M) underwent combined
esophageal manometry / pH metry using a 10 channel water perfused sleeve catheter. TLESRs
were evoked by meal ingestion. Basal LES pressure was determined as visual means of one
minute periods every 15 minutes. Samples for plasma concentration measurements were
collected. For statistical analysis, paired Student’s t-tests were used and data is presented
as mean ±SE, except the number of TLESRs which are presented as median and interquartile
range. Results: All subjects tolerated the lowest THC dose. However, due to nausea and
vomiting in the first hour after meal intake, only 8 subjects completed the 20 mg THC
session. Meal ingestion resulted in an increase in TLESRs mainly during the first postprandial
hour. This increase was dose dependently inhibited by THC compared to placebo (placebo
8.0 (6.0-9.3); THC 10 mg 5.0 (3.8-7.0); THC 20 mg 2.5 (0.0- 7.3), (P<0.018)). No significant
effect was observed in the second and third postprandial hour. In addition, THC 10 mg
significantly reduced basal LES pressure at every measured time point during the first
postprandial hour compared to placebo (mean LES pressure at 45 min after meal intake:
placebo 12 ± 2 mmHg; THC 10 mg 6 ± 1 mmHg (P<0.011); THC 20 mg 5 ± 1 mmHg
(NS)). The number of acid reflux episodes did not differ between THC and placebo (placebo
4 ± 1; THC 10 mg 4 ± 1; THC 20 mg 3 ± 1 (NS)). Conclusion: THC significantly reduces
basal LES pressure and inhibits the increase in TLESRs evoked by meal ingestion. Based on
these findings, we conclude that CB receptors are involved in the triggering of TLESRs
in humans.
S1189
How Do Consumers Take “Over-the-Counter” Omeprazole?
Nicholas J. Shaheen, Karina Berenson, John Doyle, Kurt Brown
BACKGROUND & AIM: Over-the-counter omeprazole (Prilosec OTC™ [POTC]; Procter
& Gamble), the only available OTC proton pump inhibitor in the United States, is intended
for the treatment of frequent heartburn (≥2 d/wk). Product directions instruct patients to
take 1 tablet once a day for 14 days and not repeat the 14-day courses more often than
every 4 months, unless directed by a physician. The aim of this study was to assess the
actual dosing patterns and acid suppressive medication use in consumers purchasing POTC.
METHODS: POTC users were identified and recruited via telephone and the Internet among
subjects who reported the purchase of pharmaceutical items at US retail outlets. Those
subjects agreeing to participate were administered an Internet-based questionnaire consisting
of questions about demographics, reasons for use, patterns of use, insurance status, and
perceived knowledge about gastroesophageal reflux disease (GERD). RESULTS: Of the 1076
eligible POTC users identified, 93.5% agreed to participate. The mean (SD) age was 51.7
(12.0) years, and 63% were women; 88% reported having health insurance (52%, managed
care; 16%, Medicare; 11%, indemnity; 3%, Medicaid; 9%, subject uncertain; 8%, other),
and 91% of these insured subjects reported having prescription drug coverage. Fifty-five
percent of subjects began taking POTC >1 year ago. Most subjects taking POTC (80%) were
taking the drug every day. On the days POTC was used, subjects took an average of 1.25
pills per day. Of POTC users, 33% had not received a previous diagnosis of GERD from
health care providers. Of the subjects who had not previously received a GERD diagnosis,
77% were taking POTC every day; these subjects used the drug an average of 23 weeks per
year. In the past 12 months, 53% of POTC users reported antacid medication use; 37%
reported use of an H2-receptor antagonist; and 32% reported use of a prescription proton
pump inhibitor. CONCLUSIONS: Consumers who had not received a GERD diagnosis and
who bought POTC used it for a longer time and at doses higher than recommended.
Polypharmacy for GERD was common in POTC users. The public’s use of POTC varied
substantially from what is recommended by the manufacturer. Supported by AstraZeneca
S1190
Probiotics As Prevention of Infections in GERD-Affected Children Taking
Gastric Acidity Inhibitors
Roberto Berni Canani, Gianluca Terrin, Silvia Salvatore, Pia Cirillo, Annalisa Passariello,
Riccardo Muscariello, Maria Concetta Siani, Francesco Porcaro, Alfredo Guarino
Background. We have demonstrated that gastric acidity (GA) inhibitors therapy, including
histamine-2 receptor antagonists and proton pump inhibitors, increases the risk of acute
gastroenteritis (AG) and community-acquired pneumonia (CAP) in gastroesophageal reflux
disease (GERD)-affected children (Pediatrics, 2006 in press). These effects are at least in
part attributable to modifications in intestinal microflora composition. Probiotics are able
to positively influence intestinal microflora composition and to limit the risk of infection.
We aimed to test the hypothesis that probiotics could reduce the risk of infection deriving
from GA-inhibitors therapy. Participants and Methods. We conducted a prospective, random-
ized, case-controlled study in children (age range 4-36 months) consecutively referred for
GERD and treated with GA inhibitors. Exclusion criteria were: history of GA inhibitors
therapy in the previous 4 months, H.pylori infection, diabetes, chronic lung or heart diseases,
immunodeficiency, allergy, congenital motility gastrointestinal disorders, neuromuscular
diseases or malnutrition. GA-inhibitors (omeprazole, 1 mg/kg/day) were prescribed by the
physicians for 8 weeks. Enrolled patients were randomly assigned to one of the following
treatment groups: Group 1, received a commercially available probiotic mixture (YOVIS,
Sigma Tau, Italy) containing at least 290 billion viable lyophilized bacteria per gram (S.saliv-
arus subsp.thermophilus, B.breve, B.infantis, B.longum, L.acidophilus, L.plantarum, L.casei,
L.delbrueckii subsp. Bulgaricus, S.faecium), 500 mg/day given orally for 8 weeks; Group
2, received placebo powder containing starch which looked identical to the study agent for
8 weeks. Main Outcome Measures. Number of patients presenting AG or CAP during a 8
weeks follow up period. Results. 70 subjects were enrolled. Eight were excluded (6 in Group
1, 2 in Group 2) within the first 2 weeks from the enrollment because insufficient compliance.
We obtained data in 62 subjects: 32 in Group 1, and 30 in Group 2. The two groups were
comparable for demographics characteristics and for AG and CAP incidence in the previous
8 weeks. Rate of subjects presenting AG (30% vs. 9%, p=0.041) and CAP (37% vs. 6%, p=
0.004) was significantly increased in the placebo group compared to probiotics-treated
children. In addition, the number of patients taking antibiotics was significantly higher in
the placebo group (37% vs. 6%, p =0.004). Conclusions. Probiotics could be able to limit
the risk of infections in GA-inhibitors treated children. Our results support the importance
of microflora as crucial factor to prevent infectious diseases in children.
S1191
Exposure of the Esophagus to Acid in Patients with Reflux Treated with
Tegaserod
M Bafutto, C Carvalho Aquino, A S. Borges
BACKGROUND: Studies have shown that tegaserod (T), a selective 5-HT4 agonist, enhances
production of salivary buffers, reduces post-prandial gastroesophageal reflux and improves
gastric emptying.1-3 As the direct effect of T on acid exposure is unknown, this study
evaluated esophageal acid exposure in patients with reflux treated with T. METHODS: At
baseline (pre-T), 14 patients with reflux (3 male, 11 female) underwent 24-hour esophageal
pHmetry (proximal electrode placed 20cm above the lower esophageal sphincter (LES),
distal electrode placed 5cm above the LES). Patients received T 6 mg b.i.d. for 7 days.
pHmetry was repeated after the first T dose on Day 7. Medications that may interfere with
acid secretion and/or gastric motility were not permitted. Electrode measurements were
collected after food, and in standing and supine positions. Esophageal clearance (min/reflux)
was recorded and pathologic acid reflux episodes (defined as pH<4) were evaluated using
Castell parameters (proximal electrode) and the DeMeester score (distal electrode). Statistical
analyses were performed using paired t tests. RESULTS: T significantly reduced the number
of supine acid reflux episodes, measured at the distal electrode (pre- vs post-T, mean[SEM]:
18.43[5.13] vs 5.57[1.18] p=0.022). This difference almost reached significance at the
proximal electrode (2.79[0.81] vs 0.93[0.45] p=0.056) and there were non-significant trends
for fewer reflux episodes post-T measured standing, after food and overall. Compared with
pre-T, T significantly reduced the overall duration of esophageal exposure to acid (29.50[7.56]
vs 10.43[3.52] p=0.03, 106.07[13.88] vs 61.07[14.10] p=0.03, proximal and distal elec-
trodes, respectively) and duration of supine esophageal exposure to acid (14.57[7.84] vs
2.36[1.53] p=0.138; 39.43[11.02] vs 13.00[3.93] p=0.033, proximal and distal electrodes,
respectively). Non-significant trends for reduced duration of reflux episodes post-T were
also observed for standing and post-prandial measurements. Clearance of esophageal acid
was more rapid after T compared with pre-T, the difference being significant at the proximal
electrode (3.88[1.04] vs 1.41[0.22] p=0.022, 1.96[0.18] vs 1.57[0.31] p=0.288 for proximal
and distal electrodes, respectively). CONCLUSIONS: T reduced the number of acid reflux
episodes, duration of esophageal exposure to acid and esophageal clearance of acid. T may
improve esophageal acid clearance through its prokinetic properties and therefore may be
of clinical benefit in patients with reflux. 1 Degen. Aliment Pharmacol Ther 2001;15:1745-51
2 Jaworski. Dig Dis Sci 2005;50:357-65 3 Kahrilas. Aliment Pharmacol Ther 2000;14:1503-9
S1192
Predictors of Endoscopic Remission After Healing and Maintenance Therapy
for Reflux Esophagitis: Results from the Expo Study
Joachim Labenz, David Armstrong, Sofia Andersson, Stefan Eklund, Andreas Leodolter
Objective: The EXPO study compared esomeprazole and pantoprazole treatment for the
healing and maintenance of remission in patients with reflux esophagitis (RE). This analysis
of management (healing plus maintenance) identified factors predicting endoscopic remission
at the end of the management period. Methods: In a multicenter, randomized, double-
blind study (SH-NEG-0008), patients with endoscopically confirmed RE and symptoms of
gastroesophageal reflux disease (GERD) were randomized to once-daily (qd) esomeprazole
40 mg (n=1562) or pantoprazole 40 mg (n=1589) for 4-8 weeks. Patients without moderate/
severe symptoms of heartburn and acid regurgitation, and with healed RE, were then
randomized to receive maintenance treatment with esomeprazole 20 mg qd (n=1377) or
pantoprazole 20 mg qd (n=1389) for 6 months. Factors affecting the likelihood of remission
were examined in patients who were randomized to the same medication during both the
healing and maintenance phases (esomeprazole: n=772, pantoprazole: n=797) Proton pump
inhibitor (PPI), age, severity of RE, Barrett’s esophagus, hiatus hernia, Helicobacter pylori
status, BMI, dysphagia, gender, epigastric pain, acid regurgitation, severity of heartburn and
history of GERD symptoms were investigated in univariate analyses using logistic regression.
The covariates identified as significant (p<0.05) were included in the multivariate analysis.
Remission was defined as absence of mucosal breaks according to Los Angeles grading at
final endoscopy. Results: Univariate analyses identified PPI choice, age, RE severity, presence
of Barrett’s esophagus, H. pylori status and BMI as significant prognostic factors for remission
of RE. Multivariate analysis confirmed that all of these factors, with the exception of Barrett’s
esophagus, had an independent effect on remission at the end of RE management treatment
(Table). Conclusion: PPI choice of esomeprazole, older age, less severe baseline RE, positive
H. pylori status and BMI less than 30 all have a positive influence on management of RE.
Estimated odds ratio for factors affecting endoscopic remission (ITT population)
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The Effect of Repeated Doses of Esomeprazole On Pharmacodynamic and
Pharmacokinetic Variables in Infants Aged 1 to 24 Months with GERD
Taher Omari, Geoff Davidson, Patrik Bondarov, Emma Naucler, Catharina Nilsson-Pieschl,
Per Lundborg
AIM: To measure the effects of repeated doses of esomeprazole on the pharmacokinetics
(PK), intragastric pH, intraesophageal pH and reflux episodes in patients, aged 1-24 months,
with gastroesophageal reflux disease (GERD) symptoms. METHODS: In this single-center,
randomized, single-blind study (SH-NEC-0001) infants with symptoms of GERD (irritability/
crying, vomiting, choking/gagging) and ≥5% time with intraesophageal pH<4 received oral
esomeprazole 0.25mg/kg or 1mg/kg for 8 days. On day 7 or 8 blood samples (0.6ml) were
taken before, and 0.5, 1, 1.5, 2, 3, 4 and 6 hours after dosing in patients aged ≥3 months
and 1,2,3,4,and 6 hours after dosing for patients aged ≥1 month to <3 months. 24-hour
esophageal and gastric pH were measured at baseline and on day 7 or 8 using a dual pH
probe. RESULTS: 50 infants were randomized to treatment. The mean percentage of time
with intragastric pH>4 at baseline was 30.5% and 28.6% in the esomeprazole 0.25mg/kg
and 1mg/kg groups, respectively. After treatment, the mean percentage of time with intra-
gastric pH>4 was significantly higher with esomeprazole 1mg/kg (69.3%) than with esomep-
razole 0.25mg/kg (47.9%) (p<0.001). The mean percentage of time with intraesophageal
pH<4 at baseline was 11.6% and 12.5% in the esomeprazole 0.25mg/kg and 1mg/kg groups,
respectively. Both esomeprazole dosages decreased the percentage of time with intraeso-
phageal pH<4, to means of 8.4% and 5.5%, respectively. On day 7/8, the number of reflux
episodes longer than 5 minutes decreased from a mean of 6 at baseline to 3 and 2 with
esomeprazole 0.25mg/kg and 1mg/kg, respectively. For both dosages there was large inter-
individual variability in the PK variables. Numerically there was a larger-than-dose propor-
tional increase in AUC, AUCtao and steady state maximum concentration (CSSmax) between
dosages, although this was not statistically significant. Both dosages of esomeprazole were
well-tolerated. CONCLUSIONS: Repeated administration of 0.25mg/kg and 1mg/kg of eso-
meprazole resulted in a dose-related increase in the percentage of time with intragastric
pH>4, and a reduction in the percentage of time with intraesophageal pH<4, in infants aged
1-24 months with GERD.
Pharmacokinetic results
S1194
A Comparison of Clinical, Demographic, and Endoscopic Findings Among
Patients with Erosive and Non-Erosive Reflux Disease
Sachin Wani, Ajay Bansal, Priya Maddur, Sandi Hall, Srinivas R. Puli, Amit Rastogi, April
Higbee, Prateek Sharma
Background: Gastroesophageal reflux disease (GERD) is a common disorder associated with
a huge economic burden. Erosive esophagitis is present in 30-40% of GERD patients with
the remaining 60-70% classified to have non erosive reflux disease (NERD). The factors
associated with and that could possibly predict NERD in patients with reflux symptoms are
not known. Aims: The aim of this study was to compare clinical, demographic, and endoscopic
findings among patients with NERD and EE. Methods: Consecutive patients presenting to
the GI endoscopy unit (for their first upper endoscopy ever) for the evaluation of GERD were
asked to complete a validated GERD questionnaire (GERQ). The questionnaire documents the
duration of GERD symptoms (heartburn, acid regurgitation) and their frequency and severity
over the past year. Patient demographics (age, gender, ethnicity), clinical features (smoking,
ETOH, PPI use, BMI, family history) and endoscopic findings (EE, Barrett’s, hiatus hernia)
were recorded. NERD and EE patients were compared using a univariate analysis (chi square
and t-test) and thereafter multiple logistic regression analysis was performed to determine
factors significantly different between the 2 groups. Results: 451 patients with NERD and
248 patients with EE were analyzed. The mean ages of the NERD and EE groups were
58.9+12.6 and 55.1+12.9 years respectively (p=0.0001), and included 80% Caucasians in
each group. By univariate analysis, compared to EE patients, NERD patients were significantly
more likely to be older (p=0.002), non-smokers (p=0.005), use PPIs (p=<0.0001) but with
less frequent (p=0.0009) and severe (p=0.003) heartburn symptoms. On the other hand,
EE patients were more likely to have nocturnal symptoms (p=0.0006) and hiatus hernia

















with the presence of hiatus hernia (OR: 3.8, 95% CI: 2.4-5.8, p<0.001) and nocturnal GERD
(OR: 2.4, 95% CI: 1.3-4.5) while patients with NERD were more likely to be older (mean
age 58.9 years) and using PPIs (OR: 2.3, 95% CI: 1.3-3.9). Conclusion: Presence of a hiatus
hernia appears to be an independent risk factor for EE. Prior to endoscopy, NERD patients
are more likely to use PPIs (OR 2.3) indicating that PPI use may be responsible for healing
of low grades of EE and thereby increasing the prevalence of NERD. Another possible
explanation is referral bias- NERD patients, who are more likely to fail PPI therapy compared
to EE patients, may be referred more often for endoscopy.
S1195
Inappropriate Use of Proton Pump Inhibitors in a Hospital Setting in the
Netherlands
Evelyn P.M. van Vliet, Henk J.A.M. Otten, Ernst J. Kuipers, Pieter D. Knoester, Arjan
Rudolphus, Henk C. Hoogsteden, Peter D. Siersema
Background: Guidelines suggest that proton pump inhibitors (PPIs) should be used for the
treatment of acid-related disorders and the prevention of nonsteroidal anti-inflammatory
drug (NSAID)-associated gastrointestinal symptoms. Information on the use of PPIs in a
hospital setting is not widely available. The aim of this study was to assess prescription
patterns of PPIs on two medicine wards. Methods: We prospectively assessed the number
of patients on PPIs and the indications for use of PPIs on two pulmonary medicine wards,
one from a university (240 patients) and one from a regional (60 patients) clinic in The
Netherlands. Results: On admission, 88/300 (29%) patients already used PPIs. During
hospitalization, use of PPIs was terminated in 3 (1%) patients, whereas PPIs were initiated
in 42 (14%) patients, resulting in 127 (42%) patients using PPIs. Indications for PPI use
were in 33/127 (26%) patients an acid-related disorder, in 75 (59%) patients the prevention
of medication-associated complications (mainly complications of NSAIDs, corticosteroids
and antibiotics), and in 19 (15%) patients another reason. In 72/127 (57%) patients on PPI
therapy, PPIs were used for a registered indication, whereas in 55 (43%) patients, a non-
registered indication for PPI use was present (overuse). The reasons for overuse were the
prevention of (non-registered) medication-associated complications in 41/55 (75%) patients,
or another reason in 14 (25%) patients. Contrary to overuse, 21/300 (7%) patients were
not prescribed PPIs despite the presence of a registered indication (i.e., an acid-related
disorder (mainly reflux esophagitis) or the prevention of NSAID-associated gastrointestinal
symptoms) (underuse). The only statistically significant difference between the university
and the regional pulmonary medicine ward was the number of patients with underuse of
PPIs (5% vs. 13%, resp.) (p=0.03). The number of patients on PPIs on admission (31% vs.
22%) (p=0.15) and during hospitalization (45% vs. 33%) (p=0.12), and the number of
patients with overuse (20% vs. 13%) (p=0.26) were not significantly different between the
university and the regional unit. Conclusion: More than 40% of patients on pulmonary
medicine wards in The Netherlands are on PPIs. More than 40% of these patients use PPIs for
an unregistered indication. As it is likely that the same is true for other hospital departments,
physicians working in hospitals need to be educated on the present guidelines for PPI use.
S1196
Intragastric Acidity After H.Pyori Eradication: Is More Suppression Needed?
Yuhong Yuan, Marroon Thabane, Mohammad Yaghoobi, Jenny Liu, Richard H. Hunt
Background: Some studies suggest that PPIs suppress gastric acid secretion more effectively
in H.pyori infected than in uninfected subjects. This may increase the risk of developing
reflux symptoms in some patients and whether eradication can reduce the proportion of
the time with pH above a given threshold is not clear. This study reviewed the effects of
H.pyori eradication on 24 hour intragastric pH values in H.pyori infected healthy volunteers
during PPI therapy. Methods: Medline (1984-2005) was comprehensively searched to identify
English language clinical trials investigating the effects of H.pyori eradication on 24 hour
intragastric pH in healthy volunteers during PPIs therapy. Keywords included “H.pyori”,
“eradication”, “pH metry” or “gastric acid”, “PPI(s)”. For trial eligibility, 24 hour pH values
had to be obtained by pH metry. pH parameters of day 5-8 (steady state) after PPI therapy
were compared before and after eradication . Pooled mean estimates and corresponding
95% CI for pH parameters were estimated using a random effects model. Analysis was
performed using Review Manager 4.2.8. Results: Of the 7 relevant papers retrieved, two
were excluded because gastric acidity was measured by gastric aspiration or only 8 hour
nighttime pH data was reported. The remaining 5 included trials had a pooled total sample
of 65 subjects. The sample size per trial ranged from 10 to 18. PPIs included omeprazole
(4 arm, 20mg-40mg/day) and lansoprazole (1 arm, 30mg/day). At steady state on PPI therapy,
after eradication of H.pyori, pH decreased significantly with 24 hour mean pH compared
to the pre-eradication period [weighted mean difference (WMD) =1.38 (95% CI= 0.92-
1.83)], no significant heterogeneity was observed (p=0.13). Only two studies reported %
time pH>4/24 hrs, and this decreased significantly after eradication (WMD=31.96, 4.05-
59.88), although there was significant heterogeneity for these two studies(p<0.01). Conclu-
sion: H.pyori eradication diminishes acid suppression by PPIs, resulting in a 24 hour pH
decrease of 1-2 pH units and likely reduces holding time above any given target pH threshold.
Whether this “statistically significant” difference has clinical significance on PPI treatment
in patients with reflux disease needs further research.
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Maintenance Therapy with Continuous and On-Demand Rabeprazole (RAB)
20mg in Uninvestigated Gastroesophageal Reflux Disease
David G. Morgan, Michael F. O'Mahony, William F. O'Mahony, Jean Roy, Julie Dinniwell,
Fernando Camacho, Farah A. Husein-Bhabha
This multicentre, randomized study evaluated 6 months of RAB 20mg daily continuous
therapy (COT) with RAB 20mg on-demand (ODT) maintenance therapy in uninvestigated
GERD patients demonstrating satisfactory heartburn (HB) control during the final week of
a 4-week treatment period with daily RAB 20mg. Acute phase (n=331): Excellent HB control
was seen after 4 weeks of RAB 20mg, with 78% experiencing no or mild HB, and 93%
rating HB “satisfactorily” or “completely” controlled. Maintenance phase (n=268): There
were significantly more HB-free days with COT (90%) compared to ODT (65%; p<0.0001).
Defining good symptom control as no more than 2 episodes/week with maximum severity
rated mild, more patients in COT experienced approximately 5 days/week (>70% of days)
with no or mild HB (COT=98%, ODT=86%; p=0.0004) and rated HB for >70% of weeks
“satisfactorily” or “completely” controlled (COT=94%, ODT=84%; p=0.0098). A significantly
larger proportion of COT subjects experienced ≦2 days of HB with maximum severity rated
mild (COT=84%, ODT=41%; p<0.0001). There was overall improvement in quality of life
(QOL) from baseline to end of treatment for both COT and ODT groups based on GSAS
and PAGI-QOL scores. Significant differences were noted between treatment groups, with the
COT group experiencing fewer and less severe symptoms (GSAS), and greater improvement in
all PAGI-QOL sub-scores (excepting relationships). More patients were “satisfied” or very
satisfied” with overall treatment effect of COT regimen (92%) vs. ODT (79%; p=0.0070);
however, proportions rating overall effect of regimen on HB control as “good” or “very good”
were similar between groups (COT= 89%, ODT=83%, p=NS). The ODT group experienced
a greater mean number of HB episodes (COT=7, ODT=26) and longer mean episode duration
(COT=1.4, ODT=4.4 days; p=0.0319) compared to COT. Overall mean daily antacid usage
was low (COT=0.1, ODT=0.3 tablets; p=0.0023). Both treatment regimens were safe and
well tolerated. Conclusions: HB control was better with COT maintenance therapy, with
less frequent, less severe episodes, and greater improvement in QOL compared to ODT.
Patients indicated satisfaction with HB control with both regimens. While continuous treat-
ment with rabeprazole is better overall for symptom control, on demand therapy may be
an acceptable treatment option for GERD maintenance in selected patients. Funded by an
unrestricted grant from Janssen-Ortho Inc. Toronto, Canada.
S1198
A Randomized, Comparative Study of Three Doses of Azd0865 and
Esomeprazole for Healing of Reflux Esophagitis
Peter J. Kahrilas, John Dent, Karsten Lauritsen, Peter Malfertheiner, Hans Denison, Stefan
Franzen, Pelle Lundborg
Purpose: AZD0865 is a member of a new class of acid-suppressing agents, potassium-
competitive acid blockers, with a more rapid onset of action and greater potency than proton
pump inhibitors. The objective of the study was to compare the efficacy and tolerability of
3 doses of AZD0865 and esomeprazole 40 mg in esophagitis patients. Methods: A total of
1521 patients with reflux esophagitis according to the LA classification, and with heartburn
of moderate or severe intensity for ≥4 days/week, were randomized to AZD0865 25, 50,
or 75 mg, or esomeprazole (40 mg) once daily for up to 8 weeks. The primary endpoint
was endoscopically assessed healing of esophagitis by the 3 doses of AZD0865 at 4 weeks.
Healing was also assessed at 2, 4, and 8 weeks for each AZD0865 dose and esomeprazole,
as was control of heartburn. In a subgroup of patients, 24-h ambulatory intraesophageal/
intragastric pH monitoring was performed on day 14 of therapy. Safety and tolerability
were also assessed. Results: Esophagitis severity was balanced across patient groups, with
approximately 25% of patients having LA grade C or D esophagitis. After 4 weeks of
treatment, healing rates of 76.9% (95% CI: 72.4-81.1%), 78.2% (95% CI: 73.7-82.3%),
and 81.1% (95% CI: 76.7-84.9%) were reported with AZD0865 25, 50, and 75 mg. A
comparable healing rate of 81.9% (95% CI: 77.6-88.7%) was observed with esomeprazole
40 mg at 4 weeks. Healing rates were also similar between treatment arms at 2 and 8 weeks.
When stratified by baseline LA grade, there were no significant differences in healing rates
between AZD0865 doses and esomeprazole 40 mg. Sustained absence of heartburn was
reported by 50% of patients within 7-9 days of starting treatment with AZD0865, and within
6 days of starting treatment with esomeprazole 40 mg. No significant differences for either
intraesophageal or intragastric pH were seen on day 14 for any AZD0865 dose versus
esomeprazole 40 mg. Overall, AZD0865 and esomeprazole were well tolerated, headache,
nausea, and diarrhea being the most frequent adverse events. Serious adverse events occurred
infrequently and were not considered to be treatment related. Reversible increases in liver
transaminases were observed in a small number of patients receiving AZD0865. Conclusion:
Despite theoretical advantages related to pharmacokinetics and pharmacodynamics, treat-
ment with AZD0865 25 mg, 50 mg, and 75 mg was unable to provide greater efficacy than
esomeprazole 40 mg, either in terms of esophagitis healing or in the speed and degree of
heartburn control. Both agents were in general well tolerated.
S1199
H2 Receptor Antagonists Do Not Diminish the Acid Inhibitory Effects of
Omeprazole
Lars Fandriks, Anders Pettersson, Nimish Vakil
Background: Relief from acid-related reflux symptoms is directly correlated to speed of onset
and duration of acid suppression. Theoretically, the ideal pharmacological approach for on-
demand treatment should be to combine the rapid onset of action of a histamine-2 (H2)
receptor antagonist with the more profound and long-lasting effect of a proton pump inhibitor
(PPI) to relieve recurrent symptoms. However, as proton pump inhibitors are administered
as prodrugs and require an acidic milieu for activation, concern exists as to whether an
increase in intragastric pH in response to H2 blockers, may decrease the efficacy of proton
pump inhibitors. Aims: To determine if co-administration of an H2 receptor antagonist
decreases the efficacy of acid inhibition with omeprazole. Methods: H pylori negative healthy
volunteers (n=6) were studied in an open, randomized, crossover trial (n=6) with a 2 week
washout between treatments. Intra-gastric pH was monitored on day 1 and day 8 after daily
administration of omeprazole 20 mg (Ome); famotidine 10 mg (Famo) or a combination of
these (Ome+Famo). Standardized meals were administered on the test days. Results: Time
required for the pH to rise to >4 for at least 10 minutes after ingestion of medication as
well as fraction of time pH>4 during the entire daytime was significantly better (p<0.05)
with combination therapy than Ome on day 1. No differences between the treatments were
found after 8 days treatment. Fraction of time pH>4 during nighttime was not different
between treatments at any of the test days. Conclusion: 1. A combination of an H2 receptor
antagonist and a PPI raises gastric pH>4 in less than one hour and is comparable to potassium-
competitive acid blockers 2. Acid control over the entire daytime period is significantly
better on day 1 with combination therapy 3. H2 receptor antagonists do not inhibit activation
or efficacy of omeprazole on day 1 or day 8 challenging long held beliefs on acid inhibition
Duration in minutes after ingestion (mean±SEM) to sustained intragastric pH>4:
% time (mean±SEM) pH>4 during daytime (0900 to 2300)
S1200
Nocturnal Gastric Acidity After Bedtime Dosing of Proton Pump Inhibitors in
Patients with Nighttime GERD Symptoms
Philip O. Katz, David Ballard, Frauke K. Koch, Barry Goldlust, Jacqueline M. Major,
Theresa C. Gautille, Bonnie Hepburn
Introduction: Many patients with nighttime GERD have incomplete relief when treated with
proton pump inhibitors (PPIs) once daily before breakfast. Dosing before dinner or twice
daily (before breakfast and dinner) decreases nocturnal gastric acidity when compared to
morning dosing; however, optimal control of symptoms and acid remain clinical challenges.
Previous data showed immediate-release omeprazole suspension (IR-OME) dosed at bedtime
reduced nocturnal acidity to a greater degree than pantoprazole dosed before dinner. Aim:
To evaluate the effect of bedtime dosing with IR-OME 40mg (Zegerid®), esomeprazole 40mg
(ESO) and lansoprazole 30mg (LAN) on nocturnal gastric acidity. Design: Open label, 3-
period, randomized crossover (with washouts) evaluating IR-OME, ESO, and LAN given
daily at 2200 for 7 days (self-administered on days 1-5; in the clinic with standardized
meals at 0800, 1200, and 1700 on days 6 and 7). Gastric pH was measured over 24 hrs
beginning at 0700 on day 7. Primary endpoint: Nocturnal acid breakthrough (NAB) (gastric
pH < 4 for > 1 continuous hour between 2200 and 0600). Secondary endpoints: Percent
time gastric pH > 4, median gastric pH. Results: Forty-nine patients were analyzed (51%
male, median age 31 years). Primary endpoint: Percentage of patients with NAB was less
with IR-OME (61%) vs. ESO (92%) and LAN (92%), p<0.001, both. Percent time gastric
pH > 4 (between 2200-0600) was comparable for IR-OME and ESO (53% vs. 55%), both
superior to LAN (34%), p<0.001. Median gastric pH and percent time gastric pH > 4 were
substantially different when evaluated in cumulative 2 hr intervals from 2200 to 0600 (Table).
Conclusions: Bedtime dosing with immediate-release omeprazole results in a substantial
reduction in NAB compared to ESO and LAN, and provides more rapid control of nighttime
pH. Nighttime (8 hr) acid control with immediate-release omeprazole is comparable to that
with ESO and superior to that with LAN. These data suggest that bedtime dosing with
immediate-release omeprazole may be an effective strategy for managing patients with night-
time heartburn.
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* P<0.001 when compared to IR-OME, Wilcoxon signed-rank test.
S1201
The Effect of Acid Suppression On Subjective Sleep, Gastric Myoelectrical
Functioning, and Cardiac Autonomic Function in Patients with Erosive GERD
Chien-Lin Chen, Terry Bj Kuo
Background: Autonomic dysfunction and sleep disturbances have been observed in patients
with reflux disease or non-erosive esophageal reflux disease (Gastroenterology
2001;120:A629 and 2005;128:A518). Aim: This study was to investigate whether acid
suppression changes the functional characteristics regarding to heart rate variability, subject-
ive sleep, and gastric myoelectrical activity with a non-nutrient water load in patients with
reflux esophagitis. Methods: Twenty-eight patients with erosive esophagitis underwent heart
rate variability as well as electrogastrography with a 5-min water load and a subjective sleep
questionnaire. All patients were studied before and after esomeprazole 40 mg daily for 8
weeks. Subjects were also divided into mild or moderate esophagitis in order to determine
any variation in response related to the severity of esophagitis. Results: Sleep disturbance
occurred in 56% of patients with reflux esophagitis. The reflux symptom scale significantly
improved from 4.2 at baseline to 1.0 at week 8 (P < 0.001).The global Pittsburgh Sleep
Quality Index score decreased from 5.0 at baseline to 3.6 at week 8 (P < 0.01). A significant
increase in postprandial gastric 3 cpm (normal) activity was observed at week 8 (P < 0.05).
No significant changes were seen in any heart rate variability parameters or the volume of
water load. A significant improvement in subjective sleep was observed in mild esophagitis
(P = 0.03) while a significant increase in postrandial gastric 3 cpm (normal) activity occurred
in moderate esophagitis (P < 0.05). Conclusions: Acid suppression improves not only sleep
disturbances but also gastric myoelectrical functioning. Improvement in sleep appears to be
inversely related to the severity of erosive esophagitis.
S1202
Gerdyzer™ - A New Scale for Patient-Reported Outcome of HRQOL in GERD
Shows Excellent Psychometric Criteria. Validation Trial in 396 Patients with
Erosive Esophagitis
Juan R. Malagelada, Kenneth R. Devault, Olivier Chassany, Holger Schmitt, Ursula
Gebauer, Gerald Holtmann
PURPOSE: Health-related quality of life (HRQoL) is a key parameter for the evaluation of
treatment effectiveness in chronic conditions. To assess HRQoL, no GERD specific, reliable,
sensitive, and validated questionnaire existed so far. Therefore GERDyzer™, a self-assessed,
multidimensional, short, and easy to understand questionnaire was designed for use in
international GERD clinical trials. Here, we report data from the validation trial in erosive
esophagitis (EE). METHODS: GERDyzer™ covers 10 dimensions of HRQoL: general well-
being, pain/discomfort, physical health, energy, daily activities, leisure activities, social life,
diet/eating/drinking habits, mood, and sleep. Each dimension is illustrated by a pictogram-
like drawing, simplifying the communication with the patients, and assessed by a Visual
Analogue Scale. A multinational clinical trial with 396 EE patients (LA grade A-D, per
protocol) was performed. After 7 days pre-treatment, patients were treated with pantoprazole
40 mg od for 28 days. Patients filled in GERDyzer™ on days -7 and 0 of the pre-treatment
phase, and after 7, 14, and 28 days of treatment. For scale development a factor analysis
was performed. Weights were determined by optimizing the non-parametric effect size for
the total score. Psychometric analyses included internal consistency, test-retest reliability,
and responsiveness. Construct validity was evaluated by comparison with ReQuest™ and
it’s subscales, the Gastrointestinal Symptom Rating Scale (GSRS), and the Psychological
General Well Being (PGWB) index scale. RESULTS: Factor analysis showed consistency
of the dimensions and no reduction of dimensions was necessary. Further psychometric
characteristics are summarized in the table. CONCLUSIONS: This trial demonstrates that
GERDyzer™ clearly exceeds all psychometric requirements of a valid tool to assess patient
reported outcome. High internal consistency (Cronbach’s alpha 0.94) and test-retest reliabil-
ity, as well as large responsiveness and good construct validity were shown. GERDyzer™
is a validated and sensitive instrument that reliably assesses treatment-induced changes in



















Establishment of New Oral Treatment for Nerd Patients
Akinori Koide, Taketo Yamaguchi, Hidehiko Koyama, Takeo Odaka, Yoshihiro Koma,
Kenichi Nakajima, Izumi Shinbo, Hitoshi Maeda, Masato Ai, Yoshiharu Tokoro, Hiromitsu
Saisho
We reported a study which compared PPI plus Rikkun-shi-to (Liu-jun-zi-tang: Japanese
kampo medicine) combination treatment with PPI alone treatment in patients with unidenti-
fied complaints in the upper gastrointestinal tract including GERD patients at this meeting
last year. This study was a randomized control group study, which demonstrated that
the improvement effect especially on endoscopy-negative GERD (hereinafter, NERD) was
significantly greater in the Rikkun-shi-to combination group than that in the PPI alone group.
[Gastroenterology128:A530,2005 Gastroenterology126:A440,2004]. Objective: Randomized
control study among three groups of NERD patients to evaluate each treatment effect by
PPI alone, Rikkun-shi-to alone and PPI plus Rikkun-shi-to combination. Methods: Seventy-
two NERD patients who showed no response to PPI treatment in PPI test were randomly
allocated to one of the following three groups: PPI (Omeprazole 20 mg) continuous treatment
group, Rikkun-shi-to alone group and PPI plus Rikkun-shi-to combination group. The
treatment period was 4 weeks. Evaluation method: Using the GSRS (Gastrointestinal Symp-
tom Rating Scale, Japanese edition), score improvement in 4 GSRS parameters of all gastrointe-
stinal symptoms before and after administration, reflux symptoms, abdominal pain and
dyspepsia, and differences in GSRS scores (ΔGSRS scores) among three groups (ΔGSRS
score) were compared. Results: There were no differences in background factors among the
three groups. Evaluation results: 1) In PPI alone group (n=24), significant changes in GSRS
scores of all parameters were not observed before and after administration. 2) In Rikkun-
shi-to alone group (n=21), significant improvement in GSRS score of the parameter “dyspep-
sia” was observed (p<0.05). 3) In PPI plus Rikkun-shi-to combination group (n=27), signific-
ant improvements were observed in GSRS scores of the following three parameters: all
gastrointestinal symptoms and reflux symptoms (p<0.05, respectively), and dyspepsia symp-
toms (p<0.01). Comparing ΔGSRS scores among the groups, scores of the 2 parameters of
reflux symptoms and dyspepsia symptoms in PPI plus Rikkun-shi-to combination group
were significantly lower than those in PPI alone group and Rikkun-shi-to alone group
(p<0.05). Conclusion: We investigated oral treatment for NERD patients who had no response
to PPI. The results indicated that PPI plus Rikkun-shi-to combination treatment provided
greater effect than PPI alone and Rikkun-shi-to alone treatments in terms of patients’
QOL improvement.
S1204
A Randomized, Comparative Efficacy Study of Three Doses of Azd0865 and
Esomeprazole in Patients with Non-Erosive Reflux Disease
John Dent, Peter Kahrilas, Jan Hatlebakk, Nimish Vakil, Hans Denison, Stefan Franzen,
Goran Hasselgren
Purpose: AZD0865 belongs to a new class of acid-suppressing agents, potassium-competitive
acid blockers, with a more rapid onset of action and greater potency than proton pump
inhibitors. This study compared the efficacy and tolerability of 3 doses of AZD0865 with
esomeprazole 20 mg in patients with non-erosive reflux disease. Methods: In this 4-arm
parallel group, double-blind, multicenter, dose-finding comparative study, 1469 patients
with heartburn≥4 days/week of moderate or severe intensity were randomized to AZD0865
25, 50, or 75 mg or esomeprazole (20 mg) once daily for 4 weeks. The primary endpoint
was time to sustained absence of patient-reported heartburn (time to the first 7 consecutive
days free of heartburn) for the 3 doses of AZD0865. Secondary endpoints included the
comparative efficacy of each AZD0865 dose and esomeprazole for other patient-reported
symptoms. 24-h ambulatory intraesophageal/intragastric pH was performed in a subgroup
of patients on day 14 of therapy. Safety and tolerability were also assessed. Results: Following
4 weeks of treatment, the time to sustained absence of patient-reported heartburn was similar
between the 3 doses of AZD0865, and also between each dose of AZD0865 and esomeprazole.
The cumulative incidence of sustained absence of heartburn was also similar across all
groups (e.g. 62-70% on day 21). A comparable proportion of patients were free from
heartburn during the first, second, and fourth weeks of treatment with each dose of AZD0865
and with esomeprazole 20 mg (45-53% during the 4th week). No significant differences
were observed with respect to other symptom variables between the AZD0865 doses and
esomeprazole. AZD0865 75 mg was significantly more effective than esomeprazole with
respect to time with intragastric pH≥4 and 24-h median intragastric pH, but not for time
with intraesophageal pH<4, as assessed at day 14. There were no significant differences
between AZD0865 doses on these pH parameters. Both agents were well tolerated. Adverse
events of headache, diarrhea, and nausea were reported most frequently in the study. Serious
adverse events were infrequent in all treatment groups, and assessed to be unrelated to
study drug. Reversible increases in liver transaminases were observed in a small number of
AZD0865-treated patients. Conclusions: The fast onset of acid inhibition documented
previously with AZD0865 did not translate into faster or more effective control of heartburn
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in patients with non-erosive reflux disease. Esomeprazole 20 mg was at least as effective at
controlling heartburn as the three doses of AZD0865. Both agents were well tolerated overall.
S1205
Impact of Esophagitis Classification in Evaluating Healing After Therapy with
Proton Pump Inhibitors (PPIs)
Mohammad Yaghoobi, Sara Padol, Yuhong Yuan, Richard H. Hunt
Background: The Hetzel-Dent (HD), Savary-Miller (SM), and Los-Angeles (LA) classifications
describe the severity and healing of erosive esophagitis (EE) in clinical trials with PPIs.
Whether the reported healing rates are comparable between studies using different classifica-
tions has not been evaluated. The aim of this study was to review systematically the literature
to compare EE healing rates assessed by HD, SM or LA classifications. Methods: A recursive,
English language literature search in PubMed and Cochrane databases to August 2005 was
performed using keywords: (o) esophagitis, reflux, GERD, and PPI(s) (and individual names
of PPI). Double-blind RCTs comparing a PPI with the other PPIs, H2-RAs or placebo using
endoscopic assessment of healing of EE by HD, SM or LA, or their modified classification
at 4 or 8 weeks, were included in the study. Abstracts, studies without raw ITT data for
retrieval or clear definition of classification and duplicate publications were excluded. Data
of healing rate under the same PPI, and same EE grade was pooled and compared using
Fisher’s exact test or Chi-square when appropriate. Results: Fifty-three studies were included
from 256 potential citations. Of these, 25 compared PPI with another PPI, 5 with placebo,
and 23 with H2-RAs. Study subjects in PPI arms (n=79) were 41829 (7205 in 16 studies
with HD, 3874 in 26 studies with SM, and 27670 in 11 studies with LA). There was
insufficient data for rabeprazole and esomeprazole to compare as they were evaluated by
only one scoring system. When data from all PPIs was pooled regardless of EE grades, SM
(74%) healing rate was significantly higher than LA (71%) and HD (68%) at 4 weeks while
LA (90%) was significantly higher than SM (84%) and HD (83%) at 8 weeks (P<0.001).
The proportion of different grades was not separately available in all therapeutic groups but
for pantoprazole where the distribution of EE grades was similar for both LA and SM
subgroups. When analyzing data for PPI and dose, LA showed a higher healing rate for
omeprazole 20mg/d and pantoprazole 40mg/d (significant at 8 weeks; P<0.01), while SM
was significantly higher for omeprazole 40mg/d and lansoprazole 30mg/d at 4 and 8 weeks
(P<0.001). Healing rate under individual EE grade was not always available or robust enough
for meaningful analysis. However, a non-consistent difference between systems remained.
Conclusion: There is a significant, but not always consistent, difference in EE healing rates
in PPI users reported by HD, LA or SM classifications. The possible difference between
grading classifications should be considered when interpreting or comparing EE healing
rates from different studies.
S1206
An Exploratory, Randomised, Controlled, Parallel-Group, Open-Label Study to
Evaluate Different Dosing Regimens of rabeprazole in Controlling Nocturnal
Heartburn (NT HB) Symptoms in Uninvestigated Symptomatic
Gastroesophageal Reflux Disease (s-GERD)
David G. Morgan, Subhas C. Ganguli, Michael F. O Mahony, Jean Roy, Fernando
Camacho, Bruno Teixeira, Farah A. Husein-Bhabha
This exploratory study evaluated three RAB regimens for control of NT HB symptoms in s-
GERD patients with predominant NT HB, and no more than mild, infrequent daytime (DT)
HB symptoms on standard proton pump inhibitor or histamine-2 receptor antagonist therapy.
Eligibility was determined by NT and DT scores during the 14-day run-in period (score =
summation of frequency X severity of episodes for the defined period); patients also had to
indicate a lack of satisfaction with regards to their current acid suppressive therapy. Random-
ized patients (n=48) received either RAB 20mg taken once daily prior to breakfast (QAM),
or RAB 20mg taken once daily prior to dinner (QPM), or RAB 10mg taken twice daily in
morning and evening prior to meals (BID) for 8 weeks. Diary assessments included heartburn
occurrence and severity (daily), RAB and rescue antacid usage (daily), and ratings of heartburn
control and satisfaction (weekly). Results: Mean (±SD) NT HB scores at 4 weeks were QPM:
6.9±8.0, QAM: 8.1±10.4 and BID: 12±12.6 (p=0.2330). There was significant improvement
in mean NT HB scores at 4 and 8-weeks from baseline for all regimens, with larger changes
observed for QAM and QPM regimens. There was an overall decrease in NT antacid usage
at both 4 and 8-weeks for QAM and QPM regimens; however, the change in NT antacid
usage from baseline was significant at 4 weeks for the QAM and QPM regimen, but only
significant at 8 weeks for the QAM regimen. The majority of patients in all regimens rated
NT HB control “satisfactorily” or “completely controlled” at 4- and 8-weeks, as well as rated
satisfaction with NT HB control as “satisfied” or “very satisfied” at these time points; no
differences were observed between regimens. PAGI-SYM, PAGI-QOL and WPAI-GH mean
scores improved in a similar manner for all regimens, at all time-points, compared to baseline.
The between treatments comparisons indicated that subjects in the QPM regimen tended
to report lower scores than the QAM group, and both groups, in turn, reported lower scores
than the BID group. Compliance with each regimen was excellent (>/=95%). All RAB regimens
were safe and well tolerated. Conclusions: The results suggest that the QAM, and possibly
the QPM regimen, may provide better nighttime symptom control with a corresponding
improvement in QOL and productivity than a BID RAB regimen. Further studies are needed
to provide more conclusive evidence and also to further investigate the phenomenon of NT
HB. This research was funded by an unrestricted grant from Janssen-Ortho Inc., Toronto,
Canada.
S1207
On-Demand Maintenance Therapy in Patients with Esophagitis and Non-
Erosive Reflux Disease (NERD): A Prospective, Randomized, Crossover,
Comparative Study of rabeprazole Versus Lansoprazole
Miguel Sobrino-Faya, Marta Iglesias-Rey, Enrique Dominguez-Munoz
Background: On-demand therapy with proton pump inhibitors (PPI) has been shown to be
a cost-effective approach for long-term maintenance therapy of NERD. Whether on-demand
PPI therapy is suitable for esophagitis patients is unclear. In this context, comparative studies
between different PPI are lacking. Aim: To evaluate the efficacy of on-demand therapy in
patients with low-grade esophagitis and NERD, and to compare in this context the effect
of rabeprazole and lansoprazole. Methods: 63 patients (mean age 46 yrs, 35 male) with
GERD were consecutively included in this prospective, randomized, open-labelled, crossover,
comparative study, once severe esophagitis (grades C or D) was excluded. Patients were
randomized to receive lansoprazole 30mg/day or rabeprazole 20mg/day for 8 weeks. Patients
with complete symptom relief and esophagitis healing were treated on-demand with the
same PPI for 8 weeks and then changed to the other PPI for further 8 weeks. Discontinuation
because of unwillingness to continue, incomplete heartburn control or endoscopic relapse
was considered as failure of on-demand therapy. Quality of life (QoL) was quantified by
the QOLRAD questionnaire, and PPI and antacids consume was recorded. Results: After 8-
week daily PPI therapy, 15 patients were not suitable for on-demand schedule because of
persistence of esophagitis and/or symptoms (n=11), or protocol violation (n=4). Among the
48 patients who received on-demand maintenance therapy, 32 (66.7%) completed the study
and were willing to continue under on-demand treatment. Discontinuation occurred in 11
out of 22 patients (50%) with previous esophagitis, mainly because of endoscopic relapse,
compared to 5 out of 26 NERD patients (19%) (p=0.15). Most of these patients (87.5%)
discontinued on-demand therapy during the first 8 weeks, both under rabeprazole and
lansoprazole. In total, 11 out of 43 patients discontinued during on-demand rabeprazole
and 5 out of 39 during on-demand lansoprazole (n.s.). Consume of PPI (mean 1 dose every
5 days) and antacids (mean 1 dose every 12 days) was similar for lanzoprazole and rabepra-
zole. QoL score (basal 96.5 [31.0-140.1]) improved markedly after 8 weeks of daily PPI
intake (34.5 [25.0-83.4]; p<0.001). At the end of the 16-weeks on-demand therapy, QoL
(54.5 [25.0-113.3]) remained better than basal (p<0.001), but impaired compared to daily
PPI intake (p<0.01). Conclusions: On-demand maintenance therapy is effective in most
patients with NERD, but it appears to be inadequate for patients with low-grade esophagitis.
In this context, rabeprazole and lansoprazole appear to be equally effective.
S1208
Control of Transient Lower Esophageal Sphincter Relaxations (TLESRs) and
Reflux By a Histamine H2 Receptor Antagonist (H2RA) Nizatidine (NIZ) in
Healthy Subjects
Katsuhiko Iwakiri, Makoto Kotoyori, Yoshinori Hayashi, Yuriko Tanaka, Noriyuki
Kawami, Choitsu Sakamoto, Richard H. Holloway
Background: A study in Japan has found that NIZ 150 mg bid, was more effective than
other H2RAs in treating reflux disease even though the NIZ group included more severe
reflux esophagitis (RE) compared with other H2RAs. As it has been reported that there is
no difference in the level of acid suppression among H2RAs it is possible that the NIZ has
other effects on acid reflux besides acid suppression. We have previously reported that there
is no difference between healthy subjects and patients with RE in the rate of either TLESRs
or acid reflux during TLESRs at 2cm above the LES. In this study, we have evaluated the
effect of NIZ on the rate of TLESRs and the rate of acid reflux during TLESRs at 2cm above
the LES in healthy subjects. Methods: In 10 healthy subjects, esophageal motility and pH
study were measured, with the subjects in the sitting position, for 3 hours after a 692 kcal
meal on 2 separate days at least 1 week apart. On one occasion, participants received an
oral dose of 150mg of NIZ 60 minutes before the meal and on the other placebo. Both
studies were preceded by a week of treatment with either NIZ (150mg, bid) or a placebo.
The order of treatment was randomized. Results: The rate of TLESRs, the rate of acid reflux
during TLESRs and esophageal acid exposure time after receiving NIZ were significantly
lower than after receiving a placebo. Conclusions: NIZ significantly inhibits gastroesophageal
reflux episodes by inhibiting both the rate of TLESRs and acid reflux during TLESRs. These
findings suggest that NIZ may be useful for mild esophagitis which is characterized by mild
excessive esophageal acid exposure from reflux that occurs primarily during TLESRs.
median (interquartile range),* p < 0.05, ** p < 0.01 vs. placebo
S1209
Comparison of the Effects of Fasting Morning, Fasting Evening, and Fed
Bedtime Administration of Tenatoprazole On Intragastric pH in Healthy
Volunteers: A Randomized Three-Way Crossover Study
Alan B R. Thomson, Patrick Cohen, Herve Ficheux, Florence Domagala, Michel Homerin
Background/aims: The effectiveness of marketed benzimidazole-based proton pump inhib-
itors (PPIs) is influenced by meals and administration time. Product labelling generally
recommends that they should be taken fasting before breakfast. Poor night-time acid control
and persistence of night-time symptoms often result in twice a day dosing. Tenatoprazole
is a novel imidazopyridine-based PPI with a 7-fold prolonged plasma half-life; it demonstrated
a prolonged effect and a significantly better control of night-time acid secretion than esomep-
razole at treatment initiation, 7-day steady state and 3 and 5 days after treatment withdrawal.
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This study aimed at comparing the effects of tenatoprazole on intragastric acidity in healthy
volunteers, when administered before breakfast, before dinner and at bedtime. Methods:
This randomized 3-period crossover study included 12 Helicobacter pylori-negative subjects,
who were given tenatoprazole 40 mg qd either fasting at 7:00 am, fasting at 7:00 pm or
fed at 9:30 pm for 7 consecutive days. Subjects washed out for 2 weeks between periods.
Intragastric pH was monitored for 24 hours on day 7 of each of 3 periods. Results: On day
7, the median 24-hour pH was 4.7±0.5, 5.1±0.6 and 4.7±0.5 after breakfast, dinner and
bedtime dosing, respectively (p=0.11), whereas the median night-time pH was 4.2±1.2,
5.0±1.0 and 4.4±0.8, respectively (p=0.13). The mean percentage of time spent over pH 4
in 24 hours was 62±11, 72±13 and 64±11 after breakfast, dinner and bedtime dosing,
respectively (NS), and 54±17, 68±18 and 56±10 during night-time (p=0.06). Nocturnal
Acid Breakthrough (NAB) incidence was reduced from 100% at baseline to 83%, 55% and
75% after 7.00 am, 7.00 pm and 9.30 pm dosing, respectively (p=0.18), and mean NAB
duration dropped from 6.2±3.4 to 2.8±2.2, 1.0±1.2 and 2.2±1.8 hours (p< 0.05). Conclusion:
7-day administration of 40 mg tenatoprazole once-a-day exerts a profound control of intra-
gastric acidity expanding over night-time, with little effect of food intake and time of dosing.
Clinical trials are in progress, which are aiming at demonstrating the clinical advantages of
the improved flexibility of the treatment with once-a-day tenatoprazole.
S1210
High Dose Versus Standard Dose Proton Pump Inhibitors in the short Term
Management of Reflux Esophagitis
Mostafizur Khan, Jose Santana, Clare Donellan, Cathy Preston, Paul Moayyedi
Introduction: Proton pump inhibitors (PPIs) are the most effective medical therapy for
GERD. Some GERD patients, however, do not respond to standard dose PPI therapy and
a common practice is to double the dose. The efficacy of this strategy is uncertain and is
also unclear whether there is any difference between different types of PPIs. We therefore
evaluated the efficacy of double dose versus standard dose PPI therapy in patients with
esophagitis in a Cochrane systematic review. Methods: We conducted a search of electronic
databases (Medline, Cinhal, Embase and Cochrane controlled trials register) to May 2005.
We also performed a recursive search of literature from identified articles. All randomized
control trials (RCTs) in adult patients (≥18) with endoscopically proven esophagitis compar-
ing standard dose with double dose PPI for 4- 8 weeks were eligible. Eligibility check and
data extraction were performed by two independent reviewers and discrepancies if any were
resolved by a third reviewer. Results were expressed as relative risk of esophagitis persisting
in the double dose versus standard dose PPI groups. Meta analysis was performed using a
DerSimonian and Larid random effects model (Rev-Man version 4.2.8 and Stata version 8).
Results: We identified 14 articles evaluating 11,497 esophagitis patients. Overall esophagitis
persistence in high dose group (22.6%) was lower than in standard dose group. (28.7%),
but the difference was not statistically significant. (RR of persistence at 4 weeks = 0.89,
95%CI= 0.76 to 1.04) with a number needed to treat of 33 (95%CI= benefit 14 to harm
100). Overall symptoms persisted in 25.6% patients in the group taking a high dose of
PPIs, compared to 23.1% in the standard dose group and this difference was not statistically
significant (RR of persistence at 4 weeks= 1.06, 95% CI= 0.90 to 1.25) with a number
needed to harm of 100 (95% CI = harm 25 to benefit 50). A subgroup analysis of trials that
evaluated esomeprazole 40mg once daily showed statistically significant effect on esophagitis
healing (RR of esophagitis persistence = 0.75, 95% CI= 0.62 to 0.9) compared to standard
dose PPI therapy. There was statistically significant heterogeneity between studies (chi
square= 18.2, df = 4, P=0.001) and this was not explained by the quality of trial, grade of
esophagitis or the type of PPI evaluated in metaregression model. There was no statistically
significant difference between any of the other PPIs. Conclusion: These data do not support
the practice of doubling the dose of PPI therapy in patients that do not respond to standard
dose therapy. An exception to this may be esomeprazole 40mg once daily.
S1211
Predictors of Resolution of Heartburn in Patients with Reflux Esophagitis:
Results from the Healing Phase of the Expo Study
Joachim Labenz, David Armstrong, Sofia Andersson, Stefan Eklund, Andreas Leodolter
Objective: The aim of this analysis was to identify factors predicting sustained resolution of
heartburn in patients with reflux esophagitis (RE) after 4 weeks of healing therapy with a
proton pump inhibitor (PPI) during a multicenter, randomized, double-blind trial (the EXPO
study; SH-NEG-0008). Methods: Patients with endoscopically confirmed RE and symptoms
of gastroesophageal reflux disease (GERD), including heartburn for ≥4 days of the last
7 days before enrollment (overall moderate or severe), were randomized to once-daily
esomeprazole 40 mg (n=1562) or pantoprazole 40 mg (1589) for 4-8 weeks. PPI, age,
severity of RE, Barrett’s esophagus, hiatus hernia, Helicobacter pylori status, BMI, dysphagia,
gender, epigastric pain, acid regurgitation, severity of heartburn and duration of GERD
symptom history were investigated in univariate analyses using logistic regression. The
covariates identified as significant (p<0.05) were included in the multivariate analysis. Resolu-
tion of heartburn was defined as no heartburn during the last 7 days prior to the 4-week
visit. Results: Univariate analyses identified choice of PPI, age, H. pylori status, absence of
dysphagia, epigastric pain and acid regurgitation, gender and duration of GERD symptom
history (>5 yrs vs ≤5 yrs) as significant prognostic factors for heartburn resolution at week
4. With the exception of dysphagia and history of GERD symptoms, multivariate analysis
confirmed that all of these factors were predictive of resolution of heartburn (Table). Conclu-
sion: PPI choice of esomeprazole, older age, positive H. pylori status, male gender, lack of
epigastric pain and lack of acid regurgitation all have a positive influence on sustained
resolution of heartburn during RE healing treatment.



















Predictors of Heartburn Remission in Patients with Reflux Esophagitis:
Results from the Maintenance Phase of the Expo Study
Joachim Labenz, David Armstrong, Sofia Andersson, Stefan Eklund, Andreas Leodolter
Objective: This analysis aimed to identify factors predicting remission of heartburn in patients
with reflux esophagitis (RE) during maintenance therapy with a proton pump inhibitor
(PPI). Methods: During a multicenter, randomized, double-blind trial (the EXPO study; SH-
NEG-0008) patients with endoscopically confirmed RE and symptoms of gastroesophageal
reflux disease (GERD) were randomized to once-daily (qd) esomeprazole 40 mg or pantopra-
zole 40 mg for 4-8 weeks. Patients without moderate/severe symptoms of heartburn and acid
regurgitation, and with healed RE, were randomized to receive maintenance esomeprazole 20
mg qd (n=1377) or pantoprazole 20 mg qd (n=1389) for 6 months. PPI, age, severity of
RE, Barrett’s esophagus, hiatus hernia, Helicobacter pylori status, BMI, dysphagia, gender,
epigastric pain, acid regurgitation, severity of heartburn and history of GERD symptoms
were investigated in univariate analyses using logistic regression. The covariates identified
as significant (p<0.05) were included in the multivariate analysis. Remission was defined as
absence of heartburn at clinical visits throughout the maintenance phase. Results: Univariate
analyses identified choice of PPI, age, H. pylori status, absence of dysphagia, absence of
epigastric pain, length of history of GERD symptoms and severity of heartburn as significant
prognostic factors. With the exception of dysphagia, multivariate analysis confirmed that
all of these factors had an independent effect on maintaining resolution of heartburn (Table).
Conclusion: PPI choice of esomeprazole, older age, positive H. pylori status, lack of epigastric
pain, moderate severity of heartburn (as opposed to severe) and a shorter history of GERD
symptoms all have a positive influence on the chance of heartburn remission during mainten-
ance therapy.
Odds ratio estimates for factors affecting heartburn remission (ITT population)
**p<0.01; ****p≤0.0001
S1213
Assessment of Therapy and the Patients’ QOL in Gastro-Esophageal Reflux
Disease in Japan: A Cross-Over Trial
Hiroyuki Okada, Ryuta Takenaka, Yoshiro Kawahara, Tatsuya Toyokawa, Yuuichi Mouri,
Yasuhiro Nagahara, Masahiro Takatani, Junji Shiode, Jouichiro Horii, Satoru Yagi, Takao
Tuzuki, Daisuke Tanioka, Jun Katoh, Hirofumi Kawamoto, Yasushi Shiratori
Purpose: To compare the efficacy of the proton pump inhibitor (PPI) with that of H2-
receptor antagonist (H2-RA) and to evaluate the patients’ QOL in the Japanese patients with
gastro-esophageal reflux disease (GERD). Methods: A cross-over trial was conducted on
Japanese patients with heartburn who received either PPI (20 mg of rabeprazole) or H2-RA
(300 mg of ranitidine) for 8 weeks.. If the symptom did not resolve with the initial therapy,
the drug was replaced by the other drug 2 weeks after completion of the initial therapy and
administered for 8 weeks. If the symptom recurred after relief by the initial drug, the
other drug was administered. The patients were asked about their condition using SF-36
questionnaire before and after treatment with the respective drugs. Results: One hundred
patients who completed the cross-over trial patients (Los Angeles grade A in 31, B in 27,
C in 3, D in 1, and N in 38) were the subjects of our analysis. Heartburn resolved in 81
patients (81%) with PPI and 58 patients (58%) with H2-RA, and neither drug was effective
in 7 (7%). Treatment with PPI was significantly more effective than that with H2RA in 29
patients aged under 50 years (72% versus 45%; P<0.05) and 36 patients aged from 50 to
64 years (83% versus 58%; P<0.05), whereas the efficay rate was not significantly different
between both drugs in 35 patients aged > or =65 (83% versus 66%; P=0.1). Although PPI
was significantly more effective than H2-RA in 54 patients without H. pylori infection (84%
versus 53%; P<0.05), the efficacy rate was not significantly different in 46 patients with H.
pylori infection (73% versus 60%; P=0.18). In SF-36, the scores of the scale for eight items
contributing to the degrees of physical health and mental health (sex- and age-adjusted
deviation) were lower than those of the general population at the baseline and recovered
by treatment. Especially in the patients aged under 50 years, the scores concerning body
pain and general health, among the eight items, were much inferior to those of the general
population before treatment. Conclusions: PPI is more effective than H2RA in relieving the
symptom of GERD, especially for the younger and the middle aged patients and those
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without H. pylori infection. However, in Japan where GERD is commonly mild, similar
efficacy is observed in the elderly patients or those with H. pylori infection.
S1214
A Meta-Analysis of Efficacy of Esomeprazole Compared with Other Proton
Pump Inhibitors On Erosive Esophagitis
Hong Gao, Tianshu Liu, Naiqing Zhao, Jiyao Wang
Objective Meta-analysis was performed to evaluate the efficacy of esomeprazole, an S-isomer
of omeprazole, with other proton pump inhibitors on erosive esophagitis(EE). Methods
Medline, EMBASE, CBM and AstraZeneca’s internal database were searched for abstracts
and papers(-Sep 2005). Search terms and strategy were((gastroesophageal reflux) OR (eso-
phagitis OR oesophagitis )) AND esomeprazole. The criteria for selection of trials for inclusion
were a study design that was a randomized controlled trial or retrospective control test,
direct comparison of esomeprazole 40 mg with standard healing dose of any proton pump
inhibitor, which contained endoscopic healing data or resolution rate of symptom such as
heartburn based with intention-to-treat population at 4 weeks and/or 8 weeks. The articles
whose Jadad scores were below or equal to 2 were excluded. Meta analysis was performed
with the method of General Base Variance. If the heterogeneity was significant the methods
of Der Simonian and Laird with the randomized effect model were adopted. If p value was
above 0.05 fixed effect model was adopted. The substraction healing rates of EE of the study
group and the control group was used as the effect size. The calculation of resolution rates
was the same. The sensitivity analysis was performed according to the different PPIs that
were used as control drugs. The microsoft of statistics was STATA 7.0. Results Eight trials
including 18147 patients comparing the efficacy of esomeprazole and omeprazole, lansopra-
zoel, pantoprazole on EE were identified. The average difference of healing rate of 4 weeks
(healing rate of esomeprazole - that of other PPI) was 8.8% and 95%CI was 5.9% ~11.8%
(P<0.001). The average difference of healing rate of 8 weeks (healing rate of esomeprazole -
that of other PPI) was 6.0% and 95%CI was 4.0% ~8.1% (P<0.001). The average difference
of resolution rate of 4 weeks (resolution rate of esomeprazole - that of other PPI) was 7.2%
and 95%CI was 4.0% ~10.4% (P<0.001). According to the test of heterogeneity the including
studies were heterogeneous. We classified the studies according to the different control drugs.
Test of heterogeneity showed that the studies comparing esomeprazole with omeprazole or
lansoprazole respectively were homogeneous. Fixed effect model was adopted. The result
of meta-analysis suggested that the healing rates of 4weeks, 8weeks on EE and the resolution
rate of heartburn of esomeprazole were higher than those of omeprazole and lansoprazo-
le(p<0.01). Conclusion Esomeprazole exhibits better efficacy on erosive esophagitis than
the other PPIs such as omeprazole and lansoprazole.
S1215
Multivariate Analysis of Factors Affecting the Healing of Reflux Esophagitis in
Japan
Ken Ariizumi, Shuichi Ohara, Tomoyuki Koike, Shigeyuki Kobayashi, Hatushi Yamagishi,
Atushi Miura, Yoshifumi Inomata, Yasuhiko Abe, Masashi Kawamura, Yasushi Kitagawa,
Katsunori Iijima, Akira Imatani, Tooru Shimosegawa
Background and aims: PPIs are acid suppressors that are being used to treat reflux esophagit-
is(RE), though some patients are unresponsive to PPIs. This study was designed to investigate
what kind of factors were related to the healing of RE in treatment with PPIs. Methods:
Subjects were 135 Japanese patients who had endoscopically diagnosed RE of grade A to
D by the Los Angeles(LA) classification (male/female:78/57; mean age 60.3±14.7 years).
They were treated with daily oral administration of 30mg LPZ(n=41) or 10 mg RPZ(n=94).
At 8 weeks after the start of treatment, healing of RE was evaluated endoscopically. Gender,
age, body mass index(BMI), presence of hiatus hernia, grade of RE, H.pylori infection status,
alcohol drinking and smoking were investigated by the univariate analysis and logistic
regression analysis. Results: At 8 weeks after the start of treatment, the overall healing rate
of RE was 91.1%(123/135). Healing rates in the respective factors were as follows: male
and female were 91.0%(71/78) and 91.2%(52/57), hiatal hernia(+) and (-) were 89.7%(104/
116) and 100%(19/19), H.pylori positive and negative were 90.8%(79/87) and 91.7%(44/
48), drinking habit(+) and (-) were 90.4%(47/52) and 91.6%(76/83), smoking habit(+)
and (-) were 87.9%(29/33) and 92.2%(94/102), LA classification grade A,B,C and D were
94.7%(36/38), 90.3%(65/72), 87.0%(20/23) and 100%(2/2). By the univariate analysis,
there were no significant differences in gender, presence of hiatus hernia, grade of RE,
H.pylori infection status, alcohol drinking and smoking. BMI of the healed and unhealed
patients was 24.9±3.6 and 24.2±3.9, respectively. Ages of the healed and unhealed patients
were 59.6±14.7 and 68.0±7.6, respectively. There were no significant differences in the age
and BMI for the healed and unhealed patients. By logistic regression analysis, age was
revealed to be the significant factor that affect the healing rate of RE. Conclusions: Age is
the significant factor that affect the healing rate of RE in Japan.
p-value (Logistic regression analysis)
S1216
A Quality of Life in Patients with EE and Nerd Treated by Rabeprazole-An
One-Year’s Multi-Center Open Study
Xiaohong Liu, Meiyun Ke, Zhiqiang Song, Jinyan Luo, Yaozong Yuan, Xiaohua Hou,
Youling Zhu, J.N. Sun, Hui Zha
Background: GERD significantly affects a patient’s quality of life (QOL). The QOL severity
and responsiveness to PPI have been considered different between erosive esophagitis (RE)
and non-erosive reflux disease (NERD), but few studies have compared the long-term
outcomes. Objectives: To compare the health-related quality of life (HRQoL) in the patients
with EE and NERD treated with rabeprazole (RAB, Pariet) in an one-year’s multi-center
open study. Methods: From 2002.12 to 2003.6, 80 patients with EE diagnosed by endoscopy,
and 40 patients with NERD defined as a negative endoscopic finding, the Demeester
scores>14.27 and reflux symptoms score>6, were enrolled in. All patients were treated with
RAB (10mg bid ac) for 8wks. The erosions healed endoscopically in EE patients and the
reflux symptoms score decreased>75% in patients were divided into maintenance (10mg
qd) and on-demand therapy groups, and fellowed up 52w. The impacts on HRQoL (SF-
36) and GERD-HRQoL were assessed before and after therapy. Results: Cure rate of EE was
93.4% after 8w treatment. At baseline, HRQoL in NERD was impaired greater than in EE.
After therapy, the qol was improved in all subscales in EE group, however, it was much
lower in NERD group. The scale of GERD-HRQoL improved significantly in EE than in
NERD group. 52w followup was available in 67 EE and 31 NERD patients. There was not
significant difference between maintenance and on-demand therapies in EE and NERD. The
improvement of HRQoL at 8w was still kept during 52w in EE. In NERD the HRQoL, as
well as the reflux symptoms, was upgraded gradually and close to EE (NS). Conclusions:
NERD causes a more significant impairment in the qol than EE, which can be attenuated
partly after 8w treatment with RAB, unlike the satisfactory results in EE. But in NERD
HRQoL was improved gradually in long-term PPI maintenance, therefore On-demand might
be suitable to NERD patients.
S1217
Night-Time Heartburn As a Possible Indicator of Degree of Heartburn Severity,
Frequency and Response to Standard Acid Suppressive Regimens
David G. Morgan, Subhas C. Ganguli, Michael F. O'Mahony, Jean Roy, Fernando
Camacho, Bruno Teixeira, Farah A. Husein-Bhabha
Night-time heartburn (NT HB) is common in patients with symptomatic GERD (s-GERD),
and is often an indicator of nocturnal acid reflux events. A better understanding of NT HB
has implications for the management of s-GERD patients. As part of a randomized, controlled,
open-label study evaluating different dosing regimens of rabeprazole (RAB) in controlling
NT HB symptoms, this pre-randomization phase identified patients with clinically important
NT HB (as defined by a NT HB score >/=4 (score = summation of frequency X severity of
episodes), with adequate daytime (DT) HB control, and who were not satisfied with their
current therapy. Patients screened for the presence of NT HB symptoms despite acid suppress-
ive therapy (proton pump inhibitor (PPI) or histamine receptor antagonist (H2RA)) for
minimum of 4 weeks were enrolled. Patients continued their current regimen during the
14-day pre-randomization period. Data are presented for 128 enrolled patients (60% female,
mean age 52 years, mean duration of heartburn 12 years, mean duration of NT HB symptoms
8 years); 120 patients met diary compliance requirements. All primary PPI or H2RA therapy
at entry was at recommended doses for s-GERD treatment. Dosing was reported most
commonly as morning before breakfast for PPIs, and morning and evening pre-meals for
H2RAs. Clinically important NT HB was observed in 87% (104/120) of patients; of these,
48% (50/104) had predominantly NT HB (with none, or mild, infrequent DT HB) and 52%
(54/104) had both NT HB and clinically important DT HB (moderate or greater DT symptoms
and/or more than 3 DT episodes in 7 days; DT score >5). Patients with clinically important
NT HB (group A) experienced significantly greater frequency and severity of both NT and
DT HB than those with predominantly DT HB or good overall DT and NT HB control
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(group B): NT= mean of 9.5 episodes, mean score of 19.2 for A (vs. 1.0 episodes, mean
score of 1.2 for B), DT= mean of 6.2 episodes, mean score of 9.5 (vs. 1.4 episodes, mean
score of 1.9 for B); all p-values <0.05. Group A also needed antacids for significantly longer
durations to manage DT and NT symptoms. Conclusions: Of patients self-identifying with
nocturnal symptoms at study entry, the majority had bothersome, clinically important night-
time heartburn despite acid suppressive therapy. A large proportion of these patients have
both frequent and severe daytime and nocturnal symptoms, suggesting that the presence of
night-time heartburn may require more detailed questioning about symptoms and a different
therapeutic approach than standard regimens. Funded by an unrestricted grant from Janssen-
Ortho Inc. Toronto, Canada.
S1218
Comparison Between the Combined Analysis and the Demeester Score to
Predict Reponse to PPI Therapy
Inder Mainie, Radu Tutuian, Amine Hila, Amit Agrawal, Donald O. Castell
Background: Distal esophageal acid exposure can be quantified by either the DeMeester
score (DS) or percentage time pH < 4. In addition to these parameters symptom index (SI)
is used to evaluate the association of symptoms and acid reflux. Combined analysis (CA)
including the SI and percent time pH < 4 provides a more complete interpretation of pH
monitoring. Aim: To compare the accuracy of the CA to the DS for interpretation of pH
monitoring. Method: pH studies from 450 patients (303 female; mean age 53; range 11-
88) between July 2002 and October 2004 were analyzed. DS (normal < 14.7), percent time
pH < 4 (normal; upright <6.3%, recumbent < 1.2) and SI measured, (positive SI (+SI) ≥
50%). Symptom responses to PPIs were assessed in patients with discordant DS and CA
using a chart review or contact by phone. Results: Mean duration of monitoring was 22
hours and 34 minutes. 245 (54%) patients had an abnormal study using the combined
analysis. 27 (11%) of the abnormal studies had a positive SI but normal % time pH < 4.
180 (40%) patients had a DS > 14.7. Comparing DS to CA, the sensitivity was 73% and
the specificity was 99.5%. 67 patients had discordance between DS vs CA, 66 patients had
a normal DS and an abnormal CA. 41 patients had abnormal reflux; 13 (32%) of the 41
patients had a positive SI and 16 (39%) of the patients had no symptom during the study.
25 patients had a positive SI but normal levels of reflux. 56 of the 66 (85%) discordant
patients were followed-up by chart review or phone call and 10 patients were lost to follow-
up. 43 (77%) of 56 patients improved with a PPI (including two with benefit from a
fundoplication), 5 (9%) patients had never been prescribed a PPI and 3 of these patients
were still symptomatic. 8 (14%) reported no improvement with a PPI. Of the 25 patients
with a positive SI and normal levels of reflux, follow up was available for 19. Symptom
improvement was reported by 17 patients, one with a fundoplication and 16 currently taking
a PPI. Conclusions: Interpreting the results of pH monitoring based solely on the composition
DS misses patients with an “acid sensitive esophagus”, a group of patients who benefit from
PPI therapy.
S1219
Does the Absence of Erosive Esophagitis Really Predict a Worse Response to
Proton Pump Inhibitor (PPI) Therapy in Patients with Gastroesophageal
Reflux Disease?
William D. Chey, Borko Nojkov, Richard Saad, Jennifer Rai, Susan A. Adlis, Michael J.
Shaw
Background: It has been suggested that patients with nonerosive reflux disease (NERD)
respond less well to PPI therapy than those with erosive esophagitis (EE). However, the
evidence to support this possibility comes largely from pooled trial data acquired in different
populations. There have been few trials which have directly compared the impact of PPI
therapy in patients with NERD and EE from the same population. Aims: To compare the
impact of PPI therapy on symptom severity and quality of life in patients with NERD and
EE. Methods: Patients with heartburn at least twice per week referred for EGD were recruited.
Those taking a PPI within 2 weeks of EGD were excluded. Eligible patients completed
validated surveys including: Digestive Health Symptom Index (DHSI - upper & lower GI
symptoms), Reflux Disease Questionnaire (RDQ-severity and frequency of GERD symptoms),
QOLRAD (disease-specific QoL), and SF-12 (generic QoL). All patients were treated with
open label rabeprazole sodium (Aciphex, Eisai Inc.) 20mg/d x 8wks after which follow-up
surveys were completed. Results: 99 patients have participated to date. 32 (32%) had EE
and 67 had NERD. Overall, PPI therapy led to highly significant improvements in GERD
and dyspeptic symptoms, disease specific QoL, and generic QoL. Baseline symptom severity
and response to therapy was not different between those with EE and NERD. Improvements
in QoL were also similar between EE and NERD (see table). Conclusions: Contrary to
currently accepted dogma, this open label trial which simulated clinical practice did not
identify differences in the baseline or post-PPI therapy symptom severity or QoL between
patients with EE and NERD. This study was supported by an unrestricted grant from Janssen


















EGFR Antagonist Gefitinib Inhibits ERBB Signaling and Tumor Development
in the Rat Azoxymethane Model of Colon Cancer
Sujatha Jagadeeswaran, Urszula Dougherty, Nathaniel Little, Weihua Yuan, Reba Mustafi,
Sonia Cerda, Anusara Chumsangsri, John Hart, Maria Tretiakova, Loren Joseph, Ezra
Cohen, Alessandro Fichera, Marc Bissonnette
Introduction: Up-regulation of EGFR (ErbB1) receptors and ligands occur in several tumor
types, including colon cancer. We previously showed that ErbB2 can be over-expressed and
EGFR effectors, Ras and ERK activated in azoxymethane (AOM)-induced rat colon cancer.
More recently, in AOM treated mice we demonstrated Gefitinib, an EGFR inhibitor, decreased
crypt cell hyperproliferation and ACF growth, and inhibited ErbB2 activation and ERK
effector signaling in premalignant mucosa. To directly address a requirement for EGFR in
tumor development we examined the effect of Gefitinib on tumor incidence in the rat AOM
model. Methods: Balanced groups of male Fisher F344 rats were fed standard AIN-76A
chow alone, or AIN-76A supplemented with Gefitinib (10 mg/kg body weight). Rats were
treated with AOM (20 mg ip/kg-body wt, 80 rats) or saline (20 rats) weekly for 2 wks and
sacrificed after 44 wks. Tumors were harvested and graded for histology. Activation levels
of colonic epithelial ErbB2, AKT and ERK were quantified by Western blotting using phospho-
active antibodies. Statistical comparisons in tumor incidence were calculated by Fisher exact
test and BrdU incorporation (% total cells) and kinase activations compared by Student’s t-
test. Results: AOM and Gefitinib treatments were well tolerated. Gefitinib significantly
reduced overall tumor incidence (21.6% vs. 71.5%, p<0.05), and the percentage of adenomas
and cancers (adenoma incidence 20% vs. 60%, cancer incidence 8% vs. 50%, p<0.05).
Gefitinib also inhibited tumor growth (17±3 mg vs. 80±16 mg, p<0.05). Compared with
control, AOM significantly increased levels of EGFR (2.9±0.3 fold, p<0.05), pErbB2 (2.8±0.9
fold, p<0.05), effectors pERK (10.0±3.0 fold, p<0.05) and pAKT (2.9±0.3, p<0.05 fold),
and target cyclin D1 (2.1±0.3-fold, p<0.05), whereas Gefitinib significantly inhibited up-
regulation of EGFR (35% inhibition) and cyclin D1 (41%), and activations of ErbB2 (64%
inhibition), ERK (71%) and AKT (56%). Conclusions: Gefitinib significantly reduced AOM
tumor incidence, tumor growth and progression. Concomitantly, Gefitinib limited cyclin
D1 up-regulation and activation of ErbB2, ERK and AKT in colonic epithelium. These studies
demonstrate that EGFR signaling participates in AOM-induced colonic carcinogenesis and
that Gefitinib inhibits colonic tumor development. Further studies to explore EGFR inhibition
in patients at increased risk for colon cancer should be explored.
S1221
Prevention and Treatment of Colorectal Cancer in Mice with Vitamin D and
Its Gemini Analogues
Min Yao, Catherine S. Spina, Vin Tangpricha, Wei Zhou, Hubert Maehr, Milan Uskokovic,
Luciano Adorini, Michael F. Holick, M. M. Wolfe
Background: It has been recognized that persons who live at higher latitudes and who are
vitamin D deficient are at a significantly higher risk for dying from many commonly encoun-
tered malignancies, including colorectal cancer (CRC). Purpose: To determine whether CRC
tumor growth is enhanced in mice fed a vitamin D deficient diet and whether treatment
with novel, active Gemini analogs of 1,25(OH)2D3 might inhibit the growth of CRC in a
vitamin D sufficient state. Methods and Results: Groups of BALB/C mice were transplanted
subcutaneously with 103 MC-26 cells, a mouse CRC cell line, and were fed either a vitamin
D-deficient or -sufficient diet. Serum calcium levels did not differ between the two groups.
In contrast, whereas the serum concentration of 25(OH)D was undetectable in mice fed the
vitamin D-deficient diet, levels were normal (65.6 ± 15 nmol/L) in animals administered a
vitamin D-sufficient diet. Starting at day 9, the tumor volume in mice fed a vitamin D-
deficient diet was significantly larger, and at the end of the period of observation (day 19),
tumors in these mice were 64.7% larger compared to tumors in animals administered a
vitamin D-sufficient diet (560 ± 110 mm3 vs. 340 ± 70 mm3, P<0.05). In separate experiments,
mice transplanted with MC-26 cells were fed a low calcium diet and were treated with
placebo or one of several novel 19-nor-Gemini (vitamin D) compounds. 24 h after tumor
cell implantation, the mice received one of the Gemini vitamin D analogs or vehicle 3 times
weekly. The administration of these Gemini analogs produced a dose-dependent decrease
in tumor volume. Treatments with a less potent Gemini analog at the dose level of 0.02 μg
molar equivalents, compared to 1,25(OH)2D3, reduced the mean tumor volume by 41%
(P<0.05), compared to the control group. At the same time point, mice treated with the
most potent Gemini analog, administered at the 10-fold lower dose of 0.002 μg molar
equivalents, demonstrated a 52% reduction in the mean tumor volume (P<0.05), compared
to the control group. Animals that received 1,25(OH)2D3 at 0.002 and 0.02 μg showed a
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trend in tumor volume reduction at the highest dose, but the changes were not statistically
significant. Serum calcium concentrations were normal in all groups of mice, except in those
receiving 0.02 μg molar equivalents of the most potent Gemini analog. Conclusion: The
results from these studies demonstrate that vitamin D deficiency may accelerate colorectal
cancer growth and that novel Gemini analogs of 1,25(OH)2D3 may potentially represent an
effective new approach for the prevention and treatment of colorectal cancer.
S1222
Angiotensin Converting Enzyme Inhibitors Reduce the Incidence of Colon
Cancer: A Study of Half a Million US Veterans
Vikas Khurana, Hanmanth R. Bejjanki, Gloria Caldito
AIM: To investigate the effect of Angiotensin Converting Enzyme (ACE) Inhibitors use in
reducing the incidence of colon cancer in the US veteran population. BACKGROUND:
ACE Inhibitors are commonly used antihypertensive and nephroprotective agents. Vascular
Endothelial Growth Factor (VEGF) is believed to play a major role in angiogenesis in
human tumors. Blocking the VEGF inhibits angiogenesis and suppresses tumor growth.
ACE inhibitors cause suppression of VEGF in experimental models, leading to their anticancer
effect. ACE Inhibitors have been noted to suppress tumor growth by inhibiting tumor
angiogenesis in several animal and experimental models. DESIGN: The VISN 16 database
contains clinical and demographic information about all veterans (>1.4 million patients)
cared for in the South Central VA Health Care Network (eight states in south central United
states). The data was queried from Oct 1998 to June 2004, using a retrospective case control
design. Statistical analysis was performed using SAS software version 9.0 (Chicago, IL).
Multiple logistic regression analysis was used with calculation of odds ratios and 95%
confidence intervals. The data was adjusted for age, race, gender, BMI, smoking, alcohol
use, diabetes and statin use. Patients were placed in the ACE inhibitor user group if they
were using ACE inhibitors prior to the diagnosis of colon cancer. RESULTS: A total of
483,733 patients were included in the analysis. 184,743 (38.2%) of those were using ACE
inhibitors. Colon and rectal cancer (ICD-9 codes 153 and 154) was seen in 6697 (1.4%).
ACE inhibitor users were 47% less likely to develop colon cancer (Odds ratio 0.47; 95%
CI 0.45-0.50, p <0.0001). The protective effect of ACE inhibitors was independent of statin
use. Other significant covariates include age (OR 1.054, 95% CI for OR 1.052, 1,056, p
<0.0001); prior statin use (OR 0.454, 95% CI for OR 0.427, 0.482, p<0.0001) and diabetes
(OR 1.605, 95% CI for OR 1.510, 1.706, p<0.0001). CONCLUSION: ACE inhibitors are
associated with a 47% reduced incidence of colon cancer after controlling for age, race,
gender, BMI, smoking, alcohol use, diabetes and statin use. The limitations of our data are
the VA population, the database and the fact that this is a case control study. The dose,
duration and type of ACE inhibitor used were not factored into the analysis.
S1223
Celecoxib and Curcumin Synergistically Inhibit the Growth of Colorectal
Cancer in Rat Model
Baruch Shpitz, Nis Giladi, Eyal Sagiv, Diana Kazanov, Menachem Moshkowits, Aharon
Halak, Nadir Arber
Background: Colorectal Cancer (CRC) is one of the leading causes of cancer death in the
western world. Multiple studies have indicated that specific COX-2 inhibitors may prevent
CRC. However, the long-term use of COX-2 inhibitors is not toxic free and may be limited
due to its gastrointestinal and cardiovascular side effects. The chemopreventive efficacy of
the phytochemical, curcumin has been demonstrated in several in vitro and animal models.
Previously we had shown that physiological doses of celecoxib (5 μM) that can be achieved
in human serum, and curcumin (10-15 μM) synergistic inhibit cancer cell growth in vitro
(Clin Cancer Res 2005). Aim:To examine the chemopreventive effect of this combination
in 1,2-dimethylhydrazine (DMH) rat model. Methods: Forty male rats (F344), age eight
weeks, were subcutaneously injected in the back with DMH 100µg/kg, twice, two weeks
apart. Eight rats were not injected and served as the negative control group for aberrant
crypt foci (ACF) formation. One week following the second DMH injection the rats were
randomly divided into four groups (10 rats in each group): a) AIN-076 control diet. b)
AIN-076/curcumin (0.6%); c) AIN-076/celecoxib (0.16%); d) AIN-076/celecoxib (0.16%)
and curcumin (0.6%). After one month the rats were sacrificed and their colon dissected.
ACF were identified by their characteristic elongated slit-shaped lumen, surrounded by
thickened epithelium that was more intensively stained with methylene blue than the sur-
rounding normal crypts. Results: There were no ACF in the non DMH injected rats. The
average number of ACF per rat colon was 64.2 ± 3 in the control group, 39±5 and 47±10
for the curcumin and celecoxib treated group respectively. In the group that had received
both curcumin and celecoxib, there were 29±15 ACF. This reduction of 27%, 39%, and
62% in the number of ACF per rat for the different treatment groups was statistically
significant (all P<0.05). Conclusions: in vivo, curcumin potentiates the growth inhibitory
effect of celecoxib in the DMH rat model. This is clinically important as this dose of celecoxib
(equivalent to 200 mg) can be achieved in human serum following standard anti-inflammatory
dosing. Phase III study in CRC patients has been initiated. All patients are receiving standard
therapy and curcumin (4 gr), celecoxib (200 mg), their combination or placebo.
S1224
A Randomised Study of the Effects of N-3 Fatty Acid Supplementation On
COX-2 Expression in Barrett’s Epithelium
Samir Mehta, Alexander P. Boddy, J.N. Cook, Elizabeth K. Lund, Virginia Sams, Ian T.
Johnson, Michael Rhodes
Introduction Evidence from animal and in vitro studies indicates that n-3 fatty acids may
inhibit carcinogenesis, and epidemiological studies suggest a reduced risk of oesophageal
cancer in populations with high consumption of fish. One of the possible mechanisms
for this chemopreventive effect is the suppression of arachidonic acid derived eicosanoid
biosynthesis. In this study we have determined the effects of dietary supplementation with
the n-3 fatty acid eicosapentaenoic acid (EPA) on eicosanoid levels (PGE2 and LTB4) and
the enzyme cyclo-oxygenase-2 (COX-2) in human Barrett’s oesophagus. Methods Fifty
patients with known Barrett’s oesophagus underwent an upper GI endoscopy. Biopsies were
taken at a recorded level from the area of Barrett’s. 30 patients were then randomised to
EPA supplementation (1.5g/day) for 6 months; 20 patients acted as controls. At the end of
this period patients were re-endoscoped and biopsies taken at the same level. Tissue samples
taken before and after supplementation were analysed for mucosal lipid profile, PGE2, and
LTB4 levels. We also assessed COX-2 levels by immunoblotting and by a specific enzyme-
linked immunosorbent assay (ELISA). Results There was a significant increase in mucosal
EPA content after dietary supplementation (6 months vs. baseline: 2.4% vs. 0.8% of total
lipid content; p<0.001), and a reduction in mucosal n-6 and n-9 fatty acid levels. There
was no change in the untreated controls. EPA supplementation had no significant effect on
the levels of PGE2 in Barrett’s (6 months vs. baseline: 36.1 vs. 33.1 pgs/μg protein) or on
LTB4 levels (12.6 vs. 11.8 pgs/μg protein). The enzyme COX-1 was highly expressed in all
patients, but in contrast to recent reports, COX-2 was only present at very low levels, except
in a single patient with histologically confirmed moderate dysplasia. Immunoblotting revealed
two bands for COX-2; a band at 62 kDa which was significantly reduced following interven-
tion with EPA (P<0.05) and a weaker band only present in some patients at the expected
72 kDa mark. The COX-2 ELISA confirmed a reduction in mucosal COX-2 in Barrett’s
tissue after EPA supplementation (p<0.05). Conclusion Supplementation with EPA signific-
antly altered the lipid profile of Barrett’s mucosa but failed to reduce eicosanoid levels. The
down-regulation of COX-2 expression by EPA may result in chemopreventive effects through
alternative mechanisms.
S1225
Smokers Have a Higher Risk for Significant Colorectal Neoplasia and At a
Younger Age Than Those Who Never Smoked: Implications for Screening
Guidelines
Joseph C. Anderson, Brendan J. Wiggins, Zvi A. Alpern, Carol A. Martin, Patricia
Hubbard-Ells
Background:Age and family history are the main risk factors considered when stratifying
for colorectal cancer screening. In a screening population, smoking and age were the most
predictive factors for colorectal neoplasia (Anderson et al AJG 98:2777-83,2003). One expert
has suggested that smokers should be considered a high risk group but also stated sufficient
data did not exist to justify earlier screening for smokers (Giovannucci et al, Dig Liv Dis
36:643-5, 2004). The goal of our study was to determine if smokers are at risk for colorectal
neoplasia at a younger age. Methods:Asymptomatic patients (>40 years old) undergoing
screening colonoscopy are queried with respect to age, gender,BMI, family history, smoking
history (pack years and year quit), medications, alcohol use, aspirin/NSAID use, exercise,
fruit/vegetable and red meat intake. Endoscopic findings and pathology are entered into the
database. Subjects were divided:1)Never smokers 2)Current smokers or patients with > 10
pack-years, still smoking or having quit recently 3)Low exposure smokers: < 10 pack years
or who having quit over 10 years ago. Significant colorectal neoplasia (SCN) = villous tissue,
high grade dysplasia, large tubular adenomas or > 2 adenomas. Results: 2466 patients were
screened. Current smokers had a higher prevalence (67/478;14%) for SCN than never
smokers (115/1385; 8.3%)(p<0.001) or low exposure smokers (44/566; 7.8%)(p<0.01).
Current smokers had a higher risk than never smokers for SCN(OR=1.84;95%CI=1.35-
2.49;p<0.001).The average age for smokers with SCN (58.1;95% CI: 55.5-60.6) was lower
than never smokers with SCN (62.2;95% CI:60.0-64.5)(p=0.04). There was no difference
other than age between these two groups,including gender, BMI, family history and alcohol
use. Smoking is a risk factor for SCN in younger (most who are not eligible for screening)
subjects as well(see Table). Conclusions: 1)Current smokers have a higher risk and preval-
ence of SCN than in never smokers. 2)SCN occurs in current smokers 4 years earlier than
in those who never smoked suggesting an etiological association between smoking and
colorectal neoplasia. 3)Our results strongly support the notion current smokers are at high
risk for colorectal neoplasia at a younger age and probably should be screened at an earlier
age than non-smokers.
Prevalence and Risk of Significant Neoplasia in the 40 to 55 Age Group
p<0.003;OR, after controlling for BMI, Fam Hx, gender
S1226
Growth Factors Dictate the Inhibitory Response of Target Cells to the Dietary
Agent, Curcumin
William Rengifo-Cam, Pomila Singh
Background. Progastrin (PG) and insulin-like growth factors (IGFs) exert proliferative and
anti-apoptotic effects on colon cancer cells via endocrine/paracrine/autocrine routes (Singh
P, 2000). Dietary agents such as curcumin inhibit the growth of transformed cells and inhibit
colon carcinogenesis at the initiation, promotion and progression stages (Kawamori T et al,
1999). It is not known if curcumin exerts inhibitory effects in the presence of growth factors
such as PG and IGF-II that are known to be expressed by colorectal cancers. Aim. To
examine anti-prolifeative and pro-apoptotic efficacy of curcumin in the presence or absence
of PG and IGF-II and to delineate relative phosphorylation of specific signaling molecules.
Methods. IEC-18 cells are responsive to both PG and IGF-II, and were therefore used in
these studies. Routine assays were used for examining the end points of growth, apoptosis and
phosphorylation of kinases. Results. PG (0.1nM) and IGF-1 (10nM) significantly increased the
proliferation of IEC cells by ~2.5 fold (n=4-6). 10uM-100uM curcumin decreased cell
proliferation in a dose dependent manner from 50 to 80%. IGF-II was significantly more
effective in reducing the inhibitory effects of curcumin on cell growth, than PG. Similarly
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the pro apoptotic effects of curcumin on IEC cells (activation of caspase 9), was also reversed
to control values in the presence of IGF-II, but only partially reversed in the presence of
PG. Relative levels of phosphorylated Akt, NFκB, Src, p42/44 (ERK) and p38 (MAPK) on
treatment with curcumin, in the presence or absence of the growth factors was in the order
of, IGF alone> PG alone> IGF+curcumin > PG+curcumin > serum free control> curcumin
alone. The loss in the relative levels of phosphorylated NFκB, Src and p42/44 (ERKs), in
response to curcumin, was reversed most effectively in the presence of IGF-II. Summary:
1. IGF-II is ~1.5 and >4 fold more effective in protecting the IEC cells against the anti-
proliferative and pro-apoptotic effects of curcumin, respectively. 2. Several kinases/transcrip-
tion factors mediate protective effects of the growth factors against curcumin, including
NFκB, Src and p42/44 (ERKs). Conclusion: These results suggest that intestinal tumors,
growing in response to autocrine or circulating IGFs are likely to be significantly less
responsive to the growth inhibitory effects of curcumin than tumors growing in response
to PG. Therefore the growth factor profile of the tumor cells may dictate the response of
the tumor cells to growth inhibitory effects of dietary agents, such as curcumin.
S1227
Vitamin C Suppresses H. Pylori Colonization But Has NO Effect On
Helicobacter Pylori-Induced Gastritis in Vitamin C-Deficient L-Gulono-γ-
Lactone Oxidase Knock-Out (Gulo-/-) Mice
Chung-Wei Lee, Xiang-Dong Wang, Arlin B. Rogers, Timothy C. Wang, James G. Fox
Epidemiological studies link vitamin C (VC) deficiency to more severe Helicobacter pylori
(Hp)-associated gastritis and a higher risk of gastric cancer, and suggest that high dietary
VC intake may decrease the risk of stomach cancer. Vitamin C-deficient L-gulono-γ-lactone
oxidase knock-out (Gulo-/-) mice on a C57BL/6 background were used as a model to
examine the role of VC supplementation in Hp-associated gastric lesions. Gulo-/- and C57BL/
6 (WT) mice were experimentally infected with Hp, and Gulo-/- were supplemented with
either low (0.033g/L) or high (3.3g/L) VC in their drinking water. Mice were killed at 16
or 32 weeks post infection (WPI). In Gulo-/- mice, plasma and gastric VC contents were
positively correlated with the dietary VC supplementation (Table 1). Hp colonization at 16
WPI measured by quantitative PCR was significantly lower in the low or high VC supple-
mented groups compared to WT mice (log CFU/g: 5.491+/-0.303, 5.374+/-0.272, and
6.681+/-0.434, respectively; p<0.001), suggesting a bactericidal effect of the VC or an
enhancement of the host inflammatory response to Hp. However, the Hp-specific, Th1-
associated IgG2c response was depressed in Gulo-/- mice with low VC or high VC supple-
mentation as compared with that of WT mice at 32 WPI (anti-Hp outer membrane protein
IgG2c: 0.274+/-0.065, 0.441+/-0.103, and 0.867+/-0.202, respectively, p<0.01). In addition,
no histopathological differences in stomach lesion scores were observed among these groups
with different treatments at both 16 and 32 WPI. The data indicate that the restoration of
VC status of Gulo-/- mice by dietary VC supplementation alone does not protect against H.
pylori-induced gastritis and associated lesions. These findings also support previous in vitro
data demonstrating that VC has bactericidal activity against Hp. To delineate the relationship
among gastritis, Hp colonization, and immunogenicity of Hp in VC-supplemented Gulo-/-
mice, further studies are needed.
Table 1
* p<0.001 when compared to Gulo-/- mice with high VC supplementation or WT mice †
p>0.05 when compared to group 3
S1228
Regulation of RAS in Colon Cancer Cells By Chemopreventive
Ursodeoxycholic Acid
Sharad Khare, Mehdi Baluch, Cory Holgren
Background: A number of potential mechanisms have been proposed for bile acid-induced
colonic tumor promotion. While the predominant primary bile acids are tumor promoters,
we have shown that another bile acid ursodeoxycholic acid (UDCA) has chemopreventive
effects in AOM-induced colonic carcinogenesis [Cancer Research, 54: 5071-5074, 1994;
Cancer Epidemiology, Biomarkers and Prevention, 11: 1316-1321, 2002]. More recently,
we showed UDCA also suppressed the development of tumors with ras mutations or tumors
with activated wild type Ras, the gene product encoded by ras [Cancer Research, 63: 3517-
3523, 2003]. We now investigated the mechanism of wild type Ras inhibition by UDCA in
HCA-7 cells, an adenocarcinoma colon cancer cell line. Methods: HCA-7 cells were grown
in McCoy’s 5A media containing 10% fetal calf serum. Phosphorylation status of c-Met-R,
EGF-R, IGF-1R and EphA2 was assesed by immunoprecipitation and Western blotting. Ras
activation was measured by a pull-down assay utilizing Raf1-RBD agarose. Expression of
Ras-GAP and co-association of Sos-1, Grb2 and Shc was assessed by immunoprecipitation
and Western blotting. Results: Ras-GTPase activating protein (ras-GAP), a negative regulator
of p21ras was poorly expressed in HCA-7 cells. However, we noted a significant expression

















significant effect on expression of this gene. Phoshorylation status of receptor tyrosine kinases
(RTKs) c-Met-R, EGFR, IGF-1R and EphA2 was assessed. Sos-1, a well-known Ras-guanine
nucleotide exchange factor, which favors ras activation, was constitutively associated with
growth factor receptors. UDCA significantly decreased Sos-1 association with c-Met-R and
suppressed wild type Ras activation. As a control, deoxycholic acid (DCA), a tumor promoting
bile acid dramatically increased Sos-1 association with c-Met-R in a time and concentration
dependent manner and activated wild type Ras in HCA-7 cells. Grb2 is intrinsically complexed
with the Sos and an enhanced Grb2-Sos association with Shc upon DCA stimulation was
observed. Summary: These data demonstrate that bile acids can function through RTK.
Further, for the first time, a molecular mechanism of Ras regulation by UDCA is investigated.
S1229
Vitamin D Receptor (VDR) and 25-Hydroxyvitamin D3-1α-Hydroxylase
(1α(OH)Ase) in Normal and Malignant Human Colon
Damien Matusiak, Robert Carroll, Richard Benya
Although considerable evidence exists to support the use of vitamin D to prevent and/or
treat colorectal cancer (CRC), toxic hypercalcemia limits the routine use of bioactive vitamin
D. Yet recent studies have shown that colonic epithelial cells express mRNA for 1α(OH)ase,
an enzyme that converts non-toxic pro-vitamin D [25(OH)D3] to its bioactive form. However,
nothing is known about the cellular expression of 1α(OH)ase and the VDR in the earliest
histopathological structures associated with malignant transformation such as aberrant crypt
foci (ACF) and polyps, nor is anything known as to the expression of these proteins in CRC
as a function of tumor cell differentiation or metastasis. METHODS: 10 colorectal cancers
(CRC) were randomly selected from our GI Tumor Bank, containing 53 separate and distinct
regions that were well differentiated, 66 that were moderately differentiated, and 32 that
were poorly differentiated. 1α(OH)ase and VDR expression was determined using specific
antibodies, and the amount of staining quantified as previously described [J Histochem
Cytochem 2003; 51: 205]. RESULTS: 1α(OH)ase was present at equal high levels in normal
colonic epithelium as in ACF’s, polyps, and CRC irrespective of tumor cell differentiation.
In contrast, VDR levels were low in normal colonic epithelial cells; were increased in
ACF’s, polyps, and well differentiated tumor cells; and then declined with increasing de-
differentiation. Both 1α(OH)ase and VDR levels were negligible in tumor cells metastasizing
to regional lymph nodes, irrespective of the differentiation of the tumor found in either the
primary or metastatic lesion. Finally, since the VDR acts by translocating to the nucleus
after binding ligand, we assessed the relative amounts of VDR expressed in nuclear and
cytoplasmic regions of each tumor cell. While the ratio of nuclear to cytoplasmic VDR
exceeded 4 in normal colonic epithelial cells, indicating that most of this protein was in the
nucleus, this ratio dropped to <1.0 for even ACF’s, the earliest lesion associated with CRC
formation. Thus an ever-declining percentage of VDR translocates, or is able to translocate,
to the nucleus of colonic epithelial cells that are not histologically normal. CONCLUSIONS:
Non-toxic forms of vitamin D may be useful in CRC chemoprevention. In contrast, the
absence of 1α(OH)ase and VDR in metastases, and the decreased ability of the VDR to
translocate to the nucleus in even the earliest histopathological lesions associated with
malignant transformation, suggests that vitamin D may not be useful in CRC chemotherapy.
S1230
Regulatory Mechanism for Folic Acid Induced Inhibition of Recurrence of
Colorectal Adenomas
Nataliya Razumilava, Saadia Siddiqui, Edi Levi, Hu Xu, Nadeem Ullah, Martin Tobi,
Richard Jaszewski, Adhip P. N. Majumdar
Accumulating murine as well as epidemiologic and case controlled human studies suggest
that folic acid may be an effective chemopreventive agent for colorectal neoplasia. Indeed,
data from our recently completed double-blind, placebo controlled clinical trial on 177
patients with colorectal adenomas (≥0.5 cm) [who had undergone polypectomy] demon-
strated that daily consumption of supplemental folic acid (5 mg/day) for 3 years significantly
decreased the recurrence of adenomas (Gastroenterology 128: A-93, 2005). Although the
regulatory mechanisms for folic acid mediated decreased recurrence of polyps are not fully
understood, we hypothesize that this could partly be the result of inhibition of proliferation
and/or stimulation of apoptosis. We further hypothesize that EGF-receptor (EGFR), which
regulates the growth related process, is critically involved in regulating folic acid-mediated
changes in proliferation and/or apoptosis in the colonic mucosa. Methods: Of 177 patients
enrolled in the study, 94 subjects completed the 3-year study: 46 in folic acid group and
48 in placebo. Mucosal biopsies, taken from macroscopically normal rectal mucosa (≤10
cm anal verge) at baseline and at 1- and 3-year follow-up colonoscopy, were fixed in
buffered-formalin, subsequently paraffin-embedded, sectioned (4-5 micron) and analyzed
immunohistochemically for changes in (a) proliferative activity by measuring PCNA immuno-
reactivity, (b) apoptosis by TUNEL assay, (c) EGFR and (d) EGFR-Related Protein (ERRP),
which we have identified and characterized as a negative regulator of EGFR. Results: At
baseline, no significant difference in any of the above mentioned parameters was observed
between the placebo and folic acid consumed groups. However, consumption of supplemental
folic acid for 3 years resulted in a statistically significant (20-30%; P<0.0009) reduction in
prolifetative activity without an apparent change in the rate of apoptosis in the colonic
mucosa. Folic acid mediated reduction in mucosal proliferative activity in the colonic mucosa
was associated with a marked reduction in the relative abundance of EGFR. This was
accompanied by a concomitant increase in ERRP expression. Conclusion: Our data suggest
that folic acid exerts a chemopreventive effect on colorectal neoplasia, as demonstrated by
inhibition of recurrence of adenomas. This could be attributed to reduction in proliferation.
EGFR appears to play a critical role in regulating this process.
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A New Aminoacid Derivative of Ursodeoxycholate, N-L-Glutamyl-UDCA
(UDCA-Glu) to Release Selectively UDCA in the Rat Colon
Carlo Clerici, Danilo Castellani, Stefania Asciutti, Elisabetta Nardi, Giorgio Gentili,
Roberto Pellicciari, Kenneth Setchell, Nancy O'Connell, Vittorio Giuliano, Fabio
Chistolini, Olivia Morelli, Mattia Clementi, Monia Baldoni, Antonio Morelli
Introduction: Ursodeoxycholic acid (UDCA) showed a protective effect against colon cancer
development in rats and the recurrence of high-grade dysplasia adenomas in humans. After
oral administration, UDCA is mainly absorbed in the small intestine and a small amount is
directly delivered in the colon. In our search for new strategies for the selective release of
UDCA in the colon, we synthesized UDCA-glutamate (UDCA-Glu) that utilizes the selectivity
of peptide bond cleavage exhibited by brush border enzymes to increase the concentration
of UDCA in the colon. Methods: 30 Fisher male rats were utilized in 3 experiments (A, B,
C). A: 10 animals received via an intragastric probe a daily dose of UDCA (10mg/kg/die)
or UDCA-Glu (at the equivalent dosage of 10mg/kg/die of UDCA) for 5 days; after sacrifice,
the small intestine and the colon were removed to study fecal intestinal tract bile acid
composition. B: 10 animals received UDCA (10mg/kg/die) or UDCA-Glu (at the equivalent
dosage of 10mg/kg/die of UDCA) for five days; fecal samples were collected everyday. All
fecal samples collected in the A and B experiments were analyzed by GC-MS and FAB-MS
in order to study quantitative and qualitative fecal bile acid composition. C: 10 animals
were given an intraduodenal bolus of UDCA (10 mg/kg/die) or UDCA-Glu (at the equivalent
dosage of 10mg/kg/die of UDCA) in order to study bile flow. Bile samples were collected
by an external biliary fistula every 15 min for 330 min and then weighted in order to
determine bile flow. Result. A: In the resected small intestine significantly higher UDCA
level (unconj. 1.50±0.32mg) was found in UDCA treated rats as compared with UDCA-Glu
group (unconj. 0.75±0.12mg) where high concentration of UDCA-Glu (unconj. 2.08±0.10
mg) were detected. In the resected large intestine instead significantly higher amount of
UDCA (unconj. 0.90±0.14mg) and UDCA-Glu (unconj. 1.40±0.48mg) were found in UDCA-
Glu treated rats in respect to UDCA group (unconj. UDCA 0.50±0.15mg). B: the analysis
of total fecal bile acid recovery confirmed higher UDCA concentration (unconj. 3.39±0.30mg;
conj. 6.40±1.03mg) in rats treated with UDCA-Glu as compared to those treated with UDCA
(unconj. 2.27±0.11mg; conj. 0.04±0.01mg). C: UDCA treated animals maintained bile flow
better than UDCA-Glu group where there was an evident decrement in bile flow after 3
hours from the administration of both compounds. Conclusion: Conjugation of UDCA with
glutamic acid limits its absorption in the small intestine and leads to increased colon delivery
and fecal excretion of UDCA. UDCA-Glu could be a promising pro-drug to deliver UDCA
in the colon.
S1232
NSAIDs, COX-2 Inhibitors, LES Relaxing Drugs and Esophageal Cancer: A
Case- Control Study
Satish Ranka, Jenny M. Gee, Ian T. Johnson, J.N. Skinner, Andrew R. Hart, Michael
Rhodes
Aim: To examine the association between the use of NSAIDs, beta adrenergic agonists,
theophylline and calcium channel blockers with the risk of esophageal cancer (EC). Introduc-
tion: The incidence of EC has doubled in the last three decades. It has an overall 5 year
survival rate of less than 5% and an effective preventive strategy is therefore desirable.
NSAIDs are known to affect some of the crucial metabolic pathways that control tumor
development. Beta agonists, aminophylline and calcium channel blockers, relax the lower
esophageal sphincter (LES) which may increase gastro-esophageal reflux. This may in turn
increase the risk of esophageal adenocarcinoma (EAC). Methods: Between 1999 and 2004,
411 patients with primary neoplasm of the esophagus and cardia were matched with 1644
controls with non-melanotic skin lesions. Each case was matched for age, sex and year of
hospital admission. Data on use of NSAIDs, beta adrenergic agonists, aminophylline and
calcium channel blockers was collected. Results: The mean age of patients with EC was 71
years and the commonest site of disease was the lower 1/3rd of the esophagus. Smoking
was more common in cases as compared to controls (OR 3.18, 95% CI 2.23 - 4.12). Alcohol
intake was similar in cases and controls (OR 0.90, 95% CI 0.70 - 1.21). The odds ratios
(OR) and 95% confidence intervals (CI) for exposure to different drugs in cases versus
controls are as follows: Aspirin 0.38, (0.26-0.50); other NSAIDs 0.29, (0.19-0.42); COX-2
inhibitors 0.35, (0.16-0.91), beta agonists 3.6 (95% CI 2.6 to 4.9), aminophylline 2.1 (95%
CI 1.1 to 4.1) and calcium channel blockers 2.9 (95% CI 2.1 to 4.1). Conclusion: Esophageal
cancer has a negative association with NSAIDs and a positive association with drugs which
relax the LES. Any regular use of NSAIDs may have a protective role for patients at high
risk of EC such as those with Barrett’s esophagus and widespread use of drugs which relax
the LES may be a contributing factor in increasing the incidence of EAC in this population.
S1233
Effects of Rofecoxib, a COX-2 Selective Inhibitor, in Patients with Barrett’s
Esophagus: Final Results of a 6-Month Randomized Controlled Trial
Angel Lanas, Federico Sopena, Javier Ortego, Eva Barrio, Luis Bujanda, Angel Cosme,
Adolfo Parra, Javier Alcedo, Angel Ferrandez, Eduardo Bajador, Josep M. Pique
Background: COX-2 is overexpressed in Barrett’s esophagus (BE). Short-term treatment with
COX-2 inhibitors reduce cell proliferation in BE. Aim: To determine the long-term effect
of a COX-2 inhibitor on several cellular mechanisms involved in the neoplastic progression
of BE. Methods: Multicenter randomized controlled trial of BE patients computer allocated
either to take their usual PPI alone or combined with rofecoxib 25 mg/day for 6 months.
Exclusion criteria: presence of high-grade dysplasia & contraindication to take rofecoxib.
No NSAID/ASA use was allowed. Multiple biopsy specimens of BE and duodenum were
obtained at baseline and after treatment. All patients were asymptomatic on their PPI (90.3%
standard doses)and were monitored at 0,1,3 and 6 months. The effect of Rofecoxib on cell
proliferation (Ki-67; mib1) in BE glands was the primary end point. Cell apoptotis, as well
as COX-2, cycline D1, and p53 expression were also measured blinded by inmmunohistoch-
emistry by the same pathologist. BE cell proliferation and apoptotic index (number of (+)
cells/number of cells within the gland x100) was determined by a computer assisted technique
(ImageJ, NIH;USA) in all specimens. Expression was graded from 0=No expression to 2=
moderate-intense expression. Chi square, parametric and non-parametric test were used for
data analysis. Only data for those who underwent both initial and final endoscopy are
presented. Results: Of 62 patients with BE (length=4.3±2.1; age=58.8±13.7; 77.4% males),
8 did not finalize the study; 6 due to adverse events and 2 voluntarily. Low grade dysplasia
was present in 19,4% of patients at baseline. Adverse events were present in 4 patients on the
rofecoxib arm and 2 on PPI alone. Compliance was high (89.1±22.2% of pills). Rofecoxib+PPI
treatment was not associated with reduction of cell proliferation index (40.4±13.04% at
baseline vs. 46.1±15.1% after treatment). In the same way, rofecoxib +PPI treatment did
not affect the expression of cycline D1 or p53 and did not affect the incidence of low-grade
dysplasia (24.2% at baseline vs. 15.2% after treatment).Unlike PPI alone, rofecoxib+PPI
treatment decreased COX-2 expression (moderate-intense expression in 92,8% of patients
at baseline vs 50% after treatment; p<0.01) and increased the apoptotic baseline index
(3.1±2.7‰) in cells of BE glands (215±122% vs. 67.8±32% increase in PPI alone treated;
p<0.05) Conclusions: The addition of rofecoxib 25 mg/day to PPI therapy does not affect
cell proliferation index of BE cells, p53, or cycline D1 expression , but it increases cell
apoptosis and reduces COX-2 expression after 6 months of therapy.
S1234
The Increase of 15-LOX-1 Expression On Carcinoma Cells May Enhance the
Sensitivity to NSAIDs-Induced Apoptosis in Colorectal Cancers
Masahiro Yoshinaga, Hiroyuki Murao, Yosuke Kitamura, Koutaro Koga, Satoru Tsuruta,
Hisato Igarashi, Hidefumi Higashi, Kazuhiko Nakamura
Background: Non-steroidal anti-inflammatory drugs (NSAIDs) can prevent the colorectal
cancer (CRC), but its effect is limited. To overcome the limitation, the molecular features
in CRCs from patients who have been treated with NSAIDs for a long period need to be
elucidated. Recent studies show the involvement of 15-lipoxygenase-1 (15-LOX-1) in
NSAIDs-induced apoptosis in colorectal carcinoma cells. Therefore, we compare the 15-
LOX-1 expression in CRCs from NSAID users with that from NSAID nonusers and certify
the role of 15-LOX-1 in the NSAIDs-induced apoptosis of colorectal carcinoma cells. Methods:
In 22 CRC surgical samples from NSAID users who had been constant for more than 5
years and 28 CRC surgical samples from NSAID nonusers, the expressions of 15-LOX-1,
cyclooxygenase-2 (COX-2), beta-catenin, and p53 were analyzed using immunohistochem-
istry. To identify the level of apoptosis in two groups, the terminal deoxynucleotidyl trans-
ferase (TdT)-mediated dUTP nick-end labeling (TUNEL) assay was performed for samples.
The effects of the transient transfection of 15-LOX-1 cDNA on indomethacin-induced
apoptosis were examined in HCT-116 cells. The effects of adding a major metabolite of 15-
LOX-1, 13-S-hydroxyoctadecadinoic acid (13-S-HODE) on indomethacin-induced apoptosis
were also examined in HCT-116 cells. The level of apoptosis was determined by the analysis
of the floating-cells ratio and DNA gel electrophoresis. Results: In tumor cells, the expression
of 15-LOX-1 on CRCs from NSAID users was significantly decreased compared with those
from NSAID nonusers (2/22 vs 12/28, p < 0.05); however, the expressions of other molecules
were not significantly different between two groups. In adjacent normal mucosal cells, the
expressions of all molecules were not different between two groups. The level of TUNEL
scoring in samples from NSAID users was similar to those from NSAID nonusers. One
hundred µM of indomethacin induced less apoptosis in mocked HCT-116 cells, whereas
the same concentrations of indomethacin enhanced the level of apoptosis in 15-LOX-1-
transfected HCT-116 cells. 13-S-HODE also increased the level of indomethacin-induced
apoptosis in HCT-116 cells dose-dependently. Conclusion: Results suggest that the increase
of 15-LOX-1 expression on carcinoma cells may enhance the sensitivity to NSAIDs-induced
apoptosis in CRCs from patients who are treated with the compounds.
S1235
Combination Treatment with Curcumin and Quercetin of Adenomas in
Familial Adenomatous Polyposis
Marcia Cruz-Correa, Daniel A. Shoskes, Patricia Sanchez, Rhongua Zhao, Linda M.
Hylind, Steven D. Wexner, Francis M. Giardiello
Background: Familial adenomatous polyposis (FAP) is an inherited disorder with develop-
ment of hundreds of colorectal adenomas and eventual colorectal cancer. Regression of
adenomas in FAP occurs with NSAIDs and COX-2 inhibitors, but these drugs can have side
effects. We evaluated the combination of diet derived nonprescription supplements curcumin
and quercetin to regress adenomas in FAP patients. Methods: Five FAP pts with prior
colectomy (4 with retained rectum, 1 with ileal anal pouch) received curcumin 480 mg and
quercetin 20 mg orally three times a day. Number and size of polyps were assessed at
baseline and after therapy. Wilcoxon sign-rank test was use to determine differences in
number and size of polyps. Treatment side effects and medication compliance were evaluated.
Results: All five patients had a decreased polyp number and size from baseline after a mean
of 6 months of treatment with curcumin and quercetin. The mean percent decrease in number
and size of polyps from baseline was 60.4% (p<0.05) and 50.9%(p<0.05), respectively. Patient
1 (figure) had initial regression of polyps between 0 and 3 months of therapy but was
noncompliant with treatment between 3 and 6 months. After reinstruction, the patient
continued on therapy (from month 6 to 9) with reoccurring polyp regression. Minimal
adverse side effects and no laboratory abnormalities were noted. Conclusion: The combination
of curcumin and quercetin appears to reduce the number and size of ileal and rectal adenomas
in patients with familial adenomatous polyposis without appreciable toxicity. This is the
first report of efficacy of these compounds for adenoma regression in humans, but randomized
controlled trials are needed to validate these findings. Supported by The John G. Rangos,
Sr. Charitable Foundation, The Clayton Fund, NIH grants K07 CA092445, CA 53801, and
P50 CA 62924-10.
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Induction of C-Terminal SRC Kinase (CSK) By NSAIDs: A Novel Anti-
Proliferative Target in the Chemoprevention of Colorectal Cancer
Dhananjay Kunte, Ramesh Wali, Jennifer Koetsier, Hemant Roy
Background: While the NSAIDS protect against human colorectal cancer (CRC), the molecular
mechanisms remain unclear with a myriad of potential molecular targets. We have recently
shown that the tumor suppressor gene C-terminal Src kinase (CSK) (a Src inhibitor) is
down-regulated early in colon carcinogenesis, thus inducing Src which further leads to
increased cell proliferation. Given that the CSK/Src axis impacts on many pathways that are
implicated in NSAID-chemoprevention (control of apoptosis, proliferation, invasiveness and
angiogenesis), we investigated the effect of NSAIDS on the Src/CSK axis. Methods: AOM-
treated Male Fisher 344 rats were fed with AIN-76 diet either with or without 320 ppm
sulindac for 10 weeks after which they were sacrificed. After sacrifice, the levels of CSK and
p-Src-527 were monitored by western blotting and immunohistochemistry. In order to
determine the role of CSK in the anti-proliferative activity of NSAIDs, we genetically engine-
ered HT-29 cells for knockdown of CSK gene expression using the CSK-specific shRNA
vector. The responsiveness of wild type HT-29 cells and the CSK shRNA construct to sulindac
sulfide treatment (100µM for 72 h) was assessed by western blotting. Src activity was
measured using a tyrosine kinase assay kit. Results: Treatment with sulindac resulted in
marked increase in CSK (174% of control, p<0.01) with corresponding increase in Src 527
(the inhibitory phosphorylation site) in the AOM-rats. In the CRC cell line HT-29, CSK was
induced (144% of vehicle, p=0.014) by sulindac sulfide (100 µM for 72 h) with corresponding
increase in Src 527 (141 % of vehicle, p=0.021) and a marked decrease in Src activity (30%
p<0.05). In the CSK shRNA stable construct, sulindac sulfide did not induce CSK and the
antiproliferative effect of sulindac sulfide (reduction in PCNA) was reduced by 42 % as
compared to wild type HT-29 cells. Furthermore, decrease in the E-cadherin phosphorylation
(an in vivo indicator of decreased Src activity) was reduced by 39% (p=0.023) in the CSK
shRNA construct than the wild type. Conclusion: We demonstrate, for the first time, that
CSK was modulated by NSAIDS in both the AOM-treated rat and HT-29 cells. Importantly,
blocking CSK-induction resulted in partial abrogation of the anti-proliferative effect of
NSAIDS. Thus, this report provides compelling evidence that CSK induction is responsible,
at least partly, for the chemopreventive effects of NSAIDS.
Effect of CSK status on anti-proliferative activity of sulindac sulfide.
S1237
The Effect of Helicobacter Pylori Eradication On Incident of Gastric Cancer
Keiji Ogura, Yoshihiro Hirata, Ayako Yanai, Wataru Shibata, Tomoya Ohmae, Yuzo
Mitsuno, Shin Maeda, Hirotsugu Watabe, Yutaka Yamaji, Makoto Okamoto, Haruhiko
Yoshida, Takao Kawabe, Masao Omata
[Aim] The association between chronic Helicobacter pylori infection and development of
gastric cancer is well established epidemiologically. The possibility of prevention for gastric
cancer by eradicating H. pylori infection is recently investigated by several research groups
and still controversial. The aim of this study is to explore the possibility of reduction in
gastric cancer incidence by eradication of H. pylori infection. [Methods] Three-hundred
four patients with persistent H. pylori infection and 404 H. pylori-eradicated patients were
annually examined for gastric cancer development by endoscopy for 3.1 years and 3.2 years,
respectively. [Results] During the study period, thirteen and six patients were diagnosed
as having gastric cancer in each group. The cumulative incidence of gastric cancer was
statistically different between the groups (p=0.019; log-rank test). The hazard ratio by H.
pylori eradication was 0.335 by Cox’s proportional-hazard model (p=0.047). Differentiated
gastric cancer was found in 11 patients in persistent infection group and in three in eradicated
group, respectively. The incidence of differentiated cancer was significantly different (p=
0.017) between the groups, but that of undifferentiated cancer was not (p=0.847). [Conclu-
sions] The results of the present study support the preventive effect on gastric cancer by
eradication of H. pylori. The eradication of H. pylori may not prevent the incidence of


















Mesalamine Downregulates Oncogene C-MYC and Genes Encoding
Transcription Factors and Signaling Transduction Molecules Involved in Cell
Survival and Proliferation in Colon Cancer Cells: Molecular Basis for
Chemopreventive Action
Eric Chu, Jianyuan Chai, Andrzej S. Tarnawski
BACKGROUND: Patients with ulcerative colitis have increased risk of developing colorectal
carcinoma depending on duration and extent of disease. Cohort and case-control studies
suggest that mesalamine (5-ASA) may exert a chemopreventive effect. Recent metaanalysis
demonstrated a protective association between 5-ASA and cancer or the combined endpoint
of cancer/dysplasia. Mesalamine shares close molecular similarity with aspirin and may
share chemopreventive properties comparable to aspirin and NSAIDs. Limited studies have
suggested that mesalamine may promote apoptosis and inhibit proliferation, but the molecular
mechanisms involved in 5-ASA reducing cancer risk remain incompletely explained. AIMS:
To determine the effect of mesalamine on 96 genes of a cancer pathway gene array.
METHODS: Human colon cancer Caco-2 cells were treated with vehicle or mesalamine (4
mM or 40 mM) for 2 and 5 hours. RNA was isolated from the cells and used as templates
for hybridization with a cancer pathway gene array. The following studies were performed:
1) mRNA expression by gene array, 2) protein expression by Western blot analysis, 3)
subcellular localization by immunohistochemistry, and 4) apoptosis by Annexin V-FITC
binding to membrane of cells undergoing apoptosis. RESULTS: Two-hour treatment with
mesalamine 4 mM and 40 mM downregulated expression of genes encoding transcription
factors and signaling transduction molecules such as Akt (~ 61% and 158%, respectively),
c-Ets2 (~ 74% and 77%, respectively), and c-Myc (~ 50% and 89%, respectively). In addition,
the gene encoding apoptosis regulator Bcl-x was decreased by ~ 34% and 89%, respectively.
Five-hour treatment with mesalamine 40 mM significantly decreased protein expression of
c-Myc ~ 3 fold (p<0.05) compared to cells treated with mesalamine 4 mM or control.
Immunohistochemistry likewise demonstrated reduced expression of both Akt and c-Myc
in cells treated with 40mM mesalamine. Annexin V staining demonstrated increased apoptosis
in cells treated with mesalamine compared to controls. CONCLUSIONS: 1) Mesalamine
downregulates genes encoding anti-apoptotic factors, transcription factors, and signaling
transduction molecules involved in survival and proliferation in human colon cancer cells.
2) The pro-apoptotic and growth inhibitory effects of mesalamine are dose-dependent. 3)
Expression of c-Myc protein is significantly reduced by high dose mesalamine. 4) Binding
of Annexin V to membranes of cells undergoing apoptosis is a novel quantitative method
for detection of apoptosis in colon cancer cells.
S1239
Efficacy and Safety in a Phase I Safety Trial of Celecoxib in Children with FAP
Patrick M. Lynch, Carol Burke, Ernie Hawk, Craig Eagle, Mabel Woloj, James Church,
Hennie Hasson, Sherri Patterson, Elizabeth Half, Gregory D. Ayers
Celecoxib has been approved by the FDA for adjunctive use in FAP, but safety and efficacy
in children with FAP is unknown. We undertook a 3-month, Phase I trial to establish the
highest safe dose of celecoxib in children with FAP between the ages of 10-14 years. 3
cohorts of 6 children had a 4:2 drug:placebo assignment, escalating from 4 to 8 to 16mg/
kg/d. The % change in adenoma burden was compared between baseline and end of study.
Colonoscopy to cecum was performed after PEG or PO4 prep. Number, size and location
of all polyps were documented by the endoscopist and recorded on DVD. Sedation: Propofol
+/- narcotic/benzodiazepine, with anesthesiology support. Results: 18 subjects completed
drug dosing and underwent 3-month colonoscopy. Mean age of subjects: 12.3 years. Racial
composition was 15/18 (83%) Caucasian, with 2 African American and 1 Asian. The %
female was 56%. Overall, mean number of polyps at baseline was 31. At 3 months there
was a 50% increase in polyp count in placebo subjects, while in the highest dose celecoxib
group a 50% reduction was seen (P=0.011) Fig. Adverse events(AE): 10 AEs, all grade 1,
were reported in 6 placebo subjects. In the 10 celecoxib subjects, of 16 AE’s, 14 were grade
I and 2 grade II (both GI) No overall difference in AEs was seen between placebo any of
the 3 doses. No Cardiovascular events were recorded. No complications of colonoscopy or
anesthesia were noted. Conclusions : Celecoxib dose of 16mg/kg/d significantly reduced the
number of colorectal polyps in children with FAP. Celecoxib in dose of 16mg/kg/d, which
corresponds to the adult dose of 400 mg BID is safe and well tolerated by children with
FAP. Colonoscopy with propofol-based anesthesia is very well tolerated by children in age
range 10-14 Supported by NCI/NIH contract N01-CN-05126-02 (P Lynch, PI), and by
Pfizer Pharmaceuticals
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S1240
Combination of Cetuximab and Trastuzumab Cooperatively Reduce Cell
Growth and Augment NSAID-Mediated Cell Death in Human Colon Cancer
Cells
Elizabeth Half, Ho Yee Yeung, Yunjie Sun, Frank A. Sinicrope
BACKGROUND. Up-regulation of EGFR (ErbB-1) is detected in a majority of human colorec-
tal cancers and its selective inhibition modestly reduces tumor growth rates. ErbB-2 is the
preferred heterodimerization partner of EGFR. Cyclooxygenase-2 (COX-2) is a transcriptional
target and downstream effector of both EGFR and ErbB-2. We studied the effects of anti-
EGFR and anti-ErbB-2 antibodies alone, together, and in combination with NS398 (selective
COX-2 inhibitor), on cell viability and cell death in human colon cancer cells. METHODS.
HCA-7 cells were stimulated with heregulin or EGF and then incubated with monoclonal
antibodies against EGFR [cetuximab, 20 μg/ml (Imclone)] and/or ErbB-2 [trastuzumab, 10,
20 μg/ml (Genentech)] ± NS398 (50-200 μg/ml, Sigma). p-ERK, ERK-1, and COX-2 proteins
were analyzed by immunoblotting. Cell viability was determined by MTS assay and total
cell death by propidium iodine + annexin-V labeling. RESULTS. Both cetuximab (C)and
trastuzumab (T) inhibited EGF- and heregulin-stimulated ERK activation and COX-2 expres-
sion that was further suppressed by co-treatment compared to trastuzumab alone.(C) or (T)
produced a 26.3% or 14.5% mean reduction in cell viability, respectively, and their combina-
tion did so by 66.1% relative to untreated cells (Fig. 1). While ineffective individually, the
antibody combination increased total cell death by 78.2% relative to untreated cells. NS398
at 100 μg/ml reduced cell viability by 27% and the addition of (C) or (T) further decreased
it by 46% and 41%, respectively. NS398-mediated growth inhibition was not further sup-
pressed by both antibodies compared to either alone. CONCLUSION. Combined inhibition of
EGFR and ErbB-2 signaling pathways inhibit downstream p-ERK and COX-2 to cooperatively
decrease colon cancer cell viability. Furthermore, a COX-2 inhibitor may augment the
efficacy of these molecularly targeted antibodies against colon cancers.
S1241
The Salicylate Derivative 5-Aminosalycilate (5-ASA) Affects Cell Cycle
Progression in Colorectal Cancer Cells By Activating a P53- and MMR-
Independent, Reversible Replication Checkpoint
Gloria Luciani, Christoph Campregher, Christoph Gasche
BACKGROUND: Colorectal cancer (CRC) is the second leading cause of cancer death in
the Western world. Individuals with inflammatory bowel disease are particularly at risk of
developing CRC. Findings from epidemiological, animal, and laboratory studies suggest that
5-ASA protects from the development of CRC by altering cell cycle progression and by
inducing apoptosis. Further, our previous results indicate that 5-ASA improves replication
fidelity in colorectal cells (Cancer Res 65:3993, 2005), an effect that is active in reducing
mutations, independent of its anti-inflammatory properties. We hypothesized that 5-ASA
restrains cell cycle progression by activating checkpoint pathways that would improve
genomic stability. AIM: We aimed to investigate the molecular mechanisms by which 5-
ASA prevents tumor development and progression in colorectal cancer cell lines. METHODS:
Colorectal cancer cells with different genetic backgrounds such as HT29 (p53 mutant),
Hct116 (hMLH1 mutant and p53 wt), Hct116p53-/- (hMLH1 mutant and p53 null),
Hct116+chr3 (hMLH1 and p53 wt) and LoVo (hMSH2 mutant and p53 wt), were treated
with 5-ASA (0-40mM, Sigma) for 2-72hr. Cell cycle progression was investigated by flow
cytometry with propidium iodide and BrdU staining. Phosphorylation and DNA binding
of cell cycle checkpoint proteins (p53Ser15, ATMSer1981, ATR, Claspin, Chk1Ser345,
Rad17Ser645, RPA, and H2AXSer139) was analyzed by Western blotting. RESULTS: 5-ASA
at concentrations between 10 and 40mM affects cell cycle progression within 48 hours. It
causes cells to accumulate in S-phase indicating that it interferes with DNA replication. This
effect was independent of the hMLH1, hMSH2 and p53 status as it was observed to a similar
extent in all cell lines under investigation. Moreover, wash-out experiments demonstrated
reversiblity within 24 to 48 hours. Although p53 did not have a causative role, p53Ser15
was strongly phosphorylated. Proteins involved in the ATR-dependent S-phase checkpoint
response (Chk1 and Rad17) were also phosphorylated, but not ATM. CONCLUSIONS: Our
data demonstrate that 5-ASA causes cells to reversibly accumulate in S-phase and activates
an ATR-dependent checkpoint. These findings are independent of the mismatch repair
complex and of p53. The observed p53 phosphorylation thus may be a downstream event
of ATR activation. The reversible activation of replication checkpoint(s) may slow down
DNA replication and lead to the improvement of DNA replication fidelity, both of which
increase the maintenance of genomic stability and counteract carcinogenesis.
S1242
Statins Increase the Risk of Colorectal Adenomatous Polyps
Gulam Khan, Nazia Qazi, Swarnalatha Asokan, Jyothi Tummala, Jian Jun Li, Scott Tenner
Statins are the most commonly prescribed medications in the United States. As inhibitors
of 3-hydroxy-3-methyl glutaryl CoEnzyme A Reductase, they are effective lipid lowering
agents. Recently, several studies have suggested that similar to aspirin and non-steroidal
anti-inflammatory drugs, statins may decrease a persons risk of developing colorectal cancer.
Statins have been shown to inhibit the growth of colon cancer cell lines. A case-control
study found a decreased incidence of colon cancer in persons taking statins (NEJM 2005;
352: 2184-92). In order to determine if statins prevent the development of adenomatous
polyps, the following study was performed. A consecutive series of patients who underwent
screening colonoscopy at a single institution were studied. Demographic information was
collected, including statin use, aspirin and NSAID use, family history of colon cancer. The
physician performing the colonoscopy was not aware of whether the patient was taking a
statin. One thousand patients were included in the study, 401 male, 599 female, age 61.7
+/- 7.9 years. There were 317 African American, 352 caucasion, 150 Asian and 179 Hispanic
patients. Three hundred four patients were using statins, mean duration of statin use 23.3
+/- 13.8 months. During colonoscopy, adenomatous polyps were found in 304 patients.
The patients reporting the use of a statin were significantly more likely to have adenomatous
polyps (118/227) compared to patients not taking a statin (186/452), p < 0.01. This associ-
ation remained significant after adjustment for other factors, including family history of
colon cancer, gender, age, aspirin and NSAID use. There was no association between statin
use and the size, number or location of the polyps. We conclude that the use of a statin is
associated with an increased incidence of adenomatous polyps. Given the widely accepted
“adenoma to carcinoma sequence”, our study does not support the prior finding that statin
use decreases the risk of colon cancer. Although other factors in our patient population may
be involved, our study suggests that persons taking statins are at an increased risk of
colorectal neoplasia.
S1243
Can Calcium Chemoprevention of Adenoma Recurrence Substitute for
Colonoscopic Surveillance Or Extend Surveillance Intervals?
Aasma Shaukat, Murtaza Parekh, Joseph Lipscomb, Uri Ladabaum
BACKGROUND: Most colorectal cancers (CRC) arise from adenomas. Current post-polypec-
tomy management consists of colonoscopic surveillance. Calcium may decrease adenoma
recurrence by 30% and large (>=1cm) adenoma recurrence by 50%. AIMS: To examine the
potential cost-effectiveness of calcium chemoprevention post-polypectomy, and to explore
whether it could substitute for surveillance or extend surveillance intervals. METHODS: We
constructed a Markov model of post-polypectomy adenoma recurrence and CRC develop-
ment, calibrated to data from prospective chemoprevention trials of fiber, calcium, antioxid-
ants and aspirin. We modeled 4 scenarios for 50 yr-old patients immediately after polypec-
tomy: 1) natural history (NH) with no further intervention; 2) elemental calcium 1200mg/
day (CALCIUM); 3) surveillance from age 50-80 every 5 yrs, or 3 yrs for large adenoma
(SURV); 4) calcium + surveillance (CALCIUM+SURV). Patients were followed until age 100
or death. The model accounted for missed adenomas. We assumed that 90% of CRC arise
from adenomas. Base case inputs included: relative risk (RR) of recurrence with calcium vs.
no calcium of 0.80 for small adenoma and 0.65 for large adenoma at 3 yrs; calcium cost
$12/yr; colonoscopy sensitivity 95% for CRC, 90% for large polyp, 85% for small polyp;
colonoscopy cost $820 ($1,200 with polypectomy). We estimated discounted (3%/yr) life-
yrs/pt and cost/pt. BASE CASE RESULTS: CALCIUM was more effective than NH (18.654
vs 18.642 life-yr/pt) and was cost-saving ($2350 vs $2450/pt). However, SURV was signific-
antly more effective than CALCIUM (18.729 life-yr/pt) at an incremental cost of $22,100/
life-yr gained. CALCIUM+SURV yielded a very small benefit (0.0003 incremental life-yrs/
pt) compared with SURV, at a substantial incremental cost of $421,000/life-yr gained.
Depending on the willingness to pay, surveillance intervals could potentially be extended
(e.g. surveillance every 5 yrs, or 3 yrs for large adenoma cost $325,000/life-yr gained
compared with surveillance every 6 yrs, or 4 yrs for large adenoma). This extension was
possible even without calcium use. SENSITIVITY ANALYSIS: Decreasing the RR of recurrence
with calcium to 0.67 for small adenoma and 0.52 for large adenoma increased the cost of
SURV vs. CALCIUM to $24,100 and decreased the cost of CALCIUM+SURV vs. SURV to
$182,300. At a calcium cost of $6/yr, CALCIUM+SURV cost $23,000/life-yr compared with
SURV. CONCLUSION: Post-polypectomy calcium chemoprevention is unlikely to be a
reasonable substitute for surveillance, or to allow extension of surveillance intervals. It may
be cost-effective in patients unwilling or unable to undergo surveillance.
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Sensitivity and Specificity of Immunochemical, Automated Developed, Fecal
Occult Blood Test (OC-Sensor) for Detecting Significant Colonic Neoplasia
Zohar Levi, Rachel Hazazi, Alex Vilkin, Paul Rozen, Amal Waked, Eran Maoz, Shlomo
Birkenfeld, Yaron Niv
Background: Guaiac fecal occult blood test is the standard screening test for colorectal cancer
(CRC). Automated-developed, immunochemical occult blood test (I-FOBT) is human Hb
specific, eliminates diet restriction and allows choosing an optimal Hb threshold for follow-
up colonoscopy. Aim: To evaluate performance characteristics of an I-FOBT by comparing
it to colonoscopy. The end-point being the number of colonoscopies needed to identify
significant neoplasia, CRC &/or advanced adenomatous polyps (AAP). Methods: 1,000
consecutive patients undergoing colonoscopy, either for non-bleeding symptoms or for
screening/surveillance, also prepared 3-daily I-FOBTs before colonoscopy. These were exam-
ined by the OC-Sensor automated instrument (Eiken, Japan), using Hb threshold of 100ng/
ml to determine positivity (Vilkin A et al, Am J Gastroenterol 2005, in press). Two patients
required colonoscopy to detect one significant neoplasia. Results: Table Conclusions: OC-
Sensor I-FOBT has good sensitivity and very high specificity for CRC & AAP. The suitability
and cost effectiveness for average risk population CRC screening should be evaluated.
Results: I-FOBT versus total colonoscopy
AAP - advanced adenomatous polyp CRC - colorectal cancer I-FOBT - immunochemical
occult blood test NPV - negative predictive value PPV - positive predictive value
S1245
Type 2 Diabetes Mellitus: The Impact On Colorectal Adenoma Risk in Women
Jill E. Elwing, Feng Gao, Nicholas O. Davidson, Dayna S. Early
Background & Aims: Increased risk for colorectal cancer (CRC) has been associated with
type 2 diabetes. Despite several studies linking insulin resistance to increased CRC risk,
there is limited data on colorectal adenoma risk in diabetic women. We hypothesized that
diabetic women would have increased rates of colorectal adenomas relative to a group of
non-diabetic women. Methods: 100 women with type 2 diabetes mellitus (60.0±9.5yr, 41%
Caucasian, 10% with a first degree relative with CRC, BMI 34.4±8.0, 29% on insulin therapy)
and 500 non-diabetic, hormone status matched controls (59.0±9.2yr, 68% Caucasian, 7%
with a first degree relative with CRC, BMI 28.5±7.1) were selected consecutively from women
undergoing screening colonoscopy at an outpatient university endoscopy center. Adenomas
were defined as any adenoma, or advanced adenoma (villous or tubulovillous features,
size>1cm or high grade dysplasia). A multivariate model was used to determine the independ-
ent effects of diabetes on colorectal adenoma incidence. Results: Diabetic as compared with
non-diabetics had increased rates of any adenoma (37% vs. 24%; OR1.8, 95%CI: 1.2-2.9;
p=0.009) and advanced adenomas (14% vs. 6%; OR 2.4, 95%CI: 1.2-4.7; p=0.009). 245
obese compared with 321 non-obese subjects had increased rates of any adenoma (32% vs.
22%; OR 1.8, 95%CI: 1.3-2.6; p=0.001). Obese diabetics compared with non-obese, non-
diabetics had increased rates of any adenoma (42% vs. 23%, OR 2.6, 95%CI: 1.5-4.6; p=
<0.001) and advanced adenomas (19% vs. 7%; OR 3.5, 95%CI: 1.7-7.4; p=<0.001). Multivar-
iate analysis (including age, race, diabetes, hypertension, hypercholesterolemia, and BMI)
showed that adenomas and advanced adenomas were independently predicted by diabetes
(OR 1.8, 95%CI: 1.1-2.9 and OR 2.2, 95%CI: 1.004-4.6 respectively; p<0.05) and adenomas
by age (p=0.08). Discussion: Women with type 2 diabetes mellitus had higher rates of
colorectal adenomas as compared with lean and non-diabetic women. This finding adds to
the evidence that type 2 diabetes is an important factor in the progression of the adenoma-
carcinoma sequence.
S1246
Endometrial Cancer: The Impact On Colorectal Adenoma Risk in Women
Jill E. Elwing, Feng Gao, Dayna S. Early, Nicholas O. Davidson
Background & Aims: Colorectal cancer (CRC) and endometrial cancer occur in the same
individual more frequently than by chance alone. We hypothesized that patients with
endometrial cancer would have increased rates of colorectal adenomas compared to a control
group without previous gynecologic malignancy. Methods: 60 endometrial cancer patients
(61±9.0yr, 97% Caucasian, 3% with a first degree relative with CRC, 18% diabetic, BMI
32.4±9.1) and 600 hormone status matched controls without a history of gynecologic
malignancy (59.1±9.6yr, 66% Caucasian, 7% with a first degree relative with CRC, 17%
diabetic, BMI 29.4±7.5) were selected consecutively from women undergoing screening
colonoscopy at an outpatient university endoscopy center. Adenomas were defined as any
adenoma or advanced adenoma (villous or tubulovillous features, size>1cm or high grade
dysplasia). A multivariate model was used to predict the independent effect of endometrial
cancer on colorectal adenomas. Results: Increased rates of colorectal adenomas (42% vs.
26%; OR 2.0, 95%CI: 1.2-3.5; p=0.01) and advanced colorectal adenomas (17% vs. 8%;
OR 2.5, 95% CI:1.2-5.2 p=0.02) were found in women with a history of endometrial cancer
as compared to controls. Subjects with both endometrial cancer and diabetes or with both
endometrial cancer and obesity, had highly significant increased rates of adenomas (OR 5.4,

















adenomas (OR 8.4, 95%CI: 2.3-30.1; p=0.005 and OR 3.8, 95%CI: 1.5-9.6, p=0.009,
respectively). Multivariate analysis (including age, race, diabetes, hypertension, hypercholes-
terolemia, BMI and endometrial cancer) showed that colorectal adenomas and advanced
adenomas were independently predicted by endometrial cancer (OR 1.8, 95%CI: 1.04-3.3;
p=0.04 and OR 2.2, 95% CI: 0.99-4.9 p=0.05, respectively) as well as diabetes (p=0.03,
p=0.007) and age (p=0.04, p=0.05). Discussion: Women with a history of endometrial
cancer had higher rates of colorectal adenomas as compared with controls. Women with
both endometrial cancer and diabetes or obesity had higher rates of colorectal adenomas
than did subjects with each risk factor alone. An association between adenomas and endomet-
rial cancer could have an impact on CRC screening recommendations.
S1247
Impact of Systematic 18FDG-PET On Colo-Rectal Cancer Relapse Diagnosis
and Management: Results of a Randomized, Controlled Multicenter Two Years
Follow Up Study
Iradj Sobhani, T. Andre, T. Aparicio, C. Gornet, E. Itti, D. Le Guludec, R. Lebtahi, M.
Lemann, M. Meignan, F. Mentre, E. Mitry, F. Montravers, Y. Panis, R. Parc, P. Piedbois, S.
Retout, P. Rougier, J.N. Talbot, E. Tiret, C. Vaylet
BACKGROUND: A rapid diagnosis procedure of colo-rectal cancer relapse during the survey
period represents a therapeutic challenge. Imaging procedures and increasing carcinoem-
bryonic antigen (CEA) level are tools available to attempt this challenge. We evaluated the
interest of additional systematic positron emission tomography (18FDG-PET) scan as a
means of relapse diagnosis in colorectal cancer. PATIENTS & METHODS. Patents with
rectal or colon cancer (N=135) of stage pTNM III or IV were randomised when all tumours
were surgically extirpated (R0) and adjuvant chemotherapy ended to be followed in conven-
tional -Con-arm (clinical, biological marker every three months, Chest X ray, abdominal
and pelvic CT Scan at 9th and 15th month) or PET arm (conventional procedures plus
PET -18FDG at 9th and 15th month). The end point was relapse confirmed by histology
or “a new decision therapy” during the follow up survey including surgery, chemotherapy,
and palliative therapy. RESULTS. At 2 years follow up, 129 patients (age 32 to 82 ys; median
58) were analyzed and 6 excluded from the analysis because of missing data. Two arms
were balanced in terms of number of patients (64 in PET and 65 in Con arm) included,
age, sex ratio, pTNM stage radio- and chemotherapy at baseline. All imaging procedures
were performed in a blinded way by independent doctors. When at least one of examinations
was suggestive of relapse, patient was considered in relapse if histology confirmed it. When
biopsy or surgery was not performed, the time course of tumour evolution was criteria for
relapse only if this was followed by a “new decision therapy”. Up to 24 month, tumour
relapsed in 38 patients (21 in PET vs 17 in Con; P=0.3) as documented by pathology and/
or time course of tumour evolution a “new decision therapy”, and 81 patients were considered
in remission. There was more surgery and biopsy procedures for pathology examination in
PET arm with therapy decisions made 10.3+/2.4 months from baseline in PET arm (vs
14.8+/- 4.9 in Con arm; p=0.02). This was accompanied with three false positive cases in
PET arm with 18FDG-PET being the only examination showing single abdominal tracer
accumulation and no tumour found (two after laparoscopy and 1 up to the end of survey
period). At the same time, 18FDG-PET failed to detect peritoneal carcinoma in two cases
shown by CT Scan and CEA elevated marker. In three additional cases, 18FDG-PET revealed
unexpected tumours (1 gastric GIST, 2 pulmonary primitive tumours). Conclusion. The
addition of systematic 18FDG-PET may influence therapy strategies and management of
patients with high risk colo-rectal cancer relapse.Supported by PHRC-CEDIT.
S1249
Impact of Initial Polypectomy Versus Follow-Up Surveillance Colonoscopy On
Colorectal Cancer Incidence in Post-Polypectomy Patients
Ann G. Zauber, Iris Vogelaar, Marjolein van Ballegooijen, Rob Boer, Deborah Schrag, Dik
Habbema, Sidney J. Winawer
INTRODUCTION. The National Polyp Study (NPS) demonstrated that detection and removal
of adenomatous polyps reduced subsequent colorectal cancer (CRC) by 76% to 90%. This
overall incidence reduction was achieved with initial polypectomy together with surveillance
colonoscopy (SC) for patients with adenomas in a RCT comparing surveillance intervals at
1, 3 and 6 years versus 3 and 6 years post polypectomy. Of importance is how much the
incidence reduction was due to the initial vs the SC and which patients may benefit from
SC. METHODS. The MISCAN-Colon micro-simulation model was used to assess the separate
effects of initial and SC by the patient’s adenoma characteristics. A population of adenoma
patients of the same age, sex and baseline adenoma characteristics of the NPS followed over
10 years was simulated for three scenarios - 1) no initial colonoscopy and no SC 2) initial
colonoscopy but no SC and 3) initial colonoscopy and SC. The surveillance effect was the
difference in the percent developing CRC with and without SC and assessed by the patient
characteristics of multiplicity (1 or 2 versus 3 or more) and size (<=0.5 cm (small), 0.6-0.9
cm (medium), or >=1.0 cm (large)) of the adenomas at initial colonoscopy. RESULTS. 90%
of the impact of colonoscopic intervention is due to the initial colonoscopic polypectomy
rather than to SC for the 10 years post polypectomy. SC provides the largest benefit for the
20% of NPS patients with 3 or more adenomas where SC reduces the CRC rate by 1.3%.
SC has a smaller effect for those with 1 or 2 adenomas regardless of size with 0.4% to 0.7%
reduction. CONCLUSIONS. The initial colonoscopy rather than SC provides the largest
impact on CRC incidence in the 10 years following initial polypectomy. For those with 3
or more adenomas, SC at 3 year intervals shows a benefit. Based on these results the
surveillance interval for those with only 1 or 2 adenomas could be extended to 5 to
10 years. Tailoring subsequent surveillance recommendations to the baseline colonoscopy
findings can achieve the benefits of colonoscopic polypectomy and a reduction in the number
of surveillance colonoscopies required with their associated risks.
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S1250
Results of Mass Screening with Fecal Occult Blood Test in 4 Pilot Areas in
France
Jean-Francois Bretagne, Vincent Dancourt, Bernard Denis, Gerard Durand, Jean Faivre,
Gaud Mallard, Philippe Perrin, Christine Piette, N Touillon
Aim: mass screening of colorectal cancer with biennially fecal occult blood test (FOBT)
has been recommended by health authorities in France. Twelve first pilot areas so-called
“departments” were selected to implement screening for the general population in 2003.
Here we report the pooled data of the first round in 4 “departments” (Ille et Vilaine, Côte
d’or, Saône et Loire, Haut-Rhin). Methods: the campaign has been organized according the
schedule of conditions defined by health organization. General practitioners (GPs) were
trained in small groups. The round began by sending an information letter to each invited
subject along with an information brochure. GPs offered the test free of charge to the eligible
patients seen at their office. For patients who did not consult or did not complete the test,
the coordination centre sent a new invitation letter before mailing the test and when necessary
a reminder letter. Hemoccult II tests were processed without rehydration. Results: the target
population comprised of 688 984 men and women aged between 50 and 74 years before
exclusion: 65 042 individuals were excluded because of history of colorectal adenoma or
cancer, family history of colorectal cancer, if they underwent a complete colonoscopy in
the last 5 years or for others reasons. 320 419 asymptomatic individuals had been screened
corresponding to a participation rate of 51.4%. FOBT results were positive in 9291 subjects
(2.5%) and non analysable in 4.1% of cases. A complete colonoscopy was performed in
82.4% of people referred for a positive test (n = 6901). According to the most advanced
lesion 9.5% of subjects had colonic carcinoma and 32.5% had adenoma. Among the latter
group, 51.9% had adenoma larger than 1 cm and 30.3% had adenoma with high grade
dysplasia (in situ carcinoma were classified as high grade dysplasia). Carcinoma were dia-
gnosed within resected adenomas in 37% of cases and were classified T0-T1 in 56.6%
of cases. Six cases of perforation (0.8 p.1000 examinations) resulted from colonoscopy.
Conclusions: the mass screening with FOBT in France reproduces the results of the French
controlled trial (Gastroenterology 2004;126:1674). These data should encourage health
authorities to be quick to implement FOBT screening in the whole population.
S1251
Risk Factors for Advanced Colorectal Neoplasia in Women: Comparison of the
Concern and VA 380 Populations
Brooks D. Cash, Andrew Flood, David Weiss, Arthur Schatzkin, David Lieberman, Philip
S. Schoenfeld
Background: VA Cooperative Study 380 data identified several important risk factors for
advanced colorectal neoplasia (i.e., adenomas > 10 mm, villous adenomas, adenomas with
high-grade dysplasia or carcinoma), including family history of colorectal cancer, current
smoking or current alcohol use. However, generalizability of these findings is limited since
97% of the study population was male. The CONCeRN study of asymptomatic, average-
risk women who underwent screening colonoscopy identified significant differences between
men and women in the anatomic distribution of colorectal neoplasia. The current analysis
examines risk factors for advanced neoplasia in women and contrasts these results to men
from VA 380. This is the first study to report risk factors for advanced neoplasia and risk
factors for proximal and distal adenomas for women undergoing screening colonoscopy.
Methods: Prior to colonoscopy in both studies, patients completed standardized, validated
questionnaires to assess potential risk factors for advanced neoplasia. Responses were evalu-
ated using univariate and multivariate logistic regression models to identify associations
between risk factors and advanced neoplasia and adenomas (any size). Results: Among 1463
women, 4.9% had advanced neoplasia and 20.4% had adenomas (any size). Women in the
CONCeRN study demonstrated significant associations between advanced neoplasia and
African-American race (OR = 2.06; 95% CI: 1.07-3.94), current or past regular tobacco use
(OR = 1.64; 95% CI: 1.01-2.66), BMI > 35 kg/m2 (OR = 2.73; 95% CI: 1.18-6.31), and
NSAID use (OR = 0.48; 95% CI: 0.28-0.85) while men from VA 380 did not demonstrate
these associations. Conclusions: Several risk factors appear to be associated with an increased
risk of advanced colonic neoplasia in women including a family history of CRC, African
American race, a history of current or past regular tobacco use, and BMI > 35 kg/m2, while
a history of regular NSAID use appears to be protective in women. Several of these risk
factors appear to be more important for women than men.
Risk Factor Associations in CONCeRN and VA 380
S1252
An Advance Notification Letter Increases Participation in a Fecal
Immunochemical Test-Based Colorectal Cancer Screening Program
Stephen R. Cole, Alicia Smith, Carlene Wilson, Deborah Turnbull, Adrian Esterman,
Graeme P. Young
Background: Screening by fecal occult blood test reduces mortality from colorectal cancer
(CRC), and population participation is a key factor in program success. With increasing
interest in implementing national screening programs, simple and cost effective strategies
are essential to maximize uptake and benefit. A survey of screening invitees indicated that
a better understanding of CRC risk and advocacy for screening may both be positive influences
on participation. Another strategy, advance notification of invitation, may encourage uptake
but this has never been tested in programs using fecal immunochemical tests (FIT). Aim:
To determine the impact of screening invitations incorporating risk, advocacy and advance
notification strategies on population participation in FIT-based CRC screening. Population:
2400 people aged 50-74 randomly selected from the electoral roll of the Australian Electoral
Commission (compulsory registration for all aged >18 years) who had not previously received
an invitation to participate in organized FIT screening. Methods: Those selected were ran-
domly allocated to receive (1) a standard invitation letter explaining the concept, value, risk
for CRC and method of screening (Control); (2) an invitation with additional risk messages
(Risk); (3) an invitation with additional advocacy messages from past participants with
screen detected curable CRC (Advocacy) or (4) first, an advance notification letter introducing
Control letter messages, followed after 2 weeks by a standard invitation (Notification). All
invitations were sent from a central screening facility, were of similar length and included
an FIT kit (InSure®). Participation was compared by Chi2. Results: Participation rates were:
Control: 237/600, 39.5%, Risk: 242/600, 40.3%, Advocacy: 216/600, 36.0%, Notification:
290/600, 48.3%. Participation was significantly greater than Control in the Notification
group only (p=0.003). This effect was apparent as early as 2 weeks post mail-out (25.2%
versus 18.2%, p=0.004). Age and sex were not associated with response to the notification
letter. Conclusions: An advance notification letter sent prior to mailing CRC screening
invitations significantly increased participation. Invitation letters incorporating enhanced
risk or lay advocacy messages had little effect on participation. Advance notification letters
are a simple and inexpensive way to increase participation in organized CRC screening
programs. As the advance notification letter contained simple messages covering the magni-
tude, risk and curability of CRC, it is likely that increased participation was due to greater
awareness and readiness to participate in CRC screening.
S1253
Colonoscopy with An Indigo Carmine Capsule: A Randomized Controlled
Trial
Adolfo Parra-Blanco, David Nicolas, Antonio Z Gimeno, Livia Rezende, Marta Carrillo,
Juan Adolfo Ortega, Margarita Menacho, Rosa Mari Rodriguez-Hernandez, Lourdes
Rodriguez-Perez, Cristina Rodriguez-Galito, Enrique Quintero
Introduction: pancolonic indigo carmine (IC) applied with a catheter during colonoscopy
has shown a slight benefit in the detection of polyps. In non-randomized studies oral IC
delivered in a capsule showed an increased detection of flat and depressed lesions. Aim: to
assess whether the indirect application of IC increases the detection of colonic polyps
and flat lesions during colonoscopy. Methods: 551 patients undergoing colonoscopy were
randomized in Group I: Polyethylene Glycol Solution (3 L) immediately followed by an IC
capsule (200 mg) (n=265 patients), or Group II: Polyethylene Glycol Solution (3 L) (n=
286). Four experienced endoscopists performed the colonoscopies. The following variables
were recorded: baseline features (age, gender, indication), presence of polyps, presence of
flat or protruding polyps, total number of polyps, number of flat or protruding polyps,
insertion and withdrawal time. The study was aproved by the local Ethical Commitee.
Results: patients in Group II were significantly younger (53±20 vs 57±17, p<0.05). There
were no differences in the distribution of gender or indication for colonoscopy, nor in the
presence of polyps (global, protruding or flat). The mean number of polyps and the mean
number of protruded polyps per patient were not statistically different between Groups I
and II (1.4 ±1.9 vs 1.1±1.7, and 0.8±1.4 vs 0.7±1.3, respectively). However the mean
number of flat lesions per patient with IC capsule was significantly greater than in those
receiving the standard prep (0.63±1.2 vs 0.44±0.93; p=0.04). No differences were registered
between Groups I and II in insertion time (13.0±8.3 vs 13.5 ±9.1) or withdrawal time
(22.9±14.5 vs 23.1 ±15.0). Conclusions: the administration of an IC capsule after Polyethyl-
ene Glycol Solution increases the detection rate of flat lesions during colonoscopy, with no
apparent impact on procedure duration.
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S1254
Temporal Trends in Colorectal Procedure Use Following Colorectal Cancer
Resection
Gregory S. Cooper, Jonathan D. Payes
Introduction: Colorectal procedures, including flexible sigmoidoscopy (FS), colonoscopy
(COL) and barium enema (BE) are commonly performed for surveillance care in colorectal
carcinoma survivors. Given temporal trends in the use of colorectal screening tests in the
general population, we hypothesized that similar patterns would be observed in cancer
survivors. Methods: Using the linked SEER-Medicare database, we identified all patients ≥
65 years with an initial diagnosis of colorectal carcinoma between 1992 and 1999. Patients
with distant stage or unstaged disease or who did not undergo surgical resection were
excluded. Using Medicare claims data, the use of FS, COL and BE within 1 year and 3 years
after diagnosis was measured in patients who survived through the end of that follow up
period. Results: A total of 35,447 eligible patients survived through 1 year of follow up and
28,278 patients survived through 3 years. Within one year of diagnosis, 18.9% underwent
FS, 59.5% had COL, 14.5% had BE and 69.6% had one or more of the procedures.
Corresponding rates for the 3-years after diagnosis were 24.8%, 81.3%, 17.6% and 86.9%,
respectively. Over the 8 year study period, there was a progressive decrease in the proportion
of patients with FS within 1 year of diagnosis (20.9% 1992 to 16.1% 1999, p<0.0001 by
chi-square for trend) and BE within 1 year of diagnosis (19.1% 1992 to 10.0% 1999,
p<0.0001). Similar temporal trends were observed for FS within 3 years of diagnosis (28.0%
1992 to 20.2% 1999, p<0.0001) and BE within 3 years of diagnosis (23.9% 1992 to 11.4%
1999, p<0.0001). In contrast, the use of COL remained unchanged for 1 year after diagnosis
(58.9% 1992 to 60.5% 1999, p=0.1) and increased somewhat 3 years after diagnosis (78.4%
1992 to 82.9% 1999, p<0.0001). Overall procedure use within 1 year decreased somewhat
(71.7% 1992 to 68.2% 1999, p<0.0001) but 3 year rates were unchanged over time (86.9%
1992 to 86.5% 1999, p=0.7). Conclusions: Consistent with temporal trends in the cancer-
free population, the use of FS and BE in colorectal cancer survivors decreased through the
1990’s. Although COL use increased somewhat with time, even in the most recent time
period, approximately 20% of patients did not undergo this procedure within 3 years of
diagnosis and 10-15% underwent none of the colorectal procedures. Further studies should
identify subgroups that are least likely to undergo surveillance testing as well as those with
potential overuse of procedures.
S1255
A Prospective Study of Community Screening Colonoscopy in African
American Women (AAW) and Latino Women (LW): Barriers, Compliance,
Results and Satisfaction
Moshe Shike, Alvaro Genao, Ann Zauber, Margaret Burke, Mark Schattner, Winsome
Grant, Valerie Cuyjet, Shelby Samuel, Franklin Marsh, Lianne Russo, Rian Rodriguez,
Harold Freeman
Survival of colon cancer patients is substantially lower among minorities, mainly because
of late diagnosis. There is little information on screening colonoscopy (SC) in minority
women. The only SC study specifically of women (CONCeRN) was performed in a non-
community setting and included a very small % of minorities. We report on a community
based prospective study of SC in AAW and LW. Women having mammography at a breast
center in Harlem NY were offered to participate in a SC study and those willing signed
consent. The study involved completing questionnaires, and undergoing a colonoscopy. The
rationale and alternatives were explained by a bilingual college graduate in English or
Spanish. Colonoscopy and pathology review were performed at the local hospital. The study
was offered consecutively to 5,673 women 50y or older (approximately 90% minorities);
3,057 were excluded because of prior screening or colon examination (a screening program
existed prior to the study ), 2005 refused due to: wanting to discuss with own physician
(585), lack of insurance (415), wanting colonoscopy but not study (368), already scheduled
for colonoscopy (158), fear (147), medical problems (29), inadequate knowledge (18), prefer
FOBT/Sig (15), miscellaneous (270). Of 611 women who consented, 317 (mean age 57y,
range: 50-85) attended pre-colonoscopy medical evaluation by a nurse and completed
colonoscopy, 60 are pending, 234 dropped out due to: insurance (58), lack of time (33),
colonoscopy elsewhere (32), fear (31), medical problems (24), lost to follow up (24),
miscellaneous (32). Colonoscopy findings: 70% normal, 18% had non-adenomatous polyps,
12% had adenomas, 1 colorectal cancer. Adenoma prevalence was comparable among AAW
and LW and slightly less than in predominantly white military women in the CONCeRN
study, while hyperplastic polyp prevalence was comparable in the 3 groups. There were no
colonoscopy related complications. Payment for colonoscopy: insurance 158 (50%), cash
21 (6%), philanthropy 138 (44%). Those covered with philanthropic funds would not have
had the procedure otherwise. A total 89% of women were satisfied and would have colonos-
copy again, 4% would not, 7% were unsure. Conclusions: The overwhelming majority of
minority women in this prospective study were interested in screening colonoscopy (but
not necessarily in study)after an explanation by a non-medical person. Lack of insurance is
a major barrier. Screened women were pleased with colonoscopy. Colonoscopy findings are
comparable to those in white women in tertiary centers studies. The results suggest that
colonoscopy is feasible and acceptable for screening of AAW and LW in the community.
S1256
Results and Cost of a Population-Based Biennial Faecal Occult Blood
Colorectal Cancer Screening Program
Bernard Denis, Philippe Perrin, Jean Francois Vies, Jean Paul Milleliri, Frederic Vagne,
Guy Ventre, Jean Marc Boyaval, Fernand Planchon
Despite strong evidence that screening reduces both colorectal cancer (CRC) mortality and
incidence, CRC screening tests remain underutilized. Aim: To report the results and cost
of a population-based biennial faecal occult blood (FOBT) CRC screening program in the
French area of Haut-Rhin (710 000 inhabitants), an area with one of the highest CRC

















for a CRC screening using a non rehydrated FOBT (Hemoccult II). FOBTs were first provided
by the GPs and then directly mailed to persons who didn’t comply after 2 invitations. The
processing of FOBTs was centralized. Results: 87,790 people (46.6%) completed a FOBT
and 18,995 (10.1%) were excluded for recent CRC screening, high risk of CRC or concurrent
severe disease, so that adjusted participation rate was 51.8%. Participation was higher in
women (54.2%) than in men (49.4%)(p<0.001) and ranged from 45.4% to 59.8% according
to districts. Participation was lower below 60 years (47.5%) than after (56.6%). FOBT
positivity rate was 3.3%, higher in men (3.9%) than in women (2.8%)(p<0.001). To date
2,408 colonoscopies were performed. The positive predictive value was 10% for CRC (women
7.2%, men 12.5%), 20.8% for advanced adenomas (women 13.4%, men 26.9%) and 42.2%
for neoplasia (women 30.6%, men 51.8%). Detection rates for neoplasia and CRC were
11.6 and 2.8 per 1,000 people screened. 27.2% of CRC were in situ, 50% of invasive CRC
were stage I and 23.4% stage II. The rate of proximal advanced neoplasia increased with
age (16.5% below 65 years, 25.4% after) but didn’t differ with gender. Flexible sigmoidoscopy
alone would have missed 21.4% of people with advanced neoplasia, without significant
difference according to age and gender. The overall cost of this biennial screening program
(without the fees related to colonoscopies) was $2.7 million: fixed cost was $1.88 million
($5 per year per eligible person) and variable cost $0.82 million ($4 per screened person).
The cost per screened person was $30 and the cost to find an early-stage neoplasia (advanced
adenoma or in situ CRC or stage I CRC) was $4,300. Conclusion: Participation and diagnostic
yield of randomised controlled trials of FOBT screening are reproducible at a reasonable
cost in the real world through an organized population-based program involving GPs. Efforts
should be made to enhance the participation of men and people below 60 years.
S1257
Prevalence of Anal Dysplasia in a French Population
Isabelle Etienney, Sarra Vuong, Fady Daniel, Benoit Mory, Milad Taouk, Samy Sultan,
Christian Thomas, Josee Bourguignon, De Parades Vincent, Nathalie Meary, Andre
Balaton, Patrick Atienza, Pierre Bauer
Studying anal cytology to detect intraepithelial dysplasia has been demonstrated to be useful
in highly selected populations with a high risk of epidermoid cancer of the anal canal. We
have demonstrated the acceptability and feasibility in France of taking anal canal smears
during consultations. The aim of this study was to determine the frequency of abnormal
smears in a wide sample of patients consulting for anorectal symptoms. Patients and methods:
An anal smear was systematically proposed during a consultation and carried out, after
obtaining informed consent, using a Dacron brush, without disinfection or using a retractor.
It was immediately put into suspension in a liquid phase (Thin Prep®). Results: 205 patients
(112 women, 93 men) were included between 12 July and 7 October 2005. A history of
human papilloma virus (HPV) anal lesions was found in 13% of the cases. A history of HPV
gynecological lesions or conization was noted respectively in 5% and 4% of the women.
Twenty-four (12%) patients were infected by the human immunodeficiency virus (HIV)
while 174 were not, and the serological status was unknown for 7 patients. Following the
consultation, pathology was linked to HPV in 23 (11%) of the cases (evolving lesions N=
12, follow-up of condylomas without clinical lesion N=5, follow-up of dysplasia N=3 and
monitoring of irradiated anal canal cancer without recurrence N=3). Ninety-nine percent of
the smears were able to be analyzed (2 smears were acellular). Four cases of low grade anal
intraepithelial neoplasia (AIN) were found, all in HIV patients with a history of condylomatous
lesions, 40 smears were interpreted as atypical squamous cells of undetermined significance
(ASCUS) and 159 were normal. The sensitivity of the smears was 67% and the specificity
81%, with a positive predictive value of 18% and a negative predictive value of 97%. The
prevalence in this population of AIN was 19% in HIV seropositive men, and 15% in the
case of a past history of condyloma. The factors associated with an abnormal smear (AIN
or ASCUS) were a history of anal condylomatous lesions OR 4.9 [2.1-11.5], HIV seropositivity
OR 4.0 [1.6-9.9] and smoking OR 2.1 [1.1-11.5]. In women the frequency of abnormal
smears was not significantly increased where there was a history of HPV gynecological lesions
or conization. Conclusion: This work confirms the raised frequency of AIN in HIV seropositive
men, but also where there is a history of condyloma, which confirms the necessity for regular
monitoring and screening of these patients at risk.
S1258
Potential Usefulness of Detecting Cyclooxygenase 2 and Matrix
Metalloproteinase 7 Messenger RNA in Feces for Colorectal Cancer Screening
Tetsunari Takai, Shigeru Kanaoka, Ken-Ichi Yoshida, Mutsuhiro Ikuma, Masayoshi
Kajimura, Naoyuki Miura, Haruhiko Sugimura, Akira Hishida
Background: Colorectal cancer (CRC) is one of the most common causes of death in Western
world. To reduce the mortality, it is important to point out the lesions at early stage and
to resect them before metastasis. We reported that Fecal COX-2 assay, one of RNA-based
stool assays, is useful for detecting CRC (Gastroenterology 2004; 127: 422-427). It is reported
that matrix metalloproteinase 7 (MMP-7) is upregulated in colorectal cancer and adenoma.
To raise the sensitivity of the assay keeping 100% specificity, we chose MMP-7 as a combina-
tion target for Fecal COX-2 assay. Methods: Standard histological techniques were used to
classify adenoma or malignancy at I to IV stages according to TNM classification. We purified
RNA from routinely collected stool samples and screened mRNA using COX-2 and MMP-
7 specific nested RT-PCR as previously described, consequently compared the results with
those of a single immunochemical FOBT (Magstream 1000/HemSp; FUJIREBIO, Inc., Tokyo,
Japan) on same stool samples. Results: Stool samples from 65 patients with CRC, 13 patients
with advanced adenoma, and 31 control patients without neoplastic disease were studied.
The specificity of Fecal MMP-7 assay as well as Fecal COX-2 assay was 100% (95% confidence
interval [CI], 88.8-100%), while that of IFOBT was 87.1% (95% CI, 70.1-96.4%). The
sensitivity of RNA-based stool assay, combination of MMP-7 and COX-2 as targets, was
90.8% (95% CI, 80.9-96.5%) for CRC, and 69.2% (95% CI, 38.6-90.9%) for advanced
adenoma, while that of IFOBT was 73.0% (95% CI, 60.2-84.6%) and 30.8% (95% CI, 9.1-
61.4%), respectively. COX-2 and/or MMP-7 mRNA was detected in 84.6% of stage I (n=
13), 96.8% of stage II (n=31), 85.7% of stage III or IV (n=21), while IFOBT was positive
in 41.7% of stage I, 80.0% of stage II, 81.0% of stage III or IV. Noteworthy, COX-2 and/
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or MMP-7 mRNA was detected in 17 of 22 stool samples from patients with curable cancer
or advanced adenoma who had negative IFOBT. When the size of cancer and adenoma was
limited from 1 to 3 cm, the sensitivity of RNA-based stool assay was 78.6% (59.0%-91.7%),
while that of IFOBT was 35.7% (18.6%-56.0%). Finally, the sensitivity of this assay was
87.7% (95% CI, 78.0-94.9%) for advanced adenoma to stage II cancer, while that of IFOBT
was 60.0% (95% CI, 45.8-73.1%). Conclusions: RNA-based stool assay is superior to a
single IFOBT in term of detecting colorectal cancer and advanced adenoma, especially curable
tumors. These results strongly suggest that this assay would be useful for CRC screening.
S1259
Age-Associated Mutation of the DCC Gene in Patients with Normal Colonic
Mucosa
Nolan E. Perez, Satish B. Maryala, Yingjie Yu, Adhip P. Majumdar
PURPOSE Although the incidence of colorectal and other gastrointestinal cancers increases
with advancing age, the underlying molecular mechanisms are not fully understood. Since
accumulation of genetic abnormalities is thought to drive the adenoma-carcinoma sequence
towards colorectal cancer (CRC) development, we hypothesize that aging may render target
cells more susceptible to carcinogenesis through mutation of tumor suppressor genes. Muta-
tions of tumor suppressor genes are frequently observed in patients with colonic dysplasia
or neoplasia. Deleted in Colon Cancer (DCC), a tumor suppressor gene involved in regulating
cell to cell interactions, has been shown to have allelic deletions in colorectal and other
gastrointestinal cancers. Previously, we reported that the incidence of mutations of several
tumor suppressor genes, including DCC, is higher in the gastric mucosa of subjects over
60 years of age (Am J Physiol Cell Physiol 2001:282;G932-G936). To determine if this
age-related phenomenon occurs in the colon, we tested normal (non-dysplastic and non-
neoplastic) mucosa for the presence of DCC gene mutations in patients of various ages.
Furthermore, we obtained samples from the proximal (ascending and transverse) and distal
(descending and rectosigmoid) colon to ascertain whether aging increases susceptibility to
mutation in a location-specific manner. METHODS Patients undergoing screening or dia-
gnostic colonoscopy were offered enrollment in our study if they were at average risk for
CRC and were not taking chemopreventive agents. If no dysplasia or neoplasia was found
at endoscopy (i.e. no adenomas or cancers), random biopsies were obtained from the
ascending, transverse, descending and rectosigmoid colon. DNA analysis by PCR amplifica-
tion was performed for detecting mutations in the DCC gene. RESULTS We enrolled 27
patients in our study. The age ranged from 31 to 81 years, with a mean age of 58 years.
The vast majority (81%) of subjects were male. In patients younger than 60 years, 2 of 17
(12%) patients had mutations in the proximal colon and 3 of 17 (18%) had mutations in
the distal colon. Among patients older than 60 years, 4 of 10 (40%) had mutations in the
proximal colon and 2 of 10 (20%) had mutations on the distal colon. CONCLUSION Aging
is associated with an increased rate of DCC gene mutation, especially in the proximal
colon. Although more studies are needed, we postulate that age-related mutations in tumor
suppressor genes predispose towards the development of colorectal cancer by creating a
field defect.
S1260
Long-Term Safety and Efficacy of Lubiprostone for the Treatment of Chronic
Constipation in Elderly Subjects
Ryuji Ueno, Raymond Panas, Aimee Wahle, Yan Zhu, P. Christopher Holland
Constipation is a common and bothersome gastrointestinal condition that is especially
prevalent among the elderly (those≥65 years of age). Lubiprostone is a novel type-2 chloride
channel (ClC-2) activator that has been studied to show long-term safety and efficacy for
the treatment of chronic constipation in 3 open-label clinical trials. In order to create an
adequate pool of elderly subjects, data were combined from these three studies, resulting
in 163 elderly subjects (aged ≥65 years) and 715 non-elderly subjects (aged 18-64). Safety
was assessed by adverse event (AE) incidence rates and efficacy was evaluated by improve-
ments in subject assessments of constipation severity, abdominal bloating, and abdominal
discomfort. All assessments were based on 5-point severity scales where 0=Absent and 4=
Very Severe. Results revealed that, with regard to safety, slightly fewer elderly subjects report
adverse events compared to non-elderly subjects (121/163, 74.2% vs 573/715, 80.1%).
Notably, the incidence rate for the most common AE, nausea, was markedly decreased in
elderly subjects as compared to non-elderly subjects (17.8% vs 29.4%). With regard to long-
term efficacy, improvements in assessments of constipation severity, abdominal bloating,
and abdominal discomfort were all statistically significant at all post-baseline time points
from Week 1 to Week 48 for both elderly and non-elderly subgroups (p<0.0001). Amongst
the elderly, constipation severity was improved by an average of 1.11 points at Week 1 (N=
108), 1.32 points at Week 24 (N=81), 1.21 points at Week 48 (N=58), and 0.97 points
for the last on-drug measurement (N=159). Abdominal bloating was improved by an average
of 0.76 points at Week 1 (N=108), 0.99 points at Week 24 (N=81), 1.05 points at Week
48 (N=58), and 0.71 points for the last on-drug measurement (N=159). Abdominal discom-
fort was improved by an average of 0.49 points at Week 1 (N=108), 0.75 points at Week
24 (N=81), 0.79 points at Week 48 (N=58), and 0.52 points for the last on-drug measurement
(N=159). We conclude that lubiprostone is a well-tolerated and efficacious long-term treat-
ment for chronic constipation in the elderly.
S1261
Risk Analysis of Gastrointestinal Surgery in Elderly Patients Over 80 Years
Old: Usefulness of the Possum Scoring System
Tsuneo Tanaka, Yasuhiro Matsugu
Aim: It is known well that the function of various organs is compromised at advanced ages.
However, since the degree of dysfunction varies among different organs, preoperative and
precise evaluation of the reserved capabilities of individual organs is difficult. The present
study was undertaken to evaluate the operative risk of elderly patients (over 80 years old)
scheduled to undergo surgery. Materials & Methods: The subjects of this study were 1,326
patients with gastrointestinal disease who underwent surgery between January 2002 and
June 2005. The underlying disease was benign in 471 (36%) cases and malignant in 855
cases (64%). Emergency surgery was performed on 205 cases (15%) and elective surgery
on 1121 cases (85%). They were divided by age into three groups: a younger group (below
69 years, n=834), an older group (70-79 years, n=367) and the oldest group (over 80 years,
n=125). The presence/absence of preoperative complications, hematological parameters and
magnitude of operative stress were compared among these three groups. For risk assessment
using the POSSUM system, data on 12 parameters related to physiological score (PS) and
6 parameters related to operative severity score (OS) were derived from the database or
individual patients. The risk of individual patients was rated on a three-category scale (low-
risk:12-19, moderate-risk:20-24 and high-risk:more than 25) on the basis of PS scores.
Results: The percentage of patients having preoperative complications of the respiratory,
cardiac and neurological systems was significantly higher in the oldest group than in the
younger group. Hemoglobin, albumin, prothrombin time, sodium and urea levels were
significantly lower in the oldest group than in the younger group. The PS was 15.6±3.7
(mean±SD)in the younger group, 19.9±4.4 in the older group, and 22.9±4.6 in the oldest
group. The percentage of patients rated as having high-risk increased as age advanced.
Postoperative complications were seen in 339 cases (25.6%), and death during hospital stay
occurred in 23 cases (1.7%). The hospital death rate and the incidence of postoperative
complications were significantly higher in the high-risk group than in the low- and moderate-
risk groups. Conclusion: Elderly patients over 80 years old often have preoperative complica-
tions and compromised organ function. The PS score as assessed using the POSSUM is
useful for evaluation of operative risk in elderly patients.
S1262
Efficacy and Safety of Lubiprostone for the Treatment of Chronic Constipation
in Elderly vs Non-Elderly Subjects
Ryuji Ueno, Taryn R. Joswick, Aimee Wahle, Yan Zhu, P. Christopher Holland
Constipation is a common and bothersome gastrointestinal condition that is especially
prevalent among the elderly (those≥65 years of age). Lubiprostone is a novel type-2 chloride
channel (ClC-2) activator (AJP Cell Physiol 287:C1173-C1183, 2004) that has been shown
to be efficacious and well tolerated in a number of well-controlled clinical trials of 3-4
weeks duration (Gastroenterology 122:A315, 2002; Gastroenterology 124:A38, 2003; Am J
Gastroenterol 100:S324, S328 and S329, 2005). We have examined pooled results from
these trials so that subgroups of elderly and non-elderly subjects can be compared. Methods:
In order to create an adequate pool of elderly subjects, data were combined from three
well-controlled clinical trials. Spontaneous bowel movement (SBM) frequency rates, stool
consistency ratings, and bowel straining assessments were compared between treatment
groups (placebo and lubiprostone 48 µg/day) via inferential statistics and used to assess
efficacy. Mean improvements over placebo are compared between elderly and non-elderly
subjects. Adverse event (AE) incidence rates are also compared between treatment groups
and age groups. Results: The pooled elderly subgroup consisted of 31 placebo and 26
lubiprostone subjects. Mean changes from baseline in SBM rates were significantly improved
among lubiprostone elderly subjects as compared to their placebo counterparts during Weeks
1, 3, and 4 (p≤0.0286). Improvements during each of the 4 weeks ranged from 4.6 to 5.4
additional SBMs per week for elderly lubiprostone subjects compared to 1.29-2.27 SBMs
per week for elderly placebo subjects. Results were similar for stool consistency and bowel
straining ratings. With regard to safety, fewer elderly lubiprostone subjects experienced AEs
(46.2%) compared to their placebo counterparts (61.3%). Conclusion: Lubiprostone is an
efficacious and well-tolerated treatment for chronic constipation in the elderly.
S1263
Etiology and Outcome of Acute Pancreatitis in Infants and Toddlers
Leena Kandula, Mark E. Lowe
BACKGROUND: The incidence of acute pancreatitis (AP) in children has increased in western
countries. Even so, little is known about the causes and outcome in infants and toddlers
with AP. AIM: To determine the spectrum of etiological factors and outcome of AP in infants
and toddlers. METHODS: We reviewed medical records of children < 3 years of age admitted
to Children’s Hospital of Pittsburgh with a diagnosis of AP (ICD-9 577.0) between January
1995 and December 2004. AP was defined as three fold elevation in serum amylase (normal,
< 90 IU/L) or lipase (normal, < 200 IU/L) levels, with clinical signs and symptoms or
radiological findings consistent with the diagnosis. Demographic, clinical, laboratory and
diagnostic data were collected. Patients were classified as idiopathic if no identifiable cause
was found. Severity of the disease was based on Atlanta criteria. The study was approved
by the University of Pittsburgh Institutional Review Board. RESULTS: Of 90 cases with a
diagnosis of AP, 73 (35 male, 38 female) met the diagnostic criteria. Mean age was 19.3
+/- 9 months (range: 1 week to 35 months). Common presenting symptoms included
vomiting in 30 (41%), irritability in 29 (39.7%) and abdominal pain in 19 (26%) cases. AP
was associated with multisystem disease in 42 (57.5%) cases (Sepsis, 27; hemolytic uremic
syndrome, 7; shock and multi organ failure, 8). No single organism predominated in the
patients with sepsis. AP was associated with trauma in 6 (8.2%), pancreaticobiliary disease
in 7 (9.5%) (Gall stones, 5; choledochal cyst, 1; annular pancreas, 1), liver transplantation
in 2 (2.7%), cystic fibrosis in 1 (1.3%) and was idiopathic in 15 (20.5%) cases. Mean peak
serum amylase level was 325 IU/L (range: < 30 to 1533 IU/L) and mean peak serum lipase
level was 7188 IU/L (range: 607 to 45,640 IU/L). Abdominal ultrasound was done in 32
(43.8%) and was useful in making a diagnosis in 8 cases. Abdominal CT was done in 21
(28.7%) and was diagnostic in 8 cases. MRCP was done in 3 (4.1%) and was diagnostic in
1 case. Only one patient underwent ERCP and sphincterotomy. AP was mild in 63 (86.3%),
severe in 3 (4.1%), and death from complications unrelated to pancreatitis occurred in 7
cases (9.5%). Of 3 patients with severe AP, two had pancreatic necrosis following trauma
and one had a pseudocyst. 4 patients (5.5%) had surgery involving the pancreas (pancreatic
resection, 2; pseudocyst drainage, 1; annular pancreas repair, 1). CONCLUSIONS: In this
age group, AP is most commonly associated with multisystem disease. In contrast to common
T : 89386$$CH2
05-04-06 23:18:26 Page 189Layout: 89386B : o
A-189 AGA Abstracts
teaching, biliary disease is also an important etiology. Severe AP was most often associated
with trauma.
S1264
Use of Clostridium Botulinum Toxin for the Treatment of Obstructive
Symptoms Or Enterocolitis in Patients with Non-Relaxing Internal Anal
Sphincter: A Long-Term Outcome Study
Bruno P. Chumpitazi, Steven J. Fishman, Samuel Nurko
Background: Obstructive symptoms or enterocolitis may occur due to a non-relaxing internal
anal sphincter (IAS) in children with IAS achalasia or in those with postoperative Hirschs-
prung’s disease (PHD). Clostridium botulinum toxin injections (BoTox) to the IAS are used
as therapy, but there is limited information about their long-term effects. This study evaluates
the long-term outcome of children with non-relaxing IAS who received BoTox therapy
for obstructive symptoms or enterocolitis. Methods: Retrospective review of symptomatic
children with non-relaxing IAS who received BoTox. Both BoTox and rectal biopsies were
generally done under the same anesthetic procedure. Long-term outcome was classified into
4 groups (excellent, good, fair, poor) based on symptoms, incontinence, laxatives, rectal
therapies, or surgery. Results: 55 children received BoTox; 28 had IAS achalasia, and 27
PHD. Mean follow-up was 23 ± 3 months. Mean age at the time of first BoTox was 5 ± 0.5
years. Improvement after the first BoTox was seen in 44 (77%) and predicted an excellent
or good long-term clinical outcome (p<0.01). Mean duration of response after the first
BoTox was 4.6 ± 0.9 months. 35 children received more than one BoTox (2.3 ± 0.2 injections/
patient). After BoTox there was a reduction in the % patients using rectal therapies (47 vs
25;p<0.008), and in the hospitalization rates for enterocolitis (2.4 admissions/year vs. 0.4
admissions/year;p=0.02). Five children (9%) developed transient fecal incontinence, and 1
(2%) had rectal pain after the injection. Seven (12%) underwent myectomy. Long-term
outcome is shown in the table. In those with a good/excellent outcome, the response was
maintained for 12 ± 3 months after the last BoTox. Five (18%) children with postoperative
HD were found to have residual aganglionosis, a predictor of failure to respond to BoTox
(p<0.01). There was no statistical difference comparing the response between IAS achalasia
and HD. Conclusions: BoTox is an effective and safe therapy for children with non-relaxing
IAS. An initial improvement after the first BoTox predicted an excellent/good long-term
outcome. No difference was seen in the response regardless of the etiology of the non-
relaxing IAS. Because patients with residual aganglionosis do not respond to BoTox, it is
important to perform a rectal biopsy in symptomatic patients with PHD.
* Those with residual aganglionosis are excluded.
S1265
Fanconi Syndrome in Patients with Microvillous Inclusion Disease
Karin M. Van Dael, Sven C. van Ijzendoorn, Leonie J. Pierik, D.R. J. Reijngoud, Hilda M.
Keuning, Arend Karrenbeld, Marius C. van den Heuvel, Edmond H. Rings
Introduction: Microvillous inclusion disease (MID) is a rare congenital defect of the brush
border of the intestinal epithelium and characterized by periodic acid-Schiff (PAS)-positive
secretory granules within the apical cytoplasma of the enterocytes and microvillous inclusions
in these cells as observed by electron microscopy. Furthermore, a variable degree of villous
atrophy of the intestinal villi is seen. MID leads to lifelong intestinal failure for which
total parental nutrition is required. Better homecare parental nutrition and early intestinal
transplantation is suggested to be of benefit to change clinical outcome. As enterocytes are
characterized by microvilli, we hypothesize that proximal renal tubular epithelial cells share
a similar defect leading to clinical symptoms earlier not recognized because of the short life
span of these children. Therefore we aimed to study renal function and the renal morphology
at the light microscopic and electron microscopic level, with emphasis on the proximal
tubuli, in children with MID. Materials and Methods: Two children, aged 2 years, with
confirmed intestinal MID, who were evaluated for intestinal transplantation, were studied.
Renal function was analyzed and kidney biopsies were evaluated by light and electron
microscopy. Results: Both children had a persistent and progressive metabolic acidosis in
conjunction with glucosuria, hyperaminoaciduria, beta-2-microglobinuria and tubular solute
losses as part of a Fanconi syndrome. They also developed severe carnitine deficiency and
rickets as result of impaired phosphate reabsorption. They were growth retarded, despite
total parenteral nutrition and exclusion of enteral feeding. The kidney biopsies did not reveal
histological abnormalities at the light microscopy level, although PAS-positive granules at
the apical membrane of the tubular epithelial cells were seen. At electron microscopy, a
normal architecture of the proximal tubule cells was seen, although the microvilli seemed
less well organized per cell compared to controls. In contrast to enterocytes, no intracellular
microvillous inclusions in these cells were observed. Conclusions: Proximal tubular dysfunc-
tion (Fanconi syndrome) can be part of MID. Growth retardation, which is often seen in
children with MID, may also be dependent on this renal dysfunction. Fanconi syndrome
should be taken into account in the management of children with MID before as well as after
intestinal transplantation. Microvillous inclusions, the characteristic finding in enterocytes in


















The Role of Capsule Endoscopy in the Evaluation of Patients with
Unexplained Growth Failure
Libia Moy, Jeremiah Levine
Background: Poor weight gain and growth can be caused by innumerable medical, nutritional,
behavioral, psychological and environmental disease states. Although we know that 15 to
40% of children with Crohn’s disease have growth failure, the diagnosis is not always readily
apparent. Negative findings on routine serologic, radiographic and endoscopic diagnostic
studies can result in significant delays before appropriate therapy can be instituted. Lack of
a definitive diagnosis also frequently leads to additional and potentially costly testing in an
attempt to identify the etiology of the poor growth. The aim of this study is to evaluate the
role of the Capsule Endoscopy (CE) as part of the evaluation of older children and adolescents
with unexplained growth failure. Methods: We retrospectively reviewed the records of all
children with unexplained growth failure who underwent CE at Schneider Children’s Hospital
between August 2002 and November 2005. Results: Eight patients (4 males and 4 females,
mean age of 12.1 ± 3.5 year old, mean weight of 30.6 ± 9.4 Kg) had CE studies to review.
Laboratory studies including CBC, biochemistry profiles and celiac serologies were negative
in all subjects. Only 1/8 had an elevated ESR. All had normal small bowel series perfomed
prior to the CE. All had both endoscopically and histologically normal esophagogastroduod-
enoscopy and colonoscopy as well. In 5/8 subjects, multiple small bowel apthous ulcerations
consistent with Crohn’s disease were identified by CE. Two subjects had normal CE and
one had an incomplete CE study due to delayed passage of the capsule. Conclusions: Sixty
three percent of older children and adolescents with unexplained growth failure and normal
small bowel series were found to have Crohn’s disease involving the small intestine. To
avoid further costly testing for possible endocrine or psychiatric causes of poor growth, CE
should be considered as part of the armamentarium in evaluating children with severe
unexplained growth failure.
S1267
Infliximab’s Growth Related Effects for Children and Adolescents with Crohn’s
Disease
Sean D. Sullivan, Alexandra Eidelwein, Richard Thompson, Carmen Cuffari, Oliva-
Hemker Maria
Introduction: Growth impairment commonly complicates the clinical course of pediatric
Crohn’s disease (CD). Corticosteroids, a mainstay in moderate to severe CD are also known
to impair linear growth in children. Infliximab has been proven to be an effective steroid
sparing anti-inflammatory agent.There are however, limited studies assessing infliximab’s
potential for growth promoting effects in pediatric CD. Aim: The goal of this study was to
evaluate the effect of infliximab on growth parameters before and after the initiation of
therapy in children and adolescents with refractory CD. Methods: Medical records were
reviewed of pediatric patients follwed at the Johns Hopkins Children’s Center who received
at least three infliximab infusions between March 2000 and April 2005. Data collected
included: patient demographics, CD phenotype, number of infliximab infusions, and cumu-
lative corticosteroid dose for the 6 months preceding and following the initial infliximab
infusion. Growth parameters were recorded including: weight and height corrected for age
using standardized Z-scores, BMI and BMI Z-score. Clinical data was analyzed utilizing the
student’s t-test and logistic regression analysis. Results: 59 patients were identified (56%
Male). The mean age of the patients was 15 years ± 4.2 years. Indications for infliximab
use included corticosteroid and immunomodulator refractory luminal disease (44 pts),
perianal disease (9 pts) and both (6 pts). From this population 24 children less than 15
years old were evaluated. The average number of infliximab infusions was 6 (range 3-9).
17 patients received corticosteroids during the study period. Height Z-scores increased
during 12 months of infliximab therapy with a trend toward significance, p = 0.065. For
the population of patients whose baseline height Z score was < 0, an increase in height z
score to 0.9 was noted at 12 months, p =0.0089. A trend toward significance at 12 months
was noted with BMI Z score increasing in those patients whose baseline BMI Z score was
< zero, p = 0.06. The difference between the pre- and post-infusion corticosteroid dose was
20.9 mg/kg, p= 0.0014. Logistic regression analysis in the patients receiving corticosteroids
demonstrated a significant increase in height independent of steroid exposure, p = 0.004.
Conclusions: Infliximab therapy was associated with signficiantly increased growth in
pediatric patients with CD and with height Z scores less than zero. This benefit appeared
to be independent of corticosteroid exposure. Larger prospective controlled studies are
needed to confirm these findings.
S1268
Gastrointestinal (GI) Inflammation in Children with Recurrent Abdominal
Pain (RAP) Is Not Related to Pain and Stooling Pattern
Robert J. Shulman, Danita Czyzewski, Monica Jarrett, Lonnie Zeltzer
Objective: Recent histologic studies have suggested evidence of low grade inflammation in
many adult patients with irritable bowel syndrome (IBS). Additionally, fecal calprotectin
concentration, a marker of GI inflammation has been reported to be abnormal in up to 30%
of adults with IBS (Gastroenterology 2002;123:450). Whether the same is true for children
with RAP, a condition that affects 10-15% of school age children and bears many physiological
similarities to IBS in adults (e.g., functional pain, visceral hyperalgesia) has not been studied.
Study Design: Children (age 7-10 yr.) were identified initially by chart review in pediatrician’s
or pediatric gastroenterologist’s offices. Children with RAP met Rome II criteria for functional
abdominal pain or IBS. Non-RAP Control subjects were recruited through the same
pediatrician’s offices. Further screening was done with parents by phone. After instruction
in the home by research assistants children saved a stool for measurement of calprotectin
concentration and kept a 2-wk diary to record abdominal pain frequency and severity and
number and character of stools. Results: Groups were comparable in age: RAP: 8.5 ± 1.1
vs C: 8.7 ± 1.0; mean ± SD. Fecal calprotectin concentration was greater in children with
RAP than in Controls (Table). Differences between RAP and Controls also were noted for
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mean pain score, maximum reported pain, and number of pain episodes, though not for
number of stools or number of days with no stool. However, more stools were hard balls
in RAP children (19% vs 7%, RAP vs Control). Regression analyses revealed no relationship
between fecal calprotectin concentration and abdominal pain frequency and severity and
number and character of stools for the groups combined or separately. Conclusions: 1)
Children with RAP have evidence of GI inflammation as measured by fecal calprotectin
concentration; 2) Pain and stooling pattern do not appear to be related to calprotectin
concentration; 3) GI inflammation as measured by fecal calprotectin concentration does not
appear to play a significant role in pain and bowel symptoms in children with RAP.
S1269
Cyclooxygenase 2 Expression in Polyps from a Juvenile Polyposis Syndrome
Patient with Mutant Bmpr1a
Jayde Kurland, Stayce Beck, Carol Solomon, Oscar Bran, John M. Carethers, Sherry C.
Huang
Background: COX2 expression is increased in colorectal cancers, and has been reported to
be upregulated in Peutz-Jegher polyps. To determine if germline and somatic loss of BMPR1A
in polyps from a Juvenile Polyposis Syndrome (JPS) kindred have altered COX2 expression,
we characterized a JPS kindred for BMPR1A germline mutations, and examined the polyps
for BMPR1A expression and COX2 expression. Methods: DNA analysis for BMPR1A was
performed on a JPS kindred. Multiple polypectomies were performed and several polyps
showed adenomatous change. Genomic DNA was extracted from polyp material for Loss of
Heterozygosity (LOH) analyses with microsatellite markers. Immunohistochemistry was
performed on sections using antibodies for BMPR1A and COX2. Results: The kindred
possessed a germline BMPR1A missense mutation. In polyp domains containing cystic and
adenomatous epithelium, no LOH was observed using markers near the BMPR1A locus.
Immunostaining indicated decreased expression of phospho-SMAD1 (pSMAD1), functionally
downstream of the mutant BMPR1A receptor in the cystic epithelium, with further reduction
in adenomatous portions within the polyp. COX2 immunostaining, normally not expressed
in the colon, was present and greater in the lamina propria compared to the epithelium,
and further increased in the adenomatous portions of the polyp. . Conclusion: Decreased
expression of pSMAD1 in the cystic epithelium with further reduction in the adenomatous
area, and an inverse relationship with the presence of COX2 expression in polyps from the
BMPR1A heterozygote, suggests a potential mechanism for adenomatous pathogenesis in
these hamartomatous polyps. This may imply that COX2 inhibitors could be a means for
chemoprevention in this syndrome.
S1270
CT Enterography in Children with Crohn’s Disease: Correlation with
Inflammatory Markers and Disease Activity
Mark A. Naddaf, Peter Higgins, Peter Strouse, Pamela Brown, Ellen M. Zimmermann
Background: CT enterography (CTE) produces high resolution images of the bowel. CTE
is currently used to evaluate adults with Crohn’s disease (CD); no reports in pediatric patients
exist. CTE provides information similar to small bowel follow through (SBFT), but CTE
adds detail of the bowel wall and surrounding tissue that may help guide treatment. We
retrospectively reviewed CTEs performed on pediatric patients. We evaluated whether CTE
findings correlated with clinical disease activity and markers of systemic inflammation, and
whether CTE detected novel findings not available from SBFT. Methods: We reviewed
records from 19 patients with known or suspected CD who underwent CTE. The five
findings evaluated included mucosal enhancement with contrast, luminal narrowing, bowel
wall thickening, mesenteric fat stranding, and increased vascularity. A Modified Harvey
Bradshaw Index (HBI) clinical activity score, the erythrocyte sedimentation rate (ESR), and
the C-reactive Protein (CRP) level were taken from medical records. Spearman correlations
were calculated for each comparison. Results: 10 patients had known CD based on positive
biopsy or prior SBFT. 9 patients had bowel symptoms but had negative biopsies and no
prior Crohn’s diagnosis. In the CD cohort, the mean age was 14.3 years. HBI mean was 6.6
(range 0 to 12). 8 had CD in the small bowel and 2 had colonic disease. CTE demonstrated
CD in all patients. Increased vascularity, luminal narrowing and mucosal enhancement was
detected in 3 patients, mesenteric fat stranding in 1 patient. Fistulae and sacroiliitis were
identified in 1 patient. Bowel wall thickening was detected in 6 patients. HBI correlated
with the following CTE findings (rho): bowel thickening (0.75, p=0.01), fat stranding (0.41
p>0.05), and lumen narrowing (0.42 p>0.05). CRP correlated with the following CTE
findings: bowel wall thickening (0.84, p=0.01), vascularity (0.62), and fat stranding (0.41).
ESR correlated with the following CTE findings: vascularity (0.65) and fat stranding (0.41
p>0.05). No abscesses were seen in these 10 subjects. There were no false negative exams.
In the group with no CTE findings for CD, 4/9 ultimately had UC and 5/9 had functional
pain. Conclusion: CTE provides exquisite images of the bowel lumen and surrounding
tissues. There was a significant correlation between bowel thickening and CRP, as well as
HBI; CRP and increased vascularity. A trend toward significant correlation with ESR was
also demonstrated. CTE is able to identify findings in CD not seen in SBFT. This may
indicate that CTE can predict inflammation vs. non-inflamed (fibrotic) bowel making it
extremely useful in guiding management.
S1271
Growth Failure Persists Despite Current Treatment Paradigms in Pediatric
Crohn’s Disease
Marian D. Pfefferkorn, Jeffrey Hyams, Georgine Burke, James Markowitz, Joel Rosh,
David Mack, Anthony Otley, Subra Kugathasan, Jonathan Evans, Athos Bousvaros, Susan
Moyer, Robert Rothbaum, Robert Wyllie, Vasundhara Tolia, M Oliva-Hemker, Adam
Mezoff, Neal Leleiko, Fernando Del Rosario, Wallace Crandall, David Keljo, Robert
Baldassano, Anne Griffiths
Background/Aim: Impairment of linear growth is a recognized complication of pediatric
Crohn Disease (CD), but prevalence data in the era of increased immunomodulatory and
biologic therapies are sparse. We analyzed the prevalence, severity, and predictors of growth
abnormalities in a contemporary population of newly diagnosed children with CD. Methods:
Clinical, laboratory, and growth data were gathered from the Pediatric IBD Collaborative
Research Group Registry database. This prospective observational study, established in
January 2002 at 20 US/Canadian centers, records outcomes data on children diagnosed at
<16 years of age but does not dictate treatment regimens. Results: We identified 175 children
who were Tanner I-III at diagnosis and for whom at least 1 year follow-up was available
(mean age 11 yr ± 2.7 SD, 63% male). At diagnosis, 73% of subjects had moderate/severe
CD by physician global assessment and the rest were mild. At 1 year, 57% were inactive,
33% mild, and 10% moderate/severe. Treatment in the first year included immunomodulator
(82%), corticosteroid (77%), 5-ASA (75%), infliximab (37%) and nutritional therapy (28%).
Height velocity Z score at diagnosis (n=105) was -3.7 ± 4.0 SD; 75% were below -1.8. For
the entire sample of 175, mean ht Z score at diagnosis was -0.5 ± 1.2 SD; 10% were below -
2.0. At 1 year, mean ht Z score remained at -0.5 ± 1.1 SD and 28% grew <4 cm/yr. Mean
height velocity Z score over the year post-diagnosis was -2.0 ± 2.5 SD. Height Z scores
improved over the first year for subjects with baseline ht Z scores <-1 and decreased for all
others (mean difference 0.15 and -0.10, respectively, p<.0004). Factors at diagnosis associated
with improved ht velocity Z scores at 1 year (F=6.0, p<0.0001) were low baseline height
Z score, low Hgb, high ESR, and moderate to severe disease. Conclusion: Despite the use
of aggressive medical therapy during the first year after diagnosis, children with CD remain
shorter and have a depressed growth velocity compared to healthy, age-matched peers.
While current therapy modestly helps the most severely affected children, the growth of
many others may continue to decline. Longer follow-up will determine whether ongoing
therapy ultimately results in improved linear growth.
S1273
Comparison of Quantitative Calcaneal Ultrasound and Dxa in Children with
Inflammatory Bowel Disease
Manisha Harpavat, Qianyu Dang, David Keljo, Susan Greenspan
Background: Quantitative Ultrasound (QUS) of the calcaneum provides a radiation-free and
inexpensive assessment of bone density and microstructure. Purpose: The purpose of this
study was to compare DXA measurements of the whole body and lumbar spine to QUS
measurements obtained from the calcaneus. Methods: DXA and QUS measurements were
obtained simultaneously. Bone mineral content (BMC, grams) and BMD (grams/cm2) meas-
urements of the whole body and lumbar spine were assessed by DXA (Lunar Prodigy).
Broadband ultrasound attenuation (BUA; dB/MHz) was measured in the posterior part of
the calcaneus at the region of interest (ROI) by QUS (Quidel QUS-2). Data analysis was
performed by Pearson’s correlation. Receiver operator curves (ROC) were constructed to
determine how well BUA discriminated between normal and diseased populations. Results:
70 children (46 with IBD and 24 healthy controls) underwent a total of 219 measurements
over 12 months. The IBD group and healthy control group did not differ in terms of age,
gender, or race. Correlation coefficients between DXA and QUS measurements ranged from
0.70-0.84 and were comparable between the two groups. Positive significant correlations
were found between calcaneal BUA and whole body (BMC and BMD) and lumbar spine
(BMC and BMD) for both groups. The area under the curve of a range of BUA values in
detecting reduced bone mass (BMD z score ≤ -1) and severely reduced bone mass (BMD
z score ≤ -2) of the whole body and lumbar spine was calculated from the ROC and is
shown in Table 1. Conclusion: These results indicate that QUS measurements of the calcaneus
positively correlate with DXA measurements of the whole body and lumbar spine. From
the ROC area under the curve, QUS appears to be a useful screening tool in determining
which patients have severely reduced bone mass (BMD z score ≤ -2) and require further
evaluation with DXA.
S1274
Abnormalities of the Enteric Nervous System, Smooth Muscle and Interstitial
Cells of Cajal in Children with Colonic Motility Disorders
Maartje M. van den Berg, Hayat M. Mousa, Carlo Di Lorenzo, Marc A. Benninga, Guy E.
Boeckxstaens, Mark Luquette
Background: Colonic manometry studies in children with severe defecatory disorders often
reveal abnormal contraction patterns. These patterns have traditionally been classified into
myopathic, neuropathic or mixed types. Current study evaluates the relation between colonic
manometry findings and abnormalities of the colonic enteric nervous system (ENS), smooth
muscle and interstitial cells of Cajal (ICC). Methods: Colonic specimens from surgical
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resections or full-thickness biopsies were assessed from a cohort of children who underwent
colonic manometry testing prior to surgery. Manometry and histopathologic findings of
colonic segments were correlated. Following immunohistochemistry stainings were used to
identify abnormalities of the ENS: Neuron Specific Enolase, Calretinin, Neurofilament (neur-
onal markers), Synaptophysin (synaptic vesicles marker), Tyrosine hydroxylase (adrenergic
pathway marker), S-100 (glial cell marker), GFAP (glial fibrillary acidic protein). ICC were
stained with CD117 (c-kit), and smooth muscle markers were SMA (alpha actin) and MSA
(gamma actin). Results: Eight colonic specimens from 5 patients with clinical symptoms of
dysmotility were evaluated. One patient was previously diagnosed with Hirschsprung’s
disease and had persistent symptoms of dysmotility after resection of the aganglionotic
segment. Four patients had severe constipation of unknown origin. Manometry showed an
absence of colonic contractions in 3 colonic segments and low amplitude propagating
contractions (LAPC) in 2 segments, compatible with a myogenic pattern of dysmotility.
These specimens showed abnormalities of the ENS and a marked decrease or absence
of ICC, but no abnormalities in smooth muscle markers (SMA and MSA). Simultaneous
contractions, indicative of a neuronal disorder were seen in 2 segments, Histopathology
showed an elevated level of GFAP positive cells, loss of ICC and normal smooth muscles.
One segment from a patient with severe symptoms of colonic dysmotility and who had normal
high amplitude propagating contractions showed minimal abnormalities on histopathology,
including an elevated GFAP level and reduced ICC staining. In total 7/8 specimens showed
elevated levels of GFAP positive cells, suggestive of neuronal damage. Conclusions: Although
a myogenic pattern was observed on colonic manometry, abnormalities in ICC or the ENS,
but not in smooth muscle markers were found. Loss or absence of ICC and elevated levels
in GFAP were prevalent findings in pediatric colonic motility disorders, irrespective of
the manometric pattern. Caution should be used when predicting the type of underlying
neuromuscular disorder based on colonic manometry.
S1275
Predictors of Maternal Responses to Child Gastrointestinal Symptoms
Shelby L. Langer, Lynn S. Walker, Joan M. Romano, William E. Whitehead, Rona L. Levy
Background: Prior research and social learning theory suggest that inappropriate GI illness
behaviors may be maintained at least in part by social reinforcement processes. Well-
intentioned parents may respond to their child’s somatic complaints with solicitous behaviors
and discourage activity, potentially fostering illness vs. wellness behavior (Levy et al., 2004).
Thus, identifying factors that are associated with solicitousness (or the converse, minimiza-
tion) is important in determining when interventions to reduce solicitousness may be most
useful. Aims: The purpose of this study was to examine predictors of maternal responses
to children’s abdominal pain symptoms, specifically: protectiveness (limiting the child’s
activities, giving treats), encouragement/ monitoring (encouraging activity while monitoring
symptoms) and minimization (expecting normal responsibilities, criticizing illness behavior).
Methods: Participants were 450 mother/ child dyads; 46% of the mothers had a diagnosis
of Irritable Bowel Syndrome. Demographics were as follows: child mean age = 11 (SD =
2.6), 52% female, 80% Caucasian; maternal mean age = 42 (SD = 6.2), 80% Caucasian.
Children rated the severity of their abdominal pain in the past 2 weeks. Mothers completed
the Adult Responding to Children’s Symptoms Inventory, the Brief Symptom Inventory and
the Children’s Pain Beliefs Questionnaire. The latter assessed maternal perceptions regarding
the severity of the child’s condition. Hierarchical linear regression was used to examine
demographic and psychosocial predictors of maternal response. Results: Fifty- four percent
of children reported having abdominal pain in the past 2 weeks. Minimization was predicted
by low perceived condition severity (p = .047) and, counter to prediction, maternal IBS
status (p = .005) and higher maternal anxiety (p = .029). Encouragement/ monitoring was
predicted by younger child age (p = .002), male child gender (p = .014), high perceived
condition severity (p = .013) and higher maternal somatization (p = .017). Protectiveness
was predicted by absence of a father in the home (p = .020) and a gender x condition
severity interaction (p = .018). Mothers were protective of girls regardless of condition
severity, but more protective of boys believed to have a more serious condition. Conclusions:
These findings offer implications for clinical intervention. Physicians should be aware when
risk factors for solicitousness exist and, when appropriate, encourage parents to maintain
normal child responsibilities. This could result in increased wellness behavior and reduced
disability. Supported by grant ROI HD36069.
S1276
Nuclear β-Catenin in Germline Pten Mutated Hamartomatos Polyps
Jashdeep Dhoot, John M. Carethers, Sherry C. Huang
Background: The mechanisms involving intestinal hamartomatous polyp transformation
towards adenoma or adenocarcinoma are not known. In sporadic colon cancers, the canonical
Wnt signaling pathway when altered will lead to nuclear localization of the proto-oncogene
β-catenin. GSK3β is a regulator of the Wnt pathway, and is phosphorylated by PI3 kinase
and presumed antagonized by PTEN, which negatively regulates PI3 kinase. Here, we
examined polyps from germline PTEN-mutated hamartomatous syndrome patients to discern
any regulation of Wnt signaling. Methods: Eight polyps from 3 PTEN germline mutated
hamartomatous polyposis patients were analyzed for tissue expression of PTEN, β-catenin,
total and phosphorlyated GSK3β, and APC by immunohistochemistry. We then compared
the various proteins and their expression patterns. Results: All 8 hamartomatous polyps
lacked PTEN expression in the epithelial components of the polyps. Within the epithelium,
full length APC was expressed, but β-catenin was localized to the nucleus. Phosphorylated
GSK3β, which blocks cytoplasmic degradation of β-catenin, was upregulated compared to
total GSK3β in the epithelium. Conclusions: Hamartomatous polyps from germline PTEN-
mutated patients have lost PTEN expression and show nuclear β-catenin with upregulated
phosphorylated GSK3β in the epithelial components of their polyps despite expressing full
length APC. This suggests that loss of PTEN might affect Wnt signaling in favor of the



















Azathioprine Maintains First Remission in Newly Diagnosed Pediatric Crohn’s
Disease: A Retrospective Study
Gerald J. Jaspers, Henkjan J. Verkade, Johanna C. Escher, Lissy de Ridder, Jan A.
Taminiau, Edmond H. Rings
Background: 6-Mercaptopurine has been shown to spare corticosteroid use and to maintain
remission in pediatric Crohn’s disease (CD; Gastroenterology 2000;119:895-902). We evalu-
ated retrospectively to what extent azathioprine (AZA), the active metabolite of 6-mercaptopu-
rine, was used in newly diagnosed pediatric CD patients and its relation to maintenance of
remission. Methods: We reviewed from 3 pediatric centers the data of children with newly
diagnosed CD (period 1998 - 2003, follow-up > 18 months). Two definitions of active
disease (initial or relapse) were used: Pediatric Crohn’s Disease Activity Index (PCDAI) >
10, or systemic corticosteroid use. Remission was defined as PCDAI ≤ 10 without use of
corticosteroids. Treatments were compared with respect to initial therapy, duration and
severity of active disease, and maintenance of first remission. Results: 88 children (55M/
33F, age 12±3 yr., mean±SD) were included. Only 2 patients received AZA within 1 month
after diagnosis. During the first period of active disease, 33 patients received AZA (38%),
while at the end of the follow-up period (38±17 mo.) 72 patients (82%) had been prescribed
AZA. In patients diagnosed after 2000, AZA was prescribed at 233 days after diagnosis,
compared with 686 days in patients diagnosed between 1998-2000 (median values, p<0.05).
At initial presentation, a larger fraction of AZA patients had moderate-severe disease activity
(AZA vs. non-AZA: 75% vs. 52%; p<0.05) and were prescribed corticosteroids (89% vs.
58%; p<0.005). Initial therapy with respect to aminosalicylates (~85%) and enteral nutrition
(~27%) did not differ in AZA and non-AZA patients. The first period of active disease,
according to corticosteroid use, was longer in AZA patients (232 vs. 168 days; p<0.005).
In patients who had used corticosteroids during initial disease activity, the median mainten-
ance of the first remission in AZA patients was 544 days (PCDAI) or 575 days (corticosteroid-
free) compared with 254 (p=0.08) and 259 days (p<0.05) in non-AZA patients, respectively.
In 12 months after reaching the first remission, a profoundly larger fraction of AZA patients
had maintained a corticosteroid-free period, compared to non-AZA patients (15/26 vs. 8/
28; p<0.05). Conclusion: This study demonstrates a beneficial effect of AZA in pediatric
CD with respect to maintenance of first remission. AZA therapy has become more frequently
used for pediatric CD, but its initiation within one month after diagnosis is still rare. Our
data support a more prominent role for AZA therapy in pediatric CD.
S1278
Outcome of Moderate to Severe Pediatric Crohn’s Disease: Effect of Infliximab
Therapy
Joel R. Rosh, Jeffrey Hyams, Trudy Lerer, James Markowitz, Marian Pfefferkorn, David
Mack, Anthony Otley, Subra Kugathasan, Jonathat Evans, Athos Bousvaros, Susan Moyer,
Robert Rothbaum, Robert Wyllie, Vasu Tolia, Maria Oliva-Hemker, Adam Mezoff, Neal
Leleiko, Fernando Delrosario, Wallace Crandall, David Keljo, Robert Baldassano, Anne
Griffiths
Background: There are little data on the long-term clinical outcome of moderate to severe
pediatric Crohn disease (CD) patients who receive infliximab (IFX). Aim: To compare clinical
outcomes in moderate to severe pediatric CD patients who do and do not receive IFX.
METHODS: Since January 2002, 20 US/Canadian pediatric GI centers prospectively enrolled
692 newly diagnosed children with IBD in an observational registry. All subjects were
managed according to the dictates of their physicians, not by standard protocols. A database
search identified children with moderate to severe CD at diagnosis who had at least 18
months of follow-up. IFX use was categorized as: No IFX (NI), early (within 3 months of
diagnosis = EI), and late (between 3-12 months from diagnosis = LI). Clinical and demo-
graphic characteristics were compared among the three groups at baseline and at 18 months
after diagnosis. RESULTS: Of 482 CD subjects 262 had at least 18 months of follow-up
(62% male, age range 1.4—16 yrs, mean 11.7 ± 2.8 yrs). 181 (69%) presented with moderate
to severe disease by Physician Global Assessment (PGA) or PCDAI >30. 136 (75%) were
NI. 45 (25%) received IFX with 26 (14%) EI and 19 (11%) LI. There were no significant
differences in mean age, gender, disease location, or baseline lab values (hemoglobin, sedi-
mentation rate or serum albumin) among the three IFX groups. Baseline mean PCDAI was
similar in EI (40.4 ± 16.6), NI (34.7 ± 14.3) and LI (30.8 ± 12.0). Use of steroids as the
initial induction agent was similar in all groups (85% overall). Immunomodulators were
used within 3 months of diagnosis in 88% of EI vs. 53% LI and 56% NI (p <0.01). Rapid
clinical deterioration prior to IFX was common in EI demonstrated by 58% hospitalized
and 23% with IBD surgery within 90 days of diagnosis and before the start of IFX therapy
(p<0.05 vs. LI and NI for surgery). 18 month outcome was similar among groups with PGA
of inactive/mild in 86% EI and 76% LI (p = NS). 18 month PCDAI values were also similar
in those with available data: EI = 7.7 ± 6.3; LI = 9.3 ± 13.8; NI = 9.2 ± 10.5 (p = NS).
CONCLUSIONS: 1. 25% of children presenting with moderate to severe CD received IFX
within 12 months of diagnosis. 2. Neither baseline clinical disease activity (PCDAI) nor
traditional laboratory parameters were predictive of earlier use of infliximab therapy. 3.
Despite poor early response to non-biologic therapies in some patients, current patterns of
infliximab use allow for a marked reduction in clinical disease activity at 18 months after
diagnosis in the majority of pediatric patients who presented with moderate to severe CD.
S1279
Longitudinal Effect of Corticosteroids in Pediatric Crohn’s Disease
Manisha Harpavat, Qianyu Dang, David Keljo, Susan Greenspan
Background: Corticosteroids have been implicated as a major cause of reduced bone mass
and delayed growth in children with Crohn disease (CD). Longitudinal studies examining
the effect of corticosteroids on bone mass acquisition and growth in children with CD are
lacking. Aim: To observe the effects of corticosteroids on bone mass acquisition and growth
in a group of steroid naïve children newly diagnosed with CD compared to healthy age,
gender, and race matched controls. Methods: 6 otherwise healthy steroid naïve children
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newly diagnosed with CD and 6 age, gender, and race matched controls underwent DXA
measurements at baseline, 6, and 12 months. After baseline measurements were obtained,
the 6 CD subjects were started on corticosteroids (equivalent to 2 mg/kg prednisone) for
an average of 74.2 days (range 55-99). After completing the corticosteroid course none of
the patients received corticosteroids again during the 12 months. Bone mineral content
(BMC,grams) and bone area (BA,cm2) measurements of the whole body (WB)and lumbar
spine (LS) were recorded. Results: 6 CD patients (2 male) and 6 healthy controls were
studied. Results of measured variables are in Table 1. The mean Pediatric Crohn’s Disease
Activity Index score at baseline was 32.1 (range 12.5-55), at 6 months 7.1 (0-17.5), and
at 12 months 8.8 (0-20). Height velocity was decreased in the CD group at 6 months
compared to the control group but was similar between the groups by 12 months (4±2.4
cm/yr CD group vs 3.7±3.5 cm/yr control group). WB BMC and BA at baseline was lower
for the CD group but at 12 months had increased to similar values as the control group.
LS BMC and BA at baseline was lower for the CD group, declined even further at 6 months,
but by 12 months had increased to similar values as the control group. Conclusion: In this
group of 6 previously steroid naïve children newly diagnosed with CD it appears that despite
initial corticosteroid use, bone mass acquisition and growth after 12 months was comparable
to healthy age, gender, and race matched controls. Bone mass acquisition at the LS, which
is composed of trabecular bone was affected at 6 months but WB, which is composed of
80% cortical bone was not affected. It is possible that corticosteroid use in children newly
diagnosed with CD may only have a transient impact on bone mass acquisition and growth.
A larger sample size is needed to confirm the observed findings.
Table 1.
S1280
Symptoms Refactory to PPI Therapy Associated with Non-Acid, Acid Or No
Reflux in Children
Inder Mainie, Radu Tutuian, Amine Hila, Amit Agrawal, Donald O. Castell
Background: Gastroesophageal reflux in children has been diagnosed as the cause of systemic
illnesses in children. Combined Multichannel Intraluminal Impedance (MII) detects all types
of gastroesophageal reflux (GER), (non-acid reflux, (NAR) or acid reflux) at multiple levels
of the esophagus independent of pH. Aim: To clarify the relationship of typical and atypical
GERD symptoms to reflux episodes (acid and NAR). Method: Starting January 2002, all
patients with persistent symptoms despite proton pump inhibitor (PPI) therapy referred to
the esophageal laboratory underwent combined MII-pH monitoring. Prior to the study,
parents and/or the referring physician were contacted to ensure that the patient had been
on at least twice daily PPI for at least a month or more prior to testing. In pediatrics less
than 2 years the pH was placed 2cm above the LES with impedance measurements at
2,3.5,5,6.5,8 and 9.5 cm above the LES. In pediatrics (2-6 yrs) the pH was placed 3cm
above the LES with impedance measurement at 3,5,7,9,11 and 13cm above the LES and
in the 6-10 years the pH was at 4cm above the LES with impedance measurements 4,6,8,10,12
and 14cm. Studies were recorded for 24 hrs. While taking PPI therapy bid, the symptom
index was defined as the number of symptoms associated with reflux divided by the total
number of symptoms and was positive (+SI) if ≥ 50%. Typical GERD symptoms were
heartburn, regurgitation or chest pain. Atypical symptoms were cough, nausea, wheezing,
hoarseness and throat clearing. Results: Fifty-six children (Female 18; mean age 3 years;
range 5 weeks - 15 years). Forty-six (82%) children recorded symptoms during test day;
typical GERD symptoms (n=10), atypical symptoms (n=36). Table below shows MII-pH SI
for the primary typical and atypical symptoms (p < 0.01). Conclusions: Typical symptoms
in children were more likely associated with reflux (primarily non-acid) whereas atypical
symptoms were usually associated with no reflux.
S1281
Do Abnormalities of Peristalsis Result in Abnormal Esophageal Clearance? the
Use of Esophageal Function Testing (EFT), a Novel Technology to Evaluate
Dysphagia in Children
Rachel L. Rosen, Julia Fritz, Nurko Samuel
Background: The gold standard for the evaluation of dysphagia in children is esophageal
manometry (EM). However, recent studies in adults have suggested that patients with
abnormal EM may have normal bolus transit. The recent availability of EFT (combined
esophageal manometry and impedance) provides an instrument to correlate esophageal
transit (measured by impedance) and pressure (measured by manometry). This is the first
report of the use of EFT to correlate esophageal peristalsis and bolus transit in children.
Methods: EFT tracings of all children with dysphagia studied in the motility unit were
reviewed. Patients with achalasia were excluded because of inability to calculate bolus transit.
EFT was performed with a solid state catheter that combines pressure transducers and
impedance rings. Bolus presence time, total bolus transit time, and standard esophageal
manometry variables were measured for both liquid (LS) and viscous swallows (VS). Swallows
were considered ineffective if the amplitude in the distal esophagus was less than 30 mmHg.
Results: EFT was completed in 11 children with dysphagia. Based on EM, 5 had non-
specific motor disorders and 6 had normal peristalsis. 268 swallows were recorded. 15%
of swallows had ineffective peristalsis and 23% of swallows had incomplete bolus clearance.
More than 80% of swallows classified as ineffective peristalsis had complete bolus transit.
Bolus transit varied between LS and VS, with an abnormal transit being more frequent in
those with ineffective peristalsis after VS (25% of VS) compared to LS (15.8% of LS).
Furthermore, despite the convention that distal, low amplitude contractions are pathologic,
only 19.4% of swallows with low amplitude, distal contractions had incomplete bolus transit.
When any esophageal contraction amplitude was less than 30 mmHg, complete bolus transit
was significantly reduced (table). Conclusions: This is the first report of the use of EFT in
children. Esophageal boluses are effectively cleared in more than 80% of ineffective swallows
suggesting that manometry may be inadequate to assess esophageal function in children.
EFT provides new insight into the relationship between esophageal function and pressures
and may redefine the approach to children with esophageal motility disorders.
Relationship between esophageal pressure and bolus clearance
*chi-square, p<0.0001
S1282
Worries About Childhood Functional Abdominal Pain: The Fathers
Perspective
Nader N. Youssef, Miranda van Tilburg, Annette Langseder, William E. Whitehead
BACKGROUND: In childhood functional abdominal pain (FAP), healthcare utilization is
often initiated by the affected child’s mother. Addressing the maternal concerns and providing
education during office evaluations often is part of the planned therapeutic intervention for
childhood FAP. To date, there is little data on what concerns fathers have about their
children who suffer from FAP. This lack in knowledge combined with less common access
to fathers may prevent paternal concerns from being adequately identified and addressed.
AIM: To investigate if concerns differ between fathers and mothers of children being evaluated
for FAP. SUBJECTS & METHODS: Prior to an initial evaluation at a tertiary pediatric
gastroenterology center, 48 mother-father dyads of children (mean age 9.6 years, ranging from
4 to 18 years) suffering from FAP completed the Parental Worries about RAP Questionnaires
(PWRQ). The PWRQ is a validated and reliable tool that measures parental worries. It
consists of 4 subscales: (1) Fear to ignore symptoms-worries surrounding the willingness
to ignore or focus on symptoms (6 items), (2) Desire for care- frustration with doctors for
failing to understand, treat, or diagnose (7 items), (3) Worry about coping- feeling uncertain
or unable to cope with symptoms (7 items), and (4) Exacerbating factors- recognizing the
role of stress and family (5 items). Responses are scored on a 1 (not at all worried) to 5
(very much worried) scale. Scores on items were added to create a subscale score. A diagnosis
of FAP was made utilizing the Pediatric Rome Criteria. RESULTS: Paired T-test revealed no
differences between groups. (see Table) CONCLUSIONS: Mothers and fathers of children
with functional abdominal pain do not differ in their concerns and worries. Acknowledgement
that concerns are shared by both parents may be an important issue to address during
initial evaluation of childhood FAP. Involving fathers from the very beginning of planned
educational and therapeutic interventions for childhood FAP may be a necessary feature to




Gastro-Esophageal Reflux Disease in Young Children: Incidence and
Presentation Patterns in a Population-Based Birth Cohort
Denesh K. Chitkara, Heiko de Schepper, Amy Weaver, Mary Jo Rucker, Slauvica Katusic,
Giles R. Locke, Nicholas J. Talley
Background:Gastro-esophageal reflux disease (GERD) is a common complaint of early child-
hood and affected children can continue to experience symptoms later in life. However,
little is known about the natural history, and patterns of presentation of this disorder in
young children. Aims: 1. To estimate the incidence of GERD presentation in a population
based birth cohort from birth to 5 years, and 2. To examine the patterns and proportion
of medical visits for GERD in this age group. Methods: A birth cohort of all children born
between 1976 and 1982 to mothers who were residents of Rochester, MN, and who remained
in the community until age 5 years (N=5718) was considered for this study. The vital status
of each member of the birth cohort during the 1995-1996 school year was established.
HICDA diagnostic codes for GERD for the birth cohort members were identified. The medical
records were reviewed to confirm a medical visit primarily for GERD, the date of presentation,
number of medical visits, and specific symptoms and the frequency and duration of overall
symptoms. Results: Of the 5506 birth cohort members, the overall age- and sex-adjusted
incidence was 0.9 per 1000 person-years (py). The age-specific incidences were similar for
girls (0.52 (95% C.I., 0.14-0.92) per 1000 py) and boys (1.27 (95% C.I., 0.68-1.85) per
1000 py). The mean age of initial GERD diagnosis was 7.3 months, and 90% of patients
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presented within the first year of life. Both typical (vomiting, regurgitation, and symptoms
after meals) and atypical symptoms (cough and asthma/reactive airway disease) of GERD
were reported during the incident visit (Table). Twenty percent of children with GERD had
documented symptoms for greater than 1 month, and 24% of children had 3 or more
medical visits for GERD by 5 years of age. Conclusion: This is the first examination of the
incidence of GERD in children using a population based birth cohort. In young children
who present for symptoms, GERD accounts for a high number of repeat medical visits.
Supported by an unrestricted research grant to the Dyspepsia Center from Novartis, and the Mayo
Family Endowment in Gastroenterology at Children’s Hospital Boston.
Individual symptoms during the incident visit in children with GERD from birth to 3 months
and 3 months to 1 year
S1284
ASCA Positivity Independently Predicts Oral Crohn’s Disease in a Large Early
Onset IBD Population
Richard K. Russell, Brian Ip, Marian C. Aldhous, Hazel E. Drummond, Ian D. Arnott,
Margaret McDougall, David C. Wilson, Peter M. Gillett, Paraic McGrogan, Kamal Hassan,
Lawrence T. Weaver, Michael W. Bissett, Gamal Mahdi, Jack Satsangi
Introduction: Anti-Saccharomyces cerevisiae antibodies (ASCA) have been proposed to be
useful in the diagnosis of Crohn’s Disease (CD). ASCA status and its relationship with disease
phenotype was determined in a cohort of Scottish early onset IBD patients. Patients and
Methods: ASCA status (IgA, IgG) was determined in 301 Inflammatory Bowel Disease (IBD)
patients [197 CD, 76 Ulcerative Colitis (UC), 28 IC] using an Enzyme-Linked Immunosorbent
Assay kit. ASCA data from 78 healthy adult controls was also available. ASCA status was
matched with phenotypic features of IBD at diagnosis. Results: CD patients had a higher
prevalence of ASCA antibodies compared to UC patients and healthy controls (41.6% vs.
15.8%, p=0.0001 Odds Ratio (OR) =3.80[1.93-7.50] and 41.6% vs. 7.7% p<0.0001 OR
8.56[3.55-20.62] respectively). ASCA status predicted CD with sensitivity of 41.6% and
specificity of 88.6%. In CD patients univariate analysis demonstrated a positive ASCA was
associated with oral (68.0% vs. 38.6%, p = 0.008 OR 3.39[1.38-8.34]) and perianal (50.6%
vs. 35.2%, p= 0.04 OR 1.89[1.04-3.44]) disease location, raised CRP (48.9% vs. 24.5%,
p = 0.006 OR 2.95[1.36-6.37]), hypoalbuminaemia (51.8% vs. 29.0%, p = 0.01 OR
2.28[1.19-4.37]), the need for surgery (55.1 vs. 36.6%, p= 0.03 OR 2.11[1.10-4.06]) and
the presence of granulomata (47.7% vs. 28.8%, p= 0.02 OR 2.25[1.13-4.48]). On a Multivari-
ate binary logistic regression analysis, oral Crohn’s disease location was an independent
predictor for a positive ASCA status (adjusted p = 0.001, OR 22.22[3.41-142.86). Conclu-
sions: ASCA prevalence is 41.6% in Scottish early onset CD patients. Phenotypic analysis
demonstrated association with a number of factors most notably the presence of oral
Crohn’s disease.
S1285
Detection and Characterization of Hepatic Metastases from Gastrointestinal
Endocrine Tumor with Contrast-Specific US Modes and a Sulfur Hexafluoride-
Filled Microbubble Contrast Agent
Claude D. Marcus, Hedia Brixi-Benmansour, Louis Job, Viviane Ladam-Marcus, Stephanie
Lagarde, Guillaume Cadiot
Purpose : To assess wether detection and characterization of liver metastases in patients
with gastrointestinal endocrine tumor could be improved by using ultrasonographic (US)
contrast-specific modes after injection of sulfur hexafluoride-filled microbubble a new con-
trast agent as compared with unenhanced US. Material and Methods : 37 focal hepatic
lesions in 10 patients with a history of liver metastases from gastrointestinal endocrine tumor
were examined using US and enhanced US after contrast injection. Lesion vascularity and
the kinetics of contrast enhancement within the lesions at the arterial phase, portal phase
and late phase were analysed. Findings from enhanced and non enhanced US were compared
with each other and with MRI as the reference method. Results : 25 of the 37 lesions (68%)
were identified by using unenhanced US. Lesions were hypoechoic in 11 of the 37 cases,
hyperechoic in 9 of the 37 cases, heterogeneous in 5 cases. The number of detected lesions
increased from 25 (68%) with unenhanced US to 37 (100%) after contrast agent injection
(p < 0.01). 17 of the 37 lesions (46%) enhanced markedly during arterial phase (Fig. 1).
21 of the 37 lesions (57%) showed a central hypoechoic pattern during portal phase. 37
of the 37 lesions (100%) demonstrated diffuse homogeneous hypoechoic appearance to the
adjacent liver during the late phase. Conclusion : The use of contrast-specific modes with
a sulfur-hexafluorid contrast agent led to improved detection and characterization of liver

















Figure 1 : US view at arterial phase after contrast agent injection shows diffuse heterogeneous
enhancement of the hepatic metastase
S1286
Non-Invasive in Vivo Visualization of Pancreatic Cancer Signature with
Conditionally Replicative Adenovirus System
Julia Davydova, Tatyana Gavrikova, Seiji Yamamoto, Amy Nelson, Masato Yamamoto
Recent elucidation of cancer biology has identified series of pancreatic cancer molecular
signatures. Non-invasive imaging of such signatures may enable tumor detection and deter-
mination of disease spread, and may provide a powerful method assisting clinical decision
making process. The realization of such strategy requires a system which is selective and
potent. We have been developing infectivity enhanced conditionally replicative adenoviruses
(CRAds) as a selective and potent therapeutic modality for the treatment of GI cancers, and
reported several CRAds for pancreatic cancer including cyclooxygenase-2 (Cox-2) promoter-
controlled CRAd (RGDCox2CRAdF, Gastroenterology. 2003;125(4):1203-18). In this pro-
ject, we applied CRAd structure for non-invasive imaging of Cox-2 status (one of pancreatic
cancer molecular signatures), and tested its in vitro and in vivo functionality. We incorporated
either the enhanced green fluorescent protein (EGFP) or the firefly luciferase (Luc) into the
E3 region of Cox-2 CRAds under the control of the adenovirus (Ad) major late promoter,
which turns on only when the virus is replicating, to enable reporter gene expression in
replication-restricted manner. The vectors were tested in pancreatic cancer cell lines, Cox-
2 status control cell lines (positive: A549, weak: A431, negative: BT474), and human Ad
non-permissive mouse hepatoma cell line (BNL 1NG A.2). In vitro, reporter signal from
replicative imaging vectors was more than 100-fold higher than CMV promoter based non-
replicative positive control vector. On the contrary, no signal was seen in BNL cell. When
Cox-2 control cells were infected with the Cox-2 CRAds with Luc, the signals showed clear
correlation with Cox-2 status of the cells. When an Ad fiber modification (Ad5/3) was
applied for the vectors, the signals from Ad redistant Hs766T cell was dramatically enhanced.
When Cox-2 CRAd with Luc reporter was injected into subcutaneous xenograft of Cox-2
control cell lines, the luminescence reflected the Cox-2 status of the cell lines. In contrast,
the signals with vectors without control mechanism did not show any correlation to Cox-
2 status. When the fiber modified Cox-2 CRAd with Luc reporter was injected into Hs766T
pancreatic cancer xenograft, the tumor exhibited strong signal comparable to the vector
without control elements showing non-controlled full replication. These data indicated that
CRAds strategy can provide potent and selective imaging of a cancer molecular signature.
Since this structure has versatility for combination with a number of control mechanisms,
it has a great potential for imaging of various cancer molecular signatures.
S1288
Comparison of Dynamic High Field Magnetic MR-Colonography (3-Tesla) for
Detection and Characterization of Colorectal Lesions Compared with
Conventional Colonoscopy (CC): A Feasibility Study
Peter Netzer, Juergen M. Gschossmann, Christoforos Stoupis, Wojtek Bielecki, Hanno
Hoppe, Bettina Saar
Background & Aim: CT colonography (CTC) has shown high accuracy in detection of
colorectal lesions > 10 mm and was better tolerated than CC (1). However, pts are exposed
to considerable doses of ionizing radiation. MR-colonography (MRC) may not only be an
alternative screening method for detection of colorectal lesions but may also be able to
characterize these lesions. The aim of this study was to evaluate the feasibility of dark lumen
MRC for detection and characterization of colorectal lesions using the newest MR technology
(3 Tesla) and parallel imaging technique (iPAT). Patients and Methods: Fifty pts (22 m, age
24-86 yrs) underwent dark-lumen MRC prior to CC using a 3 Tesla unit (Trio, Siemens,
Germany). After colon distension with tap water, a high resolution dynamic T1w 3D-GRE
sequence using PAT (iPAT: GRAPPA x2, TR/TE 2.53/1.03 ms, flip14, voxel 1.6 x 1.0 x 1.8
mm3, matrix 250 x 384, FOV 400 mm2, TA18-20 s) was performed. Measurements were
repeated before and 35, 75 and 110 s after bolus injection of Gadoteridol 0.1 mmol /kg
(Prohance, Bracco, Italy). Images were reviewed by a radiologist blinded to the patient`s
history. If findings were discrepant, a second look CC was performed after unblinding. In
a later workup, the dynamic behavior of the colorectal lesions was calculated by the signal-
to-noise ratio (SNR) over the time. These findings were compared with the histological
workup. Results: MRC and CC were successfully performed in all pts wt any complications.
CC showed 46 polyps in 24 pts (size: 3-45 mm) Additionally, 4 carcinoma were found. All
malignant lesions were correctly identified by MR-colonography. MRC missed 10 polyps,
all smaller than 5 mm in size with the exception of one flat adenoma at the ileocecal valve
which was thinner than 5mm but 20mm in size. The patient-based sensitivity for MRC was
92%, specificity was 96%. There were no false positive results. Residual stool could be
differentiated from colorectal lesions. All malignancies showed an early and intensive increase
of SNR and a mild wash-out phenomena. Hyperplastic polyps showed continuous increase
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of signal intensity of the colonic wall. Several extracolonic findings were detected by MR-
examination. Conclusion: MRI with a stronger magnetic filed (3-Tesla) is suited for MRC
and provides comparable results to CC for detection of colorectal lesions > 5mm with the
exception of flat adenomas <5mm of thickness. Analysis of the dynamic behavior of the
colorectal lesions may be helpful to distinguish between neoplastic and non-neoplastic lesions.
S1289
Magnetic Resonance Imaging Predicts Circumferential Resection Margin Status
in Patients Receiving Pre-Operative Chemoradiotherapy for Rectal Cancer
Laura Hancock, Colm P. Forde, Jay B. Bradbury, Fergus Gleeson, Neil J. Mortensen
Introduction: Accurate tumour re-assessment after down-sizing pre-operative chemoradi-
otherapy (CRT) for locally advanced middle and lower rectal cancer provides valuable
prognostic information prior to surgical resection. Aims: 1.To assess the accuracy of post
CRT magnetic resonance imaging (MRI) in predicting circumferential resection margin status.
2. To assess the accuracy of MRI in staging chemoradiation down-sized rectal tumours.
Methods: Patients from a single tertiary referral centre who received pre-operative CRT for
biopsy-proven rectal cancer between January 2003 and February 2005 were identified from
a database. All patients received long-course CRT (50Gy over 5 weeks and 5-fluorouracil/
leucovorin) prior to surgery. A comprehensive MRI reporting proforma was completed for
each patient and results were compared directly with histological specimens. Results: 50
patients were eligible for the study. The overall accuracy for predicting circumferential
resection margin status was 76% (38/50, P=0.006, sensitivity=96.9%, specificity=73.8%,
negative predictive value=96.9%). For T staging MRI was accurate in 52% (26/50) and for
nodal staging MRI was correct in 60% (30/50). Venous invasion was predicted in 66% (33/
50, P=0.04). A radiological rectal cancer regression grade was derived and this correlated
with histological rectal cancer regression grade in 65% (32/49). Conclusions:This study
demonstrates that post CRT MRI is accurate in predicting the circumferential resection
margin status which provides useful prognostic information prior to surgery.
S1290
3d Ultrasonography Is a Valid and Accurate Measure of Liquid Gastric
Emptying in Healthy Subjects
Diana Gentilcore, Trygve Hausken, Michael Horowitz, Karen L. Jones
Scintigraphy represents the current ‘gold standard’ for measurement of gastric emptying
(GE), but is relatively expensive and associated with a radiation burden. Recent studies
suggest that three-dimensional (3D) ultrasonography may allow a precise measure of GE,
given its capacity for accurate volume calculations of the stomach - 3D ultrasonography has
been shown to correlate well with gastric volume measurements in an in-vitro porcine model
(1) and gastric barostat volumes in humans (2). The objective of this study was to compare
and validate measurements of GE of low- and high- nutrient drinks with 3D ultrasonography.
Ten healthy subjects (6M, 4F; age 18-35 yr) had concurrent measurements of GE by
scintigraphy and 3D ultrasonography after ingestion of 500ml (low nutrient) beef soup (12
kcal) and 300ml (high nutrient) dextrose (314 kcal) labeled with 20MBq 99mTc-sulfur
colloid, on two separate days. Results are shown (mean ± SEM). There was no significant
difference between scintigraphic and ultrasonographic measurements of GE (Figure); 50%
emptying times (T50) (soup: scintigraphy - 27.7 ± 4.8 min vs ultrasonography - 23.8 ± 4.8
min; dextrose: scintigraphy - 122.2 ± 13.3 min vs ultrasonography - 131.9 ± 10.2 min).
There was a close correlation between the scintigraphic and ultrasonographic T50’s for both
soup (r = 0.92, P = 0.0005) and dextrose (r = 0.88, P = 0.0007). For the T50, the limits
of agreement were - 15.2 min and + 8.1 min for soup (mean difference - 3.6 min) and -
35.3 min and + 47.6 min for dextrose (mean difference + 6.2 min). We conclude that
3D ultrasonography has good agreement, and correlates closely, with scintigraphy in the
measurement of GE of low- and high- nutrient liquids. 1. Gilja et al. (1997). Gastroenterology
113, 38-49. 2. Tefera et al. (2002). Gut 50, 153-158.
S1291
Quantitative and Non-Invasive Assessment of Postprandial Intragastric
Dilution As Assessed By Magnetic Resonance Imaging (MRI)
Reto Treier, Andreas Steingoetter, Oliver Goetze, Peter Boesiger, Michael Fried, Werner
Schwizer
Introduction: Quantitative assessment of postprandial intragastric dilution and mixing is of
major importance for a detailed understanding of transport and emptying mechanisms in
the gastrointestinal tract. In gastric MRI, non-invasive determination of mixing and dilution
processes of contrast marker labelled test meals can be achieved by detecting T1 relaxation
times, using the mathematical interrelation between T1 and marker concentration. In this
pilot study a fast T1 mapping technique for quantitative T1 determination in the human
stomach was developed and evaluated in healthy subjects. Methods: Two fasting, healthy
volunteers were imaged in prone body position using a 1.5T whole-body MRI scanner
(Intera, Philips Medical Systems, Best, The Netherlands). After drinking the labeled test meal
(600 ml of 10% glucose @ 37°C, 1% LBG, 1200μM Gd-DOTA (DOTAREM®, Laboratoire
Guerbet, France)) and attaching a test meal sample (1000μM Gd-DOTA) as reference to
the back of the subjects, T1 mapping (6 transversal image slices) were performed every 5
min over 40 min. Mean±SD T1 values of the sample and gastric contents were calculated
within ROIs of 7x7 pixels (see figure). In addition, T1 of the sample was determined using
as standard inversion recovery (IR) spectroscopy sequence. Results: The figure shows a
transverse MRI image (left) and the corresponding calculated T1 map (right) 40 min after
drinking, both with outlined stomach wall and defined ROIs. Calculated T1 values of the
sample are in good agreement with IR T1 values (T1maps @ 10min: 149±7 ms, @ 40min:
152±5 and IR: 157±4 ms). Test meal was diluted over 40 min as observed by a 25% increase
in T1 (t = 10 min: 197±26 ms; t = 40 min: 247±28 ms) corresponding to a local dilution
of 20%. Discussion: This new and fast T1 mapping technique allows the three-dimensional
determination of intragastric dilution within 20 s (1 breathhold). This is the first method
allowing non-invasive assessment and quantification of gastric secretion in humans.
S1292
Gadobenate Dimeglumine Enhanced MRI Evaluation for Acute Bile Duct
Injury: A Pilot Study
Paari Vijayaragavan, Piyal Nag, Ajay Sharma, Sadiq S. Sikora, Vinay K. Kapoor, Sunil K.
Jain, Rakesh K. Gupta
Introduction Acute bile duct injuries (BDI) usually require a gamut of investigations such
as ultrasonogram,CT scan, MRCP, angiography, etc for a complete evaluation. Gadobenate
dimeglumine (Multihance®) contrast enhanced (CE) MRI was evaluated as a single investi-
gation in the workup of acute BDI. Patients and methods Eleven patients with post cholecys-
tectomy BDI underwent T2-MRCP and serial T1 weighted FSPGR sequences before and till
2 hours after intravenous administration of Gadobenate dimeglumine. MR angiography of
the hepatic artery and portal vein was obtained and the FSPGR images were reconstructed
to get contrast enhanced (CE) T1 MRCP. Biliary and vascular anatomy and bile leak in T1
and T2 MRCP was noted and correlated with other investigations. Results Conventional
MRCP revealed BDI of Bismuth type III in 4, type II in 3 and 2 each of type IV and V . In
all patients type of injury on CE MRCP correlated with conventional MRCP although good
quality CE MRC revealing all the segmental ducts could be obtained in only 5 patients. Biliary
leak was detected on TI FSPGR images in 10 out of the 11 patients;this was demonstrated as
contrast leak into biloma (n=7), extravasation of contrast in drainage tube (n=2) and extravasa-
tion from duodenum (n=1). Post contrast T2 MRCP images showed evidence of bile leak
in 6 patients seen as serial reduction in the intensity of intra abdominal fluid collections.
The reconstructed TI FSPGR images detected the origin of bile leak as to be from hilum in
5, duodenum in 1 and indeterminate in 4 patients. MR angiogram revealed normal portal
vein in all and a right hepatic artery injury in one patient. The study demonstrated complete
loss of biliary continuity in 9 which was corroborated by fistulogram in 4, ERC in 2 and
operative finding in 3 patients. Of the 6 patients with suggestion of internal fistula on CE
MRCP,it was confirmed in 4 out of 5 patients who were operated upon. On retrospective
review, CE MRCP provided complete information in 9 (81%) patients without the need for
any further work up. Percutaneous drainage for ongoing bile leak (n=3) and avoidance of
ERC because of loss of biliary continuity (n=5) were the therapeutic decisions influenced
by the study. Conclusion Gadobenate dimeglumine enhanced MRI evaluation is a promising
and effective single investigation in the workup of acute BDI.
S1293
Stereoscopic High-Resolution MRCP As 3D Anatomical Information of the
Cystic Duct Prior to Cholecystectomy
Tetsuya Yamagishi, Karl H. Hoehne, Takao Itoi, Takashi Kawai, Kimihiko Abe
Purpose: In conventional MRCP(c-MRCP), difficulties may occur to obtain firm anatomical
information of the cystic duct. This presentation shows that the combination of high-
resolution(HR) data and stereoscopic visualization leads to a decisive improvement for
obtaining the three-dimensional(3D) extent of the cystic duct. Materials and Methods: Thirty-
eight patients(16 males and 22 females: 38-76 year-old) with cholecystolithiasis underwent
HR and c-MRCP on the same day prior to cholecystectomy(5-24 days before operation).
(1). Stereoscopic HR-MRCP: The source images (total 88-96 slices) were collected with thin
section(0.8mm) by a respiratory-gating with PACE(Prospective Acquisition CorrEction),
which is one of the 3D data acquisitions using navigator triggering. Stereoscopic maximum
intensity projection(MIP) images were created by a commercially available 3D rendering
software(VOXEL-MAN). The resulted images were displayed as a movie with omni-direction
and viewed with Red/ Green glasses for stereoscopic visualization. (2). c-MRCP: 2D RARE
single-shot were performed with thick slab(5-7cm) around the vertical axis/ every 10-degree.
(3). Estimating the observer performance: Ten board certified radiologists and endoscopists
specializing the pancreaticobiliary region independently compared HR-MRCP with c-MRCP.
(i). The accuracy for the detection of anatomic variants of the cystic duct insertion into CBD
[a. Proximal, b. Right lateral, c. Anterior spiral, d. Posterior spiral, e. Low medial and f.
Low lateral] was evaluated. Any inter-observer discrepancy was fully discussed and standard-
ized. In all cases, the final anatomical information of the cystic duct was obtained by
T : 89386$$CH2
05-04-06 23:18:26 Page 195Layout: 89386B : o
A-195 AGA Abstracts
endoscopic retrograde cholangiogpaphy or cholangiography during operation. (ii). The con-
fidence value for making diagnosis defined as a four-point questionnaire: definite, probable,
suspected and poor. Results: The cystic duct insertion pattern was a=14, b=10, c=1, d=4,
e=2 and f=7 cases by cholangiography. The diagnostic accuracy was 92-percent by stereo-
scopic HR-MRCP versus 56-percent by c-MRCP. All observers evaluated the morphological
delineation of the cystic duct was decisively improved in HR-MRCP and diagnostic confidence
was obviously higher than c-MRCP. Stereoscopic visualization was also helpful to get rid
of the signal overlay by surrounding organs(stomach, intestine) and/ or cystic lesions of the
liver, pancreas and kidneys, which leads reduced burden for film-interpret. Conclusion:
Stereoscopic HR-MRCP could be considered as a useful alternative modality to cholangi-
ography in almost all cases, prior to cholecystectomy, because of its high accuracy and
diagnostic confidence.
S1294
Impact of Operators Experience On Value of High-Resolution Transabdominal
Ultrasound (US) in the Diagnosis of Choledocholithiasis: A Prospective
Comparison Using Endoscopic Retrograde Cholangiography (ERC) As Gold
Standard
Steffen Rickes, Gerhard Treiber, Klaus Moenkemueller, Ulrich Peitz, Antal Csepregi, Stefan
Kahl, Anika Vopel, Kathleen Wolle, Ebert P.A. Matthias, Sabine Klauck, Peter
Malfertheiner
Aim of the study: The aim of this study was to evaluate the accuracy of US in the diagnosis
of common bile duct stones depending on the operators experience. Patients and methods:
From April 2003 through November 2004, 126 patients (pts.) referred because of suspicion
of the presence of common bile duct stones were included in the study. Two pts. were
excluded because they refused ERC. Consequently, the study comprised 124 pts. US (2-5
MHz sector scanner, Siemens Elegra, Erlangen, Germany, and HDI 5000, Philips Ultrasound,
Bothel, WA, USA) was performed by operators unaware of the results of other imaging
procedures. The definitive diagnosis was established by means of ERC. Chi-square test was
used to detect significant differences. Results: Thirty-five of 124 pts. were investigated by
experienced examiners. Twenty-seven of 35 pts. (77%) were found to have stones at ERC.
Bile duct stones were found correctly with US in 22 of 27 pts. (sensitivity 82%). Of the 8
pts. without stones at ERC one false-positive diagnosis was made with US (specificity 88%).
In conclusion, correct diagnoses were observed in 29 of 35 (accuracy 83%) pts. investigated
by experienced examiners. Eighty-nine of 124 pts. were investigated by less experienced
examiners. Fifty-four of 89 pts. (61%) were found to have stones at ERC. Choledocholithiasis
was found correctly in only 25 of 54 pts. (sensitivity 46%). Of the 35 pts. without stones
at ERC 3 false-positive diagnosis were made with US (specificity 91%). In conclusion, correct
diagnoses were observed in 57 of 89 pts. (accuracy 64%) investigated by less experienced
examiners (p<0.05 in comparison to the results of experienced examiners). Conclusions:
US done by experienced examiners has a high accuracy in the diagnosis of choledocholithiasis.
Therefore, a good training and continued experience are prerequisites for a successful
detection of bile duct stones with US. Under these conditions further expensive and invasive
methods may not be necessary.
S1295
Comparison of Secretin-Stimulated Dynamic Magnetic Resonance
Cholangiography and Operative Cholangiography in the Diagnosis of
Pancreaticobiliary Reflux
Hosoki Takuya, Tokuda Yukiko, Sakai Mio, Sai Hidemi, Kashiwasaki Masaki, Nakamori
Masaji, Michida Tomoki
Simultaneous opacification of the pancreatic duct at cholangiography was considered abnor-
mal, suggesting pancreaticobiliary maljunction (PBMJ). However, this radiographic finding
has not shown to be a direct diagnostic test for pancreaticobiliary reflux (PB reflux). Secretin-
stimulated dynamic magnetic resonance cholangiopancreatography (SS-dynamic MRCP) has
been reported to be useful for diagnosing PB reflux. The purpose of this study is to evaluate
SS-dynamic MRCP findings in patients with suspected PBMJ at operative cholangiography.
METHODS: Fifteen controls and thirty-three cholecystectomy patients were prospectively
examined by SS-dynamic MRCP. The patients were divided into two groups; fourteen patients
without evidence of PBMJ (Group 1) and nineteen patients with suspected PBMJ (Group
2) at operative cholangiography. PBMJ was suspected when simultaneous opacification of
the pancreatic duct (> 2cm in length) occurred during continuous contrast injection at the
cholangiography. The patients with anomalously long PB junction were excluded from this
study. SS-dynamic MRCP was performed using a breath-hold, single-shot turbo spin-echo
T2-weighted sequence. The optimal MRCP section was repeated 35 times at 10-sec interval
after secretin injection; the acquisition time was 4s per image. The signal intensity (SI) of
the extrahepatic duct was compared between the controls and patients for the degree and
direction of SI change, i.e. whether increase in SI change occurred in an upstream to
downstream direction, or vice versa (retrograde direction). The retrograde SI change of the
extrahepatic duct after secretin injection was judged as the presence of PB reflux. Mean SI
was measured in each proximal, middle, and distal third of the extrahepatic duct, and also
on the corresponding images of serial imaging sets. Peak time (PT) was defined as an interval
between the time of the secretin injection and that at which a first peak SI was obtained.
RESULTS: In all controls, no SI change was noted in any part of the extrahepatic duct over
the observation period, providing no apparent PT. In 2 (14%) of Group 1 and 14 (74 %)
of Group 2, the extrahepatic duct showed retrograde SI increase and sequential delay in
occurrence of the PT from its distal third to its proximal third; the incidence was significantly
greater in Group 2 than in Group 1 (p<0.005). In Group 2, mean PT (s) +-SD was 113+-
57, 145+-59, and 190+-47 at the distal, middle, and proximal third of the extahepatic duct,
respectively. CONCLUSION: In patients with suspected PBMJ at operative cholangiography,


















MRI Studies of Blood Flow in the Superior Mesenteric Artery (SMA)
Adam D. Jeays, Richard Gillott, Rodney Hose, Patricia Lawford, Samuel Jacob, Paul
Spencer, Karna D. Bardhan
Introduction Chronic ischaemia of the small intestine is uncommon. It is hypothesised that
this may be related to the nature of flow in the SMA and the dynamic response to calorific
load. To investigate this, SMA blood flow was studied during fasting and following ingestion
of a controlled calorific load. Method Flow in the SMA was assessed in 18 healthy volunteers
(11 male, 7 female, mean age 36) by 1.5 Tesla magnetic resonance (MR) imaging. ECG-
gated, flow-sensitive (phase-contrast) sequences were acquired with high temporal resolution
(21 frames per heartbeat) over the cardiac cycle. Images were obtained after overnight fasting
and 30 minutes after ingestion of a 600 Kcal Scandishake® milk-shake. A period of 30
minutes post-prandial was chosen as it coincides with peak flow (as determined from Doppler
flow studies[1]). Velocity fields in the SMA were monitored throughout the cardiac cycle
and mean flow calculated throughout diastole. Results●During systole, flow disturbances,
indicative of high velocity flows, were seen in 2 subjects after fasting. After feeding, this
increased to 15 subjects (including the original 2). For this reason, only flow results from
the diastolic portion of the cardiac cycle were considered. ●At 30 minutes post-prandial,
mean diastolic flow was 153 ml per cycle (n=18, SD 67.5, range 41.6-262), compared to
40.4ml (n=18, SD 14.9, range 8.1-78.4) in the fasted case. This equates to a 3.8 fold mean
rise in flow after feeding (n=18, SD 2.2, range 0.8-9.8). ●In the cohort scanned twice,
mean diastolic flow was 2.2 times that of the fasted value (n=5, SD 0.3, range 1.8-2.5) on
the first visit, and 3.1 times that of the fasted value (n=5, SD 0.9, range 2.1-3.9) on the
second visit. Discussion & Conclusions 1. Diastolic flow in the SMA increases markedly
in response to calorific load. 2. The velocity of blood in the SMA during systole is sufficient
to cause instabilities in the flow: the resulting loss of MR signal prevents the quantitative
interpretation of velocity data at these high flows. 3. For most subjects, flow during systole
is undisturbed following fasting. 4. The change in flow regime over these time-scales may
have important effects on wall shear stress, endothelial cell morphology and risk of athero-
sclerosis. [1] Small intestinal blood flow in man: The effects of age and caloric loading. PA
Spencer et al. Gut 2000;46(S2):A67-W139 This work was funded by the Bardhan Research &
Educational Trust, Registered Charity No. 328452
S1297
In Vivo Magnetic Resonance Imaging of Experimental Mouse Colitis and
Association to Inflammatory Activity
Anna E. Larsson, Silvia Melgar, Rehnstrom Erika, Erik Michaelsson, Lennart Svensson,
Hockings Paul, Lars E. Olsson
BACKGROUND AND AIMS: Various imaging techniques such as endoscopy and computed
tomography are used to monitor ulcerative colitis and Crohn’s disease. Magnetic resonance
imaging (MRI) is emerging as an alternative because it is non-invasive and free from ionising
radiation. Today, biomarkers of inflammation are needed that can be used from mice to
man in e.g. testing of putative therapeutic drugs. Several clinical studies have shown that
contrast enhanced T1 weighted (T1w) and T2 weighted (T2w) MRI can identify pathological
bowel segments in patients with inflammatory bowel disease. The aim of the present study
was to investigate if MRI can provide biomarkers of inflammation in an experimental mouse
colitis model. METHODS: Acute and chronic colonic inflammation was chemically induced
by exposing mice to dextran sulphate sodium (DSS). A control group of healthy mice was
also included. MRI was used to assess colon wall thickness and also the T2w signal, which
mainly reflects presence of oedema. Additionally, MRI was used to measure gadodiamide-
enhanced T1w signal in the colon wall, reflecting presence of inflammation. Inflammatory
scoring, based on stiffness (0-2), oedema (0-3), visible ulcerations (0-1) and thickness (0-
4), was performed ex vivo to assess inflammation. Haptoglobin and interleukin-1β served
as systemic and local inflammatory markers, respectively. RESULTS: DSS exposed animals
had significantly higher haptoglobin and interleukin-1β levels, and also inflammatory scores
compared to healthy animals. The colon wall thickness was significantly increased in inflamed
compared to healthy animals, and a positive correlation between colon wall thickness
and inflammatory scores was observed. Moreover, the contrast enhanced T1w signal was
significantly increased in acutely inflamed mice compared to healthy mice. The T2w signal
in the inflamed animals correlated positively with haptoglobin levels and colon wall thickness.
CONCLUSION: Our results show that colon wall thickness, measured with MRI, as well
as contrast-enhanced T1w and T2w imaging of the colon wall are potential biomarkers in
characterizing inflammation. Future studies will reveal if these putative biomarkers may be
useful in evaluation of candidate drugs in longitudinal studies.
S1298
Diagnostic Accuracy of CT Colonography Evaluated By Surgically Resected
Specimen As the Gold Standard: Is Optical Colonoscopy Adequate Gold
Standard?
Shinichiro Okada, Yutaka Kawamura, Junichi Sasaki, Fumio Konishi
BACKGROUND and AIM Recently, CT colonography (CTC) has been introduced as a new
and promising modality for the diagnosis of colorectal polyps. The accuracy of CTC is
important to determine its indication, feasibility and clinical significance, however, the
evaluation of its ‘true’ diagnostic ability is thought to be difficult because the optical colonos-
copy (OCS), the gold standard for the presence of polyps, associates with overlooking even
if done back-to-back. The aim of this study is to clarify the ‘true’ diagnostic ability of CTC
using surgically resected specimens which we believe are the most reliable source of the
presence of polyps. MATERIALS and METHODS CTC was performed for 150 consecutive
patients who were scheduled to elective surgery for colorectal cancer, which was defined
as the index lesion. All patients underwent preoperative OCS. Usually about 20 cm of the
large intestine was resected with 10 cm distal and proximal margin. Of these 40 patients
had simultaneous lesions in the resected specimen and were included in this study. Location
(distance from the index lesion), configuration and diameter of the lesions were compared
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to the results of CTC and OCS. RESULTS There was no morbidity associated with CTC
and OCS. In 6 patients, tumorous stricture interfered with OCS ability to examine the colon
proximal to the index lesion. Fifty-six polyps were found in surgical specimens. Of these,
9 lesions could not be evaluated by OCS because of the stenosis and these lesions were
excluded from the comparison between CTC and OCS. Sensitivity of CTC and OCS were
82.1% / 66.0% (P=0.12), respectively, and the positive predictive value (PPV) were 88.5% /
100% (P=0.13), respectively. For 9 lesions located in the colon proximal to the stricture,
sensitivity and PPV of CTC were 89% and 80%, respectively, which were not significantly
different from those for the lesions in the distal colon. CONCLUSION The diagnostic
accuracy of OCS using surgical specimens as the gold standard was unexpectedly low.
Therefore, it is thought to be inadequate to use OCS as the gold standard for the evaluation
of diagnostic accuracy of CTC. Although not statistically significant, diagnostic ability of
CTC appeared to be better than that of OCS. Our study revealed that CTC is a reliable
modality for the diagnosis of colorectal neoplasm.
S1299
MRCP and MRI Findings in Autoimmune Pancreatitis
Pong Yui Chen, Terumi Kamisawa, Go Kuwata, Yuyang Tu, Hitoshi Nakajima, Naoto
Egawa, Kouji Tsuruta, Atsutake Okamoto, Noriko Kamata
Background and Aim: The characteristic radiological findings of autoimmune pancreatitis
(AIP) include irregular narrowing of the main pancreatic duct (MPD) on ERCP and enlarge-
ment of the pancreas on CT and US. Recently, MRCP. We evaluated MRCP findings in
conjunction with MR images in AIP patients. Patients and Methods: The subjects were 9
patients with AIP who had MRCP, ERCP, CT, and US. Seven patients had elevations of
serum IgG4. On ERCP, the irregular narrowing of the MPD (diffuse (n=1), segmental-head
(n=3), segmentally skipped-head and body (n=3), segmental-tail (n=2)) and enlargement of
the pancreas was seen in all patients. All patients were given steroid treatment and responded
both morphologically and serologically. MRCP and MR images obtained before and after
steroid therapy were examined and compared to 10 cases of pancreatic head cancer. Results:
On MRCP, the narrowed portion of the MPD noted on ERCP was not visualized, while the
noninvolved segments of the MPD were visualized. Two segmentally skipped MPD lesions
in the head and body of the pancreas were not visualized in 3 patients. Although upstream
dilatation of the proximal MPD was detected in 6 patients, the degree of dilatation was
milder than in cases of pancreatic carcinoma. Stenosis or obstruction of the lower bile duct
was detected in 8 patients; 3 of these patients also showed stenosis of the intrahepatic bile
duct. MR images showed enlargement of the pancreas with decreased signal intensity on
T1-weighted MR images compared with that in the liver, increased signal intensity on T2-
weighted MR images, and, in 3 patients, a hypointense capsule-like rim. After steroid therapy,
the previously not visualized portion of the MPD was seen, along with improvements of
the upstream dilatation of the proximal MPD and of the bile duct stenosis. Pancreatic
enlargement decreased, and the abnormal signal intensity on both T1- and T2-weighted MR
images became isointense. Conclusion: The irregular narrowing of the MPD on ERCP was
not visualized on MRCP, while the other region of the MPD was visualized. MRCP cannot
differentiate the irregular narrowing of the MPD seen with AIP from the stenosis of the MPD
seen with pancreatic carcinoma; therefore, ERCP is necessary to make the diagnosis of AIP.
However, the MRCP findings of skipped, non-visualized MPD lesions, accompanied by a
lesser degree of upstream dilatation of the MPD, might suggest the presence of AIP. These
MRCP findings in conjunction with MR imaging of pancreatic enlargement that shows
abnormal signal intensity on T1- and T2-weighted MR images are useful in supporting a
diagnosis of AIP.
S1300
Alterations in I-Kappa B Kinase (I-kK) Pathways Predict the Instability of
Mucosal Claudin Isotypes (1-5) in Patients with Inflammatory Bowel Disease:
A Novel Gut Barrier Dependent Mechanism for the Pathophysiology of Human
IBD
Ali Banan, Maliha Shaikh, Lijuan Zhang, Jeremy Z. Fields, Ece Mutlu, Ashkan Farhadi,
Christopher B. Forsyth, Ali Keshavarzian
Mucosal NF-kB hyperactivation and tight-junctional instability (& intestinal barrier disrup-
tion) appear to be early hallmarks of IBD. However, the mechanisms underlying gut barrier
instability in vivo and their contribution to tissue injury remain unclear. In vitro studies
suggest that the mechanism may depend on oxidative stress, NF-kB signaling & instability
of barrier proteins. However, these crucial events are only poorly characterized in human
IBD. Aims: We determined whether in the inflamed IBD mucosa (1) there is oxidation and
degradation of various Claudin isotypes (22-25 kDa tight-junctional Claudin isoforms, -1, -
2, -3, -4, -5); (2) dysregulated I-kK / NF-kB signaling (I-kK isotypes α/β, IkB, NF-kB
subunits, iNOS) & tissue oxidative stress. (3) These variables are comparable (correlate)
with markers of tissue inflammation & injury. Methods: Mucosal biopsies from IBD patients
(ulcerative colitis, Crohn’s Disease, specific colitis) and healthy/normal controls were used
to measure: oxidation & instability of Claudin isotypes (1-5); levels / phosphorylation /
activation of the I-kK pathway; markers of mucosal oxidation / injury (protein carbonylation /
nitration, NO levels). Results: Barrier tight-junctional Claudin-1, Claudin-2, Claudin-3,
Claudin-4, and Claudin-5 were largely carbonylated, nitrated and destabilized in inflamed
IBD mucosa, but not so in normal-appearing mucosa from the same patients. Inflamed
mucosa also showed marked increases in phosphorylation of I-kK-α/β isotypes and of IkBα;
degradation of IkBα; hyperactivation of I-kK-β and of NF-kB (p50/p65 subunits). Other
mucosal oxidative injury markers such as iNOS, NO metabolites, and protein nitration were
also increased. These changes were not seen in normal-appearing, non-inflamed, IBD mucosa.
Furthermore, degraded barrier claudin proteins and hyperactivated I-kK—NF-kB were
mainly found within the epithelial layer, and strongly correlated with IBD disease severity.
Conclusions: Our findings suggest that underlying human IBD pathophysiology are pivotal
changes in barrier function and in I-kK signaling. This novel mechanism is one in which
hyperactivation of an I-kK—NF-kB driven pathway is required for mucosal barrier protein
oxidation and instability. These crucial barrier altering events could lead to initiation and/
or perpetuation of human IBD flare-up. {Supported by NIDDK60511 & NCCAM01581;
NIAAA13745}.
S1301
Urinary Neopterin Excretion Is a Good Non Invasive Biomarker for
Monitoring Crohn’s Disease Activity
Stephane Nancey, Armand Perret-Liaudet, Driffa Moussata, Helene Navarro, Ivan Graber,
Bernard Renaud, Dominique Kaiserlian, Bernard Flourie
Background : Crohn’s disease (CD) is a chronic, relapsing T cell-mediated inflammatory
bowel disease. Neopterin is a biochemical marker released from human macrophages upon
stimulation with IFNg produced by activated T cells. Urinary neopterin excretion has been
shown to be increased in autoimmune diseases like systemic lupus erythematosus, rheumatoid
arthritis and psoriasis where the highest levels of neopterine were detected during active
diseases. Our objective was to test the usefulness of urinary neopterin in Crohn’s disease
and its relation with disease activity. Patients and Methods : 90 CD patients (49F/41M) and
100 healthy volunteers (54F/46M) provided a single urinary sample (20 mL). CD patients
were under treatment with corticosteroids (19 %), 5ASA (10 %), immunosuppressors (40
%) and/or infliximab (55 %). CD activity was assessed by the Crohn’s Disease Activity Index
(CDAI). C reactive protein level was performed by routine dosage. Urinary neopterin was
measured by HPLC and results were expressed in mmol/L corrected for urinary creatinin.
Results : Urinary neopterin excretion (mean +/- SD) was significantly higher in the 46
patients with active CD (CDAI > or = 150) than in the 44 patients with quiescent CD
(CDAI<150) and in the 100 healthy volunteers (respectively 395 +/- 221, 145 +/- 48 and
200 +/- 25 mmol/L; p<0.01). Urinary neopterin excretion was well correlated with CDAI
(Spearman test, r =0.78; p<0.001) and the correlation was better than that found between
CRP and CDAI (Spearman test, r =0.49; p<0.001). Conclusion : Urinary neopterin excretion
is a good indicator of CD activity and might help clinicians to monitor CD patients. Ongoing
study are performed to assess its value in predicting relapse of CD.
S1302
Prognostic Significance of Endoscopic Remission in Patients with Active
Ulcerative Colitis Treated with Oral and Topical mesalazine: Preliminary
Results of a Prospective, Multicenter Study
Gianmichele Meucci, Renato Fasoli, Simone Saibeni, Daniela Valpiani, Renzo Gullotta,
Enrico Colombo, Renata D'Inca', Maddalena Terpin, Giovanni Lombardi
Background: it is generally recommended that the treatment of active ulcerative colitis should
be continued until complete healing of endoscopic lesions. However, the evidence supporting
this recommendation is scanty. Aims: 1) to assess the rate of patients with active ulcerative
colitis that achieve clinical but not endoscopic remission after treatment with oral plus
topical mesalazine 2) to compare the rate of relapse in patients with clinical/endoscopic
remission and those with only clinical remission Methods: patients with active mild or
moderate ulcerative colitis extending beyond the rectosigmoid junction were eligible for the
study. Patients requiring systemic steroids, those with previous or ongoing immunosuppress-
ive treatment and those with proctitis were excluded. All patients underwent baseline
colonoscopy and were then treated with mesalazine, 4 gr/day orally and 2 gr/day per rectum
for 6 weeks. Those achieving clinical remission underwent a second colonoscopy: afterwards,
all received maintenance treatment with oral mesalazine, 2 gr/day orally. A one year clinical
follow-up was then planned. Clinical remission was defined as normal frequency of bowel
movements with formed stools, no abdominal pain and no blood in the stools. Endoscopic
remission was defined as normal appearing mucosa or only mild redness and/or friability,
without either ulcers or erosions. A formal assessment of concordance among endoscopists
in evaluating endoscopic activity was carried out before starting the study. Results: so far,
78 patients (47 males, mean age 48 years, range 19-77) have been enrolled at 9 participating
institutions. After six weeks of oral and topical treatment with mesalazine, 59 of them (75%)
were clinically in remission. Endoscopic activity was still present in only five of them (8.5%).
After a mean follow-up of 8,7 months, 15 patients (26%) relapsed. The cumulative rate of
relapse at one year was 23% in patients with clinical and endoscopic remission and 80%
in patients with only clinical remission (p < 0.0001). Conclusions: persistence of endoscopic
activity is a rare event in patients with active ulcerative colitis achieving clinical remission
after a 6-week treatment with oral plus topical mesalazine, but is a very strong predictor of
early relapse
S1303
Serological Markers Are Associated with Severity of Disease and Need of
Surgery in IBD Patients
Shuwen Xue, Joanne M. Stempak, Abdul A. Elkadri, Gordon R. Greenberg, Tom D.
Walters, Anne M. Griffiths, Hillary Steinhart, Mark S. Silverberg
IBD is a complex disorder with a spectrum of clinical manifestations. Recent data demonstrate
that serological markers are associated with disease behaviour, severity and complications.
AIM: To further elucidate the association of IBD behavior with serological markers.
METHODS: Subjects were recruited primarily from the MSH and HSC IBD Centres in
Toronto. Sera of unrelated patients with CD (n=359), UC (n=185) and healthy subjects
(HC, n=62) were tested for the presence of the following antibodies: pANCA, ASCA, OmpC
and Flagellin (Prometheus Laboratories, San Diego, CA). Review of medical charts was
performed to document clinical information including diagnosis, age of diagnosis, disease
location, behaviour (for CD, fistulizing, fibrostenotic or inflammatory) and need of surgery.
RESULTS: The seroprevalence of pANCA, ASCA, anti-OmpC and flagellin was 15%, 62%,
38% and 67% in CD; 62%, 12%, 28% and 31% in UC; and 5%, 7%, 2% and 18% in HC
(p<0.0001 for all markers). ASCA, anti-OmpC and flagellin have high specificity (89%,
79%, and 72%) for CD individually and specificity rises to 98% for those positive for all
three markers. pANCA has high specificity (86%) for UC. ASCA, anti-OmpC and flagellin
are associated with early age at diagnosis of CD (20 vs 25, p=0.0001; 20 vs 23, p=0.03; 21
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vs 24, p=0.02 respectively); need of surgery (61% vs 45%, p=0.003; 74% vs 43% p<0.0001,
61% vs 49% p=0.04 respectively). ASCA and anti-OmpC are also associated with higher
number of surgeries (1.5 vs 1.1, p=0.004; 2.1 vs 0.9, p<0.0001). ASCA, anti-OmpC and
flagellin are associated with more aggressive disease behaviour (fibrostenotic/fistulizing) in
CD (see Table). Anti-OmpC is associated with higher rate of colectomy in UC (58% vs 29%
p=0.0003). CONCLUSIONS: The presence of ASCA, anti-OmpC and flagellin seropositivity
is associated with more aggressive disease behaviour and the requirement for surgical inter-
vention. These markers are useful to identify those who should be considered for earlier
and more aggressive therapy.
S1304
A Unique Inflammatory Mechanism in Man: Dysregulation of An EGF-R and
PKC Isoform [PKC-ζ, PKC-β1] Dependent Pathway Appears to Underlie
Mucosal Oxidative Stress, NF-kB Activation and Gut Injury in Inflammatory
Bowel Disease (IBD)
Ali Banan, Maliha Shaikh, Lijuan Zhang, Ece Mutlu, Jeremy Z. Fields, Ashkan Farhadi,
Christopher B. Forsyth, Ali Keshavarzian
NF-kB activation & oxidative stress are key features of human IBD. Our in vitro studies
suggest that dysregulation of a pathway dependent on EGF-Receptors & PKC isoforms -
PKC-β1 &/or PKC-ζ (Zeta) - leads to increased oxidative stress & inflammation. Nonetheless,
molecular mechanisms involving these factors are not well-characterized for human IBD.
Aims: We sought to determine whether: [A] deactivation of EGFR & tyrosine kinase activity
and deactivation of PKC-ζ and/or PKC-β1 occur in inflamed IBD mucosa; [B] EGF-R and
PKC isoform activity correlate with markers of gut inflammation & injury. Methods: We
used pinch biopsies from IBD patients (UC, CD, specific colitis) & normal controls, and
measured: EGF-R & tyrosine kinase activity (tissue distribution/expression); PKC-ζ/ PKC-
β1 (levels/activity/distribution); markers of gut inflammation & oxidative injury (NF-kB,
IkBα, iNOS, NO, protein/cytoskeletal oxidation/instability). Results: Compared to normal
mucosa, inflamed IBD mucosa showed marked decreases in EGF-R distribution/expression
and tyrosine kinase activity, indicating EGF-R deactivation. PKC-β1 (78 kDa) and PKC-ζ
(72 kDa) were down-regulated & deactivated (both were reduced in membrane & cytoskeletal
mucosal fractions). In parallel, we found large increases in NF-kB activation (p50/p65
subunits), IkBα phosphorylation, iNOS upregulation, oxidant (NO, O2) generation, and
protein carbonylation & nitration. In normal appearing (non-inflamed) IBD mucosa, smaller
changes in oxidative markers & EGF-R / PKC isoforms were seen. Tissue structural proteins
were largely oxidized in inflamed mucosa, less so in normal mucosa. Mucosal EGF-R, PKC-
ζ, and PKC-β1 deactivation correlated positively with tissue inflammation, oxidative injury
& IBD severity. Most of the changes in EGF-R, PKC, NF-kB/iNOS & oxidation were seen
within the epithelial layer. Conclusions: 1) The EGF-R→PKC-ζ / PKC-β1 pathway is down-
regulated and deactivated in IBD mucosa while the NF-kB→NO oxidative damage pathway
is upregulated. Tissue structural proteins also exhibit oxidative damage and instability when
EGF-R is deactivated. 2) Measures of tissue inflammation, oxidative injury and IBD disease
severity inversely correlate with mucosal EGF-R/ PKC. 3) Marked deactivation of EGF-
R→PKC-ζ / PKC-β1 signaling and activation of NF-kB→NO signaling (& structural protein
oxidation) are only seen in inflamed mucosa. These findings suggest that a novel EGF-R
and PKC isoform dependent mechanism underlies upregulation of NF-kB→iNOS signaling
and that these key processes are required for mucosal inflammation and IBD flare up in
man. {Supported by NIDDK60511 & NCCAM01581; NIAAA13745}.
S1305
Positive CARD15 Mutation SNP12 and ASCA Predict Increased Disease
Severity and Surgical Cost in Crohn’s Disease
Selwyn H. Odes, Michael Friger, Hillel Vardi, Severine Vermeire, G Claessens, X Bossuyt,
Lene Riis, Frank Wolters, Maurice Russel, Ole Hoie, Patrizia Politi, Ioannis Mouzas, Colm
O'Morain, Juan Clofent, Estela Monteiro, Andrea Messori, Pia Munkholm, Reinhold
Stockbrugger
BACKGROUND: CARD15, a susceptibility gene in Crohn’s disease, is associated with ileal
pathology, intestinal stenosis and more frequent surgery. Anti-Saccharomyces cerevisiae
antibody (ASCA), a serological marker for Crohn’s disease, is associated with ileal and
more complicated disease. AIM: We hypothesized that the presence of ASCA and CARD15
mutations could predict the cost of health care in Crohn’s disease. METHODS: Crohn’s
disease patients in the EC-IBD community-based inception cohort (Denmark, Greece, Israel,
Italy, Netherlands, Norway, Portugal, Spain) had blood drawn for ASCA IgG and IgA, SNP8,
SNP12 and SNP13 (all tests done in Leuven). Days in medical hospitalization (M-days),
days in surgical hospitalization (S-days) and drug use (corticosteroids, immuno-suppressives,
infliximab) were calculated as markers of disease severity. Costs were determined of total
health care, medical hospitalizations (M-hosp), surgical hospitalizations (S-hosp) and drugs.
Data were regarded as parametric and calculated as means, with statistical analysis by
ANOVA. Since health costs are often skewed, the data were also considered as non-parametric
and calculated as medians; this part of the analysis was by Median Test with Yates’ Continuity
Correction. Results are expressed in days or euros per patient-year (€/p-y). RESULTS: Patients
were followed for mean 8.3 [SD 2.6] years. SNP12 positive patients had longer admissions
and greater costs for total, medical and surgical hospitalizations, and drugs than SNP12
negative patients (Table, means). ASCA positive patients had longer surgical admissions and

















greater drug costs than SNP negative patients. SNP8 showed no differences. By Median Test
SNP12 and ASCA retained significance for surgical admissions and cost. CONCLUSIONS:
A positive ASCA test or the presence of the CARD15 mutation SNP12 was associated with
longer and costlier surgical admissions. Genetic mutations and ASCA can forecast more
severe disease and higher costs in Crohn’s disease.
ANOVA: * SNP12 pos vs neg P<0.01, # SNP12 pos vs neg P<0.02, & ASCA pos vs neg P=
0.001, @ SNP13 pos vs neg P<0.05. MEDIAN TEST: ^ SNP12 pos vs neg P<0.05, ^^ ASCA
pos vs neg P=0.001
S1306
99mtc-Infliximab Scans Measure Disease Extent and Activity in Inflammatory
Bowel Disease (IBD)
Guru Iyngkaran, Chris Tsopelas, Suresh Sivanesan, David Hetzel, Francis D.
Bartholomeusz
In IBD there is accumulation of Tumour Necrosis Factor (TNFα) in inflamed bowel that
allows for therapy with anti TNF drugs such as Infliximab. We developed a stable kit of
99mTc labeled Infliximab (99mTc-inf) and demonstrated by in vitro tests with ELISA and
stimulated human lymphocytes that it retained >90% biological activity. In patients with
rheumatoid arthritis there was uptake of 99mTc-inf in inflamed joints but not in normal
bowel. AIM: To measure bowel uptake of 99mTc-inf in patients with active IBD and to
compare this with the extent and severity of inflammation noted on recent colonoscopy,
CT, labeled leukocyte scans and C reactive protein (CRP). METHOD: Subjects with active
IBD were studied. The CRP was measured and Disease Activity Index (DAI) was calculated
for Ulcerative Colitis (UC) and Crohn’s disease (CD). Whole body scintigraphy with SPECT
imaging of the abdomen was performed at 1 and 3 hours following intravenous injection
of 350 MBq of 99mTc-inf (1mg Infliximab). Scans were read blind to clinical information.
The 99mTc-inf uptake was calculated using regions of interest and uptake in inflamed bowel
compared to non inflamed bowel (counts/pixel). Extent of bowel uptake was compared to
colonoscopy, radiology or leukocyte scans. Degree of bowel uptake was compared to CRP.
RESULTS: Ten patients were studied (6 UC and 4 CD). The 99mTc-inf scans showed
uptake in inflamed small and large bowel at 1 and 3 hours. In UC extent of disease on the
scan correlated with colonoscopy in 4 patients. There was 1 under and 1 overestimation.
In CD the scan matched other investigations in 1 patient and there was 1 under and 2
overestimations. Patients with higher CRP had more bowel uptake of 99mTc-inf (p=0.0086).
CONCLUSION: There is specific accumulation of 99mTc-inf in inflamed bowel in IBD
patients. If confirmed in a larger group of patients the scans may have potential to localize
disease, assess activity and possibly predict response to infliximab therapy.
R=Rectum, S=Sigmoid, D=Descending, T=Transverse, A=Ascending, C=Caecum, I=Ileum
S1307
Nodular Regenerative Hyperplasia and Sinusoidal Dilatation of the Liver in a
Non-Thiopurine Using IBD-Cohort
Nanne K. De Boer, Henriette Tuynman, Elisabeth Bloemena, Johan Westerga, Chris J.
Mulder, Miquel A. Cuesta, Stefan G. Meuwissen, Carin M. van Nieuwkerk, Adriaan A.
van Bodegraven
Introduction The use of thiopurines (azathioprine, 6-mercaptopurine and 6-thioguanine)
has been associated with the induction of nodular regenerative hyperplasia (NRH) and
sinusoidal dilatation (SD) of the liver in IBD patients. However, it is unclear whether IBD
itself is not a risk factor in inducing these histological liver abnormalities. Aims & Methods
Between 1977 and 2005 liver histology was obtained from IBD patients, independent of
laboratory results or clinical signs, who underwent gastrointestinal surgery indicated for
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their IBD. The liver biopsy specimens from patients using thiopurines were excluded in
order to asses the prevalence of NRH and SD of the liver in a non-thiopurine using IBD-
cohort from a referral centre. The liver specimens (minimal staining: H&E, reticuline and
Gomorri trichrome) were evaluated by two blinded liver pathologists. Pathohistological
outcomes were related to disease and patient characteristics. Results Eighty-five patients
(M:37%/F:63% and CD:62%/UC:38%) underwent 92 surgical procedures during which liver
tissue (wedge:23%/needle:77%) was obtained. Median age at biopsy was 36 years (range
15-73 years) and median duration of disease was 5 years (range 0-56 years). Severe SD (>
2/3 of the specimen) was observed in 3,3%, moderate SD (1/3 to 2/3 of the specimen) in
8,7%, slight SD (0 to 1/3 of the specimen) in 21,7% and no SD in 66,3% of all biopsies,
respectively. A significant difference was observed in type of IBD when considering both
severe and moderate SD (combined N=12) as a histological relevant abnormality. Significantly
more patients were diagnosed with CD (N=10) compared to UC (N=2) (P=0,022). In addition,
there was a significant difference in gender as relatively more patients, with at least moderate
SD, were male (P=0,012). One liver specimen was excluded for evaluation on NRH as it
was not properly stained. Nodular regenerative hyperplasia was detected in 5,5% of biopsies
(M:2 (2xCD) and F:3 (1xCD)). The age at biopsy was significantly correlated with NRH
(r=-0,256, P=0,014). Conclusion Nodular regenerative hyperplasia (5,5%) and sinusoidal
dilatation of the liver (13% (at least moderate)) were relatively common pathohistological
findings in our non-thiopurine using IBD-cohort. The reported association between thiopur-
ine use and NRH and SD should be weighed against the background prevalence of these
two histological liver abnormalities in the IBD population.
S1308
The TNF/Adam 17 System: Implication of an ADAM 17 Haplotype in the
Clinical Response to Infliximab in Crohn’s Disease
Vinciane Dideberg, Emilie Theatre, Frederic Farnir, Severine Vermeire, Paul Rutgeerts,
Martine de Vos, Jacques Belaiche, Andre van Gossum, Denis Franchimont, Edouard
Louis, Vincent Bours
Infliximab, a chimeric anti-TNF-α antibody induces a clinical response in 70% of Crohn’s
Disease (CD) patients. The response to infliximab therapy could be partially determined by
genetic factors. The implication of both transmembrane and soluble forms of TNF-α in the
mechanism of action of infliximab has been demonstrated. ADAM17 is a member of the
adamlysin family of metalloproteinase that cleaves many membrane proteins, including the
TNF-α. This enzyme thus plays a predominant role in controlling the ratio of soluble TNF-
a versus transmembrane TNF- α, which may be important for the response to Infliximab.
The aim of our work was therefore to explore the role of TNF and ADAM-17 variants in
the response to infliximab in Crohn’s Disease. Patients and methods: the response to inflixi-
mab was evaluated in 222 Caucasian CD patients with a luminal (n = 160) or fistulizing
(n = 62) form of the disease. Clinical and biological responses were based on the evolution
of CDAI score as well as fistulae drainage and CRP levels. The entire TNF gene was sequenced
on the complete cohort. Twelve single nucleotide polymorphisms (SNPs) spanning the
ADAM 17 locus were studied. Haplotype blocks were determined using the Haploview v3.2
software and the haplotypes were rebuilt using Phase v2.1 software. Results: a clinical
response was observed in 64% of the patients and biological response in 77.1% of patients.
We identified 21 SNPs in the TNF gene. No association was found between TNF gene SNPs
or haplotypes and the clinical or biological response to infliximab. One haplotype block
was defined in the ADAM 17 gene, spanning from the rs2001658 to the rs11684747 SNP
(including 11 of the 12 SNPs). One haplotype in this block was associated with a clinical
response to infliximab in CD patients (adjusted P < 0.02). There were 16 patients homozygote
mutant for this haplotype: all had a clinical response and a decrease of at least 40% in CRP
after infliximab. Conclusion: our results exclude, with a reasonable power, any implication
of the TNF gene in the response to infliximab in CD, but reveal a potential role of the
ADAM 17 gene in this response.
S1309
A Translational Strategy Suggests a Future Direction for Inflammatory Bowel
Disease (IBD) Therapy: Changes in Tissue & Cellular Lambda (λ) Isoform of
PKC May Underlie Oxidative Stress & Inflammatory Processes in Intestinal
Mucosa
Ali Banan, Maliha Shaikh, Lijuan Zhang, Ece Mutlu, Ashkan Farhadi, Jeremy Z. Fields,
Christopher B. Forsyth, Ali Keshavarzian
Oxidative injury to gut mucosa is a major pathophysiological mechanism in IBD. Despite
nearly two decades of attempts at preventing &/or reversing IBD flare up, there remains a
lack of effective therapeutic regimes. This is, in turn, due to incomplete understanding of
abnormal intracellular processes that cause IBD. Aims: Using a unique translational strategy
involving both intestinal epithelial cells and mucosal pinch biopsies from patients, we
determined whether: (a) cellular PKC-λ is crucial in oxidative stress-induced iNOS and NO
upregulation and consequent protein oxidation & monolayer instability; (b) activation of
PKC-λ occurs in inflamed IBD mucosa; (c) activity of PKC isoforms correlate with markers
of tissue inflammation & oxidative injury (iNOS, NO, protein oxidation, etc). Methods: We
used tissue pinch biopsies from IBD patients (UC, CD, specific colitis) & normal controls
as well as innovative gut epithelial clones transfected to overexpress PKC-λ or to inhibit its
expression. We monitored barrier integrity of monolayers of intestinal cells, tissue / cellular
protein oxidation, tissue / cellular structural protein stability {e.g., actin}, PKC-λ tissue/
subcellular activity & distribution, iNOS activity / expression, NO levels, cytoskeletal oxida-
tion & nitration. Results: [A] In cells, PKC-λ expression & activation led to oxidative stress-
like conditions including iNOS upregulation, NO overproduction, general protein nitration /
oxidation, structural protein (actin) oxidation & disassembly, & monolayer instability.
Dominant mutant inhibition of cellular PKC-λ activity protected against iNOS and oxidative
stress injury. [B] In tissue IBD biopsies, inflamed mucosa showed increased expression &
activation of the 74 kDa PKC-λ (redistributed into mostly membrane + cytoskeletal mucosal
fractions with only a small cytosolic fraction) as well as increased iNOS upregulation, NO
production, & protein oxidation (carbonylation / nitration), paralleling in vitro findings. In
normal appearing (non-inflamed) IBD mucosa, smaller changes in oxidative markers & PKC-
λ were found. [C] Importantly, both mucosal & cellular PKC-λ activity correlated positively
with oxidative injury &/or with IBD disease severity. Conclusions: These translational findings
based on both in vitro and in vivo conditions indicate a novel pathophysiological mechanism
in IBD. One in which activation of a PKC-λ dependent mechanism is required for cellular
& tissue oxidative injury. If this unique mechanism underlies mucosal inflammation & flare-
up in IBD, it could provide a novel target for future anti-IBD drugs.
S1310
Interaction Between Homocystein Metabolism and TPMT Activity in IBD
Patients Under Azathioprine
Xavier Roblin, Alain Chartier, Veronique Ducros, Gaelle Hardy, Aurelie Durand, Germain
Bessard, Bruno Bonaz
Polymorphism in the methylenetetrahydrofolate reductase (MTHFR) gene is able to modulate
TPMT activity in patients under azathioprine (AZA) (1). Indeed, a defect of methylation, as
represented by hyperhomocysteinemia, can decrease TPMT activity and conversely increase
active AZA metabolite levels, particularly 6-thioguanine nucleotides (6-TGN). Aims: 1) to
compare the prevalence of hyperhomocysteinemia between 2 groups of IBD patients under
AZA. Group A: patients under AZA (dose < 2 mg/kg/d) with a pharmacologic profile which
evokes a MTHFR gene mutation without any identified mutation: low level of methylated
mercaptopurine metabolites (6-MMP+6-meTIMP < 1500 pmoles/8x108 erythrocytes) associ-
ated to a high 6-TGN level (> 550 pmoles/8x108 erythrocytes), twice controlled, without
TPMT gene mutation. Group B: IBD controls. 2) to analyse 6-TGN level modifications after
folate and/or vitamin B12 supplementation. Methods: consecutive IBD patients under AZA
followed in our department between March and September 2005 were included. Homocystei-
nemia, 6-TGN and methylated mercaptopurine metabolites (6-MMP + 6-meTIMP) levels
were systematically evaluated. Patients with TPMT genotype mutation were excluded. Results:
70 patients (20 and 50 in groups A and B respectively) were included (50 CD, 20 UC; mean
age: 41.4 ± 16.2; sex ratio M/W: 0.9). Hyperhomocysteinemia (>15µmol/l) was observed in
18 (90%) and 22 (44%) patients of group A and B respectively (p<0.05). After folate (n=
16) and/or vitamin B12 (n=12) supplementation of the 20 patients (group A), 6-TGN levels
of these patients significantly decreased from 680 ± 120 pmoles to 360 ± 90 pmoles (p=
0.02) while methylated mercaptopurine metabolites increased from 880 ±120 pmoles to
2400 ± 680 pmoles (p=0.04). Conclusion: hyperhomocysteinemia, whatever its origin, is
able to decrease TPMT activity as represented by an increase of 6-TGN levels. In that case,
folate and/or vitamin B12 supplementation decreases 6-TGN levels. These data have potential
clinical implications: a) prevention of 6-TGN myelotoxicity, b) possibility of AZA loss efficacy
after vitamin supplementation, c) systemic evaluation and treatment of hyperhomocysteine-
mia in case of heterozygote TPMT gene mutation. (1) Arenas M et al. Clin Chem. 2005;
51: 2371-2374.
S1311
A Potential Role of Soluble Angiopoietin-2 and Angiopoietin Receptor TIE-2 in
Inflammatory Bowel Disease
Ioannis Koutroubakis, Costas Xidakis, Konstantinos Karmiris, Aekaterini Sfiridaki,
Ermioni Kandidaki, Elias Kouroumalis
Background: Angiogenesis has been suggested to play an important role in inflammatory
bowel disease (IBD). Aim of the present study was to evaluate the serum markers of
angiogenesis angiopoietin-2 (Ang-2) and soluble angiopoietin receptor Tie-2, in patients
with ulcerative colitis (UC) and Crohn’s disease (CD). Methods: Ang-2 and Tie-2 serum
levels were measured in 160 inflammatory bowel disease patients (79 ulcerative colitis and
81 Crohn’s disease) and in 80 matched healthy controls (HC) using commercially available
enzyme-linked immunosorbent assays. Ang-2 and Tie-2 levels were correlated with disease
activity, type, localization and treatment. Results: Median serum Ang-2 levels were signific-
antly higher in both UC patients and CD patients compared with healthy controls
(P<0.05)(Fig 1). Similarly median Tie-2 levels were significantly higher in both UC patients
and CD patients compared with healthy controls (P<0.001)(Fig 2). IBD patients with early
disease (diagnosis during the last two years) had median serum Ang-2 significantly higher
compared with patients with late disease (diagnosis more than two years) (P=0.04). On the
other hand the levels of Tie-2 were significantly lower in patients with early disease compared
with patients with late disease (P=0.02). CD patients with active disease had significantly
higher levels of Ang-2 compared to non-active disease (P=0.02). A significant correlation
between serum Ang-2 and serum Tie-2 levels was found (r=0.19, P=0.01). No other significant
associations of these markers with the disease characteristics were found. Conclusions: Serum
Ang-2 and Tie-2 levels are elevated in patients with inflammatory bowel disease. These data
suggest that these markers may mediate angiogenesis and vascular permeability and may
participate in the restoration of the mucosa of IBD patients. Further studies of these markers
in conjunction with other angiogenesis factors in the gut tissues of IBD patients are needed.
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S1312
Feasibility and Patient Acceptance of a Home Telemanagment System in
Inflammatory Bowel Disease
Raymond K. Cross, Joseph Finkelstein
Introduction: Telemanagement is a telemedicine system designed to assist clinicians treat
and monitor patients according to current guidelines, assist in educating patients, and assist
patients in following self-care plans. Telemanagement has been successfully implemented
in chronic diseases similar to IBD. Our objectives were to test the feasibility and acceptance
of a telemanagement system for IBD (HAT). Methods: HAT consists of a laptop, a weight
scale, and a web portal. The laptop administers questions on symptoms, medical adherence,
medication side effects, delivers an educational curriculum, and measures body weight. The
results are obtained weekly and physicians can view the results on the web portal. Patients
were recruited from the IBD clinic at the University of Maryland and the Veterans Affairs,
Baltimore. Disease activity, quality of life, IBD knowledge, and satisfaction with IBD services
was assessed at baseline and after 6 months. Attitudinal surveys were obtained at the end
of the study. Results: 25 patients completed the 6-month study. 89% of subjects were
adherent with weekly self-testing. Attitudes toward HAT were very good. 95% of subjects
said that self-testing was not complicated. 90% reported that answering the symptom diary
and medication side effects questions were not difficult. Subjects reported that self-testing
took very little time and that testing did not interrupt their usual activities. 70% of patients
felt safer using the system and only 10% of the subjects did not want to use the self-testing
program in the future. At completion of the study, patient satisfaction with IBD care services
was very good. 71% reported that almost all their medical needs were met and 86% reported
that they were very satisfied with their IBD care compared to 40% and 70% respectively at
baseline. Mean self-reported compliance with IBD medications was 90% throughout the
study. Disease activity, quality of life, and patient knowledge improved compared to baseline.
See Table 1. Discussion: HAT can be easily implemented and the technology is feasible and
accepted in patients with IBD. HAT improved patient knowledge and trends to improvement
in disease activity and quality of life were seen. Further studies are needed to determine if
HAT improves outcomes compared to routine care.
Table 1: Improvement in Clinical Outcomes After Use of HAT
S1313
The MDR1 G2677Τ Polymorphism Is Associated with Gastrointestinal
Intolerance to Azathioprine
Konstantinos Katsanos, Marc Ferrante, Marie Joossens, Sofie Joossens, Liesbet Henckaerts,
Marie Pierik, Karolien Claes, Nele van Schuerbeek, Afroditi Katsaraki, Gert van Assche,
Epameinondas V. Tsianos, Paul Rutgeerts, Severine Vermeire
BACKGROUND & AIM: Some of the azathioprine (AZA) side effects are associated with
TPMT gene. We studied if the MDR1 gene is also associated with side effects of AZA in
inflammatory bowel disease (IBD) patients. METHODS: A total of 1815 IBD records were
reviewed for intake of AZA and possible reasons for discontinuation. All patients were
genotyped for TPMT (G238C, G460A and A719G) and MDR1 (G2677T/A and C3435T)
using PCR-RFLP. RESULTS: We identified 775 IBD patients receiving AZA of whom 229
(29.5%) were discontinued (disAZA) (163 Crohn’s and 66 ulcerative colitis), after a mean
of 20.5±24.5 months (range 1 week-129 months). The mean AZA daily dose was
2.16±0.84mg/Kg/day. The main reasons for discontinuation of AZA were inefficacy in 56
(24.4%) and side-effects in 142 (62%) patients (table). The MDR1 G2677T mutation was
more prevalent in the disAZA group (70.3% and 46% T allele frequency) compared to the
AZA tolerant group (63.4% and 39% T allele frequency) [p=0.028, OR 1.59 (95%CI 1.05-
2.41)]. Using multivariate analysis, an independent association was found with gastrointesti-
nal and general intolerance [p=0.009, OR 3.99 (95% CI 1.33-11.93)]. No significant differ-
ences for any of the TPMT variants were found between the AZA and disAZA group. We
also could not find an association between TPMT variants and specific side effects to AZA,
including bone marrow toxicity although the 1 patient developing leucopenia 1 week after
start carried 2 mutations (TPMT*3B/*3C). CONCLUSIONS: In this large retrospective ana-
lysis on the use of AZA in IBD, AZA was discontinued in 24.4% of patients because of
inefficacy and in another 62% due to side effects. Whereas no association was observed for
TPMT variants, patients carrying the MDR1-G2677T polymorphism more often had to

















prospective validation but suggest a role for MDR1/P-gp in the mechanism of action of azathi-
oprine.
S1314
Comparative Study of New Rapid Bedside Fecal Calprotectin Test with An
Established ELISA to Assess Intestinal Inflammation in a Prospective Study
Yogesh Shastri, Nada Povse, Jurgen Stein
Background: Estimation of fecal concentration of the neutrophil granulocyte-derived protein
calprotectin has been proposed as a screening non invasive test to assess intestinal inflamma-
tion of the gut. However, most assays for detecting calprotectin are Enzyme Linked Immuno-
sorbent Assay (ELISA) based thus require a suitable well equipped laboratory i.e. an ELISA
reader, limiting their widespread use because of logistics and higher costs. The biggest
advantages of this new bedside IFOBT are its simplicity, rapidity (needs just about 5 min),
convenience, no need of cumbersome ELISA readers and the fact that it can be performed
at the patient bedside or in physician’s office by any health care personnel. Patients and
Methods: 301 patients (139 males and 162 females) underwent estimation of fecal calprotectin
using a commercial quantitative ELISA (Immunodiagnostik, Bensheim, Germany) and the
rapid bedside test (PreventID® CalDetect, Preventis, Bensheim, Germany), which is a
semiquantitative immunochromatographic rapid test using monoclonal antibodies. There
age ranged from 7 months till 91 years (median being 40 years). The study duration was
from January 2005 till November 2005. Both these tests were performed by an experienced
technician who was blinded to the patient’s clinical profile. As per the manufacturer the cutoff
calprotectin level for both the tests was 15 ng/mL. Results: The patient’s test characteristics as
shown in Table 1. The sensitivity and specificity of the new bedside tests for diagnosing
CD and UC were 96.3 % and 94.0% as against quantitative ELISA of 96.0% and 99% (not
statistically significant) respectively. Conclusion: This new bedside fecal calprotectin assay
has proved to be an accurate, simple, convenient, noncumbersome tool as compared to the
routine ELISA based test and can replace the cumbersome ELISA fecal calprotectin estimation.
Table 1. Test characteristics in 301 consecutive patients
S1315
A Panel of Anti-Glycan Antibodies (gASCA, ALCA, ACCA and AMCA) in the
Diagnosis and Differential Diagnosis of IBD
Marc Ferrante, Marie Pierik, Liesbet Henckaerts, Nir Dotan, Rom T. Altstock, Iris Dotan,
Marie Joossens, Sofie Joossens, Konstantinos Katsanos, Karolien Claes, Nele van
Schuerbeek, Gert van Assche, Paul Rutgeerts, Severine Vermeire
BACKGROUND & AIMS: Serological markers have been proposed in IBD for distinction
between ulcerative colitis (UC) and Crohn’s disease (CD), and also contribute to disease
stratification in CD. Given the sub-optimal accuracy of the available markers in daily clinical
practice, we tested a new panel of antibodies directed against glycan-epitopes in IBD and
controls. METHODS: A total of 1225 IBD patients (913 CD, 272 UC, 40 IC), as well as
200 healthy controls and 113 patients with non-IBD gastrointestinal inflammation (GI-
controls) were tested for Anti Saccharomyces cerevisiae Antibodies (gASCA), Anti-Laminar-
ibioside Carbohydrate Antibodies (ALCA), Anti-Chitobioside Carbohydrate Antibodies
(ACCA) and Anti-Mannobioside Carbohydrate Antibodies (AMCA) by commercially available
ELISA-assays (Glycominds Ltd, Israel) in a blinded way. Using the manufacturers conditions
and reconstruction of ROC curves, a cut-off value of 50 (gASCA), 70 (ALCA) or 90 (ACCA
and AMCA) units was defined for positivity. Based on the antibody titres of gASCA, ALCA
and AMCA a combined serology score (CSS) was computed, ranging from 0 (all 3 markers
negative) to 3 (all 3 markers positive), allowing for intermediate titres (which were given a
score of 0.5). Accuracy (sensitivity, specificity, positive and negative predictive value) of the
individual markers, as well as the combined panel and CSS were calculated using SPSS.
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RESULTS: The accuracy of the individual markers is depicted in table 1 and for the combined
score in table 2. Among the 398 gASCA negative CD patients, 28 were ALCA positive and
50 were AMCA positive. DISCUSSION: Our data show that CD is associated with an adaptive
immune response against various glycan-epitopes. Although all antibodies studied in this
panel have a high specificity for IBD and CD in particular, gASCA is the preferred antibody
given its higher sensitivity. However, the use of a combined serological score, based on
gASCA, ALCA and AMCA, further increased the specificity and may have an additional




The Positivity of Systemic Cytomegalovirus (CMV) Viral Load Is Highly
Predictive of Associated CMV Colitis in Patients Hospitalized for Exacerbation
of Ulcerative Colitis Or Crohn’s Disease with Colonic Involvement
Sophie Buyse, Joel Gozlan, Corinne Amiel, Nadia Hoyeau, Isabelle Nion-Larmurier,
Philippe Seksik, Jacques Cosnes, Jean-Pierre Gendre, Laurent Beaugerie
Latent infection with CMV and Epstein-Barr Virus (EBV) is observed in the majority of
healthy adults. In patients with Crohn’s disease, transient systemic reactivation of EBV
infection may occur in the setting of severe intestinal inflammation and/or treatment by
immunosuppressants [1]. The aims of this pilot study were to assess whether significant
reactivation of systemic CMV infection in patients admitted for active IBD colitis is: i) mostly
observed under immunosuppressant therapy; ii) associated with concomitant reactivation
of EBV infection; iii) predictive of associated CMV colitis. Patients and Methods: Between
January 2004 and October 2005, 33 patients (16 males, 17 females), aged from 16 to 68
years (mean: 36)), admitted for moderate to severe attacks of ulcerative colitis (UC, n=19)
or Crohn’s ileocolitis or colitis (CD, n=14) were studied. All the patients had within the 48
hours following admission a quantification of systemic CMV and EBV viral load by real time
PCR and endoscopic evaluation of colonic lesions with biopsies. CMV inclusions were
searched for by standard histology and immunohistochemistry. Results: The positivity of
CMV viral load (above the level of 400 copies/106 leukocytes, threshold of reproducible
positivity of the technique) was observed in 12 (36%) patients (2(14%) of CD patients vs.
10(53%) of UC patients (p=0.06)). All 12 patients with positive CMV viral load were
receiving high doses of steroids (n=7) or immunosuppressants (n=5) at the time of viral
load determination. Eleven (92%) of the patients with positive CMV viral load had a
concomitant increase (>400 copies/106 leukocytes) of EBV viral load. Eight patients had
CMV colitis; all of them had a positive CMV viral load. The positive predictive value of
CMV colitis in patients with positive CMV viral load was 67%. The negative predictive value
of CMV colitis in patients with negative CMV viral load was 100%. Conclusions: A significant
positivity of systemic CMV viral load (>400 copies/106 leucocytes) at admission of patients
with active IBD colitis: is mostly observed in UC patients receiving steroids or immunosup-
pressants; is associated in most cases with a concomitant reactivation of systemic EBV
infection, suggesting a status of transient immunodeficiency; is highly correlated with the
risk of concomitant CMV colitis. [1] Reijasse D et al. Inflamm Bowel Dis 2004;10: 85.
S1317
Hyperhomocysteinemia, Folate Deficiency, and Carcinogenesis in IBD Patients
Xavier Roblin, Jean Marc Phelip, Veronique Ducros, Jean Luc Faucheron, Bruno Bonaz
In the general population, it is generally admitted that folate deficiency, which induces
hyperhomocysteinemia, increases the risk to develop cancerous or precancerous lesions (1).
To our knowledge, no data are available in IBD patients. Aim: to evaluate, in a cohort of
IBD patients, risk factors of colonic carcinogenesis, in particular folate and homocysteinemia
levels. Methods: IBD patients with carcinogenic lesions discovered under colonoscopy (low
or high grade adenoma, low or high grade dysplasia, colorectal cancers) were included and
compared to the whole population of IBD patients with a normal colonoscopy performed
during the same period. Patients with primary sclerosing cholangitis and/or with a family
history of colorectal cancers were excluded. The following parameters were collected: age,
sex, type-length-activity-extent of the disease, treatment, smoking, vitamin B12-folate-homo-
cysteinemia levels. A univariate analysis and then a multivariate analysis were performed
after adjustment according to the main parameters. Results: 110 patients (37 UC, 73 CD;
mean age: 44.7 years; sex ratio: 1) were included. Twenty two carcinogenic lesions were
isolated: 10 polyps (3 with high grade dysplasia, 7 adenomatous without dysplasia), 6 low
grade dysplasia, 2 high grade dysplasia, 4 colorectal cancers. In univariate analysis, risk
factors of carcinogenesis were: active smoking (p=0.03), folate level < 145 pmol/l (p =
0.011), hyperhomocysteinemia > 15 µmol/l (p = 0.002), length of the disease > 10 years
(p=0.006), UC (p=0.02). In contrast, immunosuppressives, pancolitis, age of onset and
clinical activity of the disease were not risk factors. A high correlation between hyperhomocys-
teinemia, folate deficiency and carcinogenic risk was observed. In multivariate analysis,
patients with hyperhomocysteinemia and folate deficiency had 15 times as much carcinogenic
risk as patients with normal homocysteinemia whatever the folate status and the length of
the disease (p<0.01). Patients with an isolated hyperhomocysteinemia had 2 times as much
carcinogenic risk than patients with normal homocysteinemia whatever the folate status;
however the difference was not significant (p=0.07). Conclusion: our data suggest that in
IBD patients with a normal homocysteinemia, the carcinogenic risk is negligible whatever
the length of the disease. Conversely, in case of hyperhomocysteinemia, folate status is
important to appreciate the carcinogenic risk. Complementary studies on a large scale are
necessary to confirm these data which suggest modifications in the carcinogenic surveillance
in IBD patients. (1) Pufulete M. et al Gastroenterology 2003; 124: 1240-48
S1318
Faecal M2-Pyruvate Kinase; A Novel, Non-Invasive Marker of Ileal Pouch
Inflammation
Matthew W. Johnson, Susan Maestranzi, David H. Dewar, Alastair Forbes, Roy Sherwood,
Paul J. Ciclitira, John R. Nicholls
There is an over expression of the dimeric M2 pyruvate kinase (M2-PK) isoform seen with
the rapid cell turnover of tumour cells. The concentration of this dimeric M2-PK in the
plasma and tumours of patients with gastrointestinal (GI) cancers correlates well with the
staging and metastatic capability of the tumour cells. We postulated that faecal dimeric M2-
PK would also be increased in inflamed ileal pouches with concentration levels correlating
to the degree of inflammation. 54 stool samples were taken from 49 ileal pouch patients.
41 had ulcerative colitis (UC) and 8 had familial adenomatous polyposis (FAP) coli. Pouchitis
was defined as an objective pouchitis score (OPS) of ≥5/12 (endoscopic score of ≥3/6 and
an acute histological score of ≥2/6) or a pouch disease activity index (PDAI) of ≥7/18.
Faecal M2-PK was determined by a quantitative sandwich-type enzyme immunoassay (ScheBo
® Biotech UK). Values of >4 U/ml represent positive results. Statistical analysis was performed
using Mann Whitney unpaired t-test (p values) and Spearman rank coefficient (r values).
The well validated inflammatory bowel marker, faecal Calprotectin, was also measured
(“PhilCal ELISA New Method”, Nycomed Pharma AS). Using the OPS, 6 patients were
diagnosed with UC pouchitis (+ pre-pouch ileitis), 13 had UC pouchitis alone, 27 had a
healthy UC pouch, 1 had FAP pouchitis (+ pre-pouch ileitis) and 7 had an uninflamed FAP
pouch. Respective median M2-PK values (U/ml) for these groups were 49.5, 12, 2.2, 19.5,
and 1, with mean [95% confidence intervals] of 52.7 [6.5-99], 46 [8.6-83.3], 11.4 [2.6-
20.2], 19.5, and 1.4 [0.4-2.3]. Statistically significant differences were noted between the
inflamed and non-inflamed pouches (p<0.0001), but not between pouchitis patients with
and without pre-pouch ileitis (p=0.4) or between healthy UC pouches and non-inflamed
FAP pouches (p=0.4). The M2-PK values correlated significantly with the OPS (r=0.63,
p<0.0001), PDAI (r=0.64, p<0.0001), endoscopy (r=0.56, p<0.0001), acute histological (r=
0.68, p<0.0001) and neutrophil scores (r=0.66, p<0.0001), but poorly with the clinical
score (r=0.22, p=0.1). The receiver operating characteristic analysis demonstrated a sensitivity
and specificity of 70.6% and 80%, respectively. Similar results were seen using the PDAI,
albeit with a slightly lower specificity. The M2-PK and faecal Calprotectin results correlated
closely (r=0.87, p<0.0001). Dimeric faecal M2-PK has become established as a screening
tool for cancer. We have, however, shown that M2-PK is also a novel and sensitive marker
of bowel inflammation, which could prove useful in differentiating between healthy and
inflamed ileal pouches.
S1319
Low Molecular Mass Polypeptide 2 (LMP2) Expression Is Enhanced in the
Intestine of Patients with Inflammatory Bowel Disease
Leo R. Fitzpatrick, Jeffrey Small, Kevin McKenna, Lisa S. Poritz, Walter A. Koltun
Low molecular mass polypeptide 2 (LMP2) is an inducible immunoproteasome subunit that
plays a role in antigen presentation, as well as in the NF-κB signaling pathway. To date,
the expression of LMP2 has not been investigated in patients with IBD. Aims: The primary
goal of this study was to examine LMP2 expression in IBD patients. A secondary goal was
to determine if there was an association between LMP2 expression and histological injury.
Methods: Resected intestinal samples from 19 patients (n = 1 to 5 per patient) were used
in this study. These patients included 5 non-IBD controls (2 colon cancer, 1 constipation,
1 FAP, 1 diverticulitis), 7 patients with Ulcerative Colitis (UC) and 7 patients with Crohn’s
Disease (CD). Intestinal samples were taken from both the colon and ileum. In control
patients, samples were taken from grossly normal areas of the bowel. Samples of intestine
were processed for immunohistohemistry, using a specific polyclonal antibody to LMP2.
The percent area of LMP2 staining was determined on coded slides, with a 25 mm ocular
grid. From the same colonic sections, histology scores were determined on a 0 to 40 point
severity scale. Intestinal LMP2 expression was also determined by western blot, in a subset
of patient samples. Western blots were quantified by a relative densitometry analysis. Results:
LMP2 expression in control patients was confined primarily to epithelial cells in the upper
1/3 of the crypts and on the mucosal surface. In contrast, prominent LMP2 expression was
observed throughout the crypts, as well as in leukocytes within the lamina propria and
submucosa. By histochemistry, percent LMP2 expression values were: 17 ± 2 (control), 45
± 2 (UC) and 52 ± 3 (CD). Overall, the percent intestinal LMP2 expression in IBD patients
was significantly greater (p < 0.01) than in the control patients. In specific areas within the
colon (proximal, mid, distal), LMP2 expression was always significantly greater in patients
with IBD. Similarly, enhanced expression of this proteasome subunit was found in the ileum
of patients with CD. Interestingly, increased intestinal LMP2 expression (36%) was found
in macroscopically normal areas from IBD patients. Western blot analysis confirmed that
intestinal LMP2 expression was enhanced in patients with IBD. Specifically, LMP2 was
increased by 3.2 fold in UC patients and 4.0 fold in CD patients. A significant correlation
(r = 0.674, p = 0.0016) was found between LMP2 expression and histological damage in
these 19 patients. Conclusions: Enhanced LMP2 expression was evident in the intestine of
IBD patients. LMP2 may be a potential marker for predicting and/or following the severity
of IBD.
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S1320
High Prevalence of Sarcopenia in Patients with Crohn’s Disease: Association
with Osteopenia
Rima Al-Jaouni, Jerome Filippi, Stephane M. Schneider, Xavier Hebuterne
Rationale: Reduction of bone mineral density (BMD) is frequent in patients with Crohn’s
disease (CD) and is associated with an increased risk of fractures. Many factors that are
known to be associated with osteopenia are also known to decrease muscle mass. The aim
of the present study was to evaluate the prevalence of sarcopenia in patients with CD in
remission, and to determine if sarcopenia was associated with osteopenia. Methods: 67 CD
patients (CDAI<150; CRP<10mg/L) (37F/30M; 37±13 years; BMI 21.2±3.6), and 39 volun-
teers (24F/15M; 40±14 years; BMI 22.1±2.4) have been studied. Appendicular muscle mass
(AMM) and BMD were measured by using DEXA (Hologic). BMD was expressed as g/cm2
and T score. The number of patients with osteopenia was assessed according to the WHO
classification. AMM was expressed in absolute (kg), and prevalence rate of sarcopenia was
determined according to the following definition: AMM/ht2 < young normal minus 2 SD.
Results: AMM was lower in patients than in controls (6.0±1.1 vs. 6.4±1.1; P=0.02). A positive
correlation was found between AMM and BMD (r=0.50; P=0.0001). Prevalence of sarcopenia
was 61.2% (19M/22F) in patients and 20.0% (4M/4F) in controls (P<0.01). Prevalence of
osteopenia was 30.0% in patients and 5.1% in controls. The prevalence of osteopenia was
43.0% in patients with sarcopenia, and 8% in patients without sarcopenia (P<0.001). BMI
was lower (P<0.05) in patients with sarcopenia (20.4±3.7) than in patients without sarcopenia
(22.5±3.0) ; a negative correlation was found between AMM and disease duration (r=0.27,
P=0.03) but not with treatments. Conclusions: The prevalence of sarcopenia is high in young
patients with CD. Sarcopenia is strongly associated with osteopenia. These two phenomena
may have synergic deleterious effects and may share similar mechanisms. Our findings
suggest that the routine determination of both BMD and AMM by DEXA may be helpful in
CD patients
S1321
Whole Blood Gene Expression Differentiates Between Active Disease and
Remission in Patients with Crohn’s Disease
Robert Burakoff, Scott Hande, Sonia Friedman, Frederick Makrauer, Peter Banks, Martha
Vander Vliet, S Mohr, C.C. Liew
Introduction: Current methods for determining disease activity in patients with Crohn’s
disease are invasive, time-consuming, and non-specific. A blood test serving as a surrogate
marker for disease activity is desirable. The differential expression of RNA in whole blood
has been used in previous studies to discriminate between disease states unrelated to IBD.
Since circulating blood cells are exposed to the inflammatory mediators of active Crohn’s
disease, their pattern of gene expression may be surrogate markers for Crohn’s disease
activity. Methods: 38 patients with documented Crohn’s disease were enrolled. CDAI scores
were obtained, as well as total RNA extracted from 10 mL of whole blood. Remission was
defined as a CDAI<150. Affymetrix U133Plus 2.0 GeneChips (Chondrogene) were used to
screen RNA samples for genes differentially expressed between patients with active Crohn’s
disease and patients with disease in remission. These gene arrays were also compared with
those of 9 healthy controls. Chip interpreters were blinded to diagnosis and disease activity.
Logistic regression analysis was used to identify linear combinations of genes that displayed
significant changes in expression level by quantitative RT-PCR. Results: 22 patients had
Crohn’s disease in clinical remission (CDAI range -7-145), and 16 patients had active Crohn’s
disease (CDAI range 155-568). A pattern of differential RNA expression distinguishing active
Crohn’s disease from both remission and healthy controls was seen on the basis of 108
genes (p<0.01). Among the genes with reduced expression in active Crohn’s were those for
occludin (p=0.003) and integrin a4 (p=0.007). The genes encoding vimentin and b-glucosid-
ase were among those over-expressed (both p<0.001). Gene expression patterns and CDAI
scores correlated poorly within the subgroup of 16 patients with active disease. Two distinct
gene expression patterns were seen in patients with Crohn’s in remission. The clinical
distinction between these remission groups remains to be determined. Conclusion: The
pattern of gene expression in circulating blood cells is different in patients with active
Crohn’s disease compared with patients in remission and healthy controls by cluster analysis.
Several of the genes aberrantly expressed in patients with active disease have previously
been implicated in the pathophysiology of Crohn’s disease. Gene arrays of circulating blood
cells may provide surrogate markers for disease activity, as well as identify inflammatory
mediators in patients with Crohn’s disease. Whole blood gene array may also be useful for
predicting disease behavior or response to therapy in Crohn’s disease.
S1322
Biomarkers for Visilizumab Therapy of Intravenous Steroid Refractory
Ulcerative Colitis (IVSR-UC)
Jacky Woo, James Sheridan, Stephen Keller, Jordan Hiller, Yu L. Chang, James Lowder,
Vladimir Vexler
Background: Visilizumab (Nuvion®), a humanized low FcR-binding IgG2 anti-CD3 mono-
clonal antibody, is currently being tested for the treatment of IVSR-UC. In clinical studies
to date ~60% IVSR-UC subjects have responded to visilizumab treatment. Clinical responses
are durable and persist long after visilizumab is cleared from the circulation. In this study,
potential associations between clinical response and an array of possible blood biomarkers
were evaluated. Methods: As part of a phase I/II dose range-finding study of visilizumab in
IVSR-UC, IV bolus doses of visilizumab were administered on day 1 and day 2 at 5, 7.5,
10, or 12.5 mg/kg dose. Treated subjects with a MTWSI score that dropped below 10, with
at least a 3 points decline, were classified as responders. Absolute numbers of CD3+CD4+
and CD3+CD8+ T cells, CD3-CD56+CD16+ NK cells and CD3-CD19+ B cells were measured
by flow cytometry (TruCOUNTÔ). Serum cytokines, chemokines, and growth factors were
measured using a validated 16-plex Luminex assay. Cell-mediated immunity (CMI) was
assessed with ImmuKnowTM assay (Cylex®), which reflects the immuno-competence of

















responded to treatment. No statistically significant associations of response with respect to
changes in CD3+CD4+ T, NK and B cell counts, or CMI were observed. In contrast, absolute
CD3+CD8+ T cell counts were significantly higher on Day 30 in the responder group
compared to non-responders. In addition, an increase in absolute CD3+CD8+cell counts
on Day 30 was associated with improvement in mucosal healing. Although levels of many
cytokines, chemokines, and growth factors were elevated in the first hours after visilizumab
dosing, only IP-10 demonstrated a sustained increase. Further, between days 30 and 60
post-treatment, serum IP-10 levels were significantly higher in responders compared with
non-responders. Conclusion: Increases in peripheral CD8+ T cell counts and serum IP-10
levels are observed long after visilizumab is cleared from the circulation and are associated
with clinical response to visilizumab in IVSR-UC subjects. These efficacy biomarkers could
be associated with durable clinical response to visilizumab and will be further evaluated
with the aim of better understanding the mechanism of visilizumab.
S1323
A High Level of Methylated Mercaptopurine Metabolites Is a Cause of
Myelotoxicity in IBD Patients Under AZA/6-MP
Xavier Roblin, Alain Chartier, Joanna Pofelski, Gaelle Hardy, Germain Bessard, Bruno
Bonaz
High levels of methylated mercaptopurine metabolites (6-methyl mercaptopurine: 6-MMP;
6-methylthioinosine monophosphate: 6-meTIMP) are potentially involved in AZA/6-MP
hepatotoxicity or myelotoxicity (1,2). Aim: to evaluate in a cohort of IBD patients under
AZA/6-MP if the levels of 6-thioguanine nucleotides (6-TGN) or methylated mercaptopurine
metabolites are correlated with hepatotoxicity or myelotoxicity of the compounds. Methods:
consecutive IBD patients under AZA/6-MP followed in our department between March and
September 2005 with 6-TGN and total methylated mercaptopurine metabolite (6-MMP and
6-meTIMP) dosages were included. Hepatotoxicity was defined as transaminases > 3N and/
or alkaline phosphatases > 3N and/or GammaGT > 3N. Myelotoxicity was defined by a
leucocyte count < 3000/mm3 and/or neutrophils < 1500/mm3 and/or platelets < 100 000/
mm3. AZA/6-MP imputability was retained after elimination of the other causes. Patients
with TPMT gene mutation, either homo- or heterozygote were excluded. Results: 66 patients
(20 UC, 46 CD; median age: 42.6 years, sex ratio: 1) were included. Fifteen cases of
myelotoxicity were observed (10 leucopoenia, 7 neutropenia, and 2 thrombopenia). If the
median 6-TGN level (pmoles/8x108 erythrocytes) was comparable in the groups of patients
with and without medullary involvement [374 pmoles (260-620) vs 352 pmoles (230-
580); p=ns], methylated mercaptopurine metabolite levels (pmoles/8x108 erythrocytes) were
significantly higher in case of myelotoxicity [16450 pmoles (3922-26680) vs 4750 pmoles
(1980- 8420); p=0.03]. After logistic regression on the following parameters: age, sex,
IBD type, 6-TGN and methylated mercaptopurine metabolite levels, only a methylated
mercaptopurine metabolite level > 10000 pmoles was isolated as a risk factor of myelotoxicity
[OR: 18.5; IC95: 1.7-220; p=0.025]. Four cases of hepatotoxicyty were observed without
any relation with 6-TGN and/or methylated mercaptopurine metabolite levels. Conclusion:
a high level of methylated mercaptopurine metabolites (6-MMP and 6-meTIMP > 10000
pmoles/8x108 erythrocytes) is highly associated (x18) with myelotoxicity in IBD patients
under AZA/6-MP. Consequently, early monitoring of methylated mercaptopurine metabolites
should be of interest to isolate high-risk patients. (1) Dubinsky M et al. Gastroenterology
2000; 118: 705-713. (2) Hindorf U et al. Gut 2005 (in press).
S1324
Immunomodulatory Therapy with Azathioprine Is Accompanied By a 28-Fold
Increase in Concentrations of Mucosal Bacteria in Patients with Ulcerative
Colitis and Indeterminate Colitis
Alexander Swidsinski, Yvonne Doerffel, Vera Loening-Baucke, Laura P. Hale, Franz
Theissig, Hartwig Andree, Herbert Lochs
Background: The efficacy of the immunosuppressant drugs azathioprine and 6-mercaptopur-
ine has been well established in the therapy of inflammatory bowel diseases (IBD). However,
its use has been complicated by a high incidence of serious adverse drug reactions such as
bone marrow and liver toxicity, pancreatitis and gastrointestinal disturbances. The impact
of azathioprine on the mucosal flora is unknown. Aims: To compare the concentrations and
spatial organization of mucosal bacteria in IBD patients treated with azathioprine and/or 5-
aminosalicylic acid (5-ASA) using fluorescence in situ hybridization with 16S rRNA-targeted
probes. Methods: The mucosal bacteria were investigated in multiple colonoscopic biopsies
from patients with ulcerative colitis or indeterminate colitis. Three different theraputic
regimes were compared: azathioprine alone (n=20), azathioprine plus 5-ASA (n=20), and
5-ASA alone (n=20). The groups did not differ in age, gender, disease duration, or concomitant
prednisolone treatment. None of the patients had a history of antibiotic treatment in the
last 12 months. Results: A steady increase in concentrations of mucosal bacteria (p<0.001),
the percent of the intestinal surface covered with adherent biofilms (p<0.001), and the
amenability of mucosal bacteria to FISH (a measure of ribosomal content and thus metabolic
activity) (p< 0.01) was seen in patients treated with azathioprine alone compared to those
treated with 5-ASA alone The concentrations of adherent Bacteroides and Enterobacteriaceae
was also higher in azathioprine-treated groups (74% versus 52%). Despite this increase in
bacteria, the histological signs of the inflammation and the number of leukocytes within
mucus was lower in azathioprine treated patients. The combined azathioprine/5-ASA group
took an intermediate position for all investigated parameters. Conclusions: Azathioprine
treatment effectively controls inflammation in IBD but has minimal to no influence on the
disturbed mucosal flora that is characteristic of IBD. Future longitudinal studies are in
progress to determine whether azathioprine treatment may enhance the development of
adherent bacterial biofilms by suppressing the local inflammation.
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S1325
Bowel Sonography for the Diagnosis and Grading of Post-Surgical Recurrence
of Crohn’s Diseas
Antonio Rispo, Luigi Bucci, Francesco Sabbatini, Giovanni de Palma, Roberto Grassia,
Alessandro Compagna, Anna Testa, Dario D'Antonio, Fabiana Castiglione
BACKGROUND: Post-surgical recurrence (PSR) is very common in patients with Crohn’s
disease (CD) and previous surgery. Endoscopy is crucial for the diagnosis of PSR, also
showing high prognostic value. Bowel sonography (BS) is accurate for CD diagnosis but its
role in PSR detection and grading is poorly investigated. AIM: to evaluate the diagnostic
accuracy of BS for PSR compared to the endoscopical Rutgeerts’s grading system. PATIENTS
AND METHODS: From March 2002 to October 2005 we prospectively performed endoscopy
and BS in 45 CD patients with previous bowel resection to gain evidence of possible PSR.
Endoscopy and BS were executed 1 year after surgery, with PSR diagnosis and grading made
in accordance with Rutgeerts’s. BS was considered suggestive for PSR in presence of bowel
wall thickness (BWT) > 3 mm. Diagnostic accuracy was calculated by StatsDirect software.
Also, a ROC curve was constructed in order to define the best cut-off of BWT to discriminate
mild from severe PSR (grade 0-2 vs 3-4 of Rutgeerts’s). Cohen’s k measure was applied to
test the consistency between endoscopy and BS for the grading of PSR. RESULTS: 24 out
of the 45 CD showed an endoscopical evidence of PSR (53%). A severe PSR was present
in 16 patients (66%). Sensitivity, specificity, positive and negative predictive values of BS
were 80%, 93%, 92% and 80%, respectively. All the patients with a false negative BS
presented a mild PSR at endoscopy. On ROC curve, a BWT > 5 mm showed sensitivity,
specificity, positive and negative predictive values of 94%, 92%, 90% and 96% for the
diagnosis of severe PSR, with a remarkable agreement with endoscopy (k=0.89). CONCLU-
SIONS: BS shows good sensitivity and high specificity for the diagnosis of PSR in CD, with
a BWT > 5 mm strongly indicative of severe endoscopical PSR. Accordingly, BS could replace
endoscopy for the diagnosis and grading of PSR in many cases.
S1326
Effectiveness of Darbepoetin Alfa in Combination with Intravenous Iron
Sucrose in Patients with Inflammatory Bowel Disease and Refractory Anemia
Ioannis Koutroubakis, Konstantinos Karmiris, Sokratis Makreas, Costas Xidakis, Georgia
Tsiolakidou, Elias Kouroumalis
Background: The combination of intravenous iron and recombinant human erythropoietin
(EPO) has been proved to be effective in the treatment of refractory anemia in patients with
inflammatory bowel disease (IBD). Darbepoetin alfa (DPO) has a three fold longer terminal
half-life than EPO. The purpose of this pilot study was to determine whether DPO is also
effective for the treatment of refractory anemia in IBD. Methods: As cases with refractory
anemia were considered patients who had received one course of intravenous iron sucrose
(mean total iron dose 1.2±0.4g) with poor response (no increase of hemoglobin, or
increase<2.0 g/dl) during a six month of follow up. Twenty IBD patients (9 ulcerative colitis
and 11 Crohn’s disease) and refractory anemia received intravenous iron sucrose (total iron
dose 1.3±0.5g, range 0.7-1.9) and DPO at the single, weekly dose of 0.9μg/Kg s.c. for 4
weeks. Serum erythropoietin, ferritin, tranferrin, soluble tranferrin receptor (sTfR), C-reactive
protein and interleukin 6 (IL-6) were measured at baseline and after treatment. Results:
Hematopoietic response (increase of hemoglobin > or = 2.0 g/dl) was observed in 15 out
of the 20 patients (75 %). The mean hemoglobin concentrations increased from 9.48±0.82
g/dl at baseline to 12.71±1.12 g/dl after treatment (P<0.0001). Mean corpuscular volume
(MCV) and serum ferritin levels were also significantly increased whereas mean CRP levels
and endogenous erythropoietin levels significantly decreased after treatment (P<0.05). CRP,
IL6 and ferritin levels were higher in responders compared to non-responders. However,
the differences did not reach statistical significance due to the small number of non-respond-
ers. Patients on therapy with infliximab had also a trend for a prompt response but the
difference compared to patients without infliximab was not statistically significant
(P>0.05).DPO treatment was well tolerated without adverse events. Concerning iron treat-
ment only one patient experienced an adverse event (facial rash). Conclusions: Our results
suggest that darbepoetin, in conjunction with intravenous iron sucrose, may be of use in
patients with inflammatory bowel disease and severe anemia refractory to iron therapy. The
use of darbepoetin at higher doses might be more effective than in the present study.
Further randomized studies directly comparing darbepoetin alfa with recombinant human
erythropoietin for the treatment of refractory anemia in IBD should be conducted.
S1327
Hepatotoxicity of Long-Term and Low-Dose 6-Thioguanine in IBD Patients
Nanne K. De Boer, Lennard P. Gilissen, Luc J. Derijks, Gijsbertus Den Hartog, Berend D.
Westerveld, Leopold G. Engels, Adriaan A. van Bodegraven, Elisabeth Bloemena, Chris J.
Mulder
Introduction Initial data on short-term efficacy and toxicity of 6-thioguanine (6-TG) in IBD-
patients who were intolerant or refractory to azathioprine (AZA) or 6-mercaptopurine (6-
MP) were promising, however these have been challenged by recent reports concerning its
potential hepatotoxic effect (nodular regenerative hyperplasia (NRH) and veno-occlusive
disease (VOD)). Nonetheless, the hepatotoxicity of 6-TG may be a dose-dependent phenom-
enon. Aims & Methods In the Netherlands 6-TG therapy was generally initiated in a standard
dosage of 20 mg/day, which is significantly lower than reported dosages in literature (40
to 80 mg/day). We conducted a study in IBD-patients treated with 6-TG for at least 30
successive months to evaluate liver histology, its relationship with 6-TG use, laboratory
parameters (including 6-TGN measurements and TPMT genotyping), and abdominal ultra-
sonography. Results Thirty patients (F:13/M:17 and CD:17/UC:13) underwent a liver biopsy
after using 6-TG (median dosage 20 mg) for a mean period of 39 months (range 30-53
months). 6-TG therapy was initiated due to intolerance to AZA/6-MP (N=26), de novo (N=
3) and refractory to AZA/6-MP (N=1). No clinically relevant changes in liver tests and whole
blood counts (no thrombocytopenia) were observed over time. The mean 6-TGN level was
580 pmol/8x10E8 RBC (SD 296, range 106-1199). TPMT genotyping (N=21) revealed only
one patient with a mutant TPMT allele (6-TGN: 1092 pmol/8x10E8 RBC). Ultrasonography
showed two cases of steatosis (7%), but no splenomegaly. The mean cumulative dose of 6-
TG was 22645 mg (range 12150-44400 mg). Histological evaluation revealed: no abnormalit-
ies (N=15, 50%), slight regenerative changes (N=7, 23%), slight steatosis (N=3, 10%), slight
fibrosis (N=2, 7% (1 x alcohol abuse)), suspicion of VOD (N=1, 3%), steatosis+mild fibrosis
(N=1, 3% (apparently NASH)) and primary sclerosing cholangitis+hemochromatosis (N=1,
3%). No cases of NRH were detected. The 6-TGN level, cumulative dose and TPMT status
were not correlated with pathohistological findings. Conclusion In the majority of this cohort
of IBD-patients, long-term use of low-dose 6-TG (20 mg/day) did not induce clinically
relevant histological liver abnormalities. Hepatotoxicity due to 6-TG use may indeed be
dependent on the dosage of 6-TG. Nonetheless, rigorous and frequent monitoring (including
a liver biopsy) of IBD patients using low-dose 6-TG as a rescue drug remains mandatory.
S1328
Endoscopic Scores of Postoperative Recurrence in Crohn’s Disease: A
Reproducibility Study
Philippe Bulois, Hugues Coevoet, Laurence Martin, Jean-Yves Mary, Yoram Bouhnik,
Arnaud Bourreille, Guillaume Cadiot, Franck Carbonnel, Benoit Coffin, Bernard Duclos,
Jean-Louis Dupas, David Laharie, Edouard Louis, Philippe Marteau, Jacques Moreau,
Jean-Claude Soule, Jean-Frederic Colombel, Marc Lemann, Getaid The
Assessment of endoscopic activity is of growing importance in Crohn’s disease (CD) both
in clinical practice and in therapeutic trials. The Rutgeerts’s score (RS) is considered as the
standard to evaluate endoscopic recurrence after surgery. The Crohn’s Disease Endoscopic
Index of Severity (CDEIS) is a prospectively developed and validated score widely used in
CD trials, but not in this specific setting. The aim of this prospective study was to compare
the two scores and to evaluate their reproducibility in assessing postoperative (po) endoscopic
recurrence. Methods. Endoscopic data of 72 patients participating in two multicentre random-
ized clinical trials for the prevention of endoscopic recurrence after curative ileocolonic
resection were used for the purpose of this study. During each procedure, endoscopic
recurrence was graded using the RS ranging from i0 (no lesion) to i4, and the po-CDEIS
was calculated for two segments (ileum and anastomosis). Endoscopies were recorded on
videos in 39 patients, and each record was re-evaluated by 4 of 13 independent blinded
observers using a balanced incomplete block randomization. The reproducibility of the two
scores was calculated using the kappa estimates for the RS (agreement was considered as
poor, moderate, good and excellent for kappa coefficients <0.4, 0.4-0.6, 0.6-0.8 and >0.8,
respectively), and the intraclass correlation coefficient for the po-CDEIS. Results. In the
whole population (n=72), a significant correlation was found between the RS grade and the
median po-CDEIS score (p<0.001), but with overlap, especially for the i2 and i3 grades. In
the subset of 39 patients used to assess the interobserver reproducibility, the kappa estimates
were 0.51 (95%CI: 0.38-0.64), 0.16 (0.02-0.20), 0.40 (0.30-0.50), 0.19 (0.03-0.35), and
0.72 (0.61-0.83) for the i0, i1, i2, i3 and i4 grades of the RS, respectively. The kappa
estimate was 0.57 (0.43-0.71) for the RS globally, 0.45 (0.23-0.66) for a score>i1, and 0.64
(0.44-0.83) for a score >i2. The intraclass correlation coefficient for the po-CDEIS was 0.52
(95%CI: 0.36-0.67; p<0.001). Conclusion. The Rutgeerts score and the po-CDEIS correlate
for assessment of endoscopic postoperative recurrence but the reproducibility of the two
scores is moderate. Definition of endoscopic recurrence based on the sole use of a cutoff
value is questionable.
S1329
Inherent Resistance to 6-Thioguanine (6-TG) Induced Apoptosis Correlates
with Disease Activity in Children with IBD
Ryan S. Carvalho, James A. Mahoney, Maria M. Oliva-Hemker, Carmen Cuffari
Introduction: The pathogenesis of IBD may represent an inherent failure to suppress the
normal immune response (Neurath et al. Trends in Immunology 2001) to antigenic stimula-
tion. Although most immunosuppressive drugs, including azathioprine are purported to
facilitate drug induced T-lymphocyte apoptosis in adult patients with Lupus and IBD, there
is little data in children (Ringheanu et al. IBD 2004). Aim: To demonstrate the inherent
resistance of peripheral T-cell lymphocytes to 6-TG induced apoptosis in children with IBD
compared to healthy volunteers. Methods: Peripheral blood was collected in CPT Ficoll
tubes. PBMCs were isolated and suspended in RPMI 1640 at a concentration of 1million
cells/ml. Cells were then stimulated with Concovin A at a concentration of 5mcg/ml and
incubated with 6TG (6 mcM) for 72-96 hours (Tiede et al. J Clin Invest 2003). Simultaneous
controls were incubated without the drug. Only double positive cells for Annexin V PE for
PS and TOPRO-3 for DNA were quantified as positive for apoptosis. The cells were also
gated for CD3 after staining with FITC-CD3. Results: The mean (SEM) percentage of apoptosis
was significantly (p<0.004) higher in healthy volunteers [31.7 (3.6)] compared to children
with IBD [13.4 (0.9)] at baseline, and after in vitro exposure to 6TG [59.4 (6.2) vs 47 (4.5),
p<0.05). This trend of apoptosis was also mirrored by CD3 gated Annexin V positive T
lymphocytes and was also shown to be higher than that observed in adult patients with
IBD (Fig.1). Conclusions: Inherent resistance to apoptosis may explain the immune pathogen-
esis of IBD in children. While inter-patient differences in 6-TG induced T-cell lymphocyte
apoptosis may correlate with clinical responsiveness to azathioprine therapy, future studies
are needed to determine if the current trend in starting anti-metabolite therapy sooner
correlates with an overall improved maintenance of clinical response.
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IgM Anti α-Enolase Antibody As a Serologic Marker in Patients with Intestinal
Bechet’s Disease: Relation to Clinical Course
Sung Jae Shin, Tae Il Kim, Byung Chang Kim, Sooyoung Park, Jae Yong Jang, Kwang
Hoon Lee, Chang Hwan Choi, Won Ho Kim
Background/Aim: Intestinal Behcet’s disease (BD) is a chronic inflammatory bowel disease
such as Crohn’s disease (CD) and ulcerative colitis (UC). But, unlike CD (ASCA) and UC
(pANCA), a serologic marker for intestinal BD is not well known. Recently, IgM anti α-
enolase antibody, one of the anti-endothelial cell antibodies, was detected in sera of BD
patients. It serves as a plasminogen receptor on the surface of endothelial cells, and modulates
pericellular and intravascular fibrinolysis. The aim of this study is to evaluate the prevalence
of IgM anti α-enolase antibody in patients of intestinal BD and inflammatory bowel disease,
and it’s clinical correlations. Methods: One hundred patients with intestinal BD, 100 patients
with Crohn’s disease, 100 patients with ulcerative colitis and 23 healthy controls were
included for serologic test. IgM anti α-enolase antibody was detected by ELISA. The positivity
of IgM anti α-enolase antibody was defined as an optical density greater than the mean plus
3SD for the 23 normal control sera. In 80 patients with intestinal BD, who were followed
for mean 88.8 months after the diagnosis, the various parameters such as demography,
subtype of BD, colonoscopic findings and treatment modality were collected from medical
records retrospectively. Because there was no activity index for intestinal BD, the Harvey-
Bradshaw index (HBI) for CD was used for disease activity estimation of intestinal BD.
Results: The prevalence of IgM anti α-enolase antibody was 63% in intestinal BD, 31% in
Crohn’s disease, 40% in ulcerative colitis and 0% in healthy controls. The positivity rate of
IgM anti α-enolase antibody was significantly higher in female patients with intestinal BD
(male vs. female; 57.4% vs. 81.8%, p=0.022). Also, it was higher in complete or incomplete
BD than suspicious BD (77.5% vs. 51.6%, p= 0.033). IgM anti α-enolase antibody (+)
patients had higher mean HBI score than (-) patients (5.60 vs. 4.61, p=0.003) and the level
of IgM anti α-enolase antibody correlated with the HBI score (r=0.224, p=0.046). Steroid
treatment and cumulative steroid use rate for intestinal as well as extra-intestinal lesions
were higher in IgM anti α-enolase antibody (+) patients than (-) patients ([81.5% vs. 53.8%,
p=0.031], [p=0.022], respectively). However, there was no correlation between IgM anti α-
enolase antibody expression and the frequency of intestinal operation due to disease flare-
up. Conclusions: Prevalence of IgM anti α-enolase antibody was 63% in intestinal BD.
Patients with IgM anti α-enolase antibody-positive intestinal BD showed higher disease
activity and steroid use rate.
S1331
Crohn’s Disease in Pregnant Women and Nursing Mothers: Which Drugs Are
Safe? A Multidisciplinary European Expert Panel (EPACT)
Christian Mottet, Pascal Juillerat, Christian Felley, Vincent Wietlisbach, Valerie Pittet,
Jean-Jacques Gonvers, Robert W. Dubois, John-Paul Vader, Bernard Burnand, Florian
Froehlich, Pierre Michetti
Introduction: High-grade evidence (randomized controlled trials) is lacking regarding the
use of drugs in pregnant and nursing Crohn’s Disease (CD) patients. Explicit panel-based
safety criteria may therefore provide the best available alternative for clinical decision-making.
Methods: An international multidisciplinary expert panel (EPACT, European Panel on the
Appropriateness of Crohn’s Disease Therapy) from 12 European countries (10 gastroenterolo-
gists, 3 surgeons, 2 general practitioners) convened in Lausanne, Switzerland, to judge the
appropriateness of CD therapy, including safety of therapy for pregnant CD patients, using
a combined evidence- and panel-based method (RAND Appropriateness Method). Treatment
options for CD in these patients before conception and in the first trimester, in late pregnancy,
as well as during nursing, were submitted to the panelists for an individual rating on a 9-
point scale: 1 = very unsafe, 9 = extremely safe. For the analysis, a median of 7-9 was
considered as safe (S); 4-6 equivocal (E); 1-3 unsafe (U). Results: Panel results are shown
in the following table with the FDA pregnancy categorization of drug risk to the fetus in
the last column, from “Category A” = safest to “Category D” = fetal risk. Conclusion:
Mesalazine, sulfasalazine and prednisone were considered safe during pregnancy and nursing.
The panel position was, however, cautious and mainly based on label recommendations
despite an accumulation of evidence from databases on the safety of AZA/6-MP and infliximab
before conception and during the first trimester. These safety criteria are freely available on

















*from the end of the first trimester. NB: methotrexate (FDA category X, demonstrated
teratogenicity) was considered contraindicated and was therefore not subjected to vote.
S1332
Visilizumab Treatment Promotes Morphological Recovery, Reduces
Inflammatory Markers and Affects T Cell Subsets in Mucosa of Ulcerative
Colitis Patients
Lili Zhang, Mien Sho, Mian Su, Jim Lowder, Jacky Woo, Debbie Law
Introduction: In the 291-408 open-label Phase I/II trial, ~ 60% of subjects with intravenous
steroid refractory ulcerative colitis (IVSR-UC) improved upon treatment with visilizumab,
a humanized anti-CD3 antibody. The effects of visilizumab treatment on morphology and
inflammatory cells/marker expression in the mucosa of subjects were assessed. Methods:
Subjects with endoscopically diagnosed UC and an MTWSI > 11 who failed to respond to
at least 5 days of i.v corticosteroids were eligible for the study. Response was defined as an
MTWSI less than 10 with a drop of at least 3 points. Colonic biopsies were collected at
baseline and Day 30. Formalin-fixed samples from 14 subjects underwent blinded histological
evaluation. Hemotoxylin & eosin-stained sections were scored using a system that assesses
both morphological changes and the severity of inflammation. Immunohistochemistry (IHC)
was used to examine the expression of inflammatory markers and cell types in serial sections
stained with antibodies specific for Ki67, STAT1, CXCR3, NFkB, CD3 and CD8. Results:
Histological and morphological changes associated with inflammation (such as increased
numbers of mononuclear cells (MNC) and neutrophils, crypt destruction, and the presence
of ulcers/erosions), were present in all baseline biopsies. By Day 30, biopsies from 9 of 11
clinical responders showed histological improvement, with mucosal healing observed in 2
of 11 subjects. No histological improvement was observed in 3/3 samples from non-respond-
ers. Based on a qualitative evaluation, the expression of inflammatory markers was decreased
in Day 30 samples from most responders. Ki67, a marker of proliferating cells showed the
greatest reduction. In contrast, biopsies from all 3 non-responders showed increased or
unaltered staining for inflammatory proteins. Further analysis of the T cells present within
the biopsies showed that CD3+ T cell numbers were reduced in the majority of responders
but remained static or increased in the 3 non-responders. Interestingly, the percentage of
the remaining T cell population that was CD8+ increased after treatment with visilizumab
but only in responders. Conclusions: The histological evaluation of biopsy samples pre and
post-visilizumab treatment demonstrates a decrease in histological disease activity in the
majority of clinical responders. Clinical response to visilizumab also coincides with reduction
of mononuclear cell proliferation in the lamina propria (assessed by Ki67 staining); reduction
in other inflammatory markers; and a relative increase of CD8+ cells within the remaining
CD3+ T cell population in the colonic mucosa.
S1333
Validation of the New “Phical” Faecal Calprotectin Test As a Diagnostic Tool
for Pouchitis
Matthew W. Johnson, Susan Maestranzi, David H. Dewar, Alastair Forbes, Ingvar
Bjarnason, Roy Sherwood, Paul J. Ciclitira, John R. Nicholls
One of the hallmarks of pouchitis is the polymorphonuclear granulocyte (PMN) infiltration
of the mucosa, thought to be driven by dysbiosis. Calprotectin is a stable antimicrobial
protein produced by activated PMN. The use of the new “PhiCal” faecal Calprotectin assay
is already well established as a diagnostic tool in inflammatory bowel disease. We aimed to
validate its use in pouchitis. 54 stool samples were taken from 49 ileal pouch patients. The
samples were processed and analysed using a qualitative type enzyme linked immunosorbant
assay (“PhilCal ELISA New Method”, Eurospital, Italy). 41 had ulcerative colitis (UC) and
8 had familial adenomatous polyposis (FAP) coli. Pouchitis was defined as an objective
pouchitis score (OPS) of ≥5/12 (endoscopic score of ≥3/6 and an acute histological score
of≥2/6) or a pouch disease activity index (PDAI) of≥7/18. Statistical analysis was performed
using Spearman Rank and Mann-Whitney. The faecal Calprotectin concentration correlated
well with the OPS (r=0.68, p<0.0001), PDAI (r=0.7, p<0.0001), endoscopy score (r=0.6,
p<0.0001), acute histological score (r=0.71, p<0.0001) and neutrophil score (r=0.68,
p<0.0001), but correlated poorly with patient’s clinical symptoms (r=0.3, p=0.03). Using
the OPS, 6 patients were diagnosed with UC pouchitis (+ pre-pouch ileitis), 13 with UC
pouchitis alone, 27 had a healthy UC pouch, 1 had FAP pouchitis (+ pre-pouch ileitis) and
7 had a healthy FAP pouch. Respectively, median faecal Calprotectin values (mg/kg) for
these groups were 865, 145, 56, 305 and 9, with means [95% confidence intervals] of 1073
[188.5-1958], 888.8 [174.1-1603], 147 [71.8-222.2], 305 and 12.86 [5.1-20.6]. Statistically
significant differences were noted when comparing inflamed and non-inflamed pouches
(p<0.0001). The pre-pouch ileitis group had higher values than those with pouchitis alone
but this proved non-significant (p = 0.2). Using the upper normal limit for calprotectin as
50 mg/kg, the receiver operating characteristic analysis revealed a sensitivity of 53%, a
specificity of 90% and a false negative rate of <5%. Using a higher threshold of 92.5 mg/
kg a sensitivity of 76.5% and a specificity of 90% were demonstrated. Similar results were
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obtained using the PDAI, albeit with a slightly lower specificity level. The new “PhiCal”
faecal Calprotectin test is a useful non-invasive diagnostic tool for differentiating between
healthy and inflamed ileal pouches. This simple test could be use to rationalise the manage-
ment of ileal pouch patients before exposing them to the potential risks of empirical antibiotic
therapy and endoscopic investigations with biopsies.
S1334
CBIR1 Serves As a Multi-Functional Predictor of Inflammatory Bowel Disease
in a Six-Marker System
Augusto Lois, Leonard Eggleston, Susan Carroll, Esther Oh, Mary Barry, Bruce Neri
The flagellin-like antigen CBir1 was originally identified in the sera from C3H/HeJBir mice
with colitis and was associated with the development of inflammatory bowel disease (IBD).
IBD comprises at least two different diseases, Crohn’s disease (CD) and ulcerative colitis
(UC). Anti-CBir1 antibodies have been found in humans diagnosed with IBD and especially
in patients with CD. Other markers associated with IBD in humans include antibodies
against several antigens from normal intestinal microbial flora. The identification of these
antibodies has provided the means to develop diagnostic tests that identify patients with
IBD and that can distinguish UC and CD. The development of a sensitive and robust ELISA
assay that quantitatively measures the levels of anti-CBir1 IgG antibodies from human serum
is described here. The IgG-CBir1 ELISA assay was combined with five other known IBD-
associated markers to create a new six-marker system. The markers consisted of IgG antibodies
to CBir1, IgA to the E. coli associated outer membrane protein C (OmpC), IgA and IgG
anti-Saccharomyces cerevisiae mannan antibodies (ASCA-IgA and ASCA-IgG), anti-neutrophil
antibodies with DNase-sensitive perinuclear staining. The contribution of CBir1 to the
diagnosis of IBD and to the differentiation of UC and CD was then assessed. IBD-predictive
models were created using classification and regression trees (C&RT). The best model showed
that CBir1 is useful in this six-marker system to classify CD patients and also to identify a
large percentage of the UC population. The C&RT model was tested in an 813 patient
cohort with 60% IBD prevalence and equivalent numbers of CD and UC samples. The
C&RT model predicted IBD with a sensitivity of 88% and specificity of 81% and correctly
predicted normal, CD and UC patients from the levels of CBir1 in 3 separate nodes (decision
points of the classification tree). For example, if the levels of ASCA IgG are below the model’s
cut-off (22 Elisa Units [EU]), ANCA ELISA levels are above 14.1 EU and CBir1 is <80 EU,
the model correctly identified most of the UC samples in the cohort. However, if the levels
of CBir1 were above 80 EU, the model correctly predicted CD. Conclusion: CBir1 was
included in a new six-marker system that utilizes a classification tree model for data analysis.
The levels of CBir1 are useful for decision making at various points of the classification tree
indicating a broad role for CBir1 in the prediction of IBD.
S1335
A New Six-Marker System That Includes CBIR1 Has Greatly Improved
Prediction Accuracy for Inflammatory Bowel Disease and for Differentiation of
Ulcerative Colitis and Crohn’s Disease Compared to Commonly Used Testing
with ANCA and ASCA
Augusto Lois, Leonard Eggleston, Susan Carroll, Esther Oh, Mary Barry, Bruce Neri
Correct and quick diagnosis of Inflammatory Bowel Disease (IBD) can be a challenging
undertaking for physicians. Serological testing has become an important component of the
process to diagnose IBD. In this report, CBir1 was included in a new six-marker system
analyzed by a novel algorithm which significantly improved the accuracy of IBD diagnosis.
The six-marker system includes IgA to the E. coli-associated outer membrane protein C
(OmpC), IgA and IgG anti-Saccharomyces cerevisiae mannan antibodies (ASCA-IgA and ASCA-
IgG), anti-neutrophil antibodies detected in alcohol-fixed neutrophils (ELISA) with a DNase-
sensitive perinuclear stain and IgG antibodies to CBir1. The new algorithm and IBD six-
marker system was validated in multiple cohorts consisting of normal individuals, Irritable
Bowel Syndrome (IBS) patients, UC patients and patients with CD (IBD prevalence ranged
from. 60%-63%). Analysis of the performance of the test system showed significant improve-
ment in the sensitivity and the specificity of IBD detection and the differentiation of CD
and UC. Greater than 90% sensitivity and specificity was attained for IBD prediction in an
813 patient cohort including UC and CD and normal and IBS samples. The positive predictive
value of the IBD six-marker system was greater than 90%. The negative predictive value
was slightly lower but greater than 75%. Receiver Operating Characteristic (ROC) analysis
indicated that the assay was accurate with an area under the curve above 0.9. Detection of
CD was substantially increased with a sensitivity of 88% and specificity above 90%. UC
detection increased similarly to a total sensitivity of 88% and specificity >90%. IBD detection
using cut-off values with ANCA and ASCA alone or in combination has very poor sensitivity
(<40%). Conclusion: Inclusion of CBir1 in a new six-marker system with a novel algorithm
dramatically improved the accuracy of IBD diagnosis.
S1336
Small Intestine Contrast Ultrasonography (SICUS) Versus Videocapsule
Endoscopy (VCE) for Assessing Crohn’s Disease Post-Operative Recurrence: A
Prospective Longitudinal Study
Livia Biancone, Emma Calabrese, Rosa Maria Bozzi, Carmelina Petruzziello, Sara Onali,
Micaela Cretella, Anna Caruso, Alessandra Geremia, Francesco Pallone
Background. Small intestine contrast ultrasonography (SICUS) is a non-invasive technique
able to detect small bowel lesions in Crohn’s Disease (CD). Videocapsule endoscopy (VCE)
allows the visualization of the small bowel inner surface. As CD patients require endoscopic
assessment after surgery, non-invasive techniques able to detect the postoperative recurrence
may well be of use. The usefulness of SICUS and VCE for assessing the postoperative
recurrence of CD is unknown. Aims. We aimed to investigate, in a prospective, longitudinal
study, the usefulness of SICUS in comparison with VCE for assessing the postoperative
recurrence of CD patients (pts) 1 year after ileo-colonic resection, when using conventional
colonoscopy (CC) as gold standard. Methods. 14 CD pts (8 M, age range 25-64 yrs)
undergoing ileo-colonic resection for CD were prospectively followed up from July 2003
to November 2005. After surgery, all patients underwent clinical assessment (CDAI) every
3 months for 1 year. At 1 year, CD recurrence was assessed by 3 independent investigators
by SICUS and CC, followed by VCE. CD recurrence was assessed by CC (Rutgeerts’ score).
SICUS was performed after PEG ingestion (375 ml). VCE was performed by using the M2A
Given (11x26 mm) (median excretion time 28 hrs). Lesions compatible with recurrence
assessed by SICUS and VCE were recorded. Results. No pts. showed side effects. At 1 year,
all 14 patients were inactive (CDAI<150). In 1 pt, VCE was not performed due to an
anastomotic stricture detected by CC. Comparison between the 3 techniques was therefore
made in 13/14 pts. CC detected CD recurrence in 12/13 pts. Lesions compatible with
recurrence were detected by SICUS in 13/13 pts (1 false positive) and by VCE in the same
12/13 pts showing endoscopic recurrence (12 true positives). CC detected recurrence at
both the anastomosis and PA-ileum in 9/13 pts and at anastomosis only in 3/13 pts.
Recurrence was detected by SICUS at both the anastomosis and PA-ileum in 10/13 (1 false
positive) and at the anastomosis only in the same 3/13 pts detected by CC (3 true positives).
VCE detected CD recurrence at both the anastomosis and PA-ileum in 7/13 pts (2 false
negatives) and at the anastomosis only in 5/13 pts (2 false positives). VCE therefore appeared
to appropriately detect the presence, but not the site of CD recurrence, which appeared
better defined by SICUS. Conclusions. Present findings from a prospective longitudinal
study suggest that SICUS and VCE represent alternative non-invasive technique for assessing
CD recurrence in patients under regular follow-up after ileo-colonic resection. VCE use
however requires the exclusion of stricturing recurrence.
S1337
Alterations in Composition and Activity of Faecal Microbiota During Anti-
TNF-α Antibody Treatment in Crohn’s Disease: A Pilot Study
H.M.C. Van Nuenen, C.J. van der Woude, K. Venema, G. Welling, E.J. Kuipers
Crohn’s disease (CD) is a multifactorial disease. Gastrointestinal microorganisms and their
metabolites may play a role in CD. We aimed to determine whether anti-TNF-α monoclonal
antibody therapy for CD has an effect on the composition of their faecal microbiota. It was
hypothesized that if the microbial composition correlates with clinical disease activity,
microbial metabolites possibly do as well, given their relationship with the microbial composi-
tion. Therefore, the second aim of this study was to investigate the possible use of microbial
metabolites as markers for disease activity in CD. The study population consisted of 23
subjects divided over three groups: healthy individuals, IBD patients in remission (CDAI<100)
and patients with active CD (CDAI 107-265). The latter patients were studied twice: immedi-
ately before and two weeks after a single, first infusion of anti-TNF-α antibody. Microbial
composition was determined using the classical plating technique and fluorescent in situ
hybridisation (FISH), and the following potential disease activity markers were determined
in the faecal samples: dry matter, pH, short-chain fatty acid, branched-chain fatty acids,
and lactate. Anti-TNF-α antibody therapy led to an increase of the density of the faecal
bacterial population (plating: 1.1*108 CFU/g before treatment, 2.4*108 CFU/g after treat-
ment; p=0.07, FISH: 3.5*109 CFU/g before treatment, 3.0*1010 CFU/g after treatment; p=
0.07), as well as an increase in faecal D-lactate compared to L-lactate (0.5 before treatment,
1.3 after treatment; p=0.07), and to an increase of faecal dry matter (11.0% before treatment,
17.3% after treatment; p=0.3). By comparing the patients with active CD with the healthy
controls and the IBD patients in remission, an increase in total number of faecal bacteria,
in faecal D:L lactate ratio, and in faecal dry matter seem to correlate overall with a lower
severity of disease activity, and thus with health status (healthy controls versus active CD:
p≤0.04 for all three parameters). The detected increase in the number lactobacilli in the
active CD patients upon therapy (8.0*103 CFU/g before treatment, 7.8*104 CFU/g after
treatment; p=0.06) can be of interest because lactobacilli were also present in lower amounts
in IBD patients in remission than in healthy controls (IBD remission: 6.1*104 CFU/g, healthy
controls: 5.2*108 CFU/g after treatment; p=0.01). Active CD is characterized by i) a significant
lower total number of bacteria; ii) a significant lower D:L lactate ratio; and iii) a significant
lower dry matter than found in healthy individuals. These faecal parameters may be used
as clinical disease activity markers of CD.
S1338
Fdg-PET Imaging of Murine Experimental Colitis
Thorsten Vowinkel, Sven Hermann, Markus Loeffler, Rudolf Mennigen, Emile Rijcken,
Markus Utech, Matthias Bruewer, Norbert Senninger, Michael Schaefers, Christian F.
Krieglstein
Introduction: Detection of disease activity in inflammatory bowel diseases (IBD) like ulcerative
colitis is of crucial importance for the management of the disease. Non-invasive quantification
of the severity of colitis would thus be advantageous. The aim of the present study was to
assess the possible value of positron emission tomography (PET) in identifying intestinal
inflammation in murine experimental colitis. Methods: Colitis was induced by feeding
wildtype (wt) Balb/c mice 5% dextran sulfate sodium (DSS) in drinking water for 7 days.
Disease activity index (DAI) was used to score colitis clinically. On day 0, 4 and 6 during
the course of DSS administration PET images were taken using the high-resolution 32-
module quadHIDAC small-animal PET scanner. Sixty minutes prior to scanning 10 MBq
fluorine-18-fluoro-deoxyglucose (F-18-FDG) was injected intravenously. The photodetection
technique is based on gas multiwire proportional chambers offering a submillimeter spatial
resolution (FWHM with resolution recovery). Results: DSS-induced colitis was characterized
by a median weight loss of 17% from the original weight and high disease activity index
values. Healthy controls showed a non-specific variation of bowel uptake of F-18-FDG
throughout the entire colon. With increased severity of the disease F-18-FDG accumulation
at day 6 was most prominent in the distal and left sided colon, which are the characteristic
sites of inflammation in the DSS colitis model. Separate PET scanning of the resected and
flushed colon showed the majority of FDG accumulation within the intestinal wall. However,
in some DSS-colitic mice the FDG signal was variable with respect to location, degree and
time course of FDG-uptake in the bowel. Conclusions: Our study demonstrates that similar
to the clinical situation DSS colitis in mice can be monitored non-invasively over time by
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FDG-PET examination. Further morphological and functional studies regarding site and
relevance of FDG-uptake into the colonic wall will follow. These may facilitate interpretation
of FDG-PET scanning in IBD patients.
S1339
Faecal S100A12 Is a Useful Non-Invasive Screening Test in Children with
Gastrointestinal Symptoms Suggestive of Inflammatory Bowel Disease
Marc A. Sidler, Steven T. Leach, Andrew Day
Introduction: We have recently shown that faecal levels of the calcium-binding protein
S100A12 are increased in children with IBD and that this test provided a sensitive and
specific non-invasive marker of gastrointestinal inflammation in children when 10 mg/kg
was used as a cut-off. We hypothesised that faecal A12 offers enhanced utility over standard
tests to distinguish IBD from non-inflammatory bowel disease (such as functional disorders)
when used as a screening test. Methods: Stools were obtained from 37 children (2.2 to 16 yrs)
with gastrointestinal symptoms and suspected IBD before undergoing upper gastrointestinal
endoscopy and colonoscopy. Faecal levels of A12 were measured by immunoassay. Results
were correlated with standard blood tests and histological findings. Results: In children with
IBD (n = 20) faecal A12 level were elevated (143.5 ± 122.2 mg/kg) compared to the non-
IBD group (n=17, 6.8 ± 14.5) (p < 0.0001). When <10mg/kg was used as upper reference
limit faecal A12 had sensitivity of 100% and specificity of 89%, which were superior
compared to the sensitivities and specificities of standard blood tests (ESR, CRP, PLT,
albumin). Serum A12 levels were not different between the two groups. There was no linear
correlation between A12 and the standard tests. Conclusion: Faecal S100A12 is a highly
sensitive and very specific non-invasive marker of gut inflammation in children presenting
with gut symptoms. S100A12 may be an additional simple test to screen and select children
who warrant further invasive and laborious procedures such as endoscopies for investigation
of their symptoms. Further larger studies are required to confirm these findings.
S1340
Higher Human Beta-Defensin 2 Levels in Feces in Active Ulcerative Colitis
and Ileal But Not Colonic Crohn’s Disease Compared to IBS
Jost Langhorst, Sigrid Elsenbruch, Andreas Rueffer, Andreas Michalsen, Gustav J. Dobos
Background: Antimicrobial peptides such as human defensins appear to be part of the innate
immune system, and provide non-specific mucosal defense in the intestinal barrier against
microorganism. The expression of human beta-defensins (HBD) is induced by pro-inflammat-
ory cytokines and by microorganism. A HBD-2 deficiency is proclaimed for the intestinal
mucous membrane of patients with Crohns disease (CD). Thus far, the expression of beta-
defensins has been quantified in the intestinal mucosa by using polymerase-chain reaction.
This is the first study to investigate fecal measurements of HBD-2. Aim: To investigate the
levels of HBD-2 in feces in patients with active Inflammatory Bowel Disease (IBD) and
Irritable Bowel Syndrome (IBS). Methods: Fecal specimens were collected from a total of
47 patients: 17 IBS patients and 30 IBD patients (15 ulcerative colitis (CU); 15 CD). Disease
status was addressed in each patient by ileocolonoscopy and histopathology. Fecal HBD-2
was measured by ELISA and reported as ng/ml feces. Results: The mean±S.D. (standard
deviation) level of HBD-2 for the 17 IBS pts was 74,2 ± 54,7. Compared to IBS, in active
UC (proved by endoscopy and histopathology) 121,5 ± 73,1 (p < .05) and in active CD
125,8 ± 79,5 (p < .05), the levels were significantly increased. The 8 CD pts with active
ileal disease 149,1 ± 75,7; (p = 0.01) but not the 5 CD pts with active colonic disease 88,6
± 78,1 (p = 0.64) showed significantly elevated HBD-2 levels. Conclusion: This is the first
study to present preliminary data on HBD-2 levels in feces in pts with IBD and IBS. The
results indicate significantly elevated levels in pts with active UC and active ileal but not
colonic CD compared to IBS pts. The lower expression of HBD-2 in colonic CD in feces
may indicate different responses of the mucosal innate defence, although the functional
significance remains to be established.
S1341
Inherent Differences in 6-Thioguanine (6-TG) Induced Apoptosis May Predict
Clinical Responsiveness to Induction and Maintenance 6-Mercaptopurine (6-
MP) Therapy Independent of 6-TGN Metabolite Levels in Children with
Crohn’s Disease
Ryan S. Carvalho, James A. Mahoney, Maria M. Oliva-Hemker, Carmelo Cuffari
Introduction: Although the measurement of 6-TGn metabolite levels has proved to be helpful
in monitoring toxicity to 6-mercaptopurine (6-MP) therapy, newer metabolites (TGTP and
TGDP) have been shown to better correlate with clinical response. Furthermore, the lack
of consensus on applying therapeutic 6-TGn drug monitoring in clinical practice may in
part be explained by inherent differences in anti-metabolite drug susceptibility (Carvalho
et al. Gastroenterology 2004). Aim: To correlate in vitro sensitivity of peripheral blood
mononuclear cells (PBMCs) to 6TG induced apoptosis in children with IBD naïve to, and
either on induction or maintenance 6-MP therapy. Clinical response will also be correlated
with erythrocyte 6-TGn metabolite levels (Prometheus Labs). Methods: Peripheral blood
was drawn from children with IBD naïve to, or on maintenance (>6months +/- mesalamine)
6MP therapy in CPT Ficoll tubes. PBMC’s were isolated and suspended in RPMI 1640 at a
concentration of 1million cells/ml. Cells were stimulated with Concovin A at a concentration
of 5mcg/ml and incubated with 6TG at a dose of 6 μM for 72-96 hours. Simultaneous,
controls were incubated without 6-TG. Flow cytometry was used to measure apoptosis.
Only double positive cells for Annexin V PE for PS, and TOPRO-3 for DNA were quantified
as positive for apoptosis. The cells were also gated for CD3 after staining with FITC-CD3.
Remission was defined as a PCDAI <10; response a decrease of 12 points from baseline.
Results: Clinical responsiveness to either induction or maintenance 6-MP therapy correlated
well with 6-TG induced apoptosis, independent of erythrocyte 6-TGn metabolite levels.
Despite presumed therapeutic 6-TGn (>240) metabolite levels, the mean apoptosis in patients

















to 6MP therapy (Table 1). Conclusion: 6-TG induced apoptosis correlates with clinical
responsiveness to either maintenance or induction 6-MP therapy independent to erythrocyte
6-TGn metabolite levels in children with Crohn’s disease. Future studies are needed to
determine if susceptibility to 6-TG induced T-cell lymphocyte apoptosis can be used clinically
to predict responsiveness to anti-metabolite therapy.
S1342
Urinary PGE-M, a Metabolite of PGE2: A Novel Biomarker of Crohn’s Disease
Activity
Jeffery C. Johnson, David A. Schwartz, Prashant R. Joshi, Jason D. Morrow, Robert J.
Coffey, Robert D. Beauchamp, Nipun B. Merchant
INTRODUCTION: The available clinical measures of Crohn’s disease (CD) activity can be
overly influenced by functional symptoms. Placebo response rates in clinical trial are high.
What is needed is a simple, non-invasive biologic measure of disease CD activity. Cyclooxy-
genase-2 (COX-2) is involved in prostaglandin E2 (PGE2) synthesis and is expressed in
epithelial inflammatory conditions and some cancers. We have developed an assay to quantify
the major urinary metabolite of PGE2, PGE-M. PGE-M has been previously shown to be
elevated in the urine of patients with advanced colorectal neoplasia relative to controls. The
purpose of this study was to determine whether urinary PGE-M levels correlated with Crohn’s
disease activity METHODS: Twenty-eight patients with a known diagnosis of Crohn’s disease
were prospectively enrolled. Disease activity was quantified using the Harvey-Bradshaw
index (HBI). Urine specimens and blood for C-reactive protein were collected at the time
of colonoscopy. Similarly, urine specimens were obtained from 72 healthy individuals who
were endoscopically proven to have no neoplastic or inflammatory colorectal disease. Urine
PGE-M levels were determined by mass spectroscopy. PGE-M levels were correlated with
HBI and serum C-reactive protein (CRP) levels. RESULTS: The median urine PGE-M level
for patients with Crohn’s disease was 21.94 ng/mg Cr (IQR 7.99 - 90.24) compared to 7.2
ng/mg Cr (IQR 1.55 - 31.5) for the healthy patients (Wilcoxon rank-sum p < 0.0001). There
was a trend toward a positive correlation between PGE-M level and HBI (Spearman’s rank
correlation p = 0.064). Furthermore, urinary PGE-M levels were able to segregate several
patients with a high functional component to their symptoms, but normal endoscopy (and
low PGE-M levels). There did not appear to be a relationship between PGE-M level and C-
reactive protein (CRP) level (Spearman’s rank correlation p = 0.68) nor was there a correlation
between CRP levels and DAS. (Spearman’s rank correlation p = 0.71) CONCLUSIONS:
Urine PGE-M levels are significantly elevated in patients with Crohn’s disease relative to
healthy individuals. There appears to be a trend towards a correlation between urinary PGE-
M levels and Crohn’s disease activity as measured by the HBI. These findings suggest that
this assay may be a useful objective measure of disease activity.
S1343
Bioequivalence of 4 G Pentasa* (mesalamine) Daily; Dosed As 4x1g Sachets
Or 2x 2 X 1g Sachet
Peggy Gandia, Isabelle Idier, Musse Foldager, Georges Houin
Aim Compare the kinetics of mesalamine and its main metabolite (acetyl-mesalamine) after
repeated oral administration of 4g/d during 8 days according 2 schedules (4g od and 2g
bid). Material and method A randomized, open, single center, two-way crossover study was
conducted in 30 healthy male subjects aged from 18 to 50 with a BMI from 18 to 28 kg/
m2, to compare plasma pharmacokinetic profile of a new dosing regimen of mesalamine
(1x4g) with a reference dosing (2x2g with 12 h between the two administrations). The two
dosing schedules were administered during 8 days and separated by a drug free wash-out
period of 2 weeks. Plasma concentrations of mesalamine and its main metabolite, 5-acetyl-
mesalamine, were determined on day 1 and day 8 from 0.5 to 21 h post dose by a
sensitive and validated HPLC assay. The concentrations were used to assess pharmacokinetic
parameters such as the Cmax, Tmax, and AUC0 24h. Bioequivalence was determined by
comparing the AUC0-24h of mesalamine (primary criterion) and 5-acetyl-mesalamine after
the once daily with the twice daily dosing at day 1 and day 8. The two ways of administration
were considered bioequivalent if the CI90% of the ratio of the AUC0-24h (1x4g/2x2g) was
between 0.80 and 1.25. A clinical and biological examination was performed on the healthy
volunteers throughout the study to determine tolerability of the treatment. Results The oral
administration of mesalamine was well tolerated with both the once and twice daily dosing
regimens. The values of the pharmacokinetic parameters and the ratio of the AUC0-24h
with the corresponding CI90% are shown in the table. Discusion and conclusion Bioequival-
ence was demonstrated for mesalamine and 5-acetyl-mesalamine for a once and twice daily
dosing regimen of 4 g PENTASA at day 1 and for mesalamine on day 8. At steady state,
one oral administration of 4g induces a slight decrease in the AUC0-24h of 5 acetyl-
mesalamine. Once daily versus twice daily dosing of 4 g mesalamine were equivalent. *
PENTASA is the registered trademark of Ferring b.v.
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A Prospective Assessment of Clinical Activity Indices vs Calprotectin in
Patients in Remission with Crohn’s Disease and Ulcerative Colitis. Are We
Understating the Level of Occult Inflammation?
Caitlin O'Mahony, John K. Collins, Eamonn Quigley, Liam O'Mahony, Fergus Shanahan
Introduction & Aims: Clinical activity indices for Crohn’s disease (CDAI) and ulcerative
colitis (UCAI) are used in clinical trials but rarely in clinical practice and have dubious value
for patients thought to be in remission. The level of calprotectin in feces is a marker of the
presence of acute inflammation in the gut and has been proposed as a surrogate disease
activity test in inflammatory bowel disease (IBD). The purpose of this study was to assess
calprotectin levels in patients following steroid-induced remission and to compare with
activity indices and systemic biomarkers. Methods: Fecal samples were collected from
patients with CD before (n=60) and after (n=20) steroid-induced remission and from those
with UC after steroid-induced remission (n=129) and at time of relapse (n=24). Controls
included patients with irritable bowel syndrome (IBS, n=41), resected colon cancer (n=78)
and healthy volunteers (n=34). Calprotectin was quantified by ELISA (mg/Kg). Results: As
expected, fecal calprotectin was significantly increased in active CD (1098±141) and active
UC (1010±209) compared with all disease controls and healthy volunteers (<40, p<0.001
for both). However, after induction of remission, calprotectin for CD (850±191) and UC
(714±78) was still significantly elevated (p <0.001 for both), despite normal activity indices.
No significant correlation between fecal calprotectin and systemic markers including CRP,
soluble IL-2 receptor-α and soluble IL-6 receptor was found. Conclusion: Elevated levels
of calprotectin during clinical remission show that conventional measures and systemic
markers of disease activity of IBD seriously underestimate the degree of inflammation present
in patients with so-called remission. This is of therapeutic relevance particularly in relation
to proposals for more aggressive use of immunomodulatory agents to prevent long term
complications of IBD.
S1345
Utility of Fecal Calprotectin in Differentiating Inflammatory Bowel Disease
(IBD) from Recurrent Abdominal Pain (RAP) in Children
Robert J. Shulman
Background: It often is difficult to differentiate IBD from RAP in children. Fecal calprotectin
concentration has been proposed as a marker to identify gastrointestinal inflammation and
it may be useful in distinguishing organic disease (i.e., IBD) from normals. However, there
are scant data regarding its utility in distinguishing IBD from RAP in children. We hypothes-
ized fecal calprotectin concentration would discriminate between IBD, RAP, and Control
children without disease. Values in children (as compared to infants) do not change with
age. Design/Methods: Children were identified from pediatrician (RAP and Controls) and
pediatric gastroenterologist (RAP and IBD) records. Parents were contacted and screened
further by phone for eligibility. Children with RAP met Rome II criteria for functional
abdominal pain or irritable bowel syndrome. The Pediatric Crohns Disease Activity Index
(PCDAI) and the Ulcerative Colitis Clinical Activity Index (UCCAI, BMJ 1989;298:82) were
calculated. A random stool was collected for determination of fecal calprotectin concentration.
Results: Mean (SD) ages were IBD: 13.6 ± 2.8 yr. (n = 52); RAP: 8.5 ± 1.1 (n = 75); Control:
8.7 ± 1.0 (n = 44). Fecal calprotectin concentration was significantly different among the
groups (ANOVA, p < 0.0001) as well as between groups: IBD: 1113 ± 1009 µg/g stool;
RAP: 59 ± 75; Control: 36 ± 21; IBD vs RAP or Control, P < 0.001; RAP vs Control, P =
0.021). Fecal calprotectin correlated weakly with the PCDAI (score: 24 ± 13; P = 0.028,
r2 = 0.11, n = 36) but not for the Clinical Activity Index (score: 4.6 ± 3.4; P = 0.1, n =
16). Sensitivity, specificity, positive predictive value, and negative predictive values are
shown in the Table (normal < 50 µg/g). Conclusions: Fecal calprotectin concentrations: 1)
are elevated in children with IBD and RAP compared with controls; 2) are greater in RAP
than controls; 3) appear to be useful as a screening test in children being evaluated for IBD
whether they have RAP or not; 2) are somewhat specific for RAP compared with Controls
but lack sensitivity and negative predictive value. (Supported by a grant from the CCFA)
* P < 0.001 **95% Confidence Interval
S1346
Prescribing Patterns and Awareness of Adverse Effects of Infliximab: A Health
Survey of Gastroenterologists
Raymond K. Cross, Meaghan Donovan, Kevin Lunney, Olivia Carter-Pokras
Introduction: Infliximab is an effective treatment for Crohn’s disease. To our knowledge
there are no studies that have examined infliximab prescribing patterns and awareness of
adverse drug reactions among gastroenterologists in the community. We sought to determine
the prescribing patterns and awareness of adverse drug reactions to infliximab among
gastroenterologists in Maryland and Washington, D.C. Methods: We developed a question-
naire to address 3 topic areas: demographics, infliximab prescribing practices, and awareness
of adverse drug reactions to infliximab. Cognitive interviews were performed with 3 members
of the gastroenterology faculty at the University of Maryland (UM) to assess the content
validity of the questionnaire. The survey was then mailed to gastroenterologists in Maryland
and Washington, D.C. identified from an existing UM database. The survey was mailed to
all nonrespondents 2 weeks later. The survey with a $2 dollar incentive was mailed to all
remaining nonrespondents 3 months later. Results: 336 gastroenterologists with valid
addresses were identified. 96 (29%) surveys were returned after all three mailings had been
completed. 40% of respondents used infliximab often and 46% used infliximab sometimes.
48% of respondents infused infliximab either in their office or in a shared infusion center.
Only 67% of respondents would prescribe infliximab loading (0, 2, 6 week infusions) followed
by every 8 weeks maintenance infusions and only 48% would use an immunomodulator prior
to infusing infliximab. 92% would order a purified protein derivative (PPD) prior to infliximab
treatment and 87% would not prescribe infliximab to a patient with a positive PPD. Surpris-
ingly, 12% would not prescribe the drug to a sexually active woman. Respondents reported
that infusion reactions occur in 12.9 +/- 14.4% of infliximab infusions and 89% would
restart an infliximab infusion at a lower rate when confronted with a mild acute infusion
reaction. Respondents had little knowledge on the incidence of adverse events associated
with infliximab use. Respondents underestimated the risk of serious infection, demyelinating
syndromes, malignancy, and death. Conversely, they overestimated the risk of worsening
heart failure. Conclusions: Considerable variation exists among gastroenterologists in regards
to prescribing patterns of infliximab. Gastroenterologists are unaware of the frequency of
adverse events associated with infliximab and report high rates of infusion reactions. Physician
education regarding infliximab use and awareness of infliximab related side effects is needed
to ensure that gastroenterologists follow current clinical guidelines.
S1347
Gastroduodenitis Associated with Ulcerative Colitis
Kazutoshi Hori, Yoshio Ohda, Nobuyuki Hida, Chizuko Hayashi, Toshihiko Tomita,
Yongmin Kim, Kazuhiko Nakajima, Noriyasu Yamamoto, Yoshio Jinno, Takashi Sakagami,
Yoshihiro Fukuda, Takayuki Matsumoto, Hiroto Miwa
Background & Aims: Ulcerative colitis (UC) is traditionally confined to the colorectum;
however, there are several case reports showing upper gastrointestinal involvement. The
aims of this study were to create criteria of gastroduodenitis associated with UC (GDUC)
and to examine the prevalence and characteristics of this condition. Methods: A prospective,
single center study was performed on 148 UC patients (84 male, 93 pancolitis and 100
postcolectomy patients). They underwent esophagogastroduodenal endoscopy with biopsies.
The endoscopic and histological findings were compared between UC and 296 non-UC
patients. The endoscopic terms of ulcerated mucosa, friable mucosa, granular mucosa and
multiple aphthae were defined as follows: mucosa with extensive ulcerations; mucosa with
erosions and with contact or spontaneous bleeding; mucosa with multiple white spots
without a red halo; and multiple white spots surrounded by a red halo, respectively.
Results: Duodenal ulcerated/friable and gastroduodenal granular mucosa resembling UC
were observed in 9 patients, although these findings were never seen in controls. Crypt
abscess or neutrophilic cryptitis were histologically recognized in 8 of 9 patients. The
remaining one patient had focally enhanced gastritis. All of these histological findings were
observed significantly more frequently in UC compared to control. Gastroduodenal multiple
aphthae were seen in 9 patients, which were significantly less seen in controls (3/296). Since
multiple aphthae were seen in other disorders and granular mucosa required distinguishing
mucosa with white spots such as duodenal lymphangiectasia, GDUC was defined as follows:
multiple aphthae or granular mucosa with one or more of the above histological findings,
or ulcerated/friable mucosa with or without histological evidence. The diagnosis of GDUC
was made in 17 (11.5%) patients. The characteristics of GDUC were found to be more
extensive colitis, less dosage of prednisolone, higher prevalence of pouchitis and longer
postoperative periods compared to non-GDUC patients. The former two characteristics were
significant risk factors for developing GDUC in a multivariate analysis. Conclusions: The
gut inflammatory reaction in UC may not be restricted to the large intestine.
T : 89386$$CH2
05-04-06 23:18:26 Page 207Layout: 89386B : o
A-207 AGA Abstracts
S1348
Local Injection of Infliximab in Crohn’s Disease Recurrence During
Endoscopy: A Prospective Longitudinal Study
Livia Biancone, Micaela Cretella, Carmelina Petruzziello, Claudio Tosti, Palmieri
Giampiero, Sara Onali, Alessandra Geremia, Emma Calabrese, Francesco Pallone
Background. Local injection of Infliximab in Crohn’s Disease (CD) gut lesions may reduce
the risk of side effects, the dose and increase the efficacy of the drug. In a longitudinal
study, we assessed the feasibility and safety of local Infliximab injection into the postoperative
recurrence of CD patients prospectively followed up for at least 1 year. Materials and
Methods. In an open-label study, 8 CD patients (3 M, age range 35-82 yrs) requiring
colonoscopy were prospectively followed up for at least 1 year after local injection. Inclusion
criteria: 1. Localized (<5 cm) CD recurrence; 2. Inflammatory pattern; 3. Inactive CD
(CDAI<150); 4. Written informed consent. The endoscopic degree of recurrence was graded
according to Rutgeerts et al. (score 0-4). All endoscopies were recorded, with pictures taken
from the peri-anastomotic area. Biopsies (n=3) were taken from involved and uninvolved
areas for histology. In all patients all the involved area (anastomosis and/or neo-terminal
ileum) was injected with Infliximab (median 20 mg; range 8-60) during the first colonoscopy.
A control endoscopy to assess the safety and efficacy of injection was performed: at 2 weeks
in 4 patients (3 performing a second injection followed by a control endoscopy at 6 weeks),
at 4 weeks in 4 patients (2 performing a second injection followed by a control endoscopy
at 8 weeks. Results. No patients showed local or systemic side-effects or clinical relapse in
the short- and long-term (median follow up 20 months, range 14-21) after local injection.
At control endoscopy after the first local Infliximab injection, the endoscopic score of CD
recurrence was reduced in 3 out of 8 and unchanged in 5 out of 8 patients, showing
macroscopic healing in 2 out of 8 patients. The median endoscopic score did not significantly
reduce after treatment (T0: 2, range 1-3; T1 and T2: 1, range 1-3; T0 vs T1 p=0.08; T0 vs
T2 p=0.1; T1 vs T2; p=0.1). However, the number and extent of the endoscopic lesions
reduced in 7 out of 8 CD patients after the first local injection. The histologic score reduced
in 4, unchanged in 1 and increased in 3 out of 8 patients after local injection. All patients
currently maintain clinical remission. Conclusions. This is the first study assessing the
feasibility and safety of local injection of Infliximab into CD recurrence. Results indicate
that local Infliximab injection into limited CD recurrence is feasible and safe, requiring a
low dose. Present findings suggest the need of controlled trials to assess the efficacy of this
new and safe endoscopic treatment in CD.
S1349
Tacrolimus Enema Treatment for Left-Sided Colitis: A Safety Study
Jolanda M. Van Dieren, Edward E. Nieuwenhuis, Ernst J. Kuipers, Janneke van der
Woude
Introduction: Systemic treatment with tacrolimus is effective in the treatment of inflammatory
bowel diseases (IBD), both ulcerative colitis and Crohn’s disease. However, this type of
systemic treatment can be associated with severe side-effects, such as liver- and renal function
disoders, insulin hyposensitivity, hypertension and myelosuppression. Topical application
of tacrolimus is effective in dermatological disorders. Aim: to investigate the safety of local
application of tacrolimus in patients with left-sided colitis. Materials & Methods: Patients
with left-sided colitis refractory to local steroid treatment or systemic steroid-, azathioprine-
or cyclosporin treatment were treated with one tacrolimus enema daily for four weeks. An
enema contained 2 or 4 mg of tacrolimus in a 150 ml aqueous solution. Endoscopic
assesement was performed and Disease Activity Index (DAI) was determined prior to and
after the treatment period. Tacrolimus whole blood trough levels (24 h after application of
the enema) were measured weekly. Bloodcounts, liver enzyme tests, renal function tests,
glucose, CRP and blood pressure were determined prior to, halfway and at the end of the
treatment period. Results: Eight patients were included in the study. One patient refused
to continue the study-medication halfway the treatment period. None of the patients reported
adverse effects or showed any laboratory function disorders during or after treatment with
the tacrolimus enemas. Furthermore, through levels did not exceed 4,2 ng/ml in patients
either receiving 2 mg (n = 4) or 4 mg (n = 2) -enemas/day. These levels are not associated
with profuse systemic immunosuppression. Patients who were refractory to at least three
immunomodulatory therapies (5-ASA, steroids, methotrexate, azathioprine, ciclosporin,
infliximab) (n = 5) also showed no improvement of DAI on treatment with tacrolimus-
enema treatment after 4 weeks. However, the two patients who had not been treated yet
with multiple but only with a single or double immunomodulatory therapy responded well
to tacrolimus enemas. One patient showed an improvement of DAI of 10 points to 2 and
another patient showed improvement from 4 points to 0. Conclusion: Tacrolimus enemas
2 or 4 mg seem to be a safe therapeutic option for left-sided colitis. None of the patients
developed side-effects, laboratory function disorders or tacrolimus whole blood levels that
may establish systemic immune suppression. Moreover, tacrolimus enemas may be an
effective early treatment for patients with left-sided colitis. However, larger studies and
placebo-controlled studies are required.
S1350
Clinical Significance of Mucosal Suppressors of Cytokine Signaling (SOCS)
Expression in Ulcerative Colitis
Yoshihiro Miyanaka, Shinji Tanaka, Yoshitaka Ueno, Kyoko Yoshioka, Tsuyoshi
Hatakeyama, Masaru Shimamoto, Kazuaki Chayama
Background and Aim: Ulcerative colitis (UC) is a chronic immune mediated disorder whose
pathogenesis and etiology are largely unknown. The suppressor of cytokine signaling (SOCS)
is a family of molecules that act as a negative regulator for cytokine signaling. The role of
SOCS has been demonstrated in several murine experimental colitis models. Our present
study was undertaken to investigate the clinical importance of SOCS expression in UC.
Method: Biopsy specimens were obtained endoscopically from the rectum of 62 patients
with UC (36 men; age 13-76years). The patients were classified endoscopically according

















obtained for histological analysis and the detection of mRNA. Mucosal SOCS1 and SOCS3
mRNA expressions were quantified in the samples using the competitive reverse transcription-
polymerase chain reaction (RT-PCR). GAPDH was used as an internal control for the efficiency
of RT-PCR and amount of RNA. Result: SOCS3 mRNA expression was significantly increased
in the inflamed mucosa of UC, compared with the uninflamed mucosa. The expression was
well correlated with the degree of both endoscopic and histologic inflammation. There
was no relationship between SOCS3 expression and disease duration. The treatment with
corticosteroids did not affect the SOCS3 expression. Interestingly, among the patients with
inactive mucosa, the group that had relatively low level of SOCS expression demonstrated
higher remission rate in one year (P<0.005). In contrast, the expression of SOCS1 mRNA
was not correlated with the activity of colonic mucosa nor prognosis. Conclusion: The
present study suggests that increased expression of mucosal SOCS3 but not SOCS1 may
play a crucial role on the development of colonic inflammation of UC.
S1351
Diagnosis of Inflammatory Bowel Disease: Which Laboratory Parameter Helps
the Most?
Alain Schoepfer, Michael Trummler, Beatrice Seibold, Petra Seeholzer, Frank Seibold
Objective: The differentiation of inflammatory (IBD) versus irritable bowel disease (IBS) can
be a clinical challenge. Several laboratory parameters in feces and blood have been evaluated
for this purpose. Hitherto it is not determined which of these parameters helps the most.
Material and methods: A prospective blinded cohort study was done in 56 patients (24
Crohn’s disease (CD), 12 ulcerative colitis (UC), 20 IBS), in which the diagnosis of either
IBD or IBS was established based on complete conventional clinical, laboratory and endos-
copic workup. In all patients we additionally measured the fecal leucocyte markers Calprotec-
tin (EIA) and Lactoferrin (EIA), Hexagon-OBTI (specific for human haemoglobin), LEUKO-
Test (lactoferrin latex-agglutination) and the antibodies ASCA, PAB and pANCA. Data are
given as sensitivity (SE), specificity (SP), statistical analysis was done with the unpaired t-test,
chi-squared test and ROC-analysis. Results: SE and SP for Hexagon-OBTI in differentiating IBS
vs IBD was 39% resp. 87% (p=0.04), for LEUKO-test 44% resp. 61% (p=0.004). Mean
calprotectin in IBS was 25ug/mL, in IBD 275ug/mL (p<0.0001), mean lactoferrin in IBS
was 0.03ug/mL, in IBD 0.34ug/mL (p<0.0001). ROC-Analysis: for Calprotectin (cut-off
50ug/mL) the SE was 94%, the SP 90%, for Lactoferrin (cut-off 0.056ug/mL) the SE was
91% and the SP 100%. Mean CRP in IBS was 5.6mg/L, in IBD 16.2mg/L (p=0.1084). Mean
leukocytes in IBS were 6G/L, in IBD 7.7G/L. Using the CD (ASCA+/PAB+/pANCA-) and UC
(pANCA+/ASCA-/PAB-) specific antibodies did not allow to differentiate between IBS and
IBD due to a low SE (56%) and SP (50%). However, ASCA+/PAB+/pANCA- had a high SP
(100%) for CD and a SE of 58% (p=0.001). The SE resp. SP of pANCA+/ASCA-/PAB- for
UC was 33% resp. 88% (p=0.14). Conclusions: In contrast to lactoferrin-latex agglutination
test and Hexagon-OBTI, EIA for lactoferrin or calprotectin are highly accurate for discrimina-
tion of IBD versus IBS. ASCA, pANCA and PAB are not useful as tests for discrimination
of IBS vs IBD, however they aid to differentiate between CD and UC. ASCA+ , PAB+ and
pANCA- help to diagnose CD, whereas pANCA+, ASCA- and PAB- will lead to the diagnosis
of UC.
S1352
Nature and Frequency of Incidental Extraintestinal Lesions Found On
Magnetic Resonance Enteroclysis (MR-E)
Hans Herfarth, Michael Grunert, Frank Klebl, Stefan Feuerbach, Juergen Schoelmerich,
Gerhard Rogler, Andreas G. Schreyer
In addition to lack of radiation, the cross sectional imaging technique of MR-E offers the
intriguing advantages to detect extraenteric lesions compared to the conventional small
bowel follow through. MR-E is currently recommended for the diagnostic work up in patients
with suspected or proven inflammatory bowel disease (IBD). The aim of this study was to
determine the occurrence of extraenteric findings in a large cohort of patients undergoing
MR-E and to classify the clinical significance of these findings. Methods: We retrospectively
analyzed 1154 MR-E performed in 1006 patients referred to our radiological department
between 1999-2005. The reasons for referral were suspected or proven IBD (n=710), further
diagnostic work-up for small bowel disease because of non-specific abdominal symptoms
(SBD; n=182) or suspected small bowel malignacies (SBT; n=114). All extraenteric findings
were reviewed by a radiologist and a gastroenterologist and were classified as having high,
moderate, or low significance for further diagnostic or therapeutic procedures. Results: The
average age of all patients was 40±16 (Mean±SD) years (y) (IBD 35±13y; SBD 49±16y; SBT
57±15y). A total of 1050 extraenteric findings were detected in 574 patients (57%; IBD
53%; SBD 65%; SBT 68%). Of these findings 117 (11%) were judged as having a high, 212
(20%) a moderate and 721 (69%) a low significance (see table 1). The most common highly
significant lesions were extraintestinal tumors, metastases or masses (n=70), pleural effusions
(n=13) and hydronephrosis or ureteral obstruction (n=16). Conclusions: MR-E reveals a
substantial number of extraenteric findings, indicating the advantage of this imaging modality.
However, the occurrence of extraenteric findings with a high clinical significance in patients
with IBD is low probably mainly due to the younger age of this patient group at the time
of the diagnostic work-up.
Table 1: Occurrence and clinical significance of extraenteric findings on MR-E
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S1353
Local Mucosal Parameters in IDB Do Not Correlate with Systemic Parameters
Sabine Buhner, Luzia Valentini, Susanne Hengstermann, Lennart Schaper, Carsten Buning,
Tatjana Schuetz, Thomas Koernicke, Martina Werich, Brigitte Winklhofer-Roob, Herbert
Lochs
Background: Fecal calprotectin (CP) and intestinal permeability have been described as
subclinical markers in IBD. A detailed analysis and correlation with systemic parameters
was done. Methods: Gastrointestinal permeability was measured using an oral sugar test in
55 persons with IBD and 9 healthy controls. Urinary sugar recovery was quantified using
HPLC. Different sugars served as permeability markers for different gut segments; sucrose
(suc): gastroduodenum; lactulose/mannitol ratio (PI): small intestine; sucralose (sucra): colon.
CP, an index for local intestinal inflammation was assed by ELISA. Additionally full blood
count and C-reactive protein (CRP) were analyzed. For classification of the disease activity
a CDAI >150 in CD (active: CDA; remission: CDR) and a CAI>4 in UC (active: UCA;
remission: UCR)were used. Results: Gastric and small intestinal permeability were signific-
antly increased in CD but not in the UC groups (table). Colonic permeability tended to be
increased in CDA but also in UC groups. CP was significantly higher in all patient groups
compared to controls. In contrast, CRP was increased only in CDA. Gastric and small
intestinal permeability values were highly correlated with CP values in both CD groups.
Neither CP nor PI and Suc clearly correlated with the CDAI, CAI (except CP in UCR group),
or with plasma CRP (only in CDA), or with other blood count parameters. Conclusions:
Data stress the importance of both, mucosal permeability and CP as markers for local and
early changes in IBD. Both parameters reflect inflammatory changes more sensitively than
activity indices or CRP.
Except for the age (means (range) all data were given in median (0.25-0.75 percentile); a:
p<0.04 compared to control; b: p<0.03 between CDR and CDA; n.s. between UCR and UCA;
Kruskal-Wallis-test / Mann-Whitney-test and alpha-adjustment by Bonferroni procedure
S1354
Efficacy and Endoscopic Prediction of Clinical Response to Leukocytapheresis
in Patients with Corticosteroid Refractory Or Dependent Ulcerative Colitis:
Results with Two Different Leukocytapheresis Systems
Kenji Watanabe, Nobuhide Oshitani, Noriko Kamata, Hirokazu Yamagami, Kazuhide
Higuchi, Takayuki Matsumoto, Tetsuo Arakawa
Background and Objective: Ulcerative colitis (UC) is empirically treated with conventional
medications (salicylates, corticosteroids, 6-mercaptopurine) and recently with biologics. Use
of these drugs is associated with side effects, which add to the disease complications.
However, UC is believed to be perpetuated by inflammatory cytokines for which peripheral
blood leukocytes (PBL) are major sources. Accordingly, recently PBL have become major
targets of therapy. Two systems are available for depleting excess and activated PBL, GCAP
(Adacolumn), which selectively depletes granulocytes and monocytes together with a small
fraction of lymphocytes (FcgR and complement receptors bearing leukocytes) and LCAP
(Cellsoeba), which non-selectively depletes all leukocyte populations. We have investigated
the efficacy of GCAP and LCAP and the use endoscopic findings to predict efficacy, especially
in corticosteroid refractory and dependent cases. Methods: Thirty-four patients, age 19-52
years and duration of UC 1-12 years were treated. Twenty-seven had total colitis, 7 had
left-sided colitis; 24 were drug refractory and 10 were steroid-dependent. Each patient
received one or two GCAP (n=21) or LCAP (n=13) sessions/week for 5 weeks, with colonos-
copy performed before and after each session. Efficacy was evaluated by measuring changes
in clinical activity index after each session. The predictive factor we evaluated was endoscopic
findings, defined by Truelove Activity Index, with a decrease of >10 points or <13 points
as marked improvement and 9 to 4 points as an improvement. A marked improvement was
when all ulcers healed; an improvement was when some ulcers healed to scars but open
ulcers remained. Results: Twenty-five patients (73.5%) had a clinical response and most
steroid-dependent patients or patients who had steroid side effects were successfully treated.
Thirteen of 24 steroid-refractory patients had a clinical response and 18 of 25 patients who
were on steroids tapered their steroid dose. Efficacy was seen about 2 weeks after the start
of treatment. Endoscopic improvements were seen in 14 of 16 (87.5%) patients with shallow
ulcers or erosions throughout the colon and 10 of 15 with deep ulcers, but 2 with massive
ulceration of the whole mucosa did not respond. These findings support the use of endoscopy
in clinical treatment decision-making. During follow-up, 9 patients underwent colectomy
due to relapse and exacerbation of UC. Conclusion: GCAP or LCAP is valuable for refractory
or steroid-dependent UC; most patients can reduce steroid dose or be spared of additional
medication. Endoscopic findings are valuable in predicting clinical effectiveness.
S1355
Correlation Between Endoscopic Disease Activity and High Sensitivity C-
Reactive Protein, Serum Amyloid A, and Plasma and Fecal Calprotectin in
Children with Inflammatory Bowel Disease
Ulrika L. Fagerberg, Lars Loof, Johan Lindholm, Lars-Olof Hansson, Yigael Finkel
Objectives: Elevated plasma concentrations of acute phase proteins, e.g. serum amyloid A
(SAA) and C-reactive protein (CRP), are common in inflammatory processes. Calprotectin,
a neutrophil-derived protein, is another marker of inflammation. Increased fecal calprotectin
excretion has previously been found in inflammatory bowel disease (IBD) but little is known
about plasma calprotectin concentrations in children with IBD. The aims of this study were
to evaluate the importance of SAA, CRP and plasma calprotectin as markers of endoscopic
disease activity in children with IBD and to compare these results with fecal calprotectin
and routine blood tests. Methods: Fecal and blood samples were collected from thirty-one
children with IBD (Crohn disease n=22, ulcerative colitis n=8, indeterminate colitis n=1)
when investigated with complete colonoscopies including multiple biopsies. Serum Amyloid
A (N Latex SAA®) and CRP (hsCRP®) were analyzed using BNII analyzer (Dade Behring).
Calprotectin was measured in plasma and fecal samples with an enzyme-linked immunosorb-
ent assay method (Calprest®, Eurospital). The concentrations of the inflammatory markers
were correlated to a histopathological, combined scoring of extent and severity of inflamma-
tion in eight colonic segments for each patient. Results: The following median values were
found: 2.4 mg/L for SAA (range 0,2-385.0 mg/L), 0.61 mg/L for hsCRP (range 0.03-80.0
mg/L), 348 mg/L for plasma calprotectin (range 78.0-4550 microg/L) and 264 mg/kg for
fecal calprotectin (5.9-1198 mg/kg). The correlations between the inflammatory markers
and the combined extent and severity score of histological inflammation were r=0.39 (p=
0.029) and r=0.44 (p=0.014) for SAA respectively hsCRP. For plasma calprotectin the
correlation was even stronger (r=0.58, p=0.001) but not as good as for fecal calprotectin
(r=0.74, p<0.001). The correlations were also calculated for erythrocyte sedimentation rate
(r=0.66, p<0.001), platelet count (r=0.57, p=0.001), plasma albumin (r= -0.54, p=0.002),
plasma orosomucoid (r=0.40, p=0.027) and haemoglobin in blood (r= -0.27, p=0.138) for
comparison. Conclusions: Fecal calprotectin seems to be a more reliable test compared to
SAA, hsCRP, plasma calprotectin and routine inflammatory markers in blood for estimation
of histological inflammatory activity in children with IBD.
S1356
Usefulness of the 13CO2 Breath Test in Patients with Active and Quiescent
Ulcerative Colitis Given [1- 13C]-Butyrate Rectally
Kimitoshi Kato, Yukimoto Ishii, Shigeaki Mizuno, Satoshi Asai, Masahiko Sugitani,
Tadashi Kohno, Sigekatu Takahashi, Sachiko Komuro, Maho Iwamoto, Shunpachi
Miyamoto, Noriko Nakajima, Takero Mazaki, Yasuyuki Arakawa
BACKGROUND: Impaired ability to metabolize butyrate has been implicated in ulcerative
colitis (UC). We investigated whether measuring the metabolic rate by breath test, after
rectal [1-13C]-butyrate administration to UC patients, is a potential noninvasive method of
evaluating inflammatory activity as an adjunct to colonoscopy and histology. METHODS:
[1-13C]-butyrate enemas were administered to 22 patients with active UC (8 mild, 12
moderate and 2 severe), to 16 with quiescent UC and to 15 control subjects. The clinical
activity index (CAI) scores are based on the Lichitiger symptom score. The rate of 13CO2
production for four hours, was measured by breath test using an infrared spectrometric
analyzer. RESULTS: During the period from 15 to 210 minutes after the enema, the quantity
of expired 13CO2 in the active UC group was significantly lower than those of the quiescent
UC and control groups. Cumulative 13CO2 production at 240 minutes showed significant
negative correlations with CAI (r= -0.65, P<0.0001), the endoscopic activity index (r= -
0.63, P=0.0001) and the histological score (r= -0. 71, P<0001). A significant increase in the
13CO2 production rate in the active as compared to the quiescent stage was found in six
UC patients, in whom clinical remission was achieved, in accordance with improvements
in CAI, the endoscopic activity index, histology and fecal butyrate concentrations. Correlation
analysis showed a significant inverse relationship between the histological score and the
cumulative 13CO2 production rate (r= -0.857, p < 0.01) in these six UC patients. All UC
and control subjects tolerated the [1-13C]-butyrate enema well. There were no adverse events
in any group. CONCLUSIONS: Measuring in vivo butyrate metabolism can be done safely,
without invasion of the colonic mucosa, when butyrate is used as the 13C compound.
Application of this breath test following a 13C butyrate enema in active and quiescent UC
appears to be a promising and reliable method for evaluating disease activity and metabolic
changes associated with improvement of inflammation.
S1357
Comparison of CRP, Clinical Activity Indices and Fecal Lactoferrin with
Disease Status in Ileocolonoscopy of Patients with IBS and IBD
Jost Langhorst, James Boone, Andreas Rueffer, Andreas Michalsen, Gustav J. Dobos
Background: Determining the presence of intestinal inflammation is the main criteria for
the discrimination of Irritable Bowel Syndrome (IBS) from Inflammatory Bowel Disease (IBD)
and for the tailoring of therapy. Clinical indices have proven too complex and time-consuming
for daily routine practice. On the other hand, single serologic parameters such as C-reactive
protein (CRP) are hampered by a low sensitivity and specificity for intestinal inflammation.
Neutrophil-derived proteins in feces such as lactoferrin have been suggested as possible
biomarkers for assessing intestinal mucosal inflammation in IBD. Aim: To investigate the
correlation of CRP, clinical activity indices and fecal lactoferrin (FLA) to ileocolonoscopy
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and histopathology in patients (pts) with IBS and IBD. Methods: Elevated serum CRP (>=
1mg/dl) and FLA (>= 7 µg/ml) were investigated as indicators of intestinal inflammation in
a total of 47 patients: 17 IBS patients and 30 IBD patients (15 ulcerative colitis (CU); 15
Crohns disease (CD)). Disease activity was determined for CU with the Colitis Activity Index
(CAI - Rachmilewitz-Index; a score of > 5 indicating active disease) and for CD with Crohns
Disease Activity Index (CDAI; a score of > 150 indicating active disease). Disease status was
addressed and classified in each patient by ileocolonoscopy and histopathology using a score
of 0-3 (0 = no inflammation to 3 = high inflammation). Results: A linear relationship was
observed between patient groups stratified by endoscopy scores 0 to 3 with CRP levels
(mean±SE) of 5.4±2.4, 1.4±0.5, 0.7±0.2 and 0.5±0.2 (r2=0.76) and LFA of 978±263,
424±196, 72±13 and 34±8.5 (r2=0.89), respectively. Serum CRP reached baseline levels for
6 of 10 pts (range 0 to 0.8) of group 1. The FLA remained elevated for 10 of 21 pts (range
15 to 103) of group 0. A significant difference (p<0.02) was achieved with LFA between
endoscopy groups 3/1, 3/0, and 1/0 (p-values=0.021, 0.016 and 0.004). No significant
difference was observed for FLA between groups 3 and 2 or for CRP with any of the groups.
CDAI scores did not discriminate between the CD patient groups stratified by endoscopy
score. There was no sufficient number of CAI scores between groups for statistical analysis.
Conclusion: These results are the first for comparing LFA together with CRP to endoscopy
score. The FLA showed the highest sensitivity followed by serum CRP for indicating presence
of intestinal inflammation in IBS and IBD pts. The CDAI index did not reflect disease activity
within our CD population. Further studies are needed to determine the role of FLA in daily
practice for monitoring disease activity in IBD.
S1358
A Prospective, Blinded Assessment of Distal Colonic Mucosal Concentrations
of 5-ASA and NAC-5ASA in UC Patients Treated with Either Balsalazide
(Colazal) Or a pH-Dependent mesalamine (Asacol)
Asher Kornbluth, Carmen Cuffari, James George, Peter Legnani, Michele Hunt, Elliot
Freid-Boxt, John Young
Introduction: Mesalamine containing compounds are the first line therapies in patients with
UC. Different mesalamine compounds have varying release systems to deliver 5-ASA to the
colonic mucosa. Balsalazide is a prodrug containing 5-ASA with an azo bond to 4-aminoben-
zoic acid, an inert carrier. Asacol is an Eudragit coated mesalamine compound designed to
release mesalamine at a pH of 7.0 However, little is known about mucosal concentrations
of 5-ASA, and its primary metabolite Nac-5ASA, in UC patients taking these medications.
Objective: The aim of this study was to determine distal colonic mucosal concentrations of
5-ASA and Nac-5ASA in UC patients treated with either balsalazide, or pH-dependant
mesalamine. Methods: UC patients undergoing sigmoidoscopy or colonoscopy for either
assessment of disease activity, or dysplasia surveillance were invited to participate, if they
had taken at least 90% of their prescribed 5-ASA dose, and were not on any topical
mesalamine therapies for at least the prior 2 weeks. Disease and endoscopic activity was
assessed with the Mayo Clinic Disease Activity Index (DAI). Patients underwent routine 4
quadrant biopsies for assessment of histologic activity, by a pathologist blinded to the
patient’s drug treatment, at 5, 15, and 25 cm from the anal verge. Four quadrant biopsies
were also taken from each patient at 5, 15 and 25 cm from the anal verge for measurements
of 5-ASA and Nac-5ASA concentrations by HPLC, by an investigator blinded to the patient’s
drug treatment. Mucosal concentrations of 5-ASA and Nac-5ASA were measured as microg-
rams/gm of dry tissue weight and adjusted for dose of mesalamine in the parent compound
(balsalazide 6.75g/d = ph-dependent mesalamine 2.4g/d). Results: 13 patients treated with
a mean of 6.75g/d of balsalazide (containing 2.4g/d of 5-ASA) were compared with 17
patients treated with a mean of 3.74g/day of pH-dependent mesalamine, respectively. Patients
in the balsalazide and ph-dependent mesalamine groups had similar DAI scores (4 vs. 2),
endoscopy subscores (1.7 vs. 1.1) and histologic scores (1.2 vs. 0.7). Although interpatient
variability was high for both treatment groups, mean mucosal 5-ASA concentrations were
102% greater with balsalazide than ph-dependent mesalamine at 5 cm, 84% greater at 15
cm and 102% greater at 25 cm, respectively. Similar differences were seen for mucosal Nac-
5ASA concentrations at each site. Conclusions; UC patients treated with oral balsalazide
had a mean of 96% greater distal colonic mucosal concentrations of 5-ASA than patients
treated with similar oral doses of ph-dependent mesalamine.
S1359
Infliximab Significantly Increases Proportion of Overweight/Obese Crohn’s
Disease Patients Receiving Longterm Maintenance Therapy
Mazen Issa, Lydia R. Weber, Sushrut V. Shidham, Dawn B. Beaulieu, David G. Binion
Background: At present, 65% of Americans are overweight (body mass index (BMI) >25)
of which 21% are obese (BMI >30). Active CD is associated with weight (WT) loss and
malnutrition, which has been linked to increased TNFα production during chronic inflamma-
tion. Treatment of refractory CD patients (pts) with the anti-TNFα antibody infliximab has
resulted in improved health with resolution of inflammation and WT gain has been described.
We characterized the effect of anti-TNFα therapy on WT gain and BMI in U.S. CD pts
receiving long-term therapy (1y or greater). Methods: This was a retrospective observational
study of CD pts receiving maintenance infliximab at a single center between 1999-2005. In
addition to demographic data and height, serial measures of WT, C reactive protein (CRP)
and quality of life (SIBDQ) were recorded prior to infliximab initiation and at 6, 12 and 24
months into maintenance therapy. BMI was calculated at start and at time of last dose.
Results: Data from 75 pts (30 male, mean age 40.4±14y (SD), 45 female, mean age 39.6±17y
(SD)) were available for analysis. WT gain in the combined cohort from the start of infliximab
therapy to last dose was 5.3 ± 2 kg (SD) and BMI increased from 24.2 ±6 to 26.0±6.3 at
the time of last dose. Among females, mean WT gain peaked at 6 months (1.96 kg), which
decreased at 12 months to 0.74 kg above the starting level. Mean CRP (mg/dL) in women
started at 1.66 and decreased to 0.6 at 6 months and was 0.65 at 12 months. In males,
there was an increase in mean WT from 81.9 kg at the start to 86.7 kg at 6 months to 88
kg at 12 months. In male pts the BMI significantly increased from 25 to 27.6 (last dose;
p=<0.04). In male pts the CRP decreased from 2.02 at start to 0.5 at 6 months and 0.6 at

















In men, SIBDQ improved from 49 (start) to 54 (both 6 and 12 months). The percentage
of total overweight pts at start was 35%, which increased to 51% at the time of last dose
(p=<0.05), and the percentage who met criteria for obesity increased from 13% to 24%.
Conclusion: WT gain is significant in U.S. CD pts treated with maintenance infliximab, with
half of pts becoming overweight beyond 1 year. Women had peak WT gain by 6 months
(approximately 6% of total body WT) which plateaued, while they continued to experience
clinical improvement with infliximab over 1 yr. Male pts experienced approximately 10%
increase in body WT and continued to gain over time, while their peak benefit from infliximab
was at 6 months. Given health concerns with obesity, WT gain should be monitored in CD
pts benefiting from long-term anti-TNFα therapy.
S1360
Elevated C-Reactive Protein On Admission Predicts Colectomy in Hospitalized
IBD Colitics with and Without Clostridium Difficile Co-Infection
Vladimir Ferrer, Mary F. Otterson, Sarah Lundeen, Lydia R. Weber, Jasmohan S. Bajaj,
Ossama A. Hatoum, David G. Binion
Background: Inflammatory markers provide objective data which may help gauge severity
of inflammation in inflammatory bowel disease (IBD: Crohn’s Disease (CD) and Ulcerative
Colitis (UC)). C-reactive protein (CRP) is a serologic measure of acute phase response which
elevates during IBD exacerbation. Recent data suggests that increased Clostridium difficile
(C. diff) co-infection may precipitate severe IBD flare, often leading to colectomy. There is
limited data correlating objective clinical or serologic markers and need for colectomy in
IBD pts with C. diff co-infection. We correlated objective clinical and serologic inflammatory
markers in hospitalized IBD colitis pts with outcome (i.e. need for colectomy) with a specific
focus on C. diff co-infection. Methods: This was a retrospective observational study involving
consecutive IBD colitics hospitalized with acute exacerbation of UC or CD between 2004-
05. Multiple C. diff ELISA toxin A/B assays were performed on all inpts until a positive result
was obtained. Clinical parameters at admission including heart rate (HR) and temperature (T)
were recorded. Measures of inflammatory activity including white blood cell count (WBC),
platelets (PLT), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) from
the first value on admission were analyzed. Outcome measures included successful medical
therapy (pts discharged for > 1month) or need for colectomy. Results: Thirty-one consecutive
IBD colitics (58% UC, 42% CD) admitted with acute exacerbation were analyzed. Mean age
of the pts was 40 ± 17y (SD). C. diff was detected in 55% (17/31). Thirteen pts (42%)
underwent colectomy due to clinical deterioration, 7 of which had concomitant C.diff.
Duration of disease was similar between colectomy and successful medical therapy groups.
The CRP (mg/dL; normal<0.5) was elevated in all pts who underwent colectomy (mean 6.7
± 3.6 (SD)) and was significantly lower in pts with successful medical therapy (mean 2.9
± 3.1 (SD); p<0.002). CRP ≥ 3 mg/dL correlated with colectomy in 87% of pts, while CRP
< 3 correlated with colectomy in 13%. No significant correlation was found between ESR,
PLT, WBC, HR or T at presentation with clinical outcome. Co-infection with C. diff alone
did not influence colectomy rate. Conclusions: CRP above 3 mg/dL was predictive of
colectomy in IBD colitics admitted for acute exacerbation with a sensitivity and specificity
of 87% and 88%, respectively. WBC, PLT, ESR, HR, T or C. diff status failed to correlate
with clinical outcome. These data suggest that CRP offers predictive value in IBD pts admitted
with severe colitis, identifying a high risk group for surgery.
S1361
North American Inflammatory Bowel Disease (IBD) Experts and Community
Providers Are Consistent in Their Use of Diagnostic Tests in Crohn’s Disease
(CD)
Eric Esrailian, Brennan M. Spiegel, Laura E. Targownik, Marla C. Dubinsky, Stephan R.
Targan, Ian M. Gralnek
Background: Diagnostic decision-making in CD is often uncertain, and this uncertainty
often leads to a potentially arbitrary sequence of diagnostic testing with various modalities.
Although published guidelines in CD are intended to minimize variation in care, it is
unknown whether current diagnostic decision-making complies with guidelines. We there-
fore measured testing proclivity in CD between established IBD experts and community
gastroenterologists. Methods: We developed a survey consisting of 5 clinical vignettes: 1)
patient with undiagnosed CD, 2) patient with newly diagnosed CD, 3) presentation of
perianal fistula, 4) patient with steroid refractory CD, and 5) patient status post ileocolonic
anastomosis for ileal/colonic CD. The survey elicited provider beliefs about the appropri-
ateness of available diagnostic tests in CD. We measured appropriateness using the 9-point
RAND Appropriateness Scale, where 1-3=inappropriate, 4-6=unsure, 7-9=appropriate and
“endorsed.” We surveyed 55 recognized North American IBD experts and a random sample
of 91 GIs from the AGA membership. For each respondent, we itemized the total number
of diagnostic tests endorsed and diagnostic cost consumed per vignette, and calculated a
mean “CD Cost Index” (CDCI) for each respondent, defined as the total consumption across
the 5 vignettes/5. We then performed multivariable regression to identify independent
predictors of CDCI. Results: Table 1 displays the results. Community providers outspent
experts in the new presentation of CD. In contrast, experts outspent community providers
in the evaluation of a perianal fistula - a direct result of significantly higher (p<0.001)
endorsement by experts of EUS and exam under anesthesia. Regression analysis revealed
that expert status did not independently predict overall resource use, and that only provider
age was a predictor of CDCI (each 10-year increase = $179 more per vignette). Conclusions:
With the notable exception of perianal fistula, experts and non-experts are consistent in
their use of diagnostic tests in CD. This lack of systematic differences in diagnostic testing
between community and expert IBD physicians suggests that the dissemination of “best
practice” guidelines in CD may have successfully standardized care.
Table 1. Diagnostic resource use in experts vs community providers
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S1362
DLG5 R30q Does Not Predict Response to Infliximab Therapy in Hungarian
Patients with Crohn’s Disease
Simon Fischer, Peter L. Lakatos, Karolien Claes, Laszlo Lakatos, Istvan Altorjay, Tamas
Molnar, Karoly Palatka, Maria Papp, Janos Osztovits, Paul Rutgeerts, Hungarian LBD
Study Group, Severine Vermeire, Janos Papp
AIM: Recent data from Germany have suggested that specific haplotypic variants of the
DLG5 gene on chromosome 10q23 are associated with susceptibility to inflammatory bowel
disease (IBD). Since DLG5 has been implicated in maintaining intracellular signal transduction
and cell-cell contact by binding to vinexin, it might be hypothesized that DLG5 affects
inflammatory responses and, as a consequence, also response to anti-inflammatory therapy,
through influencing intestinal permeability and controlling the entry of luminal antigens
into the mucosa. In this study, we investigated the possible association between common
DLG R30Q variant allele (impairs protein’s scaffolding function) and response to infliximab
therapy in Hungarian CD patients. METHODS: 52 unrelated CD patients (m/f: 21/31,age:
34.1±11.1 years, duration: 7.6± 5.0 years). DLG5 R30Q was tested by PCR-RFLP. Clinical
phenotypes - familial disease, age, age-at-onset, duration, location, disease behavior, perianal
involvement, extraintestinal manifestations (arthritis, PSC, ocular and cutaneous), need for
steroid or azathioprine, steroid resistance, need for surgery or multiple resections and
smoking habits - were determined by questionnaire. Comparisons between groups were
made by χ2 test using SPSS13.0 software. RESULTS: 28.8% of CD patients treated with
infliximab carried the 113A. Disease location was ileal in 6, colonic in 18 and ileocolonic
in 28 patients. In addition, two patient had upper GI involvement. Disease behavior was
inflammatory in 25 and penetrating in 27. Perianal complications were observed in 27
(51.9%) of the patients. 48.1% of patients had joint manifestations and the rate of cutaneous
and ocular manifestations was also high (13.5% and 15.4%). Steroids (98.1%) and azathiop-
rine (92.3%) were prescribed to almost all patients. The indication for infliximab was
fistulizing disease in 18 patients and inflammatory, non-responsive to conventional therapy
in 34. Overall, no association was found between the carriers and non-carriers of the 113A
variant allele and short term response (assessed at week 8) to infliximab induction therapy
(dose 5mg/bwkg; no response or worsening: 20.0% vs. 27.0%, partial response (CDAI
decrease by ≥70 points and/or ≥50% decrease in the number of draining fistulae) : 46.7%
vs. 43.3%, remission (CDAI<150 or closure of all fistulas): 33.3% vs. 29.7%). CONCLUSION:
DLG5 R30Q variant allele did not predict the response to infliximab therapy in this cohort
of Hungarian CD patients.
S1363
Comparative Evaluation of the Diagnostic Accuracy of Fecal Markers in the
Identification of Intestinal Inflammation: Appraisal for Monoclonal
Calprotectin
Oliver Schroeder, Marc Naumann, Yogesh Shastri, Nada Povse, Juergen Stein
Introduction: In recent years, fecal leukocyte-derived markers such as calprotectin, lactoferrin,
and PMN-elastase have been established as noninvasive diagnostic tools to test patients for
gastrointestinal inflammation as a cause of chronic diarrhea. The aim of this study was to
evaluate the clinical accuracy of various fecal marker tests to detect patients with inflammatory
bowel disease (IBD) as compared with the non-inflammatory condition, irritable bowel
syndrome (IBS). Material and Methods: 103 consecutive patients with chronic diarrhea and/
or abdominal pain who were scheduled for colonoscopy to rule out IBD were included into
the study. A full medical history was obtained and a physical examination was performed.
All patients underwent hematological and biochemical investigations, antibody testing for
coeliac disease as well as a lactose-H2 breath test before endoscopic evaluation. In addition,
each participant provided one stool sample (5g) for determining calprotectin monoclonal
and polyclonal antibody testing, PMN-elastase and lactoferrin within one week prior to
colonoscopy. Results: From the enrolled participants, a total of 11 patients had to be excluded
from further study participation because of not meeting the diagnosis of either IBD or IBS.
41 patients with Crohn’s disease, 20 patients with ulcerative colitis, and 31 IBS patients
were recruited. The mean (± SD) fecal calprotectin concentrations determined with the
monoclonal and polyclonal antibody antibody assay were 257 ± 427 µg/g and 593 ± 423
µg/g in patients with IBD, and 7 ± 6 µg/g and 33±50 µg/g in patients with IBS. The
corresponding mean (± SD) lactoferrin and PMN-elastase concentrations were 85 ± 112 µg/
g and 115 ± 169 ng/ml in patients with IBD, and 1 ± 2 µg/g and 8 ± 9 ng/ml in patients
with IBS. The diagnostic accuracy of each individual test is present in Fig. 1. Conclusions:
Among the four different assays evaluated monoclonal based calprotectin was found to be
the most accurate stool marker to detect IBD vs. IBS, which makes it an extremely useful
addition to the diagnostic armamentarium in patients with chronic diarrhea and abdominal
pain. This method can prove to be useful not only in research settings, but also in clin-
ical settings.
Diagnostic accuracy of fecal stool markers to detect IBD
S1364
Beneficial Behavioural Effects of IBD Therapy and Gluten/Casein-Free Diet in
An Italian Cohort of Patients with Autistic Enterocolitis Followed Over One
Year
Federico Balzola, Daniela Clauser, Alessandro Repici, Marina Caldognetto, Claudio
Barletti, Anna Sapino, Cristiana Barbera, Pierluigi Calvo, Dario Reggio, Fabrizio Gennari,
Antonello Nonnato, Marco Forni, Isabella Morra, Marina Gandione, Roberto Rigardetto,
Mario Rizzetto
Autism diagnoses alone have risen from 1:5000 in 1980 to a frightening 1:120 today, that
cannot only be the result of better diagnostic variation or recognition of the disease. A
substantial proportion of pts with regressive/late onset autism showed evidence of a previously
unrecognized IBD, labelled autistic enterocolitis characterized by lymphoid nodular hyperpla-
sia and chronic ileo-colitis. Although improvements in autistic behaviour has been reported
when gluten and casein exclusion diets was introduced, no data is available on the effect
of specific bowel therapy on the psychiatric symptoms. We aimed to evaluate the effects of
specific IBD therapy together with the gluten/casein free diet on specific gastrointestinal and
autistic symptoms in a cohort of regressive/late onset autistic pts with autistic enterocolitis,
followed over 12 months. Among the 85 consecutive autistic pts observed, 40 presented
with severe constipation or diarrhoea. In 12 of them (male, median age 16 yrs, 4-30) an
endoscopy and wireless capsule examination were performed because of the permission of
the parents and then enrolled in the follow-up study. Macroscopic lesions were observed
in 55% of the pts in both the upper and lower gastrointestinal tract. Microscopic involvement
was observed in 70%, 60% and in 100% of pts in the upper gastrointestinal tract, in the
terminal ileum and in the colon respectively, with different histological grade. Mesalazine
(8 pts), steroids (2 pts) and 6-mercaptopurine (2 pts) were prescribed according to the
histological/clinical score. Casein-free diet and successively glutein-free diet were introduced
within the first 3 months by a dietician. A Behavioural Summarized Evaluation (BSE, a score
with 29 behavioural items with a degree of frequency validated with a statistical correlation
with the Childhood Autism Rating Scale) was used to blindly evaluate the pts at entrance
and after 12 months. After 1 year treatment, 80% of pts with severe constipation or diarrhoea
had normal stool movements and in 75% an evident reduction of abdominal pain was also
observed. The total BSE score showed a global improvement after 12 months that ranged
from 10 to 32% (p=0.00388) in all the pts evaluated. When selected symptoms were
compared before and after the treatment a reduction of deep anxiety (53%), agitation (35%),
mood disturbance (24%), etero-aggressivity (14%), self-aggressivity (13%) as well as an
improvement of attention (77%) and sleep (44%) were also observed (p=0.009796). In
conclusion, these results proved for the first time a beneficial effect of the combination of
drug and dietetic therapy on both bowel and psychiatric symptoms in autism.
S1365
Reliability of IBD Phenotyping Within the Niddk IBD Genetics Consortium
(IBDGC)
Hillary Steinhart, Themistocles Dassopoulos, Geoffrey C. Nguyen, Alain Bitton, Gillian P.
Bromfield, L. Philip Schumm, Yahong Wu, Abdul A. Elkadri, Miguel Regueiro, Benjamin
Siemanowski, Esther A. Torres, Frederico J. Gregory, Sunanda Kane, Laura E. Harrell,
Denis Franchimont, Steven R. Brant, John D. Rioux, Huiying Yang, Richard H. Duerr,
Mark S. Silverberg, Judy H. Cho
Background: In 2002, the NIDDK IBDGC began collecting DNA and phenotypic data from
large numbers of IBD subjects in order to provide a resource to accelerate the search for
disease susceptibility genes. Inclusion of phenotypic information into genetic studies has
become a required norm. However, no studies have been performed thus far on the reliability
of phenotypic determinations in both Crohn’s Disease (CD) and ulcerative colitis (UC) using
primary records. The purpose of this study was to determine the inter-rater reliability for
the determination of basic phenotypic characteristics. Methods: The medical records of 5
IBD patients were selected from each of the 6 NIDDK IBDGC Genetic Research Centers
(GRC). Selection of records was carried out so as to ensure an appropriate distribution of
IBD disease types (CD/UC/indeterminate colitis) and CD behaviors. The entire medical
records were de-identified and 20 were reviewed by 2 phenotypers at each of the 6 GRCs.
Phenotypers rated medical records according to disease type, disease location or extent, CD
disease behavior, extraintestinal manifestations, year of diagnosis and need for surgery (240
separate evaluations of 20 datapoints each). The inter-rater reliability for each of the variables
was expressed as the kappa statistic with a 95% confidence interval. Results: Agreement for
disease diagnosis was excellent (κ = 0.84; 95% CI 0.70, 0.97). Agreement for individual
CD locations (jejunal, ileal, colorectal, perianal) was good with κ between 0.65 and 0.69
for each. Agreement for esophagogastroduodenal location was fair (κ = 0.30) but this
appeared to be due to the difficulty determining presence or absence of disease when specific
evaluation had not been performed. Agreement for UC disease extent was very good (κ =
0.72; 95% CI 0.56, 0.94) and for CD behavior was very good (κ = 0.69; 95% CI 0.46,
0.88). Insufficient numbers of extraintestinal manifestations were present to allow precise
estimates of reliability for determination of those complications. Conclusions: Detailed defini-
tions of phenotypic characteristics of disease diagnosis, CD behavior and disease location/
extent provided very good inter-rater agreement. Further evaluation of agreement regarding
less common manifestations or complications is required. These results provide a basis for
assessing which phenotypic measures are robust to interobserver variability. They also
provide explicit empiric estimates of the phenotyping error rates which should be considered
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when assessing significance estimates of subsequent genotype-phenotype studies in IBD.
Studies of intra-rater reliability are underway and results will be presented.
S1366
Relationship Between 6-Mercaptopurine Dose and 6-Thioguanine Nucleotide
Levels in Patients with Inflammatory Bowel Disease
Ahmed Morales, Sandhya Salguti, Chuan L. Miao, James D. Lewis
Background: 6-Thioguanine nucleotides (6TGN) are active metabolites of azathioprine (AZA)
and 6-mercaptopurine (6MP). Studies document higher remission rates for patients with
higher 6TGN levels. However, controlled trials of AZA/6-MP have traditionally used fixed
or weight-based doses to evaluate their efficacy, and many physicians prescribe AZA/6MP
using mg/kg dosing regimens without measuring 6TGN levels. We sought to determine the
relationship between AZA/6MP dose and 6TGN levels. Methods: Cross-sectional study of
patients treated for IBD with AZA/6MP at a tertiary care hospital who had 6TGN levels
measured. Patients with low or intermediate TPMT activity were excluded (N=13). AZA
dose was converted to 6MP equivalents. The relationship between dose and 6TGN levels
was assessed with the Spearman correlation coefficient. We also used logistic regression
after dichotomizing the 6TGN level as above or below 230 pmol/8x108 RBC to adjust for
potential confounders (age, sex, disease type, disease activity, use of oral 5-ASA, use of oral
steroids). For patients with multiple measurements, only the patient’s first measurement
was used in the analyses. Secondary analyses excluded any measurements where the 6TGN
level was less than 100 pmol/8x108 RBC (N=28) and/or patients without TPMT testing (N=
46). Results: 134 patients met our inclusion criteria (55 UC, 75 CD, 4 indeterminate colitis;
mean age 36.5±11.9; 53% in remission; median duration of AZA/6MP therapy 48 weeks,
range 2 to 832 weeks; median dose 1.09mg/kg, range .32 to 2.10 mg/kg). There was a weak
but statistically significant correlation between 6TGN levels and the absolute dose (rho=.18,
p=.04) and the dose in mg/kg (rho=.19, p=.03). The correlation between mg/kg dosage and
6TGN levels was slightly stronger in those using concomitant 5-ASA medications (rho=.24,
p=.02). Results of the logistic regression analyses adjusted for 5-ASA and disease activity
are shown in the table. Adjustment for other potential confounders did not change the
unadjusted odds ratio (OR) by more than 10%. Secondary analyses gave similar results (data
not shown). Conclusions: AZA/6MP dose is weakly associated with 6TGN levels. Less than
50% of patients prescribed 6MP dose of 1mg/kg or greater have 6TGN levels above 230
pmole/8x108 RBC. Use of standard mg/kg dosing regimens will result in low 6TGN levels
in the majority of patients.
*pmole/8x108 RBC
S1367
Does Faecal Calprotectin Predict Risk of Relapse in Crohn’s Disease Patients
Lacking Objective Clinical Evidence of Inflammatory Disease Activity?
David A. Watts, Norman Anderson, Gordon Brydon, Jack Satsangi, Subrata Ghosh
Background: Marked elevation of faecal calprotectin (>200ug/g) has been shown to be
especially valuable in predicting risk of relapse in quiescent Ulcerative Colitis. Our aim was
to evaluate the predictive value of even modest elevation of faecal calprotectin for clinical
relapse in Crohns disease in asymptomatic patients in clinical remission(GroupA) or in those
symptomatic patients lacking objective evidence of inflammatory disease activity
(GroupB).Method: 25 patients (median age 39y)were enrolled in Group A and 44 patients
(median 35y) in Group B. Informed consent obtained from all patients prior to faecal
sampling. Quantitative assay of calprotectin made by ELISA. Baseline Creactive protein (CRP)
and ESR were recorded. Relapse rates analysed by Kaplan Meier survival. Results: Group A
median calprotectin was 12ug/g (1-302) with significant correlation to ESR (p=0.03) and
CRP (p<0.0001). 2 patients were lost to follow up. 23 patients were followed up for a
median of 48 months (12 - 48). 76%(n=19)had normal (<35ug/g)calprotectin (median 3ug/
g)and remission rates at 12, 24, 36 and 48 months were 83%,76%,76% and 60%. 5 patients
had elevated calprotectin and followed up for mean 31.2 months (24 - 48 months). No
relapse was seen in this group during follow up. No statistical difference in relapse rate was
demonstrated between the 2 groups (p=0.22).Median calprotectin in group B was 63.1ug/
g (1-472). Significant correlation to ESR(p= 0.03)and CRP (p= 0.01}was shown. Clinical
outcome: 66% (n=28) had normal calprotectin (median 8ug/g)and 34% (n=16) had raised
calprotectin(median 90ug/g). 43/44 patients entered follow up. Mean follow up in those
with normal calprotectin was 43.1 months (12-48). Remission rates for those with normal
calprotectin at 12,24,36,48 months was 78%,63%,40%, 40%. In those with high calprotectin
mean follow up was 41.2 months (12 - 48). Remission rates in this group were 56%, 38%,
25% and 17% at 12, 24, 36 and 48 months. The difference between the relapse rates failed
to reach statistical significance (p=0.068).Conclusion: Faecal calprotectin correlates with
ESR and CRP at times of both clinical remission and uncertain clinical activity. A small
proportion of Crohns disease patients in clinical remission have elevated faecal calprotectin
but this data did not demonstrate a higher rate of relapse of disease in either those with
raised faecal calprotectin whilst in clinical remission or in symptomatic patients where
clinical evidence of disease activity is lacking. The conflict with previously published data



















Orofacial Granulomatosis: Experience from a Combined Oral Medicine/
Gastroenterology Clinic
Carlo Nunes, Michael P. Escudier, Pepe Shirlaw, Stephen Challacombe, Jeremy D.
Sanderson
Background: Orofacial granulomatosis (OFG) is a rare chronic inflammatory disease of
unknown aetiology sharing histological features with gut Crohn’s disease (CD). Presentation
is characterized by lip swelling but the clinical spectrum includes mucosal cobblestoning,
mucosal tags, and deep linear intra-oral ulceration. We have been running a combined Oral
Medicine/ Gastroenterology clinic since 1995 dedicated to patients with OFG. Previous
studies addressing the clinical features and natural history of OFG are limited. Objectives:
To gain insight into the overall presentation and clinical features in patients with OFG
referred to a dedicated OFG clinic. Methods: In a retrospective study, case notes of patients
with OFG attending a combined Oral Medicine/ Gastroenterology clinic were reviewed. Data
were extracted for age of onset, sex, clinical features, blood parameters, concurrent CD and
patch testing. A concurrent diagnosis of CD was established by standard criteria. Results:
Results were available on 73 patients of whom 36 (49%) were female. Median age of disease
onset was 24 years. Thirty-six percent were referred by maxillo-facial surgeons and only
15% by gastroenterologists. Fifteen (21%) had concurrent CD. Lip swelling (69%) and
buccal involvement (75%) were the most common sites involved followed by gingivae and
floor of the mouth. Mucosal tags (47% vs. 28%) and cobblestoning (40% vs. 19%) were
more common in patients with concurrent CD as were haematinic deficiencies (53% vs.
29%) and raised inflammatory markers (60% vs. 17%). Those with OFG alone (29% vs.
9%) were more likely to be patch test positive. No consistent allergen was identified from
patch testing. Conclusion: OFG affects predominantly young adults with lip and buccal
involvement the most common clinical presentation. Mucosal tags and buccal cobblestoning
are more likely in those with concurrent CD. Tests for cutaneous sensitivity are more often
positive in OFG than CD in keeping with the view that OFG has an allergic component.
S1369
Anti-Laminaribioside and Anti-Chitobioside Antibodies As Predictors of
Crohn’s Disease
Eran Israeli, Itamar Grotto, Miri Blank, Liat Anafi, Eran Goldin, Yehuda Shoenfeld
Background: Anti Saccharomyces cerevisiae mannan antibodies (ASCA) are associated with
Crohn’s disease (CD). We have previously shown that ASCA were present in the sera of
patients many years before clinical diagnosis, with an increase of antibody levels as the time
to diagnosis was approached. Novel anti-glycan antibodies, anti-laminaribioside -IgG (ALCA)
and anti-chitobioside -IgA (ACCA), were found to be specific for CD. A combined panel of
these antibodies improved sensitivity and specificity for diagnosis of CD in established
patients. We assessed the onset and development of the aforementioned antibodies before
diagnosis of CD. Methods: Utilizing the Israeli Defense Force (IDF) Serum Repository, we
identified sera samples from 28 persons obtained an average of 64 ± 55 months before onset
of CD, as well as 52 sera from controls matched for gender, age and day of recruitment.
Sera were tested for gASCA-IgG, ALCA and ACCA. Results: 12/28 (43%) of the study group
were positive when combining a positive gASCA or ALCA vs. 1/52 (2%) among matched
controls (p<0.001). ACCA was positive in 12/28 (43%) of the study group but also in 24/
52 (46%) of matched controls. The average level of all three antibodies in sera obtained
from patients after CD diagnosis was higher then in sera obtained from patients before CD
diagnosis (the study group). This difference reached statistical significance only for gASCA
(107.6±72.9 U vs. 4.5±53.5 U respectively, p=0.04). Conclusions: A panel combining gASCA
and ALCA has an improved sensitivity for predicting CD. References: 1) Israeli E et al.
Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of
inflammatory bowel disease. Gut 2005;54:1232-6. 2) Altstock RT, et. al. Gastroenterology
2005;128;A-303
S1370
Fecal Calprotecin Is a Reliable Surrogate Marker for Endoscopic Activity in
Crohn’s Disease
Geert R. D'Haens, Filip Baert, Maja Noman, Gert van Assche, Marijke van Camp, Gust
van Olmen, Doreen Iwens, Patrick Hanaway, Amy Peace-Brewer, Severine Vermeire, Paul
Rutgeerts
Introduction: Fecal calprotectin has been proposed as a marker of inflammatory activity in
inflammatory bowel disease (IBD). The test was shown to correlate with disease activity in
children and found to be a predictive marker of relapse in patients with both ulcerative
colitis (UC) and Crohn’s disease (CD)(Buhn, 2001, Costa, 2005). In addition, normal
calprotecin levels have been associated with absence of endoscopic lesions (Røseth 2004).
Since endoscopic healing has become a goal of treatment in CD, we examined the correlation
between fecal calprotectin levels and clinical and endoscopic activity in a cohort of CD
patients. Methods: 106 CD patients who were scheduled for colonoscopy at three IBD
referral hospitals were invited to deliver a sample of feces immediately prior to the start of
their bowel cleansing. All indications for colonoscopy were accepted.Patients also completed
a CDAI, Euroquol and IBDQ and had a blood test for serum CRP, albumin, Hct and
thrombocytes. All gave informed consent. Six endoscopists experienced in IBD completed
the scoring sheets for SES-CD and CDEIS immediately after the procedure. All stool samples
were frozen and sent to Genova Diagnostics for measurement of calprotectin with PhiCal
Assay (ELISA)and lactoferrin, both neutrophilic markers in the feces. Correlation analysis
was done with Spearman Rank tests. Results: 106 CD pts (57 male, age 39±13, age at
diagnosis 28.6±12.3 yrs)were studied. The median fecal calprotectin was 142 μg/gram (IQR
42-775). The Calpro values correlated in decreasing order with: SES-CD (r=0.47, p<0.0001),
CDEIS (r=0.44, p<0.0001), CRP (r=0.43 p<0.0001)and thrombocytes (r=0.32, p<0.001).
Poor correlations were seen with the clinical scores CDAI (r=0.13)(NS) and IBDQ (r=-
0.22)(NS). Fecal Calpro- en lactoferrin levels correlated at r= 0.43 (p<0.0001). Conclusion:
fecal calprotectin and lactoferrin levels correlate significantly with endoscopic disease acticity
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in CD and poorly with clinical scores. Whether the test can replace other commonly used
biological markers remains te be determined.
S1371
Fecal Excretion of Human Deoxyribonucleic Acid in Long Term Follow-Up of
Ulcerative Colitis
Francesc Casellas, Natalia Borruel, Antonio Torrejon, Encarnacion Varela, Maria Antolin,
Francisco Guarner, Juan-Ramon Malagelada
Several indices evaluate disease activity in ulcerative colitis (UC), but most of them have
drawbacks to its application and discrepancies between them are frequent. Assuming that
luminal desquamation of epithelial and inflammatory cells increases in damaged colonic
mucosa, we have previously shown that fecal excretion of human DNA is an index of mucosal
damage. However, it has not been established the potential role of fecal DNA measurement
in the follow-up of patients with UC. AIM: To determine the stability of fecal DNA in
inactive UC and its value as an objective marker of relapse. METHOD: Prospective study
in UC patients in clinical remission treated with oral mesalamine followed for 12 month or
until clinical relapse (Clinical Activty Index > 7) with determinations of fecal calprotectin
by ELISA and fecal human DNA concentration by quantitative PCR of the human beta-
globine gene. RESULTS: 54 with clinically inactive UC (median CAI 0.0, hemoglobin 13.9
g/dl, ESR 8.0 mm/fh) were included. During the follow-up, 23 patients (42.5 %) relapsed,
showing a median increase in CAI from 1.0 to 8.0 (p<0.01). Levels of fecal DNA remained
unchanged in patients with stable inactive UC, ranging between 1.4E+03 and 8.4E+04 cop/
mg (25 to 75 percentils) during the one-year follow-up. In contrast, a significant increase
in concentration of fecal DNA was observed in patients who relapsed (2.5E+05 [5.9E+04 -
2.8E+06] cop/mg at relapse vs 3.9E+03 [1.1E+03 - 4.4E+04] at entry, p<0.01). Fecal
calprotectin levels were stable in patients in remission, ranging between 41 and 1356 microg/
g (25 to 75 percentils). Relapsing patients showed a significant increase in fecal calprotectin
(2327.0 [810 - 4314] microg/g at relapse vs 389.5 [103 - 1388] at entry, p<0.01). CONCLU-
SIONS: Human fecal DNA concentration remains stable in patients with inactive UC treated
with mesalamine, but increases significantly during relapse. Determination of human fecal
DNA may be a new objective instrument in the follow-up of UC patients.
S1372
A Rapid One-Hour Infusion of Infliximab Is Well-Tolerated
Micha Rojany, Jacob Wegelin, Walter Trudeau, Thomas Prindiville
Background: Infliximab is indicated for use in moderate to severe Crohn’s disease and
has been effective for the induction and maintenance of remission in both fistulizing and
inflammatory disease. However, infusions are not without risk with approximately 4% of
infusions associated with an infusion reaction. Aim: To determine if patients with Crohn’s
disease would be able to tolerate a rapid 1 hour infusion safely with an acceptable rate of
infusion reactions. Methods: We retrospectively reviewed the charts of all adult patients
with Crohn’s disease who received Infliximab infusions between January 2003 and September
of 2004. All patients started with a standard induction therapy at 0, 2, and 6 weeks followed
by maintenance therapy every 8 weeks. Patients without history of any moderate or severe
infusion reaction, or severe systemic disease were eligible to receive a 1-hour infusion of
Infliximab. All patients were monitored for infusion reactions that were categorized as acute
or delayed and further classified as mild, moderate, or severe. For group comparison, logistic
regression was used to compare the probability of an infusion reaction between groups with
gender and age as covariates. For analysis within individual patients, generalized linear
mixed models were fit to assess the chance of a reaction by rate with sex, age, and immunomo-
dulator-use as covariates. Results: There were a total 731 infusions with 547 standard
infusions and 184 rapid infusions studied. None of the patients were on steroid therapy.
49 patients received only standard infusions and 49 received at least one rapid infusion (40
M 58 F).92% (87/95) of patients were on immunomodulators. The mean number of infusion
reactions was 0.4 reactions per patient. 11/49 (22%) patients in the standard group and
14/49 (29%) in the rapid group had at least one infusion reaction (p>0.5, chi-square test).
The rapid infusion group had a total of 14 infusion reactions (7 mild, 7 moderate). 9/49
(18%) patients in the rapid infusion group returned to standard infusions due to infusion
reactions. In the group comparison neither age nor sex was associated with infusion reactions
(p>.10). Individual analysis revealed younger men undergoing rapid infusions had a higher
probability of infusion reactions (p<0.05). Older women receiving rapid infusions also had a
higher rate of infusion reactions but this was not statistically significant (p=0.10). Conclusion:
Appropriate patients tolerated a rapid 1-hour infusion. Patients could be offered a rapid
infusion as an alternative to conventional 2 to 3 hour infusions.
S1373
Calprotectin and Lactoferrin Decrease with Maintenance Infliximab
Administration in Luminal Crohn’s Disease
Ron Palmon, Steven Brown, Thomas A. Ullman, Patrick Hanaway, Lloyd F. Mayer
Non-invasive markers of inflammation have previously been shown to be useful in the
diagnosis and assessment of disease activity in patients with inflammatory bowel disease
(IBD). Two fecal markers, calprotectin (CL) and lactoferrin (LA), have been the most extens-
ively studied. However, few studies have actually compared the reliability of these measure-
ments in patients undergoing maintenance therapy with infliximab (IFX). Methods: We
initiated a prospective study measuring fecal calprotectin (CL) and lactoferrin (LA) in 17
patients with Crohn’s disease receiving maintenance IFX treatment for luminal but not
fistulizing disease and compared the levels with a Harvey Bradshaw disease activity index
(HBI). Stool samples and HBI were collected at the time of treatment (baseline) and every
2 weeks afterward for a total of 8 weeks. Results: Median CL at baseline was 343 ug/g (range
16-2500). (CL > 250 ug /g = active IBD). At week 2, CL decreased from baseline in 13 of
the 16 patients with available levels (p=.02 by Sign test). Median CL at this time interval
was 179 ug/g (a 48% decrease from baseline). By week 4, CL had risen back toward baseline
values, with median CL of 297 ug/g. A sustained drop in LA was seen after IFX treatment:
Baseline median LA was 52.2 ug/g (range 4-1724). A decrease in LA at week 2 was noted
in 12 of 16 patients with available levels (p=0.01 by Sign test). Median LA at this time
interval was 31.8 ug/g (a 39% decrease from baseline). Median LA at week 4 remained
decreased at 32.1 ug/g. Median HBI was 6 at baseline reflecting relatively mild disease;
median HBI was 3.5 at week 2 and remained low at an HBI of 3 at week 4. Conclusions:
CL and LA levels parallel successful IFX treatment, likely reflecting decreased enteric inflam-
mation. The rise in CL but not LA at week 4 suggests that this may be a more sensitive
indicator of a subclinical rebound in inflammatory activity, although further evidence is
required to confirm this. Our results suggest that non-invasive fecal inflammatory markers
may be useful in monitoring CD patients receiving IFX therapy.
S1374
Crohn’s-Like Disease Following Ileal-Pouch Anal-Anastomosis (IPAA) for
Ulcerative Colitis (UC) Is Associated with IBD Serology Seroconversion
John B. Averette, Steve F. Polyak, John F. Valentine
INTRODUCTION: Total colectomy with IPAA is the current recommended therapy for
severe, medically refractory UC. IPAA is not recommended for patients with Crohn’s disease
(CD) due to the high rate of complications, including fistulae, strictures, abscesses, and
pouch failure. Serum perinuclear anti-neutrophil cytoplasmic antibody (pANCA) is associated
with UC, with a sensitivity of 60-80% and specificity of 90%. Antibodies to Saccharomyces
cerevisiae (ASCA) have been associated with CD, with a sensitivity of 60-70% and specificity
of 91%. Some patients develop CD or Crohn’s-like disease following IPAA. We previously
reported a series of 11 patients with IPAA CD-like complications of which 45% were ASCA
(+). Unfortunately, we did not have pre-colectomy serologies. METHODS: We report 4 cases
of patients diagnosed with UC based on clinical, endoscopic, and pathologic criteria that
developed CD-like features following IPAA. Each patient had no significant expression of
ASCA antibodies at the time of diagnosis or immediately following total colectomy with
IPAA for refractory UC. Following surgery, these patients developed CD-like complications
and therefore IBD serologies were reassessed. RESULTS: Two patients were male and two
were female. Their ages at diagnosis of UC ranged from 15 to 22 years. Time from diagnosis
to surgery ranged from two months to 25 years after diagnosis. CD-like complications
developed ten to twenty-five months after the IPAA. The CD-like disease that developed
following IPAA for UC included ulceration in the ileum above the pouch (N=3), jejunal
ulceration (N=1), persistent anal fissure (N=1), perianal fistula (N=1). None of the patients
had granulomatous inflammation. The initial and follow up IBD serologies are shown in
the table. CONCLUSIONS: This is the first report of IBD serology seroconversion in patients
with IPAA. Our findings show that expression of ASCA antibodies can change over time
and that following IPAA for UC, the development of CD-like pathology is associated with
ASCA seroconversion. The significance of this finding is unclear. ASCA antibodies may be
a marker of small bowel inflammation, or may indicate that the patient has developed CD.
Our findings question the stability of serological expression of pANCA and ASCA over long
periods of time. Larger, more detailed examination of this patient population will hopefully
clarify these issues.
IBD Serologies
All units in EU/mL
S1375
Can High-Sensitive C-Reactive Protein Be a Biomarker for Patients with
Ulcerative Colitis?
Yoshiaki Takeuchi, Fumihiko Nozu, Katsuhito Arai, Michio Imawari
Introduction: Although there is no clear gold standard, much effort has been made to evaluate
severity of ulcerative colitis (UC) by using indices including symptoms, characteristics of
stool, biomarkers, and endoscopic findings. Among them, symptoms reported by patients
appear to be appropriate, however, symptoms of mild UC is often similar to those of irritable
bowel syndrome in quiescent UC patients. Therefore, more reliable and practical measures
are required. One of the conventional and non-invasive biomarkers, C-reactive protein (CRP)
has been used for assessment of inflammatory bowel disease, and its usefulness has recently
been documented mostly in Crohn’s disease and not in UC. High-sensitive CRP (HS-CRP)
can detect as low as 0.2 mg/L quantitatively and could be a potent biomarker to assess
underestimated mild UC. The aim of this study is to evaluate whether high-sensitive CRP
can be a biomarker for UC patients. Methods: Twenty UC patients with conventional CRP
being less than 5 mg/L were recruited in this study. Patients were defined as symptomatic
if one of the followings was observed; bloody stool, four or more of bowel movements,
lower abdominal pain, rectal urgency, and continuous unformed stool. Biomarkers including
complete blood cell count, erythrocyte sedimentation rate, albumin, CRP, and HS-CRP were
obtained. Fifteen subjects underwent colonoscopic examination within two weeks of sampling
of biomarkers. Fischer’s exact test was used to assess associations of HS-CRP. All patients
gave written informed consent and this study was approved by ethical committee in our
institution. Results: Ten out of 20 subjects had co-morbid diseases such as cardiovascular
diseases and primary biliary sclerosis. Eight out of 20 patients were symptomatic and all of
them consistently presented inflamed colonic mucosa (Matt’s grade 1) by colonoscopy. While
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7 of 8 symptomatic patients had increased HS-CRP, 7 out of 12 asymptomatics also showed
elevated HS-CRP (P>0.05). Among 7 asymptomatic subjects with increased HS-CRP, 6 had
co-morbid diseases, suggesting that HS-CRP increased independent of UC activity. Even
when subjects with co-morbid diseases were excluded, HS-CRP was not associated with
symptoms. No other biomarkers were associated with increased HS-CRP. Conclusions: In
UC patients, increased HS-CRP was not associated with disease activity, rather appeared to
be influenced by co-morbid diseases. HS-CRP could not be a biomarker to assess minimal
inflammatory change in UC patients.
S1376
Serologic Markers As Quantitative Predictors of Inflammatory Bowel Disease
Activity - Clarifying the Cart and the Horse
David M. Poppers, Brian P. Bosworth, Douglas M. Weine, Quanhong Ni, Ellen J. Scherl
Background: Inflammatory Bowel Disease (IBD) comprises a spectrum of chronic illness,
and is classically categorized as Crohn’s Disease (CD) or ulcerative colitis (UC), with signific-
ant overlap between these diseases. There has been great interest in using serologic markers
(primarily anti-Saccharomyces cerevisiae antibodies (ASCA) and perinuclear antineutrophil
cytoplasmic antibody (pANCA)) to distinguish between UC, CD, and indeterminate colitis
(IC). ASCA is often detected in the serum of CD patients, and pANCA is associated with
UC. Other data suggest that ASCA is more related to small intestinal/fibrostenotic disease,
and pANCA associated with colitis. There has been no published association between severity
of disease and quantitative levels of these markers. Aim: We conducted a prospective study
to determine if alterations in serologic titers for pANCA and ASCA are associated with degree
of disease activity. Methods: A blinded, prospective cohort study of 19 patients with CD, UC,
and IC from 1998-2005 was conducted. These patients were maintained on aminosalicylates,
antibiotics, immunomodulators (azathioprine, 6-MP, cyclosporine), or infliximab, or com-
binations thereof. Patients were evaluated endoscopically and by established disease activity
indices, and with measurement of serum ESR, pANCA, ASCA (IgA/IgG), and OmpC. Results:
For 19 patients with a mean follow-up of 4.8 years, quantitative pANCA and ASCA titers
correlate with IBD activity particularly in cases of marked colitis, and with ESR and endoscopic
activity. Most strikingly, lower pANCA levels were associated with a decline in the Harvey
Bradshaw Index (HBI, p=0.03), with a trend toward lower Sutherland Index (SI, p=0.09).
This was most notable with the addition of 6-MP, cyclosporine, or infliximab in colitis
patients, with decreases in pANCA that parallel those in HBI/SI and ESR. Although not
statistically significant, a similar trend was noted for OmpC, a marker associated with small
bowel inflammation. There was likely a trend toward association between lower ESR and
lower SI (p=0.12), and lower HBI (p=0.08). A trend toward lower ASCA IgA with decreased
ESR was seen as well. Conclusions: This study demonstrates a relationship between IBD
activity and titers of serologic markers. It is intriguing to postulate that pANCA and other
markers are surrogates for disease activity, and may predict therapeutic response to immuno-
modulator or biologic therapy. Future studies evaluating novel markers, including OmpC and
flagellin/CBir1, may enhance the specificity of UC/CD discrimination, and stratify therapeutic
responses, to tailor therapy for more severe cases.
S1377
Lymphopenia Cd4 Counts in Patients with Inflammatory Bowel Disease and
Low
Darrell G. Finlay, Samir Nath, Andrew Dupont, Joseph H. Sellin
Introduction: Dysregulation of the immune response plays a major role in the pathogenesis
of IBD. In addition, many medical therapies for IBD are aimed at modulating the immune
response. To our knowledge, there are no described alterations in T-cell lineages in patients
with IBD. We describe a series of patients with documented IBD who had a profound
lymphopenia and very low CD4 count. Aims: i) Assess the frequency of decreased lymphocyte
count in patients with IBD. ii) Identify factors that may be associated with lymphopenia.
Methods: We performed a retrospective and prospective chart review of 100 consecutive
patients with IBD at 2 tertiary referral centers. Routine complete blood counts were obtained
from 3 reference laboratories. Lymphopenia was defined as less than 850 lymphocytes/cc,
which was the strictest criterion from the 3 different laboratories. The data were analyzed
by performing chi-square analyses using the NCSS statistical software package. Results: 21/
100 (21%) of patients were lymphopenic, (total lymphocyte count less than 850 lymphocytes/
cc). Of those 21 patients, all were HIV negative. Flow cytometry performed on 4 patients
revealed an abnormally low CD4 count (range 97-249). The CD4/total lymphocyte ratios
ranged from 0.28 - 0.54 for these 4 patients. 1/4 patients with a low CD4 count had an
opportunistic infection (herpes zoster). We examined factors that may be associated with
lymphopenia. 86% of lymphopenic patients were on 6-MP/Azathioprine versus 48% of
patients having a normal lymphocyte count while on 6-MP/Azathioprine (p=0.002). No
differences were found for other medications, including 5-ASA, prednisone and Infliximab.
There were no differences in disease distribution (UC vs. CD) in the lymphopenic vs.
the non-lymphopenic patients. Similarly, there were no gender differences between the 2
populations. Conclusions: The prevalence of lymphopenia in patients on 6-MP/Azathioprine
is surprisingly high. In addition, all patients who underwent flow cytometry had a low CD4
count. Use of immunosuppressives, but not other medications, appears to be associated
with the development of lymphopenia. The clinical significance of this remains to be deter-



















Does Preoperative Wireless Endoscopic Capsule Predict Long-Term Outcome
After Ileal Pouch-Anal Anastomosis (IPAA)?
Stefanie J. Schluender, Shahab Mehdizadeh, Eric A. Vasiliaukas, Marla Dubinsky,
Konstantinos A. Papadakis, Andrew Ippoliti, Simon Lo, Stephan Targan, Phillip Fleshner
PURPOSE: The extent of preoperative small bowel (SB) mucosal inflammation in ulcerative
colitis may be an important predictor of outcome after IPAA. Although small bowel follow-
through (SBFT) is the traditional method for assessing SB inflammation, wireless capsule
endoscopy (WCE) appears to be more sensitive for the assessment of mucosal lesions than
radiological testing. The purpose of this study was to investigate the value of preoperative
WCE in predicting long-term outcome of IPAA in patients with ulcerative colitis or indeterm-
inate colitis. METHODS: 24 patients undergoing WCE before having an IPAA over the 4-
year period ending October 2005 were identified. Findings on WCE were classified as
positive (erosions, ulcers, erythema), negative, or incomplete. SBFT was done in 20 patients
and was classified as positive if ulcerations, mucosal blunting, or wall thickening was
identified. Long-term outcome was assessed prospectively and included acute pouchitis (AP),
chronic pouchitis (CP), or the development of Crohn’s disease (CD). Patients with AP, CP
or CD were considered to have pouch inflammation (PI). RESULTS: WCE was positive
(WCE+) in 8 patients (33%), negative (WCE-) in 12 patients (50%) and incomplete in 4
patients (17%). After a median length of followup of 15 months in the 20 patients with a
complete WCE, AP was seen in 3 patients (15%), one patient (5%) developed CP and one
patient (5%) developed CD. Within WCE+ patients, 1 (13%) developed AP and none
developed CP or CD. Within WCE- patients, 2 (17%) developed AP, 1 (8%) developed CP,
and 1 (8%) developed CD. PI rate for WCE+ patients (13%) was lower than WCE- patients
(33%) (p=NS). SBFT was positive (SBFT+) in 3 patients (15%) and negative (SBFT-) in 17
patients (85%). Within SBFT+ patients, 1 (33%) developed AP and 1 (33%) developed CP.
Within SBFT- patients, 2 (12%) developed AP and 1 (6%) developed CD. The PI rate for
SBFT+ patients (67%) was higher than for SBFT- patients (18%)(p=0.1). There was no
significant difference in overall PI rate between WCE+ and SBFT+ patients (p=0.1). CONCLU-
SION: Early observations from this study suggest that in UC or IC patients undergoing
IPAA, preoperative WCE+ does not appear to be associated with pouchitis. WCE may not
confer any advantage over SBFT in assessing the risk of pouch inflammation after IPAA for
patients with UC or IC.
S1379
Ulcerative Colitis in Patients with Primary Sclerosing Cholangitis (PSC-UC) -
A Specific Subgroup of Inflammatory Bowel Disease
Pavel Drastich, David Kamenar, Julius Spicak
BACKGROUND: Primary sclerosing cholangitis (PSC) is commonly associated with inflam-
matory bowel disease (IBD), particularly with ulcerative colitis (UC) in 55-75% cases. PSC-
UC patients experience the extensive milder course of colonic disease, but other clinical
symptoms and endoscopic pictures have not been well described. AIM: To retrospectively
evaluate endoscopic features, clinical course and therapeutical management of PSC-UC
patients in comparison with PSC free UC patients. PATIENTS AND METHODS: A cohort
of 45 PSC-UC patients (mean age 36.8±12.3 years) and 47 UC patients (mean age 42.7±15.1
years) were enrolled. Patients were from the hospital database (IKEM, Prague, Czech Repub-
lic)) and they underwent total colonoscopic evaluation since January 2004 till November
2005. The bowel disease duration was comparable in both groups (mean 6 years in PSC-
UC group and 7 years in UC group). Chi-square test, Fischer’s exact test and stepwise
logistic regression were used for statistical analysis. RESULTS: PSC-UC patients are suffering
from more extensive disease (pancolitis) than UC patients (76% vs 49%, P<0.01), but the
disease is more often in remission/mild course than in moderate/severe course (75.6% vs
50%, P<0.01 and 24.4% vs 50.0%, P<0.01, respectively). UC patients were more likely to
find post-inflammatory polyps (46.8% vs 20%, P<0.01) and left-sided colitis was a typical
picture of these patients (42.6% vs 4.4%, P<0.001). The right-sided active colitis without
rectal involvement was almost unique feature of PSC-UC patients (20.0% vs 2.1%, P<0.01).
PSC-UC patients required less azathioprin therapy (8.9% vs 31.1%, P<0.01) for disease
management. Two groups had no significant difference in use of aminosalicylates. Number
of patients undergoing colectomy because of disease activity did not differ between the two
groups (2/47 in UC group and 3/45 in PSC-UC group). There was no difference in frequency
of backwash ileitis and dysplasia of colonic mucosa was find in just 2 patients from both
groups. Correct prediction based on multivariate analysis (pancolitis, milder disease, right-
sided colitis, absence of post-inflammatory polyps and no azathioprin therapy) was 85%.
CONCLUSION: PSC-UC patients may represent a specific IBD subgroup. Characteristic
picture of these patients is pancolitis with mild activity or active right-sided colitis with
rectal sparing. In contradistinction to UC patients, post-inflammatory polyps are rarely
detected and azathioprin was significantly less need for treatment of these patients.
S1380
A Cost Effectiveness Analysis of High Dose Oral mesalazine for the Treatment
of Moderately Active Ulcerative Colitis: A Decision Analytic Model
J Borrill, K Bodger, A Bhatt
Objective: To conduct an economic evaluation of high dose oral mesalazine as a 1st line
treatment for patients with moderately active ulcerative colitis (UC). Design: A decision tree
model was constructed to examine the patterns of treatment, resource consumption and the
cost impact of treating a moderately acute episode of UC with a 4.8 g/day dose of mesalazine
800 mg MR tablets (P&G Pharmaceuticals) compared to the currently marketed conventional
dose of 2.4 g/day mesalazine 400mg MR tablets (P&G Pharmaceuticals, UK). Differences
in treatment effects were obtained from a pooled analysis of two, phase III clinical trials.
Resource use data was derived from a UK cost of illness study that assessed the direct costs
of IBD in secondary care. These data were supplemented with information from the literature
and expert opinion. A secondary analysis was conducted in which oral prednisolone (40mg/
day) was used as the comparator treatment. The analysis was conducted from the perspective
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of the NHS using a time horizon of six months. A hypothetical cohort of 1,000 patients with
moderately active UC was passed through the model. Results are expressed as hospitalisations
avoided, incremental cost of treatment and the incremental cost per quality-adjusted life
year (QALY). Results: Treatment success at six weeks was achieved in 72% of patients treated
with mesalazine 4.8 g/day compared to 59% in the mesalazine 2.4 g/day group (p=0.0034).
The model projected that fewer patients in the mesalazine 4.8 g/day treatment arm would
undergo surgery (5% versus 7%) or intensive intravenous steroid or immunosuppressive
therapy (7% versus 10%) compared to those in the 2.4 g/day treatment arm. Over six
months, the mean expected cost per patient was £1,300 for the mesalazine 4.8 g/day
treatment group compared to £1,640 for the 2.4 g/day group - a cost saving of £340 per
patient. The difference in health related quality of life between the treatment groups was
negligible. This resulted in an incremental cost per QALY that fell comfortably within the
cost-effectiveness threshold adopted in the UK. Sensitivity analysis demonstrated that the
results of the cost-effectiveness analysis were robust to changes in both clinical and economic
parameters. Similar findings were observed when mesalazine 4.8g/day was compared to oral
prednisolone. Conclusion: From the perspective of the UK healthcare system, mesalazine
4.8 g/day is a cost-effective option for the management of moderately active UC. This result
provides an economic argument for clinicians to adopt this treatment strategy in the given
patient population.
S1381
Exposure to Diagnostic Medical Radiation in Patients with Inflammatory
Bowel Disease: An Additional Risk for Bowel Cancer
Evan Newnham, Anusha Surender, Eliza Hawkes, Peter Gibson
Awareness of the level of radiation exposure associated with medical imaging and its carcino-
genic risk is poor. Cumulative doses of diagnostic medical radiation (DMR) of 50 to 100
mSv delivered to, for example, the colon and bladder increase the risk of cancer in those
organs. Patients with IBD, who are already at increased risk of colon cancer, often undergo
medical imaging involving exposure to these and other radio-sensitive organs, yet the level
of exposure has not been documented. Aims: To evaluate the exposure from DMR within
a population of patients with IBD and to identify subgroups at higher risk of exposure.
Methods: DMR exposure was documented by review of medical records (hospital and
referring doctor) of 100 consecutive patients attending a hospital-based IBD Clinic. Only
verified imaging procedures were included. Effective radiation doses delivered to colon and
bladder were calculated using published tables of average exposure for individual test types,
and were expressed as total and yearly exposure. Predictors of exposure were also determined.
Results: The studied population had a median age of 38 (16-84) years. 43 were men. 34
had ulcerative colitis, 1 indeterminate colitis and 65 Crohn’s disease (12 ileal, 38 ileocolonic,
19 colonic). 32 had undergone disease-related surgery. 4 had not been exposed to DMR,
and 35 had no abdominal exposure. The major DMR procedures were plain abdominal X-
ray, CT abdomen and pelvis and small bowel barium studies. The median exposure to the
colon was 20 (0-424) mSv and to the bladder 22 (0-460) mSv. 25% had exposure already
in the at-risk range and, in 12, it exceeded 150mSv. Patients with Crohn’s disease had
significantly higher radiation exposure (median 30 mSv) than those with ulcerative colitis
(3 mSv (p<0.001, rank sum test)). The only other predictor of high levels of exposure to
DMR was prior surgery. Conclusion: DMR exposure in patients with IBD is high, often
above at-risk levels, particularly in Crohn’s disease and in the setting of surgery. In an often
immunosuppressed population with a chronic illness that already has an elevated risk of
bowel cancer, careful consideration should be given to the indication for medical imaging
of the abdomen, especially as it is often needed intermittently over the life of the patient.
S1382
The Granulocyte and Monocyte Adsorption Apheresis (GCAP) Therapy
Changes Surgical Indication for Patient with Ulcerative Colitis
Tetsushi Kinugasa, Masahide Kuroki, Takayuki Shirakusa, Yuichi Yamashita
There is no specific medical care for ulcerative colitis (UC), and approximately one third
of its patients undergo operative treatment. Recent evidence suggests that peripheral blood
granulocytes and monocytes/macrophages play a major role in the exacerbation of UC.
Recently, granulocyte and monocyte adsorption apheresis (GCAP) has been shown to be
safe and effective for active ulcerative colitis in Japan. Our objective was to investigate
whether the one of surgical indication factor is after GCAP therapy in patients with steroid-
refractory and -dependent UC. METHODS: Eighteen with active ulcerative colitis were
studied, of whom 5 had relapsing-remitting ulcerative colitis, 13 had chronic continuous.
GCAP was performed with an Adacolumn filled with cellulose acetate beads. Patients received
up to 10 apheresis sessions over 12 weeks; one session being for 60 min at 30 mL/min.
Eighteen patients received 5 apheresis sessions over 4 weeks. RESULTS: Sixteen of 18 patients
showed an improvement in symptoms (abdominal pain, rectal bleeding, and diarrhea) and
could avoid re-administration of steroids after GCAP. At entry, the mean dose of prednisolone
was 32.7 mg/day per patient and was reduced to 17.2 mg/day after 10 sessions. Of 18
patients treated with GCAP, 7 (38.8%) obtained remission (UCDAI < or = 4), 6 (33.3%)
showed a clinical response, and 4 (22.2%) remained unchanged and one patient (0.5%)
was getting worse. Two patients (11.1%) who hardly showed the improvement of symptom
and UCDAI score even after additional GCAP therapy underwent colectomy. GCAP therapy
was well tolerated and no serious side-effects were observed. CONCLUSIONS: The findings
of this study suggest that GCAP may be a useful alternative therapy for patients with UC,
and the efficacy of GCAP may also be useful for one of the surgical operative indication factor.
S1383
In Vivo Measurement of Colonic Butyrate Metabolism in Patients with Active
Ulcerative Colitis
Damian McKay, Stephen J. Kirk, Keith R. Gardiner, Helen Kemp, Wolfram Meier-
Augenstein
Background. Butyrate, a short chain fatty acid, is a by-product of bacterial fermentation of
non-digestible carbohydrates within the gut lumen and is the preferred fuel source for
colonic epithelial cells (colonocytes). In vitro work has shown that ulcerative colitis (UC)
may be characterised by a defect in the colonocyte metabolism of butyrate. Aim: To assess if
colonocyte butyrate metabolism improves with treatment of active ulcerative colitis. Methods.
Patients with a flare up of histologically proven UC were recruited from the Royal Victoria
Hospital. Following informed consent baseline measurements were performed including
clinical scoring questions (St Mark’s score, simple clinical colitis index), blood for inflammat-
ory markers and urine for microalbuminuria. These measurements were repeated after an
8 week treatment period. BMI was calculated to adjust individually for CO2 production. A
100ml [1-13C] butyrate enema was administered to 4 patients before and after the eight
week treatment period. Breath samples were obtained every 10 minutes for the first hour
and every 15 minutes for a further 2 hours. The breath samples were then transported to
the Environmental Engineering Research Centre to measure amount and appearance of
13CO2 released from [1-13C] butyrate by isotope ratio mass spectrometry (IRMS). Results.
There was a marked improvement in butyrate metabolism after the treatment period. The
time to maximum 13CO2 production decreased by a mean of 17.1% p=0.022 (4.09-25.9)
indicating increased rate of butyrate metabolism. The total percentage dose of 13CO2
recovered in the breath samples increased by a mean of 20.4% p=0.031 (2.73-28.59). These
results correlated well with improvements in both clinical scoring systems and inflammatory
markers. Conclusions. Butyrate oxidation by colonic epithelial cells appears to be defective
in active ulcerative colitis. Metabolism to CO2 improves after treatment of an acute flare-
up and correlates with improvements in clinical markers of the disease.
S1384
Treatment of Small Bowel Inflammatory Stricturing Crohn’s Disease with
Infliximab : An Open Pilot Study
Edouard Louis, Jacques Boverie, Filip Baert, Olivier Dewit, Martine Devos, Geert D'Haens
Stricturing small bowel Crohn’s disease (CD) may involve both fixed fibrotic changes and
an inflammatory component. While the fibrotic changes are not likely to respond to anti-
inflammatory drugs, this is not the case of the inflammatory component. Steroids may
transiently improve these patients but there is, in the majority of cases, a need for surgery
at short or mid term. Efficacy of infliximab in these patients is not documented since it was
an exclusion criteria for pivotal trials. We embarked an open pilot study to assess the
safety and efficacy of infliximab in patients with stricturing subobstructive CD. Patients and
methods: to be included, patients had to harbour a documented and symptomatic small
bowel stricture in the context of CD. They had to be refractory to steroid and or immunosup-
pressor, have no need for immediate surgery and abdomen CT had to prove the absence
of peritoneal abscess. They also had to have active inflammation assessed by a CRP > 8 mg/
l. These patients were treated with infliximab 5 mg/Kg and followed up at w1, w2, w4 and
w8 on a clinical, biological and abdomen CT scan (w8) basis. Results: 6 patients were
included and then the study was prematurely stopped because the safety thresholds of more
than 2 surgeries within the first 5 patients was reached. Only two patients completed the
8 week protcol, with a positive response to infliximab and improvement of inflammation
confirmed by the CRP and the abdomen CT scan. Two patients had to be operated early
(both 10 days after infliximab) because of clinical worsening. Two patients first did well
but worsened after one month and were operated 35 ad 42 days after infliximab, respectively.
There was no complication of surgery in the 4 operated patients. From a clinical point of
view, the two patients requiring early surgery were the only two with an abdominal mass
at baseline. From a radiological point of view, these two patients had either a small intramural
ileal abscess or intraperitoneal fluid at baseline. One of the two patient who worsened one
month after infliximab also had an intramural jejunal abscess, while the two patients who
positively responded to infliximab had no such feature. Other abdominal CT scan parameters
or clinical and biological parameters were not associated to evolution after infliximab infusion.
In conclusion a small subset of patients with subobstructive small bowel stricturing CD may
respond to infliximab. The presence of an abdominal mass before treatment may represent
a contra-indication to infliximab in this situation. The presence of intra-mural small bowel
abscess or intraperitoneal fluid may predict failure of treatment.
S1385
Serum Protein Signatures Determined By Mass Spectrometry (SELDI-ToF)
Accurately Identifies Patients with Inflammatory Bowel Disease By Support
Vector Machines with Linear Kernels
Venkataraman Subramanian, Devika Subramanian, Sanjeev Krishna, Daniel Agranoff,
Richard Pollok
Introduction: Inflammatory bowel disease (IBD) is an idiopathic chronic disease of the
gastrointestinal tract with many debilitating sequelae some of which be life threatening.
Diagnosis of IBD often depends on invasive tests. Non invasive serological testing such as
ASCA and p-ANCA are insufficiently specific or sensitive for routine diagnostic use. We
aimed to develop a novel diagnostic approaches based on differences in protein signatures
in sera obtained from individuals with IBD and controls using surface enhanced laser
desorption and ionisation time of flight (SELDI-ToF) mass spectrometry (MS). Methods: We
studied protein signatures from 55 patients with IBD and 56 controls (normal and patients
with other inflammatory pathology). Protein signatures were obtained using a CM10 chip
(weak cation exchange chip), and analysed with SELDI-ToF MS. Preliminary analysis was
performed using ‘p’ value determination of integrated peaks. Statistical and neural network
analysis was performed using support vector machine (SVM) techniques utilizing linear
function kernels. Significant peaks used for discrimination were selected using recursive
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feature elimination. SVM analysis was done using a 10 fold cross validation technique.
Results: Comparing IBD and controls using SVM analysis with a linear function kernel using
10 peaks selected by recursive feature elimination, we obtained an accuracy of 91%, sensitivity
of 83 % and specificity of 92 %. The peaks selected by SVM analysis were also significantly
discriminative when used in individual peak analysis. Conclusions: Using protein signatures
of patients with IBD and controls we have developed a model of classification which has high
accuracy and is more informative than currently available serological tests. Characterisation of
discriminant peaks is currently underway.
S1386
Inflammatory Bowel Disease Phenotype in British Children of South Asian
Origin
Nadeem A. Afzal, Lang Hans-Joerg, Sarah Mills, Michael Green, Sandhia Naik, Nigel
Meadows, Ian Sanderson, Nick Croft
Aims: In British children ulcerative/indeterminate colitis (UC/IC) (not Crohn’s Disease) has
been reported to be relatively more common in South Asian than Caucasian families (Saw-
czenko A, Lancet 2000). Majority of children of South Asian origin in the UK are of Indian
(Hindu) origin, most of the remainder being of Pakistani/Bangladeshi (Muslim) parents. In
this study we compare the disease phenotype in British children of parents from South
Asian regions. Methods: We studied consecutive children with IBD from two paediatric
gastroenterology units, from East London were Caucasian and mostly Bangladeshi/Pakistani
patients, from Leicester were mostly of Indian origin. We examined the distribution and
pattern of inflammatory bowel disease, age at diagnosis, macroscopic and histological details
of the endoscopy and presenting features with height and weight and diet. Results: 177
Caucasian and 54 children of South Asian origin were studied. 36 children were of Banglade-
shi/Pakistani origin and 18 of Indian origin. The proportion of patients with Crohn’s Disease
(58%) and UC/IC (42%) patients were identical in children of Caucasian and Bangladeshi/
Pakistani origin (MWU, p=ns). The children of Indian origin however had a higher proportion
of UC/IC (67%) (MWU, p=0.03). A comparison of the Bangladeshi/Pakistani children with
the Indian children showed no significant difference in sex distribution (58.1% males),
duration of symptoms (0.71 yrs, 1SD=1.41 yrs), BMI SDS at presentation (-0.45, 1SD=1.3),
use of azathioprine (66.1%) and age of presentation (Mean 10.9 yrs, 1SD = 4.1 yrs). No
differences were found in duration of symptoms, age of presentation, Ht SDS and Wt SDS
at presentation in different IBD types in South Asian children (KW, p=ns). Vegetarian diets
were commoner in Indian families. Conclusions: British children of Bangladeshi origin with
IBD have equal proportion of Crohns (58%) and UC/IC (42%) to Caucasian children.
However children of Indian origin have a higher incidence of UC/IC (67%) as reported in
adults and implied by previous epidemiological studies. Our data suggest IBD phenotype
in British children of South Asian origin varies by the country of their parents birth. This
implies important genetic differences between these countries and demonstrates that studies
need to define the ethnicity more precisely both for genetic and epidemiological research.
Both environmental (e.g. dietary) and genetic factors could explain these differences.
S1387
Crp and ESR Do Not Predict Disease Activity in Inflammatory Bowel Disease
(IBD)
Kapil Dhawan, Qin Li, Elizabeth Shenkman, John F. Valentine
BACKGROUND: C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are
among the most widely used markers for IBD. Several recent clinical trials of biologic agents
in IBD only showed significance in a subgroup with elevated CRP. ESR was not evaluated.
The primary objective of our study was to examine the relationship between CRP and ESR
and health-related quality of life (QoL) among a cohort of patients with IBD. Methods: A
convenience sample of patients with Crohn’s disease (CD) or ulcerative colitis (UC) at an
academic health center completed the SIBDQ and the HBI and had laboratory testing for
CRP and ESR. 55 patients with CD and 11 patients with UC were included in the analyses.
Patient gender, disease duration, and steroid use were included as covariates. Outcomes for
those with CD were the scores on the Short Inflammatory Bowel Disease Questionnaire
(SIBDQ) and the Harvey-Bradshaw Index (HBI). The outcome variable for those with ulcerat-
ive colitis (UC) was the SIBDQ score. Multivariate regression models examining the relation-
ship between the serologic makers and scores on the SIBDQ and HBI were developed using
PROC GLM and PROC MIXED in SAS. RESULTS: The mean age was 42.10 +/- 15.96. 57%
females; 43% males. The mean SIBDQ score was 47.26 +/- 14.57 and the mean HBI was
4.75 +/- 5.16. Mean CRP values were 9.11+/-12.46 and mean ESR was 33.30+/-28.75. On
average the patients had IBD for 12.24+/-10.40 years. CRP and ESR were included in the
same statistical models together as predictor variables and separately. ESR and CRP were
not significantly related to SIDBQ scores in patients with CD in any of the models. Males
with CD have higher SIBDQ scores than females when controlling for other covariates (P=
0.04) in the model. Gender, disease duration and CD location were not significant. Patients
taking prednisone reported significantly lower SIBDQ scores than those taking Entocort (p=
0.03). ESR and CRP were significantly related (P<0.0001), SIBDQ and HBI were inversely
related (P<0.0001). Among patients with UC, gender was significantly associated with the
SIBDQ scores with males having higher scores than females (p=0.04). The use of prednisone
was marginally significant and associated with lower SIBDQ scores (p=0.06). Curiously, in
the combined group, 16 patients had elevated CRP >5 and an ESR <30 and 11 had elevated
ESR >30 and a CRP <5, some of these were markedly elevated. Conclusions: CRP and ESR
do not correlate with the SIBDQ or the HBI. Better biomarkers for disease activity are needed.


















Correlation of CT Enteroclysis with Surgical Pathology in Patients with
Crohn’s Disease
Michael V. Chiorean, Dean T. Maglinte, Romil Saxena, Attila Nakeeb, Jun Ying
Background: The response to therapy in patients with Crohn’s disease (CD) is dependent
on the underlying pathology. As opposed to endoscopic mucosal biopsies, CT enteroclysis
(CTE) can detect transmural disease. The ability of CTE to differentiate pathological lesions
in CD is unknown. Aims: To determine the accuracy of CTE compared to pathology in
patients who underwent surgery for CD and to assess the correlation of specific CTE
findings with the pathological diagnosis. Methods: CTE findings from 45 adult patients who
underwent surgery for CD between 2002 and 2005 were retrospectively reviewed. The
sensitivity, specificity and accuracy of CTE compared with the gold-standard surgical patho-
logy were determined by using a composite inflammatory and fibrostenotic score. Several CTE
(mucosal and mural enhancement, wall thickness, mesenteric stranding, stenosis, proximal
dilation) and pathology findings (wall thickness, ulceration, stenosis, degree of activity,
smooth muscle and connective tissue proliferation) were used to grade the inflammatory
activity (0-3) and fibrostenosis (0-2 for CTE and 0-3 for pathology). The correlation between
specific CTE findings and surgical pathology was assessed using Spearman correlation and
cumulated logit model. Results: Ten patients were excluded (no CD diagnosis or malignancy
in the specimen). Of the 35 remaining patients, 63% were female and 80% were white.
Average age was 39 and disease duration 10 years. All had small bowel involvement. The
indications for CTE/surgery were: refractory disease in 20, bowel obstruction in 11, fistula/
abscess in 9; 16 patients had previous surgery. The average interval between CTE and
surgery was 8 weeks (0-43). The sensitivity, specificity and accuracy of CTE for fibrostenosis
was 80%, 65% and 71% respectively. There was good correlation between CTE and pathology
for both inflammatory (r=0.6) and fibrostenotic disease (r=0.6, p<0.001). The inflammatory
score correlation varied with the CTE-surgery time interval while the fibrostenotic score did
not. Wall thickness, mural enhancement and fat stranding on CTE were positively associated
with the pathology inflammatory score [OR 2.8 (p=0.1), 7.1 and 13.7 (p<0.02)]. Conclusions:
CTE can reliably differentiate between inflammatory and fibrostenotic lesions in patients
with small bowel CD. Since the management of patients with CD is dependent on the
underlying pathology, prospective studies evaluating the impact of CTE on therapeutic
outcomes in patients with CD are warranted.
S1389
Accuracy of Small Intestine Contrast Ultrasonography (SICUS) in the
Preoperative Assessment of Small Bowel Lesions in Crohn’s Disease
Nadia Pallotta, Naima Abdulkadir Hassan, Danila Guagnozzi, Enrico Corazziari
Small intestine contrast ultrasonography (SICUS) enables to visualize the entire small bowel
after the ingestion of iso-osmolar polyethylene glycol (PEG) solution. It has been shown
that the diagnostic accuracy of SICUS is comparable to that of a radiological examination,
in detecting the presence, number, extension, and sites of small bowel lesions even in
patients with undiagnosed small bowel diseases (1). AIM. To evaluate the diagnostic accuracy
of SICUS to assess the number, site, and extension of small bowel lesions in patients
submitted to surgery for Crohn’s disease (CD). Fifteen consecutive patients submitted to
surgery for CD were investigated (F 7; age range 18-70 years). Real-time US was performed
preoperatively using a 3.5-MHz convex and a 5-MHz linear array transducer (Toshiba Tosbee,
Japan) after the ingestion of 375 ml of PEG oral solution (Promefarm, Italy). After the
contrast was seen flowing through the terminal ileum into the colon, a retrograde follow-
through assessment of the entire small bowel was performed visualizing, in a caudal-
cranial sequence, the contrast-filled ileal and jejunal loops. Preoperative SICUS findings
were compared with surgery findings. RESULTS. In all patients preoperative SICUS correctly
detected the lesions and their location as identified at surgery. The mean extension of small
bowel lesions was 28.5±14.2 cm at surgery, 29.4±11 cm at SICUS (not significant versus
surgery). In the assessment of number and site of lesions the concordance index between
surgery and SICUS was 0.85 (P<0.001). CONCLUSIONS. Compared to surgical findings
the diagnostic accuracy of preoperative SICUS in detecting small bowel lesions is high.
Preoperative SICUS can be usefully employed to plan surgical treatment in Crohn’s disease
patients. 1) Pallotta et al. Ultrasound Med Biol. 2001;27:335
S1390
Efficacy of Adacolumn Selective Leukocytapheresis in Patients with Steroid
Naive and Steroid Dependent with Moderate to Severe Ulcerative Colitis
Tomotaka Tanaka, Hideharu Okanobu, Abbi R. Saniabadi, Aki Kohgame, Hiroki
Imagawa, Yoshito Takemura, Yoshio Kuga, Takashi Moriya, Toshihide Ohya
Background and Objective: In most patients with moderate to severe ulcerative colitis (UC),
corticosteroids may promote remission, but their side effects can be new complications.
However, UC is believed to be exacerbated, and perpetuated by inflammatory cytokines like
TNF-alpha, IL-1beta, IL-6 and IL-8 which are also released by granulocytes and monocytes/
macrophages. Therefore, these leukocytes might be appropriate targets for therapy of inflam-
matory bowel disease. Based on this thinking, recently an Adacolumn has been developed
for depleting excess and activated peripheral blood granulocytes and monocytes/macrophages
by selective leukocytapheresisis (SLA). This study was to assess the efficacy of SLA with the
Adacolumn in patients with moderate to severe active UC, steroid naive versus steroid
dependent patients. Methods: Twenty-nine consecutive patients, 20 male and 9 female,
mean age 43.3 years, range 18-70 years with moderate to severe active UC were treated.
Ten had total colitis and the rest had left-sided colitis. Similarly, 17 of 29 patients were
steroid naive the other 12 had steroid dependent UC. SLA was done with the Adacolumn,
each patient received one session/week for 5-10 weeks. None of the 29 patients received
new or additional medications within 4 (steroid) to 8 (immunosuppressant/immunomodul-
ator) weeks prior to entry or during SLA treatment. However, the steroid dose could be
tapered in responders to SLA. Further, during endoscopy, biopsy specimens were taken
from a randomly selected 10 patients for assessing the mucosal level of granulocytes. Results:
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At entry, the mean clinical activity index (CAI) was 12.7, range 10 to 14 (by Rachmilewitz).
Remission was defined as CAI = or <4. Efficacy assessments including endoscopy performed
one week after the last Adacolumn session showed a remission rate of 82.8% (24 of 29
patients); this included 17 of 17 (100%) steroid naive patients and 7 (58.3%)steroid depend-
ent cases. For all 24 responders, the average remission time was 11.6 months and 15.4
months for the 17 steroid naive patients. Biopsy revealed massive infiltration of granulocytes
into the colonic mucosa in patients with active disease. Adacolumn leukocytapheresis was
associated with a marked reduction of granulocytes in the mucosa in patients who achieved
remission. Conclusions: In our hospital, 100% of steroid naive patients responded to Adacol-
umn leukocytapheresis treatment, while just over half of steroid dependent patients
responded. Accordingly, we believe that steroid naive patients should be given Adacolumn
leukocytapheresis as a first line medication. Large controlled studies are warranted to
strengthen our observations.
S1391
Diagnostic Value of Faecal Calprotectin in Unselected Outpatients Referred for
Colonoscopy: A Multicenter Prospective Study
Gianmichele Meucci, Renata D'Inca', Roberto Maieron, Nicoletta Orzes, Maurizio Vecchi,
Daniela Visentini, Giorgio Minoli, Elisabetta Dal Pont, Maurizio Zilli, Elvio Benedetti,
Tiziana Virgilio, Elio Tonutti
Background and aims: Faecal levels of calprotectin are increased in several inflammatory
and neoplastic diseases of the gastrointestinal tract. However, the role of faecal calprotectin
measurement in clinical practice is still ill defined. We assessed faecal calprotectin in consecut-
ive outpatients referred for colonoscopy, in order to evaluate its reliability in identifying
patients with significant colorectal disease. Methods: Outpatients undergoing colonoscopy
at 5 participating institutions were eligible for the study. Patients were asked to collect a
faecal sample the day before examination. Written informed consent was obtained. Demo-
graphic and clinical data were collected by means of a standard questionnaire. Faecal samples
were tested at a single laboratory by means of a commercially available kit (Calprest, Eurospital
SpA, Trieste) Results: Eight-hundred seventy patients (males 413, mean age 59.1 years,
range 16-89) were enrolled. The rate of caecal and ileal intubation were 91% and 24%
respectively. Mean levels of calprotectin were significantly higher in patients with neoplastic
and inflammatory disorders when compared with subjects with a normal colonoscopy of
with trivial endoscopic findings (such as uncomplicated diverticular disease). Calprotectin
levels above the upper normal limits (> 50 mg/Kg) were detected in 88% of patients with
colorectal cancer, 85% of those with inflammatory conditions and 56% of those with inactive
ulcerative colitis but also in 39% of patients with normal or trivial endoscopic findings.
Sensitivity, specificity, PPV, NPV and accuracy for detecting “any organic disease” and
colorectal cancer respectively are shown in the table. In patients referred for chronic diarrhea,
sensitivity and negative predictive value were 100% in detecting either any organic disease
or cancer. In patients referred for symptoms of “suspected functional origin” (abdominal
pain, constipation etc) sensitivity and negative predictive value for colorectal cancer were
respectively 85% and 99%.Conclusions: In unselected outpatients referred for colonoscopy,
a single measurement of faecal calprotectin is not sufficiently accurate to identify those with
significant disease. However, a normal result can help in ruling out organic disease among
patients with diarrhea and those with abdominal pain and/or constipation.
S1392
Costs of Crohn’s Disease According to Severity States
Isabelle Jaisson-Hot, Pascale Guerre, Fady Daniel, Jean-Frederic Colombel, Eric
Lerebours, Bernard Duclos, Arnaud Bourreille, Jean-Louis Dupas, Guillaume Cadiot,
Yoram Bouhnik, Jacques Moreau, Philippe Marteau, Antoine Cortot, Louis Descos, Cyrille
Colin, Marc Lemann, Bernard Flourie, The Getaid And
Introduction : A multicenter, prospective, observational study has been undertaken aiming
to estimate costs of care and clinical evolution in Crohn’s disease. Methods : 342 patients
(37 yr mean age, 65 % female) collected data for one year relating to direct and indirect
costs (invalidity and sick leave). Patients were stratified into disease severity states using the
classification of Silverstein et al (Gastroenterology 1999;117:49-57) modified by recent
therapeutic evolutions: REM0 : Remission without medication, REM1 : Remission with minor
medication, MILD : mild symptoms and minor medication, REP : drug-responsive to a
treatment with oral corticosteroids or immunosuppressive medications or Infliximab, DEP
: drug-dependent to the same treatments, REF : drug-refractory or intolerance, SURG :
surgery within 3 months, REMPS : postsurgical remission. Costs were estimated from the
perspective of the French health insurance system. Results : Means (medians) for direct and
indirect costs by disease states are shown in table and the contribution of each cost item
to total expenditure in figure. As expected there was an incremental increase in costs with
worsening disease severity. Interestingly, drug-dependent patients (DEP) cost more than
refractory patients (REF), particularly for hospitalizations. Furthermore, indirect costs includ-
ing work disability took a significant part of total costs, especially for patients REF and
MILD. Conclusion : Our data quantify the contribution of different services to the overall
economic burden of the disease, taking into account its natural history. The great impact
of indirect costs must be considered in economic appraisal for such chronic disease.
S1393
Accuracy of Four Fecal Assays in Inflammatory Colonic Disease
Alain Schoepfer, Michael Trummler, Beatrice Seibold, Petra Seeholzer, Frank Seibold
Objective: Several fecal markers have been evaluated for the differentiation of functional
(IBS) versus inflammatory bowel disease (IBD). The aim of this study was to evaluate the
accuracy of four different fecal markers in the differentiation of patients with IBS, IBD and
other forms of inflammatory colonic disease (OCD). Material and methods: Included were
23 patients with IBS, 36 with IBD (24 Crohn’s disease, mean CDAI 103, 12 ulcerative
colitis), the group of OCD included 8 patients with infectious colitis, 5 ischemic colitis and
5 with medication-induced colitis. Diagnosis was established based on conventional clinical,
laboratory and endoscopic workup. Blinded stool samples of all patients were measured for
fecal leucocyte markers Calprotectin (EIA), Lactoferrin (EIA), Hexagon-OBTI (specific for
human haemoglobin) and LEUKO-Test (lactoferrin latex-agglutination test). Results are given
as sensitivity (SE) and Specificity (SP). Statistical analysis was done with Fisher’s exact test,
t-test and ROC-analysis. Results: SE for Hexagon-OBTI in discrimination of IBS vs IBD was
39%, SP 91% (p=0.015), SE for IBS vs OCD was 67%, SP 86% (p<0.001). Two IBS patients
with positive Hexagon-OBTI took daily Aspirin. SE for LEUKO-test in discrimination of
IBD vs IBS was 44%, SP was 91% (p=0.004). LEUKO-test was positive in 75% of patients
with infectious colitis. SE for LEUKO-test for IBS vs OCD was 43%, SP 91% (p=0.014).
No viable differentiation of IBD vs OCD was possible using Hexagon-OBTI and LEUKO-
test. Mean calprotectin in IBS was 25ug/ml, in IBD 275ug/ml (p<0.0001), in OCD 351ug/
ml (p=0.39, IBD vs OCD). Mean lactoferrin in IBS was 0.03ug/ml, in IBD 0.34ug/ml
(p<0.0001), in OCD 0.33 (p=0.97, IBD vs OCD). ROC-Analysis IBS vs IBD: for Calprotectin
(cut-off 50ug/ml) the SE was 94%, SP 90%, for Lactoferrin (cut-off 0.056ug/ml) the SE was
91% and the SP 100%. ROC-Analysis IBD vs OCD for Calprotectin: SE 57%, SP 53%, for
Lactoferrin SE 52%, SP 42%. Conclusions: In contrast to Hexagon-OBTI and LEUKO-test,
EIA for fecal Calprotectin and Lactoferrin are good tools for differentiation of inflammatory
colonic disease vs non inflammatory disease such as IBS. However, the differentiation of
IBD vs other inflammatory colonic disease such as infectious colitis is not possible with
these tests. Calprotectin may be increased in patients with Crohn’s disease even in remission.
IBS patients may however have positive leukocyte fecal markers due to the intake of Aspirin
or NSAID. Endoscopic workup remains crucial for diagnosis of colonic disease.
S1394
Health Related Quality of Life in Crohn’s Disease By Severity States
Isabelle Jaisson-Hot, Pascale Guerre, Fady Daniel, Jean-Frederic Colombel, Eric
Lerebours, Bernard Duclos, Arnaud Bourreille, Jean-Louis Dupas, Guillaume Cadiot,
Yoram Bouhnik, Jacques Moreau, Philippe Marteau, Antoine Cortot, Louis Descos, Cyrille
Colin, Marc Lemann, Bernard Flourie, The Getaid And
Introduction : A multicenter, prospective, observational study has been undertaken aiming
to evaluate the Health Related Quality of Life (HRQOL) of patients with Crohn’s disease
and clinical evolution. Methods : Every 3 months during one year, patients were examined,
disease severity state and HRQOL were assessed with the Short Form-36 (SF-36) and with
the Rating Form of Inflammatory bowel disease Patient Concerns (RFIPC). In addition, an
alternative method of evaluating HRQOL outcome was used with utility analysis by means
of the Time Trade-Off (TTO): this method assessed patient preference and measured the
number of years of life in the current health state exchanged for a shorter life in good health.
Patients were stratified into disease severity states using the classification of Silverstein et
al (Gastroenterology 1999;117:49-57) modified by recent therapeutic evolutions: REM0 :
Remission without medication, REM1 : Remission with minor medication, MILD : mild
symptoms and minor medication, REP : drug-responsive to a treatment with oral corticostero-
ids or immunosuppressive medications or Infliximab, DEP : drug-dependent to the same
treatments, REF : drug-refractory or intolerance, SURG : surgery within three months, REMPS
: post-surgical remission. Results : 342 patients (37 yr mean age, 65 % female) were followed
for one year. The remission state gathering REM0, REM1 and REMPS resulted in significantly
higher SF-36 and RFIPC scores in comparison with the state REP, then with chronically
active disease represented by the states MILD, DEP and REF. The SF-36 score for the state
MILD was the worst for all subscales, whereas the states REF and DEP had the worst scores
for the RFIPC. Contrary to what was observed with the SF-36, the TTO score for the MILD
state was the least impaired. Patients with severe disease (DEP and SURG) assigned lower
TTO scores, ie. had the lowest acceptance of their health state. Even patients in remission
(REM0, REM1 and REMPS) had a measurable decrease in TTO scores relative to their health..
Only a slight degree of correlation was present between the TTO and RFIPC scores, reflecting
the importance of taking into account patient preference. Conclusion : SF-36 and RFIPC
order the health states in the predicted manner according to the clinical state and intensity
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of medical or surgical treatment, except for the MILD state. Time Trade-Off scores reveal
that even if patients are in remission, their experiences of disease and treatment lead them
to accept to trade off many years of life in their current health state in exchange for
perfect health.
S1395
Projected Clinical Course of Crohn’s Disease
Isabelle Jaisson-Hot, Pascale Guerre, Fady Daniel, Jean-Frederic Colombel, Eric
Lerebours, Bernard Duclos, Arnaud Bourreille, Jean-Louis Dupas, Guillaume Cadiot,
Yoram Bouhnik, Jacques Moreau, Philippe Marteau, Antoine Cortot, Louis Descos, Cyrille
Colin, Marc Lemann, Bernard Flourie
Introduction : A multicenter observational study was conducted with 3 main objectives :
to evaluate disease clinical course and to estimate patient preferences and costs of illness.
Methods : Every 3 months during one year, patients were examined and the disease severity
state was defined according to the classification of Silverstein et al (Gastroenterology
1999;117:49-57) modified by recent therapeutic evolutions: REM : Remission (without or
with minor medication, or postsurgical), MILD : mild symptoms and minor medication,
REP : drug-responsive to a treatment with oral corticosteroids or immunosuppressive medica-
tions or Infliximab, DEP : drug-dependent to the same treatments, REF : drug-refractory or
intolerance, SURG : surgery within 3 months. The probabilities of transition into other states
were estimated from the data using a maximum likelihood estimate approach assuming a
Markov model for transitions among disease states. Results : 342 patients (37 yr mean age,
65 % female) were followed for one year and 1332 quarterly Case Report Forms (CRF)
were analyzed. The maximum likelihood ratio estimates of the 3-month probabilities of
transition between disease states are shown in table. According to the projected distribution
of ten future years by disease state, most of future clinical course consisted in drug-responsive
state disease (range : 57.27 to 71.58 months, for patients in initial states REM and REP
respectively). Conclusion : Our prospective data provide an evaluation of disease clinical
course, taking into account the potential impact of new treatment such as TNF alpha
antagonists. Unlike previous retrospective results showing that remission was the prominent
state of clinical course, our data show that most of the projected clinical course is spent in
the drug-responsive state: this may reflect an increasing use of immunosuppressors at least
in the present cohort. Our data will also be useful for modelling a life time cost-utility
analysis with an analytic Markov decision model.
S1396
Malnutrition in Quiescent Inflammatory Bowel Diseases Cannot Be Diagnosed
with Standard Tools
Susanne Hengstermann, Luzia Valentini, Carsten Buening, Lennart Schaper, Thomas
Koernicke, Ralf J. Schulz, Matthias Pirlich, Tanja Schuetz, Herbert Lochs
Background The aim of this project was to assess the nutritional and functional status as
well as body composition in IBD patients in clinical remission and compare the results to
healthy controls. Methods Body composition and nutritional status (bioelectrical impedance
analysis, BIA; anthropometry; subjective global assessment, SGA) were assessed in 52 (46f/
6m, 37±10 yrs) IBD patients (33 Crohn’s disease, CDAI 65±41; 19 ulcerative colitis, CAI
3.3±1.8) and 52 pair-matched healthy controls (46f /6m, 37±11 yrs, body mass index, BMI
±0.3 kg/m2). Functional status was compared by hand dynamometry (Jamar, Preston) and
by evaluating two non-disease specific questions (Q1, Q6) of the inflammatory bowel disease
questionnaire (IBDQ). Results In total, 88% of IBD patients were well-nourished according
to standard parameters as BMI, SGA, serum albumin >40 g/L and no recent weight loss.
However, muscle mass was significantly reduced and fat mass was significantly increased
in IBD compared to controls (see table). Hand grip strength correlated with body cell mass
(r=0.615, p<0.01), and was reduced in IBD patients. Additionally, IBD patients felt more
tired (IBDQ, Q1) and less energetic (IBDQ, Q6) than controls (see table). No significant
difference was found between patients with Crohn’s disease and patients with ulcerative
colitis. Discussion: Our study shows for the first time that patients with quiescent IBD and
with seemingly normal nutritional status have an abnormal body composition and reduced


















Low-Dose Naltrexone As a Treatment for Active Crohn’s Disease
Jill P. Smith, Heather E. Stock, Sandra I. Bingaman, David T. Mauger, Ian S. Zagon
Background and Aims: Endogenous opioids and opioid antagonists have been shown to play
a role in healing and repair of tissues. In an open-labeled pilot prospective trial, the safety
and efficacy of low-dose naltrexone (LDN), an opioid antagonist given at a dosage that
exacerbates opioid-opioid receptor interactions, was tested in humans as a treatment for
active Crohn’s disease. Methods: Eligible subjects with histologically and endoscopically
confirmed active Crohn’s disease with a Crohn’s Activity Index (CDAI) score of 220-450
were enrolled in a study using 4.5 mg naltrexone/day. Subjects were required to be off
infliximab for at least 8-weeks, and this medication was not allowed during the trial. Other
drug therapy for Crohn’s disease utilized 4 or more weeks prior to enrollment was continued
at the same dosages. Patients completed the Inflammatory Bowel Disease Questionnaire
(IBDQ) and the Short-form (SF-36) quality of life (QOL) surveys before treatment, every
four weeks on therapy, and 4-weeks after completion of the study drug. Drug was adminis-
tered orally each evening for a 12-week period. Laboratory tests, erythrocyte sedimentation
rates, C-Reactive protein, and CDAI scores were assessed monthly and 4 weeks after discon-
tinuing the medication. Results: Seventeen patients with a mean initial CDAI score of 356
± 27 were enrolled in the study. CDAI scores decreased significantly (p<0.01) with LDN,
and remained statistically lower than baseline 4-weeks after completing therapy (see Figure).
Eighty-nine percent of patients exhibited a response to therapy (>70-point decrease in CDAI,
p<0.001) and 67% achieved remission (CDAI score <150). QOL surveys indicated marked
improvement with LDN. No laboratory abnormalities were noted. One subject undergoing
routine endoscopic procedures showed healing of the intestinal mucosa. In both subjects
with open fistulas, closure was noted with LDN. The most common side effect of LDN was
sleep disturbances (7 patients). Conclusions: LDN therapy offers an alternative safe, effective,
and economic means of treating subjects with active Crohn’s disease
S1398
CARD15 Gene in Patients of Crohn’s Disease in India : Preliminary Evidence
of a Variable Association
Nikita Thakur, G R. Chandak, Rupa Banerjee, Rajesh Gupta, Sandeep Lakhtakia, Manu
Tandan, Venkat G. Rao, Nageshwar D. Reddy
INTRODUCTION : Linkage studies in the western population have implicated several
genomic regions as likely containing IBD susceptibility genes, with some observed uniquely
in CD or UC or others common to both. Three major coding regions SNPs (cSNPs), R702W
(Exon 4), G908R (Exon 8) and L 1007fs (Exon 11) together account for about 28-33% of
CD patients compared to 7-18% in the control population. There is no study on the genetic
basis of Crohn’s disease in the Indian Sub Continent. Methods : We sequenced the three
exons including the splice-site junctions of CARD15 gene bearing the R702W, G908R and
L1007FS mutations in 68 well-characterized CD patients and 130 unrelated controls. The
allele and genotype frequencies were calculated for each SNP and to deviation from the
Hardy-Weinberg equilibrium was investigated by Markov simulation based goodness of fit
test. Subsequently, haplotypes were generated with the Expectation-maximization algorithm
and compared between patients and controls. Results : We did not find any of the three
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common disease-causing variants (DCVs), R702W, G908R and L1007FS in our patients.
We identified several other variants, of which the mutant allele at the non-synonymous
SNP, P268S was statistically more significantly prevalent in the patients compared to the
controls (P=0.0066). Haplotype studies did not suggest any significant difference. Earlier
studies have proposed P268S to be a polymorphism and in phase with the R702W, G908R
and L1007FS mutations, the common disease causing variants (DCVs), but we did not have
any such observations. Conclusion : Crohn’s disease in Indian population is associated with
different mutations in CARD15 gene and the P268S variant may be playing an important
causal role or may be in linkage disequilibrium with some other variant in any other exon
of CARD15 gene.
S1399
Is It Possible to Differentiate Crohn’s Disease from NSAID-Enteropathy By
Capsule Enteroscopy?
Laurence P. Maiden, Bjarni Thjodleifsson, Sam Adler, Winfreid Voderholzer, Ingvar
Bjarnason
Background: Introduction of wireless Capsule Enteroscopy (CE) added a new dimension
into the investigation of small bowel disease. It is emerging as a first line investigation for
the detection of small bowel Crohn’s disease. It also appears to be the investigation of choice
for the diagnosis of NSAID-enteropathy, which affects over 50% of patients receiving these
drugs long-term. Furthermore NSAID-enteropathy is associated with serious outcomes
(bleeding, perforation and obstruction) as frequently as NSAID-gastropathy. Indeed it has
been suggested that certain NSAID-induced small bowel damage may be indistinguishable
from that of Crohn’s disease. Aim: To assess if it is possible to differentiate between Crohn’s
disease and NSAID-enteropathy by CE. Methods: The pathology recorded by CE from 18
patients with established small bowel Crohn’s disease and 13 with NSAID-enteropathy were
localised and quantitated by an established damage score (incorporating reddened (inflamed)
folds, denuded areas, petechiae and mucosal breaks (erosions and ulcers)). Four experienced
clinicians who had no knowledge of the clinical or demographic details of the patients read
the images independently. Each made a diagnosis of Crohn’s disease or NSAID-enteropathy
(‘definite’ or ‘likely’), based on their overall impression of the images. Results: There was
a high rate of concurrence (over 95%) between the investigators regarding the localisation
and type of damage. The number of denuded areas and petechia did not differ significantly
between the diseases (p < 0.1). The median number of mucosal breaks (median 10 (range
1 - 26) for Crohn’s disease and 2 (range 1-18) for NSAIDs) differed significantly (p < 0.05)
between Crohn’s disease and NSAID treated patients. However 3 (23%) patients with NSAID-
enteropathy were incorrectly labelled as ‘definite Crohn’s disease’ (3 of the 14 diagnosed as
‘definite Crohn’s disease’) and 3 (17%) patients with Crohn’s disease were incorrectly labelled
as either ‘definite’ (1 of 9 diagnosed as ‘definite’) or ‘likely’ (2 of 4) NSAID-enteropathy.
Conclusions: CE images of the small bowel show that NSAID-enteropathy has a similar
range of pathology as seen in patients with Crohn’s disease which further corroborates the
importance of the small bowel in the overall gastrointestinal damage of NSAIDs. In the
absence of a clinical history experienced CE image readers arrive at an incorrect diagnosis
in 20% of cases.
S1400
Age At Diagnosis and Disease Course in Pediatric Crohn’s Disease
Neera Gupta, Melvin B. Heyman, Alan G. Bostrom, Oren Abramson, Barbara S.
Kirschner, Harland S. Winter, Benjamin D. Gold, George D. Ferry, Stanley A. Cohen,
Robert N. Baldassano
Background: Analysis of data from our multicenter registry revealed that older age at diagnosis
of inflammatory bowel disease is associated with increased risk for intestinal resection in
pediatric patients with Crohn’s disease (CD) (Gastroenterology 2005; A-319). We determined
whether additional differences exist in the course of disease by age at diagnosis in pediatric
patients with CD. Methods: We conducted a retrospective, cohort study using the Pediatric
IBD Consortium Registry. Data collected between Jan 2000 and Nov 2003 were analyzed
in 989 pediatric patients with CD to compare disease course by age at diagnosis of disease
using Cox Proportional Hazards Modeling. Age at diagnosis was dichotomized into 0-5 years
and 6-17 years. Results: Mean follow-up time was 3.6±3.1 years in 989 patients; 98 (9.9%)
were 0-5 yrs and 891 (90.1%) were 6-17 yrs of age at the time of diagnosis. 43.3% of
patients between 6-17 yrs at diagnosis were found to be ASCA positive compared with 10%
of patients 0-5 yrs at diagnosis (p=.003).The table shows the risk of developing the listed
complications and the risk of being treated with specified medications in the 6-17 y/o
compared with the 0-5 y/o age group. Conclusions: A higher proportion of older children
(6-17 y/o at diagnosis) were found to be ASCA positive compared with children in the 0-
5 y/o age group. Additionally, children who are 6 yrs or older at diagnosis of IBD appear
to have a more severe course of disease and are at increased risk for being treated with 5-
ASA’s, immunosuppressants, immunomodulators, and biologic agents compared with
younger children (<6 y/o). Further studies are needed to determine whether diagnosis of
IBD at a younger age may alter the severity of the course of CD or represent a less severe
disease phenotype. Supported in part by NIH Grants DK007762 and DK060617.
S1401
Age At Diagnosis and Presentation of Pediatric Crohn’s Disease
Neera Gupta, Melvin B. Heyman, Alan G. Bostrom, George D. Ferry, Stanley A. Cohen,
Robert N. Baldassano, Oren `. Abramson, Barbara S. Kirschner, Harland S. Winter,
Benjamin D. Gold
Background: The influence of age on the clinical presentation of Crohn’s Disease (CD) has
not been well studied in the pediatric population. We determined the relationships between
the clinical presentation of CD and the age at disease diagnosis in pediatric patients. Methods:
We conducted a retrospective, cohort study using the Pediatric IBD Consortium Registry.
Data collected between 1/00 and 11/03 were analyzed to compare the initial classification
and presentation of CD in 989 pediatric patients by age at diagnosis of disease using the
Fisher’s Exact Test. Results: 989 pediatric patients with CD in our registry were diagnosed
with IBD between 1979 and 2003. A larger proportion of younger patients (0-5 years at
time of diagnosis) were initially classified as ulcerative colitis (UC) or indeterminate colitis
(IC) compared with older children and adolescents. A larger proportion of pediatric patients
6 years and older presented with abdominal pain or weight loss, while younger patients
more commonly presented with rectal bleeding. (Table) Gender or race was not related to
age at diagnosis in our study cohort. Conclusion: Rectal bleeding is a more common
presenting symptom of IBD in younger children, a larger proportion of whom were initially
classified as UC or IC. A greater proportion of patients who are ≥ 6 years old at diagnosis
report abdominal pain or weight loss at symptom onset. Future studies are needed to
determine the influence of age at disease onset on CD phenotype in children. Supported in
part by NIH Grants DK007762 and DK060617.
S1402
A Novel Microparticulate Drug Delivery System for the Treatment of
Inflammatory Bowel Diseases
Richard A. Kendall, Murdan Sudaxshina, Basit W. Abdul
Purpose. Oral modified-release corticosteroid formulations are used to treat moderate inflam-
matory bowel disease (IBD) affecting the ileum and proximal colon. Currently marketed
formulations designed to target the ileo-colonic region consist of tablets or pellets coated
with pH-sensitive polymers that remain intact in the acidic environment of the upper GI
tract. At the neutral to slightly basic pH encountered in the ileo-colonic region, the polymer
coating begins to ionize and dissolve, resulting in dosage form disintegration. However, due
to the limited fluid volume in the colonic region, and lower luminal pH of patients with
active IBD, dosage form disintegration and drug release from these dosage forms is often
too slow to target the affected area, and on occasion they are voided intact. We propose
that the formulation of pH-sensitive microparticles with a large effective surface area and
improved drug release characteristics may improve on the therapy of IBD using corticostero-
ids. Experimental. A novel emulsification/solvent evaporation method was developed for
the production of Eudragit S (soluble pH>7) microparticles containing the corticosteroids
prednisolone or budesonide. Drug encapsulation efficiency for all formulations was ~100%.
Electron microscopy revealed that all microparticles were spherical, non-aggregated and
non-porous with size <50µm. Microparticles displayed pH-responsive release of prednisolone
and budesonide, leaking a negligible amount of drug after 2 hours incubation in acid, while
releasing it rapidly at colonic pH (pH 7.4). This is due to the large surface area of the
microparticles and the improved solubility of the drug, which is encapsulated as a molecular
dispersion. Drug release rate increased with drug loading. The incorporation of a water-
insoluble polymer (Eudragit RS or ethylcellulose) into the Eudragit S microparticles produced
an extended-release profile at pH 7.4. Conclusions. A novel, colon-specific corticosteroid
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microparticle formulation has been developed which has great potential for the therapy of
IBD. The enhanced solubility of the encapsulated drug should allow a more rapid dissolution
in the viscous luminal contents of the colon. Furthermore, the slower colonic transit expected
for the microparticle formulation over a conventional tablet formulation should facilitate a
topical anti-inflammatory effect to a large area of inflamed mucosa in patients with active
IBD. A clinical trial in human volunteers, correlating GI transit with pharmacokinetic analysis
is planned to prove the in-vivo performance of the pH-sensitive microparticles.
S1403
Efficacy of Mesalazine in the Treatment of Symptomatic Diverticular Disease
Giuseppe Comparato, Libera Fanigliulo, Lucas G. Cavallaro, Giovanni Aragona, Giulia
Martina Cavestro, Stefania Liatopoulou, Angelo Franze', Cecilia Carloni, Veronica Iori,
Marta Maino, Giorgio Nervi, Francesco Di Mario
Background and aim. In uncomplicated diverticular disease, treatment is aimed to relieve
the symptoms in symptomatic patients. Our aim was to evaluate efficacy of mesalazine in
relieving symptoms in patients with symptomatic and uncomplicated diverticular disease of
the colon. Materials and methods. Two hundred and sixty-eight consecutive eligible outpa-
tients (122 male, 146 female; age 66.1 years, range 31-81 years) were enrolled in four
different schedules according to a randomisation list: Group R1 (66 patients) rifaximin 200
mg bid; Group R2 (69 patients) rifaximin 400 mg bid; Group M1 (67 patients) mesalazine
400 mg bid; Group M2 (66 patients) mesalazine 800 mg bid. Each treatment was administered
for 10 days every month for 12 months. Clinical evaluation was performed at admission
and at 3-months intervals for 12 months considering 11 clinical variables (upper and lower
abdominal pain/discomfort, tenesmus, diarrhoea, abdominal tenderness, fever, general illness,
nausea, emesis, dysuria) scored as 0 = no symptoms, 1 = mild, 2= moderate, 3= severe.The
Global Symptomatic Score (GSS) was calculated by the sum of each symptom score. Results.
After 12 months follow-up, Group M2 showed fewer frequency rate of lower abdominal
pain (p<0.0001),bloating (p < 0.001), tenesmus (p < 0.0001), diarrhoea (p < 0.01), fever
(p < 0.0001), general illness (p<0.02), nausea (p=0.002) , dysuria (p=0.04) ,bleeding (p=
0.01). Mean GSS was lower in Group M2 after 6 months (p < 0.001) and 12 months (p <
0.0001) respectively. Patients treated with mesalazine (Groups M1 and M2 together consid-
ered) showed a lower GSS if compared to subjects treated with rifaximin (Groups R1
and R2 together considered) after 6 (p<0.001) and 12 months (p<0.0001), respectively.
Conclusion. Cyclic administration of mesalazine is effective in obtaining symptom relief in
uncomplicated diverticular disease of the colon. Some symptoms improved more with
mesalazine 800 mg bid than with the other schedules.
S1404
Cronkhite-Canada Syndrome: Clinical Outcomes and Molecular Features
Neal K. Osborn, Schuyler Sanderson, Thomas Smyrk, Linda Murphy, David Ahlquist,
Lisa Boardman
Background & Aims: Cronkhite-Canada Syndrome (CCS) is an acquired condition involving
diffuse gastrointestinal polyposis. The polyposis, associated diarrhea, and characteristic muco-
cutaneous findings may resolve with immunosuppressive treatment. However, few data
are available on long-term outcomes and little is known about the underlying molecular
mechanisms. Methods: From a patient registry, clinical records and archival tissue from 9
well-characterized CCS patients were evaluated. Using paraffin-imbedded tissue, microarrays
were constructed of CCS polyps and controls which included polyps from patients with
Juvenile Polyposis Syndrome (JPS) and sporadic Juvenile Polyps as well as normal mucosa
from stomach, small bowel, and colon. The antibodies for four DNA Mismatch (MMR) repair
proteins (hMLH1, hMSH2, hMSH6, hPMS2) and other colorectal cancer related proteins
including APC, and IgG-4 were applied. Results: Among CCS patients treated with steroids,
85% achieved symptomatic remission; however, nearly all relapsed within 3-6 months of
stopping or tapering steroids. Two patients sustained remission on long term maintenance
with the immunomodulatory agent azathioprine. During the course of follow-up on the 9
CCS patients, 5 (56%) developed adenomatous polyps, 2 (22%) colorectal cancer, 2 (22%)
oropharyngeal polyps, and 1 (11%) cecal carcinoid tumor. Among CCS polyps, immunohisto-
chemistry staining for MMR and APC proteins was normal. In contrast, IgG4 expression
was significantly higher (>5 cells/HPF vs <5) in CCS compared with JPS (p = 0.001). The
other normal controls and CCS adenomas and CCS cancers were uninvolved. Conclusions:
Clinical manifestations of CCS may respond to steroids, and remission may be maintained
by sustained immunosuppression. The incidence of colorectal neoplasia appears to be high
with CCS. Neither MMR nor APC pathways are affected in the non-neoplastic polyps in
CCS. IgG4 expression was increased in CCS polyps compared with those in JPS, supporting
an underlying inflammatory process with CCS.
S1405
Prevalence of Disaccharidase Deficiency in Symptomatic Patients with Existing
Gastrointestinal Illnesses
Charles W. Randall, Carlo M. Taboada, Russell D. Havranek, Franz Zurita, David Stump,
Gary Gossen, Victor Ostrower, Susan Ryan, Janet Ford
Introduction In this study we followed patients with a variety of underlying GI illness whose
symptoms were not completely controlled by conventional therapy. We sought to determine
if lactose or fructose intolerance contributed to their continued symptoms. Methods 127
patients were seen in our clinic with known GI disorders. 116 had a functional syndrome
(IBS, Functional Nausea, Functional Diarrhea, Gas/Bloat Syndrome & NUD); 2 had celiac
disease; 3 had inflammatory bowel disease; 2 had motility disorders; 2 had lymphocytic
colitis; 1 with severe diverticular disease and 1 with intestinal carcinoid. All patients under-
went lactose and fructose hydrogen breath testing. For those testing positive appropriate
dietary management and follow-up were arranged. Patients with organic or inflammatory
illnesses were all evaluated to determine disease activity and all were in a quiescent phase.

















intolerant; 29 were fructose intolerant and 10 were intolerant to both. 12 patients thought
to have had a functional disorder had their diagnoses changed. These patients had been
resistant to standard therapy and responded well to dietary management. Only 4 patients
had no improvement or unsatisfactory results from dietary changes. Conclusions 1.- 49.6% of
patients with known GI disorders but persistent symptoms tested positive for disaccharidase
deficiency. 2.- 19% of patients with a disaccharidase deficiency had been misdiagnosed as
having a functional disorder. 3.- Dietary management was efficacious in controlling symptoms
in 93.6% of patients. 4.- Testing for lactose and fructose intolerance is safe and noninvasive
and leads to a positive outcome for patients.
S1406
Chronic Drug Consumption and Risk of Microscopic Colitis (MC): A Case-
Control Study
Fernando Fernandez-Banares, Maria Esteve, Jorge Espinos, Merce Rosinach, Montse
Forne, Josep Maria Viver
MC is a rare disease of unknown etiology. It has been described that some drugs could
cause or worsen the disease, suggesting a high likelihood of inducing MC for 8 drugs
(acarbose, aspirin, lansoprazole, NSAIDs, ranitidine, sertraline, ticlopidine and venotonic
drugs). However, the scientific evidence is limited. Aim: Case-control study to investigate
the possible association of chronic drug consumption with MC. Methods: Groups of cases
were: Group 1 - 39 patients with collagenous colitis (CC); Group 2 - 39 patients with
lymphocytic colitis (LC); and Group 3 - 52 patients with chronic watery diarrhea of functional
characteristics (CD). The control group was formed by 97 age- and sex-matched subjects
(56 patients of the major outpatient surgery unit, ophthalmologic and sinonasal surgery,
and 41 accompanying persons). At diagnosis, drug consumption history of at least 2 weeks
of duration was registered. Drug consumption in the control group was similar to that
described in the elderly (>65 yrs) population in Spain. An age- and sex-adjusted logistic
regression analysis was used, and the OR (95% CI) was calculated. Results: Drug consumption
was: 89.7% CC, 92.3% LC, 76.9% CD and 76.3% Control (p<0.05 LC vs control). The
mean daily number of drugs by person was: CC, 2.67±0.37; LC, 3.79±0.44; CD, 2.67±0.36;
Control, 2.13±0.22 (p=0.04 LC vs Control, ANOVA adjusted by age and sex). The following
associations as compared to control group were observed: Group 1 (CC) - Consumption of
NSAIDs (do not include low doses of aspirin) (46.2 vs 23%; p=0.008; OR=2.9, 1.3-6.4),
selective serotonin reuptake inhibitors (SSRI) (18 vs 1%; p=0.005; OR=21, 2.5-177); Group
2 (LC) - SSRI (28 vs 1%; p=0.001; OR=37.7, 4.7-304), beta-blockers (13 vs 3%; p=0.043;
OR=4.79, 1.04-20), statins (13 vs 3%; p=0.044; OR=4.6, 1.04-20), biphosphonates (8 vs
0%; p=0.022); Group 3 (CD) - SSRI (15 vs 1%; p=0.01; OR=16.2, 2-135), statins (11.5 vs
3%; p=0.025; OR=5.4, 1.2-24). Among SSRI there was an association with the use of
sertraline only in LC (15.3 vs 0%; p=0.0005). Conclusions: 1. Drug consumption in LC
was higher than in the age-matched control population. 2. Although it is not possible to
conclude if drugs are the cause or only worsen MC, the observed associations suggest that
consumption of these drugs might have a role in the pathogenesis of the disease. 3. There
were differences between CC and LC in the drug associations found. As the 95% CI of the
OR were wide, further studies in larger samples are required to confirm the strength of the
observed associations.
S1407
Mucosal Healing in the Small Intestine Detected By Wireless Capsule
Endoscopy
Ruediger Schoo, Carsten Buening, Johann Ockenga, Jutta Wirth, Jutta Weber, Guido
Schachschal, Herbert Lochs, Voderholzer Winfried
Background: Wireless capsule endoscoyp may be useful in the follow up of small intestinal
Crohn’s disease (CD) in order to detect healing of mucosal lesions. However, data on the
follow up of patients with small intestinal CD are rare. Aim of our study was healing during
standard therapy. Methods: Patients with active CD (CDAI > 200) were enrolled. Before the
WCE- procedure all patients underwent gastroscopy, colonoscopy, small bowel radiology
(CT-enteroclysis), and abdominal ultrasound. After exclusion of relevant strictures (< 1 cm
diameter) by CT enteroclysis and a regular preparation like for colonoscopy, the patients
underwent wireless capsule endoscopy. All capsule videos were evaluated by a standardized
form that gave information about specific lesions for CD (cobblestonine, fissural ulcers,
aphthes, erythema, strictures). After that, standard medical therapy was initiated. After 2
months, WCE, colonoscopy, and ultrasound were repeated. Results: So far, 14 patients have
been examined (f/m = 7/7, 35, 1 ±11.7 yrs). All Patients had a clinical improvement (CDAI
1: 316 ± 108,64, CDAI 2: 139,43 ± 87.9) after therapy with glucocorticoids and mesalazine
(10 patients), azathioprine (2), infliximab (1) and MTX (1). After 2 months of therapy, there
was no change with respect to the colonoscopic activity. Moreover, there was no change in
kind and frequency of Crohn typical lesions seen in WCE in patients who received glucocort-
icoids. The patient on MTX had pathological lesions all over the small intestine. After
treatment the extent was limited to the terminal ileum and the proximal lesions had disap-
peared. The one patient who were on azathioprine showed no change. The other patient
had almost a complete disappearance of lesions. The patient who received infliximab had
a remission of about 50% of his ulcerations. The only significant change was a minor change
of results of abdominal ultrasound (p= 0,034). Conclusions: WCE is a suitable method for
examining mucosal healing in CD. Standard therapy using glucocorticoids does not result
in mucosal healing in the small intestine, although in patients who received an immunmodula-
tory or immunsuppressive medication (infliximab and azathioprine) the lesions got rare.
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S1408
The Significance of Raised C Reactive Protein in Patients with Late Radiation-
Induced Bowel Symptoms
Usman Khalid, Andrew R. Norman, Jervoise Andreyev
Background: The production of CRP occurs in the liver as part of the acute phase response.
An elevated CRP is a valuable marker of disease activity in Crohn’s disease, predicts colectomy
in ulcerative colitis and outcome following myocardial infarction and in multiple myeloma.
It is sometimes elevated in patients with chronic gastrointestinal symptoms following pelvic
radiotherapy, but its significance in this context has not been evaluated. Aims and methods:
To investigate the significance of an elevated CRP with new gastrointestinal symptoms starting
after pelvic radiotherapy. All new patients at first presentation to one gastroenterologist had
their CRP measured routinely. The diagnoses reached following systematic investigation of
their symptoms were grouped into categories and correlated with the level of the CRP using
logistic regression analysis. Results: Since 2001, 159 patients presenting 0-34 years after the
end of radiotherapy (median 3 years) with new gastrointestinal symptoms had their CRP
checked. 91 were women aged 22-84 (median 61 years), 68 were men aged 31-84 (median
69.5 years). 5 had been treated for anal, 2 bladder, 36 cervical, 36 endometrial, 2 ovarian,
56 prostate, 6 rectosigmoid, 5 seminoma, 7 vagina and 4 other cancers. 131 patients had
a normal CRP (<10 mg/l). In the 28 with an elevated CRP, it ranged from 10-79 mg/l
(median 18). 8 categories of diagnosis were recorded for patients (more than one diagnosis
possible). These included advanced neoplasia (n=18), small bowel disease (n=43), large
bowel disease (n=42), ano-rectal disease (n=70), infection (n=5), chronic pancreatitis (n=
6), drugs (n=7) and normal/other (n=40). On univariate analysis, younger age, p=0.035
(OR 0.96 95% CI 0.94-0.99), presence of advanced neoplasia, p=0.01 (OR 3.85 95% CI
1.34-11.1) and the presence of chronic pancreatitis, p=0.026 (OR 8.13 95% CI 1.29-51.23)
were statistically associated with an elevated CRP. Gender, years since treatment, tumour
primary site, small and large bowel disease, ano-rectal disease, infection, drugs or normal/
other was not associated with abnormal CRP. Multivariate analysis was not performed in
view of the size of the cohort. Conclusions: An acute inflammatory response as manifested
by a raised C reactive protein is not a prominent feature of chronic radiation-induced toxicity
in the gastrointestinal tract. An elevated CRP in patients with gastrointestinal symptoms not
present before radiotherapy should raise the possibility of neoplasia or the rare condition,
radiation-induced pancreatic insufficiency.
S1409
Autoimmune Enteropathy Successfully Treated with Tacrolimus: A Case
Report of Two Adult Patients
Sami Mustajoki, Martti Farkkila
Background Autoimmune enteropathy (AIE) is a rare autoimmune disease of unknown
etiology characterized by refractory diarrhea, villous atrophy of small intestine, and the
presence of serum antibodies against enterocytes. Although various immunosuppressive
medications have been used, there is no established treatment for AIE. In this report we
describe two adult patients suffering from AIE treated with tacrolimus. Patient 1 A 60-year-
old female with previously diagnosed migraine and psoriasis was referred to hospital with
a 6-week history of diarrhea leading to severe hypokalaemia and weight loss of 10 kg.
Colonoscopy revealed no findings macroscopically but histologically there was active non-
specific inflammation in terminal ileum and right-sided colon. In duodenal biopsies there
was total villous atrophy and highly active inflammation. Capsule endoscopy finding sug-
gested diffuse villous atrophy in whole small intestine. Serological markers for celiac disease
were negative and the patient was negative for HLA haplotype DQ2. Anti-enterocyte antibod-
ies were positive (titer 1:10). Prednisone 40 mg/d (0.8 mg/kg/d) resulted in rapid improve-
ment in clinical status, but tapering the dose caused a clinical relapse. Azathioprine had to
be discontinued because of abdominal pain, and tacrolimus 3 mg/d (0.06 mg/kg/d) was
introduced, adjusting the dose to reach plasma concentration of 10 ug/l. Within 10 days
bowel function returned to normal and after five weeks duodenal biopsies showed only
mild and partial villous atrophy and no inflammation. Patient 2 A 23-year-old previously
healthy male had suffered for 5 months from watery diarrhea, fever and weight loss of 18
kg. In duodenal biopsies subtotal villous atrophy and inflammation was found. Villous
atrophy and active inflammation was also detected in terminal ileum. Serological markers
for celiac disease and HLA haplotype DQ2 were negative. With prednisone 60 mg/d (1.2
mg/kg/d), azathioprine 50 mg/d and gluten-free diet the clinical response was dis-appointing
and progression of villous atrophy and inflammation was seen at biopsies. Eventually, anti-
enterocyte antibodies were positive (titer 1:10) and tacrolimus was started with starting dose
of 10 mg/d (0.2 mg/kg/d), aiming at plasma concentration of 10 ug/l. After 4 weeks the
patient was asymptomatic and after 9 months duodenal biopsies showed normal villous
structure. Also anti-enterocyte antibodies were converted negative. Tacrolimus was ceased
without deterioration of symptoms. Two years later, hypothyreosis was diagnosed. Conclu-
sion Based on our experience, tacrolimus is effective, safe and well tolerated treatment for
autoimmune enteropathy.
S1410
Non-Specific Mucosal Microscopic Abnormalities Can Affect the Terminal
Ileum and Different Sites of the Large Bowel in Patients with Functional
Bowel Disorders
Adriana Marcheggiano, Alfredo Covotta, Carlo Iannoni, Danilo Badiali, Rosanna
Cantarini, Marco Paoletti, Nadia Pallotta, Enrico Corazziari
Non-specific microscopic abnormalities (NSMA) of the colonic-rectal mucosa may occur in
IBS patients. It is not known, however, whether NSMA affect one or more sites of the large
bowel and terminal ileum in patients with irritable bowel syndrome (IBS) and other Functional
Bowel Disorders (FBD). AIM of this study was to evaluate the histological pattern of the
mucosa of the large bowel and terminal ileum in patients referred for FBD to a third level
referral center. PATIENTS. Thirty-four consecutive patients (22 F; age range 22-70 yrs),
with normal serum biochemistry, CBC, thyroid function, EMA, and normal ileum-colonos-
copy were evaluated. Sixteen patients matched the diagnosis of IBS; five of functional diarrhea
(FD), and thirteen of unspecified functional bowel disorders (UFBD). Biopsies of the terminal
ileum (n=2) cecum (n=1), ascending (n=1), transverse (n=1), descending (n=1), sigmoid
(n=1) colon, and rectum (n=1) were stained with H-E for microscopic assessment by a
pathologist unaware of the clinical diagnosis. RESULTS. Histological abnormalities were
found in 9 (26.5%) patients: 3 IBS, 2 functional diarrhea and 4 UFBD. Increased lymphoplas-
macytic infiltrate and granulocyte clusters were present at the level of a) the ileum only in
1 IBS patient, and in 2 UFBD patients; b) the cecum only in 1 IBS patient. Altered crypt
architecture was present in the rectum only in 1 UFBD. Collagenous colitis was present in
1 IBS, 2 functional diarrhea, and 1 UFBD, patient. CONCLUSIONS. In a subgroup of patients
with Functional Bowel Disorders, IBS and non-IBS, non-specific microscopic abnormalities
can be present at the level of the terminal ileum and different sites of the large bowel. Non-
specific microscopic abnormalities of the ileo-colonic-rectal mucosa and collagenous colitis
may be equally present in patients with different Functional Bowel Disorders. Biopsies of
multiple sites of colon, terminal ileum, and rectum are required to detect Non-specific
microscopic abnormalities in patients with functional bowel disorders.
S1411
Management of Acute Pancreatitis: A Survey of Internal Medicine Residents
Sameer Barkatullah, Ami Shah, Aziz Aadam, Sri Komanduri
PURPOSE: We conducted a survey to evaluate the current understanding of the management
of acute pancreatitis (AP) among internal medicine residents. The survey was conducted to
assess the efficacy of current teaching patterns and to improve overall patient care at a large
urban teaching center. METHODS: We administered a 23-question survey to 58 Internal
Medicine residents. The questions were multiple choice and centered on basic aspects of
management of AP. These included appropriate use of laboratory testing and radiologic
imaging, assessment of severity, use of antibiotics, nutrition, and indications for surgical
intervention. RESULTS: Approximately 50% of the surveys collected were completed by
first year residents and the other 50% by senior residents. Though 38% could not identify
the initial appropriate laboratory testing, an even greater proportion, 62% of residents, did
not recognize Hematocrit as the most important predictor of severity on admission. About
25% felt that administration of empiric antibiotics for all cases of AP were the standard of
care. Furthermore, 21% felt the diagnosis of AP was made by identifying inflammation on
CT scan. In the setting of acute biliary pancreatitis, only 66% identified RUQ ultrasound
as the preferred initial imaging modality, and only 59% could identify the appropriate timing
and utility of ERCP. A larger gap of knowledge was seen in identification and management
of severe pancreatitis. The majority of residents (81%) underestimated the incidence of
pancreatic necrosis in the setting of severe pancreatitis. As for early feeding, only 36% of
residents felt that it decreased morbidity and mortality in necrotizing pancreatitis; 31%
preferred total parenteral nutrition to enteral feeding. Perhaps most surprising, only 55%
correlated necrotizing pancreatitis with Systemic Inflammatory Response Syndrome (SIRS).
Finally, 66% of all residents could not recognize appropriate indications for surgical interven-
tion in AP. As for the use of prognostic indices, only about two-thirds used Ranson’s criteria
occasionally, while 52% reported never using the APACHE II score to assess severity. Overall
only 21% of residents felt very confident in managing acute pancreatitis. CONCLUSION:
The morbidity and mortality of AP continues to be a problem. In addition, there continues
to be a large amount of resources utilized for this cohort of patients. The lack of understanding
and inconsistent management of severe pancreatitis is alarming. A dedicated educational
effort is needed at the resident level in order to begin to decrease the morbidity of AP as
well as to curtail ineffective use of costly resources.
S1412
Evaluation On a Mexican Cohort of a UK Computer Model Developed to
Predict Severity of Acute Pancreatitis
Callum B. Pearce, Jose A. Gonzalez-Gonzalez, D.R. A. Garcia-Cantu, Steve R. Gunn,
Colin D. Johnson
Background: It has previously been reported that a computer model using 8 variables (age,
C-reactive protein (CRP), respiratory rate, pO2 on air, arterial pH, serum creatinine, white
cell count and GCS) created using a UK cohort of patients with acute pancreatitis (AP) can
provide accurate prediction of severity using data obtained on admission to hospital. This
model has up to now only been tested on UK patients. Aim: To evaluate this model on a
retrospectively collected dataset previously obtained in a different geographical and social
setting (Monterrey, Mexico). Method: Clinical and biochemical admission data were collected
from 202 patients admitted with a diagnosis of AP between October 2002 and November
2004. The data were evaluated using a computer model (BSG March 2004), and the area
under the receiver-operating characteristic curve (AUC) was used to compare the accuracy
of this model with CRP and CREED systems (a system commonly used in Mexico) in
predicting severity in AP. Severe AP was defined by the Atlanta criteria. Results: 42 patients
(20.8%) developed severe disease, and 3 died (1.5%). 11 patients (5.4%) developed renal
failure by the Atlanta criteria, and 23 respiratory failure (11.4%); 146 patients had a biliary
aetiology (72.3%), 25 alcohol (12.4%), 11 hypertriglyceridaemia (5.4%), 14 idiopathic
(6.9%) and 6 post-ERCP (3%). The UK computer model predicted severity in the Monterrey
patients with an AUC of 0.81, (identical to the figure obtained previously in UK patients).
This represents a sensitivity and specificity for prediction of severity of 0.80 and 0.77 at
the optimum cut-off point. This compares favorably with the CREED system (AUC 0.70)
and was significantly (p=0.001) better than admission CRP (AUC 0.76) in the same group
of patients. Comments: This system combines scoring of early systemic disturbance and
admission CRP value for prediction of severe AP. The score is simple to use, can give a
prediction within a few hours of admission to hospital, and is more accurate than admission
CRP or APACHE-II. The validation of the model on a separate cohort of patients from a
different background confirms the merit of the computer-assisted approach. A prospective
multi-center study using the Southampton computer system is required.
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S1413
Trends in the Epidemiology of Acute Pancreatitis (AP): A Systematic Review
Dhiraj -. Yadav, Albert B. Lowenfels
Background and Aims: To systematically review trends in the epidemiology of first attacks
of AP based on reported population-based studies. Methods: From Medline we retrieved
18 full length English language peer-reviewed original articles published during 1966-present
with population-based information on the epidemiology of first attacks of acute pancreatitis.
We examined time-tends using linear regression analysis. Results: Nine studies were from
the UK and nine were from other European centers. The annual incidence per 100,000 for
first attacks of AP and gallstone pancreatitis increased significantly over the last 4 decades
(β=0.5, p <0.001 and β=0.39, p=0.004 respectively) after controlling for the site of study
(UK vs. non-UK). The incidence of gallstone pancreatitis was similar in UK and non-UK
studies (β= -0.19, p = 0.93), while the incidence of alcoholic pancreatitis was higher in
non-UK studies (β=4.44, p<0.001). AP incidence and mortality increased with age. Gallstone
pancreatitis was more common in females and alcoholic pancreatitis in middle-aged males.
AP case fatality (%) decreased from 15-21% earlier to about 5% presently (FIGURE), but
the overall population AP mortality rate/100,000 over time was unchanged (β=0.01, p=
0.13). Recurrent AP was milder with a substantially lower mortality. Conclusions: The
incidence of AP has increased significantly over the last few decades. The differences in the
incidence and etiology of AP present between and within countries reflect differences in the
prevalence of risk factors. The AP case fatality rate but not the population-based mortality
rate decreased over time.
S1414
Predictors of Length of Hospitalization for Acute Biliary Pancreatitis in a
Tertiary Medical Center
Sameer Barkatullah, Aziz Aadam, Garth Swanson, Ami Shah, Sri Komanduri
BACKGROUND: Several factors in the management of acute biliary pancreatitis (ABP) have
been studied for their value in predicting morbidity and mortality. In addition to these
outcomes, factors that provide insight into expected length of hospitalization (LOH) merit
evaluation. We retrospectively reviewed the management of ABP, with attention to the
predictive value of various standard practices on the LOH at a large urban teaching center.
METHODS: Patients with ABP were identified by evidence of epigastric pain, elevated lipase
and liver function tests (LFT), and abnormal transabdominal ultrasound demonstrating
cholelithiasis or choledocholithiasis with or without ductal dilatation. A total of 75 admissions
for ABP were reviewed between between January 1, 2002 and December 31, 2004. APACHE
II scores and percent change in lipase, alkaline phosphatase (AP), total bilirubin, aspartate
aminotransferase (AST), and alanine aminotransferase (ALT) values were calculated at admis-
sion, 48, and 72 hours. Time to ERCP, cholangiogram findings, and empiric antibiotic usage
were also recorded. RESULTS: The mean age was 56 years, with female preponderance
(65%), and a mean LOH of 6.8 days. 51 patients underwent ERCP. Those who had ERCP
within 72 hours had a significantly shorter LOH compared to those undergoing ERCP after
72 hours (5.8 vs. 9.9 days) (p <0.05). In addition, those who had filling defects within the
biliary tree on ERCP had higher APACHE II scores than those without filling defects at 72
hours (5.38 vs. 3.44) (p <0.05). Fluid balance, changes in lipase or LFTs did not reliably
predict LOH at any time interval. Patients receiving empiric antibiotics had a greater mean
LOH than those on no antibiotic therapy (8.4 vs. 6.5 days). This difference approached
statistical significance. CONCLUSION: Our data suggests that early ERCP (<72 hours) in
select patients with ABP decreases length of hospitalization. This is in accordance with
previous data suggesting improved outcome with early ERCP in this cohort. Interestingly,
patients with a filling defect on cholangiogram had significantly worse pancreatitis at 72
hours than those with a negative cholangiogram. This supports the concept of performing
ERCP in ABP to prevent ongoing pancreatic injury due to biliary obstruction. We found no
correlation between trends in serum lipase or liver function tests, or empiric antibiotic usage
and length of hospital stay. Our data suggests that early ERCP, when appropriate, significantly
decreases LOH in ABP. The practice of drawing daily labs and administering empiric antibi-


















Hemoconcentration Is An Independent Risk Factor for Severe Acute
Pancreatitis
Young S. Oh, Da Hea Seo, Christian D. Stone
BACKGROUND: Hemoconcentration (hematocrit [HCT] > 44) at initial presentation to the
hospital has been shown to be associated with severe acute pancreatitis (SAP). However, it
has not been evaluated as an independent risk factor for SAP in a multivariate model. We
analyzed a large database of inpatient admissions for acute pancreatitis to determine if
hemoconcentration was an independent risk factor for SAP after controlling for other known
risk factors. METHODS: A database of 629 adult admissions for an ICD-9 diagnosis of acute
pancreatitis was reviewed for demographic data, initial and subsequent HCT values, and
outcome measures. Risk factors for SAP considered included age ≥ 50, obesity (BMI ≥ 30
kg/m2), morbid obesity (BMI ≥ 40), Black race, male sex, initial HCT > 44, and increase
in HCT after 24 hours. SAP was defined as presence of acute renal failure, need for ICU
admission, or necrotizing pancreatitis on radiographic imaging. Admissions for less than 3
days were excluded because, in a subset chart review, such cases were frequently confounded
by the presence of chronic pancreatitis and/or failed to meet clinical criteria for acute
pancreatitis. Multivariate logistic regression was used to determine the risk for SAP. RESULTS:
The adjusted odds ratio (aOR) for SAP for initial HCT > 44 was 1.8 (95% confidence interval:
1.1, 3.4). The adjusted OR for increase in HCT after 24 hours was 0.9 (0.6, 1.8). Other
factors found to confer a risk for SAP were Age ≥ 50 [aOR = 2.3 (1.5, 3.5)] and morbid
obesity [aOR = 3.4 (1.4, 7.9)]. The aORs for male sex, obesity and Black race were elevated
but not statistically significant. CONCLUSIONS: Hemoconcentration with an initial HCT >
44 is an independent risk factor for SAP. Worsening hemoconcentration as manifested by
an increase in HCT after 24 hours was not an independent risk factor in our model. Age
≥ 50 and morbid obesity were also independent risk factors for SAP. These findings may
be clinically useful in assessing severity of acute pancreatitis upon initial presentation.
S1416
Prognostic Factors of Life-Threatening Local Complications in Patients with
Severe Acute Pancreatitis
Akiyoshi Hagiwara, Takehiko Tarui, Hideaki Goto, Takeaki Matsuda, Yoshihiro
Yamaguchi, Shuji Shimazaki
Objective: The objective of this study was to determine prognostic factors of arterial injuries
and gastrointestinal perforation, which are life-threatening local complications associated
with severe acute pancreatitis. Materials and Methods: 31 severe acute pancreatitis patients
with Ranson score ≥3 were included in this study (female: 8, male: 23, aged 54.6±18.3
years). Study parameters included: Ranson score, APACH II score and CRP on administration
(Day 1) and Day 7, and enhanced CT findings observed on Day 1 (1st) and Day 7-10 (2nd).
CT findings were assessed using CT severity index (Balthazar EJ et al.). Results: Local
complications developed in 11 of 31 patients. These complications consisted of 6 cases of
arterial injuries (ruptures of celiac artery [n = 1], middle colic artery [n = 1], great pancreatic
artery [n = 1], gastroduodenal artery (GDA) [n = 1], occlusion of splenic artery that caused
splenic necrosis [n = 1], ruptures of both GDA and splenic vein [n = 1]) and 5 cases of
gastrointestinal perforation (stomach [n = 1], duodenum [n = 2], colon [n = 2]). Three
patients died in association with massive bleeding from GDA (n = 1, Day 51) or perforation
of the colon (n = 2, Days 17 and 162). Ranson and APACH II scores on Day 1 were 5.3±2.1
and 12.9±8.7 for patients who developed complications (C group) and 4.3±1.1 and 9.8±5.1
for patients who did not (Non-C group), and no statistical significance was found. APACH
II scores and CRP on Day 7 were significantly higher in the C group compared to the Non-
C group (APACH II scores: 11.7±6.2 vs. 5.1±3.4, p=002, CRP: 20.5±6.6 mg/dL vs. 8.6±5.8
mg/dL, p<0.01). APACH II scores and CRP of all patients in the C group were ≥5 and
≥9.2 mg/dL, respectively. Severity index of 1st and 2nd CT were significantly higher in the
C group compared to the Non-C group (1st CT: 7.3±2.4 vs.3.4±1.9, p<0.01, 2nd CT:
7.6±2.3 vs. 3.0±1.6, p < 0.01). All patients in the C group had ≥4 severity indices. APACH
II scores and CRP in the C group continued high values after Day 7. The 2nd CT showed
severe fat inflammation in the same site of the perforation, i.e. the inflammation of transverse
mesocolon in transverse colon perforation. These inflamed and fat-accumulated lesions
gradually turned into localized low density areas. Conclusion: Life-threatening and localized
complications can occur if the APACH II score, CRP, CT severity index are high on Day 7
and CT after Day 7 shows persistent and severe fatty inflammation.
S1417
The Prevalence of Pancreatic Serine Protease Inhibitor Kazal Type 1 (SPINK1)
and Cationic Trypsinogen Gene (PRSS1) Mutations in Polish Patients with
Chronic Alcoholic Pancreatitis (CAP)
Ewa I. Malecka-Panas, Anita Gasiorowska, Renata Talar-Wojnarowska, Beata Smolarz,
Hanna Romanowicz-Makowska
We have earlier demonstrated that in more than 90% Polish patients, excessive alcohol
consumption represents the main cause of chronic pancreatitis (CP), however only around
5% alcoholics develop this diseases. The exact mechanism of CAP pathogenesis is not fully
elucidated yet. Mutations of the PRSS1 and SPINK 1 have been mostly implicated in hereditary
and idiopathic CP, but their presence in other types of this disease have also been reported.
The aim of the study was to determine the frequency of PRSS1 and SPINK1 mutations in
patients with chronic alcoholic pancreatitis (CAP) as well as to investigate their relation to
the clinical course of the disease. The diagnosis of CAP was based on clinical data, ultrasound
and computed tomography. DNA was isolated from 37 patients with chronic alcoholic
pancreatitis as well as 46 healthy subjects. The N21I mutations of PRSS1 have been detected
with ASA-PCR and N34S mutation of SPINK1 - with PCR-RFLP. Overall 9 (24.5%) - among
them five homozygous and four heterozygous - N34S SPINK1 mutations in CAP group have
been detected. The same mutations (one - homozygous, two - heterozygous) have also been
found in three (6.5 %) control subjects. PRSS1 mutations have been detected in five (13.5%)
patients with CAP and only in those with accompanying SPINK1 mutations. In addition
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the same mutation concerned two (4.3%) controls. In patients with CAP and the presence
of at least one of the mutations evaluated, pancreatic calcifications have been detected
significantly less frequently (p< 0.05) that in patients with no mutations. In addition complica-
tions requiring endoscopic or surgical treatment (p<0.01) have been also less frequently
noted in CAP with detected mutations compared with the remaining CAP group. No relations
have been found between those mutations presence and the demographic data, as well as
other clinical features of the CAP patients. Those preliminary data suggest the high incidence
of SPINK1 and PRSS1 mutations in Polish population generally, as well as in CAP patients.
It may be speculated that those mutations contribute to the development of chronic pancreat-
itis in patients with alcohol overindulgence. On the other hand the clinical course of CAP
seems to be more severe in patients with no SPINK1 and/or PRSS1 mutations detected.
S1418
A Novel PRSS1 Mutation (Arg-121 -> Thr) Highlights the Surface Exposed
Region PRSS1 A121-R122-V123 As a Hotspot in the PRSS1 Gene and
Indicates a Unreported Phenotype
Peter Felderbauer, Juergen Schnekenburger, Rainer Lebert, Tobias Meister, Kerem Bulut,
Frank Schmitz, Wolfram Domschke, Wolfgang E. Schmidt
Introduction: Since the discovery of the mutations in the cationic trypsinogen gene (PRSS1)
that cause hereditary pancreatitis the understanding of genetic risk factors for chronic
pancreatitis (CP) extended. In the specific region of the gene where the first R122H mutation
was detected subsequently two more mutations, R122C and V123M were detected that
resulted in a similar phenotype. Here we report a family with a novel A121T mutation in
the PRSS1 gene that differs from the previously described mutations in several aspects.
Methods: We collected blood samples for clinical chemistry and mutational screening of all
family members who accepted genetic testing. Coded DNA samples of the patients were
analysed for PRSS1 mutations using melting point curve analysis and DNA sequencing.
Properties of the mutated sequence were analyzed by molecular modelling. Results: The
sequencing revealed a novel G to A transition at position 133279 of the published genomic
sequence (#U66061 GenBank). The mutation results in an amino acid substitution of Arginine
by Threonine at position 121 (A121T) of the cationic trypsinogen. 5 additional mutation
carriers could be identified among the relatives while only one patient developed CP. The
molecular modelling of PRSS1 A121T revealed with high reliability an impaired autodigestion
at R122 comparable to the recently reported R122C mutation. Conclusion: The novel
PRSS1 A121T mutation emphasizes that the surface exposed region PRSS1 A121-R122-
V123 represents a hotspot for hereditary pancreatitis associated trypsinogen mutations.
Molecular modelling and recently published studies of in vitro enzyme activities of PRSS1
mutated in this region indicate a higher stability against PRSS1 autodegradation and a gain
of function as a cause of hereditary pancreatitis.
S1419
Natural History of Chronic Hereditary Pancreatitis (CHP)
Vinciane Rebours, Marie Christine Boutron-Ruault, Claude Ferec, Dermot O'Toole,
Matthieu Schnee, Frederique Maire, Pascal Hammel, Philippe Ruszniewski, Philippe Levy
The prevalence and natural history of CHP in France (population: 60 millions), occurring
largely due to mutations of cationic trypsinogen gene (PRSS1), remains ill documented. Aim
of the study: To assess genetic, epidemiological, clinical and morphological characteristics
of CHP as part of a large extensive national survey. Patients (pts) and methods: A cohort
comprising all French CHP pts was constituted by contacting all French gastroenterologists
and pediatricians (response rate: 84 %) and genetics laboratories (response rate: 100 %).
Inclusion criteria were the presence of PRSS1 gene mutation, or chronic pancreatitis in at
least 2 first-degree relatives, or 3 second-degree relatives, in the absence of another cause
of pancreatitis (notably, alcohol). CFTR and SPINK 1 gene mutations were also systematically
examined. Results: The cohort comprised 78 families and 200 pts, 181 of whom were alive
(mean number of generations/family: 3; men 53%, chronic alcoholism: 5%, smokers 34%).
PRSS 1 gene mutations were found in 68% of the pts (R122 H: 78%, N29I: 12%, others:
10%). SPINK 1 and CFTR gene mutations were found in 13 and 2 % of the pts, respectively.
Maternal inheritance was observed in 65%. Median age at first symptom and at inclusion
in the study, was 10 (1-73) and 30 (1-84) years, respectively. 17 % of the pts were symptom-
free (penetrance: 83%). Median delay between first symptoms and diagnosis was 9 years;
CHP manifestations were pancreatic pain (83%), acute pancreatitis (69%), pseudocysts
(23%), cholestasis (3%), pancreatic calcifications (61%, median age of onset 23 years),
steatrorrhea (34%), diabetes mellitus (26%) and pancreatic adenocarcinoma (5%, median
age 55 years). Exocrine and endocrine insufficiency occurred at 29 and 38 years (median),
respectively. No differences in clinical and morphological data according to genetic status
were observed. Long-term (>3 months) analgesics intake, endoscopic treatment and surgery
were necessary in 10, 16 and 23% of the pts, respectively. 19 pts died, including 10 from
CHP, at a median age of 60 years. Conclusion: The numbers of French families and pts
with CHP include at least 78 and 180 respectively. PRSS 1 gene mutations are found in 2/
3 of pts with a 83% penetrance. Mutation type is not correlated to clinical/morphological
expression. Major differences between CHP and chronic alcoholic pancreatitis, apart from
age at onset, include a lesser frequency of cholestais and pancreatic insufficiencies.
S1420
Pancreatitis in Primary Hyperparathyroidism-Related Hypercalcaemia Is
Strongly Associated with the N34s Mutation in the SPINK1 Trypsin Inhibitor
Gene
Peter Felderbauer, Volker Fendrich, Elias Karakas, Kerem Bulut, Nikolaus Ansorge, Frank
Schmitz, Detlef Bartsch, Wolfgang E. Schmidt
Background&Aims: Primary hyperparathyroidism (pHPT) related hypercalcaemia is consid-
ered to represent a risk factor for the development of pancreatitis. We therefore explored
whether mutations in genes that were previously identified to increase the risk for pancreatitis
co-exist in a cohort of 826 patients with pHPT prospectively studied between 1987 and
2002. Methods: Among 826 patients with pHPT, 38 patients were identified with pancreatitis
(4.6%). DNA was available of 25 patients (12 females and 13 males). These individuals and
25 patients with pHPT without pancreatitis, pair-matched for age, sex and other risk factors
were analysed for mutations in the serine protease inhibitor Kazal type I (SPINK1) gene
(N34S) and the cationic trypsinogen gene (PRSS1) (N29I, R122H) by melting curve analysis
and DNA sequencing. Results: 4 of 25 patients with pHPT and pancreatitis carried the N34S
missense mutation in the SPINK1-gene (16%) (OR 9.33; confidence interval 1.6-54.3; P <
0.0014), while all 25 matched controls (pHPT without pancreatitis) showed no mutation
in SPINK1 or PRSS1 genes. Mean serum calcium levels in pancreatitis patients [3.1 mmol/
l] did not differ significantly from the mean of the entire cohort [3.0 mmol/l] or pHPT
patients without pancreatitis [2.76 mmol/l]. Conclusions: Pancreatitis in primary hyperpara-
thyroidism is highly associated with the N34S SPINK1 mutation.
S1421
The Impact of Genetic Variants in TPMT, ITPA, MTHFR, SPINK1 and PRSS1
On Azathioprine-Induced Pancreatitis
Angel J. Lopez, Mattias Schwab, Heiko Witt, Azhar Ansari, Clemens Dejaco, Elke
Schaeffeler, Alexander Teml, Harald Vogelsang, Peter Ferenci, Walter Reinisch
Background: Azathioprine (AZA)-related pancreatitis develops in about 3% of patients with
inflammatory bowel diseases (IBD). The pathogenesis of this idiosyncrasy is still unknown.
The role of functional relevant genetic variants in representative candidate genes has not
been investigated so far in a large patient cohort as underlying mechanism. Methods: Fifty-
three IBD-patients (Crohn’s disease n = 49, Ulcerative coltis = 3, indeterminate colitis n =
1) with documented AZA-related pancreatitis were included. 54 IBD-patients treated with
AZA without development of pancreatitis were recorded as controls. Genotyping for TPMT
(*2, *3A-D), ITPA (C94A, IVS2+A21C), MTHFR (C677T), SPINK1 (N34S, P55S) and PRSS1
(A16V, K23R, N29I, R122H) was performed. Results: Heterozygosity for TPMT was found
in 4 patients of the control group (all *1/*3A) and in one patient with pancreatitis, resp.
showing a novel TPMT mutation in exon 10. One case of compound heterozygosity for
ITPA (C94A and IVS2+A21C) was observed both in the pancreatitis and the control group.
One homozygous mutant patient for IVS2+A21C was observed in the pancreatitis group
only. Genotyping of SPINK1 revealed 3 heterozygous carriers, 2 in the control and 1 in the
pancreatitis group; no mutation was found for PRSS1. Whereas a trend of significance was seen
in the case of homozygous mutant patients for MTHFR C677T (7 patients with pancreatitis vs.
2 controls; p=0.08), the distribution of heterozygous patients was comparable in both groups
(p=0.77). No difference in polygenetic variance was found between both groups. Conclusions:
On the basis of our patient population variants of genes related to thiopurine metabolism
(TPMT, ITPA) as well as to susceptibility for chronic pancreatitis are unlikely to explain AZA-
induced pancreatitis. An association between MTHFR C677T and AZA-induced pancreatitis
cannot be excluded. Further investigations are warranted.
S1619
Novel Mechanisms for Regulation of Grk2 Activity: Inhibition of Grk2 Via
Preferential Association with Pkc-Phosphorylated Rkip (Raf Kinase Inhibitory
Protein) and Stimulation of Grk2 Via Tyrosine Phosphorylation of Grk2 By C-
Src
Jiean Huang, Sunila Mahavadi, Karnam S. Murthy
Smooth muscle of the gut expresses mainly VPAC2 receptors coupled via Gs to stimulation
of cAMP and activation of cAMP-dependent protein kinase (PKA). VPAC2 receptor desensit-
ization is mediated by GRK2. PKA augments VPAC2 receptor phosphorylation, internalization
and desensitization via feedback phosphorylation of GRK2. Since GRK2 activity can also be
regulated by other kinases such as PKC and c-Src, contractile agonists that activate these
kinases could cross-regulate VPAC2 receptor desensitization. Aim. To determine the mechan-
isms by which ACh acting via m3 and m2 receptors regulates GRK2-mediated VPAC2 receptor
desensitization. Methods. VPAC2 receptor phosphorylation, internalization (decrease in
[125I]VIP binding) and desensitization (inhibition of cAMP response) were determined before
and after treatment of cultured gastric muscle cells with VIP. Results. VIP-induced VPAC2
receptor phosphorylation, internalization and desensitization were absent in cells expressing
dominant negative GRK2(K220R), implying that the effects were exclusively mediated by
GRK2. Stimulation of PKC by PMA or by ACh in the presence of the m2 receptor antagonist
methoctramine, inhibited VPAC2 receptor phosphorylation, internalization, and desensitiza-
tion; inhibition was blocked by the PKC inhibitor bisindolylmaleimide. In the presence of
the m2 receptor antagonist, ACh induced phosphorylation of RKIP (Raf Kinase Inhibitory
Protein), increased RKIP:GRK2 association and decreased RKIP:Raf association, suggesting
that upon phosphorylation by PKC, RKIP dissociates from its known target Raf to associate
with, and block the activity of GRK2. In muscle cells expressing RKIP (S153A), which lacks
the PKC phosphorylation site, RKIP phosphorylation was blocked and the effect of ACh
and PMA on VPAC2 receptor phosphorylation, internalization, and desensitization were
abolished. In contrast, ACh in the presence of the m3 antagonist 4-DAMP, induced tyrosine
phosphorylation of GRK2 and augmented VPAC2 receptor phosphorylation and internaliz-
ation; the augmentation was blocked by the PI 3-kinase inhibitor, LY294002 or by the
Src kinase inhibitor, PP2, suggesting that m2-mediated tyrosine phosphorylation of GRK2
increased GRK2 activity. Conclusion. This study identified two novel mechanisms for cross-
regulation of VPAC2 receptor internalization by ACh. Acting via m3 receptors, ACh stimulated
PKC, which phosphorylated RKIP and promoted its association with and inhibition of GRK2.
Acting via m2 receptors, ACh activated c-Src, which induced tyrosine phosphorylation of
GRK2 and augmented GRK2 activity.
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S1620
A Truncated FAK Lacking the Ferm Domain Displays High Catalytic Activity
But Retains Responsiveness to Adhesion-Mediated Signals
Rodrigo O. Jacamo, Enrique Rozengurt
Background: The non-receptor tyrosine kinase p125 focal adhesion kinase (FAK) is a multido-
main protein that localizes to regions of the cell that attach to the extracellular matrix, called
focal adhesions. FAK contains three major domains, an N-terminal domain, a central catalytic
domain, and a C-terminal domain. The N-terminal domain of FAK displays homology with
FERM domains and it has been proposed to repress the catalytic activity of the enzyme by
intramolecular auto-inhibition, a mechanism of negative regulation in many protein kinases.
Upon integrin-mediated cell adhesion, the cytoplasmic domain of integrins is thought to
interact with the FERM domain of FAK, relieves FERM-mediated auto-inhibition and thereby
activates the catalytic activity of the enzyme. However, the precise role of the N-terminal
region in the regulation of the autophosphorylation of FAK in response to cell-adhesion
signals remains to be clarified. Aim: To determine the role of the FERM domain in the
regulation of FAK phosphorylation at Tyr-397, the major autophosphorylation site. Methods:
We generated a truncated FAK lacking a region of the N-terminus corresponding to 384
amino acids (FAKΔ384). HEK 293 cells or FAK-/- cells were transfected with either wild
type FAK or FAKΔ384 and the role of the FERM domain in the regulation of FAK phosphoryl-
ation at Tyr-397 was determined in attached cells as well as in response to cell-adhesion
signals. Results: FAKΔ384 showed a striking increase in phosphorylation, as compared with
wild type FAK, in lysates of HEK 293 cells and FAK-/- cells. In addition, immunoprecipitates
of FAKΔ384 showed a marked increase in Raytide phosphorylation as compared with
immunoprecipitates containing wild type FAK. The striking increase in catalytic activity of
FAKΔ384 provides further support to the notion that the FERM domain of FAK represses
the catalytic activity of the enzyme by intramolecular auto-inhibition. A salient feature of
our results is that suspension of either HEK 293 cells or FAK-/- cells transfected with
FAKΔ384 also resulted in a striking, time-dependent decrease in the phosphorylation of
this truncated form of FAK. The phosphorylation at Tyr-397 of wild type FAK and FAKΔ384
was restored by replating the cells onto fibronectin-coated dishes. Conclusions: we propose
a two-step model of regulation of the catalytic activity of FAK in response to integrin-
mediated cell adhesion. We hypothesize that maximal phosphorylation of FAK at Tyr-397
requires both the release from FERM-mediated auto-inhibition and as well as the clustering
of FAK molecules in focal adhesions and to bring their catalytic domains into close proximity.
S1621
Rage Activates NfκB Through a Protein Kinase C Dependent Mechanism
Maren K. Fuentes, Thiruvengadam Arumugam, Emina H. Huang, Craig D. Logsdon
Background: Previously, we found that S100P plays a major functional role in oncogenesis
acting via the Receptor for Advanced Glycation End-products (RAGE). One important
mechanism induced by S100P interaction with RAGE is NFκB activation. However, currently
the signaling cascade between RAGE and NFκB is unknown. In this study, we sought to
identify the mechanism of RAGE activation of NFκB. Methods: The influence of exogenously
added S100P and dominant negative RAGE was analyzed in NIH-3T3 cells on NFκB activation
by EMSA and a luciferase reporter assay. Chemical inhibitors of broad spectrum Protein
Kinase C (PKC; GF109203x) and specific isoforms of PKC (Rottlerin: PKCδ, θ - specific
and Gö6976: PKCα, β, γ - specific) were tested on S100P activation of NFκB. Cell fractionation
and western blotting were used to determine PKC translocation after S100P activation of
RAGE. Results: S100P activated NFκB in NIH-3T3 cells in a concentration - dependent
manner. This activation was blocked by expression of a dominant negative RAGE indicating
that the effects of S100P are mediated by RAGE. GF109203x inhibited S100P activation of
NFκB in a concentration-dependent manner. Furthermore, rottlerin, but not Gö6976, also
blocked RAGE activation of NFκB. S100P stimulated the translocation of PKCδ from the
cytosol to the membrane, indicating an activation of this isoform of PKC by RAGE. Conclu-
sions: We have discovered a novel signaling cascade involving PKC in the S100P/RAGE
activation of NFκB in NIH-3T3 cells. Therefore, blocking or altering this cascade may be
useful for new therapeutic approaches to gastrointestinal cancer.
S1622
Protein Kinase C Negative Regulation of G-Protein Coupled Receptor-Induced
Epidermal Growth Factor Receptor Transactivation
Chintda Santiskulvong, Enrique Rozengurt
Background: GI peptides stimulate DNA synthesis and cell proliferation in a variety of
cultured cells, and thus are implicated as growth factors. Upon binding to their cognate
G-protein coupled receptors (GPCRs), GI peptides stimulate multiple signaling pathways
including Gαq-mediated activation of protein kinase C (PKC). Another critical mitogenic
pathway is the GPCR-induced epidermal growth factor receptor (EGFR) tyrosine kinase
activation, termed EGFR transactivation. While GPCRs positively regulate the EGFR via
transactivation, our results demonstrate that PKC mediates a feedback mechanism that
negatively regulates EGFR transactivation. Aim: To characterize the role of PKC in GPCR-
induced EGFR transactivation. Methods: EGFR activation was assessed by immunoprecipitat-
ing the EGFR and immunoblotting with an anti-phosphotyrosine mAb. Extracellular signal-
regulated kinase (ERK)1/2 and Akt activation were determined by immunoblotting whole
cell lysate with an anti-pThr202/pTyr204 ERK1/2 mAb or anti-pSer473Akt mAb, respectively.
Results: Treatment of rat intestinal epithelial IEC-18 cells with the PKC inhibitors GF109203X
(GF1) or Ro31-8220, or PKC downregulation via phorbol 12, 13 dibutyrate (PDB) chronic
(24h) exposure resulted in a striking increase in angiotensin II-induced EGFR transactivation.
Feedback inhibition of GPCR-induced EGFR transactivation by PKC was found in multiple
model systems, including carbachol in human colonic epithelial T84 cells, bombesin in Rat-
1 fibroblasts stably transfected with the bombesin receptor, and neurotensin in the human
pancreatic cancer cell line Panc-1. PKC inhibition also increased GPCR-induced EGFR
transactivation-dependent downstream signaling, including ERK 1/2 and Akt activation. In

















transactivation and Akt activation. Acute PDB treatment also inhibited transforming growth
factor-α (TGF-α)-induced EGFR phosphorylation, and heparin-bound-EGF- and TGF-α-
induced Akt phosphorylation. Conclusions: Our results indicate that PKC mediates a feedback
mechanism in the crosstalk between GPCRs and the EGFR, regulating the intensity of GPCR-
induced EGFR transactivation.
S1623
Secretion, Production and Biological Activity of the Human C-Terminal
Flanking Peptide of Progastrin
Kelly Smith, Oneel Patel, Shamilah Lachal, Ian Jennings, Bruce Kemp, John Burgess,
Graham Baldwin, Arthur Shulkes
Since the biological activity of gastrin-gly (Ggly) and progastrin was first described, there
has been intense interest in the physiological and pathophysiologic roles of these peptides.
However it is not generally appreciated that they constitute relatively small proportions of
the final gastrin products in the antrum and in most gastrinomas and colorectal carcinomas
(CRC). In the present study, we have analysed using region specific radioimmunoassays the
relative amounts of progastrin, gastrin-amide (Gamide), Ggly and the C-terminal flanking
peptide of progastrin (CTFP) in the antrum from normal subjects and in resected CRC. The
plasma concentrations in normal subjects and patients with CRC were also determined.
Finally, the biological activity of CTFP in vitro was assessed. The identity of the antral C-
terminal flanking peptide of progastrin was confirmed as the hexapeptide progastrin75-80
by HPLC and mass spectroscopy. The CTFP hexapeptide is by far the major stored form
of progastrin in antrum (CTFP 8690 ± 2010, Gamide 1970 ± 440, Ggly 21 ± 5, progastrin
430 ± 140 pmol/gm, n = 6) and resected CRC (CTFP 19 ± 2, Gamide 0.07 ± 0.01, Ggly
0.03 ± 0.02, progastrin 0.22 ± 0.09 pmol/gm, n = 10). Furthermore, the CTFP circulates
at 800 ± 18 pmol/l, 50-fold higher in concentration compared with Gamide. Circulating
CTFP is released by a meal in a similar fashion to Gamide but is not elevated in patients
with gastrin-secreting tumours or CRC. The biological activity of CTFP was determined
using a variety of cell lines and readouts. Contrary to previous suggestions, CTFP is biologic-
ally active with a similar potency to Ggly. CTFP stimulated the proliferation of gastric and
colonic cancer cell lines and the proliferation and migration of a non-transformed gastric
cell line and activated early stimulation of the mitogen-activated protein kinase pathway.
In summary, the CTFP is the major stored and secreted form of progastrin-derived peptides
in the antrum and circulation of normal subjects and in the tumours of patients with CRC.
Taken together with the findings that CTFP is biologically active, we suggest that CTFP is
not an inactive metabolite of progastrin processing but a bioactive peptide with potential
roles in the normal and diseased gastrointestinal tract.
S1624
Feedback Inhibition of RHOA By G12-Coupled PAR1 Receptors in Smooth
Muscle Is Mediated Via Inhibitory Phosphorylation of G12 By PKC
Wimolpak Sriwai, Wenhui Hu, Karnam S. Murthy
The protease-activated receptors PAR1 and PAR2 activate RhoA via G12 and G13, respectively,
in smooth muscle. Both receptors initiate dual RhoA-dependent pathways involving activation
of Rho kinase and protein kinase C (PKC). In vitro studies in cell lines have shown that
PKC phosphorylates and thus inhibits Gα12 but not Gα13, raising the possibility of feedback
inhibition of Rho activity upon phosphorylation of Gα12 by PKC. Aim. To characterize the
pathway for feedback inhibition of RhoA upon its activation by PAR1 receptors. Methods.
RhoA activation was measured as increase in Rho kinase activity. The role of PKC was
evaluated using the active phorbol ester, PMA, and the PKC inhibitor, bisindolylmaleimide.
Phosphorylation of Gα12 and Gα13 was determined by immunoblot analysis in cells prela-
beled with 32P. Results. Rho kinase activity stimulated by the PAR1 agonist, SFLLR, but
not by the PAR2 agonist, SLIGRL was augmented by bisindolylmaleimide implying that
PKC inhibited Rho activity stimulated via PAR1 receptors only. In support of this notion,
pretreatment with PMA inhibited Rho kinase activity stimulated by PAR1 but not by PAR2
agonists. The PAR1 agonist induced Gα12 phosphorylation, which was abolished by bisindo-
lylmaleimide and C3 exoenzyme suggesting that phosphorylation is mediated by PKC derived
from activation of RhoA. The effect of the PKC inhibitor on Rho kinase activity was additive
to that of the PKA inhibitor, PKI, suggesting that PAR1 receptors also induce an inhibitory
pathway involving PKA. Both PAR1 and PAR2 can activate the canonical NF-κB pathway
leading to degradation of IκBα and release of the catalytic subunit of PKA from its binding
to IκBα; PKA in turn inhibits RhoA via phosphorylation of RhoA at Ser188. This notion
was corroborated in cells expressing PKA phosphorylation-site deficient RhoA(S188A) or
dominant negative mutant of IKK2(K44A). The effect of the PKC inhibitor on Rho kinase
activity was augmented in cells expressing RhoA(S188A) or IKK2(K44A). Thus, PAR1 agonists
cause feedback inhibition of RhoA via two mechanisms: one mechanism involves PKA-
induced phosphorylation of RhoA at Ser188; the other involves phosphorylation of Gα12
upstream of RhoA. Conclusion. This study identified a novel PAR1-specific pathway for
feedback inhibition of RhoA involving phosphorylation of Gα12.
S1625
C-Type Natriuretic Peptide Receptor (NPR-C) in Human Pancreatic Alpha
Cells: Identification, Localization and ANP Mediated Changes in Glucagon
Secretion
William R. Gower, Kim D. Moore, Matthew Burgess, Abdel Alli, Gay M. Carter, Hirohito
Ichii, Camillo Ricordi
Background: There is evidence for the occurrence of immunoreactive atrial natriuretic peptide
(ANP) and specific binding sites for ANP in glucagon-containing α cells of the pancreas.
Identification of the specific receptor subtype and the localization of the receptor to a specific
islet cell type in the human pancreas have not been reported. The aims of this study were
to localize ANP, natriuretic peptide receptor subtypes A (NPR-A) and C (NPR-C) expression
in normal and neoplastic human islets and to assess the NPR function in clonal islet cells.
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Methods: Cell type specific localization of ANP, NPR-A and NPR-C proteins was examined
by immunohistochemistry of normal and neoplastic human pancreas as well as the mouse
clonal α cell line, αTC6. Presence of ANP and NPR transcripts and proteins were determined
by RT-PCR and immunoblot analysis. αTC6 cells (3x105 /well) were serum deprived,
incubated in Krebs-Ringer bicarbonate buffer (KRB) containing 25 mM glucose (high) for
2 h at 37C, then incubated in KRB containing high or low (2.8 mM) glucose with or without
ANP or cANF for 90 minutes. KRB was removed and assayed for glucagon by RIA and cells
were lysed for total protein. Results: Immunoreactive NPR-C, but not ANP or NPR-A, was
detected in human islets of Langerhans and αTC6 cells. No immunostaining was observed
in the exocrine pancreas or ductal structures. Double-staining revealed that the NPR-C
receptors were expressed mainly in the glucagon-containing α cells. Immunoblot results
demonstrated a 66 kDa protein corresponding to NPR-C in protein extracts of isolated
human islets and αTC6 cells. NPR-C expression in human islets and αTC6 cells was
confirmed by RT-PCR. NPR-C expression was also detected by immunohistochemistry in
glucagonoma but not in insulinoma or gastrinoma. ANP and cANF, a specific agonist for
NPR-C, had no effect on basal glucagon secretion from αTC6 cells (0.36 pg/µg/90 min).
Low glucose induced a 444±5% increase in glucagon secretion. ANP and cANF both produced
a dose-dependent (0.1 nM- 1.0 µM) inhibition of glucose-stimulated glucagon release from
αTC6 cells. Maximal effects were observed at 1.0 µM ANP (65±5% inhibition; p<0.001)
and 1.0 µM cANF (71±4% inhibition; p<0.001). Conclusion: The NPR-C receptor is expressed
in normal and neoplastic human α cells. NPR-C mediates ANP inhibition of glucose-
stimulated glucagon release from mouse clonal pancreatic α cells. These findings suggest a
role for natriuretic peptides in the regulation of glucagon secretion. This work was supported
by grants from the Veterans Administration and NIH.
S1626
Apical EGFR Phosphorylation Induced By Basolateral EGF Is Not Due to
Transcytosis of Phosphorylated Basolateral EGFR to the Apical Membrane
Nelly E. Avissar, Liana Toia, Harry C. Sax
Introduction: Epidermal Growth Factor (EGF) is a major trophic factor for the intestine,
and supports repair and adaptation after massive enterectomy. In human polarized
enterocytes EGF receptor (EGFR) is predominantly basolateral (Bl), while in injured intestine
and in cancer it is redistributed to the apical (Ap) side. The physiological functions induced
by activation of Ap EGFR differ from those of Bl EGFR. The main sources of EGF for the
enterocytes are luminal (Ap). It is believed that when the membrane barrier is compromised,
luminal EGF reaches Bl EGFR through which it exerts most of its physiological effects. We
have found that addition of Bl EGF to C2BBe1 (a subclone of Caco-2) results in phosphoryl-
ation of Ap and Bl EGFR to the same degree, implying that functional Ap EGFR is also
physiologically important. Our objective was to investigate whether the appearance of phos-
phorylated EGFR on the Ap membrane is due to transcytosis of the Bl EGFR or to cytosolic
signal transduction pathways. Methods: Confluent C2BBe1 were biotinylated on the Bl or
Ap membrane, either before or after exposure to Bl EGF (intervals of 30 sec-10 min).
Biotinylated proteins were isolated by avidin precipitation and subjected to Western analysis
for total and site-specific phosphorylated EGFR. Results: Na+K+ ATPase, a Bl protein, was
enriched in Bl membrane (over 80 fold), indicating successful isolation of the two membrane
domains. There was a delay of 1 min in the appearance of phosphorylated Ap EGFR compared
to Bl EGFR for the cells that were biotinylated after EGF exposure. This implies that the
phosphorylation of Ap EGFR is dependent on that of Bl EGFR. When EGFR was biotinylated
on the Ap membrane before addition of EGF to the Bl membrane, the degree of Ap EGFR
phosphorylation was identical to that of Bl EGFR. This indicates that the phosphorylated
EGFR on the Ap membrane is residential as opposed to the transcytosis of phosphorylated
Bl EGFR. All the EGFR receptor site-specific tyrosines tested were phosphorylated by Bl
EGF to the same degree on the two membrane domains, indicating activation of EGFR
intrinsic tyrosine kinase on both membranes. Conclusion: Ap EGFR phosphorylated by Bl
EGF is not Bl EGFR which reached the Ap membrane, but rather the residential Ap EGFR
which is phosphorylated by Bl EGF through as yet unidentified signal transduction pathway.
The latter, most probably, activates Ap EGFR tyrosine kinase. The fact that Ap EGFR is
phosphorylated even by Bl EGF implies an important physiological function of the receptor
when in this membrane location. Funded by NIH 5 RO1 DK47989-10.
S1627
Roles of Progesterone (PG) Receptors A and B On Relaxation and Contraction
of Muscle Cells from Human and Guinea Pig Colon
Arun Goswami, Ping Cong, Piero Biancani, Jose Behar
We have previously shown that colonic muscle cells from female patients with chronic
constipation have an impaired contraction induced by agonists that act on G protein coupled
receptors such as CCK-8 and Ach and G protein dependent such as GTPγS. This impairment
is due to the dual PG action on G proteins: down regulation of Gq/11 that mediates
contraction and up regulation of Gs proteins that mediate relaxation and increased mRNA
levels of PG receptors. These G protein abnormalities are consistent with the effects observed
in colonic muscle cells treated with PG for 6 h. The present studies were aimed at determining
a] whether the up regulation of Gs proteins causes an increased relaxation in response to
VIP; and b) whether each PG receptor A and B affects a different signal transduction
stimulated by PG. Muscle cells were obtained from human and guinea pig descending-
sigmoid colons. Permeable colonic muscle cells were pretreated with buffer (controls) or
specific antibodies against A or B receptors followed by treatment with PG 10 -7 M for 6
h. Muscle cell relaxation was defined as per cent inhibition by VIP (10-9 to-5 M) of the
contraction induced by diacylglycerol (10-5 M). Antibodies against PG receptor A blocked
the PG increased relaxation induced by VIP compared to controls (p<0.01); whereas, antibod-
ies against PG receptor B had no effect on VIP relaxation but blocked the PG inhibition of
the contraction induced by CCK-8 (10-8 M, p<0.001). PG increased c’AMP formation induced
by VIP. PG however did not affect the relaxation induced by dibutyryl-c’AMP that bypasses
receptors and G proteins. Western blot analysis revealed that antibodies against PG A receptor
blocked the PG induced up regulation of Gs observed in control muscle cells (p<0.01) but
had no effect on the down regulation of Gq/11 proteins. In contrast, antibodies against PG
B receptors blocked the down regulation Gq/11 proteins induced by PG in muscle cells
treated with buffer (p<0.01). It is concluded that PG increases the relaxation induced by
VIP by up regulating Gs proteins. And, each of the two actions of PG are mediated by
different receptors: PG A receptors, by mediating the up regulation of Gs, increase the
sensitivity to VIP and PG B receptors, by mediating the down regulation of Gq/11, impairs
the contraction induced by CCK-8.
S1628
Properties of Human TRPA1, a Mechanosensitive Channel and Putative
Nociceptor
Jiahui Lin, Kirk Hillsley, Pieter Peeters, Jeroen Aerssens, David Grundy, Bernard Coulie,
Ronald H. Stead
Background: TRPA1 is reported to play a role in the transduction of mechanosensitive pain.
We have shown that both gut projecting nodose and dorsal root ganglia (DRG) neurons
express TRPA1. As the availability of specific pharmacological tools to study this channel
are limited, our aim was to characterize the properties of human TRPA1 channels expressed
in a stably transfected cell line as a prelude to studies in native sensory neurons supplying
the GI tract. Methods: HEK 293 cells were stably transfected with human TRPA1 cDNA.
TRPA1 expression was induced by overnight tetracycline (1000-5000 ng/ml) incubation and
cells were plated onto Petri dishes for whole cell patch clamp recordings at room temperature
and a holding potential of -80 mV, unless otherwise noted. Regular extracellular Krebs
solution contained 2.5 mM Ca2+, whilst the pipette was filled with Cs+-rich intracellular
solution. Allyl isothiocyanate (AITC) and benzyl isothiocyanate (BITC) were used as TRPA1
agonists, and the effects of putative TRPA1 antagonists ruthenium red (RR), gadolinium
(Gd3+), amiloride and gentamicin were also tested. Results: AITC and BITC evoked dose-
dependent inward currents in HEK-TRPA1 cells. BITC (3 mM) evoked a peak amplitude
of -602.2 ± 48.4 pA (n = 23) and activation time of 17.8 ± 1.4 s (n = 23). The peak
amplitude of the inward current evoked in response to either BITC or AITC was decreased
in the absence of extracellular calcium, but the activation time was not affected. In the
absence of extracellular calcium, RR (50 μM), Gd3+ (100 μM), amiloride (500 μM) and
gentamicin (50 μM) all inhibited the response to AITC (10 μM). RR had an IC50 of 1.55
μM. However, in the presence of physiological concentrations of [Ca2+]o (2.5 mM), RR and
amiloride still inhibited TRPA1 currents but to a lesser extent, whilst Gd3+ and gentamicin
had no TRPA1 antagonist effect. Conclusions: These data demonstrate that TRPA1 channels
are potently activated in a calcium-dependent manner by the pungent organic chemicals
AITC and BITC, and inhibited by RR and amiloride. As TRPA1 is known to be expressed
on DRG and nodose neurons, it will be important to evaluate the properties of TRPA1
channels in sensory neurons innervating the GI tract, in order to reveal its function in
physiological and/or pathophysiological conditions.
S1629
Identification of Peptide-Ligand Binding Domains of the Growth Hormone
Secretagogue Receptor, Compared to the Motilin Receptor
Bunzo Matsuura, Teruhisa Ueda, Maoqing Dong, Laurence J. Miller, Sachiko Utsunomiya,
Hidetaka Matsui, Yoichi Hiasa, Morikazu Onji
The Class I family of guanine nucleotide-binding protein (G protein)-coupled receptors
that includes receptors for motilin, ghrelin, and growth hormone secretagogue (GHS) has
substantial potential importance as drug targets. Understanding of the molecular basis of
hormone binding and receptor activation should provide insights helpful in the development
of such drugs. We previously reported that perimembranous residues within the unique
second extracellular loop domain of the motilin receptor are critical for peptide ligand,
motilin, binding and biological activity (J Biol Chem 277: 9834, 2002). In the current work,
we focused on the second extracellular loop of the GHS receptor, and identified functionally
important residues. For this purpose, GHS receptor constructs were prepared that included
sequential deletions ranging from one to ten amino acid segments and replaced with alanine
in this domain using site-directed mutagenesis methods. Each construct was transiently
expressed in COS cells, and characterized for ghrelin-stimulated intracellular calcium
responses and ghrelin radioligand binding. Cys198 was critical for ghrelin binding and
calcium signaling. Moreover, perimembranous residues in the second extracellular loop
domain, Val184 and The211, were also critical for ghrelin binding and activity, same as the
motilin receptor. These results suggest that Cys in the second extracellular loop in this
group of Class I G protein-coupled receptor is likely involved in the highly conserved and
functionally important disulfide bond, and that the perimembranous residues contribute
peptide ligand binding and signaling.
S1630
Caveolin Regulates Acetylcholine-Induced Translocated Pkcα-Hsp27-RHOA
Complex On the Membrane of Rabbit Colonic Smooth Muscle Cells
Sita Somara, Jeffrey R. Martens, Khalil N. Bitar
Background: Caveolae are abundant cell surface microdomains in which multiple cell-
signaling pathways converge through interactions with caveolin to regulate excitation contrac-
tion coupling in smooth muscle. The cell surface stability of caveolae is dependent on
cytoskeletal organization which is in turn modulated by HSP27. Objective: Does caveolin
play a role in docking of acetylcholine-induced translocated PKCα-HSP27-RhoA complex
on membrane during colon smooth muscle contraction? Methods: SMC were isolated from
rabbit colon. Caveolae-enriched lipid raft fractions were isolated from colon SMC for the
studies. Isolated SMC from rabbit colon were transfected with dominant negative calveolin-
1 (cav1). Results: 1) Rabbit colon SMC probed with antibodies for cav1, cav2, and cav3
showed the presence of cav1 and cav2; 2) Western blot analysis shows that cav1 and PKCα
co fractionate in caveolae-enriched lipid raft fractions. 3) acetylcholine induced: i) a significant
and sustained increase in the association of cav1 with PKCα (166.39 ± 3.57% at 30sec and
172.46 ± 2.25% at 4min); ii) a significant and sustained increase in the association of cav1
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with RhoA (179.28 ± 0.33% at 30sec and 184.03 ± 2.59% at 4 min); iii) a significant and
sustained increase in the association of cav1 with HSP27 (156.16 ± 0.77% at 30sec and
164.06 ± 3.68% at 4min); 4) SMC transfected with dominant negative cav1 showed inhibition
of acetylcholine-induced: i) association of cav1 with RhoA (111.36 ± 5.58% at 30sec and
116.22 ± 6.45% at 4min); ii) association of cav1 with PKCα (104.74 ± 3.51% at 30sec and
112.00 ± 0.25% at 4min); iii) association of cav1 with HSP27 (108.30 ± 0.92% at 30sec
and 115.54 ± 5.03% at 4min) suggesting the importance of caveolin in docking of the
PKCα-HSP27-RhoA complex on the membrane. Summary: Colonic SMC express cav1 and
cav2, but not cav3. Acetylcholine stimulation of colonic SMC induced a significant and
sustained increase in the association of cav1 with PKCα, RhoA and HSP27. Caveolae-
enriched membrane fractions showed the presence of PKCα in the fractions enriched with
caveolae and cav1 suggesting that PKCα may translocate to caveolae on the membrane in
the particulate fraction. Introduction of dominant negative cav1 into colon SMC showed
reduction in acetylcholine-induced association of cav1 with PKCα, RhoA and HSP27. Conclu-
sions: During colonic smooth muscle contraction, caveolin is essential for maintenance of
caveolae on the plasma membrane which in turn are crucial for the docking of translocated
signaling complex PKCα-HSP27-RhoA.
S1631
Orexin-a, An Appetite Hormone, Attenuates Gastric Ischemia-Reperfusion
Injury Via of Prostaglandin/Cyclooxygenase Pathway, Vagal and Afferent
Sensory Nerves
Tomasz Brzozowski, Peter C. Konturek, Robert Pajdo, Slawomir Kwiecien, Wladyslaw
Bielanski, Atsukazu Kuwahara, Jin Kato, Stanislaw J. Konturek, Wieslaw W. Pawlik
Orexin-A (OX-A) detected in hypothalamic nuclei, enteric nerves and endocrine cells of GI
tract, stimulates both, food intake and gastric seretory activity, but its role in the mechanism
of gastroprotection has been little studied. We tested whether OX-A affects gastric ischemia-
reperfusion injury and whether prostaglandins (PG) and neural factors could contribute to
this protection. OX-A was applied intraperitoneally (i.p.) or intracerebroventricularly (i.c.v.)
and gastric mucosal lesions were induced by 30 min of gastric ischemia (by clamping of
celiac artery) followed by 3h of reperfusion without or with A) inhibition of cyclooxygenase
(COX)-1 activity by SC-560 (5 mg/kg i.g.) or COX-2 activity by rofecoxib (10 mg/kg i.g.)
B) cutting of vagal nerves (bilateral vagotomy) and C) functional ablation of sensory nerves
by capsaicin (125 mg/kg s.c.) or inhibition of vanilloid receptor (VR-1) by capsazepine (10
mg/kg i.g.). The area of gastric lesions was measured by planimetry, the gastric blood flow
(GBF) was determined by H2-gas clearance technique and gastric mucosal samples were
collected for measurement of mucosal generation of PGE2. Venous blood was withdrawn
for the measurement of plasma OX-A (RIA) and gastric biopsy samples were collected for
the determination of COX-1-, COX-2- and CGRP mRNAs by RT-PCR. Exposure to I/R
produced typical gastric bleeding erosions without influencing OX-A mRNA expression and
its plasma level. OX-A (1-60 μg/kg i.p.) or (100-2500 ng/rat i.c.v.) dose-dependently attenu-
ated gastric lesions induced by I/R. The protective effects of OX-A were accompanied by
the significant rise in plasma OX-A level and an increase in the GBF and PGE2 generation.
The protective and hyperemic effects of OX-A were completely abolished by vagotomy and
significantly attenuated by rofecoxib but not by SC-560 treatment. Capsaicin denervation
or capsazepine treatment also significantly reduced the lesions caused by I/R and this effect
was restored by addition to exogenous CGRP (10 μg/kg s.c.) to OX-A in capsaicin-denervated
rats. The CGRP mRNA was downregulated in gastric mucosa of I/R animals and this effect
was counteracted by administration of ghrelin. COX-1 mRNA was unchanged while COX-
2 mRNA was absent in vehicle-control gastric mucosa but it was upregulated in OX-A
treated animals. We conclude that OX-A attenuates I/R injury by the mechanism involving
endogenous PG, possibly derived from COX-2 pathway and activation of vagal and sensory
nerves releasing vasodilatatory neuropeptides such as CGRP.
S1632
The Inhibitory Effect of Substance P On HCO3- Secretion from the Guinea Pig
Microperfused Pancreatic Ducts
Peter Hegyi, Zoltan Rakonczay, Tamas Takacs, Gyula Papp, Janos Lonovics, Andras Toth,
Andras Varro, Mike Gray, Barry Argent
Background. We have previously shown using sealed, non-perfused, ducts that Substance
P (SP) inhibits HCO3- secretion by inhibiting Cl--dependant HCO3- efflux on the luminal
membrane of the duct cell (Hegyi et al. Am J Physiol Cell Physiol 285:C268-C276, 2003).
However, in that study we had no direct evidence that SP affected a luminal anion exchanger.
To address this issue we examined the effects of luminal H2DIDS on the inhibitory effect
of SP in microperfused ducts. Methods. Small intra/interlobular pancreatic ducts were isolated
from guinea pigs. We microperfused the ducts allowing direct access to the luminal membrane
of the duct cell. The rate of HCO3- secretion was determined by measuring the initial rate
of intracellular acidification (using BCECF) following sudden block of basolateral NaHCO3
cotransporters and Na+/H+ exchangers with H2DIDS (500 µM) and amiloride (200 µM)
respectively. The buffering capacity of duct cells was estimated and the rate of transmembrane
H+ flux, J(H+), was calculated. Since H+ and HCO3- will largely be derived from H2CO3,
we have assumed that J(H+) is equivalent to J(HCO3). All the experiments were performed
in HCO3--buffered Ringer at 37oC. Results. Rates of HCO3- secretion measured using the
inhibitor stop method were about 2 fold higher in microperfused ducts as compared to
sealed, non-perfused, ducts. Application of luminal H2DIDS (0.5 mM) caused intracellular
pH to alkalinise and, like SP, inhibited basal and secretin-stimulated HCO3- secretion. SP
did not inhibit secretion further when H2DIDS was present in the lumen, suggesting that
SP and H2DIDS both inhibit the same transporter on the luminal membrane of the duct
cell. Conclusions. SP inhibits an H2DIDS-sensitive HCO3- transport step at the luminal
membrane of the duct cell, most likely a member of the SLC26 family anion exchanger.


















A Novel Model to Study Gastric Pressure in Response to Gastric Content
Infusion in Conscious Mice: Effect of Methylatropine, Win 55,212-2 and NG-
Nitro-L-Arginine Methyl Ester
Pieter Janssen, Maria Astin Nielsen, Per-Goran Gillberg, Leif Hultin
Introduction The stomach accommodates food without major intragastric pressure (IGP)
increase. The study of transgenic mice could be of importance in understanding the mechan-
isms behind gastric accommodation and gastric muscle tone regulation in general. We
present a novel model to study the relationship between gastric content and IGP in conscious
mice. Methylatropine (unspecific muscarinic receptor antagonist), NG-nitro-L-arginine
methyl ester (L-NAME; nitric oxide synthase inhibitor) and WIN55,212-2 (unspecific
cannabinoid receptor agonist), known to affect gastric muscle tone, were used to validate
the model. Material & Methods All experiments were performed in 6 female C57/Bl mice.
After a 5-hour fast, a test-meal infusion system and a catheter to measure IGP were connected
to a gastric fistula. The test-meal was non-nutritious and contained 1gr barium sulphate/
ml in a 3% hydroxypropyl methylcellulose solution. Drugs or their vehicles were injected
subcutaneously before the start of the experiment (methylatropine and L-NAME were dis-
solved in saline, WIN55,212-2 in 5% ethanol, 40% solutol and 55% saline). After a 15 min
stabilisation period, test-meal was infused at a preset speed of 0.125 ml/min until 0.6 ml
infused. X-ray sequences were taken to estimate the gastric volume and emptying. Area
under the curve (AUC) was assessed from the IGP vs. gastric volume relationship until 0.4 ml
gastric volume. Results (mean±SEM) were compared using a paired t-test (P<0.05 considered
significant). Results IGP increased with increasing gastric volume to a maximum of 12.0±2.4
and 11.9±0.8 mmHg after saline and WIN55,212-2 solvent treatment. Methylatropine (1
mg/kg) and WIN55,212-2 (0.5 mg/kg) significantly reduced the AUC, whereas L-NAME
(30 mg/kg) significantly increased the AUC. At maximal injected volume, gastric emptying
was 31.6±3.0% and 28.4±3.3% after saline and WIN55,212-2 solvent treatment vs.
37.8±8.2% (WIN55,212-2 treatment), 7.4±2.4% (methylatropine treatment) and 14.4±1.5%
(L-NAME treatment), the latter 2 being significantly different from control situations. Discus-
sion & Conclusion For the same infused volume, methylatropine and WIN55,212-2 reduced
IGP while L-NAME increased IGP. Furthermore, we showed that methylatropine and L-
NAME treatment reduced gastric emptying. This novel model can be used to study gastric
emptying and the relationship between gastric volume and intragastric pressure in con-
scious mice.
S1634
Fasting Small Bowel Motility Reinstated By Ghrelin Infusion in Rats
Ylva Haglund, Celestine O'Shaughnessy, Gareth J. Sanger, Per M. Hellstrom, Erik Naslund
Background: Ghrelin has been shown to exert prokinetic properties in both man and rats
by increasing gastric emptying and decreasing the interval between activity fronts during
the migrating motor complex (MMC). The aim of this study was to see if ghrelin would
facilitate the return of fasting motility after food intake and if the effect of ghrelin on MMC
holds over an 6 hour infusion period. Methods: Male Sprague-Dawley rats (n=7, 300 g)
were used for the study. Three electrodes were implanted on the serosa of the small intestine
5 (D), 15 (J1), 25 (J2) cm from the pyloric sphincter and tunnelled onto the neck of the
rat. A catheter placed in the forestomach was also tunnelled to the neck. An intravenous
catheter was placed in the jugular vein for drug administration. After one week the studies
commenced. After an overnight fast, fasting small bowel motility was recorded for at least
60 min and 4 MMC activity fronts were recorded. A bolus of 2 mL of Isosource (1 kcal/
mL) was administered intragastrically over 3 min. Ten min later, either saline or ghrelin
(1000 pmol/kg/min) was infused IV and continued until a regular fasting motility pattern
was resumed (one propagated activity front). In a second set of experiments, after a 60 min
control period, ghrelin (1000 pmol/kg/min) or saline was administered over 6 hours. Data
shown as mean ±SEM. Results: The interval between activity fronts propagated from D to
J2 during fasting was 15.6 ±0.8 min (measured at J2). After feeding and during infusion of
saline, the first propagated activity front was seen 39.4 ±1.9 min after administration of
Isosource, compared to 33.4 ±1.9 min at J2 during ghrelin infusion (p<0.05). With prolonged
administration of ghrelin, the interval in between the activity fronts was significantly decreased
compared to saline. However, this effect was transient and after the first hour there was no
significant difference. Discussion: Ghrelin significantly hastens the return of fasting motility
after food intake by 6 min in rats. The effect of ghrelin on the MMC seems to be transient
and suggests a physiological role of ghrelin in which ghrelin acts transitionally to reinstitute
the basal motility pattern, which is then maintained by other factors not yet revealed.
However, this effect of ghrelin may promote a rapid gastric emptying, along with a rapid
intestinal transit in order to prepare the gut for the next meal.
S1635
The Gastrointestinal Activity and Peripheral Selectivity of Alvimopan, Adl 08-
0011, and Naloxone in Mice
Scott Armstrong, Christina C. Sandlund, Carrie Richardson, Tina Pham, Adrienne
Winans, David T. Beattie
Alvimopan, a peripherally restricted μ-opioid receptor antagonist, is in development for the
treatment of opioid-induced bowel dysfunction and post-operative ileus. Based on the similar
μ-opioid antagonist potencies of alvimopan and its metabolite, ADL 08-0011, and the higher
systemic exposure of the latter after oral dosing of the parent (Foss et al., 2005), it is likely
that ADL 08-0011 is responsible for much of the efficacy attributed to alvimopan. In this
study, the gastrointestinal (GI) and CNS activities of alvimopan, ADL 08-0011, and the
centrally penetrant μ-opioid receptor antagonist, naloxone, were determined in mice. In a
GI model of acute morphine exposure, morphine (3 mg/kg s.c.) or vehicle was dosed 15
minutes after test agent or vehicle. A charcoal meal was dosed orally and GI transit measured
60 minutes later. To assess CNS activity, test compounds were dosed prior to morphine
treatment and subsequent analgesia testing (paw lick latency on a hot-plate). In additional
studies, mice were treated for 7 days with morphine (45 mg/kg/day s.c.) or vehicle via an
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osmotic minipump. Test agent or vehicle was then administered (s.c.) prior to assessment
of GI and CNS-mediated responses (i.e. stool output, incidence of soft stools, number of
jumps and ambulatory activity). Alvimopan, ADL 08-0011 and naloxone inhibited morphine-
mediated reductions in GI transit (ID50 values of 0.03, 0.02 and 0.5 mg/kg, respectively)
and morphine-mediated increases in paw lick latency (ID50 values of 6, 0.7, and 0.02 mg/
kg, respectively). The peripheral selectivities (i.e. the ratios of ID50 values for reversal of
analgesia and delayed GI transit) for alvimopan, ADL 08-0011, and naloxone were 200, 35
and 0.02, respectively. Following chronic morphine exposure, alvimopan, ADL 08-0011
and naloxone increased defecation and had a similar incidence of soft stools. Naloxone and
ADL 08-0011 (both 10 mg/kg), but not alvimopan (0.01 - 10 mg/kg) produced a statistically
significant (p<0.05, ANOVA and Dunnett’s post-hoc test) increase in jumping behavior and
ambulatory activity. It is concluded that the rank order of peripheral selectivity in mice is
alvimopan > ADL 08-0011 > naloxone. The clinical significance of these data, particularly
the lower peripheral selectivity of ADL 08-0011 versus alvimopan, remains to be determined.
Foss, J.F. (2005). Clin. Pharm. Therap., 77, 74.
S1636
The Activity of Alvimopan, Adl 08-0011 and Methylnaltrexone in the Guinea
Pig Ileum
David T. Beattie, Madhavi Cheruvu, Shana Johnson
The peripherally-restricted μ-opioid receptor antagonists, alvimopan and methylnaltrexone
are in development for the treatment of opioid-induced bowel dysfunction and post-operative
ileus (Camilleri, 2005). In this preclinical study, the activities of alvimopan, its active
metabolite, ADL 08-0011, and methylnaltrexone were investigated. Ilea were isolated from
guinea pigs treated for 7 days with morphine (45 mg/kg/day s.c.) or vehicle (0.24 ml/day
s.c.) via an osmotic minipump, and mounted in tissue baths containing Krebs-Henseleit
solution (37 °C). The effects of test agents on spontaneous mechanical activity, and electrical
field stimulation (EFS)-evoked contractions were recorded isometrically. In morphine-naïve
ilea, alvimopan and ADL 08-0011 increased, while methylnaltrexone (each 1 nM - 10 μM)
decreased, the amplitude of EFS-evoked contractions (mean pIC50 or pEC50 values = 8.1,
7.5 and 6.4, respectively). The standard μ-opioid receptor agonists, endomorphin-1, mor-
phine and DAMGO, attenuated the EFS-mediated contractions. Alvimopan, ADL 08-0011
and methylnaltrexone antagonized endomorphin-1-mediated reductions in EFS-evoked con-
tractions (mean pA2 values = 9.6, 9.4 and 7.7, respectively). In ilea isolated from morphine-
naïve animals, methylnaltrexone reduced the spontaneous activity, while alvimopan and
ADL 08-0011 (each at 1 nM - 10 μM) produced small increases. In ilea isolated from guinea
pigs treated chronically with morphine, methylnaltrexone, alvimopan and ADL 08-0011,
each increased spontaneous contractile activity. The stimulatory activity of alvimopan and
ADL 08-0011 in morphine-naïve ilea is consistent with antagonism of endogenous inhibitory
μ-opioid tone although a non-specific effect cannot be ruled out at present. The enhanced
excitatory activity in tissue from morphine-treated guinea pigs may reflect μ-opioid receptor
inverse agonist activity (Wang et al., 1994). The inhibitory activity of methylnaltrexone in
morphine-naïve ileum is consistent with μ-opioid receptor partial agonist activity. Following
chronic morphine exposure, methylnaltrexone exerts a stimulatory effect on ileal tone,
although to a lesser extent than that of alvimopan and ADL 08-0011. The clinical relevance
of the different intrinsic activity profiles of alvimopan, ADL 08-0011 and methylnaltrexone,
remains to be determined. Camilleri, M. (2005). Neurogastroenterol. Motil., 17, 157-165.
Wang, D. et al. (1994). Life Sci., 54, 339-350.
S1638
The Effects of a Ghrelin Receptor Agonist On Motility Reflexes and Visceral
Pain in Vivo
Yasutake Shimizu, Ed C. Chang, Anthony D. Shafton, Gareth J. Sanger, Jason
Witherington, John B. Furness
Purpose: Ghrelin is an endogenous peptide messenger that occurs in greatest amount in the
stomach, where it is located to mucosal endocrine cells. It accelerates gastric emptying, but
has little effect on the upper small intestine. Ghrelin receptor mRNA is expressed in enteric
neurons of human and rat colon, as well as endocrine-like cells in the colonic mucosa (Dass
et al., 2003). Initial studies showed a lack of effect on colonic motility (Trudel et al., 2002).
We have re-assessed the effects of ghrelin receptor agonism using CP-464709, a non-peptide
ghrelin receptor agonist. Methods: Sprague-Dawley rats, 300-400 g, were anaesthetised
with α-chloralose and ketamine and colonic intraluminal pressure was recorded. In other
experiments, visceromotor responses to colorectal distension (VMR) were measured by
recording the electromyograph from the upper abdominal muscle. Fecal output was measured
from conscious rats housed in a quiet environment. Results: CP-464709 (5 - 20 mg/kg/hr,
intravenous) caused a 3-fold increase in amplitudes of propulsive contractions that was
associated with increased propulsion of colonic contents. The contractions induced by the
agonist were large and regular, but it had no direct effect on the muscle. The effect of the
ghrelin agonist was sustained for as long as the infusion was maintained, (>30 min), indicating
that there is not significant desensitisation of the receptor. The effect was slow to wash out.
Subcutaneous injection (5 mg/kg bolus) to unanaesthetised rats caused increased fecal output
for a period of four hours. In the first hour, fecal output was 5 times greater than control,
and the cumulative 4 hr output was 2.2 times control. In contrast to effects on the colon,
CP-464709 had little effect on jejunal motility. CP-464709 (20 mg/kg/hr) caused some
arousal from anaesthesia, and this resulted in a decrease in the threshold intra-colonic
pressure to elicit the VMR. If the arousal was suppressed by further anaesthesia, or lower
doses of the drug (5 - 10 mg/kg/hr) were used, the VMR threshold was unaltered by CP-
464709. Conclusion: A ghrelin receptor agonist, in conscious or anaesthetized rats, is a
powerful and selective colokinetic with no apparent adverse side effects. Dass NB., et al.
Neuroscience, 120, 443-453 (2003). Trudel L., et al., Am J Physiol., 282, G948-G952. (2002).
S1639
Tissue Distribution of the Motilin and Ghrelin Receptor Along the Human
Gastrointestinal Tract
E.J. Takeshita, Bunzo Matsuura, Maoqing Dong, Laurence J. Miller, Hidetaka Matsui,
Yoichi Hiasa, Morikazu Onji
Motilin has been recognized as an important endogenous peptide regulator of gastrointestinal
(GI) motor function in mammals, acting at the motilin receptor. Ghrelin has been demon-
strated to regulate secretion of growth hormone, and to stimulate gastric motility in rodents,
acting via a structurally-related receptor. While there have been extensive physiological and
pharmacological studies of motilin and ghrelin action, the differences in GI motor function
of these peptides and the differences in tissue distribution of these receptors in human are
not yet clear. The aims of this study were to explore the distribution of motilin and ghrelin
receptors along the human GI tract, and to establish the molecular nature of the human
motilin receptor. Post-mortem and surgical human tissue specimens with no hemorrhage,
necrosis, or tumor were obtained from lower esophagus, stomach, duodenum, jejunum,
ileum, colon, and rectum. Tissues were divided as total layer and as separated layers of
mucosa and muscle. Using the method of real-time polymerase chain reaction after reverse
transcription, we analyzed levels of expression of mRNA for motilin and ghrelin receptors
and examined their molecular identities. Specimens from stomach, small intestine, and colon
were studied for expression of motilin and ghrelin receptor by immunohistochemistry. The
long form type of motilin receptor (GPR38A), but not the short form (GPR38B), was expressed
in all parts of the GI tract we studied. Motilin receptor mRNA was more heavily expressed
in muscle layer than in mucosal layer, and motilin receptor immunoreactivity was present
on muscle cells and myenteric plexus. In contrast, ghrelin receptor mRNA was expressed
equally in all parts of the GI tract and in both the mucosal and muscle layer. Motilin receptor
expression of the specimens from diabetic patients was same as that from non-diabetic
patients. These data suggest that motilin has a specific role in regulating human GI motility,
and motilin agonists such as peptide motilide and non-peptidyl erythromycin may be useful
prokinetic drugs for dysmotility not only of the upper GI tract but also of the lower GI tract.
S1640
5ht2b Receptors Are Expressed On Neurons and Non-Neuronal Cells in the
Human Gastrointestinal Tract, Rat Colon and Rat DRG
Elizabeth C. Colley, Catherine J. Streutker, Kirk Hillsley, S M. Kelly, Gareth Hicks, Ronald
H. Stead
Background: The 5HT2B receptor (5HT2B) appears to function in the maturation of neurons
in the mouse GI tract, although 5HT2B does not seem to be functional in adult murine
intestinal neurons. In contrast there is evidence for functional 5HT2B receptors in the adult
human gut, suggesting that 5HT2B receptors participate in enteric neuronal relays. However,
the extent and cellular distribution of 5HT2B receptors in the human GI tract is not fully
defined. Methods: Formalin-fixed paraffin embedded (FFPE) samples of rat colon and DRG,
and human esophagus, stomach, small and large bowel, and rectum, obtained from the
non-involved regions of resection specimens, with consent, were stained using immunocyto-
chemistry [ICC] and in situ hybridization [ISH]). Specific antibodies employed were raised
against: human/rat 5HT2B (LifeSpan, WA), chromogranin A (Dako, CA) and serotonin
(Immunostar, WI). For ISH, 5HT2B-specific biotinylated oligonucleotide probes were used.
PC3 and KU812 cells were employed as positive and negative controls, respectively. Rat
DRG were back-labelled by IP injections of Alexa Flour 488 conjugated cholera toxin subunit
B (CTB488; Invitrogen, ON) and subsequent localization with anti-CTB. Results: 5HT2B was
localized by both ICC and ISH in some epithelial cells, EC cells, muscle cells (muscularis
mucosa, muscularis propria and vascular), most neurons (both submucous and myenteric)
and infiltrating inflammatory cells (resembling eosinophils) throughout the gut as shown
in the table. Small diameter DRG neurons were 5HT2B-IR and some co-localized with CTB.
Serotonin and chromogranin confirmed the EE/EC cell staining for 5-HT2B. PC3 cells were
positive and KU812 were negative using both IHC and ISH. Conclusions: 5-HT2B-IR was
localized to EE/EC cells and intrinsic neurons; and was also expressed on primary afferent
neurons in DRG. This suggests that 5HT2B ligands might modulate endocrine cell, muscle
and both intrinsic and extrinsic afferent neuronal activity in the gastrointestinal tract.
S1641
Ca2+ Influx Induced By Galr2 Stimulation in Smooth Muscle Cells of Rat
Small Intestine Is Mediated By the Activation of a Receptor Operated Channel
Laura Anselmi, Salvatore L. Stella, Ingrid G. Jaramillo, Catia Sternini, Nicholas Brecha
Background and Aims: Galanin modulates a variety of physiological functions in the gastroin-
testinal (GI) tract, including regulation of transmitter release and modulation of GI motility
and secretion. Galanin has both stimulatory and inhibitory effects on GI motility. Galanin
effects are mediated by the activation of three distinct receptors, galanin receptor 1 (GalR1),
GalR2 and GalR3. GalR1 and GalR3 have been shown to inhibit adenylyl cyclase activity
via Gi/Go proteins, whereas GalR2 couples predominantly to phospholipase C through a
Gq protein, implicating an important role for Ca2+. We have shown that GalR1 and GalR2
are the most abundant GalR subtypes in the GI tract, and we have found that GalR2 is
highly expressed by smooth muscle, suggesting that GalR2 mediates the direct effect of
galanin on smooth muscle. The aim of this study was to investigate the effect of GalR2
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activation on Ca2+ influx in cultured smooth muscle cells using galanin 2-11, an agonist
with high selectivity for the GalR2. Methods: Smooth muscle cells were cultured from small
intestine using rats from 6 to 10 days old. [Ca2+]i changes were monitored using the Ca2+
sensitive dye, fluo-3 with confocal microscopy. Results: Galanin 2-11 resulted in a dose-
dependent (0.01-1.0 µM) increase in [Ca2+]i. Phospholipase C (PLC) antagonist, U-73122
(2 µM) inhibited the galanin 2-11 mediated [Ca2+]i increase indicating that Ca2+ release
induced by GalR2 activation is mediated by a PLC pathway. Removal of extracellular Ca2+
abolished the galanin 2-11 mediated [Ca2+]i increase, whereas it did not change Ca2+
release induced by ATP (10 µM), suggesting that Ca2+ influx in response to galanin 2-11
was not derived from intracellular stores. Since inhibition of the PLC-mediated pathway
can suppress the galanin 2-11 evoked [Ca2+]i increase without involving intracellular stores,
it is likely that the effects of galanin 2-11 are mediated by a receptor operated channel
(ROC) at the plasma membrane. To test this hypothesis, SKF-96365, an inhibitor of Ca2+
influx mediated by ROC, was added to galanin 2-11. SKF-96365 (50 µM) prevented the
galanin 2-11 induced [Ca2+]i increase supporting our hypothesis. Conclusions: These find-
ings support the hypothesis that GalR2 mediates the postjunctionally excitatory effect of
galanin on smooth muscle and suggest that PLC mediated Ca2+ release induced by activation
of GalR2 is due to the opening of a ROC. Supported by NIH grants DK57037 and 41301.
S1642
Protease-Activated Receptor-1 (PAR1) and PAR2 Mediate Relaxations in Lower
Esophageal Sphincter
Shih-Che Huang
Protease-activated receptor-1 (PAR1), PAR2 and PAR4 activation can alter the gastrointestinal
motility. To investigate effects mediated by PARs in the lower esophageal sphincter, we
measured contraction and relaxation of transverse strips from the guinea-pig lower esophageal
sphincter caused by three PAR-1 agonists, thrombin, TFLLR-NH2 and SFLLRN-NH2, three
PAR-2 agonists, trypsin, SLIGKV-NH2 and SLIGRL-NH2, as well as two PAR4 agonists,
GYPGKF-NH2 and AYPGKF-NH2, according to the procedure published previously (Regu-
latory Peptides 2005;127:27-35). In resting lower esophageal sphincter strips, thrombin did
not cause any relaxation or contraction whereas TFLLR-NH2 and SFLLRN-NH2 caused
moderate concentration-dependent relaxation. In carbachol-contracted strips, thrombin
caused mild whereas TFLLR-NH2 and SFLLRN-NH2 caused marked concentration-depend-
ent relaxation. These indicate the existence of the PAR1 mediating relaxation. The TFLLR-
NH2-induced relaxation was not affected by tetrodotoxin or atropine, suggesting a direct
effect on the lower esophageal sphincter circular muscle. On the other hand, in resting lower
esophageal sphincter strips, trypsin caused moderate concentration-dependent relaxation
whereas SLIGRL-NH2 and SLIGKV-NH2 did not cause any relaxation or contraction. In
carbachol-contracted strips, trypsin caused marked whereas SLIGRL-NH2 and SLIGKV-NH2
caused mild concentration-dependent relaxation. These indicate the existence of the PAR2
mediating relaxation. The trypsin-induced relaxation was not affected by tetrodotoxin or
atropine. These again suggest a direct effect on the lower esophageal sphincter circular
muscle. In contrast, GYPGKF-NH2 and AYPGKF-NH2, the PAR4 agonists, FSLLR-NH2, a
PAR1 inactive control peptide, as well as VKGILS-NH2, a PAR2 inactive control peptide, did
not cause any relaxation or contraction in resting or carbachol-contracted lower esophageal
sphincter strips. Taken together, these results demonstrate that PAR1 and PAR2 mediate
relaxations in the guinea-pig lower esophageal sphincter.
S1643
Delaying Gastric Emptying and Enhancing Cholecystokinin Release and
Satiety By Using Acid Stable Fat Emulsions
Luca Marciani, Martin Wickham, Gulzar Singh, Debbie Bush, Barbara Pick, Eleanor Cox,
Annette Fillery-Travis, Richard Faulks, Charles Marsden, Penny A. Gowland, Robin C.
Spiller
Background: Consumer preferences are leading to a steady increase in consumption of
convenience foods which often contain highly palatable fat as an emulsion. We have previ-
ously shown that oil/water emulsions can rapidly separate in the acid gastric environment
leading to layering of fat. This caused rapid emptying of the resulting low fat aqueous phase
with rapid reduction of gastric distension and satiation. We hypothesised that stabilising an
emulsion would prevent intragastric fat layering and, by ensuring prolonged exposure of
duodenal receptors to fat emulsion, maximise cholecystokinin (CCK) release, delay gastric
emptying and prolong satiety. Aims: To investigate in healthy volunteers the effect of
modifying the intragastric acid stability of equicaloric fat emulsions on gastric emptying,
CCK levels and satiety. Methods: 9 healthy male volunteers attended on 2 separate days,
having fasted overnight. They were fed 500 mL of one of two olive oil-in-water emulsion
test meals with equal fat content (675kcal) and equal droplet size distributions, but opposite
acid stability. One remained intact when exposed to the stomach acidic conditions (“acid-
stable”) and the other (“acid-unstable”) broke rapidly on being acidified yielding a layer of
oil floating above an aqueous phase. Serial measurements of gastric volumes (using magnetic
resonance imaging, MRI), plasma CCK (using radioimmunoassays) and satiety feelings (using
self-assessment questionnaires) were made for 10 hours. Results: (mean±SEM) MRI images
showed a layering of oil which became apparent soon after ingestion of the unstable emulsion
but was not seen with the acid stable emulsion. This was associated with a faster gastric
half-emptying time for the acid-unstable (72±13 min) compared with the acid-stable emulsion
meal (171±35 min), Wilcoxon’s p<0.008. The acid- unstable emulsion released less CCK
than the acid-stable one (AUC 531±111 versus 1095±244 pmolmin/L), p<0.001. An overall
exponential correlation between decreasing hunger with increasing CCK plasma level was
found (r=0.91), with the acid-stable emulsion being associated with greater satiety and
higher CCK levels. Conclusion: Rendering fat emulsions stable to gastric acid is a simple
way of enhancing satiety by a combination of delaying gastric emptying and enhancing
blood levels of CCK. Modifying food production methods to manipulate the post-prandial
delivery of fats to the intestine, the gut peptides response and hence satiety, could aid in


















Effects of Cholecystokinin-8s (CCK-8s) On Identified Pancreas-Projecting
Vagal Motoneurons
Shuxia Wan, R. Alberto Travagli
It has long been known that cholecystokinin acts in a paracrine fashion to activate peripheral
vagal afferent fibers that increase pancreatic exocrine secretion via a vago-vagal brainstem
circuit. Recent evidence, though, suggests that the locus of the CCK-8s action on the
gastrointestinal (GI) system is not restricted to peripheral afferent vagal fibers, but also affects
brainstem structures directly. Within the brainstem, neurons of the dorsal motor nucleus
of the vagus (DMV) provide the preganglionic parasympathetic efferent fibers that innervate
the GI tract, including the pancreas. The aims of the present study were to investigate
whether DMV neurons were responsive to exogenously applied CCK-8s and, if so, the
mechanism of action. Whole cell patch clamp recordings were made from pancreas-projecting
DMV neurons identified by prior application of the retrograde tracer, DiI on the pancreas
body. Perfusion with CCK-8s induced a concentration-dependent excitation in approximately
50% of pancreas-projecting DMV neurons (N=90). The threshold of the excitatory response
was 1nM, the EC50 was 30nM and Emax was 100nM. At 100nM, CCK-8s induced a
12±1.4mV depolarization (HP= -70mV) and increased the firing rate from 3±2 to 121±20
a.p./min (HP=-60mV). The CCK-8s induced depolarization was reduced from 9±1 to
6.8±1.8mV by TTX (1μM) suggesting that the effects were mediated both directly, via an
effect on the DMV membrane, and indirectly, via an effect on local synaptic circuits. Further-
more, the CCK-8s mediated excitation was prevented by the CCK-A antagonist, lorglumide
(1μM), while the CCK-B agonist, CCK-ns (100nM) had no effect, indicating the involvement
of CCK-A receptors only. Experiments conducted in the voltage clamp configuration indicated
that CCK-8s induced a 70±7pA inward current (VH=-50mV) that reversed at -106±3mV
and was accompanied by a 50±15% increase in input resistance. These data suggest that
the effects of CCK-8s were mediated by a closure of a potassium conductance. Indeed, CCK-
8s reduced both the amplitude and the time constant of decay of the calcium-dependent
potassium conductance, SK, by 30±3.4%. When tested with pancreatic polypeptide (PP,
which reduces pancreatic exocrine secretion), cells that responded to CCK-8s with an
excitation were, instead, inhibited by PP. These data indicate that CCK-8s may control
pancreas-exocrine secretion via an effect on pancreas-projecting DMV neurons. Supported
by NSF grant 0456291
S1645
Ghrelin Reduces Mechanical Sensitivity of Gastroesophageal Vagal Afferents in
Ferrets and Mice
Amanda J. Page, James Slattery, Tracey A. O'Donnell, Stuart Brierley, Catherine Milte,
Rhianna Laker, L A. Blackshaw
Background: Ghrelin is a peptide, produced by endocrine cells in the stomach, which is an
important regulator of food intake. Ghrelin is thought to act by inhibiting basal activity of
vagal afferents (Gastroenterology 2002; 123:1120-8), although direct evidence is lacking on
mechanism and which vagal afferents are responsible. Aim: Determine the effect of ghrelin
on the mechanically induced activity of gastroesophageal vagal afferent subtypes in the
ferret and mouse, and expression of ghrelin receptors. Methods: Single fiber recordings of
gastroesophageal vagal mechanoreceptors were made in ferret and mouse using standard
electrophysiological techniques (Page et al J. Neurosci 1999; 19: 8597-8602). Ghrelin was
applied to the peripheral afferent endings of ferret and mouse gastroesophageal vagal afferents
and their responses to graded mechanical stimuli investigated. These afferents have been
previously characterized as tension, mucosal and tension/mucosal (TM) receptors according
to their responsiveness to circumferential tension or mucosal stroking or both (J.Physiol
1998; 512: 907-16). Results: Ghrelin (1, 3 &10nM) reduced the response of 2 out of 6
ferret mucosal receptors. This inhibition was reversed on wash out. The ferret TM (n=10)
responses to mucosal stroking were also significantly reduced in the presence of ghrelin (1,
3 and 10nM; p<0.05). The response of ferret tension receptors (n=4) and TM receptors (n=
10) to circular tension were unaffected by ghrelin. In the mouse, ghrelin (3nM; p<0.05)
significantly and dose-dependently reduced the response of tension receptors (n=10) to
circular tension. However, at the higher dose of 10nM this reduction in response was
reversed, possibly indicating action at other receptors. The GHS receptor was detected in
the nodose ganglion by RT-PCR. Conclusion: These data indicate that ghrelin selectively
inhibits mechanosensitivity in separate populations of afferents in two species. Its potency
suggests that ghrelin acts as an endogenous modulator of peripheral mechanosensory func-
tion. Supported by National Health and Medical Research Council of Australia & AstraZeneca.
S1646
Effects of Cholecystokinin-8s (CCK-8s) Microinjections in the Dorsal Vagal
Complex of Deafferented Rats On Pancreatic Exocrine Secretion
Zhongling Zheng, R. Alberto Travagli
Cholecystokinin acts in a paracrine fashion to activate peripheral vagal afferent fibers and
increase pancreatic exocrine secretion via a vago-vagal reflex. Recent evidence, however,
suggests the CCK-8s may also affect brainstem structures directly. The aim of the present
study was to investigate whether microinjection of CCK-8s in the dorsal vagal complex
(DVC) modulated pancreatic exocrine secretion even in rats that had undergone vagal
deafferentation. Sprague-Dawley rats (250-400g) were anesthetized before the common bile-
pancreatic duct was cannulated at the sphincter of Oddi and pancreatic secretion collected
every 10 min. The DVC was exposed via a dorsal approach and microinjections were made
according to the co-ordinates of Paxinos & Watson. Rats were divided into 5 groups:
1)Microinjection of PBS (60nl) 2)Microinjection of CCK-8s (450pmoles in 60nl PBS) 3)Micro-
injection of CCK-8s one week after unilateral surgical vagal deafferentation 4)Microinjection
of CCK-8s one week after unilateral surgical vagal deafferentation and contralateral subdi-
aphragmatic vagotomy 5)Acute cervical vagotomy (without microinjection) The volume of
pancreatic juice secreted was never observed to alter in any of the experimental parameters
(approximate secretion was 280μl/10minutes). In control rats (PBS injection; N=3) or rats
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that were underwent acute vagotomy (N=3), the total protein secreted remained stable
at 270±39μg every 10min for 120min without significant variations. Following CCK-8s
microinjection in the DVC, protein secretion increased from 276±41 to 715±173μg/10min
(i.e. a 220±70% increase; N=5; P<0.05), the increase was larger when CCK-8s was injected
in the left side of the DVC (from 315±60 to 1130±35μg/10min) vs the right side (from
250±60 to 440±62μg/10min). Protein secretion returned to baseline levels within 30 min.
In deafferented rats, microinjection of CCK-8s increased protein secretion from 215±34 to
507±36μg/10min (i.e. a 185±14 increase; N=10; P<0.05) while in rats that underwent
deafferentation plus subdiaphragmatic vagotomy, microinjection of CCK-8s increased protein
secretion from 200±33 to 318±67μg/10min (i.e. a 154±18% increase; N=5; P<0.05). These
data indicate that, as well as activating peripheral vagal afferents, CCK-8s increases pancreatic
exocrine secretion via an action in the DVC. Furthermore, the effects of CCK-8s are still
present, although reduced, following sensory vagal deafferentation. In physiological condi-
tions, CCK-8s acting in the DVC could originate either be from the circulation (postprandial
plasma concentration is approximately 10pM) or from local neuronal projections. Supported
by NSF grant 0456291
S1647
Hydrogen Sulfide Is Synthesized in Enteric Neurons and Acts As a Pro-
Secretory Mediator in the Guinea-Pig and Human Gut
Rudolf Schicho, Dagmar Kruger, Florian Zeller, Thomas Frieling, Isao Ishii, Hideo
Kimura, Michael Schemann
Hydrogen sulfide (H2S) has been recently identified as a gasotransmitter in the brain and
modulates various organ functions. Its role and action in the gastrointestinal tract, however,
especially in human tissue, is less elucidated. Immunohistochemistry was used to explore
expression of the two H2S producing enzymes cystathionine-γ-lyase (CSE) and cystathionine-β-synthase (CBS) in the human and guinea-pig enteric nervous system (ENS). Ussing chamber
technique was used to study effects of H2S on ion secretion (ISC) in human and guinea-pig
mucosa/submucosa preparations. Neuroimaging with potentiometric dyes was performed
to study H2S effects on neural activity of guinea-pig submucous ganglia. Double labeling
with the pan-neuronal marker anti-Hu revealed CSE-IR in almost all nerve cell bodies of
submucosal ganglia of guinea-pig ileum (99.4±0.4%) and colon (99.7±0.1 %) and human
colon (96±0.7 %) (3 patients/animals, 20-25 ganglia each). CSE-IR was also observed in
almost all myenteric neurons of guinea pig stomach, ileum and colon and in myenteric
interstitial cells of Cajal as indicated by co-localisation with c-kit antibody. All CSE-IR
myenteric and submucous neurons were also CBS-IR and vice versa. Ussing chamber experi-
ments revealed that serosal application of the H2S donor NaHS (0.1-1mM) significantly
increased ISC in guinea-pig ileum and colon (9±2µA/cm2 for 0.1mM, 20±4µA/cm2 for
1mM). Likewise, NaHS (0.2-2.5mM) evoked an increase in ISC in human ileum and colon
preparations (5±2µA/cm2 for 0.5mM, 13±6µA/cm2 for 2.5mM). The EC50 was 0.21mM for
guinea-pig and 0.51mM for human tissue which corresponds to reported physiological H2S
concentrations in the blood. In all experiments NaHS evoked a transient desensitizing
response that lasted from 1-8min. The increased ISC was bumetanide-sensitive and therefore
due to increased chloride secretion. In human and guinea-pig, ruthenium red (30µM)
significantly potentiated the NaHS evoked secretion which was now sustained lacking desens-
itization. Neuroimaging of guinea-pig submucous neurons revealed that perfusion of 500µM
NaHS evoked a profound activation consisting of action potential discharge in 16 out of 46
neurons. This effect also desensitized within 5min. Our results demonstrate for the first
time that both H2S producing enzymes are expressed in human and guinea-pig enteric
neurons. This together with the excitatory action on submucous neurons suggests that H2S
is a novel signaling molecule in the ENS. We describe a novel function of H2S as a pro-
secretory mediator in the guinea-pig and human intestine.
S1648
Role of Endocannabinoids in Gastroprotection Against Acute Gastric Lesions
Michal Pawlik, Tomasz Brzozowski, Peter C. Konturek, Anetta Targosz, Danuta
Drozdowicz, Greg Burnat, Stanislaw J. Konturek, Wieslaw W. Pawlik, Eckhart G. Hahn
Anandamide, an endocannabinoid acting via CB1 and vanilloid (VR-1) receptors affects
gastric motility and gastric emptying and exerts anti-inflammatory action in the gut but the
possibility that endocannabinoids applied peripherally or centrally can contribute to the
mechanism of gastric mucosal defense against acute gastric lesions, has not been studied.
We compared the effect of intraperitoneal (i.p.) and intracerebroventricular (i.c.v.) adminis-
tration of anandamide and an agonist of CB1 and VR-1 receptors, arvanil, on gastric acid
secretion in rats equipped with gastric fistula (GF) (series A) and on acute gastric lesions
induced by water immersion and restraint stress (WRS) (series B) in rats with or without
AM-251 (1 mg/kg i.p.), the selective antagonist of CB1 receptors, capsazepine (10 mg/kg
i.g.), an antagonist of VR-1 receptors and in those with capsaicin-denervation (125 mg/kg
s.c.). At 3.5 h after the end of WRS, the number and area of gastric lesions was determined
by planimetry, the gastric blood flow (GBF) was examined by H2-gas clearance method and
the plasma gastrin levels and PGE2 generation were assessed by specific RIAs. The expression
of mRNA for cyclooxygenases (COX-1 and COX-2) were evaluated in mucosal biopsy samples
of stressed and non-stressed rats by RT-PCR. Exposure to WRS produced typical gastric
bleeding lesions while significantly increasing gastric acid output in GF rats and decreasing
the GBF (by 35%) as compared to baseline and these effects were further enhanced in
animals with capsaicin-denervation. Anandamide (2.5-50 μg/kg or 50-500 ng/rat i.c.v),
decreased significantly gastric acid secretion; the dose inhibiting the gastric acid output by
50% (ID50) being 10 μg/kg and 200 ng/kg, respectively. Pretreatment with anandamide (20
μg/kg i.g. or 250 ng/kg i.c.v.) or arvanil (20 μg/kg i.p.), significantly reduced WRS-induced
gastric lesions while elevating significantly the GBF and plasma immunoreactive gastrin
levels and enhancing COX-2 expression and PGE2 generation in the gastric mucosa. These
protective and hyperemic effects of anandamide and arvanil were significantly attenuated
by pretreatment with AM 251 or capsazepine and completely abolished by capsaicin-denerva-
tion and further restored by the addition of exogenous CGRP (10 μg/kg s.c.) to cannabinoids
in capsaicin-deactivated animals. We conclude that central and peripheral cannabinoids
exhibit gastroprotective activity against stress damage due to activation of CB1 and VR-1
receptors, antisecretory activity and an increase in the gastric microcirculation mediated by
neuropeptides released from sensory nerves such as CGRP and activation of PG/COX-
2 pathway.
S1649
The Role of Calcitonin Receptor-Like Receptor in Colonic Inflammation and
Motility
Matthew S. Clifton, Julia J. Hoy, Prema S. Idumalla, Stephen Dada, Carlos U. Corvera,
Nigel W. Bunnett, Aditi Bhargava
Calcitonin gene-related peptide (CGRP) mediates neurogenic inflammation and pain and
controls intestinal motility. The CGRP receptor is a hetero-dimer of calcitonin receptor-like
receptor (CLR) and receptor associated modifying protein 1 (RAMP1), which are expressed
in enteric nerves and primary spinal afferent neurons. However, the specific role of CLR in
colonic inflammation and motility is unknown. We used RNA interference to silence the
CLR gene and to determine its role in control of colonic inflammation and motility. To
silence CLR, we injected double stranded RNA to rat CLR or to globin (control) into 2 sites
in the colonic wall of anesthetized rats (n=4-6/group). To examine the spatial and temporal
down-regulation of CLR, we collected tissues at 1-9 days after treatment and localized CLR
by immunofluorescence. In control animals, CLR was detected in nerve fibers within the
myenteric and submucosal plexuses and in the mucosa. CLR RNAi down regulated immuno-
reactive CLR in enteric neurons within 2-3 cm of the site of injection within 1 day, and
down regulation persisted for 7-9 days. To examine the effects of this down regulation on
colitis, we administered an enema of trinitrobenzene sulfonic acid (TNBS) in 50% ethanol
or ethanol alone (control) into the colon, and examined inflammation after 72 hours. In
animals receiving control RNAi, TNBS induced edema, mucosal destruction, and increased
submucosal infiltration of polymorphonuclear cells, as determined by staining with hematox-
ylin and eosin. The histological appearance and myeloperoxidase (MPO) levels were similar
in animals treated with control RNAi/TNBS enema and saline/TNBS enema. In animals
receiving CLR RNAi, histological examination indicated exacerbated inflammmmation, and
MPO activity demonstrated a two-fold increase over control, supporting the histological
findings. To assess motility, we measured isometric contractions of longitudinal colonic
muscle suspended in an organ bath 72 hours after RNAi treatment. In animals treated with
control RNAi, CGRP abrogated contractions entirely, and decreased resting muscular tone.
In animals treated with CLR RNAi, muscle tone decreased, but slow wave contractions of
varying amplitude persisted. Thus, RNAi can be used to specifically down regulate CLR in
the colon. Silencing of CLR exacerbated the TNBS-induced colitis, suggesting a protective
role for CGRP and its receptor in colonic inflammation. CLR RNAi also abolished the effects
of CGRP on colonic motility, which confirms that CLR mediates these effects of CGRP.
Supported by NIH grant DK39957.
S1650
Neonatal Lipopolysaccharide Increases the Severity of TNBS-Induced Colitis
in Adult Rats
Niall P. Hyland, Sarah J. Spencer, Quentin J. Pittman, Keith A. Sharkey
Early life events are recognized as having long-term health sequealae. We previously showed
that infection in adults can alter the course of colitis. However, the long term effects of
neonatal exposure to an infection, which has previously been shown to alter parameters of
adult physiology, remain to be investigated with regard to the gastrointestinal tract. The
aim of this study was to investigate the effect of neonatal LPS on enteric physiology and
colitis. Neonatal male Sprague Dawley rats were given LPS (100μgkg-1 i.p. Escherichia coli;
nLPS) or a similar volume of pyrogen free saline (nSaline). Eight to ten weeks later both
nLPS and nSaline treated rats received either saline (aSaline) or TNBS (aTNBS) intra-rectally
and were allowed to recover for three days. Alterations in body mass and body temperature
were monitored daily. Additional animals were housed in metabolic cages and food/water
and fecal/urine output was recorded daily. Colonic segments were mounted in Ussing
chambers, and responses to veratridine (30µM) or capsaicin (1µM) assessed. Adjacent seg-
ments were fixed and processed for mast cell histochemistry or were snap frozen for assess-
ment of myeloperoxidase (MPO) activity. Serum was collected for measurement of corticos-
terone (CORT) and tumour necrosis factor α (TNFα). Neonatal LPS treated animals had
more severe colitis than animals given saline injections as neonates. This was seen as lower
body weight (nLPS-aTNBS weighed ~25% less compared with nSaline-aTNBS), a significantly
increased macroscopic tissue damage score (8.7±1.1 (n=8) nSaline-aTNBS, 12.5±0.4 (n=8)
nLPS-aTNBS) and increased MPO activity. These animals were also hypothermic in response
to TNBS compared to nSaline-aTNBS animals. The reductions in body weight were not
accompanied by a change in food intake. Colonic segments from all experimental groups
taken from areas adjacent to those of the most severe damage displayed no significant
difference in basal short-circuit current or resistance nor any difference in response to
capsaicin or veratridine. Forskolin (10μM) and bethanechol (10μM) were used as internal
controls and no difference in secretory response between nLPS and nSaline treated groups
was observed. Serum CORT was unaltered in all groups, however, TNFα was significantly
increased in nLPS-aTNBS compared with nSaline-aTNBS and control animals. A single
neonatal exposure to LPS produces long-term alterations in the response to colitis. This
change is independent of alterations in submucosal secretomotor and epithelial function,
but is associated with increased circulating TNFα, suggestive of an altered immune response
in adults exposed to neonatal infection.
S1651
Role of CRF Family of Neuropeptides in Colonic Inflammation
Julia J. Hoy, Matthew S. Clifton, Prema S. Idumalla, Aditi Bhargava
Corticotropin-releasing factor (CRF) and its family of neuropeptides play a pivotal role in
a variety of physiological processes that include coordinating endocrine responses, immune
cell activation and gastrointestinal (GI) motility. Spatial distribution pattern of urocortins
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(Ucn) and their high affinity receptor CRFR2 in the brain is well established, however, their
distribution pattern in the colon is less clear. In this study, we tested the hypothesis that
final inhibitory or stimulatory outcomes of GI inflammation depend on the differing spatial
distribution (within the GI tract) and temporal expression levels of CRF family of ligands
and their receptor (that include CRF, urocortins and two CRF receptors). The distribution
pattern of Ucn2 and CRFR2 in the proximal and distal colon was established using immuno-
histochemistry (IHC). Colonic inflammation was induced by a trinitrobenzene sulfonic acid
(TNBS) enema (30 mg/animal). Male Sprague-Dawley rats were treated as follows (n=4-6/
group): saline injection, 50% ethanol vehicle enema; saline injection, TNBS enema; double-
stranded RNA (dsRNA) injection, TNBS enema. DsRNA against CRF, Ucn2, CRFR1 and
CRFR2 were injected separately. The descending colon was harvested 72 hours after adminis-
tration of dsRNA and TNBS enema. Tissues were analyzed by hematoxylin and eosin staining
for histologic damage and IHC for inhibition of expression. Concomitant changes in inflam-
mation were measured using a myeloperoxidase (MPO) assay. Urocortin 2 expression was
localized to the epithelial cells of the mucosal crypts, nerve fibres of the submucosal, and
the myenteric nerve plexus of both the proximal and the distal colon. CRFR2 expression
was most evident in the myenteric nerve plexus in the colon. As expected, TNBS enema
resulted in exacerbated tissue edema, mucosal destruction, and increased submucosal infiltra-
tion of polymorphonuclear cells on histologic staining when compared to control saline and
50% ethanol administered rats. Interestingly, colon-specific inhibition of CRF or CRFR1 did
not alter the course of TNBS-induced inflammation; histological staining and MPO activity
were comparable to rats that received a TNBS enema only. Colonic inhibition of CRFR2
resulted in tissue protection and a significant decrease in MPO activity. Surprisingly, and
in contrast to CRFR2, colonic inhibition of Ucn2 exacerbated inflammation that was reflected
in enhanced MPO activity. Thus, manipulation of the CRF system with RNAi provides an
effective starting point for understanding their GI functions, perhaps contributing to the
development of novel therapeutic treatments for inflammatory intestinal diseases.
S1652
Role of Endogenous Ghrelin in Acute and Chronic DSS-Induced Colitis in
Mice
Betty de Smet, Theo Thijs, Dieder Moechars, Larissa Polders, Bernard Coulie, Theo L.
Peeters, Inge Depoortere
Ghrelin inhibits the synthesis of proinflammatory cytokines, and the ghrelin receptor is
expressed in different immune cells, including T lymphocytes. To assess a possible anti-
inflammatory role of ghrelin in intestinal inflammation, we induced colitis with DSS in wild-
type (WT) and ghrelin knockout (KO) mice and compared disease activity and colonic
contractility. Methods. 38 KO (developed in collaboration with Lexicon Genetics) and 40
WT mice were divided in 4 groups. Control group, acute group (3%DSS for 5 days), recovery
group (3%DSS for 5 days, H2O for 5 days), chronic group (3%DSS for 5 days, H2O for
21 days). Disease activity index (DAI) was determined as the average of the scores for
weight loss, stool consistency and bleeding. Neutrophil infiltration was determined by MPO
measurements. In colonic strips we evaluated smooth muscle and neural excitatory and
inhibitory responses induced by electrical field stimulation. Results. Disease activity: During
colitis body weight loss was less pronounced and stool consistency was less loose in KO
mice, resulting in a decreased DAI score for the KO mice. The onset of neutrophil infiltration
(MPO; U/mg tissue) was delayed from the acute phase in WT mice (WT: 0.84±0.21, KO:
0.28±0.08, P<0.05) to the recovery phase (WT: 1.38±0.27, KO: 1.31±0.18) in KO mice and
was normalized in both genotypes during chronic colitis (WT: 0.54±0.18, KO: 0.43±0.11).
Functional studies: Neural cholinergic-tachykinergic responses were increased during the
acute period (WT: +16±7%, KO: +67±4%, P<0.05), decreased during the recovery period
(WT: -39±3%, KO: -57±2%, P<0.05) and again enhanced during the chronic phase (WT:
+111±16%, KO: +68±7%, P<0.05). Changes in the neural responses were paralleled by
changes in the smooth muscle response to ACh. NANC inhibitory responses were reduced
in WT mice to a similar extent during the different phases of colitis (acute: 20%, recovery:
21%, chronic: 18% reduction). In KO mice the onset of loss of inhibitory responses was
delayed (acute: 8%, recovery: 28%, chronic: 18% reduction). In inflamed WT mice the
inhibitory effect of suramin on NANC inhibitory responses was reduced from 26±2% to
17±2% (acute), 15±1% (recovery) and 21±1% (chronic), while in KO mice suramin was
only less effective during the recovery phase (8±1%). Conclusion. In contrast with what
was expected, absence of ghrelin decreases the disease activity index, delays neutrophil
infiltration and delays the onset of contractility changes from the acute until the recovery
period. Our data are at variance with a protective role of ghrelin in intestinal inflammation.
S1653
Glial Cell Line-Derived Neurotrophic Factor Promotes Pancreatic Beta Cell
Survival
Simon Mwangi, Alpana Limaye, Shanthi Srinivasan
BACKGROUND: Glial cell line-derived neurotrophic factor (GDNF) is a factor that plays
a critical role in the development and survival of the enteric nervous system, but its role in
pancreatic β cell proliferation and survival has not been established. Recent studies have
demonstrated several similarities between β cells and neuronal cells raising the possibility
that neurotrophic factors such as GDNF could play a role in β cell growth and survival.
We evaluated the role of GDNF on β cell survival, and determined the signal transduction
pathways involved focusing on the PI3K signaling pathway. METHODS: All experiments
were performed in the β-TC-6 pancreatic β cell line. In addition receptor mRNA expression
was also assessed in laser capture microscopy-isolated mouse pancreatic β cells. GDNF
receptor family α1 (GFRα1) mRNA expression was assessed by RT-PCR. The expression of
the c-Ret and GFRα1 receptors was assessed by immunofluorescence microscopy. Apoptosis
in response to GDNF withdrawal or thapsigargin treatment was evaluated by immunoblotting
for cleaved caspase-3 as well as by cleaved caspase-3 immunofluorescence with Hoechst
staining. Akt phosphorylation was assessed by immunoblotting. RESULTS: GFRα1 mRNA
was present in both β-TC-6 cells and pancreatic β cells. Expression of c-Ret and GFRα 1
receptors was also seen by immunocytochemistry in β-TC-6 cells. β-TC-6 cells cultured for

















immunoblot) compared to those cultured in the presence of GDNF (P<0.0001). Addition
of thapsigargin (24 h) resulted in a significant increase in β-TC-6 cells apoptosis (21.5 +2.3
% compared to 8.6 + 1.2 % + in control cells, cleaved caspase 3 immunostaining, p<0.0001).
In the presence of GDNF (100ng/ml) resulted in a significant reduction of thapsigargin-
induced apoptosis (6.4 + 1.5 %, P<0.0001). Analysis of the involvement of the PI3K/Akt
signaling pathway in GDNF-mediated β cell survival revealed that GDNF promoted the
phosphorylation of Akt at its C-terminus ser473 residue, and that this phosphorylation was
inhibited in the presence of the PI3K inhibitor, LY294002. CONCLUSIONS: We have
demonstrated that the receptors for GDNF are expressed in pancreatic β cells, and that
GDNF can protect against β cell apoptosis. These results suggest that GDNF plays a role
in pancreatic β cell survival.
S1654
Peripheral Nociceptin Prevents Stress-Induced Gastric Damage in Rats
Carlo Polidori, Maurizio Massi, Lucia Silvotti, Valeria Albonetti, Daniela Grandi,
Giuseppina Morini
Nociceptin (N/OFQ) has been shown to be widely expressed within the CNS and to modulate
stress-related effects and behaviors by acting at central level. The purpose of the current
study was to evaluate the distribution of N/OFQ in rat gastrointestinal tract and the possible
influence of peripheral N/OFQ on acute gastric damage caused by cold-restraint stress in rats.
N/OFQ immunoreactivity was present in the regions of the gastrointestinal tract examined:
stomach, distal ileum and distal colon. Immunoreactivity appeared to be localized in the
myenteric plexus. Cold exposure in restraint conditions for 3 h resulted in the formation
of macroscopically visible hemorrhagic lesions in the glandular portion of the stomach,
lesion index being 23.85 ± 4.85. On histological examination lesions were characterized by
extensive areas of edema and hemorrhage and by focal necrosis. N/OFQ, administered, 0.03
to 1 μg/kg/h ip, dose-dependently and significantly reduced macroscopic and histologic
lesions, with a maximal reduction of 63% achieved with the highest dose. The selective N/
OFQ receptor agonist, [(pF)Phe4Aib7Arg14Lys15]N/OFQ-NH2 (UFP112), 0.01 to 0.3 μg/
kg/h ip similarly inhibited the formation of gastric lesions by cold-restraint stress, having
an higher potency as compared with N/OFQ. Protective effect of N/OFQ was abolished by
the concurrent administration of the N/OFQ receptor antagonist, [Nphe1,Arg14,Lys15]N/
OFQ-NH2 (UFP 101), 30 μg/kg/h ip This dose of UFP 101 itself was inactive. Subdiaphrag-
matic vagotomy reduced gastric lesions induced by cold-restraint and in vagotomized rats
the protective effect by N/OFQ was no longer evident. Present results indicate that N/OFQ
is expressed in rat gastrointestinal tract and that the peptide reduces the damaging effect
of stress on rat gastric mucosa, suggesting a role of peripheral N/OFQ in modulating stress-
related gastric effects.
S1655
In Vivo Goblet Cell Responses to An Enteric Bacterial Pathogen in a Mouse
Model of Infectious Colitis
Kirk S. Bergstrom, Caixia Ma, Waliul Khan, Bruce A. Vallance
Background & Aims. Intestinal goblet cells (IGCs) are specialized epithelial cells that secrete
the mucin Muc2 into the intestinal tract, forming the protective mucus layer. IGCs play an
important role in host defense against intestinal parasitic nematodes in association with a
T helper (Th) 2 immune response. In contrast, the role of IGCs in host defense against
enteric bacterial infections is unclear. Using the Citrobacter rodentium (Cr) mouse model
of enteric bacterial infection, which causes mild diarrhea and colitis in association with a
Th1 immune response, we sought to characterize IGC responses in vivo, and assess their
role in host defense against this infection. Methods. C57BL/6 mice were infected with Cr,
and distal colons were isolated at early (days 4-6) and later (days 10-14) time points and
analyzed for bacterial numbers as well as changes in mucin biochemical properties, IGCs
numbers and morphology, & Muc2 mRNA expression. The role of IGC-derived Muc2 in
host defense was determined by infecting Muc2 -/- mice with Cr. Moreover, the role of the
host immune system in mediating IGC responses was assessed by Cr infection of RAG-1 -/-
mice that lack T & B cells. Results. The distal colons of Cr inoculated mice were heavily
infected by day 4 pi. At the same time, histological staining revealed the increased expression
of neutral mucins and an overall decrease in mucin sulfation, as well as greater numbers
of mature IGCs compared to uninfected controls. Muc2 -/- mice were highly susceptible to
Cr infection, succumbing by day 6 pi, in association with severe crypt ulceration and
increased bacterial numbers in the colon, mesenteric lymph nodes, and spleen compared
to WT mice that all survived. At later time points (day 10-14 pi), as the infection persisted
in WT mice, there was a dramatic reduction in mature IGCs, while the mucins that remained
were virtually all sulfated. These IGC changes correlated with a decrease in Muc2 mRNA
expression and an increase in Th1 cytokines. In contrast, RAG-1 -/- mice had abundant
mature IGCs at these later time points, and did not show a significant reduction in Muc2
mRNA expression, although mucins were predominantly sulfated. Conclusion. IGCs
undergo dynamic morphological, biochemical, and Muc2 gene expression changes in vivo
during Cr infection, which appear to be mediated by the adaptive immune system. Moreover,
Muc2 production by IGCs plays an important role in host defense early in infection, most
likely by limiting bacterial translocation out of the infected colon. Taken together, these
results indicate that IGCs are active players in host defense during infection by enteric
bacterial pathogens.
S1656
Activation of Toll-Like Receptor 3 Protects Against DSS-Induced Colitis
Matam V. Kumar, Hui Xia, Vasantha Kolachala, Shanthi V. Sitaraman, Andrew S. Neish,
Andrew T. Gewirtz
BACKGROUND: Mimetics of bacterial DNA, given orally or subcutaneousy, protect mice
from experimental colitis via a toll-like receptor (TLR)-9 dependent mechanism. GOAL: To
investigate whether synthetic viral RNA, poly(I:C), which is also a potent immunomodulator,
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might also affect murine colitis and, if so, define whether such effects were mediated by
TLR3, which is one of at least three known receptors for this viral RNA analog. METHODS:
Mice (8-week old female C57BL6, IL-10KO, or TLR3KO) were administered 1.5% dextran
sodium sulfate (DSS) in drinking water for 7 days. Two hours before treatment with DSS,
mice were given PBS, 20 micrograms of poly(I:C) subcutaneously, or 100 micrograms of
poly(I:C) intragastrically. Disease activity was assessed by measuring weight loss, occult
blood, colon shortening, histopathologic analysis of H&E stained tissue, and measurement
of colonic levels of myeloperoxidase activity, cyclooxygenase-2 and inducible nitric oxide
synthase protein. Furthermore, inflammation was serologically assessed by measuring ker-
atinocyte derived chemokine (KC), serum amyloid A and by ELISA and lipocalin-2 by SDS-
PAGE immunoblotting. RESULTS: In wild type (C57BL6) mice, subcutaneous administration
of poly(I:C) dramatically protected against DSS induced colitis as assessed by every parameter
analyzed. In contrast, intragastric administration of poly(I:C) offered no protection in this
colitis model nor did its administration activate the innate immune system as assessed by
serologic parameters. Subcutaneous poly(I:C) protected against DSS-induced colitis equally
well in C57BL6 and IL-10KO mice indicating that this anti-inflammatory cytokine is not
required for such protection. Protection against colitis given by poly(I:C) treatment was
ablated in TLR3KO indicating the protective action of this viral RNA analog was mediated
by TLR3. CONCLUSIONS: Activation of TLR3 on cells that are accessible by systemic,
but not oral, administration of synthetic viral RNA results in protection against the acute
inflammation that can ensue upon damage of the gut epithelium. Thus, this viral RNA
analog, which is under clinical trials for other inflammatory disorders (e.g. lupus), may also
have therapeutic value for inflammatory bowel disease.
S1657
Abnormally Differentiated Subsets of Intestinal Macrophage Induce IL-12
Hyperproduction in Response to Bacteria. -Etiology of Th1 Dominant Colitis
in IL-10 Deficient Mice-
Nobuhiko Kamada, Tadakazu Hisamatsu, Susumu Okamoto, Kiyoko S. Akagawa,
Toshifumi Hibi
BACKGROUND: Disorders in enteric bacteria recognition by intestinal macrophages (Mphi)
are strongly correlated with the pathogenesis of chronic colitis; however its precise mechan-
isms remain unclear. The aim of the current study was to elucidate the roles of Mphi in
intestinal inflammation by using an IL-10-deficient (IL-10-/-) mouse colitis model.
METHODS: GM-Mphi and M-Mphi were generated from bone-marrow (BM) CD11b+ cells
with GM-CSF and M-CSF, respectively. Colonic lamina propria Mphi (CLPMphi) and splenic
Mphi were isolated from colon lamina propria mononuclear cells or unfractionated spleno-
cytes by CD11b+ cell separation. These Mphi were then stimulated with heat-killed whole
bacteria antigens. Cytokines production from stimulated Mphi was assessed by cytometric
beads array and quantitative RT-PCR. RESULTS: GM-Mphi and M-Mphi from IL-10-/- mice
were similar to those from wild-type (WT) mice, at least in terms of morphology and cell
surface phenotypes. M-Mphi from IL-10-/- mice produced abnormal large amounts of IL-
12 and IL-23 upon stimulation with heat-killed whole bacteria antigens, whereas M-Mphi
from wild-type (WT) mice produced large amounts of IL-10 but neither IL-12 nor IL-23.
In contrast, IL-12 production by GM-Mphi was not significantly different between WT and
IL-10-/- mice. In ex-vivo experiments, cytokine production ability of CLPMphi but not
splenic Mphi from WT mice was similar to that of M-Mphi, and CLPMphi but not splenic
Mphi from IL-10-/- mice also showed abnormal IL-12p70 hyperproduction upon stimulation
with bacteria. Surprisingly, the abnormal IL-12p70 hyperproduction from M-Mphi from IL-
10-/- mice was improved by IL-10 supplementation during the differentiation process.
CONCLUSION: These results suggest that CLPMphi and M-Mphi act as anti-inflammatory
Mphi, and suppress excess inflammation induced by bacteria in WT mice. In IL-10-/- mice,
however, such Mphi subsets differentiated into abnormal phenotype under IL-10 deficient
environment, and bacteria recognition by abnormally differentiated subsets of intestinal
Mphi may lead to Th1-dominant colitis via IL-12 and IL-23 hyperproduction. Our data
provide new insight into the intestinal Mphi-gut flora relationship in the development of
colitis in IL-10-/- mice.
S1658
Irf-1 Mediates Innate Immune Response of Intestinal Epithelial Cells By
Regulating the Concerted Expression of Immunosubunits and Tlr3
Atsushi Yoshioka, Shigeru Oshima, Kiichiro Tsuchiya, Shin Namiki, Ryuuichi Okamoto,
Tetsuya Nakamura, Takanori Kanai, Mamoru Watanabe
Background & Aims: We have previously shown that IRF-1, a downstream factor of inter-
feron(IFN) signaling, transcriptionally regulates production of interleukin(IL)-7, a central
cytokine of the adaptive immune system, within the intestinal mucosa. However, it is
suggested that intestinal epithelial cells (IECs) also play indispensable roles in the innate
immune system, and that dysregulation of the innate immune response is critically required
for the pathogenesis of inflammatory bowel diseases(IBDs). In the present study, we analyzed
the possibility whether key molecules of the innate immune system might be target genes
of IRF-1 in IECs. Methods: Human IEC-derived cells were used to perform cDNA expression
array hybridization under induced expression of IRF-1 by Tet-on system. Northern blot or
real-time PCR was conducted to confirm altered expression level of the genes identified.
Functional roles of IRF-1 in transcriptional regulation for a part of its target genes were
verified using reporter assays, chromatin immunoprecipitation(ChIP) or si-RNA mediated
gene silencing. To ascertain the roles of IRF-1 in vivo, induction of the target gene expression
upon IFN-γ treatment in IRF-1 deficient mice was analyzed. Results: Expression profiling and
subsequent analysis of related genes by Northern blot revealed that 5 out of 16 components of
the immunoproteasome were up-regulated by forced expression of IRF-1. All these subunits
were confirmed to be up-regulated also by IFN-γ stimulation on IECs. Of these subunits,
transcriptional expression of LMP-7, a catalytic subunit of the immunoproteasome, was
newly identified to be directly regulated by IRF-1 via distinct IRF-E element exising in the
promotor region of LMP-7 gene. Futhermore, critical role of IRF-1 in IFN-γ inducible
concerted expression of immunosubunits was confirmed in vivo using IRF-1 -/- mice.
Additionally, analysis for mRNA expression of TLRs revealed that TLR3 was significantly
up-regulated both by IFN-γ stimulation and by forced expression of IRF-1 in IECs. Conclu-
sions: These results indicated that IRF-1 plays critical roles for innate immune response in
IECs via concerted regulation of mRNA expressions of both immunoproteasomes and TLR3.
S1659
Regulation of IL-10 Production Induced By NOD2/CARD15 and TLR2
Pathways in Human Monocyte-Derived Dendritic Cells
J.N. Li, Matija Hedl, Morassa Mohseni, Kholil Qato, Betul Yilmaz, Samuel Bracamonte,
Clara Abraham, Judy Cho
The innate immune system utilizes both NOD2 and Toll-like receptors (TLRs) to recognize
various microbial components. Defining the functional relationship between these two path-
ways is of major interest. It has been previously reported that treatment of monocytic cells
with muramyl dipeptide (MDP) and Pam3Cys, ligands for NOD2 and TLR2 respectively,
demonstrates synergy in IL-10 production. In this study, we utilized primary monocyte-
derived human dendritic cells (MDDCs) to identify inter-individual differences and define
mechanisms of regulation of IL-10 by MDP and Pam3Cys. In MDDCs from 26 healthy
individuals, we observed a 1.47 ± 0.20 (MDP 1 ug/ml), 3.26 ± 0.25 (Pam3Cys 1 ug/ml)
and 7.57 ± 1.1-fold induction (MDP 1 ug/ml plus Pam3Cys 1 ug/ml) of IL-10 treatment
demonstrating a synergistic effect between these two pathways. However, significant inter-
individual differences were observed in IL-10 responses. Synergistic responses were defined
as a greater than 30% induction with combined MDP and Pam3Cys treatment compared to
the additive effects of either treatment given individually. 50%, 69%, and 42% of individuals
demonstrated MDP-responsiveness, Pam3Cys-responsiveness, and synergistic responses,
respectively. These classifications were consistently observed within individuals tested on
multiple occasions. Surprisingly, neither genetic variants in the IL-10 promoter (-1082 and -
592) nor within NOD2 heterozygotes (Leu1007fsinsC, G908R and R702T) correlated with
IL-10 responses. Importantly, in synergistic responders, we observed a marked induction
of SP-1 activation by electromobility shift assay (EMSA) with combined MDP and Pam3Cys
compared to either agent alone. In contrast, synergistic induction of NF-kB by EMSA was
not observed. As expected, individuals not demonstrating an MDP/Pam3Cys-synergistic IL-
10 response showed no synergistic activation of either SP-1 or NF-kB. Finally, MDP and
Pam3Cys-synergistic induced IL-10 production was significantly reduced by p38 (70%),
JNK (60%) and Erk (40%) inhibitors. The capacity to mediate synergistic responses in IL-
10 production between the NOD2 and TLR2 pathways varies between individuals and is
associated with synergistic activation of SP-1.
S1660
Enteroinvasive E. Coli Activate P38, ERK and Jnk MAP Kinase
Phosphorylation and Functionally Regulate Intestinal Epithelial Cell
Proinflammatory Chemokine Production By Signaling Through NOD1
Yukiko Miyamoto, Martin F. Kagnoff
Nod1 is an intracellular pattern recognition molecule (PRR) that can be activated in the
cytoplasm of intestinal epithelial cells (IECs) by enteroinvasive bacteria or specific peptidogly-
can components of Gram negative bacteria, independent of activating membrane-associated
Toll-like receptors. We reported before that enteroinvasive E. coli (EIEC) signaling through
Nod1 activates IκB kinase, the transcription factor NF-κB, and NF-κB target genes in IECs.
Since many NF-κB target genes are co-regulated by the activation of MAP kinases, we sought
to determine if signaling of EIEC through cytoplasmic Nod1 activates MAP kinases and, if
so, whether this has functional implications for regulating epithelial cell functions that are
important in innate immunity. Methods: Dominant negative (DN) Nod1 and a control empty
vector (EV) were stably or transiently expressed in human intestinal epithelial cell lines.
Cells were infected with EIEC. P38, ERK and JNK MAP kinase phosphorylation were
determined by immunoblotting. Production of the neutrophil chemoattractant, CXCL8, was
measured by ELISA. Internalized EIEC were counted 1 and 24 h after infection. Results:
EIEC infection significantly activated phosphorylation of p38, ERK, and JNK MAP kinases
in human IECs. EIEC stimulated CXCL8 production was significantly inhibited by pretreat-
ment of IECs with the specific MAP kinase inhibitors PD98059 and SB203580, which inhibit
ERK and p38 activation, respectively. Importantly, MAP kinase activation in response to
EIEC infection was significantly inhibited in cells that express DN Nod1 but not empty
vector, and this was paralleled also by significant inhibition of CXCL8 production. Although
EIEC signaling through Nod1 activated major cellular signaling pathways important for cell
survival, proliferation and the production of proinflammatory mediators, a lack of signaling
through Nod 1 had little or no effect on the proliferation and survival of internalized EIEC.
Conclusion: EIEC signaling through the cytoplasmic PRR Nod1 is not restricted to NF-κB
activation, but importantly also includes the activation of p38, ERK and JNK MAP kinases.
Activation of MAP kinases through Nod1 in turn can regulate the expression of host epithelial
cell genes important in innate host defense. Pathogenic enteric bacteria that can activate
Nod1 in IECs have the ability to trigger cytoplasmic signaling pathways that parallel those
activated via TLR’s. This provides the host with an important mechanism for rapidly activating
innate immunity and other key host responses during infection with pathogenic gram-
negative bacteria that otherwise bypass signaling of membrane-associated TLR’s.
S1661
Toll-Like Receptor (TLR4) Is Essential for Expression of Antimicrobial
Peptides and Prevention of Bacterial Translocation in the Gut
Suneeta Krishnareddy, Masayuki Fukata, Anli Chen, Arielle Klepper, Maria Abreu
Background: We have recently demonstrated that mice deficient in TLR4 have increased
signs of colitis and bacterial translocation to mesenteric lymph nodes compared to wild-
type (WT) mice following dextran sodium-sulfate (DSS)-induced injury. We have also shown
that TLR4 regulates β-defensin 2 expression in vitro. We hypothesized that the expression
of β-defensins and α-defensins (cryptdins) in the gut is dependent on TLR4 signaling in
vivo. Methods: TLR4-/- and WT mice were given 2.5% DSS for 7 days then sacrificed.
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Bacterial translocation was assessed using homogenized mesenteric lymph nodes and spleens.
Expression of β-defensins, pan-cryptdins (the primers used detect cryptdins 1, 4, and 5)
and TLRs 1, 2, 3, 5, 6 and 9 in the colon and small intestine were analyzed by real-time
PCR. Results: All TLR4-/- mice exhibited bacterial translocation to mesenteric lymph nodes
and spleen, whereas only 25% of WT mice experienced bacterial translocation to MLN
(17%) or spleen (33%) and had significantly lower counts. The expression of β-defensin 2
was significantly lower (p=0.01) in TLR4-/- mice compared to WT mice. Cryptdin expression
in the ileum of TLR4-/- mice was also significantly decreased (p=0.02) compared to WT
mice (Figure 1). We next addressed whether the defect in defensin expression was related
only to the deficiency in TLR4 or could be due to other TLR defects. Rather than a decrease
in expression of other TLRs, all the TLRs tested, 1, 2, 3, 5, 6 and 9, were higher in TLR4-/-
mice compared with WT mice. Conclusion: We describe an important link between intestinal
antimicrobial peptide expression and TLR4 signaling in vivo. Despite increases in expression
of other TLRs, no alternate pathway compensates for the lack of TLR4. Functionally the
outcome may be a lack of containment of luminal bacteria in the setting of epithelial injury
and an adaptive immune response to commensal bacteria.
Figure 1
S1662
Akap13 Specifically Mediates NF-kB Signaling Through TLR2
Oren Shibolet, Shan Qin, Tobias Mueller, Ian Rosenberg, Ramnik Xavier, Daniel K.
Podolsky
Background: Expression cloning screens identified A-kinase anchoring protein 13 (AKAP13)
as an activator of NF-kB. AKAP13 is a scaffolding protein with guanine exchange factor
(GEF) activity. Examining microarray data sets using a pre-neighborhood enrichment
approach further suggested that AKAP13 may function as a regulator of Toll-like receptor
(TLR) signaling pathways. Aim: to examine AKAP13 expression in intestinal epithelial cell
(IEC) lines and to evaluate its potential role in NF-kB activation through different TLR
signaling cascades. Methods: AKAP13 expression in IEC and human intestinal biopsies was
assessed by real time RT-PCR. Functional assays comprised of NF-kB activation assays and
ELISA for secreted IL-8 and MCP-1 in native HEK293 or stable HEK-TLR2 and Hela-TLR4
cell lines. These cell lines were transiently transfected with AKAP13-GFP expression vector
or AKAP13 SiRNA followed by stimulation with specific TLR ligands. Phosphorylation of
MAP kinases, P-38, JNK and ERK was assessed using phosphorylation assays. Results: Caco2,
SW480, HT29, T84 and HCT116 IEC lines and human intestinal cells constitutively express
AKAP13 mRNA. Overexpression of AKAP13 in Hek293 cells, caused a 100±21-fold increase
in NF-kB activation as compared to empty vector while a point mutation interfering with
AKAP13 GEF activity caused a 50% reduction in NF-kB activation as compared to wild
type AKAP13. AKAP13 SiRNA but not scrambled SiRNA caused a significant 65±8% decrease
in NF-kB activation in response to the TLR2 ligand Pam3CSK4 but not to the TLR4 ligand
LPS in stable TLR2 and TLR4 cell lines respectively. This correlated with a 90% and 75%
decrease in secreted IL-8 and MCP-1 respectively in the HEK-TLR2 but not the Hela-TLR4
cell line. SiRNA to AKAP13 in HEK-TLR2 significantly decreased phosphorylation of JNK
and P-38 but not of ERK1 and 2 following stimulation. Conclusion: AKAP13 may play a
role in TLR2-but not TLR4-mediated NF-kB activation. This activation may be mediated
through AKAP13 GEF function, and identifies AKAP13 as a possible drug target in inflammat-
ory processes mediated via TLR2. The findings suggest that different GEF or scaffold proteins
may be involved in conferring specificity to innate immune responses through TLRs
S1663
Modulation of Lipopolysaccharide-Activated Human Dendritic Cells By
Muramyl Dipeptide Promotes the Development of T Helper-Type 2 Cells -
Relevance to Pathogenesis of Crohn’s Disease
Matt Butler, David van Heel, Rakesh Chaudhary, Raymond Playford, Subrata Ghosh
Background and aims: Sensing of commensal micro-organisms via toll-like receptors (TLRs)
appears to be essential for generating intestinal homeostasis in healthy individuals. Con-
versely, Crohn’s disease is characterized by an inappropriate T helper-type 1 (Th1)-mediated
adaptive immune response towards enteric flora. The nucleotide-oligomerisation domain-2
(NOD2; CARD15) protein mediates cellular responses to the bacterial peptidoglycan subunit,
muramyl-dipeptide (MDP), and activation via this receptor enhances TLR-mediated inflam-
matory cytokine responses from macrophages and dendritic cells (DCs). It is currently
unclear how defects in bacterial sensing via NOD2 lead to adaptive immune response
overdrive and Crohn’s disease. We thus investigated how MDP signalling, via NOD2, influ-
ences activation of DCs via TLRs. DC phenotype and function was determined and stimulation
of T lymphocytes was assessed. Methods: We generated monocyte-derived DCs from healthy
human donors and stimulated them for 24 hours with highly purified (lacking MDP activity)
lipopolysaccharide (LPS 0.1-100ng/ml) in the presence or absence of MDP (100ng/ml MDP-
Lys18 romurtide). The cell-surface antigens, cytokine production, and T cell stimulatory
capacity of these cells was then assayed by FACS analysis, ELISA and mixed lymphocyte

















LPS to amplify the production of cytokines IL-8, TNFα, and IL-10 whilst leaving secretion
of the Th1-inducing cytokine, IL-12p70, unaffected. Additionally, presence of MDP during
the LPS response enhanced DC expression of key co-stimulatory molecules such as CD80
(B7.1). These changes profoundly altered the cytokine profile of naïve, allogeneic, CD4+ T
cells in response to activated DCs - deviating them away from a LPS-induced Th1 response
and towards a Th2 response dominated by IL-5 and IL-13. Conclusion: This study demon-
strates, for the first time, that human DC responses to LPS can be modulated by MDP and
peptidoglycan resulting in protective, rather than inflammatory, Th2 responses. These results
may help explain why Crohn’s disease patients, carrying loss of function mutations in the
NOD2 protein, are unable to generate a balanced/homeostatic adaptive T cell response
towards normal enteric flora.
S1664
Probiotic Components Induce the Expression of Cathelin-Related
Antimicrobial Peptide Expression in Rat Macrophages: Its Role in Protection
Against Polymicrobial Sepsis
Xiao Wang, Heng-Fu Bu, Roxanne Y. Williams, Xiao-Di Tan
Cathelin-related antimicrobial peptide (CRAMP) is an effector molecule of the innate immune
system. It is expressed in phagocytes such as macrophages. Probiotics have been well studied
for its beneficial role in enhancing the host innate immune function. However, molecular
mechanisms through which probiotics modulate immunity have not been elucidated yet.
Recently, we found that oral delivery of a cell-free probiotic component (PC) results in
protection against cecal ligation and puncture (CLP)-induced sepsis (data will be presented
in Experimental Biology 2006 Meeting). In the present study, we further investigated whether
PC modulates CRAMP expression in vivo and in vitro. Briefly, we gavaged rats with PC for
5 days, isolated peritoneal macrophages (MΦs), and measured CRAMP gene expression with
real-time RT-PCR. We found that CRAMP is constitutively expressed in MΦs. Treatment
with PC in vivo resulted in a marked up-regulation of CRAMP gene expression in the
residential peritoneal MΦs. Furthermore, we demonstrated that PC directly induces CRAMP
mRNA (up to 6-fold) in MΦs in vitro. The effect was in a dose dependent manner (1-100
μg/ml). In contrast, treatment of MΦs with LPS (1 μg/ml for up to 24 hrs) only showed a
mild transient effect on CRAMP expression. The data suggested that PC is a potent enhancer
on CRAMP-related innate immune capacity in macrophages. To further explore the physiolo-
gical role of PC-induced CRAMP gene expression capacity, we examined whether the protect-
ive effect of PC against CLP-induced sepsis is correlated with CRAMP expression in tissues.
To this end, rats were divided into groups of normal control, sham-surgery, CLP, and “PC
+ CLP”. Three days after surgeries, we isolated RNA from the liver and measured CRAMP
expression with real-time PCR. Compared to the normal control group, CRAMP expression
was decreased in the liver of sham or CLP groups. In contrast, CRAMP gene expression did
not change in the group “PC + CLP”. These findings indicated that trauma or CLP causes
inhibition of CRAMP expression, whereas PC treatment preserves CRAMP gene expression
in tissues. In conclusion, our data suggested that PC up-regulates CRAMP gene expression
capacity, which may mediate the beneficial effects of probiotics. Study funding: IDPA, NIH,
Batts Family.
S1665
Polyamines Are Required for Expression of Toll-Like Receptors in Intestinal
Epithelial Cells and Involved in Regulation of Innate Immune Response
Jie Chen, Jaladanki N. Rao, Tongtong Zou, Lan Liu, Ai-Hong Zhang, Douglas J. Turner,
Jian-Ying Wang
The Toll-like receptors (TLRs) allow mammalian intestinal epithelium to detect various
microbes and activate the innate immune system after infection. Intestinal epithelial cells
(IECs) express TLR2 and TLR4, which are highly regulated in response to TLR ligands.
However, the exact mechanisms involved in control of TLR expression in IECs remain
unknown. Polyamines are implicated in a wide variety of biological functions, and regulation
of cellular polyamines has been recognized to be a central convergence point for multiple
signaling pathways driving epithelial cell functions. The current study tests the hypothesis
that polyamines regulate TLR expression in IECs and are involved in modulation of the
innate immunity. Methods: Studies were conducted in IEC-6 cells (line of rat intestinal
epithelial cells) and Caco-2 cells (line of human colon epithelial cells). Cellular polyamines
were depleted by DFMO, the specific inhibitor of polyamine synthesis, while TLR activation
was induced by challenge with lipopolysaccharide (LPS). Levels of TLR2 and TLR4 mRNAs
and proteins were examined by real-time RT-PCR and Western blot analysis. Results: Deple-
tion of cellular polyamines by DFMO decreased basal levels of TLR2 mRNA and protein,
but had no effect on expression of TLR4 in both IEC-6 and Caco-2 cells. When normal
cells (without DFMO treatment) were challenged by LPS (5 µg/ml), TLR2 expression was
increased as indicated by an induction of its mRNA and protein. Levels of TLR2 mRNA
increased 1 h after exposure to LPS, peaked at 2-4 h (~5-folds the control value), and then
began to decrease. The increases in TLR2 mRNA were paralleled by increases in its protein.
This LPS-induced expression of TLR2 was completely prevented by polyamine depletion.
There were no significant changes in levels of TLR2 mRNA and protein when polyamine-
deficient cells were challenged by LPS. Exposure of IEC-6 and Caco-2 cells to LPS did not
increase TLR4 expression regardless of the presence or absence of cellular polyamines.
Decreased expression of TLR2 in polyamine-deficient cells was associated with dysfunction
of epithelial barrier as shown by an increase in paracellular permeability. Conclusions: These
results indicate that polyamines are necessary for expression of TLR2 in intestinal epithelial
cells and play an important role in regulation of the innate immunity.
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S1666
TLR-Specific Cytokine Production By Preadipocytes and Adipocytes - Further
Evidence That Adipose Tissue Is Linked to Innate Immunity
Arvind Batra, Jeannette Pietsch, Thorsten Stroh, Rainer Glauben, Besir Okur, Inka Fedke,
Martin Zeitz, Britta Siegmund
Background: The biological significance of mesenterial fat hypertrophy in Crohn’s disease
is not understood. Recent data indicate that adipose tissue serves not only as energy storage,
but is a potent producer of a variety of cytokines, including IL-6, IL-10, TNF-α as well as
leptin. In addition, we could previously demonstrate the expression of Toll-like receptors
(TLR) on preadipocytes and adipocytes. In order to evaluate whether bacterial translocation
from the gut could result in an activation of adipocytes and preadipocytes, the responsiveness
to and leptin-dependency of TLR-specific stimulation was studied. Methods: Leptin- (ob/
ob), leptin-receptor (db/db) -deficient and WT preadipocytes originally isolated from mesent-
erial fat as well as 3T3L1 cells and adipocytes from all cell lines were stimulated with ligands
for TLR2,-3, -4, -5, -7 or TLR9 and supernatants were tested for IL-10, IL-6 and TNF-α.
The signaling pathways involved were analyzed. Results: TLR-specific stimulation of both
preadipocytes and adipocytes resulted in an induction of IL-6 synthesis. In WT preadipocytes
significant IL-6 release was induced by TLR4-specific stimulation whereas ob/ob cells
responded to ligands for TLR2, -3, and -5 as well. In addition, in db/db cells the responsiveness
was further extended by TLR7 and -9. However, stimulation of cultured preadipocytes and
adipocytes did not induce IL-10. Production of TNF-α was only moderate and solely
detectable following stimulation of BL6 and db/db cells via TLR4 and -7. Remarkably,
maturation to adipocytes resulted in a significant increase in TLR susceptibility. In particular
WT adipocytes responded to all TLR ligands tested. Notably, in the absence of leptin or
leptin signaling the IL-6 concentration was 10 to 30 times higher than in WT cells, thus
further underlining the regulatory function of leptin in the immune system. Signaling studies
revealed the PI3 kinase pathway as regulatory intersection for this hypersensitivity in ob/ob
or db/db cells. Conclusion: Our data provide strong evidence that TLR-ligands can induce
production of pro-inflammatory cytokines in adipocytes as well as preadipocytes. An observa-
tion that further strengthens the evidence that adipose tissue is linked to innate immunity
and which might be of particular importance in IBD where increased bacterial translocation
to the mesenteric fat might directly induce an inflammatory response.
S1667
IL-10 Production By Both Antigen Presenting Cells and Cd4+ T Lymphocytes
Maintains Mucosal Homeostasis
Bo Liu, Lisa Holt, R Balfour Sartor
IL-10 deficient mice develop TH1- mediated colitis and IL-10- producing regulatory T cells
suppress colitis, implicating IL-10 in maintaining mucosal homeostasis. However, the relative
role of IL-10 produced by antigen presenting cells (APC) vs. T lymphocytes in immunoregul-
ation is unknown. We studied this question by transferring T cells into IL-10 normal or
deficient recipients. Methods: SPF (specific pathogen free) Rag2-/-IL-10-/- and Rag2-/-IL-
10+/+ mice were generated and injected i.p. with 5 x 105 splenic CD4+ T cells from germ
free (GF) and SPF 129SvEv (WT) or IL-10-/- mice. Recipients were killed 6-8 wk after
transfer. Colitis was evaluated by blinded histological score and by IL-12p40 and IFN-γ
production by unfractionated MLN cells stimulated with cecal lysates. CD4+ T cell reconstitu-
tion was documented by FACS. APC function was assayed in vitro with CD4+ T cell co-
culture. Results: Rag2-/-IL-10-/- mice reconstituted with SPF WT CD4+ T cells developed
moderate colitis and immune activation (IFN-γ and IL-12p40 production by cecal bacterial-
stimulated MLN cells) and severe disease with transferred SPF IL-10-/- CD4+ T cells (Table).
Rag2-/-IL-10+/+ recipients developed moderate colitis and mild immune activation with
transferred IL-10-/- CD4+ T cells and no disease with IL-10+/+ cells. CD4+ T cells from GF
IL-10-/- mice induced more severe colitis and immune activation in Rag2-/-IL-10-/- recipients
than in Rag2-/-IL-10+/+ recipients (histology score 9.3 ± 0.3 vs. 5.1 ± 0.3; IFN-γ secretion
10.7 fold increased, 21.4 ± 2.5 ng/ml vs. 2.0 ± 0.4; IL-12 production increased 13 fold,
3.9 ± 0.3 ng/ml vs. 0.3 ± 0.03; P<0.001). GF WT CD4+ T cells transferred to Rag2-/-IL-
10-/- mice induced more colitis and increased IFN-γ production (13.1 ± 0.4 ng/ml vs. 4.3
± 0.8, P<0.001) and IL-12 secretion (2.2 ± 0.2 ng/ml vs. 0.2 ± 0.03, P<0.001) vs. Rag2-/-
IL-10+/+ recipients. IL-10-/- CD4+ T cells co-cultured with IL-10-/- APC induced more IFN-
γ production (1112 ± 147 pg/ml vs. 391 ± 25, p<0.05) and IL-12p40 secretion (1353 ±
259 pg/ml vs. 619 ± 19, P<0.05) than with IL-10+/+ APC. Conclusion: IL-10 produced by
APC plays a key role in regulating intestinal inflammation by inhibiting pathogenic T
lymphocyte responses that cause disease. IL-10 secreting CD4+ T cells are not sufficient to
regulate mucosal homeostasis in the absence of IL-10 produced by APC.
(*P<0.001 vs. Rag2-/-IL-10+/+ recipients; ^P< 0.001 & ^^P<0.05 vs.Rag2-/-IL-10+/+)
S1668
Pathological Role of Mucosal Mast Cells in a Mouse Model of Food Allergy:
New Insights from Phosphatidylinositol-3 Kinase Deficient Mice
Toshihisa Kodama, Takeshi Yamamoto, Naho Utsunomiya, Hirofumi Kuramoto, Makoto
Kadowaki
Although gastrointestinal allergic disorders have dramatically increased in prevalence over
the last several decades, the underlying mechanisms of food anaphylaxis have yet to be fully
defined. An essential question is to determine the specific cells and mediators responsible
for these disorders. METHODS: A murine model of food allergy was developed using BALB/
c mice. For induction of food allergy, a group of mice was primed with ovalbumin (OVA)
and aluminum hydroxide gel as adjuvant by intraperitoneal injection, and the occurrence
of diarrhea following repeated oral challenges with OVA in the primed mice was recorded.
Next, the colon of the food allergy mice was removed and used for myeloperoxidase (MPO)
activity analysis and for quantitative measurements of inflammatory cytokine mRNA. Further-
more, we examined the expression of mucosal mast cells in colon by immunohistochemical
analysis with an antibody against mouse mast cell protease-1 (mMCP-1; a marker of mouse
mucosal mast cell). Moreover, we made the food allergy experiments with phosphatidylinosi-
tol-3 kinase (PI3K) deficient mice (BALB/c background) selectively lacking gastrointestinal
mast cells, to compare severity of allergic symptoms and expression of mucosal mast cells.
RESULTS: Exposure of the primed mice to repeated oral OVA challenges developed allergic
diarrhea [85.4 ± 8.5% (mean ± S.E.) after six OVA challenges] and hypertrophy in the colon
associated with 2.4-fold increased MPO activities in the colon and with dramatically increased
IgE levels in sera. Th2 cytokine production (IL-4, IL-5, and IL-10) increased in the food
allergy mice compared with non-treated mice, whereas IFN-γ (Th1 cytokine) was not detected
even in the food allergy mice, suggesting that immune response is skewed toward Th2 in
the food allergy mice. All of the primed PI3K (+/+) mice developed allergic diarrhea after
six oral OVA challenges, while the primed PI3K (-/-) mice did not develop allergic diarrhea
at all. In the proximal colon, a number of mMCP-1 positive cells continued to increase
between one and six OVA challenges, inducing extensive mucosal mast cell hyperplasia. In
the food allergy experiments with PI3K (+/+) mice, OVA challenge induced a large number
of mMCP-1 positive mast cells in the proximal colon. In contrast, there were only few
mMCP-1 positive mast cells in the proximal colon of OVA-challenged PI3K (-/-) mice, while
IgE levels in sera of OVA-challenged PI3K (-/-) mice was not lower than those in PI3K (+/
+) mice. CONCLUSIONS: Mucosal mast cells and PI3K pathway in the colon play a critical
role in the onset of Th2-mediated food anaphylaxis.
S1669
Neutrophils Mediate Barrier Function in Cryptosporidium Parvum Infection
Leah M. Zadrozny, Stephen M. Stauffer, Martha U. Armstrong, Samuel L. Jones, Jody L.
Gookin
Cryptosporidium parvum (CP) is a minimally invasive pathogen of intestinal epithelium that
results in villous atrophy, nutrient malabsorption, diarrhea, and diminished barrier function.
Influx of neutrophils (PMN) is a consistent feature of human cryptosporidiosis. However, the
role of PMN in disease pathogenesis and their impact in limiting the extent of cryptosporidial
infection are unknown. The purpose of this study was to determine the effect of PMN on
epithelial defense and barrier function in CP infection. Neonatal piglets were infected with
108 CP oocysts and euthanized 4 days post-infection at which time sections of ileum were
removed for ex vivo study. PMN infiltrates and lipid peroxidation were quantified by
myeloperoxidase (MPO) activity and TBARS, respectively. Severity of infection was quantified
by histology, daily body weight and fecal consistency. PMN infiltrates were inhibited by
treatment with anti-CD18 (1mg/kg IV) or isotype control IgG (1mg/kg IV). Superoxide was
scavenged by treatment with pegylated superoxide dismutase (PEG-SOD 2000 IU/kg IV) or
PEG (0.001 mg/kg IV). Treatments were initiated at infection (day 0) and given daily until
euthanasia. Ileal mucosa was mounted in Ussing chambers for measurement of transepithelial
electrical resistance [TER] and flux of 3H-mannitol. CP infection resulted in significant villous
atrophy, lipid peroxidation (nmolTBARS/mg protein=17.4±1.8 cont; *36.3±6.4 CP, n=5-6)
and influx of PMN. Treatment with anti-CD18 antibody significantly inhibited PMN influx
(MPOactivity/gram tissue=21.7±6.8 CP+IgG; *8.9±1.9 CP+anti-CD18) but did not attenuate
lipid peroxidation or villous atrophy. Treatment with PEG-SOD significantly decreased PMN
influx into CP infected mucosa (MPO activity/gram tissue=21.7±1.6 CP+PEG; **9.9±2.1
CP+PEG-SOD). PMN depletion had no adverse effect on infection severity, diarrhea, body
weight or survival. Barrier function was significantly diminished by depletion of PMN (TER
Ω.cm2= 71±4 CP+IgG; *58±3.4 CP+anti-CD18)(Jms3H-mann=0.23±0.03 CP+IgG;
*0.31±0.05 CP+anti-CD18). There was no difference in PGE2 synthesis by mucosa from
piglets treated with IgG or anti-CD18 and barrier function could not be restored by treatment
with PGE2+PGI2. The present studies demonstrate significant infiltration of PMN into CP
infected mucosa and identify superoxide as an important stimulus for this event. PMN do
not contribute to peroxidative injury of CP infected mucosa and have no influence of the
severity of epithelial infection or diarrhea. The presence of PMN in CP infected mucosa
promotes barrier function by a mechanism independent of mucosal PGE2 synthesis.
S1670
Persistent Activation of Gastric Innate Immunity in MHC Class II-Deficient
Mice Induces Gastric Mucosal Hyperplasia Via Up-Regulation of Gastrin
Toshiro Fukui, Akiyoshi Nishio, Kazuyuki Saga, Masahiro Kido, Keiichi Kiriya, Tsutomu
Chiba
Background and aim: Major histocompatibility complex (MHC) class II-deficient mice have
decreased CD4+ T cells, thus making them immunologically similar to patients with acquired
immunodeficiency syndrome (AIDS). These patients have hypertrophic gastric folds, which
are usually associated with opportunistic infection. MHC class II-deficient mice also have
gastric mucosal hyperplasia. To clarify the mechanism of gastric mucosal hyperplasia, we
investigated the pathophysiology and the role of the innate immunity in the stomach of
MHC class II-deficient mice. Methods: MHC class II-deficient mice were maintained under
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specific-pathogen-free conditions. Stomachs from 1, 2, 3, 4, 5, and 6-month-old mice were
examined histologically and immunohistochemically (using anti-B220, CD4, CD8, CD11b,
Ki-67, gastrin, and Reg-Iα antibodies). Gene expression of interleukin-1β, interleukin-6,
interferon-γ, tumour necrosis factor-α, Toll-like receptor 2, Toll-like receptor 4, cyclooxy-
genase-2, and myeloperoxidase activity in the gastric mucosa was investigated. Serum gastrin
levels and gastric acidity were measured, and bacterial culture of the stomach was performed.
To clarify the roles of hypergastrinemia in the gastric mucosa, a gastrin receptor antagonist
(AG041R) was administered to MHC class II-deficient mice. Results: Certainly, CD4+ T
cells, but not CD8+ or B220+ cells, decreased in the spleen of MHC class II-deficient mice.
MHC class II-deficient mice had a diffusely thick corpus mucosa with infiltration of CD11b+
granulocytes and macrophages. Anti-Ki67 staining demonstrated expansion of the prolifer-
ating neck zone and, furthermore, the upper and the lower Ki-67 negative zone. Gene
expression of interleukin-1β, interferon-γ, Toll-like receptor 2, Toll-like receptor 4, and
cyclooxygenase-2 were up-regulated, and myeloperoxidase activity was increased. Only a
small amount of non-pathogenetic bacteria was detected in the stomach. Compared with
wild type mice, serum gastrin levels and Reg-Iα-positive cells in the gastric mucosa increased
in MHC class II-deficient mice despite normal gastric acidity. After treatment with AG041R,
the gastric mucosal thickness in MHC class II-deficient mice was significantly reduced
compared with the non-treated mice. Conclusion: Persistent activation of innate immunity
in the gastric microenvironment of MHC class II-deficient mice induced hyperplasia of the
gastric mucosa, and hypergastrinemia appears to be involved in the hyperplasia of the gastric
mucosa partly through Reg-Iα production, suggesting a pathophysiology similar to the gastric
changes in patients with AIDS.
S1671
Human Trefoil Factor Family-3 Induces Monocyte Production of IL-10 and
Inhibits T Cell Proliferation
Xianyang Yio, Jiang Yio, Jie-Yu Zhang, Ling Shao, Giulia Roda, Stephanie Dahan, Mark
Babyatsky, Steven Itzkowitz, Lloyd Mayer
Background: Trefoil factor family-3 (TFF3), a small peptide expressed by intestinal epithelial
cells, is involved in promoting mucosal healing by inducing epithelial cell migration and
inhibiting apoptosis. TFF3 knockout mice are highly susceptible to colitis caused by acute
injury. TFF3-producing intestinal epithelial cells are located in close proximity to lymphocytes
and previous studies demonstrated that TFF3 could induce monocyte migration. Little is
known about whether TFF3 might affect other monocyte functions. Aim: To test whether
TFF3 affects functions of monocytes, including migration, antigen presentation and cytokine
production. Methods: Recombinant human TFF3 (hTFF3) was produced. Mixed lymphocyte
reactions (MLR) and antigen specific (candida) lymphocyte proliferation were performed in
the presence or absence of varying concentrations of hTFF3. Normal peripheral blood
monocytes were treated with hTFF3 and cytokine production was analyzed by RT-PCR and
ELISA. Results: Similar to previous observations, hTFF3 (20-40 ug/ml) induced peripheral
blood monocyte migration. T cell proliferation was significantly inhibited in an MLR using
monocytes/DCs pretreated with hTFF3 at doses of 40 to 100 ug/ml. Similarly, hTFF3
inhibited candida-specific T cell proliferation. hTFF3 also inhibited LPS-induced IL6, IL1-
beta and TNF-alpha production by peripheral blood monocytes and a human monocyte
hybridoma, clone 63 (RT-PCR). Importantly, hTFF3 induced IL-10 production by peripheral
blood monocytes by ELISA and RT-PCR. In fact, hTFF3 treatment resulted in dramatic 20
to 120 fold increases in IL-10 production (28.3-159.3 pg/ml in untreated cells vs. 3309-
3465.6 pg/ml in treated cells). Furthermore, addition of anti-IL-10 receptor antibody reversed
the inhibitory effects of hTFF3, suggesting that the induction of IL-10 secretion in monocytes
likely mediates TFF3’s inhibitory effect. Conclusions: TFF3 is able to regulate immune
responses by altering cytokine production in monocytes. This inhibition of lymphocyte
proliferation most likely occurs via induction of IL-10 secretion. TFF3 may therefore contrib-
ute to the overall suppressed immunologic tone in the gut and contribute to an anti-
inflammatory immune response. (Sponsored in part by the AGA Centocor Excellence in
IBD Clinical Research Fellowship and CCFA grant).
S1672
Characterization of Potential Role of NADPH Oxidase Organizer 1 (NOXO1)
in Oxygen Radical-Dependent Immune Responses of Large Intestinal
Epithelial Cells
Kazuhito Rokutan, Yuki Kuwano, Kumiko Tominaga, Hideyuki Sasaki, Kensei Nishida,
Kiyoshi Masuda, Atsuo Sekiyama, Shigetada Teshima-Kondo
Reactive oxygen species regulate a variety of pathophysiological processes including hormone
biosynthesis, regulation of cell growth, atherosclerosis, and host defense. NADPH oxidase
1 (Nox1) is known as a novel superoxide-generating enzyme predominantly expressed in
surface mucous epithelial cells of the human colon. We have already shown that human
colonic epithelial cells (T84 cells) induces Nox1 and up-regulates superoxide production
in response to flagellin from Salmonella enteritidis (J Immunol, 2004) or IFN-gamma (Am
J Physiol, 2005). Although flagellin, IL-1-beta, IFN-gamma, and tumor necrosis factor (TNF)-
alpha similarly induced Nox1, TNF-alpha was the most effective activator for up-regulation
of superoxide generation by T84 cells. Recently, a novel adaptor protein, Nox organizer 1
(NOXO1), has been identified and recognized as one of the essential factors required for
Nox1 activity. Interestingly, NOXO1 was induced only when treated with TNF-alpha,
suggesting a crucial role of NOXO1 in the cytokine-triggered oxygen burst response of the
cells. To elucidate the mechanisms for TNF-alpha-stimulated transcription of the NOXO1
gene, we cloned 5’-franking region of the human NOXO1 gene. The promoter region contains
putative binding sites for several transcriptional factors, such as nuclear factor-kappaB, Sp1,
AP-1, and Ets. The promoter assay and EMSA indicated that AP-1 mainly regulated TNF-
alpha-dependent transcription of the NOXO1 gene. In fact, AP-1 oligonucleotide decoys
completely blocked the TNF-alpha-stimulated NOXO1 transcription and supreoxide produc-
tion. TNF-alpha is known as a key mediator involved in the pathogenesis of inflammatory
bowel diseases particularly in Crohn’s disease. We also confirmed that the expression of
Nox1 and NOXO1 was significantly up-regulated in the inflamed tissues of Crohn’s disease.

















result in chronic, persistent inflammation and may play a pivotal role in the pathogenesis
of Crohn’s disease.
S1673
Inhibition of Interleukin-1β Release from Monocytes By Human α-Defensins
Jishu Shi, Shelly Aono, Wuyuan Lu, Xueyou Hu, Christine Dyskstra
Although it has been well established that mutations in Nod2 increase susceptibility to
Crohn’s disease (CD), the role of Nod2 in the pathogenesis of CD remains elusive. Recent
studies on human patients and Nod2 knock-in mice have demonstrated that variants of
Nod2 are associated with decreased intestinal expression of antimicrobial α-defensins but
excessive secretion of interleukin 1β (IL-1β). However, mechanisms by which Nod2 muta-
tions lead to the up-regulation of IL-1β secretion have yet to be established. The present
study was designed to test our hypothesis that reduced intestinal expression of human α-
defensins is responsible for the over-production of IL-1β in patients with CD. LPS-activated
(20 ng/ml, 2 h), 35S-methionine-labeled (1 h) human monocytes were treated with human
α-defensin HNP-1 or HD-5 in the presence or absence of 1 mM ATP for 3 h. Media and
cell-associated fractions were harvested separately and IL-1β was recovered from each by
immunoprecipitation. The resulting immunoprecipitates were analyzed by SDS-PAGE and
autoradiography. In the absence of 1 mM ATP, LPS-activated monocytes released about
10% of 35S-labeled proIL-1β(31kDa) into the media, but no mature IL-1β (17 kDa) was
detected in extracellular milieu. The release of proIL-1β from LPS-activated monocytes was
completely blocked by 10 μg/ml of HNP-1 or HD-5. Addition of 1 mM ATP to LPS-activated
monocyte culture led to the release of 90% of newly synthesized proIL-1β from the cell
and more than 90% of that was processed to mature IL-1β and detected in the media. At
physiological concentrations (5 μg to 100 μg/ml), both HNP-1 and HD-5 blocked ATP-
mediated proIL-1β release in a dose-dependent manner. These data have demonstrated that
α-defensins may function as negative regulators of the posttranslational processing and
release of IL-1β. In addition to their antimicrobial activity, defensins may play an important
role in intestinal inflammation by controlling the production of IL-1β. Therapeutic
approaches aimed at blocking IL-1β production by defensins could lead to the reduction
of intestinal inflammation and tissue destruction in inflammatory bowel disease.
S1674
What Is the Function of Metaplastic Paneth Cells?
Jan Wehkamp, Nita Salzman, Bo Shen, Marko Estrada, Christian Leutenegger, Charles L.
Bevins
Introduction: Paneth cells (PCs) are secretory epithelial cells of the small intestinal mucosa
and a major source of antimicrobial peptides including the α-defensins HD5 and HD6,
lysozyme, and sPLA2. In the small intestine, these antimicrobials likely protect from ingested
pathogens and may regulate the intestinal microflora. In the presence of inflammation, PCs
can be also found outside the small intestine, in a well described process termed PC
metaplasia. Since virtually nothing is known about the function of metaplastic Paneth cell,
this study aimed to directly test the possible effects of metaplastic Paneth cells on the luminal
crypt microbiota. Methods: We analyzed colonic samples from FvB mice with a dextran
sodium sulfate (DSS)-induced experimental colitis. Mice were treated with DSS (1-2.5%)
and monitored at various time-points by anti-lysozyme immunohistochemistry to detect
metaplastic Paneth cells in the colonic crypts. Individual crypts, either positive or negative
for metaplastic Paneth cells from the same mouse were separately isolated using laser capture
microscopy. The isolated crypts were used for extraction of bacterial DNA. For quantification
of bacteria we used a real-time TaqMan assay which detects bacterial 16S RNA (common
motif), as well as one assay for quantification of fungi. Results:. In contrast to mice with
experimental colitis, we could not identify metaplastic Paneth cells in the colon of untreated
healthy mice. Using laser capture microscopy, we could isolate detectable amounts of bacterial
DNA in colonic crypts. In the presence of metaplastic Paneth cells (n=3), the crypts contained
significantly lower numbers of bacterial DNA (p=0.03) and fungi DNA (p=0.04) as compared
to crypts without Paneth cells from the same mouse colon (n=3). Conclusions: The presence
of metaplastic Paneth cells has a functional impact on the microbiota of colonic crypts. This
suggests that a function of Paneth cell metaplasia is to recruit antimicrobial defenses to sites
of inflammation, and as such it represents a novel mechanism of mucosal innate immunity.
Current studies are examining the bacterial species within the crypts to determine if the
metaplastic Paneth cells selectively alter the composition of the local microflora.
S1675
Interleukin-8 (IL-8) Is a Critical Signal in Intestinal Epithelial Cell-
Macrophage Cross-Talk
Akhil Maheshwari, Lesley E. Smythies, Ronnie Clements, Yolanda Hartman, Meg
Mosteller-Barnum, Phillip D. Smith
Background: Macrophages are an important host defense cell in both non-inflamed and
inflamed intestinal mucosa. We published recently (JCI 2005; 115: 66) that intestinal extra-
cellular matrix (stromal) products downregulate the inflammatory, but not host defense
activity of monocytes newly recruited to the mucosa, thereby inducing an intestinal macroph-
age function and phenotype profile. The mechanisms involved in the recruitment of blood
monocytes are not known. Since intestinal epithelial cells (IECs) produce IL-8 upon exposure
to a variety of bacterial products, we hypothesized that IL-8, a known chemoattractant and
activator of neutrophils, also acts as an important signal in the ‘cross-talk’ between IECs
and mononuclear phagocytes in the mucosa. Therefore, we investigated whether IL-8
recruited and activated blood monocytes and/or intestinal macrophages and whether IL-8
enhanced the cells’ phagocytic activity. Methods: Blood monocytes were purified by magnetic
bead (MACS) separation or counterflow centrifugal elutriation. Human intestinal macro-
phages were isolated by enzyme digestion of jejunal tissue followed by elutriation. Lamina
propria stroma (1 gm/mL) was cultured in RPMI for 24 hrs to harvest stroma-conditioned
media (S-CM). S-CM IL-8 concentrations were measured by ELISA (n = 7). Monocyte
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migration to IL-8 and S-CM was measured in a fluorescence-based microchemotaxis assay.
Monocyte and macrophage phagocytic activity for FITC-labeled latex microbeads and GFP-
expressing E. coli was measured before and after treatment with IL-8 for 1 hr. Results: We
first showed that blood monocytes and intestinal macrophages express CXCR1 (65±15% of
macrophages, 51±13% of monocytes) and CXCR2 (13.8±6% of macrophages, 59.4±16% of
monocytes), the cognate receptors for IL-8. IL-8 was detected in S-CM (208-1018 pg/mg
protein). Monocytes, but not macrophages, displayed migratory activity to IL-8 and S-CM.
S-CM-induced monocyte chemotaxis was significantly inhibited by anti-IL-8 antibody and
also by pre-treatment of monocytes with S-CM to ligate the IL-8 receptors. In addition,
IL-8 treatment also increased the phagocytic activity of monocytes as wells as intestinal
macrophages (up to 300%). Conclusion: IL-8 is a potent chemoattractant for blood monocytes
and an activator of phagocytic activity of both monocytes and intestinal macrophages. The
ability of stromal IL-8 to recruit blood monocytes supports the role of this cytokine in the
‘cross-talk’ between IECs and mononuclear phagocytes in the intestinal mucosa. These
findings are the first to expand the IL-8-neutrophil paradigm to include the mononuclear
phagocyte system.
S1676
Expression of Human Defensin-5 in Inflammatory Bowel Disease Tissue
David A. Elphick, Patrick Tighe, Susan Liddell, Yashwant R. Mahida
Introduction: Human defensin-5 (HD-5) is a major antimicrobial peptide which is present
in the lumen in its mature form but stored in normal small intestinal Paneth cells in its
precursor form. Alterations in the expression of HD-5 in Paneth cells of Crohn’s small
intestine or metaplastic Paneth cells of colon affected by inflammatory bowel disease (IBD)
may lead to impaired mucosal innate immunity. Methods: Surgical resection specimens of
terminal ileum (6 normal, 7 Crohn’s disease) and colon [4 normal, 2 Crohn’s disease & 5
ulcerative colitis (UC)] were studied. Tissue sections were used for immunohistochemistry.
Paneth cell-containing epithelial crypts were detached from mucosal strips with EDTA. HD-
5 was purified from acid extracts of epithelial crypts using cation-exchange chromatography
and C18 RP-HPLC, using anti-HD-5 antibody to identify fractions containing the alpha-
defensin. Purified HD-5 was characterised by mass spectrometry and N-terminal amino acid
sequencing. HD-5 isolated from normal and IBD tissue was also studied by acid-urea Western
blot analysis. Genotyping for the 3 single nucleotide polymorphisms (SNPs) in the NOD2
gene that have been associated with Crohn’s disease (SNP8/R702W, SNP12/G908R, SNP13/
1007fs) was also performed. Results: Immunohistochemical studies showed that HD-5 was
expressed predominantly in Paneth cells in normal terminal ileum and in IBD tissue, but
absent in normal colon. On acid-urea Western blot analysis of purified HD-5 from normal
small bowel (6), Crohn’s small bowel (7) and IBD colon (7), identically sized immunoreactive
bands were seen. Purified HD-5 from the different tissue types had a similar elution profile
on the C18 RP-HPLC column (39% acetonitrile). Identical N-terminal sequence (ESLQERA-
DEAT, the precursor form) was found for HD-5 extracted from Crohn’s small intestine (2),
UC colon (2) and normal terminal ileum. In addition to detecting the mass predicted for
the precursor form (8102 Da) in all the purified HD-5 samples tested, preparation from
one Crohn’s sample also contained similar amounts of HD-5 precursor truncated by 6 amino
acids (sequence: ADEAT, mass 7360 Da). The mature form of HD-5 was not detected in
any of the samples studied. One Crohn’s disease patient was homozygous for SNP13, one
heterozygous for SNP8 and one heterozygous for SNP12. Conclusions: In our studies to
date, in Paneth cells of Crohn’s small intestine and in metaplastic Paneth cells of IBD colon,
there was no evidence of processing of HD-5 to the mature form. Significant amounts of a
truncated form of HD-5 was identified in Paneth cell extracts of one patient with ileal
Crohn’s disease.
S1677
Human Defensin Alpha 1 (DEFA1) Expression and Interaction Are Associated
with Nucleotide Oligomerization Domain 2 (NOD2/CARD15)
Jesus K. Yamamoto-Furusho, Daniel K. Podolsky
Backgroud: DEFA1 has a broad spectrum of antimicrobial activity against bacteria, fungi,
and some enveloped viruses by perforating the cell membrane through formation of multim-
eric pores. NOD2 is a cytoplasmic protein expressed in several cell types and leads to
Nuclear Factor kappa B (NF-κB) activation as a result of intracellular recognition of muramyl
dipeptide (MDP) from bacteria. Aims: To determine the effect of Nod2 on DEFA1 expression
and to evaluate interaction between these two proteins. Methods: Immunoprecipitation and
Western blot: HCT116 cells lysate were immunoprecipitated with anti-NOD2 or anti-DEFA1
polyclonal antibodies and protein A/G sepharose beads. NF-kB activation assay: HEK293
cells were transfected with DEFA1 at different concentrations, NOD2 (1ng), pIV luciferase
reporter, renilla plasmid and MDP-LD. Real-time RT-PCR was done in an ABI Prism 7000
sequence detector using SYBR Green JumpStart detection system. Immunostaining was
performed in COS-7 cells using Texas-Red-conjugated anti-mouse IgG or FITC-conjugated
anti-rabbit IgG antibodies. Invasion assay: Gentamicin protection assay using Salmonella
typhimurium was performed in Caco-2 cells. Results: Expression of DEFA1 was minimal
in Caco-2 and HEK293 cells which lack endogenous NOD2 protein in contrast to high
expression of DEFA1 in cells with NOD2 endogenous expression such as HCT116 and
SW480 cells. A direct interaction between DEFA1 and NOD2 proteins was confirmed by
immunoprecipitation. DEFA1 colocalized with NOD2 in the cytoplasm of COS-7 cells.
DEFA1 increases the NF-kB activation concentration-dependant in HEK293 cells co-trans-
fected with NOD2 and DEFA1 constructs and stimulated with MDP-LD. Transfection with
DEFA1 siRNA significantly decreased the MDP driven response to NOD2. The invasive
ability of Salmonella typhimurium showed antibacterial activity. DEFA1 mRNA expression
was increased in involved areas from mucosa of UC and CD patients as compared to control
patients. Conclusion: Human DEFA1 associated with NOD2 mediated NF-κB activation in
colonic epithelial cell lines.
S1678
Cyclooxygenase-2 Regulates Toll-Like Receptor 2 On Intestinal Epithelial Cells
Shinichiro Shinzaki, Hideki Iijima, Satoshi Egawa, Shuji Ishii, Takanobu Irie, Tsutomu
Nishida, Yoshimi Kakiuchi, Masakazu Yasumaru, Hiroaki Murata, Tatsuya Kanto,
Masahiko Tsujii, Shingo Tsuji, Sunao Kawano, Norio Hayashi
Background: COX-2 expression and COX-2-derived prostaglandins (PGs) are reported to
affect immune function, but the contribution of COX-2 to regulate mucosal immunity in
inflammatory bowel disease(IBD) is undefined. On IECs, Toll-like receptors (TLRs) are
expressed and play an essential role on the innate immune system by activation of specific
signaling pathways and production of inflammatory cytokines and chemokines. Although
TLRs, e.g.,TLR2, TLR4 and TLR5 that recognize luminal bacterial surface components, are
reported to contribute to the pathogenesis of IBD, the mechanisms how the expression of
TLR and TLR-mediated signaling are regulated are still unclear. Aim: We investigated the
possibility that COX-2 regulates the TLR expression and TLR-mediated signaling pathways.
Method: The expressions of TLR mRNA were determined by quantitative RT-PCR in two
intestinal cell lines, Caco-2 which express low baseline level of COX-2 and HT-29 which
express large amount of COX-2. These cells were modified to overexpress or inhibit the
production of COX-2 by stable transfection of COX-2 or knock down by RNA interference
(RNAi). COX-2-transfected Caco-2 (Caco-2-COX-2) cells and the mock cells were stimulated
by Pam3CSK4, selective ligand for TLR2, and production of interleukin(IL)-8 in the culture
supernatant was measured by ELISA. Caco-2 cells were stimulated by prostaglandin(PG)E2,
and expression of TLR2 mRNA and IL-8 production was evaluated. Results: The level of
TLR2 expression was significantly higher in Caco-2-COX-2 cells when compared with Caco-
2-mock cells. In addition, the TLR2 expression was significantly decreased when COX-2
was knocked down by RNAi in the HT-29 cells in comparison to the original HT-29 cells.
Treatment of Caco-2-COX-2 cells with etodolac, a selective COX-2 inhibitor, resulted in
decrease of TLR2 expression, whereas treatment of Caco-2 cells by PGE2 increased TLR2
expression in a dose dependent manner. Ligation of TLR2 by Pam3CSK4 in Caco-2-COX-
2 cells which express high TLR2 induced significantly increased level of IL-8 production
than in Caco-2-mock cells. Production of IL-8 by stimulation of TLR2 was significantly
increased by the presence of PGE2 and the effect was dose-dependent of PGE2. Conclusion:
These results suggest that COX-2 and PGE2 regulate the expression of TLR2 and its down-
stream IL-8 production in the IECs. Controlling the TLR2 pathway by COX-2 or PGE2 will
be therapeutic benefit for IBD.
S1679
Neutrophil Activation and Neutrophil Extracellular Trap Formation in
Inflammatory Bowel Disease
Gareth Parkes, Simon Clare, David Goulding, Neil Rayment, Barry Hudspith, Jonathan
Brostoff, Gordon Dougan, Jeremy Sanderson, Liljana Petrovska
INTRODUCTION: Neutrophils play key role in killing bacteria at the early stages of infection.
Contact with microbes activates neutrophils and induces formation of neutrophil extracellular
traps (NETs) which are involved in entrapment of bacterial and prevention of bacterial
spread, and neutralisation of the virulence factors. However, various models of injury
suggested that neutrophils are a major contributor to gastrointestinal injury. NET formation
has been demonstrated in vitro and in murine models of colitis but never in vivo in humans.
AIMS: To investigate neutrophil activation and NETs formation in active inflammation in
patients with Crohn’s and Ulcerative Colitis. METHODS: Snap-frozen colonic biopsies were
taken from 10 patients with UC and Crohn’s diseas from inflammed and uninflammed areas
and 5 subjects with a normal colon, undergoing colonoscopy. Cryosections were stained
by two-colour immunofluorescence to determine the expression of activation molecules on
neutrophils. Bacteria colocalised with NETs were detected in cryosections with fluorescent
in situ hybridization (FISH) and with 16S ribosomal (r)RNA-targeted probes for all bacteria
and specific probes for the major representatives of anaerobic microflora (bifidobacteria,
Bacteroides, clostridia, atopobia) and aerobic microflora (Enterobacteriaceae, enterococci,
streptococci, lactobacilli). RESULTS: Actively inflamed IBD mucosa showed formation of
neutrophilic extracellular traps expressing myeloperoxidase and DNA. Disease controls (unin-
flammed mucosa) and normal individuals showed no NET formation. Active formation of
NETs co-localised with the luminal bacteria in the actively inflamed mucosa. NET formation
was also confirmed by scanning electron microscopy which confirmed bacterial colocalisation.
CONCLUSIONS: Neutrophil extracellular traps are formed and co-localise with luminal
bacteria in actively inflamed mucosa in IBD patients. The possible effect of NETs on prevention
or induction of gut mucosal injury is a field that warrants further investigation.
S1680
The Anti-Inflammatory Flavonoid Luteolin Attenuates Spontaneous Colitis in
IL-10-/- Mice But Worsens Chemical-Induced Colitis in Nf-κBegfp Transgenic
Mice
Thomas Karrasch, Byung-Ik Jang, Christian Jobin
Introduction: The flavonoid luteolin has anti-inflammatory properties both in vivo and in
vitro. Recently, we showed that luteolin prevents LPS induced NF-κB signaling and pro-
inflammatory gene expression through inhibition of IKK activity. However, the impact of
this flavonoid on experimental models of colitis is unknown. Aim: To establish the therapeutic
value of luteolin in the dextran sodium sulfate (DSS) and in the IL-10-/- model of acute
and chronic experimental colitis, respectively. Methods: NF-κBEGFP mice (7/group) were
fed 3% DSS in drinking water or water control for 5 days, and luteolin was administered
intragastrically (1mg/Kg body weight) daily. In a different set of experiments, germ-free IL-
10-/- mice (10/group) were transfered to a specific pathogen free environment and fed a
diet chow containing 2% luteolin or isoflavone free control chow (AIN-76) for 4 weeks.
The colons were resected and imaged using a CCD camera specific for EGFP. MAPKp38,
RelA and H3Ser10 phosphorylation were evaluated in isolated primary enterocytes by West-
ern blotting using specific phospho-antibodies. IEC18 cells were grown to confluency and
subjected to standard wounding. Results: NF-κBEGFP mice exposed to luteolin showed a
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trend toward worse DSS-induced colitis (disease activity index, histological scores, IL-12p40
secretion) compared to non-treated mice. In addition, EGFP expression (NF-κB activity) was
increased in luteolin-treated mice as compared to control as visualized by CCD fluorescence
macroscopy. Interestingly, confocal microscopy showed that EGFP positive cells were mostly
located in the lamina propria and not in the epithelium. Enhanced MAPKp38 and H3S10
phosphorylation in enterocytes isolated from DSS-exposed mice was attenuated in luteolin
treated NF-κBEGFP mice compared to control treated mice. Interestingly, in vitro experiments
showed that restitution was attenuated (63% of control, p<0.001) in luteolin-treated IEC-
18 cells, suggesting a negative impact of this flavonoid on the wound-healing response. In
contrast, luteolin (2% diet) prevented the development of spontaneous colitis in IL-10-/-
mice (histological evaluation, macroscopy) compared to AIN-76 fed mice. In addition, Rel-
A phosphorylation was decreased in colonic tissues isolated from luteolin-fed IL-10-/- mice.
Conclusion: We conclude that flavonoids such as luteolin may represent an attractive adjuvant
in the treatment of immunologically driven colitis. However, caution should be exerted in
gastrointestinal disorders involving a compromised barrier function or dysregulated wound-
healing response.
S1681
Novel Role for Chronic Stimulation of NOD2 in Mediating Tolerance to
Bacterial Products
Matija Hedl, J.N. Li, Judy Cho, Clara Abraham
The Toll-like receptor (TLR) and nucleotide-binding oligomerization domain (Nod) family
of proteins are critical for the recognition of bacterial products by the immune system which
frequently leads to pro-inflammatory responses. Loss-of-function Nod2 polymorphisms have
been associated with Crohn’s disease. To date, studies have examined consequences of acute
stimulation of Nod2. As the intestine is an environment of tolerance to chronic commensal
bacterial exposure, we hypothesized that long-term stimulation of Nod2 might contribute
to enteric tolerance to bacteria by suppressing inflammatory responses from innate immune
receptors. We find that pre-treatment of primary human monocyte-derived macrophages
with muramyl dipeptide (MDP), a ligand specific for Nod2, significantly decreased the
production of the pro-inflammatory cytokines TNF-alpha, IL-8 and IL-1-beta upon Nod2
as well as TLR4 and TLR2 re-stimulation in a time-dependent fashion. Importantly, TNF-
alpha-induced production of proinflammatory cytokines remained intact in these same cells,
demonstrating selectivity in Nod2-mediated tolerance pathways. MDP-stimulated macro-
phages from Crohn’s disease-relevant Leu1007insC Nod2 homozygote individuals were
deficient in their ability to cross-tolerize to subsequent treatment with TLR2 or TLR4 ligands.
The Nod2-induced tolerance is not the effect of Nod2, TLR2 or TLR4 downregulation.
Significantly, intestinal macrophages exhibit tolerance to MDP-induced cytokine production,
but are still able to phagocytose bacteria. These results illustrate a novel role for Nod2 in
mediating tolerance to bacterial products.
S1682
Extracellular Pressure Stimulates Macrophage Phagocytosis Via a Pathway
Involving Phosphoinositide 3-Kinase, Akt2, FAK, ERK, and P38
Hiroe Shiratsuchi, Marc D. Basson
Increased intestinal pressure is characteristic of chronic inflammatory bowel disease, and
changes in tissue pressure are associated with infection and inflammation. We have previously
demonstrated that low extracellular pressure (20 mmHg), equivalent to normal interstitial
tissue pressure, increases phagocytosis by primary human monocytes and macrophages and
PMA-differentiated human monocytic THP-1 cells, in part by FAK and ERK inhibition and
p38 activation. PI-3K (phosphoinositide 3-kinase) is known to be required for macrophage
phagocytosis through Fc-receptors, but whether the effect of pressure on complement recep-
tor-mediated phagocytosis requires PI-3K is not known. Furthermore, relatively little is
known about the role of PI-3K downstream kinases such as Akt in modulating macrophage
phagocytosis. Using PMA-differentiated THP-1 macrophages, we studied the contribution
of PI-3K, and the downstream kinase Akt to the pressure-increased macrophage phagocytosis
that occurs through complement receptors independent of Fc-receptors. Exposure to extracel-
lular pressure induced p85 PI-3K translocation from cytoplasmic to membrane fractions
and increased Akt phosphorylation by 36.1 ± 12.0% in THP-1 macrophages. Pretreatment
with the PI-3K inhibitor LY294002 (40μM) or Akt inhibitor IV (cell-permeable benzimidazole
compound) (10 μM) abrogated increased phagocytosis by pressure but did not affect basal
phagocytosis. Basal Akt phosphorylation was inhibited 90% by LY294002 and 70% by Akt
inhibitor IV and both inhibitors prevented Akt activation by pressure. LY294002 decreased
basal FAK-Y397 phosphorylation by 20% but increased basal ERK and p38 phosphorylation
1.5 fold. LY294002 prevented pressure-induced inhibition of FAK-Y397 and ERK phos-
phorylation and activation of p38. Transfection with Akt1SiRNA or Akt2SiRNA reduced
total Akt1 and Akt2 expression by 40% and 50-60%, respectively. Akt1SiRNA tended to
reduce basal, but did not affect pressure-induced THP-1 macrophage phagocytosis. On the
other hand, Akt2SiRNA did not affect basal phagocytosis, but abrogated pressure-mediated
phagocytosis. Changes in tissue pressure during infection and inflammation may regulate
macrophage phagocytosis by activation of PI-3K, which activates Akt2, inhibits FAK and
ERK, and activates p38 in response to this stimulus. In contrast, basal phagocytosis may be
more closely regulated by Akt1.
S1683
High Fat Diets Exacerbate Dextran Sulfate Sodium (DSS) Induced Colitis in
Mice By Altering Non-Classic Nkt Cells and Regulatory T Cells
Xiong Ma, Zhiping Li
BACKGROUND: Among current theories of the pathogenesis of inflammatory bowel disease
(IBD), the balance between effector T cells and regulatory T cells (Treg) plays an important
role in regulating mucosal inflammation. In addition, environmental factors, such as diet,

















fat diet is a risk factor of IBD. The aim of this study was to understand the mechanisms by
which high fat diet regulates intra-epithelial T cells, and in turn change the susceptibility
to mucosal inflammation. METHODS: Wild type C57BL6 mice were fed commercial high
fat diets (59% of calories from fat) for 6 weeks. Control mice received an isocaloric volume
of normal diets that contains less fat (12% of calories from fat). Intraepithelial lymphocytes
(IEL) were isolated from the large intestine by Percol gradient. The IEL phenotype and
cytokines profile were analyzed by flow cytometry. Then, mice were subjected to 2.5% (w/
v) DSS in drinking water. Animal weight, rectal bleeding and colonic inflammation were
monitored. RESULTS: Mice fed high fat diet have increased colonic NKT cells. Unlike classic
invariant NKT cells that are primarily either CD4+ or CD4-CD8- and restricted by CD1,
the colonic NKT cells are mostly CD8+ and CD1 independent. They express tumor necrosis
factor (TNFa) and interferon (IFNγ), which are increased in high fat diet mice. Mice fed high
fat diet also have decreased colonic Treg cells (CD4+CD25+Foxp3+) with less proliferation, as
reflected by decreased BrdU incorporation. High fat fed mice have more severe DSS-induced
colitis, as reflected by more weight loss, worse rectal bleeding and more severe colonic
inflammation. Depletion of colonic NKT cells, or adoptive transfer of Treg cells improves
colitis in these mice. Foxp3-/- mice that lack Treg cells also have increased colonic CD8+NKT
cells. Adoptive transfer of Treg cells does not reduce CD8+NKT cells in high fat fed mice.
However, adoptive Treg cell transfer does reduce CD8+NKT cell expression of TNFa and
IFNγ in mice fed high fat diets. CONCLUSIONS: High fat diets alter colonic NKT cells and
Treg cells and lead to increased susceptibility to DSS-induced colitis. This may provide one
mechanism how environmental factors, i.e. diet, may cause increased the susceptibility
for IBD.
S1684
Alterations in Human Defensin-5 (HD-5) Expression Following Gastric Bypass
Surgery
David A. Elphick, Magnus Sundbom, Yashwant R. Mahida, Robert N. Cunliffe, Tore
Midtvedt, Lars Engstrand, Sven Gustavsson, Lars-Goran Axelsson
Introduction. After Roux-en-Y gastric bypass surgery all ingested food will pass directly
(from the esophagus) into the small bowel intestine. Thus, it provides a novel human model
to investigate small bowel mucosal innate immunity, in which there is loss of gastric acid-
mediated protection against orally-acquired microorganisms. We have studied changes in
jejunal mucosal HD-5, which is an antimicrobial peptide normally produced by Paneth cells.
Methods. Mucosal samples were obtained from 18 female patients (24 - 54 yrs), from the
same segment of jejunum during and after (at endoscopy) gastric bypass surgery. Samples
were used for bacterial culture and immunohistochemistry using anti-HD-5 antibody. The
number of immunoreactive cells per crypt and villus were determined and expressed as
mean (SD). Results. No bacteria were cultured from any of the peri-operative jejunal samples
but colonies of bacteria normally present in the pharynx were identified during culture of
all post-operative jejunal biopsies (1 - >100 colonies). Paneth cell numbers per crypt were
unchanged after gastric bypass [4.16(0.71) v 4.24(0.78)]. However, following surgery, there
was an increase in: HD-positive intermediate cells per crypt [0.25(0.41) v 1.12(0.66),
p<0.01), HD-5 staining enterocytes per crypt [0.31(0.09) v 1.38(1.10), p<0.01], HD-5
staining material in the crypt lumen [crypt lumens: 5.0(10.9)% v 68.1(27.9)%, p<0.01] and
HD-5 immunoreactivity coating the luminal surface of villus enterocytes [villi sampled:
15.0(31.0) % v 67.5(42.0) %, p<0.01]. Conclusions. 1. Bacteria normally resident in the
pharynx were present in the proximal jejunal mucosa following Roux-en-Y gastric bypass
surgery. 2. After gastric bypass, there was increased secretion of HD-5 and an increase in
HD-5 expressing intermediate cells and enterocytes in the crypt. 3. The increase in HD-5
expression in the jejunal mucosa following gastric bypass surgery is likely to be secondary
to exposure to orally-acquired microorganisms.
S1685
The Role of Endogenous and Pharmacological Pparγ Agonists On Restoration
of Colonic Homeostasis After Acute Stress-Induced Inflammation and
Dysfunction
Javier R. Caso, Angel Ponferrada, Luis Alou, David Sevillano, Maria L. Gomez-Lus, Arturo
L. Colon, Ignacio Marin-Jimenez, Maria A. Moro, Ignacio Lizasoain, Pedro Lorenzo, Pedro
Menchen, Enrique Cos, Juan C. Leza, Luis Menchen
Background and aims: Psychosocial stress has been implicated in the clinical course of
gastrointestinal diseases such irritable bowel syndrome and inflammatory bowel disease, but
the mechanisms implicated and the effects of stress on the normal colon are not yet fully
understood. Methods: Male young-adult Wistar rats were exposed to immobilisation stress
(6 hours periods every day during 1, 5 or 10 days). After that, colon was dissected and
processed for biochemical and protein expression studies, including myeloperoxidase (MPO)
activity, inducible nitric oxide synthase (NOS-2) and cyclooxygenase (COX-2) expression
and activities (NO-x and PGE2/15d-PGJ2 respectively), peroxisome proliferator activated
receptor gamma (PPARγ) expression, immunoglobulin A (IgA) levels and nuclear factor
kappa B (NFκB) nuclear translocation. Mesenteric lymph nodes, spleen and liver were
processed and cultured to assess bacterial translocation. Colonic permeability to 51Cr-EDTA
was also evaluated. Results: After 1 day of immobilisation stress, significant weight loss,
increase in MPO activity, NFκB nuclear translocation, increase in NOS-2 expression and
activity and in COX-2 expression were observed in the colonic mucosa. All these parameters
returned to baseline values after 10 days of stress exposure, in parallel to an increase, starting
at day 5, of anti-inflammatory prostaglandin 15d-PGJ2 levels and PPARγ expression. IgA
levels in homogenised colonic mucosa were significantly decreased after 1 day of stress,
returning to baseline values after 10 days. No bacterial translocation was observed in control
animals, but it reached maximal levels in terms of colony forming units per gram of tissue
after 1 and 5 days of immobilisation stress, in parallel to an increase in colonic permeability
to 51Cr-EDTA. In order to study the role of the COX/PPARγ antiinflammatory pathway as
a possible homeostatic mechanism in the stressed colon, several groups of animals received
i.p. injections of the physiological PPARγ ligand 15d-PGJ2 (120 mg/kg) and the synthetic
PPARγ ligand, rosiglitazone (3 mg/kg) at the onset of stress. Both 15d-PGJ2 and rosiglitazone
prevented the increase in colonic permeability and bacterial translocation induced after acute
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immobilisation stress. Conclusions: Induction of the anti-inflammatory pathway 15d-PGJ2 /
PPARγ in rat colon in vivo during sustained, repeated immobilisation stress seems to counter-
act initial colonic inflammation and dysfunction induced by acute stress. Furthermore, these
findings open the possibility for preventing accumulation of oxidative/nitrosative species
and subsequent colonic damage after stress exposure.
S1686
Structural Requirements of Recombinant Intestinal Mucin Muc3 EGF-Like
Cysteine-Rich Domains for Cell Migration, Anti-Apoptosis, and Intestinal
Wound Healing Effects
Laurie Shekels, Rachel Moor, Kenji Takamura, David Evans, Robert L. Heinrikson,
Samuel B. Ho
The intestine expresses the related membrane-bound mucins, MUC3, MUC4, MUC12 and
MUC17, that have 2 cysteine-rich epidermal growth factor motifs in their extracellular
domains separated by a linker region. Muc3 cysteine-rich domains expressed as a GST-
fusion protein has been shown to stimulate cell migration in vitro independent of ErbB
receptor stimulation (Gastro 2004; 126: A65). The effect of purification tags, individual
Muc3 EGF domains and linker region on activity is unknown. Aim: To determine structural
factors responsible for the functional properties of Muc3 cysteine-rich extracellular domain.
Methods: Full length cysteine-rich domains (m3EGF1,2) were expressed in E-coli as GST
or His tagged proteins. Truncated GST fusion proteins containing only the first or second
Muc3 EGF-like domain (m3EGF1 or m3EGF2) were synthesized. Proteins were tested for
effect on cell migration and anti-Fas induced apoptosis. Intestinal wound healing was tested
by inducing colitis with a 5% acetic acid enema followed by protein treatment (2 rectal
doses at 12 and 24 hrs post acetic acid). Results: Full length His or GST-tagged m3EGF1,2
form large aggregates (>200 kD) in solution under non-reducing conditions. Reduction
resulted in monomeric proteins (54kD and 30kD, respectively). m3EGF2, but not m3EGF1,
formed a large MW complex in solution that could be reduced. Similar to GST-tagged
m3EGF1,2, His-m3EGF1,2 stimulated cell migration 4.1-4.7 fold (p<0.013); and reduced
fas-mediated apoptosis by 86% (p<0.0001). Enemas with 100ug His-m3EGF1,2 accelerated
healing of acetic acid colitis. Neither m3EGF1 nor m3EGF2 stimulated cell migration,
inhibited apoptosis or accelerated healing of colitis. Tyrphostin inhibition of EGF receptor
had no effect on the activity of GST- or His-tagged m3EGF1,2. However, m3EGF1,2 activity
is reversed by genestein inhibition of tyrosine phosphorylation and by wortmanin inhibition
of PI3 kinase. Conclusion: Both GST- and His-tagged Muc3 cysteine-rich EGF-like domains
form disulfide-dependent aggregates in solution and stimulate cell migration, inhibit
apoptosis, and accelerate healing of colitis. In contrast, individual Muc3EGF domains do
not have biologic activity. The His-Muc3EGF1,2 recombinant protein requires tyrosine
phosphorylation and PI-3 kinase stimulation for activity, however, activity is independent
of EGF receptor phosphorylation. These data indicate that distinct structural features are
needed for the cytoprotective activities of recombinant Muc3 extracellular cysteine rich pro-
teins.
S1687
Macrophage-Mediated Protection Against Dextran Sulfate Sodium-Induced
Colitis
Joseph E. Qualls, Alan M. Kaplan, Willem de Villiers, Donald A. Cohen
The role of macrophages (MΦs) in the development of Dextran Sulfate Sodium (DSS)-induced
colitis was evaluated in C57BL/6, BALB/c, and CB.17/SCID mice. Intrarectal treatment with
clodronate-encapsulated liposomes locally depleted colonic MΦs and increased severity of
DSS colitis in all strains of mice. MΦ-depleted mice displayed increased diarrhea and rectal
bleeding during colitis compared to non-depleted mice. Inflammatory cell infiltration in
colon tissue and loss of mucin from goblet cells was greater in MΦ-depleted mice during
colitis compared to non-depleted mice. Expression of interleukin (IL)-6 and IL-10 from
colon explants of DSS-treated mice was also greater in MΦ-depleted mice. Histological
evaluation of colons showed an increase in neutrophils in the MΦ-depleted mice compared
to those with normal MΦ levels. Moreover, KC chemokine expression and myeloperoxidase
(MPO) activity were also increased in colon explants from diseased, MΦ-depleted mice
compared to diseased, non-depleted mice. Depletion of neutrophils from DSS-treated, MΦ-
depleted mice, reduced the severity of colitis back toward levels seen in DSS-treated, MΦ-
intact mice. These data indicate that colonic MΦs are protective during the induction of
DSS-colitis and that this protection may, in part, involve the regulation of neutrophil influx
and/or activity during inflammation.
S1688
Regulatiion of Wnt Pathway By TLR9 in Intestinal Epithelial Cells
Ji-Hun Mo, Jongdae Lee, Yu-Tsueng Liu, Raz Eyal
Activation of Toll-like receptors (TLRs) via intestinal microbes plays an important role in
maintenance of colonic homeostasis. We have found that apical and basolateral activation of
TLR9 in intestinal epithelial cells(IECs) induce different immune response. While basolateral
activation of TLR9 signals inflammatory response, apical signaling of TLR9 delivers a domin-
ant anti-inflammatory response. To find out underlying genetic changes of these domain
specific TLR9 signaling, we performed cDNA microarray analysis of IECs after apical and
basolateral stimulation with TLR9 ligand. Microarray analysis revealed that apical and basolat-
eral TLR9 signaling induce distinct sets of genes with some common genes. Interestingly,
genes related to regulation of transcritption were highly induced in apically stimulated cells.
In apically stimulated cells, Fzd5 (Frizzled5), a receptor of Wnt signaling, was the most
highly inducible gene. In accordance with this, Fzd5 mRNA level along with its target genes,
cryptdins, was down regulated in small intestines of TLR9-/- mice compared to WT mice.
Fzd5 is involved in maturation of paneth cells in intestinal crypts that produce anti-microbial
peptides, such as cryptdins. Our data suggest that bacterial DNA of intestinal microbes
activates apical TLR9 to induce certain genes in IECs, some of which are involved in
intestinal homeostasis.
S1689
Chemokine-Induced Aggregation of Peritoneal Macrophages Triggers
Peritoneal Adhesion
Taeko Dohi, Akiyoshi Hoshino, Yuki I. Kawamura, Noriko Toyama-Sorimachi, Kenji
Yamamoto
Peritoneal adhesion is a significant complication of surgery and intestinal inflammation. In
spite of the large number of surgical operations performed daily, the mechanism for peritoneal
adhesion, including peritoenal immune response to surgical stress, is not fully understood.
Further, In Crohn’s disease, transmural ulcerations with fissures or fistulas are the most
important pathological findings. The characteristic changes in the serosal surface, includes
fat wrapping, correlates directly with overall extent of the stricture of the intestine; the depth
of lymphoid aggregate penetration, and the number of granulomas in the underlying intestinal
wall. These results suggest that inflammation in Crohn’s disease provoke abnormal responses
in the connective tissues of the peritoneal cavity. However, peritoneal inflammation in the
inflammatory bowel diseases has been poorly studied at the cellular and molecular levels.
Here we revealed that peritoneal macrophages (PMF) aggregated at the site of injured
peritoneum in murine models of post-operative and post-inflammatory peritoneal adhesion.
The chemokine receptor CCR8 was upregulated in the aggregating PMF when compared
with naïve PMF, while other chemokine receptors were downregulated. The upregulation
of CCR8 was also observed in PMF, but not in bone marrow-derived macrophages, treated
with inflammatory stimulants including bacterial components and cytokines. Importantly,
CCL1, the ligand for CCR8, a product of both PMF and mesothelial cells following inflammat-
ory stimulation, was the strongest enhancer of CCR8 expression. The presence of CCL1
upregulated the expression of integrins in PMF and induced formation of PMF and mesothelial
cell aggregates in vitro. Neutralization of CCL1 in vivo prevented the formation of peritoneal
adhesion in both colitis-associated and post-operational adhesion models. Our study now
establishes the presence of a positive feedback system for recruitment of PMF via CCL1/
CCR8, which triggers peritoneal immune responses and adhesion, and offers potential
avenues for therapy.
S1690
Visilizumab Induces Apoptosis of Mucosal T Cells from Ulcerative Colitis
Patients in Vitro
Qi T. Yu, Masayuki Saruta, Konstantinos A. Papadakis
Background: Visilizumab (Nuvion®), a humanized low FcR-binding IgG2 anti-CD3 mono-
clonal antibody, is efficacious in inducing clinical and endoscopic remission in patients with
intravenous steroid-refractory ulcerative colitis (IVSR-UC). Exposure of activated, but not
resting lymphocytes, to visilizumab in vitro led to the induction of T cells apoptosis. We
hypothesized that visilizumab may induce apoptosis of lamina propria (LP) T cells obtained
from patients with active UC. Methods: LP lymphocytes were isolated from surgical samples
collected from 14 patients with moderate to severe UC. Peripheral blood (PB) mononuclear
cells were collected from the same patients. Apoptosis of LP or PB T cells in response to
visilizumab treatment in vitro was assessed with annexin-V staining. Inhibitors of caspases
3, 8, and 9 were used to determine their effect on visilizumab-induced apoptosis. Caspase
3/7 activity was measured using a luminescent assay. Results: Visilizumab induced dose-
dependent apoptosis of LP T cells reaching maximal effect at a therapeutic concentration
of 100 ng/ml (Figure; mean +/- SD; n=14). In marked contrast, visilizumab did not induce
apoptosis of PB T cells (n=12). Addition of a caspase 3 or -8 inhibitor completely abrogated
the apoptotic effect of visilizumab in LP T cells. Addition of a caspase 9 inhibitor or anti-
FasL Abs had no significant effect on the visilizumab-induced apoptosis, suggesting that the
mitochondrial pathway of apoptosis or the Fas/FasL pathway are not involved in this process.
Moreover, visilizumab treatment of LP T cells caused caspase 3 activation as assessed by a
colorimetric assay. Conclusions: Visilizumab in vitro induced apoptosis of LP, but not PB,
T cells isolated from moderate to severe UC patients. The visilizumab-induced apoptosis
is mediated through caspase-8 and caspase-3 activation and does not involve the Fas/
FasL pathway.
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S1691
Diagnosis and Grading of Intestinal Acute Graft-Versus-Host Disease
Following Allogeneic Stem Cell Transplantation By Colonoscopy
Karin Potthoff, Juergen Finke, Jan Harder, Robert Thimme, Hartmut Bertz, Matthias
Egger, Annette Schmitt-Graeff, Wolfgang Kreisel
Objective: Diagnosis and grading of acute intestinal graft-versus-host disease (GvHD) are
based on clinical symptoms, e.g. diarrhoea and abdominal cramping, and are verified by
histology. Since acute GvHD grade ≥ 2 requires intensive immunosuppression, a correct
diagnosis is crucial. At time of therapeutic decision making, however, histologic results often
are pending. Previously we had found that macroscopic findings such as redness and
granulation of the mucosa, aphthous lesions, erosions, ulcerations, confluent defects, mucosal
bleeding and loss of epithelium can be regarded as criteria for intestinal involvement of
acute GvHD. Depending on the extent of these findings in sigmoidoscopy we had established
a score from grades 1 to 4 (Kreisel W et al., Eur J Gastroenterol Hepatol 1994; 6: 723-
729). Using these criteria we investigated whether colonoscopy is an appropriate method
for a rapid and reliable diagnosis of acute intestinal GvHD. Patients and methods: We
retrospectively evaluated 35 colonoscopies in 35 successive patients with acute intestinal
GvHD following allogeneic stem cell transplantation. The median age was 57.6 years (range
34.5-68.4 years). They were transplanted for AML (n=6), AML/MDS (n=9), MDS (n=6),
CML (n=1), NHL (n=5), CLL (n=1), MM (n=2) and MPS (n=3). All patients received
fludarabine, BCNU and melphalan for conditioning. GvHD prophylaxis consisted of cyclospo-
rine A and mycophenolate mofetile (n=29) or mini-MTX (n=6). In case of unrelated donor
grafts (n=13), anti-T-cell globulin ATG-S was additionally administered Colonoscopies were
evaluated using the described criteria, and a comparison between macroscopy, histology
and clinical grading was performed. Results: In no patient colonoscopy induced a complica-
tion such as major bleeding, perforation, or infections. In all 35 patients with clinically
suspected GvHD ≥ 2 and histologically proven intestinal GvHD ≥ 2 macroscopy showed
aphthous lesions (grade 3) and/or ulcerations/confluent mucosal defects (grade 4). The
sensitivity of macroscopic examination of the colon including the terminal ileum for correct
diagnosis of GvHD ≥ 2 amounted to 100%. Conclusions: (1) Colonoscopy can be safely
performed even in patients with high-grade GvHD. (2) Macroscopic grading is a reliable
method for objective diagnosis and grading of acute GvHD ≥ grade 2 following allogeneic
PBSCT. (3) Macroscopic evaluation can be obtained immediately, whereas histology may
take one or two days.
S1692
Regulation of Paneth Cell Alpha Defensin Genes By Microbial Stimuli
Suresh Sivanesan, Carolyn Koh, Sanjay Lala, Satish Keshav
Mutations in the NOD2 gene are associated with an increased risk of Crohn’s disease affecting
the ileum and the gene is expressed in Paneth cells residing in ileal crypts. These cells
mediate antibacterial host defence, partly via their production of alpha defensins. Recent
data suggest that alpha defensin levels are reduced in Crohn’s disease, particularly in the
presence of mutations in the NOD2 gene. We investigated regulation of the human alpha
defensin 5 (HD5) gene in vitro in colonic epithelial cells, to determine the effect of treatment
with bacterial products such as lipopolysaccharide (LPS) and muramyl dipeptide (MDP).
Cell lines were treated with MDP and LPS, followed by real time RT PCR quantification of
HD5 mRNA. A defensin gene reporter construct was also transfected in the cell lines and
reporter activity measured after exposure to MDP and LPS. Treatment with LPS and MDP
did not increase the expression of HD5 mRNA, which is expressed at extremely low constitu-
tive levels, although the same stimuli did induce the expression of pro-inflammatory cytokines
and matrix metalloproteinase 7 (MMP7). Using the reporter gene construct, some activation
of the HD5 promoter was seen in response to MDP treatment, although the magnitude was
lower than that of a canonical nuclear factor kappa B promoter construct. These findings
suggest that microbial stimuli that readily induce inflammatory changes do not regulate
HD5 gene expression to the same extent. The regulation of HD5 expression appears complex
and mainly constitutive. However, sensitive probes of promoter function suggest some
regulation of the defensin genes, which may not be apparent at the level of steady-state
mRNA concentration. This may contribute to the observed reduction in HD5 expression in


















CpG Oligodeoxynucleotides (CpG-ODN) Stimulate IGA Secretion in Intestinal
Mucosal B-Cells
Stefan H. Blaas, Manuela Gunckel, Juergen Schoelmerich, Gerhard Rogler
Background: Bacterial DNA motives (such as CpG-ODN) induce a response of the innate
immune system via ligation of Toll-like-receptor-9 (TLR9). Recent results indicate a role of
TLR9 activation in inflammatory bowel disease. In murine intestinal mucosa CpG-ODN has
pro-inflammatory effects and contributes significantly to chronic intestinal inflammation
when given after the induction of inflammation, whereas CpG-ODN may ameliorate colitis
when given in a prophylactic setting. In humans tonsillar B-cells have been reported to
express TLR-9, especially when activated, and to respond to CpG-ODN. Whether B-cells
in the human intestinal mucosa also express TLR-9 and whether their function can be
influenced by CpG-ODN was unknown so far. Methods: Mucosal B-cells were isolated from
surgical specimens of patients with chronic inflammatory bowel disease and from controls
by collagenase digestion followed by magnetic cell sorting using anti-CD19 antibody armed
magnetic beads (Dynabead-Detachabead® system, Dynal Biotech, Warrington, USA). TLR-
9 mRNA and protein expression was quantified by Taqman® PCR and Western blot respect-
ively. IgA secretion was measured by enzyme linked immunoassay (ELISA) after stimulation
of isolated B cells with CpG-ODN, GpC-ODN or LPS. Results: Flow cytometric analysis of
the isolated lamina propria mononuclear cells showed a purification of 73 % (+/- 22 %)
CD19 positive cells. By quantitative RT-PCR and by Western blot TLR-9 expression in this
cell population was demonstrated. The expression of TLR-9 was not further induced by
exposure to CpG-ODN or LPS. CpG-ODN significantly uprequlated secretion of IgA to 141
% (+/- 23 %) when compared to unstimulated controls. GpC-ODN (as a control motiv)
also upregulated IgA secretion to 111% (+/- 5.9 %), but significantly lower than CpG-ODN.
There was no change of IgA secretion upon LPS stimulation. Discussion: These results
demonstrate that CD19 positive mucosal lymphocytes express TLR-9 and induce release of
IgA upon stimulation with CpG-ODN. This suggests that innate immune responses are also
involved in human mucosal IgA secretion. However, as our purification of mucosal B-cells
was not 100%, an indirect mechanism can not completely be excluded.
S1694
PLCβ Is Necessary for the Maintenance of Basal Integrity of Tight Junctions,
While PLCγ Is Involved in EGF-Mediated Protection of Tight Junctions from
Acetaldehyde
Takuya Suzuki, Ankur Seth, R.K. Rao
A growing body of evidence indicates that tight junctions are dynamically regulated by a
variety of intracellular signaling pathways. Previous studies showed that EGF prevents
acetaldehyde-induced disruption of tight junctions (TJ) in Caco-2 cell monolayers. In the
present study, we investigated the role of PLC activity in EGF-mediated prevention of
acetaldehyde-induced disruption of TJ. Methods: Caco-2 cells on Transwell inserts were
incubated with acetaldehyde (400 μM) in the absence or presence of EGF (20 nM) and
U73122 (3-30 μM) or ET-18-OCH3 (2-20 μM). Permeability was evaluated by measuring
TER and FITC-inulin flux. Redistribution of TJ-proteins, occludin and ZO-1, from the
junctions was analyzed by confocal microscopy. Release of TJ-proteins from the actin cytoskel-
eton was evaluated by immunoblot analysis of Triton-insoluble fraction. Activation of PLCβ
and PLCγ was determined by immunoblot analysis for phospho-PLCs in plasma membrane
and cytoskeletal fractions. Cells were transfected with siRNA for PLCβ and PLCγ (or control
RNA) to determine the role of specific PLC isoform. Association of active PLC with EGFR
was determined by co-immunoprecipitation. Results: Administration of U73122 by itself
reduced TER, increased inulin flux in a dose-dependent manner; this was associated with
redistribution of occludin and ZO-1 from the intercellular junctions. U73122 (PLCβ-selective
inhibitor) up to 30 μM did not affect EGF-mediated protection of TJ from acetaldehyde.
On the other hand, ET-18-OCH3 (PLCγ-selective inhibitor) dose-dependently prevented
EGF-mediated protection of TJ from acetaldehyde, while ET-18-OCH3 by itself produced
no significant effect on basal TJ permeability. ET-18-OCH3 also prevented EGF-mediated
prevention of acetaldehyde-induced decrease in detergent-insoluble TJ proteins, Thr-dephos-
phorylation of occludin and redistribution of occludin and ZO-1 from the junctions. Phospho-
PLCγ was not detectable in control cells, but EGF rapidly increased p-PLCγ in plasma
membrane and EGFR-immunocomplex, which was blocked AG1478, a EGFR tyrosine kinase
inhibitor. A considerable level of phospho-PLCβ1 was present in control cells, but it was
unaffected by EGF. Conclusion: These results indicate that PLCβ may play a role in the
maintenance of basal integrity of TJ, while PLCγ is involved in EGF-mediated protection of
TJ from acetaldehyde Support by DK55532 and AA12307.
S1695
Mechanism of Heat Stress Modulation of Occludin Protein Expression: Key
Regulatory Role of Heat Shock Factor-1
Karol Dokladny, Dongmei Ye, John C. Kennedy, Robin Matuk, Thomas Y. Ma
Previous studies from our laboratory suggested that the heat stress (HS)-induced increase
in occludin protein expression may be an important protective mechanism regulating the
HS-induced increase in Caco-2 tight junction (TJ) permeability. The intracellular mechanisms
that mediate the HS-induced increase in occludin protein expression are unknown. The aim
of this study was to elucidate the intracellular mechanisms that mediate the HS-induced up-
regulation of occludin protein expression. Methods: Filter-grown Caco-2 intestinal epithelial
monolayers were used as an in-vitro intestinal epithelial model system. Results: Increasing
incubation temperatures (37-41°C) resulted in a temperature and time-dependent drop in
Caco-2 trans-epithelial resistance and increase in paracellular permeability to inulin over
the 24-h experimental period. HS (41°C) caused a marked increase (3-fold increase) in
occludin protein expression and increase in junctional localization of occludin. In the
following studies, the possible intracellular mechanisms that mediated the HS-induced
increase in occludin expression were examined. HS (41°C) induced increase in occludin
expression was proceeded by an increase in occludin promoter activity and occludin mRNA
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expression. HS did not affect the rate of occludin protein degradation as assessed by the
35S-methionine pulse-chase, indicating that occludin expression was due to an increase in
promoter activity and transcription and not a decrease in occludin degradation. HS (41°C)
produced a rapid (within minutes) activation and cytoplasmic-to-nuclear translocation of
heat shock factor-1 (HSF-1); and inhibition of HS-induced activation of HSF-1, with a
known HSF-1 inhibitor quercetin (100 µM), completely prevented the HS-induced up-
regulation of occludin gene transcription and protein expression. Moreover, quercetin inhibi-
tion of HS-induced HSF-1 activation and occludin protein expression was accompanied by
a marked greater increase in Caco-2 TJ permeability. Conclusion: Our results indicate that
the HS-induced increase in occludin protein expression and junctional localization were
due to an increase in occludin promoter activity and gene transcription. Our findings also
suggested that the HS-induced HSF-1 activation played a key regulatory role in the up-
regulation of occludin gene transcription, occludin expression, and protection against the
HS-induced disruption of the intestinal TJ barrier.
S1696
Dynamic Movement of the Tight Junction Protein Claudin 2 in the Lateral
Membrane of Live Human Intestinal Epithelial Cells
Samantha Wilson, Guy R. Sander, Barry C. Powell
Introduction: The intestinal epithelium maintains a selective barrier to molecules and patho-
gens. Access through the intercellular space is regulated by tight junctions that create
permeable seals near the apical surface of epithelial cells. To probe the nature of the tight
junction we used fluorescent protein technology to monitor the dynamics of the tight junction
protein, claudin 2, in the membrane of human intestinal epithelial cells. Methods: Various
forms of claudin-2, either singly tagged or doubly tagged with the CFP and YFP spectral
variants fused at either end were created and transiently transfected into T84 cells. The
dynamics of claudin-2 expression was analysed by confocal microscopy and fluorescence
recovery after photo-bleaching (FRAP). Results: All claudin-2 fusion proteins were able to
incorporate into the lateral membrane of polarized cells. Confocal microscopy revealed a
vesicular-like, cytoplasmic pool of protein restricted to a horizontal plane in the upper
portion of the cell, suggestive of protein destined for import into the membrane. Using
FRAP to investigate the dynamics of tagged claudin-2 in the plasma membrane of live cells,
claudin-2 was visualized moving into the membrane within 15 seconds of photo-bleaching.
Approximately 52% (± 7%) of the tagged protein was found to be mobile, with maximum
recovery by ~4 minutes. The diffusion time was 56 seconds (±19 s). Conclusion: These data
provide insight into the dynamics of claudin-2 and indicate that rapid exchange of tight
junction proteins can take place within the lateral plasma membrane of intestinal epithe-
lial cells.
S1697
LPS-Induced Alteration of Colonic Paracellular Permeability Is Linked to Mast
Cell Dependent Increase of Luminal Protease Activity
Raphael Moriez, Helene Eutamene, Vassilia Theodorou, Jean Fioramonti, Lionel Bueno
Lipopolysaccharide (LPS)-induced sepsis is associated with gut immune stimulation and
change in colonic paracellular permeability (CPP). Increased CPP is the primary event
triggering mucosal barrier dysfunction but the mechanisms involved remain unknown. The
aim of this study was to evaluate the role of mucosal mast cells (MMC) and colonic luminal
serine protease activity (PA) in CPP alterations induced by LPS. Methods: First, 6 groups
of 10 male Wistar rats equipped with an intracolonic catheter received respectively, NaCl
0.9%, LPS from E.coli 0111:B4 (1mg/kg, IP), MMC stabilizer doxantrazole (20 mg/kg, IP),
doxantrazole + LPS, MMC degranulator BRX 537A (2mg/kg, IP) or its vehicle (DMSO). CPP
was measured by intracolonic injection of 51Cr-EDTA (250μL, 0.7μCi) and expressed as
percent of radioactivity collected in the urine for 6h. Secondly, on 6 similar groups, PA and
rat mast cell protease II (RMCP-II) levels were measured in the colonic content 3h after LPS
administration (maximal effects of LPS on CPP) using azocasein as a proteolytic substrate
and ELISA respectively. Results of PA were expressed in optical density and RMCP II levels
were expressed in ng/ml of supernatant. Thirdly, the effects of colonic content on CPP were
assessed on proximal colon mounted into Ussing chambers. Colonic content of control or
LPS-treated animals (incubated or not with the protease inhibitor SBTI, 100 mg/L) was
added at the mucosal compartment. After 30 min, fluorescein isothiocyanate-labeled 4-KDa
dextran was measured at the serosal side. Results were expressed as the flux of dextran
crossing the epithelial barrier (nmol/min/cm2 ). Results: LPS increased the 0-6h colonic
permeability of 51Cr-EDTA from 0.65±0.08% in controls to 1.46±0.13% (P<0.05). Three
hours after LPS, colonic intraluminal PA was higher (P<0.05) in LPS than in controls
(0.57±0.11 vs. 0.21±0.03). Also, RMCP-II level was higher from that observed in controls
(+364%, P<0.05). Previous administration of doxantrazole suppressed (P<0.05) the LPS-
induced release of RMCP-II into the colonic lumen, the increase of luminal PA, and the
alteration of CPP. Moreover, BRX 537A mimicked the effects of LPS i.e. CPP increase, release
of RMCP-II and increase of PA. Colonic content of LPS-treated rat added in Ussing chamber
increased the dextran flux across the tissue compared with colonic content of saline-treated
rats (1.56±0.13 vs. 1.14±0.11; P<0.05). Previous treatment with SBTI abolished the effects
of colonic content of LPS-treated rat on CPP alteration. Conclusion: Taken together our
data evidence the key role of proteases, released from mast cells into the colonic lumen, on
LPS-induced alterations of CPP.
S1698
Expression of the Tight Junction Protein Claudin-2 in Resting and
Proliferating Intestinal Epithelial Cells Is Inversely Regulated By TNFAlpha
Joachim Mankertz, Shida Tavalali, Bernd Hillenbrand, Heinz Schmitz, Alfred H. Gitter,
Peter Florian, Michael Fromm, Joerg D. Schulzke
Background and aims: Inflammatory bowel diseases are associated with a dysfunction of
the intestinal epithelial barrier. Decrease of transepithelial electrical resistance (TER) is
paralleled by an increase of apoptotic leaks and a reduction of tight junction strands in
ulcerative colitis. TNFalpha treatment of the intestinal epithelial cell line HT-29/B6 shows
similar effects on apoptosis, TER and tight junction strands. The tight junction protein
claudin-2 is upregulated in ulcerative colitis. Aim of the study was to investigate expression,
stability, and intracellular localization of claudin-2 in the presence of TNFalpha and inter-
feron-gamma (IFNgamma). Methods: Resting and proliferating HT-29/B6 cells were incub-
ated with TNFalpha and IFNgamma. TER and conductivity were monitored. Claudin-2
protein and mRNA expression was measured by immunoblotting and real-time PCR, respect-
ively. Subcellular localization of claudin-2 was determined by confocal microscopy. Claudin-
2 promoter activity was analyzed by reportergene assay. Results: Claudin-2 protein expression
increased (159±17%, p<0.05 vs control) in resting epithelial HT-29/B6 cells after incubation
with TNFalpha for 24 h which was paralleled by a decreased TER (31±2%, p<0.001 vs
control), while IFNgamma had no effect on protein expression. Claudin-2 mRNA stability
was not affected by TNFalpha. The combination of both cytokines had no effect on tight
junction localization of claudin-2. Conductance scanning revealed an enhancement of trans-
and paracellular conductivity after cytokine treatment which led to a change from tight to
leaky epithelium. Proliferating cells, which contain an increased amount of claudin-2 com-
pared to resting cells, exhibited a decrease in claudin-2 protein expression (36±19%, p<0.05
vs control) after incubation with TNFalpha which can be explained by reduced promoter
activity (55±2%, p<0.001 vs control). In the same manner, accumulation of claudin-2 in
resting cells is due to an enhanced gene expression, since claudin-2 specific mRNA expression
was elevated in the presence of TNFalpha (163±14%, p<0.01 vs control). Conclusion: In
contrast to occludin and other tight junction proteins sealing the epithelial barrier, claudin-
2 expression was increased in response to TNFalpha in resting HT-29/B6 cells resembling
a tight epithelium. Since claudin-2 forms cation-selective pores, its up-regulation leads to
an increased permeability of the epithelial barrier. This is an important protective mechanism
but also contributes to diarrhea in inflammatory bowel disease, where pro-inflammatory
cytokines as well as claudin-2 protein expression are found to be elevated.
S1699
The TNF-Alpha Convertase (TACE) Regulates Intestinal Permeability Induced
By Oxidant Stress Through An EGFR and MAPK-Dependent Pathway
Christopher B. Forsyth, Ali Banan, Ashkan Farhadi, Ali Keshavarzian
Inflammatory bowel disease (IBD) is a chronic intestinal inflammatory disease affecting more
than a million Americans. One key component of IBD pathogenesis is increased intestinal
permeability to proinflammatory luminal contents. Increased permeability is thought to
result from actions of proinflammatory cytokines (TNF-α, IFN-γ) and oxidant stress on
intestinal epithelial cells due to inflammation. Pre-treatment of epithelial cells with growth
factors binding to the epidermal growth factor receptor (EGFR) has been shown to protect
against oxidant stress induced permeability. Data from others has also recently shown oxidant
signaling through the EGFR via a metalloprotease dependent pathway. Aim: Our goal was
to determine whether metalloprotease-mediated EGFR signaling was involved in regulation
of oxidant-induced intestinal permeability and investigate possible mechanisms. Methods:
The human Caco-2 cell in vitro model of tissue culture inserts was used for the permeability
(FSA dye movement, 18h) as well as cell signaling studies. For oxidative stress, cells were
exposed to H2O2 (500uM). Cells remained viable. All data represent at least three experi-
ments. Permeability data are means from triplicate wells. Western blotting of cell lysates
from oxidant treated cells was used for phosphoprotein analysis of mitogen activated protein
kinases (MAPKs: ERK1/2, JNK1/2, p38) and AKT as well as EGFR phosphorylation. Cells
were treated with oxidant ± inhibitors to EGFR, TNF-α converting enzyme (TACE), all three
MAPKs, PI3K, and Src. These inhibitors were also tested for effects on permeability. Results:
Oxidant-induced a 90-fold increase in permeability overnight. Signaling studies showed
oxidant induced phosphorylation of the EGFR, ERK1/2, JNK1/2, p38, and AKT. Inhibitors
of EGFR (kinase and blocking Ab), ERK1/2, and TACE blocked oxidant induced permeability
by greater than 90% while effects of other inhibitors were variable. Both EGFR and TACE
inhibitors eliminated ERK1/2 phosphorylation. Conclusions: These studies identify a signific-
ant and novel pathway regulating oxidant-induced intestinal permeability. The proposed
mechanism involves oxidant-induced TACE metalloprotease cleavage of EGFR surface ligands
such as EGF that then bind to and transactivate the EGFR. This transactivation results in
TACE/EGFR-dependent ERK1/2 activation which is required for the increase in permeability.
Studies are currently underway to identify targets for ERK1/2 in this mechanism as well as
specific EGFR ligands cleaved by TACE in response to oxidant stress.
S1700
Pronounced Mucosal Barrier Dysfunction of the Whole Gut After Cardiac
Surgery
Sabine Buhner, Christian von Heymann, Jan-Peter Braun, Michael Sander, Lisa Weymann,
Pascal Dohmen, Martina Werich, Herbert Lochs, Claudia Spies
Introduction: A failure of the intestinal barrier function is supposed to enhance post-surgical
complications. Cardiopulmonary bypass (CPB) operations are a risk factor in this matter,
however, mucosal permeability, as an index of barrier function has not been studied in
detail. Methods: We measured gastrointestinal permeability using an oral sugar test 24hrs
before and 6hrs after isolated coronary artery bypass graft surgery under conditions of
normothermic CPB. Urinary sugar recovery was quantified using HPLC. The different sugars
served as markers for permeability of different intestinal segments; sucrose: (suc) gastroduod-
enum; lactulose/mannitol ratio (PI): small intestine; sucralose (sucra): colon. Plasma IL-6
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and IL-10 were measured by ELISA. 41 patients (4F/37M; mean age: 63 years (38-78 years))
were studied and compared to healthy controls (29F/14M; age: 42 years (17-77 years)).
Results: Before surgery patients showed normal gastric and small intestinal permeability
patterns which did not differ from values of the control group (table). However, 6 hrs after
surgery both parameters substantially increased about 10-fold. Also colonic permeability
was higher compared to controls (table). Interestingly, the disaccharide markers (suc, lac,
sucra) permeating via paracellular tight junctions increased, whereas mannitol, which is
permeating mainly transcellularly decreased. Mannitol absorption is known to correlate well
with intestinal surface area. IL-6/IL-10 ration, an index for post-surgical outcome, increased
and highly correlated with PI after surgery (p=0.003, Spearman-Rho). Conclusions: Cardiac
surgery with CPB impairs mucosal barrier of the whole gut. A functional reduction of the
active intestinal surface combined with a reduced energy supply of mucosal tight junctions
might be underlying mechanisms. An uncontrolled macromolecule uptake and inadequate
stimulation of the immune system may predispose for postoperative complications.
median (0.25-0.75 percentile); ns between controls and patients before surgery (Mann-
Whitney); a: differences between controls and patients after surgery (Mann-Whitney); b:
differences between before and after surgery (Wilcoxon-Test for paired data).
S1701
LPS from the Commensal Microflora Participates to Stress-Induced Colonic
Epithelial Barrier Dysfunction in Mice
Julien Demaude, Jean Fioramonti, Laurent Ferrier, Lionel Bueno
Introduction. Intestinal epithelial barrier dysfunction has been described in inflammatory
bowel diseases and irritable bowel syndrome in humans. In mice, an acute stress increases
colonic paracellular permeability, involving the mucosal immune system (mast cells, T cells)
and the commensal microflora. In addition, bacterial wall components, as lipopolysaccharides
(LPS) from gram-negative bacteria, are powerful activators of the immune system, through
the binding to specific receptors. The aim of our study was to determine whether LPS is
involved in the participation of the flora in stress-induced colonic epithelial barrier impair-
ment. Material and Methods. Colonic paracellular permeability was determined by measur-
ing the passage of 51Cr-EDTA, instilled into the colonic lumen, across the epithelium for
two hours in male Swiss mice. Four groups of mice (1-4) were submitted to a mixed acoustic
and restraint stress for two hours, before paracellular permeability measurement. Four other
groups (5-8) were used as unstressed controls. Groups 1 and 5 received no treatment. Other
groups were treated through drinking water before permeability measurement, as follows:
groups 2 and 6 received non absorbable antibiotics, ampicillin (0.05%) and neomycin
(0.10%) for ten days to reduce bacterial microflora; groups 3 and 7 received antibiotics for
10 days and LPS from E. coli K235 (120 μg/mL) the last four days; groups 4 and 8 received
only LPS for four days. Results. Acute stress increases colonic paracellular permeability to
51Cr-EDTA (2.2 ± 0.1 % vs. 1.1 ± 0.1 %, P<0.001). This effect was abolished by antibiotics
(0.7 ± 0.1 %), and restored in mice treated with both antibiotics and LPS (2.8 ± 0.2 %).
Treating animals with LPS alone exacerbated the effects of stress (4.1 ± 0.2 %). In unstressed
mice, antibiotics associated or not with LPS did not affect permeability (0.8 ± 0.1 % without
LPS; 1.5 ± 0.1 % with LPS, P>0.05 vs. controls). An increased permeability was observed
in unstressed animals receiving LPS (2.5 ± 0.2 %). Conclusions. Our results confirm the
pivotal role of the commensal microflora in stress-induced colonic permeability alterations.
In addition, we provide evidence that LPS mimics the action of the microflora in antibiotics-
treated mice. Thus, we suggest that LPS mediates the effects of the flora on colonic epithelial
cell reactivity to stress.
S1702
Enteropathogenic E. Coli-Induced Activation of Myosin Light Chain Kinase
and Early Alteration of Tight Junction Protein Localization Are ESPF-
Independent
Michelle M. Muza-Moons, Andrew W. Weflen, Rajani Kanteti, Jerrold R. Turner, V.K.
Viswanathan, Gail Hecht
Enteropathogenic E. coli (EPEC) is a significant cause of infantile diarrhea and mortality
worldwide. Disruption of intestinal epithelial tight junctions (TJ) contributes to EPEC patho-
genesis. EPEC decreases transepithelial electrical resistance (TER), a measure of TJ barrier
function. The EPEC pathogenicity island harbors genes encoding attachment factors, type
III secretion (TTS) proteins, and effector molecules. TJ disruption by EPEC has been correlated
in part with myosin light chain kinase (MLCK) activation and phosphorylation of regulatory
myosin light chain (MLC), inducing contraction of the perijunctional cytoskeletal ring. The
effector molecule EspF is largely responsible for the decrease in TER. The aim of this study
was to determine the role of EspF in MLCK activation and further assess the effect of
cytoskeletal contraction on TJs. Ratiometric comparison of phosphorylated to total MLC
was performed using a phosphospecific antibody. Cultured intestinal epithelial cells (T84,
CaCo-2 and MDCK) were infected with wild type (wt) EPEC and specific mutants and the
level of phosphorylated MLC (P-MLC) was compared to uninfected monolayers. The effect
of a specific cell-permeant MLCK peptide inhibitor, PIK (330µM) was also studied. WT

















n=3), enhanced P-MLC. Mutation of espF did not significantly alter the level of P-MLC as
compared to wt EPEC (0.70 ± 0.4; p>0.10, n=3). While PIK significantly attenuated the
decrease in TER by wt EPEC (-73±10 to -55±8%), this inhibitor abolished the EspF-
independent portion of the TER decrease (-36±15% vs -3±7%, - and + PIK, respectively)
supporting that EspF is not responsible for MLCK activation. To assess the impact of MLCK
activation on TJ structure, monolayers were stained for ZO-1 and occludin at early time
points post-infection. These studies revealed a “crinkle” or “zigzag” pattern at early times
(1-3 hrs) consistent with MLCK activation and prior to severe alteration of TJ structure.
This subtle phenotype was not seen in uninfected monolayers or those infected with non-
pathogenic E. coli or the escN mutant. PIK prevented the “crinkle” phenotype indicating
that this alteration is also a consequence of MLCK activation. Screening of a panel of EPEC
mutant strains revealed that the effectors Map, Tir, and EspG are not responsible for MLCK
activation. We conclude that activation of MLCK and the associated “crinkle” phenotype of
TJs induced by EPEC infection are TTSS-dependent/EspF-independent processes and repres-
ent key early events in EPEC-mediated TJ disruption.
S1703
The Active Motif of ZOT, At1002, Increases ZO-1 and Myosin 1 Beta Serine
Phosphorylation, Their Interaction, and Intestinal Permeability
Manjusha Thakar, Tarcisio Not, Simeon Goldblum, Alessio Fasano
Background: Zonula occludens toxin (Zot) is a protein elaborated by Vibrio cholerae that
modulates intestinal epithelial tight junctions (tj) in a PKC-dependent manner. Zot structure-
function analysis and studies on its trafficking within V. cholerae identified a conserved 6-
mer protease activated receptor (PAR) motif (named AT1002) that retains Zot activity for
tj’s. Aim: To determine whether: AT1002 1) modulates tj both in vivo and in vitro; (2)
Increases serine phosphoralytion and/or affects interactions between tj integral membrane
components and their scaffolding partners. Methods: In presence and absence of AT1002
(1) Transepithelial intestinal resistance (TEER) on rat small intestine mounted in snap wells
was monitored. (2) The in vivo intestinal permeability of rat intestine was studied by dual
sugar test with HPLC technique. (3) Cell lysates from rat epithelial cells (IEC 6) were studied
by phosphoserine immunoblotting and co-immunoprecipitation assays. Results: AT1002
decreased TEER in vitro in a dose- and time-dependent manner. AT1002 also increased
intestinal permeability in vivo, while three different control scrambled peptides failed to do
so. AT1002 (100 mM) increased serine phosphoralytion of ZO-1 in a time-dependent
fashion coincident with decrease in TEER kinetic. A phosphoserine-containing protein co-
mmunoprecipitated with ZO-1 and was identified as Myosin 1 beta by MS/MS. ZO-1-myosin
1 beta protein-protein interaction increased following AT1002 exposure. These results were
confirmed by reciprocal co-immunoprecipitation experiments. Conclusions: 1) AT1002
retains the biological activity of full length Zot both in vivo and in vitro; 2) the AT1002-
induced increased intestinal permeability was coincident with serine phosphorylation of
ZO-1; 3) AT1002 increases serine phosphoralytion of myosin 1 beta and its association with
ZO-1. To our knowledge, this is the first observation of myosin 1 beta and ZO-1 serine
phosphorylation and interaction coincident with increase in intestinal tj permeability.
S1704
Disturbed Cytokine Response to Mycobacterium Avium Subspecies
Paratuberculosis Is Dysregulated in Patients with Crohn’s Disease
Shomik Sibartie, John Keohane, Paul Scully, Shaun O'Neill, Jim O'Mahony, Liam
O'Mahony, Fergus Shanahan
Background: Mycobacterium avium subspecies paratuberculosis (MAP) has been a source of
controversy since it was first suggested as a possible cause for Crohn’s disease. While a
number of studies have focused on identification of the organism in Crohn’s disease tissues
and others have assessed the serologic response to MAP, few studies have examined the
cellular immune response to MAP. Aim: To compare the cellular response to Mycobacterium
avium subspecies paratuberculosis between Crohn’s disease patients and healthy volunteers.
Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from 24 Crohn’s
disease patients and 20 healthy volunteers. After in-vitro co-incubation for 72 hrs with MAP
ATCC 43019 at several concentrations, supernatants were harvested and analysed for IL-
2,IL-4,IL-6,IL-8,IL-10,TNF-α and IFN-γ using cytometric bead analysis. PBMCs stimulated
with Salmonella typhimurium (ST)were used as positive controls. Results: Compared to
healthy volunteers, PBMCs from Crohn’s disease patients secreted higher levels(p<0.05)of
IL-6(4265±260 vs. 2865±386 pg/ml),TNF-α (2190±247 vs. 1200±228pg/ml) and IL-
10(265±53 vs. 81±12 pg/ml) upon exposure to MAP(1 MAP bacterial cell:1 PBMC) but
showed no difference when exposed to ST. There was a lower IFN-γ response from Crohn’s
disease patients to MAP(322±125 vs. 1658±424 pg/ml) but this also occurred in response
to ST. The ratio of IFN-γ to IL-10 was significantly lower for Crohn’s disease patients’ PBMCs
exposed to MAP compared to healthy volunteers (p<0.05)but not for ST. There were no
differences in IL-8, IL-2 and IL-4 levels. Prior BCG vaccination and concurrent immunosup-
pressives had no impact on the levels of cytokines secreted. Conclusion: A diminished Th1
response to MAP in Crohn’s disease patients may allow for prolonged intracellular survival
of MAP in phagocytic cells. This might account for the increased frequency of MAP detection
in patients with Crohn’s disease but does not imply cause and effect.
S1705
Intestinal Permeability Is Associated with Severity of Disease in Surgical ICU
Patients
F Hietbrink, Mgh Besselink, Mbm de Smet, W Renooij, Lma Akkermans, Lph Leenen
Increased intestinal pemeability is proposed to be the motor of sepsis in surgical critical
care patients. It is thought that the surgical stress and hypoxia induce a loss of intestinal
barrier function and therefore predispose for bacterial translocation. Sugar absorption tests
have produced a wide variation in results. Poly-ethylene glycols (PEGs) of various molecular
mass have been used as markers for intestinal permeability in non critically ill patients. PEG
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400 can freely pass the intestinal mucosal barrier, larger PEGs can only pass when intestinal
permeability is compromised. We investigated whether the intestinal permeability, as meas-
ured with PEGs, is associated with the severity of disease in surgical ICU patients. Thirty-
seven surgical ICU patients were included (mean APACHE II score 14 ± 5.5). The patients
ingested a solution of 5g PEG 400, 1.5g PEG 1500, 5g PEG 4000 and 10g PEG 10000
dissolved in 100 ml water within the first 48 hours of admission. Urine was collected in
the following 12 hours and analyzed for PEG by HPLC. The test was repeated every other
day during the first two weeks of ICU stay. PEG values from the ICU patients were compared
with control values from an earlier validation study. Severity of organ failure was assessed
by the SOFA score. Data are presented as the intestinal permeability index (IPI for PEGi =
(PEGi / PEG 400) x 100%). Statistical analysis was performed using t-test and logistic
regression. The IPI for PEG 1500 increased from 1.79 (± 0.39 mean ± SEM) in controls to
3.90 (± 1.60) in surgical ICU patients on admission (P = 0.031). The IPI for PEG 4000
increased from 0.20 (± 1.59) in controls to 0.52 (± 0.16) in surgical ICU patients on
admission (P = 0.040). A significant increase in the IPI for PEG 1500 on day 4 was found
between patients who developed severe organ failure and patients who did not (P < 0.034).
The IPI for PEG 1500 correlated with the SOFA score (P = 0.012) as it changed during the
period of ICU stay, when corrected for stomach retention and creatinin levels. In conclusion
these data suggest an association between intestinal permeability and the course of disease,
because 1) intestinal permeability of surgical intensive care patients was increased compared
to healthy controls, 2) intestinal permeability on day 4 correlated with the development of
organ failure and 3) changes in intestinal permeability correlated with changes in severity
of disease over time.
S1706
Stress Associated Changes in the Composition of Luminal Microbiota in the
Human Jejunum
Cristina Martinez, Javier Santos, Carmen Alonso, Mar Guilarte, Laura Ramos, Maria
Vicario, Maria Antolin, Francisco Guarner, Juan-Ramon Malagelada
Background: Several evidences support the relevance of intestinal flora stability in the
promotion of intestinal health whereas life stress has been linked to the development of
mucosal inflammatory disorders in the gut. However, the composition of jejunal comensal
microbiota and the effect of stress on the luminal microbiota have not been fully elucidated.
Aims: 1) To investigate whether the small bowel bacterial populations can be analyzed by
molecular approaches; and 2), to characterize the composition and dynamics of bacterial
populations of intestinal microbiota of healthy subjects under acute stress. METHODS: In
10 healthy volunteers, a 20-cm jejunal segment was isolated and constantly perfused at 5
mL/min. Intestinal effluents were collected at baseline and every 15 min for 1 h after hand
immersion in cold water for 15 min. Total DNA was isolated from intestinal effluents at
baseline (A) and 45 min after stress (B). The total predominant bacterial community was
profiled by targeting the V6-V8 region of the 16S ribosomal DNA by polymerase chain
reaction (PCR) and separating the resultant amplicons by denaturing gradient gel electrophor-
esis (DGGE). After electrophoresis, gels were silver stained. Obtained profiles were compared
using the BioNumerics software package and similarity indices (SI) calculated from densito-
metric curves using the Pearson product moment correlation coefficient. RESULTS: The
total bacterial DGGE profiles showed that each subject harbours a specific microbiota with
a low interindividual SI at baseline, but, remarkably, this SI was significantly ehhanced after
stress (A: 40.8±11.7%. vs. B: 54.4±12.5%; p<0.05). Moreover, one specific band that was
nearly undetectable in A samples appeared with high intensity in B samples. On the other
hand, the intraindividual composition of the microbiota varied notably after cold stress. The
SI of B sample versus A sample of each subject was in average 42.9±28.5%. In addition,
the diversity of the microbiota, estimated by the number of bands, decreased after cold
stress (A: 26 ± 8; B: 19±5; p<0.05), CONCLUSIONS: PCR-DGGE fingerprinting is a useful
technique to detect dominant bacterial populations in intestinal effluents. Composition of
jejunal microbiota is altered shortly after acute stress by specific changes in the small bowel
microflora. The present findings contribute to our understanding of gastrointestinal disorders
caused or aggravatted by life stress.
S1707
Ginkgo Biloba Protects Against Intestinal Epithelial Barrier Hyperpermeability
By Stabilizing Tight-Junctional Proteins: Role of NF-kB Inactivation, Occludin
and Claudin
Ali Banan, Lijuan Zhang, Maliha Shaikh, Ashkan Farhadi, Christopher B. Forsyth, Philip
Engen, Ali Keshavarzian
NF-kB activation & barrier disruption are key in the pathogenesis of inflammatory GI
diseases. Several traditional Complementary & Alternative Medicine (CAM) systems recom-
mend putative anti-inflammatory herbs such as Ginkgo Biloba (GB) for Inflammatory Bowel
Disease (IBD). Despite claims, it is not established whether this herb has anti-inflammatory
effects, is beneficial in IBD, and can prevent barrier disruption. Also, GB’s mechanism of
action has not been directly evaluated in an IBD model. Aims: To determine if NF-kB
inactivation is involved in GB-mediated protection of tight junction & barrier proteins against
oxidative injury. Methods: Human intestinal monolayers (Caco-2 cells) were incubated in
injurious doses (100 & 500 uM) of H2O2 or HOCl ± GB (1-100 ug/mL) or NF-kB modulators.
Other studies were done in IkB mutant cells where NF-kB was inactivated. We assessed:
barrier function (fluorometry), occludin / claudin integrity (laser confocal microscopy, SDS-
PAGE), NF-kB activity (EMSA, ELISA), NF-kB modulator, IkB (PAGE), n=6/grp. Results:
GB pretreatment (10 ug/mL) prior to oxidant led to: 1) decreased IkB degradation, 2) reduced
NF-kB nuclear translocation, 3) decreases in nuclear NF-kB activation, 4) maintenance of
normal occludin & claudin-1 architecture, & 5) enhanced barrier integrity comparable to
controls. These protective effects were synergistic with effects of IkB stabilizers (MG-132,
Lactacystin). Further confirming a role for NF-kB in GB protection: [A] preincubation with
any of several NF-kB inhibitors (e.g., PDTC) or stabilization of IkB by a dominant mutant
transfection synergized with the above protective effects by GB. [B] Pretreatment with
potentiators of NF-kB activation [PAO, PV] prevented GB maintenance of barrier integrity
& stabilization of tight junction structure during oxidant insult. [C] IkB stabilization due
to mutant transfection, similar to GB, protected barrier integrity and occludin & claudin-1
stability. Indeed, the disruptive effects of oxidants on the barrier were largely prevented by
mutant IkB induced stabilization while they were exaggerated by inhibitors of phosphoseryl/
threonyl protein phosphatase (i.e., NF-kB potentiators). [D] Similar to the blunting effects
of protein phosphatase, the NF-kB potentiators PAO & PV prevented protection by GB or
growth factor (EGF), & abolished decreases in NF-kB caused by these protective agents.
Conclusions: Our findings suggest that GB has unique anti-inflammatory effects and supports
our hypothesis that GB protects against oxidant-induced intestinal epithelial hyperperme-
ability by stabilizing tight junctions through the inactivation of NF-kB via stabilization of IkB.
S1708
Fluorometric Detection of Specific Binding of Cy3-Labeled Norwalk Virus-Like
Particles to Caco-2 Cells
Anne M. Hutson, Sue E. Crawford, Mary K. Estes
BACKGROUND: Noroviruses are the major cause of epidemic acute nonbacterial gastro-
enteritis worldwide, and Norwalk virus (NV) is the prototype norovirus strain. Detection
of noroviruses in the environment (i.e. groundwater and in sewage treatment) is difficult
because of the genetic divergence and antigenic differences among strains. Additionally,
studying NV infection is hindered by the lack of a cell culture system or a small animal
model supporting replication. However, the NV capsid protein expressed in the baculovirus
system produces virus-like particles (VLPs) which are structurally and antigenically similar
to NV virions and may be used as a surrogate to study virus attachment to and entry into
cells and viral movement in the environment. Previously, 35S-NV VLPs showed specific
binding to and internalization into Caco-2 cells, a human cell line with enterocyte-like
properties but is not permissive to NV replication. Metabolic radiolabeling of native NV is
not feasible, and radiolabeled VLPs are not useful for evironmental tracking studies. Thus
we hypothesized that fluorescently labeled NV VLPs can be used to track particle travel in
the environment and in cells. METHODS: We have developed a non-radioactive method of
labeling purified NV VLPs with the monovalent Cy3 fluor. RESULTS: Fluorescently labeled
35S-Cy3-NV VLPs demonstrated specific binding to Caco-2 cells identical to that of 35S-
NV VLPs. Furthermore, 35S-Cy3-NV VLPs were visualized bound to the cells. Interestingly,
visual scoring of cell-associated fluorescence was more sensitive than that of the fluorometer.
By fluorometry, the detection of Cy3-labeled VLPs was over 1000-fold less sensitive than
that of radiometric methods. CONCLUSIONS: Cy3-labeled NV VLP specific binding to
Caco-2 cells can be detected by fluorescent microscopy and fluorometry. Developing a non-
radioactive method to label and track NV VLP in the environment and in cell binding
may help elucidate modes of NV transmission and identify blocks in NV replication in
cultured cells.
S1709
Irsogladine, An Activator of Gap-Junctional Intercellular Communication,
Suppresses Paracellular Permeability of Human Intestinal Epithelial Cell
Monolayers Through Up-Regulation of Claudin-4
Hidekazu Morita, Tatsuro Katsuno, Aihiro Hoshimoto, Kazuki Hatakeyama, Yasuo Suzuki,
Yasushi Saito
Background: We reported previously that human intestinal epithelial cell monolayers overex-
pressing connexin 26, a component of gap junctions, show significantly reduced paracellular
permeability accompanied by up-regulation of claudin-4, a component of tight junctions.
(Morita H., et al. Exp Cell Res 2004). This finding indicated that enhancing gap-junctional
intercellular communication (GJIC) may suppress paracellular permeability accompanied by
altered expression of tight junction proteins. Aim: The present study was performed to
examine the effects of irsogladine [2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine maleate],
which is known to activate GIJC without influencing protein expression of connexins,
on the paracellular permeability of human intestinal epithelial cell monolayers. Methods:
Paracellular permeability of Caco-2 human intestinal epithelial cell monolayers was monitored
by measuring mannitol permeability and was chemically disrupted by treatment with oleic
acid and taurocholic acid. Western blotting analyses were performed to evaluate the protein
levels of occludin, claudin-1, -4, and β-actin. Results: Mannitol permeability of untreated
monolayers was 1.1 ± 0.1%, and was markedly increased by chemical disruption (42.2 ±
5.2%). Intriguingly, irsogladine treatment dose-dependently decreased mannitol permeability
of chemically disrupted monolayers, with a significant decrease in permeability (11.7 ±
1.2%) on treatment with 10-4 M irsogladine. To determine the mechanism by which irsoglad-
ine exerts this effect, we utilized 18α-glycyrrhetinic acid, an agent to interfere specifically
with GJIC. Addition of an excess amount of 18α-glycyrrhetinic acid to monolayers co-
treated with 10-4 M irsogladine again lead to a remarkable increase in permeability (40.1 ±
3.8%). These observations indicate that the treatment with irsogladine suppresses paracellular
permeability of human intestinal epithelial cell monolayers through activation of GJIC. We
next evaluated protein levels of components of tight junctions. Claudin-4 protein level was
significantly increased in epithelial cells treated with 10-4 M irsogladine, although no changes
were observed in those of occludin or claudin-1. Addition of an excess amount of 18α-
glycyrrhetinic acid to monolayers co-treated with 10-4 M irsogladine again decreased the
protein level of claudin-4. Conclusion: Activation of gap-junctional intercellular communica-
tion by irsogladine leads to a significant decrease in paracellular permeability of human
intestinal epithelial cell monolayers partly through up-regulation of claudin-4.
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S1710
Bile Enhances Barrier Function By a COX-2 Dependent Mechanism in Porcine
Duodenum
Jenna G. Wooten, B. D. X. Lascelles, Adam J. Moeser, Vanessa L. Cook, Dianne Little,
Anthony T. Blikslager
Previous studies suggest bile acids have a protective function in the duodenum, possibly
related to neutralizing H. pylori and by reducing the deleterious effects of stomach acid. In
preliminary studies, bile acids enhanced barrier function of porcine duodenum, suggesting
alternate protective effects. Because prostanoids have a positive effect on porcine intestinal
barrier function, we postulated deoxycholic acid would enhance duodenal barrier function
in a COX-2-dependent manner. Porcine intestinal mucosa was mounted on Ussing chambers
and transepithelial electrical resistance (TER), a sensitive measure of barrier function, was
calculated from voltage clamp measurements. Deoxycholic acid (DCA) was added in concen-
trations of 1mM-1μM to the luminal surface of porcine duodenal, stomach, and jejunal
mucosa. No effect of DCA was noted following application to stomach and jejunum. DCA
induced a dose-dependent increase in TER in the duodenum, significant at the 1mM dose.
Both the non-selective COX inhibitor, indomethacin, and a selective COX-2 inhibitor,
deracoxib, blocked the increase in TER, suggesting COX-2 is involved in DCA-induced
increased duodenal barrier function. Western analyses revealed increased expression of COX-
2 in bile treated tissues compared to untreated tissue. We have previously shown that
one mechanism for prostaglandin-mediated elevation of barrier function is blockade of
electroneutral sodium channels. Therefore, we applied the sodium channel blocker, amiloride
(1mM), to the luminal surface of duodenal mucosa. Amiloride simulated the effects of 1mM
DCA, and had no additive effects when added in combination with DCA, suggesting a
similar action of amiloride and DCA. These results indicate that DCA enhances barrier
function in duodenum in a COX-2 dependent fashion, possibly via prostenoid-induced
inhibition of amiloride-sensitive sodium channels. These findings may in part explain the
protective role of bile acids in duodenal barrier function.
S1711
Transcriptional Expression of Tight Junction Proteins in Celiac Disease and
Other Disorders with Compromised Intestinal Barrier Function
Maria G. Clemente, Amit Tripathi, Anna Sapone, Maria P. Musu, Paolo Usai, Stefano de
Virgiliis, Alessio Fasano
Background. Intestinal epithelial tight junctions (TJ) play a crucial role in regulating the
paracellular pathway. The relationship between the increased intestinal permeability observed
in several acute and chronic diseases and the expression of TJ-associated proteins is not
well established. Aim of this study was to investigate the expression at transcriptional level
of 3 transmembrane TJ proteins, occludin, claudin-1, claudin-2 and of 2 scaffold TJ proteins,
zonula occludens-1 (ZO-1) and myosin 9-beta in intestinal biopsies from patients affected
by celiac disease (CD), Crohn’s disease, peptic ulcer disease and Type 1 diabetes (T1D).
Methods. Samples of small intestinal mucosa were taken from the second/third portion of
the duodenum from subjects with active CD, CD on gluten free diet (GFD), peptic ulcer
disease, Crohn’s disease, T1D and T1D-relatives and healthy subjects. After total RNA
extraction and cDNA synthesis, quantitative real time polymerase chain reaction assays with
SYBR Green was performed. Data were normalized by using18S rRNA as standard. Results.
A significant down-regulation of all 5 genes studied was observed in CD when compared
to the controls. Specifically, occludin expression decreased by 84% (p=0.001), ZO-1 by
>99% (p=0.01), claudin-1 by 98% (p=0.01), claudin-2 by >99% (p=0.02), and myosin 9-
beta by 90% (p=0.01). Interestingly, the transcriptional level of all the 5 genes returned
within normal limits in CD subjects following the implementation of a gluten free diet. In
peptic ulcer disease, 3 out of 5 genes were found down regulated as follows: ZO-1 by >99%
(p<0.01), claudin-1 by >99% (p=0.01), and claudin-2 by >99% (p=0.02). In Crohn’s disease,
only occludin was found down regulated by 95% (p<0.01), while no transcriptional changes
were observed in T1D and their relatives. Conclusions. The down-regulation of intestinal
TJ transmembrane or/and intracellular components observed in CD, Crohn’s disease, and
peptic ulcer diseases might explain the increased intestinal permeability reported in these
pathological conditions. Conversely, our data suggest that the increased intestinal permeabil-
ity reported in T1D is probably associated to derangement of TJ protein-protein interaction
as previously reported. The meaning of TJs disruption in the pathogenesis of the pathological
conditions studied warrants further investigation. The normal transcriptional level observed
in CD patients on a gluten free diet suggests that the down-regulation of TJs in CD is
reversible and secondary to gliadin exposure rather than to a genetic predisposition.
S1712
Intestinal Permeability and Effect of NSAIDs On Permeability in Irritable
Bowel Syndrome Patients Compared to Healthy Subjects
Angele Kerckhoffs, M Samsom, M de Smet, Lma Akkermans, W Renooij
Post infectious Irritable Bowel Syndrome (IBS) patients have intestinal inflammation. Intest-
inal permeability is increased in some of these patients. In inflammatory bowel disease
NSAIDs enhance intestinal permeability. The aim of our study was to investigate intestinal
permeability in IBS patients and healthy subjects and to test the effect of NSAIDs on
permeability. Permeability was measured as urinary excretion of orally administered poly-
ethylene glycols (PEGs) of increasing molecular weights. A standard lactulose mannitol (LM)
excretion test was used for comparison. We determined intestinal permeability in 15 healthy
subjects and 14 IBS patients, diagnosed according to Rome II criteria, before and after 2
days naproxen (750 mg/day) using a PEG test and an LM test. Subjects drank a solution
of 5 g PEG 400, 1.5 g PEG 1500, 5 g PEG 4000 and 10 g PEG 10000 in 100 ml water.
Urine was collected at 2-hour intervals for 24 hours. PEGs were analyzed by HPLC, and
LM by routine clinical chemical analysis. Intestinal permeability was evaluated from areas
under the PEG -excretion time curves (AUC) ± SEM; data from IBS patients and healthy
subjects were statistically evaluated using Mann Whitney U test. P<0.0125 was considered

















statistically evaluated by the Wilcoxon test. LM ratio above 0.03 indicates increased intestinal
permeability. For statistical analysis of the LM test the Chi square test was applied. Differences
were considered significant at p<0.05. AUC of PEG 4000 in IBS patients (5.9 ± 2.4 mg/ml)
is significantly (p=0.006) smaller than in healthy subjects (16.1 ± 3.9 mg/ml). No significant
differences were found in AUCs of PEGs 400, 1500 and 10000. After NSAIDs ingestion a
significant increase of AUC of PEG 4000 to 26.4 ± 6.2 mg/ml was found in healthy subjects.
After NSAIDs ingestion by IBS patients, AUC of PEG 400 (18050 ± 3140 mg/ml), PEG 1500
(430 ± 140 mg/ml) and PEG 4000 (390 ± 19 mg/ml) were significantly increased compared
to AUC of PEG 400 (10440 ± 2290 mg/ml), PEG 1500 (160 ± 30 mg/ml) and PEG 4000
(6 ± 2 mg/ml) before NSAIDs ingestion. In the absence of NSAIDs, the LM ratio was increased
in 1 out of 15 healthy subjects and in 3 out of 13 IBS patients, which was not significantly
different. In conclusion, intestinal permeability for PEGs 4000 is decreased in IBS patients
compared to healthy subjects. NSAIDs compromise intestinal permeability to a greater extent
in IBS patients than in healthy subjects. This suggests that prostaglandin synthesis and thereby
the tight junctions are more affected by NSAIDs in IBS patients than in healthy subjects.
S1713
Sub-Population Specific Deficits of Vagal Gastric Mechanosensitivity in C-Kit
Deficient Wwv Mutant Mice
Michael Beyak, Sean Ward, David Grundy
W/Wv mutant mice (W/Wv+/-), deficient in the receptor tyrosine kinase c-kit have a loss
of interstitial cells of Cajal as well as intramuscular arrays (IMA), a type of putative vagal
mechanosensor. They also display altered meal intake patterns, either a consequence of
disturbed motility and/or altered afferent nerve function. Aim: To examine mechanosensitive
(MS) vagal afferent (VA) nerves innervating the proximal stomach of W/Wv+/- mice. Methods:
Extracellular recordings were performed in vitro from VAs innervating a 1 cm2 flat sheet
preparation of mouse gastric fundus from 6 male W/Wv +/- mice, using wild type littermates
(5), and wt C57Bl6 (5) mice as controls. Nicardipine (3µM) was used to prevent smooth
muscle contraction. Mechanical stimuli were applied using a motorized tissue stretcher,
attached to the edge of the preparation, connected to a strain gauge. Stretch was applied
0.1mm/s to a maximum tension of 10g. MS single units were discriminated using the Spike
2 software package. Results: Stretch increased VA firing in C57, WWv wt and W/Wv +/-
VAs. Responses did not differ between WWv wt and C57, and thus these were pooled as
a control group. Compliance was similar between W/Wv +/- and control preparations (mean
compliance 1.52±0.25 vs. 1.65±1.5 mm/g, p=0.5). A total of 18 mechanosensitive single
units from W/Wv +/- and 34 from WWv wt / C57 animals were examined. Response
properties at tension levels just above threshold were examined. In control preparations 2
distinct populations could be identified. One with a very low threshold (<1g), reaching
greater than 67% max firing rate at 2 g of stretch (called LT units) and another with higher
thresholds (>1g) reaching less than 33% of max firing rate at 2g stretch (called MT units).
Of 34 control single units examined, 13 were classified as LT, 14 as MT and 7 unclassified
between these. Of 20 single units from W/Wv +/- , 15 were classed as LT, 3 as MT and 2
unclassified (p<0.05, Fisher’s exact test). These differences were reflected in whole nerve
discharge patterns. W/Wv +/- preparations reached 74.5±5.2% max firing rate at 2g stretch,
control preparations reached only 55±8.5% max (p<0.05). Conclusions: Gastric VAs in W/
Wv +/- mutants are remarkably homogeneous in their stimulus response properties, reaching
maximal firing rates at low levels of stretch, consistent with previously described IGLEs.
Control animals have another class of MS units, tuned to encode more moderate stimulus
intensities. The differences in VA responses are not due to alterations in compliance. We
hypothesise that these MT units represent the IMA ending, which are significantly reduced
in W/Wv +/- mice.
S1714
Botulinum Toxin a Inhibits Gastric PYLORIC Smooth Muscle By Acetylcholine
Independent Muscle Hyperpolarization
Xue D. He, Bo Yang, Madhu Prasad, Raj K. Goyal
Objectives: Botulinum toxin A (BoTA) has been shown to have inhibitory effect on the
contractility of the gastrointestinal smooth muscles including the sphincters; and the toxin
has been clinically used in the treatment of disorders such as achalasia, gastroparesis and
other gastrointestinal motility disorders. The inhibitory effect of BoTA is generally thought
to be due to inhibition of acetylcholine release due to cleavage of SNAP 25 in the nerve
terminals by the toxin. Recent studies, however, suggest that BoTA may also directly suppress
smooth muscle contractility. However, the mechanism of the inhibitory action is not known.
We report here that BoTA acts by causing profound membrane hyperpolarization. Methods:
Intracellular recordings were made in circular smooth muscle cells of mouse antrum using
standard techniques. Effect of BoTA was investigated by incubation of these strips with the
toxin for up to 3 hours in order to allow its maximal effect on the cells. Results: Muscle
strips without treatment with atropine or nifedipine were very excitable. BoTA (10nM)
treatment within 3 sec reduced the excitability and stabilized the tissue. Atropine had a
similar effect, suggesting that BoTA acted promptly to suppress cholinergic excitation. Con-
tinued BoTA treatment (after 30 min) caused hyperpolarization that reaches its peak (-
75±0.2mV) after 3 hrs. Atropine treatment had no effect on the membrane potential. BoTA
induced hyperpolarization was not suppressed by tetrodotoxin pretreatment, suggesting that
the hyperpolarizing effect of BoTA was not neutrally mediated. BoTA induced hyperpolariz-
ation may be due to opening of potassium channels. However, the hyperpolarizing effect of
BoTA was not antagonized by K+ channel blocker TEA (10mM). In contrast, hyperpolarization
caused by chromokalim (10µM) was antagonized by TEA. We also performed whole cell
patch clamp studies on isolated smooth muscle cells and found that BoTA had marked
inhibitory effect on calcium activated BK currents. Conclusions: These observations indicate
that BoTA causes marked inhibition of smooth muscle involving mechanisms that are
independent of its effect on acetylcholine release from excitatory nerve terminals and opening
of the BK channels in the smooth muscle. BoTA may cause hyperpolarization of the smooth
muscle cells by suppressing other than BK potassium, chloride or cation channels.
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S1715
Less Expressions of Neuronal Nitric Oxide Synthase and Substance P in
Gastric Interstitial Cells of Cajal in Patients with Diabetes Mellitus
Hirohiko Iwasaki, Masayoshi Kajimura, Satoshi Oosawa, Mutuhiro Ikuma, Takahisa
Furuta, Shigeru Kanaoka, Yoshihiko Sato
Background and Aims: Interstitial Cells of Cajal (ICC) in gastrointestinal tract plays a central
role in gastrointestinal motility. Gastrointestinal motility is known to be impaired in patients
with long-standing diabetes mellitus (DM). However, there were few studies on whether
this motility disorder is associated with the impairment of ICC in DM patients. The present
study was undertaken to evaluate the density of ICC, neuronal nitric oxide synthase (nNOS),
substance P (SP) in gastric antrum in patients with DM and its relevance to the disease
severity. Materials and Methods: Paraffin-embedded gastric specimens obtained from 51
control and 36 diabetes male patients with gastric cancer were used for immunohistochemical
staining by C-KIT and mast cell tryptase specific antibodies. Further, fresh frozen gastric
specimens obtained from 6 control and 5 diabetes male patients with gastric cancer were
used for immunofluorescence staining by C-KIT, nNOS and SP specific antibodies, and C-
KIT, nNOS and SP densities were compared between control and diabetes patients. Results:
ICC density in inner circular muscle (CM) in patients with severe DM (66.1 ±23.3 / 2.5mm2)
was less than that in control(147.4 ± 11.4 / 2.5mm2). In addition, the immunofluorescence
study also demonstrated that C-KIT, nNOS and SP expressions in antrum (2.59 ± 0.35,
0.41 ± 0.18, 0.07 ± 0.01% ratio) was decreased in patients with DM compared to control(4.24
± 0.56, 2.06 ± 0.33, 0.52 ± 0.06% ratio). Further, the co-localized density of C-KIT and
nNOS or SP in patients with DM(C-KIT and nNOS 0.05 ± 0.02, C-KIT and SP 0.00 ± 0.00%
ratio) was decreased compared to control (0.44 ± 0.10, 0.14 ± 0.05% ratio). Conclusions: In
patients with DM, there were less expressions of nNOS and SP densities in gastric ICC
concomitant with deficiency of the ICC, suggesting that the presence of functional impairment
of ICC may be relevant to dysmotility symptoms observed in patients with DM.
S1716
Gastric Electrical Stimulation Entrains Gastric Slow Waves (GSWs) Via
Nitrergic Pathways in Rats
Yue Yu, Guangfu Yin, Wei Qian, Xiaohua Hou
Background & Aims: Gastric electrical stimulation (GES) had been paid more attention as
a therapeutic modality for gastroparesis. But its mechanism was still unknown. The aim of
our study was to investigate effects of nitrergic pathway on the entrainment of GSWs during
the gastric stimulation. Methods Sixty four male Wistar rats with two pairs of electrodes
were enrolled in this study. Firstly, four groups of 8 were used to investigate the effects of
L-NAME on the GSWs in vivo, including control with saline(ip), three groups with various
concentration L-NAME (50mg/kg, 25mg/kg, 12.5mg/kg, ip, respectively). Then, using
immunohistochemistry staining, the nerves containing nNOS were studied between the rats
(n=8) with GES and controls (n=8). Lastly, expression of nNOS mRNA in rats (n=8) with
GES was compared in rats without stimulation (n=8) using RT-PCR methods. Results: (1)
The lower dose of L-NAME (12.5mg/kg, 25mg/kg, respectively) had no influence on the
GSWs, but the higher dose of L-NAME (50mg/kg) induced gastric dysrhythmia. Moreever
GES normalized gastric dysrhythmia with higher energy of pacing stimuli (878.1±11.4 vs
537.5±91.6ms×mA, p<0.001). (2) In GES group, many nNOS positive fibers were observed
in the every layers of antrum, nNOS-positive ganglial cells and neuronal bodies were easily
found in the antral myenteric plexuses (AMP), but a few nNOS positive fibers were observed,
and nNOS -positive ganglial cells and neuronal bodies were difficultly found in AMP in
control group. The staining of the nNOS positive products in GES rats was stronger than
in control. (3) RT-PCR investigetion showed the levels of nNOS mRNA expression in GES
rats were much higher than in controls (1.18±0.47 vs 0.81±0.39, p<0.001). Conclusion:
Normalization of the L-NAME-induced gastric dysrrhythmias should have a high energy
gastric stimulation, which facilitate release of NO in antral myoenteric plexus. It shows
nitrergic pathways may be partly involved in the GES-induced entrainment on GSWs.
S1717
Botulinum Toxin a Inhibits Slow Waves in Mouse Gastric Antrum By a
Mechanism That Is Independent of Its Hyperpolarizing Effect
Xue D. He, Raj K. Goyal
Objectives: Botulinum toxin A (BoTA) has been shown to have marked inhibitory effect on
gastric antrum and pylorus and has been clinically used in the treatment of gastroparesis.
Although BoTA is thought to act by suppressing acetylcholine release from nerve terminals,
recent studies suggest that BoTA may directly suppress smooth muscle contractility. We
have shown that BoTA inhibits antral smooth muscle by causing profound membrane
hyprpolarization. We report here that BoTA also suppresses slow waves in the mouse antrum.
Methods: intracellular recording were made in circular smooth muscle cells of mouse antrum
using standard techniques. Effect of BoTA was investigated by incubation of these strips
with the toxin for up to 3 hours in order to allow its maximal effect on the cells. Results:
BoTA (10 nM) hyperpolarized the resting membrane potential (RMP) by 23 mV (control:
52 ± 1.4 mV vs BoTA treatment: 75 ± 2.2 mV, P<0.001, n= 7 in 5 animals) and nearly
abolished the slow waves after 3 hours of incubation. The amplitude of slow wave was 17
± 1.4 mV in control and 0.64 ± 0.3 mV after BoTA ( P<0.001). The frequency of slow wave
was 3.14 ± 0.3 cycle/min in the control and 0.4 ±0.2 cycle/min after BoTA treatment (p<
0.001), respectively. Atropine treatment had no effect on RMP or the slow waves. The effect
of BoTA on the slow waves could have been secondary to hyperpolarization of the RMP.
To determine whether the effect of the toxin on the slow waves was due to associated
hyperpolariztion, we investigated the effect of conditioning hyperpolarization using the
Tomita bath technique. Conditioning hyperpolarization of membrane from -56 mV to -81
mV did not significantly affect the slow waves. The amplitude and frequency of slow waves
were 11 ± 0.4 mV and 6 cycles/min in the control and 10 ± 0.5 mV and 6 cycles/min after
the conditioning hyperpolarization, respectively. On the other hand, potassium channel
opener chromokalim (10µM) caused membrane hyperpolarization (-15mV) and also partially
suppressed slow waves. We then examined the effect of recovery of the BoTA or chrormokalim
induced hyperpolarization by TEA (10 mM) on the slow waves. Recovery of BoTA induced
hyperpolarization did not recover the slow waves, but the recovery of chromokalim induced
hyperpolarization recovered the slow waves. Conclusions: These studies suggest that BoTA
causes hyperpolarization of the smooth muscles and loss of slow waves in gastric antrum
by two independent mechanisms.
S1718
Effect of Infused Gastric Content On Gastric Distribution, Gastric Pressure,
and Blood Pressure in Conscious Rats with Normal and Impaired Gastric
Accommodation
Pieter Janssen, Maria Astin Nielsen, Per-Goran Gillberg, Leif Hultin
Introduction The stomach accommodates food without major intragastric pressure (IGP)
increase. Impairment of gastric accommodation was associated with abnormal food distribu-
tion in the stomach (overloading the antrum) and causes symptoms in functional dyspeptic
patients. Previously we showed that Wistar Kyoto (WKY) rats have impaired gastric accom-
modation compared to Sprague Dawley (SD) rats. We set out to compare these strains in
a novel model in which we can measure IGP and gastric distribution in response to test-
meal infusion. Blood pressure was measured as a marker for visceral sensation/pain. Material
& Methods All experiments were performed in 6 weight matched female SD and WKY
rats. 2 weeks before the start of the experiments telemetric bloodpressure devices and gastric
fistulas were implanted. After an overnight fast, a test-meal infusion system and a catheter
to measure IGP were connected to the gastric fistula. After a 20 min stabilisation period,
test-meal (non-nutritious; containing 0.5gr barium sulphate/ml in a 3% hydroxypropyl
methylcellulose solution) was infused at a preset speed of 0.25 ml/min for 2 min, thereafter
2 ml/min until 9 ml infused. Mean arterial blood pressure during infusion was compared
to the mean blood pressure before the start of the infusion. Forestomach, corpus and
antrum area, calculated as % of the total stomach area, were evaluated from X-ray pictures
continuously taken during the experiments. Results are expressed as mean±SEM. Results
In SD rats IGP increased linearly to 11.2±0.6 mmHg at 4 ml infused and remained stable
at this level during further infusion. The IGP in WKY rats, however, increased linearly
during the whole test-meal infusion to a maximum of 18.9±1.9 mmHg. Blood pressure
during infusion increased 6±2% in SD rats and 11±3% in WKY rats. With increasing gastric
content, the relative forestomach and antrum area increased to respectively 55±2 and 16±1%
in SD rats vs. 48±1 and 20±2% in WKY rats, whereas the relative corpus area decreased to
30±3 and 32±2% in SD and WKY rats respectively. Discussion & Conclusion This novel
rat model can be used to study gastric distribution, intragastric pressure and cardiovascular
reflexes in response to increasing gastric content. For the same infused volume, WKY rats
showed increased IGP and blood pressure, and the content was more distally distributed
as compared to SD rats. This data suggests that increased sensitivity to gastric content is
associated with impaired gastric accommodation and can be linked to distal stomach overload
but also with increased intragastric pressure.
S1719
Esophageal-Gastric Relaxation Reflex: Dual Control of Peripheral Nitergic and
Cholinergic Transmission
Gerlinda E. Hermann, Alberto Travagli, Richard C. Rogers
Esophageal distension produced by swallowing food elicits a powerful proximal gastric
relaxation. This gastroinhibitory control by esophageal afferents involves neural pathways
between esophageal distension-sensitive neurons in the nucleus tractus solitarius, pars cent-
ralis (cNTS) and virtually all levels of the dorsal motor nucleus of the vagus (DMV)[1]. We
have shown recently that cNTS responses are excitatory and primarily involve tyrosine-
hydroxylase immunoreactive (TH-IR)cells [2], while the DMV response involves both an
α1 excitatory and an α2 inhibitory response [3]. In the present study, an esophageal balloon
distention (160uL) was used to evoke fundic relaxation (esophageal-gastric reflex = EGR)
as measured by an extraluminal strain gauge aligned with the circular smooth muscle of
the fundus. We investigated the peripheral pharmacologic basis for this reflex. Systemic
administration of atropine reduced the amplitude of the gastric relaxation to 52.0 + 4.4% of
the original EGR, while L-NAME reduced it to 26.3 + 7.2% of the original EGR. Concomitant
administration of atropine and L-NAME reduced the amplitude of the gastric relaxation to
4.0 + 2.5% of control. This reduction in amplitude of induced EGR is quite comparable
(4.3 + 2.6%) to that seen when the animal is pretreated with the nicotinic ganglionic blocker,
hexamethonium [See Figure below]. In the presence of bethanechol, the amplitude of the
esophageal-distention induced gastric relaxation was increased to 177.0 + 10.0% of control.
In this pretreatment condition, administration of L-NAME reduced the amplitude of the
gastric relaxation to 19.9 + 9.5%. Thus far, our data provide a clear demonstration that
gastroinhibitory control by the esophagus is mediated by vago-vagal reflexes causing activa-
tion of inhibitory nitrergic (NANC) and withdrawal of excitatory cholinergic transmission
to the fundus. 1. Rogers RC, Hermann GE, and Travagli RA. JPhysiol 514: 369-383,1999.
2.Rogers RC, Travagli RA, and Hermann GE. Am J Physiol 285: R479-R489, 2003. 3.
Martinez-Pena y Valenzuela I, Rogers RC, Hermann GE, and Travagli RA. Am J Physiol 286:
G333-339, 2004. Supported by NIH grants DK 56373 and 52142
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S1720
Opposite Effects of Clonidine and Sumatriptan On Postprandial Gastric
Volume Response and Liquid Emptying As Assessed By MRI in Health
Monika A. Kwiatek, Andreas Steingoetter, Dieter Menne, Oliver Goetze, Geoffrey S.
Hebbard, Peter Boesiger, Miriam Thumshirn, Werner Schwizer, Michael Fried
INTRODUCTION: Gastric barostat has shown relaxation of human proximal stomach after
clonidine, an α2-adrenergic, and sumatriptan, a 5-HT1B/D receptor agonists. While clonidine
does not affect solid gastric emptying, sumatriptan prolongs and induces a lag phase after
ingestion of solids and liquids, respectively. The physiological intragastric volumetric
responses under non-invasive conditions are uncertain. AIM: To assess the characteristics
of accommodation and gastric emptying of liquid following pharmacologic modulation of
proximal stomach motility by clonidine and sumatriptan. METHODS: Using 1.5T whole
body magnetic resonance scanner, 9 healthy fasted volunteers were examined on three
separate days directly after (t0, V0) consuming a 500mL, 200kcal glucose drink labeled with
500µM Gd-DOTA in right decubitus position. Medications were administrated at the start
of liquid ingestion in double-blind randomized order: (a) placebo (0.9% NaCl) IV, (b)
clonidine (0.01mg/min, max. dose 0.1mg) IV, (c) sumatriptan (6mg) SC. Intragastric volumes,
total gastric (TGV) and meal volumes (MV), were assessed at 5min intervals for 90min.
RESULTS: In all treatments, gastric relaxation (ΔTGV t-5→0min) was similar. The stomach
expanded to a volume greater than the ingested meal (p<0.001). Subsequent emptying was
immediately accelerated by clonidine (p=0.001) and delayed by sumatriptan (p<0.001).
Decreases in TGV and MV paralleled over the entire postprandial period (p=0.07). CONCLU-
SION: During non-invasive volume measurements, initial gastric relaxation is not amplified
by clonidine and sumatriptan, implying that initial relaxation is determined by meal volume
load. In contrast to reports after solid ingestion, clonidine accelerates liquid emptying in
health. Despite differential postprandial effects, both medications preserve the relationship
between total gastric and meal volumes.
mean±SEM; *p<0.05 vs. placebo; T50, half-emptying time
S1721
Clonidine Increases Postprandial Distal Antral Motility and Occlusion in
Contrast to Sumatriptan - Assessment By MRI in Health
Monika A. Kwiatek, Anupam Pal, Andreas Steingoetter, Dieter Menne, Oliver Goetze,
James G. Brasseur, Geoffrey S. Hebbard, Peter Boesiger, Michael Fried, Werner Schwizer
INTRODUCTION: Clonidine, an α2-adrenergic, and sumatriptan, a 5-HT1B/D receptor
agonists cause relaxation of the proximal stomach detectable by gastric barostat. Whilst
clonidine has no effect on solid gastric emptying, sumatriptan prolongs solid emptying and
induces a lag phase after ingestion of liquids. The accompanying antral motility patterns
are uncertain, especially for liquid meals and in non-invasive conditions. AIM: To assess the
propagation and geometry of distal antral contraction waves (ACWs) following pharmacologic
modulation of gastric motility by clonidine and sumatriptan. METHODS: Using 1.5T whole
body magnetic resonance scanner, 9 healthy fasted volunteers were examined in right
decubitus position on three separate days directly after (t0) consuming a 500mL, 200kcal
glucose drink labeled with 500µM Gd-DOTA. Medications were administrated at the start
of liquid ingestion in double-blind randomized order: (a) placebo (0.9% NaCl) IV, (b)
clonidine (0.01mg/min, max. dose 0.1mg) IV, (c) sumatriptan (6mg) SC. ACWs were assessed
with dynamic MR scan sequences (duration: 167s) at 5min intervals, between measures of
gastric emptying (GE), for 90min. RESULTS: Clonidine accelerated (p=0.001) and sumatrip-
tan delayed GE (p<0.001). Initially (t0→15min), clonidine increased the number of accom-
panying ACWs, while a prolonged (t0→40min) reduction was seen after sumatriptan (both
p<0.04). Propagation speed (2.6±0.3mm/s) of ACWs was not affected. Under placebo, the
immediate (t0) maximal occlusion increased over time (p<0.01). Both drugs enhanced this
maximal occlusion (p<0.01), which was maintained and steadily diminished under clonidine
and sumatriptan, respectively (p<0.02). In all treatments, ACWs had the highest amplitude
and the smallest width close (0-1 cm) to the pylorus (all p<0.01). SUMMARY: Clonidine
and sumatriptan have distinct effects on ACWs. Intensification of ACWs caused by clonidine
may contribute to faster liquid emptying. Reduction in antral motility by sumatriptan
enhances the delay in emptying. CONCLUSION: Stimulation of adrenergic and serotonergic
pathways plays a significant role in modulation of liquid emptying by inhibiting motility of

















mean±SEM; *p<0.05 vs. placebo; T50, half-emptying time
S1722
Chronic Alcohol Consumption Impairs Nitrergic Inhibition in the Mouse
Small Intestine
Monika Krecsmarik, Benedicte Y. de Winter, Joris G. de Man, Maria Bagyanski, Luc van
Nassauw, Eva Fekete, Paul A. Pelckmans, Jean-Pierre Timmermans
Introduction: Chronic ethanol administration has been shown to alter gastrointestinal motility
in alcoholic patients and laboratory animals but the cellular mechanisms underlying altered
smooth muscle contraction are largely unknown. Part of the nitric oxide (NO) producing
neurons constitute an important enteric neuronal population playing an essential role in
regulating the downstream inhibitory phase of peristalsis. Therefore, we aimed at investigating
the effect of chronic ethanol consumption on the survival rate and functioning of these
neurons and its implications on smooth muscle contractility and gastrointestinal transit.
Methods: Mice received a gradually increasing concentration of ethanol in water with a final
concentration of 20%, while the control group received isocaloric sucrose solution. Using
PGP9.5- and NOS-immunostaining, a quantitative analysis of the total number of myenteric
small intestinal neurons and of the proportion of nitrergic myenteric neurons was performed
after 4 and 6 weeks of alcohol treatment. The effect of ethanol treatment on nitrergic
relaxations to electrical field stimulation (EFS) and exogenous NO of jejunal circular muscle
strips was investigated in vitro. Gastric emptying (GE) and small intestinal transit were
measured in vivo after intragastric gavage of Evans blue and expressed as %GE and geometric
center (GC) respectively. Results: The number of NOS-IR neurons did not change in the
duodenum, however, it decreased significantly in the jejunum by 17-20% (P<0.01-P<0.001)
after 4 and 6 weeks of alcohol treatment, respectively. The total number of neurons remained
unchanged. In jejunal circular muscle preparations, the nitrergic nerve-mediated relaxations
to 1, 2 and 4 Hz EFS were significantly decreased after 5 weeks of ethanol treatment
compared to controls: from 63.79 ± 4.54 % to 30.95 ± 7.89 %; from 81.25 ± 3.85 % to
55.71 ± 6.04 %; from 84.64 ± 2.96 % to 67.92 ± 5.96 % respectively (P<0.05) while
relaxations to NO remained unchanged. GE and GC were significantly increased after 5
weeks of ethanol treatment from 26.4 ± 5.2 %GE and 2.1 ± 0.1 GC in controls to 40.6 ±
4.1 %GE and 2.5 ± 0.1 in ethanol-treated mice. Conclusions: These results are suggestive
of an adaptive, region- and time-dependent, quantitative and functional change in nitrergic
innervation within the murine enteric nervous system in response to chronic alcohol con-
sumption. These changes may partially account for the observed increased gastrointestinal
transit.
S1723
Botulinum Toxin a Inhibits Inhibitory Junction Potentials in Gastric PYLORIC
Smooth Muscles
Raj K. Goyal, Xue D. He
Objectives: Botulinum toxin A (BoTA) has been shown to have inhibitory effect on the
contractility of the gastrointestinal smooth muscle including the sphincters and the toxin
has been clinically used in the treatment of disorders such as achalasia, gastroparesis and
other gastrointestinal motility disorders. The inhibitory effect of BoTA is generally thought
to be due to inhibition of acetylcholine release due to cleavage of SNAP 25 in the nerve
terminals by the toxin. However, it is not clear whether BoTA also inhibits the release of
the inhibitory neurotransmitter. We report here that BoTA also suppresses the inhibitory
junction potentials (IJPs) in the mouse gastric antrum. Methods: Intracellular recordings
were made in circular smooth muscle cells of mouse antrum using standard techniques.
Tetrodotoxin sensitive junction potentials were produced by EFS (trains of 10 pulses of 5.0
msec and 30 mA at 20 Hz). Effect of BoTA was investigated by incubation of these strips
with the toxin for up to 3 hours in order to allow its maximal effect on the cells. Results:
BoTA (10nM) promptly suppressed cholinergic excitability of the muscles strips that was
followed by membrane hyperpolarization that reached a peak effect (-75 mV) in 3 hours.
No excitatory junction potentials (EJPs) were observed at any time after the toxin treatment.
However, the IJP amplitude was 20mV in the control period; they were progressively
suppressed with continued toxin exposure and were abolished at 3 hours. The suppression
of the IJP by BoTA could be secondary to the associated membrane hyperpolarization or
the suppression of the release of inhibitory neurotransmitters or both these effects. However,
recovery of the BoTA induced hyperpolarization by TEA (10 mM) did not recover the
IJP. Conclusions: The studies show that BoTA not only causes smooth muscle membrane
hyperpolarization but also suppresses the release of the excitatory as well as the inhibitory
neurotransmitters form the nerve terminals. However, BoTA is more effective in suppressing
the excitatory than in suppressing the inhibitory neurotransmission.
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Neurally Mediated Chronotrophic Effects On Gastric Pacemaking Is Limited
By Cholinesterase Actviity
Abigail Forrest, Sean M. Ward, Yulia Baguinov, Brian A. Perrino, Fiona Britton, Rebecca
Partain, Kenton M. Sanders
Background: Acetylcholine (ACh) released from enteric motor neurons causes chronotropic
effects on slow wave frequency in the distal stomach. Methods: We used electrophysiological,
molecular (PCR) and protein chemistry (Western blots, immunohistochemistry) techniques
to determine the relative expression of AChEsterase (AChE) in gastric corpus and antrum
and the effects of AChE inhibition on gastric slow wave frequency. We also compared AChE
expression and the effects of neostigmine (AChE inhibitor) in muscles of wildtype and W/
WV mice that lack specific classes of ICC. Results: Neostigmine had chronotropic actions
on corpus and antrum muscles. These effects were blocked by tetrodotoxin and atropine,
demonstrating that spontaneous release of ACh from nerve terminals is efficiently metabolized
by AChE and the chronotropic effects of ACh are kept in check by metabolism. In simultan-
eous intracellular recordings from the corpus and antrum, neostigmine significantly increased
slow wave frequency in both regions but did not lead to functional uncoupling between
the corpus and antrum, suggesting that there is balanced ACh metabolism in both regions.
These effects were also blocked by atropine. Chronotropic effects of neostigmine were absent
in W/WV mice that lacked intramuscular ICC (ICC-IM). Immunohistochemical studies found
AChE-like immunoreactivity occurred in a network of nerve fibers in both corpus and
antrum but not in ICC-IM. Quantitative PCR and Western blots showed that transcriptional
and translational expression of AChE were not significantly different in wildtype and W/WV
muscles from either the corpus or antrum. The enzymatic activity of the AChE was also
comparable in antral and corpus muscles from wildtype and W/WV mice. Conclusion: Potent
chronotropic effects are provided by muscarinic stimulation of gastric muscles. Efficient ACh
hydrolysis is required to maintain basal slow wave frequency. Release and metabolism of ACh
appears balanced between the proximal and distal stomach with no apparent heterogeneity in
cholinergic regulation of slow wave frequency, which if unbalanced, could result in functional
uncoupling. Neurons appear to be the major source of AChE in gastric muscles, so loss of
ICC-IM does not impact ACh metabolism. Lack of effect of AChE inhibition in W/WV
mutants is likely due to the breakdown in cholinergic neurotransmission when synapses
between cholinergic neurons and ICC-IM are lost. Imbalances in AChE expression or function
in disorders such as gastroparesis, might contribute, however, to inappropriate ACh metabol-
ism and changes in the chronotropic effects of muscarinic stimulation (Supported by
DK40569).
S1725
Abatement Effect of Daikenchuto, One of the Japanese Traditional Herbal
Medicine (KAMPO MEDICINE), On the Morphine-Induced Slowing of
Gastrointestinal Motility
Nakamura Tomonori, Mizuki Hayashi, Keiko Onoue, Shizuko Tsuchiya, Shingo Yano,
Kageyoshi Ono
Backgrounds: Morphine-induced constipation is one of the most severe adverse reactions
of drugs. A large number of patients who suffer from carcinomatous strong pain are troubled
with the heavy constipation by morphine. The herbal medicine Daikenchuto (DKT) is a
mixture of three herbs, Zanthoxylum Fruit, Ginseng Root and Dried Ginger Rhizome, and
recently has been applied to post-operative paralytic ileus in Japan. In our recent study,
DKT has been shown to abate morphine-induced slowing of gastrointestinal (GI) transit in
mice. Aim: We investigated the mechanism in eliciting stimulatory effect of DKT on the GI
motility. Methods: Morphine hydrochloride (2 mg/kg) was i.p. administered in ddY mice
(male, 6 weeks old) to make the GI disorder model. DKT (100, 300 and 1000mg/kg) was
orally administered 60 min before the onset of experiments. GI transit rate and rectal
excretion time were measured by modified charcoal meal test and glass bead test, respectively.
In the isolated ileum experiments, the contractile responses to autonomic drugs were meas-
ured using a Magnus apparatus. Results: The slowing of intestinal transit by morphine was
definitely recovered by DKT in a dose-related manner. Similarly, the rectal excretion time
was improved by DKT. In in vitro experiments, DKT transiently contracted the isolated
ileum; this effect was mediated largely through cholinergic pathway. To elucidate the long-
lasting effect of DKT on the isolated ileum, the responses to constrictors were measured
after a short-term exposure of the ileum to DKT. As a result, the contractile sensitivity to
a submaximal dose of acetylcholine, serotonin or substance P was significantly augmented
for more than 60 min after DKT exposure. These responses were also replicated by a exposure
to hydroxyl-sanshool (HS), the active component of Zanthoxylum Fruit. The potentiation
by HS was partially blocked by capsazepin, a VR1 antagonist. To confirm the enhancement
of GI motility by HS in in vivo experiments, pretreatment with HS (3 mg/kg, p.o.) was
conducted 90 min before application of mosapride (0.1~1 mg/kg, p.o.), a selective 5-HT4
agonist. The intestinal transit rate was significantly accelerated by the combination of HS
and mosapride. Conclusion: DKT improves morphine-induced slowing of GI transit in mice.
The underlying mechanism therein may be due to long-lasting effect of DKT in augmenting
the contractile response to endogenous constrictors such as acetylcholine, serotonin and
substance P in the GI tract.
S1726
How Common in Rapid Gastric Emptying in Gastroparesis? Comparison of
Area Under the Curve, Total Gastric Emptying and 1 Hour Values in Patients
and Normal Volunteers
Thomas L. Abell, Warren Starkebaum, Nighat Abidi, An Liu
Introduction: Rapid gastric emptying has been described not only in patients with nausea
and vomiting and gastroparesis but also in obesity and dyspepsia. We investigated the use
of 3 measures of rapid gastric emptying in a large group of gastroparetic patients compared
to normal controls. Patients: From a pool of 214 consecutive patients with the symptoms
of gastroparesis we reviewed the results of standardized solid gastric emptying tests and
compared the results to a groups of normal controls as previously described (AJG 95: 1456-
14622000). Patients were 39 male, 175 femalef mean age 42 years, with diagnosis of 42
Diabetes Mellitus, 26 Post Surgical and 146 Idiopathic disease. Methods: Gastric emptying
was compared by 3 models: Area under the emptying curve (AUC, rapid < 0.257), total
gastric emptying (TGE: the sum of 1, 2 and 4 hours; rapid<47), and % remaining at 1 hour
(<37%)for rapid and/or at 4 hours (>10%) for delayed emptying, using data and techniques
previously described (AGJ2004;99:S45 and NGM 2005; 17: 470). Results: Measurable gastric
emptying could be determined for 4 hour emptying in 146 patients; 87 patients had complete
1, 2 and 4 hour emptying. 44 patients had delayed emptying by 4 hour% > 10%. 7 patients
(8%) had rapid gastric emptying by AUC and 8 pts (9%) had rapid emptying by the TGE
values; and 16 (18%)pts had rapid emptying by the 1 hour value alone. Conclusion Rapid
gastric emptying of a solid meal is not uncommon in patients with the symptoms of
gastroparesis. The AUC and TGE models identified approximately the same number of
patients with rapid emptying, while the 1 hr model identified approximately twice as many
patients. Using the three techniques described to determine rapid gastric emptying awaits
prospective use in other patients, including dyspepsia and obesity. Standardized measure for
rapid gastric emptying may be useful in evaluating therapeutic outcomes for these disorders.
S1727
Delayed Liquid and Solid Gastric Emptying in Non-Dyspeptic Patients with
Irritable Bowel Syndrome
Stamatiki Kritas, Lauren V. Garritt, Lesley M. Stevenson, Geoff P. Davidson, Ross N.
Butler
Introduction: Irritable Bowel Syndrome (IBS) is the most common functional gastrointestinal
disorder affecting 15-20% of the population worldwide. The causes of IBS are unknown
and patients present with a range of recurrent and chronic symptoms. Many factors are
currently thought to be involved in the pathophysiology of IBS, such as psychological status,
gut hypersensitivity and low-grade inflammation. Impaired intestinal transit has also been
reported in IBS patients, however, the contribution of gastric motility, specifically gastric
emptying, has only been evaluated in IBS patients with concurrent functional dyspepsia.
Studies investigating gastric emptying in IBS patients without dyspepsia have all been
contradictory. The current study evaluated both liquid (GE-L) and solid (GE-S) gastric
emptying in IBS patients utilising 13C breath testing. Methods: All subjects fulfilled the
ROME II criteria and all with concurrent dyspepsia were excluded. After an overnight
fast and a baseline sample, 53 IBS patients (37.3±2.0yrs, 70%F) and 15 healthy controls
(59.4±3.7yrs, 67%F) underwent a GE-L breath test by ingesting 200mL full cream cow’s
milk. On a separate occasion, 37 IBS patients (36.1±2.1yrs, 76%F) and 11 healthy controls
(55.6±5.9yrs, 55%F) ingested a standard pancake for a GE-S breath test. Both meals (liquid
and solid) contained 100mg 13C-sodium octanoate salt and breath samples were collected
at intervals before and after ingestion of each meal for 240 and 360min, respectively. Breath
samples were analysed for 13CO2 content and gastric half emptying times were calculated
from the resulting 13CO2 excretion curves. Results: Gastric emptying time was significantly
longer in IBS patients compared to controls for both the liquid (62.1±6.8min vs. 40.6±3.0min,
p=0.001) and solid meal (87.1± 8.34min vs. 66.2±4.4min, p=0.030). Conclusions: IBS
patients without concurrent dyspepsia had significantly delayed liquid and solid gastric
emptying compared to controls. This suggests the potential involvement of altered gastric
motility in the pathophysiology of IBS. Further studies are required to evaluate the effect-
iveness of gastrokinetic drugs as potential therapies for IBS.
S1728
Relationships Between Proximal Gastric Relaxation and Gastric Emptying in
Humans: Roles of Meal Volume and Calorie Content
Karla Lourenco, Larissa Sanches, Luiz Troncon, Ricardo B. de Oliveira
BACKGROUND- Proximal gastric relaxation (PGR) and gastric emptying (GE) rate are
thought to exert mutual influences on each other. Nevertheless, the relationships between
PGR and GE in humans have not been much studied. AIMS - We investigated the relationships
between PGR and GE of liquid meals with different volume and calorie content. METHODS -
Three liquid meals labeled with 99m Technetium-phytate were administered to 15 healthy
volunteers in a random order in separate days (meal A: 60ml, 57Kcal; meal B: 60ml,
137.5Kcal; meal C: 360ml, 57Kcal). During meal ingestion and for the next 10 min, images
of the proximal stomach were acquired by dynamic scintigraphy (one frame.sec-1) for PGR
measurement. Thereafter, anterior and posterior images of stomach were acquired in static
mode at 10 min intervals up to 70 min GE assessment. PGR was expressed as the percentage
of total radioactivity retained in the proximal stomach. GE was expressed as the percentages
of total radioactivity emptied from the total stomach. RESULTS - Ten min after the low
volume, low calorie meal (A), PGR was low (median; range-7.6%; 2.3-41.5%). Increasing
both ingested calorie content (meal B) and volume (meal C) was associated with enhanced
PGR (meal B - 15.4%; 1.4-31.3%; p>0.50 vs. meal A; meal C - 16.1%; 7.0-41.8%; p=0.021
vs. meal A). Although there were no significant differences between meals regarding GER
(median; range - meal A: 34.1%; 27.9-70.6%; meal B: 25.2%; 16.9-51.2%; meal C: 29.1%;
18.9-67.9%; p>0.05). A strong (r=0.76) and significant (p=0.01) positive correlation between
PGR and GE was found for meal B. No significant correlation between PGR and GE was
observed with the meal A (r = 0.11; p = 0.75) e meal C (r = 0.03; p = 0.93). CONCLUSIONS -
In humans, both meal calorie content and volume enhances proximal gastric relaxation
within the early pos-prandial period of liquid meals, but only calorie-induced relaxation
seems to depend on the rate nutrients leave the stomach.
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Glucagon Alters Frequency and Propagation Velocity of the Gastric Slow Wave
Magnetic Field
Leonard A. Bradshaw, Jared A. Sims, Katie McDonald, William O. Richards
Alterations in the gastric slow wave may have important implications for the diagnosis of
certain diseases. Previous studies have shown that gastroparesis causes slow wave frequency
changes reflected in electrogastrography (EGG) [1]. We have previously used magnetogas-
trography (MGG) to measure spatial and temporal parameters of the gastric slow wave
noninvasively [2]. In this study, we hypothesized that spatiotemporal slow wave changes
induced by hyperglycemia would be reflected in the MGG. We measured the MGG in 20
normal human volunteers using a multichannel Superconducting QUantum Interference
Device (SQUID) magnetometer. After a 20-minute baseline recording, we injected glucagon
(9 mcg/kg IV) and recorded for an additional 40 minutes. The gastric slow wave was evident
in MGG recordings by visual analysis of waveforms. We used FFT and AR analysis to
compute the frequency spectrum, and we assessed the gastric slow wave frequency and
amplitude as the dominant peak in the spectrum. In addition, we used the FFT spectrum
to compute the percentage of power distribution (PPD) in frequency ranges denoted as
bradygastric (< 2 cpm), normogastric (2-4 cpm) and tachygastric (> 4 cpm). We also used
the spatiotemporal information from the MGG to compute surface current densities (SCDs)
that allowed us to evaluate the slow wave propagation velocity. MGGs reflecting the gastric
slow wave were measured in all 20 subjects. The slow wave frequency dropped from 2.9
± 0.1 cpm (mean ± SEM) to 2.4 ± 0.2 cpm post-glucagon (p<0.05). There was no change
in slow wave amplitude after glucagon injection (2.6 ± 0.4 pT to 2.0 ± 0.2 pT, p=0.09),
but we did note a significant decrease in the normogastric PPD (63.0 ± 3.0% to 41.5 ±
3.2%, p<0.01) and a concomitant significant increase in bradygastric PPD. We observed an
increase in tachygastric PPD that was not significant. Further, gastric slow wave propagation
velocities computed from SCD maps decreased post-glucagon from 7.9 ± 0.7 mm/s to 4.2
± 2.1 mm/s (p<0.05). The multichannel MGG noninvasively measures changes in the gastric
slow wave caused by glucagon. We are now evaluating diabetic patients with hyperglycemia
to identify slow wave abnormalities that may be associated with diabetic gastroparesis.
References [1] Abell TL, Malagelada JR. Glucagon-evoked gastric dysrhythmias in humans
shown by an improved electrogastrographic technique. Gastro 88(6): 1932-1940, 1985. [2]
Bradshaw LA, Ladipo JK, Staton DJ, Wikswo JP, Jr., and Richards WO. The human vector
magnetogastrogram and magnetoenterogram. IEEE Trans. Biomed. Eng., 46(8): 959-970,
1999.
S1730
Gastric Emptying in Diabetic and Non-Diabetic Mice
Kyoung M. Choi, Jin Zhu, Simon J. Gibbons, Gary J. Stoltz, Steven A. Vernino, Joseph H.
Szurszewski, Gianrico Farrugia
Background: Diabetic gastroparesis is a complex disorder associated with delayed gastric
emptying (GE). Mouse models are very helpful in studying the complications of diabetes.
The conventional method for measuring GE in mice requires sacrificing multiple animals
at given time points. Changes in GE in individual mice over time and during development
of diabetes however cannot be studied by this technique. Aims: Apply a non-invasive 13C-
octanoic acid-based technique to determine GE changes in non-obese diabetic mice (NOD/
LtJ) over time and as diabetes develops and to compare their GE to a closely related strain,
NOR, often used as controls. Methods: A modification of the technique described by Symonds
(Clin Exp Pharm Physiol, 2000) was used. 200 mg of egg yolk containing 13C-octanoic acid
was used as the test meal. Non-restrained mice were placed in specifically designed chambers
with a constant air flow. The amount of 13CO2 in exhaled breath was measured using an
Infra Red Isotope Analyzer (IRIS, Wagner, Germany) over 240 min. 13C-octanoic acid is
rapidly absorbed in small intestine, metabolized in liver to CO2, and exhaled giving a
measure of GE. Data were fit by non-linear regression and gastric half-emptying time (T1/
2) calculated using an inverse gamma function. T1/2 was determined in three age groups of
non diabetic mice (blood glucose < 155 mg/dl); 9-15, 16-30 and 31-45 weeks and weekly
after development of diabetes (>250 mg/dl). Results: T1/2 (min, mean±SEM) was unchanged
in the different age groups and between NOD and NOR mice (P>0.05 all groups, ANOVA,
see table). T1/2 (min) was not significantly different between pre-diabetic mice (glucose level:
156-249 mg/dl, T1/2 83±9, n=10) and mice diabetic for 1 week (75±4, n=17). However,
T1/2 was significantly faster after 2 weeks of diabetes (49±6, n=7, P<0.05). After 3-5 weeks
of diabetes the T1/2 increased back to baseline values (73±8, n=17, P>0.05 c/w prediabetic
mice). Conclusion: Gastric emptying is unchanged with increasing age in NOD and NOR
mice. NOR mice have similar GE as non diabetic NOD mice, which confirms that NOR
mice are useful controls in the study of diabetic gastroparesis. In the early weeks after
development of diabetes, GE is accelerated, not delayed. Therefore, care must be taken to
measure the actual rates of GE when studying the histological and physiological changes
associated with the early stages of diabetes. This work is supported by NIH grants DK68055
and DK57061.
S1731
Effects of short-Term L-Arginine Administration On Proximal Stomach Tone
and Gastric Emptying of a Polymeric Enteral Diet in Humans
Guillaume Savoye, Yassine Jemaa, Gregory Mosni, Celine Savoye-Collet, Paola Morcamp,
Mickael Bouin, Philippe Denis, Philippe Ducrotte
Backgrounds and aims: Endogenous nitric oxide (NO) plays an important role as non-
adrenergic, non-cholinergic inhibitory neurotransmitter in GI tract. Our study aim was to

















on proximal stomach tone and gastric emptying of a polymeric enteral diet in humans.
Methods: Eight healthy volunteers were studied in a randomized double blind cross-over
study after respectively 15 grams L-Arg, 30 grams L-Arg or placebo administered in the
stomach through a gastric tube. The drug administration was followed by a polymeric diet
infusion (500 ml/500Kcal) at a 250ml/hour rate. The gastric tone variations were recorded
with an electronic barostat, gastric emptying was concomitantly assessed by repeated ultra-
sound measurements of antral area and symptoms were recorded throughout the experiment.
Results: L-Arg administration was associated with more frequent proximal stomach relaxa-
tions and significantly higher increases in barostat bag volumes at both dosage, 30 grams
(117± 16 ml) and 15 grams (67±15 ml) as compared to placebo (46±11 ml), p<0.05. The
30 grams L-Arg challenge was associated with a significantly lower increase in maximal
barostat bag volumes in response to the polymeric diet (80±20 ml) as compared to 161±17
ml for placebo challenge and 126±30 ml for 15 grams L-Arg challenge. Antral area were
not different at any time of measurement between the 3 challenges. Bloating and diarrhea
were observed after 30 grams L-Arg administration in 5 subjects out of 8. Conclusion: Short
term L-Arg administration was able to induce a proximal stomach relaxation that allowed
a secondary response to enteral feeding only at a 15 grams dosage. This 15 grams dosage
was as well tolerated as the placebo and was associated with no significant changes in gastric
emptying patterns.
S1732
Tumor Necrosis Factor (TNF) Positively Modulates Vagal Afferent Excitability
Within the Solitary Nucleus: An in Vitro Live-Cell Imaging Study
Richard C. Rogers, Gerlinda E. Hermann
Cancer, autoimmune disorders, chronic infection, and traumatic injury are all associated
with the development of gastric stasis, nausea, anorexia and emesis. These co-morbidities
are present even though the primary disease process may not directly involve the gastrointesti-
nal tract. Production of the cytokine TNF is a common feature in these disease processes
and TNF is widely known to cause gastric stasis and other symptoms just mentioned. Our
previous work has shown that: a) TNF can produce gastric stasis thru action directly on
gastric vago-vagal reflex neuronal circuitry in the dorsal medulla; an area outside the brain-
vascular diffusion barrier, b) TNF causes a dramatic increase in the activity of solitary nucleus
[NTS]neurons known form part of the relaxatory gastric reflex control mechanism, and c)
TNF activation of NTS neurons requires intact glutamatergic neurotransmission and the
effects of gastric vagal afferent stimulation on NTS neuron activity is amplified by TNF [1].
These data, coupled with the recent finding that the principal locus for TNF receptors in
the dorsal medulla is on afferent vagal fibers [2], strongly suggests that TNF controls gastric
function by modulating vagal afferent neurotransmission within the NTS. To study this
phenomenon directly, we devised a new technique for imaging the activity of vagal afferent
varicosities within the NTS [3]. Vagal afferent fibers and terminal varicosities were preloaded
with calcium green dextran. In vitro slice preparations of the medulla were examined with
a confocal microscope. These fine vagal afferent fibers and terminal varicosities could be
readily activated by direct electrical stimulation [opening voltage gated cation channels],
exposure to capsaicin [opening VR1 ligand gated cation channels] or exposure to ATP
[opening P2X3 ligand gated cation channels]. While TNF alone had little direct effect on
vagal afferent calcium signals, TNF significantly increased the vagal afferent terminal calcium
levels generated by the other stimuli. These data support the hypothesis that TNF deranges
gastric function by increasing the excitability of vagal afferents controlling gastroinhibitory
vago-vagal reflexes. 1. Hermann GE, Holmes GM, Rogers RC. Curr Pharm Des.
2005;11(11):1391-409. 2. Hermann GE, Hebert SL, Van Meter MJ, Holmes GM, Rogers
RC. Brain Res. 2004 Apr 9;1004(1-2):156-66. 3. Rogers RC, Nasse JS, Hermann GE. J
Neurosci Methods. 2005 Aug 11 [EPUB ahead of print] Supported by NIH grants DK56373
and 52142
S1733
Predictors of Symptom Non-Responders to High-Frequency Gastric Electrical
Stimulation for Refractory Gastroparesis
Zhiyue Lin, Irene Sarosiek, Jameson Forster, Richard W. McCallum
Chronic high-frequency gastric electrical stimulation (GES) has been shown to improve
gastroparetic symptoms and quality of life (QOL) in up to 70% of patients with refractory
gastroparesis (Gastroenterology 2003;125:421-8). Little is known about factors associated
with treatment failure. Clinical and gastric function data (gastric emptying test, GET; electro-
gastrogram, EGG) were extracted from a retrospective analysis of 87 gastroparetic patients
(48 diabetic, 20 idiopathic and 19 postsurgical) who completed GES therapy (Enterra™
System, Medtronic) for at least 1 year. Total symptom score (TSS) (sum of severity of nausea,
vomiting, early satiety, bloating, postprandial fullness, epigastric pain and burning using a
5-point scale, 0= non, 4= extremely severe), quality of life (SF-36 Health Status Survey
questionnaire including physical composite score (PCS) and mental composite score (MCS))
and GET (4-hour scintigraphy of a low-fat meal) were examined at baseline and 1 year
follow-up. A non-responder had <25% reduction in TSS and a responder was defined as
having a ≧50% reduction in TSS after 1 year of GES therapy. Results: Overall the non-
responder rate was 23% (10% in diabetic vs. 16% in postsurgical vs. 35% in idiopathic
subgroup). Non-responder rates were similar for men (22%) and women (23%) and age
was not a factor. Compared to responders of GES therapy, non-responders had similar mean
baseline vomiting (2.6 vs. 3.2) and nausea scores (3.3 vs. 3.6) but a lower TSS (17.6 vs.
20.1, P<0.05). Also non-responders had less improvements in mean gastric retention both
at 2 hours (+5.4 vs. -8.7%) and at 4 hours (+4.0 vs. -10.5%), less improvement in mean
PCS (+2.0 vs. +12.4, P<0.05) and gained less weight (-0.4 kg vs. +3.7 kg) than responders.
67% of non-responders had an abnormal EGG (dysrhythmia >30% or decrease in postpran-
dial EGG power) vs. 33% in responders. Non-responders had more baseline mean tachygastria
both in the fasting state vs. responders (26% vs. 11%, P<0.05) and in the fed state (24%
vs. 11%, P<0.05) and less increase in postprandial EGG power (-1.3 dB vs. 1.6 dB, P<0.05).
Conclusions: The best symptom improvement achieved by high-frequency GES therapy in
refractory gastroparesis is in diabetics (10% treatment failure rate) and postsurgical (16%
failure) while the worst results are in idiopathics (35% non-responder rate). Baseline EGG
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abnormalities are predictors of poor symptomatic response to GES therapy and may be
useful in developing a patient profile to optimize selection and expectations for GES therapy.
S1734
Visceral Specific Analgesic Action of Mosapride Citrate, a Gastroprokinetic
Drug, and Its Metabolite Against Gastric Distension Through a 5-HT4 and 5-
HT3 Receptor in Conscious Rats
Hiroshi Kaneko, Toshihiro Konagaya, Shinichi Kakumu
BACKGROUND: Mosapride citrate is a new gastroprokinetic agent with selective 5-HT4
receptor agonistic properties. We have reported that mosapride not only enhances gastric
emptying, but also inhibites the visceromotor response by gastric distension in conscious
rats, in which gastric distension-induced pain behavior and abdominal muscle contractions
can be evaluated (AGA 2005). In the present study, receptors involved in the analgesic
action of mosapride and a selectivity of mosapride-induced analgesic action were examined.
METHODS: Male Wistar rats were anesthetized with pentbarbital and a flexible latex balloon
was surgically placed into the stomach, then a force transducer was implanted on the
abdominal muscle in order to measure its contractions estimated as an index visceromotor
response. Measurement was performed at least 4 days after surgical operation. Gastric
distension was performed by slow air-infusion into the balloon. The distension-induced
abdominal muscle contractions were measured 1 hr before and 1 or 2 hr after intragastric
(ig) administration of morphine hydrochloride, mosapride and granisetron hydrochloride
(5-HT3 antagonist), or a mosapride metabolite, M1 (5-HT3 antagonistic property) subcutane-
ously (sc). Effect of SB-207266 (a specific 5-HT4 antagonist, sc) on mosapride-induced
changes in visceromotor response was examined. The hot plate test was performed by placing
a rat on aluminum plate at 50C and measuring a hind paw licking latency 30 min before
and 1 or 2 hr after mosapride or morphine ig administration. RESULTS: When infusion of
air volume amounted to 8-12 mL, abdominal muscle contractions were induced prior to
occurrence of a typical pain behavior (writhing phenomenon). Morphine and mosapride
(3-10 mg/kg, ig) dose-dependently inhibited the abdominal muscle contraction induced by
gastric distension. An inhibitory effect of mosapride on gastric distension-induced visceral
pain was significantly, but not completely, inhibited by SB-207266. Granisetron and M1,
at a lesser potency, also significantly inhibited the muscle contractions. Morphine, but not
mosapride, significantly prolonged the licking latency. CONCLUSIONS: Mosapride, 5-HT4
receptor agonist, inhibited the visceromotor response by gastric distension in conscious rats,
The anti-visceral pain response of mosapride might be mediated via both 5-HT4 receptor
activation and antagonistic action against 5-HT3 receptor by its metabolite. In addition,
mosapride mediated analgesic action looks specific against visceral, but not somatic, pain.
(This study was performed by the collaboration with Seto Y & Yoshida N, Ph.D. at Dainippon
Sumitomo Pharmaceutical Co., Ltd, Japan.)
S1735
Effects of Postgastric 13C-Acetate Processing On Measurement of Liquid
Gastric Emptying Rates - A Systematic Investigation in Health
Oliver Goetze, Heiko Fruehauf, Monika A. Kwiatek, Daniel Pohl, Miriam Thumshirn,
Werner Schwizer, Michael Fried
Background and Aims: Uniform postgastric processing of the gastric emptying marker 13C-
acetate (AC) is an unverified assumption behind its use to measure gastric emptying. We
have performed a systematic investigation of the effects of intraduodenally (i.d.) administered
volume, caloric density, AC doses and administration rates on 13CO2 exhalation. Methods:
13CO2 recovery was assessed in 18 volunteers after i.d. administration of A (n=6): A1:
randomized boluses of 50 mg AC in 50, 100, 200 ml water injected over 1 min every 1h;
A2: randomized boluses of 12.5, 25, 50, 100 mg AC in 50 ml water injected over 1 min
every 1h; B (n=6): infusion of 100 mg AC in 200 ml water at 0.5, 1, 2.5 mg AC/min. C
(n=6): infusion of 50 (100, 200) ml Ensure®plus + 150 (100, 0) ml water + 100 mg AC
at 0.75 (1.5, 3.0) kcal/min; all at 2ml/min and 1mg AC/min. 13CO2/12CO2 ratio was deter-
mined by continuous molecular correlation spectroscopy (BreathID®, 1 sample/3min).
Results were expressed as percentage, cumulative percentage doses of 13C recovered and
time to peak (PDR [%/h], cPDR [%], tpeak [min]). For study A cPDR/mg of administered
AC [%/mg] over 1 h was calculated. Results: A1: 13CO2 recovery and kinetics were similar
for different i.d. volume boluses. A2: Increasing doses resulted in decreasing cPDR/mg of
AC (12.5 mg: 2.18 ± 0.78; 25 mg: 0.73 ± 0.20; 50 mg: 0.38 ± 0.10; 100 mg: 0.18 ± 0.02,
all in %/mg, p<0.001) and increasing tpeak (14.5 ± 2.4; 11.9 ± 2.6; 14.22 ± 4.1; 20.3 ± 3.8
min, p<0.05). B: During constant i.d. infusion increase of 13CO2 excretion over time was
only reflected in a linear fashion for the first 40 min, thereafter 13C-recovery followed zero
order kinetics, in particular for lower AC administration rates. C: cPDR after 3h as well as
13CO2 excretion kinetics were similar for all caloric loads. Conclusion: Contrary to previous
assumptions gastric emptying rates, as measured by 13C-acetate breath test, are modulated
by non linear 13CO2-exhalation kinetics. This is caused by differences in postgastric 13C-
acetate processing, dependent on the rate of duodenal marker delivery and the total marker
dose administered. Our results show that lack of steady state 13CO2 excretion by 13C-marker
redistribution to compartments independent of gastric emptying affect the accuracy of gastric
emptying measurements by the 13C acetate breath test.
S1736
Dietary Free Glutamate Modulates Gastric Emptying Rate in Humans
Hiroaki Zai, Motoyasu Kusano, Yasuyuki Shimoyama, Masaki Maeda, Atsuto Nagoshi,
Tatsuya Higuchi, Shiko Kuribayashi, Osamu Kawamura, Masatomo Mori
Background and Aim: Free glutamate activates the taste receptors in the oral cavity and
excites taste nerves to elicit a unique taste ‘umami’. Recently calcium sensing receptor
sensitive to free amino acids was also found in the gastric mucosa. Although these reports
suggest that glutamate acts as a modulator of gastric function, there is no evidence about
its effect on gastric emptying. Therefore, we studied the effect of dietary free glutamate on
gastric emptying rate in humans. Methods: Two types of control liquid test meal (400 kcal /
400 ml) labeled with 100 mg of 13C sodium acetate (Cambridge Isotope Laboratories Inc.,
USA) were used. One meal (protein-rich diet) consisted of 12.5% dextrin (TK16, Matsutani
Chemical, Janan) and 12.5% casein-calcium (EN9N, DMV Japan); another (carbohydrate
diet) contained 25% dextrin. Monosodium L-glutamate (0.5% w/v, Ajinomoto Co.,Inc.,
Japan) was added to a control liquid test meal. All meals were flavored with the non-caloric
sweetener aspartame (Ajinomoto Co.,Inc., Japan) and plum odor (GIV010790, Givaudan
Japan) to mask the taste of glutamate. To investigate whether the presence of nutrients
influences the effect of glutamate, 400ml of water was also tested. After taking a test meal
or water, continuous 13C breath tests (Breath ID System. Oridion Medical Ltd., Israel) were
performed. Results: (1) Effect of adding glutamate to the protein-rich meal (n = 10): glutamate
significantly accelerated gastric emptying rate. The gastric emptying coefficient (GEC) defined
by Ghoos et al (glutamate +/-) was 3.05±0.24 /2.69±0.28 (mean±S.D., p<0.01, multiple
ANOVA). The t 1/2 (glutamate +/-) was 153.0±34.6 /212.7±102.6 minutes (mean±S.D.,
p<0.05). The cummulative %dose at 180-min was 59.2±9.8 /45.8±14.4 (mean±S.D., p<0.05).
(2) Effect of adding glutamate to the carbohydrate meal (n = 5): glutamate had no significant
effect on gastric emptying. (data not shown) (3) Effect of adding glutamate to water (n=9)
: glutamate had no significant effect on gastric emptying. (data not shown). Conclusions:
This report shows for the first time that dietary free glutamate modulates gastric emptying
in humans. Glutamate facilitated the gastric emptying of a protein-rich meal without influence
on that of water or carbohydrate meal. These data suggest that free glutamate is an important
substance for efficient protein digestion and absorption. The reevaluation of the GI function
from the standpoints of chemical sense will help to understand better the pathophysiology
of dyspeptic symptoms.
S1737
Validation of a Novel Symptom-Predominant Classification for Gastroparesis
John M. Wo, Jamie Studts, Jennifer L. Koopman, Luwa Cai, Robert Cacchione, Steven P.
Harrell
Symptom presentation of gastroparesis (GP) is very diverse. We previously proposed a
classification for GP, but prospective studies are needed for validation. AIMS: 1) To determine
the concordance of a symptom-predominant classification of GP between physician and
patient. 2) To validate physician’s classification with a patient self-administrated question-
naire. METHODS: Subjects with symptoms of gastroparesis for >2 months and documented
delayed gastric emptying were prospectively enrolled. Physician classified each subject based
on presenting chief complaints: a) vomiting-predominant GP (vomiting with retching and
nausea), b) dyspepsia-predominant GP (discomfort centered in upper abdomen characterized
by fullness, early satiety, bloating or nausea), or c) regurgitation-predominant GP (effortless
regurgitation of acid or undigested food). Subjects also classified themselves independently
from physician. Patient Assessment of GI Disorders-Symptom Severity Index™ (PAGI-SYM)
questionnaire (0 to 5, six subscales) was administered. Cohen’s kappa (k) and analysis of
variance were used. Receiver operating characteristic (ROC) curves were constructed with
sensitivity and specificity of each PAGI-SYM subscale to differentiate subjects into symptom-
predominant subgroup. Area under the curve (AUC) was used to compare the subscales.
RESULTS: 100 GP subjects (87F, mean 48 yrs) were enrolled. There was a 78% concordance
between physician and subject’s classification of GP with substantial correlation (k=0.64).
Results are shown in table. PAGI-SYM nausea/vomiting subscale (AUC=0.79) was the best in
differentiating subjects into vomiting-predominant GP, and heartburn/regurgitation subscale
(AUC=0.73) was the best in differentiating regurgitation-predominant GP. No subscale
was adequate to differentiate dyspepsia-predominant GP. CONCLUSIONS: There was a
substantial agreement between physician and patient using a symptom-predominant classi-
fication of GP. Vomiting and regurgitation-predominant GP corresponded very well with
patient’s assessment of symptom severity, but not for dyspepsia-predominant GP.
*p<0.01 vs dyspepsia and regurgitation-predominant GP; **p<0.05 vs dyspepsia-predomin-
ant GP; †p<0.01 vs dyspepsia-predominant GP
S1738
The Role of 13c-Octanoic Acid Breath Testing in the Assessment of Gastric
Emptying in Critically Ill Patients
Nam Q. Nguyen, Marianne Chapman, Max Bellon, Laura Bryant, Carly Burgstad, Dylan F.
Bartholemeuz, Ross Butler, Geoff Davidson, Robert Fraser, Richard Holloway
Delayed gastric emptying and subsequent feed-intolerance is common in critically ill patients
and a simple, reliable technique that assesses gastric emptying is therefore needed. Although
scintigraphy remains the gold-standard, it is technically demanding in these patients, involves
radiation and can interfere with patient care. The 13C-octanoic breath test (13C-BT) is a
simple non-invasive, non-radiation technique that has been validated in healthy subjects
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and diabetic patients. Although a number of studies have reported slow gastric emptying
and beneficial effects of prokinetics with 13C-BT, the test has not been validated in the
critically ill. Aim. To correlate 13C-BT with scintigraphy for assessing gastric emptying of
a liquid meal in critically ill patients. Methods. Gastric emptying of 100ml of Ensure was
assessed prospectively in 14 mechanically ventilated patients (11M; 63+4 yrs; APACHE II:
22+2), using concurrent 13C-BT and scintigraphy. 13C levels were measured in end expirat-
ory breath samples collected from the ventilator outlet. Samples were taken immediately
before the test meal, every 5 min during the first hour and every 15 min thereafter for a
further 3h. The gastric emptying coefficient (GEC, normal=3.2-3.8) and gastric half emptying
time (t1/2(BT); normal<120min) were calculated using standard techniques. Scintigraphic
measurements were performed over 4h to determine t1/2(Sct) and % meal retention at 60,
120, 180 and 240min. Results. Seven patients with normal gastric emptying on scintigraphy
(t1/2(Sct) <60min) had normal 13C-BT results. Amongst the 7 patients with prolonged t1/
2(Sct), 13C-BT was abnormal in 5 and normal in 2 patients. In those with normal 13C-BT
but abnormal scintigraphy, the abnormality was mild with 60min< t1/2(Sct)<100min and
46+2% of the meal was retained at 120min (normal=22+4%). Compared with scintigraphy,
13C-BT had a sensitivity of 71% and specificity of 100%. A moderate correlation was found
between t1/2(Sct) and t1/2(BT) (r=0.68; P=0.008) and GEC (r=0.63; P=0.02). Meal retention
at all time points on scintigraphy correlated positively with t1/2(BT) (r=0.7-0.8; P<0.001)
and negatively with GEC (r=-0.6-0.7; P<0.001). The highest correlation achieved was between
t1/2(BT) and % meal retention at 120min (r=0.86; P<0.0007). Conclusion. In critical illness,
there is a good correlation between 13C-BT and scintigraphy. 13C-BT appears to be a reliable
measure of delayed gastric emptying in these patients.
S1739
The Effect of Food On Electrical and Mechanical Activity of the Canine
Antrum
Claudia P. Sanmiguel, Masanobu Hagiike, Scott A. Cunneen, Edward H. Phillips, Jeffrey
L. Conklin, Edy E. Soffer
Background: Gastric electrical and mechanical activities are modulated by food, however,
the pattern of food-induced changes and the mechanisms governing them are not well
defined. Aim: To characterize food-induced changes in gastric antral activity and to explore
underlying mechanisms for such changes. Methods: Experiment 1- intended to test the effect
of food on gastric signals. Two bipolar electrodes were implanted in the antrum of 7 mongrel
dogs for simultaneous recording of slow wave rate, in events /min (SWR), and contractions
assessed by electrical impedance (AI) in ohms. A strain-gauge transducer was implanted in
3 dogs to correlate changes in AI with contractions. The meal consisted of a preload of
100g of dry food followed in 10 min, by 900g of the same food, to lengthen meal duration.
SWR and AI were determined during 4 periods of 5 min/each (baseline, end of preload,
satiety, 10 min after satiety). Experiment was repeated 5 times/dog. Experiment 2- acute
study, under anesthesia with 3 tests:1) esophageal balloon distension 2) fundic balloon
distension at volumes of 50-400ml, using a balloon of 800 ml, and 3) nitroglycerin infusion,
0.5microg/kg/min for 10 min. results as Mean±SD. Results: Experiment 1- frequency of
antral contractions by strain-gauge correlated well with frequency of contractions as measured
by AI, R=0.76. SWRs at baseline, preload, satiety and post satiety were: 5.0±0.3, 4.9±0.4,
3.8±0.65, and 4.4±0.47 respectively. SW amplitudes (ohms) at the same periods were:
5.3±1.4, 8.5±2.1, 12.2±4.3 and 12.0±5.3 respectively; p<0.05 for satiety and post satiety
vs. baseline for both measurements. Both changes peaked around the time of satiety. Mean
time interval between satiety and slowest SWR was 80±40 sec. Amplitude of contractions
remained elevated for 212±110 min after the meal. Experiment 2- fundic distension caused
a transient decrease in SWR at lower volumes, but the decrease was sustained at the 400 ml
volume, 3.9±0.5 vs. 3±0.8, baseline vs. distension, respectively, p=0.002. NTG significantly
reduced SWR: 4.0±0.7 vs. 3.5+0.8, baseline vs. infusion, p=0.007. Esophageal distension
did not affect SWR. Conclusions: Food ingestion causes a significant decrease in SWR and
significant enhancement of antral contractions that peak at satiety. This suggests a possible
causal relationship that can be potentially useful when considering gastric electrical stimula-
tion for modulation of satiety signals. Both gastric distension and nitrergic pathways
affect SWR.
S1740
Variability of the 13c-Acetate Breath Test for Gastric Emptying of Liquids in
Healthy Children
Bruno Hauser, Jean de Schepper, Vicky Caveliers, Silvia Salvatore, Alessandro Salvatoni,
Yvan Vandenplas
Objective: Scintigraphy is considered as the “gold standard” for measuring gastric emptying
(GE). The 13C-acetate breath test (13C-ABT) offers an attractive alternative to measure GE
of liquids as it is non-radioactive. The aim of this study was to assess the variability of the
13C-ABT for GE of liquids in healthy children using non dispersive infrared spectrometry
(NDIRS). Methods: The 13C-ABT was repeated at least 2 times in 21 healthy children (6
girls, 15 boys), aged between 6.2 and 16.4 years, 2 to 7 days apart. After an overnight fast,
a standardised milk-drink labelled with 50 or 100 mg 13C-acetate according to weight, was
administered. Breath samples were taken before feeding, at 5 minutes intervals for the first
40 minutes and at 10 minutes intervals for the following 140 minutes after feeding. Breath
samples were analyzed using NDIRS, and 13C-recovery was used to calculate values for
gastric half emptying time (t1/2), time of peak 13C-exhalation or gastric lag phase (tlag)
and gastric emptying coefficient (GEC). Intraindividual variability of the parameters t1/2,
tlag and GEC were expressed as coefficient of intrasubject variation (CV). Results: The
median CV of t1/2 was 8.3 % (range CV 1.6-16.2 %) (interindividual range t1/2: 65-112
minutes; intraindividual range t1/2: 4-33 minutes). The median CV of tlag was 16.6 %
(range CV 2.0-26.6 %) (interindividual range tlag: 31-76 minutes; intraindividual range
tlag: 1-35 minutes). The median CV of GEC was 4.3 % (range CV 0.8-15.7 %) (interindividual
range GEC: 3.81-4.89; intraindividual range GEC: 0.08-1.31). The CV’s of t1/2, tlag and
GEC were independent of age, gender, weight, height and measured values of t1/2, tlag and

















procedure with a large intraindividual variation for measuring GE of liquids in healthy
children, but comparable to the variation reported with other techniques.
S1741
Effects and Mechanisms of Gastric Electrical Stimulation On Gastric Tone in
Rats
Yanquan Luo, J.N. Zhang, Jiande Chen
Background: Our previous studies have shown that gastric electrical stimulation (GES) with
sufficient output inhibits gastric tone and this effect is mediated via the nitrergic pathway.
However it is unknown whether this effect and mechanism are species specific. The aim of
this study was therefore to investigate the effect and mechanism of gastric electrical stimulation
(GES) in rats. Methods: Seventeen female SD rats were divided into two groups, eight rats
were given GES without L-NNA (nitric oxide synthase inhibitor) as control, nine rats were
given GES with L-NNA (10mg/kg). Laparotomy was performed under general anesthesia;
a pair of electrodes was sutured on the serosa of the lesser curvature; a balloon for gastric
tone recording was placed into the proximal stomach. The control session included 30 min
baseline, followed by 30 min with GES; the L-NNA session included 30 min baseline, 30
min immediately after a bolus of L-NNA, and 30 min with GES. GES was performed using
pulse trains with train on time of 2 seconds and off time of 3 seconds and pulse width of
3ms, amplitude of 6mA and frequency of 40 Hz. Gastric tone was measured by a computerized
barostat at 4-5 mmHg (MDP + 2 mmHg). Results: 1) In the control session, GES significantly
increased the proximal gastric volume from baseline 0.36±0.12 ml to 0.47±0.19 ml (paired
t-test, p<0.05); 2) L-NNA markedly reduced the proximal gastric volume from 0.41±0.06
ml at baseline to 0.28±0.09 ml (ANOVA P<0.05); subsequent GES was still able to increase
the proximal gastric volume from 0.28±0.09 ml to 0.45±0.10 ml (ANOVA p<0.05). Conclu-
sions: GES significantly inhibits proximal gastric tone, not like in canine, this inhibitory
effect is not blocked by the nitric oxide synthase inhibitor L-NNA, further studies should
be done to figure out pathways other than nitrergic pathway which mediate the inhibitory
effect of GES on gastric tone in rats.
S1742
Variability of the 13c-Octanoic Acid Breath Test for Gastric Emptying of Solids
in Healthy Children
Bruno Hauser, Jean de Schepper, Vicky Caveliers, Silvia Salvatore, Alessandro Salvatoni,
Yvan Vandenplas
Objective: Scintigraphy is considered as the “gold standard” for measuring gastric emptying
(GE). The 13C-octanoic acid breath test (13C-OBT) offers an attractive alternative to measure
GE of solids as it is non-radioactive. The aim of this study was to assess the variability of
the 13C-OBT for GE of solids in healthy children using non dispersive infrared spectrometry
(NDIRS). Methods: The 13C-OBT was repeated at least 2 times in 19 healthy children (6
girls, 13 boys) aged between 6.8-17.1 years, 2 to 7 days apart. After an overnight fast, a
standardised pancake labelled with 50 microliter 13C-octanoic acid was administered. Breath
samples were taken before the feeding and at 15 minutes intervals for the following 240
minutes after the feeding. Breath samples were analyzed using NDIRS, and 13C-recovery
was used to calculate values for gastric half emptying time (t1/2), time of peak 13C-exhalation
or gastric lag phase (tlag) and gastric emptying coefficient (GEC). Intraindividual variability
of the parameters t1/2, tlag and GEC were expressed as coefficient of intrasubject variation
(CV). Results: The median CV of t1/2 was 12.9 % (range CV 2.5-29.6 %)(interindividual
range t1/2: 99-204 minutes; intraindividual range t1/2: 5-84 minutes). The median CV
of tlag was 12.4 % (range CV 0.8-27.8 %) (interindividual range tlag: 65-146 minutes;
intraindividual range tlag: 1-50 minutes). The median CV of GEC was 10.9 % (range CV
3.4-30.2 %) (interindividual range GEC: 2.32-3.88; intraindividual range GEC: 0.17-1.35).
The CV’s of t1/2, tlag and GEC were independent of age, gender, weight, height and measured
values of t1/2, tlag and GEC. Conclusions: The 13C-OBT using NDIRS is an easy, non-
invasive and non-radioactive procedure with a large intraindividual variation for measuring
GE of solids in healthy children, but comparable to the variation reported with other tech-
niques.
S1743
Gastric Electrical Stimulation for Obesity: Is There a Need for a New
Generation Device?
J.N. Zhang, J D Z Chen
Background: Gastric electrical stimulation (GES) using the commercially available implantable
device has been applied for treating obesity with controversial outcomes. It is known that
all commercially available devices are designed for nerve or cardiac stimulation and the
width of stimulation pulse is limited to below 1ms. Since the stomach is composed of
smooth muscles, one wonders whether a wider pulse is needed for GES. The aim of this
study was to compare the peripheral and central effects of GES with a pulse width currently
used in clinical trials and a wider pulse in rats. Methods: GES with 2 sets of parameters
(GES1: the parameters currently used in clinical trials for the treatment of obesity: 6mA,
0.3ms, 40Hz, 2s-on, 3s-off; GES2: same as GES1 except increased pulse width of 3ms) was
applied via a pair of gastric serosal electrodes near to the less curvature of the rat stomach.
Exp.1 was performed 8 anesthetized fasting rats. A balloon was inserted to the proximal
stomach for assessing gastric volume by barastat at baseline and during GES. Exp.2 was
designed to record extracellular potentials of single neurons in the PVN and VMH of
anesthetized rats (N=58/52). Neurons were identified as gastric distension-responsive (GD-
R) if they responded to gastric distension (GD, 3~5ml, 10~30s), then GES1 and GES2 were
performed for one minute respectively. Results: 1. GES2 but not GES1 reduced gastric tone.
The gastric volume was increased from 0.38±0.07ml to 0.49±0.07 (P<0.05) with GES1. 2.
In the PVN, 104 GD-R neurons were tested with GES, 79.0% and 91.4% of these neurons
were responsive to GES1 and GES2 respectively (P=0.029, GES1 vs.GES2); In the VMH,
while there was no difference between GES1 and GES2 in the activation of the number of
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neurons (63.6% vs. 73.3%, P>0.05), the percentage of increase in neural activity was higher
with GES2 than GES1 (increase of 343.6±89.2% vs. 97.4±33.7%, P<0.05). Conclusions:
The peripheral and central effects of GES are dependent on stimulation pulse width. While
the pulse width used in current clinical trials is effective in activating neurons in the
hypothalamus, GES with wider pulses are more effective both peripherally and centrally.
As GES-induced gastric distention is known to be associated with reduced food intake, it
is anticipated that GES with wider pulses is more effective in treating obesity. Accordingly,
there may be a need for a new generation device capable of generating wider pulses.
S1744
A New Method to Improve Liquid Nutrient Load Test
Zhiqiang Song, Meiyun Ke, Zhifeng Wang, Lin Xu
BACKGROUND: Liquid nutrient load test (LNLT) may show the reduced intake volume
which may result from gastric visceral hypersensitivity or impaired accommodation, so it
is not exact to express gastric visceral sensitivity with the index of intake volume. The
intra-gastric pressure (IGP) is the main factor inducing gastric mechanical sensation. If we
determine IGP by manometric catheters during LNLT, the gastric sensitivity can be more
exactly showed by the intra-gastric pressure level. Subjects with a lower IGP at the time of
maximal intake volume (MIV) will be considered as those having gastric visceral hypersensit-
ivity. When IGP of patients are same as those of healthy subjects (HS), the reduced intake
volume can be deduced to result from impaired accommodation. AIMS: To evaluate liquid
nutrient load test combined with determination of the intra-gastric pressure in HS and
patients with functional dyspepsia (FD). METHODS: Thirty-two HS (M:F 1:1, mean age
43yr) and 52 patients with FD (M:F 1:1.6, mean age 45yr) participated in the study.
Following an overnight fast of at least 10 hours, a water-perfusion catheter was introduced
through nasal cavity into stomach. The side-hole was positioned in the proximal stomach.
Subjects lied on a test bed with a hemi-supine posture. After a 15 minute equilibration
period, subjects drank liquid nutrient (1.5Kcal/ml, Carbohydrate 48%, Fat 39%, Protein
13%, 50ml/min) until MIV with synchronous intra-gastric pressure monitoring. So both
MIV and IGP at the time of MIV could be obtained. The study was repeated in 16 HS on
separate days. RESULTS: (1) IGP and MIV in HS group are 4.0-6.3mmHg and 530-886ml
(M), 420-690ml (F), respectively. Twice studies showed quite similar results and the interclass
correlation coefficient of IGP and MIV are 0.953 (P<0.01) and 0.795 (P<0.01), respectively.
(2) The correlation coefficient between MIV and IGP is weak (r=0.357, P=0.045). (3) No
statistical differences are found in IGP divided by sex, age and body mass index (P>0.05).
(4) The proportion of gastric hypersensitivity in FD (<4.0mmHg) accounts for 37%; the
proportion of impaired accommodation (male<530ml, Female<420ml) accounts for 20%.
(5) Most subjects could tolerate the test well. CONCLUSIONS: The new method of liquid
nutrient load test combined with determination of intra-gastric pressure could differentiate
gastric visceral hypersensitivity from impaired accommodation. It is simple and clinical
feasible with less influencing factors, good repeatability and tolerability.
S1745
Evidence for Glucoresponsiveness of Gastric Vagal Afferents Mediated By Katp
Channels: Immunocytochemistry and Electrophysiology Studies
Shi-Yi Zhou, Yuanxu Lu, Chung Owyang
Hyperglycemia plays an important role in the modulation of gastric motor function by
delaying gastric emptying. We reported hyperglycemia stimulates vagal afferent pathways
which in turn activate vagal efferent cholinergic pathways synapsing with intragastric NO-
containing neurons to mediate gastric relaxation. The mechanism by which glucose is
“sensed” in the circulation and evokes neurally mediated reflexes is unknown. We investigated
if glucose modulates the activity of vagal afferents in the stomach and if the neurons express
KATP channels. Immunocytochemistry studies performed on histological sections of rat
nodose ganglia show immunostaining of glucose transporter Glut 1, 2, 3, 4. The same group
of neurons also displays immunoreactivities of the inwardly rectifying K+ channel 6.2 (Kir
6.2) and the sulfonylurea receptor (SUR1) as well as glucokinase. These findings were
confirmed by Western analysis, which shows glut 1 and 3 as the predominant proteins.
Double immunohistochemical staining shows most of these neurons contain glutamate as a
neurotransmitter. To determine if the glucose transporters and KATP channels are transported
axonally, western analysis was performed on vagal nerve trunks and showed the presence
of Glut 1, 2, 3, 4 as well as Kir 6.2 and SUR1 protein. To determine whether gastric vagal
afferents can respond to changes in glucose concentration, in vitro isolated stomach-vagus
nerve preparations were used in electrophysiological studies. This preparation eliminates
any influence of CNS and systemic factors, thus unequivocally showing glucose action at
the vagal afferent level. Thin nerve trunks (~1μm) from the distal cut end of afferent fibers
were sampled from the ventral branch of the gastric vagal trunk. The average of a 5 minute
total spike count before each treatment was normalized as 100% (Q=1). Following glucose
perfusion (250mg/dl, 20 sec), 9/21 units (43%) responded to glucose (Q=3.1 excitations).
The response was dose dependent (150-300mg/dl) and inhibited by glucosamine (250mg/
dl), a glucokinase inhibitor (Q=1.05), and the KATP channel inhibitor tolbutamide (500μM)
(Q=1.3). In contrast, the non-metabolizable 2-deoxyglucose (250mg/dl) had no effect. These
studies demonstrate for the first time that subsets of neurons in the nodose ganglia and
gastric vagal afferents are glucoresponsive. Both the glucotransporters and KATP channels
are transported axonally to the gastric vagal afferents which can be activated by high glucose
levels through modulation of KATP channels. This provides the functional basis for our
previous in vivo finding that gastric relaxation evoked by hyperglycemia is mediated via
vagal afferent pathways.
S1746
Impaired Acid-Induced Esophageal Protective Reflexes During Rem Sleep
Gregg S. Gagliardi, Ashish P. Shah, Karl Doghramji, Sidney Cohen, Anthony J. Dimarino
Background: Nocturnal acid gastroesophageal reflux (GER) events induce sleep arousals and
awakenings, which leads to esophageal acid clearance. However, the effect of sleep stage on
these events has not been investigated. Since respiratory changes (apnea induced arousals)
are markedly suppressed in REM sleep, it is possible that acid induced arousals and
awakenings may be suppressed as well. Aim: The aim of this study was to investigate the
effect of sleep stage on acid GER induced arousals and awakenings using simultaneous 24
h pH recording and polysomnography. Methods: The records of 16 patients with and without
documented reflux disease, who had previously undergone simultaneous polysomnography
and overnight esophageal pH analysis, were reviewed. Sleep stage was scored using established
polysomnographic parameters. An acid GER event was considered to have occurred when
the pH recording was < 4.0. Awakenings and arousals were reflux associated if they occurred
during the reflux event and up to 5 minutes after the pH had returned to ≥ 4.0. The
corresponding sleep stages and whether or a not an arousal or an awakening took place
was recorded. All subjects were studied without the influence of sleep hypnotics. Results:
A total of 33 nocturnal acid reflux events were recorded. In early stage 1 and 2 sleep a total
of 13 reflux events resulted in 12 arousals or awakenings (92.3%). In REM sleep there were
6 GER events recorded and only 1 (16.7%) was associated with an arousal or awakening
(p < 0.01). Fourteen events occurred while the patients were awake. There were no reflux
events in stage 3 or 4 sleep. Conclusion: 1) Nocturnal acid GER events occurring in early
stage 1 and 2 sleep were associated with an arousal or awakening which has been shown
to result in an acid clearance response. 2) During REM sleep, GER induced arousals or
awakenings were markedly suppressed, thus impairing this protective esophageal reflex.
These findings suggest that the depth of sleep during a GER episode may be an important
factor in producing arousals and awakenings. Since the duration of REM sleep is not clinically
regulated, the importance of nocturnal acid suppression becomes critical.
S1747
Sustained Hyperexcitability of Mouse Colonic Nociceptive Dorsal Root
Ganglia (DRG) Neurons Activated By Proteinase Activated Receptor 2 (PAR2)
Is Mediated By a PKC and ERK1/2 Dependent Pathway
Ahmed Kaysii, Silvia Amadesi, Nigel Bunnett, Stephen Vanner
The release of proteases from intestinal mast cells has been implicated in the genesis of
abdominal pain associated with conditions such as irritable bowel syndrome. We have
recently shown that activation of PAR2 on nociceptive DRG mouse neurons evokes sustained
excitability increase in these neurons (Gastro128:S1469,2005) but the signaling pathway
underlying this novel finding is unknown. This study examines the role of PKC and ERK1/
2 pathways using whole cell recordings of mouse nociceptive neurons (i.e.<40 pF) and
immunohistochemical techniques. DRG neurons exhibit PAR2 immunoreactivity and a sub-
population colocalize CGRP and TRPV1. The effects of PAR2 activation on neuronal excitabil-
ity were established in current clamp by measuring membrane potential, rheobase and input
resistance following a brief application of the PAR2 agonist (SLIGRL-NH2, 100μM). The
sustained depolarization (mean > 7 mV for over 30 min), decreased rheobase (> 50% for
more than 30min), and increase in input resistance (>50 min) evoked by SLIGRL-NH2 were
completely blocked at 3 and 10 min when the PKC inhibitor Calphostin (1μM; n=5) was
first applied to the bath. Similarly, when cells were incubated for 3 hr with the ERK1/2
inhibitor PD98059 (100μM; n=6) the SLIGRL-NH2 effects were abolished. The reverse
peptide LRGILS-NH2 and PKC and ERK1/2 inhibitors alone had no effect. The selectivity
of the ERK1/2 inhibitor was studied by examining its effects on the PKA agonist Forskolin
(1μM). Forskolin depolarized neurons at 3 (mean = 6 mV) and 10 (mean =7mV) min
and these responses were not altered by PD98059. To demonstrate that PAR2 activation
phosphorylates ERK1/2, immunofluorescence of antibodies staining phosphorylated ERK1/
2 (pERK) in isolated rat and mouse DRG neurons was studied using confocal microscopy.
In unstimulated neurons, there were low levels of staining for pERK. Phorbol-12-myristate-
13-acetate (PMA;100nM) or SLIGRL-NH2 (100μM) induced detection of pERK in the vicinity
of the plasma membrane within 1-5 min, suggesting activation of ERK in the vicinity of ion
channels. These treatments also induced translocation of PKCε and PKA catalytic subunit
to the plasma membrane, where they too may regulate channel activity. Together, these
studies confirm the presence of PAR2 on mouse nociceptive neurons innervating the colon
and establish that activation of PAR2 on mouse colonic neurons can phosphorylate ERK1/
2. Inhibition of PAR2-mediated hyperexcitability of these neurons by PKC and ERK1/2
antagonists suggests signaling through this pathway underlies the sustained actions of PAR2.
SUPORTED BY NIH GRANTS DK57480, 43207 and by the CIHR.
S1748
Nicotinic Agonists Activate Inward Currents in Isolated GI Projecting Nodose
Ganglion Neurons
Michael Beyak, Annemarie Surprenent, David Grundy
Background: Nicotine suppresses food intake in both animals and humans. We have previ-
ously reported that nicotinic agonists stimulate gastric vagal afferents and potentiate mechano-
sensitive responses (Beyak et al DDW 2004). The ion channel subtypes underlying these
responses are unknown. The aim of the present study was to examine the ion channels
underlying the vagal afferent response to DMPP in GI projecting nodose ganglion neurons.
Methods: GI - projecting nodose ganglion cells NGNs were labelled with a single i.p. injection
of fast blue (10µL, 4%). 2-7 days later, nodose ganglia were harvested, and dissociated.
Conventional whole cell patch clamp recordings were performed using potassium based
internal and sodium based external solutions. Pharmacological agents were applied using a
fast flow solution switching system. Results: The nicotinic agonist DMPP (3-300µM) depolar-
ized a subpopulation of GI nodose ganglion neurons. In voltage clamp experiments at -
60mV this was associated with the development of an inward current, the effect having an
EC50 of 32µM. DMPP induced currents were seen in 70% of labelled NGNs and in 55%
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of non labelled NGNs. Sensitivity to DMPP was not significantly related to cell size. Superfu-
sion of mecamylamine (10µM) completely blocked the effect of 30 µM DMPP (n=6). However
the selective α7 antagonist, methyllycaconatine (MLA, 100nM) had no effect (150±15.5 pA
control vs 135±14.5 pA MLA p>0.05, n=5). The α7 agonist, choline chloride (3mM) did
not activate an inward current (n=5). DMPP sensitive NGNs were examined with respect
to sensitivity to ATP (100µM, n=29), 2Methyl 5-HT (100µM, n=23), and CCK (100nM, n=
31). DMPP sensitivity was highly predictive of CCK sensitivity, 15/21 DMPP sensitive cells
responded to CCK, while only 1/10 DMPP insensitive cells responded to CCK (p=0.02
Fisher’s exact test) DMPP sensitivity was not correlated with ATP or 2-methyl 5-HT sensitivity.
Conclusions: Consistent with its effect on gastric and intestinal vagal afferents, the nicotinic
agonist DMPP activates an inward current in GI projecting nodose ganglion cells. Sensitivity
to mecamylamine and insensitivity to MLA is highly suggestive of α3β4 receptor subtype.
The high incidence of CCK and DMPP co-sensitive cells suggests that nicotinic receptors
are expressed on vagal afferents involved in satiety, consistent with previous studies demon-
strating an inhibitory effect of nicotine on food intake.
S1749
Estrogen Modulates Visceral Sensitivity in Adult Rats Exposed to Neonatal
Colon Irritation (CI)
J.N. Wang, Chunping Gu, Xin Peng, Kirsten Garner, Elie D. Al-Chaer
A number of chronic pain syndromes are more prevalent in women than in men, suggesting
a gonadal steroid influence. In previous studies, we showed that visceral hypersensitivity
varies with the levels of circulating sex hormones. In this study, we examined the effects
of estrogen on visceral hypersensitivity in two groups of rats: rats with neonatal colon
irritation (CI) and control rats (non-CI). When the rats reached 3 months of age, ovariectomy
(OVX), orchiectomy (OCX) or sham operations were performed. The rats were then given
20 days to recover. Visceral hypersensitivity was assessed by recording the electromyographic
(EMG) responses to graded colorectal distension (CRD) in rats mildly sedated with isoflurane
(1%). CRD was induced by rapidly inflating a latex balloon to 20, 40, 60 or 80 mmHg for
10s, with a 5 min interval between distentions. OVX and OCX rats were injected with
estrogen (E; 20μg; SC). EMG responses were obtained at 5h, 48h, 7d, 14d and 21d after
E injection and compared with those obtained from OVX, OCX, sham female or intact male
rats. Serum E levels were also measured at each time point using enzyme immunoassay.
Our results show: 1) In non-CI rats, E given to sham-OVX reduced EMG responses to 60%
(60mmHg) of the responses of controls (vehicle injection) 48h after the injection in proestrus
and estrus. In metestrus and diestrus, EMG response was reduced to 70% (60mmHg) of
the control response 7 days after the injection (n=6, p<0.05). However, in intact male rats,
EMG responses to CRD increased to 58.43% (60mmHg, n=3, p<0.05) 48h after E, and the
effect lasted for 14d. 2) In OVX rats, the sensitivity to CRD was significantly decreased to
90.25% (in control rats) or 91.95% (in CI rats) (60mmHg, n=8, p<0.001) by comparison
to sham-OVX, and the serum estrogen levels in CI rats also decreased (16.11%, n=4 p<0.05)
21d after OVX compared to intact CI female rats. In OCX rats, the sensitivity to CRD
significantly decreased to 69.56% (80mmHg) in CI rats (n=4, p<0.05) but not in control
rats compared to sham-OCX. 3) Estrogen injected after OVX or OCX in both CI and non-
CI rats restored EMG responses to the levels seen in intact rats. The present data suggest
that estrogen has a significant role in modulating viscerosensitivity in both CI and non-CI
female or male rats. The loss of gonadal hormones in CI and non-CI gonadectomized rats
decreases viscerosensitivity, but estrogen replacement leads to recovery (in female rats) and
some hypersensitivity (in male rats). (Supported by NIH / NS40434)
S1750
An Investigation Into the Role of 5HT in Mediating Jejunal Afferent
Hypersensitivity to Mechanical Stimulation in Trichinella Spiralis Infected
Mice
Chris D. Keating, Michael Beyak, Annemarie Surprenant, David Grundy
Background: Following Trichinella spiralis infection in mice, there is augmented sensitivity
of jejunal afferents responding at low threshold (LT) and high threshold (HT) levels of
distension. Here, we investigate the role of 5HT in the mechanisms underlying afferent
hypersensitivity. Methods: Experiments were performed on T. spiralis infected mice (>30d
post infection) and uninfected controls (WT). Gut projecting nodose ganglion neurons
(NGNs) from infected and control mice were labelled with an IP injection of fast blue (4%,
10uL) and whole cell patch clamp experiments were performed on labelled cells isolated
2-7 days later. The response to the 5-HT3 agonist, 2-methyl-5HT was examined using
voltage clamp electrophysiology. Multiunit recordings were also made from mesenteric
afferent bundles supplying in vitro segments of mouse jejunum taken from infected animals
and uninfected controls. Data is presented as mean±SEM (N=>6). Data analysed by one way
ANOVA or by Students t-test. P<0.05 was taken as significant. Results: In post infected
animals, isolated NGNs were more excitable than controls with a lower rheobase (60±8.0
vs 100.9±21 pA, p=0.03) and an increased number of spikes generated at two times rheobase
(5.6±0.7 vs 3.4±0.7, p=0.04). The proportion of NGNs responding to 100μM 2-methyl-
5HT was comparable between control and infected groups (10/21 vs 13/20, p=0.3 Fishers
exact test). However the current density of the 2-methyl-5HT induced current was signific-
antly smaller in infected animals (3.1±0.7 pA/pF vs 6.6±1.7 pA/pF, p=0.04). In in-situ
experiments, the WT response to ramp distensions of the jejunum consisted of a biphasic
increase in afferent firing. In infected animals there was a significant augmentation of afferent
discharge at both LT (0-10mmHg) and HT (10-50mmHg) levels of distension. In WT animals
30μM granisetron inhibited the LT response (from 28±4imp/s to 22±3.4imp/s, p=0.016)
leaving the HT response unaffected (24.6±3 imp/s inhibited to 23.1±3 imp/s, p=0.49).
However in infected animals 30uM granisetron inhibited both the LT (37.53±4 imp/s inhib-
ited to 28±5 imp/s, p=0.046) and HT response (42.5±6 imp/s inhibited to 35.4±6 imp/s,
p=0.013). Conclusion: T. spiralis infection causes an increase in the excitability of gastrointes-
tinal sensory nerves and a sensitisation of LT and HT mechano-sensitive afferent fibres that
is in part dependent upon the release of 5HT acting via 5HT3 receptors. Furthermore, there

















spiralis infection, which may represent an adaptive response to increased bioavailability
of 5HT.
S1751
Nociceptor Excitability Is Associated with Suppression of a-Type Potassium
Currents: Insights Into the Pathogenesis of Pain in Chronic Pancreatitis
Guang-Yin Xu, John H. Winston, Mohan M. Shenoy, Huaizhi Yin, Pankaj J. Pasricha
Background and Aims: The pathogenesis of pain in chronic pancreatitis (CP) is poorly
understood. We have previously developed a model of trinitrobenzene sulphonic acid
(TNBS)-induced CP that results in nociceptive sensitization characterized by referred somatic
allodynia and pancreatic hyperalgesia in rats. The aim of this study was to further explore
the cellular and ionic mechanisms underlying this sensitization, particularly focusing on
changes in potassium channel conductance, a critical factor in determining the responsiveness
of neurons to stimulation. Methods: CP was induced in adult rats by a single intraductal
injection of TNBS. Dorsal root ganglion (DRG) neurons innervating the pancreas were
identified by DiI fluorescence labeling. Whole cell patch-clamp recordings were made from
acutely dissociated DRG neurons from rats on day 21-26 after TNBS or vehicle treatment.
Results: Pancreas-specific neurons from thoracic (T9-13) DRGs of rats with CP displayed
more depolarized resting potential than those from controls (P<0.02), and tended to fire
spontaneously as compared with the much more quiescent neurons from controls. TNBS-
induced CP also resulted in a dramatic reduction in current threshold or rheobase (controls:
0.6±0.5 nA, n=17; TNBS: 0.2±0.1 nA, n=20, P<0.05) and a significant increase in the number
of action potentials evoked at twice rheobase (P<0.05). Under voltage-clamp conditions,
neurons from both groups exhibited transient A-type (IA ) and sustained outward rectifier
K+ currents (IK). Compared to controls, the IA rather than IK density was significantly reduced
in the TNBS group (control: 2.1±0.3 pA/pF, n=6; TNBS: 1.3±0.2 pA/pF, n=9, P<0.05),
without a change in cell diameter. The steady-state inactivation curve for IA was displaced
by ~45 mV to more hyperpolarized levels after TNBS treatment. Conclusions: These data
suggest that CP increases the excitability of pancreas-specific DRG neurons by suppressing
IA density, thus identifying for the first time a specific molecular mechanism underlying
chronic visceral pain and sensitization in CP. Further work is ongoing to identify the
molecular correlation of this change in current as well as the factor(s) driving it (Supported
by R01 DK62330-01 to P.J.P.).
S1752
Involvement of a 5-HT3 Receptor in the Capsaicin-Induced Inhibitory
Duodeno-Gastric Reflex in Man
George Karamanolis, Rita Vos, Josef Janssens, Jan Tack
Recently, we demonstrated that acute intra-duodenal administration of capsaicin, a TRPV1
receptor agonist, decreases proximal gastric tone and increases sensitivity to proximal gastric
distention, thereby mimicking the effects of intraduodenal acid perfusion. We have previously
shown that the acid-induced duodeno-gastric inhibitory reflex is partly mediated via a 5-
HT3 receptor (Karamanolis DDW 2005). The aim of our study was to investigate involvement
of 5-HT3 receptors in the capsaicin-induced duodeno-gastric inhibitory reflex. Methods:
Eight healthy volunteers (3 men, mean age 27) were studied on 2 occasions, at least one
week apart. An infusion tube was positioned in the second part of the duodenum, and a
barostat bag was located in the gastric fundus. Proximal stomach tone and sensitivity to
distension were assessed before and after duodenal infusion of 1.25ml of red pepper solution,
after pretreatment with saline or the 5-HT3-receptor antagonist ondansetron 8 mg i.v. in a
randomized, double-blind, cross-over fashion. Assessment of nine epigastric symptoms, on
100-mm visual analogue scales (VAS), were obtained from all volunteers. Results are given
as mean±SEM and compared by Student’s t-test and ANOVA. Results: After capsaicin instilla-
tion, a significant relaxation of the proximal stomach occurred (volume increase 133±26
ml; intragastric balloon volume 319±24 ml). Ondansetron pretreatment significantly inhibited
the intra-duodenal capsaicin-induced inhibition of proximal stomach tone (volume increase
57±14 ml, p=0.005; intragastric balloon volume 255±16 ml, p=0.06). Capsaicin increased
the slope (34±5 vs. 45±7 ml/mmHg, p<0.001) and intercept (38±7 vs. 99±21 ml, p=0.02)
of the gastric pressure-volume curve during stepwise distentions, and this was inhibited by
ondansetron (slope 23±3 vs. 47±11 ml/mm Hg, NS; intercept 71±6 vs. 86±32 ml, NS).
Pretreatment with ondansetron did not change the capsaicin-induced symptom scores and
the perception scores or perception and discomfort thresholds during gastric distention.
Conclusion: 5-HT3-receptors are involved in the capsaicin-induced duodeno-gastric inhibit-
ory motor reflex. However, ondansetron did not alter gastric sensitivity to distention and
severity of symptoms induced by duodenal capsaicin instillation.
S1753
Sensory Innervation of Intestinal Blood Vessels
Bao-Nan Chen, Xin-Yung Song, Marcello Costa, Simon Brookes
Spinal afferent neurons provide a powerful vasodilator input to blood vessels to the small
and large intestine which can be experimentally activated by the neurotoxin, capsaicin.
Recent studies from our laboratory have suggested that some varicose branching endings
of afferent axons (VBAs) on blood vessels also function as high threshold mechanotransduc-
tion sites, sensitive to localized distortion. The distribution, morphology and immunohisto-
chemistry of afferent VBAs on mesenteric blood vessels was characterised. Anterograde
labelling with biotinamide labelled VBAs on mesenteric vessels, in which TH immunoreactiv-
ity was present in 52 ± 13% which are probably sympathetic efferents. CGRP-immunoreactiv-
ity was detectable in 19 ± 6% of biotinamide labelled VBAs. Mechanotransduction sites have
previously been reported to be associated with arterial branch points: anterogradely labelled
VBAs were significantly closer to branch points (303 + 46µm, n=5) than randomly generated
sites (427 + 57µm, p<0.05). Varicose, branching nerve fibres lacking both TH and CGRP,
made up 24 ± 8% of all biotinamide labelled axons, indicating that some afferent axons
T : 89386$$CH2
05-04-06 23:18:26 Page 250Layout: 89386B : e
A-250AGA Abstracts
may lack CGRP immunoreactivity. Counts of CGRP and TRPv1 (capsaicin receptor) immuno-
reactivity on axons on mesenteric arteries supported this suggestion. Of all axons labelled
by one or both antisera, 85.9+2.0% had both CGRP and VR1, 3.6+1.3% had CGRP without
VR1 and 10.5+2.3% had VR1 without CGRP. Retrograde tracing with the carbocyanine dye,
DiI, labelled thoraco-lumbar spinal afferents which provide the major spinal afferent pathway
to the intestines. Of DiI-labelled neurons in dorsal root ganglia, 26.9+8.0% contained CGRP
and VR1 immunoreactivity, 3.1+0.6% contained CGRP alone and the remaining 69.9+7.6%
contained neither marker confirming that the gut receives innervation by spinal afferent
neurons which lack CGRP or TRPv1. We also investigated afferent axons on submucous
blood vessels. Of axons labelled by one or both markers, 91.8+1.4% contained CGRP with
VR1, 6.9+2.3% contained CGRP without VR1 and 1.3+1.2% contained VR1 without CGRP.
These results reveal that mesenteric and submucous arteries are innervated by sensory nerve
fibres, which make branching endings significantly associated with arterial branch points.
A population of these vascular primary afferents, visualised using anterograde or retrograde
tracing, appears to be non-peptidergic and may not have been identified previously using
immunohistochemical methods. This work was supported by R01-DK56986 from NIH
(USA) and #275530 from NHMRC Australia.
S1754
Effects of C.Difficile Toxin B On the Electrical Activity of the DRG Neurons
Denis G. Colomb, Minho Kang, Hamid I. Akbarali
Clostridium difficile toxins, the causative agents of pseudomembranous colitis, are glucosyl-
transferases that inactivate small GTPases of the Rho family. In addition to the initial activation
of the enterocytes, the pro-inflammatory effects of the toxins may also involve sensory
neurons. It is however not known whether the toxins can directly affect the electrical
properties of the sensory neurons. Single neuronal cells were enzymatically isolated from
the rat L6-S2 dorsal root ganglia. In current clamp mode, C. difficile toxin B (TxB; 5 ug/ml)
produced a significant hyperpolarization of the DRG cells by approx. 10-15 mV (p<0.05;
n=5) after 10 mins of perfusion, indicating that TxB selectively modulates ion channels
maintaining resting potential. Under voltage clamp conditions with high K+ intracellular
pipette solution, hyperpolarization from a holding potential of -60 mV (10 mV steps)
activated time- and voltage independent inward instantaneous (Iinst) current and, at step
potentials negative to -80 mV, an additional slow activating component (Islow), characteristic
of the hyperpolarization activated cyclic nucleotide gated cation channels (HCN) (n=55).
Both Iinst(HCN) and Islow(HCN) had reversal potential of approx. -25 mV with significant
correlation between the two components (r2 =0.62; p<0.0001). The HCN blockers, ZD7288
(10 uM) and CsCl (1 mM) abolished the slow component but did not alter the resting
membrane potential or the instantaneous current. In contrast, TxB perfusion resulted in a
time-dependent inhibition of the instantaneous current component of the HCN channel
concomitant with hyperpolarization but did not significantly affect the slow component.
Iinst(HCN) was inhibited by approx. 50% after 8-10 mins of perfusion. Within this time frame
the morphology of the cells and the cell capacitance remained unchanged. Iinst(HCN) was not
affected by either heat-inactivated TxB or rundown over 10 mins. The specificity of TxB on
the Iinst(HCN) component of HCN channels was further confirmed in heterolougsly expressed
human HCN-1 (HEK cells). These data demonstrate that 1) the Iinst(HCN) component, but
not Islow(HCN) of the HCN channel contributes towards the resting membrane potential of
the DRG neurons, 2) TxB induces hyperpolarization of the DRG soma by specific inhibition
of the Iinst(HCN) and 3) TxB affects the electrical excitability of the sensory neurons separate
from its effects on cell morphology. Furthermore, the ability to differentially block Iinst(HCN)
and Islow(HCN) suggests that separate gating mechanisms are involved in the two components
of the HCN channel. Supported by NIH DK46367, DK069628 and US Navy HSCP(DC).
S1756
Involvement of the Acid-Sensing Ion Channel ASIC3, But Not ASIC2, in Acid
Hypersensitivity Associated with Gastritis in Mice
Peter Holzer, Thomas Wultsch, Evelin Painsipp, Anaid Shahbazian, Rainer Waldmann
Introduction and Aims: Gastric acid is a potentially noxious stimulus, but the molecular
sensors relevant to gastric acid nociception await to be identified. The acid-sensing ion
channels ASIC2 and ASIC3 are expressed by vagal and spinal afferent neurons supplying
the stomach. Here we examined whether knockout of the ASIC2 or ASIC3 gene modifies
vagal afferent signaling of a gastric acid insult and whether ASIC2 or ASIC3 contributes to
the gastric acid hypersensitivity associated with gastritis. Methods: The gastric mucosa of
mice was challenged with 0.25 M HCl (0.02 ml/g) given via an esophageal catheter. Two
hours later the brainstem was removed and activation of neurons in the nucleus tractus
solitarii (NTS) visualized by c-Fos immunocytochemistry. In order to induce gastritis,
iodoacetamide (0.1 %) was added to the drinking water 7 days before the gastric HCl
challenge experiment. Results: Exposure of the gastric mucosa to HCl (0.25 M) caused a
2.7-fold (P<0.01) increase in the number of c-Fos positive neurons in the NTS. Relative to
wild-type mice, the gastric acid-evoked c-Fos expression in the NTS remained unchanged
in ASIC3 knockout mice. In contrast, ASIC2 knockout enhanced the c-Fos response to HCl
challenge by 33 % (P<0.01). Exposure of wild-type mice to iodoacetamide (0.1 %) in the
drinking water induced gastric inflammation as revealed by an increase in myeloperoxidase
activity. In addition, iodoacetamide-pretreated mice exhibited gastric acid hypersensitivity
as revealed by a 41 % increase (P<0.01) in the number of NTS neurons expressing c-Fos
in response to gastric HCl challenge. The iodoacetamide-evoked acid hypersensitivity was
completely absent in ASIC3 knockout mice but was fully conserved in ASIC2 knockout
mice. Wild-type, ASIC2 knockout and ASIC3 knockout animals did not differ in the number
c-Fos positive neurons in the NTS following intragastric administration of saline. Conclusions:
The current data indicate that ASIC3 expressed by vagal afferents plays a major role in acid
hypersensitivity associated with experimental gastritis but does not participate in the acid
surveillance of the normal gastric mucosa. To the contrary, ASIC2 appears to dampen acid-
evoked input from the stomach to the NTS, an action that is likely to take place in the
brainstem because it does not interfere with iodoacetamide-evoked sensitization of the
stomach to acid. Supported by the Jubilee Funds of the Austrian National Bank, the Zukunfts-
fonds Steiermark and the Austrian Scientific Research Funds.
S1757
Enhanced Anterior Cingulate Cortex (ACC) Nociceptive Transmission in
Visceral Hypersensitive Rats Is Restricted to Visceral Afferent Input
Jun Gao, Xiaoyin Wu, Chung Owyang, Ying Li
The anterior cingulate cortex (ACC) mediates affective processing of sensory information.
Abnormal processing of visceral sensory signals by the ACC may aggravate symptoms of
irritable bowel syndrome. We recently reported an enhanced response of the ACC to
colorectal distension(CRD) in visceral hypersensitive (VH) rats characterized by increased
spontaneous activity of CRD-excited neurons, decreased CRD pressure threshold, and
increased response magnitude. Cross-sensitization of visceral and somatic sensory pathways
has been reported. Noxious somatic afferent input from the hind limb enhances visceral
hyperalgesia in the rat, and this sensitization occurs at the spinal cord. In this study we
investigated whether cross-sensitization of visceral and somatic pathways occurs at the level
of the ACC in VH rats. We recorded single ACC neuronal discharges in response to CRD
in sham treated (control) and VH rats induced by intraperitoneal injection of egg albumin
followed by 3 days of periodic CRD. Neurons in the rostral ACC which exhibited an excitatory
response to 50 mmHg CRD were identified. Responses of these neurons in rats subjected
to noxious transcutaneous electrical stimulation (TCES) of the hind paw were recorded.
Nine of 16 neurons in control and 12 of 20 neurons in VH rats were activated exclusively
by CRD but not to TCES. The second group of CRD-excited ACC neurons (7/16 in control
and 8/20 in VH rats) responded to both TCES and CRD. To determine whether cross-
sensitization of visceral and somatic sensory pathways occurs in the ACC of VH rats, we
performed single neuron recording in the ACC neurons which only responded to both CRD
and cutaneous noxious heat stimulation of the hind paw. Compared with ACC neurons in
control rats, ACC neurons in VH rats show enhanced firing rate in response to CRD (50
mm Hg) (increased from 0.83 ± 0.1 to 1.7 ± 0.2 impulses/sec in control vs 1.66±0.15 to
4.0±0.4 impulses/sec in VH rats). In contrast, proportional increases in ACC firing rates in
response to cutaneous heat stimulation was similar between control and VH rats (from basal
0.85 ± 0.06 to 3.2±0.4 at 46°C and to 6.4±0.5 impulses/second at 52°C in control rats,
and from basal 1.67±0.25 to 4.4±0.45 at 46°C and to 7.8±0.9 impulses/second at 52°C in
VH rats). We conclude that ACC has functionally distinct regions subserving visceral and
somatic sensory pathways. In subgroups of ACC neurons which respond to visceral and
cutaneous stimulation, there is no cross-sensitization between visceral and somatic pain. In
contrast to the spinal cord, enhanced ACC nociceptive transmission in visceral hypersensitive
rats is restricted to visceral afferent input.
S1758
Responses to Mechanical Stimuli in Low-Threshold Slowly-Adapting Rectal
Mechanoreceptors After TNBS-Induced Inflammation in the Guinea Pig
Penny A. Lynn, Marcello Costa, Simon Brookes
The effects of TNBS-induced inflammation on specialised, low threshold, slowly adapting
rectal mechanoreceptors were investigated in the guinea pig. Under isoflurane anaesthesia,
300µl saline or 300µl of TNBS (15mg/ml) in 30% ethanol, was instilled 7cm from the anal
sphincter. Six or 35 days later, animals were humanely killed and single unit extracellular
recordings made from rectal nerve trunks in flat sheet preparations attached to a mechanical
tissue stretcher, while monitoring muscle tension. TNBS caused macroscopic ulceration of
the rectal mucosa at 6 days which fully resolved by 35 days. Basal motility and low-threshold
stretch-sensitive afferent discharge were unaffected by TNBS treatment at six days (saline
control n=14, N=9, TNBS-treated n=27, N=12) or 35 days (n=9, N=5 and n=10, N=5
respectively) post-treatment. Integrated mean tension, contraction frequency and amplitude
evoked by circumferential stretch were unaffected by TNBS at either 6 days (n=9) or 35
days (n=5). Responses of low-threshold rectal mechanoreceptors to stretch were similarly
unaffected by TNBS treatment at 6 days (n=12) or 35 days (n=11) post-treatment. The
threshold for von Frey hair evoked firing (0.1 - 1.1mN) was significantly reduced (p<0.01)
at 6 days but not at 35 days (NS, n=5). Responses to more intense von Frey hair stimulation
(0.3-1.1mN) were otherwise unaffected by TNBS pre-treatment. The inflammatory mediator
PGE2 (1 uM) activated low-threshold stretch-sensitive afferents (p<0.05) in TNBS-treated
preparations (6 days) with firing closely associated with evoked contractions. PGE2 (1uM)
also activated 5 stretch-insensitive afferents (p<0.01). Capsaicin (1uM) did not activate low-
threshold stretch-sensitive afferents (n=8, p= 0.87) but excited stretch-insensitive afferents,
independent of contractions (n=5, p<0.01). Neither PGE2 nor capsaicin activated stretch-
sensitive (n=6) or stretch-insensitive afferents (n=4) in control (saline-treated) animals. The
mechanical thresholds of specialised, low threshold, slowly adapting rectal mechanoreceptors
of the guinea pig rectum are slightly but significantly reduced in TNBS inflammation, but
suprathreshold responses are unaffected. Other classes of afferents are sensitised to PGE2
and capsaicin following TNBS treatment, as is smooth muscle contractility, but low threshold
mechanoreceptors are not directly affected. These results indicate differential modulation of
various classes of colonic afferents by inflammation. This work was supported by R01-
DK56986 from NIH (USA)
S1759
Colonic Serotonergic Signaling Molecule and Receptors mRNA Alteration in
Rats with Acute or Chronic Restraint Stress
Yan Sun, Gengqing Song, Fengling Liu, Wei Qian, Xiaohua Hou
Background & Aims: Serotonin (5-HT) is a critical signaling molecule in the gut and plays
an important role in initiating peristaltic, secretory, and nociceptive reflexes. Stressful factors
could induce gut motility and sensation dysfunction. The aim of this study was to investigate
the effects of acute and chronic partial restraint stress (PRS) on 5-HT synthesize enzyme,
5-HT transporter and 5-HT receptors messenger RNA (mRNA) in colon tissues of rats.
Methods: 35 male Sprague-Dawley rats were divided evenly into five groups including
control without PRS, acute PRS for 2h, acute PRS with 7-day recovery, chronic PRS for 2h
a day in 3 consecutive days, chronic PRS with 7-day recovery. Typtophan hydroxylase
(TpH), 5-HT transporter, and 5-HT1A and 5-HT4 receptors mRNA in colon tissues were
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detected by using reverse transcription- polymerase chain reaction (RT-PCR) method. The
mast cells in colon tissues were observed by using immunohistochemistry staining. Results:
(1) Compared with the rats without PRS, the TpH and 5-HT transporter mRNA were
significantly reduced in the rats with chronic PRS (0.69±0.13 vs. 1.23±0.36 and 0.63±0.18
vs. 1.20±0.35 respectively, P<0.05) and chronic PRS with 7-day recovery (0.70±0.12 vs.
1.23±0.36 and 0.56±0.15 vs.1.20±0.35, P<0.05). (2) For the TpH and 5-HT transporter
mRNA expressions, there were no significant differences among the rats with acute PRS or
acute PRS with 7-day recovery or the rats without PRS (P>0.05). (3) In comparison with
the rats without PRS, the 5-HT1A and 5-HT4 receptors mRNA were significantly higher in
the rats with acute and chronic PRS (5-HT1A receptor: 0.42±0.09 vs. 0.22±0.16 and
0.80±0.20 vs. 0.22±0.16 respectively P<0.05; 5-HT4 receptor: 0.52±0.19 vs. 0.32±0.15 and
0.93±0.31 vs. 0.32±0.15 respectively P<0.05). In the rats of 7 days after the acute or chronic
PRS, the 5-HT1A and 5-HT4 receptor mRNA expressions were still higher than the rats
without PRS (P<0.05). (4) There was no significant difference in the mast cell count in
colon tissues among all groups (P>0.05). Conclusions: These results show that chronic PRS
inhibits serotonergic signaling, whereas the acute PRS does not affect serotonergic signaling
in colon tissues. Both acute and chronic PRS increase 5-HT receptors expression. These
findings suggest that different changes of 5-HT signaling molecules and receptors may
underlie the altered gut motility and sensation under acute or chronic stress conditions.
S1760
Nippostrongylus Brasiliensis (NB)-Infected Mice Exhibit Chemical But Not
Mechanical Hypersensitivity
Kirk Hillsley, Christine McCaul, Pieter Peeters, Jeroen Aerssens, David Grundy, Bernard
Coulie, Ronald H. Stead
Background: Nb infection results in a transient inflammation and subsequent increases in
mucosal innervation, mast cells and mast cell-nerve contacts. Previous studies have reported
hypersensitivity to intestinal distension, but chemosensitivity has not been investigated. This
study determined if Nb infection had any effect on mechanosensitive and chemosensitive
responses in the murine jejunum. Methods: Balb/c mice were infected with 500 L3 Nb larvae
or saline (sham) and the following three separate studies performed 3-4 weeks later. Aortic
blood pressure was recorded in response to phasic (30 s) balloon distension with up to 0.9
ml, which evoked an intraluminal pressure (IP) of 115.9 ± 6.5 mmHg. Mesenteric afferent
nerve activity and IP were recorded in response to either ramp balloon distension up to 60
mmHg, or to a 2.5 min intraluminal perfusion (0.15 ml/min) of 50 mM hydrochloric acid
(HCl). Data are expressed as mean ± SEM and analysed with 2-way ANOVA or unpaired
t-tests. Results: Pressor responses were elicited by phasic distension. There was no significant
difference in the pressor responses elicited in sham (n = 18) and infected (n = 13) animals
(p = 0.87, see Table 1). Ramp distension evoked an increase in afferent nerve activity.
However, afferent responses in Nb infected mice (n = 49) were not significantly different
(p = 0.94, see Table 1) from sham mice (n = 48). In response to HCl perfusion there was
a rapid increase in afferent activity (acute response) that plateaued within 5 min (prolonged
response), and a gradual IP increase that peaked within 5 min. There was an increase in
both the afferent and IP responses to HCl in infected (n = 26) compared to sham (n = 25)
animals as detailed in Table 2. There was no significant direct correlation between any
changes in nerve activity and IP. Conclusions: Nb infection evokes jejunal hypersensitivity
to chemical but not mechanical stimuli. It is postulated that the Nb-induced inflammation
mainly impacts the mucosa which alters the sensitivity of chemosensitive afferents, whilst




Effects of Intraluminal Local Anesthetic On Duodenal Glucose Sensing in
Humans
Reawika Chaikomin, Selena Doran, Michael Horowitz, Chris Rayner
Enteral administration of glucose modifies gut sensation, diminishes hunger, and slows
gastric emptying by suppressing antral motility and stimulating pyloric pressures. The
mechanism of small intestinal glucose sensing is unclear. We studied 8 healthy males on
two days each, in random order. After an overnight fast, a catheter was positioned with a
sleeve sensor across the pylorus, 6 sideholes in the antrum and 7 sideholes in the duodenum.
Benzocaine, or vehicle alone, was given into the proximal duodenum as an initial bolus,
followed by a continuous infusion for 105 minutes (t = -15 to 90 min). Glucose was also
infused into the proximal duodenum at 3 kcal/min for 90 minutes (t = 0 to 90 min).
Sensations of hunger, bloating, and nausea were assessed at frequent intervals with visual

















counted, together with propagated sequences of duodenal waves. Data are mean ± SEM.
Sensations of bloating and nausea were markedly less with benzocaine when compared to
vehicle (P<0.05 for each), with no difference in hunger. In contrast, the suppression of
antral waves (19 ± 9.6 for benzocaine v 2.88 ± 1.3 for vehicle) and stimulation of pyloric
pressures (58.38 ± 9.1 v 81.5 ± 23.7), duodenal waves (782.75 ± 134 v 540.5 ± 149.7),
and propagated duodenal wave sequences (124.88 ± 27.3 vs 61 ± 20.1) during 90 minutes
of intraduodenal glucose infusion did not differ between the two days. We conclude that
nerves in the duodenal mucosa mediate unpleasant sensations induced by enteral glucose,
while feedback on appetite and gastroduodenal motility is conveyed by alternative mechan-
isms, such as gut peptides.
S1762
Adenosine Activates a Subset of Nociceptive Vagal Sensory Nerves in
Esophagus
Fei Ru, Marian Kollarik
BACKGROUND & AIMS: Clinical studies suggest that adenosine acting on the peripheral
sensory nerves in esophagus contributes to the pathogenesis of pain in a proportion of
patients with non-cardiac chest pain (NCCP) originating from esophagus (Dig Dis Sci.
47:2763). We have demonstrated in guinea pig that in addition to classically described
non-nociceptive low threshold mechanosensors (“tension receptors”) vagus nerves supply
esophagus with nociceptive sensory nerves distinguished by the capacity to discriminate
noxious stimuli (J. Physiol 563: 831). Here we address the hypothesis that adenosine
selectively activates vagal esophageal nociceptors. METHODS: Single cell RT-PCR was per-
formed from the individual primary sensory neurons enzymatically dissociated from the
guinea pig vagal nodose ganglia. Extracellular single-unit recordings were made from the
nodose ganglion neurons with the mechanosensitve receptive fields in the esophagus using
ex vivo isolated vagally innervated guinea pig esophagus preparation. RESULTS: The adenos-
ine A1 receptor mRNA was detected by the single cell RT-PCR in 10/17 nodose neurons.
Consistent with our previous studies, two types of vagal nodose nerve fibers were identified
by electrophysiology in esophagus: capsaicin-sensitive C-fibers (conduction velocity <1.2
m/s, n=16) in which nerve activity increased linearly with increasing esophageal distention up
to 100 mmHg (nociceptive C-fibers), and capsaicin-insensitive nodose A-fibers (conduction
velocity 2-10 m/s, n=9) in which response to esophageal distention saturated at <60mmHg
(“tension receptors”). Adenosine (100μM, 10min) and the selective adenosine A1 receptor
agonist CCPA (1μM, 10min) evoked action potential discharge in 6/9 (the peak frequency
3±1 Hz) and 7/9 (the peak frequency 7±2 Hz) nociceptive nodose C-fibers, respectively. In
contrast, adenosine (100μM, 10min) had no effect on the non-nociceptive nodose A-fibers
(n=7, p>0.1), although the positive control stimulus, the P2X receptor agonistα,β-methylene-
ATP (30μM, 10 min) evoked robust activation (peak frequency 15±2Hz) in these A-fibers.
CONCLUSIONS: Adenosine activates a subset of vagal esophageal nociceptors, but not non-
nociceptive low threshold mechanosensors (“tension receptors”). Our data suggest that the
response of esophageal vagal nociceptors to adenosine is at least partially mediated by the
adenosine A1 receptor. We speculate that this pathway may contribute to the perception
of pain in patients with NCCP.
S1763
Somatic Hypersensitivity in the Irritable Bowel Syndrome
Baharak Moshiree, Roger B. Fillingim, Kristy Phelan, Joseph Riley, Nicholas G. Verne
Introduction: We have shown that Irritable Bowel Syndrome (IBS) patients display hypersens-
itivity in response to nociceptive thermal stimuli (Verne et al., Pain, 2001;93:7-14). These
findings differ from previous studies that indicate IBS-associated hypersensitivity is limited
to the gut. Aim: The aim of the present study is to examine the differences in sensitivity to
ischemic pain in IBS patients compared to controls. Methods: Ten female patients (mean
age: 29.5 +/- 8.7) with IBS and 26 healthy female controls (mean age: 28 +/- 8.1) completed
the study. The right arm was exsanguinated and then occluded with a standard blood
pressure cuff inflated to 240 mmHg. Subjects then performed 20 hand-grip exercises of 2-
sec duration at 4-sec intervals at 50% of their maximum grip strength. They then rated pain
intensity on 0-100 Mechanical Visual Analogue Scale (M-VAS) every 60 seconds. Subjects
continued for 15 minutes or until the pain became intolerable. Group differences for threshold
and tolerance were determined using a series of 1-way ANOVA tests. Results: IBS patients
had a shorter ischemic tolerance (239 secs) compared to controls (444 secs) (F=4.310, p=
0.46). There were no group differences for ischemic threshold (p= 0.476). Conclusions:
Our data suggests that a more widespread alteration in central pain processing in IBS patients
may be present as they display enhanced hypersensitivity to experimental ischemic pain.
These new findings also suggest a dysfunction in inhibitory pain systems in IBS patients as
ischemic (deep) pain is under tonic inhibitory control. Supported by VA Merit Review and
a NIH RO1-NS053090.
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S1764
Peripheral Sensitization and the Role of P2X Receptors in the Pathogenesis of
Visceral Hypersensitivity in a Rat Model of Irritable Bowel Syndrome
Guang-Yin Xu, Mohan M. Shenoy, John H. Winston, Huaizhi Yin, Pankaj J. Pasricha
Background and Aims: Although sensitization to mechanical stimulation of the colon is
common in irritable bowel syndrome (IBS), its pathogenesis and underlying molecular
mechanisms remain unknown. Recent work in somatic and other visceral models suggest
a role for purinergic signaling mediated by the P2X receptor family. We have previously
described a rat model of IBS associated with persistent hypersensitivity to colorectal distention
(CRD), induced by neonatal intracolonic acetic acid (AA). In this study, we used this model
to determine the presence of peripheral sensitization and to examine a role for P2X signaling
in the pathogenesis of the same. Methods: IBS was induced by colonic injection of AA in
neonatal rats at P10. Balloon distention of the colon was performed at 8 weeks of age and
nocifensive responses measured on a behavioral scale. Dorsal root ganglion (DRG) neurons
innervating the colon were labeled by injection of DiI fluorescence into the colon wall one
week before electrophysiological studies consisting of whole cell patch-clamp recordings
from acutely dissociated DRG neurons. Results: Colonic sensory neurons from rats with
AA-induced hypersensitivity showed a dramatic reduction in current threshold or rheobase
(control: 0.55±0.07, n=32; AA: 0.21±0.03, n=27, P<0.05) and a significant increase in
the number of action potentials evoked at twice rheobase (control: 1.16±0.07, n=32; AA:
1.84±0.09, n=25, P<0.01). Under voltage-clamp conditions, application of ATP (20 µM), a
P2X receptor agonist, produced an inward current with an amplitude of 6.0±1.3 pA/pF (n=
20) in colonic neurons from control rats; this was increased two-fold in colonic neurons
from rats with hypersensitivity (n=17, P<0.05). These currents were completely blocked by
the P2X antagonist TNP-ATP (100 nM) in both groups. Further, systemic administration of
TNP-ATP (50 mmol/kg, i.p.) markedly reduced the pain behavioral response to colon
distension in rats with hypersensitivity. Conclusions: These data suggest that exposure of
the colon to a transient and mild noxious stimulation in the neonatal period can result in
permanent hypersensitivity and peripheral sensitization. Our findings also suggest that P2X
receptors may play an important role in the pathogenesis of hypersensitivity to mechanical
distention of the colon, thus identifying a specific neurobiological target for therapy.
S1765
Localization and Characterization of the Mechanosensory Innervation of the
Rat Pancreas
Ann C. Schloithe, Charmaine M. Woods, Joesph S. Davison, Laurence A. Blackshaw,
James Toouli, Gino Saccone
Background: Afferent innervation of the pancreas is poorly understood despite the fact that
management of pancreatic pain is a major clinical problem. Aim: To map and characterize
mechanosensitive afferents in the normal rat pancreas. Methods: A novel isolated pancreas
preparation that included the pancreatic duct (PD), common bile duct (CBD) and the
splanchnic nerves was obtained from anaesthetized (Nembutal; 60mg/kg i.p.) Sprague Dawley
rats (n=14). The CBD was cannulated. The preparation was placed in a 2 chamber organ
bath. One chamber accommodated the pancreatic tissue in physiological solution and the
second chamber contained the nerve fibers in paraffin oil. Extracellular nerve recordings
were obtained using fibers isolated from the left splanchnic nerve. Stimuli consisted of blunt
probing (graded and non-graded), CBD/PD distension (44 mmHg), or electrical stimulation
(ES; 20V, 0.5ms duration). Results: Discharge from 197 fibers was recorded, of which 57%
displayed spontaneous activity. Each fiber contained between 1 and 5 spontaneously firing
units with a mean discharge rate of 2.52 ± 0.32 imp/sec. Sixty one mechanosensitive
receptive fields were identified and were mainly associated with arteries/blood vessels (33/
61), particularly the gastric, splenic, and hepatic arteries, and the parenchyma (22/61).
Receptive fields were also associated with pancreatic tissue near lymph nodes (4/61), CBD
(1/61) and duodenal mesentery (1/61). 13% of the receptive fields received innervation
from 2 or 3 separate nerve fibers in 7 preparations and 70% of these receptive fields were
located on blood vessels. All mechanosensitive responses were slowly adapting and 33%
displayed continuing discharge after termination of the stimulus. Graded responses recorded
from 27 units revealed that 60% of the units displayed a response threshold less than 10g.
25% and 15% of the units had a response threshold of between 10 and 20g or greater
than 20g, respectively. Importantly, CBD/PD distension did not evoke any discharge from
spontaneous or quiescent units. Non-mechanosensitive receptive fields, stimulated by ES
only, were located in pancreatic tissue (7/17), arteries/blood vessels (9/17) or CBD/PD (1/
17) and their function is yet to be established. Conclusion: Mechanosensitive nerves are
associated with several structures in the pancreas, particularly the vasculature and paren-
chyma though, notably not with the major duct system. Our continuing studies aim to
establish the role of pancreatic afferents in physiological and pathophysiological signalling.
This study was supported by the NH&MRC of Australia (grant # 229901) and the FMC
Foundation.
S1766
Angiotensin As a Potential Mediator of Mast Cell Nerve Interactions in the
Esophagus
Shaoyong Yu, Kevin Kwong, Bradley Undem
Introduction: Mast cells are pro-inflammatory cells found in the wall of the esophagus, and
their numbers increase during various inflammatory disorders of the esophagus. We previ-
ously reported that activation of mast cells causes a substantive increase in excitability of
esophageal vagal nodose C-fiber terminals in guinea pig esophagus. Here we begin to
address the hypothesis that angiotensin may contribute to mast cell nerve interactions in
the esophagus. Aim: We hypothesize that esophageal mast cells contain renin, and that the
angiotensin presumed to be formed by the released rennin increases the excitability of
nodose neurons. Methods: We used standard immunohistochemical techniques to identify
cells in the esophagus that store renin. Mast cell tryptase was used as a marker for mast
cells. The effect of angiotensin-II on vagal sensory neuronal excitability was evaluated using
standard patch clamp recording techniques on neurons acutely dissociated from adult guinea
pigs. Results: In 7 animals an average of 10 ± 2 cells per cross section of guinea pig esophagus
were strongly positive for rennin. The average number of mast cells per cross section of the
esophagus was 27 ± 3. Among the renin positive cells, 87 ± 1% also contained mast cell
tryptase. Angiotensin-II (0.1.µM) increased the electrical excitability of 4 out of 5 vagal
sensory neurons. In these cells, studied in current clamp mode, angiotensin significantly
increased the number of action potentials evoked by a 500 msec constant current pulse
(100pAmp) from 2.5 ± 0.8 to 4.2 ± 0.8. Conclusion: Consistent with recent reports in
cardiac tissue (PNAS 101: 13607, 2004), a substantial percentage of esophageal mast cells
contain renin. If this renin is released upon mast cell activation it may convert angiotensinogin
to angiotensin I. Either mast cell chymase or angiotensi converting enzyme may then convert
angiotensin-I to angiotensin-II, a mediator that we show here to be effective at increasing
excitability of vagal sensory nerves.
S1767
Potentiation of Transient Receptor Potential Vanilloid Receptor 3 (TRPV3)
Sensing Function By Ethanol
Hong-Zhen Hu, Chumbo Wang, Michael X. Zhu, Jackie D. Wood
Ethanol can act as a noxious irritant and induce inflammatory responses (e.g., gastritis) in
the gastrointestinal tract. The transient receptor potential (TRP) channels, expressed by
intramural spinal and vagal sensory afferents, become targets for ethanol. For example, the
TRP vanilloid receptor Type 1 (i.e., the capsaicin receptor) is sensitized by ethanol (Br J
Pharmacol 2004;141:1313-20). TRPV3 is another member of the vanilloid receptor family,
which is associated with inflammation and thermal sensitivity. We now present evidence
that ethanol directly influences TRPV3 function when the receptor is expressed in either
HEK293 cells or Xenopus oocytes. Esposure to ethanol significantly increased the amplitude
of the TRPV3-activated trans-membrane ionic current that was evoked by the agonist, 2-
APB, in Xenopus oocytes injected with mouse TRPV3 cRNA. Ethanol (100 mM and 1M)
increased the responses to 100-µM 2-APB to 245.7±38.6% (n=4) and 476.9±123.6% (n=
4) of the current in the absence of ethanol. Similarly in HEK293 cells, transfected with
mouse TRPV3 DNA, ethanol (100 mM and 1M ) increased the amplitude of 2-APB-evoked
current to 239.2±12.5% and 547.6±82.3% (n=5) of the current prior to ethanol treatment.
Increasing the temperature from 23o to 40oC evoked an outwardly rectifying current in
TRPV3-expressing oocytes and ethanol increased the amplitude of the heat-activated current
to 550% of the current in the absence of ethanol treatment. The potentiation by ethanol
was unchanged by removal of extracellular calcium or intracellular injection of the calcium
chelator, BAPTA, in the TRPV3-transfected oocytes. The results suggest that ethanol directly
modulates the behavior of thermal sensitive TRPV1 and TRPV3 channels. TRPV3 might also
be involved in ethanol-evoked sensitization of primary gastrointestinal afferents in parallel
with sensitization of TRPV1. (Supported by NIH RO1 DK37238 and RO1 DK57075)
S1768
In Vivo Electrophysiological and C-Fos Study of Pelvic Primary Afferent Nerve
Fibers Encoding Colorectal Mechanosensory Signalling in Healthy Female
Wistar Rats
Heiko U. de Schepper, Benedicte Y. de Winter, Luc van Nassauw, Jean-Pierre
Timmermans, Paul A. Pelckmans, Joris G. de Man
Introduction: The pelvic nerve innervates the distal colon via the lumbosacral portion of
the spinal cord (DRG L6-S1). Afferent pelvic neurons are involved in both innoxious and
noxious mechanosensation and in extrinsic autonomic gut reflexes. Our aims were to
investigate the global behaviour of these pelvic neurons relative to their response threshold
(TH) and conduction velocity (CV). Methods: We implemented an in vivo setup for measure-
ment of pelvic afferent nerve signals. Pentobarbital-anaesthetized (60 mg/kg, i.p.) female
Wistar rats were fitted with a silver electrode wrapped around the pelvic nerve. A balloon
(5 cm) inserted in the colorectum allowed phasic colorectal distensions (CRD, 20-40-60-
80 mmHg at 4 min intervals). The lumbosacral spinal cord was exposed and the S1 dorsal
root was identified and teased into fine strands. These were individually draped over a
bipolar platinum electrode in a liquid paraffin bath (37°C). Fibers responding to CRD were
identified and stimulus-response curves were constructed. The CV was calculated from the
response time of spinal nerves to pelvic nerve stimulation (0.5 ms puls, 5-8 V). Immunohisto-
chemical c-fos staining was performed in DRG S1 in rats with and without prior CRD (80
mmHg). Results: We identified 9 pelvic afferent neurons responding to CRD, most with
an initial rapid dynamic burst followed by a lower, more sustained discharge rate. 66.7%
(6) of these showed spontaneous activity (0.7±0.4 Hz). 55.6% (5) of these fibers encoded
the entire pressure range studied and were identified as low TH (≤10 mmHg), while 44.4%
(4) showed a high TH of activation (≥28 mmHg). The firing rate to every CRD intensity
studied was significantly higher for low TH fibers compared to high TH fibers (at 60-80
mmHg: 12.2±5.1 Hz compared to 5.7±0.8 Hz, P<0.05). Of the 9 pelvic neurons studied,
55.6% (5) were identified as unmyelinated C-fibers (CV<2.5 m/s) and 44.4% (4) as thinly
myelinated Aδ-fibers (CV>2.5m/s). Aδ-fibers showed a higher firing rate to CRD compared
to C-fibers (at 60-80 mmHg: 14.6±5.9 Hz compared to 5.26±0.87 Hz). C-fos staining
showed an upregulation of S1 neuronal activity after noxious distension. Conclusions: Both
electrophysiology and c-fos staining demonstrated the involvement of S1 primary afferent
fibers in sensing CRD. Our preliminary results showed 4 groups of neurons responding to
CRD, and are as such in concert with previous reports (Sengupta & Gebhart, J Neurophysiol
1994). In our study however, Aδ- and C-fibers were equally distributed in contrast to the
C-fiber predominance reported by others. In addition, we found that Aδ-fibers responded
to CRD with a higher discharge rate than C-fibers.
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S1769
Chronic Mild Stress-Induced Visceral Hypersensitivity to Rectal Distension in
Rats: Role of Protenase-Activator Receptor-2 and Mast Cell
Yong Sung Kim, Suck Chei Choi, Moon Young Lee, Young Woo Sohn, Yong Leol Oh,
Geom Seog Seo, Tae Hyeon Kim, Chang Soo Choi, Young Mi Lee, Yeon-A Choi, Sang
Wook Kim, Myung Gyu Choi, Yong-Ho Nah
Background/Aim: Visceral hypersensitivity is one of the important pathophysiologic mechan-
ism of irritable bowel syndrome (IBS), but the causes underlying this mechanism are not
entirely understood. The increased number of mast cells and their proximity to the colonic
nerve in IBS patients were recently reported. One study suggests that proteases from degranu-
lated mast cells cleave protenase-activated receptor (PAR)-2 located on submucosal neurons
to cause acute and long-lasting neuronal hyperexcitability (Reed DE et al, 2003). This study
examined whether mast cell numbers and PAR-2 expression in a rat colon are changed after
6 weeks of chronic mild stress (CMS) protocol that induces visceral hypersensitivity and
reflects a sustained human stress situation. Method: Adult Sprague-Dawley male (N=5) rat
(200 g) spent 6 weeks under CMS protocol that has been previously described (Willner et
al, 1987). Control group (N=5) spent the same period under normal conditions. After CMS
protocol, we assessed the electromyographic response of abdominal muscles to colorectal
distension (CRD) by inflation of a balloon (0.2, 0.4, 0.6, 0.8, 1.0, 1.2mL, ascending-limits
phasic distension) using a Fogarty embolectomy catheter. Both the control and CMS rats
were killed by decapitation and their colons were then removed. Three colonic pieces
(proximal, mid, distal) from each group were stained with toluidine blue to quantify the
number of mast cells and immunostaining was performed using anti PAR-2 antibody to
quantify the number of PAR-2 expressed cells. Result: The threshold of abdominal muscle
contraction to CRD was lower in the CMS group than in the control group (0.39 ± 0.09
mL vs 0.58 ± 0.09 mL, p<0.01). Mast cells were found mainly in the submucosal area. The
number of mast cells increased higher in the CMS group than in the control group (3.47±1.64 /
mm2 vs 0.55±0.39/mm2, P<0.05). The number of mast cells in each area significantly
increased in the CMS group, but were more prominent in the distal colon (P<0.05). PAR-
2 expressed cells were found primarily in the absorptive cells and the lamina propria. The
number of PAR-2 expressed cells was higher in the CMS group than in control group
(9.07±3.37/mm2 vs 1.53±0.69/mm2, P<0.01). PAR-2 expressed cells significantly increased
in the proximal and distal colon of the CMS group as apposed to the control group (P<0.05),
but there was no statistical difference within CMS group according to area. Conclusion:
Chronic mild stress enhances abdominal muscle response to colorectal distension in rat and
an increased number of mast cells with up-regulation of PAR-2 in the colon may contribute
to visceral hypersensitivity.
S1770
The Role of TRPV1 in the Etiopathogenesis of Visceral Hypersensitivity in a
Rat Model of Irritable Bowel Syndrome
John Winston, Mohan Shenoy, Swaroop Pendyala, Pankaj Pasricha
Background: Visceral hypersensitivity is a hall mark of many functional bowel disorders
but the molecular mechanisms involved in its initiation remain unknown. The transient
receptor potential vanilloid 1 channel (TRPV1), expressed on the majority of colonic extrinsic
afferent neurons, is a key molecule in the activation and sensitization of these neurons.
Although up-regulation of TRPV1 expression has been noted in patients with IBS, little is
known about its ability to initiate long-lasting visceral hypersensitivity in functional bowel
disorders. We addressed this question in a rat model of IBS based upon neonatal exposure
of the colon to a non-injurious solution of acetic acid. As adults (8-12 weeks), these rats
display hypersensitivity to graded colorectal distention (CRD) in the absence of structural
or histological abnormalities. Aims: Our aim was to determine whether pre-treatment with
TRPV1 inhibitors prior to neonatal acetic acid treatment prevented development of persistent
sensitization to CRD. Methods: Ten days old rat pups received TRPV1 antagonists, SB-
366791 or iodo-resiniferatoxin (I-RTX) or vehicle subcutaneously 30 minutes prior to colon
acetic acid infusion, and were tested for sensitivity to CRD at 8 weeks of age. Responses to
CRD were measured by observation of the abdominal withdrawal reflex (AWR) and by
electromyographic (EMG) measurements of visceromotor responses obtained from electrodes
implanted in the external oblique muscle. Results: Pretreatment with 1.3 mg/kg SB-366791
prior to acetic acid infusion in 10 days old pups significantly reduced hypersensitivity of
eight weeks old rats to graded CRD as assessed by EMG (F=7.3, p=0.014) and by AWR
(F=11.0, p<0.001. In a second independent experiment, 2.6 mg/kg SB-366791 significantly
decreased sensitivity to CRD by AWR grade (F=35.0, p<0.001) and by EMG (F=5.4, p=0.042).
A similar pretreatment with 2 μmol/kg I-RTX also significantly reduced hypersensitivity to
graded CRD by AWR grade (F=11.1, p=0.004) and by EMG (F=7.18, p=0.044). SB-366791
was not a general blocker of neuronal activity as shown by a lack of effect on primary
colonic afferent recordings in response to CRD in normal rats. Conclusion: Pretreatment
with two TRPV1 antagonists, SB-366791 and I-RTX prior to acetic acid infusion in 10 days
old pups significantly attenuated the development of colonic hypersensitivity in adult rats.
These data suggest a critical role of TRPV1 activation in the development of persistent
visceral hypersensitivity in our model. We speculate that changes in colonic pH in the
neonatal period could activate TRPV1 and result in IBS in susceptible individuals.
S1771
Expression and Action of Corticotropin Releasing Factor (CRF) Receptor 2
and Its Ligands On the Vagal Afferents
Lixin Wang, Vincent S. Wu, Yuhua Wang, Yvette Tache
Background: CRF and urocortins (Ucn) administrated peripherally inhibit gastric emptying
and food intake mainly through CRF receptor 2 (CRF2) (AJP 1999;276:G867 and AJP
2001;281:R1401). Ucn 1 binds to both CRF1 and CRF2, while Ucn 2 and Ucn 3 bind
selectively to CRF2. A CRF2 selective antagonist has recently been reported to bind to the
rat nodose ganglia, suggesting the presence of CRF2 in vagal afferents (BJP 2002;136:896).

















Methods: The nodose ganglia from adult male SD rats were processed to detect expression
of CRF, urocortins and CRF receptors by reverse transcription and polymerase chain reaction
(RT-PCR). The peptide locations in the nodose ganglia and the vagal nerves were determined
by fluorescent immunohistochemistry using CRF2 antibody (Santa Cruz Biotechnologies),
CRF and urocortin antibodies (CURE). In an isolated gastric-vagus nerve preparation in vitro
(AJP 2000;279:E695) from fasted rats, the gastric vagal afferent responses to intra-arterial
injection of vehicle (saline, 0.1 ml), human Ucn 2 (hUcn 2; 0.025 ~ 1.2 μg) or CRF2
antagonist, astressin2-B (1.5 or 6 μg), were recorded from the ventral gastric vagal nerve
filaments. Results: CRF2α, CRF2β, Ucn 1 and Ucn 2 mRNAs were detected by RT-PCR in
the nodose ganglia, while CRF or CRF1 mRNAs were not expressed and the Ucn 3 band
was weak. CRF2-immunoreactivity (IR) was observed in neurons and fibers of the nodose
ganglia and vagal nerves, while no CRF- or Ucn 1-IR was detected in non-colchicine treated
rats. 35 out of 45 units with initial basal activity had an average of 0.90 ± 0.15 spikes/s,
27 out of 35 (~77%) units responded to hUcn 2 intra-arterial injection, and astressin2-B
pretreatment blocked the effect. Conclusions: Vagal afferents express CRF2 and urocortins,
and Ucn 2 induces a CRF2-mediated increase in vagal afferent activity. These data reveal a
possible site of action for CRF-related peptides involved in regulating food intake and gastric
motility. Supported by VA Merit Award (YT) and NIH R01 DK 33061 (YT).
S1772
Fatty Acids and Latex Microspheres Activate Discrete Cellular Sensing
Mechanisms
Anthony D. Jackson, Andrew J. Higgins, Maynard Case, John McLaughlin
Background: The enteroendocrine cell line STC-1 responds to fatty acids (FA) by secreting
biologically active CCK, via an elevation of intracellular calcium, [Ca2+]i. This therefore
represents an appropriate model of FA sensing. Previous work has suggested that the
formation of aggregates by FA in physiological media is an important factor in lipid sensing
by STC-1 cells. Synthetic latex microspheres (LM) of similar size to FA aggregates also
stimulate STC-1 cells causing CCK secretion, raising the possibility that these are sensed
by the same mechanism as FA. The cellular mechanism(s) underlying FA sensing remain
largely uncharacterized although one candidate is the newly assigned FA receptor, GPR40,
first described in pancreatic beta cells, but which is also expressed by STC-1 cells. Aims:
To evaluate (1) if LM activate GPR40, and (2) if other epithelial cell models sensitive to LM
are also FA sensitive. Methods: RT-PCR was undertaken for GPR40 in STC-1 and the
neuroendocrine cell line, PC12. Wild type (WT) PC12 cells, PC12 cells stably transfected
with mGPR40, CaCo-2 cells (intestinal epithelial model) and MDCK cells (renal tubule
epithelial model) were challenged with FA (linoleic acid, C18:2) and LM. Real-time changes
in [Ca2+]i were measured using fura-2 loaded cells and fluorescence microscopy. Results:
RT-PCR confirmed expression of GPR40 in STC-1 but not PC12 cells. PC12 FA sensitivity
was increased by GPR40 overexpression: linoleic acid stimulated PC12-WT and PC12
mGPR40+ cells, with the magnitude of [Ca2+]i response being increased 2.5-fold in mGPR40+
cells (P=0.005). PC12-WT cells responded to LM, but LM sensitivity was not increased in
mGPR40+ cells. Furthermore, the [Ca2+]i response to LM was entirely abolished in the
absence of extracellular calcium, whilst the FA-induced [Ca2+]i response was preserved.
Finally, a [Ca2+]i response was induced by LM in MDCK and CaCo-2 cell lines, but not
induced by FA. Conclusions: Cell stimulation by LM is not via GPR40, nor is it a property
restricted to FA-sensitive epithelial cells. This indicates that LM are not mimicking FA
aggregates by activating specific FA sensing mechanism(s). The mechanisms by which LM
gate intracellular calcium entry remain to be elucidated. Nonetheless, LM induce CCK
secretion in enteroendocrine cells so may provide a novel method by which to modify upper
gastrointestinal function or satiety, employing a non-nutrient signal that is retained within
the lumen of the GI tract. Supported by BBSRC
S1773
Gonadal Hormones Modulate Stress-Induced Visceral Hypersensitivity in Rats
J.N. Wang, Kirsten Garner, Elie D. Al-Chaer
Experimental and clinical studies underline the existence of sex-related differences in visceral
sensitivity. In previous studies, we showed that estrogen has a significant role in modulating
viscerosensitivity both in female and male rats. In this study, we examined the effects of
gonadal hormones on stress-induced visceral hypersensitivity in intact and gonadectomized
rats. Ovariectomy (OVX), orchiectomy (OCX) or sham operations were done at 3 months,
and rats were given 20 days to recover. Visceral hypersensitivity was assessed by recording
the electromyographic (EMG) responses to graded colorectal distension (CRD) in rats mildly
sedated with isoflurane (1%). CRD was induced by rapidly inflating a latex balloon to 20,
40, 60 or 80 mmHg for 10s, with a 5 min interval between distentions. Water avoidance
stress (WAS) was carried out in a plexiglass box [46 cm (h) x 25 cm (l) x 25 cm (w)]. The
rat was placed on an 8 cm x 8 cm square island located in the middle of the box and
surrounded by water for 45 m. OVX and OCX rats were injected with estrogen (20μg; SC),
and 48h after the injection the rats were subjected to WAS. EMG responses were obtained
immediately after WAS. Our results showed: 1) In intact males subjected to WAS, EMG
responses to CRD were significantly increased to 98.18% (20mmHg); 99.82% (40mmHg);
68.75% (60mmHg); 63.77% (80mmHg) (n=6, p<0.05) of the responses of control rats
(without WAS). In OCX rats subjected to WAS, EMG responses were increased only in
response to 80mmHg CRD to 53.19% (n=8, p<0.05) as compared with the responses of
non-WAS OCX rats. 2) In cycling female rats subjected to WAS, EMG responses to graded
CRD increased during diestrus and metestrus to 68.15% (40mmHg) and 59.7% (60mmHg)
(n=10, p<0.05) of the responses of controls (without WAS); but WAS had no significant
effect during proestrus and estrus. OVX rats did not exhibit EMG hyper-responsiveness to
CRD after WAS. 3) Estrogen injection increased EMG responses to 20 and 40 mmHg CRD
in intact male rats subjected to WAS [99.9% (20mmHg); 77.11% (40mmHg); n=6, p<0.05].
4) When coupled with estrogen injection, WAS in OVX or OCX rats had no significant
effect on EMG responses compared to OVX or OCX rats treated with estrogen but not
subjected to stress. Our data suggest that gonadal hormones, particularly estrogen, are
involved in stress-induced visceral hypersensitivity. Studies are under way to determine
T : 89386$$CH2
05-04-06 23:18:27 Page 254Layout: 89386B : e
A-254AGA Abstracts
the mechanisms and the role of testosterone and other hormones, if any. (Supported by
NIH / NS40434).
S1774
Estrogen Modulates 5-Hydroxytryptophan Induced Visceral Hypersensitivity in
Awake Female Rats
Ching-Liang Lu, Full-Young Chang, Pei-Yi Liu, Shou-Dong Lee
Background: 1) Irritable bowel syndrome (IBS) is more prevalent in women, suggesting a
sex hormone influence. 2) We have demonstrated that estrogen modulates mustard oil
induced visceral hypersensitivity. (Gastroenterology 2005; S1472). However, marked
mucosal inflammation developed in this model, a feature not seen in IBS. 3) Serotonin is
important in visceral pain regulation. 5-hydroxytrptophan (5-HTP, the precursor to 5-HT)
can cause colorectal hypersensitivity in rats. (Br J Pharmacol 1995; 114:558) 4) We hypothes-
ize that sex hormone can regulate the 5-HTP-induced visceral hypersensitivity. Method:Fe-
male rats were prepared for abdominal muscle electromyography, which was recorded in
response to phasic colorectal balloon distension at 20, 40 and 60 mmHg. The visceromotor
reflex was measured after subcutaneous injection of 5-HTP (10mg/kg). A hypersensitivity
index (HI), the ratio of the EMG intensity between 5-HTP injection and vehicle, was used
to represent the magnitude of visceral hypersensitivity. The effect of sex hormone on 5-
HTP-induced visceral hypersensitivity was evaluated by comparing the HI value between
ovariectomized (OVX) or shame-OVX rats. The roles of sex hormones in 5-HTP-related
visceral hypersensitivity were evaluated by treating OVX rats with 17-β-estradiol (E, 10 μg/
cc/kg), progesterone (P, 20mg/cc/kg), E+P, or vehicle (sesame oil). The distal colorectum
was excised for grading inflammation. Results: 1) In intact rats, 5-HTP treated rats had
higher HI than controls (enhanced visceral hypersensitivity) (HI value: 20 mm Hg: 8.61±1.04
vs. 0.88±0.05; 40mmHg: 2.80±0.36 vs. 0.99±0.3; 60 mmHg: 2.23±0.21 vs. 0.90±0.10,
p<0.05); 2) The 5-HTP-induced hypersensitivity was abolished by ovariectomy. (HI value,
shame-OVX vs. OVX; 20 mmHg: 9.41±1.31 vs. 0.87±0.09; 40mmHg: 3.88±1.04 vs.
1.10±0.14; 60 mmHg: 2.62±0.47 vs. 1.04±0.13, p<0.05). 3) OVX rats pre-treated with E
or E+P, but not P alone, exhibited significantly higher HI levels after 5-HTP injection (HI
value: vehicle vs. E vs. P vs. E+P: 20mmHg, 0.78±1.80 vs. 9.05±1.84 vs. 0.69±0.17 vs.
10.25±3.07; 40 mmHg: 0.99±0.11 vs. 3.10±0.60 vs. 0.70±0.08 vs. 2.82±0.36; 60 mmHg:
0.85±0.05 vs. 1.92±0.30 vs. 0.79±0.05 vs. 2.00±0.18, p<0.05). 4) No or very mild inflamma-
tion was noted in the colonic mucosa after 5-HTP injection. Conclusion: 1) In the absence
of mucosal inflammation, systemic injection of 5-HTP can induce visceral hypersensitivity
in awake female rats. 2) Estrogen, but not progesterone, is important in mediating the 5-
HTP-induced visceral hypersensitivity. 3) Our results may partly explain the higher female
IBS prevalence and the relatively good response of 5HT drugs in treating IBS.
S1775
The Role of NGF in Sensitization of the Nociceptive Response to Acute
Pancreatitis
Liansheng Liu, John Winston, Huaizhi Yin, Bryan Kosler, Shelley Allen, Dave Dawbarn,
Pankaj Pasricha
Background: The transient receptor potential vanilloid 1 channel (TRPV1), expressed on
the majority of pancreatic afferent neurons, is a molecular integrator of nociception and
inflammatory pain. We have previously shown that pancreas-specific DRG neurons exhibit
increased TRPV1 currents in a model of acute painful pancreatitis induced by L-arginine,
and that nerve growth factor (NGF) appears to recruit silent nociceptors, increasing the
number of capsaicin responsive pancreas-specific DRG neurons. The aim of this study was
to further assess the effect of NGF antagonism on TRPV1 activity in pancreatic primary
sensory afferents as measured directly in an in vivo model. Methods: Pancreatitis was
induced with two i.p injections of L-arginine, one hour apart. Control animals received the
same volume of saline. Three days after the injection, rats were treated with either vehicle
or the NGF sequestering peptide segment of the trkA receptor (trkA-Ig2; REN 1820) once
a day for 5 days (100 mg/0.5 ml/rat, i.p), respectively. After the last treatment, primary
sensory afferent activity was measured directly from the left pre-ganglionic great splanchnic
nerve (GSN). GSN afferent activity was recorded continuously before and after infusion of
0.05mg/0.3ml/50sec capsaicin or saline into the pancreatic duct. Five groups of rats were
tested: Controls + saline infusion; Controls + CAP infusion; Acute Pancreatitis + CAP infusion;
Acute Pancreatitis w/ vehicle + CAP infuse; and Acute pancreatitis w/REN 1820 treatment
+ CAP infusion. Results: CAP infusion significantly increased GSN activity in control animals
compared to saline infusion (152 ± 9.6 vs 102 ± 4.9, p<0.01). GSN activity in response to
CAP infusion was significantly increased in acute pancreatitis (199 ± 14, p<0.05). In rats
with pancreatitis, REN 1820 treatment significantly attenuated GSN response to CAP infusion
compared to vehicle treated rats (174 ± 10.8 vs 215 ± 8.9, p<0.01). Conclusions: These
studies demonstrate that pancreatitis enhanced TRPV1 activity on splanchnic nerve endings
in the pancreas suggesting that TRPV1 sensitization may play a role in the pain associated
with acute pancreatitis. This enhanced activity is mediated in part by NGF, providing another
potential therapeutic analgesic target.
S1776
Correlation of Anterior Insula Activity with Sensations of Satiation in Humans
Using Continuous FMRI
Mihaela Podovei, Wei Qiu, Annabel N. Yuen, Itzhak Aharon, Mark Vangel, Braden Kuo
Background: The Insula is critical to visceral sensory functions, involved in fundamental GI
functions such as feeding. Continuous fMRI imaging of the brain can demonstrate the
dynamic changes in regions within the brain in response to a constantly evolving stimulus
such as feeding. Aim: To evaluate the correlation of changes in Anterior Insular (AI) activity
in response to the changes in gastric sensation from feeding in comparison to changes in
brain activity in the motor cortex (MC) which serves as a control because it is less involved
in visceral sensation. Methods: 10 healthy subjects (2F/9M, mean age 28 yrs) had a 14F
NG tube placed and, after a 5 min baseline period, Ensure (1Kcal/cc) was instilled at 60cc/
min till subjects reached maximal satiation. Continuous fMRI activity over the whole brain
was recorded using a 3T Siemens scanner (TR/TE/q=2.5ms/39ms/90°, slice thickness=5mm,
inter-slice interval=1mm, FOV= 200mm, 64*64 matrix, whole brain coverage). Multi-echo
PACE sequences were used to compensate for scanner drift. The data was preprocessed for
motion correction, Gaussian blur with FWHM = 5mm by AFNI. EROICA was used to
identify clusters of AI and MC activity. In each subject, the average CNS activity time course
for the Right AI and Left MC was smoothed using a cubic spline algorithm with df =6 and
the curve was compared to the satiation symptom curve. Activation of the left MC was
expected due to periodic right hand movement occurring to document symptom ratings.
For each subject, the time courses of AI and MC were correlated with the satiation curve
and the correlation coefficients (CC) were calculated. A mean CC was generated for each
AI and MC. Student T-test was used to compare the 2 correlation groups: right AI and the
satiation curve, left MC and the satiation curve. Results: The mean time to maximal satiation
was 30 min (range 12-58 min). The mean correlation between right AI and the satiation
curve was 0.70 (95 % CI 0.54 to 0.86) and these correlations were significant p<0.01. The
mean correlation between the left MC and the satiation curve was-0.13 (95% CI -0.65 to
0.38) and these correlations were not significant, p=0.58. The correlations of AI activity to
satiation were different from the correlations of MC activity to satiation, p<0.003. Conclusion:
Brain activity within the Anterior Insula is strongly correlated with the satiation symptom
curve, while there is no correlation between the left motor cortex and the satiation curve,
which was used as control. Continuous fMRI imaging can demonstrate dynamic but disparate
CNS activity in different regions of the brain during a visceral stimulus such as feeding.
S1777
Distribution and Immunohistochemistry of the Mouse Spinal and Vagal
Pancreatic Afferents
Kenneth Fasanella, Julie A. Christianson, Ratsamy S. Chanthaphavong, David C.
Whitcomb, Brian M. Davis
Background: Dysfunction of primary afferents plays a central role in pain suffered by patients
with chronic pancreatitis. To begin developing a mouse model we defined the normal
innervation of the mouse pancreas for both spinal and vagal afferents. These afferents are
heterogeneous and can be grouped based on the presence or absence of neuropeptides (e.g.
CGRP, SP). Peptidergic afferents (CGRP+) typically bind nerve growth factor (NGF), a trophic
factor that has been linked to inflammatory hyperalgesia. Non-peptidergic afferents bind
the isolectin B4 (IB4). A third population expresses the GFRα3 receptor and binds the
growth factor artemin that has recently been implicated in inflammatory pain. Methods: 8-
week-old male C57Bl/6 mice were anesthetized and the pancreatic head was injected with
CTB-555. In some mice the pancreatic tail was also injected with CTB-488. After sacrifice
and perfusion with 4% paraformaldehyde, dorsal-root ganglia (DRG) and nodose ganglia
(NG) were dissected and processed for stereological cell counts. Tissue was also labeled
with antisera detecting CGRP, TRPV1, and GFRα3 and stained with IB4. Results: Spinal
pancreatic afferents were distributed between T5 and T13, with the greatest concentration
in T10-T12. The DRG projections were symmetric with equal numbers coming from right
and left ganglia. In contrast, the innervation from the left NG was significantly greater than
the right (p<.05). For both spinal and vagal afferents there was significantly greater innervation
of the pancreatic head relative to the tail (p<.05). The total number of retrogradely-labeled
afferents in the nodose was very similar to total number of DRG afferents. The neurochemical
phenotype of spinal afferents was dominated by CGRP- and TRPV1-positive neurons. In
the DRG, 79% of TRPV1-positive and 49% of CGRP-positive neurons were GFRα3-positive.
In the NG, only 2% of labeled afferents were positive for GFRα3. Conclusions: These studies
show that equal number of vagal and spinal afferents innervate mouse pancreas and that
the innervation is concentrated at the head. As seen in previous rat studies, the vagal
innervation is asymmetric. The majority of pancreatic afferents were peptidergic, and likely
respond to changes in the level of NGF. The identification of GFRα3-positive spinal pancreatic
afferents indicates that many of these cells respond to artemin. Artemin is a relatively new
member of the GDNF family and recent data from our labs show that it can potentiate the
TRPV1 responses in cultured sensory neurons and that it increases following inflammation.
Thus, both NGF and artemin may play important roles in chronic pancreatitis pain.
S1778
Target-Derived Nerve Growth Factor (NGF) Regulating Spinal Sensory Axon
Outgrowth to the Embryonic Mouse Gut
Wen Jiang, Andrew J. Furley, Karna Bardhan, David Grundy
Introduction: The factors that determine how extrinsic sensory nerves find their targets
within the gut wall during development are poorly understood. We aimed to examine how
target-derived factors influence sensory innervation to the embryonic gut. Methods: Dorsal
root ganglia (DRG) from both thoracic (T8-13) and lumbar (L) regions were co-cultured
with gut in collagen gel culture (Tessier-Lavigne et al., Nature 366, 1988). In experiment
set 1, individual T- or L-DRG were cultured in medium containing NGF (20ng/ml) either
alone, or with a segment of fresh or fixed (and washed) esophagus or colon from mice at
embryonic (E) days 13, 14 and 16. In experiment set 2, T-DRG and esophagus were co-
cultured in the absence of NGF or with anti-NGF antibodies (400ng/ml). After 2 days in
culture, DRGs were stained for neurofilament and assessed blind for directed axon outgrowth,
comparing length, angle and density of neurites outgrowth in the quadrant nearest the gut
with that in the distal quadrant. Data are expressed as the number of DRG showing directed
growth (attractive, repulsive and non-response). Results: Axon outgrowth was symmetrical
when DRG was cultured either alone or with fixed gut. However, directed outgrowth was
detected when co-cultured with unfixed gut (Table). In the absence of NGF, axon outgrowth
was not detected at E13 (n=3), but was apparent at E14 (n=17) and E16 (n=9). Axon
outgrowth was absent from either E14 (n=7) or 16-DRG (n=3) when the medium contained
anti-NGF antibody. Conclusion: The embryonic gut secretes NGF in a temporally regulated
fashion which may guide sensory innervation. Supported by the Bardhan Research and
Educational Trust
The number (%) of DRG showing directed axon outgrowth when co-cultured with gut
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*: Different region of gut had significant effect on directed axon growth from either T- or
L-DRG at E14 and 16 (P< 0.005, Chi-square Test). ψ: At E16 when co-cultured with colon,
the directed neurite response from T- and L-DRG is significant difference (P< 0.005, Fisher
Exact Test)
S1779
Effect of a 1 Week Trial of Capsaicin P.O. On Intestinal Mechano- and
Chemonociception
Johann Hammer
INTRODUCTION: Perception evoked by jejunal application of capsaicin is similar to
distension induced perception but does not involve mechanoreceptors. Oral ingestion of
capsules containing red pepper powder induced painful sensations during the first week in
patients with functional dyspepsia; patients who did not discontinue capsule ingestion
experienced improvement of their symptoms after a 5 week trial. AIM: To evaluate the
effect of one week p.o. application of capsaicin on jejunal mechano- and chemonociception
in healthy subjects. METHODS: 13 healthy subjects (age: 24±2yrs., 5 M, 8 F) ingested
capsules containing 0.5mg capsaicin tid (n=8) or placebo (n=5) for 7 days. To test jejunal
mechano- and chemonociception before (day 1) and after (day 8) capsule ingestion, subjects
swallowed a tube with an infusion site at the ligament of Treitz and a latex balloon 7 cm
distally to the infusion site. Balloon distensions with preset volumes of air (24ml and 40ml)
were performed, followed by infusion of a capsaicin solution (40 μg/ml) at a rate of 25 ml/
min for 60 minutes or until severe sensations arose. A graded questionnaire evaluated quality
and severity of 6 different sensations and was filled out during distensions and every 10
min during capsaicin infusion and when capsaicin infusion was stopped. Infusion was
stopped when a score of 9 (out of 13) was reached at either one of the sensations. Aggregate
perception scores were calculated by summing the scores for each type of sensation.
RESULTS: Infusion of capsaicin induced feeling of pressure, cramps or pain; the descriptive
quality of sensations and the location on the abdomen were similar to sensations induced
by distension. In subjects receiving capsaicin capsules, aggregate perception scores at 24ml
distension volumes were 4.2 (day 1, before capsaicin ingestion) and 3.2 (day 8, after capsaicin
ingestion), respectively (NS). At 40ml distension volume, aggregate perception scores were
10.7 (day 1) vs. 8.4 (day 8) (p<0.05). The duration of capsaicin infusion until first sensation
was reported was 12.0 min (day 1) and 8.4 min (day 8) (NS), discomfort thresholds occurred
after 41.5 min (day 1) and 33.0 min (day 8) (p<0.05). In the control group, mechano- and
chemonociception was not significantly different on study days 1 and 8. SUMMARY: 1
week ingestion of capsaicin sensitized chemonoceceptors while sensitivity of mechanonoc-
iceptors for distension decreased. CONCLUSION: Painful sensations during the first week
of treatment with capsaicin can be attributed to a sensitising effect of capsaicin on vanilloid
receptors. Repeated application of capsaicin over a one week period desensitizes mechanore-
ceptors.
S1780
NMDA Receptors Differentially Regulate the Excitability of Distinct Classes of
Splanchnic Afferent Neurons Innervating Rat Distal Colon
David Adelson, James A. McRoberts, Yuhua Wang, Emeran A. Mayer
BACKGROUND: NMDA receptors (NMDARs) are expressed on the peripheral processes of
spinal afferent neurons innervating visceral organs. We hypothesized that peripheral NMDAR
activation may play a role in normal pain transmission and/or in the development of peripheral
sensitization by altering afferent terminal sensitivity to mechanical stimuli. AIMS: To deter-
mine if a) NMDAR activation directly excites inferior splanchnic nerve afferent (ISA) fibers,
and b) if such activation alters ISA responses to subsequent colorectal distention (CRD).
METHODS: ISA activity was recorded from the distal cut end of inferior splanchnic nerve
strands innervating a 5 cm segment of SD rat distal colon maintained in an in vitro organ
bath as previously described (Gut 2005; PMID: 15985561). Basal CRD responsiveness was
determined using consecutive graded CRD (0.1-0.5 ml, 20 sec duration, 10 min interval
between CRD) via inflation of an intraluminal balloon. Next, graded doses of the potent,
selective NMDAR agonist, trans-ACBD (tACBD, 0-32 µg) were given inter-arterially (i.a.),
followed 2 min later by a single CRD (0.4 ml). Lastly, NMDA (40 µg) was given i.a., after
which the receptive field was located precisely. Single unit activity was obtained by sorting
waveforms present in multi-unit recordings using Spike 2 software. RESULTS: 43 single
units from 10 preparations were recorded. Of 25 units whose activity was influenced by
NMDAR agonists, 5 response patterns were identified: 1) 10/25 units were chemoreceptive,
responding only to trans-ACBD or NMDA, but not to CRD. 2) 7/25 units gave slowly-
adapting mechanoreceptive responses to graded CRD. 5/7 of these did not respond to tACBD
ia, but increasing doses of the agonist caused a dose-related decrease in responses to
subsequent CRD. 3) 3/25 units initially unresponsive to CRD became responsive to CRD
after i.a. tACBD. In 2/3 of these, low doses of tACBD increased CRD responsiveness, but
higher doses progressively inhibited responses to CRD. The 3rd unit gave increasing responses
to CRD with increasing doses of tACBD. 4) 2/25 units had spontaneous oscillatory bursting
behavior where increasing doses of tACBD altered the pattern of ongoing activity. 5) 3/25
units were chemo- and mechano-responsive, responding to tACBD and/or NMDA directly,
and to CRD with increased activity during and after CRD. CONCLUSIONS: NMDAR activa-

















role in shaping the pattern of sensory input from the viscera to the CNS under a variety of
normal and pathological conditions. Supported by NIH grants DK 58173 and 1 P50 DK64539
S1781
Genetic Differences Determine Inflammatory Response and Development of
Visceral Hyperalgesia in a Rat Model
Birgit Adam, Chris Tsopelas, Tobias Liebregts, F Dylan Bartholomeusz, Andrew
Ruszkiewicz, Gerald Holtmann
Background: Transient inflammation is a risk factor for the manifestation of Irritable Bowel
Syndrome (IBS) and causes long- lasting changes of visceral sensitivity. Although gastrointesti-
nal infections are common, only a proportion of patients develop post-infectious IBS. We
therefore hypothesized that genetically determined differences influence inflammatory
response and visceral sensory function. Aim: To characterize the inflammatory response and
acute and long-term effects of a transient colitis on visceral sensory function in two different
rat strains. Methods: Colitis was induced by single colorectal instillation of Trinitrobenzenes-
ulfonic acid (TNBS; 5 mg/kg) plus ethanol (70%) or saline (control) in male Fisher 344 (F)
and Lewis (L) rats. At 2 hr and 5, 14 and 28 days after induction of colitis colonic tissue
samples were analyzed by a blinded pathologist and blood samples assayed for IL-2 plasma
levels via ELISA. A subset of rats was injected intravenously with 99mTc-labelled leukocytes
(LWC) for qualitative (images) and quantitative (bio-distribution) scintigraphic assessment
of colitis at the various study days. To assess visceral sensitivity colorectal distensions (CRD)
were performed before and 5, 14 and 28 days after induction of colitis and the visceromotor
response (VMR) to CRD quantified by electromyographic recordings. Results: TNBS caused
an acute transient inflammation in both strains with a peak at day 5 and histological healing
at day 14. Compared to L rats this inflammatory response was significantly (p<0.05) lower
in F rats based on histological data and LWC assay. IL-2 was increased in both strains prior
to occurrence of mucosal lesions and remained elevated at day 14 in L but not in F rats.
VMR to CRD was significantly enhanced (p<0.01) on day 5 in TNBS treated rats (L+F)
compared to saline controls and returned to baseline level at day 14. At day 28 VMR was
significantly increased in L rats but not in F rats compared to controls. Summary: TNBS
caused a transient inflammation with mucosal lesions, leukocyte infiltration and increased
IL-2 secretion, which was significantly less severe in F rats compared to L rats. The VMR
to CRD was enhanced during acute inflammation but only in L rats developed a post-
inflammatory visceral hyperalgesia. Conclusion: Compared to F rats, L rats develop a long
lasting visceral hyperalgesia and more severe inflammation following topical administration
of TNBS. Thus the presumably genetically determined difference in the susceptibility for a
post-inflammatory visceral hyperalgesia appears to be associated with the intensity of the
mucosal inflammation and the systemic immune response.
S1782
Developing a High Through-Put, Minimally Invasive Test of Gastrointestinal
Sensitivity
Sepeedeh Saleh, Barbara J. Unsworth, Qasim Aziz, Anthony Hobson
Background: Studies of gastrointestinal (GI) sensitivity in both health and functional gastroin-
testinal disorders (FGD) reveal a broad spectrum of sensory responsiveness suggesting the
presence of distinct GI pain phenotypes within the population. Conventional approaches
to GI sensory testing require invasive intubation techniques which increase anxiety and
reduce tolerability, often adversely affecting results. The aim of this research was to conduct
a feasibility study to develop a minimally-invasive, high through-put acute GI pain model
which would allow us to study the large numbers of subjects needed to adequately define
GI pain phenotypes. Methods: 3 different types of dried chilli flakes (Caribe, Arbol and
Habanero) were purchased from an internet site. These were rated by the source as 3, 8
and 10 out of 10 respectively on a rating scale for the strength of chilli based on the Scoville
unit scale for capsaicin. Gelatin capsules containing 250mg of chilli flakes or placebo capsules
were given orally in a double blind, randomized manner, to 20 subjects. The capsules
comprised: 1 x 3/10 capsule, 1 x 8/10 capsule, 2 x 8/10 capsules, 1 x 10/10 capsule and
placebo. Self-administered questionnaires were used to obtain a psychophysiological profile
over a two-hour period. Outcome measures included pain, anxiety, nausea and unpleas-
antness. Results: Compared to placebo, 2 x 8/10-strength capsules and 1 x 10/10-strength
capsule produced significant increases in levels of pain (VAS AUC = 301±325 and 985±777
versus 29±55, p=0.001 and 0.0005 respectively) and unpleasantness (VAS AUC = 223±872
and 871±207 versus 14±39, p=0.003 and 0.002 respectively), as measured using area under
the curve (AUC) of visual analogue scores. In addition, one 10/10-strength capsule produced
a significant increase in nausea levels (370±802 versus 5±13, p=0.03) when compared to
placebo. There were no significant changes in anxiety levels throughout the experiments.
Conclusions: This is an effective, simple and minimally-invasive technique for human GI
sensory testing which was well tolerated by all subjects. 100 studies were performed over
a 6-week period proving that this approach can be used as a high through-put screening
technique. The methodology of the study can now be refined so that future studies could
target the release of specific doses of capsaicin to any region of the GI tract using specialized
drug delivery systems.
S1783
Real-Time Release of Serotonin from Mouse Ileum
Paul P. Bertrand
Introduction: Serotonin (5-HT) containing enterochromaffin (EC) cells detect chemical and
mechanical stimuli in the intestinal lumen and respond with release of 5-HT. Recent electro-
chemical studies have shown that the real-time release of 5-HT from the mucosa is a dynamic
process linked with other enteric reflexes 1,2. The aim of this study was to characterize 5-
HT release from mouse ileum and determine whether electrochemical techniques can be
applied to tissues other than guinea pig (GP) ileum. Methods: Mice (C57BL/6; n=7) or
guinea pigs (Hartley; n=9) were anesthetized with isoflurane, then killed by severing the
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carotid arteries and spinal cord. Full thickness ileum was loosely pinned, mucosa up, in a
bath of warmed physiological saline. Electrochemical recordings were made using 7 μm
carbon fiber electrodes. Data are presented as concentration of 5-HT (calculated from the
current at +350 mV and the current produced by 5 μM 5-HT); time to peak (seconds); the
potential (mV) of oxidation maxima during voltage ramps (~0.47 mV/s; from -0.5 to +1V);
all data are mean ± SEM. Results: In mouse ileum, basal release of 5-HT was 5.5 ± 2.5 μM
(n=6). Compression of the mucosa (0.8 ± 0.3 g; n=7) with the electrode stimulated further
5-HT release for a total of 9.8 ± 3.8 μM (peak: 3.8 ± 1.1 s; n=6) as compared to GP ileum
(basal: 3.7 ± 1.4 μM; compression: 9.1 ± 3.1 μM; n=9). Similar release was also observed
in GP distal colon (n=2) though these data were not quantified. In mouse ileum, with the
electrode in the mucosa, oxidation maxima occurred at +335 ± 10 mV as compared to
exogenous 5-HT (+330 ± 10 mV; n=6) and GP ileum (+360 ± 40 mV; n=7). A second,
unidentified peak occurred at 739 ± 21 mV in 5 of 7 preparations (versus GP ileum: 720
± 20 mV; n=7). Brief application of acetylcholine (0.1 to 1 mM) elicited robust release of
5-HT (4.4 ± 1.8 μM, peak: 2.0 ± 1.6 s; n=4) that was concurrent with contraction of the
circular muscle as has been reported for GP ileum. Conclusion: The release of 5-HT from EC
cells of the mouse ileum is similar to that of the GP ileum. This suggests that electrochemical
techniques can extract out data about basic release mechanisms that are applicable across
tissues. This is the first step in the process of readying these techniques for use on human
tissue. Supported by NH&MRC (Australia) and Dept of Physiology & Cell Biology, University
of Nevada. 1. Bertrand, P. P., 2004. Real-time detection of serotonin release from enterochro-
maffin cells of the guinea pig ileum. Neurogastro Mot. 16, 511-514. 2. Bertrand, P. P., 2004.
Coordination between motility and serotonin release in guinea pig ileum. Gastro. 126(4):
A32 Suppl. 2.
S1784
Effect of Pathogenic Lipopolysaccharide Translocation On Human Colonic
Smooth Muscle Cell Contraction and Toll-Like 4 Receptor Expression
Michele Pier Luca Guarino, Carola Severi, Simone Carotti, Gianpiero Ferraguti, Webiao
Cao, Alessia Cicenia, Anna Maria Altomare, Rossana Alloni, Sara Emerenziani, Renato
Caviglia, Michele Cicala
Gastrointestinal stasis induced by lipopolysaccharide (LPS) may be associated with muscle
dysfunction. In animal models, LPS suppresses contractility by production of inflammatory
mediators by macrophages, but a direct effect of LPS on muscularis cannot be excluded. A
recent study demonstrated that LPS translocates across colonic epithelial cells in normal
and LPS-infected rats. LPS is recognized by Toll-like 4 receptors (TLR4) that have been
shown to be expressed by intestinal myofibroblasts. AIM: To define if colonic mucosa
exposure to pathogenic LPS may affect muscle cell contractility and if this effect could be
related to LPS translocation and mediated by TLR4. METHODS: From fresh specimens of
human colon, the mucosa and submucosa were removed and sealed between two chambers,
with the luminal side of mucosa facing upward and covered with 5mL of Krebs solution,
and the submucosal side facing downward into 20mL of Krebs. Chambers were oxygenated
and kept at 37°C. LPS (Sigma) obtained from the pathogenic strain of Escherichia coli
0111:B4 or normal buffer were added to the luminal side of the mucosa and kept for 30
minutes. Enzymatically isolated smooth muscle cells (SMCs) were exposed for 30 minutes
to buffer from the submucosal chamber of mucosa either pre-exposed to normal buffer (n-
buffer) or to LPS (LPS-buffer). Acetylcholine (ACh) dose-response (10-12 to 10-5M) was
obtained for SMCs. To test whether LPS translocates across the mucosa, 3-deoxy-d-manno-
2-octulosonic acid (KDO), a constituent of bacterial LPS, was detected by means of spectro-
metry. TLR4 expression was tested by immunohistochemistry using a specific biotinated
TLR4 antibody (Mouse IgG HTA125, BD Biosciences). RESULTS: SMCs exposed to n-buffer
presented a dose-response to ACh (Maximal contraction: 32±8% with 1μM ACh; ED50 at
0.3nM) similar to untreated SMCs. Exposure to LPS-buffer inhibited ACh-induced contrac-
tion, with 62.9±12% inhibition of maximal contraction, and ED50 at 6 nM. Detection of
KDO in the LPS-buffer showed that, after 30 min of mucosa exposure to LPS, 30.1±6% of
KDO crosses the mucosa. When SMCs were directly exposed to LPS at a dose consistent
with the KDO concentration detected in the LPS-buffer, a significant impairment of contrac-
tion (72±4%) was also observed and this was associated with a progressive increase of cell
surface TLR4 expression whose presence was rather low on unstimulated SMCs. CONCLU-
SIONS: After acute exposure of colonic mucosa to pathogenic LPS, a relevant inhibition of
SMC contractile response is observed. It is conceivable that the translocated LPS could play
a role in the impaired muscle contractility of SMCs, mediated by TLR4 binding.
S1785
Chronic Intestinal Pseudo-Obstruction: Evidence for Autoimmune Activation
of Fas and Autophagy
Roberto De Giorgio, Rosanna Cogliandro, Giovanni Barbara, Vincenzo Stanghellini,
Umberto Volta, Chunfang Guo, Roberto Towns, John W. Wiley
Background: Chronic Intestinal Pseudo-obstruction (CIP) is a debilitating GI motility disorder
often of unknown etiology. We examined the hypothesis that sera from a well characterized
population of CIP patients contain autoantibodies that bind to neurons and activate the
death receptor complex Fas/FADD and the putative cytoprotective autophagy pathways.
Methods: Patients were screened based on their clinical presentation, serologic tests and
diagnostic studies including radiology and gastroduodenal manometry. Sera from 26 (20 F,
6 M; age range 22-62 yrs) CIP patients were screened for the presence of anti-neuronal
antibodies using immunofluorescence (intensity scored as: +, ++ and +++) and Western blot
analysis (which was negative for classic onco-neural proteins, including Hu and Yo proteins).
Seven out of 26 (27%) tested positive for anti-neuronal antibodies. Subsequently, cultured
human neuroblastoma (SH-SY5Y) cells were exposed to sera from patients without (-), n=
3 or with (+), n=2; (++), n=3; or (+++), n=2 anti-neuronal antibodies (1:10 dilution for 16-
20 h). Binding of autoantibodies to the surface of SY5Y cells was evaluated using anti-human
IgG and IgM antibodies linked to a fluorescence marker. Activation of Fas was examined
using anti-FADD (Fas-activated Death Domain) immunoreactivity (IR) and Western blot
analysis. Stimulation of autophagy was monitored using the specific marker for autophago-
somes, anti-LC3-II IR, colocalization with mitochondria using anti-mitochondrial antibody
(AMA) and Western blot analysis. Immunoglobulins (Ig) were removed by exposing sera
to protein L agarose beads. Results: The three patients that tested negative for anti-neuronal
antibodies demonstrated no evidence for binding of autoantibodies (either IgG or IgM) to
the surface of SY5Y neurons, activation of Fas/FADD or autophagy. The patients with +,
++, or +++ anti-neuronal antibodies demonstrated increased binding of both IgG and IgM
autoantibodies that correlated with the intensity of anti-neuronal IR. Activation of FADD
and autophagy also correlated with the intensity anti-neuronal IR. The increased levels of
anti-FADD and anti-LC3 IR diminished with serial dilution (1:10-1:250) of ++ and +++
sera. Exposure of sera to protein L beads markedly decreased binding of Ig, activation of
FADD and autophagy. Conclusion: Sera from a subpopulation of patients with CIP contain
autoantibodies that bind to neurons and activate Fas and the cytoprotective autophagy
pathways. These observations support the novel concept that humoral autoimmunity target-
ing neurons contributes to the pathophysiology of CIP.
S1786
Intracolonic Oil of Mustard Induces An Inflammatory Ileus with Concurrent
Alterations in Small Intestinal Secretomotor Function
Craig R. Schneider, Nathaniel H. Wallace, Jeffrey M. Palmer, Kristen M. Chevalier,
Beverley A. Moore, Paul R. Wade, Pamela J. Hornby, Edward S. Kimball
Background: Ileus is frequently associated with abdominal surgery and inflammatory situ-
ations which do not necessarily involve a direct assault to the small bowel. However, the
mechanisms and pathways leading to ileus have yet to be fully elucidated. We have developed
a model wherein intracolonic application of 0.5% oil of mustard (OM) in 30% ethanol
produces a severe, acute colitis in mice over a 3-day period. This colitis is associated with
hypersecretion of mucus and fluid accumulation in the proximal colon, and delayed transit
in the small intestine, both indicative of altered intestinal secretory and motor functions.
Purpose: To characterize the motor and secretory responses in the small intestine during
active OM-induced colitis. Methods and Results: At 48 hours post-OM administration, a
time when colon inflammation is maximal but small intestinal damage is absent, 30 minute
carmine dye transit was decreased in the small intestine (69.5 ± 5.5 % transit for OM vs
85.0 ± 4.4 % transit for untreated controls, p < 0.05). Measuring small bowel transit changes
with oral FITC-dextran demonstrated that the geometric center of distribution of the FITC-
dextran marker was shifted 22% (p < 0.0004) toward a more proximal location in OM-
treated mice. An irregular pattern of fluorescence distribution indicated dysregulated propuls-
ive motility in the small bowel. Altered neurosecretory function in the small intestine during
OM-induced colitis was evident at 24 and 48 hours. Full-thickness jejunal tissues mounted
in Ussing-type flux chambers showed significantly increased responses (4.8-fold and 3.5-
fold above age-matched controls for 24 and 48 hour samples; p < 0.0005) to electrical field
stimulation (EFS: 80 V, 0.5 ms, 10 Hz, 5 s). Conclusions: The evidence obtained is consistent
with the activation and recruitment of trans-enteric signaling pathways from the inflamed
colon to the small intestine resulting in significant functional alterations in both propulsive
motility and secretory activity. This model will be useful for understanding how inflammatory-
mediated changes in the colon can result in small intestinal dysfunction, and how this relates
to similar symptoms which appear in ileus.
S1787
Impact of Humoral Autoimmunity in Severe Gut Dysmotility: Actions of Anti-
Hu On Enteric and Visceral Sensory Neurons
Luigia Talamonti, Qin Li, Michael Beyak, Marcello Trevisani, Klaus Michel, Barbara
Campi, Giovanni Barbara, Pierangelo Geppetti, David Grundy, Michael Schemann,
Roberto De Giorgio
The role of autoimmunity in gut dysmotility is poorly understood. Our aim was to identify
mechanisms through which anti-Hu anti-neuronal antibody (A-Hu IgG) modulates gut
function. A-Hu IgG was isolated by affinity chromatography from sera of patients. Specificity
of A-Hu IgG was verified by selective staining of enteric neurons. A-Hu-free serum served
as control. Four groups of experiments were performed to examine effects on enteric and
visceral sensory neuronal function. First, calcium imaging of cultured guinea-pig myenteric
neurons revealed that A-Hu (1:50), but not A-Hu-free serum, increased the intracellular
calcium concentration in 90% of the tested neurons (total number of 55), a response
dependent on extracellular calcium. Tetrodotoxin (0.3 µM), nifedipine (1 µM), w-conotoxin
(0.1 µM) and the receptor-operated calcium channel blocker SKF 96365 (30 µM) significantly
inhibited the A-Hu induced calcium mobilization by 91%, 73%, 76%, and 88%, respectively.
Second, fast neuroimaging of freshly dissected LMMP preparations revealed that microejection
of A-Hu (400ms, 1:20, 22 ganglia, 4 guinea-pigs) but not A-Hu-free serum activated
17.3±6.2% of myenteric neurons causing an immediate spike discharge or increase in
spontaneous firing lasting several minutes. Third, local perfusion of A-Hu but not A-Hu-
free serum significantly increased firing in 15/16 vagal mechanosensitive fibers innervating
the mouse gastric fundus. The effect peaked at 76±11s and had a rapidly desensitizing
component (t1/2 10.2s) as well as a sustained response. DMPP and ATP sensitive and
insensitive hotspots responded. The response was similar in calcium-depleted buffer
(22.9±5.2 spikes/s vs. control 19.2±3.7). Fourth, in patch clamp studies on back-filled
nodose neurons A-Hu evoked an inward current in 6/18 cells which reversed around +10mV,
consistent with a non-selective cation conductance. Conclusion: A-Hu IgG isolated from
patients with severe gut motility dysfunction causes activation of both enteric neurons and
sensory vagal afferents. These data suggest that humoral autoimmunity may generate abnor-
mal immune-neural signaling in enteric and vagal mechanosensory neurons which contribute
to the neuropathophysiology of severe gastrointestinal motility disorders.
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S1788
Neuro-Immune Interactions and Anorectal Motility in Children with Food-
Allergy Related Constipation
Osvaldo Borrelli, Giovanni Di Nardo, Giovanni Barbara, Roberto De Giorgio, Cesare
Cremon, Sandra Lucarelli, Tullio Frediani, Vincenzo Stanghellini, Salvatore Cucchiara
Background. Food allergy in childhood has been suggested as a trigger of chronic constipation
(CC), but the underlying mechanism has not previously been investigated. Intestinal mast
cells (MC) are thought to be involved both in food hypersensitivity and in the pathophysiology
of abnormal sensory-motor function of the gut. Aim. To assess in children with CC, rectal
mucosal MC, neuroimmune interactions and anorectal motility before and after an elimination
diet. Patients and Methods. 25 children (median age: 4.4 years; range: 0.5-11 years), fulfilling
the Rome II criteria for functional constipation underwent anorectal manometry (ARM) and
suction rectal biopsy before and after a 8 week elimination diet. Manometric parameters
were: anal basal pressure (ABP, mmHg), percentage of relaxation (% R), residual pressure
(RP, mmHg) of internal sphincter. MC and nerve fibers were immunohistochemically identi-
fied with tryptase and neuronal specific enolase. Quantification of MC and MC-NF (MC
within 10 µm of nerve fibers) was performed using a computer-assisted analysis system.
Results. (mean±SD). 15 of 25 children were responsive (Resp) clinically to the elimination
diet, 10 did not (non-Resp). Baseline ARM showed a significant difference in ABP, %R, RP
between Resp (64.3±13.9, 80.8±11.6, 13.3±9.6) and non-Resp (51.3±12.0, 93.4±5.5,
3.2±2.8, p<0.001). After diet a significant decrease in ABP and RP, and a significant increase
in % R was observed only in Resp (49.6±14.8, 92.1±7.1, 4.3±4.2 [p<0.001 vs baseline]; non-
Resp: 47.7±12.4, 92.0±8.0, 3.1±3.2; NS). At baseline Resp showed an increased percentage of
lamina propria occupied by MC (8.05±3.0) and MC-NF (5.14±2.54) as compared with non-
Resp (4.2±1.3 and 1.8±1.8; p<0.001). After elimination diet only Resp had a significant
reduction of MC (3.3±1.1) and of MC-NF (1.6±0.8) (p<0.01) as compared to non-Resp
(3.5±2.1 and 1.3±1.0; NS). A significant correlation was found between ABP, MC and MC-
NF (r: 0.56; r: 0.59; p<0.001), as well as between RP, MC and MC-NF (r: 0.47, r: 0.55;
p<0.001). We also found a significant inverse correlation between % R, MC and MF-NF
(r: -0.35, p<0.05; r: -0.44, p<0.01). Conclusions: In children with functional constipation
related to food allergy anorectal dysmotility is sustained by abnormal rectal MC density and
spatial interactions between MC and nerves. These variables are significantly affected by an
elimination diet.
S1789
Gastrointestinal Dysmotility in 5-Fluorouracil (5-FU)- Induced Inflammatory
Intestinal Damage
Pedro M. Soares, Jose Mauricio S. Mota, Gerly Anne C. Brito, Miguel A. Nobre E Souza,
Armenio A. Santos, Ronaldo A. Ribeiro, Marcellus H. Souza
BACKGROUND & AIMS: 5-FU induced- intestinal damage is an important problem associ-
ated of cancer chemotherapy. It is characterized by mucosa epithelial ulcerations, and clinical
manifestations of abdominal pain, nauseas and diarrhea. It was described that inflammatory
intestinal damage could induced gastrointestinal dysmotility. Our hypothesis is that 5-FU
could induce intestinal inflammation and gastrointestinal dysmotility. METHODS: Wistar
rat (250-350g) received one dose of 5-FU (150 mg/Kg, ip), or saline (ip). After 1, 3, 5, 15
or 30 d, the rats were sacrificed, and pieces of duodenum, jejunum and ileum were removed
for measure microscopic epithelial damage, and neutrophil infiltration (MPO activity). After
3 d of a single 5-FU injection, other groups of rats were fed by gavage (1.5ml) with a
standard test meal (5% glucose solution with 0.05g/ml phenol red) and sacrificed 10, 20
or 30 min later. Dye recovery from the gastric contents (GDR), and from 5 intestinal segments
(IDR) were measured by spectrophotometry. Three d after a 5-FU or saline treatment,
mechanical response of the gastric fundus and duodenum, pre-contracted by carbachol
(CCh) (10-10 to 10-4 M), were recorded with an isometric force transducer and computerized
data acquisition system. RESULTS: 5-FU induced a significant (p<0.05) epithelial intestinal
damage (vilus/crypts reason reduction) in all segments (duodenum-control=3.2 ± 0.1μm,
5-FU=0.8 ± 0.2μm; jejunum-control=2.1 ± 0.2μm, 5-FU=1.0 ± 0.3μm and ileum-control=
1.2 ± 0.0μm, 5-FU=0.8 ± 0.1μm), and a increased in MPO (U/mg) activity (duodenum-
control=1.9 ± 0.2, 5-FU=12.2 ± 1.1; jejunum-control=2.4 ± 0.3, in 5-FU=11.3 ± 1.4 and
ileum-control=1.4 ± 0.2, 5-FU=10.1 ± 2.0), with the greater effect after 3 days. After 15
days, there was a complete repair of 5-FU induced- intestinal damage. After 3 days of 5-
FU administration, we observed a significant (p<0.05) increase in GDR (%) after 10 (control=
41.4 ± 5.4, 5- FU=75.6 ± 6.2), 20 (control=42.2 ± 4.4, 5-FU= 88.7 ± 10.6) and 30 min
(control=29.0 ± 10.3, 5-FU=76.2 ± 12.2). On the other hand, IDR were significant (p<0.05)
decreased in the 5 intestinal segments, at all post-prandial intervals. 5-FU induced a significant
(p<0.05) increase in stomach (% KCl) (control=202.6 ± 13.2, 5-FU= 290.8 ± 36.2) and
duodenum (control=27.5 ± 7.5, 5-FU= 89.4 ± 21.0) smooth muscle contraction at the CCh
10-5M. CONCLUSION: Our data suggest that the 5-FU intestinal inflammation induced a
gastrointestinal dysmotility. It could explain some of the gastrointestinal symptoms associated
of cancer chemotherapy. FINANCIAL SUPPORT: CNPq.
S1790
The Effect of Colonic Mucosal Mediators from Patients with Irritable Bowel
Syndrome On Tritiated ACh Release and Motor Responses in Strips of Human
Colon
Giovanni Barbara, Gianluigi D'Agostino, Elisabetta Cervio, Barbara Balestra, Cesare
Cremon, Roberto De Giorgio, Vincenzo Stanghellini, Roberto Corinaldesi, Marcello Tonini
Background & Aims: Colonic mucosal low grade inflammation and mast cell infiltration
has been recently suggested as a mechanism leading to symptom generation in patients with
irritable bowel syndrome (IBS) (Barbara et al Gastroenterology 2004;126:693-702). This
study was designed to assess the impact of colonic mucosal mediators from patients with
IBS on electrically stimulated excitatory motor responses and 3H-ACh release in strips of
human colon. Methods: Mucosal biopsies were obtained from the descending colon of IBS

















collected in HANKS medium and their effect on human colonic strips was assessed in vitro.
Longitudinal strips were mounted isometrically and stimulated electrically (EFS). The effect
of mucosal mediators was assessed on EFS-induced cholinergic contractile responses
(delivered as trains of 5 pulses at 1 Hz, 0.1 ms, 45 V, 120 s apart) in absence and presence
of the prostaglandin (PG) inhibitor BW A868C. Tissue neuronal ACh stores were labeled
with [methyl-3H] choline (74 KBequerel/ml) under EFS. After a 120 min washout period,
superfusion fluid was collected. Strips were stimulated 2 times (S1 and S2) by 600 pulses
delivered in 5 s trains at 20 Hz (0.1 ms duration, 90 V/cm, 15 s apart), and the resting and
stimulated 3H-outflow was measured and expressed as S2/S1 ratio in comparison to the
equivalent ratio obtained in their absence (control). Results: In human colonic strips, EFS
evoked neurogenic, cholinergic contractile responses that were abolished by tetrodotoxin
(TTX: 1 µM) and atropine (1 µM). Application of mucosal mediators inhibited motor
responses by approximately 20%, through a mechanism partly antagonized by the PG
inhibitor BW A868C (3 µM). EFS-induced 3H-outflow was abolished by TTX (1 µM)
indicating its neuronal origin. IBS mucosal mediators enhanced 3H-ACh release by about
30%, whereas mediators obtained from healthy controls enhanced 3H-ACh release by only
10%. Conclusions: Colonic mucosal mediators from patients with IBS inhibited colonic
excitatory motor responses via a mechanism partly sensitive to BW A868C, indicating a
direct, cAMP-mediated inhibitory effect of prostaglandin (PGE2) on smooth muscle cells.
Conversely, colonic mucosal mediators increased 3H-ACh release from cholinergic motor
neurons. It is likely that PGE2 participates also in this response. The net inhibitory effect
of mucosal mediators on cholinergic neuromuscular responses may derive from a prevalent
cAMP-mediated effect on smooth muscle cells compared to intrinsic cholinergic motor neu-
rons.
S1791
Effect of Hexamethonium and Different TRPV1 Receptor Antagonists On
Impaired Gastric Emptying Induced By Experimental Colitis in Rats
Heiko U. de Schepper, Joris G. de Man, Paul A. Pelckmans, Benedicte Y. de Winter
Introduction: Patients with inflammatory bowel disease often suffer from impaired gastric
emptying (GE). We previously demonstrated a delay in GE in rats with experimental colitis
in the absence of inflammatory changes at the level of the stomach. Our current aims were
to investigate whether neuronal transmission and transient receptor potential vanilloid type
1 (TRPV1) were involved in the colitis-induced gastroparesis by using hexamethonium,
capsaicin and different TRPV1 antagonists. Methods: Distal colitis was induced in male
Wistar rats by a colorectal enema of 30 mg trinitrobenzene sulphate (TNBS) in 50% ethanol
72 h prior to experiment. GE was measured 30 min after intragastric instillation of a semi-
liquid bolus of Evans blue. All drugs were administered intraperitoneally 1 h earlier. Capsaicin
pretreatment was started two weeks prior to experiments. Results: (table) TNBS-colitis
reduced GE significantly from 38.4±3.6% in controls to 22.7±4.4% in TNBS-treated rats
(P<0.05, n=12). Hexamethonium (20 mg/kg) reduced GE in controls but restored it to
normal values in TNBS-treated rats. Capsaicin (125 mg/kg) had a pronounced inhibitory
effect on GE in control rats, which was not seen in rats with colitis. The TRPV1 receptor
antagonists capsazepine (10 mg/kg), iodoRTX (755 μg/kg), SB366791 (0.5 mg/kg) and
AMG9810 (30 mg/kg) did not resolve the colitis-induced gastroparesis, iodoRTX even
reduced GE compared to its vehicle. Of the vehicles used, DMSO tended to increase GE at
concentrations exceeding 40%, while PEG tended to decrease GE. Conclusions: Acute
TNBS-induced colitis reduces GE in the absence of gastric inflammation. This “long distance”
effect is generated through neuronal pathways as evidenced by the beneficial effects of
hexamethonium, a neuronal transmission inhibitor. The capsaicin experiments suggest that
extrinsic afferent neurons are part of this pathway. We found no evidence for a role of
TRPV1 receptors, although the antagonists available to date may lack specificity or ideal
pharmacokinetic properties for an in vivo setup.
Table: The effect of hexamethonium, capsaicin and different TRPV1 receptor antagonists
and their respective vehicles on GE in TNBS-treated rats. GE is presented as a mean percentage
± s.e.m.*P<0.05, significantly different from vehicle-treated rats (unpaired Student’s t-test).
iodoRTX=iodoresiniferatoxin, eth=ethanol, Tw80=Tween80, DMSO=dimethyl sulfoxide,
PEG=polyethylene glycol
S1792
Increased Spontaneous Serotonin Release from Jejunum of Trichinella Spiralis
Infected Mice
Stephen Foley, Gulzar Singh, Johanna Wheatcroft, Arleta Reiff-Marganiec, Christopher
Keating, Victoria Chapman, Andrew Bennett, Charles Marsden, David Grundy, Robin
Spiller
Background. Post-infectious IBS is associated with elevated post-prandial 5-HT release. Mice
infected with Trichinella spiralis develop increased enterochromaffin (EC) cell counts in the
duodenum and jejunum. EC counts increase by 14 days after infection and this persists to
56 days, long after acute inflammation has resolved. Methods. Jejunal samples were taken
from NIH mice 14, 28 and 56 days after gavage with 300 T spiralis larvae, or from uninfected
animals. Jejunal dissection in ice cold buffer was performed immediately after cervical
dislocation, and 1cm strips taken. Mucosal samples were cut into strips, weighed and either
snap frozen in liquid nitrogen for 5HT and 5HIAA content, or incubated in gassed Krebbs
buffer (containing 10uM pargyline, 1mM N-AcetylCysteine) for 10 minutes. The 5HT released
was then assayed by HPLC. Data presented are the mean of 3 samples per animal. Relative
expression of Serotonin Transporter (SERT) and cytokeratin 20 (CK20) were assayed using
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Real Time Quantitive PCR (Taqman). Results. 5-HT levels were significantly elevated at day
14. Release of 5-HT was very elevated at day 14, and remained significantly above control
values at day 28. SERT mRNA expression was significantly reduced at day 14 (p<0.01), but
CK20 expression was also significantly reduced (p<0.01), and SERT expression relative to
CK20 expression was not significantly different suggesting that epithelial cell loss is the
major mechanism for downregulation of SERT in this model. Conclusion. 5-HT is elevated
in the jejunum of T. spiralis infected mice, paralleling the increased EC cell count. Spontan-
eous release of 5-HT is also significantly elevated and remains so at day 28. The ratio of 5-
HIAA to 5-HT is depressed at day 14, reflecting reduced 5-HT re-uptake due to reduced
SERT expression. This work was supported by the BBSRC
Results: (Mean ± SEM) (n=12 per group)
# p<0.001 * p<0.05
S1793
Protective Effect of Emodin On Severe Acute Pancreatitis Through Induction
of Apoptosis and Suppression of Cytokines Expression Via Inhibition of Nf-κB
Activation
Weiyan Yao, Yaozong Yuan
INTRODUCTION: As a major component of the widely used Chinese herb rhubarb, emodin
has been used in the remedies for many diseases including inflammation and cancers. It
has been indicated that emodin is a potent inhibitor of NF-κB activation and thus could be
useful in treating inflammatory diseases. AIMS: This study is aimed to assess the effectiveness
of emodin in the treatment of severe acute pancreatitis (SAP), and to clarify whether NF-
κB signaling is one of the pathways involved. METHODS: SAP was induced by injection of
5% sterile sodium taurocholate into bilio pancreatic duct, while control group was only
given sham operation. Emodin was administrated once at the dose of 1mg/kg after the
initiation of pancreatitis. Sera and pancreatic tissue were collected at 6 and 12 hours after
the onset of operation. The level of serum amylase, lipid and histology were evaluated. The
activation of NF-κB was determined by electrophoretic mobility shift assays (EMSA). Since
the promoter regions of TNF-α, intercellular adhesion molecule-1 (ICAM-1), and IL-6 genes
contain NF-κB binding sites and these cytokines are involved in the pathology of SAP, the
pancreatic tissue and serum level of these molecules were studied by ELISA. Apoptosis was
studied by TUNEL and electron microscope methods. The level of cIAP-1 and caspase3 was
determined by western blot. RESULTS: Taurocholate pancreatitis is characterized by massive
necrosis, haemorrhage, and severe leucocyte infiltration in the pancreas. Treatment with
emodin significantly attenuated SAP, as determined by serum amylase, lipid and histological
assessment of edema, vacuolization, inflammation and necrosis (p<0.01). Moreover, treat-
ment with emodin markedly inhibited NF-κB DNA-binding activity and the expression level
of cIAP-1 in pancreatic tissue (p<0.01, respectively vs SAP). This attenuation was associated
with decreased expression of TNF-α, IL-6 and ICAM-1 in the pancreatic tissues and serum
(p<0.05). Compared with the SAP group, apoptosis index of pancreatic acinus cells and the
expression level of activated caspase3 in pancreatic tissue were more significantly increased
in emodin-treated group both at 6h and 12h (p<0.05,respectively vs SAP). CONCLUSION:
The result of this study indicated that administration of exogenous emodin attenuates the
severity of SAP. The mechanism may be due to inhibition of NF-κB activation, which then
suppress the expression of cytokines and induce apoptosis through regulating cIAP-1 and
capspase3 expression.
S1794
Evidence of Region-Specific Activation of Cell Injury Mechanisms in Dorsal
Root Ganglion Neurons in DBTC-Induced Pancreatitic Rats
Shuangsong Hong, Chunfang Guo, John W. Wiley
Background: Chronic pancreatitis is a progressive disease that results in irreversible destruc-
tion of exocrine pancreatic tissue and extensive fibrosis. It is unknown whether mechanisms
associated with cell injury are activated in dorsal root ganglia (DRG) neurons innervating
the pancreas in chronic pancreatitis. Dibutyltin dichloride (DBTC) has been reported to
induce chronic pancreatitis with fibrosis in rats. We hypothesized that cell injury mechanisms
would be activated in DRG neurons in DBTC-induced pancreatitis rats in a region-specific
manner. Methods: Pancreatitis was induced in male Sprague-Dawley rats by DBTC (8 mg/
Kg) injection via the tail vein. In vitro studies were performed using DRGs from control
and chronic pancreatitis (2-4 weeks) rats. The following markers were examined: vanilloid
receptor 1 (VR1); substance P (SP); substance P receptor (NK1-R); the large DRG, A-fiber
marker NF200; the small DRG, C-fiber marker peripherin; 8-OHdG (marker for oxidative
stress); cytochrome c, activated caspase 3 & caspase-activated DNase (CAD) (markers for
apoptosis); and μ-calpain (a marker for oncosis). Age-matched healthy rats served as controls.
Results: Compared with the healthy controls, rats receiving DBTC demonstrated a significant
increase in the levels of VR1, SP and NK1-R protein in lower thoracic DRG neurons between
2-4 weeks after treatment, but not in lower lumbar DRGs. The up-regulation of these proteins
was colocalized in both small, peripherin-immunoreactive C- and A-δ fiber neurons and
large NF200-immunoreactive A-β fiber DRG neurons. The number of cells that were immuno-
reactive for both VR1 and SP (or NK1-R) was significantly increased as well in these DRG
neurons. Immunohistochemistry staining showed an increased immunoreactivity of the
oxidative stress marker 8-OHdG and markers of activation of the apoptosis cascade, cytosolic
cytochrome c and activated caspase 3 in DRG neurons from the DBTC-injected rats. Increased
colocalization of cytochrome c and activated caspase 3 was observed in thoracic DRGs
compared to lumbar DRGs in DBTC-treated rats, and untreated controls. Western blot
analysis demonstrated a significant increase in the levels of μ-calpain and CAD in thoracic
DRG neurons in DBTC-receiving rats, whereas the levels of μ-calpain and CAD did not
change in lumbar DRG neurons. Conclusion: DBTC-induced pancreatic rats demonstrate
region-specific activation of mechanisms associated with cell injury including increased levels
of VR1 receptor, and activation of the apoptosis cascade and oncosis.
S1795
Robust Mouse Reg-2 Induction in Response to Keratin Mutation As a
Cytoprotective Mechanism in Acute Pancreatitis
Pavel Strnad, Bihui Zhong, Diana M. Toivola, Xuhuai Ji, Harry B. Greenberg, M B. Omary
Background: The major cytoskeletal intermediate filaments in the pancreas and liver are
keratins 8 (K8) and 18 (K18). Their function differs in that liver K8/K18 are essential
cytoprotective proteins after an injury challenge while pancreatic K8/K18 appear to be
dispensable. This functional dichotomy is based on findings in pancreatic injury models in
K8-null and wild-type mice, and suggests that K8-null pancreata may undergo compensatory
regulatory or gene expression changes. Aims: We used gene expression profiling to test the
hypothesis that cytoprotective pancreatic genes are induced as a consequence of keratin
filament mutation. Methods: Total RNA was isolated from K8-null and wild-type mouse
pancreata, reverse transcribed then labeled with Cy3 (wild-type) and Cy5 (K8-null). Immuno-
fluorescence staining and real time PCR were used to confirm the mouse microarray (42,624
spots/slide) findings. Array results were analyzed using cluster/treeview programs. Transgenic
lines included those lacking acinar cell keratins (K8-null), those with membrane associated
but no cytoplasmic keratins (K18-null), those with collapsed punctate filaments due to K18
point mutation (R89C), those that express mutant K18 at two phosphorylation sites (S52A
or S33A), and those that lack ductal keratin 19 (K19). Results: Members of the Reg gene
family, particularly Reg-2, had the most dramatic up-regulation in K8-/- pancreata (15 fold)
which was confirmed by quantitative RT-PCR. The function of Reg-2 is unknown but it has
75% amino acid identity with Reg-1 (also called pancreatitis-associated protein I; confusingly
Reg-1 is sometimes termed Reg-2 in non-murine species). Anti-peptide antibodies to Reg-
2 were generated and confirmed the preferential pancreatic expression of Reg-2 and its
marked transcriptional induction at the protein level. Reg-2 but not Reg-1 is dramatically
induced when tested in the two pancreatitis models, caerulein and CDD. Reg-2 is also basally
overexpressed in K18-null and R89C but not in K19-null mice, while Reg-1 is unaltered.
Interestingly S52A but not S33A phosphorylation-mutant mice also manifest Reg-2 up-
regulation. Conclusion: Mouse Reg-2 is a likely compensatory cytoprotective factor when
the pancreatic acinar cell keratin cytoskeleton is perturbed by mutation or ablation. Reg-2
up-regulation associates with keratin phosphorylation in a site-specific fashion. Our results
combined with the structural relatedness of Reg-1, which is trophic in neuronal, pancreatic
and other tissues, to Reg-2 suggests a similarly trophic role for Reg-2 in mouse pancreas.
S1796
Prophylactic Probiotics Reduce Bacterial Translocation and Improve Outcome
in Experimental Pancreatitis
L. Paul van Minnen, Harro M. Timmerman, Femke Lutgendorff, Andre Verheem, Wil
Harmsen, Sergey R. Konstantinov, Hauke Smidt, Maarten R. Visser, Ger T. Rijkers, Hein
G. Gooszen, Louis M. Akkermans
BACKGROUND Infection of pancreatic necrosis by gut bacteria is a major cause of morbidity
and mortality in patients with severe acute pancreatitis. The use of prophylactic antibiotics to
prevent infectious complications remains a topic of debate. Furthermore, increased concerns
regarding the widespread use of prophylactic antibiotics associated complications, such as
antibiotics resistance, have been reported. Prophylactic probiotics have been suggested as
an alternative to the use of prophylactic antibiotics. Aim of this study was to determine if
prophylactic use of a specifically designed multispecies probiotic mixture (Ecologic 641)
can reduce bacterial translocation or improve clinical outcome in a rat model of acute
pancreatitis. METHODS Male Sprague-Dawley rats (n=48) were randomly allocated into
three groups: 1) controls (sham operated, no treatment), 2) pancreatitis, probiotics treated
or 3) pancreatitis, placebo treated. Acute pancreatitis was induced by intraductal bile salt
infusion (glycodeoxycholate, 15 mM) followed by pancreatic hyperstimulation (intravenous
cerulein, 5μg/kg/hr, for 6 hours). Probiotics or placebo were administered daily via a
permanent gastric cannula, from five days prior to until seven days after induction of
pancreatitis. The clinical response to pancreatitis was assessed using a health score. Surviving
animals were sacrificed at day seven, and tissue samples for microbiological and quantitative
real-time PCR analysis of bacterial translocation were taken. RESULTS Probiotic treatment
significantly reduced bacterial overgrowth of potential pathogens in the duodenum (3.5 ±
0.32 Log10 colony forming units (CFU)/gram vs. 5.0 ± 0.69, for probiotics vs. placebo,
respectively, P < 0.048), resulting in significantly reduced bacterial translocation to extra-
intestinal organs (Spleen: 2.43 ± 0.30 CFU/g vs. 3.71 ± 0.53, P = 0.039. Liver: 2.75 ± 0.47
vs. 4.56 ± 0.77, P = 0.049. Pancreas: 3.11 ± 0.52 vs. 5.38 ± 0.96, P = 0.042). Real-time
PCR demonstrated reduced bacterial loads in mesenteric lymph nodes (5.90 ± 0.44 cells/g
vs. 7.00 ± 0.14, P = 0.043) and pancreas (6.70 ± 0.25 vs. 7.71 ± 0.28, P = 0.013) of rats
treated with probiotics. Accordingly, health scores of surviving rats treated with probiotics
were higher throughout the experiment. Probiotics significantly reduced late phase mortality
(≥ 48 hrs, 0/13 vs. 4/15, P = 0.049). CONCLUSIONS This experiment demonstrates that
bacterial translocation during acute pancreatitis can be reduced by prophylactic multispecies
probiotics. Accordingly, probiotics improve the clinical course and outcome of acute pancre-
atitis.
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S1797
A Novel Possibility for Gene Transfer Into the Duct Cells Using Non-
Replicating Pseudorabies Virus Variants
Maria Kovacs, Zoltan Rakonczay, Balazs Ordogh, Tamas Takacs, Janos Lonovics, Andras
Varro, Andras Toth, Gyula J. Papp, Mike A. Gray, Barry E. Argent, Zsolt Boldogkoi, Peter
Hegyi
Background. Several types of viral vectors are currently in use for gene transfer, but there
is no available method to transfect intact pancreatic ducts. Viral invasion of cells may lead
to cytotoxicity, which may question the validity of any observations. Our aim was to establish
a model system for transferring genes into the pancreatic duct cells, which did not lead to
cell damage. Methods. The non-virulent Ka-RREp0lacgfp (KEG) genetically modified strain
of pseudorabies virus (PRV) containing the gene for GFP was used in this study. Small intra/
interlobular ducts were isolated from the pancreas of guinea pigs. Ducts were incubated in
McCoy’s based culture medium containing KEG virus at four different titers (107, 108, 109
and 1010 plaque forming units/ml) for 6 hours. The rate of HCO3- secretion was determined
as described previously (Hegyi et al. Am J Physiol Cell Physiol 285:C268-C276, 2003). Viral
structural proteins were visualized by immunohistochemistry. Native GFP expression and
immunofluorescence signals were recorded by a confocal laser scanning microscope. Results.
We observed that KEG virus infected practically all accessible epithelial cells within the duct
when used at a titer of 1010 pfu/ml after 24 hours as judged by the appearance of GFP.
Importantly, we did not observe any cytotoxic effects of KEG and could not detect viral
antigens on the cell surface, indicating the lack of viral replication. KEG did not affect ductal
HCO3- secretion at any of the titers tested. Conclusions. The high efficiency of PRV infection
in the pancreatic ductal epithelium may open the possibility for gene transfer and gene
therapy of the duct cells using non-replicating PRV variants. This work was supported by
The Wellcome Trust and OTKA.
S1799
SiRNA for Collagen-Specific Chaperone, Heat Shock Protein 47 Prevents
Collagen Secretion from Pancreatic Stellate Cells in Rats
Masashi Taguchi, Shiro Watanabe, Hiroshi Asaumi, Yoshikuni Nagashio, Yoko Nomiyama,
Makoto Otsuki
Heat-shock protein 47 (HSP47) is a collagen-binding stress protein and is assumed to act
as a collagen-specific molecular chaperone during the biosynthesis and secretion of procolla-
gen in the living cell. Chronic pancreatitis is characterized by loss of functional tissue and
its replacement by extracellular matrix (ECM), but the molecular mechanism of this process
remains unclear. We examined the expression for HSP47 in pancreatic fibrosis by repeated-
injection of cerulein in mice. HSP47 protein was markedly induced and its distribution
was spindle-shaped and inflammatory cells by western bolt analysis and immunostaining,
respectively. Serial section showed these spindle-shaped cells also positive for alfa-smooth
muscle actin (alfa-SMA), which was the marker of activated-pancreatic stellate cells (PSCs).
We isolated PSCs from the pancreas of Wister rat using collagenase digestion and centrifuga-
tion with Nycodentz gradient. Isolated PSCs were also positive for HSP47. Using small
interfering RNA (siRNA) transfection into PSCs, we knocked down HSP47 protein levels
and analyzed collagen secretion, cell proliferation, alfa-SMA expression and, transforming
growth factor-beta 1(TGF-beta 1), collagen type 1 and fibronectin mRNA, assessed by
Sirius red dye binding assay, BrdU incorporation, western blot analysis, and real-time PCR,
respectively. Collagen secretion from PSCs was significantly reduced compared with control,
but there were no significant differences for cell proliferation, alfa-SMA expression and ECM-
related gene expression. Our results indicated the involvement of HSP47 in the progression
of pancreatic fibrosis and that inhibition of HSP47 expression might merit further clinical
investigation for the treatment of chronic pancreatitis.
S1800
Engulfment of Apoptotic Acinar Cells By Pancreatic Stellate Cells Regulates
Pancreatic Fibrogenesis
Junko Tahara, Kyoko Shimizu, Keiko Shiratori
Background and Aims: Pancreatic stellate cells (PSCs) are known to play a pivotal role in
fibrogenesis in pancreatic diseases. We have previously reported finding that engulfment of
apoptotic polymorphonuclear neutrophils by PSCs is regulated by cytokines and PPAR γ
ligand. The aim of the present study was to investigate whether engulfment of apoptotic
acinar cells affects pancreatic fibrogenesis. Methods: Rat PSCs were cultured and characterized
as myofibroblast-like cells morphologically. Rat pancreatic acinar cells were incubated for
48 hours to induce apoptosis, and after allowing them to interact with PSCs for 12-48
hours, MTT assay was performed. α-SMA expression was detected by Western blot analysis.
Cell morphology was examined by light microscopy. Annexin V-FITC and propidium iodide
staining or detection of DNA fragmentation was used to identify cell death. The culture
medium of PSCs that were cultured with apoptotic acinar cells and of PSCs not cultured
with pancreatic acinar cells (control PSCs) was collected, and the TGF-β concentration of
the culture medium was measured by ELISA. Results: Most aged acinar cells were undergoing
apoptosis, and a large number of apoptotic acinar cells were engulfed by PSCs. When PSCs
were cultured with apoptotic acinar cells for 12 hours, the number of living PSCs and
expression of α-SMA significantly decreased compared to the control PSCs. PSCs cultured
with acinar cells showed DNA fragmentation and were Annexin V-positive, suggesting that
phagocytosis of apoptotic acinar cells induced apoptosis of PSCs. When PSCs were cultured
with apoptotic cells for 48 hours, the growth of the PSCs returned to the same level as that
of the control PSCs, and their level of α-SMA expressions was higher than in the control
PSCs. There was no difference between the concentrations of TGF-β in the medium of the
control PSCs and the PSCs that had engulfed acinar cells. Conclusions: Engulfment of
apoptotic acinar cells by PSCs may be essential to remove damaged acinar cells and PSCs
themselves to limit the early stage of pancreatic inflammation. When PSCs were further
cultured with apoptotic acinar cells for 48 hours, engulfment of apoptotic cells activates

















important mechanism in the regulation of inflammation and fibrogenesis in pancreatic dis-
eases.
S1801
Role of the Cholinergic System in Alcohol-Induced Pancreatitis
Aurelia Lugea, Jose Nieto, Melissa Daghighian, Akihiko Satoh, Stephen J. Pandol
Background & Aims: Although alcohol abuse can lead to pancreatitis in humans, the mechan-
isms underlying ethanol-induced pancreatic injury are poorly understood. We have shown
that ethanol sensitizes rat pancreas to the inflammatory and acinar cell injury caused by
cholecystokinin (CCK). This sensitization, in particular, results in pathologic responses with
low doses of CCK or cerulein that by themselves do not cause pancreatitis. CCK actions on
human and rodent pancreas include interactions with the cholinergic system. We hypothes-
ized that the cholinergic system contributes to the ethanol-sensitizing effects on pancreatic
injury. In the present study we assess whether atropine blocks ethanol-mediated sensitization
of pancreatitis in rats, and whether ethanol causes inflammatory responses in cholinergic-
stimulated rat pancreatic acini. Methods: Male Wistar rats were pair-fed control or ethanol-
containing Lieber-DeCarli diets for 6 weeks. Low doses of cerulein (0.5 μg/kg) or saline
were given as 4 hourly i.p. injections. Half of the animals received i.p. atropine (40 μg/kg)
as cholinergic blocking agent prior to and during cerulein treatment. Animals were sacrificed
1 h after the last cerulein injection and blood and pancreatic samples were analyzed for
parameters of pancreatitis. Dispersed rat pancreatic acini were incubated for 3 hours with
100 mM ethanol and then stimulated with 1 mM carbachol or vehicle. After 30 min, cells
were collected and NF-κB binding activity was measured by EMSA. Results: Neither carbachol
nor ethanol stimulation led to NF-κB activation in dispersed pancreatic acini. However,
these two factors in combination induced marked NF-κB activation, suggesting a sensitizing
effect of ethanol to inflammatory effects of cholinergic agonists. Similar sensitizing effects
were observed in rats fed ethanol. In these animals, low doses of cerulein caused an episode
of acute pancreatitis characterized by increase in blood lipase levels, marked vacuolization
of acinar cells and intra-pancreatic trypsin activation. Cerulein was used at low doses that
induce only minor effects in control fed animals. Interestingly, the stimulatory effects of
ethanol feeding on cerulein pathologic responses in pancreas were abolished by atropine
treatment. In particular, atropine blocked the increases in blood lipase and trypsin activation
and markedly reduced acinar cell vacuolization. Conclusions: Ethanol sensitizing effects to
pancreatic inflammatory and injury are mediated at least in part by the cholinergic system.
Ethanol may elicit cholinergic involvement via central or peripheral neural systems and/or
muscarinic signaling within pancreatic acinar cells.
S1802
Colony-Stimulating Factor Release from Human Pancreatic Periacinar
Myofibroblasts
Osamu Inatomi, Akira Andoh, Yuki Yagi, Shigeki Bamba, Kazunori Hata, Takao Saotome,
Atsushi Takayanagi, Nobuyoshi Shimizu, Yoshihide Fujiyama
Backgrounds and aims: Colony-stimulating factors (CSFs) play an important role in control-
ling the proliferation of hematopoietic progenitor cells and enhancing the functional activities
of mature myeloid effector cells. CSFs are produced by variety of cells, including monocytes,
macrophages, endothelial cells, fibroblasts and stromal cells in response to various inflammat-
ory stimuli. In cases of acute or flare-up chronic pancreatitis, a marked elevation of circulating
leukocyte counts is frequently observed. However, the local secretion of CSFs in pancreas
remains unclear. In this study, we focused on CSFs secretion in periacinar myofibroblasts
(PMFs) isolated from human pancreas. Materials and Methods: Primary cultures of PMFs
were prepared according to the method reported by Saotome et al. The cells were cultured
in DMEM containing 10% FBS. All culture media were supplemented with 50U/ml penicillin
and 50μg/ml streptomycin. The studies were performed on passage 2-6 myofibroblasts
isolated from 3 resection specimens. CSFs secretion was determined by ELISA, and CSFs
mRNA expression was evaluated by Northern blotting. The activity of secreted CSFs on
hematopoietic progenitor cells was examined by methylcellulose colony assay. Results: Un-
stimulated PMFs secreted a small amount of granulocyte (G)- and granulocyte/macrophage
(GM)-CSF, and a considerable amount of macrophage (M)-CSF. Interleukin (IL)-1β and
tumor necrosis factor (TNF)-α induced a marked increase in G- and GM-CSF release, and
weakly but significantly enhanced M-CSF release. The effect of IL-1β and TNF-α were
detected in dose- and time-dependent manner. The combination of IL-1β plus TNF-α
induced a synergistic increase in G- and GM-CSF release. Adenovirus-mediated transfer of
a stable form of IκBα markedly inhibited the effects of IL-1β and TNF-α. Conditioned
medium of IL-1β- and TNF-α-treated PMFs enhanced granulocyte and/or macrophage colony
formation. Conclusion: The present study demonstrated that human PMFs are local site for
CSF biosynthesis. CSFs derived from PMFs may play an important role in the pathophysiology
of acute or chronic pancreatitis.
S1803
The Stimulatory Effect of Various Extracellular Matrices On Rat Pancreatic
Stellate Cells
Hiroshi Asaumi, Masashi Taguchi, Mitsuo Tashiro, Shiro Watanabe, Yoko Nomiyama,
Makoto Otsuki
INTRODUCTION: Pancreatic stellate cells (PSCs) synthesize and secrete extracellular matri-
ces (ECMs) and cytokines, and contribute to the progression of pancreatic fiborisis. Secreted
cytokines are known to stimulate PSCs by themselves. In fibrotic tissue, PSCs are surrounded
by various pathological ECMs such as type I collagen. Although integrin β1 receptors is
known as major adhesion receptors to ECMs, it is not clarified that what types of integrin
β1 receptors PSCs have. We therefore examined the presence of integrin β1 receptors and
the interaction between PSCs and various types of ECMs. METHODS: PSCs were isolated
from rat pancreas, and the presence of integrin β1 receptor family in PSCs was investigated
by reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting. [2] We
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examined the reaction of PSCs against various ECMs as follows; (i) adhesion ability, (ii)
collagen secretion into the medium, (iii) various gene expressions and (iv) phospholyration
of focal adhesion kinase (FAK) by incubatin PSCs on various types of ECM-coated dishes
(type I collagen, type IV collagen and fibronectin). RESULTS: We detected mRNA and
protein expression of integrin β1 receptor family in PSCs. PSCs attached to each ECM-
coated dish in a concentration-dependent manner. Incubation of PSCs on type I collagen-
coated dish (COL I) significantly increased collagen secretion into the medium and gene
expression of type I procollagen compared with that on type IV collagen-coated dish (COL
IV) and fibronectin-coated dish (FN). Gene expression of fibronectin significantly increased
in order of COLI, FN, and COL IV. COL I and FN significantly increased gene expression
of transforming growth factor (TGF)-β1, TGF-β type II receptor, platelet derived growth
facotr-α and β receptors compared with COL IV. Adhesion of PSCs to COL I rapidly
increased phosphorylation of FAK, reaching the peak level at 1 h. PSCs on COL IV also
significantly increased FAK phosphorylation compared with suspended PSCs, the level was
less than that on COL I. CONCLUSION: These results clearly demonstrated that type I
collagen stimulates PSCs to produce ECMs, cytokine and cytokine receptors through integrin
β1 receptors. These results suggested that type I collagen may contribute to the progression
of pancreatic fibrosis.
S1804
Genome Wide Analysis and Global Gene Expression of 50 Cases of Pancreatic
Endocrine Neoplasm (PEN) with Clinical and Pathological Correlation
Laura H. Tang, S M. Chung, L Song, Jr Shia, P J. Allen, L H. Blumgart, M F. Brennan, M
I. D'Angelica, R Dematteo, H Fong, W R. Jarnagin, D P. Jaques, A Viale, D S. Klimstra
While PEN is less aggressive than its pancreatic adenocarcinoma counterpart, synchronous
and metachronous metastases occur in 40-60% cases. There has been no ideal prognostic
classification system based on clinical and pathologic criteria. We studied molecular features
of 50 PENs with clinical followup of 66±7 months. Comparative genomic hybridization
(CGH) was performed using an oligonucleotide based microarray with an average resolution
of 35 kb, and gene expression was analyzed with Affymetrix HG-U133A-2. Significantly
altered genes were further validated by quantitative RT-PCR. Overall chromosomal aberra-
tions observed in >80% of PENs included losses at 1p36, 3p21.2, 10q24.3, 11p11.22-p12,
11q13, 16p13.12-12.3, 16q22, 17-telomeres, and 22q12.3-13.2; and gains at 14q12. When
tumors were stratified by size, larger tumors had relatively more chromosomal gains than
losses. Similarly, metastases exhibited more complex chromosomal aberrations than their
corresponding primaries. Supervised clustering analysis of gene expression was performed
in subgroups of PENs (Table 1). Genes with >5 fold alterations within each subgroup were
identified. Representative genes related to angiogenesis and tumor suppression were evaluated
in primary PENs with (n=13) or without (n=17) metastasis, and with 5 cases of hepatic
metastases. The amount of target genes, normalized to an endogenous reference, was signific-
antly down regulated (19 folds) in PENs associated with distant metastases when compared
to those without metastasis (p=0.015); and it was further decreased by 2304 fold in hepatic
metastases (p=0.004). In conclusion, we have identified precise DNA aberrations in PENs
using high resolution and sensitivity CGH. Potential genes related to prognosis may provide
a more consistent and accurate biological and pathological assessment of PENs.
Table 1. Comparison of Alterations in Gene Expression Between Subgroups of PEN.
S1805
Sustained Akt Phosphorylation Is Required for Anti-Apoptotic Effect of
Insulin-Like Growth Factor-I in Pancreatic Cancer Cells: Roles of
Phosphatases
Jong Kyun Lee, Mouad Edderkaoui, Peggy P. Hong, Patrick Truong, J. David Lambeth,
Andrea Berti, Stephen J. Pandol, Anna S. Gukovskaya
Background and Aims: Insulin-like growth factor-I (IGF) plays a major role in protecting
pancreatic cancer (PaCa) cells from apoptosis. Pro-survival effects of IGF are mediated via
activation of phosphatidylinositol 3-kinase (PI3K) and the downstream Akt kinase. Growth
factors are known to cause a rapid and transient Akt activation, whereas inhibition of
apoptosis occurs hours later. In this study we sought to determine the mechanisms underlying
this temporal relationship, and in particular, the roles of phosphatases and reactive oxygen
species (ROS) in the anti-apoptotic effect of IGF in PaCa cells. Methods: In MIA PaCa-2
and PANC-1 cells cultured with and without IGF (50 μg/ml), we measured apoptosis with
Cell Death ELISA; Akt activation (i.e., phosphorylation), by Western blot; intracellular
ROS, by flow cytometry; and protein tyrosine phosphatase (PTP) activity and oxidation, by
enzymatic and electromobility shift (EMSA) assays. Results: In both cell lines, IGF induced
biphasic phosphorylation of Akt: in addition to a rapid (minutes) and transient 1st phase,
there was a slow (24-72 h) and sustained 2nd phase. PI3K inhibitors LY294002 and
wortmannin prevented both phases of Akt phosphorylation as well as the anti-apoptotic
effect of IGF. Importantly, the pro-survival effect of IGF was also prevented by inhibiting
the 2nd phase of Akt phosphorylation alone (LY294002 added 30 min after IGF). Thus,
sustained Akt phosphorylation is necessary for the IGF-induced inhibition of apoptosis.
Transfection experiments identified the phosphatase LMW-PTP as a negative regulator of
sustained Akt phosphorylation in PaCa cells. Using a recently developed non-reducing EMSA,
we found that IGF stimulated LMW-PTP oxidation thus inhibiting its activity. Previously,
we have shown that IGF activates NADPH oxidase Nox4 in PaCa cells. NADPH oxidase
inhibitor DPI and transfection with Nox4 siRNA plasmid both prevented IGF-induced
oxidation of LMW-PTP and stimulated its activity. Conclusions: The results demonstrate
that the signaling pathway mediating the pro-survival effect of IGF starts with activation of
NADPH oxidase (Nox4); leading, in turn, to oxidation (i.e., inhibition) of LMW-PTP by
ROS produced by NADPH oxidase; and resulting in sustained activation of the anti-apoptotic
PI3K/Akt. This mechanism represents a target for novel therapeutic strategies to promote
death of PaCa cells and thus overcome their resistance to treatments.
S1806
Pancreatic Tumor Cell Adhesion and Migration Is Regulated By
Phosphorylation of the Actin-Binding Protein Cortactin
Anne E. Kruchten, Eugene W. Krueger, Mark A. McNiven
BACKGROUND: Neoplastic pancreatic ductular cells disseminate and invade peripheral
tissues rapidly, making this cancer particularly aggressive and difficult to treat. Currently,
the molecular machinery that supports this active, actin-based, metastatic process is poorly
understood. Cortactin is an actin-binding protein involved in cell migration and metastasis.
In addition, cortactin is a substrate of the tyrosine kinase Src, and both of these proteins
are upregulated in pancreatic cancer. Therefore, together cortactin and Src may participate
in actin reorganization that occurs during pancreatic ductular cell migration and subsequent
metastasis. Further, phosphorylation of cortactin by Src could modulate the effects of cortactin
on actin reorganization and dynamics that occur during cell migration. For example, in vitro,
Src phosphorylation of cortactin has been shown to negatively affect actin polymerization. In
vivo, however, Src phosphorylation of cortactin has been shown to promote actin-dependent
cell migration and to enhance the metastatic capacity of cells. In addition to being phosphoryl-
ated by Src, cortactin is also serine phosphorylated by the kinase ERK. In contrast to the
negative effects of Src phosphorylation of cortactin on in vitro actin polymerization, ERK
phosphorylation of cortactin enhances in vitro actin polymerization. GOAL: This study aims
to determine the contributions of Src- and ERK-mediated cortactin phosphorylation on actin
assembly in metastatic human pancreatic cells. RESULTS: Expression of a cortactin mutant
mimicking the Src-phosphorylated state (Y384/429/445E) resulted in a dramatic extension
of lamellipodia, structures rich in actin and indicative of a migratory phenotype, whereas
expression of the phospho-blocking mutant (Y384/429/445F) inhibited lamellipodia forma-
tion. To test how Src-mediated tyrosine phosphorylation of cortactin promotes lamellipodial
extension while inhibiting actin polymerization, as suggested by in vitro data, the effects of
cortactin mutants on focal adhesions, dynamic actin-based structures that undergo turnover
during cell migration, were examined. Interestingly, cells expressing cortactin Y384/429/
445E had numerous focal adhesions with a decreased amount of cortactin and exhibited
faster spreading on fibronectin, suggesting a more migratory phenotype. CONCLUSION:
We suggest that tyrosine phosphorylation of cortactin plays a role in focal adhesion turnover
and thereby affects cell motility. These findings provide novel insights into the role of
cortactin phosphorylation in pancreatic cancer cell migration through the regulation of focal
adhesion turnover.
S1807
Suppression of C-Terminal Src Kinase (CSK) Leads to Increased Cell
Proliferation in Pancreatic Cancer
Dhananjay Kunte, Jennifer Koetsier, Ramesh Wali, Randall Brand, Hemant Roy
Background: While various molecular changes in pancreatic cancer progression are known,
the specific signaling events underlying the aggressive growth and proliferation are unclear.
The proto-oncogene Src is a member of the Src family of non-receptor tyrosine kinases
(SFKs) that control proliferation, apoptosis, invasiveness and angiogenesis. Src is commonly
activated in pancreatic cancer; however the mechanisms remain unclear. One potential
means of activating Src is through downregulation of its inhibitor, C-terminal Src Kinase
(Csk). We, therefore, investigated the role of the CSK tumor suppressor gene in pancreatic
carcinogenesis. Methods: The levels of CSK and Src-527 (the inhibitory phosphorylation
site of CSK) in the pancreatic tissues of the normal and adenocarcinoma patients were
assessed by immunohistochemistry. In order to study the role of CSK in pancreatic cancer,
we genetically engineered human pancreatic cancer cell line MIA PaCa2 for CSK gene knock-
down by stably transfecting the CSK-specific shRNA vector using standard methods. Protein
samples from the wild type and the CSK shRNA construct were processed for western
blotting to study the molecular effects of CSK-inhibition. Results: CSK was suppressed in
the pancreatic adenocarcinoma with corresponding decrease in the Src-527. In the MIA
PaCa2 cells, the CSK stable construct showed 54% decrease in CSK levels and significant
increase (133% of the wild type, p<0.05) in the cell proliferation marker PCNA. CSK gene
knockdown also resulted in the activation of the members of the MAP kinase pathway, viz.,
MAP Kinase Kinase (MEK, 201% of control, p<0.05) and MAP Kinase (MAPK) (. Conclusion:
We demonstrate that CSK is suppressed with corresponding Src activation in pancreatic
cancer tissue. Loss of CSK in pancreatic cancer cell line leads to increased cell proliferation
through activation of the MAP kinase pathway.
Possible mechanism for CSK-regulated cell proliferation in pancreatic cancer.
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S1809
Implication of S100p in Pancreatic Cancer As An Early Developmental Marker
and a Therapeutic Target
Kenoki Ohuchida, Kazuhiro Mizumoto, Eishi Nagai, Hiroyuki Konomi, Koji Yamaguchi,
Masao Tanaka
Backgrounds. Recent microarray analyses identified S100P as a candidate diagnostic marker
or therapeutic target of pancreatic cancer. Aim. To investigate the role of S100P in pancreatic
cancer. Method. We examined S100P mRNA expression in pancreatic cancer cell lines,
pancreatic tissues, cells microdissected from pancreatic tissue, and pancreatic juice from
patients with pancreatic diseases. The effect of interference with S100P on pancreatic cancer
cells was investigated by in vitro and ex vivo RNA interference experiments inhibiting S100P
mRNA expression. Results. S100P mRNA expression was significantly greater in tumoral
than in non-tumoral tissues. In pancreatic juice, S100P expression differed significantly
between patients with carcinoma and those with non-neoplastic diseases. In receiver operating
characteristic curve analyses, S100P was a good marker for preoperative diagnosis of pancre-
atic cancer. Microdissection-based mRNA analyses revealed that S100P expression differs
significantly between normal duct and pancreatic intraepithelial neoplasia (PanIN) but not
between PanIN and invasive ductal carcinoma. In vitro and ex vivo S100P inhibition decreased
cell proliferation and possibly the invasive potential of pancreatic cancer cells. Conclusion.
Our findings suggest that S100P expression is up-regulated during early carcinogenesis and
correlates with cell proliferation and possibly cell invasion. Quantitative S100P mRNA
assessment is a promising approach to evaluating the risk of pancreatic cancer.
S1810
Corn Derived Carbohydrate Inositol Hexaphosphate (IP6) Inhibits Barrett’s
Adenocarcinoma Growth By Pro- Apoptotic Mechanisms
David W. Mcfadden, Dale R. Riggs, Barbara J. Jackson, Cynthia Cunningham
INTRODUCTION: Inositol Hexaphosphate (IP6) is a naturally occurring polyphosphorylated
carbohydrate found in food sources high in fiber content. IP6 has been reported to have
significant inhibitory effects against a variety of primary tumors including breast and colon.
The effects of IP6 have not been evaluated in Barrett’s adenocarcinoma. We hypothesized
that IP6 would significantly inhibit cell growth rate of Barrett’s adenocarcinoma in vitro.
METHODS: Two Barrett’s-associated adenocarcinoma cell lines , SEG-1 (wild type p53)
and BIC-1 (mutant p53), were treated with corn derived IP6 at 0.5, 1.0, and 5.0mMolar
concentrations. After 72 hours, cell viability was measured by MTT assay. Apoptosis and
necrosis was evaluated by the Annexin V FITC assay. Statistical analysis was performed by
ANOVA. RESULTS: Reductions (p<0.01) in cellular proliferation was observed in both cell
lines. In the BIC cells, 5mM (80.0%) and 1.0mM (65.4%) of IP6 decreased cell growth
(P<0.001). In the SEG1 cells, 0.5mM (55.8%), 1.0mM (93.1%) and 5mM (86.2%) of IP6
decreased cell growth (P<0.001). IP6 increased late apoptotic activity (p=0.046) in the BIC
cells. In the SEG-1 cells, early apoptosis (p=0.038), late apoptosis (p=0.002) and necrosis
(p=0.036) were all increased by IP6 treatment CONCLUSIONS: Treatment of Barrett’s
adenocarcinoma with the common dietary polyphosphorylated carbohydrate IP6 significantly
decreased cellular growth by pro- apoptotic mechanisms. Our findings suggest that IP6 has
the potential to become an effective adjunct for Barrett’s adenocarcinoma. Further in vivo
and human studies are needed to evaluate safety and clinical utility of this agent in patients
with Barrett’s adenocarcinoma.
S1811
Correlation of DNA Ploidy Analysis By Digital Image Analysis and Flow
Cytometry in Barrett’s Esophagus
Kenneth K. Wang, Ganapathy Prasad, Navtej S. Buttar, Michel Wongkeesong, Peter
Rabinovitch, Thomas Smyrk, Lynn Borkenhagen, Sarah Papenfuss, Catherine Demars,
Lori Lutzke
Flow cytometry has been shown to be an important biomarker for cancer risk in Barrett’s
esophagus. Digital image analysis (DIA) is another method to obtain similar information
that requires a much smaller sample of cells for analysis. Aim: To compare the results of
DIA and flow cytometry in a consecutive series of patients with Barrett’s esophagus and
high-grade dysplasia. Methods: Patients referred to the Barrett’s Esophagus Unit with high-
grade dysplasia were prospectively studied with DIA and flow cytometry. All patients under-
went four quadrant biopsies taken every centimeter with histological results reviewed by
two expert pathologists. DIA was performed on cytological specimens that were Feulgen
stained and then assessed with a CAS 200 digital imaging microscope. A minimum of 50
cells were assessed for DIA. Flow cytometry was performed on histological specimens at
the University of Washington. A minimum of 20,000 cells were assessed for flow cytometry.
In cases with dichotomous results between DIA and flow cytometry, fluorescent in situ
hybridization was performed to determine if genetic abnormalities did exist in p16, p53,
c-myc, 20q, and Her-2. Results: 18 patients were assessed, 15 with high-grade dysplasia
and 3 with carcinoma found on biopsy. In one case, there was inadequate specimens available
for flow analysis. Of the remaining 17 cases, DIA and flow cytometry made concordant
assessments of DNA ploidy in 82% of the cases, (p>0.3). These included 5 cases that were
diploid and 9 that were aneuploid. There were three discordant pairs that included one
that was near diploid on DIA and aneuploid on flow, this case was completely normal on
FISH. Two cases were tetraploid on DIA and diploid on flow, Both cases were abnormal
by FISH, with loss of heterozygosity of both p53 and p16. Conclusions: DNA ploidy by
DIA or flow cytometry were reasonably concordant. In the discordant cases, examination
of other biomarkers suggest that DIA may have correlated better with genetic abnormalities.
This study suggests that DNA ploidy determined by DIA on cytology may be as useful as


















Accuracy of Wireless Capsule Endoscopy for the Detection of Barrett’s
Esophagus
Prateek Sharma, Amit Rastogi, Romeo Esquivel, Krishna Gurram, Sachin Wani, Ajay
Bansal, Srinivas R. Puli, April Higbee, Lisa Camargo, Richard Sampliner
Introduction: The initial step in the diagnosis of Barrett’s esophagus (BE) requires an upper
endoscopy to document the presence of a columnar lined distal esophagus (suspected BE),
followed by biopsies from the columnar segment. The availability of a wireless esophageal
capsule (Pillcam ESO) allows the recording of images from the esophagus and can be
potentially used as an office based screening tool in patients with GERD. Aim: To compare
esophageal capsule to standard upper endoscopy for the detection of endoscopic Barrett’s
esophagus. Methods: This study was conducted at 2 sites utilizing standardized methodology,
data collection and analysis. Patients with chronic GERD and BE were prospectively evaluated;
all patients initially underwent capsule endoscopy followed by standard upper endoscopy.
The esophageal capsule is similar to the small bowel capsule, but acquires images from both
ends (2 cameras) of the device at a rate of 7 frames/sec/camera. The quality of the images
were graded from 1-5 (not scoreable-excellent). Capsule images were analyzed by investig-
ators blinded to the upper endoscopy findings; sensitivity and specificity of these findings
were then analyzed using the standard endoscopy findings as the gold standard. Results:
Eighty-four patients were initially enrolled in the study, 3 were unable to swallow the
capsule, whereas images from 3 patients could not be evaluated. Data from 78 patients were
available for analysis; mean age of 56.9+12.3 years; 71 males. By standard endoscopy, BE
was suspected in 41 patients; 27 with short BE (<3 cm) and 14 with long BE (>3 cm). The
mean BE length was 3.17 cm. The sensitivity and specificity of esophageal capsule endoscopy
for the detection of suspected BE were 73% and 86% respectively; sensitivity and specificity
for the detection of short BE were 67% and 86% and for long BE were 86% and 86%
respectively. The quality of the images did not contribute to the false positive/negative
results. No adverse events were noted using capsule endoscopy. Conclusions: Esophageal
capsule endoscopy can be safely performed in the majority of GERD patients undergoing
screening upper endoscopy. The sensitivity and specificity of capsule endoscopy for the
diagnosis of suspected BE are high especially for long BE. Future studies should test inter
observer variability and the learning curve in the reading of images and steps to further
improve the diagnostic accuracy capsule endoscopy.
S1813
Does Degree of Acid Exposure Differ Between Distal Versus Proximal
Esophagus in Patients with Barrett’s Esophagus (BE)?
Prateek Sharma, Ajay Bansal, Sachin Wani, Srinivas R. Puli, April Higbee, Amit Rastogi
Introduction:BE pts have been shown to have abnormal esophageal acid exposure by catheter
pH systems with probe placed 5 cm above LES. However, it is not known if acid exposure
is higher in distal vs. proximal esophagus of BE pts using a wireless pH system. Aim:In BE
pts, compare acid exposure in very distal esophagus (1cm above anatomic GEJ) to conven-
tional location (6 cm above GEJ) and to a group of controls. Methods:Pts with confirmed
BE, off PPI therapy for 7 days were enrolled. Under endoscopic vision, 2 pH capsules were
placed 1 and 6 cm above GEJ. Controls [subjects without GERD symptoms on 2 validated
GERD questionnaires (GERQ and RDQ)] were also studied. All subjects were encouraged
to continue usual activities and diet. pH tracings were reviewed. Only tracings consistent
with esophageal and not gastric cardia placement and with 16 hrs of data were used for
analysis. Proximal and distal pH values in BE pts were compared using paired t-test and
Wilcoxon summed ranks test. Correlation between pH (at both locations) and BE length
was performed using Pearson’s test and scatter plot. Mean pH values of BE pts were also
compared to controls with unpaired t-test. Results: 23 BE pts were enrolled (all Caucasian
males) - mean age 65.9 yrs (range:40-81) and mean BE length 3.68±2.7 cm. Data from 19
pts could be analyzed. Within BE group, % time pH<4 in 24 hrs was significantly higher
in distal vs conventional position, Table 1. This was independent to BE length.Also, eso-
phageal acid exposure in BE pts was significantly higher at both locations compared to
controls, Table 2. Conclusions:BE pts have significantly higher acid exposure in distal
compared to proximal esophagus, independent of BE length. Its implications on preferential
location of dysplasia/cancer in distal vs. proximal esophagus needs to be evaluated. This
issue has special relevance given the significant rise in GEJ adenocarcinoma.
Table 1: Acid Exposure in the Proximal vs. Distal esophagus in BE patients
Table 2: Comparison of Percent times pH<4 in BE vs. Controls at both locations
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S1814
The Burden of Upper Gastrointestinal Endoscopy
Michelle E. Kruijshaar, Peter D. Siersema, Marjon Kerkhof, Ewout W. Steyerberg, Marie-
Louise Essink-Bot
INTRODUCTION: Upper gastrointestinal (GI) endoscopy is an invasive diagnostic procedure
that causes pain, discomfort and psychological distress in patients. Regular endoscopic
surveillance, as recommended for patients with Barrett’s esophagus (BE), may therefore be
experienced as burdensome by patients. To what extent it is experienced as burdensome
and whether the burden decreases when patients get used to it is unknown. AIM: We
prospectively assessed the burden of upper GI endoscopy in BE patients under regular
surveillance and in a control group of patients with non-specific upper GI symptoms, and
investigated whether these groups perceived the burden of endoscopy differently. METHODS:
A total of 394 patients (180 BE patients and 214 patients with non-specific GI symptoms)
filled out questionnaires one week before, on the day of, one week after and one month
after upper GI endoscopy. Inclusion criteria were a BE segment of at least 2 cm for the BE
group, and dyspepsia without alarm symptoms for the control group. Four variables were
assessed: 1) pain and burden experienced during endoscopy, 2) symptoms, 3) psychological
distress levels (Hospital Anxiety and Depression scale and Impact of Event Scale), and 4)
perceived risk of developing a malignancy. RESULTS: Patients with non-specific GI symptoms
were diagnosed with a hiatal hernia (45%), non-specific gastritis (25%), reflux esophagitis
(20%), and other (10%). Of all patients, only 16% experienced pain from the endoscopy.
However, 87% reported it to be burdensome. Apart from an increase in sore throat (47%
after endoscopy versus 22% before) the procedure did not cause symptoms. Patients’ distress
levels were increased in the week prior to the endoscopy compared to the week after. BE
patients experienced significantly more burden from the endoscopy (e.g. 7% reported no
burden versus 20% of the control group) but reported lower distress levels compared to
the control group. Patients with a higher risk perception did not report a higher burden or
more psychological distress. Having had more prior endoscopies was associated with lower
distress levels as measured by the impact of event scale. CONCLUSION Upper GI endoscopy
is burdensome for many patients and causes moderate psychological distress. Getting used
to the procedure may reduce distress but increases the burden experienced from the procedure
in BE patients. Recommendations for endoscopic surveillance should take into account the
burden and distress of upper GI endoscopy for patients.
S1815
Increased Microvascular Density Associated with Progression of Barrett’s
Esophagus: A New Target for the Next Generation of Endoscopic Technology
Andrew Ross, Lucas Campbell, Stefan Seewald, Nib Sohendra, Lynne Stearns, Charles
Dye, Amy Noffsinger, John Hart, Irving Waxman
Background: Angiogenesis has been found to be an important factor in the growth malignant
neoplasms, including esophageal adenocarcinoma (EC) arising from Barrett’s esophagus (BE).
When examined using new generation endoscopes employing narrow band imaging (NBI)
technology, irregularities in the mucosal vascular pattern have been found to be predictive
of BE with advanced histopathology (high grade dysplasia or intramucosal adenocarcinoma).
The aim of the current study was to determine whether microvascular density (MVD) is
associated with progression of BE to EC, thus providing a possible “proof-of-principle” for
the use of novel imaging technologies such as NBI in the diagnosis and possible treatment
of BE with advanced histopathology. Methods: Specimens from patients who had undergone
complete Barrett’s eradication endoscopic mucosal resection (CBE-EMR) for the treatment
of high grade dysplasia (HGD) or intramucosal adenocarcinoma (IMC) were selected. CBE-
EMR was directed by both white light endoscopy and NBI. Foci of BE, low-grade dysplasia
(LGD), HGD and EC were selected from each specimen and were stained with anti-CD31.
Following digital scanning, MVD was assessed using Chromavision® software. Mucosa from
the gastric cardia served as control (NC). Results: 178 foci were evaluated. Progression
from normal mucosa to EC was associated with a significant trend of increasing MVD (p=
0.003). Statistically significant differences in MVD (Table) were found between BE and EC
(p=0.043), LGD and EC (p=0.042), NC and HGD (p=0.007) and between NC and EC (p=
0.002). Measurement of MVD from a significant number of additional mucosectomy speci-
mens will be completed over the next several months. Conclusions: An increase in MVD
is associated with neoplastic progression of BE suggesting that neovascularization plays an
important role in the metaplasia-dysplasia-carcinoma sequence in BE. Significant differences
in MVD between the various pathologic stages of this sequence suggest that imaging technolo-
gies such as NBI may be able to accurately identify foci of advanced histopathology based
on the appearance of the mucosal vascular pattern. Such technologies hold promise for
advances in the diagnosis, surveillance and treatment of BE.
P-value comparison of MVD between histopathologic foci
S1816
Cancer Risk in Barrett’s Oesophagus: A Meta-Analysis
Titus Thomas, Keith R. Abrams, John De Caestecker, Richard J. Robinson
Background: The risk of cancer in Barrett’s oesophagus (BO) is uncertain with studies
showing a variable annual incidence (from 1/52 to 1/694). Recent reports have suggested
regional variations in cancer incidence in the West. However no formal meta-analysis has
been performed. Aims and Methods: We aimed to determine by meta-analysis the incidence
of oesophageal cancer in patients undergoing surveillance for BO and to examine geographical
variation. A MEDLINE, EMBASE and Pub Med search of all English articles from 1966 to
2004, using the key words “Barrett’s oesophagus”, “Oesophageal cancer”, “surveillance”,
“short segment Barrett’s” (SSBO) was done. References in retrieved papers and relevant
review articles were scrutinised to identify papers missed on the initial search. Studies with
patients who had histological confirmation of BO on surveillance, documented follow up
data and cancer as the outcome measure were included. Heterogeneity between studies was
calculated using the homogeneity statistic (Q value) and if significant (p<0.05) a random
effects model of meta-analysis was used. Short Segment BO was defined as length of <3cm.
Results: 42 articles were included in the analysis for conventional BO and an additional 7
articles were included for SSBO. The overall cancer prevalence was 11.4% (95% CI 7.6-
17.3%). The overall incidence rate for cancer was 8/1000 person-years duration of follow
up [pyd] (95% CI, 6-10). There was minimal geographical variation, with the incidence
rate in UK being 7/1000 pyd (95%CI 4-12), USA, 8/1000 pyd (95% CI 5-13) and Europe,8/
1000 pyd (95% CI 5-12) The overall cancer incidence in SSBO was 5/1000 pyd (95% CI
2-12). There was a non-significant increase in cancer risk in conventional BO compared to
SSBO (OR 1.6, 95% CI 0.56-4.91, p=0.30). Similarly there was a non-significant increase
in cancer risk in patients who had medical therapy compared to surgical treatment (OR
1.2, 95% CI 0.29-5.0, p=0.78). There was a non-significant reduction of Barrett’s cancer
incidence over time (p=0.11) Conclusion: We found less geographical variation BO cancer
risk than previously suggested between US and UK and a non-significant increase in the
risk of cancer in conventional BO vs SSBO . The cancer incidence in Barrett’s oesophagus
has decreased with time although this is not significant.
S1817
Fourier Transform Infrared (FTIR) Analysis of Esophagus Using Attenuated
Total Reflectance (ATR) for Quantitative Diagnosis of Low Grade Dysplasia
Thomas D. Wang, Peyman Sahbaie, Tarun Bhandari, James Crawford, Lisa Dixon, Shai
Friedland, George Triadafilopoulos, Roy Soetikno, Christopher Contag
Background/Aims: There is significant interobserver variability in the histological diagnosis
of low grade dysplasia from Barrett’s that may be improved with use of Fourier transform
infrared (FTIR). FTIR measures the spectral absorption of infrared light by tissue, producing
a molecular fingerprint that can provide quantitative concentrations of endogenous molecules
using attenuated total reflection (ATR). Methods: FTIR spectra were acquired ex vivo from
fresh biopsy specimens of esophagus (n = 63) from patients with Barrett’s (n = 25) over the
spectral range 950 to 1800 cm-1 using ATR. The concentrations of DNA, protein, glycogen,
and mucin were determined quantitatively using a partial least square fit to a calibration
set from pure components. The corresponding histology was reviewed independently by
two pathologists. Results: The mean concentrations of DNA, protein, glycogen, and mucin
for glandular mucosa (n = 43) were 0.09±0.03, 0.66±0.10, 0.05±0.03, 0.20±0.06 mg%,
respectively, and the average values for dysplasia (n = 20) were 0.13±0.04, 0.71±0.10,
0.02±0.02, 0.14±0.05 mg%, respectively. Low-grade dysplasia (n = 16), determined from
the first pathologist, could be distinguished from glandular mucosa on FTIR by increased
DNA (p=0.02) and decreased mucin (p<0.001). These results agreed with the second patholo-
gist with a sensitivity of 87.5% and a specificity of 88.7%. Conclusions: FTIR spectra can
be quantitatively measured with ATR and reduced to principle components, DNA, protein,
glycogen, and mucin. Theses concentrations can provide adjunctive information for patholo-
gists to distinguish low-grade dysplasia in the setting of Barrett’s.
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Range of FTIR spectra of esophagus (A) squamous, (B) Barrett’s, (C) low grade dysplasia.
S1818
Her-2/Neu in Barrett’s Esophagus: A Comparative Study Between Histology,
Immunohistochemistry and Molecular Technique (FISH)
Elisa Rossi, Domenico Della Casa, Vincenzo Villanacci, Guido Missale, Michele Ghedi,
Gianpaolo Cengia, Renzo Cestari
Introduction: HER-2/neu is a protooncogene frequently overexpressed in breast cancer and
recently found to be overexpressed in other carcinomas and in Barrett’s esophagus (BE).
Immunohistochemistry and Fluorescence In Situ Hybridization (FISH) are conventionally
used for HER-2 testing in carcinomas, but a single assay is not yet accepted as a “gold
standard” in BE. The aim of our study was to evaluate the correlation between histopathologic
characterstics and gene espression/amplification along the sequence BE, low grade dysplasia
(LGD), high grade dysplasia (HGD) and adenocarcinoma. Methods: we collected 50 endos-
copic esophageal biopsies in 42 men and in 8 women with a previous diagnosis of BE.
Histopathologic evaluation was carried out using Hematoxylin & Eosin staining. Paraffin
embedded tissue was studied using the HercepTest kit for immunohistochemistry (HercepT-
est DAKO) and PathVysion kit (PathVysion HER-2 DNA Probe Kit, Vysis) for FISH. HercepT-
est was scored 0, 1+, 2+ and 3+ depending on % membrane staining (cutoff 10%), and
assessment of gene amplification was based on the ratio between the copy number of HER2/
neu and 17 chromosome. The number of chromosome 17 and HER2/neu signals was scored
based on 60 non overlapping nuclei, and HER-2/neu was judged as amplified when the
ratio was >2. Results: 21 BE, 4 LGD, 12 HGD and 13 cancer of the esophagogastric junction
were observed. There was a positive correlation (correlation coefficient 0.88) between gene
amplification and protein overexpression. In no cases with HercepTest scoring 0 or 1+ was
gene amplification detected, but this was present in 20% of cases scoring 2+ and in all cases
scoring 3+. Her-2/neu amplification or overespression was never observed in BE. Coefficient
of correlation between the Her-2/neu gene and protein was lower for LGD and HGD when
compared to histology (0.51 and 0.68 respectively). Gene amplification and overespression
was observed in 7 out of 13 adenocarcinomas. Conclusion: Our results suggest that HER-
2/neu amplification/overexpression may be considered as a marker of progression from BE
to dysplasia. The FISH technique may represent an important and useful diagnostic tool to
integrate the result of HercepTest for selecting patients for immunotherapy.
S1819
Patients with Barretts Esophagus Experience Less Reflux Complaints
Ahmed Madisch, Stephan Miehlke, Susanne Sell, Bernd Wigginghaus, Manfred Stolte
Background: Barrett’s epithelium is assumed to be more resistant to aggressive stomach
contents. Thus, it can be postulated, that sensory perception may be less in patients with
Barrett’s oesophagus (BE). Aim: to assess the severity of reflux complaints in consecutive
patients presenting with Barrett’s esophagus and reflux esophagitis. Methods: Prospectively
consecutive patients with BE (diagnosed by histology) were interviewed by standardized
questionnaires comprising both current and history of reflux complaints (heartburn, acid
regurgitation). Patients with a reflux esophagitis diagnosed by endoscopy served as a control
group. Results: 181 patients with BE (60 female, mean age 58.4 years) and 85 patients with
reflux esophagitis (36 female, mean age 50.6 years) were included in the analysis. Severity
and frequency of current reflux complaints were significantly more pronounced in patients
with reflux esophagitis than in patients with BE (p<0.05). In both groups younger patients
(< 60 years) suffer from more severe and frequent reflux complaints than the older patients
(p<0.05). Endoscopy in the past was performed in 76.1% of reflux esophagitis patients due
to reflux complaints compared to 47.9% in BE patients (p< 0.0001). The history of reflux
complaints were comparable in both groups (p>0.05). Conclusion: Patients with BE suffer
less from reflux complaints than patients with reflux esophagitis. Thus, reflux complaints


















Abnormal Expression of Biomarkers in Incompletely Ablated Barrett’s
Esophagus
Katerina Dvorak, Lois Ramsey, Claire M. Payne, Richard Sampliner, Lisa Camargo, Ronnie
Fass, Harris Bernstein, Carol Bernstein, Anil Prasad, Harinder Garewal
Background & Aims: Barrett’s esophagus (BE) is a premalignant lesion of the esophagus in
which squamous epithelium is replaced by metaplastic columnar epithelium (intestinal
metaplasia, IM). Ablation of IM and its replacement by squamous epithelium is achievable
by combining a endoscopic ablation method with acid suppression. We previously found
that when there is complete ablation, the neo-squamous epithelium is normal histologically
and in biomarker expression. However, squamous islands observed after prolonged use of
PPIs were associated with abnormalities in p53 expression and Ki-67 labeling at the new
squamous junctions. The aim of the present study was to extend these observations to areas
of new squamo-columnar junctions resulting from incomplete ablation produced by reinjury
and proton pump inhibitors (PPIs) in patients with non-dysplastic (ND) BE prior to ablation.
This report extends and confirms our previous observations and includes two new biomark-
ers, DNA repair enzyme, Ref-1 and cyclooxygenase-2 (COX-2), Methods: Twenty-one non-
dysplastic BE cases with incomplete ablation were evaluated for the expression of Ref-1,
p53, COX-2 and proliferation (Ki-67) by immunohistochemistry. We focused on junctional
areas, i.e. biopsies displaying both squamous epithelium and IM, as we previously found
abnormal biomarker expression localized at the junctions. Results: Pre-ablation biopsies that
were ND showed the expected normal staining patterns in columnar epithelium, i.e. negative
or mild staining for Ref-1 and p53 expression, normal Ki-67 labeling and rare positive COX-
2 staining of interstitial cells. In contrast, post-ablation biopsies demonstrated abnormal
staining patterns in the glandular area at the new squamo-columnar junctions. Increased
expression of Ref-1 was detected in 6 out of 19 (32%) patients. In 13 of 21 post-ablation
cases (62%), increased Ki-67 staining was observed in BE glands at squamo-columnar
junctions. Similarly, in 8 of 21 post-ablation junctions (38%) there was increased p53
staining, and in 8 out of 21 patients (38%) there was increased COX-2 expression in
columnar epithelium. Conclusions: Our findings of increased expression of cancer-associated
biomarkers in BE patients with incomplete endoscopic ablation raise a cautionary note
regarding this procedure. We hypothesize that newly formed junctions contain cells experien-
cing increased stress and are thus more susceptible to genomic damage.
S1821
Systematic Review of Adenocarcinoma Risk in Barrett’s Esophagus with
Particular Reference to short Segment Barrett’s Esophagus and Intestinal
Metaplasia
Jose Santana, Mostafizur Khan, Nimish Vakil, Paul Moayyedi
Introduction: Surveillance is recommended for Barrett’s esophagus as this condition is
associated with an increased risk of esophageal adenocarcinoma. The magnitude of the risk
is uncertain as a previous systematic review suggested there was publication bias in the
literature. Furthermore definitions of Barrett’s have changed to include short segment Barrett’s
esophagus (SSBE) and to exclude those in whom intestinal metaplasia (IM) is not present
regardless of length of the Barrett’s segment. We have therefore conducted an up to date
systematic literature review to identify current esophageal adenocarcinoma risk and assess
the risk in those with SSBE and those without IM. Methods: An electronic database search
(Medline and Embase) was conducted to July 2005. Eligibility and data extraction was
performed by two independent reviewers. Rates of conversion to esophageal adenocarcinoma
were synthesised using a random effects model (DerSimonian and Laird). Funnel plots were
produced for each comparison, and Egger’s test for funnel plot asymmetry was used to
investigate whether or not the results were affected by publication bias. Results: 46 papers
were eligible evaluating 11,056 cases of Barrett’s esophagus in 42,880 patient-years follow-
up, with 255 cases of esophageal cancer. The overall incidence ratio was 0.75% per year
(95% CI = 0.56% to 1.0% per year). There was no funnel plot asymmetry (p=0.19) in these
data. Nine papers compared the esophageal cancer risk in long segment Barrett’s (LSBE)
versus SSBE. There were 66 cancers in 5295 patient years follow-up in the LSBE group
compared with 9 cancers in 1311 patient years follow-up in the SSBE group (0.67% per
year increased risk in LSBE group: 95% CI = 0.39 to 0.94%). Three papers compared the
esophageal cancer risk in Barrett’s with and without IM at baseline. There were 41 cancers
in 7834 patient years follow-up in the IM group compared with 3 cancers in 1966 patient
years follow-up in the no IM group (0.59%/year increased risk in IM group: 95% CI = 0
to 1.2%). Conclusion: This up to date systematic review suggests the annual esophageal
adenocarcinoma risk in Barrett’s patients is 0.75% (95% CI =0.56% to 1.0%) and this is
not subject to publication bias. Current practice of including SSBE but excluding patients
without IM regardless of length of Barrett’s is illogical given the relative cancer risks.
S1822
Loss of Goblet Cell Differentiation Occurs with the Progression of Dysplasia
in Barrett’s Esophagus
Amitabh Srivastava, Jason L. Hornick, Xiaohong Li, Carissa Sanchez, Brian J. Reid, Robert
D. Odze
Background: Barrett’s esophagus (BE) is defined by the presence of intestinalized epithelium
[i.e., goblet cells (GC)] in the esophagus. It is commonly believed that this type of epithelium
forms the “field” upon which dysplasia develops. However, the specific role of GC’s is the
pathogenesis of dysplasia in BE has never been evaluated. The aim of this novel study was
to evaluate GC density in relationship to dysplasia, and to correlate this feature with outcome
in a large prospective surveillance cohort of BE patients that began in 1983. Design: 3778
routinely processed biopsies from 151 BE patients (M/F ratio;134/17, mean age; 62 years,
mean length of BE; 6.5 cm, mean surveillance duration; 55.9 months), 63 of whom eventually
developed cancer, were evaluated for the number (#) of GC’s per crypt by counting all GC’s
in each biopsy and dividing this number by the total number of crypts per biopsy specimen,
in both dysplastic and non-dysplastic epithelium separately. Non-dysplastic epithelium, both
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adjacent to and distant from dysplasia, was also evaluated. The mean # of GC/crypt (“GC
density”) was correlated with the degree of dysplasia, and with cancer development, using
a Cox regression model to account for follow-up intervals and censored data. Result: The
total GC density in non-dysplastic crypts (5.1) was significantly higher than in dysplastic
crypts (0.4, p<0.0001). Interestingly, the GC density in non-dysplastic epithelium from
patients without dysplasia (5.63) was significantly higher than in non-dysplastic epithelium
from patients with either low-grade dysplasia (LGD) (4.58) or high-grade dysplasia (HGD)
(4.65) as their maximum dysplasia diagnosis (p<0.01 for both comparisons). GC density
in non-dysplastic crypts did not correlate highly with risk of carcinoma (relative risk; 0.98,
p=0.09). Conclusion: Loss of GC differentiation is associated with the progression of dysplasia
in BE. GC density in non-dysplastic crypts is not a useful predictor of cancer risk in BE.
S1823
Histological Evaluation of Resection Specimens Obtained At 244 Endoscopic
Resections in Barrett’s Esophagus
Femke P. Peters, Lianne P. Brakenhoff, Wouter L. Curvers, Wilda D. Rosmolen, Fiebo J.
Ten Kate, Kausilia K. Krishnadath, Paul Fockens, Jacques J. Bergman
Aim To study the histological evaluation of endoscopic resection (ER) specimens of early
neoplastic lesions in Barrett’s esophagus (BE). Patients and methods Routine histological
evaluations of ER specimens obtained at all ERs in BE performed between ‘00-’05 were
evaluated. Specimens were pinned down on paraffin (mucosal side up) and immediately
fixed in 2% formalin. No attempts were made to reconstruct the specimens after piece-meal
resection. Specimens were cut in 2 mm slices. Standard H&E staining was performed on
4 µm slides and, if necessary, supplemented with p53 and Ki-67 immunohistochemical
staining. All evaluations were performed by two experienced pathologists. Results 244 ERs
were performed for low-grade intraepithelial neoplasia (LGIN) in a dysplasia associated
lesion or mass (n=1), high-grade intraepithelial neoplasia (HGIN) (n=82), early carcinoma
(EC) (n=53) or removal non-dysplastic BE (n=108) for stepwise radical endoscopic resection
(SRER). In 194 ERs a piece-meal resection was performed: 97 for HGIN/EC and 97 for
SRER with median number of 3 resections (IQR 2-5). A total of 921 specimens were obtained.
Histology of the specimens revealed no dysplasia in 48 ERs (all SRER), LGIN in 42, HGIN
in 89, T1m in 50, and T1sm in 15 ERs. Fifty cancers (77%) were classified as well differentiated
(G1). Moderately (G2) or poorly (G3) differentiated lesions were found in 8 (12%) and 7
(11%) of cancers, respectively. G2-3 cancers significantly more often invaded the submucosa
than the G1 cancers (10/15 vs. 5/50, p<0.001). One G3 T1m3 (penetration into second
muscularis mucosae layer) tumor showed lymph vessel invasion. In none of the 921 resection
specimens vascular invasion was observed. Specimens of 14 ERs (5%) had a deeper margin
positive for neoplasia. Significantly more G2-3 cancers were irradically removed (6/15 vs
6/50; p=0.024). Of the attempted en-bloc resections, only 8 out of 52 specimens (22%)
had lateral margins that were found to be free of HGIN/EC. Mechanical and thermal artefacts
interfering with the histological evaluation were seen in 61 (23%) of the procedures. Conclu-
sions Most endoscopically resected early neoplastic lesions in BE contain HGIN or G1
mucosal cancers, and have a deeper margin free of neoplasia. Submucosal invasion is
associated with a poorer differentiation grade and invasion into lymph vessels or blood
vessels are rare findings. The majority of ERs require piece-meal resection and in cases
where an en-bloc resection is attempted, only the minority of the ER specimens have lateral
resection margins free of dysplasia. In addition, artefacts affect histological evaluation in a
significant percentage of specimens.
S1824
Flow Cytometry As a Marker of Occult Advanced Neoplasia in Barrett’s
Esophagus
Wai-Kit Lo, Timothy Kuo, Jason Hornick, Chinweike Ukomadu, John M. Poneros
Background: Previous studies suggest that flow cytometric abnormalities may predict malig-
nant potential better than histology in patients with Barrett’s esophagus (BE). Aim: To
compare the DNA content in non-dysplastic BE (NDBE) specimens from patients with and
without esophageal adenocarcinoma (ADC) or high-grade dysplasia (HGD). The hypothesis
being tested is that the fraction of cells in S-phase from NDBE specimens from patients with
ADC or HGD is higher than the S-phase fraction from NDBE specimens from patients
without coincident ADC/HGD. Methods: 135 biopsies were obtained from 24 patients with
known BE undergoing EGD for BE surveillance (2/24) or BE-associated ADC undergoing
EUS tumor staging (22/24). Biopsies were taken as per standard BE surveillance protocol,
consisting of 4-quadrant “jumbo” biopsies every 2 cm of BE. Biopsies were bisected; half
was sent for flow cytometric analysis and half for routine histopathologic interpretation. All
histologic samples were reviewed by a single gastrointestinal pathologist. Data were stratified
according to the pathologic diagnosis of each sample and the highest histologic grade of
dysplasia (or carcinoma) identified in each patient. Differences in cell cycle populations
were calculated using a Student’s t-test with two-tailed distribution assuming equal variance
and independence between specimens. Results: After refining the cell sorting technique, 79
samples contained cells that were sufficient for cytometric analysis; these were collected
from 18 different patients. Significantly higher fractions of cells in S-phase were found in
NDBE samples from patients with a history of ADC/HGD (n=15, avg. 27.3%), compared
with NDBE from patients without a history of ADC/HGD (n=11, avg. 20.8%) (p=0.03).
There was also a difference between the combined S-phase and G2 (tetraploid) fractions in
NDBE samples from patients with ADC/HGD (n=15, avg. 35.3%) compared with those
without ADC/HGD (n=11, avg. 29.4), although this did not reach statistical significance (p=
0.057). S-phase fractions were significantly elevated in ADC samples (n=13, avg. 28.8%)
compared with NDBE without a history of ADC/HGD (p=0.04). However, in patients with
ADC/HGD, there was no significant difference in the S-phase fractions between ADC samples
and NDBE specimens. Conclusion: S-phase fractions of cells as measured by flow cytometry
were significantly different in NDBE specimens in patients with and without ADC/HGD.
These preliminary findings suggest that flow cytometry may be useful in the detection of
coincident advanced neoplasia in patients with BE.
S1825
Prevalence of Barrett’s Esophagus in a Population Not Primarily Referred for
Gastro-Esophageal Reflux Disease
Brechje C. van Eijck, Leonieke M. Wolters, Herman van Dekken, Ernst J. Kuipers, Peter
D. Siersema
Background: Cancer of the esophagus, particularly esophageal adenocarcinoma (EAC), is
the fastest growing malignancy worldwide. Barrett’s esophagus (BE) is an important risk
factor for EAC. As it is largely unknown what the prevalence of BE is in asymptomatic
individuals, we aimed to study the prevalence of BE in a population which was not primarily
referred for upper gastrointestinal (GI) complaints. Methods: A total of 250 patients under-
going routine, non urgent colonoscopy were included in this study. All patients underwent
an upper GI endoscopy prior to colonoscopy. All patients filled out the Gastrointestinal
Symptom Rating Scale (GSRS). Biopsies were taken from the Z-line (n=4), and, if BE was
suspected, additional 4-quadrant biopsies were taken. Also, biopsies were taken from antrum
(n=2) and corpus (n=2) to detect H. pylori infection. All biopsies were reviewed by an
experienced GI pathologist. Results: In 22 of 250 patients (9%, 95% CI 5.6 - 13.0%),
endoscopical BE (20 short-segment (SS) (≤2 cm) and 2 long-segment (LS) (>2 cm)) was
found and histologically confirmed (intestinal metaplasia). In these 22 patients, 18 had no
dysplasia and 4 had low-grade dysplasia. In another 15 patients (6%), an endoscopic diagnosis
of SSBE was histologically not confirmed. In 12 patients (5%), intestinal metaplasia of
the cardia was found without endoscopical evidence of columnar epithelium in the distal
esophagus. Two patients (1%, 95% CI 0.1 - 2.9%) were diagnosed with EAC (a T2N0M0
and T2N1M1 tumor respectively). H. pylori was found in 50 of 250 patients (20%). BE
patients (mean ± SD: 59.6 ± 9.6 yrs) were older than patients without BE (51.7 ± 14.6 yrs)
(p=0.015), but gender was not different. In addition, no significant differences were found
between subjects with and without BE with respect to smoking (33% vs. 26%, respectively),
alcohol intake (66% vs. 61%), use of proton pomp inhibitors (18% vs. 18%), use of NSAID/
aspirin (23% vs. 16%), H. pylori infection (27% vs. 19%) or prevalence of a BMI>25 (57%
vs. 41%). Gastrointestinal symptoms, including reflux symptoms, were not different between
patients with BE and those without (31% vs. 33%). Conclusions: BE was detected in 9%
and EAC in 1% of patients not primarily referred for evaluation of GERD symptoms. A
major question that arises from this prospective study is whether endoscopic screening for
BE should be applied to the general population in an effort to identify patients with BE and
offer them endoscopic surveillance to detect neoplastic changes at an earlier and therefore
more curable stage.
S1826
Suppression of Acid Reflux with Double-Dose Esomeprazole for 6 Months
Does Not Alter DNA Methylation in Patients with Barrett’s Esophagus
Eric Smith, Paul A. Drew, Awni Abu-Sneineh, William C. Tam, Andrew R. Ruszkiewicz,
Mark N. Schoeman, John Dent, Richard H. Holloway
Introduction: Barrett’s esophagus is a sequela of longstanding gastroesophageal reflux and
is a major risk factor for adenocarcinoma. Aberrant DNA methylation is frequent in Barrett’s
esophagus and adenocarcinoma and may contribute to the disease progression. Aim: To test
the hypothesis that short term high-level acid reflux control by esomeprazole 40 mg bd in
patients with Barrett’s esophagus will reduce DNA methylation in the esophageal mucosa.
Method: Eighteen patients with histologically proven Barrett’s esophagus on standard doses
of PPI (omeprazole 20 mg, lanseprazole 30 mg or pantoprazole 40 mg) were studied before
and after 6 months treatment with esomeprazole 40 mg bd. Esophageal acid exposure was
measured by 24 hour pH monitoring before and 2 months after starting esomeprazole.
Biopsies were obtained at 2 cm intervals from the columnar epithelium and from the adjacent
squamous epithelium of the esophagus before and after 6 months of treatment. In each
biopsy methylation was measured in the promoter region of 9 genes - APC, CDKN2A, ID4,
HPP1, MGMT, RBP1, RUNX3, SFRP1 and TIMP3. Results: Nine patients of the 18 patients
had excessive (pH>4 of >5% of the time) acid reflux on standard PPI therapy. Esomeprazole
40 mg bd effectively eliminated acid reflux in 16 of 18 patients (pH<4, <1%) and substantially
reduced it in the other 2 patients although it remained increased (6.5% and 11.7%). There
was significantly more methylation in the columnar epithelium of all patients compared to
the squamous epithelium (p<0.0001) both before and after 6 months of treatment. However,
there was no statistical difference in the methylation in the columnar epithelium of patients
who had reflux compared to those that did not have reflux, either before commencement
or after 6 months of treatment. Conclusions: Effective control of acid reflux with esomeprazole
40 mg bd neither increased nor decreased the amount of methylation in the panel of relevant
gene promoters tested, either in patients whose reflux was controlled at the start of the trial,
or those with reflux at the start of the trial which was reversed by the treatment. These
findings suggest the need for further study to determine the benefit of the control of acid
exposure in preventing or reversing abnormal DNA methylation in Barrett’s esophagus, and
the possible development of adenocarcinoma. (Supported by Grant-in Aid from AstraZeneca)
S1827
Impaired Gallbladder Motility in Patients with Barrett’s Esophagus
Ferenc Izbeki, Andras Rosztoczy, John Y. Sebit, Janos Lonovics, Tibor Wittmann
Background: Although duodenogastric biliary reflux has been demonstrated to occur more
frequently in patients with different motility disorders of the gallbladder and biliary reflux
is claimed to have a pathogenetic role in the development of Barrett’s esophagus (BE) in
patients with gastroesophageal reflux disease (GERD), the gallbladder function in patients
with BE is yet to be studied. Therefore the aim of the present study was to investigate the
gallbladder motility in patients with Barrett’s esophagus. Materials and methods: Three
groups were studied: 18 healthy volunteers, 14 patients with GERD and 24 patients with
BE. The diagnosis of BE based on endoscopic and histological evaluation of the patients.
All patients with GERD had abnormal 24 hours esophageal pH monitoring, while those
with BE had abnormal Bilitec results as well. Each subject in the three groups underwent
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abdominal ultrasound (US) examination of the gallbladder. Gallbladder volume was calcu-
lated by the ellipsoid method. The US examination was done after an overnight fast. The
gallbladder volume was measured in fasting state (BV) and after consumption of a standard-
ized test meal at 10 minutes intervals for 90 minutes. Parameters, such as (1) Ejection
volume (EV) the difference between BV and residual volume (RV); (2) Ejection fraction
(EF%) the difference between BV and RV expressed as percentage BV; (3) Ejection rate (ER
%/min) EF divided by time requested to reach the RV were calculated. Results: All of the
studied parameters were similar in patients with GERD and in controls. Patients with BE
had significantly higher BV (24.7±3.5 ml vs. 21.6±1.9 ml), RV (9.8±2.9 ml vs. 5.1±0.7ml)
and lower EF (61.0±7.2% vs. 76.1±2.1%), ER (1.07±0.29 %/min vs. 1.39±0.21%/min)
values than healthy controls. Patients with BE had also significantly higher RV (9.8±2.9 ml
vs. 6.1±0.9 ml) and lower EF (61.0±7.2% vs. 72.9±4.3%) than those with GERD. Conclusion:
Our results support the notion that patients with BE have a more complex gastrointestinal
motility disorder involving the gallbladder also than those with uncomplicated GERD.
S1828
Prospecive Evaluation of the New Prague Classification for Barrett’s Esophagus
Andreas Leodolter, Peer Oberueber, Dietmar Zielinski, Michael Vieth, Manfred Stolte,
Jochen Labenz
An endoscopic classification of Barrett’s esophagus (BE) does not exist. In 2004 an interna-
tional consensus group proposed the Prague classification for endoscopic assessment of BE.
The aim of the present study was to evaluate the performance and validity of the new
classification in clinical practice. Methods: 110 consecutive patients (65m, 45f) with endos-
copic suspicion of columnar epithelium lined lower esophagus, attending our endoscopy
unit, entered the study. The esophageal findings were printed and the endoscopist classified
the findings according to the Prague classification: measurement of the circumferential (C)
and maximal extension of the columnar epithelium above the top of the gastric folds. Biopsies
were taken for histological assessment at the stomach, columnar epithelium of the lower
esophagus, and from the squamous epithelium 2cm above the Z-line. Furthermore all
patients answered a standardized questionnaire (GERD symptoms, past GERD symptoms,
concomitant diseases, smoking, ethanol intake). Results: In 47 patients (43%) the endoscopic
suspected BE was confirmed by histology. Symptom pattern was not different between
patients with or without confirmed BE. Even in short tongues (<5mm) the probability of
detecting intestinal metaplasia was around 30%, comparable to the detection rate in tongues
up to 20mm. In patients with tongues of 20mm or circumferential extension the likelihood
of histological confirmation of BE is high. Conclusion: The new Prague classification is useful
for standardized endoscopic assessment of BE in the daily clinical practice. In almost all
patients with circumferential extension or tongues of columnar epithelium of more than
20mm, specialized intestinal metaplasia was found on histology, whereas only one third of
the patients had true BE if the tongues were less than 20mm.
S1829
Is C-Myb mRNA Over Expression a Good Molecular Marker for Low-Grade
Dysplasia in Barrett’s Esophagus (BE)?
Christo van Rensburg, Caroline Daniels, Colleen Wright, Martin Kidd, Nico de Villiers,
Maritha Kotze
Background The subjective histological evaluation of mucosal biopsy specimens to predict
cancer risk in BE is an ongoing concern and thus the development of molecular markers
that can objectively identify these patients is highly desirable. To date, the most promising
markers seem to be molecular abnormalities (mutations and loss of heterozygosity) of p16
and p53, although DNA ploidy has potential use. In a pilot study significantly more (p=
0.03) patients (9/13) with low grade dysplasia showed over expression of c-myb mRNA
compared with patients (9/26) with only Barrett’s metaplasia (BM). Currently immuno-
staining for p53 has a potential, but undefined role in the histological assessment of dysplasia
in biopsy specimens of BE. Objective To evaluate the role of c-myb mRNA over expression
as an adjunct in differentiating low-grade dysplasia in BE from BM and inflammatory atypia
and to correlate these findings with TP53 immuno-staining of the biopsy specimens. Patients
and Methods Two expert gastro-intestinal patologists reviewed and reached consensus on
the histological diagnoses. The c-myb mRNA expression in the Barrett’s epithelium was
determined by RT-PCR. The histological specimen for TP53 immuno-histochemistry was
stained with a rabbit polyclonal antibody (NCL-p53-CM1, Novocastra Laboratories Ltd),
and scored by using a semi-quantitative scale from 0 to 3+ as follows: 0, fewer than 1% of
cells staining; 1, up to 10% of cells staining, primarily in the lower third of the crypts; 2,
more than 10% but fewer than 50% staining; and 3, more than 50% of cells staining. Results
A total of 55 Barrett’s patients of whom 36 had BM and 19 with mild dysplasia (BD) were
evaluated. Over expression of c-myb mRNA occured in 39% (14/36) of the BM patients
and 63% of the mild BD (12/19; p<0.05). The results of the consensus histological diagnoses
correlated with p53 immuno-staining intensity are summarized in table 1. Compared to

















However, TP53 staining of 2+ and 3+ intensity was similar in both groups (58%). Conclusion
In this study c-myb analysis enhanced the diagnostic assessment of low-grade dysplasia in
BE significantly. TP53 immuno-staining though positive in more than 80% patients with
mild BD, does not help to differentiate mild BD from BM.
Table 1. Results of intensity of TP53 staining of Barrett’s oesophagus specimens. Data are
given as number (percentage).
S1830
No Uniform Approach for the Treatment of High Grade Dysplasia and Early
Carcinoma in Barrett’s Esophagus Patients
Wouter L. Curvers, Henk Festen, Wim Haameteman, Gerard A. Meijer, Frans T. Peters,
Pieter D. Siersema, H W. Tilanus, Jacques J. Bergman
Introduction Barrett’s esophagus (BE) is a premalignant condition for which endoscopic
surveillance is recommended. The last few years the effectiveness of endoscopic surveillance
programs in BE patients has been questioned. In order to develop new guidelines the Dutch
Barrett’s Registration Foundation sent out a questionnaire to all Dutch gastroenterologists
and internists performing endoscopy to assess the current status of surveillance and manage-
ment of BE patients in the Netherlands. Methods A questionnaire consisting of 42 questions
on the general organisation of Barrett’s surveillance programs and daily management of BE
patients was sent to 337 endoscopists. A reminder was send to all endoscopists who had
not responded after 6 weeks. For all endoscopists who had not responded after the reminder,
the addresses were checked and a third mailing was sent. Finally, all endoscopists who had
not complied after the third mailing received again an email with the request to fill out the
questionnaire. Results The response rate was 86%. Ninety-six percent of the responders
supported Barrett’s surveillance. Barrett’s surveillance was mainly conducted according to
the current ACG guidelines. Co-morbidity and age played an important role in the decision
to initiate Barrett’s surveillance and in the treatment choice for high grade dysplasia (HGD)
and early carcinoma (EC) in BE. There was, however, no uniform approach in the management
of patients with HGD and EC. Surgical resection was often the treatment of choice despite
of the good results that are currently achieved with endoscopic treatment of these lesions.
If confronted with a 55-year old patient with HGD, 30% chose for surgical resection, whereas
91% chose surgical resection if the same patient had a 1 cm nodule with adenocarcinoma.
Fifty-four percent chose for surgery in a 75-year old patient with adenocarcinoma in a 1
cm nodule. Of all responders, 39% would treat patients with HGD and EC in a center with
no specific expertise in this field and without consulting the available multidisciplinary
Barrett’s advisory organs in The Netherlands. Conclusion Endoscopic surveillance for BE is
widely accepted in the Netherlands. The treatment of patients with HGD and EC in BE,
however, varies considerably. There is a need for more awareness of the possibilities of
endoscopic treatment of HGD and EC in BE patients. Until proven otherwise, these type
of patients should probably be treated in centers with ample experience in endoscopic
treatment. New guidelines for the treatment of HGD and EC need to be developed. Astra
Zeneca BV, Netherlands, supported this study with an unrestricted grant.
S1831
Immunohistochemical Evaluation of COX-2, CDX2 and CDC2 in Barrett’s
Esophagus-Dysplasia-Adenocarcinoma Progression
Vincenzo Villanacci, Elisa Rossi, Domenico Della Casa, Paolo Lancini, Luigi Minelli,
Guido Missale, Claudia Zambelli, Renzo Cestari
Introduction: Barrett’s esophagus (BE) is a pre-neoplastic condition and early detection of
dysplasia in Barretts’s progression to cancer is the key point in clinical practice. Gastrointesti-
nal pre-neoplastic conditions can be assessed using COX-2 (Ciclooxigenase-2), CDX2 (caudal
type homeobox transcription factor 2) and CDC2 (cell division cycle 2) expression, and the
aim of our study was to evaluate COX-2, CDX2 and CDC2 expression in the sequence BE-
dysplasia-adenocarcinoma (ADC) as a tool for early detection of dysplasia in BE. Methods:
We studied 46 esophageal biopsies (18 BE, 15 dysplasia and 13 ADC) by comparing
histopathologic characteristics (Hematoxylin & Eosin) with COX-2, CDX2 and CDC2 immu-
noistochemical expression. Monoclonal antibodies were used according to manufacturer
instructions. Results: COX-2 expression was overexpressed in all 3 conditions and did not
correlate with BE-dysplasia-ADC sequence, but it was however significantly correlated with
the degree of differentiation (grading) in ADC. Percentage of nuclear CDX2 positive cells
decreased from 71% to 35% and 17% for BE, low grade (LGD) and high grade dysplasia
(HGD), respectively. In ADC 30% of cells were CDX2 positive, a value unaffected by cancer
grading. Percentage of CDC2 positive cells significantly increased from 2% in BE, to 6% in
LGD and to 49% in HGD (p< 0.05). In ADC 63% of cells were CDC2 positive, and positivity
was significantly correlated (p=0.003) with cancer grading. Conclusions: Our results show
an uniform COX-2 expression in all samples analysed, with slight differencies in ADC. By
contrast with COX-2, CDC2 expression was increased and CDX2 was decreased during
progression from BE to ADC (Figure), suggesting that these markers might be useful in
clinical practice for early detection of HGD.
T : 89386$$CH2
05-04-06 23:18:27 Page 266Layout: 89386B : e
A-266AGA Abstracts
S1832
Meta-Analysis of Bleeding with Low-Dose Aspirin and Clopidogrel in
Randomized Controlled Trials
Kenneth McQuaid, Loren Laine
BACKGROUND: Prior meta-analyses of low-dose aspirin have shortcomings: doses outside
the accepted 75-325mg range are included, concurrent anticoagulant use is allowed, duration
of therapy is not considered, all CV prevention studies are not included, the most clinically
relevant results (absolute increase in incidence, number needed to harm (NNH)) are not
provided. METHODS:PUBMED and Cochrane CCTR were searched for RCTs of aspirin
(75-325 mg qd) and/or clopidogrel therapy for prevention of CV disease. Primary endpoints
were major bleeding (author-defined, or led to hospitalization, transfusion, or death) and
intracranial bleeding. RESULTS: 25 studies were included. Study quality was good: Jadad
score (0-5) was ≥3 in 23 studies and ≥4 in 19. Aspirin vs. Placebo: Meta-analysis of
placebo-controlled aspirin trials is shown in the Table. The weighted incidence of major GI
bleeding with placebo was 0.12% per year. The absolute increase in incidence with aspirin
above placebo was 0.12% per yr (95% CI, 0.07-0.19% per yr) and NNH at 1 yr was 833
(526-1429). Aspirin vs. Clopidogrel: No study compared clopidogrel with placebo. One
RCT (N=19,485) compared clopidogrel with aspirin 325mg. The RRs of major GI bleeding
(RR 1.45; 1.00-2.10) and all GI bleeding (RR 1.34; 1.11-1.61) were increased in patients
taking aspirin. The absolute increase in incidence of major GI bleeding was 0.12% per yr
(0.00-0.28% per yr) with an NNH at 1 yr of 833 (95 % CI, 357-∞). The cost to prevent
one major GI bleeding episode from aspirin in 1 yr by substituting clopidogrel would be
$1,216,180. Aspirin + Clopidogrel vs. Either Alone: Two RCTs (N=20,161) revealed a
decreased risk with aspirin alone (RR=0.56; 0.39-0.80) and with clopidogrel alone (RR=
0.34; 0.23-0.51). CONCLUSIONS: Low-dose aspirin doubles the risk of major GI bleeding
compared to placebo, but the absolute increase in annual incidence is modest at 1.2 patients
per thousand. An increased risk with “higher” low-dose vs. “lower” low-dose aspirin was
not seen. Aspirin increases major GI bleeding by 1.5-fold vs. clopidogrel, but the absolute
increase is small and switching to clopidogrel to avoid a major GI bleeding episode is not likely
to be cost-effective. Combined therapy significantly increases risk vs. either therapy alone.
META-ANALYSIS OF ASPIRIN VS. PLACEBO RCTS
S1833
Association of Upper Gastrointestinal Bleeding and Nonsteroidal Anti-
Inflammatory Drugs in Japan: A Case-Control Study
Choitsu Sakamoto, Kentaro Sugano, Shinichi Ota, Susana Perez, David Kaufman,
Tsugumichi Sato, Kiyoshi Kubota, Akira Terano
Background & Aims: Upper gastrointestinal bleeding (UGIB) is a common problem for all
nonsteroidal anti-inflammatory drugs (NSAIDs). There have been only a few epidemiological
studies of this relationship in Japan, where the prevalence of H. pylori infection is high. In
this study we estimated the association between UGIB and non-aspirin NSAIDs (NANSAIDs)
as well as other risk factors including H. pylori. Methods: Cases of UGIB due to duodenal
or gastric ulcer or gastritis were identified in 14 study hospitals in various areas of Japan.
The final eligibility was judged by 3 GI specialists. For each case, 2 controls were identified
from the same district from population registries. Information on drugs and other risk factors
was obtained from 175 cases and 347 controls by telephone interviews after informed
consent was obtained. Anti-H. pylori antibody in the urine was measured in a single laboratory
for all of the cases and 225 controls. Conditional logistic regression was used to estimate
risk adjusted for various risk factors Results: The odds ratio (OR) of UGIB was 5.5 (95%
CI: 2.5-11.9) for aspirin and 6.1 (95% CI: 2.7-3.4) for other NSAIDs (NANSAIDs). The OR
for regular use was higher than for occasional use both for aspirin (7.7 vs. 2.0) and NANSAIDs
(7.3 vs. 4.1). Compared with light alcohol consumption (<1 drink or 14 gram of ethanol
per day), the multivariate OR was 1.2 (95% CI: 0.6-2.5) for 1-3 drinks per day, and 2.8
(95% CI: 1.3-5.8) for≥4 drinks per day. Compared with no smoking, the OR was significantly
increased, at 3.2 (95% CI: 1.6-6.3) for <20 cigarettes per day and 3.2 (95% CI: 1.9-5.4)
for ≥20 cigarettes per day. The OR for history of non-bleeding gastric or duodenal ulcer
was 2.2 (95% CI: 1.3-3.7). When 175 cases and 225 controls with known H. pylori status
were subdivided according to the use of NSAIDs (aspirin plus NANSAIDs) and H. pylori
status, relative to a baseline of no use of NSAIDs and negative H. pylori infection, the crude
OR for the use of NSAIDs and negative H. pylori was 4.9 (1.8-13), that for no use of NSAIDs
and positive H. pylori was 5.4 (2.8-10) and that for use of NSAIDs combined with positive
H. pylori was 10.4 (4.6-23). The relative excess risk due to the interaction between H. pylori
infection and NSAIDs was only 1.2 (95% CI -5.8-8.1). Conclusions: NSAIDs increase the
risk of UGIB in Japan as in Western countries, with a similar magnitude of association.
Heavy drinking, cigarette smoking and previous history of non-bleeding gastric or duodenal
ulcer also increased the risk of UGIB. There was no evidence of biological interaction between
NSAIDs and H. pylori infection.
S1834
Impact of Aspirin and Comedications On Healing of Biopsy-Induced
Gastroduodenal Erosions
Gerhard Treiber, Michael Vieth, Thomas Wex, Peter Malfertheiner
Background: Aspirin and non-aspirin NSAIDS are known to induce lesions such as erosions
and ulcers in the upper GI tract. However, less is known about the interplay of different
comedications with aspirin in terms of healing of preexisting lesions. Other drugs are thought
either to aggravate (steroids, Cox-2 inhibitors, clopidogrel) or to speed up (proton-pump
inhibitors) healing of erosions. Prospective data on this topic are scarce. Methods: Prospective,
randomised, multiple cross-over, placebo-controlled trial in 10 healthy volunteers (HV;
H.pylori negative). HV and investigators were blinded for the comedications, which were
given during the first 2 weeks: placebo, clopidogrel 75 mg/d, rofecoxib 25 mg/d, prednisolone
10 mg/d, or esomeprazole 20 mg/d. Subsequently, aspirin 100 mg/d was added to the same
ongoing comedication during another 2 weeks. Between each treatment phase there was a
4 weeks recovery period without any medication. Upper GI endoscopy with 10 biopsies
each from the duodenal bulb, gastric antrum and corpus was performed at one treatment
phase: before, after 2 and after 4 weeks of scheduled drug intake. The number of visible
(=unhealed) erosions (due to preceeding biopsies) was the primary outcome measure, either
expressed as mean Lanza score or cumulative number of erosions (all individuals pooled:
possible maximum number of 10x10=100 erosions per region). Results: In the corpus few
erosions were seen (data not shown). Data for the antrum und bulb region were shown in
the table below. Conclusions: Compared to placebo, esomeprazole accelerates healing in
the duodenal bulb even in the presence of aspirin, but not in the antrum. Aspirin alone
and in combination with steroids produce the highest number of lesions in the duodenal
bulb. In the antrum, aspirin plus rofecoxib is the worst combination in terms of healing
of lesions.
Persistance of Biopsy induced Erosions expressed either as Lanza Score or Cumulative
Number of Erosions due to different Treatments
* significant differences vs. placebo, ** significant differences vs placebo+aspirin
S1835
Rebamipide Compared with Misoprostol for Nonsteroidal Anti-Inflammatory
Drugs Associated Gastrointestinal Toxicity Prevention
Soo-Heon Park, Chul-Soo Cho, Oh-Young Lee, San-Ren Lin, Yao-Zong Yuan, Zhao-Shen
Li, Hong-Chuan Zhao, Udom Kachintorn, Chomsri Kositchaiwat, Comson Lertkupinit
Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) had gastrointestinal side effects
such as dyspepsia, peptic ulceration, hemorrhage, and perforation. Misoprostol and proton
pump inhibitors (PPI) were used in the prevention of gastroduodenal injury. Rebamipide
increase gastric mucus and stimulate the production of endogenous prostaglandins. The
prophylactic effect of rebamipide on NSAIDs induced gastrointestinal complication is
unknown. The aim of this study was to evaluate the NSAIDs induced cumulative incidence
of gastrointestinal complication as peptic ulcer or bleeding in the rebamipide and misoprostol
treated groups in a randomized, multicenter, controlled trial. Methods: Four hundred ten
patients were enrolled from Korea, China, and Thailand. Patients were randomized two
groups and took either conventional NSAID plus rebamipide 100 mg t.i.d. or misoprostol
200 ug t.i.d. for 12 weeks. Compliance for NSAIDs and test drugs were checked every 2
weeks and less than 85% of patients were excluded. Safety test such as CBC and stool occult
blood were checked every 4 weeks. Gastric mucosal damage was evaluated by modified
Lansa score. Results: The age, sex, type of NSAIDs, and Helicobacter pylori infection rates
were not different between the two groups. The numbers of patients for per protocol analysis
were 176 in rebamipide group and 156 in misoprostol group. The prevalence of active
gastric ulcers were 7/176(3.9%) in the rebamipide group and 3/156(1.9%) in misoprostol
group (RR: 0.47, 90% CI=0.13-1.41, P=0.2847). The prevalence of peptic ulcers were 8/
176(4.5%) in the rebamipide group and 7/156(4.4%) in misoprostol group (RR: 0.98, 90%
CI=0.40-2.36, P=0.9796). The cumulative incidence of dyspeptic patients was significantly
higher in misoprostol group than rebamipide group (142/203 vs. 132/207, P=0.0136).
Conclusion: Rebamipide could prevent NSAID induced peptic ulcer as effective as misoprostol
in patients on a long-term NSAID therapy. Considering that dyspeptic symptoms are frequent
reason both for withdrawal of NSAIDs and for co-therapy with another drug, rebamipide
is reasonable drug for the prevention of NSAID induced peptic ulcer and dyspepsia because
of its therapeutic effect and safety.
T : 89386$$CH2
05-04-06 23:18:27 Page 267Layout: 89386B : o
A-267 AGA Abstracts
S1836
Upper Gastrointestinal Bleeding in Hemophiliacs: Incidence and Relationship
to Non-Steroidal Anti-Inflammatory Drugs
M. Elaine Eyster, Shonda M. Asaad, Silvia E. Cohn, Mary-Anne Ardini, James J. Goedert
The use of non-steroidal anti-inflammatory drugs (NSAIDs) in persons with hemophilic
arthropathy is controversial because of bleeding concerns, especially upper gastrointestinal
(UGI) bleeding. PURPOSE: To determine the incidence of UGI bleeding and its relationship
to the use of conventional nonselective non-steroidal anti-inflammatory drugs (nsNSAIDs
or COX-1 inhibitors) and cyclooxygenase selective (COX-2) inhibitors in persons with
hemophilia (PWH). METHODS: From May 2002 through May 2005, all PWH enrolled at
the 51 centers participating in the second Multicenter Hemophilia Cohort Study were queried
annually about use of COX-1 and COX-2 inhibitors in the previous month and for up to
or more than 12 months. These questions were repeated when a UGI bleed occurred.
UGI bleeding was defined as hematemesis, detection of occult blood in the stools with
endoscopically verified ulcer, or melena accompanied by a drop in hemoglobin of at least
2 grams or requiring red cell transfusion. Cox models were used to estimate relative hazards
(RH) with 95% confidence intervals (CI) for fixed and time-dependent covariates postulated
as risk factors. RESULTS: During a mean of 17.4 months (range 2-34), 2285 participants,
ages 13 to 89 (mean 36.5) were followed for a total of 3309 person-years (py). Forty-two
(42) experienced a UGI bleeding event, for an annual incidence of 1.27%. Identified sites
were ulcer (11), gastritis (4), varices (5), Mallory Weiss tears (8), esophagitis (1), and
angiodysplasia (1). Likelihood of bleeding was significantly increased in those who used
COX-1 inhibitors for < 1 month (n=3 events; OR 3.66; 95% CI 1.1-11.9), but not for
extended periods of time (n=2 events). Likelihood of bleeding was not increased in those
who used COX-2 inhibitors (n=6 events). In the multivariable model, likelihood of bleeding
was significantly and independently increased with age >46 yrs (RH 3.4; 95% CI 1.1-10.5),
platelet counts of <100,000/cu mm (RH 2.4; 95%CI 1.0-5.5) and hepatic decompensation
(RH 3.9; 95% CI 1.5-10.1). Adjusted for these, use of a COX-1 inhibitor was not significantly
associated with bleeding (RH 2.7; 95% CI 0.7-11.5). CONCLUSIONS: The annual incidence
of clinically important UGI bleeding events in PWH was 1.27%, similar to the 1-2% rate
reported in non-hemophilic users of nsNSAIDs. After 3309 py,use of a COX-1 inhibitor for
< 1 month was associated with a significant increase in UGI bleeding in univariate analysis,
although older age, thrombocytopenia and hepatic decompensation were major risk factors.
Use of a COX-2 inhibitor was not associated with UGI bleeding.
S1837
How Reliable Is the Clinical History of NSAID Use in Patients Who Present
with Upper Gastrointestinal Hemorrhage?
John M. Runnels, Anil Minocha
There is paucity of literature regarding the reliability of clinical history for assessing the use
of nonsteroidal anti-inflammatory drugs (NSAIDs) in patients presenting with upper GI
hemorrhage. Platelet function testing using the PFA-100 has been used to detect the effects
of NSAIDs on platelets. We hypothesized that surreptitious use of NSAIDs occurs only in
a small minority of such patients. Study Design Adult hospitalized patients undergoing
endoscopy for evaluation of melena, hematemsis or coffee ground emesis were included in
the study. Exclusion criteria included hematocrit less than 25% or platelet count less than
100,000/mm3, as these factors cause invalid measurements by the platelet function analyzer.
Results Sixty three patients met inclusion criteria. Sixteen patients were excluded due to
anemia and thrombocytopenia as above. The average (SD) age of patients was 53.65(15.55)
years. Caucasians formed 40% of the study population, whereas the remaining were African-
Americans. Patients were predominantly males (64%). Twenty one percent of the patients
tested had positive PFA-100 measurements that suggested NSAID use. However, 60% of
those with positive PFA-100 test had denied a history of prior NSAID use. Conversely, only
25% of the patients that gave a history of prior NSAID usage had positive PFA-100 test
results confirming prior NSAID use. Conclusions Clinical history is not a reliable indicator
of prior NSAID use in patients presenting with upper gastrointestinal bleeding. Alternate
testing to evaluate for surreptitious use of NSAIDs should be considered in patients with
bleeding due to non-HP, non-NSAID ulcers.
S1838
Use of GI Prophylaxis in Patients Discharged from Hospital On Ulcerogenic
Medicines
Gregory A. Cote, John P. Norvell, John R. Rice, Michael Postelnik, Colin W. Howden
Background: Gastrointestinal (GI) hemorrhage is responsible for 200,000-400,000 admis-
sions in the United States annually. Up to twenty million Americans take nonsteroidal anti-
inflammatory drugs (NSAIDs) on a regular basis. NSAIDs are responsible for >30% of
admissions due to GI hemorrhage. Misoprostol reduces the number of upper GI events due
to NSAIDs; proton pump inhibitors (PPIs) reduce the incidence of NSAID-related ulcers
seen at endoscopy. Despite this, compliance with clinical practice guidelines to minimize
medication-induced upper GI events may be poor. Aim: To measure the utilization of
appropriate GI prophylaxis in patients discharged from hospital on ulcerogenic medicines
Methods: We performed a retrospective chart review of all patients discharged from the
medical service over a 3-month period on aspirin, NSAIDs, warfarin and/or corticosteroids.
Data were collected on PPI or misoprostol administration at the time of discharge. Co-
morbidities were documented, with particular attention on known risk factors for GI hemor-
rhage (age, previous hemorrhage, type of ulcerogenic medicine). Other indications for acid
suppressive therapy were also documented. Results: 480 patients were discharged between
January and March 2005 on aspirin, NSAIDs, warfarin, corticosteroids or some combination.
142 were excluded for having a current indication for PPI therapy. Of the 338 remaining
patients, 154 (46%) were prescribed GI prophylaxis: 119 (35%) received daily PPI, 2 (1%)
misoprostol, 15 (4%) H2RA and 18 (12%) twice daily PPI. Of the 154 patients discharged
on prophylaxis, 98 (64%) had been taking it before admission. The 338 patients were also

















index, and type of medication. 24% of low-risk (n=33), 36% of moderate risk (n=99), 48%
of high-risk (n=107), and 60% of very high-risk (n=99) patients received some form of
prophylaxis. Patients were also divided by Charlson score; 40% with scores of 0-1, 47%
with scores 2-4, and 51% with scores > 5 received prophylaxis. Conclusions: Although
there was a trend towards higher use of prophylaxis in the highest risk patients, only 60%
were discharged on appropriate therapy. Further, 24% of low-risk patients were prescribed
prophylaxis without a clear indication. Although hospitalization offers an excellent opportun-
ity to recognize and manage patients at high risk of developing GI hemorrhage, adherence
with current guidelines was suboptimal. Educational efforts should be directed at residents
in training to help them recognize risk factors for GI hemorrhage and understand indications
for prophylaxis.
S1839
NSAIDs and Induction of Erosive Esophagitis
Gerhard Treiber, Charlotte Fonga, Peter Malfertheiner
Background: Non-steroidal antiinflammatory drugs (NSAIDS) are widely used and known
to induce lesions in the stomach and duodenum. The relationship between NSAIDS and
erosive esophagitis (EE) is less clear. A Medline search revealed less than 20 publications,
all of them retrospective. Methods: To investigate a possible relationship between NSAIDS
use and the presence of EE, we conducted 2 studies: 1) retrospective case-control study of
416 patients with fully available individual information about the dose and duration of
aspirin and non-aspirin NSAIDS, unselected of symptoms. 2) prospective study in 20 healthy
volunteers (HV, normal baseline endoscopy, no hiatal hernia, H.pylori negative, refraining
from alcohol, smoking, and other drug intake throughout the study period of 8 weeks); all
of them were treated by naproxen 500 mg bid for the first 2 weeks, followed by a 4 weeks
recovery period, and then rechallenged to naproxen. All HV were endoscoped at the beginning
and at the end of drug intake, biopsies were taken from the bulb, antrum, and corpus at
each endoscopy. The primary outcome measure in both studies was the presence of EE.
Results: In the retrospective study, the OR for aspirin to induce EE was 0.80 [95%-CI: 0.37-
1.72, p=0.71], while for non-aspirin NSAIDS the OR was 1.24 [95%-CI: 0.45-3.55, p=
0.59], corresponding to a prevalence of 15.8% for EE in patients with aspirin intake vs.
22.7% with non-aspirin intake. Cofactors like age, H.pylori status, and smoking were similiar
between NSAIDS users and non-users. In the prospective study, 5/20 (25%) HV developed
EE denovo (LA-A n=4, LA-B n=1), all of them were asymptomatic. 15 HV have been retreated
with naproxen, and the same 4 individuals who had EE during the first course showed EE
during the second course. No one developed EE during the second course only. Mean Lanza
score for biopsy induced erosions were similiar for all regions in the stomach and bulb. For
those 5 HV with EE the cumulative number of biopsy induced erosions in the bulb and in
the corpus were higher (RR-bulb: 2.0 [1.4-2.9], p=0.0004; RR-antrum: 1.2 [0.8-1.7], p=
0.55, and RR-corpus: 3.0 [2.1-4.2], p<0.0001) than in those 15 without EE. Conclusions:
EE is associated with NSAID intake, patients with non aspirin NSAIDS are more likely to
have EE than aspirin users. Our prospective data indicate, that even in an asymptomatic,
low-risk population (such as HV), naproxen reproducibly induces EE in 25% of investigated
individuals (similiar proportion to our retrospective data). The presence of EE due to NSAIDS
is also associated with more impaired healing of biopsy induced lesions in the bulb and
corpus, but not in the antrum.
S1840
H. Pylori Infection Is No Longer the Major Cause of Peptic Ulcer in
Copenhagen County
Bo Sondergaard, Peter Bytzer
INTRODUCTION: Peptic ulcer disease is almost always caused by infection with H. pylori
or by ulcerogenic drugs or by a combination of these. Earlier studies have found that at
least 85 % of duodenal ulcers and at least 50 % of gastric ulcers are associated with H.
pylori infection. However, more recent data indicate that the frequency of H. pylori infection
in peptic ulcer disease is decreasing and the prevalence of idiopathic ulcers, not associated
with H. pylori or with NSAIDs, may be increasing. AIMS & METHODS: We aimed to
examine the prevalence of H. pylori infection and the intake of ulcerogenic drugs, NSAIDs
and aspirin (ASA) in patients diagnosed with peptic ulcer disease at an endoscopy center.
Case forms for patients with an endoscopic diagnosis of uncomplicated peptic ulcer during
the years 2002 and 2003 were identified by searching patient lists. Patients were classified
as being H. pylori infected if a biopsy-based rapid urease test, a urea breath test or histopatho-
logy was positive. Use of ASA (any dose), NSAIDs and proton pump inhibitors during the
previous month was registered. RESULTS: 134 patients (66 males) were investigated. Mean
age was 70 years, range 12-94 years. 38 % were smokers. 83 patients had a gastric ulcer,
42 patients had a duodenal ulcer and nine patients had both a gastric and a duodenal ulcer.
In six patients H. pylori status could not be determined. A total of 66/134 (49 %) peptic
ulcer patients were infected with H. pylori. H. pylori was more common in patients with
gastric ulcer compared to patients with duodenal ulcer (61 % vs. 42 %, P=0.0024). Four
of the nine patients with combined ulcers were infected. A total of 48/83 gastric ulcer
patients had used either NSAIDs (11), ASA (30) or both (7). Six of these 83 patients were
classified as having idiopathic ulcer disease. A total of 28/42 duodenal ulcer patients had
used either NSAIDs (7), ASA (13) or both (8). Six of these 42 patients were classified as
having idiopathic ulcer disease. 10/83 gastric ulcer patients used proton pump inhibitors,
three of these patients were H. pylori negative subsequently confirmed by urea breath test.
5/42 patients with duodenal ulcer used proton pump inhibitors, three of these patients were
H. pylori negative subsequently confirmed by urea breath test, and two patients were lost
to follow-up - these were not classified as having idiopathic peptic ulcer. CONCLUSION:
The frequency of H. pylori infection in patients with peptic ulcer disease is rapidly decreasing.
Use of NSAIDs and aspirin is now the major causative factor for duodenal ulcer in Copen-
hagen County.
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S1841
Physicians’ Approaches to the Use of Gastroprotective Strategies in Low-Risk
Non-Steroidal Anti-Inflammatory Drug (NSAID) Users
Sanjay K. Murthy, Laura E. Targownik, Sangeeta Kauldher
Introduction: Gastroprotective (GP) strategies are recommended for NSAIDs users who are
at increased risk for GI bleeding. We aimed to characterize the factors which predict overuse
of GP strategies in low risk NSAID users. Methods: We distributed a questionnaire to all
family physicians and general internists in Manitoba. The questionnaire contained a clinical
vignette describing a low-risk hypothetical patient with osteoarthritis who was a candidate
for NSAID therapy. Respondents were asked whether they would prescribe this patient a
GP strategy and to estimate the risk of that patient developing a GI complication on NSAIDs
alone, as well as the risk reduction afforded by using either a concomitant PPI or a COX-
2 selective NSAID. Respondents were then separated into two groups depending on whether
they inappropriately recommended using a GP strategy in the low-risk scenario. Results:
We received 340 responses (response rate (28.3%) of which 278 supplied analyzable data.
35% of respondents inappropriately recommended a GP strategy for the low risk subject;
inappropriate prescribers were more likely older, farther out from medical school graduation,
and in family practice. Inappropriate prescribers were more likely to overestimate the risk
of GI bleeding (Table 1); this was strongly predictive of GP strategy recommendation in
logistic regression. Conclusions: A substantial proportion of physicians recommended GP
strategies for low-risk patients. These physicians tended to overestimate the risk of GI
bleeding in low risk NSAID users. Improving the knowledge base of physicians in these
areas may lead to a decrease in inappropriate utilization of GP strategies for low-risk patients
Comparison of risk estimates for NSAID-related GI complications between appropriate and
inappropriate prescribers
S1842
Increasing Prescription of Proton Pump Inhibitors in Patients Admitted to the
Verona University Hospital and Decreasing Risk of Peptic Ulcer
Giorgio Talamini, Marina Tommasi, Valeria Amadei, Benedetta Pajusco, Anna Fratucello,
Alessandro Lechi, Giovanna Scroccaro, Italo Vantini
H2-antagonists and proton pump inhibitors are the top-ranking prescribed drugs and consti-
tute a substantial economic burden for the national health-care system. This study evaluates
the prescribing trends of these drugs and their impact on the risk of peptic ulcer in hospitalised
patients. Methods: From January 2001 to June 2004, the number of prescriptions of H2-
antagonists and proton pump inhibitors in each medical or surgical department of Verona
University Hospital was monitored on a monthly basis, distinguishing between iv and oral
administration. Over the same period we prospectively recorded the number of upper
gastrointestinal endoscopies per department for inpatients with a definite diagnosis of gastric
or duodenal ulcer. The following variables were analysed in these patients: gender ratio,
age, indication to endoscopy, urgent endoscopy, use of non-steroidal anti-inflammatory
drugs, presence of Helicobacter pylori, previous surgery, smoking and drinking habits. Results:
A significantly decreasing trend in H2-antagonist prescriptions (r = -0,84; p<0.001) and an
increasing trend in proton pump inhibitor prescriptions (r = 0.97; p<0.001) were observed.
The endoscopic incidence of duodenal ulcers decreased linearly from 2001 to 2004 as
follows: 6.5% (94/1439) in 2001, 5.6% (82/1473) in 2002, 4.5% (63/1411) in 2003,
and 3.1% (22/702) (p<0.001) in 2004. Gastric ulcer incidence, gender, age, indication to
endoscopy and use of nonsteroidal anti-inflammatory drugs showed no significant change.
The prevalence of Helicobacter pylori also remained constant over the three and a half year
period, and about 32% of patients were HP-positive (p = NS). There was a significant inverse
correlation between the increase in proton pump inhibitor administration and the decreasing
incidence of duodenal ulcer (Spearman correlation r=-0.68; p<0.02). Multivariate analysis
identified only proton pump inhibitor use (coeff. -0.91; p<0.001) and non-steroidal anti-
inflammatory drug use (coeff. 0.48; p<0.035) as factors capable, respectively, of reducing
and increasing the risk of duodenal ulcer. Conclusions: In the study period we recorded a
marked decrease in the use of H2-antagonists and an increase in proton pump inhibitor
prescription. The significant reduction in duodenal ulcer endoscopic incidence in hospital
is associated with the increased prescription of proton pump inhibitors in inpatients.
S1843
INOS Inhibition Increases HIF-1α in Mesenteric Macrophages and Reduces the
Inflammatory Response to Aspirin
Irene Diez, Carlos Hernandez, Elsa Quintana, Sara Calatayud, Juan V. Esplugues, Maria
D. Barrachina
A role for hypoxia inducible factor-1α (HIF-1α) in inflammation has been reported. Nitric
oxide, an endogenous mediator associated to inflammatory process, has been shown to play
a dual role on HIF-1α stabilization. Aim: To analyze, in the mesentery of aspirin(ASA)-
treated rats, the role of nitric oxide on HIF-1α expression and the evolution of the inflammat-
ory response. Methods: Fasted rats received a single dose of 1400W (5 mg/kg, s.c., iNOS
selective inhibitor) or saline (1 ml/kg, s.c.), 10 min before ASA (150 mg/kg, p.o.) or vehicle
(1% carboxymethylcellulose, p.o.) and 6 or 24h later we analyzed in mesenteric windows:
a) leukocyte-venular endothelial cell interactions by intravital microscopy; b) iNOS or HIF-
1α immunostaining. Results: ASA induced, 6h later, an increase in the number of rolling
leukocytes (59±6) and leukocyte adhesion to the endothelium (18±3) which was significantly
(p<0.05) prevented by inhibition of iNOS-derived NO synthesis (rolling:36±8 and
adhesion:10±3). Twenty-four hours after ASA, no differences in both parameters were
observed among the different experimental groups. Quantitative analysis of migrated polimor-
phonulear cells (PMNs), in an area of the mesentery (4mm2), revealed a significant increase
(764±89 vs 379±142) 6h after ASA, which was maintained at 24 h (933±143 vs 191±15.1).
Pretreatment with 1400W significantly reduces the number of migrated leukocytes (342±88)
induced by ASA at 24h while it lacked of any effect at 6h. Immunohistochemical analysis
showed iNOS expression in both PMNs and macrophages of the mesentery of ASA-treated
rats. HIF-1 immunoreactivity was observed in 25% of PMNs, mainly around the vessels,
irrespective of the treatment and the time analyzed. Whereas no differences were observed
at 24h, 6h after treatments, the percentage of tissue macrophages showing HIF-1α immunore-
activity was significantly (p<0.05) increased in rats receiving 1400W + ASA (66±2%) com-
pared with control (15±6%) or ASA (19±8%). Conclusions: In ASA-treated rats, inhibition
of iNOS-derived NO synthesis increases HIF-1α expression in macrophages of the mesentery
and shortens the inflammatory response. HIF-1α, by increasing the macrophage phagocytic
capacity, could be involved in the resolution of inflammation.
S1844
A Critical Role of SRF in Myofibroblast Differentiation During Experimental
Esophageal Ulcer Healing
Jianyuan Chai, Manith Norng, Andrzej Tarnawski
SRF is a transcription factor that regulates genes involved in cellular response to stimulations
of growth factors released during tissue injury. The aims of this study were to examine the
effect of local overexpression or knockdown of SRF on myofibroblast differentiation during
esophageal ulcer healing and mechanisms involved. METHODS: 1) In vivo study: Esophageal
ulcers were induced in rats by topical application of acetic acid onto the serosal surface of
the lower esophagus. Immediately after ulcer induction, 100μg plasmid DNA encoding srf
or antisense srf was injected into submucosa adjacent to the induction site. Esophageal
tissues were obtained at day 1, 3, 6, 9 and 14 after treatment. 2) In vitro study: Rat connective
tissue fibroblasts were transfected with the same plasmids used for in vivo study, treated
with recombinant TGFβ1. Myofibroblast differentiation was assessed by expression of smooth
muscle α-actin (SM α-actin) and actin stress fiber formation. Smoothelin was the marker
used to eliminate smooth muscle cells from the whole population of SM α-actin-positive
cells. RESULTS: 1) Overexpression of SRF in esophageal ulcers by gene therapy significantly
increased SM α-actin expression by 73±7 % at day 6 and knockdown of SRF reduced the
amount of SM α-actin protein by 51±4 % (both P < 0.01). Overexpression of SRF increased
myofibroblast population in granulation tissue by 198±23 % per mm2 and knockdown of
SRF reduced the number of myofibroblasts by 52±10 % per mm2 (both P < 0.005). 2)
Esophageal ulceration significantly induced TGFβ1 expression through the entire 14-day-
period monitoring (P < 0.001). It reached a peak at day 6 (38-fold). 3) TGFβ1 treatment
significantly increased SRF mRNA expression by 78.5±9.3 %, 186.8±15.2 % and 164.4±22.5
% at 2, 6 and 12 hrs, respectively, and protein expression by 144±35 %, 4-, 6-, 6- and 5-
fold at 2, 6, 12, 24 and 48 hrs, respectively (all P < 0.01). EMSA analyses indicated that
TGFβ1 treatment also significantly enhanced SRF protein binding activity to sm α-actin
SRE in parallel to the elevation in SRF protein expression. 4) Overexpression of SRF induced
both SM α-actin expression and actin stress fiber formation, while knockdown of SRF
prevented TGFβ1-induced myofibroblast phenotype in fibroblasts. CONCLUSIONS: 1) Local
overexpression of SRF during esophageal ulcer healing promotes myofibroblast differenti-
ation; 2) Esophageal ulceration stimulates TGFβ1 expression and myofibroblast differenti-
ation; 3) TGFβ1 induces SRF activation in fibroblasts; and 4) SRF is required for myofibrob-
last differentiation.
S1845
Effect of Inhibition of Cyclooxygenase-2 and 5-Lipoxygenase Or Antagonism
of the Lipoxin A4/Annexin-1 Receptor On Indomethacin-Induced Gastric
Mucosal Damage in Rats
Brigitta M. Peskar, Bernhard A. Peskar, Nadia Sawka
BACKGROUND: Metabolism of arachidonic acid by aspirin-acetylated cyclooxygenase
(COX) -2 and 5-lipoxygenase yields 15(R)-epi-lipoxin (LX) A4. In the rat stomach, aspirin
increased formation of 15(R)-epi-LXA4 which attenuated aspirin-induced damage whereas
inhibitors of COX-2 or the LXA4 receptor antagonist BOC 1 aggravated aspirin-induced
injury (Fiorucci et al., 2002). In the presence of indomethacin anti-inflammatory mediators
are produced from eicosapentaenoic acid by a COX-2- and 5-lipoxygenase-dependent mech-
anism (Serhan et al., 2000). We examined whether these enzymes and the LXA4/annexin-
1 receptor might also be involved in counteracting the injurious effect of indomethacin on
gastric integrity. METHODS: Conscious rats (5-9/group) were treated with indomethacin
(10 mg/kg, po) with or without co-administration of the COX-2 inhibitor rofecoxib (10 mg/
kg, ip), the 5-lipoxygenase inhibitor A63162 (20 mg/kg, sc) or the LXA4/annexin-1 receptor
antagonist BOC 1 (2x 10 µg/kg, ip). For comparison, rats were treated with aspirin (150
mg/kg, po) with or without co-treatment with rofecoxib (10 mg/kg, ip) or A63162 (20 mg/kg,
sc). Mucosal damage was assessed after 5 h using a lesion index (LI). RESULTS: Indomethacin
induced damage with a LI of 10+-1 which was increased by co-administration of rofecoxib
(LI 19+-2.3, p<0.001), A63162 (LI 19+-2, p<0.001) or BOC 1 (LI 20+-3.1, p<0.01). Aspirin
caused damage with a LI of 12+-1.6 that was aggravated by co-treatment with rofecoxib (LI
25+-1.5, p<0.001) or A63162 (LI 20+-1.3, p<0.001). Neither rofecoxib nor A63162 nor
BOC 1 in the doses used damaged the gastric mucosa when given alone. CONCLUSIONS:
1) The findings confirm a previous report (Fiorucci et al., 2002) that aspirin-induced gastric
damage is increased by inhibition of COX-2 and interference with the LXA4 system. 2)
Gastric injury caused by indomethacin is aggravated by inhibition of COX-2, 5-lipoxygenase
or antagonism of the LXA4/annexin-1 receptor to an extent comparable to aspirin suggesting
that ulcerogenic doses of both aspirin and indomethacin lead to formation of endogenous
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protective mediators that limit gastric mucosal injury. 3) Formation of protective mediators
occurs via acetylated COX-2 in the presence of aspirin but enzyme acetylation is obviously
not a prerequisite for the indomethacin effect. 4) The formation of protective mediators in
the presence of an ulcerogenic dose (10 mg/kg) of indomethacin differs from the protection
conferred by a low dose (1 mg/kg) of indomethacin in gastric ischemia-reperfusion injury,
since this type of protection is observed even in the presence of the COX-2 inhibitor celecoxib
(Sawka et al., unpublished data).
S1846
A Novel Mechanism for NSAID Enhanced Proteasomic Degradation of
Survivin
Shiun-Kwei Chiou, Michael K. Jones, Andrzej Tarnawski
Background: Nonselective NSAIDs such as indomethacin cause gastrointestinal damage.
Apoptosis is one of the mechanisms. Survivin, a dual functioning protein, inhibits apoptosis
and facilitates mitosis. Survivin is expressed in normal human and rat gastric mucosa in
surface epithelial and progenitor cells. Previous studies demonstrated that NSAIDs target
survivin in inducing gastric injury by promoting proteasomic degradation of survivin protein
in the gastric mucosa. Evidence supporting this shows that suppression of survivin expression
by siRNA induces injury of gastric mucosal, RGM-1 cells. In this study we confirmed whether:
1) indomethacin treatment increases ubiquitination of survivin, and examined: 2) molecular
mechanisms involved in survivin protein degradation. Methods: Rat gastric epithelial, RGM-
1 cells derived from normal gastric mucosa were treated with either 20 mM of the 26S
proteasome inhibitor, MG-132, or 0.5mM indomethacin with 20 mM MG-132 for 3 hours.
The MG-132 proteasome inhibitor does not interfere with protein ubiquitination, and was
used to prevent rapid survivin degradation following ubiquitination. Survivin protein ubiquit-
ination was assessed by immunoprecipitation with anti-survivin antibodies followed by
Western blotting with anti-ubiquitin antibodies. To determine the ubiquitin ligase involved
in degradation of survivin, cIAP 1, APC and XIAP expression was suppressed in RGM-1
cells by transfection of siRNA oligomers. Survivin protein levels in cells maintained in serum
free culture with and without siRNA suppression were monitored by Western blotting at
24, 48 and 72 hours post transfection. Results: 1) Indomethacin plus MG-132 treatment
increased survivin ubiquitination by 3.8 + 0.82 fold (p<0.05) compared to MG-132 only
treatment. 2) In RGM-1 cells transfected with non-suppressing control RNA, survivin protein
level significantly decreased to 0.013 + 0.001 fold (p<0.05) by 48 hours in serum free
medium, compared to 0 hours. 3) XIAP suppression maintained survivin protein levels at
1.1 + .2 (p<0.05), 0.72 + 0.09 (p<0.05) and 0.55 + 0.1 (p<0.05) fold for 24, 48 and 72
hours, respectively, compared to 0 hours, while cIAP 1 and APC suppression by siRNA did
not increase survivin protein stability. 4) Maintainance of survivin protein levels in XIAP
suppressed cells was not due to upregulation of survivin mRNA expression. Conclusions:
1) Indomethacin treatment promotes ubiquitination and proteasomic degradation of survivin
in gastric epithelial cells, which likely facilitates gastric epithelial cell injury. 2) XIAP may
be an ubiquitin E2 ligase involved in NSAID induced survivin degradation.
S1847
The Role of Cholinergic Hypersensitivity On NSAID-Induced Gastric Damage
Changcheng Wang, Ireneusz T. Padol, Richard H. Hunt
Purpose: Flinders sensitive line (FSL) rats exhibit an increased cholinergic responsiveness
in vivo when compared to their counterparts, Flinders resistant line (FRL) rats. Our previous
study demonstrated that basal gastric acid secretion was significantly higher in FSL than in
FRL rats (Gastroenterology 2004 Suppl 2; 126: A480). In this study, we aimed to determine
whether there are differences in NSAID-induced gastric damage between these two strains
and if differences in gastric physiology play a role. Methods: The gastric damage index (mm)
was assessed macroscopically 6h after oral administration of indomethacin (5mg/kg and
20mg/kg) in FSL and FRL rats. In another set of rats, acid secretion was measured by pylorus
ligation 3h after oral indomethacin. Volume (ml) and acidity (mEq/L) of gastric juice was
measured and acid output (μEq/3h) calculated. Results: The gastric damage index was
significantly higher in FSL than in FRL 6h after oral administration of 5mg/kg and 20mg/kg
indomethacin (12.4±3.0 vs 3.4±1.1, p=0.009 and 27±5.7 vs 12.1±3.0, p=0.03; respectively).
Baseline, acidity, acid output and gastric juice volume were significantly higher in FSL than
in FRL (70.34±1.1 vs 42.65±9.68, p=0.006; 213.47±29.14 vs 92.82±36.26, p=0.02 and
3.02±0.4 vs 1.74±0.39, p=0.04; respectively). Administration of 5mg/kg indomethacin
resulted in acidity markedly higher than baseline values for both strains (FSL: 91.2±10.54
vs 70.34±1.1, p=0.008 and FRL: 80.48±7.57 vs 42.65±9.68, p=0.023), while volume and
acid output were not. After administration of higher dose indomethacin (20mg/kg), acidity
was still significantly higher than baseline in FRL rats (73.28±4.3 vs 42.65±9.68, p=0.025).
However, in FSL rats, acidity, acid output and gastric juice volume were lower than baseline
values suggesting extensive damage to gastric mucosa (51.97±14.78 vs 70.34±1.1, p=0.056;
80.77±23.39 vs 213.47±29.14, p=0.03 and 1.54±0.08 vs 3.02±0.4, p=0.055 respectively).
Conclusion: The greater NSAID-induced gastric damage in FSL rats correlates closely to its
innate hypersecretion of gastric acid. Indomethacin-induced higher acidity may play a
predominant role in gastric damage in both strains. The observed differences between FSL
and FRL rats provide the basis for an animal model of cholinergic hyperresponsiveness to
NSAID-induced gastric pathology.
S1848
Role of Cyclooxygenase-2 and Lipoxygenases in the Protective Effect of
Indomethacin and Acetaminophen in Ischemia-Reperfusion Injury of the Rat
Stomach
Nadia Sawka, Bernhard A. Peskar, Brigitta M. Peskar
BACKGROUND: Aspirin leads to formation of protective 15(R)-epi-lipoxin (LX) A4 via
acetylated cyclooxygenase (COX) -2 and further metabolism by 5-lipoxygenase (LO) (Fiorucci

















acetaminophen arrays of anti-inflammatory lipid mediators are produced from eicosapenta-
enoic acid via COX-2-dependent oxygenations and 5-LO. We examined whether indometh-
acin and acetaminophen protect against gastric ischemia-reperfusion (I-R) injury. METHODS:
In male Wistar rats (4-6/group), I-R was induced by clamping the celiac artery for 30 min
followed by reperfusion for 60 min. Gastric damage was assessed by calculation of a lesion
index (LI). Drugs were given sc. RESULTS: I-R alone induced minor damage (LI 3+-0.3).
Pretreatment (30 min) with the COX-2 inhibitor celecoxib (3 mg/kg) markedly increased
damage (LI 41+-1.3, p<0.001). Administration of indomethacin (1 mg/kg) or acetaminophen
(50 mg/kg) 30 min before or after celecoxib protected against the damage-aggravating effect
of celecoxib (LI 14+-2.7 and 7+-0.5, respectively, p<0.001 each). The protective effects of
indomethacin and acetaminophen were reversed by pretreatment (30 min) with low doses
of inhibitors of 5-LO (A63162), 12-LO (baicalein) or 15-LO (PD146176) (2.5 mg/kg each)
or the LXA4/annexin 1 receptor antagonist BOC 1 (0.15 µg/kg). These doses had no effect
on I-R damage when given alone. The inhibition of the protective effects of indomethacin
and acetaminophen against celecoxib-induced injury induced by pretreatment with LO-
inhibitors or BOC 1 was significant (p at least <0.02), damage showing a LI ranging from
27+-7.5 to 41+-1.1. In additional experiments, higher doses of A63162 (5 mg/kg) or BOC
1 (1 µg/kg) instead of celecoxib were used to aggravate I-R damage (LI 41+-2.6 and 38+-
2.2, respectively). Indomethacin (1 mg/kg) and acetaminophen (50 mg/kg) also significantly
(p<0.001) protected against the damage-aggravating effects of A63162 and BOC 1 (LI 8+-
1 and 7+-1, respectively, for indomethacin and LI 6+-0.4 and 5+-0.3, respectively, for
acetaminophen). CONCLUSIONS: 1) Acetaminophen and a low dose of indomethacin exert
gastroprotection in that they counteract the damage-aggravating effects of celecoxib, the 5-
LO inhibitor A63162 and the LXA4 receptor antagonist Boc 1 in I-R. 2) The inhibition by
indomethacin and acetaminophen of celecoxib-induced I-R damage is reversed by inhibitors
of LO or blockade of the LXA4 receptor. 3) The findings show that the protective activity
of these non-steroidal anti-inflammatory drugs is not mediated by COX-2 as it operates
when COX-2 is inhibited but is modulated by LO activity.
S1849
Is Cyr61 Required for Myofibroblast Differentiation? An Exploration of the
Role of Cyr61 in Gastric Ulcer Healing
Jianyuan Chai, Manith Norng
Myofibroblast differentiation is an important event for healing of any wounds including
gastric ulcer. Cyr61 is a growth factor-induced secreted protein but is associated with
extracellular matrix. It is reported that Cyr61 promotes fibroblast adhesion and migration
during cutaneous wound healing. The aim of this study was to explore the role of Cyr61
in gastric ulcer healing, focusing on myofibroblast differentiation. METHODS: 1) In vivo
study: Gastric ulcers were induced in rats by serosal application of acetic acid. Normal and
ulcerated gastric tissues were harvested at 1, 3, 7, 14 and 30 days after ulcer induction for
analyses of Cyr61 mRNA by Northern blotting and protein expression by Western blotting
and immunohistochemistry; 2) In vitro study: Rat connective tissue fibroblasts were treated
with either recombinant Cyr61 or Cyr61 siRNA, and examined for Integrin activation, focal
adhesion assembly, and myofibroblast phenotype. Cells were also treated with recombinant
TGFβ1 as a positive control. RESULTS: 1) Gastric ulceration induced two peaks at day 1
and 14, respectively, in the expression of Cyr61 mRNA (150±42 % and 350±44 %) and
protein (3 fold and 16 fold) (all P < 0.01). The first peak reflected inflammatory response
and angiogenesis, while the second peak (greater) concentrated in the extracellular matrix
of granulation tissue. Ulceration also massively increased the number of myofibroblasts in
the same temporal-and-spatial manner as Cyr61. 2) After 48-hour treatment with siRNA,
Cyr61 deficiency in cultured fibroblasts severely impaired cell adhesion as indicated by the
reduced number of cells on cover-glasses (62±7 % less than control, P < 0.001) and focal
adhesion complexes. 3) Exogenous Cyr61 treatment induced expression of smooth muscle
α-actin in fibroblasts, increased expression of adhesion molecules including Integrin α6 by
63±10 % and Talin by 204±32 % (both P < 0.005), phosphorylation of FAK by 75±12 %
and Paxillin by 138±17 % (both P < 0.005), and translocation of Vinculin. 4) Knockdown
of Cyr61 in fibroblasts did not prevent TGFβ-induced expression of smooth muscle α-actin
but prevented TGFβ-induced phosphorylation of FAK and Paxillin and formation of focal
adhesion complex. Conclusions: 1) Gastric ulceration induces Cyr61 expression in granula-
tion tissue; 2) Cyr61 is essential for focal adhesion assembly in fibroblasts; and 3) Cyr61
induces myofibroblast phenotype in fibroblasts, but is not required for TGFβ-induced
myofibroblast differentiation.
S1850
Evaluation of the Structural Properties and Activities of a Purified PC-NSAID
Preparation
Lenard M. Lichtenberger, Elizabeth Dial, Vasanthi Jayaraman, Z.hong Zhou, Ramanan
Krishnamorti, David E. Volk, David G. Gorenstein, Upendra Marathi
Background: It has been determined that the GI toxicity of nonsteroidal anti-inflammatory
drugs (NSAIDs) can be significantly reduced in animals and human subjects if the drugs
are pre-associated with phosphatidylcholine (PC). The development of the PC-NSAID techno-
logy has been restricted somewhat by our inability to purify PC-NSAIDs, suggesting that
the GI protective activity and therapeutic efficacy could be further optimized if such a
technique could be developed. Objective & Methods: We have attempted to develop a
method of purifying PC-NSAIDs based upon the ability of NSAIDs to induce a remarkable
increase in the solubility of PC in the polar solvent, acetone. In the absence of NSAIDs, PC
has a limited solubility in acetone (< 0.1g/ ml). In contrast, if the NSAID, ibuprofen is pre-
dissolved in acetone to a concentration of 1g/ml, the solubility of PC in the polar solvent
is increased > 2g/ml.Removal of the acetone by evaporation results in a viscous (70 poise)
oil that is highly enriched in PC-ibuprofen. This purified oil-based PC-NSAID product was
subjected to: physico-chemical; structural; and biological examination . Results: A strong
molecular interaction was observed between ibuprofen and PC involving both the aromatic
nucleus and the carboxyl group of the NSAID, and the choline head group and the carbonyl
ends of the acyl chains of the PC of the acetone-prepared oil, as determined by Fourier
transform infrared (FTIR) and proton, carbon and phosphorous nuclear magnetic resonance
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(NMR) spectroscopy. Both dynamic light scattering and transmission electron microscopy,
revealed the presence of spherical macromolecular assemblies having a diameter between 100-
150 nm. In comparison to unmodified ibuprofen, the enriched PC-ibuprofen preparation:
significantly reduced (70-80%) GI bleeding in both acute and chronic rodent ulcer models;
accelerated the healing of acetic acid-induced gastric ulcers in rats; and had significantly
greater analgesic activity in an acute model of joint inflammation. Conclusion: A method
has been developed to prepare an enriched preparation of PC-NSAIDs related to changes
in the solubility of the components in the polar solvent, acetone. We have used a number
of physico-chemical and structural techniques to localize the association of ibuprofen and
PC at an atomic level, and its macromolecular assembly characteristics. Our findings that
the enriched PC-ibuprofen product has enhanced GI safety and analgesic activity in rodent
model systems, suggest that future clinical evaluation of this PC-NSAID preparation is
warranted. (Supported by NIH grant R42 DK063882 and the Texas Higher Education
Coordinating Board).
S1851
Effects of Esomeprazole Sodium On Glutathione Levels in the Gastric Mucosa
of Rats Treated with Indomethacin
Manuela Verri, Gianfranco Natale, Federica Boschi, Ornella Pastoris, Marcello Tonini
Background: In the clinical setting, proton pump inhibitors are effective in preventing and
healing non steroidal anti-inflammatory drug (NSAID)-induced gastroduodenal lesions by
acting as antisecretory agents. Besides gastric acid, oxidative stress induced by tissue antioxid-
ant depletion is a potential mechanism for gastric mucosal damage in NSAID gastropathy.
It has been proposed that benzimidazole derivatives may exert their protective action also
through antioxidant mechanisms. Aim: To examine the effects of esomeprazole sodium on
the levels of glutathione, a major endogenous antioxidant compound, in the gastric mucosa
of rats treated with indomethacin. Methods: Male albino Wistar rats, 200-225 g body weight
(n=8/group), received one of six treatments by intragastric gavage: 1% methocel as vehicle
(controls), esomeprazole 30 or 60 µmol/kg, indomethacin 100 µmol/kg, esomeprazole 30
or 60 µmol/kg and indomethacin 100 µmol/kg. In rats treated with esomeprazole and
indomethacin, esomeprazole was administered 30 minutes before indomethacin. The animals
were sacrificed 4 hours after indomethacin administration, and the stomachs were rapidly
removed and processed for the evaluation of mucosal levels (expressed as µmol/g wet tissue)
of total (tGSH), reduced (GSH) and oxidized (GSSG) glutathione. Results: An histomorpho-
metric evaluation revealed that esomeprazole markedly reduced mucosal injuries induced
by indomethacin. Esomeprazole alone (30 or 60 µmol/kg) did not significantly affect the
mucosal concentration of tGSH, GSH and GSSG, whereas indomethacin caused a significant
reduction of tGSH and GSH contents (0.371±0.024 and 0.349±0.025, P<0.05) and a signific-
ant increase in GSSG levels (0.022±0.003, P<0.05) compared to controls (0.817±0.042,
0.805±0.043, 0.012±0.001, respectively). Esomeprazole 30 µmol/kg partly reversed the effect
of indomethacin on tGSH, GSH and GSSG levels (0.598±0.036, 0.584±0.035, 0.014±0.001,
respectively, P<0.05). Esomeprazole 60 µmol/kg reversed the effects of indomethacin on
glutathione levels (0.846±0.049, 0.830±0.048, 0.015±0.002, respectively, P<0.05) up to
control values. Conclusions: Our findings indicate that esomeprazole dose-dependently
counteracts the effects of indomethacin on gastric mucosal glutathione levels. This supports
the view that the protective effects of esomeprazole against indomethacin-induced gastric
damage are partly dependent on a restored bioavailability of mucosal sulfhydryl compounds.
S1852
The Host Specific Differences in the Shunt Toward Lipoxygenase(LOX)
Pathway Caused By the Inhibition of Cyclooxygenase(COX) Correlate with the
Differences in the Extent of NSAID-Induced Gastric Damage
Ireneusz T. Padol, Changcheng Wang, Victoria Seto, Richard H. Hunt
Premise: Arachidonic acid is metabolized universally via two distinct pathways; cyclooxy-
genase(COX) and lipoxygenase(LOX). The products of the LOX pathway such as leukotrines
and free radicals are involved in the induction and/or augmentation of gastric damage. It
has been postulated that selective and non-selective NSAIDs, in addition to inhibition of
the COX pathway, increase arachidonic acid levels, thus causing a “shunt” of metabolism
toward the LOX pathway. Our study aimed to examine the role of this shunt on the extent
of NSAID induced gastric damage using two strains of mice. Balb/c and C57BL/6 mice were
chosen as these strains posess distinctive differences in relation to gastric acid secretion,
including NSAID induced gastric damage, prostanoid metabolism (PLA2) and expression
of EP3 receptors (AJP 2005, 288, G1110). Methods: Mice from both strains were treated
intraperitoneally with two doses of indomethacin, 4 and 40 mg/kg, and aspirin, 25 and 250
mg/kg. 3 hours later stomachs were scored for mucosal damage and blood and gastric
samples collected for determination of PGE2, TBX2 and LTB4 which served as markers of
COX and LOX pathways. Results: We observed less gastric damage in C57BL/6 mice than
in Balb/c when lower doses of NSAIDs were used, 16.4 vs 7.6 mm, p=0.0003 for 4 mg/kg
of indomethacin and 8.8 vs 5.2 mm, p=0.001 for 25 mg/kg of aspirin respectively. Strain
related differences in fasted and non-fasted serum and/or gastric prostanoid levels were
noted. Serum levels of PGE2 and LTB4 were higher in Balb/c mice than in C57BL/6 mice
1.9 vs 1.1 μg/ml, p=0.05 and 247.7 vs 70.4 pg/ml, p=0.02 respectively, while tissue levels
of LTB4 were higher in non-fasted C57BL/6 mice than in Balb/c mice, 19.7 vs 3.2 μg/g, p=
0.05. NSAIDs caused remarkable inhibition of PGE2 in the stomachs from both mice strains.
However, simultaneous induction of LTB4 was seen in stomachs from Balb/c mice but not
in C57BL/6 mice which had less NSAID induced gastric damage. Discussion and Conclusion:
Our study demonstrates that the LOX shunt, associated with inhibition of the COX pathway,
results in higher levels of LTB4, with concurrent inhibition of PGE2 production in the
stomach but not in blood. Results from NSAID induced gastric damage confirmed our
previous findings that Balb/c mice are more prone to NSAID gastropathy than C57BL/6
mice (Gut 2001, 49(Suppl. 3) A1737). We suggest that the “COX to LOX shunt” is associated
with a greater extent of NSAID induced gastric damage. This implies a potential relevance
of host genetics on NSAID-induced mucosal damage in the clinical setting.
S1853
A Cause-Effect Relationship Between Deficiency of Prostaglandins and
Expression of Cyclooxygenase-2 in Rat Stomachs Following Administration of
Nonsteroidal Anti-Inflammatory Drugs
Yuji Mashita, Yoshikazu Kubo, Ryo Hatazawa, Koji Takeuchi
Background/Aim: We previously reported the up-regulation of cyclooxygenase (COX)-2
expression in the rat stomach after administration of indomethacin or SC-560 (a selective
COX-1 inhibitor), and this process is associated with gastric hypermotility induced by COX-
1 inhibition by these agents. However, it is possible that this event occurs simply as a
compensatory phenomenon resulting from prostaglandin (PG) deficiency due to COX-1
inhibition. In the present study, we investigated a cause-effect relationship between PG
depletion and COX-2 expression in rat stomachs after the administration of nonsteroidal
anti-inflammatory drugs (NSAIDs). Methods: Male SD rats were used after 18 h fasting.
Various NSAIDs (indomethacin, naproxen, dicrofenac, frulbiprophen, aspirin) were given
SC or PO, and the gastric lesion, COX-2 mRNA expression and PGE2 content were determined
4 h later. Gastric potential difference (PD) and motility were also measured. Results: All
NSAIDs tested, except aspirin, decreased the mucosal PGE2 content, increased gastric motility,
and caused gastric lesions with the up-regulation of COX-2 expression, irrespective of the
route of administration. Aspirin induced damage and COX-2 expression in the stomach
when given PO but not SC, although the mucosal PGE2 content was similarly decreased by
this agent on both routes of administration. Gastric motility was not affected by aspirin
given either PO or SC, while gastric PD was markedly decreased by aspirin only given PO.
Supplementation of PGE2 prevented the expression of COX-2 in the stomach following PO
or SC administration of indomethacin but had no effect on the COX-2 expression seen after
PO administration of aspirin. The COX-2 expression induced by indomethacin was also
inhibited by atropine, while omeprazole had no effect. In addition, SC-560 but not rofecoxib
caused a decrease in PGE2 content and an increase in gastric motility as well as COX-2
expression, without induction of any damage in the stomach. Conclusion: These results
suggest that the expression of COX-2 in the stomach after NSAID treatment may be due to
the mucosal irritative stimuli caused by the physico-chemical property of drug (aspirin, PO)
or the abnormal stomach contraction due to COX-1 inhibition (other NSAIDs) ), rather
than being a result of PG deficiency. Luminal acid does not play a role in the up-regulation
of COX-2 in the stomach following NSAIDs, inhibition of COX-1.
S1854
Transcriptome Analysis for Cytoprotective Actions of Rebamipide Against
Indomethacin-Induced Gastric Mucosal Injury in Rats
Yuji Naito, Masaaki Kuroda, Katsura Mizushima, Tomohisa Takagi, Osamu Handa, Satoshi
Kokura, Norimasa Yoshida, Toshikazu Yoshikawa
Background: Nonsteroidal anti-inflammatory drugs such as indomethacin are known to
induce gastric mucosal injury including apoptosis. We have reported that rebamipide, a
gastroprotective drug, suppresses indomethacin-induced mucosal injury in human and rats
(Dig Dis Sci 50:104, 2005, 43:83, 1998). However, the mechanisms of the cytoprotective
actions of rebamipide have not been fully addressed.Aim: We determined mRNA expression
profile of the gastric mucosa treated with indomethacin in rats, and investigated the cytopro-
tective effects of rebamipide against indomethacin-induced injury by a high-density oligonu-
cleotide array. Materials and Methods: We used the Rat Toxicology U34 GeneChip array
(1,031 probes). Gastric epithelial cells were identified on cryostat sections (8 μm) of the
specimens obtained from the rat stomach, and the cells were isolated by laser-assisted
microdissection. Using the small sample target labeling assay protocol, we obtained a sufficient
amount of biotinylated cRNA to perform the GeneChip analysis from the small amount of
gastric epithelial cells. Data analysis was performed with a GeneChip Operating Software
and Ingenuity Pathway Analysis. Results: Among 1,031 probes, the expression of 160 probes
(15.5%) showed at least a 2.0-fold up-regulation (158 probes) and down-regulation (2
probes) 2 h after indomethacin administration in comparison with the vehicle-treated rats.
Genes involved in redox-related enzymes (superoxide dismutase 1, carbonyl reductase 1,
glutathione peroxidase 3, glutathione S-transferese, etc.) and transcription regulators (c-fos
oncogene, etc) were included. By the pathway analysis of the up-regulated 123 probes
among 158 probes, 5 networks were found to be significant in that they had more of the
identified genes present than would be expected by chance. The network 1 contained the
majority of these genes, had a highly significant score, and consisted of known clusters of
cell death, cancer, and endocrine system disorders. We succeeded in listing 10 genes that
were up-regulated by the treatment with indomethacin and that were down-regulated by
rebamipide, including growth arrest and DNA damage-induced 45α (GADD45α). The induc-
tion of GADD45α mRNA by indomethacin and its inhibition by rebamipide was also
confirmed by real time PCR. Conclusions: These data obtained from transcriptome analysis
on gastric epithelial cells in vivo demonstrate that cell death, especially apoptosis, pathway
is involved in the pathogenesis of indomethacin-induced gastric mucosal injury, and that
inhibition of apoptosis-related genes is possibly important for the cytoprotective effect of
rebamipide against this injury.
S1855
Effects of Selective Cyclooxygenase-2 Inhibitors On Healing of Experimental
Gastric Ulcers and Mucosal Expression of Cyclooxygenase Isoforms
Matteo Fornai, Luca Antonioli, Rocchina Colucci, Gianfranco Natale, Fabio Baschiera,
Nunzia Bernardini, Chiara Ippolito, Corrado Blandizzi, Mario Del Tacca
Introduction. Selective cyclooxygenase-2 (COX-2) inhibitors were developed as novel gastric
sparing anti-inflammatory drugs. Recent evidence suggests an involvement of COX-2 in
gastroprotection, while its role in ulcer healing is currently debated. This study investigates
the effects of COX-2 inhibitors on healing of experimental gastric ulcerative lesions. Methods.
Male Wistar rats were subjected to induction of gastric injury by intragastric administration
of absolute ethanol (1 ml/200 g body weight) or subserosal injection of acetic acid (20%,
40 µl). Treatments with COX inhibitors started 4 hours or 4 days after induction of lesions
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with ethanol or acetic acid, respectively. Indomethacin (1 mg/kg/day, COX-1/COX-2 inhib-
itor, indoleacetic derivative), valdecoxib (1 mg/kg/day, COX-2 inhibitor, sulphonamide
derivative), DFU (5 mg/kg/day, COX-2 inhibitor, methylsulphonic derivative) or drug vehicle
were administered orally for 1, 3 or 7 days. At the end of treatments, stomachs were processed
for: a) histomorphometric evaluation of ethanol-induced injury (%); b) measurement of
acetic acid-induced ulcer area (mm2); c) COX-1 and COX-2 mucosal expression by RT-
PCR and immunohistochemistry. Results. Histomorphometric analysis displayed a necrotic
damage affecting 37.2±6.2%, 30.5±2.9% and 18.1±1.0% of mucosa at day 1, 3 and 7 after
ethanol administration, respectively. Treatment with indomethacin or DFU delayed healing
of ethanol-induced gastric lesions, the mucosal damage accounting for 37.1±1.6% and
32.0±3.4% at day 7, respectively. Valdecoxib did not affect the time course of mucosal
healing (16.1±1.0% at day 7). Acetic acid injection was followed by development of single
chronic ulcers, macroscopically evident after 1, 3 or 7 days from onset of treatments with
COX inhibitors. At these times, ulcer areas in controls were 59.3±4.3, 57.4±4.8 and 18.7±4.0
mm2, respectively. Indomethacin and DFU delayed ulcer healing at day 7 (48.3±3.6 and
57.4±4.2 mm2, respectively), while valdecoxib did not (16.7±3.5 mm2). RT-PCR and
immunohistochemistry displayed a COX-2 induction in tissue areas adjacent to ethanol- or
acetic acid-induced lesions, whereas COX-1 was unaffected. At day 7 the enhancement of
COX-2 induction was higher in animals treated with valdecoxib than in those receiving
indomethacin or DFU. Conclusions. Valdecoxib does not appear to interfere with healing
of gastric lesions, at variance of other COX-2 inhibitors endowed with different chemical
structures. The recruitment of COX-2-independent mechanisms by valdecoxib is likely to
account for the lack of effects on ulcer healing, and the concomitant enhancement of gastric
COX-2 expression.
S1856
Indigestible Solid Components of Food and Intestinal Hyper-Motilities Play
An Important Role in the Formation of Intestinal Ulcers Induced By
Indomethacin in Cats and Dogs
Hiroshi Satoh, Sachiko Shiotani, Noriko Otsuka
BACKGROUND: In the last AGA meeting we reported that dietary fiber (DF) such as cellulose
played some role in the formation of intestinal ulcers and that diets with no- or less DF
could prevent indomethacin (IM)-induced intestinal ulcers in all of rats, cats and dogs. In
the present study, the role of DF (soluble or insoluble ) and intestinal motility in IM-induced
intestinal ulcers was investigated in both cats and dogs. METHODS: Both male and female
cats (2.5-3.5kg) and dogs (7-15kg) were used (4-6 animals in each group). Role of DF:
Several types of diets containing various percentages of DF were given to animals twice a
day during the experiment. IM was administered orally once a day after a morning meal
for 3 days. The animals were sacrificed 24 hrs after the final dose of IM, and mucosal lesions
in the small intestine were examined. Role of motilities: In this study, the gastrointestinal
motilities were recorded in conscious cats implanted with force transducers in the stomach,
duodenum, jejunum and ileum. RESULTS: Role of DF: In both cats and dogs given dry
food containing 4 and 6% DF, resp., IM (3 mg/kg) produced many lesions in the middle
and lower intestine; the mean lesion areas (MLA) were 8.4±2.7 cm2 and 31.3±2.5 cm2 ,
resp. The lesions were markedly decreased in both animals given canned diets containing
no DF (MLA: 0.1±0.1 cm2, and 0.4±0.2 cm2 , resp., p<0.05). Whereas the lesions were
increased significantly in animals given the canned diet supplemented with 3 or 10% cellulose
(insoluble fiber), but not by addition of 3 or 10% pectin (soluble fiber). Role of motilities:
Atropine (0.1 and 0.3 mg/kg, s.c., x2/day, for 3 days) almost completely blocked the ulcer
formation caused by IM in both animals given dry foods. IM (1-3 mg/kg, p.o.) dose-
dependently increased the gastrointestinal motilities in cats, and the effects were blocked
by atropine (0.3 mg/kg, s.c.). CONCLUSIONS: It could be concluded that both indigestible
solid components of food and intestinal hyper-motility play an important role in the formation
of intestinal ulcers by IM, probably by causing physical damage in the surface mucosal cells
under a decreased condition of the surface mucus induced by IM.
S1857
CDNA Microarray Analysis Reveals Anti-Inflammatory Effects of
Lansoprazole, a Proton Pump Inhibitor, Against Indomethacin-Induced
Intestinal Mucosal Injury in Rats
Hiroshi Ichikawa, Norimasa Yoshida, Toshimitsu Okuda, Kazuhiro Kamata, Hirokazu
Kajikawa, Hisato Tsuboi, Takahiro Suzuki, Osamu Handa, Tomohisa Takagi, Satoshi
Kokura, Yuji Naito, Toshikazu Yoshikawa
It is well known that indomethacin produces gastrointestinal inflammation and ulceration
through a diverse number of mechanisms. We have reported that lansoprazole have anti-
inflammatory effects as well as inhibition of acid secretion. The purpose of the present study
is to evaluate the biological effects of lansoprazole by using cDNA microarray analysis in
experimental rat models on indomethacin-induced enteritis in vivo. Male Wistar rats were
administered indomethacin (10mg/kg) s.c., killed 3h and 24h later under deep ether anes-
thesia, and both the jejunum and ileum were removed. Lansoprazole was given subcutane-
ously (5mg/kg) just after following indomethacin administration. To estimate the severity
of the intestinal mucosal damage by indomethacin, we measured the concentrations of
thiobarbituric acid-reactive substances (TBA-RS), myeloperoxidase (MPO) activity and the
content of cytokine-induced neutrophil chemoattractant-1 (CINC-1) in the intestinal mucosa.
To investigate the molecular mechanisms underlying the effects of lansoprazole on this
model, we examined gene expression profiles in mucosal cells which were collected by laser
capture microdissection method. Preparation of cRNA and target hybridization was performed
according to the Affymetrix GeneChip Eukaryotic Small Sample Target Labeling Assay
Protocol (Version II). The gene expression profile was determined by the the GeneChip (Rat
toxicology U34 array, Affymetrix) microarray system. Single administration of indomethacin
at 10mg/kg provoked severe hemorrhagic lesions in the small intestine, mostly the jejunum
and ileum. The concentrations of TBA-RS, the levels of MPO activities and the content of
mucosal CINC-1 in the intestinal mucosa significantly increased 24 hr after indomethacin
administration and these increased levels were significantly inhibited by the treatment with

















of genes for enzymes involved in oxidative stress, such as metallothionein, catalase and
superoxide dismutase, in mucosal cells after 3hr injection of indomethacin. Lansoprazole
also suppressed the upregulated expression of genes for cytochrome c oxidase, N-acetyltrans-
ferase-2 and transferrin. Furthermore, some genes for enzymes involved in anti-apoptosis,
protein folding and DNA-binding protein were downregulated by indomethacin treatment,
and lansoprazole was able to restore these changes. These observations clearly illustrate that
lansoprazole protects against intestinal injury induced by indomethacin. It was suggested
that oxidative stress and apoptosis were involved in the pathogenesis of indomethacin-
induced enteritis.
S1858
Poor Metabolizer Genotype Status of Cytochrome P450 2c19 Is a Risk Factor
for Developing Gastric Cancer in Japanese with Helicobacter Pylori Infection
Mitsushige Sugimoto, Takahisa Furuta, Naohito Shirai, Akiko Nakamura, Mutsuhiro
Ikuma, Masayoshi Kajimura, Haruhiko Sugimura, Akira Hishida, Tskashi Ishizaki
Backgrounds and aims: Cytochrome P450 2C19 (CYP2C19) polymorphism, one of the
isoforms of CYP enzymes, is a clinically important enzyme responsible for the metabolism
of a number of therapeutic drugs, such as proton pump inhibitors. CYP2C19 is associated
with the development of lung, liver or esophageal cancer by detoxification of carcinogen or
activation of pro-carcinogen. The present study was designed to clarify the association
between CYP2C19 genotypes and susceptibility to gastric cancer in Japanese patients with
H. pylori infection. Methods: We determined CYP2C19 genotypes (CYP2C19*1, *2 and *3)
in 111 H. pylori-positive patients with gastric cancer and 315 H. pylori-positive controls
without gastric cancer consisting of patients with gastritis only or peptic ulcer. CYP2c19
genotypes were classified into the three groups; homozygous extensive metabolizers
(homEMs), heterozygous EMs (hetEMs), and poor metabolizers (PMs). Frequencies of
CYP2C19 genotypes and serum pepsinogen I and II levels, a biomaker of gastric atrophy,
in the gastric cancers and controls were compared. Results: Frequencies of homEMs, hetEMs,
and PMs were 31.5%, 42.3% and 26.2% in the gastric cancer patients and 38.1%, 47.0%
and 14.9% in the controls, respectively. The PM genotype of CYP2C19 was associated with
an increased risk for developing gastric cancer with the age and sex-adjusted odds ratio
(OR) of 1.975 (95% confidence interval [CI]: 1.068 - 3.649), especially for diffuse-type
gastric cancer (OR; 3.385, CI; 1.187 - 9.648). There was no significant association between
CYP2C19 genotypes and serum pepsinogen I levels or pepsinogen I/II ratios, although serum
pepsinogen I level in patients with gastric cancers were significantly decreased. Conclusions:
In H. pylori-positive Japanese, the PM of CYP2C19 appeared at an increased risk for developing
gastric cancer, especially diffuse-type. The preset study results sugget that the CYP2C19
genotyping test is useful for screening individuals with a higher risk for developing gastric
cancer when infected with H. pylori and that CYP2C19-related H. pylori-positive PMs should
undergo the eradication therapy for the prevention of gastric cancer or would require an
intensive follow-up care to scrutinize the possible future gastric cancer development.
S1859
Induction of Aberrant Methylation in Gastric Mucosae By H. Pylori Infection,
and Its Association with Risk of Single and Multiple Gastric Cancers
Takeshi Nakajima, Takao Maekita, Ichiro Oda, Takuji Gotoda, Daizo Saito, Masao
Ichinose, Toshikazu Ushijima
Purpose: CpG methylation is a stable, but plastic, modification on DNA. Aberrant methylation
of promoter CpG islands (CGIs) of tumor-suppressor genes is deeply involved in some
cancers, including gastric cancers. Here, we focused on induction of aberrant DNA methyl-
ation in gastric mucosae by Helicobacter pylori (HP) infection, and possible association
between the fraction of cells with aberrant methylation in gastric mucosae and risk of single
and multiple gastric cancers. Material and Methods: Twenty-six healthy volunteers (HVs),
30 cases with a single well-differentiated gastric cancer, and 32 cases with multiple well-
differentiated cancers were recruited. The average age of HVs was matched to those of cancer
cases. Biopsy materials were collected from three standard points of non-cancerous gastric
mucosae. HP infection status was analyzed by the culture method. Methylation levels (frac-
tions of methylated DNA molecules among all the DNA molecules) were quantified by real-
time methylation-specific PCR of seven regions, i) promoter CGIs of FLNc, HAND1, THBD,
HRASLS and LOX, and ii) exonic CGIs of p41ARC and p16. Results: (1) When methylation
levels were compared between HP-negative and -positive HVs, HP-positive individuals were
shown to have 3.0- to 14.3- fold higher average methylation levels than HP-negative indi-
viduals in all the seven regions. (2) Among the HP-negative individuals, FLNc and HAND1
showed step-wise increases of methylation levels in cases with a single cancer (1.3- and 3.0-
fold, respectively), and cases with multiple cancers (5.0- and 3.6- fold, respectively), com-
pared with HVs. Even when stratified into cases with mild atrophy and severe atrophy,
FLNc showed step-wise increases in cases with a single cancer (1.9- and 4.8-fold, respectively)
and cases with multiple cancers (4.8- and 15.8-fold). (3) In the HP-positive individuals,
methylation levels were increased highly and to various degrees in HVs and cancer cases.
(4) Methylation levels were highest in HP-positive individuals (HVs and cancer cases), and
followed by HP-negative cancer cases, most of whom were considered to have past exposure
to HP infection. Conclusion: Current HP infection potently induced DNA methylation in
gastric mucosae. The lower methylation levels in HP-negative gastric cancer cases suggested
that active HP infection induces both temporary and permanent methylation. It was consid-
ered that the permanent levels can be observed in HP-negative individuals, and that higher
levels are associated with single and multiple gastric cancers. Methylation levels in non-
cancerous gastric mucosae are a promising risk marker for single and multiple gastric cancers.
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S1860
Identification of Increased Fibrinopeptide a Serum Protein Levels in Gastric
Cancer Sera By Magnet Bead Assisted Maldi-Tof Mass Spectrometry
Matthias Ebert, Soren Deininger, Claudia Knippig, Christoph Roecken, Peter
Malfertheiner
Gastric cancer is the second most common malignancy and prognosis remains dismal. The
reasons for the poor prognosis are the lack of sensitive serum markers for early detection
and screening of high-risk individuals as well as the limited treatment options in advanced
cancer stages. Using MALDI TOF mass spectrometry after prefractionation of sera with
magnet hydrophobic C8 coated beads sera from 14 patients with gastric cancer and 14
healthy controls mass spectra were generated. A peptide fragment was found to be highly
elevated in cancer sera and was identified as fibrinopeptide A. In order to confirm proteome
analysis of gastric cancer sera we then screened a larger series of patients with gastric cancer
(n=99), high-risk individuals (n=13) and normal controls (n=111) for fibrinopeptide A
serum levels. Interestingly, the mean logarithmic concentrations of serum fibrinopeptide A
levels were significantly higher in cancer patients (mean 3.636 ±0.3738; p<0.0001) and
high-risk individuals (mean 3.569 ±0.4722; p<0.05) compared to normal controls (mean
3.303 ±0.4012). In contrast, we observed no association of fibrinopeptide A levels with
tumor stage, tumor location, presence of regional or distant metastasis, and Lauren type of
gastric cancer. In conclusion, MALDI TOF mass spectrometry of prefractionated gastric
cancer sera allows the identification of potential serum markers for gastric cancer and may
lead to the development of serum based tests for screening of high-risk individuals.
S1861
Identification of Human Esophageal Cancer Sub-Types By Serum Protein
Analysis Using Maldi-Tof Mass Spectroscopy
Timothy P. Millar, Yuliya V. Karpievitch, Elizabeth G. Hill, Charles E. Hammond, Brenda
J. Hoffman, Adam J. Smolka
The majority of patients presenting with symptoms of esophageal cancer (EC) have advanced
disease. In patients with potentially resectable disease, the cure rate is still extremely low
due to local recurrence and metastatic disease. The best hope of improving survival is
early detection and effective therapeutic intervention. This study tested the hypothesis
that characteristic protein and/or peptide markers are associated with EC, and that mass
spectroscopic human serum analysis can provide differential protein/peptide molecular signa-
tures that discriminate among healthy controls and two major EC subtypes. Sera were
obtained from 26 patients undergoing upper endoscopy and/or endoscopic ultrasonography;
nine [6 white males (wm), 2 black males (bm), 1 white female (wf)] were diagnosed with
esophageal adenocarcinoma (AC), eight (3 wm, 3 bm, 2 bf) with squamous cell carcinoma
(SC), and nine (5 wm, 3 wf, 1 bf) were normal. Sera were treated with reversed-phase
ligand (C8)-derivatized superparamagnetic particles from which adsorbed hydrophobic
serum proteins/peptides were subsequently eluted. Aliquots of serum eluates were random-
ized, mixed with α-cyano-4-hydroxycinnamic acid matrix and applied to a target plate for
matrix-assisted laser desorption ionization-time of flight mass spectroscopy (MALDI-TOF)
(Voyager STR, 337 nm N2 laser, linear mode geometry, 25 kV). Quadruplicate mass spectra
spanning an m/z window of 800-20,000 Da were acquired for each eluate on 3 separate
days. Peak detection and quantitation was restricted to masses >2000 Da to avoid bias
introduced by non-biological matrix signal. Analysis was further restricted to quality spectra
(high signal/noise ratio across the m/z window), resulting in a contribution of 11 spectra
per subject (286 spectra total). After suitable data preprocessing, 110 m/z peaks were
identified as potential biomarkers. A supervised learning algorithm (random forests) was
applied to biomarker peaks to classify patients’ disease status. Eight out of nine AC patients
(sens=89%, spec=88%), six out of eight SC patients (sens=75%, spec=89%), and eight out of
nine controls (sens=89%, spec=100%) were correctly classified. The nine most discriminatory
peaks (m/z=3285, 2031, 4348, 3384, 8760, 8771, 6392, 3885, and 4573 Da) are targets
of further biochemical analysis. We conclude that patient serum samples can be processed
using magnetic microsphere-based technology to yield complex, stable, and reproducible
MALDI-TOF spectra, statistical analysis of which provides a quantitative assessment of
correlation between specific patterns of protein/peptide expression and the presence or
absence of two subtypes of esophageal cancer.
S1862
Improved Performance of a Non-Invasive Fecal DNA (fDNA) Test to Screen for
Colorectal Cancer (CRC)
Steven Itzkowitz, Lina Jandorf, Randall Brand, Linda Rabeneck, Paul Schroy, Stephen
Sontag, David Johnson, Joel Skoletsky, Sanford Markowitz, Anthony Shuber
Background: Proof of principle that fecal fDNA testing can be a useful technique to screen
asymptomatic average-risk individuals over age 50 for CRC was recently established in a
multicenter study (MCS) (NEJM 351:2704,2004). That prototype assay (PreGenPlus Version
1; PV1) analyzed 22 DNA mutations (MuMu-22) and DNA integrity (DIA), resulting in 52%
sensitivity (SENS) for CRC and 94% specificity (SPEC). The SENS of the DIA component
was lower than expected due to DNA degradation during specimen shipping. Subsequently,
a Version 2 (PV2) assay was developed which incorporates an improved method for stabilizing
DNA with buffer (Diagn Mol Pathol 14:183,2005), better extraction of DNA by gel-capture
(J Mol Diagn 6:386,2004), and new biomarkers including vimentin methylation (V29; JNCI
97:1124,2005). Aim: To determine the SENS and SPEC of PV2 in pts with CRC and those
with normal colonoscopies (NL). Methods: Pts in this prospective multicenter study were
consented after colonoscopic findings of either a NL colon (n=122) or CRC (n=40). NLs
had no personal or family hx of CRC/polyps. Approx. 6-14 days after colonoscopy (prior
to surgery for the CRC group), pts prepared a single stool sample to which they immediately
added buffer. Stools were shipped by express mail, homogenized, and DNA was extracted
by sequence-specific gel-capture. MuMu-22 and DIA (PV1) analyses were performed as in
the MCS. Methylation-specific PCR was performed after sodium bisulfite treatment. Results:
Compared to PV1-MCS data, the addition of buffer and gel-capture technology to the
same marker panel (PV1-New) increased SENS to 72.5% for CRC [Dukes’ Stages A:B:C:D=
88:80:53:100%]. The SENS of even part of the DIA assay (DY) alone was 65%[A:B:C:D=
63:70:53:100%] and V29 alone was 72.5%[A:B:C:D=75:80:73:50%]. The optimal combina-
tion, V29+DY, resulted in 88% SENS [A:B:C:D=75:90:93:100%]. DY detected more distal
CRC (p=0.03), whereas V29 detected prox. and distal CRC equally well. V29+DY had a
SPEC of 82%. NLs with false-positive V29+DY were older than those with negative V29+DY
(mean age 62.7 vs. 57.4, p=0.01). Conclusions: Compared with the prototype PV1 assay,
an improved and simplified fDNA test demonstrates higher SENS for CRC (87.5%) with
only a modest decline in SPEC. Many false-positives may simply be due to methylation
associated with normal aging. The inclusion of fewer markers will make the test easier and
less expensive.
S1863
Elevated Genomic Instability in Aberrant Crypt Foci (ACF) Is Associated with
Tobacco Use
Sadir Alrawi, Heliodoro Medina, Merril Dayton, John Gibbs, Daniel Stoler, Garth
Anderson, Robert Carroll
Background: ACF are the earliest identifiable neoplastic lesions in the colon. We have shown
age and tobacco uses are independently linked to ACF number (CGH: March 2005). The
progression of adenoma to cancer is accompanied by progressive accumulation of mutations,
in tandem with increasing genomic instability (GI). The ability of tobacco carcinogens to
induce genomic damage is well established. To determine if this damage was evident as early
as the ACF in colorectal tumor progression, we evaluated genomic damage, chromosomal
aberrations, and specific mutations within ACF in an age-matched population of smokers
and non-smokers. Methods: ACF were identified and biopsied using magnification chromoen-
doscopy. DNA was extracted from ACF and adjacent normal tissue. Chromosomal and
intrachromosomal instability was evaluated by BAC-array Comparative Genomic Hybridiza-
tion (aCGH) and Inter-Simple Sequence Repeat PCR (ISSR PCR) respectively. The Genomic
Instability Index (GII), a measure of genome-wide inter-SSR DNA damage, was calculated
for each specimen. K-ras mutation was evaluated by diagnostic PCR amplification and BstNI
restriction digestion (sens~ 1/1000 copies). Colon cell lines with and without known K-ras
mutations were used as positive and negative controls. P53 and B-RAF mutations were
evaluated by automated sequencing of PCR amplified DNA using fluorescent dideoxy termina-
tion nucleotides. Results: 20 ACF from 12 smokers (mean age 61.7yr) were compared to
13 ACF from 8 non-smokers (mean age 60.2 yrs) Sex distribution was similar in both groups
(12M: 8F). The CGH profiles obtained for ACF showed no significant deviation from normal
diploid DNA nor were there any significant differences in CGH profiles of smokers and
nonsmokers. Genomic instability was detectable in 78% of ACF by ISSR PCR with a mean
genomic instability indices of 3.9% in smokers and 2.2% in nonsmokers (p=0.017). K-ras
codon 12 mutations were uniformly absent in all the ACF tissue evaluated, regardless of
smoking status. No p53 mutations were identified in 20 ACF samples. Two B-RAF mutation
in exon 11 and exon 15 from ACF were identified. The exon 11 mutation (T1405C) was
synonomous but the 2nd was a serine 600 to tyrosine mutation in the activation segment
of the B-RAF protein. Conclusion: DNA damage associated with smoking is an early event
and detectable within colorectal ACF prior to the occurrence of adenoma or carcinoma. K-
ras and B-RAF mutations were found at low frequency. The mutational profile of individual
ACF remains distinct from the profiles of adenoma and cancer suggesting most of these
lesions may not be direct precursors of adenoma or cancer.
S1864
Nestin, a Novel Angiogenesis Marker Correlates with Poor Prognosis of
Colorectal Cancer Patients
Nobuhisa Teranishi, Toshiyuki Ishiwata, Noritake Tanaka, Kiyonori Furukawa, Hideyuki
Suzuki, Tomoko Seya, Hayato Kan, Hiroyuki Tsuruta, Satoshi Matsumoto, Yukihiro Akiya,
Seiichi Shinji, Akihisa Matsuda, Kazumitsu Cho, Jyunpei Sasaki, Masao Kawamoto,
Tetsuro Matsunobu, Yuri Fujiwara, Takashi Tajiri, Zenya Naito
(Purposes) Angiogenesis is an important factor in the proliferation and metastasis of colorectal
cancer. Microvessel density(MVD) in colorectal cancer cell nests is reported to be closely
related to clinicopathological factors and patient survival. CD34 and Factor VIII are commonly
used as an endothelial cell marker of tumor vessels. However, these markers identify not
only newly formed small blood vessels, but also pre-existing large blood vessels. Nestin, a
class VI intermediate filament protein, has recently received attention as a marker that can
detect the endothelial cells of newly formed microvessels. In the present study, examined
the expression of nestin in colorectal cancer tissues, and compared the expression level with
CD34 and Factor VIII-related antigen. Moreover, the sizes of nestin-positive and CD34-
positive vessels were compared in subcutaneous cancer tumors formed in nude mice. (Mat-
erials and methods) 1)One hundred-five colorectal cancers cases operated at Nippon Medical
School Hospital were employed in this study. Immunohistochemical analysis was performed
using serial tissue sections with CD34, nestin, and Factor VIII. Proliferating endothelial
cells were immunohistochemically, detected by PCNA antibody. 2)MVD was determined
according to the international consensus report. Briefly, five areas where the density of positive
blood vessels was highest in the tumors ware selected. Then, the areas were photographed at
X200 magnification, and the blood vessels were counted. A clinicopathological factors and
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prognose were compared between two groups: higher or lower than median of MVD. 3)HCT-
15 cells, a human colon adenocarcinoma cell line, were subcutaneously implanted into the
dorsum of male BALB/C nu/nu mice. When the tumor size grew to 3cm in a diameter, the
tumor was harvested. These specimens were prepared for immunofluorescence staining
using CD34 and nestin antibody. (Results) 1)Immunohistochemically, nestin was localized
in the endothelial cells in small blood vessels, while CD34 and Factor VIII were localized
in mature blood vessels in human colorectal cancer tissues and subcutaneous tumor from
nude mice. 2)Ratio of co-localization of PCNA and nestin in the same vascular endothelial
cells was higher than co-localization of PCNA and CD34 in endothelial cells (p=0.0021).
3)There was no correlation with nestin-positive blood vessels or clinicopathological factors
in colorectal cancer. 4)Regarding disease-free survival, the prognosis was worse for the highly
nestin-positive MVD group (p=0.047). (Conclusion) Nestin is considered a more sensitive
marker of proliferating endothelial cells in colorectal cancer tissues.
S1865
Overexpression of Calcium Binding Protein S100a4 in Barrett’s Tumorigenesis
Ok-Jae Lee, Seung-Mo Hong, Abbes Belkhiri, Christopher Moskaluk, Wael El-Rifai
Background and Aims. The role of S100A2 in carcinogenesis has drawn a complex picture
showing down-regulation or overexpression in different tumors. The biologic function of
S100A2 in carcinogenesis has not been elucidated to date. S100A4 is a candidate as a
molecular marker for metastatic potential with high prognostic significance. In order to
evaluate the role of S100A2 and S100A4 in tumorigenesis of upper gastrointestinal adenocar-
cinoma, we have investigated the mRNA expression level and protein expression of S100A2
and S100A4 in lower esophageal, gastroesophageal junctional (GEJ), and gastric adenocarcin-
oma tissues. Materials & Method. Quantitative real-time RT-PCR was performed in 75 frozen
tissue samples of lower-esophageal, GEJ, and gastric adenocarcinomas for the expression of
S100A2 and S100A4 mRNA. Immunohistochemistry for the expression of S100A2 and
S100A4 proteins was also performed on tumor tissue array that contained 206 lower-
esophageal, GEJ, and gastric adenocarcinomas. Results. Quantitative real-time PCR analysis
revealed high levels of S100A2 and S100A4 mRNA in 96.0% and 77.1% of lower-esophageal,
GEJ, and gastric adenocarcinomas samples as compared with normal mucosae samples.
Immunohistochemical analysis showed moderate to strong expression of S100A2 protein
in 65.5% of lower esophageal, 61.2% of GE junctional, and 46.2% of gastric adenocarcinomas.
Overexpression of S100A2 was not related to any clinic-pathological variables. S100A4
protein was overexpressed in 76.6% of all cancer tissues in comparison to normal mucosa.
The overexpression of S100A4 was more frequently observed in the presence of BE (p=
0.0316). On the other hand, we noticed a change of S100A2 expression location from
nuclear (normal tissues) to both cytoplasmic and nuclear in the majority of dysplasia and
tumors. Conclusions. S100A2 and S100A4 are overexpressed in upper gastrointestinal aden-
ocarcinomas, and the overexpression of S100A4 is related to Barrett’s tumorigenesis. S100A2
undergoes a nucleo-cytoplasmic translocation which may occur at early stage of tumorig-
enensis.
S1866
Multiple Primary Cancers After Endoscopic Treatment of Esophageal
Carcinoma
Iizuka Toshiro, Yahagi Naohisa, Hoteya Syu, Yamamoto Takashi
Objective: Early detection and the wide use of endoscopic mucosal resection (EMR) have
dramatically increased survival time in patients with superficial esophageal carcinoma that
carries the risk of multiple primary cancers during the follow-up after EMR. We evaluated
our patients with multiple primary cancers who underwent EMR of esophageal carcinoma
and searched for early markers of malignancies. Subjects and methods: Of the 167 patients
who underwent EMR of esophageal carcinoma between January, 1998 and August, 2005,
156 patients, who have been followed up to date, were included in this study. On the basis
of clinical characteristics and timing of EMR, we investigated the site, frequency, and treatment
method of multiple primary cancers. Results: Multiple primary cancers were found in 57
patients (37%). Before EMR of esophageal carcinoma, 56% of 27 patients had developed
cancers in the stomach and 15% in the laryngopharynx. Synchronous cancers were detected
in 22 patients, including 68% with gastric cancer and 23% with hypopharyngeal cancer.
After EMR, the incidence of gastric cancer was 33% as well as that of oro- and hypopharyngeal
cancer. EMR of gastric cancer was performed before, with, and after treatment of esophageal
carcinoma at a rate of 27%, 53%, and 100%, respectively. For oro- and hypopharyngeal
cancer, the rates of EMR performed with and after esophageal carcinoma EMR were 40%
and 100%, respectively. Discussion Approximately one-third of patients who underwent
EMR of esophageal carcinoma developed multiple primary cancers, mostly in the stomach,
regardless of the timing of EMR. Oro- and hypopharyngeal cancer was observed more
frequently at the time of or after esophageal carcinoma EMR. The presence of esophageal
carcinoma could thus be a significant early marker for multiple primary cancers.
S1867
Expression of iNOS in Pre-Neoplastic and Neoplastic Conditions of Gastric
Mucosa After Helicobacter Pylori (H.pylori) Infection: A Molecular and
Immunohistochemical Study in Tissue Microarrays (TMAs)
Andreas Karameris, Evangelos Tsiambas, Sofia Gazi, Kyriakos Gerontopoulos, George
Vilaras, Dimitrios Stefanou, Theodore Rokkas
Background: Reactive oxygen and nitrogen species may play a crucial role in human carcino-
genesis. The reactive nitrogen species are derived from the synthesis of NO, stimulated by
iNOS, in a variety of cell types including activated macrophages and neutrophils. Recent
studies have revealed that Helicobacter pylori (H.pylori) infection leads to the formation of
nitrotyrosine, which may contribute to DNA damage and apoptosis in gastric mucosa. Aim:
To analyze the expression of iNOS by immunohistochemical and molecular methods in

















Microarrays (TMAs), in an effort to correlate the possible role of active nitric species and
H.pylori infection in the progression of gastric carcinogenesis. Material and Methods: 45
formalin fixed, paraffin embedded gastric carcinoma cases were studied for determination
of the expression of iNOS (25 H.pylori+ and 20 H.pylori-). Intestinal metaplasia (IM) type
I were observed in 5 H.pylori+ cases, IM II in 8 and IM III in 12 of them. Controls included
5 H.pylori- IM I, 6 IM II and 10 IM III cases. The TMArrayer apparatus (Chemicon, USA)
was used for the construction of TMAs. iNOS expression in molecular level was determined
by differential-PCR in microcore samples taken by TMArrayer and properly analyzed with
an Image Analysis System (DIS-200, Digital Image Systems, Hellas). The expression of iNOS
molecule was studied by immunohistochemistry using a polyclonal anti-IgG human iNOS
antibody (Santa Cruz, USA) and the evaluation of the result was done by DIS-200. Results:
12/13 of intestinal and 10/12 of diffuse H.pylori+ gastric carcinomas overexpressed iNOS
as indicated by differential PCR and immunohistochemistry. 2/5 IM Ι, 8/12 IM ΙΙ and 7/8
IM ΙΙΙ H.pylori+ cases were also expressed increased iNOS levels as well as 5 diffuse and 5
intestinal type H.pylori- carcinomas. In addition 0/5 H.pylori- IM I, 1/6 H.pylori- IM II and
2/10 H.pylori- IM III cases were also expressed high iNOS levels. A statistical significant
difference concerning the expression of iNOS between H.pylori+ Ca and H.pylori- Ca (<0.01),
between IM ΙΙ and ΙΙΙ (<0.05), as well as between H.pylori+ and H.pylori- IM ΙΙ and ΙΙΙ
(<0.01) was also observed. Conclusion: Our data suggest that high iNOS expression in
gastric mucosa is of significant importance for the initiation and promotion of gastric
carcinogenesis. The observation that high iNOS levels in IM type II and III correlated well
with H.pylori infection, may be a strong evidence for long term follow up.
S1868
Stool α-Defensin Assay for Colorectal Cancer Screening: Feasibility Analysis
Aravind Sugumar, Hongzhi Zou, Jonathan Harrington, Kristie K. Klatt, David A. Ahlquist
Tumor-specific proteins represent a class of candidate stool markers with potentially low-
cost application to colorectal cancer (CRC) screening. In a recent report, selected α-defensins
(HNP1-3) were over-expressed by CRC tissue and elevated in sera of patients with CRC
(Gastroenterology 2005;129:66-73). To date, these markers have not been reported in
stool. AIM: To evaluate the neoplasm-specificity of HPN1-3 defensins and explore their
discriminant value as stool markers for CRC. METHODS: Protein and mRNA expression
of human HPN1-3 defensins were initially evaluated in CRC cell lines (SW480, HT29) and
white blood cells (WBC); mRNA expression was additionally assessed in microdissected
CRC and normal colon epithelium. Alpha-defensin protein levels were assayed by ELISA
with HPN1-3 kit (HyCult Biotechnology, Cat# HK317); mRNA expression was quantified
by real time RT-PCR. Using a modified HPN1-3 kit assay, protein extracts from freezer-
archived stools were assayed in blinded fashion from 30 colonoscopically normal subjects,
20 patients with CRC, 10 with colorectal adenomas > 1cm, 10 with inflammatory bowel
disease (IBD), and 10 with upper GI cancers. Stool HPN1-3 defensin levels were correlated
with levels of the WBC protein, lactoferrin (Enzyme Immunoassay for Human Lactoferrin,
Oxford Biomedical Research, Cat# FR 18). RESULTS: Defensin proteins were not detected
in extracts from CRC cell lines, but levels were extremely high (>4000ng/ml) in WBC
extracts. mRNA expression levels of HPN1-3 defensins were comparably low in CRC cell
lines, microdissected CRC, and normal colon epithelium, but > 1000-fold higher in WBC.
Mean stool HPN1-3 defensin protein levels were 14 ng/ml in normal subjects, 37 in patients
with adenomas, 80 with CRC, 44 with upper GI cancer, and 92 with IBD. At 100% specificity,
sensitivity of stool defensin was 0% for adenomas, 20% for CRC, 0% for upper GI cancer,
and 20% for IBD; at 97% specificity, sensitivities were 30, 25, 30, and 60%, respectively;
and at 90% specificity, sensitivities were 50, 40, 60 and 70%, respectively. Stool defensin
levels correlated with stool lactoferrin levels (r2=0.45, p<0.001). CONCLUSIONS: Based
on our findings, HPN1-3 α-defensins are specific for WBC and not expressed by CRC cells.
Stool α-defensins are readily assayed and often elevated with CRC and other GI neoplasms.
However, these inflammatory markers are also elevated in IBD stools and correlate well with
known markers of inflammation.
S1869
Recovery of RUNX3 Expression in Long-Term Follow-Up After H. Pylori
Eradication
Takayuki Motoyoshi, Hideyuki Konishi, Shunji Tachibana, Kouichi Soga, Chohei
Sakakura, Masao Noda, Shoji Mitsufuji, Keisho Kataoka, Takeshi Okanoue
Background: It is clear that H. pylori eradication improves an inflammation of gastric mucosa,
but scientific evidence is still insufficient in view of its preventive effect for gastric carcinogen-
esis. Human runt-related transcription factor gene 3 (RUNX3 ) is known to be a growth
regulation factor of gastric epithelial cells. Recent knowledge has shown that in the majority
of gastric cancers RUNX3 expression is reduced by hypermethylation not only at the tumor
but also at the surrounding intestinal metaplasia. RUNX3 expression is therefore proposed
to be a surrogate biomarker for gastric premalignant lesion. Aim: To examine RUNX3
expression in gastric mucosa before and after H. pylori eradication therapy, and to compare
histological findings with RUNX3 expression. Materials and Methods: A retrospective review
of 52 patients of H. pylori-positive gastritis was performed. We classified them in short-term
follow-up group (less than one year) and long-term follow-up group (from one to twelve
years, mean 4.4-year) after H. pylori eradication. We evaluated their histological findings by
the updated Sydney System and compared them with RUNX3 expression in gastric mucosa.
Immunohistochemical analysis was performed on paraffin-embedded tissue samples using
RUNX3 monoclonal antibody (given by Prof. YOSHIAKI ITOH in Institute of Molecular
and Cell Biology, National University of Singapore). Results: After H. pylori eradication,
inflammation in gastric mucosa was obviously improved both in short-term and long-term
follow-up groups (p<0.001), while mucosal atrophy and intestinal metaplasia was not.
RUNX3 expression in gastric mucosa recovered in few cases of short-term follow-up group
and most cases of long-term follow-up group (p<0.05). In both groups, milder atrophy
and less intestinal metaplasia cases showed more recovery of RUNX3 expression (p<0.01).
Conclusions: RUNX3 expression recovered long-term follow-up after H. pylori eradication
especially in milder atrophy and less metaplasia cases. From the point of view of RUNX3
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expression, long-term follow-up may be necessary to prevent the development of gastric
cancer after H. pylori eradication.
S1870
Pentasialo- and Hexasialotransferrin Isoforms As a Diagnostic Tool of
Colorectal Cancer
Thierry Codden, Franz J. Legros, Jean-Pol Henry, Anne Lenaerts, Vincent Nuyens,
Sylvianne Delaunay
Background: Malignant neoplasia is known to increase sialylation of most hepatic glycopro-
teins. This remains debated about the most important glycoprotein, transferrin(Tf). The aim
of the study was to determine the ability of serum sialoTf isoforms to detect colorectal
cancer. Methods: We have used a Capillary Zone electrophoresis (PACE 5000 series, Beckman
Coulter, CA) method (CEofix CDT kit, Analis, Namur, Belgium), as a tool to carefully
discriminate Tf glycosilated isoforms following their charge/mass ratio generated by their
electronic charge of the terminal sialic acids of Tf N-glycan chains allowing for separation
of the serum asialo- to hexasialotransferrin isoforms. 0.02 mL of serum was analyzed. Protein
absorption was determined at 215 nanometers. Circulating Tf levels (percentages) were drawn
from printed electropherograms. From October to November 2005, blood measurements of
Tf were performed in 57 consecutively patients referred for screening colonoscopy. Malignant
neoplasia was assessed by histological examination. Results: The mean levels of penta- and
hexasialoTf were significantly (p<0.0001) higher in sera of colorectal cancer patients (n=
12) (Table 1). At a threshold level averaging 20% of total level, colorectal cancers appeared
to be separated from non cancerous patients (n=45) with a sensitivity of 100% and a
specificity of 97.5% of the sum (penta- plus hexasialoTf %). Conclusion: These preliminary
results fit with theory about sialylation of glycoproteins in malignant neoplasia, and offer
the opportunity of developing a reliable rapid seric detection (<15 min) of colorectal cancer,
requesting blood puncture and 0.02 mL Capillary Zone electrophoresis of serum.
Table 1. Mean percentages ± SD of disialo- to hexasialoTf (P2 to P6) in normal colonoscopy
and in colorectal cancer patients.
S1871
Expression of CDX2, Villin, Sima and Apomucins in Small Intestinal
Adenocarcinoma: A Comparison with Colorectal Adenocarcinoma
Megan Q. Zhang, Zong-Ming E. Chen, Jon H. Ritter, Pei Hui, Fan Lin, Hanlin L. Wang
Background: Aberrant expression of intestinal markers CDX2, villin and small intestinal
mucinous antigen (SIMA), and apomucins MUC1, MUC2 and MUC5AC, has been observed
in colorectal adenocarcinoma (CRC). Little is known, however, regarding their expression
in small intestinal adenocarcinoma (SIA). Methods: Formalin-fixed, paraffin-embedded tissue
sections from 31 primary, non-ampullary SIAs and 47 CRCs were immunohistochemically
evaluated for the expression of CDX2, villin, SIMA, MUC1, MUC2 and MUC5AC. A tumor
was considered negative if <5% of the tumor cells exhibited nuclear staining for CDX2,
apical staining (with or without cytoplasmic staining) for villin, or cytoplasmic staining (with
or without luminal staining) for SIMA, MUC1, MUC2 and MUC5AC. Positive staining was
recorded as diffuse if >50% of the tumor cells stained, or focal when 5-50% of the tumor
cells exhibited immunoreactivity. Results: As shown in the Table, all the six proteins were
variably expressed in SIA and CRC, but the frequencies of expression were significantly
higher in CRC with the exception of MUC1 which was expressed at a similar frequency in
SIA and CRC. SIA also more frequently exhibited a focal staining pattern for CDX2, villin,
SIMA, MUC2 and MUC5AC, whereas a diffuse staining pattern was evident in CRC. Coexpres-
sion of CDX2 and villin was observed in 11 of 26 (42%) SIAs, in contrast to all (100%)
CRCs (P<0.0001). Conclusions: The frequency of CDX2, villin, SIMA, MUC2 and MUC5AC
expression is significantly lower in SIA compared with CRC. These observations support
our recent observations that SIA is immunophenotypically distinct from CRC despite their
morphologic similarity. These results also suggest a potential value as diagnostic immunomar-
kers in the distinction between SIA and CRC when a metastasis is encountered.
Table. Differential expression of CDX2, villin, SIMA, MUC1, MUC2 and MUC5AC in SIA
and CRC
S1872
Mass Spectrometry Based Identification of Plasma Proteins That Identify
Intestinal-Tumor Bearing Mice
Kenneth E. Hung, Alvin T. Kho, David Sarracino, Larissa Georgeon Richard, Bryan
Krastins, Issac Kohane, Raju Kucherlapati
A robust colorectal cancer (CRC) screening test that utilizes a readily accessible body fluid,
such as plasma, would prove to be invaluable. For plasma biomarker discovery, mass
spectrometry based proteomics methods are particularly attractive. As a prelude to human
studies, we used the ApcMin mouse as a model for CRC. In order to increase the yield of
identified proteins, a Concavalin A column was used to enrich for glycoproteins prior to
liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. In order to avoid
any bias, we used LC-MS/MS to identify both total plasma proteome (TPP) and plasma
glycoproteome (PGP) profiles in tumor-bearing mice. LC-MS/MS analysis identified 149
proteins in the TPP and 99 proteins in the PGP. In the PGP, 27 additional proteins were
identified that were not in the TPP. Principal component analysis demonstrated that these
global plasma protein profiles were able to clearly distinguish between tumor-bearing ApcMin
and wild-type littermates. Leave-one-out cross-validation analysis established that global
TPP and global PGP profiles were able to correctly predict tumor-bearing animals in 89%
and 100% of cases, respectively. Wilcoxon’s ranksum test (p<0.05) was used on both global
TPP and PGP profiles to identify significant differentially expressed proteins in the tumor-
bearing versus control cohorts. Leave-one-out cross-validation analysis confirmed that the
significant differentially expressed proteins from both the TPP and the PGP were now able
to correctly predict tumor-bearing animals in 100% of cases. ELISA of the plasma confirmed
the presence of the most significantly upregulated protein. Analysis of the significant differen-
tially expressed proteins indicated that they might derive from both the tumor site and the
host response. Their biological significance will be discussed. As ApcMin mice present with
predominantly small bowel adenomas, we have also initiated plasma proteomic studies in
Apc Δ580 mice that present with a greater number of large bowel carcinomas. We used an
approach called Multidimensional Protein Identification Technology (MudPIT) in which
peptides are separated over a strong cation exchange column prior to LC-MS/MS analysis.
In these studies, we have identified well over 500-600 plasma proteins. These findings will
be discussed. In summary, we have identified plasma proteins from both the TPP and PGP
that segregate tumor-bearing from control mice. These results have direct clinical implications
for CRC screening. Further studies are needed to validate and investigate the biological
significance of these findings.
S1873
Clinical Significance of Prostaglandin E Synthase Expression in Gastric
Cancer Tissue
Katya Gudis, Atsushi Tatsuguchi, Ken Wada, Tetsuro Hiratsuka, Kazuhiro Nagata, Seiji
Futagami, Teruo Kiyama, Takashi Tajiri, Choitsu Sakamoto
Background: Several lines of evidence suggest that the COX-2/PGE2 pathway plays a crucial
role in cancer progression. In fact, elevated expression of cyclooxygenase-2 (COX-2) has
been found in various types of human cancer, including gastric cancer, and the selective
inhibition of COX-2 has been shown to inhibit gastric cancer growth in animal models.
Prostaglandin E synthase (PGES) functions downstream of COX-2 for PGE2 biosynthesis.
To date, at least three distinct isoforms of PGES have been cloned; one cytosolic PGES
(cPGES), and two microsomal fractions, mPGES-1 and mPGES-2. Although there have been
reports concerning the expression of mPGES-1 in gastric cancer, the clinical significance of
each of the three different prostaglandin E synthases remains unclear. Aims: To investigate
mPGES-1, mPGES-2, and cPGES expression in gastric cancer tissue, and to examine the
relationship of their expression to various clinicopathological factors and patient prognosis.
Patients and Methods: A total of 96 gastric cancer patients who had undergone surgery were
examined. mPGES-1 and mPGES-2 mRNA and protein expression levels were examined by
real-time polymerase chain reaction (PCR) and Western blot analysis, respectively. cPGES
protein expression levels were examined by Western blot analysis. mPGES-1 localization
was analyzed immunohistochemically. Immunostaining results for mPGES-1 were compared
with clinicopathological factors and COX-2 expression. Results: Real-time PCR and Western
blot analysis of mPGES-1 mRNA and protein expression showed significantly higher expres-
sion levels in gastric cancer tissues than in paired normal tissues. In contrast, mPGES-2
mRNA and protein expression levels did not differ significantly between cancer and paired
normal tissues. cPGES protein expression levels were also not significantly different between
cancer and paired normal tissues. Immunoreactivity for mPGES-1 was predominantly
observed in the cytoplasm of cancer cells in 42 cases (44%), with occasional weak mPGES-
1 immunoreactivity seen in stromal cells such as fibroblasts and macrophages. mPGES-1
expression correlated with vessel invasion, lymph node metastasis, depth, stage, and COX-
2 expression. The prognosis was significantly worse in patients with mPGES-1-positive
tumors than in those with mPGES-1-negative tumors. Conclusions: mPGES-1 protein may
have an important role in tumor progression in conjunction with COX-2, and may be a
biologic marker of prognostic significance in gastric cancer.
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S1874
Tumor M2-PK and Immunochemical FOBT: Valuable and Sensitive Tests for
Screening for Colorectal Cancer
Sanna Mulder, Monique E. van Leerdam, Rob J. Ouwendijk, Hanneke J. van Vuuren, Jan
Francke, Ernst J. Kuipers
Introduction: Screening for colorectal cancer (CRC) reduces morbidity and mortality from
this very common disease. Although biochemical fecal occult-blood testing (FOBT) is the
only non-invasive screening method proven to be effective in reducing CRC mortality, the
test has limited sensitivity. The ideal test for CRC screening should combine a high sensitivity
with an acceptable specificity. In this respect, immunochemical FOBT performs better than
biochemical tests. An alternative promising method is the determination of tumor pyruvate
kinase isoenzyme type M2 (Tu M2-PK) in stool samples. This may be a valuable new
screening tool for CRC. Aim: To compare the accuracy of faecal Tu M2-PK test with
immunochemical FOBT in patients with CRC or adenomas. Methods: Out-clinic patients
above 18 years of age referred for colonoscopy were asked to provide one stool specimen.
A subgroup of 123 subjects was analyzed, including 44 with invasive CRC, 35 with adenomas,
and 44 matched controls with a normal colonoscopy. A commercially Tu M2-PK ELISA
(Schebo Biotech) was used with a cutoff level of 4 U/ml. Two immunochemical FOBT tests,
Immo-care-C (CARE diagnostica) and OC-LIGHT (Eiken Chemical) were used for the
qualitative detection of faecal occult blood. Results: In subjects with CRC, the Tu M2-PK
test was positive in 37 of 44 (84%) patients, the Immo-care detected 40 (91%) and the OC-
Light identified 41 (93%). In subjects with adenomas, the Tu M2-PK test was positive in
9 of 35 (26%), the Immo-care detected 16 (46%) and the OC-Light identified 14 (40%).
Specificity in subjects with negative findings on colonoscopy was 91% for the Tu M2-PK
test and 95% for both the Immo-care and the OC-Light. Conclusion: Both the Tu M2-PK
and the immunochemical FOBT appear valuable and sensitive tests for screening for CRC.
The performance of these tests is similar. None of these tests is sensitive enough for detection
of advanced adenomas.
Results of three tests
PPV/NPV: Positive / Negative predicting value
S1875
The Expression of HER2 in Helicobacter Pylori Infected Intestinal Metaplasia
and Gastric Cancer
Noriko Nakajima, Yoko Ito, Kiyoshi Yokoyama, Satoshi Hayakawa, Shigeaki Mizuno,
Kimitoshi Kato, Noriko Kinukawa, Nemoto Norimichi, Arakawa Yasuyuki, Eric R. Lacy
Gastric cancers arise through a multistep process from chronic gastritis(CG) and intestinal
metaplasia(IM) and finally to invasive gastric cancer(GC). Long-term infection with Helicob-
acter pylori(HP) is one of the causalities for GC. Overexpression of HER2 gene and protein,
a transmembrane glycoprotein with tyrosine kinase activity, and a structure similar to EGF
receptor, has been reported in many adenocarcinomas of breast, esophagus and also stomach.
HER2 is a successfully exploited target molecule in biomolecular therapies of solid tumors.
IL-16, a pleiotrophic cytokine, may be involved in the pathophysiological process of chronic
inflammatory diseases. Thus it could be a factor in the final development of cancer. Aim:To
determine:1)changes in the expression of HER2 in IM and GC in gastric biopsies infected
with HP, 2)the effect of HP infection and IL-16 on epithelial cell proliferation and HER2
expression in gastric cells in vitro. Methods:HP infected gastric biopsies, were classified by
histological findings as a)CG+, b)IM or c)GC. CG without HP infection(CG-) was used as
a control. For In vitro studies, AGS cells were incubated with combinations of IL-16 and
HP. Cell proliferation was studied by BrdU uptake. The expression of Bcat was studied by
ABC, ELISA and RT-PCR. Results:IL-16 expression was detected in all HP infected gastric
mucosa. In CG+, HER2 protein(HER2-p) expression increased significantly(p<0.05) (CG-
:5.58±3.37% vs. CG+:7.56±3.36%). In HP infected mucosa, the HER2-p expression was
significantly higher in IM(12.01±7.46%) and GC(13.01±6.57%) than in CG+. In vitro stud-
ies:HP alone significantly decreased cell proliferation. Co-incubation of AGS cells with HP
and IL-16 increased BrdU uptake and HER2-p only at the higher IL-16 concentration. At
24hrs, co-incubation with IL-16 decreased the expression of HER2 mRNA in HP infected
AGS cells. Conclusions:The expression of HER2 in long-term HP infected gastric mucosa
may indicate an early stage in carcinogenesis, because it appears before the histologically
evident tumor. Short term in vitro exposure of cells to HP did not have this effect suggesting
a chronic and multi-factorial process.
In vitro cell culture using AGS cells:
All data was expressed as % of AGS cells only. *=significant difference from AGS only **=



















Analysis of Mucin Expression Patterns Is Useful for Accurate Diagnosis of
Gastric Borderline Lesions in Endoscopic Biopsy Samples
Hideki Minematsu, Yasuharu Saito, Rie Kakinoki, Akira Andoh, Ryoji Kushima, Yoshihide
Fujiyama
BACKGROUND: Recommendation for diagnosis and treatment of gastric borderline lesions
remains controversial. To elucidate those factors helpful for an accurate diagnosis of gastric
borderline lesions, we examined the mucin expression patterns in endoscopically-resected
and forceps-biopsy samples. METHODS: Sixty-three gastric lesions were histopathologically
diagnosed as borderline lesions based on endoscopic forceps biopsy. All of these patients
underwent endoscopic resection, and were divided into group A (final diagnosis an adenocar-
cinoma) and group B (final diagnosis as an adenoma). Immunostaining for MUC2, 5AC, 6
and CD10 were performed. The mucin phenotype classification was determined according
to the criteria described by Tsukashita et al[1]. Similar evaluation was performed in 28
forceps-biopsy samples. RESULTS: The percentage of lesions with redness was significantly
higher in group A than in group B (P<0.05). The percentages of a complete gastric phenotype
(positive for MUC5AC and MUC6) plus a mixed phenotype (gastric predominant type) were
significantly higher in group A (58.0 %) than in group B (21.8 %) (P<0.05). The percentage
of a complete intestinal phenotype (positive for MUC2 and CD10) was significantly higher
in group B (68.8 %) than in group A (19.4 %) (P<0.05). Similar results were also observed
in 28 samples of forceps-biopsy, which were histologically diagnosed as borderline lesion.
The percentage of a Ki-67 diffuse-immunostaining pattern was significantly higher in group
A than in group B (P<0.05). The positive ratio of p53 expression was 29.2% in group A
and 4.3% in group B, respectively, and was significantly higher in group A (P<0.05).
CONCLUSION: Determination of immunostaining for a mucin phenotype in forceps-biopsy
samples may be useful for an accurate diagnosis of gastric borderline lesions.
S1877
Alpha Fetoprotein Is a Marker of Aggressive and Progressive Neuroendocrine
Tumours
Tahir H. Shah, Mani Bhogal, Aneesha Noonan, Niroshan Sivathasan, Caroline Witney-
Smith, Tejal Amin, Daniel Hochhauser, Martyn E. Caplin
Background: Tumour markers are substances related to the presence or progression of a
tumour. Alpha Fetoprotein (AFP) is already well established as a marker for germ cell
tumours and hepatocellular carcinoma (HCC). Neuroendocrine tumours (NET) are usually
slow growing, although, a significant proportion follow an aggressive course. NETs are, in
part, characterised by an ability to secrete hormones and biogenic amines, some of which,
e.g. Chromogranin A, have been shown to correspond to disease state. Aims: To evaluate
the role of AFP as a potential tumour marker in NETs. Methods: 419 patients were randomly
selected from the Royal Free & University College Medical School NET unit database.
Retrospective analysis of AFP, histological grade and radiological progression was conducted.
These variables were correlated temporally. Raised AFP was defined as a level >50% above
the upper limit of normal. Patients in which another recognised cause of raised AFP was
identified were excluded. Radiological status was determined using the “Response Evaluation
Criteria In Solid Tumours” (RECIST) and divided into: regressive, stable, and progressive
disease. Tumour grade was based on standard histological classification and cell proliferation
markers (MIB-1), being divided into low, intermediate and high. Results: AFP was raised
in 23 of 419 patients with results available: 13 patients with metastatic NETs of unknown
origin; 9 patients with pancreatic NETs; and 1 patient with gastric carcinoid. One patient
with HCC was excluded. AFP is raised in 5.25% of the population and was associated with
tumour progression in 78% of patients as compared with 24% in the AFP negative population
(p<0.001). High-grade tumours represented 87% of the raised AFP group against 31% in
the AFP normal group (p<0.001). Conclusion: In the subset of NETs in which it is raised
AFP is a marker of aggressive disease. It is associated with both histologically aggressive
and clinically progressive disease. These patients are 3 times more likely to show radiological
tumour progression and high grade histology compared to those with normal AFP levels.
The next step is to quantify the changes in AFP and correlate these with changes in disease
state in the patients. This prospective analysis will allow us to determine the role of AFP
as a clinical parameter for monitoring tumour behaviour in individual patients.
S1878
Fluorescence in Situ Hybridization (FISH) Analysis of Endoscopic Brushings
Obtained from Barrett’s Esophagus (BE) Patients with Esophageal
Adenocarcinoma (EA)
Shannon Brankley, Aaron Harwood, Mona Legator, Lori Lutzke, Larry Morrison, Kenneth
Wang, Micheal Campion, Halling Kevin
Background: FISH is a technique that utilizes fluorescently labeled DNA probes to detect
chromosomal abnormalities in cells. Recent studies suggest that FISH can be used to detect
cells that have chromosomal abnormalities consistent with a diagnosis of dysplasia or aden-
ocarcinoma in cytologic brushing specimens from patients with Barrett’s esophagus. The
goal of this study was to assess the types of chromosomal alterations that are detected by
FISH in endoscopic brushing specimens obtained from patients with biopsy proven EA.
Methods: One hundred thirty endoscopic brushing specimens taken from 127 patients under
surveillance for Barrett’s esophagus were assessed by FISH. Eighteen (14%) of the 127
patients had a biopsy or endoscopic mucosal resection specimen showing EA. Twenty-one
brushings were obtained from these 18 patients. FISH was performed using probes to 8q24
(C-MYC), 9p21 (P16), 17q11.2-q12 (HER-2), and 20q13. One hundred consecutive non-
inflammatory, non-squamous cells were analyzed per specimen. A specimen was considered
positive for abnormality if: 1) ≥5% of the cells demonstrated polysomy (i.e. gains of two
or more of the four probes), 2) ≥5% of the cells exhibited trisomy (i.e. three copies) of the
8q24, 17q11.2, or the 20q13 probe, or 3) ≥10% of the cells exhibited hemizygous 9p21
deletion (i.e. deletion of one of the 9p21 probes). Results: The types of chromosomal
alterations detected by FISH are shown in the Table. All 18 patients were found to have
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one or more abnormality by FISH. Conclusions: DNA ploidy and cytogenetic studies have
previously shown that virtually all EA are hyperdiploid with extra copies of most of the
chromosomes. Thus, cells from these tumors should have polysomic or trisomic signal
patterns when examined with multi-color FISH probe sets such as the one used in this
study. This study reveals that the majority of the endoscopic brushing specimens did exhibit
polysomic (16 cases) or trisomic (2 cases) signal patterns. Only one patient had a FISH
result that was not consistent with the surgical pathology diagnosis of EA. The brushing
specimen from that patient exhibited hemizygous 9p21 deletion and an absence of polysomy.
Hemizyogus 9p21 deletion is a finding that is consistent with low-grade dysplasia but not
adenocarcinoma. This study suggests that FISH analysis of endoscopic brushing specimens
may be an accurate method for determining if a patient has EA.
S1879
EGFR Proteins Are Highly Expressed in Pseudomyxoma Peritonei
Elizabeth E. Half, Russell R. Broaddus, Kai Feng Liu, Laura A. Lambert, Cathy Eng, Paul
F. Mansfield, Robert S. Bresalier
Background. Pseudomyxoma peritonei (PMP) is characterized by intrabdominal accumula-
tion of large amounts of mucin secreted by adenocarcinomas (primarily of the appendix).
Complications due to mucin accumulation is the major cause of morbitidy and mortality
in patients with this disease. It is known that both COX-2 and epidermal growth factor
receptor (EGFR) are widely expressed in CRC and inhibition of these pathways may be
effective treatments. We have previously demonstrated that MUC2 and MUC5AC can be
suppressed by COX-2 or EGFR inhibitors in human colon cancer cells. There is currently
no effective treatment for patients with PMP. Aim. To determine COX-2, EGFR, and HER-
2 protein expression in human PMP tumors. Method. COX-2 (n=40), EGFR (n=30), and
HER-2 (n=16) protein expression was analyzed in formalin fixed, paraffin-embedded PMP
specimens from adenocarcinomas of the appendix. COX-2 was also analyzed from specimens
of normal appendix (n=10). Protein expression was determined by immunohistochemistry
using specific antibodies. Staining intensity (0 - 3+) and percent tumor cell positivity were
determined. A positive result was defined if > 10% of tumor cells had an intensity of > 2.
Results. EGFR protein expression was detected in 27 of 30 (87%) tumors. Strong (3+) diffuse
(>75%) membranous EGFR staining was detected in 15 of 30 (50%) of the cases. COX-2
expression was detected in only 3 of the 40 (7.5%) cases of PMP that were studied. None
of the normal specimens expressed COX-2. Only 2 of 16 (12.5%) tumors were positive for
HER-2. Conclusion. Our results indicate that in contrast to positive expression in colon
cancer, COX-2 is rarely expressed in PMP. EGFR is, on the other hand, frequently expressed
in PMP tumors, and inhibition of EGFR signaling may be a useful strategy in the treatment
of PMP.
S1880
Expression of the Tight Junction Proteins Cingulin, Occludin and Claudin-7 in
Human Gastrointestinal Tract Cancers
Ulrich-Frank Pape, Ines Eichhorn, Lutz Langbein, Werner W. Franke, Bertram
Wiedenmann
Tight junctions (TJ) are composed of various specific proteins which are differentially
expressed along the normal human gastrointestinal tract (GIT). The expression of TJ-molec-
ules in GIT-cancers and potential diagnostic implications have not yet been analyzed systemat-
ically. We have therefore studied the expression of occludin, cingulin and claudin-7 in
human GIT-cancers (n=92) by immunofluorescence microscopy using specific antibodies
and compared it to expression patterns in the corresponding normal GIT-epithelia. We
found expression of cingulin and occludin in all adenocarcinomas of the GIT (esophagus,
stomach, pancreas, liver, bile ducts, colorectum, neuroendocrine carcinomas) preferably at
luminal sites of glandular tumor structures. When no lumen was present the TJ-proteins
were localized mostly to the lateral cell membrane or diffusely within the cytoplasm. With
loss of differentiation grade cingulin and occludin expression semiquantitatively decreased
or were even absent from the neoplastic tissues. Interestingly, while claudin-7 cannot be
found in the normal human gastric mucosa it was found to be expressed in all gastric
adenocarcinomas with intermediate to strong positivity (n=12) suggesting a role of claudin-
7 as a marker of malignancy in these neoplasms. In hepatocellular carcinomas (HCC; n=8)
claudin-7 was found only weakly if at all expressed while a strong expression was found
in primary bile duct cancers(n=5) which correlates with the expression pattern in normal
tissues. Also of interest, high-grade malignant neuroendocrine carcinomas (NEC, n=8) dem-
onstrated almost no expression of occludin, cingulin or claudin-7 while low-grade malignant
NEC (n=17) expressed these TJ-proteins to a considerable stronger degree suggesting these
TJ-molecules maybe useful in pathological differential diagnosis of these tumors. In all other
GIT-cancers claudin-7 expresssion did not appear significantly different from occludin or
cingulin, however, in accordance with the subcellular localization in normal tissues claudin-
7 was localized to the lateral cell membrane rather than to the luminal site of epithelial
structures and with loss of differentiation a cytoplasmic claudin-7 staining was more apparent.
In summary, TJ-protein expression can be found not only in normal but also neoplastic
human GIT-tissues and it seems to correlate with the differentiation status at least in some
GIT-cancers to a significant degree, in particular in NEC. Furthermore, claudin-7 may be
an interesting molecule for histopathological evaluation of gastric cancers and primary liver
cancers for further differentiation of malignancy or of derivation of primary liver cancer.
S1881
Interphase Fish As a Biomarker of Gastric Cancer Risk in Helicobacter Pylori
Multifocal Intestinalized Pangastritis
Byung-Wook Kim, Mary P. Bronner, Mee-Yon Cho, Bo-In Lee
Background and aim: The only known marker of increased cancer risk in H. pylori-gastritis
is intestinal metaplasia (IM) of gastric mucosa, but IM is common and cancer develops in
only a fraction. The aim of this study is to identify better biomarkers of gastric cancer in
patients with intestinalized H. pylori-pangastritis. Method: Single endoscopic antral biopsies
with IM that was negative for dysplasia were studied in seven non-progressor (NP) patients
without gastric cancer and eight progressor (P) patients with gastric cancer. Interphase
nuclear preparations of epithelium isolated from stroma were analyzed by array-based
comparative genomic hybridization (a-CGH) and interphase fluorescence in situ hybridiza-
tion (FISH) using 18q21.1 and 4q32.3 BAC probes and a commercially available 9p21
probe. Results: A-CGH using high density 6000 BAC arrays did not reveal significant
differences between P and NP patients, nor did 4q32.3 or 9p21 FISH (p>0.05), each using
random non-dysplastic antral biopsies. Total FISH abnormalities (gains + losses) for 18q21.1,
however did distinguish P and NP patients (p<0.01). (Figure) Conclusion: Interphase FISH
for 18q21.1 offers promise as a biomarker of cancer risk in H. pylori intestinalized pangastritis,
even on single random non-dysplastic antral biopsies.
S1882
Trans-Activation of IGF-R By Fibronectin Protects from Apoptosis in
Pancreatic Cancer Cells
Mouad Edderkaoui, Izumi Ohno, Peggy Hong, Stephen J. Pandol, Anna S. Gukovskaya
Background & Aims: Pancreatic cancer is very fibrotic. Fibronectin and IGF-1 receptor (IGF-
R) are two major pro-survival environmental factors in pancreatic cancer. We hypothesize that
fibronectin trans-activates IGF-R in pancreatic cancer cells. The aim of this study is to
investigate the mechanism of IGF-R trans-activation by fibronectin and its effect on apoptosis
in pancreatic cancer cells. Methods: Human pancreatic carcinoma cells MIA PaCa-2 and
PANC-1 were cultured for up to 48h on polyHEMA (to prevent extracellular matrix protein
deposition and cell attachment) or on fibronectin. The expression and phosphorylation of
IGF-R, Akt, integin-linked kinase (ILK), protein tyrosine phosphatase (PTP) SHP-2, Bcl-2,
and BclxL were assessed by Western blot analysis. Interaction between proteins was assessed
by imunoprecipitation and Western assay. Apoptosis was measured by DNA fragmentation
using Cell Death ELISA kit, caspase activity, and AnV/PI staining. Results: The IGF-R inhibitor
AG-1024 as well as transfection with antisense IGF-R oligonucleotides prevent the pro-
survival effect of fibronectin in pancreatic cancer cells. Inhibiting IGF-R with both pharmaco-
logical and molecular approaches abolished fibronectin-induced activation of downstream
anti-apoptotic signaling, in particular, PI3-K activation and expression of anti-apoptotic
protein BclxL. We show that fibronectin trans-activates IGF-R by stimulating its phosphoryl-
ation. The fibronectin-induced activation of IGF-R is independent of IGF-1. IGF-R was
phosphorylated in cells cultured on fibronectin and in the presence of IGF-1 neutralizing
antibody. Our immunoprecipitation data indicate that fibronectin stimulates complex forma-
tion between its receptor β3 integrin, ILK and SHP-2. This complex prevents the SHP-2 from
dephosphorylating IGF-R. Conclusion: IGF-R mediates the pro-survival effect of fibronectin in
pancreatic cancer cells. Trans-activation of IGF-R by fibronectin results in activation of
downstream PI3-K and BclxL expression. Fibronectin trans-activates IGF-R by up-regulating
its phosphorylation. Fibronectin interacts with integrin β3 inducing recruitment of ILK and
SHP-2. The later prevents SHP-2 from dephosphorylating IGF-R. The results suggest SHP-
2 and ILK as potential therapeutic targets to regulate apoptosis in pancreatic cancer cells.
The results also suggest that targeting IGF-R, as well as the SHP-2 and ILK, would prevent
anti-apoptotic effects of both IGF and fibronectin in pancreatic cancer cells.
S1883
High-Resolution Genomic Profiling in Human Pancreatic Carcinoma By
Genechip Mapping 100k Array
Lian-Jie Lin, Fumihiko Kanai, Motohisa Tada, Yasuo Tanaka, Keisuke Tateishi, Masashi
Sanada, Yasuhito Nannya, Seishi Ogawa, Masao Omata
Background and Aim: Pancreatic carcinoma is characterized by aggressive tumor growth and
high metastatic rate resulting in an extremely poor prognosis. The pancreatic adenocarcinoma
genome harbors multiple amplifications and deletions, pointing to the existence of numerous
oncogenes and tumor suppressor genes driving the genesis and progression of this lethal
cancer. The initial comparative genomic hybridization (CGH) firstly enabled the genome-
wide detection of copy number changes, but at low resolution ( ∼20 Mb). In this study,
using high-density single nucleotide polymorphism (SNP) array, we sought to chart the
molecular genetic events in this cancer with the goals of improving early detection and
providing new therapeutic targets. Materials and Methods: A total of 25 established cell lines
derived from pancreatic carcinomas or their metastases were included in the investigation.
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We isolated high-quality genomic DNA from these cell lines and analyzed for high-level
amplification, homozygous deletion and loss of heterozygosity (LOH) using the Affymetrix
GeneChip Mapping 100K high-density oligonucleotide arrays, which contain 116,204 SNPs
with a mean spacing of 23.6 kb. We used the software named Copy Number Analyzer for
GeneChip (CNAG) as our original data analysis tool, which automates the detection of copy
number and LOH. Then we performed the PCR, quantitative real-time PCR and fluorescence
in situ hybridization (FISH) to verify the results of array analysis. Results: Twenty-seven
regions of high-level amplification (n > 4) were found in at least two cell lines, and the
most frequent copy number gains were found in chromosome region 12p12.1 - 12p11.23,
found in 6 cell lines. The size of minimal common amplicon was 114 kb. Thirty regions
of homozygous deletion were detected in at least one cell line, and the most frequently
region was 9p21.3, found in 12 cell lines. The size of minimal deletion was 17 kb. In
addition to known genetic abnormalities, such as amplification of K-ras gene and deletion
of p16 gene, high- level amplification region on 3q25 and homozygous deletion region on
8q23 were newly identified. LOH on chromosome arm18q, 9p, 17p, 13q, 6q, 3p, 6p, 22q,
9q, and 12q was observed with high frequency. Conclusion: The high-resolution mapping
array can help us detect the copy number alterations to understand the pathogenesis of
pancreatic cancers, and provide a highly efficient entry point for cancer gene discovery. And
the novel amplified and deleted regions discovered in this study may become the target for
early diagnosis and therapy in pancreatic cancer.
S1884
Biochemical and Functional Characteristics of Primary and Secondary Tumors
in a Spontaneous Model of Pancreatic Adenocarcinoma
Richard J. Aspinall, Sara Weis, Kevin Kuo, Paul J. Pockros, David A. Cheresh
INTRODUCTION: Micrometastases are already present at diagnosis in the vast majority of
patients with pancreatic adenocarcinoma and are an important target for future anticancer
therapies. We wished to see if cells from either primary or metastatic lesions display distinct
biochemical or functional characteristics. In particular, we examined whether abnormal SRC
family kinase activity was associated with a metastatic phenotype. We used a genetic model
of spontaneous metastatic ductal adenocarcinoma characterized by a pancreas-specific G12D
K-ras mutation and p16Ink4a/Arf knockout (Aguirre et al, Genes Dev 2003). METHODS:
Pdx-Cre/InkArf-lox mice were bred with LSL-Kras G12D mice to produce offspring with
early PanIN lesions and spontaneous pancreatic cancer. Animals with established carcinomas
were sacrificed, primary tumors were excised and internal organs (lymph nodes, lung, liver,
brain, heart, kidneys, spleen, peritoneum) harvested to isolate secondary tumors. Tissue
specimens were minced, subjected to a collagenase digestion and cells grown in sterile
medium with 10% serum. Proliferation, adhesion and migration assays were performed on
matrix proteins including collagen, vitronectin and fibronectin. Signaling profiles of starved
and growth factor-stimulated cells were obtained using immunoblotting for basal and stimu-
lated levels of FAK, p-FAK, SRC, P-SRC, B-catenin, MEK, p-MEK and ERK2. Cells were
stained on coverslips with similar immunohistochemistry antibodies before confocal micro-
scopy. Functional and biochemical profiles were also assessed in the presence of novel small
molecule inhibitors of SRC, MEK and RAF. RESULTS: All mice developed spontaneous
pancreatic cancer. None survived beyond 12 weeks. Primary tumors ranged from 0.8-4g.
Metastases were mainly in lymph nodes (retroperitoneal, mesenteric and para-aortic) but
also in the liver, lungs, peritoneum and soft tissue. A total of 25 cell lines were created,
most with primary and secondary pairs from the same mouse. Differential signaling patterns
were seen on Western blotting with identification of lymph node pairs showing enhanced
activated P-SRC in the metastases. Secondary lines from lymph node and liver metastases
appeared less responsive to SRC inhibitors than paired primaries. DISCUSSION: Pairs of
primary and secondary tumors demonstrating important biochemical and functional differ-
ences can be identified. We are currently examining whether cells with elevated basal SRC
levels have increased tumorigenicity or are more likely to metastasize in vivo. We are also
exploring whether SRC activity profiling can predict the response to SRC inhibitor drugs.
S1885
New Technologies for Nanoscale Cell Surface Analysis Reveal Potential for
New Diagnostic Tools in Gastrointestinal Tumor Detection
Ilona Bredebusch, Bjoern Kemper, Daniel Carl, Gert von Bally, Wolfram Domschke,
Juergen Schnekenburger
Introduction: The diagnosis of pancreatic tumors is impaired by low amount of available
material for molecular in vitro diagnostics and the limited applicability of novel technologies
in early in vivo diagnosis. These obstacles can be overcome by the application of nanoscale
surface analysis technologies in the measurement of morphological and physical properties
of cellular systems. Here we applied new cell surface analysis technologies to pancreatic
tumor cells modified in the expression of the tumor suppressor gene E-Cadherin. Methods:
Fixated pancreas tumor cell lines were dehydrated and dried for scanning electron microscopy
(SEM). Cells were coated with platinum and carbon and analyzed using a standard SEM.
For atomic force microscopy (AFM) and digital holographic analysis sub confluent cells on
glass slides or tissue culture plates were cultured for 24 hrs and analyzed in vivo at room
temperature and normal atmosphere. Digital holography could reconstruct a 3 dimensional
image of the morphology of living pancreas tumor cells and gastrointestinal tumor specimen.
Results: E-Cadherin regulates cell-cell contacts and is frequently downregulated during tumor
metastasis. E-Cadherin reexpression in metastatic pancreas tumor cell lines resulted in an
increased capacity of colony formation, reestablishment of cell-cell contacts and an inhibition
of the metastatic potential. Most interestingly SEM analysis of E-Cadherin reexpressing cell
lines revealed an altered morphology, the cells showed a flattened phenotype indicating a
rearrangement of the actin cytoskeleton. Atomic force microscopy and digital holography
on living cells demonstrated a decrease in cell height of more than 60 %. The measurement
of the surface elasticity of tumor tissue and surrounding healthy tissue from freshly isolated
gastrointestinal specimen using digital holography showed a significantly higher elasticity
of tumor tissue. Conclusion: These results demonstrate that in principle the correlation of
protein expression data, biological cell features and cell surface properties can generate

















analysis. Digital holography can be used for marker free and non invasive complex tissue
analysis. The future application of marker free and partly non invasive nanoscale analysis
methods like digital holography offers novel endoscopical in vivo diagnostics for the identi-
fication of malignant lesions based on physical cell properties as cell surface elasticity.
S1886
Granulocyte Colony Stimulating Factor Receptor Promotes β1-Integrin
Mediated Adhesion and Invasion of Pancreatic Cancer Cells
Arup Chakraborty, Zhimin Tong, Kai-Feng Liu, Robert Bresalier, Sushovan Guha
BACKGROUND: Pancreatic cancer (PaCa) is a devastating disease with strong invasive
potential. Understanding the molecular events that contribute to invasiveness of pancreatic
cancer (PaCa) cells is critical to the development of novel therapeutic strategies for this
potentially fatal disease. β1-integrin plays an important role in adhesion and invasion of
multiple cancer cells including PaCa. Several in vitro studies have suggested that granulocyte
colony-stimulating factor (G-CSF) can promote cancer growth. Aberrant expression of G-
CSF and its corresponding receptor (G-CSFR) are reported in multiple transformed epithelial
cell types including bladder, breast, and colorectal carcinoma cells. The role of G-CSF/G-
CSFR in cancer development, however, is not clear. We recently demonstrated that G-CSFR
signaling pathways potently promote β1-integrin-mediated adhesion and invasion of bladder
cancer cells. AIM: Determine the expression and role of G-CSF/G-CSFR in mediating adhesion
and invasion of PaCa cells. METHODS & RESULTS: G-CSFR is expressed in multiple PaCa
cells, with lower expression in Capan-2, BxPC-3, and AsPC-1 cells (well to moderately
differentiated PaCa) and higher expression in MIA PaCa-2 and PANC-1 cells (moderate to
poorly differentiated PaCa) by RT-PCR and western blot analyses. G-CSF production as
measured by ELISA was higher in MIA PaCa-2, BxPC-3, and PANC-1 as compared with
Capan-2 and AsPC-1. Using flow cytometry and western blot analyses, we demonstrated
that G-CSF potently induced expression of b1-integrin in PaCa cells. Further, G-CSFR-
mediated increased expression of β1-integrin is abrogated by G-CSF-specific antibody or
G-CSF-specific siRNA in PaCa cells. G-CSFR signaling increased adhesion of PaCa cells to
HUVEC, which was potently blocked by a β1-integrin-specific antibody. G-CSF/GSFR sig-
naling pathways significantly increased invasiveness of PaCa cells, which was reduced either
by attenuating G-CSF production (G-CSF-specific antibody and G-CSF-specific siRNA) or
by interfering with G-CSFR signaling (transient transfection of truncated G-CSFR, GR19).
Neutralization of β1-integrin with a specific antibody completely blocked G-CSFR-mediated
invasion of PaCa cells. We also confirmed aberrant G-CSFR expression in resected pancreatic
tumors with G-CSFR-specific immunohistochemistry of formalin-fixed paraffin sections.
CONCLUSION: These data suggest that autocrine/paracrine G-CSF/G-CSFR signaling signi-
ficantly contributes to β1-integrin-mediated adhesion and invasion of PaCa cells. This novel
finding may explain, in part, the mechanisms by which β1-integrin contributes to major
invasive potential of PaCa cells.
S1887
Gene Expression Profiles of Pancreatic Neuroendocrine Tumors and
Gastrointestinal Carcinoids
Eva-Maria Duerr, Yusuke Mizukami, Andrew L. Warshaw, Matthew H. Kulke, Daniel C.
Chung
Pancreatic neuroendocrine tumors (PNET) and gastrointestinal carcinoids (GI-carcinoids)
are rare tumors of neuroendocrine origin that share many common features. One particular
difficulty is distinguishing benign from malignant tumors based on histology alone. Although
some features such as tumor size, angioinvasion and proliferative activity of more than 2%
are suggestive of malignancy, the only definitive criterion is the presence of distant metastases.
Molecular markers may potentially provide a more accurate means of predicting tumor
behavior as well as distinguishing PNETs from GI-carcinoids. Methods: The gene expression
profiles of 19 PNET samples (5 benign, 6 low-grade malignant, 8 malignant) and 6 malignant
GI-carcinoids were investigated using the Affymetrix Human Genome U133 Set. Quantitative
RT-PCR was performed to confirm gene expression levels. Results: Affymetrix data were
analyzed utilizing the DChip software package. When GI-carcinoids and malignant PNETs
were analyzed together, 269 genes were dysregulated. 25 of these genes were upregulated
in GI-carcinoids only. One of them was c-Ret, an oncogene frequently mutated in MEN2A
and familial thyroid cancer. Quantitative RT-PCR confirmed the selective upregulation of
c-Ret in carcinoids. Sequencing did not reveal any mutations in tumor samples and no gene
rearrangements were identified. When PNETs only were analyzed, 2 clusters emerged. One
“malignant” cluster comprised 7/8 malignant PNETs, 1/5 benign PNETs and 2/6 low-grade
malignant PNETs. The remaining 1/8 malignant and 4/6 low-grade malignant tumors clus-
tered in a second “benign” group with 4/5 benign tumors. 330 genes were differentially
regulated. Among the upregulated genes in the “malignant” cluster were IGFBP3 and TM4SF4,
both of which regulate cell proliferation. Quantitative RT-PCR confirmed a 3-fold and
16-fold upregulation, respectively. Other upregulated genes included Nuclear Prelamin A
recognition factor, Caldesmon 1 and Adenylate Cyclase 1. Conclusion: Molecular profiling
can distinguish GI-Carcinoids from PNETs. Within the group of PNETs, histologically low-
grade malignant tumors appeared to cluster with benign tumors on a molecular level. Thus,
a molecular classification of neuroendocrine tumors may provide a more accurate tool to
predict tumor behavior, as well as provide novel insights into tumor pathogenesis.
S1888
Resveratrol and Embelin Increase Apoptosis and Decrease Proliferation in
Pancreatic Cancer Cells Through Regulation of IAPS
Mouad Edderkaoui, Izumi Ohno, Stephen J. Pandol, Anna S. Gukovskaya
Background & Aims: Pancreatic cancer is a very aggressive disease that is resistant to different
radio and chemo-therapies. One reason for that is the resistance of pancreatic cancer cells
to apoptosis because of the over-expression of anti-apoptotic proteins such as survivin and
XIAP. Survivin and XIAP belong to the IAPs family (inhibitor of apoptosis proteins), which
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prevent caspase activation and subsequent execution phase of apoptosis. Recently, two
phytochemicals have been shown to inhibit different IAPs. Resveratrol, which is present in
grapes and in a variety of medicinal plants was recently shown to decrease the expression
levels of IAP-1/2 and survivin. Embelin, phytochemical derived from the Japanese Ardisia
herb prevents XIAP inhibition of caspases without affecting its expression. Methods: Human
pancreatic carcinoma cells MIA PaCa-2 and PANC-1 were cultured for up to 72h in the
presence or absence of resveratrol and/or embelin. The expression of IAP1, IAP2, survivin
and XIAP were assessed by Western blot and analysis. Apoptosis was assessed by measuring
DNA fragmentation using Cell Death ELISA kit, AnV/PI staining, and caspase activity.
Proliferation was assessed by measuring H3-thymidine incorporation. Results: Resveratrol
dose-dependently (5-200 μM) increases apoptosis in MIA PaCa-2 and PANC-1 cells. This
effect was associated with decrease in the expression level of IAP1/2 and survivin. Embelin
stimulated apoptosis at doses from 5 to 50 μM in MIA PaCa-2 and PANC-1 cells. Both
resveratrol and embelin stimulated caspase activation. They also decreased proliferation of
pancreatic cancer cells. Combination of resveratrol and embelin increases apoptosis and
decreases proliferation to a greater extent than the phytochemicals alone in pancreatic cancer
cells. For example, at 48h resveratrol (50 μM) increases DNA fragmentation 4 times, embelin
(20 μM) increase it twice, and combination of both phytochemicals increases apoptosis by
~7 times. Conclusion: IAPs are key pro-survival proteins in pancreatic cancer. In previous
studies, we showed that caspase blokade is a major mechanism for the low apoptosis rate
in pancreatic cancer. Thus, stimulation of caspase activity by inhibiting IAPs with resveratrol
and embelin is of particular clinical importance for pancreatic cancer. Inhibition of IAPs
with resveratrol and embelin not only increases apoptosis, but also decreases proliferation.
Combination of resveratrol and embelin could be used as a potential treatment for pancre-
atic cancer.
S1889
Identification of Novel Differential Proteomic Biomarkers in Pancreatic Cystic
Neoplasm Fluid
James J. Farrell, Puneet Souda, Babak Hasanzadeh, Julian Whitelegge, Kym Faull
Background: Preoperative differentiation of premalignant and malignant(mucinous) from
benign (serous) pancreatic cysts is difficult. We applied proteomic technologies to identify
novel proteins in pancreatic cyst fluid which may more accurately predict pathology preoper-
atively. Methods: Pancreatic cyst fluid was collected by EUS-FNA from patients with patholo-
gically confirmed cysts. Cyst fluid proteomic analysis with 2-D electrophoresis (2DE) and
2 dimensional liquid chromatography (PF2D) was performed.PF2D fractions were digested
and spots from 2D gels were excised and digested. Mass Spectrometry was used to identify
unique differential proteins using LC-MS/MS and MALDI-TOF. Results: 42 pancreatic cyst
fluid samples were collected. Protein concentration ranged from 1-5 mg/ml. 5 samples (2
mucinous and 3 serous cysts) were analyzed, showing a striking differential protein profile
between serous and mucinous fluid(by PF2D in both dimensions).Overlay of the 2-D maps
of serous and mucinous cysts suggest many proteins unique to each cystic neoplasm (Fig.
1). Over 700 proteins fractions/sample were collected. Using 2-DE we have already identified
over 20 proteins using LC-MS/MS. Conclusions: This is the first report detailing the proteome
of pancreatic cystic neoplasm fluid. Differential protein expression was found between
pancreatic mucinous and serous cyst fluid. Identification of specific protein patterns may
result in highly accurate serum based or cyst fluid based biomarkers.
Fig. 1. Overlay of cyst fluid two-dimensional protein profiles. Prominent peaks observed in
pancreatic mucinous cysts but not in pancreatic serous cysts are circled.
S1890
Interleukin-13 Receptor Alpha2 Expression and Its Targeting By IL-13
Cytotoxin in Pancreatic Ductal Adenocarcinoma
Takeshi Shimamura, Syed R. Husain, Raj K. Puri
Patients with pancreatic ductal adenocarcinoma (PDA) have a median survival of less than
six months from diagnosis. Due to its late detection, rapid progression and resistance to
chemo- and radiotherapy, median survival is marginally improved with current standard
therapies. We previously demonstrated that IL-13 cytotoxin comprised of IL-13 and a
truncated form of Pseudomonas exotoxin (IL13-PE38QQR) eradicates IL-13Ra2-overexpress-
ing glioblastoma, AIDS-kaposi’s sarcoma, and head and neck tumors in mice. Based on our
pre-clinical studies, IL13-PE38QQR is being tested in a phase III clinical trial in patients
with recurrent glioblastoma. We now report for the first time that 36 of 77 (47%) tumor
samples from PDA patients also express moderate to high density IL-13Ra2 as determined
by immunohistochemistry. In contrast, IL-13Ra2 expression was not detected in the ductal
or acinar cells of normal pancreas (n=13). The RT-PCR and FACS analysis of eight PDA
cell lines revealed that three (HS766T, CaPan-1, and Miapaca-2) of them were strongly
positive for IL-13Ra2 expression. No IL-13Ra2 was detected in normal pancreas ductal cells.
As expected, these three IL-13Ra2 positive cell lines were quite sensitive to IL13-PE38QQR,
exhibiting a 50% protein synthesis inhibition compared to control cells (IC50) over a range
of >0.1-80 ng/ml. Normal pancreatic ductal cells and HUVEC were not sensitive (IC50=
>1000 ng/ml). The incidence of IL-13Ra2 expression in almost half of the clinical samples
makes PDA a good candidate for IL13-PE38QQR therapy.
S1891
Inhibition of Bcl-2/Bcl-Xl Proteins Stimulate Apoptosis and Inhibit
Proliferation of Pancreatic Cancer Cells
Izumi Ohno, Mouad Edderkaoui, Patrick B. Truong, Irina V. Odinocova, J.N. K. Lee,
Hiromitsu Saisho, Anna S. Gukovskaya, Stephen J. Pandol
Background and Aims: Inhibition of anti-apoptotic Bcl-2 and Bcl-xL proteins is a novel
strategy for cancer treatment. Two inhibitors of Bcl-2/Bcl-xL, BH3I-2’ and HA-14, have
recently become available and were shown to stimulate death in several types of cancer
cells. Pancreatic cancer (PaCa) cells are notoriously resistant to apoptosis and express high
levels of both Bcl-2 and Bcl-xL. The aim of the present study was to determine the effects
of the Bcl-2/Bcl-xL inhibitors on apoptosis and proliferation of PaCa cells, and the mechanisms
underlying these effects. Methods: MIA PaCa-2 and PANC-1 cells were cultured with and
without BH3I-2’ and HA-14 for up to 48 hours. We measured apoptosis with Cell Death
ELISA and Annexin V/PI staining (flow cytometry); cytochrome c release, by Western blot;
reactive oxygen species (ROS), with the fluorescent dye DCF; and proliferation, by 3H-
thymidine incorporation. Mitochondria were isolated from PaCa cells by differential centrifu-
gation. In isolated mitochondria, we measured the effects of BH3I-2’ and HA-14 on ΔΨm,
respiration and ROS using, TPP+ and Clark electrodes and the fluorescent dye Amplex-
Red, respectively. Results: BH3I-2’and HA-14 markedly stimulated apoptosis and inhibited
proliferation in PaCa cells. For example, in MIA PaCa-2 cells cultured for 48 h with 10 μM
BH3I-2’ apoptosis was 7-fold higher and proliferation 8-fold lower than in control cells.
The inhibitors stimulated apoptosis and suppressed proliferation in the same range of
concentrations (1-100 μM) at which they inhibited Bcl-2/Bcl-xL activities, as measured
by fluorescence polarization assay. At the molecular level, BH3I-2’ and HA-14 stimulated
cytochrome c release and inhibited mitochondrial ROS production, resulting in a decrease
in intracellular ROS. The observed stimulation of cytochrome c release, a key mediator of
apoptosis, represents one mechanism through which the Bcl-2/Bcl-xL inhibitors induce
apoptosis in PaCa cells. Another mechanism whereby Bcl-2/Bcl-xL inhibitors induce death
responses could be through inhibition of ROS. Indeed, we recently showed that ROS play
a pro-survival role in PaCa cells by activating anti-apoptotic pathways such as PI3K/Akt.
ROS are also known to mediate proliferation of cancer cells. Conclusions: Specific Bcl-2/
Bcl-xL inhibitors induced apoptosis and inhibited proliferation in PaCa cells. The underlying
mechanisms include stimulation of cytochrome c release and inhibition of intracellular
ROS. The results indicate that inhibiting Bcl-2/Bcl-xL is a promising approach to suppress
tumorigenesis and stimulate apoptosis in PaCa cells, thus overcoming pancreatic cancer
resistance to treatments.
S1892
Engineering Diphteria Toxin in Pancreatic Cancer Cells: A Promising Tool for
Therapy
Paola Fogar, Filippo Navaglia, Eliana Greco, Alessia Stranges, Carlo-Federico Zambon,
Alessandra Falda, Daniela Basso, Sergio Pedrazzoli, Mario Plebani
Backgrownd and aim: Gene therapy using diphteria toxin (DT) is a promising tool for cancer
cell killing. It causes a rapid cell death catalysing ADP-ribosylation of elongating factor 2
and kills cells by an apoptosis-mediated pathway. Our aim was to test the ability of the DT
catalytic subunit (fragment A comprising 1-193 aa residues) (DTA) to kill 5 different pancre-
atic cancer cell lines, four obtained from primary tumors (BxPC3, PANC1, PSN1 and
MIAPaCa2) and one from hepatic metastasis (CAPAN1). Methods: DTA was subcloned in
an eukariotic expression vector (pRc) under the control of a constitutive promoter (RSV).
Lipofectamine 2000 was used to transfer the DNA vector into the cells. The efficiency of
transfection was evaluated by FACS analysis, using a FITC-oligonucleotide as tracer, 24
hours after transfection. The efficiency of transcription was evaluated by FACS analysis and
western blotting after 48 hours from transfection with a reporter gene (GFP) cloned in pRc.
Study design was: 1. transfection of 250.000 cells for 6 h with 4 ug DNA; 2. after 24 h
cells were seeded in quadruplicate in a 96-well plate; 3. cell growth was evaluated daily for
3 days by the cell viability XTT test. Results: More than 50% of cells were efficiently
transfected. GFP transcription was recorded in four out of the five cell lines studied: CAPAN-
1 did not translate the inserted gene. In agreement this cell line was resistant to DTA gene
transfer. A complete growth inhibition was achieved after DTA gene transfer in BxPC3,
PANC1, PSN1 and MIAPaCa2 (figure). Conclusions: DTA expression is lethal for pancreatic
cancer cells and this supports the potential use of this toxin for pancreatic cancer gene
therapy. The lack of gene translation found in CAPAN-1 cells, a metastatic cell line, might
be consequent to the absence of specific transcription factors recognizing the RSV promoter.
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S1893
Opposing Actions of Prostaglandin E2 and Prostaglandin E3 On Pancreatic
Cancer Cell Proliferation and Invasion
Hirozumi Sawai, Makoto Satake, Sascha Hasan, Howard A. Reber, Oscar J. Hines, Guido
Eibl
Background and Aim: Epidemiologic studies suggest that fish oil, rich in n-3 polyunsaturated
fatty acids (PUFA), possesses anti-tumor activity. Increased consumption of n-3 PUFAs
appears to alter the composition of membrane fatty acids resulting in the generation of a
modified prostaglandin profile. While the n-6 PUFA arachidonic acid (AA) is the substrate
for the formation of prostaglandins of the 2-series (PGE2), the n-3 PUFAs eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA) are converted to prostaglandins of the 3-series
(PGE3). The aim of the present study was to evaluate the effects of AA and EPA, as well as
of PGE2 and PGE3, on the growth and invasion of pancreatic cancer cells in vitro. Methods
and Results: AA dose-dependently (0-10 μM) increased the growth of pancreatic cancer
(PaCa) cells within 24 hours as determined by the MTT assay and cell count, and stimulated
cell invasion as measured by the Matrigel invasion assay. This effect was restricted to PaCa
cells that expressed the COX-2 enzyme, e.g. BxPC-3. In contrast, EPA dose-dependently
(0-10 μM) decreased proliferation and invasion of COX-2 positive PaCa cells. While AA
dose-dependently increased PGE2 production of COX-2 positive PaCa-2 cells, EPA decreased
the formation of PGE2 (p<0.01). PGE2 dose-dependently (0-10 μM) enhanced proliferation
and invasion, whereas PGE3 (0-10 μM) reduced these parameters in BxPC-3 cells (p<0.01).
PGE signals by binding to EP receptors, of which 4 subtypes have been described (EP1-
EP4). The effects of PGE2 and PGE3 on cell growth and invasion were inhibited by a combined
EP1/EP2 antagonist (AH6908) and a selective EP4 antagonist (ONO-AE3-208). In contrast,
selective EP1 and EP3 antagonists (ONO-8711 and ONO-AE3-240, respectively) had no
inhibitory effect. The selective EP2 agonist butaprost (0-10 μM) increased PaCa cell invasion.
Conclusions: The n-6 PUFA AA and PGE2 stimulated, whereas the n-3 PUFA EPA and
PGE3 reduced PaCa cell growth and invasion in vitro. The effects of PGE2 and PGE3 were
mediated by the EP2 and EP4 receptors. Our findings support the notion that diets rich in
n-3 PUFAs may be therapeutic in the modulation of pancreatic cancer biology.
S1894
RNAI-Based Knockdown of Bcl-2 Sensitises Pancreatic Cancer to Gemcitabine
Treatment
Matthias Ocker, Daniel Neureiter, Gabi Sass, Steffen Zopf, Marion Ganslmayer, Kinya
Okamoto, Eckhart G. Hahn, Christoph Herold
Background: Pancreatic cancer is a tumor with high intrinsic chemotherapy resistance. This
has been linked to the overexpression of anti-apoptotic bcl-2. Knockdown of bcl-2 by siRNA
inhibits proliferation and induces apoptosis in pancreatic cancer cells in vitro and in vivo
(Ocker et al., Gut 2005;54:1298-308). We now investigated if and to what extend the
knockdown of bcl-2 sensitises pancreatic cancer cells to gemcitabine treatment in vitro and
in vivo. Methods: Knockdown of bcl-2 was achieved in YAP C pancreatic cancer cells by
transfecting specific siRNA or shRNA constructs. After 72 h, different concentrations of
Gemcitabine were added and apoptosis was determined by propidium iodide staining.
Changes in protein and mRNA levels were determined by western blotting and quantitative
RT-PCR. 5x106 cells were injected subcutaneously into male NMRI mice. Mice were treated
intraperitoneally with low dose Gemcitabine (8 mg/kg every 4th day) and siRNA against
bcl-2 or GFP. Tumor growth was determined daily and verified by immunohistochemistry,
qRT-PCR and western blotting after 21 days. Results: Gemcitabine inudeced apoptosis at
0.1 µM or higher but was ineffective at 0.01 µM or below. The pre-transfection of bcl-2-
specific siRNA and the addition of 0.01 µM Gemcitabine lead to a time-dependent induction
of apoptosis, reaching 50% after 72 h of Gemcitabine treatment. Apoptosis was not induced
in combinations of mock or control siRNA transfections with 0.01 µM Gemcitabine. In vivo,
8 mg/kg every 4th day Gemcitabine alone or in combination with siRNA against GFP lead
to a 50% reduction in tumour size after 21 days compared to saline controls. Combination
of Gemcitabine with bcl-2-specific siRNA lead to a stable tumor size for 21 days, with a
tumor size of 12.5% of untreated controls. Conclusions: RNAi-mediated knockdown of bcl-
2 sensitizes human pancreatic cancer cells to Gemcitabine-induced apoptosis in vitro and
delays growth of YAP C xenografts in nude mice. This strategy might contribute to the


















Nobel Function of Synthetic Serine Protease Inhibitor (FUT-175) As Apoptosis
Inducer of Pancreatic Cancer
Tadashi Uwagawa, Paul J. Chiao, Katsuhiko Yanaga
Background and Aims:Prognosis of pancreatic cancer is extremely poor. Most patients are
diagnosed unresectable mainly due to locally advanced or metastatic disease. Furthermore,
chemotherapy and radiotherapy have largely failed to improve survival. Advances in molecu-
lar biology have lead to improved understanding of pancreatic cancer. A number of studies
suggest that constitutive nuclear factor-κB (NF-κB) plays a key role in the growth of pancreatic
cancer. In an attempt to identify a novel and effective therapeutic agent for pancreatic cancer,
we studied the role of synthetic serine protease inhibitor, FUT-175 that has already been
used clinically for pancreatitis or disseminating intravascular coagulation (DIC) in Japan.
Methods: The human pancreatic adenocarcinoma cell line MDAPanc-28 was treated with
FUT-175, then assays were performed to investigate the effects of FUT-175 on pancreatic
cancer cells. Results: FUT-175 induced apoptosis of human pancreatic cancer cells in a
time- and dose-dependent manner. FUT-175 inactivated the antiapoptotic activity of NF-
κB by blocking IKK-mediated IκBα phosphorylation. Simultaneously, FUT-175 activated
the proapoptotic caspase-8 pathways by upregulating the expressiom of tumor necrosis
factor receptor-1 (TNFR1) and induced apoptosis in pancreatic cancer cells. FUT-175-
induced activation of caspase-8 was suppressed by RNA interference-mediated inhibition
of TNFR1 expression, suggesting that FUT-175-induced activation of caspase-8 is TNFR1-
dependent. Furthemore, expression of transcription factor PEA3 was upregulated by FUT-
175, which was essential to FUT-175-mediated TNFR1 expression. These results demon-
strated a possible mechanism by which FUT-175 may both suppress the NF-κB antiapoptic
activity and induce TNFR1-mediated apoptosis. Conclusion: As suggested by the dual func-
tion of FUT-175 as NF-κB inhibitor and TNFR1-mediated caspase-8 activator, this synthetic
serine protease inhibitor may become a novel therapeutic agent for pancreatic cancer.
S1896
Spontaneous Production of Anti-Mitochondrial Antibodies in Keratin-8
Deficient Mice
Diana M. Toivola, Aida Habtezion, Linxin Y. Zhang, William H. Robinson, Paul J. Utz,
Eugene C. Butcher, M B. Omary
Background: Keratin 8 and K18 (K8/K18) are obligate non-covalent heteropolymers that
constitute the intermediate filament cytoskeleton of hepatocytes. Mice that lack K8 or K18
are highly susceptible to liver injury and K8 mutations in humans predispose to end-stage
liver disease, including that caused by autoimmune liver disease. K8-null, but not K18-null,
mice also develop an ulcerative colitis phenotype, which together with the liver findings
suggest an association between the epithelial cell cytoskeleton and autoimmune manifesta-
tions. Aim: We tested the hypothesis that K8-null mice produce autoantibodies that may
ultimately play a pathogenic role in the liver and/or intestinal phenotype of these mice.
Methods: Sera from wild-type (WT), K8-null and K18-null mice were analyzed for the
presence of autoantibodies by immunoblotting total tissue lysates of normal mouse liver,
pancreas and colon as well as lysates of human and mouse cultured cell lines from various
tissue origins. The autoantibodies and organelle-selective markers were examined by immun-
ofluorescence staining and by immunoblotting of subcellular fractions. Results: We identified
one major autoantibody that was present in nine of fifteen (60%) sera from K8-null mice
but not in sera of WT mice. Presence of the autoantibody is age and disease severity related
since the positive K8-null sera were present in all mice 8 months or older, but not in younger
mice. The autoantibody was also found in four of ten (40%) sera from one-year-old K18-
null mice, thereby suggesting that the origin of this autoantibody is related to the liver rather
than colon pathology. The autoantibody recognizes a ubiquitous 42-48 kD protein that
partitions in a non-ionic detergent fraction, and is present in all normal tissues and cell
lines tested, as well as in livers and colons of K8-null mice. Immunofluorescence staining
and subcellular fractionation of cultured cells and tissues showed that the autoantigen is
located primarily in the mitochondria. Conclusion: K8-null liver injury is associated with
age-enhanced anti-mitochondrial autoantibody production as seen in patients with primary
biliary cirrhosis. The 42-48 kDa ubiquitous autoantigen is a mitochondrial protein which
is detergent soluble, and conserved across human and mouse species. Differences in the
frequency of the autoantibodies in K8 versus K18 null mice may be related to genetic-
background or other phenotype-related differences. Characterization of the autoantigen
may unmask a similar autoantibody response in patients with liver disease who harbor
K8 mutations.
S1897
Expression of PD-1, PD-L1 and PD-L2 Within Liver of Autoimmune Liver
Diseases
Norikazu Mataki, Kentaro Kikuchi, Toshihiro Kawai, Yoshikiyo Okada, Chie Kurihara,
Chikako Watanabe, Shunsuke Kohmoto, Ryota Hokari, Atsushi Kawaguchi, Shigeaki
Nagao, Toshiro Kondo, Kazuro Itoh, Hiroshi Miyakawa, Soichiro Miura
Background: PD-L1 (also B7-H1) expressed on macrophages and PD-L2 (also B7-DC)
expressed on dendritic cells, are ligands for programmed death-1(PD-1), which is a member
of the CD28 superfamily of co-stimulatory molecules and plays an inhibitory role in regulating
activated T cell, B cell and myeloid cell in the periphery. According to previous reports,
they are regulated by different mechanism, with the relatively greater role of interferon-
gamma (IFN-γ) in stimulating PD-L1 expression and role of interleukin-4 (IL-4) in stimulating
PD-L2 expression (Eur J Immunol 33:2706, 2003, PNAS 100:5336, 2003). Recently there
have been several reports about changes of expression and the role of PD-1 and its ligands
in autoimmune diseases. Impaired regulation of this system may cause disruption of self-
tolerance leading to autoimmunity. Therefore, we examined the expression of PD-1, PD-L1
and PD-L2 in the liver with autoimmune liver disease. Methods: Liver tissue was obtained
from patients with autoimmune liver diseases (autoimmune hepatitis (AIH) n=8, primary
biliary cirrhosis (PBC) n=12) and chronic hepatitis type C (CH-C, n=12) as controls with
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informed consent. All of patients with autoimmune liver diseases were underwent neither
corticosteroid nor ursodeoxycholic acid and CH-C patients were not underwent interferon
therapy. Immunohistochemical study was performed by using antibodies against PD-1, PD-
L1, and PD-L2. mRNA of PD-1, PD-L1, PD-L2, IFN-γ and IL-4 were determined by real-
time PCR. Results: PD-1 positive cells were mainly observed in portal area. PD-L1 and PD-
L2 positive cells were observed in both portal and sinusoidal area, but relatively dominant
in sinusoidal area. We found that the expression of PD-1, PD-L1 and PD-L2 were low in
PBC. In AIH, although the activity of inflammation in the liver was more severe than CH-
C, expression levels of PD-1 and PD-L2 was lower than those of CH-C. To compare the
relative expression to PD-1, PD-L1 and PD-L2 was lower in autoimmune liver diseases,
especially in AIH. Moreover, expression levels of both PD-L1 and PD-L2 were correlated
with the level of IFN-γ but not with IL-4, and PD-L1/IFN-γ ratio and PD-L2/IFN-γ ratio
were decreased in autoimmune liver diseases compared with CH-C, especially in AIH.
Conclusions: These results indicated that PD-1/PD-L1 and PD-L2 system was modulated in
autoimmune liver diseases. We speculate that low ability of antigen presenting cells to
express PD-L1 and PD-L2 in response to IFN-γ in the liver indirectly affects to the disruption
of self-tolerance, leading to the autoimmne liver diseases.
S1898
The Role of Regulatory T (TR) Cells On Liver Pathology in the Graft Versus
Host Reaction (GVHR) Model Mouse
Teruo Miyazaki, Mikio Doy, Akira Honda, Tadashi Ikegami, Bernard Bouscarel, Yasushi
Matsuzaki
Background/Aim An autoimmune GVHR mouse model presents similar histological and
immunological observations as those encountered in human liver diseases, such as primary
biliary cirrhosis. Recently, the Tr cells, including CD4+CD25+Tr, IL-10 receptor (R)+Tr1,
CD161+NKT cells have been shown to participate in the maintenance of immunologic self-
tolerance. The aim of this study was to investigate the time-dependent relationship between
the progression of autoimmune lesions and that of the Tr cells in hepatic tissue from GVHR
mouse. Method The GVHR mice (F1: bm/2×B6) were induced by intravenous injection of
parental B6 spleen CD4+ T cells. Normal received placebo. The mice were sacrificed either
immediately (G0), or at 2, 4, and 8 weeks later (G2, G4, G8). Furthermore, a group of
GVHR mice received an injection of anti-IL-10 monoclonal antibody at G0, and were kept
alive for 2 weeks. The respective hepatic mRNA expression level was quantitatively analyzed
by cDNA macroarray. Both the state and the profile of hepatic infiltrated inflammatory cells
were evaluated by HE stain and immunohistochemistry (IHC) using specific lymphocyte
surface markers (CD3/4/8/20/25/45ro/161, IL-10R). Results The lesions (number, area) with
inflammatory cells around bile ducts were significantly increased at G2 compared to those
at G0 and normal. However, these lesions were decreased significantly and gradually over
time up to G8. The mRNA expression levels of Th1 (INF-γ, IL-2) and Th2 (IL-4, IL-10)
cytokines and the Tr cell surface markers (CD25, IL-10R) at G2 were higher than at G0,
and these high gene expression levels were maintained up to G8. The expressions of all
examined surface markers including Tr cells were detectable by IHC stain in the GVHR
mouse at the various times, except at G0. The expression of the IL-10R+ cells was maintained
in G4 although the expression of other surface marker positive cells were gradually decreased
along with the improvement of hepatic lesions from 2 to 8 weeks. Furthermore, the inflammat-
ory lesions in the anti-IL-10 antibody-injected GVHR mouse were significantly aggravated
compared to those at G2 without antibody injection. Conclusion This study confirms that
the autoimmune hepatic lesions in the GVHR model reached a peak at 2 weeks following
the donor T cell-injection, but this condition is transient and improved gradually over time.
Furthermore, the pathological improvements of the GVHR mice are associated with the
expression of Tr cells, especially the Tr1 cells. Therefore, these findings strongly support
the expression and activity of Tr cells as key factors in the induction of immunologic self-
tolerance in autoimmune liver diseases.
S1899
Long Term Follow-Up of Autoimmune Pancreato-Cholangitis - Insights Into
the Natural History of the Disease
Henk R. van Buuren, Menno A. Brink, Sjoerd D. van der Werf, Maarten A. Meijssen,
Maarten G. Thomeer, Annette Fritscher-Ravens
Background: Autoimmune pancreatito-cholangitis (APC) is a recently noted disease in which
there is an enlarged pancreatic head, endo- and exocrine pancreatic insufficiency, pancreatic
and bile duct strictures with lymphoplasmocytic inflammation and fibrosis. There is usually
a good response to steroids. However, little is known about its natural history, especially,
when not treated with corticosteroids. Our aim was to study the natural course by reviewing
cases, in which APC started more than 10 years ago. Materials and Methods: Since 1988
40 cases with APC were recognized and treated in multiple centres and clinically followed
up. Of these, 13 patients (12 male, mean age 58.7years) were followed for 10-18 years
(mean 12 years) with regular evaluation of their general condition and liver status. Results:
10 patients had a laparotomy for presumed pancreatic malignancy, 1 refused surgery and
2 had no surgery. Only 2 of the patients were treated with corticosteroids at the time of
presentation, 5 patients had no steroids during the entire period, 1 had intermittent short-
term treatment. 5 patients started treatment 6-14 years after onset of symptoms. During the
follow-up 6/13 pts developed other autoimmune related diseases including Mb. Sjoergren
(n=3), interstitial nephritis (n=3), hypothyroidism (n=2), retroperitoneal fibrosis (n=1), and
rheumatoid arthritis (1). One untreated patient developed calcifications in his pancreas. 7/
13 patients developed liver cirrhosis, one had a liver/kidney transplant after 11 years, one
is currently on the transplant list. All of these patients did either not undergo treatment, had
only intermittent short-term corticosteroids or treatment after >8 years following presentation.
None of the 2 patients with initial therapy developed liver cirrhosis. One patient died without
autopsy to confirm liver cirrhosis. Conclusion: The development of liver cirrhosis in 54%
of the patients with long-term follow-up (all patients without treatment within the first 8
years of presentation) is remarkable. The development of liver cirrhosis was independent
of any symptoms and resulted in liver transplantation in 2/13 patients. These data present
new insights into the natural history of APC and suggest that it is worthwhile treating the
underlying autoimmune process even in the symptom free interval in order to avoid the
development of liver cirrhosis and other autoimmune related diseases.
S1900
Cyclosporine-a Versus Prednisolone for Induction of Remission in Patients
with Autoimmune Hepatitis: Interim Report of a Randomized Controlled Trial
Siavosh Nasseri-Moghaddam, Reza Malekzadeh, Saeid Karimian
Background: Autoimmune Hepatitis (AIH) is classically treated with corticosteroids (CS).
In addition to being ineffective in 13% of cases, they are associated with significant side-effects,
especially among young ladies. Alternative treatments are poorly described. Cyclosporine-A
(CA) has been used successfully for refractory cases. We have reported effectiveness of CA
in treatment naïve AIH patients in an open-label study previously. Here we report the interim
analysis of an RCT comparing CS and CA for induction of remission in treatment naïve
AIH patients. Methods: Consenting treatment naïve AIH patients in whom all other known
metabolic and viral diseases had been ruled out are being enrolled. Baseline demographic,
clinical and paraclinical information are recorded and the patients undergo a liver biopsy
if feasible. Then they are randomized (centrally) to receive either prednisolone orally (50mg
for 2 weeks, 40 mg for 2 weeks, 30mg for 6 weeks and tapering by 5mg every 6 weeks,
group-A) or CA (3mg/kg/d divided equally in two doses for one year, group-B). Both groups
receive Azathioprine (1-2mg/kg) from week 30. Patients are followed regularly (initially at
2 week intervals and then at 6 week intervals). Clinical data, adverse events (AE), and para-
clinical data (AST, ALT, INR, Bilirubin, CBC, Creat, UA) are recorded at each visit. Primary
endpoints include induction of remission, treatment failure, and serious adverse events
necessitating discontinuation of the assigned treatment. Results: Up to now 28 patients (15
in group-A, 18 females, mean age 27.6+/-10.6 years) have been enrolled. The two groups
are comparable demographically and regarding their clinical and paraclinical characteristics.
Mean AST and ALT has decreased significantly in both groups with treatment. Mean post
treatment values for these variables are not different in groups A & B (61.0 vs 61.0 for AST,
41.8 vs. 50.4 for ALT, p: NS). Of these, 22 have completed the course of treatment. One
patient in the CS group developed intractable sepsis and passed away at week 46. There
was one treatment failure in each group. Another patient in the CA group responded initially
but her liver enzymes did not decrease to below twice upper limit of normal. She did not
improve further after switching to CS. AE were more common in the CS group (p<0.05).
Coclusions: Our interim data show that CA is at least as effective and safe as CS for induction
of remission in AIH patients. AE are more common with CS. CA may be considered as first
line treatment for AIH.
S1901
Evidence That An ATP-Binding Cassette (ABC)G5/G8-Independent Pathway
Determines Cholesterol (Ch) Gallstone Formation in Mice
Helen H. Wang, David Q. Wang
A major progress in search of the canalicular Ch transporter came from the discovery that
mutations in the genes encoding human ABCG5/G8 transporters cause sitosterolemia. It has
been shown that ABCG5/G8 traffic together to the canalicular plasma membrane in cultured
polarized hepatocytes and overexpression of the human ABCG5/G8 genes in mice promotes
Ch transport: biliary Ch secretion and saturation are increased markedly. Furthermore,
Abcg5/g8 are mapped to murine chromosome 17 and are the candidate gene for Lith9.
Aims: We explored whether Ch gallstone formation may be determined by an ABCG5/G8-
independent pathway. Methods: Male ABCG5/G8 (-/-) and wild-type (WT) mice (n=20 per
group) were fed a lithogenic diet containing 1% Ch and 0.5% cholic acid for 8 wk, and
concomitantly administered by gavage with the LXR agonist T0901317 at 0 or 20 mg/kg/
day. Gallstones and gallbladder biles were examined by microscopy. Lipid compositions
and hepatic outputs of biliary lipids were analyzed by HPLC. Secretion rates of biliary Ch
were determined in mice perfused via the jugular vein with HDL labeled with 5 μCi of
[14C]Ch. Expression levels of the genes encoding hepatic lipid transporters were investigated
by real-time PCR. Results: At 8 wk on the lithogenic diet, gallstone prevalence (25%) was
reduced in mice with disruption of the Abcg5/g8 genes compared with that (80%) in WT
mice. Abcg5/g8 (-/-) mice showed a significant decrease in biliary Ch secretion rates (8±3
μmol/h/kg) and Ch saturation indices (1.2%) of pooled gallbladder biles compared with
WT mice (Ch=31±8 μmol/h/kg and CSI=1.6%). Outputs of biliary phospholipid (34±12
μmol/h/kg) but not bile salts (202±49 μmol/h/kg) were reduced markedly in (-/-) mice
compared with WT mice (phospholipid=59±14 and bile salts=217±56 μmol/h/kg). The total
amounts of radioactivity recovered in hepatic biles at 12 h after perfusion were significantly
lower (7±3%) in (-/-) mice than in WT mice (21±6%). Treatment of the LXR agonist
significantly upregulated expression levels of Abcg5/g8 but not Abcb4 and Abcb11 in the liver
and promoted biliary Ch secretion (45±12 μmol/h/kg) in WT mice but not in (-/-) mice
(10±4 μmol/h/kg). Also, gallstone formation was accelerated in LXR agonist-treated WT
mice. Expression levels of Sr-b1, Abca1, Npc1l1, Abcg1, and Abcg4 in the liver were comparable
in (-/-) and WT mice. Conclusions: Disruption of Abcg5/g8 significantly reduces but does
not eliminate hepatic secretion of Ch. Biliary Ch secretion and Ch gallstone prevalence in
(-/-) mice are decreased by ~70%, suggesting that the ABCG5/G8-independent pathway also
plays an important role in biliary Ch secretion and Ch gallstone formation.
S1902
Advanced Glycation Endproducts in the Gallbladder: The Influence of
Diabetes and Diet
Abhishek Mathur, Swartz-Basile Deborah, Lu Debao, Hayder Al-Azzawi, Attila Nakeeb,
Henry A. Pitt
Introduction: Diabetes and a high carbohydrate diet are independent risk factors for gallstone
formation. Advanced glycation end products (AGE) are produced from interactions between
sugars and proteins, lipids or nucleic acids. Once produced, AGE form covalent bonds
with various proteins, thus contributing to diabetic complications. We have previously
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demonstrated that leptin-resistant diabetic (Lep db) mice and leptin-deficient diabetic (Lep
ob) mice have impaired gallbladder motility. In addition, we have shown that AGE accumu-
lates in the gallbladder of Lep db mice. As a raised serum glucose is a prerequisite for AGE
formation, a high carbohydrate diet should cause an increase in AGE formation. However,
the effect of dietary carbohydrates on AGE accumulation is not known. Therefore, we tested
the hypothesis that 1) gallbladder AGE would be increased in diabetic leptin-deficient
compared to non-diabetic mice, and 2) within each strain AGE would accumulate more in
mice fed a high carbohydrate diet. Methods: At eight weeks of age 12 non-diabetic C57BL/
6J and 12 leptin-deficient diabetic Lep ob female mice were fed a 45% carbohydrate diet
while an additional 12 non-diabetic and 12 diabetic mice were fed a 75% carbohydrate diet
for 4 weeks. At 12 weeks of age all animals were wighed and then underwent cholecystectomy.
Bile was collected and measured, and the gallbladders were snap frozen in liquid nitrogen.
Gallbladders were pooled (n=2 per pool) and the presence of AGE was determined by
competetive ELISA using monoclonal antibody raised against N-(carboxymethyl)lysi-
ne(CML), an established biomarker for AGE. Data were analyzed by analysis of variance,
Student’s t test and Tukey test. Results: The results for mouse weight, gallbladder volume
and AGE concenteration in the gallbladder in non-diabetic and diabetic mice on the 45%
and 75% carbohydrate (CHO) diets are presented in the table. Conclusions: These data
suggest that 1) AGE is increased in the gallbladder of diabetic leptin-deficient mice, 2)
gallbladder AGE is not influenced by dietary carbohydrates and 3) gallbladder volume is
altered by both diabetes and diet. We conclude that the accumulation of advanced glycation
end products in the gallbladder may play a role in the propensity for diabetics to form gall-
stones.
*p < 0.01 vs Non-diabetic, †p <0.01 vs Diabetic 45% CHO, §p<0.05 vs Non-diabetic 45%
CHO, Δ p<0.01 vs Other groups
S1903
Construction of a Partial Full-Length Prairie Dog cDNA of Sodium Hydrogen
Exchanger Isoform-3 (NHE3)
Ramakrishnan Ramugounder, Gregg J. Johannes, Mohammad Z. Abedin
Background & Aims: Gallbladder Na+ and water absorption is linked to gallstone formation.
Gallbladder Na+ transport is predominantly mediated through apically restricted Na+/H+
exchangers NHE2 and NHE3. We have recently shown that gallbladder NHE is up-regulated
prior to cholesterol crystal formation. The mechanisms by which gallbladder NHE become
altered are not known. The aim of the present study was to clone and construct the cDNA
coding for gallbladder NHE3 in prairie dog. Methods: Total RNA of prairie dog gallbladder
was reverse transcribed, and amplified by PCR using three-different length of NHE3-specific
primers designed on the basis of conserved sequences among human, rabbit, and rat. These
PCR-products were pooled, amplified using three-different blunt-end NHE3-specific primers
(683bp+652bp+463bp=1798bp), ligated, and amplified again by PCR using NHE3-specific
primers of 1798bp length. The PCR-product was analyzed by 1.0% agarose-gel and the
predicted 1798bp NHE3 cDNA was purified and cloned using 2.1 PCR-vector and sequenced.
Results: We have cloned the NHE3 mRNA from prairie dog gallbladder (1.798kb of the
2.213kb rat-NHE3 open-reading-frame). The cDNA-sequence of 1798bp was found to be
89, 89 and 88 % homologous to the corresponding sequences of NHE3 in human, rabbit
and rat, respectively. The deduced amino acid sequence of 599 residues was 94, 94 and
97% identical to the human, rabbit and rat NHE3. Conclusion: This NHE3 cDNA-construct
may be used for in-vitro study to examine the mechanisms of gallbladder NHE regulation
during gallstone formation.
S1904
Estrogen Receptor Alpha Is Expressed By Gallbladder Epithelium in Prairie
Dogs
Ross M. Goren, Misbah Zaheer, Ramakrishnan Ramugounder, Mohammad Z. Abedin
Background & Aims: Gallstone disease is one of the most common and costly digestive
diseases. The incidence of gallstones is 2 to 3 times higher in females than in males. Female
sex hormones have been implicated as contributory factors to the promotion of gallstone
by increasing biliary cholesterol saturation and decreasing gallbladder (GB) motility. The
sex hormones mediate its effects by binding to specific estrogen receptors (ER), which appear
to regulate gene expression through activation or repression of transcription. Alterations in
ER expression may in part account for the increased incidence of gallstones in females. Aim
of the present study was to isolate and clone ER-alpha in GB epithelium. Methods: Total
RNA was isolated from male and female prairie dog GBs, reverse transcribed, and then
amplified in PCR using ER-alpha specific primers. An aliquot of the PCR product was
analyzed by 1% agarose gel and the predicted 360 base pair ER-alpha cDNA was cloned
using 2.1 PCR vector, and subsequently sequenced by Sanger method. Results: RT-PCR
analysis demonstrated the GB expression of 365 base pair ER-alpha cDNA in both male and
female prairie dogs. The cDNA sequence was 92, 92 and 93% homologous to the correspond-
ing ER-alpha sequences in mouse, rat and human, respectively. Deduced AA sequence of
121 residues was 100% identical. Studies are in progress to examine the gender differences
in GB ER-alpha abundance and will be reported. Conclusion: These data will provide an



















Amorphous Calcium Carbonate is the in Vitro Unstable Precursor of the
CACO3 Polymorphs Vaterite, Calcite and Aragonite, But Is Stable in
Gallstones Containing CACO3 from Leeds UK and Galveston TX
Roger D. Soloway, D.R. Taylor, Mark D. Stringer, Jinguang Wu
Background: Amorphous CaCO3 (ACC) has been formed in vitro to serve as a standard for
use in Fourier transform infrared (FT-IR) spectroscopy of gallstones. ACC forms small, ovoid
solids, 1-3 µ in diameter, which, in vitro, in a matter of hours, convert to 15µ spheroids of
vaterite or 15 µ cubes of calcite, at room temperature and average humidity. Newly synthe-
sized vaterite is stable in vitro at 100°C for at least 7 days, but at 25°C converts to calcite
within hours. Each of these CaCO3 polymorphs has been identified in gallstones, years after
formation, suggesting that the in vitro unstable forms have been stabilized in vivo by proteins.
Aim: To examine gallstones containing large amounts of CaCO3 to determine if ACC could
be identified and if ACC interaction with other stone components could be identified as
the basis for stabilization. Methods: A particle from a stone from Leeds containing 94%
CaCO3 and a particle from a stone from Galveston containing 20% CaCO3 were examined
by FT-IR microspectroscopy and by Scanning Electron Microscopy (SEM). FT-IR methodo-
logy was based on serial subtraction of standard spectra from the original spectra containing
mixtures of CaCO3 forms. Remainder spectra were examined for peak shifting to demonstrate
binding. Components were also identified using unique peaks detected using deconvolution
and curve-fitting computer programs on the original spectra. Results: The stone from Leeds,
containing more than 90% CaCO3 and the stone from Galveston containing 20% CaCO3,
as a layer within a cholesterol stone, both contained calcite as the major component and
ACC as the minor component. After both ACC and calcite were subtracted from the original
spectrum, a small amount of altered amorphous carbonate with a major peak at 1400 cm-
1 remained together with protein peaks. This indicated that a proportion of ACC had bound
to protein which may have served both as a template and a stabilization structure. Spectra
will be presented. Conclusions: 1. Amorphous CaCO3 (ACC) has been identified in unique,
virtually pure UK CaCO3 gallstones and US cholesterol stones with CaCO3 layers. 2. This
data shows that a portion of ACC is altered by binding to protein. 3. Protein in these stones
may act to nidate and stabilize ACC which would otherwise be unstable. 4. This probably
occurs on the AAC precipitate surface, allowing the centers to remain as unaltered and
otherwise unstable ACC.
S1906
Prevalence of Gallbladder Disease Among Persons with Viral Hepatitis and
Cirrhosis
Hyun-Jin Kim, Gyeong-A Jung
Background/Aim: Gallbladder stone is one of the major digestive diseases, and has a high
morbidity in adults. In Korea, gallstone prevalence has reported about 2.2 to 3.5%. The
risk factors of gallbladder disease(GBD) related to gallstone are age, obesity, rapid weight
hypertriglyceridemia, diabetes mellitus, women, smoking, etc. Moreover, cirrhosis is well
known for the risk factors of GBD. But, relationship between chronic viral hepatitis and
GBD is not exactly known. Some studies suggest that Hepatitis virus infection facillitates
gallstone formation. The purpose of the present study was to compare with prevalence of
GBD in chronic viral hepatitis C, chronic viral hepatitis B, and the cirrhosis patients who
was progressed from viral hepatitis in long period. Methods: A retrospective analysis was made
of patients who underwent abdominal ultrasonography in Gyeongsang National University
Hospital from 2000 January to 2004 December for hepatitis C virus infection(420 patients)
and hepatitis B virus infection(1,397 patients). Each patients was devided into chronic viral
hepatitis and cirrhosis. In a control group, a total of 4,094 persons undergoing routine health
screening enrolled. Gallbladder disease was defined as ultrasound-documented gallstones or
evidence of cholecystectomy. Results: The 12.1% (41/338 persons) among chronic viral
hepatitis C had a GBD, and this was significantly higher prevalence than 5.6% (228/4094
persons) in control group(p<0.001). The odds of GBD (Male=3.026, Female=1.624) among
chronic viral hepatitis C was significantly higher compared with control. In chronic viral
hepatitis B, prevalence of GBD was 9.1% (48/526 persons)(p=0.001). The prevalence of
GBD was 20.7% in Anti-HCV positive cirrhotics, 19.7% in HBsAg-positive cirrhotics, and
33% in alcoholic cirrhotics. Conclusion: In chronic viral hepatitis patients, prevalence of
GBD was significantly higher than control group and GBD was much more development
in chronic viral hepatitis C. Chronic viral hepatitis as well as viral hepatitis related cirrhosis
is considered as risk factor of GBD.
S1907
Genetics of Gallstone Disease - Who Should Be Investigated?
Clemens Schafmayer, Juergen Tepel, Sandra Freitag, Heike Wolken, Michael Wittig, Ilka
Vogel, Herrmann Dittrich, Juergen Belz, Rainer Quaeschling, Hofjat Schekarriz, Volker
Mendel, Werner Neugebauer, Friedrich Kallinowski, Anton Schafmayer, Jiri Klima, Henry
Voelzke, Ulrich R. Foelsch, Fred Faendrich, Michael Krawczak, Stefan Schreiber, Jochen
Hampe
Background: A genetic contribution to the aetiology of gallstones has been recognized as
early as 1925. Quantitative trait mapping in mice has since identified up to nine gene loci
for bile stone susceptibility. In humans, by contrast, data on gall stone risk loci are scarce,
possibly due to the lack of high-risk groups facilitating efficient genetic studies. Aims: To
identify human subpopulations suitable for the successful genetic investigation of gallstones
and to obtain reliable estimates of the power of such studies. Patients and Methods: A total
of 2474 patients who had undergone cholecystectomy were recruited in Northern Germany.
Demographic data and family histories were obtained via questionnaires and telephone
interviews. Potential predictors of the presence of gallstones and of a history of cholecystec-
tomy were investigated using Cox regression analysis, including frailty terms. Results: The
relative risk (RR) of siblings was significantly associated with the age of disease onset in the
index patient (p<0.001). If the disease in the index patient presented before 20 years of
age, the sibling hazard ratio is 111.8 (95% CI: 17.8 - 700) as compared to the case in which
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the index patient got affected at the population median age of onset of 65 years. Hazard
ratio estimates for age groups 20 - 30 years and 30 - 40 years were 20.5 (CI 8.0 - 50.5)
and 11.8 (CI 5.8 - 23.7), respectively. Conclusions: The increased gallstone risk among
siblings of patients with an early age of onset of the disease further supports a genetic
contribution to gallstone aetiology. Early onset patients and their families are thus showing
a stronger genetic contribution and represent a useful high-risk population for the identifica-
tion of major disease genes.
S1908
Analysis of the Risk Factors Helicobacter Infection, Overweight, Sex, and Age
in Gallstone Disease and Gallbladder Carcinoma in Germany
Ulrich R. Bohr, Doerthe Kuester, Frank Meyer, Thomas Wex, Morena Stillert, Antal
Csepregi, Hans Lippert, Albert Roessner, Peter Malfertheiner
Background & Aims: Recently, Helicobacter infection of the hepatobiliary system has been
proposed as a novel risk factor in the pathogenesis of gallstones and biliary tract malignancies.
Colonization of the biliary tract by Helicobacter species was reported predominantly for
regions with a high incidence of gallbladder carcinomas. In Germany gallstone disease is
frequent, but the incidence of gallbladder carcinoma is relatively low. This prompted us to
investigate if Helicobacter infection of the biliary tract is present in the German population.
Methods: Gallbladder tissue from 99 patients having undergone cholecystectomy (43 male,
56 female, age range 7-94 years, mean age 59.1 years) were investigated: 57 patients with
gallstone disease (GSD), 20 cases of adenocarcinoma of the gallbladder (GBC), and 22
patients without malignancies or gallstones. The presence of Helicobacter spp. was investigated
by culture, immunohistochemistry, and a group-specific PCR targeting the 16S rRNA and
detecting all currently known Helicobacteraceae. Helicobacter was cultured by plating dissected
gallbladder mucosa onto selective agar and incubation under microaerophilic conditions.
PCR was performed with DNA obtained from native or paraffin-embedded tissue. Immuno-
histochemistry was done using two different anti-Helicobacter pylori-antibodies with cross-
reactivity to other Helicobacter species. Results: Of the 99 cases investigated, only one patient
with GSD was PCR-positive for Helicobacteraceae. Here, sequence analysis of the 16S rRNA
showed closest homology to the 16S rRNA sequence of H. ganmani. Helicobacteraceae were
not detected by culture or immunohistochemistry. Statistical analysis of the clinical data
showed a significantly higher body mass index in patients with GSD compared to controls
(p<0.05). Prevalence of GSD in female patients was higher than in male patients (79.1%
vs. 63.9%; odds ratio = 2.14, 95% confidence interval 0.71-6.56). Mean age of patients
with GBC was significant higher than for GSD (p<0.01) or control patients (p<0.005), while
there was no difference between GSD and controls. Conclusions: These data suggest that
Helicobacteraceae play no predominant role in the pathogenesis of gallstone formation and
gallbladder carcinoma in the German population. However, the low prevalence of Helicobac-
teraceae in the gallbladder mucosa of German patients may explain in part the relatively
low prevalence of GBC compared to other populations with a high risk of GBC.
S1909
Cholelithiasis and Biliary Sludge in Children: Predisposing Diseases and Mode
of Presentation
Denise Herzog, Guylaine Bouchard
The rising prevalence of gallstone disease (GD) in the adult population of industrialized
countries is a cause of concern. European pediatric prevalences range from 0.13 to 1.9%.
Aim: to assess the mode of presentation, predisposing diseases, and the prevalence of GD
and biliary sludge (BS) in a pediatric population of a tertiary care center. Method: Retrospect-
ive review of abdominal ultrasounds recorded at Sainte Justine Hospital over a period of
24 months (8/2003 to 8/2005) in patients <19 years of age. Patients were grouped into
children < 2 and > 2 to <19 years of age. Results: A total of 9203 abdominal ultrasounds
were reviewed. GD was found in 127 (1.3%), with 107 (1.1%) new diagnoses, BS in 84
(0.91%), and post-cholecystectomy status in 26 patients. During this period 57 cholecystec-
tomies for gallbladder disease were performed. In total, 48 (46%) patients had idiopathic GD
presenting with abdominal pain (32 girls). Of these 48, 29(27.6%)had associated pancreatitis,
cholestasis, or choledocholithiasis; cholecystectomy was done in 28 (58%), 24 girls (86%).
In hemolytic disease (HD), cystic fibrosis, oncologic disease or organ transplantation patients
GD was detected during routine abdominal ultrasound. Preventive cholecystectomy was
carried out in 9/19 patients with HD. Post-cholecystectomy status was noted in 14 HD
patients and 12 with idiopathic GD, (5 boys (19%). BS was mainly seen in patients requiring
total parenteral nutrition (TPN) (67% < 2 years, 72% > 2 years of age). In 10 patients sludge
was found to preceed the formation of gallstones. Conclusion: Mode of presentation, age
and gender distribution and prevalence of GD found in these 2 years retrospective study
resembles that found in a 10 year-retrospective European study (Wesdorp et al). Idiopathic
GD represents 46% of gallstones and is mainly found in adolescents. The complication rate
in our patients with gallbladder disease is similar to that of adult patients. GD in children
under two years of age was found to be associated with infections and prolonged use of TPN.
Prevalence of Gallstones and Biliary Sludge in Pediatric Patients according to Disease and Age
HD=hemolytic disease, CF/H=cystic fibrosis + hepatobiliary diseases, OT=oncologic/ trans-
plantation, IC=infectious/congenital, SM = neonatal surgery/malformation, I= idiopathic
S1910
Aminoguanidine Impairs Gallbladder Contractility
Hayder Al-Azzawi, Abhishek Mathur, Debao Lu, Deborah Swartz-Basile, Attila Nakeeb,
Henry A. Pitt
INTRODUCTION: Diabetes is associated with an increased incidence of gallstones. Advanced
glycation endproducts (AGE) have been found to be increased in the tissues of diabetic
patients and animals. As a result, AGE have been implicated in diabetic complications
including nephropathy, retinopathy, neuropathy and atherosclerosis. Data from our laborat-
ory have shown that leptin-resistant diabetic mice have higher AGE concentrations in their
gallbladders, increased gallbladder volume, and decreased gallbladder contractility compared
to non-diabetic mice. Aminoguanidine is an agent that prevents the formation of AGE in
tissues and, therefore, prevents diabetic complications. However, no data are available on
the influence of aminoguanidine on gallbladder motility. Therefore, we tested the hypothesis
that the addition of aminoguanidine to the diet of leptin-deficient diabetic mice would
improve gallbladder contractility. METHODS: 20 six-week old female leptin-deficient diabetic
mice were fed a 60% carbohydrate, 1% cholesterol lithogenic diet for 6 weeks. Half of the
animals had aminoguanidine 0.7% added to their diet. Both at 6 and 11 weeks, all mice
were fasted overnight and underwent ultrasonography of the gallbladder under inhalation
isoflurane anesthesia. Gallbladder volume before (resting volume) and 45min after an intrap-
eritoneal injection of 2nmol/kg cholecystokinin (residual volume) were determined using
the Visual Sonics Vivo 660TM High Resolution Imaging System. Gallbladder ejection fraction
was determined from the gallbladder volumes obtained at 0 and 45 minutes. At 12 weeks
of age, all the mice were fasted overnight and underwent cholecystectomy. Bile was aspirated
and examined under polarized light microscopy for cholesterol crystals, and gallbladder dry
weight was measured. RESULTS: Results for gallbladder resting volume (μl), gallbladder
residual volume (μl) and ejection fraction (%) at 11weeks, and gallbladder dry wt (mg) are
presented in the table. Cholesterol crystal numbers did not differ between groups. Data
were analyzed by Student’s t test. CONCLUSION: These data suggest that in leptin-deficient
diabetic mice fed a lithogenic diet, aminoguanidine 1) increases residual gallbladder volume,
2) decreases gallbladder ejection fraction and 3) increases gallbladder weight. Therefore,
we conclude that aminoguanidine may increase the propensity for gallstone formation by
enhancing gallbladder stasis.
*p<0.05 vs Control,†p<0.03 vs Control
S1911
The Gut Microflora Is Involved in Ethanol Metabolism and Ethanol-Induced
Impairment of the Epithelial Barrier in Rodents
Laurent Ferrier, Florian Berard, Laurent Debrauwer, Chantal Chabo, Philippe Langella,
Lionel Bueno, Jean Fioramonti
Background. Hepatic toxicity of alcohol is associated with endotoxemia and increased
intestinal permeability. Since the colon is the main reservoir of endotoxins, impairment of
the epithelial barrier may lead to endotoxemia. Alcohol diffuses easily from blood to colonic
lumen, and colonic bacteria are able to metabolize alcohol into acetaldehyde, known to be a
potent mast cell activator and to impair the intestinal barrier. This study aimed at investigating
whether alcohol metabolism by the colonic flora may be responsible for the alcohol-induced
impairment of the colonic mucosal barrier. Methods. Male Wistar rats were given an acute
intragastric administration of ethanol (1.5, 3.0 and 4.5 g/kg), or isocaloric amounts of
dextrose (controls). A group was treated with non absorbable antibiotics (ampicillin and
neomycin ; ATB) in drinking water for ten days. The involvement of mast cells was assessed
by treating another group with the mast cell stabilizer, doxantrazole. Gut paracellular per-
meability (GPP) was assessed by the passage of orally administered 51Cr-EDTA into urine,
and ethanol and endotoxin blood levels were measured. Ethanol metabolism by microflora
was evaluated by measuring acetaldehyde in colonic contents. Finally, colonic strips from
rats pretreated or not with doxantrazole, were mounted in Ussing chambers to measure
permeability to dextran. Results. An acute administration of 3.0 and 4.5 g/kg ethanol
increased GPP (3.2±0.2% and 3.4±0.4%, respectively, vs. 2.2±0.2% for dextrose, p<0.05),
which was significantly reduced either by doxantrazole or ATB treatment. Two hours after
intake, ethanolemia was 17.4±0.2 mmol/L, and reached 34.3±0.2 mmol/L (p<0.001) under
ATB treatment. Portal endotoxins were increased 90 minutes after ethanol intake (789.3±73.7
IU/L vs. 382.2±34.2 IU/L, p<0.01). Under ATB, endotoxemia returned to basal values.
Acetaldehyde lumenal concentration within the colon (22.2 ±1.5 μmol/L) reached 132.6
±31.6 μmol/L (p<0.05) and only 86.2 μmol/L±10.9 under ATB treatment. In Ussing cham-
bers, 17 mmol/L ethanol were ineffective. Acetaldehyde dose-dependently increased dextran
flux from 120 μmol/L concentration, its effects being inhibited by doxantrazole. Conclusion.
The increase in alcoholemia observed under ATB treatment indicates an important role of
colonic bacteria in alcohol metabolism in rats. Colonic epithelial barrier alterations by acute
ethanol intake involve colonic bacterial metabolism of ethanol into acetaldehyde, which in
turn induces mast cell degranulation. These alterations may be responsible for an excessive
lumen-to-blood endotoxin crossing, frequently observed in patients suffering of alcoholic
liver disease.
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S1912
Accuracy of Indices Utilizing Common Lab Values in Predicting Hepatic
Fibrosis and Cirrhosis in Hepatitis C Patients in a Community Setting
Sedat Ekici, Jeffrey Kim, Brian Wolfman, Toomas Sorra, Adnan Khdair, Irwin Grosman
Several indices utilizing commonly available lab tests have been proposed for predicting the
presence of significant fibrosis or cirrhosis in patients with chronic hepatitis C (CHC).
However, their applicability outside the setting of referral centers has not been well studied.
Aim: To assess the accuracy of the aspartate aminotransferase (AST)-platelet (PLT) ratio
index (APRI), AST/alanine aminotransferase (ALT) ratio (AAR), age-PLT index (API) (Poynard
et al. J Viral Hepatol 1997;4:199-208) and the Hepatitis C Antiviral Long-Term Treatment
Against Cirrhosis Trial model (HALT-CM) (Lok et al. Hepatology 2005;42:282-292)in pre-
dicting significant fibrosis or cirrhosis in our cohort. Methods: Records for 149 consecutive
patients with CHC who underwent biopsy at our institution from 2000 to 2005 were
reviewed. Only treatment naïve patients, 18 or older, with no other concurrent liver disease
or HIV were included. Lab values, including AST, ALT and international normalized ratio
(INR) were obtained. All lab values were within 6 months of the biopsy date. APRI was
calculated using the formula: ((AST/upper limit of normal)/PLT)x100. AAR equaled AST/
ALT. API and HALT-CM were calculated using published formulas. Fibrosis (F) was staged
using the modified Ishak scale (F0 to F4), with F≥2 representing significant fibrosis and
F4 denoting cirrhosis. Published cut-off values for cirrhosis and significant fibrosis were
used to determine sensitivity, specificity, positive predictive value (PPV) and negative predict-
ive value (NPV) for each test. Results: 107 patients who met the criteria were identified; 54
were male. The mean age was 50±7.5; the mean fibrosis score was 1.8±0.9; 63% had
significant fibrosis and 5% had cirrhosis. Sensitivity, specificity, PPV and NPV for each index
are presented on the table. Conclusions: Both API and APRI>1.5 have low sensitivity but
high specificity and PPV for significant fibrosis. APRI>2.0 was both sensitive and specific
for cirrhosis. The APRI and HALT-CM could be used to reliably exclude cirrhosis. None of
the indices studied had a high PPV for cirrhosis, most likely due to its low prevalence in
our cohort. The AAR was not a useful predictor of cirrhosis.
S1913
Serum Hyaluronic Acid (HA), Ykl-40, Fibrospect-II (FS-II) Test and Digital
Quantification of Fibrosis (DQF) Correlate with Ishak Fibrosis Scores in
Patients with Chronic Hepatitis C (HCV)
Preeti Mehta, Robert Ploutz-Snyder, Jyotirmoy Nandi, Robert A. Levine
Liver biopsy has limitations of sampling variation and interobserver bias. Direct serum
markers of fibrosis such as HA, YKL-40 and FS-II (HA, TIMP-1 and α-2 macroglobulin)
have been used as surrogate markers to assess liver fibrosis. We reported that DQF discrimin-
ates between varying stages of liver fibrosis in HCV and has excellent interobserver reliability
(Liv Intl 2005; 25: 1142). AIMS: To correlate the accuracy of HA, YKL-40, FS-II and DQF
parameters with Ishak fibrosis scores. METHODS: Ishak scores, DQF, HA, YKL-40 and FS-
II were evaluated retrospectively in 96 patients with HCV. Mean liver biopsy length was
≧15 mm having ≧5 portal tracts. Statistical analysis was performed using SPSS
(v.13.0.1)software. The Spearman’s Rho statistic assessed the correlational relationships
among Ishak score and the above parameters. Receiver operator characteristic (ROC) curves
evaluated the accuracy of these parameters when compared to Ishak stages of fibrosis, as
well as between incremental steps of the Ishak scale. Area Under the Curve (AUC) and false
positive rates were determined for each predictor of fibrosis. Variable sample sizes for some
of the analyses are due to pending data. RESULTS: All four diagnostic parameters were
highly correlated with one-another (p<.01) and with Ishak scores (Table 1). ROC curves
discriminated patients into various fibrosis categories (Table 2). The areas under the ROC
curves were significant, indicating excellent diagnostic abilities for all four measures to detect
the broad categories of the Ishak (4-6) vs (0-3), and Ishak (4-6) vs (2-3). All three parameters,
except YKL-40, were able to differentiate between Ishak (2-3) vs (0-1). DQF showed the
highest AUC of all measures tested for discriminating patients into these broad Ishak categor-
ies. CONCLUSION: Our data supports the overall ability of serum markers to discriminate
between clinically relevant stages of fibrosis/cirrhosis.
Table 1. Spearman’s Rho Correlation Matrix Among Diagnostic Parameters
Correlation significant at the *p<.01 and **p<.001(2-tailed). n = number of patients tested.


















Co-Stimulatory Expansion of Hepatitis C Virus-Specific T Cells: Exploring the
Potential for Immunotherapy in Chronic HCV Infection
Jennifer Coleclough, Yun Li, Mark Bonyhadi, Bruce Levine, Barbara Vance, Robert H.
Vonderheide, Kyong-Mi Chang
Background: Hepatitis C virus (HCV) persists with impaired capacity for virus-specific T
cells to expand and produce antiviral effector cytokines. Since IFN-alpha therapy does not
generally increase HCV-specific T cell response (Kaplan et al, Hepatology 2005), approaches
to enhance the number and function of HCV-specific T cells may complement the effectiveness
of antiviral therapy. Aim: Based on the efficient T cell expansion demonstrated in-vitro with
CD3/CD28 costimulation, we asked if functional HCV-specific T cells may be efficiently
expanded in-vitro from peripheral blood mononuclear cells (PBMC) of chronically HCV-
infected patients with CD3/CD28 costimulation and T cell growth factors (IL2, IL15).
Method: PBMC from chronically HCV-infected (HCV Ab+/RNA+) and spontaneously HCV-
recovered subjects (HCV Ab+/RNA-) were stimulated as follows: 1) rIL2 and HCV-derived
peptides; 2) rIL2 and HCV peptides with anti-CD3/anti-CD28-conjugated costimulatory
beads; 3) rIL2, HCV peptides, anti-CD3/anti-CD28 beads and rIL15. HCV-specific T cell
expansion, phenotype and cytokine profile were monitored by FACS with MHC-peptide
tetramers specific for 3 HCV and 1 influenza-derived HLA-A2 restricted CD8 epitopes,
intracellular cytokine staining and CFSE. Result: Compared to rIL2 and peptide alone, overall
expansion of cells in culture was enhanced by about 5 fold with CD3/CD28 costimulatory
beads and 10 fold with additional rIL15 (median fold expansion in 2 weeks: 0.5 vs 2.5 vs
5.8). While highest HCV-specific CD8 T cell enrichment was observed with rIL2 and peptide
alone, total number of expanded HCV-specific CD8 T cells tended to be greater with CD3/
CD28 costimulation, especially with rIL15, due to increased total T cell expansion in the
latter 2 conditions. Yet, compared to patients with spontaneous HCV clearance, expanded
HCV-specific CD8 T cells demonstrated poor production of antiviral cytokines (IFNg, TNFa).
Conclusion: We conclude that HCV-specific CD8 T cells can be expanded from chronic
HCV patients using CD3/CD28 costimulation and that this expansion may be further
enhanced with rIL15. However, despite their increased expansion, HCV-specific CD8 T cells
did not show efficient antiviral cytokine production. Further studies are ongoing to explore
strategies to enhance expansion and function of HCV-specific T cells and mechanisms of T
cell dysfunction in HCV persistence. *This study is supported by RO-1 AI47519; XCyte
Therapies Inc; Philadelphia VAMC; NIH/NIDDK Center of Molecular Studies in Digestive
and Liver Diseases P30DK50306 and its Molecular Biology and Cell Culture Core Facilities.
J.A.C is supported by the AGA Student Research Fellowship.
S1915
Metabolic Syndrome in Veterans with Chronic HCV Infection Correlates with
NAFLD Activity Score
Prashant K. Pandya, Priyank Shah, Peggy Callahan, Dean Reker, Sharad C. Mathur
Background: Several retrospective studies have estimated that histopathologic features of
NAFLD are present in 4-7% of patients chronically infected with HCV and are associated
with parameters of the metabolic syndrome (MS). Given the increased prevalence of insulin
resistance and type 2 diabetes, we systematically evaluated the the clinical and laboratory
parameters of MS and correlated these with concomitant histologic findings of NAFLD.
Methods: Demographic, anthropometric, serologic, and metabolic parameters were studied
in a cross-sectional study of treatment naïve veterans with chronic hepatitis C. Insulin
resistance was defined as a HOMA > 2.5. MS was defined by the presence of 3 or more
ATP III criteria. Serum levels of TNF-α, IL-6, adiponectin and leptin were measured.
Liver biopsies were evaluated for degree and distribution(zone III) of steatosis, ballooning
degeneration, mixed inflammation, and perisinusoidal fibrosis to calculate a NAFLD activity
score(NAS) as recently proposed to assess the likelihood of NAFLD. Chronic hepatitis C
inflammatory activity and fibrosis were determined according to the modified hepatic activity
index (HAI). Histologic findings and NAS were correlated with clinical and laboratory
markers of MS using Spearman correlation coefficient. Results: Liver biopsies from 35
veterans(69% Caucasian and 17% African American; 97% male) were evaluated. The average
age and BMI were 53.1±7.2 and 28.0±6.0 respectively. 18 of the 35 veterans(51%) met
criteria for MS. No histological features suggestive of NAFLD were present in 13 of 17(76%)
veterans without MS, compared to 6 out of 18(33%) with MS (p<0.05, Chi-square). Findings
highly suggestive of NAFLD (NAS≥5) were seen only in the group with MS(17%). In
univariate analysis, the presence of MS showed statistically significant association with
steatosis (p=0.002) and NAS (p=0.016) but not with ballooning degeneration or perisinuso-
idal fibrosis (p=NS). The degree of ballooning degeneration showed an increasing trend
with increasing HAI score, but this was not statistically significant. In addition, the NAS
was associated with TNF-α(p=0.012) and HOMA(p=0.005) but not with leptin, adiponectin,
and IL-6(p=NS). Conclusion: In chronic hepatitis C the presence of MS is significantly
associated with steatosis and NAS. Findings highly suggestive of NAFLD were observed at
in 17% of veterans, which is 2-3 times higher than reported previously. In the presence of
chronic hepatitis C, zone III perisinusoidal fibrosis and ballooning degeneration do not
appear to be specific for NAFLD and may be modulated by the activity and stage of
chronic hepatitis.
T : 89386$$CH2
05-04-06 23:18:27 Page 284Layout: 89386B : e
A-284AGA Abstracts
S1916
Chronic Hepatitis C May Be the Most Common Association for Hepatic
Granulomas
Juan G. Martinez, Shu-Yuan Xiao, Ned Snyder
Background: Hepatic granulomas have been reported in up to 10 % of liver biopsie, most
of which today are performed for staging of chronic hepatitis C (HCV).Increased frequency
of hepatic granulomas may be associated with both mild and severe forms of HCV. It has
been postulated that HCV may have a role in granuloma formation. (Yamatamoto. Hepato-
Gastroenterol 42: 291; Emile,Human Pathology 24:1095 ; Goldi. Histopathology 28: 265).
Purpose:We reviewed the cases of hepatic granulomas at our institution the last decade to
determine 1) the causes of hepatic granulomas 2) whether hepatic granulomas are associated
with HCV. Methods: Following institutional review board approval, we used the data from
our laboratory information system to identify all patients with the word “granuloma” or
“granulomatous” in their final diagnosis or the pathologist’s description. When appropriate,
reports, patient’s charts, and slides were reviewed, and information on special stains and
cultures was obtained. Lipogranulomas were excluded from our study. The diagnosis of
HCV was based the presence of serum HCV RNA. Results: 31 patients with hepatic epitheloid
and/or giant cell granulomas were identified. Special stains for at least AFB and fungi were
performed on 24, and tissue cultures on 5. Twelve (38.7%) of the patients had HCV. Among
the patients with HCV, three had other associations (HBV, sarcoidosis, or HIV). Overall, 9
patients had HCV only, 3 sarcoidosis, 3 histoplasmosis, 2 HIV only, 2 mycobacterium
avium complex, 2 primary biliary cirrhosis, 1 Q fever, 1 mucormycosis, 1 tuberculosis, 1
coccidiomycosis, 1 Hodgkin’s Disease, 1 cryptococcus, 1 chronic hepatitis B (HBV), 1 HCV/
HBV, and 2 with no associations. Polarizing light revealed crystalloid foreign bodies in only
one of the 12 patients with HCV. Conclusions: HCV is the most common association with
hepatic granulomas found on liver biopsy at our institution. This may partly reflect that a
majority of our liver biopsies were done for chronic HCV. Most of our HCV patients had
a history of intravenous drug use, and the granulomas could also result from foreign
material. However, we were only able to identify a crystalline substance in one patient.While
granulomas are uncommon in HCV and may sometimes be associated with other problems,the
finding that 29% of our cases of hepatic granulomas had HCV as their only association
poses the question whether granulomas are part of the histological spectrum of chronic
HCV. Granulomas may be another manifestation of the immunological abnormalities seen
in HCV.
S1917
Helicobacter Pylori Infection Does Not Have a Significant Impact On the
Natural History Or Response to Treatment of Chronic HCV
Christopher J. Christensen, Gagan K. Sood, Diana Little, Maher Azzouz
Introduction: Helicobacter Pylori infection(HP) is seen with increased frequency in patients
with chronic HCV infection. The impact of chronic HP on immune and cytokine response,and
its relationship to several chronic diseases such as coronary atherosclerosis, lymphoma,
cholelithiasis, chronic fatigue, cerebral ischemia and migraine are frequently recognized in
recent medical literature. We studied the impact of HP on the natural history of HCV
infection including degree of histopathological changes, response to treatment and the
incidence of cholelithiasis. Methods: Patients treated for HCV through our hepatitis
clinic(1999-2005) were retrospectively evaluated. 158 patients were included, 78
patients(53%) had evidence of HP infection(group 1) and 70 patients(47%) were nega-
tive(group 2). Data collected and compared on the two groups included race, sex, age,
BMI, serum ferritin, genotype, AST, ALT, HCV RNA level, ETOH history, and Diabetes
Mellitus(DM). Liver biopsies were compared regarding histological activity and fibrosis stage.
Gallstones were documented by imaging and treatment response was compared between
the two groups. Results: The two groups had no statistically significant differences with
regard to ETOH history, prevalence of DM, HCV genotype or RNA level. Mean age for
group 1 was lower (49.81 +/- 5.86) vs (51.86 +/- 6.54) p<0.046. HP prevalence was higher
in the African American AA patients, 52/78 (70%) of group 1 compared to 22/70 (30%) of
group 2 (chi square 18.32, p<0.001). Laboratory parameters were similar in the two groups
including ALT (92.69 vs 97.23) AST (72.08 vs 70.64), and ferritin (289 vs 289). No significant
histological differences were noted between the two groups with portal inflammation score
(1.83 vs 1.74, p=0.49), interface hepatitis score (1.80 vs1.76, p=0.78), lobular hepatitis
score (1.46 vs 1.46, p=0.96) and (fibrosis score 1.68 vs 1.8, p=0.59). Although gallstones
were noted less frequently in HP infection 21% vs 29%, this was not statistically significant(p=
0.23). Our sample data analysis revealed a correlation between AST and fibrosis (r=0.40).
Conclusion: Our sample did not demonstrate any significant impact of HP infection on the
natural history of chronic HCV or response to treatment. HP infection was more prevalent
in younger and African American patients. A larger size sample would be needed to make
a conclusion regarding the need for HP testing and treatment prior to the initiation of anti-
viral therapy in patients with chronic HCV and its impact on the formation of gallstones.
S1918
Mortality Among Subjects Positive for Anti-Hepatitis C Virus Antibody in a
Hyperendemic Area of Japan: A Prospective Study
Keiko Toyama, Hirofumi Uto, Chinatsu Hujimoto, Joji Kuroki, Katsuhiro Hayashi, Kenji
Nagata, Yuka Takahama, Akio Ido, Sherri O. Stuver, Hirohito Tsubouchi
Background/Aim: Chronic hepatitis C virus (HCV) infection is a major health problem
worldwide. HCV is a common cause of fatal liver diseases, including liver cirrhosis and
hepatocellular carcinoma (HCC). However, the natural course of HCV infection is not fully
understood. The aim of this study is to analyze mortality among subjects positive for anti-HCV
antibody in a community-based study in a HCV hyperendemic area in Japan. METHODS: This
study enrolled 816 anti-HCV antibody positive subjects who were followed from 1995
through 2004. Information on cause-of-death was obtained from death certificates. Serum
HCV core antigen (HCVcAg) was quantified in all subjects by fluorescence enzyme immuno-
assay (FEIA), and the presence of HCV RNA was determined by RT-PCR in subjects whose
HCVcAg levels were below the FEIA detection threshold in 1995. Subjects positive for
HCVcAg or HCV RNA were considered to have chronic HCV infection. Subjects negative
for HCVcAg and HCV RNA were considered to have cleared their HCV infection. RESULTS:
Of the 816 subjects studied, 557 were chronic HCV carriers in 1995 (median age, 65 years),
and 260 appeared to have cleared their HCV infection (median age, 64 years). Although
alanine aminotransferase (ALT) levels were significantly higher in those with chronic HCV
infection than in those with prior HCV infection, there were no significant differences in
age, gender, alcohol intake, prior history of surgical operations, or blood transfusions between
the two groups. The cumulative incidence of mortality was 23.9% for the chronic HCV
carriers and 16.5% for those with prior infection (P=0.044). In addition, the risk of death from
HCC or other liver diseases in the chronic HCV subjects was 4.8% and 4.3%, respectively. In
contrast, no HCC deaths were observed in the subjects with prior HCV infection, and the
risk of death from other liver diseases was 0.8%. Furthermore, the risk of non-liver causes
deaths, including cardiovascular diseases was not associated with the chronic HCV carriers.
In the chronic-HCV group, there were no differences in age, gender, HCV serotype, alcohol
intake, prior history of surgical operations, or blood transfusion between death from liver
disease including HCC and from non-liver causes. Conclusions: The results of this prospective
study show a strong effect of chronic HCV infection on liver-related mortality during a 10-
year follow-up. In addition, the risk of mortality was increased in subjects with chronic
HCV infection compared to subjects with prior HCV infection.
S1919
Serum Alanine Aminotransferase Flares in Hepatitis C Virus Carriers with
Normal Or Persistently Normal Alanine Aminotransferase Levels in a
Hyperendemic Area of Japan
Hirofumi Uto, Kazunori Kusumoto, Katsuhiro Hayashi, Satoru Hasuike, Mayumi Kodama,
Kenji Nagata, Keiko Toyama, Yuka Takahama, Akio Ido, Sherri O. Stuver, Hirohito
Tsubouchi
Background: Since 1993, we have been analyzing hepatitis C virus (HCV) antibody-positive
residents in a hyperendemic HCV area of Japan. In this community-based population, we
previously reported that abnormal alanine aminotransferase (ALT) levels (>= 35 IU/L)
increased the rate of HCC by almost four-fold in comparison to normal ALT levels. However,
late ALT reactivation can occur after many years in some normal or persistently normal ALT
(PNALT) individuals, which may lead to progressive liver disease. The clinical features of
HCV carriers with normal ALT or PNALT levels (<= 34 IU/L) have not been fully elucidated.
In the present analysis, we evaluated the occurrence of serum ALT flares in HCV carriers
with normal ALT or PNALT levels within our study population. Subjects and Methods: We
initially evaluated 544 seropositive study subjects who were HCV core antigen- or HCV
RNA-positive six months or more after their initial anti-HCV testing and were judged as
having persistent HCV infection in 1995. We examined the first occurrence of an ALT
elevation, or flare (ALT >= 35 IU/L), over the follow-up period of August 1996 through
February 2005. An additional analysis focused on the subgroup of 159 HCV carriers who
had at least four annual ALT measurements available between 1993 and 2000 and who had
PNALT during that time period. For these subjects, the risk of an ALT flare from July 2001
through February 2005 was examined. Results: In 1995, serum ALT levels were <= 19 IU/
L in 116 (21%) of the 544 HCV carrier subjects and 20-34 IU/L in 206 (38%) subjects.
Among these 322 subjects with a normal ALT level, an ALT flare occurred in 42 (36%)
subjects in the first group and 148 (72%) subjects in the second group over a follow-up
period of almost 10 years. Serum ferritin levels in 1995 were significantly higher in subjects
with an ALT flare than in subjects without an ALT flare [138.6±98.2 vs. 97.0±63.8 μg/dl;
P<0.001]. Among the 159 HCV-infected subjects who were found to have PNALT through
2000, the cumulative risk of an ALT flare was calculated to be 31.6% between 2001 and
2005. In addition, although there were no differences in age, gender, alcohol intake, blood
transfusion or HCV core antigen levels between PNALT subjects who did or did not experience
a subsequent ALT flare, a significant association was observed between serum ferritin levels
measured before 2000 and ALT flares [114.7±56.7 vs. 86.4±55.9 μg/dl; P=0.019] Conclu-
sions: HCV carriers with normal or persistently normal ALT in this population experienced
ALT flares. Serum ferritin levels appeared to be a potential predictor of such ALT flares.
S1920
A Study to Assess Expertise and Training in Transcutaneous Liver Biopsy
Amongst Trainee Gastroenterologists in the United Kingdom
Peter F. Marden, Ben Colleypriest, John D. Linehan
Introduction: The U.K. Joint Committee of Higher Medical Training (JCHMT) in Gastroenter-
ology Curriculum Feb 2005, states trainees should be skilled in liver biospy. Increasingly
transcutaneous liver biopsy in the UK is conducted under ultrasound guidance by radiologists.
This raises the possibility that gastroenterology trainees are neither exposed to the procedure
or trained in performing liver biopsy despite the stated curriculum aims. This is due to
diminishing training oportunities and a move away from biopsying without ultrasound
guidance. Aim :This study aims to determine the level of training and competence in
transcutaneous liver biopsies amongst trainees in gastroenterology in a U.K. training region
(Wessex deanery).This comprises of 13 hospitals covering a population of approximately 4
million people. Methods: All gastroenterology trainees in the region received a questionnaire
aimed at assessing their training in liver biopsy and knowledge of the current British Society
of Gastroenterology guidelines on the use of liver biopsy in clinical practice. Results: Thirty
one trainees were eligible for the study and 77% responded. None currently worked in a
trust where liver biopsies were routinely conducted by a gastroenterologist. Only 54% had
practical experience of liver biopsy under supervision and 29% without supervision. Just
25% had a written record of this training. None had conducted a liver biopsy in the last
twelve months. Only 4% knew the pre-procedure platelet count quoted as safe in the BSG
guidelines, although 94% knew the safe level of INR. With regards to pain post procedure
and significant haemorrhage only 4% and 16% respectively knew guideline figures. Only
25% could quote accurate mortality figures post liver biopsy. No respondent had received
training in transabdominal ultrasound although 45% felt gastroenterologists should be trained
in conducting liver biopsies. Conclusion: This study suggests U.K trainees in gastroenterology
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have a low level of practical and theoretical knowledge with regards to transcutaneous liver
biopsy. Only a more comprehensive survey can determine if this is a national phenomenon.
If stated JCHMT curriculum aims are to be addressed, training in transabdominal ultrasound
scanning may need to be compulsory for gastroenterology trainees. At present this is not
the case, in contrast to equivalent gastroenterology training programmes throughout the
rest of Europe or in the USA.
S1921
Prevalence of HCV Risk Factors in Hispanic-American Subpopulations
Stacey B. Trooskin, Maricruz Velez, Steven K. Herrine, Simona Rossi, David J. Axelrod,
Robert Winn, Scott McNeal, Victor J. Navarro
HCV disproportionately affects Mexican Americans. The epidemiology of HCV has not been
evaluated as thoroughly in other Hispanic-American subpopulations. Therefore, as part of
a larger prospective cohort study to investigate barriers to care for HCV among minority
patients, we aimed to assess differences in the prevalence of HCV risk factors that may exist
among Hispanic-American subgroups. Methods: New patients, 18 or older, were prospect-
ively enrolled at four primary care practices in Philadelphia. These practices included two
federally qualified health centers serving predominantly minority populations and two univer-
sity-based primary care practices, one family medicine practice and one internal medicine
practice. Demographic information, including race/ethnicity, was ascertained from all parti-
cipants as well as risk factors for HCV acquisition, both conventional (injection drug use
(IDU), transfusion prior to 1992, health care worker needle stick) and non-conventional
(tattoos, piercings, incarceration, had a spouse or significant other with HCV). Results: Of
the 1415 patients enrolled in this study, 468 participants identified themselves as being
Hispanic; 235 were born in Puerto Rico (PR) or mainland US. The remaining 233 participants
were born in 19 other countries. A small percentage of individuals born in each of the
following countries reported having a risk factor for HCV acquisition: 14.8% of those born
in the Dominican Republic (n=81), 10.2% of those born in Mexico (n=49), 10.5% of those
born in Colombia (n=19), 15.8% of those born in Guatemala (n=19), 8.3% of those born
in Honduras (n=12), and 12.5% of those born in Ecuador (n=8), and 14.3% of those born
in Peru (n=7). Comparatively, 45% of individuals born in PR and 50% of Hispanics born
in mainland US reported having an HCV risk factor; 39% of Whites (n=512) and 48% of
Blacks (n=435) reported having a risk factor for HCV acquisition. Both groups had similar
prevalence of non-conventional risk factors. However, prevalence differed between the two
groups with respect to prevalence of conventional risk factors, specifically IDU. IDU was
more commonly reported among Hispanics born in the US or PR. In a logistic regression
model, Hispanics born in the US were more likely to have a risk factor (conventional or
non-conventional) than Hispanics born outside the US (p<.0001). This relationship remained
after controlling for age and sex. In conclusion, Hispanics born in the US or PR have a higher
prevalence of conventional HCV risk factors, specifically IDU, as compared to Hispanics born
in other countries.
S1922
Bone Mineral Density Correlates to Insulin-Like Growth Factor I, in Non-
Cirrhotic Osteopenic Hepatitis C Patients with Low Dairy Calcium Intakes
(n=23)
Marcel H. Van Gemert, Cmj van Nieuwkerk, Jc Roos, E Bloemena, Ac van Doorn, Cjj
Mulder
Dystrophic bone metabolism is frequently associated with chronic hepatitis C (HCV). Its
etiology cannot be attributed solely to one mediating determinant. We postulated that chronic
hepatitis C patients exhibiting associative osteopenia will have serum markers reflective of
their bone pathology. Our goal was to correlate these markers to bone mineral density (BMD)
and determine the prevalence and extent of non-cirrhotic related osteopathy. Concurrently we
assessed dietary calcium and vitamin D intake status. Our study investigated 23 consecutive
patients undergoing treatment for chronic active HCV infection. BMD was determined by
means of a Dual Energy X-ray Absortiometry scan; hepatic histopathology by biopsy. A
dietary questionnaire was completed by each patient to assess daily dairy calcium and vitamin
D intake. Biochemical values of the following were taken at the time of BMD measurements:
alkaline and acidic phosphatase, 25OHD, osteocalcin, PTH, TSH, IGF-I, and serum calcium.
73.9% of patients had a significant reduction in BMD defined as a T-score <-1. The majority
of patients were both non-cirrhotic and osteopenic. Of this osteodystrophic group, 4 patients
had T-scores <-2.5, indicating osteoporosis; one was cirrhotic. Mean PTH values of osteodys-
trophic patients were significantly lower as compared to normal-BMD patients (3.94pmol/
l, p=0.027, 95%CI:3.12-4.98 vs. 6.83pmol/l, CI:3.73-12.49). IGF-I correlated significantly
with BMD at the lumbar spine (r=.434, p=0.044). Osteocalcin was shown to have a positive
correlation with both alkaline phosphatase; (r=.548, p=0.007) and PTH; (r=.645, p=0.001).
The average daily calcium intake, based on dairy products was found to be significantly
low overall when compared to the mean recommended daily allowance (RDA) of 1050mg/
Ca/day for standard population groups 19 through 70 years of age (patient ages; range 26-
66 years, group mean 635.2mg/Ca, p<0.001). The proportion of patients failing to achieve
the minimum calcium- RDA for their individual age group was 86.9%. The osteodystrophic-
HCV group had lower calcium intakes than normal BMD-HCV patients; 600 vs 734mg/Ca/
day respectively. Further investigations into chronic HCV as it pertains to osteopenia and
or osteoporosis need to establish calcium intake status, precluding causal link judgments.
Thus far this simple determinant of bone health in the multifactorial spectrum of viral
hepatic osteodystrophy has been overlooked. As well as body mass indices, the specific
nutritional calcium intakes warrant more consideration. Dystrophic bone metabolism is not



















The Influence of Cigarette Smoking On Response to Treatment with Pegylated
Interferon Alfa-2b and Ribavirin in Patients with Chronic Hepatitis C
Mary P. Pauly, Alan J. Sheinbaum, Jean-Luc I Szpakowski, Joanna B. Ready, Robert S.
Brown, Bradley Freilich, Nezam Afdhal, Paul Kwo, John Santoro, Scott Becker, Ira
Jacobson, Louis Griffel, Clifford Brass
Background: Cigarette smoking has been associated with increased inflammation and fibrosis
in patients with HCV. There is little data on the effect of cigarette smoking on response to
antiviral therapy patients with HCV. Aim: To study the characteristics and response to
therapy of HCV infected patients who smoked cigarettes and were treated with pegylated-
interferon (PEG IFN) alfa-2b and ribavirin (RBV), compared with those who did not smoke
cigarettes. Methods: The WIN-R study randomized 4913 patients to either PEG IFN alfa-
2b and RBV 800 mg (FD) or RBV 800-1400 mg (WBD) (Jacobson, AASLD 2005). Patients
with genotype 1 and 4 were treated for 48 weeks. Patients with genotype 2 or 3 were further
randomized to 24 vs 48 weeks of therapy. Sustained viral response (SVR) was the primary
endpoint with primary efficacy analysis including only those patients who were over 65 kg.
Results showed that weight based dosing resulted in significantly greater SVR, especially in
those with genotype 1, and that 24 weeks of therapy for genotype 2 and 3 was as effective
as 48 weeks. During enrollment,it was noted whether patients were smokers or non-smokers.
Smoking data was available on 2859 of 4223 (67.7%) patients included in the primary
efficacy analysis. We evaluated the influence of smoking on SVR. Results: Of patients with
available data, there were 893 ( 31.3%) smokers and 1966 (68.7%) non smokers. SVR for
smokers and non smokers in each group is noted in table 1. Conclusions: Cigarette smokers
with genotype 2 and 3 had lower SVR than non smokers. This difference was not seen in
the patients with HCV genotype 1.
SVR for Smokers and Non-Smokers by Group
S1924
Knowledge Deficits Concerning Hepatitis C Among Racial and Ethnic
Minorities: A Prospective Study
Stacey B. Trooskin, Maricruz Velez, Steven K. Herrine, Simona Rossi, David J. Axelrod,
Robert Winn, Scott McNeal, Victor J. Navarro
Background: HCV disproportionately affects racial and ethnic minorities. However, these
groups have less knowledge of HCV-related issues than their White counterparts (Buffington,
2000). We therefore aimed to further characterize differences in knowledge of HCV that
may exist among minority patients in primary care settings. Methods: New patients, 18 or
older, were prospectively enrolled, at four primary care practices (PCPs) in Philadelphia.
The PCPs included two federally qualified health centers, primarily serving minorities and
two university-based PCPs, one family medicine and one internal medicine. Demographics
including race/ethnicity were ascertained and an 11 question survey was administered, in
English or Spanish, querying general knowledge of HCV. “True”, “False” and “I don’t know”
were used as responses to all statements. Log-linear regression was used assuming a gamma
distribution, to assess the relationship between race and knowledge, measured by percentage
of correct answers. Results: Of the 1657 patients enrolled in this study, there were 507
Hispanics, 691 Whites, and 459 African Americans (AA). Whites were most likely to choose
the correct answers. Race overall and all comparisons by race remained significant after
adjusting for age and education (p<0.0001). Among Hispanic subpopulations, those born
in the U.S. (including Puerto Rico), had a similar percentage of correct answers compared
to AA. Non-US born Hispanics knew significantly less than their US born counterparts (p=
.0005); this relationship was significant after adjusting for education and age. Non-US
born Hispanics living in the United States for five years or more were less likely to have
misconceptions regarding HCV than individuals who have been living in the US for less
than five years. Discussion: AA and Hispanics know significantly less about HCV than
Whites; even greater knowledge deficits exist among Hispanics born outside the US and
Puerto Rico. Culture, language and literacy level appropriate HCV educational interventions
are needed, particularly for those who have recently immigrated to the US.
S1925
Lack of Adherence As a Critical Factor for Non-Sustained Virological
Response to Combination Therapy of Interferon and Ribavirin in Chronic
Hepatitis C Patients of Genotype 2 Infection
Yoshiaki Iwasaki, Daisuke Tanioka, Hiroshi Ikeda, Kouichi Takaguchi, Haruhiko Kobashi,
Yasuyuki Araki, Minoru Tomita, Noriaki Hashimoto, Kazuhisa Yabushita, Masaharu Ando,
Tomonori Senoh, Yasuhiro Makino, Kohsaku Sakaguchi, Yasushi Shiratori
Background and Aims: Hepatitis C virus genotype is the most important variable influencing
outcomes of interferon treatment for patients with chronic hepatitis C, and patients infected
with genotype 2 or 3 have the best response rate. However, some of the patients of genotype
2 infection can not achieve a sustained response to combination therapy of interferon and
ribavirin. Factors associated with non-sustained virological response to combination therapy
in these patients were analyzed. Methods: We consecutively enrolled 121 chronic hepatitis
C patients of genotype 2 infection; 69 men and 52 women, age (mean ± SD): 55 ± 11 years
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old. Interferon alpha-2b therapy was conducted daily for two weeks, followed by three times
per week for 22 weeks, and ribavirin (600 or 800 mg) was administered daily. Patients
were assessed for efficacy, safety, and tolerance by monitoring hepatitis C virus status and
adverse events including laboratory abnormalities every 2-4 weeks. Sustained virological
response and dose modification and premature discontinuation of the combination therapy
due to adverse events or laboratory abnormality were the endpoints. Results: Of the 121
study patients, dose reduction and discontinuation of therapy was required in 51 (42%)
and 14 (12%) patients, respectively. Seventy-four (61%) patients achieved 80%-adherence,
while 47 (39%) could not. Univariate logistic regression analysis revealed gender (male)
(95% CI of Odds ratio: 1.25-5.62), neutrophil count (≥ 2500/μL) (1.10-4.95), creatinine
clearance (≥ 100 mg/day) (1.09-5.10), body weight (≥ 60 kg) (1.05-4.72), and hemoglobin
level (≥ 14 g/dL) (1.05-4.72) at baseline to be associated with adherence to therapy. A
sustained virological response was achieved in 93 (77%) patients. Univariate analysis revealed
that adherence to therapy was the only factor significantly associated with the achievement
(Odds ratio (95% CI): 3.97 (1.63-9.71), P = 0.002). A sustained virological response was
achieved in 86% (64/74) and 62% (29/47) of patients with and without 80%-adherence,
respectively (P = 0.003). Univariate analysis revealed that adherence to therapy was still
associated with the achievement, even when analyzed in the adherent patients. Conclusions:
These results demonstrate an importance of adherence to combination therapy even in
chronic hepatitis C patients of genotype 2 infection. Thus, it is suggested that a further
improvement in response to combination therapy could be expected in these patients by
improving adherence to combination therapy.
S1926
Successful Treatment with High Dose Consensus Interferon and Ribavirin of
Patients with Chronic Hepatitis C Who Are Resistant to PEG-Interferon and
Ribavirin Therapy
Kenneth D. Rothstein, Ramesh Koka, Angel Fernandez, Holly Hargrove, Shailender Singh,
Victor Araya, Santiago J. Munoz
Background: The majority of nonresponder and relapser patients with chronic hepatitis C
are unable to achieve a sustained virologic response (SVR) with the combination of PEG-
Interferon (PEG-IFN) and ribavirin (RBV), especially those who have genotype 1 and
advanced disease. Consensus interferon (Interferon alfacon-1, CIFN) is a bio-optimized alfa
interferon that exhibits increased in-vitro antiviral activity than the naturally occurring alfa
interferons 2a and 2b. Improved response rates have been reported with high-dose CIFN
therapy and RBV for patients who have failed to respond to PEG-IFN / RBV. Aim: Evaluate
efficacy and safety of high-dose daily CIFN and RBV in HCV patients who failed therapy
with PEG-IFN / RBV. Methods: Patients who had been treated with PEG-IFN/ RBV for HCV
but did not obtain a SVR were eligible for treatment if they: 1) tolerated treatment with
PEG-IFN / RBV, and 2) had advanced liver disease. Patients were given 27 ug of CIFN daily
and RBV 400 mg BID during the first four weeks, followed by 18 ug daily and ribavirin
400 mg BID daily for the next eight weeks. At 12 weeks, CIFN was decreased to 15 ug
daily while RBV was increased to 1,000-1,200 mg daily for 36 weeks. Results: Thirty eight
patients have been enrolled in the study to date,74% male with a mean age of 51 years.
97% had genotype 1. 79% of patients had stage 3 fibrosis or greater, of which 55% of
patients had cirrhosis. 82% of patients were nonresponders. 22 patients (62%) have achieved
an early virologic response (EVR) at 12 weeks. 16 patients (56%) were undetectable at 24
weeks and 8 patients (42%) achieved an End-of-Treatment response(EOT). Of the 17 patients
who have completed 72 weeks of treatment,9 patients discontinued therapy, 8 patients
achieved EOT response, 3 of these patients (18%) have achieved a Sustained Virological
Response (SVR). 50% of patients required growth factors, 29% required Epopoetin alfa,
Filgastrim 5% and both 16%. Conclusion: This regimen was well tolerated with dose
reduction and discontinuation rates similar to other nonresponder trials using PEG-IFN and
RBV.For HCV patients with advanced fibrosis who have previously failed therapy with PEG-
IFN and RBV, high dose CIFN and RBV combination therapy is an effective option.
S1927
High Dose Induction Therapy with Consensus Interferon (CIFN) in Patients
with Chronic Hepatitis C Is Safe and Highly Efficient: An Open-Label Pilot
Study
Thomas Witthoeft, Diether Ludwig
Abstract: Treatment options for patients with chronic hepatitis C are limited. Before introduc-
tion of pegylated interferons in combination with ribavirin in 2001 common interferon-α
three times weekly and ribavirin on a daily dosing was recommended. Sustained virological
response rates were low and patients often stopped therapy due to side effects. Method: We
started, before PEG-Interferons were available, an open-label study to investigate the efficacy
and tolerability of high dose induction therapy with CIFN and ribavirin in treatment-naiive
patients with chronic hepatitis C. 58 patients got enrolled receiving 18ug of CIFN daily for
8 weeks, followed by 9ug daily for up to week 24 or 48 and 800mg of ribavirin daily. End
point of the study was tolerability and eradication of the virus at week 48 and sustained
virological response at week 72. The study was approved by the local ethic committee and
informed consent of patient was obtained prior to treatment. Results: More than 52% of
patients did respond at week 48 showing a negative qualitative PCR (GT 1 fourteen patients
(56%), GT 2 two (50%), GT 3 thirteen (87%), GT 4 one (50%)). Only five of the patients
presenting negative PCR at EOT showed a relapse at week 72. 48% of genotype 1 patients
showed SVR six months after end of treatment. 13 patients did not respond to therapy. Six
patients showed a relapse of i.v. drug use and one of them died due to an overdose. Four
patients stopped treatment due to side effects (low WBC, epistaxis, depression). 4 patients
did not show up for follow up visits during therapy. Conclusion: High dosing of CIFN on
a daily basis was well tolerated and side effects like leuko- and thrombocytopenia were
moderate. EOT rates were slightly lower compared to newer standard therapy with pegylated
interferons. From our study CIFN on a daily basis might be a favourable therapy regimen
for patients with subtype 1 and high viral load. Head to head studies to compare consensus-
interferon and pegylated interferons are therefore warranted.
S1928
Real-Time, Acetylcholine-Induced Early Phasic Oscillatory Force Generation
Analysis of 3D Bioengineered Colon Circular Smooth Muscle Constructs
Using Dominant Negative RHOA Or Dominant Negative PKCα
Saumya S. Vanderwyst, Suresh B. Patil, Robert R. Gilmont, Sita Somara, Khalil N. Bitar
Background: We have previously shown that bioengineered GI smooth muscle rings mimic
the phasic physiological response of in vivo muscle tissue. Objective: To further understand
the real-time, very early sequence of events in acetylcholine-induced force generation medi-
ated by RhoA and PKCα. Methods: Rabbit colon circular smooth muscle cells were harvested
and cultured in vitro. A. Molecular biology: Cells were transfected with either dominant
negative PKCα or dominant negative RhoA. B. Bioengineering: 3D rings were bioengineered
from stably transfected dominant negative (-ve) constructs using a fibrin gel surrounding a
circular mold. We have studied the response to acetylcholine (0.1μM) in these rings using
an optical force transducer capable of micro-Newton sensitivity and a 0.1 second sampling
rate. Results: 1) We were able to successfully create bioengineered rings from stably trans-
fected cells. Also, we maintained the functional rings for up to 1 month post-ring formation.
2) Both bioengineered ring types responded to: a) ~50% stretch and b) 10mM KCl addition.
3) The frequency of baseline oscillations were similar for both ring types; however, average
baseline amplitudes were slightly lower for dominant negative RhoA (-ve PKCα = 4.365 ±
0.179 μN vs. -ve RhoA = 3.929 ± 0.002 μN, p < 0.05). 4) Both bioengineered ring types
responded equally to acetylcholine with maximum force generation. However, there was a
significant difference in the early response pattern in reaching sustained force. The bioengine-
ered rings expressing -ve PKCα (active RhoA pathway) showed a period of oscillation with
14 ± 1 peaks occurring within the first 30 seconds before reaching sustained force generation.
The bioengineered rings expressing -ve RhoA (active PKC pathway) exhibited a sustained
force generation in response to acetylcholine without any pre-oscillatory pattern. These data
suggest a crucial role for RhoA in modulating very early (within first 10s) phasic oscillatory
force generation response, in the absence of PKCα. Summary: We have been able, for the
first time, to successfully develop bioengineered rings from colonic smooth muscle cells
transfected with either dominant negative PKCα or dominant negative RhoA. These rings
show that RhoA modulates early phasic oscillatory force generation while PKC, in the
absence of RhoA, is incapable of generating early oscillatory response. Conclusions: Using
bioengineering and molecular biology tools, we have developed a technique to discern the
molecular contribution of PKC and RhoA pathways, and the early sequence of events
modulating phasic oscillatory force generation in response to acetylcholine in colonic
smooth muscle.
S1929
Colonic Electrical Stimulation with Trains of Short Pulses Not Long Pulses
Enhances Colonic Transit in Awaken Rats
Shi Liu, Wenpo Li, Xiaohua Hou, Jiande Chen
Background: Our recent study has shown an acceleration of colonic transit with colonic
electrical stimulation (CES) with trains of short pulses, this accelerative effect was prevented
by nitric oxide inhibitor L-NNA. However, little is known about potential roles of CES with
long pulses on colonic transit. Aims: To evaluate the effect of CES with long pulses on
colonic transit in conscious rats and investigate whether cholinergic pathway was involved
in accelerative effect of CES with trains of short pulses. Methods: Male rats implanted with
one pair of stimulation electrodes on the proximal colon serosa were used for the study. A
small catheter was inserted into the proximal colon and fixed with sutures. Three days
after surgery, saline or muscarinic receptor antagonist atropine (5mg/kg) were administered
subcutaneously. 1.5ml solution of phenol red (0.5 mg/ml) was injected via the catheter as
a marker of colonic transit. Colonic transit with or without CES was determined by calculating
the output of phenol red from the anus every 10-min for 90-min. CES was performed
during the first 40 min. In saline group, the stimulus was composed of long pulses with a
frequency of 20 cpm, a width of 200 ms and amplitude of 10 mA. The parameters of
stimulation in atropine group was trains of short pulses with an on-time of 2s and off-time
of 3s, a pulse frequency of 40 Hz, a width of 4 ms and amplitude of 10 mA. Results: 1)
CES with long pulses had no effect on colonic transit at any times. There were no significant
changes in the percentage of recovered phenol red between the group of CES with long
pulses compared with the group without CES (at 90-min: 46.4 ± 5.9 % vs. 49.5 ± 5.3 %,
P > 0.05). 2) Atropine delayed colonic transit compared with saline. The percentage of
recovered phenol red at 90 min was decreased from 49.5 ± 5.3 % in the control session to
14.2 ± 2.5 % with atropine (P < 0.001). 3) Atropine did not prevented accelerative effect
of colonic transit caused by CES with trains of short pulses. At the presence of atropine,
CES with trains of short pulses still accelerated colonic transit: the percentage of recovered
phenol red was 14.2 ± 2.5% in the control session (atropine alone) and 36.9 ± 5.6 % with
CES session (atropine plus CES) (P < 0.01). Conclusions: Colonic electrical stimulation with
trains of short pulses not long pulses enhances colonic transit and this accelerative effect
may not be mediated via cholinergic pathway.
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S1930
Colonic and Gastric Muscle Contraction in the Obese (OB/OB) Mouse
Ping Cong, Gyorgy Baffy, Piero Biancani, Jose Behar
The prevalence of gastrointestinal symptoms is higher in obese patients than in the general
population. However, the mechanisms responsible for this higher prevalence are not known.
Obese patients tend to have higher levels of serum cholesterol (Ch). We have previously
shown that gallbladders with lithogenic bile with high Ch concentrations impair the muscle
contraction and relaxation. Those muscle cells incorporate higher Ch levels in the caveolae
and impair muscle contraction because of caveolar sequestration of receptors that results in
decreased recycling back to the bulk plasma membrane (plasma membrane-caveolae) and
lower ligand binding by membrane receptors. The aim of these studies therefore was to
examine whether colonic and gastric muscle cell functions is affected by an abnormal
incorporation of Ch in OB/OB mice. We studied seven OB/OB mice and six lean mice. The
levels of serum Ch of OB/OB mice was 10.9± 2.0 mmol/lt significantly higher than the levels
of lean mice of 3.1±0.6 mmol/lt (p<0.001). The contraction of dissociated gastric and colonic
muscle cells from OB/OB mice in response to increasing concentrations of CCK-8 (10-11
to 10-8 M) were lower than those from lean mice (Anova, p<0.01). In addition, caveolar
Ch levels in gastric and colonic muscle cells were higher in the OB/OB mice than in lean
mice (p<0.001). Western blot studies using specific antibodies revealed higher concentrations
of caveolin 3 proteins in the caveolae of muscle cells from OB/OB mice than from lean
mice. We also determined the distribution of CCK-1 receptors in the caveolae and bulk
plasma membrane using specific antibodies. The optical density of the CCK-1 receptor band
was significantly increased in the caveolae and decreased in the bulk plasma membrane in
the OB/OB mice compare to those detected in the caveolae and bulk plasma membrane of
muscle cells from lean mice (p<0.01). The results in this obese mouse model suggest that
similar mechanisms may be responsible for the high prevalence of gastrointestinal symptoms
in the obese population. That the gastrointestinal muscle cell response to agonists that act
on receptors that internalize through caveolae may be defective due to higher incorporation
of caveolar Ch from high serum concentrations increasing the concentrations of caveolin
3 proteins and of receptors in the caveolae resulting in reduced recycling back to the
plasma membrane.
S1931
Biofeedback Is an Effective Treatment for Functional Constipation: A
Randomized Controlled Study
Wayne H. Hu, Joanne H. Li, Annie O. Chan, Nina Y. Wong, Stephen H. Wong, Wai M.
Hui
Introduction: Constipation affects up to 20% of the general population. Biofeedback is a
newer way to treat constipation but most studies are uncontrolled. We performed a controlled
trial to evaluate biofeedback in patients with functional constipation. Methods: Patients with
chronic constipation according to the Rome 2 criteria with symptoms lasting more than one
year were randomized. Full colonoscopy was performed to rule out organic pathology.
Patients were asked to stop all laxative medication for two weeks and record daily bowel
habits on a diary card, as well as complete a constipation symptom severity questionnaire.
Use of rescue laxatives was recorded. Biofeedback consisted of teaching of proper defecation
posture, abdominal muscle exercise, pelvic floor retraining with pressure and biofeedback
and also training of balloon expulsion from the rectum. Each session lasted 30-60 minutes
and was repeated every two weeks for six sessions. Control group consisted of lifestyle,
dietary and general advice regarding defecation only. Bowel symptoms, defecation frequency
were assessed at baseline and after twelve weeks. Severity of bowel symptoms were assessed
in a 5 point Likert scale. Changes in symptom severity from baseline were compared using
Mann-Whitney U test. Results: Sixty patients were recruited (mean age 44, 95% female)
and randomized equally to treatment and control groups. After completion of treatment,
the number of complete spontaneous bowel movements increased similarly in both treatment
and control groups (1.3 to 2.6 and 1.2 to 2.3). In the biofeedback group, there was decrease
in bloating (from 2.6 to 0.8), incomplete evacuation (from 2.4 to 1.0), straining (from 2.8
to 1.3) and laxative use (1.9 to 0.4) after treatment. The control group did not show
improvement in symptoms and laxative use (2.2 to 2.4, 2.1 to 2.4, 2.3 to 2.3 and 1.9 to
1.4 respectively). Change from baseline were significant between treatment and control
groups for the symptoms assessed. Conclusions: Biofeedback treatment is effective in improv-
ing the dynamics of defecation and decreasing symptoms in patients with idiopathic constipa-
tion when compared to controls. Acknowledgements: This study is supported by the Simon
To fund for nutrition and functional gastrointestinal disorders.
S1932
Responses of Rat Proximal, MID and Distal Colonic Muscularis Mucosae to
ATP and Bradykinin Are Mediated By Different Mechanisms
William Percy
Bradykinin and ATP each contract rat colonic muscularis mucosae (MM) in vitro, with an
oral to aboral decrease in efficacy. The aim of this study was to determine the pharmacologic
basis of the effects of these agents on this muscle layer in three separate colonic regions.
METHODS: Strips of MM 3cm x 4mm from the proximal, mid and distal colon were placed
in 2ml tissue baths under a 0.5g (4.9mN) load for isometric recording. Responses were
expressed as a percentage of each tissue’s maximum contraction to acetylcholine. RESULTS:
Bradykinin (4x10-13-4x10-6M) elicited MM contractions that reached 461.7±110.0%,
136.3±8.0% and 108.6±12.1% (n≥5 each) in the proximal, mid and distal regions. Proximal
responses to bradykinin were reduced to 228.7±23.1% and 270.4±55.8% following pretreat-
ment with either indomethacin (10-6M) or TTX (10-6M) respectively (both p<0.05; n≥5).
Mid and distal responses to bradykinin were unaffected under the same conditions. The
selective B1 agonist Des-Arg9-bradykinin (5.2x10-12-5.2x10-6M) elicited proximal MM
responses of≤45% of the bradykinin maximum; in the mid and distal region the correspond-
ing responses were ≤20% of the bradykinin maximum. Proximal, mid and distal MM

















each). Proximal ATP responses were unaffected by indomethacin whereas, mid and distal
responses were reduced to 18.5±8.7% and 21.5±6.8% (p<0.01; n≥7) respectively. Only
distal MM responses to ATP were attenuated by TTX, falling to 43.9±2.3% (p<0.001; n=
8). When compared to other purines on an equimolar basis, the order of efficacy in each
region was, ATP≈ADP>AMP=adenosine. CONCLUSIONS: 1. Colonic MM responses to
bradykinin are mediated by B2 and, to a lesser extent, B1 receptors; responses to ATP occur
via P2 receptors. 2. Proximal MM responses to bradykinin involve prostaglandin production
and an excitatory neural component; bradykinin contracts mid and distal colonic MM by
a direct action. 3. Proximal MM responses to ATP are direct, mid MM responses are
prostaglandin-mediated, but in the distal region both prostaglandins and an excitatory neural
pathway are utilized. 4. The inhibitory innervation of the rat colonic MM is unaffected by
ATP or bradykinin. 5. Although both the excitatory innervation and prostaglandin synthesis
associated with the colonic MM are involved in this muscle’s responses to bradykinin and
ATP, their relative contributions to the contractile process are region-specific.
S1933
The Prokineticin Receptor 1 Mediates Inhibition of Spontaneous Giant
Contractions in the Murine Proximal Colon
Willemijntje A. Hoogerwerf
Background: Prokineticins are novel peptides with reported effects on gastrointestinal con-
tractility. We previously showed prokineticin receptor 1 (PKR1) expression in the myenteric
plexus of the mouse proximal colon. The aims of this study were (1) to characterize the
cell types expressing PKR1 (2) to determine the effect of prokineticin 1 on mouse proximal
colon contractility and (3) to determine the effect of prokineticin 1 on nitric oxide release
in vitro. Methods: Immunohistochemistry was used to characterize the cell types expressing
PKR1 by using double-labeling immunofluorescence in longitudinal muscle myenteric plexus
(LMMP) preparations with antibodies to HuC/D (neuronal marker) and neuronal nitric oxide
synthase (marker for myenteric inhibitory neurons). Proximal colon rings from adult male
C57BLK6/J mice were used for circular muscle recordings in organ baths. The effect of PKC
on nitric oxide release was determined from LMMP cultures using a commercial nitric
oxide assay kit. Results: Quantification analysis showed that 23.8 ± 1.85 % of all HuC/D-
immunoreactive neurons express PKR1 (504 neurons, 3 mice). Of PKR1- immunoreactive
neurons, 7.7 ± 1.02 % express nNOS-immunoreactivity (233 neurons, 3 mice). Conversely,
5.6 ± 1.98% of nNOS-IR neurons expressed PKR1-IR (318 neurons, 3 mice). PKC suppressed
giant contractions (GC) in circular muscle. PKC 1 mM, 10 mM and 100 mM, significantly
decreased the frequency from 2.22 ± 0.48/5 at baseline to 0.89 ± 0.20, 0.56 ± 0.30 and
0.22 ± 0.15 GC/5 minutes, respectively (n=8, P<0.05). PKC 1 mM, 10 mM and 100 mM,
significantly decreased the amplitude from 5.12 ± 1.05 to 3.25 ± 0.85, 2.20 ± 0.80 and
1.43 ± 0.40 mN, respectively (n=8, P<0.05). PKC 100 mM did not significantly alter the
frequency or amplitude in the setting of L-NAME. Under non-adrenergic, non-cholinergic
conditions, PKC 100 mM significantly decreased the amplitude of the contractions from
3.54 ± 1.13 mN to 1.04 ± 0.27 mN (n=5; P<0.05). PKC stimulated nitric oxide release
from LMMP cultures in a dose-dependent manner in vitro: PKC 1 mM, 10 mM and 100
mM produced 0.59 ± 0.22 mMol/10 mg tissue weight, 1.19 ± 0.28 mMol/10 mg tissue
weight, and 1.55 ± 0.39 mMol/10 mg tissue weight, respectively. This effect was blocked by
l-NAME. Conclusion: PKR1 mediates an inhibitory effect on spontaneous giant contractions in
the murine colon, most likely through direct or indirect stimulation of nitric oxide release.
PKR1 and its natural ligand, prokineticin 1, may be important for modulation of colonic mot-
ility.
S1934
Genome-Wide Transcriptional Signals from Colonic Neuromuscular Tissue in
Patients with Slow Transit Constipation
Lu Liu, Rohan B. Williams, Fei Shang, Denis W. King, Elizabeth Burcher
Introduction: Slow transit constipation (STC) is a serious motility disorder of unknown
etiology. Surgery is often the only effective treatment. In this study, we have applied a novel
approach by using expression microarrays (measuring mRNA) with integrated bioinformatics
follow-up (Gene Ontology (GO)) to describe transcriptional levels of individual genes,
functional gene clusters and putative molecular mechanisms underlying the pathophysiology
of STC. Methods: Microarray profiling was performed in sigmoid colon muscle from 6
female patients (age range 23-65 years) undergoing colectomy for STC, in comparison with
normal colon from 6 age-matched female patients (30-64 years) undergoing resection for
carcinoma. Normal colon was taken 10-20 cm from the tumor. Total RNA (sourced from
circular and longitudinal muscle, and myenteric plexus) was extracted, pooled from each
group, reverse transcribed and fluorescent dye coupled prior to hybridization onto microarray
slides (19,000 unique human transcripts, n=6 replicates). Following normalization, differenti-
ally expressed genes were identified using a Bayesian linear model (log-odds>4 significance
level). Results: Of the 272 differentially expressed transcripts, 230 were significantly down-
regulated in STC, whereas only 42 genes were up-regulated (e.g. DEEPEST, NUP98, 4E-T,
SNAP23). We employed GO annotations when known (163/272 transcripts), clustered to
identify any major functional groupings of differentially expressed genes. The two top ranking
clusters comprised 25 genes associated with protein metabolism and 23 genes with signal
transduction (e.g. S100 calcium binding protein, guanylate cyclase activator). Unexpectedly,
there was a notable down-regulation of multiple genes encoding for mucus production
(mucins 2,3,5,11 and 12, and trefoil factors 1 and 3). Another unexpected finding was the
down-regulation of EMAP2 (echinoderm microtubule associated protein 2: annotated to
‘mechanosensation’ in GO): an intriguing finding because it highlights potential differences
in integration of cytoskeletal signaling that might have implications for mechanical function
of smooth muscle in STC. There was no obvious change in genes linked to the enteric
nervous system. Neuronal tissue comprised only a small portion of the total tissue examined,
minimizing the likelihood of observing any neuronal changes. Summary: This study has
described alterations in gene transcripts in human STC, measured using high-throughput
transcriptomics. We have identified several novel transcripts, cellular subsystems and mech-
anistic leads that may have relevance in the pathogenesis of this disorder. Supported by
NHMRC Australia.
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S1935
Differential Role of A1 and A2a Purinergic Receptors in the Control of
Colonic Neuromuscular Function in the Presence of Experimental Colitis
Luca Antonioli, Matteo Fornai, Corrado Blandizzi, Rocchina Colucci, Narcisa Ghisu,
Maria Cristina Breschi, Mario Del Tacca
Introduction. Adenosine regulates innate immunity and is implicated in the pathophysiology
of intestinal inflammation. Adenosine receptors are expressed throughout the digestive tract,
but their involvement in gut dysmotility associated with inflammatory bowel disease has
not been described. This study examines the role of adenosine A1 and A2a receptors in the
control of colonic motility in experimental colitis. Methods. Colitis was induced in male
Sprague-Dawley rats by intrarectal administration of 2,4-dinitrobenzenesulfonic acid (DNBS).
Colonic longitudinal muscle strips were suspended in Krebs solution containing antagonists
of neurokinin receptors and connected to isotonic transducers (load = 1 g) to determine
the effects of A1 and A2a receptors ligands, dipyridamole (DIP, adenosine reuptake inhibitor)
and adenosine deaminase (ADA) on atropine-sensitive motor responses evoked by: a) trans-
mural electrical stimulation (TES: 0.5 ms, 30 mA), delivered as single (sTES: 10 Hz, 100
pulses) or repeated trains (rTES: 5 Hz, 25 pulses every 60 s); b) carbachol in the presence
of tetrodotoxin. RT-PCR was used to examine A1 and A2a receptor mRNA expression.
Results. In normal colonic preparations, sTES-induced contractions were enhanced by DPCPX
(A1 antagonist; +32.6%) and ZM 241385 (ZM, A2a antagonist; +21%). In inflamed tissues,
the enhancing action of ZM was more pronounced (+45%), whereas DPCPX had no effects.
The stimulant effects of ZM, in normal or inflamed colon, were prevented by Nω-propyl-
L-arginine (nNOS inhibitor), whereas those of DPCPX in normal colon were insensitive to
nNOS blockade. After incubation of colonic preparations with DIP plus ADA, to decrease
extracellular adenosine, CGS 21680 (A2a agonist) decreased motor responses to rTES, being
more effective in inflamed (EC50 = 16 nM; Emax = -58%) than normal tissues (EC50 = 20
nM; Emax = -27%). Under these conditions, CCPA (A1 agonist) inhibited rTES-induced
contractions with similar efficacy in normal (EC50 =120 nM; Emax= -74.3%) and inflamed
tissues (EC50 = 130 nM; Emax = -66.5%). A1 or A2a ligands did not affect carbachol-
induced contractions. RT-PCR showed an increase in A2a, but not A1, receptor expression
in neuromuscular layer of inflamed colon. Conclusions. 1) Adenosine is involved in the
inhibitory control of colonic motility via activation of A1 and A2a receptors; 2) A1 receptors
appear to directly modulate cholinergic nerves, whereas A2a receptors act through the
recruitment of inhibitory nitrergic pathways; 3) Experimental colitis modifies this regulatory
pattern, leading to an enhanced inhibitory control operated preferentially by A2a receptors.
S1936
Tegaserod Improves Symptoms and Function in Patients with Chronic
Constipation
Brian Lacy, Jeffrey Kralstein, Michael Dolker, Michael Shetzline
Purpose The efficacy of tegaserod in patients with Chronic constipation (CC) is well estab-
lished based on improvement in complete spontaneous bowel movements (CSBM) over a
defined period. However, patients and physicians frequently use spontaneous bowel move-
ments (SBM) and subjective symptoms to assess bowel function. This study assessed the
benefit of 12 weeks of tegaserod (T) versus placebo (P) on SBM assessments as well as
satisfaction of bowel habits in CC. Methods Data from separate double-blind, randomized,
controlled clinical trials in CC for T dosed at 6 mg bid (N=882) and placebo (N=863) were
pooled for analysis. A bowel movement was considered spontaneous if the patient had not
used a laxative or enema within the preceding 24 hours. Straining and satisfaction of bowel
habits were assessed using 3 and 5 point ordinal scales and stool consistency was assessed
using the Bristol stool scale. Data were analyzed for the intent to treat population comparing
T and P for change from baseline using van Elteren tests at each time point over the 12-week
active treatment period. Results Tegaserod demonstrated a consistent benefit quantitatively in
stool frequency compared to P as well as a significant improvement in stool form, consistency,
straining and satisfaction with bowel habits during the 12 week trial period (compared to
baseline; all results p<.05). Conclusion Tegaserod dosed at 6 mg bid provided a sustained
response over placebo for 12 weeks in both quantitative and qualitative assessments of
constipation in patients with CC.
* A negative change denotes improvement
S1937
Corticotropin-Releasing Factor (CRF) Potentiates Rat Inferior Splanchnic
Nerve Afferent (ISA) Unit Responsiveness to Serotonin (5-HT) in Vitro
Yuhua Wang, Mulugeta Million, Lixin Wang, David Adelson, Jen Yu Wei, Yvette Tache
Background: CRF plays a role in regulating brain serotoninergic neurotransmission. Activa-
tion of CRF1 and CRF2 receptors in the dorsal raphe nucleus (DRN) inhibits and increases
5-HT activity, respectively (Neuroscience 129, 509,2004). Our previous in vitro studies in
a rat ISA-colon preparation model indicated that ~53% and ~78% of ISA fibers responded
to intra-arterial (ia) injection of CRF and tegaserod, a 5-HT4 agonist, respectively (Gastroenter-
ology 2001;120:A717 and 2002;122:A317). Aim: Determine whether CRF ia injection
modulates 5-HT-induced ISA fiber activity in a rat in vitro preparation. Methods: The
colorectal-inferior splanchnic nerve preparation was isolated from fasted, isoflurane anesthet-
ized male SD rats (250 - 300 g) and put in a chamber as detailed previously (Gut 2005;
PMID: 15985561). Responses of ISA fibers to consecutive ia injections of vehicle (saline
0.1ml), 5-HT (40 ng), CRF (400 ng) and a 2nd dose of 5-HT (40 ng) at 15 - 30-min intervals,
and to local mechanical receptor field stimulation (RFs) were recorded. In the control group
the CRF injection was replaced by saline. Response magnitudes were presented as a Q = 5-
min spike count after/before treatment. A total of 28 units from 14 preparations were
analyzed, including 20 units with basal activity averaging 1.10 ± 0.13 spikes/s and 8 silent
units. Control group (5 rats) had 9 units with 2 silent units, while test group (9 rats) had
19 units with 6 silent units. Results: CRF ia, which had no effect on ISA activity at
this dose, significantly enhanced subsequent 5-HT-induced ISA fiber discharge (Table). In
addition, CRF increased the number of 5-HT-responsive units from 6/13 to 12/13 and that
of silent units from 2/6 to 4/6. In the control group, responses to the 1st and 2nd 5-HT
injections were similar. All 28 units responded to RFs. Conclusions: These in vitro studies
provide evidence that CRF acts peripherally to enhance responsiveness of ISA fibers to 5-
HT, suggesting a potentiating interaction between CRF and 5-HT that may have implications
for stress-related induction of hypersensitivity to colorectal distention. Supported by NIH
grants DK 33061 and P50 DK64539 (YT).
Peptides activated ISA fibers
Values are mean ± SEM. [F=1.43, P=0.26, control group (n=7), and KW=23.11, P<0.0001,
test group (n=13), parametric or nonparametric ANOVA test], *P<0.05 vs. 5-HT (1st).
S1938
Effect of Lactobacillus Casei Shirota On Colonic Transit Time in Patients with
Slow-Transit Constipation
Franka Schlieger, Heinz Krammer, Andreas Franke, Hermann Harder, Irmtrud Wagner,
Manfred V. Singer
Background: Slow-transit constipation is based on a motility disorder of the colon which
leads to delayed transit (>72 hours). Recently, it could be shown that Lactobacillus casei
Shirota improves constipation related symptoms (stool frequency and consistency). Aim: To
determine the effect of Lactobacillus casei Shirota on the colonic transit time in patients
with slow-transit constipation under randomized double blind placebo controlled conditions.
Methods: Colonic transit time of all consecutive outpatients with chronic constipation was
determined by the Hinton-Test using radioopaque markers. If the transit time was at least
72 hours, subjects have been included in our study. 24 patients were given daily for four
weeks either a dairy drink containing 6,5x109 colony forming units (cfu) of Lactobacillus
casei Shirota or a placebo. After four weeks of therapy, measurement of colonic transit time
was repeated. Results: The intervention with Lactobacillus casei Shirota resulted in a signific-
ant acceleration of the total colonic transit time (before: 95,6 hours, after: 77 hours, respect-
ively; p=0,05). This effect was mainly due to a reduction of the transit time in the sigmoid
and rectum (p<0,007), see table 1. In the placebo group, the decrease of the total colonic
transit time did not reach statistical significance (93,7 vs 87,1 hours, respectively; p=0,393).
Conclusion: Lactobacillus casei Shirota decreases delayed colonic transit times in patients
with slow-transit constipation. This effect is mainly due to an acceleration in the sigmoid
and rectum.
Transit times before and after intervention with Lactobacillus casei Shirota
S1939
Regulation of Intestinal Smooth Muscle Cell Growth and IGF-I Production By
Tegaserod
John F. Kuemmerle, Jennifer G. Bowers, John R. Grider
We have previously shown that intestinal smooth muscle cells express both 5-HT4 receptors
mediating relaxation, and 5-HT2A receptors mediating contraction. 5-HT stimulates prolifera-
tion of intestinal smooth muscle cells. Endogenous Insulin-like Growth Factor-I (IGF-I) is
a key mediator of intestinal smooth muscle cell growth. Upregulation of IGF-I in the
chronically inflamed muscle of Crohn’s Disease regulates hyperplasia of muscle and may
contribute to stricture formation. Tegaserod, a partial agonist of 5-HT4 receptors and in
some cells an antagonist of 5-HT2B receptors, is used widely for a variety of gastrointestinal
motility disorders although its effects on smooth muscle proliferation and interplay with
IGF-I has not been examined. Aims: The aims of the present study were to determine
whether tegaserod regulates muscle cell growth and identify the receptors involved, and to
determine whether activation of 5-HT receptors can modulate IGF-I production by muscle.
Methods: Colonic smooth muscle cells of the mouse colon were isolated by enzymatic
digestion and used to initiate primary cultures. Muscle cell growth was measured in response
to tegaserod using [3H]thymidine incorporation. IGF-I production was measured using a
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murine specific ELISA. GR113808A was used as a 5-HT4 antagonist and BW723C86 was
used as a 5-HT2B antagonist. Results: Incubation of quiescent muscle cells for 24 h with
tegaserod (10 nM - 1 μM) elicited concentration-dependent inhibition of basal [3H]thymidine
incorporation (1 μM: 28 ± 2%). In the presence of the 5-HT4 antagonist, GR113808A (1
μM), the effects of tegaserod were inhibited by 40-70%. Unlike tegaserod, incubation of
muscle cells with the 5-HT2B antagonist, BW723C86 (1 μM), did not affect basal [3H]thymid-
ine incorporation. Incubation of quiescent muscle cells for 24 h with tegaserod also elicited
concentration-dependent inhibition of IGF-I production (1 μM: 44 ± 7% inhibition). The
effects of tegaserod on IGF-I production were not altered by the 5-HT4 antagonist,
GR113808A (1 μM). In contrast to proliferation, incubation of muscle cells with the 5-
HT2B antagonist, BW723C86, significantly inhibited IGF-I production (1 μM: 25 ± 5%).
Conclusions: Tegaserod inhibits colonic smooth muscle cell proliferation by activation of
5-HT4 receptors and inhibits IGF-I production via its ability to inhibit 5-HT2B receptors on
muscle cells. Both effects suggest tegaserod might be useful in reducing the muscle hyperplasia
associated with disorders such as Crohn’s disease or intestinal obstruction.
S1940
Peripheral Corticotropin Releasing Factor (CRF) 2 Receptor Activation
Decreases the CRF1-Mediated Colonic Motor and Secretory Function
Mulugeta Million, Pu-Qing Yuan, Pascale Plaisancie, Paul R. Saunders, Karina
Pambukhchian, Armen Karapetyan, Yvette Tache
Background: CRF1 receptor activation by stress or CRF induces defecation and diarrhea in
rats (Gastroenetrology, 119:1569-79, 2000). Despite the presence of CRF2 receptors in the
colon, and selective CRF2 ligands such as urocortin 2 (Ucn 2) their role in colonic function
is not well known. We showed that peripheral CRF2 receptor activation dampens hypersensit-
ivity to colorectal distention (Gut 2005; PMID: 15985561). Aim: Determine 1) whether the
CRF1/CRF2 agonists, CRF and urocortin 1 (Ucn 1) stimulatory actions on colonic motor
function(fecal pellet output) and secretion (mucus) is the result of simultaneous activation
of CRF1 exitatory and CRF2 inhibitory pathways and 2) the location of CRF2 on nitric oxide
(NO) colonic enteric neurons. Methods: Adult male SD rats (280-320 g) were injected IP,
in 10 min interval, with either saline + saline, CRF (3 µg/kg) or Ucn 2 (10 µg/kg) or Ucn
2 + CRF (10 + 3 µg/kg), and fecal pellet output (FPO) was monitored for 60 min. Rats
were then euthanized and distal colonic longituidinal muscle myenteric plexus (LMMP)
whole mount preparation used for CRF2 and nitric oxide synthase (NOS) expression analysis.
Fixed and parafin embedded colonic tissues were processed for mucus detection by alcian
blue/PAS/hematoxylin staining. CRF2 antagonist astressin2-B (100 µg/kg) was injected 10
min before Ucn 1, at 3 and 10 µg/kg) and FPO as well as diarrhea monitored for 2 h.
Results: Ucn 2 (10 µg/kg) + saline IP did not affect FPO, whereas CRF at 3 µg/kg or Ucn
at 3 and 10 µg/kg increased FPO (0.0±0.0 v 4.5±0.5 /h; 5.8±0.6/2h, 7.7±1.6/2h, p<0.05,
respectively) and induced diarrhea. The CRF effect was reduced by Ucn 2 (2.0±0.3 v 4.5±0.5,
p<0.05 ). Conversely, Astressin2-B+Ucn 1 at 3 or 10 µg/kg v saline + Ucn 1, had higher
diarrhea prevalence (0% v 44%, p<0.05; 40% v 80%, p<0.05 respectively). CRF2 receptors
were expressed and colocalized with NOS positive neurons in colonic LMMP. Rats treated
with Ucn 2, compared to saline, had increased number of mucus stained cells/crypt (18.3±1.0
v 15.2±0.5, p<0.05) whereas CRF treated rats had a decreased number. The effect of CRF
on mucus cells was blocked by pretreatment with Ucn 2 (15.5±0.6 v 10.5±0.6, p<0.05).
Conclusions: Blockade of peripheral CRF2 enhances the CRF1/CRF2 receptor agonists-
induced FPO and diarrhea while CRF2 activation blunts CRF1-mediated colonic motor and
mucus discharge. The data suggest that CRF2 receptor exerts an inhibitory effect on a
stimulated colon, probably involving NOS activation. CRF2 inhibitory signaling may represent
a stress coping pathway in the CRF1-mediated alterations of colonic function during stress.
Supported by R01 DK57238(YT) & R21DK068155-01A1(MM)
S1941
A Course of Tegaserod Treatment Modulates CNS Processing of Visceral
Afferent Information
Lisa Kilpatrick, Jen Labus, Steve M. Berman, Brandall Suyenobu, Jean Stains, Bruce D.
Naliboff, Emeran A. Mayer
Introduction: Tegaserod (Teg) is a partial 5HT-4 receptor agonist which improves symptoms
in IBS patients with constipation predominant bowel habit (IBS-C). The neural mechanisms
underlying subjective symptom improvement are incompletely understood, but may include
effects on peripheral visceral afferent pathways. Aims: 1.Do changes in brain responses to
rectal distention (INF)correlate with IBS symptom changes? 2. Does a 3 week course of Teg
affect brain circuits concerned with visceral perception and autonomic control? Design and
Methods: Study protocol: Brain responses to controlled rectal INF (5,25 and 45mmHg) were
assessed in 10 women with IBS-C following 3 week treatment with Teg (6mg bid) and
placebo during a randomized cross-over clinical trial. fMRI analysis: Normalized contrast
images for effects of moderate(45mmHG)INF in each session were generated using statistical
mapping software(SPM2). Covariate analyses assessed the relationship of within-subject fMRI
response to INF to symptom outcomes in regions of interest pre-selected for association
with IBS symptom ratings. Multivariate task partial least squares (PLS) tested for distributed
patterns of brain activity associated with the three INF levels. A seed PLS was subsequently
applied to test for, and identify common and treatment-specific functional networks operating
during rectal INF. Results: Positive correlations (more activity - more symptoms, p<0.01)
were observed between 24-hr (as well as diary) symptom ratings and the INF-induced
activation in several brain regions including amygdala and dorsal pons. Negative correlations
included those for left anterior insula, ventral striatum and bilateral PAG. Task PLS revealed
a significant pattern of regions (p<.001) that maximally differentiated 5 and 45mmHg INF
across placebo and Teg treatment, and included medial thalamus. Seed PLS revealed a
network of regions associated with the medial thalamus that functioned differently during
the two INF conditions (but not during 5mmHg) following Teg vs placebo treatment, p<.001.
This treatment-dependent medial thalamic network included the insula, amygdala, midbrain,
ventral and dorsal ACC and prefrontal cortices. Conclusions: 1. Brain responses to rectal
INF correlate with IBS symptom changes. 2. Network analyses are consistent with Teg

















consistent with a known spinal-thalamic-cortico-limbic circuit operating during experience
of noxious visceral stimuli. FMRI assessment of brain responses to drug treatment in a small
sample of patients may be a useful technique to assess drug effectiveness in IBS patients.
S1942
The Effect of Mosapride Citrate On Colonic Motor Function in Guinea Pig:
Does It Differ Between Proximal and Distal Colon?
Hyojin Park, Eun Ju Choi, Sang In Lee
Backgrounds/Aims: Mosapride citrate (mosapride), a substituted benzamide, is a novel 5-
HT4 receptor agonist. The 5-HT4 receptor detected in the myenteric plexus may be located
on the excitatory neurotransmitter, and participate in the stimulation of motility, whereas
stimulation of the receptors located on the circular muscle induce the relaxation of the
muscle. We previously demonstrated mosapride significantly shortened the colonic transit
in guinea pig (Yonsei Med J 2003;44:653-64). However, there have been some debates in
its effects depending on gut regions what they used. Therefore, we undertook this study to
validate our previous study, evaluate the different effect of mosapride between proximal
and distal colonic motor function in guinea pig and, and to demonstrate the distribution
of 5-HT4 receptor both in proximal and distal colonic wall. Methods: Proximal (approximately
8 CM from the ileocolic junction) and distal colon (approximately 8 CM from the anus)
was removed. For the measurement of colonic transit time, artificial feces were inserted into
the oral side of lumen, and moved toward the anal side by intraluminal perfusion via a
peristaltic pump. Total 6 CM was observed and the time taken from moving each 2 CM
was measured as a colonic transit. Tissue bath study by using electrical stimulation was done
to estimate the contractile activity of the circular muscle of colon. Immunohistochemistry of
5-HT4 receptor of colonic wall of both proximal and distal colon was done to to clarify the
mechanism of different action of mosapride according to the site of colon. Results: Transit
time of proximal colon was significantly delayed compared with distal colon. Mosapride
(10-9-10-7M) significantly shortened transit time of proximal colon but not distal colon.
Mosapride increased the amplitude of contraction both in proximal and distal colon, which
is rather more on the proximal colon. 5-HT4 receptor is located more predominantly in the
myenteric plexus of the proximal colon, whereas receptor is more in the circular muscle of
the distal colon. Conclusions: Mosapride shortened colonic transit in guinea pig and this is
primarily due to an accelerated transit in proximal colon through the increased amplitude
of contraction, which is rather more on the proximal colon. This effect may be relevant
with the different distribution of 5-HT4 receptor in the gut wall.
S1943
Dendritic Cells Can Secrete Corticotropin Releasing Factor
Mariko Hojo, Toshifumi Ohkusa, Akira Harada, Tomoyoshi Shibuya, Harumi Tomeoku,
Kaoru Kushima, Akihito Nagahara, Nobuhiro Sato
Purpose: Corticotropin releasing factor (CRF) influencing gut motor function and visceral
perception appears to be involved in the pathogenesis of IBS. CRF has been found to be
secreted not only by the hypothalamus, but also by lymphocytes and macrophage, and the
secreted CRF appears to participate in the inflammatory-immune system. Dedritic cells in
the intestinal mucosa seem to be key players in the intestinal immune system, but to our
knowledge, there is no report on the secretion of CRF from these cells. In this study, we
investigated whether CRF secretion occurred in dendritic cells, and if so, whether or not
intestinal mucosal bacteria could stimulate and increase its secretion from the cells. Methods:
JAWSII cells (ATCC CRL-11904), a mouse dendritic cell line, were seeded into 24-well
culture plates (1X105 cells / well) and grown for three days. Commensal bacterial strains
of E.coli (JCM1649), C.clostridiforme (JCM1291), B.vulgatus (JCM5856) or F.varium
(ATCC8501) (1 x 108 cells each) were added to the cells, and incubated for two hours.
After incubation, the culture medium was collected and CRF was measured by means of
an ELISA assay. Results: CRF (29.6 pg/mL) was detected in the medium of JAWSII cells
treated with no bacteria. When E.coli, C.clostridiforme, or F.varium was added to cells, a
small increase in the level of CRF was detectable. However, an approximately 7-fold increase
in the level of CRF (~209.3 pg/mL) was observed when cells were treated with B.vulgatus.
Conclusions: These results suggest that dendritic cells are able to secrete CRF, and that
B.vulgatus in the gut may induce the secretion of CRF from dendritic cells. From these
observations, we suggest that dendritic cells stimulated by commensal bacteria in the gut
may be implicated in the development of IBS.
S1944
Irritable Bowel Syndrome (IBS) Patients Show Hyper-Reactive Motility
Responses to Intraluminal Distention Which Are Unrelated to Pain
Hypersensitivity
Motoyori Kanazawa, Olafur S. Palsson, Syed Im. Thiwan, Marsha J. Turner, Miranda Al.
van Tilburg, Michael D. Crowell, Shin Fukudo, Douglas A. Drossman, William E.
Whitehead
Previous studies reported that IBS patients have exaggerated colonic motility responses to
experimental stress, intraluminal distention, or eating, but reports have been inconsistent.
Aims: (1) Compare IBS patients to healthy controls with respect to colon motility during
sustained intraluminal distention and following a standard meal, (2) determine what propor-
tion of IBS patients show a motility response that is outside the normal range, and (3)
determine whether motility reactivity is correlated with increased pain sensitivity in IBS.
Methods: 89 IBS patients and 23 healthy controls were studied. A manometric catheter
containing a 10 cm latex balloon with 2 perfusion ports above and 2 below the balloon for
recording intraluminal pressure, was positioned in the descending colon. Pain threshold in
the colon was assessed using an electronic barostat by the ascending method of limit before
the motility recording. After a 10 min fasting baseline, the balloon was inflated to 20 mmHg
above intraoperating pressure (IOP) for 10 min, then deflated for a 15 min recovery period.
Next a standardized 810-cal meal was consumed and postprandial motility was recorded
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for 30 min. Motility index was manually computed as the sum of the areas of all contractions
divided by recording time. Average barostat bag volume was recorded as a measure of
smooth muscle tone. Results: Motility indices during the distension were significantly higher
in IBS patients than in controls (944+94 vs 531+98; mean+SEM, p<0.05). There were no
differences in motility indices during the baseline (290+22 vs 244+25), recovery (434+37
vs 308+36), or postprandial (459+30 vs 426+56) periods. 54% of IBS patients had pain
thresholds below the range of healthy controls (95% CI 41-49 mmHg). Barostat bag volumes
during the baseline (41.3+3.2 vs 58.9+9.9 mL), distension (191.5+7.2 vs 230.3+14.1 mL)
and recovery (38.6+3.1 vs 58.7+9.7 mL) periods was significantly lower in IBS patients
compared with controls (all p<0.05) but not during the postprandial period (19.8+1.6 vs
20.4+2.7 mL, p>0.1). IBS patients showed lower pain threshold to the colonic stimulation
(38 [10-50] vs 50 [16-50]; median with range, p<0.01), but there was no relationship
between colonic motility and visceral sensitivity. Conclusions: 45% of IBS patients showed
hypercontractivity in the colon in response to intraluminal distension. IBS patients also
showed increased smooth muscle tone. However, hypercontractility was not associated with
hypersensitivity for pain. [Supported by RO1 DK31369, R24 DK67674, and RR00046.]
S1945
Alterations in Bile Acid Metabolism in Constipation
Hasse R. Abrahamsson, Ann-Margret Lindqvist, Ralf Nilsson, Magnus Simren, Per-Goran
Gillberg
Bile acids (BA) are derived from cholesterol and are potent physiological laxatives. However,
little is known about the role of BA in patients (pts) with functional constipation (FC) and
constipation predominant IBS (IBS-C). We hypothesized that BA synthesis may be altered
in constipation. METHODS: Female pts (23 IBS-C, 4 FC, Rome II criteria) were studied
and compared with non-constipated (non-C) subjects (17 IBS-D, 20 healthy women). BMI,
blood lipids, colonic transit time by a radiological method (OATT; Reference≤4.3 days)
and stool frequency were measured. C4 reflecting bile acid synthesis was measured before
breakfast (8 a.m.) and after lunch (1 p.m.). Lanosterol and sitosterol as markers of cholesterol
synthesis and cholesterol absorption, respectively, were assessed. RESULTS: When the whole
groups of constipated and non-constipated subjects were compared only stool frequency
and OATT differed between groups (P<0.001). When constipated pts were categorized
according to OATT marked differences related to colonic transit time were observed (see
TABLE). Absence of the ordinary C4 peak at lunchtime was noted in 82% of pts with
delayed OATT compared with 17% in subjects with normal OATT (P<0.001). Symptom
severity and frequency did not differ between pt groups. CONCLUSION: Patients with IBS-
C and FC have marked changes in BA synthesis related to colonic transit. The diurnal
rhythm is altered in slow transit colon with lack of the C4 peak at lunchtime. C4 levels indicate
decreased BA synthesis in IBS-C with normal OATT. Alterations in bile acid metabolism may
be involved in the pathophysiology of constipation.
TABLE. Mean values. P-values: Difference between Constipation with slow transit vs. Con-
stipation with normal transit
S1946
Effect of Yohimbine On Gastrointestinal Transit and Symptoms in Healthy
Subjects
Christopher N. Andrews, Adil Bharucha, Michael Camilleri, Barbara M. Seide, Kari L.
Baxter, Duane D. Burton, Alan R. Zinsmeister
Background-The sympathetic nervous system tonically inhibits gastrointestinal (GI), and
particularly colonic motility under physiological circumstances predominantly via α2 adreno-
receptors (α2AR). Yohimbine (Y), a α2AR antagonist, increased colonic tone and can induce
colonic HAPCs in healthy subjects; however, the effect of Y on GI transit is unknown. Aims-
To evaluate the effects of Y on gastric emptying (GE), small bowel transit (SBT) and colonic
transit (CT) and on bowel symptoms in 30 healthy volunteers (25F; mean age 30 ± 1 yr)
randomly assigned to p.o. placebo or Y 16.2 mg p.o. tid for 7 days in double-blind fashion.
Methods-Transit was measured by scintigraphy from days 5-7 using egg labeled with 99mTc-
sulfur colloid for GE and SBT, and a delayed-release capsule containing 111In-activated
charcoal for CT. Food challenge was simulated by assessing volume of Ensure intake to
maximum satiation and postprandial symptoms 30 min later (100mmVAS). Transit data
were analyzed by ANOVA adjusted for gender (and BMI, age, and baseline values where
appropriate). Results-29 subjects completed the study. Y tended to increase maximum
tolerated volume (MTV). Y also increased stool frequency relative to placebo (p = 0.02),
and this effect was greater in males than females (p=0.05). The Y dose tested also increased
BP, heart rate, and norepinephrine (NE) levels. Conclusion-Yohimbine (16.2 mg tid)
increased stool frequency but did not significantly affect GI transit in healthy subjects.
Therefore, this dose is appropriate to assess for hypersensitivity at α2AR in disease. Supported
NIH PO1 DK-068055.
S1947
Role of Tachykinin Nk1 Receptors On Novelty Stress-Induced Defecation in
Mongolian Gerbils
Shiho Okano, Hideaki Nagaya, Nobuhiro Inatomi
Background and aim: It is known that stress affects gastrointestinal functions such as gastric
emptying, intestinal transit and colonic motility. We have previously demonstrated that
tachykinin NK1 receptor antagonists inhibit restraint stress induced colonic motility. In this
study, we established a new stress-induced defecation model involving the placement of
animals in a novel environment (novelty stress), and examined the effects of TAK-637, an
NK1 receptor antagonist, and several drugs on novelty stress-induced fecal pellet output.
Methods: The male Mongolian gerbils kept in groups (10 animals per cage) were placed
individually in small cages. The fecal pellets of each animal were collected every hour. The
animals were given drugs orally 0.5 h (alosetron, a 5-HT3 receptor antagonist) or 1 h (other
drugs) before 2-h novelty stress. The plasma concentration of adrenocorticotropic hormone
(ACTH) was measured using a radioimmunoassay. Upper intestinal transit was evaluated
using a charcoal method. Results: Animals under novelty stress, displayed active mobility
and exploratory behavior compared to the non-stressed group, and the concentration of
plasma ACTH was moderately but significantly increased by the novelty stress. The fecal
pellet output significantly increased during the first 2 h. The upper intestinal transit was
suppressed during restraint stress, but not changed during novelty stress. TAK-637, alosetron
hydrochloride, trimebutine maleate (a peripheral opioid receptor agonist) and atropine sulfate
(a muscarine receptor antagonist) exhibited dose-dependent and significant inhibitory effects
on novelty stress-induced defecation, with ID30 values of 0.03, 0.38, 12 and 0.29 mg/kg,
respectively. To clarify whether the effect of the test drugs may be ascribed to the inhibition
of normal defecation, stress-stimulated defecation or both, the effects of the drugs on the
4-h spontaneous fecal output was examined. TAK-637 did not inhibit normal defecation,
however, alosetron hydrochloride, trimebutine maleate and atropine sulfate markedly inhib-
ited normal defecation, with ID30 values of 0.96, 22 and 0.56 mg/kg, respectively. Conclu-
sions: The present study indicated that novelty stress increases fecal pellet output without
affecting the upper intestinal transit, and this model may be useful for evaluating the effects
of drugs on stress-stimulated colonic motility. The findings that NK1 receptor antagonist
inhibited stress-stimulated defecation without affecting normal defecation suggest its thera-
peutic potential for improving stress associated colonic dysfunctions, such as irritable
bowel syndrome.
S1948
Expression of 5-HT3, 5-HT4 and 5-HT7 Receptors in the Guinea Pig Distal
Colon and Their Role in Peristaltic Activity
Barbara Balestra, Elisabetta Cervio, Roberto De Giorgio, Giovanni Barbara, Fabrizio de
Ponti, Vincenzo Stanghellini, Catia Sternini, Marcello Tonini
Background: In the guinea pig colon activation of 5-HT3 and 5-HT4 receptors enhances
peristaltic activity, whereas in ileal segments 5-HT7 receptors participate in the accommoda-
tion of the circular muscle during the preparatory phase of peristalsis. Aims: To determine
the presence of 5-HT3, 5-HT4 and 5-HT7 receptor mRNAs in the guinea pig distal colon
by using reverse transcription-polymerase chain reaction (RT-PCR), to evaluate their relative
expression by quantitative real time RT-PCR and to define their role in the peristaltic activity
in isolated colonic segments. Methods: Male albino guinea-pigs (350-500 g) were used.
Total RNA was isolated from distal colon fragments with the Rneasy Protect Mini Kit (Qiagen).
First-strand cDNA was synthesized from the total RNA using the SuperScript III Reverse
Transcriptase kit (Invitrogen) for the RT-PCR, or the ThermoScript RT-PCR system (Invi-
trogen) for real time RT-PCR. PCRs were carried out using primers specific for 5-HT3, 5-
HT4 and 5-HT7 receptors. Real time RT-PCR experiments were performed using FastStart
SYBR Green Master kit (Roche Applied Science) and myosin light chain kinase (MLCK) was
the housekeeping gene used as internal standard. In functional studies, propulsion was
elicited by intraluminal distension of a thin rubber balloon (0.05-0.1 ml). The velocity of
balloon propulsion was considered as the main parameter of peristaltic activity. Selective
5-HT3 (ondansetron: 1 µM,), 5-HT4 (RS-39604: 1 µM), and 5-HT7 (SB-269970: 100 nM)
antagonists were used to determine the involvement of the three receptors in peristaltic
activity. Results: PCR products corresponding to 5-HT3, 5-HT4 and 5-HT7 mRNA were all
present in the distal colon and real time RT-PCR showed differences in the 5-HT3, 5-HT4
and 5-HT7 receptors expression. The 5-HT3 and 5-HT7 receptor mRNAs were found in
comparable amounts, but lower in density compared to the 5-HT4 mRNA. In functional
studies, peristaltic activity was reduced by approximately 65%, 85% and 40% by 5-HT3,
5-HT4 and 5-HT7 receptor blockade, respectively. Peristaltic activity was invariably blocked
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by the simultaneous administration the three antagonists. Conclusions: In the guinea pig
distal colon, 5-HT3, 5-HT4 and 5-HT7 receptors are all expressed. 5-HT plays a key role
in the modulation of peristalsis since simultaneous blockade of the three receptors suppresses
peristaltic activity. Among receptor subtypes, 5-HT4 receptors seem to be the most abundant
and functionally important for peristalsis.
S1949
Motility of the Interposed Colon for Esophageal Replacement
Susumu Ohwada, Susumu Kawate, Yoshihiro Sato, Masaru Izumi, Kunihiro Hamada,
Kentaro Hirai, Yutaka Sunose, Hiroyuki Tsutsumi, Takayuki Yamada, Yuichi Iino
Backgrounds: Besides the stomach, the colon is considered a well functioning and durable
esophageal substitute. However, long term motility of the interposed colon has not been
determined, and effects of prokinetic agents on the interposed colon have not been studied.
Aim: The aim of this study was to evaluate the motor activity of the interposed colon for
esophageal replacement following radical surgery for esophageal carcinoma, and to examine
the effects of different doses of erythromycin (EM) on the interposed colon. Methods: We
studied six patients with seven procedures, within six months (n=3, ranging 1 to 6 months)
and over one year (n=4, ranging 1.4 to 5 years) after the isoperistaltic left colon interposition
in the esophageal bed following radical esophagectomy for esophageal carcinoma. The age
of the patients ranged from 47 to 60 years (median, 54 years). Two patients had almost
whole stomach, and other four patients 30% remnant stomach. All patients had no disease
recurrence. After the patients had fasted for 16 hours, we used a catheter and three micro-
transducers with 5 cm interval connected to a Microdigitrapper portable data-logger. The
tip of the catheter was placed below the diaphragma. EM was intravenously administered
at 1 mg/kg/15 min and 5 mg/kg/60 min at least four-hour intervals. Results: All patients
exhibited the 14-16 cpm base line component. Spontaneous migrated contractions were
observed in all three patients having the colon interposition within 6 months and one patient
at 1.4 year after the colon interposition. Spontaneous segmental contractions appeared in
the patients having the colon interposition over 2 years. EM 1 mg/kg/15 min induced
migratory contractions in all patients having the colon interposition within 6 months, and
two of four patients having the colon interposition over one year. EM 5 mg/kg/60 min also
induced migratory contractions in all patients. The induced migrating contractions were
similar amplitude, duration, frequency, and motor index to spontaneous. Conclusions: The
interposed colon may become quiescent time long after surgery. Erythromycin may have
therapeutic potential for the treatment of interposed colonic motility.
S1950
Intestinal Gas Retention in Patients with Slow-Transit Idiopathic Constipation
(STC)
Ana C. Hernando-Harder, Hermann Harder, Heinz-Juergen Krammer, Manfred V. Singer
BACKGROUND: The healthy gut avoids symptomatic gas retention during a jejunal gas
challenge; duodenal lipids inhibit whereas acute fasting hyperglycemia accelerates gas propul-
sion and evacuation. Whether dysfunction of intestinal motor activity and sensory function
in patients with STC affect intestinal gas dynamics and tolerance was evaluated. METHODS:
On 3 separate days, jejunal gas infusion (12 ml/min) was performed in 10 healthy volunteers
and 10 patients with STC in randomized order for 120 min during duodenal lipids (1 Kcal),
intravenous glucose (hyperglycaemic clamp; ~12 mmol/l) or saline infusion. Rectal gas
evacuation was continuously measured; perception and abdominal girth changes were separ-
ately evaluated. RESULTS: In contrast to healthy controls, patients with STC exhibited
significant final intestinal gas retention during saline perfusion which was similar during
duodenal lipids and fasting hyperglycemia without significant differences between the groups.
The increase in abdominal perimeter correlated with volumes of trapped intestinal gas (r=
0,82 p<0.001; pooled data for all patients) but without significant abdominal symptoms
(Table 1). CONCLUSIONS: Dysfunction of intestinal motor activity in patients with STC
includes neurohormonal mechanisms for clearance of gaseous intestinal contents, but without
hypersensitivity for the gaseous intestinal stimulus.
Table 1: Final gas retention, abdominal sensation and perimeter changes after 2-hour jejunal
gas challenge in 10 healthy volunteers and 10 patients with STC during the studies with
duodenal saline (A), duodenal lipids (B) and intravenous glucose (C) (* p<0.01 vs. healthy).
S1951
The Effect of Naloxone-3-Glucuronide (NX3G) On Gastro-Coecal Transit Time
in Healthy Volunteers Under Morphine Medication
Peter Netzer, Michael P. Wissmeyer, Alexander Sendensky, Catarina Batista, Stefan
Baumeler, Rudolf Brenneisen, Thomas Krause, Peter Reber, Juergen M. Gschossmann,
Ulrich Scheurer
Background: Constipation is one of the most troublesome side effects of opioid therapy.
While naloxone counteracts this unwanted side effect, it also reduces the analgesic potential
of opioids. Recently, we could demonstrate in an animal model that naloxone-3-glucuronide
(NX3G) antagonizes the motility lowering effect of morphine in the rat colon but without
absorption by the colonic wall (1). In healthy volunteers, we showed a partial inhibition of
the morphine-induced delay of colonic transit time by NX3G without absorption into the

















also delays the gastro-coecal transit time and b) orally administered NX3G reduces this
morphine-induced delay in healthy volunteers. Methods: Fourteen male volunteers were
included into this double-blind, randomized 3-times crossover study. Gastro-coecal transit
time was measured by scintigraphy. At the start of the experiment, NX3G (0.16mg/kg b.wt.)
or placebo (crossover) was given orally together with the radio-nucleotide capsule. Thereafter,
NX3G or placebo was administered 5 times every 4 hours. Morphine (0.05 mg/kg b.wt.)
or placebo (crossover) was injected subcutaneously 2 hours after start and thereafter 3 times
every 6 hours. Finger pain tests were performed at start and 1 hour after morphine injection.
Standardized meals were given during the day after the first medication. Results: In these
14 volunteers the slowest transit time was measured during the morphine phase (6.21hrs),
which was significantly (p <0.05) longer than in the morphine/NX3G phase (4.57hrs) and
the placebo phase (3.32hrs). However, there was no statistically significant difference between
the morphine/NX3G phase and the placebo phase (p>0.1). Pain perception was not signific-
antly influenced by NX3G. Conclusion: In healthy volunteers, morphine significantly reduces
the gastro-coecal transit time. This effect could be reversed by NX3G. Thus, our data suggest
that NX3G may be a helpful therapeutic tool for prevention and therapy of constipation in
patients under morphine medication. References: 1)Reber P et al. The effect of naloxone-
3-glucuronide (NXG) and N-methylnaloxone (MNX) on the motility of the isolated, perfused
rat colon after morphine stimulation. Gastroenterology 2004;126:A219. 2)Netzer P et al.
The effect of naloxone-3-glucuronide on colon transit time in healthy volunteers under
morphine medication. Gastroenterology 2005;128:A275.
S1952
Evidence for Alterations in Central Autonomic Activity During Sleep in
Women with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
Heng Y. Wong, Emeran A. Mayer, Bruce D. Naliboff, Britta Dickhaus, Teresa I. Olivas,
Vanessa Z. Ameen, Joyce Reinholdt, Lin Chang
Background: Patients with irritable bowel syndrome (IBS) show evidence for alterations in
waking autonomic nervous system (ANS) activity, which may contribute to IBS symptoms
such as alterations in bowel habits. It is not known if these ANS alterations are due to
enhanced ANS responsiveness to environmental stimuli, or to a tonically increased ANS
activity. Aims: 1) To quantify nocturnal ANS activity (colonic motility, cardioautonomic
tone, plasma norepinephrine (NE) levels) during sleep; and 2) To determine the relationships
between this tonic ANS activity and subjective GI symptom ratings in female patients with
IBS-D. Methods: 11 female Rome II positive IBS-D patients (mean age 38±2.5 yrs) and 13
female age-matched healthy controls (Ctrls, mean age 33.8±2.7 yrs) were admitted for a 2-
night sleep study to the General Clinical Research Center (GCRC). Patients with psychiatric,
sleep, other chronic pain, or cardiovascular disorders, or who were on drugs that interfered
with the ANS or sleep were excluded. Current gastrointestinal (GI) symptoms were self-
assessed from none to very severe. Left colonic motility (motility index, MI), heart rate
variability (HRV) and plasma NE were measured simultaneously at 90 min intervals during
the second night of sleep after 1 night of acclimatization. HRV measures included power
of the high frequency band (HF) to assess vagal tone and ratio of low frequency (LF)/HF
to assess sympathetic/parasympathetic balance. Results: Compared to Ctrls, IBS-D patients
had higher plasma NE levels (P<0.05) and lower cardiovagal tone (HF; P=0.08) throughout
the sleep period. In contrast, colonic MI only showed a significant difference during the
initial sleep period. Nocturnal NE levels correlated positively with overall GI symptom
severity (r=0.55 to 0.76, P<0.05). Overall, cardiovagal tone correlated negatively with colonic
MI (β=-9.7; P=0.006). However, there was a significant interaction between groups, i.e., the
slope was steeper in Ctrls than IBS-D (P<0.01). Conclusions: Female IBS-D patients show
evidence for altered central ANS activity during sleep. While colonic motor activity is only
altered during early sleep, patients show enhanced sympathetic/vagal balance throughout
the night, and this alteration correlates with the severity of GI symptoms in IBS-D. These
findings implicate alterations in nocturnal ANS tone in the pathophysiology of IBS symptoms.
The IBS-related differences in the relationship between cardiac and colonic autonomic activity
suggests alterations in central autonomic pathways. Supported by NIH grants GCRC #M01-
RR00865, P50 DK64539, DK 48351 and GlaxoSmithKline.
S1953
Mechanisms Underlying the Neurokinin A - Induced Contraction of Guinea-
Pig Taenia Coli
Takanori Nakatsuji, Satoshi Ieiri, Junko Akiyoshi, Tomoaki Taguchi, Sachiyo Suita
Background and Aims:Neurokinin A (NKA) belongs to tachykinins which are a family of
neuropeptides that also includes substance P (SP) and neurokinin B (NKB). Tachykinins have
a wide range of physiological functions including smooth muscle contraction, particularly in
the gastrointestinal tract. However, no detailed analysis in the effects of NKA on digestive
smooth muscle using a direct measurement of the intracellular Ca2+ concentration
([Ca2+]i),has yet been reported before. The mechanisms for the contraction induced by
neurokinin A (NKA) in the smooth muscle of guinea-pig taenia coli were investigated by
means of simultaneous measurements of the [Ca2+]i and tension. Methods:Hartley guinea-
pigs (male, 6 week, body weight 350-400 g) were used throughout the experiments. The
guinea-pig taenia coli strips were loaded with Ca2+ indicator dye, fura-2 in the form of
acetoxymethyl ester (Fura-2/AM). The peak level of both the force development and the
fluorescence ratio in response to agonists was expressed as a percentage, assigning the values
of 5.9 mM K+ PSS and the steady state contraction induced by 60 mM K+ PSS depolarization
to be 0 % and 100 %, respectively. Results: NKA (100 pM-10 μM) caused a concentration-
dependent contraction. A maximum response was obtained at 1 μM and the EC50 value
was 84.1±12.9 nM. The peak levels of the [Ca2+]i elevations induced by 1 μM NKA was
104±3.80%, whereas those of force development induced by 1 μM NKA was 153±22.8%.
The rise in [Ca2+]i induced 1 μM NKA was similar to the increase in [Ca2+]i induced by
60 mM K+ PSS depolarization, but the developed force during the contraction induced by
1 μM NKA was significantly larger than that of 60 mM K+ PSS depolarization. Both the L-
type Ca2+ channel blocker, diltiazem and the NK2 receptor selective antagonist, NK2-ra
significantly inhibited the NKA induced [Ca2+]i elevation and contraction. The NK1 receptor
selective antagonist, TAK637 had no effect on the NKA induced contraction.NKA induced
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only transient increases in [Ca2+]i and the force in a Ca2+ - free solution in smooth muscle
of guinea-pig taenia coli.Rho kinase inhibitor, Y-27632, significantly inhibited the NKA
induced force development, while it had no influence on the [Ca2+]i elevation. Conclu-
sion:NKA was found to induce the contraction of the guinea-pig taenia coli by elevating
[Ca2+]i , as well as increasing, the Ca2+ sensitivity of the contractile apparatus. NKA induced
elevation of [Ca2+]i is caused by not only the Ca2+ influx but also by the Ca2+ release from
the sarcoplasmic reticulum. The contraction induced by NKA based on [Ca2+]i elevation
was enhanced through the rho kinase pathway.
S1954
Purinergic P2X Neuro-Neuronal Transmission Underlies the 5HT3 Receptor
Mediated Inhibition of Rabbit Distal Colon Propulsion
Luciano Onori, Annalisa Aggio, Giovanni Latella, Giuseppe Frieri, Gennaro Taddei, Dina
Melideo, Marcello Tonini
BACKGROUND:Purine P2X receptors(P2X r) and serotonin 5HT3 receptors(5HT3 r) may
contribute to cholinergic nicotinic receptors in the generation of fast-excitatory transmission
in the enteric nervous system. We reported that neurally located P2X r and 5HT3 r may
mediate either enhancement or inhibition of rabbit distal colon velocity propulsion. The
inhibitory role of P2X and 5HT3 r was inferred by the prokinetic effect induced by lower
concentrations of their receptor antagonists, pyridoxal phosphate-6-azophenyl-2’,4’-disul-
phonic acid (PPADS)(from 1X10-8M to 1X10-7M) and Ondansetron (OND)( from 1X10-
9M to 1X10-8M),respectively. These enhancing effects on propulsion where reverted in an
inhibitory effect in the presence of Ng-nitro-L-arginine(L-NNA), a NO-synthase inhibitor.The
latter finding indicated that the inhibitory role of P2X r and 5HT3 r was mediated by a
common mechanism represented by the final activation of a nitrergic pathway. AIM:To
assess whether P2X r and 5HT3 r activate the nitrergic inhibitory mechanism independently
of each other (receptors located in parallel neural circuitries) or by interacting along a sole
circuitry (receptors located in series). METHOD:The propulsion was studied in vitro and
elicited by distending an intraluminal balloon with 0.3 and 1 mL of water. The corresponding
velocity of oro-aboral balloon displacement was 2.3 and 2.7 mm/sec,respectively. The role
of P2X receptors was investigated by PPADS, a compound that at relatively low concentration
(less than 1x10-5M) has been used as antagonist for neural P2X receptors in the guinea pig
ileum (Bian, J Physiol. 2000, Monro; Neurogastr. 2002). The drugs were applied to the
bathing bulk solution and the effect was expressed as % of the basal value or of the velocity
induced by the former compound in the sequential administration. RESULTS: In the presence
of OND, which (at 1x10-8M) induced the enhancing effect on propulsion by 38.7% and
25.3% at 0.3 and 1mL of distention, PPADS (1x10-7M), further induced a pro-propulsive
effect by 26.3% and 23.2%, respectively. Conversely, in the presence of PPADS (1x10-7M),
which induced an enhancing effect by 58.8% and 27.3%,at 0,3 and 1 ml of distention,
OND (1x10-8M), induced an inhibitory effect by 40.1% and 44.3%, respectively. CONCLU-
SIONS: Our results indicate that a neuro-neuronal purine P2X r transmission mediates the
serotonin-5HT3 r inhibition of the rabbit distal colon propulsion, suggesting that P2X r and
5HT3 r are located in series. Furthemore, the blockade of P2X r unveils the 5HT3 r-mediated
enhancement of propulsion which, therefore, appears to be independent of purinergic P2X
receptor transmission.
S1955
CB1 and TRPV1 Receptors Mediate Protective Effects On Colonic
Electrophysiological Properties in Mice
A. Sibaev, F Massa, B Yuece, G Marsicano, H A. Lehr, B Lutz, B Goeke, H D. Allescher,
Martin Storr
Background: CB1 and TRPV1 receptors modulate enteric neurotransmission and colonic
inflammation. AIM: The aim of this study was to investigate early electrophysiological changes
in distal colon of wild-type and receptor deficient mice following an inflammatory insult
set by dinitrobenzene sulfonic acid (DNBS). Methods: Colitis was induced by DNBS in
CB1-/- mice, TRPV1-/- mice and their respective wild-type littermates. Electrophysiological
properties consisting of membrane potentials (MP) and electrically induced inhibitory junc-
tion potentials (IJP) were evaluated at different time points. Additionally a histological colitis
severity score was evaluated. Results: Inflammation caused spontaneous atropine insensitive
rhythmic action potentials in CB1-/- and TRPV1-/- mice but not in wild-type animals
indicating that membrane stability is disturbed, indicating a lack of protective mechanisms.
Focal electrical neuronal stimulation of the myenteric plexus induced IJP in the smooth
muscle cells. 24 hours after initiation of inflammation the duration of the IJP is prolonged
in all animals, indicating disturbances within neuromuscular interaction. Interestingly in
CB1-/- mice duration of IJP was significantly extended as compared to CB1+/+ mice pointing
towards missing protective mechanisms in the CB1-/- mice. Conclusion: Inflammatory insults
in the mouse colon induces reproducible changes in the electrophysiological properties and
such changes correlate with duration of colitis. In mutants, these electrophysiological changes
display different patterns suggesting the lack of protective properties for neuromuscular
interactions and membrane stability.
S1956
Platelet Activating Factor (PAF) Affects Sigmoid Smooth Muscle Contraction
in Ulcerative Colitis (UC)
Sharad Kunnath, Victor E. Pricolo, Karen M. Harnett, Neal S. Leleiko, Weibiao Cao
We have previously shown that sigmoid circular muscle cells from UC patients exhibit
reduced contraction and Ca2+ signaling in response to the endogenous neurotransmitter
neurokinin A (NKA) and that hydrogen peroxide (H2O2) is elevated in the UC circular
muscle layer. The H2O2 scavenger catalase restored the decreased Ca2+ signal and cell
shortening to normal levels, suggesting that H2O2 contributes to the motor dysfunction of
UC. It is known that PAF levels are elevated in colonic mucosa from patients with ulcerative
colitis. In the present study we examined the role of PAF in motor dysfunction and H2O2
production in UC. PAF levels were significantly elevated in sigmoid circular muscle from
patients with ulcerative colitis, when compared to normal controls. Treatment of normal
sigmoid circular smooth muscle cells with PAF (10-6M, 2 hours) significantly decreased
NKA-induced contraction. Treatment of UC sigmoid muscle strips with the PAF antagonist
CV3988 (10-6M) for 2 hours, however, did not improve the motor dysfunction, suggesting
that other inflammatory mediators e.g. H2O2 and IL-1β may be present and affect muscle
contraction, even after blockade of PAF. PAF 10-8M significantly increased H2O2 production
in sigmoid smooth muscle cells in primary culture, and H2O2 production was abolished by
the NADPH oxidase inhibitor apocynin, suggesting that NADPH oxidases mediate PAF-
induced production of H2O2. PAF-induced H2O2 was significantly reduced by the MEK1
inhibitor PD98059, the P38 MAP kinase inhibitor SB203580 and the cytosolic phopholipase
A2 inhibitor AACOCF3, suggesting that PAF-induced H2O2 production depends on activation
of MAP kinases (ERK1/2, p38) and cytosolic phospholipase A2. We conclude that PAF may
contribute to motor dysfunction of sigmoid colon in UC and that PAF-induced H2O2
production depends on activation of MAP kinases (ERK1/2, p38), cytosolic phospholipase
A2 and NADPH oxidases. Supported by NIDDK R21 DK62775-01.
S1957
Power Dynamics of Colonic Electrical Activity in Patients with Constipation
and Irritable Bowel Syndrome Assessed By Transcutaneous Electrodes
Manuel A. Amaris, Melchor V. Demetria, Bashar M. Attar, Daniel C. Sadowski, Martin P.
Mintchev
BACKGROUND: The cause of chronic constipation is poorly understood. Recent data suggest
impaired colonic myoelectrical function that manifests itself in some patients as weak or
near absent electrical control activity (ECA). AIM: To determine if any abnormality in the
colonic ECA can be found in patients with constipation using transcutaneous electrodes.
MATERIALS AND METHODS: Ten patients with chronic constipation (age 49±13, male/
female=2/8, intestinal habit 1.7±0.4/week), 11 patients with constipation predominant irrit-
able bowel syndrome (CPIBS) (age 40±10, male/female=2/9, intestinal habit 1.3±0.6/week),
and 20 normal volunteers (age 40±16, male/female=10/10, Intestinal habit 7.3±3.2/week)
underwent 8-channel bipolar fasting recording of colonic ECA via transcutaneous electrodes.
Both groups of patients were defined by the Rome II criteria. Eight active electrodes were
attached to the skin along the abdominal projections of the longitudinal axes of the right,
transverse and left colon. Bipolar electrode combinations of these electrodes formed 8 ECA-
recording channels. Colonic electrical activity was recorded and digitally analyzed using
custom-designed software in a frequency band of 0.02 to 0.2 Hz. RESULTS. Spectral analysis
showed no significant differences in the mean frequencies of patients and normals. Periods
of unstable and/or weak power of ECA were recorded in 15/21 of the patients and only in
6/20 of the normal volunteers. There was a consistent pattern of unstable power dynamics
in patients with CPIBS. Analysis of the power stability in isolated colonic channels showed
statistically significant differences (p < 0.025)(Table 1). CONCLUSION: Weak or unstable
colonic ECA may be the cause of constipation in selected patients. This may represent an
increased level of physiological fluctuations in the power of ECA in some patients with
irritable bowel syndrome and constipation. Further studies with a larger number of patients
are needed to confirm these findings.
Table 1. Power dynamics.
Unstable: Power change of more than 80 % for more than 2 consecutive minutes. Statistically
significant differences are denoted with an asterisk*.
S1958
Serine 16 Phosphorylation-Dependent Translocation of HSP20 in Colonic
Smooth Muscle Cells May Modulate HSP27 Dependent Contraction
Robert R. Gilmont, Khalil N. Bitar
Background: Hsp20, a member of the stress response family of proteins is able to protect
cardiac muscle cells against oxidant insult and ischemia/reperfusion injury. Hsp20 is known
to bind to hsp27, and may form mixed oligomers. The PKG and PKA phosphorylation of
hsp20 on serine 16 (p-ser16), is associated with relaxation, while hsp27 phosphorylation
is associated with contraction in smooth muscle. Hsp27 phosphorylation leads to a transloca-
tion from the cytosolic fraction to the particulate. Objective: To characterize the role of
hsp20 in colonic smooth muscle cells. To determine the presence of hsp20 in colonic smooth
muscle, its phosphorylation status and if phosphorylation determines its cellular localization.
Methods: 1. Cultured rabbit colonic smooth muscle cell lysates were analyzed by SDS-PAGE
and Western blotting, using a commercially available antibody directed against hsp20. 2.
For indirect determination of hsp20 phosphorylation, whole cell lysates from cultured cells
treated with either sodium nitroprusside (SNP), 8-bromo cAMP or acetylcholine (Ach) were
separated by isoelectric focusing and analyzed by Western blotting. 3. Hsp20 was cloned
by PCR using specific primers and cDNA from rat heart, and then ligated into pcDNA3.1/
myc-His. The 16 S/D and 16 S/A conversions were produced by site-directed mutagenesis.
4. These constructs were transfected into rabbit colon smooth muscle cells and maintained
in culture under G418 selection for greater than two weeks. Particulate and cytosolic fractions
were separated by high speed centrifugation. Results: 1. The presence of hsp20 in rabbit
colonic smooth muscle cells was demonstrated. 2. Changes in phosphorylation status follow-
ing treatment with SNP or 8-bromo cAMP occurred slowly with maximum phosphorylation
at 30 minutes post-treatment in each case, while Ach treatment induced a rapid (30 sec- 4
min) phosphorylation. 3. Phospho-hsp20 was preferentially localized in the pellet in normal
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smooth muscle cells. 4. In cells transfected with the 16 S/D form, the recombinant protein
is preferentially compartmentalized in the particulate fraction. 5. In cells transfected with
the 16 S/A mutant there was more protein associated in the cytosolic fraction. Summary:
Phospho-hsp20 and the mimic of ser-16 phospho-hsp20 partition preferentially to the
particulate fraction of colonic smooth muscle. Conclusion: Hsp20 translocates to the partic-
ulate fraction of colonic smooth muscle upon phosphorylation of serine residue 16. Here
it may interact with hsp27 to inhibit hsp27 action and induce relaxation.
S1959
Effects of Sibutramine On Gastric Emptying, Intestinal Motility and Rectal
Tone in Conscious Dogs
Junying Xu, Jiande Chen
Background & Aims: Sibutramine is a serotonin- norepinephrine uptake inhibitor, used in
the treatment of obesity. Serotonin is a major neurotransmitter in Gastrointestinal (GI) tract.
It appears to be very important in the control of GI function. It has never been reported
whether sibutramine affects gastrointestinal motility and myoelectrical activity. The aim of
this study was to evaluate the effects of sibutramine on gastric emptying, small bowel
contractions, rectal tone and compliance and GI myoelectrical activity. Methods: The study
was performed in 14 healthy female dogs (18-27 Kg); seven of the dogs were surgically
prepared for a duodenal cannula and placement of serosal recording electrodes. The study
was composed of 3 separate experiments: gastric emptying of liquids and gastric and intestinal
slow waves; small bowel contractions; and rectal tone and compliance. Each experiment
included two sessions: a control session and a treatment session with sibutramine (5mg/Kg
p.o, Generic Meridia, United Pharmacies) administrated 2 hours before the recording. Seven
dogs with the cannula underwent a gastric emptying study of liquids and a small bowel
contraction study in the fed state. Seven dogs without cannula underwent a rectal barostat
study. Results: (1). Sibutramine significantly accelerated liquid gastric emptying at 75min
and 90 min after the meal but did not alter gastric or intestinal slow waves. Gastric emptying
was 61.42 ± 19.34% at 75 min and 66.32 ± 19.38% at 90 min in the control session, and
increased to 71.27 ± 13.5% at 75min (p =0.046, vs. control) and 75.93 ± 15.05% at 90min
(p = 0.036, vs. control) in the session with sibutramine. (2). Sibutramine significantly
inhibited postprandial small bowel contractions. The area under the curve (AUC) was 14.57±
4.11 in the control session and decreased to 10.64 ± 4.18 (p = 0.014, vs. control) in the
session with sibutramine. The contractile frequency was 12.49 ± 0.88 cycles/min in the control
session and reduced to 8.8 ± 1.08 cycles/min (p = 0.0004, vs. control) with sibutramine. (3).
Sibutramine did not alter the rectal tone (P>0.05), but significantly increased rectal compli-
ance .The rectal compliance expressed as the slope of the pressure-volume curve was
significantly increased from 7.59±2.05 ml/mmHg at baseline to 9.97 ± 3.25 ml/mmHg
after sibutramine administration (p = 0.003). Conclusions: Sibutramine accelerates gastric
emptying of liquids but inhibits small bowel contractions. These findings suggest the peri-
pheral mechanisms of sibutramine in reducing food intake and causing weight loss in
obesity patients.
S1960
Partial Replacement of Dietary Long-Chain Triglycerides (LCT) By Medium-
Chain Triglycerides (MCT) Fed Ad Libitum Is Hepatotoxic Whereas Total
Replacement Or Dietary Restriction Is Beneficial
Charles S. Lieber, Qi Cao, Leonore M. Decarli, Maria A. Leo, Ki M. Mak, Anatoly
Ponomarenko, Chaoling Ren, Xiaolei Wang
We have previously shown that rats develop hepatotoxicity when given for 3 weeks our
high fat NASH diet (Lieber et al. Amer J Clin Nutr 2004;79:502-509). When supplemented
with MCT (replacing 35% of the dietary LCT calories) this resulted in a significant increase
in hepatic inflammation associated with a rise in the inflammatory cytokine TNF-α
(131.5±15.4 vs. 220.3±13.1 pg/mg protein; p=0.0002). There was also an increase in collagen
type 1 (1017±201 vs. 1947±151 pg/mg protein; p<0.001) as well as collagen type 1 mRNA
(3.1±0.2 vs. 3.93±0.3 units; p<0.01). Since a comparable amount of MCT is being given
for the treatment of obesity, we wondered how one could continue the therapeutic use of
MCT while minimizing its toxicity. We now found that in rats given the same MCT diet
but restricted to 2/3 of the amount they were consuming when fed ad libitum, there was a
striking reduction of the adverse effects, including less liver steatosis with lower hepatic
triglycerides (36.3±10.1 vs. 81.1±10.9 mg/gm liver; p<0.01) and a decrease in the hepatic
levels of TNF-α (from 220.3±13.1 to 113.1±21.4 pg/mg protein; p<0.001). There was also
a reduction of collagen type I (from 1947±151 to 1207±84 pg/mg protein; p<0.01) and
collagen type I mRNA (from 3.93±0.3 to 1.97±0.3 units; p<0.001). Furthermore, the plasma
triglycerides decreased (from 288.1±22.4 to 59.8±17.2 mg/dl; p<0.001). When MCT (35%
of calories) was given together with carbohydrates (instead of LCT) there was also a reduction
in hepatic TNF-α (from 131.5±15.4 to 25.2±4.2 pg/mg protein; p<0.001). Moreover, when
71% of the fat calories were replaced by MCT with no LCT remaining in the diet, except
for 3% of calories as safflower oil, no steatosis developed and hepatic TNF-α was low
(23.5±4.0 pg/mg protein). Thus, even in large amounts (such as 71% of dietary calories),
MCT is not hepatotoxic provided the diet contains no significant amount of LCT. According
to these rat studies, 35-40% of calories as MCT (commonly given to obese patients) should
not be detrimental if no substantial LCT are simultaneously consumed. The mechanism
whereby the combination of LCT with MCT acquires hepatotoxicity is now being investigated.
CONCLUSION: Total replacement of dietary LCT with MCT fed ad libitum is beneficial
whereas partial replacement becomes hepatotoxic, unless the dietary intake is restricted.
Thus, if the adverse interaction between MCT and LCT shown in rats is verified in patients,
especially obese subjects, the clinical implication is that diets containing some LCT with


















Effects of Optifast Very Low Calorie Diet On Liver Size and Regional
Adiposity
James Toouli, Mark Lewis, Madeleine Phillips, Sara Wahlroos, John Slavotinek, Robin
Valentine, Lilian Kow, Campbell Thompson
Background: Obesity leads to liver steatosis and large volume livers. We determined the
effect of a very low calorie diet (Optifast VLCD) on liver volume and regional lipid deposition
in obese, non-diabetic females awaiting laparoscopic gastric banding surgery (LAGB).
Methods: 14 obese subjects (mean BMI 45±7kg/m2) were provided with a 6-week supply
of the Optifast meal replacement and were seen two weekly in order to monitor adherence
to the diet plan. Anthropometry (weight, waist circumference) and fasting blood; free fatty
acids (FFA), liver enzymes, insulin and glucose were performed at baseline and following
6 weeks of the diet. Insulin sensitivity was estimated using the homeostasis model assessment
(HOMA). Abdominal lipid deposition subcutaneously (SAT), viscerally (VAT) and in the
liver were determined before and after 6 weeks on the VLCD using previously validated
magnetic resonance spectroscopy and imaging techniques. Results: Presented as mean +/-
SD. All subjects adhered to the 6 weeks VLCD intervention. Mean body weight reduced by
8.5 ± 3.0kg (pre VLCD 119.2±16.0 vs 110.6±16.9kg post VLCD; p<0.001). Mean liver
volume and lipid content at baseline were 2.2 +/- 0.4L and 0.13 +/- 0.12 AU (range 0.01
to 0.34). Liver fat content in 64% of subjects (n=9) was >0.05 AU, indicative of steatosis.
Baseline VAT and SAT were 0.22 +/- 0.11L and 0.68 +/- 0.2L, respectively. Significant
reductions occurred in liver volume (0.35 +/- 0.35L; 15 ± 12%), VAT (0.04 +/- 0.05L; 15
± 14.8%) and SAT (0.05 +/- 0.06L; 8 ± 8.6%) but not in insulin sensitivity. Liver fat content
reduced significantly by 63 ± 25% in those subjects with liver steatosis. The reduction in
liver fat was significantly associated with the reduction in liver size (r=0.758, p=0.003).
Conclusion: Adherence to a 6-week VLCD produces significant reductions in liver size and
lipid content as well as VAT and SAT depots. Weight loss and VAT reduction following 6
weeks of VLCD (7.4% and 15% respectively) was similar to that occurring 3 months following
LAGB at our centre (9% and 18%). In contrast to 3 months following LAGB however, 6
weeks of Optifast VLCD produces half the reduction in SAT and almost twice the reduction
in liver fat. The perceived perioperative reduction in liver size seen in patients who have
undergone pre-LAGB treatment with Optifast VLCD, is likely due to the preferential reduction
in liver fat.
S1962
Laparoscopic Roux-en-Y Gastric Bypass Is a Viable Option in the Treatment of
Mega Obesity (BMI >70kg/M2)
William Watson, Bradley Needleman, Vimal Narula, S. Scott Davis, Matthew Goldblatt,
W. Scott Melvin, Dean Mikami
Purpose: Super-obese patients (body mass index (BMI) > 50 kg/m2), were previously not
considered candidates for laparoscopic Roux-en-y gastric bypass (LRYGB) surgery. As surgical
experience and technology improves, LRYGB in the super obese has become more widely
accepted. The aim of this study is to define a new classification of obesity (megaobesity,
BMI > 70 kg/m2), as well as to evaluate the outcome of LRYGB in this patient population.
Methods: We conducted a retrospective review of patients with BMI > 70 kg/m2 undergoing
LRYGB at a single university-based comprehensive weight loss program from January 2003 -
November 2005. We reviewed preoperative demographics, operative techniques and postop-
erative course. Results: Nineteen patients were eligible for the study (13 female, 6 male),
with an average age of 42.1 ± 8.3 years of age. Preoperative mean weight was 217 kg (range:
180 - 297 kg). Preoperative mean BMI was 76.8 kg/m2 (70.1 - 119.0 kg/m2). Patients were
261 ± 56% above their ideal bodyweight. Patients had on average 5.0 ± 2.5 co-morbidities
attributed to obesity, and averaged 6.5 ± 3.6 medications for those co-morbidities. Eighteen
of 19 cases were completed laparoscopically. One surgery was converted to open secondary
to adhesions from previous surgeries. No patients required re-operation. There were no
mortalities or anastamotic leaks. Operating times were 121.1 ± 43.4 minutes. Peri-anastamotic
drains were placed in 9 of 19 patients (47%) and all were removed prior to discharge. There
were 4 minor postoperative complications in 4 patients: ileus, hypoglycemia, asymptomatic
elevated WBC without source and myoglobinuria treated with hydration and alkylinization
of urine. Hospital stays was 3.3 ± 1.7 days. Percent excess weight loss (%EWL) was 14.3
± 2.9% at 2 months (m) postoperative (n=14), 24.8 ± 4.3% at 6 m postoperative (n=8) and
42 ± 6.6% at 12 m (n=-6). Five of 19 patients (26%) developed superficial wound infections.
Two patients (11%) developed anastamotic strictures. Four of 9 patients (44%) reported
decreased insulin requirements, 4 of 9 patients (44%) discontinued as least 1 oral hypergly-
cemic agent and 3 of 12 patients (25%) stopped at least one antihypertensive drug by 2
months postoperatively. Summary: LRYGB is a technically feasible surgery in the megaobese.
Operative times are similar to LRYGB patients with a BMI of < 70 kg/m2. Superficial wound
infections appear to be more prevalent in the megaobese. Percent EWL at 6 months are
similar to those with a BMI of < 70 kg/m2. Long term follow-up will provide more information
on resolution of comorbidities. LRYGB is a viable treatment option in the treatment of megaob-
esity.
S1963
Sibutramine Significantly Delays Gastric Emptying Without Altering Volume
Or Postprandial Symptoms in Obesity
Maria I. Vazquez-Roque, Debra Stephens, Duane Burton, Kari Baxter, Michael Ryks,
Matthew Clark, Michael D. Jensen, Sarah Kalsy, Karen Graszer, Alan R. Zinsmeister,
Michael Camilleri
Background: Sibutramine is associated with weight loss and acts as a noradrenergic (NE)
and serotonergic (5-HT) reuptake inhibitor. NE and 5-HT alter gastric functions. It is unclear
whether weight loss with sibutramine is associated with altered motor and sensory functions
of the human stomach. Aim: To compare in a randomized, double-blinded, controlled study
with concealed allocation the effects of placebo and sibutramine, 15 mg daily for 12 weeks,
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on gastric volumes, emptying, maximum tolerated volumes (MTV) and post-challenge symp-
toms in obese volunteers who were otherwise healthy. Methods: We planned a study of 24
obese [body mass index (BMI) >30kg/m2] participants and documented lean mass and %
fat by body composition (DEXA). All subjects underwent at baseline and post-treatment the
following measurements using validated tests: gastric emptying for solids and liquids by
scintigraphy (GE t1/2); gastric volumes by SPECT; maximum tolerated volume and 30 minute
post-challenge symptoms by satiation test. All participants received the same behavioral
modification classes using the LEARN manual. Statistical analysis used ANCOVA with
baseline observations, gender, and BMI as covariates. Results: To date, 20 people have
completed all studies. One subject was withdrawn due to hypertension. The table summarizes
the data baseline and post-treatment, mean±SEM. Changes in weight were -0.9±1.2kg for
placebo and -4.4±0.9kg for sibutramine (p=0.034). Changes in BMI were -0.1±0.4 kg/m2
for placebo and 1.6±0.3 kg/m2 for sibutramine (p=0.011); changes were somewhat more
pronounced in females. No significant differences in lean mass or % fat were noted in the
two treatment groups. There was significantly delayed gastric emptying of solids and liquids
with sibutramine, but no treatment differences in gastric volumes or satiation. Conclusion:
Delayed gastric emptying may contribute to the weight reduction in response to sibutramine
in obese people.
* p≤0.05; # p≤0.01
S1964
Pre-PYLORIC Neural Electrical Stimulation Produces Cholinergically-Mediated
Retrograde Peristalsis in Acute Canine Model of Microprocessor-Invoked
Gastric Motility for the Treatment of Obesity
Emil Neshev, Denis Onen, Ehsan Jalilian, Martin P. Mintchev
BACKGROUND. Gastric electrical stimulation (GES) has been suggested as an alternative
minimally-invasive surgical procedure for the treatment of obesity. Among the three known
GES methods, neurostimulation (NGES) provides direct control of contractility without
utilizing the spontaneous gastric electrical activity as an intermediary. AIM. We explored
the possibility of producing NGES-controlled retrograde peristalsis in acute canine models,
utilizing single and dual electrode sets implanted in the pre-pyloric area. METHODS. Eight
healthy mongrel dogs underwent laparotomy and subserosal implantation of one distal and
one proximal set of 10-mm temporary cardiac pacing electrode pairs located at the opposite
sides of the imaginary circumference perpendicular to the gastric axis in the distal antrum.
The distal set was placed 2-3 cm proximally from the pylorus, and the second set was
implanted 3.5-4 cm proximally to the first. In four of the dogs the electrodes were implanted
parallel to the gastric axis. In the remaining four dogs the electrode implantations were
perpendicular to the gastric axis. In both groups gastric motility patterns were captured
using three force transducers implanted 3.5-4 cm apart along the projection of the gastric
axis on the anterior wall. Custom-designed implantable neurostimulator was utilized for
delivering controlled, charge-balanced, bipolar, 50-Hz 16-V (peak-to-peak) 8-second rectan-
gular voltage waveforms to the distal electrode set only, and subsequently to both electrode
sets in a sequential and overlapping fashion, starting with the distal electrode set. Normalized
motility indices were utilized to quantify the produced contractions, and their propagation
velocities were assessed. At the end of each test 0.05 mg/kg atropine sulfate i.v. was adminis-
tered and NGES was re-applied. RESULTS. Both single and dual electrode set NGES produced
circumferential lumen-occluding contractions in the vicinity of the electrode sets. The invoked
contractions propagated in a retrograde fashion. The scope of the propagated contractions
was 10-12 cm for dual-set stimulation, and 5-8 cm for single-set stimulation. Propagation
velocities of the invoked retrograde contractions using parallel electrode implantations were
significantly higher (p<0.05). Motility indices dynamics reflected by the three force trans-
ducers followed similar pattern regardless of the electrode implantation technique utilized.
Dual-set NGES resulted in higher motility indices. Atropine sulfate inhibited all NGES-
invoked contractions. CONCLUSION. Pre-pyloric NGES can produce controlled choline-
rgically-mediated retrograde peristalsis with minimal surgical intervention.
S1965
A Multi-Component Model Can Predict Outcome of Restrictive Surgery for
Obesity At Baseline and 3 Months
Naeem Aslam, Hani Rashed, Atul K. Madan, David S. Tichansky, Teresa Cutts, William D.
Johnson, Thomas L. Abell
Introduction: We previously reported that a multi-component model of autonomic and
enteric factors may correlate with ultimate weight loss or gain after restrictive obesity surgery
(NGM 2005; 17:472). Patients: We report on 39 patients, 4 male, 35 female, mean age 37.2
years, followed for up to 16 years post-operatively after vertical banded gastroplasty. Methods:
Two autonomic measures (adrenergic: PAR and VC and cholinergic: RRI) and one enteric
measure (electrogastrogram: EGG) were recorded at baseline as previously described (DDS
44: 74s-78s, 1999). We performed a discriminant function analysis to investigate whether
a patient’s EGG, PAR, RRI, and VC values could be used to classify that patient as a loser
or gainer following weight control surgery. The patients were divided into two categories
(10 gainers, 29 losers), depending on the latest weight compared to baseline; discriminant
criterion derived from the patient’s data was applied to each patient’s autonomic and enteric
values to determine whether these measurements separated the patients into their true weight
category. Results: A discriminate model based on baseline measures successfully predicted
ultimate weight gain in 8/10 (80%) of patients who subsequently gained weight and weight
loss in 24/29 (83%) of patients who in subsequently lost weight for a total correct classification
rate of 32/39 (82%). The same model with data at 3 months post-operatively predicted
weight gain in 9 of 10 (90%) of patients and weight loss in 24 of 29 (83%) of patients, for
a total correct classification rate of 34/39 pts (87%) (see table). Conclusions: A multi-
component model demonstrates that baseline and 3 months post-operative measures can
predict ultimate weight outcome from restrictive obesity surgery.
Four Component Model
S1966
Effects of Duodenum/Ileum Electrical Stimulations On Duodenum Distention-
Response (DD-R) Neurons in the Vmh of Rats
J.N. Zhang, J D Z Chen
Background and Aims: Intestinal electric stimulation (IES, especially Duodenum electrical
stimulation) has been shown to produce an inhibitory effect on gastric motility/secretion,
gastric emptying and food intake in rats, suggesting a therapeutic potential of IES for obesity.
However, the small intestine is lengthy and it is unknown whether stimulation at the proximal
intestinal has a similar effect with stimulation at the distal intestine. It is well established
that the VMH in the hypothalamus is closely related to the regulation of feeding behavior
and plays an important role in the mediation of satiety. The aims of this study were to 1).
explore the hypothesis that the neurons in the VMH are involved in the central mechanisms
of the IES treatment of obesity; 2). compare the effects of IES at the duodenum and at the
ileum on neuronal activities of the VMH. Methods: Extracellular potentials of single neurons
in the VMH were recorded in 18 anesthetized rats. After VMH neurons with duodenum
distension (0.5ml, 10-30s) were identified, IES at the duodenum or ileum with 3 sets of
parameters were performed for one minute randomly via one of 2 pair of platinum electrodes
sutured onto the serosal surface of the duodenum 2-4cm below the pylorus or 3-4cm above
the ileocecal junction. IES1 (pulse trains: 4mA, 2s-on, 3s-off, 2ms, 20Hz), IES2 (long pulse:
6mA, 20cpm, 100ms), IES3 (same as IES1 but 40Hz). Results: Fifty nine percent of 34
(59%) neurons in the VMH were responsive to duodenum distension (DD, 0.5ml, 10~30s).
IES1 at duodenum and ileum activated 70.6% and 73.3% of the DD-responsive neurons
respectively (P=1.0); Similar percentages of the neurons were activated with IES3 at the
duodenum or ileum (70.6% vs. 66.7% P=0.91). However, IES2 at these locations activated
only 25% and 46.2% of these neurons. Conclusions: IES with different parameters can
activate the VMH neurons responsive to DD (25-73.3%) and the pattern of stimulus (pulse
trains or long pulses) plays an important role. However, it seems that the location of electrical
stimulation in the small intestine does not alter its effects on the neuronal activity in the
VMH of rats.
S1967
Intragastric Balloon for Refractory Obesity: Poor Compliance with Dietary
Education and Follow-Up Does Not Preclude Weight Loss
Erik Francois, Jean Marc Dumonceau, Marie Barea, Karine Buedts, Michael Piagnerelli,
Jacques Deviere, Axel Hittelet
Background: the intragastric balloon (IB) has been proposed as an aid to weight loss for
patients with moderate obesity. By increasing satiety, the IB helps patients learn and adhere
to new eating habits, which must be maintained after balloon removal if weight is to be
stabilized. Thus, dietary education and follow-up before, during, and after IB placement are
strongly recommended. Methods: From July 1999 to June 2004, 80 patients (68 women;
body mass index, or BMI, range 28.4 to 58.5 kg/m2; mean±SD: 36.9±7.8) were treated with
the BioEnterics® Intragastric Balloon (Inamed corporation, Santa Barbara, California, USA),
placed endoscopically under sedation with midazolam or anesthesia with propofol. Patients
were screened by a dietician before placement, and monthly dietary follow-up was prescribed
thereafter. Results: IB placement was successful and uneventful in all cases. Three patients
were lost to follow up. One-year post-removal follow-up was obtained in 77 patients.
One IB migrated spontaneously and 76 IB were removed endoscopically, 3 of which had
spontaneously deflated while remaining in the stomach (spontaneous deflation rate: 5%).
Early removal (<3 months) for intolerance was necessary in 14% of patients. The only other
complication was one case of severe hypokalemia. Mean duration of IB placement was 180
days (range: 8 to 548 days). Mean weight loss at removal was 11.3 kg (±8.5 kg); mean %
of excess weight lost (EWL) was 44.7% (±39.2%). Twenty-six percent of the patients lost
less than 20% of excess weight. Six months after IB removal, the mean EWL was 26.2%
T : 89386$$CH2
05-04-06 23:18:27 Page 295Layout: 89386B : o
A-295 AGA Abstracts
(±40.3%) and was maintained at 22.4% (±58.5%) at one year. Weight loss was greater if
BMI was >40 kg/m2 (mean: 16.9 +/-13.2 kg) than if BMI was <35 kg/m2 (mean: 10±6.6
kg) (p=0.01). Only 10 out of 80 patients were fully compliant with the prescribed dietary
follow-up during IB and after removal. There was a trend to greater weight loss in the
compliant group, but statistical significance was not achieved. Overall, 43% of the patients
were satisfied with the IB. Conclusions: The IB appears to be safe and moderately effective
in achieving sustained weight loss 1 year after removal despite poor compliance to dietary
follow-up in this series.
S1968
Rediscovered Therapeutic Option for Morbid Obesity: Multicenter Pilot Study
with a New Pneumatic Stomach Balloon
Yogesh Shastri, Irina Blumenstein, Udo Martin, Stephan Haass, Jurgen Stein, Wolfgang
Caspary, Nicolas Hoepffner
Background: Morbid obesity is a rapidly growing problem mainly of western society. Over
60% of the American population is either obese or overweight. Conventional treatment
with reduced caloric intake, increased physical activity and pharmacotherapy are minimally
effective in inducing sufficient weight loss, however the loss weight is often regained once the
treatment is stopped. Given the comorbidities in these obese high risk patients, experienced
bariatric surgeons often advocate a less invasive first stage intervention. The endoscopic
implantation of various balloons in 80’s and 90’s could not come into vogue because of its
associated complications. Since 2004 a new pneumatic intra-gastric balloon has come into
practice. Ours is the first study reporting the safety, effectiveness, and tolerance of this new
gadget in clinical practice. Patients and Methods: A pneumatic intra-gastric balloon system
(heliosphere® bag, Helioscopie, France) was placed endoscopically 27 times in 24 patients
in a multicenter pilot study since September 2004 till November 2005. They were followed
up prospectively with data about symptoms, complications, loss of weight, BMI, etc. Results:
There were 12 male and 12 females (age range 24-60, median 43 yrs) with a BMI range of
30-57 (median 37) and a body weight of 71-194 kg (median 113 kg). In 2 female and 1
male patients the procedure was repeated twice (after 5, 10 and 11 months). There were
no procedure related complications. 16 (59%) of patients had balloon induced immediate
side effects like occasional nausea with vomiting lasting 3 days in 6 patients (22%), 7 patients
(32%) had more severe nausea, vomiting and abdominal pain, whereas 3 (11%) patients
required admission and intravenous fluid administration for the same. In two patients we
had to perform premature extraction of the balloons after 5 and 14 days of implantation
because of intolerance and severe bleeding (Dieulafoy’s ulcer) respectively. The remaining
balloons were explanted 9 months (range 5 to 13 months) after implantation. Except for
one patient all patients lost weight ranging from 1 to 29 kg with a fall in BMI ranging from
1 to 9. Conclusion: With this new found “old” technique the results are promising. It was
efficient in inducing weight loss in mild or moderate obesity and can also be very useful
for preoperative weight reduction as a first stage, low risk and less invasive procedure in
morbidly obese patients.
S1969
Post Adjustable Gastric Banding Syndrome. pH-Metric and Manometric
Recordings in 19 Patients
Mohamed Merrouche, Jean Marc Sabate, Pauline Jouet, Simon Msika, Severine Ledoux,
Benoit Coffin
Background: Adjustable gastric banding (GB) is one of the most common surgical procedure
for the treatment of morbid obesity. However, GB frequently induces upper gastrointestinal
symptoms. The consequences of GB on acid reflux and oesophageal motility have been poorly
evaluated. The aim of this study was to describe pH-metric and manometric abnormalities in
patients complaining of upper gastrointestinal symptoms after adjustable GB for morbid
obesity. Patients and Methods: a standardized questionnaire, 24-hrs pH-metric recording
(% of time with pH < 4) and esophageal manometry [lower esophageal sphincter pressure
(LES), morphology, amplitude and propagations of oesophageal contraction waves] were
performed in patients with GB addressed for upper gastro-intestinal symptoms and/or GB
failure (insufficient weight loss) to a tertiary unit specialized in the treatment of morbid
obesity. Results: (mean ± SD) 19 patients (F: 17; age 44.0 ± 10.2 yrs) were included 24 to
36 months after GB. BMI was 45.8 ± 6.9 kg/m2 (range : 39.9-67 kg/m2) before surgery
and 37.8 ± 9.2 kg/m2 (range: 22.2-59.4 kg/m2) at the time of the study. Mean weight loss
was 20.8±14.4 kg (range : 0-50 kg). None of these referred patients had had preoperative
pH-metry or manometric recordings. At the time of the study, 13 patients (68.4%) had one
or more upper gastrointestinal symptoms: vomiting more than 3 times a week in 9 (47.3
%), dysphagia in 6 (31.6 %), heartburn in 5 (26.3%) and epigastric pain in 3 (15.7%). pH-
metry was abnormal in 6 out of 15 patients (40%) with a percentage of time with pH<4 of
29.5 ± 24.8 % (range: 8.5-71 %). Esophageal manometry was abnormal in 12 out of 19
patients with incomplete LES relaxation in 9 (47.4%) associated with abnormal oesophageal
contractions in morphology, amplitude and duration; presence of non peristaltic waves were
also noted. Conclusion: the presence of major reflux disease and oesophageal motor disorders
that could be defined as pseudo-achalasia are frequent in patients consulting for upper
gastrointestinal symptoms and/or insufficient weight loss after adjustable gastric banding.
These preliminary results in a small cohort of symptomatic patients without preoperative
data suggest that complete oesophageal investigations are mandatory before performing


















Incidence of Stomal Stricture and Efficacy of Endoscopic Intervention: A
Tertiary Center’s Experience with Gastric Bypass Surgery
Michael A. Veliuona, Fedele J. Depalma, Robert N. Cooney, Abraham Mathew
Introduction: The Roux-en-Y gastric bypass is a highly effective surgical approach for morbid
obesity but is not without associated complications. We report our institution’s experience
with gastric bypass surgery and endoscopic intervention in treating stomal strictures.
Methods: Patients who had undergone gastric bypass surgery at our institution between
January 2000 and August 2004 were identified. Medical records were reviewed to obtain
pertinent patient demographics and peri-operative data and outcomes. Results: Eight hundred
and eighty eight patients underwent gastric bypass surgery at our institution by one of five
surgeons. Among these patients, 94 (10.6%) underwent esophagogastroduodenoscopy (EGD)
for evaluation of possible stomal stricture and 58 (6.5%) were found to have one. Laparoscopic
approach was associated with more strictures (43 or 74.1%, p=0.0003). When controlled
for the laparoscopic procedures, stomal stricture rate was similar between high volume and
low volume surgeons. A total of 125 dilations were performed with an average of 2.2 dilations
per patient (range 1-7). There was a total of 4 perforations (3.2%) related to endoscopic
dilation and 3 (75%) perforations occurred in patients who had undergone repeated EGD
and dilations (2, 5, 7 dilations). The one patient in which a perforation occurred with a
single dilation was dilated to 20 mm. The other 3 perforations occurred with dilations to
10 mm and 12 mm (2). The average number of post-operative days for endoscopically
confirmed strictures was 66.2 days (range 12-365). Of the 94 patients thought to have
stomal strictures, 87 underwent either computed tomography (CT scan) or barium Xray
prior to endoscopic evaluation. Abnormal radiographic findings were seen in 42 patients
and 5 (11.9%) of these patients had a normal EGD without evidence of stomal stricture.
19 (42.2%) patients with normal radiologic studies were found to have stomal strictures
requiring dilation. Using EGD as the gold standard, radiographic studies demonstrated a
sensitivity of 66% (95% CI: 52-77), specificity of 83% (95% CI: 65-93), positive predictive
value (PPV) of 88%, and negative predictive value (NPV) of 57%. Conclusion: Endoscopic
dilation of stomal strictures at our institution is safe with a perforation rate at the low end
of the published range. Radiographic findings can assist in diagnosing the presence or
absence of stomal strictures, but there is not always a direct concordance between radiographic
and endoscopic findings.
S1971
Botulinum a Toxin Injected Into the Gastric Wall for the Treatment of Class
III Obesity: A Pilot Study
Aloisio Cardoso Jr., Paulo Roberto Savassi-Rocha, Luiz Gonzaga Vaz Coelho, Maria
Matilde Mello Sposito, Walton Albuquerque, Marco Tulio Costa Diniz
BACKGROUND - Obesity represents a main public health problem in western countries.
Initial studies suggest that injection of botulinum A toxin (Btx-A) into the antropyloric
region inhibits propulsive contractions of the antral pump, with delay in gastric emptying,
early satiety and body weight loss. METHODS -After approval by University Ethics Commit-
tee, we prospectively evaluated 12 patients with class III obesity divided into four groups
of three patients each. In groups I and II, 200 U Btx-A were injected into the antropyloric
region at 8 and 16 sites, respectively. Groups III and IV received 300 U Btx-A into the
antropyloric region at 16 and 24 sites, respectively. Body weight and gastric emptying time
(GET) of solids and semi-solids using 13C-octanoic acid breath test and 13C-acetic acid
breath test, respectively, were determined before and after injection over a period of 12
weeks. RESULTS - Pre- and post-treatment body weight or solid and semi-solid GET did
not differ significantly between groups (p>0.05). All patients reported a feeling of early
satiety. No adverse effects related to Btx-A or complications resulting from the endoscopic
procedure were observed. CONCLUSION - The injection of different doses of Btx-A at
different sites in the antropyloric region of patients with class III obesity did not interfere
significantly with the solid and semi-solid GET or body weight of these individuals. However,
early satiety was reported by all patients, the procedure was safe and no side effects of
the treatment were observed. Further controlled studies involving different methodologies
regarding dosage of Btx-A and sites of injection are necessary.
S1972
Short Duration Vs Continuous Bouts of Excercise in Childhood Obesity
Treatment Programs
Sari Acra, Megan Neumman, Andrea Klint, Kong Chen
Introduction: Exercise and increased physical activity (PA) are integral to life-style weight
management programs in obese children and success hinges on compliance. Studies have
shown that children appear to spontaneously perform leisure PA in short bursts. We examined
whether exercise regimens tailored after this pattern (10 min tid) led to increased compliance
and total daily PA compared to a single bout of 30 min/day by obese children as part of a
10-week obesity lifestyle management program (ShapeDown). Both exercise prescriptions
were for greater than moderate intensity PA performed daily. Methods:Using a randomized,
crossover design (investigator- blinded), this pilot study examined PA patterns in 9 boys
and 9 girls, ages 9-11, BMI 85-98%. Minute-by-minute PA during awake hrs was monitored
using an RT3 tri-axial accelerometer continuously for 11 weeks, including 1 week prior to
any intervention (baseline 1 PA). Participants then entered the program and were randomized
to: (Group 1) 4 wks of 10 min .t.id of exercise (period 1) followed by 4 wks of 30 min q
day (period 2), or to (Group 2) 30min q day x 4 wks (period 1) followed by 4 wks of 10
min t.i.d (period 2). A 1-week washout period followed by a second 1-week baseline (baseline
2 PA), during which ad-lib PA occurred, separated each exercise period. Results: Baseline
characteristics were similar between Groups 1 and 2 (BMI, gender, race, baseline 1 and 2
PA). Furthermore, Groups 1 & 2 had similar changes in BMI (p=0.98; -0.02 +/- 0.03 vs -
0.02 +/- 0.04, respectively) and dietary intake by 24-hr (0.4 % vs. 1.8%, p=0.42) over the
study period. While self-reported compliance was significantly greater for 30 min q day vs.
10 min t.i.d, measured compliance using accelerometers was similar between the two exercise
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forms (31% vs 55%, respectively; t-test, p=0.12). The normalized average changes (from
the respective baselines) in PA during interventions were 1.06 +/- 0.27 for 10 min t.i.d and
1.11 +/- 0.31 for 30min q day (p=0.67). No carryover or period crossover effects were
noted. Conclusion: Short bursts of prescribed PA did not lead to an overall greater daily
PA compared to a single daily bout of exercise, an effect mediated at least in part by poor
compliance with both forms of exercise in obese children undergoing a life-style modification
weight management program. This highlights the challenges facing obesity intervention
programs in children.
S1973
Long Term Follow-Up of Morbidly Obese Patients Undergoing Bioenterics
Intragastric Balloon (BIB) Placement
Spyros Michopoulos, Georgios Stamatis, Stephanos Karagiannis, Fotis Dimopoulos, Helen
Chrysanthopoulou, Chris Karatsoras, Emmanouel Archavlis, Michael Theodorakis,
Athanassios - Meletios Dimopoulos
The obesity worldwide epidemic poses serious health hazards, particularly in Western
societies. Current clinical evidence suggest that surgery offers significantly beneficial long
term results to people with morbid obesity, compared to conventional methods, since even
modest weight loss is associated with substantial reduction of co-morbidities. However, a
large number of patients are unwilling to undergo surgical procedures. Alternatively, the
BIB® System consists of a small size, silicone-made balloon, filled with sterile-saline water
that can be inserted via endocscopy so that the stomach is partly filled. To our knowledge,
reports of long term results with this procedure is scarce in the literature.The aim of our
study was to follow-up and compare two groups of obese (BMI > 40 kg/m2) patients: Group
A (N=14) was comprised of those reluctant to surgery, who underwent the BIB procedure,
whereas patients of the other group (Group B; N=13) were only put on appropriate low
caloric diet. Group A patients were put on the same diet scheme as those in Group B through
out the follow-up period. Results: All patients were hospitalized for 1-4 days after the
procedure. Discomfort, nausea and vomiting occurred frequently but did not lead to BIB
removal during the first 6 months. There were no statistical differences in age, gender ratio,
duration of follow-up period and initial BMI between groups. However, the magnitude of
BMI reduction was significantly higher at 6 months as well as at the end of the follow-up
period in patients having undergone the BIB procedure, compared to those that underwent
no intervention. Results are summarized in the table (Mean ± SD). Conclusions: 1) The
BIB® System leads to significant short- as well as long-term weight reduction in patients
with morbid obesity, mainly when patients concurrently adhere to a diet protocol 2) Unfortu-
nately, most patients regain weight in the long term although significantly less so following
the BIB procedure. The persistence of difference is mainly due to the initial (during the first
6 months) weight loss, as the regain after the 6th month is the same in both groups.
M1073
Effect of Chromoendoscopy with Alcian Blue On the Detection of Incomplete
Intestinal Metaplasia in the Stomach
Serguei V. Mouzyka, Mykhailo Zakharash, Alexandra Fedoseeva
Background/Aims: Incomplete intestinal metaplasia (IIM) is generally considered to be an
early stage in the multi-step process leading to the development of gastric cancer or to be
associated with an increased risk of gastric cancer. The intestinal metaplasia is categorized
as type II if the intermediate cells secrete neutral mucins and acid sialomucins. Alcian blue
is a basic histological stain that stains sialomucins. Apparently, it can be used with endoscopy
to diagnose IIM. However, there are no works studying the effectiveness of chromoendoscopy
with alcian blue. The aim of our prospective study was to evaluate the use of chromoendos-
copy with alcian blue in the differentiation of gastric lesions. Methods: A total of 40 patients
(male: female = 35:5, age 49.5 years) with different gastric abnormalities participated in the
study. After obtaining permission, we used to spray reagents onto the gastric mucosa in the
following order: 1 % alcian blue solution and intensive water irrigation (after 1 minute).
The volume of each reagent depended on the size of the abnormalities (from 2 to 5 ml of
alcian blue solution). The overall alcian blue staining pattern on the mucosa was classified
into: group A: no appreciable staining, group B: patchy, group C: diffuse. Biopsy specimens
were obtained from alcian-stained areas as well as alcian-unstained areas. All endoscopic
procedures were performed by a single endoscopyst. Earlier diagnosed IIM patients were
excluded. Results: In group A all 25 lesions were classified as inflammatory changes. In
group B lesions were classified as inflammatory changes (2), low grade dysplasia (2), complete
intestinal metaplasia (2), IIM with high grade dysplasia (1). In group C all 8 lesions were
IIM. The sensitivity and specificity of chromoendoscopy with alcian blue for diffuse staining
for detecting IIM were 88,9% and 100% respectively. A significant positive correlation
(Pearson coefficient 0,84, p<0,001) was found between grade of endoscopic alcian-stained
mucosa and IIM. CONCLUSION: Chromoendoscopy with alcian blue is simple and effective
method of detection of IIM in the stomach.
M1074
Terminal Ileal Photography Or Biopsy: Does the Microscope Agree with the
Endoscope?
Nick Powell, David Yeoh, Bu Hayee, David Rowbotham, Vishal Saxena, Alistair McNair
Background: Some authorities advocate routine acquisition of terminal ileum (TI) biopsies
in all patients undergoing colonoscopy to document the extent of examination. However, the
additional costs and uncertain diagnostic yield in patients whose TI appears macroscopically
normal raises issues regarding the cost effectiveness of this approach. We sought to demon-
strate that photographs of the TI illustrating the presence of villi are a reliable means of
documenting the extent of colonoscopy and that routinely acquired TI biopsies have a
minimal diagnostic yield. Methods: We conducted a prospective study of 211 unselected
patients referred for colonoscopy. In all patients the macroscopic appearance of the TI was
described and photographs taken following instillation of water to flood the TI and demon-
strate villi. Biopsies were sampled from the same visual field. Photographs were independently
evaluated by 3 gastroenterology specialists and categorised as “definitely”, “probably” and
“definitely not” depicting villi. Results: Histological assessment of TI biopsies confirmed
small bowel mucosa in 202/211 (95.6%) patients. In 9 cases the sample was insufficient,
the tissue received unidentifiable or no sample was received by the laboratory. Photographs
taken from the 202 patients in whom TI intubation was confirmed histologically were
evaluated by the 3 reviewers. Villi were described as “definitely” present in 93.0%, “probably”
present in 6.7% and “definitely not” present in 0.3% of cases. There was good agreement
between the 3 reviewers (Cohen’s kappa value for concordance = 0.78). Routine ileoscopy
and TI biopsy was associated with a low rate of abnormal findings. The macroscopic
appearance of the TI was described as “normal” by the endoscopist in 96% of cases. In
these patients microscopic abnormalities of the TI were only identified in 4 (2.1%) patients.
In all instances there were microscopic features of IBD present and in all cases there were
macroscopic features of IBD present in the colon. Conclusions: A photograph of the TI that
clearly demonstrates villi is a reliable means of documenting that the TI has been reached
and that the whole colon has been examined. Routine TI biopsy has a poor diagnostic yield
and is not necessary unless there are macroscopic mucosal abnormalities or other features
to suggest IBD.
M1075
Decision Analysis: An Aid to the Diagnosis of Whipple’s Disease
Martin Olmos, Edgardo G. Smecuol, Eduardo Maurino, Julio C. Bai
Background/aims: The diagnosis of Whipple’s disease (WD), a rare systemic infection affecting
predominantly the small bowel, is based on the identification of the bacterium Tropheryma
whipplei. Our aim was to make explicit diagnostic uncertainties in WD through a decision
analysis considering patients with either mainly intestinal involvement or those with a
predominant focal neurological compromise at presentation. Methods: Using appropriate
software, we constructed a decision tree to estimate the consequences after testing different
strategies for diagnosis of WD. Probabilities and outcomes to determine the optimum expected
value were based on a MEDLINE search through July 2005. Results: In patients with
predominant intestinal compromise, diagnostic strategies considering endoscopic intestinal
biopsies for histology, including PAS and Ziehl-Nielsen (ZN) staining, and the PCR testing
for bacterial DNA were similarly effective. The expected value for both was 17.03 survival
years. In case of failure of one procedure the best sequential choice was a PCR analysis after
a negative histology compared with histology after a negative PCR determination (expected
values: 15.74 and 15.11 survival years, respectively). For cases with predominant neurological
involvement, of the five strategies tested (“watchful waiting”, intestinal biopsy for histology
[including PAS and ZN staining], PCR determination of either intestinal biopsy samples,
cerebrospinal fluid or stereotaxis cerebral biopsies), evidenced the highest expected value
(14.92 survival years) for the cerebral biopsy. However, using quality-adjusted life-years as
utility considering morbidity of different methods, intestinal biopsy for PCR determination
was the best choice (14.00 survival years). Conclusions: In this decision model, intestinal
biopsies for histology (PAS-ZN) should be indicated firstly for WD with predominant digestive
compromise and if negative, a PCR determination should be the next option. In neurological
WD, the molecular PCR assessment of cerebral biopsies had the highest diagnostic yield;
however, its associated morbidity turns intestinal molecular assessment or histological testing
as with the highest utilities.
M1076
Predictive Value of Alarm Symptoms for Gastric Cancer in Korea
Yu Kyung Cho, Myung-Gyu Choi, Jae Myung Park, Jung Hwan Oh, Chang Nyol Paik,
Joon Wook Lee, In Seok Lee, Sang Woo Kim, In-Sik Chung
Background: The diagnostic value of alarm symptoms for predicting gastric cancer has not
been evaluated in Korea where gastric cancer is prevalent. Aim: We aimed to evaluate the
prevalence and predictive value of alarm symptoms in dyspeptic patients. Method: Patients
with dyspepsia were recruited consecutively from non-referral and referral hospitals June
2001 to May 2002. They were evaluated by dyspepsia questionnaire, endoscopy and Helicob-
acter testing. Alarm symptoms were defined as anemia, weight loss, dysphagia, gastrointestinal
bleeding, recurrent vomiting, anorexia, palpable abdominal mass and familial history of
gastric cancer. Result: Of 3,177 patients enrolled, 1368 (43.1%) didn’t have any alarm
symptom (uncomplicated dyspepsia group) and 1809 (56.9%) were presented with one or
more alarm symptoms (complicated dyspepsia group). Of 196 gastric cancer patients, 31
(15.8%) were identified in the uncomplicated dyspepsia group and 165 (84.8%) were
identified in the complicated dyspepsia group. The ages of the patients with gastric cancer
in the uncomplicated dyspepsia group were <35 in 1, 35 to 40 in 2, 40 to 45 in 3, 45 to
50 in 2 , 50 to 55 in 9 patients and ≥55 in 14 patients. Patients with gastric cancer less
than 45 years old in uncomplicated dyspepsia group represented 3% of all the gastric cancers.
Using multivariate analysis, age (Odds ratios 1.07 (95% confidence interval 1.06-1.08)),
male (OR 2.1 (95% CI 1.4-3.2)) anemia (OR 18.1 (95% CI 11.3-28.8)), weight loss (OR
3.8 (95% CI 2.7-5.3)), dysphagia (OR 2.0 (95% CI 1.1-3.6)) and smoking (OR 1.9 (95%
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CI 1.2-2.8)) were predictive of gastric cancer. However, for only early gastric cancer, age
(OR 1.07 (95% CI 1.04-1.09)) and smoking (OR 2.9 (95% CI 1.6-5.2)) were predictive
features. The positive predictive value of anemia, weight loss and dysphagia were 34%, 16%
and 16%, respectively. Conclusion: Some alarm symptoms had predictive value for gastric
cancer but were not optimal for predicting early stage cancer. The high prevalence of alarm
symptoms in patients with gastric cancer, also in young patient, suggests that age and alarm
symptoms will be an effective approach for selecting patients who have the risk of gastric
cancer in Korea.
M1077
Performance Improvement (PI) Is a Valid Mechanism to Introduce Sedation-
Risk Free (Unsedated) Colonoscopy Into Routine Practice
Felix W. Leung, Steven Aharonian, Paul H. Guth, S K. Chu, B T. Nguyen, P Simpson
Background Sedation is standard for colonoscopy in the U.S. Serious cardiopulmonary
complications occur in up to 1.6% of sedation procedures (Joint Commission J Quality
Improvement 27:28-41,2001). 6.2% to 7% of one expert colonoscopist’s patients requested
no sedation (J Clin Gastro 2005;39:516-9). Predictors are being male and educated profes-
sionals. 4 other U.S. studies reported up to ¼ of all patients accepted unsedated colonoscopy
when the option was offered. Hypothesis We tested the hypothesis that PI is a valid mechanism
to introduce sedation-risk free (unsedated) colonoscopy into routine practice. Method In
2002, VAGLAHS consolidated sedation procedures at WLAVA. Patients at Sepulveda ACC
requested alternative(s) to the limited local access to colonoscopy. The unsedated option as
reviewed in Table 1 was offered. Outcomes were tracked by PI questionnaires. Results From
2002 to 2005, 145 of 483 patients (30%) accepted the unsedated option. Colonoscopy was
performed by supervised trainees. Overall success rate of cecal intubation was 81%. Only
1 LVN was needed for technical assistance. Transient vasovagal reaction occurred in 2
patients. Table 2. 85% of patients with successful cecal intubation reported good experience,
and 90% indicated they would likely accept unsedated colonoscopy in the future. Mean
wait time has increased from 27 ± 4 to 46 ± 5 and 72 ± 6 days from the 1st to the 2nd
and 3rd year, for 31, 50 and 64 patients during each of the three periods, respectively. This
program placed 3rd in a VAGLAHS-wide PI poster competition. Conclusion Sedation-risk
free (unsedated) colonoscopy can meet ¼ of the workload demand successfully with minimal
requirement for technical support. Patients value the interaction with the endoscopist devoid
of amnesic influence of sedative medication. The lengthening of wait-time confirms the
steady increase in patient acceptance of this “non-standard” option. Winning placement
reflects recognition by the administration.
M1078
Stool Caprotectin Detection Accurately Excludes Organic Disease in Patients
Presenting to Gastrointestinal Clinic
Ariella Gar-gil Shitrit, Dan Braverman, Julien Paz
Background: Calprotectin (MRP8/14) is a heterodimer calcium-binding protein present in the
cytoplasm of neutrophils and is expressed in the membrane of monocytes. Upon neutophil/
monocyte activation, calprotectin is released and can be detected in serum and body fluids,
including stool. Therefore, it can be a potentially useful clinical inflammatory and neoplastic
marker. Recent studies showed elevation of fecal calprotectin levels in inflammatory bowel
disease patient as well as chronic inflammatory and neoplastic disorders. Gastroenterologists
are often hampered by the lack of a non-invasive index of colonic pathology. Stool calprotectin
can be a promising and useful non-invasive tool in evaluating patients with suspected bowel
pathology. Aim To evaluate the predictive value of fecal calprotectin in the diagnosis of
colonic pathology. Methods: Seventy two consequent patients referred for colonoscopic
examination in the department of gastroenterology, Shaare-Zedek Medical Center, Jerusalem,
Israel were included. All supplied a stool specimen taken before colonoscopic preparation.
The stool specimen was stored in a household freezer and was brought by the patient on
the day of examination. Fecal calprotectin levels were determined in our gastroenterology
laboratory. In addition, all patients have performed blood tests for CRP, ESR, CBC, and a
general stool tests for WBC and occult blood. The calprotectin levels were compared to the
clinical and laboratory parameters of the patients. Results: Mean calprotectin level in patients
with colonic pathology (n= 27) was 232±114 mg/kg compared to patients without pathology
80±98 mg/kg (n=45); (p=0.001). Calprotectin levels were statistically significant with C

















r=0.50, p=0.002; r=0.36, p=0.04; r=0.32, p=0.02, respectively). The sensitivity, specificity,
negative and positive predictive value of calprotectin to predict colonic pathology were 75%,
84%, 75% and 80%, respectively Conclusions: Stool caprotectin level can be a useful tool
to exclude organic disease in patients presenting to gastrointestinal clinic
M1079
Quality Assurance Committee: An Old Concept with New Significance
S. D. Feldshon, Glenda Tims
Traditional quality assurance activities have been overshadowed in recent years by quality
improvement initiatives. Minnesota GI, a 50+ MD single specialty practice, has had a standing
quality assurance committee for many years. The committee reviews all complaints and
complications reported by physicians, staff, and patients. Database was reviewed from 9/
04-9/05 to assess the types and frequencies of complications and complaints. In that time
35,000 clinic visits and 68,000 procedures were performed. A total of 203 complications
were reported by physicians on 179 patients. 41% were self reported by the treating MD
and 59% were reported by a physician partner. The most common complications reported
were: hemorrhage with and without transfusion, perforation, and pancreatitis. There were
no behavioral issues reported by MD’s. The reported rate of complicatons is compared to
expected national rates below. Procedure Complication % of total % Natl av Colonoscopy
Bleed 0.15 0.03-1.9 Colonoscopy Perforation 0.04 0.2-0.4 Upper Endo Bleed 0.05 <0.15
Upper Endo Perforation 0.05 0.02-0.2 ERCP Pancreatitis 1.6 1.9-5 ERCP Bleed 0.22 1-2
There were a total of 108 patient complaints. 83% of the complaints were physician behavior
related. 17% were concerns related to real or perceived complications. The most common
issues reported were: rude, uncaring or disrespectful (36%), appeared rushed (23%), discom-
fort during or after the procedure (22%). Interestingly, the 5 physicians with the highest
number of complaints did not have the highest number of complications. In summary,this
study of traditional quality assurance activities suggests that physicians in a private practice
setting DO report their complications and can be responsible for self monitoring their quality
of care. Complications are reported at a near expected rate and used as opportunities for
improvement. In addition, the patient complaints demonstrate patient dissatisfaction with
physician behavior. This aspect of the patient physician interaction has previously been
relatively unappreciated, yet behavioral issues are known to correlate with litigation. We
intend to utilize this data to improve our patient experience as well as minimize complications
where feasible.
M1080
Outcome of Cases with Acute Pancreatitis in a Single Center and a
Comparison of Ranson’s and Sofa Scoring System in Predicting the Outcome
Ari Wiesen, Kostas Sideridis, Pashun Jalal, Baez Mishiev, Simmy Bank
Background: Acute pancreatitis is associated with considerable morbidity and mortality
throughout the world. The mortality of acute pancreatitis has been reported in literature as
10-15%, but it may have improved significantly over time with early recognition of its
severity based on various scoring systems and institution of appropriate management. Aim:
To evaluate the outcome of cases admitted with acute pancreatitis in our center over the
past 3 years (2001-2004), and compare Ranson’s and SOFA scoring systems in predicting
the outcome. Methods: Data from consecutive patients admitted with acute pancreatitis
were analyzed retrospectively. The primary outcomes were ICU admission and mortality.
Secondary outcomes were development of pancreatic necrosis, pseudocyst, culture positive
sepsis, interventions required such as ERCP and surgery, and hospital stay. Ranson’s score
at admission and at 48 hrs, and SOFA scoring system were used in patients when recorded
to predict the outcome parameters. Results: Total Number of cases with the diagnosis of
acute pancreatitis over the period was 109 (age range 21-96 yrs, median 54 yrs; 59 male,
50 female). Aetiology was identified as gallstone in 44 (40%), alcohol in 32(29%), post-
ERCP in 4(3.6%), hypertriglycerdemia in 2, and 27 cases were diagnosed as idiopathic. ICU
admission was required in 23 patients (21%) and four patients (3.6%) died. Pancreatic
necrosis was seen in 9 cases (8.2%); pseudocyst also developed in 9 cases (two with necrosis).
Culture positive sepsis was seen in 12 cases (11%). ERCP was done in 21, surgical intervention
(necrosectomy/cholecystectomy) in 36. The range of hospital stay was 1 to 49 days (median
8 days). Total parenteral nutrition (for >1 week) was required in 6 patients (5.5%). No
difference was seen in predicting mortality by Ranson’s score at admission and SOFA score,
possibly due to small number of deaths. However, SOFA scores at day 1 and day 3 were
superior to Ranson’s score at admission and at 48 hrs for ICU admission (p<0.05). Ranson’s
score of 3 or more at 48 hrs was significant for predicting necrosis (p<0.001), but not the
score at admission. Similarly, SOFA score at day 3 was significant in predicting necrosis
(p<0.001), but comparable with Ranson’s at 48 hrs (p>0.5). Conclusions: Acute pancreatitis
still has a very high morbidity and complications, but mortality has improved. Ranson’s
and SOFA scores are comparable in predicting mortality and necrosis, but SOFA score is
superior in predicting ICU admission.
M1081
Fecal Occult Blood Testing in Thrombolytic Therapy
Alex J. Gershenhorn, Mojdeh Momeni, Rana Khan, Sowmya Kanikkannan, Kell Julliard,
Linus Yoe, Vinod Kurupath, Sushil Duddempudi, Sury Anand, Kiran Bhat
Purpose: The incidence and severity of gastrointestinal bleeding (GIB) in patients receiving
thrombolytic therapy is not well known. There is little data on the risk stratification of these
patients for GIB. The purpose of this retrospective analysis was to evaluate the practice of
performing fecal occult blood testing (FOBT) in patients prior to administering thrombolytic
therapy and to determine whether FOBT positive stools led to worse outcomes. Methods:
A retrospective chart analysis was done to evaluate all patients who received full-dose
thrombolytic therapy from July 2003 to March 2005. There were no exclusion criteria.
Ninety-eight charts were reviewed from three medical institutions - The Brooklyn Hospital
Center, New York Methodist Hospital, and Lutheran Medical Center. The indications for
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thrombolysis included myocardial infarction, cerebral vascular accident, deep venous throm-
bosis, pulmonary embolism, and graft occlusion. Prior history of GIB, FOBT results pre-
thrombolytic therapy, overt GIB post-thrombolysis, and all deaths were recorded. The chi-
square test or fisher’s exact test was used to determine statistical significance. The alpha
was set at 0.05. Results: Ninety-eight patients were studied; 58 (59.2%) male and 40 (40.8%)
female. Fifteen (15.3%) were under 50 years of age, 31 (31.6%) were 50-65, and 52 (53.1%)
were over 65. When comparing pre-thrombolytic FOBT positive and negative groups, there
was no statistical difference in GIB rates post-thrombolysis (p=0.769). There was, however,
a statistically significant increase in GIB post-thrombolysis in the prior GIB history group
vs. no prior history of bleed (p=0.022). There were no deaths from GIB. Conclusions: The
incidence of GIB post-thrombolysis is low (4.1%). The value of performing a FOBT prior
to thrombolytic therapy is questionable, and a positive FOBT may not be predictive of GIB
post-thrombolysis. In our study, a history of prior GIB was associated with GIB post-
thrombolysis (p=0.022). A positive FOBT alone should not necessarily be used to withhold
thrombolytic therapy when indicated. Reliable criteria need to be defined to risk stratify
patients for GIB when given thrombolytics.
M1082
Clinical Efficacy of Gabapentin in Persistent Hiccups
Francisco Huerta-Iga
BACKGROUND: Hiccups have many causes that are difficult to establish. In terms of its
duration they can be categorized as follows: acute, when last up to 48 hours; persistent,
longer than 48 hours and intractable when last more than two months. Treatment options
include both pharmacologic and nonpharmacologic agents. We present our experience with
the use of GABAPENTIN in the treatment of persistent hiccups (PH). MATERIAL AND
MÉTHODS: This is a clinical observational prospective study held form March 1999 to
February 2005 and include patients more than 18 years old with diagnosis of PH. We
investigated history of hiccups, GERD, concomitant diseases and cancer and recent use of
medications related to singultus. A subjective scale for grade the intensity of Hiccups was
used for the patients during the study: 1= No Hiccups, 2= Occasional hiccups. Don’t affect
sleep or daily activities, 3= Frequent hiccups that affect daily activities but don’t affect sleep,
4= Frequent hiccups that affect daily activities and sleep, 5= Persistent hiccups that don’t
allow the patient to eat or sleep and is accompanied of weight loss. RESULTS: A total of 9
patients were enrolled in a 72 months period. All were men, with a mean age of 50.7 years
(28-78). Three had history of Diabetes and one of Hypertension. Carlsson-Dent questionnaire
were positive for GERD in 77.7%. All were on PPI and cisapride at conventional dose
treatment for at least one week. Two patients were also on carbamazepine. Initial mean
symptom score was 3.88. The PPI and cisapride were continued and adjusted for all the
patients, we only added Gabapentin 300 mg twice a day. The patients filled the score cards
every day until the disappearance of hiccups and Gabapentin was suspended three days
after this. The mean first response day was 1.88 and the mean number of days until hiccups
disappear was 3.77. Follow up for up to 6 months demonstrate no recurrence of hiccups
in any patient. We can only correlate the hiccups disappearance with the use of Gabapentin
in 8 of the 9 (88.8%) patients in terms of a rapid response. Sedation and dizziness were
present in 33.3%. Only one patient accepted the pH monitoring after the study and was
negative for acid reflux. CONCLUSIONS: Gabapentin is a useful empirical treatment for
persistent hiccups with an 89% rate response in addition to PPI and prokinetic therapy via
the GABA-ergic nerves on the hiccup centre. We suggest using it as a first line therapy
because of its great clinical response and the less common, less important adverse effects
rate comparison with Baclofen.
M1083
Clinical Utility of Esophagogastroduodenoscopy in the Management of
Recurrent or Intractable Vomiting in Pregnancy
Abraham Debby, Abraham Golan, Marek Glezerman, Haim Shirin
OBJECTIVE: The indications to perform esophagogastroduodenoscopy (EGD) and the yield
of this procedure during pregnancy are still in debate. AIM: To determine the impact of
EGD on the clinical management of pregnant women with recurrent vomiting and their
pregnancy outcome. METHODS: We retrospectively evaluated 65 pregnant women who
underwent diagnostic EGD between January 1987 to October 2003. Computer analysis of
medical records for diagnostic codes, procedures codes, endoscopic results and pregnancy
outcome were obtained from the medical charts of the patients. RESULTS: Pregnant women
were divided into two groups according the indications for EGD: group1- intractable vomiting
with or without epigastric pain (n=54) and group 2- vomiting and gastrointestinal bleeding
(n=11). The endoscopic findings found in both groups were: esophagitis (28/65), gastritis
(10/65), normal EGD (19/65) and other (8/65). The diagnostic yield for EGD was 68% for
group 1 and 82% for group 2. EGD was helpful for clinical management when performed
for suspected gastrointestinal bleeding rather than for other indications. Mean gestational
age at delivery, fetal weight and mean Apgar score did not differ by groups. No fetal
malformations were observed. CONCLUSIONS: Results of EGD are not helpful for the
clinical management in pregnant women with intractable or recurrent vomiting except for
those with upper gastrointestinal bleeding. Whenever indicated, EGD can be safely performed
in pregnancy with no maternal or fetal complications.
M1084
The Utility of Immunohistochemistry in the Diagnosis of Viral Enteritis in
Small Bowel Transplant Recipients
Ivan A. Klement, Galen R. Cortina
BACKGROUND: Viral enteritis is relatively common in the immunosuppressed small bowel
transplant recipient, and must be distinguished from acute rejection to assure appropriate
clinical management of the patient. The purpose of this study was to assess the utility of
immunohistochemistry in the diagnosis of cytomegalovirus, adenovirus, and herpes simplex
virus infection in small bowel transplant (SBT) recipients. METHODS: Over a period of two
years, immunoperoxidase stains for cytomegalovirus (CMV), adenovirus (AV), and herpes
simplex virus (HSV) were performed on all biopsies of small bowel from transplant recipients.
In general, H&E stained slides were available to the pathologist the day after the biopsy
procedure, while immunoperoxidase slides were available after an additional one to three
days. The pathologist had the option of holding the case until immunoperoxidase slides
were delivered, or of issuing a preliminary diagnosis based on H&E stain, and then later
issuing an addendum to report the immunoperoxidase results. For this study, the results
of immunoperoxidase staining were compared to preliminary diagnoses based only on H&E
stain, and cases which were held for immunoperoxidase were compared to those in which
a preliminary diagnosis was rendered based on H&E stain. RESULTS: A total of 117 biopsies
from 35 patients were processed over the two-year period. For 13 of these biopsies, a final
diagnosis was issued based only on H&E stain, and immunoperoxidase results were not
recorded. For 11 biopsies, the case was held for immunoperoxidase; of these 10 were
negative for viral inclusions and one was positive for AV. For the remaining 87 biopsies, a
preliminary diagnosis was issued based on H&E stain and a subsequent addendum reported
the immunoperoxidase results. In this group, there was one discrepancy between H&E
diagnosis (negative for viral inclusions) and immunoperoxidase diagnosis (positive for AV).
However, overall, there were only 3 biopsies demonstrating AV infection, and no biopsies
were positive for CMV or HSV infection. CONCLUSIONS: In this series of SBT biopsies
collected over a two-year period, the utility of immunoperoxidase stains to detect viral
infection was modest, mainly due to the low overall frequency of positive biopsies. However,
the sensitivity of H&E for detection of adenovirus was only 67%, and furthermore, 9% of
the H&E diagnoses were deferred to immunoperoxidase. Thus, immunoperoxidase may a
useful adjunct method in selected cases where the clinical suspicion is high or the histologic
diagnosis is equivocal.
M1085
Prescribing of Acid Suppressive Therapy: Interactions Between Hospital and
Primary Care
Aleksander Krag, Jesper Hallas, Lars Teglbjerg, Axel Malchow-Moller, Peter Bytzer
Background: Overuse of acid suppressive therapy (AST) in the hospital setting as well as in
primary care is well documented. In Denmark the defined daily doses (DDD) of AST per
1000 inhabitants rose from 20,6 in 2000 to 28,6 in 2004. Data on the interaction between
prescriptions in primary and secondary care are lacking. Aim: To describe interactions
between prescriptions of AST in hospital and in primary care. Methods: In a 24-months
period all patients who were treated with AST while in the medical department were
identified. Details about the prescription were retrieved from electronic medical records. All
prescriptions on AST (H2RA and PPI) redeemed by these patients 12 months before and
after discharge were retrieved from a large prescription database, which has complete capture
of all prescriptions in the region. Results: 549 of 4477 patients (12.3%) were treated with
AST while in hospital, but AST was prescribed de novo in only 192 (35%) of these cases.
439 patients (80%) were discharged with AST. Information about indication for AST and
planned duration of therapy were given in the discharge letter in only 25% and 17% of the
cases, respectively. Among patients treated with AST during admission, prescriptions on
AST were redeemed by 67% in the year before admission and by 74% in the year after
discharge. Among patients who had the AST discontinued during admission (n=67), 48%
resumed AST within the following 12 months. Of all AST treated subjects in the catchment
area, 7.8% were seen in our department. Conclusions: Decisions about acid suppressive
therapy prescribing in hospital does not influence prescription behaviour in primary care.
Communication between hospitals and primary care concerning the background for AST
prescribing is insufficient and hampers rational pharmacotherapy.
Patients characteristics
De novo prescriptions compared with continued therapy
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M1086
The Availability of Faecal Occult Blood Tests Should Be Restricted in Hospital
Practice
Bernard Denis, Stephane Jux, Pascale Chiappa, Gilles Breysacher, Jacques Bottlaender,
Anne Marie Weiss, Andre Peter
FOBTs (faecal occult blood tests) are colorectal cancer (CRC) screening tools which are
sometimes used as diagnostic tests. Aim: to assess the appropriateness and diagnostic yield
of the use of FOBTs in hospital practice. Methods: retrospective chart review of all patients
hospitalized in medicine services at Pasteur Hospital (Colmar, France) who had a FOBT
during a 5 months period. FOBTs were performed on spontaneously voided stool samples
using immunochemical tests. Results: FOBTs were performed in 200 patients: 81 men and
119 women with a mean age of 71 years (range 20 - 98). FOBT was performed on a single
stool specimen in 58 patients (29 %), 2 samples in 32 (16 %) and 3 samples in 104 (52
%). No FOBT was performed for CRC screening. All were performed for the assessment of
anemia (n = 141), gastrointestinal symptoms (n = 30), weight loss (n = 44) or deep vein
thrombosis (n = 7). 23 patients had a doubtful FOBT result but were not retested. 65 had
a negative FOBT: 15 had nevertheless endoscopic procedures (6 colonoscopies, 3 flexible
sigmoidoscopies and 11 upper endoscopies) and 45 had no further gastrointestinal investi-
gation despite symptoms. 112 (56 %) had a positive FOBT: the test was repeated in 9 (8
%); 46 (41.1 %) had no further gastrointestinal investigation; 33 (29.5 %) had a colonoscopy
and 13 (11.6 %) a flexible sigmoidoscopy; 50 (44.6 %) patients had an upper endoscopy
even though immunochemical FOBTs fail to detect upper GI bleeding. The diagnostic yield
was colorectal neoplasia in 10 patients (CRC in 4 patients, adenomatous polyps > 1 cm in
1 and < 1 cm in 5) (positive predictive value = 8.9 %). Other endoscopic diagnoses included
6 non adenomatous polyps, 1 Crohn’s disease, 1 colonic vascular ectasia, 3 gastric cancers,
16 gastroduodenal ulcers, 1 reflux esophagitis and 1 portal hypertension. In the anemia
group, serum ferritin level had not been measured in 64 patients (41.6 %) and was normal
or increased in 75 (48.7 %). 15 patients had an iron-deficiency anemia: 10 had a positive
FOBT, 6 of them had a colonoscopy and 8 an upper endoscopy; 1 had a negative FOBT
but had both upper and lower endoscopy and 4 had a doubtful FOBT result, 1 of them
had a colonoscopy. Conclusion: the FOBT, which is validated only for CRC screening, is
almost always performed inappropriately in hospitalized patients. Whatever the result of
the FOBT, only a minority is followed by appropriate investigation. The rate of positive
FOBT is very high and the diagnostic yield quite low. Considering the potentially serious
medical consequences and the cost of this widespread misuse, the availability of FOBTs
should be restricted in hospital practice.
M1087
Audit of Biochemical Monitoring of Nasogastrically Fed Hospital Inpatients
Ranjan Sanyal, Sanjeev Kumar, Shankar Dhandapani, C Emm, K Mairs, D Barrett, W
Lycett, C Charles, K Evans, S.D. Hearing
Introduction: Malnourished patients given nasogastric tube feeding (NGTF) are at risk of
developing potentially fatal refeeding syndrome (RFS). British Society Gastroenterology (BSG)
guidelines recommend biochemical monitoring of all NGTF patients to detect and treat RFS
at an early stage. Aims and Methods: In Staffordshire General Hospital, UK, it is recommended
that all patients have biochemical monitoring including potassium, magnesium and phos-
phate performed for the first 4 days after NGTF is commenced, (Day 1 = 1st day after NGTF
commenced) as per BSG guidelines. We undertook a prospective audit of all adult hospital
patients receiving NGTF between Jan 2004 to Jan 2005. Result Number of patients = 93.
Median age (IQR) =71 (64-80) yrs. M:F ratio=1:1. Median duration of feeding (IQR) = 5
(2-14) days, 86 patients (92%) were malnourished at commencement and 42 (45%) had
poor oral intake in 2 weeks prior to NGTF. After NGTF, 28 (30%) resumed oral diet 16
(17%), 14 (15%) had a PEG placed and 3 (3%) received TPN. Overall 48 (52%) patients
died, 18 (19%) were discharged home, 22 (24%) to Nursing Home and 5 (5%) to other
hospitals. Indications for NGTF included CVA (41%) dementia (16%) and Parkinson’s
disease (11%). Patients were admitted to ITU (55%), medical (31%) surgical (11%) and
rehabilitation wards (3%). Electrolyte abnormalities were detected in 42 (45%) patients.
These patients were older (median 76 yrs), all were malnourished and 32 (76%) had
inadequate intake prior to NGTF. Of this subgroup, 26 (62%) died. Hypophosphataemia
was detected in 21 (22%) patients, requiring treatment (<0.5mmol/L) in 5 cases (3 intravenous
2 oral). Hypomagnesaemia was detected in 32 (35%) cases, requiring treatment (<0.5mmol/
L) in 6 cases (intravenous). Hypokalaemia requiring treatment was detected in 18 cases
(19%), all requiring treatment. Peak incidence of electrolyte abnormalities were hypomagne-
saemia (day 1) hypokalaemia (day 2) and hypophosphataemia (day 3). Biochemical mon-
itoring was incomplete and performed as follow: Day 1 Day 2 Day 3 Day 4 Phosphate 34%
34% 17% 17% Magnesium 48% 43% 27% 27% Potassium 73% 60% 34% 32% The above
table demonstrates that monitoring was incomplete and in particular measurement of serum
phosphate was low. Furthermore 10(11%) patients had no biochemical monitoring. 1 had
monitoring performed for all 4 days after NGTF was commenced. Conclusion These data
confirm that patients receiving NGTF are at high risk of developing electrolyte abnormalities



















Usefulness of Transabdominal Ultrasonography in Diagnosing Gastric
Submucosal Tumor
Madoka Nakao, Noriaki Manabe, Ken Haruma, Jiro Hata, Shinji Tanaka, Kazuaki
Chayama
OBJECTIVES: We have made reports about the usefulness of transabdominal ultrasonography
(US) in diagnosing gastric submucosal tumors (G-SMT). In the present study, we evaluated
the diagnostic ability of US in cases of G-SMT as well as the usefulness of the technique in
the follow-up of the course of the growth of G-SMT. METHODS: The present study assessed
the visualization rate and diagnostic ability of US in 206 subjects (104 males and 102
females; mean age: 56±15) who had been given the diagnosis of G-SMT during the period
from April 1995 to April 2004 and then underwent both endoscopic ultrasonography (EUS)
and US. Moreover, in 21 of the 206 subjects, we followed up the course of tumor growth
by US over the period of 38.6 months on average. RESULTS: In the 206 subjects, lesions
could be visualized in US in 84.5% (174/206 cases) and US-based diagnoses agreed with
EUS-based ones in 58.7% (121/206 cases). In the follow-up of the course of tumor growth,
no subject had a lesion which had been once visualized and given a specific diagnosis but
later became unvisualizable or was given different diagnosis. CONCLSION: US is useful in
diagnosing G-SMT and may be a useful examination technique for use in the follow-up of
the course of the growth of G-SMT which has been once diagnosed based on EUS findings.
M1089
Unique Case of Muscularis Mucosae Leiomyomata Polyposis
Christine M. Hobbs, Rehana Begum
Background: Leiomyomas of the muscularis mucosae (MM) are known to occur in the GI
tract. GI leiomyomas present as submucosal nodules and are usually incidental. Multiple
leiomyomas of the MM in the GI tract have not been previously described. Case: A 55 year-
old male was evaluated for heme occult positive stools, mild anemia and constipation. His
family history included a father with lymphoma and a sister with an intra-abdominal
malignancy of unknown primary site. Colonoscopy revealed numerous sessile polyps, 0.6-
1.3 cm, extending from the rectum to the ascending colon. Snare polypectomies were done
on one polyp from the ascending colon and four from the transverse colon. Subsequent
EGD showed multiple sessile polyps in the antrum and distal esophagus. Representative
antral polyps were biopsied. The duodenum was grossly normal. Microscopy of the ascending
and transverse colon polyps showed classic histologic features of benign leiomyomas of the
MM, namely, circumscribed bundles of cytologically bland, mitotically inactive, smooth
muscle fibers, moderate in cellularity, predominantly occupying the submucosa but contigu-
ous with the MM. The overlying mucosa was unremarkable. Case materials for the colon
polyps were sent to a GI pathology consultant who agreed with the original histologic
impression and confirmed the diagnosis immunohistochemically. Immunostains for desmin,
CD117, CD34 and S100 were performed on one of the colon polyps. The spindle cells were
diffusely and strongly positive with desmin and negative for CD117, CD34 and S100,
essentially excluding a GIST or neural tumor. Microscopy of the antral biopsies revealed
mucosal tissue only, as is typical for intramural lesions. Discussion: We refer to this patient’s
multiple leiomyomas of the MM of the GI tract as “muscularis mucosae leiomyomata
polyposis,” since this condition differs from leiomyomatosis, which occur exclusively in the
esophagus, the veins of the uterus, and the peritoneum (in fertile females). Management:
Since multiple leiomyomas of the MM have not been previously described, this patient will
continue to receive regular endoscopic follow-up with polypectomies of representative polyps
in each area of the GI tract along with polypectomies of any unusual polyps or polyps that
have enlarged. In the future, extramucosal excision of a few of the esophageal and gastric
antral polyps will be done to confirm their diagnosis. Capsule endoscopy is being considered
to evaluate the small intestine for polyps. No treatment other than polypectomies is expected
unless the patient should develop extensive ulceration of polyps with significant bleeding.
M1090
150 Endoscopic Mucosal Resections Carried Out Without Morbidity Having
High Adrenalin Submucous Infiltration in 4 Different Techniques in the
Digestive Tract
Mario Rey
Objective: Comparing 4 endoscopic mucosectomy techniques (EMR) in treating carcinomas
and premalign lesions in terms of complete resections, bleeding, perforations, recurrence
and survival in the digestive tract. Materials and Methods: 150 mucous or submucous lesions
were endoscopically analysed in 145 patients having an average age of 59.6 (23-83 years);
28 lesions were in the oesophagus, 79 were gastric, 4 duodenal and 39 colorectal having
an average size of 19.3 mms diameter which were resected using plastic cap (68 cases),
snare (45 cases), overtube (10 cases) or IT knife (27 cases) over a lapse of 6 years, following
submucousal infiltration with saline solution plus adrenalin at 1:1000. They had a 2.1 year
endoscopic follow up on average (0.2-7.1). Oesophageal lesions were type IIa and IIb ranging
from 5 to 20 mms, half were associated with Barrett’s oesophagus. 81.2% of those in the
stomach had an antral localisation; most rectal lesions were localised in the rectum and
sigmoid. Results: final histological diagnosis was 41 carcinomas, 13 carcinoids, 7 leiomyomas,
61 high and low dysplasias, 24 adenomas, 2 aberrant pancreas, an angiolipoma and a gist.
Most type I and IIa more severe lesions were resected with snare and overtube and flat or
depressed ones required cap and IT knife. There were no significant differences between
the average size of high degree dysplasias and carcinomas (15 mms cf 19 mms) p=0.17.
Lesions could be resected in one fragment in 85% of cases, mainly being done with IT knife
and endoscopic overtube. Resected lesions in several fragments were significantly associated
with the cap technique (p=0.02) and these with positive edges (3 cases). Recurrence was
identified in 1 carcinoid tumour (0.7%), extensive submucous infiltration in 2 lesions and
indifferentiation in another case requiring surgical treatment. 2 cases (1.3%) had metachron-
ous lesions after 1 and 3.5 year’s follow-up; these were initially resected with cap and then
treated again with mucosectomy leading to complete cure. No bleeding was presented during
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the procedure or later, perforations or mortality with the 4 EMR techniques in the series.
No side effects were found in relation to the high adrenaline dose infiltrated Conclusions:
Endoscopic resection of the mucous was seen to provide effective and safe treatment in
intramucous carcinomas and dysplasias when using the 4 techniques with high adrenaline
submucous infiltration. However, resection in fragments was shown to have greater risk of
having positive edges and recurrence associated with using the cap.
M1091
Prospective Randomized Controlled Trial Assessing the Impact of Feedback on
Small Bowel Biopsy Performance
Diahann L. Seaman, Gavin Harewood, Bret Petersen, Beverly Ott
Introduction: Endoscopy is an operator-dependent procedure that relies heavily on both
the judgment of the performing physician and their compliance with requests of referring
physicians. This study aimed a) to characterize small bowel biopsy (SBBx) practice among
patients undergoing EGD in whom SBBx was requested by the referring clinician, and b)
to prospectively assess the impact of feedback on SBBx practice among a large cohort of
endoscopists. Methods: Procedural data was recorded from all outpatient EGD procedures
performed between 07/01/05 and 10/28/05 for which SBBx was requested. Endoscopists
were randomized to receive feedback or no feedback on SBBx practice; randomization was
stratified according to endoscopist experience level. SBBx performance was recorded during
07/05 (pre-feedback baseline); the feedback group then received their performance data by
e-mail every three weeks for 12 weeks (total of four feedback e-mails) documenting the
proportion of patients in whom SBBx was performed when requested. Results: 54 endoscop-
ists were randomized to receive feedback (29) or no feedback (25, control group). There
was no difference in experience level between both groups (p=0.9) with overall mean of
10.3 yrs. In the feedback group, SBBx increased by 4.9%, from 87.1% (95% CI, 79-93%)
to 92.0% (95% CI, 90-95%), while in the control group, SBBx declined by 1%, 96.7% (95%
CI, 93-99%) to 95.7% (95% CI, 93-98%) (Figure1). Conclusions: Feedback by e-mail
appears to improve compliance among endoscopists for SBBx practice. Further study would
help to characterize the utility of e-mail feedback in enhancing uniformity in endoscopy prac-
tice
M1092
Use of Acid-Suppressive Therapy On the General Medical Ward
Ifat Kamin, Tandon Manish, Julio C. Ayala
Medications to suppress gastric acid are among the most commonly prescribed drugs in the
hospital and in the general practice. There is relatively little data regarding the overall use
and misuse of acid suppressive medications in the general medical ward population. The
purpose this study is to determine the frequency of appropriate or inappropriate use, and
indications for prescribing acid suppressive medications to patients admitted to the general
medical ward in a community teaching hospital. Chart review was undertaken of patients
admitted to Mount Auburn Hospital, who were prescribed acid suppressive therapy upon
admission or during their hospitalization. Data was gathered to determine the indication
for prescribing acid suppressive therapy, type of medication prescribed and whether the
medication was discontinued upon discharge. Note was also made if the patient was on
therapy prior to admission or started subsequently in the hospital. A total of 194 charts
were reviewed. Proton Pump Inhibitors were the most commonly prescribed (183 patients,
94%). Overall 111 of 194 acid-suppressive prescriptions (57.2%) were not indicated. Acid-
suppressive therapy initiated in the hospital was not indicated in 67 of 83 (80.7%) of the
patients, whereas among patients receiving therapy prior to admission, the frequency of
prescribing acid suppressive therapy without an indication was 44 of 111 (39.6%; p<0.05).
Of patients prescribed acid suppressive therapy in the hospital and subsequently discharged
on therapy, 25 of 37 (67.6%) of the prescriptions were not indicated. Among low risk
patients started on acid suppressive therapy for stress ulcer prophylaxis, 31 of 72 (43%)
were discharged home with a prescription for the medication. In our logistic regression
model we found that smokers were most likely to be put on acid-suppressive therapy for
a non-indicated reason (OR - 3.119, CI 0.952-10.2). The odds ratio for anticoagulants was
1.851 (CI 0.868-3.950), steroids was 1.174 (CI 0.482-2.860) and aspirin was 1.046 (CI
0.560-1.956). In conclusion, there is significant use of acid suppressive therapy in nonindic-
ated cases on the general medical service in the hospital. Majority of inappropriate prescrip-
tions are given for stress ulcer prophylaxis in low risk patients. A significant number of
these patients are discharged with a prescription to continue the medication, inducing further
inappropriate use of acid suppressive therapy.
M1093
How Accurate Is a Clinical “Hunch” After the First Office Consultation in
Gastroenterology Out-Patients?
Shital Amin, Niall van Someren, Kalpesh Besherdas, Steven Mann
Background: The United Kingdom National Health Service is under increasing pressure to
cut costs and process patients as quickly as possible. Investigations focused on the initial
working diagnosis are likely to be cost-effective if the clinical ‘hunch’ is accurate. Aim: To
review the accuracy of our working diagnosis after first consultation in the office. Method:
Consecutive new patients referred to Gastroenterology out-patient clinics (NVS, KB, SM)
were given a working diagnosis (12 categories) following the consultation. Data was then
re-analysed after appropriate investigations to determine the accuracy of the initial working
diagnosis. Non-parametric analysis was used to evaluate any associations. Results: Data were
available for 154 patients (F:n=78 [51%]). 95% of the initial diagnoses were the same as
the final diagnosis following a diagnostic work-up (χ2=16.93 (n-1) < p0.05=19.6). Conclu-
sion: Our initial “hunch” in out-patients is accurate in more than 95% of cases. This is very
reassuring and suggests that investigations can usually be targeted at confirming the diagnosis
avoiding unnecessary follow-up appointments which may generate further investigations.
We acknowledge that there will always be a few patients who are challenging and don’t fit
into an obvious diagnostic category.
Legend
M1094
Need for ERCP Delays Surgery in Patinets with Acute Cholecystitis
Christopher N. Dainiak, David Peretz, William Hale
Background: Until the 1970’s, common practice was to “cool down” patients with acute
cholecystitis and to subsequently perform open cholecystectomy several weeks later. In the
early 1990s, with the advent of laparoscopic CCY, acute cholecystitis was regarded as a
contra-indication to early operation. However, evidence from numerous retrospective and
prospective studies have shown that laparoscopic cholecystectomy within 72 hours of admis-
sion decreases length of hospital stay and cost, while also decreasing patient complications
and potentially mortality. Objectives: To describe our experience with acute cholecystectomy
in a community-based hospital and to assess performance of our hospital in comparison
with current recommendations. Methods: The authors performed a retrospective medical
record review from January to December 2004 of 50 consecutive patients with acute cholecys-
titis at our institution. Data collected included age, sex, symptoms and physical findings at
presentation, laboratory and radiological investigations performed (including ERCP), co-
morbidities, time from admission to surgery, length of stay, complications, and admission
service (medical or surgical). Results: Mean age at presentation was 56 years old (range 33-
79). Median length of stay was 5 days (1-20). 12/50 (24%) had a length of stay more than
6 days. Median time from admission to surgery was 24 hrs (1-204). 43/50 (86%) were
operated within 72 hrs of admission. 14/50 (28%) were operated on the day of admission.
Only 6/50 (12%) had surgery more than 72 hrs after admission. These patients with delayed
surgery required ERCP more often (67% vs 2%), had more underlying co-morbidities (83%
vs 48%), and had more post-operative complications (67% vs 15%). Admission to the
medical service vs the surgical service was associated with a prolonged time to operation
(65 hrs vs 19 hrs), increased length of stay (6.0 days vs 3.0 days), a greater likelihood of
a “cool down” period (18% vs 3%), and a greater likelihood of ERCP (36% vs 5%).
Conclusions: Early laparoscopic surgery for acute cholecystitis is being performed at this
community hospital consistent with current recommendations. Patients admitted to the
medical service are more likely to be older, sicker, and more often to require an ERCP. Patients
requiring ERCP are more likely to have delayed operations and post-operative complications.
M1095
Association Between Proton Pump Inhibitors and Respiratory Infections: A
Systematic Review and Meta-Analysis of Clinical Trials
Nabil Sultan, Jose Nazareno, Jamie Gregor
BACKGROUND: Proton pump inhibitors (PPI) have become the mainstay of treatment and
prevention of many serious gastrointestinal diseases. Increase in gastric pH caused by PPIs
may be linked to increased bacterial colonization of the stomach and possibly predispose
to respiratory infections. AIM: To examine the association of proton-pump inhibitor treatment
with respiratory infections. METHODS: A literature search was conducted in PubMed,
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Medline and Cochrane databases of randomized placebo controlled trials evaluating the
efficacy of proton pump inhibitors. Studies which listed and quantified the specific adverse
events of ‘respiratory infection’ or ‘upper respiratory infection’ (or equivalent) and compared
their rates between PPIs and placebo were included. Chi Square analysis was used to calculate
significance of association in individual studies and a meta-analysis of the selected studies
was performed. RESULTS: Out of 7457 studies initially identified and more than 60 relevant
RCTs selected, 7 studies met the inclusion criteria. A total of 16 comparisons for Chi square
analysis were possible given the multiple dosage arms used in several studies. PPIs included
in the studies included esoprazole, rabeprazole, pantoprazole and omeprazole. More than
half of the studies showed a trend towards association between PPI use and respiratory
infections, although the majority of the studies failed to show significant correlation. A single
study using high dose esoprazole (40 mg) showed a significant association: 4.3% rate of
respiratory infections in the active group compared to 0% in placebo (p<0.05). Meta-analysis
showed a trend towards association of PPI and respiratory infections, although it failed to
reach significance (odds ratio = 1.42, 95% CI:0.86 to 2.35, P=0.17). CONCLUSION:
Although a trend was evident in both Chi Square analysis of individual studies as well as
meta-analysis, this review and meta-analysis failed to show a conclusive association between
PPIs and respiratory infections. Our study revealed that very few RCTs actively sought out
respiratory infections which excluded the majority of RCTs identified. A well structured,
placebo controlled, prospective study would help determine if a true association between
PPIs and respiratory infections exists.
M1096
Misinterpretation of the Acid-Inhibitory Effect of PPIs in Western Populations
Due to Cyp2c19 Genotype?
N G. Hunfeld, B H. Graatsma, E J. Kuipers, W P. Geus
The acid-inhibitory effect of PPIs is influenced by the CYP2C19 status of an individual. In
Western populations 70% of the individuals are homozygous extensive metabolizers
(homEMs), 25-30% are heterozygous extensive metabolizers (hetEMs) and 2-5% are poor
metabolizers (PMs). In most studies with PPIs in Western populations the incidence of
CYP2C19 genotype and the influence of genotype on the acid-inhibitory effect have not
been assessed. Aim: To investigate the incidence of CYP2C19 genotype and the influence
of genotype on the acid-inhibitory effect of PPIs in studies performed in Western populations.
Methods: CYP2C19 genotype was assessed in Hp-negative Caucasian subjects who particip-
ated in 2 randomized two-way cross-over trials. In the first study the acid-inhibitory effect
of lansoprazole 15 mg (L15) was compared with omeprazole 10 mg (O10). In the second
study omeprazole 20 mg (O20) was compared with pantoprazole 40 mg (P40). In both
studies intragastric pH was monitored continuously for 24 hr at day 0 (baseline), day 1 and
day 6 of dosing. Subjects’ percentages of time above pH 4 in 24-hr periods were calculated,
corrected for baseline. Acid-inhibitory effects of hetEMS and PMs were compared to the
effect in homEms. Results: Study L15 vs. O10: 11 subjects: 6 subjects were homEMs (55%),
5 were hetEMs (45%). Study P40 vs. O20: 16 subjects: 12 subjects were homEMs (75%),
3 were hetEMs (19%) and 1 was PM (6%). At day 1, responses of hetEMs and PM were
significantly higher with O10, O20 and P40 compared to the homEMs (O10: p=0.04, O20:p=
0.004, P40: p=0.01), with L15 there was a trend visible. At day 6, a trend was seen towards
increased acid-inhibition in hetEMs and PMs for all studied PPIs. Individual responses and
median values are shown in Figure 1. Conclusions: In Western populations: 1.The acid-
inhibitory effect of PPIs is influenced by CYP2C19 status, especially at day 1 of administration.
2.Misinterpretation of the acid-inhibitory effect of PPIs is possible when (incidence of)


















Endoscopic Surveillance After Gastrectomy: What Do We Accomplish?
Mona Skoog, Stephen J. Sontag, Thomas G. Schnell, Jack Leya
Introduction: Gastric surgery (GS) is associated with a higher incidence of gastric adenocarcin-
oma (AdCa) and regular endoscopic surveillance is accepted as a means of early AdCa
detection. There is little information on whether such surveillance actually improves the
lives of those we seek to help. Nevertheless, large numbers of surveillance EGDs are performed
in GS patients (Pts). Methods: From our large Hines VA GI Database, which contains the
data of all procedures performed since January 1979, we identified all GS Pts who were
referred for EGD between Jan 1990 and July 2003. The electronic and paper records of
these GS Pts were reviewed in detail. The number of EGDs, EGD findings, Histology findings,
H. Pylori status and outcomes were recorded. A control group comprised all Pts without
GS (NGS) from the same period. The “Index EGD” was the first EGD performed at Hines
VA. Only Pts without AdCa at Index EGD were included. To avoid missing Pts with AdCa,
we used 3 identification methods: (1) the Hines VA GI Database, (2) the VA DHCP Pathology
Data System, (3) review of individual records. No systematic EGD surveillance or biopsy
protocol was followed. Results: Index EGD’s were performed on 347 Pts with GS and 2751
Pts with NGS. In both groups, 98-99% were males. The mean ages of the GS and NGS
groups at Index EGD were similar (63.8 Vs 63.9), but the mean follow-up times were
significantly different: 4.1 yrs Vs 5.3 yrs (Diff=1.2; CI: 0.7-1.7). The shorter follow-up time
was due to a significantly shorter survival of GS Pts (median survival: 79.7 Vs 81.9: X2=
6.0; P=0.01)(Hazard Ratio: 0.80; CI: 0.65-0.95), but this shorter survival was independent
of AdCa. During the 13-year period, 774 EGDs were performed to detect the 7 Ca’s in the
GS group. Incident Ca was detected in 7 (2.0%) of the 347 GS Pts: 0.5% per year. The
mean and median ages at diagnosis of Ca were 74 and 78 years, respectively, and the mean
time from index EGD to Ca was 6 years. Each Ca pt had an average of 4.3 EGDs. Of the
7 Ca pts: - 3 died of non-Ca related causes. - 1 died from complications 2 months after
total gastrectomy. - 3 died of metastatic disease from recurrent gastric AdCa. Conclusion:
Our data do not support surveillance of GS patients in order to detect early curable AdCa.
M1098
A Study On the Clinicopathologic and Endoscopy Ultrasonographic
Characteristics of Gastrointestinal Mesenchymal Tumor in 265 Cases
Ji Feng, Jianwen Ning, Lijun Wang, Guoqiang Xu, Youming Li
Objective:to investigate the clinicopathologic characteristics of gastrointestinal mesenchymal
tumor(GIMT) and combine with edoscopic ultrasonography(EUS) of pre-operation and
immunohistochemistry of post-operation for exploring the value of EUS in the diagnosis .
Methods: the morphologic characteristics of GIMT in 265 cases was observed by light
microscopy and the expression of CD117,CD34,SMA,S-100,KI-67 was detected by Envision
immunohistochemical method , 32 of 265 cases performed EUS examination were retro-
spected to explore the value of EUS in the diagnosis and differentiate benign and malignant.
Result:among 265 GIMT cases ,there were 146 gastrointestinal stromal tumor (GIST) cases
, 113 leiomyoma or leiomyosarcoma cases and 6 neurogenic tumour cases . CD117 showed
diffuse strong expression in 135 of 146(92.5%) GIST cases and CD34 in 109 of 146 (74.6%)
cases .SMA and S-100 were specially differential expressed in leiomyoma or leiomyosarcoma
and neurogenic tumour respectively. 7 among 9 GIST(77.8%) cases expressed ki-67 with
more karyokinesis(≥3/50HPF)were malignant tumors . Most borderline and malignant
tumors were found in male. The site specific positive predictive value of EUS for diagnosis
of leiomyoma(leiomyosarcoma) and GIST was 96.9%,qualitative diagnosis rate was
84.4%,differentiating diagnosis rate of nonmalignant and malignant was 71.9%. Conclu-
sion:GIST is the most common group of GIMT but not leiomyoma ,and it express various
differentiation and morphologies . In morphology it is difficult for GIST to be distinguished
from leiomyomas and neurogenic tumour .it is very necessary to distinguish them using a
series of immunohistochemical markers such as CD117,CD34,SMA,S-100 .The expression
of ki-67 combined with more karyokinesis supports diagnosis of malignant tumor . EUS is
helpful in evaluating the gastrointestinal origin of GIMT, in differentiating between benign
and malignant GIMT and in instructing clinical treatment and estimating prognosis.
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M1099
Effect of Serum Gastrin Concentration On Insulin Resistance
Yoshihisa Urita, Susumu Ishihara, Kenichiro Arai, Jun Kondo, Tastuo Akimoto, Hiroto
Kato, Noriko Hara, Hideyuki Koshino, Yoshiko Honda, Yoko Nagai, Kazushige Nagai,
Nagato Shimada, Motonobu Sugimoto, Kazumasa Miki
Background: Incretin hormones are gut-derived factors, which are secreted in response to
the presence of nutrients in the intestinal lumen, and which act to potentiate meal-induced
insulin secretion. Following oral ingestion the nutrients first come into contact with the G-
and D-cells of the antrumand elicit the release of gastrin and somatostatin. It has been
reported that gastrin-17 and its C-terminal tetrapeptideamide are able to stimulate insulin
in man. This suggests a possible association between serum gastrin and insulin secretion.
On the other hand, a serum gastrin level increases in patients with atrophic gastritis. We
therefore investigate the insulin secretion in patients with atrophic gastritis. Patients and
Methods: A standard 75 g oral glucose tolerance test (GTT) was performed in 42 subjects,
29 women and 13 men, aged 39-87 years. The patients received 75g (225 ml) of glucose
solution in the sitting position after an overnight fast. Venous blood samples were obtained
before ingestion and at 30, 60, 90, 120 minutes and blood glucose and serum insulin
concentrations were measured. A serum gastrin level was also measured before ingestion.
Results: A high value of serum gastrin more than 200 pg/mg was detected in 14 patients
who were classified into group G. The remaining 28 were classified into the control group.
HOMA-R was significantly higher in group G than in control (2.05 +/- 1.11 v.s. 1.44 +/-
0.71, p=0.036). Fasting insulin concentration and a total of insulin were also higher in
group G (6.3 +/- 2.4 μU/ml and 177 +/- 126μU/ml, respectively) but with no statistical
significance, compared with the control group (4.9 +/- 2.3μU/ml and 162 +/- 92μU/ml,
respectively). There was no difference in insulinogenic index, which was considered a
parameter of initial insulin secretion, between two groups (0.39 +/- 0.64 v.s. 0.29 +/- 0.29).
Conclusions: It is concluded that gastrin is a potential candidate to affect insulin resistance,
which has a close association with metabolic syndrome, We should duly recognize the effect
of serum gastrin concentration on insulin resistance when the patient receive a drug affecting
serum gastrin level, such as proton pump inhibitors, or H2-receptor antagonists.
M1100
The Efficacy of High Dose Ondansetron for Reducing Motion Sickness in
Highly Susceptible Subjects
Eric R. Muth, Amanda Elkins
Current drug remedies for motion sickness are not always effective and often induce undesir-
able side-effects such as drowsiness. Ondansetron is currently being explored as an alternative
due to its prophylactic effect on post-operative nausea, the nausea and vomiting associated
with chemotherapy, as well as its lack of side effects. There were 63 participants screened
to have a history of frequent motion sickness and positive report of self treatment of
motion sickness with over-the-counter medications selected from 750 student volunteers.
Participants were divided into three condition groups: placebo, 100 mg dimenhydrinate, or
24 mg ondansetron. Participants were given 1 of the 3 treatments 1 hour before exposure
to the rotating chair stimulus. Then participants were rotated in complete darkness for up
to 20 minutes at 20 rpm while making timed head movements. Electrogastrogram (EGG)
data were collected prior to and during chair rotation. 60 participants were included in the
overall data analysis while 48 were included in the EGG analysis. There were no statistically
significant differences between dimenhydrinate, ondansetron, or placebo in the number of
head movements tolerated, the amount of time tolerated in the rotating chair, or on subjective
motion sickness symptoms as reported on questionnaires. All groups showed a marginally
significant decrease in normal 3 cycle per minute activity (F[1,45]=3.04, p<.10) and a
significant increase in gastric tachyarrhythmia (F[1,45]=9.71, p<.05), a pattern typically
associated with motion sickness development. There were no significant differences between
the groups and no significant interactions of time (baseline vs. rotation) found in the EGG
data. This study revealed that ondansetron is not an effective remedy for motion sickness
for highly susceptible individuals. Interestingly, the findings that ondansetron did not affect
the gastrointestinal measures is in direct contrast with previous findings that suggest ondanse-
tron may inhibit tachyarrhythmia (Levine et al., 2000). This study also provides evidence
that dimenhydrinate may not be effective for reducing motion sickness in highly susceptible
individuals. From both a subjective and objective perspective, all groups developed motion
sickness. Interestingly, not even the “gold standard” dimenhydrinate treatment was effective.
Therefore, it appears that there is a group of motion sickness sufferers who lack the adequate
treatment that they need.
M1101
Autologous Haematopoietic Stem Cell Transplantation in Refractory Coeliac
Disease with Aberrant T-Cells : A Pilot Study
Abdulbaqi Al-Toma, Otto Visser, Cindy van Roessel, B Blomberg, Gerrit Ossenkoppele,
Peter Huijgens, Chris Mulder
Background: Autologous Haematopoietic Stem Cell Transplantation (ASCT) is now being
investigated for patients with severe refractory autoimmune disorders unresponsive to con-
ventional therapies. Refractory Coeliac Disease with monoclonal aberrant T cells (RCD-type
II) is usually unresponsive to available therapeutic regimens and carries a high risk of
transition into Enteropathy Associated T-cell Lymphoma (EATL) . The objective of this pilot
study is to assess the feasibility, safety and efficacy of high dose chemotherapy followed by
ASCT in patients with RCD type II. Methods: Four patients [ (3 males, 1 female, mean age
64.2 years (range 61-69 years )] with RCD-II have been treated. Stem cells were collected
by leucopheresis after pre-treatment with granulocyte colony-stimulating factor(G-CSF).
After conditioning with fludarabine and melphalan, ASCH was performed. Patients were
monitored for response of disease , adverse effects and haematopoietic reconstitution. Results:
All 4 patients completed the mobilization and leucopheresis procedures successfully and
subsequently received conditioning and transplantation. Engraftment occurred in all of these
patients. No major non-haematological toxicity nor transplant related mortality was observed.
Marked improvement of clinical condition was recorded in all patients (Follow-up 11.2
months, range 3-19 months ).There was a significant reduction in the percentage of aberrant
T-cells in duodenal biopsies associated with improvement in clinical wellbeing ,and normal-
ization of haematological and biochemical markers. Conclusions: High-dose chemotherapy
followed by ASCT seems feasible and safe, and might result in long-term improvement of
clinical condition in RCD patients with monoclonal aberrant T cells whose condition previ-
ously did not respond to the available drugs , and possibly prevents or delays the development
of EATL. Long term follow up and a prospective randomized study will be needed to confirm
the efficacy of this therapy.
M1102
Nature and Prevalence of Gastrointestinal Symptoms in Fabry Disease - A
Retrospective Analysis from the Fabry Outcome Survey
Bjoern Hoffmann, Martin Schwarz, Atul Mehta, Satish Keshav
BACKGROUND: Fabry disease is a rare X-linked lysosomal storage disorder caused by
deficiency of α-galactosidase A. The condition typically manifests in childhood with acropa-
raesthesia in hands and feet. The disease is progressive, and causes premature death from
cerebrovascular accident, cardiac failure, and renal insufficiency. In 2001 enzyme replacement
therapy (ERT) has been approved. So far, no systematic analysis of gastrointestinal (GI)
symptoms and their response to ERT has been documented. AIM: To describe the nature
and prevalence of GI symptoms in a large cohort of patients with Fabry disease and to
evaluate the possible response of these complaints to ERT with agalsidase alfa. METHODS:
Retrospective analysis of data from the Fabry Outcome Survey (FOS), which is a Europe-
wide registry of patients. Data from the medical history, physical examination, and clinical
investigations are recorded on entry into FOS, and updated periodically. In addition, specific
questionnaires are used to evaluate limb pain, and health-related quality of life. RESULTS:
752 patients from 11 countries in Europe had been enrolled in the database by October
2005. Evaluable clinical data on GI symptoms were available in 691 individuals (349 females
and 342 males). Mean age at entry into the database was 32.8+15.8 years, and 31.1% of
the patients reported abdominal pain at that time (34%.0 males, 28.0% females). Other
complaints include diarrhea (overall 21%; males 28.5% females 14.2%), nausea (14.8%;
16.0% vs. 13.6%), constipation (13%; 10.4% vs. 15.3% in females), and vomiting (8.8%;
10.4% vs. 7.4%). Despite the high prevalence of these symptoms, no cases were initially
diagnosed by GI physicians. CONCLUSION: GI symptoms in Fabry disease affect a large
proportion of patients, and increased recognition of the condition may now allow the prompt
initiation of a novel and effective treatment. Furthermore, quantification of these symptoms
may allow the rapid evaluation of the effect of ERT.
M1103
Quality and Outcomes Assessment of Endoscopic Retrograde
Cholangiopancreatography: A Prospective Audit of 500 Procedures
Bernard Denis, Andre Peter, Gilles Breysacher, Pascale Chiappa, Anne Marie Weiss,
Jacques Bottlaender
The American Society for Gastrointestinal Endoscopy (ASGE) recommended that some
quality indicators should be routinely tracked on all patients undergoing endoscopic retro-
grade cholangiopancreatography (ERCP)(GIE 2002). Aim: to assess the quality of ERCPs
performed in our hospital according to ASGE recommendations. Methods: prospective audit
of 500 consecutive ERCPs performed by 2 operators between July 2002 and November
2005. 45 process and outcomes measures were assessed for each ERCP. Results: mean age
was 69 years and 60 % were women. American Society of Anesthesia Score was III in 28.3
% of patients. An endoscopic ultrasonography (EUS) was performed before 33 % of ERCPs
(93 % during the same endoscopic session). During the same period EUS performance
avoided 110 unnecessary diagnostic ERCPs. The annual procedure volumes of both operators
were respectively 69 and 87 ERCPs (62 and 80 therapeutic ERCPs). The main indications
were bile duct stones (65.8 %) and malignant biliary obstruction (27 %). All were ASGE
approved. The procedure intent was diagnostic in 9 % of cases, therapeutic in 45.5 % and
mixed in 45.5 %. The procedure difficulty was grade 1 in 85.1 % of cases, 2 in 5.6 % and
3 in 9.3 %. Rates of complete technical success at first attempt were 92.7 % for cholangi-
ography, 94.5 % for pancreatography, 91.1 % for sphincterotomy, 87.9 % for stone extraction
and 80 % for stent insertion. Rates of success of cholangiography differed significantly
according to anatomy and indication: intradiverticular papilla (53.8 %), Billroth II (75 %),
choledocholithiasis (95.6 %), malignancies (88.7 %)(p < 0.01). A precut sphincterotomy
was needed in 7.8 % of ERCPs, successful in 87.1 % of cases. Rates of clinical success by
intent-to treat were 89.5 % for diagnostic procedures and 81.3 % for therapeutic procedures.
The latter decreased significantly with difficulty grade: grade 1 (83.8 %), 2 (71.4 %) and 3
(67.4 %)(p = 0.01). In case of cannulation failure, the appeal to a backup endoscopist was
successful in 72.2 % of cases. Second attempts after prior failure were successful in 80 %
of cases. The rate of complications was 3.6 % without difference according to operator,
difficulty grade, indication, and use of precut sphincterotomy. Conclusion: Modern imaging
techniques have lowered the rate of diagnostic ERCPs to less than 10 %. In the real world
the rate of clinical success of therapeutic ERCPs is around 80 %. This audit enabled us to
modify certain practices and to improve patient care: pancreatobiliary EUS prior to ERCP
to lower the rate of diagnostic ERCPs; appeal in case of failure to a backup endoscopist
either in the same session or in another.
M1104
Evaluation and Management of Patients Referred for Suspected Sphincter of
Oddi Dysfunction Type III (SODIII)
Niraj D. Jani, Jennifer Dorfmeister, Arnold Wald, Adam Slivka
Introduction: In clinical practice, SODIII comprises a heterogeneous group of patients
with abdominal pain and no objective markers of disease. Standard therapy, performing a
sphincterotomy of the biliary and/or pancreatic segment if basal pressures are elevated, is
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associated with high risk, variable outcomes, and lacks validation. Aims: To prospectively
characterize patients referred to a tertiary care center for evaluation and management of
SODIII. Methods: Sequential patients referred to a single provider for suspected SODIII over
a 3-year period were enrolled in an IRB-approved clinical registry. Patients with known
structural biliary abnormalities or elevated liver/pancreas enzymes were excluded. In addition
to routine labs/imaging, patients completed an SF-36™ quality of life (QOL) questionnaire
at enrollment and during subsequent office visits. Follow-up ranged from 2 months to 18
months. Physical and mental outcome scores were calculated to determine baseline and
treatment response. Results: 38 patients with abdominal pain (35 F/3 M), mean age 45 years
were enrolled. Common concurrent medical conditions included thyroid disease in 24%,
psychiatric illnesses in 22%, and cholecystectomy in 58%. Out of the 38 patients, only 4
(10%) met clinical criteria for SODIII according to Rome II consensus. Subsequent work-
up disclosed gastroparesis in 2 patients and breakthrough reflux in 1. The remaining 31
patients were assigned a diagnosis of functional bowel disease. Baseline SF 36 scores demon-
strated significant impairment in physical and mental well being for all patients. A total of
25 out of 38 patients including the 4 SODIII patients, were treated with visceral analgesics
(tricyclics) and/or anti-spasmodic agent. None of the patients were subjected to manometry
or sphincterotomy. For physical wellness, 17 (68%) improved (including 3 of the 4 SODIII),
5 had no change and 3 were worse. For mental wellness, 18 (72%) improved, 3 had no
change and 4 were worse. Conclusions: The vast majority of patients referred for evaluation
of SODIII does not meet defined clinical criteria, and should not be routinely subjected to
high-risk endoscopic procedures. Significant impairment in QOL exists in these patients.
Improvement can be expected with pharmacological therapy for functional disease in the
majority of patients, including those fulfilling criteria for SODIII.
M1105
Major GI Events Among Elderly Chronic Users of Coxibs and Non-Selective
NSAIDs, with/Without Aspirin
Jingshu Wang, C. Daniel Mullins, John Naradzay, Kimberly B. Howard
Objective: The gastrointestinal (GI) risks associated with the use of COX-2s versus traditional
non-steroidal anti-inflammatory drugs (NSAIDs) were documented in clinical trials. The
objective of this study was to estimate the rates of major GI events among elderly chronic
users of COX-2s versus traditional NSAIDs, with and without aspirin (ASA), in routine
clinical practice. Methods: This analysis utilized a retrospective cohort from the GE logician
database (Centricity EMR), which contained the medical records of 3 million patients seen
by 5,000 physicians across 27 states. Inclusion/exclusion criteria: chronic use (defined as 2
or more medication mentions of the same drug class within 60 days) of NSAIDs or COX-
2s between January 1, 1999 and June 30, 2003, age 65 or older on index date, no switch
between COX-2s and NSAIDs during the follow-up period, which continued until the earlier
of the end of one year or when a major GI event occurred. Major GI events were defined
as GI hemorrhage including melena (ICD-9 codes: 578, 578.0, 578.1, and 578.9). Descriptive
and multivariate logistic analyses were conducted to determine how the rate of major GI
events differed across chronic users of COX-2s (reference group), NSAIDs, COX-2s+ASA,
and NSAIDs+ASA. In order to account for channeling bias, we controlled for major and
minor GI events in the year prior to the index date, and prior GI protective drug use. Other
control variables included: gender, age, and pre or post-index GI harmful drug use. Results:
Of the 12,729 patients in the study, 7,338 were on COX-2s alone (105 major GI events in
the year prior to the index date and 127 in the year after), 3,826 were on NSAIDs alone
(40 and 79), 963 were on COX-2s+ASA (13 and 17), and 602 were on NSAIDs+ASA (4
and 16). Compared to chronic COX-2s-alone users, NSAIDs-alone users had a statistically
significantly higher rate of GI events (OR=1.35, 95% CI: 1.01-1.80). Chronic users of
NSAIDs+ASA also had a higher rate of GI events, and the effects approached statistical
significance (OR=1.68, 95% CI: 0.99-2.86). COX-2s+ASA users had similar rates of GI
events as COX-2s-alone users (OR=0.96, 95% CI: 0.57-1.61). Conclusions: The risk of
major GI events was highest among chronic users of NSAIDs+ASA, followed by those on
NSAIDs alone. Only the chronic users of NSAIDs alone had a statistically significant higher
risk than users of COX-2s alone. The addition of ASA did not significantly increase the risk
of GI events among COX-2 users.
M1106
Adverse Lower Gastrointestinal Effects of Non-Selective and COX-2 Selective
NSAIDs: A Systematic Review
Loren Laine, Rebecca A. Smith, Kejia Min, Connie Chen, Robert W. Dubois
BACKGROUND: NSAIDs have been suggested to cause adverse effects on the lower GI
(LGI) tract, but no published systematic review exists. We reviewed the literature on LGI
effects of non-selective (NS) and COX-2 selective (coxib) NSAIDs to determine if the evidence
indicates that they increase the risk of LGI effects and to determine if coxibs decrease the
risk compared to NS NSAIDs. METHODS: PubMed and Cochrane (CCTR) from 1950 to
2005 were searched. Inclusion criteria were studies of NSAID use reporting on LGI integrity
(permeability, intestinal inflammation, microscopic lesions), visualization of LGI lesions at
endoscopy or autopsy, and LGI clinical events (bleeding, perforation, diverticular disease).
Two reviewers independently evaluated 930 published titles, identified 46 studies that met
inclusion criteria, and performed independent data extraction. RESULTS: Study designs
were RCTs (N=18), case-control (N=13), cohort (N=8), and before-after comparisons (N=
7). Methodologic quality was highly variable. NS NSAID vs No NSAID or Placebo: 11 studies
assessed LGI bleeding: 2 underpowered RCTs had non-significant increases in bleeding with
NS NSAID (RRs 1.6, 0.5-5.0; 3.0, 0.1-73.6); 7 of 8 case-control studies had significant
associations with NS NSAIDs (ORs 1.9-18.4); and an 8-patient before-after study showed
no NSAID effect. The 2 LGI perforation studies (case-control) noted a significant association
with NS NSAIDs: ORs 2.5 (1.2-5.5), 8.1 (2.5-26.6). Complicated/symptomatic diverticular
disease was associated with NS NSAIDs in 5 case-control studies (ORs 1.8-11.2) and 1
cohort study (RR 1.5), but not in a 10-day RCT (RR 1.5, 0.1-36.5). Gross mucosal injury
(e.g., breaks, ulcers) was increased with NS NSAIDs in 5 of 7 studies; a low-dose aspirin
flexible sigmoidoscopy study (N=29) and a retrospective study of 96 colonoscopies showed

















vs NS NSAID: In the 2 RCTs, coxibs had fewer LGI clinical events (RR 0.5, 0.2-0.9) and
less hematochezia (RR 0.4, 0.2-0.8) than NS NSAIDs. In the 1 endoscopic study, coxibs
had fewer mucosal breaks than NS NSAIDs (RR 0.3, 0.2-0.5) but more than placebo (RR
2.2, 1.002-4.9). Coxibs caused less injury than NS NSAIDs in 3 of 4 integrity studies, but
no increase vs placebo in 2 of 2 studies. CONCLUSIONS: An increase in LGI injury and
clinical events with NS NSAIDs appears relatively consistent across this heterogeneous
collection of trials. Coxibs also appear to cause less LGI injury than NS NSAIDs. Additional
high-quality trials are warranted to more precisely estimate the effects of NS NSAIDs and
coxibs on the LGI tract.
M1107
Longterm Prevention of Esophageal Variceal Bleeding with rabeprazole :
Results of a 5 Year Study in Japan
Kuwayama Hajime, Nishiki Ryoichi
Our previous reported that the PPI treatment was effective in prevention of esophageal
variceal bleeding and recurrent variceal bleeding in cirrhotic patients. We investigated the
effect of rabeprazole (RPZ) in prevention of esophageal variceal bleeding in 5 years using a
randomized controlled trial design. Subjects & Methods: We enrolled 134 patients with
confirmed cirrhosis and esophageal varices. 41 of these patients had at least one previous
episode of confirmed variceal bleeding, and had been treated with endoscopic ligation. The
134 patients were randomized to receive either PPI (oral rabeprazole 20mg/day, N=73) or
no anti-secretory treatment (N=61), and followed for up to 5 years. Patient demographics
(age, gender, Child-Pugh score, variceal size, red color signs, and previous variceal bleeding)
were not significantly difference in both groups. The evaluated association between vareices
bleeding and patients risk factors, odds ratios (OR) and the corresponding 95% CI were
computed by means of logistic regression models. Results: The rate of variceal bleeding was
significant lower in the PPI-treated group (6.8%, 5/73) than the untreated group (26.2%,
16/61, P=0.0034). Five- year rate for occurrence of variceal bleeding, calculated by Kaplan-
Mayer analysis, was 14.0% in the PPI-treated group, which was significantly lower than the
rate of 29.0% in the untreated group, P=0.0019 by log rank test. Subanalysis of patients
with pre-study variceal bleeding (secondary prevention) showed that variceal re-bleeding
rate was significant lower in PPI-treated pts (10.0%, 2/10) than untreated patients (52.4%,
11/21, P=0.0063). Five-year rate for recurrence of variceal bleeding, calculated by Kaplan-
Mayer analysis, was 11.3 % in PPI-treated patients, significantly lower than the 56.5% rate
in untreated patients, P=0.0091 by log rank test. Rabeprazole use was found to be significant
factor for varices bleeding (OR: 0.207, 95%CI:0.071-0.604, P=0.0004. Conclusion: Rabepra-
zole treatment was effective in prevention of esophageal variceal bleeding and recurrent
variceal bleeding for 5 years.
M1108
Ethnicity and Gender Are Not Predictors of in-Hospital Mortality for Patient
with Initial Esophageal Variceal Hemorrhage
Linda Diteodoro, Juan Carlos Munoz, Louis Lambiase, Kenneth Vega
Ethnicity and gender have been found to effect the outcome of a number of conditions such
as heart failure, oral cancer, hepatitis C, post liver transplant infections, and survival after
portosystemic shunting. Recent advances in the management of bleeding esophageal varices
have lead to improvements in patient outcomes. Very little is known regarding the effect
of ethnicity and gender on outcome in these patients. Previously we found that African
American patients had a higher in-hospital mortality rate after their initial variceal hemor-
rhage. AIM:To examine a large sample of patients with variceal hemorrhage to determine
if there was any difference in presentation or outcome when the patients were grouped by
ethnicity or gender. Also, to determine whether ethnicity or gender were independently
associated with differences in in-hospital mortality. Methods: A retrospective study was
conducted. All patients undergoing endoscopy for their initial episode of esophageal variceal
bleeding from April 1999 to October 2005 were identified via the Shands Jacksonville
endoscopy database. These patient’s charts were reviewed. Data collected included: demo-
graphics, self reported ethnicity and gender, etiology of liver disease, clinical presentation,
laboratory data, Child-Pugh classification at presentation, variceal grade at endoscopy, initial
therapy for bleeding control and hospitalization outcome. The data was analyzed for differ-
ences between race and gender using one-way ANOVA and Kruskal-Wallis test. Further
analysis was performed via binary logistic regression using survival as the dependent variable.
Results:200 patients were identified. There were 150 Non-Hispanic Caucasians and 50
African Americans. There were 154 men and 46 women. The in-hospital mortality was
11.5%. African Americans were more likely to have a more prolonged prothrombin time,
lower albumin, more advanced grade of varices at endoscopy, and more advanced Child
classification at presentation (p<0.05). There was no difference in outcome between the
groups. Women were more likely to have lower diastolic blood pressure and less likely to
have alcoholic liver disease (p<0.05). There was no difference in outcome between men and
women. Logistic regression identified only age (p=0.001), lower systolic blood pressure at
presentation (p = 0.004) and prolonged PTT (p=0.01) as predictors of outcome. Ethnicity
(p= 0.866) and Gender(p=0.256) did not influence survival. Conclusion: Although African
Americans present somewhat differently than Non-Hispanic whites there does not appear
to be any difference in outcome between the two groups. Likewise, gender also appears to
not predict outcome.
M1109
Serum Markers of Prognosis Following Emergency Department Presentation
for GI Bleed
Sara M. Echelmeyer, Latha G. Stead
Objective: To study mortality after presentation to the Emergency Department (ED) for GI
bleed, and to determine whether any serum laboratory values were associated with a worse
prognosis. Methods: All patients presenting to the ED of an academic medical center for
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acute GI bleed between 1/2002-6/2004 were included. Patients had standard laboratory
evaluation. Time-to-event methodology was used for the analysis of patient survival. Duration
of follow-up was calculated from the date of ED visit to the date of death or last follow-
up, with all events censored at 1 year. Survival estimates were based on the Kaplan-Meier
method. Cox proportional hazards models were fit to evaluate the association between each
of the laboratory values and death. Associations were summarized with risk ratios (RR) and
95% confidence intervals (CI). Laboratory values were evaluated univariately by fitting
separate models, and then with a multivariate model using a combination of stepwise
backward procedures and an inclusion criterion of p<0.05. A total of 255 adults presented
during the study period. Of these, 24 denied research authorization. The cohort was 55%
male with a mean age of 64.2 years (SD, 18.0; median, 68; range, 18-100 years). A total
of 50 patients died; 9 within 30 days, 11 within 31-90 days, 9 within 91-365 days, 17
within 1-2 years, and 4 after 2 years. Among the remaining 181 patients alive at last follow-
up, the median duration of follow-up was 1.2 years (interquantile range, 0.5-2.0 years).
The survival estimates at 6-months, 1-year, 18-months, and 2-years following ED presentation
were 89.0%, 85.4%, 79.0% and 69.0%, respectively. Univariate analysis identified the
following variables as being significantly associated with poorer patient survival: older age,
leukocytosis, elevated creatinine, elevated troponin, elevated AST, elevated lactate, low
platelet count, low sodium, low bicarbonate, low chloride, high potassium, high glucose,
high aPTT, and high bilirubin (all p<0.05). Multivariate analysis identified older age, elevated
troponin, elevated creatinine, low sodium, and high aPTT as being jointly associated with
poorer patient survival. Conclusion: Hyponatremia, renal insufficiency, an elevated troponin
or aPTT are associated with increased risk of death at one year following ED presentation
for gastrointestinal hemorrhage.
M1110
Upper and Lower Gastrointestinal Findings in Patients with Anemia, But
Without Evidence of Iron Deficiency
Nick Powell, Alistair McNair
Background: Occult blood loss in to the gastrointestinal (GI) tract is the most common
cause of iron deficiency anemia (IDA). Evaluation of both the upper and lower GI-tract is
warranted to identify culprit lesions. IDA is readily defined by hemoglobin levels below
laboratory reference ranges in combination with microcytic/hypochromic red cell indices or
reduced serum ferritin concentrations. Gastroenterologists frequently receive referrals for
invasive investigation of patients with anemia in the absence of supporting evidence of iron
deficiency. Methods: We conducted a retrospective study designed to evaluate whether
significant GI-tract pathology exists in patients with a macrocytic or normocytic anemia and
elevated, normal or undetermined serum ferritin concentrations. For comparison we studied
a control group with documented IDA. We identified 130 patients referred to our unit for
endoscopic evaluation with a macrocytic or normocytic anemia without evidence of iron
deficiency. All 130 patients were investigated with upper GI endoscopy and 65 patients
(50.0%) were additionally investigated with colonoscopy or double contrast barium enema.
The comparator group comprised 201 patients with documented IDA (microcytic/hypch-
romic anemia and reduced serum ferritin concentrations), all of whom were investigated
with both upper GI endoscopy and lower GI tract investigations. Results: There were no
lower GI-tract malignancies identified in the 65 patients with a macrocytic or normocytic
anaemia who underwent either colonoscopy or barium enema, as compared to 23 colon
cancers diagnosed in patients with documented IDA (11.4%), (p<0.01). Similarly, there
were no upper GI-tract cancers found in the macrocytic/normocytic group as compared to
9 (4.5%) upper GI tract cancers found in their iron deficient counterparts (p<0.025). Other
potential cause of occult blood loss were identified in the upper GI tract (ulceration in the
esophagus, stomach or duodenum, celiac disease or vascular lesions) in 21.9% of patients
with documented IDA as compared to only 7.7% of patients without evidence of IDA
(p<0.001). Conclusion: Evaluation of the GI tract in patients with macrocytic or normocytic
anemia without evidence of iron deficiency has a very low diagnostic yield and is not war-
ranted.
M1111
Association Between Referral Indications for Open Access Upper GI
Endoscopy and Endoscopic Findings
Lieke A.S. V. Kerkhoven, Sally J. van Rijswijck, Leo G.M. van Rossum, Robert J.F. Laheij,
Ellen M. Witteman, Adriaan C.I.T.L. Tan, Jan B.M.J. Jansen
Background: General practitioners refer patients with gastrointestinal symptoms for open
access upper gastrointestinal endoscopy when symptoms possibly underlying a malignancy
are present or when empirical treatment fails to relief symptoms. The aim of this study was
to investigate the association between referral indications for upper gastrointestinal endos-
copy, as given by general practitioners, and endoscopic outcomes. Method: Endocopy
outcomes of consecutive patients who were referred to a primary care hospital for open
access endoscopy between January 2002 and December 2004 were included. Their general
practitioners were asked to specify the reason for referral on a specially designed form.
Relevant organic disorders were defined as findings at endoscopy that might explain symp-
toms or influence treatment strategy, i.e. gastroesophageal carcinoma, peptic and duodenal
ulcer, duodenitis, Barrett’s oesophagus or reflux-oesophagitis. Results: A total of 1,298
subjects was included. A relevant organic disorder was found in 35% of patients. Alarm
symptoms had a positive predictive value (PPV) of 4% for carcinoma and 5% for Barrett’s
oesophagus, while prevalences were 2% and 5%, respectively. The PPV of treatment failure
for carcinoma and Barrett’s oesophagus are 1% and 5%, respectively. The only indication
with a slightly increased PPV was reflux-like symptoms; PPV was 33% for reflux-oesophagitis,
while prevalence was 22%. Conclusion: None of the positive predictive values of different
referral indications varies substantially from prevalences of organic endoscopic findings.
Only reflux-like symptoms have a slightly increased PPV for reflux-oesophagitis, which is,
however, of little clinical relevance since this finding rarely alters therapeutic strategy. In
particular treatment failure and the presence of alarm symptoms, which are referral indications
for open access endoscopy as described in the Dutch guideline for general practitioners, are
not associated with any relevant organic finding. In conclusion, referral indications do not
distinguish organic from functional diseases.
M1112
Comparative Study On the Efficacy of Famotidine and Rebamipide for Gastric
Mucosal Lesions in Patients Receiving Long-Term Administration of NSAIDs
Junichi Yamao, Hideyuki Kojima, Akira Mitro, Motoyuki Yoshida, Masayuki Yoshikawa,
Eiryo Kikuchi, Masami Matsumoto, Masaki Nakayama, Tatsuichi Ann, Hiroshi Fukui
(Purpose) We used an endoscopy procedure to compare the effects of famotidine and
rebamipide on gastric mucosal lesions (hemorrhage and/or erosion) in patients receiving
non-steroidal anti-inflammatory drugs (NSAIDs) for a long period. (Subjects) The subjects
were 261 patients who had been receiving NSAIDs (excluding aspirin) for 28 days or
longer and were enrolled after providing written informed consent. (Methods) An upper
gastrointestinal endoscopy was performed in all patients, with and without symptoms. Gastric
mucosal lesions were evaluated using a modified LANZA scoring system. Patients with the
presence of gastric hemorrhage and/or erosion (LANZA score 1-4) were divided into 2
groups, F and R, by dynamic storage allocation based on the presence of the anti-Helicobacter
pylori antibody and LANZA scoring severity. Famotidine (20 mg/day) was administrated to
the patients in group F (n=57), while rebamipide (300 mg/day) was given to those in group
R (n=55). Without stopping NSAID administration, an endoscopy was re-performed following
the 4-week administration of famotidine and rebamipide. LANZA scores were evaluated by
a endoscopist who belongs to another institute and had no knowledge of the drugs used
or timing of the endoscopy. (Results) The screening endoscopic procedures revealed gastric
hemorrhage and/or erosion in 137 (52%) of the 261 patients, while gastric ulcers were seen
in 20 (8%), duodenal ulcers in 5 (2%), and combined gastroduodenal ulcers in 2 (1%).
Ninety-six (37%) of all patients had no gastric mucosal lesions. In addition, malignant lesions
were found in 3 (1%) patients (gastric cancer n=2, esophageal cancer n=1). The mean
LANZA score for group F significantly (p<0.001) decreased from 2.4 to 1.3 following the
4-week administration of famotidine, whereas that for group R did not show a significant
change (2.4 to 2.2, p=0.478). The efficacy ratios for group F and group R were 68% and
36%, respectively. The difference in LANZA score between before and after medical treatment
in group F (1.2) was significantly greater (p=0.002) than that in group R (0.2). (Conclusion)
Gastric mucosal lesions were observed in 63% of patients who had been receiving NSAIDs
for a long period. Famotidine demonstrated an excellent efficiency toward gastric mucosal
lesions (hemorrhage and/or erosion) induced by NSAIDs and during their continued adminis-
tration. We concluded that the effect of famotidine was significantly superior than that
of rebamipide.
M1113
Is a short Infusion of 80 Mg OMEPRAZOLE Once Daily the Optimal Dose for
Stress Ulcer Prophylaxis in ICU Patients?
W P. Geus, W J. Hofste, J A. de Haas, N G. Hunfeld, E J. Kuipers
Key factor in the prophylaxis for stress ulcer bleeding is a postulated critical pH target of
at least 4. It is known that PPIs such as omeprazole can give a more predictable and sustained
pH control during prolonged dosing than H2-receptor antagonists like ranitidine. However,
the optimal dose and way of PPI administration for stress ulcer prophylaxis need to be
established. Aim: To assess the acid-inhibitory effect of a short infusion of 80 mg omeprazole
given once daily in different ICU populations. Methods: Glass electrodes connected to data
loggers were positioned in the gastric corpus to monitor intragastric pH continuously during
day 0 (baseline) and day 1 and 2 of dosing in postoperative non-ventilated (NV) patients
and during day 0 and day 1, 2 and 3 in mechanically ventilated (V) patients. Only patients
whose intragastric pH fell below 4 for 70 % of time on day 0 (baseline) were included. At
day 1 all patients received a short infusion of 80 mg omeprazole. At day 2 patients were
randomized to placebo or continuation of omeprazole treatment. Severity of illness was
estimated in both groups with APACHE II score. Results: 17 patients were included in the
NV group and 10 in the V group. APACHE II score was significantly higher in the V patients
(16 vs.10, p=0.013). At day 0 median % of time with intragastric pH < 4 did not significantly
differ between the V and NV patients (98 vs. 94%, p=0.2). During day 1, following a single
dose of omeprazole the % of time < pH 4 was 9.7% in V patients and 48.8% in NV patients
(p=0.024). During day 2, NV patients had an intragastric pH < 4 for 3.9% of time when
treated with omeprazole (n=9), resp. 81% of time when given placebo (n=8, p=0.01). For
the V patients the corresponding figures were 8.6% after omeprazole (n=5) and 62% after
placebo (n=5, p=0.465). At day 3 the % of time < pH 4 in the latter group increased to
21.7% during omeprazole treatment and to 100% during placebo (p=0.113). Conclusions:
A once daily dose of 80 mg omeprazole given as short infusion is not the optimal dose for stress
ulcer prophylaxis in ICU patients: 1. In postoperative non-ventilated patients, intragastric pH
remains below the target pH of 4 for 49% of the first 24 hours. 2. In mechanically ventilated
patients the acid-inhibitory effect of this dose omeprazole is still insufficient after 72 hours
of treatment, with further increase of acid-output despite repeated treatment on consecut-
ive days.
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M1114
Disaster Medicine: Is Stress Ulcer Prophylaxis Needed for Crush Syndrome
Patients After Earthquakes? Experience of a Referral Hospital,Turkey
Hakan Akin, Zekaver Odabasi, Huseyin Atalay, Huseyin Kocak, Gulcin Kantarci, Nadi
Bakirci, Cetin Ozener, Osman Ozdogan, Nurdan Tozun
Objective: To determine the frequency and the risk factors of stress ulcer related gastrointesti-
nal (GIS) bleeding in patients with Crush Syndrome (CS) after Marmara Earthquake Disaster,
Turkey. Background: On 17 August 1999 a very destructive earthquake disaster has stroked
the north-west region of Turkey which has resulted in 17480 deaths and 43953 injured
victims. Marmara University Hospital was one of the nearest backup hospital to the disaster
epicenter. Methods: After the Earthquake out of 476 hospital admission, 87 earthquake
victims developed CS that mainly consist of acute renal failure secondary to the traumatic
rhabdomyolysis. All CS patients were given i.v. Famotidine 20mg/day from the first day of
the admission and observed for overt GIS bleeding related to stress ulcer. The possible risk
factors are determined by univariate and multivariate analyzes. Results: Out of 87 CS patients
nine (10.3 %) had overt GIS bleeding which was shown to be related to stress ulcers by
endoscopy. In 8 patients the bleeding was originated from upper GIS site whereas in one
patient it was both upper and lower site. All the bleeding patients were male. Mean bleeding
day was 7.7 ± 3.4 (between 3rd-14th days) after the rescue from the ruins. Mean age was
43.8 ± 19.2 years (range 24 -71 years).Seventy six CS patients were admitted within the
first 3 days of the disaster but 11 patients were transferred to our hospital after the third
day. Five patients out of 76 (6.6%) who were admitted in the first 3 days of earthquake
developed GI bleeding whereas 4 patients out of 11 (36.4%) that were transferred to our
hospital after the third day had GI bleeding (p: 0.012). All of the study patients had multiple
extremity trauma and 41 of them had (47.1%) fasciotomies. Intermittent hemodialysis was
needed in 58 of the patients whereas 29 patients could be managed by conservative renal
replacement therapy. In univaried analyzes; male sex (p: 0.01) and having no i.v. famotidine
treatment in the first 3 days (p: 0.01) were found to be the significant risk factors for GI
bleeding. In multivariate logistic regression analyze; initializion iv famotidine treatment in
the first 3 days was the only independent factor for the protection of stress ulcer related GI
bleeding in CS patients (p:0.007, beta:-2.55, OR:0.077, %95 CI 0.012-0.504). Discussion:
This is the only CS series report in the literature that evaluates specifically overt GIS bleeding
and its risk factors. In our series overt GIS bleeding is highly frequent in CS patients
group and intializing i.v. famotidine treatment within the first 3 days seems be decreasing
that significantly.
M1115
Use of Blatchford and Clinical Rockall Score in Screening Low Risk Patients
with Acute Upper Gastro-Intestinal Haemorrhage - Which Score Is More
Useful?
Asad R. Shah, Nadia A. Malik, David Sheridan, Athar Saeed
Introduction Acute Upper GI haemorrhage is one of the commonest medical emergencies.Re-
liable early identification of low risk patients can help guide decisions relating to early
hospital discharge and define a group of patients who may not even require endoscopy.
The risk scores employed either use clinical parameters only or include endoscopic findings
as well. Both Blatchford and Clinical Rockall Scores make use of only clinical parameters
to screen low-risk patients (a value of 0 for both). Objective The purpose of this study was
to assess the use of Blatchford and Clinical Rockall score in screening out patients at low
risk of re-bleeding and mortality and to find out which score screens more patients and
how effectively. Methods This study was conducted in two limbs. One limb was a retrospective
case-review of patients undergoing OGD for acute upper GI haemorrhage between November
2003 and March 2004 . The second limb was a prospective audit of patients presenting in
the Accident and Emergency Department with Acute upper GI haemorrhage between March
and May 2005. Both Blatchford and Clinical Rockall scores were determined for each patient
as were the endoscopic findings,length of hospital stay, the incidence of re-bleeding, surgery,
mortality. Results There were 37 patients in the first group and 45 in the second. The mean
ages were 57.5 years ( SD 19.9) and 61.1 years (SD 21.5) with a male predominance (57%
in both). The commonest presentation was haematemesis either alone or with melaena in
both groups. 4 (10%) and 8 (18%) patients were screened out as low risk by the Blatchford
score while the Clinical Rockall score was able to screen out 9 (24%) and 11 (24%) patients;
none of them had recurrent bleeding or died (100% negative predictive value). The Mean
age of the low-risk group was 39.2(SD 12.4, Range 19-57)years . The median length of
hospital stay was 1 day (range 1 -10 days). 16 of the 20 (80%) low-risk patients had
endoscopy; none had any stigmata of recent haemorrhage. The range of endoscopic diagnoses
was: 4 normal, 4 erosive esophagites, 1 gastritis, 1 Barrett’s esophagitis, 2 gastric erosions,
1 pyloric and 1 duodenal ulcer. The difference in performance of both scores was found
to be statistically significant (p=0.05). Conclusion Our study has validated both Blatchford
and Clinical Rockall scores to have equal negative predictive value for re-bleeding and
mortality. The Clinical Rockall score screens out more patients and therefore is more useful
than Blatchford score at identifying low risk patients. Furthermore a case can be made for
early discharge of the low-risk patients without having endoscopy
M1116
How Did Rofecoxib Withdrawal Impact on NSAID and PPI Prescribing?
Kathleen Bennett, Mary Teeling, John Feely, Colm O'Morain, Humphrey O'Connor
In September 2004 the selective COX-2 inhibitor rofecoxib (vioxx®) was withdrawn globally
from the market due to concerns about increased risk of cardiovascular mortality and
morbidity with its use. AIMS: The aim of this study was to examine the switching patterns
of patients prescribed rofecoxib after withdrawal in September 2004 to alternative non-
steroidal anti-inflammatory drugs (NSAIDs), and the impact this had on proton pump
inhibitor (PPI) prescribing. METHODS: A national prescribing database was used to identify
study subjects in the Eastern Health Region, the largest in Ireland. Medicines are coded

















(chronic use) between Jan-Sept 2004 were identified. A longitudinal monthly prescribing
history was used to determine the switching pattern to other COX-2 inhibitors, non-selective
(NS) NSAIDs or nimesulide (marketed as a COX-2 inhibitor) from Oct 2004-April 2005.
Chi-square tests and logistic regression was used to determine the likelihood of switching
to an alternative COX-2 inhibitor versus a NS NSAID, and the effects on coprescription of
PPIs. Adjusted odds ratios (for age and gender, ORadj) and 95% confidence intervals are
presented. RESULTS: A total of 1,954 patients were identified as chronic users of rofecoxib
prior to its withdrawal. Of these, 620 (31.7%) did not receive a prescription for any NSAID
after September 2005. Of the remainder, only 363 (18.6%) were switched to an alternative
COX-2 inhibitor; 404 (20.7%) to a non-selective NSAID, 207 (10.6%) to nimesulide, and
360 (18.4%) to a combination of NSAIDs. Of those who had received rofecoxib, 37.8%
were concurrently prescribed aspirin, compared with 27.6% of those prescribed NS NSAIDs
(n=13,677), between Jan-Sept 2004 (p<0.0001), and 44.2% were concurrently prescribed
a PPI compared with 29.4% on NS NSAID, between Jan-Sept 2004 (p<0.0001). The likelihood
of switching to an alternative COX-2 inhibitor versus a NS NSAID was related to aspirin
being previously prescribed or not (ORadj=0.66, 95% CI 0.49, 0.90), and male gender
(ORadj=1.39, 95%CI 1.01, 1.90). Chronic users of rofecoxib, who were previously on PPI
therapy, were most likely to continue on PPI therapy after rofecoxib withdrawal (ORadj=
27.6, 95% CI 21.4, 35.7). CONCLUSIONS: Withdrawal of rofecoxib usually led to either
withdrawal of NSAID therapy altogether or a switch to a NS NSAID. Rofecoxib withdrawal
had no obvious impact on coprescription of PPIs and patients continued with PPI therapy
after withdrawal. These prescribing trends also call into question the need for NSAID therapy
in the first place in a substantial proportion of patients.
M1117
Prevalence and Predictive Factors of Upper Gastrointestinal Symptoms in
Patients Treated with NSAIDs: COMPLAINS study
Gerard Thiefin, Rene-Marc Flipo, Thierry Schaeverbeke, Philippe Barthelemy, Christine
Soufflet
Introduction-Aim Ten to 40 % of all patients treated with NSAIDs complain of upper
gastrointestinal symptoms. The pattern of these symptoms and the factors influencing their
occurrence are not well known. The aim of this study is to evaluate the prevalence and type
of upper gastrointestinal symptoms in patients treated with NSAID as well as the predictive
factors of occurrence. Method This transverse epidemiological study was carried out on a
representative sample of hospital and private practice rheumatologists. The data were col-
lected using a standardized questionnaire from all patients over 18 years old, treated with
NSAID for at least 3 days and seen in consultation over a period of one week. Results Six
hundred and thirty rheumatologists included 8269 patients (4878 women; mean age : 57
± 15 years) treated by non selective NSAID (82.8 %) or by coxibs (17.2 %). Half of these
patients received their treatment for at least 2 weeks and 61.7 % received a gastro-protection
(PPI in 97 % of cases). The prevalence of the upper gastrointestinal symptoms was 34.7 %
(2799 patients): 7.6% of the patients suffered from heartburn, 8.8% acid regurgitation, 17.3
% epigastric burning, 14.3% epigastric pain/discomfort, 4.8% nausea and 4.3% bloating.
According to the definition used, the prevalence of gastroesophageal reflux (GER) symptoms
was: heartburn and/or acid regurgitation, 12.8% and pyrosis and/or acid regurgitation and/
or epigastric burn 24.5%. The prevalence of dyspeptic symptoms (epigastric discomfort/
pain and/or nausea and/or bloating) was 18.2 %. In multivariate analysis, the predictive
factors of GER disease were a history of GER symptoms (OR : 2.4) or upper gastrointestinal
symptoms (OR : 1.4). The predictive factors for dyspeptic symptoms excluding those associ-
ated with GER disease were a history of upper gastrointestinal symptoms (OR :3.5), UGD
(OR : 2) and GER disease (OR : 1.8). Age and sex did not have a significant effect. The
difference was not significant between patients treated with non selective NSAID and those
treated with coxibs. Conclusion One patient out of 3 treated with NSAIDs suffers from
upper gastrointestinal symptoms. Among those, symptoms of GER are most common. History
of upper gastrointestinal symptoms or GER or peptic ulcer significantly increase the risk of
upper gastrointestinal symptoms in patients treated with NSAID.
M1118
Identification and Distribution of Distinct Patterns of Symptoms in NSAID
Induced Dyspepsia: Results from a Survey in 3500 Patients
Dominique Lamarque, Philippe Goupille, Christine Soufflet, Pierre Clerson, Pierre-Louis
Prost, Philippe Barthelemy
Dyspepsia affects 10 to 40% of NSAID users. Dyspeptic symptoms are usually classified
using the Rome criteria. However these criteria have been established in non NSAID users.
The aim of this survey was to differentiate among the different patterns of dyspeptic symptoms
associated with NSAID. Methods: The study was conducted in a random sample of general
practitioners (GPs) who included patients with upper abdominal symptoms occurring or
worsening under NSAID treatment. Patients with history of abdominal surgery were excluded.
The following symptoms were assessed: epigastric pain, heartburn, eructation, regurgitation,
bloating, postprandial fullness, nausea and dysphagia. The intensity of each symptom was
graded from mild to severe. Risk factors associated with NSAID were searched. A multivariate
analysis was performed to isolate the independent patterns of symptoms. Distinct clinical
presentations were clusterized around these patterns (proc fastclus SAS 8.2 SAS Institute,
Cary, NC, USA). Results: From September 2004 to January 2005, 3500 patients entered
the survey. The analysis incorporated 81% of patients with a fully completed questionnaire.
The mean age (±SD) was 50 ± 14. 58% were male. History of heartburn or dyspepsia was
present in 29 % and 19%, respectively. Onset of symptoms occurred after initiation of
NSAID in 78%. Epigastric pain, heartburn, eructation, regurgitation, bloating, postprandial
fullness, nausea and dysphagia was reported in 90%, 70%, 34%, 34%, 33%, 29%, 22%
and 16% respectively. These symptoms were experienced daily on more than 60%. Multivari-
ate analysis isolated 14 patterns of symptoms and patients could be grouped within 3
clusters. The first cluster, which included 95% of the patients, was associated with mild to
moderate epigastric pain, heartburn and regurgitation. The second cluster (3.6%) included
patients with nausea, dysphagia associated with severe heartburn and regurgitation. The
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third cluster concerning 1.4% was characterized by bloating and postprandial fullness associ-
ated with severe epigastric pain. No risk factor was significantly associated with a specific
cluster. GPs stopped NSAID treatment in 54% (cluster 2 : 60% vs other clusters : 54%, p<
0.001) and referred 6% of the cohort to endoscopy (cluster 2 : 14% vs other clusters: 6%,
p<0.001). Conclusion. Gastroesophagal reflux and epigastric pain are the main clinical
complaints experienced under NSAID treatment. A cluster of patients with dysphagia and
severe gastroesophagal reflux was identified. Those patients more frequently stopped NSAID
and were referred to endoscopy.
M1119
Upper Gastrointestinal Symptoms in Patients Treated with NSAIDs :
Evaluation of Physician-Patient Agreement and Impact On Compliance
(COMPLAINS study)
Gerard Thiefin, Rene-Marc Flipo, Schaeverbeke Thierry, Philippe Barthelemy, Christine
Soufflet
The aims of the study were to evaluate the physician-patient agreement in the assessment
of upper gastrointestinal symptoms associated with NSAID intake, the impact on patients
daily life and the impact on the NSAID treatment compliance. Method This transverse
epidemiological study was carried out on a representative sample of rheumatologists. All
the patients were over 18 years old, treated with an NSAID for at least 3 days and were
seen in consultation over a one week period. The data were collected in a register by means
of a standardized questionnaire. In the first 2 patients with upper gastrointestinal symptoms
seen by each rheumatologist, 2 additional questionnaires were completed, one by the rheum-
atologist, the other by the patient, thereby enabling analysis of the physician-patient agree-
ment in the evaluation of the symptoms. Results 630 rheumatologists participated in this
study. 8 269 patients were included in the register. Among them, 1 213 patients presenting
upper gastrointestinal symptoms were selected for the physician-patient questionnaires. The
table summarizes the results of the questionnaires The physician-patient agreement was
good for the epigastric pain, poor for the heartburn (under-estimation by the physician)
and fair for the other symptoms. The fear of serious gastric complications was higher among
patients than among physicians (67.3% versus 38.3%). Thirty-five % of the patients said
that they were « fairly bothered » by the upper gastrointestinal symptoms and 16 % « a
great deal » or « enormously bothered » in daily life (5 graded Likert scale). The impact of
NSAIDs on daily life was under-estimated by the physicians. The occurrence of upper
gastrointestinal symptoms with NSAID resulted in the definitive withdrawal of the NSAID
treatment by the patient (10.8%), a temporary withdrawal (17.2%) and a reduction in the
dosage (5.8%). Conclusion The evaluation of the physician-patient agreement regarding
upper gastrointestinal symptoms associated with NSAID revealed : 1) an under-estimation
of the diagnosis of heartburn by the physicians and 2) an under-estimation of the impact
on daily life. Upper gastrointestinal symptoms also have a negative impact on NSAID
treatment compliance in one patient out of three.
Type and distribution of the upper gastrointestinal symptoms reported by the questionnaires
M1120
Concomitant Bisphosphonate Use Tends to Peptic Ulcer Formation in
Rheumatoid Arthritis Patients Taking Long-Term Non-Steroidal Anti-
Inflammatory Drugs
Kazumasa Miyake, Masafumi Kusunoki, Tomotaka Shindo, Tatsuhiko Hamamoto, Nobue
Ueki, Kenji Suzuki, Yoko Shinji, Tetsuro Hiratsuka, Hitoshi Nishigaki, Seiji Futagami,
Ken Wada, Katya Gudis, Taku Tsukui, Atsuo Nakajima, Choitsu Sakamoto
Objective: Non-steroidal anti-inflammatory drugs (NSAID) usage is aggressive factors for
peptic ulcer disease. Although patients with rheumatoid arthritis (RA) require long-term
therapy with NSAID, the pathogenesis of peptic ulcer in RA patients has been considered
to be multifactorial. Although elderly age, prior gastric event and concurrent use of anti-
coagulant or prednisolone (PSL) have been identified as markers of risk for NSAID-related
gastric event, high-risk NSAID users have yet to be characterized in Japanese population.
Therefore, we estimated the potential risk or the protective factors for peptic ulcer occurrence
in Japanese patients with RA taking long-term NSAID. Methods: Users of proton pump
inhibitors, prostaglandin, and high-dose histamine-H2 receptor antagonists (H2RA), which
have been demonstrated to have the high preventive effects for NSAID-induced peptic ulcers,
were excluded. 162 patients with RA treated over a long-term with NSAID were enrolled.
Their demographic data were recorded and laboratory data were measured. Endoscopy was
performed to assess the prevalence of peptic ulcer. Ulcers were defined as mucosal loss over
3 mm or mucosal loss accompanied by fold convergence. Helicobacter(H.) pylori infection
was diagnosed on the basis of serologic test and histological examination. The calculations
were performed using SPSS software (for Windows). Results: Thirty-seven (22.8%) of 162
RA patients had peptic ulcer disease, including 30 with gastric ulcer, 6 with duodenal ulcer
and 1 with gastric plus duodenal ulcer. 52 patients (32%) had used bisphosphonate (BP)
and 76 patients (48%) had H. pylori infection. The majority of peptic ulcer disease subjects
showed the characteristics of age>60 years and BP users (P>0.05). Multivariate analysis
revealed that BP use [odds ratio (OR), 2.38; 95% confidence intervals (CI), 1.01-5.59; P=
0.047] was the predominant risk factor for the development of peptic ulcer among these
patients, whereas regular or half-dose H2RA showed a tendency of protective role (OR,
0.38; 95% CI, 0.14-1.05; P=0.062). In another population which was composed of 29 RA
patients without NSAID and anti-ulcer agent treatment, no peptic ulcer disease was found
in BP users (0/12, 0%). Conclusions: Concomitant BP use tends to peptic ulcer formation
in RA patients under long-term NSAID treatment. It should be used with caution in
those patients.
M1122
Upper Gastrointestinal Bleeding in General Population: Prelimininary Results
of a French Prospective Study Including More Than 1000 Patients
Herve Hagege, Jean Paul Latrive, Bernard Nalet, Isabelle Rosa, Bruno Bour, Roger Faroux,
Philippe Gower, Jean Pierre Arpurt, Jacques Denis, Jean Henrion, Alex Pariente, Lizzie
Marek, Groupe Hemorragies Digestives Hautes Angh
Aims Upper gastrointestinal bleeding (UGIB) in general population represents a common
emergency in clinical practice. The aim of this study was to describe current epidemiology,
medical practices, morbidity and hospital mortality in a large, prospective series of UGIB.
Patients and methods The inclusion period is scheduled to be one year, from March 2005
to February 2006. From March 1 to August 31, 2005, consecutive patients with UGIB were
recruited in 53 French hospitals. Clinical, biological and endoscopic data were collected
until the hospital discharge. Results 1682 patients were included during this period of the
study. The current analysis includes the first 1080 patients: 729 men and 351 women, of
mean age 64 ± 17 years. The mode of presentation of the haemorrhage was hematemesis
with or without melena in 57% of the cases, melena only in 38% and acute anaemia in 5%.
At admission, systolic blood pressure was 120 ± 25 Hg mm and heart rate was 94 ± 20 /
min. Haemoglobin was 9 ± 3 g/dl. An antecedent of UGIB was noted in 23 % of the cases
and of cirrhosis in 33%. Before the UGIB episode, 11% of the patients had taken non
steroidal anti-inflammatory drugs, 28% aspirin or anti platelet agents and 10% vitamin K
antagonists. During endoscopy, signs of recent bleeding were present in 60 % of the cases.
The cause of the UGIB was attributed to: gastric ulcer in 129 cases, duodenal ulcer in 198,
gastroduodenal erosions in 62, esophageal or gastric varices in 228, portal hypertensive
gastropathy in 57, esophagitis in 233, oesophageal cancer in 8, gastric cancer in 18 and
other lesions in 73. Mean Rockall score was: 5.11 ± 2.34. Hemostatic therapy was performed
during the first endoscopy in 34% of the cases. Transfusion of 3.8 ± 2.6 units was realized
for 63% of the patients. Rebleeding occurred among 10% of the patients. In multivariate
analysis, predictive factors of rebleeding were: cirrhosis (p=0.01), anti platelet agents or
anticoagulants (p=0.04), blood systolic pressure (p=0.03), haemoglobin rate (p=0.01), Rock-
all score (p<0.0001) and transfusion (p<0.0001). In-hospital mortality was 9%. In multivari-
ate analysis, predictive factors of death were: age (p=0.008), precedent UGIB episodes (p=
0.003), systolic blood pressure (p=0.03) and Rockall score (p<0.0001). Conclusion During
upper gastrointestinal bleeding, mortality remains important in spite of medical management
progresses and particularly the use of endoscopic hemostasis. The continuation of this study
will allow knowledge of predictive factors for rebleeding and of mortality and also will
contribute to the improvement of medical management.
M1123
Modifying Physician Behavior On the Correct Use of IV Proton Pump
Inhibitors in the ICU
Dennis Sinar, Mary Seymour, James Worden
Background: Proton pump inhibitors, with their high safety and effectiveness, are used in
the ICU for a variety of clinical conditions. Purpose: to measure the effect of prescriber
education on appropriate use of intravenous proton pump inhibitors (IV PPI) in an ICU
setting. The study was conducted among two groups of tertiary medical center practioners:
private physicians (caring for their own patients) and academic physicians (orders written
by housestaff on monthly rotations through the ICU). For a 3 month baseline period followed
by a 3 month intervention period, all patients admitted to the ICU were included. During
each period, IV PPI use in each patient was assessed. Appropriate indications were defined
as treatment of gastric/duodenal ulcer and/or UGI bleeding and/or erosive esophagitis in
patients who are NPO (patients may have received oral PPI prior to admission). Appropriate
dosing was defined as a single bolus dose of IV PPI q24 hrs. Appropriate switch time was
when the patient resumed oral intake. In the academic/housestaff group the baseline period
was followed by a required monthly lecture and dialog with a GI attending reviewing
indications, dosing, and pharmacology of IV and oral PPI. Attendance at one or more of
the lectures was 95%. No informational lectures were given to private physicians. The
proportion of patients that physicians prescribed the correct indications, dosing, and appro-
priate switch to oral PPI during the 3 month intervention was compared to those proportions
at the baseline period for both groups. Results: 511 patients were included (total 372
academic, 139 private). Eighty five percent of ICU patients were on IV PPI during the
baseline period and 70% of ICU pts were on IV PPI during the test period. Unit acuity and
occupancy were similar during both periods. The academic/housestaff group showed a
significant improvement in correct dosing after lectures (37.3% to 62.7%, p < 0.001 Pearson
Chi Square); numeric improvements, but not significant changes were made in other measure-
ments. For private physicians, no change in practice was observed. The most common
incorrect doses were BID or infusion. Appropriate switches to oral medications or discontinu-
ation of PPI were high (94% academic, 88% private physicians). Conclusions: ICU patients
who are NPO have a high likelihood of receiving IV PPI. Instruction on indications, dosing,
and pharmacology can improve the physician choice of an appropriate PPI dose. In this
study population, there is a high appropriate switch schedule within 24 hrs of the patient
resuming oral intake to either receive oral PPI or discontinue PPI.
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M1124
The Value of Baylor and Rockall Scores in Inpatients with Non Variceal Upper
Gastrointestinal Bleeding
Jose A. Gonzalez-Gonzalez, Juan O. Gaytan-Torres, D.R. A. Garcia-Cantu, Hector J.
Maldonado-Garza, Arnoldo Guerrero-Chapa
Introduction: Differences in etiologies have emerged in recent studies in both outpatients
(OUTPTs) and inpatients (INPTs) with non variceal bleeding (NVB). Little data about the
use of Baylor score and Rockall score in INPTs is available Objectives: To compare the
clinical characteristics, bleeding etiologies, co-morbidities, Baylor score and Rockall score
among OUTPTs and INPTs with NVB.Material and Methods: We prospectively studied all
pts admitted to our institution with NVB (2001-2005) with information obtained from our
database. We studied age, gender, co-morbidities, alcohol, tobacco and NSAIDs use, history
of previous GI bleeding and Hp. status. We compared bleeding manifestations, diagnoses,
treatment, transfusions required, rebleeding, Baylor score and Rockall score, surgery and
mortality. Statistical Analysis: The variables are expressed as mean, range. Chi-square and
Fishers exact test were used for comparisons. Results. 653 pts: 85% OUTPTs; M/F 360/
197, mean age 58 vs 15% INPT; M/F 61/36 mean age 57. Risk factors as DM, CRF, HTN,
pulmonary and liver disease, OH, tobacco, NSAIDs use, Hp status and previous GI bleeding
was not different among OUTPTs and INPTs, only cardiac disease 9% (16%) was significant
in INPTs (p = 0.03). Presence of bright red blood hematemesis 36% (19%) and melena
64% (50%) was significant in OUTPTs (p= 0.001, p = 0.01). The gastric and duodenal
ulcer, tumors and erosive duodenitis, was not different. Only erosive gastritis was significant in
INPTs 23 % (33%) p = 0.04. The need for endoscopic treatment, units of blood requirement,
rebleeding rate and surgery was not different, only the mortality rate was more frequent in
the INPTs (p= 0.02). In the OUTPTs the Baylor score was useful to predict rebleeding and
mortality (p= 0.0001, p= 0.003) and the Rockall score was only significant for mortality
(p= 0.0001). Both scores for INPTs are shown in Table 1 Conclusions: In our study, INPTs
with NVB had more coronary disease, erosive gastritis and higher mortality when compared
to OUTPTs who usually presented with either melena or bright red blood hematemesis. In
OUTPTs, the Baylor score was useful in predicting re-bleeding rates and mortality but was
not useful in INPTs, whereas the Rockall score was helpful in predicting mortality in
both groups.
M1125
Deletion and G:C to A:T Transitions Are the Specific Mutation Patterns in the
Inflamed Colon of the IL-10 Knockout Mouse
Yuichirou Sato, Seiichi Takahashi, Yoshitaka Kinouchi, Eiki Nomura, Kenichi Negoro, Sho
Takagi, Hiroyuki Aihara, Tooru Shimosegawa
Background & aims: Individuals with inflammatory bowel disease are at increased risk of
developing gastrointestinal cancer. It has not been fully elucidated what kind of genomic
mutations is critical for tumorigenesis. Recently, a new transgenic mouse line, gpt delta
(gpt+), was established to facilitate the detection and analysis of mutations in vivo. The
striking feature of gpt+ mice is their ability to reveal deletions and point mutations. To
examine genotoxic effects of chronic inflammation of the colon, we used recombinant
mice, gpt delta IL10-/-, which spontaneously develop intestinal inflammation and facilitates
detection of genomic mutations. Then we characterized mutation spectrum of the inflamed
colon. Methods: Genomic DNA was extracted from the colon. The 6-TG selection(detection
of point mutation and small deletion) and the Spi- selection(detection of large deletion)
were performed. The 6-TG mutant frequency and the Spi- mutant frequency were calculated.
Then DNA sequencing of the mutants were carried out. Results: The 6-TG mutant frequency
of the inflamed colon in the gpt+IL-10-/- mice was about 5 times higher than that of the
normal colon in the gpt+IL-10+/+ mice. The frequency of G:C to A:T transitions of the 40-
weeks gpt+IL-10-/- mice was 4.1 times higher than that of the 40-weeks control mice, and
4.1 times higher than that of the 15-weeks gpt+IL-10-/- mice, and the small deletions and
insertions strikingly increased in the gpt+IL-10-/- mice. The majority of the deletion or
insertion mutations were observed in the monotonous base runs or adjacent repeats of short
tandem sequences. The Spi- mutant frequency of the inflamed colon in the gpt+IL-10-/-
mice didn’t significantly increase compared with that of the normal colon in the gpt+IL-
10+/+ mice, and the pattern of the mutations was not significantly different. Conclusions:
In our data of the gpt+IL10-/- mice, several types of mutations increased, but in the mutations,
short deletions or insertions in the monotonous base runs or adjacent repeats of short
tandem sequences and G:C to A:T transitions were striking mutations.
M1126
Risk Factors for Ulcerative Colitis-Associated Colorectal Cancers in a
Hungarian Cohort of Ulcerative Colitis Patients. Results of a Population-Based
Study
Laszlo Lakatos, Zsuzsanna Erdelyi, Gyula David, Tunde Pandur, Mihaly Balogh, Simon
Fischer, Peter Vargha, Peter L. Lakatos
Background: There is an increased risk of colorectal cancer (CRC) UC and prevalence of
UC-associated CRC is different in various geographical regions. The risk depends primarily

















for and the epidemiology of CRC in Hungarian UC patients. Patients and methods: We
retrospectively evaluated the relevant epidemiological and clinical data of all UC patients in
Veszprem province in our thirty-year IBD database (723 UC patients, m/f:380/343, familial
disease:5.2%, non-CRC related colectomies:3.7%). Results: CRC was diagnosed in 13 patients
(male: 6, female: 7, 13/8564 person year duration) during follow-up. The median onset of
UC in patients with UC associated CRC was 30 (13-61) years, 6 years younger compared
to UC patients without CRC. Median age of UC-CRC patients at diagnosis of CRC was 51
(27-70) years, almost 15 years younger than the average in sporadic CRC population in
Hungary (duration of UC at the diagnosis of CRC: 17 (1-33) years). Eight patients are still
alive (survival: 58.5 (10-163) months), five patients died because of CRC (survival: 6.5
months), one died due to unrelated cause after 10 years of the diagnosis of CRC. Longer
disease duration, chronic continuous disease, more extensive colitis, the presence of iron
deficiency or chronic anaemia, primary sclerosing cholangitis (PSC) and dysplasia were
identified as risk factors for developing CRC in univariate analysis. In a logistic regression
model longer disease duration, extensive colitis, PSC and dysplasia were associated with
increased risk. The cumulative risk for developing CRC after a disease duration of 10 years
was 0.6% (95%CI:0.2-1.0%), 20 years 5.4% (95%CI:3.7-7.1%) and 30 years 7.5% (95%CI:
4.8-10.2%). CRC diagnosed at surveillance colonoscopy was associated with a tendency for
longer survival (p=0.08). Conclusions: The cumulative risk of CRC was high in our UC
patients; however it was lower compared to that reported in Western European and North
American studies. CRC developed approximately fifteen years earlier compared to sporadic
CRC patients in Hungary. Longer disease duration, extensive colitis, dysplasia and PSC were
identified as important risk factor for developing CRC.
M1127
Increased CPG Methylation Status of Low-Grade Dysplasia in Patients with
Extensive Ulcerative Colitis
Niraj Jani, Yuan Yao, Adrian Gologan, Miguel Regueiro, Antonia R. Sepulveda
Introduction: With increasing duration of disease, patients with ulcerative colitis (UC) are
at increased risk of colonic dysplasia and cancer. Currently, histologic examination of colonic
biopsies is the only tool available to determine the presence and grade of dysplasia. CpG
methylation of multiple gene loci has been reported in colorectal cancer, and studies in UC-
associated neoplasia have focused on carcinomas and high-grade dysplasia. Little is known
about the CpG island methylation status in low-grade dysplasia (LGD) arising in UC patients.
Aims: To compare the promoter methylation status of p16INK4a, MLH1, and MGMT in
the background colitis-positive mucosa of UC patients and co-existing dysplastic lesions,
and to correlate the clinical phenotype with histologic findings and molecular genotype.
Methods: Cases were selected among UC patients identified with LGD from a prospectively
clinically phenotyped IBD patient registry. Fifteen biopsy samples of LGD from nine UC
patients and non-dysplastic mucosa from the same patients were studied. Normal colonic
mucosa from 10 individuals without UC or dysplasia was selected as control. Paraffin
embedded tissue sections were microdissected, DNA was extracted, and then treated with
bisulfite to convert unmethylated cytosines to uracils. Methylation specific PCR (MSP) was
performed with primers for p16, MLH1, and MGMT CpG islands. The presence of a band
on gel electrophoresis indicated methylation was present. Results: There were nine patients
with LGD, (7 M/2F), mean age 54.6 years. Mean duration of UC was 13.3 years. All patients
had extensive disease, moderate colitis activity and were on mesalamine. Positive CpG
methylation status for p16, MLH1 and MGMT was identified in the following number of
cases, respectively: 30%, 20%, and 10% in normal colonic mucosa controls; 13%, 36%,
and 10% in the background colitis-positive colonic mucosa of patients with co-existing low-
grade dysplasia; 42%, 60%, and 21% in dysplastic lesions. Although the differences were
not statistically significant trends could be observed towards increased frequency of methyl-
ation in LGD at the three loci when the background colitis-positive mucosa and the dysplastic
lesions of the same individuals were compared. Conclusions: The frequency of methylation
at each gene locus in LGD specimens was higher than in colitis specimens and the overall
frequency of methylation was higher in dysplasia and colitis specimens compared to normal
controls. Quantitative methylation analyses are needed to improve the diagnostic applications
of CpG methylation status to distinguish non-neoplastic mucosa from dysplasia in UC
patients.
M1128
Inflammatory Cells and Factors Modulate Intestinal and Mammary
Carcinogenesis in APCMin/+ Mice
Varada P. Rao, Theofilos Poutahidis, Zhongming Ge, Prashant R. Nambiar, Bruce H.
Horwitz, James G. Fox, Susan E. Erdman
Cancers of bowel and breast are increasingly frequent in humans in recent years. Chronic
inflammation is known to be a risk factor for these malignancies, yet cellular and molecular
mechanisms linking inflammation and carcinogenesis remain poorly understood. Here we
apply a widely used T-cell transfer paradigm, involving adoptive transfer of pro-inflammatory
CD4+CD45RBhi (TE) cells and anti-inflammatory CD4+CD45RBloCD25+ (TR) cells in mice,
to investigate roles of inflammation in the ApcMin/+ mouse model of intestinal polyposis. We
find that transfer of TE cells significantly increases intestinal and mammary tumor multiplicity,
whereas cotransfer of anti-inflammatory TR cells prevent tumors. Although TE cells promote
intestinal and mammary tumors in this model, cells of adaptive immunity are not required
for tumors. Indeed, Rag-deficient ApcMin/+ mice lacking functional lymphocytes develop
increased number of tumors in both intestine and breast when compared with ApcMin/+ mice.
Both intestinal and mammary tumors are abolished by neutralization of key pro-inflammatory
cytokine TNF-α. These findings define a novel mouse model of inflammation-driven intestinal
and mammary carcinoma and suggest that epithelial carcinogenesis is modulated by cells
and cytokines integral in inflammatory bowel diseases in humans and mice.
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M1129
Retrospective Analysis of Surveillance Colonoscopy for Patients with
Longstanding Ulcerative Colitis
Kenichi Shindo, Masahiro Iizuka, Hiroaki Itou, Shiho Sagara, Yasuo Horie, Sumio
Watanabe
[Background] The risk of colorectal cancer is critical for patients with longstanding ulcerative
colitis (UC). Thus, surveillance colonoscopy for such patients has been conducted to detect
colorectal cancer in early stage. However, it is controversial how we should perform the
surveillance colonoscopy, namely, with random biopsies or with targeted biopsies. We
retrospectively analyzed the results of surveillance colonoscopy for UC patients performed
in our hospital and assessed the effectiveness of the methods of surveillance colonoscopy.
[Methods] Surveillance colonoscopy was done 62 times for 23 patients with longstanding
UC (male 5, female 18; average age: 49.2 yrs) between 1987 and 2005. Between 1987 and
1998, surveillance colonoscopy was performed with 20 random biopsies and some targeted
biopsies from dysplasia-like lesions using 0.03% methylene blue. Between 1998 and 2005,
surveillance colonoscopy was performed with only targeted biopsies using 33% indigo
carmine dye spraying. [Results] In 62 times of surveillance colonoscopies, 822 biopsies were
taken. High- grade dysplasia was found in 3 patients (13%) with total colitis. Low-grade
dysplasia, or sporadic adenoma was found in 2 (8.7%), or 3 patients (13%), respectively.
All dysplastic lesions were detected by targeted biopsy from polypoid lesions, large polyp,
or flat elevations. No dysplastic lesions were detected by random biopsies. [Conclusion]
Our results suggest that the surveillance colonoscopy with targeted biopsies is more effective
for detecting dysplasia in patients with longstanding ulcerative colitis compared to that with
random biopsies.
M1130
Ordering the Activating Mutations of BRAF and KRAS Genes During
Oncogenesis in Inflammatory Bowel Diseases
Celine Bossard, Marc G. Denis, Jean-Paul Galmiche, Magali Svrcek, Jean-Francois Flejou,
Pierre Levillain, Anne-Sophie Thirouard, Claire Magois, Genevieve Aillet, Christian L.
Laboisse, Jean-Francois Mosnier
The search for KRAS mutations and BRAF mutations have contributed to our understanding of
sporadic colorectal oncogenesis. In fact, KRAS mutations are associated with the chromosomal
instability pathway while BRAF mutations are associated with the microsatellite instability
pathway. More than 80% of sporadic colorectal carcinomas (CRC) display either KRAS or
BRAF mutations, that are mutually exclusive. In order to explore the oncogenetic pathway
involved in inflammatory bowel disease (IBD)-associated oncogenesis, we studied BRAF and
KRAS mutations during the progression of inflammatory mucosa to colorectal cancer in a
series of 104 patients with IBD-related neoplasias [ulcerative colitis (UC) n=76, Crohn’s
disease (CD) n=27, and 1 indeterminate colitis]. Samples comprised adenocarcinoma (n=
79), high-grade dysplasia (n=17), low-grade dysplasia (n=37), indefinite for dysplasia (n=
7). We collected also samples from regenerative mucosa (n=9) and matched inflammatory
mucosa (n=35). We selected 22 patients with IBD without neoplasia (UC, n=20 and CD,
n=2) who served as controls. We determined BRAF codon 600 (V600E) (1) as well as KRAS
codon 12 and 13 mutations by a quantitative allele-specific PCR from genomic DNA extracted
from histologically microdissected paraffin-embedded tissue sections. BRAF mutations were
found in two lesions from 1 patient with UC, i.e. a serrated adenoma with low-grade
dysplasia and a mucinous adenocarcinoma from the right colon. KRAS mutations were found
in 21 samples from 10 patients (CD, n=9 and UC, n=1), including 12/70 adenocarcinoma
(17%), 8/49 dysplasia (16%) and 1 inflammatory mucosa (2.8%). One mutation was also
found in the inflammatory controls. We observed a mutually exclusive relationship between
BRAF and KRAS mutations. In conclusion, this study is the first to correlate the epithelial
changes (regenerative, dysplastic, cancer) to the molecular alterations in BRAF and KRAS
genes. Here we show that both BRAF and KRAS mutations occur early during the oncogenetic
process. Finally, although BRAF and KRAS mutations are less frequent, their proportion is
similar to that observed during sporadic CRC oncogenesis. (1) Jarry et al., Mol Cell Probes.
2004;18:349-352. Supported by grants “Projet Hospitalier Régional de Recherche Clinique”
BRD04/6/P and BRD05/10-C.
M1131
Are Crohn’s Disease and Ulcerative Colitis More Common Among Patients
with Digestive System Cancers in the U.S.? A Population-Based Case-Control
Study
Aasma Shaukat, David Howard, Jonathan M. Liff
Background: Adenocarcinoma of the small bowel has been reported in patients with Crohn’s
Disease. However, the association of Crohn’s Disease and Ulcerative Colitis with esophageal,
gastric and small bowel adenocarcinoma has not been well studied at the population level.
Aims: To study the prevalence of Crohn’s Disease or Ulcerative Colitis (CD/UC) among
cases with adenocarcinoma of esophagus, stomach, small bowel and colorectum and compare
it to the prevalence in controls never diagnosed with one of these tumors using a nationally
representative database. Methods: We used the SEER-Medicare database, which consists of
records from the SEER cancer registry linked with Medicare claims. Cases consisted of
patients 65+ diagnosed with cancer of the esophagus, small intestine, colon, rectum, and
stomach diagnosed in 1994-1999. Controls consisted of Medicare beneficiaries never dia-
gnosed with one of these cancers but residing in a SEER registry catchment area. We required
that both cases and controls be enrolled in Medicare for at least two consecutive years. We
identified CD/UC using the ICD-9 codes on Medicare outpatient, office, and inpatient claims
during the two year window centered on the date of diagnosis for cases or a randomly
selected date for controls. We assessed the statistical significance of differences between
groups using logistic regression controlling for age (65-74 yrs, 75-84 yrs, 85+ yrs), sex, and
year of diagnosis. Results: The final sample consisted of 62,097 cases and 99,485 controls.
The prevalence of CD/UC, standardized by age and sex to the 2001 US population, among
cases was 0.95% versus 0.40% for controls (p < 0.001). There was a significant association
between CD/UC and adenocarcinoma of the stomach (OR 1.972; 95% CI: 1.485, 2.617;p-
value <0.001), small bowel (OR 7.22; 95% CI 4.97, 10.629; p-value <0.001) and colorectum
(OR 2.76; 95% CI 2.408, 3.179; p-value <0.001). Among cases, the age and sex-standardized
prevalence of CD/UC by tumor type was as follows: esophagus, 0.43%; stomach, 0.71%,
small bowel, 2.84%; colorectum, 1.10%. Among cases, the prevalence of CD/UC was higher
among patients diagnosed with a non-gastrointestinal cancer (for example, lung cancer),
0.92%, versus cases never diagnosed with cancer of any type, 0.39%, suggesting confounding
by some other factor or a detection bias. Conclusions: These results suggest that the prevalence
of esophageal, gastric, small bowel and colorectal adenocarcinoma is higher in patients with
Crohn’s Disease or Ulcerative Colitis. However, the higher prevalence of Crohn’s Disease
or Ulcerative Colitis among cases may be due in part to better detection.
M1132
Cytokeratin 7/20 and Mucin Core Protein Expression in Ulcerative Colitis-
Associated Colorectal Neoplasms - A Distinct Histogenetic Pathway Showing
Gastric Phenotype
Natsuko Tatsumi, Ryoji Kushima, Michael Vieth, Ken-Ichi Mukaisho, Hidetoshi Okabe,
Rie Kakinoki, Franz Borchard, Manfred Stolte, Takeshi Okanoue, Takanori Hattori
INTRODUCTION: Different histogenetic pathways have been suggested between ulcerative
colitis (UC)-associated neoplasia and sporadic colorectal neoplasia. Little is known about
the cytokeratin (CK) and mucin expression in UC-associated neoplasms. CK7 has also been
reported to be a possible marker of transient dedifferentiation in the sequence between
gastritis, metaplasia, dysplasia and cancer of the stomach. AIM: In this study, we targeted
the expression of CK7, CK20, MUC2, MUC5AC and MUC6 in UC-associated colorectal
neoplasms as compared it to sporadic colon adenomas and adenocarcinomas, to further
investigate colitic cancer carcinogenesis. MATERIAL AND METHODS: we examined the
immunohistochemical expression of CK7, CK20, MUC2, MUC5AC and MUC6 in 90 colorec-
tal neoplasms; including 22 UC-associated adenocarcinomas (colitic cancer; CC), 10 high-
grade dysplasias (HGD) in UC, 9 low-grade dysplasias (LGD) in UC, 24 sporadic tubular
adenomas (TA) and 25 adenocarcinomas (AC). The extent of positivity was scored according
to the percentage of neoplastic cells stained: -, no positive cells or essentially none (<5%);
1+, some positive cells (5-30%); 2+, well-defined areas of positive cells (30-60%); 3+,
extensive areas of positive cells (>60%). The chi-square test with Yates correction was used
for statistical analysis. Differences were considered to be significant at p<0.05. Fisher’s test
was applied whenever appropriate. RESULTS: CK7 was positive in most of UC-associated
neoplasms: 59% of CC cases, 80% of HGD and 89% of LGD respectively, whereas in non-
UC associated neoplasia 21% of TA and 12% of AC. None of sporadic adenoma-carcinoma
group showed 3+, whereas 39% (16 of 41) of UC-associated neoplasms expressed 3+. The
frequency of MUC6 expression in UC-associated neoplasia was 32% in CC, 30% in HGD
and 44% in LGD respectively, whereas in non-UC associated neoplasia: 4.2% in TA and
0% in AC. MUC5AC expression in UC-associated neoplasia was detectable in 73% of CC,
90% of HGD and 89% of LGD respectively, in non-UC associated neoplasia 67% in AC
and 20% in TA. There were obvious differences in the expression of CK7 and MUC6 between
UC-associated neoplasms and sporadic tumors. The incidence of MUC5AC expression in
UC-associated neoplasms was also higher than sporadic tumors. There was no significant
difference in MUC2 and CK20 expression among all categories. CONCLUSION: These
results suggest that UC-associated neoplasms develop and progress under induction of gastric
differentiation. CK7 and gastric-type mucins may be useful in the differential diagnosis
between UC-associated neoplasms and sporadic tubular adenomas and adenocarcinomas.
M1133
Hepatocyte Growth Factor May Not Accelerate Neoplastic Development in
Two Experimental Models
Masatsugu Numata, Mayumi Kodama, Hirofumi Uto, Chihiro Nakanishi, Shuji Kanmura,
Hiroo Abe, Tadashi Miike, Kazunori Kusumoto, Satoru Hasuike, Kenji Nagata, Katsuhiro
Hayashi, Akio Ido, Hirohito Tsubouchi
[Background] Hepatocyte growth factor (HGF), originally purified from the plasma of patients
with fulminant hepatic failure, is the primary agent that promotes hepatocyte proliferation.
HGF also functions as a pleiotropic factor, acting as a mitogen, morphogen, and motogen
for multiple subsets of epithelial cells, including gastrointestinal epithelial cells. Recently,
we reported that HGF promoted colonic mucosal repair in animal models of experimental
colitis; thus, HGF has the potential to be an important new treatment modality that promotes
intestinal mucosal repair in patients with inflammatory bowel disease (IBD). However, we
cannot exclude the possibility that the repeated administration of recombinant human HGF
might accelerate carcinogenesis. This study sought to clarify if repeated administration of
recombinant human HGF affects colonic carcinogenesis in two experimental models.
[Methods] (A) F344 male rats were injected subcutaneously with 1,2-dimethylhydrazine
(DMH, 20mg/kg body weight) once a week for four consecutive weeks. Four weeks later,
recombinant human HGF (0.5mg/kg/day) was injected intravenously every day for four
weeks. Control rats were injected with PBS. (B) F344 male rats were injected subcutaneously
with DMH (40mg/kg body weight) three times a week. The 1.0% dextran sodium sulfate
(DSS) is administered to the rat concomitantly with the DMH, rats were also administered
DSS for 2 weeks . Recombinant human HGF (0.5mg/kg/day) was injected intravenously for
2 weeks during the administration. These rats were maintained until final sacrifice at week
26. Control rats were injected with PBS. [Results] Recombinant human HGF did not affect
the size of DMH-induced colonic aberrant crypt foci (ACF) compared to PBS-treated rats.
Furthermore, development of ACF or colorectal tumors induced by DMH/DSS was not
significantly accelerated by administration of human HGF compared to control rats. The
incidence of adenocarcinoma and multiplicities did not differ significantly between HGF-
and PBS-treated rats. [Conclusions] These findings suggest that HGF may not accelerate
neoplastic development in the colon.However, because the possibility of HGF-associated
carcinogenesis has not been completely excluded, complete informed consent is required.
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M1134
High-Resolution Endoscopy and the Additional Value of Chromoendoscopy in
the Evaluation of Duodenal Polyposis in FAP-Patients
Evelien Dekker, Jan Dees, Lisbeth Mathus-Vliegen, Jan Werner Poley, Johan Offerhaus,
Joep Bartelsman, Ernst Kuipers, Paul Fockens
Introduction: Duodenal polyps occur in approximately 90% of all patients with familiar
adenomatous polyposis (FAP). An estimated 5% of them develop duodenal cancer, nowadays
being the leading cause of death in FAP-patients. Endoscopic surveillance of the duodenum
has become standard care in these patients, making use of the Spigelman classification. This
classification includes number, size and histology of duodenal polyps and correlates with
the risk of developing duodenal cancer. Guidelines for endoscopic surveillance have been
developed in which interval is dependent on the Spigelman-classification. Since the introduc-
tion of these guidelines, the quality of endoscopic imaging has dramatically improved and
chromo-endoscopy has further enhanced our ability to detect small polyps. Aim: To investig-
ate the use of high-resolution endoscopy and the additional value of chromoendoscopy in
the evaluation of duodenal polyposis in FAP-patients. Methods: All consecutive FAP-patients
scheduled for a surveillance endoscopy in 2 academic centers underwent gastroduodenoscopy
with high-quality forward- and sideward-viewing endoscopes. After scoring the number and
size of polyps in the duodenum (bulb, DI and DII seperately), indigocarmine 0.5% was
sprayed onto the mucosa and the polyps were scored again. Biopsies were taken from the
larger lesions and the papilla and were evaluated by an expert pathologist. Spigelman
classifications were assessed for both procedures. Results: A total of 47 endoscopies were
performed in 39 patients (19 men, mean age 48 yrs) were examined. Before the application
of dye, in 37 patients (95%) duodenal polyps were seen. Spigelman-classifications were:
stage 0, 2 patients (5%); stage I, 2 patients (5%); stage II, 9 patients (23%), stage III, 13
patients (33%) and stage IV, 13 patients (33%). The papilla was enlarged in 21 patients
(54%); biopsies revealed dyplasia in 18 (46%). Chromoendoscopy detected more duodenal
polyps in 13 procedures (mean # of polyps 27 vs 30, p=0.03) and maximum size of the
polyps increased in 5 (15 vs 16 mm, NS). The total number of points for the Spigelman-
classification was increased in 7 procedures. However, this resulted in an increased Spigel-
man-classification in only 3 (6.4%). Discussion: Compared to historic endoscopic studies
evaluating duodenal polyposis in FAP-patients, the use of high-resolution endoscopes results
in increased polyp detection and subsequently a higher Spigelman-score. Although chromo-
endoscopy detected significantly more polyps, this resulted in a higher Spigelman stage in
only 6% of endoscopies and therefore its additional value seems to be limited compared to
high-resolution endoscopy.
M1135
Novel Fiberoptic Confocal Fluorescence Microendoscope
Shai Friedland, Roy Soetikno, Jonathan Liu, Peyman Sahbaie, Mandeep Singh, James
Crawford, Christopher H. Contag, Thomas D. Wang
Background: Confocal fluorescence microscopy (CFM) provides high resolution images of
tissue with optical sectioning, and has the potential to provide in vivo histopathology. Here
we demonstrate the use of a novel catheter-based confocal imaging system (Cellvizio-GI,
Mauna Kea Technologies, France). Methods: Images were collected from 180 patients under-
going routine upper and lower endoscopy. The mucosa was prepared by spraying 5% acetic
acid followed by 0.05% fluorescein. 0- and 50-micron working-distance probes were used
to obtain fluorescence images at 12 frames per second using 488nm excitation. Results:
Architectural and cellular features of normal mucosa were readily appreciated. Significant
differences in glandular architecture and fluorescein uptake between normal and neoplastic
colonic mucosa were observed. Average lamina propria fluorescence intensity was 94 ± 4
in normal mucosa and 44 ± 14 in adenoma. Average intensity in the basolateral colonocyte
border was 96 ± 24 in normal mucosa and 172 ± 16 in adenoma. The fast frame rate of
the device allows for tracking of dynamic physiological events such as fluorescein uptake
into tissue and cellular movement within mucosal capillaries. Conclusions: CFM images and
movies can be collected in vivo in real time using a novel microscopy catheter compatible
with conventional endoscopes, demonstrating the potential to perform real time histopatho-
logy and to study dynamic physiological events such as cellular uptake of fluorescent molec-
ules.
Normal Colonic Mucosa (Left) and Tubular Adenoma (Right)
M1136
Nuclear-Cytoplasmic Exchange of PKD3 in Human Pancreatic Cancer (PANC-
1) Cells: Tracking Photoactivable GFP-PKD3 By 2-Photon Activation and 1-
Photon Confocal Microscopy
Steven H. Young, Osvaldo Rey, Jennifer Lippincott-Schwartz, Enrique Rozengurt
Background: The development of photoactivatable GFP (PA-GFP) has increased the resolu-
tion of studies of the distribution of functioning proteins in living cells in real time. After
exposure to a short flash of 405 nm light, PA-GFP photoconverts to new configuration that
exhibits a 30-fold increase in green emission intensity (at 520 nm) when being scanned by
blue (488 nm) light. In time, if these molecules move away from the activation region,
they can be traced anywhere within the cell, as they irreversibly maintain increased green

















in single cells through the use of 2-photon confocal microscopy, which produces a very
limited focal volume, in order to photoconvert the PA-GFP, and then using 1-photon confocal
microscopy to track the movement of activated molecules. Protein kinase D3, a molecule
present in both nucleus and cytoplasm is a member of a family of serine/threonine kinases
which are implicated in the regulation of many cellular processes. We have expressed a PA-
GFP PKD3 fusion protein in PANC-1 cells, and have photoactivated this protein within
narrow depth planar regions of the nucleus or the cytoplasm of single living cells. Results:
We directly demonstrate that in time, PA-GFP PKD3 will translocate out of the nucleus and
into the cytoplasm. Reciprocally, we show that activation of PA-GFP PKD3 in a restricted
area of the cytoplasm results in a spread through the cytoplasm as well as into the nucleus,
resulting in a dynamic distribution of PA-GFP PKD3 between nucleus and cytoplasm.
Conclusion: The narrow depth of activation of 2-photon photoactivation provides for a far
more precise region of activation than can be achieved by 1-photon activation. We expect
this technology to extend capabilities of spatial resolution in studies of the movement of
molecules within and between compartments within living cells.
M1137
Detection and Classification of Adenomas Using High Resolution Endoscopy,
Video Autofluorescence Imaging and Narrow Band Imaging Incorporated in
One Colonoscope
Evelien Dekker, Mohammed A. Kara, Christine C. Cohen, James Hardwick, Johan
Offerhaus, Bergman J. Jacques, Paul Fockens
INTRODUCTION: Video autofluorescence imaging (AFI) and narrow band imaging (NBI)
are novel techniques that may improve the detection and classification of colonic polyps.
In a recent prototype, high resolution endoscopy (HRE) has been combined with AFI and
NBI (Olympus, Tokyo, Japan). AIMS & METHODS: The aim was to evaluate the feasibility
and efficacy of HRE, AFI and NBI for the detection and classification of adenomas. The
prototype used in this study enables switching between HRE, AFI and NBI by using two
knobs on the handle of the endoscope. During AFI, blue light is used for autofluorescence
excitation and a narrow band of green light is used for reflectance. During NBI, narrowed
red, green and blue light bands, with a higher intensity of blue light are used for excitation,
enabling optimal visualization of the mucosal patterns without the use of stains. We enrolled
patients attending for surveillance colonoscopy because of prior adenoma(s) or a family
history for CRC. Segmental examination of the colon during withdrawal was performed
using HRE and AFI in a randomized sequence. NBI was used to classify the pit-patterns of
polyps according to the Kudo classification. Lesions were photographed using all three
modalities prior to polypectomy or biopsy. Procedures were performed by 2 colonoscopists
and the pathologists were blinded to the findings with AFI and NBI. RESULTS: Up to date,
41 patients were enrolled in this ongoing study (22 males, mean age 54 yrs SD 15). A total
of 106 polyps (56 adenomas) were detected in 25 patients. In patients examined with HRE
first (N=21), 43 polyps were detected with HRE (24 adenomas) and 12 additional polyps
(7 adenomas) were detected with AFI; 17 of the 24 adenomas detected with HRE were also
suspicious on AFI. In patients examined first with AFI, 31 polyps were detected with AFI
including 15 adenomas and 20 additional polyps (10 adenomas) were detected with HRE.
The table below shows the diagnostic test values for AFI, NBI and the combination of both
for the detection and classification of adenomas. CONCLUSION: The consecutive use of
high resolution endoscopy (HRE), video autofluorescence imaging (AFI) and narrow band
imaging (NBI) incorporated in one colonoscope is feasible. HRE and AFI increase the
detection rate of adenomas and NBI can be used to classify polyps and diagnose adenomas
without the need for staining solutions. The combination of AFI and NBI may improve the
diagnostic accuracy for adenomas.
M1138
Detection of Residual Barrett’s Mucosa After Photodynamic Therapy (PDT)
Using High Definition Narrow Band Imaging (HD-NBI)
Herbert Wolfsen, Lois L. Hemminger, Michael B. Wallace
Endoscopic ablation using porfimer sodium PDT significantly decreases the risk for progres-
sion to invasive carcinoma in Barrett’s high grade dysplasia (BE+HGD) patients. After PDT,
Barrett’s mucosa persists in nearly 50% of patients and must be detected and destroyed to
prevent metachronous carcinoma. Use of chromoendoscopy with Lugol’s dilute iodine for
residual disease detection is cumbersome and associated with risk of toxicity. The aim of
this study was to compare detection of residual Barrett’s mucosa after PDT with standard
endoscopy, high definition (HD) endoscopy and HD-NBI. Methods: After IRB approval,
consecutive patients undergoing treatment with Ps-PDT for BE+HGD were studied using
standard definition white light endoscopy (Olympus GIF-Q180), high definition white light
endoscopy (Olympus XGIF-H160Y2) and HD-NBI (Olympus XGIF-H160Y2, 415 and 540
nm). Endoscopic imaging was performed at a single session under identical conditions with
digital imaging documentation. Detection rates of residual areas of glandular mucosa were
compared. Results: After Ps-PDT, 50 consecutive BE+HGD patients were studied (42 men,
8 women; mean age 68 yrs, range 51-83 yrs). The pre-Ps-PDT mean BE segment length
was 4 cm; range 1-12 cm. The mean time interval after PDT was 20 mos; range 3-66 mos.
Areas of persistent glandular mucosa (peninsulas or islands of glandular epithelium) were
found in 22 pts using standard endoscopy, 25 pts using HD white light endoscopy and 38
pts using HD-NBI imaging. Conclusions: 1) The use of Narrow Band, high definition
endoscopic imaging in patients treated with PDT for Barrett’s high grade dysplasia detected
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additional areas of glandular dysplasia in more than 50% of cases compared with standard
conventional and high definition video endoscopy. 2) The use of NBI obviated the need for
Lugol’s chromoendoscopy. 3) Long term studies are underway to determine the impact of
NBI on clinical outcomes in patients who have undergone endoscopic ablation therapy.
M1139
In Vivo Molecular and Subsurface Imaging By Confocal Real Time Mini-
Microscopy
Martin Goetz, Christian Fottner, Esther Schirrmacher, Sebastian Gregor, Peter Delaney,
Constantin Schneider, Dennis Strand, Manfred Relle, Andreas Schwarting, Mathias M.
Weber, Oliver Kempski, Martin Anlauf, Guenther Kloeppel, Michael Vieth, Peter R. Galle,
Peter Bartenstein, Markus F. Neurath, Ralf Kiesslich
Introduction: Early and rapid diagnosis is essential for the successful management of diseases,
but remains a technical challenge. We evaluated a newly developed miniaturized hand-held
confocal laser mini-microscopy probe for in vivo molecular, functional and morphological
fluorescence imaging in rodent models of human diseases. Methods: In the confocal laser
probe, a single line laser delivers an excitation wavelength of 488 nm. Optical slice thickness
is 7 µm, lateral resolution 0.7 µm. The range of the z-axis is 0-250 µm below tissue surface.
Imaging was performed using different fluorescent staining protocols. Fluorescein-labeled
octreotate was synthetized for molecular targeting of Somatostatin receptor (sstr) 2. Results:
Cellular and subcellular details could be readily visualised at high resolution (n=30 healthy
mice). Sstr2 targeting allowed in vivo molecular staining of AR42-J induced carcinoma (n=
2 mice) and pancreas islet cells (n=2 rats). Blood cell labeling visualised homing in small
vessels and a spontaneous thrombosis formation in gerbils. Vessels in HEK-293-induced
tumor (n=2 mice) could be easily differentiated from normal vessels, and glomerulonephritis
was diagnosed (n=2 MLR/lpr mice). In vivo imaging was confirmed by ex vivo (immuno-)
histology. Discussion: Confocal mini-microscopy allows real-time subsurface in vivo molecu-
lar, functional and morphological imaging of inflammation, cancer and thrombosis. Since this
probe is applicable to humans, it will be of fundamental impact on clinical and basic science.
Left: Thrombosis of a brain venule (FITC-dextran, Acriflavine, FITC-labeled RBC) Right:
Molecular targeting of sstr2, cytoplasmic islet cell fluorescence in rat pancreas
M1140
Fractal Analysis with Classification Tree for Classification of Dysplasia in
Barrett’s Esophagus Using Multiple Endoscopic Optical Coherence
Tomography Images
Xin Qi, Douglas Y. Rowland, Michael V. Sivak, Andrew M. Rollins
We have shown that endoscopic optical coherence tomography (EOCT) using a first prototype
has a 70% accuracy for the diagnosis of dysplasia in Barrett’s Esophagus (BE) (GIE 2003;
57:AB77). Also, we showed that a computer-aided-diagnosis (CAD) algorithm, based on a
standard texture analysis of digital EOCT images (center-symmetric auto-correlation with
principal component analysis), achieved a sensitivity of 82%, specificity 74% and accuracy
84% (SPIE Proceedings, 2004; Vol.5316:33-40) in the diagnosis of dysplasia. This analysis
yields parameters representing texture on a single spatial scale, but EOCT features that
differentiate dysplastic and non-dysplastic tissue occur on various spatial scales. Also this
analysis classified images based on a single parameter, rather than the several quantifiable
parameters available. Finally, the CAD algorithm used only one EOCT image per site, although
multiple images are usually available. HYPOTHESIS: fractal analysis with a classification tree
using multiple EOCT images of a single tissue site is more accurate than our previous CAD
algorithm in defining dysplasia in EOCT images of BE. METHOD: EOCT images were
recorded at biopsy sites in patients undergoing BE surveillance. At each site, EOCT frames
acquired before the forceps entered the EOCT field of view were used as our CAD data
set. With our biopsy/EOCT system, there is an exact correlation between histology and
corresponding EOCT images. 812 EOCT images (13 patients, 70 non-dysplastic biopsy sites
[499 images] and 38 dysplastic sites [313 images]) were analyzed. Fractal analysis was used
to compute a fractal signature of the region of interest which is a quantitative measure of
texture and self-similarity at many spatial scales. The scores of the first 10 principal compon-
ents of the fractal signature were input to the classification tree to differentiate images of
normal and dysplasitc tissue. RESULT: Using only one frame for classification, sensitivity
was 95% (95% CI: 82%, 100%) and specificity 94% (95% CI: 86%, 98%). Using three
frames per site (with a requirement that 2 be positive for the site to be classified as positive)
sensitivity was 100% (95% CI: 89%, 100%) and specificity 100% (95% CI: 94%, 100%);
97% of the sites had at least three frames available. CONCLUSIONS: Versus our previous
algorithm, fractal analysis with classification tree substantially improved in the classification
of dysplasia in BE in EOCT images. Use of multiple images from a single biopsy site improved
accuracy. With further improvements, CAD could potentially enable EOCT surveillance of
large areas of Barrett’s mucosa for dysplasia.
M1141
Confocal Microscopy: A Novel Method to Assess Aberrant Crypt Foci in
Apcmin+/- and Apcmin+/- (Pparα-/-) Mice
Shonde Anthony, Krish Ragunath, George K. Anagnostopoulos, D R. Bell, A J. Bennett,
Christopher J. Hawkey
Background: Peroxisome proliferator-activated receptorα (PPARα) is expressed at low levels
in colon tumours. APCmin+/- mice fed with methylclofenapate (a PPARα ligand) have 50%
less tumour burden in the small intestine and colon than control1. Recent studies showed
that aberrant crypt foci (ACF) are the earliest morphological lesion detectable in colorectal
epithelium that may lead to cancer. However the relationship between PPARα and ACF
formation is not known. Dissection microscopy is the most common method used for
quantifying ACF. However it is time consuming and requires a great deal of skill to obtain
a good preparation. Aims: (1) To assess whether Confocal Microscopy is a viable method
for identifying ACF in scientific practice. (2) Examine the role of PPARα in colon carcinogen-
esis using APCmin+/- and APCmin+/-(PPARα-/-) mice. Method: Once weaned APCmin+/-
mice and APCmin+/-(PPARα-/-) mice were fed standard chow throughout the study. Mice
were weighed weekly, until mice showed signs of anaemia or lost >20% of weight at which
time they were sacrificed. ACF were assessed using Cell~vizio Confocal Microscopy probe
(Mauna Kea technologies, Paris) made of 30,000 optical fibers following colonic staining
with acryflavine. Result: High definition images with 2.5 µm lateral resolution of normal
crypts and ACF were clearly identified using Confocal Microscopy. APCmin+/-(PPARα-/-)
mice have more ACF than APCmin+/-mice in the colon, but this failed to reach significance
(n=9). The mean number of ACF was 5.0/ 10 fields (CI 2.10- 7.90) in APCmin+/-(PPARα-/-
) mice and 2.75/ 10 fields (CI 1.22- 4.27) in APCmin+/- mice. Conclusions: Confocal
Microscopy using the Cell~vizio probe is a simple and quick method of accessing ACF,
with the potential of refining experiments so that mice can be studied serially. PPARα role
in colon carcinogenesis may be to inhibit the formation of ACF rather than their progression.
Greater understanding of PPARα dependant genes may enable the pathogenesis of colon
cancer to be further understood. 1. Potential role for peroxisome proliferator activated
receptor (PPAR) in preventing colon cancer. Jackson L, et al Gut. 2003 Sep;52(9):1317-22.
M1142
Clinical Utility of Narrow Band Imaging (NBI) Endoscopy in Patients with
Gastroesophageal Reflux Disease (GERD)
Prateek Sharma, Amit Rastogi, Ajay Bansal, Srinivas R. Puli, Sharad Mathur
Background : NBI is a novel imaging technique that uses narrow band filters (415, 445,
500 nm) and higher intensity blue light (smaller wavelength-less penetration) to show details
of esophageal mucosal and vascular patterns. Aim: To compare findings seen only on NBI
in pts with GERD and controls and to calculate sensitivity and specificity of these findings
for GERD diagnosis. Methods: Reflux pts and controls without GERD symptoms filled 2
validated questionnaires (GERQ and RDQ). Then, distal esophagus was examined by white
light followed by using NBI endoscope(Olympus GIFQ240Z, and 115 X) by a single investig-
ator. Features seen only by NBI were noted:number, dilation and tortuosity of intra-papillary
capillary loops (IPCL), micro erosions (ME), increased vascularity at squamocolumnar junc-
tion (SCJ), columnar islands (CI) in distal esophagus (CI) and ridge villous pattern (R/V)
below squamocolumnar junction. NBI images were then evaluated by another blinded
endoscopist. IPCLs were classified as increased, dilated or tortuous and other findings noted
to be present or absent. Findings were compared using Fisher’s exact test; sensitivity and
specificity of findings individually and in combination for GERD diagnosis were calculated.
Results:72 pts were prospectively evaluated (mean age 60 yrs,67 males)- 48 GERD and 24
controls. NBI revealed a striking contrast of squamous and columnar mucosa at SCJ. Increased
number, dilation and tortuosity of IPCLs, presence of micro-erosions and increased vascularity
at SCJ were significantly higher in GERD pts compared to controls (Table 1). Accuracy of
their combinations are shown in Table 2. Conclusion: NBI shows details of mucosa and
vascularity in distal esophagus - IPCLs, micro erosions and increased vascularity at SCJ
being significantly higher in GERD pts vs. controls. Also, distinctive features like increased
number, dilation or tortuosity of IPCLs have a high accuracy for GERD diagnosis. These
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M1143
Novel Ultrahigh Resolution Endoscopic Optical Coherence Tomography
Imaging of the Stomach
Saleem Desai, Hiroshi Mashimo, Aaron D. Aguirre, Yu Chen, Qin Huang, Shu-Wei
Huang, Joseph Schmitt, James G. Fujimoto
BACKGROUND/AIMS: Optical coherence tomography (OCT) provides high resolution cross-
sectional images of tissue microstructure in real time. Images are obtained in a minimally
invasive manner without tissue excision using a small catheter introduced through the biopsy
channel of a standard endoscope. Most OCT investigations in the upper gastrointestinal
tract have focused on the diagnosis of Barrett’s and dysplastic esophagus. There are relatively
few studies of stomach pathology. In contrast to standard OCT which has 10-15 um axial
resolution, the recently developed ultrahigh resolution endoscopic OCT (UHR EOCT) is
capable of imaging with 5 um axial resolution and allows enhanced discrimination of tissue
features in vivo. The goal of this study was to evaluate UHR EOCT for imaging of normal
stomach and of various lesions of the gastric mucosa. METHODS: UHR EOCT imaging was
performed of the normal stomach and of gastric lesions in vivo using an ultrahigh resolution
OCT system based on a Cr:Forsterite laser source. Images were acquired with a 1.8 mm
diameter linear-scanning catheter introduced through the accessory port of a standard
endoscope. Specimens removed by endoscopic mucosal resection (EMR) were also sub-
sequently imaged with an OCT microscope, and three-dimensional (3D) reconstructions
were made of polyp microstructure. Specimens were submitted for histopathology and
correlated with OCT images. RESULTS: In normal stomach, UHR EOCT could clearly
visualize the gastroesophageal junction as well as gastric pit architecture. UHR EOCT also
discriminated mucosal subtypes in the cardia, corpus, and pylorus, although imaging depth
was significantly reduced compared to images of the esophagus. Gastric polyps could be
surveyed and various polyps including mucinous, hyperplastic, inflammatory, adenomatous
and dysplastic were characterized. Ex vivo images of resected gastric polyps with UHR OCT
showed similar features to in vivo images but allowed three-dimensional reconstructions
and high-resolution visualization in any section plane. CONCLUSIONS: UHR EOCT provides
visualization of subsurface tissue structure in the stomach. This technology may prove useful
in characterizing gastric polyps and masses. Future work on high speed and 3D UHR OCT
promises new visualization methods in vivo.
M1144
Novel Technique in Understanding the Sequence of Biochemical Changes in
Carcinogenesis of Esophagus
Geeta Shetty, Catherine Kendall, Neil Shephard, Nicholas Stone, Hugh Barr
Background: Most reports emphasise genetic changes in understanding the carcinogenesis
sequence of esophageal adenocarcinoma. Biochemical changes occurring in carcinogenesis
have not been evaluated to their full potential. We propose a technique, which helps to
understand the biochemical events involved in the development of malignancy in Barrett’s
esophagus. Methods: 70,404 Raman spectra were measured on 24 snap frozen endoscopic
biopsy samples. Contiguous sections were stained with H&E for analysis by a consultant
gastrointestinal pathologist. Mapping studies were performed on 20μm thick sections on
CaF2 slides with spectra measured at 100μm steps across the samples. Analysis of spectra
was done in Matlab generating principal components and pseudocolour maps. Results: Using
pseudocolour maps the lines of interest were selected representing the surface changes or
understanding the depth profile of tissue (Figure 1). The spectra along the selected line
were analysed for the relative concentration of different biochemical constituents using
mathematical least fit square method. Marked variation in the distribution of oleic acid,
actin, triolene, glycogen and DNA were seen. Conclusion: Raman spectroscopy is an optical
diagnostic tool, which can be used to demonstrate the biochemical changes in carcinogenesis
of esophagus and identify early disease. Work is in progress to develop an in vivo endoscopic
probe for real time analysis.
M1145
In Vivo Diagnosis of Microscopic Colitis By Confocal Laser Endomicroscopy
Ralf Kiesslich, Arthur Hoffman, Martin Goetz, Katharina Lammersdorf, Stefan Biesterfeld,
Michael Vieth, Peter R. Galle, Markus F. Neurath
Background: Microscopic colitis is subdivided into collagenous and lymphocytic colitis. The
diagnosis of microscopic colitis relies on histopathologic examination of biopsy specimens.
Aim of the current study was to investigate the value of confocal laser endomicroscopy

















colonoscopy. Methods: Patients scheduled for colonoscopy with chronic diarrhea were
examined with a newly developed Endomicroscope (Pentax, Tokyo, EC-3870CIFK). Fluor-
escein was applied intravenously to enable confocal endomicroscopy of colonic mucosa (0-
250μm). Confocal images from macroscopic normal apparent mucosa were obtained from
the right, transverse colon and rectum. Confocal image data were collected at a scan rate
of 1.6 sec/frames (1024x1024 pixels) using an optical slice thickness of 7µm (lateral resolution
≤1µm). The presence of collagenous bands or lymphocytes within the lamina propria was
graded and targeted biopsies were applied. Results: In 4 out of 57 patients with normal
apparent mucosa microscopic colitis (3 collagenous, 1 lymphocytic) could be diagnosed by
confocal laser endomicroscopy which was proved by histology in all cases (sensitivity 100%).
Subepithelial, thickened collagenous bands or lymphocytes could be readily identified and
quantified by performing endomicroscopy. In addition crypts and vasculature could be seen
at high resolution. The patchy distribution of the affected mucosa with accentuation of the
right colon could be predicted with high accuracy (97.5%) within these patients. Conclusions:
Confocal laser endomicroscopy allows localizing and measuring the amount of collagenous
bands and lymphocytes in the mucosal layer. Thus, endomicroscopy offers the possibility
to diagnose and targeted biopsy microscopic colitis during ongoing colonoscopy.
M1146
Automated Virtual Microcopy of Specimens from Gastric Biopsies Can
Accurately Diagnose Gastritis and Adenocarcinoma
Levente Ficsor, Viktor Varga, Lajos Berczi, Pal Miheller, Attila Tagscherer, Mark Li-Cheng
Wu, Bela Molnar, Zsolt Tulassay
Background: Automated virtual microscopy of specimens from gastrointestinal biopsies is
based on cytometric parameters of digitized histologic sections. Diagnoses rendered by
automated virtual microscopy are potentially more reproducible and more efficient than
diagnoses rendered by conventional optical microscopy. To our knowledge, cytometric
parameters of gastritis and of adenocarcinoma have yet to be fully characterized. Our
objective was to classify gastritis and adenocarcinoma based on cytometric parameters. We
hypothesized that automated virtual microscopy using this novel classification can reliably
diagnose gastritis and adenocarcinoma. Methods: Routinely processed hematoxylin-and-
eosin-stained histologic sections that showed normal mucosa (14 specimens), gastritis (25
including 6 non-atrophic , 17 atrophic, 12 intestinal metaplasia), and adenocarcinoma (30
specimens) were scanned and digitized at high resolution (0.3 µm/pixel) using the Zeiss
Mirax Scan (Carl Zeiss Jena GmbH, Germany, Jena). Thirty-eight cytometric parameters
based on density and morphometry were applied to glands, foveolae, and superficial epithe-
lium. Twelve cytometric parameters based on cytologic detail were applied to individual
cells. Statistical analysis was performed using Statistica 6.0 software (StatSoft Inc., USA).
Results: Statistically significant differences in cytometric parameters for normal mucosa,
gastritis, and adenocarcinoma were found ( p<0.0.5,). The most discriminatory parameter
was the ratio of the total number of cells to the number interstitial cells (normal mucosa
1.43±0.12; gastritis 1.23±0.13; adenocarcinoma 1.1±0.05; p<0.01) . These differences cor-
rectly classified normal and gastritis cases versus adenocarcinoma (100%) with reasonable
accuracy (86% overall). The different gastritis cases could be classified by 56% (atrophic
gastritis), 86% intestinal metaplasia, 65% gastritis without atrophy and intestinal metaplasia
, respectively. Conclusions: We describe a novel classification of gastric mucosa based on
cytometric parameters. Automated virtual microscopy can be uses to diagnose normal
mucosa, gastritis, and adenocarcinoma with reasonable accuracy. Downstream classification
of gastritis groups needs further alteration specific paremeters to be included in the morpho-
metric parameters.
M1147
Cell Membrane Fluidity Assays of Fluorescence Anisotropy and Excimer
Formation in Indomethacin-Treated Gastric Epithelial Cell-Line RGM-1
Tsuyoshi Kaneko, Hirofumi Matsui, Osamu Shimokawa, Takashi Mamiya, Jyunpei Udo,
Nagano Yumiko, Mutsumi Muramatsu, Ken-Ichi Hirano, Atsunori Tsuji, Yasushi
Matsuzaki, Ichinosuke Hyoudou
[Bachgrounds & Aims] Gastric complications of indomethacin, a non steroidal anti-inflam-
matory drugs (NSAIDs), involves reactive oxygen species (ROS) formation, which induces
cell membrane lipid peroxidation and gastric musocal injuries. When peroxidized by ROS,
the amounts of unsaturated fatty acids in cell membrane lipid bilayers are reportedly
decreased, which affects cell membrane fluidity. We thus investigate the cell membrane
fluidity change after indomethacin treatment both with fluorescence anisotropy and with
excimer formation using fluorescence indicators decanoylaminofluorescein (DAF) and 1,3-
di (1-pyrenyl) propane (PC3P), respectively, in gastric epithelial RGM-1 cell line. [Methods]
Indomethacin-pretreated RGM-1 cells were treated with DAF and PC3P and both their
fluorescence anisotropies and fluorescence intensity ratios were measured and calculated
with an image intensified CCD (IICCD)-mounted fluorescence microscope and an image-
processor. Indomethacin-pretreated RGM-1 cells were also treated with another fluorescence
indicator, diphenyl-1-pyrenylphosphine (DPPP), which reacts with membranous organic
hydroperoxides and hydrogen peroxide to emit fluorescence, and their fluorescence intensit-
ies were measured with the previous system. [Results] After indomethacin treatment the
fluorescence intensities of DPPP in RGM-1 were increased in a time- and dose-dependent
manner, indicating cell membrane lipid peroxidation was induced. The fluorescence aniso-
tropy values of DAF and the fluorescence intensity ratios of PC3P excimer to monomer
were both increased, indicating that the fluidity of cell membrane was decreased by the
indomethacin treatment. [Conclusion] We demonstrated indomethacin treatment decreased
cell membrane fluidity in a gastric epithelial cell line. Together with the result of DPPP
fluorescence observation, the fluidity change reflects compositional changes of membranous
lipid bilayers induced by lipid peroxidation. We thus propose the fluorescence observation
of the cell membrane fluidity can apply to the detection of cellular pathphysiological changes
in NSAID-induced gastric lesions.
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M1148
Antibody Aided Confocal Laser Endomicroscopy Allows Molecular Imaging of
Colorectal Lesions in Humans
Ralf Kiesslich, Martin Goetz, Brigitte Bartsch, Katharina Lammersdorf, Arthur Hoffman,
Constantin Schneider, Manfred Vieth, Manfred Stolte, Peter R. Galle, Markus F. Neurath
Introduction: Confocal laser endomicroscopy (CLE) enables in vivo histology of the mucosal
layer with cellular and subcellular resolution during ongoing endoscopy. Aim of the current
study was the evaluation of distinct fluorescein labeled antibodies for immediate molecular
imaging and characterisation of different colonic lesions in humans. Methods: Patients with
known colorectal adenomas and/or aberrant crypt foci were enrolled in the study and
underwent total colonoscopy with CLE (Optiscan, Australia; Pentax, Japan; excitation of
488nm argon ion laser; detection >515 nm; optical slice thickness 7μm; lateral resolution
0.7μm; frame rate 0.8 or 1.6 frames/sec with 1024x1024 or 1024x512 pixels). After reaching
the colonic lesions, a fluorescent contrast agent (fluorescein) for transient staining of vessels
and crypts was administered intravenously and endomicroscopic evaluation was performed
using the confocal pattern classification. Endoscopic resection was performed and the resected
specimens were immediately incubated with FITC-labeled Anti-EGFR (n=4), Anti-CD44v6
(n=2) or Anti-Actin (n=1) antibodies (dilution; 1:50) for 30 minutes. Lesions were re-assessed
ex vivo with CLE-endoscope after a thorough washing step. Subsequently, conventional
histology and ex vivo immuno-staining on resected specimens was performed to correlate
histology with the CLE findings. Results: Antibody aided confocal laser endomicroscopy
specifically highlighted the corresponding epitopes on the cell surface. Cellular and subcellu-
lar detail could be seen at high resolution. Aberrant crypt foci were readily visible and
highlighted by staining with Anti-CD44v6 antibodies. EGFR receptors could be quantified
at the cell membrane with CLE and were confirmed histologically by ex vivo immuno-
staining. Anti-Actin antibodies aimed at intracellular targets showed no contrast by CLE in
the absence of cell permeability and served as a negative control. Conclusions: Confocal
laser endomicroscopy enables molecular imaging in humans at high resolution. Resected
colonic lesions can be immediately analysed and characterised for the presence of different
receptors. Thus, antibody aided CLE may offer a rapid analysis of colorectal lesions with
important implications for targeted tumour therapy.
M1149
Quantum Detection of Inflammatory Markers in Vivo in DSS Model of Colitis
Amolkumar Karwa, Sreekant Murthy, Elisabeth Papazoglou, Kambiz Pourrezaei, Som
Tyagi
The ability to sense and image the biomolecules with nanotools has significant effect in
unraveling the disease pathogenesis as well as nanodelivery of drugs at the disease site.
Quantum Dots (QDs) are novel nanometer sized fluorescent particles, with distinct advantages
of high quantum yield and excellent photostability making them great tools for dynamic
monitoring of disease progression. With these excellent properties of QDs it is possible
to image and quantify biomarkers that are important indicators of inflammation. IL1α,
Myeloperoxidase (MPO), and TNFα are three different biomarkers that play an important
role in Inflammatory Bowel Diseases. These markers show an increased presence in the
acute and chronic phase of animal model of DSS induced colitis, which resembles human
ulcerative colitis. We report here targeting of these biomarkers in vivo with QDs and their
subsequent quantification in the DSS model of ulcerative colitis. To target these biomarkers
in vivo, the antibodies for Myeloperoxidase and cytokines IL1α and TNFα were conjugated
to different sizes of QDs with emission at different wavelength. Acute and chronic colitis
was induced in Swiss Webster mice according to the established protocols with conjugates
being tested in vivo on pre determined days. A colonic loop was prepared and colon was
directly exposed to QD conjugates, washed, excised, and frozen. Histological slides (15
micron thickness) were prepared and imaged with a confocal microscope. The subsequent
images obtained showed gradual increase in presence of QDAb conjugates with increase in
inflammation. In the acute stage of the colitis starting from Day 3 to Day7 of DSS feed the
fluorescent intensity of QDs gradually increased with the disease severity (correlation, R=
0.96). In the acute phase MPO intensity was observed to be highest followed by IL1α
whereas TNFα intensity was the lowest. In the chronic phase MPO could be still detected,
however TNFα showed increased presence and IL1α presence showed gradual decline. QDs
were absent in control colon tissue devoid of inflammation. The observations made here is
in accordance with the previous biochemical studies done in the same DSS model albeit
the nanotechnology based method applied here is less cumbersome and highly reproducible.
In summary our results showed that QDs can be successfully used to image the biomarkers
presence and relate their presence to the disease severity. The technique developed here
can be extended in future to identify potential biochemical targets using multiple biomarkers
for different pathological events taking place in the progression of disease.
M1150
Probiotics May Reduce Inflammation By Enhancing PPARγ Activation in
Intestinal Epithelial Cells
Chang Soo Eun, Dong Soo Han, Seung Hyun Lee, Yoon Kyoung Park, Byoung Kwan
Son, Hyun Joo Jang, Sea Hyub Kae, Jin Lee, Yong Seok Kim, Ronald M. Evans
Background: The peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear
receptor highly expressed in the colon and playing an anti-inflammatory role through
inhibition of NF-κB pathway. Probiotics, living organisms in food and dietary supplements,
have been shown to exert beneficial effects on clinical trials of inflammatory bowel diseases
treatment. However, the exact mechanism by which probiotics exerted protection against
the intestinal inflammation is not well understood. The aims of this study were to evaluate
attenuation of inflammation by probiotics in intestinal epithelial cells and to study the
possible relation between probiotics and PPARγ. Methods: HT-29 human epithelial cells
were stimulated with E. coli LPS (20 µg/mL) and probiotics, Lactobacillus casei (10*5-10*7
cfu/mL), or with LPS (20 µg/mL) alone for 24 hours. L. casei were administered either 6
hours before LPS stimulation or concomitant with LPS stimulation. COX-2, IL-8, TLR-4
and PPARγ mRNA expression were assessed by RT-PCR. IL-8 protein secretion levels were
analyzed by ELISA. To evaluate whether the action of L. casei was correlated with the
activation of PPARγ, HT-29 cells were transfected with tk promoter-luciferase plasmid
containing a PPRE. After stimulation with L. casei or PPARγ agonist (15d-PGJ2, ciglitazone),
luciferase activities were measured. Results: LPS stimulation on HT-29 cells increased COX-
2, IL-8, TLR-4 mRNA expression and IL-8 protein secretion. Costimulation with LPS and
L. casei, in comparison to LPS stimulation alone, decreased COX-2, IL-8, TLR-4 mRNA
expression and IL-8 protein secretion. Costimulation with LPS and PPARγ ligand (15d-
PGJ2) decreased COX-2, IL-8, TLR-4 mRNA expression and IL-8 protein secretion compared
to LPS stimulation alone. L. casei increased PPARγ mRNA expression in proportion to
stimulation doses. L. casei activated PPRE in HT-29 cells transfected with PPRE3-tk-luciferase
construct in a dose-dependent manner. Conclusions: Probiotics, L. casei, suppress inflamma-
tion in intestinal epithelial cells. The anti-inflammatory action of L. casei may be partially
related to PPARγ activation.
M1151
Systemic Exposure to E.Coli DNA and Microbial Antigens During the Neonatal
Period Triggers a Loss of Tolerance to Gut Microflora in Later Life
Phil Bach, Francis Cheung, Dave Thiel, Brendan Diederichs, Julia Ewaschuk, Claire
Arrieta, Karen Madsen
Impairment of innate immunity and heightened T-cell responsiveness to enteric microflora
are associated with inflammatory bowel disease (IBD). Failure of the innate immune system
to clear microbes could result in increased exposure of the adaptive immune system and
induce a loss of tolerance to gut microflora. Previous studies have shown that some CpG-
DNA can render protein antigens highly immunogenic. Bacterial DNA, which contains CpG
motifs, elicits variable immune responses in a strain-dependent manner and can be found
in the serum of patients with increased gut permeability. In children, the onset of IBD often
follows intestinal infection, when gut barrier function may be compromised. Aim: The aim
of this study was to determine if exposure of the neonatal adaptive immune system to
microbial antigens and immunogenic bacterial DNA would trigger a loss of tolerance to
enteric microflora. Methods: Neonatal (3 wks of age) and adult 129 Sv/Ev mice were injected
subcutaneously once only with Clostridium sordelli (CS; n=24) or Viridans group Streptococci
(VGS; n=24) protein sonicates ± E. coli or Bifidobacterium DNA (50μg). After 4 wks, ileal
and colonic tissue were removed for histological assessment and measurment of basal and
microbe-induced secretion of TNFα (as an indicator of innate immunity) and IFNγ (adaptive
immunity) by organ culture. Splenocytes were isolated and cytokine secretion assessed.
Results: 4 wks following systemic exposure, intestinal tissue from mice injected with E. coli
DNA and CS responded to CS and other bacterial sonicates with a significantly increased
IFNγ and TNFα secretion compared with mice receiving CS alone (p<0.05). In contrast,
intestinal tissue from mice injected with Bifidobacteria DNA and CS did not respond to CS
sonicates, but did have increased basal TNFα secretion, suggesting an enhancement of innate
immune function. This mucosal response was strain-dependent, as mice injected with VGS
± bacterial DNA did not demonstrate any changes in gut cytokine secretion. Neonatal mice
injected with CS or VGS sonicates in the absence of bacterial DNA did not exhibit any
differences in gut cytokine secretion. Adult mice injected with CS or VGS ± E. coli DNA
did not demonstrate any alterations in intestinal cytokine secretion, but did have a heightened
systemic response to CS protein. Conclusions: Exposure of the neonatal systemic immune
system to E. coli DNA and bacterial antigens results in a loss of mucosal tolerance to gut
microflora which is maintained into later life. The presence of probiotic bacterial DNA can
suppress these adaptive immune responses, while enhancing the innate immunity of the gut.
M1152
1.4-Dihydroxy-2-Naphthoic Acid (DHNA) Shows Anti-Inflammatory Effect On
NSAID-Induced Colitis in IL-10-Knockout Mice Through Suppression of
Inflammatory Cell Infiltration and Increased Number of Genus
Bifidobacterium
Yoshikiyo Okada, Ryota Hokari, Shingo Kato, Norikazu Mataki, Keisuke Okudaira, Koichi
Takebayashi, Hisayuki Matsunaga, Yoshikazu Tsuzuki, Shunsuke Komoto, Chikako
Watanabe, Atsushi Kawaguchi, Shigeaki Nagao, Kazuro Itoh, Soichiro Miura
BACKGROUND: 1.4-dihydroxy-2-naphthoic acid (DHNA), a component of Propionibacter-
ium freudenreichii ET-3, is known to promote proliferation of Genus Bifidobacterium.
Therefore this compound is expected to have a beneficial effect as a prebiotics for intestinal
inflammation. We previously reported that administration of DHNA can ameliorate dextran
sodium sulfate-induced colitis (Okada et al. Gut 2005). In this study, we examined whether
DHNA attenuates inflammation in nonsteroidal anti-inflammatory drug (NSAID)-induced
colonic injury in IL-10 knockout (K/O) mice. MATERIALS & METHODS: DHNA (2.0 mg/
kg) or vehicle (control) was administered for 14 days in free drinking water. Thereafter, for
the induction of colitis, IL-10 K/O mice (5 weeks of age) was fed with rodent chow containing
the NSAID (piroxicam, 200ppm). After seven-days as feeding period, mice were euthanized
and the colon was removed for further experiments. The degree of colonic inflammation
was determined using H&E sections. CD4, CD8, B220, beta7-integrin, F4/80 and MAdCAM-
1 expressions were determined by immunohistochemistry. mRNA levels of proinflammatory
cytokines (IL-1 beta, IL-6 and TNF-alpha) were determined by quantitative real-time PCR.
In addition, cecal contents were examined for bacterial flora . RESULTS: A rapidly progressed
colitis was induced after piroxicam treatment in IL-10 K/O mice characterized by the
infiltration of the colonic mucosa with lymphocytes and monocyte lineage cells. DHNA-
pretreatment significantly attenuated the piroxicam-induced histological changes including
cell infiltration in the colonic mucosa. The increased infiltration of beta7-integrin+ cells,
CD4+ cells, F4/80 cells and increased vascular MAdCAM-1 expressions in the colonic mucosa
were also significantly attenuated by DHNA pre-treatment. The increased mRNA levels of
TNF-alpha, IL-1 beta, and IL-6 and TNF-alpha in the colonic tissue induced by NSAID were
also significantly suppressed by DHNA pretreatment. Furthermore, the increased number of
Genus Bifidobacterium was observed in cecal contents after DHNA administration. CONCLU-
SIONS: NSAID treatment in IL-10 K/O mice induced significant colonic inflammation
accompanied by inflammtory cell infiltration, up-regulation of vascular adhesion molecules,
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and the expression of proinflamatory cytokines. These changes were significantly ameliorated
by DHNA treatment concominant with the recovery of Genus Bifidobacterium, suggesting
the beneficial role of this component as prebiotics in NSAID-induced colonic injury.
M1153
Effects of the Probiotic E. Coli Strain M-17 On Chronic Dextran Sulfate
Sodium-Induced Colitis in Mice
Leo R. Fitzpatrick, Jeffrey Small, Eileen Bostwick, Robert Hoerr, Walter A. Koltun
Probiotic bacteria are effective for attenuating colitis in animal models of inflammatory
bowel disease. The mechanisms of anti-colitis action for probiotics include decreasing the
production of pro-inflammatory cytokines and maintenance of the colonic mucosal barrier.
Purpose: Our primary goal was to assess the efficacy of the probiotic E. coli strain M-17
(EC-M17) in a chronic dextran sulfate sodium (DSS) colitis model. A secondary goal was
to determine the effects of this probiotic on pro-inflammatory cytokines, as well as two
parameters (colonocyte proliferation and apoptosis) associated with colonic mucosal
homeostasis. Methods: A chronic model of DSS-induced colitis was established in C57 BL/
6 mice, by alternating 7-day cycles of 1% DSS and water. On day 21 (end of the second
DSS-cycle), mice (n = 19 to 20 per group) were administered EC-M17 (6 x10^8 CFU),
metronidazole (40 mg/kg), or 0.6% saline (vehicle). Disease Activity Indices (DAI’s) were
determined every other day and on day 35. The colons were excised from mice on day 35,
and distal colonic samples were taken for histological evaluations (0 to 40 point scoring
system). Pro-inflammatory cytokines (IFN-γ, IL-12, IL-1β) and IL-10 were measured by
ELISA, from an adjacent segment of colon. In a subset of mice, colonic epithelial cell
proliferation was determined by the PCNA method, while epithelial cell apoptosis was
determined by TUNEL histochemistry. Results: On day 35, the DAI’s were: 0 ± 0 (vehicle/
Water), 1.6 ± 0.2 (vehicle/DSS), 0.5 ± 0.2 (EC-M17/DSS) and 0.8 ± 0.2 (metronidazole/
DSS). Mice treated with the probiotic, or antibiotic, had significantly less histological damage
(p < 0.01) than in vehicle treated mice. The colonic histology scores were: 5.4 ± 0.5 (vehicle/
Water), 15.0 ± 1.5 (vehicle/DSS), 9.8 ± 0.8 (EC-M17/DSS) and 10.7 ± 0.5 (metronidazole/
DSS). Levels of IFN-γ and IL-1β, but not IL-12, were reduced (38 to 46%) in the colons
of mice receiving EC-M17. IL-10 was not affected by the probiotic or antibiotic treatments.
An increase in the number of PCNA positive cells was found only in the crypts of vehicle/
DSS treated mice. In mice treated with EC-M17, the mean number of TUNEL positive cells
per 20 crypts (73 ± 14) was reduced, as compared to the number of positive cells in vehicle
treated mice (112 ± 19). Summary: EC-M17 attenuated various parameters of chronic DSS-
induced colitis in mice, including pro-inflammatory cytokines and colonic epithelial cell
apoptosis. EC-M17 demonstrated a similar efficacy profile to that of metronidazole. Conclu-
sion: EC-M17 represents a novel probiotic therapy, which can potentially be used for the
treatment of intestinal inflammation.
M1154
DSS Induced Colitis Is Prevented By Lactobacillus Reuteri Through Reduction
in P-Selectin Expression in Rats
Joel Petersson, Olof Schreiber, Stefan Roos, Michael Perry, D. Neil Granger, Lena Holm
Background: Recent findings indicate that DSS induced colitis is associated with a prothrom-
bogenic phenotype in the colonic microcirculation, with P-selectin playing a major role in
recruitment of platelets. Since probiotics have been suggested to reduce the severity of
colonic inflammation we wanted to investigate how pretreatment with Lactobacillus reuteri
influence P-selectin expression and colitis severity in DSS treated rats. Methods: Rats were
divided into four groups; I/Non treated, II/DSS treated, III/L. reuteri treated and IV/ L. reuteri
and DSS treated. The L. reuteri treated groups were given four different strains of reuteri
(JCM 5869, R2LC, MM2-3 and ATCC55730) by gavage (109 bacteria in 0.5 ml saline) daily
for 16 days. Colitis was induced by feeding rats 5% dextran sulphate sodium (DSS) in
drinking water for 9 days. Group IV was given DSS from day 8 to day 16 of the L. reuteri
treatment. The rats were anesthetized with inactin (120mg×kg-1ip)and the dual radiolabeled
monoclonal antibody technique was used to quantify the expression of P-selectin in different
parts of the GI tract (Circ Res 1996;79:560-569). The colon was divided in half; proximal
and distal colon. The superficial mucosa was scraped off one part of the distal colon
(distal colon mucosa) leaving the deeper mucosa, submucosa and muscularis (distal colon
subm+musc). Severity of colitis was assessed using clinical parameters (Lab Invest
1993;69:238-249). Results: DSS in the drinking water for 9 days induced a colitis with a
disease activity index (DAI) of 2.18±0.18. Pretreatment with L. reuteri resulted in substantial
protection against DSS induced colonic inflammation (DAI 0.67±0.11). P-selectin expression
increased significantly in ceacum and the entire colon after DSS treatment, but was signific-
antly reduced with L. reuteri treatment during the DSS period (Table 1). Conclusion:
Lactobacillus reuteri protects against DSS induced colitis in rats. The protection is accompanied
by a reduced P-selectin expression down to control levels.
Table 1. P-selectin expression (ng P-selectin Ab/g tissue)


















Bifidobacterium Infantis Modulates Human Intestinal Epithelial Cell Function
by Attenuating the Secretion of Ccl20
Ann M. O'Hara, Jude Ryan, Aine Fanning, Liam O'Mahony, Fergus Shanahan
Background and aims: Enteropathogenic bacteria elicit mucosal immune responses that
can lead to the secretion of pro-inflammatory mediators including CCL20. Bacterial flagellin
is a key inducer of CCL20 secretion by intestinal epithelial cells. CCL20 is chemotactic for
immature dendritic cells, and T and B lymphocytes. Previous studies have demonstrated
that probiotic bacteria may limit intestinal inflammation by attenuating pathogen-induced
interleukin (IL)-8 secretion. In this study, we investigated whether the probiotic bacterium
Bifidobacterium infantis modulates CCL20 induction by flagellated pathogens. Methods: HT-
29 human intestinal epithelial cells were incubated with increasing doses of B. infantis, or
with Clostridium difficile (ribotype 001), Salmonella typhimurium, or 0.5 mg/ml of its flagellin
for varying times. In some studies, HT-29 cells were pre-treated with B. infantis for 2 h
prior to infection or flagellin stimulation. CCL20 protein levels in cell culture supernatants
were measured by ELISA. Results: Compared to untreated cells (106±23 pg/ml), C. difficile
(1044±233 pg/ml), S. typhimurium (6167±1700 pg/ml), and flagellin (2620±690 pg/ml)
stimulated a significant secretion of CCL20 by HT-29 cells. B. infantis did not augment
CCL20 production (123±35 pg/ml). In contrast, B. infantis dose-dependently reduced the
baseline secretion of CCL20, and at a concentration of 1x107/ml this inhibition was significant
(22% reduction). In cells pre-treated with the probiotic bacteria, C. difficile-, S. typhimurium-
, and flagellin-induced CCL20 secretion were attenuated by 15%, 22%, or 28%, respectively.
Conclusion: Flagellin and flagellated pathogens, but not B. infantis, stimulate CCL20 secretion
by intestinal epithelial cells. This study is the first to demonstrate that a commensal strain
can attenuate CCL20 secretion at baseline and in response to pro-inflammatory stimuli.
Collectively, the study suggests that by mediating CCL20 secretion, B. infantis can exert
immunomodulatory effects on intestinal epithelial cells that mediate host responses to flagellin
and enteric pathogens.
M1156
Distinct Regulation of Cell Activation and Apoptosis in γ/δ T Cells By the
Probiotic Bacterium E. Coli Nissle 1917 (EcN)
Claudia Guzy, Daniela Paclik, Uta Berndt, Daniel C. Baumgart, Bertram Wiedenmann,
Axel Dignass, Andreas Sturm
BACKGROUND: γ/δ T cells directly recognize unprocessed or non-peptide antigens such
as pathogen-associated molecular patterns (PAMPs), respond rapidly to infections, display
an increased cytotoxicity and expression of TNF-a and IFN-g and localize to mucosal surfaces.
PAMPs are recognized by corresponding receptors of the innate immune system, such as
Toll-like receptors (TLRs). We previously demonstrated that EcN modulates T cell function
through a TLR-2 dependent pathway, prompting us to investigate the effect of EcN on γ/δ
T cells. METHODS: Peripheral blood T cells (PBT) from healthy volunteers were magnetically
separated in α/β and γ/δ T cells. Cells were then stimulated with anti-CD3 and -CD28 mAb
and cultured in the absence or presence of 25% (vol/vol) sterile filtered EcN supernatants
for 48 h after which cell activation (CD69), cell cycling (Cyclin B1 and PI), apoptosis
(annexin V) and necrosis (PI) was determined by flow cytometric analysis. RESULTS: As
determined by CD69 staining, cell free supernatants of EcN inhibited T cell activation in
α/β T cells significantly more potent that in γ/δ T cells (reduction by 37±2.1% vs 21.0±1.8%,
respectively; p<0.05). In addition, EcN inhibited cell cycle progression into the S/G2/M-
phase significant more potent in α/β (reduction by 60±4.8%) than in γ/δ T cells (reduction
by 32±3.1%) (p<0.05). When apoptosis and necrosis was determined by annexin-V and
propidium iodide staining, EcN did not induce apoptosis or necrosis of stimulated α/β PBT.
In contrast, in γ/δ T cells, EcN increased the proportion of apoptotic cells by 24±4.8% and
necrotic cells by 38±5.1% (p<0.05) compared to γ/δ T cells cultured in the absence of EcN.
CONCLUSION: EcN exclusively induces apoptosis and necrosis in γ/δ T cells and thus may
explain down-regulation of TNF-a and IFN-g secretion by EcN. The distinct regulation of
α/β and γ/δ T cell activation, cycling, and apoptosis by EcN provide evidence that probiotic
bacteria have the ability to directly influence the human immune system and may explain
the beneficial effect of EcN in intestinal inflammation.
M1157
Survival of E. Coli Strain Nissle 1917 Given in Combination with Oral
mesalamine to Healthy Volunteers
Thai Hoa Nguyen-Xuan, Gabriele Blum-Oehler, Barbara Plaschke, Joerg Hacker, Lars
Joeres, Stefan Saar, Juergen Schulze, Wolfgang Kruis
Background: Mesalamine and the probiotic E. coli strain Nissle 1917 (EcN) are both thera-
peutically effective agents for the treatment of ulcerative colitis. In the interest of even better
efficacy the effects of a combined therapy are highly worth to look for. However, for some
theoretical reasons, there may exist antimicrobial effects of Mesalamine against EcN. Methods:
In this prospective, randomized, double-blind, placebo-controlled study healthy volunteers
(n=48) were treated with either EcN (2 capsules Mutaflor® od; 2.5 - 25 x 109 viable bacteria
per capsule) plus Mesalamine (Salofalk®; 1500 mg bid) or EcN plus placebo. After a run-
in period of 17 days with all volunteers taking only EcN, volunteers detected positive for
EcN received combination treatment for 7 days. Faecal samples were examined in 2- to 3-
days intervals for EcN by Multiplex-PCR assay and cultivation. Diaries were completed for
tolerability of the treatment and compliance. Blood samples and urine samples were addition-
ally taken for safety and compliance. Results: During the run-in period faecal samples with
positive results of the EcN analysis increased and viable EcN was detected in 83 % of the
vols (40/48). 8 volunteers were not eligible for combination treatment as no EcN was detected
during the run-in period. From day 1 to day 7 of combination treatment, the number of
volunteers with a positive EcN detection varied between 70 % (14/20) and 80 % (16/20)
in the Mesalamine group and between 85 % (17/20) and 95 % (19/20) in the placebo group.
The differences between the groups were statistically not significant (normal approximation,
day 3 p>0.15, day 5 p>0.25, day 7 p>0.076). After one week of the follow up when
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treatments were stopped, the proportion of positive EcN detection amounted to 16/20 in
the Mesalamine group and 15/20 in the placebo group and dropped down continuously
up to week 12 after combination treatment. It decreased to 7/20 and 4/20 in the Mesalamine
and placebo group, respectively. No differences between both groups in tolerability and
safety could be seen. Conclusions: EcN was detected in the intestine of 83 % of the healthy
subjects after the treatment with EcN for 17 days. Mesalamine shows no significant effects
on the survival of EcN in the intestine of healthy subjects. Therefore a combination of both
treatments seems to be possible, further studies are necessary to estimate a benefit of a
combined therapy with EcN and Mesalamine.
M1158
Development of Strain-Specific Molecular Method for the Identification of
Bifidobacteria Infantis 35624
Duane Charbonneau, Russ Poehner, Rebecca Donovan-Brand, Jun Xu, Diana Fawcett
Background & Aim: Evidence from controlled clinical trials indicates that the benefits of
probiotic supplementation are strain specific, and limited to specific clinical conditions.
Bifidobacterium infantis 35624 is the only probiotic strain clinically proven to provide
multiple symptom relief in IBS. The literature also shows that many commercial probiotic
preparations lack necessary quality control, as often the probiotic preparations are nonviable,
incorrectly identified or worse contain microorganisms not recognized as probiotics. Thus,
there is a need for strain-specific methodologies to assure consumers of product quality.
We examined a method for the strain-specific identification of B. infantis 35624. Methods:
A library of 32 strains of Bifidobacteria were obtained from ATCC and used as references.
Where appropriate, library strain identity was confirmed using species-specific PCR reactions.
Library strain identity was further confirmed via 16S gene sequencing. B. infantis 35624
was grown in pure culture, and examined in a freeze-dried powder preparation. The method
of rep-PCR was examined as a means for strain differentiation. DNA was isolated using the
Ultra Clean Microbial DNA Isolation Kit as modified by Diversilabs. DNA extracts were
processed using the Diversilab Bacterial Bar-Code system. Results: The Diversilabs Bacterial
Bar-code system was very reproducible and effective in strain-specific identification among
Bifidobacteria. This assay distinguished B. infantis 35624 from the other Bifidobacteria
regardless of whether the DNA was isolated from pure cultures or the freeze-dried preparation.
Conclusions: Bacterial Bar-Code assay provided a molecular method for strain-specific identi-
fication of B. infantis 35624. These results further confirm the uniqueness of this clinically
effective probiotic Bifidobacterium infantis 35624.
M1159
In Vitro Experimental Data Supporting the Zinc Use in the Treatment of Acute
Gastroenteritis in Children
Roberto Berni Canani, Francesco Porcaro, Serena Ruotolo, Vittoria Buccigrossi, Annalisa
Passariello, Maria Concetta Siani, Roberta Maiorino, Bracale Ileana, Francesco Maria
Ruggeri, Silvia Lima, Giulio de Marco, Alfredo Guarino
Background: Acute diarrhea continues to carry a high morbility and mortality in the pediatric
age worldwide. Zn2 has been proposed in the treatment and prevention of diarrheal disease,
but the mechanisms and the specificity against common intestinal pathogens (i.e. Rotavirus,
RV) of these effects are largely undefined. We have recently demonstrated that, through a
direct interaction with the enterocytes Zn2 induces a pro-absorptive effect in basal condition
and inhibits V. cholera toxin but not E.coli heat-stable enterotoxin secretive action (JID,
2005). However, the Zn2 effects against others mechanisms of diarrhea and RV are still
unknown. Aims: To investigate whether Zn2+ is able: 1) to reduce intestinal ion secretion
mediated by Ca2+ or by NO in an in vitro model of secretory diarrhea; 2) to inhibit the
enterotoxic and cytotoxic activity of RV in human enterocytes. Methods: Ion transport
was investigated by monitoring electrical parameters of a human intestinal epithelial cells
monolayer (Caco-2 cell line) mounted in Ussing chambers and exposed to increasing doses
of Zn2+ in the presence of an agonist of Ca2+: carbachol (10-9M), or NO: Interferon-γ
(IFN- γ, 300 U/ml), or RV (strain SA-11, 5 PFU/cell). Intracellular concentration of Ca2+,
as well as the end stable degradation products of NO (NO2-/NO3-) were also measured.
Transepithelial electrical resistance (TEER) was monitored up to 96 h in Caco-2 cell monolayer
exposed to RV, in the absence or in the presence of Zn2+. The viral load in cell culture
supernatant was determined at the end of each experiment by immunocytochemistry. Results:
Zn2+ addition to Caco-2 cells resulted in a significant reduction of ion secretion elicited by
carbachol (-68%) or by IFN- γ (-100%). Zn2+ was also able to significantly inhibit intracellular
increase of Ca2+ and NO, in response to carbachol and IFN- γ, respectively. Zn2+ was able
to inhibit RV-induced ion secretion (-86%, p<0.01) and TEER decrease (-70%, p<0.01).
These effects were associated with a significant reduction of viral load (12000+/-120 vs.
6000+/-490 pfu/ml). Conclusions: Through a direct interaction with the enterocyte Zn2+
inhibits ion secretion elicited by activation of 3 out of 4 main intracellular signal transduction
pathways of diarrhea. Zn2+ is able to reduce viral replication and to counteract RV-induced
enterotoxic and cytotoxic activity in human enterocytes. These data support the Zn2+ use
as adjunctive preventive/therapeutic strategy against diarrheal diseases induced by the major-
ity of enteric pathogens, specially RV diarrhea.
M1160
Treatment of Travelers’ Diarrhea: Rifaximin, Rifaximin Plus Loperamide Or
Loperamide Alone
Herbert L. Dupont, Zhi-Dong Jiang, Jaime Belkind-Gerson, Pablo C. Okhuysen, Charles
D. Ericsson, Shi Ke, David B. Huang, Margaret W. Dupont, Javier A. Adachi, F. Javier de
la Cabada, Francisco M. Sandoval
Antimotility agents such as loperamide can be useful for rapid symptomatic relief of travelers’
diarrhea, but they do not eradicate causative bacteria. Antibacterial drugs can eradicate
causative bacteria and effect a clinical cure. The combination of an antimotility agent and
an antibiotic may confer better therapeutic benefit than treatment with either alone. This
study was conducted to compare the efficacy of the combination of the nonabsorbed (<0.4%)
antibiotic rifaximin and loperamide with that of each agent administered alone. Consenting
adults (n=319) ≥18 years of age from the U.S. studying in Mexico during the summers of
2004 and 2005 with acute diarrhea (passage of ≥3 unformed stools in 24 h with ≥1 sign/
symptom of enteric infection) lasting ≤72 hours were enrolled (1:1:1) in a double-blind
study to receive one of three drug regimens: rifaximin 200 mg TID for 3 days (R); loperamide
4 mg initially followed by 2 mg after each unformed stool, not to exceed 8 mg/day for 48
h (L); or both drugs in the same dosage schedule (R/L). Placebos were used to blind the
study. Patients completed a daily diary reviewed each day in the clinic for 5 days. The major
cause of illness was enterotoxigenic Escherichia coli found in 112 patients (35%). Over the
5-day study period, the median time from first dose of study drug until passage of last
unformed stool (TLUS) was shorter with both rifaximin-containing regimens: R 23 h; R/L
19.5 h; than with loperamide alone: 41.5 h (P=0.01). The incidence of treatment failure
(not achieving wellness in 5 days) was lower with the rifaximin-containing regimens: R 8/
107 (7.5%); R/L 7/108 (6.5%); vs. L 17/104 (16.3%) (P=0.032). The median/mean numbers
of unformed stools passed for the duration of illness were lower with R/L 2.5/3.99 than
with either treatment alone R 4/6.23; L 4/6.72 (P=0.002/0.004). In the first 10 h after dosing,
results for TLUS favored loperamide; however, after the first 10 h, results favored rifaximin-
containing regimens. An initial loperamide response was also observed for median number
of stools during the first 0-24 h: R 2; L 1; R/L 1 (P=0.002). 48 subjects had a TLUS of 0
h: R10; L 15; R/L 23 (P=0.049). While loperamide alone conferred rapid symptomatic
improvement in travelers’ diarrhea, the effect was transient, with a high rate of continuing
diarrhea. Rifaximin treatment resulted in clinical cure. The combination of rifaximin and
loperamide, which together confer rapid initial symptomatic improvement coupled with
clinical cure, may be the optimal treatment for non-dysenteric travelers’ diarrhea.
M1161
The Probiotic E. Coli Nissle 1917 Stops Acute Diarrhoea in Infants and
Toddlers
Jobst R. Henker, Boris Blokhin, Jury Bolbot, Vitaly Maydannik, Lars Joeres, Corinna
Wolff, Juergen Schulze
Background and Objective: In most cases acute diarrhoea will be self-limiting during the
first few days after onset. For young children health risks may arise when diarrhoea lasts
longer than 3 days. The purpose of the present trial was to normalize the stool frequency
of infants and toddlers suffering from acute diarrhoea by administering the probiotic E. coli
strain Nissle 1917 (EcN) quicker than by treatment with placebo. Patients and Methods: In
total, 113 children (aged 2 to 47 months) with acute diarrhoea (> 3 watery or loose stools
in 24 hours) were randomized to either verum (probiotic EcN suspension, n = 55) or placebo
(n = 58) in a confirmative, double-blind clinical trial. Depending on the age of patients 1-
3 ml per day of verum suspension (108 viable EcN per ml) placebo were administered
orally. Results: As a reason for the acute diarrhoea viral infection was stated in 31% (35/
113) of the cases, bacterial infection in 11.5% (13/113), and mainly unspecific infection in
the rest of the children. Onset of the response to treatment (reduction of stool frequency
to ≤3 watery or loose stools in 24 hours over a period of at least 2 consecutive days) in
the EcN group was more rapid (median of 2.5 days) than in the placebo group (median of
4.8 days). The time saved by EcN therapy in comparison to placebo was a significant 2.3
days (p = 0.0007, Kaplan-Meier analysis). The number of patients showing response was
significantly higher (p = 0.0003) in the EcN (94.5%) than in the placebo group (67.2%).
Conclusion: EcN showed significant superiority compared to placebo in the treatment of
acute diarrhoea in infants and toddlers. This concerns the time to response as well as the
response rate which were much more favorable than under self-limiting conditions. Key-
words: acute diarrhoea, infants, probiotics, Escherichia coli Nissle
M1162
Efficacy of Partially Hydrolyzed Guar Gum (Benefiber) Added WHO-
Recommended Oral Rehydration Solution in the Treatment of Cholera in
Adult
Nur H. Alam, Hasan Ashraf, Shafique A. Sarker, Shahanaz Parvin, Maryam Olesen,
Niklaus Gyr, Remy Meier
Introduction: In cholera, small intestinal function is affected involving stimulation of secretory
process and reduction in absorption of water and electrolytes from small and large intestine
in response to cholera toxin. That Leads to profuse watery diarrhea resulting in hypovolemic
shock or death if immediate rehydration therapy is not instituted. The human colon has
the capacity to absorb water and electrolyte and absorption is increased in the presence of
short chain fatty acids (SCFAs). SCFAs also inhibit c-AMP mediated chloride secretion in
the colon. Partially hydrolyzed guar gum (Benefiber) is a water-soluble fiber and if added
to oral rehydration solution (ORS) undergoes fermentation in the colon liberating SCFAs.
SCFAs stimulate water and sodium absorption in the colon thus reducing the severity of
diarrhea. Aim: examine the effect of Benefiber added ORS in reducing the stool output and
duration of diarrhea in the treatment of adult patients with cholera. Methods: In an open
randomized controlled trial 130 male adult cholera patients were studied; a) 65 received
ORS plus 25 g of Benefiber; b)65 received ORS alone (control). All patients received
doxycycline 300 mg once immediately after randomization. The study was carried out at
Dhaka Hospital of ICDDRB from August 2003 to July 2005.The study protocol was approved
by the Ethics committee of the ICDDRB. Written informed consent was obtained from all
the patients. Main outcome measures were stool weight and duration of diarrhea. Results:
Baseline clinical characteristics were comparable between the groups. No significant differ-
ences were found in stool weight(g) during 1st 24 h, mean ±SD (Benefiber plus ORS group,
10206 ± 5770 vs. control group, 10231 ± 3750, p=0.977); 2nd 24h (Benefiber plus ORS
group, 2418 ± 3472 vs. control group 2172 ± 3931 p= 0.708). Duration of diarrhea (h)
after admission in hospital was also similar in both groups (Benefiber plus ORS group, 31.4
± 11.1 vs. control group, 32 ± 12.5, p=0.805). However, in a subgroup analysis (excluding
very high purging patients, stool weight 1st 24 h >10 kilogram), the stool weight was
significantly reduced in 1st 24 h in the Benefiber receiving group (Benefiber plus ORS group,
5940 ± 2920 vs. control group 7913 ± 1515, p=0.001). Conclusion: Benefiber added to
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WHO-recommended ORS is beneficial in reducing the stool weight in less severely purging
adult choera patients.
M1163
Open-Label, Dose Escalation Phase I Study in Healthy Volunteers to Evaluate
the Safety and Pharmacokinetics of Clostridium Difficile Toxin a Human
Monoclonal Antibody (CDA1)
Claribel Taylor
Claribel P. Taylor, Sanjeev Tummala, Deborah C. Molrine, Richard J. Farrell, Anthony
Lembo, Patricia L. Hibberd, Lisa Davidson, Israel Lowy, Ciaran P. Kelly Background: Clostrid-
ium difficile is the leading cause of nosocomial infectious diarrhea in industrialized countries,
and 15-20% of patients develop recurrent diarrhea after treatment with metronidazole or
vancomycin. Prior human studies correlate antibody responses to C. difficile toxin A and
protection against symptomatic disease and recurrence. We examined the safety and pharma-
cokinetics of a novel neutralizing human monoclonal antibody against C. difficile toxin A
(CDA1) in healthy adult volunteers. CDA1 was developed by the Massachusetts Biologic
Laboratories in partnership with Medarex, Inc. Methods: Five cohorts with 6 subjects each
received a single intravenous infusion of CDA1 over at least 2 hours at escalating doses of
0.3, 1, 5, 10, and 20 mg/kg. Subjects returned on days 1, 2, 3, 7, 14, 28, and 56 for safety
evaluations. The immunogenicity of CDA1 was determined by measuring serum human
anti-human antibody (HAHA) titers by a bridging ELISA. Samples for pharmacokinetic (pk)
analysis were obtained pre-infusion, and 0.5, 1, 2, 4, 6, and 8 hours post-infusion, and at
each study visit through day 56. Serum CDA1 antibody concentrations were measured by
a standardized ELISA, and pk analysis performed using a noncompartmental model. Results:
Thirty subjects were enrolled; the median age was 27.5 years, 73% were white, and 10 were
men. All subjects completed the study. There were no serious adverse events (AE) assessed
to be possibly, probably, or definitely related to CDA1. Of the 48 non-serious AE reported
during the study period, 21 were possibly related to CDA1, and included transient changes
in blood pressure requiring no treatment, nasal congestion, headache, abdominal cramps,
nausea, and diarrhea that occurred on days 0 to 2 post infusion. Mean CDA1 concentrations
increased with escalating doses; the Cmax was 6.82 mcg/mL, 26.3 mcg/mL, 109 mcg/mL,
223 mcg/mL, and 511 mcg/mL for the 0.3, 1, 5, 10 and 20 mg/kg cohorts respectively.
The geometric mean values of the half-life of CDA1 for the five cohorts ranged between
25.3 and 31.8 days, and the volume of distribution approximated that of serum. HAHA
titers were not detected in any subject. Conclusion: CDA1 was safe and well tolerated among
healthy adults, and Cmax increased proportionally with escalating doses. A randomized
study of CDA1 in hospitalized patients with C. difficile-associated diarrhea is now underway.
M1164
Successful Therapy of Unspecific Prolonged Diarrhoea in Infants and Toddlers
with the Probiotic E. Coli Nissle 1917
Jobst R. Henker, Boris Blokhin, Jury Bolbot, Vitaly Maydannik, Lars Joeres, Corinna
Wolff, Juergen Schulze
Background: Infants and toddlers with prolonged diarrhoea over several days are in danger
of developing dehydration and an acute deterioration of their general state of health. So far
no effective causal therapy exists. Therefore in a confirmatory, randomized, double-blind
clinical trial the efficacy of the probiotic bacterial strain E. coli Nissle 1917 (EcN) as compared
to a placebo was tested. Patients and Methods: In total, 151 children aged 1 month to 47
months (Ø 25 months) with unspecific prolonged diarrhoea (> 3 watery or loose stools
without blood in 24 hours of a diarrhoeal episode, which has been persisting for more than
4 consecutive days but not longer than 14 days) were randomized in a double-blind design
to receive either the probiotic EcN suspension (n = 75) or placebo (n = 76). All children
were dehydrated to a medium extent (5 - 10% loss of body weight) and received 1 to 3 ml
verum or placebo suspension orally per day depending on the age (1 ml suspension contained
108 viable EcN bacteria) for 21 days. At study commencement, rehydration (ORL according
to WHO) was performed once. Results: The number of patients showing a reduction of
stool frequency to less than 3 watery or loose stools in 24 hours over a period of at least
4 consecutive days (response rate) was higher in the EcN group than in the placebo group
already on day 7 (EcN 78.7%, placebo 59.2%) The response rate increased continuously
as was measured on days 14 (EcN 93.3%, placebo 65.8%) and 21 (EcN 98.7%, placebo
71.1%). The two-sample test of rates following a group sequential test design showed
statistically significant superiority for EcN on both days 14 (p = 0.0017) and 21 (p<0.0001).
Conclusion: Prolonged diarrhoea can be successfully treated. Due to its excellent efficacy
the probiotic EcN is a suitable remedy. Keywords: prolonged diarrhoea, infants, probiotic,
Escherichia coli Nissle 1917
M1165
Increasing Incidence of Clostridium Difficile Associated Diarrhea in African
American and Hispanic Patients - Is the Use of Proton Pump Inhibitor a
Culprit?
Abbasi J. Akhtar, Magda A. Shaheen, Cindy Vo
Background: Clostridium difficile (C. difficile) associated diarrhea (CDAD) has been increas-
ingly diagnosed in recent years especially in hospitalized patients. The number of prescrip-
tions for proton pump inhibitors (PPI) has also been increased significantly during last few
years. Prolonged and intense suppression of gastric acidity may adversely effect the protection
against ingested microorganisms. Few studies have reported an association between CDAD
and PPI use, however the results are inconclusive. Aims: to determine the relationship
between CDAD and the use of antibiotics and PPI in African American and Hispanic patients.
Methods: A retrospective review of medical records of 684 patients with CDAD over 9 years,
diagnosed by the presence of C difficile toxin in the stools, was undertaken in our hospital
caring for predominantly African Americans and Hispanics. We excluded 44 patients because

















650 patients with diarrhea (age 21-97 years) but absent C. difficile toxin in stool were used
as controls. There was no significant difference between the two groups for age, gender,
and race/ethnicity. Data were analyzed to assess the relationship between the CDAD and
the use of antibiotics and PPI using the Chi Square test and calculate the Odds Ratio (OR)
and 95% Confidence Interval (CI). Results: Of the 640 patients in CDAD group, 576 (90
%) received antibiotics during the preceding 3 months, and 32 (5%) received chemotherapy
within preceding 3 months. In comparison, of the 650 control patients with diarrhea but
negative C. difficile, 540 (83%) received antibiotics and 39 (6%) received chemotherapy.
The odds of experiencing CDAD for subjects treated with antibiotics or chemotherapy is
about 2.3 times that of those who are not using antibiotics or chemotherapy (OR=2.3, 95%
CI=1.5-3.7). Of the 608 CDAD patients receiving antibiotics or chemotherapy, 274 (45%)
also received PPI within the preceding 3 months. Of the 579 control patients who received
antibiotics or chemotherapy, 169 (26%) also received PPI within the preceding 3 months.
The odds of experiencing CDAD for subjects treated with PPI is about 2 times that of those
who are not using PPI (OR=2.0, 95% CI=1.6-2.6). Conclusions: PPI therapy may increase
the risk of CDAD in hospitalized African American and Hispanic patients receiving antibiotics.
Prospective studies are needed to determine whether PPI therapy is an independent risk
factor for CDAD. In the interim, the clinician should discourage liberal use of PPI therapy
in hospitalized patients needing antibiotics, unless strongly indicated.
M1166
Nitazoxanide in the Treatment of Clostridium Difficile Associated Disease
Daniel M. Musher, Nancy Logan, Richard Hamill, Herbert L. Dupont, Arnold Lentnek,
Arvind K. Gupta, Jean-Francois Rossignol
Clostridium difficile associated disease (CDAD) has emerged as a major nosocomial infection
in the developed world, having increased in incidence and prevalence, as well as in severity.
Failure of treatment with metronidazole has increasingly been documented. Concern over
vancomycin-resistant organisms in the hospital environment has motivated the search for
an alternative therapy. Methods. We carried out a prospective, randomized, double-blind
study comparing metronidazole with nitazoxanide in treating hospitalized patients with
CDAD. Inpatients from 7 hospitals in the United States were eligible for inclusion if they
had diarrhea (≥3 unformed stools in 24 hr), a positive EIA for C. difficile, and fever,
abdominal pain or leukocytosis. Patients were excluded if they had other known causes of
diarrhea, were currently taking intravenous metronidazole or had been treated with more
than 2 doses of oral metronidazole or vancomycin within the preceding 7 days. Patients
were randomized to receive metronidazole 250 mg 4 times daily for 10 days, nitazoxanide
500 mg twice daily for 7 days or nitazoxanide twice daily for 10 days in double-blinded
fashion. Response was evaluated after 7 days of treatment as either “well” (resolution of all
symptoms of CDAD at baseline) or “failure”. Secondary efficacy endpoints included sustained
response at study day 31, time from first dose to passage of last unformed stool and time
from first dose to resolution of symptoms. Results. After 7 days of treatment, 28 of 34
(82.4%) patients had responded to metronidazole vs. 68 of 76 (89.5%) who had received
nitazoxanide (difference = +7.1%, 95% CI: -7.0%, +25.5%). Thirty-one days after the
beginning of treatment, sustained responses were observed in 19 of 33 (57.6%), 25 of 38
(65.8%) and 26 of 35 (74.3%) of patients who had received metronidazole for 10 days,
nitazoxanide for 7 days and nitazoxanide for 10 days, respectively (P=0.34 for comparison
of all groups, P=0.20 for comparison of nitazoxanide 10-day and metronidazole groups).
The median time to last unformed stool and resolution of symptoms was 3 days for the
nitazoxanide and metronidazole treatment groups. All isolates of C. difficile collected during
the study were susceptible to metronidazole, nitazoxanide and its metabolite, tizoxanide.
Median MICs (µg/mL) were 0.5 (range 0.25 to 2) for metronidazole, 0.5 (range 0.25 to 1)
for both nitazoxanide and tizoxanide, and 4 (range 1 to 8) for vancomycin. Conclusions.
Nitazoxanide is at least as effective as metronidazole in treating CDAD.
M1167
Symptoms, Course, and Complications of Abdominal Attacks in Hereditary
Angioedema Due to C1-Inhibitor Deficiency
Konrad Bork, Petra Staubach, Eckardt J. Alexander, Jochen Hardt
OBJECTIVES: Recurrent abdominal attacks belong to the cardinal symptoms of hereditary
angioedema (HAE) due to C1 inhibitor deficiency. They are characterized by crampy pain,
but may include vomiting, diarrhea, and other features. Detailed clinical data about the
symptoms and course of abdominal attacks have not been previously reported. METHODS:
This observational study was divided into a prospective and a retrospective part. A total of
33,671 abdominal attacks were observed in 153 patients in the retrospective analysis (1973-
2004). A subgroup of 23 patients was prospectively followed over a 2-year period (2002-
2004). Symptoms, course, frequency of attacks, and complications were analyzed. RESULTS:
The relation of mild, moderate and severe attacks was 1:1.4:5.6 in the prospective part.
Our data suggests that a typical abdominal attack can be divided into 5 stages. One hundred
percent of the prospectively reported abdominal attacks followed this clinical course(phase1-
4). Extra-abdominal symptoms preceded the abdominal symptoms (pre-phase/phase 0) in
70% of patients. The mean maximal pain score was 8.4 (range 1-10). Vomiting occurred
in 73% (24,696) and diarrhea in 41% (13,682) of the attacks. Circulatory collapse accompan-
ied 4.4% (1468) of the attacks, with loss of consciousness occurring in 2.2% (739). Nine
patients could clearly distinguish 2 types of abdominal attacks, one with vomiting and one
with diarrhea. Rare complications included tetany, hemorrhagic stools, and intussusception
of the colon. In 28% (43) of the patients, recurrent abdominal attacks had started before
the characteristic swelling of the skin had ever occurred. The average onset of the first
abdominal pain attack occurred at 14.1 +/- 10.1 years (range: 1 to 59 years). Most patients
experienced their first abdominal pain-attack within the first two decades of life. CONCLU-
SIONS: This is the first systematic study of untreated abdominal attacks in HAE. Our data
suggests that these attacks are more disabling and complex than previously assumed. The
retrospective analysis showed that abdominal attacks usually begin during adolescence, and
may predate the characteristic swelling of the skin. Based on prospective data, we propose
that a typical attack can be divided into 5 distinct clinical phases, and prodromal symptoms
may aid in early recognition of an impending attack.
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M1168
Altered Bowel Morphology, Function and Bacterial Colonization in Patients
with Chronic Heart Failure
Juergen Bauditz, Anja Sandek, Alexander Swidsinski, Sabine Buehner, Jutta Weber-Eibel,
Mathias Rauchhaus, Stephan von Haehling, Tim Karhausen, Wolfram Doehner, Stefan D.
Anker, Herbert Lochs
Introduction: Chronic heart failure (CHF) causes edematous swelling and impairment of
several organ systems. However, the effects of CHF on morphology and function of the
small bowel and colon are unclear. A disturbed gut barrier function facilitates penetration
of luminal bacteria, possibly contributing to the chronic inflammatory state in CHF. Aim:
The aim of the study was to investigate whether chronic heart failure is associated with
disturbances in intestinal morphology, function and bacterial colonization. Methods: A total
of 42 patients were studied. Bowel investigations were performed in 21 CHF patients (LVEF
31 ± 2%, NYHA class 2.3 ± 0.1, peak VO2 15.6 ± 1.0 mL/kg/min, BMI 26.4 ± 1.7 kg/m2),
and 21 normal controls (LVEF 68 ± 2%, peak VO2 25.2 ± 1.4 mL/kg/min, BMI 25.0 ± 1.0
kg/m2). Bowel wall thickness was measured by high-resolution transcutaneus sonography,
intestinal permeability was assessed by lactulose-mannitol test, passive carrier-mediated
transport by D-xylose test. Mucosal bacterial biofilm was investigated by fluorescence in
situ hybridisation (FISH) in sigmoidal biopsies. Results: Patients with CHF demonstrated
edematous thickening of the entire colon and terminal ileum as compared to normal controls
(terminal ileum: 1.5 ± 0.1 vs 0.9 ± 0.1 mm, ascending colon: 2.3 ± 0.2 vs 1.2 ± 0.1 mm,
transverse colon: 2.2 ± 0.2 vs 1.2 ± 0.1 mm, descending colon: 2.5 ± 0.2 vs 1.3 ± 0.1 mm,
sigmoid: 2.9±0.2 vs 1.5±0.2 mm, (p<0.002 for all segments). Corresponding to edematous
thickening of the bowel wall, an increased intestinal permeability (lactulose/manitol ratio:
2.2 ± 0.1% vs 1.8 ± 0.1%, p=0.023) and decreased D-xylose absorption indicating bowel
ischemia (25 ± 3% vs 38 ± 2%, p=0.003) was found in CHF patients. FISH demonstrated
a higher concentration of bacteria in the mucosal biofilm of CHF patients as compared to
controls (p=0.046). Conclusion: CHF is associated with edematous thickening of the small
intestine and colon, a disturbed intestinal barrier and an increased concentration of bacteria
within the colonic biofilm. These observations further support the hypothesis that a disturbed
gut barrier function is involved in chronic inflammation in CHF
M1169
Colonic Mucosal Lesions Associated with Long-Term and Short-Term
Administration of Nonsteroidal Anti-Inflammatory Drugs
Tomoyoshi Shibuya, Toshifumi Ohkusa, Takeshi Terai, Satoshi Abe, Osamu Kobayashi,
Kazuko Beppu, Naoto Sakamoto, Akihiko Kurosawa, Taro Osada, Mariko Hojo, Akihito
Nagahara, Tatsuo Ogihara, Nobuhiro Sato
Background: The effects of long-term and short-term administration of non-steroidal anti-
inflammatory drugs (NSAIDs) on the colon have not been well characterized. There are no
case-control studies in Japan on the prevalence of NSAID-induced colitis, so we investigated
colonoscopic findings and the prevalence of adverse events following the long-term and
short-term use of NSAIDs. Methods: The study included 2157 patients who underwent
colonoscopy between June 2001 and October 2004. They were divided into the three groups;
258 patients treated for over six months with NSAIDs, 67 patients treated for under one
week with NSAIDs, and 1832 patients not treated with NSAIDs as a control group. A case-
control study was performed by medical record review for endoscopic findings, underlying
disease, pre-endoscopic symptoms, category of NSAID used, and duration of use. Results:
Colonic lesions were found in 16 of the 258 patients (6.2%) with long-term use of NSAIDs.
Among these, the duration of use ranged from 0.5 to 18 years (mean 4.4 years). The
most frequently used NSAIDs were low-dose aspirin by nine patients (56%), followed by
loxoprofen, and diclofenac. The most frequent features of colitis were longitudinal linear
ulcers and redness, seen in five patients (31%). The rectum (6 patients), and either sigmoid
colon (3 patients), descending colon (3 patients) or both were commonly involved. In the
short-term NSAID group, 4 of the 67 patients (6.0%) had colonic lesions. Three of the
patients were taking a cold complex preparation, and one patient was taking loxoprofen.
Of the 4 patients, two had rectal ulcers, one had an unshaped ulcer on the ileocecal valve,
and one had redness in the descending to sigmoid colon. In the control group, 55 of the
1832 patients (2.8%) had colonic ulcers or colitis. The group with long-term use of NSAIDs
had a significantly higher incidence of colonic lesions than the control group with the chi-
square test (p=0.0077). Conclusion: The prevalence of colonic lesions in long-term and
short-term NSAID users was found to be about 6%. It was shown that especially long-term
usage of NSAIDs had a statistically significant increased incidence of colonic ulcers or colitis.
M1170
Delayed Gastric Emptying Accelerate Bacterial Overgrowth in Both the
Stomach and the Intestine
Yoshihisa Urita, Susumu Ishihara, Kenichiro Arai, Jun Kondo, Tatsuo Akimoto, Hiroto
Kato, Noriko Hara, Hideyuki Koshino, Yoshiko Honda, Yoko Nagai, Kazushige Nakanishi,
Nagato Shimada, Motonobu Sugimoto, Kazumasa Miki
Background: Bacteria represent the sole source of gut hydrogen (H2), making this particular
gas attractive for the identification of bacterial overgrowth states. Previous studies showed
the close relationship between gastric emptying and intragastric fermentation, reflecting
bacterial overgrowth in the stomach, in diabetic patients. Several neuroendocrine peptides,
such as peptide YY (PYY) and glucagon-like peptide (GLP) 1, have been proposed as ileocolic
mediators of upper digestive tract inhibition, and fermentation in the upper digestive tract
may affect the gastric motility. The aim of this study was to evaluate a relationship between
gastric emptying and fermentation in the digestive tract. Patients and Methods: Studies were
performed in 25 patients (mean age 63.1 years, male/female=6/19) undergoing esophagogas-
troscopy. At the time of endoscopic examination, we intubated the stomach and the duo-
denum without inflation by air, and 20 ml of intraluminal gas samples of both sites was
collected through the biopsy channel. Intraluminal hydrogen concentrations were measured
by gaschromatography. Within a week, 13C-acetate breath test was performed in all patients
to measure the gastric emptying. Breath tests were performed in the sitting position after
an overnight fast. The patients received a liquid test meal (OKUNOS-A) containing 100mg
of 13C-acetate in the sitting position. Breath samples were collected at baseline and at 5,
10, 15, 20, 30, 40, 50, 60, 75, 90, 105, 120, 135, 150, 165, 180, 210, 240 min after
ingestion of a test meal. 13C was measured as the 13CO2/12CO2 isotope ratio and was
expressed as delta per mil (). The results of 13C-acetate breath test, gastric emptying, were
expressed as the time of peak excretion (Tmax). Delayed gastric emptying was defined when
Tmax was more than 90 min. Results: Twelve patients had Tmax more than 90 min and
their mean values of intragastric, intraduodenal, and breath H2 gas were 12.3 +/- 16.7 (0-
49), 58.0 +/- 141.5 (0-502), and 11.1 +/- 21.9 ppm (0-79), respectively. Those in patients
with normal gastric emptying were 5.6 +/- 6.6 (0-21), 4.5 +/- 3.9 (0-12), and 0.8 +/- 0.9
ppm (0-3), respectively. Patients with delayed gastric emptying had higher intraluminal and
breath H2 concentrations, possibly reflecting bacterial overgrowth not only in the stomach
but in the intstinal tract. Conclusions: In conclusion, there was a close correlation between
the bacterial overgrowth and delayed gastric emptying.
M1171
Long-Term Efficacy of Lubiprostone for the Treatment of Chronic Constipation
John F. Johanson, Raymond Panas, P. Christopher Holland, Ryuji Ueno
Constipation is a common and bothersome gastrointestinal condition. Current treatment
options are often ineffective. Lubiprostone is a novel type-2 chloride channel (ClC-2) activator
(AJP Cell Physiol 287:C1173-C1183, 2004) that has been shown to be efficacious and well
tolerated by subjects with chronic constipation in a number of well-controlled clinical trials
of 3-4 weeks duration (Gastroenterology 122:A315, 2002; Gastroenterology 124:A38, 2003;
Am J Gastroenterol 100:S324, S328 and S329, 2005). We describe results from three open-
label, long-term (6 to 12 months) trials where efficacy assessments were periodically captured
(approximately every 6 weeks). Methods: Study 1 was a 24-week open-label extension to
a 4-week double-blind pivotal trial that enrolled 308 subjects. Study 2 was a 48-week open-
label trial in 248 subjects, 87 of whom were examined in a 7-week randomized withdrawal
study period prior to the open-label portion. Study 3 was a 48-week open-label trial in 324
treatment-naïve subjects. In each of the three trials, subjects assessed treatment effectiveness,
their constipation severity, and abdominal symptoms of bloating and discomfort using a 5-
point scale at each study visit. Results: Improvements in assessments of constipation severity,
abdominal bloating, and abdominal discomfort were statistically significant in all studies
and at all visits (p<0.0001). Across all three studies, constipation severity was improved by
an average of 1.28 points at Weeks 4-6 (N=828), 1.47 points at Week 24 (N=512), 1.38
points at Week 48 (Study 2 and 3 only, N=281), and 1.15 points for the last on-drug
measurement (N=866). Abdominal bloating was improved by an average of 0.89 points at
Weeks 4-6 (N=829), 0.98 points at Week 24 (N=512), 1.00 points at Week 48 (Study 2
and 3 only, N=282), and 0.79 points for the last on-drug measurement (N=867). Abdominal
discomfort was improved by an average of 0.74 points at Week 1 (N=619), 0.91 points at
Week 24 (N=512), 0.87 points at Week 48 (N=282), and 0.72 points for the last on-drug
measurement (N=867). Conclusion: These results demonstrate that the effects shown in the
short-term, double-blind trials continue for at least 24 to 48 weeks, as observed in these
three long-term trials. Lubiprostone provides significant relief for a variety of constipation
symptoms and efficacy is potent and sustained for up to 48 weeks of treatment.
M1172
Is Visceral Obesity Really a Risk Factor for Colorectal Neoplasm?
Tae-Hoon Oh, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Ja Young Kim, Kwi-
Sook Choi, Hyung Joon Lee, Jun-Won Chung, Kee Don Choi, Gin H. Lee, Hwoon-Yong
Jung, Jin-Ho Kim, Jae H. Byun
Backgrounds/Aims: Although several risk factors for colorectal neoplasm (CRN) have been
suggested, there has been controversy about obesity as a risk factor for CRN because of the
methodological difference in the measurement of obesity between studies. We conducted a
prospective cross sectional survey to evaluate obesity as a risk factor for CRN. We used
abdominopelvic CT scan for more objective analysis of visceral and parietal obesity. Method:
We consecutively enrolled asymptomatic average-risk subjects who underwent both colonos-
copy and abdominopelvic CT scan for the routine health evaluation. The amount of visceral
and parietal fat was calculated from abdominopelvic CT scan. Other indices of obesity such
as body mass index (BMI) and waist circumference were also evaluated. Various blood
markers for metabolic syndrome such as fasting blood glucose, Hb A1c, and serum lipid
profile, and family history of CRN were investigated. The presence or absence of CRN was
analyzed in relation to obesity and metabolic markers. Results: 200 subjects were enrolled.
Of these, 53 subjects (26.5%) had CRN. Male to female ratio was not different between
those with CRN and those without (3.0:1.0 vs. 1.7:1.0, p=0.127). Mean age was significantly
higher in those with CRN than those without (55.0±7.7 vs. 49.5±8.3 years, p<0.001). Visceral
fat amount was significantly higher in those with CRN than those without (124.8±49.8 vs.
99.7±51.6 cm2, p=0.003). Waist circumference was also higher in those with CRN (86.5±7.7
vs. 83.1±9.0 cm, p=0.018), but BMI was not different between those with CRN and those
without. Out of various metabolic markers, only fasting blood glucose was higher in those
with CRN than those without (103.9±26.9 vs. 96.5±14.6 mg/dL, p=0.021). In multivariate
analysis for the risk of CRN with an adjustment of age, sex, and family history of CRN,
odds ratio of those with visceral fat over 136.61cm2 (quartile 4) to those with visceral fat
under 67.23 cm2 (quartile 1) was 4.6 (95% confidence interval 1.1-18.4). Visceral fat
amount was the only independent risk factor for CRN. Waist circumference and various
metabolic markers were not risk factors for CRN in multivariate analysis. In cases with CRN,
visceral fat amount was not associated with the location, number, and degree of villous
component or dsyplasia. However, visceral fat amount tended to increase as the size of CRN
increased (r=0.29, p=0.03). Conclusion: Our data shows that visceral fat is an independent
risk factor for the presence of CRN and it may influence the progression of small CRN to
large one. Further large scale study is necessary to clarify the role of visceral fat in the
development of CRN.
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M1173
Helicobacter Pylori Infection Is Associated with An Increased Risk of Colonic
Adenomatous Polyp
Takashi Ando, Shigeto Mizuno, Yoshinori Morita, Toshio Inui, Akihiro Asakawa, Naohiko
Ueno, Takeshi Ishikawa, Yasuyuki Nagao, Nobuyuki Seto, Akiko Komatsu, Tuguhiro
Matsumoto, Haruki Kato, Toshikazu Yoshikawa, Akio Inui
Compelling evidence from epidemiological, histopathological and animal studies has linked
Helicobacter pylori infection to the subsequent development of gastric cancer.2 Nevertheless,
the currently available data regarding a possible link between Helicobacter pylori seropositivity
and colorectal cancer risk are limited and inconclusive. We sought to determine whether
Helicobacter pylori is associated with colon neoplasia in Japanese population. We examined
332 patients who underwent routine highresolution total colonoscopy and serologic testing
for IgG antibodies agonist Helicobacter pylori. Subjects who received cyclooxygenase-2 inhib-
itors or previous eradication therapy and those with borderline titer levels were excluded
from data analysis (n=27). Seronegative control subjects were from the same study population
to maximize the representativeness. There were no significant differences in age and sex
between the two patient groups. A significant increase in the incidence of adenomatous
polyps (p<0.0001) and decrease in normal colonoscopic findings (p<0.0005) were observed
in seropositive patients than those seronegative. This study indicates an etiological link of
Helicobacter pylori infection to colorectal neoplasia and the need of routine colonoscopy in
seropositive patients.
Presence or absence of Helicobacter pylori and colonoscopic findings
Numbers in parentheses are percentages. Plus values are mean plus and minus SEM. Analysis
of variance followed by Bonferronit test were used to assess the differences among groups.
P was considerd to be statistically significant.
M1174
A Dose-Finding Study of Rifaximin in the Treatment of Small Bowel Bacterial
Overgrowth in Patients with Irritable Bowel Syndrome
Ernesto Cristiano Lauritano, Andrea Lupascu, Emidio Scarpellini, Maurizio Gabrielli,
Alessia Cazzato, Mario Pescatori, Angelo Santoliquido, Roberto Flore, Paolo Tondi,
Giovan Battista Gasbarrini, Antonio Gasbarrini
Introduction: Small bacterial overgrowth (SIBO) is a condition characterized by abnormally
high bacterial population level in the small intestine, exceeding 105 organisms/ml. SIBO
often requires lifelong management based on sporadic or periodic oral antibiotic therapy.
Up to date, given the diversity of intestinal bacterial populations involved and the small
number of clinical trials, the choice of antibiotic and the duration of the therapy are still
uncertain. Recent findings suggest that rifaximin, a broad spectrum non-assorbable derivate
of rifamycin, is effective in the treatment of SIBO. The aim of the present study was to
investigate the efficacy and tolerability of two different doses of rifaximin in the treatment
of SIBO. Patients and methods: We enrolled 60 pts affected by SIBO among our IBS
population. The diagnosis of IBS was based on the Roma II criteria. The presence of SIBO
was based on the occurrence of a peak of H2 values more than 10 ppm above the basal
value after 50 gr glucose ingestion. All pts were randomised in two 7 days treatment:
rifaximin 1200 mg/die group 1 and rifaximin 1600 mg/die group 2. Glucose breath test
was reassessed 1 month after the end of therapy. Results: Two drop-outs were observed in
group 2 due to taste disturbance whereas no drop-outs were observed in group 1. Glucose
breath test normalization rate was 60% in group 1 in both intention-to-treat and per protocol
analyses whereas glucose breath test normalization was achieved in 63 and 68% in group
2 in intention-to-treat and per protocol analysis, respectively. Differences between groups
were not statistically significant. Side-effects were significantly lower in group 1 than group
2. Conclusions: Seven days-1200 mg rifaximin therapy is a good option in terms of efficacy
and tolerability for SIBO treatment. Higher dosage of rifaximin doesn’t increase the therapeutic
efficacy in SIBO eradication and is associated with major intensity of side effects.
M1175
Improved Outcomes and Potential Avoidance of Transplantation with
Multidisciplinary Intestinal Rehabilitation for Intestinal Failure - Intent to
Treat Analysis
Kishore Iyer, Timothy Sentongo, Valeria Cohran, Lisa Keys, Kim Kazmerski, Margaret
Richard
Background Intestinal transplantation is the standard of care for patients with irreversible
intestinal failure and life-threatening complications of parenteral nutrition (PN). A very high
mortality rate on the national waiting list (25 - 30%) has led us to search for rational

















approach to managing pediatric intestinal failure in a transplant program. Methods Retro-
spective review identified all patients who were managed within the program over a 3-year
period. The primary end-point was patient survival; secondary endpoints were impact on
PN utilization and impact on liver dysfunction (PNALD). Even in the presence of established
transplant indications at referral, transplantation was reserved for patients who fail all
conservative strategies. Where PN dependence and PN failure appear irreversible, patients
are listed for intestinal transplantation, often in parallel with application of conservative
strategies. Results Of 64 patients managed with this approach, 60 patients are alive for an
overall patient survival of 93.8%. Two of the 4 deaths occurred in patients who were listed
elsewhere for combined liver-intestinal transplantation (LIT) and transferred to our care
with worsening advanced PNALD. In both cases, death occurred within weeks from sepsis
without the opportunity for transplant. One death occurred after isolated intestinal transplant
(SBT) and 1 death occurred from complications of lung-disease of prematurity. 49 of the
60 (81.7%) survivors achieved full enteral autonomy from PN and 8 (13.3%) achieved
partial autonomy. Of 28 patients who met criteria for PNALD, 25 patients are alive. 24 of
the 25 patients have normalized biochemical tests of liver dysfunction. 2 patients underwent
SBT for PNALD, and 1 patient underwent isolated liver transplantation after achieving enteral
autonomy from PN. Of 6 SBT performed since September 2004, 5 patients are alive, 4 with
functioning grafts. Discussion Our preliminary results suggest that multidisciplinary intestinal
rehabilitation may help address the significant mortality on the waitlist in infants awaiting
combined LIT and allow overall improved patient survival. Majority of these patients achieve
enteral autonomy from PN even in the setting of complicated intestinal failure and can
achieve biochemical liver recovery often without need for transplant. Two of the 4 deaths
in our series emphasize the need for rapid access to transplantation for success with this
approach.
M1176
Racial Differences in the Distribution of Initial and Recurrent Colonic
Adenomatous Polyps Among Veterans
Nadeem Ullah, Sunita Duttala, Martin Tobi, Adhip Majumdar
OBJECTIVES: Previous small studies have suggested that African Americans have predomin-
antly proximal distribution of colonic adenomas as compared to general population but
whether this distribution persists on follow up after polypectomy is not known. The purpose
of current study was to determine the differences in the distribution of colonic adenomas
in African American (AA) Veterans as compared to Caucasian Veterans and to see if this
difference persists on follow up colonoscopy. METHODS: We retrospectively analyzed the
data of 151 patients who were found to have at least one adenoma on clinically indicated
colonoscopy and had follow up colonoscopies. Based on polyps distribution the patients
were divided into three groups; 1- Only left-sided polyp, if the patient had all polyps distal
to splenic flexure. 2- Only right-sided polyp, if the patient had all the polyps proximal to
splenic flexure. 3- Right and left-sided polyps, if the patient had synchronous polyps proximal
and distal to splenic flexure. Eighty AA subjects were matched with 71 Caucasians for age,
BMI, nutritional assessment, serum B12, folate and calcium levels. RESULTS: All 151 subjects
except 8 were male. On initial colonoscopy AA had statistically significant increased incidence
of only right sided adenomas as compared to Caucasians (p<0.002) as shown in the table.
On follow up (average 3 years) although more AA patients showed recurrence of adenomas
(70% AA vs 55% C) but this difference was not statistically significant. The distribution of
adenomas on follow up colonoscopy was not statistically significant different between these
two groups (table). CONCLUSION: AA Veterans have increased incidence of only right
sided colonic adenomas but once these adenomas are removed the distribution of recurrence
of colonic adenomas assumes the same distribution as in Caucasians. Therefore, the surveil-
lance strategies should be tailored accordingly.
Distribution of Colonic Adenomatous Polyps on Initial and Follow up Colonoscopy
AA --> African American, * --> p<0.002, Initial --> Initial colonoscopy, Follow up --> Follow
up colonoscopy.
M1177
Same Day Bi-Directional Endoscopy in Patients with Functional
Gastrointestinal Disorders
Ivan Bottoli, Michael Shetzline, Nora Mattek, Jennifer Holub, David Lieberman, Glenn
Eisen
Background: It is apparent that numerous patients with functional gastrointestinal disorders
undergo endoscopic evaluation. The utility of these exams remains in question as patients
tend to be younger and the yield of significant findings may be less than for patients with
other indications such as bleeding and weight loss. Same day bi-directional endoscopy
(panendoscopy) may be performed in this patient group but the overall yield is unknown.
Our group utilized the CORI national endoscopic database to assess this question. Methods:
All patients undergoing same day bi-directional endoscopy between 2000-2004 were
included in the dataset. Demographics, indications and significant findings were assessed.
Functional GI disorders for EGD were defined as dyspepsia and/or abdominal pain/bloating
excluding reflux symptoms, dysphagia and Barrett’s surveillance. For colonoscopy, functional
GI disorders were defined by abdominal pain/bloating, diarrhea, constipation and or change
in bowel habits excluding surveillance of or established IBDm weight loss or bleeding
(anemia, iron deficiency, positive FOBT, hematochezia or melena). Significant findings for
EGD were any of the following: suspected malignancy, AVM, ulcer , Barrett’s, stricture; for
colonoscopy: suspected malignancy, polyp > 9 mm, or AVM. Results: During the study
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period, 706,775 unique patients had EGD and/or colonoscopy. 66,265 (9.4%) patients
underwent same day bi-directional endoscopy. 23,360 (33.7%) of these patients had a
functional GI disorder. Of these 33.9% had a functional disorder as the indication for the
EGD only, 41.7% for the colonoscopy only and 24.4% for both procedures. Patients who
had functional indications for both procedures tended to be younger (mean age 55.9) and
more often female (68.3%) (p<.0001) than the other 2 groups and the procedure was more
likely to be performed in a community/HMO setting. Conclusions: A significant number of
patients with functional GI disorders undergo same day bi-directional endoscopy according
to our national endoscopic database. The yield of significant findings is very low. Patients
with functional indications for both procedures have the lowest rate of findings.
M1178
Systematic Evaluation of the Causes of Chronic Watery Diarrhea with
Functional Characteristics
Fernando Fernandez-Banares, Maria Esteve, Montse Alsina, Carme Farre, Clarisa
Gonzalez, Montse Buxeda, Montse Forne, Merce Rosinach, Jorge C. Espinos, Antonio
Salas, Josep Maria Viver
Causes of chronic watery diarrhea are multiple. A diagnosis of either functional diarrhea or
diarrhea-predominant IBS is performed when routine complementary explorations are normal
and there are not alarm symptoms/signs. However, the same clinical picture may be caused
by several entities which should be excluded by diagnostic testing. Although tests to rule
out bile acid malabsorption (BAM) and sugar malabsorption (SM) are recommended, they
are not routinely performed. Besides, it has been described that some of these patients have
mild forms of gluten-sensitive enteropathy (GSE). Aim: To assess prospectively the presence
of GSE, BAM and SM in consecutive patients with chronic watery diarrhea of origin previously
unexplained fulfilling Rome II criteria of functional disease. Methods: 62 patients (52.2±2
yrs; 15M, 47W) with chronic watery diarrhea (24-h stool weight>200 g/d), and with normal
physical exam and routine blood analysis (including C reactive protein, T4/TSH, celiac
serology, IgA), negative stool ova & parasites, and normal full colonoscopy with multiple
biopsies were included. Median previous duration of diarrhea was 24 m (range, 7-72). In
all cases the following tests were performed: 1- HLA-DQ2/DQ8 genotyping; 2- In case of
DQ2/DQ8+, endoscopic biopsies from distal duodenum were obtained. The number of
intraepithelial lymphocytes (N<25%) and villous architecture were assessed, and intestinal
damage was classified according Marsh; 3- SeHCAT abdominal retention test (N>10% at
7th day); 4- Small bowel follow-through; and 5- Hydrogen breath test (lactose,
fructose+sorbitol) if previous tests were normal. Gluten- or sugar-free diet, or cholestyramine
were administered according to results. Functional disease was diagnosed if all tests performed
were normal or if there was no response to specific therapy after a follow-up of 6-12 m
Results: 12 GSE (11 Marsh I, 1 Marsh II), 37 BAM and 22 SM were found. BAM was
considered to be the cause of diarrhea in 29 (46.8%) patients, SM in 10 (16.1%), GSE in
9 (14.5%), and both BAM and SM in 2. Twelve (19.3%) patients were diagnosed as functional
diarrhea/IBS. Diarrhea stopped in the 50 patients with an specific diagnosis, decreasing the
daily stool number from 5.4±0.3 to 1.5±0.1 (p<0.0005), without relapse after follow-up
(12 m in 79%; >6 m in 100%). Conclusions: The diagnosis of functional disease in patients
with chronic watery diarrhea should be performed with caution since in most cases there
is an organic cause which justifies diarrhea. Mild GSE is an entity to be considered in the
diagnostic work-up of chronic watery diarrhea. Sponsorized by Fundació Banc Sabadell.
M1179
Primary Bile Acid Malabsorption - A New Insight Into Prevalence
Gautam Mehta, Mathena Vinayaga-Pavan, Neil Galletly, Benedict Ancock, Geoff V. Smith,
Devinder Bansi, Andrew V. Thillainayagam
Background and Aims: Bile acid malabsorption (BAM) is increasingly recognised as a cause
of chronic diarrhoea. Malabsorption of bile acids can occur secondary to gastrointestinal
disease or due to a primary defect in the distal ileal sodium-dependent bile acid transporter.
The prevalence of primary BAM is unclear. The aim of this study was to clearly establish
the aetiology and prevalence of BAM in chronic diarrhoea. Methods: A retrospective review
was conducted of 149 patients with chronic diarrhoea, investigated for BAM using SeHCAT
imaging between 2001-2005. A positive result was defined as <15% retention of SeHCAT
at 7 days. All patients had previously undergone assessment of haemoglobin, C-reactive
protein, colonoscopy, colon histology, barium small bowel imaging and either duodenal
histology or anti-tissue transglutaminase antibodies. Patients with BAM were classified as
(i) BAM1 - previous ileal resection, ileocolonic resection or ileal disease, (ii) BAM2 - idiopathic
BAM, or (iii) BAM3 - previous cholecystectomy, peptic ulcer surgery, irritable bowel syn-
drome, coeliac disease, chronic pancreatitis, diabetes mellitus or bacterial overgrowth. Results:
The mean age of the study population was 50 years (57 males, 92 females). Incomplete
previous investigations excluded 23 patients. There was no significant difference in age
between the groups with normal and abnormal SeHCAT retention (49.3yrs vs 53.0yrs).
Normal SeHCAT retention was found in 78 patients. Impaired SeHCAT retention was found
in 48 patients (38%). Of these, 13 patients (27%) were classified as BAM1, 19 patients
(40%) as BAM2, and 16 patients (33%) as BAM3. Patients with primary BAM were signific-
antly younger than those with secondary BAM (47.0yrs vs 57.0yrs, p=0.02). Discussion:
This cohort is more comprehensive than any in the current published literature. Our study
is in accordance with the largest study to date by Wildt and colleagues1. They diagnosed
primary BAM in 33% of patients with abnormal SeHCAT retention, but did not exclude
enteropathy assiduously by ileal imaging and coeliac disease testing in every patient. The
results of our study validate and enhance previous work with more stringent exclusion
criteria. Idiopathic BAM accounts for a considerably greater proportion of cases with abnormal
bile acid absorption than previously recognised. Therefore this condition must be actively
sought in patients with chronic diarrhoea, particularly those of a younger age. 1. Wildt S,
Nørby Rasmussen S, Lysgard Madsen J, Rumessen JJ. Bile acid malabsorption in patients with
chronic diarrhoea: clinical value of SeHCAT test. Scand J Gastroenterol 2003;38:826-830.
M1180
Serum 7alpha -Hydroxycholestenone in Patients with Idiopathic Bile Salt
Malabsorption - A Detailed Comparison with Conventional SeHCAT Testing
Simon Campbell, Nischay Chandra, Gladman Lisa, Mee Anthony
INTRODUCTION: Bile salt malabsorption(BAM) is a common cause of chronic diarrhoea.
Causes include Crohn’s disease, SB resection, bacterial overgrowth, post infective, post
cholecystectomy and idiopathic(IBAM). A diagnosis of IBAM is made by measuring bile salt
turnover/excretion, usually by SeHCAT test. This measures % retention of 75Se labelled bile
acid 7days after oral admin.; <19% uptake indicates BAM. Another Ix is measuring serum
7alpha-hydroxycholestenone(7HC), a bile acid metabolite. This is raised in BAM pts(normal
<35ng/ml). 7HC is a quicker Ix than SeHCAT and avoids radiation exposure. Serum 7-HC
is not widely used because the standard material was not commercially available until recently.
There are few data regarding cost-effectiveness of 7-HC, its correlation with symptoms in
IBAM or sensitivity compared to SeHCAT. AIMS & METHODS: To compare serum 7-HC
in pts with IBAM, compare sensitivity and cost with SeHCAT. We collected data from 64
pts who had SeHCAT test. Pts with SeHCAT of <19% were included and pts with other
causes of BAM excluded. 40 pts had a diagnosis of IBAM and 11 healthy controls were
included - all had serum 7HC measured. Other data included demographics, all clinical Ix,
stool freq. pre/post Rx. Comparison was by log rank analysis and MWT. Statistical significance
was taken as p=0.05. RESULTS: 40 pts (22M:18F, median age 53 yrs, range 25-75) had
IBSM, with a SeHCAT <19% and normal clinical Ix (median SeHCAT 7.3%, range0.3-
17.6%). All pts had serum 7HC measured. Median bowel freq. pre-Rx was 5x/day (range3-
12) - all pts improved post Rx (median 3x/day, range1-6). 11 healthy asymptomatic controls
(6M:5F, median age 53 yrs, range26-60) also had serum 7HC measured. There was a strong
correlation between 7HC vs. SeHCAT results (r2=0.37, p<0.0001) and 7HC vs. stool freq
(r2=0.33,P<0.001). 7HC levels in IBAM pts (median 67.0ng/ml, range14-280) were higher
than controls (median 27.0ng/ml, range10-40) and was significant(MWT, p<0.001). Median
cost of Ix each pt was £587 (range£347-£1170). The cost of 7HC(£60/test) was less than
SeHCAT(£257/test) comparing well with other Ix(eg EMA-£45/test). CONCLUSION: 7HC
is an accurate method of diagnosing BAM in pts with IBAM (93% sensitivity). In IBAM
serum 7HC correlated with degree of BAM and symptoms. We speculate if 7HC was widely
used the convenience of the Ix would lead to earlier diagnosis and avoid other invasive Ix -
saving more money. Serum 7HC is cheaper, safer and should replace SeHCAT.
M1181
The 13C-Xylose Breath Test Is Inferior to the H2-Glucose Breath Test for the
Diagnosis of Intestinal Bacterial Overgrowth in Children with Cystic Fibrosis
Arne R. Schneider, Stefanie Klueber, Hans-Georg Posselt, Benjamin Funk, Lydia
Murzynski, Wolfgang F. Caspary, Juergen Stein
Introduction: The 13C-xylose breath test has been proposed as an alternative to the H2-
glucose breath test for the diagnosis of intestinal bacterial overgrowth. However, data on
the accuracy of the xylose breath test with 13C labeled substrates are lacking. Since recent
studies reported a high prevalence of bacterial overgrowth in cystic fibrosis (CF), we aimed
to compare both breath tests in this group of patients. Patients and methods: 40 children
with CF (21 boys; median age 12,5 years (4-18)), 10 healthy children (7 boys; 10 years
(6-15)) and 22 adult patients (10 men; 53 years (21-73)) underwent a combined H2-glucose/
13C-xylose breath test. In children, 50mg [13C]-D-xylose and 1g/kg b.w. glucose were
dissolved in water and orally applied. Adults received 100 mg [13C]-D-xylose and 80g
glucose. Breath samples were collected every 30 minutes for 3 hours and analysed for H2
concentration [ppm] and 13CO2-enrichment (DOB [‰]). An H2-increase of >20ppm above
baseline was considered pathologic. Results: In 27/40 CF-children (68%), already baseline
breath hydrogen content exceeded 20ppm and remained above this threshold during the
test. None of the remaining 13 CF-children developed pathologically increased breath
hydrogen concentrations. 13CO2-enrichment (DOB) did not differ between CF-children with
or without pathologic H2-breath test results (p>0,05). The 27 CF-children with increased
baseline H2-concentrations had a significantly lower DOB compared with the 10 healthy
children (p=0,04). DOB after 3 h correlated significantly with age if all 50 children of the
study population were considered (r = -0,65, p<0,0001). Among 22 adult patients, H2-
concentration pathologically rose in 8 (36%). This subgroup produced significantly higher
DOBs compared with the remaining 14 adults (p=0,02). A DOB-cutoff of 6,8 ‰ yielded a
sensitivity of 79% and a specificity of 63% in adults. Discussion: Bacterial overgrowth is
frequently encountered in children with cystic fibrosis. Compared with the H2-glucose breath
test, the 13C-xylose breath test lacks sensitivity and specificity, probably due to an age-
dependent decrease of 13CO2-enrichment. Moreover, considerably higher costs for the
labelled substrate and a long period of 13CO2-breath sampling are major drawbacks of the
13C-xylose breath test, the latter particularly in young children.
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M1182
13c-Sucrose Breath Test to Differentiate Congenital Sucrase-Isomaltase
Deficiency from Pandisaccharidase Deficiency
Claudia Robayo, Antone R. Opekun, Roberto Quezada-Calvillo, Susan S. Baker, Buford L.
Nichols
Introduction: A substrate-paired breath test using 13C-sucrose (S) and 13C-glucose (G) has
been developed to assess congenital sucrase-isomaltase deficiency (CSID). The aim was to
determine if CSID could be detected without duodenal enzyme assay. Methods: Two patients
(1F:1M, aged 1 & 15 yrs.) with CSID (duodenal mucosa biopsy-proven), 3 patients with
pandisaccharidase deficiency (P) (1F:2M, aged 10-15 yrs.) & 5 normal patients (4F:1M,
aged 3-15 yrs.) were studied. All had mucosal enzyme activity determinations done. Uni-
formly-labeled 13C-substrates (G & S; 20 mg. each, Isotec, Miamisberg, OH) were given
in 10 gm unlabeled glucose oligomers (10%) vehicle after an overnight fast and reference
sampling on 2 separate days. Serial 13CO2 breath enrichments (every 15 min * 6) were
assayed using a 13CO2 infrared spectrophotometer (POCone®, Otsuka Electronics, Tokyo,
Japan). A coefficient of glucose oxidation (CGO) was calculated for S breath enrichments
to adjust for individual differences for each time-paired sample. Normal control patients
were used to define CGO lower reference levels (LL) defined as mean-1 SD. Results: The
CSID patients had S-CGO significantly below the LL and the P patients had relatively normal
S-CGO results above the LL. Duodenal S enzyme activity levels and S-CGO results closely
correlated (R^2 0.72). Conclusions: The S/G substrate-paired breath test distinguished CSID
patients from controls and differentiated CSID patients from the secondary forms of S
deficiency. It appears that patients with low S-CGO could benefit from mucosal biopsy to
identify additional enzyme deficiencies.
M1183
Variability in Gastrointestinal Permeability in Healthy Subjects
Paul Lundin, Jonas E. Pettersson, Karin Nelander, Lars Lofgren
BACKGROUND: Intestinal permeability has previously been assessed using different markers
as a single test. Variations in repeated permeability tests over a period are not well known.
Aim of the study was to investigate daily inter- and intraindividual variability of the intestinal
permeability in healthy subjects. Furthermore we evaluated whether a fasting or non-fasting
state alter the urine recovery of administered markers. METHODS: A combination of four
sugar markers was used to reflect the gastroduodenal (sucrose), small intestinal (mannitol
& lactulose) and distal gastrointestinal (sucralose) permeability. After overnight fasting,
healthy subjects (five male, five female) ingested a solution of the markers, then urine was
collected for 0-3, 3-6, 6-12 and 12-24 h. To reduce variability, all subjects had a standardized
diet during the study days. This procedure was repeated in five consecutive weeks. On the
fifth visit subjects did not fast prior to marker administration. The sugar markers in urine
were analysed using gas chromatography - mass spectrometry (GC-MS). A statistical model
was designed to estimate inter- and intraindividual variability for each marker. RESULTS:
All subjects had a normal kidney function measured as glomerular filtration rate. The major
part of the recovered sugar markers was found in the 0-6 h interval. For all sugar markers
in fasting state, variations within and between subjects were of the same order. At the non-
fasting day the sucrose recovery at the 0-3 h interval was significantly (p<0.05) lower than
at the fasting visits. For sucralose, more than 20 % of the dose recovered in urine was found
in the 12-24 h interval, indicating an uptake in the distal GI-tract. CONCLUSIONS: In
fasted healthy subjects, the inter- and intraindividual variability was of the same magnitude
for each sugar marker and interval, respectively.



















Von Willebrand Disease - An Underestimated Cause of Gastrointestinal
Bleeding from Angiodysplasia?
Bruno Neu, Sebastian Noe, Monther Bajbouj, Georg Moessmer, Alexander Meining,
Christian Prinz, Holger Seidl, Wolfgang Schepp, Michael Anzinger, Wolfgang Schmitt,
Roland M. Schmid
Background: Angiodysplasias (AD) are the most common reason of chronic bleeding from
the gastrointestinal (GI) tract. However, asymptomatic AD are often seen during routine
endoscopy. In this study we looked systematically, in a prospecitve manner for concomitant
disorders of hemostasis, underlying diseases, and characteristics of AD which may be linked
to bleeding from AD. Patients and Methods: 38 patients (22 women, mean age 71 years)
with gastrointestinal bleeding from AD were included. All subjects were investigated by
upper, lower, and capsule endoscopy. Platelet function was measured by closure time in a
whole blood test, activated by collagen/epinephrine resp. collagen/ADP (platelet function
analyser, PFA-100). Furthermore, PT, aPTT, thrombin time, factor XIII, factor VIII:C, ristoce-
tin cofactor activity and von Willebrand factor (vWF) Ag were determined. Results: Before
study entry the patients suffered from bleeding for 2 years, needed 2 units of packed red
cells, and had a minimal hemoglobin level of 7.4 mg/dl (median values). An average of 2.5
AD was found (1-10 mm in diameter), localised 5% in the stomach, 55% in the upper part,
6% in the middle part, 5% in the lower part of the small intestine, and 29% in the colon.
25 of 38 patients had a disorder of primary hemostasis. 13/38 patients showed a pathological
platelet function, measured by an increased closure time as a possible hint for a functional
vWF-defect. 3 of them had also low levels of vWF-Ag and therefore, were suspicious of a
quantitative vWF-defect. 12 patient presented with increased closure times due to ASS
medication or were under ASS treatment during the bleeding episode. Conclusion: Interest-
ingly, most of the AD are localised in the upper third of the small intestine. Two-third of
patients with bleeding angiodysplasia had a dysfunction in primary hemostasis. Half of them
might suffer from a defect in the vWF, the other half had platelet-inhibiting medication.
M1185
Long-Acting Octreotide As Rescue Therapy in Preventing Rebleeding from
Gastrointestinal Angiodysplasias
Giuseppe Scaglione, Lorena Pietrini, Pasquale Sarracco, Domenico Di Pietro, Mariarosaria
Franco, Francesca Russo, Fernanda Mirco, Italo Sorrentini
BACKGROUND: angiodysplasias are the most common source of obscure gastrointestinal
bleeding (GIB) in the elderly. Management of such vascular abnormalities is still an open
clinical problem in patients not elegibile for surgical or endoscopic therapy. Octreotide has
shown to have some benefit in this subgroup of subjects, but it has not been extensively
studied. AIM: to investigate the efficacy of long-acting octreotide (LAR-OCT) in the prevention
of rebleeding from gastrointestinal angiodysplasias in patients not candidate for surgery and
resistant to endoscopic treatment. PATIENTS AND METHODS: ten patients (M/F 4/6, mean
age±SD 77.6±8.1) with a long history of chronic occult or overt GIB due to multiple upper
and lower angiodysplasias referred to our unit from 2000 to 2004 entered the study. In
each patient diagnosis was made by upper and lower endoscopy, push enteroscopy and
wireless video capsule endoscopy, when appropriate. After obtaining written informed con-
sent, LAR-OCT was administered intramuscularly to all patients at a dosage of 10mg monthly
for a minimum period of 1 year. Patients were followed up monthly and haemoglobin levels,
number of blood transfusions, amount of iron parenteral supplementation, number of
hospitalizations one year before and after starting LAR-OCT therapy were recordered to
evaluate the efficacy of the treatment. RESULTS: follow-up ranged from 12 to 60 months,
median 33. There was a significant difference in haemoglobin values (mean±SD 5.8±1 vs
9.1±1.6, p=0.002), iron parenterally administered (mean±SD 26.6±14 vs 13.3±10, p=0.05),
blood units transfused (mean±SD 6.6±2.4 vs 3.1±3.8, p=0.01), number of hospitalizations
(mean±SD 3.6±1.2 vs 1.6±1.5, p=0.002) between the year before and after LAR-OCT treat-
ment. Six patients successfully stopped blood transfusions and iron supplementation during
the follow up period. In one patient a partial improvement, requiring only iron supplementa-
tion, was observed, while no effect was found in the other three. No significant side-effect
was registered in any patient. CONCLUSIONS: to our knowledge, this is the first non-
anecdotical paper reporting on LAR-OCT treatment for preventing rebleeding from gastroin-
testinal angiodysplasias in patients who cannot undergo surgery due to old age and/or
concomitant diseases. Our data demonstrate that chronic administration of octreotide may
be useful as rescue therapy in this subgroup of patients.
M1186
Long-Term NSAID Use and Small Bowel Pathology: A Cross-Sectional
Quantification By Capsule Enteroscopy
Laurence P. Maiden, A Seigal, Ingi Bjarnason, B Birgisson, Bjarni Thjodleifsson, Ingvar
Bjarnason
Background & Aims: Capsule enteroscopy has shown small bowel mucosal breaks (erosions
and ulcers) in 40% of volunteers taking the NSAID diclofenac (with a proton pump inhibitor)
for 2 weeks, however the full range of pathology in a large group of long-term users has
not been assessed. We undertook a capsule enteroscopy in 117 patients on long-term NSAIDs
to assess the range of small bowel damage caused by these agents. Methods: Patients with
established osteoarthritis, rheumatoid arthritis or low back pain who had been regularly
taking any one NSAID for 3 months or longer underwent a capsule enteroscopy. Patients
with known or suspected Crohn’s disease, spondylarthropathy, including seronegative athrit-
ides, and other small bowel pathologies were excluded as the gastrointestinal damage might
not readily be distinguished from that of NSAIDs. Sixty healthy volunteers acted as controls.
Results: The volunteers had no damage. 81 of the 117 (69%; p < 0.001) had evidence of
intestinal pathology attributable to the drug on enteroscopy. Forty-one (35%) had more
than one lesion concurrently. The commonest lesion seen was the denuded lesion in 47
(40%; p < 0.001). Forty-one (35%; p < 0.001) had red spots. Thirty-one (26%) demonstrated
mucosal breaks, of which 1 was bleeding at the time of enteroscopy. Reddened folds were
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seen in 14 patients (12%; p < 0.05). Strictures without a mucosal break or bleeding were
seen in 2 of the patients (2%; p > 0.05) and a further 2 patients revealed evidence of bleeding
without an obvious source. Conclusion: Capsule enteroscopy demonstrates small bowel
lesions in 69% of patients on long-term NSAID. Clinically significant pathology (mucosal
break, stricture and bleeding) is detected by capsule enteroscopy in 30% of patients on
long-term NSAIDs, which is greater than that seen in the stomach. This may explain why
the serious outcomes (perforation, bleeds and obstruction) associated with NSAIDs from
the upper and lower gastrointestinal tract are comparable.
M1187
Safety and Efficacy of 0.5mg Qd, 1mg Qd and 1mg Bid Alosetron
Hydrochloride in Women with Chronic, Severe Diarrhea-Predominant IBS (D-
IBS)
Richard Krause, Vanessa Ameen, Susan Gordon, Marquita West, Amy Heath, Teresa
Perschy, Eric Carter
The 5HT3 receptor antagonist alosetron is indicated for women with chronic, severe D-IBS
who have not responded adequately to conventional therapy. Previous trials with alosetron
1mgBID showed efficacy with an NNT =7, but 29% of pts reported constipation. Lower
alosetron doses were assessed in severe D-IBS pts in a randomized, double-blind, placebo-
controlled study (S3B30040) to determine efficacy and evaluate changes in the constipation
rate. Methods: 705 women with chronic, severe D-IBS were equally randomized to 12wks
of placebo, 0.5mgQD, 1mgQD, or 1mgBID alosetron. The primary endpoint was the propor-
tion of responders on the Global Improvement Scale (GIS) at wk12, defined as pts with
moderate or substantial improvement in IBS symptoms. Secondary endpoints were the
average rate of Adequate Relief (AR) of IBS pain and discomfort, and improvements in bowel
symptoms, (urgency, frequency, and consistency). Results: The proportion of GIS wk 12
responders was significantly higher for all doses of alosetron compared to placebo (treatment
effects ≥ 11.9%, p ≤ 0.012). Results were similar for the average adequate relief rate
(treatment effect ≥12%, p≤0.038). The 0.5mgQD and 1mgQD regimens were superior to
placebo in improving all bowel symptoms. Alosetron 1mgBID was superior to placebo in
reducing stool frequency and improving stool consistency. Constipation was the most com-
mon adverse event (9%, 16%, and 19% of pts in the 0.5mgQD, 1mgQD, and 1mgBID
groups, respectively). 27 serious adverse events occurred in alosetron treated pts, including
1event of intestinal obstruction and 1 event of ischemic colitis in the 0.5mgQD group, and
1 event of fecal impaction in the 1mgBID group. The events were self-limited and resolved
without sequelae. Conclusion: The 0.5mgQD and 1mgQD alosetron dosing regimens are
effective in providing global improvement in IBS symptoms, adequate relief of IBS pain and
discomfort, and improvement in bowel urgency, frequency, and consistency in women with
chronic, severe D-IBS. These regimens also resulted in a decreased incidence of constipation
relative to 1mgBID.
M1188
Risk Factors for Colonic Diverticular Bleeding
Atsuo Yamada, Hirotsugu Watabe, Makoto Okamoto, Yutaka Yamaji, Keiji Ogura, Shintaro
Kondo, Miki Ohta, Takafumi Sugimoto, Takao Kawabe, Masao Omata
Background: Colonic diverticula are occasionally responsible for severe lower gastrointestinal
bleeding. A majority of the cases are elderly and often have concomitant diseases. Non-
steroidal anti-inflammatory drugs (NSAIDs) have been previously reported as a risk factor
for diverticular bleeding. However, little has been studied about concomitant conditions as
risk factors for diverticular bleeding. We conducted the present study to elucidate their
significance as a risk factor. Methods: From July 1988 to September 2005, patients with
diverticular hemorrhage were enrolled in this study among 13320 colonoscopic examinations
performed in the University of Tokyo Hospital and its affiliated hospitals. Their clinical
features such as age, gender, site of bleeding diverticular, and outcome of the patients were
reviewed. Control subjects (n=74) were chosen from 2487 patients with diverticula who
have no history of lower gastrointestinal bleeding, as age, sex and site of diverticulum were
matched to each case. Effects of concomitant diseases including hypertension, hyperlipidemia,
diabetes mellitus, alcohol consumption, smoking and NSAIDs use on diverticular bleeding
were evaluated. Results: During the study period, 37 patients (mean age; 68±12 years, male:
female 30:7) had diverticular bleeding. Twenty-one patients (57%) bled from right-sided
diverticulum. Eleven patients were successfully treated by endoscopic procedures (clipping
or local injection of epinephrine saline). Eleven patients needed blood transfusion because
of severe anemia (2-14 units of packed red blood cells). The patients with diverticular
bleeding had hypertension more frequently (78%, P=0.0012) than in the control (45%).
Thirteen patients (35%) in the bleeding group have received NSAIDs while 11 (15%) had
in the control group (P=0.026). The estimated odds ratio of hypertension for bleeding risk
was 3.6 (95% CI: 1.32-10.04, p=0.012). The odd ratio of NSAIDs was 2.9 (95% CI: 0.997-
8.648, p=0.051). Conclusion: The results of the present study suggest that hypertension is
an independent risk factor of diverticular bleeding. Treatment of hypertension may lead to
prevention of diverticular bleeding.
M1189
The Spectrum of Luminal Gastrointestinal Involvement in Amyloidosis
Dustin G. James, Hanlin L. Wang, Gary R. Zuckerman, Chandra Prakash
Background: Amyloidosis is characterized by accumulation of insoluble proteins in multiple
organ systems. Gastrointestinal involvement is likely underestimated, and characterization
of endoscopic findings is sparse in the literature. We reviewed our institutional experience
with amyloidosis, with the aim of describing gastrointestinal manifestations, endoscopic
findings, and outcome. Methods: The pathology database was interrogated to identify patients
with the finding of amyloid on tissue samples obtained during endoscopy over the past 15
years. Clinical presentation, endoscopic findings, patient course and outcome were then
analyzed from review of inpatient and endoscopy records. Results: Amyloidosis was diagnosed
on histopathology of endoscopic biopsies in 22 patients (8F/14M) during the study period.
The mean age at diagnosis was 68±0.6 years (range 46-90 years), and 77.3% of patients
were ≥60 years at presentation. The most frequent clinical presentation was gastrointestinal
bleeding seen in 11 patients (50%), with overt bleeding in 9 and occult bleeding in 2
patients. Other presenting symptoms included change of bowels in 22.7%, dyspepsia in
22.7%, anorexia with weight loss in 13.6%, abdominal pain and small bowel obstruction
in 4.5% each; amyloid was incidentally found in a polypectomy specimen in one instance.
On further evaluation, 45.5% had evidence of renal involvement, 50% had evidence of
neural involvement (including at least 18% with gut related symptoms), and 27.3% each
had skin findings and cardiac involvement. Abnormal hematologic testing was noted in
63.6%. Endoscopic abnormalities were seen in the colon in 50%, small bowel in 31.8%
and stomach in 18.2%. Macroscopic findings included nodules in 36.4%, and ulcers or
erosions in 27.3%. Nodules with a bluish appearance, visualized endoscopically in five
patients (22.7%), were significantly associated with overt gastrointestinal bleeding as a
presenting manifestation (p<0.005). On histopathologic examination, amyloid deposition
was most commonly seen in the submucosa and deeper layers in 40.9%, with evidence of
vascular involvement in 45.5%. Amyloid type was known in 18 patients, and was as follows:
AL type in 13, AA type in 2, and localized amyloid in 3. At least 18.2% died within a month
after diagnosis. Conclusions: Gastrointestinal manifestations of amyloidosis are varied, and
awareness of the spectrum of gastrointestinal involvement is important for accurate diagnosis.
Characteristic bluish nodules on endoscopy may represent a marker for overt gastrointestinal
bleeding from amyloidosis. Multisystem involvement is frequent, even when presentation
is predominantly gastrointestinal.
M1190
Testing for Lactose and Fructose Intolerance Should Be Standard Protocol for
Patients with Chronic Abdominal Complaints
Charles W. Randall, Carlo M. Taboada, Gary Gossen, David Stump, Franz Zurita, Victor
Ostrower, Russell Havranek, Susan Ryan, Janet Ford
Introduction Deficiencies in Lactase and Fructase are relatively common but often not
considered in patients with chronic gastrointestinal (GI) complaints. The purpose of this
study was to determine if these patients with chronic symptoms benefited from testing for
disaccharidase deficiencies. Methods 191 patients ranging in age from 17 to 87 years of age
presented to our clinic for evaluation. 46 were male and 145 were female. Appropriate labs,
imaging studies and endoscopic procedures were performed when deemed appropriate.
Each patient underwent hydrogen breath testing to determine presence of disaccharidase
deficiency. Dietary management was initiated in all patients testing positive with appropriate
follow-up to determine efficacy of therapy. Results Of the 191 patients, 42 were found to
be lactose intolerant, 46 fructose intolerant and 16 were intolerant to both. Dietary manage-
ment was initiated with a mean follow up time of 10.8 months and a median follow up
time of 10 months. 97 patients experienced improved quality of life, while 7 had unsatisfactory
results. Improvement was described as a return to a normal lifestyle and not requiring any
additional therapy. Conclusions 1. - In this cohort of patients, 54.5% were found to have
disaccharidase deficiencies. 2. - Dietary management allowed significant symptom relief in
93.3% of patients. 3. - Determination of a patient’s lactose and fructose tolerability clearly
has a positive impact on patients with chronic GI symptoms and should be utilized in the
initial evaluation.
M1191
Symptom Overlap and Irritable Bowel Syndrome (IBS-C) Comorbidity in
Women with Chronic Constipation (CC)
Michael Crowell, V. Ann Schettler, Lucinda Harris, Ivan Bottoli, Jeffrey Kralstein
Background: Chronic constipation is a multi-symptom disorder thought to result from
different pathophysiologic etiologies. However, the prevalence of overlapping symptoms
between CC and IBS-C has not been well defined. Additionally, the differential impact of
psychosocial function on constipation-related symptoms has not been established between
patients with CC and IBS-C. Aim: To assess the prevalence of IBS in women presenting
with a diagnosis of CC from their referring physicians and to evaluate symptom overlap
and comorbidities between these patients. Methods: Consecutive patients clinically diagnosed
with CC (n=136) without organic disease completed a validated GI symptom questionnaire
and the SCL90-R. The proportion of patients reporting upper and lower GI symptoms were
evaluated using Pearson Chi-square analyses and the Mantel-Haenszel Odds Ratios for
categorical variables and the Student’s t-test or the Mann-Whitney Test as indicated. Signific-
ance levels were set at p < 0.05. Results: In this tertiary female sample, the majority of
patients met the Rome Criteria for IBS-C (70/136; 51.5%). Therefore, one group included
CC patients who met criteria for IBS-C and the second CC patients who did not meet IBS-
C criteria. Both groups did not differ in age or other demographics. Stepwise logistic
regression revealed significantly higher odds in the IBS-C group for pain frequency (OR=
1.22, 95%CI=1.06-1.40), bowel frequency (OR=1.09, 95%CI=1.01-1.17), and incomplete
evacuation (OR=1.68, 95%CI=1.22-2.31). The number of pain sites was also increased in
the IBS-C group (OR=1.40, 95%CI=1.07-1.84). Somatization was slightly lower in CC
patients compared to IBS-C (OR=0.94, 95%CI=0.90-0.98), otherwise psychosocial distress
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was not significantly different between the two groups. No differences were seen in Quality
of Life measures between groups. Conclusions: A substantial percentage of patients with
clinically diagnosed CC will be found to meet diagnostic criteria for IBS-C, and the chief
distinction between the clinically diagnosed CC patients that meet criteria for IBS-C is the
degree to which patients report abdominal pain, bowel frequency and incomplete evacuation.
Psychosocial distress does not reliably differentiate patients with CC from IBS-C.
M1192
Complete Spontaneous Bowel Movement (CSBM) Correlates Better Than
Spontaneous Bowel Movement (SBM) to Global Endpoints in Chronic
Constipation (CC) Trials
Ivan Bottoli, Williams D. Chey, Cornelia Ddunger-Baldauf, Jeffrey Kralstein
Background: According to current guidelines1,2, chronic constipation (CC) is characterized
by multiple symptoms (straining, hard stools, sensation of incomplete evacuation, insufficient
frequency, need for manual maneuvers, sensation of anorectal obstruction). Yet most physi-
cians focus on stool frequency when diagnosing and assessing the success of medical therapies
for this condition. CSBM is an outcome that incorporates a qualitative component to the
assessment of bowel habits and, therefore, may provide a better outcome measure for clinical
trials than quantification of stool frequency alone (SBM). In a post-hoc analysis from two
randomized, placebo-controlled, double-blind clinical trials, we determined how CSBM and
SBM correlated with two global assessments (satisfaction with bowel habits and bother-
someness of constipation). Methods: The pooled data from two twelve week trials including
CC patients on tegaserod 6mg BID (n=882) or placebo (n=863) were used for this analysis.
Bowel habit parameters included frequency of spontaneous (not induced by laxatives or
enemas) bowel movements with a sense of complete evacuation (CSBM) and of spontaneous
bowel movements (SBM). The global assessments were satisfaction with bowel habits (“How
satisfied were you with your bowel habits over the past week?”; 0= a very great deal satisfied,
4=not at all satisfied) and bothersomeness of constipation (“How bothersome was your
constipation over the past week?”; 0= not at all, 4= a very great deal). Spearman correlations
with bowel habit and bothersomeness of constipation averaged over weeks 1-12 are presented.
Results: CSBM had a higher correlation than SBM to both global assessments (Table 1).
Both global assessments showed almost identical correlations to each symptom, therefore,
showing equivalent global reach. The correlations were independent from the treatment.
Conclusion: CSBM, with its additional qualitative component, better correlates to global
efficacy variables than SBM, supporting that frequency alone is likely not sufficient to assess
therapeutic outcomes in CC patients. 1. Brandt et al, 2005 Gut;100(Suppl1) :S1-S4 2.
Thompson et al, 1999Gut;45(Suppl II):II43-II47
CSBM had a Higher Correlation than SBM to both Global Assessments
M1193
Gastrointestinal Transit Measurement May Simplify the Detection of Motility
Disturbances in Clinical Practice
Riadh Sadik, Per Ove Stotzer, Magnus Simren, Hasse Abrahamsson
The management of patients with GI-symptoms may vary between different centers. The
aim of this prospective study was to analyze the yield and utility of a GI-transit measurement
procedure in clinical practice. Methods: All patients referred by gastroenterologists to a
tertiary centre for transit measurements were prospectively included. 243 patients were
included. Smoking status and body mass index were recorded. The patients were categorized
according to the main GI-symptom into five groups: diarrhea, constipation, nausea, and
vomiting and abdominal pain. The patients recorded their bowel movements and three GI-
symptoms daily for the week before the transit measurement. These symptoms were abdom-
inal pain, gas and distention. The patients had to chose between four levels of symptoms: 0=
no symptom,1=light symptoms,2=pronounced symptoms, 3=severe symptoms. All patients
underwent a measurement of gastric emptying, small bowel residence and colonic transit
using radiopaque markers (Sadik et al. Am J Gastroenterol.2004;99:711-8). The area under
the colonic filling profile was utilized to calculate the colonic filling time. Percentile five
and 95 of the transit values in 83 healthy subjects served as reference values. Results: 63%
of the patients had at least one transit abnormality. The transit abnormalities are shown in
the figure. These abnormalities were more frequent in men compared with women, p=0.003.
Smoking women had more abnormalities compared with non-smoking women, p=0.01.
Patients with underweight had also more disturbances compared with other patients with
normal weight and with overweight, p=0.03. The reported severity of abdominal pain, gas
and distention had no influence on the frequency of the detected transit abnormalities.
Conclusion: Large-scale transit measurement is useful in a clinical prospective and may


















The Prevalence of Irritable Bowel Syndrome Among the General Population in
Japan
Sen Shimaya, Masashi Matsuzaka, Makoto Yaegaki, Takao Oyama, Ippei Takahashi,
Takashi Umeda, Shigeyuki Nakaji, Daisuke Sasaki, Eiko Oka, Tadashi Shimoyama
Introduction: Irritable bowel syndrome (IBS) is a common condition among the general
population worldwide, however, few studies have reported on the degrees of prevalence
among the general population in Japan. Subject and methods: We surveyed bowel habits
in a general population in northern Japan (n=1067, 407 males and 660 females; 51 under
30 y.o., 92 in the 30-39 yrs age group, 142 from 40-49yrs, 262 from 50-59 yrs, 286 from
60-69 yrs, and 234 70 yrs or over), and diagnosed IBS based on Rome II criteria. Result:
The questionnaire was completed by 1067 individuals (407 males and 660 females, 100%
response rate). The prevalence of IBS and constipation were as follows (see Table). 1. The
number (prevalence) of IBS with constipation (IBS-C); 5 (1.2%) in men, 23 (3.5%) in women
and 28 (2.6%) in total. 2. The number (prevalence) of IBS with diarrhea (IBS-D); 8 (2.0%)
in men, 6 (0.9%) in women and 14 (1.3%) in total. 3. The number (prevalence) of mixed
IBS (IBS-M); 12 (2.9%) in men, 20 (3.0%) in women, and 32 (2.9%) in total. 4. The number
(prevalence) of total IBS (CIBS+DIBS+MIBS); 25 (6.1%) in men, 49 (7.4%) in women and
74 (6.9%) in total. On the other hand, the prevalence of IBS in subjects in their 20’s was
10.0% and for those in their 30’s was 9.8%, the highest rates among all generations. By
contrast, the prevalence of IBS for subjects of 70 yrs and over was 2.9%, the lowest rate.
As for prevalence by gender, the prevalence of IBS in men (6.1%) was lower than in women
(7.4%). Discussion: The prevalence of IBD (6.9%) in the current survey was lower than
those previously reported in the Japanese and Western literature (over 10% in most studies).
This difference may be due to differences in lifestyle, physical characteristics and so on.
The number of prevalence of IBS by age-group
IBS-C: IBS with constipation, IBS-M: Mixed IBS, IBS-D: IBS with diarrhea
The number of prevalence of IBS by gender
IBS-C: IBS with constipation, IBS-M: mixed IBS, IBS-D: IBS with diarrhea
M1195
Efficacy and Safety of Lubiprostone for the Treatment of Chronic Constipation
in Male vs Female Subjects
Ryuji Ueno, Taryn R. Joswick, Aimee Wahle, Yan Zhu, P. Christopher Holland
Constipation is a common and bothersome gastrointestinal condition, affecting nearly 30
million individuals in North America. Lubiprostone is a novel type-2 chloride channel (ClC-
2) activator (AJP Cell Physiol 287:C1173-C1183, 2004) that has been shown to be efficacious
and well tolerated in a number of well-controlled clinical trials of 3-4 weeks duration
(Gastroenterology 122:A315, 2002; Gastroenterology 124:A38, 2003; Am J Gastroenterol
100:S324, S328 and S329, 2005). We examine pooled results from these trials so that
subgroups of male and female subjects can be compared. Methods: In order to create an
adequate pool of male subjects, data were combined from three well-controlled clinical
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trials. Spontaneous bowel movement (SBM) frequency rates, stool consistency ratings, and
bowel straining assessments were compared between treatment groups (placebo and lubipro-
stone 48 µg/day) via inferential statistics and used to assess efficacy. Mean improvements
over placebo are compared between male and female subjects. Adverse event (AE) incidence
rates were also compared between treatment groups and genders. Results: The pooled
subgroup of males consisted of 27 placebo and 32 lubiprostone subjects. Male subjects
taking lubiprostone experienced approximately twice as many SBMs per week as their
placebo counterparts (5.69-6.05 SBMs/week vs 2.55-3.23 SBMs/week). Despite the small
sample size, differences were statistically significant for the first 3 weeks (p<0.0489) and
were nearly significant at Week 4 (p=0.0503). Compared to female lubiprostone subjects,
these rates are slightly higher (rates among female lubiprostone subjects ranged from 4.99-
5.75 SBMs/week). With regard to safety, one-third (33.3%) of male placebo subjects experi-
enced at least one AE compared to 50.0% of male lubiprostone subjects. Conclusion:
Lubiprostone is an efficacious and well-tolerated treatment for chronic constipation in
male subjects.
M1196
Effect of Tamoxifen On Clinical Course of Sclerosing Mesenteritis
Salma Akram, Darrell S. Pardi, Thomas C. Smyrk
BACKGROUND: Sclerosing mesenteritis (SM) is a rare, fibro-inflammatory disorder of
unknown etiology that affects the small bowel mesentery. The rarity of cases and the
heterogeneity of the natural history have limited the ability to study this disease and to
evaluate its response to therapy. In 2002 we reported our institution’s twenty years experience
with this disorder. We have since identified 28 additional cases of SM or its variants, many
of whom we have treated with tamoxifen. AIM: To describe clinical characteristics, therapy
and outcome of all patients with SM or its variants evaluated at the Mayo Clinic, Rochester
between 12/02 and 10/05. METHODS: Cases were identified through the diagnostic index
and Department of Pathology database. Demographic, treatment, and clinical outcome data
were abstracted from their records. Results: Among 28 patients, 23 (82%) were male with
median age at diagnosis of 64.5 yrs (range 42-82). Median follow-up was 10 month (mo)
(range 1-60). Presenting symptoms were: abdominal pain (36%), weight loss (29%), diarrhea
(25%), nausea/vomiting (18%), anorexia (7%), fever (7%). Prior history of abdominal surgery
was present in 25%. SM was an incidental finding in one pt (4%). Concurrent intra-
abdominal pathology was noted in 5 (18%): Non-Hodgkin’s lymphoma 2 (7%), sclerosing
pancreatitis 1 (4%), metanephric adenoma 1 (4%), retroperitoneal fibrosis 1 (4%). SM related
complications included bowel obstruction (36%), chylous ascites (18%), need for long-term
TPN (11%), superior mesenteric vein thrombosis (7%). Two (7%) deaths were noted during
the study period. Surgical resection of the mesenteric mass was done in 10 (36%), 6 (60%)
of whom remained symptomatic. Overall, 19 (68%) received pharmacotherapy, 4 improved
after surgery alone, and 5 (18%) received no treatment. Response was assessed by clinical
symptoms and imaging studies. Tamoxifen (10 mg BID) in combination with a prednisone
taper (beginning at 20-40 mg daily) was used in 13/19 (68%) for a median of 6 mo (1-33
mo) and 7/13 (54%) improved within 4 to 6 weeks of treatment. Prednisone alone or
combination with colchicine (0.6 mg BID, n=3) or azathioprine (1-1.5 mg/kg, n=2) was
given to 5/19 for a median of 4 mo (1-13 mo) and 1/5 (20%) improved. One pt received
thalidomide (200 mg/d) for 5 mo without improvement. Serious side-effects include deep
venous thrombosis on tamoxifen (n=2, 7%) and sepsis-related death on thalidomide in one
patient. CONCLUSION: This uncontrolled data suggests that symptomatic SM patients may
benefit from tamoxifen/prednisone combination treatment. Long-term follow-up is needed
to substantiate the results.
M1197
Peppermint Oil (Mintoil®) in the Treatment of Irritable Bowel Syndrome: A
Prospective Double Blind Placebo Controlled Randomized Trial
Giorgio Cappello, Mariangela Spezzaferro, Daniela Coraggio, Laurino Grossi, Leonardo
Marzio
Introduction: Peppermint oil has been shown to relax gastrointestinal smooth muscle in
vitro and to be useful in patients with irritable bowel syndrome (IBS) and bacterial overgrowth
(BO). Aim: Aim of the study has been to test the efficacy of peppermint oil (Mintoil®,
Cadigroup, Rome, Italy) in patients with IBS without BO and lactose intolerance . Methods:
Forty eight patients with IBS according to Rome II criteria with normal lactose and lactulose
breath test were randomly treated with Mintoil® (2 enteric-coated capsules twice per day
or placebo) for four weeks. Symptoms score was assessed before the beginning of therapy
at the end of therapy (4 weeks). The symptoms evaluated were: diarrhea (Di), abdominal
bloating (AB), constipation (Co), pain lower abdomen (PLA), pain on defecation (PoD),
feeling of incomplete evacuation (FIE), difficulty on evacuation (DoE). For each symptom
intensity and frequency graded 0 to 4 were scored. Intensity 0: absent, 1: mild, 2 moderate,
3:severe, 4: intolerable, Frequency : 0 absent, 1 once a month, 2: once a week, 3 three
times per week, 4 everyday. The mean value between intensity by frequency was calculated
for comparison. Results: The results show statistical significant improvement in all symptoms
evaluated after 4 week of Mintoil® (24 patients) (Table 1), while only diarrhea and abdominal
bloating improved after placebo (26 patients) (Table 2). The improvement in symptoms
score for AB is greater with peppermint oil than with placebo. Conclusion: Peppermint oil
and placebo both improve abdominal symptoms in patients with irritable bowel syndrome.





Development of a Hybrid Algorithm Based On Learning Classifiers That
Improves Diagnosis of Inflammatory Bowel Disease and Differentiation
Between Crohn’s and Ulcerative Colitis in a Six-Marker System
Augusto Lois, Frank Wadleigh, Bruce Neri
The use of combinations of serological markers has resulted in improved IBD diagnosis.
Currently, marker cut-offs are commonly used to predict IBD. Generalized linear and non-
linear regression analyses have improved the prediction capability of these assays. However,
significant advances have been made recently in the use of learning statistical classifiers like
Neural Networks (NN), Support Vector Machines (SVM) and Classification and Regression
Trees (C&RT) to classify complex data, find underlying patterns and discover non-linear
relations in data from multiple variables. These methods have been used successfully to
predict the outcome and prognosis of cancer, glaucoma and other diseases. In this study,
learning statistical classifiers were used to create an algorithm that predicts IBD and differenti-
ates UC from CD with a six-marker system. C&RT and NN were chosen because they can
produce models with complementary analytical capabilities. Serological data was obtained
from multiple markers using a cohort of 813 patients with 60% IBD prevalence. The markers
comprised IgG antibodies to Cbir1, IgA to the E. coli-associated outer membrane protein C
(OmpC), IgA and IgG anti-)Saccharomyces cerevisiae mannan antibodies (ASCA-IgA and
ASCA-IgG), anti-neutrophil antibodies with a DNase-sensitive perinuclear staining. Multilayer
Perceptron NN was trained with Back Propagation using results from 500 patients of the
cohort. Multiple NN models were then tested using data from the remaining 313 patient
samples. Similarly, standard and boosted C&RT were trained and tested using different data
sets. Both, NN and C&RT produced models that improved the sensitivity and specificity of
the assay in comparison to regression analysis (5%-15% increase in sensitivity and specificity).
However, the best outcome was obtained with a hybrid algorithm that uses a C&RT model
in tandem with a NN model. The sensitivity and specificity of the hybrid algorithm for IBD
prediction was >90%. Positive and Negative Predictive Values were 90% and 80% respect-
ively. The sensitivities and specificities for CD and UC prediction were above 88%. Conclu-
sion: The use of a hybrid algorithm based on C&RT and NN to analyze the results from
six serological markers resulted in a significantly more accurate detection of IBD, CD and UC.
M1199
Multiple Adenomatous Polyposis (MAP) Patients in France: Prospective
Characterization of This Population
Graber Ivan, Moussata Driffa, Gelas Dore Benedicte, Barthelemy Claude, Pelletier Michel,
Phelip Jean-Marc, Lapalus Marie George, Pillon Didier, Nallet Bernrd, Leroux Dominique,
Prieur Fabienne, Saurin Jean-Christophe
Aim: MAP is defined by the presence of 3-100 colorectal adenomas. The clinical and
endoscopic characteristics of this population are poorly known. Retrospective series have
suggested a role for APC/familial adenomatous polyposis (FAP) germline mutations in 8%
of cases. Our first aim was to identify epidemiologic and endoscopic characteristic features
of these patients. Patients and methods: Consecutive patients with 3-100 synchronous
colorectal adenomas, from 9 hospitals of the French Rhône-Alpes region were included
prospectively in this study after exclusion of known FAP and HNPCC cases. The study
protocol included colonoscopy and duodenoscopy with indigo-carmin dye, a standardized
epidemiological questionnaire and genetic counselling. Biological analysis of adenomas and
analysis of germline APC and MYH mutations will be performed in a second part of this
study. Results: From September 2003 to April 2005, 118 consecutive patients (90 males,
76.2%,mean 61.2 years old, 95% CI 45-80) were included. Colon (82 pts): diffuse polyposis
after dye spraying in the right colon 1.2%, in the sigmoid colon 7.1%. At least 1 adenoma
per site: right colon 76.4%, transverse colon 47.1%, left colon 72.3%, rectum 40%.Adenoma
maximal size(%pts):<5mm 22.6, 5-10mm: 37.8, >10mm: 39.6. Histology (%pts): high-
grade dysplasia 22.7, intra-mucosal cancer: 2.7, >or=sub -mucosal: 8.1. Morphology(%pts):
pedunculated 36.5%; plan or sessile 98.0%. Stomach and duodenum (42pts): At least 1
duodenal adenoma 2 cases (4.76%); fundic gland polyp 2 cases (4.76%). Epidemiology
(84pts): tobacco consumption 71.4%(mean duration 26.9 years, 95%CI: 2.35-52.45, 23.3%
ongoing); alcohol 76.2%(wine, mean 17.9 glasses/week, mean duration 23.5 years). NSAIDs
intake 22.7% (aspirin 16.7%). Genetic counselling (52 pts) revealed the existence of a first
degree relative with adenoma or colo rectal cancer in 50% and 40% of cases respectively.
Criteria for HNPCC were unfrequent: one case of colorectal cancer before 50 years in the
family in 9.4% and two first degree relatives with colorectal cancer in 9.4 %. Conclusion:
We indentified unexpected epidemiologic characteristics of the MAP population: high male
predominance with alcohol and tobacco consumption background. Less than 7% of MAP
patients present endoscopic features compatible with attenuated FAP. Genetic counselling
is not in favour of a high proportion of HNPCC cases.
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M1200
Pancreas Evaluation Using the Endoscopic Ultrasound in Crohn’s Disease
Everson F. Malluta, Fauze Maluf-Filho, Carmem O. Agostinho, Ieda Nishitokukado,
Andre A. Leite, Damiao O. Aderson, Sipahi Aytan
BACKGROUND Pancreas injury usually is not mentioned as an extra-intestinal manifestation
of Crohn’s disease, but the few available series suggest pancreatic injury in a significant
proportion of these patients, ranging from 6% to 38% in this series. Endoscopic ultrasound
(EUS) presents the advantage of having a much higher sensitivity than the abdominal
ultrasound or computadorized tomography in evaluating pancreas abnormalities. Compared
to the endoscopic retrograde cholangiopancreatography, EUS has at least an equal sensitivity,
with a lower complication rate. AIMS To evaluate the incidence of pancreatic alterations by
means of the EUS in Crohn’s disease, correlating them with clinical, endoscopic and biochem-
ical data, in order to determine possible predictive factors. METHODS Fifty patients with
Crohn’s disease, age between 18 and 60 years-old (mean = 38), without previous history
of pancreatic disease, diabetes mellitus or alcoholism, were submitted to EUS. Thirteen
variables were analyzed, both in pancreatic parenchyma and ducts. The patients with 3 or
more alterations were submitted to magnetic resonance. The control-group was formed by
patients submitted to EUS with no previous history of pancreatic or Crohn’s disease. RESULTS
Of the 50 analyzed patients, 55% were female, with mean diagnosis time of seven years (1-
25) and Crohn’s Disease Activity Index (CDAI) of 102 (20-419). Two patients (4%) presented
4 alterations in the EUS exam, 3 (6%) presented 3 alterations, 10 (20%) had 2 alterations
and 13 (26%) had 1 alteration in the EUS, which were statistically significant when compared
to the control-group, in whom only 16% presented 1 exam alteration (p<0.001). In both
groups, all the abnormalities were parenchymal, while ductal changes were not found. The
patients with 3 or more alterations in the exam were submitted to magnetic resonance;
however, pancreatic lesions were not detected. The only predictive factor that correlated
with the number of alterations in EUS was ileal disease. CONCLUSIONS Patients with
Crohn’s disease had a higher incidence of pancreatic abnormalities (10% with 3 or more
alterations in endoscopic ultrasound) in comparison to the control-group. These alterations
were found in the pancreatic parenchyma, which might explain the lack of correlation with
the magnetic resonance, which is more prone to detect duct abnormalities. The only predictive
factor to these alterations on EUS was ileal disease.
M1201
Good Long-Term Results Are Possible with Anterior Anal Sphincter Repair
Sushil K. Maslekar, Angela B. Gardiner, Graeme S. Duthie
Introduction Anterior anal sphincter repair (ASR) is standard treatment for faecal incontinence
due to a structurally damaged anal sphincter. Long-term results of repair have generally
been shown to be poor. This review of single surgeon series aimed to determine the long-
term outcome of primary ASR for patients with faecal incontinence due to anatomical
sphincter defects. Methods This study included patients undergoing ASR from 1995 to 1999.
We perform standard ASR, but external and internal sphincters are repaired separately. The
internal sphincter is repaired only if damaged. Telephonic interview was conducted with
all the patients, following which questionnaires including SF-36 survey, faecal incontinence
quality of life (FIQOL) questions and Wexner score-type questions were sent at 6 months
and at median follow-up of 6 years. The questionnaire and telephonic interview also assessed
bowel function and continence, restriction in activities related to bowel control and overall
satisfaction. Demographic data and anorectal physiology was obtained from a review of
clinical case notes. Results 64 of 72 patients returned questionnaires and operation was
considered success in 75% of patients at median follow-up of 72 months. Six patients had
undergone further procedure for incontinence and 58 patients were analysed. 10 patients
reported complete continence to stool and flatus (18%), which is best ever reported. Median
continence scores had improved from Wexner score of 14 to 5 (p<.0.001). 75% of patients
reported an improvement of continence, with 70% patients who improved at 6 months
continuing to do so. 95% of patients were satisfied with their operation. There was an
improvement in all aspects of FIQOL and in the mental health components of SF-36. None
of the anorectal physiology variables including pudendal nerve terminal motor latency were
of any value in predicting the outcome. Conclusion We have shown that good long term
results can be achieved with anterior anal sphincter repair. The modified technique could
explain the improved outcomes.
M1202
Association of Helicobacter Pylori Infection and Persistent Diarrhea in
Malnourished Young Bangladeshi Children
Pradip K. Bardhan, Shafiqul A. Sarker, Zahid Hasan, Niklaus Gyr, Christoph Beglinger
Background: Gastric acid is an important nonimmune defence mechanism against gastrointe-
stinal infections. In the developing countries, H. pylori (HP) infection occurs very early in
the life, and the resulting gastritis may lead to hypochlorhydria and increased susceptibility
to gastrointestinal infections, particularly in malnourished children. Studies examining the
relationship between HP infection and diarrhea have reported conflicting results. Aim: To
examine the association between HP infection and acute diarrhea (AD) and persistent diarrhea
(PD) in young Bangladeshi children. Methods: This was a clinic-based case-control study
with community controls. The cases were children aged 6-24 months suffering from AD
(diarrhea <3 days) or PD (diarrhea >15 days, acute onset). The controls were asymptomatic
age-matched children selected randomly from rural and peri-urban Bangladeshi communities.
None received any antibiotic in the preceding 3 months. Status of HP infection was deter-
mined by 13C-urea breath test (UBT) and HP fecal antigen (FA) test. Only children with
concordant results from both UBT and FA were included. Anthropometric, fecal microscopic
and microbiological, nutritional, socioeconomic, and dietary data were also collected. Data
were analyzed by X2 test and logistic regression. Results: The study included 61, 51 and
64 children as PD, AD and controls respectively. Age and socioeconomic status among the
three groups were comparable. Malnutrition (wt./age <75% of NCHS median) was noted

















of HP positive children was 34 (56%) in PD, 23 (45%) in AD, and 25 (39%) in controls,
without any significant difference. However, among the malnourished children, HP infection
was significantly more often present in the PD group, but not in the AD group, when
compared to the controls (Table). In logistic regression, HP infection appeared to be a
significant risk factor for PD (Odds ratio 1.91, 95% confidence interval 1.06-3.44, p=0.042),
but not for AD. The covariates in the regression equation were age, gender, nutritional
status, socioeconomic status, fecal pathogens, breast-feeding, immunization, mother’s educa-
tion, and place of residence. Conclusion: A significant association was noted between HP
Infection and PD in malnourished Bangladeshi children. Intervention of HP infection may
decrease the incidence of PD in this vulnerable population.
X2 test, p = Overall 0.08; PD vs Control 0.04; AD vs Control 0.58
M1203
Gastrointestinal Inflammation Modulates Differentially the Expression of
Cellular Prion Protein PRPC
Peter C. Konturek, Karolina Bazela, Vitalyy Kukharskyy, Detlef Schuppan
Background and aims: The main entry of infectious prions inducing transmissible spongiform
encephalopaties (TSE) represents the gastrointestinal (GI) tract. Our previous studies demon-
strated that mucosal epithelial cells in GI tract express PrPc which may represent a first
target for infectious prions after oral inoculation. However, it is not known whether GI
inflammatory states could influence PrPc expression and thus potentially modeluta the
propagation of prions from G tract. The analysis of PrPc expression at mRNA and protein
level was analyzed in biopsy specimens from 3 different chronic human diseases of GI tract
: H.pylori gastritis, sprue nad Crohn disease. Patients and methods: The biopsy material was
obtained during endoscopy from patients with Hp gastritis before and after eradication
therapy (n=12), sprue under gluten free diet (n=10) or without treatment (n=10) and in
patients with active Crohn disease (CDAI>150). The expression of PrPc was analyzed at
mRNA and protein level by quantitative RT-PCR (Taqman) and Western blot, respectively.
In addition, two different cell lines (gastric MKN 45 and colonic LoVo) were incubated with
different mediators of inflammation such as prostaglandin PGE2 (10-100µM), IL-1β (1-
10ng/ml), TNFα (1-10 ng/ml), TGFb (0.1-1 ng/ml) and gastrin (1-100 nM). Results: PrPc
was upregulated in Hp gastritis and decreased after eradication to the level observed in the
control (gastric mucosa without Hp). In contrast, in the intestinal mucosa of sprue patients
and colonic mucosa of Crohn patients a significant downregulation of PrPc as compared to
normal intestinal mucosa was observed. The incubation of gastric epithelial cells with gastrin
and PGE2 caused a significant dose-dependent upregulation of PrPc. Colonic cells (LoVo)
incubated with PGE2 and TGFβ and IL1β caused a significant downregulation of PrPc
expression in these cells. Conclusion: Chronic inflammatory states can differentially modulate
the expression of PrPc in the GI tract. PrPc is significantly upregulated in Hp gastritis and
this upregulation may be linked to Hp-induced hypergastrinemia and increased PGE2 and
IL1β synthesis. In the intestinal mucosa of sprue patients and colonic mucosa of Crohn
patients PrPc is downregulated. Il1β, TGFβ and PGE2 may mediate at least partly this downre-
gulation.
M1204
Double-Balloon Enteroscopy Had Superior Diagnostic and Therapeutic Impact
Than Push Enteroscopy for the Diagnosis and the Treatment of Lesions
Identified By Videocapsule Endoscopy
Thibaut Maniere, Bruno Landi, Marion Simon, Joel Edery, Bernard Boboc, Raymond Jian,
Christophe Cellier
Introduction Double balloon enteroscopy (DBE) is a new tool for the investigation of the
small bowell. The aim of the study was to compare DBE and with classical push enteroscopy
(PE) in patients with a lesion diagnosed by the videocapsule endoscopy (VCE) Patients and
methods Seventy-eight DBE were performed between january 2004 and september 2005 in
67 patients (37 F, 30 H, mean age 64 years [12-90] for an obscure gastro-intestinal bleeding
(occult GI bleeding 30 pts, macroscopic bleeding 38 pts). A standardized data form was
prospectively filled for all the patients. Sixty-two oral route and 16 anal route DBE were
performed (double route DBE in 8 pts, 2 oral route DBE in 2 pts). All patients have had
previously negative upper and lower GI endoscopy and at least one positive finding at VCE.
The potential bleeding of the lesions visualized at CE were classified as follow: P0 (low) in
14 cases, P1 (intermediate) in 32 cases, and P2 (high) in 21 cases. The results of DBE were
compared with those obtained in a control group of 27 patients explored for obscure GI
bleeding by PE after VCE in a previous prospective study of our group. Results DBE was
considered as normal or unconclusive in 31 pts. The diagnostic yield was of 60 % : 58%
in occult GI bleeding, 62% in macroscopic bleeding. The diagnostic yield was related to
the degree of bleeding potential of the lesion at VCE: 74% in case of lesion P2, 45% in case
of lesion P1, 44% in case of lesion P0 (p=0.1). The diagnostic yield was higher by upper
way (67%) than by lower way (37%; p=0.06). A treatment by argon plasma electrocoagulation
was performed in 39 cases (61%). The diagnostic yield was higher for DBE than PE (60%
vs 41%; p=0.1), as well as the therapeutic yield (61% vs 22%; p=0.003). Conclusion: In
patients explored for GI bleeding with a lesion diagnosed at CE, DBE is superior to PE in
terms of diagnotic and therapeutic yield.
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M1205
Routine Ascitic Fluid Analysis in Ambulatory Outpatients with Ascites Is Not
Necessary
Karin Cesario, David Barnes, William Carey, Robert O'Shea, Nizar Zein
Background/Aims: AASLD practice guidelines (2004) recommend ascitic fluid analysis with
outpatient therapeutic paracentesis. Aims were to determine the incidence and significance
of neutrocytic ascites in an ambulatory population and to evaluate if routine cell counts are
warranted. Methods: All patients who had therapeutic paracentesis between November 2004
and May 2005 were identified. Those hospitalized, on antibiotics [other than spontaneous
bacterial peritonitis (SBP) prophylaxis] and/or complaining of fevers, chills or abdominal
pain at the time of the procedure were excluded. Demographic and laboratory parameters
were examined; neutrocytic ascites was defined as a polymorphonuclear (PMN) count of >
250/mm3. Patients with neutrocytic ascites underwent repeat paracentesis with ascitic fluid
analysis/cultures within 24 hours and prior to initiation of antibiotic therapy. Results: 361
therapeutic paracenteses in 95 patients were performed. Subject mean age and MELD scores
were 58.4+ 9.6 years and 15.0 + 6.7, respectively. The majority of subjects were male (64%),
Caucasian (78%) and had cirrhotic ascites secondary to alcohol (25%), chronic hepatitis C
virus infection (13%) or a combination of both (11%). Four cases of neutrocytic ascites
were identified; a 1.1% incidence. There were no significant differences in age, serum
albumin or sodium between subjects with and without neutrocytic ascites (all p-values >0.05
using unpaired t-test). Likewise, there were no statistical differences in race, gender or ascites
etiology (all p-values >0.05 using Fisher’s exact test). Upon repeat paracentesis and prior
to antibiotic therapy, two of the four subjects no longer had elevated PMNs and had negative
ascites cultures. The third again had elevated PMNs and was treated with a course of
intravenous antibiotics. The fourth refused repeat paracentesis and was treated with a 5-
day course of oral antibiotics. Paracentesis after completion showed resolution of neutrocytic
ascites and negative ascites cultures. Conclusions: In asymptomatic outpatients, neutrocytic
ascites is (1) uncommon (2) may be transient and (3) is not well correlated with positive
cultures or clinical infection. Our data suggests that routine ascitic fluid analysis in an
ambulatory outpatient population may not be cost-effective or justified. This issue should
be readdressed in future AASLD practice guidelines.
M1206
Predictive Factors of Survival After TIPS Insertion for Refractory Ascites
Sylvie Evrard, Frederik Nevens, Abbas Mroue, Michael Adler, Jacques Deviere, Olivier Le
Moine
Background: TIPS may improve the control of refractory ascites (RA) in patients with
cirrhosis. However, it may induce severe liver failure and therefore jeopardise their chance
to benefit from liver transplantation. Currently, no criteria exist to adequately select patients
for TIPS and assess their short-term prognosis after the procedure. Aim: To identify pre-
procedural clinical and biological variables associated with survival after TIPS placement in
a large cohort of patients with RA. Methods: 117 consecutive patients, from 2 belgian referral
centers, who underwent non covered TIPS for RA between January 1992 and August 2004
were retrospectively analysed. Univariate and multivariate analysis (Cox regression) were
performed to find the independent variables associated with 1 and 6 months survival.
Results: The population included 75% of alcoholic cirrhosis and 62% of Child B patients.
No procedure related deaths were encountered and survival was 85%, 66% and 58% at 1,
6 and 12 months, respectively. Ascites control was observed in 87% and 91% of surviving
patients after 1 and 12 months, respectively. Thirty eight % of patients developed encephalo-
pathy after TIPS. Alcoholic etiology (ETIO), pre-TIPS low bilirubin level (BILI) and high
PTT were independent predictors of 1-month survival (OR: 2,5; 1,08 and 0,96 respectively).
A prognostic index (pi) could be calculated as following: pi=exp {(0,085xBILI)+(-
0,038xPTT)+(0,903xETIO)} where BILI is expressed in mg/dl, PTT in % and ETIO as 1 if
alcoholic or 2 non-alcoholic. By plotting pi on a Youden curve, the best cut-off value was
1,2. Values of pi < 1,2 predicted 96% of the patients who will survive 1 month after TIPS
(specificity) whereas values > 1,2 were less sensitive to predict death (44%). When analysing
6 months survival, ETIO and PTT were still independently predicting outcome. Conclusions:
Alcoholic cirrhosis and preserved liver function are predictive of survival after TIPS for RA.
The prognostic index (pi) may help select the patients who will benefit the most of the
procedure without jeopardising further liver transplantation. Prospective validation of this
index is now mandatory.
M1207
Cost Comparison of Transjugular Intrahepatic Portosystemic Shunt Versus
Paracentesis in the Treatment of Refractory Ascites
Jason Taylor, Layla Hajjafar, Anthony Post
Background: Ascites is a common complication of cirrhosis, refractory to medical treatment
in about 10% of cases. Current treatment modalities include repeated large volume paracent-
esis (LVP) or transjugular intrahepatic portosystemic shunts (TIPS). Neither treatment has
been shown to be superior with respect to mortality. We performed a cost comparative
study of TIPS vs. repeat LVP with albumin infusion for cirrhotic patients with refractory
ascites. Methods: We created a decision model using data from 5 previous randomized
controlled trials. We determined the one and two-year rates of treatment failure, complica-
tions, and mortality for both TIPS and LVP. In our analysis, we assumed that when patients
failed the treatment in which they were randomized, they would then receive the alternative
treatment. The costs of procedures and complications were calculated for each treatment
group using Medicare reimbursement rates for the corresponding DRG or CPT codes on an
intention-to-treat basis. The software program Data 3.5 was used (TreeAge,William-
stown,MA). Results: As illustrated in the table below, only at a frequency of 1.5 LVPs per
month over one year of treatment did we find the cost per patient treated to be less for the
LVP group than for the TIPS groups. Otherwise, the cost of treating with TIPS was lower
for all other frequencies and time periods. In addition, TIPS has lower mortality rates than
LVP at both one and two years of treatment. Conclusion: TIPS is more cost-effective than
LVP for the treatment of refractory ascites.
M1208
The Hemodynamic Role of Albumin in the Therapy of Type II Hepatorenal
Syndrome
Carmen Fierbinteanu-Braticevici, Laura Tribus, Lucian Negreanu, Andreea Bengus, Radu
Usvat, Dan Andronescu
Background: Type II hepatorenal syndrome(HRS) is a major complication of cirrhosis associ-
ated with gradual reduction of renal function and with a median survival time of 6 months,-
which recommends liver transplantation Aim: to assess the role of albumin in the therapy
with terlipressin in type II HRS cirrhotic patients. Methods: 38 cirrhotic patients with type
II HRS, were hemodynamicaly studied at diagnosis and after 14 days of treatment with
terlipressin : 19 patients with albumin supplement (group I) and 19 patients without albumin
(group II. The groups were matched for age, etiology and severity of cirrhosis.The patients
underwent: creatinine clearance, urinary metanephrines, plasma renin activity (PRA), serum
aldosteron and sodium homeostasis. Systemic, renal and hepatic hemodinamics were evalu-
ated by mean arterial pressure (MAP), cardiac index (CI), resistance index (RI) of renal
artery, portal flow volume and velocity. Paired -t test was used to compare the values among
the groups. Results: Albumin treatment caused a significant improvement of the circulatory
function as compared with group II indicated by an increse in the CI (4,6 vs 3,2 -p<0,05),
MAP (85 vs71 -p<0,03) as well as in portal flow velocity (15 vs 11 cm/sec -p < 0,04).
Albumin substitution therapy also improved renal function consisting of a decrease in serum
creatinine more than 30% from baseline values, normalisation of RI, increased urine volume
and urinary sodium excretion. These changes were associated with a significant decrease of
PRA (3,6 vs 7ng/ml/h - p<0,001) and aldosterone (8 vs 14ng/dl - p< 0,05). Conclusions:
Due to the beneficial circulatory effectiveness, the combination of terlipressin and albumin
therapy restored renal function in cirrhotic patients with type II HRS, and this may be a
solution for increasing the survival after liver transplantation.
M1209
Prevalence and Predictors of Venous Thrombosis in Hospitalized Patients with
Cirrhosis
Kuntal M. Thaker, Raman Battish, Pradnya Mitroo, Kuldip S. Banwait, Madhusudhan R.
Sanaka, Victor Navarro, Steven K. Herrine
Background: Cirrhosis results in impaired regulation of coagulation due to an imbalance of
procoagulants, anticoagulants, and fibrinolytics. Despite the coagulopathy commonly seen
in patients with cirrhosis, vascular thromboses have been described. Previous studies have
shown an incidence of deep vein thrombosis (DVT) in the general hospital population of
0.1-3.17%. However, the incidence of DVT in patients with cirrhosis has not been determined.
Aim: To investigate the incidence and predictors of venous thrombosis in hospitalized
patients with cirrhosis. Methods: A retrospective review of patients discharged from a tertiary
care institution from 1/1/1985 to 3/31/2005 utilizing an electronic billing database was
conducted. Diagnoses of venous thrombosis, DVT, pulmonary embolism (PE), and cirrhosis
were searched. Charts were manually reviewed and only those admissions with documented
acute venous thrombosis were included. Results: There were a total of 3547 patients (1254
females, 2293 males) with cirrhosis with mean age of 55±15 years. There were 16 cases of
PE in patients with cirrhosis (16/3547=0.4%). DVT occurred in total of 103 (2.9%) patients.
Patients with cirrhosis and DVT (group 1) were compared to patients with cirrhosis and
without DVT (group 2). Compared to group 2, patients in group 1 were older and had
higher rate of mechanical ventilation, and previous history of DVT. There was no difference
between the groups in respect to rate of malignancy, use of central lines, and coagulation
profile (See Table 1). Conclusions: 1) Prevalence of DVT in patients with cirrhosis is similar
to that of a general hospital population. 2) DVT and PE occur in patients with cirrhosis
even in the setting of coagulopathy. 3) Older age, previous history of DVT and use of
mechanical ventilation may serve as risk factors for DVT in patients with cirrhosis. 4) Future
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M1210
Diabetes Mellitus Worsens the Clinical Outcome of Acute Variceal Bleed in
Cirrhotic Patients
Hasnain A. Shah, Shahid Majid, Mohammad Salih, Fasail W. Ismail, Khalid Mumtaz,
Saeed S. Hamid, Wasim Jafri
Introduction: Association of Diabetes Mellitus (DM) and hepatic cirrhosis is well recognized
and hyperglycemia induces splanchnic hyperemia with increase in portal pressures. There
is scanty data regarding the clinical outcome in cirrhotic diabetics following variceal bleed.
Aim: To compare the clinical outcome of gastro-esophageal variceal (GOV) bleed in cirrhotic
diabetic patients with those without diabetes. Patients and Method: We reviewed the case
notes of patients with GOV bleed admitted from June 2000-2005, under gastroenterology
service at Aga Khan University Hospital. Diagnosis of cirrhosis was made on clinical, laborat-
ory, radiological findings. Liver biopsy was done in selected patients. Acute Variceal bleeding,
failure to control bleed and rebleeding were defined according to Baveno III consensus
report. Results: A total of 839 admissions with variceal bleed occurred in 382 patients.
Diabetes was present in 148(39%) patients.Comparison between diabetic and non diabetic
cirrhotics with variceal bleed is presented in Table 1. Conclusion: The presence of Diabetes
mellitus in patients with cirrhosis signifies a worse prognosis for control of acute gastro-
esophageal bleed and incidence of rebleed in hospital. The risk of rebleed following discharge
is also increased in diabetic cirrhotics as compared to non diabetics.
Comparison between diabetic and non diabetic cirrhotics with variceal bleed is presented
in Table 1.
M1211
Proinflammatory Cytokines Are Not Associated with Malnutrition in Liver
Cirrhosis But with Altered Electric Tissue Properties
Kristina Norman, Nina Babel, Herbert Lochs, Petra Reinke, Matthias Pirlich
The inflammatory state has been hypothesized to trigger cachexia in liver cirrhosis and
impair outcome. In addition low capacitance and phase angle as measured by bioimpedance
(BIA) have been shown to be predictors of poor clinical outcome in liver cirrhosis and
liver transplantation. Aims: We therefore investigated correlations between proinflammatory
cytokines, the nutritional status and impedance parameters in 65 patients with liver cirrhosis.
Methods: Nutritional status was assessed with the Subjective Global Assessment, arm muscle
area, arm fat area were measured anthropometrically. Bioelectrical impedance analysis (BIA-
2000M, Data Input Germany) was performed in order to obtain the impedance parameters
capacitance and phase angle. Cytokines, tumour necrosis factor (TNF-alpha) and interleukin
6 (IL-6), were measured with ELISA. Albumin and CRP were measured according to standard
methods. Results: Sixty-five patients with liver cirrhosis (age 56,6±12,4 years, 35 male and
30 female Child A: 26 B: 22 and C: 17 patients; albumin 3,4±0.62g/dl) were recruited. 35
patients were classified well (SGA A) vs. 30 patients malnourished (SGA B or C). The
capacitance and the phase angle were 72,2±12,8 Ohm and 4,9±1,0° in well vs. 42,1±14,0
Ohm 4,1±0,9° in malnourished patients. No correlations were found between TNF-alpha,
IL-6 and nutritional parameters such as arm muscle area or arm fat area and cytokines were
not higher in the patients classified malnourished by the SGA. (TNF alpha 12,1±10pg/mL,
IL-6 9,6±6,1pg/mL, CRP 0,27±1,1mg/dl in well nourished patients vs. TNF alpha 11,4±4,4pg/
mL, IL-6 14,0±8,8 pg/mL, CRP 2,33 ±2,4mg/dl in malnourished patients, all n.s.). However,
IL-6 was shown to correlate closely with capacitance (r=-0.420, p=0.001) and with the
phase angle (r=-0.440, p=0.01), whereas TNF-alpha did not correlate at all. Capacitance
was also correlated to CRP (r=-0.297, p=0.04) and albumin (r=0.411, p=0.001). No correla-
tions were obtained between cytokines, impedance parameters and disease severity as deter-
mined by the Child Pugh score. Conclusion: Inflammatory state does not seem to be
associated with nutritional state as determined by the SGA or anthropometry. However



















Cardiovascular Disease in Liver Cirrhosis. Correlations of Nutritional Status
and Insulin Resistance with Serum Cholesterol Levels and Arterial Blood
Pressure
Evangelos Kalaitzakis, Katrin Rabie, Einar Bjornsson
The prevalence of cardiovascular disease(CVD) in patients with liver cirrhosis(LC) has been
reported to be low despite the frequent presence of diabetes(Marchesini et al, Am J Gastro
99). Malnutrition, low cholesterol and low arterial blood pressure(BP) are common in
cirrhotics and have been proposed to be involved in this “protective” effect of LC. However
data on the possible relation of CVD with nutritional status, cholesterol and BP in cirrhotics
are scarce. The effects of nutritional status and insulin resistance on cholesterol and BP in
LC are unclear. Methods:128 consecutive cirrhotics (mean(SD) age 57(11); Child-pugh
8.6(2.3); MELD 13.2(5.6);50F;55 alcoholic etiology) were prospectively evaluated for a
history of CVD(stable angina, previous myocardial infarction or unstable angina), diabetes
and hypertension. BP was measured and nutritional status assessed by anthropometry. In
a subgroup of 95 patients fasting serum low- and high-density lipoprotein(LDL,HDL), glucose
and insulin were measured. Insulin resistance was expressed as homeostasis model assessment
index(HOMA). 59 healthy subjects(age 48(11),37F) served as controls. Results:20 cirrhot-
ics(16%) had CVD(8 stable angina, 9 previous infarction, 7 previous unstable angina).
33(26%) patients had diabetes, 32(25%) had hypertension and 38(30%) were malnourished.
Patients with vs without CVD were older(66yr(10) vs 56yr(11);p<0.01), more often hyper-
tensive(60% vs. 20%;p<0.01) or diabetic(50% vs 22%;p<0.01) and had lower LDL(1.8mmol/
l(0.9) vs 2.5mmol/l(1.4);p<0.05) but did not differ in nutritional status, etiology or severity
of LC. Patients with vs without malnutrition had lower diastolic BP(70mmHg(10) vs
75mmHg(11);p<0.05). The correlations of age, BMI and insulin resistance with cholesterol
and BP were found to be altered in LC compared to controls(table). Cirrhosis severity indices
were negatively related to cholesterol(table). Conclusion:In cirrhosis, cardiovascular disease
is related to age, hypertension and diabetes but not to etiology or severity of liver disease,
malnutrition or cholesterol. Malnutrition is related to a lower diastolic blood pressure in
cirrhotics. The effects of age, BMI and insulin resistance on cholesterol and blood pressure
seem to be altered in cirrhosis.
* Pearson correlation coefficient for significant results (p<0.05)
M1213
Tube Feeding Does Not Affect Subclinical Hepatic Encephalopathy in Patients
with Liver Cirrhosis
Tatjana Schuetz, Kristina Norman, Ute Friedrich-Pagels, Johann Ockenga, Tam N. Luu,
Herbert Lochs, Matthias Pirlich
Background: Protein-energy malnutrition is frequent in patients with liver cirrhosis (LC).
However, nutritional supplementation with protein rich diets is considered contraindicated
due to the risk of hepatic encephalopathy (HE). The aim of this study was, therefore, to
investigate the effect of tube feeding with a high energy and protein intake on HE in a
randomized controlled trial. Methods: Twenty-two hospitalized patients with LC (16 male;
6 female; age 59.9±10.4years) were randomly assigned to receive tube feeding in addition
to normal food (TF-group, n=11; 3 Child B, 8 Child C) or normal food alone (C-group,
n=11; 6 Child B, 5 Child C) for two weeks. The severity of HE was analyzed by 6 usually
applied psychometric paper-pencil tests (number connection tests A and B, digit symbol
test, pointing test, line tracing test time and line tracing test mistakes). In addition a
newly established neurophysiologic tool (Gernot Schuhfried Inc., Austria) measuring visual
discrimination ability (critical flicker frequency: CFF, fusion frequency: FF) was used to
identify patients with subclinical HE. Results: TF-patients received 2098±823 kcal/d and
80.8±42.2 g protein/d compared to C-patients with 1409±527 kcal/d and 52.9±19.0 g
protein/d. Before intervention both groups had a similar performance in both psychometric
(TF: -8.2±4.0 points; C: -7.6±5.0 points) and neurophysiologic tests (TF: FF=31.7±2.8 Hz;
CFF=32.0±3.0 Hz; C: FF=31.4±4.5 Hz; CFF=32.3±3.9 Hz). Additional protein-rich tube
feeding did not cause a deterioration in HE neither in psychometric (-8.5±3.7 points) nor
in the neurophysiological tests (FF: 31.4±4.5 Hz; CFF: 32.3±3.9 Hz) after two weeks.
Conclusion: Tube-fed LCI patients showed no deterioration in HE despite a high protein
intake. Therefore high protein diets can be recommended in patients with LCI to meet their
increased protein requirements.
M1214
Nonabsorbed (< 0.4%) Antibiotic Rifaximin Improves Hepatic Encephalopathy
Symptoms in Patients with Cirrhosis Due to Hepatitis C
Melissa Palmer
Background: Lactulose, administered for the treatment of hepatic encephalopathy (HE), is
often poorly tolerated. Data suggest antibiotics may be a useful treatment option for HE.
Oral rifaximin (Xifaxan®, Salix Pharmaceuticals, Inc., Morrisville, NC) is a gut-selective,
nonabsorbed (<0.4%) antibiotic with broad-spectrum activity in vitro. We prospectively
investigated whether rifaximin in an outpatient setting would be effective and well tolerated
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for the treatment of stage 1 HE in patients with cirrhosis due to hepatitis C virus (HCV).
Methods: Consecutive patients with cirrhosis due to HCV diagnosed with stage 1 HE
(determined by West Haven criteria) were treated with rifaximin 400 mg 3 times daily for
14 days. All patients were assessed 24 hours prior to the start of therapy and 14 days after
completion of therapy for multiple parameters, including ability to perform mental tasks,
asterixis, and a quality of life (QoL) composite score (i.e., altered sleep patterns, personality
change, short-term memory loss, attention span, reaction time, slow/slurred speech, and
general QoL). Results: A total of 37 consecutive patients were enrolled and no patient was
receiving therapy for HE at study entry. Twenty-three patients were receiving pegylated
interferon (IFN) plus ribavirin for chronic HCV, and 17 of these 23 patients were receiving
a selective serotonin reuptake inhibitor for mild IFN-induced depression. Type 2 diabetes
mellitus (DM) was reported in 12 patients. Rifaximin treatment lowered serum ammonia
to normal levels in all patients, and overall, HE symptoms improved. Rifaximin was also
well tolerated, with all patients completing treatment. One patient missed 2 rifaximin doses
on day 9 due to complaints of flatulence and abdominal bloating, which resolved without
medical intervention. There was a low incidence of adverse events (AEs): 3 patients (8%)
reported mild bloating, and there was 1 report each of mild abdominal pain, diarrhea,
nausea, and headache. No hypo- or hyperglycemic episodes were reported during the study.
Conclusion: This pilot study indicated that rifaximin is well tolerated and effective in
improving symptoms of stage 1 HE in patients with cirrhosis due to HCV. In addition, no
glycemic episodes were reported in patients with DM. Given that neomycin is associated
with a risk for nephrotoxicity and lactulose administration in patients with DM is not ideal,
rifaximin may be the more appropriate treatment for patients with DM. In addition, symptoms
of HE can be mistaken for pegylated interferon and/or ribavirin AEs, and patients treated
with these medications should be periodically evaluated for HE.
M1215
Disrupted Diurnal Rhythm of Autonomic Balance in Patients with Non-
Alcholic Liver Cirrhosis
Chung-Wang Ko, Chi-Sen Chang, Gran-Hum Chen, Hong-Zen Yeh
AIM: To evaluate the impairment of autonomic system in cirrhotic patients. METHOD:18
non-alcoholic cirrhotic patients and 17 normal subjects were enrolled. The signals of ECG
for analysis of heart rate variability were measured by ambulatory 24-hr ECG.Power spectrum
analyses of heart rate variability were performed. The low-frequency band (LF,0.04~0.15
Hz) and high-frequency band (HF,0.15~0.50 Hz)were computed by estimating the power
or variance of the beat-to-beat fluctuations in the heart period that fall into slow and fast
rhythm. Parameters include power of HF, LF, and ratio of LF-to-HF (LF/HF) which represents
parasympathetic, sympathetic modulation, and point of autonomic balance respectively.
Each of them was evaluated in daytime(9AM~8PM)and nighttime(11PM ~5AM) periods. To
evaluate the diurnal rhythm, the nighttime to daytime ratio of HF, LF, and LF/HF were
calculated. Mann-Whitney U test was applied for statistic analysis. RESULT: Comparing to
normal subjects, the daytime HF, LF, and LF/HF in cirrhotic group are 65.8±79.9 vs
89.9±35.6msec2(p <0.05); 134.7±185.3 vs 261.7±147.6msec2(p<0.05); and 2.17±1.40 vs
3.15±1.75(p<0.05) . The night t ime HF, LF, and LF/HF are 126.0±134.0 vs
225.0±182.1msec2(p< 0.05); 201.1±167.5 vs 368.4±393.1msec2(p> 0.05); 2.27±1.86 vs
1.75±1.08 (p>0.05). The ratios of nighttime to daytime parameters are 2.68±2.01 vs
2.89±2.97 in HF(p>0.05); 2.49±2.46 vs 1.46±1.25 in LF(p>0.05); 1.05±0.71 vs 0.61±0.29
in LF/HF(p<0.05, figure).CONCLUSION: Our unique finding is the disruption of diurnal
variation in autonomic balance. Other abnormalities in autonomic regulations include sup-
pressed parasympathetic modulation in both daytime and nighttime periods and suppressed
sympathetic modulation in the daytime. (Supported by Taichung Veterans General Hospital
Research Program-TCVGH93).
M1216
Autoimmune Pancreatitis: Response to Therapy in a UK Series
Nicholas I. Church, Stephen P. Pereira, Adrian R. Hatfield, George J. Webster
Background Autoimmune pancreatitis (AIP) is a rare condition which usually presents with
a pancreatic mass, biliary and pancreatic duct stricturing, jaundice and a raised serum IgG4.
A response to steroids is a diagnostic criterion, although historical data from our unit suggest
that spontaneous improvement may occur. This is the first UK series of AIP patients in
which objective responses to active treatment are reported. Methods All 9 patients treated
for AIP at our centre in 2004-5 were included. Intrahepatic/hilar stricturing was present in
8 at diagnosis, and plastic stents for jaundice/dominant CBD/hilar strictures were sited at
ERCP in 5 (although 4 patients remained jaundiced despite apparently optimal stenting).
Oral prednisolone 30mg OD was commenced in all patients, with gradual dose reduction
over 4 weeks. In cases of disease relapse following steroid reduction, azathioprine was
commenced. Response was assessed in terms of pre- and post-steroid symptoms, liver
biochemistry and radiological appearances. Results Within 4 weeks of starting steroids, all
patients reported significant symptomatic improvement. After 8 weeks, median bilirubin
levels had fallen from 38 μmol/l (range 8-232) to 9 μmol/l (5-27),(p = 0.004 by Wilcoxon
matched pairs test); median ALT from 88 IU/l (22-276) to 57 IU/l (26-76),(p = 0.008), and
ALP from 496 IU/l (149-978) to 193 IU/l (64-424),(p = 0.004). Repeat ERCP (7 patients)
and MRCP (2 patients) after 3-6 months showed improvement in pancreatic and extra-
hepatic/intra-hepatic biliary stricturing in all cases, with almost complete resolution in 4.
Biliary stents were removed in all cases, with no recurrence of jaundice (median follow-up
4, range 3-12 months). CT/MRI showed resolution of mass lesions in 3, and significant
improvement in the rest. Eight patients remain on low dose steroids (range 3-12 months).
Two patients relapsed on steroid dose reduction, with improvement on adding azathioprine.
One patient discontinued steroids after nine months and has remained well. Conclusion
Patients with AIP appear to show a good objective response to steroids. Disease relapse may
occur following steroid reduction, but introduction of azathioprine may be of benefit. Further
work is required to define the clinical course of this unusual condition, its aetiopathogenesis,
and the optimal treatment regimen.
M1217
Clinicopathological Features of Autoimmune Pancreatitis in Relation to
Elevation of Serum IgG4
Terumi Kamisawa, Naoto Egawa, Hitoshi Nakajima, Kouji Tsuruta, Atsutake Okamoto
Background and Aim: Autoimmune pancreatitis (AIP) is characterized serologically by eleva-
tion of serum IgG4 concentration. Incidence of serum IgG4 elevation in patients with AIP
was reported to be from 68% to 95%. In AIP, the characteristic histological finding of diffuse
lymphoplasmacytic infiltration with fibrosis is observed in the peripancreatic retroperitoneal
tissue, the biliary duct, and the salivary glands as well as in the pancreas. We have previously
reported that infiltrations of abundant IgG4-positive plasma cells were detected in various
organs in AIP patients but were not detected in other diseases, and suggested that AIP
represented a pancreatic lesion of an IgG4-related systemic disease. This study aimed to
examine the clinicopathological differences between patients with AIP in relation to presence
or absence of elevated serum IgG4 concentrations. Patients and Methods: We divided 21
patients with AIP into two groups on the basis of serum IgG4 concentration measured before
steroid therapy or surgical resection; elevated (>135 mg/dL) and low. Number of IgG4-
immunoreactive plasma cells in the pancreas (n=9), bile duct (n=8), gallbladder (n=8),
gastric mucosa (n=15), and abdominal lymph nodes (n=6) resected or biopsied from these
patients was examined. Results: Serum IgG4 concentrations were elevated in 14 patients
(150-1890 mg/dL) and ranged from 11 to 128 mg/dl in the other 7 patients. No significant
differences in age (68.0 yr vs. 77.0) and sex (male/female; 10/4 vs. 5/2), frequencies of
pancreatic swelling (14/14 vs. 7/7), biliary stenosis (13/14 vs. 6/7), presence of autoantibodies
(7/14 vs. 2/7), and salivary glands enlargement (5/14 vs. 0/7) were identified between the
two groups. Abdominal lymphadenopathy was detected at laparotomy more frequently in
patients with high serum IgG4 (5/5 vs. 0/3, p<0.05). Although, no difference in the number
of IgG4-positive plasma cells infiltrating the pancreas (median 60.5/high power field (HPF)
vs. 36.0/HPF) and gallbladder (32.0/HPF vs. 8.0/HPF) was identified between the 2 groups,
numbers of IgG4-positive plasma cells infiltrating the wall of the bile duct (56.0/HPF vs.
30/HPF, p<0.1) and the abdominal lymph nodes (55.0/HPF vs. 26.0/HPF, p<0.1) tended
to be greater in the group with elevated IgG4. The number of IgG4-positive plasma cells
infiltrating the gastric mucosa was also significantly higher in this group (10.0/HPF vs. 1.5/
HPF, p<0.01). Conclusion: IgG4-related phenomena occurred in various organs of patients
with AIP associated with elevated IgG4, while these phenomena tended to be rather confined
to the pancreas in patients with low serum IgG4.
M1218
The Japanese Diagnostic Criteria for Autoimmune Chronic Pancreatitis: Is It
Completely Satisfactory?
Eun Kwang Choi, Myung-Hwan Kim, Jong Cheol Kim, Jimin Han, Dong Wan Seo, Sang
Soo Lee, Sung Koo Lee
Objectives: Autoimmune chronic pancreatitis (AIP) is a very attractive disease to clinicians
in terms of its dramatic response to the oral steroid therapy in contrast to ordinary chronic
pancreatitis. In the year 2002, the Japan Pancreas Society published the diagnostic criteria
of AIP and many clinicians around the world use this criteria for its diagnosis. The purpose
of this study was to evaluate whether Japanese criteria for the diagnosis of AIP is adequate
or not. Methods: We retrospectively analyzed the clinical, radiologic, laboratory and histologic
features of 31 patients with AIP who have been successfully treated with oral corticosteroid.
All the enrolled patients showed normalization or marked improvement in symptoms,
laboratory and imaging findings after steroid treatment. Results: The mean patients’ age was
56 years (range, 32-78 years) and were comprised of 25 males and 6 females. Seven patients
who responded to the steroid did not satisfy the Japanese imaging criterion because the
extent of irregular narrowing was less than one third of the entire length of main pancreatic
duct. Among these seven patients, one patient did not meet the laboratory and histopathologic
criteria as well. Another two patients fulfilled Japanese imaging criterion only and showed
normal IgG level, negative results of autoantibody measurements and nondiagnostic pancre-
atic histopathology. Taken together, nine (29%) of 31 patients did not meet the Japanese
diagnostic criteria for AIP, yet responded to the steroid. Conclusions: Clinicians may miss
a substantial portion of AIP patients who may benefit from steroid therapy when the diagnosis
is confined to those who satisfy the criteria proposed by the Japan Pancreas Society. It is
necessary to convene a worldwide consensus to develop an improved diagnostic criteria for
AIP. Key words: autoimmune pancreatitis, diagnosis, criteria
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M1219
Pancreatic and Biliary Abnormalities in Patients with Autoimmune
Pancreatitis (AIP) At MRI and Endoscopic Ultrasound (EUS)
Dermot O'Toole, Marie-Pierre Vullierme, Vinciens Rebours, Laurent Palazzo, Alain Aubert,
Philippe Ponsot, Karine Nahon-Uzan, Anne Couvelard, Philippe Levy, Valerie Vilgrain,
Philippe Ruszniewski, Pascal Hammel
Introduction: Although AIP is an increasingly recognised entity, in the absence of histology
or a well-defined associated autoimmune disease (~ 40% [1]), the diagnosis remains difficult.
Certain parenchymal and/or ductal abnormalities have been suggested to occur at both MRI
and EUS but data are limited [2]. Aims: Examine for pancreatic and biliary signs of AIP at
MRI and EUS in a cohort of patients (pts) with AIP followed in a single centre. Methods:
Prospective study of 24 pts (15 men) with AIP (diagnosis based on either histology, or
pancreatitis without a definable cause associated with another autoimmune disease and/or
a favourable response to steroids) undergoing pancreatic MRI (axial sequences at T1 and
T2, with MR-cholagio-pancreatography) and pancreatic and biliary EUS. Results: 1) MRI -
changes on T1 included: a hypointense zone (n=14), a pseudotumour (n=5); on T2: a
hyperintense ring (n=11); parynchemyal pseudocyst (PC) (n=5). Ductal changes at MR-
pancreatography were - main pancreatic duct (MPD): not visualised (n=15, (63%); which
was segmental in nature, n=13) or a thin irregular MPD (n=6); dilated segments (n=5;
>10mm in 1 pt); - secondary ducts: moderate dilatation (n=5). Stenosis of the intra-pancreatic
CBD was observed in 8 pts with dilatation of the intra-hepatic bile ducts in 6 (4 of whom
were irregular). 2) EUS - the pancreatic parenchyma was diffusely hypertrophic in 8 pts.
The echo pattern was heterogeneous or hypoechoic in 6 and 1 pts, respectively. Calcifications
were observed in 1 pt. A focal hypoechoic mass was noted in 13 pts (54%) (head/uncinate
process: 9, isthmus: 2 and body/tail: 2). Abnormalities of the MPD included a stenosis in
15 pts (63% : diffuse, n=13) with hyperechoic walls in 11 pts (disuse in 10). Segmentary
or diffuse dilatation of the MPD was observed in 4 and 1 pts, respectively. A peri-pancreatic
inflammatory reaction was noted in 4 pts including 2 cases of vascular encasement and 4
intra-pancreatic PCs. Stenosis of the intra-pancreatic CBD was found in 13 pts (54%) with
signs of cholangitis in 8 of these. Lymph nodes >10mm were visualised in 6 pts. Conclusion:
1) Abnormalities of the MPD appear constant in AIP observed at MRI (88%) or EUS (75%):
including non-visibility or a thin irregular duct, and these changes are rare in pancreatitis
from other causes. 2) Other frequent changes at MRI and EUS supporting the diagnosis of
AIP include a pseudotumoral aspect and cholangitis. [1] Nahon-Uzan et al. Is idiopathic
chronic pancreatitis an autoimmune disease? Clin Gastroenterol Hepatol 2005;3:903-9. [2]
Sahani et al. Autoimmune pancreatitis: imaging features. Radiology. 2004;233:345-52.
M1220
Sclerosing Cholecystitis Associated with Autoimmune Pancreatitis
Terumi Kamisawa, Naoto Egawa, Hitoshi Nakajima, Kouji Tsuruta, Atsutake Okamoto
Background and Aim: Patients with autoimmune pancreatitis (AIP) frequently have stenosis
of the bile duct system. Fibrosis and dense lymphoplasmacytic infiltration with abundant
IgG4-positive plasma cells is detected in the bile duct as well as in the pancreas of AIP.
These findings suggest a close relationship between AIP and sclerosing cholangitis, but
there is only one study that has evaluated the gallbladder in AIP. This study evaluated
histopathological and radiological findings of the gallbladder in AIP patients. Patients and
Methods: Radiological findings of the gallbladder of 19 AIP patients were reviewed. Stenosis
of the extrahepatic bile duct occurred in 16 patients. At least 3 sections of the resected
gallbladder of the 8 AIP patients were histologically examined and immunostained by anti-
IgG4 antibody. Pattern of gallbladder inflammation was classified into 2 types: transmural
in which inflammatory infiltrates extended through the gallbladder wall and included involve-
ment and focal destruction of the muscularis; and mucosal-based, in which the inflammatory
infiltrates were prominently detected within the lamina propria. Controls consisted of
gallbladders resected for symptomatic gallstones (n=10) and those removed during pancreato-
duodenectomy for pancreatic carcinoma (n=10), as well as extrahepatic bile ducts and
pancreases removed by pancreatoduodenectomy for pancreatic carcinoma (n=10). Results:
Thickening of the gallbladder wall was detected by US and/or CT in 10 patients with AIP
(3 severe: thickness ≥8mm, and 7 moderate: thickness from ≥4mm to <8mm); in these
patients severe stenosis of the extrahepatic bile duct was also noted. Histologically, thickening
of the gallbladder was detected in 6 of 8 patients with AIP; 4 cases had transmural lymphoplas-
macytic infiltration with fibrosis, and 2 cases had mucosal-based lymphoplasmacytic infiltra-
tion. Considerable transmural thickening of the extrahepatic bile duct wall with dense fibrosis
and diffuse lymphoplasmacytic infiltration was detected in 7 patients. Immunohistochem-
ically, infiltration of abundant IgG4-positive plasma cells (>10/high power field) was detected
in the gallbladder, bile duct, and pancreas of all 8 patients, but was not detected in controls.
Conclusion: Thickening of the gallbladder wall is one of the extrapancreatic lesions that are
frequently detected in patients with AIP. It is characterized by transmural wall thickening
with fibrosis and abundant infiltration of IgG4-positive plasma cells. We propose the use
of a new term, sclerosing cholecystitis, for these cases that are induced by the same mechanism
as sclerosing pancreatitis or sclerosing cholangitis in AIP.
M1221
High Prevalence of Nonalcoholic Steatohepatitis in Autoimmune Pancreatitis
Takayoshi Nishino, Etsuko Hashimoto, Fumitake Toki, Hiroyasu Oyama, Itaru Oi, Makio
Kobayashi, Keiko Shiratori
Background and Aim: Autoimmune pancreatitis (AIP) is known to frequently associate with
type 2 diabetes mellitus (DM). DM is also a high risk factor for nonalcoholic steatohepatitis
(NASH), however, there have been no studies about the prevalence of NASH in AIP. The
present study was undertaken to identify characteristic features of liver biopsy and prevalence
of NASH in patients with AIP. Methods: We retrospectively reviewed the clinical findings
and outcomes of 30 AIP cases (M:F=20:10; age ranged from 45 to 83 yr, median age 65
yr). Liver biopsy was performed in 9 patients. The diagnosis of NASH was based on the

















intake less than 20 g, and (3) exclusion of other liver diseases. A second liver biopsy was
performed in 3 of the 9 AIP patients during predonisolone (PSL) therapy. Results: The
profile of 9 biopsied-AIP patients (M:F=6:3; median age 72 yr) was as follows. Mean BMI
was 22.2 (range 18.0 to 25.2).Insulin resistance was observed in 78 % (7/9), hyperlipidemia
was in 22 % (2/9). The nine AIP patients in whom liver biopsy was performed reflected
the characteristic profile of the 30 AIP patients. The characteristic liver pathological features
were: (1) mild to moderate portal or periportal hepatitis manifested by minimal fibrosis.
Inflammatory changes were consisting of lymphoplasmacytic infiltration with or without
lobular hepatitis (9/9); Immunohistochemistry revealed many CD8-positive, CD4-positive
lymphocytes and IgG4-positive plasma cells in the periportal area; (2) duct and ductuler
proliferation with or without zone 3 cholestasis (9/9), and (3) steatohepatitis (8/9). Three
patients had typical steatohepatitis (grade severe in three, stage 2 in two and 4 in one,
Brunt’s criteria) throughout the specimens. Cirrhotic NASH (stage 4) patient had 10 year
history of overweight and DM before diagnosis of AIP. The other two patients with normal
weight were diagnosed DM and AIP simultaneously. The other five patients were diagnosed
with focal steatohepatitis (grade mild to moderate, stage 0-1), which located in zone 3 and
consistent of 10 % to 20 % of the specimen. Examination of the second biopsy specimen
revealed improvement of steatosis and ballooning degeneration in all three patients even
during PSL treatment. Improvement of periportal and lobular inflammation with decrease
number of IgG4-positive plasma cells was seen in two patients. Conclusions: This study
revealed a high prevalence of NASH in AIP. This is a very important finding, and further
study of the pathogenesis of AIP and NASH is needed.
M1222
Autoimmune Pancreato-Cholangitis - Which Parameters Help Diagnose the
Disease? Results of a Multicenter Study Group
Annette Fritscher-Ravens, Menno Brink, Sjoerd D. van der Werf, Maarten J. Thomeer,
Maarten C. Meijssen, Henk R. van Buuren
Background: An autoimmune process causing pancreato-cholangitis (APC) has recently been
proposed in Europe. The frequency of this entity, which presents with an enlarged pancreatic
head, pancreatic and bile duct strictures and lympho-plasmocyticatic inflammation, fibrosis
and good response to cortiosteroid therapy is yet unknown. As the awareness of this disease
is not widespread in Europe correct diagnosis is rarely made at the onset of symptoms and
many patients are subjected to unnecessary surgery. Immunosuppressive treatment is often
only started some years after presentation, when the diagnosis is finally made. The aim of
this study was to explore whether there are symptoms or labatory tests that may suggest
this diagnosis and avoid unnecessary surgery prior to correct treatment. Materials and
Methods: 40 cases with APC were collected in a multicenter approach and reviewed. The
diagnostic criteria were evaluated retrospectively. Results: 37/40 patients (92%) presented
with remarkable weight loss of 6-17kg and nearly painless jaundice. 36/40 (90%) patients
had exocrine insufficiency. 10/40 (25%) patients had gastro/duodenal ulcers with bleeding
and BII/BI resection in 5. Lab investigations during follow up included antinuclear antibodies
(ANA) in 37 patients, 32 of which were negative at diagnosis, but became positive within
1-5 years after presentation in 6 cases. 5 patients had positive ANA at the time of diagnosis.
All but one of these had or developed additional autoimmune diseases: Sjoegren, interstitial
nephritis, lupus erythematosus, hypothyroidism or rheumatoid arthritis. Before treatment
serum immunoglobulin (IGG) was available in 33 patients, 26 (79%) of which were elevated
(16-33 g/l: mean: 20.1). IGG4 subclass was measured before treatment in 24 patients, in
15 (62%) it was elevated (2.1-30; mean: 8.4). If both of the tests (IGG and IGG4) were
available prior to treatment, patients with APC had an elevated level for either IGG or IGG4
in 91% (21/23 patients). The CA19.9 was elevated at the time of diagnosis in 45% of
cases. Conclusion: Patients with suspicion of pancreatic cancer, hilar cholangiocarcinoma
or intrahepatic strictures of unknown origin with extreme weight loss, exocrine insufficiency,
possible gastroduodenal ulcers, either elevated IGG and/or IGG4 have a strong likelihood
of >90% to have an autoimmune etiology of their disease.
M1223
Outcome of Autoimmune Pancreatitis Without Corticosteroid Treatment
Kenji Hirano, Saburo Matsubara, Osamu Togawa, Toshihiko Arizumi, Takeshi Sasaki,
Natsuyo Yamamoto, Yousuke Nakai, Takeshi Tsujino, Naoki Sasahira, Hiroyuki Isayama,
Minoru Tada, Nobuo Toda, Takao Kawabe, Kazumi Tagawa, Tetsuo Katamoto, Ryo
Nakata, Tateo Kawase, Masao Omata
Aim: Autoimmune pancreatitis (AIP) is a unique form of chronic pancreatitis characterized
by irregular narrowing of pancreatic duct, swelling of parenchyma, lymphoplasmacytic
infiltration and fibrosis, and a favorable response to corticosteroid treatment (CST). Since
little is known about the outcome of AIP patients without CST, we attempted to clarify their
clinical course. Patients and Methods: Diagnosis of AIP was based on imaging findings such
as pancreas swelling and narrowing of main pancreatic duct and pathological features such
as fibrosis with infiltration of lymphocytes and plasmacytes. Among 35 patients with AIP
we experienced, 21 patients were followed up without CST at first because they were
asymptomatic or became asymptomatic after biliary drainage. Their clinical features were
retrospectively reviewed. Resoults: The patients without CST consisted of 17 males and 4
females and their average age was 67 years (range 41 to 80). Nine patients received biliary
drainage before observation without CST. During follow-up of 54 months in mean (12 to
152 months), 12 patients developed symptoms including pancreatitis in 3 and bile duct
involvement (sclerosing cholangitis) in 9. In analysis of risk factors for developing symptoms,
severe bile duct stricture was identified. All the patients with late occurrence of sclerosing
cholangitis had severe bile duct stricture at the diagnosis of AIP. Age, gender, serum IgG4,
or abdominal pain was not related. The patients with developing symptoms were managed
with CST and had favorable response. Conclusion: Patients with AIP tend to suffer from
recrudescence without CST. Particularly in patients accompanied with severe bile duct
stricture, CST is indispensable.
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M1224
Utility of Total Immunoglobulin and IgG4 Levels in the Diagnosis and
Management of Autoimmune Pancreatitis
Suresh T. Chari, Thomas C. Smyrk, Amaar H. Ghazale, Michael Levy, Mark Topazian,
Naoki Takahashi, Jonathon Clain, Randall Pearson, Bret Petersen, Santhi Swaroop Vege,
Michael Farnell
Background: Autoimmune pancreatitis (AIP) remains a diagnostic challenge. Presence of
serologic abnormalities (elevation in titers of gammaglobulin and a variety of antibodies)
are an important adjunct to diagnosis of AIP. Elevation of levels of the IgG4 subclass of IgG
has been reported to be highly sensitive and specific for the diagnosis of AIP. Its usefulness
in monitoring patients on steroid therapy remains unknown. Aims: Our aims were to a)
assess the diagnostic accuracy of elevated levels of total IgG and IgG4 for AIP and b)
determine the response of serum IgG4 levels to steroid therapy in AIP and its correlation
with activity of the disease assessed radiologically. Methods: Total IgG levels (normal 600-
1500 mg/dl) and IgG4 (normal 8.0-140 mg/dl) levels were measured in 154 patients including
28 with AIP, 44 with pancreatic cancer, 36 with acute/chronic pancreatitis and 32 without
pancreatic disease. Follow-up IgG4 levels were noted in the 15 AIP patients that had IgG4
measurement during and/or after completion of steroid treatment. Results: For diagnosis of
AIP, elevation of IgG4 levels had better sensitivity compared to total IgG (23/28 (82%) vs
16/28 (57%), p=0.04). All 16 AIP patients who had elevated total IgG also had IgG4 elevation.
Of the 5 patients with AIP and normal IgG4 levels, one had the measurement after steroid
therapy and another after pancreatic resection. Frequency of total IgG and IgG4 elevation
was similar in patients that did not meet criteria for AIP (9/126 vs 14/126, p = 0.1). Of the
14 patients with IgG4 elevation (range 146-366 mg/dl) that did not meet criteria for AIP,
4 had biopsy-proven pancreatic cancer (range 168-330 mg/dl), 3 had idiopathic pancreatitis,
one had type 1b diabetes and pancreatic steatorrhea, 3 had idiopathic pancreatic steatorrhea
and 3 had no detectable pancreatic abnormality or any known extra-pancreatic manifestation
of AIP. During steroid therapy IgG4 levels decreased or normalized in all patients studied.
IgG4 were normal in all patients studied after completion of therapy. However, IgG4 levels
did not correlate with intra-abdominal radiologic abnormalities. Conclusions: IgG4 elevation
is more sensitive for diagnosis of AIP than total IgG. However, IgG4 elevation is characteristic
but not diagnostic of AIP. In AIP patients on steroid therapy IgG4 levels normalize with
treatment, but IgG4 levels do not appear to correlate with radiologic evidence of disease
activity.
M1225
IgG4 Immunostaining in Autoimmune Pancreatitis and in Extra-Pancreatic
Disease
Maesha G. Deheragoda, Nicholas I. Church, Manuel Rodriguez-Justo, Edward Seward,
Marco R. Novelli, Steve Pereira, Adrian R. Hatfield, George J. Webster
Aims: Patients with autoimmune pancreatitis (AIP) usually present with a pancreatic mass,
jaundice, and pancreatic and bile duct stricturing. Recognition of this entity is vital to avoid
unnecessary resection of suspected malignancy. Originally thought to be restricted to Japan,
we have recently reported a series of AIP patients from the UK, with a high frequency of
extra-pancreatic involvement. Definitive diagnosis is difficult, relying on a combination of
clinical, radiological and biochemical features including raised serum IgG4. The aim of this
study was to investigate the utility of IgG4 immunostaining in the diagnosis of autoimmune
pancreatitis and associated extra-pancreatic disease in biopsy specimens. Methods: All
patients seen in our centre from 2004 to 2005, in whom the diagnosis of AIP was made
on the basis of the typical characteristics were studied. Biopsy specimens from patients and
controls were immunostained with human monoclonal IgG4 antibody. Numbers of IgG4
positive plasma cells were assessed in 10 high power fields (HPF). Correlation was made
with serum IgG4 levels.Results: Results IgG4 positive plasma cell numbers were consistently
elevated in pancreatic and extra-pancreatic biopsy tissues even in cases with normal serum
IgG4. The majority of AIP patients had >10 IgG4 positive plasma cells per HPF. Control
tissues showed ≤ 2 IgG4 positive plasma cells per HPF. The percentage of total plasma
cells which expressed IgG4 was >80% in AIP patients compared with <10% in controls.
Conclusions An IgG4 positive plasma cell infiltrate appears to be specific to AIP when
compared with other inflammatory disorders. IgG4 immunostaining may be of use in the
routine investigation of intra- and extra-pancreatic disease in clinically suspected cases of
autoimmune pancreatitis.
*insufficient portal tract tissue **Control tissues (10 per organ system): Liver (chronic
hepatitis C), Pancreas (chronic alcoholic pancreatitis), Gall bladder (chronic cholecystitis),
Kidney (tubulointerstitial nephritis), Salivary gland (chronic sialadenitis), Duodenum
(chronic duodenitis), Bone marrow (normal bone marrow) *** Severe fibrosis
M1226
Novel HLA Allele Associated with Autoimmune Pancreatitis in the Korean
Population
Do Hyun Park, Myung-Hwan Kim, Heung-Bum Oh, Sang Soo Lee, Dong Wan Seo, Sung
Koo Lee, Sun-Joo Kim
Backgtorund/Aims: Autoimmune chronic pancreatitis (AIP) is associated with hypergammag-
lobulinemia, histologic evidence of lymphoplasmacytic infiltration, coexistence of other
autoimmune diseases and a favorable response to steroid therapy, which are clinical evidence
of autoimmunity. However, definite pathogenesis of AIP has been unclear. There was only
one HLA study using low resolution typing in patients with AIP to determine close association
between AIP and particular alleles of major histocompatibility complex genes. Sequence-
based typing (SBT) for HLA has become the method of choice for HLA genotyping because
of its ability to provide the highest resolution as well as to identify any new alleles. To
determine whether certain alleles or haplotypes of major histocompatibility complex gene
are associated with AIP in Korean population, we undertook this study with high-resolution
typing (sequence-based typing) for HLA. Methods: Between October 2002 and August 2005,
we obtained samples from consecutively enrolled 25 patients with AIP: there were 18 men
and 7 women aged 34-74 years. HLA class I and II allelic genotypes from 153 healthy
subjects were obtained for this study as a control. All patients with AIP met the diagnostic
criteria of Japanese pancreas society. Results: In patients with AIP compared with healthy
subjects, among class II antigen, DQ2 was significantly associated with AIP compared with
health subjects (40% vs. 16%, corrected p=0.01), Among the DQ 2 subtype, we found a
significant association between DQB1*0202 allele and AIP (28% vs. 11%, odd ratio=3.11,
p=0.022). No other HLA class I and II antigen and DRB1 or DQB1 were significantly
associated with AIP compared with healthy subjects. Conclusions: Using high-resolution
typing for HLA, HLA DQ1*0202 may be associated with AIP in the Korean population.
Staitistical analysis of DR and DQ subtype among patients with autoimmune pancreatitis,
and healthy subject
M1227
Corticosteroids Are Efficacious in Patients with Lymphoplasmacystic
Sclerosing Pancreatitis (LSP) But Relapses Are Frequent
Pascal Hammel, Vinciens Rebours, Dermot O'Toole, Marie-Pierre Vullierme, Karine
Nahon-Uzan, Frederique Maire, Philippe Ponsot, Alain Aubert, Annie Sibert, Laurent
Palazzo, Philippe Levy, Philippe Ruszniewski
Clinical, biological and morphological features of LSP (either “autoimmune”: AIP or eosino-
philic [EP]) are currently better characterized; however the effects of medical treatment to date
has been poorly evaluated. Aim: To assess therapeutic management (indications, treatment
modalities and results) of patients with LSP in a monocentric series. Patients (pts) and
methods: Prospective inclusion of all pts with LSP between 01-2002 and 08-2005. The
diagnosis of LSP was made in view of clinical biochemical and imaging according to Yoshida’s
criteria (1). Symptomatic pts received oral corticosteroids in the absence of untreated biliary
stenosis or sepsis. Results: 29 pts (21 M, 8 F, median age 39 years (17-73), 25 with LSP,
4 with EP) were included with a median follow-up of 14 months (1-55). Median age at
symptom onset was 39 years (16-69). The first symptom was abdominal pain, acute pancreat-
itis, weight loss, and jaundice in 35 %, 24 %, 21 % and 17 % of pts, respectively (fortuitous
diagnosis in one symptom-free pt). Associated auto-immune or inflammatory bowel diseases
were present in 6 (21%) and 4 (14%) pts, respectively. Pathological data obtained from
EUS-guided biopsy were available in 12 (41%) pts, showing typical features of LSP in 11
and fibrosis alone in 1. Prednisolone (1 mg/kg day for 1 month with progressive tapering
over 3 months) was given to the 13 pts (45%) with pain or jaundice. Biliary drainage was
necessary in 3. Symptoms improved in 12 of the 13 pts (92%), and radiological improvement
was observed in 58 % of cases. In one patient, septicaemia led to treatment withdrawal.
Pancreatic (n=3) or biliary (n=5) symptoms relapsed in 8 pts (67%) at time of treatment
withdrawal, 3 of whom had ≥ 2 symptomatic relapses. A second course of prednisolone
was given in 7 pts (2 of whom also required biliary stenting), and biliary stenting alone
was performed in 1 pt. Azathioprine or imatinib were prescribed in 2 and 1 pt experiencing
at least two relapses, respectively, with no further recurrence after 9-11 months. Conclusion:
Corticosteroid treatment of pancreatitis was necessary in 45% of pts, occasionally associated
with biliary drainage. Treatment efficacy concerning symptoms was high (> 90 %) but
relapses were frequent (2 out of 3 pts). Immunosuppressive therapy can be envisaged for
steroid-dependent pts.
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M1228
Serum IgG4 Levels in Pancreatic and Biliary Diseases
Kenji Hirano, Saburo Matsubara, Toshihiko Arizumi, Takashi Sasaki, Natsuyo Yamamoto,
Yousuke Nakai, Takeshi Tsujino, Naoki Sasahira, Hiroyuki Isayama, Minoru Tada, Takao
Kawabe, Nobuo Toda, Kazumi Tagawa, Tetsuo Katamoto, Ryo Nakata, Osamu Togawa,
Tateo Kawase, Masao Omata
Purpose: Recently, it has been reported that the serum level of IgG4, a minor component
of IgG subclasses, is elevated in autoimmune pancreatitis. About IgG4 levels in other pancre-
atic or biliary diseases, however, little has been studies. Thus, this study was conducted to
resolve this issue. Methods: Serum IgG4 was measured in 116 patients with pancreatic or
biliary diseases (35 autoimmune panceatitis, 24 chronic pancreatitis except autoimmune
pancreatitis, 11 primary sclerosing cholangitis, 23 pancreatic cancer, 3 islet cell tumor, 2
papilla cancer, 15 bile duct cancer, and 3 gallbladder cancer patients). We employed 135
mg/dl as a cut-off level of IgG4. Results: Elevation of serum IgG4 was observed in 33 of 35
patients with autoimmune pancreatitis, 0 of 24 with chronic pancreatitis, 4 of 11 with
primary sclerosing cholangitis, 0 of 23 with pancreatic cancer, 0 of 3 with islet cell tumor,
0 of 2 with duodenal papilla cancer, 0 of 15 with bile duct cancer and 0 of 3 with gallbladder
cancer patients. Conclusions: Elevation of serum IgG4 was observed in autoimmune pancreat-
itis. In other pancreatic or biliary diseases except primary sclerosing cholangitis, it remains
within normal limits.
M1229
Clinical Aspect of Extra-Pancreatic Complications with Autoimmune
Pancreatitis
Kazushige Uchida, Tsukasa Ikeura, Syoichiro Takamido, Masaaki Shimatani, Mitsunobu
Matsushita, Makoto Takaoka, Kazuichi Okazaki
Background & Aim: Autoimmune pancreatitis (AIP) is a new clinical entity of pancreatitis.
Recently several investigators reported that AIP has often complicated with extra-pancreatic
disease. For example, sclerosing cholangitis with AIP (SC-AIP) is showing similar cholangiog-
ram with classical primary sclerosing cholangitis (PSC). But SC-AIP is thought that pathogen-
esis is different from PSC. Because clinical coarse is quiet different. AIP sometime complicated
with sialoadenitis also. This sialoadenitis might be different from Sjogren syndrome. To clarify
these problems, we analyzed complications with autoimmune pancreatitis immunologically.
Methods: Fifty patients with AIP (31 men and 19 women; average age 59.1 years old) were
recruited for this study. Forty five patients were fulfilled the diagnosis criteria for AIP as
Japan pancreas society’s criteria. Five patients were diagnosed histrogically. These patients
were measured serum IgG, IgG4 and autoantibodies (rheumatoid factor (RF), anti-nuclear,
lactoferrin (LF), carbonic anhydrase II (CA-II), mitochondria (AMA), SS-A/SS-B, and GAD
antibodies). All patients were screened extra-pancreatic complications Diabetes mellitus was
complicated in 42% of the patients, sclerosing cholangitis 26%, sialoadenitis 14%, arthritis
12%, retroperitoneal fibrosis 10%, interstitial nephritis and thyroiditis 8%, and hepatic
pseudo-tumor 2%. We also studied infiltrating cells by Immunohistochemistry. Results:
High level of serum IgG was detected in 80% of the patients. IgG4 was 70%. Anti-nuclear
or LF antibody was detected in 75% of the patients. Anti CA-II antibody was detected in
55% of the patients. RF 25%, SS-A/SS-B 3%. AMA is not detected in any patients. Anti-LF
or CA-II antibody was detected in 90% of the patients. High level of IgG4 was correlated
with sclerosing cholangitis (PSC like cholangiogram, p<0.05). Anti-LF antibody had a tend-
ency with the showing of abnormal cholangiogram (p=0.08). In the immunohistochemical
study, IgG4 positive plasma cells infiltrated in extra pancreatic lesions (salivary glands,
retroperitoneum and liver). Two third patients with diabetes mellitus were improved HbA1c
after steroid therapy. On the other hand, one-third patients were getting worse. Conclusions:
To measure anti-LF and CA-II antibodies is useful for the diagnosis of AIP.
M1594
Commensal Microflora Attenuate Adaptive Growth in the Colon, But Not the
Small Intestine, Following Ileo-Cecal Resection
Rachael J. Rigby, Christopher M. Dekaney, Susan J. Henning, P. Kay Lund, Michael A.
Helmrath
Background: Surgical resection of ileum and proximal right colon is common in Crohn’s
disease and necrotizing enterocolitis. Adaptive growth of remnant bowel is beneficial in
restoring normal nutrient, fluid, vitamin, bile acid and mineral absorption. Recent studies
in models of intestinal inflammation indicate that commensal microflora impact on crypt
homeostasis and promote mucosal healing. However, the role of bacteria in adaptive growth

















(ICR) in germ free (GF), conventionally-raised (CON), and conventionally-raised and antibi-
otic treated (CON-A) mice, to test the hypothesis that commensal microflora alter adaptive
growth of the small intestine or colon. Methods: ICR or control transection (T) was performed
on 8-12 week old GF or CON C57BL6 mice. CON-A mice were orally fed broad-spectrum
antibiotics in liquid diet for 3 days before and 7 days after surgery. Mice were killed 7 days
after surgery and jejunum and colon harvested. Crypt depth and BrdU incorporation were
assayed. Adaptive growth after ICR in each group was assessed as percentage change in ICR
versus T controls. Results: In T controls, crypt depth was significantly lower in small intestine
of GF (100±1) than CON (124±14) mice, and CON-A mice had intermediate values (114±7).
After ICR, adaptive increases in crypt depth in small intestine were virtually identical in all
groups GF (31±4 % increase), CON (32±7% increase), and CON-A (35±4% increase). In
both small intestine and colon, data for BrdU incorporation was consistent with crypt depth
data. In colon, crypt depth did not differ significantly in T control groups. However, after
ICR, colon of GF mice showed a dramatic increase in crypt depth (95±2%; p≤0.001), this
response was absent in CON mice (8±4% p=0.19) and evident, but attenuated, in CON-A
mice (25±10%; p≤0.09). Conclusions: Commensal microflora do not significantly affect
adaptive growth of the small intestine following ICR. In contrast, commensal microflora
impair colonic adaptation after ICR. Significant adaptive growth of colon in GF, but not
CON mice and moderate growth in the colon of antibiotic-treated CON mice, supports a
concept that clinical therapies to modify commensal microflora may augment adaptive
growth of colon and benefit patients after ICR.
M1595
Effect of Ghrelin Administration On the Healing of Chronic Duodenal Ulcers
in Rats. Role of Growth Hormone and Insulin-Like Growth Factor-1
Artur Dembinski, Zygmunt Warzecha, Ryszard Sendur, Piotr Ceranowicz, Jakub
Cieszkowski, Marcin Dembinski, Wieslaw W. Pawlik, Peter C. Konturek, Atsukazu
Kuwahara, Ikuo Kato
Background: Ghrelin, a 28-residue peptide, was primary isolated from the human and rat
stomach. It is a natural ligand of growth hormone secretagogue receptor and apart from
the stimulation of growth hormone, ghrelin exerts several biological activities including the
stimulation of appetite, intestinal motility and protection of the heart, stomach and pancreas
against damage evoked by different noxious agents. Study performed on rats has shown
that induction of duodenal ulcers by cysteamine enhances plasma level of ghrelin, but the
role of ghrelin in the maintenance of duodenal mucosal integrity has not been studied. The
aim of this study was to examine the influence of ghrelin administration on the healing of
chronic duodenal ulcers in animals with intact or removed pituitary. Methods: Two weeks
after sham-operation or hypohysectomy, chronic duodenal ulcers were induced by 75%
acetic acid applied to the serosal surface of duodenal wall. Animals were treated intraperitone-
ally twice a day with saline or ghrelin at the doses: 4, 8 or 16 nmol/kg/dose. At 6 or 10
days after induction of ulcers, rats were anesthetized; the duodenum was exposed for
measurement of duodenal blood flow and the duodenal ulcer area. Blood was taken for
determination of serum level of growth hormone (GH) and insulin-like growth factor-1
(IGF-1). Biopsy samples from the duodenal mucosa were taken for determination of mucosal
DNA synthesis, as an index of mucosal cell proliferation. Results: In animals with intact
pituitary, treatment with ghrelin increased serum level of ghrelin, GH and IGF-1. These
effects were accompanied by the increase in mucosal cell proliferation, duodenal blood flow
and acceleration of healing rate of duodenal ulceration. Ghrelin at the dose 8 nmol/kg
exhibited maximal beneficial effect. After hypophysectomy, the healing of duodenal ulcers
was delayed. This was accompanied by a significant increase in serum level of endogenous
ghrelin and decrease in serum concentration of GH and IGF-1. Also, duodenal blood flow
and mucosal DNA synthesis were reduced. In hypophysectomized rats, administration of
exogenous ghrelin increased serum level of this peptide, but it was without effect on serum
level of GH and IGF-1. Also, in hypophysectomized rats, treatment with ghrelin was without
effect on healing rate of chronic duodenal ulcers, duodenal blood flow or mucosal cell
proliferation. Conclusion: Treatment with ghrelin accelerates healing rate of chronic duodenal
ulcers and this effect is dependent on the release of endogenous GH and IGF-1.
M1596
Induced Trpc1 Expression Sensitizes Intestinal Epithelial Cells to Apoptosis
By Inhibiting NF-κB Signaling Pathway Through a Process Involving Ca2+
Influx
Bernard S. Marasa, Jaladanki N. Rao, Tongtong Zou, Lan Liu, Kaspar M. Keledjian, Ai-
Hong Zhang, Jose Greenspon, Lan Xiao, Jie Chen, Jian-Ying Wang
Apoptosis occurs within crypts and at the luminal surface of gut and plays a critical role in
mucosal homeostasis. We have recently demonstrated that TRPC1 (canonical transient recep-
tor potential-1) is expressed in intestinal epithelial cells (IECs) and functions as a Ca2+
permeable channel mediating capacitative calcium entry (CCE). TRPC1 regulates intestinal
epithelial cell motility by altering levels of cytosolic free Ca2+ ([Ca2+]cyt) through CCE, but
its involvement in modulation of apoptosis in IECs remains unknown. The current study
determined if increased TRPC1 expression sensitizes intestinal epithelial cells to apoptosis
by inactivating NF-κB activity. Methods: Studies were conducted in IEC-6 cells, derived
from rat intestinal crypts. Apoptosis was induced by tumor necrosis factor-α (TNFα) and
cycloheximide (CHX), while ([Ca2+]cyt) was measured by fluorescence digital imaging ana-
lysis. Functions of TRPC1 were investigated by stable expression of the TRPC1 gene and
transfection with small interfering RNA targeting TRPC1 (siTRPC1). NF-κB activity was
examined by measuring its sequence specific DNA-binding and NF-κB transcriptional activity.
Results: Stable TRPC1-transfected IEC-6 cells (IEC-TRPC1) highly expressed TRPC1 mRNA
and protein. Levels of TRPC1 mRNA and protein were ~5-folds the value of parental IEC-
6 cells. Although resting [Ca2+]cyt and transient Ca2+ release from the store depletion were
unchanged, sustained Ca2+] influx through CCE after Ca2+ store depletion was increased
by ~2-folds in IEC-TRPC1 cells. Susceptibility of IEC-TRPC1 cells to TNFα/CHX-induced
apoptosis increased dramatically as measured by changes in morphological features, DNA
fragmentation, and caspase-3 activity. Apoptotic cells were increased from ~38% in parental
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IEC-6 cells to ~79% in IEC-TRPC1 cells 4 h after exposure to TNFα/CHX. Stable IEC-
TRPC1 cells also exhibited decreased NF-κB transactivation as indicated by decreases in
levels of nuclear NF-κB proteins (including p65, p52, and p50), its DNA-binding activity,
and NF-κB-dependent promoter activity. Inhibition of TRPC1 expression by siTRPC1 in
stable IEC-TRPC1 cells and Cdx2-IEC cells (highly expressing endogenous TRPC1) not only
increased NF-κB transactivation but also prevented the increased susceptibility to TNF-α/
CHX-induced apoptosis. Similarly, exposure of IEC-TRPC1 cells to the Ca2+ free medium
also promoted NF-κB activity and blocked increased sensitivity to apoptosis. Conclusions:
These results indicate that induced TRPC1 expression sensitizes intestinal epithelial cells to
TNF-α/CHX-induced apoptosis by inhibiting NF-κB activity through a process involving
Ca2+ influx.
M1597
Deletion of the Mtgr1 Transcriptional Co-Repressor Sensitizes the Colonic
Epithelium to DSS-Induced Colitis
Jose A. Martinez, Joseph Amman, Isabel Moreno-Miralles, Kay Washington, Scott Hiebert
Myeloid Translocation Gene Related-1 (MTGR-1) is a member of the Myeloid Translocation
Gene (MTG) family of transcriptional co-repressors. Two members of this gene family are
disrupted by chromosomal translocations that are associated with acute myeloid leukemia.
Chromosomal translocations affect master regulators of cell proliferation, differentiation and
survival. Biochemical analysis of the fusion proteins created by these translocations suggest
that all three MTG family member act as transcriptional co-repressors that associate with
histone deacetylases and that are recruited to regulate gene expression. Genetic studies have
now been undertaken to uncover the physiological role of this gene family. An Mtgr1
knockout mouse model was developed and mice lacking this transcriptional co-repressor
display impaired secretory cell lineage development in the small intestine, but no histological
changes in the colon. However, there was an increase in proliferation in the crypts of both
the small and large intestine. Despite this increase in proliferating cells, the colons of Mtgr1-
null mice have a normal cell lineage distribution and normal architecture. The disruption
of homeostasis between proliferation and apoptosis in the colonic epithelium contributes
to the pathogenesis of human ulcerative colitis. To uncover colonic phenotypes in Mtgr1-/-
mice, we challenged the Mtgr1-null mice with low molecular weight Dextran Sodium Sulfate
(DSS), which is a well-studied model of murine ulcerative colitis. Treatment with DSS
uncovered a dramatic sensitization of the Mtgr1-/- colonic epithelium to apoptosis, which
led to a severe colitis. Transplantation of wild type and Mtgr1-null bone marrow into
irradiated wild type mice, demonstrated that the severe DSS-induced ulceration seen in
Mtgr1-null mice was due to a colonic, rather than a hematological, defect. Analysis of crypt
proliferation and apoptosis both before and after challenge indicated that Mtgr1-/- mice
have higher levels of apoptosis when compared to wild type mice, which indicates an
increased colonic cell turnover rate. Importantly, the epithelium of DSS-treated Mtgr1-null
mice failed to completely regenerate, showing changes consistent with chronic colitis, even
10 weeks after a single DSS treatment. These findings suggest that Mtgr1 has an important
role in crypt survival and regeneration after colonic epithelial ulceration, which may indicate
that Mtgr1 functions at the level of the colonic stem cell or progenitor cells.
M1598
Smad3 Regulates Both Colonic Epithelial Cell Proliferation and Cell
Positioning in the Crypt Epithelium
Kiyoshi Furukawa, Toru Sato, Tatsuro Katsuno, Kazuki Hatakeyama, Atsushi Isono,
Atsuko Tokumasa, Yasuo Suzuki, Kotaro Yokote, Yasushi Saito
Background: We reported previously that deficiency of Smad3, an intracellular mediator
of TGF-β, significantly accelerates re-epithelialization of the colonic mucosa (Tokumasa A.,
et al. BBRC 2004). However, little is known about how Smad3 affects proliferation of colonic
epithelial cells. Aim: This study was performed to address the molecular mechanisms by
which Smad3 controls colonic epithelial cell proliferation and colonic crypt formation.
Methods: Smad3ex8/ex8 C57BL/6 mice (a gift from Dr. Anita B. Roberts, NCI) and wild-type
littermates as controls were used in this study. Cell proliferation was assessed by monitoring
Ki-67 staining and BrdU uptake. Protein levels of p21, p27, and β-actin were evaluated by
Western blotting. Results: Hematoxylin & eosin staining demonstrated that the colonic
crypts of Smad3-/- mice were similar in structure to those of Smad3+/+ littermates. However,
Ki-67 staining of the colonic mucosa indicated that number of proliferating cells in the
crypts of Smad3-/- mice was twice as much as that of Smad3+/+ littermates. Analysis of
BrdU uptake in isolated colonic epithelial cells also demonstrated a significant increase (205
± 27%) in number of cells in cell cycle in the colonic epithelium of Smad3-/- mice, even
when treated with 10 ng/ml TGF-β (288 ± 83%). Protein levels of the cell-cycle inhibitors
p21 and p27 were significantly decreased in the colonic epithelium of Smad3-/- mice. These
results indicated acceleration of the cell cycle in the crypts of Smad3-/- mice due to down-
regulated p21 and p27 expression. Intriguingly, Ki-67 staining of the colonic mucosa also
indicated that proliferating cells were scattered from the bottom to the top of the crypts in
Smad3-/- mice, whereas they were restricted to the bottom of the crypts in Smad3+/+
littermates. This finding prompted us to examine whether the EphB/ephrin-B system, which
is critical for maintenance of proliferating cells at the bottom of the crypts, was disturbed
in the colonic crypts of Smad3-/- mice. In Smad3+/+ littermates, EphB3 protein expression
was restricted to the bottom of the crypts, coinciding with the localization of Ki-67-positive
cells. However, the level of EphB3 protein expression at the bottom of the crypts was
significantly reduced in Smad3-/- mice. These observations suggest that Smad3 deficiency
leads to mispositioning of the proliferating cells in the crypts by disturbing the EphB/ephrin-
B system. Conclusions: Smad3 not only negatively regulates proliferation of colonic crypt
epithelial cells by up-regulating p21 and p27 expression, but also plays an essential role in
maintaining the position of proliferating cells in the crypt epithelium.
M1599
Implication of Ilk in the Control of Extracellular Matrix/Cytoskeletal
Organization in Human Intestinal Epithelial Cells
David Gagne, Pierre H. Vachon, Jean-Francois Beaulieu
Interactions between cells and their surrounding matrix control many different functions of
the cell. Integrin linked kinase (ILK) is a serine-threonine kinase found in focal adhesion
points that has been found to be involved in the process of integrin signaling in many
different tissues and its de-regulation leads to several pathologies including cancer. However,
the role of ILK in normal intestinal cells has not yet been established. The objective of this
study was to characterize the involvement of ILK in the proliferation, differentiation, migration
and survival of human intestinal epithelial cells. Immunolocalization studies performed on
cryosections of the intestinal crypt/villus axis showed a diminishing expression of ILK from
the base of the crypt to the tip of the villus. Analysis of the expression of ILK in the HIEC
and Caco-2/15 cell models revealed a strong expression of the ILK transcript and protein
in proliferating cells. The forced decrease of ILK expression in the HIEC cell line using a
synthetic siRNA led to an 80% reduction in the protein level without causing a toxic
interferon response. This decreased ILK level did not affect cell survival however it did lead
to a pronounced decrease in the rate of proliferation of the cells. We have also observed a
marked change in cell morphology and actin cytoskeleton organization, associated with an
inhibition of fibronectin deposition as well as a decrease in the rates of cell spreading and
migration. Preliminary studies of actin cytoskeleton organization suggest the involvement
of ILK in the modulation of the Rho-family GTPase protein. In summary, we have observed
a differential expression of ILK along the intestinal crypt/villus axis and our data suggests
an important function for ILK in the control of extracellular matrix/cytoskeletal organization
in human intestinal epithelial cells.
M1600
Kinase Suppressor of RAS Promotes Raf-1 Kinase Activation in TNFR-Induced
Cell Survival
Karen L. Edelblum, D. Brent Polk
Although inflammatory bowel disease is associated with increased production of apoptosis-
inducing cytokines such as tumor necrosis factor (TNF), activation of TNF receptor-1 (TNFR)
promotes anti-apoptotic signaling during intestinal homeostasis. During inflammation KSR
is required for the intestinal epithelial cell survival through the activation of anti-apoptotic
signaling pathways including ERK/MAP kinase (MAPK). This study addresses the anti-
apoptotic role of Raf-1, a serine/threonine kinase that regulates ERK/MAPK and is the only
known substrate of KSR. Methods: The impact of Raf kinase activity on cell survival was
determined with apoptosis assays performed in young adult mouse colon (YAMC) cells
pretreated with pharmacological Raf-1 kinase or MEK inhibitors prior to TNF exposure. To
determine if TNFR-mediated Raf activation required Ras activation, whole cell lysates of
TNF- or EGF-treated YAMC cells were subjected to an activated Ras pull-down assay. YAMC
cells expressing dominant-negative Ras were also treated with TNF or EGF. Activation and
membrane translocation of Raf was analyzed in TNF-treated YAMC and KSR-null colon
epithelial cells by subcellular fractionation and immunofluorescence with phospho-specific
and total Raf antibodies. Results: Loss of Raf kinase activity, but not MEK inhibition, increased
YAMC cell sensitivity to TNF-induced apoptosis. To address the mechanism by which TNFR
mediates Raf activation, we showed that while TNF and EGF treatment of YAMC cells
activated Raf/MAPK signaling, only EGF stimulated Ras activation. Furthermore, expression of
dominant-negative Ras completely blocked EGF-, but not TNF-stimulated MAPK activation.
Activated Raf was localized to the plasma membrane following TNF treatment of YAMC
cells, as was determined by immunostaining with phospho-specific antibodies for several
Raf activation sites, including the proposed site of KSR activation, Raf T269. Phosphorylated
Raf was localized to the plasma membrane following stimulation in YAMC cells but not in
the absence of KSR, suggesting that both KSR kinase activity and scaffolding function is
required for Raf activation in response to TNF. Conclusion: Our recent report citing the
role of KSR in protecting the intestinal epithelium from cytokine-induced apoptosis may be
attributed to KSR promotion of Raf activitation at the plasma membrane through a novel Ras-
independent pathway. Furthermore, Raf kinase activation mediates TNF-induced intestinal
epithelial cell survival in a MEK-independent manner, implicating this as an important
regulatory kinase in gastrointestinal response to injury and repair mechanisms.
M1601
The Motogenic Effects of Cyclic Strain On Intestinal Epithelial Monolayer
Wound Closure Are Matrix-Dependent
Jianhu Zhang, Cheri R. Owen, Jerrold R. Turner, Marc D. Basson
Complex deformation during peristalsis or villous motility may be trophic for the intestinal
mucosa. Cyclic strain induces matrix-dependent intestinal epithelial proliferation on collagen
(COL), an effect inhibited by fibronectin (FN). Since inflammation causes tissue FN depos-
ition, we sought to evaluate the effects of strain and FN on intestinal epithelial wound
healing. We made 1mm circular holes in confluent monolayers on flexible membranes coated
with COL I or tissue FN that were then subjected to static conditions or repetitive average
10% strain at 10 cycles/min. We used human Caco-2 and non-transformed rat IEC-6
intestinal epithelial cells to assess strain effects on wound closure, and Caco-2 cells to
delineate the responsible mechanism. We measured wound closure morphometrically, and
ERK and MLCK activity by blotting with antibodies for phospho-ERK (pERK) and phospho-
MLC (pMLC). pERK and pMLC localization were evaluated by confocal microscopy. Although
strain is mitogenic for intestinal epithelial cells on COL but not FN, strain inhibited wound
closure on COL, but enhanced it on FN. Strain was motogenic, promoting motility and
wound closure, as early as 6 hrs on FN, too soon for proliferation. This persisted for 24-
72 hr. Ablating proliferation with mitomycin C did not prevent the motogenic effect of
strain. Strain activated MLCK on FN. Inhibiting MLCK by H-7, ML-7, or PIK, a peptide
inhibitor of MLCK, prevented the motogenic effect. Strain activated ERK on both FN and
COL. MEK inhibition by PD98059 blocked pERK and prevented motility on FN. Confocal
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microscopy revealed nuclear relocalization of pERK on COL and FN substrates following
strain, but pERK redistribution to the lamellipodial edge only on FN. MEK inhibition did
not prevent pMLC but disrupted its subcellular reorganization to the migrating edge in
response to strain on FN. Conversely, MLCK inhibition did not affect pERK activation or
reorganization. These results suggest that repetitive strain acts in conjunction with the matrix
to regulate intestinal epithelial biology. FN deposition induced by inflammation may trigger
a shift from a mitogenic to a motogenic strain effect. Strain activation of ERK appears central
to both the mitogenic effect of strain on COL and the motogenic effect of strain on FN, with
specificity determined by matrix-dependent subcellular relocalization of pERK in response to
strain. In particular, the motogenic effect of strain likely requires lamellipodial ERK activation,
as well as MLCK activation and downstream pMLC at the migrating edge. Loss of strain-
induced signaling during ileus or sepsis may be an important target to promote mucosal hea-
ling.
M1602
Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Activity
Attenuates TNF-Stimulated Intestinal Cell Apoptosis
Toshimitsu Yamaoka, Rebecca S. Dise, Wei Tong, D. Brent Polk
Background. EGFR tyrosine kinase activity, through cytokine and growth factor stimulation,
is upregulated in ulcerative colitis and colon cancer, suggesting that the activation of EGFR
is a response to these diseases in humans. In the present study, we tested the hypothesis
that EGFR tyrosine kinase regulates cytokine-mediated colon epithelial cell survival. Method.
Young adult mouse colon (YAMC) cells, colon cancer HT-29 cells, EGFR-null mouse colon
epithelial (EGFR-/-MCE) cells, stable clonal cell lines expressing either wild-type (wt) or
kinase-inactive (ki) EGFR and controls consisting of vector (v), ADAM17-deficient mouse
colon epithelial (ADAM17-/-MCE) cells, retroviral expression of wild-type ADAM17 and
catalytically-inactive (E406A) ADAM17 mutant MCE cells were used for these studies. Cells
were treated with cytokines only, which include TNF (100 ng/ml), IL-1 (10 ng/ml) and
IFN-γ (100 ng/ml), or in the presence of either a PI 3-kinase inhibitor (wortmannin 100
nM), MAP kinase inhibitor (U0126 10 μM) or EGFR tyrosine kinase inhibitor (AG1478
150 nM). Apoptosis and signal transduction pathway activation were determined by TUNEL
staining and Western blot analysis, respectively. Results. In EGFR-/-MCE, ki and v cells,
TNF induced apoptosis 3-, 5- fold compared to YAMC or wt cells. Furthermore treatment
of YAMC or wt cells with TNF in the presence of EGFR tyrosine kinase inhibitor increased
apoptosis 10-fold. Similarly, treatment of YAMC or wt cells with TNF failed to increase
apoptosis except in the presence of PI 3-kinase inhibitor, which increased the apoptotic
response 10-fold. In HT-29 cells, TNF enhanced apoptosis 10-fold in the presence of EGFR
tyrosine kinase inhibitor, but not other cytokines, IL-1 and IFN-γ. Treatment of YAMC and
wt cells with TNF in the presence of MAP kinase inhibitor did not increase apoptosis. TNF
stimulated AKT/PKB activation via EGFR tyrosine kinase activation in wt cells but not in
ki or v cells and TNF enhanced apoptosis in ADAM17-/-MCE and E406A ADAM17 mutant
cells, but not in wild-type ADAM17 expressing MCE cells, suggesting TNF-stimulated EGFR
transactivation via ADAM17 cleavage abrogates TNF-induced intestinal cell apoptosis. Con-
clusion. Loss of EGFR tyrosine kinase activity significantly increases TNF-initiated colon
epithelial cell apoptosis and conversely, EGFR tyrosine kinase activation blocks TNF-induced
apoptosis. These effects may be mediated through activation of PI 3-kinase/AKT pathway.
This novel observation has significant implications for understanding the role of EGFR
regulation in maintaining intestinal epithelial cell homeostasis in an environment of chronic
inflammation, injury and repair.
M1603
Regulation of Intestinal Epithelial Cell Proliferation By the Nuclear Receptor
Corepressor (N-CoR)
Genevieve Doyon, Claude Asselin, Francois Boudreau
INTRODUCTION: The intestinal epithelium is a tissue that undergoes constant renewal
where proliferation and differentiation processes are tightly regulated. However, the transcrip-
tional mechanisms implicated in these processes remain to be ascertained. We have previously
shown that N-CoR protein is located in the bottom part of the intestinal crypts. Moreover,
expression of N-CoR was associated with the proliferation state in the IEC-6/Cdx2 and
Caco-2 cell models that are capable to differentiate in culture. AIM: To investigate the
putative role of N-CoR in the control of proliferation and differentiation of intestinal epithelial
cells. METHODS AND RESULTS: The profile of N-CoR protein expression was first evaluated
in the IEC-6 intestinal epithelial cell line that do not differentiate in culture. A stable level
of N-CoR expression was maintained along with proliferation of the cells. An RNA interference
based on the generation of shRNA was then used to knockdown N-CoR in IEC-6. Among
three different shRNA constructs tested, one led to a drastic reduction of N-CoR protein
expression as determined by Western Blot analysis. The decrease in N-CoR protein was
highly specific since a related nuclear corepressor, the Silencing mediator for retinoid and
thyroid receptors (SMRT), was not affected by the shRNA construct. The putative relationship
between N-CoR expression and cell proliferation was then investigated. Kinetics over a
period of 10 days of cell proliferation assessments were done using the stable cell line
expressing the shRNA against N-CoR. The downregulation of N-CoR resulted in a decreased
in cell growth rate of 50 % as compared to IEC-6 shRNA control cells without any significant
change in the cell death rate. CONCLUSION: Our results suggest that N-CoR is important
to maintain a proliferative state in intestinal epithelial cells. The identification of the molecular
targets of N-CoR involved in the regulation of cellular proliferation is currently under


















Characterization of Molecular Targets of the Thyroid Hormone Signalling
Pathway in Intestine Epithelium Progenitor Cells
Elsa Kress, Jacques Samarut, Michela Plateroti
Hypothyroid newborn mice show a strongly altered development of the small intestine with
a deep reduction in the number of proliferating epithelial progenitor cells within the intestinal
crypts (1). Inactivating either the α or the β isotype of thyroid hormone receptors (TRs) in
mice, showed that the TRα1 receptor is the major actor mediating T3 signalling in these
cells (2, 3). In order to analyse the mechanisms responsible, we studied the expression of
genes belonging to and/or activated by the Wnt/β-catenin pathway, a major actor in the
control of physiological and pathological epithelial proliferation in the intestine (4). We
show that T3-TRα1 controls the transcription of the β-catenin gene in an epithelial cell-
autonomous way. This is parallel to a positive regulation of proliferation-controlling genes
such as type D cyclins and c-myc, known targets of the Wnt/β-catenin. In addition, we
show that the regulation of the β-catenin gene is direct as TR binds in vitro and in chromatin
in vivo to specific Thyroid Hormone Responsive Element present in the intron 1 of this
gene (Plateroti et al, under revision). As Wnt/β-catenin plays a crucial role in intestinal
tumorigenesis, our observation opens a new perspective on the study of TRs in intestinal
pathology. To further elucidate and to analyse in detail the molecular mechanisms which
govern the thyroid hormone-dependent response of intestine epithelial cell progenitors, we
are currently using two different experimental approaches: 1.Analysis of intestine epithelium
regeneration after gamma-ray treatment of WT and TR mutant mice. This will enable to
clarify whether the TH signalling pathway plays a role in this function and which are the
molecular mechanisms. 2.Gene profiling of crypt cells isolated by laser microdissection from
WT and TR KO intestines. Affimetrix microarray technology has been used to compare the
pattern of expression of genes increased or decreased in TR mutants compared to the
WT. Bioinformatic analysis is going to be performed. Bibliography 1.Flamant, et al. 2002.
Congenital hypothyroid Pax8(-/-) mutant mice can be rescued by inactivating the TRalpha
gene. Mol Endocrinol, 16: 24-32. 2.Plateroti et al. 1999. Involvement of T3Ralpha- and
beta-receptor subtypes in mediation of T3 functions during postnatal murine intestinal
development. Gastroenterology, 116: 1367-1378. 3.Plateroti et al. 2001. Functional interfer-
ence between thyroid hormone receptor alpha (TRalpha) and natural truncated TRDeltaalpha
isoforms in the control of intestine development. Mol Cell Biol, 21: 4761-4772. 4.Moon et
al. 2004. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet, 5: 691-701
M1605
Influence of Cell-Cell Contacts On Survival of Primary Human Colonic
Epithelial Cells and Regulation of Bcl-2 Family Proteins
Claudia Hofmann, Monika Artinger, Johannes Grossmann, Werner Falk, Juergen
Schoelmerich, Gerhard Rogler, Florian Obermeier
Background: Intestinal epithelial cell homeostasis is crucial for the maintenance of the barrier
function and prevention of cancer formation. Colonic epithelial cells (CEC) are highly
anchorage-dependent. They undergo detachment-induced apoptosis (anoikis) as soon as
they lose contacts. Cell-matrix anchorage and cell-cell anchorage are of equal importance
for survival of primary human CEC as previous studies revealed, that the induction of
anoikis can completely be blocked by maintenance of CEC cell-cell contacts despite the
loss of cell-matrix anchorage. The signaling pathways mediating this anti-apoptotic effect,
however, are unknown. Methods: CEC anoikis was modulated by incubation of ex-vivo
isolated CEC in the presence of an E-cadherin-Fc construct. To maintain cell-cell contacts,
intact CEC crypts were isolated and gently centrifuged to form a cell aggregate (“pellet”; P-
CEC) before disruption of CEC cell-cell contacts could occur. Induction of apoptosis in
CEC was assessed by Western Blot (Caspase-3), a colorimetric assay (DEVD-pNA), and
DAPI staining. Regulation of pro- and anti-apoptotic members of the Bcl-2 family (Bcl-2,
Mcl-1, Bcl-xL, Bax, Bak, Bad, Bid, Puma, Bim) was investigated by Western Blot analysis.
Results: After simulation of cell-cell contacts by soluble E-cadherin-Fc caspase-3-activation
and consecutively anoikis was significantly reduced by 30 % (p=0.027). In contrast, a
complete prevention of anoikis was achieved when existing cell-cell contacts were preserved
as demonstrated by lack of caspase-3 activation and DAPI staining of P-CEC (p=0.0002).
On the other hand, anoikis could still be induced in P-CEC after several hours in pellet
culture by disrupting cell-cell contacts. P-CEC displayed increased levels of the anti-apoptotic
proteins Bcl-2 and Mcl-1, whereas no significant changes in for Bcl-xL, Bax, Bak, Bad, Bid,
Puma and Bim were detected. In contrast, a degradation of Mcl-1 as well as a cleavage of
Bid was observed in CEC undergoing anoikis. Conclusions: CEC anoikis can be partially
blocked by simulation of E-cadherin-induced signaling and can completely be blocked by
the preservation of cell-cell contacts. Anti-apoptotic members of the Bcl-2 family are involved
in the cell-cell contact-mediated CEC survival. Cell aggregation in the pellet model does
not change principal anoikis-mechanisms CEC as anoikis could still be induced after several
hours of pellet culture. In summary, E-cadherin mediated cell-cell signaling serves as a
cooperative mechanism providing survival signals capable of compensating the loss of cell-
matrix contacts.
M1606
Adherens Junction-Dependent PI3K/Akt Activation Decreases Sensitivity to
DNA Damage-Induced Apoptosis in Differentiated Colonic Epithelial Cells
Tae Il Kim, Boah Chae, Kyoung Min Yang, Byung Chang Kim, Sung Jae Shin, Won Ho
Kim
Background: The balance between proliferation and apoptosis is important for homeostasis
during differentiation in crypt-villus axis of intestinal epithelium. In addition, cellular
responses to diverse stimuli also vary by the degree of cellular differentiation. However,
their mechanisms remain largely unknown. Aim: We investigated the differences in apoptotic
sensitivities and its mechanism in genotoxin-induced apoptosis, based on the degree of
differentiation of epithelial cells. Methods: Differentiation was induced by post-confluence
culture in Caco-2 cells. MMS (methyl methanesulfonate), which is a direct-acting DNA
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alkylating agent, was used for apoptosis induction. The apoptotic cell death was measured
by cytochrome c staining and MTT assay, and the expressional changes of differentiation-
and cell survival-associated molecules (NF-κB, p21, β-catenin, E-cadherin, PI3K/Akt path-
way) were evaluated by western blot, immunofluorescent study and immunohistochemical
staining. EGTA and LY294002 were used for inhibition of cell-cell adhesion and PI3K,
respectively. Results: Compared to the subconfluent Caco-2 cells, 7 days post-confluent cells
showed resistance to MMS-induced apoptosis. In our differentiation model, NF-κB activation
or cytoplasmic p21 expressions, which are known to be important in differentiation-induced
resistance to apoptotic stimuli in other cell systems, were not observed. The expression of
nuclear and cytoplasmic E-cadherin and β-catenin decreased in 7 days post-confluent Caco-
2 cells, while their adherens junction components increased. E-cadherin and p-Akt expression
increased in 7 days post-confluent Caco-2 cells, and, in human intestinal tissue, the expression
of E-cadherin and p-Akt also increased in the upper portion of villi, compared to crypt.
Inhibition of cell-cell adhesion using EGTA decreased Akt phosphorylation, which was
reversed by calcium restoration. Akt phosphorylation by calcium-mediated cell-cell adhesion
was more prominent in differentiated cells. In addition, LY294002 treatment inhibited Akt
phosphorylation by calcium-mediated cell-cell adhesion. The difference in MMS-induced
apoptotic sensitivity between subconfluent and 7 days post-confluent Caco-2 cells was
eliminated by inhibiting cell-cell adhesion or PI3K. Conclusion: Our data demonstrate
that apoptosis-resistant phenotype of differentiated epithelial cells in DNA damage-induced
apoptosis is mediated by activation of cell adhesion-mediated PI3K/Akt pathway.
M1607
Translocation of BMF During Anoikis in Primary Intestinal Epithelial Cells
Martin Hausmann, Claudia Hofmann, Stephan Kiessling, Werner Falk, Juergen
Schoelmerich, Hans Herfarth, Gerhard Rogler
BACKGROUND: Apoptosis is a conserved genetic program for the removal of malfunctioning
or potentially dangerous cells. Anoikis is a specific form of apoptosis induced by loss of cell
attachment. Loss of cell-anchorage specifically triggers the release of a BH3-only protein,
Bcl-2 modifying factor (Bmf)-2, from the actin cytoskeleton. Bmf is a sentinel placed to
register damage at the cytoskeleton and then to convey the death signal to Bcl-2. Bcl-2,
intrinsic promoting cell survival, is neutralised by Bmf and cytochrome c release from the
mitochondrium is initiated. As this mechanism might be of great importance during colonic
epithelial cell (CEC) anoikis we investigated it in our primary CEC culture model.
METHODS: Primary human CEC were isolated ex-vivo from surgical specimens. To induce
anoikis a single cell suspension of epithelial cells was shaken for 2 hours in medium at
37°C. Sub-cellular localization of Bmf in CEC was analysed by immunofluorescence (rat anti-
Bmf, Alexis). Mitochondria were localized by a mitochondria selective probe (MitoTracker,
Molecular Probes). Mitochondria were isolated from epithelial cells by digitonin-based sub-
cellular fractioning. Bmf and cytochrome c was analysed by Western Blot. RESULTS: DAPI
staining revealed that > 90% of primary human CEC exhibited a fractionated nucleus within
2 hours after ex-vivo isolation. Bmf protein could not be co-localized with mitochondria in
freshly isolated CEC. However, immunofluorescence revealed a significant increase in Bmf
protein associated with mitochondria after induction of anoikis by loss of cell attachment.
Translocation of Bmf to the mitochondria was confirmed by Western Blot applying sub-
cellular fractions. Initiation of cytochrome c release after translocation of Bmf was demon-
strated by Western Blot. Re-constitution of cell-matrix or cell-cell contacts prevented Bmf
translocation and subsequently induction of anoikis. CONCLUSION: This study shows for
the first time the translocation of Bmf in primary CEC induced by the loss of cell attachment.
This mechanism is likely to play an important role in the regulation of CEC survival, both
in inflammation and carcinogenesis.
M1608
Cyclic-AMP Mediated Activation of NF-κB in Intestinal Epithelial Cells:
Implications for Cellular Survival
Jeffrey A. Rudolph, Julia Pratt, Kris A. Steinbrecher, Mitchell B. Cohen
Background: The ability of an intestinal cell to withstand a potentially lethal stress is in part
governed by active cell survival signaling mechanisms. Two well characterized survival
pathways include the extracellular signal regulated kinase (ERK1/2) cascade and nuclear
factor κB (NF-κB) signal transduction. We have previously shown cAMP to mediate cell
survival in T84 cells, an intestinal epithelial cell line, via activation of the ERK1/2 signaling
cascade. In some non-intestinal cell lines, the major effector protein of cAMP, protein kinase
A, regulates transcriptional activity of NF-κB through direct serine phosphorylation. We
hypothesized that in T84 cells, cAMP also mediates phosphorylation of NF-κB and nuclear
translocation of its p65 subunit to activate anti-apoptotic NF-κB transcription. Methods:
Confluent T84 cells were incubated with media alone, Tumor Necrosis Factor-α (TNFα-
positive control), or cholera toxin (CT) to increase intracellular cAMP. Protein was harvested
from whole cell extracts for immunoblot analysis and separated into nuclear and cytoplasmic
fractions for nuclear localization experiments. In a second set of experiments, RNA was
obtained for real time RT-PCR analysis of two anti-apoptotic proteins, cIAP-2 and Mcl-1,
based upon their known regulation by NF-κB transcription and a preliminary microarray
analysis. Results: Nuclear localization experiments demonstrated that CT incubation led to
a time dependent accumulation of p65 in nuclear extracts. Accumulation started in as little
as 6 hours, peaked at 18 hours and subsequently decreased thereafter. Analysis of whole
cell extracts for IkBα degradation and phosphorylation of p65 at serine 536, two markers
of TNFα mediated NF-κB activation, were not present in CT treated samples. RT-PCR
analysis of both cIAP-2 and Mcl-1 showed increased expression after a 24 hour exposure
to CT, a time consistent with NF-κB transcriptional regulation. Conclusions: Cyclic-AMP
accumulation in T84 cells leads to time-dependent activation of NF-κB signaling as evidenced
by nuclear accumulation of p65. NF-κB does not appear to be activated by phosphorylation/
degradation of IκBα or phosphorylation of p65 at serine 536, suggesting an alternative
pathway of induction similar to that seen in some non-cytokine mediated NF-κB activation
mechanisms. Expression of the anti-apoptotic proteins cIAP-2 and Mcl-1 is consistent with
NF-κB transcriptional regulation and increased cellular survival. We speculate that the anti-
apoptotic effect of cAMP on T84 cells is more complex than ERK1/2 signaling alone and is
affected by NF-κB and potentially other signaling pathways.
M1609
Reciprocal Targeting of Hath1 and β-Catenin By Wnt-Gsk3 in Colonocyte
Differentiation and Proliferation
Kiichiro Tsuchiya, Tstsuya Nakamura, Ryuichi Okamoto, Takanori Kanai, Mamoru
Watanabe
Background & Aims: The canonical Wnt pathway plays a crucial role in the cell fate decision
of intestinal epithelial cells (IECs); however, the influence of the Wnt pathway on cellular
differentiation remains unclear. Recently, it has been shown that a member of bHLH transcrip-
tion factors, Math-1 and its human homolog; Hath1, acts as a critical factor for terminal
differentiation of IECs, although Math1- and Hath1- mediated regulation to balance between
differentiation and proliferation remain poorly understood. In this study, we tested the
possibility that Wnt pathway might directly target the Hath-1 function, especially focusing
on the proteolytic mechanism of Math-1 in IECs. Methods: An expression plasmid encoding
Hath-1 gene was transfected into 293T cells or colonic carcinoma-derived SW480 cells, and
Western blotting was performed to analyze the expression levels of Hath-1 protein. The
effects of various protease inhibitors were tested to assess the involvement of proteolysis in
the regulation for Hath-1 protein. The molecular domain responsible for the degradation
was analyzed by using various mutants of Hath-1 proteins. The role of Wnt signaling in
the Hath-1 degradation was examined by cotransfecting the wild-type (wt) APC into SW480
cells, or the Wnt1 into 293T cells, respectively. Results: The Hath-1 protein was actively
degraded in SW480 cells where the Wnt signal is constitutively activated. In contrast, the
breakdown of Hath-1 did not occur in 293T cells in which the Wnt signal remains inactivated.
The degradation of Hath-1 in SW480 cells was inhibited by the treatment with MG132, an
inhibitor for the proteasome, and the accumulated Hath-1 was shown to be ubiquitinated,
indicating a role of ubiquitin-proteasome pathway in this process. Mutational analysis of
Hath-1 showed that the critical residues regulating the proteolysis in SW480 cells are
S54 and S58 that correspond to the consensus sequence for GSK-3 substrates. Indeed,
pharmacological GSK-3 inhibitors blocked the Hath-1 degradation in SW480 cells. Import-
antly, the degradation of Hath-1 in SW480 cells was also inhibited by cotransfection of wt-
APC, which reciprocally enhanced the degradation of β-catenin. Conversely, coexpression
of Wnt1 in 293T cells resulted in the proteolysis of Hath-1, while it facilitated the accumula-
tion of β-catenin. Conclusion: We showed a novel branching of the Wnt-GSK-3 axis of
signaling pathway, suggesting its important role in balancing the cellular differentiation and
proliferation via the inverse regulation for the stability of Hath-1 and β-catenin proteins.
M1610
Polyamine Depletion Stabilizes P53 and Nucleophosmin (NPM) By Regulating
Cytoplasmic Translocation of RNA-Binding Protein Hur in Intestinal Epithelial
Cells
Tongtong Zou, Lan Liu, Jaladanki N. Rao, Bernard S. Marasa, Kaspar M. Keledjian, Lan
Xiao, Myriam Gorospe, Jian-Ying Wang
Our previous studies have demonstrated that polyamines are required for normal intestinal
mucosal growth and that decreasing cellular polyamines inhibits intestinal epithelial cell
renewal primarily by stabilizing p53 and NPM mRNAs. However, the exact mechanism by
which polyamines modulate RNA stability remains unknown. The RNA-binding protein
HuR is a critical regulator of the post-transcriptional fate of target transcripts and has shown
to regulate the stability of labile mRNAs. Inactivated HuR is localized in the nucleus, but
it can be activated after translocation to the cytoplasm. The present study tests the hypothesis
that polyamines modulate stability of p53 and NPM mRNAs by regulating HuR in normal
intestinal epithelial cells (IEC-6 line). Method: Cytoplasmic, nuclear and total HuR proteins
were examined by Western blot analysis. HuR binding activity was identified by RNA pull-
down technique and HuR-immunoprecipitation (IP). Stability of p53 and NPM mRNAs was
examined by measurement of their mRNA half-lives with real-time RT-PCR analysis. Func-
tions of HuR were investigated by using siRNA that specifically targets HuR (siHuR). Results:
Depletion of cellular polyamines by DFMO, the specific inhibitor of polyamine synthesis,
dramatically increased HuR translocation to the cytoplasm, along with a significant decrease
in nuclear HuR, although it did not alter levels of total cellular HuR. The level of cytoplasmic
HuR protein was increased by ~4.5-folds the control value on day 6 after DFMO treatment,
while nuclear HuR was decreased by >50%, which were completely prevented by exogenous
polyamine spermidine. Induced HuR in the cytoplasm following polyamine depletion directly
bound to the 3’-untranslated regions (3’-UTR) of p53 or NPM mRNA as measured by RNA
pull-down assays. HuR-IP study further showed the presence of endogenous p53 and NPM
mRNAs in the materials immunoprecipitated by the specific anti-HuR antibody but not in
those precipitated by nonspecific antibody (IgG1). Inhibition of HuR expression by transfec-
tion with siHuR in polyamine-deficient cells not only destabilized p53 and NPM as indicated
by decreases in their mRNA half-lives but also prevented the increased levels of p53 and
NPM proteins. Conclusions: These results indicate that 1) decreasing cellular polyamines
results in the cytoplasmic translocation of HuR and 2) increased HuR in the cytoplasm binds
to the 3’-UTRs of p53 and NPM mRNAs and plays a critical role in stabilization of NPM
and p53 following polyamine depletion, thus involving in the negative control of intestinal
epithelial cell proliferation.
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M1611
BMP Signaling Regulates Proper Terminal Differentiation of Intestinal Goblet
Cells in Mice
Yannick D. Benoit, Benoit A. Auclair, Yuji Mishina, Deborah L. Gumucio, Nathalie
Perreault
BACKGROUND: Bone morphogenetic proteins (BMPs) are morphogens known to regulate
numerous cell processes in various tissues. In the intestine, BMPs are primarily produced
by the mesenchymal compartment. These factors can activate signaling pathways following
a paracrine or autocrine route. Recent publications have shown links between BMP signaling
and colorectal carcinogenesis. However, the potential effects of this cascade on other import-
ant cell functions in the gastrointestinal tract have not yet been explored. AIM: To investigate
the paracrine role of BMP signaling during intestinal epithelial cell fate. METHODS AND
RESULTS: With the use of the Cre/loxP system, we have generated a mouse with the BMPR1A
receptor deleted exclusively in the gut epithelium by crossing floxed BMPR1A mice with
the Villin-Cre line In order to characterize goblet cells in the jejunum of Villin-Cre/BMPR1A-
loxP/loxP mice, we performed Alcian Blue staining. We have observed that the number of
goblet cells is not significantly changed in the mutants as compared to their wild-type
littermates. However, these cells are consistently smaller in the mutant mice suggesting a
lack of maturity of goblet cells. Electron microscopy analysis exposed smaller mucigen
granules and confirmed the reduction in size of the goblet cells in the mutant animals. We
then analyzed, by quantitative PCR, the levels of expression of the goblet cell-specific marker
Muc2 in both mutant and wild-type animals. We have confirmed a 2.2 fold decrease in
Muc2 expression in the mutant compared to the wild-type animals. The zinc-finger transcrip-
tion factor Klf4 is known to play a crucial role in goblet cell terminal differentiation in the
colon. Comparative analysis of Klf4 expression between mutant and wild-type littermates
has revealed a dramatic decrease of both protein and mRNA levels in the mutant animals.
CONCLUSION: Altogether, these results demontrate that paracrine BMP signaling plays an
important role in the terminal differentiation of intestinal goblet cell type through regulation
of the zinc-finger transcription factor Klf4. Further analysis is currently underway in order
to determine if other cell types from the secretory lineage are regulated by BMP signaling
as well.
M1612
PDX-1 Regulates Gene Expression and Spatial Pattern Formation in the Small
Intestine
Chin Chen, Rixun Fang, Ying Hao, Anson W. Lowe, Charalambos Maravelias, Philip L.
Chou, Eric Sibley
Background: Transcription factor pancreatic duodenal homeobox-1 (PDX-1) plays a key role
in pancreatic development and maintaining pancreatic islet function. However, the role of
PDX-1 in intestinal development and gene expression is less well defined. Objective: We
aimed to characterize PDX-1 regulation of spatial patterning of gene expression in small
intestinal epithelial cells and to identify PDX-1 intestinal target genes. Methods: To character-
ize PDX-1 regulation of intestinal pattern formation and gene expression in vivo, conditional
knockout (KO) mice with PDX-1 inactivation restricted to the intestine were generated.
Total RNA isolated from the small intestine segments of control and conditional KO mice
was analyzed by real-time RT-PCR. To identify novel target genes regulated by PDX-1,
microarray analysis and real-time RT-PCR were performed with total RNA isolated from
transfected human intestinal Caco-2 cells stably expressing mouse PDX-1 or the control
empty vector. Results: Conditional inactivation of PDX-1 in the small intestine results in
altered expression of candidate target genes along the anterior-posterior gut axis. The expres-
sion of adenosine deaminase (ADA) was reduced significantly in the proximal small intestine
of the KO mouse, consistent with published reports that PDX-1 activates ADA. Sucrase-
isomaltase and lactase gene expression was increased in the proximal small intestine of the
KO mouse, in agreement with reports that PDX-1 is a repressor for both genes. In Caco-2
cells stably expressing mouse PDX-1, 88 genes were activated while 49 genes were repressed
(>4-fold) by PDX-1 overexpression, when compared to the non-PDX-1 expressing Caco-2
control cells. The effect of PDX-1 on selected genes was confirmed by real-time RT-PCR.
Genes that were regulated by PDX-1 overexpression include transcription factors, growth
factors, kinases, digestive glycosidases, nutrient transporters, nutrient binding proteins, and
structural components. Conclusions: PDX-1 gene expression is necessary for appropriate
spatial patterning of small intestinal target gene expression. The PDX-1 conditional KO
mouse represents a useful tool for investigating in vivo the role of PDX-1 during gut
development. The broad spectrum of genes regulated by PDX-1, as detected by microarray
analysis, further supports an important role for PDX-1 in intestinal gene regulation.
M1613
Generation of a Functional in Vitro Model for Differentiation of Pluripotent
Cells Into Multiple Intestinal Epithelial Cell Lineages
Carine R. Lussier, Benoit A. Auclair, Nathalie Perreault, Francois Boudreau
INTRODUCTION: As an ongoing renewal system in which proliferation, differentiation,
migration and apoptosis are tightly regulated, intestinal epithelium is an excellent model to
study these cellular processes at the molecular level. However, normal intestinal epithelial
cells able to recapitulate these processes in culture is not yet available. The aim of this work
was to produce a functional model for intestinal epithelial cell differentiation. METHODS
AND RESULTS: An IEC-6 cell line that stably expressed Cdx2 was seeded on a monolayer
of human fetal intestinal mesenchymal cells. Co-cultures were maintained for 12 days. At
day 5 after seeding, up-elevated structures appeared and multiplied through day 12. Electron
microscopy revealed that these structures consisted in a monolayer of polarized epithelial
cells presenting brush border and cell-cell junctions. These cells looked very similar to newly
differentiated intestinal epithelial cells when compared to cells located at the base of the
villus in the rat ileum. Western analysis showed a stable expression of HNF-1beta and HNF-

















induction of HNF-1alpha and HNF-4alpha protein expression at day 6 after seeding when up-
elevated structures started to expend. This observation confirmed that all known transcription
factors involved in the regulation of specific genes related to intestinal epithelial differentiation
are present in this model. Consequently, it was possible to detect induction of three specific
epithelial cell type markers by RT-PCR analysis. Indeed, the sucrase-isomaltase (enterocytes),
trefoil factor 3 (goblet cells) and cholecystokinin (enteroendocrine cells) genes were induced
after 8 days following the deposition of IEC6-Cdx2 cells on primary mesenchymal cells.
Finally, cells were harvested after 3, 5 and 7 days after seeding and submitted to a gene
expression analysis (affymetrix) to identify novel molecular determinants for intestinal epithe-
lial cell differentiation. CONCLUSION: Our results suggest that IEC-6 cells expressing
exogenous Cdx2 are able to rapidly differentiate in a co-culture system with human intestinal
mesenchymal cells, giving rise to at least three different intestinal epithelial cell types.
Therefore, our co-culture system is the first in vitro model to reproduce normal pluripotent
intestinal epithelial cell differentiation, generating a new opportunity to investigate molecular
mechanisms involved in this process. (This work was supported by CIHR, NSERC, CFI,
CRS and FRSQ)
M1614
Crypt-Restricted Expression of the Integrin α6a Subunit in the Human
Intestinal Epithelium: Implications in Proliferation But Not Differentiation
Anders B. Dydensborg, Joelle Auclair, Elizabeht Herring, Inga C. Teller, Daniel Menard,
Jean-Francois Beaulieu
Integrins are heterodimeric adhesion receptors that function as platforms for intracellular
signalization of importance for cellular growth, differentiation and survival. The integrin α6
transcript undergoes alternative splicing leading to the A and B variants, which differ only
in their short cytoplasmic domains. While no specific function has yet been ascribed to
either variant in epithelial cells, distinct signalization capacities for the two variants exist
such as the potentially exclusive activation of the Ras-MAPK pathway by the A variant. In
this study, we have investigated the involvement of the α6A and B variants in human
intestinal cells. Using indirect immunofluoresence we have evaluated the expression pattern
of the two variants in the adult human intestine and have found that the A variant is
predominantly expressed in the crypt while the B-variant is distributed evenly all along the
crypt-villus axis. RT-PCR and western blotting showed the A variant to be primarily expressed
at both the transcript and protein level in the normal undifferentiated human crypt cell line
HIEC, while fully differentiated primary human epithelial cells were found to predominately
express the B variant. Furthermore, two human intestinal epithelial cell lines capable of
undergoing differentiation (Caco-2/15 and HT-29) were observed to down-regulate the
expression of the A variant upon initiation of the differentiation process. To investigate
whether these distinct expression patterns are of importance to cellular processes associated
with proliferation and/or differentiation, we analyzed the capacity of the two variants to
stimulate the transcriptional activity of reporter plasmids responsive to c-Myc and β-catenin/
TCF (proliferation) as well as their capacity to stimulate lactase-phlorozin hydrolase and
sucrase-isomaltase promoter activity (differentiation). Both reporter plasmids, responding
to c-Myc and β-catenin/TCF, were significantly stimulated by the over-expression of the A
compared to the B variant, while the promoters of the two differentiation markers were not
differentially stimulated by the two variants. We conclude that even though predominant
in differentiated cells, the α6B variant does not appear to play a significant role in the
differentiation process while the α6A subunit, which is predominant in less differentiated
cells, promotes proliferation under a mechanism that appears to involve the β-catenin
pathway.
M1615
Diverse Cellular Responses to Glucocorticoid in the Developing Small
Intestine
Murat B. Yaylaoglu, Barbara M. Agbemafle, Thomas J. Oesterreicher, Christina Thaller,
Susan J. Henning
Glucocorticoids (GC) are known to exert both physiological and pharmacological effects on
the gastrointestinal tract. Amongst the physiologic effects are an ability to elicit functional
maturation. Although the latter has been widely studied in rodent models, to date the
molecular mechanism of GC action on the developing intestine have not been elucidated.
Our previous microarray studies identified 66 transcripts as being rapidly induced in the
jejunum following dexamethasone (DEX) administration to suckling mice. In the current
work we explored the hypothesis that these primary response genes would display cell
specific patterns of expression. A secondary hypothesis was that robotic-based in situ hybrid-
ization (ISH) would allow quantitation of mRNA at the cellular level. Methods: Mouse pups
at P8 received DEX (0.4 µg per g BW) or vehicle injections. Samples of jejunum were
collected 3 - 4 hr later for ISH and Northern blotting. Robotic-based ISH was performed
with digoxygenin-labeled riboprobes using tyramide signal amplification. Results: A subset
of 5 of the 66 DEX induced transcripts were studied: three known genes (Ndrg1, Sgk and
c-fos) and two unknown genes (G9 and G36). As predicted, ISH revealed marked diversity
of cellular expression. Four of the five transcripts were localized to the epithelium and of
these: Sgk mRNA was found in all epithelial cells; c-fos mRNA was confined to the villus
tip and Ndrg1 and G36 mRNAs were localized to the upper crypt and villus base. The
remaining transcript (G9) was expressed in the lamina propria and the muscle layers.
Quantitation of ISH signals showed that the average fold-increase in tissues from DEX-
treated mice as compared with vehicle-treated mice was very similar to that measured by
Northern blotting. Pseudo-color images allowed visualization of the location of strong,
medium and weak ISH signals. In the case of G9, this approach showed that the magnitude
of the DEX induction was much greater in the muscle layers than in the lamina propria.
Conclusions: Although this survey included a modest number of transcripts it demonstrated
that, at the cellular level there is a great diversity in the immediate early genes of GC action
on the developing intestine. Furthermore, the ISH methods used here represent a significant
technical advance, being to our knowledge, the first report of quantitative ISH with GI
tissues. This work was supported by NIH grants R01 HD14094 and P30 DK56338.
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M1616
Effect of Lactobacillus Plantarum 299v Administration On the Gut Function in
Suckling Rats
Frida Fak, Siv Ahrne, Ann Linderoth, Goran Molin, Bengt Jeppsson, Bjorn Westrom
After birth, the gastrointestinal tract undergoes structural and functional maturation pro-
cesses, eventually preparing it for the change in food at weaning. In the present study, we
have studied whether these maturational changes can be affected by exposure to a probiotic
Lactobacillus-strain, using a suckling rat model. Methods: Lactobacillus plantarum 299v
(Lp299v, DSM9843) (Probi AB, Lund, Sweden) was administered (3.0 x 106 CFU/g body
wt per day) for 7 days to Sprague Dawley rats pups aged 3, 7 or 14 days old, after which
gut organ growth, intestinal disaccaridase pattern, intestinal permeability and pancreas
proteins were analyzed. Results: Exposure to Lp299v resulted in different effects depending
on the age of the animals. In the youngest age group, fed with Lp299v from 3 to 10
days of age, the intestinal mucosal protein content increased and a reduction in intestinal
permeability, indicated by a decreased uptake of the gavaged marker, bovine IgG, was
observed as compared to the control littermates. This appeared to correlate with a ten-fold
numerical increase in ceacal lactobacilli. The rat pups treated from 7 to 14 days of age,
showed a decrease in pancreas weight and protein content, whereas the pups in the weaning
group (14 to 21 days of age) showed little effect from the Lp299v treatment. Conclusions:
Exposure to Lp299v during the early neonatal period stimulated the small intestine, leading
to increased intestinal barrier properties. Administering Lp299v later during the suckling
period resulted instead in decreased pancreas enzyme content, suggesting that an increase
in gut lactobacilli could lead to decreased demand for pancreatic enzymes.
Effects of Lp299v on the mucosal protein content (mg/g body wt), the plasma level of BIgG
(μg/ml) 3 h after gavage and the pancreatic protein content (mg/g body wt) for 10, 14 and
21 day-old rats treated during one week with either Lp299v or NaCl.
Values are mean (SD) and differences between Lp299v-fed and NaCl are considered significant
when p<0.005 (**), p<0.001 (***).
M1617
Molecular Mechanisms of Lactobacillus Rhamnosus GG (LGG) Regulation of
Mouse Intestinal Functional Maturation
Fang Yan, Hanwei Cao, Robert Whitehead, D. Brent Polk
Background. Intestinal functional maturation occurring during weaning is coincident with
the transition of aerobic to anaerobic bacteria in the gastrointestinal tract. Studies indicate
that establishing the host-bacterial relationship plays critical roles in functional maturation of
the intestine during early postnatal stage, including regulation of gastrointestinal maturation-
regulated gene expression. We reported that LGG regulates intestinal cell homeostasis, in
part, through secreted proteins. To this end, we have isolated two LGG soluble proteins,
p75 and p40, which promote cell growth and inhibit cytokine-induced apoptosis. The
purpose of this study is to determine the mechanisms of LGG and its protein products
regulating mouse intestinal functional development. Methods. Fetal C57BL/6 mouse midgut
explants isolated from E20 embryos were cultured on top of transwell inserts in DMEM
medium containing 0.5% FBS. After culture with LGG, or p40 for 24 hours, total RNA was
isolated from tissue for mouse MEEBO 38.5K oligonucleotide microarray to detect intestinal
transcriptional responses. Midgut and hindgut isolated from E20 embryos or small intestine
and colon from P2 newborns were treated with LGG, LGG-conditioned medium (LGG-
CM), p40 or p75 for 24 hours, and paraffin-embedded tissue sections were studied by
immunohistochemistry to detect epithelial proliferation by ki67 staining, differentiation by
PAS staining, and epithelial glycosylation pattern by lectin staining. Results. LGG and soluble
protein, p40, up-regulate expression of genes (greater than 2-fold) involved in several
important functions, including intestinal functional maturation (for example, Adenosine
deaminase, Carbonic anhydrase, GATA, TGFb, and Fucosyltransferase), nutrient absorption
(Colipase), barrier fortification (Integrin, Trefoil factor), cellular function (Na/K transporting
ATPase), intestinal neuro-development (Glutamate transporter). Furthermore, LGG, LGG-
CM, p40 and p75 all promote midgut and small intestinal epithelial proliferation and mature
fucosylation, consistent with gene microarray results. Proliferation and PAS positive cells in
hindgut and colon are also increased by LGG, LGG-CM, p40 and p75. Conclusion. These
studies suggest that LGG modulates mouse intestinal development through secretory proteins,
which enhance host transcriptional responses as one of the mechanisms of bacterial-epithelial
interaction regulating intestinal maturation. Furthermore, this responsiveness to LGG and
its secretory proteins suggests they may have preventive or therapeutic applications for the
premature intestine in intestinal developmental diseases, such as necrotizing enterocolitis.
M1618
Role for L-Type Ca2+ Channels in Developmental Regulation of the ENS
Phenotype
Julien Chevalier, Philippe Naveilhan, Jean-Paul Galmiche, Michel Neunlist
Introduction: The developmental regulation of the phenotype of the ENS remains largely
unknown. Therefore, the role of this study was to characterize in vitro the differentiation
of enteric neurons and glial cells in an model of primary enteric cells culture and to study
the effects of KCl upon the neurochemical phenotype. Methods: Small intestine of rat
embryos (E15) were removed and finely diced. Tissue fragments were digested with trypsin
and DNAse I and the cell suspension was seeded in gelatin coated 12 well plates. Following
culture with conditioned medium in absence or presence of KCl (40mM), cells were processed
for immunohistochemistry or quantitative PCR after 3, 7 and 13 days (D). The effects of
KCl were studied after D13 of culture. Immunohistochemical studies were performed using
antibodies against Nestin, GFAP, PGP9.5, Tuj, VIP, NOS and TH and neurochemical coding
was evaluated on at least 20 ganglia per preparation and per marker. Pharmacological studies
with the L-type Ca2+ blocker nifedipine (1µM) were performed. Results: At day 0 (D0),
65% of the cells were Nestin-immunoreactive (IR). At D3, GFAP-IR cells appeared and
localized within ganglionic structure. These structures also contained neurons that were
Tuj-IR and PGP 9.5-IR. The number of neurons/ganglia increased over time and ranged
from 3±1 at D1 to 35±6 at D13 (n=7). Over the 13 days of culture, there was a significant
decrease in the proportion of VIP-IR and nNOS-IR neurons. At D3, 78±5% and 87±6% of
neurons (% of PGP 9.5; n=5 and n=4 respectively) were VIP and NOS-IR respectively. At
D13, these proportions reached 30±8% and 33±7% respectively. Following 13 days of
culture with KCl, major changes in the phenotype were observed and characterized by a
significant increase in the proportion of VIP (+43%, p=0.007; n=4) but no change in the
proportion of nNOS neurons. This increase in VIP was associated to an increase in VIP
mRNA expression. KCl treatment induced also a massive induction of TH expression (2±1%
TH-IR cells in control vs 61±2% with KCl, p<0.001; n=7) which was significantly blocked
by nifedipine (3±1% TH-IR cells, p=0.004; n=3). Conclusion: In conclusion, this study
suggests that KCl can modulate the developmental differentiation of the ENS, in part via
L-type Ca2+ channels. The mechanisms and factors involved in this regulation remain to
be identified.
M1619
Structure-Function Relationships in HLX Homeobox Transcription Factor
Regulation of Intestinal Mesenchymal Promoters
Michael Bates, Angela Mendell
The Hlx homeobox transcription factor gene is expressed in developing intestinal and hepatic
mesenchyme. Hlx is required for normal embryonic growth of intestine and liver as well as
development of the enteric nervous system. Further, Hlx is required for differentiation of
enteric smooth muscle, likely through direct regulation of enteric muscle-specific gene
expression. However, the relation between Hlx protein structure and function is unknown.
We addressed this question using deletions and point mutations (including reported non-
synonymous single nucleotide polymorphisms, or SNPs) of the 488 amino acid human HLX
(hHLX) protein to define the importance of protein segments and specific amino acid residues
of the HLX protein in regulation of promoters for α-smooth muscle actin (αSMA) and
laminin α4 (lama4). The hHLX cDNA was subcloned into the bicistronic expression vector
pMSCV-IRES-GFP. Point mutations in the hHLX cDNA corresponding to known SNPs or
at other codons of interest were prepared using the Quik-Change system (Stratagene).
Deletions were prepared by restriction digests resulting in in-frame deletions either using
native restriction sites or sites engineered by silent point mutations. All mutations and
deletions were confirmed by restriction digests and DNA sequencing. The gene regulatory
activities of hHLX constructs (and control vector without HLX sequence) were tested by
co-transfection with luciferase reporter constructs (pGL3, Promega) containing αSMA or
lama4 promoter fragments into mesenchymal cell lines prepared from Hlx-/- embryos. We
found that there was no effect on the regulation of either promoter by deletion of aa residues
78-164, which includes a proline-glutamine rich region that is conserved among mammals.
A larger deletion (residues 27-221) still retained partial activity. Surprisingly, deletion of
residues 216-290, which includes the N-terminal 15 aa of the 60 aa homeodomain (the
DNA binding domain of the protein), retained significant gene regulatory activity. None of
the non-synonymous SNPs had discernable effects on function. However, the mutation of
a conserved tyrosine in the homeodomain that is within a tyrosine phosphorylation consensus
sequence (Y299F) resulted in decreased HLX regulatory activity on both promoters, consistent
with the idea that HLX activity may be regulated post-translationally by tyrosine kinases.
These structure-function studies will help to identify mechanisms of gene regulation by the
HLX transcription factor that are required for digestive system development. SUPPORT:
NIH DK61219 and DK02791.
M1620
Melanin Concentrating Hormone (MCH) Stimulates Proinflammatory
Responses in Human Colonic Epithelial Cells
Alan C. Moss, Kara Gross, Iordanes Karagiannides, Daniel Torres, Charlabos Pothoulakis,
Efi Kokkotou
Background & Objectives: Melanin-concentrating hormone (MCH) is a hypothalamic neuro-
peptide known to regulate appetite and body weight. We have previously shown that MCH
deficient mice have reduced intestinal inflammation. Our studies also demonstrated that
expression of MCH, and its MCHR1 receptor, is increased in the colonic mucosa during
experimental inflammation in mice and human intestinal xenografts grown in SCID mice.
Our aim was to delineate the inflammatory signaling pathways associated with the MCHR1
receptor in human colonocytes. Methods: NCM460 cells were transfected with a MCHR1-
carrying vector to increase the expression of this receptor in colonocytes. MCHR1 overexpres-
sion was confirmed by real-time RT-PCR and western blotting in the transfected cells.
NCM460/MCHR1 cells were stimulated with MCH (10-6) and forskolin (10-6) for 30 min
and intracellular cAMP levels were measured. Cells were exposed to MCH (10-6) for 0-60
minutes and cell lysates were examined by western blot for MAPkinase activation and
IkappaB degradation. MCH-induced IL-8 mRNA levels and protein release at different time
points was measured by real-time RT-PCR. Results: MCH significantly inhibited cAMP
induction by forskolin in human colonocytes by > 50% (p<0.001). It also induced erk1/2
phosphorylation as early as 2min post-treatment; both findings are consistent with MCHR1
signaling in other cell types. Stimulation of NCM460/MCHR1 cells with MCH produced a
time-dependent increase in IL-8 expression that was 2-fold greater than baseline at peak (4
hours) (p <0.01). Western blot analysis revealed that MCH exposure resulted in IkappaB
degradation which was evident 20 minutes after treatment, suggesting activation of the
NFkappaB pathway. Conclusions: This is the first study demonstrating a direct proinflammat-
ory role for MCH in colonic epithelial cells. The current findings also provide a molecular
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mechanism that explains, at least in part, the relative resistance of the MCH-deficient mice
to intestinal inflammation. Grant support: supporter by a grant from Harvard Clinical
Nutrition Research Center (P30-DK040561)
M1621
Adoptive Transfer of Th2 Polarized Cd4+ T Cells Up-Regulates 5-HT
Production in Gut
Waliul Khan, Rami T. El-Sharkawy, Huaqing Wang, Monica Verma-Gandhu, Daniel
Cohen-Lyons, Richard K. Grencis, Yasuaki Motomura
BACKGROUND/AIM: 5-hydroxytryptamine (5-HT) has been implicated in the pathophysiol-
ogy of a number of functional and inflammatory bowel disorders but the mechanisms
regulating the 5-HT production in the gut are unknown. Enterochromaffin (EC) cells are
the main source of 5-HT in the gut and we have shown EC cell hyperplasia in nematode
infection in mice. Here we studied whether the EC cell hyperplasia is driven by lymphocytes
by determining EC cells and 5HT production are attenuated in nematode-infected SCID
mice, and whether transfer of Th2 polarized CD4+ T cells from nematode-infected mice
into naïve recipient SCID mice induces changes in these parameters. METHODS: SCID mice
on C57BL/6 background and control (C57BL/6) were infected with nematode, Trichuris
muris and sacrificed to study EC cells and colonic 5-HT. To study the role of CD4+ T cells
on EC cells and 5-HT, SCID mice were reconstituted with purified CD4+ T cells (2.5x106
cells/mouse,ip) from non-infected and infected C57BL/6 mice. Cytokine release was measured
from Con A stimulated splenocytes. Immunohistochemical studies evaluated CD3+ T cells
in colon. RESULTS: The number of EC cells was significantly higher in T. muris infected
C57BL/6 mice. This infection-induced increase in EC cells was not evident in SCID mice
[9.9±2.5 cells/10crypt unit (CU) vs. 2.9±0.5 cells/10CU in C57BL/6 vs. SCID mice on day
14 post-infection (pi)]. Colonic 5-HT amount was also significantly lower in infected SCID
mice (132±18.1 ng/ml vs. 93.2±11.9 ng/ml in C57BL/6 vs.SCID on day 14 pi). The number
of EC cells significantly increased following reconstitution of SCID mice with CD4+ T cells
from infected mice (4.5±0.1 cells/10CU vs. 2.4±0.6 cells/10CU in SCID reconstituted with
infected cells vs. SCID control on day 14 post-reconstitution). Colonic 5-HT amount was
also markedly increased by 34% and 31% in SCID mice reconstituted with cells from infected
mice on days 7 and 14 post-reconstitution. The increase in EC cells and 5-HT in reconstituted
SCID mice was correlated with an up-regulation of colonic CD3+ T cells and IL-13 production
(IL-13:319.7±99.4 pg/ml vs. 22.5±1.9 pg/ml in SCID mice reconstituted with infected cells
vs. SCID control). Number of EC cells or 5-HT amount was not significantly altered in
SCID mice reconstituted with cells from non-infected mice. CONCLUSION: These results
provide evidence for a critical role for Th2 polarized CD4+ T cells in 5-HT production in
gut. Considering the importance of 5-HT in gut physiology, these results provide new
insights into the mechanisms of gut function which may ultimately lead to improved thera-
peutic strategies in gut functional and inflammatory disorders.
M1622
Characterization of Pkcε Translocation in Submucosal Neurons: Interaction
with Cortical Actin and Altered Distribution During Inflammation
Daniel P. Poole, Trung V. Nguyen, Shane Reeve, Ian Smith, Christopher J. Fowler, Craig
B. Neylon, John B. Furness
Background: Protein kinase C (PKC) activation in myenteric intrinsic primary afferent neurons
leads to hyperexcitability of these cells. Similarly increased neuronal excitability is exhibited
in models of inflammatory bowel disease and these changes may be partially mediated
through PKC. One consequence of inflammation is hypersecretion, suggesting that there
may be altered secretomotor function. Purpose: 1) To characterize PKCε translocation in
submucosal neurons; 2) To identify which neurons respond to inflammatory mediators 3)
To identify PKCε-interacting proteins; 3) To examine PKCε translocation in an experimental
model of ileitis; 4) To identify molecular targets of PKCε activity. Methods: All experiments
were performed using the guinea-pig ileum. PKCε translocation was analyzed immunohisto-
chemically in submucosal neurons and by Western blotting. PKCε interacting proteins were
identified by immunoprecipitation from submucosal lysates and mass spectrometry. Effects
of PKC activation were examined electrophysiologically using intracellular microelectrodes.
Ileitis was induced by TNBS injection into the ileum, 6-7 days before tissue was taken.
Results: PKCε translocated from the cytoplasm to the plasma membrane in response to
phorbol esters and to the protease activated receptor 2 (PAR2) activators trypsin and SLIGRL-
NH2. PAR2-evoked translocation was restricted to VIP-immunoreactive secretomotor neu-
rons. Translocation was significantly reduced by PKCε-specific inhibition. Cortical actin was
identified as a major PKCε interacting protein and confirmed by co-immunoprecipitation,
f-actin disruption and immunohistochemistry. PKCε translocation was significantly increased
6-7 days post TNBS and was reduced by indomethacin treatment. Specific activation of
novel PKCs resulted in an approximately 2-fold increase in input resistance of submucosal
neurons. Conclusions: PKCε translocates to the actin cortex of submucosal neurons in
response to activators and a similar response occurs during inflammation of the gut. We
hypothesize that activated PKCε translocates to the actin cortex and is anchored close to
K+ ion channels in the plasma membrane. Phosphorylation of these channels results in
channel closure and an increase in the excitability of the neurons. Based on our results,
modulation of PKCε activity by pharmacological agents may be of therapeutic value in



















Protease Activated Receptor 2 (PAR2) Sensitization of TRPV1 Currents Is
Mediated By Protein Kinase Cε and Protein Kinase A
Francisco Bautista, Silvia Amadesi, Rustrum Karanjia, Carlos Barajas-Lopez, Nigel
Bunnett, Stephen Vanner
Mast cell proteases cleave PAR2 on spinal dorsal root ganglia (DRG) neurons that innervate
the intestine causing visceral hyperalgesia. Studies of the underlying mechanism demonstrate
that PAR2 agonists sensitize TRPV1 currents in DRG neurons and HEK cells expressing
TRPV1 by activating PKC (Amadesi et al. 2004). However, the PKC isozyme that mediates
this sensitization of TRPV1 currents and the contribution of PKA in this important signaling
pathway remains to be determined. Therefore, we examined the role of PKCε and PKA
using whole cell voltage clamp recordings in HEK cells naturally expressing PAR2 and stably
transfected with TRPV1, a model system of PAR2-TRPV1 signaling in DRG neurons. Fast
flow application of capsaicin (300nM) induced inward currents and repeat applications at
5 min intervals elicited reproducible responses in control cells (n=5). Following application
of the PAR2 agonist SLIGRL-NH2 (100μM) for 2 min currents elicited by re-application of
capsaicin 30s later were increased 3 fold (n=10), indicative of TRPV1 sensitization. Repeated
applications at 3 min and then 5 min intervals up to 18 min demonstrated this sensitization
persisted during this interval. Peak responses (4.4 fold increase; p<0.01) were observed at
3min after PAR2 application. When the PKCε inhibitor PKCεI (200μM) was included in
the pipette, PAR2 sensitization of the capsaicin-evoked TRPV1 currents was markedly inhib-
ited (mean inhibition = 60% at 3 min; p<0.05). Similarly, when the PKA antagonist H89(3μM)
was included in the pipette this sensitization was also markedly inhibited (mean inhibition =
70% p<0.05). To test the selectivity of H89, we examined the effects of the PKC activator
phorbol dibutyrate (10μM) combined with H89. Phorbol dibutyrate alone caused a 3 fold
increase in the TRPV1 currents at 3 min applied as described for SLIGRL-NH2. When H89
was added to the pipette, this sensitization was not inhibited. To demonstrate an effect of
AR2 activation on TRPV1 currents in mouse DRG neurons we used the same protocol in
whole cell recordings from acutely dissociated mouse DRG neurons. SLIGRL-NH2 (100μM)
elicited sensitization of TRPV1 currents in a subpopulation of the neurons studied. These
studies demonstrate that PAR2 sensitizes TRPV1 currents by a PKCε and PKA-dependent
mechanism. Further studies are needed to determine if PKCε and PKA regulate TRPV1 in
an additive or synergistic fashion, or whether one pathway is upstream of the other.
M1624
Dual Role of Vanilloid Sensitive Neurons in the Concanavalin a Induced
Model of Hepatic Tissue Injury
Jaroslaw Biernat, Ryszard Sendur, Rafal Obuchowicz, Michal Pawlik, Artur Dembinski,
Wieslaw W. Pawlik
Vanilloid sensitive neurons endings have been described to have a close contact with the
hepatic stellate cells. A dual role has been attributed to the neuropeptides released from the
vanilloid sensory neurons in the liver. Substance P and other tachykinins are known to
stimulate neurogenic inflammation by releasing TNF-α and IFN-γ in a variety of experimental
models of hepatic injury. However in our previous experiments we proved that CGRP-
mediated vascular mechanism has a protective effect in acetaminophen-induced liver injury.
We performed the experiments using a Concanavalin A - induced liver injury to explore
the role of both tachykinins and CGRP in the mediation of hepatic injury. Experiments
were performed on Wistar rats weighing 200-220 under pentobarbital anesthesia. Mean
arterial blood pressures (AP), portal blood flow (PBF) and microcirculatory hepatic blood
flow (HBF) using laser-Doppler flowmetry were measured. At the end of each experiment
the venous blood samples were taken to establish the levels of hepatic tissue injury markers
(ALT, AST). Experimental groups: control group (placebo pre-treated), ConA pre-treated
animals, ConA + CGRP receptor antagonist (CGRP 8-37), ConA + NK-1, Con A + NK-2,
Con A + NK-3 and ConA + NK-1, NK-2 and NK-3 receptor antagonist. In the additional series
of experiments we used capsaicin-denervated and vanilloid receptor-blocked (ruthenium red)
rats. In ConA alone pre-treated animals ALT and AST serum levels raised to 4233 ± 1540
and 2578 ± 980 U/L whilst HBF were reduced by 12% (NS) in comparison to the values
in the control group. In CGRP receptor- blocked rats both ALT and AST serum levels were
raised by 35% and 21% and HBF was reduced by 27% in comparison to ConA alone pre-
treated rats. In capsaicin-denervated and vanilloid receptor-blocked (ruthenium red) ALT
levels were increased by 42% and 36% respectively while HBF values were reduced by 32
and 29% respectively (NS versus ConA alone pre-treated rats) In contrast NK-1 receptor
blockade decreased ALT and AST serum levels to 3267 ± 789 and 2436 ± 652 U/L without
affecting the HBF values in this group. Both NK-1 and NK-3 receptor antagonists failed to
influence the circulatory and enzymatic parameters in the Con-A induced model of hepatic
injury. Vanilloid sensitive neurons play dual role in the Con-A induced model of hepatic
injury. Tachykinins released from sensory endings exacerbate hepatic tissue injury acting
via stimulation of NK-1 receptors whilst CGRP has a potent protective effect in this experi-
mental model. The protective effect of vanilloid sensitive neurons is strictly correlated with
vasodilatatory action of CGRP upon hepatic circulation.
M1625
Effects of TNBS-Induced Ileitis On Secretory Function in the Non-Inflamed
Guinea Pig Colon
Jennifer R. O'Hara, Alan E. Lomax, Gary M. Mawe, Keith A. Sharkey
Altered gut motility and secretion are features of inflammatory bowel disease. Disturbances
in intestinal function occur locally, but also at distant, non-inflamed sites of the gut. We
therefore investigated whether animals with an inflamed small intestine had altered
secretomotor function in the non-inflamed distal colon. Ileitis was induced by intraluminal
administration of TNBS into the distal ileum of guinea pigs and experiments were conducted
on day 3. The extent of inflammation was assessed macroscopically and by measurement
of myeloperoxidase (MPO) activity. To assess secretory function, distal colon was excised
and the external muscle layers were removed by blunt dissection. The submucosa/mucosa
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preparations were mounted in Ussing chambers, voltage clamped at 0 mV and maintained
at 37°C in oxygenated Krebs solution. Following an equilibration period, veratridine (30µM),
bethanechol (10µM) or forskolin (10µM), in the presence or absence of the neuronal blocker
tetrodotoxin (TTX), were added to the serosal compartment and the change in short circuit
current (Isc) was recorded as a measure of electrogenic ion transport. Three days after
induction of ileitis, the colon appeared macroscopically normal and the MPO activity was
not different in the colon of animals with ileitis when compared to controls. Variations in
basal Isc occurred such that 58% of the control group had a positive basal Isc; whereas
91% of the TNBS- treated animals had a positive basal Isc. When pooled, the basal Isc in
the colon of animals with ileitis was significantly greater than the average basal Isc in the
colon of controls (Control: 11 ± 9μA/cm2; TNBS: 91 ± 18μA/cm2). Mucosal resistance was
also significantly increased in the colon of animals with ileitis when compared to controls
(Control: 116 ± 10Ω/cm2; TNBS: 150 ± 13Ω/cm2). Addition of bethanechol or forskolin to
the serosal bath evoked an increase in Isc that reached average peak responses of 180 ±
38μA/cm2 and 232 ± 68μA/cm2, respectively. The increase in Isc elicited by bethanechol
and forskolin were significantly attenuated in the presence of TTX; however, there was no
difference in the response to either drug in the colon of animals with TNBS-induced ileitis
vs. controls. In contrast, the Isc response to veratridine was significantly attenuated in the
colon of animals with TNBS-induced ileitis when compared to controls (Control: 494 ±
40µA/cm2; TNBS: 313 ± 50µA/cm2). The altered basal electrical parameters and hyporespons-
iveness to veratridine in the colon of animals with ileitis suggest that inflammation at
one site leads to functional consequences in secretomotor regulation at a distant, non-
inflamed site.
M1626
Targeted Disruption of the 5-Ht4 Receptor (5-HT4R) Gene in Mice Did Not
Affect Gastric Emptying (GE) and Restraint Stress-Exaggerated Defecation But
Paradoxically Increased Basal Defecation Rate
Robert Mader, Weber Eckhard, Bruno Tigani, Hans-Ulrich Gremlich, Stefan Marcaletti,
Hans-Juergen Pfannkuche, Moriko Ito
BACKGROUND. In the gastrointestinal (GI) tract and in the central nervous system (CNS),
5-HT4Rs play multiple roles. Activation of peripheral 5-HT4Rs with agonists like tegaserod
has been shown to accelerate GE and improve symptoms of constipation in animals and
men. Our studies aimed to elucidate whether mice with targeted disruption of the 5-HT4R
gene display a GI phenotype, e.g. delayed GE and/or reduced defecation. METHODS. Studies
were performed in adult 5-HT4 knock-out mice (KO) on C57BL/6 background (7f/7m,
22.4±0.7g) and corresponding wildtypes (WT) (7f/7m, 22.0±0.9g). Mice were treated intrap-
eritoneally or orally with tegaserod (0.1mg/kg) or vehicle 30min prior to experiments.
Gastric emptying: Mice were fasted for 6hrs; subsequently, 0.2ml of a viscous nutrient meal
containing fluorescent beads was administered via gavage (meal: Novasource, 1kcal/ml, 7.5%
methylcellulose; beads: 50mg/ml TentaGel 1% Cy5.5, diameter 0.1mm). GE was examined
10min after the meal. The ratio of fluorescence activity (non-invasive near-infrared fluores-
cence imaging) measured in the stomach and, respectively, small intestine reflected the GE
rate. Defecation: Following adaptation to the experimental conditions, non-fasted animals
were isolated in metabolic cages, and basal defecation or exaggerated defecation during
restraint stress was monitored for 1hr (number of fecal pellets/hour: FP/hr). RESULTS. The
disruption of the gene encoding 5-HT4R by the insertion of lacZ was confirmed by negative
RT-PCR and positive LacZ staining in gut and brain. GE of a viscous caloric meal was similar
in KO and WT mice (KO: 39.5±7.9%, WT: 36.0±2.4%, mean±SEM, P=0.696, ANOVA, n=
8). Tegaserod significantly accelerated GE in WT but not in KO mice (KO: 36.8±5.7%, WT:
51.4±3.4%, P=0.046, n=8). Basal defecation was significantly higher in KO than in WT
mice (KO: 3.8±0.6 FP/hr, WT: 1.7±0.3 FP/hr, P=0.007, n=14). Tegaserod significantly
increased defecation in WT but not in KO mice (KO: 3.4±0.7 FP/hr, P=0.446, n=14; WT:
4.4±0.5 FP/hr, P<0.001, n=14). Restraint stress significantly increased defecation in both
KO and WT mice (KO: 8.1±0.6 FP/hr, P=0.013) WT: 7.8±0.9 FP/hr, P<0.001, n=14). The
difference observed between KO and WT mice under basal conditions was not apparent
during stress (P=0.742, n=14). CONCLUSIONS. 5-HT4R knock-out mice do not display
an apparent phenotype in GE and stress-exaggerated defecation. The paradoxical finding of
an increased defecation rate in KO mice under basal conditions could be due to an impaired
adaptation of these animals to mild stressors (new environment stress, separation stress)
and might reflect a CNS rather than a GI phenotype.
M1627
Importance of Corticotropin-Releasing Factor (CRF) in the Development of
Colonic Sensitivity Using CRF1Receptor Deficient Mice
Anthony C. Johnson, Nancy Trimble, Alan C. Foster, Beverley Greenwood-van Meerveld
Symptoms of irritable bowel syndrome (IBS) are worsened in response to episodes of stress
and anxiety. Corticotropin-releasing factor (CRF) is an important mediator in the stress
response. Our previous studies in rodent models demonstrated that stress-induced colonic
hypersensitivity was attenuated by a CRF1 receptor antagonist. Since CRF1R deficient mice
have an impaired stress-response our goal was to further explore the importance of CRF1R
in the development of colonic sensitivity. Methods: Using conscious CRF1R (+/+), CRF1R
(+/-) and CRF1R (-/-) mice, colonic sensitivity was assessed via a visceromotor behavioral
response (VMR) recorded using an EMG electrode positioned on the external oblique abdom-
inal musculature and quantified as the number of spikes > 300 mV per 10 s, to graded
colorectal distension (CRD, 0-60 mmHg). Results: See Table for summary data (mean ±
SEM). In the CRF1R (+/+) mice there was a pressure-dependent increase in the VMR to
CRD that was attenuated in the CRF1R (+/-) mice. However in the CRF1R (-/-) mice a VMR
to CRD was only observed at the highest distension pressure (60 mmHg). A CRF1R antagonist,
NBI 30775 (30 mg/kg i.p.) significantly decreased the VMR to CRD in all CRF1R +/+ mice.
An identical inhibitory effect of NBI 30775 was observed in 43% of the CRF1 +/- mice,
however in the remaining CRF1 +/- mice no inhibitory effect was seen. Conclusion: This
study provides pharmacological and genetic evidence for the importance of CRF1R in colonic
sensitivity and substantiates a link between stress and visceral perception.
VMR to CRD in the Various CRF1R Genotypes (# of spikes > 300 mV/10s)
* p < 0.05. ** p < 0.01 compared to +/+, † p < 0.05 compared to +/-. resp = responders,
no resp = non-responders.
M1628
Targeted Knock Down of NMDA Receptors in Dorsal Root Ganglia Neurons
James A. McRoberts, Helena S. Ennes, Juan Carlos Marvizon, Bryce Vissel, Michael
Fanselow, Emeran A. Mayer
BACKGROUND: NMDA receptors (NMDARs) expressed on the central and peripheral ter-
minals of spinal afferent neurons are thought to play an important role in nociceptive
transmission and possibly neurogenic inflammation, however their exact role remains contro-
versial. The cell bodies of these nerves are located in the dorsal root ganglia (DRG), most
of which express peripherin during development. AIM: To develop a genetic approach to
this problem by targeting the knockout of the critical NR1 subunit of the NMDAR to DRG
neurons using transgenic mice expressing Cre recombinase under the control of the peripherin
promoter. METHODS: Mice engineered with loxP sites flanking exons 11-22 of the NR1
subunit gene (floxed-NR1) were crossed with mice engineered to express Cre recombinase
under the control of the peripherin promotor (Prph-Cre). At 100 days of age, adult male
mice were sacrificed and various tissues isolated and assayed for expression of NR1 using semi-
quantitative RT-PCR, Western blotting and immunocytochemistry. RESULTS: Homozygous
floxed-NR1, Prph-Cre+ mice were viable and fertile. At 100 days of age, there was a ~43%
reduction of NR1 mRNA extracted from DRG, with no effect on NR1 mRNA expression in
the spinal cord, cortex, or cerebellum. Western blot analysis demonstrated a 59% reduction
in NR1 protein expression in DRG neurons with no effect on expression in spinal cord or
cortex. Immunocytochemistry with antibodies to NR1 in sections of DRG, revealed less NR1
immunoreactivity (-ir) next to the nucleus in the mutant mice with most of the remaining
NR1-ir is next to the cell surface. Scion Image was used to quantitatively measure the
intensity of the NR1-ir in confocal images from 3 sections per mouse. The integrated optical
intensity (in arbitrary units) decreased from 9.5 ± 2.8 in phenotypically wild type littermates
to 3.1 ± 0.7 (67% decrease) in the targeted knock out mice (p<0.05, t-test). The decrease
in staining was observed in DRG neurons of all sizes. CONCLUSIONS: Targeted knock
down of NMDARs using Cre expression driven by a peripherin promoter produced a 43-
67% decrease in NR1 expression in DRG neurons with no change in NR1 expression in the
spinal cord or the CNS . These mice are likely to be useful in dissecting the role of NMDARs
located on peripheral and central terminals of DRG neurons in nociception, sensitization
and neurogenic inflammation. Supported by NIH grants DK 58173 and 1 P50 DK64539and
R24 AT002681
M1629
Elucidating the Role of the Glucagon-Like Peptide 2 Receptor in the Enteric
Nervous System
Sean C. Mcdonagh, Jenny Lee, Patricia L. Brubaker
Glucagon-like peptide 2 (GLP-2) is a proglucagon-derived peptide secreted from the
enteroendocrine L cell of the distal gut in response to enteral nutrition. Administration of
GLP-2 results in expansion of the small intestinal mucosa and improved nutrient absorption,
primarily due to increased epithelial proliferation. GLP-2 also decreases gut motility and
enhances intestinal blood flow. The mechanisms through which these effects of GLP-2 are
achieved are poorly understood, but are likely indirect, as the G-protein coupled GLP-2
receptor (GLP-2R) is expressed in the enteric nervous system (ENS), enteroendocrine cells
and the lamina propria, but not in proliferating enterocytes. To examine the role of the
GLP-2R in the ENS, we have therefore studied the effect of GLP-2 administration in a mouse
model of ENS deficit, the glial cell line-derived neurotrophic factor family receptor alpha 2
(GFRα2) knockout mouse. As a result of defective mitotic and trophic support of neural
crest cells as they migrate to colonize the gut during development, these mice exhibit a
pronounced deficit in enteric cholinergic innervation. This deficit results in a demonstrable
impairment in gut motility, as charcoal transit studies revealed a 39 ± 9% decrease in the
rate of transit of gut contents in knockout mice as compared to wild-type littermates (P<0.05,
n=5). Furthermore, acute administration of GLP-2 decreased gut motility in wild-type (75
± 7% of controls, P<0.05) but not in GFRα2 (124 ± 23% of controls) mice (n=4). In contrast,
analysis of mucosal growth parameters (small intestinal wet weight, villus height, crypt
depth and Ki67 staining of proliferating crypt cells) indicated no difference between GFRα2
knockout and wild-type animals (n=5-10). Furthermore, the effect of chronic GLP-2 adminis-
tration to increase small intestinal wet weight (by 44 ± 6%, P<0.001), villus height (by 42
± 4 %, P<0.001) and crypt depth (by 16 ± 5%, P<0.001) was not different between GFRα2
and wild-type mice (P>0.05; n=5-10). Intriguingly, GFRα2 knockout mice exhibited higher
proglucagon (314 ± 133%; P<0.01) mRNA transcript levels relative to wild-type littermates, as
determined by quantitative RT-PCR (n=5-7), suggesting the presence of adaptive mechanisms.
These findings indicate that the ENS GLP-2R is important in the regulation of gut motility,
but do not demonstrate a primary role in the tropic effects of GLP-2 on mucosal growth.
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M1630
Haplotype Insufficiency for Socs2 Enhances Intestinal Growth and Promotes
Polyp Formation in GH-Transgenic Mice
Carmen Z. Michaylira, Nicole Ramocki, James G. Simmons, Kirk K. McNaughton, John
T. Woosley, Christopher J. Greenhalgh, Rachael Rigby, P. Kay Lund
Growth hormone (GH) may improve intestinal growth or function in patients following
intestinal resection or on total parenteral nutrition for short bowel syndrome. Excessive
trophic effects of GH or its downstream target, insulin-like growth factor I (IGF-I), however,
may contribute to neoplastic growth. Patients with acromegaly have increased risk of colorec-
tal cancer. Identification of mechanisms that limit the tumorigenic potential of GH and IGF-
I is desirable. Suppressor of cytokine signaling-2 (SOCS2) limits GH action on body and
organ growth, but its role in GH action on intestine is unknown. These studies tested the
hypothesis that SOCS2 limits GH-induced intestinal growth or neoplasia in vivo. GH-
transgenic (GH-TG) mice were crossed with SOCS2 null mice in attempt to generate trans-
genic (TG) or wild-type (WT) mice with 0 (HO-WT and HO-TG), 1 (HT-WT and HT-TG)
or 2 (WT-WT and WT-TG) copies of SOCS2. No HO-TG mice were derived from crossbreed-
ing. WT-WT, HT-WT, WT-TG and HT-TG were therefore compared for body weight, small
intestine and colon weight, length and BrdU incorporation as a measure of crypt proliferation.
Levels of IGF-I and sucrase-isomaltase mRNAs were measured in jejunum. Colon was
analyzed for the presence of abnormal lesions. HT-WT did not differ from WT-WT in any
parameter. Compared with WT-TG, HT-TG had significantly greater (P<0.05) GH transgene-
induced increases in body weight, small intestinal growth, crypt proliferation, and local
IGF-I expression, and showed decreases in sucrase-isomaltase expression. In colon, HT-TG
but not WT-TG developed multiple, histologically-confirmed, hyperplastic and lymphoid
polyps which were positive for BrdU staining and composed primarily of B cells. Polyps
had prominent nuclear staining for phosphorylated STAT3. In conclusion, haplotype insuffi-
ciency for SOCS2 promotes the trophic actions of GH in small intestine and, in association
with GH excess, promotes pre-neoplastic changes in colon of young adult mice. Small
variations in the levels of SOCS2 may have a major impact on the effects of therapeutic GH
on small intestinal growth and on susceptibility of patients with acromegaly to the develop-
ment of colonic polyps.
M1631
Use of Growth Hormone Releasing Peptide-6 for the Prevention of Hepatic
and Multi Organ Failure
D Cibrian, H Ajamieh, J Berlanga, O Leon, J Alba, Mjt Kim, T Marchbank, J Boyle, E
Ntatsaki, F Freyre, D Garcia del Barco, P Lopez-Saura, G Guillen, S Ghosh, R Goodlad,
Raymond Playford
Background/Aims: Novel therapies for the treatment of multiple organ failure are required.
Methods: We examined the effect of synthetic growth hormone releasing peptide-6 (GHRP-
6) on cell migration and proliferation using rat intestinal epithelial (IEC-6) and human
colonic cancer (HT29) cells as in vitro models of injury. In addition, we examined its efficacy
when given alone and in combination with the potent protective factor epidermal growth
factor (EGF) in an in vivo model of multi-organ failure (using two hepatic vessel ischemia-
reperfusion protocols; 45 min ischaemia-45 min reperfusion and 90 min ischaemia-120 min
reperfusion). Results: In vitro studies showed GHRP-6 directly influenced gut epithelial
function as its addition caused a three-fold increase in the rate of cell migration of IEC-6
and HT29 cells (P<0.01) but did not increase proliferation ([3H]-thymidine incorporation).
In vivo studies showed that, compared to baseline values, ischemia/reperfusion caused
marked hepatic and intestinal damage (histological scoring), neutrophilic infiltration (MPO
assay, 5-fold increase) and lipid peroxidation (MDA assay, 4-fold increase). Pre-treatment
with GHRP-6 (120 ug/kg sc.) alone truncated these effects by 50-85% (all P< 0.05) and
additional benefit was seen when GHRP-6 was used in combination with EGF (1 mg/
kg sc.). Lung and renal injuries were also reduced by these pre-treatments. Conclusion:
Administration of GHRP-6, given alone or in combination with EGF to enhance effects, may
provide a novel, simple approach for the prevention and treatment of multi-organ failure
and other injuries of the gastrointestinal tract. Further studies appear justified.
M1632
Upregulation of Proangiogenic Growth Factors By Leptin During Gastric Ulcer
Healing
Tetsuya Tanigawa, Toshio Watanabe, E.J. Sasaki, Masatsugu Shiba, Kazunari Tominaga,
Yasuhiro Fujiwara, Nobuhide Oshitani, Kazuhide Higuchi, Testsuo Arakawa
Background & Aim; Leptin, an important regulator of food intake and energy metabolism,
has been demonstrated to be involved in cutaneous wound healing. Leptin is produced in
gastric tissue, but its role in gastric ulcer healing is unclear. In this study we investigated
the role of leptin in healing of acetic acid-induced gastric ulcer using leptin-deficient mice.
Methods; C57BL/6J wild-type and leptin-deficient mice (ob/ob mice) were used in this study.
Gastric ulcers were produced by focal serosal application of 60% acetic acid for 30 sec. Mouse
recombinant leptin (0.5 μg/g BW) or vehicle (normal saline) was given intraperitoneally twice
daily to ob/ob mice from 3 days after ulceration for up to 7 days. Stomach was removed
and ulcer size was measured by day 7 of treatment. Expression of mRNA for leptin, leptin
receptor, vascular endothelial growth factor (VEGF) and basic-fibroblast growth factor (bFGF)
in ulcerous tissue and normal mucosa were assessed by real-time RT-PCR, while localization
of leptin, leptin receptor, and VEGF was evaluated by immunohistochemistry. Angiogenesis
of ulcerous tissue was evaluated by counting the number of microvessels in the ulcer bed
identified by immunohistochemical staining of CD31 (an endothelial cell marker). Results;
Genetic disruption of leptin resulted in delay of ulcer healing (ulcer index: 3.43±1.02 mm2
in wild-type mice vs. 5.36±1.45 mm2 in ob/ob mice). In wild-type mice, ulceration increased
mRNAs for leptin receptor, VEGF, and bFGF by 25.6-fold, 1.5-fold and 5.1-fold, respectively,
whereas it did not change mRNA level of leptin. The levels of mRNAs for VEGF and bFGF

















of leptin reversed the delay of gastric ulcer healing (ulcer index: 5.36±1.45 mm2 in vehicle-
treated group vs 1.60±0.84 mm2 in leptin-treated group), accompanied by upregulation of
mRNA expression of VEGF and bFGF. The number of microvessels in the ulcer bed was
smaller in ob/ob mice than that in wild-type mice. Restoration of leptin also reversed the
inhibition of angiogenesis in ob/ob mice. In epithelial cells at ulcer margins, leptin colocalized
with VEGF. Conclusion; These results suggest that leptin contributes to gastric ulcer healing
via upreguration of proangiogenic growth factors.
M1633
Characterisation of the Nk2 Antagonist Slv332 in Vitro and in Vivo
Holger Sann, Daniel Jasserand, Reinhard Brueckner, Michael Firnges, Natasja Mj de Jong,
Eric Ronken, Ulf Preuschoff, Jochen Antel
In preclinical models, blockade of neurokinin 2 (NK2) receptors reduce visceral hypersensit-
ivity, suggesting that NK2 antagonists might be useful in the treatment of irritable bowel
syndrome (IBS). Here we report the in vitro and in vivo activity of the newly developed
NK2 antagonist SLV332. SLV332 exhibits a high binding affinity for the human (h) NK2
receptor (pKi=9.1) but was less active on the hNK1 and hNK3 receptor (pKi NK1: 7.5, pKi
NK3: 6.5). A receptor binding profile for SLV332 at 1 µM using 72 other receptors did not
reveal any displacement of more than 50%, suggesting a high specificity for the NK2 receptor.
In functional assays, SLV332 concentration-dependently inhibited the neurokinin A (NKA)-
induced mobilization of intracellular calcium and phosphorylation of mitogen-activated
protein kinase in CHO cells expressing the hNK2 receptor with a pA2 of 9.7 and 9.2,
respectively. It was less active in functional NK1 (pA2=7.6) and NK3 (pA2=6.6) assays.
Furthermore, SLV332 concentration-dependently inhibited the (NKA)-induced contraction
in the guinea-pig gall bladder preparation with a pEC50 of 10.1. To investigate the NK2
antagonistic potency of SLV332 in vivo, its ability to antagonise NKA induced changes in
blood pressure, bronchoconstriction and colonic motility was investigated in anaesthetised
guinea-pigs. The ED50 after i.v. administration was 9 nmol/kg for colonic motility. After
oral administration, SLV332 dose-dependently inhibited the NK2 responses with an ED50
(determined using mean data from 1-180 minutes) of 1.1 µmol/kg for the colonic motility.
SLV332 (30 and 100 µmol/kg) was also tested in a rat model of visceral hypersensitivity
by oral and subcutaneous administration. After sensitisation of colonic afferents by previous
instillation of diluted acetic acid, colonic distension induced nociceptive behavioural
responses such as abdominal cramps and writhing. SLV 332 inhibited significantly and long
lasting (>2h) the visceral hypersensitivity by up to 80.3% after oral administration of the
highest dose (100µmol/kg). The data demonstrate that SLV332 is a potent and orally active
NK2 antagonist. The ability of the drug to reduce visceral hypersensitivity suggests that
SLV332 might be beneficial in IBS and potentially other GI disorders showing up with
abdominal pain.
M1634
Differential Modulation of Colonic Mucus Secretion By Peripheral CRF1 and
CRF2 Receptors in Conscious Rats
Mulugeta Million, Pascale Plaisancie, Paul R. Saunders, Yvette Tache
Background: Peripheral CRF acting on CRF1 receptors stimulates colonic myenteric neurons
and motility in responses to stress and may have a role in stress-related manifestation of
irritable bowel syndrome (IBS) (Br J Pharmacol 2004;141:1321-). In contrast, CRF2 activation
dampens CRF1-mediated endocrine (Endocrinology 2001;144:2396-403) and colonic motor
responses (Gut 2005; PMID: 15985561). Passage of mucus is part of symptoms supporting
diagnosis of IBS (Gastroenterology 2002;123:2108-). Intraperitoneal (IP) injection of CRF
causes colonic mucin release and a CRF1/CRF2 antagonist prevented restraint stress-induced
colonic mucin release in rats (AJP 1996;271:G884). Aims: To investigate the influence of
IP CRF (preferential CRF1 agonist) and urocortin 2 (Ucn 2, selective CRF2) on colonic
mucus and processes of mucus discharge. Methods: Non fasted male SD rats (280-320 g)
were injected IP twice at a 10 min interval with either saline + saline, CRF (3 µg/kg) or
Ucn 2 (10 µg/kg) or Ucn 2 + CRF (10 + 3 µg/kg), and fecal pellet output (FPO) was
monitored. Sixty min later, distal colon was processed for mucus detection by alcian blue/
PAS/hematoxylin. Results: CRF, compared to saline, increased the percentage of cavitated
mucus cells (57.6±4.0 v 45.3±2.1%). The number of stained mucus cells per crypt section
was also significantly reduced: CRF 10.5±0.6, v 15.2±0.5 in saline. Pretreatment with Ucn
2 abolished the CRF-induced decrease in number of stained mucus cells (15.5±0.6 v 10.5±0.6
for CRF alone, p<0.05) and the percentage of cavitated mucus cells (35.1±3.6 v 57.6±4.0%
for CRF alone, p<0.05). Interestingly, in Ucn 2 alone treated rats, the colonic epithelium
exhibited an increase in the number of stained mucus cells compared with control prepara-
tions (18.3±1.0 v 15.2±0.5, p<0.05). Ucn 2 also showed a tendency to decrease the percentage
of cavitated mucus cells: 35.1±3.1 v 45.3±2.1 for controls. Ucn 2 did not increase FPO
(0.0±0.0 v 0.5±0.5 FPO/h for saline), but blunted the stimulatory action of CRF (1.8±0.5
v 5.4±1.0 FPO/h for CRF). Conclusions: These data indicate that 1) CRF induces mucus
secretion by a dual mechanism implicating both compound exocytosis, as shown by the
cavitation of the apical membrane, and by the non cavitation process; 2) CRF action is CRF1
mediated because, Ucn 2 does not reproduce the effect of a preferential CRF1 agonist, CRF
and 3) Ucn 2 prevents mucus discharge in the colon. These data demonstrate differential
regulation of colonic mucus secretion by CRF receptor subtypes that may have relevance
to the action of stress on colonic mucus secretion. Supported by RO1 DK57238(YT) and
R21 DK068155-01A1(MM).
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M1635
Comparison of Selective Neurokinin Receptor Antagonists (NK1, NK2, NK3)
and Mixed Profile Antagonists (NK1/2, NK1/2/3) in a Model of Visceral
Hypersensitivity in Rats
Dania Reiche, Daniel Jasserand, Holger Sann, Ulf Preuschoff, Jochen Antel
There is good evidence that the neurokinin (NK) family (substance P, NKA, NKB) may be
present in many parts of the nociceptive system. The transmission of visceral nociception
has been shown to be mediated by these neuropeptides acting on NK1, NK2 and NK3
receptors. In a preclinical model we evaluated the efficacy of selective NK1, -2 and -3
receptor antagonists as well as the effect of dual NK1/2 receptor antagonists and a triple
NK1/2/3 receptor antagonist. Rats were fasted for 24 hours prior to the experiments with
free access to water. Acetic acid (0.6 %) was injected into the colon. Colorectal distension
(CRD) was performed by inserting a rubber balloon rectally and setting the balloon pressure
to 100 mbar for 10 minutes. During this time the number of abdominal constrictions was
monitored by visual inspection. The first CRD served as a control. Subsequently the animals
received compound or vehicle and the CRD was repeated at 30, 60, 90 and 120 minutes
post application. The number of abdominal constrictions was compared to prevalues by
paired two sided t-tests. The selective NK1 receptor antagonists SLV317 and vofopitant
significantly reduced the visceral sensitivity by up to 70.3% and 78.2%, respectively, after
subcutaneous (sc) administration of 100µmol/kg. The selective NK2 receptor antagonists
SLV321, SLV332 and saredutant reduced the visceral sensitivity by up to 28.6%, 21.3% and
52.1%, respectively, after sc administration of 30µmol/kg. However, the oral administration of
100µmol/kg showed a very prominent inhibition of the visceral sensitivity for SLV321
(80.1%) and SLV332 (80.3%), but not for saredutant. The selective NK3 receptor antagonist
osanetant showed with a dose of 10µmol/kg sc a significant reduction of the visceral sensitivity
of up to 47.0%. The dual NK1/2 receptor antagonists SLV336 showed a potent inhibition
of the visceral sensitivity. After sc administration of 10µmol/kg SLV336 inhibited the visceral
sensitivity by up to 57.1%. Another NK1/2 receptor antagonist ZD6021 (racemate) was less
active (10µmol/kg sc, 28.2% maximal inhibition). Similarily, the triple NK1/2/3 receptor
antagonist SCH206272 (racemate) showed a reduction of up 52.5% of the visceral sensitivity
(10µmol/kg sc). The present results show that selective NK1, -2 and -3 receptor antagonists
and antagonists with mixed profiles potently reduce the visceral sensitivity. We hypothesize,
that the combined blockade of different NK receptors (NK1/2 and NK1/2/3) might show
synergistic effects. In conclusion NK receptor antagonists might be beneficial in the treatment
of patients with irritable bowel syndrome or other disorders associated with visceral pain.
M1636
Measurement of Ca2+ Signaling Dynamics in Exocrine Cells with Total
Internal Reflection Microscopy
David I. Yule, Jong Hak Won
In non-excitable cells, such as exocrine cells from the pancreas and parotid, agonist-stimulated
Ca2+ signals consist of both Ca2+ release and Ca2+ influx. We have investigated the
contribution of these processes to near membrane Ca2+ signals in pancreatic and parotid
acinar cells using Total Internal Reflection Fluorescence (TIRF) microscopy which allows
imaging with unsurpassed resolution in the “Z” dimension. These near membrane Ca2+
signals were compared to those obtained with conventional wide-field microscopy (WFM).
Physiological agonist stimulation resulted in Ca2+ oscillations in both pancreas and parotid
when measured an initial peak followed by a substantial maintained plateau phase. The
contribution of Ca2+ influx and Ca2+ release in isolation to near plasma membrane Ca2+
signals was investigated. In the absence of extracellular Ca2+, the profile and magnitude of
the response following stimulation with maximal concentrations of agonist was similar to
that obtained with WFM. In contrast, when Ca2+ influx was isolated using a Ca2+ re-addition
protocol, either following maximal agonist stimulation or after depletion of intracellular pools
with SERCA pump inhibitor, the Ca2+ signals evoked were more rapid and robust than
measured with WFM and in parotid acinar cells often resulted in the saturation of fluo-4,
but not of the low affinity dye fluo-4 FF (kd=9700nM). Interestingly, Ca2+ influx as measured
by this protocol in parotid acinar cells was substantially greater than that initiated in pancreatic
acinar cells. Indeed, robust Ca2+ influx was observed in parotid acinar cells even at low,
physiological concentrations of agonist. These data indicate that TIRFM is a useful tool to
monitor agonist-stimulated near membrane Ca2+ signals mediated by Ca2+ influx but not
Ca2+ release in exocrine acinar cells. In addition, TIRFM reveals that the extent of Ca2+
influx in parotid acinar cells is greater than pancreatic acinar cells when compared using
identical methodologies.
M1637
Stimulatory Effects On the Exocrine Pancreas, Via Two CCK-Receptor
Subtypes
Sofia A. Rengman, Bjorn R. Westrom, Stefan G. Pierzynowski
Introduction: In pigs, the secretion of digestive enzymes from the exocrine pancreas is
stimulated by cholecystokinin, CCK, via CCK2-receptors, CCK2R, located in the duodenum
and antrum, in doses mimicking postprandial levels (1,2) while CCK1-receptors, CCK1R,
are not believed to be involved (3). The main aim of the study was to establish a dose-
response curve and to examine the exocrine pancreatic response to increasing doses of CCK-
33 infused directly to the duodenum/antrum region or via the jugular vein, in order to
determine how the response differs and whether more than one CCK-receptor subtype is
affected. Methods: Five anaesthetised piglets were used in acute experiments. The piglets
were surgically fitted with catheters in the gastric artery, the jugular vein and the pancreatic
duct. CCK-33 was infused via the gastric artery in increasing concentrations (factor 2) from
4 to 128 pmol/kg/10 min. The pancreatic juice was collected every ten minutes. The piglets
were given a 30 minute rest period, then the procedure was repeated but the increasing
doses of CCK-33 was infused via the jugular vein instead. The pancreatic juice was analysed
for protein and trypsin and the blood plasma was analysed for CCK. Results: During the
arterial infusion, the pancreatic secretion increased (from 1 to 3 U/kg/h for trypsin and 1
to 5 mg/kg/h for protein) starting at the infusion levels of 4 pmol/kg/10 min and reached
a plateau at 32 pmol/kg/10 min. From 64 to 128 pmol/kg/10 min, a second phase of
stimulation of pancreatic secretion was observed (up to 10 U/kg/h for trypsin, and 15 mg/
kg/h for protein). The infusion of CCK-33 via the jugular vein had to exceed 64 pmol/kg/
10 min to initiate any response. This dose is identical to the dose observed in the second
phase of secretion after local, arterial CCK-33 infusions. Conclusions: The exocrine pancreatic
response appeared to be elicited via two different receptor subtypes after local infusions to
the duodenum/antrum region of CCK-33. Low doses of CCK-33, mimicking the postprandial
plasma levels, stimulate the secretion in a dose-dependent manner. CCK-33 infused via the
jugular vein can only reproduce the second phase of the response which does not involve
CCK2R and demands high doses of CCK-33. The second phase, elicited by the high CCK-
33 doses, independent of infusion route, was twice as high as the response elicited via
CCK2R in the duodenum-antrum region but is considered to be pharmacological since the
plasma level of CCK-33 by far exceeds postprandial levels observed in pigs.
M1638
Interruption of the PDGF and EGF Signal Pathways By Curcumin Contributes
to the Induction of Gene Expression of PPARγ in Activated Hepatic Stellate
Cells in Vitro
Yajun Zhou, Anping Chen
BACKGROUND: A dramatic feature during the pathogenesis of liver fibrosis is enhanced
cell growth of hepatic stellate cells (HSC), the major effector during hepatic fibrogenesis,
triggered by PDGF and EGF. This process is coupled with the sequential up-expression of
PDGF-beta receptor (PDGF-βR) and EGF receptor (EGFR), as well as a dramatic reduction
in the expression of the peroxisome proliferator-activated receptor-gamma (PPARγ). Signal
pathways of PDGF and EGF, including the PI3K/Akt pathway and the MAPK pathways, are
implicated in stimulating HSC proliferation. PPARγ has inhibitory effects on HSC growth.
However, the relationship between the activation of the signaling for PDGF-β and EGF and
the expression of PPARγ in activated HSC remains completely obscure. Curcumin, the yellow
pigment in curry, was previously shown to inhibit cell growth of activated HSC and induce
the expression of PPARγ in activated HSC in vitro [(2003) Am J Physiol. 285, G20; (2004)
Biochem J, 384, 149]. The underlying mechanisms are largely unknown. AIM AND HYPO-
THESIS: This study is to elucidate the mechanisms of curcumin in the induction of PPARγ
gene expression in activated HSC, focusing on the effects of the PDGF and EGF signaling
on the expression of PPARγ. We hypothesize that interruption of the PDGF and EGF signal
pathways by curcumin contributes, at least partially, to the induction of gene expression of
PPARγ in activated HSC. RESULTS: Studies herein indicate that exogenous PDGF or EGF
inhibits the expression and trans-activation activity of PPARγ in passaged HSC. Further
experiments show that curcumin interrupts the PDGF and EGF signaling in activated HSC by
inhibiting the phosphorylation of PI3K/Akt, Erk and JNK and by suppressing the expression of
PDGF-βR and EGFR. Inhibiting the activity of PI3K/Akt, Erk or JNK respectively by specific
inhibitors Ly294002, PD98059 or SP600125 significantly increases the expression of PPARγ
in activated HSC. CONCLUSION: Our studies demonstrate that activation of PDGF and
EGF signaling suppresses the expression of PPARγ in activated HSC. The interruption of
the PDGF and EGF signal pathways by curcumin contributes, at least partially, to the
induction of gene expression of PPARγ in activated HSC. Our results provide novel insights
into the relationship between the activation of PDGF and EGF signaling and the expression
of PPARγ during HSC activation. In addition, these results provide additional evidence and
elucidation of the mechanisms of curcumin in inhibition of HSC activation. [The work was
supported by the grant DK 47995 from NIH/NIDDK to A. Chen and by the Bridging Award
to A. Chen from LSUHSC-S].
M1639
ACF Formation and Colon Cancer Growth Is Reduced in Growth Hormone
Deficient Rats By Alteration in Proliferative Pathways and Receptor Signaling
Robert Carroll, Robert Goodlad, Jai Marchandani, Heliodoro Medina, Young Choi, Sean
Lee, Kevin Leung, Gregory Nemtsov, Tatiana Kouznetsova, Alexandra Ivanovic, Steven M.
Swanson, R Brooks Robey, Terry G. Unterman
Background: The Spontaneous Dwarf rat (SDR) possesses a nonsense mutation in the growth
hormone (GH) gene that results in absent serum GH and reduced levels of insulin-like
growth factor I (IGF-I). To evaluate the GH-IGF axis in colon carcinogenesis, we examined
the formation of aberrant crypt foci (ACF) and tumor development in wild type (WT) and
SDR littermates exposed to the carcinogen azoxymethane (AOM). Subsequently, we evaluated
apoptosis and proliferation in response to carcinogen as well as the expression of hexokinase
activity, IGF-I receptor (IGF-IR), epidermal growth factor receptor (EGF-R) and p27kip/cip
protein expression in control and AOM treated WT and SDR animals. Methods: Eight week
male Sprague-Dawley and SDR littermates received 15 mg/kg of AOM subcutaneously (s.c.)
twice 7 days apart (total dose 30 mg/kg). Rats were weighed weekly and euthanized by
CO2 asphyxiation at 10, 25, and 28 weeks. ACF were quantified by stereomicroscopy and
tumor number and weights were recorded for each animal. Cell proliferation was measured by
vincristine metaphase arrest, flow cytometry and bromodeoxyuridine (BrdU) incorporation.
Apoptosis was measured by Tunel staining and cleaved caspase 3 IHC. IGF-I was measured
by RIA and northern blotting. Hexokinase activity was measured by spectrophotometric
assay. PARP cleavage, and IGF-IR, EGF-R and p27kip/cip expression were measured by
western blotting. Results ACF formation is markedly reduced (~85%) in AOM treated SDR
rats at 10 wks, 25 wks, and 28 wks compared to WT and tumor incidence. number and
weight were reduced by ~50% in SDR vs WT rats. Apoptosis rates are similar in AOM
treated WT and SDR rats and correlate inversely with hexokinase activity in the colon.
Though, baseline cell proliferation is increased in the proximal (1.5X) and distal (2.25X)
colon of SDR rats compared to WT rats, it selectively decreases cell proliferation in the
distal colon in response to AOM~-40%, and these changes correspond to reduced ACF and
tumor formation whereas AOM treatment significantly increases proliferation in WT rats as
early as 72 hrs post AOM. These changes correspond with reduction in serum IGF-I and
colonic IGF message in SDR rats but significantly increased IGF-IR, EGF-R, and p27kip/
cip protein levels in the distal colon suggesting that IGFR/EGFR signaling and/or action may
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contribute to reduced proliferative response to AOM and decreased ACF formation in SDR
vs WT rats. Conclusion: Early neoplastic lesions (ACF) are reduced in GH deficient animals.
The SDR rat is a promising model for studies regarding the role of GH/IGF system in the
initiation and promotion of colon cancer.
M1641
Role of Cholesterol (Ch) and Caveolin 3 Proteins (CAV3) in the Regulation of
CCK-1 Receptor Recycling in Human Gallbladder (GB) Muscle
Ping Cong, Piero Biancani, Jose Behar
The contraction of muscle cells from GB with Ch stones is impaired in response to G protein
coupled receptors such such as CCK-8 that act on CCK-1 receptors. This impaired response
is associated with high caveolar Ch, CAV3, and CCK-1 receptors levels and a 50% reduction
of 125I-CCK-8 binding. These abnormalities are corrected when cells are incubated with
Ch-free liposomes that remove the excess Ch from the caveolae. The mechanism whereby
high levels of Ch cause these abnormalities has not been elucidated. The present studies
were performed in muscle cells from GB with Ch stones that have high caveolae Ch and from
pigment stones (controls). We first examine the effect of CCK-8 on CAV3 phosphorylation (P)
using antibodies against total and phosphorylated CAV3. In normal muscle cells CCK-8
increased the phosphorylated CAV3 band compared with basal levels (p<0.01). This increased
phosphorylation of CAV3 was absent in muscle cells from GB with Ch stones or was blocked
after incubation with Ch-rich liposomes. This inhibition of CAV3 phosphorylation was
associated with increased caveolar levels of Ch, CAV3, and CCK-1 receptors. Pretreatment
of normal muscle cells with PP2 (a Src tyrosine kinase inhibitor) blocked CCK-8 induced
CAV3 phosphorylation and increased the concentrations of CCK-1 receptors in the caveolae.
Sucrose gradients and co-immunoprecipitation studies using antibodies against EEA1 (a
marker of early endosomes) and Rab 11 (a marker of late recycling endosomes) show that
in normal muscle cells CCK-8 increases the transfer of CCK-1 receptors to early endosomes
at 5 and 10 min, to late endosomes at 15 and 20 min and back to normal levels in the
plasma membrane at 30 min. In contrast, high caveolar Ch inhibit the transfer of receptors
to the endosomes and decrease CCK-1 receptor band in the bulk plasma membrane. It is
concluded that receptors that internalized through caveolae phosphorylate CAV3 that facilit-
ate their transfer to recycling endosomes suggesting that acts as chaperone in receptor
recycling. Excess Ch inhibits receptor trafficking by blocking CCK-1 dependent CAV3 phos-
phorylation.
M1642
Functional Epithelial Cells Proteomics Identified Novel Disease Targets for the
Colitogenic Mechanisms of Enterococcus Faecalis in IL-10 Gene Deficient
Mice
Anna Shkoda, Pedro A. Ruiz, Sandy C. Kim, Hanelore Daniel, Balfour R. Sartor, D.R.
Haller
Background & Aim. Colitogenic Enterococcus faecalis initiate and perpetuate experimental
colitis in Interleukin 10 gene deficient mice (IL-10-/-). To identify novel disease mechanisms
for experimental colitis, we used 2D-gel SDS-PAGE and MALDI-TOF mass spectrometry to
characterize altered protein expression profiles in primary intestinal epithelial cell (IEC)
from E. faecalis-monoassociated wild type and IL-10-/- mice. Functional and molecular
analysis revealed novel disease mechanisms for the glucose regulated protein (grp)-78 and
galectin-3. Methods. Germ-free wild type and IL-10-/- mice were monoassociated with E.
faecalis for 14 weeks. Primary IEC from cecal and colonic tissue were purified to perform
proteome analysis. Molecular mechanisms of significantly altered proteins were characterized
in the Mode-K cell culture model. Results. Intestinal epithelial cell proteomics identified 14
differentially regulated proteins in IEC from severely inflamed IL-10-/- mice (14 weeks),
including creatine kinase, serpin clade B, dnaK type molecular chaperon grp-78 and galectin-
3. Immunoblot analysis linked the induction of grp-78 expression in IL-10-/- IEC with an
increased level of NF-κB RelA phosphorylation. In addition, TNF-induced NF-κB/IκB activa-
tion in IEC lines was associated with the recruitment of grp-78 into the IKK complex. Most
importantly for the understanding of molecular mechanisms, the siRNA-mediated knock-
down of grp-78 inhibited TNF-induced RelA phosphorylation, suggesting a role for grp-78
in maintaining RelA phosphorylation. Interestingly, IL-10-mediated p38 signaling decreased
grp-78 expression in primary wild type IEC and susceptible IL-10 receptor reconstituted
IEC, suggesting protective mechanisms of IL-10 at the epithelial cell level. In addition to
grp-78, the siRNA-mediated knock-down of galectin-3 in IEC lines triggered caspase-3
cleavage. In vivo validation confirmed the increased expression levels of cleaved caspase-3
in IL-10-/- IEC. In addition, the decreased expression of galectin-3 was associated with
decreased expression of the junctional protein E-cadherin in primary IEC from inflamed
colonic tissue, suggesting a mechanistic role for galectin-3 in maintaining barrier integrity.
Conclusion. Functional epithelial cell proteomics assigned novel disease mechanisms for
grp-78 and galectin-3 expression in the epithelium under the pathological conditions of
progressive chronic inflammation targeting the NF-κB signaling pathway and barrier function.
M1643
Flagellin-Dependent and Independent Responses to Attaching and Effacing
Bacterial Pathogens in Intestinal Epithelial Cells
Mohammed A. Khan, Caixia Ma, Bruce A. Vallance
Introduction: Enteropathogenic Escherichia coli (EPEC) is an attaching and effacing (A/E)
bacterial pathogen that causes diarrhea and intestinal inflammation in children. EPEC directly
infects human intestinal epithelial cells which release pro-inflammatory interleukin-8 (IL-
8). EPEC Flagellin, a product of the fliC gene, is a major factor that triggers IL-8 release
from epithelial cells. Presently, it is unclear if other inflammatory mediators are released
from epithelial cells in EPEC infection, and whether these responses are fliC dependent or
independent. Moreover, little is known about negative regulation of innate epithelial

















(SIGIRR) protein negatively regulates Toll-like receptor responses in epithelial cells; however,
its role in innate response to A/E pathogens has not been tested. Objectives: Our aims were
a) to examine the mechanism of flagellin-dependent and independent IL-8 secretion and
other pro-inflammatory mediators in A/E infection; b) to compare temporal expression of
these responses with SIGIRR expression in infected intestinal epithelial cells. Results: We
infected Caco-2 colonic epithelial cells with wild type (WT) and ΔfliC EPEC and observed,
in addition to IL-8 release, an up-regulated expression of several pro-inflammatory and anti-
microbial genes such as MIP-3α, MCP-1, COX-2 and β-defensin, predominantly in a fliC
dependent manner. These fliC dependent responses required PI-3K pathway and p38 MAPK
activation, with involvement of key innate proteins e.g. MyD88 and IRAK. Interestingly,
some of these genes were activated at later time points in epithelial cells infected with ΔfliC
EPEC, but in a NF-kB dependent manner. Similarly, infection by Citrobacter rodentium
(Cr), a related A/E pathogen, induced pro-inflammatory responses in the mouse colon
independently of fliC, during Cr colitis. Preliminary data suggests that WT EPEC suppresses
SIGIRR expression in a fliC dependent manner which temporally correlates with release of
IL-8 from epithelial cells. Conclusion: The above findings indicate that A/E pathogens trigger
an array of pro-inflammatory innate responses from infected intestinal epithelial cells through
both fliC dependent and fliC independent mechanisms. Future studies will assess if innate
epithelial response to A/E pathogens requires suppression of SIGIRR. These observations
increase our understanding of how intestinal epithelial cells respond to bacterial pathogens,
and may have important implications for inflammatory conditions triggered by enteric
bacteria, including infectious colitis and inflammatory bowel disease.
M1644
IBD Mucosal E. Coli Isolates Mediate IL-8 Release from Colon Epithelial Cells
By Shed Flagellin Acting Via Mapkinase Pathways
Sreedhar Subramanian, Jonathan M. Rhodes, Anthony C. Hart, Benjamin A. Tam, Lugang
Yu, Helen M. Martin, Barry J. Campbell
Background & Aims: Increased mucosa-associated E. coli are found in IBD and colon cancer.
They commonly adhere to colon epithelial cells and cause IL-8 release(Gastroenterology
2004;127:80-93). We have now investigated the mechanisms for this IL-8 release. Methods:
Confluent HT29 cells were incubated in triplicate wells for 4h with 33 E. coli mucosal
isolates (14 colon cancer, 7 Crohn’s disease (CD), 6 ulcerative colitis (UC) and 6 control
(IBS/polyps) at a bacterium:cell ratio of 10:1 and IL-8 measured in the supernatant by ELISA.
The effect on the IL-8 response of pre-treatment with U0126, SB203580, or SP600125 (60-
90min, at 10μM), specific inhibitors of the MAPkinases: ERK1/2, p38 and JNK, respectively,
was studied. Pooled supernatants were also generated from 24 mucosal E. coli isolates, 6
from each of the 4 disease groups, passed through a 0.2µm filter and assessed for their
ability to release IL-8 from HT29 cells. IL-8 response to whole bacteria was assessed in
TLR5 transfected HEK293 cells or control LacZ transfected cells. Results: All 33 E. coli
isolates induced an IL-8 response (408±370 pg/ml, mean±SD). This was significantly higher
with haemagglutinin-positive bacteria (n=16;548±427 pg IL-8/ml) than for haemagglutinin-
negative bacteria (n=17;281±252 pg/ml) (p <0.0001). Inhibition of ERK and p38 MAPK
reduced average IL-8 response (n=33) by 77±14% and 84±18% respectively (both p<0.001
ANOVA) in contrast to JNK inhibition (36±28%). The IL-8 response to whole bacteria was
TLR5 (flagellin receptor)-dependent in 14/33 E. coli of which 6/14 were haemagglutinin-
positive. IL-8 response was 389±249 pg/ml in TLR5 transfected cells versus 36±50 pg/ml
in LacZ transfected control cells. Inhibition of LPS by polymixin B, 10μg/ml caused no
significant reduction (7±4%) in IL-8 response to whole bacteria. The IL-8 response to filtered
supernatants (mean 659±239 pg/ml) was approximately half that produced by whole bacteria
(1393±478 pg/ml). Following ultracentrifugation of the pooled supernatant from 6 UC E.
coli, 99±5% of the IL-8 stimulating activity sedimented with outer membrane vesicles.
Digestion of flagellin in the with neutrophil elastase inhibited IL-8 release by 68±30%
(p<0.001) or pre-treatment with anti-H6 flagellin antibody inhibited IL-8 release by 50±19%
(p=0.008). Conclusion: Mucosal E. coli cause IL-8 release from colon epithelial cells through
ERK and p38 MAPkinase pathways, largely triggered by interaction between flagellin/TLR5.
Much of the IL-8 triggering activity is present in a shed microvesicle preparation. The IL-
8 response is only partially related to bacterial adhesion and may be as relevant to UC as
to Crohn’s disease.
M1645
Further Characterisation of Mucosa-Associated Escherichia coli Isolates from
Crohn’s Disease and Colon Cancer Patients
Helen Martin, Barry Campbell, Sree Subramanian, Anthony Hart, Jonathan Rhodes
INTRODUCTION: We previously reported that E. coli isolated from biopsies taken from
Crohn’s disease and colon cancer patients displayed enhanced adherence to erythrocytes
and intestinal cell lines whilst lacking the conventional markers of bacterial pathogenicity
(Gastroenterology 2004; 127:80-93). Here we describe further phylogenetic and phenotypic
characterisation of these strains. METHODS: For phylogenetic analysis, 21 strains of CD
and colon cancer-associated E. coli (14 adherent and 7 non-adherent strains) were screened
for the presence of the chuA, and yjaA genes, and the TSPE4.C2 DNA fragment (Applied
and Environmental Microbiology 2000; 66:4555-4558). Haemagglutination (HA) and HEp-
2 cell adhesion assays were performed using all adherent E. coli strains. RESULTS: All
adherent isolates and 2/7 non-adherent isolates were classed into E. coli phylogenetic groups
D1 or D2, characteristic of virulent extra-intestinal E. coli. This grouping was performed on
the basis of the presence of the chuA gene required for heme transport in enterohaemorrhagic
O157:H7 E. coli. Five out of seven non-adherent isolates were classed into E. coli phylogenetic
groups A1 or B1, characteristic of commensal E. coli. All haemagglutinating isolates displayed
adherence to HEp-2 cells in a pattern characteristic of diffusely adherent E. coli (DAEC).
All adherent strains displayed chloramphenicol resistant HA indicative of specificity to cell
surface receptors other than DAF (CD55), possibly CEACAMs. Strong haemagglutinating
activity was found in some bacterial supernatants suggesting secretion of a bacterial adhesion
factor, possibly on shed microvesicles. CONCLUSIONS: Adherent mucosa-associated E. coli
strains isolated from CD and colon cancer display attributes characteristic of virulent extra-
intestinal E. coli, and probably represent typical or atypical DAEC.
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Intestinal Alkaline Phosphatase, a Gut Defense Factor?
Xiaobo Zhang, Madhu S. Malo, Richard A. Hodin
INTRODUCTION: Intestinal alkaline phosphatase (IAP) is a brush border enzyme that is
highly expressed in the mammalian small intestine and is thought to function as an inhibitor
of dietary fat absorption. Previous investigations have reported the ability of the IAP enzyme
to detoxify lipopolysaccharide (LPS), but the physiological significance of this finding has
not been determined. We therefore sought to investigate the cellular functions of IAP in
intestinal epithelia using an in vitro model system. METHODS: We first established a stable
clone of T84 intestinal cells that over-expresses the IAP protein. The human 1.6 kb IAP
cDNA was subcloned into the pIRES2-EGFP vector and transfected into T84 cells. Stable
lines were purified through G418 selection, and confirmed by RT-PCR and IAP enzyme
assay. Transient transfections were performed with an NF-kB-luciferase reporter plasmid
along with expression plasmids for TLR4 and MD2, essential components of the LPS signaling
pathway. Luciferase activity was determined as a function of LPS treatment. RESULTS: IAP
mRNA was absent in T84 wild type (T84-WT) and T84 vector alone (T84-vector) cell lines,
but was highly expressed in the IAP expressing cells (T84-IAP). IAP enzyme activity was
5-fold higher in the T84-IAP cells compared to the two control cell lines. NF-κB-Luc activity
was induced in a dose-dependent manner by LPS (4-fold activation at 100 ng/ml) in T84-
WT cells and T84-vector cells, but only when both TLR4 and MD2 were co-transfected.
The magnitude of NF-κB-Luc activation by LPS in the T84-IAP cells was dramatically inhibited
(approximately 40% inhibition) compared to T84-WT and T84-vector cells. CONCLUSION:
Intestinal alkaline phosphatase is able to inhibit the LPS effects on intestinal cells in vitro,
suggesting that IAP represents a previously unrecognized component of the gut mucosal
defense system. These findings could have important implications for our understanding of
how the host is protected against gut-derived bacteria and toxins.
M1647
Surface Expression of TLR9 Is Upregulated in Response to Pathogenic
Bacterial DNA
Julia B. Ewaschuk, Jody L. Backer, Karen Madsen
Bacterial DNA elicits both pro- and anti-inflammatory responses in epithelial and immune
cells in a strain-dependent fashion. In addition, DNA from probiotic bacterial strains can
modulate and suppress epithelial cell cytokine secretion in response to pathogenic bacteria
DNA. To date, the only known receptor that recognizes bacterial DNA is toll-like receptor
9 (TLR9). TLR9 appears to be localized in intracellular compartments in immune cells;
however, the location of TLR9 in epithelial cells has not been investigated. Intestinal epithelial
cells (IEC) are constantly exposed to high levels of bacterial DNA, and must recognize and
respond appropriately to the presence of pathogenic bacteria. Objective: The aim of this
study was to investigate TLR9 expression and localization in colonic epithelial cells under
basal conditions and in response to stimulatory and inhibitory bacterial DNA. Methods:
HT-29 epithelial cells were exposed to purified DNA from Bifidobacteria breve (Bb; probiotic)
or Salmonella dublin (Sd; pathogenic) in varying concentrations (10-50 μg). A time course
of TLR9 mRNA expression was determined using real-time RT-PCR. IL-8 secretion as a
response to bacterial DNA was measured by ELISA. Localization of TLR9 was determined
by flow cytometry and confocal microscopy. Chloroquine and ethidium monoazide were
used to block endosomal TLR9 interactions and label bacterial DNA, respectively. Results:
Immunofluorescence and flow cytometric analyses demonstrated both intracellular and
surface expression of TLR9 in HT-29 cells under basal conditions. Ethidium monoazide-
labelled DNA from both Bb and Sd appeared at the cell surface of HT-29 cells. However,
exposure of HT-29 cells to Sd DNA, but not to Bb DNA, resulted in a significant increase
(p<0.05) in IL-8 secretion after 6 hrs. This was associated with a greater than 20-fold increase
in TLR9 mRNA within 30 min, and an increased surface expression of TLR9, as assessed
by flow cytometry. Chloroquine did not block IL-8 secretion in response to Sd DNA,
suggesting that TLR9 can signal from the cell surface. There was no change in mRNA levels
or cellular localization of TLR9 in response to Bb DNA. Conclusion: These data indicate
that intestinal epithelial cells can recognize pathogenic bacterial DNA and respond by
increasing surface localization and expression of TLR9. This suggests that the inflammatory
response to Salmonella DNA is mediated at least in part by this increase in TLR9 expression.
M1648
Helicobacter Pylori Strain Specific Induction of Cyclin D1 But Not Beta-
Catenin Regulates Gastric Epithelial Cell Proliferation
Dharmalingam Subramaniam, Vineet Ahuja, Douglas E. Berg, Courtney W. Houchen,
Brian K. Dieckgraefe, Shrikant Anant
Helicobacter pylori (Hp) is a genetically diverse species whose members vary markedly in
vigor of inflammatory and other responses they elicit. Hp uses a cag pathogenicity island
(PAI)-encoded type IV secretion system to inject CagA protein into gastric epithelial cells
and induce proinflammatory interleukin-8 (IL-8) secretion. Recent studies have indicated
that synthesis of≤-catenin, which regulates numerous cancer-related genes, including cyclin
D1 and cyclooxygenase-2 (COX-2), is induced by carcinogenic Hp strains in a CagA-
dependent manner. Here, we determined the importance of Hp strain diversity on induced
beta-catenin and cyclin D1 expression in AGS gastric epithelial cells by western blot, and
further, analyzed IL-8, and COX-2 expression by Real Time RT-PCR. Four different strains
of Hp, based on their cag-PAI and VacA status were utilized in the study: SS1 (cag-PAI+,
VacA s2m2), CH1 and CH8 (both cagPAI+, VacAs1m1), and CH5 (cag negative, VacAs1m1).
The levels of CagA protein following SS1 infection was 50% less than that observed following
CH1 and CH8 infection. However, all four Hp strains increased beta-catenin protein levels
to similar levels, 2 h following infection. At 6 h following infection, the beta-catenin levels
were significantly reduced to levels below that observed in uninfected cells, suggesting that
a transient increase in beta-catenin levels may be sufficient for Hp-mediated activity. However,
nuclear beta-catenin levels were lower than that of controls at both 2 and 6 h following
infection. This localization is similar to that observed in primary gastric cancers and suggests
beta-catenin activity to be through cytoplasmic signaling and not at the level of transcription.
We next determined the effects of Hp infection on the expression of cyclin D1, an important
mediator of cell cycle. Strains CH1 and CH8 significantly inhibited, while strains SS1 and
CH5 induced cyclin D1 expression. In contrast, while strains CH1 and CH8 were robust
inducers of proinflammatory mediators IL-8 and COX-2, SS1 and CH5 were weak inducers.
In addition, while CH1 induced apoptosis of AGS cells, SS1 induced proliferation. Together,
these data suggest that Hp strains that induce a robust host gene response induce cellular
apoptosis, while those that induce a weak host gene response enhance cell proliferation,
probably through increased cyclin D1 expression
M1649
Hydrocortisone Modulates An Age-Dependent Cholera Toxin-Response By
Regulating the Developmental Endocytosis in Immature Human Enterocytes
Lei Lu, W Allan Walker
We have reported that cholera toxin (CT) elicited an excessive secretory response in immature
enterocytes. Recently, we have also reported that this difference in response to CT is due,
at least in part, to an enhanced endocytosis of the CT-GM1 complex in immature enterocytes.
In this study, we have tested the hypothesis that trophic factors in breast milk can modulate
the CT-response in immature enterocytes by regulating the development of endocytosis. A
human fetal small intestinal line (H4) and an adult crypt-like colonic carcinoma cell line
(T84) were used in this study. Endocytic inhibitors and hydrocortisone, a known human
breast milk trophic factor, were used to test our hypothesis. H4 cells were incubated with
hydrocortisone (1mM) or media alone for 7 days before exposure to CT. CT-uptake and
cAMP accumulation in the cells were monitored. In H4 cells, only chlorpromazine (CPZ, a
clathrin-pathway inhibitor) significantly inhibited CT-uptake and the cAMP response,
whereas in T84 cells only methy-β-cyclodextrin (MβCD, a caveolar pathway inhibitor)
blocked CT-uptake and cAMP response. Hydrocortisone decreased CT-uptake and the cAMP
response without affecting CT-GM1 binding in H4 cells. Moreover, hydrocortisone signific-
antly attenuated the inhibitory effect of CPZ on clathrin-endocytosis and the CT-response.
In contrast, these cells were more sensitive to MβCD. Immunogold labeling and electron
microscopy was used to confirm our biochemical observation that the predominant endo-
cytosis of CT is via clathrin-coated pits in immature enterocytes and is down-regulated
during enterocyte maturation. In H4 cells, a co-localization of the CT-B subunit with clathrin
was present initially but is absent in H4 cells pretreated with hydrocortisone. In contrast, there
is a significantly increased co-localization of CT-B with caveolin-1/caveolae in hydrocortisone
treated cells similar to that seen in T84 cells. To further investigate the role of clathrin-
coated pits in CT intracellular trafficking, we used RNA interference (RNAi) of clathrin with
siRNA in H4 cells. There was a dose-dependent decrease in clathrin levels in H4 cells
transfected with clathrin siRNAs and a diminished CT-uptake and cAMP elevation respect-
ively. In contrast, though there was a similar level of clathrin knockdown in H4 cells
pretreated with hydrocortisone, there was no inhibition of CT-uptake and decrease in cAMP
elevation. Our studies suggest that the enhanced response to CT is partially due to an
excessive uptake of CT by a developmentally regulated clathrin-endocytic pathway and
that hydrocortisone can modulate CT-uptake by the induction of endocytosis in immature
human enterocytes.
M1650
Transepithelial Transport of Cholera Toxin (CT) By Ganglioside Gm1 Sorts
Strictly Away from the Golgi Apparatus: A Test of the Indirect Transcytosis
Hypothesis
Joy Wan, Eli Kern, Anne Wolf, David Saslowsky, Randy Holmes, Wayne Lencer
Microbial products affect intestinal development and biology. The way this cross-talk occurs
is highly diverse and not completely understood. Studies on microbial pathogens have been
highly informative. Cholera toxin (CT) typifies the structure and function of the bacterial
AB5-subunit toxins (including the E. coli and Shilgella toxins) that enter host cells by moving
retrograde from the cell surface through the Golgi apparatus into the endoplasmic reticulum
(ER). Over a decade ago, we discovered a pathway by which CT breeches the intestinal
barrier by moving from the luminal surface all the way across the epithelial cell to the
basolateral membrane via transcytosis. The toxin appeared to move across the cell by first
binding its receptor, ganglioside GM1 and entering the Golgi (and perhaps ER). This pathway
is unlike the classic transcytotic pathway described for the polymeric Ig receptor pIgR and
Fc-receptor FcRn, and we proposed the idea of “Indirect Transcytosis”: a pathway from
apical to basolateral membrane in mucosal epithelial cells that requires cargo movement
through the Golgi and perhaps other compartments of the secretory pathway. Aim: We test
this idea using CT that moves retrograde from PM to ER, the E. coli toxin LTIIb that sorts
strictly away from the Golgi apparatus and ER, and a mutant of CT containing sulfation
motifs (CT-GS). Methods: Selective cell surface biotinylation of intestinal T84 cell monolayers
is used to measure transcytosis; and toxin-sufation to measure transport into the Golgi (this
reaction is specific to the Golgi apparatus). Results: Only CT moves into the transcytotic
pathway and can be detected on the basolateral membrane of T84 monolayers. This result
is consistent with a requirement to enter the Golgi apparatus before moving to the basolateral
membrane (indirect transcytosis). However, two independent initial studies show that the
fraction of CT on the basolateral membrane is not sulfated, while the fraction of CT that
moved into the retrograde pathway of the same cells is strongly sulfated. Conclusion:
Ganglioside GM1 sorts CT from the apical PM to ER and to the basolateral membrane by
separate pathways. Sorting CT by GM1 across mucosal barriers is specific to GM1 as the
related ganglioside GD1a that binds LTIIb cannot do this.
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M1651
Mesalazine (5-ASA), But Not Hydrocortisone, Inhibits E. Coli-Induced IL-8
Release from Colonic Epithelial Cells At Therapeutic Concentrations
Sreedhar Subramanian, Barry J. Campbell, Helen M. Martin, Anthony C. Hart, Lugang
Yu, Jonathan M. Rhodes
Background & aims: Inflammatory bowel disease colonic mucosal E. coli isolates release
interleukin-8 (IL-8) from colonic epithelial cells (Gastroenterology 2004;127:80-93). We
have now investigated the effect of 5-ASA and hydrocortisone on this IL-8 response. Materials
& Methods: Preliminary experiments showed that 0.2μm-filtered supernatant, pooled from
6 E. coli mucosal isolates from 5 UC patients, induced a substantial IL-8 response from
HT29 colon epithelial cells (pooled supernatant, 1262±110 pg IL-8/ml; pooled whole bacteria,
1901±67 pg IL-8/ml add basal plus p value). HT29 cell monolayers were therefore pre-
treated for 1h with 2.5-20mM 5-ASA or 10-100μM hydrocortisone followed by addition of
the pooled supernatant. After 4h treatment, IL-8 release was measured by ELISA. In parallel
experiments, IL-8 release was assessed in the presence and absence of BAY11-7082, an
NFκB inhibitor. Results: 5-ASA dose-dependently inhibited the IL-8 response to a pooled
E. coli supernatant, with reductions of 22±15% at 2.5mM, 45±17% (5mM), 51±11% (10mM)
and 97±1% at 20mM (all p<0.01; ANOVA). Hydrocortisone only caused significant inhibition
of the IL-8 response (49±13%, p=0.01) at a supra-therapeutic concentration (100μM). This
is in keeping with the fact that inhibition of NFκB, a principal target for corticosteroids,
only had a modest effect on IL-8 release (mean reduction 29±23%, n=33). A parallel study
showed that the IL-8 response was largely MAPkinase-mediated (submitted). In a separate
experiment, 5-ASA (5mM) and hydrocortisone (100μM) in combination inhibited IL-8
response by 82±7%, compared with 38±8% for 5-ASA alone and 51±6% for hydrocortisone
alone (p<0.001). Conclusions: 5-ASA, at therapeutic concentrations, markedly inhibits the
release of IL-8 by colon epithelial cells in response to mucosal E. coli whereas hydrocortisone
only has a significant inhibitory effect at concentrations almost 20-fold greater than are
likely to be seen therapeutically. This confirms the epithelial cell as the target for mesalazine
(JEM 2005 201:1205-15) but implies that other cell-types probably represent therapeutic
targets for corticosteroids in IBD.
M1652
Over-Expression of a 72-Kda Heat Shock Protein Protects Rat Gastric Mucosal
Cells from H2O2-Induced Necrosis and Apoptosis
Tamotsu Matsuhashi, Michiro Otaka, Sumio Watanabe
Background; We have demonstrated the importance of a 72-kDa heat shock protein (HSP72)
for gastric and colonic mucosal protection in vitro and iv vivo experiments. However, the
problem of our previous studies was that it was impossible to exclude a possible contribution
of other cytoprotective factors other than HSPs, since systemic stress including heat shock
(hyperthermia), chemicals or stress-related hormones had to be applied to induced HSPs
in those experimental systems. Therefore, in order to solve this problem, we have established
HSP72-overexpressing gastric epithelial cells by transfecting full length of human hsp72
cDNA, and we successfully cloned HSP72-highly expressed gastric epithelial cells that
expressed approximately 350% of HSP72 (in protein level) compared with vector-control
cells. We examined the cytoprotective function of these cells against H2O2-induced necrosis
and apoptotic cell death. Methods; The RGM-1 cells were transfected with the pBK-CMV
vector alone (pBK-CMV12) or transfected with the vector containing full length of cDNA
of human hsp72 (7018-RGM1). The cationic liposomal-mediated method (lipofection
method) was employed for transfection and the resistance to geneticine (G418) was used
for selection of successfully transfected cells. To examine anti-necrotic ability, these cells
were challanged with high concentration of H2O2 (0-50mM) and the cell viability was
measured by WST-1 assay. To examine anti-apoptotic ability, these cells were treated with
low concentration of H2O2 (0-1mM) for 24 hours and the cell viability was measured in
the same manner. Also, to determine apoptotic cell damage by morphological changes,
fluorescence staining for DNA was performed using Hoechst 33342 to quantify histone-
complexed DNA fragments. Further, we assessed the levels of Poly-ADP-Ribose-Polymerase
(PARP) using western blot. Results; H2O2 induced necrotic and apoptotic cell injury to
pBK-CMV12 in a concentration-dependent manner. This phenomenon was significantly
diminished in 7018-RGM1 compared to pBK-CMV12. The numbers of apoptotic cells
were reduced in 7018-RGM1 morphologically and suppressed significantly genomic DNA
fragmentation. The detection of a Western blot of PARP cleavage fragments was suppressed
in 7018-RGM-1 compared to pBK-CMV12. Conclusion; These results suggest that HSP72
plays an important role in protecting gastric epithelial cells against oxidant stress-induced
cellular apoptosis and necrosis.
M1653
Flagellin Is the Essential Factor of E. Coli Nissle Mediated Human β-Defensin-
2 Expression in Caco-2 Cells
Miriam Schlee, Sabine Nuding, Artur Altenhoefer, Tobias A. Oelschlaeger, Jan Wehkamp,
Eduard F. Stange, Klaus Fellermann
Background: The probiotic strain E. coli Nissle is established in maintaining remission in
patients with ulcerative colitis as an alternative to 5-ASA. However, the mechanisms of
action are still enigmatic. Recently, we have reported its capacity to stimulate the intestinal
innate defence by inducing the antimicrobial peptide hBD-2 in epithelial cells (Wehkamp
et al., Infect Immun 2004). The aim of the present investigation was to identify the bacterial
factor responsible for hBD-2 induction. Methods: Different E. coli Nissle deletion mutants
encompassing known fitness factors (e.g. microcin (ΔSK22D), fimbriae (ΔfimΔfoc), sidero-
phore (ΔHPI), flagellin (ΔfliC), sigma factor (ΔfliA), hook (ΔflgE)) were constructed. Bacteria
were grown to mid-log phase and heat inactivated. CaCo-2 cells were incubated with bacteria
culture supernatants for 4.5 h or 6 h, respectively and the hBD-2 induction determined by
reporter gene assay or RT-PCR. Flagellin was isolated from different strains including E.
coli Nissle, Salmonella enteritidis and the uropathogenic strain CFT073 (same flagellin

















with the deleted genes to verify the flagellin dependent hBD-2 induction. Furthermore, the
effect of an H1-flagellin antiserum on hBD-2 inducing capacity of E. coli Nissle flagellin
and supernatant was investigated. Results: E. coli Nissle supernatant was more potent to
induce hBD-2 expression in CaCo-2 cells than the bacterial pellet. Therefore, we searched
possible secreted or shedded factors originating from E. coli Nissle. Of several mutants
tested, only those with a deficient flagellin, hook or sigma factor expression, all necessary
for proper flagellin synthesis, were unable to stimulate hBD-2 in CaCo-2 cells. Complemented
mutants regained their inducing capacity comparable to wild-type E. coli Nissle. Isolated
flagellins from E. coli Nissle, Salmonella enteritidis and CFT073 were potent inducers of
hBD-2 mRNA expression. Coincubation experiments with H1-flagellin antiserum reduced
the hBD-2 induction of E. coli Nissle supernatant or flagellin by 70 % or 50 %, respectively.
Conclusion: E. coli Nissle strains (ΔfliC, ΔfliA and ΔflgE) with a loss of flagellin expression
fail to induce hBD-2. This is in accordance with the finding that isolated flagellin is capable
of inducing hBD-2 and identifies flagellin as the sole factor responsible for the E. coli Nissle
mediated hBD-2 gene expression in Caco-2 cells. Flagellin with its immunomodulatory
effects may be the mechanistic principle for remission maintenance in ulcerative colitis.
M1654
Helicobacter Pylori Induction of Matrix Metalloproteinase-7
Seth R. Ogden, Aime T. Franco, Uma S. Krishna, Mary K. Washington, Dawn A. Israel,
Barbara Fingleton, Lynn M. Matrisian, Howard C. Crawford, Richard M. Peek
Helicobacter pylori infection is the strongest identified risk factor for distal gastric cancer.
Strains that possess the cag pathogenicity island (cag+) are known to augment this risk.
Matrix metalloproteinase-7 (MMP-7), an epithelial cell-derived MMP that is induced by
bacterial contact, is overexpressed within human gastric adenocarcinoma specimens and
enhances tumor formation in rodents. We have shown that H. pylori cag+ strains are associated
with MMP-7 protein expression in vivo and induce expression during co-culture with gastric
epithelial cells in vitro. This induction is dependent on activation of ERK 1/2 by specific
components within the cag island. In addition, aberrant activation of beta-catenin, a multi-
functional host molecule that plays an important role in regulating intercellular adhesion,
has been implicated in transcriptional activation of target genes involved in carcinogenesis.
Beta-catenin activation leads to its nuclear accumulation and the formation of heterodimers
with the transcription factor lymphocyte enhancer factor/T-cell factor (LEF/TCF). Binding
sites for this complex have been identified in the promoter region of MMP-7, implicating a
role for MMP-7 as a beta-catenin target gene. To discern the level at which H. pylori
regulates MMP-7, we determined whether induction of MMP-7 expression by H. pylori was
transcriptionally regulated. Further, we examined the response of beta-catenin within gastric
epithelial cells to co-culture with H. pylori. Methods: Following co-culture of AGS cells
with the highly carcinogenic H. pylori cag+ strain 7.13 production of MMP-7 RNA transcripts
were quantified by real time RT-PCR. In addition, immunofluorescence was used to determine
the cellular localization of beta-catenin in response to co-culture with 7.13. Results: Tran-
scription of MMP-7 was induced within two hours of bacterial-AGS cell contact and remained
elevated for as long as 24 hours (p<0.005), with an increase as high as 4.5-fold at 6 hours
(p<0.003). Nuclear localization of beta-catenin was observed in 45% of AGS cells co-cultured
with 7.13 by 6 hours post infection, compared to 8% of untreated cells (p<0.05) Conclusions:
The H. pylori cag+ strain 7.13 activates transcription of MMP-7, and this induction correlates
with movement of beta-catenin to the nucleus, which may explain in part the increased
gastric cancer risk associated with cag+ H. pylori.
M1655
Carcinogenetic Potential of the WSR Caga Region of Helicobacter Pylori
Carlo-Federico Zambon, Daniela Basso, Alessia Stranges, Alessandra Falda, Michela
Fasolo, Laura Del Giudice, Graziella Guariso, Claudio Belluco, Francesco Di Mario,
Filippo Navaglia, Eliana Greco, Paola Fogar, Massimo Rugge, Giuseppe Basso, Mario
Plebani
Within the H. pylori virulence factor CagA a different number of repeats of the EPIYA,
the tyrosine phosphorylation site of CagA, might be found in different strains. A higher
phosphorylated CagA interferes much more with intracellular signalling and it is suggested
to worse the outcome of H. pylori CagA positive infected patients. The aim of this study
was to ascertain whether a different number of the first repeat region (FR) or of the second
repeat region (WSR) repeats of the cagA gene, which comprise the sequence encoding for
the EPIYAs, correlates with different inflammation patterns and outcomes of H. pylori cagA
positive infected patients. We studied Italian patients with antral (n=18) or diffuse (n=16)
gastritis, with duodenal ulcer (n=16) and with histologically proven non-cardia gastric cancer
(n=25). All patients were infected by cagA positive H. pylori strains, the diagnosis being
made on the basis of histology, culture and genetic analysis (ureA, cagA, s and m vacA) of
H. pylori isolates. FR and WSR regions were PCR analysed using isolates from the antrum;
the number of repeats was evaluated on the basis of amplicons dimension (agarose gel
electrophoresis). In a subset of 28 isolates, 14 from NCGC, the whole FR and WSR region
was sequenced. In all patients the FR region contained one repeat. The WSR repeats ranged
from 0 to 3. Some patients (n=22) were co-infected by strains with a different number of
WSR repeats. H. pylori strains with less than 2 WSR repeats had more frequently the m1
vacA allele (X2=5.88, p<0.05) and the infection was correlated with more severe corpus
activity (X2=13.74, p<0.005). NCGC was associated with infections caused by H. pylori
strains with two WSR repeats or with co-infecting H. pylori strains exerting two or more
WRS cagA repeats, while those with less than two repeats were correlated with duodenal
ulcer (X2=12.45, p<0.05). No significant association was found between nucleotide sequences
and disease diagnosis and degree of inflammation. In conclusion the FR region of cagA in
Italian isolates does not vary. The variations of cagA WSR region are probably involved in
causing different disease outcomes in patients infected by apparently similar H. pylori strains:
those with less than two repeats mainly causing duodenal ulcer, those with two or more
repeats probably being more carcinogenetic.
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M1656
Gut Mucosal Immunity Against Core Types of LPS of Escherichia Coli- a Novel
Strategy for Oral Vaccine
Syed S. Hoque, Ian R. Poxton
Background: Gut mucosa is an interface and acts as a barrier against infectious organisms
or their products, gaining access to the systemic circulation. In sepsis syndrome,the source
of LPS/Endotoxin is debated but still gut considered as one of the prime source. LPS is an
essential component of the outer membrane of all Gram-negative bacteria including E.coli
. Structurally, most types of LPS are composed of three distinct region: the lipid A, the core
oligosaccharide and the O-polysaccharide.The LPS core regions are conserved, with a little
variability in sugar molecules in outer core, it can be classified in 4 chemo types (R1-R4).
Studies show that the antibodies to lipid A or core oligosaccharide should be more broadly
cross-protective than antibodies directed against the more variable outer core and the O-
antigen portion of LPS.It is essential to examine the mucosal antibody response against
various core types of LPS of E.coli. These information would be highly relevant in oral
vaccines against E.coli infection. Methods: 11 healthy male control from Dhaka, Bangladesh,
median age 24(18-32 years and 12 healthy control (4 male, 8 female ) median age 39 (23-
48) from Edinburgh, Scotland were studied. All controls underwent Whole gut lavage using
polyethylene glycol electrolytes-based solution drank at a standard rate of one litre/hour.
The first clear effluent was collected. An ELISA technique was developed to measure IgA
antibody against various core types LPS of E.coli. Results: There were IgA antibody responses
against the whole range of available core types (R1,R2,R3,&R4). In Edinburgh groups the
antibody responses were in descending order of magnitude (R1>R2>R3>R4). In Dhaka
groups the order was (R1>R3>R2>R4). There was a generalised increase in IgA response
against whole range of core types in Dhaka control groups as compared to Edinburgh.
However, significant differences were observed in R1, R3, & R4 (P<0.021, P<0.032 &
P<0.015 respectively. Conclusion:This study shows for the first time that there is mucosal
IgA antibody response present against the specific LPS core types of E.coli. As several gram
negative-enteric pathogen share closely related LPS core [ eg. E.coli O157:H7 and Shigella
flexneri (R3), Shigella sonnei (R1)] and there was some constant association between O
serotypes and core types, it is thus possible to develop orally administered mucosal vaccine
targeting these conserved core types of LPS. This vaccine would be more broadly cross-
protective against a wide range of gram-negative pathogens. However, further study will be
needed to know the mechanisms that evokes immune response.
M1657
Therapeutic Effect of the Immunomodulator Glatiramer Acetate On Dextran
Sulfate Sodium-Induced Experimental Colitis
Rina Aharoni, Basak Kayhan, Ruth Arnon
glatiramer acetate (GA, Copaxone, Copolymer 1), an approved drug for the treatment of
multiple sclerosis, acts by induction of Th2 cells and a Th1 to Th2 cytokine shift. Recently
we demonstrated that GA ameliorates the clinical signs in an animal model of Crohn’s
disease - trinitrobenzene sulfonic acid (TNBS) induced colitis. In this study, we have tested
the efficacy of GA in another model - dextran sulfate sodium (DSS)-induced colitis. GA
treatment significantly suppressed the various manifestations of DSS induced colitis, in the
highly susceptible strain C57BL/6, exposed to either one or three cycles of various DSS
concentrations and durations. This was manifested by significantly lower weight loss, reduced
rectal bleeding, prevention of decrease in colon length, marked reduction of histological
damage and improved survival. Combined results of 3 experiments demonstrate in the
untreated group a loss of 33% of the original body weight with full mortality by day 12,
whereas in the GA-treated group (daily injections, 2mg/mouse), only slight weight loss with
subsequently regain and full survival. The effect of GA on the immune system was manifested
by suppression of the proliferation of local mesenteric lymphocytes in response to syngeneic
colon extract and by diminished secretion of the detrimental cytokine tumor necrosis factor
alpha. On the other hand, GA induced an elevated secretion of the beneficial cytokine
transforming growth factor beta. In conclusion, the innunomodulatory drug Glatiramer
Acetate is effective in abrogating DSS induced colitis.
M1658
Protection Against Experimental Colitis By Filamentous Hemagglutinine a of
Bordetella Pertussis Is Not Exclusively Mediated By IL-10
Inge L. Huibregtse, Henri Braat, Peter McGuirk, Kingston Mills, Sander J. van Deventer
Introduction: Filamentous haemagglutinin A (FHA), a membrane antigen of the pathogenic
B. pertussis causes immune evasion of this bacterium by inducing regulatory immune
responses that include induction of IL-10. Our previous experiments revealed that FHA is
able to ameliorate disease activity in a chronic T-cell mediated model of colitis by the
induction of regulatory immune responses. We have now further explored whether IL-10
critically mediates the protective effects of FHA in experimental colitis. Materials and methods:
The CD4+CD45RBhigh transfer model of colitis was adopted by using IL10 KO
CD4+CD45RBhigh T-cells to induce colitis. Three groups of six mice were injected with
CD4+CD45RBhigh T cells; the first group was also injected with CD4+CD45RBlow T cells.
The second and third group were injected with respectively 10 ug FHA and 0.9% NaCl,
subcutaneous, every two weeks. Group four was injected with IL-10 KO CD4+CD45RBhigh
T cells and treated with FHA as previously described. After eight weeks, mice were sacrificed
and the colon was taken out for histological assessment using routing H&E staining. Results:
Mice treated with FHA showed less weight loss compared to control mice during the entire
course of the experiment (p<0.01), the colon weight was significantly lower (140 +/- 1 mg.
vs. 343 +/- 2 mg., p<0.01), the colon length significantly longer (10.1 +/- 0.6 cm. vs. 7.9
+/- 0.3 cm., p<0.01) and histological comparison showed a reduced inflammatory score
(1.7 +/- 0.3 vs. 3 +/- 0.5, p<0.01) after treatment with FHA. There was no significant
difference between the wt and IL10 KO CD4+CD45RBhigh treated with FHA. Both were
protected from the development of wasting disease. Conclusion: FHA of pathogenic B.
pertussis is able to ameliorate disease activity in a chronic, T cell mediated model of colitis.
The observation that also IL-10 KO T cells are able to prevent the development of colitis
after injection of FHA indicate that IL-10 is dispensable for the induction of immune
regulation by FHA.
M1659
Sirna Therapy of Inflammatory Bowel Disease (IBD)
Patricia Cristofaro, Amana Nasir, Tamako Konkin, Virginia Hovanesian, Paul R. Monfils,
Murray B. Resnick, Bharat Ramratnam, Steven F. Moss
RNA interference (RNAi) mediated by single- or double-stranded RNA can silence specific
genes through post-translational and post-transcriptional mechanisms. The therapeutic
potential of this technology is currently being explored. Increasing understanding of the
molecular basis of IBD affords opportunity for highly targeted therapy - especially for
luminally delivered agents. Aim: To examine in detail the gene silencing durability and
specificity of mucosal RNAi and its therapeutic potential in an animal model of IBD. Methods:
Acute colitis was induced in C57BL/6 mice with dextran sodium sulfate (DSS) on days 0
through 5. siRNA targeting murine TNF-α or lamin A/C (expressed constitutively in epithelial
cells) or control siRNA’s (irrelevant, scrambled or mismatched) were administered intrarect-
ally on days 0 and 2. Mice were sacrificed at days 0-10. Colitis severity was assessed
histologically (Murano, Clin Exp Immunol 2000;120:51) and mucosal transcript levels
evaluated by real-time PCR and Northern blot. Fluorescein-tagged siRNA was localized by
confocal microscopy. Non-specific systemic effects were explored with a commercial mouse
interferon response microarray (SuperArray). Results: Naked siRNA administration had no
effect on mucosal gene expression or disease amelioration. In normal mice (no DSS treatment)
20 nmol lamin A/C siRNA as a liposomal preparation [Lipofectamine 2000 (Invitrogen) with
OptiMEM (Invitrogen)] at 4 nmol siRNA/mouse produced lamin A/C knockdown persisting
for 7 days, with maximal effect (70-85% knockdown) on days 2 and 4, and recovery by
day 10. Confocal microscopy showed fluorescein-tagged siRNA was taken up throughout
the mucosa with penetration into the submucosa. In mice receiving DSS, colonic TNF-α
mRNA levels were 58-fold increased compared with normal controls but only 5.5-fold
increased in mice who received liposomal TNF-α siRNA intrarectally (p <0.01). Although
severe colonic inflammation (grade 4) was evident in all mice treated with DSS, those treated
with DSS and siRNA had a mean grade of 1.9 in the left colon (p<0.003). siRNA treatment
had no appreciable effect on levels of >100 interferon-related genes in mucosal tissue
compared to liposome-only treated animals. Conclusion: Intrarectal administration of siRNA
produces a highly specific, potent and transient reduction in mucosal gene expression.
Rectal TNFα siRNA markedly improves left colonic histology without promoting nonspecific
interferon responses. These results provide proof of concept for the development of
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mucosally-delivered siRNA preparations to interrupt/inhibit the inflammatory cascade
responsible for IBD.
M1660
Saccharomyces Boulardii Attenuates Mucosal Inflammation and Maintains
Colonic Barrier Function in Citrobacter Rodentium-Induced Colitis in Mice
Xiujuan Wu, Lee Boyer, Bruce A. Vallance, John Walker, Karen L. Madsen, Alison M.
Buchan, Kevan Jacobson
Saccharomyces boulardii, a non-pathogenic yeast, has received increasing attention in preven-
tion and treatment of infectious and inflammatory bowel diseases. While studies have begun
to explore mechanisms of action of Saccharomyces boulardii further studies are required to
elucidate its action. The aim of the present study was to examine the ameliorating effects
of Saccharomyces boulardii on mouse colitis induced by Citrobacter rodentium in vivo and
to further explore the relationship in vitro. Methods: C57BL/6 mice received 2.5 × 108 C.
rodentium by gavage on day 0, followed by S. boulardii (25 mg/ml; 5 x 108 live cells)
gavaged twice daily from day 2 to day 9. Animals weights were monitored every second
day and all animals were sacrificed on day 10. The colons were removed and assessed for
epithelial barrier function, histology and myeloperoxidase activity. For epithelial barrier
function, tissues were mounted in Ussing chambers for measurement of permeability as
assessed by mannitol movement and cAMP-dependent chloride secretion in response to
forskolin. The antimicrobial effects of S. boulardii were assessed both in vitro and in vivo.
Results: When tested in vitro, S. boulardii had significant bacteriocidal effect. Moreover, S.
boulardii significantly reduced the number of adherent colonic C. rodentium by 82%. C.
rodentium infection was associated with mild diarrhea, significant decrease in body weight
by day 4 post-infection, (31% decrease from baseline) with partial recovery by day 10,
marked crypt hyperplasia, transmural infiltration on neutrophils and mononuclear cells and
a disruption in epithelial barrier function. Treatment with S. boulardii ameliorated the disease
associated with C. rodentium infection. S. boulardii significantly attenuated the weight loss
(13% decrease from baseline at day 4) with full recovery by day 10, ameliorated the crypt
cell hyperplasia (234.7±7.2 µm vs. 297.8±17.6 µm), the histological damage score (0.5±0.2
vs.1.25±0.5) and elevated myeloperoxidase activity of infected mice (2.1±0.4 U/mg vs.4.7±0.9
U/mg). Moreover, oral administration of S. boulardii attenuated the increase in mannitol
flux (17.2±5.0 nm/cm2/hr vs. 31.2±8.2 nm/cm2/hr) and normalized the response to forskolin
(98.0±11.6 µA/cm2 vs. 63.2±8.3 µA/cm2) in infected mice colons. Conclusion: This study
demonstrated that S. boulardii ameliorated the sequelae associated C. rodentium infection
through mechanisms that included inhibition of bacterial growth, reduction of mucosal
inflammation and maintenance of colonic epithelial barrier integrity. S. boulardii may be
beneficial in the treatment of infectious diarrheal illnesses and inflammatory bowel diseases.
M1661
22-Ene-25-Oxa-Vitamin D: A New Vitamin D Analogue with Profound
Immunosuppressive Capacities in TNBS-Colitis
Carolin Daniel, Heinfried H. Radeke, Ulrich Zuegel, Juergen M. Stein
Background & Aims: In addition to its well-established role as a regulator of calcium and
bone metabolism, calcitriol has been established as a prominent regulator of immune cell
functions. However, its clinical use as an immunosuppressant is limited because of the
hypercalcemic toxicity occurring after systemic application. The aim of the following study
was to investigate the in vivo immunomodulatory capacities of 22-ene-25-oxa-vitamin D
(ZK156979), a new low calcemic vitamin D analogue, in TNBS-colitis in mice. Methods:
A rectal enema of TNBS [100 mg/kg body weight (BW)] was applied to male Balb/c mice,
and calcitriol [0.2 µg/kg] or ZK156979 [0.2 or 2.0 µg/kg] were administered intraperitoneally
from day 0-3 following the instillation of the haptenating agent. The study is conforming
to the Guiding principles in the care and use of animals and was performed under approval
of the ethical committee of Darmstadt/Germany (F134/03). Body mass and clinical activity
score of colitis were determined daily. Cytokines (TNF-α, IFN-γ, IL-10, IL-4) in colon
homogenates were determined by immunoassay. Colonic myeloperoxidase (MPO)-activity
was analyzed as a marker for neutrophil infiltration. Serum calcium was analyzed photomet-
rically. Results & Conclusion: Treatment with ZK156979 reduced the severity of TNBS-
colitis abrogating body weight loss, diarrhea, and macroscopic intestinal inflammation with
similar potency compared to calcitriol. The therapeutic effects of ZK156979 were associated
with a downregulation of TNF-α and MPO-activity, while IL-10 and IL-4 were induced.
Thus the member of novel low calcemic vitamin D analogues ZK156979 may provide
a considerable therapeutic potential in T-cell mediated diseases including inflammatory
bowel disease.

















a = P<0.05; b = P<0.01; c = P<0.001 vs. TNBS-treated mice.
M1662
Administration of Exogenous Interleukin-18 Prevents the Dextran Sodium
Sulfate-Induced Colitis in Mice
Mana Mitamura, Hiroyuki Higashiyama, Lihua Shan, Toshihiko Kaise, Hideo Kikkawa,
Mine Kinoshita
BACKGROUND & AIM Interleukin-18 (IL-18) is one of the key mediators that play important
roles in host defense. IL-18 is a unique cytokine involved in both the destructive pathway
through induction of interferon-γ and the compensatory pathway through induction of Th2
cytokines and prostanoids via cycloxygenase-2 (COX-2). In inflammatory bowel disease
(IBD) patients, IL-18 is highly expressed in the inflamed mucosa, however, its pathophysiol-
ogical role in IBD has not been elucidated well. COX-2 is also highly expressed in the
epithelium in IBD patients, and it has been reported to play a crucial role in the defense of
the intestinal mucosa, and in the restitution and the repair of injured tissue via hepatocyte
growth factor (HGF) production. In the present study, to elucidate the therapeutic potential
of IL-18 in IBD, we examined the effect of exogenous IL-18 on clinical symptoms, histopathol-
ogical features, and COX-2 and HGF mRNA expression in dextran sodium sulfate (DSS)-
induced colitis model in mice. METHODS Acute colitis was induced by ingesting 3% DSS
in drinking water from day 0 to 5 in BALB/c mice. Murine IL-18 (0.3 and 1 μg/mouse/day)
was administered intraperitoneally from day 0 to 9. The severity of colitis was evaluated by
scoring the clinical symptoms, such as loss of body weight, stool consistency and occult
blood in the stool, and the histopathological features in the colon. Gene expression of COX-
2 and HGF in the colon was analyzed by quantitative real-time PCR (TaqMan). RESULTS
Severity of clinical symptoms induced by DSS was gradually increased and reached at peak
on day 7. Exogenous administration of murine IL-18 (1 μg/mouse/day) suppressed the
development of clinical symptoms, especially body weight loss and occult blood in the stool
in DSS-treated mice. Both COX-2 and HGF mRNA were up-regulated and reached at peak
on day 7, in well correlation with the development of clinical symptoms. In IL-18-treated
mice, the up-regulation of COX-2 and HGF mRNA were accelerated in comparison with
vehicle-treated mice: on day 5, the levels of COX-2 and HGF mRNA expression in the IL-
18-treated group were increased over 5.4 and 1.7 times of those in vehicle-treated group,
respectively. Histopathological analysis on day 10 showed that the mucosal epithelial damage
in the colon induced by DSS was suppressed by IL-18 treatment. CONCLUSION IL-18
attenuated the DSS-induced clinical symptoms and histopathological alteration in the colonic
tissue. Up-regulation of COX-2 and HGF accelerated by IL-18 probably contribute to the
maintenance of intestinal mucosal integrity, resulting in the prevention of DSS-induced
colitis in mice.
M1663
Preventive Effect of Nimesulide On Colorectal Carcinogenesis in Experimental
Murine Ulcerative Colitis
Takuya Inoue, Mitsuyuki Murano, Yosuke Abe, Eijiro Morita, Naoko Murano, Shingo
Yasumoto, Ken Toshina, Takashi Nishikawa, Kentaro Maemura, Ichiro Hirata, Ken-Ichi
Katsu
Background: One of complications of ulcerative colitis (UC) is an increased risk for develop-
ment of cancer of the colon and rectum, and the incidence of colorectal cancer increases
as the region and duration of the disease increase. Cyclooxygenase- 2 (COX-2) inhibitor is
known to suppress sporadic colorectal cancer, but preventive effect of selective COX-2
inhibitor in UC- associated neoplasia is still unknown. In the present study, we investigated
preventive effect of a selective COX-2 inhibitor on colorectal carcinogenesis in experimental
murine UC. Methods: Chronic colitis was induced in mice by four cycles of administration
of dextran sulfate sodium (DSS) (i.e., 5% DSS for 7 days and distilled water for the following
14 days), and the mice were sacrificed 120 days after the end of the fourth cycle. The mice
were divided into the following five groups: Group A, fed only basal diet served as a disease
control; Group B, received a diet mixed with 400 ppm of nimesulide (NIM), a selective
COX-2 inhibitor, during the whole period; Group C, received a diet mixed with 400ppm
of NIM during the four cycles of DSS administration; Group D, received a diet with 400ppm
of NIM for 120 days from the end of the fourth cycle; Group E, received no agents including
DSS, served as a normal control. Results: The incidence of dysplasia and/or cancer was
28.0%, 15.0%, 11.8%, 6.7% and 0% in Groups A-E, respectively. In Group D, NIM signific-
antly suppressed the occurrence of dysplasia and/or cancer (P < 0.05). Tumor size in Groups
A-D was 4480±469.9μm, 2560±416.3μm, 4100±70.7μm and 2350±106.1μm, respectively.
Strong COX-2 expression was immunohistochemically found in cancer and dysplastic lesions
T : 89386$$CH2
05-04-06 23:18:28 Page 344Layout: 89386B : e
A-344AGA Abstracts
in the colon of the disease control mice, but diffusely weak COX-2 expression was also
found in the residual colon (i.e., lesion-free colon) of the disease control mice. Mucosal
concentration of prostaglandin E2 (PG E2) was significantly lower in Groups B (8.80±1.66μg/
g protein) and D (8.70±2.31μg/g protein) than in Group A (15.19±1.75μg/g protein).
Conclusion: NIM, a selective COX-2 inhibitor, showed suppressive effects on development
of dysplasia and/or cancer in DSS mice colitis model, which had relevance to long standing
UC in human.
Incidence of dysplasia and/or cancer
*p<0.05 vs Group A
M1664
Pegylated Arginine Deiminase (ADI-PEG) Protects Against DSS-Induced Mice
Colitis By Decreasing Macrophage-Derived Nitric Oxide
Jian Zhong, Marion Steiner, Sheldon Steiner, Helieh S. Oz, Munira Nasser, Willem J. de
Villiers
Background & Aims: The microbial enzyme arginine deiminase (ADI) metabolizes arginine
into citrulline. Several tumor cell lines require arginine for growth and selective elimination
of arginine from the circulation is a potential treatment modality. Previously we have shown
that ADI covalently attached to polyethylene glycol (PEG) (ADI-PEG) is effective in attenuating
intestinal inflammation in dextran sodium sulfate (DSS)-induced colitis in both IL-10
knockout (C57BL/6) and BALB/C mice. Here we further studied the potential mechanism
of ADI-PEG treatment on the development of colitis in mice. Methods: Colitis was induced
in BALB/c and IL-10-deficient mice by oral ingestion of 3% for 7 days and assessed by serial
weights, survival curves, colon weight and histological grading scores. ADI-PEG (5 IU i.p.)
was administered on day 0 and day 5. We measured levels of the acute phase protein, serum
amyloid A (SAA). We also determined levels of Nitric Oxide (NO) and the pro-inflammatory
cytokines, IL-6 and IL-12, in serum and supernatants from colonic explants. Furthermore,
immunohistochemistry for CD68 (the macrophage specific marker) and iNOS in the colon
tissues was performed to evaluate macrophage infiltration and activation. Results: DSS alone
induced a severe colitis in BALB/c and IL-10-deficient mice demonstrated by increases in
SAA levels and histological damage scores. ADI-PEG treated animals had significantly less
severe colitis as manifested by improved survival, increased weights, decreased SAA, NO,
and cytokine levels and decreased distal and proximal colonic histological damage scores.
Colonic explants from ADI-PEG treated mice produced significant less cytokines compared
with mice treated with DSS alone. Immunohistochemical study revealed that administration
of DSS caused marked macrophage infiltration in the lamina propria of the colon. The
expression of iNOS was up-regulated in the colons of DSS-treated mice but not in those of
ADI-PEG treated mice. Conclusion: Macrophage infiltration/activation is one of the major
potential mechanisms for the DSS model of colitis. We show that ADI-PEG treatment has
a marked dampening and protective effect on the induction of colitis in two mouse models.
The reduction in the intestinal inflammation is related to decreased macrophage-derived
NO levels by ADI-PEG, as shown by decreased macrophage infiltration and iNOS expression.
These data suggest ADI-PEG is of potential therapeutic use in IBD.
M1665
Angiotensin II Type 1 Receptor Blocker, Candesartan Attenuated Colonic
Inflammation in Dextran-Sulfate Induced Colitis Via Inhibition of Madcam-1
Expression
Tsuneya Wada, Makoto Sasaki, Tadayuki Oshima, Naotaka Ogasawara, Satoshi Tanida,
Hiromi Kataoka, Takashi Joh
Background: Mucosal cell adhesion molecule-1 (MAdCAM-1) is one of the most important
adhesion molecules up-regulated in inflammatory bowel disease (IBD) and is thought to be
associated with the onset and progression of IBD. We show in this study that angiotensin
II receptor blocker, world-widely used for anti-hypertension treatment could prevent experi-
mental colitis via inhibition of cytokine-induced MAdCAM-1 expression. Method: The mRNA
expression of angiotensin II type 1 receptor (AT1) was measured under stimulation of
cytokine. The role of AT1 in the expression of MAdCAM-1 on cytokine stimulated endothelial
venular cells (SVEC4-10) was assessed using AT1 blocker candesartan (10-50μM) and siRNA
method. The effect of candesartan on p42/44 MAPK and NF-κB which are intracellular
signaling of MAdCAM-1 expression by cytokine was examined. Furthermore, candesartan
(0.4 mg/kg) was injected intraperitoneally in C57/BL6 mouse once a day during administra-
tion of 5% dextran sulfate sodium (DSS) orally for 5 days and colonic inflammatory scales
(body weight (BW), disease activity index (DAI) including BW, stool characteristic, and fecal
blood on a scale of 0 to 4, myeloperoxidase (MPO) activity, and histology) were examined.
Result: The mRNA expression of AT1 on endothelial cell was up-regulated by TNF-α (50ng/
ml). TNF-α induced MAdCAM-1 expression was significantly prevented by AT1 blocker,
candesartan (10-30μM) dose-dependently. Furthermore, siRNA mediated knockdown of
AT1 blocked MAdCAM-1 induction by cytokine. Candesartan had no effects on p42/44
MAPK and NF-κB under TNF-αstimulation. Candesartan recovered BW loss (from 19% to
13%, p < 0.05) and colonic MPO activity (from 0.08 to 0.03, p < 0.05). Control mice
receiving DSS showed a significant increase in DAI, which was more attenuated by a treatment
with candesartan (p = 0.05). By H.E. staining, colon histology was altered by DSS and led
to mucosal thickening, leukocyte infiltration, crypt damage, and loss of goblet cells; however
candesartan protected against the DSS induced destruction of the colon and maintained
epithelial integrity. Immunohistochemical staining of MAdCAM-1 was remarkably enhanced
in the mucosa of DSS-treated mice. The increase in MAdCAM-1 staining was reduced but
not eliminated by candesartan treatment. Conclusion: Angiotensin II type 1 receptor blocker,
candesartan could be useful for the treatment of IBD, however further study is necessary
about inhibition mechanism of MAdCAM-1.
M1666
Inhibition of Dipeptidyl Peptidase Activity in Dpiv Knock-Out Mice and Wild
Type Mice Decreases Disease Activity in Experimental Colitis
Roger Yazbeck, Catherine A. Abbott, Gordon S. Howarth, Hans-Ulrich Demuth
Introduction: Glucagon-like peptide-2 (GLP-2(1-33)) is a potent intestinotrophic growth
factor, whose activity is limited by dipeptidyl peptidase (DP)-mediated degradation. It
has been established that the proteolytic enzyme, DPIV/CD26, cleaves GLP-2(1-33) to the
biologically inactive GLP-2(3-33). Work in our lab has suggested that other DPs, including
DP8 and DP9, may also cleave GLP-2(1-33). We hypothesised that DPIV knockout mice
(DPIV-/-) treated with DP inhibitor, Isoleucine-thiazolidine (Ile-thia), would have an
increased GLP-2(1-33) bioavailability, thus decreasing the severity of experimental colitis.
Methods: Four groups of DPIV-/- (n=52) and wild-type (n=49) mice were treated twice
daily by oral gavage with 0.9% saline, or a 10mg/kg dose of Ile-thia in a 6, 9 and 14-day
trial. Mice simultaneously consumed 2% dextran sulphate sodium for 6-days to induce
colitis followed by a recovery period of 3 and 8-days for the 9 and 14-day time points.
Inhibitor treatment continued throughout the entire experimental period. Disease severity
was assessed daily using a disease activity index (DAI). Pair-wise comparisons with a Holmes
post-hoc test between saline and treatment groups were made at each day with a family-
wise significance level of 0.05. Results: Colon weight was greater in Ile-thia (0.19±0.01g)
treated wild-type mice compared to saline treatment (0.16±0.01g) at day 6, and this was
consistent following correction for bodyweight. At day-14 colon weight had increased from
day-9 in the wild-type group treated with Ile-thia by 40% (0.15±0.02g at day-9 to 0.25±0.02g
at day-14, p<0.05) compared to saline treated wild-type mice, where no significant change
was observed (0.19±0.04g at day-9 to 0.21±002g at day 9). DPIV-/- and wild-type mice
treated with Ile-thia had a significantly lower DAI (p<0.05) at 5 and 6-days compared to
saline treated DPIV-/- and wild-type mice for the 6 and 9-day trial. Conclusions: Inhibition
of DP activity in DPIV-/- and wild-type mice partially ameliorates experimentally induced
colitis, indicating that DPIV may not be the sole target of the inhibition. Although total
recovery from experimental colitis was not observed, it may be that physiological levels of
GLP-2(1-33) are insufficient to promote growth of a damaged intestine. Future work would
thus look at mechanisms of elevating physiological GLP-2(1-33) alongside DP inhibitor
treatment. DPIV/CD26 also has a role in immune modulation, and this may further explain
the observed results. This study provides further evidence that DP inhibition has potential
as a novel strategy for the treatment and control of IBD.
M1667
Photopheresis Induces the Generation of Regulatory T Cells
Frank Strobl, Kim Campbell, Janine Huber, Amy Krutsick, Ulrich Thienel, David Peritt
Extracorporeal photopheresis (ECP) involves the clinical reinfusion of autologous apoptotic
peripheral blood leukocytes that have been exposed ex vivo to 8-methoxypsoralen (8-MOP)
and UVA light. ECP is approved for the palliative treatment of cutaneous T cell lymphoma
and has exhibited promising activity in several autoimmune diseases including Crohn’s
disease (Aliment Pharm Ther 15:1313). The biological mechanism of action of ECP, however,
remains unresolved. In animal models, delivery of apoptotic cells has been shown to regulate
immune responses through the downregulation of antigen-presenting cell (APC) function,
the modulation of cytokines, and the generation of regulatory T cells. We and others, have
shown that activation of naive T cells in the presence of APCs that have engulfed ECP-
treated apoptotic cells leads to the generation of a T cell population that can suppress
syngeneic T cell proliferation and function. In the present study, we demonstrate that the
direct interaction of ECP-treated peripheral blood mononuclear cells (PBMCs) with naive
human CD4+ T cells in vitro also promotes a T cell phenotype with regulatory activity.
Transfer of ECP-derived regulatory T cells to a secondary mixed lymphocyte reaction results
in a greater than 50% inhibition of syngeneic responder T cell proliferation and IFNg
production at a Treg:responder ratio of 1:10. In addition, transwell assays demonstrate that
inhibition of responder T cells by ECP-derived regulatory T cells is contact-dependent. The
generation of human regulatory T cells by ECP is dependent on the presence of ECP-treated
monocytes and can be reversed by the addition of IL-2. These regulatory T cells also
proliferate in response to concanavalin-A, but do not express increased levels of Foxp3 or
IL-10, nor do they secrete significant levels of the pro-inflammatory cytokines IL-2, IFNg,
IL-4, and TNFa. Additional studies are underway to further characterize the phenotype of
these regulatory cells and to determine their suppressive capacity in vivo. Regulatory T cells
have shown protective effects in an animal model of colitis (J Immunol 170:3939). Two
international open label phase II clinical trials in Crohn’s patients who failed standard therapy
including anti-TNFa are currently underway to determine the efficacy of photopheresis in
these patients.
M1668
Differential Effects of Selective Or Complete PI3K Inhibition in a Murine
Inflammatory Bowel Disease Model
Lindsey N. Jackson, Piotr G. Rychahou, Scott R. Silva, B. Mark Evers
Inflammatory bowel disease (IBD) affects the mucosal lining of the gastrointestinal tract;
the etiology is unknown and treatment is directed at systemic immunosuppression. The
phosphatidylinositol 3-kinase (PI3K) pathway, consisting of p85α regulatory and p110α
catalytic subunits, regulates multiple cellular processes, including cell survival. Although
PI3K plays an important role in inflammation, the mechanisms remain unclear. The purpose
of this study was: (i) to define the role of PI3K and its subunits in the pathogenesis of IBD,
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and (ii) to determine if complete blockade of PI3K, using wortmannin, or selective inhibition,
using siRNA directed to the p85α subunit, will attenuate the inflammation associated with
IBD. METHODS. (i) Female Swiss-Webster mice (n=40) were randomized into 8 groups
of 5 mice to receive normal water or 5% dextran sulfate sodium (DSS) drinking water to
induce colitis. Mice were treated with either vehicle (5% EtOH) po or iv, or wortmannin
(0.75 mg/kg in 5% EtOH) po or iv every 12 h for 7 days. Disease activity index score (DAI)
was determined daily. At sacrifice, tissues were harvested for H&E, immunohistochemistry
(IHC), and myeloperoxidase (MPO) assay. (ii) Female Swiss-Webster mice (n=20) were
randomized into 4 groups of 5 mice to receive normal or 5% DSS drinking water. Mice
were treated with either non-targeting control (NTC) siRNA or p85α siRNA (10 µg ip, every
24 h starting day 3 after DSS exposure and continuing until the time of their death). DAI
was determined daily. RESULTS. (i) Wortmannin-treated mice had significantly more rectal
bleeding and higher DAI scores when compared to the vehicle-treated group, with more
colonic ulceration and less leukocytic infiltration in the affected colon, reflected by H&E
staining and MPO assay, and decreased pAkt expression by IHC. (ii) p85α siRNA-treated
mice had lower DAI scores, improved stool consistency, and virtually no gross rectal bleeding
throughout the course of treatment, with improved survival (12.8 days) when compared to
NTC siRNA-treated mice (9.4 days). H&E staining revealed increased mucosal regeneration
and less ulceration in p85α siRNA-treated mice. CONCLUSIONS. Total inhibition of
PI3K with wortmannin decreased leukocyte infiltration but increased mucosal ulceration by
inhibiting cell survival and proliferation. In contrast, targeted interference of p85α resulted
in increased mucosal cell regeneration, less ulceration, and increased survival in a murine
IBD model, possibly by a paradoxical increase in PI3K activity. Selective targeting of specific
PI3K pathway components by RNA interference may prove to be a novel and more effective
treatment for IBD.
M1669
The Effect of Novel NF-kB Inhibitor, Dehydroxymethyllepoxyquinomichin in
DSS Colitis Model Mice
Tadakazu Hisamatsu, Kumiko Arai, Nobuhiko Kamada, Hiroshi Chinen, Susumu
Okamoto, Kazuo Umezawa, Toshifumi Hibi
Background and Aims: NF-kB is a transcription factor that is rapidly activated in response
to pro-inflammatory stimuli, infections and physical and chemical stressors. NF-kB particip-
ates in the induction of numerous pro-inflammatory cytokines, chemokines, and adhesion
molecules that are important in pathogenesis of inflammatory bowel disease (IBD). In this
study, DHME-Q (Dehydroxymethyllepoxyquinomichin), novel NF-kB inhibitor that prevents
the nuclear translocation of p65 specifically, was used to elucidate the role of NF-kB in
colitis. Materials and Methods: 1) In vitro, mice CD11b+ bone marrow derived monocytes
were stimulated by LPS with or without DHME-Q. TNF-a in culture supernatant was
measured by cytkokine beads array. 2) The effect of DHME-Q on DSS colitis model mice
in acute phase. To induce colitis, C57BL/6 mice were given 1.5 % DSS in their drinking
water and administered DHME-Q 20μg i.p./day (from day0 to 5). Colitis level was evaluated
by body weight loss, DAI score, and histological score. 3) The effect of DHME-Q on DSS
colitis model mice in recovery phase. To induce colitis, C57BL/6 mice were given 1.5 %
DSS in their drinking water from day 0 to 5. On day 5, they were switched to regular
drinking water and started the administration of DHME-Q 20μg i.p./day from day 5 to 12.
Colitis level was evaluated by body weight loss,DAI score,and histological score. 4) The
effect of DHME-Q on rat intestinal epithelial cell (IEC-6) restitution was studied by migration
assay. Results: 1) DHME-Q significantly suppressed LPS induced TNF-a production from
mice monocyte dose-dependently. 2) In acute phase, body weight loss at day4 (p<0.05)
and DAI score at day5 (p<0.05) was significantly improved in DHME-Q treated mice. 3)
Administration of DHME-Q in recovery phase significantly inclined and delayed the recovery
of body weight(control 98% vs DHME-Q 92.2% of initial BW at day11, p<0.05). 4) DHME-
Q inhibited IEC-6 cell restitution in dose dependent manner. Conclusion: p65 specific NF-
kB inhibitor, DHME-Q can inhibit pro-inflammatory cytokine production and may suppress
inflammation in acute phase, however, in recovery phase, DHME-Q delays the restoration
of body weight and inhibited intestinal epithelial cell restitution. Thus, because NF-kB
has dual roles both in induction of inflammation and recovery of epithelial cells, careful
consideration is necessary to use NF-kB inhibitor as therapeutic target of IBD.
M1670
Selective Inhibition of IKK Prevents TH1 Triggered Colitis in Vivo
Wataru Shibata, Shin Maeda, Keiji Ogura, Tomoya Ohmae, Ayako Yanai, Yoshihiro Hirata,
Haruhiko Yoshida, Takao Kawabe, Masao Omata
Background & Aims: IkappaB kinase (IKK) is a critical regulator for the activation NF-κB,
which plays a key role in inflammation. In Crohn’s disease (CD), clinical specimens display
elevated NF-κB activity and this may be involved in its pathogenesis. To determine a role
of IKK/NF-κB activation in intestinal inflammation, we administered cell-permeable IKK
complex inhibitor peptide NBD (NEMO Binding Domain) into TNBS-treated mice, a model
of CD. Methods: TNBS-colitis was induced in C57BL/6 mice receiving intracolonic instillation
of 200μL of TNBS in 50% ethanol, whereas control mice received 200μL of water or 50%
ethanol alone. We injected mice intraperitoneally (i.p.) either with vehicle alone (DMSO)
or with the wild-type or mutant NBD peptide at 4 hours after TNBS administration and
again on day 1 and 2. The mice were monitored for weight, mortality, colon length, colon
histology, and cytokine mRNA expression in colon tissue 7 days after TNBS administration.
Mice defected in interleukin-6, whose expression is tightly regulated by NF-κB, were also
used. Results: Mice treated with wild-type NBD peptide had shown improvement of their
weight loss and low mortality compared to those treated with mutant NBD peptide (mortality
rate; wild-type vs. mutant, 10% vs. 60%, P<0.05). Wild-type improved intestinal injury and
inflammation determined by microscopic grading 7 days after TNBS administration while
mutant peptide did not (score; wild-type vs. mutant, 1.3+/-0.6 vs. 2.3+/-0.6, p<0.05). Th1
mediated NF-κB downstream genes mRNA expression of colonic homogenates significantly
reduced in mice treated with wild-type but not with mutant NBD peptide (TNF-α, IL1-
β, IL-12, IFN-γ, ICAM-1, and IL-6). IL-6(-/-) mice showed less weight loss after TNBS

















inhibition of IKK/NF-κB activation offers an effective therapeutic approach, in part through
inhibition of Th1 mediated cytokine expression, for treatment of human IBD.
M1671
Selective Inhibition of Leukotriene A4 Hydrolase Attenuates Tissue Injury,
Cytokine Production and Inflammation in Rat Colitis
Paul J. Dunford, Csaba Vargas, Anne Fourie, Brendan J. Whittle
Leukotrienes (LTs), particularly LTB4, formed from arachidonic acid by the 5-lipoxygenase
(5-LO) enzyme, are highly active pro-inflammatory lipid mediators, yet inhibition of 5-LO
activity has not proved consistently effective in experimental models of colitis or in the
therapeutic management of IBD. Moreover, 5-LO inhibitors may also prevent the production
of endogenous anti-inflammatory factors such as the lipoxins that promote lesion resolution.
Since leukotriene A4 hydrolase (LTA4H) is involved downstream of 5-LO in the biosynthesis
of LTB4, we have now explored a more specific approach through selective inhibition of
LTA4H and modulation of LTB4 production alone. Thus, we have evaluated the actions of
the novel, highly selective LTA4H inhibitors, JNJ 10392980 and JNJ 26993135, that are
active in the nanomolar range in vitro, in a hapten-provoked model of acute colitis. Colitis
was induced in rats by the intracolonic instillation of trinitrobenzene sulfonic acid (TNBS)
and the extent of colonic inflammation assessed after 3 days in terms of macroscopic
injury and the colonic levels of the neutrophil marker, myleoperoxidase (MPO) and the
inflammatory biomarker cytokines, tumor necrosis factor alpha (TNFα) and interleukin-6
(IL-6). Oral administration of JNJ 10392980 (30 mg/kg b.i.d) commencing 24h prior to
challenge, abolished the fall in body weight following TNBS challenge and significantly
reduced the area of macroscopic injury by 57% (n=15; P<0.001) while attenuating the
TNBS-provoked increase in the colonic levels of MPO, TNFα and IL-6 by 59%, 67% and
82% respectively (P<0.001 for each). Likewise, treatment with JNJ 26993135 (5-30 mg/kg,
b.i.d., p.o.) significantly attenuated the fall in body weight and caused a dose-dependent
reduction in all indices of colonic inflammation; thus, the highest dose of JNJ 26993135
which reduced colonic LTB4 levels by 79 ± 5%, reduced macroscopic injury, MPO, TNFα
and IL-6 levels by 49%, 48%, 63% and 66% respectively (P< 0.01 for each). These findings
with both JNJ 10392980 and JNJ 26993135 suggest that selective inhibition of LTA4H
could provide a more specific approach to attenuating the biosynthesis of the chemotactic and
pro-inflammatory lipid LTB4 in colitic tissue and invading cells. These novel pharmacological
agents reduce the macroscopic, neutrophil and cytokine biomarker indices of experimental
colitis and may thus point to a novel strategy for therapeutic intervention.
M1672
Disease Modifying Effects of Everolimus, Distinct from Immunosuppression,
in Cd45rbhigh T Cell-Induced Murine Colitis
Henrietta D. Moore, Amy Martland, Martina Pfann, Marzieh Edjlalipour, Eva Kern, Isabell
Buttron
BACKGROUND: We have shown that the mTOR inhibitor, everolimus (EVR) both protects
against development of disease and can halt and reverse established severe inflammation in the
SCID mouse model of IBD induced by transfer of naïve T cells (Gut 2005,54(suppl.VII);A61).
Calcineurin inhibition via FK506 protects against disease onset but only at doses with
associated toxicity. AIM: To further differentiate the strong anti-inflammatory benefit of
EVR in the intestine from its immunosuppressive properties we tested if EVR has prolonged
effects after ceasing administration, as recently shown in a rat tumor model. (Cancer Res.
2004,64;252) METHODS: SCID mice were reconstituted with naïve (CD4+CD45RbHi) T
cells and treated with 1mg/kg/d EVR or 10mg/kg/d FK506 for 7 or 21 days. Mice were
euthanized on day 29, serum haptoglobin measured by ELISA, colitis was evaluated histolog-
ically and lymphocyte numbers in blood, spleen and mesenteric lymph nodes (MLN) were
measured by FACS analysis. Body weight (BW) was measured throughout and a score for
diarrhea made at the end. RESULTS: In 2 similar studies with n=8 mice per group placebo-
treated mice lost a mean %BW of 23.1±2.6 whilst EVR-treated mice lost only 8.8%±5.3
relative to non-transferred controls. In a third study, BW loss was the same in FK506 or
placebo-treated mice. Colitis severity in the placebo-treated groups was 7 and 7.4 (out of
8) whilst EVR treatment for only the first 7d resulted in reduced mean scores of 5.0 and
4.2, respectively. EVR treatment for 21d resulted in significantly (p<0.01) reduced mean
scores of 2.3 and 0.1, respectively. In stark contrast, no FK506-treated mice were protected
against colitis. Serum haptoglobin in the 7d EVR-treated mice was reduced by 72 and 56%,
respectively whilst FK506 treatment, even for 21d, failed to reduce this acute phase protein.
However, a significant reduction of 75.9%±4.9 was measured when this dose of FK506 was
given continuously for the entire 28d. There was no significant reduction in lymphocyte
numbers in blood, spleen or MLN after EVR treatment. Diarrhea scores were also lower in
7d EVR-treated mice with scores of 4 and 4.8 (out of 8) whilst placebo-treated mice scored
5.9 and 6, respectively. CONCLUSIONS: Since the half-life of EVR in the mouse is measured
in hours these data suggest that EVR is modifying the early events of disease progression
without preventing T cell expansion. Calcineurin inhibition clearly needs to be kept constant
for any protective benefit. Further studies are necessary to elucidate if the EVR effects are
mediated via specific factors of the mTOR pathway in intestine, eg the translational activator
ribosomal protein S6 kinase 1.
M1673
Hypnotherapy Decreases Rectal Mucosal Release of Substance P, Histamine
and IL-13 in Patients with Active Ulcerative Colitis
Joel Mawdsley, David Jenkins, David Rampton
Introduction: Hypnotherapy is effective for functional GI disorders and has been claimed
to improve UC. The mechanisms by which hypnotherapy may act are unknown but could
involve reductions in the mucosal production of inflammatory neurotransmitters, mast cell
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mediators and inflammatory cytokines. Aim: To assess the effects of one session of hypnother-
apy on the concentrations of substance P (SP), histamine, TNF-α and IL-13 in rectal peri-
mucosal fluid in patients with active UC. Methods: For 50 mins patients with active UC
(Simple Clinical Colitis Activity Index>3, Baron sigmoidoscopy score>1) underwent either
(i) Hypnotherapy - stress reduction and gut-focused symptom management (ii) Control
session - listening to relaxing music. The autonomic response was assessed by pulse and
BP every 15 mins. A sample of peri-mucosal fluid was collected before and after each protocol
by placing a 7 x 30mm strip of filter paper through a rigid sigmoidoscope in contact with
rectal mucosa for 1 minute until wet. The filter paper was incubated in 1ml Bovine Serum
Albumin (0.3%), sodium azide (0.01%) and Tween 20 (0.002%) in phosphate buffered
saline for 24 hours and SP, histamine, TNF-α and IL-13 levels in the buffer measured by
ELISA.1 Results: The control protocol caused no changes in any variable (Table). Hypnother-
apy reduced pulse rate by median 7bpm, systolic BP by 2mmHg, and concentrations of SP
by 81%, histamine by 35% and IL-13 by 54%. Conclusion: Hypnotherapy reduces rectal
mucosal release of substance P, histamine and IL-13, but not of TNF- α, in patients with
active UC. These changes could provide a basis for a beneficial effect of hypnotherapy in
UC. References 1. E. Carty, M. De Brabander, R. M. Feakins, D. S. Rampton, Gut 46, 487-
492 (2000).
*p<0.05 from pre-hypnotherapy value. Median and IQR shown.
M1674
The Timing of Administration of Ro26-2198, a Vitamin D3 Analog, Causes
Opposing Effects On Dextran Sulphate Sodium (DSS)-Induced Colitis
Alessandro Fichera, Nathaniel Little, Sujatha Jagadeeswaran, Urszula Dougherty, Reba
Mustafi, Sonia Cerda, Yanliang Sun, Yan C. Li, Lucas Campbell, Loren Joseph, John Hart,
Amy Noffsinger, Marc B. Bissonnette
Introduction. Dextran sulfate sodium (DSS) induces an inflammatory colitis and repeated
cycles induce colitis associated colon cancer. Vitamin D analogues are chemopreventive in
several experimental models of colon cancer, but limited by hypercalcemia. While vitamin
D compounds are anti-inflammatory in other models of inflammation and inhibit proliferation
of transformed colonocytes, their effects on DSS-induced colonic mucosal inflammation and
normal colonocyte regeneration have not been examined. For these studies we investigated
a fluorinated non-hypercalcemic analogue of vitamin D3, Ro26-2198 (Ro26). The aim of
this study was to compare the effects of Ro26, administered during or after DSS treatment,
on clinical colitis and crypt loss. Methods. Male A/J mice were divided in three groups:
controls, receiving standard mouse diet alone; group 2, receiving Ro26 (0.05 µg/kg body
wt/day) orally for the entire study; and group 3, receiving Ro26, after the peak of DSS-
induced inflammation (day 12). All groups received 2.5% DSS x 7 days in the drinking
water, followed by two wks recovery. The Disease Activity Index (DAI) that integrates clinical
scores for weight loss, stool consistency and bleeding was evaluated daily. Two animals/
group were sacrificed at 2-3 day intervals. Crypt Loss Score (CLS) was determined from
H&E sections and Ki67 stained to assess proliferation. Results. DAI: In the group receiving
Ro26 during DSS treatment, peak clinical inflammation occurred significantly earlier (day
7 vs. day 10) compared to control. This group, however, also showed an accelerated recovery
that was complete by day 12. When administered after DSS, Ro26 caused an accelerated
reduction in DAI, with clinical resolution by day 18 vs. day 20 in the control group. CLS:
When administered during DSS treatment, Ro26 caused a significantly earlier and higher
peak (day 7 vs. day 10) in CLS compared with control. Following DSS withdrawal, this
same group, however, recovered earlier than the other groups. When Ro26 was started
following DSS treatment, prompt reduction of the CLS and complete histological recovery
were achieved earlier than the control group. Proliferation: In the groups receiving Ro26,
complete mucosal regeneration, with inhibition of residual proliferation, was noted earlier
than the control group. Conclusion. When administered during DSS injury and recovery,
Ro26 accelerated inflammation and recovery. When given after DSS withdrawal, Ro26
hastened recovery. Further studies are in progress to elucidate differential effects induced
by the timing of Ro26 administration on the innate immune system and epithelial cells in
DSS colitis.
M1675
The Immunomodulatory Activity of 1,25-Dihydroxyvitamin D3 and
Dexamethasone in TNBS-Colitis Is Mediated Via the Transcription Factors T-
Bet, Gata3 and Foxp3
Carolin Daniel, Heinfried H. Radeke, Juergen M. Stein
Background & Aims: Previously, we have demonstrated that 1,25-dihydroxyvitamin D3
(calcitriol) revealed in vivo strong Th1-selective immunosuppressive and immunomodulatory
capacities in combination with classical immunosuppressants like the corticosteroid dexame-
thasone. The objective of the present study was to elucidate the relevant transcription factors
mediating the effects of 1,25-dihydroxyvitamin D3 in combination with dexamethasone in
experimental Th1-colitis. Methods: A rectal enema of TNBS [100 mg/kg body weight (BW)]
was applied to male Balb/c mice, and dexamethasone [0.6 mg/kg] and/or calcitriol [0.2
µg/kg] were administered intraperitoneally from day 0-3 following the instillation of the
haptenating agent. The study is conforming to the Guiding principles in the care and use
of animals and was performed under approval of the ethical committee of Darmstadt/
Germany (F134/03). Colitis severity was evaluated macroscopically and microscopically.
Western blot analysis of T-bet-, GATA3- and FoxP3-expression, as well as of IL-23p19-
and IL-27 was performed from colon protein extracts. IL-10 and TGFβ were analysed by
immunoassay. Serum calcium was analyzed photometrically. Results & Conclusion: The
combined application of 1,25-dihydroxyvitamin D3 and dexamethasone most prominently
downregulated the Th1-transcription factor T-bet, as well as the recently discovered cytokines
IL-23p19 and IL-27, in contrast the Th2-lineage commitment factor GATA3 was significantly
induced. Moreover, the provided Th1/Th2-shift was accompanied by a significant induction
of FoxP3, raising evidence for a distinct enhancement of regulatory T cell capacities (see
Table). These findings underlie the combined application of dexamethasone and calcitriol
as an auspicious new treatment regimen for Th1-mediated diseases offering distinct corticoid
sparing properties.
Results Calcitriol and dexamethasone in TNBS-colitis
a = P<0.05; b = P<0.01; c = P<0.001; n.s. = non significant vs. TNBS-treated mice.
dex. = dexamethasone
M1676
Dipeptidyl Peptidases and Their Expression in a Murine Model of
Experimental Colitis
Roger Yazbeck, Melanie L. Sulda, Gordon S. Howarth, Catherine A. Abbott
Introduction: Glucagon-like peptide-2 (GLP-2) is a potent intestinotrophic growth factor;
however its actions are limited by dipeptidyl peptidase (DP) IV mediated degradation. Recent
work has suggested that there may be other enzymes with DP activity in addition to DPIV
that are also responsible for the in vivo degradation of GLP-2. Fibroblast activation protein
(FAP), DP8 and DP9 all exhibit DP activity and share sequence identity with DPIV as they
are all members of the S9b enzyme family. Another DP also exists, DPII but this belongs
to a different enzyme class. We hypothesized that there was greater than one enzyme with
DP activity present in the colon and that the expression of these enzymes would differ in
normal compared to colitic colon samples. We hypothesized that if any of these enzymes
were present in colitis, then they may also be targeted by DPIV inhibitors. Methods: Wild-
type (WT) and DPIV knockout (DPIV-/-) mice consumed 2% dextran sulphate sodium (DSS)
for 6 days to induce colitis (n=6 for each group). Mice were sacrificed at days 0 and 6.
Messenger RNA (mRNA), protein and enzyme levels of all enzyme members of the DPIV
gene family and DPII were measured in the colon for each group using real-time RT-PCR,
quantitative western blotting, DP-like enzyme activity assays and immunostaining techniques.
Results: All enzyme members of the DPIV gene family and DPII were present in the colon
of both normal and colitic mice at the mRNA level. DP8 and DPII mRNA levels were
significantly increased (p<0.05) in WT mice with colitis compared to normal mice. DP
enzyme activity but not DPIV protein was significantly increased (p<0.05) in colitic WT
mice compared to normal WT mice, and DPII activity was significantly increased (p<0.05)
in colitic DPIV-/- mice compared to day 0 DPIV-/- mice. DPIV, DP9 and fibroblast activation
protein (FAP) mRNA levels were considerably reduced in colitic samples in both WT and
DPIV-/- (DP9 and FAP only) mice. Conclusion: This study is the first to demonstrate that
enzyme members of the DPIV gene family and DPII are present in the colon and that their
expression differs in colitic samples compared to normal samples. Thus these other dipeptidyl
peptidases may also play a role in the induction and resolution of colitis. This study together
with previous work in our group provides further indication that DP inhibition may be a
novel strategy for the treatment and control of IBD.
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M1678
Fibratide, a Synthetic Fgf Mimetic,Alleviates Experimental Ulcerative Colitis
Xinhua Lin, Paul O. Zamora, Kazu Takahashi
Existing IBD treatments modulate the immune response. However, many patients are non-
responsive or develop significant side effects. Hence new therapies are needed. In animals,
recombinant human fibroblast growth factors (rhFGFs) limit the mucosal tissue damage,
but their delivery is largely limited to parenteral administration. Synthetic peptide mimetics
of FGF, that have the potential for being tailored to oral or rectal administration, would be
attractive as IBD treatment options. Fibratide, a synthetic FGF mimetic peptide, was evaluated
for its ability to protect mice from experimental colitis. Colitis was induced by providing
C57BL/6 mice drinking water containing 3% dextran sulfate (DSS). Starting at 3 days after
DSS treatment, animals were left untreated or treated once a day for 5 consecutive days
with Fibratide (1 and 5 mg/kg) or rhFGF2 (1 mg/kg; positive control) by intraperitoneal
injection. On day 11 the animals were euthanized, and the lengths and weights of colons
determined. Specimens were then processed by standard histological methods. In colitis
mice with no therapy, body weights decreased gradually from day 4 to day 9 and the loss
of body weight was not regained at the end of the experiment. The colons in these animals
were shortened and had clear signs of inflammation including thickening of the bowel and
increased vascularisation. Histological evaluation showed a loss of epithelium and crypt
morphology, depletion of goblet cells, necrosis, ulceration and transmural infiltration of
granulocytes. In contrast, colitis animals treated with Fibratide had slower rates of weight
loss during the study. Moreover, Fibratide promoted the recovery of weight loss compared
to untreated mice once DSS treatment was stopped. Colons of these animals exhibited milder
signs of inflammation including less shortening and thickening. Histologically, colons of
mice treated with Fibratide exhibited morphologies more reminiscent of normal tissue
architecture with an intact epithelium and complete crypts. Inflammation, while present,
was mild and considerably less extensive than in untreated animals. The return to more
normal morphology was especially noticeable in animals receiving doses of 5 mg/kg. Animals
treated with hrFGF-2, the reference treatment, also had increased body weights and histolog-
ically were similar to those treated with Fibratide at 5 mg/kg. Collectively, the results
demonstrate therapeutic effects of Fibratide in experimental ulcerative colitis. Future studies
are targeted to modification of Fibratide to be permissive of oral or rectal administration to
affect a local/regional therapy and to minimize dose and spurious systemic effects.
M1679
Integrin α2β1 Regulates Neutrophil Recruitment and Inflammatory Activity in
Experimental Colitis in Mice
Sofie Lundberg, Johan Lindholm, Lennart Lindbom, Per M. Hellstrom, Joachim Werr
Receptors of the β1 integrin family mediate leukocyte adhesion to extracellular matrix (ECM)
proteins and are believed to regulate leukocyte migration to sites of inflammation and tissue
injury. Human inflammatory bowel disease (IBD), e.g. Crohn’s disease and ulcerative colitis,
is associated with leukocyte accumulation in the inflamed intestinal tissue and recent studies
strongly suggest a role of β1 integrin receptors in regulating tissue damage and disease
symptoms related to IBD. In this study, we investigated the role of the collagen-binding
α2β1 integrin (CD49b/CD29) in dextran sodium sulfate (DSS) -induced colitis in mice.
Rectal administration of function-blocking antibodies directed against the murine α2 integrin
subunit was found to significantly reduce mucosal neutrophil infiltration in DSS-treated
mice as shown by a decrease from 47.2±10.0 to 6.6±8.0 neutrophils per counted area (P<
0.05). Clinical signs of colitis such as weight loss was reduced from 14.7±3.9% to 2.2±0.2%
and shortening of colon length was reduced from 5.8±0.8 cm to 7.4±0.8 cm, (healthy
control 9.1±1.0 cm). Blockage of α2β1 integrin also down-regulated gene expression of
metalloproteinases (MMPs) -2, -7 and -9. These MMPs have been demonstrated to be elevated
in colitis and are known to contribute to inflammatory tissue damage in IBD. For comparison,
the protective effect against colitis seen after anti-α2β1 integrin treatment was found to be
favorable to the effect seen after high dose oral betamethasone. In conclusion, we demonstrate
an alleviating action of the collagen-binding α2β1 integrin in experimental colitis in mice
and suggest this effect to be mediated via inhibition of neutrophil migration and activation.
Local administration of function-blocking antibodies against integrin α2β1 may provide
novel avenues to treat inflammatory bowel disease.
M1680
Therapeutic Effect of Tv-5010 On Dextran Sulfate Sodium - Induced
Experimental Colitis
Rina Aharoni, Basak Kayhan, Ruth Arnon
TV-5010 is a higher molecular weight version of glatiramer acetate (GA), the active ingredient
of Copaxone. GA, which exerts its effect by inducing a Th1 to Th2 shift, has been shown
to ameliorate both trinitrobenzene sulfonic acid (TNBS) and dextran sulfate sodium (DSS) -
induced experimental colitis in mice. TV-5010 induces a similar immunomodulatory activity
as GA, albeit with less frequent administration. In this study, we investigated the efficacy
of TV-5010 on DSS-induced colitis, and compared it to the beneficial effects demonstrated
previously for GA. TV-5010 ameliorated colitis in the highly susceptible strain C57BL/6
induced by either one or three cycles of DSS. This was manifested by significantly lower
weight loss, improved long-term survival, reduced rectal bleeding, as well as by prevention
of decrease in colon length and reduction of histological damage, in TV-5010 treated mice
compared to untreated mice. In contrast to GA, which was more effective when administered
daily by injection of 2.0mg/mouse, TV-5010 was most effective when administered every
5-7 days, 0.2-1.0mg/mouse, indicating that smaller doses and less frequent injections of
TV-5010 are needed to obtain therapeutic effect. The weekly injections of TV-5010 were
most effective when started from the day of disease induction, but a beneficial effect was
observed even when treatment started 10 days after disease induction, when the mice reached
maximal weight lost. The effect of TV-5010 (injected weekly) as well as that of GA (injected
daily) on the immune system was studied using RT-PCR analysis of cytokines in colons of

















colitis associated Th1 inflammatory cytokines interferon-gamma and tumor necrosis factor
alpha were reduced. Moreover, the levels of the Th2/3 anti-inflammatory cytokines interleu-
kin-10 (IL-10) and transforming growth factor beta were elevated, in comparison to untreated
mice. In conclusion, TV-5010 was effective in the suppression of DSS induced colitis similarly
to Glatiramer Acetate, with the advantage of less frequent administration.
M1681
Improving the Objectivity and Sensitivity of Rodent IBD Models Using
Histometric Analyses and mRNA Profiling to Complement Traditional
Readouts
Catherine Booth, Gregory Tudor, Gerard Brady
Despite the wide range of rodent IBD models available the assays themselves remain notori-
ously poor indicators of eventual clinical efficacy. Several models are generally needed to
provide sufficient supporting efficacy and mechanism of action data. Part of the problem is
that the data is often not reproducible due to the insensitive or subjective scoring assessments
used (animal weights, colon length, visual scores of inflammation) etc. We have developed
a method to generate quantitative histometric data from simple H&E sections. Areas of lesions
(overt ulcers and areas of intramural inflammation) are measured, along with indicators of
mechanism of action such as crypt length, number of proliferative and apoptotic cells per
crypt, changes in overall crypt cell turnover (including crypt density) and number of neutro-
phils and T cell phenotpyes per unit area of lesion or epithelium. An indicator panel of mRNA
profiles is also generated from an adjacent area of the same treated tissue to demonstrate effects
on key disease activity regulators such as IL-6, TNFa, IFNg etc. Dose and time dependent
changes in the above parameters were measured in the mouse DSS IBD model, and time
dependent changes were detected in the TNBS model. Significant suppression of some,
but not all, parameters following treatment with clinical standards such as prednisalone,
sulfasalasine and budesonide, were consistently observed in animals within and between
studies. In IL10-/- mice the kinetics of development of crypt hyperplasia and subsequent
ulceration was easily quantified, and were suppressed by IFNg inhibition. However, in all
models the actual parameters most affected depended upon the drug and the model, indicating
that careful consideration needs to be given to the MOA of any novel agent when determining
the best model to screen suppression of disease severity. For example, some agents that
reduced the intramural inflammation significantly had no statistical effect on the actual ulcer
sizes, whereas some did both, and others the converse. The selected panel of parameters
for each model will serve as useful biomarkers and may also be useful indicators in clinical
trial biopsy material.
M1682
Targeting Epigenetics: Modifying Histone Acetylation As Novel Therapeutic
Approach in Inflammation-Dependent Carcinogenesis
Rainer Glauben, Arvind Batra, Inka Fedke, Hans A. Lehr, Paolo Mascagni, Martin Zeitz,
Britta Siegmund
Histone deacetylase inhibitors (HDACi) are potent inducers of growth arrest and apoptotic
cell death and are currently in clinical studies for solid tumors. In addition, an anti-
inflammatory potency was recently demonstrated by our group for HDACi from different
classes in vitro as well as in vivo by using different models of experimental colitis in mice.
Since IBD in humans is associated with an increased risk of developing colorectal cancer,
a therapeutic approach including anti-inflammatory as well as anti-proliferative properties
is highly intriguing. Thus with the present study HDACi from various classes (SAHA,
trichostatin A, apicidine and valproic acid (VPA)) were first evaluated for their capacity to
induce apoptosis and histone 3 (H3) acetylation in vitro. Here, for each HDACi class, a
dose-dependent induction of apoptosis was observed in stimulated murine monocytes, CD4+
T-cells as well as lamina propria lymphocytes (LPL). These findings were associated with a
parallel increase in H3 acetylation in the HDACi-treated cells. Second, in order to characterize
the combined effect of the anti-inflammatory and anti-proliferative potency of HDACi in
vivo, the AOM/DSS-model of inflammation-mediated colon carcinogenesis was applied. In
this model the carcinogen AOM reveals its effect after the induction of a chronic DSS-
colitis within 40 days. The HDACi SAHA or VPA were administered throughout the entire
experimental time course via oral gavage and tumor progression was monitored by lower
endoscopy. HDACi treatment resulted in a delay of tumor development as evaluated by
endoscopy and histology. In addition, the absolute number of adenomas was significantly
reduced by 30 % in the HDACi-treated group when compared to vehicle-treated animals
as determined by histology. Subsequent immunoprecipitation experiments revealed, that
this inhibition of tumor development went in parallel with a hyperacetylation of p65, a subunit
of NF-κB, which was recently shown to act as a key molecule during the carcinogenesis in
this model. In summary, our results suggest that inhibition of HDAC exerts an anti-inflammat-
ory as well as an anti-proliferative effect in vitro as well as in vivo. Therefore HDAC inhibitors
could be of particular interest in the control of the hyperresponsiveness of mucosal immunity
as seen in inflammatory bowel diseases, where chronic inflammation is linked to an increased
risk for colon cancer.
M1683
Induction of Ho-1 Attenuates Trinitrobenzen Sulfonic Acid-Induced Colitis As
Ho-1 Blocks Intracellular Calcium Mobilization and Inhibits TNF-α-Induced
Nf-κB Activity
Sang Wook Kim, In Hee Kim, Seung Hun Kim, Seung Ok Lee, Soo Teik Lee, Dae Ghon
Kim, Woo Sung Moon, Geom Seog Seo, Suck Chei Choi, Yong Sung Kim, Chang Soo
Choi, Jae Min Oh
Crohn’s disease is characterized by a chronic relapsing inflammation of the bowel in which
proinflammatory cytokines play an important perpetuating role. Heme oxygenage-1 (HO-
1) is the rate-limiting enzyme in heme catabolism, which leads to the generation of carbon
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monoxide (CO), biliverdin, and free iron. HO-1 has been known to show strong immunosup-
pressive properties although its mechanisms are not completely understood. In this study,
it was therefore investigated whether HO-1 has anti-inflammatory properties in vitro and in
vivo. In a mouse model, an HO-1 inducer, cobalt-protoporphyrin IX (CoPPIX) administration
significantly improved the clinical and histopathologic symptoms of trinitrobenzene sulfonic
acid (TNBS) colitis and also notably suppressed the expression of several inflammatory
mediators such as TNF-α, IL-1β and ICAM-1 induced by TNBS. The HO-1 activity inhibitor,
zinc protoporphyrin IX(ZnPPIX) reversed the protective effects of CoPPIX in TNBS colitis.
Pre-treatment of human epithelial HT-29 cells with CoPPIX significantly blocked the I-kBα
degradation by TNF-α or IL-1β. Inhibition of HO-1 activity by ZnPPIX reversed the suppress-
ive effects of CoPPIX on I-kBα degradation by TNF-α or IL-1β as the in vivo study shows.
Calcium chelating agent BAPTA/AM suppressed I-kBα degradation by TNF-α in HT-29
cells. Like ZnPPIX, calcium ionophore A23187 also dose-dependently reversed the suppress-
ive effects of CoPPIX on I-kBα degradation by TNF-α. Calcium channel blockers such as
Verapamil and Flunarizine blocked the effects of ZnPPIX on the suppressive effects of CoPPIX
on I-kBα degradation by TNF-α. Interestingly, the pre-treatment of ZnPPIX increased the
intracellular calcium level in HT-29 cells. Collectively, these results suggest that HO-1 should
exert anti-inflammatory effects by down-regulation of NF-kB activity via intracellular calcium
regulation during the pathogenesis of TNBS-induced colitis.
M1684
Up-Regulation of Anandamide Levels As An Endogenous Mechanism and a
Pharmacological Strategy to Limit Colon Inflammation
Giuseppe D'argenio, Marta Valenti, Giuseppe Scaglione, Vittorio Cosenza, Giovanna
Mazzone, Ilenia Grandone, Lorena Pietrini, Valeria Dargenio, Italo Sorrentini, Vincenzo Di
Marzo
Background. Direct stimulation of cannabinoid CB1 receptors exerts a protective function
in animal model of inflammatory bowel diseases (IBDs). However, it is not known whether
endocannabinoids are up-regulated during IBDs in animals or humans, nor whether pharma-
cological elevation of endocannabinoid levels can be exploited therapeutically in these
disorders. Aim of this study was to addressed these questions. Methods. Colon inflammation
was induced in mice and rats with 2,4-dinitrobenzene- and 2,4,6-trinitrobenzene sulfonic
acids (DNBS and TNBS), respectively. DNBS-treated mice were treated chronically (for 3
or 7 days) with inhibitors of anandamide enzymatic hydrolysis (N-arachidonoyl-serotonin,
AA-5-HT) or reuptake (VDM11), 10 or 5 mg/kg, s.c., or with 5-amino-salicilic acid (5-ASA,
1.4 mg/kg, i.r.). Endocannabinoids (anandamide and 2-arachidonoylglycerol, 2-AG) were
quantified in mouse colon, or in rat colon mucosa and submucosa, and in bioptic samples
from the colon of patients with untreated ulcerative colitis, by liquid chromatography-mass
spectrometry. Results. A strong elevation of anandamide, but not 2-AG, levels was found
in the colon of DNBS-treated mice, in the colon submucosa of TNBS-treated rats, and in
the biopsies of patients with ulcerative colitis. VDM-11 significantly elevated anandamide
levels in the colon of DNBS-treated mice and concomitantly abolished inflammation, whereas
AA-5-HT did not affect endocannabinoid levels and was significantly less efficacious at
attenuating colitis. 5-ASA also increased anandamide levels and abolished colitis. Conclu-
sions. Anandamide is elevated in the inflamed colon of patients with ulcerative colitis, as
well as in animal models of IBDs, to control inflammation, and elevation of its levels with
inhibitors of its cellular reuptake might be used in the treatment of IBDs. Indeed, data
from our laboratories indicate that also during celiac disease and diverticulosis, intestinal
anandamide levels are increased, and that in the former case they are normalized during
remission. Therefore, it is possible to hypothesise for this compound a general protective
role against inflammatory conditions of both the upper and the lower tracts of the intestine.
M1685
Enhanced Anti-Inflammatory Activity of Hydrogen Sulfide Releasing
Derivative of mesalamine in Rodent Models of Colitis Involves Direct
Inhibition of Nf-κB
Stefano Fiorucci, Eleonora Distrutti, Andrea Mencarelli, Barbara Renga, Giuseppe Cirino,
John L. Wallace
Background. Evolving research suggests that hydrogen sulfide (H2S) may exert anti-inflam-
matory activities. We have previously shown that H2S reduces neutrophils-endothelial inter-
actions in acute models of mesenteric inflammation. ATB429 is an H2S -releasing derivative
of mesalamine. Aim. To test the efficacy and immunomodulatory actions of ATB429 in
TNBS and DSS-induced colitis in comparison with mesalamine. Methods. Colitis was induced
by intrarectal administration of 1-2 mg/mouse TNBS in 50% ethanol or 5% DSS in the
drinking water for 7-10 days. Mice were administered 50 or 100 mg/kg mesalamine or 25,
50, 100 mg/kg ATB429 by gavage. Mucosal cytokine content cytokines was assessed by
quantitative (q)RT-PCR. Isolated lamina propria (LP) mononuclear cells composition was
assessed by flow cytometry. Nuclear binding of NF-κB was assessed by electromobility shift
analysis (EMSA). Results. At the dose of 100 mg/kg ATB429, but not mesalamine, protected
against mortality induced by administering mice with 2 mg/mouse TNBS. Mortality rate
was: 30% in TNBS treated mice, 25% in mice administered mesalamine, while no mortality
was observed in animals administered ATB429. When administered from day 1 to day 7 at
the dose of 50 and 100 mg/kg ATB429 was effective in protecting against development of
TNBS- and DSS-induced colitis by all disease endpoints measured: weight loss, inflammation,
disease activity/diarrhoea scores and macroscopic/microscopic scores (p < 0.05). Therapeutic
administration (from day 4 to day 10) of equimolar doses of mesalamine (50 mg/kg) and
ATB429 (100 mg/kg) resulted in a significant reduction (50-60%) of colon inflammatory
scores with ATB429 but not mesalamine (P<0.05 versus TNBS). In the treatment protocol
ATB429, but not mesalamine, attenuated mucosal increases of COX-1, COX-2, iNOS IL-2,
IL-6, IL-12, TNF- α, IFN- γ and RANTES mRNA expression as well as TNF-α protein
induced by TNBS (P<0.05 versus TNBS). Further, ATB429, but not mesalamine, reduced
the accumulation of CD11b+/Gr1+ cells in the lamina propria as measured by flow cytometry.
Using human peripheral blood-derived monocytes we found that ATB429 concentration
dependently inhibits NF-kB translocation and TNF-α release induced by LPS. This effect
was replicated by exposing cells to the H2S -releasing moiety of ATB429. Detectable amount
of H2S were found in supernatant of monocytes exposed to ATB429 but not to mesalamine.
Conclusions .ATB429 prevents and treats DSS- and TNBS-induced colitis in mice. Protection
by ATB429 in TNBS-colitis is associated with inhibition of NF-kB regulated genes.
M1686
Treatment of Murine IBD Via Non-Viral Delivery of NF-KappaB Decoy
Christopher De Vry, Srinivasa Prasad, Laszlo Komuves, Carlos Lorenzana, Christi Parham,
Tina Le, Sarvesh Adda, Jennifer Hoffman, Nicole Kahoud, Radhika Garlapati, Radha
Shyamsundar, Wanda Williamson, Leslie M. McEvoy, Rolf O. Ehrhardt
Many of the currently available therapeutics for IBD, such as steroids, 5-ASA compounds,
and Remicade work through interactions with the nuclear factor-kappa B (NF-kappaB)
pathway. This key transcriptional regulator is utilized by a variety of immune cell types and
signaling cascades involved in the inflammation process and represents a prime target for
drug development. We have developed a fully phosphorothioated Decoy oligonucleotide
with improved stability that specifically binds NF-kappaB and blocks key inflammatory
mediators regulated by this transcription factor without the aid of viral-assisted delivery. In
this preclinical study, we demonstrate that intracolonic administration of NF-kappaB Decoy
results in the focal delivery of Decoy to inflammatory lesions in the colon which leads to
amelioration of disease at the clinical, histological, and molecular levels in established acute
and chronic murine colitis models. Specifically, in the Th1-driven TNBS-induced colitis
model we find that mice receiving NF-kappaB Decoy treatment exhibit a dose-dependent
reduction in disease severity and a more rapid recovery to normal body weight similar to
a clinically-relevant dose of budesonide. This observed clinical efficacy is corroborated by
significant reductions in both colitis pathology and the tissue levels of several pro-inflammat-
ory markers. Rapid restoration of tissue homeostasis is observed in Decoy-treated animals
as evidenced by the re-emergence of functional goblet cells and reduction in muscle cell
proliferation. We also show that NF-kappaB Decoy mitigates disease activity in the Th2-
like oxazolone colitis and epithelial injury-related acute and chronic DSS colitis models
indicating that locally administered NF-kappaB Decoy can effectively treat both Th1 and
Th2 mediated disease. This data supports the potential use of NF-kappaB Decoy as a cross-
functional therapeutic for the treatment of both Crohn’s disease and Ulcerative colitis. Topical
NF-kappaB Decoy is currently in Phase 1/2 clinical trials for atopic dermatitis.
M1687
The Nutrient and Octn Ligand L-Carnitine Induces Remission in Experimental
Models of Crohn’s Disease
Genevieve Fortin, Catherine Collette, Ekaterina Yurchenko, Alexandra-Chloe Villani,
Ihsan Elimrani, Gary Wild, Alain Bitton, Ciriaco Piccirillo, Ernest Seidman, Denis
Franchimont
L-Carnitine (L-C) is consumed in the diet and available as an over-the-counter nutritional
supplement. This compound is a critical factor in the β-oxidation pathway of long chain
fatty acids and is thus essential in mitochondrial metabolism. Additionally, the causative
mutation at the IBD5 locus leading to an increased susceptibility to Crohn’s disease (CD)
was localized to the OCTN gene, which encodes the L-C transporter. We therefore chose
to assess the potential impact of L-C in mouse models of CD and in primary intestinal organ
cultures. Methods: Animal study: TNBS (n=12) and DSS (n=10) colitis were induced in
Balb/c mice and treated IP with 150 mg/kg L-C per day. Drug efficacy was determined by
weight loss, macroscopic score, serum cytokine levels by ELISA, and mucosal cytokine
expression by quantitative real-time PCR. Cytokine secretion (ELISA) and apoptosis (PI/
Annexin V) were assessed in vitro in LPS- and anti-CD3-stimulated splenocytes and purified
(cell sorted) CD4+ lymphocytes. Human study: Intestinal biopsies were taken from healthy
subjects (HS) (n=13) and patients with CD (n=9). OCTN1 and 2 expression were determined
by quantitative real-time PCR. Biopsies were also stimulated with LPS, treated with L-C,
and cytokine production was measured by ELISA. Results: Expression of OCTN1 and 2
were confirmed in mouse and human intestinal mucosa, as well as in mouse CD4+ T cells.
Mouse study There was a significant amelioration of TNBS colitis in L-C-treated mice as
compared to untreated mice in all of the following parameters (p<0.05): body weight (97.5+/-
4.4% vs 85.2+/-5.5% of baseline), Wallace colitis severity score (2.8+/-2.7 vs 8.7+/-3.3),
serum IL-1β (18.5+/-9.3 vs 37.5+/-7.5 pg/ml) and IL-6 (53.5+/-26.8 vs 128.7+/-73.7 pg/
ml), as well as colonic expression of IL-1β and IL-6 (2.7- and 4.8-fold decrease in treated
mice, respectively). L-C was also beneficial in mice with DSS colitis, with a significant
decrease in the expression of IL-1β and of IL-6 by 2.3- and 15.5-fold, respectively. In
vitro experiments demonstrated that L-C significantly inhibited pro-inflammatory cytokine
secretion by LPS-induced mouse splenocytes. Similarly, L-C suppressed IFNγ secretion by
TCR-stimulated CD4+ lymphocytes without affecting cell survival or apoptosis. Human
study: We confirmed the immunosuppressive action of L-C on human intestinal mucosa
as L-C significantly reduced IL-6 secretion in LPS-stimulated intestinal explant cultures.
Conclusion: L-C therapy is effective in treating experimental colitis and suppressing the
production of pro-inflammatory cytokines in vitro. Therefore, L-C could represent a novel
and safe alternative therapeutic strategy in CD.
M1688
TGF-Beta Induced Cd4+Foxp3+ Cells Prevent TH1 Colitis: Role of TGF-Beta
and Exogenous IL-2
Massimo C. Fantini, Christoph Becker, Markus F. Neurath
Background: the imbalance between effectors cells and regulatory T cells contributes to the
development of Inflammatory Bowel Diseases (IBDs). Thymus derived CD4+CD25+ regu-
latory T cells have been shown to mediate an important immunomodulatory effect in the
intestinal mucosa. In addition to these cells, a novel class of regulatory cells characterized
by the expression of the transcription factor FoxP3 has been recently shown to be induced
by the TGF-beta from a population of naïve cells. Aims: The aim of the present work was
to evaluate the in vivo capacity of TGF-beta induced regulatory cells (Ti-Tregs) to suppress
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colitis and analyze the requirements for their function. Methods: In order to investigate the
in vivo immunnoregulatory effect of Ti-Tregs, these cells were challenged in a model of Th1
colitis induced by the adoptive transfer of CD4CD62L+ T cells in SCID immunodeficient
mice. Moreover we have analyzed the role played by IL-2 in the Ti-Tregs expansion and
suppressive capacity. Results: We observed that Ti-Treg cells are able to suppress Th1 colitis
induced by the adaptive transfer of CD4+CD62L+ cells in SCID mice, as determined by
macroscopic, histologic and endoscopic criteria. These cells were able to control the inflam-
matory process acting both on the acquired and innate immunity by preventing CD4+ and
CD11c+ cell accumulation in the lamina propria. Furthermore, we found that neutralization
of IL-2 abrogates the generation of Ti-reg cells and that exogenous IL-2 is able to enhance
survival of these cells. Consistent with the pivotal role of IL-2 in the peripheral generation
of Ti-Treg cells we were able to induce Ti-Tregs cells from a population of CD4+CD25- T
cells isolated from IL-2 deficient mice (IL-2-/-) upon activation with TGF-beta and exogenous
IL-2. Conclusions: We propose a model in which TGF-beta induced regulatory T cells can
be generated at the site of inflammation by both TGF-beta and exogenous IL-2, the latter
provided by ongoing inflammatory immune responses. Once the pathologic immune reaction
has been turned off, such regulatory cells release the immune system from their control by
loosing their regulatory function due to lack of exogenous IL-2. Furthermore, such TGF-
beta induced regulatory T cells emerge as a novel therapy for Th1 mediated chronic intest-
inal inflammation.
M1689
Suppression of DSS-Induced Ulcerative Colitus in Mice By Orally-Available
Inhibitors of Sphingosine Kinase
Lynn W. Maines, Leo Fitzpatrick, Charles D. Smith
We have developed novel, specific, small molecule inhibitors, A2 and A7, of human sphingos-
ine kinase (SK) for the treatment of intestinal inflammation. Sphingosine-1-phosphate (S1P),
produced by SK, is proving to be a critical component in inflammation, making SK an
excellent, novel target for anti-inflammatory drugs. Purpose: Our goals were to investigate
the mechanism of action of SK inhibitors in vitro and evaluate them in acute and chronic
DSS-induced mouse colitis models. Methods: Cellular studies were conducted in rat IEC6
and human endothelial cells. SK activity was determined by mass spectroscopy of S1P levels.
An NFκB reporter cell line (cat no. E1500, Promega) was used. Western analysis looked at
TNFα-induced expression of ICAM, VCAM and E-selectin. ELISA was used to measure
TNFα-induced PGE2 secretion. Acute 6 day (2% DSS) and chronic 35 day (alternating
water and 1.5% DSS 7 day cycles) were used with oral administration of 50 mg/kg A2, A7
and dipentum, carried as a positive control, on days 0-5 for acute and 28-34 for chronic
studies. Colons were excised with the distal third taken for 0 to 40 point scoring histology.
MPO activity, cytokine profile (Cytokine Core Labs, Baltimore, MD) and S1P levels (mass
spectroscopy) were evaluated in the middle third. Results: Cellular SK activity was present
and markedly inhibited by the A2 and A7. NFκB activation by TNFα was suppressed by
SK inhibitors (approximate 40 fold induction of activity reduced to near baseline). TNFα
treatment resulted in marked increased ICAM, VCAM and E-selectin expression that was
clearly attenuated by A2 and A7. TNFα-induced Cox-2 activity, as measured as PGE2 level,
was strongly suppressed by both A2 and A7 (from 30-100%). Both animal models revealed
similar and excellent protection by all 3 compounds as compared to DSS controls. The three
drug-treated groups in both models (representative acute data shown, day 6, W: water only
control) showed significantly reduced DAI’s (W:0.15, DSS:2.80, A2:1.1, A7:1.0, DP:1.4),
histology scores (W:5.7, DSS:24.3, A2:19.0, A7:15.7,DP:13.86), MPO levels (W:12, DSS:
87, A2:41, A7:34, DP: 57 units/g tissue), as well as longer colons (W: 7.25, DSS:5.4, A2:6.5,
A7:6.3, DP:6.30 cm) and a more favorable cytokine panel as measured by TNFα, Il-1β,
IFN-γ, IL-6 and IL-10. Finally, colonic S1P levels were also shown to be reduced (W: 2.4,
DSS:5.3, A2:3.2, A7:1.0, DP:0.7 pM) by the SK inhibitors in the in vivo models, providing
an excellent pharmacodynamic marker for drug activity. Summary/conclusion: These studies
lend evidence that our selective sphingosine kinase inhibitors may prove an effective treatment
in intestinal inflammation.
M1690
Photodynamic Therapy As a Novel Therapeutic Approach for the Treatment of
Crohn’s Disease
Laurent Favre, Dominique Velin, Francois Borle, Daniel Bachmann, Stefan Schreiber,
Hanifa Bouzourene, Hubert van den Bergh, Georges Wagnieres, Christian Felley, Gian
Dorta, Pierre Michetti, Maria-Anna E. Ortner
Background: Photodynamic therapy (PDT) may modify the mucosal immune response and
thus serve as a therapy for Crohn’s disease (CD). Aim: Safety (1) was evaluated in BALB/c
mice. The effect (2) of «low dose» PDT was investigated in a SCID mouse colitis model.
Methods: 1) Delta-aminolevulinic acid (δ-ALA 15mg/kg bodyweight; Medac, Hamburg,
Germany) was orally administered 3 hours before illumination [635 nm; argon dye laser
(Coherent Inc. Santa Clara, USA); cylindrical diffuser (length 20mm, diameter 0.95 mm;
Medlight, Ecublens, Switzerland); energy dose 5 or 10 joules (J)/cm2]. At 74 hours, body
weight, overall wellness, histology, and cytokine expression index (normalized number of
mRNA copies of each manipulated mouse/normalized number of mRNA copies of the
unmanipulated mice) were measured. 2) A single «low dose» PDT (15mg/kg (δ-ALA; 10J/
cm2) was performed in 3 independent experiments. An endoscopic index of colitis (EIC
consisting of ulcers, vascular pattern, granularity, erythema, length involved) was developed,
Mice with moderate (EIC>7) or marked colitis (EIC>10) were randomized to «low dose»
PDT (group A) or no treatment (group B). EIC, cytokine expression indices, weight and
length of the colon and histology were evaluated. Results: 1) «Low dose» PDT neither
induced inflammation, nor mucosal damage, nor changes in body weight or overall wellness
in BALB/c mice. 2) EIC (mean/SEM) improved 1 week after PDT in moderate colitis (group
A: 8.2+0.7 vs. 5.2+0.7; group B 7.4+0.4 vs. 9.0+0.7; p=0.007). Healing occurred already
3 days after PDT in marked colitis (group A: 11+0.6 vs. 6.3+1.1; group B:10.3+0.2 vs.
10.9+1.3, p=0.01). EIC correlated with standard indices of inflammation like reduction of
colon length (correlation coefficient R=0.58; p<0.0001), increase in colon weight (R=0.55,

















indices of IFN-γ (p< 0.05), TNF-α (p<0.05) and IL-10 (p<0.01) were lower than in the
disease control group. EIC correlated with cytokine expression indices of IFN-γ (R=0.77;
p<0.0001), TNF-α (R=0.62; p=0.0033) and IL-10 (R=0.79; p<0.001). Conclusion: «Low
dose» PDT is a promising novel therapeutic approach for the treatment of CD. In a mouse
model it downregulated the proinflammatory immune response and improved colitis. PDT
is the first local treatment that excludes toxic systemic side effects and can therefore easily
be repeated at any time point, if indicated. In our opinion, it is now expedient to evaluate
the effect of «low dose» PDT in patients with CD.
M1691
Ethyl Pyruvate Ameliorates T-Helper-1 (TH1)-Mediated Murine Colitis
Shaival H. Dave, Fengling Li, Richard A. Demarco, Donna B. Stolz, Antonia R. Sepulveda,
Mitchell P. Fink, Michael T. Lotze, Scott E. Plevy
BACKGROUND: Degraded matrix and substances released by necrotic cells, or “damage
associated molecular pattern” (DAMP) molecules, can initiate or perpetuate inflammation.
A prototypical DAMP, high mobility group box 1 (HMGB1), activates innate immune
responses and is elevated in murine chronic colitis. Ethyl pyruvate (EP) has been shown to
inhibit secretion of HMGB1 and other cytokines by immunostimulated macrophages and
improve survival in murine models of endotoxemia, sepsis, and hemorrhagic shock. We
reasoned that EP may be protective in chronic colitis, where pathogenesis also depends on
activation of inflammatory cytokine responses. OBJECTIVES: The current study investigates
the immunomodulatory effects of EP in cultured macrophages and in a murine model of
chronic colitis. METHODS: Murine bone-marrow derived and cell line macrophages were
incubated with EP for 1 hour before stimulating with LPS and IFN-γ. Expression of IL-12
p40 was detected by RT-PCR (4 h) and ELISA (24 h). Nitric oxide (NO) was assessed using
the Greiss reagent. IL-10 deficient (-/-) mice at 10 weeks of age were injected i.p. with EP
(40 mg/kg every other day) for two weeks and compared to a cohort injected with vehicle.
Histological colitis was scored by a pathologist blinded to treatment group. Spontaneous
cytokine production in intestinal explants was assessed by ELISA (mean±SD). Colonic fecal
samples were collected in PBS and analyzed for HMGB1 via a specific ELISA. Values were
normalized to total protein. Expression of HMGB1 and its receptor, RAGE, was determined
in murine intestinal sections by immunohistochemistry. RESULTS: In a concentration-
dependent fashion, EP decreased expression of IL-12 p40 and NO production in cultured
macrophages. IL-10-/- mice treated with EP (n=4) demonstrate amelioration of colitis com-
pared to IL-10-/- mice treated with vehicle (n=6) (colitis score 0.7±0.5 vs. 6.2±2.1). Intestinal
explants of EP-treated mice (n=4) express less IL-12 p40 than explants from vehicle-treated
controls (n=4) (201±106 vs. 621±142 pg/ml). Furthermore, fecal HMGB1 levels were lower
in EP-treated mice (n=4) than vehicle-treated controls (n=4) (18±28 vs. 122±70 ng/mg).
IL-10-/- mice demonstrate increased HMGB1 and decreased RAGE immunoreactivity in
intestinal epithelial cells (IEC). EP-treated IL-10-/- mice demonstrate decreased HMGB1 and
increased RAGE immunostaining. CONCLUSIONS: Anti-inflammatory effects of EP are
mediated in part through inhibiting HMGB1 release and decreased proinflammatory cytokine
expression in macrophages. EP ameliorates established chronic colitis in IL-10-/- mice and
therefore may have therapeutic potential in inflammatory bowel disease.
M1692
A High Sucrose Diet Exacerbates Immune-Mediated Colitis in IL-10 Deficient
Mice
Kang Moon Lee, Byung Ik Jang, R Balfour Sartor
Background: Environmental factors play a significant role in the pathogenesis of inflammatory
bowel disease (IBD). Diet is an important environmental factor that provides luminal antigens,
serves as substrate for bacterial metabolism, and alters commensal microflora. Many epidemi-
ological studies found that increased sugar consumption is associated with IBD. The effect
of fiber intake on disease activity is controversial, but some studies show increased growth
of commensal probiotic bacterial species and production of protective butyrate. This study
evaluated the effect of clinically relevant diets on Th1-mediated experimental colitis. Methods:
Purified control (5% fat from vegetable oils, 3% cellulose, 15% sucrose), high fiber (5% fat,
20% cellulose, 15% sucrose), and high sucrose (5% fat, 3% cellulose, 66% sucrose) isocaloric
diet were given to specific pathogen free (SPF) IL-10-/- mice (susceptible 129SvEv back-
ground, 6/group). Feeding was started at the time of weaning (age ~21 d) and necropsy
was performed at age 12 weeks. Inflammation was quantified by blinded histology scores
(0-4+), spontaneous IL-12p40 secretion by cultured colonic strips, and IFNγ secretion from
mesenteric lymph node cells stimulated with cecal content lysates from SPF mice. Results:
Table 1 and 2 show colonic inflammatory scores and cytokine secretion. Mice on the high
sucrose diet had more severe colitis and higher IL-12p40 and INFγ production compared
to the control diet group. There were no differences between the control and high fiber diet
group. Conclusion: A high sucrose diet enhanced colonic inflammation in IL-10-/- mice.
These results confirm the importance of dietary factors in IBD and suggest an opportunity
for therapeutic manipulation.
Table 1. Histology scores (0-4). Mean (SEM)
* <0.05 vs. control
Table 2. IL-12p40 (pg/0.05 gm colonic tissue) and INFγ production (pg/ml). Mean (SEM).
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* <0.05 vs. control, CL: cecal content lysates
M1693
R-Spondin1, a Novel Intestinotrophic Mitogen, Reduces Acute and Chronic
Colitis in Mice
Jingsong Zhao, Eric Beck, Servando Palencia, Josephine de Vera, Kyung-Ah Kim, Yi Liu,
Pauline Shinkawa, Peter Emtage, Walter Funk
R-Spondin1 (Rspo1) is a novel epithelial mitogen that stimulates the growth of the small
and large intestine. As an intestinotrophic protein, we investigated the therapeutic potential
of Rspo1 in ameliorating dextran sulfate sodium (DSS) and trinitrobenzene sulfonic acid
(TNBS)-induced colitis in mice. Therapeutic administration of Rspo1 reduced body weight
loss, occurrence of diarrhea, and rectal bleeding in a mouse model of DSS-induced colitis.
Histological evaluation revealed that Rspo1 improved mucosal integrity in both villus and/
or crypt compartments in the small intestine and colon in DSS-treated mice. Rspo1 overcame
DSS-induced suppression of crypt epithelial cell proliferation in both the small intestine
and colon in mice, suggesting that Rspo1 attenuates intestinal injury by stimulating crypt
cell growth and mucosal regeneration in DSS-treated mice. Rspo1 significantly reduced DSS-
induced myeloperoxidase (MPO) activity and overproduction of pro-inflammatory cytokines,
including tumor necrosis factor (TNF)-α, interferon-γ, interleukin (IL)-10, and IL-12, in
mouse intestinal tissue, indicating that Rspo1 may down-regulate DSS-induced inflammation
in mouse bowel by preserving the mucosal integrity. Moreover, in a chronic DSS-induced
colitis model in mice comprising multiple cycles of colitis attack and remission, Rspo1
showed a regenerative effect in reducing colitis. Likewise, Rspo1 therapy also alleviated
TNBS-induced interstitial inflammation and mucosal erosion in mouse colon. In addition,
Rspo1 protein was localized to villus epithelium and crypt Paneth cells in mouse small
intestine. Our results demonstrate that Rspo1 may be clinically useful in the therapeutic
treatment of inflammatory bowel disease by stimulating crypt cell growth, accelerating
mucosal regeneration, and restoring intestinal architecture.
M1694
A PPARα Ligand Delays Whereas a PPARδ Ligand Accelerates the Onset of
Inflammatory Bowel Disease in Interleukin 10 Deficient Mice
Jimmy W. Lee, Poonam J. Bajwa, Christian Lytle, Daniel S. Straus
Background and Aims: We demonstrated recently that rosiglitazone, a ligand for peroxisome
proliferator-activated receptor-γ (PPARγ), delayed the onset of spontaneous colitis in the IL-
10 knockout model of inflammatory bowel disease (IBD) [Lytle et al. (2005) Inflam. Bowel
Dis. 11:231-243]. The purpose of the present project was to test the possible therapeutic
activity of the PPARα ligand fenofibrate, and the PPARδ ligand GW0742, in IL-10 knockout
mice, and to determine the cellular distribution of PPARα in the colon. Methods: The effect
of long-term treatment with fenofibrate or GW0742 on progression of spontaneous colitis
in IL-10 knockout mice was evaluated. The cellular distribution of PPARα in the colon was
determined by confocal immunofluorescence microscopy. Results: Treatment with fenofibrate
1) delayed the onset of disease activity, 2) decreased the colonic histopathology score, and
3) decreased the colonic expression of genes encoding the inflammatory cytokines interferon
γ and interleukin 17, in IL-10 knockout mice. The target for fenofibrate, PPARα, was
expressed in crypt and surface epithelial cells of the colon, and treatment of mice with
fenofibrate resulted in decreased electrogenic chloride secretion by isolated colonic epithe-
lium. In contrast to the beneficial effect of fenofibrate, treatment of IL-10 knockout mice
with the PPARδ ligand GW0742 accelerated the onset of IBD in IL-10 knockout mice.
GW0742 inhibited the catalytic activity of cyclooxygenase-1 (COX-1) and was shown by
molecular modeling to fit into the substrate-binding pocket of COX-1. Action as a COX
inhibitor may account for the adverse effect of GW0742 in IL-10 knockout mice. Conclusions:
PPARα is expressed in mucosal epithelial cells, and the PPARα ligand fenofibrate has
preventative activity toward IBD in IL-10 knockout mice. Conversely, the PPARδ ligand
GW0742 has an adverse effect in IL-10 knockout mice, possibly due to its ability to
inhibit cyclooxygenase.
M1695
Pathophysiological Role of the Cholinergic Anti-Inflammatory and Immune
Pathway in Mouse Oxazolone-Induced Ulcerative Colitis Model
Takeshi Yamamoto, Toshihisa Kodama, Naho Utsunomiya, Hirofumi Kuramoto, Makoto
Kadowaki
It is well known that T helper cell type 1 (Th1) immune responses may play an important
role in Crohn’s disease (CD), whereas Th2 responses may be involved in ulcerative colitis
(UC). However, there has been a fewer studies focused on UC than CD, because of the lack
of suitable Th2-mediated experimental colitis models. Epidemiologic reports suggest that
smoking and nicotine may improve the symptoms of UC. The purpose of the present study
was to modify mouse oxazolone (OXZ)-induced colitis model which has been reported as
Th2-mediated colitis model and investigate pathophysiological role of the cholinergic anti-
inflammatory and immune pathway via nicotinic receptors in the modified OXZ colitis.
METHODS: To enhance the immune response to the colonic instillation of the haptenating
agent, OXZ, mouse (BALB/c) was first primed with painting the low concentration of
OXZ on the skin of abdomen on days 0 followed by intrarectal administration of the low
concentration of OXZ on day 7. OXZ colitis was assessed with the disease activity score
(DAS) on weight loss, diarrhea and hemorrhage until day 10. Macroscopic examination of
the colitis with colonic damage score (CDS) was performed, and then the colon was used
for myeloperoxidase (MPO) activity analysis. RESULT: Exposure of the primed mice to
intrarectal OXZ challenge developed a colitis marked by weight loss, hemorrhagic diarrhea,
ulceration, erosion etc. associated with about 13-fold increased MPO activities in the colon.
However, OXZ failed to induce the colitis in C57BL/6 mice which are used for Th1-
mediated disease models. In addition, pretreatment with calcineurin inhibitor to suppress
Th1 responses deteriorated OXZ colitis. Therefore, oxazolone colitis is Th2-mediated and
has similar histologic features to UC. Although oral administration of 5-ASA (100mg/kg)
had no significant therapeutic effect on OXZ colitis, prednisolone (10mg/kg p.o.) significantly
alleviate the disease state. Noteably, the central stimulation of vagus nerves with 2-deoxy-
d-glucose (200mg/kg i.p.) significantly (P<0.05) improved OXZ colitis [DAS: 5.9±1.8 vs
2.3±0.8; CDS: 4.4±1.3 vs 1.5±0.3; MPO: 3562.5±1034.2 vs 1399.0±353.4 units/g wwt (OXZ
colitis control vs mice pretreated with 2-deoxy-d-glucose)]. Furthermore, subcutaneous
administration of nicotine (3.2 mg/kg) significantly (P<0.05) suppressed OXZ colitis [DAS:
10.5±1.6 vs 5.1±1.8; CDS: 7.6±1.3 vs 3.7±1.3; MPO: 5258.6±1466.9 vs 2585.7±234.7
units/g wwt (OXZ colitis control vs mice pretreated with nicotine)]. CONCLUSION: Nicotinic
acetylcholine receptors work on the cholinergic anti-inflammatory and immune pathway to
alleviate Th2-mediated OXZ colitis.
M1696
Sp304, An Analog of Uroguanylin, Ameliorates Inflammation in a Model of
Experimental Colitis
Refaat Hegazi, Fengling Li, Gabriel Calilao, Antonia Sepulveda, Kunwar Shailubhai, Scott
Plevy
Introduction: Guanylyl cyclase C (GC-C) agonists (uroguanylin (UG) and guanylin), regulate
water and ion homeostasis in a variety of tissues and organs, including the gastrointestinal
(GI) tract, via cyclic GMP (cGMP). GC-C and its agonists are expressed by intestinal epithelial
cells (IEC). The cGMP pathway mediates anti-inflammatory effects of cellular molecules such
as nitric oxide and heme oxygenase-1, and therapies that induce cGMP (phosphodiesterase-4
inhibitors) demonstrate efficacy in murine models of IBD. Accordingly, we reasoned that
agonists of GC-C, when orally administered may demonstrate anti-inflammatory effects in
murine IBD. Aim: The present study investigates the immunomodulatory effects of a GC-
C agonist, SP304 (Callisto Pharmaceuticals, Inc., NY) in TNBS-induced murine colitis.
Methods: GC-C, guanylin and UG mRNA expression was studied by RT-PCR in intestinal
tissue from 12-week old IL-10 deficient (-/-) mice. To induce colitis, 0.1 ml of 2.5% tri-
nitro benzene sulfonic acid (TNBS) in 50% ethanol was administered via catheter into the
colonic lumen of 8 week old female in BALB-c mice (day 0). Mice were administered the
GC-C agonist SP304 at 10 (n = 6), 50 μg/day (n = 5) or vehicle PBS for 7 days (n = 8 each)
by oral gavage starting at day 0. On day 7, mice were sacrificed. H&E stained colonic tissue
sections were assessed for colitis by a pathologist blinded to treatment group. Intestinal
explants were cultured for 24 hours and levels of IL-12 p40, IL-12 p70, IL-23 and TNF
protein secretion were measured in culture supernatants by ELISA. Results: GC-C, guanylin
and UG mRNA are expressed in intestinal tissue of IL-10-/- mice. Intestinal guanylin and
UG mRNA expression is induced during interventions in IL-10-/- mice that ameliorate colitis.
In TNBS-induced colitis, histological assessment of colonic tissue demonstrated significant
improvement of the colitis in the SP304-treated mice compared with the vehicle treated
mice (Table). Intestinal explant cultures from SP304 treated mice express less IL-12 p40,
IL-12 p70, IL-23 and TNF than the vehicle treated control group. Conclusions: Histological
improvement in IL-10-/- mice correlates with upregulation of UG and guanylin mRNA.
Treatment with SP304 exhibited anti-inflammatory effects in TNBS-induced colitis in mice.
Importantly, amelioration of colitis was associated with downregulation of proinflammatory
cytokines such as TNF.
*P<0.05
M1697
Lansoprazole, a Proton Pump Inhibitor, Suppresses Induction of TNF-α in
Experimental Colitis in Rats-New Molecular Implication for Therapy for
Intestinal Mucosal Inflammation Beyond Acid Suppression
Tetsuya Tanigawa, Toshio Watanabe, E.J. Sasaki, Masatsugu Shiba, Kazunari Tominaga,
Yasuhiro Fujiwara, Nobuhide Oshitani, Masahiko Nakamura, Kazuhide Higuchi, Tetsuo
Arakawa
Background and Aim: Enteric bacteria play a crucial role in the pathogenesis of inflammatory
bowel diseases which are characterized by leukocytic infiltration and overexpression of
cytokines in intestinal mucosa. Lansoprazole (LAN), a proton pump inhibitor, has been
shown to exert anti-inflammatory effect other than inhibitory effect on acid secretion. We
have previously demonstrated that LAN inhibits development of dextran sodium sulfate
(DSS)-induced experimental colitis in rats. In this study we investigated molecular mechan-
isms underlying preventive effect of LAN on colitis. Methods: Experiment (1) Experimental
colitis was induced in male Wistar rats by administration of 3% DSS solution for 3 days.
The rats were also orally given LAN (30 mg/kg BW) or vehicle from day 1 of experiment
for 3 days. Colonic tissue was subjected to measurement of myeloperoxidase (MPO) activity
(a marker of neutrophil infiltration), assay of mRNA level of tumor necrosis factor-α (TNFα)
by real-time RT-PCR, and double-immunostaining with antibodies against TNFα and mono-
cytes/macrophages. To clarify the uptake sites of LAN in the colonic tissues, 3H-labeled
LAN (0.5 mCi/100g BW) was given through intraaortic catheter and localization of 3H-LAN
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was visualized by autoradiography. Experiment (2) Human promonocytic THP-1 cells were
pretreated with LAN (1~100 μM) and then incubated with lipopolysaccharide (LPS). Produc-
tion of TNFα was determined by ELISA and phosphorylation and degradation of IκBα and
phosphorylation of ERK were evaluated by Western blotting. Results: (1) Administration
of DSS caused inflammation and damage in the colonic mucosa and increased MPO activity
and expression of TNFα mRNA. Treatment with LAN inhibited increase in MPO activity
and overexpression of TNFαmRNA induced by DSS by 70% and 49%, respectively. Double-
immunostaining demonstrated that monocytes/macrophages were main source of TNFα.
The uptake site of 3H-LAN in the normal colon mucosa were few, while in inflamed colonic
mucosa, 3H-LAN was extensively accumulated in inflammatory cells including macrophages
and polymorphonuclear cells. (2) LPS induced production of TNFα, which was inhibited
by pretreatment with LAN. LPS induced phosphorylation and degradation of IκBα and
phosphorylation of ERK within 60 min. LAN inhibited phosphorylation and degradation of
IκBα and phosphorylation of ERK induced by LPS. Conclusion: These results suggest that
LAN suppresses colonic mucosal inflammation induced by DSS via reduction of TNFα
expression in inflammatory cells and this reduction by LAN is due to inhibition of activation
of NFκB and ERK signaling pathways.
M1698
Anti-Inflammation and Repair Induced By Bone Marrow-Derived Mesenchymal
Stem Cells for Dextran Sulfate Sodium-Induced Colitis in Rats
Fumio Tanaka, Kazunari Tominaga, Masahiro Ochi, Tetsuya Tanigawa, E.J. Sasaki,
Masatsugu Shiba, Toshio Watanabe, Yasuhiro Fujiwara, Nobuhide Oshitani, Kazuhide
Higuchi, Tetsuo Arakawa
Background: Bone marrow-derived cells including a small amount of mesenchymal stem
cells (MSCs) had therapeutic effects for clinical human and experimental animal colitis. Its
detailed mechanism(s) may be partly mediated by mucosal regeneration, since MSCs have
potential for differentiation to several parts of cells. But MSCs were thought to have other
functions such as anti-inflammation as well as mucosal regeneration, because anti-inflammat-
ory system is involved in the repair of colitis. We examined the therapeutic efficacy and
anti-inflammatory effects of bone marrow-derived MSCs for dextran sulfate sodium (DSS)-
induced acute colitis in rats. Materials & Methods: Experimental colitis was induced by
orally administration of 0, 1, 2, or 4% DSS in drinking water for 7 days in inbred male
Lewis rats. Bone marrow was extruded from tibias and femurs. Then, its mononuclear cells
were isolated and cultured in low-glucose DMEM containing 10% fetal calf serum for MSCs
outgrowth. On 0, 2, and 4 days after the administration of DSS, MSCs (5 × 106 cells) were
injected via tail vein. We checked the volumes of food and water intake, stool condition,
and body weight everyday. On day 7, total colon was excised and each colonic mRNA
expression of inflammatory cytokines such as TNF-α, IL-1β, IL-10, and COX2 was measured
by real time RT-PCR method. Results: We confirmed the MSC’s characterization by both
the immunostaining for vimentin and α-smooth muscle actin and the cell surface markers
such as CD90, the bone marrow progenitor cell marker, but not CD45, HLA-DR, CD11b,
nor CD31 using flow cytometric technique. Optimal dose of DSS for the rats used was
confirmed at 4% by the assessing for loss of body weight and appetite, bloody fluid stool,
and the shortening of colon length. MSC treatment improved the bloody stool and body
weight loss, and significantly inhibited the shortening of colon length. At the rectum of
MSC-treated rats, expressions of local inflammatory cytokines such as TNF-α and IL-1β
were markedly decreased to about 40 and 15%. Local COX2 expression was also suppressed
to 15%. IL-10, an anti-inflammatory cytokine, expression was also decreased to 25%. At
the distal colon site (slightly oral side of rectum), similar tendency was observed about the
expressions of cytokines in the MSC-treated colons. Conclusion: These findings suggested
that MSC could have the therapeutic efficacy for the experimental colitis via anti-inflammat-
ory functions.
M1699
Induction of Regulatory T Cell Capacities By the Sphingosine-1-Phosphate
Analogue Fty720 in TNBS-Colitis
Carolin Daniel, Nico Sartory, Heinfried H. Radeke, Gerd G. Geisslinger, Juergen M. Stein
Background & Aims: The sphingosine-1-phopshate analogue FTY720 is known to alter
migration and homing of lymphocytes via sphingosine-1-phosphate receptor interactions.
We studied the effect of FTY720 in acute and established trinitrobenzene sulfonic acid
(TNBS)-colitis focused on the induction of regulatory T cell capacities. Methods: A rectal
enema of TNBS [100 mg/kg body weight (BW)] was applied to male Balb/c mice, and
FTY720 [1 or 3 mg/kg] was administered intraperitoneally from day 0-3 or from day 3-5
following the instillation of the haptenating agent. The study is conforming to the Guiding
principles in the care and use of animals and was performed under approval of the ethical
committee of Darmstadt/Germany (F134/03). Colon tissue was analyzed macroscopically
and microscopically, and IL-10, transforming growth factor β (TGFβ) and FoxP3 expression
were determined in colon protein extracts. Results: Treatment with FTY720 reduced the
histopathologic severity of TNBS-colitis abrogating macroscopic and microscopic intestinal
inflammation. Additionally, treatment with FTY720 resulted in a significant induction of
IL-10, TGFβ and FoxP3 (see Table). Conclusion: FTY720 exhibits beneficial prophylactic
as well as therapeutic effects in TNBS-colitis. Moreover, the induction of IL-10, TGFβ and
FoxP3 raised evidence for a tolerance inducing activity also contributing to the beneficial



















a = P<0.05; b = P<0.01; c = P<0.001; n.s. = non significant vs. TNBS-treated mice.
dex. = dexamethasone
M1700
Therapeutic Efficacy of a Recombinant Soluble Interleukin-1 Type II Receptor
(sIL-1RII) in Experimental Crohn’s Disease: A Preclinical Study
Genevieve Fortin, Catherine Collette, Thierry Gustot, Alexandra-Chloe Villani, Andre van
Gossum, Jacques Deviere, Edouard Louis, Alain Bitton, Gary Wild, Denis Franchimont
Auto-inflammation is the fundamental underlying process of chronic relapsing inflammatory
diseases such as Crohn’s disease (CD) and involves an impairment in Interleukin-1β (IL-
1β) processing. NOD2 knock-in mice for CD mutations demonstrate an altered processing
of IL-1β, leading to an overwhelming mucosal production of this pro-inflammatory cytokine.
Therefore, the neutralization of IL-1β is reemerging as a potential therapeutic modality in
CD. We have recently identified sIL1-RII as a top corticosteroid-inducible gene with potent
anti-inflammatory actions. In this study, we examined the regulation of sIL-1RII in CD,
and the therapeutic potential of a recombinant sIL-1RII Fc fusion protein (sIL-1RII/Fc) in
trinitrobenzene sulfonic acid (TNBS) colitis in mice. Methods: Serum and intestinal biopsies
were taken from CD patients (n=50) and healthy subjects (HS) (n=15). sIL-1RII levels were
quantified in serum and biopsy supernatants by ELISA. TNBS colitis was induced in Balb/
c mice and treated with either 2 mg/kg sIL-1RII/Fc (n=12) or the Fc fragment alone (Fc)
(n=9). Drug efficacy was assessed by mortality, the Wallace criteria, myeloperoxidase (MPO)
activity and by measuring cytokine production. Results: Phase 1: Circulating levels of sIL-
1RII were significantly decreased in CD patients in remission (rCD) as compared to those
of healthy subjects (HS) (16007 [9855-25507] vs. 20073 [14537-28505] pg/ml; p<0.05).
This decrease was even more pronounced in active CD (12516 [6270-23996] pg/ml) as
compared to rCD (p<0.05) and HS (p<0.01). sIL-1RII secretion was also lower in CD non-
inflamed (CDnon-inf) (p<0.05) and CD inflamed (CDinf) (p<0.01) mucosa than in healthy
mucosa (HCM). Interestingly, this decrease in sIL-1RII was associated with higher IL-1β
levels in CDinf than in HCM and CDn-inf (p<0.01 and p<0.01 respectively). Phase 2: 5
days after TNBS instillation, sIL-1RII/Fc-treated mice displayed significant (p<0.05) improve-
ments in all criteria, including: a greater percent body weight than Fc-treated (control) mice
(87.4+/-4.4 vs 78.5+/-2.5), fewer mortalities (8% vs 34%), a lower Wallace score (6.3+/-
4.1 vs 12.2+/-1.4), MPO activity index (1.2+/-0.6 vs 2.7+/-0.5), serum IL-6 concentration
(43.9+/-15.3 vs 123.3+/-63.5), and mucosal expression of IL-1β and IL-6 (3.6-fold and 8.4-
fold decrease in treated mice versus controls, respectively). Conclusion: sIL-1RII/Fc appears
to be an effective therapy in experimental CD that could compensate for the relative deficiency
of endogenous sIL-1RII in CD patients.
M1701
Acylcarnitine Reduces the Severity of Murine DSS Colitis
Pascal Muller, Ijaz Qureshi, Ihsan El Imrani, Catherine Collette, Ginette Fortin, Justine
Dassa, Lynda Abed, Luc Oligny, Emile Levy, Serge Dionne, Denis Franchimont, Ernest G.
Seidman
INTRODUCTION: Carnitine is critical to cellular metabolism, including the β-oxidation
of long chain fatty acids in mitochondria. Polymorphisms of the organic cation/carnitine
transporters OCTN1 & 2 (IBD5 locus 5q31) confer susceptibility to IBD. We have previously
demonstrated the presence of OCTN 1 & 2 in intestinal epithelium and shown that acetylcar-
nitine (AC) deficiency aggravates experimental colitis. We thus hypothesized that AC could
improve the severity of colitis. METHODS: We utilized the dextran sulphate sodium (DSS)
colitis model. BALB/c mice were divided into 4 groups of 8: 2 groups were injected (IP)
with AC (100 or 500mg/kg), and 2 groups with saline. Colitis was induced 1 week later
using DSS 4% in the drinking water (1 week) in 3 groups; a 4th control saline group was
given plain water. The murine colitis disease activity index (DAI) was employed to compare
outcomes (comprising % body weight, severity of diarrhea and fecal blood loss). Mice
were then sacrificed and their colons examined macro- and microscopically by pathologists
unaware of treatments. Colonic IL-1b & IL-6 gene expression was determined by quantitative
real time PCR. Short chain acylcarnitine and free radical levels (malondialdehyde, MDA)
were also measured. RESULTS: The only deaths due to DSS colitis occurred in unsupple-
mented mice (3 of 8). Weight loss was reduced in the AC supplemented mice with colitis
(16% & 4% losses in DSS/carnitine 100mg/kg and 500mg/kg groups respectively, vs 24%
in DSS/saline group; p<0.05 & p<0.01, respectively) Overall DAI scores were also significantly
lower in the 2 AC supplemented DSS colitis groups vs the DSS/saline group (total score 9.6
and 7.1 vs. 11.2 respectively; p<0.05 and p<0.01). Mean total histological damage scores
were lowest for the 500mg/kg AC group (14.0 +/- 0.9 SD) compared to the DSS/saline treated
mice (22.8+/- 0.5; p<0.01). MDA levels were significantly higher in the unsupplemented DSS
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colitis animals (p<0.01), whereas tissue AC levels were highest in both AC supplemented
groups. Colonic expression of IL-1b & IL-6 were reduced in AC supplemented animals
(500mg/kg) compared to the non-supplemented DSS colitis group (4.4 and 3.8 fold, respect-
ively). DISCUSSION: AC supplementation effectively reduced the severity of DSS induced
colitis, suggesting a potential novel therapeutic intervention for IBD patients.
M1702
Novel Orally Active α4 Integrin Antagonist, T-728, Attenuates Dextran
Sodium Sulfate-Induced Chronic Colitis in Mice
Ken-Ichi Hayashi, Hiroyuki Meguro, Sunao Hara, Rie Sasaki, Yoko Koga, Meiko
Takeshita, Naoyoshi Yamamoto, Hiroe Hirokawa, Mie Kainoh
BACKGROUND AND AIM: Recruitment of circulating leukocytes into colonic tissue is a
key feature of intestinal inflammation. Alpha4 integrin is expressed in leukocytes and plays
an important role in adhesive interactions between leukocytes and endothelial cells. A
humanized anti-α4 integrin mAb was recently reported to be effective in patients with
Crohn’s disease, and thus orally active α4 integrin antagonists have received much attention
as a potential approach for the treatment of inflammatory bowel disease. In the present
study, we investigated the effects of T-728, a novel orally active α4 integrin antagonist, on
chronic colitis in mice. METHODS: Chronic colitis was induced in female BALB/c mice after
three cycles of dextran sodium sulfate (DSS) application. T-728 (0.1-150 mg/kg) was orally
administered once or twice daily over a 5-day period after the final dose of DSS. The effects
of T-728 on disease activity index (DAI) and histological inflammation score were compared
with those of anti-mouse α4 integrin mAb (10 mg/kg, i.p.). The DAI includes weight loss,
stool consistency and rectal bleeding, and the histological inflammation score considers
crypt damage, intensity of inflammation and extent of inflammation. The effects of T-728
on lymphocyte homing to Peyer’s patches were evaluated 75 min after oral administration
in the chronic colitis model. RESULTS: T-728 at a dose of 0.1 mg/kg or higher improved
DAI and/or histological inflammation score in DSS-induced chronic colitis. The efficacy of
T-728 was comparable to that of anti-α4 integrin mAb. Moreover, T-728 at doses of 0.4,
2 and 10 mg/kg prevented lymphocyte homing. CONCLUSIONS: Oral administration of
T-728 or anti-α4 integrin mAb inhibited chronic colitis in mice. The novel orally active α4
integrin antagonist T-728 may be beneficial for the treatment of patients with inflammatory
bowel disease.
M1703
Attenuation of Mouse DSS Colitis By Naked Hepatocyte Growth Factor Gene
Transfer Into the Liver
Yusuke Kawauchi, Kenji Suzuki, Masaaki Takamura, Satoshi Yamagiwa, Hiroyuki
Yoneyama, Gi Dong Han, Hiroshi Kawachi, Fujio Shimizu, Hitoshi Asakura, Jun-Ichi
Miyazaki, Hiroki Maruyama, Yutaka Aoyagi
Background: Hepatocyte growth factor (HGF) has multiple biological effects on a wide
variety of cells. It modulates intestinal epithelial proliferation and migration, and critically
regulates intestinal wound healing. Aims: To investigate the therapeutic effect of the HGF
gene transfer, we introduced HGF gene into the liver of mice with acute colitis. Methods:
The rat HGF expression plasmid vector, pCAGGS-HGF was injected via the tail vein into
C57BL/6 mice, followed by dosing with sodium dextran sulfate in distilled water. Firstly,
the HGF gene was injected once on day 0. Secondly, the HGF gene was injected on day 0
and again on day 2. In addition we performed the ex vivo organ culture experiments, which
could reveal the direct effect of HGF on immune response in the colon. We analyzed the
expression of mRNA of IFN-γ and IL-10 in the colonic explants of mice with DSS colitis.
Results: Injection of the HGF gene ameliorated colitis with inhibition of both loss of body
weight and shortening of colon length. It protected the colon from epithelial erosions and
cellular infiltration. Expression of mRNAs for IFN-γ, IL18, and TNF-α was reduced in the
colon. In contrast, expression of mRNA for IL-10 was increased. The numbers of BrdU-
positive intestinal epithelial cells were increased, and the numbers of TUNEL-positive apop-
totic cells were decreased. Furthermore, a second injection prolonged the elevation of serum
HGF levels, and ameliorated the symptoms better than a single injection. The empty pCAGGS
plasmid did not ameliorate the acute colitis. The expression of mRNA for IFN- γ was clearly
reduced by the treatment with HGF on explants, whereas expression of mRNA of IL-10
was increased markedly in the ex vivo colon tissue cultured with HGF . Conclusions: HGF
gene transfer attenuated acute colitis by facilitating intestinal wound repair as well as inhibiting
the inflammation. HGF directly regulates the transcription of pro-inflammatory and anti-
inflammatory cytokine in the diseased colonic tissue.These results suggest that HGF gene
therapy could be new therapeutic approach to inflammatory bowel disease.
M1704
Stat5b Promotes Mucosal Tolerance in Crohn’s Disease and Murine Colitis
Xiaonan Han, Bankole Osuntokun, Nancy Benight, Kimberly Loesch, Stuart J. Frank, Lee
A Denson
Background: Current data suggest that Crohn’s disease (CD) is due to an exaggerated adaptive
immune response to the enteric flora, driven by primary defects in the epithelial barrier and
innate immune system. A recent analysis of the global pattern of gene expression in CD
and Ulcerative Colitis colonic biopsies has identified down regulation of the STAT5b.We
have reported that growth hormone(GH)dependent STAT5b activation is reduced in affected
CD colon at diagnosis. However, the mechanism by which a local reduction in STAT5b
activation and expression might promote chronic gut inflammation was not known.We
hypothesized that STAT5b controls susceptibility to colitis by regulating genes involved in
maintaining both the mucosal barrier function and the normal tolerant response to the
enteric flora. Methods: STAT5b, PPARg, NFkB activation and mucosal barrier function were
determined in normal and CD colon, in STAT5b deficient mice with TNBS-induced colitis,
and in mice with colitis due to IL-10 deficiency. The effect of chronic GH administration
on STAT5b activation and disease severity was determined in the two murine models of
colitis. RNA interference was used to knock down STAT5b expression in the T84 colon
epithelial cells (CEC) line and the effect upon TNFa dependent NFkB activation was deter-
mined. Results: GH dependent STAT5b activation and PPARg expression were reduced in
affected CD colon, in both CEC and lamina propria macrophages. Chronic GH administration
activated STAT5b and up regulated PPARg in both normal and inflamed IL-10 deficient
mouse colon, leading to reduced NFkB activation in the inflamed colon. STAT5b deficient
mice exhibited reduced colonic expression of the tight junction proteins (TJPs) ZO-1, ZO-
2, and ZO-3, as well as reduced PPARg nuclear abundance. Occludin serine phosphorylation
was also reduced. This was associated with mucosal edema and increased NFkB activation,
and then more severe weight loss and proximal colitis following TNBS administration.
Chronic GH administration following induction of TNBS colitis enhanced weight gain in
wild type but not STAT5b deficient mice, relative to PBS treated controls. Knock down of
STAT5b expression in T84 cells led to a significant increase in NFkB activation induced by
TNFa. Conclusions: STAT5b activation is impaired in affected colon in CD, and STAT5b
deficiency increases susceptibility to experimental colitis, through down regulation of TJPs
which regulate the mucosal barrier, and PPARg which regulates the response to the enteric
flora. STAT5b activation may therefore represent a novel therapeutic target for restoring
both barrier function and mucosal tolerance in IBD.
M1705
Dependence of Intestinal Granuloma Formation On a Unique F4/80+ Dendritic
Cell Subset
Ken Sugimoto, Atsuhiro Ogawa, Yasuyo Shimomura, Takashi Nagaishi, Emiko Mizoguchi,
Richard S. Blumberg, Atsushi Mizoguchi, Atul K. Bhan
BACKGROUND & AIMS: Granulomas represent localized inflammatory reactions that
are characteristically observed in several inflammatory conditions. In IBD, granulomatous
inflammation specifically develops in CD but not UC. However, the mechanisms leading to
granuloma formation have not been fully defined. Interestingly, the UC-like colitis in TCRα
knockout (TCRαKO) mice changes to a distinct type of colitis characterized by granuloma
formation in the absence of both IL-4 and B cells in TCRαKO mice (αμ4 triple KO mice).
Therefore, this study was designed to define the mechanism of granuloma formation using
αμ4TKO mice. METHODS: Cells from areas of granulomatous inflammation in αμ4TKO
mice were functionally and phenotypically analyzed and also subjected to local cell transfer
studies. RESULTS: Flow cytometric and immunohistochemical analyses found that approx-
imately 20% of cells within granulomas of αμ4TKO mice show immature myeloid dendritic
cell phenotype as indicated by the surface profile (CD11c+CD11b+CD86lowB220-Gr1-CD8α-
). Interestingly, these cells also expressed a macrophage marker, F4/80, but not another
macrophage marker, MOMA1. Functionally, the unique F4/80+ immature myeloid dendritic
(IMD)-like cells were characterized by the presence of phagocytic ability as judged by uptake
of FITC-dextran and by the absence of antigen-presenting ability as judged by mixed
lymphocyte reaction. Of note, the purified F4/80+ CD11c+ cells exhibited fine dendrites, a
specific feature for dendritic cells. The IMD-like cells produced large amounts of IL-23 that
was further upregulated in the presence of ligands of TLR9 (CpG) and TLR7 (loxoribine).
In contrast, this IL-23 production was efficiently inhibited by the presence of IL-4 as well
as intact IgG but not its F(ab)2 fragment. Importantly, local transfer of granuloma-derived
CD11c+ cells induced granuloma formation in the ileocecal junction, liver and kidney of
recipient TCRαKO mice in the absence, but not presence, of IL-4 and B cells. In addition,
continuous administration IL-4 through implanted osmotic pump or repeated i.p. injection
of IgG suppressed the IMD-like cell-mediated granuloma formation in the recipient mice.
CONCLUSION: We have identified a unique CD11c+ dendritic subset that co-expresses
the macrophage marker (F4/80) and induces granuloma formation under intestinal inflam-
matory conditions.
M1707
Transforming Growth Factor-β Signaling and Matrix Metalloproteinase Pattern
in Intestinal Strictures in Crohn’s Disease
Antonio Di Sabatino, Mark Buckley, Karen M. Pickard, Raffaele Morera, Paolo Cazzola,
Gino R. Corazza, Tom T. MacDonald, Sylvia L. Pender
“Background & Aims”: In addition to its crucial role in dampening tissue-damaging immune
responses in the gut, transforming growth factor (TGF)-β has a potent profibrogenic action
that it exerts by inducing fibroblast proliferation, by down-regulating matrix metalloprotein-
ase (MMP) expression and by enhancing tissue inhibitor of matrix metalloproteinases (TIMP)
expression. To elucidate the mechanisms which may underlie intestinal fibrogenesis and
stricture formation in Crohn’s disease (CD), we explored intracellular proteins, whose phos-
phorylation is involved in activating (pSmad2/3) or inhibiting (Smad7) TGF-β signal trans-
duction, and MMP patterns in CD patients. “Methods”: Endoscopic ileal and colonic biopsy
specimens were collected from strictured and non-strictured mucosa of 12 patients affected
by fibrostenosing CD. Biopsies from inflamed mucosa of nine non-fibrostenosing CD patients
and from 11 control subjects were also studied. pSmad2/3, Smad7, MMP-3, MMP-12 and
TIMP-1 were determined by Western Blotting of homogenized tissue samples. Each blot
was stripped and analyzed for Smad3 or β-Actin as an internal loading control. TGF-β
transcripts were analysed by RT-PCR. “Results”: A lower expression of Smad7 was found in
strictured than in non-strictured mucosa in CD patients. As expected, Smad7 was strongly
upregulated in CD inflamed mucosa. pSmad2/3 was significantly higher in strictured than
in non-strictured mucosa. Strictures expressed greater number of TGF-β transcripts than
non-stricures. MMP-3 and MMP-12 were significantly decreased in strictured in comparison
to non-strictured mucosa. High expression of MMP-3 and MMP-12 was found in CD
inflamed lesions. TIMP-1 was significantly higher in strictured that in non-strictured areas.
“Conclusions”: Our findings of decreased Smad7 and increased pSmad2/3 expression in
strictures support the profibrogenic role of TGF-β in CD. The reduced expression of MMP-
3 and MMP-12 together with the increased expression of TIMP-1 in strictured mucosa
suggest that TGF-β may induce intestinal fibrogenesis by changing the balance between
MMP and TIMP expression in CD.
T : 89386$$CH2
05-04-06 23:18:28 Page 353Layout: 89386B : o
A-353 AGA Abstracts
M1708
Cd4+ T Cells Are Regulators in An Hapten Specific Cd8+ T Cell Mediated
Relapsing Colitis in Normal Mice
Stephane Nancey, Sebastien Holvoet, Ivan Graber, Bernard Flourie, Dominique Kaiserlian
Background : We have demonstrated that CD8+, but not CD4+ T cells, were pathogenic in
an antigen-specific model of relapsing colitis in normal mice (Gastroenterology 2005, 128,
T1576 abstract). In this model, mice progressively recover from colitis and a second hapten
challenge is responsible for a relapse of colitis, mimicking the course of CD. Our aim was
to study the role of CD4+ T cells in this colitis model. Materials and Methods: BALB/c mice
previously sensitized by the hapten DNBS developed a relapsing colitis upon each hapten
administration in the colon (challenge) using non inflammatory doses of the hapten. The
role of CD4+ T cells was investigated in BALB/c and C57Bl/6 mice, the former strain being
sensible and the latter resistant to the usual load of the hapten. CD4+ T cell depletion using
i.p. injections of CD4 mAb were performed. CD8+ T cells were isolated from mesenteric
LN (MLN) and spleen and their proliferation and release of IFNg production (ELISA) after
DNBS stimulation were studied. Results :Firstly, using BALB/c mice, we found that in vivo
CD4+ T cell depletion did not affect significantly the severity of colitis after the first hapten
challenge but enhanced its severity after the second challenge with DNBS (increased of body
weight loss and histologic lesions). Secondly, a challenge dose of DNBS unable by itself to
induce colitis in previously sensitized mice resulted in the development of evident signs of
colitis only in CD4+ T cell depleted mice. Thirdly, CD4+ T cells regulated in vitro hapten
specific CD8+ T cell priming in MLN but not in spleen (higher levels of hapten specific
CD8+ T cell proliferation and IFNg production after hapten stimulation in CD4+ T cell
depleted mice). Fourthly, whereas C57Bl/6 strain mice did not develop colitis, the resistance
to colitis was abrogated in Abeta deficient syngeneic mice (MHC class II deficient) that are
characterized by the absence of CD4+ T cells. Conclusion: Altogether these data strongly
suggest that class II restricted CD4+ T cells behave as regulatory cells in the antigen-specific
CD8+ T cell mediated model of relapsing colitis. Their phenotype and the mechanism of
regulation warrant further studies.
M1709
Btnl2, a Butyrophilin/B7-Like Molecule, Is a Negative Costimulatory Molecule
Modulated in Intestinal Inflammation
Heather A. Arnett, Sabine S. Escobar, Eva Gonzalez-Suarez, Alison L. Budelsky, Lori A.
Steffen, Norman Boiani, Ming Zhang, Gerald Siu, Avery W. Brewer, Jo L. Viney
Butyrophilin-like 2 (BTNL2) is a butyrophilin family member with homology to the B7
costimulatory molecules, polymorphisms of which have been recently associated through
genetic analyses to sporadic inclusion body myositis and sarcoidosis. We have characterized
the full structure, expression, and function of BTNL2. Structural analysis of BTNL2 shows
a molecule with an extracellular region containing 2-4 Ig domains, a transmembrane region
and a previously unreported cytoplasmic tail. Unlike other butyrophilin members, BTNL2
lacks the prototypical B30.2 ring domain. Taqman and Northern analysis indicate BTNL2
is predominantly expressed in digestive tract tissues, in particular small intestine and Peyer’s
patches. Immunohistochemistry with BTNL2-specific antibodies further localizes BTNL2 to
epithelia and dendritic cells within these tissues. Despite its homology to the B7 family,
BTNL2 does not bind any of the known B7 family receptors such as CD28, CTLA4, PD1
or ICOS. Because of its localization to the gut and potential role in the immune system,
BTNL2 expression was analyzed in a mouse model of inflammatory bowel disease. BTNL2
is overexpressed during both the asymptomatic and symptomatic phase of the Mdr1a model
of spontaneous colitis. In functional assays, soluble BTNL2-Fc protein inhibits the prolifera-
tion of murine CD4+ T cells from the spleen, mesenteric lymph node, and Peyer’s patch,
suggesting a role for BTNL2 as a negative costimulatory molecule.
M1710
Unfolded Structure of Paneth Cell α-Defensin Disrupts the Microbicidal
Function in Patients with Crohn’s Disease
Atsuo Maemoto, Hiroki Tanabe, Toshifumi Ashida, Yutaka Kohgo, Tokiyoshi Ayabe
Background&Aim: Paneth cells contribute to intestinal innate immunity by sensing bacteria
and secreting microbicidal α-defensins, such as HD5 in human. HD5 is stored as precursor;
pro-HD5 in Paneth cells and cleaved by trypsin at secretion. In Crohn’s disease (CD), the
microbe-epithelia interaction has been suggested to contribute to the pathology. To clarify
the involvement of Paneth cell α-defensins in CD, we investigated processing of α-defensins
and their function in Paneth cells of patients with CD. Methods: Ileal mucosa were obtained
from surgical specimens resected from patients with CD, and normal ileum from patients
with colon cancer under informed consent. Immunohistochemical analyses on tissue speci-
mens were conducted using anti-HD5 antibody. Crude peptides extracted from non-inflamed
ileal mucosa from patients with CD were subjected to MALDI-TOF/MS for pro-HD5. Products
cleaved by trypsin from crude peptides were analyzed by AU-PAGE western blotting against
HD5. Isolated normal crypts or crypts from CD patients were co-cultured ex vivo at 37C
for 30 min with S. typhimurium or E. coli 1,000 CFU/crypt, and supernatants are assayed
for bactericidal activities against defensin-sensitive S. typhimurium. Results: HD5 co-localized
in Paneth cell granules was detected in the ileum of CD patients. Western blot analyses showed
that pro-HD5 peptides from CD patients cleaved by trypsin was degraded, meanwhile, those
from normal controls donated mature HD5. MALDI-TOF/MS confirmed that the structure
of pro-HD5 from CD patients was linear, i.e. tridisulfide array of pro-HD5 was disrupted,
otherwise from controls was folded. We confirmed that the microbicidal activity of the
degraded, linear HD5 was significantly low relative to those of folded. Bactericidal activities
released from isolated crypts from CD patients in response to S. typhimurium or E. coli were
significantly diminished relative to normal controls on a per crypt basis. Conclusion: In
Crohn’s disease, the tertiary structure of Paneth cell α-defensin was not folded and degraded
during precursor processing so that those α-defensins failed to kill bacteria effectively. The


















Negative Regulation of Toll-Like Receptor By C-Type Lectin in Murine TNBS
Colitis
Hideki Iijima, Masahiko Tsujii, Satoshi Egawa, Shinichiro Shinzaki, Shuji Ishii, Takanobu
Irie, Tsutomu Nishida, Masakazu Yasumaru, Yoshimi Kakiuchi, Hiroaki Murata, Tatsuya
Kanto, Shingo Tsuji, Norio Hayashi
Background and Aims Toll-like receptors (TLRs) expressed on the intestinal innate immune
cells play important roles for the initiation of inflammation against luminal pathogens.
Inappropriate regulation of TLRs is suggested to have a role in the pathogenesis of inflammat-
ory bowel disease (IBD). Recently, C-type lectins, e.g., mannose receptor (MR) and Dendritic
Cell-Specific Intercellular Adhesion Molecule-3-Grabbing Nonintegrin (DC-SIGN), have been
shown to downregulate inflammatory cytokines and to induce IL-10 in macrophages and
dendritic cells under TLR4 stimulation. In the present study, we investigated the role of C-
type lectins in the mouse model of IBD. Methods Peritoneal macrophages from C57BL/6
mice were cultured in vitro with lipopolysaccharide (LPS; the lidgand for TLR4) for 24h
and were further cultured with lipoarabinomannan (LAM: the ligand for MR and DC-SIGN)
for 24h. Culture supernatants were collected and were analyzed for TNF-α and IL-10
production. TNBS colitis was induced in C57BL/6 mice (8-10 wks) and expression of MR
and DC-SIGN after the induction of TNBS colitis was analyzed by flow cytometry. These
mice were treated by intraperitoneal administration of LAM every other day started from
one day before TNBS administration. Production of TNF-α and IL-10 from peritoneal
macrophages was analyzed. Mononuclear cells from spleen and colonic lamina propria were
stimulated in vitro with anti-CD3 and anti-CD28 mAb and culture supernatants were analyzed
for IFN-γ and IL-10 production. Results LPS induced TNF-α production from peritoneal
macrophages in vitro and LAM induced significant suppression of TNF-α production and
enhancement of IL-10 production in a dose dependent manner. Expression of DC-SIGN,
but not MR, on macrophages in the peritoneum and colonic lamina propria was upregulated
by the administration of TNBS when compared with the PBS-treated mice. In the TNBS
colitis model, administration of LAM induced IL-10 production from peritoneal macrophages
and splenic mononuclear cells. IFN-γ productions from spleen and colonic lamina propria
were not affected by the treatment of LAM in the TNBS colitis model. Conclusions Ligation
of C-type lectin suppressed the pathway of TLR4 to induce inflammatory TNF-α by LPS.
On the other hand, regulatory IL-10 was induced by the treatment of LAM. Modulation
of TLR4 pathway by C-type lectin can be a new therapeutic candidate of inflammatory
bowel disease.
M1712
Phenotypic and Functional Characterization of Ccr9+ T Lymphocytes in Small
Intestinal Crohn’s Disease (CD)
Qi T. Yu, Masayuki Saruta, Stephan R. Targan, Konstantinos A. Papadakis
Background and Aim: C-C chemokine receptor (CCR)-9 expression characterizes a subset
of T lymphocytes with homing potential to the small intestine (SI). CCR9+ T cells are
increased in the circulation of patients with SI Crohn’s disease (CD) and celiac disease. The
aim of the current study was to analyze the phenotype and cytokine profile of CCR9+ T
cells in mucosal lymphoid tissues in patients with CD. Methods: The phenotype of CCR9+
T cells in mucosal lymphoid tissues, lamina propria (LP) and mesenteric lymph nodes (MLN)
was analyzed by flow cytometry. Analysis of IFN-gamma and IL-10-producing cells was
performed by intracellular cytokine (IC) staining and IFN-gamma was measured by ELISA
in culture supernatants. Results: Phenotypic analysis of T lymphocytes isolated from MLN
draining inflamed CD SB revealed that CCR9+ T lymphocytes express higher levels of
activation makers (CD25, CD69, HLD-DR), co-stimulatory molecules (OX-40, CD40L,
CTLA-4), and chemokines receptors CXCR3 and CCR5, compared to CCR9- T lymphocytes;
indicating that CCR9 expression is acquired on activated T cells in draining MLN in SB CD.
Compared to CCR9+ T cells obtained from MLN draining normal SB, those from SB CD
express higher levels of OX40, CD40L, and HLA-DR, but not CD25 or CD69. Similar
phenotypic differences were observed in CCR9+ T cells isolated from PB of SB CD patients
compared to normal donors. Interestingly, no major phenotypic difference among CCR9+
T cells was observed in LP between normal and inflamed CD SB. Most CCR9+ T cells from
both normal and inflamed CD SB produced IFN-gamma and a low percentage of them
were IL-10-producing cells as assessed by ic staining. However,IFN-gamma production was
significantly higher among CCR9+ T cells isolated from inflamed compared to normal SB
following CD3 or CD2 activation. In addition, priming of CCR9+ T cells with IL-12/IL-18
led to significantly higher level of IFN-gamma production in inflamed compared to normal
SB mucosa. Moreover, the addition of TL1A markedly enhanced (~ 4 fold) IFN-gamma
production from CCR9+ T cells isolated from inflamed compared to normal SB. Conclusions:
CCR9+ T cells represent effector Th1 cells in SB CD since they produce large amount of
IFN-gamma following anti-CD3 or -CD2 as well as IL-12/IL-18 and TL1A stimulation.
Therefore, the use of CCR9 antagonists represents a rational novel treatment for human SB
Crohn’s disease. Supported by a grant from the Broad Medical Research Foundation
M1713
The Frequency of Mucosal Cd4+Cd25High Regulatory T Cells Increases with
Colonic and Systemic Disease Activity in Ulcerative Colitis; Presence of
Functional Colonic Treg Cells
Nathalie Holmen, Anna Lundgren, Samuel Lundin, Ann-Marie Bergin, Anna Rudin,
Henrik Sjovall, Lena Ohman
AIM: The aim of this study was to characterise regional differences in the colonic lamina
propria CD4+CD25high T cell (Treg) population in ulcerative colitis (UC), the relationship
of colonic Treg cell frequency and phenotype to the colonic and systemic disease score of
UC patients, and to investigate the functional properties and the T cell receptor repertoire
of colonic Treg cells. METHOD: Patients with UC in either remission or with active disease
(n=25) were compared to controls (n=11) without gastrointestinal symptoms. Biopsy samples
were taken during colonoscopy and intestinal tissue was also obtained from surgical resections
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of UC patients. The frequency of mucosal and peripheral blood Treg cells was analysed by
flow cytometry. The suppressive effects and cytokine production of mucosal and peripheral
blood Treg cells was compared and determined by co-culture proliferation assays and
cytometric bead array, respectively. Furthermore, the diversity of the T cell receptor Vβ
repertoire of Treg cells was determined by flow cytometry. RESULTS: The frequency of Treg
cells among CD4+ T cells was found to be significantly increased in the ascending colon LP
(lamina propria) as compared to the sigmoid colon LP in healthy control subjects (p<0.05).
This regional difference of colonic Treg cells was however not present in UC patients in
either exacerbation or remission and both UC groups had comparable levels of Treg cells
in right- and left regions of the colon. The frequency of colonic LP Treg cells was positively
correlated to both colonic disease activity score (p<0.03) and the systemic acute phase
protein CRP (p<0.05) in UC patients in exacerbation. Functional studies revealed that the
colonic and peripheral Treg populations from UC patients were equally suppressive, accord-
ing to the ability in reducing the proliferation of activated CD4+ T cells. Co-culture of LP
Treg cells with activated LP T cells also resulted in decreased secretion of IFN-γ and IL-2.
Furthermore, analysis of the T cell receptor Vβ repertoire showed that LP Treg cells in major
reflected peripheral Treg cell receptor use, although the Vβ2 T cell receptor was less frequent
on Treg cells in the colonic mucosa than in the periphery. CONCLUSIONS: Inflammation
in the intestinal mucosa of patients with ulcerative colitis is probably not due to a functionally
impaired or decreased numbers of Treg cells failing to suppress CD4+ T cell activity. On
the contrary, the LP Treg cell frequency increases with colitis severity.
M1714
The Ectonucleotidase CD39 Is a Selective Surface Marker of Regulatory T
Cells and An Immunosuppressive Catalyst
Karen M. Dwyer, Silvia Deaglio, David Friedman, Beat M. Kunzli, Keiichi Enjoji, Terry B.
Strom, Simon C. Robson
Introduction: Multiple mechanisms are involved in regulation of immune responses in
transplanted organs, the liver and intestinal tract. These include active suppression by
regulatory CD4+CD25+ T cells (Treg). Despite several recent advances, there are still no
reliable, specific surface markers of Treg and minimal understanding exists of their cellular
function. Extracellular nucleotides are released at inflammatory sites, bind specific purinergic-
type 2 receptors (P2-R) and trigger activation responses in multiple cell types. Ectonucleotid-
ases hydrolyze these mediators to nucleoside derivatives and the balance of extracellular
nucleotides to nucleosides appears to modulate immune reactions. Aim: To study expression
of CD39/NTPDase1, an ectonucleotidase expressed on immune and vascular cells, on Treg
and determine functional sequelae of this. Methods and Results: We demonstrate that
functional CD39 is expressed by resting and activated Treg and efficiently distinguishes this
functional subset from other T cells. CD39 serves as an integral functional component of
Treg, modulating extra- and pericellular levels of adenosine through the phosphohydrolysis
of nucleotides such as ATP and ADP. The co-ordinated expression of CD39 on Treg and
of the adenosine A2A receptor on activated effector T cells generates an immunosuppressive
loop. Importantly, Cd39 null Treg cells are unable to prevent skin allograft rejection in vivo.
Furthermore, Cd39 null mice spontaneously develop autoimmune manifestations and exhibit
exacerbation of experimental colitis secondary to deviated Th1 responses. Conclusions:
CD39 is a key molecule expressed by Treg and has functional relevance for cellular immunore-
gulation.
M1715
Analysis of NOD2-Mediated Proteome Response to Muramyl-Dipeptide in
HEK293 Cells: Implications for Crohn’s Disease
Philip C. Rosenstiel, Dieter Weichart, Johan Gobom, Gustavsson Niklas, Susanne
Billmann, D.R. Seegert, Stefan Schreiber
Background & Aims: NOD2, a cytosolic receptor for the bacterial proteoglycan fragment
muramyl-dipeptide (MDP), plays an important role in the recognition of intracellular patho-
gens. Variants in the bacterial sensor domain of NOD2 are genetically associated with an
increased risk for the development of Crohn disease, a human chronic inflammatory bowel
disease. To understand the proteomic signature pattern associated with NOD2 dysfunction
in Crohn disease, global protein expression changes after MDP-stimulation were analysed.
Methods: Two-dimensional polyacrylamide gel electrophoresis of total protein extracts of
human cultured 293 cells stably transfected with expression constructs encoding for wildtype
NOD2 (NOD2wt) or the disease-associated NOD2 L1007fsinsC (NOD2SNP13) variant. Differ-
entially regulated proteins were identified by MALDI-TOF MS peptide mass fingerprinting
and MALDI MS/MS. Results were verified in myelomonocytic cells. Gene specific knock-
down to assess the impact of up-regulated genes on NOD2 signalling was performed using
siRNA technology. Results: A complex pro-inflammatory program regulated by NOD2wt that
encompasses a regulation of key genes involved in protein folding, DNA-repair, cellular
redox homeostasis and metabolism was observed both under normal growth conditions and
after stimulation with MDP. The upregulation of Y-Box Factor 1 and Peroxiredoxin4 was
specific for the NOD2wt response and was absent in NOD2SNP13 cells. Using a myelomono-
cytic cellular model, it is demonstrated that Peroxiredoxin 4 is part of a negative feed-back
loop on NOD2-induced NF-κB activation. Conclusions: The comparison of NOD2wt and
disease-associated NOD2SNP13 variant identified a proteomic signature pattern that may
further our understanding of the influence of genetic variations in the NOD2 gene in the
pathophysiology of chronic inflammatory bowel disease. The failure of NOD2SNP13 to induce
Peroxiredoxin 4, a negative regulator of the NF-κB pathway, may contribute to the chronic
intestinal inflammation observed in Crohn disease.
M1716
A Novel Enterohepatic Helicobacter Species Induces Ulcerative Colitis-Like
Intestinal Inflammation with Intraepithelial Neoplasia in Interleukin-10
Knockout Mice
Ulrich R. Bohr, Doerthe Kuester, Steffen Backert, Thomas Wex, Manfred Rohde, Wolfgang
Koenig, Albert Roessner, Peter Malfertheiner
Background & Aims: Interleukin-10 knockout (IL-10 KO) mice are known to develop a
spontaneous intestinal inflammation that resembles Crohn’s disease. However, several studies
showed that initiatiation and perpetuation of intestinal inflammation depends on the presence
of intestinal bacteria. In this study, we investigated if a novel enterohepatic Helicobacter
species (HM-007) is capable to induce intestinal inflammation in IL-10 KO mice. Methods:
C57BL/6J IL-10 KO mice and the corresponding wildtype strain C57BL/6J (WT) were bred
under specific pathogen-free conditions. At the beginning of the experiment, all mice were
tested free of Helicobacter spp. by fecal group-specific PCR. At the age of 12 months, WT
and IL-10 KO mice were exposed to HM-007. These animals as well as uninfected control
WT and IL-10 KO mice were monitored weekly for weight loss and diarrhea, and were
sacrificed 60 days after exposure. The entire gastrointestinal tract was routinely processed
for histopathology, and intestinal inflammation was scored by an established IBD-score.
Results: 83.3% of the Helicobacter-exposed IL-10 KO mice developed colitis compared to
12.5% of the unexposed IL-10 KO mice (p<0.001). None of the unexposed and exposed
WT animals developed IBD (p<0.001). In diseased IL-10 KO mice, intestinal inflammation
was mainly found in the colorectum and was limited to the mucosa. It was characterized
by severe acute and chronic inflammation through widespread infiltration with inflammatory
cells, crypt hyperplasia, distortion of architecture and the presence of ulcers and crypt
abscesses similar to human ulcerative colitis. Furthermore, focal colitis-associated intraepi-
thelial neoplasia was frequently observed in the inflamed distal colorectum. Conclusions:
Colonization of IL-10 KO mice with HM-007, a novel enterohepatic Helicobacter species,
resulted in a unique model of colitis, whose distribution and histological features have
characteristics resembling human ulcerative colitis and that may progress to intraepithelial
neoplasia. Moreover, this study provides strong evidence that the composition of the intestinal
flora decides (I) whether or not a susceptible host develops IBD and (II) whether the
inflammation type is rather Crohn’s disease or ulcerative colitis-like.
M1717
Defective TGF-β and IL-10 Mediated Regulation of Interleukin 12-Stimulated
Cytokine Responses in HLA-B27 Transgenic Rats
Bi-Feng Qian, Susan L. Tonkonogy, Balfour R. Sartor
We have reported that commensal luminal bacterial lysates induce an active in vitro IFN-
β response in mesenteric lymph node (MLN) cells from HLA-B27 transgenic (TG) rats with
chronic colitis but not from non-diseased specific pathogen free (SPF) non-TG, germ free
(GF) TG or non-TG rats. However, equivalent amounts of IL-10 and TGF-β are produced
by the TG and non-TG cell types that make these two cytokines. In this study we examined
IL-12 stimulation of cytokine responses to luminal bacteria and its regulation by suppressive
cytokines in cells from TG and non-TG rats. Methods: Non-TG and TG MLN cells were
collected from SPF or GF rats. Antigen presenting cells (APC) and T lymphocytes were
enriched by negative selection. Cells were stimulated by cecal bacterial lysate (CBL), with
or without exogenous recombinant rat IL-12, in the presence or absence of added TGF-β
or IL-10 for 3 days. IFN-γ and IL-10 in supernatants were quantified by ELISA. The expression
of IL-12p40 mRNA in cells after CBL stimulation for 18 hrs was analyzed by RT-PCR.
Results: CBL induced much higher secretion of IFN-γ in TG than in non-TG MLN cells,
but IL-12 mRNA expression was equal in the two cell types. Addition of exogenous IL-12
elicited a significant increase in the CBL-induced IFN-γ response in SPF TG cells. CBL and
IL-12 synergistically induced IFN-γ from baseline low response in non-TG cells (from both
SPF and GF rats) and in GF TG cells. However, the interactions between proinflammatory
and suppressive cytokines were different in non-TG vs. TG cells. TGF-β fully counteracted
the effect of IL-12 on non-TG cells, almost completely inhibiting IFN-γ production. In
contrast, TG cells were less susceptible to TGF-β-mediated down regulation with a substantial
residual IL-12 induced IFN-γ response. Cell mixing experiments further demonstrated that
response to TGF-β was defective in both TG APC and T cells. Addition of exogenous IL-10
partially inhibited IFN-γ production by non-TG cells but did not affect TG cells. Conversely,
exogenous IL-12 suppressed CBL-induced IL-10 production to a greater degree in TG
compared to non-TG cells. Conclusion: IL-12 enhanced IFN-γ production by MLN cells
from both HLA-B27 TG and non-TG rats in response to in vitro stimulation with intestinal
bacteria. The cells from TG rats that produce IFN-γ in response to IL-12 are defectively
regulated by suppressive IL-10 and TGF-β with a concomitant inhibition of IL-10 production
by IL-12. These results suggest that a self-perpetuating cycle of exacerbated induction and
lack of regulation of T cell responses to commensal bacteria leads to uncontrolled chronic
colonic inflammation in HLA-B27 TG rats.
M1718
Weakening of the Intestinal Epithelial Barrier with NSAIDs Can Lead to IBD
Following Mono-Association with Non-IBD Causing Bacteria
Beate C. Sydora, Sarah M. Martin, Andrea L. Dmytrash, Thomas A. Churchill, Jason
Doyle, Richard N. Fedorak
Background: In the IL-10 gene-deficient mouse development of intestinal inflammation
occurs in conjunction with a defect in epithelial barrier integrity that permits passage of
bacteria, or their antigens, into the lamina propria and thereby initiating a systemic immune
and mucosal inflammatory response. Our mono-association experiments with endogenous
Bacteroides vulgates (B. vulgatus) have shown that this bacterium, or its antigens, can initiate
a systemic immune response but not an intestinal mucosal inflammatory (IBD) response.
Objective: We thus investigated whether pre-weakening of epithelial barrier integrity was
a prerequisite for non-IBD-causing bacteria, such as B. vulgatus, to cause a mucosal inflammat-
ory response. Methods: A sub-optimal dose of indomethacin (2mg/kg/d) causes intestinal
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epithelial barrier disruption without any inflammatory response. Axenic IL-10 gene-deficient
mice were mono-associated by oral gavage with B. vulgatus and were concomitantly fed sub-
optimal doses of indomethacin in the drinking water for 1 wk. At the end of the week
epithelial barrier integrity was determined by mannitol transmural flux and systemic immune
and mucosal inflammatory responses assessed by cytokine profile and histologic injury score.
Results: Treatment with sub-optimal doses of indomethacin (2mg/kg/d for 7 days) alone
caused a disruption of epithelial barrier integrity (mannitol flux of 28±3 nm/cm2/h versus
19±1 nm/cm2/h in untreated controls, respectively, p=0.002) but did not cause a systemic
nor mucosal inflammatory response (no significant increase in IFNγ release in supernatants
of intestinal explant or spleen cell cultures compared with those of untreated controls).
Monoassociation with B. vulgatus alone did not cause epithelial barrier disruption nor a
mucosal inflammatory response despite a systemic immune response. In contrast, monoassoc-
iation with B. vulgates into mice with an indomethacin-induced disruption of epithelial
barrier integrity resulted in an intense mucosal inflammatory (7-fold increase in IFNγ release
from intestinal explants of indomethacin-treated, mono-associated mice compared with those
from untreated control mice) and systemic immune (50-fold increase in IFNγ release from
spleen cells stimulated with B. vulgatus antigens compared to B. vulgatus antigen-stimulated
spleen cells from untreated control mice) response. Conclusion: This study demonstrates,
for the first time, that non-IBD-causing endogenous bacteria are able to cause a marked
intestinal inflammatory response provided that an initial weakening of the epithelial barrier
function has occurred.
M1719
Fractalkine and Its Receptor CX3CR1 Are Upregulated in Inflammatory Bowel
Disease
Taku Kobayashi, Susumu Okamoto, Yuko Iwakami, Atsushi Nakazawa, Tadakazu
Hisamatsu, Toshio Imai, Toshifumi Hibi
Background: Fractalkine is a unique chemokine that mediates not only leukocyte migration
but also adhesion. It has been reported that the interactions of fractalkine and its receptor
CX3CR1 might contribute to the pathogenesis of some inflammatory diseases mainly by
recruiting monocytes to the inflamed sites. We investigated the pathogenic contribution of
fractalkine/CX3CR1 in patients with inflammatory bowel disease(IBD). Methods: CX3CR1
expression on peripheral blood mononuclear cells was examined using flow cytometric
analysis. About CD4+CX3CR1+ cells, expressions of surface antigens were assessed by
flow cytometry. Productions of cytokines and cytotoxic granules were determined by flow
cytometry and enzyme linked immunosorbent assay(ELISA). Fractalkine expressions in
inflamed and non-inflamed tissue were analysed by immunohistochemistry and quantitative
reverse transcription-polymerase chain reaction. Chemotaxis assay was examined using
Transwell system. Additionally, Some patients having expanded CX3CR1+CD4+ cells were
followed up to determine whether the expression of CX3CR1 on CD4+ cells changes in the
course of therapeutic interventions such as granulocyte apheresis, cyclosporine A, or surgery.
Results: CX3CR1-expressing CD4+ and CD8+ cells were expanded in patients with IBD.
Especially, CX3CR1+CD4+ cells were found only in IBD patients, and its percentage was
correlated with disease activity. These unusual CD4 cells expressed natural killer cell markers
such as CD11b, CD56, and CD161. More interestingly, they lacked co-stimulate molecule
CD28, while CX3CR1-negative CD4+ cells always expressed CD28. CD4+CX3CR1+ cells
produced more IFN-γ and TNF-α but less IL-4 and IL-2 compared with CD4+CX3CR1-
cells. It was also confirmed that CD4+CX3CR1+ cells contained and released cytotoxic
granules such as granzyme. Immunohistochemistry revealed that fractalkine was strongly
expressed mainly on epithelial cells in inflamed tissue. Consistently, mRNA expression was
about 4 folds higher in inflamed mucosa of ulcerative colitis(UC) and 6 folds in Crohn’s
disease(CD) than control. Chemotaxis assay showed that fractalkine could work as a chemoat-
tractant for CD4+ cells which express CX3CR1. Furthermore, in some patients, CX3CR1
expression on CD4+ cells slightly decreased after treatment, but had never reached to normal
range. Conclusion: These data suggest that fractalkine/CX3CR1 plays some roles in IBD not
only through monocytes but also unique CD4+ cells found only in IBD patients.
M1720
IgG Plasma Cells in Inflammatory Bowel Disease Express Large Quantities of
Stromelysin (MMP-3)
John N. Gordon, Karen M. Pickard, Patrick M. Goggin, Thomas T. MacDonald
Introduction: In both ulcerative colitis and Crohn’s disease there is a marked increase in
IgG plasma cells in the lamina propria which may be of primary pathogenic significance.
In addition, gut plasma cells can secrete functionally active immune mediators capable of
driving inflammation in the gut. Using a novel method for isolating gut plasma cells we
have previously shown that long-lived IgG plasma cells persist in IBD and may contribute
to tissue injury. In this study we have investigated the production of MMP-3 by gut plasma
cells from normal subjects and patients with IBD. Methods: Biopsy and resection tissue
specimens were obtained from patients with active IBD and from normal controls. Lamina
propria mononuclear cells were isolated and immunomagnetic selection used to positively
select plasma cell populations. MMP-3 expression was investigated using western blotting,
and Taqman PCR. The types of plasma cell making MMP3 were studied by confocal micro-
scopy. Results: Plasma cells from patients with CD and UC expressed significantly higher
levels of MMP-3 protein and transcripts (100,000 fold increase) than controls (p<0.001).
Levels of TIMP-1 were not significantly different from controls. In patients with IBD, 92%
of IgG+ve plasma cells expressed MMP-3 compared with 20% of IgA+ve cells. In contrast very
few plasma cells from controls expressed any MMP-3. Conclusion: We have demonstrated that
plasma cells from subjects with IBD express large amounts of MMP-3. Furthermore the
primary source of MMP-3 is IgG+ve plasma cells. These results identify a new pathway by


















Activated Lymphocytes, Which Are Arrested from Proliferation By 6-
Mercaptopurine, Still Maintain Their Viability and Their Pro-Inflammatory
Effector Functions: A Novel Mechanism for the Delayed Effect of Anti-Purines
in IBD
Shomron . Ben-Horin, Itamar Goldstein, Orit Picard, Zohar Yerushalmi, Ella Fudim, Yifat
Goldschmid, Alon Lang, Simon Bar Meir, Yehuda Chowers
Background: The reason for the slow onset of effect of purine analogues is still unclear, as
the pharmacokinetic based explanation has been challenged by conflicting evidence. The
aim of this study was to explore immune mechanisms possibly responsible for the delayed
onset of effect of these drugs in IBD. Methods: Peripheral blood (PB) lymphocytes from IBD
patients and healthy controls were triggered by anti-CD3 with or without 6-Mercpatopurine
(6-MP) and 6-Thioguanine (6-TG). Proliferation of CD4+ and CD8+ T-cells was determined
by CFSE dilution, and apoptosis induction was examined by Annexin-V/PI assays. Cytokine
secretion was assessed by FACS read-outs of intra-cellular staining and by ELISA assays.
Finally, expression of activation and adhesion molecules was examined by flowcytometry,
and cell-mediated killing of K562 target cells was assessed. Results: 6-MP and 6-TG at
pharmacologically-relevant concentrations abrogated the proliferation of PB CD4+ and CD8+
T-cells by 80% in 3-7 day cultures in controls (n=8) and IBD patients (n=7). However, the
percentage of apoptotic cells was not different between lymphocytes triggered by anti-CD3
in the presence or the absence of 6-TG (10.3±8.3% versus 10±6.4%, respectively), and the
viability of resting lymphocytes was also unaffected. T-cells, arrested from division by 6-
TG, were still equally capable of secreting IFN-gamma and TNF-alpha, as were cells triggered
via the T-cell receptor (TCR) in the absence of the drugs. Anti-CD3 stimulation resulted in up-
regulation of activation and adhesion molecules on CD4+ T-cells, which was only minimally
inhibited by 6-TG and 6-MP, and adhesion to collagen IV and fibronectin was not reduced.
Finally, T-NK cell-mediated killing of target cells was not inhibited by pre-treatment of
effector cells with 6-TG. In contrast, Prednisolone rapidly induced marked apoptosis of T-
cells and effectively inhibited the above lymphocyte effector functions. Conclusions: These
data suggest that T-cells stimulated via the TCR are effectively arrested from expansion by
anti-purine metabolites, but undergo little apoptosis and maintain their immune effector
functions. These cell-cycle arrested lymphocytes, which nevertheless continue to exert their
pro-inflammatory functions and perpetuate tissue inflammation, may constitute a novel
mechanism accounting for the delayed onset of effect of 6-MP and Azathioprine in IBD.
M1722
Atypical Colonic Paneth Cell Metaplasia in Crohn’s Disease with NOD2
Mutations
Jan Wehkamp, Hiu Chu, Bo Shen, Michael Weichenthal, Elke Schaeffeler, Matthias
Schwab, Klaus Fellermann, Eduard F. Stange, Charles L. Bevins
Introduction: Paneth cells (PCs) are epithelial cells located in the crypts of the small intestinal
mucosa and secrete antimicrobial peptides including the α-defensins HD5 and HD6, lyso-
zyme, and sPLA2. PCs also express NOD2, a receptor for muramyl dipeptide and an important
susceptibility gene for Crohn’s disease (CD). In CD of the small intestine, there is a specific
reduction of PC α-defensin expression, and this reduction is more pronounced in specimens
harboring a L1007fs mutation (snp 13) in NOD2. In the presence of inflammation, PCs can
be frequently found outside the small intestine, a process termed PC metaplasia. PC metaplasia
in the colon is common in inflammatory bowel disease (IBD), but further details especially
the impact of NOD2 on this process remain to be elucidated. Methods: Using real-time PCR
and northern blot analysis, the mRNA expression of the 4 aforementioned PC antimicrobial
peptides, anion trypsin as another PC product, and G3PDH were measured in two cohorts
of colonic samples of a total of 65 patients with IBD, and nonIBD controls from both the
colon and small intestine. To assess protein levels, we also performed immunohistochemistry
and western blot analysis of selected products. Inflammation was assessed by histology and
quantitation of IL-8 mRNA levels. All patients were screened for three common NOD2
mutations (SNP8, 12 and 13). Results: In metaplastic Paneth cells of the colon, the levels
of HD5 and HD6 were about a factor of 100-1000 lower than in the small intestine. As
compared to controls, PCs were significantly more often observed in the colon of IBD
patients, especially in areas of inflammation. As compared to ulcerative colitis (UC) samples
and CD specimens with wildtype NOD2, colonic specimens from CD patients with a NOD2
mutation showed a significant decrease of PC defensins HD5 (p=0.001) and HD6 (p=0.001)
mRNA, and HD5 protein levels. Strikingly, in the colonic specimens with a NOD2 mutation,
there were significant decreases of the other PC products anionic trypsin (p=0.002) and
sPLA2 (p= 0.02) mRNA and protein levels. Lysozyme was not altered by NOD2 status
(mRNA and protein levels), but immunohostochemistry revealed that lysozyme was also
found in many inflammatory cells and therefore is not PC cell specific. Conclusions: PC
metaplasia is a common feature of CD and UC. In patients with CD and a mutation in the
NOD2 gene, the colonic expression of a variety of PC products is altered, indicating that
these metaplastic PCs are atypical. This suggests that NOD2 and bacterial recognition may
be an important factor in PC metaplasia.
M1723
Adoptive Transfer of Mature Dendritic Cell Worsens Dextran Sulphate Sodium
(DSS)-Induced Colitis
John Y. Kao, Brad Berndt, Min Zhang, Juanita L. Merchant
Background: Individuals with active inflammatory bowel diseases (IBD) have been shown
to have more activated dendritic cells (DCs). Since antigen presenting cells such as dendritic
cells are important for induction of host immunity against microbial pathogens, we hypothes-
ize that an increased number of mature DCs may worsen colitis severity in IBD. Aims: To
demonstrate the effect of adoptive transfer of mature dendritic cells on DSS-induced colitis.
Methods: Optiprep-enriched, day 6, bone marrow-derived DCs from C57BL/6 mice were
plated in culture with GM-CSF and IL-4 for 3 h and non-adherent DCs were isolated. FACS
analyses for surface MHC class II, CD40, CD80 and CD86 were performed to show expression
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of these co-stimulatory markers on DCs. DCs were stimulated with live H. pylori SS1 for
18 h and IL-12 release was measured by ELISA (BD PharMingen). A mixed leukocyte assay
was performed with naïve syngeneic splenocytes and proliferation was quantified by the
ViaLight Cell Proliferation Kit (Cambrex). For in vivo studies, mice were injected i.p. with
1x106 mature DCs on day -1 and given 5% DSS water from days 0 to 7. Daily stool
hemoccult tests were performed and mice were sacrificed on day 7 and paraffin blocks of
colon prepared in swiss-rolls for H & E staining and histological scoring (Rachmilewitz et
al. 2002). Results: Non-adherent DCs expressed higher levels of MHC class II, CD40, CD80
and CD86 compared to adherent DCs. There non-adherent cells are referred to as mature
DCs. The production of IL-12 and the priming of naïve splenocyte proliferation were higher
by H. pylori-stimulated mature DCs than adherent (e.g., immature) DCs (IL-12: 366.4 pg/
mL vs. 180.3 pg/mL and splenocyte proliferation: 11460 vs. 2100 RLUs, respectively).
Adoptive transfer of mature DCs prior to 5% DSS treatment was associated with a significantly
higher bleeding score (on day 1 post DSS-treatment: 0.63 ±0.18 vs. 0.13+0.13, n=11,
P<0.05), and an increased colitis index (30.4 ± 6.6 vs. 19.8 ± 2.3, P<0.05) compared to
mice receiving PBS prior to 5% DSS treatment. A higher mortality was observed in the
mature DC group than the PBS controls (3/10 or 33% vs. 0/11 or 0%, respectively).
Conclusions: Adoptive transfer of mature DCs prior to initiation of DSS treatment worsened
colitis disease activity. Our study provides further support that mature DCs play an important
role in the pathogenesis of IBD and therapies that target these immune cells may be highly
efficacious in the treatment of IBD.
M1724
Microsomal Triglyceride Transfer Protein Regulates Endogenous and
Exogenous Antigen Presentation By Group 1 Cd1 Molecules
Arthur Kaser, David L. Hava, Masaru Yoshida, Timothy T. Kuo, Takashi Nagaishi,
Stephanie K. Dougan, Bryan Vander Lugt, Wael Haddad, Michael B. Brenner, Richard S.
Blumberg
Background. Lipid antigens are presented to T cells by the non-polymorphic MHC class I-
related CD1 molecules and play an important role in a variety of diseases. This laboratory
recently reported that microsomal triglyceride transfer protein (MTP), which has until then
been known for lipidating apolipoproteins B48 and B100 and generating chylomicrons and
VLDL particles, regulates CD1d function and hence natural killer T (NKT) cell biology.
While CD1d is expressed in humans and rodents, the type I CD1 genes CD1a, CD1b, and
CD1c are only present in humans but not rodents and therefore not accessible for study in
murine in vivo disease models. Aim. We therefore asked whether MTP regulates class I CD1
(CD1a, CD1b, CD1c) antigen presentation, which primarily present microbial lipid antigens,
in particular mycobacterial lipid antigens and are key restriction elements for the host
immune response. Methods & Results. Here we report that MTP regulates the function of
type 1 CD1 molecules CD1a, CD1b, and CD1c. Pharmacological inhibition of MTP in human
monocyte-derived dendritic cells (DC) and the lymphoblastoid B cell line C1R transfected
with type 1 CD1 molecules resulted in a substantial decrease in endogenous antigen pre-
senting function to several CD1-restricted T cell lines. Silencing MTP expression in CD1c-
transfected Hela cells similarly resulted in decreased antigen presentation. Inhibition of
endoplasmic reticulum (ER)-resident MTP decreased presentation of exogenous mycobacter-
ial lipid antigens to CD1a- and CD1c-restricted T cells. Impaired presentation by MTP
inhibition was associated with decreased cell surface staining for type 1 CD1 molecules on
DCs, but not C1R transfectants. The stability of CD1c heavy chain and beta-2-microglobulin
was decreased in inhibitor treated C1R transfectants, suggesting that MTP-mediated lipid
transfer in the ER is essential for proper folding and function of CD1 molecules on the cell
surface and/or that in the absence of initial lipid association in the ER, endosomal lipid
exchange by saposins and GM2 activator proteins might be impaired. Conclusion. Our data
implicate that the immune system has co-opted a key protein of lipid metabolism, MTP,
for its antigen presentation pathways, and via MTP’s regulation of CD1a, b, and c function,
this protein has a key role in the host immune response toward microbial pathogens. This
might have implications for mucosal inflammation in IBD, as CD1a, CD1b, and CD1c
molecules are expressed on dendritic cells in the intestinal mucosa (unpublished observation,
Per Brandtzaeg & RSB). (AK and DLH contributed equally)
M1725
The Constitution and Distribution of Intestinal Bacterial Flora in Patients
with Inflammatory Bowel Disease: Genus Or Species Specific Analysis Based
On 16s rRNA Gene Sequences of Intestinal Bacterial Flora in Human Feces
and Colonic Mucosa
Atsushi Nakazawa, Toshihiko Takada, Takahiro Matsuki, Shoichi Kado, Takashi Asahara,
Koji Nomoto, Ryuichiro Tanaka, Atsushi Sakuraba, Tomoharu Yajima, Nagamu Inoue,
Haruhiko Ogata, Yasushi Iwao, Hiromasa Takaishi, Toshifumi Hibi
Background & Aims: Intestinal flora is thought to play a critical role in the inflammatory
process at the intestinal mucosa of inflammatory bowel disease (IBD). As previously reported,
Bacteroides fragilis group is assumed as one of the cause of IBD. The analysis of intestinal
flora is important for elucidating the pathogenesis of chronic inflammation in IBD, but only
50% of bacteria consisting of intestinal flora can be cultivable by conventional cultivation
techniques. To examine the intestinal flora constitution and distribution in the colon in
IBD patients, we analyzed intestinal flora by fluorescence in situ hybridization (FISH) and
quantitative PCR using 16S rRNA-gene-targeted group specific probes and primers. Methods:
Fecal samples were collected from IBD patients and healthy volunteers. In order to detect
the predominant intestinal bacteria (Bacteroides fragilis group, Bifidobacterium, Clostridium
coccoides group, Clostridium leptum subgroup and Atopobium group) and to analyze the
distribution of these flora in the colon, we newly established multi-color FISH system. FISH
was conducted using 16S rRNA-gene-targeted group-specific probes for the predominant
intestinal bacteria in the feces or on the colonic mucosa. The ratio (%) of each bacterial
cluster shown in the multi-color FISH photographic images were calculated by setting the
DAPI stained bacteria at 100. To confirm the data through the novel FISH system, we
performed previously established quantitative PCR. Results: Using our novel FISH system,
Bacteroides fragilis group was predominantly detected in feces of ulcerative colitis (UC)
patients, while hardly demonstrated on the colonic mucosa. In contrast C. coccoides group
and Bifidobacterium were predominantly demonstrated on the colonic mucosa of UC patients.
Bifidobacterium was mainly located on sigmoid colon (27.0% on sigmoid colon; 6.4% on
ascending colon) and C. coccoides group was predominantly located on ascending colon
(33.8% on ascending colon; 24.3% on sigmoid colon). By quantitative PCR, Bacteroides
fragilis group, C. coccoides group, C. leptum subgroup and Atopobium cluster were decreased
in feces of IBD patients compare to healthy volunteers, similar to the data from FISH.
Conclusion: We established FISH system using group-specific probes based on 16S rRNA
gene sequence. Unexpectedly Bacteroides fragilis group was rarely detected on the colonic
mucosa of UC patients and this data suggested that Bacteroides fragilis group might not
contribute to the pathogenesis of UC. The pathogenesis of IBD could be involved in the
disorder of the intestinal flora constitution, not in specific intestinal bacteria cluster or species.
M1726
Increase Expression of Corticotropin Releasing Factor (CRF) Receptor Type
1(CRF1) On Macrophages in Colonic Mucosa of Patients with Ulcerative
Colitis (UC)
Pu-Qing Yuan, Million Mulugeta, Peter A. Anton, Julie Elliott, Ekaterini Chatzaki, Dimitri
Grigoriadis, Yvette Tache
Background: UC is characterized by a long-standing chronic inflammation of the bowel with
intermittent periods of exacerbation and remission. Its pathogenesis and acute exacerbation
appear to be modulated by various stress (Am J Gastroenterol 2000, 95:1213). CRF and its
related peptide urocortin 1 (Ucn 1) acting on CRF1 and CRF2 receptors are key mediators
of stress response and CRF expression is elevated in the colonic mucosa of UC patients
(Gut 1995,7:544; J Clin Endocrinol Metab 2004 89:5352). The actions of CRF and Ucn 1
on colonic function in experimental animals are mediated by CRF1 receptor (Br J Pharmacol
2004,8:1321). Aims: To examine the local expression and cellular location of CRF1 in
colonic mucosa of healthy subjects (control) and in UC patients in active (UCact) and
remission (UCrem) phases. Methods: Sigmoid colonic biopsies were obtained by colonoscopy
from 6 control subjects, 6 UCrem and 4 UCact patients. The diagnosis of UC was based
on history, clinical examination, endoscopic examination, and pathological findings. CRF1
immunohistochemistry and double immunostaining of CRF1 and ED2(CD163), a marker
for macrophages, were performed on 6-µm paraffin-embedded sections. The number of
CRF1 immunoreactive (IR) positive cells and double labelled cells in lamina propria were
counted in 5 fields from each specimen. The total RNA was extracted from 3 biopsy samples
in each group and cDNA was synthesized and processed for CRF1 real-time quantitative
polymerase chain reaction (PCR) by ABI TaqMan. Data were quantitated using comparative
cycle threshold (Ct) method. Results: CRF1 immunoreactivity was mainly found in scattered
cells of lamina propria and in the cell base of epithelia and crypts of the colonic mucosa.
Compared to the control, the intensity of CRF1 immunoreactivity and the number of CRF1
IR positive cells in the lamina propria were significantly increased in UCact (26±7 vs 7±3/
field in control, p<0.05), particularly in UCrem (35±11 vs 7±3 field in control, p<0.05).
Macrophages labeled by CD163 are dramatically increased in UCact and UCrem and more
than 90% of them were double-labeled by CRF1 and CD163. Real time PCR showed that
CRF1 mRNA level was remarkably increased by 150% in UCrem but not in UCact compared
to the controls. Conclusion: CRF1 is locally synthesized in both lamina propria macrophages
and epithelial cells and significantly increased along with the increased population of macro-
phages in patients with UC, especially in those in remission periods. These findings indicate
that CRF1 receptor may be involve in the mediation of the immune-inflammatory reactions
in colonic mucosa of UC patients. Supported by NIH P50 DK64539.
M1727
Bone Marrow Latently Retaining Colitogenic Cd4+ T Cells May Be a
Pathogenic Reservoir for Lifelong Chronic Colitis
Yasuhiro Nemoto, Takanori Kanai, Shin Makita, Rei Fujii, Ryuichi Okamoto, Teruji
Totsuka, Mamoru Watanabe
Background & Aims: Crohn’s disease (CD) is characterized by chronic intestinal inflamma-
tion. Surgery does not cure CD, and recurrence following surgery is the rule rather than
the exception. There is no correlation between recurrence of the disease and the dissection
of regional mesenteric lymph nodes and spleen. The evidence suggests that other sites might
play a critical role in the recurrence of diseases as reservoirs of colitogenic memory T cells.
Bone marrow (BM) is known to harbor memory T cells, suggesting that this compartment
is a preferential site for migration and/or selective retention of memory T cells. However,
linking BM CD4+ memory T cells with a pathological role in chronic colitis is yet to be
reported. Methods: To investigate the role of BM in consecutive immunopathology in chronic
colitis, we assessed the latent BM CD4+ T cells in colitic SCID mice induced by the adoptive
transfer of CD4+CD45RBhigh T cells. Results: We found that a high number of
CD4+CD44highCD62L-IL-7Rhigh effector-memory T (TEM) cells resided in the BM of the colitic
SCID mice induced by the adoptive transfer of CD4+CD45RBhigh T cells. Colitic BM CD4+
TEM cells divided to a greater extent of colitic lamina propria (LP) CD4+ TEM cells, and
produced large amount of Th1 cytokines. Furthermore, a substantial part of the colitic BM
CD4+ TEM cells expressed integrin a4b7 gut-homing receptors. Importantly, SCID mice
transferred with the colitic BM TEM cells induced colitis to a similar extent of mice transferred
with colitic LP CD4+ T cells. Furthermore, these colitogenic BM CD4+ TEM cells were
preferentially attached to IL-7-producing BM stromal cells, and the accumulation of BM
CD4+ TEM cells was significantly decreased in IL-7-/- x Rag-1-/- recipients reconstituted with
the colitogenic LP CD4+ TEM cells as compared with IL-7+/+ x Rag-1-/- recipients. The BM
CD4+ T cells in IL-7-/- x Rag-1-/- mice expressed lower levels of Bcl-2 and CD69 as compared
with those of IL-7+/+ x Rag-1-/- mice. Conclusions: Collectively, these findings suggest that
the BM latently retaining IL-7-dependent colitogenic CD4+ TEM cells plays a critical role as
a reservoir for persisting lifelong colitis.
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M1728
Acute Gastroenteritis Is Followed By An Increased Risk of Inflammatory
Bowel Disease
Julian Panes, Ana Ruigomez, Luis Alberto Garcia Rodriguez
Bacterial intestinal infections have been implicated as a possible cause of exacerbation
of inflammatory bowel disease (IBD). We explored the relationship between infectious
gastroenteritis (GE) and the occurrence of IBD using data from the General Practice Research
Database. Methods: A cohort of patients aged 20 to 74 who had a first ever episode of acute
gastroenteritis (n=38,187) was identified. From the same source population an age, sex and
calendar time-matched control group free of GE was sampled (n=50,000). Both cohorts
were followed-up during a mean duration of 3.5 years. Results: The estimated incidence
rate of IBD in patients after an episode of GE was 70.9 per 100,000 person-years and 30.3
in the control cohort. The hazard ratio (HR) of IBD was 2.4 (95% CI: 1.7-3.4) in the GE
cohort compared to the control cohort and the excess risk was greater during the first year
after the infective intestinal episode with a HR of 4.0 (95% CI: 2.2-7.3). In patients with
positive stool culture, the pathogens most commonly isolated were Campylobacter, Salmon-
ella and Shigella species. The relative risk of developing Crohn’s disease in the GE cohort
was slightly greater than the one of ulcerative colitis, especially during the first year after
the infective episode (HR = 6.0; 95% CI: 1.7-20.7). A nested case-control analysis after
adjusting for a number of risk factors, including age, sex, calendar time, smoking habits,
appendectomy, and anxiety, produced similar results: The OR of IBD in the GE cohort
compared to the control cohort was 1.9 (95% CI: 1.3-2.7); the OR of UC was 1.8 (95%
CI: 1.1-2.9); and the OR of CD was 2.4 (95% CI: 1.2-4.6). Treatment with antibiotics in
the two weeks after the episode of GE was associated with a higher risk of IBD: HR=2.7
(95% CI: 1.6-4.5). Conclusions: Our results are compatible with the hypothesis that infectious
agents causing an episode of infectious gastroenteritis could play a role in the initiation and/
or exacerbation of inflammatory bowel disease.
M1729
Mixed IBD Families: A Distinct Entity Within IBD
Marie Pierik, Marie Joossens, Liesbet Henckaerts, Sofie Joossens, Karolien Claes, Paul
Rutgeerts, Severine Vermeire
BACKGROUND & AIM: Twenty percent of inflammatory bowel disease (IBD) patients report
a positive familial history. Although there is high concordance for disease type, location and
behavior within families, in some families both ulcerative colitis (UC) and Crohn’s disease
(CD) are present (=mixed families). We were interested in differences in genetic background,
serologic response and phenotypes between patients belonging to mixed families and other
IBD patients. We also studied environmental, genetic and serologic factors that modulated
the development of CD or UC in these families. MATERIALS & METHODS We confirmed
the diagnosis of CD and UC in 33 mixed families. Demographic and clinical characteristics
in these patients were compared to 929 independent IBD patients and 209 controls. All
subjects were genotyped for TLR4 D299G and the 3 CD associated CARD15 variants. Patients
with IBD show antibodies in their serum directed against microbial antigens. ASCA are
directed against the Saccharomyces cerevisiae strain Su1. Anti-Omp against Eschericia coli
outer membrane porin. gASCA and anti-Omp were assessed with ELISA (Glycominds Ltd
and Inova diagnositics inc respectively). RESULTS: CD patients belonging to mixed families
more often had pure colonic disease (27.3% versus 13% p=0.03), and TLR4 variants (28.6%
versus 11.5%, p=0.01) than other familial CD patients. UC patients of mixed families more
often carried mutations in CARD15 compared to sporadic UC patients and compared to
controls (51.7%, 19.3% and 20.6% both p<0.01). More UC patients of mixed families were
female (72.7%) compared to sporadic UC patients (49.7%; p<0.01). Within the mixed
families, active smoking and a positive ASCA were more often associated with a CD phenotype
(p=0.02 and p<0.01 respectively). CONCLUSION: IBD patients belonging to mixed families
behave differently and CD patients from these families more often present with pure colonic
disease whereas UC patients more often carry CARD15 variants. The reason for the divergent
phenotypes in these families is not clear but smoking and ASCA appear important modulating
factors. Furthermore female gender seems to play a role and future studies focusing on
disease modulating genes on the X-chromosome might be interesting.
M1730
Proteomic Analysis Distinctively Separates Crohn’s Disease (CD) and
Ulcerative Colitis (UC)
Uta Berndt, Lars Philipsen, Sebastian Bartsch, Bertram Wiedenmann, Axel Dignass,
Andreas Sturm
BACKGROUND: Although CD and UC share several clinical features, the mechanisms of
tissue injury may differ in each condition. Up to now, most studies have been performed
by analyzing protein lysates or RNA extracted from CD or UC tissue. However, since cellular
function depends upon the protein network environment as a whole, we aimed to explore
changes in the expression, distribution, and association of proteins to predict key proteins
involved in the disease pathways. METHODS: Endoscopic biopsies were taken during
colonscopy from CD, UC, and non-inflamed tissue. After fixation, Multi-Epitope-Ligand-
Kartographie (MELK) immunofluorescence microscopy with 30 different antibodies was
performed. MELK is a novel, highly multiplexed robotic whole-cell imaging technology
which stains the tissue subsequently with more than 30 different FITC-conjugated antibodies
and bleach between every staining step. This technique allows integrating cell biology and
biomathematical tools to simultaneously visualize dozens of proteins in a structurally intact
cell or tissue with the ability to correlate cellular localization of proteins with function.
RESULTS: Performing MelTec’datamining procedure with the significance level of p<0.001
(Student’s t-test) and the search depth of combinations of 5 out of the 30 antibodies, controls
and CD can be differentiated by 899, controls and UC by 1054 and CU from CD by 740
distinct protein combinations including extracellular, cell surface and intracellular target
structures. For example, the number of CD45RA+,Bcl-2+,Caspase3-,Caspase8- and

















control tissue, whereas the amount of CD45RA-,Bcl-2+,Caspase3-,Caspase-8- cells is compar-
ably in controls, CD and UC. Concerning regulatory T cells, the number of cells colocalising
CD4+,CD25+,Caspase3+,Caspase8+ are decreased in CD compared to controls and UC,
explaining a higher expression of CD4+,CD25+ cells in CD than UC or controls tissue. In
contrast, CD4+,CD25-,Caspase3+,Caspase8+ cells are increased in UC compared to control
and CD tissue. Furthermore, CD29+,CD11a+ cells are, compared to controls, comparably
lower in both, CD and UC, indicating a down-regulation of integrin-α and -β bearing cells
in both forms of IBD. CONCLUSION: Analysis of key proteins involved in the pathogenesis
of IBD and in-situ detection of their modification demonstrated for the first time that in
CD and UC tissue apoptosis is executed distinctively within specific T cell populations. Thus,
topological proteomic analysis may help to reveal the pathogenesis of IBD and understand the
markedly different pathogenic events in CD and UC.
M1731
CD2 Deficiency Ameliorates Immunpathology and Improves Immune Defence
in Murine T. Gondii Infection
Nina Pawlowski, Daniela Struck, Katja Grollich, Anja A. Kuehl, Martin Zeitz, Oliver
Liesenfeld, Joerg C. Hoffmann
Introduction: Infection of mice with Toxoplasma gondii (T. gondii) leads to a Th1 mediated
immunopathology of the small intestine. The aim of this study was to characterise the
relevance of CD2 in T. gondii infection with regard to parasite control and relevance for
Th1 mediated immunopathology.Material/Methods: WT (n = 10) and CD2 deficient (CD2-/-
) (n = 16) mice were infected with 100 cysts of T. gondii (ME49) by gavage. On day 7 after
infection 18 mice were killed (10 WT and 8 CD2-/- mice). Necrosis and the number of
parasites per cm ileum were determined. Furthermore, cytokine levels in supernatants of
CD3/CD28 or toxoplasmalysat antigen (TLA) stimulated cells as well as sera were evaluated.
Survival of the 8 remaining CD2 -/- mice were analysed using Kaplan-Meier analysis;
histologic scores, parasite load and cytokine levels were compared by Mann-Whitney U-
test.Results: After oral infection with 100 cysts of T. gondii survival was significantly increased
in CD2 deficient mice (n = 8) as compared to WT mice (n = 7; 23.5 vs. 7.1, p = 0.001).
Histologic examinations 7 days after T. gondii infection showed less loss of weight and
decreased inflammation of the ileum (histologic score: 2.3 vs. 4.3, p = 0.02) of CD2-/-
compared to WT mice. Furthermore, in the ileum of CD2-/- mice the parasite load was
significantly lower than in WT mice (88 ±12 vs. 349 ± 58, p < 0.01). The decrease in
parasite load was paralleled by less production of IFN-g from TLA-stimulated lymphocytes
of mLN (p = 0,039) and lower IFN-g levels in the serum (p = 0,009). Surprisingly, TLA-
stimulated CD2-/- splenocytes induced higher levels of IFN-g (p = 0,021). On the other
hand, IL-6 production by CD3/CD28 or TLA stimulated lymphocytes of mLN of CD2-/-
mice was decreased compared to WT cells (p = 0,011). Discussion: In summary, CD2
deficiency decreases parasite load as well as intestinal immunopathology leading to increased
survival. This is the first example with improved immune surveillance and decreased Th1-
mediated inflammation. Two possible mechanisms are the decreased IFN-g- and IL-6 produc-
tion of mesenteric lymphnode lymphocytes. Further in vitro and in vivo studies are required
in order to investigate the mechanisms behind these findings.
M1732
Constitutively Activated Notch Signaling Suppresses Goblet Cell Phenotype in
Human Intestinal Epithelial Cells
Ryuichi Okamoto, Tetsuya Nakamura, Shigeru Oshima, Kiichiro Tsuchiya, Takanori
Kanai, Mamoru Watanabe
Background & Aims: The intestinal epithelia are a unique tissue in the human body that
continues rapid renewal throughout life. Continuous generation of functional, differentiated
intestinal epithelial cells (IECs) is maintained by intestinal stem cells residing in the lower
part of the crypt. However, precise molecular mechanism how undifferentiated status of
stem and progenitor cells is maintained remains largely unknown. Notch signaling is one of
the signaling pathways that are known to have indispensable role in mammalian development.
Recent studies have shown that Notch signaling also regulates cell fate decision of stem or
progenitor cells in adult tissues such as blood, lung and skin. To determine whether Notch
signaling also regulates cell differentiation within the human intestinal epithelia, we per-
formed both immunohistochemical and cell-based functional assays and analyzed the func-
tional role of Notch signaling in human IECs. Methods: Immunohistochemical analysis using
surgically ressected human intestinal tissues was performed to determine expression and
localization of cleaved Notch1 and Hes1, a known target gene of Notch signaling. Cell-
based functional assays were performed using human IEC-derived cells in which forced
expression of constitutively activated Notch1 could be induced by Tet-on system. Results:
Immunohistochemical examination of human intestinal tissues showed nuclear localization
of cleaved Notch1 and its target gene Hes1 protein in epithelial cells of the crypt region.
Immunohistochemical analysis of Ki-67 expression suggested that Notch1 is activated in
the stem/progenitor cell population in the human intestinal epithelia. Surprisingly, Notch1
was also broadly activated in distorted crypts observed in inflamed regions of ulcerative
colitis patients, where goblet cells are depleted. Induction of constitutively activated Notch1
in LS174T cells significantly up-regulated Hes1 transcription, but reciprocally down-regu-
lated E-box dependent transcription. More over, continuous expression of constitutively
activated Notch1 down-regulated both mRNA and protein expression of MUC2 gene, a gene
specifically expressed in goblet cells, and subsequently reduced mucin production in LS174T
cells. Conclusions: These results not only provide physiological distribution and function
of Notch1 activation in the human intestinal epithelia , but also suggests that constitutively
activated Notch1 in IECs might be involved in the pathogenesis of inflammatory bowel dis-
eases.
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M1733
Central Regulatory Role of the Transcription Factor NFATC2 in Cyclosporine
a Treatment in Ulcerative Colitis
Benno Weigmann, Raja Atreya, Jonas Mudter, Hans A. Lehr, Peter R. Galle, L H.
Glimcher, Markus F. Neurath
Cyclosporine A (CsA) is widely used as a immunosuppressive drug in the treatment of
inflammatory diseases. Various studies showed a therapeutic effect of CsA in the treatment
of steroid-refractory ulcerative colitis (UC). After treatment with CsA an anti-inflammatory
effect was observed, resulting in the induction of rapid remission. However this result could
not be observed in patients with crohn<’>s disease. The aim of our study was to identify
the molecular mechanism through which CsA exerts its therapeutic effect. Biopsies from
patients suffering of UC and Crohn’s disease (CD) were taken and fluorescence-stained with
Anti-Nuclear factor of activated T cells (NFAT) c2 antibodies. Surprisingly a higher expression
of NFATc2 was found in UC and CD tissue compared to control specimen. Furthermore
isolated Lamina propria mononuclear cells (LPMC) from intestinal biopsies of patients with
inflammatory bowel disease were examined regarding their rate of apoptosis induction upon
treatment with CsA for 48 h. Cytometric analysis of annexin V/propidiumiodide staining
revealed a high number of apoptotic cells in UC compared to LPMC’s from CD and control
patients. ELISA of supernatants from cultivated LPMC revealed no significant difference
regarding the production of IL-2, 4 ,5. Significant reduction of the viability of cultivated
CD4+ T cells from NFATc2 deficient mice in comparison to T cells from control mice could
be observed. Due to downregulation of caspase 3 and 9, the induction of apoptosis was
elevated in control mice compared to NFATc2 deficient mice. Moreover, CD4+CD62L+ T
cells from NFATc2 deficient mice and controls were isolated and transferred to RAG-2
deficient mice. In contrast to NFATc2 deficient mice, controls showed a significant loss of
weight. Furthermore histological score and miniendoscopy revealed a significant lower
intestinal inflammation in NFATc2 deficient mice. Our data points out the central regulatory
role of NFATc2 in the pathogenesis of UC. This NFATc2 induced apoptotic pathway is
responsible for the clinical efficacy of CsA in the treatment of acute steroid-refractory
ulcerative colitis.
M1734
Altered Barrier Function Is Associated with Increased Serum Levels of
Lipopolysaccharide and TNF-Alpha in Crohn’s Disease
Vincenza Di Leo, Francesca Lamboglia, Daniela Pizzuti, Renata D'Inca, Sergio Varotto,
Maria G. Vettorato, Giacomo C. Sturniolo
BACKGROUND: Increased intestinal permeability and impaired response to bacterial prod-
ucts are both involved in the pathogenesis of Crohn’s disease (CD). Binding of lipopolysac-
charides (LPS), a component of Gram-negative bacteria, to its specific receptor CD14, leads
to the production and release of proinflammatory cytokines, such as TNF-alpha. Serum
levels of soluble CD14 (sCD14) reflect CD14 activation by LPS. We hypothesized that the
inflammatory response associated with increased intestinal permeability may derive from
abnormal passage of LPS through the gut wall. PATIENTS AND METHODS: Eight-two CD
patients (39 F, 58 in remission) and thirty three healthy volunteers (HV) were studied. We
analysed intestinal barrier function by lactulose/mannitol (L/M) test and in Ussing Chambers,
serum levels of sCD14 and TNF-alpha by ELISA and LPS by LAL chromogenic assay.
Statistical analysis was performed by non parametric tests. RESULTS: Median (25th-75th
percentiles) L/M test was significantly increased in CD patients compared to HV (0,024
(0,013-0,038) vs 0,010 (0,070-0,080); p<0,001). Increased levels of sCD14 (3799 pg/ml
(3163-4833) vs 2929 pg/ml (2603-3640); p<0,05), TNF-alpha (7 pg/ml (4-10) vs 3 pg/ml
(2-4); p<0,001) and LPS (0,28 EU/ml (0,15-0,68) vs 0,06 EU/ml (0,03-0,09); p<0,001)
were found in CD patients vs HV. Altered intestinal barrier function in CD patients was
found in the Ussing chambers study as well. L/M test and LPS levels were significantly
increased in patients with active disease compared to those in remission (L/M 0,037 (0,020-
0,050) vs 0,021 (0,012-0,029; p<0.05) (LPS 0,67 EU/ml (0,20-0,90) vs 0,23 (0,14-0,46);
p<0,05) with a significant correlation between the two parameters (r=0,4, p<0,05) in CD
patients. No significant difference was demonstrated between sCD14 and TNF-alpha levels
in patients with active disease vs patients in remission. CONCLUSION: A primary defect
in barrier function, which allows increased passage of bacterial products into the intestinal
wall, causes sCD14 activation in CD. Active disease, albeit associated with increasing intestinal
permeability and LPS absorption, does not result in further immunological stimulation.
M1735
Clinical Response to Visilizumab in Intravenous Steroid Refractory Ulcerative
Colitis (IVSR-UC) Is Associated with Changes in Cd8+ T Cells
Jacky Woo, Tanny Tsao, Lili Zhang, James Sheridan, Debbie Law, James Lowder, Vladimir
Vexler
Background: Visilizumab (Nuvion®), a humanized low FcR-binding IgG2 anti-CD3 mono-
clonal antibody, is currently being tested for the treatment of IVSR-UC. Visilizumab induces
rapid and transient disappearance of blood T cells. CD8 counts recovered faster than CD4+
counts with CD4/CD8 ratio being inverted post-treatment. In clinical study to date ~60%
of IVSR-UC subjects treated with visilizumab had a clinical response. Clinical responses are
durable and persist long after visilizumab is cleared from the circulation. Clinical response
to visilizumab is hypothesized to be associated with the effect on CD8+ T cells. Aims: To
compare the effects of visilizumab on (1) peripheral and mucosal CD8+ T cells among
clinical responders and non-responders and (2) phenotype and function of CD8+ T cells
in vitro. Methods: In phase I/II dose range-finding study of in IVSR-UC, IV bolus infusions
of visilizumab on day 1 and day 2 were administered at 5, 7.5, 10, or 12.5 mg/kg dose.
Treated subjects with a MTWSI score that dropped below 10, with at least a 3 points decline,
were classified as responders. Absolute numbers of T cells were measured by flow cytometry
(TruCOUNT). In 14 subjects colonic biopsies were collected at baseline and Day 30 and T
cell composition was analysed by immunohistochenistry. Effects of visilizumab in vitro on
the phenotype and function of CD8+ T cells was evaluated in PBMC isolated from healthy
subjects. Results: Of 76 treated subjects evaluated, 51 responded to visilizumab. In responders
CD3+CD8+ (but not CD3+CD4+) counts on Day 30 were significantly higher in the responder
group compared to non-responders. Histological improvement was associated with a reduc-
tion in number of mucosal CD3+ cells and a relative increase in the percentage of CD8+ T
cells. In vitro, visilizumab preferentially expanded CD8+ T cells and resulted in an inverted
CD4/CD8 ratio. Visilizumab-treated CD8+ cells expressed CTLA-4+, a phenotype attributed
to regulatory T cells. Regulatory activity of these cells was confirmed by inhibition of
proliferation and CD25 upregulation of autologous PBMC. Conclusion: In visilizumab-
treated IVSR-UC subjects, clinical response is associated with changes in peripheral and
mucosal CD8+ T cells and visilizumab can induce CD8+ regulatory T cells in vitro. The
induction of regulatory CD8+ T cells may contribute to visilizumab’s observed clinical activity.
M1736
Endothelial Expression of PSGL-1 in Murine Colitis and Sepsis
Thorsten Vowinkel, Katherine C. Wood, Christoph Anthoni, Norbert Senninger, Paul
Kubes, D. Neil Granger, Christian F. Krieglstein
Introduction: P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) are vascular adhesion
molecules that play an important role in leukocyte-endothelial, leukocyte-platelet and plate-
let-endothelial interactions during inflammatory responses. In contrast to P-selectin, little
is known about the endothelial expression of PSGL-1. The aims of the present study were
1) to quantify endothelial PSGL-1 expression in different regional vascular beds and 2) to
determine whether constitutive endothelial PSGL-1 expression is altered in response to
inflammatory stimuli. Methods: The dual radiolabeled monoclonal antibody (mAb) technique
was used to quantify the expression of endothelial PSGL-1 in different vascular beds of
C57Bl/6J mice after 1) intraperitoneal injection of lipopolysaccharide (LPS) or 2) dextran
sulphate sodium (DSS; 3% in drinking water for 7 days) induced colitis. Healthy wild-type
(WT) mice, PSGL-1 knockout (KO) mice and WT mice transplanted with bone marrow
(BM) from PSGL-1 KO mice (deficient in PSGL-1 on circulating blood cells) all served as
controls. Results: Endothelial PSGL-1 expression was detectable in various tissues of untreated
mice and was significantly reduced in almost every organ of PSGL-1 KO mice. Systemic
administration of LPS increased PSGL-1 expression in the vasculatures of the intestines
(small and large), kidneys, and brain as early as four hours. The LPS-induced increase in
PSGL-1 was not associated with neutrophil accumulation since pretreatment with anti-
neutrophil serum did not reduce PSGL-1 expression. However, PSGL-1 expression levels
in BM chimeric mice deficient in PSGL-1 on circulating blood cells were significantly reduced,
suggesting that platelets contribute to some of the PSGL-1 expression detected. Mice with
DSS-induced colitis also exhibited significantly increased PSGL-1 expression in the large
bowel, liver, lung and brain, compared to untreated controls. Conclusions: These findings
suggest that PSGL-1 is constitutively expressed on vascular endothelium, where its expression
is significantly increased in response to inflammatory stimuli such as sepsis and colitis. (DFG
VO 998/1-1, DK65649)
M1737
Reversible Defect of Mitochondrial Thiolase Activity in Ulcerative Colitis
Srikanth Santhanam, Aparna Venkatraman, Balakrishnan S. Ramakrishna
Background: Colonocyte oxidation of butyrate is defective in ulcerative colitis (UC). The
cause of this defect has not been established. Aims: This study aimed to determine whether
the activity of specific colonocyte enzymes involved in butyrate oxidation was defective in
UC. Methods: Rectosigmoid mucosal biopsies were obtained at colonoscopy from 30 patients
with UC and 41 control subjects (colon cancer and irritable bowel syndrome) and stored
at -20 degrees C until analysis. Biopsies were homogenized and the activities of the following
enzymes estimated - thiolase, crotonase, and beta-hydroxyacyl CoA-dehydrogenase. Results:
Mitochondrial thiolase activity was markedly reduced in biopsies from patients with UC
compared to control (Table). This was reversible by addition of mercaptoethanol. In contrast,
activity of crotonase and of beta-hydroxyacyl CoA dehydrogenase were not reduced. Further
studies of mitochondrial thiolase in control biopsies showed that addition of 0.2 mM
hydrogen peroxide reduced enzyme activity to 60 (8) nmol/mg protein (P<0.01), while
addition of 300 μM mercaptoethanol increased enzyme activity to 91 (15) nmol/mg protein.
Conclusions: There is a defect of mitochondrial thiolase activity in UC. Reversal of this
defect by addition of mercaptoethanol suggests that the mechanism may be catalytic site
inactivation by cysteine sulfhydryl oxidation or disulfide formation, a conclusion further
strengthened by the demonstration of reduction in enzyme activity induced by hydrogen
peroxide. Oxygen free radicals generated in mitochondria may be responsible for this defective
enzyme activity which may in turn contribute to impaired butyrate oxidation by colonocytes
in UC.
Activities of enzymes in biopsy homogenates.
Values are mean (SEM) expressed as nmoles/mg protein. *P<0.01 compared to control (t-test).
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M1738
Unstable Fecal Microbiota in Ulcerative Colitis During Remission
Cristina Martinez, Maria Antolin, Javier Santos, Antonio Torrejon, Francesc Casellas,
Natalia Borruel, Francisco Guarner, Juan-Ramon Malagelada
Several studies have identified abnormal characteristics of the fecal microbiota in patients
with clinically active IBD, but whether the changes are causal or secondary to inflammation
remains uncertain. AIM: To investigate the composition and dynamics of the fecal microbiota
in patients with ulcerative colitis (UC) in remission by using a molecular ecology approach
(denaturant gradient gel electrophoresis, DGGE). METHODS: A group of 34 patients with
UC in clinical remission (CAI <4) and on maintenance 5-ASA therapy were recruited. Fecal
samples were collected over a period of one year, at entry (w0) and at months 1, 3, 6, 9
and 12 (m1, m3, m6, m9, and m12). Eight healthy volunteers served as controls. Sixteen
patients who remained in remission during the study period were included in the analysis.
Total DNA was isolated from the fecal samples and used as a template to amplify by PCR
the V6 to V8 variable regions of fecal bacterial 16S rRNA gene. The PCR amplicons were
then separated by DGGE. The gel profiles were compared using the BioNumerics software
package and similarity indices were calculated from densitometric curves using the Pearson
product moment correlation coefficient. RESULTS: The DGGE profiles showed that each
patient harbours a unique microbiota with a low similarity index (SI) between patients
(15±14%, mean ± SD). The diversity of the microbiota estimated by the number of bands
was 17±4 in UC, and 28±5 in healthy controls (p<0.05). Moreover, in UC, but not in
healthy controls, the composition of the microbiota varied notably over time. Thus, similarity
indexes versus w0 were 58±21% at m1, 42±24% at m3, 35±20% at m6, 26±20% at m9
and 23±19% at m12 (all p<0.05 vs w0). In healthy subjects, however, the SI was 77±11%
at 4 months. The SI of the same sample analyzed several times was 97%. CONCLUSIONS:
Molecular analysis of fecal microbiota in patients with inactive UC as compared with healthy
individuals show low bio-diversity and temporal instability. These findings suggest an abnor-
mal susceptibility of the intestinal ecosystem to environmental factors in UC.
M1739
Macrophage Migration Inhibitory Factor (MIF) -173 G/C Polymorphism
Influences Upper Gastrointestinal Tract Involvement in Crohn’s Disease
Julia Dambacher, Zeljka Sisic, Tanja Staudinger, Simone Pfennig, Fabian Schnitzler, Katrin
Hofbauer, Jan-Michel Otte, Julia Seiderer, Cornelia Tillack, Burkhard Goeke, Peter Lohse,
Thomas Ochsenkuehn, Stephan Brand
Background: Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine
which has been shown to be involved in the development of chronic murine colitis. A C
nucleotide at position -173 in the 5’-flanking region of the MIF gene creates a binding site
for the transcription factor activator protein-4 (AP-4). Aims: We analyzed the role of the -
173 G/C single nucleotide polymorphism (SNP) in Crohn’s disease (CD) and its influence
on the CD phenotype. Methods: Using restriction fragment length polymorphism (RFLP)
analysis, genomic DNA from 198 patients with CD and from 159 unrelated controls was
analyzed for the -173 G/C SNP in the MIF gene. Genotype distribution between CD patients
and controls and the association of patients’ genotypes with clinical parameters were statistic-
ally evaluated using Student’s t-test for continuous data and Fisher’s exact test for categorical
data. CD phenotypes were classified according to the Vienna classification of CD (Inflamm
Bowel Dis 2000; 6:8-15). The diagnosis of upper gastrointestinal tract involvement was
based on endoscopic and histologic findings. Results: No difference in the frequency of the -
173 G/C genotypes was observed in CD patients compared to the control group. In the CD
group, 74.2% were G/G wildtype, 22.2% were G/C heterozygous, and 3.5% were C/C
homozygous compared to 67.9%, 28.3%, and 3.7%, respectively, in the control group.
Thirty-one of the 147 wildtype carriers (21.1%), but only one of the 44 G/C heterozygotes
(2.1%) were diagnosed of upper gastrointestinal tract involvement (p=0.002). In contrast,
there was no statistical significant difference between the different genotypes regarding other
disease characteristics such as incidence of stenoses, fistulas, abscesses, surgical procedures,
and the use of immunosuppressive agents. Interestingly, 56.8% of the G/C heterozygotes
were also carriers of at least one common CARD15 mutant (R702W, G908, or 1007fs)
compared to only 37.4% in the wildtype group (p=0.02). However, the observed negative
association of the -173G/C genotype with upper gastrointestinal tract involvement was
independent of the CARD15 genotype. Conclusions: The frequency of the -173 G/C MIF
polymorphism in patients with CD is similar to that observed in the normal population.
Nevertheless, this polymorphism appears to be a factor contributing to a particular CD
phenotype characterized by the lack of upper gastrointestinal tract involvement.
M1740
Low Human β-Defensin 2 Gene Copy Number in Crohn’s Colitis
Hartmut Schmalzl, Elke Schaeffeler, Matthias Schwab, Klaus Fellermann, Daniel Stange,
Bo Shen, Jan Wehkamp, Walter Reinisch, Eduard F. Stange
Background: Defensins are small cationic peptides that are crucial components of innate
immunity possessing a broad spectrum of antimicrobial activity. The human defensin gene
cluster including HBD-2 as well as other beta defensins is one of few with a gene copy
number polymorphism. HBD-2 copy number is known to correlate with HBD-2 expression
in leukocyte cell lines. Beta defensins have been shown to be significantly induced in
macroscopically inflamed colonic biopsy specimens of ulcerative colitis (UC) but less in
Crohn’s disease (CD), suggesting a defective antimicrobial barrier in CD. Aim: We hypothes-
ized that this defective HBD-2 and 3 induction in colonic CD was related to a low HBD-2
gene copy number. Methods: We adopted a TaqMan protocol for the determination of HBD-
2 gene copy number from whole blood. Real-time PCR was performed and quantitative
HBD-2 amplification data were normalized to albumin as an internal reference gene which
was coamplified simultaneously in a single-tube biplex assay. The assay was validated with
a selection of previously genotyped DNA samples containing three, four, five and seven
HBD-2 gene copies.Mucosal HBD-2 mRNA expression was determined and correlated to

















phenotype of CD patients was categorized according to the Vienna classification. Statistical
comparisons were performed with the Mann-Whitney test (two-sided). Results: The four
independent cohorts consisted of 54 CD/38 UC (I), 111 CD/37 UC (II), 85 CD (III, surgical
cohort) and 103 controls (IV). The gene copy number ranged from 2-10 copies per genome
and the median HBD-2 gene copy number was 4 in the control group. Both ulcerative colitis
cohorts (I and II) and ileal CD (I, II and III) had a distribution similar to the control groups
with a median of 4 whereas colonic CD had a median of only 3 copies per genome (colonic
CD vs. control p<0.031). Median for gene copy number was 4 in case of ileal vs. 3 for
colonic CD (p=0.032). The differences between ileal and colonic CD was most pronounced
in the severe surgical cohort III (p<0.008). We confirmed our earlier findings of an enhanced
HBD-2 mRNA expression in active UC. HBD-2 gene copy number was positively related
to mucosal mRNA expression in inflamed specimen.Conclusion: The cohorts showed a
significantly lower HBD-2 gene copy number in colonic CD compared to ileal CD, UC
or controls. This affects mucosal HBD-2 expression as gene copy number translates into
corresponding mRNA. Thus, we postulate that a low HBD-2 gene copy number predisposes
to colonic CD through diminished beta defensins.
M1741
Cytoprotective Role of Multidrug Resistance Associated Protein 1 (MRP1) in
Intestinal Inflammation: Involvement of the Cysteinyl Leukotriene Pathway
Axel Van Steenpaal, Hans Blokzijl, Sara Vander Borght, Lisette I.H. Bok, Louis Libbrecht,
Mariska Geuken, Tania A.D. Roskams, Gerard Dijkstra, Han Moshage, Peter L.M. Jansen,
Klaas Nico Faber
Background: Multidrug Resistance-associated Proteins (MRPs) are known to cause multidrug
resistance in cancer cells. Additionally, they may protect non-malignant cells against inflam-
mation-induced cell damage. Here, we studied the regulation of MRP expression during
intestinal inflammation and the role of MRP1 in protecting the intestinal epithelium (IE)
against cytokine and/or α-Fas-induced cell death. Methods: Inflamed and non-inflamed
colon tissue was obtained from patients with Crohn’s disease (CD) (n=20) or ulcerative
colitis (UC) (n=15). Quantitative RT-PCR and immunohistochemistry were used to analyse
expression of MRP1-6 and MDR1. DLD-1 colon carcinoma cells and stable derivatives
expressing MRP1-GFP were treated with α-Fas or TNF-α. MRP function and leukotriene
C4 synthesis (LTC4; MRP1 substrate) were inhibited by MK571 and AA861, respectively.
Apoptosis was assessed by caspase-3 activity assays and PARP-cleavage Western blotting.
Results: MRP1, but not MRP2-6 or MDR1, was upregulated in inflamed IE from UC and
CD patients, specifically in the crypts.α-Fas- and TNF-α-induced caspase-3 activity and PARP
cleavage in DLD-1 cells was strongly increased in the presence of MK571. Overexpression of
MRP1-GFP resulted in reduced α-Fas and TNF-α-induced caspase-3 activity and/or PARP
cleavage in DLD-1 cells. MK571/α-Fas-induced caspase-3 activity was reduced by AA861
to levels comparable to AA861/α-Fas treatment. Conclusion: The leukotriene transporter
MRP1 appears to be involved in the cytoprotection of intestinal crypt cells during inflamma-
tion. Most likely, it exports proapoptotic compounds from the cysteinyl leukotriene biosyn-
thesis pathway since 1) Inhibition of the leukotriene pathway decreases apoptosis and 2)
LTC4 is a high affinity substrate for MRP1.
M1742
Mdp Induces Apoptosis in Immunocompetent Cells: A Possible Link Between
NOD2/CARD15 Mutations and Crohn’s Disease
Vanessa E. Beynon, Juergen Glas, Alexander Faussner, Rudolf Gruber, Kerstin Maier,
Laurian Tonenchi, Ilona Endres, Matthias Folwaczny, Christian Folwaczny, Helga-Paula
Toeroek
Background: The underlying pathogenetic mechanisms linking CD to mutations in NOD2
have not yet been elucidated. NOD2 mediates NF-κB activation in response to muramyl
dipeptide (MDP), an effect impaired in presence of CD associated mutations. For several
pathogen-associated molecular patterns pro- and also anti-apoptotic effects have been
described. Moreover, members of the NOD family have been shown to induce apoptosis.
To determine the role of NOD2 in apoptosis, herein peripheral blood mononuclear cells
(PBMC) and intestinal biopsies were stimulated with MDP, NOD2 variants were overex-
pressed in transfected cell lines and the effect on apoptosis has been studied. Methods:
PBMC from 5 healthy controls (NOD2 wt) were isolated by gradient centrifugation. Lympho-
cytes and monocytes were further isolated from 4 healthy controls (NOD2 wt) by MACS.
Intestinal biopsies from 2 healthy controls were collected during surveillance endoscopy.
Cells or biopsies were cultured for 8 and 24h in presence of 100μg/ml MDP or medium
alone. The Flp-In T-REx HEK 293 cell line has been stably transfected with wt-NOD2 and
the variants L1007fs, R702W and G908R. NOD2 expression was induced by tetracycline
for 48h. Apoptosis was determined by flow cytometry analysis of annexin V binding popula-
tions and immunohistochemical staining of biopsies for CytoDEATH and Bax. Results: The
percentage of apoptotic PBMC significantly increased in presence of MDP after 8h (13±5%
vs. 17±7%; p<0.05). A similar effect was observed in isolated monocytes after 24h (50±12%
vs. 58±12%; p<0.05). In contrast, lymphocytes did not show an increase of apoptosis. Short-
term culture of intestinal biopsies in presence of MDP resulted in increased CytoDEATH
and Bax positive epithelial cells. Overexpression of wt-NOD2 protein resulted in significant
increase of apoptotic cells compared to parental HEK293 cells (17±10% vs. 31±17%; p<0.05).
In contrast, expression of mutant L1007fs NOD2 protein did not result in increased apoptosis.
For the R702W and G908R variants an intermediate response has been observed. Conclu-
sion: Herein a proapoptotic role of MDP in human PBMC has been demonstrated for the
first time. This effect was absent in isolated lymphocyte populations which suggests a
mediation through monocytic cells. A proapoptotic effect of MDP has also been observed
in intestinal epithelial cells ex vivo. These observations and the described proapoptotic effects
of NOD2 overexpression in transfected cells are compatible with an implication of NOD2
protein in apoptosis. An impairment of this process caused by CD associated variants could
represent an important pathogenetic link between NOD2 mutations and CD.
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Increased Levels of β7 Integrin On T Cells Activated By Colonic Dendritic
Cells (DC) from Ulcerative Colitis Patients: Altered DC Control of T Cell
Homing in Inflammatory Bowel Disease?
Rachael J. Rigby, Ailsa L. Hart, Neil McCarthy, Sabita Islam, Hafid Omar al-Hassi, Stella
C. Knight, Michael A. Kamm, Michael Burke, John Lambert, Andrew J. Stagg
Introduction: Mucosal immune responses are compartmentalized. Studies in the mouse
indicate that gut DC, but not those from non-intestinal sites, condition T cells that they activate
to traffic selectively back to intestinal tissue by upregulating homing markers including α4β7
integrin. Although lymphocyte homing to intestinal tissue is central to the pathogenesis of
human inflammatory bowel disease (IBD), it is not known whether DC condition gut-homing
lymphocytes in Man or whether such imprinting is altered by intestinal disease. Therefore,
we examined the expression of homing markers on human T cells activated by DC from
colon (from healthy controls and ulcerative colitis (UC) patients), blood, skin and respiratory
tract. Methods: Colonic and skin DC were enriched, using metrizamide gradients, from
cells migrating from tissue during overnight culture. Blood DC were similarly enriched after
overnight culture of mononuclear cells. Cells present in induced sputum were the source
of respiratory tract DC. Naïve CD4+ allogeneic peripheral blood T-cells were labelled with
CFSE, and stimulated with DC (at 2% of T cells) for 4 days. Flow-cytometry was used to
measure expression of gut homing (β7 integrin, CCR9) and skin homing (CLA, CCR4)
makers on proliferating (CFSElo) cells. Results: Enriched DC from all tissues were potent
stimulators of allogeneic CD4+ T cells (p<0.001 to p<0.1). Dividing cells expressing β7
integrin, CLA, CCR4 and low levels of CCR9 were detected irrespective of the source of
stimulating DC. A proportion of β7+ dividing cells co-expressed the skin homing markers
CCR4 or CLA; again this pattern of expression was observed for all DC. When compared
with T cells activated by blood DC assessed in parallel, the level of β7 integrin was higher
on T cells activated by DC from healthy colonic tissue (p<0.02). Moreover the level of β7
integrin on T cells activated by DC from non-inflamed colonic tissue of UC patients was
greater than on cells activated by control colonic (p<0.01) or blood (p<0.005) DC. DC from
UC tissue also generated a greater proportion of β7hi cells (p<0.05 versus blood DC).
Conclusions: Human tissue DC induce a broader range of homing markers than do their
murine counterparts suggesting that other factors may contribute to compartmentalization
of mucosal responses in Man. Nonetheless, colonic DC induced higher levels of the intestinal
homing integrin β7 than did blood DC. Increased induction of β7 by colonic DC in UC
supports a role for dysregulated control of homing by DC in IBD.
M1744
Characterization oF Reactive Oxygen Species Production (ROS) and Activity
of Antioxidant Enzymes in Peripheral White Mononuclear Cells (PWMC) from
Patients with Crohn’s Disease (CD) At Onset
Belen Beltran, Pilar Nos, Francisco Dasi, Marisa Iborra, Guillermo Bastida, Marcial
Martinez, Mariam Aguas, Vicente Ortiz, Julio Ponce
Background: CD patients have an increased ROS peripheral leukocyte damage and decreased
plasma antioxidants. However, the ROS directly implicated, their place of production and
the state of enzymatic antioxidant defenses have not been characterized. Mitochondria are
organelles with high capacity of ROS production. Aims: To characterize at onset of CD
disease: 1) The basal and stimulated production of superoxide (O2-), hydrogen peroxide
(H2O2) and nitric oxide (NO) in PWMC. 2) The activity of cellular antioxidant enzymes
(Superoxide dismutase (SOD) and Catalase (CAT)). 3) Their mitochondrial activity. Methods:
Blood samples from healthy subjects (n=15, mean age 32 ± 8 y) and from patients at first
flare of CD (n=17, mean age 36.9 ± 9.2 y) were obtained. PWBC were isolated by Ficoll-
Histopaque sedimentation. O2-, H2O2 and NO production were measured by flow cytometry
after 1 hr incubation with hydroethidine (5 µM), H2DCFDA (20 µM) and DAF (5 mM)
respectively. Production of O2- and H2O2 were stimulated by adding plumbagin (Pb) (2.5
mM) and t-butyl-hydroperoxyde (Tb) (10 mM) respectively. SOD and CAT activity were
measured spectrophotometrically by enzymatic assays. Mitochondrial activity was measured
by searching the mitochondrial membrane potential (ym) after incubation (1h) of cells with
TMRM (0.5 mM). Results: C Reactive Protein (CRP) levels were: controls (2.7 ± 0.7) and
CD (63.67 ± 21). Basal and stimulated O2- and H2O2 production are shown in the table.
NO production was lower in CD (113 ± 22 FU) than in controls (167 ± 20 FU, p=0.02).
SOD activity was significantly increased in CD (2.1 ± 0.3 U/mg vs 0.97 ± 0.1 U/mg in
controls; p< 0.001)) whereas CAT activity was significantly inhibited (14.9 ± 4 U/mg in CD
vs 35.5 ± 4 U/ mg in controls, p<0.01). ym was inhibited in CD patients (25.4 ± 1.4 vs 14
± 1.1 in controls, p< 0.001). There was a significant negative correlation between ym
inhibition and CRP (Rho Spearman -0.778). Conclusions: PWMC from CD patients have
an increased production of H2O2. The increased SOD activity prevents O2- damage, however
its H2O2 yield cannot be completely cleared. CAT inhibition facilitates oxidative stress. The
inhibition of ym shows impaired mitochondrial activity in CD which usually facilitates O2-
production. This inhibition does not depend on NO blocking the respiratory chain, as NO
is diminished in PWMC of CD patients.
Reactive Oxygen Species (RFU +/- SEM)
(* p-value: [O2-] vs [O2- + Pb] † p-value: [H2O2] vs [H2O2+ Tb])
M1745
Increased Serum Levels of Anti-Tissue Transglutaminase Antibodies in
Patients with Ulcerative Colitis
Helga P. Torok, Laurian Tonenchi, Juergen Glas, Rudolf Gruber, Molla T. Yirsaw, Daniel
Schneider, Vanessa Beynon, Sebastian Cotofana, Christian Folwaczny
BACKGROUND: Several observations reported an increased prevalence of celiac disease
among patients with inflammatory bowel disease. Tissue transglutaminases (tTG) represents
the key autoantigens in celiac disease. Recent studies suggest that in the damaged colon
transglutaminases are needed for the response to chronic injury and play an important role
in the mucosal healing process. In the present study antibodies against tTG have been
assessed in patients with inflammatory bowel disease. The levels of the antibodies were
compared with those observed in healthy controls. SUBJECTS AND METHODS: The study
population comprised 187 patients with Crohn’s disease (CD), 138 patients with ulcerative
colitis (UC) and 253 healthy blood donors. The levels of serum tTG antibodies have been
assessed employing commercially available ELISA. Patients with CD and UC were charac-
terised regarding disease phenotype, disease extension, age at diagnosis and disease duration.
Statistical analysis was performed using the Mann-Whitney-U test and Pearson correlation.
RESULTS: The levels of anti-tissue transglutaminase antibodies was significantly increased
in the group of patients with UC when compared to controls (6.06±2.67 vs. 4.57±2.03 IU/
ml, p<0.001) or patients with CD (4.54±2.26 IU/ml). No significant correlation with disease
extension (proctitis, left sided colitis or pancolitis) has been noted. A weak correlation of
antibody levels with age (Pearson 0.263, p=0.002) has been observed in UC. There was no
significant increase in number of patients with CD or UC displaying sprue-significantly (>25
IU/ml) or border suggestive (>20 IU/ml) levels of tTG antibodies. Only 1 patient with CD,
1 patient with UC and 4 control persons displayed antibody levels higher than 20 IU/ml.
DISCUSSION: In patients with ulcerative colitis a significant increase of the levels of antibod-
ies against tissue transglutaminases has been found. This is not related to an increased
prevalence of celiac disease in these patients, as highly positive, sprue specific levels have
not been more frequently identified compared to controls. Rather, these slightly increased
levels might suggest implication of tTG in the constructive mucosal healing processes taken
place in the colon after ulcerative colitis related mucosal damages.
M1746
Inflammatory Bowel Disease After Liver Transplantation: Risk Factors for
Recurrence and De Novo Disease
Robert C. Verdonk, Gerard Dijkstra, Elizabeth B. Haagsma, Valerie K. Shostrom, Aad P.
van den Berg, Jan H. Kleibeuker, Alan N. Langnas, Debra L. Sudan
INTRODUCTION: Inflammatory bowel disease (IBD) is associated with primary sclerosing
cholangitis (PSC) and autoimmune hepatitis (AIH) and can recur or develop de novo after
liver transplantation (OLT). AIM: To investigate the incidence and severity of inflammatory
bowel disease after liver transplantation and to perform an analysis for possible risk factors.
PATIENTS AND METHODS: Ninety-one patients transplanted for PSC or AIH, without
prior colectomy, were included. Sixty patients were transplanted for PSC, 31 for AIH.
Inflammatory bowel disease activity before and after OLT were studied, and possible risk
factors for recurrence or de novo disease analyzed in a multivariate model. RESULTS AND
DISCUSSION: Forty-nine patients (54%) had IBD before OLT, mainly ulcerative colitis.
Forty patients (44%) had active IBD after transplantation: recurrence in 32 and de novo in
8 patients. Cumulative risk for IBD after OLT was 15, 39 and 54 % after 1, 5 and 10 years,
respectively. In 59% of the patients with IBD prior to OLT the disease was more active after
transplantation. Risk factors for recurrent disease were: symptoms at time of OLT, short
interval between diagnosis of IBD and time of OLT and use of tacrolimus after transplantation.
5-aminosalicylates were protective. A cytomegalovirus (CMV) positive donor/negative recipi-
ent combination increased the risk for de novo IBD. Possible explanations for the increase
in IBD seen in patients using tacrolimus are a decrease in regulatory T-cells, diminished
apoptosis of T-cells, and an increase in intestinal permeability in patients using this drug.
CMV infection could contribute to IBD-pathogenesis by influencing endothelial VCAM-1
expression, mucosal interleukin-6 production, and increasing intestinal permeability. CON-
CLUSIONS: 1. Recurrent and de novo IBD are common in patients transplanted for PSC
or AIH 2. In patients with previous IBD the disease runs an active course compared to pre-
transplantation 3. Risk factors for recurrence are: symptoms at time of OLT, short interval
between diagnosis of IBD and time of OLT and use of tacrolimus. 4. Risk factor for de novo
disease is: a cytomegalovirus (CMV) positive donor/negative recipient combination
M1748
Non-T Cell-Derived Galectin-3 Is Immunoregulatory and Is Reduced in the
Inflamed Intestinal Epithelium in IBD
Stefan Mueller, Beatrice Flogerzi, Thomas Schaffer, Andrew Fleetwood, Alain Schoepfer,
Frank Seibold
Background and aims: Galectins represent a family of animal lectins and may play important
roles at different stages in inflammation. Galectin-3, although mostly described as a pro-
inflammatory molecule, can induce apoptosis in T cells. The present study aims at the
determination of galectin-3 expression in the normal and inflamed gut and to define its role
in T cell activation. Methods: Galectin-3 was detected by quantitative PCR with total RNA
from endoscopic biopsies and by immunohistochemistry. Selected biopsies and PBMC
samples were stimulated in vitro, and the latter were used to assess the functional consequences
of inhibition or exogenous addition of galectin-3. Results: Galectin-3 mRNA was constitutively
expressed at high levels in controls and IBD. In the normal mucosa galectin-3 protein was
mainly observed in differentiated intestinal epithelial cells, preferentially at the basolateral
side. Galectin-3 was significantly downregulated in inflamed biopsies from patients with
IBD. In vitro stimulation of biopsies with TNF lead to similar galectin-3 mRNA downregulation
as in vivo. No intrinsic differences in the regulation of galectin-3 mRNA expression could
be detected between IBD and controls. Inhibition of galectin-3 mRNA during stimulation
of PBMC resulted in increased proliferation and decreased activation-induced death of T cells,
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while addition of exogenous galectin-3 reduced proliferation. Conclusions: Downregulation of
galectin-3 in the inflamed mucosa may reflect a normal immunological consequence and
can be mimicked in vitro. Increased T cell activation after inhibition of galectin-3 mRNA in
PBMC may indicate a regulatory role for galectin-3 when expressed by non-T cells. The
constitutive expression of epithelial galectin-3 may, thus, help to prevent inappropriate
immune responses against commensal bacteria or food compounds. Therefore, galectin-3
may proof valuable for manipulating disease activity.
M1749
Is Infection By Mycobacterium Avium Subspecies Paratuberculosis a Risk
Factor for Crohn’s Disease?
Antonio Lozano-Leon, Manuel Barreiro-Acosta, Enrique Dominguez-Munoz
Background: Etiopathogenesis of Crohn’s disease (CD) remains unknown and the influence
of inflammatory, infectious and genetic factors have been proposed. Mycobacterium avium
subspecies paratuberculosis (MAP) is the causative agent of Johne’s disease, a chronic granulo-
matous inflammatory bowel disease of the cattle, similar to human CD. The presence of
MAP has been recently described in CD patients. We hypothesize that MAP infection could
be associated to the risk of developing CD. Aim: To evaluate the potential association between
CD and the presence of MAP infection. Methods: A case-control study was designed, in
which patients with CD and healthy unrelated controls (1:1), matched by ethnic, sex and
age were included. Patients and controls were from Galicia, a region in the North-West of
Spain. Diagnosis of CD was made by clinical, radiological, endoscopic and histological
criteria. All patients were classified according to the Vienna Classification. A venous blood
sample (4 ml) was obtained from all cases and controls in EDTA tubes. Samples were
immediately processed and the whole blood tube was transferred into a separate sterile tube
(1,5 mL). Genomic DNA was extracted by Puregene DNA purification system and the
genotyping was performed by polymerase chain reaction. The Oligonucleotide primers were
derived from the DNA insertion sequence IS900, with is a unique to MAP. The primers
P90 and P91 were used to amplify a unique 294 bp fragment of IS900 gene. The association
of MAP with CD should be expressed as OR and 95% confidence interval. Results: A total
of 73 CD patients (40 female, 33 male, mean age 38 years, range 21-67 years) and 73
matched controls were included. According to the Vienna classification, 21 patients suffered
from a non stenotic-non penetrating disease (B1), 22 had a stenotic disease (B2), and 30
patients presented with a penetrating CD (B3). Ileal location (L1) was found in 34 patients,
whereas 13 and 25 patients had colonic (L2) and ileo-colonic (L3) involvement, respectively.
One patient presented with disease in the upper gastrointestinal tract (L4). Despite the
analysis of an important number of patients, presenting with all different forms of CD, PCR
blood analysis for the presence of MAP was consistently negative in all cases and controls.
Conclusion: MAP infection is not present in our patients with Crohn’s disease. Therefore,
MAP is unlikely to be involved in the etiopathogenesis of the disease.
M1750
Detection of Helicobacter Species in Archival Human UC Tissue By
Fluorescent in-Situ Hybridisation (FISH)
John Thomson, Ian Cooper, Georgina Hold, Nikki Fyfe, Malcolm Smith, Ashley Mowat,
Zeli Shen, James G. Fox, Emad El-Omar
Background The role of Helicobacter species in human inflammatory bowel disease (IBD)
is controversial. This in part is due to differences in techniques used and to lack of definition
of disease phenotypes. Aim To investigate archival paraffin embedded tissue from patients
with confirmed ulcerative colitis (UC) for the presence of Helicobacter species. Subjects
and Methods 100 UC patients (65 relapsing, 35 de novo) and 39 controls with a normal
colonoscopy, had archival biopsies investigated. The biopsies were taken from throughout
the colon. FISH assays were designed to differentiate H. pylori from non-pylori Helicobacter
species. The sections were analysed in triplicate. Results The Helicobacter genus was present
in 33 of the 100 patients with UC. Of these, 31 were non-pylori and 2 were pylori species.
However in the control group 23 (60%) were positive for the Helicobacter genus but only
9 (23%) were non-pylori Helicobacter and 14 (35%) were H. pylori. The only statistically
significant difference between the UC cases and controls was the lower prevalence of H.
pylori in the colitis group (p<0.01). There was no difference in prevalence of non-pylori
Helicobacters between de novo presenting and relapsing colitis patients. The distribution
of Helicobacter species was predominately in the left side of the colon in both the colitis
and control patients. The Helicobacter species were detected on the mucosa and in colonic
crypts, in both inflamed and non-inflamed biopsies. Conclusions Non-pylori Helicobacter
species are commonly detected in UC patients and subjects with normal colons. The role
of these species in the pathogenesis of UC, if any, remains to be established.
M1751
Corticosteroid Usage in Patients with Crohn’s Disease Is Associated with
Decreased Peripheral T Regulatory Cells
Jeanne Tung, Phyllis A. Svingen, William A. Faubion
Background: Functional studies of human CD4+ T cells identified cells highly expressing
CD25 (CD25++) with regulatory potential. CD25 positivity may reflect activated T cells,
thus contaminating functional analyses of CD25++ T cells. The transcription factor FOXP3
is a more reliable marker of these regulatory T cells (T regs), particularly in patients with
inflammatory diseases. However, intracellular staining for FOXP3 precludes functional ana-
lyses. Thus, we aimed to quantify coexpression of FOXP3 and CD25 in patients with Crohn’s
disease (CD). Methods: CD4+ T cells were isolated from the peripheral blood of 15 patients
with CD and 4 controls by magnetic cell sorting and analyzed by flow cytometry. Data are
expressed as percentage of CD4+ T cells (median, range). Results: No difference exists in
the percentage of CD25++ T cells [0.3 (0.1-1.4) vs. 0.3 (0.2-2.2)] or FOXP3+ T cells [3.4
(1.8-6.3) vs. 3.8 (2.6-7.2)] between patients with CD and controls. Subanalysis of patients

















[1.9 (1.8-3.1) vs. 4.4 (3.0-3.6)]. Furthermore, CD25++ T cells from patients on CS do not
frequently express FOXP3, as compared to steroid-free patients and controls [38.5 (24.4-
60.7) vs. 78.2 (63.2-87.3) vs. 76.5 (52.1-85.6), respectively] (figure). CDAI did not differ
between the two groups of patients. Expression of CD25 or FOXP3 did not correlate with
disease activity, thiopurine use, or anti-TNF therapy. Conclusions: Patients with CD do not
differ from controls in the number of CD25++ or FOXP3+ CD4+ T cells in the periphery,
and the majority of CD25++ T cells express FOXP3. An important exception is those patients
on CS, in whom fewer T regs exist and are not enriched in the CD25++ population. Isolates
of CD25++ cells from CD patients may be used in future studies of T reg cell function, but
one should avoid patients on corticosteroids.
M1752
Sera from Active Ulcerative Colitis (UC) Contain IgG Antibodies Against
Human Tropomyosin Isoform 5 (hTM5) That Kills Normal Colonic Epithelial
Cells Through Antibody and Complement Lysis
Ellen C. Ebert, Xin Geng, Jim Lin, Kiron M. Das
Introduction: Patients with UC, but not Crohn’s disease (CD) have IgG1 antibodies in their
serum and colon against hTM5, a cytoskeletal protein expressed both intracellularly and on
the surface of colonic epithelial cells. Whether this is an epiphenomenon or related to the
disease process is unknown. Since serum can gain access to the epithelium, we hypothesized
that cytolytic IgG antibodies recognize and destroy epithelial cells in UC by antibody and
complement lysis. Methods: Sera were obtained from UC patients (n=60), CD patients (n=
28), and normal individuals (Nl)(n=13) and were preincubated for 10 min with recombinant
hTM5 or bovine serum albumin. Then, they were cultured for 4 hrs with a 51Cr-labelled
colonic adenocarcinoma cell line (LS180 cells) with up to 40% of the cells expressing surface
hTM5. In some experiments, the IgG fraction was obtained by a protein G column from
pooled samples of UC or CD sera. Cytotoxicity was determined by the 51Cr-release assay.
Results: To evaluate the role of hTM5, recombinant protein was added to the sera before
addition of radiolabelled LS180 cells. There was a 20 + 3% reduction in cytotoxicity with
addition of pure hTM5 to UC sera but not to CD or Nl sera (both p<0.001 compared to
UC). When evaluating the site of disease, those UC patients with left-sided or pan-colitis
had significant declines in cytotoxicity with hTM5, while those with proctitis did not,
suggesting that proctitis has a different pathogenesis. Disease activity and medications did
not affect the results. However, increasing age correlated with the most inhibition by hTM5
(p<0.01), while increasing duration of disease had a similar, but nonsignificant, trend. Using
10% inhibition by hTM5 as the cut-off, those values greater than 10% were from UC patients
with a 15% false negative rate and a 2.5% false positive rate. To prove that IgG was involved,
UC and CD sera were fractionated by a Protein G column. The IgG fractions from UC but
not CD sera demonstrated hTM5-induced cytotoxicity. To determine whether complement
was involved, sera were heat inactivated (560C for 45 min) or mixed with Fc fragments.
Both maneuvers markedly reduced cytolytic activity by UC sera (p<0.05 and p<0.01),
suggesting complement-mediated injury. Conclusions: This study shows that hTM5-specific
IgG from UC, but not CD or Nl sera, kills LS180 cells by complement-mediated lysis. This
provides a direct pathogenic role of anti-hTM5 antibodies in the disease process and leads
the way to novel diagnostic and therapeutic possibilities.
M1753
Antibodies to Self and Bacterial Antigens in Patients with Crohn’s Disease and
Ulcerative Colitis: A Co-Twin Case-Control Study
Martina E. Spehlmann, Arno Kromminga
Abstract Introduction: Antibodies against self and bacterial antigens have been discussed to
be associated with inflammatory bowel diseases (IBD). Methods: To evaluate these findings
we have analyzed antibodies against the recombinant outer-membrane porin C (OmpC)
from Escherichia coli and recombinant Pseudomonas fluorescens-associated I2 antigen as
well as to saccharomyces cerevisiae antigens and tested perinuclear antineutrophil cytoplasmic
antibodies in sera of monocygotic twin pairs discordant for Crohn’s disease (n=6) and
ulcerative colitis (n=12). Results: Anti-OmpC-antibodies were exclusively found in twins
with UC (5/12 of affected (41.7%) and 4/12 of the corresponding non-affected co-twin
(33.3%)). Anti-I2-antibodies were measured in both UC (2/12 of the affected twins and 2/
12 of the non-affected siblings (16.7%;)) and CD (1/6 affected and 1/6 of the non-affected
siblings(16.7%)). Surprisingly, ASCA were found in both UC (25.0%) and CD (50.0%)
patients. P-ANCA were detected only in UC twins (9/12 in the affected (75.0%) and 1/12
in the non-affected sibling (8.3%)). Discussion: These findings confirm the specificity of p-
ANCA for UC, whereas the detection of antibodies to OmpC, I2 and ASCA neither discrimin-
ated between CD and UC nor indicated a manifestation and severity of the disease. Due to
the co-existence of anti-OmpC- and I2-antibodies in affected as well as non-affected UC
patients we assume that the occurrence of these antibodies is a result of a genetic predisposi-
tion.
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M1754
Invasive E. Coli Strains Are Increased in Crohn’s Disease
Joel A. Alpern, Maiko Sasaki, Shanti V. Sitaraman, Robin E. Rutherford, Henry C.
Olejeme, Qiang Cai, Jan-Michael A. Klapproth
Background: Bacteria and their products have been implicated in the pathogenesis of inflam-
matory bowel disease. Recent studies from Europe have described a new class of Adherent
Invasive E. coli (AIEC) strains in patients with Crohn’s disease (CD), but not ulcerative colitis
(UC) or healthy controls. Representative AIEC strain LF82 was found to efficiently invade
epithelial cell cultures and proliferate without inducing apoptosis. Hypothesis: Invasive E.
coli strains are present in American patients with CD. Methods: Twenty-eight patients were
enrolled (CD 11, UC 4, pouchitits 3, normal controls 10). Macroscopically normal and
inflamed appearing endoscopic mucosal biopsies were subjected to DMEM/Gentamicin treat-
ment for one hour, lysed, and plated on McKonkey agar. A total of 933 lactose fermenting
bacterial strains were analyzed by invasion assay. Antibiotic-free, confluent Caco-2 mono-
layers were infected in triplicate with 5μl of an overnight culture of individual clones.
Following three hours of infection, cells were treated with DMEM/Gentamicin. Dilutions of
Triton-X-100 cell lysates and bacterial cultures were plated on LB agar. Colonies were
enumerated and invasion indices expressed as percentage of initial inoculum. Invasion
indices ≥ 1.0% were considered significant comparing pathogenic (LF82, EPEC, EIEC,
EHEC) to non-pathogenic commensal E. coli strains. Invasive strains were further analyzed
using Api20E bacterial identification kit. Results: Significant invasion was determined for
19.8% of all examined strains (CD 25.9%, UC 18%, pouchitis 20.4%, control 13.5%). As
determined by biochemical analysis, the most common invasive isolate in all biopsies was
E. coli (64.1%). Invasive E. coli strains were more commonly identified in CD (88/98-89.8%)
and pouchitis (16/21-76.2%) in comparison to UC (6/20-30%) and normal controls (1/46-
2.2%). Invasion indices for all E. coli isolates from patients with CD (8.8%, p<0.05) were
significantly higher in comparison to UC (4.16%) or pouchitis (1.6%). The highest invasion
indices for E. coli strains were observed in inflamed mucosa from patients with CD (11.7%,
p<0.05) vs. non-inflamed mucosa (8.8%), healthy or inflamed pouch mucosa (1.27%, 1.63%,
respectively). Not a single invasive E. coli strain was isolated from inflamed UC mucosa.
Summary and conclusion: CD patients harbor a significantly increased number of E. coli
strains in comparison to UC, pouchitis and normal controls. In comparison to normal
appearing tissue, invasive E. coli strains are especially prevalent in inflamed CD mucosa.
Invasive E. coli strains are a feature of and might contribute to the pathogenesis of CD.
M1755
Native, Circulating Plasmacytoid and Myeloid Dendritic Cells from Patients
with Inflammatory Bowel Disease Secrete Increased Amounts of Inflammatory
Cytokines and Drive a Pro-Inflammatory T-Cell Proliferation and Polarization
Daniel C. Baumgart, Ingo Przesdzing, Christiane Bielecki, Diana Metzke, Saskia Thomas,
Andreas Sturm, Bertram Wiedenmann, Axel U. Dignass
BACKGROUND: Breakdown of tolerance against the commensal microflora is believed to
be a major factor in the pathogenesis of inflammatory bowel disease (IBD). The key role of
dendritic cells (DC) in this process has been demonstrated in various animal models, while
data on native human DC is still limited. PATIENTS AND METHODS: Plasmacytoid (PDC)
and myeloid (MDC) dendritic cells and naïve T-cells (TC) were isolated with magnetic cell
separation from peripheral blood of 32 patients (Crohn’s disease (CD) n=18, ulcerative
colitis (UC) n=14) and healthy controls (n=22). DC cytokine production and secretion
were evaluated following incubation with microbial surrogate stimuli such as CpG motifs,
staphylococcal enterotoxin B (SEB) or lipopolysaccharide (LPS). PDC and MDC were also
co-cultured with naïve T-cells. FACS analysis was used to identify, enumerate, and phenotype
cells. Proliferation was measured after CFSE staining. RESULTS: Upon culture and stimulation
with microbial surrogate stimuli, PDC and MDC from IBD patients secrete more TNFa, IL-
8 and IL-6 than healthy controls (Table 1). DCs from IBD patients appear to induce a Th1
type polarization and proliferation in naïve T-cells. CONCLUSION: An aberrant response
of DC to microbial surrogate stimuli suggests a disturbed interaction with commensals. The
effect of DCs on T-cell proliferation and polarization underscore their critical role in the
pathogenesis of human IBD.
Table 1: Cytokine Secretion
M1756
Bacterial-Aluminum Interactions. The Role of Aluminum in Bacterial-Induced
Colitis in IL-10 Deficient Mice
Aaron Lerner, Swathi Eluri, Daniel Perl, Sharon Moalem, David Sachar, Susan Tonkonogy,
Ryan B. Sartor
Aluminum (Al) is a common environmental element with immune adjuvant activity and
the ability to induce granulomatous inflammation. Al exposure through food additives,
municipal water supplies and air pollution is ubiquitous in Western cultures. Since loss of
tolerance to commensal intestinal bacteria appears to be involved in the pathogenesis of
IBD, we postulated that dietary Al could increase luminal bacterial virulence and/or enhance
mucosal immune responses to enteric bacteria. To explore the effects of Al on experimental
colitis, we monitored its effects on bacterial growth, on the capacity of lyates from Al-
preloaded murine E. coli to enhance immune responses in vitro, and the in vivo effect of
dietary Al on immune-mediated murine colitis. Methods: Growth of murine intestinal bacteria
in the presence of increasing Al concentrations (0-662uM) was assessed by spectrophotome-
try. Immune responses to bacterial lysates were measured in vitro by [H]3 thymidine
incorporation and by IFNγ secretion by IL-10 KO colitic mouse splenocytes. To assess the
in vivo effects of dietary Al, IL-10 KO germ free mice were colonized with SPF enteric
microbiota, fed a low Al, low iron diet, and exposed to 3 different Al concentrations: low
(0 uM), middle (5uM) and high (500uM) Al L-lactate added to their drinking water (N=5/
group). Iron (II) sulfate heptahydrate (1uM) was added to the drinking water of all groups.
Colitis was measured by histologic scores (0-4+) and spontaneous IL-12p40 secretion by
cultured colonic fragments. Results: Bacterial growth was suppressed slightly by high Al
concentrations in the media. E. coli grown in low Al concentrations (150-200uM) stimulated,
while those grown in higher concentrations inhibited in vitro T cell proliferation and IFNγ
secretion by splenocytes. In vivo Al feeding worsened colitis, with increased cecal histological
scores accompanying progressively higher Al intake (2.0+ 0.2 low vs.3.8+0.2 high, p<0.05).
IL-12 secretion by colonic strip cultures also increased with higher Al intake (3.5+ 1.6 vs.
4.9 +0.4 ng/ml). Dietary Al altered luminal bacterial metabolism by inducing pink E.coli
colonies on MacConkey agar plates. Conclusions: Environmental Al stimulates immune
responses to enteric bacteria in vitro and enhances bacterial-induced experimental colitis in
IL-10 KO mice. Exposure to environmental Al may in part explain the increased incidence
of IBD in countries adopting Western diets, industrial and public health practices.
M1757
Gene Expression Profile in Crohn’s Disease Related NOD2 Variants
Zuzana Zelinkova, Astrid J. van Beelen, Floor de Kort, Emiel Ver Loren van Themaat,
Anje A. Te Velde, Esther C. de Jong, Sander J. van Deventer, Daniel W. Hommes
Background: NOD2 variants are associated with Crohn’s disease (CD) but the underlying
mechanism is not completely understood. Recent studies in CD patients showed a defective
proinflammatory cytokines production upon TLR and NOD2 stimulation leading to hypo-
thesis of impaired pathogen elimination that would result in a chronic inflammatory condi-
tion. However, our previously reported observations suggest that NOD2 deficiency may lead
to a specific stimulation of interleukin-12 (IL-12) production in antigen presenting cells
together with deficient IL-10 production upon NOD2 stimulation. In order to study the
possible mechanism of CD resulting from NOD2 mutations, we used this cell type to analyse
differences in gene expression profile upon NOD2 stimulation in CD patients. Patients and
Methods: Monocyte-derived dendritic cells (DCs) from CD carriers of double-dose NOD2
mutations, wild type CD patients and wild type healthy volunteers were stimulated for
6 hours with NOD2 ligand muramyl dipeptide (MDP). Agilent Human Whole Genome
Oligonucleotide arrays were used to assess the differential gene expression in the three
studied groups. The statistical analysis was performed by ANOVA test using Rosetta Resolver
v 5.0 Expression Data Analysis System. For pathway analysis gene ontology mapping online
software has been used. The expression of selected significantly up-regulated genes was
tested by confirmatory PCR. Results: The three groups showed substantially different gene
expression profiles upon MDP stimulation with only 3 genes overlapping between all three
groups. In NOD2 mutants group 301 genes were significantly changed among which different
costimulatory molecules, chemokines and cytokines. Pathway analysis showed a clustering
of these genes in pathways of negative regulation of apoptosis, regulation of DNA recombina-
tion and chromatin modification. In the group of wild type CD patients 694 genes were
significantly changed, mostly genes clustering in pathways of response to external stimuli.
Surprisingly, in the wild type healthy volunteers groups only 52 genes significantly changed,
belonging to the response to pathogen pathway. Conclusion: Our observations support the
hypothesis of NOD2 variants leading to Crohn`s disease through inappropriate non-specific
inflammatory reaction.
M1758
Enhancement of Substance P mRNA Expression in Non-Inflamed Small Bowel
of Crohn’s Disease Patients
Christoph Michalski, Frank Autschbach, Federico Selvaggi, Michael Muller, Pierluigi Di
Sebastiano, Markus W. Buchler, Thomas Giese, Helmut Friess
Background: Substance P (SP) as a mediator of neurogenic inflammation plays an important
role in inflammatory disorders. In different bowel sections from patients with ulcerative
colitis (UC), Crohn’s disease (CD) or from normal control donors, we simultaneously analyzed
the Neurokinin Receptor-1 (NK-1R) isoforms NK-1R-Long and NK-1R-Short, its ligand
Substance P encoded by Preprotachykinin-A (PPT-A) and the SP degradation enzyme Neutral
Endopeptidase (NEP). Methods: CD and UC tissues were obtained from patients undergoing
intestinal resection due to complications of the disease. Normal human intestinal tissue
samples were obtained from patients undergoing surgical bowel resection for other reasons
than inflammatory bowel disease. Real-time quantitative reverse transcription polymerase
chain reaction (RT-PCR) was used to simultaneously determine the expression of NK-
1R-L, NK-1R-S and PPT-A. Protein expression of NK-1R and NEP was determined by
immunohistochemistry and immunoblot analysis. Results: In non-inflamed ileal samples of
CD patients, PPT-A mRNA expression was significantly increased compared with normal
controls. There was no difference between inflamed or non-inflamed UC tissues and normal
intestinal tissue samples. Subgroups of diverse intestinal segments with various levels of
inflammation revealed no differences in NK-1R-L or NK-1R-S expression. Immunoblot
analysis revealed an upregulation of NK-1R protein levels in IBD with a more pronounced
enhancement in CD (p<0.001) than in UC (p<0.003). Immunostaining confirmed the immu-
noblot findings and demonstrated stronger NK-1R immunoreactivity in the chronically
inflamed tissues while the overall staining was more increased in CD than in UC samples.
For NEP there was no difference in either immunohistochemistry or immunoblot analysis
in normal, CD and UC intestinal tissues. Conclusions: These observations suggest a contribu-
tion of substance P and its receptor NK-1R in the local inflammatory reaction in IBD and
particularly in Crohn’s disease. Moreover, the significant upregulation of PPT-A mRNA in
the non-inflamed ileum of patients with CD may constitute a precursor lesion of the local
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inflammation and therefore allow to predict the extent of inflammation of yet unaffected
small bowel.
M1759
Acute Psychological Stress Increases Rectal Mucosal and LPS-Stimulated
Whole Blood Release of TNF-Alpha in Patients with Inactive Ulcerative Colitis
Joel Mawdsley, David Rampton
Introduction: Psychological stress is reported to increase the likelihood of relapse in ulcerative
colitis (UC) but the mechanism is unclear. We hypothesized that stress might act by stimulat-
ing colorectal mucosal and lipopolysaccharide (LPS)-stimulated whole blood production of
TNF-α, an important cytokine in the pathogenesis of IBD. Aim: To assess the effects of
acute psychological stress on the concentration of TNF-α in rectal peri-mucosal fluid, and
on the production of TNF-α by LPS-stimulated whole blood in patients with inactive UC.
Methods: For 50 mins, patients with inactive UC (Simple Clinical Colitis Activity Index<4,
Baron sigmoidoscopy score<2) underwent either (i) Stress - modified dichotomous listening
test (IQ test whilst listening to different types of music in either ear), or (ii) Control - relaxing
music. The autonomic stress response was assessed by pulse and BP every 15 mins. Peri-
mucosal fluid was collected before and after each protocol by placing a 7 x 30mm strip of
filter paper through a rigid sigmoidoscope in contact with rectal mucosa for 1 min until
wet. The filter paper was then incubated in 1ml Bovine Serum Albumin (0.3%), sodium
azide (0.01%) and Tween 20 (0.002%) in phosphate-buffered saline for 24 hrs and TNF-
α concentrations in buffer subsequently measured by ELISA.(1) In blood taken before and
after each protocol, LPS-stimulated TNF-α production (1ml whole blood incubated with
25mcg/ml LPS at 37C in 95%O2/5%CO2 for 24 hours) was measured by ELISA. Results:
The control protocol did not change any variable (Table). Stress increased pulse rate by
median 7bpm, systolic BP by 12mmHg, TNF-α concentrations in rectal peri-mucosal fluid
by 102% and LPS-stimulated TNF-α production by whole blood by 54%. Conclusion: Acute
psychological stress increases the release of TNF-α by rectal mucosa and by LPS-stimulated
whole blood. Both mechanisms could contribute to the pathogenic effects of psychological
stress in UC. Reference: 1. Carty E, De Brabander M, Feakins RM, Rampton DS, Gut 46,
487-492 (2000).
*p<0.05 from pre-stress value. **p<0.01 from pre-stress value. Median and IQR shown.
M1760
Exotoxin a from Pseudomonas Aeruginosa Promotes Leukocyte Adhesion to
Gut Mucosal Smooth Muscle Cells
Alana Majors, Melissa Jedlicka, Scott A. Strong
OBJECTIVE: Mounting evidence suggests that both luminal bacteria and the mucosal extracel-
lular matrix play pivotal roles in the pathogenesis of inflammatory bowel disease (IBD)
through mechanisms that have yet to be precisely identified. Pseudomonas aeruginosa is a
normal component of the intestinal flora, but is also a pathogen whose virulence is primarily
mediated by Pseudomonas exotoxin A (PEA) that inhibits protein synthesis and may elicit
additional affects. In IBD, alterations in the hyaluronan (HA) of the extracellular matrix
likely contribute to an enhanced binding interaction between immune cells and mesenchymal
cells of the mucosa, but it is not unclear how bacterial products may affect the extracellular
matrix. Accordingly, we attempted to determine whether PEA alters the extracellular matrix
and influences mononuclear leukocyte binding to mucosal smooth muscle cells (M-SMCs).
METHODS: Human M-SMC cultures were derived from fresh surgical specimens of patients
undergoing colonic resection. Confluent cultures were treated both with and without PEA
(optimal conditions: 100 ng/ml; 23 hours), incubated with non-stimulated mononuclear
leukocytes, and subjected to morphologic as well as functional studies. RESULTS: Affinity
histochemistry and confocal fluorescent microscopy demonstrated that HA was deposited
in cable-like structures in PEA-treated cultures, but not in untreated, control M-SMC cultures.
Furthermore, quantitative leukocyte adhesion assays demonstrated that the PEA-treated
cultures were significantly more adhesive for U937 cells as well as Jurkat and MOLT-4 T-
cells than the untreated M-SMCs. Visualization of the bound leukocytes by fluorescent
microscopy revealed that the leukocytes were bound to the HA-containing cables. DNA
quantification confirmed that the PEA was not toxic under the experimental conditions.
CONCLUSIONS: These results suggest that bacterial exotoxins may play an integral role in
the pathogenesis of inflammatory bowel disease by altering the mucosal extracellular matrix


















Receptor Activator of Nfk-B Ligand (RANKL), Rank and Osteoprotegerin in
Inflammatory Bowel Disease: Implication in Chronic Inflammation and Bone
Loss
Catherine D. Reenaers, Nathalie Franchimont, Cecile Oury, Cecile Lambert, Jacques
Belaiche, Michel Malaise, Philippe Delvenne, Edouard Louis
Crohn’s disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD)
associated with osteopenia. RANK (Receptor activator of NF-κB) is expressed by osteoclasts
and by antigen presenting cells (APC). With its ligand RANKL, expressed by osteoblasts
and T lymphocytes, RANK plays a critical role in bone resorption but also in DC-T cells
interaction. Osteoprotegerin (OPG), a soluble decoy receptor for RANKL, inhibits the RANK-
RANKL interaction. The aim of our work was to study the expression of RANK, RANKL
and OPG in IBD. Material and methods: Total RNA was extracted from normal colon samples.
RANK, RANKL and OPG mRNA expression was studied by RT-PCR (n=5). The level of
soluble RANKL (sRANKL) and OPG in the gut was analysed by specific ELISA on supernatant
of cultured colonic biopsies (15 CD patients, 7 controls patients). Fixed colonic samples
from 14 CD patients, 10 UC patients, 10 diverticulitis patients and 5 controls were studied
by immunostaining and immunofluorescence. Serum levels of sRANKL and OPG were also
assessed by specific ELISA (CD=18, UC=14, inflammatory controls =11, controls=14). We
studied the cells expressing RANK and RANKL in the serum by flow cytometry on PBMC
isolated from CD, UC, inflammatory controls and healthy controls. Results: Transcripts for
RANK, RANKL and OPG were confirmed in the human colon by RT-PCR. We observed by
immunostaining and immunofluorescence an important number of RANK+ cells in areas of
chronic inflammation in CD, UC or diverticulitis. Double staining suggested that theses cells
corresponded to CD68 and S100 cells. Levels of sRANKL and OPG were significantly
increased in cultured colonic biopsies from CD, particularly in inflamed areas. Only OPG
was correlated to pro and anti-inflammatory cytokines. Important levels of sRANKL and
OPG were also detected in the serum of active CD. The study of PBMC in flow cytometry
demonstrated that RANK and RANKL positive cells corresponded to 5 to 10% of PBMC.
All these cells were CD4+ and CD1a+. Conclusion: There is an expression of RANKL, RANK
and OPG in the human colon. The level of RANK in the gut is increased in chronic
inflammation in different pathologies (CD, UC, diverticulitis). Moreover, we observed import-
ant levels of RANKL and OPG in the supernatant of cultured colonic biopsies and in the
serum, mainly in active CD. The cells expressing RANKL and RANK in the colon and in
the blood have characteristics of APC. These data suggest that RANK, RANKL and OPG
system could be involved in immunology processes taking place in the gut in several
inflammatory diseases. These proteins could also have a role in the associated bone loss,
particularly in CD.
M1762
Immunophenotype and Apoptosis of Colonic Mononuclear Cells in Active
Steroid-Responsive Ulcerative Colitis
Rebeca Santaolalla, Maria Esteve, Josep Manye, Elisabet Pedrosa, Antonio Salas, Fernando
Fernandez-Banares, Merce Rosinach, Montserrat Forne, Jorge Espinos, Eugeni Domenech,
Miriam Manosa, Miquel Angel Gassull, Josep Maria Viver
BACKGROUND: Apoptosis is a programmed cell death that plays an important role in T-
cells proliferation control. It has been suggested that corticosteroids may induce lymphocyte
apoptosis by poorly known mechanisms. AIMS: To assess if steroid treatment may induce
apoptosis and changes in the percentage of lamina propria (LP) colonic mononuclear cells
in steroid-responsive ulcerative colitis (UC). METHODS: 10 patients with moderate or severe
UC [5 men, 5 women, age: 44.9 ± 4.8 years] and 6 healthy controls [2 men, 4 women,
age: 57.8 ± 6.5 years] were included. Disease activity was assessed by clinical (Truelove
Index), endoscopic (Gomes Index) and histopathological (Gomes Index) criteria. Eigth
endoscopic biopsies were taken just before starting steroid therapy and also 7-10 days after
it, from the same afected area. Immunopheynotype and apoptosis were analized by flow
citometry using a double staining with anti-CD3 (T lymphocytes), anti-CD38 (plasma cells),
anti-CD19 (B lymphocytes), anti-CD14 (monocytes, macrophages) and annexin-V. Data are
shown as mean ± SEM of % phenotyped population / LP total cells, and % apoptotic
phenotyped population / same type total cells. Analysis of the results were made by t
Student test (paired and unpaired data). RESULTS: In the basal determination, an increase
of CD38+CD19- cells (8.9 ± 1.6 vs. 4.5 ± 1.1; p=0.04) and CD38+CD19- apoptotic cells
(18.1 ± 2.4 vs. 8.8 ± 1.6; p=0.009) was found in UC patients compared to healthy controls.
After 7-10 days of treatment, a decrease in the clinical and endoscopic activity (p=0.005
and p<0.0001 respectively) was found. Meanwhile there was only a tendency to a decrease
in the histopathological activity index (p=0.152) and in the % of CD19+ cells (p=0.084).
No significant changes neither in other cellular markers nor in the % of apoptotic cells were
detected. CONCLUSIONS: 1- The beneficial effect of steroids in UC is not related to an
increase of LP apoptotic mononuclear cells in vivo, suggesting that this mechanism is not
involved in its therapeutic effect. 2- The contrast between rapid clinical and endoscopical
improvement observed in steroid sensitive patients and the relative resistance to histopathol-
ogical and LP mononuclear cells restitution, suggests that the abnormalities observed in
immunoregulatory mechanisms (increase of CD38+ and CD38+ apoptotic cells) are not
primary phenomena but epiphenomena related to inflammation in ulcerative colitis. This
study has received financial support from the “Fundacio La Marato de TV3” (Id.031730)
of Catalonia (Spain).
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M1763
Increased Expression of Lipocalin-Type-Prostaglandin D Synthase (L-PGDS) in
Colonic Mucosa of Ulcerative Colitis Patients: Its Regulatory Role Against
TH1 Response
Ryota Hokari, Keisuke Okudaira, Yoshikiyo Okada, Chie Kurihara, Hisayuki Matsunaga,
Koichi Takebayashi, Yoshikazu Tsuzuki, Masaaki Higashiyama, Norikazu Mataki,
Shunsuke Komoto, Chikako Watanabe, Atsushi Kawaguchi, Shigeaki Nagao, Kazuro Ito,
Soichiro Miura
Background: The pathogenesis of ulcerative colitis (UC) is unclear, but abnormal infiltration
of T lymphocytes and proinflammatory cytokines (cytokine imbalance) in the colonic mucosa
has been implicated for colonic injury. Recently enhanced biosynthesis of prostaglandin
(PG) D(2) has been suggested to contribute to resolution of inflammation in kidney or
venular wall. PGD2 affects Th1/2 balance by stimulating Th2 cells via CRTH2 (chemoattract-
ant receptor-homologues molecule specifically expressed on Th2 cells) and suppressing Th1
cells via DP receptor in vitro. PGD2 is coverted from PGH2 by two kinds of enzymes,
lipocalin-type-prostaglandin D synthase (L-PGDS) and hematopoietic-type-prostaglandin D
synthase (H-PGDS). However, the change of these enzymes in colonic mucosa has not been
studied at all. In this study we investigated how expression of enzymes for PGD2 synthesis
altered its relation to the activity of colonic inflammation in UC. Methods: Tissue samples
were obtained by colonic biopsies from patients with UC or colonic polyps with informed
consent. Th1/2 cell infiltration was studied immunohistochemically using antibody against
CC chemokine receptor 5 (CCR5) as Th1 marker and CRTH2 as Th2 marker. Th1 related
chemokine, MIP1-a and Th2 related enzymes, L-PGDS and H-PGDS were studied by m-
RNA expression using quantitative RT-PCR. mRNA expressions of IFN-gamma, IL-4 and
Fox-P3 were also measured by quantitative PCR. Result: CCR5 positive cells significantly
increased in the inflamed mucosa and their number pararelled with the disease activity of
UC. Mip1 alpha expression well correlated with the infiltration of CCR5 positive cells.
CRTH2-positive cells was predominantly observed in the mildly inflamed or the margin of
inflamed mucosa, but their number decreased in severely active UC patients. Both L-PGDS
and H-PGDS mRNA expressions were observed in the colonic mucosa and the L-PGDS
expression was increased in UC patients. On the contrary, H-PGDS expression in UC did
not differ from control mucosa. L-PGDS expression pararelled with the disease activity.
Expression of FoxP3 was also increased as activity of inflammation advanced. IL-4 was not
detected in the UC mucosa. Conclusion: We first reported the presence of two types of
PGD synthase in the colonic mucosa and that only lipocalin-type PGDS increased with active
mucosa of UC patients. From the absence of Th2 related cytokines and the decreased
CRTH2 cells in severe colitis we speculate that L-PGDS-derived PGD2 may play important
antagonizing roles through DP receptor against Th1 response to ameliorate colonic inflamma-
tion in severe colitis.
M1764
Decreased Hyaluronidase 2 (Hyal2) Expression By Colon Smooth Muscle Cells
(SMC) May Contribute to Pro-Inflammatory Hyaluronan (HA) Accumulation
in Inflammatory Bowel Disease (IBD)
Hyunjin K. Rho, Carol A. de la Mott, Csaba Fulop, Scott A. Strong
Background: Increased hyalruronan (HA) levels in colonic mucosa involved in active inflam-
matory bowel disease (IBD), as compared to non-inflamed tissue, has been shown by our
laboratory. HA is frequently muscularis associated. Additionally, we have shown the genera-
tion of leukocyte adhesive hyaluronan structures in vitro from colonic mucosal smooth
muscle cells (M-SMC) stimulated with a virus or the viral mimetic, poly I:C (synthetic double
stranded RNA). Conceivably, HA accumulation in tissue or on cells may be achieved either
by increasing synthesis or inhibiting catabolism. Therefore investigation into the regulation
of the three HA-synthase (HAS1, HAS 2, HAS3) and two active somatic hyaluronidase
(HYAL1, HYAL2) enzymes by poly I:C treated M-SMC from Crohn’s disease (CD), ulcerative
colitis (UC) and non-IBD colon samples was initiated. Methods: Human M-SMCs were
isolated from colon tissue obtained after surgical resection, grown in culture and assayed
in the first sub-culture. M-SMC cultures from 25 patients were treated with or without poly
I:C for 6 hours. RNA was extracted by a phenol-chloroform method, and comparative RT-
PCR was performed using primers of human HAS 1,2 and 3, and also Hyal1 and 2. The
data was analyzed quantitatively after normalization to β-actin expression. HA production
by M-SMCs was also monitored by microscopy and its function by measuring the binding
of radiolabeled monocytic cells. Results and Discussion: The change in the HA synthetic
enzymes HAS2 and HAS3 mRNA levels upon poly I:C treatment of M-SMC was variable
among the patient samples, while HAS 1 was not detected in any. Likewise the HA degrading
enzyme HYAL 1 was not detected in any M-SMC sample. Strikingly, however, HYAL 2
mRNA expression was dramatically decreased in poly I:C treated UC patients. Among the
UC patients, 78% showed a >75% decrease, while the rest were reduced 20 to 65%. The
response by CD patient M-SMC s was variable, with 50% showing an increase in HYAL2
expression upon poly I:C stimulation. Hyaluronan mediated leukocyte adhesion was also
higher in poly I:C stimulated UC-derived M-SMCs than CD M-SMCs . This suggests disease
specific differences in regulation of HA accumulation and function. Significance: We have
reported inflammation-associated HA accumulation in IBD colon tissue and provided evid-
ence that HA participates in the inflammatory process. The balance of synthesis and catabolism
likely regulates the amount of HA sequestered in tissue. Here we provide novel evidence
that controlling the break down, ie inhibiting clearance, of HA from M-SMC surface likely
favors the formation of the HA pro-inflammatory environment in UC patients.
M1765
Peripheral Natural Killer T-Cell Numbers and Serum IL-13 Concentrations Are
Raised in Active Ulcerative Colitis and Correlate with Disease Activity
Joel Mawdsley, Marion Macey, David Rampton
Introduction: The pathogenesis of ulcerative colitis (UC) is incompletely understood. It has
been reported recently that mucosal biopsies from patients with UC contain a population
of non-classical Natural Killer T (NKT) cells which may be important in disease pathogenesis
(1). These NKT cells have been shown to produce IL-13, a cytokine which impairs the
barrier function of colonic epithelial cells in vitro.(2) However, peripheral NKT cells numbers
and serum IL-13 concentrations in patients with UC have not been studied. Aim: To measure
the numbers of non-classical NKT cells and serum IL-13 concentrations in peripheral blood
in patients with UC and to correlate this data with disease activity. Methods: To measure
NKT cell numbers, blood samples were collected from 30 patients with UC, anti-coagulated
with CTAD, stained with fluorescent monoclonal antibodies and analysed by flow cytometry.
Non-classical NKT cells were identified as CD3+, CD4+ and CD161+ cells. Serum IL-13
levels were measured in a different but overlapping group of 50 patients with UC by ELISA.
Disease activity was assessed by the Simple Colitis Activity Index (SSCAI).(3) Active UC
was defined as SSCAI>4. Results: NKT cell numbers and serum Il-13 concentrations were
higher in patients with active than with inactive UC (p=0.03 and p=0.003, respectively).
SSCAI was directly related to both NKT cell numbers (R=+0.39, p=0.04) and serum IL-13
concentrations (R=+0.58, p<0.0001). However, in the 10 patients who had both variables
measured, there was no correlation between NKT cell numbers and serum IL-13. Conclusion:
The number of non-classical NKT cells and IL-13 concentrations in peripheral blood are
increased in patients with active UC and correlate with disease activity. These findings are
consistent with the possibility that IL-13-producing NKT cells contribute to the pathogenesis
of UC. References (1) Fuss et al. Journ Clin Invest. 2004;113(10):1490-7 (2) Heller et al.
Gastroenterology. 2005;175(5):3207-13 (3) Walmsley et al. Gut. 1998;43(1):29-32
NKT cell numbers and serum IL-13 concentrations in active and inactive UC
Median and IQR are shown. *P<0.05 from values for patients with inactive UC.
M1766
Dietary Microparticles Impair Macrophage Phagocytosis and Act As Adjuvants
in the Presence of a Microbial Stimulus - Potential Relevance for Pathogenesis
of Crohn’s Disease
Matt Butler, J Boyle, R Playford, R Chaudhary, Jj Powell, Subrata Ghosh
Background and aims: Western diets regularly expose the gastrointestinal tract to a large
quantity of man-made, submicron-sized, particles (>1012/day) derived from food additives.
These are taken up by M cells, accumulate in gut macrophages, and are resistant to degrada-
tion. Microparticles also have charged surfaces that readily adsorb luminal biomolecules
such as bacterial lipopolysaccharide (LPS). Binding of luminal antigens or toxins to micropart-
icles and delivery to intestinal macrophages in a particulate form could potentially overcome
tolerogenic processes in susceptible individuals and lead to inflammatory bowel diseases
such as Crohn’s disease. We aimed to determine the effect of microparticles on human
macrophage function. Methods: We have investigated the effect of two types of common
dietary microparticle, (aluminium silicates and titanium dioxide) on human macrophage
function in vitro. Monocyte-derived macrophages from active Crohn’s patients or healthy
controls were incubated with microparticles for 24 hours before being assayed for cytokine
production (IL-8, TNFα, IL-10, and TGFβ), phagocytic activity and T cell stimulatory
capacity. Results: Microparticles had little effect on macrophage function unless given at
very high (toxic) doses (>10μg/ml). However, in the presence of LPS, microparticles acted
as adjuvants - improving cytokine responses by ~10%. This was shown to result from
adsorption of LPS to the surface of microparticles in the presence of calcium (Ca2+) in the
culture medium. Microparticles also reduced the levels of phagocytosis, inhibited accumula-
tion of engulfed latex beads and partly inhibited macrophage T cell stimulatory capacity.
Significantly, although the responses were generally larger, cells from Crohn’s disease patients
were no more susceptible to the presence of microparticles than cells from healthy controls.
Conclusions: Although they are immunologically ‘inert’ on their own, adsorption of luminal
biomolecules to the surfaces of dietary microparticles could turn them into potent stimuli
which might exacerbate established inflammation. Dietary microparticles also affect phagocyt-
osis and T cell stimulatory capacity. In addition, since microparticles are selectively targeted
to phagocytic macrophages, we believe they could potentially be used as delivery systems
to enhance the efficacy of therapeutic agents. Our observations provide potential mechanisms
by which dietary microparticles may alter immune regulation at the level of macrophages.
Funded by: Broad Medical Research Program
M1767
NOD2 (CARD15) Mutations Are Associated with Mycobacterium Avium
Subspecies Paratuberculosis (MAP) DNA in Intestinal Tissue But Not with
Viable MAP in the Blood of Crohn’s Disease (CD) Patients
John F. Valentine, Xiao-Hong Song, Jerome Elam, Saleh Naser
BACKGROUND: MAP is an intracellular pathogen that causes Johne’s disease, a chronic
granulomatous enteritis in animals. The role of MAP as an etiologic agent or as an environ-
mental cofactor for CD is controversial. Recent studies have been more consistent in the
identification of MAP in patients with Crohn’s disease. NOD2 is an intracellular pattern
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recognition receptor recognizing muramyl dipeptide, a component of bacterial cell wall
peptidoglycans and is expressed in monocytes, macrophages, dendritic cells, paneth cells
and intestinal epithelial cells. Mutations in NOD2 have been associated with impaired
clearance of intracellular pathogens in the experimental setting. We determined the relation-
ship of the presence of CD associated NOD2 mutations in patients that had blood cultured
for MAP or had presence of MAP IS900 DNA evaluated in intestinal tissue. METHODS:
DNA was available on 23 of 28 CD patients that had previously had blood cultured for
MAP (group 1). DNA was available for all 21 additional CD patients had previously had
surgically resected intestinal tissue evaluated for the presence of MAP IS900 DNA (group
2). CD associated NOD2 mutations (R702W, G908R, 1007fsinsC) were determined using
a TaqMan based allelic discrimination assay. The results were analyzed with respect to MAP
culture data and MAP IS900 DNA data. RESULTS: For group 1, 12 of the 23 (52%) had
(+) MAP blood cultures, 6 of the 23 (26%) had NOD2 mutations (1 heterozygous R702W,
1 heterozygous G908R, 3 heterozygous 1007fsinsC and 1 homozygous 1007fsinsC). There
were no compound heterozygotes. 2 of the 6 (33%) with NOD2 mutations also had positive
MAP cultures (NS). For group 2, 17 of 21 (81%) were MAP IS900 DNA (+), 8 of 21 (38%)
had NOD2 mutations (2 heterozygous R702W, 4 heterozygous 1007insC, and 2 compound
heterozygotes R702W and 1007insC). 7 of the 8 (87.5%) with NOD2 mutations also had
MAP DNA detected in intestinal tissue (P<0.02). For groups 1 and 2 combined, 14 of 44
(32%) carried NOD2 mutations. CONCLUSIONS: NOD2 mutations are associated with the
identification of MAP DNA in the intestinal tissue of patients with CD but not with those
with MAP bacteremia. The association of NOD2 mutations with MAP in intestinal tissue
may be related to a decreased bacterial clearance related to a defect in NOD2 dependant
intracellular killing or an increased viability due to NOD2 dependant defects in the epithelial
barrier such as production of defensins.
M1768
Increased Expression of Tlrs’ Is Associated with An Upregulation of Signalling
Molecules Irak-1 and NfκB in Colonic Biopsies of Patients with Inflammatory
Bowel Disease (IBD)
Anushka De Costa, Neil Rayment, Maria Mylonaki, Barry N. Hudspith, Liljana Petrovska,
Jonathan Brostoff, Carlo Nunes, Gareth Parkes, Jeremy Sanderson, David Rampton
Background: Toll like receptors are innate cellular pattern recognition receptors (PRR’s)
which recognise specific bacterial antigens and are, in part, responsible for the immunological
unresponsiveness towards normal commensal flora. We have previously reported changes
in mucosal associated bacterial flora in IBD patients and the presence of E.coli within
macrophages in the lamina propria. We have now investigated the activation status of both
epithelial cells and lamina proprial macrophages and compared co-expression of TLRs’ 2,
4 and 5 with signalling molecules IRAK-1 and NFκB. Methods: Snap-frozen rectal biopsies
were taken at routine colonoscopy from patients with ulcerative colitis (UC, n=8), Crohn’s
(CD, n=8.) and controls with normal colorectal mucosa (n=8). Toll like receptor 2, 4
and 5 expression, signalling molecules IRAK-1 and NFκB and macrophages (CD68)were
determined using indirect immunofluorescence. Epithelial cells were identified by their
histological appearance and co-localisation confirmed using confocal microscopy. Results:
Moderate epithelial expression of TLRs’ 2 and 4 with little or no epithelial expression of
TLR 5 was seen in controls and correlated with absence of signalling molecules IRAK-1 or
NFκB. IBD biopsies showed increased epithelial expression of TLRs’ 2 and 4 (not 5) and
was associated with increased IRAK-1 and NFκB levels. A similar pattern of TLR expression
was seen in lamina proprial macrophages with greater expression of TLRs’ 2 and 4 in IBD
patients compared to controls. Modest amounts of TLR-5 were also seen in this group but
none in control samples. In IBD biopsies, co-localisation of TLR’s with IRAK-1 and NFκB
in lamina proprial macrophages showed a significant increase in expression compared to
that seen in epithelial cells. Conclusion: Increased expression of TLRs’ and signalling molec-
ules IRAK-1 and NFκB in IBD is consistant with a heightened immunological response to
enteric microflora and may contribute to the pathogenesis of the disease
M1769
Dose Dependent Interaction of NOD2 with TLR2 in Human Monocytes
Michelle Borm, Adriaan A. van Bodegraven, Chris J. Mulder, Georg Kraal, Gerd Bouma
Background and aims: The mechanism by which mutations in NOD2 predispose to Crohn’s
disease (CD) is poorly understood. Nod2 is an intracellular receptor for the bacterial product
muramyl dipeptide (MDP). Previous studies in mice have shown that Nod2 signalling inhibits
Toll-Like Receptor (TLR)-2 responses. So far, this effect could not be reproduced humans,
in fact, several groups have shown that simultaneous stimulation of Nod2 with MDP and
different TLRs with their appropriate ligands may lead to a stronger inflammatory response.
Here we show that the effect of Nod2 signaling on TLR responses is dose-dependent. In
the current study we intend to further explore this discrepancy. Methods: Monocytes were
isolated from venous blood from healthy volunteers. After stimulation with different doses
of MDP (Nod2 ligand) together with synthetic TLR2 and TLR7 ligands, and lipopolysaccharide
(LPS, TLR4 ligand), culture supernatants, nuclear extracts and RNA were isolated. NF-κB
activation and production of pro-inflammatory cytokines were measured with ELISAs, and
mRNA levels of the cytokines were measured with real time RT-PCR. Results: Monocytes
respond to Nod2 stimulation in a dose dependent fashion, although this response is weak
compared to TLR stimulation. Simultaneous addition of TLR ligand and low doses of MDP
to the culture medium resulted in a significant increase in the NF-κB activation as well as
cytokine production, (as compared to TLR stimulation alone) both on mRNA level and
secreted protein. Importantly however, addition of higher doses of MDP abolished this effect
specifically in TLR2 signaling, whereby the cytokine responses returned to the baseline
production of cytokines with TLR2 stimulation alone. Conclusions: Contrary to the resent
findings in mice, in which a clear reduction of cytokine responses was detected when
mononuclear cells are co-incubated with Nod2 and TLR2 ligands, we did not observe such
an inhibition in human monocytes in this pilot experiment. In fact, we show for the first
time that monocytes from healthy Nod2 wild-type donors respond to Nod2 stimulation in
a biphasic fashion. First, at low doses, Nod2 stimulation enhances the TLR2 response, then,

















dose-dependent mode of interaction of Nod2 and TLR2 activation. Whether or not there
is true negative regulation of TLR2 responses as is seen in mice, remains to be determined
in humans. Studies with monocytes from CD patients in the CARD15/NOD2 are underway.
M1770
Critical Role of Cxcl12-Cxcr4 Interaction in the Pathophysiology of
Inflammatory Bowel Disease
Sakae Mikami, Hiroshi Nakase, Takashi Nagasawa, Tsutomu Chiba
Background: Chemokines have been widely studied owing to their important role in regulat-
ing the trafficking of leukocytes under normal conditions and to sites of inflammation.
CXCR4 is a constitutive chemokine receptor, which is widely expressed on leukocytes and
is involved in the recirculation of naïve lymphocytes through high endothelial venules into
lymphoid tissue. Moreover, recent studies indicate that CXCL12-CXCR4 chemotactic axis
are involved in several inflammatory conditions. However, it remains unclear whether this
interaction is associated with the pathophysiology of inflammatory bowel disease (IBD).
Aim: The aim of our study is to examine the role of CXCL12-CXCR4 chemokine axis in the
pathophysiology of IBD. Methods: (1) We evaluated the expression of CXCR4 in peripheral T
cells and CXCL12 in colonic tissue of dextran-sulfate sodium (DSS)-induced colitis. C57/
B6 mice were fed 3% DSS in their drinking water for up to 5 days. Infiltration of inflammatory
cells into the mucosa and the expression of CXCL12 were analyzed by immunohistochemistry.
Expression of CXCR4 in peripheral blood cells was analyzed by FACS. (2) We also evaluated
the change of CXCR4 expression in peripheral T cells from 4 patients with ulcerative colitis
(UC) during the leukocytapheresis (G-CAP or L-CAP). Result: (1) In animal study, FACS
analysis revealed that CXCR4 expression in peripheral T cells was approximately five-fold
in DSS-induced colitis mice compared to normal mice. Moreover, the expression of CXCL12
in inflamed colonic tissue was increased in colitis mice compared to control mice. (2) In
human study, FACS analysis revealed that CXCR4 expression in peripheral T cells from
patients with active UC was significantly higher than normal controls. Interestingly, after
starting leukocytapheresis for these patients, CXCR4 expression was gradually decreased in
all patients. Moreover, when these patients got into clinical remission, CXCR4 expression
became normal. These results suggested that the intensity of CXCR4 expression in peripheral
T cells was correlated with the activity of patients with UC. Conclusion: CXCR4-mediated
lymphocytes recruitment may be critically involved in colonic inflammation. We firstly
found the increased CXCR4 expression in T cells of DSS-induced colitis mice. Our results
raise the possibility that the enhancement of CXCR4 expression in T cells contributes to
the perpetuation of colonic inflammation. Therefore, the inhibition of CXCL12-CXCR4
interaction in peripheral T cells may be one of the promising therapies for patients with
IBD in the future.
M1771
Alternative Mechanisms of Action of Tacrolimus in IBD: Inhibition of
Intestinal Epithelial Cell- and NKT Cell- Activation
Jolanda M. Van Dieren, Janneke van der Woude, M E. Lambers, Ernst J. Kuipers, Edward
E. Nieuwenhuis
Background: Tacrolimus is a calcineurin inhibitor, which has been shown to be effective in
the treatment of IBD. Inhibition of T cell activation has been suggested as the major
mechanism of action of tacrolimus function. Other mucosal cells such as the intestinal
epithelial cells (IEC) are known to contribute to the pathogenesis of IBD through the
production of cytokines and chemokines. Furthermore, CD1d restricted T-cells have recently
been found to be a major source of enhanced IL-13 production in human ulcerative colitis.
The aim of this study was to determine whether tacrolimus exerts its effects through inhibition
of activation of either CD1d restricted T-cells and/or IECs. Methods: A CD1d restricted
Natural Killer (NK) -T cell-line (DN32.D3) was stimulated by overnight incubation with a
CD1d transfected intestinal epithelial cell-line (T84-d) that was pulsed with aGalactosylcera-
mide (aGalCer). aGalCer is a glycolipid antigen that is known to activate NKT cells in a
CD1d restricted fashion. Another intestinal epithelial cell-line (Caco-2) was stimulated by
overnight incubation with peptidoglycan at 10 μg/ml. Both in vitro assays were performed
in the absence or presence of different concentrations of tacrolimus. NKT cell activation
was determined by measurement of IL-2 production and Caco-2 stimulation by IL-8 produc-
tion by means of ELISA. Results: Pre-treatment of NKT cells with tacrolimus caused a
dose-dependent reduction of IL-2 production upon stimulation with an exogenous antigen
(aGalCer) as presented by T84-d cells, an IEC line. Interestingly, the same dose dependent
reduction of NKT cell activation was observed when the antigen presenting T84-d cells were
pre-treated with tacrolimus. Caco-2 cell activation by peptidoglycan could also be inhibited
by tacrolimus, albeit at higher dosages. Conclusion: These data show that the inhibitory
functions of tacrolimus can be extended to CD1d restricted NKT cells as well as IECs, which
may explain the effectiveness of tacrolimus in IBD.
M1773
Infliximab Induces a Genotype-Dependent Mucosa Protective Matrix
Metalloproteinase Phenotype in Inflammatory Bowel Disease
Martin J. Meijer, Marij A. Mieremet-Ooms, Wim van Duijn, Annie M. van der Zon,
Roeland Hanemaaijer, Jan H. Verheijen, Ruud A. van Hogezand, Cornelis B. Lamers, Hein
W. Verspaget
Previous studies have shown an upregulation of matrix metalloproteinases (MMPs) in intest-
inal tissue of patients with inflammatory bowel disease (IBD) and a significant clinical and
endoscopical improvement of the patients after administration of the anti-TNF-α antibody
infliximab. We determined the expression and secretion of MMP-1, -2, -3, -9 and their
inhibitors TIMP-1, -2 by IBD vs control intestinal mucosa ex vivo and assessed the regulatory
capacity by infliximab of the proteolytic phenotype. Intestinal mucosal explants from 20
IBD and 15 control patients, were cultured in medium with or without infliximab and/or
the T-cell activator pokeweed mitogen (PWM). Explants and culture supernatants were
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analysed for MMPs, TIMPs and TNF-α protein, activity and/or mRNA levels by ELISA, BIA
and semi-quantitative RT-PCR. All patients were genotyped for functional TNF-α, MMP and
TIMP single nucleotide polymorphism (SNP) loci by RFLP or tetra primer ARMS PCR. The
expression of MMP and TIMP protein/activity in basal medium was higher for IBD vs control
explants, and for the MMPs also within the explants. Infliximab downregulated genotype-
dependently MMP-1, MMP-3 and MMP-9 relative to TIMP-1 and -2, and also decreased
MMP-1 and MMP-3 activities, while PWM enhanced these levels, partly counteracted again
by infliximab. The expression of MMP-2 relative to TIMP did not change by treatment with
infliximab and/or PWM. Conclusions: The high expression of MMPs in patients with IBD
suggests a role for these proteinases in the pathogenesis of the disease. Infliximab induces
a genotype-associated matrix protective phenotype by downregulating MMP-1, -3 and -9
relative to TIMP, which may contribute to the observed therapeutic efficacy of this drug in
IBD, particularly at the mucosal surface.
M1774
The Peripheral Immune Cell Population Reflects the Local Disease Activity
and Colonic Extension At the Onset of Ulcerative Colitis
Lena Ohman, Stefan Isaksson, Evangelos Kalaitzakis, P-O Stotzer, Magnus Simren, Hans
Strid
AIM: The colonic localization of ulcerative colitis (UC) is highly individual and the under-
standing of underlying factors resulting in the individual variation of the disease severity
and extension of the mucosal inflammation in UC is currently limited. The aim of this study
was to investigate if peripheral immune activity is correlated to the local disease extension
and/or disease activity at the onset of UC. METHOD: Blood samples were taken from 25
untreated patients (11 women, age 37.3±16.3) within the first week of UC onset. The colonic
disease extension was established during colonoscopy. 13 patients had an extensive colitis,
7 patients had a left sided dominated colitis, whereas 4 patients had proctitis. The disease
activity was determined by using the well validated Mayo score. The frequency of peripheral
blood T cells was analysed by flow cytometry and ANCA specific ELISA analysis was
performed from serum samples. RESULTS: There was no correlation between the frequency
of peripheral CD4+ T cells or CD8+ T cells and the disease activity or the colonic disease
extension. However, the frequency of peripheral CD4+ T cells expressing an activated
phenotype, defined as CD62L-CD45RA-, was negatively correlated to the disease activity
(p=0.048) (R=0.38). There was no correlation between the frequency of peripheral activated
CD8+ T cells and the disease activity or the extension of the disease. There was no correlation
between CD4+ or CD8+ T cells expressing integrinβ7 and the disease activity, although
patients with a left sided colitis tended to have an increased frequency of Intβ7+CD8+ T
cells (56.7±12.8 vs 46.6±17.0, p=0.15) as compared to patients with an extensive colitis.
The frequency of CD19+ B cells in blood was not associated to the disease activity or the
colonic disease extension, although the frequency of activated CD19+ B cells, defined as
CD38high, was positively correlated to the disease activity (p=0.02) (R=0.44). The frequency
of peripheral natural killer cells (NK cells) was found to be negatively correlated to the
disease activity (p=0.045) (R=0.39), and tended to be increased in patients with left sided
colitis/proctitis (8.7±5.0) as compared to patients with extensive colitis (6.0± 3.3)(p=0.08).
The levels of ANCA in serum did not correlate to the disease activity or the colonic disease
extension. CONCLUSIONS: The results from this limited number of patients indicate that
the disease activity and the colonic extension of ulcerative colitis are reflected by the peripheral
immune cell population. This might be a useful tool as part of the evaluation of disease
activity and extension in patients with ulcerative colitis.
M1775
Clostridium Difficile Toxin a Increases Focal Adhesion Kinase (FAK) and
Paxillin Dephosphorylation Through Inactivation of Src Kinase
Ho Kim, Charalabos Pothoulakis, John T. Lamont
C. difficile toxin A glucosylates Rho, Rac, and cdc42 in cultured cells, inactivating these
proteins and eventually causing actin filament disaggregation and cell rounding. We previ-
ously showed that toxin A impaired tight junction formation colonocytes. We investigated
the roles of toxin A on FAK and paxillin involving focal contact formation. we assessed
effects of toxin A on the Src kinase dependent FAK/paxillin activation in non-transformed
human colonocytes (NCM460). The dephosphorylation of FAK and paxilline in response
to toxin A was measured by western blotting. The changes of Src kinase activity induced
by toxin A were studied by in vitro kinase assays. Toxin A increased dephosphorylation of
paxillin at tyrosine 118 in colonocytes within 1 hour. In colonocytes exposed to toxin A,
dephosphorylation of FAK, which has been known to phosphorylate paxillin at tyrosine
118 also strongly detected and which completely correlated with the time pattern of paxillin
dephosphorylation. Blockage of glucosyltransferase activity of toxin A or toxin A induced
production of reactive oxygen species by using several chemical inhibitors did not affect
toxin A induced dephosphorylation of FAK and paxillin. However, Src kinase inhibition by
PP2 or SU6656 increased dephosphorylation of FAK/paxillin similar to effect of toxin in
colonocytes. We also found that EGF-induced phosphorylation of Src at tyrosine 416 (its
active phosphorylation site) were markedly decreased in colonocytes exposed to toxin A.
In vitro kinase assay also showed that addition of toxin A suppressed the kinase activity of
Src. By analyzing immunoprecipitation, we demonstrated that toxin A added to whole
colonocyte extracts could bind to intracellular Src protein in a dose dependent manner.
Toxin A suppression of the Src kinase-mediated activation of FAK/paxillin did not require
glucosyltransferase activity of toxin A. These results suggest that direct binding of toxin A
to c-Src kinae, without involvement of protein tyrosine phosphatase, could cause inhibition
of Src kinase and subsequent FAK/paxillin activation, which may result in failure of focal
contact formation of colonocytes. These results provide insight into the profound disturbance
in intestinal tight junction formation observed in C. dfficile infection.
M1776
Identification of a Role for Shiga Toxin (STX1) in Enterohemorrhagic Colitis
Includes Increased TNFα and Downregulation of Galectin-3
Marina Laiko, C. Zu, Okana Gustal, Edward Boedeker, Robert Cole, Mark Donowitz,
Olga Kovbasnjuk
The rabbit cecum model of enterohemorrhagic colitis (EHEC), which most closely resembles
the intestinal pathology seen in human EHEC, was used to test the hypothesis that Shiga
toxin1 (Stx1) contributes to the intestinal pathophysiology. In this model RDEC-1, an E.
coli strain that adheres to rabbit mucosa and causes an attaching and effacing lesion , and
RDEC-H19A, a strain engineered to express recombinant Stx1, were fed to New Zealand
White male rabbits. 7 days later, experimental animals (n=3) infected with RDEC-H19A
strain developed hemorrhagic diarrhea, while control RDEC-1 infected animals (n=3)
developed mild watery diarrhea. Animals were sacrificed and cecal tissue was obtained for
biochemical, immunofluorescence, and Mass Spectroscopy studies. The production of Stx1
in rabbits infected with RDEC-H19A was confirmed in cecal lysates by Western blot analysis.
Mass spectroscopy with iTRAQ analysis of protein expression profiles showed significant
downregulation of galectin-3 (Gal-3) in rabbits with Stx1 compared to the bacteria alone.
Immunoblotting validated a significant decrease in Gal-3 expression from 0.28 ± 0.03 units
in control to 0.14 ± 0.01, (p=0.02) in Stx1-exposed animals. TNF-α levels were increased
2-3x in Stx1 exposed cecum compared to bacteria controls. The downregulation of Gal-3
by Stx1 in intestinal epithelial cells was also confirmed using a T84 cell model, in which
incubation of cells for 72 h with holotoxin or B-subunit of Stx1 (Stx1B) both significantly
decreased the Gal-3 amount compared to control non-treated cells. Gal-3 is a galactose
binding protein, which is predominantly expressed in the upper crypt region of human
colon and is involved in regulation of cell inflammation, maintenance of epithelial barrier
function, and apoptosis. Gal-3 is downregulated in intestine in patients with Crohn’s disease
and this is due to elevation of TNF-α. We conclude: 1) An animal model of EHEC showed
that the presence of Stx1 is associated with TNF-α upregulation and a downregulation in
Gal-3. 2) It is likely that the changes in TNF-α contribute to the changes in Gal-3. This is
the first report of Gal-3 involvement in Stx1-induced intestinal disease. These results identify
a potential role for Stx1 in EHEC diarrhea, specifically that Stx1 may trigger inflammatory
mechanisms similar to those that occur in Crohn’s disease.
M1777
Transgenic Epithelial Cell Toll-Like Receptor (TLR) Signaling Reduces
Inflammation in DSS Colitis
Rachel S. Levi, Laurens Kruidenier, Lisa Meijer, Xiao Ping Lu, Meera Sebastian, Sven
Pettersson, Ian R. Sanderson
Commensal bacterial may protect against intestinal inflammation through TLR signaling
(Rakoff-Nahoum et al, Cell 2004,118:229). However, it is not yet clear which intestinal cell
type transduces the beneficial bacterial signals. We hypothesized that TLR signaling by the
epithelium would inhibit intestinal inflammation. Methods: We developed a transgenic mouse
using a constitutively active human TLR4 cytoplasmic domain linked to the extracellular
domain of CD4, under the control of the intestinal epithelial cell-specific fatty acid binding
promoter (Fabpi). Colitis was induced in transgenic and wild-type male littermates with
1% dextran sodium sulfate (DSS). Weight loss and fecal consistency was monitored daily
and after 1 week inflammation was assessed by histology. Results: Transgenic mice expressed
CD4-TLR4 mRNA in the small and proximal large intestine, which appeared normal without
any signs of spontaneous intestinal inflammation. However, their response to DSS-induced
colitis differed significantly. Typical symptoms of colitis, such as loose stools, rectal blood
loss, and loss of body weight, were observed in 7/8 (88%) of the wild type mice, but only
in 7/37 (19%) of the TLR transgenic littermates. As a consequence, cumulative weight loss
(Figure) was significantly more severe in the normal mice (20.1±3.7% at day 7) than in the
transgenics (5.5±1.1%, P<0.01). Furthermore, histopathological assessment showed fewer
neutrophils and lymphocytes and less mucosal damage and remodeling in the transgenic
mice than in wild-type littermates. Conclusions: TLR signaling through intestinal epithelial
cells is sufficient to reduce intestinal inflammation. Thus, the epithelial cell may transduce
the effect of commensal bacteria in inhibiting IBD.
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M1778
Helicobacter Pylori Caga Dependent Activation of the Signal Transducer and
Activator of Transcription 3 (STAT3) Signaling Pathway
Dana Bronte-Tinkew, Nicola Jones
Infection with CagA positive Helicobacter pylori strains enhances the risk for the development
of gastric cancer. However the underlying mechanism(s) whereby this bacterium causes
gastric cancer remain unknown. Recent evidence indicates that aberrant activation of the
STAT3 signaling pathway may play a role in the development of gastric cancer. Therefore,
we hypothesized that H. pylori infection modulates STAT3 signaling. To investigate possible
alterations in STAT3 signaling, HEp-2 epithelial cells were infected with wildtype H. pylori
strains (60190, G27 or 251) or the corresponding isogenic mutants: cagA, cagA EPISA with
a mutation in the tyrosine phosphorylation domain (EPIYA), cagE, and cagM mutant strains
at a multiplicity of infection (MOI) of 100:1 for up to 4hrs. As a positive control the
known STAT3 activator IL-6 was employed. To determine STAT3 activation, expression of
phosphorylated STAT3 was detected by Western blotting. In addition, fluorescence-recovery
after photobleaching (FRAP) was performed on cells transfected with STAT3-GFP constructs.
To delineate potential mechanisms for STAT3 activation, cells were incubated with IL-6/
gp-130 receptor antagonists gp130mAb or sant7. Wildtype H. pylori strains induced activation
of STAT3 in HEp-2 epithelial cells, which was independent of changes in IL-6. In contrast
isogenic mutants of the type IV secretion system did not induce STAT3 activation. Further-
more, the cagA mutant failed to activate the STAT3 pathway. However, the H. pylori EPISA
mutant strain activated the STAT3 pathway in a similar manner to its parental wildtype
strain G27 indicating that tyrosine phosphorylation of cagA was not required. Inhibition of
IL-6 receptor activation blocked the H. pylori-mediated increase in STAT3 phosphorylation.
Taken together these results indicate that H. pylori activates the STAT3 signaling pathway
in epithelial cells in a CagA dependent manner, however tyrosine phosphorylation of the
injected CagA protein is not required. Activation appears to occur early in the signaling
pathway at the receptor level and is not due to a direct increase in IL-6. These findings provide
a potential mechanism by which chronic H. pylori infection promotes the development of
gastric cancer.
M1779
Dramatic Increase of Mucosal But Not Peripheral Regulatory T Cells in
Untreated HIV Infection, Normalization By Suppressive Haart
Hans-Jorg Epple, Christoph Loddenkemper, Desiree Kunkel, Hanno Troeger, Jochen
Maul, Verena Moss, Reiner Ullrich, Jorg-Dieter Schulzke, Harald Stein, Rainer Duchmann,
Martin Zeitz, Thomas Schneider
Background: Recent evidence indicates that regulatory T cells (Treg) play an important role
in the pathogenesis of HIV infection. However, although the gastrointestinal mucosa is a
key compartment in HIV disease, no data on mucosal Treg in HIV infection are available.
Aim: In this study, we compared the frequency of Treg in the duodenal mucosa and peripheral
blood of treatment-naive and suppressively treated HIV-infected patients with those of
normal controls. Methods: Mucosal Treg cells were determined in duodenal biopsies of 11
treatment-naive and 9 treated HIV-infected patients, 6 patients with norovirus infection and
12 patients without upper GI pathology (healthy controls) by immunhistochemistry with
double immunoenzymatic (CD3+FOXP3+ or CD25+FOXP3+) detection of Treg. The specifi-
city of the immunhistochemistry was confirmed by demonstration of co-expression of FOXP3
with cell surface markers for Treg by FACS (CD4+CD25high), immunhistochemical or
confocal analysis (FOXP3+CD25high, FOXP3+GITR+). The frequency of Treg in peripheral
blood was determined by FACS (CD3+CD4+FOX3+ and CD3+CD4+CD25high) and by
immuncytochemistry (CD3+ FOXP3+). Results: Mucosal Treg were highly increased in
untreated (40% of mucosal CD4+ T cells versus 1.2% in healthy controls, p<0.001) but
normal (1.8%) in treated patients. In contrast, no significant differences in the frequencies

















mucosal Treg returned to normal after suppression of HIV replication by HAART. Further-
more, in Norovirus infection, the frequency of mucosal Treg in the CD4+ T cell subset was
only marginally elevated compared to normal controls. Therefore, the high increase in the
frequency of mucosal Treg seems to be a characteristic feature of untreated HIV infection
and is linked to active viral replication. Conclusions: The accumulation of Treg in a major
site of HIV replication suggests a significant contribution of Treg to the pathogenesis of HIV
disease. Their role, however, may be ambivalent, attenuating HIV-induced T cell hyperactiv-
ation while suppressing the immune response to HIV and opportunistic pathogens.
M1780
Differential Pattern of CD62l Expression On CD1d-Unrestricted and CD1d-
Restricted T Cells Following Listeria Infection Is Regulated By IFN-Gamma
Hyun Kim, Victor Arrunategui-Correa
BACKGROUND: CD62L, a member of the selectin adhesion family, is required for lymphocyte
homing to peripheral lymph nodes (PLN) and to sites of inflammation. Unlike other leukocyte
adhesion molecules, CD62L is rapidly down-regulated from the cell surface upon cell
activation. CD62L expression is observed in a subset of CD4+ regulatory T-cell populations
(CD25+). Previously, we have demonstrated distinct trafficking patterns of NKT cells in
PLN, mesenteric lymph nodes (MLN), and non-lymphoid tissues isolated from Listeria
monocytogenes (Lm)-infected WT, invariant NKT (iNKT) cell deficient Jα18 KO, and CD1d
KO mice. AIM: We have therefore investigated the role of CD62L and CD122 (IL-2/IL-15R)
expression in PLN and MLN in these 3 strains of mice to determine if CD62L was an
important determinant in the migration pattern we have observed. METHODS: WT, CD1d
KO, and iNKT Jα18 KO mice were infected orally with 5x108 Lm and CFUs were measured.
PLN and MLN were then prepared by standard methods and suspended in PBS/0.2% BSA
for flow cytometric analysis using CD62L and CD122 mAb. Production of cytokines from
cultured supernatants of activated MLN was measured using an ELISA kit. RESULTS: Lm
colonies were detected in MLN at day 1, and reached the maximal CFU by day 3 post-
infection in all three strains, with CD1d KO mice displaying the highest CFU of viable Lm.
Flow cytometric analysis at day 1 revealed that CD62L+ cells were decreased in both PLN
and MLN isolated from iNKT Jα18 KO and CD1d KO when compared with WT mice. In
contrast, CD122+ cells were inversely increased in PLN and MLN of iNKT and CD1d KO
mice. The increased CD122+ cell population was most pronounced in MLN of CD1d KO
mice (30%), while PLN from Jα18 KO and WT mice showed a modest increase (8%
and 2%, respectively). Thus, CD122 is preferentially expressed in CD1d-unrestricted T
lymphocyte subset, whereas CD62L is predominantly expressed in CD1d-restricted T cell
subset. Double CD62L+CD122+ cells were also increased only in the MLN of CD1d KO
mice, but not in PLN where the level was similar to Jα18 KO and WT mice. Cytokine
production in the MLN culture supernatants showed a strong IFN-gamma production in
CD1d KO mice when compared with Jα18 KO and WT mice, suggesting a Th1-dependent
pathway in the regulation of CD62L and CD122 expression. CONCLUSION: CD1d-restricted
and CD1d-unrestricted T lymphocytes show opposite CD62L and CD122 expression patterns
following oral Lm infection. CD122-expressing CD1d-unrestricted T cells were activated
early after infection to produce IFN-gamma and display a unique trafficking pattern distinct
from CD1d-restricted T cells.
M1781
Helicobacter Pylori Infection Induces a T Regulatory Response Mediated By
TGF-B and IL-10 in Children, in Contrast to the TH1 Response Characterized
By IFN-G Observed in Adults
Lesley Smythies, Paul Harris, Ronald H. Clements, Lisa M. Mosteller-Barnum, Guillermo
Perez-Perez, Phillip D. Smith
Background: In developing countries, such as Chile, >60% of children are infected with H.
pylori, but rarely develop ulcerative disease, whereas infected adults frequently develop
ulceration. To determine if T cell responses are involved in this down-regulated inflammatory
response to H. pylori in children, we characterized gastric T cell responses in infected children
and adults and blood T regulatory (CD4+/CD25+) cell responses in adults. Methods: Gastric
mucosal TGF-b, IL-10, IFN-g, IL-13 and IL-4 were measured in supernatants of homogenized
biopsies from Chilean children (<12 years; n=36, 50% infected) and adults (>18 years; n=
44, 75% infected). Purified CD4+/CD25+ and CD4+/CD25- T cells from H. pylori-infected
and uninfected patients were stained for FOXP3, LAG 3 and CTLA-4 (regulatory cell profile)
and cultured alone or with homologous monocyte-derived dendritic cells pre-stimulated
with H. pylori urease or Cag A, and culture supernatants were assayed for IL-2, IL-10, TGF-
b and IFN-g. Results: 11% of H. pylori-infected children had gastric ulceration compared
to 40% of adults. Gastric mucosa from H. pylori-infected children had significantly higher
levels of T regulatory cell cytokines IL-10 and TGF-b compared to infected adults. In contrast,
gastric mucosa from infected adults had significantly higher levels of the Th1 cytokine IFN-
g compared to infected children. Among uninfected children and adults, gastric levels of
TGF-b were higher in children. Th2 cytokines IL-13 and IL-4 were similar among the groups
and unchanged by infection. Unsorted T cells (and CD4+/CD25- cells) from infected persons
produced IFN-g and IL-2 in responses to H. pylori antigens, and these responses were
strongly inhibited by CD4+/CD25+ cells in association with increased IL-10 and TGF-b.
Conclusions: H. pylori-infected children have significantly less gastric ulceration than infected
adults. Increased levels of gastric TGF-b and IL-10 in infected children, but increased levels
of IFN-g in infected adults, suggests that H. pylori introduces a gastric T regulatory response
in children and a Th1 response in adults. Higher levels of TGF-b in gastric tissue from
uninfected children may predispose children to mucosal T regulatory cell responses. The
CD4+/CD25+ T cell-mediated down-regulation of IFN-g and IL-2 released from circulating
T cells of H. pylori-infected persons suggests the presence of a T regulatory cell population.
We speculate that CD4+/CD25+ T cells down-regulate host responses to H. pylori infection
in children and possibly adults without ulcer disease.
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M1782
Bacterial Antigens Alone Can Break Epithelial Barrier Integrity While Live
Bacteria Are Required to Initiate Intestinal Inflammation
Beate C. Sydora, Sarah M. Martin, Maryla Lupicki, John W. Walker, Levinus A. Dieleman,
Thomas A. Churchill, Jason Doyle, Richard N. Fedorak
Background: It is well established that the intestinal microflora plays a critical role in the
initiation and perpetuation of inflammatory bowel diseases (IBD) and that bacteria are
involved in driving the intestinal and systemic immune responses. We have recently demon-
strated that fecal slurry containing both live bacteria and bacterial antigens can rapidly
(within 7days) lead to a disruption of epithelial barrier integrity and sustained intestinal
inflammation when fed to axenic IL-10 gene-deficient mice. Objective: To further understand
the mechanism of this inflammatory process we separated the role of live bacteria and
bacterial antigens on the alteration of epithelial barrier integrity and the systemic and intestinal
inflammatory response. Methods: Axenic (confirmed luminally sterile) IL-10 gene-deficient
mice at 12wk of age were administered either fresh fecal slurry with live bacteria and bacterial
antigens or a sterile fecal slurry with bacterial antigens only, devoid of live bacteria through
lysation and filtration. Intestinal and systemic immune and inflammatory responses (intestinal
and splenic cytokine profiles) and epithelial barrier integrity (mannitol transmural flux) were
assessed 1wk later. Results: The fecal slurry with live bacteria and bacterial antigens resulted
in both a disruption of epithelial barrier integrity (mannitol flux: 22±3 nm/cm2/h vs 13±1
nm/cm2/h in fecal slurry-treated vs axenic controls, respectively; p=0.005) and increase in
intestinal (5- and 10-fold increase in colonic and cecal IFNγ release compared to axenic
controls, respectively) and increase in systemic (up to 20-fold increase in splenic IFNγ
release following stimulation with various bacterial antigens compared to axenic controls)
inflammatory response. In contrast, the identical sterile fecal slurry, devoid of live bacteria
and with bacterial antigens only, disrupted the epithelial barrier integrity (mannitol flux: 19±2
nm/cm2/h vs 13±1 nm/cm2/h in sterile fecal slurry-treated vs axenic controls, respectively p=
0.01) but did not induce a systemic or intestinal inflammatory response (zero increase in
IFNγ release in cultures from intestinal or splenic tissue compared to cultures from axenic
controls, respectively). Conclusion: We have demonstrated, for the first time, the discordance
between the ability of bacterial antigens to disrupt the epithelial barrier integrity but not
cause sustained intestinal or systemic inflammatory responses until live bacteria are present.
M1783
Intestinal Microflora Modulates Mucosal Expression of Macrophage Colony-
Stimulating Factor (M-CSF) and Granulocyte-Macrophage Colony-Stimulating
Factor (GM-CSF)
Koichi Takebayashi, Ryota Hokari, Yoshikiyo Okada, Keisuke Okudaira, Chie Kurihara,
Hisayuki Matsunaga, Norikazu Mataki, Syunsuke Komoto, Chikako Watanabe, Atsushi
Kawaguchi, Shigeaki Nagao, Kazuro Itoh, Yoshikazu Tsuzuki, Soichiro Miura
BACKGROUND & AIMS: Enterobacteria have been implicated in the pathogenesis of inflam-
matory bowel diseases (IBD), and reported to be essential for the initiation of experimental
murine colitis. Mucosal macrophages (mMΦ) are also related to the pathogenesis of IBD by
secreting both inflammatory and inhibitory cytokines in response to enterobacteria. Because
mMΦ differentiates into two different phenotypes under macrophage colony-stimulating
factor (M-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF), we speculate
enterobacteria may modulate intestinal inflammation through different CSF induction in the
intestinal mucosa. However, there is no report how changes of bacterial flora affects CSF
expression in vivo. In this study, we compared CSF expression in the intestine under germ
free (GF) or specific pathogen free (SPF) condition. We also examined effects of specific
enterobacterial colonization on CSF expression in GF mice. MATERIALS & METHODS: We
used male IQI mice bred under GF or SPF conditions. Jejunal, ileal and colonic mucosa
were removed. Messenger RNA of M-CSF, GM-CSF, M-CSF receptor, GM-CSF receptor and
TNF-α were measured by quantitative RT-PCR. The expression of adhesion molecules in
the ileal mucosa were evaluated by immunohistochemistry. In some GF mice, Bifidobacterium
bifidum or Bacteroides vulugatus was inoculated and changes of CSF expression were evaluated
after 21 days. RESULTS: In colonic mucosa, GM-CSF expression significantly decreased
and GM-CSF receptor expression decreased slightly in GF mice compared with SPF mice.
Interestingly, on the other hand M-CSF expression increased slightly in GF mice. TNF-α
expression was significantly suppressed in GF mice, comparable with the deviation to M-
CSF dominant environment in GF condition. Immunohistochemical study revealed the
significant increase in infiltration of CD4+ and β7-integrin+ cells and expression of MAdCAM-
1+ vessels in SPF mice than GF mice. Even after inoculation of enterobacteria in GF mice,
however, there was no sign of inflammation and both bacteria significantly decreased GM-
CSF receptor expression, while M-CSF receptor expression increased slightly, maintaining
the enhanced M-CSF dominance. In the jejunal or ileal mucosa, effects of enterobacteria to
the M-CSF deviation was less dominant than in the colonic mucosa. CONCLUSIONS: Results
suggest that intestinal microflora regulates cytokine production and adhesion molecule
expression via modulation of M-CSF and GM-CSF expression. The M-CSF dominant environ-
ment in GF mice may be related to the decreased inflammatory cytokine response, thus
giving us a suggestion of CSF as one of therapeutic targets for IBD.
M1784
Identification of Antigens Encoded By Enterococcus Faecalis That Display
Serum Reactivity and Stimulate T Cell Responses in E. Faecalis -
Monoassociated IL-10-/- Knockout Mice
Sandra C. Kim, James P. Moran, Michael J. Lodes, Robert Hershberg, Susan L.
Tonkonogy, R. Balfour Sartor
Background/aims: Germ-free (GF) IL-10 knockout (-/-) mice develop immune-mediated
distal-predominant colitis when monoassociated with a non-pathogenic E. faecalis (Ef) strain.
An oligoclonal TCR expression pattern in the colonic tissue and mesenteric lymph node
cells (MLN) suggests that restricted T cell expansion in this model is due to activation by
a limited profile of bacterial antigens. We sought to identify antigenic components of Ef
that induce these T cell responses. Materials and Methods: A genomic random shear lambda
expression library was generated from our published Ef strain and screened with sera from
colitic Ef - monoassociated IL-10-/- mice. Three of 20 gene products identified by anti - Ef
antibody binding were selected to be cloned and expressed as recombinant proteins (EF-
20, EF-33 and EF-60) and used for further analysis of T cell reactivity. GF IL-10-/- and
wild-type (WT) control mice were monoassociated with Ef and studied 16-30 wks after
inoculation; Ef - monoassociated IL-10 -/- animals develop severe colitis at this time point.
CD4+ MLN were stimulated with antigen presenting cells (APC) that were pulsed overnight
with a control protein (KLH) or the recombinant Ef proteins. IFNγ was measured in co-
culture supernatants as an indicator of T cell reactivity. To determine non-specific T cell
activation, we tested each stimulant in unfractionated splenocyte cultures in the presence
of an anti-IL-12 neutralizing antibody or an isotype matched control antibody. Results: EF-
60 stimulated IFNγ secretion from IL-10 -/- CD4+ MLN/APC co-cultures that was significantly
greater than the response to KLH. Responses to EF-20 and EF-33 were minimal (KLH:
0.2±0.1 ng/ml, EF-20: 0.4±0.03, EF-33: 0.5±0.1, EF-60: 4.6±1.3; p < 0.006). Anti-IL-12
neutralizing antibody reduced the IFNγ response to EF-60 by nearly 80% in splenocyte
cultures, but it had little effect on the IFNγ levels in splenocyte cultures stimulated with
EF-20 or EF-33 (Table). The same antibody concentration completely blocked IFNγ produc-
tion in cultures stimulated with 20 ng/ml of LPS. Conclusions: Colitic IL-10 -/- mice
monoassociated with Ef develop immune responses that display both antibody and T cell
reactivity to Ef - encoded antigens. Much of the T cell response to EF-60 was suppressed
by IL-12 neutralization. Further studies are required to determine whether EF-60 contains
adjuvant activity in addition to a T cell epitope.
Table 1. IFNγ measurements in IL-10 -/- splenocyte (SPL) culture supernatants (ng/ml).
M1785
Enteropathogenic E. Coli Promotes the Transactivation of Epidermal Growth
Factor Receptor
Jennifer L. Roxas, Athanasia Koutsouris, V.K. Viswanathan
Enteropathogenic Escherichia coli (EPEC), a diarrheagenic pathogen, is responsible for
significant infant mortality and morbidity, particularly in developing countries. While the
precise mechanism by which EPEC causes diarrhea remains to be delineated, infection-
dependent alterations in intestinal epithelial barrier function and the induction of pro-
inflammatory cytokines contribute to the process. EPEC transfers specific virulence factors
into host cells via a type III secretion system. EPEC, by an unknown mechanism, activates
the PI-3 kinase and MAP kinase signaling pathway in host cells. EPEC activation of the MAP
kinases ERK1/2 contributes to the production of the pro-inflammatory cytokine, interleukin 8.
The aim of this study was to explore the effect of EPEC on the epidermal growth factor
receptor, a known upstream activator of both the PI-3 kinase and MAP kinase pathways.
Caco-2 BBE monolayers were infected with WT EPEC or a type III secretion mutant for
specific time points, washed, and the extracts immunoblotted against EGFR, EGFR pY1068,
ERK1/2, phospo-ERK1/2, Akt or pAkt. EPEC induced a progressive increase in EGFR auto-
phosphorylation (pY1068) in intestinal epithelial cells, and this was blocked by the EGFR
tyrosine kinase inhibitor, tyrphostin. A type III secretion mutant (ΔescN) also activated
EGFR, ruling out the involvement of secreted effector molecules in EGFR autophosphoryl-
ation. Moreover, filter-sterilized EPEC growth medium promoted EGFR phosphorylation,
suggesting that bacterial attachment is not required for this process. EPEC stimulated the
phosphorylation of Akt, a PI-3 kinase substrate, and this was significantly attenuated by
tyrphostin. Tyrphostin significantly inhibited EPEC-induced phosphorylation of ERK1/2,
and attenuated interleukin 8 production in infected epithelial cells. The effect of tyrphostin
was specific, since it did not impair attachment of bacteria to host cells, the recruitment of
actin, or EPEC-induced barrier function alteration. Taken together, this suggests that EGFR
transactivation is an early signaling event associated with EPEC infection that contributes
to the innate immune response of host intestinal epithelial cells.
M1786
Important Role of Cytolethal Distending Toxin in Campylobacter Jejuni-
Induced Host Proinflammatory Cytokine Responses and Loss of
Transepithelial Electrical Resistance in Colonic Epithelial Cells
Ming L. Chen, Zhongming Ge, James G. Fox, David B. Schauer
BACKGROUNDS AND AIMS: Campylobacter jejuni (Cj) is the leading cause of human food-
borne enteritis, however, microbial virulence factor(s) responsible for host inflammation
have yet to be elucidated. Cytolethal distending toxin (CDT), a secreted tripartite toxin
composed of A, B and C subunits, has been identified in several bacterial pathogens including
Cj. CDT has been shown to induce proinflammatory cytokine secretion and cell cycle arrest;
the latter event could be partially attributed to the DNase-like activity of CDTB. We previously
generated an isogenic cdtB mutant by inactivating the gene in Cj strain 81-176 and found
that this mutant lacks the capacity to induce gastroenteritis in NF-kB-deficient mice (Infect.
Immun. 72: 1116). The aim of this study was to further investigate the mechanisms by
which CDT contributes to gastroenteritis. METHODS: T84 cells were grown on collagen-
coated Transwell inserts (0.4 µm pore-size) and reached 1500-2000 ohm*cm 2 weeks after
seeding. Polarized monolayer was apically infected with Cj or the cdtB mutant at a bacterial:cell
ratio of 100:1. IL-8 secretion and transepithelial electrical resistance (TER) were determined
by ELISA and with a voltohmmeter, respectively. RESULTS: Basolateral IL-8 secretion was
elevated from 159 +/- 19 pg/ml (n = 6) in mock infected cells to 328 +/- 29 pg/ml (n = 6)
in Cj-infected cells 48 hrs post-infection. The amount of IL-8 secreted by T84 cells infected
with the cdtB mutant (231 +/- 62 pg/ml, n = 6) was reduced compared to the wild type.
TER is a measurement of tight junction (TJ) barrier function. Cj infection caused a significant
loss in TER (22.2 +/- 12.8% of control, n = 4); while a more modest decrease in TER (43.4
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+/- 12.3% of control, n = 4) was found in cdtB mutant-infected cells. CONCLUSIONS:
Increased proinflammatory cytokines and disruption of TJ barrier function are hallmarks of
microbe-induced gastroenteritis. Our data demonstrate that Cj induces proinflammatory
cytokine responses and disrupts TJ barrier function in polarized T84 cells. Furthermore,
CDT plays an important role in mediating pathophysiological alterations in Cj infection.
Future studies are aimed at elucidating the host intracellular pathways modulated by Cj
leading to these changes. (This work was supported by NIH grant DK52413).
M1787
Upregulation of the TH1 Immune Response By Inducing Colitis Through
TNBS Or Citrobacter Infection Results in Stereotypic Changes in Colonic
Smooth Muscle and Epithelial Function
Thomas L. Sutton, Aiping Zhao, Justin E. Elfrey, Kathleen B. Madden, Carolyn A.
Sullivan, Allen Smith, Terez Shea-Donohue
IBD results from a complex interaction among genetics, bacteria, and the environment
resulting in a Th1 dominant inflammation. Murine Citrobacter rodentium (CR) infection of
the colon is an emerging model of IBD with notable similarities to clinical disease. The
impact of CR on colonic smooth muscle and epithelial cell function, however, is unknown.
Aim: To determine 1) the functional changes in smooth muscle and epithelium in response
to CR colitis and 2) compare these results with the more established model of TNBS induced
colitis. Methods: BALB/c mice (n>9/group) received intrarectal TNBS (2mg/mouse in 40%
ETOH) or saline and studied 4 days later. C57/BL/6 mice (n>3/group) were infected orally
with live CR (5x1010 cfu) or vehicle and studied 12 days later. Microscopic damage was
assessed blindly. Stripped colonic mucosae were mounted in Ussing chambers to measure
mucosal resistance (R) and changes in short circuit current upon serosal addition of acetyl-
choline (ACH), 5-HT, or histamine (HIST). Colonic muscle segments were suspended in
organ baths and responses to ACH (1mM), HIST (1mM) and electrical field stimulation
(EFS)(5Hz) were determined. Real-Time PCR determined the colonic expression of IFN-g,
TNF-a, IL-4, and HIST 1 and 4 receptor (H1R; H4R). Results: CR and TNBS induced a
colitis featuring significant (p<0.05) mucosal damage and upregulation of IFN-g (51.3- &
2.4-fold) and TNF-a (4.2- & 2.1-fold) with no change in IL-4 (1 & 1.4-fold). Despite
evidence of mucosal damage, CR improved mucosal resistance, likely due to marked mucosal
hyperplasia. Smooth muscle and epithelial cell responses to ACH were unchanged. In
contrast, both models inhibited contractility to EFS and HIST and reduced secretory responses
to HIST and 5-HT. Inhibited responses to HIST were associated with a >50% reduction in
H1R expression. The >3.5-fold increase in the expression of the proinflammatory H4R reflects
the increase in the number of hematopoeitic cells. Conclusions: These data demonstrate that
1) greater expression of Th1 cytokines in CR versus TNBS does not lead to a corresponding
greater effect on gut function; and 2) upregulation of Th1 cytokines induces a stereotypic
hyposecretion and hypocontractility of the colon that is independent of the etiology.
*p<0.05vsVEH
M1788
Downregulation of TNF-α Gene Expression in Human Intestinal Mucosa By
Non-Adherent Probiotic Bacteria
Marta Llopis, Maria Antolin, Francisco Guarner, Siv Ahrne, Goran Molin, Juan R.
Malagelada
Introduction: The mechanisms by which certain bacteria modulate cytokine secretion by
intestinal mucosa have not been clarified. The probiotic bacteria Lactobacillus plantarum
299v has the ability to adhere in vitro to human intestinal epithelial HT29 cells, but its
spontaneous mutant strain (A-) lacks this property. Aim: To determine the potential anti-
inflammatory effect (TNF-α inhibition) of three known Lactobacillus strains and to investigate
their mechanism of action. Methods: Macroscopically normal explants (n=6) of colonic
mucosa were obtained from patients undergoing colectomy for colonic neoplasia. Mucosal
explants were stimulated ex vivo with PMA/Ionomycin and incubated during 4 hours with
10E6 CFU/mL of test probiotic bacteria: Lactobacillus plantarum 299v (Lp),Lactobacillus
plantarum 299vA- (LpA-), Lactobacillus casei ATCC334 (Lc) or no bacteria (blank). Release
of TNF-α (ELISA), pH, and LDH enzyme (viability) were assessed in supernatant and relative
quantification of the TNF-α mRNA was determined in the tissue. Mucosal colonisation by
the probiotic bacteria was assessed by microbiological culture using the following formula:
(CFU in the tissue/ CFU in supernatant + tissue) x 1000. The in vitro capacity of the
probiotics to degrade TNF-α was tested in parallel by incubation with standard TNF-α in
the absence of tissue. Results: All three strains decreased TNF-α release by the mucosa
(% inhibition versus blank, mean±sem: Lp 67±4.1%*, LpA- 54±10.0%*, Lc 63±16.0%*,
*p<0.001 vs. blank). The three strains showed TNF-α degradation activity in vitro (%
degradation versus blank: Lp 68%±13*, LpA- 66%±3*, Lc 58%±2*, *p<0.001 vs. blank).
Both L.plantarum strains downregulated TNF-α gene expression, but Lc had no effect (relative
TNF-α mRNA expressed as ratio test/blank, Lp 0.67±0.23, LpA- 0.49±0.05*, Lc 0.89±0.22,
*p<0.05 vs. blank). Mucosal colonization by the non-adherent strain LpA- was negligible
(index of 0.7) and much lower than colonization by Lp (2.4) or Lc (35.7). Conclusion:

















This effect is unrelated with epithelial adherence or mucosal colonization, which suggests
mediation by a soluble anti-inflammatory substance of bacterial origin.
M1789
Cytomegalovirus Reverses the Normal Inflammation-Suppressing Effect of
Intestinal Stroma On Blood Monocytes
Akhil Maheshwari, Lesley E. Smythies, Ronnie Clements, Yolanda Hartman, Meg
Mosteller-Barnum, William J. Britt, Phillip D. Smith
Background: Cytomegalovirus (CMV)-mediated gastrointestinal disease is an important cause
of morbidity and mortality in immunocompromised patients. CMV mucosal disease is
characterized by prominent inflammatory cell infiltration despite the presence of relatively
few CMV-infected cells. Since the absence of inflammation in normal intestinal mucosa is
due, in part, to extra-cellular matrix (stromal) down-regulation of the pro-inflammatory
function of monocytes newly recruited to the mucosa (JCI 2005; 115: 66), we hypothesize
that CMV-induced mucosal inflammation is initiated when CMV infection of monocytes
reverses the normal stroma-induced downregulation of chemokine and cytokine production.
Reversal of the normal stroma-induced downregulation of IL-8 would enhance neutrophil
recruitment to mucosal sites of inflammation. Methods: Blood monocytes were isolated by
magnetic bead (MACS) separation or counterflow centrifugal elutriation. Lamina propria
stromal tissue (1 gm/mL) was cultured in RPMI for 24 hrs to harvest stroma-conditioned
media (S-CM). Monocytes were infected with a clinical (TR) or laboratory (AD169) isolate
of CMV (1 pfu/mL). Cultures were treated with S-CM (5-500 μg/mL) for 2 hrs and then
stimulated with LPS (1 μg/mL) for 1 hr. Monocyte IL-8 production was measured in
supernatants after 24 hrs by ELISA (R&D). Control CMV was UV-irradiated (to kill), heated
(to inactivate), heparin-treated (to prevent viral binding to cell membrane heparan sulfate),
or treated with CMV-treated serum (to inactivate). Results: Cultures of monocytes exposed
to the TR and AD169 strains of CMV expressed CMV IE-1 gene product in 29% and 35%
of the monocytes, respectively after 48 hrs after infection. LPS increased monocyte IL-8
production ten-fold. Exposure to S-CM completely inhibited LPS-stimulated IL-8 production.
However, CMV-infected monocytes, but not control CMV-infected monocytes, produced
increased level of IL-8 (6-fold) following S-CM treatment and LPS stimulation. Conclusion:
Our findings indicate that CMV-infection reverses the normal S-CM downregulation of
monocyte chemokine production leading to an increase in inducible IL-8 production. Reversal
of the normal stroma-induced downregulation of IL-8 provides a mechanism for enhanced
neutrophil recruitment to mucosal sites of CMV infection.
M1790
Colonization with Helicobacter Bilis Increases Susceptibility to DSS-Induced
Colitis in Gnotobiotic Mice
Abigail L. Henderson, Andrea Dorn, Zhiping Liu, Jennifer H. Wilson-Welder, Mark R.
Ackermann, Albert E. Jergens, Michael J. Wannemuehler
Background: The etiology of inflammatory bowel diseases (IBD) including ulcerative colitis
and Crohn’s disease is unknown. In addition to genetic predisposition to IBD, the develop-
ment of aberrant immune responses to the intestinal flora have been implicated in the
pathogenesis of IBD. It is hypothesized that colonization of the intestinal tract with an
environmental provocateur (e.g., Helicobacter bilis) may induce T cell responses to members
of the normal flora that enhance susceptibility to colitis. Infection with Helicobacter has been
associated with the development of IBD-like lesions in immunodeficient mice. The effect of
H.bilis colonization on the development of host mucosal immune responses is poorly under-
stood. Aim: To evaluate the mechanisms by which H.bilis colonization enhances susceptibility
of DF mice to DSS-induced colitis. Methods: Groups of 6-8 week old, gnotobiotic C3H/
HeN:tac mice bearing the altered Schaedler flora (ASF) were colonized with H.bilis. Three
to 20 weeks postinfection, mice were treated with low dose of DSS (1.5%) in the drinking
water for 5 days. Mice were euthanized 6 days after cessation of DSS treatment and evaluated
for gross/histologic lesions and cell-mediated immune responses. Comparisons were made
between DSS treated, H.bilis colonized, DSS/H.bilis (dual) treatment mice and non-treated,
non-colonized (control) mice. Results: Gross cecal scores were significantly increased (p <
0.05) in dual treated mice compared to mice in all other groups at all times post-colonization
with H.bilis. Colon length of dual treated mice was significantly decreased (p < 0.05)
relative to control or H.bilis colonized mice. Cecal histopathology revealed increased mucosal
cellularity, hyperplasia of lymphoid follicles and crypts, and moderate to severe epithelial
erosions in the dual treated groups compared to all other groups. Mice colonized with H.bilis
developed ASF antigen-specific T cell proliferative responses following in vitro stimulation.
Sensitivity to DSS and the severity of lesions induced by DSS was correlated to the magnitude
of the host response to the ASF antigens. Relative to control mice, cytokine analysis of cell
culture supernatants showed increased secretion of IFN-Υ and TNF-α for all 3 experimental
groups. Additionally, increased antigen-specific secretion of IL-12 and IL-10 were observed
in the dual group versus all other groups. Conclusion: These studies demonstrate that
colonization of DF mice with H.bilis increased their susceptibility to DSS-induced colitis.
The increased sensitivity to low dose DSS correlated with host immune responses as demon-
strated by development of antigen-specific proliferation.
M1791
Antibiotic Therapy Temporaryly Suppresses Mucosal Bacterial Biofilms in IBD
and Enhances Them Upon Cessation of Therapy
Alexander Swidsinski, Yvonne Doerffel, Vera Loening-Baucke, Laura P. Hale, Franz
Theissig, Hartwig Andree, Herbert Lochs
Background: Antibiotics are commonly used in IBD for treatment of septic complications,
abscesses, and wound infections. Little is known about the influence of antibiotics on the
mucosal flora. Aims: To compare the concentrations and spatial organisation of mucosal
bacteria in IBD patients treated with metronidazole and ciprofloxacin for different length
of time with those who have not received antibiotics. Patients and methods: Six groups
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were investigated, including 20 patients each with ulcerative colitis or indeterminate colitis.
Groups were selected with regard to duration of/interval to antibiotic therapy: Group 1= 1
day of therapy; Group II = 7 to 14 days of therapy; Groups III to V included patients 1 to
4, 12 to 18, and 26 to 36 weeks after the end of antibiotic therapy, respectively. The control
group VI included patients without documented antibiotic therapy for >2 years. Biopsies from
ileum, ascending colon and sigmoid colon were investigated using 40 different fluorescent in
situ hybridization (FISH) probes that represented the diversity of the human intestinal flora.
Results: No biofilms could be detected by rRNA-directed FISH in any of the biopsies obtained
from patients during active treatment with antibiotics. However, adherent bacteria could be
found in 12 patients of group I and two patients of group II using a DAPI stain that detects
DNA. Prolific adherent biofilms could be observed after cessation of antibiotic therapy, with
mean concentrations of mucosal bacteria of 13.2±4.3 (p<0.001); 5.8±2 (p<0.001); 1.1±0.8
(ns); 0.5±0.4 (x 1010/per milliliter) in groups III to VI, respectively. The composition of the
biofilm differed significantly between these groups. For example, the Eubacterium rectale
Clostridium coccoides bacterial group was the highest in the patients in group III, while
Fusobacterium prausnitzii dominated in group IV. The concentration of both bacterial
groups decreased in patient of groups V and VI. The concentration and occurrence of
Enterobacteriaceae did not differ between patients in groups III to V, but was significantly
higher (p<0.001) in these groups than in group VI with no exposure to antibiotics. Conclu-
sions: Antibiotic treatment suppresses the viability of mucosal bacteria, however their concen-
trations rapidly increase upon antibiotic cessation to a level that is at least 10-fold higher
than in patients not treated with antibiotics. Statistically significant changes in composition
of mucosal bacteria can be found up to 8 month after the cessation of antibiotic therapy.
M1792
Alteration of TM7 Bacterial Phylogenies in Inflammatory Bowel Disease
Tanja Kuehbacher, Ateequr Rehman, Ulrich R. Foelsch, Stephan J. Ott, Stefan Schreiber
Introduction: TM7 is a recently described subgroup of gram-positive unculturable bacteria
originally found in natural environmental habitats. Recent studies have shown an association
of TM7 bacterial division with inflammatory mucosal diseases, especially periodontitis and
subgingival plaques. The TM7 family of bacteria is suggested to play an important role in
the early stages of inflammatory mucosal processes, probably by modifying growth conditions
for competing bacterial populations. Aims: To investigate the TM7 bacterial subgroup in
inflammatory bowel diseases (IBD). Methods: Mucosal biopsy samples of patients with Crohn
disease (CD) and ulcerative colitis (UC) were compared to healthy controls. The colonic
mucosal TM7 consortia have been examined using molecular techniques based on the 16S
rDNA phylogeny, such as clone libraries, sequencing, and in-situ hybridization (ISH). Results:
TM7 molecular 16S rDNA signatures could be cloned from mucosal samples of IBD patients
and controls, but the composition of the clone libraries differed significantly (p<0.05) for
both the CD and UC patients compared to healthy controls. Taxonomic analysis of the
sequences revealed a higher diversity of TM7 subspecies in UC (n=18) and CD (n=16)
compared to healthy individuals (n=6). The clone libraries obtained from IBD patients
showed a high number of novel sequences (n=27 for CD, n=10 for UC) while no novel
sequences were observed in healthy controls. A highly atypical base substitution for bacterial
16S rRNAs associated with antibiotic resistance was detected in most of the TM7 sequences.
In-situ hybridization of colon tissue section demonstrated the presence of TM7 group as
filamentous bacteria. Conclusions: As previously demonstrated for oral inflammatory dis-
eases, TM7 subgroup of bacteria might also play a pivotal role in inflammatory bowels
diseases. The microbiotic shift of TM7 bacteria and the genetically determined antibiotic
resistance of TM7 species in IBD could be a relevant part of a more general alteration of
bacterial microbiota in IBD as recently found and could also be a basis for new thera-
peutic approaches.
M1793
Changes in Mucosal Gene Expression Profiles Following Colonization of
Gnotobiotic Mice with Helicobacter Bilis
Zhiping Liu, Andrea Dorn, Daniel S. Nettleton, Jennifer H. Wilson-Welder, Abigail L.
Henderson, Albert E. Jergens, Michael J. Wannemuehler
Background: Dysregulation of host immune responses to gut microflora and genetic defects
are considered as two important contributors to inflammatory bowel diseases. Helicobacter
bilis is a gram-negative bacterium that has been shown to induce colitis in immunodeficient
mice. Our data suggest that H. bilis infection can induce host immune responses to microflora
without observable inflammation and increased susceptibility of mice to DSS-induced colitis.
Aims: To define mucosal changes in gene expression in order to evaluate molecular mechan-
isms that may contribute to the increased susceptibility to colitis. Methods: Gnotobiotic
C3H/HeNTac mice bearing the altered Schaedler flora were colonized with H. bilis. As an
acute inflammatory control, mice were treated with 2% dextran sulfate sodium (DSS) for 5
days. Mice were necropsied at 15, 30, or 45 days after H. bilis infection and 6 days after
DSS treatment. Total RNA was isolated from mice ceca and converted into cRNA followed
by submission to the Iowa State University Genechip Facility. The samples were evaluated
for gene expression using Affymetrix Genechip Mouse Expression Set 430 2.0 arrays. Data
were analyzed with R software and Bioconductor package. Data were normalized by Robust
Multi-array Average methods. Genes were selected by false discovery rate q value less than
0.1 and fold change more than 1.5 compared to negative controls. Results: 1) There were
3 gene expression patterns with the greatest changes in gene expression noted at 15 days
postinfection (DPI). The gene expression pattern at 30 DPI was similar to that at 45 DPI.
2) Innate immune response genes were notably upregulated (e.g., mast cell proteases and
FcεR) relative to other genes. 3) Series of interferon-regulated genes, including IFN-inducible
GTPase P47 and P65 gene family, were significantly (p < 0.05) upregulated at15 DPI. Gene
expression of IL-10, Stat3 and Socs3 were also significantly (p < 0.05) at 15 DPI suggesting
that there was no obvious Th1/Th2 bias in immune responses. 4) In contrast to DSS-induced
colitis, gene expression induced by H. bilis infection resulted in the upregulation of B cell
differentiation and immunoglobulin genes. 5) Both DSS treatment and H. bilis infection
induced the downregulation of cytochrome P450 gene family. Conclusion: H. bilis infection
induced upregulation of innate and acquired immune response genes in the absence of overt
inflammation. Down-regulation of cytochrome P450 gene family may explain the increased
susceptibility to DSS observed following H. bilis colonization.
M1794
Assessment of Immunological Ignorance Or Tolerance to Antigens-Derived
from the Enteric Flora Prior to and After Infection with Helicobacter Bilis
Jennifer H. Wilson-Welder, Albert E. Jergens, Charles Johnson, Jon Sullivan, Michael
Drey, Andrea Dorn, Jesse M. Hostetter, Michael J. Wannemuehler
Background: The enteric flora is a critical co-factor in the pathogenesis of inflammatory
bowel diseases. This is supported by increased serum antibodies to antigens derived from
the flora (e.g., yeast antigens, OmpC, flagellin) and that antibiotic treatment can ameloriate
colitis. Data from our lab has previously shown that antigen-specific immune responses to
the normal flora are increased following infection of gnotobiotic mice with Helicobacter bilis,
a bacterial provocateur of colitis. It is unclear whether mechanism(s) governing the induction
of host responses to the normal flora are related to a loss of mucosal tolerance or overcoming
ignorance. Aim: These studies were designed to evaluate tolerance or ignorance to the host’s
enteric flora prior to microbial perturbations with H. bilis. We hypothesize that mucosal
tolerance is broken following colonization with a novel bacterial species. This alteration
induces local and systemic immune reactivity to resident bacterial antigens that contributes
to the development of colitis. Methods: Bacterial antigens were prepared by acid gylcine
extraction from each of the eight members of the altered Schaedler flora (ASF), H. bilis, or
novel organisms (Escherichia coli, Staphylococcus epidermidis) isolated from healthy C3H/
HeOuJ mice. Immune responses (serum IgG, intestinal IgA, footpad delayed-type hypersensit-
ivity (DTH) response and in vitro lymphocyte proliferation) to these antigens were evaluated
in ASF flora-bearing naïve, systemically primed, and H. bilis-infected mice. DTH responses
were confirmed histologically. Results: Mice systemically primed with antigens derived from
novel organisms exhibited a greater increase in serum antibodies and DTH response than
naïve mice or mice systemically primed with ASF antigens. Mice systemically primed with
antigens from ASF 356, 360, 361, and 519 exhibited a very modest increase in serum
antibody and little or no DTH response. ASF 500 and 492 induced both a significant increase
in serum antibodies and DTH response in both naïve and primed animals despite robust
serum antibody response to 492 in the naïve state. H. bilis colonization increased serum
antibody, DTH responses, and lymphocyte proliferation to H. bilis, normal flora, and novel
antigens suggesting a heightened immune status in these mice. Conclusions: Gnotobiotic
mice exhibit tolerance to their flora with heterogeneous levels of local and systemic reactivity.
Heightened host immune responsiveness following selective colonization of gnotobiotic mice
with H. bilis reflects dysregulation of tolerogenic mechanism(s) to the resident flora in a
susceptible host.
M1795
Assessment of Microbial Diversity in Neoplastic Colonic Tissue
Mairi E. Hope, Georgina L. Hold, Susan Berry, Mowat Ashley, Emad M. El-Omar
Background: The colonic microbiota is very diverse and is essential for promoting the host’s
health but imbalance of this microbiota has been implicated in the pathogenesis of colonic
inflammation and colorectal cancer (CRC). Molecular techniques have recently shown that
fecal microbial diversity does not accurately reflect mucosal populations, which are more
relevant to colonic health and disease. Recent work shows that healthy individuals harbor
their own unique microbial cohort that remains uniform throughout the healthy colonic
mucosal surface. It is not known if this uniformity is disturbed in neoplastic lesions of the
colon. Aims: To compare mucosal bacterial populations present in neoplastic (adenomatous
polyp and CRC) tissue with immediately adjacent normal mucosa (less than 2 cm apart)
using molecular techniques based on the 16S rRNA gene. Methods: Samples of paired
mucosal biopsies from neoplastic and adjacent normal mucosa from the same individuals
were obtained at colonoscopy (adenomatous polyps: n=72 patients) and at surgical resection
(CRC: n=83 patients). DNA was extracted from samples and subjected to PCR directed at
the bacterial 16S rRNA gene. Post-PCR analysis using denaturing gradient gel electrophoresis
(DGGE) was used to generate microbial profiles for each paired sample set. Results: DGGE
analysis showed the presence of bacterial DNA in both healthy and neoplastic tissues.
Comparison of adjacent normal and neoplastic profiles showed that 40% of tubular adenomas
and 70% of tubulovillous adenomas demonstrated altered microbial profiles. The more
advanced polyps were more likely to harbor a different microbial profile from their paired
normal tissue compared to the less advanced polyps (p<0.05). Likewise, 60% of CRC samples
had a different microbial profile compared to paired normal tissue, but the diversity did
not correlate with Duke stage indicating that altered microbiota may play a role in progression
of the earlier stages of neoplasia. Conclusions: To our knowledge this is the first demonstra-
tion of alterations in microbial diversity between paired normal and neoplastic colonic tissue.
The perturbation of colonic microbial diversity in some neoplastic lesions may be a marker
of disturbed homeostasis and may be relevant to the pathogenesis of CRC. The nature of
the microbial diversity in normal and neoplastic tissue is currently under study.
M1796
Consumption of the Probiotic Bifidobacterium Infantis 35624 Influences
Subsequent Immune Responses to in Vitro Challenge of Isolated Murine
Peyer’s Patch Cells with Bacterial Stimuli
Barbara Sheil, John MacSharry, Louise O'Callaghan, Avril O'Riordan, Alison Waters, John
Morgan, John K. Collins, Liam O'Mahony, Fergus Shanahan
Background: The impact of Bifidobacterium infantis 35624 on proinflammatory cytokine
production has been shown in models of enterocolitis. However, the influence of this
probiotic in healthy animals and prior to onset of colitis has not been well investigated.
Aims: To examine the effect of oral consumption of B. infantis 35624 on cytokine responses
from isolated Peyer’s patch cells following subsequent in vitro exposure to bacterial stimuli
using wild-type (WT) mice and IL-10 knock-out mice prior to the onset of colitis. Methods:
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Mice were fed B. infantis or placebo for 5 weeks. Peyer’s patch cells were removed and
cultured with and without Salmonella typhimurium. Cytokine production was assessed by
ELISA. Results: Non-stimulated IFN-γ secretion from Peyer’s patch cells was significantly
reduced for both WT and IL-10 KO mice following B. infantis 35624 consumption. However,
a striking difference between IL-10 KO and WT mice following probiotic consumption and
in vitro stimulation with S. typhimurium was noted where IFN-γ was significantly attenuated
in IL-10KO mice but was significantly enhanced in WT mice. CCL2 was significantly reduced
while CCL5 was significantly enhanced in Peyer’s patch cells from IL-10 KO mice fed B.
infantis 35624 following in vitro challenge. CCL5 and CCL2 levels did not change in WT
mice following B. infantis 35624 consumption. Conclusions: Oral consumption of B. infantis
35624 can influence cytokine response in the Peyer’s patch of healthy mice when subsequently
exposed to a different organism. This response is not exclusively dependent on IL-10.
M1797
Increased Diversity of the Mucosa-Associated Fungal Microflora in Patients
with Inflammatory Bowel Disease
Stephan J. Ott, Tanja Kuehbacher, Kenneth N. Timmis, Ulrich R. Foelsch, Stefan
Schreiber
Introduction: An altered bacterial diversity on the intestinal mucosa may reflect the net
influence of life-style factors associated with the development of chronic inflammatory bowel
diseases (IBD). While a reduced bacterial diversity as been reported in IBD, little is known
about the fungal microflora, which is part of the fecal ecosystem. There is experimental and
clinical evidence that fungi may be important trigger factors in the inflammatory pathophysiol-
ogy. Aims: This study aimed at a systematic analysis of the intestinal fungal microflora in
IBD. Patients and Methods: The mucosa-associated fungal microflora of 104 (colonic biopsy
tissue of 47 controls and 57 IBD patients) was investigated using 18S rDNA based denaturant
gradient gel electrophoresis (DGGE), clone libraries, sequencing, and fluorescence (FISH)
or conventional in-situ hybridization. Results: Fungi-specific 18S rDNA signatures could be
detected in all 104 patients. An overall fungal biodiversity of 43 different operational
taxonomic units (OTUs) was found in the clone libraries. The qualitative composition of
the fungal microflora was different between patients with IBD and controls. The DGGE
profiles revealed a higher mean fungal diversity in the Crohn disease (CD) patients in
comparison with controls (10.8 ± 3.1 vs. 6.2 ± 2.4 for CD, p = 0.001). A separate analysis
showed no association of fungal diversity with drug treatment or histological activity. Conclu-
sions: A high number of fungal species is part of the normal enteric microflora, but diversity
was increased and composition of the fungal communities varies in IBD. Further work is
needed to investigate whether the alteration of the fungal flora in IBD is secondary to an
imbalanced bacterial microflora or a independent etiologic factor.
M1798
Role of the Reduced Folate Carrier (RFC) in Intestinal Folate Uptake
Krishnaswamy Balamurugan, Hamid M. Said
Background: Humans and other mammals cannot synthesize folate, and thus, they must
obtain the vitamin from exogenous sources. We have previously investigated different aspects
of intestinal folate uptake process and have cloned the RFC from human and mouse intestine
and characterized its function in homologus and heterologus cellular systems (e.g., Gastroen-
terology. 112:783-91, 1997; J. Biol. Chem. 272:6226-31, 1997; J Biol. Chem. 277:33325-
33, 2002). To date, however, little is known about the contribution of the RFC system
toward total carrier-mediated folate uptake by intestinal epithelial cells. Attempts to generate
RFC knock out mice model to address such an issue have proven to be un-successful due
embryonic lethality. Here we describe the use of the new approach of lentiviral- mediated
short hairpin RNA (shRNA) to selectively silence the endogenous RFC and examined the
effect of such silencing on intestinal carrier-mediated folate uptake. Methods: The rat-derived
intestinal epithelial IEC-6 cells and RFC specific shRNA were used in this study. Levels of
RFC mRNA and protein were determined by mean of Real-time PCR and Western blotting
using RFC specific polyclonal antibodies. Results: Initial rate of uptake of 16 nM 3[H]-folic
acid in un-treated cells showed a marked increase as a function of lowering incubation
buffer pH from 8.0 to 5.5. Addition of unlabelled folic acid to the incubation buffer lead
to a severe inhibition in initial rate uptake of 3[H]-folic acid (16 nM) at incubation buffer
pH 5.5 (~95%) but not at pH 7.4. Treating IEC-6 cells (for 72 hrs)with RFC specific shRNA
lead to a severe reduction (~80 and 78%) in the endogenous levels of RFC mRNA and
protein levels, respectively. Such a treatment also led to a severe inhibition (~90%) in carrier-
mediated folate uptake at pH 5.5 but not at pH 7.4. On the other hand, uptake of the
unrelated biotin was not affected by treating the cells with RFC specific shRNA. Conclusions:
The results show that the carrier-mediated folate uptake system in intestinal epithelial cells
is functional at acidic pH and that RFC is the major (if not the only) folate uptake system
that is involved in intestinal folate absorption. [Supported by the grants from DVA and NIH
(DK58057 and DK56061)]
M1799
Mechanism of Increased Intestinal Na+/Glucose Co-Transporter (SGLT1)
Expression in Human Type 2 Diabetes
J.N. Dyer, Anthony Ellis, Soraya P. Shirazi-Beechey
We have reported previously that there is a coordinated 4-fold increase in the expression
of the luminal membrane monosaccharide transporters SGLT1 and GLUT5, and 3-fold
increase in basolateral membrane GLUT2 in the small intestine of human type 2 diabetic
patients. This increase is independent of blood glucose and insulin levels as low carbohydrate
diet and the taking of sulfonyl urea or metformin drugs had no effect on reducing expression
levels. In this work we set out to determine the mechanism(s) involved in this up-regulation.
In order to perform nuclear run-on experiments we first had to modify current protocols
for the isolation of intact nuclei to be applicable to duodenal biopsies (approximately 5 mg

















produce strong, reproducible signals from minimal numbers of nuclei. Biopsies were
removed, during routine endoscopy, from the second part of the duodenum of both diabetic
and healthy individuals, with the permission of the Liverpool Ethics Committee and the
written informed consent of the patients. Individual biopsies (both control and diabetic)
yielded an average of 1.25 x 106 nuclei and nuclear run-on experiments with 3 x 106 nuclei
produced around 10 kBq of purified, newly synthesised [α32P]UTP labelled, RNA. Three
separate experiments, each utilising nuclei from two control and two diabetic patients, were
carried out, and equal amounts of radiolabelled RNA were hybridised at 55oC for 20 h to
5 μg of cDNAs for SGLT1, GLUT2, GLUT5, HNF1α(transcription factor involved in the
glucose-regulation of SGLT1 transcription) and β-actin (control) loaded onto nylon mem-
brane using a slot blotter. Results show that the rate of SGLT1 transcription is 4- to 4.5-
fold higher in nuclei isolated from diabetic duodenal biopsies than controls, indicating that
the increase in the expression of SGLT1 in the intestine of diabetic individuals is entirely
due to increased SGLT1 transcription. However, the transcription rates for GLUT2 and
GLUT5, along with HNF1α, were essentially unchanged suggesting that post-transcriptional
mechanisms are involved in changes seen in the expression of these genes.
M1800
Calcium-Activated Potassium Channels in Human Colonic Crypts: A Target
for the Treatment of Secretory Diarrhea?
John E. Linley, Arun Loganathan, Malcolm Hunter, Geoffrey I. Sandle
Background: In rat and human distal colon, Ca2+-activated K+ channels are involved in K+ and
Cl- secretion. Apical large conductance (BK or KCNMA1) channels are a critical component of
active K+ secretion, whereas basolateral intermediate conductance (IK or KCNN4) channels
contribute to maintaining the driving force for Cl- secretion, which is mediated by CFTR
located in the apical membrane. In many examples of secretory diarrhea, an increase in
intracellular Ca2+ concentration is the dominant factor involved in eliciting the K+ and/or
Cl- secretory responses, which depend on the relative magnitudes of the apical and basolateral
K+ conductances. Aims: To quantify the Ca2+-sensitive ion conductances of the apical and
basolateral membranes of human colonic crypts. Methods: Human distal colonic biopsies
were obtained with consent from patients undergoing routine colonoscopy as part of the
investigation of altered bowel habit. In all cases, the colonic mucosa was normal macro-
scopically and histologically. Crypts were isolated by Ca2+ chelation (Bowley KA et al. Gut
52,854-860,2003). Whole-cell currents were measured from the middle third of crypts using
the perforated patch-clamp technique (240μg/ml amphotericin in pipette). Results: Addition
of the Ca2+ ionophore, ionomycin (1μM), increased whole-cell conductance from 1.9 ±
0.4nS to 4.8 ± 1.0nS (P<0.0005; n = 17), which was accompanied by cell hyperpolarization
from -47 ± 6mV to -70 ± 4mV. The Ca2+-stimulated whole-cell current was inwardly
rectifying with a reversal potential of -70mV, approaching the equilibrium potential for K+
(-87mV), indicating that it was predominantly K+ selective. Addition of 100nM penitrem A
(a selective inhibitor of BK channels) in the presence of ionomycin reduced cell conductance
from 5.3 ± 0.5nS to 3.7 ± 0.7nS (P<0.05; n = 8). Subsequent addition of 10μM clotrimazole
(an inhibitor of IK channels) abolished the penitrem A-insensitive conductance (P<0.01;
n = 8). Post-penitrem A and clotrimazole, cell conductance was 1.0 ± 0.4nS, with a reversal
potential for the whole-cell current of -39mV, close to the equilibrium potential for Cl- (-
35mV). Thus, the ionomycin-stimulated whole-cell conductance reflects activation of IK
and BK channels, without any significant contribution from Cl- channels. Conclusions: In
human colonic crypts, the dominant effect of increased intracellular Ca2+ concentration on
ion channels is the activation of basolateral IK channels. This would hyperpolarize the cell,
thereby increasing the driving force for Cl- secretion. IK channels are therefore a potential
target for the treatment of secretory diarrheal diseases.
M1801
Prevention of Taurodeoxycholate (TDC) Cytotoxic Effect On Human Colon
Mucosa By Sphingomyelin. Electrophysiological Studies in Ussing Chambers
Piero Portincasa, Anna Diana, Laura Castellano, Antonio Moschetta, Helen H. Wang,
David Q. Wang, Francesco Marino, Donato F. Altomare, Giuseppe Palasciano, Lucantonio
Debellis
The secondary cytotoxic bile salt TDC has been shown to impair colonic ionic transport in
animals and cell lines, but little is known in humans. Detrimental effects of TDC include
prosecretory and detergent actions with relevance to clinical conditions such as bile salt
malabsorption and colon cancer. Dietary sphingomyelin (SM) is resistant to intestinal hydro-
lysis and by reaching the distal colon may protect against bile salt-induced cytotoxic effects.
Aims: We studied the human colon in Ussing chambers to assess if TDC-induced changes
in human colonic epithelial function could be prevented by SM. Methods: The effects of
TDC (1, 2, 4, and 8 mM) on electrophysiological parameters of human colon mucosa bathed
in Krebs solution were studied in the absence or with the addition of SM at 0.1 to 0.3 SM/
(SM+TDC) ratio. Transepithelial potential (Vt), resistance (Rt) and short circuit current (Isc)
were measured by a computerized voltage clamp system in the Ussing chamber. Results: In
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129 sigmoid colon specimens, basal Vt and Rt were -3.5±(S.E.)0.2 mV and 117±5 Ω*cm2
respectively and Isc was 33.5±2.2 µA/cm2. With TDC 8 mM (n=11), Isc increased by
84.7±25.5% (p<0.002) and Rt decreased by 46.9±5.25 % (p<0.001) while Vt remained
virtually unchanged. Similar but less pronounced effects were observed with TDC 2 and 4
mM, where Isc increased significantly by 18 % (p<0.02 n=13) and 32 % (p<0.05 n=11)
respectively, while Rt was reduced by about 20 %; TDC 1 mM was uneffective. SM prevented
almost completely TDC 2 and 4 mM changes of Isc and Rt. In the presence of the phospholi-
pid, TDC 8 mM increased Isc by only 27% and 5% at ratio 0.1 (n=5) and 0.3 (n=5)
respectively. Incubations with SM alone (4.28 mM) did not affect colonic epithelial transport
function. Conclusions: In the human colon, the Ussing chamber model can accurately
estimate prosecretory and detergent activities of secondary bile salts (e.g. TDC) within normal
and supraphysiological concentrations. For the first time we show here that SM prevents
TDC-induced epithelial transport alterations in human colon, possibly by decreasing free
bile salt activity in the medium. Our findings may have implications for dietary manipulation
during bile salt malabsorption or colon cancer prevention.
M1802
Acute Ileal Inflammtion Alters CFTR-Mediated Anion Secretion
Sadasivan Vidyasagar, Hui Zhang, Nadia Ameen, Franca Golin-Bisello, James Melvin,
Srisaila Basavappa
In vivo treatment of mice with anti-CD3 mAb is an established model of T-cell-mediated
acute inflammation, characterized by increased pro-inflammatory cytokines, decreased
absorption and acute diarrhea. In addition, increased fluid secretion by crypt cells during
acute inflammation may also contribute to the diarrhea. As intestinal fluid secretion is driven
by CFTR Cl- conductane, we investigated the alterations in Cl- and HCO3 transport mediated
by CFTR channels. For these studies, ileal tissues were removed three hours after intraperi-
toneal injection of anti-CD3 mAb or sham-injected mice. In Ussing chamber studies,the
basal Isc was increased significantly by ~260% in anti-CD3 injected mice. The subsequent
exposure to forskolin significantly increased Isc in both sham- and anti-CD3-injected mice.
However, the cAMP-mediated increase in Isc was significantly lower in anti-CD3 mAb-
injected mice when compared to that of the control. Addition of 300 μM glibenclamide
abolished the cAMP-stimulated increase in Isc in both control and anti-CD3 mAb injected
mice, suggesting CFTR mediated conductance. In contrast, in CFTR KO mice, the basal Isc
was reduced to 5.9 ± 0.9 μA/cm2 as compared to 11 ± 1.2 μA/cm2 in WT mice . Treatment
of CFTR KO mice with anti-CD3 did not alter the basal Isc. Furthermore, exposure to
forskolin did not significantly increase Isc in either sham- or anti-CD3 injected CFTR KO
mice. As CFTR is known to be permeable to HCO3, we investigated the effect of anti-CD3
treatment in CFTR KO mice using the pH stat method. In the presence of lumen Cl-, HCO3
secretion was 4.2 ± 0.2 and 4.6 ± 0.2 µeq/cm2/h in WT and CFTR KO mice respectively.
Removal of lumen Cl- abolished HCO3 secretion in both WT and CFTR KO mice, suggesting
ileal electroneutral HCO3 transport is not significantly altered in CFTR KO mice. Injection
of anti-CD3 decreased HCO3 secretion by ~31% and 8% in WT and CFTR KO mice,
respectively, in the presence of luminal Cl-. The subsequent removal of luminal Cl- in WT
mice did not abolish HCO3 secretion but decreased it by ~55% ,whereas as in CFTR KO
mice HCO3secretion was abolished. This suggests that CFTR-mediated HCO3 secretion is
enhanced during acute inflammation. The role of CFTR playing a pivotal role during acute
ileal inflammation was further confirmed as the protein expression of CFTR was significantly
increased in vivo in anti-CD3 treated ileal crypts. In addition, cAMP levels as detected by
immunoassay were elevated ~3.7 fold in anti-CD3 injected mice. Conclusion. The increased
Cl- and HCO3 secretion via CFTR during acute ileal inflammation may contribute to the T-
cell mediated acute diarrhea
M1803
Epidermal Growth Factor Chronically Enhances Colonic Epithelial Secretory
Capacity By Upregulating NKCC1 Expression
Fiona O'Mahony, Kim E. Barrett, Stephen J. Keely
Background: Although epidermal growth factor (EGF) is well known to promote intestinal
epithelial barrier function, its role in regulating transport function is less well understood.
Our previous data show that EGF chronically enhances epithelial responsiveness to both Ca2+
and cAMP-dependent secretagogues. Here we set out to examine the molecular mechanisms
involved. Methods: T84 colonic epithelial cells were grown as polarized monolayers on
permeable supports. Changes in Isc, indicative of electrogenic ion transport, were measured
by the Ussing chamber/voltage clamp technique. Protein expression was measured by Western
blotting and real time PCR, respectively. Intracellular Ca2+ was measured by Fura-2 fluores-
cence and protein kinase A (PKA) activity with a commercially available kit. Results: Acute
treatment of T84 cells with EGF (100 ng/ml; 15 min) chronically enhanced subsequent Isc
responses to the Ca2+- dependent agonist, carbachol (CCh, 100 µM). This effect was only
apparent after 3 hrs and was maximal by 6 hrs after stimulation with EGF at which time
responses to CCh were 206.1 ± 28.3% of those in control cells (n = 4; p< 0.01). The
potentiating effect of EGF was sustained for at least 24 hrs. The Na/K/2Cl cotransporter
(NKCC1) inhibitor, bumetanide (100 µM), abolished the effect of EGF, indicating Cl-
secretion to be involved. Neither basal nor agonist-stimulated levels of intracellular Ca2+ or
PKA activity were altered by EGF pretreatment, implying the effects of the growth factor
are not due to chronic alterations in levels of second messengers. Western blot analysis
revealed that EGF increased the expression of NKCC1 with a time course that closely
paralleled its effects on Cl- secretion. This effect of EGF was maximal after 6 hrs, at which
time NKCC1 expression in EGF-treated cells was 199.9 ± 21.9% of that in control cells
(n = 21; p<0.0001). EGF also increased the CFTR expression (by 3.9 ± 1.1 fold; n = 5; p
< 0.01) but not that of the Na/K ATPase pump. EGF-induced NKCC1 expression was
abolished by actinomycin D, implying EGF upregulates NKCC1 expression at the level of
gene transcription. Conclusions: These data reveal a novel role for EGF in chronically
regulating epithelial secretion at the fundamental level of transport protein expression. EGF
enhances epithelial secretory capacity by inducing NKCC1 expression, an effect which in
vivo would serve to promote epithelial hydration, thereby enhancing barrier function. These
data support the idea that further elucidation of EGF-dependent signalling pathways will
yield new targets for drug development in treatment of intestinal transport disorders.
M1805
The Intestinal Anion Exchanger DRA (Down Regulated in Adenoma) Is
Inhibited By Intracellular Calcium By Not By PMA
Georg Lamprecht, Julia Schaefer, Michael Gregor
Introduction: In the intestine NaCl is absorbed by parallel Na/H exchange and Cl/HCO3
exchange. The respective proteins are NHE3 and DRA (down regulated in adenoma =
SLC26A3). In the native tissue and in Caco-2 cells NHE3 is inhibited by increased intracellular
calcium. This mechanism is mediated by the interaction of NHE3 with the PDZ adapter
protein E3KARP (NHE3 kinase A regulatory protein) involving α-actinin-4 and protein
kinase C. The interaction of NHE3 with the calcineurin homologous protein (CHP) may
also mediate calcium inhibition. Aim: Is DRA also inhibited by intracellular calcium? Methods:
DRA activity was studied in HEK cells stably expressing an EGFP-DRA construct. Cl/HCO3
exchange was measured as transients of the intracellular pH (pHi) upon Cl removal and Cl
readdition in the presence of 5% CO2/HCO3. Results: In these transfected cells exogenous
DRA activity was 8-times higher than endogenous Cl/HCO3 exchange. Raising the intracellu-
lar calcium by incubation with 10 µM 4-Br-A23187 inhibited intracellular alkalinization by
45% upon Cl removal (0.013 ± 0.004 pH/s, n=8 vs. 0.007 ± 0.003 pH/s, n=9; p < 0.05).
10 µM 4-Br-A23187 did not change basal intracellular pHi (7.28 ± 0.12 vs 7.32 ± 0.06).
But the maximal alkalinization was reduced from 7.89 ± 0.09 to 7.68 ± 0.09 (p < 0.05).
Similar effects were seen with 5 µM ionomycin. Preincubation with 100 nM phorbolesther
(PMA) for 20 minutes did not inhibit DRA (n=4-5 for each group). In HEK cells, which do
not express CFTR, DRA is also not influenced by stimulation of protein kinase A by forskolin.
When a clonal cell line was measured that expresses an EGFP-DRA construct that lacks the
C-terminal PDZ interaction motif (EGFP-DRA-ETKFminus) there was a tendency for stronger
inhibition compared to the wild type construct. Conclusion: DRA is inhibited by increased
intracellular calcium but the effect is not mimicked by direct activation of protein kinase
C. This suggests a direct effect of calcium on DRA, that also does not require downstream
activation of protein kinase C. Preliminary data indicate that the effect of calcium does not
require the interaction of DRA with the endogenous PDZ adapter proteins of HEK cells.
This may be due to the relative overexpression of DRA compared to an interacting PDZ
adapter protein. Alternatively other mechanisms may mediate the effect of calcium.
M1806
SCFA-Dependent Colonic Transport Alters cAMP-Stimulated Ileal HCO3
Secretion in in Vivo Ileal and Colonic-Dual Loop Model
Sadasivan Vidyasagar, Srisaila Basavappa
In vitro pH stat studies of HCO3 secretion in stripped colonic sheets established short chain
fatty acid (SCFA)-stimulated HCO3 secretion that is lumen Cl- independent. SCFA inhibited
both Cl-HCO3 exchange and cAMP-stimulated lumen Cl-independent HCO3 secretion in
rat distal colon (Am J Physiol Gastrointest Liver Physiol 288: G1217-G1226, 2005). Down-
regulation of Cl-dependent and cAMP-induced HCO3 secretion was established to be second-
ary to the presence of SCFA and not due to one of its metabolite. However, exact mechanism
by which SCFAs alter electrolyte transport is, however, not known. Ileal HCO3 secretion
was measured in vivo using bi-burette pH stat technique in which lumen solution was
continuously titrated and re-circulated using a peristaltic pump. Simultaneously ligated
colonic loops were made which were then incubated with regular Ringer or with a SCFA-
containing solution. In the presence of lumen Cl, there was significant HCO3 secretion (4.3
± 0.13 µeq/cm2/h) in the ileum. Addition of 100 µM DIDS (0.25 ± 0.03 µeq/cm2/h) or
removal of lumen Cl abolished ileal HCO3 secretion (0.12 ± 0.03 µeq/cm2/h) indicating a
basal Cl-dependent HCO3 secretion. Addition of dibutryl cAMP to the colonic lumen solution
resulted ileal lumen Cl-independent HCO3 secretion (3.7 ± 0.11) that was inhibited by 10
µM NPPB (0.01 ±0.01 µeq/cm2/h) and by 300µM glubenclamide (0.05 ± 0.01 µeq/cm2/
h). In the presence of SCFA in colonic loop, glibenclamide had no effect on dibutryl cAMP-
stimulated HCO3 secretion in the ileal loop (3.7 ± 0.21 vs 3.5 ± 0.16 µeq/cm2/h) indicating
that colonic SCFA had inhibited cAMP-stimulated HCO3 secretion in ileum. However,
presence of SCFA in colonic loop did not alter lumen Cl-dependent, DIDS-sensitive HCO3
secretion in the ileal loop (4.3 ± 0.14 and 4.7 ± 0.11µeq/cm2/h). Summary: 1) presence of
SCFA in a colonic loop inhibits cAMP-stimulated HCO3 secretion, but does not alter Cl-
dependent HCO3 secretion. We conclude that colonic SCFA are essential in regulating
electrolyte transport at a site proximal to their production and play a more active role in a
secretory state than under basal conditions.
M1807
Decreased Expression of Breast Cancer Resistance Protein (BCRP) in the
Duodenum of Patients with Obstructive Cholestasis
Petr Hruz, Christian Zimmermann, Heike Gutmann, Luigi Terracciano, Lukas Degen,
Ulrich Beuers, Christoph Beglinger, Juergen Drewe
Human breast cancer resistance protein (BCRP/ABCG2) is present on the apical membranes
of the liver, in epithelial cells of the small and large intestine, and in kidney cells; the
transporter mediates energy dependent efflux of drugs and potentially toxic compounds,
and of various endogenous substrates such as bile acids. During obstructive cholestasis with
a disrupted enterohepatic circulation, an adaptive regulation of several transporters for bile
acids, bilirubin and cholesterol has been documented (Hepatology 2002;35:732f; Gastroen-
terology 2004;126:1044f; Gut 2006; in press). An adaptive regulation of human intestinal
BCRP during obstructive cholestasis has, however, not been described before. Aim: The aim
of this study was therefore to investigate the expression of BCRP in the duodenum of healthy
controls and compare the results to patients with obstructive cholestasis. Methods: BCRP
mRNA was quantified by real time PCR (Taqman) in duodenal biopsies of 14 control subjects
and compared to the duodenal BCRP mRNA expression of 19 patients with obstructive
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cholestasis. In addition, duodenal BCRP mRNA expression was measured in 4 patients with
obstructive cholestasis after reconstitution of bile flow. BCRP protein levels were determined
in 6 cholestatic patients and in 6 healthy control subjects by immunohistochemistry. Finally,
fasting bile acid and bilirubin concentrations were determined by specific assay systems.
Results: Normalized duodenal BCRP mRNA expression (mean BCRP/Villin ± SEM) was 0.51
(± 0.03) in controls and 0.27 (± 0.02) in cholestatic patients (p<0.001). In a semiquantitative
analysis of immunohistochemical protein assessment (0 = no expression, 1 = low, 2 =
intermediate, 3 = high expression) mean BCRP protein expression (mean±SEM) was signific-
antly reduced in 6 patients with obstructive cholestasis (1.67 ± 0.38) when compared to 6
healthy control subjects 2.91 (± 0.08) (p< 0.005). Bilirubin and bile acid plasma concentra-
tions were inversely correlated with BCRP mRNA expression (p<0.05). After reconstitution
of bile flow, bile acid and bilirubin plasma levels returned to normal and BCRP mRNA
expression increased by 1.44-, 1.71-, 1.05-, and 1.90-fold, respectively (N= 4 patients).
Conclusion: BCRP is down-regulated in the human duodenum during obstructive cholestasis.
We infer that a reduced intestinal BCRP expression during cholestasis influences the accumu-
lation of bile acids, food-derived carcinogens, and the pharmacokinetics of various drugs
that are transported by BCRP.
M1808
Short-Term Regulation of Intestinal Epithelial Type 2 Na+/K+ Exchanger By
Serotonin
Fernando Magro, Patricio Soares-da-Silva
5-HT plays a critical role in the regulation of gastrointestinal motility, secretion, and sensation.
5-HT initiates peristaltic and secretory reflexes in gastrointestinal tract. The present study
evaluated the effect of serotonin (5-HT) on intestinal Na+/H+ exchange activity and the
cellular signaling pathways involved in T-84 cells. T-84 cells express endogenous NHE1
and NHE2 proteins, detected by immunoblotting. Eipa (IC50=519[465,579]nM) was more
potent than cariporide (IC50=630[484,819]nM) and amiloride (IC50=19[16,24],μM) on
NHE activity inhibition. This different inhibitory sensitivity indicates that NHE 2 is a
dominant isoform in T-84 cells. Short term exposure (0.5h) of T-84 cells to 5-HT-induced
an increase NHE activity in a concentration-dependent manner (vehicle: 0.0063±0.0005 Vs
5-HT: 0.0090±0.0005; pH units/s). This effect was not affected by cariporide (300nM) and
S-3226 (300 nM). The next series of experiments were intended to explore the receptor
and the signaling pathways from 5-HT stimulation. The stimulation induced by 5-HT was
completely abolished by WAY 100135 (300nM) and Ketanserin (300nM), antagonists of 5-
HT1A and 5-HT2A receptors, respectively. In the presence of 8-OH-DPAT and alpha-metil-
5-HT, agonists of 5-HT1A and 5-HT2A receptors, respectively, the NHE activity was increased
(vehicle: 0.006330±0.0004 Vs 8-OH-DPAT: 0.0093±0.0008, alpha-metil-5-HT:
0.009±0.0003; pH units/s). The coincubation with 5-HT and pertussis toxin abolished the
effects of 5-HT. Therefore the cells were treated with antibodies anti Gi, Gs and Gq/11. The
effect induced by 5-HT was blocked by both anti- Gi and Gq/11. In contrast, the overnight
treatment with antibodies anti- Gi and Gq/11 only blocked the stimulatory effect of 8-OH-
DPAT and alpha-metil-5-HT, respectively. Finally, the pretreatment with anti-bodies against
to alpha Gi -1,2 prevented the NHE stimulatory effect induced by 5-HT and 8-OH-DPAT.
Conclusions: Serotonin increases intestinal NHE isoform 2 activity by stimulation of 5-HT1A
and 5-HT2A receptors.
M1809
Leptin Inhibits Na+/H+ Exchanger NHE3
Dongsheng Wang, Jennifer Johnson, Chris Yun
The epithelial brush border Na+/H+ exchanger isoform-3 (NHE3) in the intestine and kidney
is regulated by a wide variety of hormones and growth factors. Leptin is a hormone mainly
secreted by the adipose tissue. Although the effects of leptin are mediated primarily via the
central nervous system, studies have shown that nonadipose tissues, such as gastric and
intestinal epithelia, can produce leptin, suggesting that leptin has effects on other organs.
Previous studies have shown that leptin stimulates the intestinal absorption of peptide,
butyrate, and cholesterol while it inhibits galatose absorption. In addition, leptin increases
the activity of NHE1 in erythrocytes. In the current study, we determined whether leptin
affects the activity of NHE3. We utilized opossum kidney (OK) cells, which express NHE3
and lack other NHEs. The Na-dependent changes in intracellular pH by NHE3 was deter-
mined using the ratio-fluorometric, pH-sensitive dye BCECF-AM. Confluent OK cells were
serum-starved and treated with 10 nM leptin or carrier. An exposure of cells to leptin for
less than 30 min showed no apparent effect on NHE3 activity. On the other hand, incubation
of the cells with leptin for 16 h significantly decreased NHE3 activity in OK cells. The rate
of Na-dependent recovery of intracellular pH was 0.0278 + 0.0013 ΔpH/sec for control
versus 0.0189 + 0.0013 ΔpH/sec for cells exposed to leptin for 16 h. Incubation of cells
for 3 h with leptin exhibited a smaller effect compared with the 16 h exposure. The rate
of Na-dependent pH recovery was 0.0250 + 0.0008 ΔpH/sec for control versus 0.0214 +
0.0017 ΔpH/sec. The mechanism underlying the leptin-mediated inhibition of NHE3 activity
is not known. However, preincubation of cells with the protein kinase A blocker H-89
completely blocked the effect of leptin at 3h, suggesting a potential involvement of protein
kinase A. Our data show that leptin inhibits NHE3 activity but this inhitbition requires a
at least 3 h of exposure to leptin.
M1810
Effects of Lubiprostone On Morphine-Induced Constipation and Analgesia
Ryuji Ueno, Hiroyoshi Osama, Kory J. Engelke
Lubiprostone is a novel and selective activator of type-2 chloride channels (ClC-2) (AJP Cell
Physiol 287:C1173-C1183, 2004) that is currently under development for the treatment of
opioid-induced bowel dysfunction. In the present studies, the effects of lubiprostone on
morphine-induced constipation and analgesia were examined using morphine-treated mice.

















followed by an oral graphite marker. Immediately thereafter, vehicle or lubiprostone (0.1,
1, 10, or 100 μg/kg) was administered orally. Control animals orally received the graphite
marker and vehicle without morphine. All animals were sacrificed 150 minutes after adminis-
tration of the marker. Animals were then scored based upon the presence of the marker
found in the cecum. Lubiprostone significantly increased the intestinal transit of the marker
in the morphine-treated animals when compared with that of the morphine-treated control
group (p<0.01 at 1 μg/kg or higher). In addition, the effect of lubiprostone on the analgesic
effects of morphine was also evaluated. ICR mice received 5 mg/kg morphine hydrochloride
intraperitoneally followed immediately by the oral administration of vehicle or 0.1, 1, 10,
or 100 μg/kg lubiprostone. An additional control group received vehicle without morphine.
At 30, 60, 90, 120, and 150 minutes after administration of morphine, the base of the tail
was pinched with forceps and the time required for a response was measured. A significant
increase in response time was observed for the morphine-treated control group compared
with the normal (no morphine) control group at 30 minutes after morphine injection. In
addition, all animals treated with morphine and lubiprostone responded in a manner similar
to that observed with the morphine-treated control group at all time points, even at doses
100-fold higher than necessary to inhibit the morphine-induced constipation. These results
indicate that lubiprostone significantly antagonizes the constipating effect of morphine with-
out affecting the central analgesic effect of morphine.
M1811
Expression of Taste Receptors, T1r Family Members, and the G-Protein, α -
Gustducin, Along the Crypt-Villus Axis of the Small Intestine
Kieron S. Salmon, Soraya P. Shirazi-Beechey
We have shown previously, using real time PCR, that the taste receptors, T1R1, T1R2 and
T1R3, and the α-subunit of the taste - transduction G protein, gustducin, are expressed in
the mouse intestine and in an enteroendocrine cell, STC1. Furthermore we have demon-
strated, using western blotting, that the receptors along with Gα-gustducin are expressed
on, or associated with, the luminal aspect of the cells (1). The mammalian intestine is lined
with a monolayer of epithelial cells that undergo rapid and continuous renewal. The stem
cells located near the base of the crypts of Lieberkuhn give rise to daughter cells that
differentiate into several different lineages; polarised absorptive enterocytes, mucous produ-
cing goblet cells, and enteroendocrine cells. In contrast to polarised absorptive enterocytes
which constitute 90% of the villus enterocytes, enteroendocrine cells represent <1% of
the terminally differentiated cells of the intestinal mucosa. However, at least 15 different
subpopulations of enteroendocrine cells have been defined (2). In this work we have deter-
mined the cell-specific expression of i) T1R family members, ii)α gustducin, iii) chromogranin
A and iv) intestinal glucose transporter (Na+/glucose cotransporter, SGLT1), along the
crypt-villus axis of the mouse small intestine, using, in situ hybridisation and immuno-
histochemistry. We show that T1R2 and T1R3, the sweet taste receptors, are expressed in
a subpopulation of the villus cells, with no expression in the crypt region. In contrast,
SGLT1 is expressed on the entire villus enterocytes, with negligible expression in the crypts.α-
gustducin is also expressed in same subpopulation of cells that manifest T1R2/R3 expression.
Chromogranin A expression is depicted in a very few cells on the villus. We conclude that the
sweet taste receptors along with the G-proteinα gustducin are expressed in a subpopulation of
the villus cells, likely to be enteroendocrine cells. References 1. Dyer, J., K.S.H., Salmon,
L. Zibrik, and S.P. Shirazi-Beechey (2005) Biochem. Soc. Trans. 33(Pt 1): 302-305. 2. Lewin,
K.J. (1986), Pathol. Annu, 1: 1-27.
M1812
New Insights On Genotype of Congenital Chloride Diarrhea
Gianluca Terrin, Giuseppe Cardillo, Annalisa Passariello, Giuseppe Castaldo, Francesco
Porcaro, Maria Concetta Siani, Cuono Puzone, Riccardo Troncone, Francesco Salvatore,
Roberto Berni Canani
Background. Congenital Chloride Diarrhea (CLD) is an inherited disorder of intestinal
electrolyte transport transmitted by autosomal recessive manner caused by a defect in
SLC26A3/DRA gene that codifies for Cl-/HCO3- exchanger. Patients affected by this disorder
present clinically with intestinal Cl- malabsorption that induce severe life-threatening chronic
diarrhea with neonatal onset. Early identification of this disorder is essential because an
early introduction of appropriate therapy could be life-saving for these patients. Data on
the prevalence and on molecular genetics of CLD are missing in many countries. Aims. To
describe the genotype of children from different countries affected by CLD and to investigate
genotype-phenotype correlations. Patients and Methods. Using automated direct sequencing
(310 Abi Prism, PE, Transgenomic), we screened the whole coding region of SLC26A3 gene
in 7 patients affected by CLD: 2, unrelated, from Southern Italy, 3 (2 siblings) from Morocco,
1 from Zimbabwe and 1 from USA. Main clinical characteristics of each child were recorded
(number of bowel movements per day; total fecal volume per day; stool consistency according
the following score: 1: formed, 2: loose, 3: semiliquid; 4: liquid; urgency or incontinence;
average doses of Cl- as mmol/kg in the substitution therapy). Results. Molecular analysis
revealed two novel missense mutations and a large homozygous novel deletion in patients
from Southern Italy, a novel frameshift in one patient and a known Arabic homozygous
mutation in siblings patients from Morocco, four novel homozygous mutations in patient
from Zimbabwe and a missense and a point deletion, both novel, in the patient form USA.
Not clear correlation between genotype and phenotype was evidenced in this population.
Conclusions. Molecular analysis can contribute to rapid and specific diagnosis of CLD, and
can be used to investigate the disease prevalence in different ethnic groups. We confirm
the strong genetic heterogeneity of CLD in ethnic groups where the disease is sporadic,
and conflicting genotype-phenotype correlations in this condition. The complex genotype
observed in patient from Zimbabwe, born to unrelated parents bearing to two different
ethnic groups of Southern Africa, led to the hypothesis that such mutations could spread
in such ethnic groups due to some yet unidentified protective effect.
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M1813
Down-Regulated in Adenoma (DRA, Slc26a3) Is the Predominant Cl-/HCO3-
Exchanger in the Lower Villous Epithelium of Murine Duodenum
Janet E. Simpson, Nancy M. Walker, Clifford W. Schweinfest, Lane L. Clarke
Previous studies have shown that Cl-/HCO3- exchange contributes to duodenal mucosal
HCO3- secretion and formation of the alkaline mucus barrier against gastric acid effluent.
Three anion exchangers have been immunolocalized to the apical membrane in murine
duodenum: DRA (Slc26a3), the putative anion transporter -1 (PAT-1, Slc26a6) and anion
exchanger 4 (AE4, Slc4a9). We hypothesized that activity of each anion exchanger dominates
in different regions along the crypt-villus axis. Using mice with gene-targeted deletion of
these anion exchangers, we have recently shown that apical membrane Cl-/HCO3- exchange
activity in the upper villous epithelium of the duodenum is dominated by PAT-1 (60-70%)
with a smaller contribution from DRA (20-30%) and virtually no contribution from AE4.
In the present study, we extended the investigation to evaluate the contribution of these
anion exchangers to Cl-/HCO3- exchange in the lower villous epithelium. Using BCECF
microfluorimetry, intracellular pH (pHi) was measured in intact murine duodenal mucosa
mounted in a horizontal Ussing-like chamber that allowed independent superfusion of the
mucosal and basolateral surfaces. A short section of the mucosa was elevated to enable rapid
solution changes and visualization of epithelial cells at the villous base. Epithelia of the
villous base were defined by the presence of crypt openings in the microscopic field. In
initial studies of wild-type (WT) duodenum, it was found that the baseline pHi was reduced,
but that the rate of Cl-/HCO3- exchange in the lower villous epithelium was comparable in
magnitude to the exchange rate in the upper villous epithelium. Investigation of PAT-1(-)
and WT littermate duodena (gift of M. Soleimani, Univ. of Cincinnati) revealed that PAT-
1, unlike its role in the upper villus, does not significantly contribute to Cl-/HCO3- exchange
activity in the lower villous epithelium. In contrast, it was found that typical Cl-/HCO3-
exchange activity was eliminated and, paradoxically, the pHi of the epithelial cells acidified
then re-alkalized during luminal Cl- removal and exposure, respectively, in the DRA(-) lower
villus. Preliminary studies of DRA(-)/CFTR(-) double knockout duodena (n = 2) indicated
that the paradoxical acidification in the absence of luminal Cl- was CFTR-dependent. We
conclude from these studies that, in contrast to the upper villous epithelium, DRA is the
dominant Cl-/HCO3--exchanger in the lower villous epithelium of the murine duodenum
where it operates in a complex interaction with CFTR. Supported by NIH and CFF.
M1814
Ileal Bile Acid Transporter Expression in Patients with Chronic Diarrhea:
Evidence for Differences in Transcriptional Regulation
Julian R. Walters, Sara Balesaria, Konstantia-Maria Chavele, Umma Khair
Background: Primary idiopathic bile acid malabsorption is a frequent cause of unexplained
chronic diarrhea and its causation is largely unknown. The aim of this study was to determine
whether changes in expression or transcriptional regulation of ileal bile acid transporters
could be identified. Methods: Ileal biopsies were obtained with informed consent at colonos-
copy from two groups of patients: chronic diarrhea (n=17) and controls without diarrhea
(n=21). No evidence of any ileal disease or of other causes of diarrhea was present. Duodenal
biopsies were obtained from other patients for comparison of proximal and distal intestinal
expression. RNA and cDNA were prepared using standard methodology. Transcript expres-
sion was measured by quantitative real-time RT-PCR (Taqman). Expression was normalised
to that of the housekeeping gene GAPDH. Results: Expression of the apical membrane
sodium-linked bile acid transporter (ASBT) and the cytoplasmic ileal bile acid binding protein
(IBABP) was much higher in ileum than in duodenum. The putative basolateral organic solute
transporters (OST) alpha and beta were found at similar levels. No significant differences in
the mean or median values were found for transcripts of these transporters in the two patient
groups. ASBT and IBABP were significantly correlated in those with diarrhea (r=0.67, p<0.05)
but not in controls. Expression of transcription factors that affect ASBT or IBABP expression
was then determined. Farnesoid X receptor (FXR) and liver receptor homologue (LRH-1)
were more abundant in ileum, unlike short heterodimer partner (SHP), c-Fos, or CDX2.
Mean or median values for FXR, LRH-1, SHP, c-Fos or CDX2 were not significantly different
between the two patient groups. The relationships of expression of these factors with ASBT
and IBABP differed. Using multiple stepwise regression, ASBT was significantly related
(p<0.05) to LRH-1 and SHP in controls, and with SHP and CDX2, but not LRH-1, in
diarrhea. IBABP was related to LRH-1, SHP and CDX2 in controls, but only to CDX2 in
diarrhea. Fibroblast growth factor (FGF)-19, which is proposed to have a role in signalling
between ileum and hepatic bile acid synthesis, was expressed much more abundantly in
ileum than duodenum, but at similar values in both patient groups. Conclusion: Although
differences between duodenum and ileum can be demonstrated, bile acid transporters and
putative transcription factors were expressed at similar levels in ileal biopsy RNA from
patients with chronic diarrhea and controls. Regression analysis suggests that ASBT and
IBABP may be regulated differently in patients with chronic diarrhea.
M1815
Ontogenic Regulation of the Rat Heteromeric Organic Solute Transporter
Ostα-Ostβ
Melissa Halpern, Nazzareno Ballatori, Jessica Clark, Sarah Doelle, Tara Saunders,
Bohuslav Dvorak
Background Enterohepatic circulation of bile acids (BA) is regulated in the distal ileum
through transport from the apical surface of enterocytes into the cell by the apical sodium-
dependent bile acid transporter (Asbt). BA can then be bound to the ileal bile acid binding
protein (Ibabp) for transport across the enterocyte. The recently described heteromeric
organic solute transporter Ostα-Ostβ may be a mechanism by which BA are then removed
from the cell and transported into portal circulation. Aims To determine the ontogenic
regulation of the Ostα and Ostβ genes in rats from birth to weaning. Methods Ileal tissue
was taken from rats at day 0, 1, 3, 7, 13, 21 or 28. To determine if introduction of BA
would increase Ostα or Ostβ mRNA levels in the early neonatal period, newborn rats were
given 288 mg/kg sodium deoxycholic acid 2X/day for 2 days (DOC). Control rats were
gavaged with vehicle (PBS). Four day-old rats with Necrotizing Enterocolitis (NEC) have
elevated ileal BA levels and mRNA were examined and compared to control pups without
disease (Control). RNA was isolated from each sample and real-time-PCR assays were used
to quantify steady-state mRNA levels for Ostα and Ostβ. All mRNA levels were normalized
according to the level of 18S within each sample, which was used as an endogenous control.
Results Under normal physiologic conditions, Ostα and Ostβ mRNA were very low in
neonatal animals and increased to adult levels 28 days after birth (Table 1). Introduction
of exogenous BA in the early neonatal period did not significantly increase expression of
either Ostα or Ostβ, even though Ibabp mRNA can be up-regulated in response to the same
dose of BA. However, in neonatal animals with NEC, Ostβ expression was significantly
increased (Table 2). Conclusions Like other ileal BA transporters, Ostα and Ostβ are
expressed at very low levels prior to the initiation of solid food diet. However, the Ostα
and Ostβ response to exogenous BA in the early neonatal period differs from Ibabp. Further,
under pathological conditions when ileal BA levels are elevated, Ostβ mRNA is precociously
up-regulated.
Table 1.
All time points n = 12. Data are expressed as fold-change in mRNA (SD). * p ≦ 0.01 vs
day 0.
Table 2.
Data are expressed as fold-change mRNA (SD). # p≦0.01 vs PBS; *p≦0.05 vs control
M1816
The Relationship Between Bile Salt Malabsorption and Cholesterol 7-Alpha
Hydroxylase Gene (CYP7A1) Promoter Polymorphism in Patients with
Inflammatory Bowel Disease
Martin Lenicek, Milan Lukas, Lucie Budisova, Milan Jirsa, Jan Kovar, Libor Vitek
Background: Bile salt malabsorption (BSM) is a common complication of Crohn disease
(CD) contributing to further clinical consequences such as increased prevalence of gallstone
disease. In the present study the relationship between CYP7A1 promoter polymorphism
and serum levels of 7alpha-hydroxy-4-cholesten-3-one (cholesten), a novel marker of BSM,
was investigated in patients with various clinical manifestation of inflammatory bowel disease.
Materials and Methods: Serum levels of cholesten were determined by HPLC in a group of
CD patients with ileal resection (n=31), ileal inflammation (n=20), colonic involvement only
(n=12), ulcerative colitis (UC) patients (n=12) and healthy controls (n=40). Two common
linked promoter polymorphisms of CYP7A1 , -203A/C and -469C/T, were analyzed by PCR-
RFLP. Results: As compared to controls, serum cholesten levels corrected to serum cholesterol
were increased in CD patients with ileal resection and ileal inflammation and not affected
in CD patients with colonic involvement only as well as in those with UC [median (min-
max); 2.3 (0.6-10.9) vs. 32.2 (3.7-112.5) μg/mM, p<0.001; 4.2 (0.6-40.2) μg/mM, p=0.009;
2.4 (0.6-60.2) μg/mM, p=0.536; and 2.9 (1.2-22.7) μg/mM, p=0.066, respectively]. Patients
with CD and UC homozygous for the alelles [203C; -469T] had lower serum cholesten/
cholesterol ratio (p<0.05) and higher serum cholesterol (p<0.025) than patients with -
203A/A, -469C/C haplotype. Conclusions: 1) Serum cholesten level, in particular cholesten/
cholesterol ratio, is a useful marker of bile salt malabsorption and correlates well with the
degree of ileal involvement. 2) CYP7A1 gene promoter haplotype affects bile salt synthesis
rate in patients with BSM.
M1817
Sumo Modification of the Na+/K+/2CL- Cotransporter 1 in Colonic Secretory
Epithelial Cells in Response to Epidermal Growth Factor
Alfred E. Chappell, Kim E. Barrett
Background and Aim: Post-translational modification of proteins by the small ubiquitin-like
modifier (SUMO) has been shown to regulate target protein activities through a number of
different mechanisms including altered cellular localization, biochemical modifications, and
protection from ubiquitin modification and subsequent targeting for proteosomal degrada-
tion. The epidermal growth factor receptor (EGFr) is an important regulator of chloride
transport in intestinal epithelia and activation of EGFr has been shown to modulate activity
of the Na+/K+/2Cl- cotransporter (NKCC), but the mechanisms were unknown. The aim of
this study was to investigate the involvement of SUMO, if any, in regulating the activity of
NKCC in secretory epithelia in response to epidermal growth factor (EGF). Methods: T84
human colonic epithelial cells were grown on transwell membranes. Cells were treated
basolaterally with EGF for 1, 3, 5, 10, or 20 minutes or Ringers as a control at 37°C.
After treatment, cells were lysed at 2-8°C and lysates were immunoprecipitated using a
commercially available Pan-SUMO antibody that is immunoreactive against all three SUMO
isoforms. Precipitates were then analyzed by Western blot for NKCC1. Results: Treatment
of T84 cells with EGF for 1 minute resulted in 66% ± 13% more SUMO-modified NKCC1
than in controls (mean ± SEM, n=6, p<0.001). However, levels of SUMO-modified NKCC1
at later time points were not significantly different from those found in untreated cells.
Conclusions: Basolateral exposure of T84 cells to EGF results in rapid modification of NKCC1
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by one or more SUMO isoforms. Subsequent to this modification, NKCC1 is likely rapidly
de-SUMOylated. The dynamic regulation of SUMOylation of NKCC1, and perhaps of other
transport proteins involved in chloride secretion, may account for the ability of EGF to
regulate this important transport process. Our findings, therefore, have implications for
disease states where chloride secretion is abnormal.
M1818
Altered Regulation of Lipogenic Genes in Mouse 3T3-L1 Fibroblasts and
Adipocytes Co-Cultured with Human HEPG2 Hepatoma Cells
Edwin Ouyang, David Cohen
Background: Adipocytes secrete adipokines, which are cytokine-like hormones that can
influence lipid metabolism in the liver. Whether hepatocytes regulate lipid metabolism in
extrahepatic cell types by endocrine mechanisms has not been well explored. Aim: To
examine the influence of hepatocytes on expression of lipogenic genes in fibroblasts and
adipocytes. Methods: Mouse 3T3-L1 fibroblasts were differentiated into adipocytes by a
standardized procedure using dexamethasone, insulin and 3-isobutyl-1-methylxanthine.
Fibroblasts or adipocytes were then cultured alone or together with an equal number of
human HepG2 hepatoma cells for 48 hr in DMEM with 10% FBS. Cellular RNA was purified
and utilized to prepare cDNA. Quantitative real time PCR was performed using gene-specific
primers for mouse sterol regulatory element binding protein-1c (SREBP-1c), a transcription
factor that promotes lipogenesis, as well as the lipogenic genes stearoyl CoA desaturase 1
(SCD1) and fatty acid synthase (FAS). Gene amplification was quantified using SYBR green
and normalized to beta-actin. Results: Compared with fibroblasts cultured alone, there was
a marked 4.6-fold increase in SREBP-1c mRNA expression when fibroblasts were co-cultured
with HepG2 cells. By contrast, SCD1 was decreased by 67% and FAS was unchanged. As
expected, adipocytes alone displayed much higher expression of SREBP-1c, SCD1 and FAS
than fibroblasts by 30-fold, 320-fold and 18-fold, respectively. However, when adipocytes
cells were co-cultured with HepG2 cells, mRNA expression levels of SREBP-1c, SCD1 and
FAS in fibroblasts were reduced by 61%, 99% and 96%, respectively. Similar changes in
lipogenic gene expression in fibroblasts and adipocytes were observed when the percentage
of HepG2 cells was increased from 50% to 90%. Conclusions: HepG2 cells modulate
expression of lipogenic genes in both fibroblasts and adipocytes. Because SCD1 and FAS
are downstream target genes of SREBP-1c, the lack of coordinate upregulation of these genes
in fibroblasts suggest that HepG2 cells influence lipogenesis by multiple mechanisms under
co-culture conditions.
M1819
Impact of Ezetimibe and NPC1L1 On SRBI-Mediated HDL Selective Uptake
and VLDL Secretion By Liver Cells
Philip Howles, Eric Labonte, Lisa Camarota, Dean Gilham, Yiannis Ioannou, Joanna
Davies, David Y. Hui
Background: Ezetimibe potently blocks cholesterol absorption and is thought to be an inhibitor
of NPC1L1 (Nieman Pick C type 1-like protein 1). Interestingly ezetimibe has also been
shown to bind SRBI (scavenger receptor class B type I) and to decrease cholesterol uptake
by SRBI transfected cells. The role of NPC1L1 and the effects of ezetimibe in the intestine
have been extensively studied. However, NPC1L1, along with SRBI, is also abundant in human
liver but the role of this protein in hepatic cholesterol metabolism is poorly understood. Thus,
the purpose of these experiments was to determine the effects of ezetimibe and NPC1L1
on VLDL production and SRBI-mediated selective uptake of HDL. Methods: HepG2 cells
were used as an in vitro model of human hepatocytes. Human HDL3 was radiolabeled with
[3H]cholesteryl oleoyl ether or [3H]cholesteryl oleate. Selective uptake of HDL-CE (cholesteryl
ester) by cells treated with 20µM ezetimibe or with SRBI blocking antibodies was measured
and compared to untreated cells. After 4 hr, cells were harvested, homogenized and fraction-
ated on iodixanol gradients. Selective uptake was determined on total homogenates and the
distribution of radiolabel and protein was determined from gradient fractions. The amount
and distribution of SRBI and ABCA1 (ATP binding casette transport protein A1) was deter-
mined by Western blot analysis. VLDL production by fasted control and NPC1L1-null mice
was determined by measuring plasma triglyceride increases after intravenous injection of
triton WR1339. Results: Selective uptake of HDL-CE was reduced 25% by ezetimibe treatment
as compared to ~40% inhibition by SRBI blocking antibody. Acute ezetimibe treatment
reduced SRBI expression by 20%, while overnight treatment increased SRBI expression by
40%. ABCA1 expression was similarly affected. Distribution of radiolabel in gradient fractions
indicated that ezetimibe decreases the delivery of HDL-CE into intracellular cholesterol
storage pools. The VLDL secretion rate was 35% lower in NPC1L1-null mice as compared
to normal mice. Conclusions: The data suggest that NPC1L1 is part of the SRBI-mediated
selective uptake pathway in hepatocytes and that disruption of this pathway by ezetimibe
results in futile overexpression of the SRBI protein. Reduced delivery of HDL-CE to the
cellular pool observed in HepG2 cells treated with ezetimibe is consistent with reduced
VLDL secretion by NPC1L1-null mice.
M1820
The Molecular Structure That Allows FXR to Override the Stimulation of
CYP7A1 By LXR
Quan Shang, Luxing Pan, Monica Saumoy, John Y L. Chiang, G Stephen Tint, Gerald
Salen, Guorong Xu
We cloned the rabbit CYP7A1 promoter and found that there is a 9 bp α-fetoprotein
transcription factor (FTF) binding site within the 16 bp binding site for the liver X receptor
(LXR). We hypothesized that this overlapping structure alters regulation of the CYP7A1
promoter. Gel shift assays demonstrated that [35S]-FTF protein binds to the LXR binding
site (LXRE). We further noted that FTF competes with LXR for binding to LXRE. In a gel
shift assay of [35S]-LXR protein incubated with unlabeled LXRE, the addition of FTF reduced

















experiment, FTF reduced the binding of LXR/RXR to [32P]-LXRE. Although SHP (short
heterodimer partner) alone was not able to bind to LXRE, adding SHP significantly enhanced
the ability of FTF to compete with LXR for binding. This result was confirmed by our
observation that, as more SHP was added, less amounts of [32P]-LXRE bound to LXR/RXR
when a minimum amount of FTF was present. Furthermore, in HepG2 cells transfected
with the rabbit CYP7A1 promoter, adding SHP with FTF significantly enhanced the inhibitory
effect of FTF and abolished the stimulating effect of LXR/RXR on the promoter. We conclude
that FTF competes with LXR for binding to LXRE because its own binding site lies within
the LXR binding motif. We propose that SHP enhances the ability of FTF to compete with
LXR/RXR because it forms heterodimers with FTF which then bind more efficiently to the
LXR binding site and block LXR/RXR to bind to LXRE. Activated FXR (farnesoid X receptor)
is known to upregulate expression of its target gene SHP. Increased levels of SHP, together
with FTF, will then prevent LXR/RXR from binding to LXRE and will abolish the stimulatory
effect of LXR on the CYP7A1 promoter.
M1821
Compensatory Hepatic Up-Regulation of Bile Acid Synthesis in Liver Fatty
Acid Binding Protein (FABP1) Knockout Mice Provides Novel Insights Into the
Physiological Role of FABP1
Mulugeta Seneshaw, Dietmar Klass, Newberry Elizabeth, Elke Preiss, Udo Seedorf, Guido
Adler, Nicholas O. Davidson, Michael Fuchs
FABP1 is a cytosolic lipid binding protein expressed in hepatocytes and enterocytes. In vitro
studies demonstrated that FABP1 can bind bile acids in addition to fatty acids. Recently we
and others demonstrated that bile acid secretion is decreased in Fabp1 knockout mice. To
explore the molecular mechanism responsible for bile acid hyposecretion, male Fabp1-/-
and wild-type mice were fed either a normal (ND) or cholic acid (CD) containing diet for
4 weeks. Hepatic bile was collected for 1 hour to measure bile flow and biliary lipids. Bile
acid composition of hepatic bile was analyzed by gas chromatography mass spectrometry.
Livers were harvested to study steady-state gene expression of bile acid synthetic enzymes
employing TaqMan-PCR. Fabp1-/- mice had significantly reduced body (13%) and liver
weights (23%) but food intake was unchanged compared with wild-type mice. Steady-state
Cyp7a1, Cyp27a1 and Hmgcr mRNA expression was increased by 2.3- (p<0.05), 1.7-
(p<0.05) and 2-fold (p<0.001) in knockout mice, whereas Cyp8b1 mRNA expression was
slightly reduced by 43% (p>0.05). The bile flow rate was 45% lower than in wild-type mice
(1.15 vs. 0.63 µl/min/g liver; p<0.05). In addition, biliary secretion rates for cholesterol,
phospholipids and bile acids were substantially reduced in Fabp1-/- mice (cholesterol: 0.6
vs. 1.3; phospholipids: 4.1 vs. 7.1; bile acids: 33 vs. 46 nmol/min/g liver). The two major
bile acid species present in hepatic bile of both groups of mice were cholic acid and beta-
muricholic acid, representing 70% of total bile acids. Alpha-muricholic acid (4%) was only
detectable in Fabp1-/- mice. This suggests that bile acid pool composition in mice is not
critically dependent on proper FABP1 expression. In response to the CD, biliary lipid
secretion rates increased significantly in all mice. However, bile acid secretion increased less
pronounced in Fabp1 -/- mice compared to wild-type mice (248 vs. 466 nmol/min/g liver,
p<0.01). Based on our findings we propose that Fabp1 gene ablation impairs intestinal bile
acid absorption inducing increased fecal bile acid loss and compensatory hepatic up-regula-
tion of bile acid synthesis.
M1822
Enteral Starvation Induces Enterohepatic Cycling of Bilirubin: A Putative
Mechanism for Total Parenteral Nutrition (TPN)-Associated Liver Disease and
Pigment Gallstone Formation
Scott A. Elisofon, Martin C. Carey
Aims: Liver disease and ‘black’ pigment sludge/gallstones are common in TPN patients. We
asked whether enteral starvation with TPN infusion leads to induction of enterohepatic
circulation (EHC) of bilirubin accompanied by conjugated “hyperbilirubinbilia”. We hypo-
thesized further that absence of secretin release might produce less alkaline bile via diminished
cholangiocyte expression of CFTR. Both anomalies should provide the necessary conditions
for increased hydrolysis of bilirubin glucuronides to unconjugated bilirubin (UCB) leading
to bilirubinate injury to the hepatobiliary tree. Methods: Male Sprague Dawley rats received
intravenous TPN/enteral starvation (n=5) or sham surgery/regular chow diet (n=5). At 7
days, hepatic bile was collected via acute biliary fistulae and assayed for pH, bilirubin
concentrations and molecular species, and common biliary lipids by standard methods.
Hematocrit, haptoglobin, plasma indices of liver injury, and liver histology were examined.
Stool outputs were weighed. Results: TPN rats displayed significantly lower 7-day stool
weights (7.1 vs 59.3g, p<0.05). Bilirubin secretion rates were markedly higher in TPN rats
than in controls (51.5±6.7 vs 25.3±1.2 nmol/hr/100g BW, p<0.05). Phospholipid (PL)
secretion rates were significantly lower in TPN rats than in controls (1.2±0.1 vs 1.6±0.1
µmol/h/100g, p<0.05), with a trend toward lower cholesterol (CH) secretion rates (0.14±0.02
vs 0.21±0.04 µmol/h/100g, p=0.09). No significant differences in bile salt (BS) secretion
rates or biliary pH occurred. In plasma, only total bilirubin levels were increased in the
TPN group (0.20 vs 0.12 mg/dL, p<0.05). Over 50% of hepatocytes from TPN livers
demonstrated microvesicular steatosis; control livers were healthy. Haptoglobin and hematoc-
rit did not differ between the two groups. Conclusions: Seven days of enteral starvation/
TPN infusion in rats showed hepatic steatosis consistent with the human disease. Marked
decrease in intestinal motility was evident by significant reductions in stool outputs, which
allowed for more exposure time for EHC of UCB and hyperbilirubinbilia. In the absence of
hemolysis or ineffective erythropoiesis, elevated serum total bilirubin in TPN rats is also
consistent with induced EHC. In addition, decreased PL and CH secretion rates are consistent
with lipid decoupling from BS secretion by increased endobiotic dianion excretion. Hyperbili-
rubinbilia as well as decreased biliary PL to BS ratios suggest that with prolonged TPN
infusions, particularly in the setting of intestinal disease and/or resection, the biliary tree
may become compromised by elevated UCB as well as increased detergency of bile acids.
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M1823
No Evidence for Enterohepatic Cycling (EHC) of Bilirubin in the Slc10a2
(ASBT/IBAT)-/- Mouse
Folke U. Freudenberg, Bian B. Yu, Monika R. Leonard, Paul A. Dawson, Martin C. Carey
Introduction. Passive EHC of unconjugated bilirubin (UCB) is a well established contributor
to neonatal hyperbilirubinemia, but there is inadequate proof that EHC of bilirubin occurs
in adult life. Data from mouse and rat models with ileectomy or chemical inhibition of
ASBT are consistent with EHC of bilirubin secondary to bile salt malabsorption. We hypothes-
ize that, due to massive spillage of bile salts into the colon, there should be EHC of UCB
in Slc10a2-/- mice. Methods. We collected hepatic bile from Slc10a2-/- mice within 30min
of fistulation, and gallbladder (GB) bile after cholecystectomy. We assessed biliary pH by
microelectrode, bilirubins by HPLC, and 72hr fecal bile acid excretion by enzymatic assay.
Lipid analyses and total lipid concentrations were determined by standard methods. Results.
In hepatic bile of Slc10a2-/- compared to wild type (WT) mice, conjugated bilirubins (CBR)
are not elevated (25.0±3.6 vs 31.9±4.8 nmol/hr*100 g BW) but UCB is slightly higher
(0.46±0.07 vs 0.29±0.05 nmol/hr*100 g BW). There is a modest difference in hepatic bile
pH (8.7±0.06 in Slc10a2-/- ; 8.5±0.04 in WT). GB size is significantly smaller in Slc10a2-/-
(19.0±3.2µl) than in WT (47.9±5.8µl) mice. Fecal bile acid excretion in Slc10a-/- mice is
increased two- to threefold. Bile salts, phospholipids and cholesterol (11.1±2.1 mM; 2.7±0.3
mM; 0.32±0.07 mM, respectively) are markedly decreased in hepatic bile of Slc10a2-/-
compared to WT mice (26.5±7.4 mM, 4.1±0.8 mM; 0.65±0.17 mM, respectively). In GB
bile of Slc10a2-/- mice, bile salts are decreased fivefold (p< 0.0001), and pH is more alkaline
(8.1±0.1 vs 7.7±0.1). Conclusions. There is no evidence for EHC of bilirubin in Slc10a2-/-
mice. Massive bile acid loss leads to contraction of the bile acid pool, which reduces biliary
lipid concentrations in hepatic and GB biles. Smaller GB sizes and higher pH values in
Slc10a2-/- mice may be related to increased coprophagy and hyperphagia, resulting in more
frequent GB emptying and more alkaline GB bile. Although increased bile acid losses have
been shown to facilitate uptake of UCB from the colon in animal models and in patients
with Crohn’s disease, our study revealed no increases in CBR in hepatic bile. Flooding of
the colon with bile salts most likely induces rapid colonic evacuation and insufficient time
of exposure for UCB resorption. These results are consistent with the observation that
congenital bile salt malabsorption secondary to ASBT null mutations does not pose a risk
of pigment gallstone formation in humans.
M1824
An Ancillary Subunit Mutation Alters Activation of KCNQ1
Andrea E. Goldstein, Michael Duffey, Derek Beahm, Cynthia Dlugos, Michael Morales,
Randall Rasmusson
In the liver, collecting ducts transport bile acid-rich bile to the duodenum, and secrete a
HCO3--rich fluid. Basolateral membrane K+ channels in duct epithelial cells play a critical
role in secretion by establishing the negative cell interior membrane potential necessary for
anion transport. In secretory epithelial cells, KCNQ1, a voltage-gated K+ channel, associates
with the KCNE3 subunit to form a constitutively active, voltage-insensitive channel. We
hypothesize that KCNQ1+KCNE3 is the dominant K+ channel in biliary duct cells. We
demonstrated by RT-PCR the presence of KCNQ1 and KCNE3 mRNAs in the human
liver secretory cell line, Mz-ChA1, and showed using immunofluorescence that KCNQ1 is
expressed in rat liver secretory ducts. In the heart, KCNQ1 interacts with the KCNE1 subunit
to form a voltage-gated K+ channel, mutations of which are responsible for long QT syndrome.
To determine mechanisms of subunit interaction, we expressed KCNQ1 in Xenopus oocytes
and determined the effects of the blocker Ba2+ on current-voltage relationships. Bath Ba2+
(5 mM) slowed activation and reduced (24%) KCNQ1 currents. Ba2+ caused the constitutively
active K+ currents of KCNQ1 co-expressed with KCNE3 to become slowly-activating and
dramatically reduced (42%). KCNQ1+KCNE1 currents were very slowly activated and Ba2+
had little (16%) effect. The dose-inhibition curve for Ba2+ on KCNQ1 showed two binding
components with affinities at 10 μM and 20 mM. The curve for KCNQ1+KCNE1 showed
only one component (20 μM) and KCNQ1+KCNE3 showed one component (100 μM). We
determined the effects of a V72T mutation in KCNE3. This mutation altered a single amino
acid within the “activation triplet” of the ancillary subunit KCNE3. KCNQ1+KCNE3(V72T)
currents were slowly-activating, like KCNQ1+KCNE1, and inhibition by Ba2+ (2 mM) was
identical to that of KCNQ1+KCNE3. These results suggest that the site of regulation of
KCNQ1 by KCNE3 or KCNE1 involves both the voltage-sensitive gating mechanism and
extracellular pore region of KCNQ1. (NIH 62465)
M1825
Induction of MLC20 Gene Expression By Spontaneous Release of
Acetylcholine At Neuroeffector Junction in Rat Colonic Circular Smooth
Muscle Cells
Xuan-Zheng Shi, Sushil K. Sarna
During the course of normal gut motility function, acetylcholine (ACh) is released at the
neuroeffector junction to contract circular smooth muscle cells. The aim of this study was
to investigate whether spontaneous release of ACh also induces gene expression of specific
signaling molecules in excitation-contraction coupling. The experiments were performed in
fresh circular muscle strips and in conscious rats. Methods: Surgically implanted osmotic
pumps infusing atropine intramuscularly blocked the effect of spontaneous release of ACh
on colonic circular smooth muscle cells in intact conscious rats. The contractile activity of
the colonic circular muscle was recorded in vivo by implanted strain gauge transducers and
in vitro in muscle bath. Results: Osmotic pump infusion of atropine at 100, 200, and 300
nmol/kg/h for 24 or 48 h significantly inhibited the spontaneous contractile activity of the
colon and it reduced the number of stool pellets from 16 ± 3 to 4 ± 1, 3 ± 0.5 and 3 ±
0.4/day respectively (all p<0.05). The response of colonic circular muscle strips to KCl (30
to 65 mM) and acetylcholine (10-6 to 10-2 M) was significantly suppressed in muscle strips
from atropine-treated rats when compared to those treated with saline infusions. Atropine
treatment did not alter the expression of α1C and β3 subunits of L-type Ca2+ channels and
of smooth muscle α-actin. However, it significantly reduced the expression of MLC20 to 42
± 6% of saline control (p<0.05). When naive colonic circular muscle strips were incubated
with 1 mM cholinergic muscarinic agonist methacholine, the expression of MLC20 was
enhanced time-dependently. The expression of MLC20 began to increase at 6 hours, and
the maximal increase at 24 h was 182 ± 21% of control (p<0.05). Furthermore, the contractile
response to KCl (30 to 65 mM) was significantly greater in the methacholine-treated muscle
strips than in those cultured in control medium (p<0.05. When the muscle strips were
treated periodically, every 25 min for 5 min for a total of 6 h, with 1 mM acetylcholine,
their response to KCl was also enhanced. The expression of MLC20 increased to 131 ± 10%
in ACh-treated strips compared with medium-treated strips. Conclusions: Our results
demonstrate that spontaneous release of ACh at the neuromuscular junction not only causes
colonic circular muscle contractions, but it also regulates gene expression of myosin light
chain in colonic circular smooth muscle cells. This novel function of acetylcholine may help
to maintain normal colonic smooth muscle contractility.
M1826
R-Type Calcium Channel Expression and Function At Nerve Terminals of
Guinea Pig Ileum Myenteric Neurons
Xiaochun Bian, James Galligan
Introduction. Myenteric neurons in the guinea-pig ileum express N, L, P/Q and R-type
calcium channels. Currents carried by R-type channels account for at least half of the total
calcium current recorded from these neurons but the function of these channels is not
known. Methods. We studied the localization and function of R-type calcium channels in
guinea pig myenteric neurons maintained in primary culture using electrophysiological
and immunohistochemical techniques. Calcium imaging and photometry with the calcium
indicator dye, Fluo-4 (2 μM), were used to assess calcium channel function in nerve cell
bodies and nerve terminals. Results. Immunohistochemical studies revealed strong expression
of R-type calcium channel immunoreactivity on most nerve cell bodies and nerve fibers.
Patch clamp studies of individual neurons revealed that depolarizations from -70 to 0 mV
elicited inward currents in all neurons tested; these currents were blocked by CdCl2 (100
μM), a non-selective calcium channel blocker indicating that the inward currents were
calcium currents. SNX-482 (0.1 μM) or NiCl2 (50 μM), selective R-type calcium channel
blockers inhibited calcium currents by 50%. R-type calcium currents recorded from the
nerve cell bodies were inhibited in a pertussis toxin-sensitive manner by UK 14,304 (1 μM),
an α2-adrenergic receptor agonist. Pertussis toxin inhibits Gi/Go G-proteins. KCl (60 mM)-
induced depolarization caused increases in nerve cell body and nerve terminal Fluo-4
fluorescence that were blocked by CdCl2. This result indicates that increases in Fluo-4
fluorescence were due to activation of voltage-gated calcium channels. UK 14,304 reduced
KCl-induced increases in Fluo-4 fluorescence by about 50% in nerve terminals and cell
bodies. SNX-482 and NiCl2 also inhibited KCl-induced fluorescence by about 50%. UK
14,304 did not reduce Fluo-4 fluorescence in the presence of SNX-482 or NiCl2. Conclusions.
R-type channels are expressed by most myenteric neurons and nerve fibers. These channels
are modulated by α2-adrenergic receptors using a Gi/Go-dependent pathway. R-type calcium
channels in nerve fibers are also the target for α2-adrenergic receptor modulation. Norepi-
nephrine released from sympathetic nerves may inhibit transmitter release from myenteric
neurons by acting at nerve terminal α2-adrenergic receptors to inhibit R-type calcium
channels. (Supported by DK57039)
M1827
5-HT4 Receptor Agonists Increase Transmitter Release Probability from
Myenteric Nerve Terminals
Jim Ren, James Galligan
Background. 5-HT4 receptors are localized to nerve terminals in the myenteric plexus.
Activation of 5-HT4 receptors increases fast excitatory postsynaptic potentials (fEPSPs) medi-
ated by acetylcholine (ACh) acting at nicotinic acetylcholine receptors (nAChRs). While it
is known that 5-HT4 receptors couple to the stimulatory G-protein Gs, the underlying
mechanism(s) for 5-HT4 receptor-mediated facilitation of fast synaptic transmission is
unknown. Methods. This mechanism was investigated using acutely isolated longitudinal
muscle-myenteric plexus (LMMP) preparations and myenteric neurons maintained in primary
culture and intracellular and patch clamp electrophysiological recording techniques. Results.
In LMMP preparations, a train of 20 electrical stimuli at 10 Hz evoked fEPSPs that declined
in amplitude with a time constant of 0.6 ± 0.1 s from an initial amplitude of 17 ± 2 mV
to a steady state level of 0.7 ± 0.3 mV (n=9). In the presence of the 5-HT4 receptor agonist,
renzapride (0.1 μM), fEPSPs declined with a time constant of 0.6 s ± 0.1 s but the amplitude
of the first fEPSP was 28 ± 3 mV and this declined to a steady state level at the 20th stimulus
of 6 ± 2 mV (both P<0.05 vs. control). Under control conditions, fEPSP amplitude recovered
from run-down with a time constant of 7 ± 2 s while in the presence of renzapride the
recovery time constant was only 1.6 ± 0.2 s (P<0.05). Forskolin (1 μM), an adenylyl cyclase
activator, mimicked the action of renzapride. H-89 (10 μM), a protein kinase A (PKA)
inhibitor blocked renzapride’s effects. We then tested the hypothesis that 5-HT4 receptor-
mediated increases in fEPSP amplitude are due to an increase in release probability from
single varicosities. This was accomplished using outside-out patches obtained from myenteric
neurons containing nAChRs to detect ACh release from individual varicosities. Renzarpride
increased release probability from 27% to 52% (P<0.01). To confirm the 5-HT4 receptor
nature of the observed response, studies were also performed with the 5-HT4 receptor
agonist, tegaserod (0.1 μM). Tegaserod also increased release probability from 27% to 49%
(P<0.01). Conclusions. These data suggest that an increase in release probability from single
varicosities is a mechanism by which 5-HT4 receptor agonists facilitate fEPSPs. This maintains
synaptic transmission during periods of high frequency activity and accelerates recovery
from transmitter depletion. Facilitation of fast synaptic transmission would contribute to
the prokinetic actions of 5-HT4 receptor agonists. (Supported by DK57039. Tegaserod was
a generous gift from Novartis, E. Hanover, NJ)
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M1828
Effects of Serotonin Transporter Inhibition On Gastrointestinal Motility and
Colonic Sensitivity in the Mouse
Matthew D. Coates, Anthony C. Johnson, Beverley Greenwood-van Meerveld, Gary M.
Mawe
Serotonin (5-HT) released from enterochromaffin cells is an important activator of intrinsic
and extrinsic reflexes in the bowel. The serotonin-selective reuptake transporter (SERT),
which is expressed on intestinal enterocytes, terminates the actions of 5-HT by removing
it from the interstitial space. SERT expression is decreased in animal models of intestinal
inflammation and in individuals with inflammatory bowel disease (IBD) or irritable bowel
syndrome (IBS). It is possible that resultant changes in serotonin signaling contribute to the
manifestation of clinical features associated with these disorders. This investigation was
conducted to test whether inhibition of SERT function leads to changes in gut motility and/
or sensitivity. METHODS: C57BL/6 mice (male; 5-8 weeks of age) underwent a 14 day
treatment with the SERT inhibitor, paroxetine (20 mg/kg), or vehicle (50% propylene glycol
in 0.9% NaCl). In mice from both treatment groups, small intestinal transit was evaluated
by dividing the distance the leading edge of a charcoal meal from the pylorus by the total
length of the small intestines. Colonic motility was assessed by measurement of stool fre-
quency. Electromyographic recording from the rectus abdominis muscle was used to assess
sensitivity to colonic distension. RESULTS: Small intestinal transit was significantly decreased
in mice treated with paroxetine (vehicle, 0.81 ± 0.03, n = 10; paroxetine, 0.67 ± 0.03, n =
10; p <0.05). Stool pellet elimination was reduced in mice treated with paroxetine (vehicle,
9.2 ± 0.6 pellets/30 min, n = 12; paroxetine, 5.8 ± 0.7 pellets/30 min, n = 16; p<0.05).
Responsiveness to colorectal distension at a nociceptive level (60 mm Hg) was attenuated
in mice treated with paroxetine (control, 120.0 ± 30.4 spikes/10 sec, n = 9; paroxetine,
50.1 ± 19.9 spikes/10 sec, n = 7; p < 0.05). SUMMARY AND CONCLUSIONS: These
results demonstrate that pharmacological inhibition of SERT function significantly alters
gastrointestinal motility and sensitivity in mice, and support the concept that altered SERT
expression and function could contribute to symptoms associated with IBS and IBD. It is
possible that the decrease in viscerosomatic sensitivity detected in the paroxetine group was
due to an effect of the compound on serotonergic pain inhibitory pathways in the spinal
cord. Supported by NIH grant DK62267, Novartis Pharmaceuticals and NIH P20 COBRE
grant RR16435.
M1829
Role of Oxidative Stress and Prostaglandins On Colonic Muscle Cell Damage
Induced By Exposure of Human Mucosa to a Pathogenic Lipopolysaccharide
Michele Pier Luca Guarino, Carola Severi, Simone Carotti, Webiao Cao, Ivan Tattoli,
Anna Maria Altomare, Rossana Alloni, Renato Caviglia, Sara Emerenziani, Michele Cicala
The suppression of intestinal muscle contractility induced by lipopolysaccharide (LPS) in
animal models of septic ileus has been suggested to be mediated by acute activation of
macrophages which primarily release inflammatory mediators and reactive oxygen species.
Suppression of colonic smooth muscle cell (SMC) contractility induced by inflammation
and oxidative stress seems to be mediated by the activation of the transcription factor NF-
kappa B. AIM: To define if human mucosal exposure to LPS is related to oxidative stress
and whether this leads to suppression of muscle cell contractility via activated NF-kappa B
and prostaglandin release. METHODS: From fresh specimens of human colon, the mucosa
and submucosa were removed and sealed between two chambers, with the luminal side of
mucosa facing upward and covered with 5mL of Krebs solution, and the submucosal side
facing downward into 20mL of Krebs. Both chambers were oxygenated and kept at 37°C.
LPS (Sigma) obtained from the pathogenic strain of Escherichia coli 0111:B4 was added to
the luminal side of the mucosa and kept for 30 minutes. Enzymatically isolated SMCs were
exposed for 30 minutes to normal buffer or to buffer from the submucosal chamber of
mucosa pre-exposed to LPS (LPS-buffer). SMCs were incubated for 15 minutes with LPS-
buffer in the absence or presence of H(2)O(2) scavenger catalase (1,200U/mL) or indometh-
acin (5μM), a cyclooxygenase inhibitor. Furthermore SMCs were pre-incubated with MG132
(0.1 μM, for 15 min), an inhibitor of NF-kappa B activation, before direct LPS exposure
(50ng/mL). At the end of pre-incubation periods acetylcholine (ACh) (10-6M) contraction-
response was tested. RESULTS: SMCs incubated with normal buffer showed a maximal
contraction of 26±2%. SMCs exposed to LPS-buffer presented no change in the resting cell
length (5.5±2% decrease of unstimulated cell) but inhibition of maximal contraction of
75.3±6% compared to response in normal buffer. The inhibition was reversed by preincuba-
tion of SMCs with either indomethacin or catalase (18.5±5% and 7.8±2% inhibition of
maximal contraction, respectively). Inhibition of maximal contraction was also reversed in
cells pretreated with MG132, before direct LPS exposure (11.2±3%). CONCLUSIONS: The
relevant impairment of SMC contractile response, observed after acute exposure of colonic
mucosa to a pathogenic LPS, is reversed by the inhibition of cyclooxygenase expression and
NF-kappa B activation and by removing H(2)O(2). It is conceivable that excessive mucosal
and/or muscular oxidative stress triggers an increased production of prostaglandins which
leads to suppression of muscle cell contractility via NF-kappa B activation.
M1830
Heterogeneities in ICC Activity Within the Canine and Murine Large Intestine
in Situ Are Revealed By Ca2+ Fluorescent Imaging
Peter Bayguinov, Hyun-Tai Lee, Kyu Joo Park, Grant W. Hennig, Nick J. Spencer, Sean M.
Ward, Kenton M. Sanders, Terence K. Smith
Background: Both fast and slow electrical rhythms have been recorded across the muscularis
of the large intestine in a variety of species including human, dog and mouse. A ~20 cycles/
minute rhythm called myenteric potential oscillations (MPOs), has been observed in both
the longitudinal muscle (LM) and myenteric circular muscle (CM) of the dog and human
colon; this rhythm is unstable and waxes and wanes over time. In contrast, within the
CM at the submucosal border a regular 5-7 cycles/minute rhythm is observed. Aims: We

















would have different rhythms and firing patterns in the murine and canine large intestine.
Methods: Segments of canine or murine proximal colon were opened, the mucosa removed,
and pinned flat with either the LM uppermost (ICC-MY flap) or the submucosal surface
uppermost (ICC-SM flap) in an organ bath and perfused with Krebs solution at 36°C. In
the ICC-MY flap, strips of LM were peeled away to reveal the ICC-MY network. Tissues
were loaded with the Ca2+ indicator (fluo-4) and activity monitored using an upright
microscope and CCD camera. Results: In both species, individual ICC-SM cells within the
submucosal network of ICC were observed to elicit rhythmic Ca2+ transients in a coordinated
manner at a frequency between 5-8/min. Activity in ICC-SM was associated with Ca2+
waves in CM followed by CM contraction. In dramatic contrast to ICC-SM, ICC-MY fired
in a disorderly and uncoordinated fashion. Both intramuscular ICC (ICC-IM) aligned with
the CM or LM and ICC-MY fired in a similar but irregular fashion (~17/min). Conclusions:
In both the murine and canine colon, ICC at the level of the myenteric plexus form a loosely
coupled network of oscillators, whereas ICC on the submucosal surface of the CM are tightly
coupled. These different activities of ICC may partially explain the differences in electrical
activities generated on opposite sides of the CM. Supported by grants from NIH (NIDDK):
RO1 DK45713 (TKS), DK41315 (KMS) and Core laboratory Cobre grant P2O RR-18751.
M1831
Control of Intestinal Epithelial Cell Proliferation By Enteric Glial Cells:
Impact in Colorectal Cancer
Laurianne Van Landeghem, Tor Savidge, Philippe Aubert, Emmanuel Coron, Bernard
Lardeux, Francois Paris, Jean-Paul Galmiche, Michel Neunlist
Introduction : Enteric glial cells (EGCs) are a major component of the enteric nervous system
(ENS). Mucosal EGCs are organised in a dense cellular network that closely contacts intestinal
epithelial cells (IEC). Recent in vitro studies suggest that EGCs greatly inhibit IEC prolifera-
tion. Nevertheless, it is not known whether EGCs control IEC proliferation in vivo and
whether the EGC network is altered in colorectal cancer. Material et Methods : In vivo
proliferation experiments were performed in transgenic mice expressing herpes simplex
virus thymidine kinase under control of the GFAP promoter, a specific marker for EGCs in
the intestine. Injection of ganciclovir in these animals induced a selective destruction of
proliferating EGCs. After ganciclovir treatment, mice were injected i.p. with methyl 3H-
thymidine (37kBq.g-1 body weight) and intestinal tissues were processed for autoradiography
studies. In addition, fragments of human colon (involved and margin) were obtained from
patients undergoing surgery for colorectal cancer. These fragments were processed for
immunohistochemistry and quantitative rtPCR studies of S100b, a marker of glial cells. In
addition, the effects of soluble S100b on human intestinal adenocarcinoma proliferation
were characterized in vitro using Caco-2 cells seeded on Transwell filters for 6 days in the
presence or absence of S100b. Results : EGC ablation in transgenic mice induced crypt cell
hyperplasia with a significant increase in the number of 3H-thymidine labelled epithelial
cells as compared to control nontransgenic littermates (28% ± 4% vs 19% ±3%; n=4; p<0,05).
Immunohistochemisty performed on human colonic adenocarcinoma (n=4) demonstrated
a marked decrease in mucosal S100b-immunoreactivity when compared to marginal control
tissues (n=4). This was corroborated further by a significant 62% reduction in S100b mRNA
expression in control tissues (n=4). Finally, in vitro studies demonstrated that S100b (1nM)
significantly reduced Caco-2 cell numbers as compared to controls (19%, n=6; p<0,01).
Discussion : Our results demonstrate a novel role for EGCs in inhibiting IEC proliferation
in the gastrointestinal tract. The significant diminution of EGC found in the proximity of
colonic tumours suggests that an alteration of the EGC network may favour the development
of colorectal cancer.
M1832
Ca2+ Imaging of Pacemaker Activity in Interstitial Cells of Cajal in Human
Jejunum in Situ
Hyun-Tai Lee, Grant W. Hennig, Neal Fleming, Sean M. Ward, Kathleen D. Keef, Nick J.
Spencer, Kenton M. Sanders, Terence K. Smith
Background: Interstitial cells of Cajal (ICC) are present in human gastrointestinal tract
between the longitudinal and circular muscle layers where they form a dense network (ICC-
MY), but we know very little about the function of these cells. Morphological studies of
ICC in human small intestine suggest that they resemble ICC in both larger and smaller
mammals. Aims: Therefore, we attempted to study whether ICC in the human jejunum
have a similar pacemaker role as they do in other mammals. Methods: Segments of human
jejunum were pinned flat with the longitudinal muscle uppermost in an organ bath perfused
with Krebs solution at 36°C. Strips of longitudinal muscle were peeled away to reveal the
ICC-MY. The tissues were then loaded with the Ca2+ indicator (fluo-4 AM) and activity
monitored using an upright microscope and CCD camera. Results: The structure of the ICC-
MY network in the human jejunum consisted of bands or bundles of multipolar cells that
had long processes and were immunoreactive for Kit. Rhythmically oscillating Ca2+ transients
were observed in these cells that were similar in waveform to slow waves. Activity within
ICC-MY spread through the network of ICC at rates consistent with the propagation of
electrical slow waves. Activity in ICC-MY was coupled to activity in muscle layers. Ca2+
signals in ICC-MY networks were not affected by nicardipine (1~3 μM), TTX (1 μM),
atropine (1 μM), or ryanodine (10 μM), but their rhythmicity was reduced or abolished by
CPA (10 μM), 2-APB (50 μM), FCCP (1 μM), Ni2+ (100~250 μM), or mibefradil (10~30
μM). The gap junction blocker β-glycyrrhetinic acid (30 μM) caused ICC to fire in an
uncoordinated fashion. Conclusions: For the first time, we demonstrate that ICC-MY are
pacemaker cells in human jejunum and that the spread of activity within the ICC-MY
network can be readily studied using fluorescent Ca2+ imaging. Supported by NIH grants
from NIDDK: RO1 DK45713 (TKS), PO1 DK41315 (KMS) and Cobre grant P2O RR-18751
which funded the imaging core.
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M1833
Enteric Glia - Quantitative Comparison Between Human and Guinea Pig (GP)
Enteric Nervous System (ENS)
Sebastian Hoff, Christian Pehl, Florian Zeller, Claus von Weyhern, Michael Wegner,
Michael Schemann, Anne Ruhl
Enteric glia (EGC) are the most abundant cell type in the ENS, and loss of EGC has been
shown to alter enteric neuronal phenotype and function. Because exact glial cell numbers
have not yet been reported for the human ENS, we have used a recently identified monoclonal
anti-Sox antibody as pan-glial marker in conjunction with a pan-neuronal marker to quantify
EGC in the human vs. gp. Whole-mount preparations of the myenteric (MP) and the
submucous plexus (SMP; 3 layers in man) from normal human and gp ileum, proximal and
distal colon were immunostained with anti-Sox and anti-neuron specific enolase antibodies.
Cell counts were performed semi-automatically and expressed as cells per ganglion to rule
out stretch-dependent effects. In all human gut regions, EGC numbers per ganglion were
34.8fold higher in the MP than in the SMP (p<0.01); in contrast, neuronal numbers were
9.5fold higher. This was mirrored by a 4fold higher glia:neuron ratio (“glia-index”) in MP
vs. SMP (p<0.05). Strikingly, neuronal numbers per ganglion were similar between man
and gp MP, whereas glial cell numbers per ganglion differed significantly by a factor of 3.6
(cf. Table 1). This resulted in significantly different glia-indices, which are 5.9 for ileum,
6.5 for ascending and 6.1 for sigmoid colon while the respective gp regions have a glia-
index of 1.7, indicating that the glia-index in the human ENS is consistently higher than
in the corresponding gp tissues (p<0.01). It would further increase if extraganglionic EGC
were included. Overall, our data constitute the first comprehensive data set on human EGC
numbers and density and provide a basis for pathological assessment of glial proliferation
or degeneration in the diseased human gut. Furthermore, we have revealed marked differences
between the enteric glia indices of man and gp. The glia-index appears to be correlated
with functional complexity and integrative potential of the respective neuronal structures.
Supported by Broad Medical Research Program IBD-0105R.
Glial cell numbers/ganglion in the human/gp ENS
Data are expressed as means±SD. *: significantly different from inner SMP; **: significantly
different from all SMP and gp or human MP, respectively.
M1834
Regional Differences in Nitrergic Innervation to Mouse Lower Esophageal
Sphincter (LES) Circular Smooth Muscle (CSM)
Yong Zhang, Hiroshi Mashimo, William G. Paterson
AIM: To characterize the inhibitory nitrergic innervation of mouse LES CSM and determine
the relative contributions of nNOS and eNOS enzymes. METHODS: Nerve-mediated
responses were studied using conventional intracellular recordings. Mouse LES, consisting
of two “C”-like clasps (left and right), were studied separately. In the presence of atropine
(3 µM), nifedipine (1 µM), guanethidine (3 µM) and substance P (1 µM), resting membrane
potential (MP) and response to nerve stimulation (NS; 4 square wave pulses, each 0.3 ms
duration, 20 Hz) were measured. RESULTS: In wild type mice, resting MP was ~ -42 mV
in both left and right LES. NS of left LES invariably induced a monophasic IJP with amplitude
of 17.5 ± 1.8 mV and duration of 1091 ± 108 ms (n=4). However, NS of right LES evoked
a biphasic IJP consisting of an initial faster IJP with amplitude of 29.4 ± 1.5mV and duration
of 720 ± 45 ms, followed by a slower IJP with amplitude of 9.5 ± 1.8 mV and duration of
14485 ± 2097 ms (n=5). Apamin (300 nM) depolarized MP by 7.3 ± 1.8 mV over control
and decreased IJP amplitude by 4.6 ± 1.6 mV (n=6, p<0.05) in left LES, while it depolarized
MP by 6.5 ±1.2 mV over control and decreased the fast and slow IJP amplitudes by 11.5
± 1.5 and 1.5 ± 1.3 mV, respectively, in right LES (n=5, p<0.05). L-NAME (200 µM)
markedly inhibited IJP amplitude from 19.5 ± 3.5 mV to 2.5 ± 1.5 mV (n=3, p<0.05) in
left LES, and the fast and slow IJP amplitudes from 19.9 ± 2.5 mV and 8.3 ± 1.4 mV, to
8.1 ± 1.5 mV and 0.3 ± 0.2 mV, respectively, in right LES (n=5, p<0.05). Moreover, nitrergic
IJPs and biphasic IJPs were significantly inhibited by niflumic acid (200 nM), a Ca2+-activated
Cl- channel blocker. To distinguish neuronal and myogenic contributions to the biphasic
IJP in right LES, both nNOS- and eNOS-deficient mice were studied. In right LES of nNOS-
deficient mice, only apamin-sensitive monophasic IJPs were recorded (n=4). In eNOS-
deficient mice (n=4), the biphasic nitrergic IJPs recorded in right LES were identical to those
recorded in control mice. Furthermore, sodium nitroprusside (SNP, 200 µM), a NO donor,
hyperpolarized MP by 20.3 ± 2.2 mV (n=3) and 22.4 ± 1.5 mV (n=4) in wild type and eNOS-
deficient mouse, respectively, and this hyperpolarization was unaffected by pre-application of
L-NAME. However, SNP abolished the biphasic nitrergic IJPs and left apamin-sensitive
purinergic IJPs intact. CONCLUSIONS: These data suggest nitrergic IJPs are regionally
different in mouse LES (biphasic in the right and monophasic in the left). The mechanism(s)
underlying the biphasic nitrergic IJP in right LES are unclear, but does not involve activation
of myogenic NOS (eNOS).
M1835
Interaction Between Enteric Glia and Neurons in a Primary Cell Culture
Model Derived from Embryonic Mice
Priya Gomes, Werend Boesmans, Jozef Janssens, Jan Tack, Pieter Vanden Berghe
Disruption of enteric glial cells has detrimental effects on neuronal integrity in the enteric
nervous system (Bush, 1998; Aubé, 2005). However, the role of glia in sustaining enteric
neurons under non-pathological conditions has not been addressed. Our aim was to establish
a cell culture model that allows studying glia-neuronal interactions. Therefore, intestinal
cells were isolated using enzymatic dissociation of embryonic (E15) mouse intestines. Har-
vested cells were cultured in fetal bovine serum (10%) medium containing and maintained
for up to 14 days. Nerve growth factor (NGF), neuron (N2) or glia (G5) specific supplements
(INVITROGEN) were used to modify neuronal and glial growth and maintenance. Expression
of specific markers was checked by immunohistochemistry and intracellular Ca2+ changes
were measured using Ca2+-sensitive dyes (Fluo-4). From day 7 onwards cells formed ganglia-
like structures, in which MAP-2/PGP9.5-positive neurons and GFAP/S100-positive glial cells
were present. Within subsets of neurons we confirmed the expression of nitric oxide synthase
(NOS), choline acetyltransferase (ChAT) and calretinin. Neurons established synaptic contacts
as revealed by punctate expression of synaptophysin in the network. Growth and survival
of neurons and glia could be directed by adding supplements. In the presence of N2, there
was a 1.1-fold increase in number of neurons as compared to control. G5 supplemented
cultures showed not only an increased amount of glia, but also an increased number of
neurons (4.6-fold), which was further enhanced (14-fold) by N2. Combination of two
neuronal supplements (N2 and NGF) was not able to yield as many neurons as G5 on its
own. The viability of the neurons was tested by brief high K+ exposure, to which they
responded with a rise in intracellular Ca2+ (3.03 ± 0.22, T50%:15 ± 1s, n=48, N=12 dishes).
Neurons also responded (2.08 ± 0.07, n=12, N=4) to electrical fiber stimulation (1s, 20Hz).
None of the glial cells displayed Ca2+ transient caused by K+ depolarization. We also used
lipophosphatidic acid (LPA, 10 μM), an EDG2 receptor agonist and proposed glia activator.
LPA induced a robust [Ca2+]i rise (2.76 ± 0.13, T50%: 20 ± 2s, n=32, N=2) in the glial cells.
Conclusion: We established a primary co-culture of enteric glia and neurons that allows
studying interaction between these two cell types. Neurons and glia expressed the classical
neuronal and glial markers respectively and displayed transient Ca2+ rises upon stimulation.
The number of enteric neurons was highly dependent on glial cell supplements, which
suggests an essential role for these cells in the growth and maintenance of enteric neurons.
M1836
Local Inhibitory Reflexes Evoked By Mucosally Applied Nutrients and Sensory
Mediators in Isolated Guinea-Pig Jejunum
Rachel Gwynne, Joel Bornstein
Purpose. The motility of the gut depends on the chemicals contained in the lumen, but the
stimuli that modify motility and their relationship to the enteric neural pathways are unclear.
This study examined local inhibitory reflexes activated by various amino acids and putative
sensory mediators (ATP, serotonin (5-HT), cholecystokinin (CCK)) applied to the mucosa
to characterise effective physiological stimuli and the pathways they excite. Methods. Seg-
ments of jejunum were opened along the mesenteric border and dissected to allow access
to the circular muscle on one half of the preparation. The mucosa was left intact on the
circumferentially adjacent half. Circular muscle cells were impaled close to the intact mucosa
and chemicals were transiently applied to the mucosa (duration 150ms) 1-2 mm circumferen-
tial and oral to the impalement site. Results. 5-HT (10µM), ATP (1mM), CCK (1-10µM),
L-alanine, L-phenylalanine and L-tryptophan (all 1mM) each elicited time-locked inhibitory
junction potentials (IJPs) (latency 160-180ms, amplitude 3-15mV, each N>6) when applied
to the mucosa. IJPs elicited by 5-HT were abolished by ondansetron and were resistant to
5-HT4, nicotinic, P2, NK1, AMPA or NMDA receptor antagonists (each N≥4). ATP evoked
IJPs were reduced by PPADS (10µM) but were unaffected by ondansetron or tropisetron
(10µM). CCK evoked IJPs were reduced by the specific CCK B receptor antagonist L-365260
(100nM) or by a combination of 5-HT3 and 5-HT4 receptor antagonists. They were unaffected
by the CCK A receptor antagonist devazepide (100nM), PPADS, or when the 5-HT3 or 5-
HT4 antagonists were added individually. The amino acids each evoked IJPs reduced by
combined 5-HT3 and 5-HT4 receptor antagonism and also by PPADS. The CGRP antagonist
alpha-CGRP 8-37 had no effect on responses evoked by CCK or L-alanine. In most prepara-
tions, a large component of the response remained even after addition of effective antagonists.
Conclusion. Chemical stimulation of the mucosa activates distinct local reflex pathways
whose pharmacologogy depends on the nature of the stimulus. 5-HT, CCK and ATP activate
reflexes involving 5-HT3, CCK B and P2X receptors respectively. L-alanine, L-phenylalanine
and L-tryptophan evoke reflexes that appear to involve P2X receptors and/or 5-HT3 and 4
receptors acting together. However, in most cases the responses were only partially reduced.
Other transmitters involved in these reflexes remain to be identified, but do not appear to
include acetylcholine acting at nicotinic receptors, CGRP, or glutamate acting at AMPA or
NMDA receptors
M1837
Functional Metabotropic Glutamate Receptors Are Expressed On Enteric Glia
and Their Expression Is Reduced During Colitis
Yasmin Nasser, Catherine M. Keenan, Adrienne C. Ma, Donna-Marie McCafferty, Keith A.
Sharkey
Although glutamate is present in the enteric nervous system (ENS), its role in neurotransmis-
sion is not well understood. Glutamate is a neurotransmitter in the brain, but it also modulates
glial function. Enteric glia are the most numerous cell in the ENS, but little is known about
their role in gastrointestinal physiology or pathophysiology. We hypothesize that enteric
glia are a target of neurotransmitters and play an active role in intestinal inflammation. We
investigated whether enteric glia express functional metabotropic glutamate receptors, and
whether receptor expression is altered during intestinal inflammation. In the myenteric
plexus of the ileum and colon of mice, rats and guinea pigs, we observed widespread glial
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expression of the metabotropic glutamate receptor 5 (mGluR5). In vitro incubation of isolated
guinea pig ileal segments with the specific mGluR5 agonist CHPG caused a dose-dependent
increase in the expression of the immediate early gene product, Fos in enteric glia. We also
observed that CHPG increased the expression of the phosphorylated form of the extracellular
signal-regulated kinase (pERK1/2) in enteric glia. Preincubation of the tissues with the
metabotropic glutamate receptor antagonist 4-CPG, had no effect on Fos expression alone,
but abolished the effects of CHPG. CHPG did not stimulate the expression of neuronal Fos
or pERK1/2, suggesting that the effects of mGluR5 stimulation were specific to enteric glia.
In order to determine whether mGluR5 expression was altered by inflammation, we examined
10 week old IL-10 knockout mice, a model of spontaneous intestinal inflammation. Glial
mGluR5 expression was significantly reduced in the colonic myenteric plexus when compared
to controls, as assessed with real-time quantitative RT-PCR (relative expression of control
compared to GAPDH: 1.25 ± 0.25, n=4; relative expression of IL-10 knockout: 0.31 ±
0.22, n=7, p= 0.02). Substantial reductions in protein expression were also observed by
immunohistochemistry and image analysis. Expression of the glial specific marker, glial
fibrillary acidic protein, was unchanged in knockout mice, suggesting that inflammation
did not cause widespread glial destruction. Our results suggest that enteric glia are a functional
target for the glutamatergic neurotransmitter system and that changes in glutamatergic
receptor expression may play a modulatory role in colitis.
M1838
Neuropeptide Y Promotes the Survival and Proliferation of nNOS-Containing
Enteric Neurons
Mallappa Anitha, Simon Mwangi, Shanthi V. Sitaraman, Shanthi Srinivasan
Background: Alterations in NPY have been noted in diseases affecting the enteric nervous
system such as diabetes. We investigated the role of NPY in the proliferation and suppression
of apoptosis in a primary enteric neuronal culture as well as in an NPY knock out mouse
model (NPY KO). Methods: Using a primary culture system of enteric neurons (EN)obtained
by immunoselection from E14 rat embryonic intestines we examined the effect of NPY on
enteric neuronal proliferation (BrdU incorporation) and apoptosis (Hoechst method and
immunocytochemistry for cleaved caspase-3. nNOS and ChAT staining neurons were identi-
fied by immunocytochemistry. NPY-mediated phosphorylation of Akt was assessed by west-
ern blot analysis. For the in vivo studies segments of proximal colon obtained from WT
and NPY KO mice were fixed and stained for peripherin, NADPH diaphorase and acetylchol-
ine esterase to assess total number of myenteric neurons, nNOS containing neurons and
excitatory neurons respectively. Electric field stimulation (EFS) of proximal colon strips was
used to evaluate the inhibitory neuronal mediated relaxation of the colon. Results: Exposure
of NPY (1μM, 24h) significantly increased proliferation of EN(% BrdU positive: Vehicle:
37.6 + 4.3; NPY: 60 + 2, n=4, p<0.006). NPY (1μM, for 24h) also significantly reduced
apoptosis in EN compared to controls assessed by the Hoechst method (p<0.002) and
cleaved caspase 3 immunocytochemistry (p<0.0001). NPY induced a significant increase in
nNOS+ EN compared to vehicle treated cells (P<0.01). No change in ChAT+ cells was noted
with NPY for 24 h. NPY significantly increased phosphorylation of Akt compared to vehicle
and this was lost when treated with PI-3-Kinase inhibitor LY294002 (p<0.05 vs. NPY, n=
3). We next examined the effects of NPY on enteric neurons in vivo. In NPY KO mice, there
was a significant decrease in the number of NADPH staining neurons and large fibers in
the colon compared to WT mice. (neurons:0.01; large fibers: p=0.0009, n=6). No change
was noted in the number of acetylcholine esterase staining excitatory neurons or large fibers
in the proximal colon of the NPY KO vs. WT mice (p=0.3760, neurons; p=0.2943, large
fibers; n=6). EFS evoked relaxation of the proximal colon was significantly impaired in NPY
KO mice compared to WT mice. (% relaxation at 48V: WT: 40.94 + 4.6, NPY KO: 15.27
+ 1.3, p=0.002, n=4). The neuronal staining as well as EFS data is consistent with a decrease
in the inhibitory neurons in NPY KO. Conclusions: Loss of NPY in the NPY KO mouse
model is associated with a decrease in nNOS containing neurons demonstrated by neuronal
staining and by EFS recording from muscle strips.
M1839
Characteristics of the Serotonergic (1A) Receptor Expressed By Mast Cells in
Guinea-Pig Intestine
Xi-Yu Wang, Guo-Du Wang, Yun Xia, Sumei Liu, Na Gao, Gui-Jun Fei, Hong-Zhen Hu,
Jackie D. Wood
Enteric mast cells sense the presence of threats in the intestine(food allergens and parasites)
and signal their presence to the enteric nervous system (ENS) by releasing paracrine medi-
ators. The ENS responds by programing secretory and motor behavior, which functions
rapidly to eliminate the threat. Cramping abdominal pain,fecal urgency and explosive diarrhea
are symptoms that reflect “running” of the mast cell/ENS program. In view of the large
amounts of 5-HT known to be released from enterochromaffin cells in the mucosa, we
tested the hypothesis that mast cells express 5-HT receptors, which influence release of
mediators from mast cells to the ENS and other intramural sites (e.g., primary afferent
nerve terminals). Immunofluorescence and ELISA assay were used to study expression and
stimulation of 5-HT receptors expressed by mucosal mast cells (MMC) and connective tissue
mast cells (CTMC) in 7 guinea-pigs. The results revealed immunoreactivity(IR)for the 5-
HT1A receptor in 92.4% (2585/2798) of MMCs and 92.4% (1521/1647) of CMCs in the
small intestine. Nearly all tryptase-IR mast cells expressed 5-HT1A-IR. No 5-HT1A-IR cells
expressed anti-S-100-IR, which is a glial cell marker, or anti-Hu-IR, which is a pan-neuronal
marker. Immunoreactivity for neither the 5-HT4 nor the 5-HT2 receptor was expressed by

















cells and only by 3 of 246 that did not express 5-HT4-IR. Exposure to the 5-HT1A agonist,
BP554 (10 µM) suppressed basal release of histamine from 720±56 to 492±49 ng.gtissue-
1. This action of BP554 was suppressed when co-applied with the selective 5-HT1A antagonist
spiroxatrine (20-50 µM). Exposure to 20-µM 5-HT stimulated the release of histamine into
the bathing medium. This stimulatory action of 5-HT was not reversed by any of the selective
5-HT receptor antagonists that included spiroxatrine, the 5-HT2 antgonist LY-53857, the 5-
HT3 antagonist Y-25130, the 5-HT4 antagonist GR113808, or the 5-HT7 antagonist SB269970
when applied at 30 µM in 5 preparations. Tetrodotoxin (1 µM) suppressed the stimulatory
action of 5-HT. Application of 200-nM substance P elevated the concentration of histamine
in the bathing medium by 25.37±2.3% of basal release. The results suggest that stimulation
5-HT1A receptors on enteric mast cells suppresses the release of histamine and perhaps other
mast cell mediators. Part of the 5-HT-evoked release of histamine in this study was secondary
to stimulation of release of substance P from enteric neurons and activation of NK-1 receptors
on the mast cells. (Supported by NIH RO1 DK37238, RO1 DK57075 and KO8 060468)
M1840
Nitric Oxide Enhances Inhibitory Synaptic Input to Non-Cholinergic
Secretomotor Neurons of Guinea Pig Ileum, But Also Enhances Their
Excitability
Joel Bornstein, Peipei J. Foong, Kathryn A. Marks, Zhihong Wang
Background and Aim: Nitric oxide synthase (NOS) is found in many nerve terminals within
the submucous ganglia of the gut, but the role(s) of nitric oxide (NO) in enteric neural
communication is unclear. The NO donor sodium nitroprusside (SNP) selectively enhances
cyclic GMP production in non-cholinergic secretomotor neurons of guinea pig ileum, i.e.
those immunoreactive for vasoactive intestinal peptide (VIP). This study aimed to determine
whether NO modifies either synaptic or firing properties of these neurons. Methods: Guinea
pigs were stunned and killed by severing their carotid arteries and spinal cords. Preparations
of ileal submucosa were dissected using standard methods and pinned out for intracellular
recording. Recording electrodes were often filled with biocytin dissolved in 1M KCl to allow
subsequent confirmation that impaled neurons contained VIP; but it was mostly assumed
that neurons with inhibitory synaptic potentials (IPSPs) were VIP-neurons. Internodal strands
were stimulated focally with 1, 2, 3, 5 and 10 pulses (30 Hz) to evoke slow excitatory
synaptic potentials (EPSPs) and IPSPs in impaled neurons. All neurons exhibited fast EPSPs
that were unaffected by the drugs used. Results: SNP (100 µM) enhanced amplitudes of
IPSPs in all VIP neurons studied (n=44) and for all stimulus protocols; e.g., IPSPs evoked
by a single stimulus pulse increased from 4.7±0.9mV to 9.1±1.0mV (n=29, P<0.001) and
those evoked by 5 pulses (30Hz) increased from 21.8±1.3mV to 25.6±1.2 mV (n=34,
P<0.001). SNP also depressed slow EPSPs evoked by 1, 2, 3, 5 and 10 pulse stimuli. The
effects of SNP were blocked by an inhibitor of soluble guanylyl cyclase (ODQ, 10µM). The
α2-receptor antagonist idazoxan (2µM) depressed IPSP amplitudes, without affecting slow
EPSPs. In idazoxan, SNP enhanced IPSPs evoked by long stimulus trains (5, 10 pulses), but
not those evoked by short trains (1-3 pulses). VIP neurons typically fire action potentials
only at the start of long depolarizing current pulses. SNP markedly enhanced firing in
response to such depolarizations, often converting transient firing to sustained firing. In
contrast, the NOS inhibitor NOLA (100µM) depressed IPSPs, enhanced slow EPSPs and
depressed firing during depolarizing current pulses. Conclusions: NO enhances inhibitory
transmission to VIP secretomotor neurons largely via an action on sympathetic inputs.
Paradoxically, this increased inhibition is accompanied by enhanced excitability of these
neurons indicating that NO differentially affects intrinsic and extrinsic neural pathways
converging on the VIP neurons. Endogenous NO apparently has similar effects, suggesting
new roles for enteric NOS neurons.
M1841
Stretch-Induced Relaxation of the Lower Esophageal Sphincter
Ravinder K. Mittal, Ibrahim Dogan, Jianmin Liu, Valmik Bhargava
Swallow and esophageal-distension induced relaxation of the lower esophageal sphincter
(LES) is associated with its cranial movement, of up to 20 mm, due to a concurrent
longitudinal muscle contraction of the esophagus. We hypothesized that longitudinal muscle
contraction causes a cranially directed mechanical stretch of the LES, which in turn may
be responsible for the LES relaxation. Methods: We studied 7 opossums. A silicon tube was
placed via mouth into the esophagus and surgical laprotomy was performed. Two needles
with silk sutures were passed, 90 degrees apart, through both esophageal walls and silicon
tube 1-2 cm above the LES. Tube was withdrawn and one end of each of the 4 sutures was
anchored to the esophageal wall and the other end exited through the mouth. The 4 sutures
were used to exert graded cranial stretch on the LES using pulley and weights. LES pressure
was monitored using a sleeve sensor anchored to LES. Effect of nitric oxide antagonist (L-
NNA 20mg/kg, I.V. bolus) on the stretch effect was also studied. Results: Cranial stretch
caused LES relaxation with the recovery of LES pressure following cessation of stretch.
Degree of LES relaxation induced by stretch increased with applied weight. A nearly complete
LES relaxation was observed in all animals 78±12% (mean±SD) before L-NNA (with a
residual pressure of 11±6 mmHg); however, weight required to induce complete LES relaxa-
tion differed in animals (714±348g). A cranial movement of 15-20 mm of the esophagus
occurred with the weights used for the cranial stretch. Increased duration of stretch resulted
in increased duration of relaxation. L-NNA, resulted in inhibition of the stretch induced
LES relaxation (19±11% with a residual pressure of 46±14 mmHg). Conclusions: Our data
support the presence of a stretch activated inhibitory neuron in the pathway to the LES.
The role of stretch activated neuron in the mediation of swallow-induced LES relaxation
requires further investigation.
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M1842
Neurogenic Mucosal Bicarbonate Secretion Mediated By the Purinergic P2y1
Receptor in Guinea-Pig Duodenum
Gui-Jun Fei, Xiucai Fang, Xi-Yu Wang, Guo-Du Wang, Sumei Liu, Na Gao, Hong-Zhen
Hu, Yun Xia, Jackie D. Wood
We reported earlier that ATP is released as a neurotransmitter in the guinea-pig submucosal
plexus where it becomes a ligand for the P2Y1 receptor subtype expressed by secretomotor
neurons (J Physiol 2003;550:493-504) and that ATP, applied in Ussing flux chambers, acts
at P2Y1 receptors on secretomotor neurons to increase short-circuit current as a reflection
of stimulation of mucosal chloride secretion (Gastroenterology 2004;126:A148.). The present
study investigated involvement of ATP and the neuronal P2Y1 receptor in stimulation of
mucosal secretion of bicarbonate (HCO3-) in guinea-pig duodenum. Muscle-stripped pre-
parations were micro-dissected from the duodenum and mounted between the halves of
Ussing flux chambers. Under continuous short-circuited conditions, the actions of exogen-
ously applied ATP on mucosal HCO3- secretion were investigated with the pH-stat technique
for measurement of the concentration of HCO3- in the bathing medium. Application of ATP
to the submucosal side of the preparations increased HCO3- in a concentration-dependent
manner over a range of 10-7 to 10-5 mol/L with an EC50 of 0.16 µM/L (P<0.0001, N=6
preparations). The maximal response to ATP occurred at 3x10-6 mol/L (net peak HCO3-
output 0.49±0.06 μmol . cm2 h-1). MRS2179 (10-5 mol/L), a selective P2Y1 purinergic
receptor antagonist, significantly suppressed ATP-evoked HCO3- secretion by 47%
(P<0.0001) and short circuit current (Isc) by 63% (P<0.002). Pretreatment with tetrodotoxin
(0.5x10-6 mol/L) or a selective VIP1 receptor antagonist (10-6 mol/L) suppressed ATP-
evoked HCO3- secretion by 61% and 41% respectively (P<0.001) and Isc by 97% and
70% respectively (P<0.0001 and P<0.001). Pretreatment with the muscarinic antagonist,
scopolamine (10-5mol/L), or the alpha2 noradrenergic antagonist, idazoxan (10-5mol/L), did
not alter ATP-evoked HCO3- secretion or Isc. The results suggest that ATP stimulates
duodenal HCO3- secretion mostly through an excitatory action at purinergic P2Y1 receptors
on neurons in the submucosal division of the enteric nervous system. Stimulation of VIPergic
secretomotor neurons accounts for a significant component of the ATP-evoked secretory
response. (Supported by NIH R01 DK 068258)
M1843
Brain-Derived Neurotrophic Factor (BDNF) and Serotonin Are Co-Stored in a
Population of Mucosal Enteroendocrine Cells of Intestine and Colon of Rat
and Guinea Pig
John R. Grider, Melissa Gulick, Liya Qiao
Previously, we have shown in isolated segments of rat colon, that Brain-Derived Neurotrophic
Factor (BDNF) is released during the peristaltic reflex and that BDNF enhances the release of
serotonin (5-HT) and calcitonin gene-related peptide (CGRP) elicited by mucosal stimulation
thereby leading to an augmentation of the peristaltic reflex. We have also shown that BDNF
and CGRP are co-stored in neurons of myenteric ganglia cultured from guinea pig intestine
indicating a neural source of BDNF, and suggesting that the augmentation of the peristaltic
reflex occurs at the level of the intrinsic sensory neuron. Aim: to determine if BDNF is also
present in the mucosa and if there is a relationship between BDNF-containing and 5-HT-
containing cells. Methods: Segments of colon and intestine from guinea pig and rat were
fixed in 4% paraformaldehyde and transverse sections cut at a thickness of 10 micrometers.
The sections were co-stained for 5-HT and BDNF. BDNF-immunoreactive mucosal cells
were counted in each cross-section; the number of cells that were co-stained for 5-HT was
determined and expressed as a percentage of total BDNF-immunoreactive cells. Results: In
the rat colon, neurons of the submucosal and myenteric plexus, and cells in the mucosa
were immunostained for BDNF. In the myenteric and submucosal plexus, both cell bodies
and fibers were stained; BDNF-positive fibers were also present in circular smooth muscle.
In the mucosa of the rat colon, BDNF-immunoreactive cells had a morphology typical of
enteroendocrine cells and were more frequent in the basal area of the colonic crypts; there
were 58±4 BDNF-immunoreactive mucosal cells per transverse section. Dual staining with
5-HT antibody indicated that 27.8±5.4% of these BDNF-immunoreactive mucosal cells were
co-stained for 5-HT. Examination of the rat small intestine, and guinea pig small intestine
and colon produced similar patterns of staining. In the rat small intestine, 30.1±4.8% of
BDNF-immunoreactive mucosal cells were co-stained for 5-HT; in the guinea pig colon,
32.8±5.2% of the BDNF-immunoreactive mucosal cells were co-stained for 5-HT; and in
the guinea pig intestine, 36.1 ±6.4% of the BDNF-immunoreactive mucosal cells were
co-stained for 5-HT. Conclusion: BDNF is present in enteric neurons and in mucosal
enteroendocrine cells of rat and guinea pig intestine and colon. A significant percentage of
mucosal BDNF cells also contain 5-HT suggesting that the augmentation of the peristaltic
reflex by BDNF might be mediated at the level of the mucosal sensory apparatus in addition
to the augmentation at the level of the intrinsic sensory neurons.
M1844
Enhanced Jejunal Secretory Function in Patients with Irritable Bowel
Syndrome (IBS)
Magnus Simren, Jenny Gustavsson, Evan A. Thomas, Joel C. Bornstein, Henrik Sjovall
Background: The pathophysiology of IBS is complex and incompletely understood. A few
small studies exists suggesting abnormal secretory function in the small intestine in IBS.
Potential difference (PD) measurement in the small intestine reflects electrogenic chloride
secretion, which depends on mechanosensitive submucosal neurons. Phase III of the migrat-
ing motor complex (MMC) represents a sustained mechanical stimulation of these neurons.
Secretory events, measured by PD, before, during and after phase III therefore reflect
submucosal neuronal function. We aimed to evaluate small intestinal secretory function,
using PD, in a large sample of IBS patients. Methods: We included 82 patients with IBS
according to the Rome II criteria (59 females; mean age 37 (19-67) years) and 25 healthy
controls (13 females; mean age 39 (21-71) years). Submucous plexus function in the jejunum,
and its linkage with motor activity, was studied by modified multilumen manometry, using
two manometry channels as flowing electrodes. Motor activity and transmucosal PD were
measured during 3 hours in the fasting state, and one hour in the fed state. Secretory events
associated with the different phases of the MMC were evaluated using an automated system
and compared between the groups. Results: Mean fasted PD did not differ between the
groups (-0.61±1.6 vs. -0.53±2.3 mV; NS), and there were also similar PD values during
phase I and phase II in IBS patients and healthy controls. The maximal PD during phase
III was higher (=more lumen negative) in the IBS group compared with controls (-12.7±6.0
vs. -9.5±5.0 mV; p=0.03), but the slope of the rise at onset of phase III did not differ
between groups (NS). The PD during the fed state was also higher in the patient group (-
4.9±2.6 vs. -3.8±2.6 mV; p<0.05). As a measure of the responsiveness of the system the
PD signal was corrected for pressure and this measure was also higher in the IBS patients
than in the controls (-1.0±0.6 vs. -0.2±0.4 mV/mmHg; p<0.0001). There were no significant
differences in PD between IBS subgroups based on the predominant bowel habit. Conclusion:
Patients with IBS demonstrate enhanced jejunal secretory function, suggesting upregulated
motility-secretion linkage in these patients. This probably reflects disturbed submucosal
neuronal function in IBS patients. However, this seems to be unrelated to the predominant
bowel pattern of the patient.
M1845
Targets of 5-HT Innervation in Guinea Pig Myenteric Plexus
Kath B. Neal, Joel C. Bornstein
Serotonin (5-HT)-immunoreactive (-IR) interneurons in the myenteric plexus form long
anally-directed chains in the small intestine and make connections to other uniaxonal cell
types which have not been identified. We used confocal microscopy to survey 5-HT-IR
appositions to other myenteric neurons. Methods: 10 guinea-pigs were stunned and their
carotid arteries severed. Segments of jejunum (4-6cm) were removed, cleaned and placed
in an organ bath at 37°C, containing 500nM 5-HT in physiological saline bubbled with
95% O2 and 5% CO2, for 4 hours. This selectively loads intrinsic 5-HT interneurons and
not sympathetic terminals. Tissue was pinned flat and fixed in Zamboni’s fixative at 4°C
for 12 hours. Myenteric plexus was dissected, washed and incubated at 4°C for 36 hours
in antisera against 5-HT and one of calbindin, calretinin, nitric oxide synthase (NOS) or
neuropeptide Y (NPY). Preparations were washed in phosphate buffered saline, incubated
for 3 hours in cocktails of secondary antisera and mounted in fluorescence mounting medium.
Stacked images of stained cells were collected with Biorad MRC 1024 confocal software
using a 100x objective at a centre-to-centre step of 0.2-0.6µm. Appositions between 5-HT-
IR terminals and other neurons were defined when no intervening pixel (0.2µm) was seen.
Results: Each stain was analysed in tissue from 3-4 animals. n is the number of cells
examined. 76% of calbindin-IR neurons (n=49) received 5-HT appositions; these cells
received 5.3±0.5 appositions. Calretinin cells were divided into inter- and longitudinal
muscle motor neurons according to morphology and position. Interneurons (n=22) received
28.9±1.7 appositions which were distributed trimodally (x<6 n=7; 16< x <36 n=9; x>53
n=6). 63.2% of calretinin motor neurons (n=23) received appositions; none received more
than 11. NOS-IR neurons (n=19) received 30.7±1.8 appositions which were bimodally
distributed (x<36 n=15; x>54 n=4). All NPY cells (n=22) received large numbers of 5-HT
appositions (81.5±1.0). Conclusion: Myenteric neurons targeted by 5-HT comprise several
cell types. Subgroups of calretinin-IR interneurons and NOS-IR neurons which are not
currently distinguishable by other criteria receive large numbers of 5-HT appositions.
Although some myenteric calbindin-IR cells receive serotonergic slow excitatory postsynaptic
potentials, these cells receive very small numbers of appositions, suggesting that even small
numbers of contacts can have physiological roles. Myenteric NPY-IR cholinergic secretomotor
neurons are highly targeted by 5-HT, consistent with a role for 5-HT in cholinergic secretomo-
tor pathways.
M1846
Expression of the Transient Receptor Potential Vanilloid 4 (TRPV4) Channel
in the Enteric Nervous System of the Rat
Na Gao, Hong-Zhen Hu, Xiucai Fang, Sumei Liu, Gui-Jun Fei, Xiyu Wang, Guo-Du
Wang, Yun Xia, Jackie D. Wood
Transient receptor potential vanilloid (TRPV4) belongs to the vanilloid subfamily of the
transient receptor potential (TRP) channels. The expression of TRPV4 is found in a broad
range of tissues, including brain, smooth muscle, liver, lung, spleen, kidney, fat, and vascular
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endothelium. In mammals, the physiological roles for TRPV4 are highly divergent because
TRPV4 is activated by a variety of stimuli including thermal stress, fatty acid metabolites
and hypotonicity. TRPV4 has been proposed to a mechanosensor and osmosensor. We used
indirect immunofluorescence techniques to study the expression pattern for TRPV4 in the
rat enteric nervous system. TRPV4 immunoreactivity (IR) was found in 46.0% (1253/2721)
of the population of submucosal neurons and 61.7% (1236/2002) of myenteric neurons
by co-labeling with anti-Hu antibody. Neuronal localization of chemical codes, including
calretinin, calbindin, neuropeptide Y (NPY), vasoactive intestinal peptide (VIP) and nitric
oxide synthase (NOS) were used to study the chemical coding for TRPV4. In the myenteric
plexus, 86.6% (1017/1174) of TRPV4-IR neurons expressed calretinin-IR and 80.7% (1017/
1260) of calretinin-IR neurons expressed TRPV4-IR. All 486 NPY-IR neurons expressed
TRPV4-IR and about 38.5% (486/1264) of TRPV4-immunoreactive neurons expressed NPY-
IR. About 40.1% (73/182) of calbindin-IR neurons expressed TRPV4-IR while only 4.4 %
(73/1677) of TRPV4-IR neurons expressed calbindin-IR. None of 1090 NOS -IR neurons
had overlapping images with 1524 TRPV4-IR neurons in the myenteric plexus. In the
submucosal plexus, TRPV4-IR was found in 71.4 % (1088/1522) of calbindin-IR neurons
and 56.5% (1088/1925) of TRPV4-IR neurons expressed calbindin. All 1496 TRPV4-immu-
noreactive neurons expressed calretinin-IR and 84.1% (1496/1779) of calretinin-IR neurons
expressed TRPV4-IR. About 96.8% (655/677) of NPY-IR neurons expressed TRPV4-IR and
42.4% (655/1546) of TRPV4-IR neurons had NPY-IR. All 665 VIP-IR neurons expressed
TRPV4-IR and 48.9% (665/1360) of TRPV4-IR neurons expressed VIP-IR. The results suggest
that TRPV4 is expressed abundantly in rat enteric nervous system and that the chemical
coding for TRPV4-IR differs between the myenteric and submucosal plexuses. Expression
of TRPV4 channels might be involved in sensing functions of neurons in the enteric nervous
system. (Supported by NIH RO1 DK37238 and DK57075)
M1847
Temporal and Regional Differences in the Gastrointestinal Motor Response to
Infection with Schistosoma Mansoni
Faiza B. Abdu, Osama Tayeb, David Grundy
Background: Mouse models of schistosomiasis have been used to investigate inflammation
induced changes in intestinal motor function. Previously we described intestinal motor
dysfunction during acute Schistosoma mansoni (S. mansoni) infection (Abdu & Grundy,
Gastroenterology Volume: 128, Suppl 2, page A-76, 2005). Our aim in this study was to
investigate the role of inflammatory mediators in the mechanisms underlying post-inflammat-
ory changes during chronic inflammation. Methods: Experiments were performed in Swiss
mice 8- and 16-wk following infection with S. mansoni compared to untreated controls.
Jejunal and colonic motility were assessed using a Trendelenburg type preparation to study
aboral directed motor complexes (MC) as described previously (Abdu et al., AJP. Am J
Physiol Gastrointest Liver Physiol. G624-G633). Data were expressed as mean ± SEM (n =
4-17) and were analysed by paired or un-paired t tests as appropriate. Results: Infection
had profound effects on jejunal and colonic motility where there was a significant increase
in MC amplitude and an increase in frequency reflected by a decease in the interval between
MC. Naproxen (10µM) caused a significant increase in amplitude and decrease in interval
in the jejunum of control (5.29 versus 9.86 ± 1 cmH2O, P < 0.002; 39.58 ± 5 versus 24.10
± 2s, P < 0.02 respectively) and 8-wk infected animals only (17.93 ± 1 versus 24.73 ± 0.3
cmH2O, P < 0.008; 49.06 ± 3 versus 19.01 ± 0.6s, P < 0.004 respectively). In the colon
Naproxen caused a decrease in amplitude in control animals and throughout the post-
infection period (P<0.02) but increased the MC interval in control (81.09 ± 14 versus 105.31
± 14s, P < 0.02) and early periods of infection only (137.29 ± 37 versus 245.27 ± 49s, P
< 0.01). The 5-HT3 antagonist Y-25130 (1µM) had no effect on MC interval in control and
infected animals (P>0.05) but in both jejunum and colon it caused a significant decrease
in amplitude in control (75.87 ± 9 versus 42.77 ± 5 cmH2O, P < 0.008 and 8-wk (79.45
± 9 versus 41.10 ± 5 cmH2O, P < 0.005) infected animals but not at 12- and 16-wk.
Conclusions: These data demonstrate temporal differences in the sensitivity of jejunal and
colonic motor function following infection with S mansoni. Prostanoids and 5-HT3 play an
important role in the regulation of motor function in both control and infected animals but
altered sensitivity in the early and late post-infection period may point to plasticity in the
mechanisms responsible for intestinal dysmotility.
M1848
Choline Transporter: An Additional Marker of Cholinergic Nerves in the
Enteric Nervous System
Andrea M. Harrington, Margaret Lee, Sim-Yee Ong, Eric Yong, Pam Farmer, John M.
Hutson, Bridget R. Southwell
Purpose: The cholinergic circuitry of the enteric nervous system (ENS) is labelled using
antibodies against molecules involved in acetylcholine (ACh) synthesis and release. A new
component of ACh synthesis, the high affinity choline transporter (CHT), which is essential
in the uptake of choline into cholinergic nerves, has been isolated and cloned. Recently,
antiserum against CHT has been used in the central nervous system to label cholinergic
nerves, but has not been located in the ENS. The aim of this study was to localise CHT
immunoreactivity (IR) within rat and human intestine and determine if CHT colocalised
with other cholinergic markers in the ENS. Methods: Segments of rat (n = 3) ileum and
colon and human paediatric (n = 3) colon were fixed, prepared for sections and wholemounts
and incubated with antisera against the full length human CHT sequence, followed by a
fluorescent secondary antibody. Tissue was double labelled using antibodies to neuronal
nitric oxide synthase (nNOS), common choline acetyltransferase (cChAT), substance P (SP)
and vesicular acetylcholine transporter (VAChT). Colocalisation was quantitated in 3 confocal
images from each segment. Results: In human and rat intestine, CHT-IR was present in
nerve fibres in the circular muscle and myenteric ganglia and in myenteric nerve cell bodies.
In human colon, CHT-IR was present in almost all VAChT-IR cholinergic nerve fibres in
the circular muscle and myenteric ganglia. In contrast, in the rat only 56% of circular muscle
VAChT-IR nerve fibres were CHT-IR, with this accounting for 79% of CHT-IR nerve fibres.
In the myenteric ganglia, 48% of VAChT-IR nerve fibres were CHT-IR, accounting for 50%

















40% of CHT-IR nerve cell bodies were SP-IR (tachykinergic), accounting for 12% of SP-IR
nerve cell bodies. In both species, there was little localisation of CHT-IR in nitrergic NOS-
IR inhibitory nerve fibres. Conclusions: In human paediatric colon, there was almost complete
colocalisation of CHT-IR and VAChT-IR in nerve fibres in the circular muscle and myenteric
ganglia. Therefore the CHT antisera would be useful for studying the enteric cholinergic
circuitry in human intestine and complimentary to currently used labels. In rat, CHT-IR
identified VAChT-IR positive, VAChT-IR negative nerve fibres and cChAT-IR negative cell
bodies. This result suggests the antibody does not bind to all the cholinergic circuitry
identified by cChAT-IR or VAChT-IR. Further studies are needed to determine if the CHT
antibody is specifically labelling cholinergic nerves in the rat.
M1849
Localization of 5-HT3 Receptors to Subsets of Myenteric Neurons in the
Mouse Small Intestine
Dima Alkawwas, James Galligan
Introduction. 5-hydroxytryptamine (5-HT) is an important neurotransmitter and paracrine
signaling molecule in the gastrointestinal tract. Enterochromaffin cells and neurons release
5-HT which acts on myenteric neurons to stimulate acetylcholine release causing contractions
of the muscle layers. The present studies were designed to characterize 5-HT receptors on
myenteric neurons in the mouse small intestine and to determine if 5-HT3 receptors were
localized to functional subsets of myenteric neuron. Methods. The aims of this studies were
accomplished by using pharmacological methods. Isometric force transducers were used to
measure longitudinal muscle contractions of segments of mouse ileum maintained in vitro.
Results. 5-HT caused concentration-dependent (0.1-30 μM) contractions that were not
inhibited by individual treatment with methysergide (1 μM, 5-HT1/5-HT2 receptor antagon-
ist), ketanserin (1 μM, 5-HT2A receptor antagonist), scopolamine (1 μM, muscarinic receptor
antagonist), tetrodotoxin (TTX, 0.3 μM, axonal sodium channel antagonist), or Y25130
(10 μM, 5-HT3 receptor antagonist). However, combined application of methysergide and
scopolamine or methysergide and TTX inhibited 5-HT induced contractions. Similarly,
combined application of methysergide and Y25130 or ketanserin and Y25130 also inhibited
5-HT induced contractions. 5-HT-induced contractions were not inhibited by spantide (10
μM) a NK1/NK2 receptor antagonist. The 5-HT3 receptor agonists 2-Me-5-HT (0.3-30 μM)
and m-chlorophenylbiguanide (CPBG)(0.1-30 μM) mimicked 5-HT induced contractions.
In addition, combined application of apamin and nitro-L-arginine to block inhibitory nerves,
potentiated CPBG-induced contractions. All responses caused by CBPG were blocked by
the 5-HT3 receptor antagonist, Y25130 (10 μM). Conclusions. These data indicate that 5-
HT3 receptors are localized to cholinergic excitatory neurons and to inhibitory neurons, but
not to neurons that release tachykinin peptides supplying the longitudinal muscle. In addition,
an excitatory, methysergide and ketanserin-sensitive 5-HT receptor is localized to the longit-
udinal muscle in the mouse small intestine. (Supported by DK57039)
M1850
Distribution of R-Type Calcium Channels in the Enteric Nervous System of
the Guinea Pig
Vinogran Naidoo, Xiaochun Bian, James Galligan
Introduction. Previous electrophysiological studies have shown that many myenteric neurons
in the guinea pig ileum express R-type calcium channels. However, the specific neuronal
subtypes expressing R-type channels have not been established. The purpose of these studies
was to characterize the distribution of R-type calcium channels in the enteric nervous system
of the guinea pig gastrointestinal tract. Methods. R-type calcium channels were localized
using an antibody against the α1E calcium channel subunit which encodes R-type calcium
channels. Neuronal subtypes were identified using antibodies against markers for specific
neuronal classes. All studies were done in whole mount preparations of adult guinea pig
gastrointestinal tract. Results. α1E-immunoreactivity (ir) was found in myenteric nerve cell
bodies in the stomach and colon but not the small intestine. α1E-ir co-localized with
substance P (SP) in myenteric neurons in the colon and with nerve fibers in the myenteric
plexus and muscle layers throughout the gut. α1E-ir also co-localized with vasoactive
intestinal peptide (VIP) and nitric oxide synthase (NOS) in nerve fibers supplying the muscle
layers throughout the gut. α1E-VIP neurons were detected in the colon. Gastric myenteric
neurons exhibited α1E-nNOS staining. α1E-ir was not co-localized with 5-HT in the myent-
eric plexus. α1E-ir was also co-localized with tyrosine hydroxylase containing nerve fibers
in the myenteric plexus throughout the gut. α1E-ir was not detected in the submucosal
layer of any gut region. Conclusions. These data indicate that R-type calcium channels are
present in SP-containing excitatory motorneurons, ascending interneurons and/or intrinsic
primary afferent neurons. α1E-ir is also found in inhibitory (VIP, NOS) neurons supplying
the muscle layers. α1E-ir is not found in 5-HT-containing descending interneurons or
submucosal neurons. Finally, α1E-ir is localized to the endings of sympathetic nerve fibers
(tyrosine hydroxylase) supplying the myenteric plexus. Drugs targeting R-type calcium
channels might be useful in facilitating or inhibiting functionally distinct subsets of myenteric
neurons. (supported by DK57039)
M1851
Synaptic Transmission Between the Submucous Plexus and Myenteric Plexus
of the Guinea Pig Ileum
Rebecca L. Monro, Paul P. Bertrand, Joel C. Bornstein
Background and Aim: In the ileum, there is a clear correlation between motility and secretion
or blood flow. Vanner et al has shown that stimulation of the myenteric plexus results in
activation of submucous neurons and dilatation of arterioles 1,2. The present study aimed to
examine the converse, whether myenteric neurons receive synaptic input from the submucous
plexus. Methods: Guinea pigs were stunned then killed by severing the carotid arteries and
spinal cord. A preparation (modified from Moore & Vanner 2) containing exposed myenteric
ganglia in one half and submucous plexus in the other, was tightly pinned mucosa up in
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a bath of warmed physiological saline. Intracellular recordings were made from myenteric
neurons while the submucous plexus was electrically stimulated. Submucous ganglia (up
to 1.3 mm away) were stimulated using a 7 μm carbon fiber bipolar stimulating electrode
with either a single pulse or a train of 10 pulses at 100 Hz, typically 0.075 mA and 0.5
ms duration. Fast excitatory post-synaptic potentials (EPSPs) were recorded at membrane
potentials around 70 mV while slow EPSPs were recorded near resting membrane potential.
Muscarinic EPSPs were not blocked. In every S neuron, the stimulating electrode was first
tested on a myenteric fiber tract to ensure both that the neuron had synaptic input and that
the stimulus strength was adequate to evoke a synaptic potential, but not so great as to
stimulate myenteric ganglia through the submucous plexus. Results: Of the 29 neurons
studied (13 S and 16 AH neurons), stimulation of the submucous plexus evoked a synaptic
potential in only 7 cases, or 24% of neurons. When the stimulated submucous plexus was
situated orally with respect to the myenteric plexus, 4 of 13 neurons (31%) had synaptic
input. When it was situated circumferentially, 2 of 8 (25%) had input, and when it was
situated anally 1 of 8 (13%) had input. In terms of neuronal type, 5 of 13 S neurons (38%)
responded with fast EPSPs,1 of which also had a slow EPSP, while 2 of 16 AH neurons
(13%) responded with slow EPSPs. Conclusion: This study has shown that, contrary to the
situation explored by Moore & Vanner where many submucous neurons received input
from the myenteric plexus, the synaptic input to myenteric neurons from the submucous
plexus appears to be sparse. These data suggest that local input from the submucous plexus
less important for the coordination of reflexes by the myenteric plexus. Supported by the
NH&MRC (Australia). 1. Vanner (2000) AJP 279(2); G380-7. 2. Moore & Vanner (2000)
AJP 278(2):G273-80.
M1852
Sodium Hydrosulfide Changes Amplitude and Kinetics of Inward Sodium
Current in Human Jejunal Circular Smooth Muscle Cells
Robert Kraichely, Peter Strege, Michael Kendrick, Michael Sarr, Joseph Szurszewski,
Gianrico Farrugia
Background: Gaseous molecules such as nitric oxide and carbon monoxide are known to
play an important role in gastrointestinal physiology. H2S is another gaseous monoxide that
is endogenously produced and is found at micromolar concentrations in the serum and in
tissues, including the gastrointestinal tract. H2S has recently been shown to influence the
activity of vascular smooth muscle, intestinal afferent fibers and voltage gated channels.
Aims: The aim of the study was to determine the effect of NaHS, a source of H2S, on the
SCN5A-encoded NaV1.5 sodium channel expressed in human jejunal circular smooth muscle
cells. Methods: NaHS (0.1 mM, 1 mM, 10 mM) was dissolved in Ringers solution buffered
with HEPES. This was pH balanced to physiologic range (7.35 - 7.45). At this pH one third
of NaHS forms H2S gas, soluble in aqueous solution. Inward currents from dissociated
human jejunal smooth muscle cells were recorded by the amphotericin perforated-patch
technique in HEPES-buffered Ringers solution using a Cs+ based intracellular solution to
block outward K+ currents. NaHS was applied via pipette directly into the bath to avoid
mechanoactivation of the currents. Results: NaHS increased peak inward Na+ current (0.1
mM 18±6% increase, P>0.05, n=3; 1mM 18±6% increase, P<0.05, n=9; 10mM 34±11%
increase, P<0.05, n=9). At the highest concentration tested (10mM), a large (20±2.9 mV)
rightward shift in the activation voltage and voltage at maximum inward current was observed.
This effect was largely reversed with washout of the NaHS with HEPES-buffered Ringers
solution. Conclusion: A product of NaHS in aqueous solution, likely H2S, modulates Na+
current density and kinetics in human jejunal smooth muscle cells suggesting a potential
role for a third gaseous molecule in regulating gastrointestinal smooth muscle function.
Supported by NIH grants DK52766, DK57061 and DK 17238
*=P<0.05
M1853
Exon 10 in the CFTR Gene Is Critical for the Anti-Apoptotic Pancreatic
Phenotype in Mice: Lessons Learned from Separate CF Mouse Models
Matthew J. Dimagno, Sae-Hong Lee, Yibai Hao, Chung Owyang
BACKGROUND AND AIMS: Multiple CFTR genotypes, including the DF508 mutation in
exon 10 of the CFTR gene, are associated with idiopathic recurrent acute pancreatitis (AP).
Recently, we showed that UNC cftr “null” mutant mice, which have an exon 10 replacement,
develop more severe experimental AP compared to WT mice that was associated with an
anti-apoptotic acinar cell response and exuberant pancreatic inflammation. We hypothesized
that exon 10 in the CFTR gene is of critical importance to the anti-apoptotic pancreatic
phenotype and aberrant apoptosis execution steps in CF models. To test this hypothesis we
performed experimental AP studies in a more clinically relevant but less well characterized
mouse model of CF having the DF508 CFTR gene mutation in exon 10 (the most common
in humans). METHODS: DF508 cftr (+/-) mice were bred & weaned offspring were fed
Peptamen. In vivo AP was induced by 12 hourly IP caerulein injections (50 ug/kg). Histolog-
ical severity of AP was characterized by assessing three sequential execution steps of apoptosis:
caspase-3 catalysis, PARP cleavage and DNA fragmentation. RESULTS: During caerulein-
induced AP, DF508 cftr mice had exaggerated neutrophil infiltration and tissue edema by
blinded histological examination (n=3). Also, mirroring observations observed in the UNC
cftr (-/-) mouse pancreas, during AP, DF508 cftr pancreas had reduced apoptosis, based on
undetectable DNA fragmentation (laddering) in mutant mice (& strong laddering in WT
group) & 50% less cleavage of PARP, a caspase-3 downstream target. Unexpectedly, after
induction of AP, the upstream apoptosis execution step of capase-3 catalysis was markedly
enhanced in DF508 cftr vs WT groups (n=3); active caspase-3 was immunohistochemically
detected in the majority (95%) of DF508 cftr pancreatic acinar cells vs <5% of WT acinar
cells (n=3). CONCLUSIONS: This study supports the clinical observation that CFTR gene
mutations may predispose to pancreatitis. Further, within exon 10 of the CFTR gene, both
a “null” gene mutation and the DF508 mutation (arising from amino acid substitutions)
contribute to the same anti-apoptotic pancreatic phenotype and more severe AP, but by
distinctly different effects on apoptosis execution steps. This data raises the possibility that
different amino acid substitutions in the exon 10 region may differentially modulate apoptotic
pathways. Moreover, in the DF508 mouse CF model, the unexpected inhibition of apoptosis
signal transduction from execution caspase-3 to downstream PARP may be biologically
relevant in the pathogenesis of AP associated with CFTR mutations and serve as a novel
target for potential therapies.
M1854
Experimental Pancreatitis in Cathepsin B-Overexpressing Mice
Matthias Beier, Barbara Brandt-Nedelev, Manuel Ruthenbuerger, Iveta Jaroscakova,
Norbert Schachke, Thomas Reinheckel, Julia Mayerle, Walter Halangk, Markus Lerch
Background: Premature activation of pancreatic zymogens is believed to play a critical role
in the initiation of acute pancreatitis. The lysosomal proteinase cathepsin B (CTSB) is thought
to be involved in this process by directly activating trypsinogen within acinar cells. In
experimental pancreatitis of CTSB-deficient mice we found trypsinogen activation to be
reduced by 90%. In the present series of experiments we investigated whether pancreatic
overexpression of human CTSB in the mouse pancreas would increase the severity of
pancreatitis. Materials and methods: Pancreatitis was induced in FVB wild type (WT) and
FVB CTSB overexpressing mice (CTSB +++) by seven intraperitoneal injections of caerulein
(50 µg/kg body weight) at hourly intervals and mice were sacrificed after 8 hours. Using
immunocytochemistry we determined the intraacinar localization of trypsin (polyclonal
rabbit anti trypsin) and human CTSB (monoclonal mouse anti human cathepsin B). Acini
were incubated with 100nM cholecystokinin (CCK) to measure time- and CCK-dependent
intraacinar trypsin activity. Trypsin and trypsinogen activities (after enteropeptidase incuba-
tion) were measured fluorometrically. Trypsinogen and CTSB content was measured in
zymogen granule, lysosomal and cytosolic subcellular fractions after density gradient centrifu-
gation. Total CTSB was measured fluorometrically after incubation with dithioerythrol. To
distinguish between total and active CTSB we probed subcellular fractions with NS-196, a
high specific biotinylated CTSB inhibitor and Western blotting. Results: In spite of a 4 fold
increase in pancreatic CTSB expression in transgenic animals we found no difference in
trypsin activity or disease severity during caerulein-induced pancreatitis in comparison to
WT animals. Immunocytochemistry of pancreatic sections and acini revealed the expected
intracellular sorting of the transgenic human CTSB into the lysosomal and secretory compart-
ment and this was confirmed in subcellular fractions. Trypsin and human CTSB were clearly
colocalized. The 4fold increase in total CTSB in CTSB +++ animals, however, did not result
in an increase in total CTSB activity in the NS-196 biotinylated inhibitor studies. Conclusion:
The transgenic overexpression of human CTSB does not result in increased trypsinogen
activation or more severe pancreatitis. Whether this is caused by a failure of human CTSB
to participate the intraacinar protease activation events, by a difference in intracellular
processing of human and murine CTSB, or by the fact that maximal CTSB-induced tryp-
sinogen activation cannot be increased by adding available CTSB, needs to be elucidated.
M1855
Pathogenic Role of Endothelial Nitric Oxide Synthase On Caerulein-Induced
Acute Pancreatitis in Rats
Yusuke Sugiyama, Shinichi Kato, Shoji Mitsufuji, Takeshi Okanoue, Koji Takeuchi
Background/Aim: Nitric oxide (NO) is a potent pancreatic vasodilator, yet the pathogenic
role of NO in acute pancreatitis still remains controversial. NO is generated from L-arginine
by NO synthase (NOS), classified into three isozymes; neuronal (nNOS), inducible (iNOS)
and endothelial NOS (eNOS). In the present study, we investigated the role of NO/NOS
isozymes in the pathogenesis of caerulein-induced acute pancreatitis in rats. Methods: Acute
pancreatitis was induced in male Wistar rats by two SC injections of caerulein (20 μg/kg).
NG-nitro-L-arginine methyl ester (L-NAME: a nonselective NOS inhibitor) or aminoguanidine
(a relatively selective iNOS inhibitor) was given PO, while tetrahydrobiopterin (BH4), a
critical cofactor for NOS, was administered IP 30 min before the first caerulein injection.
The animals were killed 6 h after the first caerulein injection, and then pancreas weight,
serum amylase, myeloperoxidase (MPO) activity and thiobarbituric acid reactants (TBARS)
were evaluated. The microvascular permeability was determined by Evans blue extravasation
into pancreatic tissue 3 h after the first caerulein injection, while the levels of NO metabolites
in the pancreas were determined by Griess method. The expression of total eNOS was
examined by conventional Western blot, while dimeric eNOS was evaluated by Western
blot after low-temperature SDS-PAGE. Results: Caerulein given repeatedly twice produced
acute pancreatitis with concomitant increases in the serum amylase level, pancreas weight,
MPO activity, TBARS and microvascular permeability. Prior administration of L-NAME, but
not aminoguanidine, significantly prevented these changes, in a dose-dependent manner,
and this effect was antagonized by the co-administration of L-arginine. The total eNOS was
clearly expressed in the pancreas of normal rats and the expression was not affected by
caerulein injection. However, the expression of dimetric eNOS in the pancreas was markedly
suppressed by caerulein injections, together with a decrease in NO production, but the
response was partly reversed by the prior administration of BH4. The increases in the serum
amylase level and pancreas weight as well as TBARS in response to caerulein were significantly
attenuated by the administration of BH4. Conclusion: These results suggest that the
uncoupled eNOS, probably caused by the decrease in endogenous BH4 availability, plays
a deleterious role in the pathogenesis of caerulein-induced acute pancreatitis. It may be
assumed that the stabilization of eNOS by the supplementation of BH4 is a useful and novel
approach for the treatment of acute pancreatitis.
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M1856
Treatment with Anandamide, a Cannabinoid 1 Receptor Agonist, Increases the
Severity of Edematous Acute Pancreatitis
Artur Dembinski, Zygmunt Warzecha, Jakub Cieszkowski, Wieslaw W. Pawlik, Ryszard
Sendur, Romana Tomaszewska, Beata Kusnierz-Cabala, Jerzy W. Naskalski, Peter C.
Konturek
Background: Marijuana is well known herbal drug that has for centuries been use in native
medicine for treatment of wide array of health concerns, acting on cannabinoid 1 (CB1)
and cannabinoid 2 (CB2) receptor. CB1 receptor activation by exogenous and endogenous
cannabinoids has been shown, between others, to reduce of ischemic myocardial necrosis
area, to inhibit gastric and intestinal secretion, and gastrointestinal transit, and to protect
gastric mucosa against stress-induced ulcers. In the pancreas, usage of CB1 receptor antagonist
has prolonged the survival of rats with taurocholate-induced pancreatitis. Aim of the present
study was to check whether the administration of CB1 receptor agonist or antagonist affects
the development of edematous pancreatitis. Methods: Acute pancreatitis was induced in
Wistar rats by i.p. administration of cerulein (50 mcg/kg) five times with 1 h intervals.
Anandamide, a natural ligand for CB1 receptor (Ki = 61 nM), was administrated twice (30
min prior to cerulein or saline injection and after next 3 h) at the dose: 0.3, 1.5 or 3 mcmol/
kg i.p. AM 251 (ALEXIS® Biochemicals), a synthetic CB1 receptor antagonist (Ki = 7.49
nM), was administrated i.p. at the dose 4 mcmol/kg alone or in combination with anandamide
(at the dose 1.5 mcmol/kg/dose) twice (40 min prior to cerulein and after next 3 h). After
last injection of cerulein, the study was terminated. Results: Administration of anandamide
or AM 251 did not affect pancreatic condition in animals without acute pancreatitis. In
animals treated with cerulein, administration of anandamide increased dose-dependently
the severity of acute pancreatitis. In histological examination, we observed an increase in
pancreatic edema and inflammatory infiltration. Also, anandamide administration augmented
the pancreatitis-induced increase in serum level of lipase, amylase, poly-C ribonuclease, and
pro-inflammatory interleukin-1beta (IL-1), but was without effect on the pancreatitis-evoked
fall of pancreatic blood flow. Treatment with AM 251 reduced histological signs of pancreatic
damage, serum activity of pancreatic digestive enzymes and serum concentration of pro-
inflammatory IL-1 in animals with acute pancreatitis. Also, administration of AM 251 reversed
the anandamide-evoked aggravation of cerulein-induced acute pancreatitis. Conclusions:
(1) Activation of CB1 receptors by anandamide increases the severity of edematous acute
pancreatitis; (2) Blockade of CB1 receptor by AM 251 attenuates pancreatic damage in
acute pancreatitis.
M1857
Extracellular Acidification Sensitizes the Rat Pancreatic Acinar Cell to
Cerulein-Induced Protease Activation
Thomas Jung, Thomas Kolodecik, Christine Shugrue, Fred Gorelick
Pathologic protease activation in pancreatic acinar cells initiates acute pancreatitis. Supraphy-
siologic concentrations [10-7M] of cerulein cause protease activation and pancreatitis. Clinical
studies have shown a correlation between decreased extracellular pH (pHe) and AP. Work
from our laboratory suggests that protease activation requires an acidic intracellular compart-
ment that is vacuolar ATPase (vATPase)-dependent. This study examined the hypothesis
that pHe acidification or inhibition of Na-H exchange (NHE) could sensitize acinar cells to
cerulein-induced trypsinogen/ chymotrypsinogen activation. Medium acidification (pHe 7.6
to 6.8) dramatically sensitized cells to cerulein [10-7M]-induced protease activation, but
did not affect basal protease activation or the secretory response to cerulein. The sensitizing
effects of acidic pHe were observed with a range of cerulein [10-10 to 10-7 M]; the sensitizing
effects were reversible. Although the low-pH sensitization was also observed with muscarinic
agonist, carbachol (1 mM), it was less dramatic than cerulein. NHEs regulate proton extrusion
from the acinar cell. PCR analysis confirmed the presence of NHE1 and NHE4 in acinar
cells. Addition of HOE-694, a selective inhibitor of NHE1 that causes cytosolic acidification,
enhanced cerulein-induced protease activation. Finally, the vATPase inhibitors bafilomycin
and concanamycin (100nM) blocked the effects of an acidic pHe on cerulein-induced protease
activation. These studies suggest that perturbations which potentially acidify the acinar cell
cytosol sensitize it to ligand-induced protease activation. The mechanism of this effect may
be through increasing the availability of protons for the vATPase. The effects of acidosis on
acinar cell protease activation may be relevant to the pathogenesis of acute pancreatitis.
M1858
Dual Effect of Ca2+ On Cytochrome C Release from Pancreatic Mitochondria:
Role of Reactive Oxygen Species
Irina V. Odinokova, Olga A. Mareninova, Kai Feng Sung, Yuri V. Evtodienko, Anna S.
Gukovskaya
Background and Aims: We previously showed that mitochondrial dysfunction, resulting in
cytochrome c release and depolarization, mediates death responses of pancreatitis.
Cytochrome c release mediates apoptosis while loss of mitochondrial membrane potential
(DYm) leads to necrosis. Excessive increases in Ca2+ and reactive oxygen species (ROS) are
associated with pancreatitis; however, the regulation of pancreatic mitochondria by Ca2+
and ROS has not been studied. In this study, we determined the effects of Ca2+ and ROS
on cytochrome c release and DYm of pancreatic mitochondria. Methods: Mitochondria were
isolated from rat pancreas by differential centrifugation. We measured respiration with Clark
electrode; DYm with TPP+ electrode or fluorescent probe TMRM; ROS levels, with Amplex-
Red; and cytochrome c release, by Western blot. Free Ca2+ concentration in the medium
([Ca2+]e) was clamped at “zero” to 40 μM using Ca2+/EGTA buffers. Results: Ca2+ at
micromolar concentrations induced depolarization and cytochrome c release from isolated
pancreatic mitochondria. Both effects were blocked by the permeability transition pore (PTP)
inhibitor cyclosporin A, indicating that they are mediated by PTP opening. Depolarization
only increased with [Ca2+]e (or duration of mitochondria exposure to Ca2+). By contrast,
we found a non-monotonous dependence of cytochrome c release on Ca2+, with a maximum

















DYm loss. We hypothesized that depolarization blocks cytochrome c release by inhibiting
mitochondrial ROS. We measured that Ca2+-induced depolarization, indeed, decreased
mitochondrial ROS. We next measured that cytochrome c release was blocked by the
mitochondrial uncoupler FCCP; the inhibitors of complex I, rotenone and diphenyl-iodon-
ium; and by the lipid peroxidation inhibitor, butylene hydroxytoluene. The inhibitors (except
FCCP) did not depolarize mitochondria, but all of them drastically decreased mitochondrial
ROS. Conclusions: Ca2+ depolarizes pancreatic mitochondria and has a dual effect on
cytochrome c release. It stimulates cytochrome c release via PTP and inhibits it through
inhibition of ROS. These findings have important implications for the mechanism of pancreat-
itis. Excessive (or sustained) increases in Ca2+ could both stimulate necrosis through loss
of DYm and inhibit apoptosis by blocking its key mediator, cytochrome c release. Thus,
the intensity and/or duration of Ca2+ signals may determine the pattern of death responses
in pancreatitis.
M1859
Expressions of TLR2 and TLR4 in the Intestinal Mucosa from Rats with
Severe Acute Pancreatitis
Hidehiro Sawa, Takashi Ueda, Yoshifumi Takeyama, Takeo Yasuda, Naoki Matsumura,
Takahiro Nakajima, Yoshikazu Kuroda
Background and Aim. Infectious complication in the late phase is contributor to mortality
in severe acute pancreatitis (SAP). This complication is thought to be a result of the bacterial
translocation (BT) from the gastrointestinal tract, and breakdown of intestinal integrity is
considered to be implicated in BT. We recently demonstrated that accelerated apoptosis of
intestinal mucosa may be participated in BT. On the other hand, it is reported that toll-like
receptors (TLRs) are involved in not only the innate immune response but also acquired
immune activation, and that TLRs make important roles for the protection against infection.
TLR2 recognizes lipoteicoic acid of Gram-positive bacteria, and TLR4 recognizes lipopolysac-
charide of Gram-negative bacilli. We have recently reported that expression of TLR2 and
TLR4 on alveolar macrophage was diminished in SAP. This study aimed to investigate the
expressions of TLRs in the intestinal mucosa in SAP. Methods. Male Wistar rats weighing
250-300 g were used. Severe hemorrhagic necrotizing pancreatitis was induced by retrograde
injection of 3% sodium deoxycholate into the biliopancreatic duct. Ileum was removed 2,
6, 12, and 18 hours after induction of SAP, respectively. The expressions of TLR2 and TLR4
proteins in intestinal mucosa were assayed by western blotting. Localization of TLR2 and
TLR4 in intestinal mucosa was also evaluated by immunohistochemical staining. Results.
The expression of TLR2 and TLR4 proteins were detected in intestinal mucosa from control
rats. Two and 6 hours after induction of pancreatitis, both expressions were increased in
comparison with control level. Thereafter, 12 and 18 hours after induction of pancreatitis,
the expressions were decreased in comparison with control level. Immunoreactivities for
TLR2 and TLR4 were detected at the top of villi and crypt in intestinal mucosa from control
rats. They were increased at the top of villi and crypt (especially Paneth cells) 2 hours after
induction of pancreatitis in comparison with control. They were diminished 12 hours after
induction of pancreatitis accompanied with the breakdown of intestinal mucosa. Conclusions.
In rats with SAP, expressions of TLR2 and TLR4 were increased in the early phase, and
thereafter they were decreased to lower level as compared with control. These results suggest
that enhancement of the mucosal immune response in the early phase may be related with
the protection against infection, and that suppression of the mucosal immune response in
the late phase may be implicated in the mechanism of bacterial translocation.
M1860
Ethanol Stimulates Akt Phosphorylation in the Pancreas Through PTEN
Oxidation: A Predisposing Factor in Alcoholic Pancreatitis?
Olga A. Mareninova, Aurelia Lugea, Irina V. Odinokova, Hidekazu Tsukamoto, Ilya
Gukovsky, Stephen J. Pandol, Anna S. Gukovskaya
Background and Aims: Although alcohol abuse is a major cause of pancreatitis, the mechan-
isms of ethanol toxicity to pancreas are poorly understood. We and others recently showed
that the phosphatidylinositol 3-kinase (PI3K) pathway mediates key pathologic responses
of cerulein (CR) pancreatitis, including intrapancreatic activation of trypsinogen and the
transcription factor NF-κB. Most of PI3K effects are mediated through downstream Akt/
PKB kinase, which is negatively regulated by the phosphatase PTEN. It is not known how
alcohol affects this key signaling pathway in pancreas. In this study, we determined the
effects of ethanol feeding and CR pancreatitis on pancreatic PI3K/Akt/PTEN system. Methods:
Rats were fed for 6 weeks control and ethanol-containing diet (either intragastrically or as
liquid Lieber-deCarli diet). Pancreatitis was induced by 4 hourly i.p. injections of 50 μg/kg
CR. In pancreatic tissue, we measured Akt phosphorylation by Western blot; PI3K activity
with in vitro kinase assay; and PTEN oxidation and activity, with electromobility shift and
enzymatic assays. Results: We found that CR time dependently stimulated pancreatic Akt
phosphorylation in control-fed rats. The increase was evident at 30 min and reached 8-fold
at 4 h after the 1st CR injection. PI3K activity was not increased at these time points. PTEN
oxidation was dramatically stimulated during CR pancreatitis in control-fed rats, which
resulted in inhibition of PTEN activity. Time-dependencies of PTEN oxidation and Akt
phosphorylation superimposed suggesting PTEN oxidation as a mechanism for Akt activation
in pancreatitis. Ethanol feeding by itself stimulated both Akt phosphorylation and PTEN
oxidation in pancreas. In particular, 6 weeks of intragastric ethanol feeding increased Akt
phosphorylation ~9-fold. In rats fed ethanol, CR stimulated Akt phosphorylation to a greater
extent (~16-fold) than in control-fed rats (~8-fold versus saline). Conclusions: The results
indicate that ethanol feeding and CR pancreatitis both activate Akt. One mechanism of Akt
activation is through oxidation and thus inhibition of PTEN. Persistent Akt activation could
be a factor predisposing pancreas to alcoholic pancreatitis.
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M1861
Pancreatitis Associated Protein (PAP) Modulates Cytokine Expression in Rat
Macrophages
Domenico Viterbo, Yin Yao Lin, Cathy M. Mueller, Michael E. Zenilman, Martin Bluth
Background: Pancreatitis-associated proteins (PAP) are minimally expressed in normal pan-
creas but strongly induced in acute pancreatitis. We have previously demonstrated that
expression of PAP may modulate the severity of acute pancreatitis, and that serum obtained
from pancreatitic rats was able to induce phenotypic changes in macrophages. Since pancreat-
itis is associated with immune activation, we investigated the effect of PAP on macrophages.
Methods: Rat macrophages (NR8383 alveolar cell line) were cultured, with and without LPS
(1.0ug/ml), in concentrations of 2.5-15ug/ml of recombinant PAP for 24 hr and then evaluated
for cytokine (IL-1α, IL-1β, TNFα, IL-6) expression (RT-PCR) and morphologic changes
(agglutination, adhesion, granule content) by light microscopy. Controls consisted of cells
cultured with medium, vehicle alone or neutralizing PAP antibody. Significance between
groups was set at p < 0.05 (Student’s t-test). Results: Macrophages cultured in the presence
of PAP resulted in increased expression of IL-1α, IL-1β, TNFα, and IL-6 when compared
with controls (156, 178, 210 and 242 fold, respectively at 5ug/ml; p<0.05), which were
reversed (IL-1α, IL-1β) with neutralizing anti-PAP antibody. When macrophages were cul-
tured in the presence LPS, similar increases in cytokine expression were observed. However,
when PAP was co-cultured with LPS-stimulated cells, inflammatory cytokine expression was
reduced (up to 50%), with the observed reduction occurring at half the concentration of
the stimulatory effect observed with PAP alone (7.5ug/ml vs 15ug/ml) (p<0.05). When
macrophages were cultured with PAP, phenotypic changes including increased agglutination/
adhesion, and granule content were observed and were dose dependent (85% with 10ug/ml;
p<0.05). These changes were not observed in any control groups. Conclusions: Pancreatitis is
an immune phenomenon in which PAP is increased. PAP alone induces macrophage cytokine
expression in a dose related fashion. However, PAP can modulate inflammatory cytokine
expression by co-stimulants such as LPS, and induce morphologic changes in cultured
macrophages. This dual effect may explain the modulatory role of PAP in acute pancreatitis.
M1862
Intragastric Ethanol Depresses Sphincter of Oddi Function in the
Anaesthetized Australian Brush-Tailed Possum
Yukio Sonoda, Masahiko Kawamoto, Charmaine M. Woods, Ann C. Schloithe, James
Toouli, Gino Saccone
Background: The role of sphincter of Oddi (SO) function in alcoholic acute pancreatitis is
unclear. Data from previous animal studies have been conflicting, however these studies
have not used a technique that directly measures SO function (i.e. trans-sphincteric flow;
TSF). Aim: To examine the effect of intragastric ethanol on sphincter of Oddi TSF and
investigate possible mediation via neural mechanisms using prior acute vagotomy, pretreat-
ment with atropine or nitric oxide synthase inhibition. Methods: Australian Brush-tailed
possums were anaesthetized (sodium thiopentone) for the duration of the experiments. In
TSF studies, ethanol (1.0, 2.0 or 3.0g/kg, in water) or water was instilled into the stomach
(n=20). In separate studies, possums were subject to bilateral cervical vagotomy, pretreatment
with atropine (360ug/kg/h, continuous i.v. infusion) or with L-nitro arginine methyl ester
(L-NAME; 15mg/kg bolus followed by 6mg/kg/h continuous i.v. infusion) prior to administra-
tion of intragastric ethanol (2g/kg) or water (n=26). Blood ethanol concentrations were
determined at 0.5h intervals. Results: Intragastric ethanol decreased TSF whereas water had
no effect. After 1.0g/kg ethanol, TSF decreased to 60% of baseline at 1h and then recovered
to 80% of baseline. The 2.0 and 3.0g/kg doses of ethanol gradually decreased TSF to 30-
40% of baseline at 3h (both P<0.05 vs water). Blood pressure was not significantly changed
by ethanol administration (vs water). Instillation of 1.0, 2.0 and 3.0g/kg ethanol elevated
blood ethanol levels peaking at 108±8 (1.5h), 221±12 (3h) and 281±11mg/100ml (3h)
respectively. Acute vagotomy, pre-treatment with atropine or with L-NAME, reduced the
blood ethanol level at 3h to 131±17, 178±26 and 106±13 mg/100ml respectively. Following
intragastric water, acute vagotomy did not alter the TSF rate over the 3h period whereas
pre-treatment with atropine or L-NAME reduced TSF to 77±4% and 47±5% of baseline at
3h respectively. Acute vagotomy or pre-treatment with atropine or L-NAME delayed the
increase in blood ethanol concentration following intragastric ethanol but the TSF rates under
these conditions corresponded to those produced by the lower blood ethanol concentration.
Conclusion: These data demonstrate that intragastric ethanol (and/or its metabolites) reduces
sphincter of Oddi TSF. This effect is primarily due to the direct effect of blood ethanol.
The depressed SO function would contribute to increased pancreatic duct pressure which
could be one of the necessary events required for the onset of acute pancreatitis. Supported
by the NH&MRC of Australia (grant # 229901) and the FMC Foundation.
M1967
Is Proton Pump Inhibitor (PPI) Therapy a Risk Factor for C. Difficile
Infection?
Rohinee Beri, Michael P. Jones, Colin W. Howden
Background and Aims: PPIs suppress gastric acidity and may predispose to certain enteric
infections. PPI use may increase the risk of C. difficile infection (J. Hosp Infect 2003; 54:
243; CMAJ 2004; 171: 33). We performed a case-control study to examine this and assess
whether PPI use increased the risk of C. difficile among patients with other known risk
factors including antibiotic (ABx) use and cytotoxic chemotherapy (CC). Methods: 154
cases were identified from a hospital in-patient database. These were patients admitted
between 2001 and 2005 for various reasons other than diarrhea or known C. difficile infection,
but who had positive culture and toxin assay for C. difficile while in hospital. Median age
was 62 years (range 23 to 92); 47.4% were male. Controls, with no positive tests for C. difficile
infection, were selected from a random list provided by the Medical Records department and
matched individually to cases by age, sex, and month of hospital admission. Univariate and
stepwise logistic regression analyses were performed to determine the association of drug
classes with C. difficile infection. Results: Cases were significantly more likely to be using
PPIs, ABx and CC than controls. OR (95% confidence intervals (CI)) for PPI, ABx and CC
use by cases were 3.06 (1.87-5.01), 4.16 (2.48-6.98) and 3.51 (1.82-6.77) respectively.
Cases were not significantly more likely to be using H2-receptor antagonists (H2RAs; OR =
0.58; 95% CI = 0.29-1.16). Using stepwise logistic regression to predict C. difficile positive
cases, a three step model was identified: ABx (R2=0.13); ABx+PPI (R2=0.194) and
ABx+PPI+CC (R2=0.229). Conclusions: In this study, ABx use was most highly associated
with C. difficile infection. PPI but not H2RA use was also significantly associated with C.
difficile infection. In regression analysis, PPI use was more predictive of C. difficile infection
than CC. Potent suppression of gastric acidity by PPIs likely impairs host defenses against
C. difficile. H2RAs, which cause less potent acid suppression, are not associated with an
increased risk of C. difficile.
M1968
Acidic Media Increases the Expression of Dickkopf Homolog 1 (DKK-1) and 4
(DKK-4) in Esophageal Epithelial Het-1A Cells
Irshad Ali, Parvaneh Rafiee, Vicki Nelson, Aaron Rogaczewski, David G. Binion, Reza
Shaker
INTRODUCTION: Dkk family of secretory proteins is inhibitors of the Wnt pathway, and
activation of the Wnt pathway up-regulate Dkk-1 levels. Dkk-1 over-expression increases
apoptosis in stressed cells. LiCl activates the Wnt and the pro-survival phosphatidylinositol
3-kinase (PI3K) pathways. Recently studies have demonstrated increased Dkk-1 and Dkk-
4 expression in the non-injured distal squamous mucosa of esophagitis patients compared
to the healthy controls and Barrett’s patients suggesting that gastric acid exposure may up-
regulate their expression in this group. AIM: To determine whether low pH exposure of
Het-1A cells leads to increased Dkk-1 and Dkk-4 expression and whether this mechanism
involves the Wnt pathway. METHODS: Confluent Het-1A cells were incubated in basal
media (free of growth factors) overnight. They were then treated with acidified (pH 4.5)
media or LiCl for various times followed by incubation in fresh basal media for 3 hours.
The effect of phosphatidylinositol 3-kinase (PI3K) inhibitor (wortmanin) was also determined.
Dkk-1 and Dkk-4 mRNA expression was determined by real-time PCR and Dkk-1 protein
levels in the culture media was determined by ELISA. RESULTS: Dkk-1 mRNA and protein
expression were increased maximally after 10 minutes exposure to acidic media followed
by 3 h incubation in normal basal media (n=4) whereas Dkk-4 mRNA expression was
maximized at 30 min (n=4). LiCl increased Dkk-1 and Dkk-4 mRNA expression in a time
and concentration dependent manner. Dkk-1 protein was increased by LiCl (40 mM, n=4).
Wortmanin further increased the expression of Dkk-1 protein and mRNA by acidified media
and LiCl (n=4). Wortmanin decreased Dkk-4 mRNA expression by acidified media and did
not affect Dkk-4 expression by LiCl (n=4). CONCLUSION: Acidic media up-regulates Dkk-
1 and Dkk-4 expression in a temporally differential manner in esophageal epithelial Het-
1A cells suggesting a difference in sensitivity to low pH exposure for the activation of these
genes. Increased expression of Dkks by LiCl suggests that the Wnt pathway may be involved
and the enhanced expression of Dkk-1 by wortmanin suggests that the pro-survival PI3K
pathway may also regulate its activity.
M1969
Ghrelin Attenuates the Experimental Induced Esophagitis
Peter C. Konturek, Tomasz Brzozowski, Grzegorz Burnat, Robert Pajdo, Eckhart G. Hahn,
Konturek J. Stanislaw
Background and Aims: Ghrelin is a novel growth hormone (GH)-releasing and orexigenic
peptide which was recently isolated from the fundic portion of the stomach. Recently anti-
inflammatory and gastroprotective effect of this hormone have been demonstrated, but the
role of ghrelin in the protection of esophageal mucosa against injury has not been evaluated.
The aim of the study was 1) to analyze the expression of ghrelin and its receptor in humans
with esophagitis; 2) to assess the effect of exogenous ghrelin on experimentally induced
esophagitis; 3) to study the effect of ghrelin on expression of COX-2 and proinflammatory
cytokine IL-1β and inducible NO synthase (iNOS) in esophageal cell line (OE-19). Methods:
20 patients with reflux esophagitis were included in the study. The expression of ghrelin
and its receptor was assessed by quantitative RT-PCR. In Wistar rats, the esophageal experi-
mental ulcers were induced by serosal application of acetic acid on subdiaphragmatic portion
of esophagus. Following experimental groups were included: 1) control (esophageal ulcers
+ placebo) and 2) esophageal ulcers + ghrelin 10 µg/k/day i.p.. The ulcer area was assessed
by planimetry and esophageal mucosal blood flow by H2 gas clearance method. In addition,
in vitro experiments were performed in which OE-19 cells were incubated with ghrelin
alone (150 and 450 nM) or ghrelin with addition of TNF-α (10 ng/ml) to simulate inflammat-
ory state. The expression of COX-2, iNOS and IL1β was assessed by quantitative RT-PCR.
Results: In humans with reflux esophagitis expression of ghrelin and a significant upregulation
of ghrelin receptor were recorded in the esophageal mucosa as compared to intact esophageal
mucosa. In rats with esophageal ulcers, the treatment with ghrelin reduced significantly the
esophageal injury and this effect was accompanied by a significant rise in esophageal mucosal
blood flow. The “in vitro” experiments demonstrated expression of COX-2 in OE-19 cells
which was significantly upregulated by TNFα, but this effect was attenuated by ghrelin.
Ghrelin caused also decrease in IL1β expression and significant increase in inducible NO
synthase. Conclusion: Ghrelin represents a novel ulcer healing and antiinflammatory factor
for the esophageal mucosa. Its beneficial effects seems to be due to iNOS and increased
generation of NO, contributing to anti-inflammatory effects of ghrelin.
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M1970
Prevalence, Incidence and Disappearance Rate of Symptoms of
Gastroesophageal Reflux During Pregnancy: A Prospective Longitudinal Study
Enrique Rey, Puy Sanchez, Miguel Angel Herraiz, Angel Alvarez Sanchez, Fernando
Rodriguez-Artalejo, Manuel Escudero, Manuel Diaz-Rubio
Gastroesophageal reflux symptoms (GERS) are frequent during pregnancy. Most studies on
this issue have used a cross-sectional design and non-validated instruments, except one,
which showed a decreasing incidence of GERS. AIM: to examine the prevalence, incidence
(new cases and worsening of pre-existing occasional symptoms), and disappearance rate of
GERS during pregnancy. MATERIAL AND METHODS: We recruited 355 women with a
pregnancy of 12 weeks or less. They completed three phone interviews at 12, 24 and 36
weeks after the last menses, using the GERQ, adapted for a recall period of 12 weeks. In
the first interview, information about GERS in the year before pregnancy was collected with
GERQ. A control group of 350 women was interviewed once to compare basal information.
GERS was defined as frequent (at least weekly) heartburn and/or acid regurgitation. A case
was labelled as new case if she reported frequent GERS not previously reported. Disappearance
rate was calculated as the percentage of GERS cases that reported no frequent symptoms
in the subsequent interviews. Data were summarized as incidence (new cases) and disappear-
ance rate in the 1st, 2nd and 3rd trimester of pregnancy. RESULTS: Data were analysed for
the 272 pregnant women who provided complete information after discarding 34 abortions,
9 withdrawal of consent, 33 unreachable and 7 protocol violations. Prevalence of GERS at
baseline was similar in pregnant (22.8% with occasional and 7.0% with frequent GERS)
and control women (28% with occasional and 6.6% with frequent GERS). Prevalence of
frequent GERS increased during pregnancy, with 27.6%, 32% and 40.8% of pregnant women
suffering from them at 12, 24 and 36 weeks of pregnancy, respectively. Incidence and
disappearance rate, according to GERS status at baseline, is summarized in the table: CON-
CLUSION: During pregnancy, prevalence of GERS increased progressively, but incidence
of new cases of GERS (about 25% each trimester) and disappearance rate (about 30% each
trimester) remained stable. Occasional GERS before pregnancy was associated with a higher
incidence and with a lower disappearance rate of GERS. Funded by FIS grant PI030718
(Instituto de Salud Carlos III, Ministry of Heath, Spain)
M1971
Long-Term Gastric pH Monitoring with Bravo Wireless System: Effect of
Omeprazole On Acidic Environment in Patients with Endoscopically Resected
Gastric Cancer
Jin Yonezawa, Mitsuru Kaise, Takuji Yamasaki, Yukinaga Yoshida, Mori Naoki, Kato
Masayuki, Kenichi Gouda, Hisao Tajiri
Background and aim: Superficial gastric cancers can be curably treated by endoscopic mucosal
resection (EMR). Proton pump inhibitors (PPIs) are empirically administered to gastric ulcers
artificially induced by EMR for preventing gastric hemorrhage. However, the effect of PPIs
on an acidic environment in gastric cancer patients has not been well known. The study
aims are (1) to evaluate the feasibility of long-term gastric pH monitoring with Bravo wireless
system, (2) to demonstrate a gastric acidic environment of gastric cancer patients, and (3)
to elucidate the effect of PPIs on an acidic environment in gastric cancer patients with EMR
ulcer. Methods and subjects: Bravo capsule was detached from the delivery system and
treaded with a suture string in advance. The capsule with a looped string was endoscopically
attached with endoclips on the wall of the upper gastric corpus. Ambulatory pH monitoring
with the system was performed in gastric cancer patients from one day before EMR (Pre1)
to 4 days after EMR (POD4). Acid inhibitory drugs were restricted from a week before EMR.
For two days from the day of EMR (POD1), omeprazole (20mg x 2 ) was intravenously
administered to patients under nothing per os. From the day 3 after EMR (POD3), omeprazole
(20mg x 2) was orally administered and ingestion was started. Eleven patients with mean
age of 71 years old were enrolled. All of gastric cancers were intestinal types and limited
in the mucosa. The percentage of time that the pH was less than 4(% time pH<4) was
calculated and used as a parameter of a gastric acidic environment with the system. Results:
(1) All patients were successfully monitored with the system except for one patient, whose
capsule were detached one day after attachment. (2) % Time pH<4 on Pre1 were 30.2 +/-
33.4 (mean +/- SD). Gastric acidity environments of gastric cancer patients could be classified
into hyper-acidic (% time pH<4 larger than 80, n=3), meso-acidic (% time pH<4 from 20
to 80, n=5) and hypo-acidic (% time pH<4 smaller than 20, n=3). (3) Average values of %
time pH<4 on Pre1, POD1, POD2, POD3 and POD4 were 0, 0, 0, 0, 0 and 31, 1, 0, 0, 0
in the hypo-acidic and meso-acidic groups, respectively. In contract, those were 92, 88, 86,
68, 57 in the hyper-acidic group. Conclusions: Long-term gastric pH monitoring was feasible
with Bravo wireless system using novel methodology. Gastric acidic environments of gastric
cancer patients can be classified into hyper, meso and hypo-acidic, and one third of gastric
cancer patients were hyper-accidic. Omeprazole absolutely inhibited gastric acidic environ-


















A Novel Technique for Prolonged Studies of Gastric Acid Secretion in Free
Roaming Conscious Rats
Tobias Rudholm, Colin A. Campbell, Peter G. McLean, Per M. Hellstrom, Erik Naslund
Background: Evaluation of gastric acid secretion in rats has historically relied upon the use
of gastric fistula or pylorus ligation techniques. The aim of this study was to assess the
feasibility of measuring rat intragastric pH with the Bravo Capsule system (SynMed, Solna,
Sweden) and compare these results with a gastric fistula model. Method: Male Sprague-
Dawley rats (350 g) were used for this study. Using a midline incision, a small opening was
made in the stomach along the greater curvature. The gastric contents were evacuated. A
calibrated Bravo Capsule was placed inside the stomach with the pH sensor pointing distally.
The capsule was anchored with a suture in the mucosa of the stomach. Studies commenced
two days after surgery and the intragastric pH profile was studied during free feeding of
standard chow for 5 consecutive days. The effects of an intravenous (IV) injection of
esomeprazole (1, 3, 5 mg/kg), on 8-hour gastric pH was studied, as well as, the effect of
IV esomeprazole 3 mg/kg on 2-hour gastric pH. For the gastric fistula studies, a fistula was
placed at the greater curvature of the stomach and passed through the skin slightly to the
left of the midline. The fistula was capped/closed. During studies the rat was placed in a
Bollman cage. Gastric fluid was collected at 30-min intervals for one hour before and 2
hours after IV esomeprazole (3mg/kg) and acid output calculated. Data are mean ±SEM.
Results: All rats rapidly recovered after surgery and placement of the Bravo capsule, and
gained weight. The average 24-hour pH with during free feeding was 1.6 ±0.2 (n=9). After
treatment with esomeprazole at IV doses of 1, 3, and 5 mg/kg, 8-hour pH was 3.2 ±0.5
(n=5), 3.6 ±0.5 (n=8), and 4.0 ±0.5 (n=5), respectively. pH one hour before and two hours
after esomeprazole (3 mg/kg) was 1.7 ±0.3 and 4.0 ±0.5, respectively. Average gastric acid
output, in the fistula model, one hour before IV esomeprazole (3 mg/kg) was 78.2 ±7.4
mmol/30 min and 37.7 ±5.5 mmol/30 min for the two-hour period after esomeprazole.
Conclusion: The Bravo Capsule system can be used for prolonged studies of gastric acid
secretion in free roaming conscious rats over days and was well tolerated. The pH measure-
ments with the Bravo Capsule system were stable and gave reliable recordings, comparable
to those seen in the gastric fistula model. The attenuated variations in pH as seen after
administration of a proton pump inhibitor indicate that true biological responses were
recorded. The Bravo Capsule system optimizes our aim to record intragastric pH levels over
prolonged periods in a closed environment and allows both short and long-term evaluation
of drug effects.
M1973
Nighttime Acid Suppression with Proton Pomp Inhibitor (PPIs): Are All
Nights the Same?
Jenny Liu, Yuhong Yuan, Richard H. Hunt
Background: Nighttime pH is an important outcome in pharmacodynamic studies, and
several report early nighttime pH is lower than late nighttime. However, definition of
nighttime varies widely between studies. This systematic review explores how differences
in nighttime definitions impact on pH in PD studies of PPIs. Methods: Medline and EMBASE
were searched for English-language RCTs from 1984-2005 investigating the effect of PPIs
on intragastric pH in healthy volunteers on day 5-8. Keywords were: “intragastric pH”, “pH
metry”, “ambulatory pH”, “proton pump inhibitor(s)”, and PPI names. pH values (mean
and/or % time pH>4 /night) were obtained. Studies required a nighttime definition. Under
the same PPI dose, unique nighttime periods were termed a group. When two or more arms
under the same group reported the same pH parameter and included SD or 95% CI, data
was pooled. For the same PPI dose, pooled data for groups were compared using StatsDirect®
version 2.4.6. Results:Ten relevant studies (25 arms, n=183) provided intragastric nighttime
pH values for healthy volunteers after 5-8 days PPI therapy [esomeprazole (ESO, 7 arms),
lansoprazole (LAN, 9 arms), rabeprazole (RAB, 1 arm), pantoprazole (PAN, 3 arms), omepra-
zole (OME, 5 arms)]. Sample size ranged from 9 to 40. All PPIs provided significant
antisecretory effects at steady state compared with baseline. However, few studies reported
all 2 parameters, while some did not report SD or CI. There were 17 groups, where nighttime
varied 8-12hrs. Of these, 13 groups were excluded because of single arms (7 studies). Only
6 groups (6 studies, 10 arms) had poolable values. For ESO 40mg om and OME 20mg bid,
no comparison could be made since the complementary nighttime periods had only one
arm, but mean % time pH>4 /night ranged widely from 46.8-57.9 and 71.7-91.1, respectively.
LAN 30mg om was the only dose with two different nighttime definitions, each of which
had a pooled mean % time pH>4 /night. For 22:00-06:00 and 23:00-08:00, the values
were 26.27 % (20.95-31.59) (2 arms, n=24) and 67.82% (45.35-90.29) (4 arms, n=38),
respectively. The 95% CIs did not overlap, suggesting nighttime pH values between the
two nighttime definitions were significantly different. Conclusion:In 24hr pH studies, the
definition of nighttime varies widely and ranges from 8-12 hrs, making comparisons between
PPIs difficult. Simply pooling nighttime pH data may be inappropriate since the variability
in nighttime definitions may influence the pH value. Standardized nighttime definitions are
needed before comparing the role of antisecretory drugs in the management of nighttime
reflux.
M1974
Validation of the Gastroesophageal Reflux Disease Impact Scale - A Patient
Management Tool for Primary Care
Roger Jones, Karin Coyne, Ingela Wiklund
To make appropriate management decisions, primary care physicians need to know how
gastroesophageal reflux disease (GERD) affects their patients’ everyday lives. Objectives: Our
study aimed to develop and test a simple, one-page, patient-completed tool to communicate
to the physician the frequency of reflux symptoms and their effect on patients’ lives. Patients
& Methods: A draft version of the GERD Impact Scale (GIS) was developed from focus
groups of patients and primary care physicians, and a literature review. Items assessed the
frequency of the following over the past week on 4-point scales: acid-related symptoms;
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chest pain; extra-esophageal symptoms; impact of symptoms on sleep, work, meals and
social occasions; use of additional non-prescription medication. A validation study was
conducted based on two consultations (16 ± 2 days apart) in primary care patients newly
diagnosed with GERD or with an existing GERD diagnosis. Ancillary measures included the
Quality of Life in Reflux and Dyspepsia (QOLRAD) and the Reflux Disease Questionnaire
(RDQ). Results: A total of 100 newly diagnosed GERD patients and 105 patients with an
existing GERD diagnosis from 9 primary care clinics participated in the study. Exploratory
factor analysis reduced the number of items from 12 to 8 and identified 3 distinct factors:
‘upper gastrointestinal symptoms’, ‘other acid-related symptoms’, and ‘impact of symptoms’.
Psychometric validation demonstrated high internal consistency (Cronbach alpha: 0.8),
reproducibility (intraclass correlation coefficient in stable patients with an existing GERD
diagnosis: 0.75), and construct validity (Spearman correlations of the GIS with QOLRAD
and RDQ: 0.5-0.8 in both patient groups). Effect sizes in patients newly diagnosed with
GERD and those with an existing GERD diagnosis were 1.5 and 0.4, respectively. In 35%
of patients (46% of newly diagnosed GERD patients versus 25% of patients with an existing
GERD diagnosis), physicians reported altering their treatment decision based on information
provided by the GIS. Overall, 76% of physicians found the GIS useful. Conclusion: The
GIS demonstrated good psychometric properties, and was found to be useful by the majority
of participating primary care physicians. By highlighting the impact of reflux symptoms on
patients’ lives, the GIS can help physicians identify newly diagnosed GERD patients in need
of effective treatment and patients with an existing GERD diagnosis with uncontrolled
symptoms in need of more effective treatment.
M1975
The Correlation Between Upper Gastrointestinal Symptoms and Plasma
Ghrelin in Patients with Peptic Ulcer
Sun Young Yang, Oh Young Lee, Sung Hee Han, Dae Won Jun, Byoung Joo Roh, Chang
Ok Yoon, Hang Lak Lee, Byung Chul Yoon, Ho Soon Choi, Jun Soo Hahm, Min Ho Lee,
Dong Hoo Lee, Choon Suhk Kee
Background: Ghrelin is a peptide produced in the stomach, which influences appetitie, food
intake, and gastric motility. Recently, Helicobacter pylori infection has been reported to be
associated with a reduction in plasma and gastric ghrelin levels in patients with gastritis.
However, the effect of H. pylori eradication on plasma ghrelin level remain controversial.
The aims of this study were: (1) to compare the effects of plasma ghrelin on the course of
healing of peptic ulcers; (2) to examine the effect of H. pylori positive peptic ulcer on plasma
ghrelin expression; (3) to study the relationship of upper gastrointestinal symptoms with
plasma ghrelin. Methods: Plasma ghrelin were measured via radioimmunoassay after over-
night fast, before and after cure of gastric and duodenal ulcer in 20 patients (13 H. pylori-
positive and 7 H. pylori-negative). 14 asymptomatic healthy volunteers who visited for health
screening were enrolled as a control group. H. pylori status was assessed with rapid urease
test. Patients with H. pylori-positive peptic ulcer received a triple regimen(esomeprazol,
clarithromycin, and amoxicillin trihydrate) for 7 days, and esomeprazol following 3 weeks.
Patients with H. pylori-negative peptic ulcer received only esomeprazol for 4 weeks. They were
completed the questionnaires about 7 upper gastrointestinal symptoms (nausea, vomiting,
epigastric pain, heartburn, acid reflux, early satiety, bloating) before and after treatment.
They gave upper gastrointestinal symptom score from zero to ten before and after treatment.
Results: Compared to the control group, plasma ghrelin was not significantly different in
patients with peptic ulcer. The mean ghrelin level in patients with peptic ulcer seemed to
increase (from 4.6 ± 1.1 ng/ml to 4.9 ± 0.7 ng/ml) after treatment, but there was no significant
difference(p=0.07). Only the ghrelin level in the H. pylori-positive peptic ulcer subjects was
significantly increased (from 4.7 ± 1.7 ng/ml to 5.3 ± 1.9 ng/ml) after treatment(p=0.02).
Among 7 upper gastrointestinal symptoms, there was significant correlation between plasma
ghrelin and symptom of early satiety(r=-0.57, p<0.05) and bloating(r=-0.64, p<0.001).
Conclusions: The ghrelin level in the patients with H. pylori-positive peptic ulcer was
significantly increased after treatment. There was significant correlation between plasma
ghrelin and symptom of dysmotility.
M1976
Is Abdominal Obesity Associated with Symptoms of Gastroesophageal Reflux
in General Population?
Enrique Rey, Cristina Moreno Elola Olaso, Fernando Rodriguez Artalejo, Manuel Diaz-
Rubio
Gastroesophageal reflux symptoms (GERS) are associated with excess weight. Increased in
abdominal pressure due to higher content of abdominal fat in overweight subjects may be
one of the main mechanisms. If so, abdominal obesity, which can be estimated by waist
circumference, should be associated to GERS. AIM: To evaluate if waist circumference is
associated to GERS in general population MATERIAL AND METHODS: 700 persons living
in the 7th Health Area of Madrid were interview at home by trained professional interviewers.
They were selected at random from the whole population and inclusion was stratified by
age and sex. All of them answered the gastroesophageal reflux questionnaire; also we
measured weight, height and waist circumference at their home. BMI was calculated and
subjects were classified as normal (BMI lower than 25) or overweight. According to Lean
et al (BMJ 1995), subjects were classified by waist circumference in normal (79 cm or lower
for women and 93 cm or lower for men) and larger waist circumference (abdominal obesity).
Typical GERS were assessed with GERQ and categorized as occasional (less than weekly)
or frequent (at least weekly). We compared the annual prevalence of GERS by the existence
of general overweight and abdominal obesity. Comparisons were done by chi squared test.
RESULTS: We included 690 subjects who completed anthropometric measurements, but
97 subjects where excluded from the analysis to avoid any bias because they recognized to
have taken any dose of PPI during the past year. Visceral obesity were significantly more
frequent in overweight than non overweight subjects (79.5% vs 30.5%; p<0.0001). Among
those with normal BMI, prevalence of occasional symptoms was similar in subjects with
and without abdominal obesity (17.3% vs 16.2%; p=ns) but the prevalence of frequent
symptoms was significantly higher in those with abdominal obesity compared to those
without (11.1% vs 2.2%; p=0.007). Among those subjects with overweight, there were no
differences between subjects with and without abdominal obesity in the prevalence of
occasional (15.8% vs 10.4%) and frequent GERS (5.8% vs 4.5%). CONCLUSION: Abdominal
obesity is associated with frequent GER symptoms in non overweight subjects. This study
was supported by an unrestricted grant from Fundacion Mutua Madrileña
M1977
Acid Output Control with Esomeprazole in Patients with Zollinger-Ellison
Syndrome and Idiopathic Gastric Acid Hypersecretion: Final 12-Month Results
David C. Metz, Joseph R. Pisegna, Philippe Ruszniewski, Christopher E. Forsmark, John
Monyak, Mark B. Sostek
OBJECTIVE: To evaluate the effects of esomeprazole on basal acid output (AO) control
in patients with documented Zollinger-Ellison syndrome (ZES) or idiopathic gastric acid
hypersecretion (IGH) over 12 months. METHODS: This 12-month, open-label, multicenter
study (D9612C00025) included 19 patients with ZES and 2 patients with IGH. Patients
were switched from their previous PPI to esomeprazole 40 mg twice daily (n = 19) or 80
mg twice daily (n = 2). At baseline and day 10, AO was evaluated by nasogastric aspiration
and pH titration. Adequate control of AO was defined as AO <5 mmol/h and <10 mmol/h
for patients who had and who had not had prior gastric-acid-reducing surgery, respectively.
Patients with controlled AO were maintained on the same dose, and AO was measured
again at 3, 6, and 12 months. If AO was not controlled, doses were uptitrated (to a maximum
dose of 240 mg/d) until control was attained. At any time, doses could be increased at the
investigator’s discretion in patients reporting potentially acid-related symptoms or because
of inadequate AO control. Endoscopies were performed at baseline and at 6 and 12 months.
RESULTS: Of the 15 men and 6 women (mean age, 55 years), 3 had multiple endocrine
neoplasia type-1 syndrome, and 8 had metastatic ZE disease. AO was controlled in 19
patients at baseline. No patient withdrew from the study. At 12 months, AO was controlled
with esomeprazole 40 mg twice daily in 14 patients (67%), with esomeprazole 80 mg twice
daily in 4 patients (19%), and with 80 mg 3 times daily in 1 patient (5%) and was not
controlled with esomeprazole 40 mg twice daily in 2 patients (10%; see table). Of the 20
patients with controlled AO at day 10, 18 had sustained AO control for the rest of the
study. At 12 months, no patient had endoscopic evidence of erosive esophagitis or gastric
or duodenal ulcers. Esomeprazole was generally well tolerated at all doses. Two patients
had serious adverse events that the investigator attributed to treatment (hypomagnesemia
and abdominal pain), and both resolved during continued treatment. CONCLUSIONS:
Esomeprazole effectively maintains AO control in patients with ZES or IGH. These efficacy
and safety results show esomeprazole is an effective and well-tolerated long-term medical
therapy for these patients. Supported by AstraZeneca LP
Basal Acid output (mmol/h)
M1978
Nitric Oxide Arising from the Lumen At Gastro-Esopahgeal Junction Could
Have Cytotoxic Effect to the Adjacent Gastric Tissue in Human
Kiyotaka Asanuma, Katsunori Iijima, Nobuyuki Ara, Syuichi Ohara, Tetsuhiko Yoshimura,
Tooru Shimosegawa
Back Ground The recent study reported high concentrations of nitric oxide (NO) were
generated luminally at the gastro-esophageal junction (GEJ) through the entero-salivary re-
circulation of dietary nitrate in human. In our recent study, using a rat animal model in
which luminal NO was generated mainly at GEJ, concentrations of NO in the gastric
tissue of the rats were measured by using the NO trapping technique combined with EPR
spectroscopy. It was revealed NO generated luminally was diffused into the adjacent tissues
at a level comparable to that of iNOS derived-NO production. But the NO trapping reagents
were not adapted to human because of cytotoxcity and it is unknown whether the NO
arising from the lumen can actually affect the gastric tissues in human. Since an NO has a
high affinity for Fe-S cluster proteins such as aconitase, which serves as an important catalyst
of energy-yielding reactions, this protein can become one of an intracellular target of NO
toxicity. Dinitrosyl dithiolato iron complex (DNIC) is considered to be generated as a product
when the Fe-S cluster proteins interact with an NO, leading to inactivation of the enzyme
activity. Aim To examine whether DNIC could be generated in the tissues as a consequence
of the reaction of NO arising from the GE junctional lumen with Fe-S cluster proteins in
the adjacent tissues in human. Method At first, using the animal model, a DNIC and an
aconitase activity in the gastric tissuewere measured. Secondly, Biopsy specimens of H.pylori
negative volunteers were obtained from cardia, antrum after 10 mmol sodium nitrate solution
was administered and a DNIC of the tissue was measured. Results A DNIC was observed
in the rats gastric tissue of the GEJ and was increased with time and dose-dependent manners,
when administered nitrite, whereas no signal was observed at the distal stomach in same
rats. An aconitase activity of the tissues at the GEJ was significantly lower in nitrite-adminis-
tered rats compared to control rats (22.6 ± 2.2 mU/mg protein vs. 26.6 ± 7.0 p < 0.05),
while that in the distal stomach was similar between the two groups. in human, the DNIC
was detected in the biopsy specimens from cardia, not antrum. Conclusion A DNIC formation
and accompanying inhibition of aconitase activity at the GEJ was observed in the tissue
which was exposed to abundant luminal NO. This suggests that the NO diffuses into the
adjacent tissue and there interacts with Fe-S cluster proteins such as aconitase, leading to
reduction of the enzyme activity. This mechanism may be involved in the high prevalence
of inflammation and intestinal metaplasia at GEJ in human.
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Angiotensin II Type 1A Receptor Blockade Attenuates Gastric Inflammation
and Fibrosis in Experimental Ulcer Healing
Takahiro Suzuki, Masaaki Kuroda, Norimasa Yoshida, Tomohisa Takagi, Osamu Handa,
Satoshi Kokura, Hiroshi Ichikawa, Yuji Naito, Takeshi Okanoue, Toshikazu Yoshikawa
Background & Aims : We have reported that angiotensin II receptor blockade (ARB) has
an anti-inflammatory effects via suppressing neutrophil-endothelial cell interactions. On the
other hand, the recent report demonstrated that ARB could protect against progression of
fibrosis in liver and pancreas or promote wound healing, however, the role of angiotensin
II receptor in ulcer healing following gastrointestinal mucosal injury remains unknown, The
aim of the present study was to determine the role of angiotensin II receptor in healing
stage of chronic gastric ulcer model. Materials & Methods : Exp1. Seven weeks old male
C57/BL6 mice and angiotensin II type1 receptor (AT1a) deficient mice were used in this
study. Under anesthesia, mice underwent laparotomy via midline epigastric incision. After
exposing the stomach, 40% acetic acid solution was focally applied to the anterior serosal
surface of stomach for 30 seconds with a modified methods of Okabe et al. On day 14, we
estimated the macroscopic and microscopic findings of gastric lesions. At the same time,
total RNA was extracted from gastric mucosa and the gene expression related to inflammation
(TNF, IL-1), cell growth (EGF, VEGF) and fibrosis (procollagen) was assessed by real time
PCR. In addition, we determined myeloperoxydase (MPO) activity as index of neutrophil
infiltration. Exp2. Seven weeks old male C57/BL6 mice were used in this study. In the same
way as Exp1, experimental gastric ulcers were made by acetic acid injection. On day 3 after
operation, male C57/BL6 mice were divided randomly into the control group (physiological
saline) and ARB (candesartan at 0.1mg/kg/day and at 1.0mg/kg/day) groups. These agents
were orally administered from 3 to 14 days after acetic acid injection. On day 14, we
estimated various mediators in the same way as Exp1. Results : Exp1. On day 3, there were
no significant differences in both the size of gastric lesion and MPO activity between AT1a
deficient mice and wild type mice. On day 14, the size of gastric ulcer and MPO activity
in AT1 deficient mice were significantly decreased compared with wild type mice. The gene
expression related to inflammation and fibrosis were decreased in AT1 deficient mice. Exp2.
In the ARB group, the gene expression related to inflammation and fibrosis was decreased,
but VEGF mRNA was significantly increased compared with control group without ARB.
Conclusions: These results indicate that inhibition of angiotensin II/AT1a signal pathway is
implicated in promotion of gastric ulcer healing. Its mechanisms may be partially mediated
by inhibition of fibrosis and inflammation and progression of cell growth.
M1980
Endogenous Prostaglandins (PG) and Melatonin in Ulcer Healing
Stanislaw Konturek, Tomasz Brzozowski, Peter C. Konturek
Background: (PG) and melatonin (MT) are generated by the gastric mucosa and exhibit
gastroprotective activity but their role in mucosal repair and ulcer healing has not been
established. Aims and Methods: This study carried out on rats with chronic acetic acid
induced gastric ulcerations was designed to determine the involvement of endogenous PG
and MT in ulcer healing process of gastric ulcerations in rats with intact and suppressed
mucosal generation of PG by COX-1 and COX-2 inhibitors and blockers of MT receptors.
Results; The ulcerated tissue and ulcer margin showed significant up-regulation of COX-2
and excessive generation of PGE2, but reduced formation of MT,when compared to intact
mucosa. Misoprostol in gastroprotective dose (10 μg/kg i.g) failed to affect the ulcer healing
and COX-2-PGE2 system in the ulcerated mucosa. Larger, gastric acid inhibitory dose of
misoprostol (50 μg/kg i.g) accelerated ulcer healing that was significant after 1 and 2
wks of treatment and, paradoxically, was accompanied by the upregulation of COX-2
protein(without change in expression of COX-1) and increased PGE2 generation at the ulcer
area. COX-2 (Celecoxib - 200 mg/kg) and COX-1/COX-2 inhibition (indoemtahcin - 20
mg) as well as blockade with Luzindole MT2 receptors, retarded dose-dependently ulcer
healing and reduced ulcer tissue generation of PGE2, while increasing the expression of
COX-2. Melatonin or its precursor L-tryprophan, also dose-dependently accelerated acetic
acid ulcerations and this was accompanied by up-regulation of COX-2 and generation of
PGE2 as well as expression of NO synthase (NOS) and increased formation and release of
NO into the ulcerated tissue and gastric lumen. Omeprazole (proton pump inhibitor) in
gastric acid inhibitory dose (40 mg/kg) accelerated ulcer healing, mainly due to its antisecret-
ory activity but also through increasing the activity of COX-2-PGE2 system in ulcer tissue.
Conclusion: Endogenous PG are generated at the ulcer margin due to up-regulation of COX-
2 induced by melatonin.
M1981
Intravenous Administrations of Proton Pump Inhibitor (Omeprazole) Before
and After Meals Produce Similar Effects On Inhibitions of Gastric Acid
Secretions
Pradermchai Kongkam, Varocha Mahachai, Sutep Gonlachanvit
Background: The inhibitory action of a proton pump inhibitor on gastric acid secretion is
believed to depend on the administrative time related to a meal. Although it is recommended
that PPIs should be administered before meals, the effects of PPIs on gastric acid secretions
have not been well compared between before and after meal administrations. Aim: To study
the inhibitory action on gastric acid secretion of omeprazole when administered intravenously
30 minutes before meals compare to 2 hours after meals. Methods: 18 healthy volunteers
(10M, 8F; age 32±13 years, mean±SD) were randomized to receive either omeprazole (40
mg intravenously every 12 hours for 2 days) administered 30 min before meals or 2 hours
after meals. All volunteers underwent 48 hour intragastric pH monitoring using Mark III
Digitrapper with a pH catheter. Gastric pH sensor was positioned at 10 cm below the upper
border of the LES localized by esophageal manometry. Results: All volunteers completed
the studies. Mean basal gastric pH during 30 min fasting periods before iv omeprazole were
2.0±0.9 for before meal and 1.2±0.4 for after meal study arms, respectively (p>0.05). The

















30 min before meals were 82±24%, 88±13%, 84±13%, and 89±8%, respectively. Whereas,
the % time of gastric pH>4 during the first 4, 8, 24, and 48 hour after iv omeprazole
administered 2 hour after meals were 80±19%, 84±20%, 86±18%, and 90±14%, respectively,
not significantly different compared to the administration before meals (p>0.05). Mean
intragastric pH during the first 4, 8, 24, and 48 hour after iv omeprazole given before
meal were 5.7±1.4, 5.9±0.9 , 5.7±0.9 and 5.9±0.6, respectively, not significantly different
compared to after meal (5.4±0.8, 5.8±0.9, 5.7±0.9, and 6.0±0.8, respectively, p>0.05).
Conclusions: Omeprazole 40 mg IV every 12 hours produces similar inhibitory effect on
gastric acid secretion when given either 30 minutes before or 2 hours after meal. This result
suggested that administration time related to meals did not significantly affect the inhibitory
action on gastric acid secretion by IV omeprazole.
M1982
Effect of Naprosyn On Gastric Acid Secretion and Gastric pH
Sheila Rodriguez-Stanley, Nancy Redinger, Philip B. Miner
Background: Non Steroidal Anti-Inflammatory Drugs (NSAIDs) are inflammatory to the
stomach and associated with gastric ulcers and gastritis, however mechanisms for the inflam-
mation are unclear. NSAIDs may change gastric secretory physiology. Aims: To determine
if a commonly used NSAID, Naprosyn 500 mg BID, alters pentagastrin-stimulated Maximal
Acid Output (MAO), Basal acid output (BAO), and fasting gastrin in normal, H pylori negative,
asymptomatic subjects, aged 18-70. Methods: Informed consent and medical evaluations were
performed during screening. Pre-NSAID BAO and MAO gastric aspirations were performed,
followed by treatment with Naprosyn 500 mg BID for 7 days. Then, post-NSAID BAO and
MAO were performed on day 8. BAO consisted of one hour of gastric fluid collection via
nasogastric tube in 15-minute intervals (4 samples). At the end of the BAO period, pentagas-
trin (sc) was given at 6 mcg per kg body weight, and gastric fluid was aspirated and collected
for one hour in 15-minute intervals (4 samples) for MAO. Volume was measured in each
sample and an aliquot was taken for determination of pH and mEq of acid by titration.
Prior to gastric collections, blood was drawn for fasting gastrin levels. Significant differences
between baseline BAO, MAO and gastrin and post-NSAID BAO, MAO and gastrin were
determined using ANOVA. Comparisons were made using paired T-tests (α = 0.05). Results:
Twenty-six subjects signed consent. Two subjects did not meet entry criteria. Twenty-four
subjects were dispensed Naprosyn and completed the study (16 males; 8 females; age range
20-41 years). Mean pH of the gastric fluid aspirate during the basal collection period was
not altered by Naprosyn (3.34 vs 3.12; NS). Mean pH during the pentagastrin-stimulated
maximal collection period was not altered by Naprosyn (2.70 vs 2.62; NS). Volume of
gastric aspirate during the basal period was significantly decreased post-NSAIDS (83 vs 61
ml/hr; P=0.012), with no change in pentagastrin-stimulated gastric fluid volume post-NSAIDS
(196 vs 188 ml/hr; NS). Basal mean gastric acidity (meq/ml) was significantly increased
post-NSAIDS (0.41 vs 0.49 meq/ml; P=0.03), with no change in mean pentagastrin-stimulated
maximal gastric acidity due to Naprosyn (0.95 vs 1.03; NS). Fasting gastrin level was not
altered by Naprosyn (19.9 vs 17.45; NS). Conclusions: Naprosyn decreases basal gastric
fluid volume in normal volunteers, which corresponds to the significant increase in basal
gastric acid concentration. These data indicate another mechanism by which Naprosyn, and
perhaps other NSAIDs contribute to gastric injury. This research was supported by an
AstraZeneca ISS grant.
M1983
Gastrointestinal Complications in Post Renal Transplant Patients - A Single
Center Experience
Nandini Nagaraj, Chukwuma I. Egwim, Douglas G. Adler
Background: The incidence of gastrointestinal (GI) disease following or related to renal
transplantation has not been well described. The aim of this study was to examine the
frequency and characteristics of post-transplantation GI complications. Methods: We retro-
spectively evaluated a database of renal transplant recipients at our institution since 1998
for severe gastrointestinal complications following renal transplantation. Results: There were
789 consecutive adult renal transplantations (190 living related donors and 599 cadaveric
donors) performed on 781 patients during the period between January 1998 and November
2005 at our center. Of these, 87 (11.1%) patients had severe or persistent GI problems
requiring gastroenterology evaluation. Out of the 87 patients, 19 had combined renal -
pancreas transplant. There were 45 male and 42 female patients, with age range between
5 and 68 years (mean of 45 years). The median duration of follow up was 3 years (Range-
1 month to 88 months). The most common reason for evaluation was persistent, unexplained
nausea/vomiting and abdominal pain (49%). Thirty four of 87 (39%) patients had severe
post-transplantation GI complications including ulceration (16), hemorrhagic gastritis (2),
severe opportunistic GI infections (9), severe colitis, diverticulitis with stricture or colon
abscess requiring surgery (7), with 64% (22 patients) occurring in the first year of transplanta-
tion. Only 2 patients had Helicobacter pylori related gastritis. Six patients had biopsy proven
cytomegalovirus infection of the gut, of these 4 occurred between 1998 and 2000 and only
2 occurred between 2001 and 2005 indicating a low incidence of post transplant opportunistic
infections. The only tumor found was a gastric carcinoid, which occurred in one patient.
Conclusion: Severe GI complications occur frequently following renal transplantation. Most
complications occurred in the first year following transplantation. Prophylaxis with anti-
secretory medications seems warranted. The incidence of opportunistic GI infection appears
to be low.
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Is There Any Relationship Between Pernicious Anemia and Iron Deficiency ?
Stephanie Lagarde, Nicolas Jovenin, Marie-Daniele Diebold, Roland Jaussaud, Virginie
Cahn, Eric Bertin, Damien Jolly, Gerard Thiefin, Guillaume Cadiot
Introduction : Previous studies have suggested that iron deficiency could be due to atrophic
body gastritis. The aim of this study was to determine iron deficiency prevalence in patients
with pernicious anemia and associated factors. Patients and methods : All patients with
pernicious anemia diagnosed at our institution between January 1990 and February 2005
were included. Inclusion criteria were : 1- histological diagnosis of atrophic body gastritis
and 2- autoimmunity criteria (antibody and/or autoimmune disease). A blind histological
rereading of gastric biopsies was done. Iron deficiency was defined by serum ferritin level
< 15 mg/L in women and < 40 mg/L in men. We estimated iron deficiency prevalence and
associated factors. Results : 102 patients (73 women), mean age 60 years (range 23-90)
were included. 20 patients (19.6%) had normal hemogram; 14 patients (13.7%) have
microcytosis with or without anemia and 57 patients (55.9%) have macrocytosis with or
without anemia. Serum ferritin levels were measured in 64 patients, 17 (26.6%) of whom
had iron deficiency. These 17 patients were women, significantly younger (40.3 years) than
patients without iron deficiency (61.7 years, p<0.0001). 76.5% of women with iron deficiency
were less than 50 years vs 28.6% of women without iron deficiency (p=0.002). The anemia
frequency was similar in patients with or without iron deficiency (70.6% and 70.2%).
Microcytosis was more frequent in patients with iron deficiency (47.1% vs 6.4%) and
macrocytosis more frequent in the other group (63.8% vs 29.4%). Cobalamin deficiency
frequency was similar in the 2 groups (56.2% in group with iron deficiency vs 68.2%).
Serum gastrin levels did not differ between the 2 groups. The grade of atrophic body gastritis
(graded from 1 to 3), the severity of the inflammatory infiltrate of the corpus and that of
fundic endocrine cell hyperplasia were no significantly different between patients with or
without iron deficiency. Multivariate analysis showed that iron deficiency was linked to
female sex and age < 50 years. Conclusion: Iron deficiency and microcytic anemia are not
rare in patients with pernicious anemia and should not rule out the diagnosis. Iron deficiency
does not appear to be related to the degree of atrophic body gastritis but is linked to female
sex and young age, suggesting the role of menstrual blood loss. Whether decreased iron
absorption due to acid hyposecretion favours the expression of gynaecological iron loss
cannot be ascertained.
M1985
The Burden of Non-Heartburn Predominant Dyspepsia On Patients Lives.
Results from the STARS II Study
Katarina Halling, Ingela Wiklund, Nigel Flook, Nimish Vakil, Sander Veldhuyzen van
Zanten, Karsten Lauritsen, Tore Persson, Johan Brun, Lars-Erik Svedberg, Nicholas J.
Talley
Objectives: To assess how dyspeptic symptoms affect patients’ lives. Methods: Uninvestigated
patients presenting in primary care, with predominant symptoms of pain or burning centered
in the upper abdomen for more than 3 months, were included in this study (SD-NED-
0022). Prior to treatment patients completed the validated Reflux Disease Questionnaire
(RDQ) rated 0-5 (worst score), the Gastrointestinal Symptom Rating Scale (GSRS) rated 1-
7 (worst score), the Quality of Life in Reflux and Dyspepsia (QOLRAD) rated 1-7 (best
score), SF-36 (0-100 best score) and the Hospital Anxiety and Depression (HAD) Scale
(proportion of definite cases of anxiety and depression were calculated). The baseline values
are presented for all questionnaires. Results: A total of 1250 patients (mean age 35.3, 59
% women) were analyzed. The most pronounced symptom burden was dyspepsia according
to both GSRS and RDQ (mean GSRS abdominal pain 3.5 vs 2.9 reflux; mean RDQ dyspepsia
2.8 vs heartburn 1.5). A marked dysfunction was reported in the food/drink and vitality
dimensions of QOLRAD (mean 4.5 in both) while the physical social functioning was least
affected (mean 5.5). GSRS abdominal pain (r=-.41 food/drink problems, r=-.40 physical/
social functioning, r=-.40 vitality) and the RDQ dyspepsia dimension (r=-.41 food/drink
problems, r= -.41 vitality) correlated moderately with QOLRAD impairment (p<0.001). The
SF-36 dimension scores were considerably lower than in a random reference population.
The table shows greatest impairment in the bodily pain component and role physical
(difference of 24.2 and 16.5 respectively). With the exception of physical function all
dimensions differed by more than 5 score units which is considered clinically relevant.
According to HAD, 24 % were classified as definite anxiety cases and 5 % as definite
depression cases. Anxiety correlated moderately (p<0.001) with QOLRAD score impairment
(r=-.48 emotional distress, r=-.40 vitality). Conclusion: Dyspeptic symptoms profoundly
impact patients’ lives. The most negative QOL influence was on bodily pain.
M1986
Acceptability and Tolerance of Lansoprazole Orally Desintegrating Tablet in
Patients Requiring a PPI Treatment
Ruszniewski Philippe, Terpereau Arara
Introduction and objective: Lansoprazole is presently available in France as a capsule formula-
tion. An orally disintegrating tablet has been developed as a therapeutic alternative to the
capsule, allowing dosing without water at any time. The objective of this study was to evaluate
the acceptability and tolerance of the new formulation of Lansoprazole oral dispersible tablet
(LODT) 15 mg in patients currently treated by lansoprazole 15 mg capsule for at least 7
days . Patients and methods: A phase III, non comparative, multicentre, single arm, open
label study was conducted in France. 30 general practitioners participated in this study.
After a period of 7 days treatment with lansoprazole 15 mg/day capsule, the LODT 15 mg
was substituted to all the patients. Each patient was seen at the inclusion visit and again at
the end of the study. A patient questionnaire allowed an estimate of preference between the
capsule and new formulation LODT. Acceptability concerning taste, ease of use, the speed
of dissolution, mouth sensation and the possible presence of aftertaste, was collected by
means of a visual analogue scale (VAS) going from 0 to 10 (0: completely unacceptable and
10 completely acceptable). Results: 105 patients were included, 103 analysed in the ITT
analysis, with mean age 55.08 years (±14.01), 59.2 % female. The patients were mainly
treated for GERD (62.2 %). 53.4 % of the patients preferred LODT, 21.4 % preferred the
capsule formulation and 24.3 % were without preference between the 2 forms. On average
on a scale of 10, the ease of use was quoted as 9.17 (±1.7 ), convenience of use without
water 8.9 ( ±2.19 ), rapidly dissolved in the mouth and pleasant taste was 8.64 (±2.2 ) and
7.9 (±2.92 ) respectively. Pleasant sensation in the mouth of the LODT was quoted 6.88
(±3.26) and the aftertaste in 6.8 (±3.41 ). These results are comparable when matched for
sex, age and treated pathology. The lansoprazole orally disintegrated tablet (LODT) was well
tolerated, with occurrence of three adverse events of which one was serious, all were
considered not related to treatment. Conclusion: This study shows that in the patients
requiring treatment with lansoprazole, the orally disintegrated tablet is well accepted. The
majority of the patients preferred this new formulation, for its ease of use and the practicality
of administration without water
M1987
Three Centuries of Stomach Symptoms in Scotland
J H. Baron, Fiona Watson, Amnon Sonnenberg
Aims: Stomach pain and discomfort have been reported since antiquity. The present study
follows the long-term time trends of non-ulcer dyspepsia, gastric ulcer, duodenal ulcer, and
benign oesophageal disease in Scotland to test when non-ulcer dyspepsia started to become
a major clinical problem. Methods: The annual in- and outpatient records of the last three
centuries from the Scottish Royal Infirmaries of Edinburgh, Aberdeen, Glasgow, and Dundee
were analysed. In addition, dispensary attendances, clinicians’ casebooks, students’ notebooks
and medical texts were scrutinised for historic statistics of upper gastrointestinal disease.
Results: No hospital admissions for dyspepsia occurred before 1750. Non-ulcer dyspepsia
was first recorded in the middle of the eighteenth century and subsequently increased
markedly to levels ranging between 200 and 1000 per million living populations. The results
of outpatients or public dispensaries during the first half of the nineteenth century show
similarly high dyspepsia attendance with annual rates between 700 and 5100 per million
living population, confirming the data of hospital admissions to the infirmaries at the same
location and during the same time period. The high levels of hospitalization for dyspepsia
persisted even after gastric and duodenal ulcers appeared in the late nineteenth century.
Gastric ulcer started to occur only after 1850 mostly in females. Duodenal ulcer started to
occur after only 1890 mostly in males. Within a few decades the hospitalization rates for
gastric and duodenal ulcer rose from 0 to 500 per million living population. During the
beginning of the 20th century hospitalization rates of gastric and duodenal ulcer came to
surpass that of non-ulcer dyspepsia. In all four cities, hospital admissions for esophageal
disease remained rare, never exceeding more than 50 per million with intermittent stretches
of no admissions at all. Conclusion: The current twenty-first century commonest diagnosis
of stomach pain, non-ulcer dyspepsia, dates from the mid-eighteenth century. Any explana-
tions of its causation need to consider this peculiar time trend.
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Chronic Urticaria Is Associated with Mast Cell Infiltration in the
Gastroduodenal Mucosa
Francesca Minnei, Charlotte Wetzels, Gert De Hertogh, Peter van Eyken, Nadine Ectors,
Rossano Ambu, Gavino Faa, Anne-Marie Kochuyt, Karel Geboes
Chronic urticaria (CU) is characterized by recurrent itching skin eruptions caused by mast
cell degranulation. Relapses can be provoked by food intake. The aim of this study was to
investigate if the mast cell number in the gastroduodenal mucosa is increased in CU patients,
and whether mast cell counting by pathologists is clinically useful. We defined 2 study
groups: 50 disease controls (16 Belgians and 34 Italians) and 43 Belgian CU patients. Mast
cells were detected using immunohistochemistry for tryptase and CD117. The mast cell
number in the disease controls was 20.2/HPF (133.3/mm2) in the stomach and 32.5/HPF
(209.2/mm2) in the duodenum. There was no difference between Belgian and Italian controls,
indicating that dietary habits have no influence on the normal gastroduodenal mast cell
number. In CU patients mast cell numbers were significantly higher: 32.4/HPF (186.0/mm2)
in the stomach (P < 0.0001) and 44.8/HPF (246.0/mm2) in the duodenum (P = 0.0002).
Chronic urticaria is thus associated with mast cell infiltration in the gastroduodenal mucosa,
even if patients do not have gastrointestinal symptoms. Mast cell counting in gastroduodenal
biopsies of CU patients can be useful to select patients who may respond to a therapy with
intestinal mast cell stabilizing agents.
M1989
Effect of Increasing Esomeprazole and Lansoprazole Dose On Day- and
Nighttime Acid Control in Healthy Subjects
Clive Wilder-Smith, Tore Lind, Christina Lundin, Mia Svensson, Catharina Nilsson-
Pieschl, Kerstin Rohss
BACKGROUND: In clinical practice, doubling the standard dose of a proton pump inhibitor
is often considered in response to problems such as nocturnal symptoms, which may occur
as a result of inadequate 24-hour acid control. In this study, we compare the benefit to
patient acid control of increasing doses of esomeprazole (ESO) and lansoprazole (LANSO)
in terms of the amount of time with intragastric pH > 4 achieved during 0-12 hours and
12-24 hours post-dose. METHODS: In an open-label, randomized, single center, 6 way
crossover study, 40 healthy subjects (19 males; mean age: 31 yrs; mean weight: 69 kg)
received ESO 20, 40 and 80 mg and LANSO 15, 30 and 60 mg orally once daily, 30 minutes
before breakfast, for 5 days. Continuous 24-hour intragastric pH monitoring was performed
following drug administration on day 5 of dosing using glass electrodes. Treatment periods
were separated by a washout period of at least 13 days. RESULTS: See table below. ESO
40 mg provided significantly greater acid control during both the day and night than ESO
20 mg, although no further statistically significant improvement was achieved when the
dose was increased to 80 mg. LANSO 30 mg provided significantly better daytime acid
control than LANSO 15 mg , as did LANSO 60 mg compared with LANSO 30 mg. ESO
40 mg provided significantly better acid control than LANSO 30 mg and 60 mg for the full
24 hours after dosing, as did ESO 80 mg versus LANSO 60 mg. ESO and LANSO were
well tolerated throughout the study. CONCLUSIONS: In patients with inadequate acid
control, either dose escalation from ESO 20 mg to ESO 40 mg, or a change from LANSO
to ESO may improve day and nighttime acid control.
Additional hours with gastric pH >4 on day 5 of dosing with ESO and LANSO
*p<0.05; **p<0.01; ***p<0.001; ****p≤0.0001
M1990
20mg Six Hourly Bolus Dosing of rabeprazole As Effective As Infusion: A
Wireless Intragastric pH Assessment
Rupa Banerjee, Rajesh Gupta, Sandeep Lakhtakia, Arun Maseeh, Manu Tandan, Venkat G.
Rao, Nageshwar D. Reddy
Introduction : Intravenous proton pump inhibitor (PPI) infusion is the mainstay of pharmaco-
logic management of upper gastrointestinal bleeding where a high intragastric pH >6 is
required for adequate haemostasis. However data on the efficacy of these drugs in bolus
doses are limited. Objectives of study: To assess and evaluate the effect of 20 mg and 40
mg Rabeprazole in six and eight hourly doses as compared to bolus injection followed by
infusion at 4mg/hr. Methods: Five subjects received Rabeprazole in a five -way crossover
design study.48 hour intragastric pH assessment was done by the wireless pH capsule
(Bravo,Medtronic) 1. The measured endpoints were the median time required to achieve a

















and severity of adverse events. Results: 20mg and 40mg IV Rabeprazole achieved a steady
pH >6 at a median time of 10 min and 12min respectively. The % time with pH >4 and
pH>6 was 64% and 72%(mean) with eight hourly dosing. 20 mg six hourly injections of
IV Rabeprazole maintained a steady pH>6 for the total duration of injections. This intragastric
pH response was similar to 40mg IV bolus followed by infusion at 4mg/hr (Graph).All doses
were well tolerated. Graph: Intragastric pH tracing with infusion(a) and six hourly bolus
dosing(b) Conclusions: Six hourly injections of Rabeprazole are as effective as infusion for
maintaining a steady intragastric pH>6. Referrence: 1.Banerjee R,Lakhtakia S,Reddy DN et
al. Endocsopy assisted wireless intragastric pH measurement. Endoscopy 2005;37:922.
M1991
High Blood Pressure and Symptoms of Gastroesophageal Reflux: Impact On
Health-Related Quality of Life
Enrique Rey, Cristina Moreno Elola Olaso, Fernando Rodriguez Artalejo, Manuel Diaz-
Rubio
Overweight is a risk factor of both high blood pressure (HBP) and gastroesophageal reflux
symptoms (GERS). Association between HBP and GERS has not been evaluated, although
an association between Barrett’s esophagus and HBP was reported. Moreover, the relative
impact of both HBP and GERS on health-related quality of life (HRQL), and the contribution
of overweight to such relationship, is unknown. AIM: To examine: 1) the association of
HBP with GERS; 2) the association of HBP and GERS with HRQL. MATERIAL AND
METHODS: Study subjects were interviewed at home by trained professional interviewers.
They were selected at random from the general population. Typical GERS (heartburn and
acid regurgitation) was assessed with the GERQ. The SF-36 health questionnaire was used
to ascertain HRQL. Lastly blood pressure (automatic device), weight and height were deter-
mined. Logistic regression was used to evaluate the predictors of GERS, including in the
model HBP and other known risk factors. Differences in each of the dimensions of the SF-
36 by GERS, overweight, and HBP were analyzed with ANCOVA, including interactions.
RESULTS: Study sample comprised 705 individuals (369 with HBP and 336 with normal
pressure). There was no difference in the prevalence of GERS between both groups (24.9%
in HBP and 24.1% in normal pressure). In logistic regression model, PSC score, obesity
(BMI > 29.9 kg/m2) and familiar history of GERS were independently associated with GERS,
but HBP was not (adjusted OR 0.96 [0.6-1.4]). Results of SF-36 dimensions (mean and
CI95%) according to the presence or not of GERS are shown in table In ANCOVA, GERS
were statistically significantly associated with lower values of each dimension of SF-36
(except physical functioning). No association was observed between most dimensions of the
SF-36 and HBP. BMI-GERS-HBP interaction was statistically significant for the social function
dimension of the SF-36, and the BMI-GERS interaction attained significance for the body
pain dimension. CONCLUSION: HBP and GERS are not associated in the general population.
GERS is associated with lower HRQL, and this association is independent of overweight.
Supported by a grant from Fundacion Mutua Madrileña
*p<0.001 (ANOVA)
M1992
The Effect of Candida Albicans On Healing of Duodenal Ulcer Induced By
Cysteamine in Rats
Longxue Jin, Masashi Yoshida, Tetsuya Nakamura, Hideki Ishikawa, Yoshiro Saikawa,
Kaori Kameyama, Koichiro Kumai, Tetsuro Kubota, Yoshihide Otani, Go Wakabayashi,
Minoru Tanabe, Shigeyuki Kawachi, Katsuko Sano, Masaki Kitajima
Background and purpose: It was known widely that Candida albicans (C. albicans) not only
inhabits frequently the gastrointestinal tract of humans, but also was cultured in the ascites
in the patients who were undergone the operation for gastroduodenal ulcer perforation.
This experiment was performed to clarify the effect of C.albicans infection to gastroduodenal
ulcer in rats. Methods: [Experiment 1; Effects of Candida on incidence of duodenal ulcer
perforation.] In this study, male Wistar rats (220-250g) were separated into the Candida
group and the saline group. After the rats were anesthetized with ether, the rats were
administrated cysteamine (310mg/kg body weight) three times intragastrically every 4 hours;
C. albicans was administrated to the Candida group rats at one hour before and 12, 24
hours after the first dose of cysteamine. The control group rats were administrated saline.
The rats were sacrificed after 72 hours after the first administration of cysteamine. The
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immunohistochemical stain was done with an anti-Sap2 (secretory aspartyl protease2) mono-
colonal antibody. ELISA was performed with anti-Sap2 monocolonal antibody. [Experiment
2; Effects of C. albicans on healing of duodenal ulcer.] The rats in the Candida group were
administrated with C. albicans at 48 hours after the first dose of cysteamine administrated
like above. Rats in the control group were administrated saline. The rats were sacrificed one
week after the first administration of cysteamine. Result: [Experiment 1] The rate of duodenal
ulcer perforation in the Candida group is 94.1% (16/17) that was higher than the control
group (26.7%, 4/15). The size of duodenal ulcer area in the Candida group (40.89mm2)
was larger than the control group (16.53mm2); the survival rate of the Candida group was
significantly lower than that of control group. In immunohistochemical analysis, the ulcer
bed in the Candida group was positive, whereas the control group was negative. The Sap2
concentration in the duodenal ulcer bed in the Candida group was higher than that of the
control group significantly. [Experiment 2] The incidence of duodenal ulcer in the Candida
group (63.6%, 14/22) was higher than that of the control group (31.6%, 6/13). Conclusion:
It was shown that the infection of C. albicans not only promote the process of duodenal
ulcer perforation but also delay the wound healing process of duodenal ulcer induced by
cysteamine in rats.
M1993
Severe Burn Injury Alters Gastric Slow Wave and Gastric Emptying in Rats
Hanaa S. Sallam, Hermes M. Oliveira, Jiande Chen
Introduction: Severe burn injury is known to delay gastric emptying in both animals and
humans; however no data are available on its effect on gastric myoelectrical activity (GMA).
We aimed at studying the effect of burn injury on GMA as it might contribute to burn-
induced delayed gastric emptying. Methods: A pair of cardiac pacemaker wires was surgically
implanted to the stomach serosa of 20 adult male Sprague-Dawley rats. Following recovery,
GMA was recorded for 30min in both fasting and fed conditions. The following day, rats
received a sham or a 3rd degree scald burn injury under anesthesia. Proper fluid resuscitation
and analgesia were given to all animals. Six hours after sham/burn injury, GMA was recorded
for 30min again in both fasting and fed conditions. A methylcellulose meal was mixed with
phenol red (marker), so that the percentage of gastric emptying could be calculated based
on the amount of phenol red recovered from the stomach. GMA parameters were computed
using previously validated spectral analysis software developed in our laboratory, including
dominant frequency/power and percentages of normal slow waves, bradygastria, tachygastria
and arrhythmia. The normal slow wave frequency range was 4-6 cycles per min (cpm) in
rats, while ≤4cpm and ≥ 6cpm were considered bradygastria and tachygastria respectively.
Arrhythmia was established if the slow wave frequency had no specific range. Results: 1)
None of GMA parameters showed any statistical differences in the fasting condition after
burn (p>0.05). 2) Significant changes in GMA with burn were only observed postprandially,
including: a decrease in dominant frequency (4.5±0.2 vs. 5.1±0.2, p= 0.002) and in the
percentage of normal slow waves (67.2±7.3 vs. 84.5±4.1, p=0.02) and an increase in the
percentage of bradygastria (24.7±6.8 vs. 9±3.9, p=0.02). 3) The percentage of gastric empty-
ing was decreased after burn to 40.3 ±6.5 vs. 77±3.2 in previously obtained controls (p=
0.0003), however, it did not correlate significantly to any of GMA parameters before or after
burn, whether in fasting or in fed conditions (p>0.05). Conclusion: Severe burn injury
impairs both GMA and gastric emptying in rats. However, these alterations are not correlated
with each other, suggesting that gastric dysrhythmia is a manifestation of burn but not the
cause of burn-induced delayed gastric emptying.
M1994
Pepsinogen I Correlates with Severe Esophagitis and Barrett’s Esophagus
Klaus Moenkemueller, Ulrich Peitz, Thomas Wex, Daniel Jaspersen, Joachim Labenz,
Wolfgang Meyer-Sabellek, Sn Willich, Marc Nocon, Manfred Stolte, Tore Lind, Peter
Malfertheiner
Introduction: Gastrin and pepsinogens (pepsinogen I and II) reflect the functional state of
the gastric mucosa. Preliminary data have indicated that circulating levels of gastrin are
lower in pts with Barrett’s esophagus than in healthy controls. Furthermore, the role of
gastrin and pepsinogens in GERD is unclear. Aim: To evaluate whether serum levels of
gastrin and pepsinogens correlate with the different forms of GERD [non-erosive (NERD),
erosive reflux disease (ERD)] Patients and Methods: Four groups of 87 patients each (1:
NERD; 2: ERD Los Angeles A and B, 3: ERD Los Angeles C and D; 4: BE) were selected
from the prospective ProGERD study (multicenter open cohort study comprising an initial
treatment phase and a 5-yr follow-up of 6,215 patients with various forms of GERD). The
four groups were matched for age (median 56, range 29-79 years) and gender (male n=65).
All patients underwent clinical examination, responded to validated reflux questionnaires
and underwent EGD (LA classification). The diagnosis of BE was based on endoscopic and
histological criteria. Gastritis was classified according to the updated Sydney classification.
None of the patients had taken any form of acid inhibition therapy for at least 4 weeks
before endoscopy or giving the serum sample. Serum was analyzed for gastrin-17, pepsinogen-
I, pepsinogen-II und H. pylori using specific EIA tests (Biohit Plc, Laippatie, Helsinki,
Finland). Statistical analysis: Mann Whitney. Results: Significant differences among groups
were identified for pepsinogen-I, but not for pepsinogen-II or G-17 levels. Pepsinogen-I
serum levels were lowest in NERD (90.7 µg/l) and highest in BE (114.2 µl/l, P=0.012).
Pepsinogen-I serum levels were higher in BE (114.2 μg/l) compared to ERD Los Angeles
C+D=101.8 µg/l (p=0.07). Pepsinogen levels were higher in H. pylori- positive subjects, but
this expected finding did not account for the differences of pepsinogen-I serum levels among
various categories of GERD. Conclusions: The increased levels of pepsinogen I in more
severe forms of GERD suggest that the mass of oxyntic glands may be a determinant among
others for the severity of GERD. This finding correlates well with higher esophageal acid
exposure previously reported in patients with more severe forms of GERD.
M1995
Polymorphisms of Exon 4 of P53 Gene in Gastric Intestinal Metaplasia in
Hungary
Dominika Szoke, Bela Molnar, Zsolt Tulassay
Aims: Many studies have investigated the association of P53 polymorphisms with increased
risk of different cancers, including gastric cancer. The literature of the polymorphisms in
exon 4 in gastric cancer preceding intestinal metaplasia (IM) is not plentiful. Materials and
methods: After informed consent, gastric biopsy samples were taken from the antrum of 51
consecutive patients with IM and 51 biopsy samples from histologically negative patients
as control group. The genotype of the polymorphisms in exon 4 of P53 gene was determined
by capillary sequencing. Results: We could not found any patient neither with codon 34
nor with codon 47 polymorphism. Codon 36 polymorphism was found in heterozygote
form in three cases. The R72P polymorphism is the most common, the allele frequency for
proline is 0.29 in 102 Caucasian individuals. The allele frequencies were significantly different
with χ2-probe between H.pylori positive IM patients and the normal control group (p=
0.0018), between H.pylori negative IM patients and the normal control group (p=0.0005)
and between the group of H.pylori positive and negative IM, male patients and the normal
control group (p=0.0221). Discussion: There is a significant linear correlation between the
frequency of R72P polymorphism and latitude. Our finding corresponds with the expected
allele frequencies in our region. The control and IM patients group are not different statistic-
ally, however, significant differences can be found if we consider the H. pylory status and
gender, too.
M1996
Natural History of Dyspepsia in Primary Care: Incidence, Risk Factors,
Comorbidity and Mortality
Mari-Ann Wallander, Saga Johansson, Ana Ruigomez, Luis A. Garcia Rodriguez
Upper gastrointestinal symptoms affect between one quarter and one half of the UK popula-
tion at least once every six months. Many patients who consult primary care physicians
with these symptoms do not receive a firm diagnosis of the underlying cause of their
symptoms, and are classified as having dyspepsia. Objectives: To determine the natural
history of upper gastrointestinal symptoms of unspecified origin presenting in primary care
in the UK and identify risk factors and comorbidity associated with a diagnosis of dyspepsia.
Methods: Data were extracted from the UK General Practice Research Database. Patients
with a new diagnosis of dyspepsia in 1996 were identified (n = 6913) and were compared
with an age- and sex-matched control cohort (n = 11036). We determined the incidence
of dyspepsia, potential risk factors and comorbidity, and the risk of mortality and of new
onset morbidity in the year following the index date. Odds ratios (ORs) and 95% confidence
intervals (CIs) were calculated using unconditional logistic regression. Results: The incidence
of dyspepsia was 15.3 per 1000 person-years (95% CI: 15.0-15.6), and was greater in
women than men. A slightly increased probability of a new dyspepsia diagnosis was associated
with chest pain (OR: 2.4; 95% CI: 2.1-2.7), general pain (OR: 1.8; 95% CI: 1.7-1.9), sleep
disorders (OR: 1.5; 95% CI: 1.2-1.8), angina (OR: 1.5; 95% CI: 1.2-1.8) and osteoarthritis/
rheumatoid arthritis (OR: 1.4; 95% CI: 1.2-1.6). The association of smoking (OR: 1.3; 95%
CI: 1.2-1.4) and obesity (BMI ≥ 30 kg/m2) (OR: 1.2; 95% CI: 1.1-1.3) with dyspepsia
were of only borderline significance. Current use of non-steroidal anti-inflammatory drugs
and aspirin was associated with a significant increase in the risk of dyspepsia (OR: 1.8; 95%
CI: 1.7-2.0 and OR: 1.3; 95% CI: 1.2-1.5, respectively). During the follow-up year, patients
with dyspepsia were more than 60 times more likely to receive a diagnosis of gastroesophageal
reflux disease (GERD) than patients without dyspepsia (OR: 62.8; 95% CI: 31.1-127.0).
They were also more likely to receive a subsequent diagnosis of angina (OR: 2.7; 95% CI:
1.8-4.0) or chest pain (OR: 3.9; 95% CI: 3.7-4.2). There was an increased risk of death
(RR: 1.6; 95% CI: 1.2-2.2) in the dyspepsia cohort compared with the control cohort during
the follow-up year. Conclusions: Lifestyle changes appear unlikely to have a major role in
the development of upper gastrointestinal symptoms. Many dyspepsia patients subsequently
receive a GERD diagnosis, suggesting that GERD may be underdiagnosed in primary care.
M1997
Declining Incidence of Duodenal Ulcers Compared to Gastric Ulcers in a 10
Years Endoscopic Database
Marcel Groenen, Ernst J. Kuipers, Rob J.Th. Ouwendijk
Background and Study aims Over the past decades, important changes have occurred in
the epidemiology of ulcer disease. Already more than forty years ago, a decline in the
incidence of peptic ulcer was suggested on the basis of a cohort analysis. The discovery in
the early eighties of H. pylori as major cause of peptic ulcer disease had a further major
impact on the incidence of ulcer disease. Our aim was to evaluate the further change of
incidence in time of duodenal and gastric ulcer as diagnosed by endoscopy. Material and
Methods With the help of Endobase®, a computerized endoscopic database, the data of all
patients who underwent upper endoscopy from 1996-2005 were analyzed. Data were col-
lected in an open-access endoscopy unit of a district hospital. The incidence of duodenal
and gastric ulcers was compared over time. SPSS was used to statistically evaluate the
endoscopic data. Results Overall, 13081 upper endoscopies were performed. In 511 investi-
gations (3.9%) duodenal ulcers were diagnosed. Duodenal ulcers were found more frequent
in men (56.6%). 125 of the duodenal ulcers (24.5 %) had signs of recent bleeding. Twenty-
one of these duodenal ulcers (4.1%) were classified as Forrest I, six of these as Forrest Ia.
A visible vessel was diagnosed in 45 patients (8.8%), Forrest IIb in 31 (6.1%) and Forrest
IIc in 28 patients (5.5%). Gastric ulcers were found in 317 (2.4%) endoscopies. 49 of the
gastric ulcers (15.5%) presented with signs of bleeding. Forrest I was diagnosed in 17
patients (5.4%) and Forrest II in 32 (10.1%). The incidence of gastric ulcers remained stable
over time with about 30 cases per year. However, the incidence of duodenal ulcers declined
from 4.1% to 2.8% with a linear regression coefficient of -.126 (p 0.087). There was a
tendency of leveling incidence of gastric and duodenal ulcers in the last years of the
investigated period. Conclusions In the past 10 years, the incidence of gastric ulcer disease
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has remained stable, whereas the incidence of duodenal ulcer disease decreases. With further
treatment of H. pylori the incidence of gastric ulcers is expected soon to exceed the incidence
of duodenal ulcer in the near future in our Western community
M1998
The Gastric Sling Fiber/Clasp Fiber Pressure Profile Is Significantly Decreased
in Patients with GERD
Thomas McKenna, Annapurna Korimilli, Anil K. Vegesna, Parkman Henry, Brasseur
James, Larry S. Miller
Purpose: To determine the contribution of the gastric sling fiber/clasp fiber complex to the
antireflux barrier in normal control subjects and patients with GERD. Methods: A simultan-
eous ultrasound and manometry catheter was pulled through the proximal stomach and
the gastroesophageal junction high-pressure zone at a constant velocity in ten normal control
subjects and 10 patients with GERD. Pressure was correlated to the ultrasound images
during breath holding in expiration. The ultrasound images were used to locate the beginning
of the right crural diaphragm. The area under the pressure curve was measured from the
beginning of the pull-through to the beginning of the right crural diaphragm. Gastric pressure
was used as a zero baseline. Any increase in pressure prior to the start of the crural diaphragm
was assumed to be due to the gastric sling fiber/clasp fiber complex. Results: The area under
the pressure curve in GERD patients, was only 18% of the area under the pressure curve
in normal control subjects. The pressure difference between the normal control subjects
and the GERD patients was a mean of 19,15,13 and 12 mmHg at 5,10,15 and 20 mm
before the beginning of the crural diaphragm. Conclusions: The gastric sling fibers form a
V shape configuration on ultrasound imaging. This configuration acts as a pinchcock to
prevent the reflux of gastric contents in normal subjects. It does this by providing a pressure
barrier between the stomach and the crural diaphragm. This pressure barrier is significantly
decreased in patients with GERD. We hypothesize that an underlying cause of GERD may
be the absence of the pressure profile due to a defective gastric sling fiber/clasp fiber complex.
Funded through an NIH grant R01 DK59500.
This graph shows the pressure profile of the gastric sling fiber clasp fiber complex in normal
control subjects and patients with GERD. The beginning of the crural diaphragm is at x = 0.
M1999
Changes in Compliance Following Laparoscopic Nissen Fundoplication
Measured By a New Technique (FLIP)
Hanneke Beaumont, Barry P. McMahon, Willem Bemelman, Hans Gregersen, Guy
Boeckxstaens
Background & Aims: Increased distensibility or compliance of the esophagogastric junction
(EGJ) was shown to play an important role in the pathogenesis of gastroesophageal reflux
disease (GERD). However, to measure EGJ distensibility, radiographic imaging involving
radiation is required limiting its application in research protocols. Therefore, a functional
lumen imaging probe (FLIP) was constructed measuring eight cross sectional areas (CSA)
at 4mm intervals inside a saline-filled bag using impedance planimetry and containing two
pressure side holes allowing assessment of EGJ compliance . The present study was designed
to evaluate whether this technique could be used to detect changes in EGJ compliance
between healthy volunteers, untreated GERD patients and patients who had a laparoscopic
Nissen fundoplication (LNF) Methods: 5 GERD patients (57 (43-67), 3M), 4 post Nissen
patients (54 (43-60), 3M) and 5 HV (40 (20-58), 3M) were evaluated. They underwent a
compliance measurement using the FLIP, esophageal manometry and 24 hrs pH metry. The
FLIP was positioned with the bag straddling the EGJ using manometry readings and point
of respiratory inversion as a guide. The bag was filled with saline at a rate volume of 25
ml/min to a maximum of 60 ml. Bag pressure and CSA were recorded. A pH below 4 >
5.78% of total time was considered to be pathological. For statistical analysis of pH and
manometry, unpaired Student’s t-tests were used and data is presented as mean ± SE.
Results: GERD patients have significant more pathological acid reflux 5 cm above the lower
esophageal sphincter (LES) compared to LNF patients and healthy volunteers (GERD patients:
10.5 ± 3.2 %, LNF: 0.7 ± 0.4 %, HV: 2.3 ± 0.7 % (P<0.031)). The basal LES pressure did
not differ between the three groups (GERD patients: 6 ± 2 mmHg; LNF: 8 ± 3 mmHg; HV:
9 ± 3 mmHg (NS)). At a bag pressure of 7 mmHg during distension the average diameter
of the EGJ in GERD patients and HV was 13 mm while the LNF average diameter was 7
mm. However, at 13 mmHg, the diameter remained about 13 mm in HV and 8 in LNF
patients whereas it increased to 22 mm in GERD patients. Conclusion: FLIP studies showed
a greater distensibility in GERD patients compared to HV, accompanied by an increased
esophageal acid exposure. Conversely, we showed that FLIP detects a significant decrease
in compliance after LNF associated with a decrease in acid reflux. These results suggest that


















The Effect of Food Composition (Energy Density and Fat Content) in Patients
with Gastro-Oesophageal Reflux Disease
Mark Fox, Carole Barr, Suzanne Nolan, Miranda Lomer, Angela Anggiansah, Terry Wong
INTRODUCTION & AIM: Patients with symptoms of gastro-oesophageal reflux disease
(GORD) are often told to avoid fatty food; however it is not certain whether reflux severity
is associated with fat content or overall energy density of the diet. The catheter-free Bravo™
system provides prolonged oesophageal pH monitoring that is well tolerated by patients,
providing an opportunity for repeated investigation of dietary interventions in GORD.
METHODS: Patients referred for investigation of reflux symptoms were recruited (n=21).
The Bravo™ capsule was placed by endoscopy. The study design allowed the effects of
calorie density, fat content and food consistency on GORD to be assessed independently.
High fat (50%) vs. low fat (25%) diet (calories controlled), and high calorie (1000kcal) vs.
low calorie (500kcal) diet (fat controlled) were compared. The effects of food consistency
on GORD were examined by comparing mixed solid/liquid vs. liquid diet. Meal volume
was 800ml for all diets. All meals were supplied, providing 24hr in each ‘dietary condition’.
Patients returned after 48h and 96hr to download data. Associations of dietary composition
and consistency with esophageal acid exposure and reflux symptoms were analyzed by
repeated measures ANOVA and pairwise comparisons. RESULTS: Complete data was avail-
able for 15/21 patients (6M:9F, 48(26-70)yrs, BMI 26(21-35)kg/m2). Demographic variables
and meal sequence had no effect on reflux parameters. ANOVA demonstrated significant
effects of ‘dietary condition’ on esophageal acid exposure (F=7.4, p<0.005) and reflux
symptoms (F=24.2, p<0.001). No effects of ‘dietary consistency’ on esophageal acid exposure
or reflux symptoms were present. Esophageal acid exposure was less during the low calorie
than high calorie diet (fat controlled); mean 5.2±1.4 vs. 8.6±2.0 %time@pH<4/24hr;
(p<0.01). No difference was observed between low and high fat diets (calories controlled);
mean 8.2±1.6 vs. 8.6±2.0 %time@pH<4/24hr; (p=ns). In contrast, the frequency of reflux
symptoms was not affected by the calorie density of the diet (median 6 (2-12) vs. 8 (2-13)
reports; p=ns) but was increased during the high fat diet (median 11 (5-18) vs. 6 (2-12)
reports; p<0.05). Conclusion: This study provides clear evidence that calorie density rather
than fat content of the diet determines the severity of acid reflux in GORD. However the
fat content of the diet has important effects on the frequency of reflux symptoms. The effects
of diet on GORD were clinically relevant with a >30% decrease in esophageal acid exposure
and >40% decrease in reflux symptoms in low vs. high calorie and low vs. high fat diets
respectively.
M2001
Does Gastric Leptin in the Refluxate Contribute to Healing of the Esophageal
Mucosa?
Fritz Francois, Adam J. Goodman, Jatin Roper, Michelle Mourad, Asalia Z. Olivares de
Perez, Guillermo I. Perez-Perez, Zhiheng Pei, Martin J. Blaser
BACKGROUND: Although heartburn is a hallmark of GERD, only a subset of affected
individuals develop mucosal injury. Leptin, a hormone produced in the human stomach,
stimulates cell growth in vitro and inhibits gastric ulcer formation in rats. We hypothesized
that gastric leptin in the refluxate may contribute to the healing of the esophageal mucosa.
Our aims were to evaluate whether leptin receptors are present in the esophagus and to
determine whether regional gastric leptin levels correlate with esophageal pathology (esophag-
itis and/or Barrett’s). METHODS: Patients referred for EGD were enrolled if they reported
heartburn for ≥ 6 months in the prior year. A detailed medical history, height, and weight
were obtained, and BMI calculated. Serum was collected, and biopsies obtained from antrum,
fundus, and esophagus were reviewed by a blinded GI pathologist. Based on endoscopic
and histologic findings, patients were classified as having esophageal pathology (EP+) or
not (EP-), and immunohistochemistry was performed on representative sections from both
groups to determine density and localization of leptin receptors. Leptin levels in plasma
and gastric biopsy samples were determined by specific ELISA, and gastric concentrations
were normalized according to biopsy protein (pg/mg protein). RESULTS: Among 48 patients
enrolled with heartburn, 27 were EP- and 21 were EP+. The two groups did not differ
significantly in ethnicity, mean age, BMI, and gastric pH, or in proportions using PPIs, or
with H. pylori, or in plasma leptin. Receptors for leptin were highly expressed on esophageal
epithelial cells, with similar density and staining pattern in the EP- and EP+ specimens. The
EP- group had significantly higher antral leptin levels than the EP+ group (median 94 pg/
mg IQR (40-156) vs. 49 pg/mg (34-98); p=0.047). Similarly, the EP- group had significantly
higher fundic leptin levels than the EP+ group (median 221 pg/mg IQR (93-357) vs. 103
pg/mg (72-163); p=0.003). Although the groups did not differ in symptom chronicity, the
duration of heartburn was significantly correlated with fundus leptin levels in the EP- group
(r=0.59, p=0.005), but not the EP+ group. CONCLUSIONS: Extensive expression of the
leptin receptor on esophageal epithelial cells suggests that they are susceptible to leptin-
mediated signal transduction. Differences in gastric leptin levels between EP+ and EP- persons
could provide a mechanism for differential esophageal healing after reflux-induced injury.
These data support the hypothesis that gastric leptin plays a protective role against esophageal
pathology among patients with heartburn.
M2002
Patients with Non-Erosive Reflux Disease (NERD) Demonstrate Upregulation
of TRPV1 Receptors in the Distal Esophagus As Compared to the Other GERD
Groups
Ram Dickman, Pankaj J. Pasricha, John Winston, Mohan Shenoy, Diley Hernandez,
Ronnie Fass
Background: There is no correlation between severity, frequency or intensity of symptoms
and the presence or absence of esophageal mucosal injury. Visceral hypersensitivity and
thus upregulation of TRPV1 receptors has been suggested to play an important role in
symptom generation of NERD patients. Aims: To compare the extent of distal esophageal
expression and proximal distribution of TRPV1 receptors among the different GERD groups
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and normal controls. Methods: Five normal healthy controls, 5 patients with NERD, 5 with
erosive esophagitis (EE) and 5 with Barrett’s esophagus (BE) were recruited into the study.
All participants underwent an upper endoscopy to ascertain the diagnosis and to obtain 2
biopsies from normal looking squamous mucosa, 6 cm and 15 cm above the esophagogastric
junction. Patients with GERD symptoms and normal endoscopy underwent pH testing. Only
those with an abnormal pH test (>4.2%) were included in the study as NERD patients. The
biopsies were evaluated for TRPV1 expression using Western blots. Results: The mean age
and M/F ratio was 49.8 ± 8.9 yrs, 3/2, for healthy controls; 47.8 ± 4.8 yrs, 4/1, for NERD;
52.0 ± 3.5, 3/2, for EE; and 62 ± 4.3, 5/0, for BE. The mean length of the Barrett’s mucosa
was 5.9 ± 0.5 cm (4.5-7.0 cm). The distribution of erosive esophagitis was Grade A - 1,
Grade B - 3 and Grade C - 1. The mean % total time pH < 4 in the NERD group was 15.4%
± 3.7. Patients with NERD had the highest distal expression of TRPV1 = 0.6572 among the
GERD groups, followed by EE = 0.4167 and BE = 0.0377 (p <0.05). TRPV1 expression in
normal controls was 0.5151 (p = NS). All participating groups demonstrated an increase in
TRPV1 expression in the proximal esophagus: NERD = 0.7226, EE = 0.5074, BE = 0.6679
and control = 0.5451. Healthy controls demonstrated the least increase (5.8%) in proximal
distribution of TRPV1 receptor as compared to the GERD groups (NERD = 10%, EE = 22%
and BE = 77%, p <0.05). Conclusions: NERD patients demonstrate upregulation of TRPV1
receptors in the distal esophagus as compared to EE and BE. All GERD groups demonstrate
increase in proximal distribution of TRPV1 receptors, which may explain why proximal
migration of an acid reflux event is associated with higher likelihood of symptom generation.
M2003
Influence of Intra-Esophageal Capsaicin Instillation On Heartburn Induction
and Desensitisation in Man
Sebastien Kindt, Rita Vos, Daniel Sifrim, Jozef Janssens, Jan Tack
Heartburn is the most typical symptom in gastro-esophageal reflux disease (GERD). It has
been suggested that heartburn sensation is mediated by the transient receptor potential
vanilloid receptor 1 (TRPV1), a cation channel expressed by sensory neurons and activated
by heat, acid pH, capsaicin, lipoxygenase products and anandamide. Exposure of the TRPV1
receptor to the agonist capsaicin, the pungent ingredient of chilli peppers, is characterized
by activation, followed by receptor desensitization. The aim of the present study was to
investigate the effect of intra-esophageal capsaicin instillation on esophageal symptom percep-
tion (activation) and on sensitivity to esophageal acid perfusion (desensitization). Methods:
Ten healthy volunteers (4m, mean age 27±1) were studied on three separate occasions, at
least one week apart. During standard esophageal manometry, a 10 ml solution of saline
containing 0 (placebo), 0.5 (low dose) or 3 (high dose) ml of a capsaicin solution (0.17
mg/ml) were instilled in the mid-esophagus. Thirty minutes later, 0.1 N hydrochloric acid
was infused in the middle third of the esophagus at a rate of 6 ml/min for 30 min. At 5-
minute intervals, throughout the study, the intensity of 10 symptoms (discomfort, pain,
retrosternal burning, epigastric burning, fullness, bloating, nausea, belching, satiety, cramps)
was assessed on 10 cm visual analog (VAS) scales. Areas under the curve (AUC) for symptom
intensities under different conditions were recorded and compared by paired t-test and
ANOVA. Results: Instillation of the high dose of capsaicin induced significantly higher
symptoms of retrosternal burning and epigastric burning (AUC 203±61 and 155±52 mm*min
respectively) compared to the low dose (18±11 and 35±24 mm*min, p<0.05) and to placebo
(65±40 and 53±43 mm*min, p<0.05). High dose of capsaicin also induced more pain (AUC
55±29 vs. 15±15, p<0.05) and discomfort (AUC 138±63 vs. 33±30, p=0.05) compared to
placebo. During acid perfusion, regardless of the time interval of assessment, capsaicin
pretreatment did not significantly alter perception scores for retrosternal burning (AUC
1015±254, 1113±217 and 890±243 respectively for placebo, low dose and high dose, NS),
epigastric burning (AUC 740±265, 390±239 and 408±207 respectively for placebo, low
dose and high dose, NS), or any other symptom. Conclusion: Instillation of the TRPV1
receptor agonist capsaicin in the esophagus induces symptoms of heartburn and epigastric
burning in a dose-dependent fashion. However, as the doses used do not desensitize the
esophagus to acid perfusion, identification of the receptor involved in esophageal acid
sensitivity awaits other approaches.
M2004
High Resolution Manometry (HRM) of the EGJ in Normal Subjects and
Symptomatic Patients; a Selective Analysis of the Crural Diaphragm (CD)
Component
John E. Pandolfino, Qing Zhang, Sudip K. Ghosh, John Rice, John P. Norvell, Peter J.
Kahrilas
Aim: HRM provides a spatially enhanced, dynamic representation of the EGJ high-pressure
zone. This study utilized HRM to compare the CD contribution to EGJ pressure profile in
normal subjects and symptomatic patients. Methods: 75 asymptomatic controls and 178
consecutive patients being evaluated for GERD symptoms underwent HRM with a 36 sensor
solid state manometric assembly (1 cm spacing) positioned to record from the hypopharynx
to the stomach. The EGJ axial pressure profile was analyzed with spatial pressure variation
plots over 5 to 6 respiratory cycles to quantify the position and contractile vigor of the CD
relative to the LES. EGJ and CD pressures were measured at end inspiration; LES pressure
at expiration. In instances of a double pressure peak, the distal peak was taken to be the
CD. Results: HRM can dynamically isolate the pressure signal of the CD from that of the
LES once they are spatially separated by > 2 cm, a finding exhibited by 1/75 normal subjects
and 46/178 (26%) of the patients (p<0.01). There was no significant difference in expiratory
LES pressure between normal subjects and patients (Table). In contrast, inspiratory EGJ
pressure was significantly lower in patients with ≥2cm LES/CD separation than in either
patients with <2cm separation or controls (ANOVA p<0.01). There was no difference in
inspiratory EGJ pressure between normal subjects and patients with <2cm CD/LES separation.
There was an inverse correlation between LES/CD separation and inspiratory augmentation
of EGJ pressure (R=0.53, P <0.0001). In addition, it appeared that once axial separation
was ≥3 cm LES pressure would decrease during inspiration and increase during expiration.
Conclusions: CD augmentation of the EGJ during inspiration becomes progressively attenu-
ated once these EGJ elements are spatially separated by ≥2cm. Thus, this HRM parameter
may be used as a surrogate marker for CD dysfunction and hiatus hernia. Although it
appeared that inspiratory augmentation was a better discriminator between patients and
normal subjects, future studies will need to determine if CD dysfunction parallels GERD
severity.
†P<0.05 vs. NL, * P<0.05 vs. Patients with separation
M2005
Effect of Body Position Changes On Postprandial Gastroesophageal Reflux and
Gastric Emptying in the Premature Neonate
Michiel P. Van Wijk, Nathalie Rommel, Ros Lontis, Louise Goodchild, Ross Haslam, Marc
A. Benninga, John Dent, Geoff P. Davidson, Taher Omari
BACKGROUND: In infants, left side positioning decreases triggering of transient lower
esophageal sphincter relaxations (TLESR) and gastroesophageal reflux (GER) but paradoxic-
ally delays gastric emptying (GE).1 The aim of our study was to establish a positioning
regimen that would both promote GE and reduce GER by changing body position one hour
after feeding. METHODS: Six healthy preterm infants (4 male, post menstrual age: 36 (34-
38) weeks, weight 2390 ± 120g) were studied using combined esophageal impedance and
manometry technique. After catheter placement, infants were positioned on the left or right
side and then gavage fed via an infusion port. After one hour, the infant’s position was
changed to the opposite side. All infants were studied on two occasions such that position
was changed from right to left (protocol 1) and from left to right (protocol 2) in a cross-
over fashion (3 patients protocol 1 first, 3 patients protocol 2 first). GE rate was determined
with a 13C-Na octanoate breath test. Manometry and impedance tracings were blinded for
analysis. RESULTS: Right positioning overall resulted in triggering of more TLESR and liquid
GER than left positioning (mean: 3.3±2.2 vs 1.9±1.5 (p=0.004) and 4.8±3.4 vs 0.8±1.3 (p=
0.003) per hour respectively), but less gas GER (0.3±0.7 vs 1.3±1.05, p=0.04). Data before
and after position change are presented in the table (p values for right position (RP) vs left
position(LP) shown in parentheses). The total number of all GER episodes did not differ
between the two protocols however protocol 1 significantly reduced TLESR and liquid GER
in the second hour after feeding. GE was faster during protocol 1 than during protocol 2
(table). The GE rate for protocol 1 was similar to premature infants previously studied in
the right position only (p=0.89) and GE rate for protocol 2 was faster (p<0.001) than infants
previously studied in the left position only.1 CONCLUSIONS: A postural strategy of right
positioning for the first postprandial hour with a position change to left afterwards promotes
GE while at the same time reduces liquid GER in the late post-prandial period when liquid
reflux of pH<4 occurs. Infants with GERD have increased acid GER in association with
TLESR and right to left positioning may be a useful and simple therapeutic strategy for
promoting GE and reducing acid GER. 1. Omari TI et al. J.Pediatr. 2004;145:194 - 200.
M2006
Effects of Ecabet Sodium On Chronic Acid Reflux Esophagitis in Rats
Daisuke Asaoka, Akihito Nagahara, Yuko Izumi, Akimitsu Ohkawa, Akihiko Kurosawa,
Masato Kawabe, Mariko Hojo, Toshoku Minoo, Ryuichi Ohkusa, Toshifumi Ohkusa,
Hiroto Miwa, Nobuhiro Sato
Background: Ecabet sodium (ES) is a new anti-peptic ulcer drug, which is derived from a
constituent of pine resin. ES exerts its effects on gastric ulcer by binding to gastric mucosal
lesions directly in rats and humans. Further, protective effects of ES on ulcerative colitis
have been also observed. Purpose: To investigate protective effects of ES on esophageal
mucosa by observing esophageal mucosal damages macroscopically and histologically in rat
chronic acid reflux esophagitis model. Methods: Chronic Acid Reflux Esophagitis in rats
was developed by modified Omura’s method. That is, using 10 week-old Wistar male rats,
duodenum near the pylorus ring was wrapped with 18 Fr Nelaton catheter (width: 3 mm)
. Further, border between forestomach and glandular portion was ligated with 2-0 silk
thread. ES (65 mg/kg) was only once intragastrically administered immediately after the
surgery, and drinking water including ES (21.39 ± 2.74 mg/kg/day) was taken from the
next day to day 7. Seven days after the surgery, esophageal damages were macroscopically
and histologically examined in the upper (approx. 5 mm under crico-pharyngeus), the
middle (midpoint between crico-pharyngeus and esophago-columnar junction, EC junction)
and the lower (approx. 0.5 mm upper EC junction) areas. Results: In control group, eso-
phageal damages of the lower area were the most severe among three areas (mucosal thickness
of the lower, the middle and the upper area was 210.8, 204.2 and 47.5 μm, respectively).
In ES group, mucosal thickness in the lower area was significantly decreased (97.5 μm, p=
0.0112) compared with that of control. Furthermore, ES had the tendency to decrease areas
and the number of ulcers in whole esophagus and to decrease the number of leukocytes
infiltrated in the lower area of esophagus. Conclusions: Ecabet protected esophageal mucosa
from chronic reflux gastric juice. This suggests its usefulness in the treatment for gastroeso-
phageal reflux disease.
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M2007
Pattern of Acid Reflux During Transient Lower Esophageal Sphincter
Relaxations (TLESRs) Differ Among Patients with Mild and Severe Reflux
Esophagitis and Healthy Subjects
Katsuhiko Iwakiri, Yoshinori Hayashi, Makoto Kotoyori, Noriyuki Kawami, Yuriko
Tanaka, Akihiko Kawakami, Choitsu Sakamoto, Richard H. Holloway
Background: We have reported that there is no difference in the rate of TLESRs and the
rate of acid reflux during TLESRs at 2 cm above the LES between patients with severe reflux
esophagitis (RE) of LA grade C and healthy subjects, but the groups differ with respect to
whether or not refluxed gastric acid comes up to 7 cm above the LES. It is possible the
proximal extent of reflux differs among healthy subjects, mild and severe RE patients,
however, acid reflux patterns in patients with mild RE are unclear. In this study, we
investigated whether or not there are any differences in acid reflux patterns during TLESRs
among healthy subjects, mild and severe RE patients. Method: 13 patients with RE of LA-
grade C, 13 patients with LA-grade A or B and 13 healthy subjects underwent esophageal
manometry with a 21-lumen perfused assembly that monitored pressure in the pharynx,
the upper esophageal sphincter, the esophageal body, LES and the proximal stomach.
Esophageal pH was monitored at 2 and 7cm above the LES. Recordings were made in the
sitting position for 3 hours after a meal (692 kcal, 33 % fat). Results: There was no difference
in the rate of TLESRs or the rate of acid reflux during TLESRs (a pH drop of at least 1 pH
unit) at 2 cm above the LES among the 3 groups. However, the incidence of acid reflux at
7 cm above the LES during TLESRs in severe RE patients (50.9% (28.3-72.5), median
(interquartile range)) was significantly higher than that in mild RE patients (27.7% (14.2-
45.9)) (p = 0.0056) and healthy subjects (5.7% (3.8-6.2)) (p < 0.0001). In addition, the
rate of acid reflux during TLESRs in mild RE patients was significantly (p = 0.0009) higher
than that in healthy subjects. Conclusions: The rate of acid reflux during TLESRs does not
differ in reflux esophagitis from that in healthy controls. However, reflux disease is character-
ized by a more proximal extent of the refluxate in patients with reflux disease and this
extent is related to the severity of esophagitis.
M2008
What Is the Transsphincteric Pressure Gradient Before a TLESR Takes Place?
R Frankhuisen, Ma van Herwaarden, Rch Scheffer, Hg Gooszen, Gs Hebbard, M Samsom
Background: Increased pressure gradients across the esophagogastric junction (ΔEGJp) are
pivotal for the occurrence of reflux during TLESRs. The question has arisen whether these
observations are related specifically to that point in time, during sphincter relaxation, or
whether comparable pressure differences are present before the sphincter pressure drops,
leading to a TLESR. Aim: To compare ΔEGJp during a 3-min period before TLESR and
during TLESR in patients with gastroesophageal reflux disease (GERD) and healthy controls
(HC). Patients and methods: 17 GERD patients (10 men, mean age 50 (29-69)) with
pathologic esophageal reflux (pH<4 or > 6%) and or a symptom association probability
index > 95% were enrolled along with 18 HC (10 men, mean age 28 (18-53)). One hour
before and 2 hr following a liquid meal (500 ml/300kcal) combined esophageal pH and
high-resolution manometry was performed using an assembly including 11 side holes spaced
by 1 cm positioned across the EGJ. The 2 side holes proximal to the upper and distal to
the lower border of the EGJ were used to calculate intrathoracic - and intragastric pressures
at maximal inspiration. ΔEGJp was defined as mean intragastric pressure minus mean
intrathoracic pressure and was analyzed 180, 60 and 10 seconds before TLESRs and during
TLESRs. Statistics: One-way ANOVA was used to compare different time points in each
group. If p<0.05, a Bunnet post hoc test was performed. Results: The proportion of TLESRs
associated with acid reflux was 49% in controls and 62% in GERD patients (p=0.05). In
HC the ΔEGJp for TLESRs with acid reflux at t=-180 sec (7.6±0.7 mmHg), t=-60 sec (7.2±0.8
mmHg) and t=-10 sec (6.9±1.1 mmHg) is significantly lower than at t=0 (10.5±0.7 mmHg)
(all p<0.05). In GERD, this difference is only observed between t=-10 sec (8.0±0.6 mmHg)
and t=0 (11.8±0.9 mmHg) (p<0.05). The ΔEGJp for TLESRs without acid reflux was compar-
able during all time periods in both GERD patients as HC. The intragastric pressure for
TLESRs with acid reflux in both GERD patients and HC increases between t=-10 (3.9 and
2.1 mmHg) and t=0 (6.6 and 3.6 mmHg) (all p<0.05), while intrathoracic pressure did not
change. Conclusion: The transsphincteric pressure gradient observed during TLESR associ-
ated with acid reflux is not present before TLESR commences and is a consequence of an
increase in intragastric pressure in both GERD patients and healthy controls.
M2009
One to One Relationship Between Esophageal Contractions, Bolus Transit and
Perception of Dysphagia in Healthy Subjects and Patients with GERD
George Karamanolis, Tony Lerut, Jiry Silny, Jan Tack, Daniel Sifrim
Abnormal clearance of swallowed food could lead to generation of esophageal symptoms.
Evaluation of patients with esophageal symptoms is usually performed using esophageal
manometry. Recently, esophageal impedance has been added to assess bolus transport and
combined manometry-impedance is considered an advanced tool for evaluating esophageal
function. However, the relationship between the patient’s perception of the esophageal
passage of a bolus and the objective measurement of esophageal pressures and bolus transit
during individual swallows is not clear. The aim of our study was to assess simultaneously
perception, pressures and transit of viscous boluses in healthy subjects (HS) and patients
with gastro-esophageal reflux disease (GERD). Methods: Simultaneous stationary esophageal
manometry-impedance was performed in 10 HS (7 men; mean age: 27 yrs) and 10 GERD
patients (6 men; mean age: 48 yrs). Ten viscous swallows (5 ml) were tested in each subject
in the supine position. Perception of each swallow was evaluated using a standardized 1-5
scoring system (1=fluid passage and 5=complete blockade). Manometry was considered
abnormal if the amplitude of contractions in the distal esophagus was < 30mmHg or if the
contractions were simultaneous; bolus transit by impedance was abnormal if bolus exit was
not identified at one or more of the measuring sites or if total bolus transit time was >12.5

















200 viscous swallows showed 132 swallows with normal esophageal function and normal
perception (score 1). 12 with abnormal function (ineffective peristalsis or incomplete bolus
clearance) and increased perception (1 in HS vs. 11 in GERD, p=0.003), 45 with normal
esophageal function (effective peristalsis and complete bolus clearance) and abnormal percep-
tion (13 in HS vs. 32 in GERD, p<0.001), and 10 with abnormal function and normal
perception (5 in HS and 5 in GERD). The per-subject analysis showed concordance between
manometry and impedance in 87±7% in HS and 88±7% in GERD. The concordance between
bolus transit measured by impedance and perception scores was of 83%±6 in HS and
60%±12 in GERD. Conclusion: The correlation between objective measurements of eso-
phageal function and perception of bolus passage is good but still incomplete, particularly
in patients with GERD. In healthy subjects 70-80% of swallows showed concordance between
objective measurements and perception. In contrast, patients with GERD showed a less
accurate correlation with increased perception after swallows with both normal and abnor-
mal function.
M2010
The Definition of GERD: A Global, Evidence-Based Consensus
Nimish Vakil, Sander Vanzanten, Dent John, Peter Kahrilas, Roger Jones
The aim of this study was to develop a globally acceptable definition and classification of
reflux related diseases. Methods: A new definition was developed using a Delphi process
over a period of 18 months. The Consensus Group of 45 experts from 19 countries, including
a non-voting chairman, represented a diversity of views and expertise in GERD(Barrett’s
esophagus, surgery, and primary care). Systematic literature reviews, with defined inclusion
and exclusion criteria, were conducted to identify the evidence to support each statement.
The group voted anonymously on four iterations of the statements, twice electronically and
at two Consensus Group workshops. Agreement with a statement by two thirds (i.e. >67%)
of the group was classed as consensus. Results: The level of agreement strengthened through
the Delphi process with consensus on all statements, for each iteration, accordingly 86%,
88%, 94%, and 100%. Over 90% (n=39) of the group strongly agreed with 48 (94%) of
the 51 final statements. GERD was defined as a condition which develops when the reflux
of stomach contents causes troublesome symptoms and/or complications. A classification
system was developed based on symptoms and evidence of esophageal damage for the
esophageal syndromes and the extra-esophageal syndromes of GERD. This classification
makes it possible to diagnose GERD based on symptoms alone and also based on tests such
as endoscopy. The consensus group concluded that the term Barrett’s esophagus is variably
interpreted and lacks the clarity needed for clinical and scientific communication about
columnar metaplasia of the esophageal mucosa. Endoscopically Suspected Esophageal Meta-
plasia (ESEM) is a term proposed by the consensus group that describes endoscopic findings
consistent with Barrett’s esophagus that await histological evaluation. The group concluded
that when biopsies of ESEM show columnar epithelium it should be called Barrett’s esophagus
and the presence or absence of intestinal metaplasia specified. The group concluded that
chronic cough, chronic laryngitis, and asthma are usually multi-factorial disease processes
and gastroesophageal reflux can be an aggravating co-factor, though it was rarely the sole
cause. Conclusions: 1. A consensus of expert gastroenterologists from around the world is
possible using structured consensus development techniques. 2. Critical reviews of evidence
strengthen the level of consensus even when controversial subjects such as Barrett’s esophagus
are considered.3 The global definition and classification should help provide a common
terminology that bridges cultures and countries. supported by Astra-Zeneca
M2011
Effect of Proton Pump Inhibitor Therapy On Inflammatory Changes in the
Gastric Cardia (Carditis)
Shailender Singh, Sharad Mathur, Amit Rastogi, Srinivas R. Puli, Ajay Bansal, Prateek
Sharma
INTRODUCTION: Inflammation and intestinal metaplasia in the gastric cardia have assumed
importance given the rising incidence of adenocarcinoma in this location. The etiology of
inflammation of the gastric cardia i.e. carditis is controversial with both GERD and H. pylori
infection being proposed as possible factors. It has been shown that H. pylori eradication
leads to a decrease in the degree of carditis, however, the effect of acid suppressive therapy
on carditis has not been evaluated. AIM: To investigate the effect of proton pump inhibitor
(PPI) therapy on the carditis score. METHODS: In GERD pts undergoing upper endoscopy,
4 quadrant biopsies were obtained from the gastric cardia (within 1 cm of the anatomic
gastroesophageal junction) at baseline and after PPI therapy. All cardia biopsies were stained
with H& E and reviewed by a single pathologist in a blinded fashion. The updated Sydney
Classification was used to score the biopsies from 0 (absent) to 3 (marked) for the following:
mononuclear cells, neutrophils, intestinal metaplasia, and atrophy. Carditis scores (pre and
post PPI therapy) were compared using the paired t test and Wilcoxon signed ranks test.
RESULTS: 31 pts with a mean age of 61 years (range 47-82 years) were evaluated including
30 Caucasians and 30 males. Results from 5 pts were excluded from the analysis because
at least one set of biopsies did not document the presence of cardiac mucosa. The mean
duration of PPI therapy was 30 months (range:2-58 months). There was no significant
change in the carditis scores after PPI therapy; the mean carditis scores before and after PPI
therapy with their corresponding p values (paired t test) are shown in the table. Also, using
the Wilcoxon signed ranks test, there were no statistically significant trends in the scores
after PPI therapy. Only 4 pts had H. pylori infection and a sub-analysis showed that the
presence of H pylori did not affect the overall results. CONCLUSIONS: Long term acid
suppression therapy with PPI’s (mean duration of 30 months) does not lead to a significant
reduction in the carditis scores. These results suggest that GERD does not play a major role
in the pathogenesis of inflammation in the gastric cardia. These findings need to be confirmed
by future prospective trials with larger number of patients.
Mean gastric carditis scores before and after PPI therapy
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M2012
Mast Cells Promote Neutrophil Infiltration in a Mouse Model of Reflux
Esophagitis
Jeffrey Morganstern, Ming-Yu Wang, Barry K. Wershil
Background: Mast cells play a role in allergic and parasitic diseases of the gastrointestinal
tract, but recent evidence suggest that mast cells may be involved in a variety of non-allergic
conditions, including reflux esophagitis. However, the precise contribution of the mast cell
to the pathogenesis of reflux esophagitis is not known. The goal of this study was to define
the role of mast cells in acid reflux esophagitis. Methods: Mast cell-deficient Kitw/Kitw-v
mice (n=14) and normal (+/+) mice (n=15) were examined in a mouse model of reflux
esophagitis described by Fujino, et al (DDW, 2004). Briefly, mice were fasted overnight in
a metabolic cage and then underwent a surgical procedure to ligate the proximal duodenum
and a region between the forestomach and the glandular portion of the stomach. The mice
were sacrificed four hours after surgery and the distal third of the esophagus removed and
processed for morphometric quantification of neutrophil infiltration in 1 micron, Giesma-
stained sections. As reported by Fujino, et al. this procedure induced a reproducible acute
inflammatory response that was inhibited by acid suppression. The number of neutrophils
in the esophageal tissue was determined and expressed as neutrophils per mm2 tissue. Results:
The number of neutrophils in the esophageal mucosa and submucosa was significantly greater
in the normal (+/+) mice compare with the Kitw/Kitw-v mice (30 ± 25 vs. 9 ± 7, respectively
p < 0.01). Neutrophil infiltration in the submucosa of +/+ mice was statistically greater than
Kitw/Kitw-v mice (42 ± 32 vs. 17 ± 16, p <0.05). Similarly, the neutrophil accumulation
in the epithelium was greater in the +/+ mice, but did not reach statistical significant (18
± 16 vs. 3 ± 2, respectively, p<0.1). Conclusion: Mast cells contribute significantly to the
neutrophil accumulation associated with a model of reflux esophagitis in mice.
M2013
Gene Expression of IL-8 and IL-1β: Quantitative Biomarkers of Esophageal
Squamous Injury
Koji Tanaka, Daniel S. Oh, Steven R. Demeester, Jeffrey A. Hagen, Dong Yun Yang,
Hidekazu Kuramochi, Kathleen D. Danenberg, Peter V. Danenberg, Cedric G. Bremner,
John Lipham, Tom R. Demeester
Background: Endoscopic and histologic criteria are used to define injury of esophageal
squamous mucosa in patients with GERD. These endpoints are subjective, particularly when
assessing response to therapy. Alternatively, measurement of the expression of inflammation-
related genes has potential as an objective and quantitative method of assessing injury. We
hypothesized that injury in the setting of GERD would be associated with upregulation of
the inflammatory genes Cox-2, IL-8, IL-1β, and iNOS. Methods: 93 patients were evaluated
for GERD with pH/Bilitec® montoring. Upper endoscopy was performed and squamous
mucosal biopsies were taken within 3 cm of the squamocolumnar junction. Mucosal injury
was defined as either endoscopic or histologic esophagitis. Controls were those with a normal
pH/Bilitec® study without mucosal injury while reflux patients were defined by the presence
of abnormal acid and/or bile exposure in the distal esophagus. All patients were off acid
suppression therapy and none had previous foregut surgery. Paraffin embedded biopsy
blocks were sectioned and microdissected. RNA isolation and reverse transcription was
followed by quantitative real-time PCR to measure gene expression relative to the reference
gene β-Actin. Expression in controls was compared to that found in reflux patients with
injury. The maximal chi-square method was used to determine the threshold value to best
predict injury. Results: Expression of IL-8 and IL-1β was significantly higher in reflux
patients with injury compared to controls (Table). The optimal cutpoint value to predict
injury in reflux patients was 0.48 for IL-8 and 0.28 for IL-1β. Cox-2 expression did not
differ in controls compared to reflux patients with injury (p=0.33). There was no detectable
iNos expression in any squamous biopsy. Conclusion: Gene expression of IL-8 and IL-1β
is increased in injured squamous mucosa of GERD patients. Measuring the expression of
these injury-related genes has potential usefulness as quantitative endpoints when assessing
the effectiveness of antireflux therapy.
Median values (IQR) based on gene x100/β-Actin mRNA expression
M2014
Excessive Post-Prandial Transient Lower Esophageal Sphincter Relaxation
(TLESR) Causes GERD in Obesity. A Study of Esophageal Motility in Patients
with Moderate and Severe Obesity
Justin Wu, Lik Man Mui, Carrian Cheung, Philip Chiu, Joseph Sung
BACKGROUND: Obesity has been associated with GERD and its complication but the
underlying mechanism is unclear. We hypothesize that obesity leads to impairment of
esophageal motility function and predisposes to development of GERD. AIM: To evaluate
the esophageal motility function in patients with obesity. METHODS: We prospectively
recruited consecutive patients referred for weight reduction endoscopic therapy or surgery
because of moderate to severe obesity (BMI >/=35). Exclusion criteria included endoscopic
erosive esophagitis, weekly attacks of heartburn and acid regurgitation, need of proton
pump inhibitor therapy for upper gastrointestinal symptom, sliding hiatus hernia >2 cm as
diagnosed by endoscopy, and diabetes mellitus with established microvascular complication.
All recruited patients underwent stationary esophageal manometry (EM), 2-hour postprandial
EM and pH-metry after a standard 400 kcal test meal; and ambulatory 24-hour pH metry.
Age-and-sex matched asymptomatic non-obese (BMI: 20-23) subjects were recruited as
controls. RESULTS: 12 obese patients and 12 controls (10 male subjects in each group)
were studied. In stationary EM, both groups had comparable mean lower esophageal sphincter
(LES) pressure (Obese Vs control: 15.8+/-6.9 Vs 14.7+/-8.8 mmHg, p=0.33), mean LES
length (Obese Vs control: 3.6+/-0.8 Vs 3.8+/-0.4 cm, p=0.28), mean % of primary peristalsis
(Obese Vs control: 86.6+/-10.3 Vs 84.5+/-9.2%, p=0.87) and secondary peristalsis (Obese
Vs control: 63.9+/-22.3 Vs 68.5+/-26.3%, p=0.15). In 2-hour postprandial study, however,
obese patients had significantly higher rate of transient LES relaxation (TLESR) with and
without acidic reflux than controls. Total, postprandial and upright esophageal acid exposure
was also significantly higher in obese patients (Table). CONCLUSION: Obesity is associated
with excessive TLESR during postprandial period, which results in higher postprandial and
upright esophageal acid exposure. This finding suggests that obesity leads to abnormal
postprandial LES function, which predisposes to development of GERD in susceptible
patients.
M2015
The Acid Pocket Rivisited with Wireless pH Monitoring
Roberto Penagini, Ausilia Grigolon, Paolo Cantu', Ivana Bravi
Background and aim Data obtained by pH electrode pull-through have recently suggested
the existence of a 2-3 cm layer of highly acidic unbuffered gastric juice at the gastric cardia
after meals. This so called “acid pocket” could be involved in the high prevalence of disease
at this site. The new Bravo wireless pH monitoring system could be a technique suitable to
confirm the presence and relevance of this acid pocket by using pH electrodes clipped to
the mucosa for a prolonged period of time. Aim of our study was therefore to measure pH
at the gastric cardia and in the stomach for 24 h in healthy subjects using 3 Bravo pH
capsules. Methods Nine healthy subjects, (aged 24-51 yr, 4 men) underwent transoral
placement of three Bravo pH capsules during upper gastrointestinal endoscopy, so that the
electrodes were at the squamo-columnar junction (SCJ), 2 cm and 9 cm below respectively.
Two Bravo receivers were used, pH recordings were synchronized and lasted 24 h during
which all subjects performed their usual activities. Position of the pH capsules was checked
by xRay at the beginning and at the end of the studies. A standardised mixed nutrient 2.1
MJ lunch was given to all subjects. Median pH of 1 h before the standardised meal (fasting),
1 h after the standardised meal (post-prandial) and of all 24 h was compared among the
three electrodes. Results (median; interquartile range). Recordings of all 3 capsules were
available for analysis in 8 subjects. pH data were captured by the receivers for 93%+2 of
time. At the SCJ 6/8 tracing had an esophageal pattern with a baseline of pH 6-6.5 and
acid reflux episodes, whereas the remaining two showed wide fluctuations in pH. All tracing
2 and 9 cm below the SCJ (SCJ+2 cm and SCJ+9 cm) had an intragastric pattern with a
fasting baseline of pH 0.9-1.5. pH readings at SCJ and SCJ+2 cm (gastric cardia) were not
lower than those at SCJ+9 cm (gastric body). See table. Conclusions a) prolonged pH
monitoring using the Bravo wireless system in healthy subjects does not confirm the existence
of a layer of acidic unbuffered gastric juice at the cardia, as measured by the electrodes at
the SCJ and SCJ+2 cm, either in the postprandial period or during 24 h. b) The Bravo
wireless system is a valuable tool in the study of intragastric and SCJ pH environment.
*higher than SCJ+2 cm and SCJ+9 cm, p<0.001 by ANOVA followed by Fisher test.
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M2016
Transient Lower Esophageal Sphincter Relaxation (TLESR) Is Associated with
Arousal, But Reflux Esophagitis (RE) Has Multiple Causes in Patients with
Obstructive Sleep Apnea Syndrome (OSAS)
Shiko Kuribayashi, Motoyasu Kusano, Yasuyuki Shimoyama, Osamu Kawamura, Masaki
Maeda, Tatsuya Higuchi, Atsuto Nagoshi, Hiroaki Zai, Kunio Dobashi, Masatomo Mori
Background: We have reported that gastroesophageal reflux (GER) mainly occurs during
the sleeping period and is most often induced by TLESR in patients with OSAS. RE is
common in patients with OSAS, but the precise pathophysiology involved and the effect of
GER on further arousal are unknown. Subjects and Methods: Seventeen OSAS patient, who
had an apnea-hypopnea index (AHI) ≧ 5, and 8 normal volunteers (mean AHI: 2.9)
were enrolled. Polysomnography (CHEST, Japan) and gastroesophageal manometry were
performed simultaneously. Gastroesophageal manometry was done by using an infused
catheter system (Arndorfer, USA) to monitor the pressures in the esophageal body and the
LES with a Dent sleeve sensor as well as the gastric body. Esophageal pH was also measured
at 5 cm above the LES by using a micro-glass electrode. All subjects ate a standard meal
(800 kcal) together with 500 ml of water, and the subjects were requested to adopt a supine
position for 10 hours until the next morning. Manometry and pH data were recorded
simultaneously with the polysomnography data and stored in a personal computer. Helicob-
acter pylori (Hp) infection was assessed by measuring the serum titer of Hp IgG antibody.
To investigate the effect of GER on arousal, changes of the sleep stage on the electroencephalo-
gram (EEG) at one minute after reflux associated with TLESR and changes of the EEG after
TLESR without GER were compared. All subjects underwent upper GI endoscopy, and the
findings were compared among patients with RE (RE+, n=8), patients without RE (RE-, n=
9), and healthy volunteers (C, n=8). Results: There was a statistically positive correlation
(R=0.54, p<0.05) between the number of arousal and that of TLESRs in OSAS patients, but
the mean AHI did not differ between the RE+ group (42.0 ± 25.9, mean ± SD) and the RE-
group (35.7 ± 18.3). The number of TLESRs in both OSAS groups was significantly higher
than in the C group and the number of TLESRs associated with GER was significantly higher
in the RE+ group (24/104 TLESRs) than in the RE- group (7/101). BMI of the RE+ group
(31.0 ± 5.8) was significantly greater than that of the RE- group (24.8 ± 2.0). The Hp
infection rate of the RE+ group (20%) was significantly lower than that of the RE- group
(62%). A change of sleep stage (further arousal) was observed after 19 % of GER events
with TLESR versus 20 % of TLESR events without GER, and there was no significant
difference. Conclusions: TLESR was associated with arousal in OSAS patients, while RE was
dependent on GER event, and on factors like dietary habits or gastric acid secretion. GER
did not induce further arousal in patients with OSAS.
M2017
Do We Finally Understand the Underlying Mechanism of Increased Reflux
During TLESRs in GERD Patients?
R Frankhuisen, Ma van Herwaarden, Rch Scheffer, Hg Gooszen, Gs Hebbard, M Samsom
Background: Increased pressure gradients across the esophagogastric junction (ΔEGJp) are
pivotal for the occurrence of reflux during TLESR. It remains unclear if ΔEGJp differs
between GERD patients and healthy controls (HC). Aim: To investigate ΔEGJp (=intragastric
(IGp) - intrathoracic (ITp) pressures), during and 3 min preceding a TLESR in HC and
GERD patients. Patients and methods: 18 HC (10 men, mean age 28 (18-53)) and 17 GERD
patients (10 men, mean age 50 (29-69)) were enrolled. One hour before and 2 hr after a
liquid meal (500 ml/300kcal) combined esophageal pH and high-resolution manometry,
using an assembly with 11 side holes spaced by 1 cm, positioned across the EGJ, was
performed. The 2 side holes proximal to the upper and distal to the lower border of the
EGJ were used to calculate mean ITp and IGp. ΔEGJp was analyzed during TLESRs and at
180, 60 and 10 seconds before. Statistics: repeated measures ANOVA. Results: ΔEGJp and
IGp were increased in GERD compared to HC at all points in time for TLESRs irrespective
of reflux and both for TLESRs with and without reflux (ΔEGJp: all p<0.05, IGp: all p=
0.001). ITp was comparable in both groups at all intervals. Conclusion: An increased ΔEGJp
caused by a higher intragastric pressure is responsible for the increased prevalence of GER
during TLESRs in GERD patients. Lowering intragastric pressure might be a new strategy


















The Junctional Adehesion Molecules Occludin and Zonulin (ZO-1) Are
Expressed in Squamous and Cardia Mucosa of Patients with Non-Erosive and
Erosive Gastroesophageal Reflux Disease
Klaus Moenkemueller, Ulrich Peitz, Thomas Wex, Mike Beyer, Sven Kolfenbach, Peter
Malfertheiner
Introduction: Erosive reflux disease (ERD) as well as non-erosive reflux disease (NERD)
present with dilatation of the intercellular spaces of the esophageal mucosa. Junctional
adhesion molecules may play a role in maintaining the integrity of the intercellular spaces.
Little is known about the expression of these adhesion proteins in human gastroesophageal
reflux disease (GERD). Aim: To determine the gene expression of Occludin and ZO-1 in
cardia mucosa and distal esophagus in patients with NERD and ERD. Patients and Methods:
We studied 73 GERD patients with typical esophageal symptoms, (ERD, n=35; NERD, n=
38). Fifty-five patients (25 NERD, 30 ERD were not taking any form of acid suppression
therapy at the time of endoscopy. The presence of autoimmune gastritis, corpus-predominant
H. pylori-gastritis and Barrett’s mucosa were exclusion criteria. Endoscopic characterization
of esophagitis was performed according to the Los Angeles classification. Histological classi-
fication of gastritis was based on the Sydney criteria. In addition to antrum and corpus
biopsies for histology and rapid urease test, biopsies for molecular studies were taken from
cardiac and squamous epithelium of each patient. The gene expression levels of occludin
and Z0-1, as major components of tight junctions, were analyzed by quantitative RT-PCR
and statistically evaluated by non-parametric Mann-Whitney U test. Results: In general,
independent of underlying endoscopic appearance of GERD, Occludin and ZO-1 are
expressed in the esophagus and cardia mucosa. Occludin transcript levels in cardia were 2-
fold higher than those determined in distal esophagus [median: 0.096 vs. 0.045 artificial
units (a.u.), P<0.0001]. In contrast, ZO-1 was found to be oppositely expressed, squamous
epithelium revealed 1.6-times higher transcript levels than cardiac mucosa (median: 0.0082
vs. 0.0051a.u., P<0.0001). Interestingly, no significant differences were found in the expres-
sion of both genes at both regions (cardia, esophagus) with respect to (I) the endoscopic
grades of esophagitis and (II) the treatment with proton pump inhibitors (PPI) within the
NERD and ERD groups. Conclusions: Both junctional adhesion molecules, Occludin and
ZO-1, are expressed in both cardia and squamous mucosa of patients with ERD and NERD.
There is no difference in expression of Occludin and ZO-1 between ERD and NERD. Ongoing
studies are aimed to investigate the corresponding protein level of both genes and to
characterize the subcellular localization of both, Occludin and ZO-1.
M2019
Relationship Between Acidity of Gastroesophageal Reflux, Acidity of Gastric
Content and Gastric Emptying. Effect of Erythromycin
Daniel Sifrim, Kathleen Blondeau, Sara Emerenziani, Jan Tack, Jeremy Gale, Jozef
Janssens, Jiry Silny
Acidity of gastroesophageal reflux determines patterns of symptoms and mucosal damage
in GERD. The pH of the refluxate is not identical but correlates with gastric pH changes.
After a meal, gastric pH follows a neutralization-re-acidification curve (gastric titration time =
time gastric pH >2) which is shorter with increased postprandial acid secretion and/or faster
gastric emptying. Erythromycin (ERY) accelerates gastric emptying and reduces gastric acid
secretion. Aim: To further characterize the relationship between acidity of the refluxate,
acidity of gastric contents and gastric emptying in healthy subjects. Methods: Concomitant
esophageal impedance-pH and scintigraphic gastric emptying recordings were performed in
14 asymptomatic subjects [12 M, age 23 (19-60)]. The gastric emptying study used a caloric
solid-liquid meal (700 Kcal, fat 60%) and considered separately the emptying of total,
proximal and subcardial stomach. Gastroesophageal reflux events (detected by impedance
with acidity characterized by pH) gastric pH (measured with a sensor located 10 cm distal
to LES) and half emptying times and areas under the emptying curve for liquids and solids
were measured during 3hs after the meal. During the meal, saline or ERY 3mg/kg were
infused IV (20 min) in a randomized, double blind, cross-over design. Linear mixed models
were used to describe the evolution of pH of reflux as a function of gastric emptying and
titration time and Wilcoxon test was used to assess the effect of ERY. Results: With saline
infusion, the median gastric titration time was 50 min (27-72) and the longer the titration
time, the higher the pH of reflux (p < 0.05). The faster the proximal and subcardial gastric
emptying of liquids, the shorter the titration time (r: 0.57) and the lower the pH of reflux
(p <0.05). There was no correlation between gastric emptying of solids and pH of reflux.
ERY significantly prolonged gastric titration time to 90 min (49-140) and decreased the
proportion of acid reflux events (pH < 4) from 52% to 18% without reducing the total
number of reflux events/3h [11(8-13) vs. 9.5 (7-10)]. ERY had no effect on gastric emptying
of liquids but accelerated gastric emptying of solids (½ time: 102±32min vs. 67±30min, p<
0.05). Conclusion: The acidity of postprandial reflux is highly affected by the gastric titration
time which depends on gastric secretion, buffering effect of the meals and gastric emptying.
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ERY, in spite of accelerating gastric emptying of solids, prolongs gastric titration time and
reduces acid reflux, probably by inhibiting postprandial acid secretion and enhancing the
buffer capacity of the meal by a better mixing of acid and chyme.
M2021
Transient Lower Oesophageal Sphincter Relaxation and Mechanisms of
Gastro-Oesophageal Reflux in Twins Discordant for Gord Symptoms
Imtiyaz Mohammed, Angela Anggiansah, Roy Anggiansah, Lynn F. Cherkas, Tim D.
Spector, Nigel J. Trudgill
Background: Transient lower oesophageal sphincter relaxation (TLOSR) is the principal
mechanism associated with acid reflux episodes. We have therefore examined TLOSR in
twin pairs who are discordant for GORD symptoms, i.e. only one of the pair has GORD
symptoms, to establish whether differences in TLOSR may contribute to the aetiology of
GORD. Methods: 4 monozygotic (MZ) and 12 dizygotic (DZ) twin pairs, who were repeatedly
discordant for GORD symptoms over two years, were studied. LOS function using a sleeve
sensor and oesophageal pH were monitored for 30 mins before and 60 mins after a 250mls
(1200 Kcal) lipid meal. Results: MZ twins were aged mean 63 (range 53-75) years and DZ
twins 57 (44-74) years. TLOSR frequency increased from median 2(0-4) to 3(1-8) per hour
post-prandially (p=0.001) in the symptomatic twins and from 0(0-2) to 2.5 (1-9) post-
prandially in the asymptomatic twins (p=0.001). Comparison between the groups revealed
that pre-prandial TLOSR were more frequent in symptomatic twins (p=0.03) but there was
no difference in post-prandial TLOSR frequency (p=0.6). However, only 6% of pre-prandial
TLOSR were associated with acid reflux compared with 24% of post-prandial TLOSR. Acid
reflux episodes increased post-prandially (symptomatic twins 0(0-2) to 1(0-9) per hour (p=
0.01), asymptomatic twins 0(0) to 1(0-8) (p=0.01)) but there was no difference between
the groups in pre- (p=0.3) or post-prandial acid reflux episode frequency (p=0.9) or total
post-prandial acid exposure (symptomatic twins median 11(range 0-1051) s, asymptomatic
twins 4(0-487) s (p=0.4)). Conclusion: There was no difference in post-prandial TLOSR
frequency in twins discordant for GORD symptoms. Although pre-prandial TLOSR were
more common in twins with GORD symptoms this is unlikely to contribute to the aetiology
of GORD, as they were rarely associated with acid reflux.
M2022
GERD, BMI, and Body Fat Distribution: A Large Cross-Sectional Study
Douglas A. Corley, Ai Kubo, Wei Zhao
BACKGROUND: Almost no published data evaluate the association between GERD and body
fat distribution; if present, such an association may help explain gender/ethnic differences in
GERD complications such as esophageal adenocarcinoma. METHODS: We evaluated GERD
risk factors in a large cross-sectional study. Participants were members of a large health
maintenance organization undergoing a systematic health check-up. They completed detailed
questionnaires, recorded symptoms in the last 6 months (including multiple heartburn
questions), and underwent an examination that included height, weight, and anterior-
posterior diameters of the abdomen and thigh. GERD was defined as burning abdominal
pain that radiated into the chest. Fat distribution was the ratio of the abdomen/thigh
diameters. Analyses utilized unconditional logistic regression and adjusted for age, smoking,
alcohol use, and ethnicity. RESULTS: Questionnaire and BMI data were available for 189,447
unique participants; abdominal/thigh measurements were available for 111,398. There was
statistical evidence of interaction between gender, fat distribution and GERD symptoms
(P<0.01). A significant GERD:abdominal fat association (4th vs. 1st quartile) was present
in white men (OR 1.2, 95% CI 1.1, 1.3) but not in black men (OR 1.2, 95% CI 0.9, 1.5).
CONCLUSIONS: 1. GERD symptoms were independently associated with both an increased
BMI and an increased abdomen/thigh ratio. 2. A substantial portion of the BMI-GERD
association is mediated through an increased abdominal fat distribution pattern. 3. The
GERD-abdominal fat association was strongest among those with a normal to moderately
elevated BMI suggesting there may be a threshold BMI above which further increases in
abdominal fat have less effect on GERD symptoms. 4. The strongest GERD-abdominal fat
association was in males with a BMI between 22.9 and 24.2 (2nd quartile).
*All fully adjusted for BMI
M2023
Don’t Eat Before You Sleep, Or Your Nightmares May Come True
Michael Piesman, Inku Hwang, Corinne Maydonovitch, Roy K. Wong
Background: Lifestyle modifications, including avoidance of late evening meals, are often
prescribed to patients with gastroesophageal reflux disease (GERD) to improve symptoms
of reflux. However, prospective evidence supporting the efficacy of this recommendation is
lacking. The purpose of this study was to determine the difference in the degree of reflux
in patients consuming early or late meals relative to bedtime on 2 consecutive nights.
Methods: 32 adult patients with symptomatic GERD referred to our clinic were prospectively
enrolled and acted as their own controls. Standard evening meal consisting of 1200 kCal
(35% fat, 15% protein, and 50% carbohydrates) was consumed either at 1700 or 2100
hours in a randomized fashion. The patients went to bed at 2300 hours on both nights and
arose at 0600. Acid exposure was measured for 48-hours using a Bravo wireless pH system.
Reflux symptom score was recorded. Anti-secretory agents were discontinued for 10 days.
Analysis was done using a paired T test. Results: 30 patients completed the study (19M/
11F, 70% Caucasian, mean age 46 (24-74), mean BMI 28 (18-40). EGD revealed esophagitis
in 37% and hiatal hernia in 47% of patients. Average time from dinner to bedtime was 93
min for the late meal and 330 min for the early meal. There was a positive correlation
between BMI and degree of reflux (r2=0.189). The 24 hr JD score was significantly higher
in patients following the late meal, as were the % time total and supine reflux, and the
longest episode of reflux. Following the late meal, patients had on average 228% greater
supine reflux compared to the early meal. There was no significant difference in total
symptom score between the late and early evening meal. (See Table). Conclusions: 1. GERD
patients consuming a late-evening meal had significantly greater total JD score and supine
reflux versus an early-evening meal. 2. GERD increased with increasing BMI. 3. There was
no difference in individual and total symptom scores between the late and early-meal groups,
suggesting that symptoms do not always correlate with acid reflux. 4. This study indicates
that eating meals early before bedtime significantly decreases esophageal acid exposure.
Reflux Parameters and Symptoms
Data expressed as mean ± SEM, JD=Johnson-Demeester
M2024
Obstructive Sleep Apnoea (OSA) Is a Risk Factor for GERD in Morbidly
Obese Patients
Mohamed Merrouche, Julien Pouzoulet, Dominique Maillard, Jean Marc Sabate, Pauline
Jouet, Simon Msika, Severine Ledoux, Christine Clerici, Benoit Coffin
Obesity has been demonstrated to be a risk factor for GERD and to increase the risk of
obstructive sleep apnoea (OSA). Previous studies have suggested that OSA could increase
GERD because of the negative thoracic pressure produced by upper-airway collapse occurring
during apnoea . The aim of this study was to evaluate in a group of patients with morbid
obesity the prevalence of OSA and GERD and to look for a relationship between these two
syndromes. Patients and methods: patients with morbid obesity [Body Mass Index (BMI) >
40 kg /m2 or BMI >35 kg /m2 in association with comorbidities] selected for bariatric
surgery were prospectively included in the study between April 2003 and January 2005.
Every patient underwent a standard 24-hour ambulatory pH monitoring (GERD when %
of time with pH < 4 higher than 4.2%), oesophageal manometry and nocturnal polysomno-
graphic recording [OSA when apnoea-hypopnoea index (AHI) >10]. Results (mean ± SD):
68 patients (59 F, mean age 38.9 ±10.4 yrs ; BMI 46.5 ± 6.4 kg/m2) have been included.
Thirty patients (44 %) had GERD (% of time with pH<4 : 7.5 ± 2.7 %) and 55 (80.9 %)
had OSA. Severe OSA, defined by AHI>50, was present in 17.4 %. The lower esophageal
sphincter pressure (LES pressure) was significantly lower in patients with GERD (11.6 ±
3.4 vs 13.4 ± 3.6 mmHg, respectively; P= 0.039). There was a significant relationship
between AHI and BMI (r = 0.337; P = 0.005) in patients with (P = 0.019) or without GERD
(P = 0.015). Patients with OSA were significantlly older (40.5 ± 10.9 vs 33.5 ± 10.4 yrs;
P = 0.039). There was a trend for more frequent GERD in patients with OSA (49.1% vs
23.1% respectively; P = 0.089). There was no significant relationship between pH-metry
criteria and AHI neither in the 24-h total recording time (% of time with pH < 4: r = -
0.173, P=0.16; number of acid reflux r= - 0.179; P = 0.14), nor in the nocturnal recording
time (% of time with pH <4: r = - 0.088, P = 0,48; number of acid reflux: r= - 0,32, P =
0,29). In multivariate analysis, GERD was significantly associated with a low LES pressure
(P= 0.031) and with OSA (P= 0.045) but not with sexe, age and BMI. Conclusion: In this
population of morbidly obese patients, OSA and GERD were extremely frequent and GERD
was significantly associated with LES hypotonia and OSA. Motility disorders induced by
OSA and their evolution after OSA specific treatment warrant further studies.
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M2025
Esophagitis Is Associated with Enlarged Unbuffered Postprandial Acid Pocket
Alan T. Clarke, Angela A. Wirz, Jonathan J. Manning, S Ballantyne, D Alcorn, Kenneth E.
McColl
Background: Previous work has demonstrated the presence of an unbuffered pocket of highly
acidic juice at the gastric cardia after a meal in healthy volunteers. Aims: To compare the
postprandial acid pocket in healthy volunteers and patients with severe reflux esophagitis and
to define it’s position relative to the squamocolumnar junction and manometric landmarks.
Methods: 12 healthy volunteers and 16 patients with grade III/IV reflux esophagitis or
Barrett’s esophagus were studied. At endoscopy radiopaque clips were placed at the most
proximal margin of the gatric folds and, in the subjects with endoscopic evidence of hiatus
hernia, at the diaphragmatic pinch. A barium meal was then performed to document the
anatomy and confirm the position of the clips. While fasted, a pull-through study was
performed using a combined dual pH and solid state manometry catheter, withdrawing at
consecutive 1cm intervals every minute. The position of the pH/manometry apparatus relative
to the anatomical landmarks was obtained by identifying the radiopaque clips on lateral
chest x-ray. The patients were then fed a standardized fatty meal and 15 minutes after the
meal, the pull-through study, x-rays and barium meal repeated . Results: A hiatus hernia
was identified endoscopically in 13 of the reflux esophagitis patients and it’s median length
was not significantly altered by the meal (fasting =1.6cm, range 0.9cm to 4.1cm vs. postpran-
dial=2.3cm, range 0.6cm to 4.7cm). Fasting and postprandial maximal mid-body intragastric
pH were similar between the two groups studied. A region of unbuffered acid (pH<2)
immediately distal to the proximal gastric folds was seen in 8/12 healthy volunteers and
13/15 reflux esophagitis patients. This unbuffered “acid pocket” was a significantly longer
in the esophagitis patients versus healthy volunteers (median length 2cm, range 0cm to
15cm vs. 0 cm, range 0cm to 4cm; p=0.003). It’s location in the esophagitis patients
corresponded with the hiatus hernia sac, the midpoint of which remained highly acidic
(median pH 1.405, range 0.78 to 7.54) after the meal. Postprandial barium studies showed
no evidence of particulate food material within the hiatal sac. Conclusion: Severe esophagitis
is associated with an enlarged unbuffered postprandial acid pocket. This may be partially
due to the hiatus hernia providing a reservoir of highly acidic gastric juice isolated from
food in the main stomach which may reflux into the esophagus.
M2026
Rilevance of Cell Proliferation in the Esophageal Mucosa Defence
Carlo Calabrese, Davide Trere, Anna Fabbri, Manuela Vici, Giovanna Cenacchi, Desiree
Zahlane, Massimo Derenzini, Giulio Di Febo
Background: Erosive esophagitis (ERD) is a frequent macroscopic feature in patients with
gastroesophageal reflux disease (GERD).However, most of patients with heartburn/regurgita-
tion have a non-erosive reflux disease (NERD).The reason of this heterogeneous behavior
of GERD is unknown to date. Aim: to value the cell proliferation of esophageal epithelium
in healthy normal subjects and in patients with GERD with or without erosions. Material
and methods: of the 60 subjects 9 were healthy controls with normal pH-testing and
macroscopical, histological and ultrastructural pattern; 27 patients with ERD and 24 with
NERD. Subjects underwent endoscopy and biopsies were taken from the distal esophagus.
Specimens were analyzed at histology and at transmission electron microscopy (TEM). Cell
proliferation was evaluated by MIB1 immunostaining and by measuring the nucleolar size
after selectively silver staining. Results: at histology of the 27 patients affected by ERD,22
had normal mucosa and 5 showed a mild esophagitis.No patients with NERD showed signs
of oesophagitis at histology. At TEM,all patients with GERD had an ultrastructural pattern
of damage and all controls had a normal ultrastructural pattern.The mean (±SD) MIB1-LI
values of normal subjects and NERD and ERD patients were 62.2% (±9.1), 30.3% (±8.1)
and 16.2% (±5,6), respectively, and were significantly different among the three groups
(p<0.001).On the other hand, the mean nucleolar areas did not differ significantly among
normal,NERD and GERD patients. Conclusions: esophageal mucosa exposed to chronic acid
and pepsin insult present a decreased proliferation status that could have a relevant role in
determining ERD or NERD features in GERD patients.
M2027
A Polymorphism in PTPN11 and Not Interleukin-8 Is Associated with GERD
Among Helicobacter Pylori Infected Japanese
Takafumi Ando, Yasuyuki Goto, Osamu Maeda, Kazuhiro Ishiguro, Osamu Watanabe,
Naoki Ohmiya, Yasumasa Niwa, Nobuyuki Hamajima, Emad M. El-Omar, Hidemi Goto
Background and aims: Gastro-esophageal reflux disease (GERD) patients have increased
exposure to gastric acid and interleukin 8-mediated inflammation in the lower esophagus.
A polymorphism of the PTPN11 gene that encodes src homology 2 domain-containing
protein tyrosine phosphatase-2 (SHP-2) is associated with gastric atrophy and might protect
against GERD, while the IL-8 A-251T>A polymorphism affects IL-8 production. We aimed
to study the association between GERD and the PTPN11 G>A and IL-8 A-251 T>A poly-
morphisms. Methods: Upper gastro-intestinal endoscopy was performed on 120 consecutive
patients with GERD symptoms and 120 asymptomatic controls and biopsies were obtained
from the squamo-columnar junction (SCJ) for histological examination and in vitro organ
cultures for IL-8 measurement by ELISA. Polymorphisms in the PTPN 11 and IL-8 genes
were genotyped by polymerase chain reaction with confronting two-pair primers. Results:
The prevalence of H. pylori infection was significantly higher in the control (94/120, 78%)
compared to the GERD group (74/120, 62%)(p=0.005). Using the Los Angeles Classification,
74 patients (62%) in the GERD group had reflux esophagitis (Grade A: 45, Grade B: 23,
Grade C: 6), compared to 16 subjects (13%) in the control group (Grade A: 14, Grade B:
2)(p<0.001). The IL-8 T-251T>A polymorphism had no significant correlation with GERD
symptoms, reflux esophagitis or IL-8 mucosal levels at the SCJ, despite the GERD patients
having significantly higher IL-8 mucosal levels than the controls (mean±SD = 107±59 ng/
mg protein compared to 59±32 in the controls; p<0.001). In contrast, the PTPN11 G/A

















to the common PTPN11 G/G genotype, the A/A genotype (which protects against gastric
atrophy) was associated with increased risk of GERD symptoms (odds 2.53, 95% CI 1.06-
6.03) and reflux esophagitis (odds ratio 5.23, 95% CI 2.09-13.07). Conclusions: The PTPN11
G>A polymorphism appears to influence risk of GERD, most probably through its association
with gastric atrophy while the IL-8 polymorphism is probably not relevant. This highlights
the role of host genetic determinants of gastric acid in the pathogenesis of GERD.
M2028
Salivary Gland Scintigraphy in Gastro-Esophageal Reflux Disease
Yoshihisa Urita, Susumu Ishihara, Kenichiro Arai, Jun Kondo, Tatsuo Akimoto, Hiroto
Kato, Noriko Hara, Hideyuki Koshino, Yoshiko Honda, Yoko Nagai, Kazushige Nakanishi,
Nagato Shimada, Motonobu Sugimoto, Masaaki Takano, Sanshin Hayashi, Kazumasa Miki
Background: Gastro-esophageal reflux disease (GERD) is associated with a decreased salivary
flow as well as gastric acid production. Recent evidences prove the esophagoprotective ability
of salivary secretions. For example, EGF is produced and secreted by salivary glands into
the gastrointestinal tract for promoting regenerative functions. This study therefore aimed
to investigate functional disorders of salivary glands in patients with GERD. Patients and
Methods: Forty-four consecutive patients with GERD underwent salivary gland scintigraphy.
GERD was diagnosed by endoscopy and gastro-esophageal reflux self-report questionnaires.
Following intravenous injection of 180 to 200 Mbq 99mTc-pertechnetate, anterior sequential
imaging was performed every minute for 40 minutes. At 20 minute4s after injection of
radionuclide, a lemon candy was administrated intraorally to stimulate salivary secretion.
Regions of Interests (ROI) were selected on the individual submandibular and parotid glands,
oral cavity, and thyroid gland. Time activity curves were drawn for each of these. Washout
ratio (peak count before lemon candy administration-lowest count after administration/ peak
count before administration) was examined as a functional parameter. All of the patients
were asked to refrain from drugs known to affect salivary secretion for at least one week
prior to salivary scintigraphy. They were also asked to abstain from swallowing, chewing,
sucking or any other mechanical stimulation of salivary flow. Results: The mean washout
ratio was 55.8% in the right parotid gland, 59.8% in the left parotid gland, 61.6% in the
right submandibular gland, and 65.3% in the left submandibular gland. If the washout ratio
of less than 50% is defined as functional disorders of salivary glands, a decreased salivary
secretion of four major salivary glands was found in 12 (27%), 4 (9%), 12 (27%), and 8 cases
(18%), respectively. An earlier increase of oral cavity count, which may reflect spontaneous
secretion from all four major salivaru glands, was found in 20 cases (47%) with GERD.
Overall, salivary function disorder of at least one major salivary glands was found in 36
patients (82%) with GERD. Conclusions: Salivary gland function was more frequently dimin-
ished than expected. We concluded that the presence of impaired salivary gland function
was considered to be one of risk factors for developing RE.
M2029
Obesity Is Associated with Increased Esophageal Acid Exposure
Hashem El-Serag, John Pandolfino, Stephanie Fitzgerald, Jennifer R. Kramer, Thomas
Tran, Gulchin Ergun
Background: Obesity has been associated with GERD. The mechanism of this relation is
unclear. The association between esophageal acid exposure and total body or abdominal
anthropometric measures has not been examined. Methods: This is a prospective cross-
sectional study of consecutive patients undergoing 24 hour pH-metry at an open access
Reflux Center. Standardized measurements of body weight, height, and waist and hip
circumference were obtained. The association between several parameters of esophageal
acid exposures and anthropometric measures were examined in univariate and multivariate
analyses. Results: We enrolled 206 patients (63% women) with a mean age of 51.4 years.
The mean values for weight, height, and BMI were 76.4 Kg, 168 cm, and 27.0 Kg/m2,
respectively. BMI>30 (but not BMI 25 to 29.9) was associated with a significant increase in
the number of acid reflux episodes, the number of long reflux episodes (> 5 minutes), and
time (and % time) with pH<4. This increase affected total, postprandial, upright and supine
pH measurements at the distal probe (and less consistent associations at the proximal probe).
Similar findings were seen for the waist circumference except for upright measurement
where the correlation was not significant. However, when adjusted for waist circumference
(included in the same model), the association between BMI>30 and measures of esophageal
acid exposure became attenuated and no longer significant (Table) Conclusions: This indicates
that obesity operates primarily through abdominal obesity to increase esophageal acid expo-
sure and hence the risk of GERD.
Association between BMI>30 and several parameters of esophageal acid exposure at the
distal probe
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M2030
Characteristics of Gastroesophageal Reflux in Symptomatic Patients with and
Without Excessive Distal Esophageal Acid Exposure
Albert J. Bredenoord, Bas L. Weusten, Robin Timmer, Andre J. Smout
Background and aim: In a subset of GERD patients a positive relationship between symptoms
and reflux episodes can be demonstrated in the absence of excessive distal esophageal acid
exposure. It is assumed that hypersensitivity of the esophagus to acid plays an important
role in these patients. Besides acidity of the refluxate other factors such as its proximal
extent may determine whether the episode is perceived or not. The aim of this study was
therefore to investigate the profile of reflux episodes in GERD patients without excessive
esophageal acid exposure. Methods: Combined 24-hr impedance and pH monitoring was
performed in 14 GERD patients with excessive reflux (GERD pH+), 14 GERD patients with
physiological reflux (GERD pH-) and 14 controls. All patients had a positive symptom-
reflux association during 24-hour monitoring. Results: The esophageal acid exposure time
in GERD pH+ patients was 9.8% compared to 3.5% in the GERD pH- patients and 2.9%
in the controls. The incidence of acid reflux episodes in GERD pH- patients (25.5 ± 4.9)
and controls (20.2 ± 3.9) was comparable but significantly lower (p<0.05) than the incidence
in GERD pH+ patients (69.8 ± 7.3). However, no differences in the number of weakly acidic
reflux episodes were observed between GERD pH- patients, GERD pH+ patients and controls
(27.2 ± 3.8 vs 26.8 ± 4.6 and 21.0 ± 3.7, respectively). There was also no difference in the
number of pure gas reflux episodes between GERD pH+ patients (23.7 ± 6.7), GERD pH-
patients (24.2 ± 5.9) and controls (20.8 ± 2.9). The proportion of reflux episodes that
reached the proximal esophagus was significantly higher in the GERD pH+ patients (19.6
%) and GERD pH- patients (17.8 %) patients than in the controls (5.7 %, p<0.05). Of the
158 symptomatic reflux episodes in the GERD pH+ patients 53 (33.5%) were due to reflux
episodes that reached the proximal esophagus. Of the 55 symptomatic reflux episodes in
the GERD pH- patients, 21 (38.2%) were due to reflux episodes that reached the proximal
esophagus. Conclusions: Not only in GERD patients with excessive reflux but also in those
with a normal distal esophageal acid exposure a higher proportion of reflux episodes reaches
the proximal esophagus than in controls. These findings suggest that not only esophageal
hypersensitivity but also proximal extent may play a role in symptom generation in GERD
patients without excessive reflux.
M2031
Air Swallowing, Belching and Reflux in Patients with Gastroesophageal Reflux
Disease
Albert J. Bredenoord, Bas L. Weusten, Robin Timmer, Andre Smout
Background and aim: It has been suggested that belching induces gastroesophageal reflux.
The aim of this study was to investigate whether gastric air insufflation and spontaneous
air swallowing and intragastric air promotes both belching and gastroesophageal reflux.
Methods: Esophageal impedance, pH and pressure were measured during a 20-min recording
period in 12 healthy controls and 12 patients with GERD before and after intragastric
inflation of 600 mL of air in order to simulate an intragastric volume of swallowed air. This
was repeated 90 min after ingestion of a meal. Subsequently, ambulatory 24-hr impedance-
pH measurement was performed and the incidence of air swallowing, belching and acidic
and weakly acidic reflux was assessed. Results: After air infusion in the preprandial period
the incidence of gas reflux episodes was increased in both patients (1.00 ± 0.35 vs 3.33 ±
0.65, p<0.05) and controls (0.42 ± 0.15 vs 5.67 ± 1.14, p<0.05). In contrast, the incidence
of acid and weakly acidic reflux episodes was not increased after air infusion, neither in
patients (acid: 0.25 ± 0.13 vs 0.25 ± 0.13, weakly acidic: 0.50 ± 0.15 vs 0.33 ± 0.14), nor
in controls (acid: 0.08 ± 0.08 vs 0.0 ± 0.0, weakly acidic: 0.17 ± 0.11 vs 0.42 ± 0.26). Air
infusion led to an increase in TLESRs in patients (1.42 ± 0.23 vs 2.00 ± 0.39, p<0.05) and
controls (1.08 ± 0.31 vs 2.42 ± 0.60, p<0.05), but this was completely due to an increase
in gas reflux-associated TLESRs. Similar results were obtained with air infusion after consump-
tion of the meal. During the 24-hr impedance-pH study, patients showed a higher incidence
of air swallows (287±45 vs 176±24, p<0.05), belches (52.4 ± 6.6 vs 32.7, p<0.01) and acid
reflux (42.3 ± 7.6 ± 19.1 ± 2.8, p<0.01) than controls. Patients did not show more weakly
acidic reflux episodes (21.0 ± 5.3 vs 14.5 ± 1.1) and regular swallows (782.1 ± 89.0 vs
818.0 ± 57.3) during the 24-hr study. Conclusions: Patients with GERD swallow air more
frequently and belch more frequently than healthy subjects. However, intragastric infusion
of air does not result in an increase in acidic and weakly acidic reflux suggesting that air
swallowing is not causing acidic and weakly acidic reflux.
M2032
SERT Genotype in GERD Compared to Healthy Volunteers
D.R. de Vries, Jose Ter Linde, Margot A. van Herwaarden, Melvin Samsom
Background: The insertion/deletion polymorphism in the promoter region of the serotonin
transporter protein (SERT) is associated with many diseases. The polymorphism results in
a short or long promoter region with a difference in length of 44 bp. The presence of a
short promoter region results in lower SERT expression, less re-uptake and higher availability
of serotonin (5HT). The short/short genotype (SS) is associated with diarrhoea predominant
irritable bowel syndrome (IBS). In mice lacking SERT, gut motility increases. Moreover, the
mice develop diarrhoea and intermittent periods of constipation. The aim of this study was
to investigate whether the relation of the SERT polymorphism with gut motility results in
an association with gastroesophageal reflux disease (GERD). Methods: GERD was defined
using 24-hour esophageal pH-monitoring and symptom association scores (total time pH<4
≥6% or SI≥50% or SAP≥95%). Whole blood samples were taken from 260 GERD patients
(156 male, mean age 48,7, SD 13,4) and 138 age and sex matched healthy controls. DNA
was extracted using QIAamp DNA Blood Mini Kit according to manufacturer’s instructions.
SERT genotype was determined by PCR amplification of the SERT promoter region and gel
electrophoresis of the product. Allele frequencies were tested for Hardy-Weinberg equilibrium
for both groups. Genotype frequencies were compared between groups using chi-square-
tests. Results: In both the patient and the volunteer group, allele frequencies were in Hardy-
Weinberg equilibrium. The genotype frequencies were similar for volunteers and patients,
and are depicted in the figure. SERT genotype was not associated with GERD. Subsequently
the phenotypic characteristics of the GERD patients were used to make subdivisions in the
group. There was no association between SERT genotype and upright, supine or total
esophageal acid exposure, nor was there an association with SI or SAP. Conclusion: There
is no major association between SERT genotype and GERD in general, nor with characteristics
of the reflux disease itself. This suggests that the pathophysiological mechanism which leads
to GERD and GER symptoms could be located in another signalling pathway.
M2033
Prevalence of Nocturnal Heartburn and Night-Time Reflux in Patients with
Non-Erosive Gastroesophageal Reflux Disease and Erosive Esophagitis
Jose M. Remes-Troche, Maribal Gonzalez-Gutierrez, Mariel Mejia, Ana T. Abreu y Abreu,
Jose A. Chavez-Barrera, Miguel A. Valdovinos
Background/Aim: Sixty to 70% of GERD patients report night-time symptoms. Nocturnal
heartburn (NH) interferes with sleep and impairs quality of life. Night-time reflux (NTR)
has been associated with increased prevalence of GERD complications. The information
regarding NH and NTR is limited, and there are no studies that address the frequency of
these conditions in the different groups of GERD. Our aim was to evaluate the prevalence
of NH and NTR according to the clinical variants of Non-Erosive GERD (NERD) and erosive
esophagitis (EE). Material and Methods: Consecutive patients with symptomatic GERD were
evaluated from January to June 2005. Esophageal mucosal injury was assessed by upper
endoscopy. All patients underwent esophageal 24-h pH monitoring. NH was defined as
presence of symptoms at night and in supine position. Abnormal pH was considered when
total % of time of pH<4 was >4.2%. Abnormal NTR was defined as a % of time of pH<4
>1.2% at night. A symptom index (SI) > 50% was considered as positive (+). Patients were
classified in 4 groups: I) Erosive esophagitis, II) NERD with abnormal 24-h pH, III) NERD
with normal 24-h pH,+SI, and IV) NERD with normal 24-h pH,-SI. Data were analyzed
with Mann-Whitney U, Kruskal-Wallis and χ2 tests. Results: 83 patients, 66 F (81%) with
a mean age of 45 years (range 20-75) were included. Distribution of patients according
groups was: 26 (I), 14 (II), 7 (III) and 36 (IV). Overall prevalence for NH and NTR was
53% (n=44) and 54% (n=45), respectively. There was no correlation between NH and NTR
(p>0.05).Only 21 of 45 patients with NTR had NH. There was no difference in the prevalence
of NH between groups (p>0.05). However, prevalence of NTR, total reflux episodes, nocturnal
reflux episodes, and % of pH<4 in the night were significantly higher in groups I and II
(Table). Conclusions: Prevalence of NH is similar in the different groups of GERD patients.
Despite this high prevalence (53%), there was no correlation between symptom perception
and abnormal acid esophageal exposure during the night. However, patients with EE and
NERD with abnormal 24h-pH had an increased prevalence of NTR compared with the other
groups. These findings suggest that other mechanisms besides acid reflux contribute to
nocturnal symptoms in GERD.
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Determinants of Proximal Extent of Gastroesophageal Reflux: Esophagitis,
Acidity and Viscosity of the Refluxate
Sara Emerenziani, Michele Cicala, Xin Zhang, Mentore Ribolsi, Renato Caviglia, Michele
Pier Luca Guarino, Daniel Sifrim
Proximal extent of reflux (PER) is a determinant of symptom elicitation in GERD patients.
The volume of the refluxate could affect PER, however, other factors i.e mucosal inflammation
and/or physical characteristics of the refluxate might be involved. Weakly acidic reflux,
likely more viscous than acid reflux, is less perceived by patients. We evaluated proximal
extent of reflux in the presence or absence of esophagitis both in patients with GERD and
in an animal model of acute esophagitis and compared proximal extent of acid versus weakly
acidic reflux in humans as well as more or less viscous refluxates in the animal model.
Methods: We measured proximal extent of reflux during 24-hr ambulatory esophageal pH-
impedance monitoring in 17 patients with esophagitis (grade I =10, grade II =7), 27 patients
with NERD and 10 asymptomatic controls. In 6 adult cats, reflux events were simulated by
fast intraesophageal retrograde injection (via a percutaneous gastrostomy) of a radiopaque
solution of increasing viscosity [0, 0.5 and 1% of metilcellulose (MC)]. Proximal extent of
simulated reflux was fluoroscopically assessed before and after acute esophagitis (0.1N HCl,
perfusion, 80minutes). Results: Esophagitis was associated with higher proximal extent of
reflux both in patients and cats. Compared to acid reflux, weakly acidic reflux showed a
lower proximal extent in patients and controls (table). In cats, the most viscous solution
(1%MC) had the lowest proximal extent and reached the proximal esophagus significantly
slower. Conclusions: Esophagitis, irrespective of refluxate volume, is associated with PER.
Weakly acidic and more viscous refluxates are characterized by lower proximal extent and
slower migration.
M2035
Significant Enhancement of Salivary Protective Components in Males with
Chronic Heartburn Symptomatology: A New Insight Into the Balance Between
Aggressive Factors and Protective Mechanisms
Tomasz Jaworski, Marek Majewski, Irene Sarosiek, Stanley Edlavitch, Grzegorz Wallner,
Richard W. McCallum, Jerzy Sarosiek
Salivary glands elaborate a plethora of protective components that are instrumental in the
maintenance of the integrity of the esophageal mucosa. Gender-related differences in the
rate of gastric acid secretion are well established. Is the rate of secretion of salivary protective
components in patients with chronic symptoms of heartburn also affected by gender, remains
to be established? Aim: To measure inorganic and organic salivary protective components
in basal conditions, during mastication as well as intraesophageal stimulation in patients
with chronic GERD symptoms of both genders. Methods: The study was approved by HSC
at KUMC and conducted in patients with chronic symptoms of heartburn (26F & 12M;
mean age of 41, 23-61 range). Subgroups of M & F were comparable in terms of mean age
and symptomatology. The samples of saliva were collected basally, during mastication as
well as during the esophageal mechanical (tubing & balloons) and chemical (perfusion with
NaCl followed by HCl/pepsin and final NaCl) stimulation to mimic the natural gastroeso-
phageal reflux scenario, using a specially designed esophageal perfusion catheter (Wilson-
Cook Med.). In salivary samples their volume and the content of salivary buffers, protein,
mucin, EGF, TGFα, and PGE2 were measured using commercial assays. Collected data were
analyzed using SPSS statistical software. Results: The rate of salivary secretion among males
was 79% (P<0.01), 44% (P<0.02), and 51% (P<0.05) higher in basal conditions, mastication,
and intraesophageal mechanical stimulation respectively. Salivary bicarbonate secretion
among males was 191 % higher (P<0.02) during basal conditions whereas salivary non-
bicarbonate buffers were 71% higher (P<0.01) in basal conditions and 38% higher (P=0.05)
during intraesophageal mechanical stimulation. The rate of salivary mucin secretion in males
was 134% higher (P<0.01) in basal conditions and 62% higher (P<0.01) during mastication.
Salivary TGFα in males was also 66% higher (P<0.05) during mastication. Conclusions: 1.
Significantly higher rate of secretion of salivary inorganic and organic protective components
among males may represent a gender driven phenomenon or compensatory mechanisms
resulting from esophageal mucosal exposure to stronger acid from the gastric secretion. 2.
The role of these protective components in prevention of injury and healing of mucosal


















Experience from the Progerd Study Suggests That GERD Is Not a Categorical
Disease
Joachim Labenz, Michael Kulig, Marc Nocon, Stefan Willich, Daniel Jasperson, Andreas
Leodolter, Tore Lind, Wolfgang Meyer-Sabellek, Michael Vieth, Manfred Stolte, Peter
Malfertheiner
Background: There is controversy as to whether GERD exists as a spectrum of disease severity
or as a categorical disease in three distinct groups: non-erosive (NERD) and erosive (ERD)
reflux disease and Barrett’s esophagus (BE). Aim: To assess whether there is progression or
regression of GERD over 2 years in a large cohort of patients (ProGERD) under routine
clinical care in Germany, Austria and Switzerland. Method: Patients with predominant
heartburn with or without esophagitis were recruited and classified according to endoscopic
status at baseline ie. NERD, ERD-LA grade A/B and -LA grade C/D, and BE. After initial
treatment with esomeprazole, they were followed, regardless of their response, and any
medical therapy or endoscopy was instituted at the discretion of their primary care physician.
At two years, endoscopy with biopsy was performed according to the protocol. Results: The
proportions of patients (excluding those with confirmed BE at baseline) who progressed or
regressed or remained the same in their GERD classification after 2 years were calculated
(see table). At this timepoint, 22% of patients had been off medication for at least 3 months.
Patients with ERD-LA grade C/D were at greatest risk of developing BE: 5.8% compared
with 1.4% for A/B and 0.5% for NERD. Conclusion: GERD does not seem to be a categorical
disease. Progression and regression between grades was observed in this large cohort of
patients under routine clinical care.
M2037
The Relevance of Helicobacter Pylori Eradication to Reflux Esophagitis
Satoru Yagi, Hiroyuki Okada, Ryuta Takenaka, Yoshiro Kawahara, Masatsugu Miyoshi,
Humiya Yoshinaga, Tatsuya Toyokawa, Jiro Miyaike, Atsushi Imagawa, Eiichiro Yumoto,
Akiko Hujiwara, Yasushi Shiratori
Objectives: We analyzed the incidence of reflux esophagitis, and the change in the grade
of pre-existing reflux esophagitis after Helicobacter pylori (H.pylori) eradication in correlation
with the patient’s factors.Methods: A total of 1030 Japanese patients, who were estimated
the grade of reflux esophagitis according to the Los Angeles (LA) classification before and
after H.pylori eradication therapy, were enrolled in this study Results: There was no esophagitis
before H.pylori eradication therapy in 970 of the 1030 patients. H.pylori was eradicated in
806 (83.1%) of them while 164 (16.9%) patients had treatment failure. Reflux esophagitis
developed after H.pylori eradication therapy in 67 (8.2%, LA classification A/B/C/D = 42/
22/2/1) of the 806 patients who had successful therapy and 7 (4.3%, LA classification A/
B/C/D = 6/0/1/0) of the 164 patients with persistent infection. The incidence of reflux
esophagitis tended to be higher among the patients cured of infection (p = 0.07). We also
investigated the effects of sex, age, basal disease, the existence of hiatus hernia, and successful
H.pylori eradication on the incidence of reflux esophagitis. In the Cox’s proportional hazards
model, the male sex and hiatus hernia were significant risk factors for the development of
reflux esophagitis. Forty eight (80.0%) of the 60 patients with pre-existing reflux esophagitis
had successful H.pylori eradication therapy, and 12 (20.0%) patients had treatment failure.
The grade of reflux esophagitis worsened in 8 (16.7%) of the 48 patients who had successful
therapy and in 1 (8.3%) of the 12 patients with persistent infection. Reflux esophagitis was
improved in 22 (45.8%) of the former 48 patients and 5 (41.7%) of the latter 12 patients.
There was no significant difference between the patients cured of infection and the patients
with persistent infection in the change of the grade of pre-existing reflux esophagitis. In the
Cox’s proportional hazards model, none of the items mentioned above had a significant
influence on the worsening or improvement of pre-existing reflux esophagitis.Conclusion:
The incidence of reflux esophagitis tended to be higher among the patients who had successful
H.pylori eradication therapy. The male sex and existence of hiatus hernia were significant
risk factors for the development of reflux esophagitis.
M2038
Is Eradication of H. Pylori Infection Ever Followed By GERD? A Meta-Analysis
Mohammad Yaghoobi, Yuhong Yuan, Richard H. Hunt
Background: Some studies suggest that eradication of H. pylori (Hp) might cause reflux
symptoms or erosive esophagitis (EE) in a proportion of patients. We aimed to investigate
whether eradication of Hp infection is associated with the development of erosive esophagitis.
Methods: A comprehensive English literature search was performed using PubMed from
1983 to August 2005 based on the keywords: H pylori, (o)esophagitis, reflux, heartburn,
peptic ulcer, proton pump inhibitor (and individual commercial names of PPIs). 438 potential
articles were reviewed. Only RCTs and prospective cohort studies comparing the prevalence
of heartburn or erosive esophagitis (free from EE at baseline) in patients with Hp eradication
versus those with persisted Hp were included. Only ITT data was used. Quality of studies
was assessed by Jadad score. Meta-analysis of pooled odds ratio (fixed model) was performed
using Review Manager 4.2. Results: Four RCTs (n=1594) and four cohort studies (n=1194)
in patients with duodenal ulcer (DU) as well as 3 RCTs (n=1405) and one cohort (n=125)
in dyspeptic patients using endoscopic diagnosis of EE as the endpoint were included. We
also included 5 RCTs (n=1422) in dyspeptic patients using development of heartburn as
the endpoint. Test of heterogeneity was not significant for all following analyses. With meta-
analysis of all RCTs, there was no association between Hp eradication and development of
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newly diagnosed GERD [OR=1.05 (CI: 0.89-1.23), P=0.57]. Similarly, there was no associ-
ation in dyspeptic patients assessed either endoscopically [OR=0.96 (CI: 0.74-1.24), P=0.74]
or symptomatically [OR=1.03 (CI: 0.82-1.29), P=0.80]. However, when analyzing studies
in DU patients separately, the prevalence of EE in patients cured of Hp infection was
consistently higher than in the control group in both cohort and RCT meta-analysis. There
was no significant difference in length of follow-up between cohort studies and RCTs. In
cohort studies, the average prevalence of new diagnosis of GERD (40.0%) in patients with
Hp eradication was significantly higher than in the control group (16.4%) [OR=1.98 (CI;
1.39-2.88), P=0.0004]. In RCTs, the rate was 6.3% (n=55) in eradication group and numeric-
ally higher than the control group (3.4%) [OR=1.58 (CI; 0.96-2.61), P=0.07]. Conclusion:
There is no association between Hp eradication and development of new cases of GERD in
the population of dyspeptic patients. However, in cohort studies, there appears to be a risk
of development of EE by 1.5-2.0 folds in patients cured of DU. The effect in RCTs increased
but non-significantly and this could be partly due to the small number of EE cases in
study groups.
M2039
Relevance of Liquid-Gas and of Weakly Acidic Reflux in Non Erosive Reflux
Disease
Sara Emerenziani, Xin Zhang, Mentore Ribolsi, Renato Caviglia, Michele Pier Luca
Guarino, Daniel Sifrim, Michele Cicala
The mechanism underlying symptoms in patients with GERD, particularly in non erosive
reflux disease (NERD), is not completely known. Weakly acidic reflux and presence of gas
in the refluxate could be relevant in the pathogenesis of NERD and it has been reported
that balloon distension of the oesophagus may induce symptoms of heartburn and chest
pain. AIM of this study was to assess the symptom association of weakly acidic, acid and
mixed (liquid + gas) reflux, in NERD patients compared to a group of erosive reflux disease
(ERD) patients. METHODS: Following a 3-week washout from PPI or H2 antagonists, 24-
hour ambulatory esophageal pH-impedance monitoring was performed in 22 NERD patients,
without history of erosive disease, and in 20 ERD patients (grade I n=12, grade II n=8).
Upper endoscopy was performed in all patients 3 to 11 days before pH-impedance. Reflux
was classified as acid (pH drop below 4), weakly acidic (nadir pH between 4 and 7) and
weakly alkaline (impedance drop without pH change below 7). Pure liquid reflux and mixed
reflux were defined according to published criteria. Heartburn and acid regurgitation were
considered in the analysis of symptoms. RESULTS: Weakly acidic refluxes were about 30%
of all refluxes in patients and nearly 2/3 occurred in post-prandial periods. Gas was present
in 40-50% of reflux in all study groups. 19 NERD patients reported 231 symptoms during
the study day [mean 9 (range 1-23)], 13 ERD patients reported 72 symptoms [4 (1-16)].
Out of the symptoms, heartburn was reported in nearly 70%, regurgitation in nearly 30%
of cases. In NERD patients, of all symptomatic refluxes (n=150), 17% were weakly acidic
whereas 83% were acid (vs 6% weakly, 94% acid in ERD patients). Multivariate logistic
analysis showed that the risk of reflux perception was very high when gas was present in
the refluxate (odds ratio: 1.7; 95% confidence interval: 1.1-2.8, p<0.01), being maximal in
patients (n=7) with normal acid exposure time (odds ratio: 2.5; 95% confidence interval:
1-6.1 vs 1.2; 95% CI: 0.7-2, p:ns in ERD patients). CONCLUSIONS: In all patients, the
great majority of symptoms are related to acid reflux. In NERD patients, presence of gas in
the refluxate significantly increases probability of reflux perception. NERD patients are more
sensitive to less acidic reflux than ERD patients. These findings could play a role in the
reduced response to PPI treatment, frequently observed in these patients.
M2040
Is the Postprandial Acid Pocket At the Gastro-Esophageal Junction Associated
with a Bile Pocket?
Raf Bisschops, Daniel Sifrim, Rita Vos, Jozef Janssens, Jan Tack
Gastro-oesophageal reflux (GOR) typically occurs postprandially and is more pronounced
in the distal oesophagus. Fletcher et al (2001) have previously established that a pocket of
highly acidic gastric juice is present at the gastro-oesophageal junction (GOJ) after intake
of a solid meal in healthy volunteers. Bilitec® studies have established that GOR often
consists of a mixture of acid and bile, and that duodeno-gastric bile reflux is a physiological
postprandial event. It is unclear how refluxed bile is distributed in the stomach after a meal.
The aim of the current study was to investigate whether the postprandial acid pocket is
associated with a bile pocket in healthy volunteers. Methods: 16 healthy volunteers under-
went dual pH electrode and Bilitec® probe stepwise pull-through (1cm/min, LES-10 to
+5cm) to measure regional difference in pH and bile absorbance before and 10, 30 and 50
min after a liquid meal (200 ml Nutridrink®, 300 Kcal). LES position was determined
preprandially with pull-through manometry. Results: Preprandial intragastric pH was signi-
ficantly lower than the oesophageal pH (1.89±0.09 vs 5.26±0.22, p<0.0001). After the meal
pH in the gastric body was increased to 5.18±0.39 (p<0.001). During pull-through, a
significant pH drop of on average 1.8 units (p< 0.05), was present between LES-2 and
+2cm, 10 minutes after the meal. A similar pattern was found after 30 and 50 mins with
a significantly lower pH at LES-1cm and at the level of the LES (pH drop 1.26 and 1.45
resp., p<0.05). The averaged preprandial Bilitec® pull-throughs (n=14; 2 failures) did not
show a significant variance in the proximal stomach. Postprandial gastric bile content was
elevated compared to preprandially (absorbance 0.08±0.002 vs. 0.11±0.003, p<0.0001),
and Bilitec® tracings displayed a small but non-significant absorbance drop at the level of
the acid pocket. Analyses of individual tracings showed the presence of a “bile pocket”
(segmentary rise in Bilitec® absorbance>0.14) on 11 of the 42 (26%) successful Bilitec®
pull-throughs in 8 subjects (57%).The majority of the “bile pockets” (7/11) were situated
2 cm distal to the acid pocket; 3/11 coincided with the acid pocket and 1/11 was situated
2 cm proximal to the acid pocket. Conclusion: We confirmed the presence of a postprandial
acid pocket at the GOJ in healthy volunteers. In half of the healthy subjects this was
accompanied, at least transiently, by the presence of a “bile pocket”. Studies in patients will
be needed to confirm whether a synergistic action of acid and bile may contribute to the
pathogenesis of GERD related distal oesophageal lesions.
M2041
Impedance Monitoring (Imp) Shows That Body Position and Fasting Influence
Reflux Composition
Steven Shay
Introduction: Imp is the only method that can determine if reflux composition is liquid-
only, gas-only, or both liquid and gas. Aim: Assess with Imp the effect of posture and of
a meal on reflux composition in different groups. Method: Nineteen patients with typical
GERD symptoms either with (n=10) or without esophagitis (n=9) and 10 normal volunteers
underwent Imp (6 sites: 3,5,7,9,15,17 cm above LES) simultaneous with manometry and
pH (5 cm above LES). The 2-hr study consisted of three 40-min intervals, each 10-min left
recumbent, 10-min right recumbent, and 20-min upright. One interval was fasting, and
two intervals postprandial. Reflux events (RE) were defined by Imp as a retrograde fall
(liquid) or rise (gas) in Imp >50% from baseline in at least the two distal sites. Results:
Reflux composition in the right recumbent posture was liquid-only near exclusively (93%).
In stark contrast, 85% of RE’s in the left recumbent posture and 74% of RE’s in the upright
posture were gas-only or both liquid and gas (see figure, p<.001). There were more gas-
only RE’s fasting (80%, p<.01) vs postprandial as expected, though 26/30 fasting RE’s in
the right recumbent posture were liquid-only. The proportion of RE’s that were liquid-only,
gas-only, and both liquid and gas was similar in the 3 study groups and the two postprandial
intervals (all p>.25). Conclusions: 1) In contrast to the left and upright postures, RE’s in
the right recumbent posture are nearly all liquid-only, even fasting. 2) RE’s fasting are more
likely gas-only than postprandial RE’s. Implication: Different posture and fasting times may
partially explain variations in acid exposure during prolonged pH monitoring.
M2042
Facilitating Mechanisms for Gastroesophageal Reflux (GER): Evidences for
Uneven Mixing of Gastric Juice and Food Content
Bermudez Jimena, Raul G. Yazigi, Pruzzo Rossana, Morales Barbara, Monica Pena
INTRODUCTION: GER is a frequent condition, not yet fully understood. Post prandial
reflux may be an important symptom. There have been suggestions of an acid “pocket” in
the cardial region and regional differences in postprandial acidity. Parietal cells exhibit
Technetium (Tc-99m) uptake and later secrete it into the lumen. OBJECTIVES: To demon-
strate that the mixture of swallowed food and gastric juice is not homogeneous and identify
the area of higher concentration of postprandial acid. MATERIAL AND METHOD: After
approval of the Ethics Committee a prospective SPECT study of 11 consenting healthy
subjects (4 females, 7 males), mean age 27 years (19-35), using Tc-99 as a marker of parietal
cell area and later of acid secretion. After an 8 hr. fast, Tc-99 was injected IV. Scans in the
supine position were performed at 10, 17 and 24 minutes later. (The scanner did not allow
for scans in the upright position). The first scans define the gastric parietal cell area. Additional
recordings register acid secretion in this same area. At the 17th min. 575 ml of a liquid
meal (ENSURE™, Abbott Laboratories) was drank. Two areas of interest were defined
(proximal and mid third of the corpus of the stomach), quantifying the counts and pixels
in each area. ANOVA and Student t test were used for statistical analysis. RESULTS: Both
the anterior and posterior halves of the gastric proximal third in transaxial projections
showed a statistically significant higher counts and pixels, with even higher activity in the
anterior upper third; range 1.3-2.4 (1.64;SD=0.27). In the middle third no significant
difference was found. The highest concentration of isotope (Tc-99m+acid secretion) was
found in the lesser curvature. CONCLUSION: Uneven mixture of a liquid meal and an
isotope in the supine position is demonstrated, confirming an acid pocket at the gastroeso-
phageal junction. Solid meals and prone position should exaggerate the differences.
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M2043
Shortening of the Abdominal Component of the Lower Oesophageal Sphincter
Following a Meal
Jonathan J. Manning, Angela Wirz, Kenneth E. McColl
Introduction: There is a high prevalence of intestinal metaplasia and inflammation of the
gastric cardia in H. pylori negative healthy subjects. This may represent relaxation of the
distal (abdominal) portion of the lower oesophageal sphincter (LOS) and consequently,
gastric juice damaging the most distal oesophageal squamous mucosa. The LOS is under
most strain following a large meal. Aim: To study the effect of a large meal on the LOS of
healthy volunteers. Method: 15 healthy volunteers (8 male), all Helicobacter Pylori negative
by breath test, attended fasted on 3 separate occasions. Initially, a gastro-oesophageal pH-pull-
through profile was performed. Baseline slow motorised pull-through (SMPT) manometry was
then performed, during quiet respiration, with a standard water-perfused manometry system.
The subject was then given a battered fish and chip meal, with a glass of still water to drink.
The SMPT was repeated 5 minutes following the meal. Recordings were analysed from the
4 distal manometry channels. Pooled data was analysed (n=45), each subject acting as their
own control. Distances quoted are means and are measured from the nares. Results: Following
the meal the total length of the LOS reduced from 4.94cm to 3.48cm (p<0.0001). The
upper border position did not change. The respiratory inversion point (RIP) elevated from
44.76cm to 44.17cm (p<0.0001). The lower border of the LOS elevated from 47.63cm to
45.98cm (p<0.0001). The thoracic portion of the LOS reduced from 2.1cm to 1.7cm
(p<0.0001). The abdominal portion of the LOS reduced from 2.87cm to 1.80cm (p<0.0001).
The maximum end expiratory pressure reduced from 24.5mmHg to 21.2mmHg (p<0.04)
and the intragastric pressure increased from a baseline of 0mmHg to 4.9mmHg (p<0.00001).
Discussion: This study demonstrates shortening of the LOS after a meal due to shortening
of the abdominal sphincter. There is also a small but significant shortening of the thoracic
sphincter. As there is no movement of the upper border of the LOS, excluding shortening
of the oesophagus, but there is movement of the RIP proximally, this probably reflects a
mild elevation of the diaphragm caused by gastric distension. At only 6mm this is likely to be
missed if studied by x-rays and radio-opaque clips. Conclusion: Shortening of the abdominal
segment of the LOS following a large fatty meal will predispose to gastric acid reaching and
damaging the squamocolumnar junction. This may explain the high prevalence of carditis
and intestinal metaplasia at this anatomical site.
M2044
Gastroesophageal Reflux Disease, But Not Helicobacter Pylori Infection Leads
to Major Changes of Lectin Staining Patterns in Chronically Inflamed Cardiac
Mucosa
Helmut Neumann, Thomas Wex, Michael Vieth, Ulrich Peitz, Albert Roessner, Peter
Malfertheiner
Background: Lectins are carbohydrate binding proteins which are ubiquitously expressed
in nature. Commonly, plant and invertebrate lectins specifically bind defined carbohydrate
structures, and therefore are commonly used as glycohistochemical tools for the analysis of
normal and altered structures of glycans in histology and pathology. Aim: To investigate
the staining patterns of the lectins UEA-I (binding to alpha-L-Fuc), DBA (alpha-D-GalNAc),
HPA (D-GalNAc) and PNA (D-galactosyl-N-acetylgalactosamine) in cardiac and esophageal
mucosa in context to the existence of gastroesophageal reflux disease (GERD) and Helicobacter
pylori (HP) infection. Methods: In total, about 300 consecutive patients were initially investig-
ated by endoscopy and characterized by histopathology and clinical aspects. The presence
of autoimmune gastritis or corpus-predominant HP-gastritis were exclusion criteria. After
complete clinical work-up and an unequivocal presence of HP-infection or GERD without
Barrett’s mucosa, 87 patients were stratified into four subgroups concerning both etiologies.
Furthermore, 33 unrelated GERD patients with histologically proven Barrett’s esophagus
(GERD+BE) were investigated. The staining pattern of lectins was assessed by immunohisto-
chemistry in paraffin-embedded samples of cardiac and esophageal mucosa. Stainings were
semiquantitatively evaluated using the Remmele score. Primary data were statistically analyzed
by non-parametric Mann-Whitney U test. Results: UEA-I binding was increased in the
stratum superficiale of GERD+BE compared to those with GERD (P<0.02), whereas the
staining of all other lectins were unchanged in squamous epithelium among all subgroups.
Major differences were identified for the binding of lectins to basal and superficial glands
of cardiac mucosa in patients with GERD and GERD+BE compared to patients with HP or
controls. HPA binding was increased in basal glands (P<0.02), whereas UEA-I and PNA
staining of this compartment was decreased (P<0.001, P<0.04, respectively). In addition,
superficial glands of cardiac mucosa revealed a decreased binding of DPA (<0.001) and
UEA-I (P<0.001). Conclusion: In general, GERD (with and without Barrett’s mucosa) is
associated with major changes in the lectin binding to cardiac mucosa implying molecular
differences in glycosylation patterns or in the expression of glycoproteins. Since HP infection
did not affect lectin staining in cardiac samples, the lectins PNA, DBA, UEA-I and HPA
might be useful for differentiating histological changes in chronically inflamed carditis with
respect to both etiological factors (HP-infection and GERD.
M2045
Role of Aracidonic Acid Metabolism in Rat Acid Reflux Esophagitis
Tsuyoshi Hayakawa, Yasuhiro Fujiwara, Masaki Hamaguchi, Takashi Sugawa, Masatsugu
Okuyama, E.J. Sasaki, Toshio Watanabe, Kazunari Tominaga, Nobuhide Oshitani,
Kazuhide Higuchi, Tetsuo Arakawa
Background: Eicosanoids, products of aracidonic acid metabolism play roles in various
inflammatory events. Their roles in pathogenesis of gastroesophageal reflux disease are
unknown. Aims: We examined dynamics of cyclooxygenase (COX), prostaglandin E synthase
(PGES), 5-Lypoxygenase (LOX), Leukotriene (LT) A4 hydrase and, synthetic activity of PGE2
and LTB4 to determine aracidonic acid’s metabolism in rat acid reflux esophagitis. Methods:
Acid reflux esophagitis was induced in 9 week-old Wistar rats by ligating the transitional

















near the pylorus. Rats were killed on day 3 (acute phase) and day 21 (chronic phase) after
induction of esophagitis. Esophageal proliferation was assessed by PCNA staining. Protein
and mRNA expression by western blotting or immunohistochemistry and real-time RT-PCR.
LTB4 and PGE2 synthesis were assessed by EIA. To determine role of COX-2 in esophagitis,
rats were given subcutaneouly with celecoxib or nimesulide (10 mg/kg/day). Results: Expres-
sion of COX-2, microsoml PGES (mPGES)-1 was markedly increased in esophagitis, while
modest changes in COX-1, cytosolic PGES (cPGES), mPGES-2 expression were observed.
COX-2 and mPGES-1 were co-localized in epithelial cells of basal layer, and inflammatory
and mesenchymal cells in lamina propria and submucosa. PGE2 synthesis of esophageal
lesions was significantly increased. COX-2 inhibitors significantly reduced severity of chronic
esophagitis but not affect acute esophageal lesions. COX-2 inhibitors significantly inhibited
increase in PGE2 synthesis of esophageal lesions both on day 3 and day 21. Expression of
5-LOX and LTB4 synthesis were slightly increased in esophagitis. Epithelial proliferation on
day 21 was significantly increased in the basal layer. Conclusion: Eicosanoid, especially
PGE2 derived from COX-2 and mPGES-1, plays a significant role in pathogenesis of chronic
acid reflux esophagitis.
M2046
A Study of Bile Exposure Immediately Above the Gastro-Oesophageal Junction
in GERD Patients
Raf Bisschops, Daniel Sifrim, Toon de Greef, Rita Vos, Jozef Janssens, Jan Tack
Lesions in patients with gastro-oesophageal reflux disease (GERD) are thought to arise
from a synergistic action of acid and duodeno-gastro-oesophageal reflux (DGER). Reflux is
traditionally monitored 5 cm above the gastro-oesophageal junction (GOJ), but the majority
of patients with erosive oesophagitis or Barrett’s oesophagus display endoscopic lesions
closer to the GOJ. Recently, an increased acid exposure and number of acid reflux events
have been demonstrated 1 cm proximal to the GOJ in non-erosive GERD (Fletcher 2004).
The aim of the current study was to investigate DGER exposure 1 cm proximal to the
GOJ in suspected GERD. Methods: 18 consecutive patients with typical GERD symptoms
underwent upper endoscopy followed by simultaneous Bilitec® and pH monitoring. The
tip of the Bilitec probe was clipped 1 cm above the GOJ during endoscopy. A pH catheter
was positioned conventionally 5 cm above the GOJ. Study patients were compared to an
age-, sex- and endoscopy-matched control group who underwent conventional combined
24 hour pH and Bilitec monitoring at 5 cm. Values are given as mean±SEM and compared
with unpaired Student’s t test or Mann-Whitney test. Results: In both groups, 3 patients
had grade A oesophagitis and 1 had grade C (L.A.), and acid exposure time (3.4±1.0 vs.
6.0±2.3% of time, NS) and number of acid reflux episodes (48±13 vs. 50±8, NS) did not
differ between study and control patients. For the entire patient group, DGER exposure
time (absorbance>0.14) was similar at 1 cm or 5 cm above the GOJ (15.4±5.8 vs. 15.7±5.4%
of time, NS), but the number of DGER episodes was significantly higher at 1 cm (53±14
vs. 17±15, p<0.05). Furthermore, in patients with pathological acid exposure at 5 cm, a
significantly higher number of DGER episodes was detected at 1 cm ( 87±36 vs. 19±6.5,
p<0.05) and DGER exposure time tended to be higher (28.2±13.8 vs. 6.2±2.2% of time,
p=0.07). In patients without pathological acid exposure at 5 cm, the difference in DGER
episodes at 1 or 5 cm did not reach significance (40±13 vs. 15±4 respectively, NS). There
was no significant difference in DGER exposure between erosive and non-erosive GERD.
The difference in number of DGER episodes at 1 cm in patients with or without pathological
acid exposure did not reach statistical significance (87±36 vs. 40±13, NS). Conclusion: The
distal oesophagus is exposed to significant high levels of bile reflux in patients with patholo-
gical acid exposure on conventional pH testing. The observations that both acid and bile
reflux are more elevated close to the GOJ, is compatible with a synergistic action of acid
and bile in the pathogenesis of GERD related distal oesophageal lesions.
M2047
Duodenogastro-Esophageal Reflux in Children with Refractory Gastro-
Esophageal Reflux Disease
Ilse Hoffman, Toon de Greef, Nancy Haesendonck, Jan Tack
Duodenogastro-esophageal (DGE) reflux is involved in the pathogenesis of refractory reflux
esophagitis in adults. The role DGE reflux plays in gastro-esophageal reflux disease (GERD)
in children has not been addressed in depth. The aim of the study was to investigate acid
and bile reflux in children with refractory GERD. Methods: Twenty two children (12 girls,
mean age 13.2±0.4 years) with GERD symptoms that persisted despite omeprazole (1 mg/
kg) were investigated using upper gi endoscopy, 24 h pH and bile reflux (Bilitec®) mon-
itoring, and a 13C octanoic acid gastric emptying breath test. Results: Patients presented
mainly with epigastric pain (90%), regurgitation (76%) and nausea (67%) followed by
retrosternal pain (38%), night-time pain (33%) and anorexia (29%). Pathological reflux was
confirmed in 86% of patients. Endoscopy revealed persisting grade 1 esophagitis in 8
patients and grade 2 in 4 patients. Esophageal acid exposure and DGE reflux exposure were
pathological in respectively 54 and 62% of the children. Acid exposure did not differ
according to endoscopy findings (4.5±0.8, 7.4±3.7 and 6.2±2.1 % of time respectively in
grade 0,1 and 2, NS). DGE reflux exposure increased with increasing severity of esophagitis
(9.6±1.9, 9.1±5.3 and 26.7±10.9% of time respectively in grade 0,1 and 2, p<0.05). Gastric
emptying did not correlate with endoscopic or reflux monitoring results. Conclusions:
Epigastric pain, nausea and regurgitation are the most common presenting symptoms of
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childhood with refractory GERD. DGE reflux seems to be an important contributor to the
pathogenesis of refractory GERD and esophagitis in children.
M2048
Ecto-Enzymes Carbonic Anhydrase and Alkaline Phosphatase Coordinately
Alter Rat Duodenal Bicarbonate Secretion
Yasutada Akiba, Misa Mizumori, Tetsu Takeuchi, Claudiu T. Supuran, Paul H. Guth, Eli
Engel, Jonathan D. Kaunitz
Duodenal brush border membrane (BBM) has multiple highly-expressed ecto-enzymes,
such as membrane carbonic anhydrase (CA) and intestinal alkaline phosphatase (IAP). The
physiological function of these enzymes, despite their discovery decades ago, is incompletely
understood. Since CA activity affects duodenal bicarbonate secretion (DBS), and since AP
hydrolyzes organic phosphates at alkaline pH, we hypothesized that these enzymes co-
regulate DBS. We examined the effect of CA and AP inhibitors on AP activity in rat BBM
in situ and on DBS in vivo. BBM AP activity was measured in situ in duodenal frozen
sections with the enzyme-linked fluorescent substrate ELF®-97 phosphate using fluorescence
microscopy. Sections were reacted with ELF phosphate (0.1-0.5 mM) in pH 8.6 Tris buffer
at 25 °C for 5 min. ELF fluorescence intensity was measured ± IAP inhibitors L-cysteine,
L-phenylalanine, or sodium tungstate (0.1-10 mM), or the tissue non-specific AP inhibitor
levamisole (0.1-10 mM). We further examined the effects of high (pH 6.4, pCO2 = 206
mmHg) or low (pH 6.4 Tris buffer, pCO2 ≈ 0) CO2 solutions on AP activity ± the cell-
permeant CA inhibitor methazolamide (1 mM) or novel cell-impermeant benzene sulfonam-
ide CA inhibitors (1 μM). DBS through duodenal loop was measured with a pH-stat or
flow-through pH and CO2 electrodes. The loop was perfused with high CO2 solution (pH
6.4, pCO2 278 mmHg) or pH 2.2 saline ± cell-impermeant CA inhibitors (0.1 μM) or AP
inhibitors (10 mM). ELF fluorescence appeared intensely on the BBM of villous cells, and
was low intense in the mucus gel layer. Less activity was recognized in the crypt cells and
no activity in Brunner’s glands. IAP inhibitors dose-dependently inhibited ELF-based AP
activity, whereas levamisole was less effective. Despite low CO2 solution decreased AP activity
due to its pH, the high CO2 solution enhanced BBM AP activity. Surprisingly, CA inhibitors
inhibited the CO2-related augmentation of AP activity. Augmented DBS in response to
perfusion of high CO2 or acid solution was reduced with methazolamide pretreatment,
which inhibits cytosolic CA, whereas cell-impermeant CA inhibitors and AP inhibitors
enhanced the DBS response. In vivo fluorescent microscopy revealed AP activity on the
epithelial surfaces and in the mucus gel. ELF fluorescence enabled us to develop a simple
in situ measurement assay of AP activity in the duodenal mucosa. Interaction between ecto-
CA and IAP suggests that these ecto-enzymes coordinately and negatively regulate DBS,
which may affect juxtamucosal pH regulation. Regulation of DBS represents a novel and
incompletely studied function of IAP.
M2049
Phosphodiesterase Isozymes Involved in Regulation of HCO3- Secretion in
Mouse Duodenum in Vitro
Masamune Hayashi, Kazutomo Kita, Eitaro Aihara, Koji Takeuchi
Background and Aim: The secretion of HCO3- is one of the protective mechanisms in the
duodenal mucosa against acid injury. Prostaglandins (PGs) and nitric oxide (NO) are known
to stimulate duodenal HCO3- secretion both in vivo and in vitro, by increasing intracellular
levels of cyclic nucleotides such as cAMP or cGMP, respectively. We reported previously
that IBMX, the nonselective inhibitor of phosphodiesterase (PDE), potentiated the HCO3-
response to PGE2, yet there is no information about the isozymes of PDE involved in this
process. In the present study, we examined the effects of various isozyme-selective PDE
inhibitors on HCO3- secretion in the mouse duodenum in vitro and investigated which
type(s) of PDE isozymes are involved in the HCO3- response to PGE2 and NO. Methods:
Male DDY mice were used. The duodenal mucosa was stripped of the muscle layers and
mounted on an Ussing chamber. The tissue was bathed in saline gassed with 100% O2 on
the mucosal side and HCO3- Ringer’s solution gassed with 95% O2-5% CO2 on the serosal
side. HCO3- secretion was measured at 7.0. using a pH-stat method and by adding 2 mM
HCl. PGE2 (10-7~10-6 M) or NOR3 (NO donor: 10-4~10-3 M) was added to the serosal
solution. The EP4 antagonist (AE-3-208: 10-6 M) or methylene blue (10-4 M) was added to
the serosal solution 10 min before PGE2 or 30 min before NOR3, respectively, while various
PDE inhibitors (10-7~10-4 M) were applied to the serosal solution 30 min before. The
expression of mRNAs of PDE isozymes was examined by RT-PCR. Results: Both PGE2 and
NOR3 increased the secretion of HCO3- in a dose-dependent manner, and the response to
PGE2 or NOR3 was inhibited by the EP4 antagonist or methylene blue, respectively. IBMX,
a nonselective PDE inhibitor, caused a significant increase of basal HCO3- secretion and
potentiated the responses to both PGE2 and NOR3. Likewise, vinpocetine (PDE1 inhibitor)
and cilostamide (PDE3 inhibitor), either alone at high doses, also stimulated the HCO3-
secretion and significantly potentiated the response to PGE2 at the doses that had no effect
by themselves on basal HCO3- secretion. The HCO3- stimulatory action of NOR3 was
significantly potentiated by vinpocetine but not cilostamide. Other PDE inhibitors, including
PDE2, PDE4 and PDE5, had no effect on the HCO3- secretion under both basal and stimulated
conditions. RT-PCR analyses revealed the expression of PDE1 and PDE3 mRNAs in the
duodenal mucosa. Conclusion: These results suggest that both PDE1 and PDE3 are involved
in the regulation of duodenal HCO3- secretion and that the response to PGE2 is associated
with both PDE1 and PDE3 while the response to NO is mainly modulated by PDE1.
M2050
Phosphodiesterase Isozymes Involved in Regulatory Mechanism of Gastric
HCO3- Secretion
Yoko Nomura, Masamune Hayashi, Kazutomo Kita, Eitaro Aihara, Koji Takeuchi
Background and Aim: Gastric HCO3- secretion is stimulated by both prostaglandin E2
(PGE2) and nitric oxide (NO), mediated intracellularly by Ca2+ and cyclic 3',5'-guanosine
monophosphate (cGMP), respectively. We previously reported that NOR-3, the NO donor,
increased HCO3- secretion in rat stomachs while forskolin the stimulator of adenylate cyclase
or pituitary adenylate cyclase activating peptide did not, suggesting an involvement of
cGMP in gastric HCO3- response. However, there is no information about the isozymes of
phosphodiesterase (PDE) involved in this process. In the present study, we examined the
effects of various isozyme-selective PDE inhibitors on the secretion of HCO3- in rat stomachs
in vivo and mouse stomachs in vitro, and investigated which type(s) of PDE isozymes are
involved in the HCO3- response to NO. Methods: Male SD rats and Male DDY mice were
used. The rat stomach mounted on an ex-vivo chamber was perfused with saline, and HCO3-
secretion was measured at pH 7.0 using a pH-stat method. NOR-3 (NO donor, 0.3~3 mg/
ml) was given intraluminally while sildenafil (1~10 mg/kg, intraduodenally) the inhibitor
of PDE5 was given 30 min before NOR-3. The mouse gastric mucosa was stripped of the
muscle layers and mounted on a Ussing chamber, and the tissue was bathed in saline gassed
with 100% O2 on the mucosal side and HCO3- Ringer’s solution gassed with 95% O2-5%
CO2 on the serosal side. The HCO3- secretion was measured at pH 7.0 by a pH-stat method
using 2 mM HCl. NOR-3 (10-4~10-3 M) was added to the serosal solution. Methylene blue
(10-4 M) or various PDE inhibitors was added to the solution 30 min before NOR-3. The
expression of mRNAs of PDE isozymes was examined by RT-PCR. Results: NOR-3 increased
HCO3- secretion in a dose-dependent manner in both rat and mouse stomachs, and the
response to NOR-3 was inhibited by methylene blue. Sildenafil, the PDE5 inhibitor, caused
a significant increase of the secretion of HCO3- and potentiated the response to NOR-3 in
rat stomachs. On the other hand, in the mouse stomach both vinpocetine (the PDE1 inhibitor,
10-4 M) and zaprinast (the PDE5 inhibitor, 10-4 M), but not other PDE inhibitors including
PDE2, PDE3 and PDE4, increased the HCO3- secretion and potentiated the response to
NOR-3 at the dose that had no effect by itself on basal HCO3- secretion. RT-PCR analyses
revealed the expression of PDE1 and PDE5 mRNAs in the mouse gastric mucosa. Conclusion:
These results confirmed that NO stimulates gastric HCO3- secretion mediated intracellularly
by cGMP, and further suggested that this action is regulated by both PDE1 and PDE5.
M2051
Hypoxia, Endothelial Dysfunction and Enhanced Apoptosis Are Key
Mechanisms for Increased Susceptibility of Aging Gastric Mucosa to Ethanol
Injury
Andrzej S. Tarnawski, Rama Pai, Tetsuya Tanigawa, Tomohiko Akahoshi, Jianyuan Chai,
Aihua Li, Eric Chu
Aging gastric mucosa has increased susceptibility to injury and delayed injury healing. The
molecular mechanisms of these phenomena are not fully explained. Methods: We examined
abnormalities of aging (vs. young) gastric mucosa at baseline and following ethanol injury
with focus on hypoxia, endothelial function and apoptosis-related factors. Studies: In 64
Fisher F344 rats, 3 months young and 24 months old (aging), non-treated (baseline) and
2, 8 and 24 hrs after intragastric ethanol administration (8 ml/kg of 50%) we studied: 1)
mucosal histology and ultrastructure (TEM); 2) blood flow with a laser-Doppler and mucosal
hypoxia with specific hypoxy-probe; 3) apoptosis using TUNEL and apoptosis-related genes
using Oligo-microarray; 4) expression of PTEN (negative regulator of PI 3-K/Akt pathway
essential for cell survival), survivin (anti-apoptosis protein) and VEGF; 5) the extent of
macroscopic and histologic mucosal injury and 6) angiogenesis following to injury by
immunostaining and TEM. In in-vitro studies, we examined in human microvascular endo-
thelial cells (HMVEC) derived from aging and young individuals, cells membrane permeability
using LDH assay and cell ability to form tubes. We also examined expression of PTEN and
survivin in gastric mucosa of patients older then 70 years and younger than 40 years.
Results: Aging gastric mucosa at baseline exhibits reduced blood flow (~ 60%; p<0.002);
prominent tissue hypoxia; increased Bax (2.9-fold), caspase-9 (3.6-fold), p53 (2-fold);
decreased survivin (3-fold) and VEGF, and increased apoptosis (all p<0.001 vs. young rats).
Ethanol administration increased gastric mucosal injury in aging rats by ~3.5-fold (p<0.001
vs. young rats) and increased PTEN expression and apoptosis (p<0.001). Injury of gastric
microvascular endothelial cells preceded epithelial damage. At 24 hrs after ethanol injury
in aging rats, angiogenesis in the mucosa bordering necrosis was reduced by 14-fold; p<0.001
vs. young rats. Aged endothelial cells in vitro demonstrated increased LDH leakage and
impaired tube formation. Gastric mucosa of patients > 70 years of age exhibits a significant
increase in PTEN and decrease in survivin expression vs. young patients. Conclusions: 1)
Aging gastric mucosa exhibits at baseline significant hypoxia due to reduced blood flow,
endothelial dysfunction and increased apoptosis; 2) HMVEC from aging patients exhibit
membrane dysfunction, increased PTEN, reduced survivin and increased apoptosis; 3) In
aging gastric mucosa alcohol-induced injury is increased by 350%, endothelial cells of
microvessels are the major targets of injury, and angiogenesis in response to injury is abol-
ished.
M2052
Regulation of HCO3- Secretion in Esophageal Submucosal Glands
Solange M. Abdulnour-Nakhoul, Nazih L. Nakhoul, Scott A. Wheeler, Roy C. Orlando
Introduction: The esophageal submucosal glands (SMG) secrete HCO3- and mucin into the
esophageal lumen, which can contribute to esophageal protection against refluxed gastric
acid. We have previously demonstrated that cholinergic receptor stimulation by carbachol
almost doubles HCO3- secretion in these glands. This secretion is dependent on serosal Cl-
and is mediated by DIDS-sensitive transporters Na (HCO3-)n and Cl- -HCO3-, which we
immunolocalized in the ducts and serous demi-lunes of the glands. This study was undertaken
to further elucidate the pathways that govern HCO3- secretion in this model. Methods: The
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experiments were done on pig esophagi stripped of their muscularis propria and bathed in
HCO3- Ringer solution. HCO3- secretion was measured by cannulating the esophagus at
both ends and recirculating unbuffered saline solution through the lumen to which a pH
stat system was attached. Ion transporters were localized using specific antibodies and
immunofluorescence technology. Results: Basal HCO3- secretion in these tissues ranged
from 0 to 0.2 μEq/hr.cm2. Following serosal addition of forskolin, an adenylyl cyclase
activator, and an activator of the luminal Cl- channel CFTR, HCO3- secretion increased
from 0.03±0.007 to 0.08±0.008 μEq/hr.cm2 (n=6). Serosal addition of the phosphodiesterase
inhibitor, 3-isobutyl-1-methylxanthine (IBMX), which stimulates both cAMP and CFTR also
stimulated HCO3- secretion (0.14±0.01 to 0.22 ±0.01 μEq/hr.cm2, n=6). Genistein, an
activator of CFTR, which does not increase intracellular cAMP, stimulated bicarbonate
secretion from 0.016±0.001 to 0.065±0.004 μEq/hour.cm2 (n=7). Addition of carbachol,
following the use of forskolin, IBMX or genistein, resulted in no further stimulation of
HCO3- secretion. Immunofluorescence using an antibody to Na-K-2Cl showed intense
labeling of the basolateral membrane of mucous and duct cells. Conclusions: SMG HCO3-
secretion in pig esophagus is stimulated by elevation in intracellular cAMP. Na-K-2Cl, a
likely mechanism for Cl- entry into the cell, is present at the basolateral membrane of
mucous and duct cells . Compounds that activate CFTR and hence Cl- secretion cause
similar effects on HCO3- secretion. Support: VA Merit grant
M2053
Phosphatidylinositol-3 Kinase Is Involved in Prostaglandin E2-Mediated
Murine Duodenal Bicarbonate Secretion
Biguang Tuo, Ursula Seidler
Background & Aims: Prostaglandin E2 (PGE2) plays an important role in regulation of
duodenal mucosal bicarbonate (HCO3-) secrtetion. In the present study, we made investi-
gation on signal pathways involved in PGE2-mediated duodenal HCO3- secretion. Methods:
Murine duodenal mucosal HCO3- secretion was examined in vitro in Ussing chambers by the
pH stat in the presence of a variety of singal transduction modulators. Phosphatidylinositol-3
kinase (PI3K) activity was measured by immunoprecipitation of PI3K and ELISA. Results:
PGE2 markedly stimulated duodenal HCO3- secretion. cAMP-dependent signaling pathway
inhibitors MDL-12330A and KT5720 respectively reduced PGE2-stimulated HCO3- secretion
by 22.99% and 19.54%, and the Ca2+-influx inhibitor verapamil by 26%, the calmodulin
antagonist W-13 by 24%, whereas the PI3K inhibitors wortmannin and LY294002 reduced
PGE2-stimulated HCO3- secretion by 51% and 47%, respectively. Neither mitogen-activated
protein kinase (MAPK) inhibitor PD98059 nor tyrosine kinase inhibitor genistein altered
PGE2-stimulated HCO3- secretion. PGE2 application caused a rapid and concentration-
dependent increase in duodenal mucosal PI3K activity. Conclusions: PGE2 stimulates duo-
denal mucosal HCO3- secretion via cAMP-, Ca2+-, and PI3K-dependent signaling pathways,
and the PI3K pathway plays a major role in PGE2-mediated duodenal HCO3- secretion.
This study has therefore revealed a novel signal transduction mechanism for the regulation
of duodenal HCO3- secretion
M2054
Effect of Sparkling Water On HCO3- Secretion in Rat Stomach and Duodenum
Yoko Sasaki, Eitaro Aihara, Yoko Nomura, Fumitake Ise, Koji Takeuchi
Background/Aim: The proximal duodenum is exposed to extreme elevation of PCO2 because
of the continuous mixture of secreted HCO3- with gastric acid. Recent study showed that
luminal CO2 diffused in the duodenal epithelial cells, followed by secretion of HCO3-, the
process being regulated by carbonic anhydrase and dependent on a basolateral Na+/H+
exchanger and endogenous prostaglandins (PGs). However, it remains unknown whether
the same occurs in the stomach. In the present study, we examined the effect of sparkling
water on HCO3- secretion in the rat stomach and duodenum and investigated factors involved
in these responses. Methods: Male SD rats were used after 18 h fasting. Under urethane
anesthesia, a chambered stomach or a duodenal loop was perfused with saline, and the
HCO3- secretion was measured at pH 7.0 using pH-stat method and by adding 2 mM HCl.
The mucosa was perfused with sparkling water (Suntory: pH. 4.5; 7.5 g/L CO2) for 10 min.
Acetazolamide (100 mg/kg), indomethacin (5 mg/kg) or NG-nitro-L-arginine methyl ester
(L-NAME: 10 and 20 mg/kg) was given SC 30 min or 3 h before the treatment while 5-
(N,N-dimethyl)-amiloride (DMA:50 μM) was add to the loop 40 min before. Ablation of
capsaicin-sensitive afferent neurons was achieved by repeated SC injections of capsaicin
(total dose of 100 mg/kg) for 3 days. Effect of Coca-cola (pH 2.2; 7.1 g/L CO2) on the
secretion was also examined. Results: The mucosal perfusion with sparkling water markedly
increased the secretion of HCO3- in both the stomach and duodenum. The HCO3- response
in the duodenum was partly inhibited by indomethacin, acetazolamide or sensory deaffer-
entation, and totally abolished by co-administration of indomethacin and acetazolamide. In
contrast, the HCO3- stimulatory action in the stomach was totally inhibited by acetazolamide
but not by indomethacin or sensory deafferentation. DMA, an inhibitor of NHE1 and NHE2,
partially mitigated the HCO3- response to sparkling water in the duodenum but not the
stomach. Similarly, Coca-cola (pH 2.2, g/L CO2) also increased HCO3- secretion in both
the stomach and duodenum, and the effects were significantly suppressed by indomethacin
as well as acetazolamide. Conclusion: These results suggest that sparkling water induces
HCO3- secretion in both the stomach and duodenum, but the mechanism differs between
these two tissues; the response in the former is mainly due to the intracellular supply of
HCO3- with the aid of carbonic anhydrase, while in the latter the response is mediated by
both endogenous PGs and capsaicin-sensitive afferent neurons, probably related to the acidic


















Lafutidine, a Mucosal Protective H2 Receptor Antagonist, Prevents Acid-Pepsin
Induced Interstitial Acidification in Rat Esophagus
Yasutada Akiba, Jonathan D. Kaunitz
Perfusion of acid in the rat esophageal lumen provokes a hyperemic response, implying that
submucosal acid sensors are activated, although acid penetrates only superficially into the
mucosa. Capsaicin-sensitive afferent nerve (CSAN) is involved in the acid-sensing mechanism
in the duodenum and mediates capsaicin-induced hyperemia, one of important defenses in
esophagus as well. Lafutidine is an H2 receptor antagonist possessing mucosal protective
effects through sensitization of CSAN to acid, producing efferent responses that protect the
mucosa from acid-induced injury in rat esophagus. Lafutidine, however, is not a direct
agonist of acid-sensing TRPV1 receptors. We thus hypothesized that lafutidine enhances
the mucosal protective responses elicited by luminal acid in the esophagus by augmenting
CSAN function. We examined the effects of lafutidine on the regulation of interstitial pH
(pHint) and blood flow (BF) in response to luminal acid and on the acid-pepsin induced
injury in rat esophagus using in vivo fluorescence microscopy. Under isoflurane anesthesia,
the lower esophageal mucosa of rat was exposed and topically superfused with pH 7.0
buffer, pH 1.0 or pH 1.0 pepsin (1 mg/ml) solution with or without lafutidine co-superfusion
(0.1-10 mM). pHint was measured with 5,6-carboxyfluorescein (5 mg/kg) loaded into the
interstitial space of the esophageal mucosa by bolus intravenous injection and BF with laser
Doppler flowmeter. Lafutidine alone dose-dependently augmented BF, and increased pHint.
pH 1.0 solution increased BF, but did not change pHint, whereas pH 1.0 pepsin solution
gradually lowered pHint, consistent with mucosal injury. During pH 1.0 superfusion, pHint
was increased in the lafutidine-perfused rats, whereas sensory denervation using high-
dose capsaicin (125 mg/kg, sc) pretreatment abolished the alkalinizing effect of lafutidine,
acidifying the submucosa. Lafutidine also prevented interstitial acidification by pH 1.0 pepsin
solution and enhanced hyperemia in response to acid perfusion, the effect inhibited by sensory
denervation. Lafutidine activated esophageal CSAN, producing hyperemia and interstitial
alkalinization. The preventive effect of lafutidine on interstitial acidification by acid-pepsin
solution through CSAN suggests that lafutidine enhances the defensive response via acid
sensors on CSAN.
M2056
Effects of Inhibition of Epithelial Ion Transport and Carbonic Anhydrase On
the Regulation of Intracellular pH in Response to CO2 Perfusion in Mouse
Duodenal Villous Cells
Tetsu Takeuchi, Yasutada Akiba, Misa Mizumori, Claudiu T. Supuran, Paul H. Guth, Eli
Engel, Jonathan D. Kaunitz
Epithelial ion transporters and carbonic anhydrase (CA) participate in the regulation of
intracellular pH (pHi) in duodenal villous cells. Luminal acid or elevated luminal pCO2
(CO2 stress) acidifies duodenal epithelial cells in rats. The Na+/H+ exchange-1 (NHE-1)
inhibitor dimethyl amiloride (DMA) or the Na+:HCO3- cotransport (NBC) inhibitor DIDS
enhances cellular acidification, whereas the CA inhibitors methazolamide (MTZ) or ben-
zolamide (BNZ) abrogates acidification in rat duodenum. We examined the effects of these
inhibitors on pHi regulation under CO2 stress in mouse duodenum. Mouse duodenal villous
cells were exposed and loaded with a pH-sensitive fluorescence dye BCECF, and pHi was
measured with in vivo fluorescent microscope. The duodenal mucosa was exposed to high
CO2 solution (pH 6.4, pCO2 260 Torr) with or without DMA (0.1 mM), DIDS (0.5 mM),
MTZ (1 mM), or novel cell-impermeant CA inhibitor positive-charged benzene sulfonamide
compounds (1-10 μM). Furthermore, the expression of membrane-bound CAs (CA IV, IX,
XII and XIV) was investigated in mouse and rat duodenum by immunofluorescence. Perfusion
with the high CO2 solution (CO2 stress) rapidly acidified the cells, followed by pHi recovery
over baseline (overshoot) after CO2 removal. DMA as well as DIDS enhanced CO2-induced
pHi decrease, whereas DMA, not DIDS, delayed pHi recovery and abolished the overshoot.
The cell-permeant CA inhibitor MTZ reduced the acidification during CO 2 stress, but the
cell-impermeant CA inhibitors had no effect on pHi response to CO2 stress. Immunofluoresc-
ence study revealed the basolateral expression of CA IX in mouse villous cells (mouse =
rat), and the apical, less expression of CA XIV (mouse << rat). Augmented acidification by
DMA and DIDS confirms the involvement of the basolateral NHE-1 and NBC in the pHi
regulation in response to CO2 stress in mouse duodenal villous cells. The divergent actions
of DMA and DIDS on pHi recovery and overshoot in mice, in comparison to their effects
in the rat, suggest that NHE-1 is more important than is NBC for pHi regulation in response
to CO2 stress in mice. The results that MTZ reduced, but cell-impermeant CA inhibitors
had no effect on pHi response is consistent with the less expression of the apical CA in
mouse villous cells. These data suggest a marked species difference between rat and mouse
duodenum for pHi regulation by CA and by plasma membrane acid-base transporters.
M2057
Accumulation of the Anti-Apoptosis Protein, Survivin, in Gastric Epithelial
Cells Following Exposure to Low-Dose Ethanol Is Mediated Via Increased
Expression and Activation of Cyclin B1-P34Cdc2: Implications for Adaptive
Cytoprotection Against Gastric Injury
Michael K. Jones, Oscar R. Padilla, Nicole A. Webb
BACKGROUND/AIMS: Survivin confers resistance to apoptosis and we have previously
demonstrated a possible role for survivin in adaptive cytoprotection against ethanol (ETOH)-
induced gastric injury. It is postulated that survivin phosphorylation by the p34cdc2 cell
cycle-dependent kinase stabilizes it against degradation. This study was aimed to determine
the mechanism by which mild irritant ETOH leads to increased survivin levels in the gastric
epithelium and whether this is a key to adaptation against injury. METHODS: Rat gastric
epithelial (RGM1) cells, pretreated with either vehicle alone, survivin antisense siRNA (to
knockdown survivin protein levels), or control siRNA, were first incubated with serum-free
medium alone (control) or serum-free medium containing 1% ETOH and then incubated
in medium containing 6%, 6.5% or 7% ETOH. STUDIES: 1) Total survivin, cyclin B1 and
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p34cdc2 expression levels, and survivin and p34cdc2 phosphorylation levels by Western blot;
2) apoptosis by TUNEL staining; 3) necrosis by MTT and LDH assay. RESULTS: Pre-
incubation of RGM1 cells in medium containing 1% ETOH prior to incubation in medium
containing 6-7% ETOH resulted in increased expression levels of cyclin B1 and total p34cdc2
by 190% (P<0.05) and 85% (P<0.05), respectively, vs. controls. This treatment also resulted
in reduced p34cdc2 phosphorylation (indicating an enhanced activation state) by 250%
(P<0.01), and increased survivin phosphorylation and total expression levels by 98% (P<0.05)
and 170% (P<0.001), respectively, vs. controls. In contrast, these parameters were not
significantly affected when cells were incubated in medium containing 6-7% ETOH without
prior exposure to 1% ETOH. Preincubation in medium containing 1% ETOH also reduced
apoptosis and necrosis, in response to subsequent incubation in the presence of 6-7 %
ETOH, by 83% (P<0.001) and 65% (P<0.01), respectively. The resistance to both apoptotic
and necrotic cell death, as a result of 1% ETOH pretreatment, was significantly reduced
>73% (P<0.05) by survivin siRNA treatment. CONCLUSIONS: 1) Pre-exposure of gastric
epithelial cells to low-dose ETOH leads to activation of cyclin B1- p34cdc2 resulting in survivin
accumulation via phosphorylation/stabilization. 2) Suppression of survivin attenuates the
gastric adaptive cytoprotection provided by pre-exposure to low-dose ETOH against sub-
sequent exposure to high-dose ETOH. 3) Activation of cyclin B1- p34cdc2 in response to
low-dose ETOH likely mediates stabilization/accumulation of survivin resulting in increased
resistance to apoptotic/necrotic cell death that underlies adaptive cytoprotection to the gastric
epithelium. *NIH R01AA14946
M2058
Ghrelin-Induced Gastric Secretory Activity and Gastroprotection Against
Acute Gastric Lesions Involves Increased Expression of Histidine
Decarboxylase (HDC) and Histamine Release
Tomasz Brzozowski, Peter C. Konturek, Zbigniew Sliwowski, Danuta Drozdowicz, Michal
Pawlik, Greg Burnat, Stanislaw J. Konturek, Wieslaw W. Pawlik, Eckhart G. Hahn
Histamine and agonists of histamine H1 and H2 receptors were shown to afford gastroprotec-
tion against ethanol damage, predominantly due to enhancement in the protective mucus
secretion and the formation of histodilutional barrier but whether histamine is implicated
in gastroprotective action of ghrelin, an orexigenic peptide of gastric mucosa origin, remains
unknown. We studied the effect of ghrelin applied intraperitoneally (i.p.) in a graded doses
ranging from 2.5-40 μg/kg on gastric secretion in conscious rats equipped with gastric fistula
(GF) and gastric mucosal lesions induced by 75% ethanol with or without: 1) inhibition of
H2 receptors by ranitidine (30 mg/kg i.g.); 2) suppression of histidine decarboxylase (HDC)
activity with α-fluoromethylhistidine (α-FMH), 3) subdiaphragmatic vagotomy, and 4) pre-
treatment with neurotoxic dose of capsaicin (125 mg/kg s.c.) to induce inactivation of
sensory nerves. The area of gastric lesions was measured by planimetry, the gastric blood
flow (GBF) was determined by H2-gas clearance technique and blood was withdrawn for
the measurement of plasma ghrelin and histamine levels by specific radioimmunoassays
(RIA) and the mucosal expression of ghrelin and HDC mRNA was evaluated by RT-PCR.
Ghrelin dose-dependently increased gastric acid output in GF rats and this effect was
completely abolished by ranitidine and significantly attenauted by α-FMH, vagotomy and
capsaicin denervation. Ethanol produced widespread mucosal lesions and this was accompan-
ied by the gastric mucosal expression of mRNA for ghrelin and the increase in the plasma
ghrelin levels. Pretreatment with exogenous ghrelin dose-dependently attenuated ethanol-
induced gastric lesions; the dose reducing these lesions by 50% (ID50) was 20 μg/kg. The
protective effects of ghrelin was accompanied by the significant rise in the GBF (by 32%)
and the significant increase in plasma ghrelin and histamine levels. The ghrelin-induced
protection and accompanying increase in the GBF were significantly reduced by pretreatment
with ranitidine and α-FMH and completely abolished by vagotomy and capsaicin-denerva-
tion. We conclude that 1) ghrelin increases gastric acid secretion via histamine release acting
through H2 receptors and exhibits gastroprotective activity against acid-independent injury
induced by strong irritant such as ethanol, and 2) this gastroprotective effect of ghrelin
involves the enhancement in gastric microcirculation mediated by vagally-stimulated HDC
activity and histamine release.
M2059
Profound Differences in the Rate of Secretion of Esophageal Protective
Components Between Males and Females with Gastroesophageal Reflux
Disease Could Be a Factor Contributing to Mucosal Injury and Complications
Marek Majewski, Tomasz Jaworski, Irene Sarosiek, Kathy Roeser, Sandra Sostarich,
Stanley Edlavitch, Grzegorz Wallner, Richard W. McCallum, Jerzy Sarosiek
The integrity of the esophageal mucosal depends upon equilibrium between aggressive
factors and protective mechanisms (Sarosiek et al. J Pract Gastroenterol, 18:20J-20Q,
1994). Although males and females are equally affected by gastroesophageal reflux disease
(GERD) symptomatology, females are less likely to develop its most severe complications
such as Barrett’s esophagus and esophageal adenocarcinoma. Little is know, however, if the
rate of secretion of esophageal mucosal protective components, in response to aggressive
factors is determined by gender. Purpose: To measure the esophageal mucosal secretory
response in terms of protective components in GERD patients of both genders during the
mucosal challenge mimicking the natural gastroesophageal reflux scenario. Methods: The
study was approved by HSC at KUMC and conducted in 32 GERD patients (21F & 11M;
mean age of 42, 23-62 range). Subgroups of M & F were comparable in terms of mean age
and GERD symptomatology. The esophageal secretions from submucosal mucous glands
were collected, using a specially designed esophageal perfusion catheter (Wilson-Cook Med.),
during mucosal exposure to initial NaCl followed by HCl/pepsin (HClP) and final NaCl to
mimic the natural gastroesophageal reflux scenario. In collected samples their volume and
the content of bicarbonate and non-bicarbonate buffers, protein, mucin, EGF, TGFα, and
PGE2 were measured using commercial assays. Collected data were statistically analyzed
using SPSS statistical software. Results: After the esophageal mucosal challenge with HClP,
the rate of esophageal bicarbonate and non-bicarbonate secretion among females was 47%
and 44% higher respectively (P=0.05) than in males. Esophageal mucin secretion among
females was 150% higher and esophageal PGE2 secretion 257% higher (P<0.05) than in
males. The rate of esophageal EGF secretion among males, however was 224% higher
(P<0.01) than in females. Conclusion: Profound differences in the rate of secretion of
esophageal protective components after the mucosal challenge, mimicking the natural gastroe-
sophageal reflux scenario, between males and females may at least partly explain the differ-
ences in the rate of development of mucosal injury and complications.
M2060
Tegaserod Stimulates Bicarbonate Secretion By Esophageal Submucosal Glands
and Protects Against Acid-Pepsin Injury in a Pig Model
Solange M. Abdulnour-Nakhoul, Nelia Tobey, Ximena C. Vanegas, Scott A. Wheeler,
Karen Brown, Roy C. Orlando
We assessed the effects of tegaserod, a 5-hydroxytryptamine-4(5HT4)agonist, on HCO3-
and mucin secretion by the esophageal submucosal glands (SMG). The experiments were
done on pig esophagus whose muscularis propria was removed and which was bathed in
HCO3- Ringer solution. The ends of the esophagus were cannulated for timed collections
of instilled saline solution (mucin study) or for recirculation of an unbuffered saline solution
attached to a pH-stat apparatus (HCO3- study). After baseline recordings, tegaserod, 0.25
μM -1 μM, or vehicle was added to the serosal solution and readings taken every 10 min
for 1hr. Following tegaserod, carbachol, 10μM, was also added serosally and then atropine,
10μM. Results: Tegaserod increased HCO3-, but not mucin, secretion in a dose-dependent
fashion, and at 1μM, the increase in HCO3- was ~33% greater than control (0.15±0.05
μEq/hour.cm2 versus 0.21±0.05 μEq/hour.cm2, n=7, p<0.005). Adding carbachol yielded
no further increase in HCO3- secretion while adding atropine abolished all secretion. Since
serosal tegaserod stimulated SMG HCO3- secretion, it was also tested for a protective effect
in esophagus against luminal acid-pepsin exposure (HCl, pH 2.5 + pepsin 1 mg/ml) for
1hr. This was done in Ussing chambers using both SMG-bearing pig esophagus and, for
comparison, SMG-free rabbit esophagus. Tegaserod had no effect on basal electrical data in
either species; however following acid-pepsin washout, tegaserod treatment resulted in
significantly higher resistances than controls for the pig, but not the rabbit, esophagus.
Conclusions: Tegaserod stimulates HCO3-, but not mucin, secretion from esophageal SMGs,
an effect mediated via a cholinergic pathway. Stimulation of SMG HCO3- secretion likely
accounts for tegaserod’s ability to protect SMG-bearing pig, but not SMG-free rabbit, eso-
phagus from acid-pepsin injury. Supported in part by a grant from Novartis and by a VA
Merit grant.
M2061
Lafutidine, a Mucosal Protective H2 Receptor Antagonist, Sensitizes the
Mucosal Response to Luminal Acid in Rat Duodenum
Yasutada Akiba, Jonathan D. Kaunitz
Capsaicin-sensitive afferent nerves (CSAN) sense luminal acid and coordinate duodenal
mucosal defense mechanisms, such as hyperemia and mucus secretion. Since lafutidine, an
H2 receptor antagonist possessing CSAN-dependent mucosal protective effects, augments
capsaicin-related calcitonin gene-related peptide release in rat stomach, we hypothesized
that lafutidine upregulates mucosal defense responses to luminal acid in the duodenum.
We thus examined the effects of lafutidine on the regulation of epithelial intracellular pH
(pHi), blood flow (BF) and mucus gel thickness (MGT) in response to luminal acid in rat
duodenum using in vivo fluorescence microscopy. Under isoflurane anesthesia, rat duodenal
mucosa was exposed and topically superfused with pH 7.0, 4.5, 3.5 or 2.2 solution with
or without lafutidine co-superfusion (1 mM). pHi was measured with pre-loaded BCECF,
BF with laser Doppler flowmeter, and MGT with differential focal-plane measurements. Acid
dose-dependently lowered pHi, increased BF and MGT (Table). Lafutidine alone alkalinized
the epithelial cells, augmenting BF and MGT increase. Co-perfusion of lafutidine with pH
2.2 solution reduced the acid-related decrease of pHi, further increased BF and MGT. De-
afferentation with high dose capsaicin (125 mg/kg, sc) abolished the lafutidine-related
augmentation of these protective mechanisms, implicating the CSAN in lafutidine-mediated
protection. Lafutidine reduced the intracellular acidification, and enhanced hyperemia and
MGT increase induced by acid dose-dependently (Table). Lafutidine activated CSAN in
duodenum, alkalinizing pHi, a cellular signal preceding stimulated bicarbonate secretion
and mucus secretion. Augmentation of protective mechanisms such as acid-induced hypere-
mia and mucus secretion suggests that lafutidine sensitizes CSAN to its endogenous
ligand, H+.
veh: vehicle, laf: lafutidine, *p<0.05 vs pH 7.0 group, †p<0.05 vs veh group.
M2062
Pathogenic Importance of Pepsin in Ischemia/Reperfusion-Induced Mucosal
Injury in Rat Stomachs
Tohru Kotani, Atsushi Kobata, Kikuko Amagase, Koji Takeuchi
Background/Aim: Ischemia followed by reperfusion (I/R) leads to tissue injury. Although
there is a substantial body of data characterizing the factors that promote gastric lesions
under I/R-induced conditions, including superoxide radicals, the exact mechanism remains
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still unexplored. Gastric acid secretion is known to substantially decrease after I/R, yet the
antisecretory agents reportedly had a protective effect on I/R-induced gastric lesions through
the suppression of acid secretion. However, there is no information about the role of pepsin
in the pathogenesis of I/R-induced gastric injury. In the present study, we focused on changes
in pepsin secretion in rat stomachs during I/R-induced conditions and investigated the role
of pepsin in the development of I/R-induced gastric injury. Methods: Male SD rats were
used after 18 h fasting. Under urethane anesthesia, the pylorus was ligated, the celiac artery
clamped, and 1 ml of 100 mM HCl was instilled in the stomach. Reperfusion was established
15 min later by removal of the clamp, and after 2 h reperfusion period the stomach was
examined for hemorrhagic lesions under a dissecting microscope. Pepstatin (a specific inhib-
itor of pepsin) or pepsin was given intraluminally after pylorus ligation. Cimetidine, omepra-
zole or atropine was given SC 30 min before ischemia. During I/R-induced conditions, both
pepsin output and luminal acid loss were measured; the former was determined by the
modified Anson method, while the latter was measured in presence of omeprazole. Results:
I/R produced hemorrhagic injury in the gastric mucosa in the presence of HCl. The develop-
ment of the I/R-induced gastric lesions was significantly prevented by atropine, yet neither
omeprazole nor cimetidine had any effect. Intragastric administration of pepstatin also
reduced the severity of I/R-induced gastric lesions in a dose-dependent manner, the effect
being significant even at 0.3 mg/kg, while that of pepsin markedly aggravated these lesions.
Of interest, the secretion of pepsin was significantly increased following I/R, and these
changes were in parallel with the increase in luminal acid loss. In addition, the increased
pepsin output during I/R-induced conditions was significantly inhibited by atropine but not
cimetidine or omeprazole while pepstatin significantly inhibited the proteolytic activity of
pepsin. Conclusion: These results suggest that 1) pepsin plays a pivotal role in the pathogen-
esis of I/R-induced gastric lesions, and 2) pepsin secretion is increased during I/R-induced
conditions, the process being in association with acid back-diffusion and mediated through
a cholinergic pathway.
M2063
Aggravation By Selective Serotonin RE-Uptake Inhibitors (SSRIs) of Antral
Lesions Induced By Indomethacin in Rats: Effects of Antisecretory and
Mucosal Protective Drugs
Akiko Tanaka, Yuka Takahira, Nahoko Izumi, Koji Takeuchi
Background/Aim: Recent clinical studies suggested a risk of gastric adverse reaction on the
concomitant use of selective serotonin re-uptake inhibitors (SSRIs) with nonsteroidal anti-
inflammatory drugs (NSAIDs). In the present study, we used indomethacin as a conventional
NSAID and investigated the adverse effect of SSRIs on gastric antral ulcers induced by
indomethacin in rats and further investigated the effects of several antiulcer drugs on the
occurrence of antral ulcers induced by NSAID and SSRI. Methods: Male SD rats were used.
The animals fasted for 24 h were refed for 1 h, and then administered indomethacin (30
mg/kg), dicrofenac (30 mg/kg) or flurbiprofen (30 mg/kg) SC 1 h after refeeding and killed
6 hr later. Paroxetine (1~10 mg/kg) and other anti-depressants were given PO 30 min before
indomethacin. Various serotonin (5-HT) receptor subtype-selective antagonists or several
antiulcer drugs were given SC or PO 1 hr before indomethacin, respectively. Results:
Indomethacin caused antral ulcers in re-fed rats. Paroxetine dose-dependently worsened the
severity of antral ulcers in response to indomethacin, despite provoking by itself no damage;
the original ulcers induced by indomethacin were mostly non-hemorrhagic while they became
hemorrhagic by co-administration of paroxetine. Similar results were obtained by proxetine
when antral lesions were induced by other NSAIDs such as dicrofenac and flurbiprofen as
well as SC-560 plus rofecoxib. This effect of paoxetine was mimicked by fluvoxsamine as
well as milnacipran but not by imipramine and maprotiline. Exogenous 5-HT (10 mg/kg,
SC) also worsened indomethacin-induced antral ulcers while the worsening effect of paroxet-
ine was attenuated by ondansetron the selective 5-HT3 antagonist but not other subtype
selective antagonists. The development of antral ulcers induced by indomethacin plus paroxe-
tine was significantly prevented by omeprazole and atropine as well as pepstatin, although
these agents, except pepstatin, had no effect on antral lesions induced by indomethacin
alone. Likewise, the aggravating effect of paroxetine was significantly prevented by rebamipide
and superoxide dismutase (SOD) but not by teprenon. Conclusion: These results suggest
that SSRIs exert a harmful influence on the antral mucosa when given with NSAIDs, resulting
in aggravation of antral ulcers, and 5-HT3 receptors may be involved in the aggravating
action of SSRI. Rebamipide is useful for preventing such adverse effects in the antral mucosa
caused by the combined administration of NSAID and SSRI, and this action may be partly
accounted for by the scavenging action of superoxide radicals.
M2064
Bile Acids Induce a Shift Towards a TH2 Cytokine Profile in Barrett’s
Esophagus
L.M.G. Moons, P.D. Siersema, Z.M.A. Groothuismink, A.H.M. van Vliet, E.J. Kuipers, J.G.
Kusters
Introduction: Barrett’s esophagus (BE) is associated with a predominant humoral immunity
(Th2). Analogous to other pro-inflammatory conditions predisposing for cancer, this develop-
ment of a Th2 immune responses is associated with suppression of the cell-mediated immune
response (Th1). Bile acids are known to suppress cell-mediated immunity in cholestatic
liver disease and are thought to play an important role in the genesis of esophageal carcinogen-
esis. The latter specifically relates to deoxycholic acid (DCA) as this bile acid is present in
increased concentrations in the bile pool of patients with BE. Aim: To determine whether
DCA could suppress cell-mediated immunity in BE. Methods: Isolated human peripheral
blood mononuclear cells (PBMCs) of 5 healthy controls were stimulated with 5 μg/ml Con
A for 5 days in the presence of increasing concentrations of DCA (0-100 μM). The effect
on T cell responses was determined by measurement of proliferation (CFSE labelling), T
cell activation (CD25/CD69), and IL-4, IFN-γ, IL-10, IL-2 cytokine production (ELISA &
RT-PCR). Induction of apoptosis was determined by FACS analyses of Caspase 3 and Annexin
V. Cell viability was determined by 7-AAD. Results: T cell proliferation was decreased in a
DCA concentration dependent manner, with a 1.4±0.1 fold decrease at 100 μM DCA as

















or induction of apoptosis, as there was no difference in cell viability (at all concentrations
>90%), and Caspase 3 and Annexin V expression after 24 and 72 hours incubation between
100 μM DCA and no DCA control. DCA was found to modulate activation of T cells, since
T cells showed lower expression levels of the activation markers CD25 and CD69 (both
1.8±0.4 fold), lower levels of IL-2 mRNA (1.3±0.15 fold; p=0.04) and IFN-γmRNA (1.4±0.16
fold; p=0.02), as well as lowered IL-2 protein levels (5±1.2 fold; p=0.03) at 100 μM DCA
versus untreated PBMCs. IL-4 mRNA levels were unaffected by treatment with DCA, whereas
IL-4 protein levels were even increased at higher concentrations of DCA (1.4±0.15 fold p=
0.048) after 5 days of stimulation. IL-10 protein and mRNA levels were below detection
limits. Conclusion: DCA exposure of PBMCs results in a concentration-dependent decrease
of T cell proliferation, T cell activation, suppression of IL-2 and IFN-γ (Th1 cytokines), and
stimulation of IL-4 (Th2 cytokine) expression This indicates that DCA may be an important
factor involved in suppression of cell-mediated immune responses in the esophagus, and
may be involved in the observed shift towards a predominant humoral immune response
in Barrett’s esophagus.
M2065
Further Evidence for Involvement of Prostaglandin E Receptor Subtype 3 in
Duodenal HCO3- Secretion in Rats
Eitaro Aihara, Yoko Sasaki, Fumitaka Ise, Yoko Nomura, Koji Takeuchi
Background/Aim: Prostaglandins (PGs) play as a potent biological mediator in diverse physio-
logical functions, including duodenal HCO3- secretion. We previously reported that the
HCO3- stimulatory action of PGE2 in the duodenum is mediated by the activation of both
EP3 and EP4 receptors. However, these data were obtained only in EP3 receptor knockout
mice and not confirmed pharmacologically. Thus, the involvement of EP3 receptors in
duodenal HCO3- secretion remained pending. Recently, a selective EP3 receptor antagonist
becomes available. In the present study, we examined using the specific EP3 agonist and
antagonist the involvement of EP3 receptors in duodenal HCO3- secretion in rats and further
confirmed a synergic phenomenon of the responses mediated by EP3 and EP4 receptors.
Methods: Male SD rats were used after 18 h fasting. Under urethane anesthesia, a proximal
duodenal loop was perfused with saline, and HCO3- secretion was measured at pH 7.0
using a pH-stat method and by adding 5 mM HCl. PGE2 (1 mg/kg), sulprostone (EP1+EP3
agonist, 1 mg/kg) or AE1-329 (EP4 agonist, 3 μg/kg) was given IV as a single injection.
Mucosal acidification was performed by exposing the loop to 10 mM HCl for 10 min. AE5-
599 (EP3 antagonist, 1~10 mg/kg, intraduodenally) or AE3-208 (EP4 antagonist, 1 mg/kg,
IV) was given 30 min or 5 min, respectively, before the administration of PGE2 or Sul or
the mucosal acidification. Results: Duodenal HCO3- secretion was stimulated by AE1-329
as well as sulprostone, the responses being equivalent to that induced by PGE2at 1 mg/kg
or mucosal acidification. The HCO3- stimulatory action of AE1-329 but not sulprostone was
significantly attenuated by AE3-208. By contrast, AE5-599 dose-dependently inhibited the
HCO3- response to sulprostone but not AE1-329. Both AE5-599 and AE3-208 partially but
significantly mitigated the HCO3- responses to both PGE2 and mucosal acidification, and
co-administration of these two agents completely blocked these responses. Duodenal damage
caused by mucosal perfusion with 150 mM HCl for 4 h was worsened by pretreatment
with the EP3 and EP4 antagonist as well as indomethacin and further aggravated by co-
administration of these antagonists. In addition, neither the EP3 nor EP4 antagonist had
any effect on gastric HCO3- response induced by PGE2 or mucosal acidification. Conclusion:
These results suggest that 1) EP3 receptors are involved in the regulation of HCO3- secretion
in rat duodenum, in addition to EP4 receptors, 2) the presence of both EP3 and EP4
receptors is essential for the full response of HCO3- secretion as well as the maintenance of
mucosal integrity of the duodenum against acid injury.
M2066
Role of Glucocorticoid Hormones in Protective Influence of Preconditioning
Mild Stress Against Stress-Induced Gastric Ulceration in Rats
Ludmila Filaretova, Akiko Tanaka, Kozue Ishikawa, Tatiana Bagaeva, Koji Takeuchi
Background and Aim: It is known that preconditioning stress may attenuate stress-induced
gastric injury and this effect is mediated by prostaglandings. Accordingly to our previous
findings glucocorticoid hormones produced in a response to an acute stress are gastroprotec-
tive hormones, but not ulcerogenic ones as was generally accepted. This fact allows hypothes-
ized the contribution of glucocorticoids to gastroprotective effect of preconditioning stress.
The present study was designed to verify this hypothesis. Methods: Male SD rats weighing
about 300 g were used after 18 h fasting. Rats were exposed to severe stress (cold-restraint
stress at 10°C for 6 h) with preconditioning mild stress (cold-restraint stress at 10°C for 30
min and restraint at room temperature for 60 min) or without mild stress. The experiments
were carried out: 1) in adrenalectomized rats (with or without corticosterone replacement)
and in sham-adrenalectomized animals; 2) in medullectomized and sham-medullectomized
animals; 3) in rats with occupation of glucocorticoid receptors by the antagonist RU-38486
and in control group. Adrenalectomy or medullectomy was performed one or three weeks,
respectively, before stress. RU-38486 (20 mg/kg, PO) was administrated 30 min before mild
stress. During experimental period, blood corticosterone and glucose levels as well as body
temperature was monitored. At the end of each experiment, gastric erosions and myeloperoxi-
dase (MPO) activity were measured. Results: Both mild and severe stress induced blood
corticosterone and glucose rise and severe stress also produced gastric erosions. Mild stress
decreased the gastric ulceration caused by severe stress and this effect was prevented by
both adrenalectomy and occupation of glucocorticoid receptors but not medullectomy.
An acute corticosterone replacement (4 mg/kg, SC) mimicking the mild stress-induced
corticosterone rise in adrenalectomized rats protected the gastric mucosa of these animals
against the severe stress. Adrenalectomy resulted in dramatically decrease in body temperature
and blood glucose levels during stress and the replacing corticosterone attenuated these
effects. MPO activity was observed in gastric mucose of adrenalectomized rats. Conclusions:
These results suggest that glucocorticoids released during preconditioning mild stress contrib-
ute to the protective effect of this stress on gastric mucosa against cold-restraint stress-
induced gastric injury. The effect is functionally associated with prevention of lowering
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of glucose levels and body temperature. Manifestation of anti-inflammatory properties of
glucocorticoids may contribute to their gastroprotective action.
M2067
Mechanisms Underlying Compensatory Gastroprotective Action of
Glucocorticoid Hormones During Desensitization of Capsaicin-Sensitive
Sensory Neurons in Rats
Ludmila Filaretova, Peter Bobryshev, Tatiana Podvigina, Tatiana Bagaeva, Akiko Tanaka,
Hanae Shiraishi, Koji Takeuchi
Background and Aim: Capsaicin-sensitive sensory neurons (CSN) play a pivotal role in
gastroprotection. Accordingly to our previous results glucocorticoid hormones also contribute
to gastroprotection and may play a pivotal compensatory role in the maintenance of gastric
mucosal integrity in the case of desensitization of CSN. The present study was designed to
investigate mechanisms underlying compensatory gastroprotective action of glucocorticoids
during desensitization of CSN. Methods: Male SD rats about 350 g were used after 18 h
fasting. The effects of desensitization of CSN or adrenalectomy alone or their combination
on indomethacin (35 mg/kg)-induced gastric erosions, gastric microcirculation and mucus
contents as well as blood glucose levels were investigated. Functional ablation of CSN was
performed with neurotoxic dose of capsaicin (100 mg/kg SC, 3 days) two weeks before
indomethacin administration. Adrenalectomy was created one week before indomethacin
and followed by corticosterone replacement (4 mg/kg SC). An in vivo microscopy technique
for the direct visualization of gastric microcirculation and the analysis of red blood cell
(RBC) velocity was employed. For estimation of mucus production the hexose content was
measured by the phenol-sulphuric acid method. Results: Indomethacin-induced gastric
erosions were aggravated with similar extension by adrenalectomy or desensitization of CSN.
Desensitization of CSN profoundly aggravated the erosion formation in adrenalectomized
rats without corticosterone replacement. Indomethacin slightly decreased RBC velocity and
blood glucose levels in sham-adrenalectomized animals, but caused profound fall in both
these parameters in adrenalectomized rats. Corticosterone replacement prevented these effects
of adrenalectomy. Desensitization of CSN slightly potentiated the decrease in RBC velocity
and did not significantly influence the blood glucose levels in sham-adrenalectomized rats.
However, in adrenalectomized rats desensitization of CSN markedly potentiated indometh-
acin-induced falls in RBC velocity and in blood glucose levels. In adrenalectomized rats
with corticosterone replacement the effects of desensitization of CSN on RBC velocity, blood
glucose levels as well as gastric erosions were similar to those in sham-adrenalectomized
rats. Conclusions: The results suggest that compensatory protective action of glucocorticoids
against indomethacin-induced injury during desensitization of CSN is provided by their
maintenance of gastric blood flow and glucose homeostasis. It is unlikely that gastric mucus
production is involved in the mechanisms of this compensatory gastroprotective action.
M2068
Dual Influence of Portal Hypertension On Gastric Mucosal Defense
Kazuhiro Fukushima, Takuya Endo, Yoshikazu Kubo, Shinichi Kato, Koji Takeuchi
Background/Aim: Portal hypertension, one of the most disastrous conditions related to
chronic hepatic diseases, is known to be the major factor of pathogenesis of gastric abnormal-
ity. Indeed, the gastrointestinal bleeding is commonly observed in patients with liver cirrhosis.
The purpose of this study was to investigate the change of gastric function in portal hypertens-
ive rats. Methods: Male SD rats were used. Portal hypertension was produced by partial
ligation of the portal vein, and 1 week later we carried out two experiments. First, animals
were administered HCl/ethanol PO, killed 1 h later, and the gastric ulcerogenic response
was examined. Second, a rat stomach mounted in an ex vivo chamber was perfused with
100 mM HCl under urethane anesthesia, and transmucosal potential difference (PD) and
gastric mucosal blood flow (GMBF) were measured before and after exposure of the mucosa
to 20 mM taurocholate (TC) for 30 min. The expression of mRNA was examined by RT-
PCR. Levels of PGE2 and NOx were measured by EIA and Griss reaction, respectively.
Results: Portal hypertension by itself did not cause any damage in the stomach, and signific-
antly decreased the mucosal susceptibility to HCl/ethanol-induced injury. Pre-treatment with
L-NAME (a NOS inhibitor) reversed the protective effect of portal hypertension against HCl/
ethanol. Aminoguanidine (a selective iNOS inhibitor) also mitigated the protective effect of
portal hypertension, though the effect was much less as compared to L-NAME. Likewise,
both indomethacin (a nonselective COX inhibitor) and rofecoxib (a selective COX-2 inhibitor)
also restored the gastric ulcerogenic response to HCl/ethanol in portal hypertensive rats.
On the other hand, mucosal application of TC caused a marked reduction in PD and an
increase of GMBF. However, in portal hypertensive rats this treatment did not increase
GMBF, despite causing a similar degree of PD reduction. Perfusion of TC-treated stomachs
with 100mM HCl caused only minimal damage in normal rats, yet produced gross lesions
in portal hypertensive rats. Gastric PGE2 levels were significantly increased in portal hyper-
tensive rats, in a rofecoxib inhibitable manner. Gastric NOx contents were also increased
in portal hypertensive rats, in an aminoguanidine inhibitable manner. The expression of
both COX-2 and iNOS mRNAs was up-regulated in the stomach of portal hypertensive rats.
Conclusion: These results suggest that portal hypertension exerts a dual influence on the
gastric mucosal defense, a protective effect mediated by PGs/COX-2 and NO/iNOS against
HC/lethanol damage and a deleterious effect on the damaged stomach through the impairment
of GMBF response.
M2069
Lansoprazole Protects Gastric Mucosa from H.pylori-Induced Oxidative Injury
by Up-Regulating NRF2-Dependent Antioxidant Enzymes in Mice
Akinori Yanaka, Ken Itoh, Hirofumi Matsui, Masafumi Tauchi, Hideo Suzuki, Takeshi
Shibahara, Akira Nakahara, Ichinosuke Hyodo, Masayuki Yamamoto
Background: Lansoprazole (LPZ), a well known proton pump inhibitor, protects gastric
mucosa from H.pylori (Hp)-induced gastric mucosal injury, presumably by its potent acid
inhibitory action and/or by suppressing Hp activity. However, recent studies in ischemic
colitis model have shown that LPZ protects intestinal mucosa from ischemia-reperfusion
injury (World J Gastroenterol 2004;10:2814-7), suggesting that LPZ possesses an acid-
independent antioxidant effect on intestinal mucosa. On the other hand, we have previously
reported that nrf2 (NF-E2 p45-related factor-2), a transcription factor, which regulates
cellular response against oxidative stress, plays an important role in activation of antioxidant
enzymes in gastric mucosa during Hp infection (AGA meeting 2003, 2004). Based on these
backgrounds, we hypothesized that, in addition to its acid inhibitory effects, LPZ up-regulates
nrf2-dependent antioxidant enzymes, thereby affords gastric mucosal protection against
oxidative stress during Hp infection. The present study was conducted to determine if LPZ
stimulates antioxidant enzymes in Hp-infected gastric mucosa via nrf2-dependent mechan-
isms. Methods: Standardized mice model of Hp infection were set up by inoculating C57/
BL6 female mice (nrf2+/+ and nrf2-/-) with Hp Sydney Strain; SS1. Mice were maintained
with high salt diet (7.5% NaCl). Some mice were treated with 10 mg/kg/day LPZ. Mice
were sacrificed at 4 wks later. Degree of gastritis was evaluated by updated Sydney system.
DNA damage was estimated by measuring mucosal level of 8-OHdG. Expression of TNF-
α, IL-1β, COX-2 and HO-1 (Heme Oxygenase-1) was analyzed by real time RT-PCR. Mucosal
levels of PGE2, and 15-deoxy PGJ2 were measured using ELISA. Results: 1. In nrf2+/+
mice, treatment with Hp + high salt diet caused severe inflammation in corpus mucosa,
accompanied by marked elevation of TNF-α, IL-1β, and 8-OHdG, while HO-1 expression
was not prominent. 2. LPZ inhibited up-regulation of TNF-α, IL-1β, enhanced expression
of HO-1, and mitigated corpus gastritis. 3. Treatment with NS-398 altered neither the
protective effects of LPZ on corpus gastritis nor the expression of HO-1, although it decreased
expressions of COX-2, PGE2 and 15 dexy-PGJ2. 4. In nrf2-/- mice, stimulation of antioxidant
enzymes by LPZ was completely abolished, and protective effect of LPZ on corpus mucosa
against Hp + high salt was markedly attenuated. Conclusion: These results suggest that LPZ
affords gastric mucosal protection against oxidative stress during Hp infection, at least in
part by up-regulating nrf2-dependent, but not COX-2 dependent pathways.
M2070
Effect of Inflammatory Cytokines On the Expression of TFF1 (pS2) in Gastric
Epithelial Cells
Tadahito Shimada, Takero Koike, Kyoko Tabei, Takashi Namatame, Akihiro Tajima,
Masashi Yoneda, Hideyuki Hiraishi
Background and Aim: Trefoil factor family is a group of small peptides that play important
roles in the defense of the gastrointestinal mucosa. Among TFF subtypes, TFF1 (formerly
pS2) is expressed at a high level in gastric epithelial cells. TFF1 was originally discovered
as an estrogen-inducible gene in MCF-7 breast cancer cells and TFF1 expression is estrogen-
dependent in MCF-7 and other hormone sensitive breast cancer cells. However, TFF1
expression appears to be estrogen-independent in the stomach and the regulatory mechanisms
of TFF1 expression is not fully understood in gastric epithelial cells. In this study, we
examined whether inflammatory cytokines (TNF-alpha and IL1-beta) affect TFF1 expression
in gastric epithelial cells. Methods: MKN45 and AGS, cell lines derived from human gastric
cancers, were used. Endogenous TFF1 mRNA expression was analyzed by real-time quantitat-
ive RT-PCR using ABI-PRISM 7700 sequence detection system. Beta-actin mRNA measure-
ment was also performed for standardization. The promoter sequence of the human TFF1
gene (-956 to +36) was cloned into pGL3-basic vector to make a TFF1 reporter gene (TFF1-
Luc) and various mutant reporters were also made. In each reporter gene assay, phRL-TK
vector was co-transfected for standardization. NF-kappaB activation was monitored by using
a reporter vector that contained multiple copies of NF-kappaB responsive element upstream
of the luciferase gene (NF-kappaB-Luc). Results: (1) TNF-alpha (10 ng/ml, 24 h-incubation)
caused about 3-fold increase in the expression of endogenous TFF1 mRNA in MKN45 and
AGS cells. (2) Consistent with this, in reporter gene assays, TNF-alpha upregulated the
transcription of TFF1-Luc in a dose-dependent manner. (3) IL-1beta also showed similar
stimulatory effect on endogenous TFF1 mRNA expression and TFF1-Luc transcription. (4)
TNF-alpha and IL-1beta stimulated NF-kappaB activity in the cell types used in this study.
(5) TNF-alpha and IL-1beta responsive element was mapped between -393 and -364 and
between -256 and -216 from the transcription start site of the TFF1 gene. Within the latter
region, we found two potential NF-kappaB binding sites. Conclusion: These results suggest
that inflammatory cytokines upregulate TFF1 expression in gastric epithelial cells. NF-
kappaB pathway appears to be involved, at least in part. Upregulation of TFF1 expression
may benefit the protection of the gastric mucosa under inflammatory conditions.
M2071
Oral But Not Parenteral Aspirin Upregulates COX-2 Expression in Rat
Stomachs: A Causal Relationship Between COX-2 Expression and
Prostaglandin Deficiency
Kaoru Nishikawa, Aya Yokota, Yuji Mashita, Masaki Taniguchi, Koji Takeuchi
Background/Aim: Nonsteroidal antiinflammatory drugs (NSAIDs) produce damage in the
rat stomach, irrespective of the route of administration, yet aspirin (ASA) causes gastric
lesions only when it is given orally. It is also known that NSAIDs up-regulate the expression
of cyclooxygenase (COX)-2 in the stomach, and the inhibition of this enzyme is a key to
their ulcerogenic action. In the present study, we compared the ulcerogenic effects of ASA
and indomethacin in the rat gastric mucosa depending on the route of administration,
together with the expression of COX-2, and investigated a causal relationship between COX-
2 expression and deficiency of prostaglandins (PGs). Methods: Male SD rats were used after
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18 h fasting. Animals were given ASA or indomethacin, either PO or SC, and the gastric
mucosa was examined 4 h later. PGE2 contents were determined by EIA while COX mRNAs
were examined by RT-PCR. Effects of these agents on gastric motility and transmucosal
potential difference (PD) were also measured. Results: Indomethacin decreased the mucosal
PGE2 level, increased gastric motility, and caused gastric lesions with the up-regulation of
COX-2 expression, irrespective of the route of administration. ASA induced both damage
and COX-2 expression in the stomach when given PO but not SC, despite decreasing the
mucosal PGE2 level similarly via either route of administration. Gastric motility was tem-
poralily increased and gastric potential difference (PD) was markedly decreased by the
administration of ASA PO. PGE2, although preventing ASA-induced gastric lesions as well
as motility, affected neither the COX-2 expression nor PD reduction following the administra-
tion of ASA PO. By contrast, the COX-2 expression induced by indomethacin was prevented
by both PGE2 and atropine at the dose that inhibited gastric hypermotility. In addition, SC-
560 (a selective COX-1 inhibitor) but not rofecoxib (a selective COX-2 inhibitor) caused a
decrease in PGE2 content and an increase in gastric motility as well as COX-2 expression,
without induction of any damage in the stomach. Conclusion: These results suggest that
ASA given PO caused damage in the stomach, together with the up-regulation of COX-2
expression, and the up-regulated expression may be due to the topical irritative action (PD
reduction), rather than being a result of PG deficiency. The expression of COX-2 after
indomethacin treatment is associated with gastric hypermotility due to PG deficiency.
M2072
Involvement of Muscarinic Acetylcholine Receptors Subtype 4 in Carbachol-
Induced Acid and Pepsinogen Secretion in Mice
Takuya Endo, Takeshi Aihara, Kikuko Amagase, Minoru Matsui, Susumu Okabe, Koji
Takeuchi
Background/Aim: Muscarinic acetylcholine receptors (mAChRs) consist of five subtypes (M1-
M5) and are widely expressed to mediate diverse autonomic functions in many peripheral
organs, including the gastrointestinal tract. It is considered that both M1 and M3 receptors
play an important role in the regulation of gastric acid and pepsinogen secretion in response
to acetylcholine. However, this idea is mainly derived from the data obtained by use of
selective antagonist or those on their expressions in the tissue, and the precise role remains
unclear. Especially, the data on pepsinogen secretion have mainly been obtained in-vitro
but not in-vivo studies. In the present study, we investigated the roles of mAChRs subtypes
in the cholinergic regulation of acid and pepsinogen secretion using muscarinic receptor
knockout (KO) mice and demonstrated the involvement of M4-receptors, in addition to M3-
and M5-receptors. Methods: C57BL/6J mice (12-16 wks old) of wild-type (WT) and M1-,
M3-, M4- or M5-knockout (KO) were used. Under urethane anesthesia, the abdomen was
incised, the cardiac portion ligated, and an acute fistula prepared with a polyethylene tube
was provided in the stomach through a pylorus. Then the stomach was instilled with saline
(0.4 ml) through the fistula, and the solution was changed every 20 min. Acid secretion
was measured by titrating the gastric content with 10 mM NaOH. Carbachole (30 μg/kg)
was given SC as a single injection. Atropine (0.3 mg/kg) was given SC 20 min before the
administration of carbachol. Results: Carbachol caused an increase of both acid and pep-
sinogen secretions in WT mice, the effect being completely inhibited by prior administration
of atropine. These acid and pepsinogen responses to carbachol were similarly observed in
M1KO mice but significantly decreased in the animals lacking M3-receptors. Likewise, both
the acid and pepsinogen secretions in response to carbachol were significantly impaired in
M4KO mice as compared with WT mice; especially, the pepsinogen response was almost
completely abolioshed. In M5KO mice, however, the pepsinogen response to carbachol was
observed similar to WT mice, but the acid response was slightly reduced when compared
to WT mice. Conclusion: These results suggest that under cholinergic stimulation the acid
secretion is mediated mainly by the activation of both M3- and M4-receptors and partly
through M5-receptors but not M1-receptors, while the pepsinogen secretion is mediated
mainly by the activation of M4-receptors and partly through M3-receptors but not M1-and
M5-receptors.
M2073
Inhibitory Mechanism of Tenatoprazole in Vivo
Jai M. Shin, Michel Homerin, Florence Domagala, Herve Ficheux, George Sachs
Background: Tenatoprazole belongs to the class of proton pump inhibitors (PPIs). There is
a surprisingly rapid rate of recovery of acid secretion after short or long term treatment
with most of the PPIs except for pantoprazole and tenatoprazole. This has been ascribed to
glutathione-dependent reversal of the inhibitory PPI-disulfide linkage in the luminal vestibule
of the pump at cysteine 813 with the linkage of tenatoprazole at cysteine 822 being inaccess-
ible and truly irreversible ( Gastroenterology 123, 1588-97,2002 and Biochem Pharmacol,
2006 (in press)). These experiments were performed in vitro on the H,K-ATPase isolated
from PPI inhibited rats and their relevance to the situation in the intact stomach needed to
be established. Aims: To compare the binding sites and the stability of PPI binding to the
gastric H,K ATPase in vivo after stimulation of acid secretion in rats. Methods: Rats were
injected with 14C-omeprazole or 14C-tenatoprazole after stimulation of acid secretion and
the decay of radioactivity bound to the H,K-ATPase followed as a function of time after
administration. Quantitative data reflecting stability of the PPI-pump complex were obtained
using Western immunoblots of gradient-gel separated ATPase and determining specific
radioactivity of the 100 kDa band representing the target catalytic subunit. Results: The rate
of loss of bound omeprazole from the pump in vivo was faster than expected from the 54
hr half-life of the protein whereas the rate of loss of tenatoprazole corresponded to the
expected turnover of the ATPase. Conclusions: The results demonstrate that the PPI-cysteine
813 bond formed by omeprazole is accessible to glutathione in vivo and that reversal of
inhibition by this mechanism plays a role in the rate of recovery of acid secretion in this
species and probably also in people. In contrast the binding of tenatoprazole to cysteine
822 is not reversed in vivo as predicted from the ex vivo enzyme analyzed in vitro. These
data would predict a longer duration of inhibition of acid secretion during tenatoprazole



















Gastric Acid Secretion in Isolated Rat Gastric Glands Is Inhibited By Insulin
Roman Schniepp, Philipp A. Lang, Philipp Kirchhoff, Basil Hirshowitz, John Geibel
Background Unregulated gastric acid secretion plays a major role in the pathophysiololgy
of reflux diseases. Previous studies in diabetic patients demonstrated a reduced tendency
to hypersecretory associated reflux disease, with in fact reduced basal and stimulated levels
of acid secretion. However this is explained by loss of vagal function in these patients. In
this study we chose to investigate the direct effects of insulin on secretagogue induced acid
secretion. Methods We used a digital-imaging system to observe proton efflux from parietal
cells. Gastric glands were isolated by a hand dissection technique, loaded with the pH
sensitive dye BCECF, and acid extrusion was monitored in the absence of bicarbonate as
intracellular alkalinization after removal of Na+ and K+ from the perfusate. Glands were
stimulated with histamine [100µM], carbachol [100µM] or pentagastrin [100µM] and rates
of alkalinization were calculated following K+readdition to the perfusate ± (400nM) insulin.
Results We found that the potassium dependent recovery induced by histamine (dpH/dT=
0.095 ± 0.0075 pH/min) or carbachol (dpH/dT 0.101 ± 0.0072 pH/min), is decreased by
insulin (0.073 ± 0.0078 pH/min), (0.068 ± 0.0088 pH/min) respectively, in rat gastric glands.
There was no effect of insulin on the pentagastrin stimulated K+ dependent alkalinization.
(Arithmetic means ± SEM). Conclusion This study demonstrates that insulin has a direct
inhibitory effect on histamine or carbachol induced gastric acid secretion. However, insulin
has no effect on pentagastrin stimulated acid secretion. These studies provide direct evidence
that increased insulin levels, can reduce secretagogue dependent acid secretion. These obser-
vations may help to explain the reduced levels of acid related disease in diabetic patients
and the reduction in both basal and secretagogue dependent acid secretion.
M2075
Identification of Rab27b in Gastric Parietal Cells
Serhan Karvar, Lixin Zhu, James M. Crothers, John G. Forte
Acid secretion by parietal cells involves secretagogue-dependent recycling of the HK-ATPase.
Rab proteins have been implicated as participants in membrane trafficking, docking, and
fusing processes during the secretory cycle. Rabbit parietal cell tubulovesicle fractions were
used to identify Rab proteins. Highly enriched HK-ATPase-containing tubulovesicle mem-
branes were run on SDS-PAGE, followed by in-gel digestion and peptide analysis by mass
spectrometry. Seven peptides were matched with Rab27b protein. We confirmed the Rab27b
expression in highly purified tubulovesicle fractions by western blot. We also used cultured
parietal cells to examine the cellular localization and stimulation-associated distribution
dynamics of Rab27b. Parietal cells infected with adenoviral vectors containing Yellow Fluores-
cent Protein (YFP)-tagged wild type and mutant Rab27b were visualized by fluorescence
microscopy. In resting parietal cells, YFP-Rab27b wild type and Rab27b Q78L constitutively
active mutant were detected throughout the cytoplasm in a pattern that was similar to
immunostaining for H,K-ATPase. After stimulation, YFP-Rab27b translocated to the apical
plasma membrane. Dominant negative mutant Rab27b N133I was localized through the
cytoplasm in resting and stimulated cells. Our results suggest that Rab27b is associated with
tubulovesicle membranes in the parietal cell and Rab27b may play a role in stimulation-
associated membrane recruitment and acid secretion.
M2076
Postprandial Gastric Acid Neutralization-Reacidification Measured with An
Ingested pH Telemetry Capsule: Correlation with Emptying of Digestible and
Indigestible Solids
William L. Hasler, Henry P. Parkman, Alan Hutson, William D. Chey, Kenneth L. Koch,
Richard W. McCallum, John M. Wo, Braden Kuo, Michael Sitrin, Kevin Stevens, Beverly
Landrigan, Jack R. Semler, Radoslav Coleski
Background: Gastric emptying profiles of digestible and indigestible solids exhibit distinct
temporal characteristics which are proposed to relate to specific gastric motor patterns.
Recently, an ingestible telemetry capsule was developed which continuously measures luminal
pH and pressure (SmartPill Corp.). Using this method, indigestible solid emptying is meas-
ured by detecting the abrupt pH rise as the capsule passes into the duodenum. It is well
known that gastric pH transiently neutralizes with solid meal ingestion and reacidifies
with subsequent acid secretion and gastric emptying. Hypothesis: We hypothesized that
intersubject differences in postprandial gastric pH profiles reflect differential rates of emptying
of digestible solids. Methods: Data from 25 healthy volunteers and 45 patients with docu-
mented gastroparesis on prior scintigraphy from 7 centers were analyzed. Acid suppressants
were discontinued for 1 week prior to study. Following capsule ingestion, subjects consumed
standardized solid meals (120 g Egg Beater, 60 kcal; bread, 120 kcal; jam 74 kcal; and 120
ml water—72% carbohydrate, 24% protein, 2% fat) with 1 mCi 99Tc-sulfur colloid tracers.
Luminal pH measurements were obtained every 5 sec; scintiscans were acquired every 30
min for 4-6 h. Results: Meal ingestion elicited initial pH rises to a mean of 4.40±0.18
followed by slow declines to stable pH nadirs of 0.93±0.12 prior to capsule emptying. The
time to empty 90% of the digestible radiolabelled meal on scintigraphy correlated modestly
with the time needed to reduce gastric pH by 50% from the peak to the nadir values
(pHT50)(r=0.47). pHT50 values correlated less well with duodenal passage of the indigestible
capsule (r=0.30). In subjects with delayed scintigraphic emptying (<90% emptied at 240
min), pHT50 values were significantly prolonged (64.7±12.9 min) vs. those with normal
emptying (≥90% emptied at 240 min)(25.8±2.2 min)(P=0.0001). The positive predictive
value of a pHT50 value of ≥60 min for detection of delayed solid emptying defined
scintigraphically was 89%, whereas the negative predictive value was 78%. Conclusions:
Quantification of intragastric pH neutralization and subsequent reacidification recorded by
an ingested telemetry capsule after consumption of a nutrient meal can provide a measure
of gastric emptying of digestible solids which correlates with accepted scintigraphic methods
and which complements the ability of the capsule to assess indigestible solid emptying. The
capability to concurrently determine gastric emptying of both digestible and indigestible
solids may be an important research and clinical tool in future investigations.
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M2077
Arfgap-6 Is Essential for Acid Secretion in Gastric Parietal Cells
Xia Ding, Zhen Guo, Zhiyou Fang, Fengsong Wang, Rihong Zhou, Xinwang Cao, John G.
Forte, Xuebiao Yao
Stimulation of gastric acid secretion involves an activation of a cAMP-dependent protein
kinase cascade that triggers the translocation and insertion of the proton pump enzyme,
H,K-ATPase, into the apical plasma membrane of parietal cells. The stimulation-mediated
relocation of the H,K-ATPase from the cytoplasmic membrane compartment to the apical
plasma membrane is mediated by a small GTPases such as Rab11 and ARF6. To further
understand the role of ARF6 in parietal cell secretion, we searched for proteins in parietal
cell extracts that bind the GTPase-deficient ARF6Q67L mutant but not wild-type ARF6.
Mass spectrometric analysis of a 97 kDa polypeptide specifically bound to ARF6Q67L led
to the identification a 903 amino acid protein of unknown function. We named this protein
as ARFGAP6 as our biochemical characterization demonstrated a PIP2-dependent GAP
specific for ARF6. Immunocytochemical study revealed that ARFGAP-6 is mainly located
to the apical membrane of parietal cell within the gastric glands. Our deletion analysis
revealed that ARFGAP-6 binds to ezrin via its N-terminus and is co-localized with ezrin to
the apical canaliculi. The siRNA-mediated depletion of ARFGAP-6 or a block of ARF6
GTP hydrolysis suppresses ARF6-dependent proton pump mobilization, suggesting that a
continuous GTPase cycle is required for gastric acid secretion in parietal cells. Thus, ARFGAP-
6 may provide a novel link between signal transduction, vesicular trafficking and membrane
cytoskeletal dynamics underlying parietal cell activation.
M2078
Dual Influence of Nitric Oxide On Gastric Hypersecretion Caused By Stomach
Distension; Inhibition of Acid Secretion and Stimulation of Pepsin Secretion
Ryo Matsuo, Yuuki Matsuzaka, Shinichi Kato, Koji Takeuchi
Background/Aim: It is known that distention of the stomach increases gastric secretion by
both direct and indirect pathways such as neural reflex, although the detailed mechanism
is still unclear. We previously showed that nitric oxide (NO) causes an inhibitory influence
on the acid hypersecretion in response to stomach distension. However, the role of NO in
pepsin hypersecretion in the distended stomach remains unknown. In the present study,
we examined the effect of stomach distention on acid and pepsin secretion in rats and
investigated the role of NO in these responses. Methods: Male SD rats were used after 18
h fasting. Under urethane anesthesia, the abdomen was incised, the cardiac portion ligated,
and an acute fistula prepared with a polyethylene tube was provided in the stomach through
a pylorus. Then the stomach was distended with instillation of saline (6 ml) through the
fistula, and the solution was changed every one hour. Acid secretion was measured by
titrating the gastric content with 100 mM NaOH while pepsin concentration was determined
by the Anson method. L-NAME (10 mg/kg), atropine (3 mg/kg), cimetidine (100 mg/kg)
or omeprazole (30 mg/kg) was given SC 1 h before the distention. In some cases, FK-409
(1 and 3 mg/ml), the NO donor, was given intraluminally, and the acid and pepsin secretion
was measured before and after the application. The amounts of NO in the luminal solution
were determined by Griess method. Results: Both acid and pepsin secretions were markedly
increased by distention of the stomach (the intraluminal pressure being about 20 cmH2O).
The increased acid secretory response was completely inhibited by omeprazole, significantly
mitigated by vagotomy, atropine and famotidine, while the response of pepsin was signific-
antly inhibited only by vagotomy and atropine. By contrast, L-NAME markedly enhanced
the acid hypersecretion in response to the distension while reduced the pepsin secretion
induced by gastric distension, both in a L-arginine inhibitable manner. Distention of the
stomach increased the luminal release of NO, and the response was significantly suppressed by
both vagotomy and L-NAME. Intragastric application of FK-409 dose-dependently stimulated
pepsin secretion but reduced acid secretion in the stomach without distension. Conclusion:
These results suggest that 1) the stomach distention increases both acid and pepsin secretions
through vagal-cholinergic pathway, in addition to the luminal release of NO, and 2) endogen-
ous NO affects these responses in opposite directions, suppressing the acid response and
enhancing the pepsin response.
M2079
Inihibition of COX-1, But Not COX-2, Enhances Proton Pump (PP) Expression
in Rabbit Parietal Cells (PC)
Jyotirmoy Nandi, Natalie Pavelock, J. Michael Zinkievich, Robert A. Levine
We have previously shown that non-selective NSAIDs augment basal and histamine-stimu-
lated gastric acid secretion in vivo (Gut 1984; 25:718) and in vitro (Gastroenterology 1991;
101:756). We reported that COX-1 is solely expressed in PC, and that COX-1, but not
COX-2 inhibition augments basal and histamine-stimulated aminopyrine (AP) uptake in
isolated rabbit PC with concomitant inhibition of PGE2 synthesis (Gastroenterology 2005;
128:A589). AIMS: To further investigate the precise mechanism of NSAIDs-induced augmen-
tation of gastric acid secretion, we determined whether COX-1 inhibition enhances expression
and/or activation of the PP. METHODS: Isolated rabbit PC were used (J Clin Invest 1990;
86:400) to assess [14C] AP uptake ratio and PGE2 synthesis, using a non-selective NSAID
(indomethacin, INDO, 10-4M) and selective COX-1 (SC-560, 10-5M, Calbiochem) and COX-
2 (DFU, 10-5M, Merck) inhibitors. Concentrations were selected based on IC50 values. PC
(5x106 cells/ml) were incubated in the presence and absence of INDO, SC-560, and DFU
for 1 h at 37°C. PP expression and activation were assessed by Western blot and pNPPase
activity, respectively, in partially purified PC plasma membranes. RESULTS: Basal and
histamine-stimulated AP uptakes were augmented by INDO and SC-560, but not by DFU.
Augmentation of AP uptake was reduced to basal levels with lansoprazole (10-5M), whereas
ranitidine (10-4M) failed to inhibit such augmentation, thereby implicating NSAIDs potenti-
ation of acid secretion in PC to a locus in the PP. We found that INDO and SC-560
significantly enhanced PP expression by 28% and 29% and pNPPase activity by 65% and
61%, respectively, compared to control PC, while DFU failed to enhance PP expression and
pNPPase activity (Table). Concomitant inhibition of PGE2 synthesis was induced by INDO
and SC-560, but not by DFU, indicating participation of COX-1 rather than COX-2 in
modulating gastric acid secretion. CONCLUSION: Our data suggest that NSAIDs-induced
gastric acid secretion in PC is due to enhancement of expression and activation of PP,
presumably mediated by inhibition of COX-1, but not COX-2.
NSAID Effect on PP Expression, pNPPase Activity, and PGE2 Synthesis (% of Control)
Control PP expression, pNPPase activity, and PGE2 synthesis were 0.75 ± 0.06 arbitrary
units/105 PC, 1.06 ± 0.19 μmol/h/106 PC, and 461 ± 23 pg/106 PC, respectively (n = 4).
*P < 0.05 compared to control.
M2080
ΔF508 Is Necessary for CFTR-Modulated Secretagogue-Induced Acid Secretion
Shafik M. Sidani, Philipp Kirchhoff, Elisa Ferreira, Marie Egan, John P. Geibel
Backround: The cystic fibrosis transmembrane conductance regulator (CFTR) is a multifunc-
tional protein that plays a role not only in Cl- secretion, but also as a regulatory protein.
The ΔF508 mutation is the most frequent CFTR defect causing the protein to be trapped
and destroyed inside the endoplasmic reticulum before reaching the plasma membrane,
resulting in cystic fibrosis. Acid secretion requires a complex interaction of transporters and
channels at the apical pole of the parietal cell. Involved in this process is at least one K+
channel to recycle K+ for the H,K-ATPase, and a Cl- channel that secretes Cl- to combine
with H+ ions to generate HCl into the gland lumen. CFTR has previously been shown to
interact with and modulate ROM-K channel activity when co-expressed in Xenopus oocytes,
so that it is possible that CFTR could be acting as a regulatory protein for ROM-K and
thereby modulate acid secretion. In the present study we measured secretagogue induced
acid secretion from wild-type and ΔF508 deficient mice in isolated gastric glands. Methods:
We used a digital-imaging system to observe proton efflux from parietal cells in hand
dissected gastric glands loaded with the pH sensitive dye BCECF. Individual glands were
exposed to either: Histamine (100μmol), Pentagastrin (100 μmol), or Carbachol (100μmol)
and a HCO3-/Na+ free perfusate to induce an acid load. We included 2 groups of mice:
wild type and ΔF508. To inhibit CFTR in wild type mice we used 100µM Glibenclamide
and compared recovery rates to the transgenic mice. Results: Δ508 deficient mice had
greatly reduced acid secretion. Glibenclamide effectively inhibited secretagogue induced acid
secretion which was similar to the result obtained in the ΔF508 deficient mice. Conclusion:
Acid secretion induced by Histamine, Pentagastrin, and Carbachol in wild-type mice could
be significantly reduced with an inhibitor of CFTR. In Δ508 deficient mice, Histamine-
induced acid secretion was significantly less than wild-type mice due to absence of CFTR
from the plasma membrane. These results demonstrate a substantial regulatory role for the
CFTR protein in normal gastric acid secretion.
M2081
Partial Inhibition of Acid Secretion in Isolated Rat Gastric Glands with Low
Concentrations of Etoh
Artur Vardanyan, John Geibel, Stanley Dudrick
Background: Multiple previous studies evaluating the effect of ethanol on gastric acid secretion
demonstrated suppression of maximal acid output (MAO) with high (>10%) concentrations
of ETOH, which do not directly correlate with gastric mucosal injury caused by alcohol
consumption. Additional human and animal studies investigating the effect of various alco-
holic beverages produced by fermentation processes showed either marked stimulation or
inhibition of acid secretion. The current study was designed to investigate the effect of low
concentrations of pure ethanol on acid secretion by isolated rat gastric glands. Methods: To
investigate the chronic vs. acute effects of ethanol on acid secretion 2 groups of animals
were studied. In the first group male Sprague-Dawley rats were isolated and kept on regular
food, with 5% ETOH in the drinking water for 2 weeks (chronic).The second group were
age/sex matched rats maintained on the same food and water minus ETOH (acute). Both
groups were sacrificed and rates of H+ efflux measured using the following protocol. We
used a digital-imaging system and the pH sensitive dye BCECF to observe proton efflux
from hand dissected gastric glands. Glands were stimulated with histamine (100μmol) or
Carbachol (100µM) and exposed to bicarbonate and Na+ free 20mM NH4Cl perfusate to
induce an acid load. H+, K+-ATPase inhibition was determined by calculating pHi recovery
(dpH/dT) rates. In a separate group 2% ETOH was added to the bath perfusate. In a final
series of experi-ments we used whole stomach pH measurements following Histamine
[100µM] ± 5% ETOH infusion with isotonic non-buffered saline. Serial luminal pH measure-
ments were made for each group. Results: Our data shows: i) that addition of ETOH to the
bath perfusate partially inhibits H+ extrusion from parietal cells, and increases overall rate
of alkalinization, ii) ingestion of 5% ETOH for 2 weeks had no effect on acid secretion, iii)
direct infusion of 5% ETOH gave a modest reduction in the rate of histamine induced acid
secretion in whole stomachs compared to saline controls. Conclusion: Acute exposure to
low concentrations of ETOH has an inhibitory effect on neuro-endocrine mechanisms of
gastric acid secretion. Chronic expo-sure to low concentrations of pure ethanol did not elicit
any changes in MAO, which suggests receptor/transporter remodelling to re-establish normal
rates of acid secretion. Using low dose chronic and acute models of in vivo and in vitro
acid secretion we have gained further insight into both alcohol-related malabsorption of
food, and the pathogenesis of development of gastro-esophageal erosions secondary to
excessive alcohol consumption.
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M2082
Which Has Superior Acid-Suppressive Effect, Omeprazole 10 Mg Once Daily
Or Famotidine 20 Mg Twice Daily? Effect of Single Or Repeated
Administration of Omeprazole Or Famotidine in Helicobacter Pylori-Negative
Cyp2c19 Extensive Metabolizers
Tomohiko Shimatani, Masaki Inoue, Tomoko Kuroiwa, Mutsuko Moriwaki, J.N. Xu,
Masuo Nakamura, Hiroshi Mieno, Susumu Tazuma, Kazuro Ikawa, Norifumi Morikawa
Background: Low-dose omeprazole is superior to full-dose famotidine in maintenance
therapy for gastroesophageal reflux disease; whereas, in ‘on-demand’ therapy, famotidine is
more effective for relief of heartburn episodes than omeprazole. This discrepancy has not
been fully explained. Aims: To compare acid-suppressive effects of single or repeated
administration of omeprazole and famotidine considering of their respective pharmacokinetic/
pharmacodynamic characteristics. Methods: Study-1: In eight healthy Helicobacter pylori-
negative cytochrome P450 (CYP) 2C19 extensive metabolizers, intragastric pH was measured
for 24 h seven times; on the 1st, 8th, and 15th days of repeated administration of 10 mg
once daily omeprazole or 20 mg twice daily famotidine, and before medication. Study-2:
In nine healthy Helicobacter pylori-negative CYP2C19 extensive metabolizers, blood samples
were collected in heparinized tubes before and at 1, 2, 3, 4, 6, 8 and 10 h after the 1st,
8th and 15th dose of repeated administration of 10 mg once daily omeprazole, and plasma
concentrations were determined. Results were expressed as means±S.D. Results: Study-1:
During repeated administration of omeprazole, the median value of intragastric pH and the
percent of time that intragastric pH was above 4.0 for 24 h were significantly higher and
became greater; 1.7±0.1 and 6.5±3.3% before medication, 2.3±0.5* and 19.1±11.9%* on
the 1st day, 3.3±1.4*# and 38.8±19.7%*# on the 8th day, and 4.3±1.3*#† and 53.2±23.6*#
on the 15th day, respectively (*P<0.05 vs. before medication, #P<0.05 vs. the 1st day, and
†P<0.05 vs. the 8th day). With famotidine, while these parameters were significantly higher,
the degrees became smaller; 3.9±0.6* and 50.4±13.0%* on the 1st day, 3.4±0.5*# and
36.2±8.7*# on the 8th day, and 2.8±0.3*#† and 22.9±8.2%*#† on the 15th day. Con-
sequently, acid-suppressive potency was in the order; 20 mg twice daily famotidine > 10
mg once daily omeprazole on the 1st day (P<0.05), omeprazole ≈ famotidine on the 8th
day, and omeprazole > famotidine on the 15th day (P<0.05). Study-2: Omeprazole increased
its bioavailability following repeated administration: The area under the plasma concentra-
tion-time curve from 0 to 10 h for omeprazole also increased, with relative ratios of 1, 1.77,
and 2.10 on the 1st, 8th and 15th days, respectively. Conclusions: The effectiveness of
full-dose famotidine in ‘on-demand’ therapy and that of low-dose omeprazole in maintenance
therapy possibly result from the phenomenon of ‘tolerance’ to famotidine, and a ‘potentiation’
of the acid-suppressive effect of omeprazole because of its increased bioavailability following
repeated administration.
M2083
Somatostatin Receptor Type 2 Knockout Mice Display Inhibitory Effect of
Galanin On ECL Cells But Enhanced Action of Gastrin On Parietal Cells
Chun-Mei Zhao, Vicente Martinez, Laura Piqueras, Yvette Tache, Duan Chen
Background/Aim: Somatostatin receptor type 2 (SSTR2) and gastrin receptor (CCK2) are
expressed in both parietal cells and histamine-producing ECL cells in the oxyntic mucosa
of the stomach, whereas galanin Gal1 receptor is expressed mainly on the ECL cells. In the
present study, we attempt to characterize the regulatory pathways that control acid secretion
in SSTR2-deficient mice using a combined morphological and functional approach. Methods:
Gastric acid secretory responses to pentagastrin, histamine, somatostatin-14 and galanin
were compared between SSTR2 knockout (KO) and wild-type (WT) mice that were anesthet-
ized with urethane. Tissue samples were collected from the oxyntic mucosa in freely fed
mice for quantitative analyses by immunocytochemistry and electron microscopy. Results:
The acid secretion induced by pentagastrin (16 µg/kg/h, iv) was enhanced (>15-fold) in KO
mice when compared to that in WT animals. On the other hand, histamine (5 mg/kg/h, iv)
induced a similar acid response in both groups (WT: 11±2 µmol/2 h and KO: 13±1 µmol/
2 h). In KO mice, galanin (10 µg/kg/h, iv) inhibited pentagastrin-induced acid secretion by
49% while somatostatin-14 (20 µg/kg/h, iv) had no effect. Immunocytochemistry revealed
that the expression of Gal1 receptor in the ECL cells was significantly increased (>7-fold)
whereas histidine decarboxylase and vesicle monoamine transport type 2 were significantly
reduced (by 23-35%) in KO mice. Further electron microscopic analysis showed an accumula-
tion of the secretory granules (> 2-fold) in the ECL cells. The number and the proportion
of secreting parietal cells containing secretory canaliculi were unchanged in KO mice. In
addition, there were no differences between WT and KO mice in terms of the densities of
immunoreactive cells stained for pancreastatin, ghrelin, or proliferating cell nuclear antigen.
Conclusion: Upon genetic removal of somatostatin SSTR2 inhibitory pathway, galanin inhibit-
ory signalling may be up-regulated in the ECL cells, while the stimulatory action of gastrin
is enhanced on the parietal cells.
M2084
Direct Visualization and Aspiration During Endoscopic Gastric Analysis
Enhances Accuracy and Reproducibility of Acid Output Measurement in
Zollinger-Ellison Syndrome
Hank S. Wang, David S. Oh, Gordon V. Ohning, Joseph R. Pisegna
Objectives: Gastric analysis (GA) has traditionally been considered the gold standard in the
diagnosis of Zollinger-Ellison Syndrome (ZES). Patients with ZES initially require gastric
analysis at 3 month intervals both to monitor disease progression and to assess therapeutic
success. Conventional GA using a nasogastric tube is burdensome and complex, requiring
more than an hour to complete and results in high levels of patient discomfort. In this
study, we have validated endoscopic gastric analysis (EGA) as a more accurate and reprodu-
cible technique for measuring acid output in ZES and possibly in other hypersecretory
conditions. Methods: In a prospective, crossover study, 12 patients with ZES underwent
gastric analysis, first by GA and then by EGA performed on the same day by the same

















concentration of each 15 minute sample was determined by titration, the volume recorded
and a 15 minute acid output level was calculated and added to give an hourly acid output.
EGA was then performed with sedation, and acid output was determined in a similar manner.
To assess reproducibility, 5 patients underwent repeat examination at least once including
both GA and EGA at a mean follow-up of 7.2 months. Root mean square of the difference
(RMSE) between EGA and GA was calculated to test for equivalence. Pearson’s correlation
coefficient was statistically significant when the calculated p for a two-tailed test was < .05.
Results: No statistical equivalence was detected between volume (RMSE 13.4 ml), acid
concentration (RMSE .007 mEq/ml) and acid output (RMSE 1.05 mEq/hr). Moderate correla-
tion was seen between EGA and GA regarding acid output (r = .54, p < .02). In addition,
EGA was highly reproducible (r = .94, p < .01) while GA was not (r = .27, p > .05). Finally,
measurements of acid concentration also had high correlation between EGA and GA (r =
.85, p < .01), while volume did not (r = .059, p > .05). Conclusions: We introduce a new,
rapid, simple endoscopic technique to measure gastric acid output and report significant
correlation between GA and EGA acid concentration and acid output. We derived a calibration
equation in ZES patients showing that EGA can predict GA acid output values to within ±
1.10 mEq/hr with a 95% confidence interval. While statistically nonequivalent, calculated
differences between EGA and GA acid output values were of little clinical importance.
Further evaluations of the accuracy and reproducibility of both GA and EGA in hypersecretory
and non-hypersecretory conditions are required to determine which test is the true gold
standard.
M2085
Endogenous Cannabinoids (Endocannabinoids) Regulate Gastric Acid
Secretion Via Cb1, Cb2, and VR1 Receptors
Robert Flynn, Prabhat Dwivedi, Shyamal Premaratne, Wei Hou, Robert McCuen, Mitchell
Schubert
RATIONALE. We previously identified anandamide, an endocannabinoid, in rat gastric
oxyntic mucosa by HPLC/gas chromatography/mass spectrometry. The activity of cannabino-
ids may be mediated via CB1, CB2, and VR1 receptors. Cannabinoids are inactivated by a
two-step process that involves a transporter that promotes cellular uptake followed by
intracellular hydrolysis. AIM. The aim of the present study was to determine the physiologic
role and mechanism of action for gastric endocannabinoids in the regulation of gastric acid
secretion. METHODS. CB1, CB2, and VR1 receptor expression were identified by RT-PCR
and immunoblotting in rat oxyntic mucosa and isolated parietal cells. Acid secretion was
measured by titration in isolated luminally perfused mouse stomach. RESULTS. CB1 and
VR1 receptors were expressed in oxyntic mucosa; CB2 receptors were expressed on isolated
parietal cells. In isolated stomach, the anandamide membrane transport inhibitor, VDM11
(1 μM), stimulated acid secretion (18±2% above basal level; P<0.001), implying that gastric
endocannabinoids are tonically active and contribute physiologically to basal acid secretion.
Consistent with this notion, anandamide (1 pM to 10 μM) caused a concentration-dependent
increase in acid secretion (EC50, 70 pM; maximal, 33±5% above basal level at 1 μM;
P<0.01). The effect of 10 nM anandamide (23±1% above basal level; P<0.001) was augmented
by the VR1 antagonist, 5’-iodoresiniferatoxin (1 μM; 31±3% above basal level; P<0.01 for
the difference), implying that anandamide, acting via VR1 receptors, inhibits acid secretion.
Conversely, both the CB1 antagonist, SR141716 (0.1 μM), and the CB2 antagonist, SR144528
(0.1 μM), each inhibited basal acid secretion (19±4% and 5±1% below basal level, respect-
ively; P<0.01) and significantly attenuated anandamide-stimulated acid secretion, implying
that activation of CB1 and CB2 receptors leads to stimulation of acid secretion. The axonal
blocker, tetrodotoxin (5 μM), partly inhibited the acid response to 10 nM anandamide by
52%; the residual response (11±2% above basal level; P<0.01) was abolished by the CB2
antagonist but not the CB1 or VR1 antagonist. CONCLUSION. Endocannabinoids in gastric
oxyntic mucosa physiologically regulate acid secretion. The dominant effect is stimulatory
and mediated via CB1 receptors on neurons and CB2 receptors on parietal cells. A concurrent
inhibitory effect is mediated via VR1 receptors on neurons.
M2086
Expression of Prostaglandin E2 Receptor Subtypes in Barett’s Esophagus and
Esophageal Adenocarcinoma
Pilar Jimenez, Elena Piazuelo, Mark Strunk, Sonia Santander, Pilar Irun, Miguel Angel
Simon, Asuncion Garcia, Ricardo Sainz, Angel Lanas
Background & Aim: Accumulating evidence suggests that COX-2-derived prostaglandin E2
is involved in esophageal adenocarcinogenesis. PGE2 exerts its biological action through
binding to specific receptors (EP1, EP2, EP3, EP4). Recent studies have shown that EP1,
EP2 and EP4 are implicated in colon carcinogenesis. Since it is not known which receptors
regulate PGE2 signals in esophageal adenocarcinoma (EAC),we investigated the expression
pattern of PGE2 receptor subtypes as well as COX-1, COX-2, in tissues from normal
squamous mucosa, Barrett’s esophagus (BE) and EAC. Methods: m-RNA expression of COX-
1, COX-2 and PGE2 receptor subtypes was determined by quantitative RT-PCR in esophageal
biopsies taken from patients with BE and EAC. The housekeeping gene hu-TBP was used
as reference gene for normalization the amount of sample (ΔCt values). Relative quantification
was expressed as fold-induction or decrease of the gene compared with the control (normal
squamous epithelium) according to the formula 2-ΔΔCt. The Mann-Whitney test was used
to compared ΔCt values obtained among groups. Results: RT-PCR analysis showed that EP1,
EP2, EP3 and EP4 are expressed in human esophageal mucosa. Levels of COX-2, EP2 and
EP4 mRNA expression were increased in BE and EAC compared to normal esophageal
mucosa. By contrast, COX-1 expression was decreased in both BE and EAC. The median
relative values and range of the mRNA expression levels are listed on the table. Conclusions:
PGE2 receptor subtype EP2 expression is markedly increased in Barrett’s esophagus and
adenocarcinoma, in clear contrast with the decrease observed for the COX-1 isoenzyme. In
addition to COX-2, EP2 receptors could be a selective target in the prevention and/or
treatment of esophageal adenocarcinoma associated with BE.
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(increase of expression: value>1) or (decrease of expression: value<1) vs (normal squamous
mucosa, value=1). (*p<0.05, **p<0.01 vs normal squamous mucosa).(n = 9-4)
M2087
Endoscopic Mucosal Resection As a Diagnostic Modality: Interrater Diagnostic
Correlation for Endoscopic Mucosal Resection Specimens Is Better Than
Biopsy Specimens
Mari Mino-Kenudson, Mindy J. Hull, Ian Brown, Alona Muzikansky, Amitabh Srivastava,
Joseph Misdraji, Do-Youn Park, Jonathan Glickman, Lawrence R. Zukerberg, Robert D.
Odze, Gregory Y. Lauwers
Background: Endoscopic mucosal resection (EMR) is advocated for the treatment of superficial
neoplasms arising in Barrett esophagus (BE). It represents a superior staging modality
compared to EUS. EMR can also improve diagnoses compared to biopsies, and therefore
facilitate optimal therapeutic decisions. However, the status of interobserver variation between
pathologists reviewing EMR specimens has not been evaluated. Design: Nine pathologists
from 3 academic centers reviewed 25 pairs of esophageal EMR specimens and peri-operative
biopsy (either pre- or post- EMR) from the same lesion. Each cases were classified into the
following diagnostic schema: 1) non-neoplastic; 2) low grade dysplasia (LGD); 3) high grade
dysplasia (HGD); 4) intramucosal adenocarcinoma (IMC); and, 5) invasive adenocarcinoma
(Inv Ca). The results were analyzed for concordance between raters, with the goal to evaluate
if the observer agreement was the same for EMR specimens and biopsies. Analysis included
intraclass correlation (ICC) and Kendall’s coefficient (KC) of concordance (for ordinal data)
to describe agreement of EMR & biopsy specimens as individual groups. Significant difference
between the rater classification of EMR versus biopsy specimens was assessed by finding
the proportion of agreement of all possible permutations of paired raters, and seeing if this
was higher for EMR than biopsy (unidirectional analysis). The proportion of agreement for
any given lesion was evaluated for both exact classification (ex. 1st and 2nd rater both
diagnose LGD) and 1-grade discrepancies (ex. 1st rater diagnoses LGD, 2nd rater diagnoses
HGD) using the one-sided Wilcoxon Signed-Rank test. Significance was considered to be
p<0.05. Results: The ICC and KC for the 25 esophageal biopsies was 0.938 (95% CI =
0.880-0.965) and 0.677, respectively. The ICC and KC for the 25 EMR specimens was
improved at 0.977 (95%CI=0.957-0.987) and 0.831 (p=<0.0001). The proportion of agree-
ment for EMR specimens was significantly better than that of biopsy specimens (p=0.015),
indicating that pathologists are more likely to agree on a diagnosis on an EMR specimen
than they are on a biopsy. Conclusion: The histopathologic assessment of dysplasia in BE,
which remains the basis for therapeutic decision, is criticized for its lack of interobserver
agreement. The causes for this limitation may be: biopsy sampling and artefacts, and lack
of diagnostic confidence on small biopsy specimens. We demonstrate that the same group
of pathologists has a better interobserver agreement on EMR specimens. It suggests that
EMR, in addition to being a staging and therapeutic procedure, provides improved dia-
gnostic consistency.
M2088
Reg I Expression in Untreated Endoscopic Biopsy Specimens Predicts Long-
Term Survival Among T4 Thoracic Squamous Cell Esophageal Cancer Patients
Treated with Chemoradiotherapy Followed By Esophagectomy
Satoru Motoyama, Toshihiro Sugiyama, Yasuharu Ueno, Hiroshi Okamoto, Shin
Takasawa, Hiroshi Nanjo, Kiyotomi Maruyama, Manabu Okuyama, Kenji Sasaki, Jun-Ichi
Ogawa
Background and Aim: The prognosis of T4 (direct invasion to adjacent organs) thoracic
esophageal cancer patients is extremely unfavorable, therefore we have been administering
neoadjuvant chemoradiotherapy (CRT) followed by esophagectomy to these patients. The
purpose of this study was to determine whether expression of REG I protein in untreated
endoscopic biopsy specimens is predictive of their responsiveness to CRT and/or survival
after treatment. Patients and Methods: Between 1992 and 2003, 50 patients with T4 thoracic
esophageal cancer were administered neoadjuvant CRT followed by curative esophagectomy.
REG expression was assessed in untreated endoscopic biopsy specimens and correlated with
clinical and histological responses and survival in 37 patients. Results: Among the 37 cases
that received CRT followed by surgery, the therapeutic response rate for neoadjuvant CRT
was 68% and a complete histological response in resected specimens from the primary lesion
was achieved in eight (22%) patients. These clinical and histological responses to neoadjuvant
CRT did not significantly correlate with survival, however. By contrast, nine patients were
judged REG-positive based on analysis of their untreated endoscopic biopsy specimens, and
their 5-year survival rate was significantly higher than that of the 28 REG-negative patients
(Figure). Conclusions: T4 thoracic squamous esophageal cancer patients expressing REG in
untreated endoscopic biopsy specimens achieved long-term survival when treated with
neoadjuvant CRT followed by esophagectomy.
M2089
Value of Endoscopic Ultrasound (EUS) and Clinical/Endoscopic Findings As
Predictors of Disease Extent and Regional Lymph Node Status in Esophageal
Cancer (EC)
Gregory Zuccaro, Thomas W. Rice, John J. Vargo, John R. Goldblum, Lisa A. Rybicki,
Rocio A. Lopez, Dumot A. John, David J. Adelstein, Patricia A. Trolli, Eugene H.
Blackstone
Background. Either disease extent (defined as limited to wall: pTis-T2, pN0 vs. advanced
beyond wall: pT3-T4, or pN1) or lymph node status (pN0 vs. pN1) may guide therapy in
EC. EUS is commonly used to predict the presence or absence of advanced disease or pN1;
however, these predictions are more frequently erroneous than previously recognized (AJG
2005; 100:601-606). Purpose. Determine accuracy in predicting advanced disease and pN1
in EC using EUS alone, clinical/endoscopic information alone, and a combination of clinical/
endoscopic information with EUS. Methods. 314 pts with EC underwent clinical evaluation
with endoscopy, and EUS, followed by esophagectomy. No pt received preoperative chemora-
diation. Post-operative pathologic classification was the gold standard. Accuracy of prediction
of both advanced disease and pN1 was determined using: (1) EUS alone, (2) logistic regression
using clinical/endoscopic (non-EUS) information alone, and (3) logistic regression combining
clinical/endoscopic information with EUS result. The clinical/endoscopic factors examined
were: age, gender, weight loss, dysphagia, tumor traversibility, length, location, and morpho-
logy, histopathologic type, and histologic grade. Receiver Operating Characteristic (ROC)
curves were created, and area under each curve (AUC) calculated (AUC reflects accuracy
of a diagnostic test and is used to compare two or more tests). Results. Pathologic classification
at esophagectomy (gold standard): 138 (44%) limited, 176 (56%) advanced; 171 (55%)
N0, 143 (45%) N1. Risk factors for advanced disease and pN1 were: dysphagia, weight
loss, increased tumor length, poor histologic grade, and EUS prediction of advanced disease
or pN1. AUC for each ROC curve is shown (table). Using all available information (clinical/
endoscopic plus EUS) was superior to EUS alone in predicting advanced disease and pN1.
Clinical/endoscopic (non-EUS) information alone was equivalent to the combination of
clinical/endoscopic and EUS information in predicting advanced disease and pN1. Conclu-
sions. (1) While EUS alone is a good test for predicting advanced disease and pN1, use
of clinical/endoscopic information combined with EUS significantly improves prediction
accuracy. (2) Clinical/endoscopic information without EUS is virtually identical to the com-
bination of this information with EUS in predicting advanced disease and pN1 in EC.
AUC for Methods of Predicting Advanced Disease or pN1 in EC
* P<0.001; # P<0.0001
M2090
Gastric Atrophy May Be Associated with the Development of Squamous Cell
Carcinoma of the Esophagus in Japan
Katsunori Iijima, Tomoyuki Koike, Hitoshi Sekine, Akira Imatani, Shuichi Ohara, Tooru
Shimosegawa
Background:Hypochlorhydric atrophic gastritis is a well-known premalignant condition of
gastric cancer. Recent study in Swedish population demonstrated that gastric atrophy induced
by H. pylori infection may also increase the risk of esophageal squamous-cell carcinoma
(SCC) (W Ye, et al, JNCI 2004). However, this observation needs to be confirmed among
different ethnic groups with high prevalence of H. pylori infection and accompanying gastric
atrophy, like in Japanese population. The aim of this study is to investigate weather gastric
atrophy was associated with the risk for esophageal SCC in case-control study. Methods:
From April 2004 to March 2005, 64 consecutive subjects (60 men, mean age: 69 years)
who had had early esophageal SCC and had received endoscopic mucosal resection before
the entry were prospectively enrolled. For each case, age- and sex- matched asymptomatic
control subjects were randomly selected from patients who visited our hospital during the
same period. H. pylori status was determined by RUT, histology, and serum Ig-G antibody.
Biopsy specimens from the gastric body were evaluated histologically regarding the prevalence
of mucosal atrophy and intestinal metaplasia (IM). Gastric atrophy was also evaluated
serologically by measuring serum pepsinogen (PG) concentration. A value of PG I/II ratio
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lower than 2.0 was considered as an indicator of gastric atrophy. Results: Prevalence of H.
pylori infection was similarly high in both groups (SCC group: 82%, controls: 78%). Mucosal
atrophy and IM were more prevalent in SCC group compared with controls (atrophy: 56%
vs. 32%, p < 0.05; IM: 34% vs. 5%, p < 0.01). Serologically diagnosed gastric atrophy was
also more prevalent in SCC group than in controls (53% vs. 33%, p < 0.05). Proportions
of current smokers were similar between SCC group and controls (37% vs. 33%). Conclusion:
Gastric atrophy concomitant with IM was more frequently observed in the stomach of SCC
group compared with controls, suggesting its relevance to the pathogenesis of SCC of the
esophagus. It is known that carcinogenic agent such as acetaldehyde or nitrosamine is
produced by the microbial overgrowth in the hypochlorhydric atrophic stomach. Such
carcinogens may reflux into the esophagus and be responsible for the development of SCC.
M2091
Evidence from Barrett’s Carcinogenesis That CYP26A1 Is Implicated in Cancer
Chih-Long Chang, Pierre Lao-Sirieix, Rebecca C. Fitzgerald
Background Retinoic acid (RA) is an important signalling molecule for Anterior-Posterior
(AP) patterning in embryogenesis. Tight control of intracellular RA levels results in an
anterior shift in endoderm gene expression and induction of the caudal gene CdxA. CYP26A1
is the major RA catabolising enzyme responsible for maintaining exquisite control over
cellular RA concentrations. Hypothesis We hypothesised that RA signalling may have a role
in determining the altered differentiation status in Barrett’s carcinogenesis. Aims In this study
we have investigated 1) the relationship between RA and CYP26A1 on Barrett’s metaplasia
and associated dysplasia and adenocarcinoma. 2) The functional role of CYP26A1 in vitro.
Methods and Results By using retinoic acid response element (RARE)- reporter cells we
demonstrated that non-dysplastic Barrett’s cell lines (BAR, QhTERT) and non-dysplastic
Barrett’s tissues had the highest levels of RA bioactivity, which decreased with dysplasia in
cell lines (Chtert, Gihtert), and patient tissues (p<0.001). The degree of RA bioactivity was
inversely correlated with CYP26A1 gene levels. Functionally, over-expression of CYP26A1
in Gihtert cells increased proliferation as determined by their cytometric DNA profile and
an MTT assay. An in vitro matrigel assay demonstrated that cells overexpressing CYP26A1
were more invasive (p<0.001). The increased invasion is likely to be due to alterations in
matrix metalloproteinase expression (up-regulation of MMP-3, down-regulation of TIMP-1
and TIMP-3 p<0.05) which were demonstrated by quantitative RT-PCR. Using an organotypic
culture system we also demonstrated that CYP26A1 gene over-expressing cells are “dedifferen-
tiated” as shown by co-localization with a stem-cell marker Oct-4. Pathway arrays showed
induction of c-myc and EGFR expression in these CYP26A1 over-expressing cells. Discussion
Over-expression of CYP26A1 causes intracellular RA depletion and drives the cell into a
highly proliferative, undifferentiated and invasive state with induction of other known
oncogenes. This data suggests a previously unknown role for this gene in cancer.
M2092
Expression of Stem Cell Markers CD34 and THY1 in Adenocarcinoma of
Esophagogastric Junction and Their Prognostic Implications
Kuniaki Aridome, Henning C. Fiegel, Bjoern-Christian Link, Dean Bogoevski, Jussuf T.
Kaifi, Robin Wachowiak, Dietrich Kluth, Emre F. Yekebas, Takashi Aikou, Jakob R. Izbicki
Background: The increase in cancer incidence associated with chronic injury supposed to
be strongly correlated with stem cell renewal as a continuous state of repair. In addition,
bone marrow-derived cells, which are frequently recruited to site of chronic tissue injury
and inflammation, are also suggested to represent a potential source of malignancy. Here,
we focused on carcinoma of the esophagogastric junction as this type of carcinoma frequently
arises after chronic inflammation in association with gastroesophageal reflux. Therefore, we
examined the expression of CD34 class III and Thy1 (CD90) as well established bone marrow
stem cell markers in adenocarcinoma of the esophagogastric junction. Methods: Forty-nine
patients with primary adenocarcinoma of the esophagogastric junction, who underwent
operation with curative intention at the Department of General, Visceral and Thoracic Surgery
at the University Medical Center of Hamburg-Eppendorf, Germany, were included in the
study. Frozen sections were examined by immunohistochemical analysis using monoclonal
antibodies against CD34 class III or Thy1 epitopes. To assess correlation between immunohis-
tochemical findings and clinicopathologic factors Fischer’s exact test and Kaplan-Meier
method with log-rank test was performed. Results: Expression of CD34 as a class III epitope
was confirmed in 14 (29%) out of 49 patients, as cluster of positive tumor cells. Thy1
expression of tumor cells in the membrane and in the cytoplasm appeared in 35 (71%) out
of 49 patients. Thy1 expression was significantly higher in tumors classified as Siewert’s
Type I/II compared to Type III tumors (p<0.05). Thy1 positive patients had distant metastasis
at significantly higher frequency than Thy1 negative group (P<0.01). Patients with positive
Thy1 expression showed worse overall and disease free survival as compared to negative
Thy1 patients (p<0.05). On the other hand, we did not find any significant correlation
between CD34 class III expression in primary tumors and clinicopathological features of
carcinoma of esophagogastric junction. Conclusions: CD34 class III positive cell clusters
were detected and may be regarded as evidence for cancer stem cells in adenocarcinoma of
the esophagogastric junction. Expression of the stem cell marker Thy1 has significant impact
on overall and disease free survival.
M2093
Environmental Risk Factors for Cancer Development Are Not Different
Between Patients with Esophageal and Gastric Cardia Adenocarcinoma
Leonieke Wolters, Pieter-Jan F. de Jonge, Ernst J. Kuipers, Peter D. Siersema
Background: Over the past 3 decades, the major subtype of esophageal carcinomas has
shifted from squamous cell carcinomas (SCC) to adenocarcinomas (EAC). This change in
incidence is attributed to differences in etiology. However, it is largely unknown whether
the same or different risk factors for cancer development are present in patients with EAC

















between patients with SCC and EAC on the one hand and patients with EAC and GCA on
the other hand. Methods: Between January and November 2005, all patients who were
evaluated in the Erasmus MC for esophageal or gastric cardia cancer by endoscopic ultrason-
ography were asked to fill out a questionnaire. This questionnaire comprised information
on the subjects’ history of diet habits, physical activity, gastro-esophageal reflux disease,
history of proton-pump inhibitors (PPIs), H2-receptor antagonists (H2RAs) and NSAID/
aspirin use. Chi-square tests and t-tests were used for statistical analysis. P<0.05 was consid-
ered statistically significant. Results: A total of 208 patients filled out the questionnaire of
whom 112 patients were diagnosed with EAC (90% males, mean age±SD: 62 ± 10 yr), 42
patients with GCA (85% males, 65 ± 11 yr) and 54 patients with SCC (65% males, 63 ±
9 yr). Age, race and education were comparable between the three groups. More female
patients were diagnosed with a SCC compared to EAC (p<0.001). Mean body mass index
at age 20 years was significantly higher in EAC patients compared to SCC patients (24±3
vs. 22±3 kg/m2, p<0.001) but did not differ between EAC and GCA (24±5 kg/m2, p=0.46).
Symptoms of heartburn were more frequently present in EAC patients compared to SCC
(50% vs. 23%, p=0.001) and GCA patients (31%, p=0.031). Use of PPIs was more common
in EAC patients compared to SCC patients (48% vs. 30%, p=0.04), but did not differ
between EAC patients and GCA patients (48% vs 38%, p=0.27). As compared to GCA
patients, EAC patients more often used NSAIDs or aspirin (47% vs 29%, p=0.036; 51% vs
24%, p=0.003). No difference between EAC and SCC patients was observed in NSAID or
aspirin use (47% vs 33%, p=0.078; 51% vs 39%, p=0.167). Smoking and alcohol consump-
tion was not different between the three groups. Conclusion: Patients with EAC and GCA
do not differ grossly with regard to environmental risk factors for cancer development. In
contrast, patients with EAC experienced more reflux symptoms than patients with SCC as
could be expected from the etiologic sequence in development of EAC.
M2094
The Biological Role of Low Affinity Neurotrophin Receptor (p75NTR) in
Esophageal Squamous Cell Carcinoma
Tomoyuki Okumura, Shigeru Tsunoda, Yukiko Mori, Tetsuo Ito, Keiji Kikuchi, Timothy
C. Wang, Shigeru Yasumoto, Yutaka Shimada
Background: Recent observations using several malignancies have demonstrated the identi-
fication of a limited number of cells with a remarkable self renewal potential and extensive
proliferation capacity. Most of these cells are isolated based on the expression of markers
which characterize the stem cells of original normal tissues. The low affinity neurotrophin
receptor (p75NTR) is expressed in a stem/progenitor cell fraction of human normal esophageal
keratinocyte. However, the expression and biological role of p75NTR in esophageal squamous
cell carcinoma (ESCC) have not yet been reported. Methods: Written informed consent was
obtained from the patients for surgery and to use resected samples for research. First
the expression of p75NTR in 187 resected ESCC specimens was immunohistochemically
investigated. Next we investigated the expression of p75NTR in 30 ESCC cell lines (KYSEs)
by RT-PCR, immunocytochemistry and flow-cytometry. We then isolated p75NTR-positive
and negative cells from KYSE150 by magnetic beads to investigate their colony formation.
The role of p75NTR in KYSEs was assessed by transient transfection of siRNA. Results:
p75NTR was expressed in 92 of 187 (49.2%) cancer specimens. In well differentiated tumors,
positive staining was apparent in the first 1-2 layers from infiltrative margin of the tumors
where most of the cells were actively proliferating. In moderately differentiated cases, p75NTR
was expressed in more wide range from the margin of the tumors. The p75NTR was diffusely
distributed in poorly differentiated tumors. p75NTR was expressed in all examined KYSEs
and the mean proportion of the p75NTR-positive fraction was 30.1% (ranged from 0.5%
to 91.8%). Our investigation using KYSE150 demonstrated that p75NTR was expressed in
118 (60.8%) of 194 colonies. The mean diameter of p75NTR-positive and negative colonies
were 969±513μm and 414 ±182μm, respectively (p<0.0001). When the fractionated cells
were plated and cultured, p75NTR was expressed in 178 (82.0%) of 217 colonies and 65
(30.1%) of 216 colonies derived from p75NTR-positive and -negative fraction, respectively
(p<0.0001). Down regulation of p75NTR expression by SiRNA resulted in marked growth
inhibition at 72 hours after siRNA transfection. The TUNEL assay demonstrated that the
Apoptotic Index in the siRNA treated cells and control RNA treated cells were 15.5% and
3.0%, respectively. Conclusion: Our findings suggest that p75NTR is expressed in the actively
proliferating, undifferentiated cell component of ESCC and is necessary for survival and
maintenance of the tumors, providing us with a potential target for novel therapies.
M2095
Socio-Economic Status Plays NO Role in Decision Making On Diagnosis and
Treatment of Esophageal Cancer in the Netherlands
Evelyn P.M. van Vliet, Marinus J.C. Eijkemans, Ernst J. Kuipers, Ewout W. Steyerberg,
Ate van der Gaast, Peter D. Siersema
Background: The socio-economic status (SES) of patients with esophageal cancer in the
United States correlates with tumor histology, staging approach and surgical treatment.
Patients with lower SES have an excess incidence of esophageal squamous cell carcinoma,
whereas those with higher SES more often develop adenocarcinoma. Lower SES patients
more often do not undergo staging procedures and it is demonstrated that black patients
less frequently undergo esophageal resection. It is unknown whether such correlations are
also present in esophageal cancer patients in Western Europe. We therefore assessed whether
a correlation existed between SES of esophageal cancer patients and tumor histology, staging
approach and treatment in The Netherlands. Methods: Between 1994 and 2003, 888 eso-
phageal cancer patients were included in a prospective database with findings on diagnosis
and treatment of esophageal cancer in the Erasmus MC Rotterdam, The Netherlands. The
SES of patients was defined as the mean yearly income, which is collected on a zip code
level by the Central Office of Statistics in The Netherlands. Chi-Square testing (linear-by-
linear association) and multivariate logistic regression analyses were used to determine a
correlation between SES of patients with esophageal cancer and tumor histology, type of
staging procedures and treatment modality. Results: Linear-by-linear association testing
revealed that esophageal adenocarcinoma was more frequently observed in patients with a
higher SES (p=0.02). Multivariate logistic regression analysis showed no correlation between
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SES and the different staging procedures. The odds ratios (OR) for the correlations between
SES and stent placement, and SES and undergoing chemotherapy were however statistically
significant, with a negative correlation between SES and stent placement (OR: 0.79; 95%
C.I. 0.65-0.96) and a positive correlation between SES and chemotherapy (OR: 1.16; 95%
C.I. 1.02-1.32). Finally, no correlation was found between SES and undergoing radiotherapy
(OR: 1.05; 95% C.I. 0.85-1.28), and SES and undergoing esophageal resection (OR: 1.15;
95% C.I. 0.99-1.32). Conclusions: Socio-economic factors do not play a role in the decision
making on diagnosis and treatment of esophageal cancer in The Netherlands. The negative
correlation between SES and stent placement, and the positive correlation between SES and
chemotherapy probably suggests that patients in a higher income class are more eager to
fight their disease.
M2096
The Changing Epidemiology of Esophageal Cancer in the Middle East -
Twenty Year Experience from Kuwait
Iqbal Siddique, Saeed Akhtar, Anjum Memon, Fuad Hasan
Aim: The incidence of adenocarcinoma of the esophagus and gastric cardia has been reported
to be increasing in a number of regions throughout the world, while the incidence of
squamous cell carcinoma of the esophagus is mostly stable or decreasing. However, there
are no reports of the incidence of these malignancies from the Middle East. The aim of this
study is to determine the incidence rates of these malignancies in Kuwait over a 20 year
period. Methods: A population-based Kuwait Cancer Registry was established in Kuwait in
1979. Notification of all cancers to the registry by all hospitals in the country is compulsory
through a Ministerial Decree. The registry collects information on malignant neoplasms
according to the recommendations of the International Agency for Research on Cancer
(IARC). Kuwaiti nationals with adenocarcinoma of the esophagus and gastric cardia, as well
as squamous cell carcinoma of the esophagus were identified in the registry for a 20 year
period between 1980 and 1999. Age-standardized rates (ASR) were calculated for these
malignancies using the World Health Organization (WHO) world standard population
distribution as reference. Results: The ASR (per 100,000) for adenocarcinoma of the eso-
phagus and gastric cardia and squamous cell carcinoma of the esophagus are shown in
Table 1. The ASR for adenocarcinoma of the esophagus and gastric cardia has increased
slightly from 4.6 in 1979-1984 to 6.0 in 1995-1999, while the ASR for squamous cell
carcinoma has fallen from 31.2 in 1979-1984 to 7.9 in 1995-1999. Conclusions: The
incidence of adenocarcinoma of the esophagus and gastric cardia has increased slightly,
while the incidence of squamous cell carcinoma of the esophagus has decreased markedly
in Kuwaiti citizens between 1980 and 1999. Further research into esophageal and gastric
cardia adenocarcinoma is needed to clarify the risk factors and mechanisms responsible for
these changing trends as well as geographical disparities in incidence.
Table 1. Age-standardized Rates for Adenocarcinoma of Esophagus and Gastric Cardia and
Squamous Cell Carcinoma of Esophagus in Kuwait (1980-1999)
M2097
Clinical and Endoscopic Factors Predict Higher Pathologic Grades of Barrett’s
Esophagus
Sharmila Anandasabapathy, Marta Davila, Caimaio Wei, Jeffrey Morris, Robert Bresalier
Background: Barrett’s esophagus is highly prevalent in the western world, however, only a
minority of those who develop Barrett’s progress to esophageal adenocarcinoma. While many
studies have examined risk factors for development of Barrett’s metaplasia, little data is
available on risk factors for progression to neoplasia. Identifying simple, reliable, clinical
and endoscopic predictors of risk for development of high-grade dysplasia and adenocarcin-
oma would be helpful for risk stratification in screening and surveillance programs. Methods:
Clinical, endoscopic, and histologic data were retrospectively reviewed on patients with a
new diagnosis of Barrett’s esophagus seen at M.D. Anderson Cancer Center between the
years 2002-2005. Patients were classified, by an expert GI pathologist, as having intestinal
metaplasia alone, indefinite-for-dysplasia or low-grade dysplasia, high-grade dysplasia, and
esophageal adenocarcinoma. Gender, age, race, hiatal hernia presence, hiatal hernia size,
Barrett’s length, H. pylori status, BMI, alcohol, smoking, PPI use and duration, and duration
of reflux symptoms were evaluated by logistic regression analysis for their association with
dysplasia severity. Results: 109 patients (26 women, 83 men, mean age: 58.8) were newly
diagnosed with either Barrett’s metaplasia (n=39), indefinite/low-grade dysplasia (n=35) and
high grade dysplasia/esophageal adenocarcinoma (n=35) over a three-year period. On logistic
regression analysis, duration of reflux symptoms for > 20 years (OR: 5.67, P=0.0090),
Barrett’s segment length ≥ 6 cm (OR: 8.37, P<0.0001), hiatal hernia size > 4 cm (OR:10.63,
P=0.0270), and male gender (OR: 4.03, P=0.0018) were associated with higher grades of
disease. Duration of reflux symptoms, Barrett’s length, and hernia size were significant as
both discrete and continuous variables. Absence of H. pylori (OR: 2.73, P=0.0607) approached
significance in predicting dysplasia severity. In a bivariate model, gender and Barrett’s length
(OR: 2.52, P=0.0490 and OR: 1.30, P<0.0001,) were both significantly associated with grade
when considered together, as were gender and hernia size (OR: 4.64 , P=0.0049 and OR:
12.18, P=0.0197). Conclusions: Male gender, longstanding GERD, hiatal hernia size, and
length of Barrett’s esophagus are strongly associated with higher grades of dysplasia at index
diagnosis. These factors, as well as H. pylori status, warrant further prospective evaluation
as predictors of risk for development of high-grade dysplasia and esophageal adenocarcinoma
in Barrett’s esophagus.
M2098
Angiotensin Converting Enzyme Inhibitors Reduce the Incidence of
Esophageal Cancer: A Study of Half a Million US Veterans
Vikas Khurana, Kondal Kyanam, Gloria Caldito
AIM: To investigate the effect of Angiotensin Converting Enzyme (ACE) Inhibitors use in
reducing the incidence of esophageal cancer in the US veteran population. BACKGROUND:
ACE Inhibitors are commonly used antihypertensive and nephroprotective agents. Vascular
Endothelial Growth Factor (VEGF) is believed to play a major role in angiogenesis in
human tumors. Blocking the VEGF inhibits angiogenesis and suppresses tumor growth.
ACE inhibitors cause suppression of VEGF in experimental models, leading to their anticancer
effect. ACE Inhibitors have been noted to suppress tumor growth by inhibiting tumor
angiogenesis in several animal and experimental models. DESIGN: The VISN 16 database
contains clinical and demographic information about all veterans (>1.4 million patients)
cared for in the South Central VA Health Care Network (eight states in south central United
States). The data was queried from Oct 1998 to June 2004, using a retrospective case control
design. Statistical analysis was performed using SAS software version 9.0 (Chicago, IL).
Multiple logistic regression analysis was used with calculation of odds ratios and 95%
confidence intervals. The data was adjusted for age, race, gender, BMI, smoking, alcohol
use, reflux, NSIAD use, and diabetes. Patients were placed in the ACE inhibitor user group
if they were using ACE inhibitors prior to the diagnosis of esophageal cancer. RESULTS: A
total of 483,733 patients were included in the analysis. 185,830 (38.4%) of those were
using ACE inhibitors. Esophageal cancer (ICD code of 150) was seen in 659 (0.14%). ACE
inhibitor users were 55% less likely to develop esophageal cancer (Odds ratio 0.546; 95%
CI 0.450-0.662, p <0.01). The protective effect of ACE inhibitors was independent of statin
use. Other significant covariates include age (OR 1.021, 95% CI for OR 1.015, 1,028, p
<0.01); reflux (OR 2.20, 95% CI for OR 1.849, 2.618, p <0.01); prior statin use (OR 0.452,
95% CI for OR 0.369, 0.553, p<0.01) and diabetes (OR 1.314, 95% CI for OR 1.064,
1.622, p<0.01). CONCLUSION: ACE inhibitors are associated with a 55% reduced incidence
of esophageal cancer after controlling for age, race, gender, BMI, smoking, alcohol use,
reflux, NSIAD use, diabetes and statin use. The limitations of our data are the VA population,
the database and the fact that this is a case control study. The dose, duration and type of
ACE inhibitor used were not factored into the analysis.
M2099
Loss of Klf4 Alters the Proliferation-Differentiation Equilibrium in Mouse
Esophageal Epithelia
Bree G. Goldstein, Yizeng Yang, Jonathan P. Katz
Background and aims: Klf4 (Krüppel-like factor 4, previously known as GKLF) is a DNA-
binding transcriptional regulator highly expressed in skin and gastrointestinal epithelia,
specifically in regions of differentiating cells. Homozygous null mice for Klf4 die shortly
after birth from skin defects, and conditional ablation of Klf4 in stomach alters epithelial
proliferation and differentiation. In esophageal epithelia, Klf4 transcriptionally regulates a
number of genes vital to proliferation, differentiation, and transformation, including keratin
4, keratin 19, and ED-L2. The aim of this study was to analyze the function of Klf4 in
esophageal epithelial proliferation and differentiation in vivo. Methods: The ED-L2 promoter
of Epstein-Barr virus, previously shown to target expression to the squamous epithelia of
tongue, esophagus, and forestomach, was used to drive Cre recombinase in esophageal
epithelia. ED-L2/Cre founder lines were mated to Gt(ROSA)26tm1Sor reporter mice to screen
for Cre expression and to Klf4loxP/loxP mice to produce esophageal-specific gene ablation of
Klf4. Mice were examined grossly and tissues were harvested at 1, 2 and 6 months of age
for histology, immunohistochemistry, and RNA analyses. Mice were injected with BrdU 1
hour prior to sacrifice. Results: Using Gt(ROSA)26tm1Sor reporter mice, we demonstrated
Cre-mediated recombination in esophageal epithelia of two independent ED-L2/Cre lines.
ED-L2/Cre;Klf4loxP/loxP mice were born at appropriate Mendelian ratios, appeared grossly
normal, and survived into adulthood. Staining for Klf4 revealed expression in skin of
both control and ED-L2/Cre;Klf4loxP/loxP mice. In contrast, Klf4 expression was absent from
esophageal epithelia of ED-L2/Cre;Klf4loxP/loxP mice. Esophageal epithelia of ED-L2/Cre;Kl-
f4loxP/loxP mice were hyperplastic and had evidence of proliferation in suprabasal cells, which
normally have ceased dividing and begun the differentiation program. Moreover, Klf5, a
KLF family member with pro-proliferative and transforming properties which is normally
confined to proliferating basal cells, was expressed throughout the suprabasal layer of ED-
L2/Cre;Klf4loxP/loxP mice. Conclusions: ED-L2/Cre transgenic mice represent a valuable tool
for studies of esophageal function of genes where ablation in skin leads to early lethality.
Loss of Klf4 in esophagus causes epithelial hyperplasia, and Klf4 inhibits proliferation in
differentiating esophageal epithelial cells and downregulates Klf5 during the switch from
proliferation to differentiation in esophageal epithelia. Thus, Klf4 is a key regulator of
esophageal epithelial proliferation and differentiation in vivo.
M2100
Her-2/Neu Amplification and Over Expression in Esophageal Adenocarcinoma
Bernard S. Stacey, James D. Shutt, Ghasem Yadegarfar, Praful Patel, Adrian C. Bateman
Aims: To test the hypotheses that HER-2/neu amplification is a frequent genetic event in
esophageal adenocarcinoma and that gene amplification is associated with HER-2/neu protein
expression, histopathological tumour characteristics and clinical outcome. Methods: Fluores-
cence in situ hybridization (PathVysion; Vysis, Downers Grove, IL) and immunohistochem-
istry (Herceptest; Dako, Glostrup, Denmark) was performed on formalin-fixed and wax-
embedded sections of 100 archival specimens of esophageal adenocarcinoma with a minimum
five year clinical follow up, to assess HER-2/neu gene amplification and protein over expression
respectively. Both the Herceptest and Pathvysion kits have been approved by the US Food
and Drug Administration for use in breast cancer for determining which patients might
benefit from trastuzumab therapy. The relationship of gene amplification and protein over
expression to histopathological tumour characteristics and survival was determined. Results:
Amplification of HER-2/neu was identified in 12 cases (12%) of esophageal adenocarcinomas
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and this correlated with HER-2/neu protein over expression (scoring 2+ or 3+ by the
Herceptest protocol) in 4 of these cases (p<0.001). Amplification of HER-2/neu and chromo-
some 17 polyploidy co-existed in 2 cases. Chromosome 17 polyploidy alone was present
in 26 cases (26%), with 2 of these cases over expressing HER-2/neu protein (p=0.09). No
HER-2/neu protein over expression was seen in the 62% of tumours that were diploid for
chromosome 17 and without HER-2/neu amplification. Cox regression analysis indicated
that patients with HER-2/neu gene amplification (HR=1.95, 95% CI: 0.94 - 4.01, p=0.07)
and chromosome 17 polyploidy (HR=1.73, 95% CI: 1.04 - 2.88, p=0.04) had higher risk
of death than patients with disomy. However, there was no association between HER-2/neu
amplification or chromosome 17 polyploidy and histopathological features such as tumour
grade, pathological stage and node metastasis. Conclusions: Amplification of HER-2/neu as
determined by fluorescence in situ hybridization occurs in some oesophageal adenocarcin-
omas and is associated with a trend to impaired survival. It is possible that this gene
amplification might indicate the potential response of these tumours to trastuzumab therapy.
M2101
Prospective Comparison of Transthoracic (TTe) Versus Transhiatal (THe)
Oesophagectomy Following Neoadjuvant for Oesophageal Cancer
Matthew Morgan, Wyn Lewis, S Burrows, D Goricha, Neil Hopper, Michael Stephens,
Ashley Roberts, Alison Brewster, Tom Crosby, Timothy Havard, Geoffrey Clark
Aims. Transthoracic esophagectomy has been championed as a better cancer operation than
transhiatal esophagectomy because the approach facilitates meticulous wide tumour excision
and lymphadenectomy. Neoadjuvant chemoradiotherapy (CRTS) and chemotherapy (CS)
have recently been reported to improve outcomes, and we aimed to compare outcomes after
neoadjuvant treatment related to operative approach. Methods. One hundred and nine
consecutive patients managed by a regional upper GI multidisciplinary team (3 specialist
surgeons) were studied prospectively. All patients were staged with both CT and EUS, and
treatment decisions were stage and performance status, related with THe reserved for patients
with impaired respiratory reserve. Results (table). Conclusion. Despite the fact that patients
undergoing THe were less fit, operative time was significantly less, operative mortality was
similar, and there was a modest survival benefit associated with the transhiatal approach in
addition to neoadjuvant therapy. Although follow up is relatively short, these results support
the role of neoadjuvant therapy followed by THe in patients with respiratory comorbidity.
Results
Figures are median, P<0.0001.
M2102
Over-Expression of mRNA and Protein of CDC25B and LAMC2 in Esophageal
Squamous Cell Carcinomas from a High-Risk Population in China
Philip Taylor, Jin-Zhong Shou, Nan Hu, Mark Roth, Laura Lee Johnson, Carol Giffen,
Quan-Hong Wang, Chaoyu Wang, Yuan Wang, Hua Su, Li-Hui Kong, Michael Emmert-
Buck, Alisa Goldstein, Stephen Hewitt
Purpose: To evaluate CDC25B and LAMC2 mRNA and protein expression in esophageal
squamous cell carcinoma (ESCC). Experimental design: (i) Seventy-three ESCC cases with
frozen tumor and matched normal tissues were evaluated for CDC25B and LAMC2 mRNA
expression using a real-time quantitative RT-PCR and the 2 -ΔΔCT method; and (ii) 373
cores on a tissue microarray representing 294 ESCC cases were evaluated for CDC25B and
LAMC2 protein expression using immunohistochemical analysis. Results: (i) CDC25B mRNA
was over-expressed (≥2 N-fold over-expression in tumor compared to normal) in 66% of
the 73 cases evaluated, while LAMC2 mRNA was over-expressed in 89% of cases. (ii) CDC25B
protein was detected by immunohistochemistry in 93% (240/259) of tumors on the tissue
microarray compared with only 39% (9/23) of histologically normal esophageal tissue cores
(P<0.05); LAMC2 was detected in 92% (263/296) of tumor cores as well as all cores of
normal epithelium. LAMC2 protein expression was significantly associated with a number
of favorable tumor characteristics (differentiation, non-metastatic disease, and lower tumor
grade) and patients who expressed LAMC2 protein had longer median survival (24 versus
14 months, P=0.017). Conclusions: CDC25B and LAMC2 showed marked over-expression
of both mRNA and protein in ESCC, suggesting that these two genes may play an important
role in development of ESCC and are potential early detection and prognosis biomarkers
for ESCC.
M2103
Comparison of DNA Ploidy Determination By Flow Cytometry (FC) and
Image Cytometry (IC) in Esophageal Adenocarcinoma (EAC)
Qin Huang, Chenggong Yu, Raj K. Goyal
Introduction. Purpose of this study was to compare the sensitivity of detection of DNA
aneuploidy in EAC by flow cytometry (FC) with DNA content analysis of the affected cells
using image cytometry (IC). Methods and Materials. 21formalin fixed and paraffin embedded

















were dissociated to generate single cells suspension; cells were stained with propidium iodide
and analyzed on the FACS Calibur instrument. IC was performed using two adjacent 7 µm
sections, one H&E stained for identification of the affected areas and the adjacent one
Feulgen-stained for IC on the Automated Cellular Imaging System (ACIS). In FC aneuploidy
was diagnosed when there was a distinct aneuploid peak in addition to a diploid peak. In
IC, DNA index (DI) of the primary peak was determined and cases with DI ≥ 1.3 were
considered to be aneuploid. Results. FC detected aneuploid peaks in 12 (57%) and diploid
peaks with a high S-phase fraction over 15% in additional 3 samples. In all, 15 (71%)
tissues were aneuploid and 6 (29%) were diploid. The diagnosis of aneuploidy on FC was
poorly reproducible. In contrast all (100%) EAC tissues reproducibly showed aneuploidy
on IC. IC also showed that 2/3rd of the samples also had elevated cell fractions (>14%)
outside the primary peak. These samples may represent cancers with unstable aneuploidy.
Summary and Conclusion: Our preliminary data showed that: (1) 29% of EAC tissues were
diploid on flow cytometry but aneuploid on image cytomtry; (2) Aneuploidy determination
by flow cytometry was poorly reproducible. (3) Aneuploidy detection by IC using ACIS is
more sensitive and reproducible than that by FC.
M2104
Photodynamic Therapy Is of Benefit in Treatment of Early Oesophageal
Carcinoma
Carol F. Craig, Mhari MacPherson, Heather Hodgson, Joanna Gray, Mark Zammit, Grant
Fullarton
INTRODUCTION The current gold standard treatment of early oesophageal carcinoma is
oesophagectomy. The primarily elderly population affected are often medically unfit for this
radical intervention and less invasive curative options are required. AIM To relate our
experience of photodynamic therapy (PDT) as an alternative to surgery in early oesophageal
cancer patients. METHODS 30 oesophageal cancer patients (M=20, F=10; median age 74
years; 80% adenocarcinoma, 20% squamous) over a six year period were found to have
early stage disease based initially on endoscopy/ CT assessment and latterly on CT/ Endoscopic
ultrasound criteria. Although potentially suitable for major surgical resection these patients
were judged to be medically unfit and were selected to have PDT. 48 hours prior to endoscopy
patients received iv porfimer sodium (photofrin™), 2mg/kg as a photosensitising agent. Red
laser light activation of the drug was initiated at endoscopy using a 630nm fibre delivering
a light dose of 300j/cm. Patients were followed up endoscopically at 6-12 week intervals
indefinitely. Routine biopsies of the treated area were obtained. Median follow up was 30
months (2-56 months). RESULTS Overall 20/30 patients had an initial complete endoscopic
and histological response to therapy 8 weeks post procedure. 1 patient died before reassess-
ment of unrelated disease. 9 patients had residual tumour at endoscopy and were considered
treatment failures. 8/20 complete responders remained disease free for a median follow up
of 1103 days (249-2019). 12/20 developed recurrent local disease treated with further PDT
with a median survival of 922 days (254-2049). Only the latter 14 patients assessed had
EUS staging. EUS accurately predicted response as shown in table 1: All T1 N0 patients (9/
14) has initial complete response to treatment although 5/9 have required further PDT
sessions. All remain disease free currently. No patients with T2/3 N0 disease had complete
response to treatment. The major complication of PDT encountered was stricture formation
which occurred in 50% of cases and required a median of 5 dilations (Range 1-31). CONCLU-
SION PDT is a well tolerated and potentially curative treatment in selected patients with
early oesophageal carcinoma. Accurate T staging with EUS is essential in selection of suit-
able patients.
Table 1. Response to PDT.
*1 patient died prior to reassessment
M2105
Prognostic Significance of Body Mass Indices (BMI) in Patients Undergoing
Esophagectomy for Carcinoma
Matthew Morgan, Neil Hopper, Wyn Lewis, Xavier Escofet, Alison Brewster, Tom Crosby,
Timothy Havard, Geoffrey Clark
Aims. Obesity is prevalent in Western society, even in patients with esophageal cancer, and
apart from increased technical operative difficulty, overweight patients are more likely suffer
co-morbidity and post operative complications. The aim of this study was to determine the
role of body mass index (BMI) in a Western population on outcomes after esophagectomy
for esophageal cancer. Methods. Between June 1, 1998 and August 30, 2005, 203 consecutive
patients underwent esophagectomy by three specialist consultant upper GI surgeons. Patients
with a BMI of greater than 25kg/m2 were classified as overweight [n=111 (55%), median
age 62 yr, 87m), and 29 patients (14%) were classified as obese (BMI >30Kg/m2). Results
(table). Conclusion. Thus 55% of patients were overweight, and although high BMIs were
associated with higher anaesthetic risk, this did not translate into higher operative mortality.
Recurrence rates were 16% higher and long-term survival 13% worse after R0 esophagectomy
in patients with high when compared with low or normal BMIs.
Results
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Figures are median. P not significant. TTe = transthoracic esophagectomy. THe = transhia-
tal esophagectomy.
M2106
Prospective Cohort Comparison of Neoadjuvant Chemoradiotherapy Versus
Chemotherapy for Patients Diagnosed with Oesophageal Cancer
Matthew Morgan, Sarah Burrows, Deenita Goricha, Neil Hopper, Xavier Escofet, Ashley
Roberts, Alison Brewster, Tim Havard, Geoff Clark, Tom Crosby, Wyn Lewis
Aims. Despite neoadjuvant chemo radiotherapy’s (CRTS) early promise, associated post-
operative morbidity and the publication of the results of OEO2, have resulted in neoadjuvant
chemotherapy (CS) being the current neoadjuvant treatment of choice for resectable T3 N0/
1 M0 oesophageal carcinoma. We aimed to study the effects of both therapies on outcomes
for patients treated within the framework of a regional multi disciplinary team. Methods.
Between January 1, 1998, and 2000, 88 patients with resectable oesophageal carcinoma of
any cell type received neoadjuvant chemo radiotherapy [2 cycles cisplatin (60mg/m2) with
225 mg/m2 per day of infusional 5FU, prior to 45 Gy in 25 F concurrent with 3 weekly
cisplatin (60 mg/m2) and infusional 5FU 200mg/m2/day]. After the publication of OEO2
in 2002, 97 patients received neoadjuvant chemotherapy (two 4-day cycles, 3 weeks apart
of Cisplatin 80 mg/m2 plus fluorouracil 1000mg/m2). Results (table). Conclusion. Patients
receiving neoadjuvant chemo radiotherapy were almost twice as likely to survive long-term
than patients receiving chemotherapy provided they did not suffer serious postoperative
morbidity and mortality. Neoadjuvant chemoradiotherapy should arguably remain an option
for oesophageal cancer patients of satisfactory performance status.
Results.
Figures are median (range), *P= 0.019 **P=0.04, ***P<0.00001, ****P= 0.049, ****P=
0.009.
M2107
Gadd45 and P27 mRNA Expression in Esophageal Cancer: Association with
Histopathologic Response to Neoadjuvant Therapy and Prognosis
Daniel Vallbohmer, Hiroshi Higashi, Shuichi Hokita, Ralf Metzger, Ute Warnecke-Eberz,
Stephan E. Baldus, Jan Brabender, Martin Kocher, Rolf-Peter Mueller, Takashi Aikou,
Arnulf H. Hoelscher, Paul M. Schneider
Background: The DNA damage-inducible gene GADD45 and the tumor suppressor gene
p27 are key factors in cell cycle regulation and apoptosis. There is some evidence that both
genes might play a role in chemo- or radiation sensitivity of solid tumors. Recently, we have
demonstrated that histomorphologic regression is a significant prognostic parameter for
patients with esophageal cancer receiving neoadjuvant radiochemotherapy followed by sur-
gery. The aim of this study was to examine the association of quantitative Gadd45 and p27
mRNA expression with histopathologic response to neoadjuvant radiochemotherapy followed
by transthoracic en bloc esophagectomy and prognosis of patients with locally-advanced
esophageal cancer. Patients and methods: 46 patients with potentially resectable esophageal
cancers (cT2-4, Nx, M0) received neoadjuvant radiochemotherapy (cisplatin, 5-FU, 36 Gy)
followed by transthoracic en bloc esophagectomy. Histomorphologic regression was defined
as major response when resected specimens contained less than 10 % of residual vital tumor
cells and minor response when resected specimens contained more than 10 % of residual
vital tumor cells. RNA was isolated from endoscopic biopsies (paired tumor and normal
tissue) prior to neoadjuvant treatment and quantitative real-time RT-PCR was performed to
determine Gadd45 and p27 mRNA expression levels. RNA expression levels were standard-
ized for β-actin. Results: The mRNA expression of Gadd45 and p27 in pretherapeutic
biopsies was not significantly different between paired tumor and normal tissue specimens
(Wilcoxon test: p=0.34;. p=0.32). Neither absolute mRNA expression levels in tumors or
normal tissues nor the RNA ratio between tumor and paired normal tissue was associated
with pT, pN, grading, or prognosis. Histopathologic regression following neadjuvant therapy
itself was significantly associated with patients` prognosis (log rank: p = 0.01). Absolute or
relative expression levels of Gadd45 or p27 in pretherapeutic biopsies however, did not
indicate histopathologic response following neoadjuvant treatment. Conclusion: Expression
patterns of Gadd45 and p27 appear not to be involved in the pathogenesis or progression
of esophageal cancer. In addition, Gadd45 and p27 mRNA expression levels did not predict
histopathologic regression to neoadjuvant therapy or prognosis in patients with eso-
phageal cancer.
M2108
What Is the Relationship Between H.pylori Infection and Esophageal
Malignancy?
Changcheng Wang, Yuhong Yuan, Richard H. Hunt
Purpose: A possible role of H.pylori infection in esophageal malignancies is unclear. No
systematic review has analyzed the relationship between H.pylori infection and different
types of esophageal cancer. We explored the relationship between H.pylori infection and
development of esophageal cancer. Methods: MEDLINE and EMBASE English language
searches for human studies were performed using keywords “(o)esophageal cancer or (o)eso-
phageal neoplasms or (o)esophageal carcinoma” and “Helicobacter pylori or Campylobacter
pylori” published to Oct 2005. Searches generated 132 citations, and 10 met inclusion
criteria: cohort or case-control studies with raw data on prevalence of H.pylori infection in
esophageal cancer and controls; H.pylori detected by histology and/or serology; studies in
adult populations. Exclusion criteria: studies without controls or raw data for retrieval and
duplicate publications. Results: 1194 patients with esophageal cancer and 3497 controls
were identified. Overall prevalence of H.pylori infection and cagA+ strains in esophageal
cancer cases compared with controls was 32.6% (389/1194) vs 44.7% (1563/3497)
(p<0.0001, OR=0.60, 95% CI 0.48-0.76) and 25.9% (173/669) vs 33.5% (611/1824)
(p<0.0001, OR=0.66, 95% CI 0.54-0.81), respectively. The prevalence of H.pylori infection
and cagA+ strains was significantly lower in esophageal adenocarcinoma than that in controls
[34.3% (184/536) vs 47.7% (1196/2506), p<0.0001, OR=0.55, 95% CI 0.41-0.73] and
[18.9% (79/417) vs 33.5% (611/1824) (p=0.0002, OR=0.47, 95% CI 0.32-0.70)], respect-
ively. In 3 small studies in squamous cell cancer (n=91) there was marked heterogeneity
(test for heterogeneity: p<0.0001) and no significant difference between H.pylori prevalence
in esophageal squamous cell cancer and controls [34.3% (91/265) vs 40.5% (356/880), p=
0.80, OR=0.89, 95% CI 0.35-2.25]. Conclusion: H.pylori infection and cagA+ strains are
inversely related to esophageal adenocarcinoma strongly suggesting that H.pylori infection
has no aetiological role in esophageal adenocarcinoma. There is no clear relationship between
esophageal squamous cell cancer and H.pylori infection.
Fig. Prevalence of H.pylori infection in esophageal adenocarcinoma and controls
M2109
No Methylation Or Reduction in the Expression of TIMP3 in Squamous Cell
Carcinoma of the Esophagus from a Region of High Incidence in China
Eric Smith, Maria Caruso, Zi-Qing Tian, Jun-Feng Liu, John J. Kelly, Andrew R.
Ruszkiewicz, Paul A. Drew
TIMP3 is an inhibitor of the proteolytic activity of matrix metalloproteinases and therefore
may have the potential to reduce tumour invasion and metastasis. It has also been reported
to induce apoptosis in cancer cells and suppress tumour growth and angiogenesis. It is
downregulated in a number of cancers, and linked to a poor outcome. Loss of expression
has been associated with methylation of the TIMP3 gene promoter in tumors, including
esophageal adenocarcinoma. In a study of patients from Gunma, Japan, the only report of
TIMP3 expression in esophageal squamous cell carcinoma, a reduction in its expression was
seen in 67% of 90 tumours, which correlated with invasive activity and metastasis. Although
methylation was suggested as a possible mechanism for the observed downregulation, it
was not assessed in the study. The aim of this study was to measure methylation in the
promoter of the TIMP3 gene in squamous cell carcinoma and relate this to any change of
gene expression. Tumours and proximal resection margins were obtained from 51 patients
operated on for esophageal squamous cell cancer at the 4th Hospital of Hebei Medical
University, China. During the follow up period (mean 569 days) 9 patients had died (mean
survival of 476 days after the operation), 27 were alive, and 15 were lost to follow up.
There were 3 T1 tumours, 11 T2, 30 T3 and 4 T4, with node involvement recorded for
30%, and for 3 no staging information was available. No methylation was detected in the
TIMP3 gene promoter in any of the tumour or proximal margin tissues. Expression of TIMP3
was determined by immunohistochemistry. After microwave induced antigen retrieval the
sections were stained using a monoclonal antibody to TIMP3 (Chemicon) and the MACH4™
universal probe HRP-polymer kit (Biocare Medical). All cases showed strong heterogeneous
cytoplasmic staining in cancer cells. Strong heterogeneous cytoplasmic expression of TIMP-
3 was also observed in the normal proximal resection margin mucosa in 5 cases, but was
limited to the basal layers of squamous epithelium. There was no evidence of reduced or
partial staining. In this cohort of patients with esophageal squamous cell carcinoma of the
esophagus there was no methylation of the TIMP3 gene promoter nor alteration in TIMP3
protein expression, regardless of the stage of or outcome from the disease. Further studies
are required to determine if the conflicting results on TIMP3 expression in this cancer are
a result of methodological differences, or reflect a difference in aspects of the molecular
biology of the disease between regions.
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M2110
Late Toxicity After Definitive Chemoradiotherapy for Patients with Esophageal
Squamous Cell Carcinoma
Yosuke Kumekawa, Kazuhiro Kaneko, Hiroaki Ito, Toshinori Kurahashi, Taikan
Yamamoto, Meiko Kuwahara, Yotaro Kubota, Takashi Muramoto, Michio Imawari
Background/Aims: We retrospectively investigated the long-term toxicity after concurrent
chemoradiotherapy (CRT) for patients with esophageal squamous cell carcinoma (ESCC).
Patients and Methods: Concurrent chemoradiotherapy was performed in 110 patients with
T1 to T4 disease containing M1 lymph node (LYM) disease. Our recruitment criteria were
defined as follows: age < 75 years, ECOG performance status 0 to 2, normal heart and
pulmonary function, and clinical stage I to IVA. Chemotherapy consisted of protracted
infusion of 5-fluorouracil 400 mg/m2/24 hours on days 1 to 5 and 8 to 12, combined with
2-hour infusion of cisplatin 40 mg/m2 on days 1 and 8. Radiation treatment at a dose of 30
Gy in 15 fractions of the mediastinum was administered concomitantly with chemotherapy. A
course schedule with 3-week treatment and 2-week break was applied twice, with a total
radiation dose of 60 Gy, followed by two or more courses of 5-fluorouracil 800 mg/m2/24
hours on days 1 to 5 and cisplatin 80 mg/m2 on days 1. For the assessment of toxicity, the
Radiation Therapy Oncology Group/European Organization for Research and Treatment of
Cancer late radiation morbidity scoring schema was adopted. Results: Of 110 patients who
received definitive CRT, 29 patients who received palliative CRT and did not match the
recruitment criteria were excluded from this study. A total of 81 patients were recruited,
and their characteristics were as follows: median age, 63 years ranging from 42 to 75 years;
74 men and 7 women. The clinical staging was as follows: stage I in 8 patients, stage II in
14 patients, stage III in 25, and stage IV in 34. There were 22 patients with T3 disease
(27%), and 44 with T4 disease (54%). Of 81 patients, 33 had M1 LYM disease (41%). The
median survival time was 14 months, and the 3-year survival rate was 22%. Thirty-four
patients (42%) achieved complete response (CR). Of 34 patients with CR, one patient died
as a result of acute myocardial infarction. Grade 2, 3, and 4 late toxicities occurred with
the following incidences: pericarditis in 3 patients, 1 patient, and 2 patients, respectively;
heart failure in 0, 0, and 3 patients; pleural effusion in 2, 3, and 0 patients; and radiation
pneumonitis in 0, 0, and 1 patient, respectively. In total, 4 patients died without cancer
recurrence, and these causes of death may have been related to cardiopulmonary toxicity.
Conclusion: Definitive chemoradiotherapy for ESCC is effective with substantial toxicities.
Further investigation is warranted to minimize the normal tissue toxicities.
M2111
The Effect of CDGP On Phosphorylation of Histone H2ax Induced By
Irradiation in Esophageal Squamous Cancer Cells
Takahisa Furuta, Naohito Shirai, Mitsushige Sugimoto, Akiko Nakamura, Satoshi Osawa,
Mutsuhiro Ikuma, Masayoshi Kajimura, Akira Hishida
Backgrounds/Aims: Chemoradiation therapy with irradiation (IR) and a platinum agent,
such as CDDP (Cisplatin) or CDGP (Nedaplatin), yields high cure rate in esophageal cancer.
However, the mechanisms by which the platinum agent enhances the cellular susceptibility
to IR have not been fully elucidated. When irradiation induces DNA double strand breaks
(DSBs) in cells, histone H2AX is immediately phosphorylated. The phosphorylated H2AX
is called as gH2AX, which is the sensitive marker of DSBs. Then, we studied the effect of
platinum agent, such as CDGP, on the IR-induced gH2AX. Methods: Esophageal squamous
cancer cells (JCRB0190 [KYSE-70]) were exposed to 0 or 2 Gy of IR. At 15 min before IR,
CDGP or control medium was added to the culture medium (the final concentration of
CDGP was 3 µM). The medium was changed with the fresh medium without CDGP at 3
hours after IR to remove the CDGP. Before and 1, 3, and 24 hours after IR, induction of
gH2AX was determined by an immunofluorescence and westernblotting analyses. Tunnel
staining was also performed. Results: 2 Gy of IR induced gH2AX, which reversed within
24. This reversal was inhibited by incubation with 3 µM of CDGP for 3 hours. gH2AX
induction by 3 µM of CDGP alone was weak. At 24 hours after IR, tunnel positive cells
were observed in cells treated with IR and CDGP. When cells were treated with 2 Gy of IR
alone or 3 µM of CDGP 3 hours alone, tunnel positive cells were very small throughout
the study period (0 - 24hrs). Conclusion: The low dose of CDGP inhibits the repair of DSBs
induced by IR, which would be related to the high cure rates of chemoradiation therapy
for esophageal cancer with IR and CDGP.
M2112
Therapeutic Gene Transfer of a Glycosyltransferase, Which Is Exclusively
Expressed in Normal Gastrointestinal Mucosa, Efficiently Prevents Gastric
Cancer Metastasis
Yuki I. Kawamura, Yasuo Adachi, Rei Kawashima, Noriko Mizutani, Noriko Toyama-
Sorimachi, Norihiro Nishimoto, Taeko Dohi
Increased expression of sialyl Lewis x and sialyl Lewis a carbohydrate determinants correlates
with clinical stages and formation of metastatic lesions for both gastric and colon cancer.
Recently we reported that forced expression of a β1,4N-aceytylgalactosaminyltransferase
synthesizing Sda carbohydrate antigen (Sda-β1,4GalNAcT) in gastrointestinal (GI) cancer
cells reduced their expression of sialyl Lewis x/a carbohydrates, ligands for E-selectin, and
decreased the metastatic potential (Cancer Res., 65, 6220-6227, 2005). Here, we aimed to
control expression of sialyl Lewis x/a carbohydrate determinants of cancer cells using Sda-
β1,4GalNAcT gene in vivo, and eventually prevent metastasis. For this purpose, we used
fiber-knob-modified adenoviral (Ad) vector, which contains the chimeric construct with a
serotype 5 shaft and a serotype 3 knob (Ad5/3). Using Ad5/3 vectors to introduce the Sda-
β1,4GalNAcT gene into human gastric cancer cell line KATO III in vitro, we confirmed that
almost all cells expressed Sda along with the concomitant decrease of sialyl Lewis x antigen.
Ad5/3-Sda-β1,4GalNAcT-infected KATO III cells showed significantly decreased adhesion
to E-selectin-expressing CHO cells compared with Ad5/3-GFP-infected cells. We assessed
the therapeutic effect of treatment with Ad5/3-Sda-β1,4GalNAcT vectors in vivo mouse

















vectors after inoculation of KATO III cells significantly reduced the incidence of metastasis
compared with that of Ad5/3-GFP. These results indicate that Sda-β1,4GalNAcT gene transfer
modified carbohydrate chains of cancer cells in vivo and has therapeutic interference with
selectin-mediated tumor progression.
M2113
An Orthotopic Nude Mouse Model to Evaluate Novel Treatment Strategies for
Gastric Cancer in Corpus and Cardia
Birgit Hotz, Hubert G. Hotz, Sarah Bhargava, Heinz J. Buhr
Background: Carcinoma of the stomach remains one of the most common causes of cancer
death. In particular, the incidence for cancers of the gastro-esophageal junction (cardia) is
rising in the western world. A clinically relevant animal model does not exist for this
malignancy. The aim of the present study was to establish an orthotopic model for human
gastric cancer of the corpus and the cardia in nude mice. Methods: 5 million cells of the
human gastric cancer cell line MKN-45 (diffuse type) were injected subcutaneously into the
flanks of nude mice. These donor tumors were harvested after 4 weeks and minced into
small tumor fragments (1 cmm). One donor tumor fragment was orthotopically implanted
by microsurgery into the wall of either gastric corpus or cardia in 30 other mice. The animals
were sacrificed 4, 8, and 12 weeks after tumor implantation. Volume of the primary tumor,
local and systemic tumor spread (dissemination score) were determined at autopsy. H&E
stained sections were analyzed from all resected organs in order to confirm the macroscopic
findings. Results: The microsurgical implantation technique resulted in a tumor take rate
of 100%. An artificial dissemination of tumor cells into the abdominal cavity due to the
procedure was not observed. The time course of local and systemic tumor development is
summarized in the table (means ± SD). Conclusions: This study reports for the first time
the development of a clinically relevant nude mouse model for human gastric cancer of the
corpus and cardia. Primary tumors, local and systemic spread grow continuously during
the observation period and mimic the human situation. This model may be suitable to
evaluate novel treatment strategies for this still deadly malignancy.
(means ± SD; * = p < 0.05 vs. 4 weeks)
M2114
Use of Angiogenesis Inhibitor Bevacizumab in Minimizing Peritoneal
Dissemination of Stomach Cancer - A Randomized Control Trial in An Animal
Model
Enders K. Ng, Angela M. Hui, Lydia K. Lung, Wai Keung Leung, Joseph J. Sung
Background: Transcelomic dissemination is a peculiar feature of gastric adenocarcinoma.
Angiogenesis induced by free floating cancer cells may be an important mechanism for
gastric cancer deposits to sustain and survive on the peritoneum. This study aims to determine
whether Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody, is effective
in minimizing peritoneal spread of stomach cancer in an in vivo animal model. Methods:
Fifteen female nude mice of age 4 to 6 weeks were inoculated intraperitoneally with a fixed
dose (1 x 106) of MKN45 (gastric cancer cell line)suspension. They were immediately
randomized into 3 groups. Group A and Group B were given once weekly intra-peritoneal
Bevacizumab at low dose (5ug per g body weight) and high dose (10 ug per g body weight),
respectively. Group C was served as the control and administered with only normal saline.
All nude mice were nursed in the same ambient environment and fed de liberal. Their body
weight was monitored daily till abrogation on day-28. Results: By day-28, the overall weight
loss was more prominent in the control group (14.5%) when compared to that of Group
A (5.9%) and Group B (11.4%). Upon laparotomy, significantly more peritoneal tumor
deposit was found in the control group. In addition, the control group had significantly
larger mean peritoneal tumor mass load than the treatment groups (Group A = 41 mg,
Group B = 62 mg, Group C = 154 mg; p = 0.0001, One-way ANOVA). When peritoneal
tissues adjacent to the peritoneal tumour nodules were harvested for immunohistochemical
stain, those treated with Bevacizumab had significantly lower microvascular density when
compared to the control. Conclusion: Inhibition of VEGF reduces the extent and amount
of peritoneal gastric cancer dissemination in a nude mice model. The low dose regimen
appears to work better than the high dose regimen. Clinical studies are warranted to
assess its potential role in preventing or controlling peritoneal dissemination related to
stomach cancer.
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M2115
Helicobacter Pylori and Upper Gastrointestinal Tract Cancers: The Results of a
Long-Term Prospective Study
Farin Kamangar, You-Lin Qiao, Hormuzd Katki, Christian C. Abnet, Zhi-Wei Dong,
Philip R. Taylor, Sanford M. Dawsey
Helicobacter pylori is an important risk factor for gastric non-cardia adenocarcinomas. How-
ever, its association with gastric cardia adenocarcinoma and esophageal squamous cell
carcinoma is less clear. We conducted this long-term prospective case-cohort study to
estimate the magnitude of the association of H. pylori seropositivity with risks of these upper
gastrointestinal cancers, and to examine these associations by time from serum collection
to cancer diagnosis, age, and CagA positivity. Cases and controls for this study were selected
from a cohort of 29,584 healthy residents of Linxian, China, who participated in a nutrition
intervention trial. The study participants were followed from 1985 to 2001. Loss to follow-
up was < 1%. We selected a random sample of esophageal squamous cell carcinomas
(N = 300), gastric cardia adenocarcinomas (N = 600), all diagnosed gastric non-cardia
adenocarcinomas (N = 363), and a random sample of the entire cohort (N = 1050). Ninety-
five percent of these subjects had adequate serum for H. pylori assays and were enrolled in
this study. Serum was evaluated for IgG antibodies to whole-cell and CagA H. pylori antigens
by enzyme-linked immunosorbent assay (ELISA). Risks of both gastric cardia and non-cardia
cancers were similarly increased in individuals exposed to H. pylori (Hazard ratio and 95%
CIs = 1.64; 1.26 - 2.14, and 1.60; 1.15 - 2.21, respectively), whereas risk of esophageal
squamous cell carcinoma was not associated with exposure to H. pylori (1.17; 0.88 - 1.57).
The strength of these associations was not modified by time from serum collection to cancer
diagnosis or by CagA positivity. Consistent with previous studies, associations were stronger
in younger individuals, but the interaction terms between age and H. pylori were not
statistically significant. The associations between H. pylori exposure and gastric cardia and
non-cardia adenocarcinoma development were equally strong, which is different from obser-
vations made in Western countries. This difference may be due to the absence of Barrett’s
esophagus and esophageal adenocarcinomas in Linxian, which makes all tumors classified
as “cardia cancers” of gastric origin, rather than a mixture of gastric and esophageal tumors.
M2116
Comprehensive Analysis of Allelic Imbalance By Using High-Density Single
Nucleotide Polymorphism Array in Gastric Cancer Cell Lines
Motohisa Tada, Fumihiko Kanai, Yasuo Tanaka, Lian-Jie Lin, Keisuke Tateishi, Osamu
Yokosuka, Masashi Sanada, Yasuhito Nannya, Seishi Ogawa, Masao Omata
(Background and Aim) Chromosomal copy number alterations can lead to activation of
oncogenes and inactivation of tumor suppressor genes in human cancers and multiple genetic
alterations, occurring sequentially in a cell lineage, underlie the carcinogenetic process in
gastric cancer. Though comparative genomic hybridization (CGH) was initially used to
detect chromosomal copy number changes, it was difficult to identify key molecule for
carcinogenesis because of low resolution (about 20 Mbp).In this study, we sought to identify
the key molecule in gastric cancer pathogenesis by using high-density single nucleotide
polymorphism array. (Materials and Methods) We analyzed 34 gastric cancer cell lines for
areas of DNA copy number changes (high grade amplification and homozygous deletion)
and loss of heterozygosity (LOH) through genome-wide analysis of 116, 204 SNPs distributed
across all human chromosomes with Affymetrix GeneChip Human Mapping 1OO K Set (mean
intermarker distance 23.6 Kbp). Copy Number Analyzer for GeneChip (CNAG)(Nannya et
al, Cancer Res 2004), our original analysis tool that automates the detection of copy number
and regions of LOH, was used for data analysis. The results from the array analysis were
verified by PCR and quantitative real-time PCR. (Results) Thirty-four regions of high grade
amplification (n ≧ 5) were found in at least two cell lines. The size of minimal common
amplified region was 60 Kbp. Thirty regions of homozygous deletion were detected in at
least one cell line. The size of minimal deletion was 11 Kbp. In addition to known genetic
abnormality, such as amplification of K-ras gene and deletion of FHIT gene, high grade
amplification of Chr.11q21 region and homozygous deletion of Chr.16p13.3 region were
newly identified. LOH at 3p, 4p, 4q, 5q, 7q, 8p, 8q, 9p, 12q, 17p, 18q was observed with
high frequency. Moreover, this study detected allelic homozygosity (AH) at each chromosome.
Among them, AH was detected at 4q, 16q, 17p and18q with high frequency. (Conclusion)
By using Affymetrix GeneChip Human Mapping 100 K Set and CNAG, we could detect
minimal region of copy number alteration, which had never been able to detect by other
methods. Moreover this study demonstrated that AH might be one of the mechanisms of
gastric carcinogenesis. The novel amplified and deleted regions discovered in this study may
be significant and useful for early diagnosis and novel therapy based on molecular targeting
in gastric cancer.
M2117
Predictive Markers for Responsiveness to Chemo-Radiation Therapy in
Patients with Esophageal Squamous Cell Carcinoma: Immunohistochemical
Analysis of Pretherapeutic Biopsy Specimens
Yukihiro Nakanishi, Yae Kanai, Setsuo Hirohashi
(Background) The responsiveness of esophageal squamous cell carcinoma (ESCC) to chemo-
radiation therapy (CRT) is difficult to evaluate before treatment. Therefore, it would be of
considerable value to define parameters in pretherapeutic biopsy specimens that would
identify patients likely to benefit from CRT for ESCC. (Methods) Nine previously reported
predictive markers for responsiveness of ESCC to CRT (cyclin D1, p53, hypoxia-inducible
factor, metallothionein, c-erbB-2, vascular endothelial growth factor, cyclooxygenase 2, MIB-
1, CD31 (microvessel density)) were investigated immunohistochemically in pretreatment
biopsy samples from 75 consecutive patients staged at II and III who underwent definitive
chemo-radiation therapy with 5FU+cisplatin+ radiation (60 Gy). We looked for correlations
between these nine molecules and their associations with clinical response to CRT, and tried
to determine the best combination of the molecules for predicting response to CRT. When
more than 5% of the tumor cells were positively stained in pretreatment biopsy specimens,
tumors were scored as positive. The percentage of MIB-1-positive tumor cells was obtained
by counting positive tumor cell nuclei in the whole area of each biopsy specimen. Microvessel
density was obtained by counting brown-stained vessels in the highest vascular density area
within the tumor. In terms of clinical response to CRT, 27 (36%) cases showed complete
response (CR) without recurrence, 23 (31%) cases showed recurrence after CR, and 25
(33%) cases showed partial response, stable disease, or progressive disease (mean follow-
up period: 40.8 months (range, 16.8-74.4 months)). (Results) Univariate analysis revealed
significant associations between the responsiveness to CRT and negative expression of cyclin
D1 and p53 (p=0.03, 0.01, respectively). Multivariate analysis also revealed significant
associations between the responsiveness to CRT and negative expression of cyclin D1 and
p53 (p=0.03, 0.01, respectively). Trend test revealed that a combination of cyclin D1 and
p53 expression most accurately predicted the responsiveness to CRT (p=0.001). (Conclusion)
Immunohistochemical examination of pretherapeutic tumor biopsy samples for expression
of cyclin D1 and p53 could help to identify patients with ESCC who would benefit from CRT.
M2118
Inhibition of VEGFR Reduces Polyp Burden in a Mouse Model of Intestinal
Cancer
Denis Alferez, Robert A. Goodlad, James Watkins, Anderson Ryan, Steve Wedge, Richard
Poulsom, Ian Pyrah, Nikki Mandir, Robert Wilkinson
Introduction: AZD2171, a novel, orally active inhibitor of vascular endothelial growth factor
receptor-2 (VEGFR-2) tyrosine kinase activity was used to study the effect of angiogenesis
blockade in multiple intestinal neoplasia (ApcMin/+) mice. ApcMin/+ mice develop numerous
polyps due to a mutation in the adenomatous polyposis coli (APC) gene, as in familial
adenomatous polyposis (FAP) in humans. Methods: Two studies were performed in which
5 mg/kg/day of AZD2171 or vehicle was administered daily by oral gavage to 6-week old
or to 10 week old ApcMin/+ mice for 28 days after which the number and size of polyps
in the small and large intestines were scored. Results: AZD2171 reduced polyp number in
the small bowel and colon by 46% and 62%, respectively P<0.05 in the first study. Polyp
diameter was also reduced by 39% in the small bowel (P<0.001) but was unchanged in the
colon. Mean tumour burden (the product of number and volume) in the small intestine
was thus reduced 85% (P<0.001). In the second study small bowel polyp number was not
altered by AZD2171 but diameter was reduced by 24%, in turn decreasing polyp burden
by 46% (P<0.059). AZD2171 had little effect on the nuclear localisation of β-catenin but
reduced the number of cells expressing VEGFR-2 (from 7.4 ±0.6 to 4.0 ±0.9 per villus,
P<0.022). Conclusion: AZD2171 significantly reduced the number and size of polyps,
mainly in the earlier stages of polyp formation. VEGFR-2 signalling plays a key role in the
development of intestinal adenomas.
M2119
The Disintegrin Metalloproteinase ADAM17 Is Increased in Gastric Cancer
K Danjo, A Corvalan, Pa Robinson, Je Crabtree
Introduction: The ADAM (A disintegrin and metalloproteinase) family of enzymes are mem-
brane-anchored cell surface glycoproteins which have a key role in ectodomain shedding
of membrane bound receptors, growth factors and cytokines. Previous studies have shown
increased ADAM17 transcripts in gastric tumour tissue, and that Helicobacter pylori upregul-
ates ADAM17 transcript levels in gastric cancer cell lines in vitro. The aims of this study
were to evaluate whether the differential expression of ADAM17 in gastric cancer tissue at
the transcript level could be confirmed immunohistologically, and to evaluate the relation
of ADAM17 to clinicopathological variables. Methods: Tissue and clinicopathological data
were collected from 54 patients (mean age 58.3 + 14.9 years) undergoing surgical resection
for gastric cancer. Endoscopic gastric biopsies from seventeen patients without gastric cancer
were used as non-cancer controls. ADAM17 was detected using a mouse monoclonal antibody
M220 (0.16 mg/ml), biotinylated anti-mouse antibody and avidin-biotin-peroxidase. Primary
antibody was omitted as a negative control. Cytoplasmic ADAM17 positivity in gastric cancer
cells was scored on a scale of 0-3. Results: Forty four of fifty four (81.5%) gastric cancer
patients were positive for cytoplasmic ADAM17 with gastric tumour cells having immunore-
activity scores ranging from 1 to 3. In contrast, in non-cancer controls, ADAM17 was
detected in lamina propria mononuclear cells, but cytoplasmic epithelial immunoreactivity
was observed in only one of seventeen patients (p < 0.001). There was no significant
difference between ADAM17 positivity and grading score between intestinal-type and diffuse-
type gastric cancers, or anatomic location of the tumour (cardia, body or antrum). Increased
ADAM17 positivity was evident in gastric tumours greater than 5 cm (20/23; 87%) than
tumours less than 5 cm (9/13; 69%). ADAM17 positivity was also increased in advanced
(39/47; 83%) cancers compared to early gastric cancers (4/6; 67%). Conclusion: Higher
ADAM17 transcript levels reported previously are matched by increased expression of
ADAM17 in the cytoplasm of both intestinal and diffuse-type gastric cancer cells. Increased
levels of ADAM17 expression in gastric cancer cells resulting in enhanced ectodomain
shedding of EGF ligands may promote tumour progression
M2120
In Vitro Functional Assessment of CDH1 Germline Missense Mutations and
Implications for Clinical Management of Asymptomatic Mutation Carriers
Gianpaolo Suriano, Fatima Carneiro, Carla Oliveira, Fernando Regateiro, David G.
Huntsman, Sergio Castedo, Jose Carlos Machado, Raquel Seruca
Background: Hereditary diffuse gastric cancer (HDGC) is an autosomal dominantly inherited
gastric cancer susceptibility syndrome caused by CDH1 germline mutations. Carriers of
these mutations have a >70% lifetime risk of developing diffuse gastric cancer (DGC).
Currently, total prophylactic gastrectomy is offered only to carriers of CDH1 germline
inactivating (truncating) mutations. Nevertheless, about 20% of the HDGC families harbor
germline mutations of the missense type, and their clinical management remains controversial.
We report here the first prophylactic gastrectomies performed on HDGC-carriers of CDH1
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germline mutations of the missense type, based upon in vitro assessment of their pathogenic
nature. Methods: Mutation screening at the CDH1 locus was performed by polymerase
chain-reaction amplification and Single-Strand Conformational Polymorphism (PCR-SSCP)
of the entire coding region of the CDH1 gene, including all intron/exon boundaries and
promoter region, followed by direct sequencing of the abnormal bands. Slow-aggregation
and matrigel invasion assays were used to address the functional relevance of the missense
changes. Total prophylactic gastrectomy was performed in two unrelated carriers of germline
missense mutations, and the entire mucosa of the stomach sampled for histological analysis.
Results: Both missense alterations impaired in vitro the ability of E-cadherin to mediate cell-
to cell adhesion and to suppress cell invasion, demonstrating their pathogenicity. Foci of
early invasive diffuse carcinoma (signet ring cell type) were found in specimens from both
individuals submitted to prophylactic gastrectomy. Conclusions: In vitro testing should
be used as an adjunct in deciding on the potential pathogenic role of CDH1 germline
missense mutations.
M2121
An Important Role of Rhoc in the Metastasis Progress of Gastric Cancer
Guoyun Zhang, Na Liu, Feng Bi, Yanglin Pan, Yulei Du, Daiming Fan
Objective: To study the effect of RhoC on the metastasis progress of gastric cancer cells.
Methods: The expression of RhoC was examined by immunohistochemistry in gastric cancer
tissues and non-tumorous tissues. The vector pCEFL-GST- RhoC was transfected into gastric
epithelial cells(GES-1).Under the assistance of computer, a group of RhoC-specific small
interfering RNAs (siRNA) were designed and the related vectors were generated and trans-
fected into human gastric cancer cell SGC7901 separately by the lipofectamine. The protein
expression of RhoC in the transfectants was examined by Western blot. Cell growth rate
was determined by counting viable cells with a Cell Counting Kit-8. MTT assay was used
to evaluate the sensitivity of the transfectants to anticancer drugs. A wound-healing and a
Transwell assays were used to examine the migration and invasion ability, respectively.
Results: Only weak staining of RhoC was detected in 3 of 33 non-tumorous cases (9.10%).
The expression of RhoC was significantly higher in gastric cancer tissues(23/42, 54.76%)
than in non-tumorous tissues(p<0.01) and RhoC positively expressed in 18 out of 20
metastases(90.0%), even higher than that in primary gastric cancer tissues. Western blot
showed that RhoC was up-regulated in gastric cancer cell lines (AGS, XGC-9811,SGC7901
and KATOIII), but not expressed in SV40 transformed immortal GES-1. Overexpression of
RhoC GTPase in GES-1 cells could produce a motile and invasive phenotype, but does not
alter the monolayer growth rate (p>0.05). Five RhoC-specific siRNAs were designed and
the related vectors were generated. Western blot showed that RhoC-specific siRNA, RhoC-
s362, inhibited RhoC expression dramatically (62.57%). Though down regulation of RhoC
expression didn’t affect the proliferation and chemo-sesitivity of the transfectants(p>0.05),
it did restrain RhoC mediated cell migration and invasion(relative invasion index
0.263±0.01,p<0.05). Conclusion: RhoC may play a very important role in the metastasis of
gastric carcinoma. Therapeutic strategies targeting RhoC and RhoC-mediated pathways may
be a novel approach for treating metastasis of gastric cancer.
M2122
Net1 - A Novel Activator of RHOA and Gastric Cancer Cell Invasion
David W. Murray, Jan Leyden, Gerry McEntee, Conor O'Keane, Padraic MacMathuna,
Peter Doran
Introduction Using computational informatics, we have identified a novel gastric cancer
(GC) associated gene, NET1, a guanine nucleotide exchange factor. NET1 activity has been
reported in other cancers but its role in GC remains unclear. Aims To investigate the role
of enhanced NET1 expression GC by a) evaluating the effect of NET1 knockdown on cancer
invasion and proliferation and b) to determine whether the bio-activity of NET1 in GC is
promoted by LPA and is mediated by the GTPase RhoA. Methods Real time PCR was used
to quantitate NET1 expression levels in tumour and normal tissue. NET1 knockdown
using siRNA-mediated suppression was used to determine effects on the cell invasion and
proliferation. The response of NET1 expression to treatment with LPA, IL1-β and TNFa
was also monitored. Western blot analysis was used to determine levels of active RhoA.
Results Net1 expression was significantly enhanced by 34% in gastric tumour tissue samples
as compared to healthy tissue (P<0.05). NET1 siRNA transfection resulted in a dramatic
decrease in RhoA activation as well as a 100% significant decrease in cell invasion and a
49% decrease in cell proliferation (P<0.05). NET1 expression was increased 10 fold (P<0.05)
in response to treatment with LPA but unaltered in response to IL1-β and TNFa. Conclusions
Using computational informatics, we have identified a novel gastric cancer (GC) associated
gene, NET1a and validated its function and enhanced expression in human GC tissue and
cell lines. NET1 is LPA responsive and it’s bio-activity in GC proliferation and invasion is
RhoA mediated. This data supports the involvement of NET1 and RhoA in the progression
of gastric cancer.
M2123
Relative Benefit of Laparoscopy in Addition to CT in Staging Junctional
Gastric Cancer
Jonathan Barry, Neil Hopper, Michael Stephens, Guy Blackshaw, Paul Edwards, Matthew
Morgan, Gerald Thomas, Wyn Lewis
Aims. Junctional adenocarcinoma of the gastric cardia is believed to behave in a particularly
aggressive fashion, and anatomical constraints limit the sensitivity and specificity of staging
computed tomography (CT). The aim of this study was to assess the relative additional
staging yield of laparoscopy in patients diagnosed with adenocarcinoma of the gastric cardia
when compared with helical CT. Methods. Eighty consecutive patients with Siewert type
III adenocarcinomas of the oesophagogastric junction [median age ] were studied prospect-
ively. All patients underwent a preoperative CT examination and laparoscopy with or without

















laparoscopic stage, and the final histopathological stage was determined by the weighted
Kappa statistic (Kw, range -1 no agreement to +1 perfect agreement). Results. The strengths
of agreement between the perceived preoperative stage as determined by CT compared with
laparoscopy for T, M1 Liver and M1 peritoneum were 0.627 vs. 0.743, 0.429 vs. 0.719
and 0.108 vs. 0.964 (P<0.05) respectively. Unsuspected metastases that were not detected
by CT, were found in 15 patients at laparoscopy (4 Liver, 11 peritoneum) all of whom had
T3 (n=4) or T4 (n=11) locally advanced tumours on CT criteria. Conclusion. Despite the
potential difficulties of visualising primary junctional oesophagastric tumours at laparoscopy,
this additional staging modality improved the detection of unsuspected distant metastases
9 fold and no fewer than 19% of patients were saved an open and close laparotomy. All
patients diagnosed with an oesophagogastric type III junctional tumour of stage T3 and any
N by CT criteria should undergo staging laparoscopy.
M2124
May Expression of Basic Fibroblast Growth Factor and Vascular Endothelial
Growth Factor Combined with Epstein-Barr Virus Infection Influence On the
Prognosis of Gastric Carcinoma?
Jeong-Seon Ji, Hiun-Suk Chae, Jin-Hyoung Kang, Kyoung-Mee Kim, Gyeong-Sin Park,
Hyung-Keun Kim, Young-Seok Cho, Sung- Soo Kim, Kyu-Yong Choi, In-Sik Chung
Background: Angiogenesis has been shown to be necessary for tumor growth and metastasis.
Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are
important angiogenetic factors. And EBV (Epstein-Barr virus)-positive gastric carcinoma is
6-16% of total gastric carcinoma. Feature of pathology in EBV-positive gastric carcinoma is
fibrosis. These lymphoepitheloid reaction is predominant in EBV-positive gastric carcinoma.
So we hypothesized EBV-positive gastric carcinomas may be related with angio-fibrogenic
factors, such as FGF and VEGF. We assessed VEGF and bFGF in the tissue of EBV-positive
gastric carcinoma and also evaluated the relationship between this angiogenetic factors and
other various clinicopathologic parameters. Methods: EBV In situ hybridization was per-
formed at 621 patients who confirmed pathologically as gastric carcinoma after resection.
Among them, 31 patients with EBV-positive gastric carcinoma and 69 patients with EBV-
negative ones were randomly selected (72% male; mean age 58.0±1.2 years). Gastric carcin-
oma tissues were stained with VEGF and bFGF antibody by immunohistochemical technique.
Clinicopathologic parameters were morphologic and pathologic classification, location, stage,
lymphatic invasion and survival data (mean follow up duration: 42.6 ± 1.8 months). Results:
Male sex, positive VEGF, positive bFGF, upper location, tubular adenocarcinoma and early
carcinoma were more common in EBV-positive gastric carcinomas than in EBV-negative
ones (p <0.05). And positive EBV, upper location, lymphatic invasion and advanced carcin-
oma were more common in bFGF-positive gastric carcinomas than bFGF-negative ones (p
<0.05). And also positive EBV, lymphatic invasion, upper location, tubular adenocarcinoma
and lymph node invasion were more common in VEGF-positive gastric carcinomas than
VEGF-negative ones (p <0.05). However neither EBV or VEGF influenced to the survival
rate of gastric carcinoma. And survival rate of bFGF-positive gastric carcinoma was statistically
insignificant but lower than bFGF-negative one (p = 0.128). Interestingly, survival rate of
bFGF-positive gastric carcinoma was significantly lower than bFGF-negative one in patients
with lymph node invasion. (p = 0.036). Conclusions: As we expected, bFGF and VEGF
expressed more in EBV-positive gastric carcinomas than EBV-negative ones. And interestingly,
bFGF may be a marker of prognosis in the patients with gastric carcinoma, particularly in
the case of lymph node invasion.
M2125
Possible Involovement of Ghrelin in Gastric Cancerogenesis
Peter C. Konturek, Kazimierz Rembiasz, Anna Zub, Grzegorz Burnat, Joanna Kania,
Eckhart G. Hahn, Stanislaw J. Konturek
Background and aims: Ghrelin is brain-gut peptide with growth hormone-releasing and
appetite-inducing activities. It is mainly secreted from the gastric mucosa. Recently, a possible
involvement of ghrelin in cancerogenesis was postulated. The aim of the present study was
1) to compare the ghrelin expression in the gastric cancer with the ghrelin expression in
the non-malignant gastric mucosa adjacent to the tumor; 3) to analyze the effect of ghrelin
on cell proliferation and expression of COX-2 in gastric cancer cell line (KATO III). Methods:
10 H.p. positive patients and 10 GC patients were included in the study. In all patients
was performed gastroscopy. The gastric biopsies were taken from the antrum, corpus and
tumor. The expression of ghrelin and its receptor was assessed by quantitative RT-PCR. In
addition, the effect of exogenous ghrelin on the cell proliferation (by BrdU) and the mRNA
and protein expression of COX-2 was assessed by RT-PCR and Western blot, respectively.
The plasma level of ghrelin was assessed by RIA Results: The expression of ghrelin in the
antral gastric mucosa was significantly lower in than in corpus mucosa. In the gastric cancer,
significant decrease in ghrelin expression was found, whereas in the adjacent corpus mucosa
a significant overexpression of ghrelin was found. In contrast to negligible expression fo
ghrelin in GC, ghrelin receptors were expressed in both GC tissue and adjacent gastric
mucosa. Compared to Hp+ve controls, the plasma level of ghrelin was significantly higher
in GC patients. The in vitro analyzes showed a significant effect of ghrelin on cell proliferation
after 64 hours of incubation (by 120% of control). Ghrelin caused a significant increase in
the expression of COX-2 in KATO III cells. Conclusion: Ghrelin is overexpressed in the
gastric mucosa adjacent to gastric cancer and the ghrelin receptors are expressed by cancer
what suggests a possible role of ghrelin in the gastric carcinogenesis. The possible mechanisms
by which ghrelin promotes the gastric carcinogenesis involves an increased PG generation
due to increased COX-2 expression.
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M2126
Mixed Intestinal and Diffuse Type Histology Is a Risk Factor for Lymph Node
Metastasis of Early Gastric Cancer
Naoko Tsuji, Singo Ishiguro, Masatoshi Kudo
Background: Technical progress in endoscopic procedures such as endoscopic submucosal
dissection is expected to increase the number of node-negative early gastric cancers treated
conservatively. Evaluation of lymph nodes status before any such procedure is very important.
Methods: To clarify indications for conservative therapy, we investigated histologic character-
istics of node-positive and node-negative early gastric carcinomas. Seven-hundred and forty
cases of mucosal cancer (m-cancer) and 270 cases of submucosal invasive cancer (sm-
cancer) treated surgically were analyzed clinicopathologically. Comparison was made between
patients with node-positive (n=23 in m-cancer and n=33 in sm-cancer) and node-negative
cancer. Whole sections of surgical specimens were reviewed and reclassified as pure intestinal-
type, pure diffuse-type and mixed intestinal and diffuse-type. The intramucosal and submuco-
sal components of sm-cancer were also described histologically. Clinical outcome of all cases
were also obtained. Results: The percentage of mixed intestinal and diffuse-type histology
was significantly higher in the node-positive group than in the node-negative group (78%
vs. 33% in m-cancer, and 76% vs. 29% in sm-cancer, P<0.01). The percentage of sm-cancer
showing lymphatic permeation was significantly higher in the node-positive group (79%
vs. 36%, P<0.01). The percentage of mucosal components showing mixed-type histology
was significantly higher in the node-positive sm-cancer group than in the node-negative
group (58% vs. 33%, P<0.01). Recurrence rates of the node-positive and the node-negative
groups were 13% vs. 0.5% in m-cancer and 9.1% vs. 6.3% in sm-cancer respectively. Average
disease free survival was 5.1 years, and there was no difference between node-positive and
node-negative groups. Conclusions: Histologic heterogeneity is a risk factor for metastasis
of early gastric cancer to lymph nodes. Heterogeneity of mucosal components of sm-cancer
is also a significant risk factor and thus a good predictor of lymph node metastasis, potentially
useful in distinguishing patients ineligible for conservative therapy. Long term follow up is
necessary after conservative therapy, for disease free survival of early gastric cancer is long.
M2127
Regulation of HIF-1 Induced Multidrug Resistance By MGR1-Ag in Gastric
Cancer Cells
Li Sun, Lili Liu, Yongquan Shi, Xiaoxuan Ning, Changcun Guo, Yanglin Pan, Tao Lin, Jie
Liang, Shuang Han, Yu Chen, Kaichun Wu, Daiming Fan
Previous studies of our work reported that MGr1-Ag was a novel protein associated with
multidrug-resistance (MDR) in gastric cancer cells. The aim of our study was to explore the
role and the underlying mechanisms of MGr1-Ag in HIF-1 induced MDR of gastric cancer
cells. Methods: Sense or siRNA vectors for MGr1-Ag and HIF-1 were introduced to achieve
genetical up- or downregulation respectively. Western blot analysis or semiquantitative RT-
PCR were performed to characterize the expression level of MGr1-Ag, HIF-1, P-glycoprotein
(p-gp), multidrug resistance associated protein (MRP), Bcl-2 and Bax. The sensitivity of
gastric cancer cells to the chemotherapeutic drugs was detected by colony-forming assay
and the evaluation of intracellular adriamycin accumulation and retention were conducted by
flow cytometry. AnnexinV/PropidineIodide staining method was used to detect adriamycin-
induced apoptosis. Double immunofluorescence assay was recruited to characterize the
coexpression of HIF-1 and MGr1-Ag. Results: The expression level of both HIF-1 and MGr1-
Ag in MDR gastric cancer cells were much higher than that in their parental cells. Drug-
sensitive gastric cancer cells showed resistance to 5-fluorouracil (2.74±0.86 fold IC50
increase) and vincristine (2.40±0.72 fold IC50 increase) under hypoxic condition. A signific-
ant increase of MGr1-Ag mRNA level was revealed under hypoxic condition than that of in
normoxia. The coexpression level of HIF-1 and MGr1-Ag were increased concomitantly
upon hypoxia pretreatment at indicated time via both Western blot and double immunofluo-
rescence assay. This concomitance was also confirmed by the expression level of MGr1-Ag
in exogenous up- or downregulated expression level of HIF-1 in gastric cancer transfected
cells. Overexpression of exogenous MGr1-Ag could promote MDR phenotype and show
the significantly increased resistance to 5-fluorouracil (2.40±0.04 fold IC50 increase) and
vincristine (2.65±0.33 fold IC50 increase). Upregulation of MGr1-Ag could decrease
intracellular adriamycin accumulation and retention (2.87±0.06 fold releasing index increase)
by downregulation of P-gp and MRP and also protect gastric cancer cells from adriamycin-
induced apoptosis (0.43±0.19 fold apoptosis index decrease) by downregulation of Bax
and upregulation of Bcl-2, whereas downregulation of MGr1-Ag had the reverse effects.
Conclusions: Under hypoxic condition, HIF-1 may promote MDR of gastric cancer cells by
upregulating the expression level of MGr1-Ag via a decrease in intracellular drug accumulation
and inhibition of drug-induced apoptosis.
M2128
Expression of Thrombospondin-1 and VEGF in Gastric Carcinoma
Wan-Sik Lee, Chang-Hwan Park, Young-Eun Joo, Hyun-Soo Kim, Sung-Kyu Choi, Jong-
Sun Rew, Sei-Jong Kim, Chang-Soo Park
Backgrounds : Thrombosponding-1 (TSP-1) is an multifunctional platelet and extracellular
matrix protein that is involved in angiogenesis on a variety of cancers. As to its role in
angiogenesis, it has been proposed that TSP-1 functions as an angiogenic stimulator or
inhibitor according to organ and histologic types. Vascular endothelial growth factor (VEGF)
has a potent angiogenic activity and is well correlated with microvascular density. This study
was to evaluate the expression of TSP -1 protein in gastric carcinomas and its relationship
with VEGF expression and clinicopathological factors. Materials and methods : We conducted
an immunohistochemical investigation of TSP-1 and VEGF in 108 tissue samples obtained
from gastric cancer patients receiving curative surgical treatment. AJCC TNM classificaion
of gastric cancer was used to analyze gastric cancer staging. Results : Positive staining for
TSP-1 was seen in the cytoplasm of the cancer cells. Expression of TSP-1 protein was
detected in 72% (77 of 108) of the cases, among which strong expression was encountered
in 42%. VEGF expression was significantly higher in tumors with strong TSP-1 protein
expression than in those without expression or weak expression of TSP-1 (P=0.01). Significant
correlation was found between TSP-1 expression and clinicopathological parameters of gastric
carcinoma (T and N factors). Conclusions : TSP-1 expression might be closely related to
the development and progression of gastric cancer. Moreover, TSP-1 may contribute to the
angiogenesis in the process of gastric carcinogenesis given the fact that it is closely correlated
with VEGF expression.
M2129
Expression of Nonsteroidal Anti-Inflmmatory Drug-Activated Gene in Gastric
Adenoma and Carcinoma
Jeong Youp Park, Seungmin Bang, Myoung Hwan Kim, Kyung Hwa Park, Seung Woo
Park, Jae Bock Chung, Sang Suk Koh, Si Young Song
NAG-1, one of TGF-β superfamily gene, is reported to be responsible for NSAID-induced
apoptosis. To find whether it can be also applied to gastric cancer which is one of the
leading causes of cancer death worldwide, we tried to analyze its expression in gastric cancer
according to cell differentiation and tumor stage. In addition, its expression in adenoma
was also analyzed. Tissue specimens were obtained from individuals who underwent gastrec-
tomy with curative purpose for gastric cancer, and with them tissue microarray was made.
Immunostaining was performed using standard procedures with antibody to NAG-1. The
intensity of immunostaining was evaluated using internal control. Tumor tissues with intens-
ity weaker than normal tissue was graded as 0 (no expression) similar as + (weak expression)
and stronger as ++ (strong expression). The level of NAG-1 expression was also evaluated
using Western blot analysis. NAG-1 was stained in the cytoplasm of normal epithelial cells,
adenoma and cancer cells. Among 15 cases of adenoma, 12 cases (80%) showed strong
expression. Western blotting confirmed strong expression in adenoma. Among 168 cases
of gastric cancer, there were 69 cases with stage I, 25 with stage II, 43 with stage III, 31
with stage IV. According to stage by stage analysis, in stage I, 31 out of 69 cases (44.9%)
showed strong expression in tumor tissue. However, in stage IV, only three out of 31 cases
(9.7%) showed strong expression in tumor tissue and 18 cases (58.1%) showed no expression.
Western blotting showed NAG-1 expression was weaker than or similar to normal tissue.
Significant correlations were noted between NAG-1 expression and the degree of cell differen-
tiation, T, and N stage. (p<0.05) Pearson correlation index for the degree of cell differentiation
was -0.157, for T stage -0.421, and for N stage -0.397. In summary, NAG-1 was expressed
strongly in adenoma, and reversely correlated to tumor stages. This interesting finding may
provide new targets for chemoprevention and future development of drugs.
M2130
C/EBP-Beta Is Over-Expressed in Gastric Carcinoma and Is Associated with
the Expression of Cyclooxygenase-2
Goncalo Regalo, Paulo Canedo, Gianpaolo Suriano, Carlos Resende, Maria J. Oliveira,
Ceu Figueiredo, Fatima Carneiro, Raquel Seruca, Jose C. Machado
The C/EBPbeta transcription factor has been associated with several cancer models. Recent
studies suggest that the interleukin-6R/GP130 receptor signalling pathway, where C/EBPbeta
plays a key role, is likely to be involved in gastric cancer (GC). In this study, expression of
C/EBPbeta was analysed in a series of 90 GC. CEBPB gene mutations were screened for in
a series of 35 primary GC. The functional activity of C/EBPbeta was analysed in GC cell lines.
In normal gastric mucosa, C/EBPbeta expression was restricted to cells with a proliferative
phenotype. In intestinal metaplasia, dysplasia, and GC of the intestinal and atypical subtypes,
C/EBPbeta was overexpressed (P=0.0005, for the association with histological type). C/
EBPbeta and Ki67, a marker of cell proliferation, were also co-expressed in primary GC. In
one GC we found a mutation of the CEBPB gene. Using GC cell lines we showed that
transfected C/EBPbeta is able to regulate the expression of endogenous cyclooxygenase-2
(COX-2). Back in the series of metaplasia, dysplasia and GC lesions we observed a high
degree of overlap between expression of C/EBP-beta and COX-2. In GC cell lines we have
also shown that transfected C/EBP-beta is able to modulate proliferation in these cells. These
results suggest that C/EBPbeta may both be a marker of neoplastic transformation and play
an active role in gastric carcinogenesis through its ability to up-regulate COX-2 expression.
M2131
Usefulness of DAS-1 Monoclonal Antibody to Detect the Intestinal Metaplasia
Associated with Gastric Cancer
Montse Forne, Clarisa Gonzalez, Jaume Casalots, Ferran Fernandez-Banares, Maria Esteve,
Merce Rosinach, Jorge Espinos, Josep Maria Viver, Antonio Salas
Preventive strategies of gastric cancer should lead to diagnosis at an early stage. The role of
endoscopic surveillance in patients with atrophic chronic gastritis and gastric intestinal
metaplasia (IM) is not established. It has been suggested, recently, that Das-1 monoclonal
antibody (mAb) is useful in the identification of incomplete IM (IIM) -or colonic form of
gastric IM- that is the specific subtype associated with an increased risk of intestinal type
gastric adenocarcinoma in H. pylori (Hp) infected people (Mirza et al, Gut 2003). Aim: 1.To
validate mAb Das-1 in the diagnosis of IM associated with gastric cancer in our geographical
area. 2. To identify the expression of Das-1 in the histological subtypes of IM and its possible
relationship with the infection for Hp. 3.To assess the usefulness of mAb Das-1 in the
detection of IIM as compared to routine histological techniques. Methods: The following
patients were studied: Group -: (n=50) gastric cancer (paired samples of mucosa from both
cancer areas and histological proved IM areas distant from cancer segment). Group 2: (n=
25) gastro-duodenal ulcer, Hp (+), IM and chronic gastritis. Group 3: (n=25) autoimmune
atrophic chronic gastritis with IM and without Hp infection. Group 4- (n=25) chronic
gastritis with and without Hp infection and without evidence of IM. Conventional histological
study (H&E) was carried out, and complete IM (CIM) and IIM were diagnosed. Immunohisto-
chemical assay using mAb Das-1 was performed, and the results were interpreted according
to Mirza et al (Gut 2003). Results: Group 1: 22 patients had CIM, 25 IIM, and 3 both types
of IM (Mixed). Das-1 was positive in 20 patients in cancer areas and in 13 in areas of IM
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(CIM 5, IIM 8). In 7 patients Das-1was positive in both areas studied. Group 2: 17 patients
had CIM and 8 IIM. Expression of Das-1 was observed in 2 CIM. Group 3: 17 cases had
CIM, 7 IIM and 1 mixed. No case was positive for Das-1. Group 4: No case was positive
for Das-1. In summary, expression of Das-1 was observed in 7 of 56 CIM and in 8 of 40
IIM (ns). On the other hand, there were differences between the expression of Das-1 in the
IM of group 1 as compared to IM of groups 2-3 (13/50 vs 2/50; p<0.01). Conclusions: 1.
In our geographical area the described association of gastric cancer with IIM was not observed.
2. mAb Das-1 was not useful to differentiate between CIM and IIM. 3. The high expression
of Das-1 in the group of gastric cancer, even in non neoplastic area, suggest that it might
be a risk marker of neoplasia, and thus, patients with Das-1 expression would benefit from
an strict follow-up. This possibility has to be further assessed.
M2132
Clinical Significance of CT-Defined Minimal Ascites: An Analysis Focusing On
Survival Outcome of Gastric Cancer
Hyuk Lee, Dong Kyung Chang, Poong-Lyul Rhee, Jae J. Kim, Jong Chul Rhee
Backgrounds: The clinical significance of minimal ascites, which was only defined by dynamic
CT, is unknown. Furthermore, this CT-defined minimal ascites (CTMA) in preoperative
staging for gastric cancer tends to force into a dilemma on therapeutic modality or outcome.
The objective of this study was to investigate the clinical significance of CTMA in patients
with gastric cancer, in relationship to survival outcome. Methods: The medical records and the
dynamic CT films of 5080 patients, who had been examined 6 years ago, were retrospectively
reviewed. Asymptomatic 892 and symptomatic 2928 patients without history of prior trauma,
abdominal surgery and chemoradiotherapy were selected. Experienced two radiologists
calculated the volume of ascites in all patients presenting ascites. Results: The prevalence
of minimal ascites (< 50mL) was 1.12% and 7.48% in asymptomatic and symptomatic
group, respectively. The proportion of patients without accompanying other pathologic
finding was 90.0% and 8.2% in both groups with CTMA. 57.1% of the symptomatic patients
with CTMA were associated with malignant disease. Gastric cancer with CTMA was identified
in 21.5% of CTMA in symptomatic group. Peritoneal carcinomatosis was 37.5% of CTMA
of which the nature was surgically confirmed. CTMA without lymph node enlargement and
peritoneal enhancement, which were 23.3% of CTMA with gastric cancer, was not associated
with peritoneal carcinomatosis. No recurrence occurred in these patients, and they survived
for 6-year period. On the contrary, mean survival time of patients with CT finding accompany-
ing lymph node enlargement was 63.4 months and that of patients with peritoneal enhance-
ment was 46.9 months. The patients with both findings presented the mean survival time
of 33.6 months. Conclusions: Gastric cancer with only CTMA tends not to be associated
with peritoneal carcinomatosis if it does not accompany other CT finding. Therefore, curative
resection should be attempted if CTMA is the only ambiguous sign.
M2133
Does Early Upper GI Cancer Cause Symptoms?
Martin J. Maida, Rosie Crimmins, Jill Swift, Green John
INRODUCTION Current British Society of Gastroenterology guidelines recommend open
access gastroscopy for all patients with new onset dyspepsia over the age of 55 years and
in those with alarm symptoms at a younger age, to look for malignancy. We previously
found that patients with upper gastrointestinal (GI) malignancy usually present with alarm
symptoms and those without alarm symptoms often had advanced disease1. AIMS AND
METHODS In this study, we identified prospectively patients who over an eighteen month
period from April 2004 to October 2005 had findings suggestive of malignancy at their
index gastroscopy, and determined via a questionnaire their presenting symptoms, the
duration of presenting features, and how often they had seen their general practitioner (GP)
in the lead up to referral. RESULTS 31 patients were found to have upper GI malignancy
(12 gastric 19 oesophageal) during the study period. The mean age was 72 years (44 - 91
years), 19 male patients and 12 female. The average duration of symptoms prior to gastroscopy
was 5 months (2 weeks - 18 months). All 12 patients with gastric carcinoma presented with
weight loss as the initial symptom, with associated dyspepsia in 6 patients (50%), anaemia
in 4 (33%), nausea in 3 (25%) and melaena in 2 patients. Two of the 19 patients with
oesophageal carcinoma presented with a four week duration of reflux symptoms having
previously been asymptomatic; one additional patient had anaemia and worsening of long-
standing reflux symptoms, and the remaining 16 patients (84%) were referred with dysphagia
as their initial symptom. 13 out of 31 patients were on antacid treatment, which in all but
one case had been commenced for their current symptoms, and only the one patient with
longstanding reflux symptoms had seen their GP for dyspeptic symptoms prior to presenting
with alarm symptoms. CONCLUSION Patients with upper GI cancer only had a short history
of symptoms, and had not been to their GP or been on treatment that could mask symptoms
prior to presenting with cancer. This implies that the cancer could not have been diagnosed
any earlier, confirming that early upper GI cancer is asymptomatic. 1. GUT 2003;52(Suppl
VI): A200
M2134
Early Gastric Carcinoma: Results of Endoscopic Mucosal Resection
Michael Sackmann, Klaus-Dieter Schmidt, Hans Brehm, Hans-Martin Baumueller
BACKGROUND: According to first data mainly provided from Japanese groups, early gastric
carcinoma may be treated by endoscopic mucosal resection (EMR) in selected patients. We
attempted to prospectively evaluate the results of EMR and the early recurrence rate after
successful therapy. METHODS: During a time period of 18 months, n=22 patients (age, 57
to 83 years; median, 78 years) were referred consecutively to our institution for evaluation
of early gastric cancer. All patients underwent video endoscopy including application of
zoom endoscopy (Fujinon) and chromo-endoscopy, endoscopic ultrasonography, mapping
biopsy, and computed tomography. The options for treatment were then discussed by an

















73% (n=16; 6f, 10 m) of the 22 patients fulfilled the criteria suggested by the Japanese Society
of Gastroenterology for endoscopic therapy of early gastric cancer, e.g., macroscopically type
I or type II, histopathological grading G1 or G2, tumor restricted to the mucosal layer or
to the first submucosal layer (Sm1), tumor size <21 mm. The ligation technique or the
resection cap technique were used for EMR. Subsequently, the patients were followed up
regularly at months 1, 3, 6, 9, 12, 18, 24, and 36, respectively. RESULTS: Complete EMR
(T1G1R0V0) was obtained in 13 (81%) of the 16 patients. Three patients were operated
due to tumor exceeding the lateral margins (n=2), or due to invasion of lymph vessels (n=
1). Two complications were handled non-surgically (small perforation by clip application
and antibiotic therapy, bleeding seven days after EMR by endoscopic injection therapy).
During follow-up (1-22 months; median, 8 months), recurrence of early gastric cancer was
observed in three patients. The three patients were again treated by EMR (R0). By actuarial
analysis, the probability of recurrence was 23% at two years. CONCLUSIONS: In selected
patients with low-risk early gastric cancer, EMR is a suitable alternative to gastric surgery.
Due to the risk of recurrence, regular follow-up of the patients is mandatory after EMR.
M2135
Influence of Gender On Precancerous Changes Leading to Intestinal Type
Upper Gastrointestinal Cancer
Mohammad H. Derakhshan, Reza Malekzadeh, Valerie Fyfe, Abbass Yazdanbod, Masoud
Sotoudeh, Nasser Rakhshani, Abbass Kazemi, Kenneth E. McColl
Background and Aim: Intestinal type upper GI cancers are more prevalent in males than
females. This type of cancer arises due to progression of chronic inflammation to atrophic
gastritis to intestinal metaplasia and finally to adenocarcinoma. The histological stage in this
pathway where gender acts is unclear. We have investigated the influence of gender on the
frequency of the intestinal type cancer and its precancerous lesions. Method and Materials:
The association between gender and histological subtypes was assessed in 124 cases with
upper GI cancer in Ardabil province of Iran. In addition, in the general population (234
males, 274 females) with mean age of 54.6 ± 11.3 of the same region, we evaluated the
relationship between gender and precancerous histological changes. Mean scores of active
and chronic inflammation, as well as mucosal atrophy and intestinal metaplasia in 3 different
biopsy sites were compared between male and female. Results: Male gender showed potent
relationship with intestinal vs. diffuse type adenocarcinoma [OR: 5.7 (95% CI: 2.5-13.1)].
In the general population, the mean scores of active inflammation in all biopsy sites between
both genders were similar. Chronic inflammation at antral site (incisura angularis) in males
was more severe than females, but at other biopsy sites, there was no difference between
sexes. Mean scores of non metaplastic atrophy at all biopsy sites were similar in both genders.
Intestinal metaplasia showed significant relationship with male gender at each subsites
(Table): Conclusion: In this population, male gender is associated with increased frequency
of intestinal metaplasia as well as intestinal type adenocarcinoma.
Relationship of male gender with precancerous lesions of intestinal type cancer (OR, 95% CI)
M2136
Clinical and Pathologic Characteristics of Gastric Cancer in Elderly Koreans
Dong Ho Lee, Youn Joo Kim, Nayoung Kim, In Sung Song, Hyun Chae Jung, Young Soo
Park, Suk Hyang Jung
Purpose:Gastric cancer is one of the most important cancers in Korea, considering its
incidence and mortality rate. Since the number of elderly people is increasing in Korea, the
proportion of elderly patients with gastric cancer will continue to increase. We have obtained
preliminary data concerning the diagnosis and treatment of gastric cancer in elderly people
by analyzing the clinical features, endoscopic findings, pathology, postoperative recovery
time and operation-related complications. Method:We retrospectively analyzed 270 patients
who were diagnosed with gastric cancer from May, 2003 to May, 2005, and who underwent
surgical procedures in Bundang Seoul Nationall University Hospital. Patients were divided
into two groups, age<65(N=164) and age≥65(N=106). We compared sex, age, symptoms,
location, morphology, pathology, stage, ASA classification, postoperative recovery time and
operation-related complications between the older and younger groups. Results:There was
no statistically significant difference in sex, symptoms and family history between the elderly
group and the younger group. There were no differences in the distribution of early gastric
cancer and advanced gastric cancer, or stages. The younger group had a higher incidence
of poorly differentiated carcinoma(38.3%) and signet ring cell carcinoma(21.6%), and the
elderly group had more patients with moderately differentiated carcinoma (33.0%), based
on the WHO classification(p<0.001). Using the Lauren classification, the younger group
had a higher incidence of dif fuse type(58%) and the elderly group intest inal
type(59.4%)(p<0.001). The incidence of high frequency microsatellite instability(MSI-H)
was higher in the elderly group(17% vs 5.6%)(p=0.01) and an intact hMLH1 gene was
higher in the younger group(80.2% vs 68.9% p=0.034). The incidence of p53 was similar
between the two groups. Even though the younger group had more patients with lower
risks, according to the ASA classification, there was no significant difference in postoperative
recovery time(p=0.154) and the operation-related complication rates between the two groups.
Conclusion: Gastric cancer in elderly patients demonstrated more pathologic types known
to have a favorable outcome, when compared to the younger patient group. The elderly
patients had a higher incidence of MSI-H, which is known to be associated with less frequent
lymphatic metastasis. Since the older patients, when compared to the younger ones, did
not have a longer postoperative recovery time or a higher incidence of operation-related
complications, we should more frequently consider surgery in the elderly patient with
operable gastric cancer.
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M2137
Protein Kinase C Theta (Pkcθ) Differentiates Gastrointestinal Stromal Tumors
(GISTs) from Other Spindle Cell Tumors Expressing Kit
Linan Wang, Anette Duensing, Adrian Gologan, Shih-Fan Kuan
Background: Immunoperoxidase staining for the receptor tyrosine kinase KIT (CD117) is
the key diagnostic marker to establish the diagnosis of GIST. However, KIT expression is
not uncommon in other spindle cell tumors, thereby impeding the differential diagnostic
process. PKCθ has recently been found to be expressed in the interstitial cells of Cajal (ICC)
of the digestive tract and has shown promising features as a supplemental diagnostic tool
in assisting with the diagnosis of GISTs. This study is to establish the prevalence of PKCθ
expression in KIT-positive and -negative non-GIST spindle cell tumors in comparison to
GIST. Methods: The study group comprised of 62 spindle cell tumors (both intra- and
extraabdominal) from 62 unselected patients (F/M=29/33, mean age: 60.7) in which KIT
immunoperoxidase staining was performed at UPMC from 2000 to 2005. The pathology
reports and status of KIT immunostaining were reviewed to divide cases into KIT-positive
and -negative groups. The KIT-positive group consisted of 30 histologically and immunohis-
tochemically proven GISTs (F/M=12/18, mean age: 62.9) and 10 non-GISTs (F/M=5/5, mean
age: 52.8). The remaining 22 cases were KIT-negative non-GISTs (F/M=12/10, mean age:
61.5). The non-GISTs included a wide spectrum of spindle cell tumors: schwannoma (4),
leiomyosarcoma/leiomyoma (6), desmoid (2), glomus tumor (1), angiomyolipoma (1), react-
ive spindle cell proliferation (2), low-grade malignant spindle cell tumors (4), inflammatory
fibroid polyp (1) and high-grade sarcoma, NOS (11). Immunoperoxidase staining was
performed on formalin-fixed paraffin-embedded sections using a mouse monoclonal antibody
to PKCθ (BD Biosciences; 1:50 dilution). Results: All 30 KIT-positive GISTs (100%) also
expressed PKCθ in a mostly diffuse pattern. By contrast, PKCθ expression was absent in
80% (8/10) of the KIT-positive spindle cell tumors, and only barely detectable in 2 cases.
Moreover, PKCθ was not expressed in 91% (20/22) of the KIT-negative non-GISTs; the
PKCθ expression in 2 cases of this group was focal weaker than that in GISTs. Conclusion:
Immunohistochemical expression of PKCθ was confirmed to be specific for GIST and can
be a useful adjunct marker in separating GISTs from other KIT-positive spindle cell tumors.
M2138
The Natural History of Gastrointestinal Stromal Tumors and Leiomyomas: A
Prospective Evaluation Via Serial Endoscopic Ultrasound Surveillance
Vu Kwan, Ian D. Norton, David B. Jones
Introduction: The natural history of gastrointestinal stromal tumors (GIST) is not clearly
defined. Recent consensus guidelines suggest that malignant transformation occurs invariably
and that surgery is mandatory[1]. The majority of current literature has an oncological or
surgical bias, with little data regarding small lesions found incidentally at endoscopy. Periodic
surveillance with endoscopic ultrasound (EUS) may be another option for lesions of apparent
low malignant potential, as EUS can accurately monitor size and internal echotexture. We
aim to provide further insight into the natural history of small GISTs & leiomyomas (GIST/
Ls) by evaluating outcomes of serial EUS surveillance. Methods: Consecutive patients with
an EUS diagnosis of GIST/L were identified from an endoscopic database. Clinical progress
& management were documented via mail-out to patients, contact with referring practitioners
& review of surgical pathology. Patients managed non-surgically were prospectively recalled
for repeat EUS. Growth velocity was determined as change in size(mm) over time(years).
Results: Between 1997 and 2005, 125 patients received an EUS diagnosis of GIST/L. Median
age=65 (range 31-92), males=62, median follow-up=4.1 years (0.5-15), lesion location
gastric=87, oesophageal=35, duodenal=2, rectal=1. Median lesion size was 17mm (3-65).
Surgery was performed in 41 patients based on EUS criteria for potential malignancy or
patient preference. EUS diagnosis of GIST/L was confirmed in 33 (others: inflammatory =
4, cyst=1, pancreatic cancer=1, pancreatic rest=1, hemangioma=1). None were of high
malignant potential at histopathology. Serial EUS has been performed in 30 patients. Median
follow-up since index EUS was 5 years (1-15yrs, some with initial EUS elsewhere). Median
initial size was 15mm (3-44). Median growth velocity was 0mm/yr (0-5). The majority (n=
24) have not changed in size. No EUS-related complications occurred. Of the remaining
patients, 2 are deceased due to advanced GIST/L, 3 deceased from other causes, 8 lost to
follow-up. Clinical and/or endoscopic follow-up is available for the remaining, with no cases
of malignant transformation identified. Conclusion: The natural history of this subset of
GIST/Ls appears to be characterised by slow growth, with the majority exhibiting no change
in size over the follow-up period. Abrupt malignant transformation was not observed.
Therefore, serial EUS surveillance of GIST/Ls may be a reasonable alternative to surgery for
lesions with benign appearance at index examination. 1.Blay et al. Report of the GIST
Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann of
Oncol,2005. 16, 566-578.
M2139
Significant Correlation Between Helicobacter Pylori Genotypes and Time to
Clinical Remission After Eradication Therapy in Low-Grade Gastric MALT
Lymphoma - First Results from a Prospective Multicenter Trial
Renate Schmelz, Dana Grossmann, Christian Thiede, Monic Dawel, E Kuhlisch, Stephan
Miehlke, Daniela Aust, Gerhard Ehninger, Manfred Stolte, Andrea Morgner-Miehlke
Background: Helicobacter pylori ( HP) may possess different factors of pathogenicity which
can be associated with diseases like peptic ulcer or gastric adenocarcinoma. Prevalence of
HP pathogenic factors in positive low-grade gastric MALT lymphoma have been determinded
to some extend, however their potential influence on clinical outcome after eradication of
HP is unknown. Aim & Methods: The HP genotypes cagA, babA2, iceA1, vacAm, vacAs,
JHP950, JHP1462, oipA and sabA were determined using formalin fixed paraffin wax
embedded gastric tissue from patients with HP positive MALT lymphoma ( n= 35) and
Patients with gastritis (n=33) only. The different genotypes of HP were correlated with time
to complete remission (CR), age at first diagnosis, monoclonality, t[11;18] and disease stage
at first diagnosis. Results: HP from 35 patients (18 female, age range 30-78 years) with
MALT lymphoma have been analyzed. 3 patients were lost of follow up (9%) and another
3 (9%) had to be irradiated because lack of complete remission after 12 months. First
complete remission occured 3.6 months (mean) after HP eradication. 56% of patients showed
monoclonality, 7 % had the translocation t(11;18). There was a significant correlation
(p<0.01) between a positive status for JHP1462 and time to CR. Patients with positive
JHP1462 (n=9) were in CR after a mean of 1.4 months compared to 3.4 months in JHP1462
negative patients (n=26). Patients with vacAm1 positive HP also showed a significant (p<0.05)
shorter time to CR than VacAm2 positives( 1.7 vs 3.7 months). Conclusion:. Patients with
low-grade gastric MALT lymphoma and positive JHP1462 status appear to achieve clinical
remission faster after HP eradication than those with a negative JHP1462 status. The same
trend has been seen for patients with vacAm1 positive HP. Larger patient numbers are
needed to further confirm these findings.
M2140
Epidemiology of Gastrointestinal Stromal Tumors in a Defined Canadian
Health Region: A Population Based Study
Brian Yan, Gil G. Kaplan, Stefan Urbanski, Carla L. Nash, Paul L. Beck
Background and Objectives: Gastrointestinal stromal tumors (GISTs) are the most common
mesenchymal tumor of the GI tract. At present there is only one population based study
on the epidemiology of GIST. The aim of the present study was to determine the incidence
of GIST within a well defined Canadian Health Region. We also describe the demographics,
clinical presentation, disease associations, risk factors,and tumor and pathological character-
istics of GIST. The use of KIT staining (CD117) in the diagnosis of GIST was assessed.
Methods: This was a population based retrospective analysis for all adult patients diagnosed
with GIST in the Calgary Health Region from April 1 2000 to March 31, 2004. Cases were
identified through the Calgary Lab Services pathological data base with the search terms
“GIST” and “gastrointestinal stromal tumors”. Charts of all included patients were reviewed
for clinical history, pathology and immunohistochemical characteristics. All pathological
specimens were stained for CD117, CD34, vimentin, smooth muscle actin, keratin, and
protein S100 and reviewed by a single pathologist for specific mitotic rates, predominant
tumor cell type and antigenic determinants. Category-specific risks for developing GIST
were reported as relative risks (RR) with exact 95% confidence intervals (CI). Results: A
total 22 cases were identified in the study giving a crude incidence rate of 0.68/100000,
and age and gender adjusted rate of 0.73/100000. Of these, 59% were female (p=0.4) and
the average age was 62.5 years. An increased incidence with advanced age was noted: 18-
44 (0.26/100000), 45-64(0.63/100000), and ≥65(2.84/100000), resulting in a RR4.6(p=
0.0006)for age ≥50. 8 cases were identified prior to routine CD117 staining of which only
3 were stained. 14 cases were identified post routine CD117 staining of which 11 were
stained. On repeat staining, all cases were positive for CD117 and vimentin, 96% for CD34,
64% for smooth muscle actin, and 45% for protein S100. Gastrointestinal bleeding (59%)
and abdominal pain (55%) were the most common symptoms. No specific diseases were
associated with GIST in our series. Stomach (50%) and small bowel (27%) were the most
common primary tumor sites. Metastatic disease at presentation was found in 19% of cases.
73% were spindle cell tumors. At presentation, 27% were very low risk, 36% low, 19%
intermediate, and 19% high. Conclusions: GISTs are rare tumors of the GI tract with an
age and gender adjusted incidence of 0.73/100000. Those over age 50 are at increased risk.
Cases are more readily identified with KIT staining. Most cases are low risk at presentation,
but 37% will be intermediate to high risk.
M2141
Long-Term Outcome of Low-Grade Gastric MALT Lymphoma After
Helicobacter Pylori Eradication: A Prospective Single Center Study
You Sik Choi, Jae Hee Cheon, Jong-Yeol Lee, Byung Duk Ye, Sang Gyun Kim, Joo Sung
Kim, Hyun Chae Jung, In Sung Song
Background/aims: Most cases of low-grade gastric MALT lymphoma are associated with
Helicobacter pylori infection. Therefore, eradication of H. pylori has been accepted to be a
main strategic target against localized gastric MALT lymphoma. However, long-term outcome
of gastric MALT lymphoma after H. pylori eradication remain unknown. We aimed to evaluate
prospectively the long-term outcome of gastric MALT lymphoma after H. pylori eradication
in single center. Methods: Sixty-five patients with H. pylori-positive low-grade gastric MALT
lymphoma (Ann Arbor stage IE1 and IE2) were prospectively enrolled from January 1996
to October 2004. Diagnosis and staging were performed by endoscopic biopsy, chest X-
ray, abdominal CT, bone marrow examination and endoscopic ultrasonography. After the
eradication of H. pylori, the patients were followed up with endoscopic and histologic
assessment at every 2-3 months in first year, every 6 months in the second year and thereafter.
Results: H. pylori eradication was confirmed in all of the 65 patients by first- and second-
line therapy. Complete remission of low-grade gastric MALT lymphoma was achieved in
56 patients (86.2%). Nine patients without remission of gastric MALT lymphoma underwent
gastrectomy and one of them underwent radiation therapy because of incomplete resection.
The median duration of follow-up of the 56 patients with complete remission after H. pylori
eradication was 28.7 months (range 6.1-106 months). During follow-up period, H. pylori
reinfection occurred in 6 of 65 patients (9.2%) with no evidence of disease relapse, and H.
pylori was eradicated in all of them. Only one patient (1.5%) with complete remission
experienced disease relapse after 12 months without the evidence of H. pylori reinfection
and underwent gastrectomy. Complete remission of gastric MALT lymphoma was not associ-
ated with the age, sex, endoscopic features, location or eradication regimens. Furthermore,
there was no difference in remission rate between the lymphomas restricted to mucosa and
those that invaded submucosa by endoscopic ultrasonography. Conclusions: Our study
demonstrated that H. pylori eradication is an efficacious primary treatment option for low-
grade gastric MALT lymphoma because of high remission and very low recurrence rate of
gastric MALT lymphoma by a long-term observation.
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M2142
Single Nucleotide Polymorphisms (SNPs) Associated with Sporadic Colorectal
Cancer: A Case-Control Study
David Weinberg, Kathryn Irenze, Daniel Chasman, Kristin Ardlie
Introduction: Colorectal cancer (CRC) is a common, multi-factorial disease resulting from
the variable contribution of lifestyle, dietary and genetic factors. The search for genetic
susceptibility factors has been extensive with a particular recent emphasis on low penetrance
genes or gene variants. Ultimately the comprehensive identification of the various genetic
factors that contribute to CRC development will likely require whole genome scanning in
large populations, with follow-up association studies of promising SNPs or gene candidates.
At present, most studies have employed a candidate gene approach where well-described
variants of genes already implicated, or putatively implicated, in colorectal carcinogenesis
are interrogated in an effort to identify those variants more frequently seen in patients with
colorectal cancer compared to healthy controls. Methods: A panel of single nucleotide
polymorphic (SNPs) variants of a range of genes associated with colorectal cancer was
identified. Using a candidate gene approach, we genotyped multiple (5-10) SNPs from each
of 21 genes on a sample of 750 patients with well phenotyped, sporadic CRC. In addition
a similarly sized group of matched, healthy controls were also collected and genotyped. We
then compared individual SNP frequencies in all cases and controls. Results: Of the 29 most
promising SNPs, 5 demonstrated significant association between genotype and case/control
status: TCF4 (rs599550), MSH2 (rs2303428), DCC (rs2298606), TGFB1 (rs1800472),
IGF2R (rs894817). Although associated odds ratios were relatively small (0.5 to 1.4), allele
frequencies were in the range of 10-20%, suggesting that the overall impact on attributable
risk for a common disease like CRC may be substantial. Conclusions: Beyond potentially
shedding light on the underlying biology of CRC, use of these SNPs or others may provide
more accurate estimates of CRC risk in the future. Improved gene-based risk assessment
may ultimately allow for more tailored screening programs, where the “molecular” risk level,
determined by the assessment of a panel of relevant, but low penetrance markers informs
the frequency or the type of screening.
M2143
Gastric Cancer Susceptibility Is Not Linked to Pro- Or Anti-Inflammatory
Cytokine Gene Polymorphisms in Caucasians: A Nation-Wide Multicenter
Study
Maria Asuncion Garcia-Gonzalez, Mark Strunk, Rafael Benito, Angel Lanas, Enrique
Quintero, David Nicolas, Santos Santolaria, Federico Sopena, Miguel Angel Simon,
Cristina Pascual, Adolfo Parra-Blanco, Jesus Espinel, Rafael Campo, Marisa Manzano,
Fernando Geijo, Maria Pellise, Ferran Gonzalez-Huix, Miguel Nieto, Jorge Espinos, Lluisa
Tito, Luis Bujanda, Manuel on Behalf of the Spanish AEG Zaballa
Background & aim: Recent studies have supported the relevance of host immunogenetic
factors on gastric cancer (GC) susceptibility. The aim of our study was to analyze the
influence of H. pylori infection and host genetic factors in a population of Spanish Caucasian
GC patients by studying several functional polymorphisms localized in pro- and anti-
inflammatory genes. Methods: DNA from 404 unrelated Spanish patients with GC and 404
sex- and aged- (± 5 years) matched healthy controls (HC) with no gastrointestinal symptoms
was typed for several functional polymorphisms in the pro-inflammatory IL-1B (-511, +3954),
TNFA (-238, -308), LTA (LTA NcoI, LTA BsI), and IL-12p40 (+1188) genes, and the anti-
inflammatory IL-4 -590, IL-1RN (VNTR in intron 2), IL-10 (-597, -1087) and TGFB1 (+869,
+915) genes by PCR, RFLP and TaqMan assays. H. pylori infection and CagA/VacA antibody
status were also determined by western blot in patients and controls. Results: H. pylori
infection with cagA strains was associated with increased risk of GC (OR: 2.5; 95% CI:
1.85-3.37; p< 0.0001). H. pylori prevalence was identical (70.3%) in patients with cardia
GC (n=70) than in patients with non-cardia GC (n=334) When considering the histological
type of the tumor, H. pylori infection was significantly higher in patients with diffuse GC
than in patients with the intestinal subtype (80% vs 69 %; OR: 1.98; 95% CI: 1.11-3.52,
p= 0.024). Among the overall cytokine gene polymorphisms analyzed in this study, only
TNF-A -238 SNP was weakly correlated with decreased risk of non-cardia GC. Thus,
individuals homozygous for the rare allele TNFA-238A were significantly less frequent in
patients with non-cardia GC compared to controls (8/334 in GC and 1/334 in HC, OR:
0.12; 95% CI: 0.01-0.98; p= 0.03). In addition, some simultaneous combinations of pro-
inflammatory genotypes reported to be associated with increased risk of GC were analyzed.
Frequencies of IL-1B-511T/IL-1RN*2/*2 combination in patients and controls were 8.2%
and 5.5% respectively. The haplotype IL-10 -597A/IL-10 -1087A frequency was almost
identical in GC patients (22.3%) than in HC (19.4%), and carriage frequency of IL-1B-
511T/IL-1RN*2*2/TNFA-308A alleles was 6.6% in GC and 7.4% in HC. Conclusion: Our
data show that IL-1B, IL-1RN, IL-12p40, LTA, IL-10, IL-4 and TGF-B1 gene polymorphisms
are not involved in the susceptibility to GC in Caucasians. Studies to elucidate the real
contribution of genetic host factors on GC susceptibility are warranted at different geographic
areas and ethnic groups.
M2144
Influence of Single Nucleotide Polymorphism in the Promoter Region of
Interleukin-8 Gene On Progression and Metastasis of Gastric Cancer
Ayumu Taguchi, Naoki Ohmiya, Nobuyuki Mabuchi, Takafumi Andoh, Osamu Maeda,
Akihiro Itoh, Yoshiki Hirooka, Yasumasa Niwa, Hidemi Goto
Background: Host genetic susceptibility may influence gastric carcinogenesis caused by
Helicobacter pylori infection. We previously reported that Interleukin (IL)-8 T-251A single
nucleotide polymorphism (SNP) is associated with the elevated risk of atrophic gastritis and
gastric cancer. In this study we aimed to investigate the influence of IL-8 T-251A SNP on
progression and metastasis of gastric cancer. We also investigated the effect of IL-8 polymorph-
ism on IL-8 production and on histological degree of gastritis in gastric mucosa. Methods:
A total of 863 subjects were enrolled, including healthy controls (n = 252), individuals with

















was genotyped by PCR-RFLP. The levels of IL-8 protein were measured by chemiluminescent
immunoassay. Results: A/A genotype held a higher risk of overall gastric cancer (OR, 2.22;
95% CI, 1.08-4.56) than T/T genotype. We also found that A/A genotype increased the risk
of diffuse (OR, 2.79; 95% CI, 1.21-6.39), poorly differentiated (OR, 2.70; 95% CI, 1.14-
6.38), lymph node (OR, 2.50; 95% CI, 1.01-6.20) and liver metastasis (OR, 5.63; 95% CI,
1.06-30.04), and p53-mutated (OR, 1.91; 95% CI, 1.13-3.26) subtype of gastric cancer. A/
A and A/T genotypes were significantly associated with higher levels of IL-8 protein than
T/T genotype. Neutrophil infiltration score was significantly higher in A/A genotype than
in T/T genotype. Conclusion: We demonstrated that IL-8 T-251A SNP is associated with
higher expression of IL-8 protein, severer neutrophil infiltration and increased the risk of
gastric cancer, especially diffuse type, poorly differentiated adenocarcinoma, lymph node
and liver metastasis, and p53 mutations. These findings suggest that IL-8 T-251A SNP
influence progression and metastasis of gastric cancer by autocrine and/or paracrine mech-
anism.
M2145
Contribution of MYH Mutations to Colorectal Cancer in a British Asian
Population
Sunil Dolwani, Geraint Williams, West Kevin, Joseph Newman, David Stock, Paul
Griffiths, Jacqueline Best, Jeremy Cheadle, Julian Sampson
Bi-allelic mutations in the base excision repair gene MYH have recently been discovered to
cause the multiple colorectal adenoma and carcinoma phenotype. Our previous study identi-
fied 25 such cases from 111 eligible families with non dominant inheritance out of 614
studied from 6 UK regional polyposis registers. An interesting observation in this study was
that all 4 cases with homozygous E466X mutations and the case with a Y90X mutation
were unrelated individuals of British Asian origin. We postulated that MYH mutations might
contribute more significantly to colorectal cancer among British Asians than indigenous
Northern Europeans. We therefore conducted a retrospective study to assess the contribution
of MYH mutations to colorectal cancer a condition which is otherwise rare in this ethnic
group. Subsequent to Multicenter ethics approval from the MREC 120 British Asian cases
with CRC and 100 controls with inflammation without neoplasia from the same ethnic
group were identified from pathology depts of the 5 participating centres. DNA was extracted
and successfully analysed from paraffin blocks of normal tissue from these. All samples in
the case group were subjected to histopathological re-examination to ensure analysis of only
normal background tissue. PCR and restriction enzyme digestion was used for identification
of the Asian mutations E466X (using ApoI ) and Y90X (using RsaI) and also to identify the
common Northern European mutation G382D (using BglII). ARMS PCR was used for
detection of the second common European mutation Y165C. Positive results were confirmed
by bidirectional sequencing (ABI Prism 3100). One case (1/120) and one control (1/100)
were found to be heterozygous for the E466X variant in MYH. Sequencing of all exons of
MYH in these 2 individuals did not reveal any second mutations. We conclude that these
four MYH mutations are unlikely to be a major contributor to colorectal cancer in British
Asians. A much larger series would be required to quantify accurately the proportion of
colorectal cancer attributable to MYH in this group. None the less, the frequency with which
the E466X allele was observed is comparable to the frequency of Y165C and G382D in the
general British population and there is a strong case for initial testing for this mutation in
Asian individuals with adenomatous polyposis or colorectal cancer with apparent recessive
transmission.Studies in other ethnic subgroups have also suggested that the identification
and characterisation of population-specific ancestral variants such as 1395delGGA in Italians
may be helpful for the provision of molecular diagnostics for MYH associated polyposis (MAP).
M2146
Possible Association of Polymorphisms in the COX-2 Gene with Risk of
Adenoma Development in An African-American Case-Control Study
Hassan Ashktorab, Lucile Adams-Campbell, Mamoon Elbedawi, Mohammad
Daremipouran, John Kwagyan, Ahmad Akhgar, Akhter Shahina, Shirly Tsang, David J.
Munroe, Iu Ali, Duane Smoot
Cyclooxygenase-2 (Cox-2), a key enzyme in the arachidonic acid signaling pathway is often
over-expressed in colorectal adenoma. Recent evidence indicates that single nucleotide
polymorphisms (SNPs) in the Cox-2 gene may modulate the risk of adenoma development.
We explored this possibility of association between Cox-2 polymorphisms and risk of
adenoma in an African American case-control study. We used an exhaustive approach of
genotyping 13 haplotype-tagging SNPs (ht SNPs) in the Cox-2 gene in 72 cases of advanced
adenomas and 146 polyp-free controls. All ht SNPs, except for one, were from the regulatory
regions distributed over the entire gene (three in the promoter region at positions -466, -
663, and -861; one in exon 1 at 2331; two in intron 5 at 5072 and 5229; one in intron 6
at 5625; one in intron 7 at 6064; five in the 3’ untranslated region (UTR) of exon 10 at
8334, 8494, 10494, 10848, and 10935). Associations were analyzed with logistic regression
models assuming a dominant effect for rare variants to increase statistical power. Our analysis
showed an association of the intron 5-5229 G variant with increased risk of adenoma
development. Compared to individuals with the wild type genotype GG at intron 5-5229,
carriers of TG/TT genotypes had more than two-fold risk of adenoma development. (odds
ratio (OR) 2.1 with 95% confidence interval (CI) 1.07 - 4.41, p=0.0044). Another trend of
increased risk was observed at the 3’UTR- position 10935 (OR, 1.6: CI, 0.73 - 3.38).
Interactions between COX2 genotype and use of nonsteroidal anti-inflammatory drugs,
smoking, alcohol consumption, and risk of colorectal cancer were also explored. Our results,
if confirmed in a larger African-American cohort, would be helpful in identifying individuals
at increased risk for developing colorectal cancer.
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M2147
The Risk of Interleukin-1beta Gene in Esophageal, Gastric and Colorectal
Carcinomas
Hiroaki Ito, Kazuhiro Kaneko, Toshinori Kurahashi, Taikan Yamamoto, Yosuke
Kumekawa, Meiko Kuwahara, Yutaro Kubota, Takashi Muramoto, Michio Imawari
[Background] Interleukin (IL)-1 gene polymorphisms are associated with development of
gastric atrophy and with increased risk of gastric carcinoma. A -31 C-to-T base transition
in the promoter region of this gene is involved in carcinogenic changes within the stomach,
especially in Helicobacter pylori infected individuals. We examined association between 1L-
1 locus polymorphisms and risk of esophageal, gastric,colorectal carcinomas, and ulcerative
colitis (UC) in Japanese patients with H. pylori infection.[Patients and Methods] Control
subjects and all patients with esophageal, gastric, colorectal carcinoma cases, and UC cases
were confirmed H.pylori infection by the use of 14C-urea breath test,18 culture, and histopa-
thological examination. IL-1B and IL1-RN polymorphisms were analyzed in 136 controls,
75 patients with esophageal carcinoma, 186 patients with gastric carcinoma, 69 patients
with colorectal carcinoma, and 18 patients with UC. For IL-1B-511 and -31 polymorphisms
were determined by fluorescence-based polymerase chain reaction-single-strand conforma-
tion polymorphism (PCR-SSCP) analysis. For IL-1 receptor antagonist gene (IL-1RN), penta-
allelic variable number of tandem repeats (VNTR) was determined by PCR-standard agarose
gel electrophoresis. [Result] For gastric carcinoma, IL-1B-511 heterozygotes (OR: 0.48, 95%
CI: 0.3-0.9, p=0.0115) and T carriers (OR: 0.52, 95% CI: 0.3-1.0, p=0.0185) had a signific-
antly reduced risk of carcinoma. For colorectal carcinoma, IL-1B-511 heterozygotes (OR:
0.34, 95% CI: 0.2-0.7, p=0.0028) and T carriers (OR: 0.43, 95% CI: 0.2-0.9, p=0.0015)
had a significantly low risk of carcinoma. Genotype frequencies in patients with esophageal
carcinomas and UC were similar to controls, showing no genotypic specific risk. No significant
difference also was observed in the frequencies of IL-1B-31C/T and IL-1RN genotypes
between controls and the esophageal carcinoma patients, and the UC patients. [Conclusion]
Our results in Japanese subjects showed that IL-1B -31 and -511 genetic polymorphisms
and IL-1RN polymorphisms are not associated with the risk of esophageal carcinoma.
However, IL-1B -511 C/T and T carrier state may be less at risk for gastric and colorectal
carcinoma in the Japanese population.
M2148
APC Polymorphism in Subjects At Average and Increased Risk for CRC
Oleg Dolkart, Eliezer Liberman, Moshe Leshno, Miri Revivo, Nadir Arber
Background: Mutations in the APC gene are the major event in familial adenomatous polyposis
and in the majority of sporadic CRC. I1307K APC gene variant occurs in about 6% of
Ashkenazi Jews, and has been suggested to represent a genetic change leading to susceptibility
for colorectal cancer (CRC) in this ethnic group. Nevertheless, recent publications have
questioned the useful role of I1307K in determining the risk for CRC (OR 1.4-2.0). Much
less is known about the E1317Q variant in the APC gene. Objective: To prospectively assess
the clinical importance of these two polymorphisms in Israeli Jews at average and increased
risk for CRC. Methods: 3650 consecutive attendees at the Integrated Cancer Prevention
Center (between 12.97-12.05) were consented, including an average risk group (asymptom-
atic subjects without a personal or family history of colorectal neoplasia) and a high risk
group (patients with a personal and/or family history of colorectal neoplasia). DNA from
peripheral blood lymphocytes was amplified by real time PCR using primers that were
specifically designed to detect, simultaneously, I1307K and E1317Q. E1317Q was evaluated
in the last 1911 subjects (12.02-12.05). A life-style habits questionnaire, (cigarette smoking,
alcohol consumption, BMI, physical activity, vitamins, and medications and anti-oxidants
intake) was administered to all participants. Results: Overall I1307K was detected in 301
subjects (8.6%) (9% among Ashkenazi and 2.4% among non-Ashkenazi Jews). The carrier
rate was 10.1% and 7.7% in high and average risk subjects, respectively (P=0.78). In both
average and high risk study groups, no significant differences were found among carriers
and non-carriers in the incidence of colorectal neoplasia, their histological features and age
of diagnosis. The odds ratio (OR) for CRC was 1.2. E1317Q was detected in only 19 (1.1%)
cases. However, 18 of these subjects (95%) had colorectal neoplasia (9 CRC and 9 adenoma).
The last E1317Q carrier is a young subject that was enrolled into a tight surveillance
program. Both, I1307K and E1317Q variants, were not associated with any of the known
epidemiological risk factors for CRC, or vitamins/supplements intake. Conclusions: E1317Q
is not just a polymorphism, but a rare gene variant of APC that carries a significant high
risk for CR neoplasia (OR-4.3). Meticulous surveillance program is recommended in this
setting. I1307K, on the other hand, posses only very slight increases in CRC risk (OR- 1.4)
as we had previously shown (CEBP, 2002). I1307K carriers should be involved in CRC
screening programs like the average risk population.
M2149
The Role of Alcohol Dehydrogenase in Alcohol-Associated Colorectal
Carcinogenesis
Michael Marks, Monika Benesova, Felix Stickel, Markus W. Buechler, Helmut K. Seitz
Background and Aims: Chronic alcohol consumption has an increased risk for colorectal
cancer (Su and Arab, Nutr Cancer 50: 111, 2004). It has been shown that acetaldehyde
(AA) causes DNA damage and contributes to cancer development. In the upper aerodigestive
tract individuals homozygous for the ADH1C*1 allele which codes for an ADH enzyme
with high AA producing capacity have an increased risk for cancer (Visapää et al, Gut 53:
871, 2004). ADH is also important for the oxidation of retinol to retinoic acid, an important
factor for cell differentiation which is reduced following chronic alcohol consumption, at
least in the liver. The aim of this study was to investigate whether the ADH1C*1 allele also
plays a role in alcohol-associated colorectal cancer and whether the expression of the
ADH phenotype changes during carcinogenesis. Methods: Genotype and allele frequency of
ADH1C were studied in 101 patients with colorectal cancer and an alcohol intake of more
than 20 g/day (average 70+45 g), in 60 patients with colorectal cancer and an alcohol intake
of less than 10 g/day, and in 204 healthy controls without cancer and an alcohol intake of
14+8 g/day. Genotyping of the ADH1C locus was performed using polymerase chain reaction
based on restriction fragment length polymorphism methods on leucocyte DNA. In addition,
starch gel electrophoresis for the characterization of ADH phenotype was performed using
biopsies from normal colonic mucosa (M) (n=17), polyps (P) (n=8) and from carcinoma(C)
(n=9). In addition, total ADH activity was measured. Results: The allele frequency of the
ADH1C*1 allele was found to be significantly increased in alcohol consumers with colorectal
cancer as compared to lightly drinking cancer patients and healthy controls (65.4% vs.
54.6% vs. 51%, p<0.05). In addition, ADH1C*1/1 homozygosity was also significantly
different between cancer patients who consumed alcohol compared to the other groups
(41% vs. 23% vs. 22%, p<0.05). Furthermore, total mucosal ADH activity decreased from
2.6+0.34 (M) to 0.94+0.34 (P) to 0.44+0.27 (C) nmol/mg prot/min. (p<0.05) during carcino-
genesis. This was associated with a decrease in the presence of γ-ADH (94% vs. 50% vs.
33%) and χ-ADH (100% vs. 88% vs. 88%). However, σ-ADH was neither detected in
normal mucosa nor in cancer tissue, whereas in 38% of polyps σ-ADH was found. Conclu-
sion:These data shown an increased risk for the development of colorectal cancer in alcohol
consuming individuals with the ADH1C*1 allele. One explanation for the de novo expression
of σ-ADH in polyps could be retinoic acid deficiency in a critical premalignant condition
to guarantee increased generation of retinoic acid.
M2150
MDR1 Polymorphism Is Associated with Reduced Risk of Gastric Carcinoma
in Japanese Population
Tomomitsu Tahara, Tomiyasu Arisawa, Tomoyuki Shibata, Mituo Nagasaka, Yoshio
Kamiya, Hiroshi Fujiita, Ichiro Hirata, Hiroshi Nakano
Background: Host genetic factors play a key role in gastric carcinogenesis, but all the
mechanism is not clearly demonstrated. P-glycoprotein/Multidrug resistace 1(MDR1) medi-
ates the active transport of various substrates including xenobiotics, and it thus has a
protective function in various tissues and organs including gastrointestinal epithelial cells.
Recently, it has been reported that P-glycoprotein/MDR1 is associated with intestinal tumorg-
enesis in Apc(Min/+)mice. Further, MDR1 gene C3435T polymorphism in exon26 influences
P-glycoprotein expression and activity in gastrointestinal tract Aims: We investigated the
effects of a MDR1 gene polymorphism on the risk of gastric cancer. Subjects: The study
was performed in 157 gastric cancer (GC) cases [mean age 64.9, F:M=0.28, intestinal
type(58.2%), diffuse type(37.0%), mixed type(4.8%)] and 107patients without evidence of
GC [mean age 64.0, F:M=0.31, Peptic ulcer diseases (43.0%), gastritis(57.0%)] as a control
group. Methods: MDR1 C3435T polymorphism was determined by PCR-RFLP in all the
patients. Results: MDR-1 3435 TT genotype frequency was significantly higher in controls
than GC cases (31.1% v 14.7%, OR: 2.12, p<0.05). Furthermore, 3435 TT was more strongly
associated with reduced risk of intestinal type histopathology (31.1% v 12.2, OR: 2.55,
p<0.05). There was no significant difference in CT and CC genotype frequencies between
GC and controls. Conclusion: Our data suggest that MDR1 3435T/T is associated with
reduced risk of gastric cancer in Japanese population.
M2151
The Angiotensin I-Converting Enzyme Gene Insertion/Deletion Polymorphism
Is Linked to Early Gastric Cancer
Matthias Ebert, Jutta Dierkes, Christian Folwaczny, Manfred Stolte, Christoph Roecken,
Peter Malfertheiner
The insertion/deletion polymorphism of the angiotensin I-converting enzyme (ACE) gene
has recently been linked to the pathogenesis and progression of human cancers. Using
genomic DNA from 88 patients with early gastric cancer confined either to mucosa (pT1a)
or submucosa (pT1b) we assessed the insertion (I) and deletion (D) polymorphism by PCR
analysis and compared it with a large non-cancer control population (n=145). In the non-
cancer control group the II genotype was observed in 33 (23%) individuals, whereas the
ID and DD genotypes were found in 72 (50%) and 40 (27%) individuals, respectively.
Interestingly, in the cancer group we found the II genotype in 6 (7%) patients and the ID
genotype in 46 (52%) individuals, while the DD genotype was observed in 36 (41%)
individuals (p=0.0034). Accordingly, the odds ratio (OR) for the II genotype was 0.20 (95%
CI 0.08-0.54, p=0.009) and 0.55 for the ID/II genotype (95% CI 0.31-0.96, p=0.044) using
the high-activity genotype DD as the reference category. No correlation was found between
tumor type, tumor stage, the presence of Helicobacter pylori and the ACE genotype. Our
study provides further evidence that the ACE insertion/deletion gene polymorphism may
be linked to the development of early gastric cancer.
M2152
Effect of Vitamin D Receptor Polymorphisms On Colorectal Cancer
Progression
Damien Matusiak, Robert Carroll, Richard Benya
Activation of the vitamin D receptor (VDR) is thought to play an important role attenuating
and modulating CRC progression. However, the VDR gene is highly susceptible to mutation,
with over 200 single nucleotide polymorphisms (SNP) having been identified. Of those
altering function, Bsm1, Taq1 and Fok1 are among the best studied. Yet the clinical con-
sequence of each SNP has only been considered in the context of altering CRC risk; while
the studies to date have reported variable, conflicting and inconclusive effects. In contrast,
no studies have been performed evaluating the effect of these SNPs on CRC behavior post
malignant transformation. METHODS: 67 consecutively resected flash-frozen CRC from 3/
04 to 5/05 were obtained from the NCI Cooperative Human Tissue Network (CHTN).
Sections of adjacent non-malignant colon along with the primary tumor and all lymph
node (LN) metastasis were evaluated for predominant histology. Regions that were well
differentiated were scored 1, moderately differentiated 2, and poor 3, and entire specimen
scored using a weighted average. Relevant regions of the VDR genome were amplified by
PCR, SNP status assessed, and wild type (ie, SNP not present) indicated as TT, BB, or FF,
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while mutations to 1 or both alleles are identified by small case. CHTN pathologists deter-
mined tumor size. Statistical comparisons were performed by ANOVA in all circumstances.
RESULTS: There was no correlation between tumor differentiation and tumor size. Taq1
status had no effect on tumor size, differentiation, or number of LN metastases (Table).
Fok1 status significantly affected tumor size and number of LN metastases, but had no
impact on overall differentiation. Finally, Bsm1 SNPs resulted in progressively smaller and
better differentiated CRC that decreased tumor metastasis. CONCLUSIONS: VDR SNP status
significantly alters CRC growth, differentiation, and propensity to metastasize. Although the
mechanism whereby VDR SNPs alter tumor behavior has yet to be determined, assessing
this status may identify patients benefiting from vitamin D chemoprevention.
Data expressed as means+/-SE.
M2153
Cost As a Barrier to Acceptance of a Pancreatic Cancer Surveillance Program
in Familial High-Risk Individuals
Jennifer Simon, Sara Olson, Emmy Ludwig, Robert C. Kurtz
Familial pancreatic cancer (FPC) represents about 10% of pancreatic cancers. Surveillance
programs for healthy FPC family members use expensive imaging and endoscopic modalities.
We have shown that the cost associated with such surveillance is a barrier to recruitment
of FPC family members. Methods: In 2002, we began our FPC registry for FPC patients
and their relatives. Our protocol includes both a family registry and a surveillance program
that utilizes Magnetic Resonance Cholangiopancreatography and Endoscopic Ultrasonogra-
phy. In 2005, a grant to help defray the cost of surveillance was obtained and applied to
newly recruited FPC family members; those who had previously refused surveillance were
re-contacted. We compare acceptance of our FPC surveillance program after the 1st year
of the study, and after obtaining grant support. Results: During the 1st year of our program,
51 eligible FPC patients and relatives were asked to join the study. Eighteen FPC relatives
(8 female) agreed to participate and 14 relatives (5 female) refused. The main reason for
refusal was the cost of surveillance in 12 of the 14 (86%) relatives. Eight of the 18 (44%)
relatives who accepted the registry also refused surveillance for the same reason. At 34
months 273 patients and relatives had been approached and 152 people agreed to participate.
Of these 96 are healthy FPC relatives (60 female, 36 male, mean age 49.1 years). Only 13
of the 96 (14%) eligible relatives refused surveillance due to cost. Thirty-one relatives (22
female) refused our registry. Seven of the 31 (23%) relatives who refused gave the cost of
surveillance as the reason. We re-contacted 19 relatives (10 female) who initially entered
the program but refused surveillance due to cost; 8 agreed to participate in surveillance, 4
refused again, and 7 are pending. FPC family members who accepted surveillance are more
likely to be self-referred, under 50, female, have graduate-level education, and have 3 or
more relatives with pancreatic cancer. Conclusions: Since obtaining grant support to cover
surveillance costs, the percentage of relatives who rejected FPC surveillance has decreased
from 44% to 14% for those who initially entered our FPC registry only. The overall rejection
rate for both the registry and surveillance decreased from 86% to 23%. While some of this
decrease in rejection rate may be attributed to personnel changes and to our increasing
experience with the program, we believe that the key factor is the ability to support the
cost of FPC surveillance.
M2154
Ubiquitin Specific Protease 14 Induced Pancreatic Cancer Cell Growth
Inhibition and Apoptosis
Toshiyuki Ishiwata, Kazumitsu Cho, Shunji Ishiwata, Taeko Suzuki, Kiyoshi Teduka, Yoko
Kawamoto, Takenori Fujii, Kiyoko Kawahara, Nando Nakazawa, E.J. Uchida, Takashi
Tajiri, Zenya Naito
Background: Ubiquitin specific protease 14 (USP 14), also known as the 60kDa subunit of
tRNA-guanine transglycosylase (TGT 60kD), belongs to the ubiquitin-specific processing
protease (UBP) family. UBP family releases ubiquitins that are conjugated to various sizes
of proteins by aNH-peptide bonds and an eNH-isopeptide bond. One of the members of
the UBP family, herpesvirus associated ubiquitin-specific protease (HAUSP), stabilized p53
even in the presence of excess Mdm2 by which p53 was ubiquitinated and thereafter
degraded. Furthermore, HAUSP induced the p53-dependent apoptosis. USP 14 expression
was reported in leukemic and colorectal cancer cells, however, the role of USP 14 in cancer
cells has not get been well elucidated. In the present study, we attempted to examine the
expression and role of USP 14 in human pancreatic cancer cell lines and pancreatic cancer
tissues. Methods: USP14 mRNA and protein expression were examined in Panc-1, MIA-
PaCa-2, PK-45H and PK-8 pancreatic cell lines by real time-PCR and Western blot analysis.
Immunohistochemical analysis using anti-USP 14 antibody was performed in 53 pancreatic
cancer cases. Furthermore, in situ hybridization analysis was performed to examine the
expression of USP 14 mRNA in pancreatic cancer. USP 14 cDNA was cloned into pIRES2-

















USP 14 stable transfectants were obtained. Results: USP14 mRNA and its protein were
detected in four pancreatic cancer cell lines. Immunohistochemically, USP 14 was weakly
localized in the islets of control pancreatic tissues. In 19 of 53 pancreatic cancer patients
(35.8 %), USP14 was strongly detected in the cytoplasm of cancer cells and USP-14 positive
patients tended to show a better prognosis. USP14 stably transfected Panc-1 cells decreased
the growth rates as compared to mock cells. The USP 14 transfectants showed a balloon-
like appearance and apoptosis-related proteins, Bax and cleaved Caspase-3, were markedly
increased in the cells. Conclusion: USP 14 was expressed in some human pancreatic cancer
cells and overexpression of USP 14 induced apoptosis and cell growth inhibition in pancreatic
cancer. These findings indicate that USP 14 may be a novel target for pancreatic cancer
therapy.
M2155
Impact of CIS-Hydroxyproline On JAK/STAT3 Pathway in Pancreatic
Carcinoma Cells
Gisela Sparmann, Christoph Mueller, Robert Jaster, Stefan Liebe, Joerg Emmrich
Background and Aims: The proline analogue cis-hydroxyproline (CHP) has been shown
to mediate endoplasmic reticulum (ER) stress resulting in growth inhibition and apoptosis
induction of the rat pancreatic tumor cell line DSL6A (Mueller et al., Gastroenterology
2004;126:A548). The aim of this study was the characterization of biological and molecular
effects exerted by CHP on human pancreatic tumor cells. Methods: The human cell lines
Capan I, BxPc-3, MiaPaca-2 and rat pancreatic stellate cells (PSC) as a control were used.
Cell proliferation was assessed by bromo-deoxy-uridine (BrdU) incorporation. Apoptosis
was analyzed by detection of caspase-3 activation, necrotic cell death was demonstrated
through the intake of ethidium bromide using fluorescence microscopy. ER stress was
investigated by RT-PCR and Western blot technique detecting the proteins glucose related
protein (GRP)78 and growth arrest and DNA damage inducible factor (GADD)153. Activation
of signalling pathway components (STAT3, ERK) was analyzed by immunoblotting using
antibodies specific for the respective phosphorylated protein. Results: CHP inhibited the
proliferation and induced cell death in all investigated cell lines. However, there were
differences in the susceptibility of individual cell lines with respect to the required CHP
concentrations and incubation time. CHP had no significant influence on the levels of ER
stress marker proteins which were constitutively expressed in human pancreatic tumor cells.
The constitutive activation of STAT3 in the cell lines has been completely abolished by
CHP. We could exclude that the CHP-mediated dephosphorylation of STAT3 was only an
unspecific toxic reaction since ERK activation remained unchanged or even increased after
CHP incubation. Conclusion: We could show that the impairment of human pancreatic
tumor cells by CHP has been associated with the disruption of the JAK/STAT3 pathway.
The CHP-mediated ‘knock-out’ of constitutively activated signal cascades in tumor cells
could provide the basis for a potent anticancer strategy.
M2156
Down Regulation of LET-7 Micro RNA in Human Pancreatic Adenocarcinoma
Michele Bouisson, Barbara Bournet, Nicole Vaysse, Lucien Pradayrol, Jean Escourou,
Louis Buscail, Pierre Cordelier
Background: pancreatic ductal carcinoma (PC) is the 5th leading cause of cancer related
deaths in Western countries, with an increasing incidence and a poor prognosis. Thus, there
is an urgent need for the development of new modalities to improve diagnosis and treatment
of PC. Micro RNAs (miR) are small non-coding transcripts that regulate gene expression by
promoting the degradation of transcribed messages or by inhibiting translation. Emerging
studies suggest that many miR may participate in human disease, including oncogenesis.
Recently, expression levels of the human let-7 gene have been shown to vary among various
adult tissues. Down regulation of let-7 miR has been reported in lung tumors and hepatocarci-
noma. The aim of the present study was to establish the pattern of expression of Let-7 miR
in PC-derived samples. Methods: RNA was purified from PC-derived cell lines (n=7), PC
tumors (n=5) and endoscopic ultrasound-guided, fine needle aspiration biopsies (FNAB)
(n=11). RNA collected by FNAB was amplified using the Full Spectrum ® kit(SBI). As
controls, we used ready-made RNA (Ambion), and RNA purified from normal, adjacent
pancreas to PC. Let-7 miR a1, a2 and a3 precursors were quantified using real time PCR
followed by in situ hybridization. GAPDH RNA was used as a control. Results: using real-
time RT-PCR, we demonstrated the down regulation of let-7 a1 (-79±5%, p<0.05), a2 (-
88±4%, p<0.05) and a3 (-89±8.5%, p<0.05) in Capan1, AsPC1, Capan2, Panc1, Miapaca,
BxPC3 and NP29 PC-derived cells. In contrast, S100P, which plays a major role in the
aggressiveness of PC, was found elevated in all of the cell lines tested (+1743±511%, p<0.05).
In addition, let-7 miR levels were reduced (-84.7±3.8%, -75.7±5.8% and -75.8±5.5% for
let-7a1, a2 and a3 respectively, p<0.05) and S100P levels elevated (+1736±612%, p<0.05)
in PC tumors compared to normal adjacent pancreatic tissue. Eventually, let-7 miR were
found down expressed in FNAB (-37.4±26.7%, -97.4±1.3% and -70.6±17.6% for let-7a1, a2
and a3 respectively, p<0.05), whereas S100P levels were elevated (+31050±1356, p<0.005).
Expression patterns of let-7 miR in PC tumors were confirmed by in situ hybridization.
Conclusion: the present study represents the first report of reduced expression of let-7 in
PC samples. Because (i) activating mutations of k-ras are frequently detected in PC, and (ii)
the 3'UTRs of the human RAS genes contain multiple let-7 complementary sites, such
alteration in let-7 expression might participate in PC induction or progression. Taken
together, the present study could lead to the development of new molecular markers for
either early diagnosis or targeted therapy for PC.
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M2157
The Bioflavonoid Myricetin Induces Pancreatic Cancer Cell Death by a
Mechanism Which Is Independent of HSP70
Phoebe Phillips, Vikas Dudeja, Rifat Sharif, Rajinder Dawra, Ashok Saluja
Pancreatic carcinoma is the fourth leading course of cancer deaths in the United States due
to its poor response to chemotherapy and radiation treatments. One of the underlying
mechanisms is their resistance to apoptosis. Studies suggest that foods rich in polyphenolic
compounds contribute to reducing the risk of cancer and that these compounds can reduce
tumor growth in vivo. We have previously shown that the bioflavonoid quercetin induces
pancreatic cancer cell apoptosis via the inhibition of heat shock protein 70 (HSP70). The
aim of the present study was to examine the effect of the flavonoid myricetin [structurally
similar to quercetin, with an additional OH group on the 5’ position of benzene ring B] on
i) pancreatic cancer cell viability compared to non-transformed pancreatic ductal cells; and
ii) HSP70 levels in cancer cells. Methods - The human pancreatic cancer cells (PANC-1 or
MiaPaCa-2) or normal pancreatic ductal cells were incubated with varying concentrations
of myricetin (5-100µM) for 24 hours in serum free culture medium. Control cells were
incubated with the vehicle alone (<0.2% DMSO). Cell viability was studied using the
tetrazolium salt WST-8 assay. HSP70 expression was assessed by real-time quantitative PCR
and western blotting of cell lysates. Results - Incubation of both PANC-1 and MiaPaCa-2
cells with myricetin resulted in significantly reduced cell viability at concentrations greater
than 25µM (40µM myricetin decreased cell viability by 50% and 100% in PANC-1 and
MiaPaCa-2 cells respectively). In contrast, normal duct cell viability was unaffected by
incubation with myricetin. Both of these pancreatic tumor cell lines had very high levels of
endogenous expression of HSP70 levels compared to normal pancreatic duct cells, however,
myricetin had no effect on HSP70 mRNA or protein levels. Conclusions - The presence of
an additional hydroxyl group in the B ring of the flavonoid base skeleton of myricetin results
in a greater inhibitory effect of this flavonol on pancreatic cancer cell viability as compared
to our previous observations with quercetin. It also alters the mechanism of action, while
quercetin’s effect is mediated by its inhibition of HSP70 expression, myrecetin inhibits cell
growth by a mechanism which is independent of HSP70 expression. These results suggest that
myricetin may be a potential therapeutic agent to prevent the progression of pancreatic cancer.
M2158
Prognostic Factors for Survival in Pancreatic Cancer: A Population-Based
Study
Mohamad Eloubeidi, Renee Desmond, Charles M. Wilcox, Reda Wilson, Pavan
Manchikalapti, Mona Fouad, Isam Eltoum, Selwyn Vickers
Background: There is currently no population-based study from the Deep South of the
United States (with >25% African American residents) evaluating survival of patients with
pancreatic cancer. Our aims were to1) analyze prognostic factors influencing pancreatic
cancer survival using the population-based Alabama Statewide Cancer Registry (ASCR) 2)
to determine whether race/ethnicity is an independent determinant of outcomes in patients
with pancreatic cancer. Methods: Eligible cases included all persons diagnosed with pancreatic
cancer from 1996-2000 and reported to the ASCR. Survival time was calculated from time
of diagnosis to death for pancreatic cancer deaths or to date of last contact or death from
other causes for censored cases. Risk factors associated with survival were assessed with the
Kaplan-Meir survival method and the log-rank test. Demographic, tumor and treatment
variables were assessed using Cox proportional hazards model. Results: Of 2,230 patients,
the median age at diagnosis was 71 years and the male to female ratio was approximately
1:1. Seventy-three percent of patients were White, and 27% of patients were Black. The
distribution by stage was 12.5% localized disease, 29.6% regional, 35.3% distant and 22.6%
unstaged. The median survival for all cases was 0.39 (SD 0.01) years. Patients that underwent
surgical treatment were less likely to die from pancreatic cancer (HR 0.48 95% CI, 0.41-
0.56). Similarly, patients that underwent either chemotherapy or radiation therapy had
improved survival (HR 0.62 95% CI, 0.53-0.73). Across all stages, Black patients were
significantly less likely to receive chemotherapy compared to White patients (27.8% vs.
32.7%, p= 0.03) and were significantly less likely to receive surgical intervention (15.2%
vs. 18.9%, p= 0.049). When examining patients who were offered the therapy of choice
but refused, we found across all stages that a greater proportion of Black patients refused
therapies vs. Whites (4.3% vs. 2.1% (p=0.02) for chemotherapy; 2.1% vs. 0.8% (p=0.05)
for radiation and 3.3% vs. 1.4% (p= 0.01 for surgery). Cox proportional hazard model
showed no effect of race on overall survival while controlling for stage at presentation, type
of therapy received, age at diagnosis and site of primary tumor. Conclusion: Survival in
patients with pancreatic cancer remains dismal. Tumor characteristics and treatment factors
are directly related to survival in patients with pancreatic cancer. Black patients were less
likely to receive therapy but were also more likely to refuse indicated therapy. Factors leading
to racial disparity in treatment of pancreatic cancer warrant further investigation.
M2159
Predictive Markers of Treatment Response to 5-FU and Gemcitabine in
Pancreatic Cancer. Results from the RTOG 9704 Prospective Randomized
Adjuvant Treatment Trial
James J. Farrell, Raymond Lai, Kathryn Winter, Marius van Rijnsoever, William Regine,
Philip Schaefer, A Bowen Benson, John MacDonald, Chris Willett, Hany Elsaleh, John
Mackey
Introduction: Thymidylate synthase (TS) thymidine phosphorylase (TP) and methylenetetra-
hydrofolate reductase (MTHFR) are key enzymes in the metabolism of folate and 5-fluorour-
acil. Human equilibrative nucleoside transporter (hENT1) is involved in gemcitabine trans-
port into cells. Retrospective studies in pancreatic cancer suggest that these markers may
have prognostic and predictive value. We aim to evaluate these markers in resected tumors
from patients particpating in the RTOG 9704 prospective multicenter randomized adjuvant
treatment trial which compared 5-FU with Gemcitabine. Methods: A Tissue Microarray was
constructed using 3 separate cores from 225 resected pancreatic tumors. Immunohistochem-
istry was performed to define TS, TP and hENT1 protein expression. TS promoter genotype
(2 or 3 tandem repeats) and MTHFR genotype (C667T) was assessed using tumor DNA.
Correlations between protein expression or genotype and prognostic or predictive factors were
sought, by unconditional logistic regression analysis. Results: High TS nuclear expression, TP
cytoplasmic expression, TP nuclear expression and TP stromal expression is seen in 30%,
86%, 65% and 92% of cases. There are statistically significant associations between higher
pathologic grade and high expression of TP nuclear (p=0.05) and TP cytoplasmic (p=0.02).
There is a trend towards nodal status and high TP nuclear marker levels ( p=0.09). The
frequencies of TS promoter tandem repeat 2R/2R, 2R/3R and 3R/3R are 27%, 33%, and
38%. There is a non-significant trend towards 3R/3R TS genotype and high TS protein
expression. 22% of cases had no expression of hENT1, compared with 38% with high
expression. The frequencies of the MTHFR 667CC, 667CT, and 667TT genotypes are 48.8%,
41.1%, and 10.1%, respectively. 27.6% of patients with either 667CC or 667CT vs. 8.3%
of patients with 667TT are early T stage (p=0.12). Correlation analysis with treatment
outcome and toxicity for this trial is currently underway. Conclusions: This is the first study
to analyze prognostic and predictive markers in a prospective randomized pancreatic cancer
clinical trial. There is limited association between TS or TP protein expression and tumor
demographic factors. There is a trend towards correlation between TS genotype 3R/3R and
high TS protein expression in pancreatic cancer. MTHFR TT genotype was more likely to
be associated with advanced T stage and may be associated with disease progression. The
majority of tumors expressed hENT1. These markers may serve as useful predictors markers
of response and toxicity in pancreatic cancer treatment.
M2160
TGF[Beta] Activates Calcium-Dependent PKC[Alpha] to Suppress PTEN
Expression in Pancreatic Cancer Cells
Jimmy Y.C. Chow, Jennifer Cabral, Hui Dong, Sherry C. Huang, John M. Carethers
BACKGROUND: TGF[beta] switches to promote tumor growth at the later stages of tumor
progression. TGF[beta] downregulates PTEN, a tumor suppressor gene that is mutated in
the germline of some pancreatic cancer prone hamartomatous syndromes. PTEN, however,
is rarely mutated in sporadic pancreatic cancers, and its regulation by TGF[beta] may mediate
TGF[beta]’s growth suppression and/or oncogenic actions. Protein kinase Cs (PKC) are
widely expressed in cancer cells in various isoforms and have various physiological functions.
Here, we examined if TGF[beta]-induced PTEN modulation was influenced by PKCs.
METHODS: We used a SMAD4-null pancreatic cancer cell line (BxPC3), which expresses
TGF[beta] surface receptors. Cells were treated with TGF[beta]1 (10 ng/mL) that has been
shown previously to reduce PTEN expression at both mRNA and protein levels, and observed
up to 48 hours. The cells were lysed and separated into cytosolic and membrane fractions and
analyzed by Western blotting using antibodies against various PKC isoforms (conventional:
[alpha], [beta], [gamma], novel: [delta], [epsilon], [mu], [theta], and atypical: [iota]/[lambda],
[zeta]). PTEN mRNA levels were assessed by reverse transcriptase PCR. A conventional PKC
inhibitor, Gö6976 (a calcium-dependent PKC inhibitor) was used to block activation of
PKC[alpha]. The levels of intracellular calcium was also determined using FURA-2/AM.
RESULTS: TGF[beta] was previously shown to reduce PTEN mRNA expression 24 hours
and protein expression 48 hours after treatment. Most of the PKC isoforms tested except
PKC[theta] were expressed in BxPC3 cells at the protein level. TGF[beta] treatment led to
membrane translocation of PKC[alpha] and [iota]/[lambda] as early as 15 min and remained
activated until 48 hours after treatment. Other isoforms were not activated by TGF[beta].
Furthermore, extracellular calcium influx was induced immediately after TGF[beta] treatment
in BxPC3 cells. Using the conventional PKC inhibitor, Gö6976, TGF[beta]-induced PTEN
suppression was reversed. Moreover, Gö6976 treatment suppressed TGF[beta]-induced cell
growth in SMAD4-null cells, while Gö6976 treatment alone had no effect on PTEN expression
and cell growth. CONCLUSIONS: Calcium-dependent PKC[alpha] appears to mediate
TGF[beta]-induced transcriptional downregulation of the tumor suppressor PTEN in SMAD4-
null pancreatic cancer cells and induces cell growth. PKC[alpha] appears to constitute a
TGF[beta]-induced pathway that promotes tumor growth in opposition to the classical SMAD
pathway, which suppresses growth.
M2161
Blocking Programmed Death 1 Ligands and PD 1 Pathway Induces Antitumor
Effect of CC Chemokine CCL2 in Pancreatic Cancer
Keisuke Okudaira, Ryota Hokari, Yoshikazu Tsuzuki, Yoshikiyo Okada, Chie Kurihara,
Norikazu Mataki, Hisayuki Matsunaga, Koichi Takebayashi, Syunsuke Komoto, Chikako
Watanabe, Atsushi Kawaguchi, Shigeaki Nagao, Kazuro Itoh, Ko Okumura, Miyuki
Azuma, Hideo Yagita, Soichiro Miura
Background The negative signal provided by interactions of programmed death-1 (PD1)
and its ligands, PDL1 (B7H1) and PDL2 (B7DC), has been suggested to play important roles
in tumor evasion from host immunity. However, the role of PD1 signals on pancreatic cancer
development has not been reported. CCL2 positively correlates with tumor macrophage
infiltration in pancreatic cancer, possibly induces recruitment of tumor infiltrating lympho-
cytes. In this study we investigated whether CCL2 immunotherapy is effective in murine
pancreatic cancer model and if not, we examined how PD1/PDL systems are involved as
negative signals in tumor immunity. Material & Method C57BL6 mice and murine pancreatic
cancer cells (pan02) were used. 3x105 tumor cells were orthotopically inoculated in mice
pancreas. 4 weeks later, tumor sizes were measured. Recombinant CCL2 (3μg) was injected
intraperitoneally once a week for 4 weeks. Tumor proliferation rates were calculated from
their size after treatment. Effects of CCL2 on leukocytes migration to cancer vessels were
observed by intravital microscope. Blocking study by antibodies against PD1, PDL1 or PDL2
(200μg, 3 times /week for 4 weeks) were also conducted. Infiltrating cells in tumor were
characterized by immunohistochemistry. Effects of antibodies against PD-1, PDL1 and PDL2
on cytokine expression in tumor were studied by quantitative RT PCR. Results Panc02 cells
expressed PD1, PDL1 and PDL2 at rest, but after interferon (IFN)gamma stimulation, only
PDL1 was expressed in vitro. Panc02 cells developed tumor of 5.6 mm diameter on average.
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Microscopic study showed increased leukocytes migration to tumor vessels by CCL2. Immu-
nohistochemical study showed significant increase in CD4 and CD8 cells and PD1 positive
infiltrating cells in tumor area after CCL2 treatment. PDL2 + cells were observed in peritumor
area. PD1 and PDL2 mRNA expression significantly increased after CCL2 treatment. Despite
the significant infiltration of immune cells, long term treatment of CCL2 alone did not
decrease tumor proliferation rates. However, antiPD1 or antiPDL2 treatment significantly
decreased the tumor expansion. Cytokine study showed increased intratumoral expression
of IL4 and IL10 after CCL2 treatment. This increase was ameliorated by antiPD1 or antiPDL2.
Conclusion PD1 ligand/PD1 pathway upregulated by CCL2 appeared to induce tumor evasion
from immunity in spite of the increase in tumor infiltrating immune cells in murine model
of pancreatic cancer. A successful inhibition of tumor growth by blockade of the PD1 ligand/
PD1 signalling pathway may implicate a new approach of immunotherapy for pancreatic
cancer.
M2162
Inhibition of the Proto-Oncogene Slug Modulates Proliferation in Pancreatic
Cancer (PC) Through Activation of β-Catenin Signaling
Jennifer L. Koetsier, Harrison Brand, Dhananjay Kunte, Randy Brand, Ramesh Wali,
Hemant Roy
Background: β-catenin dysregulation is an important early event in the pathogenesis of PC;
however, the mechanisms are unclear. The transcriptional repressor SLUG modulates β-
catenin signaling in several cancers. There are no previous reports on the role of SLUG in
PC. Methods: Immunohistochemical analysis of Tissue sections (PC and control) were
performed using standard methods. The human PC cell line Mia PaCa-2 was transfected
with SLUG siRNA and subjected to mRNA and protein analysis by RT-PCR and Western
blot analysis. A scramble siRNA was used as a control. β-catenin signaling was assessed
using the Tcf TOPFLASH reporter plasmid. Results: SLUG was detectable in PC tissue
sections and 3/3 cell lines tested. In Mia PaCa-2 cells, siRNA caused a reduction in proliferation
as measured by PCNA (64.5% of control) with a corresponding decrease in β-catenin
transcriptional activity as assessed by Tcf TOPFLASH reporter assay (68.6% of control).
Furthermore, there was a corresponding decrease in cyclin D1 (85% of control), a pro-
proliferative β-catenin-regulated protein. β-catenin protein, but not message, was decreased
with SLUG siRNA (63.4% of control, p<0.05) suggesting altered β-catenin stability. Intri-
guingly, Mia PaCa-2 cells do not express E-cadherin indicating a novel mechanism is involved.
In this regard, we noted that SLUG siRNA altered Akt activity (55.4% of control, p<0.05)
implicating the Akt/GSK-3β axis. Furthermore, by pre-treatment with the PI-3 kinase inhib-
itor, LY294002, we were able to abrogate both the ability of SLUG siRNA to down regulate
β-catenin and also to inhibit proliferation. Conclusion: We demonstrate, for the first time,
that SLUG expression in PC is involved in the dysregulation of β-catenin signaling with
concomitant hyperproliferation. While the mechanisms are unclear, our data indicates that
this may be through regulation of the PI-3 kinase cascade.
M2163
Angiotensin Converting Enzyme Inhibitors Reduce the Incidence of Pancreatic
Cancer: A Study of Half a Million US Veterans
Vikas Khurana, Ankur Sheth, Gloria Caldito, Jamie S. Barkin
AIM: To investigate the effect of Angiotensin Converting Enzyme (ACE) Inhibitors use in
reducing the incidence of pancreatic cancer in the US veteran population. BACKGROUND:
ACE Inhibitors are commonly used antihypertensive and nephroprotective agents. Vascular
Endothelial Growth Factor (VEGF) is believed to play a major role in angiogenesis in
human tumors. Blocking the VEGF inhibits angiogenesis and suppresses tumor growth.
ACE inhibitors cause suppression of VEGF in experimental models, leading to their anticancer
effect. ACE Inhibitors have been noted to suppress tumor growth by inhibiting tumor
angiogenesis in several animal and experimental models. DESIGN: The VISN 16 database
contains clinical and demographic information about all veterans (>1.4 million patients)
cared for in the South Central VA Health Care Network (eight states in south central United
States). The data was queried from Oct 1998 to June 2004, using a retrospective case control
design. Statistical analysis was performed using SAS software version 9.0 (Chicago, IL).
Multiple logistic regression analysis was used with calculation of odds ratios and 95%

















use, diabetes and statin use. Patients were placed in the ACE inhibitor user group if they
were using ACE inhibitors prior to the diagnosis of pancreatic cancer. RESULTS: A total of
483,733 patients were included in the analysis. 185,852 (38.43%) of those were using ACE
inhibitors. Pancreatic cancer (ICD-9 code 157) was seen in 475 (0.1%). ACE inhibitor users
were 48% less likely to develop pancreatic cancer (Odds ratio 0.484; 95% CI 0.386-0.607,
p <0.01). The protective effect of ACE inhibitors was independent of statin use. Other
significant covariates include age (OR 1.020, 95% CI for OR 1.012, 1,027, p <0.01); prior
statin use (OR 0.458, 95% CI for OR 0.363, 0.580, p<0.01) and diabetes (OR 3.837, 95%
CI for OR 3.089, 4.767, p<0.01). CONCLUSION: ACE inhibitors are associated with a 48%
reduced incidence of pancreatic cancer after controlling for age, race, gender, BMI, smoking,
alcohol use, diabetes and statin use. The limitations of our data are the VA population, the
database and the fact that this is a case control study. The dose, duration and type of ACE
inhibitor used were not factored into the analysis.
M2164
Proteosome Inhibitor Bortezomib Induces Lysosomal Disruption and a
Caspase-2-Dependent Apoptosis in Human Pancreatic Carcinoma Cells
Ho Yee Bonnie Yeung, Der Chen Huang, Frank A. Sinicrope
BACKGROUND. Bortezomib is a potent and reversible proteosome inhibitor that functions
to degrade intracellular polyubiquitinated proteins. Bortezomib has shown broad in vitro
antitumor activity and can induce apoptosis. We determined the effect of bortezomib on
lysosomal and mitochondrial permeabilization, including the role of caspase-2 in apoptosis
induction in human pancreatic carcinoma cells. METHODS. BxPC-3and CFPAC-1 cells were
incubated with bortezomib (Millenium Pharmaceuticals) at indicated concentrations and
times. For measurement of ROS, cells (3 x 106) were incubated in dihydroethidium ± tiron.
Mitochondrial depolarization was analyzed using JC-1. Apoptosis was measured by annexin
V-FITC labeling. Expression of caspase-2, -8, -9, cytochrome c, Smac, and Bcl-2 family
members were analyzed by immunoblotting; Bcl-2, Bcl-xL mRNA by RT-PCR. Inhibitors of
caspase-2 (z-VDVAD-fmk) and cathepsin B (R-3032; Celera Genomics) were utilized. BxPC-
3 cells were stably transfected with an RNA interference (siRNA) construct against caspase-2.
Cathepsin B redistribution was analyzed using fluorescence confocal microscopy. RESULTS.
Bortezomib induced a dose-dependent apoptosis in association with reactive oxygen species
(ROS) generation and cleavage of caspase-2 to its 33 kD and 14 kD fragments. Bortezomib
disrupted lysosomes with redistribution of cathepsin B to the cytosol that was blocked by
the free radical scavenger tiron, but not by a caspase-2 inhibitor (z-VDVAD-fmk). Bortezomib-
induced caspase-2 activation was attenuated by a selective cathepsin B inhibitor (R-3032),
suggesting that cathepsin B release occurs upstream of caspase-2. Bortezomib-induced mito-
chondrial depolarization was attenuated by z-VDVAD-fmk, tiron and bongkrekic acid (inhib-
itor of mitochondrial permeability transition pore), and by caspase-2 siRNA compared to
control cells, confirming that caspase-2 directly regulates mitochondrial permeabilization.
Bortezomib-induced cytochrome c release and annexin V binding were attenuated by z-
VDVAD-fmk and partially by R-3032. In support of these data, bortezomib also activated
caspase-2 and induced apoptosis in CFPAC-1 pancreatic cancer cells that was attenuated
by z-VDVAD-fmk, and to a lesser extent by R-3032 compared to BxPC-3 cells. Bortezomib
activated the BH3-only proteins Bik and Bim and downregulated Bcl-2 and Bcl-xL mRNA
and proteins. CONCLUSION. Bortezomib induces lysosomal cathepsin B redistribution
upstream of caspase-2. Caspase-2 activation regulates bortezomib-induced mitochondrial
depolarization and apoptosis, suggesting that caspase-2 may serve as a link between lysosomal
and mitochondrial permeabilization.
M2165
Evaluation of the Combined Use of Cyclooxygenase-2-Inhibitors and Tumor
Antigen-Loaded Dendritic Cells for the Immunotherapy of Pancreatic
Carcinoma in a Murine Vaccination Model
Christian A. Bauer, Franz Bauernfeind, Max Schnurr, Rosi Kiefl, Walther Heldwein, Stefan
Endres, Andreas Eigler, Marc Dauer
Background: Overexpression of cyclooxygenase-2 (COX-2) plays an important role in gastro-
intestinal carcinogenesis. Here, we investigated whether COX-2-inhibitors can increase the
efficacy of dendritic cell (DC)-based vaccination therapy for pancreatic carcinoma. Material
and methods: DCs were loaded with lysate from the pancreatic carcinoma cell line Panc-1
and cocultured with autologeous T cells. Restimulations with autologeous, tumor-lysate
pulsed DCs were performed at weekly intervals. Lysis of Panc-1 cells left untreated or pre-
treated with the COX-2-inhibitor NS398 was determined in a standard chromium release
assay. In addition, apoptosis of the pancreatic carcinoma cells Panc-1, MiaPaca and BxPc-
3 treated with NS398 (20 or 100 µM) or left untreated was induced by CD95-activating
antibody CH-11 and measured by Annexin-V/PI-staining. The in vivo effect of the COX-2-
inhibitor Parecoxib on DC-based vaccination was investigated in a murine model of pancreatic
carcinoma. DCs derived from the bone marrow of C57BL/6 mice were pulsed with syngeneic
apoptotic Panc02-cells and matured with LPS/IFN-gamma. After establishment of subcutane-
ous Panc02-tumors, DCs were injected into the contralateral flank of C57BL/6 mice at
weekly intervals. Parecoxib was administered i.p. daily; tumor size and weight loss were
monitored. Results: Lysate-pulsed DCs primed tumor-specific, IFN-gamma-producing T cells
in vitro. CTLs derived from cocultures with lysate-pulsed DCs specifically lysed Panc-1 cells.
Pre-treatment of Panc-1 cells with NS-398 prior to coculture with CTLs enhanced MHC
class I-restricted, specific lysis. Blocking of CD95 on tumor cells prevented this increase in
lysis. In vitro, COX-2-inhibitor NS398 sensitized Panc-1 cells to apoptosis (14 % apoptotic
cells after CD95-treatment in untreated cells versus 23 % in NS398-treated cells). In the in
vivo-model, DC vaccination and Parecoxib therapy were successful in preventing tumor
growth and increased overall survival. However, combined therapy with Parecoxib was not
more effective in preventing tumor progression than DC-based vaccination alone. Conclu-
sions: Pancreatic carcinoma cells can be sensitized in vitro to CTL-mediated lysis by treatment
with COX-2-inhibitors. Studies using CD95-blocking antibody as well as agonistic anti-
CD95 antibody indicate that COX-2-inhibitors specifically sensitize tumor cells to CD95-
mediated CTL killing. Currently, studies are performed to analyze whether the observed
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effects are COX-2-dependent and to characterize alternative downstream mechanisms
involved in tumor cell sensitization to CTL-mediated killing.
M2166
Sphingolipid Metabolite Levels Determine Pancreatic Cancer Cell
Responsiveness to the Chemotherapeutic Gemcitabine Drug
Julie Guillermet-Guibert, Lise Davenne, Dimitri Pchejetski, Nathalie Saint-Laurent, Olivier
Cuvillier, Christiane Susini, Corinne Bousquet
Resistance to chemotherapy is the major reason for failure of clinical cancer treatment.
Pancreatic cancer is the fifth leading cause of death by cancer, and chemotherapy using
gemcitabine has unfortunately not improve prognostic of this deadly disease. Compelling
evidences suggest that aberrant sphingolipid metabolism results in chemotherapeutic drug
resistance. Therefore, a correlation between pancreatic cancer cell resistance to gemcitabine
and sphingolipid metabolism was here attempted. Two pancreatic cancer cell lines, BxPC-
3 and Panc-1, were chosen regarding their relative sensitivity and resistance to gemcitabine,
respectively. When assessing endogenous levels of the tumor-suppressor ceramide versus
tumor-promoting sphingosine-1-phosphate (S1P) lipids, which is a metabolic product of
ceramide into sphingosine and then into S1P through ceramidase and sphingosine kinase
(SK) activity, respectively, BxPC-3 showed higher level of ceramide as compared to Panc-
1 cells. Conversely S1P levels were not different in both cell lines, which is consistent with
a similar SK activity measured in these cells. As a consequence BxPC-3 cells displayed higher
ceramide/S1P ratio as compared to Panc-1. Interestingly, cell-treatment with gemcitabine
did not affect this ratio although gemcitabine unexpectedly up-regulated SK activity through
increased SK mRNA expression. This was a consequence of gemcitabine-induced ceramide
level as well. To investigate whether unbalancing the ceramide/S1P ratio might affect cell-
sensitivity to gemcitabine, BxPC-3 and Panc-1 cells were either treated with exogenous C2-
ceramide or processed to up- or down-regulate SK activity. Interestingly, C2-ceramide
treatment decreased Panc-1 cell survival in a greater extent than BxPC-3. Furthermore,
ceramide sensitized Panc-1, but not BxPC-3, cells to gemcitabine cytotoxic action. Alternat-
ively, overexpressing SK in BxPC-3 cells decreased the ceramide/S1P ratio by upregulating
S1P production, and consequently rendered these cells more proliferative, invasive and
resistant to gemcitabine cytotoxicity, as assessed in vitro and in a xenograft mouse model.
Conversely, inhibiting SK activity through Panc-1 cell-treatment with a SK-directed siRNA
or with specific SK inhibitors increased the ceramide/S1P ratio, and consequently sensitized
these cells to gemcitabine cytotoxicity. We therefore conclude that the ceramide/S1P ratio
level is critical to predict pancreatic cancer cell-sensitivity to gemcitabine action. Balancing
this ratio in gemcitabine-resistant cells using SK inhibitors might represent a promising
approach to improve the clinical benefit of gemcitabine chemotherapy for pancreatic cancer.
M2167
Role of RAC1-Dependent NADPH Oxidase in the Growth of Pancreatic Cancer
Jingru Liu, Larry W. Oberley, Joseph J. Cullen
Background: K-ras mutations occur in as high as 95% of patients with pancreatic cancer.
K-ras activates Rac1-dependent NADPH oxidase a key source of superoxide. Our group has
demonstrated that superoxide plays an important role in pancreatic cancer cell proliferation
and that scavenging or decreasing the levels of superoxide inhibits pancreatic cancer cell
growth both in vitro and in vivo (Cancer Res. 63:1297, 2003; Molecular Cancer Therapeutics
2:361, 2003). DNA microarray analysis and RT-PCR has demonstrated that Rac1 is also
upregulated in pancreatic cancer (Oncogene 20:7437, 2001). The aim of this study was to
determine if inhibiting Rac1 would alter pancreatic tumor cell behavior. Methods: Rac1
dependent effects were inhibited by using an adenoviral vector encoding a dominant-negative
isoform of Rac1 (AdN17Rac1). Human pancreatic cancer cells with mutant K-ras (MIA PaCa-
2) and wild-type K-ras (BxPC-3) were infected with AdN17Rac1 (25, 50, 100, and 200
MOI). Cells were harvested and analyzed via Western blot analysis for the HA-tag expressed
by AdN17Rac1. To determine pancreatic cancer cell behavior, cell growth and plating
efficiency were determined following infection with the AdN17Rac1. Results: In MIA PaCa-
2 human pancreatic cancer cells, AdN17Rac1 (25-200 MOI) increased Rac1 protein as
demonstrated by immunoblots. AdN17Rac1 (25, 50, 100 and 200 MOI) significantly inhib-
ited cell growth (P < 0.01 vs controls), while AdN17Rac1 (100 and 200 MOI) significantly
decreased plating efficiency (P < 0.01 vs controls). In contrast, AdN17Rac1 had no effect
in altering growth in the BxPC-3 human pancreatic cancer cell line. Conclusions: These
results suggest that mutant K-ras activation of Rac-1-dependent NADPH oxidase leads to
pancreatic cancer cell proliferation. In pancreatic cancer cells with mutant K-ras, inhibition
of Rac1 may be a potential therapeutic target. Support: DK60618, CA66081
M2168
Promotor Polymorphisms of the UGT-Glucuronosyltransferase UGT1A4
Impact Activity and Inducibility of Human Hepatic Glucoronidation
Thomas J. Erichsen, Ursula Ehmer, Tim O. Lankisch, Tordis M. Mueller, Tracey Gillman,
Nicole Freiberg, Michael P. Manns, Christian P. Strassburg
Introduction: UDP-Glucuronosyltransferases (UGT) are a family of metabolizing enzymes
which glucuronidate endogenous and exogenous substrates including the detoxification of
carcinogens. We and others have described functional polymorphisms (SNPs) of individual
members of the UGT1A gene family. Among these functional SNPs for UGT1A1 and UGT1A7
have been associated with the glucoronidation of chemotherapeutics. Recently two functional
SNPs of exon1 of the human hepatic UGT1A4 gene were reported. The aim of this study
was to identify and charactericize UGT1A4 SNPs outside the coding region with potential
impact on UGT1A4 expression. Methods: Genomic DNA of 109 patients was analysed
by polymerase chain reaction and re-sequencing. Promoter activity, point mutations and
inducibility with TCDD and 3-MC were tested in cellculture by luciferase reporter gene
assays using in Hep G2 cells. Human liver microsomes of genotyped samples were examined
for specific UGT activity. Results: In the 5’ UTR region of the UGT1A4 gene we identified
two novel polymophisms (-163 G>A and -219 C>T) with an allelic frequency of 0.12. A
linkage disequilibrium was observed between -163 G>A, -219 C>T and the L48V SNP in
exon 1 of the UGT1A4 gene. Reporter gene assays demonstrated a 40% reduction of the
UGT1A4 transcription of the variant 5’ UTR. TCDD and 3-MC were found to be able to
induce UGT1A4 expression, which was significantly lower in the genetic variants. Patients
with UGT1A4 SNPs showed a reduction of microsomal hepatic glucuronidation of steroids
and cyproheptadines. Discussion: In our study we identified two novel functional SNPs of
the UGT1A4 gene promotor region leading to a 40% reduction in transcriptional activity.
The specific activity of the UGT1A4 protein with steroids, analgesics, anti-histaminics, anti-
convulsive drugs and carcinogens suggests that genetic variations in the coding and promoter
regions are the genetic basis for interindividual variations of metabolism. These data were
functionally correlated and confirmed by glucuronidation activity determinations using
human liver microsomes indicating that promoter and exon-based SNPs of the human
hepatic UGT1A4 gene are biologically relevant factors for individual drug and possibly
disease predisposition.
M2169
Gilbert’s Disease and Drug Therapy: Lessons from Jaundice Under Atazanavir
Treatment
Tim O. Lankisch, Ulrike Moebius, Georg Behrens, Michael Wehmeier, Reinhold E.
Schmidt, Michael P. Manns, Christian P. Strassburg
Introduction: Single nucleotide polymorphisms (SNP) of drug metabolizing enzymes such
as uridine diphosphate glucuronosyltransferases (UGT) have been studied regarding their
association with inheritable and mutagen-induced diseases, as well as risk factors for
unwanted drug effects. Gilbert’s disease is characterized by a TATA box polymorphism
of the hepatic bilirubin-UGT (UGT1A1*28) leading to mild unconjugated non-hemolytic
hyperbilirubinemia. Other SNPs at the 5’-UTR of the UGT1A gene locus such as UGT1A3-
66 T/C at the hepatic UGT1A3 gene and UGT1A7-57 T/G at the extrahepatic UGT1A7 gene
have been identified and functionally lead to a reduction of steroid, carcinogen or drug
glucuronidation. The protease inhibitor atazanavir represents a major drug for the treatment
of patients with HIV infection and has been shown to lead to severe jaundice in individual
patients. Based on the hypothesis of genetically determined metabolic risk factors we per-
formed an UGT gene haplotype analysis in atazanavir treated HIV patients including
UGT1A1*28, UGT1A3-66 T/C as well as UGT1A7-57 T/G to test the involvement of these
UGT in atazanavir toxicity. Methods: SNP detection of UGT1A1*28, UGT1A3 -66 T/C,
UGT1A7-57 T/G was performed by DNA sequencing and Taqman 5’-nuclease assays in 82
atazanavir-treated HIV-patients and 104 healthy blood donors. Patients were divided in 4
groups depending on their bilirubin serum level (group 0= normal value, group 4=5 x upper
limit) Results: We detected a significantly higher incidence of homozygous allelic variants
and a higher allelic frequency of all three SNPs in the HIV patient group compared to
healthy blood donors. Furthermore, most of all HIV patients with allelic variants were found
in group 3 and 4 and all patients in group 4 carried the homozygous allelic variants of
UGT1A1, UGT1A3, and UGT1A7. Statistical analysis revealed that the combination of all
SNPs tested is the best predictor of atazanavir-induced hyperbilirubinemia. Discussion: Our
findings show a higher frequency of hepatic and extrahepatic functional polymorphisms at
the UGT1A gene locus in HIV patients. The combination of these SNPs of hepatic and
extrahepatic UGT genes (haplotype) are a significant predictor of atazanavir-induced hyperbi-
lirubinemia in HIV patients. In these patients Gilbert’s associated jaundice is a phenotype
which indicates an additional predisposition towards drug side effects based on the specificit-
ies of the other involved UGT genes. Therefore, the detection of variants at the UGT1A gene
locus serve as a potential pharmacogenetic tool to predict drug associated toxicity and
disease susceptibility.
M2170
Pathophysiology of Hepatobiliary Disease in Cystic Fibrosis (CF) Employing a
ΔF508 Mouse Model
Folke U. Freudenberg, Jonathan N. Glickman, Bian B. Yu, Monika R. Leonard, Martin C.
Carey
Introduction. Hepatobiliary complications of CF include cholestasis and focal biliary cirrhosis,
but their pathobiology is not understood. We hypothesize that impaired CFTR function on
large cholangiocytes prevents alkalinization of biliary pH and leads to a physical-chemical
environment that facilitates precipitation of metal salts of unconjugated bilirubin (UCB) and
bilirubin monoglucuronides (BMG) in the biliary tree and liver cells; moreover, hyperbilirub-
inbilia could aid this by enterohepatic cycling (EHC) of UCB secondary to bile acid spillage
into the colon. Methods. Following genotyping, we studied homozygous ΔF508 and wild
type (WT) mice. We assessed liver histopathology and Fe and Ca accumulation by H&E,
Prussian blue and von Kossa staining. We measured hepatic and gallbladder (GB) bile pH
and quantified bilirubin species by HPLC. We assessed gallbladder bile by light microscopy
for mucin gel and gallstones and assessed GB sizes gravimetrically. Fecal bile acid excretion
was quantified enzymatically. Results. Histologically, CF livers show mild cholangiopathy
characterized by reactive changes in biliary epithelium, bile ductular proliferation and mild
portal fibrosis. Those findings that were not present in WT mice. Multifocal Fe and Ca
deposition was found in 17% and 33%, respectively, of mutants compared to 6% in WT.
Hepatic bile pH values were not significantly different, but gallbladder biles were more
acidic in CF (pH 7.2±0.2 vs 7.9±0.1; p<0.05). GB sizes were markedly larger in CF than
in WT mice (26.4±4.5 vs 12.5±2.1 μl; p<0.01), and contained mucin gel and significantly
higher total bilirubin levels, but black stones occurred in only 1 of 7 mice. Paradoxically,
conjugated bilirubin (CBR) levels were lower in hepatic bile of CF than WT mice (56.3±6.7
vs 80.3±5.0 μM; p<0.05), due to marked decreases in BMG (38.8±3.6 vs 54.5±4.0 μM,
p<0.05). Fecal bile acid excretion is elevated in all CF mice, but significantly (2-3 fold) in
males only. Conclusions. Our study indicates that, although increased fecal bile acid losses
should facilitate EHC of UCB, paradoxically hepatic hypobilirubinbilia was observed in CF
mice. This is most likely caused by resorption of UCB and BMG by large cholangiocytes
secondary to CFTR dysfunction. Taken together with increased Fe and Ca staining of the
liver, presumably by UCB and BMG salts, our data suggest that chronic liver disease in CF
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may be triggered by both intrahepatic hydrolysis of CBR as well as deposition of insoluble
metal salts of BMG and UCB in cholangiocytes and hepatocytes.
M2171
Identification of Multiple Interacting Quantitative Trait Loci (QTL) for Hepatic
Fibrosis in Mice
Sonja Hillebrandt, Tilman Sauerbruch, Frank Lammert
Background: Recently we identified genetic loci that determine susceptibility to liver fibrosis
in experimental crosses between fibrosis-susceptible and resistant inbred strains of mice
(Hillebrandt et al. Nat Genet 2005;37:835-43). Despite the potential significance of gene-
gene interactions (epistasis), their role in fibrosis susceptibility is unknown, since previous
QTL analyses for liver fibrosis modeled the effects of single QTLs only. Our aim now was
to identify interacting QTLs for liver fibrosis. Methods: We intercrossed F1 hybrids of the
fibrosis-susceptible strain BALB/cJ and the resistant strain FVB/NJ to obtain 350 F2 progeny.
To induce liver fibrosis, we challenged the mice with CCl4 (2 mg/kg/wk i.p. for 6 wks).
For phenotypic characterization, we determined the histological stage of liver fibrosis and
measured hepatic collagen contents. We performed a genome scan with microsatellite markers
(average distance 14 cM) in 100 mice with the largest deviations from the mean to the
upper and lower ends of the distribution of each trait, followed by simultaneous genome
scans of all possible pairwise interactions, as implemented in R/qtl. LOD thresholds were
estimated by permutation tests. Results: In addition to the previously described fibrogenic
QTLs (Hfib1 and Hfib2), we detected a a new QTL on mouse chromosome 1 (Hfib3). According
to standard nomenclature, this major QTL with significant effects on the progression of
liver fibrosis (LOD 3.9) is named Hfib3. Furthermore, the two-dimensional scans identified
a locus on chromosome 18 that affects fibrosis by interacting with loci on chromosomes 1
and 6. In addition, we found interacting gene pairs between chromosomes 6 and 7, 9 and
13 as well as 3 and 16. Of note, the interacting loci display no significance on their own;
however, their interactions made notable effects on both the stage of fibrosis and hepatic
collagen concentrations. Conclusions: Our findings demonstrate the importance of both
single susceptibility loci and gene-gene interactions in liver fibrogenesis and provide the
basic framework to investigate how systems of genes work together affecting this complex
trait during chronic liver injury.
M2172
Increased Susceptibility to Estrogen-Induced Cholestasis in Mice
Overexpressing the Hepatic ABCB11 Gene
Helen H. Wang, Minoru Sakomoto, Anne Schmitz, Frank Lammert, David Q. Wang
Estrogen could be involved in intrahepatic cholestasis of pregnancy and oral contraceptive-
induced cholestasis, which represent a prominent feature of liver injury characterized by
accumulation of bile salts (BS) and other toxic bile constituents within hepatocytes and
blood. Because only a minority of patients develops cholestasis, we hypothesized that
differences in estrogen metabolism could lead to differential inhibition of Abcb11-mediated
BS transport in predisposed individuals. Methods: We investigated ovariectomized female
wild-type (WT) and Abcb11 transgenic (tg) mice with or without disruption of the estrogen
receptor α (Erα) gene (i.e., Abcb11.tg and Abcb11.tg/ErαKO), and treated the mice with
17β-estradiol (E2) at 3, 6, 12, 24 μg/day for 14 days. Biliary BS outputs were examined by
HPLC and bile flow was determined gravimetrically. Expression levels of the genes encoding
hepatic BS transporters and synthesis enzymes were analyzed by real-time PCR. Results:
There were dose-dependent 5 to 7-fold increases in expression levels of the hepatic Erα,
Abcb11, Ntcp, Cyp7a1, and Cyp27 genes in WT mice, coupled to significant dose-dependent
increases in bile flow and biliary BS output from 91±8 to 136±15 μl/min/kg, and 215±54
to 327±82 μmol/h/kg, respectively. The highest dose (24 μg/day) of E2 significantly down-
regulated expression levels of the genes for hepatic BS transporters and synthesis and reduced
bile flow and biliary BS outputs to 45±7 μl/min/kg and 125±36 μmol/h/kg, respectively. In
contrast, when doses of E2 were ≥6 μg/day, Abcb11.tg mice displayed significant decreases
in expression levels of the genes regulating hepatic BS transport and synthesis by 30 to
50%, coupled to significant reductions in bile flow and biliary BS output to 45±7 μl/min/
kg and 118±29 μmol/h/kg, respectively, all in a dose-dependent manner. Although being
treated with various high (6 to 24 μg/day) doses of E2, Abcb11.tg/ErαKO mice showed
essentially stable bile flow (95±10 μl/min/kg) and biliary BS output (238±64 μmol/h/kg),
as well as constant mRNA expression levels of hepatic BS transporters and synthesis enzymes,
all of which were comparable to those in WT mice treated with 3 μg E2/day. Conclusions:
Era plays a critical role in the biphasic (choleretic vs. cholestatic) effects of E2 on the
regulation of hepatic BS transport and synthesis, as well as bile formation. The expression
levels of Abcb11 partly account for variations in susceptibility to E2-induced cholestasis in
mice. These studies point to a better design of individualized estrogen therapy in genetically
susceptible patients and to improved prediction of the cholestatic potential of novel drugs.
M2173
Bcl-2,Bax and Bad mRNA Expression in Chronic Active Hepatitis, Cirrhosis,
and Hepatocellular Carcinoma
Marina Bortolami, Andromachi Kotsafti, Chiara Carlotto, Romilda Cardin, Fabio Farinati
Background: Members of the Bcl-2 family are important key apoptosis regulators, either
promoting or inhibiting molecules. In HCV- and HBV-related chronic liver diseases, the
apoptotic process seems to be the result of interaction between virus, hepatocyte and immune
response. Failure of apoptosis is now known to contribute to the onset of human malignancies.
Aims: To clarify the role of intracellular anti- and pro-apoptotic pathways, we studied the
mRNA expression of Bcl-2, Bax and Bad in liver biopsies from patients with different degrees
of liver damage, to determine whether HCV and HBV infection modulates their expression.
Methods: We examined 87 liver samples from: 39 patients with chronic active hepatitis
(CAH) (31 HCV-related and 8 HBV-related); 14 patients with cirrhosis (13 HCV-related

















tissues of 7 in virus-related liver cirrhosis (6 HCV-related and 1 HBV-related) and 5 in non-
viral cirrhotic tissue]. Bcl-2, Bax and Bad mRNAs were quantified by absolute Real-Time
PCR using beta-actin as the housekeeping gene. Results: Bcl-2 transcripts were significantly
higher in cirrhotic tissues than in cases of CAH (p=0.0008). CAH coincided with higher
Bad levels than in cirrhotic or HCC tissues (p=0.0007 and p=0.00005, respectively). These
data were confirmed by the difference in Bcl-2/Bad ratio between CAH and cirrhosis (p =
0.0002) and between CAH and HCC (p=0.011). No aetiology-related difference was found
in Bax expression. In CAH, only Bad mRNA expression was significantly different in HBV-
related infection versus HCV-related infection (p=0.018). Conclusion: The upregulation of
the Bad-induced pro-apoptotic pathway in CAH seems to be more relevant in controlling
apoptosis in liver tissues with HBV infection. Moreover, the Bcl-2 hyperexpression observed
in cirrhotic tissues seems to play an important part in regulating cell survival in damaged
liver cells, which may contribute to the persistence of HBV or HCV and thus activate cell
proliferation and cell transformation.
M2174
Evaluation of Topo Iia and Topo I Gene Co-Expression in Hepatocellular
Carcinoma: A Combined Immunohistochemistry and Chromogenic in Situ
Hybridization Study Using Tissue Microarrays
Evangelos Tsiambas, Theodore Rokkas, George Vilaras, Andreas Karameris
Background: Hepatocellular Carcinoma (HCC) is one of the most frequent cancers worldwide
and remains a highly chemoresistant neoplasm. Among chemotherapeutic agents, DNA
Topoisomerase (Topo) I and II inhibitors, such as irinotecan-topotecan and etoposide-
doxorubicin respectively, demonstrate a strong cytotoxic activity. But the selection of patients’
sub groups, which may earn survival benefits and avoid treatment complications, remains
unknown. Although Topo I and II immunohistochemical expression is observed in many
cancers, only a small proportion is eligible for target chemotherapeutic response. Materials
and Methods: Using Tissue Microarray Technology (TMArrayer 100, Chemicon), twenty
(n=20) histologically confirmed primary hepatocellular carcinomas (Grade I 7, Grade II 8
and Grade III 5) were obtained and embedded into one-paraffin block (2 spots of each case
with a core diameter of 1mm). Immunohistochemical stain for anti-Topo II and Topo IIa
was performed using monoclonal antibodies in 2μm tissue sections. Chromogenic In Situ
Hybridization (CISH-Zymed/In Vitrogen) for the detection of chromosome 17 instability
and Topo IIa gene status was performed in 5 μm serial sections. Finally using a semi-
automated Computerized Image Analysis System we evaluated the immunohistochemical
stain optical density of both proteins. Statistical analysis was performed by the application
of SPSS version 11.0 software. Results: A significant proportion of the tumors showed over
expression of the proteins. Topo I and Topo IIa overexpression were observed in 14/20
(70%) and 16/20 (80%), respectively. CISH application showed Topo IIa amplification in
cell sub populations of 4/16 and gene deletion in 2/16 cases. Chromosome 17 instability
(aneuploidy) was detected in 5/20 cases. Correlation between protein overexpression, chro-
mosome instability 17 and biological behavior (Grade-Stage) of the tumors was statistically
significant (p<0.05), especially in co-expression of Topo IIa and Topo I. But Topo IIa over
expression was not significantly correlated with gene amplification (p>0.05). Interestingly,
only Topo IIa overexpression was significantly correlated with history of the patients (HBV
infection). Conclusions: The results indicate that accurate detection of Topo IIa amplification
is a critical process because this genetic event correlates with response to chemotherapy
(anthracyclines) in many cancers including hepatocellular carcinoma. Also chromosome 17
instability and Topo I-Topo IIa gene co-deregulation correlates with aggressive biological
behavior.
M2175
Hepatic Malignancies in Patients with Nonalcoholic Steatohepatitis
Ken Sato, Hiroaki Hashizume, Akira Kojima, Naondo Sohara, Satoru Kakizaki, Hitoshi
Takagi, Masatomo Mori
Background: Hepatic malignancies including HCC arising in nonalcoholic steatohepatitis
(NASH), without hepatitis B or C virus infection have been a rare observation. Recently,
NASH comes to be recognized as a cause of hepatocellular carcinoma (HCC). However, few
studies have focused on a large series of studies of liver tumors with NASH. Methods: One
thousand three hundred and ten patients with hepatic malignancies, diagnosed and observed
from January 1992 to November 2005, were included in this study, and their clinical data
were collected prospectively. Clinical and histological changes were required to diagnose
NASH. Among them, thirty-four cases are arising in liver diseases without hepatitis B or C
virus infection and autoimmune liver diseases. Of these patients, nine cases were diagnosed
as NASH histologically. In addition, we comfirmed the presence of HCC by ultrasonography-
guided tumor biopsy or surgery. Results: Hepatic malignancies include eight HCC and one
cholangiocellular carcinoma (CCC). Nine patients comprise of six men and three women,
aged 45-82 years. Of these patients, seven, five and four patients were associated with
obesity, hyperlipidemia and hypertension, respectively. Hepatic malignancies measured 15-
70mm in diameter and two cases of HCC were well differentiated. When hepatic malignancies
were diagnosed, chronic hepatitis or liver cirrhosis was present in four or five cases, respect-
ively. Homeostasis model assessment of insulin resistance values in all cases were high (3.5-
36.2) except one case of CCC (1.76). Treatment of HCC consisted of surgery in five cases,
radio frequency ablation in one case, transcathether arterial embolization in one case or
infusion in the case of CCC and symptomatic therapy in one case. The median survival
time is 35 months (25-38) after surgery and all cases after surgery have no recurrence even
though the observation time is short. Conclusions: HCC arising from NASH is not always
based on liver cirrhosis. The prognosis of HCC cases arising from NASH after surgery seems
to be relatively good, suggesting that active treatment for HCC arising from NASH should
be considered. Hepatic malignancies develop commonly to warrant regular screening for
this complication in NASH patients.
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M2176
Can Biliary Cytology Predict Prognosis of Biliary Tract Carcinoma? Its
Relation to Mucin and Adhesion Molecules
Takeshi Tomokane, Naoki Muguruma, Tetsuo Kimura, Hiromi Yano, Yoshitaka Imoto,
Tatsuzo Itagaki, Miyako Niki, Masako Kaji, Hiroshi Miyamoto, Seisuke Okamura, Susumu
Ito
Purpose: Biliary cytology is feasible and noninvasive method following ERCP or drainage
of obstructive jaundice to obtain definitive diagnosis of biliary tract lesions. However, its
sensitivity is not sufficient. It is known that MUC1 role as an anti-adhesion molecule and
MUC2 may control cell proliferation. The aim of this study is to evaluate the correlation
between mucin and cell adhesion protein expressions of surgical specimens and preoperative
cytological positive rate, and to examine if cytology can predict postoperative prognosis.
Methods: Sixteen patients with biliary tract carcinoma treated surgically in our hospital whose
bile cytology was evaluated presurgically were included in this study. Immunohistochemical
stainings were performed on paraffin-embedded tissue sections by ABC method. Biliary
juice cytology was classified into 2 categories by Papanicolaou classification: negative and
suspicious as Group-N and positive as Group-P. We analyze the relationship between positive
rate of biliary cytology and expression of mucin, cadherin, catenins, and clinical stage,
number of cytological examination, and evaluate cytological positivity. Evaluation of mucin
immunoreactivity was based on the percentage of positively staining of cancer cells; 0%:
none, 1-10%: mild, 11-50%: moderate, 50<: strong. Reduced expression of cadherin and
catenins was defined that positively stained neoplastic membrane is extended less than 80%
comparing with normal glands. Results: There was no relationship between cytological
positivity and clinical stage grouping, and also number of cytological examination. Preoperat-
ive cytology significantly proved positive in mucin group A (MUC1 moderate-strong and
MUC2 none), while it proved negative in mucin group B (MUC1 none-mild or MUC2 mild-
strong). Postoperative survival time of mucin group A was significantly poor than that of
mucin group B. Postoperative survival time of Group-N tended to be better than that of
Group-P (median survival time: 1243.1±671.1days vs, 693.7±853.4days). There was no
significance in expression of cadherin, catenins and cytological positivity. Conclusion: These
results suggest that characteristics of mucin expression is highly associated with exfoliation
of neoplastic cell from biliary tract to bile juice and cytological positivity. Considering MUC1/
MUC2 expression reflects various cancer prognosis, this study suggests mucin expression
is relevant to prognosis of biliary tract carcinoma and cytological positiveness could be
informative for predicting the courses and choosing postoperative adjuvant treatments in
biliary tract carcinoma.
M2177
Caveolin-1 Expression in Patients with Biliary Tract Cancers
Hong-Ja Kim, Se Young Yoon, Bung Ha Kim, Seok Bae Kim, Jung Eun Shin, Il Han Song
Background; Caveolin-1 is the principal protein of caveolae, the vesicular invaginations of
the plasma membrane. Several reports have suggested that caveolin-1 may have a role in
intracellular signaling pathways and thus is associated with carcinogenesis. But previous
studies of the expression and function of caveolin-1 in cancer have still shown controversial
results. We studied the expression of caveolin-1 in normal and noncancerous bile duct
epithelium and biliary tract cancer and evaluated its possible role in carcinogenesis. Method;
Formalin-fixed, paraffin-embedded sections of 20 cases of bile duct carcinoma, 20 cases of
bile duct from the benign gallstone diseases, and 5 cases of normal bile duct were stained
immunohistochemically with anti-caveolin-1 antibodies. Caveolin-1 RNA expression was
also analyzed by RT-PCR in normal biliary epithelium and biliary tract cancer cell line
(TGBE2TKB). Results; Expression of caveolin-1 was mainly observed in the bile duct cancer
cell. 12 of 20 cases of bile duct cancers (67%) showed positive staining results. But none
of normal bile duct epithelium and bile duct epithelium of benign disease showed staining
(p<0.05). RT-PCR result showed increased expression in cancer cell line compared to no
expression in normal bile duct epithelium. However, there was no significant statistical
correlation between expression of caveolin-1 and clinical status of biliary cancer patients
such as age, sex and laboratory findings (SGOT, SGPT, bilirubin, CA19-9), differentiation
status of tumor cells, tumor stage or LN metastasis. Conclusion; Caveolin-1 showed positive
staining in 67% of patients with biliary tract cancers. There was no staining in bile duct
epithelium of normal and benign disease. Increased expression of Caveolin-1 RNA was also
observed at biliary tract cancer cell line. We will further evaluate the role of caveolin-1
expression in carcinogenesis of bile duct.
M2178
Clinical Characteristics of the Patients Initially Unsuspected But Finally
Proven to Have Gallbladder Cancer
Jae Seon Kim, Byung Gyu Kim, Ji Hyun Kim, Jin Yong Kim, Jong-Jae Park, Young-Tae
Bak
Background/Aim: Gallbladder (GB) cancer is a malignancy with poor prognosis because of
its rapid progression. Although early diagnosis is essential in the management, it is challenging
even in the advanced stages. The aim of this study was to clarify the clinical characteristics
of patients finally confirmed as GB cancer, initially unsuspected by radiological and/or other
preoperative studies. Methods: We selected the cases diagnosed as GB cancer from 1997 to
2004 in a single tertiary hospital. After reviewing the medical records, we investigated the
clinical characteristics including the radiologic findings (US, CT) of patients initially dia-
gnosed as other than GB cancer. Results: Among 91 patients with confirmed GB cancer, 18
cases (7 men and 11; mean age 65.4 years) were diagnosed as other diseases initially (table).
About 60% of the 18 cases were advanced stages (stage III and IV according to TNM
classification). GB wall appearances of GB stone cases are as follows: diffuse thickening 8
cases, suspicious focal or irregular thickening 4 cases and unremarkable 4 cases. In cases
of GB polyp, the size of the polyps ranged from 8mm to 10mm ; one case showed anomalous
pancreaticobiliary ductal union and underwent operation (stage I), 10mm polyp case also
underwent operation (stage II). The patient with 8mm sized polyp and the patient with
adenomyomatosis were lost from follow-up and then showed up with stage IV state two
years later. Mean serum CEA and CA 19-9 levels were 17.9 (2.9-118.5) ng/ml and 153
(3.1-1983) U/ml respectively. Conclusion: There was no definite tool for early detection
and differential diagnosis about GB cancer. We cannot overemphasize the intensive follow-
up even with minimal suspicion of GB cancer and aggressive cholecystectomy case by case.
Table. Initial Diagnoses of Unsuspected Cases
M2179
What Happens to Patients with Obstructive Jaundice?
Einar Bjornsson, Jonas Gustafsson, Jakob Borkman, Anders Kilander
Background: Patients with obstructive jaundice (OJ) is a heterogeneous group with different
etiologies and prognosis. Limited systematic data exists on the etiology and prognosis of
unselected patients with OJ. We aimed to study the clinical features, etiology and prognosis
of patients presenting with OJ. Methods: Over a two year period, 2003-2004, all adult
patients with bilirubin >100µmol/L were identified by the clinical chemistry laboratory
serving a university hospital in Sweden. Patients with an ultrasound evidence of obstructive
jaundice with dilated biliary ducts were identified and relevant clinical information obtained.
Results: A total of 749 patients with severe jaundice were identified (bilirubin >100µmol/
L) and out of these 243 (32%) had obstructive jaundice (median age 72 years, 130 females),
no patient was lost to follow-up. The biliary obstruction was due to malignancy in 151
(62%) cases (median age 72 years, 83 females). Of malignancies, pancreatic cancer was the
cause in 69 (46%) cases, cholangiocancer (CC) in 41 (27%), papilla vateri cancers in 6 (4%)
and other malignancies in 35 (23%). Among the 92 cases with benign obstruction (median
age 69 years, 46 females), choledocholithiasis (CDL) was present in 57 (62%), biliary
strictures in 14 (15%), PSC in 5 (5%) and other causes in 16 (17%). Abdominal pain was
present in 34% of patients with malignant obstruction vs. 68% of benign obstruction
(p<0.05). Abdominal pain occurred among 38% in PC, 27% with CC, and no abdominal
pain was present in 6 (10%) out of 57 patients with CDL. The median bilirubin was higher
in malignant vs. non-malignant cases (290 (210-420 IQR) vs. 155 (120-200); p<0.001) and
ALP was also significantly higher in malignant vs. non-malignant cases, respectively. A total
of 48 patients were operated on, 22 out of 151 with malignancy (15%) whereas 26 out of
the non-malignant cases (28%; p<0.05) underwent surgery. At the end of the follow-up
only 7 (4.6%) out of 151 with a malignant obstruction were alive, whereas 70 (76%) out
of those with benign obstruction were alive. Of 57 with CDL, 11 (19%) died, but in only
one of these could death be attributed to gallstone disease. The median survival time of CC
patients was 103 days (27-217, IQR) and 74 days in PC (34-228). One and two years
survival rates were 6/69 (8.7%) and 1/69 (1.4%) in PC and 3/41 (7.3%) and 2/41 (5%) in
CC. Conclusion: Among patients with severe jaundice, one third was due to OJ. The
majority of OJ was due to malignancy with high bilirubin levels indicating prolonged biliary
obstruction. OJ due to malignancy with severe jaundice at diagnosis carried a very poor
prognosis with a 95% two years mortality.
M2180
The Role of Ascitic Fibronectin and Cholesterol Concentrations in the
Differential Diagnosis of Malignant Ascites
S Karatapanis, L Skorda, Philip Lisgos, A Spiropoulos, N Papantoniou, K Komnianides, S
Afantenou, Th. Anagnostou, K Prodromidou, C Psellas, A Delaportas, A Zervos, A
Koliadi, M Gini, S Manolitsis, V Artikis
Background : There have been few trials comparing the efficacy of determinations of ascitic
fibronectin and cholesterol in the differential diagnosis of ascites. Aim : To evaluate the
efficacy of ascitic cholesterol and fibronectin levels in the differential diagnosis of ascites in
comparison with other known parameters. Patients and Methods : In our study we included
210 patients with ascites (102 with cirrhosis, 54 with extra-hepatic tumors, 41 with hepatocel-
lular carcinoma-HCC and 13 with spontaneous bacterial peritonitis-SBP). Their ascitic fluid
pH, cholesterol, fibronectin, albumin, LDH, and total proteins were analyzed to distinguish
between different etiologies of ascites. The diagnosis of cirrhosis was based on histological
findings and/or clinical, biochemical and endoscopic/imaging findings in those patients
where liver biopsy was contraindicated. Results: Ascitic levels of fibronectin (81.5+-23.4
μg/ml vs 28.5+-6.7 μg/ml) and cholesterol (91.6+-23.8mg/dl vs 23.4+-9.8mg/dl) were signi-
ficantly higher in patients with extrahepatic tumors compared to patients with cirrhosis
(P<0.001 in both parameters), while serum-ascites albumin gradient was significantly higher
in patients with cirrhosis compared to the patients with extrahepatic tumors (P<0.001). We
found no differences in these parameters between cirrhotic ascites and malignant ascites
due to primary hepatocellular carcinoma.We found that ascitic fluid LDH and cholesterol
were best at diagnosing malignant ascites, whereas ascitic fluid pH and LDH were best for
diagnosing SBP. Fibronectin, cholesterol and serum-ascites albumin gradient at discrimina-
tion values of 52μg/ml, 45mg% and 1.1g/% respectively, separated patients with malignant
ascites from patients with cirrhosis with an accuracy of 94%, 96% and 88% respectively.
Conclusions : Ascitic fluid determinations of fibronectin and cholesterol offer an excellent
method of discriminating between cirrhotic ascites and ascites due to peritoneal carcinomatos-
is,and are superior to conventional tests. These parameters don’t help in differentiating
patients with ascites due to cirrhosis and HCC.
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M2181
MicroRNA-21 Regulation of Survival Signaling: A Novel Mechanism of
Chemoresistance in Cholangiocarcinoma
Fanyin Meng, Roger Henson, Hania Wehbe, Jinmai Jiang, Janna M. Mize-Berge, Thomas
Schmittgen, Tushar Patel
Background: Cholangiocarcinomas are highly treatment refractory cancers. microRNA
(miRNA) are endogenous regulatory RNA molecules that modulate gene expression. Altered
expression of miRNA has been shown in many cancers and could contribute to chemoresist-
ance by altering the functional expression of critical genes involved in cell survival. Our
AIMS were to identify specific miRNA involved in the modulation of chemoresistance in
human cholangiocarcinoma. Methods: miRNA expression in malignant (KMCH, MzChA-1,
TFK) and non-malignant (H69) human cholangiocytes was assessed using a hybridization
based microarray. Expression of selected miRNA and their precursors was evaluated by
Northern blots and real-time PCR respectively. miRNA specific antisense oligonucleotides
or precursor miRNAs were used to decrease or increase cellular expression respectively. In
vivo miRNA expression was assessed in tumor cell xenografts in nude mice under basal
condition or during treatment with systemic gemcitabine. Results: Compared to non-malig-
nant cholangiocytes, the expression of most miRNA was decreased in cholangiocarcinoma
cells. However, some miRNA such as miR-21 were highly over-expressed in several cholangi-
ocarcinoma cell lines (MzChA-1 2.7 + 0.1-fold, KMCH 1.8 + 0.2-fold, TFK 4.4 + 0.1-
fold). Inhibition of miR-21 in MzChA-1 cells decreased sensitivity to gemcitabine in vitro.
Furthermore gemcitabine treatment of MzChA-1 xenografts increased miR-21 by 4.1 + 0.3-
fold. Using a bioinformatics approach, the PTEN tumor suppressor gene was identified as
a potential target gene for miR-21. PTEN is a PIP3 phosphatase which negatively regulates
PI-3 kinase signaling which mediates cell survival. Antisense inhibition of miR-21 increased
PTEN expression by 210 ± 30% in MzChA-1 malignant cholangiocytes. Meanwhile, the
expression of phosphorylated PI-3 kinase p85 subunit, a downstream target of PTEN was
reduced to 49 ± 2% of controls. Moreover, gemcitabine treatment of tumor cell xenografts
decreased PTEN expression and increased activation of PI-3 kinase in vivo. Conclusions:
We have identified a microRNA (miR-21) that is over-expressed in human cholangiocarcin-
oma, and report a previously unrecognized mechanism for chemoresistance involving this
microRNA. Chemotherapeutic stress increases the expression of miR-21 which can activate
survival mechanisms by modulation of the PI3 kinase-PTEN signaling pathway. Targeting
miR-21 dependent signaling pathways involved in chemoresistance may provide new thera-
peutic approaches for the treatment of cholangiocarcinoma.
M2182
Lack of Effect of Elevated Plasma Cholecystokinin Concentration On Proximal
Gastric Motor Activity in Critically Ill Patients
Laura Bryant, Carly Burgstad, Nam Q. Nguyen, Robert J. Fraser, Marianne Chapman,
Richard H. Holloway, Michael Horowitz
Delayed gastric emptying is a major cause of feed intolerance in critical illness. In these
patients, proximal gastric relaxation in response to duodenal nutrient is also impaired 1. In
patients intolerant of nasogastric feeding, Cholecystokinin concentrations [CCK] are elevated.
Whether plasma [CCK] plays a role in proximal gastric dysmotility in the critically ill is
unknown. Aim: To assess the relationship between [CCK] and proximal gastric motility in
critically ill patients. Methods: Proximal gastric motility was measured (using a barostat)
in 22 critically ill patients (18M; 49 ± 4 years) during a continuous 60 min duodenal infusion
of Ensure (2 kcal/min). Plasma [CCK] was measured (using radioimmunoassay) at baseline
and every 20 min during nutrient infusion. Proximal gastric volume and fundic wave activity
(changes in volume > 30ml that revert to a volume within 50% of the previous level in less
than 2 min) were determined. Patient data were compared to 28 healthy subjects (21M; 43
± 2 years). Results: Fasting [CCK] was higher in critical illness than in health (8.7 ± 1.1 v
4.7 ± 0.4 pmol/L; P<0.05), with an augmented rise in [CCK] during nutrient infusion in
patients (P<0.01). Baseline gastric volumes were similar in the two groups. Proximal gastric
relaxation in response to nutrient infusion was less in critically ill patients (peak volume
response: 252 ± 25 v 148 ± 30 ml; P=0.01). There was a positive correlation between
changes in [CCK] and proximal gastric volume during nutrient infusion in healthy subjects
(r=0.525; P<0.001), but not in critically ill patients. Fundic wave frequency during fasting
and in response to nutrient infusion was reduced in patients compared to healthy sub-
jects(fasting: 6.1 ± 1.2 v 11.7 ± 1 waves/10min; and nutrient infusion: 3.9 ± 0.8 v 7.7 ±
0.8 waves/10min; P<0.01). There was a negative correlation between peak [CCK] and fundic
wave frequency during nutrient infusion in healthy subjects (r= -0.51; P<0.05), and a non-
significant trend in patients (r= -0.38; P<0.1). Conclusion: Elevated [CCK] does not appear
to directly influence proximal gastric motility in the critically ill, in contrast to healthy
subjects where increased [CCK] may contribute to a slowing of gastric emptying in response
to duodenal feedback. In patients, [CCK] may contribute to slow gastric emptying via actions
on the distal stomach or the integration of proximal and distal gastric motor activity. 1
Nguyen NQ, Chapman M, Fraser R, Bryant L, Holloway RH, Vozzo R, Feinle-Bisset C,
Horowitz M. Impaired proximal gastric relaxation in response to small intestinal nutrients
in critically ill patients. Gastroenterology 2005; 128 (4): A548.
M2183
Gastric Emptying (GE), Major Contributor to Postprandial Hyperglycemia in
Patients with Type 1 Diabetes Mellitus (T1DM)
Juergen Woerle, Maximilian Albrecht, Rainer Linke, Mathias Nicolaus, Martin Storr, Joerg
Limmer, Burkhard Goeke, Joerg Schirra
Postprandial (PP) hyperglycemia has been identified as an important risk factor for cardiovas-
cular disease. The pancreatic hormone amylin is released postprandially and delays gastric
emptying. T1DM are amylin deficient. Accordingly, we hypothesised that 1) in the absence
of neuropathy, T1DM have accelerated GE, 2) accelerated GE may be an important regulator
of PP glycemia, 3) amylin substitution should delay GE in T1DM and reduce PP glucose

















with T1DM on two occasions each, after ingestion of a mixed 472 kcal meal with s.c.
administration of either placebo (PBO) or the amylin analogue pramlintide (30 mcg). T1DM
were infused with IV insulin to establish a fasting euglycemia of 90 mg/dl and to prevent
PP hyperglycemia >180 mg/dl in order to avoid the effects of hyperglycemia on gastric
emptying. Insulin was infused in an identical manner on both days. GE was determined by
high-resolution scintigraphy (20 fr/min) over 330 min. Results: PP glucose excursions in
T1DM exceeded those of HS during the first 150 min after meal ingestion (AUC 416±64
vs 307±24 mg/dl/150 min, p<0.05), and remained greater throughout, even though PP plasma
insulin levels were 3-fold greater in T1DM. During this time period, GE was accelerated in
T1DM (55.7±4.7 vs 41.7±4.6% emptied, p<0.05). GE was closely correlated with peak
plasma glucose excursions (r=0.75, p<0.001). Pramlintide delayed gastric emptying in HS
(50% emptying at 225±16 vs 177±10 min) and T1DM (217±10 vs 149±10 min; both
p<0.001). It abolished the increase in glycemia during the first 150 min in T1DM (-12±56
vs 416±64 mg/dl/150 min) and markedly reduced overall PP glucose excursions in both
HS and T1DM compared to PBO (195±21 vs 283±25 and 119±73 vs 389±75 mg/dl/150
min, both p<0.01). Although GE was significantly accelerated between 150 and 330 min
in T1DM receiving pramlintide, peak glucose levels did not exceed 138±8 mg/dl in T1DM
compared to PBO (178±9 mg/dl, p<0.01). None of the volunteers reported nausea or bloating.
Discussion: Gastric emptying was increased rather than delayed in T1DM and that may be
an important contributor to PP hyperglycemia. The amylin analogue pramlintide delayed
gastric emptying and significantly reduced PP hyperglycemia in T1DM. Modulation of gastric
emptying is a promising tool in regulating intestinal nutrient flow and reducing PP glycemia
M2184
Somatostatin Accelerates Gastric Emptying, But Does Not Improve Symptoms
in Functional Dyspepsia
Jeoffrey J. Haans, Ingrid M. de Zwart, Albert de Roos, Ad A. Masclee
Background: It has been suggested that the somatostatin analog octreotide reduces symptoms
in patients with functional dyspepsia (FD). Symptoms in patients with FD may result from
several factors such as visceral hypersensitivity, impaired fundus relaxation or alterations in
gastric emptying. Magnetic Resonance Imaging (MRI) is unique in that it allows simultaneous
recording of motility, emptying and volume changes of the stomach. The present study was
undertaken to investigate the effect of somatostatin on volume changes of the stomach,
gastric emptying and motility in patients with FD. Methods: Eight patients with functional
dyspepsia (6F; mean age 46 yrs; range 38-62 yrs) agreed to participate. MR images of the
stomach and symptom scores in response to meal ingestion were obtained during two
sessions in random order under continuous intravenous infusion of saline or somatostatin
(250 μg/h). Gastric emptying and motility were evaluated using 3D-volume scans and 2D-
dynamic scans. Measurements were obtained before consumption of a liquid meal and at
regular intervals (15 min) thereafter. The liquid meal (400 ml; 600 kCal) was labeled with
the paramagnetic MRI contrast agent meglumine gadoterate. Symptoms scored included
nausea, epigastric pain and postprandial fullness and tension (individual symptom score 0-
10). Data obtained during somatostatin infusion were compared to data obtained during
saline infusion. Results (mean ± SD): Initial total gastric volume did not differ between
both experiments before (40 ± 26 ml vs. 42 ± 24 ml, somatostatin vs. saline) and after meal
ingestion (476 ± 71 vs. 493 ± 108 ml), but reduced significantly (p<0.001) faster during
somatostatin infusion (298 ± 58 vs. 432 ± 128 at 90 min). During somatostatin infusion
gastric emptying was significantly (p<0.001) faster than during saline infusion (64 ± 20 vs.
94 ± 13 % at 45 min; 43 ± 14 vs. 73 ± 14 % at 90 min). Total postprandial symptom score
did not differ between both experiments neither before (1.1 ± 3.2) nor after meal ingestion
(9.5 ± 9.1 vs. 10.9 ± 8.8, somatostatin vs. saline). For epigastric pain the scores were even
significantly higher during somatostatin infusion compared to saline infusion. Gastric motility
(contraction frequency) did not differ significantly between both experiments. Conclusion:
Administration of somatostatin accelerates gastric emptying. Administration of somatostatin
does not result in postprandial symptom reduction in patients with FD. On the contrary
postprandial symptoms tended to increase. This may be related to more rapid gastric
emptying, as other motility parameters were not affected.
M2185
Gastroscopy Guided Implantation of Temporary Gastric Electrodes: A New
Minimal Invasive Technique
Hasse R. Abrahamsson, Anders Elfvin, Stina Andersson, Anders Edebo, Magnus Simren,
Hans Lonroth
Temporary (temp) leads have been used for gastric electrical stimulation (GES) to evaluate
whether gastroparetic patients (GP pts) respond to GES (Abell et al 2002&2005). Previous
techniques required general anesthesia, or an oral or PEG route. We have elaborated a
simple, minimal invasive principle for electrode implantation and tested the appropriateness
of placement in animals and in pts by various recording and stimulation techniques.
METHODS: Leads were constructed so that the tip of the lead could be anchored to the
gastric submucosa. Part I: Acute 1-2 hr experiments (expts) were performed in anesthetized
pigs. Under endoscopic control two leads were introduced and gastric EMG (G-EMG)
recorded. Part II: Three pts (1 male, M; 2 females, F) with drug refractory nausea (N) and/
or vomiting (V) with non-established indications for GES were evaluated with percutaneous
temp leads, implanted at gastroscopy (slight sedation plus local skin anesthesia). Detailed
studies of electrode function were done measuring distance between electrodes (fluoroscopy),
impedance, G-EMG compared with manometry and the effect of temp GES for 7-9 days on
symptoms (sympt) (stimulator: Enterra, Medtronic, 12 imp/min, 5mA). Diagnoses and main
sympt were: chronic intestinal pseudoobstruction (CIP; 1 F, V+N), functional dyspepsia
(FD) without GP (1 F, N; 1 M, V). RESULTS: Part I: In the pigs a slow wave (SW) rhythm,
3-4/min, was recorded throughout the expts with some decrease in frequency at the end
of expt. SWs were accompanied by a second potential, suggestive of phasic contractions.
Part II: In the pts implantation time from start of gastroscopy to end of electrode placement
was 12-20 min. Electrode distance varied from 12 to 45 mm. Impedance was 1100-420
ohm at gastroscopy, decreased after implant in 2 pts and was 510-629 on day 7-9. G-EMG
showed a regular SW rhythm about 3/min. Antral pressure waves had intervals being
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multiples of the SW to SW-time observed in each patient. With temporary GES for 7-9
days weekly frequency of main sympt decreased: CIP, F: N 20 to 1 hrs, V 7 to 1. FD, F:
N 17 to 1hrs; M: V 5 to 3/w. The sympt decrease was independent of electrode distance.
No complications from the leads or lead extraction were noted. Permanent implant and 1
yr follow up showed very good results in the two pts with marked effect of temp GES (CIP;
FD, F), the third pt (FD, M) had moderate effect at 1 yr. CONCLUSIONS: Temporary
percutaneous gastric leads can easily be implanted at endoscopy and may be used for testing
of GES and study of gastric electrophysiology.
M2186
Disruption to Integration of Proximal and Distal Gastric Motor Activity in
Critically Ill Patients
Nam Q. Nguyen, Robert J. Fraser, Marianne Chapman, Laura Bryant, Carly Burgstad,
Richard H. Holloway
Normal gastric emptying is complex and involves coordination of the proximal and distal
gastric motor activity in response to small intestinal nutrient feedback. Fundic waves (FWs)
may play a role in transferring gastric contents more distally for antral trituration and
emptying. Slow gastric emptying and subsequent intolerance of gastric feeds are common
in critically ill patients. Although both proximal and distal gastric motility are abnormal in
critically ill patients, the effect of critical illness on the coordination of 2 regions is unknown.
Aim. To determine the association between proximal and distal gastric motility during
fasting, and in response to duodenal nutrient stimulation in critical illness. Methods. Concur-
rent proximal and distal gastric motility was recorded in 10 critically ill patients and 10
healthy volunteers. Proximal gastric motility (barostat) and antro-pyloro-duodenal (APD)
motility (perfused multi-lumen manometric assembly) were recorded during fasting, and
two 60-min duodenal infusions of Ensure (1kcal/min and 2kcal/min) administered in random
order separated by a 2h “washout” period. Proximal gastric volume (PGV), FW activity
(number and volume amplitude) and APD waves were determined. The association between
these variables were also assessed. Results. During fasting, PGVs were similar (patients:
206+47mL vs. healthy: 196+274mL, P=0.7). Patients had fewer FWs and propagated antral
waves (PAWs) than healthy subjects. In patients, duodenal nutrients was associated with
less proximal gastric relaxation (at 10th min: 45+26 vs. 196+29mL; P<0.001) and fewer
FWs and PAWs than in healthy subjects (Table). During both fasting and in response to
duodenal nutrients, the median proportion of FW that were followed by a distally PAW
was lower in patients (0% (0-8%)) than in healthy subjects (36% (11-44%); P<0.001). The
volume amplitude of FW in patients was smaller than that in healthy subjects (87+8mL vs.
44+3mL; P<0.001). Conclusions. In critical illness, both proximal and distal gastric motility
are impaired. Furthermore, the coordination between proximal and distal gastric motor
activity is also disrupted, which may further contribute to delayed gastric emptying in these
patients by interfering with transfer of gastric contents from proximal stomach to distal
peristaltic pump.
M2187
Gastric Antro-Fundic Sensitivity and Helicobacter Pylori Infection in Idiopathic
Dyspepsia
Maria Pia Caldarella, Flora Sacco, Angelo Milano, Chrysanti Balatsinou, Francesco
Laterza, Elena Serio, Franco Cuccurullo, Matteo Neri
BACKGROUND: Recent data (Caldarella MP et al, Gastroenterology. 2003; 124:1220-9)
have shown that the gastric antrum, in addition to the gastric fundus, may be the site of
origin of symptoms in dyspeptic patients. Helicobacter pylori (H. pylori), has been advocated
as a cause of dyspepsia, but this association is still unproven. AIM: To evaluate the role of
H. pylori infection on gastric fundic and antral sensitivity in patients with idiopathic dyspepsia
(ID). METHODS: 8 H. pylori positive patients with ID (mean age 36+6,6 females and 2
males) and 8 H. pylori negative healthy subjects (mean age 26+6, 5 females, 3 males) were
studied. H. pylori status and grade of gastritis (Sidney System) were assessed by 13C-UBT
and histology. Gastric antral and corpus biopsies in patients were taken at endoscopy at
baseline and six months after H. pylori eradication. In all participants, in two separate days
a flaccid bag was located into the gastric antrum or into the fundus under fluoroscopy guide
and connected to a tensostat; subsequently, isotonic distensions of the distal or proximal
stomach were performed by 4 gr increments up to 64 gr or discomfort. These studies were
performed at entry and at least six months after H. pylori eradication. RESULTS: All patients
with ID exhibited antral and fundic hypersensitivity in comparison to healthy subjects. At
baseline, antral perception threshold was 13+3 gr in patients vs. 32+6 gr in health; and the
discomfort threshold was 29+5 gr in patients, while healthy subjects tolerated all distensions
without discomfort. In the gastric fundus, the threshold of perception and discomfort were
significantly lower in patients (8±2 gr and 16±1 gr respectively) than controls (p<0.05). In
all patients the main symptom evoked at antral distension was cramp/colicky sensation
(58+8%). After eradication, fundic sensation thresholds did not change in comparison to
baseline, while in the antrum a significant increase of the discomfort threshold was observed
(48+4 gr, p< 0,05 vs. baseline). At this time, an equal distribution of evoked symptoms was
present (cramp/colicky 30+4% nausea 32+6, fullness 28+6, other 10+2%). After eradication,
activity of gastritis was significantly decreased (1,25 vs 0,4 score, p<0.001). CONCLUSION:
Hp infection may modulate gastric antral hypersensitivity and symptoms pattern in patients
with idiopathic dyspepsia, while having no effect on fundic sensitivity.
M2188
A Sham-Controlled Study of Intra-PYLORIC Injection of Botulinum Toxin in
Gastroparesis
Joris Arts, Philippe Caenepeel, Lieselot Holvoet, Daniel Sifrim, Dominiek Dewulf, Verbeke
Kristien, Jozef Janssens, Jan Tack
Recent uncontrolled studies in limited numbers of patients suggest a benefit of intrapyloric
injection of botulinum toxin (botox) for the treatment of gastroparesis. Improvement seems
to occur within the first 4 weeks, but controlled data are lacking. The aim of the present
study was to investigate the effect of botox on symptoms and gastric emptying in gastroparesis
in a double-blind randomised cross-over design. Methods: Consecutive gastroparesis patients
underwent two upper gastrointestinal endoscopies with 4 weeks interval, during which
intra-pyloric injection with saline or botox 4x25U was performed in a randomised double-
blind fashion. Injections were prepared by a nurse who was otherwise not involved in the
care of these patients. Before the start of the study and 4 weeks after each treatment, they
underwent a solid and liquid 14C octanoic acid and 13C glycin gastric emptying breath
test, and symptom severity was assessed using the Gastroparesis Cardinal Symptoms Index
(GCSI). GCSI scores and gastric half emptying times (t1/2) were calculated and results
(mean±SEM), both parallel and pooled data, were compared using Student’s t test. Results:
23 gastroparesis patients (5 men, mean age 45±3 years, 21 idiopathic, 2 diabetic and 2
post-Nissen) were recruited; 12 received botox first and 11 saline first. After initial saline
injection, significant improvement was seen for GCSI sore and solid and liquid t1/2 (respect-
ively 32.1±1.7 vs. 26.3±2.2; 121±14 vs. 87±8 min and 107±11 vs. 69±6 min, all p<0.01).
After the second injection, with botox, GCSI improved further to 21.4±3.0 (p<0.05) while
no significant changes were seen for solid and liquid t1/2 (respectively 101±17 and 81±10
min, NS). Initial botox injection was associated with similar significant improvement of
GCSI score and solid t1/2 (respectively 21.3±2.8 vs. 15.7±3.2, and 111±7 vs. 93±9 min,
both p<0.05), while liquid t1/2 did not reach significance (104±30 vs. 76±10 min, NS). No
significant further improvement occurred after the second injection, with salin (GCSI
13.4±3.3, solid t1/2 94±11 min and liquid t1/2 74±8 min, all NS). When data for both
treatment periods were pooled, no significant difference was seen for improvements respect-
ively after botox or saline injection for GCSI (6.1±1.5 vs. 3.8±1.5,NS), solid t1/2 (3.4±7.4
vs. 16.3±8.3,NS) and liquid t1/2 (8.2±13.7 vs. 22.5±7.7,NS). CONCLUSION: In a cohort of
gastroparesis patients of predominantly idiopathic origin, intra-pyloric injection of botulinum
toxin does not seem superior to placebo in improving symptoms and solid or liquid gastric
emptying rate.
M2189
Noninvasive Recordings of Electrical Response Activity Using a Squid
Biomagnetometer
Andrei Irimia, William O. Richards, Leonard A. Bradshaw
Clinical efforts in electrogastrography (EGG) are typically focused on the evaluation of the
gastric slow wave frequency and amplitude. The study of spiking potentials (electrical
response activity or ERA, which is associated with smooth muscle contraction) may have
significant clinical relevance, though no one has ever recorded ERA using cutaneous EGG.
To record ERA noninvasively, we acquired magnetogastrogram (MGG) recordings from ten
healthy New Zealand rabbits using a 37-channel Superconducting Quantum Interference
Device (SQUID) biomagnetometer located in the Gastrointestinal SQUID Technology (GIST)
Laboratory at Vanderbilt University. After a 30 minute baseline recording, the stomach of
each animal was surgically divided and MGG data were acquired for an additional 30
minutes. We employed principal and independent component analysis (PCA and ICA,
respectively) to isolate the gastric slow wave and ERA from MGG recordings. Whereas PCA
is a dimensionality reduction technique for multivariate data, ICA is a powerful analysis
method for extracting signal components from a set of multi-channel recordings. By using
PCA and ICA, we ensured that extraneous artifacts such as motion, cardiac and intestinal
activities, etc. were removed from the analyzed gastric signal. The slow wave frequency
measured across subjects was 3.2 ± 0.6 cpm (cycles per minute, mean ± SEM) pre-division
and 1.3 ± 1.4 cpm post-division. The mean percentage of slow waves exhibiting ERA spiking
dropped from 52% pre-division to 23% post-division, a statistically significant decrease of
44% after stomach division (p < 0.001). The ERA dominant frequency was 73.4 ± 3.5 cpm
pre-division and 47.1 ± 5.7 cpm post-division, a significant post-division decrease of 64%
(p < 0.001). In all animal subjects, ERA frequencies as cited above were found to be
significantly below those of the cardiac signal, whose dominating frequency was found to
be 213.7 ± 8.9 cpm across rabbits. In conclusion, stomach division in rabbits is accompanied
by significant changes in MGG-recorded ERA patterns which can be detected noninvasively
using a SQUID. The capability of SQUIDs to noninvasively record ERA in addition to the
frequency, amplitude and propagation velocity of the slow wave demonstrates the future
diagnostic potential of noninvasive SQUID recordings in human subjects.
M2190
Continuous PYLORIC Manometry Determines the Effectiveness of Botulinum
Toxin Injection in Patients with Gastroparesis
Linda Anh B. Nguyen, Shelly Parker, Stephen Bunker, William J. Snape
Background: Gastroparesis is a disorder of gastric motility that results in delayed gastric
emptying in the absence of mechanical obstruction. Pylorospasm (tonic pyloric contractions
≥10mmHg) has been implicated in gastroparesis(Mearin et al.Gastro 1986). Botulinum
toxin A injection (80-200 U) into the pylorus has been shown in a number of studies to
improve symptoms and gastric emptying. The success rate has been variable. Gupta and
Rao(Gastrointest Endosc 2002) showed that botulinum toxin(BT) attenuated isolated pyloric
pressure waves on ambulatory antropyloroduoenal manometry 3 weeks after injection with
200 units of BT. Our hypothesis is that the subset of patients with pylorospasm are the
patients who would benefit from BT injection. Aims:1)Evaluate the feasibility of recording
pyloric pressures using a Dent sleeve before and immediately after the injection of BT and
2)Correlate post-injection pyloric pressures with clinical response. Patients and Methods: 7
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patients with gastroparesis (4 diabetics, M=6, age 35.1±2.5, mean 4hr gastric retention
23.5%±6.9) underwent upper endoscopy with pyloric pressure measurements using a Dent
sleeve (Mui Scientific). Positioning of the sleeve was confirmed flouroscopically. Basal and
peak pyloric pressures were measured before and immediately after BT injection. The Dent
sleeve was left in position during BT injection. Patients with tonically elevated basal pyloric
pressures received a total of 100 units of BT injection into the pylorus. 3 patients had a
follow up gastric scintigraphy (1,3 and 18 days) after the injections. One patient underwent
2 treatment sessions after not responding to the first injection. Results: Basal pyloric pressures
(PP) and peak PP decreased immediately after the injection of BT (28.8 mmHg+5.2 vs. 9.9
mmHg±2.1, p=0.002; 68.5±8.3 vs. 34.8±5.4, p=0.01). 3 patients who were hospitalized
had immediate improvement and were discharged from the hospital 2 days later. The 3
patients who improved, had their basal PP decrease from 12.8 to 0, 33.0 to 7.0 and 14.7
to 7.6mmHg, respectively. Two patients who did not have symptomatic improvement had
post BT basal PP the decreased but remained elevated at 18.7 and 17.0. The patient whose
basal PP decreased from 38.6 to 18.7 had an improvement in gastric emptying but not
symptoms. This patient had a second procedure 3 weeks later where the post BT pressure
decreased to 10.9, at which point he symptomatic improvement. Conclusions: 1)Pyloric
pressures decrease immediately following BT injection. 2)Since 100 units of BT did not
reduce basal PP to <10 mmHg in all patients, this may indentify patients who need higher
doses of BT.
M2191
Characteristics of Gastric Emptying and Neuropathy in Patients with Different
Durations of Type-1 Diabetes
Tamas Varkonyi, Eva Borcsok, Robert Takacs, Richard Roka, Csaba Lengyel, Mate Lazar,
Miklos Papos, Laszlo Pavics, Peter Kempler, Janos Lonovics
The roles of the disease duration and age in the pathogenesis of impaired gastric emptying
in type-1 diabetes (DM) are still not clearly elucidated. The aim of this study was to determine
the postprandial gastric emptying, and the autonomic and the sensory neuropathy in groups
of DM patients (pts) with different disease durations and age. Patients, methods: 17 pts had
a shorter, and 23 pts a longer history of type-1 DM (age: 30.7±2 vs 44.6±2.6 yrs, p<0.001;
duration: 8±1.4 vs 25.3±2.3 yrs, p<0.0001; mean±SE). The emptying of the stomach was
evaluated by a scintigraphic gastric emptying procedure. Autonomic neuropathy (AN) was
assessed by means of the five cardiovascular reflex tests. Sensory nerve function was studied
with a Neurometer (Neurotron Inc. Baltimore, Md), using transcutaneous electrical stimula-
tion. Results: There was a tendency to a longer half-time of gastric emptying (HTE) in the
type-1 DM pts with longer duration, but the difference between the groups did not reach
the level of significance (HTE: 93.5±10.1 vs 67.8±6.7 min., p>0.05; long-standing vs short-
standing type-1 DM). The overall severity of AN and the results of three reflex tests differed
between the groups (AN score: 4.3±0.5 vs 2.5±0.4, p<0.05; heart rate response to breathing:
12.7±1.5 vs 19.4±2.2 beats/min., p<0.05; Valsalva ratio: 1.3±0.05 vs 1.75±0.1, p<0,0001;
orthostatic hypotension: 23±3.4 vs 11±3.7 mm Hg, p<0.05). A positive correlation was
observed between HTE and the AN score in long-standing DM (r=0.57, p<0.01). The
correlations between heart rate response to breathing and HTE (r=-0.57, p<0.01) and between
the Valsalva ratio and HTE (r=-0.43, p<0.05) in this group were negative, while a positive
association was found between the orthostatic hypotension and HTE (r=0.51, p<0.01). The
current perception thresholds (CPT) detected at 2 kHz frequency differed between the
groups in the upper and lower limbs (CPT at the median nerve: 3.66±0.35 vs 1.84±0.25
mA, p<0.001; CPT at the peroneal nerve: 5.39±0.71 vs 3.70±0.68 mA, p<0.05). Conclusions:
Impaired gastric emptying was found more frequently in pts with long-standing type-1 DM,
but this difference between the groups was not significant. Both the parasympathetic and
the sympathetic systems and the sensory function of the large myelinated fibres were more
seriously altered in long-standing DM. The severe autonomic dysfunction exhibited a correla-
tion with the slower gastric emptying. These data support the hypothesis that the most
progressive manifestations of diabetic neuropathy might be responsible for the development
of gastroparesis.
M2192
Patients with Gastroparesis Have a Decreased Expression of the 5-Ht4(C)
Splice Variant in the Duodenum
Niels Van Lelyveld, Jose Ter Linde, Marguerite Schipper, Melvin Samsom
Background & Aims: Studies using 5-HT3 and 5-HT4 receptor agonists, selective serotonergic
reuptake inhibitors (SSRI), and tryptophan depletion, have revealed that serotonergic signal-
ling is involved in the regulation of gastric emptying rate and, potentially, in the generation
of upper abdominal symptoms. To increase the understanding of the pathophysiologic basis
of idiopathic gastroparesis at the molecular level, we compared the expression of genes
encoding components of serotonergic signalling in the duodenum and stomach between
patients with idiopathic gastroparesis and healthy controls. Methods: Mucosal biopsy speci-
mens were collected from the duodenum, antrum, and fundus of 11 patients with idiopathic
gastroparesis (2 male, mean age 46.5 ± 4.0 years) and 11 healthy controls (1 male, mean
age 46.3 ± 2.5 years). Enteroendocrine (EE) cells (chromogranin immunoreactive) and
enterochromaffin (EC) cells (serotonin immunoreactive) were counted and mRNA levels of
TPH-1 (the rate-limiting enzyme of 5-HT biosynthesis), SERT (regulates 5-HT availability
by high affinity uptake), 5-HT3(C) and 5-HT3(E) (subunits of the 5-HT3 receptor), the 5-
HT4 receptor, and three 5-HT4 splice variants (A, B, and C) were quantified by real time
RT-PCR and compared between the two groups. Results: EE and EC cell number were
comparable in the three regions between the two groups. In addition, no differences were
found in the percentage of EE cells that were EC cells in any of the three regions. The
expression of TPH-1 and SERT in all three regions was comparable between the groups (P
> 0.05). In antrum and fundus, the expression of the 5-HT3 receptor subunits, the 5-HT4
receptor, and the 5-HT4 receptor splice variants was too low for accurate quantification. In
the duodenum, the overall expression of the 5-HT4 receptor was comparable, however the
5-HT4(C) splice variant was expressed more abundantly in healthy controls compared to
patients (P = 0.015). No differences were found in 5-HT4(A) or 5-HT4(B) expression. Finally,

















Conclusion: These data suggest that delayed gastric emptying or the presence of upper
abdominal symptoms does not result from altered 5-HT biosynthetic and uptake capacity
or changed expression levels of the 5-HT3 and 5-HT4 receptor in the stomach and duodenum
at the mucosal level. However, a different distribution of 5-HT4 splice variants, as shown
by the lower expression level of the 5-HT4(C) variant, may cause a different functional
response of 5-HT4 receptors upon stimulation and be of importance in the pathophysiology
of gastroparesis.
M2193
Impaired Fundo-Antral Reflex in Diabetic Gastroparesis
Ashok Attaluri, Issam Nasr, Konrad Schulze, Satish Rao, Anjana Kumar
BACKGROUND & AIM: Fundic balloon distension induces reflex antral pressure waves
in normal subjects- the fundoantral reflex. This may play a role in trituration and transport
of food. Here, we tested whether an altered fundo- antral reflex plays a role in the pathophysi-
ology of diabetic gastroparesis. METHODS: We examined 13 diabetics (m/f = 5/8; mean
age 39 yrs) with gastroparesis and 15 healthy volunteers (m/f = 7/8, mean age 32 yrs).
Antral activity was assessed by positioning two antral pressure sensors 5 cm apart and fundic
distension was accomplished by a 10 cm long, highly compliant balloon connected to a
barostat. Phasic distensions were performed in increments of 3 mm Hg. The number and
area under the curve (AUC) of antral pressure waves were analyzed. RESULTS: Both in
controls and diabetics, the antral activity was higher during balloon inflation, compared to
the deflation periods (p< 0.05). All healthy controls showed reflex antral activity, compared
to 62% of diabetics (p< 0.05). The number and AUC of antral pressure waves were signific-
antly lower (p <0.05) in diabetics (table; mean ± SD). Also, in diabetics, antral pressure
activity did not correlate with either gastric emptying time or symptoms such as post-
prandial fullness, nausea, bloating, abdominal pain, vomiting, and weight loss (Spearman
correlation coefficient rs = -0.24 to 0.32; p> 0.05). CONCLUSIONS: Diabetic patients with
gastroparesis demonstrate either an impaired or absent fundo- antral reflex and this may
play a role in the pathophysiology of diabetic gastroparesis. However, there is poor correlation
between reflex antral activity, gastric emptying and individual upper GI symptoms. This
may either be due to multiple independent mechanisms that contribute to the pathogenesis
of diabetic gastroenteropathy or a type II error. Supported by ACG reseach grant and R01
DK-57001-03.
M2194
Gastric Compliance By Barostat Does Not Correlate with Gastric Emptying Or
Accommodation
Linda Anh B. Nguyen, Shelly Parker, Stephen Bunker, William J. Snape
Background: Proximal gastric compliance is a function of the physical elasticity of the
stomach wall. Accommodation is a vagally mediated reflex that occurs after a meal. Patients
with nonulcer dyspepsia and early satiety have been found to have impaired gastric accom-
modation compared to normals (Tack et al.Gastro 1998). There has been no difference in
compliance between controls and patients (Mearin et al. Gastro 1991). Our hypothesis is
that compliance correlates with accommodation and inversely with gastric emptying. Aims:
1)Correlate gastric compliance with gastric emptying and accommodation and 2)Determine
if there is a physiologic difference in patients with impaired compliance compared to those
with normal compliance. Patients and Methods: 36 patients (F=32, age 38.3±11.1) with
upper GI symptoms had gastric barostat testing to evaluate their symptoms. Minimal disten-
tion pressure (MDP), sensory threshold, compliance(stepwise distention) and accommoda-
tion(dV) were assessed. All patients had gastric scintigraphy(GET) to measure 2 and 4 hour
gastric retention. The correlation coefficient of compliance with GET, sensory threshold and
dV were calculated. In addition, the correlation of dV with GET was also assessed. Patients
were then grouped by compliance (normal vs. abnormal<20 ml/mg). The 2 groups were
compared with GET, dV and gastric volume change after sumatriptan (5HT1 agonist).
Results: 19.4% of patients had impaired compliance (mean=13.1±2.3mg/mmHg). Gastric
compliance did not correlated with 2hr GET (r= -0.05, p=0.77), 4hr GET (r=0.17, p=0.32),
sensory threshold (r=0.09, p=0.61) or dV (r= -0.02, p=0.93). There was also no correlation
between dV and GET. When comparing patients with impaired compliance vs. normal
compliance (mean=43.5±3.5 ml/mg), there was no differences in dV (76.7±28.7 ml vs.
57.1±24.5 ml, p=0.7), 2hr GET (28.1±3.9% vs. 35.0±9.7%, p=0.5), or 4hr GET (9.1±3.1%
vs. 7.3±2.7%, p=0.8). 5 patients in the impaired compliance group and 6 patients in the
normal group received sumatriptan 6mg SQ after being found to have impaired accommoda-
tion. The post sumatriptan response was greater in the normal group (252.8±115.1 mL vs.
11.4±11.4 mL, p=0.9) but not statistically significant. Conclusions: 1)Gastric emptying
cannot predict gastric compliance or accommodation as measured by gastric barostat.
2)Impaired gastric accommodation with normal compliance may indicate an abnormality
in the neural reflex as seen by the trend toward increase response to sumatriptan. In
comparison, patients with both abnormal dV and compliance may have problems with
gastric elasticity which would not improve with a 5-HT agonist.
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M2195
Effect of a Proton Pump Inhibitor On Postprandial Gastric Volume, Emptying
and Symptoms
April B. Grudell, Duane D. Burton, Debra A. Stephens, Michael Camilleri
Background: Intravenous 99mTc-pertechnetate is taken up by gastric mucosa. This principle
is used to image stomach volume in single photon emission computed tomography (SPECT).
Proton pump inhibitors (PPIs) are beneficial in some patients with functional dyspepsia.
The effects of PPIs on measurements of gastric volume and emptying are incompletely
understood. Aim: To assess the effect of inhibition of gastric secretion on gastric volume
and emptying measurements obtained with SPECT. Methods: In a double-blind, placebo-
controlled trial, 13 participants were randomized to a PPI, rabeprazole, 20 mg b.i.d., or
placebo 2 days prior to the study visit. Medication allocation was concealed. During the
study visit, fasting gastric volume was measured using SPECT-99mTc-pertechnetate. After
the last dose of study medication, an 111In-chloride charcoal-labeled egg meal (300kcal)
was ingested, followed by SPECT measurements of postprandial gastric volume and gastric
emptying (GE 2h, GE 4h) by a previously validated method (Am J Physiol 2005;289:G261-
6). Symptom ratings using a visual analog scale (fullness, nausea, bloating, abdominal pain)
were obtained postprandially at 30 minutes. Group comparisons were performed using the
Mann Whitney test. Results: Technical failure due to subcutaneous infiltration of 99mTcO4
led to exclusion of 1 participant’s data. Gastric imaging was not compromised by the
administration of the PPI. Patient demographics, fasting and postprandial gastric volumes,
and gastric emptying percentages are shown in the table. There were no significant differences
in the 2 groups. Rabeprazole resulted in reduced aggregate postprandial symptoms, particu-
larly fullness, 30 minutes after the meal (p=0.01). Post-hoc analysis showed that 30 particip-
ants per treatment group would be required to show a significant effect of rabeprazole on
gastric emptying and 48 per group to show an effect on gastric volume. Conclusion: In
healthy participants, rabeprazole 20 mg b.i.d. did not significantly change gastric volume or
emptying, but it reduced symptoms postprandially. The mechanism of reduced postprandial
symptoms with a PPI requires further study.
Data show median (IQR).
M2196
Effect of Gastric Electrical Stimulation On Cerebral Blood Flow in Patients
with Gastroparesis
Thomas V. Nowak, Gary Hutchins, Joel Hammond, Yang Wang, Lyn Ring, Kativa Leal
Gastric electrical stimulation (GES) of the stomach is an effective treatment of nausea and
vomiting in patients with gastroparesis (Gastroenterology 125: 421-28, 2003). However,
the mechanism is unclear, as many patients show resolution of nausea and vomiting yet
continue to exhibit delayed gastric emptying. This suggests GES may relieve symptoms by
activation of a mechanism involving the central nervous system. The purpose of this study
was to determine whether GES produces changes in the brain evidenced by alterations in
cerebral blood flow on positron emission tomography (PET). Eight patients (6 female, 2
male) ranging in age from 27 to 68 yr were studied. Each patient had profound gastroparesis
and had undergone implantation of a GES device from 6 to 57 mo (mean 25) prior. All
patients studied had significant improvement in symptoms of nausea, vomiting, and early
satiety after implantation of the GES device. PET scans were performed after an overnight
fast and with the GES device in the ON mode. Each patient was then given an iv injection
30-40 mCi O15-water. After PET image data were obtained the GES device was then turned
to the OFF mode for 30 min. The O15-water injection and PET image scanning was then
repeated. Respective PET images obtained with the GES device in the ON and OFF modes
were then analyzed and compared. PET images were analyzed using SPM2 (Statistical
Parametric Mapping), implemented using Matlab 6.5 Prior to statistical analysis all images
were realigned to correct motion movements and spatially normalized into the MNI standard
template to remove inter-subject anatomical variability. Spatially normalized images were
smoothed using an isotropic Gaussian kernel with 16 mm FWHM to increase the signal-
to-noise ratio. Statistical comparisons between ON and OFF scans were performed on a
voxel-by-voxel basis using paired t statistics. Significant voxels were superimposed on a
high resolution MRI template provided by SPM2, thus allowing anatomical identification.
Significant increases in blood flow during GES were noted in the middle, superior, and
inferior gyri, in the middle occipital and middle temporal gyri, and in the amygdala and
parahippocampal gyri (P<.05 for each locus, respectively). Likewise, significant decreases
in blood flow during GES were noted in the pre and post central gyri, in the anterior
cingulate gyri, and in the caudate head and putamen (p<.05 for each locus, respectively).
Conclusions: 1)GES produces significant alterations in cerebral blood flow in gastroparetic
patients; 2)central nervous system mechanisms during GES may be responsible for the relief
of nausea and vomiting in these patients.
M2197
Influence of Helicobacter Pylori Infection On Gastrointestinal Motility of
Dyspeptic Patients—Real-Time Ultrasonographic Study
Hiroaki Kusunoki, Ken Haruma, Jiro Hata, Tomoari Kamada, Motonori Sato, Toshiaki
Tanaka, Hideki Koga, Masaharu Takeda, Kenichi Tarumi, Keisuke Honda
Background: Helicobacter pylori infection has been proposed as one of the pathogenic mechan-
isms of functional dyspepsia (FD), but its effects on proximal gastric compliance and gastroin-
testinal motility are still unclear. The aim of the present study was to clarify these effects
using ultrasonography. Methods: Fourteen FD patients with Helicobacter pylori infection
(mean age, 59.8 years) and 14 uninfected FD patients (mean age, 43.2 years) were studied
ultrasonographically. Ultrasonographic assessment of gastrointestinal motility was performed
using previously reported methods (Scand J Gastroenterol 1994; 29 897-902, J Gastroenterol
Hepatol 2000; 15 1022-1027, Gut 2002; 51 A188). For the assessment of gastric compliance,
a cross-sectional area of the proximal stomach was measured after stepwise ingestion of a
liquid meal (consomme soup: 3.25 kcal / 100 ml ), up to 400 ml. Then, gastric emptying,
antral contractions and duodenogastric reflux (DGR) were observed in the sitting position.
Result: There were no significant differences in % gastric emptying, antral contractions and
DGR between the FD patients with and without Helicobacter pylori infection (% gastric
emptying : 57.2 vs 57.8, motility index : 8.90 vs 8.79, DGR : 22 vs 26 ). Although the
cross-sectional area of the proximal stomach tended to be smaller in the FD patients with
Helicobacter pylori infection than in the patients without infection after the ingestion of 300
ml (30.3 vs 34.8, p=0.166 ) and 400 ml (39.2 vs 43.3, p=0.273 ) of a liquid meal,
there were no statistically significant differences. Conclusion: Impaired meal-induced gastric
compliance was present in a higher proportion of FD patients with Helicobacter pylori infection
than in patients without infection. There was little influence of Helicobacter pylori infection
on gastrointestinal motility.
M2198
Artificially Sweetened, Compared to Regular Mixers, Accelerate Gastric
Emptying and the Rate of Alcohol Absorption
Keng-Liang Wu, Reawika Chaikomin, Selena Doran, Karen L. Jones, Michael Horowitz,
Chris Rayner
Mixed alcoholic drinks are increasingly being consumed in “diet” varieties, as opposed to
“regular” versions containing sugar. Almost no consideration has been given to the potential
for artificially sweetened drinks to empty more rapidly from the stomach, with an increased
rate of alcohol absorption, when compared with the original formulations. Eight fasting
male volunteers were studied twice, in randomized order. On each day, subjects consumed
an orange-flavored vodka beverage (30 g ethanol in 600 mL), made with either a “regular”
mixer containing sucrose (total 478 kcal), or a “diet” mixer (225 kcal). Gastric emptying
was calculated from ultrasound measurements of antral area. Blood was sampled at intervals
for 180 minutes for measurement of blood ethanol concentration. Data are mean ± standard
deviation. The gastric half-emptying time was less for the “diet” than the “regular” vodka
drink (21.1 ± 9.5 vs 36.3 ± 15.3 minutes, P < 0.01). Both the peak blood ethanol concentration
(0.053 ± 0.006 vs 0.034 ± 0.008 g%, P < 0.001) and the area under the blood ethanol
concentration curve between 0 - 180 minutes (5.2 ± 0.7 vs 3.2 ± 0.7 units, P < 0.001) were
substantially greater with the “diet” drink. Substitution of artificial sweeteners for sucrose
in mixed alcoholic beverages may have a marked effect on the rate of gastric emptying and
the blood alcohol response.
M2199
Which Time Interval Is Required Between Performance of Two 13c-Breath
Tests?
Jutta Keller, Karola Schmidt, Christiane Fibbe, Peter Layer
Background: 13C-breath tests have become important gastroenterological diagnostic tools
and several 13C-breath tests may be performed in one patient for varying indications. The
13C-octanoic acid breath test allows measurement of gastric emptying of solids. However,
it has been demonstrated that 13CO2 continues to be excreted long after gastric emptying
was shown to be complete by scintigraphy. This might be due to the fixation of the isotope
in the bicarbonate pool of the body and its subsequent delayed release. Thus, it is of
importance to know which time interval is required before performance of a second 13C-
breath test in order to avoid overlap. Methods: On day 1 a standardised 13C-octanoic acid
breath test was performed in 60 patients with upper abdominal symptoms (450 kcal meal
including scrambled egg, egg yolk doped with 91 mg 13C-octanoic acid, breath sampling
at 15 min intervals for 4 h, analysis by isotope-selective infrared spectrometry). Data were
evaluated using non-linear regression analysis (Ghoos et al Gastroenterology 1993). On day
2, 24±1 h after collection of the first basal breath sample, another fasting breath sample
was obtained from every patient. Results (mean±SEM): For all patients, mean half and lag
time were 173±15 and 98±11 min, respectively, and 23±1% of the 13C-dose administered
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were cumulatively exhaled within 4 h. 18 patients showed delayed gastric emptying (t 1/
2: 327±23 min) according to our laboratory’s normal values (t 1/2 < 200 min). These patients
had significantly longer t lag and lower cumulative 4 h-13C-exhalation than patients with
normal gastric emptying (194±18 vs. 58±7 min, p<0.0001; 20±2 vs. 24±1% of dose, p=
0.026). Basal 13C-concentrations in breath were similar before and 24 h after application
of 13C-octanoic acid for patients with normal and delayed gastric emptying and did not
differ between the two groups (tab). Moreover, the delta between basal 13C-concentrations
on day 1 and 2 did not correlate with half or lag time of gastric emptying or cumulative
13C-exhalation in either group. Conclusions: 24 hours after ingestion of a standard dose
of 13C-octanoic acid fasting 13C-exhalation has returned to basal in patients with normal
and prolonged gastric emptying. Thus, a second 13C-breath test may be performed on the
next day even in patients with gastroparesis.
Fasting 13C-exhalation before and 24 h after performance of a 13C-octanoic acid breath test
Data are given as delta %o, mean+/-SEM
M2200
Poor Correlation Between Electrogastrography and Antroduodenal Manometry
in Patients with Motility Disorders
Shahab Abid, Greger Lindberg
Antroduodenal manometry (ADM) records lumen-occluding contractions of the gastric
antrum, while electrogastrography (EGG) measures gastric myoelectric activity using cutane-
ous electrodes placed on the abdominal wall. Under physiological conditions there is a
temporal correlation between myoelectric slow waves and contractile activity of the antrum.
It is unclear if there is also a spatial correlation between electric and contractile activity.
Aim of the study. To determine the relationships between electrical activity measured by
EGG and antral contractile activity measured by ADM. Material and methods. This is a
retrospective analysis of patients with various motility disorders of the gut subjected to
simultaneous ADM and EGG recording. A single bipolar channel measured the EGG and
ADM was done using either 6 or 8 channels. EGG parameters analysed were: (i) percentage
of time with a dominant frequency (DF) in normogastric (2-4 cpm), tachygastric (4-10 cpm)
and bradygastric (0.5 - 2 cpm) frequency bands, (ii) EGG power attributed to the three
frequency bands (normogastria, tachygastria and bradygastria), (iii) the ratio of postprandial
to fasting power of the DF, (iv) the overall DF, (v) variability of the dominant frequency
(DFIC) and (vi) variability of the dominant power (DPIC). The ADM parameters measured
were: mean frequency and amplitude of contractions and the motility index that was calcu-
lated by multiplying the amplitude (mm) by the frequency per minute. Data from one hour
before and the first hour after a test meal were compared. Results. A total of 151 patients,
125 (83%) females, mean age 45±14 years, were analysed. There were 52 patients with
irritable bowel syndrome, 26 patients with slow transit constipation, 22 patients with enteric
dysmotility, 11 patients with chronic intestinal pseudo-obstruction and 13 patients with
gastroparesis or functional dyspepsia, three patients with previous gastric surgery and 24
patients with other motility disorders of the gut. We found no relation between any of the
21 EGG parameters and 8 ADM parameters. Comparison between EGG response to meal
ingestion (ratio between postprandial and fasting power) and ADM response to meal ingestion
(ratio between postprandial and fasting motility index) revealed no correlation (r= 0.06 p=
0.44). Conclusions. No consistent relationship was observed between EGG and ADM in this
series of patients with motility disorders. EGG and ADM give different kinds of information.
M2201
Postprandial Gastric Acid Neutralization and Reacidification in Diabetic Vs.
Idiopathic Gastroparesis: Relation to Degree of Gastric Stasis
William L. Hasler, Radoslav Coleski, William D. Chey, Kenneth L. Koch, Richard W.
McCallum, John M. Wo, Braden Kuo, Michael Sitrin, Kevin Stevens, Beverly Landrigan,
Jack R. Semler, Henry P. Parkman
Background: Gastric acid-related complaints including GERD are prevalent in patients with
gastroparesis, especially with diabetes. Demographic and clinical differences in diabetic and
idiopathic gastroparesis suggest the two conditions have distinct pathophysiology. Though
acid-associated symptoms have been related to autonomic neuropathy, the acid milieu of
the stomach in gastroparesis is poorly understood. Further, the roles of different etiologies
of gastroparesis and the magnitude of gastric stasis on gastric pH are unknown. Recently,
an ingestible telemetry capsule was developed to continuously measure luminal pH and
pressure (SmartPill Corp.). Hypotheses: We hypothesized (i) severely delayed gastric empty-
ing is associated with increased gastric acidity and (ii) postprandial pH profiles differ in
diabetic vs. idiopathic gastroparesis suggesting dissimilar disease pathogenesis. Methods:
Data from 44 patients with gastroparesis on prior scintigraphy (20 diabetic, 24 idiopathic)
from 7 centers were analyzed. Acid suppressants were stopped x 1 week prior to study.
After capsule ingestion, subjects consumed standard meals (120 g EggBeaters, bread, jam,
and 120 ml water; 255 kcal) with 1 mCi 99Tc-sulfur colloid. Luminal pH was measured
every 5 sec; scintiscans were acquired every 30 min x 4-6 h. Results: Meals elicited initial
pH rises that were greater in diabetics (4.98±0.32) than idiopathics (3.89±0.39)(P=0.04).
This declined to stable pH nadirs which were similar in diabetics (1.50±0.23) and idiopathics
(0.93±0.31)(P=0.16). Cumulative postprandial reacidification was quantified by measuring
areas under pH curves (AUC) from meal ingestion to the time of nadir pH. AUCs (pH x
hr) were greater in diabetics (4.10±0.51) than idiopathics (2.61±0.40) indicating less gastric
acidity after eating in diabetics (P=0.02). Times for 90% gastric emptying (T90) were similar
in diabetics (249±15 min) and idiopathics (249±16 min). Compared to those with mild
gastroparesis (T90≦300 min), patients with profound stasis (T90>300 min) had higher peak

















2.79±0.29)(all P<0.03). Conclusions: Diabetics with gastroparesis exhibit lesser degrees of
postprandial gastric acidity than idiopathic gastroparetics that are not due to differences in
gastric emptying rates. However, those with profound stasis exhibit higher rather than lower
gastric pH regardless of etiology. These findings suggest that the pathophysiology of diabetic
gastroparesis differs from idiopathic disease and indicate that factors other than low gastric
pH may contribute to symptoms in diabetics with gastric retention.
M2202
Exaggerated Cephalic Gastric Relaxation and Gastric Accommodation in
Nausea-Predominant Patients with Functional Dyspepsia
Tomotaka Shoji, Fukudo Shin, Yuka Endo, Kazuto Karahashi, Yashuhiro Sagami, Joe
Morishita, Yuko Kimura, Atsushi Utsumi, Michio Hongo
(Back ground) Patients with functional dyspepsia (FD) are considered to have heterogeneous
pathophysiology. Nausea-predominant patients may have specific gastric function. Therefore
we tested whether fundic function was altered in nausea-predominant patients with functional
dyspepsia (npFD). (Subject and method) Ten healthy subjects and seven npFD patients
participated in this study after informed consent. The npFD patients satisfied the Rome II
criteria and their dominant symptom was nausea. After 12 hours fasting, barostat bag was
placed in the gastric funds. Gastric perception was measured by 1 mmHg/min step wise
gastric distension and two first (FS) and discomfort (D) gastric sensation thresholds were
determined. After the perception session, two (sham feeding and tube feeding) barostat
sessions were performed with MDP (minimal distending pressure) + 2 mmHg distending
pressure. After the gastric volume measurement for 30 minutes, sham feeding was carried
out by repeated taste and spit of Ensure liquid® for 10 minutes and then the measurement
continued for 30 minutes. After 20 minutes interval, baseline was measured again. After
the second baseline, Ensure liquid® (200 ml, 200 kcal) was injected into gastric funds
through a feeding tube and gastric volume was measured for 30 minutes. In both the
perception session and barostat session, all subjects evaluated gastric sensation with visual
analogue scale (VAS). All data was analyzed by Mann-Whitney’s U test or ANOVA. (Result)
Two gastric sensation thresholds (mmHg) were same in both healthy subjects and npFD
patients (FS: 10.6+/-3.3 vs. 10.8+/-4.4, D: 13.7+/-4.0 vs. 12.3+/-3.9). In the barostat session,
the baseline gastric volume (ml) was tended to be higher in FD than healthy subjects (193+/-
124 vs. 93+/-46, p=0.087). After both sham and tube feeding, gastric volume significantly
increased in npFD than controls (after sham: 309+/-204 vs. 129+/-65 and after tube: 476+/-
284 vs. 280+/-94 ml, ANOVA; p<0.05). On the VAS, only nausea score was significantly
higher in npFD after both sham and tube feeding (after sham: 23.6+/-15.7 vs. 11.0+/-21.4
and after tube: 47.1+/-38.7 vs. 10.3+/-17.0, p<0.05). (Conclusion) These data suggested
that excessive cephalic gastric relaxation, excessive gastric accommodation and nausea were
induced by nutrient stimulation in npFD patients. Nausea-predominant FD patients may
have different fundic response to stimuli from the other form of FD patients.
M2203
Correlation of Plasma Ghrelin Levels and Delayed Gastric Emptying Time in
FD Patients with Loss of Emptiness Feeling
Tetsuro Hiratsuka, Seiji Futagami, Tomotaka Shindo, Tatsuhiko Hamamoto, Nobue Ueki,
Kenji Suzuki, Yoko Shinji, Masafumi Kusunoki, Ken Wada, Kazumasa Miyake, Katya
Gudis, Taku Tsukui, Katsuhiko Iwakiri, Choitsu Sakamoto
Background/Aims: Since functional dyspepsia (FD) seems to be caused by multifactorials
such as gastric motility, depression, and visceral hypersensitivity, its clinical symptoms are
complex and resistant to cure. Gastric emptying has been reported to be delayed in some
FD patients. However, the involvement of gut hormones and local cytokines in gastric
emptying has yet to be elucidated in these FD patients. Thus, we measured gastric emptying
time and plasma ghrelin levels, one of the motility factors released into the peripheral
circulation from the stomach, and examined the relationship between these data and symptom
patterns in FD patients. Methods: 47 patients with FD and 30 healthy controls were enrolled
according to Rome II criteria after endoscopy for this study. 47 FD patients were separated
into three groups: subjects with symptoms of dismotility-like dyspepsia (dismotility group),
ulcer-like dyspepsia (ulcer-like group) and unspecified dyspepsia (unspecified group). Gastric
motility was evaluated by measuring gastric emptying time using 13C-acetate breath test,
and partly assessed by abdominal ultra-sonography. Upper abdominal symptoms including
pain, nausea, fullness, discomfort, and emptiness were assessed by questionnaire scores.
Scores from the Self-rating Questionnaire for Depression (SRQ-D) were also used to evaluate
depression. Plasma ghrelin levels were measured by ELISA method in patients with FD.
Results: Gastric emptying time in the dismotility group (33 % of FD) was significantly
delayed compared to the healthy control group (58.6±3.6 vs. 46.2±0.65 min, p<0.05), while
emptying time in the ulcer-like (14% of FD) and unspecified (53% of FD) groups did not
differ significantly from healthy controls. In contrast, SRQ-D scores for the ulcer-like and
unspecified groups (11.7±2.5 and 11.7±1.3, respectively p<0.05) were significantly higher
than for healthy controls, while scores for the dismotility group did not differ from that of
the healthy control group. One of the symptoms of FD patients with delayed gastric emptying
time was characterized as loss of emptiness feeling compared to patients with normal gastric
emptying time (3±1.5 vs. 8.9±1.3, p<0.05). However, states of depression did not differ
between FD patients with normal and delayed gastric emptying. Furthermore, levels of
ghrelin phenotypes, acylated and desacylated ghrelin, decreased significantly in patients with
delayed gastric emptying time compared with those in patients with normal gastric emptying
time. Conclusion: Our results suggest that decreased plasma ghrelin levels might be involved
in delayed gastric emptying time and loss of emptiness feeling in FD patients.
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M2204
Symptoms in Functional Dyspepsia (FD) and Irritable Bowel Syndrome
Patients with Dyspepsia (IBS+D) Are Correlated with Impaired Gastric
Relaxation Identified By Magnetic Resonance Imaging (MRI)
Ivo R. van der Voort, Marco Schmidtmann, Peter Kobelt, Hassan Abou-Rebyeh, Bertram
Wiedenmann, Hubert Monnikes
Impaired gastric relaxation has been proposed to be present in up to 40 % of patients with
FD using invasive barostat techniques. This technique itself might interfere with physiological
gastric function. The aims of this study were to compare postprandial (pp) gastric relaxation
and emptying in healthy volunteers, patients diagnosed with FD, and IBS plus dyspepsia
using the non-invasive technique of MRI, and to assess if altered gastric function is correlated
with dyspeptic symptoms. Material & Methods: Fifteen healthy controls (HC; 7 female,
mean age (MA) 36 yrs), 20 patients (10 female, MA 41 yrs) diagnosed with FD, and 20 patients
suffering from IBS and dyspeptic symptoms (IBS+D; 11 female, MA 38 yrs) underwent MRI
studies in supine position. Symptoms were assessed using the Nepean Dyspepsia Index
(NDI) and a gastrointestinal symptom questionnaire (GSQ). MRI sequences covering the
complete gastric region were performed before and after a liquid meal (500 ml, 500 kcal).
Gastric and meal volumes were measured up to 90 minutes pp and changes in gastric and
meal volumes calculated. Results: The NDI symptom scores in FD and IBS patients with
dyspepsia were significantly higher compared to HC (p<0.001), but were not different
between patient groups. The quality of life (QoL) score of the NDI was significantly higher
in both patients groups compared to HC (p<0.001), indicating a diminished quality of life.
The cumulative increase of gastric volume in the early pp phase was significantly lower in
FD and IBS+D compared to HC. Nine out of 20 patients (45 %) with FD and 6 out of 20
patients (30 %) with IBS+D showed no increase in pp gastric volume. In contrast, an increase
in the pp gastric volume was found in all HC. Patients with impaired gastric relaxation had
significantly higher dyspepsia scores in the GSQ (median: 78.5, range 68.0-94.0) and NDI
(median: 106.5, range 94.0-117.0) compared to patients with normal gastric relaxation
(median: GSI: 64.0, range 61.0-70.5, p=0.021; NDI: 72.0, range 59.0-91.5, p<0.001). The
increase in intragastric liquid volume in the early pp phase was significantly diminished in
FD and IBS+D. Overall gastric emptying, calculated as area under the curve, showed a
significantly delayed gastric emptying in FD compared to IBS+D and HC (ml/90min: FD=
213 ± 7, IBS+D=198 ± 6, HC=174 ± 7; p<0.05). Conclusion: The technique of MRI allows
to non-invasively identify alterations of gastric function in a subgroup of patients with
otherwise unexplained dyspepsia. Impairment of pp gastric relaxation as measured by MRI
is clearly accompanied with more severe dyspeptic symptoms FD and IBS plus dyspepsia.
M2205
Smartpill, a Novel Ambulatory Diagnostic Test for Measuring Gastric
Emptying in Health and Disease
Braden Kuo, Richard W. McCallum, Kenneth Koch, William D. Chey, John M. Wo,
Michael Sitrin, William Hasler, Jeffrey Lackner, Leonard Katz, Beverly Landrigan, Kathy
Selover, Alan Hutson, David Barthel, Jack Semler, Henry P. Parkman
Introduction: Gastric emptying scintigraphy (GES) using a radiolabeled solid phase meal,
is widely used to measure gastric emptying but the technique is non-ambulatory, involves
radiation and is performed variably. Recently an ambulatory wireless capsule SmartPill (SP)
which measures pH and pressure of the GI lumen when swallowed has been developed.
The rapid luminal pH change from acidic to alkaline marks the transit of the ingested SP
from the stomach into the duodenum. Aim: 1)To demonstrate the correlation between gastric
residence time (GRT) as determined by the gastric emptying of the SP and the gastric
emptying time of a radiolabeled meal in both healthy subjects and patients with documented
gastroparesis, 2)To demonstrate that GRT can discriminate between healthy subjects and
gastroparetics. Methods: In a multicenter study, simultaneous measurements of transit of
SP and GES was performed in 86 healthy subjects and in 60 patients with previously
diagnosed gastroparesis based on scintigraphy. SP was ingested after an overnight fast and
then GES was performed in a standardized fashion with imaging taken up to 6 hours after
ingestion of a 99mTc-SC radiolabeled meal (120 g Eggbeaters, 2 pieces of bread with jam;
255 kcal, 2% fat) and 120 cc water. Correlations between GRT and time to 50% emptying
(T-50%), time to 90% emptying (T-90%) were performed. Receiver operating characteristic
(ROC) curves were used to summarize the sensitivity and specificity in differentiating the
normal subjects from gastroparetic patients for the T-50, T-90%, and GRT. Results: The
correlation between GRT and T-90% emptying was 0.85±0.06 and for T-50% emptying,
0.66±0.15. The c statistic for the area under the ROC curve (AUC) assessing overall diagnostic
accuracy for classifying normals and gastroparetics for GRT was 0.83 (95% CI 0.74-0.87)
and for T-90%, 0.85 (95% CI 0.80-0.90), not statistically different from each other. The
AUC for T-50% was 0.77 (95% CI 0.70-0.83). The cut off point that maximizes both
sensitivity and specificity for T-90%, 182 min, gave a sens of 84.8% and spec of 77.9%,
whereas the cut off point for T-50% was 102, giving a sens of 71% and a spec of 74%. The
cutoff for GRT was 240 min, giving 85% sens and 72% spec. Conclusion: The GRT of the
SP has a high correlation with T-90% of scintigraphy suggesting that the GRT more closely
represents a time near the end of the emptying of a solid meal. The study demonstrates
that GRT of the SP was able to differentiate normals from gastroparetics similar to scintigraphy.
This study suggests that the SmartPill can be used as a novel ambulatory method for assessing
gastric emptying in health and disease.
M2206
Factors Associated with Gastric Dysrhythmias in Patients with Type 1
Diabetes and Without Dyspeptic Symptoms
Francesco De Giorgi, Clelia Verde, Lisa Faiella, Elisabetta Atteo, Riccardo Pascucci,
Giovanni Sarnelli, Giovanni Annuzzi, Angela Rivellese, Rosario Cuomo
Impairment of gastric function in diabetes has been attributed to autonomic neuropathy
(AN). Multichannel electrogastrography (EGG) is a non-invasive method to detect gastric
electrical activity (GEA). Type 1 diabetes occurring at early age allows to study GEA abnormal-
ities without interference of aging. Our aims are to study the presence of early GEA disturb-
ances in patients with type I diabetes and to test the correlation between GEA and glycaemia
levels, duration of disease and presence of AN. 37 patients with type-1 diabetes (17 m; 23-
54 y), diagnosed from more than 5 years, without dyspeptic symptoms, 34 dyspeptics (15
m, 20-51 y) and 10 healthy volunteers (7 m, 23-37 y) that served as positive and negative
controls were studied. After an overnight fasting, all subjects underwent multichannel EGG
study 30 min before and after a standard liquid meal (300 kcal). Pre and postprandial
percentage and power of normogastria (2-4 cpm), bradygastria, tachygastria and arrhythmias
were calculated by running spectral analysis. In diabetics AN was assessed by ECG beat-to-
beat variation analysis and lying-to-standing blood pressure variations. Dyspeptic symptoms
were assessed by a standardized questionnaire. Data were expressed as mean±SD. Diabetics
had a significantly higher rate of gastric arrhythmias than dyspeptics and controls during
the fasting phase (27±16%, 18±11 and 20±14, p<0.05) especially at the pace-maker recording
site. In a longer history of diabetes (>20 y) percentage of pre-prandial normogastria was
lower than in subjects with a history < 10 y (59±15 vs 79±15, p<0,01). Fasting glycaemia
> 200 mg/dl correlated with a higher percentage (8,4±5,9 vs 4,2±4,8, p<0,05) and power
(44,5±15,8 vs 33,7±15,3, p<0,05) of postprandial bradygastria. Presence of AN correlated
with lower fasting normogastria power (22±8 vs 33±17 p<0,05) and postprandial bradygastria
percentage (4,1±4,8 vs 10,9±6,5, p<0,001). We confirmed that gastric electric activity is
altered in diabetics. Type I diabetics without dyspepsia had gastric arrhythmias and increased
power of bradygastria. These events mainly occurred at the gastric pacemaker region and
were associated with disease duration, severity of hyperglycaemia and AN. Gastric
dysrhytmias precede dyspeptic symptoms appearance and probably represent an early gastric
neuromuscolar injury.
M2207
Gastric Emptying Response to Temporary Gastric Electrical Stimulation Is
Independent of Symptom Improvement But Dependent On Baseline Emptying
Thomas L. Abell, Anil Minocha, Nighat Abidi
Introduction: Gastric electrical Stimulation (GES) is an accepted therapy for drug refractory
gastroparesis, but its effect on gastric emptying is controversial. Patients: To examine the effect
of GES on GET we examined 140 consecutive patients undergoing temporary endoscopic GES
as previously described (GIE 2005: 61:455-461). Pts were 29 m, 111 f , mean age 41 yrs
with diagnosis (DX): 44 diabetes (DM), 14 post-surgical (PS) and 82 idiopathic (ID). Methods:
Symptom Assessment, Gastric emptying and EGG were evaluated at baseline and after
temporary endoscopic GES (mean 3 days of therapy). Patients at baseline were stratified
into 3 groups based on GET: Delayed, Normal and Rapid, as previously described (AJG
2004: 99: S41-42). Symptoms (SX) of nausea (N), vomiting (V), and total SX (TSS), and
GET were compared by paired t-tests and reported as mean values. Results: All patients had
Symptoms improvement, irrespective of their DX or baseline GET:( N: 3.5 baseline to 0.9
after; V: 2.5 to 0.6; TSS: 15.2 to 5.1, p< 0.0001 for all patients with similar changes in
subgroups.) There were no significant changes in GET for the whole patient group. However,
when stratified by baseline GET: the delayed group accelerated and the rapid group slowed
(see table). Conclusion: Temporary GES performed on patients with the SX of gastroparesis
shows an immediate symptom improvement, which is independent of baseline GET. The
effect of temporary GES on gastric emptying is dependent on baseline emptying, with
improvements seen in both delayed and rapid gastric emptying sub-groups. Investigations
into the effect of electrical stimulation on gastric emptying need stratification for baseline
gastric emptying.
M2208
Effects of Erythromycin and Tegaserod On Upper Gut Motility - A
Comparative Study
Issam Nasr, Askok Attaluri, Konrad Schulze, Robert Summers, Satish Rao
BACKGROUND & AIM: Both Erythromycin and Tegaserod are increasingly used for their
prokinetic effects on the upper gut. To date, the effects of these agents on the stomach,
duodenum and jejunum have not been directly compared. Our aim was to assess and
compare the effects of Erythromycin and Tegaserod on upper gut motility in an open label
study. METHODS: 22 patients (M/F = 4/18; mean age = 37 yrs) with upper gut dysmotility
underwent 24 hour manometry using a 6 sensor solid state probe, with 2 sensors located
in each of the antral, duodenal and jejunal segments. On day 1, in the fasted state, all
patients received 125 mg of intravenous Erythromycin Lactobionate, and on day 2, 12 mg
of oral Tegaserod. Baseline (30 min prior to drug) and post-drug motility changes were
analyzed (Erythromycin for 90 min, Tegaserod for 180 min) by measuring the Area Under
the Curve (AUC) of pressure waves at each sensor and by examining motor patterns.
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RESULTS: Both drugs increased motor activity in all 3 segments compared to baseline
period (table), but after Erythromycin the motor response was significantly higher (p<0.05)
in the antrum and occurred within the first 30 min , whereas after Tegaserod it was
higher (p<0.05) in the jejunum and occurred during the 2nd and 3rd hours. Following
Erythromycin, large amplitude (> 100 mmHg) antral contractions at 3 cycles/min were seen,
whereas after Tegaserod a ‘fed-response’ like pattern was seen. Following Erythromycin and
Tegaserod, Phase III MMCs were seen in 12(55%) and 10(41%) patients, respectively (p>
0.05). CONCLUSIONS: Both drugs increase upper gut motility, and induce MMC’s, but
exert a differential response. Erythromycin predominantly increases antral motor activity
but its effect is short lived, in part because the drug was given intravenously. In contrast,
Tegaserod induces a more pronounced prokinetic effect in the jejunum and causes a more
sustained increase in upper gut motor activity.
M2209
Characteristics of Symptoms and Functional Gastric Tests in Patients Referred
for Electrogastrography (EGG)
Deborah M. Bethards, Lihua Xu, Kwangmi Ahn, Kenneth L. Koch, Ann Ouyang
The association between symptoms (Sx) and tests of gastric function remains unclear. The
aims of this study were to determine whether specific clinical presentations and the history
of gastroesophageal reflux disease (GERD) were associated with gastric emptying (GET) or
electrogastrogram (EGG) parameters. Charts of 163 patients (39 M,124 F) who underwent
both GET and EGG were reviewed for the clinical Sx of nausea, pain, vomiting, bloating
and altered bowel habits as well as weight and diabetes. Sx were scored as absent/mild or
moderate/severe. The GET at 1 hr and 2 hr, the EGG final diagnosis as well as the percent
power in the frequencies 1-2.5 cpm, 2.5-3.75 cpm, 3.75-10 cpm and 10-15 cpm at baseline
and volume of water tolerated during the water load test during the EGG were noted. Data
is reported as median, 5-95 percentile. Comparisons were performed using the Wilcoxon-
Mann-Whitney and Chi-Squared tests. Results: Women(F) complained of pain more than
men (M) and more men had altered bowel habits. Sx complaint data F:M: Pain 70%:43%
(p=0.003), Nausea 89%:85%, Vomiting 58%:54%, Bloating 46%:31%, Normal bowel habits
43%:23% (P=0.02). Women weighed less than men and drank less during the water load
test (480 vs 604 ml, p=0.001). Gastric emptying was slower in women than men: at 2 hr
the % emptied was 63%, 7-97, (median, 5-95 percentile) in women and 78%, 27-99, in
men, p<0.001. There was no major difference in EGG diagnoses between women and men.
When comparing diabetic patients vs nondiabetic, diabetic patients were older (52 vs 42,
p<0.01) and weighed more (187 lb vs 146 lb, p<0.0001). Nondiabetics had more normal
baseline EGG frequency spectra with a tendency towards baseline bradygastria in diabetics.
Overall, the Sx of pain was associated with a lower volume of water tolerated on water load
test, 450ml, 150-750 vs 600 ml, 250-750, p=0.002. The Sx of pain was associated with
delayed gastric emptying at one hour but the relationship did not persist when adjusted for
gender. No association between the other Sx and GET was noted. No Sx complaint was
associated with any specific final EGG diagnosis. As expected, a complaint of GERD was
associated with greater weight (156 lb vs 140 lb, p<0.05) but not with a greater delay in
GET or any specific EGG characteristics. Conclusions: Gastric emptying was slower in women
than in men. Pain was a more common presentation in women in the patients referred for
study and the association of pain with a lower tolerated water load volume suggests that
this symptom is related to an abnormal sensory process. These finding suggest a different
therapeutic approach to patients in whom pain is a major complaint.
M2210
Pathophysiological Studies of Gastrointestinal Manifestations of Addison’s
Disease
Hubert Piessevaux, Dominique Maiter, Yves Horsmans
Background: Upper GI symptoms are frequent in Addison’s disease. The mechanism leading
to these symptoms is unknown. Aim: To study upper GI motor physiology in patients with
Addison’s disease before and after chronic glucocorticoid replacement therapy. Patients and
methods: Three patients (A: F 42y; B: M 25 y; C: M 42 y) recently diagnosed with Addison’s
were studied in our motility lab. Esophageal manometry, 24-hour small bowel manometry,
gastric emptying and gastric barostat studies were performed before and after initial replace-
ment therapy as accepted by the patients. Results: Esophageal manometry (n=2:A&B) showed
severely decreased wave amplitudes (12 +/- 5 mmHg) when peristaltism was still present
(20% of swallows). The LOS resting pressure was normal (17 and 12 mmHg respectively)
and relaxation was complete. After substitution both studies were completely normalized.
Small-bowel manometry (n=1:A) showed reversible antral hypomotility, with normal conver-
sion to the fed pattern. Scintigraphic gastric emptying studies (n=3) showed completely
reversible severe gastroparesis (mean t1/2 for solids 243 min). Gastric barostat (patient B&C)
showed normal sensitivity to distension and defective accommodation. No control study
was performed. Conclusions: Myogenic motor abnormalities of the upper GI tract may be





















Electrogastrography Is of Limited Value in the Diagnosis of Motility Disorders
Shahab Abid, Greger Lindberg
Electrogastrography (EGG) is a technique for recording gastric myoelectric activity. Con-
flicting results were obtained in previous studies when EGG was applied in motility disorders
of the stomach associated with various systemic diseases. Aim of the study. To investigate
whether the underlying diagnosis or the presence of symptoms could be predicted from
EGG parameters. Material and methods. This is a retrospective analysis of patients with
motility disorders who underwent EGG as part of their clinical work-up. A single bipolar
channel measured the EGG. The ability of EGG to identify diagnostic groups and epigastric
symptoms was tested by comparing EGG parameters for each diagnostic group or symptom
against all other patients in the sample. Results. A total of 151 patients, 125 (83%) females,
mean age 45±14 years were analysed. There were 52 patients with irritable bowel syndrome
(IBS), 22 with enteric dysmotility, 26 with slow transit constipation (STC), 11 with chronic
intestinal pseudo-obstruction (CIP), 13 with gastroparesis or functional dyspepsia, 3 post-
surgical, and 24 patients with other diagnoses. In general, the discriminatory power of EGG
for underlying motility disorder was low. Only those with STC showed a reasonable number
of differences in EGG parameters compared to all other groups (Table). Patients with IBS
had lower fasting and postprandial variability of the dominant frequency (DF) and a higher
percentage of postprandial time with normogastric DF and those with CIP had higher power
in normal and tachygastric ranges during fasting and a higher fasting period dominant
power. Among the symptoms, vomiting was associated with a higher postprandial normal
power (4.2±0.6 vs. 3.9±0.5), a higher postprandial period dominant power (2.6±0.7 vs.
2.3±0.5) and a lower postprandial percentage in bradygastric range. Conclusion. The ability
of EGG to identify motility disorders as well as symptoms in general was poor. EGG findings
in patients with STC require validation.
Significant EGG variables in slow transit constipation (STC) and other diagnoses
DF = dominant frequency; DFIC = dominant frequency instability coefficient; PDP = period
dominant power; § = log values; † = median (range)
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M2212
The Role of Gastric Sensorimotor Dysfunction in Gastrointestinal Symptoms
and Energy Intake in Liver Cirrhosis
Evangelos Kalaitzakis, Magnus Simren, Hasse Abrahamsson, Einar Bjornsson
Altered gastric sensorimotor function is related to the symptomatology in several gastrointesti-
nal (GI) diseases. GI symptoms in liver cirrhosis may result in low energy intake contributing
to malnutrition and increased morbidity. We aimed to investigate gastric accommodation
to a meal and sensitivity to gastric distension with reference to energy intake, nutritional
status and GI symptoms in cirrhosis. Methods: 16 cirrhotics (median age 56 (IQR 48-61);
3 female; 7 with alcoholic cirrhosis; 3 with mild ascites; Child-Pugh score 7(6-9); MELD
score 9.5 (7.5-13.8) underwent a gastric barostat to assess gastric accommodation to a caloric
200ml-drink. Gastric accommodation was expressed as the difference of the area under the
time-volume curve between the post- and pre-prandial periods. Sensory thresholds for first
perception and discomfort were evaluated. Patients underwent also a satiety drinking test,
where a caloric drink (1.5kcal/ml) was ingested at a constant rate, 15ml/min, until maximal
satiety. A validated questionnaire was used to measure GI symptoms in cirrhotics. Energy
intake was assessed by a dietary diary and nutritional status by anthropometry and estimation
of weight loss in the previous 6 months. 15 healthy subjects (age 52 (49-62); 5 female) served
as controls. Results: Cirrhotics compared to controls had increased gastric accommodation
(1985ml×min (1337-2776) vs. 1025ml×min (353-2137);p<0.05) but lower daily energy
intake (21kcal/kg (15-29) vs. 26.5kcal/kg (24.5-37.5);p<0.05). Patients with vs. without
compromised nutritional status had increased gastric accommodation (2776ml×min (2197-
3605) vs. 1813ml×min (692-2451);p<0.05). Gastric accommodation was related to daily
energy intake in controls (r=0.67,p<0.05) but not in cirrhotics (r=0.2;p>0.4). The endpoint
of the satiety test was inversely related to gastric volumes before (r=-0.7, p<0.005) and after
the meal (r=-0.55,p<0.05) in cirrhotics. Mean postmeal gastric balloon volumes were related
to the Child-Pugh (r=0.57, p=0.026) and MELD (r=0.61, p=0.017) scores. Sensory threholds
did not differ between patients and controls (p>0.05). In cirrhotics, discomfort thresholds
were inversely related to GI symptom severity (r=-0.63,p=0.01), and the Child-Pugh (r=-
0.64,p<0.01) and MELD (r=-0.54,p<0.05) scores. Conclusion: Gastric accommodation is
increased in cirrhotics compared to controls and its relation to energy intake seems to be
disturbed. The satiety drinking test is not a good surrogate marker of accommodation in
cirrhotics. In cirrhosis gastric sensitivity is related to severity of GI symptoms and cirrhosis
severity indices.
M2213
Management of Patients with Constipation Within a Physician Group Setting
Allison Egger, Vickie Andros, Ken Wong, Annamaria Cerulli, Vipin Popat
Background: Constipation affects up to 27% of North Americans and has been shown to
significantly reduce patient quality of life. The objectives of this study were to assess the
characteristics of patients with constipation and examine the management of patients with
this condition in a physician group setting. Methods: Retrospective claims data and medical
record review of patients with constipation was conducted at 3 large physician group practices
consisting mostly of primary care physicians. A random sample of 300 patients per group,
between the ages of 18-79, were identified through outpatient billing records using Interna-
tional Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes
from June 2003 to July 2004. Subsequent medical record review was conducted; data
collected included patient demographics, specialist referral, other gastrointestinal (GI)-related
symptoms, GI-related procedures, and treatment. Patients were excluded from the review
if they were deceased, had received treatment with tegaserod, or had a primary or secondary
claim for intestinal tract infections, malignancies, inflammatory conditions, or history of
malabsorption in the previous 12 months. Results: A total of 738 patients were identified
with constipation and were eligible for medical record review. Mean patient age was 51.4
years; 67.8% of patients were female. Physician-confirmed diagnosis of constipation was
noted in 74% of the medical records versus outpatient billing claims; however, 1 physician
group had confirmed diagnosis in only 26.5% of medical records. Almost half of patients
(42%) were referred to a GI specialist; of these, 76.2% had constipation diagnosis confirmed
in their chart. Patients reported having 2 other GI-related symptoms on average; abdominal
pain was the most commonly reported GI-related symptom (48%). Other symptoms included
straining (26.2%), gastroesophageal reflux disease-related (19.5%), and bloating (19.2%).
Patients underwent 1 GI-related procedure on average; colonoscopy was the leading GI-
related procedure in 26.7% of patient records, followed by pelvic and/or abdominal radiology
imaging (19.5%) and computed tomography (12.9%). Thirty-four percent (n=251) of patients
had at least 1 constipation-related office visit in the previous 12 months. No documentation
of drug use was available in 64.8% of patients’ records. Conclusions: Our study found
physician documentation of constipation may vary by physician group. Patients reported
multiple GI-related symptoms; 48% reported abdominal pain. The variety of GI-related
symptoms reported indicates that treatment of constipation may require a multi-symptom
approach
M2214
A Multi-Component Model Can Predict Gastric Emptying in Diabetic
Gastroparesis
Naeem Aslam, Hani Rashed, William D. Johnson, Thomas L. Abell
Introduction: We have previously reported that a multi-component model of autonomic
and enteric factors can help predict gastric emptying in diabetes mellitus. Patients: We studied
87 patients (38 males,49 females; mean age 39 years) with Diabetes Mellitus presenting with
signs and symptoms of Gastroparesis. Methods: We profiled the patients by autonomic
nervous sytem testing including adrenergic tests by VC (vasoconstriction to cold) and PAR
(postural ratio), and cholinergic tests by EKG R to R interval (RRI). The enteric nervous system
measure (EGG) was measured by cutaneous electrogastrography. (Previously described: DDS,
1999; 44:74-78). These data were compared to results of standardized solid gastric emptying
reported as T50. Results: Patients were distributed in 5 groups based on gastric emptying
time (GET): 28% very delayed, 15% delayed, 22% normal, 17% rapid and 18% very rapid.
There were statistically significant differences among the 5 group means for VC and RRI
but not for EGG and PAR.(See table). Conclusions: A multi-component model demonstrates
specific autonomic and enteric differences in subgroups of diabetic gastroparesis. Therapies
for diabetic gastroparesis, including drugs and devices, may need to take into account these
physiologic differences when looking at therapeutic outcomes.
Means
M2215
A Novel Method for the Assessment of Gastric Motility in Patients Using
Wireless Capsule Endoscopy
Kishore Gaddipati, Henry Parkman, Benjamin Krevsky
Wireless capsule endoscopy (WCE), first FDA approved in August 2001 for diagnosis of
obscure GI bleeding, is being increasingly used for the evaluation of esophageal, gastric,
and small intestinal pathology. However, WCE has not been used previously to assess gastric
motility. The aim of this study was to determine if WCE could be used as an investigative
and perhaps clinical modality to simultaneously image and quantitate gastric motility.
Methods: We analyzed gastric contractile activity on a retrospective basis by reviewing 25
WCE recordings performed between 2003-2005 (PillCam™ SB, Given Imaging). No patients
were known to have a gastric motility disorder. Periods of fasting gastric slow wave activity
were identified by searching for repetitive contraction patterns of greater than 3 complete
cycles in length. The length and frequency of the cycles, % of gastric imaging time with
recognized slow wave activity, and esophageal, gastric, and small bowel transit times were
determined. A second observer reviewed several cases to determine interobserver variability.
Results: 7 males and 18 females were evaluated; mean age = 63 years. All subjects underwent
WCE for the evaluation of occult GI bleeding. Two of the patients were diabetic. The capsule
remained >8 hours in the stomach in 2 patients and did not reach the small intestine in 2
patients. For the remaining 21 patients the average gastric contractile activity was 3.1±0.1
(mean±SEM) cycles/min (cpm), with a range of 2.4 to 5.5 cpm. The gastric contractile
activity constituted 24.9±3.7% of the overall gastric transit phase. Average esophageal transit
time was 141±60 sec, gastric transit time was 21.7±3.9 min, and small bowel transit time
was 3.9±0.3 hr. These transit times excluded patients with gastric (2) and small bowel (2)
capsule retentions. No obvious gastric or small bowel MMC activity was identified. The
average cycles/min determination for the 2 observers differed by less than 4% (NS). Conclu-
sions: This is the first report of the assessment of gastric contractile activity using wireless
capsule endoscopy. The average fasting periodic contractile activity in our subjects was 3.1
cpm, which correlates well with established values of 2.7 - 4.2 cpm in healthy individuals
as determined by electrogastrography. Wireless capsule endoscopy may have a novel applica-
tion as a complimentary test to scintigraphic emptying tests, manometry, and electrogastrogra-
phy in the evaluation of gastric dysmotility. It permits a quantitative analysis of fasting
contractile and emptying activity with simultaneous endoscopic imaging using a minimally
invasive modality.
M2216
Acute Cold Stress Impairs Postprandial Gastric Accommodation in Healthy
Humans
Maria Maluenda, Jordi Serra, Fernando Azpiroz, Juan R. Malagelada
Patients with functional dyspepsia often complain that postprandial symptoms are precipit-
ated or worsened by stress. Previous studies have shown that either nutrients or stress alone
induce reflex relaxation of the stomach, but the interaction of concomitant nutrients and
stress is unknown. Thus, our present aim was to establish the effect of acute stress on
nutrient-induced gastric relaxation. METHODS. In 8 healthy subjects (3 female, 5 men)
gastric tone variations were quantified as isobaric volume changes using a barostat. Gastric
tone was monitored: a) during a 15-min basal period; b) during a 30-min duodenal nutrient
infusion mimicking normal gastric emptying (Ensure® 2 Kcal/min) and c) during duodenal
nutrient infusion plus two consecutive periods of either cold stress or sham stress, applied
in random order (hand immersion in 4° C or 30° C water for 10 min, respectively). RESULTS.
During basal recording, intragastric volume showed minimal variations (-10±7 % volume
change after 15 min; NS). Nutrient infusion was followed by a progressive relaxation of the
stomach, that reached its maximum after 20 min (volume increased by 200±57 ml; p<0.05
vs basal), and thereafter plateaued (-10±15 % volume change; NS). Application of cold
stress during duodenal nutrient infusion produced an immediate contraction of the stomach
that after 2 min had completely blocked the nutrient-induced gastric relaxation (volume
reduced by 205±44 ml; p<0.05 vs nutrients alone), remaining steady thereafter (10±35 %
volume variation; NS). Sham stress (hand immersion at 30° C ) induced no significant effects
on gastric tone (volume reduced by 85±50 ml; NS vs nutrients alone). CONCLUSION.
Acute cold stress antagonizes the response of the stomach to nutrients, resulting in defective
gastric accommodation. These observations may have important pathogenetic implications
in patients suffering from functional dyspepsia.
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M2217
Influence of Naloxone On Gastric Sensitivity and On Gastric Response to a
Meal in Health
Brecht Geeraerts, Lukas van Oudenhove, Rita Vos, George Karamanolis, Jan Tack
BACKGROUND: It has been suggested that failure of descending anti-nociceptive pathways
(with opioids as the main candidate neurotransmitters) contributes to the pathogenesis of
functional disorders, including functional dyspepsia (FD). Barostat studies of the proximal
stomach have revealed hypersensitivity to gastric distension and impaired accommodation
to ingestion of a meal in FD. The AIM of the present study is to investigate the effect of
suppression of endogenous opioid action by naloxone on the sensorimotor function of the
proximal stomach in normal volunteers. METHODS: Ten healthy subjects (mean age 29.0±1.7
years) participated in a placebo-controlled, double blind, and randomized gastric barostat
study to assess sensitivity to distension and meal accommodation. Two stepwise distensions
(2 mmHg steps at 2 minute intervals, until discomfort or pain) separated by 30 minutes of
adaptation were followed by 90 minutes of gastric tone measurement. Thirty minutes after
the second distension a standardized meal (Nutridrink®, 200ml, 300kcal) was ingested.
Continuous infusion of saline or naloxone (20 µg/kg/h after 0.4 mg bolus) was started 15
minutes before the 2nd distension.. Perception during distensions was scored on 0-6 graded
scales (0=no sensation, 6=maximal) and VAS scales were used to quantify individual dyspeptic
symptoms. RESULTS: Naloxone did not influence gastric compliance (43.5±5.3 vs. 46.4±6.4
ml/mmHg, NS) and sensitivity to gastric distension compared to saline. Consequently, the
pressures needed to induce first perception (score=1) (11.7±0.9 vs. 12.4±1.0 mmHg, NS)
or discomfort (score ≥5) (19.7±1.0 vs. 19.2±0.9 mmHg, NS) and corresponding intra-
balloon volumes (respectively 218±46 vs. 319±66 and 565±74 vs. 643±71 ml, NS) did not
differ between saline and naloxone. Naloxone did alter VAS scores for pain or discomfort
(AUC respectively 22.2±9.9 vs. 24.5±9.2 and 37.8±11.4 vs. 43.1±11.0 mm*mmHg, NS).
Naloxone did not alter preprandial gastric volumes (202±20 vs. 203±33 ml, NS), but gastric
accommodation to a meal (volume increase after the meal) was significantly lower during
naloxone compared to placebo (two-way ANOVA for repeated measures, p=0.001). The
intensity of epigastric symptoms after meal intake did not differ between placebo and saline.
CONCLUSION: In healthy subjects, naloxone does not alter gastric compliance or sensitivity
to distension, but inhibits gastric accommodation to a meal. These observations suggest that
the endogenous opioid system is involved in control of gastric tone rather than sensitivity.
M2218
Multi-Channel Electrogastrography (MEGG) in Patients with Functional
Dyspepsia
Weihong Sha, Nonko D Pehlivanov, P Jay Pasricha, Jiande Chen
The aim of this study is to assess differences in gastric slow waves measured by a newly
approved multi-channel electrogastrogram (MEGG) device between patients with functional
dyspepsia and healthy controls. Materials and Methods: 64 patients (20M, 44F, mean
age 46.1, Range 14-79) with functional dyspepsia were assessed for severity of upper
gastrointestinal symptoms. Gastric myoelectrical activity of this group of patients and 16
health volunteers (8M, 8F, mean age 40.9. range 20-68) was measured by surface multi-
channel electrogastrography for one hour in the fasting state and for two hours after a solid
meal (Turkey sandwich-450 cals.). Computerized spectral analysis methods were utilized
to compute the following EGG parameters in the fasting and fed state: dominant frequency
(DF)/power (DP), % of 2-4 cycles/min slow waves, %of tachygastria, %of bradygastria, %of
arrhythmia and slow wave coupling. Common gastrointestinal symptoms were assessed for
symptom severity and graded. Results: 1) EGG was abnormal in 70.3% of patients. Response
to the test meal was abnormal (a decrease in dominant power) in 32.8% of patients. 2)
Compare with the controls, the patients had a significant decrease in % of normal slow
waves and a significant increase in % of tachygastria both in fed state. No significant difference
was recorded in any other EGG parameters. 3) The response to the test meal was similar
between the controls and patients. That is, postprandially, there was a significant increase
in DF and DP, but no significant changes in %of normal slow waves, %of dysrhythmias or
slow wave coupling. 4) This group of patients had high symptom scores particularly to
nausea, upper abdominal pain and bloating, with an average symptom score of 2.5/4 for
nausea; 2.3/4 for upper abdominal pain and 2.1/4 for bloating. The mean total score was
21/52 for all symptoms. However, no significant correlation was noted between the EGG and
the symptoms. Conclusions: EGG is abnormal in most FD patients. Postprandial percentage of
normal slow waves and postprandial percentage of tachygastria are more sensitive than other
parameters of EGG in distinguishing FD patients from healthy controls.
M2219
Measurement of Changes in Intragastric Pressure During Air Insufflation in
Patients with Functional Dyspepsia - Evaluation of Gastric Function Using a
Pharmacological Load
Tsuyoshi Suzuki, Masanori Hirano
(Aims)Visceral hypersensitivity and impaired gastric relaxation are thought to play a part
in functional dyspepsia (FD). We previously reported that visceral hypersensitivity and
impaired gastric relaxation were readily assessed through the measurement of changes in
intragastric pressure (IP) during air insufflation as part of upper gastrointestinal tract endos-
copy (UGITE) (JIMR 33(2),160-9,2005). In this study, we further examined the effects of
the administration of antispastic agents to patients with FD. (Methods)The 30 FD patients
and 18 healthy controls were enrolled. During UGITE, we induced gastric distension by air
insufflation with epigastric symptoms, and measured IP using a pressure transducer intro-
duced through the instrument channel. The parameters calculated were basal IP (mmHg),
IP at onset of symptoms (threshold value:mmHg), time to reach threshold value (sec) and
rate of increase in IP (mmHg/sec): (0-5 mmHg gradient and 5-10 mmHg gradient). A
pharmacological load was administered in the form of atropine sulfate (0.5 mg) to 3 controls
and 3 FD patients, scopolamine hydrobromide (20 mg) to 4 controls and 6 FD patients,

















was detected between the control and FD in basal IP, pressure at threshold (21.5 vs 26.6
mmHg) and time to threshold (45.0 vs 66.5 sec, P=0.002) tended to be lower in the FD
than in the control group. The rate of increase in IP tended to be higher in the FD than in
control for both the 0-5 mmHg and 5-10 mmHg gradients (0.52 vs 0.33 mmHg/sec and
0.30 vs 0.19 mmHg/sec). 2) Pharmacological load (i) The time to threshold tended to
decrease in control, and increase in the FD, following the atropine load. (ii) The rate of
increase in IP tended to be lower in both groups following the scopolamine load. The time
to threshold was unchanged in control, but tended to be longer in the FD (from 45.8 to
52.6 sec). (iii) The rate of increase in IP tended to be lower in both groups following the
glucagon load at the 0-5 mmHg gradient. The time to threshold was unchanged in control,
but tended to be longer in the FD (from 44.2 to 55.4 sec). (Conclusions) We attempted to
evaluate of gastric function using a pharmacological load during air insufflation, finding
different responses to antispastic agents in control and FD. Furthermore, the response to
an atropine load was different to those to the other two agents in FD.
M2220
Evaluation of Gastrointestinal Motility in Vivo Using Fluoroscopy
Kent C. Williams, Robia G. Pautler, Norman Weisbrodt, Margaret E. Conner
Currently, evaluation of gastrointestinal motility often utilizes invasive or ex-vivo methodolo-
gies that are not feasible for many models and limit longitudinal analyses of motility. In
light of this, we tested whether fluoroscopy was useful to measure gastrointestinal motility
in vivo in control and rotavirus infected mice. Neonatal (12 day) and adult (6-8 week) CD-
1 mice were inoculated with murine ECwt rotavirus or media. Gastrointestinal motility was
evaluated at 0, 2, and 4 (adult) or 0 and 2 (neonatal) days post inoculation. To study
motility in vivo, mice were gavaged with barium, digital images of the gastrointestinal tract
were obtained with a C-arm fluoroscopy unit, and rates of contraction and changes in
stomach sizes were determined by image analysis. To measure rates of intestinal contraction
in vitro, whole sections of intestine were mounted in organ baths using standard procedures
and analyses. In adults, rates of contraction in the stomach and small intestine of rotavirus
infected mice (n=5) did not vary significantly from the controls (n=4) at any time point
with either method. However, the average rate of intestinal smooth muscle contractions
measured in vivo (40.5 ±3.9 contractions/min.) was slightly less than that recorded in vitro
(45.9 ± 5.4 contractions/minute; n=8). In neonates, rates of intestinal contractions measured
by either method were not significantly different between control and rotavirus infected
mice, but similar to the adults the in vivo rates of intestinal contraction (28.7 ± 2.4 contrac-
tions/min., n=8) were slightly less than measured in vitro (35.9 ± 2.0 contractions/min., n=
10). Of note, the basal rates of contraction determined by both methods differed significantly
between neonatal and adult mice. Gastric contractions were rarely observed in neonates but
visible differences in the amount of barium leaving the stomach and entering the small
intestine in control and rotavirus infected mice were noted. Therefore, gastric size was
determined in fluoroscopic images as a measure of gastric emptying. A significant difference
in initial gastric size (64.7±14.5mm2 vs 52.2±6.5mm2) (p=0.009) and change in gastric
sizes over 5 minutes (2.6±1.6mm2 vs 8.5±3.5 mm2) (p=0.0005) were observed in rotavirus
infected (n=10) compared to control neonates (n=8). Rotavirus infection did not alter gastric
contraction rates but did delay gastric emptying in neonates. Fluoroscopy and digital image
analysis provided a reliable and accurate method to detect differences in gastrointestinal
motility in vivo. This work was partially supported by the Texas Gulf Coast Digestive
Disease Center.
M2221
Meal Related Dyspeptic Symptoms in Healthy Subjects: Association with
Gastric Motor Function and Clustering of Symptoms
Guru Iyngkaran, Birgit Adam, Tobias Liebregts, F Dylan Bartholomeusz, Max Bellon,
Jacob Bolwell, Suresh Sivanesan, Nicholas J. Talley, Gerald Holtmann
Introduction: Little is known about the association between symptoms and gastric motor
function during the ingestion of a meal. We hypothesized that a) in healthy subjects meal
related symptoms are associated with delayed gastric emptying and impaired gastric nutrient
distribution (i.e. due to impaired fundic relaxation), b) factor analysis will separate meal
induced dysmotility-type and ulcer-type symptoms. Methods: 14 healthy subjects (8 males,
aged 21- 45 mean 27.3) without a history of relevant dyspeptic symptoms were recruited.
After at least an 8 hrs fast, they received every 5 minutes 200 ml of a standardized 99mTc-
labelled enteral feeding solution (EnsureR) up to a cumulative volume of 800mL. After each
200 ml drink, symptoms were assessed with the Adelaide-Dyspepsia-ToolR (ADT). This tool
assesses 7 key symptoms (fullness, abdominal pain, retrosternal/abdominal burning, nausea,
regurgitation, other) and determines peak and cumulated symptom response. The gastric
nutrient distribution and emptying was assessed with a gamma camera. Data analysis: The
cumulated symptom response during the 240 minute meal and post meal period was
calculated separately for all symptoms. In addition, the time from the start of nutrient
ingestion until the peak of symptoms was determined. Non parametric correlations were
utilized to assess the association between symptoms and gastric emptying parameters. Factor
analysis with varimax rotation was used for the categorization of symptoms. Results: The
average peak of symptoms was different for the various symptoms (50 minutes for pain, 22
minutes for fullness, 18.1 min for nausea, 18.3 min for burning and 26.7 min for regurgita-
tion). Maximal pain was significantly correlated to maximal fullness (r=0.57, p = 0.03) and
cumulative fullness (r=0.60, p=0.02) but not with gastric retention at 100 minutes. Cumulat-
ive fullness was linked to gastric retention at 100 min (r=0.64, p= 0.01). Factor analysis
addressing the maximum symptom intensity revealed a three factorial model. While pain,
fullness and nausea loaded on one factor (35 % of variance), epigastria and retrosternal
burning (21.6 % of variance) and regurgitation (18.8 % of variance) loaded on separate factors.
Conclusions: Based upon these experiments in healthy subjects, meal related symptoms can
be categorized into three categories: 1) pain, fullness and nausea, 2) retrosternal and epigastric
burning and 3) regurgitation. Severity of symptoms appears inversely associated with the
gastric emptying rate and lag time. The data suggest that the spectrum of meal related
symptoms consists of distinct domains that are linked to different underlying mechanisms.
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M2222
Comparison of Gastric Emptying Time and Plasma Ghrelin Levels in Patients
with Functional Dyspepsia and Non-Erosive Reflux Disease
Tomotaka Shindo, Seiji Futagami, Tetsuro Hiratsuka, Tatsuhiko Hamamoto, Nobue Ueki,
Yoko Shinji, Masafumi Kusunoki, Ken Wada, Kazumasa Miyake, Katya Gudis, Taku
Tsukui, Katsuhiko Iwakiri, Choitsu Sakamoto
(Background/Aims) Reports have shown that NERD (Non-Erosive Reflux Disease) is not just
a milder form of erosive GERD, but rather to have its own pathogenesis under the control
of various independent mechanisms; including visceral hypersensitivity, prolonged contrac-
tion of the esophagus and distention of the upper stomach. However, there have been no
clinical studies regarding the association between gastric motility and NERD. Therefore, we
analyzed gastric emptying time and plasma ghrelin levels, a possible candidate factor for
gastric motility in NERD patients, and compared data with that of patients with functional
dyspepsia (FD). (Material and Methods) 30 patients with FD, 28 patients with NERD, and
30 healthy controls were consecutively enrolled according to Rome II criteria after upper
gastrointestinal endoscopy. In this study, diagnosis of NERD was based on typical reflux
symptoms of 12 weeks duration within a one year period, despite the lack of endoscopically
detectable mucosal lesions. Gastric motility in the three groups was evaluated by gastric
emptying time (T-max) using the 13C-acetate breath test, and partly assessed by abdominal
ultra-sonography. We also evaluated upper abdominal symptoms, and depression based on
SRQ-D scores. Plasma levels for both acylated and desacylated ghrelin were measured by
ELISA method. (Results) Gastric emptying time was significantly delayed in FD patients
versus healthy controls (62.4±4.1 vs. 46.2±0.65 min, p<0.05). Although gastric emptying
time in NERD patients (51.46±4.7) was either delayed or shortened compared to healthy
controls and FD patients, respectively, the differences were not significant. SRQ-D scores
for FD and NERD patients (10.7±2.5, 12.3±2.3, respectively p<0.05) were significantly
higher than for healthy subjects. However, there was no significant difference in SRQ-D
scores between FD and NERD patients. BMI for NERD patients (22.3±2.1) was near the
level of that of FD patients (20.4±2.4). 51% of FD patients versus 14% of NERD patients
had delayed gastric emptying time. Plasma acylated ghrelin levels in FD patients with delayed
gastric emptying time was significantly decreased compared with that in FD patients with
normal gastric emptying time. In contrast, acylated ghrelin levels in NERD patients were
the same levels as in healthy subjects. Conclusions: Our results suggest that in a subset of
NERD patients delayed gastric emptying might be associated with the occurrence of symp-
toms.
M2223
Anatomical Evidence of Region Specific Effects of Acupuncture On Rat Gastric
Motor Function
Masahiro Iwa, Megumi Matsushima, Theodore N. Pappas, Mineko Fujimiya, Toku
Takahashi
Background; Acupuncture has been used for gastric diseases, such as functional dyspepsia
(FD) and diabetic gastroparesis. However, the mechanisms of acupuncture in affecting gastric
function remains unknown. Our previous functional studies suggest that acupuncture at
the lower limbs stimulates gastric motility via vagal cholinergic pathways (Am J Physiol 285,
R862-72, 2003), while acupuncture at the abdomen inhibits gastric motility via sympathetic
pathways in rats (Dig Dis Sci, 48, 59-68, 2003). To obtain the anatomical evidences of
possible neural pathway in mediating acupuncture-induced gastric motor responses, we
studied c-Fos immunohistochemistry of the brain stem in response to electroacupuncture
(EA) in rats. Methods; Acupuncture needles were inserted at the bilateral acupoints of ST-
36 (lower limb) or ST-25 (abdomen) and needles were stimulated by electricity (0.1 msec,
1 mA and 2 Hz) for 30 min in conscious rats. Non EA-treated rats served as controls.
Immediately after EA, rats were transcardially perfused with 0.01 M PBS and 4% paraformal-
dehyde for 10 min. The brainstem was removed from the skull, immersed for 24 hours in
the post fixative. The brainstem was cut into 20 μm coronal sections by a cryostat. The
sections were incubated in c-Fos antibody at 4 °C for 1 week. The total number of c-Fos
immunoreactive cells was counted in the dorsal motor nucleus of the vagus (DMV), the
nucleus tractus solitarius (NTS) and the rostral ventrolateral medulla (RVLM). Results; EA
at ST-36, but not ST-25, significantly increased the number of c-Fos immunopositive cells
at the DMV to 8.1 +/- 0.4 cells/section, compared to that of controls (1.8 +/- 0.3 cells/
section) (n=3, P<0.05). EA at ST-25, but not ST-36, significantly increased the number of
c-Fos immunopositive cells at the RVLM to 9.9 +/- 0.7 cells/section, compared to that of
controls (5.1 +/- 0.3 cells/section) (n=3, P<0.05). EA at ST-36 also increased the number
of c-Fos immunopositive cells at the caudal NTS. On the other hand, EA at ST-25 increased
the number of c-Fos immunopositive cells at the medio-caudal NTS. Conclusion; It is
suggested that somatic afferents activated by EA at ST-36 is conveyed to the caudal NTS
and stimulates the DMV neurons. In contrast, somatic afferents activated by EA at ST-25 is
conveyed to the medio-caudal NTS and stimulates the RVLM neurons. The RVLM neurons
are known as premotor sympatho-excitatory neurons that provide drive to the sympathetic
preganglionic neurons in the intermediolateral nucleus of the spinal cord. Thus, EA at ST-
36 stimulates gastric motility via vagal efferents, while EA at ST-25 inhibits gastric motility
via sympathetic efferents in rats.
M2224
TRP Channels in Murine Spinal and Vagal Visceral Afferents
Pieter J. Peeters, Jeroen Aerssens, Ronald de Hoogt, Kirk Hillsley, Andrzej Stanisz, David
Grundy, Ronald H. Stead, Bernard Coulie
Background: Mammalian Transient Receptor Potential (TRP) channels comprise six related
protein families. All TRP channels are putative six-transmembrane proteins assembling as
tetramers to form cation-permeable pores. TRPs mediate sensory transduction both at the
whole organism and single cell level. The aim of this study was to evaluate murine TRP
channel expression in dorsal root (DRG) and nodose ganglia (NG) projecting to the gut.
Methods: Intraperitoneal injection of Cholera toxin B-488 in 11 Balb/c mice identified
neurons projecting to the abdominal viscera. Fluorescent neurons in DRG (T10 to T13) and
NG were isolated using laser-capture microdissection. RNA was hybridised to Affymetrix
Mouse whole genome arrays. Differential expression was defined as at least 1.5 fold difference
in expression and false discovery rates were calculated using significance analysis method
for microarray data (SAM) and expressed as a q-values. Results: Arrays allowed detection
of mRNA expression levels of 22 different TRP channels, of which 15 were reliably detected
in DRG or NG. Of these 7 were equally expressed in DRG and NG, 4 had significantly
(q<0.01) higher expression in DRG and 4 were higher in NG. As expected, mRNA for the
capsaicin receptor Trpv1 was present in both DRG and NG, with 3.8-fold higher levels in
the former (q<0.001). The membrane stretch sensitive Trpv2 is the only other Trpv channel
family member detected in visceral afferents (more abundant in NG vs. DRG). The Trpa1
channel, gated by mechanical stimuli as well as by cold temperatures, mustard oil, and
cannabinoids, showed high levels of expression in both NG and DRG, with 7-fold more
abundance in the latter (q<0.001). As such Trpa1 could confer mechanosensitivity on the
peripheral endings of both spinal and vagal afferents. Trpm8, another cold activated channel
was not detected in visceral afferents. Other Trpm family members that were detected include
Trpm2, Trpm4, Trpm6 and Trpm7. The latter two can heteromerize and are important for
Mg2+ homeostasis. Whereas Trpm7 was equally expressed in DRG and NG, Trpm6 was
enriched in DRG (3-fold). With respect to Trpc channels, the putative store-operated Ca2+
channels Trpc1, Trpc3 and Trpc5 were detected in visceral afferents. Trpc3 is predominantly
expressed in DRG, whereas Trpc1 and Trpc5 are equally expressed in DRG and NG.
Conclusions: These data provide an inventory of TRP channels present in NG and DRG
neurons supplying the gut and demonstrate clear differences in TRP channel expression.
These divergences may underlie the contrasting roles of NG and DRG, and contribute to
differences in chemo-and mechanosensitivity of the gastrointestinal tract.
M2225
Anxiety-Induced Colonic Hypersensitivity: The Role of Glucocorticoid (GR)
and Mineralocorticoid Receptors (MR) in the Amygdala
Brent Myers, Armstrong Isiaho, Beverley Greenwood-van Meerveld
In patients with IBS, abdominal pain is worsened during periods of anxiety. Although the
amygdala is a key limbic structure involved in the regulation of anxiety, the importance of
amygdaloid-mediated mechanisms in the regulation of colonic function is not completely
understood. Our previous studies have shown that stimulation of the central amygdaloid
nucleus (CeA) with corticosterone (CORT) increases indices of anxiety coupled with a
hypersensitive colon. The goal of this study was to examine the relative importance of
amygdaloid GR and MR-mediated mechanisms in the development of a hypersensitive colon
as demonstrated by an exaggerated visceromotor response (VMR) to colorectal distention
(CRD) in rats with CORT implants on the CeA. Methods: In male F-344 rats, CORT (30µg)
or inert cholesterol (30µg) micropellets were stereotaxically implanted bilaterally at the
dorsal boundary of the CeA either alone or in combination with a GR antagonist, mifepristone
(30μg) or a MR antagonist, spironolactone (30μg). After 5 days, anxiety was assessed on
the elevated plus maze (EPM) and quantified by the percentage (%) of time spent in the
open arms. On day 7, colonic sensitivity was assessed by measuring the VMR i.e. the number
of abdominal muscle contractions in response to CRD (0-60mmHg). Results: In CORT
implanted rats there was a significant reduction in the % time spent in the open arms
compared to cholesterol controls (CORT=28.3±7.2%, cholesterol=67.8±16.1%; p<0.05, n=
5), indicative of anxiety. Furthermore, a higher number of abdominal contractions were
observed in response to CRD when compared to rats with cholesterol implants (CORT:
20mmHg=20.0±3.9, 40mmHg=25.8±5.1, 60mmHg=34.4±4.5; p<0.01, n=5; cholesterol:
20mmHg=6.5±0.9, 40mmHg=14.3±1.7, 60mmHg=20.2±2.8). In rats with CORT implants
combined with the GR or the MR antagonist there was an inhibition of anxiety and a
significant reduction in the VMR induced by CRD at all distention pressures (CORT/GR
antagonist: 20mmHg=5.6±0.8, 40mmHg=12.8±2.5, 60mmHg=24.6±4.6; p<0.01, n=5;
CORT/MR antagonist: 20mmHg=7.0±1.6, 40mmHg=11.8±1.7, 60mmHg=16.0±2.6; p<0.01,
n=5). Summary: In rats, elevating amygdaloid CORT induces anxiety and colonic hypersens-
itivity. When combined with either a GR or MR antagonist, the CORT-induced responses
were significantly inhibited. Conclusion: We have shown that at a concentration of CORT
known to induce anxiety, both GR and MR in the amygdala play a role in colonic hypersensit-
ivity, supporting the hypothesis that both amygdaloid GR and MR play key roles in the
brain-gut axis.
M2226
The Vagus Nerves Contributed to LPS-Induced Increase of Colonic
Paracellular Permeability By Central Release of IL-1β
Raphael Moriez, Helene Eutamene, Vassilia Theodorou, Jean Fioramonti, Lionel Bueno
Subdiaphragmatic vagotomy (SDV) has been shown to inhibit behavioral effects of peripheral
lipopolysaccharide (LPS), including anorexia and fever response. These behavioral effects
implicate the central release of IL-1β, abrogated by previous SDV. However, while it has
been showed that IP administration of LPS increased the colonic paracellular permeability
(CPP), no data report the involvement of vagus nerves in this process. The aim of this study
was to evaluate the role of vagus nerves (afferent vs. efferent fibres) in the LPS-induced
increase of colonic permeability. Methods: All experiments were carried out in male Wistar
rats equipped with an intracolonic catheter. Firstly, a bilateral SDV was performed on 2
groups of 10 rats; a similar surgical approach was conduced on 2 other groups without
section of the vagal trunks (SHAM group). Each of these 2 groups received either NaCl
0.9% (250μL, IP) or LPS from E.coli 0111:B4 (250μL, 1mg/kg, IP). A second series of
experiment was carried out on 5 groups of 10 rats prepared for intracerebroventricular (icv)
injections using polyethylene catheters inserted into the lateral ventricles of the brain. These
5 groups received respectively NaCl 0.9% (5μL, icv) + NaCl (250μL, IP) / NaCl (icv) + LPS
(250μL, 1mg/kg, IP) / recombinant rat IL-1 receptor antagonist (IL-1ra, 2x20 μg in 5μL at
30 min before and 3h after LPS, icv) + LPS (IP) / recombinant rat IL-1β (rrIL-1β, 1μg in
5μL, icv) + NaCl (IP) with/without a previous SDV. In all these groups, animals recovered
during 14 days and CPP was evaluated by intracolonic infusion of 51Cr-EDTA and expressed
as percent of radioactivity collected in the urine for 6h after LPS. Results: In SHAM rats,
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LPS increased the CPP (1.69±0.16% vs. 0.69±0.03% in controls; P<0.05). In SDV group,
administration of LPS failed to increase the CPP (0.68±0.07% vs. 0.69±0.03% in SHAM
control, P>0.05). SDV alone had no effect on CPP at 0-6h period. In the second series of
experiment, icv injections of IL-1ra diminished the effects of LPS on the CPP (0.87±0.19%
vs. 1.87±0.22%, P<0.05). In the same way, icv administration of rrIL-1β reproduced the
effects of LPS characterized by an increase of the CPP (1.53±0.20% vs. 0.55±0.09% for
controls, P<0.05). A previous SDV abolished the effects of central administration of rrIL-
1β on the CPP (0.79±0.13% vs. 1.53±0.2%, P<0.05). Conclusion: These data indicate a key
role of vagus nerves in the alterations of gut permeability induced by IP administration of
LPS. These effects involved central release of IL-1β, activating in turn vagal efferents fibers
to produce alterations of the colonic permeability.
M2227
Post-Infective Changes in Behavior: A Model of Functional Dyspepsia in the
Mouse
Premysl Bercik, J.N. Foster, Patricia Blennerhassett, Elena F. Verdu, Stephen M. Collins
Background/Aim: The concept that previous infection can be a basis for the development
of functional GI disease is now accepted. However, the lack of symptomatic improvement
following eradication of Helicobacter pylori (Hp) infection is construed as evidence against
the role of this organism in functional dyspepsia. Early post-prandial satiety is a dominant
feature of functional dyspepsia. Here, we examine the hypothesis that Hp infection produces
long lasting changes in feeding behavior reminiscent of functional dyspepsia. Methods:
Control and Hp infected Balb/c mice were studied before and two months after Hp eradication.
Gastric emptying was assessed by videofluoroscopy image analysis. Frequency of eating
bouts and amount of food was recorded during 24 hours by a computer-assisted method
and IL-1β and TNF-α were detected in brain frozen sections by in situ hybridizations of
35S-labeled RNA probes. Results: Hp infected mice exhibited changes in feeding behavior
characterized by the more frequent ingestion of smaller meals - analogous to early satiety -
and no weight loss. Uninfected mice had 14 ± 4.1 eating bouts/24 hours while Hp infected
mice had 19.0 ± 4.5 bouts/24 hours (p<0.05). Hp infected mice consumed 0.20 ±0.11 g/
bout compared to 0.32 ±0.14 g/bout in controls (p<0.05). Infected mice exhibited a significant
42% delay in gastric emptying. Successful eradication of Hp resulted in normalization of
gastric emptying but the altered feeding behavior persisted. This was accompanied by the
selective up-regulation of TNF-α expression in the circumventricular median eminence
whereas IL-1β expression was similar in both groups. Conclusions: Hp infection in mice is
accompanied by a feeding pattern reminiscent of early satiety. While delayed gastric emptying
may contribute to the altered feeding during active infection, it cannot explain its persistence
after Hp eradication. The expression of TNF-α in the brain is a putative mechanism for
altered feeding behavior in this model. We thus extend the current concept of post-infective
gut dysfunction to include changes in the CNS which, in the context of functional dyspepsia,
may explain the lack of symptom resolution post-eradication of Hp.
M2228
Sensitization of the Entire Esophagus to Distension By Distal Esophageal Acid
Exposure
Adeyemi Lawal, Mark Kern, Arthi Sanjeevi, Tanya Rittmann, Reza Shaker
Peripheral and central esophageal sensitization is believed to contributes to symptom develop-
ment in esophageal chest pain and acid-related disorders. We have previously shown that
esophageal central sensitization is manifested in both insula and cingulate gyrus. However,
regional contribution within the esophagus to sensitization has not been systematically
studied. AIM: To compare the effect of sensitization on processing of subliminal(neural
activity) and liminal (neurocognitive activity) mechanical stimulation of the proximal and
distal esophagus.METHODS: We studied 12 healthy adult subjects(age:18-35)during fMRI
scanning of the insula (n=6) or cingulate gyrus(n=6)(eleven 2.5mm thick sagittal slices,
96x96 pixel resolution, 24 cm FOV).Paradigm-driven, 2-minute fMRI scans were performed
during randomly timed 15-second intervals of barostatically controlled proximal and distal
esophageal distensions and rest before and after 30 min of distal esophageal acid perfusion
(0.1N HCl, 1ml/min). We tested two pressure levels: 2-6 mmHg (unperceived/subliminal
stimulating neural activity without perception) and barely perceived distension. FMRI volume
elements(voxels) showing magnetic signal changes temporally related to the stimuli were
tallied as a representation of the regional cortical activity associated with distal and proximal
esophageal distension. RESULTS: The effect of distal esophageal acid exposure on regional
cortical fMRI activity showed significant increases in the average number of activated voxels
after acidification for both subliminal and liminal esophageal distension in the proximal and
distal esophagus (*p<0.05). (Table) The amount of cortical activity associated with distal
distension was significantly greater than that associated with proximal distension both before
and after acid exposure(Δ p<0.05)(Table). There were also significant differences in the
amount of cortical activity during subliminal compared to liminal stimulation.(# p<0.05)
(Table). CONCLUSIONS: 1) Distal esophageal acid exposure results in sensitization of
the entire esophagus to distention. This sensitization is manifested at both neural and
neurocognitive levels. 2) Registration of distal esophageal stimulation in the insula and
cingulate seems to be more robust than in the proximal esophagus. 3) These findings may



















Sex Differences in Brain Responses to Aversive Pelvic Visceral Stimulation in
Healthy Subjects - An FMRI Study
Steven M. Berman, Bruce D. Naliboff, Brandall Suyenobu, Jennifer S. Labus, Joshua
Bueller, Kim Ruby, Michael Minnema, Jean Stains, Emeran A. Mayer
Background: Women often have lower thresholds and tolerance for pain than men and a
greater prevalence of a variety of functional pain disorders. Brain imaging studies using
somatic and visceral stimuli have shown some sex based differences in brain activation.
However, potentially sex-related deactivations have not been studied. Aim & Methods:
fMRI brain imaging (3T) of the BOLD signal was used to compare brain responses to aversive
rectal distention and cued anticipation of distention between 6 healthy women (mean age
35 ± 8) and 7 age-matched men. Ten regions of interest (ROIs) were assessed for the presence
of significantly activated or deactivated voxels (p<0.05) in response to moderate distention
(45 mm Hg), mild distention (25 mm Hg) and sham distention (5 mm Hg). Results: Rectal
distention reliably increased the BOLD signal in typical pain regions (dorsal anterior cingulate,
insula). Some subjects also showed significant effects in prefrontal cortex, and subcortical
or limbic regions (thalamus, peri/infragenual cingulate, amygdala, ventral striatum, dorsal
brainstem). Deactivations within all ROIs were also noted. Men activated more voxels than
women in the majority of structures during moderate (10 of 10 ROIs), mild (9/10), and
sham distention (10/10). However, women deactivated more voxels than men (9/10 in all
3 distention conditions). ANOVA indicated that the proportion of affected voxels that
deactivated was significantly influenced by sex (Sex x ROI interaction F=3.48, p<0.001).
Women showed a greater proportion of deactivations than men in brainstem, thalamus and
ventral striatum (ps<0.05). Planned comparisons indicated no significant sex differences
during sham inflation, but p<0.05 effects in all three ROIs and the amygdala during mild
inflation, and in thalamus and dorsal cingulate during moderate inflation. Conclusion: Sex-
based differences in CNS response to aversive pelvic visceral stimulation consist of a greater
proportion of deactivations in women in regions implicated in pain processing and modula-
tion. These deactivations may reflect inhibition or differential connectivity with other modu-
latory brain regions. Supported by DK48351, R24 AT002681, P50DK64539 (EAM),
NR04881 (BN).
M2230
Central Glucagon Like Peptide-1 Delays Solid Gastric Emptying Via a Central
CRF and Peripheral Spinal-Celiac Pathway in Conscious Rats
Yukiomi Nakade, Kiyoshi Tsukamoto, Constant Masere, Theodore N. Pappas, Toku
Takahashi
Background: Glucagon like peptide-1 (GLP-1), one of the gastrointestinal (GI) regulatory
peptide, is secreted from the alimentary canal in response to absorbed nutrients. A major
role of GLP-1 is to stimulate insulin secretion on the islet beta cell to maintain glucose
control. Besides the role of incretine, GLP-1 is also thought to be a brain neurotransmitter
mediating GI function. Previous report has shown that central administration of GLP-1
inhibits liquid gastric emptying via vagal mediated pathways in rats (Am J Physiol 273,
G920-927, 1997). This mimics the effect of central-injection of corticotropin releasing factor
(CRF), which also delays liquid gastric emptying. However, it remains unknown how central
GLP-1 delays solid gastric emptying. It also remains unknown how GLP-1 interacts with
CRF within the brain in mediating the inhibitory effect of solid gastric emptying. Methods:
Male Sprague-Dawley rats were fasted for 24 hours. Ten min after the feeding of solid rat
chow (1.5 g), GLP-1 or saline was injected intracisternally (IC) or subcutaneously (SC).
Ninety minutes after the peptide injection, rats were sacrificed. The gastric content was
recovered from the stomach, dried and weighed for calculating solid gastric emptying. To
examine the mechanism of GLP-1-induced delay of solid gastric emptying, atropine (50 µg/
kg, IP) or NG-nitro-L-arginine methyl ester (L-NAME) (10 mg/kg, IP) was applied 20 minutes
before the feeding. Celiac ganglionectomy underwent 1 week before the gastric emptying
study. CRF antagonist, astressin, was applied (IC) 20 minutes before the feeding. Results:
Gastric emptying was 66.2 +/- 4.5% in vehicle-treated rats (n=6). IC-injection of GLP-1
(0.03-3.0 nmol) dose-dependently delayed solid gastric emptying. Maximum effect was
observe by GLP-1 (3.0 nmol), which significantly delayed gastric emptying to 20.3 +/- 4.5%
(n=6). In contrast, SC-injection of GLP-1 (3 nmol) did not affect gastric emptying (61.6 +/-
3.5 %, n=6). IC-injection of GLP-1 (3 nmol)-induced delay of gastric emptying was partially
inhibited by celiac ganglionectomy (43 +/- 3.4 %, n=6, P<0.05, but not by atropine (25.8
+/- 3.6%, n=6), or L-NAME (11.3 +/- 3.6 %, n=6). IC- injection of astressin (2.8 nmol)
partially inhibited GLP-1-induced delay of solid gastric emptying (41.3 +/- 2.5%, n=6,
P<0.05). Conclusions: These results indicate that central CRF and peripheral spinal-celiac
pathway are, at least in part, involved in mediating central GLP-1-induced delay of solid
gastric emptying in conscious rats.
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Acupuncture Improves Restraint Stress-Induced Delay of Gastric Emptying Via
Central Glutaminergic Pathways in Conscious Rats
Masahiro Iwa, Yukiomi Nakade, Theodore N. Pappas, Toku Takahashi
Background; Acupuncture has been used for treating functional gastrointestinal (GI) dis-
orders, including irritable bowel syndrome (IBS) and functional dyspepsia (FD). Animal
studies demonstrated that acupuncture improves various stress-induced physiological
responses. We have recently showed that electroacupuncture (EA) at the lower limbs (ST-
36) significantly improved delayed gastric emptying induced by restraint stress in rats (Dig
Dis Sci; in press). Glutamate and γ-Aminobutyric acid (GABA) are major excitatory and
inhibitory neurotransmitters within the dorsal vagal complex (DVC) regulating GI motility.
We studied whether glutamate and GABA receptors are involved in mediating the stimulatory
effects of EA on delayed gastric emptying induced by restraint stress. Methods; Rats were
given a solid pellet (1.5 g) for 10 minutes. Immediately after the feeding, the rats were placed
on a stereotaxic apparatus under short isoflurane anesthesia. GABAA receptor antagonist
(bicuculline methiodide; 5 nmol in 5 µl), GABAB receptor antagonist (phaclofen; 100 nmol
in 5 µl), NMDA receptor antagonist (kynurenic acid; 0.1 μmol in 5 µl) and saline (5 µl)
were injected intracisternally (IC). Then, the rats were submitted to the restraint stress for
90 minutes. Acupuncture needles were inserted to a depth of 5 mm into the skin and
underlying muscles at ST-36 bilaterally. Needles were stimulated by electricity (0.1 msec
and 10 Hz). Electroacupuncture (EA) was performed for 90 minutes throughout the stress
loading. Ninety minutes after the stress loading, rats were euthanized and the gastric content
was recovered from the stomach, well dried, and weighed for calculation of solid gastric
emptying. Results; Solid food gastric emptying in 90 min was significantly delayed by
restraint stress (27.3 +/- 2.1%, n=8), compared to that of controls (64.3 +/- 2.1%, n=8).
Restraint stress-induced delay of gastric emptying was significantly restored by the IC-
injection of bicuculline methiodide (46.5 +/- 3.1%; n=6) and phaclofen (48.3 +/- 3.3%; n=
6). Delayed gastric emptying induced by restraint stress was significantly improved by EA
at ST-36 (49.7 +/- 1.4%, n=8). The stimulatory effect of EA on stress-induced delay of
gastric emptying was prevented by pretreatment with IC-injection of kynurenic acid (30.1
+/- 2.1%, n=6). Conclusion; Restraint stress-induced delay of gastric emptying is mediated
via central GABAA and GABAB receptors. EA at ST-36 stimulates glutaminergic neurons
in the brainstem resulting in improvement of stress-induced delay of gastric emptying.
Acupuncture may be useful for the treatment of delayed gastric emptying associated with
stress.
M2232
A Comparison of the Cortical Responses to Selectively Attended Visceral and
Somatic Pain
Paul Dunckley, Qasim Aziz, Richard G. Wise, Jonathan Brooks, Irene Tracey, Lin Chang
Background/Introduction. Visceral and somatic pain differ in several key aspects - visceral
pain is described as ill-defined and is often described as more unpleasant than somatic pain.
These differences in perception must be reflected in differing cortical patterns of activation.
We have used a paradigm of attentional modulation to study the differences in selectively
attended visceral and somatic pain matched for both pain intensity and unpleasantness.
Methods.12 healthy, pain-free, right-handed subjects were recruited for the study. Simultan-
eous electrical pulses and auditory tones lasting 6 seconds were delivered to the subjects
during a whole-brain functional magnetic resonance imaging scan acquisition. The electrical
catheter was placed into the rectum for the visceral scan and onto the lower abdomen for
the somatic scan. Subjects were instructed to attend to and count either the auditory tones
or electrical pulses. Electrical pulses and auditory tones were delivered at either 2, 3.5 or
4.3Hz thereby varying the cognitive demand of the tasks. Pain intensity, unpleasantness
and tone/pulse count were recorded after each stimulus. Anxiety levels were measured prior
to the scan. Results. Pain intensity and unpleasantness were well matched for the 2 sensory
modalities. Selective attention to both modalities resulted in activation in sensory-discriminat-
ive (secondary somatosensory cortex), affective (anterior insula, anterior mid cingulate cortex
(ACC)) and cognitive (ACC) regions. Subtraction analysis identified greater activation during
visceral pain in the right thalamus, ACC, bilateral cerebellum, the right anterior insula
(during the 4.3Hz condition alone) and right amygdala. There were no areas of greater
activation during somatic pain. A separate focus of activation was observed in the anterior
ACC during visceral pain at each frequency. Right anterior insula cortex activity correlated
with anxiety rating for both somatic and visceral pain. Conclusions. Selectively attended
visceral pain results in greater activation of affective (right anterior insula, right amygdala
and anterior mid-cingulate) and attentive (ACC) regions compared with matched selectively
attended somatic pain. Visceral pain is preferentially represented in the right anterior insula
cortex. As unpleasantness and anxiety were both matched between sensory modalities, this
suggests an added interoceptive role of this region during visceral pain. Greater representation
of visceral pain in the affective regions of the cortex is consistent with the James-Lange theory
of emotion whereby the physical sensation of emotions are dependent on visceral sensation.
M2233
Effects of Glucagon-Like Peptide-1 (GLP-1) On Identified Pancreas-Projecting
Vagal Motoneurons
R. Alberto Travagli, Kirsteen N. Browning, Shuxia Wan
Glucagon-like peptide-1 has been shown to increase insulin secretion via a vagally-dependent
mechanism. A high density of GLP-1 containing neurons is present in the vagal circuits
within the brainstem. The dorsal motor nucleus of the vagus (DMV) comprises the neurons
forming the preganglionic parasympathetic vagal motor output to abdominal viscera, includ-
ing the pancreas. The aims of the present study were to investigate whether DMV neurons
were responsive to exogenously applied GLP-1 and, if so, whether the responsive neurons
could be distinguished from DMV neurons controlling other pancreatic functions. The
hypothesis is that DMV neurons that control endocrine secretion (i.e. responsive to GLP-
1) are different from those that control exocrine secretion (i.e. responsive to pancreatic
polypeptide, PP). Whole cell patch clamp recordings were made from pancreas-projecting
DMV neurons identified by prior application of the retrograde tracer, DiI, to the body
of the pancreas. Perfusion with GLP-1 induced a concentration-dependent excitation in
approximately 50% of pancreas-projecting DMV neurons (N=56 of 114 cells tested). The
threshold of the excitatory response was 10nM, the EC50 was approximately 30nM and
Emax was 300nM. At 100nM, GLP-1 induced a 5.8±0.4mV depolarization and increased
the firing rate from 8.4±4.0 to 35.9±5.3 a.p./min (HP=-60mV). The GLP-1 mediated excita-
tion was mimicked by Exendin-4 (100nM), which induced a 5.5±0.8mV depolarization (N=
4), and was completely antagonized by Exendin 9-39 (100nM; N=3). The GLP-1 induced
depolarization was reduced from 6±1.1 to 2.2±1.4mV by TTX (1μM) suggesting that the
effects were mediated both directly, via an effect on the DMV membrane, and indirectly, via
an effect on local synaptic circuits. Experiments conducted in the voltage clamp configuration
indicated that GLP-1 increased by 44±9.4% the amplitude of excitatory postsynaptic currents
induced by stimulation of the nucleus tractus solitarius (N=11 of 15 cells). Cells that
responded to GLP-1 with an excitation were, instead, unresponsive to PP (which reduces
pancreatic exocrine secretion). Viceversa, cells that were responsive to PP were unresponsive
to GLP-1 (N=38 cells tested). These data indicate that 1) GLP-1 may control pancreas-
endocrine secretion via an effect on pancreas-projecting DMV neurons; and 2) DMV neurons
that control endocrine secretion (i.e. responsive to GLP-1) are different from those that
control exocrine secretion (i.e. responsive to PP). Supported by NSF grant 0456291
M2234
Altered Expression of Trp, Ca2+ and K+ Channels in Vagal Visceral Afferents
in a Post-Infectious Model of Irritable Bowel Syndrome (IBS)
Jeroen Aerssens, Pieter J. Peeters, Ronald de Hoogt, Kirk Hillsley, Andrzej Stanisz, David
Grundy, Ronald H. Stead, Bernard Coulie
Background: Extrinsic afferent neurons supplying the gut are prime targets for new treatments
of chronic visceral pain disorders such as IBS. The pathogenesis of IBS is heterogeneous
but at least in a subpopulation of patients emotional stress and enteric infection have been
implicated. The aim of this study was to investigate long-term changes in gene expression
of ion channels in vagal visceral afferents in a mouse model of IBS. The model consisted of a
transient inflammation induced by the nematode Nippostrongylus brasiliensis (Nb) combined
with exposure to stress. Methods: Balb/c mice housed in control / stress conditions were
infected with 500 L3 Nb larvae. Four groups of animals were studied: sham/non-stressed
(ShNS), infected/non-stressed (InfNS), sham/stressed (ShS) and infected/stressed (InfS). After
acute inflammation had resolved (21 days post infection), vagal gut-specific neurons in
nodose ganglia (NG), labeled by intraperitoneal injection of cholera toxin B-488, were
isolated by laser-capture microdissection. RNA was hybridized to Affymetrix mouse whole
genome 430 2.0 arrays. Expression profiles were analyzed by two-way ANOVA for microarray
data evaluating the effects of stress and infection with control of false discovery rate (using
the Benjamini and Hochberg approach). Confirmation was done using quantitative PCR.
Results: In NG visceral neurons, significantly different expression levels were found for 14
ion channel genes including a putative Ca2+ channel, 3 TRP channels and 3 K+ channel
subunits. Cacng2, also known as stargazing (which modulates AMPA receptor gating and
trafficking), was expressed significantly lower in infected animals (2.3-fold). With respect
to K+ channels, significant changes were found for Kcnd1 (KV4.1), Kcnj10 (Kir4.1) and
Kcnab1 (Kvβ1). The increased expression of Kcnab1 (1.5-fold), the auxiliary subunit of
voltage-gated K+ channels, was observed in both stress (ShS) and infection (InfNS and InfS)
exposed animals. This could differentially affect the function of multiple KV1 channels. The
TRP channels Trpa1 (2.1-fold), Trpc4 (2-fold) and Trpv1 (2.1-fold) were all upregulated
after combined exposure to stress and infection (InfS and to a lesser extent in InfNS). All
of these channels are thought to be involved in chemosensation. Conclusion: A plethora of
ion channel genes are altered in visceral sensory NG neurons by Nb infection and stress,
at a time point when the acute inflammation has subsided. Overall these changes point
towards long-term alterations in synaptic transmission/plasticity and increased chemosensi-
tivity. These findings may impact on future therapeutic strategies for IBS.
M2235
Cross-Talk Between Colon and Bladder Involves the Up-Regulation of
Calcitonin Gene-Related Peptide (CGRP) and Receptor Tyrosine Kinase TRKB
in Bladder and Colon/Bladder Convergent Afferent Neurons in DRG Following
TNBS Colitis
Liya Qiao, John R. Grider
The concurrency of gut and bladder symptoms is a common occurrence in humans. Experi-
mental animals with colitis induced by tri-nitrobenzene sulfonic acid (TNBS) showed over-
active bladder. We hypothesized that primary afferent neurons located in dorsal root ganglia
(DRG) may contribute to the cross-activation of bladder in colitis. AIM: to determine the
effects of TNBS-induced colitis on rat bladder afferent neurons by examining the expression
of CGRP and TrkB in these neurons. METHODS: Bladder and colon afferent neurons were
labeled by injection of neuronal tracing dye Fast Blue into muscle wall of bladder or
dicarbocyanine dye DiI into muscle wall of colon. Colitis was induced by colonic instillation
of TNBS (0.25ml of 60mg/ml in 50% ethanol) and animals were killed on day 7 by intracardiac
perfusion with 4% paraformaldehyde. DRG from lumbosacral regions L1, L6 and S1 were
removed, sectioned, and immunostained with specific CGRP or TrkB antibody. DRG from
control rats were also isolated, dispersed and cultured in DMEM-10 plus Ara C (10 uM).
The effects of 2 nM of nerve growth factor (NGF), neurotrophin-3 (NT-3) or brain-derived
neurotrophic factor (BDNF) on CGRP expression were determined in these cultures.
RESULTS: Bladder afferent neurons from DRG of control rats constitutively expressed CGRP
and TrkB. After TNBS colitis, the percentage of bladder afferents expressing CGRP increased
in L1 (56.5±5.1 in colitis vs. 23.2 ± 3.7 in controls; p<0.05) but not in L6 or in S1. Colitis
also caused a significant increase in the percentage of bladder afferents expressing TrkB in
L1 (38.3 ± 3.5 in colitis vs 25.5 ± 5.2 in controls, p<0.05) and in L6 (62.1 ± 5.2 in colitis
vs 19.3 ± 4.1 in controls, p<0.01), but not in S1. After colitis, the percentage of convergent
neurons (dually projecting from colon and bladder) in DRG from L1 expressing CGRP was
significantly increased 5-fold (p<0.01). Co-localization studies showed that there was also
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an increase in the subpopulation of DRG neurons from L1 expressing both CGRP and
TrkB (2.5-fold, p<0.05). In cultured DRG neurons, all three Trk agonists increased CGRP
expression with the rank order NGF>NT-3>BDNF. CONCLUSION: TNBS-induced colitis
results in up-regulation of CGRP in bladder and colon/bladder convergent afferent neurons
in DRG. Colitis also increased TrkB expression in bladder afferent neurons. The increase in
the subpopulation of DRG neurons co-expressing TrkB and CGRP in colitis and the ability
of neurotrophins to increase CGRP in cultured DRG suggests a role for neurotrophins in
the induction of CGRP expression during colitis.
M2236
Alterations in Behaviour, Hpa Axis Function and Cytokine Profiles Following
Neonatal Maternal Separation: Evidence for Dysregulation of the Brain-Gut
Axis
Paul Scully, S M. O Mahony, S Murphy, L O Mahony, E M. Quigley, T G. Dinan
Background & Aims: Evidence suggests that early-life trauma and psychological stress can
affect the course of intestinal disorders and increase the risk of irritable bowel syndrome (IBS)
development. Studies have demonstrated that neonatal stress following maternal separation in
the rat results in an altered adult phenotype, which includes development of cardinal IBS
features such as visceral hyperalgesia and reduced somatic analgesia. Permanent functional
alterations in the hypothalamic-pituitary-adrenal (HPA) axis have also been observed. Using
the maternal deprivation model, the aim of this study was to assess the long-term impact
of early life stress on brain-gut function in rats by assessment of alterations in behaviour,
HPA axis function, systemic inflammatory response, and gut associated cytokine production.
Methods: 22 Male Sprague-Dawley rats were randomly divided into two groups. From post-
natal day 2 to 14, neonates were separated daily from the dams for 180mins. Control pups
remained with their mothers. Behavioural tests were performed at days 50-70 and the rats
were then sacrificed by decapitation. Following sacrifice, blood samples were obtained,
stimulated with LPS and cytokine production measured after 48 hours. Plasma levels of
cortisol, corticosterone and TNF-α were analysed by ELISA. Peyer’s patches (PP) and mesen-
teric lymph node cells (MLNCs) cytokine levels of TNF-α, IL-4, IL-6, IL-10 and IFN- γ
cytokine levels were measured by cytometric bead array. Results: Maternally deprived
animals showed a significant increase in anxious behaviour in open field experiments (P <
0.05). Whole blood cultures for the maternally deprived group showed a significant increase
in TNF-α following LPS stimulation when compared to controls (P < 0.05). No significant
changes in TNF-α were observed in plasma. Plasma levels of corticosterone were significantly
increased in the maternally deprived animals (P < 0.01). The levels of TNF-α, IL-4, IL-6,
IL-10 and IFN- γ in the MLNCs were found to be consistently higher in the control animals
compared to maternally deprived animals. No significant differences were observed in the
level of cytokines in the PP. Conclusions: This study indicates that maternal separation
results in alterations in behaviour, HPA axis function, mesenteric cytokine profiles and the
systemic cytokine response to inflammatory stimuli. Such changes may be important in the
pathophysiology of IBS.
M2237
Feasibility and Reproducibility of Functional Magnetic Resonance Imaging in
Medetomidine Sedated Rodents
Venelin J. Kounev, James Hyde, Mark Kern, Jyoti Sengupta, Christopher Pawela, Douglas
Prah, Eric Paulson, Reza Shaker
INTRODUCTION:Visceral sensory function in animals has traditionally been evaluated by
assessing the visceromotor response to colonic distension.Although quantitative,this tech-
nique is an indirect measure of neurosensory response to visceral stimulation.Brain imaging
techniques provide a direct representation of visceral sensation, but because of the use of
anesthesia necessary for restraining the animals, their full potential remains unrealized. Our
aim was to study the feasibility and reproducibility of direct quantification of cerebral
cortical response to visceral stimulation using fMRI technique in a rat model sedated by
Medetomidine.METHODS:We studied adult Sprague-Dawley rats(480-550g) under continu-
ous infusion of Medetomidine(100mcg/kg/hr),a potent non-narcotic α-2 adrenoreceptor
agonist.Phasic barostat controlled air distensions(20,40,60,80,100 mmHg)were applied to
the hind gut of rats in a block paradigm fashion.All animals were imaged on a 9.4T MRI
scanner(Bruker Biospin)utilizing BOLD contrast(gradient echo EPI, TR 2s,TE 21ms,FOV 4
cm, matrix 96x96,slice thickness 1.5 mm, voxel size 0.625 mm3).We used AFNI,deconvolu-
tion method for analyses.RESULTS:All tested animals exhibited cortical activity with disten-
sion pressures as low as 20 mmHg.The number of fMRI activated voxels in response to
increasing distension pressures progressively increased(P<0.05)(Fig)in a dose-dependent
manner(R=0.87).Moreover,these findings were reproduced in each experiment with different
duration of stimulus presentation.The cerebral activity was spread throughout the brain
with largest magnitude in MR signal change observed in voxels in the cingulate cortex.
CONCLUSIONS:Functional imaging of the cerebral cortex by fMRI is feasible in rats under
Medetomidine sedation and yields reproducible results.Increasing rectal distension pressure


















Ghrelin Stimulates Solid Gastric Emptying Via a Vagal Afferent Pathway in
Conscious Rats
Yukiomi Nakade, Cindy Chen, Kiyoshi Tsukamoto, Theodore N. Pappas, Toku Takahashi
Background: Ghrelin is a newly discovered orexigenic peptide originating from the stomach
and has been shown to regulate gastric motor activities. Previous reports showed that ghrelin
accelerates liquid gastric emptying in mice (Regulatory peptide 2004 120 23-32). We studied
whether exogenous ghrelin accelerates solid gastric emptying and modify postprandial antral
contractions in conscious rats. It has been demonstrated that ghrelin receptors are located
at vagal afferent. We also studied whether ghrelin-induced acceleration of solid gastric
emptying is mediated via vagal afferent pathway. Methods: Using male Sprague-Dawley rats,
one strain gauge force transducer was sutured on the serosal surface of the antrum. One
week after the operation, rats were fasted for 24 hrs. After recording of basal gastric motility
for 120 min, rats were fed of solid rat chow (1.5 g). Ten minutes after the feeding, ghrelin
(4 microg/kg) was administered by intraperitoneal (IP)-injection and antral motility was
monitored for 120 min thereafter. For gastric emptying study, rats were fasted for 24 hrs. Ten
minutes after the ingestion of rat chow (1.5 g), ghrelin (0.3-8 microg/kg) was administered by
IP injection. Ninety minutes after the feeding, rats were sacrificed. The gastric content was
recovered from the stomach, dried and weighed for calculating solid gastric emptying. To
investigate whether ghrelin-induced acceleration of solid gastric emptying is mediated via
vagal afferent pathway, capsaicin was applied on cervical vagus nerve bilaterally. Two weeks
after the perivagal capsaicin treatment, the gastric emptying study was performed. Control
rats received the vehicle-treatment on the vagus nerve. Results: Postprandial-injection of
ghrelin induced phase III- like contractions of the antrum for over 30 minutes. Postprandial-
injection of ghrelin (0.3-8 microg/kg) dose dependently increased solid gastric emptying.
Maximum effect was obtained by ghrlin (4 microg/kg), which significantly accelerated gastric
emptying to 76.6 +/-3.6% (n=6), compared to that of saline-injected rats (58.3 +/-3.6, n=
6). Ghrlin (4 microg/kg)-induced acceleration of gastric emptying was attenuated in rats
treated with perivagal capsaicin (66.3+/-3.2 %, n=6, P<0.05), compared to that of vehicle
treated rats (73.0 +/- 3.6 %, n=6). Conclusions: These results indicate that postprandial
ghrelin-injection changes postprandial gastric motor pattern to interdigestive motor pattern,
resulting in acceleration of solid gastric emptying. The acceleration of solid gastric emptying
induced by ghrlin is mediated via capsaicin-sensitive vagal afferent pathway.
M2239
The Gut Response to Stress Can Be Pharmacologically Modulated -
Amitriptyline Modifies Visceral Hypersensitivity in Irritable Bowel Syndrome
(IBS)
Charles Murray, Wendy J. Winchester, Eric Tripoli, Maxton C. Pitcher, Michael A. Kamm,
Anton V. Emmanuel
Introduction: Acute physical stress causes a measurable acute alteration of gut autonomic
function and visceral hypersensitivity in patients with IBS (Murray et al Gastroenterology
2004). Low doses of amitriptyline are effective in over 50% of IBS patients, through mechan-
isms that are unclear. We present the first report of the effects of amitriptyline on the gut
neural response to acute stress. Methods: 19 patients with constipation-predominant IBS
(16 female, mean age 32, range 19-58) were given amitriptyline 25-50mg at night. Patients
underwent stress assessment at baseline and after three months of treatment. Stress assessment
comprised a physical (cold-pressor) and psychological (dichotomous listening) stress given
in random order at least one day (median 1, range 1-4 days) apart. Physiological parameters
measured included: perception of stress (visual analogue scale); systemic autonomic tone
(heart rate and blood pressure); gut-specific autonomic innervation (laser Doppler flowmetry
of rectal mucosal blood flow (RMBF)); and visceral sensitivity (rectal electrosensitivity). 13
patients underwent barostat assessment of rectal sensitivity. Results: 14 of 19 (74%) patients
were symptomatically improved after 3 months of amitriptyline (median dose 25mg). Acute
stress resulted in increased perception of stress and systemic autonomic tone, and reduced
RMBF, which was similar in responders and non-responders (p>0.05 for all). In contrast,
all non-responders and only three out of 14 of responders, continued to exhibit stress-
induced reduced pain threshold at 3 months (change from baseline -31% vs +2%, p<0.03
respectively). Responders increased thresholds for pain from 21 (pre-) to 31mmHg (post-
treatment) above distending pressure (p<0.03). No such change was seen in non-responders
(from 23 to 24mmHg, respectively). Discussion: Amitriptyline is effective in constipation-
predominant IBS patients. This effect is primarily on stress-induced visceral hypersensitivity,
independent of autonomic tone. The gut response to acute stress is a viable target to study
drug efficacy in IBS.
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M2240
Abnormal Vagal Regulatory Function of Brainstem Thyrotropin-Releasing
Hormone (TRH) Is Involved in the Delayed Gastric Emptying (GE) in Type 2
Diabetic (T2D) Goto-Kakizaki (GK) Rats
Yan Ao, Natalie Toy, Moon K. Song, Viang W. Go, Mulugeta Million, Hong Yang
Background: Gastroparesis is common in diabetes, occurring in 30-50% of diabetic patients.
Caudal brainstem TRH-containing raphe-dorsal vagal complex (DVC) pathways play an
important role in vagal regulation of gastric motility (Tache & Yang, 1994). Neuropeptide
Y (NPY) in the brainstem selectively innervates caudal raphe nuclei and the DVC and
modulates TRH action in regulating vagal efferent function (Yang et al, Br J Pharmacol,
1998). We found altered brainstem TRH, NPY, and TRH receptor 1 (TRH R1) gene expression
in male T2D GK rats (Ao et al, Society for Neuroscience, 2005). Aim: To test the hypothesis
that abnormal vagal regulatory function of brainstem TRH is responsible for the delayed
GE in T2D. Methods: Brainstem NPY, TRH, and TRH R1 mRNA of normally fed adult
female Wistar and GK rats (4-6/group) were measured by Northern blot analysis. Additional
groups of female Wistar and GK rats were fasted overnight and intracisternally (ic) injected
with saline or the stable TRH analog RX77368 (10 ng) under short isoflurane anesthesia;
20 min later, liquid GE was measured by the methylcellulose/phenol red method. Some
rats were pretreated (-20 min) with atropine (1 mg/kg, sc). Results: 1) Brainstem TRH gene
expression is significantly reduced by 47% in female T2D GK rats while TRH R1 gene
expression increased by 2-fold compared with Wistar rats; 2) liquid GE in 35 min is 32%
slower in GK rats; 3) ic TRH analog-induced acceleration of GE is 61% greater in GK than
in Wistar rats; 4) the elevated GE response to ic RX 77368 in GK rats is reversed by atropine.
Conclusion: 1) Altered vagal function resulting from reduced brainstem TRH gene expression
may contribute to the abnormal gastric motility in T2D; 2) T2D GK rats are extremely
sensitive to exogenous ic TRH analog due to increased brainstem TRH R1 gene expression
as a compensatory adaptation to reduced brainstem TRH synthesis.
Table 1. Brainstem TRH, NPY, and TRH R1 mRNA levels in female Wistar and GK rats
* P<0.05 vs Wistar rats
Table 2. Effect of ic RX77368 on liquid GE (duration in min) in Wistar and GK rats (%)
* P<0.05 vs Wistar rats
M2241
Corticotrophin Releasing Hormone (CRH) Acts On Mast Cells to Induced
Intestinal Barrier Dysfunction
Ping-Chang Yang, Aaron A. Teitelbaum, Jennifer Jury, Mary H. Perdue
Ping-Chang Yang, Aaron A. Teitelbaum, Jennifer Jury, Mary H. Perdue Intestinal Disease
Research Program, McMaster University, Hamilton, Canada The intestinal epithelial barrier
plays a critical role in maintaining intestinal homeostasis. Several intestinal diseases such as
IBD and food allergy are associated with intestinal barrier dysfunction. We and others have
reported that psychological stress increases intestinal barrier permeability that is mast cell
dependent; however, the mechanism of the stress-induced intestinal barrier dysfunction and
its relation with mast cells remain to be further elucidated. Here we report that stress
hormone CRH, via a mechanism of receptor ligation and mast cell activation, plays a critical
role in stress induced intestinal barrier dysfunction. Methods: Mast cell-deficient (Ws/Ws)
rats and their +/+ normal littermates were implanted with minipumps containing CRH (50
µg/kg/day was delivered); minipumps containing saline were implanted in control rats.
After 10 days of infusion, intestinal segments were excised and functional parameters were
determined in Ussing chambers: ion secretion measured by short-circuit current (Isc); macro-
molecular permeability measured by flux of horseradish peroxidase (HRP). In vitro studies
of epithelial barrier function were carried out in T84 epithelial cell monolayers co-cultured
with CRH-stimulated mast cells (HMC-1 or RBL cells); barrier functions were assessed by
measuring the transepithelial resistance (TER) and HRP flux. CRH receptor expression by
mast cells was determined by RT-PCR and Western blot. Results: The +/+ rats treated with
CRH showed significantly increased Isc (48.4 ± 3.2 µA/cm2, mean ± SE) compared with
Ws/Ws rats (13.2 ± 1.5) and +/+ saline controls (14.6 ± 1.4). CRH-treated +/+ rats also
showed significantly elevated HRP flux (37.1 ± 5.1 pmol/hr/cm2) vs Ws/Ws rats (7.1 ± 1.2)
and +/+ saline controls (9.2 ± 1.7). Mast cell degranulation was observed by electron
microscopy: 1) in the intestine of the CRH treated rats, and 2) in cultured RBL mast cells
after the addition of CRH (50 nM). The CRH-activated mast cells significantly reduced the
epithelial TER (48.5 ± 3.8% compared with control) and increased the HRP flux (3.5 ± 1.1
fold) in T84 monolayers. Expression of CRH receptors were detected in the mast cells at
mRNA and protein levels. Conclusions: Chronic administration of CRH mimics the effect
of chronic stress in compromising intestinal barrier function. CRH activates mast cells; mast
cell-derived mediators directly influence intestinal epithelial barrier function.
M2242
Increased Colonic Sensitivity in Irritable Bowel Syndrome Is the Result of
Increased Perceptual Response Bias Rather Than Increased Perceptual
Sensitivity
Spencer D. Dorn, Olafur S. Palsson, Syed Im. Thiwan, Motoyori Kanazawa, W. Crawford
Clark, Miranda Al. van Tilburg, Douglas A. Drossman, Yolanda Scarlett, Rona L. Levy,
Yehuda Ringel, Michael D. Crowell, Kevin W. Olden, William E. Whitehead
Background: Patients with irritable bowel syndrome (IBS) report pain at lower pressures
and volumes of intra-luminal balloon distension than subjects without IBS. These lower
pain thresholds have been attributed to heightened visceral sensitivity and labeled a biological
marker for IBS. However, because the methods used to ascertain pain thresholds are subject to
perceptual response bias, differences in pain thresholds might reflect underlying psychological
differences rather than biological differences [Gastroenterol 1998;115:1263-1271]. Aims:
To determine and explain differences in pain and urge thresholds in IBS patients compared
to controls. Methods: Sensory thresholds were tested in the descending colon using ascending
methods of limits (AML) in 121 IBS subjects and 28 control subjects. In addition, potential
psychological (response criterion bias: 1/β) and sensory (perceptual sensitivity: p(a)) deter-
minants of pain and urge thresholds were determined using sensory decision theory [Anes-
thesiol 1974;40:272-287]. Psychological distress was assessed using the Brief Symptom
Inventory (BSI) and Trauma Symptom Checklist (TSC-40). The data were analyzed using
non-parametric statistical tests. Results: In response to painful stimuli IBS patients had
lower AML pain thresholds (median: 36 vs. 50mmHg; p<.001) and a higher response bias
(.25 vs. .19; p<.001) but similar perceptual sensitivity (.50 vs. .50; p=.691). There was a
strong inverse correlation between AML pain thresholds and response bias (r=-.75; p<.001),
and a weak correlation with perceptual sensitivity (r=-.18; p=.03). Response bias was weakly
correlated with BSI global score (r=.18; p=.035), BSI somatization (r=.26; p=.001) and TSC-
40 anxiety (r=.29; p=.001). IBS patients scored higher than controls on each of these
psychometric scales (p<.001). IBS patients also had lower AML thresholds for the non-
painful sensation of urge to defecate (26 vs. 48mmHg; p=.002) and a higher response bias
(.33 vs. .24; p=.006) but similar perceptual sensitivity (.55 vs. .50; p=.168). There was a
strong inverse correlation between AML urge thresholds and response bias (r=-.71; p<.001)
and a weak, non-significant correlation with perceptual sensitivity (r=-.16; p=.052). Conclu-
sions: Increased colonic pain sensitivity in IBS is largely explained by increased perceptual
response bias rather than increased perceptual sensitivity. Thus, increased colonic sensitivity
in IBS is determined more by psychological factors than by biological factors. [Supported
by grants R24 DK67674, R01 DK31369 and RR00046]
M2243
Chronic Mild Stress Model in a Rat: A Real Model of the Visceral
Hypersensitivity That Reflects a Sustained Stressful Situation of Irritable
Bowel Syndrome in a Patient
Yong Sung Kim, Suck Chei Choi, Moon Young Lee, Young Woo Sohn, Yong Leol Oh, Tae
Hyeon Kim, Geom Seog Seo, Eun Young Cho, Seoul Lee, Sang Wook Kim, Myung Gyu
Choi, Yong-Ho Nah
Background/Aim: Psychological stress is believed to play a major role in irritable bowel
syndrome(IBS). However, most of the studies about the effect of stress on the gastrointestin-
al(GI) tract used acute, short and intense stress tests such as cold water immersion, spinning,
electrical shock or chemical injury. The effect of chronic stress on the GI tract needs to be
investigated, but there were ethical limitations of human study and no valid animal model.
We tried to find an appropriate animal model for chronic stress and adopt a chronic mild
stress(CMS) model from psychiatric research field. In this study, we evaluate the impact of
chronic mild stress exposure on GI tract and hypothalamic-pituitary-adrenal(HPA) activity
using CMS model. Method: Adult Sprague-Dawley male(N=5) rat(200g) spent 6 weeks under
CMS protocol. Control group(N=5) spent the same period under normal conditions. The
stressors were: food & water deprivation, cage tilt at 45°& wet bedding, intruder sound,
stroboscopic light, restriction in a small cage, replacement of sawdust with sand, strong
illumination, white noise during dark phase. Each stressor lasted 8~18 hours each week.
The body weight of each animal was measured once per week. After CMS protocol, we
assessed EMG response of abdominal muscle to colorectal distension(CRD) using Fogarty
embolectomy catheter and obtained blood sample for hormonal assay in both group. The
adrenal glands were dissected for measurement of weight and colonic samples were collected
to evaluate the change of mast cell using toluidine blue staining. Result: After following
CMS protocol for 6 weeks, the weights of the CMS group were lower than the control
group(310.67±12.94g vs 408.33±16.07g, P<0.01). The threshold to elicit a abdominal muscle
contraction in response to CRD decreased from 0.58±0.09mL in the control group to
0.39±0.09mL in the CMS group(P<0.01). The plasma corticosterone level and absolute
adrenal weight were slightly high in CMS group, but was not statistically significant. But
the relative adrenal weight to body weight was significantly higher in the CMS group
(0.88±0.11mg/g vs 0.69±0.11mg/g, P<0.01). The number of mast cell increased more in
the CMS group(3.47±1.64/mm2 vs 0.55±0.39/mm2, P<0.05). Conclusion: These CRD
response and mast cell changes are consistent with those of human studies and CMS model
induce chronic change of HPA activity; therefore the CMS model of a rat seems to be an
appropriate animal model to research the pathophysiology of IBS in terms of chronic stress.
And chronic stress-induced change of HPA activity may contribute to the alteration of visceral
sensation together with peripheral immune activation.
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M2244
Gastric Electrical Stimulation Modulates Hypothalamic CRF Producing
Neurons During Post Operative Ileus in Rat
Gourcerol Guillaume, Gallas Syrine, Mounien Lourdes, Leblanc Isabelle, Bizet Patrice,
Leroi Anne Marie, Ducrotte Philippe, Vaudry Hubert, Jegou Sylvie
Introduction: Gastric electrical stimulation (GES), a new therapeutical approach in the
treatment of medically refractory gastroparesis, causes symptomatic improvement despite a
modest acceleration of gastric emptying. We aimed to assess the effects of acute GES
on cotricotropin-releasing factor (CRF) producing neurons in paraventericular nucleus of
hypothalamus (PVN), which are involved in gastric ileus induction during laparotomy.
Method: Two electrodes were implanted in the rat gastric antrum during laparotomy, then
stimulation (amplitude: 2 mV; duration 0,3 ms; frequency: 2.1 Hz; 1 minute ON / 2 minutes
OFF) or sham stimulation was applied. Using immunohistochemistry, the number of c-Fos
protein-expressing neurons (FOS-IR) was quantified in PVN after 1 hour of stimulation (n=
10) or sham stimulation (n=10). The number of neurons expressing simultaneously c-Fos
protein and CRFmRNA was measured using in situ hybridization associated with immunocy-
tochemistry, and silver grain density in PVN was calculated both in stimulated (n=6) and
sham (n=6) animals. Finally, c-fos and CRF mRNA levels were determined by quantitative
PCR in the dorsal hypothalamus in sham (n=8) and stimulated (30 min) animals (n=8).
Results: Compared to sham group, FOS-IR in PVN decreased after 1 hour of stimulation
(respectively 295+46 vs 135+31; p<0.05), and was not significantly modified by sub-dia-
phragmatic vagotomy. In PVN, 86.4 % and 72.4 % CRF mRNA positive cells of sham and
stimulated group were c-Fos-positive (p < 0.05). Silver grain density throughout the PVN
was 39% reduced in stimulated group compared to sham group (p < 0.05). Last, both c-
fos and CRF mRNA levels were respectively 56% and 36% decresed after stimulation (p <
0.05). Conclusion: Acute GES modulates CRF producing neurons in PVN during post-
operative gastric ileus and decrease CRF synthesis at this level.
M2245
Gastritis Causes Acid Hypersensitivity and Gender-Related Changes in
Circulating Corticosterone and Anxiety-Related Behavior of Mice
Peter Holzer, Evelin Painsipp, Thomas Wultsch, Anaid Shahbazian
Background and Aims: Gastrointestinal disease is associated with changes in gut function,
abdominal pain and mood disturbances in a gender-dependent manner. In this study we
investigated whether experimental gastritis would alter gastric acid sensitivity, circulating
corticosterone and behavioral indices of anxiety and depression. Methods: Gastritis in female
and male OF1 mice was induced by adding iodoacetamide (0.1 %) to the drinking water
for 7 days; control mice received normal tap water. Inflammation was assessed by the
myeloperoxidase (MPO) activity in the gastric wall, and the plasma levels of corticosterone
were determined with an ELISA. The afferent signaling of a noxious stimulus, hydrochloric
acid (0.25 M HCl), was visualized by immunohistochemistry for c-Fos in the nucleus tractus
solitarii (NTS). Anxiety-related behavior was assessed on the elevated plus maze (EPM) and
via stress-induced hyperthermia (SIHT), while depression-like behavior was estimated with
the tail suspension test (TST). Results: Chronic addition of iodoacetamide to the drinking
water induced gastritis as shown by an increase in MPO activity in the gastric wall. The
increase in MPO activity in female mice was significantly larger than in male mice. The
basal plasma levels of corticosterone in male mice remained unaltered by iodoacetamide,
but were reduced by 65 % in female mice treated with iodoacetamide. Expression of c-Fos
in the NTS evoked by gastric acid challenge was enhanced by 67 % following treatment
with iodoacetamide. The depression-related behavior in the TST was left unaffected by
iodoacetamide. On the EPM, female mice treated with iodoacetamide exhibited fewer entries
into the open arms than control mice, while iodoacetamide-treated male mice did not differ
from their controls. The baseline rectal temperature of male mice treated with iodoacetamide
was enhanced and SIHT was significantly reduced by iodoacetamide treatment. In contrast,
the baseline rectal temperature of female mice was diminished and SIHT elevated following
administration of iodoacetamide. Conclusions: These data indicate that iodoacetamide-
induced gastritis is associated with hypersensitivity to gastric acid challenge. Female, but
not male, mice also exhibit reduced levels of circulating corticosterone and behavioral
signs of anxiety. It is hypothesized that inflammation of the stomach leads to gastric acid
hypersensitivity and gender-dependent alterations in anxiety-related behavior and the hypo-
thalamus-pituitary-adrenal axis. Supported by the Austrian Scientific Research Funds, the
Jubilee Funds of the Austrian National Bank and the Zukunftsfonds Steiermark.
M2246
Trinitrobenzene Sulfonic Acid (TNBS) Colitis Activates ERK in Rat
Lumbosacral Spinal Cord
Liya Qiao, Melisa Gulick, John R. Grider
Activation of extracellular signal-regulated kinase (ERK) in rat spinal cord and peripheral
organs is reported to be essential for pain perception after inflammation or nerve injury.
Our previous study demonstrated activation of ERK5 but not ERK1/2 in lumbosacral dorsal
root ganglia following TNBS colitis. The AIM of this study was to examine the changes in ERK
(ERK1/2 and ERK5) activation in spinal cord following TNBS-induced colitis. METHODS:
Inflammation was induced in rats by colonic instillation of TNBS (0.25ml of 60mg/ml in
50% ethanol). After 7 days, rats were killed by intracardiac perfusion with 4% paraformal-
dehyde for immunohistochemistry or killed by CO2 inhalation and thoracotomy for western
blot. Spinal cord segments from lumbosacral levels L1, L6 and S1 were collected for analysis.
Specific primary antibody against phospho-ERK1/2 or phospho-ERK5 was used for immu-
nohistochemical or western blot determination of phospho-ERK. Fluorchem 8800 software
was used for densitometry analysis. RESULTS: Western blot analysis showed that TNBS
colitis significantly induced phospho-ERK1/2 in L1 (3-fold, p<0.05) and S1 (2-fold, p<0.05)
but not in L6 spinal cord levels. Immunostaining with the specific phospho-ERK1/2 antibody
showed that the increase in phospho-ERK1/2 occurred at the superficial dorsal horn (DH)

















also caused an increase in the density and number of neurons expressing phospho-ERK1/
2 in the region of the gray commisure of L1 spinal cord (3-fold increase, p<0.01). In S1
spinal cord, colitis caused a significant increase in the density of phospho-ERK1/2 in the
region of the sacral parasympathetic nucleus (SPN, 1.7-fold, p<0.01). After colitis, strong
phospho-ERK1/2-stained nerve bundles appeared in S1 lamina I along the lateral edge of
the DH and extended into the region of SPN. Western blot showed no changes in phospho-
ERK5 in any level of spinal cord examined. CONCLUSION: TNBS-induced colitis results
in region-specific changes in phospho-ERK1/2, but not phospho-ERK5 in spinal cord. This
is in stark contrast to our previous studies showing TNBS colitis-induced changes in phospho-
ERK5 but not phospho-ERK1/2 in dorsal root ganglia.
M2247
Abnormalities of Sleep Architecture and Colonic Motility Are Limited to Early
Sleep in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Patients
Heng Y. Wong, Emeran A. Mayer, Bruce D. Naliboff, Britta Dickhaus, Vanessa Z. Ameen,
Joyce Reinholdt, Preetam J. Schramm, Jennifer S. Labus, Teresa I. Olivas, Lin Chang
Background: Subjective reports of poor sleep are a common extraintestinal manifestation
of irritable bowel syndrome (IBS) and have been related to the severity of IBS symptoms.
Even though some studies have reported objective evidence of abnormal sleep in IBS, the
relationships between objective and subjective measures of sleep and colonic motility are
not known. Aims: 1) To compare sleep EEG and colonic motility during consecutive REM
sleep periods in IBS-D patients and healthy individuals, and 2) To assess the relationship
between sleep EEG activity with subjective sleep and colonic motility. Methods: 11 female
IBS-D patients (mean age 38 ± 2.5 yrs) and 13 age-matched controls (Ctrls, mean age 33.8
± 2.7 yrs) were recruited for a 2-night sleep study in the General Clinical Research Center
(GCRC). After 1 night of acclimatization, polysomnograms and left colonic motility index
(MI) were measured simultaneously. Objective sleep measures included duration and number
of REM periods, REM density and alpha wave intrusion during slow wave sleep (expressed
as alpha/delta ratio). Quality of sleep was measured using the Medical Outcomes Study
sleep questionnaire. Results: IBS-D patients showed several abnormal sleep EEG and colonic
motility findings compared to Ctrls only during the first REM sleep period, but normalized
during subsequent REM periods: 1) longer REM duration (27.4 ± 5.4 min vs 11.1 ± 1.4
min, p<0.05), 2) greater REM density (4.0 ± 0.5 vs 2.7 ± 0.3, p<0.05), and 3) greater
colonic MI (p<0.05). In addition, alpha wave intrusion was greater during the first period
of stage 3/4 sleep in IBS-D patients vs Ctrls (3.1 ± 0.5 vs 1.6 ± 0.3, p=0.01). While there
was a positive association between colonic MI and REM duration in all subjects (β=11.9,
p<0.05), correlations between colonic MI and REM density were greater in IBS-D vs Ctrls
(p<0.01). Subjective ratings of sleep adequacy were lower in IBS-D patients vs Ctrls (p<0.005)
and correlated negatively with duration of REM sleep (r=-0.41, p=0.08) and REM density
(r=-0.41, p=0.08) during the first REM period. Conclusions: IBS-D patients have abnormal
sleep EEG and colonic MI in the early part of sleep, but these abnormalities resolve with
sleep progression suggestive of a restorative role of sleep. Increased alpha wave activity
during non-REM sleep in IBS is a novel finding and has been associated with increased
arousability and non-regenerative sleep. These findings are consistent with a compromised
ability of the CNS to downregulate arousal mechanisms during the early phases of sleep.
Supported by NIH grants GCRC #M01-RR00865, P50 DK64539, and GlaxoSmithKline.
M2248
A Role of Stress and Stress-Related Neuropeptide of the Brain in the
Progression of Non-Alcoholic Steatohepatitis (NASH)
Masashi Yoneda, Yukiomi Nakade, Kimihide Nakamura, Masaya Tamano, Tadahito
Shimada, Akira Terano, Hideyuki Hiraishi
BACKGROUND: NASH is a distinct clinical entity characterized by steatosis with inflamation
and fibrosis of the liver. Although the causes of NASH are not well defined, “two hit theory”
is generally accepted but the second hit is still unclear. Epidemiological study has showed
that mental stress is the risk factor for NASH, suggesting a crucial role of mental stress as
the second hit in the progression of NASH. Several neuropeptides are overexpressed in the
brain and play a role in the regulation of stress-related phenomenon. Corticotropin-releasing
factor (CRF) is synthesized in the hypothalamus under stress condition and acts as neuro-
transmitter to control hepatic functions. PURPOSE: To investigate an influence of stress and
involvement of endogenous CRF of the brain in the progression of NASH from simple fatty
liver. METHODS: Fatty liver was induced by subcutaneous injection of CCl4 (2 ml/kg).
Rats were subjected partial body restraint stress just after the CCl4 administration for 6 h.
Serum ALT and hepatic histological changes are assessed 24 h after CCl4 administration.
In another experiment, Either CRF antagonist, astressin, (0.1-1 μg) or saline vehicle was
injected intracisternally just before and 6 h after CCl4 administration. 6-hydroxydopamine
(6-OHDA, 100 mg/kg ip, -7 days and 80 mg/kg ip, -4 days), atropine methyl nitrate (0.15
mg/kg ip, -30 min), hepatic sympathectomy (-3 days), hepatic branch vagotomy (-3 days),
or respective vehicle treatment or sham operation was performed. RESULTS: CCl4 induced
hepatic steatosis with an increase of serum ALT level (106 ± 15 IU/L) 24 after the injection.
Restraint stress induced hepatic necrotic change besides steatosis, and aggravated serum
ALT level (278 ± 35 IU/L). Intracisternal astressin dose-dependently lessened hepatic necrosis
and elevated serum ALT level. The exacerbating effect of restraint stress on CCl4-indiced
liver damage was abolished by sympathectomy or 6-OHDA pretreatment but not by hepatic
branch vagotomy or atropine pretreatment. CONCLUSION: These findings provide a basical
scientific evidence for a crucial role of stress and endogenous CRF of the brain in the
progression of NASH.
T : 89386$$CH2
05-04-06 23:18:29 Page 444Layout: 89386B : e
A-444AGA Abstracts
M2249
Vagal Dependent Gastric Prostaglandin (PG) Release Induced By Intracisternal
(IC) TRH Analog, Rx 77368, Dampens the Gastric Motility Response Through
EP-1 Receptor in Anesthetized Rats
K.K. Kanamoto, Keishi Kawakubo, David W. Adelson, Yvette Tache
BACKGROUND: The stable TRH analog, RX77368 (RX) injected intracisternally (ic) at low
doses (2-10 ng) induces a vagally-mediated, atropine-sensitive and dose-related increase in
gastric PGE2 release that mediates gastric cytoprotection and blunts the acid response in
rats (AJP 1998 274:G170-7). RX ic also induces vagal-dependent stimulation of gastric motor
function (Endocrinology. 1998 139:3730-5). AIM: To assess whether endogenous gastric
PGs also modulate the gastric motility response to ic RX via EP receptors (EPR). METHODS:
Intragastric luminal pressure (ILP) was monitored via a catheter led into the corpus via a
forestomach incision in urethane-anesthetized SD rats. Consecutive ic injections of RX (2.5,
10 ng) were done at a 60 min interval. Integrated (AR: cmH2O*min) and peak responses
(PR: cmH2O) were calculated using computer software (DADiSP ver. 4.1). Basal ILP was
3.9±0.1 cmH2O. Effects of pretreatment with indomethacin (IM, 5 mg/kg, ip) or ONO-
8713, a selective EP-1R antagonist (ONO, 10 mg/kg, IP) were examined. RESULTS: Ic RX
at 2.5 and 10 ng induced a dose-related increase in ILP. In IM treated rats, the AR to ic
RX at 2.5 and 10 ng was increased by 186% and 92%, and PR by 220% and 67%, respectively,
compared with vehicle-pretreated group. Likewise, in ONO pretreated rats, the AR following
ic RX was increased by 109% and 61%, and PR by 292% and 45%. IM and ONO had no
effect by themselves. CONCLUSIONS: Blockade of PG synthesis or EP-1R potentiates the
increased motility induced by ic RX at low doses. This indicates the existence of a PG/EP-
1 inhibitory mechanism recruited by low vagal stimulation that dampens vagally stimulated
gastric motility.
Area of response (AR) and Peak Response (PR). Mean±SEM.
* p≤0.05 vs. RX ic+vehicle#1, †p≤0.05 vs. RX ic+vehicle #2 (ANOVA).
M2250
Neonatal Gastric Suctioning Results in Visceral and Somatic Hyperalgesia in
Adult Rats
C.S. R. Smith, Jyoti N. Sengupta, Adrian Miranda
Objectives: Gastric suctioning of newborn infants is a common procedure in neonatal
intensive care units. Recent evidence suggests that nasogastric suctioning in premature infants
may play a role in the development of visceral hyperalgesia. Animal models have demonstrated
a critical time during development in which the spinal cord is vulnerable to functional
alterations in pain pathways. We hypothesize that repeated orogastric suctioning during the
neonatal period results in chronic alterations in visceral and somatic sensation leading to
hyperalgesia in adult rats. Methods: Neonatal male Long Evans rats (n=13) received daily
orogastric suctioning for 10 days starting at postnatal day two (P2). A separate group of
control (n=15) rats were handled similarly without orogastric suction. At 2 months of age,
electrodes were implanted in the external oblique muscle in both groups for EMG recordings.
The viscero-motor response (VMR) to graded colorectal distension (CRD) was used to assess
visceral sensation (10-80mmHg, 30s, 180s inter-stimulus intervals). Withdrawal thresholds
using noxious heat applied to the hind paws were used to test alterations in cutaneous
sensitivity. Results: Neonataly suctioned rats demonstrated a significant increase in the VMR
to graded CRD when compared to non-suctioned controls (p<0.05). Cutaneous heat evoked
paw withdrawal latencies of control rats (left hind: 13.8±0.7s, right hind: 14.2±0.7s) were
significantly higher than orogastric suction rats (left hind: 10.0±0.7s, right hind: 9.4±0.4s,
p=0.001). Conclusions: Orogastric suctioning during the neonatal period results in global
chronic somatic and visceral hyperalgesia in adult rats. These findings validate the existence
of a critical period early in the development of the nervous system that can be associated
with long-term neural plasticity.
M2251
The Esophagus Is Topographically Organized in the Brainstem According to
Peripheral Location As Well As Receptor Type
Ivan M. Lang, Bidyut K. Medda, Reza Shaker
Prior studies have found a topographical representation of the esophagus in the brainstem
based on peripheral spatial distribution; but evidence suggests that other digestive tract
organs, i.e. tongue, may also be organized in the brainstem according to receptor type. AIM:
To determine whether the esophagus is organized in the brainstem according to receptor
type as well as location. METHODS: Twenty anesthetized cats, 4 per group, were prepared
to determine the brainstem projections of cervical or thoracic esophageal receptors sensitive
to H+ or distension; and the role of the vagus nerves. The cervical or thoracic esophagus
was perfused (1ml/min) with 0.1N HCl for 1.5 hours followed by 0.1M PBS (pH 7.3) for
1.5 hours. A balloon was positioned in the cervical or thoracic esophagus and slowly inflated
to 40-60mmHg 3 times per minute for 3 hours. The cervical H+ receptor protocol was
performed after bilateral vagotomy. At the end of the experiments the brains were removed,
sectioned, and stained for c-fos immunoreactivity. RESULTS: HCl perfusion but not disten-
sion of the cervical esophagus activated neurons in NTSis, NTScom and AP, but not in
NTSce (Table). HCl perfusion or distension of the thoracic esophagus activated neurons in
NTSce, but not in NTSis or AP (Table). Vagotomy blocked all responses to HCl perfusion
of the cervical esophagus (Table). CONCLUSIONS: 1. Receptors of the cervical and thoracic
esophagus project to different sets of brainstem sensory nuclei. 2. Mucosal H+-sensitive but
not muscularis slowly adapting tension-sensitive receptors of cervical esophagus project to
NTSis, NTScom and AP via the vagus nerves. 3. Muscularis slowly adapting tension and
muscosal H+-sensitive receptors of the thoracic esophagus project to the NTSce. 4. Therefore,
the esophagus is topographically organized in the brainstem according to periperal location
as well as receptor type. Supported in part by DK-25731
Table. Number of c-fos positive neurons in brainstem nuclei activated under different condi-
tions
Values are mean ± SE of number of c-fos positive neurons per section. Cerv, cervical; Thor,
thoracic; Eso, esophagus; H+, HCl perfusion; Dist, distension; VX, vagotomy; NTS, nucleus
tractus solitarius; CE, central; IM, intermediate; IS, interstitial; Com, commisural; AP, area
postrema. *, P<0.05 for a difference between groups.
M2252
Sex-Specific Alterations in Central Autonomic Function Among Patients with
Irritable Bowel Syndrome
Kirsten Tillisch, Joshua Bueller, Steve Berman, Brandall Suyenobu, Emeran A. Mayer,
Bruce Naliboff
Background: Sex related differences in autonomic nervous system (ANS) activity have been
described in IBS patients. In general, male patients show greater sympathetic (SNS) activity
compared to females. Skin conductance (SC) is a noninvasive measurement of SNS function
highly sensitive to central arousal. Aims: To examine sex differences in central SNS response
to rectal balloon inflation using PET imaging and SC. Methods: 36 patients (18 male)
with non-constipated Rome+ IBS underwent H215O PET imaging and simultaneous SC
measurement during 0 mmHg and 45 mmHg rectal balloon inflations. Ratings of discomfort
were obtained following the scans. Regression analysis (SPM 99) was used to identify voxels
whose activation positively covaried with SC level across scans in males and females. A
priori regions of interest including the amygdala, insula, midcingulate, and dorsolateral
prefrontal (DLPFC) cortices were determined based on previously described ANS networks.
Statistical threshold for these regions was based on small volume correction (significance
set at p<0.05). A whole brain analysis (significance set at p(uncorrected)<0.001 for apriori
regions) was also performed. Results: Male IBS subjects showed SC positive covariance with
the midcingulate cortex (left: p=0.004, t=4.0 and right: p=0.002, t=5.9), right amygdala (p=
0.014, t=5.2), and left anterior and bilateral posterior insula (p=0.015, t=3.6; p<0.05, t>3.5).
Female IBS subjects showed a positive SC covariance with the DLPFC , left anterior insula
(p=0.034, t=3.5), and left amygdala (p=0.025, t=6.2). As expected with the small samples
size, the greater SC response seen in male patients did not reach statistical significance
(p>0.05). No sex differences were seen in discomfort ratings. Conclusions: 1. Both male
and female patients show a strong positive relationship between SC and limbic brain regions
known to be involved in central autonomic control (amygdala, insula). 2. Sex related
differences in laterality of the amygdala correlation are analogous to previously reported
findings of laterality for memory processing of emotional material. 3. The strong correlation
with MCC in male but not female patients is consistent with greater SNS responsiveness in
men to a pelvic visceral stimulus found in previous studies. 4. The increased DLPFC - SC
relationship found only in women may be related to sex-based differences in corticolimbic
interactions. Supported in part by NIH grants P50 DK64539, DK 48351 and R24 AT002681
M2253
Chronic Restraint Stress Causes NO More Stimulation of Colonic Motor
Function in Conscious Rats
Constant S. Masere, Cindy Chen, Yukiomi Nakade, Kiyoshi Tsukamoto, Christopher
Mantyh, Kirk Ludwig, Theodore N. Pappas, Toku Takahashi
Background; Previous studies have shown that acute stress stimulates colonic motor function,
at least in part, via a central corticotropin releasing factor (CRF) in rodents. However, little
is known whether colonic motility is altered in chronic stress. We studied the changes of
colonic motor function in response to chronic restraint stress or daily administration of CRF
in rats. Methods; For colonic motility study, two force transducers were sutured on the
proximal and distal colon. One week after the surgery, rats were subjected to wrapping
restraint stress for 90 minutes every day for 5 consecutive days (chronic stress). Another
group received intracisternal (ic)-injection of CRF (1 µg) every day for five consecutive days.
Colonic motility was monitored before, during and after the stress loading and CRF-injection.
For colonic transit study, a catheter was inserted into the proximal colon. One week after
the surgery, rats were subjected to chronic restraint stress for 5 consecutive days. On the
5th day, 51Cr was injected via the catheter into the proximal colon before stress loading.
Ninety minutes after the administration of 51Cr, entire colon was removed and divided into
10 equal segments. The radioactivity of each segment was counted and the geometric center
(GC) was calculated as a distribution of 51Cr. Results; At the 1st day of restraint stress,
calculated motility index was significantly increased to 330 +/- 34% and 310 +/- 28% of
basal in the proximal and distal colon, respectively (n=6). Similar results were obtained at
the 2nd and 3rd day of restraint stress. In contrast, at the 5th day, restraint stress caused
no more significant increase of colonic motility. IC-injection of CRF at the 1st day increased
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colonic motility index to 231 +/-38% and 271 +/- 42% of basal in the proximal and distal
colon, respectively (n=5). IC-injection of CRF at the 2nd and 5th day showed similar increase
of colonic motility in the proximal and distal colon. Colonic transit was significantly reduced
following 5 consecutive days of restraint stress (GC=4.8 +/- 0.4; n=6), compared to that of
acute restraint stress (GC; 7.3 +/- 0.5, n=8, P<0.01). Conclusion; Our current study indicates
that colonic motor function is no more stimulated following chronic restraint stress loading
for 5 consecutive days. In contrast, colonic motor responses to central CRF are still observed
following daily-treatment with CRF for 5 days. It is suggested that the decrease in colonic
motor function in chronic stress is not be due to reduced sensitivity of central CRF receptors.
M2254
Clinical Characteristics of IBS Patients with Dysfunctional Endogenous Pain
Modulation
Clive H. Wilder-Smith, Joan Yap-Robert
It has previously been demonstrated that a majority of IBS patients are hypersensitive towards
tonic visceral and somatic stimuli, which coincides with dysfunctional endogenous pain
inhibitory mechanisms (Wilder-Smith et al. Gastroenterology 2005;128(suppl 2):M1492).
These mechanisms comprise a neuromatrix of brainstem, limbic and cortical pathways which
filter and process noxious input and determine emotional, autonomic and motor responses
to pain. In this study we compared characteristics of IBS patients with and without abnormal
endogenous pain modulation. Endogenous pain modulation (diffuse noxious inhibitory
controls, DNIC) was assessed by use of the validated heterotopic stimulation method in 40
female IBS patients (20 IBS-A/D and 20 IBS-C) and 20 matched female healthy controls.
Heterotopic stimulation consisted of simultaneous painful rectal distensions (individual pain
threshold pressure plus 10% for 120s) and cold pain on the left foot (immersion in water
at 4°C for 120s). Rectal pain intensity was rated on a visual analogue scale (0-100) during
rectal distensions without and with the simultaneous cold foot pain. Correlation between
functioning of DNIC and clinical characteristics was performed by multiple regression
analysis. Mean rectal pain during heterotopic stimulation compared to rectal distension
alone decreased in controls but increased in IBS patients (p<0.05), 63% of whom had pain
inhibition values below normal range (<95%CI of controls). Regression analysis showed IBS
patients with abnormal DNIC were significantly more likely to have fibromyalgia, bloating,
imperative urge, more frequent weekly bowel movements, belong to the IBS-A/D group
(p<0.02) than those with normal DNIC. Abnormal DNIC was seen in 14/21 (67%) of IBS
patients with fibromyalgia, in 16/22 (73%) of IBS patients with imperative defecatory urge,
and in 14/20 (70%) of IBS-A/D patients. DNIC malfunction correlated with pain ratings
during separate rectal distension and foot cold pain stimulation (R>0.45, p<0.005). Abnormal
endogenous pain modulation is evident in the majority of IBS patients and is reflected in
clinical IBS characteristics, such as an increased risk of fibromyalgia and IBS-A/D status.
M2255
Gastric Symptom Threshold Requirements for Gastric Wall Electrical
Stimulation in Different Body Mass Index (BMI) Classes
Kathryn A. Stecco, Jacob A. Bashyam, Mohammed A. Habeeb, Chitoor M. Habibullah,
Mir A. Imran
Background: Gastric wall electrical stimulation has been proposed as a way to treat obesity
by altering the brain-gut-axis. Different electrical energy parameters elicit different gastric
symptoms when applied to different locations within the stomach. There is currently no
standard gastric electrical wall stimulation parameter set used to predict the effectiveness
of adequate stimulation. It is also unknown if energy parameter sets will differ between
patients of different body mass indices. Objective: The primary goal of this study was to
electrically stimulate the gastric wall in order to determine the threshold necessary to produce
gastric symptoms across body mass index class range. The secondary goal was to characterize
the gastric symptoms for each regimen of stimulation used. Methods: 26 patients underwent
endoscopic placement of temporary screw-in pacing electrodes in the distal stomach. Patients
were stratified into BMI classes: 5 Normal, 2 Overweight, 7 Class-1, 7 Class- 2, and 5 Class-
3. Each patient received electrical stimulation in the microsecond (uS) range starting with
a pulse width of 100 uS that was increased by intervals of 100 uS up to a maximum pulse
width of 1000 uS. Next 22 out of the 26 patients received electrical stimulation in the
millisecond (mS) range starting with a pulse width of 100 mS that was increased by intervals
of 100 mS up to a maximum pulse width of 500 mS. The pulse repetition frequency was
fixed at 12 CPM and each regimen was repeated for amplitudes ranging from 3 milliamps
(mA) to 20 mA. Gastric symptom scores consisting of nausea, vomiting, satiety, fullness,
pain, bloating and other, were taken at baseline and after each regimen change. Results:
The three most frequently reported gastric symptoms were abdominal pain (non-specific),
crampy abdominal pain, and nausea across all electrical stimulation regimens. Pulses in the
microsecond range were significantly more likely to produce symptoms of nausea than
pulses in the millisecond range (34% vs. 0 %). Class- 3 obese patients required significantly
higher pulse widths in the millisecond range to evoke gastric symptoms than people of
smaller body masses. Conclusion: A certain minimum threshold of distal gastric wall electrical
stimulation is necessary to elicit gastric symptoms in patients across all BMI classes (Normal
through Class-3). Class-3 obese patients required statistically higher pulse widths to evoke
gastric symptoms compared to patients in the lower BMI classes when millisecond pulse
widths were used. The different gastric symptoms may serve as a marker to demonstrate


















Central Neuronal Mechanism of Intestinal Electrical Stimulation: Effects On
Duodenum Distention-Responsive (DD-R) Neurons in the VMH of Rats
J.N. Zhang, J D Z Chen
Background and Aims: Intestinal electric stimulation (IES) has been shown to produce an
inhibitory effect on gastric motility/secretion, gastric emptying, food intake and weight loss
in rats, suggesting a therapeutic potential for obesity. However, possible central mechanism
of this entero-gastric inhibitory effect induced by IES is unknown. It is well established that
the VMH in the hypothalamus is closely related to the regulation of feeding behavior and
plays an important role in the mediation of satiety. The aim of this study was to explore
the hypothesis that the neurons in the VMH are involved in the central mechanisms of the
IES. Methods: Extracellular potentials of single neurons in the VMH were recorded in 18
anesthetized, ventilated male adult rats. After VMH neurons with duodenum distension(DD,
0.5ml, 10~30s) were identified, IES with 3 sets of parameters was performed for one minute
via a pair of platinum electrodes sutured onto the serosal surface of the duodenum 2-4 cm
below the pylorus. IES1 (pulse trains: 4mA, 2s-on, 3s-off, 2ms, 20Hz), IES2 (long pulses:
6mA, 20cpm, 100ms), IES3 (same as IES1 but 40Hz). Results: Fifty nine percent of 34
(59%) neurons in the VMH were responsive to duodenum distension. About Seventy percent
(12/17, 70.6%) of the DD-responsive neurons with DD responded to IES1 and IES3 (increased
pulse frequency), which was significantly higher than that of IES2 (25%, P=0.041). Conclu-
sions: IES with different parameters activated 25-70.6% of the VMH neurons responsive to
DD. Moreover, IES with trains of short-pulses seems more effective than IES with long-
pulses in activating the neuronal activity in the VMH, but an increase in pulse frequency
does not make a difference (IES1 vs. IES3, P>0.05). The modulatory effects of IES on the
central neurons in the satiety center suggesting therapeutic potential of IES for obesity.
M2257
Effect of FMRI Signal Analysis Methods On Quantification of Brain Activity
Associated with Esophageal Acid Exposure in GERD Patients and Healthy
Controls
Mark Kern, Arthi Sanjeevi, Adeyemi Lawal, Venelin Kounev, Reza Shaker
Brain imaging has been frequently used in recent years to study the brain-gut axis. The
effect of various signal analysis techniques on the absolute value of detected cortical activity
volumes is not well known. Aim: To determine whether different analysis techniques are
in concordance in quantifying brain activity during esophageal acid exposure. Methods:
Seven controls (age: 20-44 years, 4 female) and seven GERD patients (age: 20-62 years, 4
female) were studied using a paradigm-driven fMRI experimental protocol to detect regions
of brain activity associated with esophageal acid perfusion. Two 25-minute whole brain
scans were performed. In the first scan, three randomly spaced, two-minute intervals of
esophageal acid perfusion (1 ml/min) were alternated with saline perfusion. The second
scan consisted of two 5-minute intervals of esophageal acid exposure alternated with saline
perfusion. Measured parameters included the number of activated voxels in the fMRI rendered
volumes from each type of scan for three methods of fMRI wave form analysis: 1) cross
correlation analysis; 2) Deconvolution/linear regression analysis and 3) nonlinear regression
analysis. For comparison purposes, the number of activated fMRI volume elements (voxels)
shown to be associated with the acid perfusion stimuli detected by the three analysis
techniques exceeding the probability threshold (p<0.05, corrected for multiple comparisons)
were evaluated. Results: Significant differences in the amount of cortical fMRI activity between
2 minute and 5 minute acid exposure scans were found in both GERD and control groups.
(* p<0.05) These differences were independent of analysis method; however, the absolute
number of activated voxels was highly dependent upon analysis technique. (table) Cortical
region of interest Kappa analysis for the presence or absence of cortical activity showed that
agreement of the three analysis techniques was moderate to very good with the percent
agreement ranging from 71% to 100%. Conclusions: Within- and between-group changes
can be reliably detected irrespective of fMRI signal analysis technique. Absolute values of brain
activity are analysis-technique-dependent and can be used only for comparative purposes.
Comparative studies must be done using the same analysis technique. These findings need
to be taken into account when using fMRI techniques for studies of the brain-gut axis.
M2258
Peripheral Injection of CCK-8s Induces FOS Expression in the Dorsomedial
Hypothalamic Nucleus in Rats
Hubert Moennikes, Stephan Paulitsch, Marco Schmidtmann, Ivo R. van der Voort, Andrea
Riedl, Burghard F. Klapp, Bertram Wiedenmann, Peter T. Kobelt
Cholecystokinin (CCK) plays a physiological role in the regulation of food intake. In the
gastrointestinal tract, it is mainly synthesized in the upper small intestine and released
postprandial. The dorsomedial hypothalamic nucleus (DMH) has been implicated in the
brain regulation of food intake and satiety. The aim of this study was to determine if
peripherally CCK affects neuronal activity in the DMH, as assessed by Fos expression.
Methods. The study was performed in non-fasted Sprague-Dawley rats. At the end of the
dark phase animals received intraperitoneally (ip) 2 µg CCK-8S/kg body wt (n=6) or vehicle
solution (0.15 M NaCl; n=6). Brains were removed 90 min after injection. Fos immunohistol-
ogy (FLI) and additional double staining with anti-thyrosine-hydroxylase (TH) were per-
formed in free-floating technique. Density of Fos positive neurons was semi-quantitatively
determined in the DMH, paraventricular nucleus of the hypothalamus (PVN), arcuate nucleus
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of the hypothalamus (ARC) and ventromedial hypothalamus (VMH) by use of a confocal
laser microscope. Results. CCK-8S (2 µg/kg) injected ip increased Fos immunoreactivity in
the DMH (mean ± SEM: 108±10 vs 54±6 cells/section, p<0.0009) and PVN (120±12 vs
20±3, p<0.0001) compared to the vehicle treated animals. CCK-8S had no effect on fos
expression in the ARC (13±2 vs 12±1, p>0.75) and VMH (25±2 vs 23±2, p>0.56) compared
to the vehicle. The CCK-8S ip-induced FLI positive neurons, mainly localized in the ventral
part of the DMH, were encircled in a network of TH-LI positive fibers. Conclusion. The
present observation that peripherally CCK induces an increase of neuronal activity in the
DMH suggests that the DMH is involved in the CNS regulation of satiety and food intake
mediated via peripheral CCK. It has been shown that numerous afferents from the brainstem
projecting to the DMH originate from the noradrenergic α2-cell group of the nucleus of
the solitary tract (NTS); thus, one can speculate that activation of neurons in the DMH by
peripheral CCK ensues from noradrenergic (i.e. TH-positive) cell groups in the NTS projecting
to the DMH.
M2259
Modulatory Effects and Afferent Pathway of Gastric Electric Stimulation
(GES) On Spinal Neurons Receiving Inputs from Stomach in Rats
J.N. Zhang, Robert D Foreman, J.D.Z Chen, Chao Qin
GES has been suggested as therapy for patients with obesity or gastric motility disorders.
The aim of this study was to investigate the spinal mechanism of GES effects on gastric
function. Extracellular potentials of single spinal (T9-T10) neurons were recorded in pento-
barbital anesthetized, paralyzed, ventilated male rats (n=19). Gastric distension (GD) was
produced by air inflation of a balloon. One pair of platinum electrodes (1.0-1.5 cm apart)
was sutured onto the serosal surface of the lesser curvature of the stomach. GES with four
sets of parameters was applied for one minute: GES-A (6 mA, 0.3 ms, 40 Hz, 2s on, 3s
off), GES-B (6 mA, 0.3 ms, 14 Hz, 0.1s on, 3s off), GES-C (6 mA, 3 ms, 40 Hz, 2s on, 3s
off), GES-D (6 mA, 200 ms, 12 pulses/min). 61/157 (39%) spinal neurons responded to
GD (20 and/or 60 mmHg, 20s). Most GD-responsive neurons (n=47) were excitatory; the
remainder was inhibitory (n=10) or excitatory-inhibitory (n=4). GES-A, -B, -C and -D affected
activity of 32%, 16%, 78% and 35% of GD-responsive neurons, respectively. Bilateral cervical
vagotomy did not significantly alter effects of GES on 6/6 neurons. Resiniferatoxin (2.0 µg/
kg, i.v.), an ultrapotent agonist of vanilloid receptor-1, abolished neuronal responses to GD
and effect of GES in 4/4 rats. The results suggested that GES mainly had an excitatory effect
on T9-T10 spinal neurons with gastric inputs; neuronal response to GES was strengthened
with stimulation at an increased pulse width and/or number of pulses. The modulatory
effect of GES involved thoracic spinal (sympathetic) afferent fibers containing vanilloid
receptor-1. (Supported by a grant from OCAST)
M2260
Chemopreventive ω-3 Fatty Acids Inhibit Colon Cancer Cell Proliferation By
Pkc-δ-Dependent Mechanisms
Sonia R. Cerda, Reba Mustafi, Merry J. G. Bolt, Anusara Chumsangsri, Holly Little, Marc
Bissonnette
Introduction: Previously, we demonstrated PKC-δ inhibited cell cycle progression and
enhanced apoptosis in Caco-2 colon cancer cells by mechanisms involving growth-inhibiting
alterations in G1 cyclins and Bcl-2 family members. In preliminary studies chemopreventive
fish oils (ω-3 fatty acids) increased PKC-δ expression, whereas tumor promoting ω-6 fatty
acids down-regulated the expression of this isoform in azoxymethane-induced colon tumors.
We have recently shown in Caco-2 cells thatω-3 fatty acids up-regulate PKC-δ and antagonize
its down-regulation by the physiological regulator diacylglycerol (DAG). In this study, we
investigated the role of PKC-δ in the anti-proliferative actions of ω-3 fatty acids in Caco-2,
HT-29, and HCT-116 colon cancer cells. Methods: Colon tissues were obtained by endos-
copic biopsy and immediately processed for protein analysis. Cells were cultured for 2-5
days in medium containing 2.5% serum, supplemented with albumin alone or with 100
mM indicated fatty acid complexed to albumin(3:1): ω-3 [eicosapentaenoic acid (EPA),
docosahexaenoic acid (DHA)] and ω-6 [linoleic acid (LA)]. DAG molecular species were
identified by reversed phase HPLC and confirmed by GLC analysis. PKC-δ expression was
inhibited using PKC-δ-specific siRNA oligonucleotides. Protein expression was assessed by
quantitative Western blotting and cellular proliferation by WST-1 and BrdU assays. Results:
In human colon, PKC-δ was significantly decreased in adenomas and carcinomas by more
than 60% and 80%, respectively, compared to adjacent colonic mucosa (n=8, p<0.05).
Consistent with an anti-proliferative role for PKC-δ in colon cancer cells, PKC-δ knock-
down with specific siRNA (>80% inhibition), significantly and dose dependently increased
cell proliferation in Caco-2, HCT-116, and HT-29 cells (p< 0.05). Activating changes in
PKC-δ phosphorylation were assessed in fatty acid treated cells. ω-3 fatty acids (EPA,DHA)
increased levels of phospho-Ser643 and phospho-Thr505 PKC-δ. These free fatty acids also
caused species-specific alterations in DAG fatty acid composition in Caco-2 cells. Further-
more, knock down of PKC-δ in these cells with specific siRNA blocked growth inhibition
by ω-3 fatty acids (EPA,DHA), supporting our hypothesis that the chemopreventive actions
of fish oils are mediated in part by PKC-δ dependent mechanisms. Conclusion: We have
identified novel DAG-dependent mechanisms regulating PKC-δ expression that contribute
to the anti-proliferative actions of ω-3 fatty acids. We postulate these PKC-δ-dependent
anti-proliferative pathways mediate the chemopreventive effects of fish oils in colonic carcino-
genesis.
M2261
Glutamine, Butyric Acid, and Antioxidants in Combination Inhibit
Proliferation and Induce Differentiation in Colorectal Tumor Cell Lines
Independent of Apoptosis
Torsten Steinbrunn, Theodor Kudlich, Juergen Schauber, Ralph Melcher, Hardi Luehrs,
Andrea Gostner, Wolfgang Scheppach, Thomas Menzel
Rationale: Glutamine, butyric acid, and antioxidants are used as nutritional immune modu-
lating compounds for critically ill patients. While glutamine serves as a major energy source
for rapidly dividing cells it also promotes growth of neoplastic cells and inhibits apoptosis.
Butyric acid stimulates growth of normal colonic cells in vivo but reduces proliferation of
neoplastic cells in vitro. Antioxidants like ascorbic acid or selenium may selectively induce
apoptosis in tumor cells while stimulating growth of normal cells. The combination of these
substrates could lead to an immune and growth enhancing effect in normal cells without
stimulating tumor cell growth. Methods: The colorectal carcinoma cell lines SW-620 and
HT-29 and the adenoma cell line Geki-2 were incubated with an enteral immunonutrition
supplement consisting of high doses of glutamine, butyric acid, and antioxidants (Intesta-
min®) for 24h, 48h, and 72h in standard medium ranging from 1.25% to 10%. Cell cycle
distribution and apoptosis were measured with FACS using annexin V/propidium iodide
staining. Cell proliferation and differentiation were determined by cell count and levels of
alkaline phosphatase (AP), respectively. Expression of factors of cell cycle control and
apoptosis (PCNA, P21, P53, Cdk-2, Bcl-2, Bax, Bak) was investigated by western blot and
a cDNA-array testing 12000 genes was performed. Results: Proliferation was inhibited in
all tested cell lines time and dose dependently. Compared to untreated controls, treated
cells (5% vol.) showed a significant decrease in proliferation to 68±5% (HT-29, 24h), 74±7%
(SW-620, 24h), and 33±4% (Geki-2, 72h). AP levels significantly increased time and dose
dependently from 3U/l to 30U/l in HT-29 (10% vol., 72h) and from 28U/l to 71U/l in SW-
620 (2.5% vol., 72h), indicating an increase in cellular differentiation. While P21 protein
levels increased in SW-620 cells, the expression patterns of the other tested factors were
not modulated. The cDNA-array showed all genes being regulated less than 1.5. Accordingly,
cell cycle distribution and rate of apoptotic cells remained unchanged. Conclusion: The
combination of glutamine, butyric acid, and antioxidants inhibits tumor cell proliferation
and stimulates cell differentiation. Apoptosis is not inhibited and cell cycle remains stable.
If clinically well tolerated, critically ill patients could benefit from the combined immune
stimulation and energy provided by these substrates while growth of transformed and
potentially malignant cells would not be promoted but selectively inhibited. Therefore, the
combination might improve outcome also in cancer patients.
M2262
Omega-3-Fatty Acids Inhibit the Proliferation of Colorectal Cancer Cells -
Evidence for Pparγ Independent Mechanisms
Sandra Ulrich, Yasemin Turan, Loitsch Stefan, Juergen Stein
Introduction: Recent studies have shown that lipid emulsions, containing the ω-3 polyunsat-
urated fatty acids (ω-3-FA) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
exhibit potent antiinflammatory and antiproliferative properties. While the transcription
factor PPARγ seems to mediate antiinflammatory effects, an involvement in ω-3-FA-induced
cell growth inhibition of cancer cells is discussed controversially. The aim of this study was
to characterize anticarcinogenic effects of ω-3-FA in colorectal cancer cells and to further
specify a possible role of transcription factor PPARγ. Materials and Methods: The colorectal
cancer cell lines Caco-2 and HCT-116 were cultured under standard conditions and were
treated with increasing concentrations of standardized lipid emulsions containing ω-3- [10-
100µM EPA and DHA] and ω-6-FA. Treatment with butyrate [2mM] was performed to
induce PPARγ expression (BBRC, 2000) which is described to be a molecular target both
of EPA and DHA. Cell growth was determined by MTT assay and crystal-violet staining.
Caspase-3 induction was determined via an activity assay. PPARγ, p27Kip1 and Cyclin E
protein was determined by Western blot analysis. A dominant-negative PPARgamma mutant
was transfected in Caco-2 cells to suppress PPARgamma-mediated functions. Results: In
contrast to ω-6-FA, treatment with ω-3-FA leads to a significant dose- and time-dependent
reduction of cell counts and cell proliferation, whereas co-incubation with butyrate signific-
antly enhances these effects [Means ± SE, ***p<0.001 at EPA [50µM]]. In contrast to ω-
6-FA,ω-3-FA further significantly induce caspase-3 activity Means ± SE, *p<0,05). Incubation
with ω-3-FA on the one hand leads to an upregulation of p27Kip1 protein concentration
and on the other hand to an decrease of Cyclin E expression. Althought PPARγ mediated
effects are suppressed, no differences in cell growth inhibitory actions could be observed
in PPARγ mutant and empty vector cells after treatment with ω-3-FA. Conclusion: The
current results confirmed cell growth inhibitory effects of ω-3-FA in a cell culture model
of colorectal cancers, which seem to be mediated through an activation of cell cycle inhibitor
p27Kip1 as well as an inhibition of cyclin E. However, in contrast to the involvement of
PPARγ in antiinflammatory properties of ω-3-FA, these effects are indicated to be mediated
PPARγ-independently.
M2263
Moderate Alcohol Consumption Protects Against Colorectal Adenomas
Gregory Austin, Joseph Galanko, Christopher Martin, Robert Sandler
Background: Alcohol in moderation has been recommended to decrease the risk of cardiovas-
cular disease. The effect of moderate alcohol consumption on other outcomes is not as well
known. Previous studies have shown an association between excessive alcohol consumption
and an increased risk of colon cancer. However, the effect of moderate alcohol consumption
on the risk of colorectal adenomas and cancers has not been well-studied. Aim: To determine
the effects of moderate alcohol consumption on colorectal adenomas. Methods: 725 eligible
patients were included from the Diet and Health Study 4, a case-control study to evaluate
risk factors for colorectal adenomas. There were 203 cases and 522 controls. All patients
underwent a full colonoscopy. Alcohol consumption was obtained using the National Cancer
Institute’s Food Frequency Questionnaire. Patients were divided into five groups based on
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the average number of alcoholic drinks consumed per week: 1) 0 drinks/week; 2) >0 and
<2 drinks/week; 3) 2-<7 drinks/week; 4) 7-<14 drinks/week; and 5) >=14 drinks/week.
Odds ratios were calculated using logistic regression, controlling for potential confounders
sex, age, body mass index, use of non-steroidal anti-inflammatory medications, race, and
smoking. Results: The groups consuming >0 and <2 and 2-<7 drinks of alcohol/week had
the lowest adjusted probability of having an adenoma. Using the group consuming >0 and
< 2 drinks/week as the reference group, non-drinkers had an adjusted OR of 1.41 (95%CI:
0.83-2.39); patients consuming 7-<14 drinks/week had an OR of 1.67 (95% CI: 0.88-3.18);
patients consuming >= 14 drinks/week had and OR of 2.51 (95% CI: 1.24-5.07). The
patients consuming >=14 drinks/week were also at significantly increased odds of having
an adenoma compared to the group consuming 2-<7 drinks/week (OR 2.34, 95% CI: 1.14-
4.83). Conclusions: Individuals who consume moderate amounts of alcohol are at lower
risk of colorectal adenomas than nondrinkers and heavy drinkers. Moderate alcohol consump-
tion may benefit the colon as well as the heart.
M2264
Antineoplastic Effects On Colorectal Cancer Cells of Plantago Ovata Husk
After Fermentation with Human Gut Flora
Anna Giros, Xavier Llor, Elisenda Pons, Lurdes Fluvia, Rosa M Xicola, Anna Anguera,
Miquel A Gassull
Introduction: Wide geographical differences in colorectal cancer (CRC) incidence and a
rapid adaptation of migrant populations to the incidence of hosting regions suggest that
environmental factors, among them nutrients, play a crucial role in CRC development. Data
on the effects of dietary fiber on CRC incidence has often been inconclusive. At the experi-
mental level, few studies have attempted to evaluate the effects of fiber on colorectal malignant
cells under conditions that mimic the process that fiber undergoes inside the human gut.
Objectives: To establish the capacity of products generated by plantago ovata husk fermenta-
tion in human feces to induce apoptosis and regulate proliferation in two colorectal adenocar-
cinoma cells lines, Caco-2 and HT-29. Methods: Fresh stool specimens were collected from
healthy volunteers. Fecal homogenates (dilution 1:5 with sodium bicarbonate) were incubated
with either plantago ovata husk powder (20mg/ml) or with no fiber addition, under anaerobic
conditions at 37°C for 48h. Bacterial fermentation was stopped by freezing at -80°C. Short
chain fatty acids were determined by GLC using a semipolar column. Samples were then
filtered with a 0.22mc filter for bacterial elimination and immediately frozen in small aliquots
at -80°C. HT-29 and Caco-2 cells were supplemented with sera-free media plus: A)the
products of fermentation with plantago ovata husk; B)control buffer; and C)pure butyrate
at 1.5mM. Apoptosis was assessed 48h post supplementation by flow cytometry. Proliferation
was evaluated through counting of [H3] thymidine incorporation 4h after incubation at 24h
post supplementation. All experiments were repeated at least 6 times. Statistical analysis
was performed using the Kruskal-Wallis one-way analysis of variance by rank and the Mann-
Whitney U-test (P< 0.0) Results: Apoptosis experiments: results are expressed as apoptosis
index (AI) defined as percentage of apoptotic cells out of the total number of counted cells
(10,000), SE+/-1: In HT-29 cells, mean AI was: cells supplemented with A: 44.3; supplement
B: 11.24; and supplement C: 43.13. In Caco-2 cells, A supplement: 39.55; B: 9.04; and C:
42.11. In both cases there were no statistically significant differences between plantago ovata
husk and butyrate and both were statistically different from control, P<0.005. Thymidine
incorporation with supplements A: 943; B: 4123; C: 4635 u. Plantago ovata husk was
statistically different from control and butyrate (P< 0.005). Conclusions: Products resulting
from plantago ovata husk fermentation with human gut flora behave as antineoplastic agents
through the induction of apoptosis and inhibition of cell proliferation.
M2265
Leptin and Leptin Receptor Expression in Colo-Rectal Cancer: Role of
Microsatellite Instability
Nijez Aloulou, Marie-Therese Chaumette, Amel Sekour, Karen Leroy, Mohammad
Abolhassani, Iradj Sobhani
Leptin regulates nutriment intake via specific hypothalamic receptor (ObRb). Colo-rectal
cancer (CRC) is influenced by nutritional factors. Leptin stimulates colonocyte proliferation
and invasiveness of CRC cells in vitro. The aim was to investigate leptin receptor (ObRb)
expression in CRC in reference with serum leptin level and mismatch repair status. Patients
& methods. Consecutive patients (73 F, 92M; 70+/-12 yrs) with rectal (33) or colon (132)
adenocarcinoma underwent surgery. Microstallite instability (MSI) phenotype was character-
ized by immunohistochemistry (IHC) and PCR in tumours. ObRb was evaluated in tumours,
homologous normal tissues, and culture cells (HT29, HCT116 and HCT116 with a transferred
Ch-3) by both IHC and RT-PCR. Patients were ranged in two categories, with and without
ObRb tumoral overexpression as compared to normal homologous tissue. The level of nuclear
fraction of PPARgamma in normal colon tissue, in tumours (N=3), and in HT29 culture
cells before and 24h after leptin (0.1 microM) treatment, was measured (ELISA, Kit). Exact
Fisher, Anova t tests and multiple regression analysis were used for statistical analyses.
Results. ObRb was expressed in normal and tumor tissues. In reference to normal tissue,

















with MSI-H phenotype (93.7% versus 62.5% in MSS; P=0,01), right sided (85% vs 63%,
P<0,04), and individuals > 60 yrs (76% vs 57%; P=0.04), when size-, pTNM- and differenti-
ation of the tumors, were not significant related. ObRb was expressed more in HCT116
cells than in HCT116-Ch3. Serum leptin level, although was informative of BMI>30, failed
to predict location, staging and ObRb expression in tumours or normal colo-rectal mucosa.
The level of PPARgamma was significantly higher in tumour than in normal homologous
tissue; in HT29 culture cells, it was three-five fold increase after treatment by leptin. Conclu-
sion. Specific leptin receptor ObRb is overexpressed in CRC with microsatellite instability
and may influence regulation of energy in tumours since it is accompanied with PPARgamma
enhancement. This may be an adaptative pattern of some colon tumour cancer cells to
energy uptake and expenditure.
M2266
Nutritional Status Is Predictive of Clinical Complete Response to
Chemoradiotherapy in Locally Advanced Esophageal Cancer
Stephane Lecleire, Frederic Di Fiore, Eric Lerebours, Pierre Michel
Introduction. Definitive chemoradiotherapy (CRT) is to date considered as an alternative
curative option in patients with locally advanced esophageal cancer (LAEC). Severe undernu-
trition is found in approximately 60% of these patients. Impact of nutritional status on
complete response to definitive CRT has not been demonstrated yet. The aim of the study
was to assess the influence of ongoing undernutrition prior to CRT on the clinical complete
response in patients with LAEC. Patients and Methods. Fifty-nine patients with LAEC treated
by definitive CRT were retrospectively included in the study. CRT encompassed external
beam radiation (50 to 60 Grays) and 5-Fluorouracile (5-Fu)-cisplatine chemotherapy courses.
Clinical complete response was defined by the absence of tumor at endoscopy and the
absence of distant metastases at CT scan two months after the end of CRT. Nutritional status
of all patients was assessed prior to CRT by the serum albumin level and by the weight loss
percentage as compared to the initial weight. Clinical and nutritional characteristics of
responder patients to CRT were compared to those of non-responder patients using the chi-
square and Student’s tests. Results. Thirty-seven patients (63%, group 1) were complete
responders after CRT, and 22 (37%, group 2) were non-responder patients. Mean age (63
vs 65 year-old), Tumor Node Metastasis Classification, Atkinson’s dysphagia score (2.1 vs
2.4) and Who Performance Status (0.7 vs 1) were not different between the two patient
groups. Prior to CRT, patients from group 2 presented with a poorer nutritional status as
compared to patients from group 1. Patients from group 1 had a lower serum albumin level
(33 vs 40 g/L; p=0.025) and a more important weight loss (10% vs 5%; p=0.009) than
patients from group 2. More, esophageal dilation prior to the CRT was more often required
in patients from group 2 (59% vs 19%; p=0.004). Conclusion. Patients with LAEC who do
not respond to CRT appear to have significant undernutrition prior to CRT. Early nutritional
intervention could increase the rate of complete response to CRT in these patients. These
results suggest the value of nutritional status assessment prior to CRT in the management
of patients with LAEC.
M2267
Impact of Bariatric Surgery On the Gastro-Esophageal Reflux Disease and
Esophageal Motility in Morbid Obesity Patients
Vicente Ortiz, Ponce Marta, Marisa Iborra, Belen Beltran, Bastida Guillermo, Jose Luis
Ponce, Garrigues Vicente, Julio Ponce
Esophageal motility disorders and gastro-esophageal reflux disease (GERD) are more preval-
ent in patients with morbid obesity (MO) than in the general population. However, the
influence that bariatric surgery have on these variables is unknown. Aim: To evaluate the
influence that bariatric surgery have on GERD and esophageal motility. Methods: Eighty-
two consecutive patients with MO (body mass index (BMI)≥ 40 kg/m2) were prospectively
evaluated before and six months after having bariatric surgery. In all cases the surgical
technique used was a vertical gastroplasty plus a gastro-jejunal bypass. The parameters
investigated were: 1) Esophageal symptoms registered through a structured clinical question-
naire. The consensus diagnostic criteria for GERD of having two or more episodes of
heartburn in one week was used. 2) Esophageal exposure to acid which was achieved
through a pH-metry (considered positive when time of exposure to pH< 4 was greater than
5 % of the time). 3) Alterations of esophageal motility observed in a manometry. None of
the patients was on anti-secretory therapies at least for 10 days previous to their evalutation.
Results: The mean age of the patients was of 41.3±10.1 years (61 women/21 men). The
BMI previous to surgery was of 50.1±6.4. Six months after the bariatric surgery their BMI
was 37.5±5.4 with a mean weight loss of 35.6±13.2 Kg. The main changes observed on
symptoms and esophageal function are shown in table. The prevalence of GERD (symptoms)
and the rate of pathological exposure to acid (positive pHmetry) were significantly reduced
six months after the bariatric surgery. The percentage of time with pH <4 (n=82) was
8.1%±11.8 (females 5.9%/males 14.7%) and after the surgery was 2.9%±5.4 (females 3.1%/
males 2.6%) (p=0.005). The initial lower esophageal sphincter pressure was of 14.9±7.0
mmHg and it was not modified after surgery. The manometry of the MO patients showed
that they had an hyper-contractile oesophagus (nutcracker pattern which is defined by
presenting peristaltic waves with a mean amplitude > 180 mmHg) in the 18.3 % of the
patients. This percentage was reduced after surgery to 6.1 % of the patiens. No other changes
in the esophageal motility was observed after surgery. Conclusion: The prevalence of GERD
(symptoms and pHmetry) and their esophageal hypercontractility decrease after bariatric
surgery in patients with MO.
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M2268
Effects of Retrograde Gastric Electrical Stimulation with Pulse Trains On
Gastric Emptying of Solids and Plasma Hormones in Dogs
Gengqing Song, Yan Sun, Xiaohua Hou, Bin Yang, Wei Qian, Jiande Chen
Retrograde Gastric Electrical Stimulation (RGES) is proposed as a novel therapy for obesity.
However, mechanisms of RGES involved in treating obese patients are not fully investigated.
Aims: The aim of this study was to investigate the effects of RGES with trains of pulses on
gastric slow waves, gastric emptying of solids and plasma concentrations of satiety-related
peptides and glucose. Methods: Seven female beagle dogs implanted with four pairs of gastric
electrodes on the gastric serosa were studied in two randomized sessions (control and RGES).
Gastric emptying was measured by scintigraphy using a 99mTc-labeled egg meal (255 kcal)
for a period of 4 hours in each session. Blood samples were collected at 45 and 15min
before, 30, 60 and 120min after the meal. Plasma leptin, insulin and glucagon were measured
using radioimmunoassay method. Plasma glucose was assessed with a commercially available
glucometer. In the RGES session, RGES was applied via the distal pair of electrodes (2cm
above the pylorus) with trains of pulses (frequency: 40 Hz; pulse width: 2ms; amplitude:
5mA; train on-time, 2s; off-time, 3s). RGES was initiated 30 min before the first blood
sample and maintained for a period of 2.5 hours. Gastric slow waves and symptomatic
response were also recorded in each session. Results: 1) Similar to long pulses, RGES with
pulse trains (12 trains/min) was capable of turning regular gastric slow waves into tachygastria.
The percentage of tachygastria (>6 cycles/min) in the fed state with RGES was 78.1±5.3%
compared with 0.4±0.3% in the control session (p<0.01). 2) RGES was able to delay gastric
emptying of solids (P<0.05). The mean T50 of gastric emptying was significantly increased
from 177.7±27.1 min without RGES to 254.6±71.7 min with RGES (P=0.024). 3) Compared
with the control session without RGES, the total AUC’s of plasma insulin with RGES was
significantly decreased in the fasting and postprandial periods (p<0.05). However, the total
area under curves (AUC’s) of plasma leptin, glucagon, and glucose were not significantly
affected by RGES (p>0.05). 4) This method of GES induced no noticeable symptoms.
Conclusion: RGES with at a tachygastrial frequency decreases gastric emptying of solids and
plasma insulin, but has no effect on plasma leptin, glucagons, and glucose. These findings
are indicative of therapeutic potential for obesity.
M2269
Relationship Between Obesity, Nocturnal Heartburn and Night-Time Reflux
Maribal Gonzalez-Gutierrez, Jose M. Remes-Troche, Mariel Mejia-Rivas, Ana T. Abreu y
Abreu, Jose A. Chavez-Barrera, Miguel A. Valdovinos
Background/Aim: Night-time GERD symptoms are more troublesome than those that occur
during the day. Several mechanisms have been related to night time reflux (NTR), including
an impaired esophageal acid clearance, low production and flow of saliva, and reduced
lower esophageal sphincter pressure. Although obesity has been associated with an increase
risk for GERD symptoms and erosive esophagitis, the relationship with nocturnal heartburn
(NH) and NTR is not known. Our aim was compare the prevalence of NH and NTR in
both obese and non-obese patients with GERD. Material and Methods: Consecutive patients
with symptomatic GERD were evaluated from January to June 2005. Esophageal mucosal
injury was assessed by upper endoscopy. All patients underwent esophageal 24-h pH mon-
itoring. NH was defined as presence of symptoms at night and in supine position. Abnormal
pH was considered when total % of time of pH<4 was >4.2%. Abnormal NTR was defined
as a % of time of pH<4 >1.2% at night. According to body mass index (BMI) patients were
classified in 2 groups: I) non-obese patients (BMI ≤ 30), and II) obese patients (BMI> 30).
Data were analyzed with Mann-Whitney U and χ2 tests. Results: 79 patients, 60 F (76%)
with a mean age of 45 years (range 20-75) were included. There were 50 patients in group
I and 29 in group II. Overall prevalence for NH and NTR was 42 %(n=33) and 52% (n=
41), respectively. There was no correlation between NH and NTR. Prevalence of NH was
similar in both groups (p>0.05, Table). In contrast, NTR prevalence was significantly higher
in obese patients (OR 3.06, 95% CI 1.18-7.9,p=0.04). Total reflux episodes, nocturnal
reflux episodes, and % of pH<4 were also significantly higher in group II patients (Table).
Conclusions: Obesity is a risk factor for abnormal acid esophageal exposure during the
night. However, symptomatic perception during the night was not associated with a high BMI.
These findings suggest that for nocturnal GERD symptoms perception, other mechanisms are
more important than obesity.
* p<0.05
M2270
RELMβ Is an Intestinal Epithelial-Derived Hormone Responsible for Host
Metabolic Adaptation to Chronic Parasitic Nematode Infections
Marie A. Hildebrandt, Qi Yong, Seana M. Thrasher, Laila M. McVay, Wolfgang Stehr, Brad
W. Warner, Judith A. Appleton, Rexford S. Ahima, Gary D. Wu
We have shown that RELMβ is an intestinal goblet cell-specific protein that is constitutively
expressed in the colon and can be strongly induced upon Th2 immune activation by intestinal
parasitic nematode infections. Previously reported studies have demonstrated a role for a
closely related protein, resistin, in the regulation of glucose homeostasis in mice. In order
to elucidate the function of RELMβ in vivo, we have developed a RELMβ knock-out mouse
and determined its metabolic response in a murine model of diet-induced type 2 diabetes
mellitus and upon parasitic infection with Heligmosomoides polygyrus. Although RELMβ is
secreted into the stool, it is also detectable in serum. Serum levels of this protein decrease
dramatically after a subtotal colectomy in mice confirming the colon as the source of
circulating RELMβ. Through the use of glucose and insulin tolerance tests as well as hyperin-
sulinemic-euglycemic clamps, we show that compared to wild-type mice, RELMβ knock-
out mice exhibit increased insulin resistance through an increase in hepatic glucose produc-
tion and a decrease in glucose uptake in both adipose tissue and skeletal muscle. These
results demonstrate that RELMβ is a circulating hormone that functions to enhance insulin
sensitization. Upon infection with the small intestinal nematode, H. polygyrus, there is a
dramatic induction of RELMβ in the small intestine with a resultant 8-fold increase in serum
levels. Whereas wild-type mice are able to compensate well for the metabolic challenges
imposed by parasitic infection, RELMβ knock-out mice demonstrate a significant loss in
weight due to a decrease in adipose tissue mass. These results show that RELMβ enhances
insulin-dependent effects on both glucose homeostasis and anabolic function in the same
target tissues, thus protecting host nutritional status in the setting of a chronic parasitic
infection. As a newly described gut hormone produced by goblet cells, RELMβ may provide
novel insights into the pathogenesis and therapy of type 2 diabetes mellitus.
M2271
Gastric Electrical Activity Before and After Bionterics Intragastric Balloon
(BIB) Placement
Gustavo A. Torres-Barrera, Francisco Bosques-Padilla, Hector Maldonado-Garza
BACKGROUND: Obesity is increasing worldwide. BIB has been used by some groups as an
alternative to Surgery or in preparation to it. The mechanisms involved are partially studied.
Recently the effect of BIB has been published, observing a reduction in Ghrelin levels as a
factor in BIB effect. We hypothesized that the presence of the BIB can promote gastric
dysrrhytmia, and early satiety.AIM:The aim of this study was to evaluate the effect of the
presence of BIB on gastric electrical activity.METHODOLOGY: We included 15 overweight
patients that meet the following criteria: 1) Body Mass Index (BMI) above 30, 2) Age above
18, 3) Informed consent. Exclusion criteria: 1) Previous gastric surgery, 2) Associated
diseases with effect on gastric motility 3) Peptic ulcer or erosive esophagitis, 4) Hiatal hernia
>3cms.METHODS. An electrogastrogram (EGG) was performed before and one month after
BIB placement. We used a Medtronic polygraph and EGG software. The procedure was
performed early in the morning, after an overnight fast and in the absence of medication
with effect in motility. The recording included a preprandial and a postprandial period. We
used a standard meal (250grs normal yogurt providing 204kcal) We evaluated the results
in frequency in cpm in channels with the best recording of the electrical activity. A Wilcoxon
test was used in statistical analysis.RESULTS. Patients were 13F/2M, mean age 34±8 range
20-51; mean BMI 36±4 range 30-43.6. In every patient gastric electrical activity before BIB
placement was in the normal range (2.5-3.5cpm). Frequency was significantly reduced after
BIB placement in all patients p<0.001 and in 6 /14 reduction was below the normal
range.Conclusion. BIB reduced gastric electrical activity in obese patients which can be one
of the mechanism involved in its satiety effect
M2272
Gastric Motor and Sensory Functions in Normal Weight, Overweight and
Obese People
Maria I. Vazquez-Roque, Debra Stephens, Duane Burton, Kari Baxter, Michael Ryks,
Matthew Clark, Michael D. Jensen, Alan R. Zinsmeister, Michael Camilleri
Background: The literature on motor and sensory functions of the human stomach in relation
to body mass presents contradictory information, in part because the functions have not
been systematically studied in the same cohort of people. On the other hand, obesity is
associated with several upper gut symptoms, and the mechanisms of symptom generation
are unclear. In obesity, measured gastric volumes were normal except in the presence of
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bulimia (Physiol Behav 2004;81:735-40). Aim: To compare gastric volumes, emptying,
maximum tolerated volumes (MTV) and post-challenge symptoms in normal, overweight,
or obese volunteers who were otherwise healthy. Methods: We studied 68 of 72 participants
in normal, overweight, or obese (WHO criteria) groups (all non-bulimic) and documented
their lean mass and % fat by body composition (DEXA). All underwent the following
measurements using validated tests: gastric emptying for solids and liquids by scintigraphy
(GE t1/2); gastric volumes by SPECT, a validated imaging method (Gut 2002;51:781-6);
MTV and 30 min post-challenge symptoms by satiation test (Neurogastro Motil 2002;14:249-
53). Statistical analysis used one-way ANCOVA adjusted for gender. Results: The table
summarizes the data, mean±SEM. There were significant differences in lean and fat mass
and significantly lower fasting gastric volumes in the overweight and obese groups. We also
observed borderline lower postprandial volume changes in obese and borderline faster gastric
emptying of liquids. Conclusion: Being overweight or obese is associated with lower fasting
gastric volumes, but there is no difference in food volume tolerated or symptom score after
a challenge meal. The significance of lower fasting gastric volumes to upper gut symptoms
in obesity requires further study.
Compared to normals: * p=0.003; ** p=0.055; $ p=0.03; # p≤0.10
M2273
Organ-Specific Function of Pparα As Revealed By Gene Expression Profiling
Meike Bunger, Heleen van den Bosch, Mechteld Grootte Bromhaar, Philip de Groot,
Sander Kersten, Guido Hooiveld, Michael Muller
Introduction The peroxisome proliferator-activated receptor alpha (PPARα) is a fatty acid-
activated transcription factor expressed at high levels in small intestine and liver, two key
organs in whole-body metabolism of (dietary) triglycerides (TGs). The importance of PPARα
in TG metabolism is illustrated by the fact that agonists targeting PPARα, such as poly-
unsaturated fatty acids (PUFAs) and fibrates, are commonly used for the treatment of
dyslipidemia. Whether PPARα functions differently in small intestine and liver is currently
unknown. The aim of this study was to compare genome wide effects of PPARα activation
between small intestine and liver. Methods Wild-type and PPARα-null mice were fed a diet
supplemented with a synthetic PPARα ligand (0.1% WY14643) for 5 days. RNA was extracted
from small intestine and liver and hybridized to Affymetrix MOE430 2.0 arrays. Data was
analyzed applying the packages gcRMA for data processing, and LIMMA for statistical
analyses. Differentially expressed transcripts were selected based on fold change (>1.5) and
false discovery rate (<0.05). Data was functionally analyzed based on Gene Ontology using a
score resampling method, metabolic and signal transduction routes using gene set enrichment
analysis, and biological interaction networks using text-mining software. Results qRT-PCR
analyses showed that PPARα is expressed in small intestine and liver at comparable levels.
Feeding studies identified 1918 respectively 4003 PPARα target genes in SI and liver. These
target genes could be divided into three sets, namely those regulated in both tissues (668
genes; corresponding to 35% respectively 17% of regulated genes in SI and liver), those
regulated exclusively in small intestine (1250 genes) and those regulated exclusively in liver
(3335 genes). Processes that were affected in both tissues include metabolism of lipids and
energy-rich intermediates, organelle organization and biogenesis, and humoral immune
response. Specific PPARα-dependently regulated processes in small intestine were antigen
presentation via MHCII, B-lymphocyte proliferation, various cell signalling pathways, and
bile acid metabolism. Liver specific processes were coagulation and wound healing, non-
lymphocyte mediated immune response, non-lipid nutrient metabolism, and control of cell
growth. Conclusion PPARα in small intestine and liver controls the expression of a distinct
set of genes, demonstrating that these organs use different strategies to adapt to high
levels of agonists. We speculate that this differential regulation is an important mechanism
explaining the well-known health-promoting effects of PUFAs and lipid-lowering drugs.
M2274
Comparison of Glycine and Leucine Kinetics in Obese Subjects
Yoshihisa Urita, Susumu Ishihara, Kenichiro Arai, Jun Kondo, Tatsuo Akimoto, Hiroto
Kato, Noriko Hara, Hideyuki Koshino, Yoshiko Honda, Yoko Nagai, Kazushige Nakanishi,
Nagato Shimada, Motonobu Sugimoto, Kazumasa Miki
Background: Although it is well established that human obesity is accompanied by abnormal-
ities in glucose and lipid metabolism, it has been unclear whether protein metabolism also
is disturbed. The aim of this study is to evaluate small intestinal absorption of nutrients,
including glucose, amino acid, and short-chain fatty acid in obese subjects. Patients and
methods: Consecutive 130 subjects who underwent upper gastrointestional endoscopy were

















(BMI). The obesity group consisted of 21 patients with BMI of more than 26. At endoscopy,
a tip of endoscope was placed to the second part of the duodenum and 20 ml of water
containing 100 mg of 13C-glycine (n=65) and 13C-leucine (n=65) was sprayed into the
second part of the duodenum. Breath samples were taken at baseline and at 5, 10, 20, 30,
40, 50, and 60 min after administration for analysis of the 13C/12C ratio and were expressed
as delta over baseline. Absorptive function was determined as cumulative % dose at 60 min.
Results: Absorption values in 3C-glycine breath test (cumulative % dose at 60 min) in obese
patients and non-obese patients were 13.6+/-3.2% and 11.8+/-3.8%, respectively. 13CO2
concentrations in the exhaled air were significantly (p<0.05) higher in the obesity group at
15, 20, and 30 min, than in the non-obese groups. In contrast, for 13C-leucine breath test,
breath 13CO2 concentrations were significantly (p<0.05) lower in the obesity group at 10
minutes and later. Absorptive function was not influenced by aging. Conclusions: Contrary
to our expectations, absorption and oxidation of glycine was enhanced in obese subjects,
whereas leucine metabolism was decreased. The decreased rate of leucine oxidation in the
obesity may be a consequence of decreased substrate availability. It is concluded that changes
in kinetics of amino acid may be one of causes of obesity.
M2275
Effects of Gastric Distension On Myoelectrical Activity of the Stomach in
Obese People
Shukun Yao, Lili Chang, Ruixing Zhang
A number of studies have suggested that enlarged gastric accommodation and accelerated
gastric emptying may play a role in obesity. Gastric motility is known to be regulated by
gastric myoelectrical activities. For understanding the characteristics of myoelectrical activities
in the obese people, this study was to observe the alterations of gastric myoelectrical activity
induced by gastric distension between obese and non-obese healthy subjects. Methods: 31
obese (BMI 30.95 ±1.52kg/m2, age30.95±1.52yr) and 26 non-obese healthy volunteers (BMI
20.99±1.92kg/m2, age 22.73±6.93yr) were studied with barostat and electrogastrography.
Following an overnight fast, a polyethylene balloon attached at the end of a catheter was
placed in the proximal stomach. By filling the gastric balloon with air, different visceral
sensation (initial satiety and maximal tolerance) was induced and electrogastrogram (EGG)
was recorded simultaneously. Results: (1)At baseline, initial satiety and maximal tolerance, the
dominant power of the EGG was increased from 31.52±4.93 to 33.15±4.85 and 35.85±5.05 in
obese people, which were higher than those in non-obese group (29.02±3.22, 30.43±3.95,
31.12±6.25, P<0.05). The dominant frequency showed a tendency to decrease and no
difference between the two groups. (2)A tendency was seen that the percentage of normal
slow waves (N%) decreased and tachygastria (T%) increased as the volume of intragastric
balloon was increased in obese group, and bradygastria (B%) increased in non-obese group.
(3)The dominant frequency instability coefficient (ICF), dominant frequency standard devi-
ation (SDF) and power ratio (PR) in obese group were similar to the non-obese group
(P>0.05). The dominant power instability coefficient (ICP) and dominant power standard
deviation (SDP) in obesity were higher than those in control subjects (P<0.05). Conclusion:
Gastric distension results in an increase of DP, ICP and SDP. The increase of those in obese
people was higher than those in non-obese people. These changes of gastric electrical
activity may attribute to strengthened gastric motility and accelerated gastric emptying in
obese people.
M2276
Effects of Gastric Electric Stimulation On the Expression of NPY, CCK and
Growth Hormone Secretagogue Receptor mRNA in Rodent Brain
Luo Xu, Xiangrong Sun, Feng Zhong, J D Z Chen
Recently, gastric electrical stimulation (GES) has been introduced for treating obesity. How-
ever, the possible central mechanisms remain to be revealed. Neusopeptide Y (NPY) (an
orexigen), cholecystokinin (CCK) (a powerful anorexigen) and ghrelin have been shown to
be involved in the regulation of food intake and energy metabolism. The purpose of this
study was to explore the effect of GES on the contents of NPY immunoreaction (IR) and
CCK-IR, and the expression of growth hormone secretagogue receptor (GHS-R) mRNA in
rat brain. Methods: The contents of NPY-IR and CCK-IR in the brain, spinal cord and plasma
were detected by radioimmunoassay (RIA) after GES (6mA, 3ms, 40Hz, 2s-on, 3s-off) for
2 h. The expressions of GHS-R mRNA in the brain and spinal cord were investigated using
real-time PCR after GES for 2 h. Results: The expressions of NPY-IR were decreased with
GES in the hypothalamus, pituitary, solitary tract nucleus (NTS) and spinal cord (P<0.05),
but increased with GES in the hippocampus (P<0.01). However no significant difference
was observed for NPY-IR in plasma between GES and control groups. Conversely, the
contents of CCK-IR were increased in hypothalamus (P<0.01), hippocampus (P<0.05), NTS
(P<0.05) and plasma (P<0.05) after GES for 2 h, but decreased in pituitary (P<0.05). The
expression of GHS-R mRNA was not altered in the hypothalamus, pituitary, hippocampus
or spinal cord with 2-h GES, compared with the control group (P>0.05). However, it was
found that the expression of GHS-R mRNA was highest in pituitary (△Ct 5.877 ±0.34),
followed with the hypothalamus (△Ct 7.605 ±0.45), the hippocampus (△Ct 8.811 ±0.26)
and the spinal cord (△Ct 9.840 ±0.36) (P<0.05~0.01). Conclusion: Gastric electrical stimula-
tion increases the content of CCK-IR and decreases the expression of NPY-IR in rat brain,
but does not alter the expression of GHS-R mRNA in brain. The expression of GHS-R mRNA
is highest in the pituitary and lowest in the spinal cord.
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M2277
Association of Variations in Candidate Genes Affecting Serotonergic and
Adrenergic Mechanisms with Body Mass in Humans
Maria I. Vazquez Roque, Paula Carlson, Debra Stephens, Alan R. Zinsmeister, Michael
Camilleri
Background: Genetic factors have a role in obesity. Previous studies have suggested that
genetic variations in serotonergic, adrenergic, and several G protein coupled receptors are
associated with obesity, but this is still unclear. These are also candidate genes associated
with gut dysfunction, as in irritable bowel syndrome (Gut 2004;53:829-37) and functional
dyspepsia (Gastroenterology 2004;126:971-9). Obese people have high prevalence of gastro-
intestinal symptoms such as heartburn, postprandial bloating and diarrhea (Am J Gastroenter-
ology 2004;99:1801-6). Aim: To characterize the association of polymorphisms of SERT-P
(promoter for SLC6A4, the protein controlling 5-HT reuptake), α-2 adrenoreceptor (α-2
MspI) and GNβ3 (C825T) with body mass in normal, overweight, or obese individuals.
Methods: Two hundred and six healthy, predominantly Caucasian volunteers from a Midwest
U.S. population in the three body mass index (BMI kg/m2) ranges using WHO criteria (normal
22.1±2.2, overweight 27.0±1.1, obese 34.7±4) were recruited by public advertisement and
letters. After informed consent, a venous blood sample was drawn for genetic analysis for
SERT-P, α-2 MspI and GNβ3 C825T genotypes. Logistic regression and Chi-square analyses
were performed to assess the associations of these genotypes and body mass. Results: The
table summarizes the data, mean±SD and percent. No statistically significant associations
were found between the genotypes and BMI; however there was a weak univariate association
of α-2 MspI with BMI group (likelihood ratio x2, p=0.05). After adjusting for age, race, and
gender, an increased odds for obesity was found for the polymorphic heterozygous α-2
MspI polymorphism and obesity (p=0.04). However, this was not demonstrated for the
overweight group. Conclusion: Our data suggest that genetic variation in α-2 adrenoceptor
function may be associated with obesity. The influence of this adrenoceptor genotype on
development of gastrointestinal symptoms and responses to agents that affect noradrenergic
reuptake, such as sibutramine, deserves further study.
M2278
Obesity Is An Independent Risk Factor for Chronic Gastrointestinal
Symptoms in a Sample of Australian Adults
Nicholas J. Talley, Stuart C. Howell
Introduction: Obesity has been identified as a potential risk factor for gastrointestinal (GI)
complaints, although the data from community samples remains sparse. We assess the
associations between GI symptoms and obesity in a population-based sample of Australian
adults. Method: The prevalence of 26 gastrointestinal symptoms was determined by postal
questionnaire which was sent to 5000 residents across western Sydney, Australia (60%
response rate). These were classified into five broader symptom groups according to the
Rome II Criteria - abdominal pain, esophageal symptoms, dysmotility symptoms, diarrhea
and constipation. Obesity was defined according to body mass index using self-reported
height and weight. Socioeconomic characteristics and eating behaviors were also evaluated.
Results: The prevalence of obesity (BMI>=30 kg/m2) was 25.1%; 36.1% were overweight.
There were significant and positive univariate associations between obesity and abdominal
pain (OR=1.57; 95% CI: 1.21-2.03; p=0.001), esophageal symptoms (OR=2.21; 95% CI:
1.65-2.95; p<0.0001), dysmotility symptoms (OR=1.27; 95% CI: 1.01-1.60; p=0.05) and
diarrhea (OR=2.11; 95% CI: 1.69-2.65; p<0.0001). The adjustment for socioeconomic
characteristics and eating behaviors had minimal effect on the associations for abdominal
pain (OR=1.46; 95% CI: 1.10-1.95; p=0.01), esophageal symptoms (OR=1.84; 95% CI:
1.36-2.50; p<0.0001) and diarrhea (OR=1.84; 95% CI: 1.44-2.35; p<0.0001); however, the
association between obesity and dysmotility symptoms became non-significant (OR=1.26;
95% CI: 0.96-1.65; p=0.09). Obesity was not related to constipation. Being overweight did
not emerge as a significant risk factor for GI symptoms in this cohort. Conclusion: Obesity
is an independent risk factor for abdominal pain, esophageal symptoms and diarrhea, but
is not associated with dysmotility symptoms or constipation.
Table 1: Symptom prevalence for each BMI group
M2279
Ingested Lipid Modulates Hypothalamic and Brainstem Neuronal Activity in
Man
Dan Lassman, Shane McKie, Simon Lal, Lloyd Gregory, Graham Dockray, Steve Williams,
David Thompson
Ingested lipid signals via cholecystokinin (CCK) to limit food intake, but in man, brain
responses to ingested lipid have not been shown. Methods: 5 fasted healthy volunteers
underwent blood oxygenation level dependent (BOLD) 1.5 T functional magnetic resonance
(fMRI) brain imaging before and after intraduodenal infusion of either saline or a CCK-
releasing lipid on separate occasions. The average BOLD signal for each 2 minute time bin
was compared to the pre-infusion 2 minute time bin. A random effects ANOVA was used
to investigate significant differences over time between the two conditions. Visual analogue
scores of satiety sensations were also recorded. Results: The comparison of lipid infusion
to saline highlighted an increase of the BOLD response in the hypothalamic region (figure
1) and brainstem (figure 2) (mean +/- 95% CI p<0.05). At 10 minutes, infusion of lipid
was associated with a 64% (4.9) increase in fullness scores compared to 10% (10) with
saline. (Mean +/- SE, p0.007). Conclusion: These findings are consistent with a role of
ingested lipid in the brainstem and hypothalamic control of eating in man.
M2281
Gastric Emptying of Solids and Semi-Solids in Class III Obesity: An
Assessment Using the Non-Invasive (13)C-Octanoic Acid and (13)C-Acetic
Acid Breath Test
Aloisio Cardoso Jr., Luiz Gonzaga Vaz Coelho, Paulo Roberto Savassi-Rocha, Aline
Miranda Almeida, Emanuela Eudes Dias, Gerival Vieira Jr., Mariana Moreira Castro, Yara
Vieira Lemos
BACKGROUND: It has been suggested that obesity is associated with an altered rate of
gastric emptying. An enhanced gastric emptying rate might reduce the satiating effect of
food and thereby promote obesity. Gastric emptying rate has previously been compared
between obese and lean subject with conflicting outcome. OBJECTIVE: The purpose of this
study was to determine whether class III obese patients have different rates of solid and
semi-solid gastric emptying compared to lean subjects. METHODS: Gastric emptying time
(GET) of solid and semi-solid meals was measured using the (13)C-octanoic acid breath
test and (13)C-acetic acid breath test, respectively, in 24 lean (healthy) and 14 class III
obese individuals of both sexes. The age of the patients ranged from 17 to 77 years. Following
an overnight fast, subjects were given a standard egg meal labelled with 100 mg of (13)C-
octanoic acid. Breath samples were collected before the meal (baseline) and at 15-minute
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intervals during the first 2 hours and at 30-minute intervals thereafter for 2 hours. Semi-
solid GET was measured by the (13)C-acetic acid breath test. The test meal consisted of 75
ml of milk mixed with 30 g of oat labeled with 150 mg of 13C-acetic acid. Breath samples
were collected before the meal (baseline) and at 5-minute intervals during the first 2 hours
and at 10-minute intervals thereafter for 2 hours. The expired air samples were analysed
using infrared isotope spectrometry (IRIS®, Wagner Analysen Technik Vertriebs-GmbH,
Bremen, Germany) and the data fitted to the established gastric emptying model. The lag
times t(lag) and half excretion times t(1/2) were calculated. The Student t-test was used to
compare the mean data of the lean and class III obese groups. A p value < 0.05 was
considered to be significant in both analyses. RESULTS: The mean t(1/2)-values to the GET
of solids (+/-standard error of the mean) were 203.6 min +/- 76.0 min and 143.5 min +/-
19.1 min for lean and obese, respectively (p = 0.0010). The mean t(lag)-values to the GET
of solids were 127.3 min +/- 42.7 min and 98.4 min +/- 13.0 min for lean and obese,
respectively (p = 0.0044). There was no significant difference in the GET of semi-solids
between the lean and class III obese groups. CONCLUSIONS: The present study demon-
strated a significantly faster lag phase and a significantly enhanced gastric emptying in class
III obese patients when compared to lean subjects. This findings are compatible with the
hypothesis that gastric emptying, satiety, food intake and body weight are integrated para-
meters in subjects with class III obesity.
M2282
CNS Expression of Ghrelin and Cholecystokinin (CCK) with Gastric Electrical
Stimulation in Rats
Suhuan Liu, Ming Tang, Shangmin Tao, Jiande Chen
Background and aim: Gastric electrical stimulation (GES) has recently been shown to be
safe and effective in the treatment of obesity, in the peripheral tissue, it induces gastric
distention, impairs gastric myoelectric activity, delays gastric emptying, but its effects in the
central nervous system (CNS) are remained unclear, the aim of this study was to explore
the possible central mechanisms involved in GES by investigation of the expression of food
intake-related peptides. Methods: the experiment was designed in two parts: an acute
experiment with 2h GES and a long term experiment with 14- day continuous GES, each
experiment contained two groups: stimulation group and Control group. After stimulation,
the expression of orexigenic hormone - ghrelin in the hypothalamus and anorexigenic
hormone -CCK in the hippocampus were detected by immunohistochemical method. GES
was performed using pulse trains (train on-time of 2s, off-time of 3s, pulse amplitude of
6mA, width of 0.3ms and frequency of 40Hz). Results: Compared with the control group,
2h GES resulted in a decrease in the number of ghrelin immunoreactive neurons in the
hypothalamic paraventricular nucleus (PVN, 34.8±1.86 vs. 57.2±2.95, P=0.02) and in the
supraoptic nucleus (SON, 51.2±3.21 vs. 82.8±3.08, P=0.01). The number of CCK immunore-
active neurons in the hippocampus was of no changes (7.4±0.87 vs. 6.2±0.58, P=0.29).
After 14-day GES, the number of CCK immunoreactive neurons in the hippocampus was
increased compared with that of the control group (4.0±0.32 vs. 2.4±0.51, P=0.03). However,
there were no changes of the number of ghrelin immunoreactive neurons either in the PVN
(55.5±5.49 vs. 61.6±3.53, P=0.66) or in the SON (65.5±3.13 vs. 80.0±3.39, P=0.20).
Conclusions: These results indicate that the expression of ghrelin and CCK can indeed be
altered by GES. For the first time, we have demonstrated that GES may alter energy homeost-
asis by modulating the expression of food intake-related hormones in the central nervous
system-reducing acutely the level of orexigenic ghrelin and increasing chronically the level
of anorexigenic CCK.
M2283
Polyunsaturated Fatty Acids Derived from Korean Pine Nuts Affect Appetite
Suppressing Hormones and Appetite Sensations in Overweight Women
Wilrike J. Pasman, Jos Heimerikx, Carina M. Rubingh, Robin van den Berg, Marianne O
Shea, Louisa Gambelli, Henk F. Hendriks, Alexandra W. Einerhand
Background: In the United States today almost two thirds of the entire adult population is
either overweight or obese, roughly double the percentage twenty years ago. Western Europe
is catching up fast and obesity is also on the rise in Asia and other parts of the world. In
the face of this global epidemic there is an urgent need to find means to combat obesity.
Controlling food intake by suppressing appetite might be one of the principal approaches
to prevent overweight. The most widely investigated gut hormone in relation to appetite
control is cholecystokinin (CCK). Previous experiments showed that polyunsaturated fatty
acids (PUFAs) derived from Korean pine nuts (Pinus koraiensis) induced high amounts of
CCK release by STC-1 enteroendocrine cells in comparison to other PUFAs and MUFAs.
Aim: This study investigates the effect of Korean pine nut PUFAs on appetite sensations
and appetite-regulating hormones in humans. Methods: A randomized, cross-over, placebo-
controlled double-blind study was carried out with 18 overweight post-menopausal women
(BMI=25-30 kg/m2) receiving capsules with 3 g PUFAs derived from Korean pine nuts or
olive oil (placebo) in combination with a light breakfast consisting of two slices of white
bread and marmalade. At 0, 30, 60, 90, 120, 180 and 240 min following supplementation
blood samples were taken for analyses of CCK and glucagon-like peptide-1 (GLP-1), two
appetite suppressing hormones, and appetite sensations were evaluated by using visual
analogue scales. Results: Korean pine nut PUFAs significantly induced CCK after 30 min
and GLP-1 after 60 min relative to placebo. Over a period of 4 hours the total amount of
plasma CCK and GLP-1 in response to pine nut PUFAs was 60% (P<0.0001) and 25%
(P<0.05) higher than in response to placebo, respectively. Korean pine nut PUFAs affected
appetite sensations during the 4 hours after intake. Especially, at 30 minutes the “desire to
eat” and the “prospective food intake” scores were, 29% and 36% lower relative to placebo,
respectively. Similar results were obtained with Korean pine nut triglycerides. In conclusion:
Korean pine nut PUFAs induced CCK and GLP-1 levels significantly for up to 4 hours,



















Comorbidities in Rural Obese Children
Mark Brunner, William Cochran, Michael Komar, Stacy Prall
Introduction The epidemic of childhood obesity is associated with multiple medical complica-
tions adversely affecting health in childhood and subsequently adulthood. Purpose To
describe obesity-related comorbidities in children and assess for associations between insulin
resistance or BMI with comorbidities. Methods Chart review of children seen in our obesity
clinic from 1999-2005 to identify multiple comorbidities. BMI Z-score (BMIZ) was adjusted
for gender and age. Hypertension was defined as 3 consecutive systolic pressures >97th
percentile for age, gender, and height. Insulin resistance was defined as fasting Homeostasis
Model Assessment >2.5. Chi-square was used to correlate comorbidities with mean BMIZ
and insulin resistance. Results 506 children were evaluated. 53% were female, and 96%
were non-Hispanic white. Mean BMIZ for all patients was 2.61. Insulin resistance was present
in 69%. Table 1 summarizes BMIZ by comorbidity. Children with higher BMIZ were more
likely to snore, have hypertension, and higher transaminases. Table 2 summarizes insulin
resistance by comorbidity. Children with insulin resistance were more likely to have daytime
somnolence, acanthosis, striae, and higher transaminases. Conclusions: Extremely obese
children have obesity-related comorbidities. The presence of nocturnal snoring, daytime
somnolence, and hypertension are associated with the degree of obesity. Insulin resistance
is directly related to acanthosis, striae, dyslipidemia, and elevated transaminases. We suggest
additional studies include normal and overweight children. This will allow more precise
correlation of BMI with comorbidities, providing a target weight for children who cannot
practicably reach ideal body weight.
Table 1: BMI Z-score for comorbidities
X=Chi-Square testing. T&A=tonsillectomy and adenoidectomy for obstructive symptoms
Table 2: Insulin Resistance for Comorbidities
IR= insulin resistance.
M2285
Association of Ghrelin Receptor Gene Polymorphism (171T/C), Not of CCK-a
Receptor (-81A/G, -128G/T) Or Beta3 Adrenalin Receptor (Try64Arg) Gene
Polymorphism, with Bulimia Nervosa in a Japanese Population
Kyoko Miyasaka, Hiroko Hosoya, Ayako Sekime, Minoru Ohta, Setsuko Kanai, Saeko
Akimoto-Takano, Sachio Matsushita, Kenji Suzuki, Susumu Higuchi, Akihiro Funakoshi
Background: Ghrelin, an endogenous ligand for the growth hormone secretagogue receptor
(GHSR), known to enhance appetite and increase food intake, and human ghrelin plasma
levels are inversely correlated with body mass index (BMI). Extremely high levels of ghrelin
were observed in patients with anorexia nervosa (AN). Aims: Eating disorders (EDs) have
a highly heterogeneous etiology and multiple genetic factors might contribute to their
pathogenesis. As no subject with ghrelin gene polymorphism (Leu72Met) has been detected
in a Japanese population, we examined the 171T/C polymorphism of GHSR gene. In addition,
beta3 adrenergic receptor (adr-R) gene polymorphism (Try64Arg) and cholecystokinin-A
receptor (CCK-AR) gene polymorphism (-81A/G, -128G/T), which are both associated with
obesity (Obes Res 2004), were investigated. Methods: The subjects consisted of 228 Japanese
patients with EDs [96 AN, 116 bulimia nervosa (BN) and 16 not otherwise specified (NOS)].
AN patients were classified into two subtypes: the restricting type (ANR: n = 47) and the
binge-eating and/or purging type (ANP: n = 49). BN patients were classified into the purging
type (BNP: n = 91) and the non-purging type (BNNP: n = 25). The age- and gender-matched
control group consisted of 284 unrelated Japanese subjects. Genomic DNA was extracted
from peripheral leukocytes, and the171T/C in the coding region of the GHSRs were examined
using a mismatch PCR-RFLP method (JCEM 2004). Beta3 adr-R and CCK-AR polymorphisms
were determined according to the methods previously reported (Obes Res 2004). Results:
In BN patients, the CC type occurred significantly more frequently than in control subjects
(chi-square = 4.47, p = 0.035, odds ratio = 2.05, 95% CI, 1.088-4.935), while the frequency
in AN patients did not differ from that in control subjects. The frequency of the CC type
tended to be lower in the ANR group than in other subgroups (ANP + BNP + BNNP)(chi-
square = 3.60, p = 0.058). When the frequency of the CC type was compared between ED
patients with binge-eating and/or purging (ANP + BNP) and those without purging (ANR
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+ BNNP), there were no significant differences (chi-square = 1.83, p = 0.21). The frequency
of the beta3 adr-R gene polymorphism in AN patients tended to be lower than in control
subjects (chi-square =3.179, p = 0.075). The difference between AN and BN subjects was
also not significant (chi-square = 3.736, p = 0.053). The distribution of CCK-AR gene
polymorphism did not differ between ED and control subjects. Conclusions: The CC type
of GHSR gene polymorphism (171T/C) is a risk factor for BN, but not for AN.
T1000
Comparison of GERD and Sleep-Related Medication Use Among Individuals
with Daytime and Nighttime GERD
Robert W. Dubois, Ronnie Fass, Daniel Aguilar, Richard Lynn, Amitabh Singh, Michael A.
Tedeschi
Objective:To compare GERD and sleep medication(med)use among individuals with daytime
and nighttime GERD. Methods: An Internet-based survey was conducted among full-time
working adults living in the US. A screening questionnaire that assessed frequency and
severity of GERD symptoms (during past 12 months and past 7 days) was used to identify
symptomatic GERD cases. GERD status was determined by using the validated GERD
Symptom and Med Questionnaire (GERD-SMQ).Symptomatic GERD was defined as GERD-
SMQ score >9 and at least 1 episode of either heartburn or acid regurgitation during the
past 7 days.Symptomatic nighttime GERD (NTG) was defined as at least 2 nights with GERD
symptoms during the past 7 days. Questionnaire respondents were asked to report GERD
symptoms as well as GERD and sleep related med use.Results:Of65,001 individuals invited
to participate in the survey, 13,231 responded. Of these, 1,002 satisfied GERD study criteria
and were defined as having symptomatic GERD {476 NTG cases vs 526 daytime GERD
(DTG) cases}.Results are presented in the table below. Among NTG cases, 59% of subjects
took an OTC GERD med before going to bed to help prevent nighttime symptoms of GERD
compared to 40% among DTG cases (at least 1 night/7days).70%of NTG cases reported
taking an OTC GERD med to reduce nighttime symptoms after waking vs 60% in the DTG
group.GERD-related med use (in the past 6 M) was reported by a substantial number of
GERD cases. Among cases with NTG and reporting the use of antacids, 28.3% reported the
daily use of antacids vs 9.7% among DTG cases(p<.0001). Conclusions:A greater proportion
of NTG patients depend on OTC and Rx GERD meds to help prevent GERD symptoms at
night. NTG is associated with higher use of OTC&Rx sleep meds to help subjects have a
good night’s sleep
Use of Sleep & GERD Med to Prevent/Reduce Nighttime Symptoms of GERD Among NTG
(n=476) & DTG (n=526) Cases
**Only among respondents with DTG who reported 1 night with symptoms (n = 305)
T1001
Risk Factors for Adulthood GERD in Persons with Childhood GERD
Hashem El-Serag
Background GERD that develops during childhood in patients without underlying predispos-
ing disorders may persist or predispose to GERD in early adulthood. However, the extent
and determinants of adulthood GERD in these individuals are unclear. The predisposing
factors for GERD in early adulthood are not well examined. Methods We identified a cohort
of eligible individuals who were diagnosed with GERD in childhood between 1994 and 1996
in Texas Children’s Hospital in Houston, TX. Patients with neurodevelopmental disorders,
tracheoesophageal anomalies, or severe chronic pulmonary disorders were excluded. Com-
puter assisted telephone interviews were conducted in 2004 and 2005 using a standard
validated questionnaire for GERD symptoms and potential risk factors. We calculated the
prevalence of GERD as defined by at least weakly heartburn or acid regurgitation. We
examined potential determinants of GERD in unadjusted and adjusted logistic regression
analyses. This cohort does not overlap with our previous pilot study (Am J Gastro, 2004).
Results We have thus far recruited 95 subjects (participation rate: 67%). The mean age at
the time of the interview was 17.3 (SD 2.0), while the mean age at the time of childhood
GERD diagnosis was 12.5 years. There were 59 (62%) females. The racial distribution was
57% Caucasian, 2% black, 10% Hispanic, and rest 25% unreported. At least weakly heartburn
or regurgitation was reported in 41/95 (43%); most of whom (95%) were taking PPI, H2RA,
or antacids. An additional 18 subjects reported no symptoms but were using PPIs. Patients
with adulthood GERD symptoms were more likely to have at least weakly dysphagia (32%
vs. 6%; p=0.003) or chest pain (32% vs. 11%; p=0.013) than those without GERD symptoms.
GERD was significantly more frequent in females using OCP as compared to females not
on OCP, or males (12/16 vs. 19/43 vs. 10/36, respectively; p=0.006). In logistic regression,
OCP use was associated with adulthood GERD independent of PPI use or recent weight
gain; the adjusted odds ratio was 6.61 (95% CI, 1.56 to 27.98; p=0.01). On the other hand,
race, family history of GERD, education level, employment status, tobacco smoking, alcohol,
or coffee drinking were not significant predictors of adulthood GERD. Conclusions Childhood
GERD can persist and or predispose to GERD in early adulthood in approximately half of
all cases. The use of oral contraceptives is a potential risk factor for GERD symptoms in
early adulthood among persons of GERD in childhood.
T1002
Temporal Trends in New and Recurrent Esophageal Strictures
Hashem El-Serag
Background There has been a significant recent increase in the prevalence of GERD (7-8),
Barrett’s esophagus, as well as esophageal adenocarcinoma. On the other hand, anecdotal
experience suggests that gastroenterologists are encountering fewer patients with esophageal
strictures. Conceivably the wide spread use of PPIs could have led to the decline in esophageal
strictures, however, there has been no published data on the temporal trends of either
new or recurrent esophageal strictures. Methods We examined the incidence rates of new
esophageal strictures among patients presenting to VA facilities between 1998 and 2003 as
a proportion of the annual frequency of all endoscopic procedures and/or imaging procedures.
Recurrent strictures were defined as those recorded at least three months after the index
date of a new stricture or the date of the preceding recurrent stricture. Stricture was defined
only in the presence of an upper endoscopy or UGI contrast imaging within 30 days before
or after the date of diagnosis. This algorithm was validated by manually reviewing the
medical records of 180 patients; the positive predictive value was approximately 84%. The
risk of recurrent strictures was examined using Cox proportional hazards model for multiple
failures using the PWP method. Results There were 19,157 patients identified between FY
1998 and FY 2003 with new esophageal strictures. The annual frequency of new esophageal
strictures ranged between 3070 and 3425 with no clear temporal trend during 1998 - 2003.
New strictures comprised a constant annual proportion of total EGD and UGI imaging
studies. However, new strictures declined by 11.6% as a proportion of all upper endoscopy
(not including UGI imaging). Among patients with new esophageal strictures, 15,930 (83.2%)
had no recurrent esophageal strictures through 10/2003, while the rest (16.8%) had at least
one episode of recurrence. The one-year incidence rate of recurrent strictures declined
significantly (-36.0%) from 13.9 per 100 person-years for patients diagnosed with new
strictures in 1998 to 8.9 per 100 person-years for patients diagnosed with new strictures
in 2003. In the full multivariable model, new strictures diagnoses during 2001-2003 were
associated with 13% reduction in risk of having recurrent strictures independent of age,
gender, race, geographic region, or the presence of BE. Conclusion The incidence of recurrent
strictures has declined between 1998 and 2003 by approximately one third. On the other
hand, there has been only a small decline in the incidence of new esophageal strictures.
PPI use is likely to explain these trends.
T1003
The Prevalence of Heartburn in Elderly in Russia: Sub-Analysis from the
Database of National Population-Based Study
Ekaterina S. Stavraki, Sergey V. Morozov, Vasily A. Isakov
The prevalence of heartburn is high in all age groups in developed countries. The data about
prevalence of heartburn in Russia are scarce especially in different age groups. Aim: To
evaluate the prevalence of heartburn and its impact on the quality of life in elderly in Russia.
Methods: A questionnaire was designed for patients in the primary care setting. It included
questions on the presence and frequency of heartburn, risk factors provoking heartburn,
influence on the quality of life. Eight structured questions were organized in a self filled-in
form. The questionnaire was validated in 115 GERD patients and 104 controls and found
to have an acceptable sensitivity (89%) and specificity (92%). The mean time for completing
the questionnaire was 5.4±1.2 min. The study was performed in 14 of the largest cities in
Russia. Results: Twenty thousand questionnaires were distributed, the response rate was
81.3% and 14,521 questionnaires were analyzed. The presence of heartburn was evaluated
in 8037 women and 6486 men. Among them, 8661 subjects reported heartburn (59.7% of
the respondents) and 1248 subjects≥ 60 years old. Thus, the heartburn was more prevalent
in elderly then in other age groups: 61.9% vs 59.3%; p<0.03. In total the frequency of
heartburn was equal in women and men (59.1 vs 60.4%, p=0.1). Elderly women experienced
heartburn more often than men (64.0% vs 58.2% p=0.01). Frequent (2-3 times a week)
and daily symptoms were more prevalent in elderly in comparison to younger people (30.6%
vs 21.4% p<0.001). The timing of heartburn in elderly was as follows: after a meal (47.7%),
bending (15.6%), fasting (10.5%), at night (10%), during physical activity (9.9%) or under
the stress (5.7%). The distribution of the frequencies of heartburn timing was similar in
elderly and in younger people. However, heartburn appeared in elderly more often in bent
position (15.6% vs 12.0%) in comparison to younger. Major differences in changes of the
quality of life between elderly and others are shown in table. Conclusions. The prevalence
of heartburn in elderly urban population in Russia is higher than in other age groups. Daily
and frequent heartburn are more prevalent among the elderly. However, the quality of life
is lower in younger patients who suffered from heartburn than in correspondent elderly popu-
lation.
Quality of life changes in elderly and younger subjects.
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T1004
The Efficacy of Several Over-the-Counter GERD Therapies: A Meta-Analysis
Thomas Tran, Angus M. Lowry, Hashem B. El-Serag
Background: Over-the-counter (OTC) medications, including histamine-2 receptor antagon-
ists (H2RAs) (half prescription dose), antacids, and alginate/antacids are commonly used
for GERD. Many studies have evaluated the efficacy of individual agents. However, the
overall efficacy of these agents has not been systematically reviewed. Methods: We performed
a MEDLINE search up to December 2005 to evaluate randomized, placebo-controlled trials
that examined the efficacy of H2RAs, antacids, and alginate/antacids. Study design and
report qualities were measured by the Jadad scoring (from 0 to 5). Data on complete and
adequate relief of GERD symptoms, subjective global improvement, and the use of rescue
antacids were extracted and analyzed by using a random-effects model. Results H2RAs: A
total of 12 randomized, double-blinded, parallel-group trials (n = 4075, placebo = 3561;
mean Jadad score 3.5) compared H2RAs (4 different agents) versus placebo. Six studies
examined adequate relief of GERD symptoms within 2 hours of drug ingestion that lasted
for at least 3 hours; the combined effect favored H2RAs (OR 1.55, 95% CI 1.41- 1.70, p
< 0.0001). Three studies evaluated complete relief of GERD symptoms for at least 3 hours
(OR 2.01, 1.59-2.66, p = 0.003). Five studies evaluated the % of GERD episodes requiring
rescue antacids; patients on H2RAs were less likely use rescue antacids (OR 0.58, 0.50 to
0.67, p < 0.0001). There were no significant differences between the 4 H2RA agents.
Antacids: Five randomized trials (n = 597, placebo = 588; mean Jadad score 3.8) compared
the efficacy of antacid versus placebo. Four trials evaluated patients’ symptomatic improve-
ment after at least 2 weeks of therapy with a combined OR of 1.42 (0.97 - 2.07, p = 0.07)
in favor of antacids. Two trials found patients on antacids less likely to have heartburn
episodes requiring rescue antacids (OR 0.70, 0.58 to 0.85, p < 0.0001). Alginate/antacid:
Three randomized trials (n = 108, placebo = 108; mean Jadad score 3.3) compared alginate/
antacid combination versus placebo in improving heartburn with a combined OR of 3.86
in favor of alginate/antacid (2.16 to 6.87, p < 0.0001). Conclusions: OTC medications for
GERD therapy are effective. Histamine-2 receptor antagonists are 50% to 100% superior to
placebo in providing adequate and complete symptom relief, improving patients’ global
rating, and reducing rescue antacids. Alginate/antacid combinations are also superior to
placebo in improving symptom. There is a non-significant trend in symptomatic improvement
in favor of antacid therapy versus placebo.
T1005
Objective Measurement of Hourly and Annual Productivity While At Work in
Employees with Gastroesophageal Reflux Disease (GERD) Compared with
Employees Without GERD
Peter Wahlqvist, Richard A. Brook, Sara Campbell, Mari-Ann Wallander, Ingela Wiklund,
Nathan L. Kleinman, James E. Smeeding
OBJECTIVE: Results from studies using patient-reported data in employed populations
indicate that Gastroesophageal Reflux Disease (GERD) causes a reduction in productivity
while at work of around 10%. The aim of this study is to assess if a link between GERD
and reduced productivity while at work can be established by using objective measurements
of hourly and annual at-work productivity. METHODS: We examined the Human Capital
Management Services Research Reference database of employees where units-of-production
are captured on a per-employee-per-day basis. ICD-9 Codes were used to distinguish
employees with GERD from the non-GERD cohort. The index date in the GERD cohort was
defined as the date of first diagnosis during 2001 or later, while the average GERD index
date was used in the non-GERD cohort. Hourly and annual productivity were measured
during the year following each employee’s index date. Regression modeling was used to
measure the productivity differences between employees with GERD and employees without
GERD while controlling for age, marital status, race, full-time/part-time status, location,
and comorbidity (Charlson Comorbidity Index). RESULTS: Data were available for 27,316
employees: 541 employees with GERD and a control group of 26,775 employees without
GERD. The mean age of employees with GERD was 40 years, and 77% were full time
employees. The analysis of at-work productivity (Table) show that GERD employees’ average
units processed were significantly lower by 4.4% hourly and 6.0% annually (P<0.05).
CONCLUSIONS: Even though quality aspects of work productivity are not captured, object-
ive productivity measurements from real work-output data (the number of units of work
performed by each employee on a daily basis) show that GERD has a significant impact on
productivity while at work. Interventions focused on managing GERD could increase


















Long-Term GERD Symptom and Quality-of-Life Improvement in Subjects with
Healed Erosive Esophagitis Treated for Up to 7 Years with Titrated-Dose
Lansoprazole
Thomas O G Kovacs, Stuart Atkinson, James Spalding, Barbara Hunt
BACKGROUND: Gastroesophageal reflux (GERD), a chronic symptomatic condition, may
be associated with erosive esophagitis (EE). Long-term GERD symptom prevention and
patient quality of life (QoL) data are limited. Purpose: To determine the effect of maintenance
lansoprazole (LAN) treatment on long-term GERD symptoms and QoL in subjects with
healed EE. METHODS: All subjects had EE (≥Grade 2) and had previously enrolled in an
8-week acute treatment followed by a double-blind treatment of up to 12 months. Subjects
whose EE had healed started on LAN 15 mg QD and the LAN dose was titrated up or down
so that subjects received the minimum dose required to control their symptoms or EE.
Questionnaires with disease-specific scales and validated QoL scales were self-administered
annually. Scales were transformed to 0-100, with higher numbers indicating improvement.
RESULTS: 195 patients (64 F/131 M; mean age, 50.8 years) received open-label LAN with
a mean dosage of 24 mg; 120 were exposed ≥5 yrs. All disease-specific scales except sleep
improved significantly (p<0.001) at each timepoint from open-label baseline. Of the global
health scales, both general and comparative health had statistically significant improvements.
CONCLUSIONS: Long-term LAN treatment in healed EE subjects resulted in sustained
improvements from therapy start, not only in GERD symptoms and general health but also
in QoL indicators, including activity, eating, drinking, and social functioning.
*,*** p>0.05 and 0.001, respectively, all timepoints (a) p>0.05, all timepoints except month
60 (data not shown)
T1007
Health State Utilities and Health-Related Quality of Life (HRQOL) in Patients
with Dysphagia
Nick Stern, Edel Doorley, Sanchoy Sarkar, Keith Bodger
BACKGROUND Swallowing disorders may impact on physical, psychological and social
functioning. Clinical assessment often focuses on severity of dysphagia without capturing
other aspects of HRQoL. Global valuation of health status is increasingly favoured in health
technology appraisal but has not found a place in routine practice. Health state utility
assessment produces a single cardinal measure of wellbeing grading health on a scale from
zero (death) to one (perfect health). Techniques include direct measures of ‘patient preference’
(eg. Time Trade Off, TTO), visual analogue rating scale (VAS) and pre-scored multi-attribute
health indices (eg. EQ-5D). There have been few studies of utilities in dysphagia. We aimed
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to measure utility weights in a range of dysphagic complaints by different methods and to
correlate scores with simple clinical and endoscopic gradings and a multi-item, disease-
specific HRQoL instrument. METHODS Face-to-face interviews were conducted with dys-
phagic subjects prior to endoscopy, including oesophagogastric malignancy (Cancer), benign
stricture (Benign) and non-obstructive dysphagia (Dysmotility). Clinical severity was graded
by dysphagia scale (DysScale: 0=None;1=Solids;2=Soft or Liquidised;3=Saliva) and luminal
narrowing scale (EndoScale) for obstructive causes. Health utility weights were elicited by
TTO, VAS and EQ5D. Patients completed the EORTC QLQ-C30 HRQoL instrument with
oesophageal module OES18. Follow up interviews were performed after intervention to test
reliability and sensitivity. RESULTS First 59 patients: mean age 62 yrs (25-85 yrs). 95%
completed the TTO question. Mean utilities by VAS (0.62) and EQ5D (0.63) were significantly
lower than by TTO method (0.9), as reported in other diseases. Overall, Spearman correlation
(rho) values for utility scores versus DysScale or EndoScale were weak (below 0.1). There
were strong correlations for EQ5D (0.451) and VAS (0.77) utilities versus EORTC ‘global
health’ domain (p<0.001). Sub-group analysis showed better correlation between utility
scores versus DysScore for the benign group (EQ5D=0.31, VAS=0.39, TTO=0.1) than for
Cancer or Dysmotility. CONCLUSIONS Eliciting utility scores by different methods is feasible
for dysphagic conditions but absolute values vary according to methodology. Utility scores
and EORTC indicate significant impairment of well-being that is only weakly correlated
with grading of dysphagia, particularly in the case of Cancer and Dysmotility. Disease-
specific instruments are time-consuming but measurement of utility scores is simple and
may prove a useful adjunct to basic clinical assessment.
T1008
CDX-2 and P-27/CDK-2 Identify a New Pattern of Expression in Barrett
Esophagus
Massimo Milione, Emilio Digiulio, Gabriele Capurso, Francesco Panzuto, Antonella
Carnuccio, Giuseppe Montrone, Andrea Sbrozzi, Antonella Stoppacciaro, Emanuela
Pilozzi, Andrea Vecchione, Cristina Colarossi, Ludovica Feigush, Luigi Ruco, Gianfranco
Delle Fave
Background: Barrett’s Esophagus (BE) is the single most important precursor lesion and risk
factor for adenocarcinoma of the distal oesophagus. BE is defined as squamous epithelium
replaced by specialized intestinal one. The histological diagnosis of BE involves the presence
of goblet cells, but this finding may not be the first indicator of intestinal metaplasia. CDX-
2, a transcription factors associated with intestinal differentiation may be engaged in BE
development. CDX-2 is in relationship with cdk-2 and p27Kip1. cdk2 binds ciclinE and
promotes cell progression into the S phase. p27Kip1 inhibits cyclinE/cdk2 complexes, and
blocks cell in G1 phase. The targeted degradation of CDX2 following its phosphorylation
by Cdk2 identifies a new mechanism through which CDX2 activity can be regulated in
coordination with the cell cycle machinery. The possible link between CDX-2 and cdk-2/
p27 expression has not been specifically investigated in patients with ES and/or BE. Aim:
To investigate the expression pattern of CDX-2, p27Kip1 and cdk-2 in BE and in esophagitis.
Material and Methods: Immunohistochemestry (IHC) with antiCDX-2, anti-p27Kip1 and
anti-cdk-2 monoclonal commercial antibodies was performed on paraffin embedded tissue
sections of 12 BE , of 18 esophagitis (ES), and of 10 healthy gastro-esophageal junction
(GEJ), from 30 patients. At least four biopsies for each patient were obtained during endos-
copy. Results: CDX-2 was positive in all BE samples (12/12), negative in both ES(0/18) and
in GEJ (0/10). p27Kip1 staining was positive in ES(18/18) and in BE (12/12), negative in
GEJ (0/10).cdk-2 was positive in all GEJ samples (10/10), negative in BE and in ES sections.
Conclusions: The link between CDX-2, p27Kip1 and cdk-2 seems a promising model to
explain the pathogenesis of BES and ES. Evaluation of their expression may suggest the
presence of three different expression pattern showed in table. Moreover the co expression
of CDX-2 and p27 could be a predictive marker of BES, which comes first goblet cells. cdk-
2 may be useful to distinguish columnar gastric cells against intestinal ones. Table DIAGNOSIS
CDX-2 + p27 + Cdk-2 + BE 12/12 12/12 0/12 ES 0/18 18/18 0/18 GEJ 0/10 0/10 10/10
T1009
The Effect of Definitive Chemoradiotherapy (ChemoRT) Against
Esophagectomy On Pulmonary Function in Patients with Squamous
Esophageal Cancer - Results from a Prospective Randomized Trial By Chinese
University Research Group for Esophageal Cancer (CURE)
Philip W. Chiu, Frances K. Cheung, Wilfred L. Mui, Man Yee Yung, Candice C. Lam,
Angus C. Chan, Wing Tai Siu, Enders K. Ng
Background From our randomized study, ChemoRT achieved a similar early survival com-
pared to esophagectomy for squamous esophageal cancer (J GI Surg 2005; 9:794-802). This
study investigate the effect of ChemoRT compared to esophagectomy on the pulmonary
function of patients with squamous esophageal cancer. Patients & Method From 2000 to
2004, 80 patients with resectable carcinoma of mid or lower esophagus were randomly
assigned to receive ChemoRT or esophagectomy. Patients treated with ChemoRT received
continuous 5-FU infusion (200mg/m2/day) and cisplatin (60mg/m2) on days 1 and 22. The
tumor was concomitantly irradiated to 50-60 Gy. The esophagectomy included a two or
three-staged esophagectomy with two field dissection. Pulmonary function were assessed
before and after treatment at 3 monthly intervals. Results 44 patients received standard
esophagectomy, while 36 were treated with chemo-radiotherapy. No difference in the early
cumulative survival was found between the two groups (RR 0.89, 95% CI 0.37 to 2.17;
Log rank test p = 0.45). The pretreatment FEV1 and FVC were similar between the two
groups, and there is a significant decline in FEV1 and FVC after treatment for both groups
at 3 months (Figure 1). The ChemoRT group showed a significant recovery of both FEV1
and FVC as compared to esophagectomy group from 6 months after treatment till 24 months.
From 30-question based survey, patients treated with esophagectomy had a significantly
poorer dyspnoea on various activities than those treated with ChemoRT (56.1 vs. 33.6; p =
0.05). Conclusions Both ChemoRT and esophagectomy induced a significant reduction in
the pulmonary function in patients with squamous esophageal cancer. ChemoRT group
showed a significantly better recovery in pulmonary function and less dyspnoea during daily
activities when compared to esophagectomy group.
Figure 1
T1010
Treating Nighttime GERD Reduces Overall Costs More Substantially Than
Treating Daytime GERD - A Population Based Economic Model
Stephen M. Lange, Quan Doan, Adam B. Elfant, Lynda S. Welage, Stephen Brunton,
Richard B. Lynn, Robert W. Dubois
OBJECTIVE: To assess the economic impact of treating daytime (DG) and nighttime (NG)
GERD with proton pump inhibitors (PPIs). METHODS: An economic model was constructed
from the perspectives of employer and payer to compare the overall costs of treatment (Tx)
with no treatment over 1 year among a population of 1 million (M) lives. Patients received
daily PPI at standard doses. Patients with breakthrough symptoms or incomplete symptom
resolution were given double doses of daily PPI for 4 weeks and then resumed standard
daily doses. Parameter estimates were obtained from the literature and modified by experts
as necessary to reflect generalizability to all GERD patients. GERD prevalence rate of 20%
was assumed with half classified as DG and the rest NG. Fifty-six percent experienced
complete symptom resolution after 4 weeks of standard dose PPI therapy; 78% in those
requiring treatment of breakthrough symptoms. Without treatment, symptom relief of 24%
after 4 weeks was assumed based on placebo response in clinical trials. Breakthrough
symptoms at 6 months were 25% and 68% for PPI and no treatment, respectively. The
published per patient per year costs of visits, hospitalizations, and procedures attributable
to GERD was $240. Applying utilization weights of 0.4, 0.6, and 2.4 to $240, the costs for
patients with mild, moderate, and severe symptoms were $97, $146, and $590. Indirect
costs represented the hours of productivity loss multiplied by the national average hourly
earnings. The daily cost of regular dose PPI therapy was $2. RESULTS: The burden of GERD
was substantial ($663M). Treatment resulted in an overall savings of $386M ($1,930 saved
per treated patient per year) driven mostly by reduction in “indirect” costs compared with
no treatment. Similar trends were observed in DG and NG, but treatment produced greater
savings among NG patients. Savings associated with treating DG disappeared if the price of
daily regular doses of PPI exceeded $3.80. In contrast, results supporting treating NG were
robust when varied from $1 to $5 per day for standard dosing of PPI. CONCLUSIONS:
Treating GERD patients with PPI daily resulted in a substantial cost savings over a wide




Incidence of Esophageal Adenocarcinoma After Endoscopic Ablative Therapy
for Barrett’s Esophagus: A Systematic Review and Meta Analysis
Srinivas R. Puli, Brenda Westhoff, Nicholas J. Shaheen, J Wei, Sanjeev Slehria, Ajay
Bansal, Amit Rastogi, Prateek Sharma
Purpose: The goal of ablative therapy in pts with Barrett’s esophagus (BE) is to decrease the
risk of developing cancer. The extent of any reduction of cancer incidence in BE pts following
endoscopic ablation is not known. Our aim was to determine the cancer incidence after
ablative therapy in pts with no dysplasia (ND BE), low grade dysplasia (LGD), and high
grade dysplasia (HGD). Methods: We performed a MEDLINE search of the English language
literature from 1980 to 2005. The search combined the keywords Barrett esophagus, eso-
phageal adenocarcinoma, ablation, laser, argon, photodynamic, multipolar, and recurrence.
Abstracts from DDW and ACG meetings from 2000 to 2005 were also included. All studies
with mean/median follow-up duration of <6 months were excluded. Because most studies
had no control arm, the rate of cancer development in the ablation studies was compared
to historical data on BE pts not undergoing ablation The standardized incidence rate difference
(IRD) was obtained using both the fixed and random effect models. Tests of heterogeneity
were performed using the DerSimonian-Laird random effects analysis. Weighted mean event
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rate for a study population was utilized to obtain a summary standardized rate, which was
expressed as the direct standardized incidence rate (DSR). Approximate confidence intervals
for DSR were calculated by Chiang’s normal approximation to Poisson rate sums. Results:
62 articles met the inclusion criteria and were included in the analysis. These studies included
1,153 pts with ND BE, 239 with LGD, and 611 with HGD. For pts undergoing ablative
therapy, the DSR for cancer was 1.99/1000 pt-yrs (95% Cl: -0.108 to 4.04) for ND BE pts,
1.58/1000 pt-yrs (95% Cl: -0.66 to 3.84) for LGD, and 26.89/1000 pt-yrs (95% Cl: 17.33
to 36.46) for the HGD pts. Pooled data for controls obtained from 8 published articles
showed a cancer incidence of 5.3/1000 pt-yrs in ND BE, 6.4/1000 pt-yrs in LGD, and 59.4/
1000 pt-yrs in HGD. The Standardized IRD for ND BE, LGD and HGD were 5.29, 6.12
and 58.08, respectively (p<0.001). The number needed to treat to avoid an additional cancer
in ND BE, LGD and HGD were 303, 208 and 31 respectively. Conclusions: Endoscopic
ablation of BE is associated with a statistically significant reduction in cancer incidence rate
compared to historical controls not undergoing ablation therapy; the higher the grade of
dysplasia, the greater the incidence rate reduction following ablation. Although in ND BE
and LGD pts undergoing ablation, the incidence of cancer was also reduced significantly,
the NNT was prohibitive. The greatest benefit of ablative therapy appears to be in pts with
HGD patient group.
T1012
Complete Symptom Resolution in Patients with Erosive Esophagitis and Non-
Erosive Reflux Disease: A Meta-Analysis and Systematic Review
Srinivas R. Puli, Ajay Bansal, Amit Rastogi, Jiten Patel, Sandra Hall, Prateek Sharma
Purpose: To compare the efficacy of treatment with proton pump inhibitors (PPI), histamine
2 blockers (H2B), and placebos in completely resolving gastroesophageal reflux disease
(GERD) symptoms in patients with erosive esophagitis (EE) and non-erosive reflux disease
(NERD). Method: Study Selection Criteria: Only studies which were randomized, double-
blinded, and compared complete symptom resolution with two difference classes of drugs,
were selected. The patient selection criteria included: age 18 to 80 yrs, GERD symptoms
for at least 7 days before trial, no intake of acid suppressive medications 2 week prior to
enrollment, and patients had endoscopy proven EE or NERD before start of treatment.
Data collection and extraction: Articles were searched in Medline, Pubmed, Ovid journals,
Cumulative index to nursing & Allied health literature, International pharmaceutical
abstracts, old Medline, Medline nonindexed citations, FDA database, and Cochrane control
trial registry. Two reviewers independently extracted data. Areas of difference were resolved
by mutual agreement. Statistical Method: A meta-analysis was conducted by combining
data using both fixed and random effect models. Mantel-Haenszel and DerSimonian-Liard
methods were used to analyze data using those models. Test of Heterogeneity was done
using Mantel-Haenszel method. Results: Eleven studies for patients with EE (N= 4227) and
twelve studies for patients with NERD (N= 3768) met study criteria (two studies had data
for both the groups). At 4 weeks, the odds ratio (OR) of being symptom free on treatment
with PPI compared to H2B was 6.0 (95% CI: 4.81-7.49) in the EE group and 1.94 (95%
Cl: 1.05-3.62) in the NERD group (test of heterogeneity, p = 0.6 and 0.3 respectively). The
OR of being symptom free at 4 weeks on treatment with PPI compared to placebo was
10.23 (95% Cl: 8.59-12.2) in the EE group and 4.76 (95% Cl; 4.08-5.58) for the NERD
patients (test of heterogeneity, p <0.001 for both EE and NERD groups). Although test of
heterogeneity was significant in PPI compared to placebo, on manual comparison, there
were no significant heterogeneities between the studies. Conclusion: Complete symptom
resolution at 4 weeks in EE patients is significantly higher in patients treated with PPI
compared to either H2B or placebo. In the NERD subgroup, although treatment with PPI’s
is significantly better than H2B in complete symptom resolution, the benefit is marginal
and much lower compared to EE patients. Future studied should attempt to improve
symptom response in the NERD population as well as help define those NERD patients who
will respond to acid suppressive therapy.
T1013
A Ten-Year Natural History of Gastro-Esophageal Reflux Disease
Alexander C. Ford, Alastair G. Bailey, David Forman, Anthony T. Axon, Paul Moayyedi
Introduction: Gastro-esophageal reflux disease (GERD) is common in the general population,
with a reported incidence as high as 20 percent. However, there is little information regarding
the long-term natural history of the disorder. Methods: The authors performed a 10-year
follow-up cross-sectional survey of individuals recruited into a community screening and
treatment program for Helicobacter pylori. All surviving, traceable participants were contacted,
by validated postal dyspepsia questionnaire, which contained items relating to GERD symp-
toms. Baseline demographic data and GERD symptom data were stored on file from the
original study. Results: Of 8407 individuals, 4003 (48%) responded to the questionnaire.
The mean age of responders was 55 years, and 2247 (56%) were female. Males, those with
dyspepsia at baseline, smokers, and those of lower social class were significantly less likely
to respond (p<0.0001). There were 550 (14%) subjects with GERD symptoms at a frequency
of more than once a week at baseline. Of these, 240 (44%) still had at least one dyspeptic
symptom at a frequency of once a week or more at ten-year follow-up, and heartburn
remained the predominant symptom in 167 (30%), whilst 301 (55%) had symptoms less
than once a week or were entirely asymptomatic. Of the 3421 individuals who were asympto-
matic at baseline, 629 (18%) had heartburn at a frequency of once a month or more, 196
(5.7%) once a week or more, and 39 (1.1%) once a day or more. Heartburn was the
predominant dyspeptic symptom in 540 (16%) of these individuals at ten years. Conclusions:
During ten years of follow-up approximately a third of individuals with GERD at baseline
remained symptomatic, whilst in those without symptoms more than five percent had


















Prevalence of Heartburn in Russia: Preliminary Results of a National
Population-Based Study
Vasily A. Isakov, Sergey V. Morozov, Ekaterina S. Stavraki
Introduction. Heartburn is a common symptom of gastroesophageal reflux disease (GERD).
It has been shown that more than half of the adult population of Western Europe and the
United States experience some heartburn, and a third of them suffer from heartburn daily
or 2-3 times a week. The prevalence of heartburn in Russia has not yet been studied . Aim.
To evaluate the prevalence of heartburn in Russia. Methods. A questionnaire was designed
for patients in the primary care setting, which included questions on the presence and
frequency of heartburn, risk factors provoking heartburn, influence on the quality of life.
Eight structured questions were organized in a self filled-in form. The questionnaire was
validated in 115 GERD patients and 104 controls and found to have an acceptable sensitivity
(89%) and specificity (92%). The mean time for completing the questionnaire was 5.4±1.2
min. The study was performed in 14 of the largest cities in Russia. Results. Twenty thousand
questionnaires were distributed, the response rate was 81.3% and 14,521 questionnaires
were analyzed. The presence of heartburn was evaluated in 8,037 women and 6,486 men.
Among them, 8,661 subjects reported heartburn (59.7% of the respondents). The heartburn
prevalence was similar in women and men (59.1% vs 60.4%; p=0.1). Amongst subjects
with heartburn, 46.1% experienced infrequent heartburn, 16.4% weekly, 21.9% several
times a week, and 15,6% had daily symptoms. In total 22.7% of the respondents experienced
frequent heartburn (daily or 2-3 times a week). The timing of heartburn was as follows:
after a meal (74.3%), bending (19.1%), fasting (16.1%), during physical activity (13.5%),
at night (12%), or under stress (10.4%). The presence of heartburn had an effect on the
quality of life of those subjects: general considerable discomfort was noted by 56.8%, 38%
avoided favorite dishes and beverages, 26% reported limited physical activity, sleep disorders
were noted in 20%, and low efficiency was reported by 14.6% of the respondents. Conclusion.
This is the largest and the first population based study to report the prevalence of heartburn
in more than 14,000 subjects in Russia. More than half of the studied Russian urban
population suffers from heartburn, 75% of them have post-prandial symptoms. Every fifth
respondent experiences heartburn frequently and this also has a major impact on their
quality of life.
T1015
Epidemiology of Esophageal Carcinoma in a Statewide Cancer Registry
Linda C. Cummings, Gregory S. Cooper
Background: Differences in etiologic factors and demographics associated with esophageal
cancer have not been extensively studied at a population-level. Specifically, the impact of
race, gender, age, and histology on the incidence and staging of esophageal cancer deserves
further study. The primary aim of this study was to compare age-adjusted incidence rates
of invasive esophageal adenocarcinoma (EAC) and squamous cell carcinoma (ESCC) by race
and gender. Other aims were to evaluate the impact of race, age, gender, anatomical site,
and histology on stage at presentation; and to assess tobacco use among patients with
esophageal cancer. Methods: This is a population-based cross-sectional study using state
cancer registry data. Cases of invasive esophageal cancer (ESCC, n=937 and EAC, n=1,815)
diagnosed between 1998 and 2002 were included. Analysis of predictors of stage was
restricted to incident staged cases of EAC or ESCC. Results: The incidence rate of ESCC
was higher among African-Americans (5.0 cases/100,000/year) than whites (1.3 cases/
100,000/year). However, EAC incidence was higher among whites, with the highest rate in
white males (6.4 cases/100,000/year). 80% of esophageal carcinoma, 85% of ESCC, and
77% of EAC cases for which tobacco history was reported occurred in past or current
smokers. In univariate analyses, histology, race, age, gender, and primary site differed
significantly by stage. 36% of males but only 26% of females had distant disease (p=0.001).
31% of patients ≥ age 65 presented with distant disease, compared with 37% of patients
< age 65 (p<0.001). 32% of African-Americans presented with distant stage, versus 34% of
whites (p=0.048). However, in a logistic regression model, male gender [OR 1.43, CI(1.10,
1.86)], and age <65 [OR 1.28, CI(1.05,1.57)], but not race, predicted distant stage. There
was a trend towards EAC histology being a predictor of distant disease, but it did not reach
statistical significance [OR 1.27, CI(0.99, 1.62)]. Conclusions: EAC incidence rates are higher
among whites, whereas African-Americans have higher ESCC rates. Most EAC cases were
associated with smoking. To our knowledge, this is the first population-based study evaluating
tobacco use in EAC. Unlike prior studies, we found that African-Americans are not more
likely to present with distant stage. Further research is needed to elucidate racial differences
in stage at presentation. Male gender and age < 65 were independent predictors of distant
stage, and although these differences could be due to socioeconomic factors, further studies
are needed to explore this possibility.
T1016
Impact of BRAVO pH Telemetry On Ambulatory Esophageal pH Monitoring
John M. Wo, Jennifer Koopman, Robert Cacchione, Steven Harrell
Bravo pH telemetry is a more tolerable method of ambulatory pH monitoring without a pH
catheter through the nose. It is unclear if Bravo has altered the use of pH monitoring. AIM:
To compare the clinical utilization and associated costs between transnasal and Bravo pH
testing. METHODS: A comprehensive review was performed on physician ordering patterns
for all pH tests during the past 2.5 years since Bravo became available at our institution.
The following parameters were obtained: # of pH tests (transnasal and Bravo), patient’s chief
complaints, ordering physician (community physician through open access or division
faculty), test condition (on or off antireflux meds), # of esophageal manometry studies (EMS)
to locate lower esophageal sphincter for transnasal pH catheter placement, and # of EGDs
to locate gastroesophageal junction (GEJ) for Bravo capsule placement. Professional and
facility fees for transnasal test, Bravo, EMS and EGD were determined using Medicare
reimbursement for our state from 2003 to 2005. New technology ambulatory payment
category for Bravo was used for facility reimbursement after 4/1/2004. Cost per pH test,
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including EMS or EGD, was determined for each subject. Unpaired t-tests and χ2 tests were
used. RESULTS: 642 pH tests (51% Bravo and 49% transnasal) were performed since Bravo
was introduced. Results are shown in table. There were no significant differences in patient’s
age or gender between the two test methods. 70% of Bravo pH tests were performed on
antireflux therapy compared to only 13% of transnasal pH tests (p<0.001). Repeat pH testing
occurred in 5% of Bravo patients compared to only 2% of transnasal subjects (p=0.03).
Open access referral from community physician accounted for only 4% of Bravo tests
compared to 83% of pH transnasal tests (p<0.001). Of the 252 subjects who underwent
EGD to locate the GEJ for Bravo placement, 132 (52%) already had an EGD in the past.
CONCLUSIONS: A dramatic shift toward Bravo pH telemetry for esophageal pH monitoring
has occurred in a short period of time despite a higher cost and similar indications. Costs
may be minimized by recording GEJ location during all routine EGDs. More pH tests were
performed on antireflux therapy using Bravo.
*Mean ± SD; **p<0.001
T1017
Objective Definition of Symptom Relief in Clinical Studies: Determination of
International GERD Symptom Thresholds Based On Request™
Vincenzo Stanghellini, David Armstrong, Hubert Monnikes, Karna Dev Bardhan, Holger
Schmitt, Iris Velten, Peter Berghofer, Ronnie Fass
PURPOSE: Symptom assessment as a primary endpoint is of increasing interest in GERD
clinical trials. The validated ReQuest™ offers daily monitoring of treatment-induced symptom
changes. Since individuals without evidence of GERD may experience mild symptoms
commonly ascribed to GERD, ReQuest™-based GERD symptom thresholds were recently
evaluated in a German population. Thresholds were established as objective criterion for
symptom relief. Here, we aimed to verify the validity of the concept in an international
setting. METHODS: 2,032 individuals from France, Italy, Spain, and USA were screened
for evidence of GERD. Applying stringent exclusion criteria (e.g. history of gastrointestinal,
cardiac, respiratory disorders/symptoms, consultation of a specialist, history of endoscopic
examination, intake of GERD medication), 1,167 were eligible for analysis. Participants
completed ReQuest™ on 4 consecutive days. Two subscales exist: ReQuest™-GI (acid
complaints, upper abdominal/stomach complaints, lower abdominal/digestive complaints,
nausea) and ReQuest™-WSO (general well-being, sleep disturbances, other complaints).
Intensity and frequency of these dimensions (general well-being intensity only) were scored
and weighted resulting in sum scores. The maximum sum scores are 46.28 (ReQuest™),
30.77 (ReQuest™-GI), and 15.51 (ReQuest™-WSO). Based on the maximum values for
each patient over the 4-day period, sum scores of ReQuest™ and its subscales corresponding
to the 95%-percentiles were calculated as international GERD symptom thresholds. The
influence of demographics (age, weight, height, BMI, gender) and country-specific effects
was determined by covariance analysis and Kruskal Wallis Test. RESULTS: The international
GERD symptom thresholds were 4.12 (ReQuest™), 1.60 (ReQuest™-GI), and 2.87
(ReQuest™-WSO). They correspond well with values recently obtained in the Germany
study: 5.04, 1.73, and 3.68, respectively. Demographics and country-specific effects on
GERD symptom thresholds could be excluded (p-values >0.05). CONCLUSIONS: This
study confirms that individuals without evidence of GERD experience low levels of symptoms
commonly ascribed to GERD. These individuals do not seek medical help and take no GERD
medication demonstrating that the impact of symptom burden is below a subjective threshold
of impairment. It is therefore sufficient to treat GERD patients until symptom burden is
below the GERD symptom threshold. Comparable GERD symptom thresholds assessed in the
German and this international evaluation suggest this concept of GERD symptom thresholds is
reliable and valid to prospectively define symptom relief in GERD therapeutic trials on a
global level.
T1018
Relationship Between Gastroesophageal Reflux Symptoms and Esophagitis in
the General Population: Results from the Loiano-Monghidoro Study
Rocco Maurizio Zagari, Paolo Pozzato, Silvia Damian, Maria Luisa Bianchi, Liza Ceroni,
Lorenzo Fuccio, Maria Eugenia Minardi, Mari-Ann Wallander, Saga Johansson, Bahman
Farahmand, Enrico Roda, Franco Bazzoli
Background & Aims: Gastroesophageal reflux disease (GERD) is characterized by typical
symptoms of heartburn and regurgitation, and/or endoscopically evident lesions such as
esophagitis. The relationship between symptoms and endoscopic findings in the general
population is unclear, as endoscopic data are usually obtained only in selected subgroups.
Our study aimed to establish the relationship between endoscopic findings and reflux
symptoms in a representative sample of the general population. Methods: We approached
a representative sample of 1533 adults from two Italian villages (Loiano and Monghidoro)
between 2000 and 2004 to undergo symptom assessment and gastrointestinal endoscopy.
Endoscopic findings were assessed using the Savary-Miller classification. We recorded the
frequency of heartburn and regurgitation during the previous 12 months using a validated
questionnaire. We also collected data on smoking, alcohol and coffee consumption, history
of peptic ulcer disease and medication use. Odds ratios and 95% confidence interval calculated
by unconditional logistic regression models were used as measures of association between
esophagitis and reflux symptoms. Results: Data were obtained from 1069 individuals repres-
entative of the general population (a response rate of 70%). The overall prevalence of
heartburn and/or regurgitation was 45.3%; 21.1% of the study population had symptoms
monthly, 21.5% weekly and 2.7% daily. Esophagitis was a risk factor for monthly (OR: 2.0;
95% CI: 1.2-3.5) and at least weekly (OR: 3.2; 95% CI: 2.0-5.1) reflux symptoms. Others
potential risk factors such as smoking, alcohol and coffee consumption, and the use of
aspirin, nonsteroidal anti-inflammatory drugs and corticosteroids had no effect. The overall
prevalence of esophagitis was 11.9%. Females were less likely than males to have esophagitis.
Hiatus hernia (OR: 4.4; 95% CI: 2.8-6.8) and typical reflux symptoms increased the risk
of esophagitis. Esophagitis was detected in 6.8%, 14.2%, 20.4% and 27.6% of subjects with
no, monthly, weekly and daily symptoms, respectively. Compared with subjects with no
symptoms, esophagitis was associated with monthly (OR: 2.1; 95% CI: 1.2-3.5), weekly (OR:
2.8; 95% CI: 1.7-4.6) and daily (OR: 5.0; 95% CI: 1.9-13.5) reflux symptoms. Conclusion: We
detected a linear relationship between the prevalence of esophagitis and the frequency of
reflux symptoms in the general population. Our data show that subjects with even monthly
typical reflux symptoms have a two fold increased risk of esophagitis.
T1019
Assessment of Satisfaction Following the Treatment of Gastro-Oesophageal
Reflux By Proton Pump Inhibitors in Primary Care : The « Reflex » Physician-
Patient Agreement Study
Etienne Dorval, Jean-Francois Rey, Philippe Barthelemy, Agnes Caekaert, Christine
Soufflet
The paim of this study is to evaluate the physician-patient agreement concerning satisfaction
with the treatment of gastroesophageal reflux (GER) symptoms on a large population of
adult patients treated with proton pump inhibitors (PPI) in primary care. Patients and
Methods A sample of 2500 PCPs were selected by random draw with geographical stratifica-
tion. Each PCP had to select the first 3 patients suffering from GER symptoms who were
treated for at least one month by PPI prescribed daily or at least 14 days during the previous
month. Two questionnaires were filled in for each patient included, one by the physician,
the other by the patient, assessing the presence, frequency and intensity of the GER symptoms.
The impact of GER on everyday life, overall satisfaction and expectations with respect to
treatment (symptoms, quality of life, self-medication) were assessed trough a 5 grades Likert
scale. Agreement between the physician and patient answers were analyzed by the kappa
method. Results 5326 patients were included (57 % men ;mean age : 53 + 15 years. 45%
had an upper GI endoscopy within the 3 previous years showing oesophagitis in 77 % of
the cases. PPI was prescribed continuously in 69 % of the patients, intermittent in 20 %
and on demand in 11 %. The analysis included 5174 physician-patient binomes. The
agreement was good for the presence and frequency of GER symptoms (kappa > 0.6) and
also good for the impact on everyday life (kappa = 0.64). However, it was only fair for the
intensity of the symptoms (kappa 0.4 to 0.5) with an assessment in general lower on the
physician questionnaire. While the overall treatment satisfaction was deemed good or excel-
lent by the physicians and the patients in 72 % of the cases, the agreement for satisfaction
was only fair (kappa = 0.6) and fair or poor (kappa<0.40) for expectations with regards to
treatment. Conclusion The level of satisfaction associated with the treatment of GER by PPI
as perceived by the physicians and the patients is high and exceeds 70 %. However, there
are disagreements in the perception between patients’ and physicians’ assessment concerning
the intensity of residual symptoms and their expectations with respect to the treatment.
T1020
Epidemiologic Risk Factors for Reflux Esophagitis in Healthy Population
Su Youn Nam, Chan Gyoo Kim, Il Ju Choi, Woo Jin Lee, Kyung Woo Park, Ho June
Song, Joo Hyuk Lee
Background/Aims: The prevalence of gastroesophageal reflux disease (GERD) have increased
in western world over the 20 years but are not known in Korean population. We investigated
the prevalence and epidemiologic risk factors for reflux esophagitis in general population.
Methods: A total of 16580 healthy individuals who had undergone the endoscopy in center
for cancer prevention and detection from May, 2001 to October, 2005 were enrolled in this
study. GERD symptoms, dietary intake, education, economic status, housing environment,
current job, smoking, alcohol consumption, age, and sex were interviewed by participants.
Body mass index (BMI), hiatal hernia, and rapid urease test (CLO test) were evaluated.
Male:female ratio was 1.28:1. Data analysis was performed using the Pearson χ2 test and
logistic regression with the SPSS 12.0 for windows statistical package. Results: The prevalence
of reflux esophagitis (RE) defined as LA classification was 4.03% (667/16580). RE was more
common in men than in women (5.9% vs 1.7%, p < 0.001), current smoker or ex-smoker
than in non-smoker (6.8%, 5.2% vs 2.2%, p < 0.001), current drinker than in non-drinker
(5.1% vs 2.2%, p < 0.001), persons with heartburn than in those without heartburn (7.8%
vs 4.5%, P = 0.001), and CLO negative individuals than in CLO positive individuals (4.57%
vs 1.83%, p < 0.001). RE was more common in persons with hiatal hernia than in those
without hiatal hernia (18.8% vs 4%, P < 0.001). The prevalence of RE was increased
according to BMI (p < 0.001); BMI<18.5 (2.6%), 18.5<BMI<23 (2.7%), 23<BMI<25 (3.5%),
25<BMI<29 (5.3%), BMI>29 (7.4%). RE was more common. The prevalence of RE was
showing decreasing tendency to increased age (p = 0.06); <40 year (4.6%), 40-60 year
(4.1%), >60 year (3.6%). Dietary intake, educational level, economic status, housing environ-
ment, and current job did not affect reflux esophagitis. Multivariate analysis revealed that
hiatal hernia (P = 0.004 / OR = 3.105 / 95% CI 1.430-6.742), heartburn (0.001 / 1.823 /
1.279-2.596), male sex (0.004 / 1.702 / 1.182-2.452), current smoker (0.018 / 1.496 /
1.072-2.086), current drinker (0.046 / 1.370 / 1.005-1.867), increased BMI (0.001 / 1.587 /
1.321-1.920), and negative CLO test (0.001 / 2.631 / 1.866-3.703) were confirmative risk
factors for reflux esophagitis. Conclusion: Male sex, smoking, alcohol consumption, absence
of H. pylori, increased BMI, presence of heartburn and hiatal hernia are distinctive risk
factors for RE in general population.
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T1021
Gastroesophageal Reflux Disease (GERD) and Gastroesophageal Reflux
Disease (GERD) Related Non-Cardiac Chest Pain (NCCP) in the Population:
Prevalence, Risk Factors and Health Care Seeking
Guy D. Eslick, Nicholas J. Talley
BACKGROUND: Whether the epidemiology of gastroesophageal reflux disease (GERD) in
the general population is changing remains uncertain. Less is known about GERD related
chest pain. We aimed to evaluate risk factors for both these conditions in the community,
and health care seeking. METHODS: A random sample of 1,000 residents of Penrith were
mailed the Chest Pain Questionnaire (CPQ), a validated self-report questionnaire. Measured
were symptoms, risk factors, psychological distress, quality of life, and demographics.
RESULTS: The response rate was 73% (n=672; mean age 46 years; 52% female) (figure).
A total of 78 (12%) were classified as having GERD (at least weekly heartburn and/or acid
regurgitation); only 14% had consulted a physician about GERD in the prior year. There
were two independent cardiac risk factors for GERD, high cholesterol (OR=3.28, 95% CI:
1.42-7.57, p=0.005) and current smoking (OR=2.47, 95% CI: 1.07-5.70, p=0.03). GERD-
related non-cardiac chest pain (NCCP) severity and frequency were independent predictors
of healthcare seeking for GERD (OR=9.36, 95% CI: 3.05-28.70, p<0.001; OR=3.48, 95%
CI: 1.07-11.33), respectively. None of the psychological conditions (anxiety, depression and
neuroticism) were significantly associated with GERD in the community. CONCLUSION:
GERD is remarkably common in the general population. High cholesterol levels (possible
indicating a high fat diet) and smoking are independently associated with GERD. GERD-
related NCCP severity and frequency were independent predictors of healthcare seeking
for GERD.
T1022
Increased Symptom Severity But Not Symptom Frequency Are Associated with
a Worse Quality of Life (QOL) in Gastroesophageal Reflux Disease (GERD): A
Population-Based Study
Guy D. Eslick, Nicholas J. Talley
BACKGROUND: There is a dearth of population-based studies that determine the impact
of gastroesophageal reflux symptoms on quality of life (QOL). We aimed to evaluate the
magnitude of this problem in the community. METHODS: A random sample of 1,000
residents of Penrith were mailed the Chest Pain Questionnaire (CPQ), a validated self-
report questionnaire. Measured were GERD symptom severity and frequency, risk factors,
psychological distress, demographics and quality of life (using the SF-36). The symptom
severity scale assessed mild, moderate, severe and very severe. The symptom frequency scale
assessed <1/month, 1/month, 1/week, >1/week, and daily. RESULTS: The response rate
among eligible subjects was 73% (n=672; mean age 46 years; 52% female). GERD ever was
reported by 52% of the population. The majority of QOL sub-scale scores were associated
with the severity of both heartburn (Figure) and acid regurgitation symptoms. Those with
mild, moderate, severe and very severe GERD symptoms had significantly poorer scores
than those with no GERD (P<0.05 for sub-scales physical function, body pain, vitality, and
social function). The frequency of heartburn and acid regurgitation (comparing <1/month
and daily vs nil) were not associated with significantly reduced QOL sub-scale scores.
CONCLUSION: Increasing GERD symptom severity is associated with worse QOL scores,
whereas GERD symptom frequency (<1/month and daily) did not impact the QOL scores.



















Gastroesophageal Reflux Disease (GERD) Associated Osteopenia
Stjepan Mise, Ante Tonkic, Ante Punda, Marina Titlic, Valdi Pesutic Pisac, Ivana Jukic,
Sven Seiwerth, Predrag Sikiric
The pathophysiology of bone loss associated with gastrointestinal diseases has not been
clearly defined. In addition to previous relation to inflammatory bowel disease or post-
gastrectomy status, we report an association with gastroesophageal reflux disease (GERD).
In this study 131 subjects were randomly assigned, 62 with endoscopically determined
GERD patients (35 female, 27 male), and 69 patients with normal endoscopy findings
examined because of degenerative rheumatic disorders that need NSAIAs therapy (32 female,
37 male). Patients had not different ages GERD (min/med/max: 34-65-84), rheumatic patients
(min/med/max: 30-53-82), high GERD (min/med/max: 146-166-186 cm), rheumatic patients
(min/med/max: 151-165-190), weight GERD (min/med/max: 47-72-117 kg), rheumatic
patients (min/med/max: 48-76-107), menarche GERD (min/med/max: 12-14-19 years),
rheumatic patients (min/med/max: 11-14-18), menopause GERD (min/med/max: 35-49-57
years), rheumatic patients (min/med/max: 38-49-55 years). Lumbosacral spine and left hip
were used for densitometry analysis (>-1=normal, -1.0 / -2.5 =osteopenia, <-2.5 = osteopor-
osis). The following values were obtained: lumbosacral spine: GERD (min/med/max: -4.6/-
1.3/2.1) , rheumatic patients (min/med/max: -3.2/-0.3/2.6) (P<0.0002), left hip: GERD
(min/med/max: -2.9/-0.9/2.8) : rheumatic patients (min/med/max: -2.5/-0.2/2.2) (P<0.003).
Frequency of osteopenia: rheumatic patients: left hip 22%, lumbosacral spine 10.1%, GERD:
left hip 43.5% (P<0.008), lumbosacral spine 22.6 % (P<0.05). Sex relation in GERD-patients:
lumbosacral spine: male (min/med/max: -2.7/-0.6/1.4), female (min/med/max: -4.6/-1.4/2.1)
(P<0.014), left hip: male (min/med/max: -1.5/-0.4/2.8), female (min/med/max: -2.9/-1.1/
1.1) (P<0.028). No special difference was noted in nutrition, physical activity, alcohol
consumption, as well as neither of patients received any therapy for osteoporosis. Conclusion.
Thus, these data indicate an indicative association between GERD and osteopenia, and their
relation remain to be further determined.
T1024
Can It Be Predicted Prior to Treatment the Necessity for Additional
Prokinetics with PPI Using Frequency Scale for the Symptoms of GERD
(FSSG), a GERD-Specific Questionnaire?
Miyamoto Masaki, Haruma Ken, Mizooka Masafumi, Kuwabara Masao
Background:PPI monotherapy cannot cure all GERD patients, and combination therapy with
a prokinetics and PPI achieves symptomatic improvement for the patients. Few studies have
been performed to predict the need for prokinetics before treatment for GERD commenced.
Using the frequency scale for the symptoms of GERD (FSSG), a GERD-specific questionnaire
developed in Japan (Kusano et al., J Gastroenterol 2004), we retrospectively investigated
whether pre-treatment FSSG scores can be used to predict the need of prokinetics after 12
weeks. Patients and Methods:The 163 patients (64 male, mean age 53.1±16.6 years) with
gastroesophageal reflux (GER) symptoms were evaluated using the FSSG and upper gastroin-
testinal endoscopy, and were administered rabeprazole 10 mg daily. After 12 weeks, the
patients were offered a choice of 4 treatment regimens according to their degree of satisfaction
(satisfied group: 1)no need for further treatment, 2)opt for continued PPI treatment, 3)step-
down from PPI to H2RA; dissatisfied group: 4)dissatisfied with present treatment, so opt
for combination treatment with prokinetics, mosapride citrate 5 mg X 3 daily). The patients
continued with the treatment of their choice for a further 12 weeks, and they were again
offered the same 4 choices according to their degree of satisfaction. The evaluated the
association predictor for choice of treatment after 12 weeks, odds ratio (OR) and correspond-
ing 95% CI were computed by means of logistic analysis models. Results:1. After 12 weeks,
the satisfied groups were 79.1% <129/163, 1)21 pts, 2)98 pts, 3)10 pts>, and the dissatisfied
group was 20.9% (34/163). After 24 weeks, 98.2% of subjects were in the satisfied group.
2. We compared 4 treatment regimens by baseline FSSG scores, the dissatisfied group
<4)17.4±1.4> were significantly higher than the satisfied groups <1)12.3±1.3, 2)12.8±0.8
and 3)10.2±1.8) (P<0.05). 3. Male gender (OR 0.12: 0.02-0.56, P=0.007), the baseline FSSG
score (OR 1.15: 1.03-1.28, P=0.017), body mass index (OR 0.74: 0.60-0.91, P=0.005), and
symptomatic constipation (OR 21.6: 2.41-193.76, P=0.006) were found to be significant
predictors for additional prokinetics after 12 weeks. Conclusions As a result of selecting
treatment regimens from request oneself, the patients satisfactory at 24 weeks in 98.2%.
The dissatisfaction by with continued PPI was useful for additional prokinetic The logistic
regression analysis corrected for high baseline FSSG score and symptomatic symptomatic
constipation show a significant predictor for the necessity for additional prokinetic.
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T1025
Is Eosinophilic Esophagitis Underdiagnosed in Patients Presenting with
Dysphagia Or Food Impaction?
Rekha Attigere, Alison Schneider, Eric Miller, Richard Lee, Asyia Ahmad
Eosinophilic esophagitis is a disease of rising incidence and prevalence that should be
considered in the differential of unexplained dysphagia and food impaction. Structural
alterations may not be apparent during endoscopy and random esophageal biopsies are
required to confirm the diagnosis. While the prevalence of eosinophilic esophagitis has
increased, there are still no clear AGA guidelines for the diagnosis of this disorder. Our aim
was to determine if the diagnosis of eosinophilic esophagitis is being considered by commun-
ity and academic physicians during the evaluation of patients presenting with food impaction
or dysphagia. METHODS: A survey was randomly sent to 700 gastroenterologists via elec-
tronic mail. Practitioners were asked about diagnostic and therapeutic interventions for
dysphagia and food impaction. RESULTS: There were 117 responses (47 community gastro-
enterologists, 49 academic gastroenterologist, and 21 gastroenterology fellows). During the
endoscopic evaluation of a patient presenting with a food impaction, 82% of academic, 79%
of community gastroenterologists, and 81% of gastroenterology fellows stated they were
likely to pursue further investigation. Surprisingly only 34% percent of academic physicians
stated they would perform esophageal biopsies during the evaluation of a food impaction.
However this was still significantly higher than both community gastroenterologists (14%)
and fellows (17%) (p≤ 0.05). In addition, academic physicians were more likely to mention
eosinophilic esophagitis as their reason for performing biopsies than both community and
fellows (20.4% academic vs 0% community vs 14% fellows; p < 0.01). During the evaluation
of unexplained dysphagia, all groups were likely to start with an EGD as their first test with
community gastroenterologists performing this most commonly (p < 0.05). Despite this,
only 26% of academic physicians, 25% of community physicians, and 33% of fellows were
likely to perform biopsies during upper endoscopy for unexplained dysphagia. There was
no significant difference between these groups although there was a trend for academic
physicians to mention eosinophilic esophagitis in their diagnosis more often. CONCLUSION:
While eosinophilic esophagitis is an increasing cause of dysphagia and food impaction, the
diagnosis is not being evaluated in practice. Academic gastroenterologists consider eosino-
philic esophagitis more often than community physicians but neither group consistently
includes eosinophilic esophagitis in their differential diagnosis or endoscopic plan. Further
education is needed amongst all gastroenterologists to ensure that the diagnosis is not missed.
T1026
Usefulness of Rapid HP Star, a New Immunochromatographic, Monoclonal
Antigen-Based Faecal Test, for Diagnosing Helicobacter Pylori Infection in
Dyspeptic Patients
Mariela Quesada, Xavier Calvet, Victoria Calvet, Theresa Choat, Barbara Fallowfield,
Isabel Sanfeliu, Ferran Segura
Objective: To evaluate the usefulness of two new monoclonal tests for detecting Helicobacter
pylori antigens in dyspeptic patients’ faeces: a rapid immunochromatographic test (RAPID
Hp StAR, DakoCytomation, Cambridge, UK) and an ELISA (Amplified IDEIA Hp StAR,
DakoCytomation, Cambridge, UK). Methods: H. pylori infection was determined in 68
dyspeptic patients who underwent endoscopy due to concordance of urease test and histology
results. Faecal tests were performed according to the specifications of the manufacturer.
Sensitivity, specificity, positive and negative predictive values (PPV and NPV respectively)
were calculated for both RAPID Hp StAR and Amplified IDEIA Hp StAR. Concordance
between different measurements was estimated by Kappa statistics. Results: The sensitivity
of the RAPID Hp StAR ranged from 96-98% and its specificity was 67%. PPV was 92% and
PNV 80-90%. Corresponding Amplified IDEIA Hp StAR values were 98%, 83%, 94% and
94%. Conclusions: both RAPID Hp StAR and Amplified IDEIA Hp StAR were highly sensitive
and easy-to-perform diagnostic tools for the diagnosis of H. pylori infection.
T1027
Evaluation of Four Different Faecal Tests for Determination of CURE After
Helicobacter Pylori Treatment
Mariela Quesada, Xavier Calvet, Angelina Dosal, Victoria Calvet, Isabel Sanfeliu, Laura
Ribera, Theresa Choat, Barbara Fallowfield, Antonia Montserrat, Valenti Puig, Ferran
Segura
Background: Data evaluating the monoclonal tests for determination of cure after Helicobacter
pylori treatment are scarce. Goals: This study was aimed to evaluate the usefulness of four
stool tests - two new RAPID monoclonal immunochromatographic tests (RAPID Hp StAR™,
DakoCytomation, Cambridge, UK and ImmunoCard STAT! HpSA, Meridian Diagnostics,
Cincinnati, OH) a monoclonal EIA test (Amplified IDEIA™ Hp StAR, DakoCytomation,
Cambridge, UK) and a polyclonal EIA test (Premier Platinum HpSA, Meridian Diagnostics,
Cincinnati, OH) - to confirm cure of H. pylori infection after eradication treatment. Study:
Ninety-seven patients who underwent eradication treatment were included. Cure of H. pylori
infection was determined using two consecutive reference tests. Faecal tests were performed
according to the specifications of the manufacturer. Sensitivity, specificity, positive and
negative predictive values (PPV and NPV) were calculated. Results: After H. pylori eradication,
the RAPID Hp StAR™ test has a sensitivity of 73% for detecting persistent infection, a
specificity of 96-98%, a PPV of 73-80% and a NPV of 96%. For ImmunoCard STAT! HpSA
the corresponding values were 91%, 97%, 77% and 99%, for Amplified IDEIA™ Hp StAR
73%, 97%, 73% and 97%, and for Premier Platinum HpSA 91%, 79%, 35% and 98%.
Conclusions: All tests except Premier Platinum HpSA were highly accurate confirming
eradication after treatment.
T1028
Serological Analysis of Helicobacter Hepaticus Infection in Japanese Patients
with Chronic Hepatitis C Using New Monoclonal Antibodies
Tadashi Shimoyama, Ryoki Takahashi, Juichi Sakamoto, Takeo Ohmura, Shinsaku
Fukuda, Akihiro Munakata
Background: Infection of Helicobacter hepaticus has been associated with the development
of hepatocellular carcinoma in mice. It is generally known incidence of hepatocellular
carcinoma in patients with chronic hepatitis C is high in Japan. However, prevalence of H.
hepaticus infection has not been understood. We examined the prevalence of H. hepaticus
infection serologically comparing with H. pylori, particularly in patients with chronic hepatitis
C. Methods: Serum samples obtained from 182 patients with chronic hepatitis C (106 males
and 76 females, mean age 47.4) and 142 control subjects who were not infected with
hepatitis virus (69 males and 73 females, mean age 60.0). Seropositivity of H. pylori and H.
hepaticus was tested by E-plate and antigen-capture ELISA using monoclonal antibody to
H. hepaticus antigen, respectively. Results: H. hepaticus seropositivity was significantly higher
in patients with chronic hepatitis C (29.4%) comparing control subjects (13.7%, p<0.05)
while H. pylori seropositivity was not different between groups (67.0% and 77.4%, respect-
ively). Higher H. hepaticus seropositivity was observed in H. pylori-seropositive patients
(32.1%) than in H. pylori-seronegative patients (15.3%, p<0.01). Different seropositivity of
H. hepaticus was observed according to birth year. H. hepaticus seropositivity was 37.3% in
patients who were born before 1950 while it was only 12.7% in patients born after 1960
(p<0.01). H. pylori seropositivity was also showed the same trend in this series of patients.
Conclusions: Present results suggest the possibility that prevalence of H. hepaticus is high
in patients infected with hepatitis C virus. Association of seropositivity may suggest the
presence of similar transmission routes between H. hepaticus and H. pylori.
T1029
Helicobacter Pylori Infection Confers An Increase in Ten-Year Mortality from
All Causes: Data from a Community Screening and Treatment Program
Alexander C. Ford, Alastair G. Bailey, David Forman, Anthony T. Axon, Paul Moayyedi
Introduction: Population screening and treatment of Helicobacter pylori has been advocated
as a means of reducing mortality from gastric cancer. Several screening programs have been
conducted in the West, but follow-up has been limited to two years, therefore long-term
mortality data are not yet available. Methods: The authors performed a ten-year follow-up
study of individuals, currently aged 50 to 59 years, previously recruited into a community
screening and treatment program for H. pylori. Those testing positive were randomized to
receive either eradication therapy, or placebo. All individuals originally involved were traced
with a list cleaning service provided by the Office for National Statistics, and death certificates
were obtained for deceased individuals. Results: Of 8407 original participants, 140 (1.7%)
were dead at ten years. 92 (66%) were male. 64 (46%) deaths were due to cancer, and 31
(22%) to ischaemic heart disease (IHD). Mortality from all causes and IHD were significantly
increased in H. pylori positives compared to negatives (odds ratios (OR) 1.65; 95% confidence
interval (CI) 1.15 to 2.36 and 2.46; 95% CI 1.13 to 5.32 respectively), but there was no
significant difference detected in cancer mortality (OR 1.37; 95% CI 0.78 to 2.36). Following
logistic regression controlling for age at study entry, gender, tobacco and alcohol consump-
tion, and socioeconomic status all-cause mortality remained significantly higher in H. pylori
positives (OR 1.46; 95% CI 1.02 to 2.09). There was a trend towards higher all-cause
mortality and mortality from IHD in those receiving eradication therapy at ten years compared
to placebo (relative risks 1.46; 95% CI 0.85 to 2.49 and 2.0; 95% CI 0.69 to 5.84 respectively),
though neither were statistically significant. Two individuals died from upper gastrointestinal
(GI) cancer, one gastric and one esophageal adenocarcinoma (both H. pylori negative), and
a further died from upper GI hemorrhage from a duodenal ulcer (H. pylori negative).
Conclusions: Infection with H. pylori is associated with an increased mortality from all
causes, even when possible confounding factors are controlled for. The reasons for this are
unclear. However, screening and treatment of positive individuals may confer an increased
risk of death from IHD, which should be borne in mind when recommending the adoption
of such a strategy.
T1030
Size of the Peptic Ulcer in H. Pylori Positive Patients: Association to the
Clinical and Histological Characteristics
Perttu E. Arkkila, Arto Kokkola, Kari Seppala, Pentti Sipponen
BACKGROUND AND AIM: Based on the large trial of H. pylori (Hp) positive peptic ulcers,
we clarified which are the symptoms and clinical characteristics to predict the size of peptic
ulcer. We also studied if the size of the ulcer and other clinical and histological characteristics
are independent factors for the healing of peptic ulcers. METHOD: A total of 333 consecutive
patients with Hp infection and peptic ulcer were enrolled, the mean age of 54.8+/-12.7
years. Ulcer location was recorded by gastroscopy and the presence of Hp was assured by
rapid urease test, histology and by serum Hp IgG and IgA antibody measurement. The
diameter of the peptic ulcer was measured by setting the opened biopsy forceps (7 mm)
beside the peptic ulcer. Biopsy specimens were stained by haematoxylin and eosin, alcian
blue-periodic acid Schiff and by modified Giemsa methods. Specimens were examined
according to the Sydney system. RESULTS: Mean size of the peptic ulcer was in corpus
13.2+/-8.3, in antrum 11.3+/-5.3, in angulus 13.8+/-7.8, in prepylorus 9.5+/-5.3 and in
duodenum 9.2+/-4.7 mm (duodenal vs. gastric type p<0.05). The average size of ulcers was
9.4+/-5.3 mm in patients with Forrest III type of ulcer and 11.5+/-6.8 in other types of
ulcers (n=119) (p<0.05). Patients, who were ≥50 years old or currently smoking or who
had corpus predominant chronic gastritis, atrophic gastritis or epigastric pain at day or night
time, had larger ulcers than others. The size of index ulcer, the successful eradication of
Hp and the presence of atrophic gastritis were independent factors for healing of the index
ulcers. The odds ratio was 11.5 (95% CI 3.3-40.5, p<0.01) for H. pylori and 3.5 (95% CI
1.1-11.2, p<0.05) for the size of index ulcer (≤10mm versus >10mm) and for atrophic
gastritis versus no atrophy 3.4 (95% CI 1.2-9.8, p<0.05). CONCLUSIONS: A number of
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clinic and endoscopic variables (age, current smoking, corpus predominant gastritis, Forrest
classification) associated with the size of peptic ulcer in Hp positive patients. The size of
peptic ulcer, Hp infection and atrophic gastritis were indenpendent factors for the healing
of peptic ulcers.
T1031
Evaluation of Endoscopy Outcomes a Decade After Nationwide Introduction of
Protontonpump Inhibitors and Guidelines for Helicobacter Pylori Eradication
Lieke A.S. Van Kerkhoven, Sally J. van Rijswijck, Leo G.M. van Rossum, Adriaan C.I.T.L.
Tan, Robert J.F. Laheij, Jan B.M.J. Jansen
BACKGROUND: In several studies incidences of different gastrointestinal diseases have
been investigated among patients referred for open access endoscopy. However, since the
nationwide introduction of protonpump inhibitors and guidelines for H. pylori eradication
over a decade ago, it is expected that incidences of endoscopic findings have changed. AIM:
To compare the prevalences of different gastrointestinal diseases before and after nationwide
introduction of protonpump inhibitors and guidelines for H. pylori eradication in a population
referred for upper gastrointestinal endoscopy in an open access setting. METHODS: Data
about endoscopy outcomes of consecutive patients referred to the Canisius-Wilhelmina
Hospital Nijmegen for open access endoscopy between January 2002 and December 2004
was collected from medical files. These were compared with data from three historical
populations with similar characteristics publishes by Schaap et al, Numans et al. and Adang
et al. a decade ago. Outcomes were compared using chi-square. RESULTS: Our current
study population consisted of 1298 subjects: 49% were male and mean age (range) was
53.7(18-91). The historical population included a total of 3.062 subject, with a mean age
of 50 (SD=15) and 57% was male. The prevalences of peptic ulcer disease and duodenitis
statistically significant decreased from 18.2% to 5.7%; a decrease of 12,5% (95%CI: 10,2-
14,9) and from 11.8% to 5.4%; a decrease of 6,4% (95%CI: 4,4-8,4) respectively. The
prevalences of reflux-oesophagitis, functional dyspepsia and Barrett’s oesophagus statistically
significant increased with 6,7% (95%CI: 4,3-9,2), 10,5% (95%CI: 7,3-13,7) and 2,0%
(95%CI: 0,4-3,6), respectively. Gastroesophageal cancer is currently as frequent as it was
in the historical population: 2.2% vs 1.8%; p=0.53. CONCLUSIONS: Since the nationwide
introduction of protonpump inhibitors and guidelines for H. pylori eradication, prevalences
of peptic ulcer disease and duodenitis have decreased significantly. The increase of oeso-
phagitis at endoscopy supports the hypothesis that H. pylori eradication might contribute
to the development of oesophagitis. 1 Schaap NPM et al. Ned Tijdschr Geneesk
1993;137(23):1142-6. 2 Numans ME et al. Scand J Gastroenterol 2001; 36(4):437-43. 3
Adang RP et al. Eur J Gastroenterol Hepatol 1994; 6:329-335.
T1032
The Relationship Between Previous Fluoroquinolone Use and Levofloxicin
Resistance for Helicobacter Pylori Infections, 1998-2002
John J. Carothers, Michael G. Bruce, Thomas W. Hennessy, J Michael Bensler, Julie M.
Morris, Alisa L. Reasonover, Debby A. Hurlburt, Alan J. Parkinson, John M. Coleman,
Brian J. McMahon
Purpose: With increasing antimicrobial resistance among H. pylori to conventional therapies,
interest in using fluoroquinolones as a viable second or third line therapy has increased.
The relationship between prior fluoroquinolone use and levofloxacin resistance in H. pylori
is unknown. Methods: We recruited adults from a clinical practice at a referral hospital in
Alaska serving primarily Alaska Native/American Indians. One-hundred-twenty-five adults
infected with H. pylori were enrolled. Medical records were reviewed for antimicrobial use
in the 10 years prior to diagnosis with H. pylori infection. Fluoroquinolone susceptibility
of H. pylori isolates obtained from endoscopic gastric biopsy was determined using the E
Test method. The purpose of this study was to determine the relationship between prior
fluoroquinolone use and levofloxacin resistance in H. pylori infected Alaska Native persons.
Results: Among the 125 patients, 11 (8.8%) were found to have H. pylori isolates resistant
to levofloxacin. Resistance to levofloxacin was associated with any prior fluoroquinolone
use (9 of 11 patients with levo-resistant isolates vs 19 of 114 patients with levo-sensitive
isolates, p<0.001). The odds of an isolate being resistant to levofloxacin increased in relation
to the total number of courses of fluoroquinolones prescribed. Conclusion: Previous use of
fluoroquinolones is associated with increased H. pylori resistance to levofloxacin. A history
of fluoroquinolone use may be helpful in predicting H. pylori susceptibility to levofloxacin.
T1033
Prevalence of Helicobacter Pylori Infection in Young Children: Non-Invasive
Stool Antigen Testing
Michal Kori, Eva Goldstein, Esther Granot
OBJECTIVE: To noninvasively study the prevalence of Helicobacter pylori infection in young
children attending day care facilities using an H. pylori stool antigen test (HpSA). METHODS:
Children attending day care facilities aged 2 months and above were recruited. Stool samples
were collected and tested for HpSA. Parents filled out a questionnaire regarding family size,
residential crowding, parent’s education, country of birth of the child and parent. RESULTS:
316 children (mean age 18.9 ±10.9 months) were tested by HpSA. 78 (24.7%) were positive
and 236 (76.3%) negative. 98 (31%) of the children were younger than 12 months, 164
(52%) were between 12 and 24 months and 54 (17%) were older than 24 months. Seven
(7.1%) of children younger than 12 months tested positive for HpSA as compared to 52
(31%) of the 12-24 month old children and 19 (35%) of the children older than 24 months
(P<0.001). 158 stool samples were collected and tested during the summer and an identical
number were examined during the winter. 67 (42.4%) of the samples tested during the
summer were positive as opposed to 11 (6.9%) tested during the winter (P<0.001). Mean
age of the children tested during the different seasons was the same. CONCLUSIONS: By
two years of age more than 30% of infants attending day care facilities in Israel are already

















lower (7%). The observed increased incidence of HpSA positive tests during the summer
as opposed to winter is intriguing and warrants further evaluation.
T1034
Effect of Sibling Number and Birth Order On Prevalence of Helicobacter Pylori:
A Cross-Sectional Survey
Alexander C. Ford, Alastair G. Bailey, David Forman, Anthony T. Axon, Paul Moayyedi
Introduction: Social conditions influencing the acquisition of Helicobacter pylori in childhood
are well recognized, but the effect of number of siblings, and birth order on prevalence of
H. pylori has not been extensively reported. Methods: The authors performed a ten-year
follow-up cross-sectional survey of individuals previously enrolled in a community screening
and treatment program for H. pylori. Prevalence of H. pylori was assessed at baseline with
13carbon-urea breath testing. All involved individuals who were alive, and could be traced
to a current address, were contacted by postal questionnaire, to obtain information on both
total number of siblings, and their order of birth. Data concerning other social conditions
in childhood were stored on file from the original study. Results: 3928 (47%) of the 8407
original participants provided complete data. Prevalence of H. pylori infection increased
steadily according to total number of siblings, from 20% in those with no siblings, to 63%
with 8 or more. The odds of having H. pylori infection was significantly increased when the
individual had three siblings (odds ratio (OR) for infection 1.79; 95% confidence interval
(CI) 1.34 to 2.38), and a clear gradient of effect continued up to eight or more siblings (OR
for infection 6.66; 95% CI 3.94 to 11.44). In addition, odds of H. pylori infection was
significantly higher in those individuals with two older siblings (OR for infection 1.32; 95%
CI 1.04 to 1.68), and again increased steadily up to six (OR for infection 3.78; 95% CI
1.51 to 9.74). Even amongst first-born individuals, prevalence of infection significantly
increased with three or more siblings (OR 1.59; 95% CI 1.02 to 2.44). When total number
of siblings, and other social conditions in childhood, such as sharing a bed or bedroom
with a sibling, lack of an inside toilet, and father’s socioeconomic status were controlled for
in a logistic regression model, the association between birth order and odds of H. pylori
infection was no longer statistically significant. Conclusions: Number of siblings and birth
order appear to influence prevalence of H. pylori infection, though the observed effect of
birth order may be due to confounding by other factors in childhood.
T1035
Prevalence of Helicobacter Pylori Within Duodenal Ulcers in a District General
Hospital
Shamaila K. Butt, Steve Mann, Niall van Someren, Kalpesh Besherdas
Background and Aims. The association between Helicobacter pylori and duodenal ulcers is
well established, with infection being present in up to 95% of duodenal ulcer patients in
published studies, the majority of the remainder being attributed to non steroidal anti-
inflammatory drugs (NSAIDS). One way of confirming presence of H.pylori infection at
Endoscopy is by use of CLO test. In view of the high prevalence of H.pylori infection in
duodenal ulcers, some advocate the empirical use of H.pylori eradication therapy in their
management. The aim of this study was to assess the prevalence of H.pylori in duodenal
ulcer patients from North London attending a district general hospital from the year 2000.
Methods. This was a retrospective analysis of patients (in a non-teaching hospital) with
endoscopically diagnosed duodenal ulceration and considered to be infected with H.pylori
if CLO test was positive. The data between July 2000 until July 2005 was gathered using
the endoscopy Endoscribe reporting system along with CLO test records. Results. A total
of 175 patients (age range was 20 to 101 years with a male to female ratio of 91:84) were
identified as having duodenal ulceration on gastroscopy and were biopsied for H.pylori using
the CLO test. The following table demonstrates the prevalence of H.pylori positive duodenal
ulcers in our patients. Conclusion. We have shown that over five consecutive years the
prevalence of H.pylori positive ulcers as measured by CLO test is in the range of 34% to
53%, a much lower prevalence than proposed by previous studies. Although H.pylori infection
is an important factor in the aetiology of duodenal ulceration, other factors (such as NSAIDS,
and rarer causes like Crohn’s disease, Coeliac disease, malignancy, hypergastrinaemia, gastrin-
oma and hyperparathyroidism) should be determined for as they may predominate. In
addition, the empirical use of antibiotics in the management of patients with duodenal ulcers
cannot be suggested by this study.
T1036
Calcium Channel Blockers May Radiosensitize Patients to Radiation Proctitis
While Statins, NSAIDs May Radioprotect: A Case-Control Study
Bradley C. Irwin, Rasna Gupta, Kyung Kim, Sue Han, Edgar Ben-Josef, Bradley Axelrod,
Martin Tobi
Background: We studied factors associated with the development of chronic radiation
proctitis (RP) in prostate cancer (PC) patients. We specifically targeted potential contributions
of medications taken concomitantly with radiotherapy (RTx) since HMG-CoA reductase
inhibitors (STATINS) and non-steroidal anti-inflammatory medication (NSAIDs) have been
reported to enhance or reduce radiation effects in a number of organ systems. Methods:
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From 1987-2002 there were 1,177 PC patients diagnosed at our center and 63 patients
were found to have endoscopy-proven RP. 61 similarly diagnosed and irradiated PC patients
with negative endoscopy served as controls. Demographics including body mass index were
also compared. Results: Of the study population African Americans comprised 63% of the
sample. Average age was 67.7 years with median Gleason score of 7. There were 61 controls
and 63 patients with RP. Of the RP patients 60% were taking calcium channel blockers
(CCB) versus 39% of controls; 19% of RP patients were taking STATINS versus 55% of
controls; 15% of RP patients were taking NSAIDs versus 53% of controls. Logistic regression
showed increased relative risk of RP in patients taking CCBs (OR 2.97, CI 1.29-6.87, p=
0.0107). A decreased relative risk was seen in patients taking Statins (OR 0.178, CI 0.069-
.46, p=0.0004), and patients taking NSAIDs (OR 0.36, CI .15-.82, p=0.015). Multivariate
regression analysis revealed CCBs to be an increased independent risk factor for RP (p=
0.023), whereas Statins and NSAIDs proved to be independent indicators for reduced risk
(p=.0003 and p=0.0158, respectively). BMI, aspirin, folic acid, and multivitamin medications
were also analyzed but no significant differences were detected between the groups. Conclu-
sions: Medicinal intake of CCBs is a clinically significant and independent predictor for
increased risk for RP. To the best of our knowledge this is a novel finding. Recent studies
suggest that up-regulation of epidermal growth factor receptors (EGFR) plays a role in
radioresistance in certain tumors. Calcium channel blockers interfere with the transactivation
of endothelial EGFR and EGFR phosphorylation in vitro thus CCBs may Radiosensitize the
rectal mucosa, thereby increasing the risk of RP. Conversely, STATINS and NSAIDs may
be radioprotective by reducing RTx-induced chemokine and COX-2 expression, respectively.
These findings may prove clinically useful to reduce the incidence of RP and prospective
studies should be undertaken to determine their utility.
T1037
Does Colon Ischemia Have a Worse Prognosis When Isolated to the Right
Side?
John Sotiriadis, Igal Khorshidi, Brandt J. Lawrence
The colon is the hollow viscus most commonly involved in gastrointestinal ischemia and
colon ischemia (CI) accounts for approximately 1 in 1000 hospital admissions at our medical
center. In general, CI has a very good prognosis but, because blood flow to the ascending
colon and the small intestine are both from the superior mesenteric artery, it has been
questioned whether the presentation of isolated right colon ischemia (IRCI) should be
considered an emergency situation with a grave prognosis just as is ischemia acutely involving
the small intestine. Indeed, we have seen several cases in which IRCI has been accompanied
or followed by small bowel ischemia (acute mesenteric ischemia), and in which the mortality
was higher than with the usual case of CI. This study was designed to answer the following
clinical questions: 1) does IRCI have a worse prognosis than CI involving other segments
of colon? 2) does associated acute mesenteric ischemia account for any differences in observed
morbidity or mortality and, if so, 3) can emergency intervention alter the prognosis? A
retrospective chart review was performed of all cases of biopsy-proven CI identified in the
years 2000-2005. Age, gender, co-morbid conditions, anatomic location of the ischemia,
pathology reports, radiologic imaging, colonoscopy reports and patient outcomes including
hospital stay, need for surgery, morbidity and mortality were evaluated. 182 cases of CI
were identified of which 46 (25.3%) involved only the right side. In no case did acute
mesenteric ischemia accompany or follow the index episode of IRCI. However, patients with
IRCI had a worse outcome than those with CI involving other colon regions. 21 patients
(45.7%) with IRCI had a colectomy, of which 6 (28.6%) died; another 4 died prior to
surgery, yielding a total mortality rate of 54.3%. The mortality rate for patients with non-
right-sided CI was 4.4%. In conclusion, IRCI is more common than previously reported,
has a higher mortality rate than CI involving other regions of the colon and is not associated
with or followed by acute mesenteric ischemia. Given these findings, it does not appear as
if mesenteric angiography is appropriate in the evaluation of patients with IRCI, but the
substantial mortality rate of this occurrence mandates its aggressive medical and surgical care.
T1038
The Spiraling Use of CT for Abdominal Pain: Is Colonoscopy Necessary If
Colonic Thickening Is Reported?
Jordan H. Wolff, Jeffrey D. Potter, Waymon Lattimore, Murray B. Resnick, Brian L.
Murphy, Steven F. Moss
Introduction: Computed tomography (CT) is often used in the investigation of acute abdom-
inal pain. Not infrequently, colonic wall thickening is reported. Is a colonoscopy warranted
to investigate this finding further? Only two small studies of a heterogeneous group totaling
73 patients have been published previously, with equivocal results. Given the lack of clinical
guidelines regarding the management of such patients, our aim was to determine the utility
of colonoscopy in the diagnosis and management of patients found to have colonic wall
thickening on CT. Methods: All patients from July 2000 to April 2004 who were investigated
by abdominal CT at our large university teaching hospital were considered. Cases were
selected if any colonic wall thickening was reported. Patients were excluded if the indication
for the CT did not include abdominal pain, if the patient had a history of a gastrointestinal
disorder involving the colon such as a malignancy, any inflammatory bowel disease (IBD),
infectious colitis or diverticulitis, or if they did not undergo colonoscopy within 30 days of
the abnormal CT. Clinical, endoscopic and pathological data were extracted from the medical
records of all eligible patients. Results: One hundred four cases were identified. Of these,
8 (7.7%) were found to have adenocarcinoma of the colon or rectum. In 10 patients (9.6%)
a new diagnosis of IBD was made during the admission. Sixteen (15.4%) had findings
consistent with acute self-limited (infectious) colitis, 36 (34.6%) had evidence of ischemic
colitis, 27 (26%) were found to have no abnormality that could explain the CT finding,
and 7 patients (6.7%) had other miscellaneous findings that may have been responsible for
the “colonic thickening” - these were diverticulitis (3 cases), appendicitis (1), serosal abscess
(1), acute proctitis (1), and mucosal friability related to thrombocytopenia (1). Notably, of
those diagnosed with colorectal carcinoma or IBD, only 5 of the 18 patients (28%) presented
with evidence of gastrointestinal bleeding or anemia. Conclusions: Following colonoscopy
a new diagnosis of colorectal carcinoma or IBD was made in 17.3% of these patients who
had no known previous gastrointestinal disorder. Most of these patients had no other
indication for diagnostic colonoscopy. Additionally, diagnoses of ischemic or infectious
colitis were made in 50% of patients overall. Based on this high frequency of significant
findings, we recommend that patients with acute abdominal pain in whom CT demonstrates
colonic thickening should undergo colonoscopy promptly.
T1039
The Cecum Is Inflamed in Health: The Danger of Considering a Diagnosis of
Microscopic Colitis with Right Colon Biopsies
Shirley C. Paski, Robert Wightman, Marie Robert, Norman Pettigrew, Charles N.
Bernstein
BACKGROUND AND PURPOSE: Accurately diagnosing “normal colonic mucosa” is essential
under many circumstances. An inherent degree of non-pathological mild inflammation,
particularly in the cecum, has been informally described among gastrointestinal pathologists.
This poorly described low-grade inflammation is often reported as “nonspecific colitis” which
can be confusing to clinicians. The objective of this study was to characterize and quantify
the low-grade inflammation present in the cecum and compare this to the rectum of healthy
adults.METHODS: 85 healthy adult volunteers free of gastrointestinal symptoms and history
of gastrointestinal disease consented to undergo colonoscopy + biopsy. Colonoscopy prep
was with oral magnesium citrate and fleet phosphosoda. Biopsies were taken from the cecum
and rectum. Biopsy slides were coded and mixed prior to scoring. Biopsy slides of cecum
and rectum from 15 patients with ulcerative colitis were randomly distributed within our
sample to limit observer bias. Histology scores 0 (none) to 3 (severe) were assigned for each
of: lamina propria cellularity, subcryptal cellularity, crypt architecture, cryptitis/abscess, and
epithelial injury. Activity = epithelial injury + cryptitis/abscess. Chronicity = lamina propria
cellularity + subcryptal cellularity + crypt architecture changes. The total score for inflamma-
tion was measured as the sum of all histology scores for each slide.RESULTS: Histology
scores for inflammation were significantly greater in the cecum vs rectum for all categories
except there was no difference in subcryptal cellularity between cecum and rectum. See
table. For persons with ulcerative colitis that did not reach the cecum, histology scores for
cecal inflammation were no different compared with healthy individuals with respect to all
measures of inflammation, activity, chronicity, and total scores. CONCLUSION: Increased
microscopic inflammation of the cecum is present in healthy individuals free of gastrointesti-
nal disease, compared to the rectum. Caution should be used when diagnosing “colitis”
based on a cecal biopsy, particularly in the setting of low-grade inflammatory changes.
Mean score (0-3)
all comparisons significant at p<0.05
T1040
Treatment of Anal Ulcers in HIV-Infected Patients
Claudia Gonzalez-Ruiz, Bill Briggs, Israelit Shlomo, Paul Selvidoss, Glenn Ault, Robert W.
Beart, Andreas M. Kaiser, Petar Vukasin
Introduction: About 30% of HIV-infected patients will seek attention for anorectal diseases
at some point in their lives. The vast majority of their anorectal pathology is comprised of
Human Papilloma Virus infections and anal ulcerations. The aim of this study was to review
our experience in an HIV dedicated anorectal clinic within a large urban county system of
the treatment of anal ulcers in HIV-Infected patients. Methods: The Los Angeles County -
University of Southern California HIV clinic, is an Institution solely dedicated to the care
of HIV patients. A colorectal clinic was established within this environment in 1991, and
has served as the exclusive provider for the care of anorectal pathology to these patients. A
well established prospective database of patients treated at this clinic was reviewed for visits
spanning Jan 2001 through Nov 2005. Included were patients with HIV-related anal ulcers.
Excluded were patients with anal fissures anal pathology which did not include anal ulcers,
and those with incomplete medical records. Data collected included general demographics,
type of treatment and outcome. Treatment was considered successful if ulcer healing or
resolution of anal symptoms was recorded. Results: A total of 307 HIV-infected patients
were treated at our institution during the study period. Sixty patients (20%) had the diagnosis
of anal ulcers of which fifty one had adequate records for inclusion to the study. Nine
patients were lost to follow-up. The Male: Female ratio was 57:3. Mean Age was 41 years
(range 20-78). 50/60 patients (83%) healed or became completely asymptomatic with a
combination treatment of Acyclovir + metronidazol for 7 to 10 days. Ten patients (16%)
required two or three courses of antibiotics in order to heal completely. Only one patient
required surgical intervention. Four patients presented with chronic ulcers that had burrowed
in to perianal fistulas, all of which resolved with antibiotic treatment. Conclusion: Antibiotic
treatment of HIV associated anal ulcer disease is highly effective in the resolution of symptoms
and avoidance of surgical intervention.
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T1041
Profile of Patients Consulting for Ano-Rectal Symptoms and Having a
Prescription of a Local Treatment in Primary Care Setting
Marc Andre Bigard, Laurent Siproudhis, Francois Pigot, Ghislain Staumont
Background : Prescription of a local symptomatic treatment (ointment or suppository) is
frequent by general practitioners but reasons of prescription are poorly understood. Methods
: A survey was carried out in France by 161 general practitioners in a population of patients
consulting for anal symptom. A questionnaire was filled out by physicians including questions
about symptoms, history and prescription. Patients filled out a questionnaire with questions
about nature of treatment, symptomatic effect and tolerance. Results : A response was
obtained for 885 patients (Female = 56,7%). The mean age was 48,6 years (16-85 years).
Patients described one symptom for 65,1%, two symptoms for 25,1% and three symptoms
or more for 9,8%. The major symptoms were pain (48,7% of patients), bleeding (38,4%),
swelling (31,2%) and pruritus ani (25,5%). Bleeding was more frequent in men (42,2% vs
33,8%) and pain was more frequent in women (51,6% vs 42,7%). Reasons of medical advice
were mainly intensity of symptoms (61,5%) or anxiety (32,5%). Medical prescription included
2 or 3 medications in 76,3%. The most frequent prescription was an association of ointment,
suppository and diosmine p.o (31,5%). A combination of ointment and diosmine was made
in 24,7%. The duration of treatment was 10 days for ointment and suppositories and 30
days for oral diosmine. Conclusion : In case of anal symptoms (pain, bleeding, pruritus ani,
swelling) attributed by general practitioners to hemorroids, symptomatic treatment with 2
or 3 medications is commonly prescribed in France. Satisfaction of patients is obtained in
about 60% of the cases. In spite of lack of convincing randomized trials of these treatments,
symptomatic effect seems correct in most of the cases.
T1042
Fecal Incontinence: Still Common and Underreported
Susan McCormick
Background & Aims: Fecal incontinence (FI) is a fairly common problem, though is is
rarely discussed. There is no new medication to bring it to the limelight. Instead, it is an
embarrassment. Patients rarely bring it up and doctors rarely ask, as the therapies are less
than satisfactory. Though studies are sparse, the prevalence of FI has varied widely, from
1%(in an older study) to 18%. Prevalence increases with age in most of the studies. This
survey was undertaken to determine the prevalence and severity of FI in a young to middle
aged group of health care professionals attending a gastroenterology lecture series. Methods:
151 attendees of a Nurses and Associates Gastroenterology Update Conference were asked
to fill out a questionnaire. Attendees included nurses, technicians, customer service represent-
atives and secretaries. The questionnaire asked about demographics, obstetrical history,
severity of FI (incontinence of mucous, liquid or solid stool; incontinence daily, weekly, 2-
3 times a month or less than once a month; need for pads, restriction of activity) and
whether FI had been discussed with their doctor. Results: 146 of 151 chose to answer the
questionnaire (96.5%). 5 respondents did not answer clearly, so 141 questionnaires were
tallied (93% of total). The mean age of the respondents was 45.2 (+/- SD 10). 136 of the
respondents were women. 128 were caucasian, 6 were Asian, 4 were African American, 1
was Hispanic. 18 respondents had FI (13%), mean age 49 (+/- SD 8). 8 were incontinent
of liquid stool and 10 of solid stool. The frequency of FI was weekly in 3/18, 2-3x a month
in 4/18, and <1/month in 11/18. 3 restricted their activities because of FI, 4 wore pads,
and 2 had discussed the problem with their physician (1%). 4 respondents had had primary
caesarean section (C/S). None of these had FI. 100 labored and then had either vaginal
delivery or C/S. 15 of these women had FI (15%). 32 of the women had no children. This
was a younger group (mean age 38.4 vs. 47.5 in the group that had had children.) 3 of
these had FI (10%). Conclusion: In a survey of a relatively young group (mean age 45), FI
was still quite prevalent (13%). More than half had FI of solid stool and 39% had episodes
weekly or 2-3x a month. Only 1% had discussed the symptoms with their doctor. FI remains
common and underreported.
T1043
Joint Hypermobility and Rectal Prolapse in Children
Sonia Michail, Adam Mezoff
The etiology of rectal prolapse is unknown, but it has been associated with long-standing
constipation, cystic fibrosis, parasitic infection, chronic diarrhea, malnutrition, or neurolo-
gical disease. A number of children with rectal prolpase do not display such associated
disorders. An underlying connective tissue abnormality is a consideration in this subset of
children but has not been previously described. The purpose of this study is to determine
whether joint hypermobility is associated with rectal prolapse in the pediatric population.
Records of all children with rectal prolpase seen over a period of five years were evaluated.
Children having any of the above associated disorders were excluded. Joint hypermobility
as assessed by Beighton’s criteria were evaluated in children with rectal prolapse as well as age-
matched controls. Nine children were identified with rectal prolpase without an associated
disorder. Average age was 8.8 years (range: 3-17). Male to female ratio was five to four. All
children had a Beighton score more than 4 suggesting joint hypermobility (5.6±0.53). All
sixteen sex- and age-matched control children scored less than four. The average Beighton
score for the control group was 1.6±0.67 (p=0.0018). The presence of joint hypermobility
in children with rectal prolapse suggests an underlying connective tissue abnormality. This
abnormality may contribute to a weakness in the rectal fixation and the subsequent prolapse


















Using Computed Tomography to Validate An Ultrasonography-Based
Classification of Mild to Moderate Acute Colonic Diverticulitis
Akira Mizuki, Masayuki Tatemichi, Hiroshi Nagata, Satoshi Kaneda, Nobuhiro Tsukada,
Toshifumi Hibi
Background & Purpose: The purpose of this study was to validate an Ultrasonography-
based (US-based) diagnosis and classification of mild to moderate acute colonic diverticulitis
(ACD). We recently proposed a new US-based classification of ACD and indicated that
patients with an inflamed diverticulum (with an abscess of 2cm in diameter or smaller)
diagnosed as US-grade I were treatable as outpatients (Aliment Pharmacol Ther. 21:889-
97, 2005). Since CT is considered the gold standard for ACD diagnosis, a study validating
the US-based classification, using CT as a benchmark, was necessary. Material and Methods:
From 1998 to 2005, both US and CT examinations were performed in 24 ACD patients
(16 male and 8 female patients; (55.4 (16.5) years; mean (SD)). To compare US-based
grade I severity with CT, three sub-classifications were defined: Ia indicated an inflamed
diverticulum, where the inflammation was limited to the diverticulum; Ib indicated an
inflamed diverticulum with pericolitis (inflammation clearly extended to the pericolic tissue
around the diverticulum); and Ic indicated an inflamed diverticulum with an abscess of 2
cm in diameter or smaller. Grade II indicated an inflamed diverticulum with an abscess
greater than 2 cm in diameter, or with perforation from the colon into the abdominal cavity.
All US and CT images were examined by three Radiologists. Results: Of 5 patients with US-
grade Ia, 4 were diagnosed as grade Ia by CT, and one as grade Ib. Of 6 patients with US-
grade Ib, all cases were diagnosed as grade Ib by CT, whereas of 6 patients with US-grade
Ic, all cases were diagnosed as Ib by CT. In other words, a pericolic abscess with a maximum
diameter of 2cm, as revealed by US, was not evident on the CT. Of 7 patients with US-
grade II, 6 were classified as grade II by CT while one was diagnosed as grade Ib by CT
(since the size of the abscess could not be determined by CT). According to our US-based
findings, CT was unable to detect an abscess that was less than 3 cm in diameter. Conclusion:
Our research shows that using CT to diagnose mild to moderate ACD can result in underestim-
ating the severity of the ACD and, therefore, can result inappropriate treatment. Through
our study we found that US-based diagnosis and classification is more accurate, which
ultimately means that patients receive better treatment.
T1045
Impact of Alcohol Dependence On the Health Values of Patients Infected with
HCV
Muslim Atiq, Susan N. Sherman, Kenneth E. Sherman
Background: The CAGE questionnaire is a simple instrument used to assess alcohol depend-
ence. The relationship between CAGE outcomes, health utilities and quality of life measures
have not been previously assessed in HCV infected subjects. Materials and Methods: This
cross-sectional study was carried out at the University of Cincinnati Medical Center. One
hundred twenty-four patients with chronic HCV infection were administered a disease-
specific version of the SF-36 Health Survey, the Beck Depression Inventory, and 3 direct
health value measures, including the Rating Scale, Time Trade-off (TTO), and Standard
Gamble (SG). Correlation among measures and factor analysis was performed for the patients
who were positive by CAGE criteria defined as > 2 variables. Results: There were a total of
124 patients including 80 (64 %) males and 44 (36 %) females. Mean age was 46.59 +/-
8.78 years. Sixty patients (48.4 %) patients were found to have alcohol dependence by
CAGE criteria. Alcohol dependence was associated with a history of depression (p=0.036),
consumption of >20 grams/day of alcohol (p=0.01), history of IV drug abuse (p<0.001),
nasal cocaine use (p=0.007) and tattoos (p=0.001); whereas it was independent of gender,
ethnicity, marital status or sexual orientation. Alcohol dependence did not correlate with
the presence of cirrhosis or decompensated liver disease. Mean RS, TTO and SG scores were
not different between the two groups. Composite mental function QOL (MCS) scores were
lower in patients with alcohol dependence (P<0.01). Social Functioning (SF), Role emotional
(RE) and Mental Health (MH) scores on the SF-36 questionnaire were lower amongst patients
with alcohol dependence (p<0.02; p<0.04 and p<0.08 respectively). There was a strong
correlation between RS and MCS (r-0.81; p<0.01) in the subset of patients with alcohol
dependence whereas SG (r=0.44; p-0.02) and TTO (r=0.56; p<0.01) were only weakly
correlated with MCS. There was a very strong correlation between SG and TTO (R-value
0.77; p-value<0.01). The TTO and SG scores were significantly greater than the RS score
(P<0.01) and did not differ from each other. Conclusion: Alcohol dependence significantly
affects the QOL in HCV infected individuals; however the health utility indices are not
affected. CAGE positive response is not associated with alteration of patient behavior related
to medical decision making compared to those not meeting criteria for alcohol abuse. This
study was funded by a grant from NIH AHRQ (grant number HS10366-01).
T1046
Outcome of Screening for Hepatitis C Virus Infection in the Veteran
Population
Carol Mallette, Kittichai Promrat, Maura Flynn
Purpose: Screening for hepatitis C virus (HCV) infection in high risk individuals is currently
recommended by most, but not all, health authorities. There is a lack of data on the outcomes
of screening. This study identifies clinical characteristics and outcomes of patients diagnosed
with HCV through a screening program targeting patients with increased risk. Methods:
Veterans presenting for care in VA facilities are assessed for HCV risk factors by a self-
administered questionnaire. Those who identify a risk factor are offered an anti-HCV test.
Review of the local HCV registry from October 1998 through May 2004 identified 25,701
patients who were assessed for risk factors. No risk factor was reported by 17,767 patients
who were not offered anti-HCV testing unless clinically indicated. Risk factors for HCV were
identified in 8471 patients, of which 5646 were tested for HCV antibody. Patients were
considered to be diagnosed through the screening program if risk assessment led to anti-
HCV testing. Clinical characteristics and outcomes of these patients were prospectively
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obtained by chart review and medical evaluation. Candidacy for anti-HCV therapy was
assessed using pre-determined criteria. Results: The prevalence of a positive HCV antibody
in veterans who identified a risk factor was 7.3%. Among 412 anti-HCV positive patients,
260 were diagnosed through the screening program. 98% of the patients were male with a
mean age of 59. 47% of patients were viremic, 34% were aviremic, and 19% had no
confirmatory test. Among patients who had chronic HCV infection (n=122), 34% had
persistently normal ALT defined by ALT <40 on 3 separate occasions over 6 months. 39
patients (32%) underwent liver biopsy, and two-thirds had minimal or no fibrosis (Scheuer
stage 0 or 1). Advanced liver disease based on thrombocytopenia or abnormal synthetic
function was evident in 10% of patients. After a mean follow up of 26 months, 22 patients
(8%) were deceased; 2 were liver-related deaths. Of patients with chronic HCV, 54 (44%) were
not immediate candidates for therapy secondary to medical and psychiatric co-morbidities or
active substance abuse. Thus far, 16% of the screen-detected patients with chronic HCV
infection have received anti-HCV therapy. Conclusion: The prevalence of a positive HCV
antibody in veterans with risk factors is significantly higher than the general population.
Approximately half of the patients are viremic but few have advanced disease. Approximately
half are not immediate candidates for therapy based on contraindications or ongoing sub-
stance abuse. This data has major implications in designing an optimal screening strategy
for hepatitis C.
T1047
Initial HCV Response in Patients with End Stage Renal Disease Treated with
Combination Pegylated Interferon α-2a and Ribavarin
Wyel Hakim, Shehzad Sheikh, Irteza Inayat, Margaret Bia, Cary Caldwell, Dhanpat Jain,
Douglas Smith, Fadi Lakkis, Amy Friedman, Marc Lorber, Richard Formica, Wajahat
Mehal
Background. Treatment of hepatitis C virus (HCV) with pegylated interferon and ribavirin
has been widely studied, but there is little data on combination treatment of patients with
HCV and end-stage renal disease (ESRD). We designed a pilot study to determine the initial
and sustained viral response of combination treatment of these patients. Methods. A non-
randomized, prospective observational study of combination therapy with low dose pegylated
interferon α-2a and ribavarin. 20 patients who met the criteria for inclusion (age over 18yrs,
viremic for HCV, any genotype, on dialysis) were enrolled for the study. Exclusion criteria
were decompensated liver disease, immunosuppressive therapy, hepatocellular cancer, and
use of antiviral therapy in the last 6 months. After undergoing liver biopsies, patients began
PEG-IFN at 135 microgram/week sc, and 4 weeks later ribavarin was started at 200mg PO
weekly, increasing gradually to three times a week for a total of 48 weeks. Results. 20
patients: M:F 18:2; mean age 52.4 yrs; African American 15, Caucasian 3, Hispanic 2;
genotype 1: 18, non-1: 2. All patients underwent liver biopsy (stage I: 4; stage II: 9; stage
III 7). Of the 20 patients, 4 withdrew from the study prior to starting treatment. 2 patients
discontinued before three months of treatment (1 for moderate fatigue and 1 patient moved
out of state). 11 patients have reached the three-month time point to determine initial viral
response, while 3 have not. Of the 11, 5 patients have had initial viral response, defined
as at least a two log drop in their HCV viral count (45%). Of the 3 patients that have not
reached 3 months on treatment 1 has had a viral response. Side effects included 2 cases of
anemia (Hgb less than 9.5g/dl) requiring temporary withholding of ribavirin, and one
patient with headaches not requiring stopping treatment. Conclusions. Low-dose pegylated
interferon and ribavarin therapy of patients with HCV and ESRD in this study has not been
associated with any serious adverse effects. The response rate in individuals taking three
months of treatment is comparable to studies in non-ESRD patients. These results demonstrate
that combination therapy with low dose pegylated interferon α-2a and ribavirin is a safe
therapeutic option in the ESRD population with HCV infection. Conclusive results will be
obtained once all patients complete the treatment and the follow-up period for determining
a sustained response. This study was supported by Roche Pharmaceuticals.
T1048
The Positive Impact of a Multi-Faceted Educational Intervention On Physician
Knowledge and the Actual Practice of Primary Care Physicians Regarding
Hepatitis C
Am Rebecca Daniel, Anna M. Jankowski, Naresh T. Gunaratnam, Thomas M. Shehab
Background: The majority of hepatitis C (HCV) patients remain undiagnosed. Multiple
studies have shown knowledge and practice deficits among primary care physicians (PCPs).
In addition, previous interventions have failed to improve patient care. Aim: To assess the
impact of a multi-faceted educational intervention on HCV knowledge and practice of PCPs
in a community based setting. Methods: Internal medicine faculty and residents were surveyed
regarding knowledge of HCV risk factors, diagnosis and management. Charts were reviewed
to determine physician practice. An intervention was then undertaken for 6 weeks. This
intervention included lectures, e-mails, educational materials regarding HCV and chart cues
prompting questions regarding risk factors. The physicians were resurveyed and a post
intervention chart review was performed. Results: Over 800 pre intervention charts were
reviewed (patients seen by 20 physicians). Patient Demographics: 58% female, 22% African
American, mean age: 52 yr. At baseline, 0.4% of patients were asked about common HCV
risk factors, 0.1% were identified as having a risk factor and < 0.1% were tested. There were
no statistically significant differences between demographics of the pre and post intervention
patient populations. There was notable improvement in all parameters of HCV management.
There was a statistically significant difference in the proportion of patients asked about HCV
risk factors (21.0 vs 0.4%, p<0.001), identified as having risk factors (3.1 vs 1.1%, p<0.001)
and undergoing testing (1.5 vs 0.08%, p=0.003). The number of new HCV cases doubled
post-intervention. Results were not impacted by race, gender or visit type. 72/79 (91%)
physicians participated in the survey. The physicians reported low levels of confidence in
caring for HCV patients. 62% had not made a new diagnosis in the last year. A significant
proportion of physicians demonstrated a lack of knowledge with regard to HCV risk factors,
testing, and effectiveness of therapy. Post intervention, there was a statistically significant
improvement in risk factor identification, physician comfort in caring for HCV, and know-
ledge of treatment effectiveness (p < 0.5). Conclusion: This multi-faceted intervention showed
impact in virtually all areas of physician knowledge and a dramatic improvement in physician
practice. The intervention led to increased screening and testing for HCV. This is one of
the first studies to demonstrate this degree of impact on the identification of primary care
patients at risk for HCV. Future studies should assess the durability of this change to
determine the reproducibility in other settings.
T1049
Percutaneous Radio-Frequency Ablation Versus Surgical Resection in the
Treatment of Small Hepatocellular Carcinoma
Shinichiro Nakamura, Yoshiyuki Kobayashi, Hironori Tanaka, Yasuhiro Miyake, Ryo
Terada, Hideki Ohnishi, Bon Shoji, Shouta Iwadou, Kenji Miyoshi, Hirokazu Miyatake,
Kazuhiro Nouso, Kohsaku Sakaguchi, Yasushi Shiratori
PURPOSE: The purpose of this study was to compare the effectiveness of percutaneous
radio-frequency ablation (RFA) and that of surgical resection for the treatment of small
hepatocellular carcinoma (HCC). STUDY DESIGN: Retrospective cohort study. METHODS:
Between July 1997 and June 2005, consecutive 623 patients who were diagnosed with HCC
for the first time were enrolled from our institute and Okayama Hepatocellular Carcinoma
group. Two hundred and ninety-three patients received RFA (RFA group) and 330 patients
received surgical resection (resection group). RFA was performed percutaneously using a
17-gauge internally cooled-tip electrode under real-time US guidance. All survival probabilit-
ies were estimated by means of the Kaplan-Meier method. Patients were stratified based on
JIS score and CLIP score, and clinical outcomes in terms of survival and recurrence rates
were compared. Furthermore, the multivariate analysis of factors affected to survival or
recurrence rates were done using the Cox proportional hazards model. RESULTS: Clinical
characteristics of patients were shown in Table 1. Four-year survival rates and recurrence
rates were summarized in Table 2. Adjusted with age, gender, tumor number, Child-Pugh
grade, tumor diameter, vascular invasion and serum level of alpha-fetoprotein, the relative
risk of death and recurrence of RFA compared to resection was 1.58 (95% C.I.: 0.79-3.18)
and 1.26 (95% C.I.: 0.87-1.82), respectively. CONCLUSION: No significant differences
were found between the therapeutic outcome of RFA and surgical resection, even stratified
according to JIS score or CLIP score.
Table 2. 4-year survival rates and 4-year recurrence rates
Table 1. Clinical Characteristics of Patients
T1050
The Treatment of Malignant Ascites in Patient with Advanced Cancer:
Peritoneovenous Shunt Versus Paracentesis
Masahiro Seike, Iruru Maetani, Takuro Endo, Hiroaki Shigoka, Tomoko Tada, Takeo
Ukita, Yoshihiro Sakai
Background: Malignant ascites often appears in the end-stage patients with advanced cancer,
and such patients must be admitted to the hospital due to refractory ascites. Malignant
ascites is difficult to treat and effective palliation is often not achieved. Methods: We performed
peritoneovenous shunt (PVS) placement in patients with malignant ascites, who were admit-
ted to our institution between January 2000 and March 2005. The outcome of PVS placement
was compared with the outcome in patients who underwent paracentesis to drain ascites
during the same period. Comparison included changes in abdominal girth, hematocrit (Hct),
blood urea nitrogen (BUN), and creatinine (Ct) measurements before and up to seven days
after PVS placement. The changes in performance score after the procedure, the median
survival from the time of PVS placement and the first paracentesis, possibility of discharge,
and complications were compared in the 2 groups. Furthermore, the median survival in
PVS group was compared between patients who had malignant cells identified in their ascites
cytology and those who did not have malignant cells in their ascites. Results: Twenty
patients underwent PVS placement and 49 patients were subjected to paracentesis. After
PVS placement, abdominal girth and Hct decreased significantly. BUN and Cr also tended
T : 89386$$CH2
05-04-06 23:18:29 Page 463Layout: 89386B : o
A-463 AGA Abstracts
to decrease. The postoperative performance score showed a significant improvement follow-
ing PVS placement (p = 0.0026). The median survival for PVS group was significantly longer
than that for paracentesis group (42 days vs. 18 days; p = 0.003). The rate of possible
discharge was significantly higher in PVS group (p = 0.0076). Severe complications associated
with mortality were observed in 1 patient in the PVS group and in 7 patients in the paracentesis
group. Patients with positive and negative ascites cytology evaluation for malignant cells
had a median survival of 35 days and 54 days, respectively, and there was no statistically
significant difference between them (p = 0.9655). Conclusions: PVS placement decreased
ascites in advanced cancer patients and improved circulating blood volume. The performance
score, the median survival time, and possibility of discharge were better for the PVS group
than for the paracentesis group. PVS was found to be a safe and effective treatment to
improve the patient’s quality of life.
T1051
What Is the Annualized Risk of Gastrointestinal Bleeding from Aspirin Use?
The Results of Pooled RCT Trials
Keith Tsoi, Yuhong Yuan, Richard H. Hunt
Background: Gastrointestinal injury due to aspirin is widely accepted. Although relative risk
of aspirin-induced gastrointestinal injury has been reported, absolute risk data has only been
shown in cohort studies. Recently the temporal profile of NSAID-induced gastrointestinal
bleeding has been shown to be linear. Using this assumption, we attempt to derive an
annualized risk of aspirin-induced injury. Data Source: Medline, Embase, ACP Journal Club,
EBM databases from 1985 to 2004 Study Selection: Inclusion criteria for this study were
as follows: 1) An RCT published in English which involves at least one arm with aspirin
alone as the treatment group; 2) Upper gastrointestinal bleeding identified as a clinical
outcome; 3) Clearly-defined follow-up period of at least 12 months; 4) Aspirin and NSAID
groups must be analyzable separately; 5) Defined temporal period of aspirin use. Key word
search strategies with Booleans algorithm were employed to the above databases. Results:
A total of 5232 abstracts were identified; 333 full texts were further screened. Only 35 were
RCTs involving aspirin, and of these, 4 identified gastrointestinal bleeding as an outcome
with well-defined temporal exposure of aspirin use and clearly delineated follow-up of at
least 12 months. A total 12960 patients were involved in 4 trials. Aspirin dose ranged from
50 mg to 1000 mg per day. Average length of follow-up ranged from 12 to 38.2 months.
A total of 26826.6 patient-years were observed, with 449 gastrointestinal bleeding events.
Limitations: Our study utilizes data in which gastrointestinal bleeding was not the primary
endpoint, resulting in a population that carries confounding risk factors such as advanced
age and use of SSRIs. Further analysis inclusive of retrospective and crossover studies may
be beneficial for providing an estimate that is applicable outside the clinical study setting.
Conclusion: Assuming risk is linear for aspirin and gastrointestinal bleeding, the annualized
risk in RCTs was ~ 1.67% per year.
T1052
Watermelon Stomach & Portal Hypertensive Gastropathy in Patients with UGI
Bleeding: Does Histopathology Help in Diagnosis?
Dennis M. Jensen, Wilfred M. Weinstein
For patients with chronic UGI bleeding (B), the diagnosis of Watermelon Stomach (WMS)
or portal hypertension gastropathy (PHTG) is usually endoscopic. However, endoscopic
biopsies (EndoBx) may help distinguish other non-vascular red antral lesions (MISC-RED)
from WMS/PHTG & may confirm endoscopic diagnoses. Purposes were: 1) to compare the
histopathology (Histo) of WMS with PHTG & MISC-RED lesions resembling WMS & 2)
to delineate whether EndoBx was safe & helped distinguish WMS/PHTG from MISC-RED
antral lesions. Methods: 22 consecutive patients with anemia from recurrent UGIB (10 WMS,
8 PHTG, 4 MISC-RED) gave informed consent for EndoBx & endoscopic hemostasis. There
were 15 females & 7 males with mean age of 70 yrs (range 40 to 86). EndoBx were taken
with large (“jumbo”) forceps (3.2 mm diameter, 8 mm open) in pairs of mid-antral red
stripes & adjacent mucosa & from the mid-body greater curvature (MBGC). Hemostasis
was performed with MPEC or APC of WMS/PHTG & biopsy sites with continued bleeding.
EndoBx’s were fixed in formalin & stained with H & E & trichrome. All biopsies were read
from coded sections by one investigator (WMW), without knowledge of the endoscopic
subgroup diagnosis or clinical history. Results: Biopsy was safe & often confirmed the
clinical/endoscopic diagnosis of WMS or PHTG. Antral reactive gastropathy (including
mucularis mucosae muscle splaying) was noted in all lesions. 90% WMS & 100% PHTG
(vs. 0% of MISC-RED) cases had vascular ectasia in deep mucosa with some penetrating
the muscularis mucosae. For WMS or PHTG, oxyntic gland atrophy in MBGC was uncommon
(17%) & inflammation was absent or mild. Edema of MBGC or antrum was always (100%)
seen with PHTG but rare in WMS (10%) or MISC-RED (0%). The previously reported focal
fibrosis was seen in 30% of our WMS cases but not other lesions. Conclusion: 1) Endoscopic
biopsy was safe & histology was clinically helpful in distinguishing WMS & PHTG from
MISC-RED antral lesions. 2) Reactive gastropathy was the most uniformly dominant &
frequent finding on antral biopsies for all lesions. 3) Edema without inflammation or atrophy
in MBGC was always present in PHTG, but rare in WMS or MISC-RED lesions. 4) Vascular
ectasia were seen in all cases of WMS & PHTG, but not in MISC-RED antral lesions. 5)
Although previous reports emphasized superficial location of vascular ectasia in WMS &

















the muscularis mucosae. Identification was facilitated by trichrome stain. Partially supported
by K24 NIH DK02650 & CURE Human Studies Core NIH P30 DK41301.
T1053
Stress Ulcer Syndrome: A Reappraisal
Sonal Kumar, Gary R. Zuckerman, Scott T. Micek, Chandra Prakash
Although designated a dreaded complication of ICU stay, the incidence of upper gastrointesti-
nal bleeding (UGIB) from stress ulcers (stress ulcer syndrome, SUS) is thought to be decreasing
over the past decades. We reviewed our institutional experience with SUS in the current
era of stress ulcer prophylaxis. Methods: The endoscopy database was interrogated to identify
subjects with gastric ulcers or erosions with UGIB in five specialty ICUs. Subjects who
developed UGIB from gastric erosions/ulcers after ICU admission and without prior peptic
disease were extracted to form the SUS study group. Clinical characteristics were compared
to ICU admissions with UGIB from non-SUS gastric ulcers/erosions during the same period.
Results: Of 12,580 total ICU admissions over a 22 month period, 30 subjects (0.24%, 11F/
19M, mean age 60±0.6 yr) fulfilled study inclusion criteria for SUS. In contrast, 93 subjects
(39F/54M, mean age 65±1.4 yr), were admitted to the ICUs with non SUS gastric ulcer
bleeding (incidence 0.74%, p<0.001 compared to SUS). Medical ICUs had the highest
incidence of SUS (medical ICU: 0.53%, cardiac ICU: 0.24%, neuro ICU: 0.04%, surgical
ICU: 0.13%, p=0.0004 across groups). SUS prophylaxis was administered in 29 subjects
(97%) prior to the bleeding episode, and included enteral proton pump inhibitors (PPIs)
in 80%, IV PPIs in 3%, enteral and IV histamine 2 receptor antagonists (H2RA) in 7% each.
Subjects had a mean of 3.3±0.1 risk factors; 90% had≥2 risk factors. Mechanical ventilation
was a risk factor in 80%; others included shock (73%), coagulopathy (57%), sepsis (53%),
renal failure (47%), cerebrovascular disease (20%). Stigmata of bleeding were seen in 53%;
endoscopic therapy was performed in 40%, and effective for hemostasis when attempted.
There were 11 deaths (37%), 9 within 30 days of SUS diagnosis. On regression analysis,
only the presence of concurrent cerebrovascular lesions predicted 30-day mortality (p=0.04).
Overall mortality rate was 50% in the medical ICU; other ICUs had lower mortality rates
(cardiac ICU 25%, surgical ICU 14%, neuro ICU 0%, p=ns). Ten subjects who died received
enteral PPI prophylaxis, and one received IV H2RA. Mortality rate for non-SUS gastric ulcers
was 3.2% (p<0.0001 compared to SUS), all deaths occurring in the medical ICU. Conclusions:
The incidence of SUS is low, if not rare in some specialty ICUs. Despite use of prophylactic
PPIs, mortality from SUS is significantly higher than non-SUS gastric ulcers, especially in
patients in medical ICUs. Presence of cerebrovascular lesions may predict a higher likelihood
of 30-day mortality. Endoscopic therapy is highly successful for short term bleeding control.
T1054
Epidemiology of Acute GI Bleeding (AUGIB) Between 1983-85 and 2002-04: A
Population-Based Study
Silvano Loperfido, Elena Piovesana, Ludovica Bellina, Katia Rossi, Marzia Groppo, Nadia
Dal Bo, Helena Heras, Alessandro Caroli, Fabio Monica, Luisa Maifreni, Adelina Salvador,
Luca Fabris, Lajos Okolicsanyi
Aim: To study in a population the incidence, causes and outcome of AUGIB during two
different management eras. Methods: 539 hospitalized pts for AUGIB during 2002-04, were
compared with 587 pts in 1983-85 prior to the introduction of endoscopic therapy (ET)
in our hospital. Results: The overall incidence decreased from 112/100,000/year in 1983-
85 to 90 in 2002-04: it decreased from 101 to 74 among emergency admissions, while it
increased from 11 to 15 among in-hospital pts. The male/female ratio decreased from 2.7
in 1983-1985 to 1.8 in 2002-2004 and mean age increased from 61±14 to 68.7±16 yr. The
intake of NSAIDs (43% vs 46%) and frequency of associated diseases (69% vs 70%) were
similar; cirrhosis decreased from 29% to 20% (p<0.001). Endoscopy was carried out in
96% in 1983-1985, while in 99% in 2002-2004. Diagnoses in 1983-1985 and 2002-
2004 were: ulcer bleeding (UB) 59.1% vs 53.1%, variceal bleeding (VB) 13.8% vs 11.5%,
miscellaneous 22.3% vs 30.4%, and unknown 4.8% vs 5.0%. The incidence of UB decreased
from 66/100,000/yr to 48. In 2002-04, 208 pts (39%) received ET, and in a quarter of
them ET was repeated. Out of 57 pts with VB, 70% underwent single techniques and 30%
combined or sequential techniques. Out of 151 pts with non-VB, 34% underwent single
techniques and in 66% combination techniques were performed. In 2002-04, no pts with
VB were treated with vasoactive drugs; in 49% of pts with non-VB, PPI were used (80mg/
24hr in most cases) and others received H2-antagonists. Overall, from 1983-85 to 2002-
04, further bleeding decreased from 32% to 7.4% (p<0.001), surgery from 10% to 2%
(p<0.001) and mortality from 15.5% to 9.1% (p<0.05). The mortality decreased from 12.9%
to 5.6% among emergency admissions (p<0.001), and from 37.7% to 26% among in-hospital
pts (NS). The table shows the outcomes of VB and non-VB: there was a clear-cut decrease
of further bleeding and surgery, while the difference in mortality achieved statistical signific-
ance for VB, but not for non-VB. Conclusions: 1) From 1983-85 to 2002-04, mean age
increased from 61 to 69 yrs; 2) The male/female ratio decreased; 3) Annual incidence
decreased overall by 20% and by 27% in UB; 4) ET dramatically reduced further bleeding
and the need for surgery; 5) Mortality decreased both in pts with VB and non-VB, but the
difference achieved statistical significance only for VB.
Comparison of outcome between 1983-85 and 2002-04
VB=Variceal Bleeding, FB=Further Bleeding, S=Surgery, M=Mortality
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T1055
A Comparison of Intravenous (IV) Versus Oral Proton Pump Inhibitors (PPIs)
for Patients with High-Risk Acute Nonvariceal Upper GI Bleeding (ANVUGIB)
Laura E. Targownik, Leila Keyvani, Sanjay K. Murthy, Shanua Leeson
Background: The use of IV PPIs in patients with ANVUGIB following performance of
endoscopic hemostasis is currently the standard of care. A 72 hour course of IV PPI following
performance of endoscopic hemostasis for high-risk lesions has been shown to decrease the
risk of rebleeding when compared to placebo. However, providing PPIs intravenously is
associated with high medication costs and the need for a continuous intravenous infusion
may prolong hospital stays. High-dose oral proton pump inhibitors have also been proven
to be efficacious in reducing the risk of rebleeding for high-risk patients. There are no direct
comparisons of IV versus oral PPIs for ANVUGIB patients following endoscopic hemostasis.
Methods: We performed a retrospective review of all patients who presented to one of two
tertiary care hospitals in Winnipeg, Manitoba from 1999-2004 with an admitting diagnosis
of ANVUGIB who were found to have high-risk stigmata on diagnostic upper endoscopy
and underwent therapeutic hemostasis. We separated the patients into one of two groups,
based on whether they received intravenous PPIs following performance of endoscopy or
they received oral PPIs only. Patients were excluded if the first dose of IV or po PPI was
given more than 24h after endoscopy. The primary outcome measure was the development
of any adverse outcome (in-hospital rebleeding, surgery, in-hospital mortality, readmission
within 30 days for ANVUGIB). Other outcomes included the time to endoscopy, transfusion
requirements both prior to endoscopy and after 24h following the initial endoscopy, and
the length of hospital stay. Results: We identified 145 subjects who underwent therapeutic
hemostasis of whom 59 received IV PPIs and 82 received oral PPI (4 received H2RAs only).
There were no significant differences in baseline demographics, or severity of presentation
by pre-endoscopic Rockall score. Patients receiving IV PPIs were non-significantly more
likely have arterial bleeding or a non-bleeding visible vessel (68% vs. 56%, p=0.17). There
were no differences in the rates of adverse outcomes (22% IV PPI vs. 18%, p>0.2), or
likelihood of requiring a transfusion more than 24h following initial endoscopy. (29% vs.
26%, p >0.2). The overall length of hospital stay was comparable between the two groups.
Conclusions. IV PPIs do not appear to provide any incremental benefit over oral PPIs for
ANVUGIB patients undergoing endoscopic hemostasis for high risk lesions. Prospective
research needs to be performed to determine whether provision of oral PPIs is an acceptable
substitute for high risk ANVUGIB patients. Unrestricted Grant from Altana Pharma
T1056
Prospective Randomized Study Comparing the Effect of Oral Versus IV
Pantoprazole On 30-Day Rebleeding Rates in Patients with Acute Non-Variceal
GI Bleed: A Pilot Study
Kulwinder Dua, Jasmohan S. Bajaj, Kristin Hanson, Kenneth Presberg
Background: Previous studies have shown that IV proton pump inhibitors (PPI) reduce the
rate of rebleeding in patients with acute non-variceal upper GI bleed (NVGIB). Studies have
also shown that oral & IV PPIs are equipotent in raising gastric pH. Since majority of patients
with NVGIB can take oral medications and IV PPIs are comparatively expensive and require
dedicated IV lines for administration, the aim of the present study was to conduct a pilot
study comparing the efficacy of oral vs IV pantoprazole on reducing rebleeding after NVGIB.
Method: Consecutive patients with NVGIB were randomized to receive oral (PO) (80 mg
BID for 3 days) or IV pantoprazole (80 mg IV bolus and 8mg/hr infusion for 3 days) followed
by pantoprazole 40mg PO BID for 30 days. All enrolled patients underwent urgent upper
GI endoscopy and if required, endoscopic intervention, within 24 hours of admission.
Patients were followed for 30 days with the primary endpoint being rebleeding. Secondary
endpoints were mortality, end-organ failure and blood transfusions. Results: Twelve patients
were randomized to PO and 13 to IV pantoprazole. There were no significant differences
in the age (IV 66.2±6 vs PO 59.5±19yrs), hematocrit (IV 25.7±8 vs PO 24.9±9), INR (IV
1.4±1 vs PO 1.1± 0.2), Rockall scores (IV 5.3±2.5 vs P0 4.5±2.1) and comorbidity scores
(IV 3.3±2.6 vs PO 2.2±1.9) between the groups. Ulcer characteristics and therapeutic
interventions were similar across groups (Table 1). Two patients in the IV arm rebled. Both
these patients had adherent clot and underwent BICAP cautery and epinephrine injection
on initial endoscopy and were retreated endoscopically after rebleeding. Another patient in
the IV arm had reversible renal failure (Table 2). No patient in the PO arm had to be
changed to IV pantoprazole. Conclusion: In this pilot study, the effect of oral pantoprazole
on 30-day rebleeding rate in patients with NVGIB was similar to IV pantoprazole. Further
trials with larger study populations are needed.
Table 1
p = 0.32 Fisher exact test
Table 2
p = 0.48 Fisher exact test
T1057
Eradication of Helicobacter Pylori for the Prevention of Ulcer Bleeding
Recurrence
Javier P. Gisbert, R Garcia-Gravalos, D Olivares, X Calvet, F Feu, Jm Pique, A Cosme, F
Bory, N Canete, S Santolaria, M Montoro, A Benages, P Almela, F Borda, R Aznarez, M
Castro, A Perez-Aisa, N Fernandez
AIM: Eradication of H. pylori is associated with a very low rate of ulcer recurrence. Our
purpose was to verify the effect of H. pylori eradication on ulcer bleeding recurrence secondary
to peptic ulcer disease. METHODS: Patients with acute hemorrhage secondary to gastroduod-
enal ulcer were prospectively included. NSAID use was not considered an exclusion criteria.
H. pylori infection was confirmed by rapid urease test, histology or 13C-urea breath test.
Several therapies were used, mainly omeprazole or ranitidine-bismuth citrate based regimens.
Afterwards, an H2-antagonist (ranitidine 150 mg o.d.) was administered until eradication
was confirmed by 13C-urea breath test 8 weeks after completing eradication therapy. Patients
with therapy failure received a second or third course of therapy. Patients with eradication
success did not receive maintenance anti-ulcer therapy, and were controlled yearly up to 5
years with a 13C-urea breath test. NSAID use was not permitted during follow-up. RESULTS:
Up to now, 238 patients have been followed up for at least 12 months, with a total of 410
patient-years of follow-up. Mean age was 59 years, 73% were males, and 39% were previous
NSAID users. Seventy-one percent had duodenal ulcer, 22% gastric ulcer, and 8% pyloric
ulcer. Recurrence of bleeding was demonstrated in 2 patients at 1 year (incidence: 0.49%
per patient-year of follow up), which occurred after NSAID use in both cases. CONCLUSION:
Rebleeding does not occur in patients with complicated ulcers after H. pylori eradication.
Maintenance anti-ulcer (antisecretory) therapy is not necessary if eradication is achieved.
However, NSAID intake may cause rebleeding in H. pylori-eradicated patients.
T1058
Coffee Ground Vomit - Can We Spot It?
Christian P. Selinger, Nicola M. Jones, Cornelle R. Parker
Introduction: It is assumed that healthcare professionals can identify coffee ground vomit
as a sign of gastrointestinal (GI) bleeding. However, there is no published evidence to
support this. Aims & Methods: The aim of this study was to investigate the sensitivity and
specificity of nurses’ and physicians’ assessment of coffee ground vomit. Photographs of
nine samples of vomitus were obtained from medical inpatients. Two samples were classified
as positive with signs of upper GI bleeding on endoscopy. Two negative samples were from
patients suspected of bleeding with normal endoscopy. A further five negative samples were
from patients suffering from other medical conditions with no clinical evidence (tachycardia,
postural hypotension, drop in haemoglobin, rise in urea) of GI bleeding. One hundred and
one healthcare professionals (56 nurses, 45 doctors) were asked to assess these pictures
with the question: “Is this a coffee ground vomit from a significant GI bleed?” Results: The
pictures of samples with confirmed bleeding were correctly identified in 197 cases and
missed in five cases. Whereas the pictures of non coffee ground vomit were identified
correctly in 419 cases and interpreted false positively in 288 cases. This results in a sensitivity
of 97.5%, specificity of 59.3%, a positive predictive value of 0.41 and a negative predictive
value of 0.99. Subgroup analysis did not show a significant difference in assessment by
nurses and physicians and by staff with different levels of experience. Conclusion: Coffee
ground vomit is difficult to identify with certainty. High negative predictive value allows
ruling out of a significant bleed. Low positive predictive value however does not allow the
diagnosis of a GI bleed solely based on vomit appearance. Further clinical parameters and
a risk factor profile should be taken into consideration when deciding on referral for upper
GI endoscopy.
T1059
Cardiac Scoring Systems Predict Morbidity and Mortality in Patients with
Acute Gastrointestinal Bleeding and Acute Coronary Artery Disease
Praveen Rapolu, Tejal Shah, J.N. Preis, Jian Jun Li, Scott Tenner
The morbidity and mortality of patients with acute gastrointestinal bleeding (GI) is increased
in the setting of acute coronary syndromes (CS), such as unstable angina and acute myocardial
infarction. The management of patients with these disorders is further complicated by
medications that increase the risk of bleeding while decreasing the risk of death from
coronary artery disease. In order to better determine the factors that affect mortality in
patients with Acute GI bleeding and Acute CS, we followed 100 consecutive patients who
suffered from both gastrointestinal bleeding and acute coronary syndromes during the first
week of hospitalization. One-hundred consecutive patients were studied. The mean age of
the patients was 75.4 + 12.2, 45 female, 55 male. Twenty patients presented with acute
gastrointestinal bleeding initially and developed acute coronary syndromes over the ensuing
days. Eighty patients presented with acute coronary syndromes and subsequently developed
gastrointestinal bleeding. There were 15 deaths within the hospitalization, all attributable
to the underlying gastrointestinal bleeding and coronary artery disease. In order to determine
independent variables that were associated with mortality, multiple regression analysis was
performed. The risk of death was significantly associated with age (p = 0.02), Goldman Criteria
(0.01), NYHA Congestive Heart Failure Class (p = 0.02). Eighty-six patients underwent upper
endoscopy due to significant gastrointestinal bleeding. Clean based ulcers were found in
30/86 patients (34%), varices in 3/86 patients (3.4%). Stigmata or recent hemorrhage or
active bleeding was found in 17/86 patients (19%). Admission hematocrit, the presence of
coagulopathy, and presenting vital signs were not associated with death. The time interval
from admission to correcting the hematocrit, coagulopathy and vital signs did not correlate
with mortality. Mortality was not associated with aspirin, clopidogrel, or anticoagulation
with heparin, coumadin, thrombolytics, or IIb/IIIa inhibitors. We conclude that in the setting
of acute gastrointestinal bleeding and acute coronary syndromes, mortality is related to the
patients age, admission tropinin, the presence of congestive heart failure, renal failure and
The Goldman Criteria. Gastroenterologists must become familiar with the Goldman Criteria
and New York Heart Association Congestive Heart Failure Classification which appear to
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be most predictive of mortality in patients with acute gastrointestinal bleeding and acute
coronary syndromes.
T1060
Success of Argon Plasma Coagulation for Management of Gastric Antral
Vascular Ectasia
Kuldip S. Banwait, Madhusudhan R. Sanaka, Kuntal M. Thaker, Karl Kwok, Stephanie
Moleski, David Assis, Thomas Kowalski, David Loren
Background: The gastric antral vascular ectasia (GAVE) syndrome is an uncommon cause
of anemia and GI bleeding. A subset of patients with GAVE will require endoscopic thermal
ablation to manage bleeding complications and argon plasma coagulation (APC) has increas-
ingly become the therapeutic modality of choice. We hypothesize that the success of thermal
ablation may be affected by the coexistence of portal hypertensive gastropathy and present
what we believe to be the largest reported experience using APC for the management of
GAVE. Aims: The aims of this study were to evaluate the efficacy of APC in treating GAVE
in a large patient cohort and to assess the impact of portal hypertensive gastropathy on the
clinical success of ablation therapy. Methods: A retrospective review of all EGD reports from
a single tertiary care hospital was performed between 2000 and 2005. All patients in whom
GAVE was diagnosed based upon endoscopic findings were included in the analysis. The
clinical presentation, number of treatment sessions with APC, response to therapy, and
clinical recurrence were recorded. The chi square test and Students t-test were used where
appropriate. Results: 24,349 upper endoscopies were performed during the study period of
which 133 (0.55%) patients were diagnosed with GAVE. The mean age of affected individuals
was 65.2 yrs (range 34-99) compared to 57.7 yrs for the entire cohort. Women comprised
62.5% of affected individuals and represented 56.3% of all patients undergoing upper
endoscopy. The most common presentation was GI bleeding (35.5%) followed by anemia
(30.9%). Of patients with GAVE, 17.3% (23/133) were diagnosed with coexistent portal
hypertensive gastropathy. 69/133(51.9%) of affected patients underwent ablation therapy
with APC with a mean of 2.2 sessions per patient (median=2). 34/69 patients (49.3%)
required only a single ablative session to manage bleeding or anemia. Of those requiring
multiple sessions, the mean number was 3.5 (median=3, range=2-12). The mean interval
between sessions was 6.3 months. When patients were stratified according to the coexistence
of portal hypertensive gastropathy there was no significant difference in the percent of
patients requiring therapy or the mean number of sessions required. No procedure related
complications were observed. Conclusions: APC is a safe and effective treatment modality
for the management of GAVE. The coexistence of portal hypertensive gastropathy does not
appear to affect clinical outcomes of those requiring ablative therapy. Our results are similar
to those of the previously reported smaller cohorts of patients with GAVE treated with APC.
T1061
Accuracy of H. Pylori Diagnostic Tests in Patients with Bleeding Peptic Ulcer:
A Systematic Review and Meta-Analysis
Javier P. Gisbert, Victor Abraira
OBJECTIVE: To perform a systematic review and a meta-analysis of diagnostic accuracy of
the different tests aimed to detect H. pylori infection in patients with upper gastrointestinal
bleeding (UGIB). METHODS: Selection of studies: assessing the accuracy of H. pylori dia-
gnostic methods in patients with UGIB. Search strategy: electronic bibliographical searches.
Data extraction: independently done by two reviewers. Data synthesis: meta-analyses of the
different tests were performed combining the sensitivities, specificities, and likelihood ratios
(LRs) of the individual studies. RESULTS: Studies showed a high degree of heterogeneity.
Pooled sensitivity, specificity, LR+ and LR- (95% confidence interval) for the different
methods were: Rapid urease test (16 studies/1,417 patients): 0.67 (0.64-0.70), 0.93 (0.90-
0.96), 9.6 (5.1-18.1) and 0.31 (0.22-0.44). Histology (10 studies/827 patients): 0.70 (0.66-
0.74), 0.90 (0.85-0.94), 6.7 (2.5-18.4) and 0.23 (0.12-0.46). When subanalysis depending
on the biopsy site was performed, and only studies with samples obtained from both the
antrum and corpus were considered, heterogeneity substantially decreased, and pooled
sensitivity for rapid urease test and histology increased (0.78 and 0.83, respectively). Culture
(3 studies/314 patients): 0.45 (0.39-0.51), 0.98 (0.92-1.00), 19.6 (4-96) and 0.31 (0.05-
1.9). Urea breath test (8 studies/520 patients): 0.93 (0.90-0.95), 0.92 (0.87-0.96), 9.5 (3.9-
23.3) and 0.11 (0.07-0.16). Stool antigen test (6 studies/377 patients): 0.87 (0.82-0.91),
0.70 (0.62-0.78), 2.3 (1.4-4) and 0.2 (0.13-0.3). Serology (9 studies/803 patients): 0.88
(0.85-0.90), 0.69 (0.62-0.75), 2.5 (1.6-4.1) and 0.25 (0.19-0.33). CONCLUSION: Biopsy-
based methods, such as rapid urease test, histology and culture, have a low sensitivity, but
a high specificity, in patients with UGIB. Biopsy samples from both the antrum and corpus
may be recommendable, as with this strategy sensitivities of rapid urease test and histology
seem to be higher. The accuracy of 13C-urea breath test remains very high in these patients.
Stool antigen test is less accurate in UGIB. Although serology seems not to be influenced
by UGIB, it cannot be recommended as the first diagnostic test for H. pylori infection in
this setting.
T1062
The Mallory Weiss Tear
John Thomson, David Armour, Andrew Fraser, John Masson, Norman A. Mowat
Introduction Bleeding from Mallory Weiss Tear (MWT) is generally considered to be
trivial, self-limiting and rarely requiring acute intervention. There is, however, only limited
community based published data to support this benign perception. The 10 year prospectively
collected data from the Aberdeen Gastrointestinal Bleeding Unit (AGIBU) has given us the
opportunity to evaluate this further. Aim To evaluate the natural history of Mallory Weiss
Tears in the stable at risk population (458,536) of Grampian over a 10 year period. Method
Prospectively collected data on all admissions with gastrointestinal bleeding to the AGIBU
were stored on a Microsoft Access® database. Analyses were then performed on the data

















1991 to October 2001, 9.3% (n=658) of admissions to the AGIBU, with suspected upper
GI bleeding, bled from a MWT. A positive correlation (p<0.0001) was seen with young
male patients, acute and chronic alcohol intake, smoking and a history of vomiting when
compared to the other AGIBU admissions. Of those with haematemasis, 36% did not have
a prior history of retching or vomiting. The bleeding episode was defined as significant
(haemodynamic compromise, Hb <10g/dl) in 36.7%. The proportion with significant bleed-
ing increased with age (p<0.01) and was more common in females (p<0.01). The majority
had a short hospital admission with no complications. However 5% (n=28) rebleed within
30 days and 1.71% (n=9) died within 30days. All of the deaths were associated with
significant comorbid disease. Conclusions Contrary to popular belief bleeding from MWT
is not only common but is often significant. It often occurs without retching or prior vomiting
and can be associated with rebleeding. There is a small but significant mortality.
T1063
Trends in the Incidence and Outcomes of Acute Non-Variceal Upper
Gastrointestinal Bleeding (ANVUGIB) in Canada, 1994-2003
Laura E. Targownik, Alice Nabalamba
Background: ANVUGIB is a common reason for admission to hospital, and has been tradition-
ally associated with a mortality rate of 5-10%. There have been numerous innovations in
the prevention and management of ANVUGIB in the last 10 years, though the magnitude
of the effect of these innovations in unknown. Methods: We used the Canadian Institute of
Health Information (CIHI) hospital database, which is contains data characterizing every
inpatient hospital admission in Canada from April 1994 until March 2003. We identified
admissions consistent with non-variceal upper gastrointestinal bleeding using a validated
list of ICD-9 and ICD-10 codes. Data was extracted concerning patient demographics, length
of hospital stay, incidence of surgery for complications of upper gastrointestinal bleeding,
and overall mortality. Results: Between 1994 and 2003, the incidence of ANVUGIB decreased
from 76.4 to 52.8 cases per 100,000/yr. The decrease in incidence rates by age groups and
year of admission are shown in Figure 1. The mean age of persons admitted with ANVUGIB
rose from 62.06 to 66.77 years. The mean length of hospital stay decreased from 7.63 to
6.62 days, and the proportion of patients with hospital stays of less than 2 days increased
from 22% to 33% of all admissions. The mortality rate remained constant at approximately
5% between 1994 until 2003. Conclusion: The incidence of ANVUGIB appears to be steadily
declining since 1994 in all groups, though there has been relatively little impact on mortality.
The decreasing incidence of ANVUGIB may be due to a decreasing prevalence of Helicobacter
pylori infection and increasing use of gastroprotective medications. The lack of effect on
mortality suggests changes in management undertaken in this era have had little impact on
clinical outcomes. Decreasing lengths in hospital stays may be reflective of adoption of early
discharge guidelines for low-risk patients.
T1064
Are Patients with Acute Non-Variceal Upper GI Bleeding (ANVUGIB)
Presenting Outside of Regular Hours Receiving Quality Care
Laura E. Targownik, Leila Keyvani, Sanjay K. Murthy, Shanua Leeson
Background: ANVUGIB is among the most common reasons for presentation to a hospital’s
emergency room. The standard of care for patients presenting with signs and symptoms of
ANVUGIB is to receive prompt resuscitation and early endoscopy to confirm the diagnosis
and to provide endoscopic therapeutics. While endoscopists are generally on site during
regular working hours, they generally provide “on call” services on evenings and weekends,
only coming into hospital if endoscopy is required. Therefore, it is possible ANVUGIB
patients presenting to hospital overnight or on the weekend may not receive the same level
of care as those presenting when endoscopists are “in house”. This disparity could result in
poorer outcomes and longer hospital stays for patients presenting at night or on weekends.
Therefore, we sought to determine if there are significant differences in the process and
outcomes of care between ANVUGIB patients presenting during regular hours and those
arriving while endoscopists are “on call” Methods: We performed a retrospective review of
all patients presenting to one of two tertiary care hospitals in Winnipeg, Manitoba from
1999-2004 with a admitting diagnosis of ANVUGIB who underwent diagnostic upper endos-
copy. We separated the patients into one of two groups, based on whether they presented
to the emergency room during regular working hours (Mon-Fri 8am-5pm), or during “call”
(all other times). The primary outcome measure was the development of any adverse outcome
(in-hospital rebleeding, surgery, in-hospital mortality, readmission within 30 days for ANVU-
GIB). Other outcomes included the time to endoscopy, the need for endoscopic hemostasis,
and the length of hospital stay. Results: We analyzed 500 subjects of whom 195 presenting
during regular hours, and 305 presented while the endoscopist was on call. There were no
significant differences in baseline demographics, severity of presentation by pre-endoscopic
Rockall score, or likelihood of receiving endoscopy within 8 h, or likelihood of undergoing
endoscopic hemostasis. There were no differences in the incidence of adverse outcomes
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(19% vs. 20%, P>0.2) or in the mean length of hospital stay. Patients presenting from 11pm-
8am did not fare worse than those presenting from 5pm-11pm. Also, sicker patients (Pre-
endoscopic Rockall Score >=3) fared equally well independent of time of presentation.
Conclusions. ANVUGIB patients presenting outside regular hours do not suffer any comprom-
ise in the quality of care. It is reasonable for endoscopists to provide “on-call” services
outside regular hours instead of remaining “in house.”
T1065
The Effect of Various Doses of Pantoprazole On the Intragastric Acidity for
Preventing Ulcer Rebleeding After Endoscopic Therapy in Korean Patients
Myung-Gyu Choi, Jung-Hwan Oh, Jae-Myung Park, Chang-Nyol Paik, Joon-Wook Lee,
Yu-Kyung Cho, In-Seok Lee, Sang-Woo Kim, Hae Won Han, Kyu Yong Choi, In-Sik
Chung, Mi-Sook Dong
Background/Aim: Proton-pump inhibitor(PPI) therapy for ulcer bleeding has been more
efficacious among Asian than non-Asian patients. This may be explained by an enhanced
pharmacodynamic effect of PPIs in Asian patients related to lower parietal cell mass, ae well
as high prevalence of both the slow metaboliser phenotype or of H. pylori infection. The
aim of this study was to evaluate the effect of various doses of pantoprazole on the intragastric
acidity for preventing ulcer rebleeding after endoscopic therapy in Korean patients. Methods:
We enrolled 49 patients with bleeding pectic ulcers after successful endotherapy and 40
patients receiving endoscopic mucosal resection. Patients were randomly assigned to intraven-
ously receive one of the 4 regimens: pantoprazole 40 mg bolus qd, pantoprazole 40 mg
bolus bid, high dose of pantoprazole (80 mg bolus then continuous 8mg/hr) and ranitidine
300 mg continuous. Twenty-four hour intra-gastric pH monitoring was undertaken after
second-look endoscopy. Genetic polymorphism of CYP2C19 and the presence of H. pylori
were tested. Results: No patient in each group underwent surgery or died. Two patients
had rebleeding after EMR. Pantoprazole groups, except pantoprazole 40 mg qd, were superior
acid inhibitions compared to ranitidine (p<0.05, table). A pantoprazole 40 mg qd bolus
provided worse intragastric acid control in the day’s last half compared to the 1st half (p<
0.05), whereas there were no differences in acid control between the 1st and 2nd half of
the day in the other regimens. The significant inter-individual variation of acid inhibition
was observed in a low dose of pantoprasole, which was significantly dependent on the
CYP2C19 genotype. There was no statistical difference in the medians of 24-h pH values
between pantoprazole 40 mg bid and the high doses regardless of the status of H. pylori
infection. Median intragastric pH < 4 was observed in only two patients of 40 mg bid group
(N=30), who were extensive metabolizer and H. pylori positive. Conclusion: Even a daily
40 mg bid dose of pantoprazole sufficiently keeps the pH almost constantly > 6 in Korean
patients, except in a small number of patients with extensive metabolizer.
The effect of various doses of pantoprazole on the intragastric acidity
mean+SD, *<0.05 compared to ranitidine
T1066
Gastric Antral Vascular Ectasia: 75 Cases with Long Term Follow-Up
Abdullah M. Al-Osaimi, Christopher W. Lawrence, Li H. Tri, Lawrence W. Comerford,
Patrick G. Northup, Stephen H. Caldwell, Stephen J. Bickston
Background and Aims: Gastric antral vascular ectasia (GAVE) is an increasingly recognized
entity involving mainly the gastric antrum that can be associated with significant gastrointesti-
nal blood loss in patients with and without liver cirrhosis. Studies have been sparse on this
entity. The aim of our study was to review the clinical features of this disease in a University
based population including demographic features, presenting symptoms, associated diseases,
endoscopic findings, methods of management, and the final outcomes when possible.
Methods: A search of our institution’s Clinical Data Repository between July 1997 and June
2002 using the ICD codes for nonbleeding and bleeding GAVE identified 278 patients. A
review of the medical records distilled this to 75 patients whose records clearly substantiated
the diagnosis. Results: 75 patients were followed for a mean of 32±27SD months. The
majority of GAVE patients were females 77%. The mean age was 69±10SD (range: 45-96)
years, 47 (92%) were Caucasian. Anemia was present in 63%, while 21% had overt GI
bleeding and 15% were discovered incidentally. Among symptomatic patients, the symptoms
were present a mean of 12±12 months before diagnosis. Cirrhosis was documented in 53%
of patients; nonalcoholic steatohepatitis (NASH) in 48%, cryptogenic cirrhosis in 30% and
alcohol in 10% as the main etiologies. Endoscopic findings include watermelon type in
61%, diffuse type in 28%, and nodular type of GAVE in 11%. Active bleeding was in 23%,
portal hypertensive gastropathy in 40%, and esophageal varices in 37% of these patients.
Patients were managed endoscopically in 57%, of which 36 sessions were argon plasma
coagulation, 15 bipolar electrocautery, and 4 Yttrium laser ablations. 43% of patients who
underwent endoscopic therapy required multiple sessions with a mean of 4.2±3.3 sessions.
One patient underwent orthotopic liver transplantation for advanced liver disease with
resolution of his GAVE. Conclusion: Because of the limitations of current therapy, GAVE
remains a challenge to clinicians. Further analysis of this population may help identify
patients at risk and to clarify which approaches to treatment are most promising. Regarding
etiology, the proportion of patients with liver disease as an associated condition in our center
is congruent with earlier reports. However, it is noteworthy that a substantial proportion
of patients had either NASH, cryptogenic cirrhosis or alcohol-related liver disease -disorders
united by abnormalities in fat metabolism. This suggests that the metabolic derangements
caused by lipotoxicity with associated mitochondrial dysfunction may therefore underlie
many cases of GAVE.
T1067
High-Dose Oral Proton Pump Inhibitor Is As Effective As Intravenous
Administration in the Aspect of Increasing Intragastric pH and Reducing
Rebleeding After Endoscopic Treatment of Bleeding Peptic Ulcers
Jae-Young Jang, Seok Ho Dong, Ji Heon Jung, Myung Jong Chae, Nam Hoon Kim, Sang
Kil Lee, Kwang Ro Joo, Hyo Jong Kim, Byung-Ho Kim, Young-Woon Chang, Joung Il
Lee, Rin Chang
Badkground/Aims: The use of proton pump inhibitor (PPI) prevents rebleeding by elevating
intragastric pH in patients with bleeding peptic ulcers after hemostasis has been achieved.
We assessed that the high-dose oral pantoprazole is as effective as high-dose intravenous
pantoprazole on 24-hour intragastric pH and determined their ability to prevent rebleeding
after having achieved initial hemostasis in patients with active bleeding or nonbleeding
visible vessels. Methods: Forty patients with bleeding peptic ulcers, who had obtained
initial hemostasis, were enrolled in this randomized controlled trial. In the high-dose oral
pantoprazole group (n=20), 40 mg of pantoprazole was given orally twice daily for 5 days.
In the high-dose intravenous pantoprazole group (n=20), 80 mg intravenous bolus of
pantoprazole was given, followed by 8 mg/hour of continuous infusion daily for 3 days.
Thereafter, 40 mg of pantoprazole was given orally once daily for 8 weeks. A pH meter was
inserted in each patients’ fundus and then the pantoprazole was administered within 5
minutes (10 patients in oral group and intravenous group, respectively). Results: The two
groups were similar with respect to all background variables. Rebleeding occurred in 2
patients (10.0%) in the intravenous group and did not occur in the oral group by day 30
after enrollment (p=0.154). There was no significant difference in terms of therapeutic
endoscopic sessions (1 vs. 1.18±0.53), surgery (0% vs. 0%), mortality (0% vs. 5.9%), and
mean number of units of blood transfused (1.9 vs. 1.9 pints). Pantoprazole maintained the
mean gastric pH for 24 hours at the level of 4.8±1.4 in the oral group, as compared with
5.7±0.3 in the intravenous group (p<0.001). The duration of intragastric pH higher than
6.0 was longer in the intravenous group (64.4%±38.3%) than that of the oral group
(43.7%±26.2%, p<0.005). But, after 7 hours of administration, there was no significant
difference in the mean gastric pH (oral; 5.6±0.6 vs. intravenous; 5.8±0.2, p=0.554). Conclu-
sions: The high-dose oral pantoprazole is as effective as intravenous administration in
increasing intragastric pH and reducing rebleeding episodes in patients with bleeding peptic
ulcers after successful endoscopic therapy.
T1069
Prognosis Prediction of Stage II Colon Cancer By Gene Expression Profiling
Alain Barrier, Antoinette Lemoine, Didier Brault, Sidney Houry, Francois Lacaine,
Sandrine Dudoit, Antoine Flahault
Background and aims. The aims of the present study were: 1) to identify a prognosis signature
(PS), based on microarray gene expression measures, in stage II colon cancer patients and
to assess its accuracy with resampling techniques ; 2) to assess the accuracy, also with
resampling techniques, of a previously proposed 23-gene PS. Material and methods. Colon
tumor mRNA samples from 50 patients were profiled using the Affymetrix HGU133A
GeneChip (22283 sequences). In a first part, the 50 patients were randomly divided into
2 groups (G1 and G2) of equal size that were considered alternately as training and validation
sets. In a second part, the 50 patients were randomly divided into 1600 training (size=n)
and validation (size=50-n) sets. Informative genes were selected on the training set by taking
the 30 most differentially expressed genes between patients who recurred and those who
remained disease-free; the accuracy of this PS was assessed by comparing the predicted
prognosis (using a diagonal linear discriminant analysis (DLDA)) and the actual evolution
for all the validation set patients. Using the same random splits, the accuracy of the 23-
gene PS was assessed with a DLDA that used learning set patients as reference samples.
Results. The 30-gene PS that was identified from G1 (G2) patients yielded a 80% (84%)
prognosis prediction accuracy when applied on G2 (G1) patients. With resampling tech-
niques, the prediction accuracy regularly increased with the learning set (LS) size: 65.5%
(range=52.5-75%) with LS of size 10, and 82.7% (range=60-100%) with LS of size 40.
Comparisons of compositions of the 100 PS for a given value of n suggested a high instability
of informative genes; with LS of size 10, 7 genes were part of at least 10% of signatures;
with LS of size 40, 7 genes were part of all the 100 signatures. The accuracy of the previously
proposed 23-gene PS also increased with the learning set size. Conclusion. Microarray gene
expression profiling represents a promising technique to predict the prognosis of stage II
colon cancer patients. The present study also outlines the high instability of informative
gene selection and suggests the usefulness of resampling techniques to obtain an honest
assessment of prognosis prediction accuracy.
T1070
Prognostic Effects of Orotate Phosphoribosyl Transferase and
Dihydropyrimidine Dehydrogenase in Colorectal Cancer After Surgery
Yukihiko Tokunaga, Hirokazu Sasaki, Tohru Saito
Background and Objectives: Orotate phosphribosyl transferase (OPRT) is an essential enzyme
for activation of 5-fluorouracil (5-FU) and its derivatives. Dihydropyrimidine dehydrogenase
(DPD) is a rate-limiting enzyme for degradation of 5-FU. In colorectal cancer (CRC), few
studies have evaluated the relationship between OPRT, DPD, and clinicopathological features,
since monoclonal antibody sensitive for human OPRT and that for DPD have not been
established. Now, new antibodies for human OPRT and DPD are available. Methods: The
study included 150 patients whose CRCs were classified into stage II to IV, and resected
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surgically. OPRT and DPD expression were evaluated using immunohistochemistry with
new antibodies. Relationships between their expressions and clinicopathological features.
Survival curves were calculated using Kaplan-Meier method, and differences were evaluated
with log-rank test. Cox proportional hazards model was also used. Results: OPRT expression
showed a negative correlation with advances in venous invasion (p=0.041), though DPD
expression showed positive correlations with advances in venous invasion (p=0.0053), and
cancer stage (p= 0.0064). The patients survival rates were higher in those OPRT(+) than in
those OPRT (-) (p=0.004), and higher in those DPD(-) than in those DPD(+) (p=0.008). In
regard to the combination of OPRT and DPD expression, the best survival curve was obtained
for the OPRT(+) DPD(-)group followed by those for the OPRT(-) DPD(-), OPRT(+) DPD(+),
and OPRT(-) DPD(+) groups in descending order. The estimated hazard ratio for patients
death with OPRT and DPD expression were 2.43 and 6.55 (p=0.0047 and 0.0096) respect-
ively. Conclusions: Using new sensitive antibodies, the present results indicated that OPRT
expression was negatively associated with CRC progression and related with better prognosis
in postoperative CRC patients, although DPD expression was positively correlated with CRC
progression and related with poor prognosis. The overall patients survival rates were best
in the patients OPRT(+)DPD(-), and worst in those OPRT(-)DPD (+) in treatment with
fluoropyrimidine after surgery. The use of two determinants of response may identify a high
percentage of responding patients.
T1071
Pathological Classification and Clinical Behavior of 63 Cases of Goblet Cell
Carcinoids of the Appendix
Laura H. Tang, Jinru Shia, Douglas D. Wong, Philip Paty, Martin Weiser, Jose Guillem,
Larissa Temple, Antonio Picon, Leslie Sobin, Klimstra D
Appendiceal tumors exhibiting neuroendocrine differentiation, mucin production and
glandular differentiation are uncommon and have caused difficulty in pathological classifica-
tion, prediction of prognosis, and the clinical management. They are variously designated
as adenocarcinoid, goblet cell carcinoid (GCC), and mixed adenocarcinoma-carcinoid. We
undertook a retrospective investigation of 63 such cases and classified them into low grade
GCC, high-grade GCC, and mixed GCC-adenocarcinoma based primarily on their histological
features. The clinical characteristics and prognosis were compared within the 3 subtypes
and with the conventional appendiceal adenocarcinoma. The mean followup time was 49±5
months. The stage IV-matched disease specific survival is demonstrated in Table 1. Our
studies demonstrate that utilization of specific morphological criteria may predict the clinical
behavior of GCCs. Both low grade and high grade GCCs share a similar immunoprofile,
which includes preserved immunoreactivity for neuroendocrine markers, a normal intestinal
type mucin glycoprotein profile (Table 2). The proliferative index (Ki67) is relatively low
in this group of tumors, and is slightly increased from low grade to high grade tumors. The
mixed GCC-adenocarcinoma demonstrated markedly increased proliferative activity and
abnormal p53 immunoreactivity. In conclusion, the GCC is a distinct appendiceal neoplasm,
which exhibits unique pathological features and clinical behavior. They display a spectrum
of low and high-grade histology and possess a potential to differentiate or transform to an
adenocarcinoma phenotype or frank adenocarcinoma. Thus careful evaluation of morpholo-
gical features of the GCC at its primary site is crucial for the clinical management and may
predict its outcome.
Table 1.Prognosis of Stage IV GCC Compared with Primary Adenocarcinoma of the Appendix.
DOD = Died of Disease; DSS = Disease Specific Survival
Table 2. Immunoprofile of GCC and Adenocarcinoma of the Appendix.
”-” - immunostain not performed. + = Staining intensity (1-4)
T1072
Ultrasound or CT Scan for the Detection of Supraclavicular Lymph Nodes in
Patients with Esophageal Or Gastric Cardia Carcinoma
Evelyn P.M. van Vliet, Aad van der Lugt, Ernst J. Kuipers, Hugo W. Tilanus, Ate van der
Gaast, John J. Hermans, Peter D. Siersema
Background: Malignant supraclavicular lymph nodes in patients with esophageal or gastric
cardia carcinoma are considered to be distant metastases. As the palliative treatment of these
patients differs from the intent-to-cure treatment of patients with apparent non-metastatic
disease, screening for malignant supraclavicular lymph nodes is thus of crucial importance

















institutions, both methods are routinely combined, however others prefer to screen with
CT alone and combining it with US with fine needle aspiration (FNA) if metastases are
suspected. It is presently unknown whether CT scan alone is sensitive enough to investigate
the supraclavicular region and, consequently, whether US with FNA should only be used
in cases with suspected malignant lymph nodes on a CT scan. Aim: To retrospectively
compare US, if indicated with FNA, with CT for the detection of supraclavicular lymph
node metastases. Methods: From 1994 to 2004, 567 patients underwent US and CT of the
supraclavicular region for staging of esophageal or gastric cardia carcinoma. The gold standard
was a radiological result with≥ 6 months of follow-up (N=402), FNA (N=122) or postoperat-
ive detection of malignant lymph nodes in the resected specimen (N=43). Results: Based
on the gold standard, 65/567 patients (11%) had malignant supraclavicular lymph nodes.
Sensitivity of US with FNA was 72% (47/65), compared to 25% (16/65) for CT (p<0.001).
Specificity was 100% (502/502) and 99% (500/502), resp. (p=NS). Prior to performing
FNA, US had classified lymph nodes as being malignant in 49 patients, resulting in a
sensitivity of 75% (49/65) and specificity of 91% (458/502). In 4 patients with malignant
nodes according to our gold standard, only CT classified lymph nodes as being malignant,
whereas the initial US with FNA was negative. In 35 patients, US with FNA detected true-
positive lymph node metastases where the CT scan was negative. Conclusions: Both US
with FNA and CT of the supraclavicular region should probably be used in patients with
esophageal or gastric cardia carcinoma, as both techniques are complementary for the
detection of metastases. Nevertheless, US with FNA and CT scan alone were not able to
detect malignant supraclavicular lymph nodes in as many patients as desirable. Therefore,
a prospective, blinded, comparative study is needed to determine whether other preoperative
investigations, such as PET scanning, alone or in combination with US with FNA or CT, are
better able to determine the presence of malignant lymph nodes in the supraclavicular region.
T1073
Expression of Angiotensin II Receptor-Type 1 Is a Predictor of Nodal Spread
in Gastric Cancer
Christoph Rocken, Stacy Carl-McGrath, Juliane Hoffmann, Peter Malfertheiner, Matthias
Ebert
Aims: We studied the putative significance of angiotensin II-receptor type 1 (AT1R) and 2
(AT2R) on gastric cancer biology. Methods: Local expression of AT1R, AT2R and angiotensin
converting enzyme (ACE) was investigated by immunohistochemistry in tumor and corres-
ponding non-tumor specimens obtained from 100 patients with gastric cancer and compared
with the ACE insertion/deletion gene polymorphism. Results: AT1R was expressed in tumor
epithelial cells of 26 (26%), and AT2R in tumor epithelial cells of 95 (95%) patients. AT1R
was found highly significantly more common in intestinal-type gastric cancer, where its
expression correlated significantly with the N-category (p=0.009) and the UICC tumor stage
(p=0.024). AT1R+ intestinal-type gastric cancers had a significantly larger number of lymph
node metastases and a significantly higher UICC tumor stage than AT1R- tumors. Twenty-
one (21%) of the 100 patients with gastric cancer had the ACE II-, 51 (51%) the ACE ID-
, and 28 (28%) the ACE DD-genotype. Patients with AT1R- tumor cells and ACE II-genotype
carried a low risk of developing lymph node metastases (OR 0.044; 95%-CI: 0.004-0.453).
In contrast, patients with AT1R+ tumor cells and an ACE ID- (OR 10.833; 95%-CI: 12.00-
97.798) or DD-genotype (OR 10.667; 95%-CI: 0.551-206.36) carried a high risk of lymph
node metastasis. Conclusions: We show that angiotensin II receptors are expressed in gastric
cancer and that the combination of AT1R-expression and ACE I/D gene polymerphism
allows the risk assessment of nodal spread in gastric cancer.
T1074
Clinical Significance of Prostaglandin E Synthase Expression in Colorectal
Cancer
Tsuguhiko Seo, Atsushi Tatsuguchi, Ken Wada, Masaoki Yonezawa, Keigo Mitsui,
Kazuhiro Nagata, Shu Tanaka, Shunji Fujimori, Katya Gudis, Seiichi Shinji, Tkashi Tajiri,
Teruyuki Kishida, Choitsu Sakamoto
Background: Several lines of evidence suggest that the COX-2/PGE2 pathway is a significant
contributor to the development and progression of cancer. In fact, elevated expression of
cyclooxygenase-2 (COX-2) has been found in various types of human cancer, including
colorectal cancer (CRC). Prostaglandin E Synthase (PGES) functions downstream of COX
in the biosynthesis of PGE2. To date, at least three distinct isoforms of PGES have been
cloned; one cytosolic PGES (cPGES), and two microsomal fractions, mPGES-1 and mPGES-
2. Although there have been reports concerning the expression of mPGES-1 in colorectal
cancer, the clinical significance of each of the three different PGE synthases remains unclear.
Aims: To investigate mPGES-1, mPGES-2, and cPGES expression in CRC tissue, and to
examine the relationship of their expression to various clinicopathological factors and patient
prognosis. Patients and Methods: A total of 99 CRC patients who had undergone surgery
were examined. PGES mRNA and protein expression levels in cancer tissue were compared
with those in normal tissue by real-time polymerase chain reaction (PCR) and Western blot
analysis, respectively. mPGES-1 localization was analyzed immunohistochemically. Immuno-
staining results for mPGES-1 were compared with clinicopathological factors. Results: Real-
time PCR and Western blot analysis of mPGES-1 mRNA and protein expression showed
significantly higher expression levels in CRC tissue samples than in normal tissue counter-
parts. Western blot analysis showed cPGES and mPGES-2 protein expressed in all CRC and
normal tissue samples, with no significant difference in their expression levels. Immunoreac-
tivity for mPGES-1 was predominantly observed in the cytoplasm of cancer cells in 43 cases
(43%). Weak mPGES-1 expression was also seen in a few stromal cells such as fibroblasts
and macrophages. mPGES-1 expression correlated with venous invasion (P=0.02), but with
no other clinicopathological factors. mPGES-1 expression correlated with COX-2 expression.
The prognosis was significantly worse in patients with mPGES-1-positive tumors than in
those with mPGES-1-negative tumors. Conclusions: Among the three PGE synthases, only
mPGES-1 immunoreactivity varied between colorectal cancer and normal tissue; cPGES and
mPGES-2 were uniformly expressed in both tissue types. Thus, only mPGES-1 may play
an important role in CRC progression in conjunction with COX-2.
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T1075
Percutaneous Radio-Frequency Ablation Inproves the Prognosis of the Patients
with Unresectable Hepatic Metastasis from Colorectal Cancer
Yukihiro Koike, Shuichiro Shiina, Haruka Kajiwara, Eriko Goto, Kazuhiko Ohira, Osamu
Goto, Kazuhiro Watanabe, Masao Omata, Tateo Kawase
Background The liver is the most common site of metastases from colorectal cancer. At
present, surgery is supposed to be the only therapy that offers the possibility of cure for
patients with hepatic metastatic diseases. However, there are never many patients with
colorectal liver metastases set as the candidates for surgical resection, while the remaining
are treated with chemotherapy or best supportive care. This study was conducted to clarify the
safety and efficacy of percutaneous radiofrequency ablation for unresectable liver meatstases of
colorectal cancer. Methods; From Feb. 2002 to Dec. 2005, 67 patients with unresectable
liver metastases from colorectal cancer were treated by percutaneous radiofrequency ablation,
regardless of extrahepatic lesions. At the initial ablation, the mean number and size of tumor
foci were 6.8±8.0 (mean±SD , range 1->30) and 50±36 mm (mean±SD, range; 18-178 mm).
Patients were not considered for surgical metastatectomy due to extrahepatic metastases (26
patients), prior hepatic resection (11 patients), disease extent (more than 5 lesions, 22
patients, more than 50 mm, 22 patients), age (over 75 y.o., 13 patients), and/or comorbidity.
There were 29 patients with the previous history of anticancer agents administration. Com-
plications and survival after radiofrequency ablation were calculated. Survival rates were
compared with those of the 18 patients who did not receive either surgical resection or
radiofrequency ablation for metastatic liver tumor of colorectal cancer developing from 1999
to 2000. Prognostic factors of the patients were evaluated by univariate Cox proportional
hazard model. Results; The overall procedure mortality was 0%. Two complications of live
abscess were observed. 1- and 2-year survival rates of the patients who received radiofre-
quency ablation for liver metastases were 74% and 49%, while those of the control were
only 50% and 0% (P<0.01, log rank test). Prior administration of anticancer agents was
the only significant prognostic factor. Conclusion; This study indicated that percutaneous
radiofrequency ablation might safely prolong the prognosis of patients with unresectable
liver metastases from colorectal cancer.
T1076
Aspirin Use and Survival After Diagnosis of Colorectal Cancer
Andrew T. Chan, Jeffrey A. Meyerhardt, Edward L. Giovannucci, Jennifer A. Chan, Eva S.
Schernhammer, Charles S. Fuchs
Randomized trials and cohort studies have demonstrated that aspirin reduces risk of colorectal
adenoma and cancer. In animal models, aspirin has been shown to inhibit tumor growth
and metastasis. However, the influence of aspirin on survival in patients with established
colorectal cancer is unclear. In an study of Stage III colon cancer patients enrolled in an
adjuvant chemotherapy trial, aspirin users had a reduced risk of recurrent disease and death.
Nonetheless, this study was not able to determine whether aspirin use before or after
diagnosis was more influential for survival. Methods: We conducted a prospective study of
aspirin use pre- and post-diagnosis of colorectal cancer among 724 women enrolled in the
Nurses’ Health Study. Since 1980, participants have provided aspirin data biennially. In the
present study, we examined women diagnosed with Stage I, II, or III colorectal cancer
between 1980 and 2002. We used Cox proportional hazards models with biennially updated
aspirin data to assess the relation between aspirin use with colorectal cancer-specific and
overall mortality. Results: Compared to non-users, women who used aspirin regularly after
colorectal cancer diagnosis experienced a hazard ratio (HR) for colorectal cancer-specific
mortality of 0.51 (95% CI, 0.33-0.79) and overall mortality of 0.66 (CI, 0.47-0.92) after
adjustment for age, age at diagnosis, date of diagnosis, stage, grade, tumor site, and aspirin
use pre-diagnosis. In contrast, compared to non-users, women who used aspirin regularly
before diagnosis did not have a survival benefit (HR 0.99; CI, 0.66-1.49 for colorectal-
cancer specific mortality and HR 0.84; CI, 0.60-1.16 for overall mortality). Notably, among
369 women who did not use aspirin before diagnosis, aspirin use initiated after diagnosis
was associated with HRs for colorectal cancer-specific mortality of 0.42 (CI, 0.0.20-0.86)
and overall mortality of 0.49 (CI, 0.28-0.85). Although low doses of aspirin were beneficial,
the association between post-diagnosis aspirin use and survival appeared dose-dependent.
Compared to non-users, the HRs were 0.53 (CI, 0.33-0.86) for women who used 0.5-7
standard aspirin tablets and 0.47 (CI, 0.23-0.96) for >7 tablets per week (Ptrend=0.03).
Conclusions: Regular aspirin use after the diagnosis of colorectal cancer may reduce the risk
of colorectal cancer-specific and overall mortality. In contrast, aspirin use before diagnosis
did not influence survival. These results suggest that aspirin may favorably influence the
biology of established colorectal tumors in addition to preventing their occurrence.
T1077
Evaluation of Prognostic Factors in Chemotherapy for Patients with Advanced
Pancreatic Cancer
Ken Hirao, Hirofumi Kawamoto, Hironari Kato, Naoko Kurihara, Yuko Okamoto,
Hirotoshi Fukatsu, Jun Kato, Hiroyuki Okada, Yasushi Shiratori
<Purpose>Pancreatic cancer is a disease of ominous prognosis. Therefore, the sooner the
response to the chemotherapy is evaluated, the better management on these patients we
can perform. As a reference index for early decision of prognosis, we evaluated prognostic
factors of the patients with advanced pancreatic cancer <Methods>Between March 2003 and
August 2005, forty-five consecutive patients with advanced pancreatic cancer were included
in this study (Male: Female=27: 18, Median age 58.0 years old; range 38-80, Average
observation period 218 days; range 11-638). All patients had histologically or cytologically
proven stage IV pancreatic cancer. The performance status was evaluated using Karnofsky
performance status (KPS) (KPS 50-60%: 70-80%: 90-100% = 4: 24: 17). The protocol of
chemotherapy was as follows : gemcitabine alone(1,000mg/m2 on days 1, 8 and 15 of each
28-day cycle; n=12), a combination of gemcitabine and carboplatin(1,000mg/m2 gemcitabine
and 10mg/m2 carboplatin on days 1 and 8 of each 21-day cycle; n=33). To predict the
prognosis of patients, we divided the patients into two categories according to the following
parameters: age, gender, KPS, location of primary tumor, metastasis, protocol of chemother-
apy, response to treatment, and decrease in two tumor markers level during initial one
month after chemotherapy (carcinoembryonic antigen; CEA, carbohydrate antigen 19-9;
CA19-9). The multivariate analysis was performed using the Cox proportional hazards
model, respectively. <Results>The overall response rate was 15.5%, and the overall survival
time was 7.1 months. The independent prognostic factors identified by multivariate analysis
were a KPS of 90-100% (RR: 4.3, CI: 1.84-9.98), a response to treatment of partial response
(PR) or stable disease (SD) (RR: 33.5, CI: 9.34-120.0), and the decrease in both tumor
makers level (RR: 5.3, CI: 2.07-13.57). Median survival time (MST) were as follows: KPS
(≦80%: ≧90% = 6.3months: 11.5months, p<0.01), response to treatment (PD: PR or SD =
1.6months: 10.3months, p<0.001), decrease in both tumor markers level (increase: decrease =
2.6months: 9.3month, p<0.001). In patients with stable disease (n=25), combination of KPS
≧90% and decrease in tumor markers level was also identified as a significant predictor of
survival by univariate analysis (RR: 13.7, CI: 1.67-112.6). MST were as follows: KPS + both
tumor makers level (≦80% + increase: ≧90% + decrease = 7.1months: 12.4 months, p<
0.05). <Conclusions>Good performance status and decrease in both tumor markers level
during initial one month after chemotherapy may be helpful to predict the prognosis of
patients with pancreatic cancer.
T1078
Colon Cancer in Young Patients: Have Worse Outcomes?
Hang Lak Lee, Oh Young Lee, Yong Chul Jeon, Dong Soo Han, Byung Chul Yoon, Ho
Soon Choi, Seung Sam Paik, Jin Bae Kim
Background and Aims: Many articles have previously reported poor outcomes for young
colon cancer patients relative to the older population. However, these studies tend to be
small and have various biases. So we conducted a retrospective study concerning the clinical
courses and survival rate of young colon cancer patient compared to old patients. Methods:
All patients diagnosed with colorectal cancer between 1991 and 2001 were evaluated. Duke
stage D patients were excluded and a total of 544 patients were included. All of 544 patients
have been followed up regularly after surgery and/or chemotherapy. Patients were organized
into two age categories: a young patient group (<50 years) and an old age group (>50 years).
Cancer related death was only included. Results: (1) Among the total of 544 patients, young
group included 123 patients, and older group contained 421 patients. (2) Cancer diameter
was significantly large in young group (6.06 ± 2.19 vs. 5.47 ± 2.13 cm, p=0.012) (3) There
were no significant differences between two groups in stage at diagnosis, differentiation,
degree of lymph node involvement, cancer location and gross finding. (4) Median cancer
specific survival time was worse for the old group (>50 years) compared with the young
group (<50 years)(3216.42 ± 101.05 vs. 3696.99 ± 160.35 days)(Figure 1). We performed
a subgroup analysis (age <45 years vs. age 55-60 years) to exclude effect of old age on
survival time, and there were no significant differences between two groups in median cancer
specific survival time. (5) Multivariate logistic regression analysis demonstrated that age (p=
0.001), stage at diagnosis (p=0.002), lymph node involvement (p=0.041) are independent
factors associated with survival rate. Conclusions: Contrary to prior reports, younger patients
appear to have similar or better survival rate than older patients.
T1079
Ability of Surgery to CURE Patients with Entero-Pancreatic Endocrine Tumors
Francesco Panzuto, Michela Di Fonzo, Cristina Nisita, Gabriele Capurso, Vito D. Corleto,
Massimo Milione, Elsa Iannicelli, Massimo Falconi, Vincenzo David, Giovanbattista
Grassi, Gennaro Nuzzo, Paolo Pederzoli, Vincenzo Ziparo, Gianfranco Delle Fave
Background. Surgery is the only treatment able to cure patients with entero-pancreatic
endocrine tumors (EP ETs). However, data on the outcome of these patients during long-
term follow-up are poor. Aim. To determine outcome and survival of EP ETs patients after
surgery. Patients and methods. Among all consecutive patients with EP ETs evaluated at
our Department, those who underwent surgical procedures were enrolled. Surgery was
considered radical when all the visible tumor lesions were removed. Patients were considered
cured when, after radical surgery, no disease recurrence occurred during follow-up. Cox-
proportional hazards regression and Kaplan-Meier method were used to calculate the risk
factors for disease recurrence, and the survival. Results. Among the 168 EP ETs evaluated,
35 were excluded, due to the lack of follow-up data. 80 out of the 133 remaining patients
(60.1%; 42 M, median age 49 yrs), underwent surgery, and were considered in the final
analysis. Tumor originated from the pancreas (PETs) or the GI tract (GI carcinoids) in 38
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(47.5%) and 42 patients (52.5%), respectively. At time of surgery, 41.2% of patients had
primary tumor only, whereas 58.8% had metastases (nodes only 12.5%, liver 46.3%). Surgery
was considered radical in 48/80 (60%) patients [29/42 (69%), and 19/38 (50%) of patients
with GI carcinoids and PETs, respectively (p=ns)]. None received adjuvant treatment. Of
them, 13 patients (27.1%; 7 GI tumors and 6 PETs, p=ns) experienced disease recurrence
at a median interval of 22 months (range 6-92) after radical surgery. Of these, before surgery,
6 had primary tumor only, whereas 7 had metastases (3 nodes only, 4 liver). The remaining
35 patients (43.7% of the operated patients; 26.3% of the 133 enrolled patients) were
considered cured after surgery, throughout a median 27 months follow-up. The presence
of ≥ 2 liver lesions was a significant risk factor for developing disease recurrence after
radical surgery (RR=4.85, p=.01). A total of 7 patients died of disease at a median interval
of 15.5 months after non radical surgery, overall 5-yr survival rate being 85.2%. Conclusions.
Surgery was considered radical in 60% of the operated patients. In this group, disease
recurrence occurred in 27.1% of cases. The overall rate of curative surgery in EP ETs patients
was 26.3%. The presence of 2 or more liver metastases was the major risk factor for disease
recurrence after radical surgery. Since recurrence occurred at a median interval of 22 months
after surgery (range 6-92), patients receiving radical surgery should undergo long-term
post-surgery follow-up. In these patients, the possible use of an adjuvant therapy should
be considered.
T1080
Evaluation of An Inflammation-Based Prognostic Score (GPS) in Patients with
Inoperable Gastro-Esophageal Cancer, Receiving Active Treatment
Andrew Crumley, Donald C. McMillan, Margaret McKernan, Alexander C. McDonald,
Robert C. Stuart
Background: There is increasing evidence, that the presence of an ongoing systemic inflam-
matory response, is associated with poor outcome in patients with advanced cancer. The
aim of the present study, was to examine whether an inflammation-based prognostic score
(GPS), was associated with survival, in patients with inoperable gastro-oesophageal cancer.
Methods: Patients attending the Royal Infirmary, Glasgow between the 1st January 2000
and the 31st December 2004 were included in the study. A blood sample was obtained for
measurement of albumin and C-reactive protein concentrations, at the time of diagnosis.
Patients with an elevated C-reactive protein (>10 mg/l) and hypoalbuminaemia (<35g/l)
were allocated a GPS score of 2. Patients in whom only one of these biochemical abnormalities
was present were allocated a GPS score of 1 and patients with a normal C-reactive protein
and albumin were allocated a score of 0. Results: Of the 195 patients studied 153 (78%)
patients died, 144 patients of their cancer and 9 of intercurrent disease in the follow-up
period. On multivariate survival analysis, stage (HR 1.37, 95%CI 1.15-1.63, p<0.001) and
the GPS (HR 1.87, 95%CI 1.45-2.42, p<0.001) were significant, independent predictors of
cancer survival. Twelve month survival in patients with stage III/ IV disease was 57%, 25%
and 12% for a GPS of 0, 1 and 2 respectively. Conclusions: In the present study, the GPS
predicted cancer specific survival, independent of stage and treatment received, in patients
with inoperable gastro-oesophageal cancer. Moreover, the GPS may be used in combination
with stage to improve the prediction of survival, in these patients.
T1081
Selection Criteria for Immediate Hepatectomy Without Neoadjuvant
Chemotherapy in Patients with Multiple and Bilateral Liver Metastases
Masami Minagawa, Masatoshi Makuuchi
Objective: To determine selection criteria for immediate hepatectomy without neoadjuvant
chemotherapy in patients with multiple and bilateral liver metastases. Background Data:
Effectiveness of neoadjuvant chemotherapy followed by hepatectomy in patients with initially
unresectable liver metastases has been shown. The indication of neoadjuvant chemotherapy
is gradually extending, and the boundary of immediate resection and neoadjuvant chemother-
apy followed by hepatectomy is becoming unclear. Methods: During the past 22 years, 369
patients underwent curative resection without neoadjuvant chemotherapy for liver metastasis
from colorectal cancer; 156 had single, 76 had multiple and unilateral, 137 had multiple
and bilateral metastases. Seventeen clinicopathological factors were analyzed in the last
group. Results: The 5-year survival rate and the median survival time (95% confidence
interval) of 137 patients with multiple and bilateral metastasis were 28%, and 2.3 years
(2.1~2.8 years) respectively. There was no in-hospital death. Factors that significantly affected
the prognosis were 4 or more lymph node metastases around the primary cancer (P<0.001)
and carcinoembryonic antigen >/=50ng/ml (P=0.003). Age, sex, number of liver nodules,
size of metastasis, synchronous or metachronous appearance of liver deposits, vascular of
biliary invasion of metastasis, existence of extrahepatic metastasis or invasion, were not
significant factors. The location, size, depth of wall invasion, lymphatic duct invasion, vascular
invasion, and grade of differentiation of primary colorectal cancer were not significant. In
patients with 3 or less lymph node metastases around the primary cancer, the 5-year survival
rates of those with 2~3, and 4 or more liver metastases were 40% and 40% respectively,
while these were 25% and 0% in patients with 4 or more lymph node metastases around
the primary cancer. Conclusion: Resection of multiple and bilateral metastases was feasible

















metastases around the primary cancer. However, in patients with 4 or more colorectal lymph
node metastases, biological selection by neoadjuvant chemotherapy may be more suitable.
T1082
The Expression of Sparc in Tumor Stroma May Facilitate Gastric Cancer
Metastasis and Invasion
Christoph Rocken, Stacy Carl-McGrath, Uwe Lendeckel, Peter Malfertheiner, Matthias
Ebert
Aims: Using cDNA microarray technology we searched for genes that might be involved in
tumor spread in gastric cancers. Methods: cDNA microarray analysis of a primary gastric
carcinoma and matched lymph node metastasis was carried out. Using quantitative real time
RT-PCR, the expression levels of SPARC mRNA was confirmed in non-neoplastic, carcinoma,
and metastasis tissues from 7 patients. Immunohistochemistry with anti-SPARC antibodies
was performed on 40 cases of primary gastric carcinomas (20 diffuse, 20 intestinal) and the
corresponding lymph node metastases. Results: SPARC was identified by a cDNA microarray
as being up-regulated in the lymph node metastasis compared to the primary gastric carcin-
oma. The level of expression of SPARC mRNA in non-neoplastic tissues, carcinomas and
metastases was validated by quantitative RT-PCR. Using immunohistochemistry, SPARC was
found in intestinal metaplasia, as well as in fibroblasts, and occasionally in tumor cells.
However, the level of immunoreactivity was extremely strong in stromal cells surrounding
the tumor cells, and also frequently in metastatic carcinoma cells in lymph nodes. Conclu-
sions: SPARC is a protein regulating cell-ECM interactions. The tumor-stroma interactions
mediated by SPARC may contribute to the loss of cell-cell contacts that allows dissemination
and metastasis of gastric cancer cells.
T1083
Arterial and Systemic Combination Chemotherapy of 5-Fluorouracil with
Radiation in the Treatment of Advanced Gallbladder Cancer
Takashi Sasaki, Hiroyuki Isayama, Toshihiko Arizumi, Osamu Togawa, Saburou
Matsubara, Yousuke Nakai, Natsuyo Yamamoto, Naoki Sasahira, Kenji Hirano, Takeshi
Tsujino, Nobuo Toda, Minoru Tada, Takao Kawabe, Masao Omata
BACKGROUND: The prognosis of patients with advanced gallbladder cancer is poor and
existing chemotherapy is relatively ineffective. The aim of this study was to determine the
efficacy of arterial and systemic combination chemotherapy of 5-Fluorouracil(5-FU) with
radiation in the treatment of advanced gallbladder cancer. PATIENTS AND METHODS: The
records of all patients who had histologically or cytologically confirmed gallbladder cancer
were retrospectively reviewed. The regimen of arterial and systemic combination chemother-
apy of 5-FU with radiation was as follows; arterial and systemic infusion of 5-FU(350mg/
m2) was given five consecutive days for four weeks with radiation therapy(Total 48Gy).
Then 5-FU was administered biweekly at the same dose. Patients were evaluated for response
rate, survival, toxicity and patency of metallic stent in case of malignant biliary obstruction.
RESULTS: Of fourty-four patients with advanced gallbladder cancer, seven patients were
treated by arterial and systemic combination chemotherapy of 5-FU with radiation. The
response rate of this treatment was 71.4% (complete response rate of 14.3%, and a partial
response rate of 57.1%) and a median survival period was 9.8 months (a mean survival
period was 13.6±6.8 months). The response rate of other treatment groups were 18.8%
(Chemotherapy; n=16) and 20% (Radiation; n=5). The median survival period of other
treatment groups were 5.1 months(Chemotherapy), 3.8 months(Radiation), 2.4 months(Best
supportive care; n=16). As for patency of metallic stent, median stent patency were 9.7
months (Arterial and systemic combination chemotherapy of 5-FU with radiation; n=6), 3.8
months (Radiation; n=4) and 2.7 months (Chemotherapy; n=10). The major toxicity of
arterial and systemic combination chemotherapy of 5-FU with radiation was hematological
(Grade 3 to 4 neutropenia occurred in 28.6% of patients without febrile neutropenia).
CONCLUSION: Treatment with arterial and systemic combination chemotherapy of 5-FU
with radiation resulted in clinically significant response rate, survival and local control in
patients with advanced gallbladder cancer. Future clinical investigations for this treatment
are warranted.
T1084
The Clinical Significance of Mucin Phenotype of Gastric Adenocarcinoma
Ok-Jae Lee, Hyun-Jin Kim, Woo-Song Ha, Hidenobu Watanabe
Background/Aim: Histochemical and immunohistochemical studies for mucin contained in
tumor allowed the mucous phenotypic classification of gastric adenocarcinomas. The clinical
significance of mucin phenotype has not been clarified. We investigated the mucous pheno-
typic expression of gastric adenocarcinomas and its clinical significance as a prognostic factor.
Methods: Histochemical and immunohistochemical stainings for paradoxical concanavalin A,
MUC5AC, MUC-2 glycoprotein and CD10 of mucin were performed in 74 surgically obtained
gastric adenocarcinomas. We determined mucin phenotype and analyzed its relationships
with clinical and histopathological variables. Results: Among 74 gastric adenocarcinomas,
30 (40.5%) expressed gastric phenotype (10 foveolar and 20 foveolo-glandular), 20 (27.0%)
intestinal phenotype (7 complete and 13 incomplete), 15 (20.3%) mixed gastric-intestinal
phenotype and 9 (12.2%) undetermined type. The gastric and gastric predominant types
were 54.1% (40/74), and intestinal and intestinal predominant types 31.1% (23/74). No
relationship between mucous phenotypic expression and tumor location was found. Among
21 well differentiated adenocarcinomas, 12 (57.1%) expressed predominantly intestinal
phenotype and only 5 (23.8%) gastric phenotype. Among 53 poorly differentiated adenocarci-
nomas, 35 (66.0%) were gastric predominant and only 11 (20.8%) were intestinal predomin-
ant phenotypes. Thirty-five out of 40 (87.5%) gastric dominant cancers were poorly differenti-
ated adenocarcinomas. Helicobacter pylori infection rates were 87.5%, 91.3%, and 66.7% in
gastric predominant, intestinal predominant and undetermined phenotypes, respectively.
For about 6 years, 58 patients were followed up and the overall death rate was 39.7%
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with 62.5% for undetermined, 35.5% gastric predominant, 36.8% intestinal predominant
phenotypes. Cumulative survival rate was lower in the undetermined than intestinal and
gastric phenotypes. Conclusions: Gastric adenocarcinomas expressed predominantly gastric
phenotype in Korea. Mucin phenotype may be associated with differentiation of gastric
adenocarcinoma and Helicobacter pylori infection, and may have a role as a prognostic factor.
T1085
Prognostic Impact of DNA Ploidy Is Stronger Than and Independent of
Microsatellite Instability in Human Colon Carcinoma Patients
Frank A. Sinicrope, Rafaela L. Rego, Kevin C. Halling, Nathan Foster, Daniel J. Sargent,
Amy French, Megan Garrity, Richard M. Goldberg, John A. Laurie, Laurence J. Burgart,
Stephen N. Thibodeau, Thomas E. Witzig
BACKGROUND. DNA ploidy and microsatellite instability (MSI) are highly correlated in
human colon cancers and confer prognostic information. We determined whether MSI
accounts for the prognostic impact of ploidy shown in prior studies. We studied the relation-
ship between ploidy and MSI, allelic imbalance on chromosome arms 5q, 8p, 17p,18q, and
p53 expression. MATERIALS & METHODS. Dukes’ stage B2 (n= 158) and C (n= 370)
primary colon carcinomas from patients enrolled in six 5-fluorouracil-based adjuvant trials
conducted by North Central Cancer Treatment Group. Tumors had been analyzed for DNA
ploidy by flow cytometry. MSI and allelic imbalance were determined using 11 microsatellite
markers [(instability at ≥ 30% of loci (MSI-H)]. Expression of mismatch repair proteins
(hMLH1, hMSH2) and nuclear p53 were analyzed by immunostaining. Overall survival
(censored at 8 yr) was analyzed in univariate and multivariate Cox models adjusting for
stage, treatment, and stratifying by study. RESULTS. Diploid DNA content was detected in
223 (42%) colon cancers. Ninety-five (18%) tumors were MSI-H and 70 (74%) of these
were diploid. Of 58 MSH-H cases tested, 54 showed loss of hMLH1 (n= 50) or hMSH2 (n=
4) proteins; all MSI-L (n= 30) and 240/241 MSS cases tested showed intact expression.
Female gender, proximal site, high histologic grade, infrequent p53, and diploidy were more
likely to be MSI-H (vs. MSS/MSI-L; all p ≤ 0.0002). Patients with diploid tumors had a
better overall survival (OS) compared to those with aneuploid/tetraploid tumors (HR= 0.64,
p= 0.002) in all patients and in MSS/MSI-L cases (p= 0.01). The prognostic impact of ploidy
was similar within Dukes’ B2 and C colon cancers (interaction p-value = 0.98). Survival
curves for diploid MSS/MSI-L and MSI-H patients overlapped (p= 0.69). Neither MSI status
(p= 0.17) nor loss of mismatch repair proteins (p= 0.13) were prognostic for OS. High
grade histology (p = 0.0002) and 8p allelic imbalance (p= 0.034) were associated with poor
OS and when stratified by ploidy, 8p status added additional prognostic information to
diploid tumors (p= 0.021). Allelic imbalance at 5q,17p,18q and p53 expression failed to
predict outcome. In multivariate analysis, DNA ploidy (p= 0.002) and histologic grade (p<
0.0001), but not MSI (p= 0.203), were stage-independent prognostic variables. CONCLU-
SION: DNA ploidy was the strongest stage-adjusted prognostic variable and was independent
of MSI status. Diploid MSS/MSI-L patients had similar survival rates as did patients with
MSI-H tumors. These data suggest that ploidy may be useful in therapeutic decision-making,
including selection of patients for adjuvant therapy.
T1086
Frequency of Gastrointestinal Lesions in Iron Deficient Patients Without
Anemia: A Prospective Endoscopic Study
Bani Chander, Edmund J. Bini
Background: Iron deficiency anemia occurs only after body stores of iron are completely
exhausted and is, therefore, a late manifestation of the iron-depleted state. Although endos-
copy is recommended for all patients with iron deficiency anemia, the need for an endoscopic
evaluation in iron deficient patients without anemia is not known. The aims of this study
were 1) to determine the frequency of gastrointestinal (GI) lesions in iron deficient patients
with and without anemia and 2) to evaluate if colonoscopy can detect colorectal cancer at
an earlier stage in iron deficient patients who have not yet developed anemia. Methods:
Consecutive patients who were referred for the evaluation of iron deficiency anemia were
prospectively enrolled at a single medical center. Patients were interviewed by a research
assistant who obtained detailed demographic and clinical data, and all subjects had same-
day EGD and colonoscopy. Iron deficiency was defined as a transferrin saturation of <15%
and a ferritin of <20 ug/L, whereas anemia was defined as a hemoglobin of <13 g/dL in
men and <12 g/dL in women. Lesions were classified as clinically important according to
standard predetermined criteria. Results: Of the 1,346 iron deficient subjects enrolled,
1,081 were anemic and 265 had normal hemoglobin levels. Clinically important lesions
were identified in 60.7% of patients with anemia and 58.1% of those without anemia (P =
0.44). The frequency of upper GI tract lesions (35.4% vs. 31.2%, P = 0.20) and lower GI
tract lesions (40.5% vs. 35.1%, P = 0.10) did not differ between anemic and non-anemic
subjects. However, anemic patients were significantly more likely to have a clinically import-
ant colonic lesion identified proximal to the splenic flexure (23.8% vs. 14.7%, P = 0.001)
and were more likely to have clinically important lesions detected in both the upper and
lower GI tract (15.1% vs. 8.0%, P = 0.003). Although the prevalence of colonic adenomas
≥1 cm (24.1% vs. 23.4%, P = 0.82) and colorectal cancer (10.2% vs. 7.5%, P = 0.19) was
similar in anemic and non-anemic patients, non-anemic subjects with colorectal cancer were
significantly more likely to have earlier stage cancers (Dukes’ A & B) than those with anemia
(50.0% vs. 19.1%, P = 0.003). Conclusions: Iron deficient patients should undergo a
thorough endoscopic evaluation of the GI tract, irrespective of the presence of anemia. Early
endoscopy in iron deficient patients who have not yet developed anemia can detect colorectal
cancer at a potentially curable stage. The effectiveness and cost-effectiveness of using ferritin
to screen non-anemic patients for iron deficiency requires further evaluation.
T1087
Home Fecal Occult Blood Testing in Average Risk Veterans Detects Only
Advanced Colorectal Neoplasms
Christopher M. Mathews, David C. Whitehead, Christopher R. Marino
Background: Colorectal cancer (CRC) screening methods are designed to detect and remove
pre-malignant lesions. Home fecal occult blood testing (FOBT) is used in many VA medical
centers because it is easy to perform and has been shown by RCT to save lives. It is
controversial, however, whether FOBT actually detects colorectal neoplasms or randomly
targets individuals for interventions that subsequently identify these common lesions. We
hypothesized that FOBT in average risk veterans does not select for individuals with colorectal
neoplasia. Methods: The Clinical Outcomes Research Initiative (CORI) endoscopic database
at the Memphis VAMC was retrospectively reviewed for male veterans age ≥50 who under-
went colonoscopy between 1999-2005 for a “positive home FOBT”. Patients with anemia,
personal or family history of colonic neoplasia, or symptoms such as abdominal pain, weight
loss, change in bowel habits, or rectal bleeding were excluded by thorough review of
medical records in the VA Computerized Patient Record System (CPRS). The prevalence of
adenomatous polyps and CRC in veterans with a positive FOBT was compared to that in
asymptomatic veterans who underwent screening colonoscopy using the same exclusion
criteria (control group). Prevalence rates for colonic neoplasia in published autopsy studies
were also compared. Results: The CORI database identified 663 veterans who underwent
colonoscopy for positive screening FOBT and 301 who underwent screening colonoscopy
without prior FOBT. CPRS review narrowed the FOBT cohort to 147 (45 black, 102 white)
and the screening colonoscopy cohort to 138 (36 black, 102 white). Findings are summarized
in the Table below. Published autopsy studies (Cancer 43:1847, 1979; Gut 23:835, 1983)
report the prevalence of adenomatous polyps in males age ≥50 to be 40-50% and CRC to
be 3-4%. Conclusions: The prevalence of adenomatous polyps in male veterans with positive
screening FOBT does not differ from that in the general population. The lack of FOBT
selectivity for adenomas results from the failure of FOBT to detect small (<1 cm) adenomas
present in a large percentage of individuals over age 50. FOBT positivity does, however,
appear to select for the smaller subgroup of individuals with more advanced neoplasms
(polyp size ≥1cm or CRC). Whether this sensitivity limitation enhances or detracts from
the value of FOBT as a screening tool is subject to debate.
*p-value 0.21. †p-value 0.08. p-value 0.03 for advanced neoplasm (adenoma≥1cm or CRC).
T1088
RNA-Based Stool Assay Is Superior to a Single Immunochemical Fecal Occult
Blood Test for Detecting Early Colorectal Cancer and Adenoma
Shigeru Kanaoka, Tetsunari Takai, Ken-Ichi Yoshida, Mutsuhiro Ikuma, Masayoshi
Kajimura, Naoyuki Miura, Haruhiko Sugimura, Akira Hishida
Background and Aims: It has been reported that fecal occult blood test (FOBT) is less
sensitive for early colorectal cancer (CRC) and adenoma. We reported that Fecal COX-2
assay, one of RNA-based stool assays, is useful for detecting CRC (Gastroenterology 2004;
127: 422-427). It is reported that Snail is a repressor of both E-cadherin and vitamin D
receptor gene expression, which is involved in colon carcinogenesis (Nature Cell Biol 2000;
2: 84-89, Nature Med 2004; 10: 917-919). We aimed to perform a study of whether RNA-
based stool assay, combination of Snail and COX-2 as targets, allows us to improve further
sensitivity for colorectal cancers and advanced adenomas compared the results with those
of a single immunochemical FOBT (IFOBT). Methods: Standard histological techniques were
used to classify adenoma or malignancy at I to IV stages according to TNM classification.
We purified RNA from routinely collected stool samples and screened mRNA using COX-
2 and Snail specific nested RT-PCR as previously described, consequently compared the
results with those of a single immunochemical FOBT (Magstream 1000/HemSp; FUJIREBIO,
Inc., Tokyo, Japan) on same stool samples. Results: Stool samples from 65 patients with
CRC, 13 patients with advanced adenoma, and 32 control patients without neoplastic disease
were studied. The specificity of Fecal Snail assay as well as Fecal COX-2 assay was 100%
(95% confidence interval [CI], 89.1-100%), while that of IFOBT was 87.5% (95% CI, 71.0-
96.5%). The sensitivity of RNA-based stool assay was 87.7% (95% CI, 76.6-94.5%) for
CRC, and 76.9% (95% CI, 46.2-95.0%) for advanced adenoma, while that of IFOBT was
73.0% (95% CI, 60.2-83.5%) and 30.8% (95% CI, 9.1-61.4%), respectively. COX-2 and/
or Snail mRNA was detected in 84.6% of stage I (n=13), 93.5% of stage II (n=31), 81.0%
of stage III or IV (n=21), while IFOBT was positive in 41.7% of stage I, 80.0% of stage II,
81.0% of stage III or IV. Snail mRNA was detected in 2 of 5 stool samples from patients
with advanced adenoma who had negative Fecal COX-2 assay and IFOBT. Noteworthy,
COX-2 and/or Snail mRNA was detected in 17 of 22 stool samples from patients with early
cancer or advanced adenoma who had negative IFOBT. Finally, the sensitivity of this assay
was 87.7% (95% CI, 76.2-94.9%) for advanced adenoma to stage II cancer, while that of
IFOBT was 60.0% (95% CI, 45.6-73.1%). Conclusions: We could improve further sensitivity
to add Snail as a target to RNA-based stool assay, which is superior to a single IFOBT in
term of detecting curable colorectal cancer and advanced adenoma. These results strongly
suggest that this assay would be useful for CRC screening.
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T1089
Urgent Investigation of Alarm Symptoms of Suspected Upper Gastrointestinal
Cancer Within Two Weeks Has a Low Yield for Diagnosis of Malignancy
David Dewar, Manil Chouhan, David Reffitt, John O'Donohue
Background: In the UK, the ‘two week wait’ (TWW) referral initiative for suspected upper
gastrointestinal cancer was introduced in July 2000. This standard allows general physicians
to refer suspected cases of upper gastrointestinal cancer for urgent investigation which must
be performed within a 14 day period in an attempt to improve on the poor survival. Alarm
symptoms include anemia, weight loss, dysphagia, new onset dyspepsia and jaundice. We
wished to explore the outcome of investigating this group of patients urgently. Methods:
We identified all the urgent TWW referrals for the year 2004 and examined their medical
records. This list was correlated with a database of all cases of diagnosed upper gastrointestinal
cancers in our institution. The results were compared with a previous study at our institution
which took place in 2000-2002, following the initial implementation of the two week wait.
We included all diagnosed cases of upper GI malignancy. Results: In the year 2004, 321
patients (mean age 62.7 yrs, 57% female) were referred using the TWW route, out of which
12 cases (3.73%) were diagnosed with upper GI cancer. This constituted 16% (12/75) of
all diagnosed cases of upper GI cancer in that year. In particular 288 endoscopies (11.4%
of total upper GI endoscopy activity) were performed of which 9 (3.1%) showed cancer,
50 (17.4%) showed gastroduodenal pathology related to H.Pylori and 94 (32.6%) were
normal. Figures from 2001/2002 showed an annual TWW referral rate of 200.5 patients,
with cancer being diagnosed in 5.7% of referrals. This constituted a similar proportion of
the total upper GI cancers in this period (15.4%). The incidence of diagnosis of upper GI
cancers remains similar with 65 cancers annually in 2001/2002 and 75 cases in 2004. It is
noteworthy that only one of the urgently referred cancer was amenable to curative resection.
Conclusion: The proportion of actual cancer cases amongst TWW referrals appears to have
fallen, whilst the referral activity has risen. This may suggest that referring physicians have
become less discerning in selecting patients for urgent investigation. The yield of cancers
is low both in absolute terms (3.7%) and in the proportion of total cancers (16%) being
diagnosed in this way. This reaffirms the fact that alarm symptoms correlate poorly with a
diagnosis of cancer and that many cases of cancer present with more insidious symptoms
which physicians may feel do not warrant urgent investigation. In the UK, the TWW route
remains the preferred pathway for rapid cancer diagnosis but poses a significant workload
for a small overall return.
T1090
Colorectal Cancer Screening By Primary Care Physicians: A Prospective Chart
Audit
Bernard Denis, Guillaume Schon, Marcel Ruetsch, Jean Christian Grall, Michel Leveque,
Jean Martin Meyer, Serge Moser, Jean Claude Tschiember, Philippe Perrin
Cancer screening requires 1) identification of individuals at high risk for cancer mainly
through an adequate family history assessment and 2) documentation of dates and results
of past screening examinations. Little data exist about the quality of charts in the field of
colorectal cancer screening in primary care. Aim: to assess the completeness of the family
history and past screening examinations interview in primary care. Methods: prospective
chart audit of data on family cancer history and past screening examinations. Volunteer GPs
self audited the completeness of their charts of 20 (10 men, 10 women) established patients
aged 40-74 years for colorectal, breast and cervix cancer. Results: 37 GPs participated and
736 charts were analysed. Family history information on colorectal cancer was collected on
367 (51.3 %) charts. The individual rate of family history recording ranged from 5 to 100
% according to GP. Specific information regarding age at diagnosis and degree of kinship
was present in 103 of the records. 134 charts (20.5 %) mentioned a past colon examination,
but 85 (63.4 %) only mentioned the date of examination and its result. Among 490 50-74
years old average risk people, 251 charts (51.2 %) mentioned a past FOBT, 78.5 % of them
mentioned the date of the FOBT and 63.3 % contained information about family history.
Family history of breast cancer was documented in 139 (49.8 %) charts. 126 charts (62.7
%) of women aged 50-69 years mentioned a past mammogram, but 52 charts only (25.9
%) were complete and correct for breast cancer screening (family history, date and result
of mammogram and < 2 years mammogram). 99 charts (44.2 %) of women aged 40-65
mentioned a past pap smear but 53 charts only (23.7 %) were complete and correct for
cervix cancer screening (date < 3 years and result). Conclusion: quality of charts in primary
care is globally poor but very heterogeneous, ranging from bad to excellent according to
GP: family history of cancer is correctly documented in about a half of charts; about a
quarter of charts are complete and correct for each cancer screening (date and result of past
screening examinations documented and correct, family history collected). The collection
of updated information on family history and past screening examinations must be improved
in primary care. We designed paper tools to aid GPs in this task: posters and patient-
completed forms intended for GP’s waiting rooms.
T1091
Reappraisal of Fecal DNA Testing (fDNA) in Light of Evolving Test
Performance Characteristics and Increasing Colorectal Cancer (CRC)
Treatment Costs
Murtaza Parekh, A. Mark Fendrick, Uri Ladabaum
BACKGROUND: CRC screening and treatment are dynamic fields. Some patients prefer
non-invasive testing. As new tests evolve and CRC treatment costs rise with use of agents
like bevacizumab and cetuximab, the cost-effectiveness of screening changes. Fecal occult
blood testing (FOBT) decreases CRC incidence and mortality, but adherence with annual
testing is poor. fDNA detects more CRCs and advanced neoplasia than FOBT (Imperiale
NEJM 2004), it may have better patient acceptance, and fDNA test costs have decreased.
AIMS: To reappraise the cost-effectiveness of fDNA in people unwilling or unable to undergo
colonoscopy, but amenable to non-invasive screening. METHODS: We used our published

















yearly FOBT or no screening (NS) from age 50-80. Colonoscopy was done after positive
fDNA or FOBT, and every 5 yrs after polypectomy. Base case inputs included: fDNA sensitivity
for CRC 0.52, large (≥1cm) polyp 0.18, specificity 0.94, cost $300 (Exact Sciences); FOBT
sensitivity for CRC 0.4, large polyp 0.1, specificity 0.92, cost $20; CRC treatment costs
$46,000/localized, $91,000/regional, $195,000/disseminated CRC; test adherence 100%.
Sensitivity analyses focused on test performance characteristics and adherence. BASE CASE
RESULTS: fDNA decreased CRC incidence by 24% and yielded 18.720 life-yrs/pt vs 18.686
life-yrs/pt with NS, costing $18,000/life-yr gained (in contrast with our published estimate
of $73,200/life-yr gained assuming $695/fDNA test and lower CRC treatment costs). With
100% adherence, FOBT was both more effective and less costly than either NS or fDNA
(CRC reduction 36% vs NS; 18.742 life-yrs/pt). SENSITIVITY ANALYSES: A newer generation
fDNA test with improved CRC sensitivity (0.65) would yield 18.725 life-yrs/pt at $14,200/
life-yr gained vs NS. Further improved fDNA sensitivity (CRC 0.82, large polyp 0.2) at the
expense of decreased specificity (0.82) would yield 18.733 life-yrs/pt at $13,000/life-yr
gained vs NS. fDNA with 100% adherence every 5 yrs and FOBT with 35%/yr adherence
had comparable effectiveness, but FOBT remained cost-saving vs NS or fDNA. fDNA with
100% adherence cost <$100,00/life-yr gained compared to FOBT when FOBT adherence
was ≤24%/yr. CONCLUSION: As CRC treatment costs increase and test costs decrease,
fDNA may become a progressively more cost-effective CRC screening strategy in patients
unwilling or unable to undergo colonoscopy. FOBT may be cost-saving given higher CRC
treatment costs, but adherence with yearly testing is challenging. Present generation fDNA
could be preferred if it achieved significantly higher adherence rates than FOBT.
T1092
Cancer Investigation At Peking University Using Fourier Transform Infrared
(FT-IR) Spectroscopy. Immediate Spectroscopic Separation of Colitis from
Cancer in Colon Biopsies
Q-B Li, X Li, Roger D. Soloway, Y-Z Xu, X-J Sun, G-J Zhang, Y-F Zhang, J-G Wu
Background: FT-IR spectroscopy can identify variability at the molecular level in biological
specimens. This method is rapid and accurate and can be used intraoperatively to modify
surgical procedures. Applications of newer statistical programs allow analysis of entire spectra
simultaneously to utilize the maximum amount of information to characterize samples. Aim:
To identify and separate cancer from colitis on endoscopic colon biopsies. Methods: After
informed consent, one 1-3 mm pinch biopsy was obtained from each of 89 patients from
the First Hospital of Xi’an Jiaotong University, China. 41 patients had colitis and 48 had
cancer. Specimens were placed on a modified attenuated total reflectance (ATR) accessory
linked to a WQD-500 FT-IR spectrometer with a MCT detector for greater stability and
sensitivity. The spectral range was 4000 to 999 cm-1. Later, specimens were processed and
read by pathologists without knowledge of the spectroscopic findings. Results: FT-IR spectral
curves were smoothed by computer to reduce high-frequency noise. A Resampling Half-
Mean outlier statistical method was repeated 500 times and identified 4 samples as outliers
(3 colitis, 1 cancer), thus 38 colitis and 47 cancer specimens were compared. Preprocessed
spectra with first-order derivative after smoothing and normalization were used for discrim-
ination analysis. A K-nearest neighbor model was constructed for diagnostic classification.
A leave-one-out cross validation method was utilized to assess the discrimination results.
39 of 47 cancer specimens and 35 of 38 colitis specimens were correctly identified. This
gave a sensitivity of 83% and specificity of 92% for cancer and a sensitivity of 92% and
specificity of 83% for enteritis. This gave a 92.9% predictive value of a positive test for
cancer and 81.4% predictive value for enteritis. Conclusions: 1. Colon cancer can be distingu-
ished from colitis with high accuracy using FT-IR spectroscopy and chemo metrics. 2. This
should be extended to analysis of cancer vs normal colon or polyps. 3. This technique has
promise for in vivo diagnosis with the development of endoscopic FT-IR miniprobes and
is practical for immediate diagnosis at endoscopy. ***Project supported by State Key Project
for Fundamental Research of MOST (2002CCA01900), National Natural Science Foundation
of China (No. 30371604) and Doctoral Project of Education Ministry of China
T1093
Development of a Risk Assessment Tool for Patients Undergoing Colonoscopy
to Identify Individuals At Risk for Hereditary Colorectal Cancer Syndromes
Fay Kastrinos, David H. Stockwell, Radhika Venugopal, Elena M. Stoffel, Muthoka L.
Mutinga, Earl F. Cook, Sapna Syngal
BACKGROUND: Complex criteria and time constraints are cited as reasons why clinicians
fail to identify patients with hereditary colorectal cancer syndromes. Incomplete risk assess-
ment can lead to inadequate surveillance for patients at highest risk for developing colorectal
cancer (CRC). OBJECTIVE: To develop a practical and efficient risk assessment tool that
will identify individuals at high risk for CRC and help gastroenterologists provide appropriate
recommendations for surveillance intervals and referrals for genetic evaluation. METHODS:
Patients undergoing outpatient colonoscopy at a tertiary-care center and a community hospital
were asked to complete a 34-item self-administered questionnaire assessing CRC risk based
on personal and family history of CRC, hereditary nonpolyposis colon cancer (HNPCC)-
related malignancies and colonic polyps. Subjects reporting any of the following criteria
were defined as high risk: Personal history of CRC < 50 years, polyps < 40years, endometrial
cancer < 50 years, ≥ 2 HNPCC-associated cancers, ≥ 10 cumulative polyps; Family history
of first-degree relative (FDR) with CRC < 50 years, FDR with polyps < 50years,≥ 3 relatives
with CRC, FDR with HNPCC-associated cancer <50years. HNPCC-associated cancers include
genitourinary, gynecologic, gastric, small bowel, biliary, pancreatic or brain cancers. Recursive
partitioning analysis was used to develop an algorithm of the fewest number of questions
that successfully captured the largest proportion of individuals fulfilling high-risk criteria.
RESULTS: Data were analyzed from 615 subjects. Of these, 18.9% of individuals fulfilled
high-risk criteria. Recursive partitioning identified the following four questions as most
informative: 1. “Do you have a FDR with an HNPCC-associated cancer at age < 50 years?”
2. “Do you have three or more relatives with CRC?” 3. “Do you have a FDR with polyps at
< 50 years?” 4. “Do you have a personal history of polyps diagnosed before age 40?” When
asked in succession, these questions captured 75.9% of high-risk individuals, with 100%
specificity. CONCLUSION: We have developed a four-question Colorectal Cancer Risk
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Assessment Tool that can efficiently identify high-risk individuals who may require more
aggressive colonoscopic surveillance than average or moderate risk patients, and may benefit
from referral for genetic evaluation. This tool can be easily incorporated into the routine
pre-procedural evaluation for patients undergoing colonoscopy.
T1094
Oesophageal Cancer Survival According to Route of Diagnosis: Impact of the
United Kingdom ‘Two Week Rule’ and Barrett’s Surveillance in a Tertiary
Cancer Centre
Nick Stern, Neil Kapoor, Richard Sturgess, Keith Bodger
BACKGROUND Oesophageal cancer (OCa) has a high mortality. Surveillance for patients
with Barrett’s metaplasia aims to detect early adenocarcinoma (AdCa). Most cases of O-Ca
are diagnosed at a symptomatic stage. Delayed investigation is cited as a factor contributing
to poor outcomes in the UK. The National Cancer Plan (2000) stipulated a 14-day waiting
time standard for secondary care providers to investigate patients with alarm symptoms
referred from primary care (the ‘two week rule’, TWR). This provided new fast-track services
for patient with suspected cancer. AIMS (1) To compare survival for OCa before and after
implementation of the TWR; (2) To examine survival according to route of diagnosis after
implementation of the TWR, and to compare with outcomes for Barrett’s surveillance; (3)
To determine the proportion of all AdCa detected by surveillance. SETTING University
Hospital serving a population of >330,000, implementing a Rapid Access Upper GI Cancer
Service (RAUGICS) METHODS Using hospital IT systems, a cancer service database (Ref.
1) and casenote review, we audited outcome of all OCa diagnosed during two 2-year periods,
one before (Pre-) and the other after (Post-) service re-organisation. Data for tumour type,
stage, operability and 2-year survival were obtained. For the post-TWR period, route of
cancer diagnosis was designated as: ‘RAUGICS’ (fast-track route, n=3008 referrals to this
service), ‘Other’ (includes non-urgent open access endoscopy, GI clinic and emergency
room) and ‘BarS’ (Barrett’s surveillance, n=420 patients) RESULTS (1) Pre- versus Post-
periods: Cases: 72 v 95; Mean age: 68 v 68 yrs; Surgery with curative intent: 38% v 26%;
2-yr survival: 19.4% v 24.2% (AdCa: 22.5% v 25.4%; Squamous Cell Ca: 16.1% v 25%).
All non-significant. (2) 2-year survival according to route of diagnosis (post-TWR period):
RAUGICS: 18%; Other routes: 30%; and BarS 50%. BarS detected Ca at a rate of 0.49%
per annum (6.5% of all AdCa cases). Conclusions Fast-track service based on alarm symptoms
selects patients with poor 2-year survival (18%). It provides prompt palliation but doesn’t
improve survival. Patients who continued to access care via traditional routes had better
survival (30%), perhaps reflecting earlier stage disease, lack of alarm symptoms or ‘chance’
diagnosis. Highest survival was achieved for surveillance detected AdCa (50%), though
these represent only a minority of AdCa diagnosed in population (6.5%). Screening for
asymptomatic, early stage disease is required if outcomes are to improve for O-Ca. Ref 1.
Kapoor N et al. Gut 2005;54(1): 40-45.
T1095
Prospective Evaluation of Fecal Tumor Pyruvat Kinase Typ M2 (M2-PK) As a
Screening Biomarker for Colorectal Neoplasia
Marc Naumann, Yogesh Shastri, Gerhard Oremek, Ernst Hanisch, Wolfgang Roesch,
Joachim Moessner, Juergen Stein
Introduction: Tumor formation is usually linked to an expansion of glycolytic phosphometa-
bolite pools and aerobic glycolytic flux rates. To accomplish this, tumor cells generally
overexpress a special glycolytic isoenzyme, termed fecal pyruvate kinase type 2 (M2PK).
Here, we assessed fecal M2PK as a screening biomarker for colorectal neoplasia. Fecal M2PK
was compared to fecal haemoglobin (Hb) and colonoscopy which are currently the existing
standards for stool screening and structural evaluation, respectively. Methods: A total of
347 consecutive patients referred for colonoscopy were included. Stool specimens were
collected before purgation, processed appropriately, and quantitatively analyzed for M2PK.
A positive M2PK test was defined by a M2PK level >4 U/g. Experienced colonoscopists
performing the procedure were blinded about the fecal M2PK results. Results: Based on the
pre-established cut-point of 4 U/g of stool, the fecal M2PK assay had a sensitivity of 81.1%,
specificity of 71.1%, PPV of 61.9%, and NPV of 86.7% for subjects with any colorectal
neoplasms. For the subset of subjects with clinically relevant disease, these performance
estimates were 70.3%, 71.1%, 80.6%, and 58.3%, respectively. Fecal Hb concentrations of
stool had a sensitivity of 36.5%, specificity of 92.2%, PPV of 72.9%, and NPV of 71.5%
for subjects with any colorectal neoplasms. For clinically relevant disease, these estimates
were 38.4%, 92.2%, 89.4%, and 46.6%, respectively. Conclusions: Fecal M2PK was found
to be a poor screening biomarker for colorectal neoplasia based on its prospective comparison
against colonoscopy in a subject population at above average risk. We believe that the
marginal performance characteristics demonstrated by the fecal M2PK assay do not warrant
its application as a screening tool for colorectal neoplasia in this clinical setting.
T1096
Impact of a Public Educational Intervention On Colorectal Cancer Screening
Behaviour
Antonio Z Gimeno, Adolfo Parra-Blanco, David Nicolas, Marta Garcia-Velazquez,
Alejandro Jimenez, Enrique Quintero
Background: Low public awareness is an important barrier for increasing participation and
compliance in colorectal cancer (CRC) screening campaigns. Aim: to evaluate the effectiveness
of a public educational intervention for CRC screening in the average-risk population.
Methods: during a CRC screening campaign, 158 subjects from 50 to 79 years were consecut-
ively included. Participants were randomly assigned either to a control or an intervention
group: the control group received written information about CRC and watched a 5 minutes
non-related CRC video-tape, whereas the study group received additional written information
about CRC prevention and watched a 5 minutes educational video-tape that specifically
explained the prognosis of advanced and early CRC, the usefulness of performing a faecal
occult blood test (FOBT) and showed how colonoscopy and polypectomy are performed
under conscious sedation. Prior and after the provider’s visit, every participant completed
a 5 items of a previously validated questionnaire on the knowledge of CRC which included:
age of risk for developing CRC, risk factors, warning symptoms, 5-year prognosis and
incidence. Subjective risk perception for developing CRC barriers or benefits and intention
of screening were also investigated. Finally, every subject received a FOBT and was requested
to return it back in 2 weeks. Results: educational intervention significantly improved the
the 5 items regarding public knowledge of CRC (p<0.001). The intervention group returned
significantly more FOBT than the control group (70% vs 54%, p<0.03). In addition, barrier
scores decreased significantly (p<0.05) only in the study group. Besides, educational interven-
tion was the only independent predictor associated with compliance improvement (OR 1.91
[95% IC, 1.0 to 3.7] p=0.05). Conclusion: educational intervention highlighting the most
important features of CRC significantly reduces the barriers to screening and improves public
awareness and compliance in CRC screening campaigns.
T1097
Efficacy of a New Immunochemical Faecal Occult Blood Test for Colorectal
Cancer Screening in a High-Risk Population
Antonio Z Gimeno, David Nicolas, Marta Garcia-Velazquez, Alejandro Jimenez, Manuel
Hernandez-Guerra, Enrique Quintero
Background: Colonoscopy is empirically recommended as the first choice strategy for colorec-
tal cancer (CRC) screening in the high-risk population, but its efficacy is limited by a low
compliance. Aim: to determine the efficacy of a new faecal occult blood test (FOBT) for
CRC screening in a family-risk population. Methods: 175 first-degree relatives of patients
with CRC were prospectively assessed. On the whole, 38 were excluded because of a personal
history of colorectal neoplasm, inflammatory bowel disease, coagulopathy, having recently
been screened for CRC or age <40 years if the index case was older than 50. All subjects
were invited to receive colonoscopy and 2 FOBT: a qualitative inmunochemical latex-
agglutination test (OC-Light®) and a guayac-based test (Hemo-Fec®). Results: 137 subjects
were included: 106 (77%) returned both FOBT tests and 86 (81%) underwent colonoscopy.
FOBT was positive in 19/106 (17%): 18 to OC-Light® and 1 to both FOBT. Colonoscopy
detected neoplasms in 43/86 (50%): 33/43 (77%) were non-advanced adenomas, and 10/
43 (23%) advanced adenomas (>1cm in size, villous pattern or high grade dysplasia). None
CRC was detected. OC-Light® detected 9/10 (90%) of the advanced adenomas whereas
Hemo-Fec® did not detect any. Considering colonoscopy as the gold standard test, OC-
Light® showed a sensitivity, specificity, positive and negative predictive values for advanced
neoplasia detection of: 90%, 88%, 50% and 98%, respectively. One patient (5%) with OC-
Light®(+) regret colonoscopy. Conclusión: In the family-risk population, FOBT screening
with the qualitative immunochemical latex-agglutination test (OC-Light®): 1) detects most
colorectal advanced neoplasms; and 2) might improve adherence to screening, allowing for
a better selection and saving of colonoscopies.
T1098
An Automated Developed, Quantitative, Immunochemical Fecal Occult Blood
Test Has a Higher Positive Predictive Value for Significant Colonic Neoplasia
Than a Sensitive Guaiac Test
Zohar Levi, Rachel Hazazi, Paul Rozen, Alex Wilkin, Amal Waked, Suzana Fishman,
Yaron Niv
Background: The guaiac fecal occult blood test (G-FOBT) is the standard average-risk
population screening test for colorectal cancer (CRC). An automated-developed, quantitative,
immunochemical fecal occult blood (I-FOBT) is specific for human hemoglobin eliminates
diet restriction and allows choosing a suitable hemoglobin threshold for follow-up colonos-
copy. Aim: To compare the diagnostic yield of a sensitive G-FOBT with an I-FOBT. Methods:
101 asymptomatic patients with positive G-FOBT and 51 patients with negative G-FOBT
underwent colonoscopy either because of the positive G-FOBT or their screening protocol.
All patients underwent 3-day consecutive I-FOBTs prior to colonoscopy using the OC-
Sensor automated instrument (Eiken, Japan) with hemoglobin threshold of 100 mg/ml to
determine positivity; and 3-day G-FOBT with Hemoccult Sensa. The endoscopic end-point
was “significant” neoplasia, CRC or advanced adenoma. Results: Significant neoplasia was
identified in 10 patients; 8 patients had advanced adenoma and 2 patients had CRC.
Sensitivity, specificity, negative and positive predictive values for significant neoplasia were
75.0%, 34.5%, 92.1%, and 11.8%, for G-FOBT and 75%, 94.8%, 96.9%, and 63.1% for
I-FOBT. The number colonoscopies needed to detect one significant neoplasia was 8.5 with
the G-FOBT and 1.5 with the I-FOBT. Conclusions: A quantitative I-FOBT is more specific
than G-FOBT of comparable sensitivity. Thereby, reducing the number of negative colonos-
copies with their associated costs and morbidity.
T1099
Endoscopic Capacity and Manpower Planning in the Netherlands in the Era of
Colorectal Cancer Screening
Jochim S. Terhaar Sive Droste, Mike E. Craanen, Jeroen J. Kolkman, Chris J. Mulder
Background: Currently, there is still debate on the necessity of population screening for
colorectal cancer (CRC) in The Netherlands. One of the main arguments against an endoscopic
screening program is the lack of adequate capacity and manpower. Before embarking on a
nation-wide CRC screening program, it is mandatory to provide a clear insight in the Dutch
endoscopic practice and manpower planning. This study is part of an interim analysis which
will be conducted every five years in the Netherlands. In this way, trends in endoscopic
production and manpower planning can be monitored. Aims: To determine endoscopic
production and manpower planning in the Netherlands and to investigate the ability to
meet the extra endoscopic demand associated with the intended implementation of a CRC
screening program. Methods: A questionnaire was sent to all Dutch endoscopy units (N=
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100) in the spring of 2005. Results: Ninety-eight percent of the units returned the question-
naire. The total number of endoscopies performed in 2004 was 408.982. The total number
of colonoscopies was 116.815, corresponding with 719 colonoscopies per 100.000 inhabit-
ants. The mean waiting time for routine gastroscopy and colonoscopy was 3,0 weeks (range
1-12 weeks) and 5,1 weeks (range 1-15 weeks), respectively. The total number of endoscopists
was 598. Fifty-two percent of the endoscopy units could not manage the projected increase
in the number of colonoscopies related to a CRC screening program, resulting in 1334 to
1641 colonoscopies per 100,000 inhabitants. Conclusions: The quantitative and qualitative
alterations in endoscopic practice will definitely hamper the implementation of a CRC
screening program, due to the lack of adequate capacity and manpower. Although FOBT
based screening may temporarily alleviate the capacity problems, it is a clearly inferior
screening modality compared to colonoscopic screening. Hence, rigorous cost-effectiveness
studies as well as adequate insights in the current and future endoscopic capacity and
manpower will hopefully persuade the Dutch central government together with the healthcare
insurance companies to create the opportunities and to provide the funding to realize the
increase in colonoscopic capacity and manpower necessary for a successful, large-scale
implementation of a nation-wide CRC screening program.
T1100
Primary Care Physicians Knowledge and Practices Regarding Colorectal
Cancer Screening
Mohamad Eloubeidi, Michele Shipp, Renee Desmond, Tykeysha Boone, Norman
Weissman, Marion Nadel, Mona Fouad
Background: Colorectal Rectal Cancer (CRCA) screening with Flexible sigmoidoscopy (FS)
is associated with decreased mortality. Alabama Primary care physicians’ (PCPs) knowledge
and practices regarding CRCA screening are unknown. In particular, no data exist regarding
training and practices of PCPs for FS to screen for CRCA. Objectives : 1) To gain understanding
of Alabama PCPs knowledge and practices regarding CRCA screening, 2) to assess the need
for PCPs to a) gain additional training in flexible sigmoidoscopy (FS) and b) to implement
it in their offices. Methods: Self-administered questionnaires were mailed to 1916 PCPs in
Alabama. Data were sought on personal demographics, practice characteristics, CRCA screen-
ing knowledge and practices as they pertained to fecal occult blood testing (FOBT), colonos-
copy, double contrast barium enema (DCBE) and FS. The questionnaire also addressed
issues of physicians’ training in FS, the use of FS within practices, and physicians’ willingness
and ability to perform FS in their practices once trained. Results: Out of 1916 , 660 (34%)
PCPs returned completed questionnaire. Sixty-one percent of the participants practiced in
urban locations, while 39% practiced in rural areas. Sixty-four percent recommended FOBT
testing to their patients. In contrast, only 16% (95 % CI: 13.2, 18.8) of the physicians
recommended FS . Sixty-six percent recommended colonoscopy, while only 8% recom-
mended DCBE. Sixty-three percent of PCPs received prior FS training and the majority of
those trained received it while in residency training (76%). Of those, only 21% performed
more that 25 FS procedures during training. Only 17% (95% CI: 14.2, 19.8) reported actually
performing FS in their offices. Patients’ non-compliance, cost to conduct the procedure, lack
of practice time, cumbersome regulations related to endoscope disinfection, and difficulty
in finding and training assistants were among the reported obstacles preventing PCPs from
performing FS in their offices. Most of the physicians who did not perform FS reported that
training is not available to them (49%). Thirty-seven percent reported interest in pursuing
training were it available. Eighty-seven percent of those interested in training reported that
they would perform FS if adequately trained. Eleven physicians already enrolled in the
hands-on-training program. Conclusions: Most survey respondents recommend adequate
screening tests for CRCA. However, only a minority recommend FS as a screening procedure.
Very few PCPs perform FS currently in their office. Whether providing these PCPs with
training opportunities in FS will increase FS utilization remains to be seen.
T1101
Cancer Investigation At Peking University Using Fourier Transform Infrared
(FT-IR) Spectroscopy. FT-IR Separation of Gastric Cancer from Normal
Stomach Using Chemometrics
Q-B Li, X Li, Y-Z Xu, Roger D. Soloway, X-F Ling, J-S Wang, G-J Zhang, X-S Zhou, J-S
Shi, B-B Wang, Q-H Pan, J-G Wu
Background: The ability to accurately identify cancer during an operation can facilitate the
proper surgical procedure at the time of the original surgery. We have previously reported
the ability to utilize portions of the infrared spectra to separate gastric cancer from normal
stomach. This required the involvement of an expert infrared spectroscopist. To simplify
and automate this process, we have employed a series of computer based chemometric
techniques to the spectra to make the separation more facile and more accurate. Aim: To
improve FT-IR identification of gastric cancer from normal stomach by modifying spectra
using chemometric techniques. Methods: Spectra were obtained using application of the
biopsies from 37 cases of cancer and 26 normal gastric samples to an attenuated total
reflectance (ATR) crystal attached to a Nicolet Magna 750 H spectrometer. To use all of the
spectral information, spectra were smoothed and then subjected to Resampling Half-Mean
and standard normal variate methods. Samples were cross-validated using a KNN method.
These programs were followed using Matlab 6.5 statistical package. Results: Among 37
samples from cancer patients, 36 were correctly diagnosed, one was judged to be benign.
Among 23 samples from normal stomach 19 were correctly diagnosed while 4 were thought
to be malignant. The sensitivity of cancer detection was 98% while the specificity was
83%. Steps in the process will be presented. Conclusion: Applying chemometric statistical
techniques to FT-IR spectra of biopsies improves and automates the spectral determination
of cancer. The technique is highly sensitive but there were 17% false positive determinations.
***Project supported by State Key Project for Fundamental Research of MOST
(2002CCAQ01900), National Natural Science Foundation of China (No. 30371604) and


















Patient Experience and Preference of Conventional Colonoscopy Versus
Stronger High Field Magnetic MR-Colonography (3-TESLA): A Feasability
Study
Juergen M. Gschossmann, Bettina Saar, Corinna A. Messikommer, Wojtek Bielecki,
Christoforos Stoupis, Peter Netzer
BACKGROUND: Overall, conventional colonoscopy (CC) is still the gold standard for colorec-
tal cancer screening. However, virtual colonoscopy has reached a technical level to become
an increasingly attractive alternative for these questions given the non-invasive nature of the
respective radiological imaging techniques. While comparative studies of CT colonography
versus CC suggest a patient preference for radiological examination, data on patient assess-
ment of CC versus MR colonography (MRC) are missing. AIMS: to analyze and compare
experiences of and preferences for CC versus MRC in patients scheduled for elective endos-
copy of the lower gastrointestinal tract in a tertiary referral center. METHODS & PATIENTS:
In this feasibility study, 55 pts (mean age 58 yrs, 19-88 yrs, 21 females) were included. At
the day of the scheduled endoscopy, all pts underwent first MRC with contrast enema,
followed by CC. During CC, analgo-sedation (pethidin/midazolam) was only given upon
patient request. To assess patient perception of both examinations, interviews were performed
at two occasions: a) before discharge from the endoscopy unit (time point A) and b) 4-6
weeks after discharge (time point B). Main parameters of the assessment were “overall
preference”, “pain”, “discomfort” and the question which technique they would prefer for
re-examination of the colonic frame (only time point B). RESULTS: At time point A, 24/55
(44%) pts preferred CC to MRC, the same number of patients preferred MRC, while 7
(12%) had no preference. Twenty-nine of 55 (53%) pts received analgo-sedation for CC.
Fourteen of these pts were in favour of MRC while 13 pts preferred CC. The analysis of
the parameter “pain” showed that 28 (51%) pts experienced more pain during CC than
during MRC while for 11 (20%) pts MRC was more painful. Sixteen (29%) pts did not
notice any difference. As to “discomfort” associated with the examinations, 21 (38%) pts
regarded MRC more uncomfortable than CC whereas for 16 (29%) pts CC was associated
with more discomfort. Similarly, the intensity of pain during CC was higher compared to
MRC while the intensity of discomfort was higher during MRC. At time point B, 28/55 (51
%) of the pts preferred MRC to CC while 21/55 (38%) chose CC as preferred examination
technique. CONCLUSION: Directly after the examinations, patient satisfaction was similar
for MRC and CC with analgo-sedation in case of painful examination. Whereas CC was
more painful, MRC was more uncomfortable. In the follow-up interview, a tendency towards
higher patience acceptance of MRC compared to CC was noted.
T1103
Oesophageal Cancer: How Reassuring Is a Negative Endoscopy in the Last 3
Years?
Benjamin Colleypriest, Peter Marden, Sarah Bailey, Aram Fard, John Linehan
Introduction Oesophageal cancer carries a grave prognosis with a 5-10% 5 year survival.
The incidence of oesophageal cancer has increased rapidly over the last 30 years. This
corresponds to an increase of 8% per year and is thus the fastest growing cancer in the
western world. Symptoms of early upper GI cancer are non-specific and many patients may
be referred for endoscopy at this stage. The aim of this study was to look at the current
frequency of normal investigations during a 3 year period prior to a diagnosis of oesophageal
cancer in a hospital that serves a population of 500 000 people. A similar study completed
in Bath for colorectal cancer found that 4% of patients had had a previously normal
investigation within the last 3 years. Methods All patients with a new diagnosis of oesophageal
cancer, including tumours of the gastro-oesophageal junction, during a 3.5 year period
(2001-2004) were identified. Records were examined to find patients who, during the 3
years prior to diagnosis, had had either a barium swallow or endoscopy. The results of all
previous investigations during the three year period were recorded along with patient
demographics. Results 180 patients, 67% males and 33% females, were found with a new
diagnosis of oesophageal cancer. The majority of tumours found were adenocarcinoma on
histology. 17 patients had been investigated with a barium swallow. Of these tests 15 were
abnormal and prompted an endoscopy. Both of the normal barium swallows were 21 months
before the diagnosis. 33 patients were found to have had endoscopies in the 3 years prior
to diagnosis. Of these 18 prompted repeat endoscopy, 6 were part of a Barrett’s surveillance
program and 7 were normal (6-36 months prior to diagnosis). Conclusion This study sought
to answer the question, ‘How reassuring is a normal investigation within the last three years?’
We found a low but significant miss rate for upper gastrointestinal investigations in a three
year period prior to diagnosis. 5% (3.9% endoscopy 1.1% barium) of patients presenting
with oesophageal cancer had been investigated. Oesophageal cancer is a rapidly growing
tumour that often presents late with no previous symptoms. The rates of diagnosis of early
cancer in the UK are lower than is other countries. Does this represent differences in
techniques or the lack of a screening program for upper GI cancer? This low but significant
miss rate suggests that patients who develop new symptoms need repeat investigation.
Results
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T1104
Characteristic of Colorectal Neoplasm in Symptomatic Asian Population:
Prospective Survey of 4,681 Consecutive Patients Undergoing Colonoscopy
Abdul Aziz Rani, Murdani Abdullah, Aru W. Sudoyo, Sung J. Yoseph, The Asia-Pacific
Working Group on Colorectal Cance For
Background: The incidence of colorectal cancer is rising in some Asian countries. However,
there is scarcity of data on prevalence and characteristics of colorectal neoplasia in Asian
region. Aim: To determine the prevalence and characteristics of colorectal neoplasm in
consecutive symptomatic subjects undergoing colonoscopic examinations in different Asian
countries Method: From July to 2004 to September 2005, we conducted a prospective
survey at 17 centers from 11 Asian cities. Participating centers entered data into a computer-
ized registry from consecutive subjects who underwent colonoscopic examinations. The
registry was designed based on CORI database of the ASGE. We included symptomatic
subjects older than 16. Those with a history of previous colorectal resection, with a history
of colonoscopy within 5 years, with incomplete colonoscopy or indeterminate histological
results were excluded. Those who underwent surveillance colonoscopy for inflammatory
bowel disease were also excluded. Advanced neoplasm was defined as adenoma larger than
10 mm, having >25% villous features, or high grade dysplasia and invasive carcinoma.
Result: A consecutive of 4,681 subjects (mean (SD) age 54.8+15.2 yrs; men 50.2%) were
studied. 132 (2.8%) had a family history of colorectal cancer(defined by the first degree
relatives being affected). The ethnicity was predominantly Chinese (2373, 50.7%) and Korean
(1012, 21.6%). Indications for colonoscopy were abdominal pain (20.0%), rectal bleeding
(15.0%), change in bowel habit (13.5%), gastrointestinal bleeding (8.1%), anemia (8.1%),
diarrhoea (7.5%) and others. Predicting factors for prevalence of proximal advanced neoplasm
in symptomatic and distal polyp-free patients were increasing age and Korean (p=0.004)and
Japanese (p=0.007)ethnic groups. Age groups 60-69 years (OR 4.8,95%CI:1.8-12.7), 70-
79 years (OR 6.7, 95%CI:2.5-18.0), 80 year (OR 10.3,95%CI:3.3-32.5) showed significant
difference in prevalence of proximal advanced neoplasms. Prevalence of proximal advanced
neoplasm according to the distal finding were 11.0% (RR3.8,95%CI:2.4-5.9) after adjusting
for age and sex Conclusion: There is an ethnic variation in prevalence and characteristics
of colorectal neoplasms in the Asian population
Prevalence and location of neoplasm are listed in table 1.
T1105
Acid Suppression and Upper Gastrointestinal Endoscopy Prior to Diagnosis in
Patients with Adenocarcinoma of the Esophagus
Eva van Soest, Peter D. Siersema, Jeanne P. Dieleman, Miriam C. Sturkenboom, Ernst J.
Kuipers
Background: The incidence of the adenocarcinoma of the esophagus (ACE) is rapidly increas-
ing. The main risk factors for ACE are gastroduodenal reflux and Barrett’s esophagus (BE).
Gastroduodenal reflux symptoms are usually treated with H2-receptor antagonists (H2RA)
or proton pump inhibitors (PPIs), and if persistent, further investigated by upper gastrointesti-
nal (GI) endoscopy. There is limited knowledge how these resources are being used in
patients at risk for ACE. Aim: To assess the use of medical resources in the medical history
of ACE patients prior to diagnosis. Methods: We identified all ACE cases diagnosed between
1996 and 2003 within the Integrated Primary Care Information database, a general practice
research database containing the complete longitudinal electronic medical records of more
than 600 000 persons. Rates of H2RA use, PPI use and performed upper GI endoscopy in
the 3 years prior to ACE diagnosis were examined. Results: In total, 51 incident ACE cases
were identified with a mean follow-up of 4.1±1.8 years prior to diagnosis. Thirty-nine (76%)
were males and mean age at diagnosis was 67.7±9.6 years. In the 3 years prior to ACE
diagnosis, 9 patients (26%) with sufficient follow-up (n=34) underwent diagnostic gastros-
copy, which was in all but one performed in the last 12 months prior to ACE diagnosis.
Only one of these patients was diagnosed with BE, which was suspected for early malignancy.
In the 3 years prior to ACE diagnosis, 18 (53%) used acid suppressive drugs (22% used
H2RAs, 67% PPIs, 11% both).The proportion of patients using acid suppression was 38%
in the 3rd and 29% in the 2nd year before ACE diagnosis, but increased to 57% in the 1st
year before ACE diagnosis. Conclusion: The use of medical resources is limited in patients
at high risk for ACE. Only a small proportion is previously studied by upper GI endoscopy,
and those who undergo endoscopy are often not diagnosed with BE. The majority of patients
developing ACE have not used acid suppressive drugs in the 2nd and 3rd year before ACE
diagnosis, which may be related to a relatively low frequency or severity of symptoms. The
use of resources increases in the last year before ACE which is probably due to early
symptoms of cancer development.
Number of ACE patients using medical resources prior to diagnosis
T1106
Ethnic Differences in the Prevalence of Advanced Colorectal Neoplasia in Asia
Ida Hilmi, Kl Goh, Jjy Sung, Wk Leung, J Lau, Kg Yeoh, L Ho, Mh Chen, Cj Li, G
Makharia, R Tandon, M Abdullah, R Fujita, Jy Kim, Hj Kim, Sk Yang, Wh Kim, Ti Kim,
Js Byeon, Tan J, E Ong, J Sollano, Cw Wang, Dc Wu, P Kongkam
Introduction In the Asia Pacific region, colorectal cancer is the fastest emerging GI cancer.
However, there are marked ethnic differences in Asia and in this multicenter collaborative
study we sought to determine the prevalence of advanced neoplastic lesions (ANL) amongst
the different races in the region. Methods An Asia-Pacific Working Group on Colorectal
Cancer was formed in September 2003 to study the epidemiology of colorectal neoplasia
in the region. Consecutive colonoscopy records from July 1 2004 to December 31 2004
were obtained from 17 centres in 11 cities (Bangkok, Delhi, Guangzhou, Hong Kong, Jakarta,
Kuala Lumpur, Manila, Seoul, Singapore, Taipei, Tokyo). We used a common database
modified from the CORI of American Society of Gastrointestinal Endoscopy. Data collected
includes indication, clinical data, findings and histology. ANL was defined as adenomas
>1 cm, severe dysplasia, >75% villous feature or carcinoma. Results 7290 consecutive
colonoscopies were carried out, of which 5474 with complete data were analyzed. Advanced
colorectal neoplasms were found in 448 of cases (7.8%). The prevalence in each ethnic
groups was as follows: Japan 18% (32/177) Korea 9.9% (143/1441) Chinese** 7.2% (203/
2831) Thai 5.9% (18/306) Malay* 5.7% (17/297) Fillipino 5.1% (19/371) and Indian 4.3%**
(11/257). Conclusions High prevalence races for ANL were Japanese, Korean and Chinese
whereas the low prevalence races were Thai, Filipino, Malay and Indian. This suggests that
there are host genetic or environmental factors specific to the racial group in the pathogenesis
of ANL. Ethnic differences have major implications in screening strategies for CRC in Asia.
* Malay and Indonesian were grouped together as they belong to the same racial stock.
**Indian and Chinese patients from different Asian countries were grouped together
With Malay as reference race
T1107
Detection of Aberrant Fecal DNA Methylation May Be a Useful Screening
Strategy for Asymptomatic Gastrointestinal Neoplasia
Nagahide Matsubara, Takeshi Nagasaka, Hiromi Sasamoto, Takuyuki Uchida, Ajay Goel,
Richard C. Boland, Noriaki Tanaka
BACKGROUND Current noninvasive screening tools for colorectal neoplasia remain ineffect-
ive because of poor sensitivity and specificity. The aim of this study was to develop a more
sensitive and accurate screening strategy for detecting gastrointestinal neoplasia through
analysis of fecal DNA methylation. METHODS We used six genes as potential markers and
investigated the methylation status of the promoters in 755 gastrointestinal specimens,
including neoplastic tissues and normal epithelium of the colorectum and stomach by using
a simplified assay that does not require the pre-extraction of DNA from the stool samples.
We examined the methylation status of the six genes in 166 stool samples; 33 samples came
from patients with adenocarcinoma, 30 with advanced polyps, 39 with minor polyps, and
64 without neoplasia using a newly developed bisulphite modification technique. RESULTS
Promoter methylation was observed in all the gastrointestinal specimens and was a gradual
increase in the number of genes methylated from normal to cancer, both in the large intestine
and stomach. As similar trend was observed in the stool samples, these findings provide
proof of principal that gene methylation in stool can be used to detect gastrointestinal
neoplasia. Receiver-operating-characteristic (ROC) curves obtained from the fecal DNA
methylation assay offered various cut-off values using six methylated genes to differentiate
between the presence or absence of carcinoma, of carcinoma and advanced polyps, or of
carcinoma, advanced and minor polyps. CONCLUSIONS The detection of early, asymptom-
atic gastrointestinal neoplasia can be facilitated by the analysis of fecal DNA methylation
status.
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T1108
Performance of Capsule Endoscopy in Obscure Intestinal Bleeding - A Multi-
Center Outcome Study
Joerg G. Albert, Mathias Dollinger, Leonore Hahn, Detlef Heinig, Konrad Schoppmeyer,
Heiner Porst, Rainhard Lorenz, Mathias Plauth, Karel Caca, Wolfgang E. Fleig
Introduction: Capsule endoscopy (CE) has proven reliable in establishing bleeding sources
in the small bowel in obscure intestinal bleeding. Its impact on therapeutic and long term
outcome in defined patient groups is unknown. Methods: Patients in whom CE investigations
were done for obscure intestinal bleeding (bi-directional endoscopy without findings) in
five study centers between Dec 2001 and Dec 2004 have been included in this longitudinal,
prospective cohort study. Thereby, 299 investigations in 291 patients were identified and
293 investigations in 285 included. Results: A bleeding source was detected in 224 cases
(76.5%). CE was diagnostic in 177 (79.0%) of these cases, and repeated or additional
investigations resulted in findings in 47 cases (21.0%), and therapeutic measures (endoscopic
intervention, surgery, and medical) were initiated in 142 cases (48.5%); (table 1). In 44
cases (17.9%), patients were re-admitted due to digestive bleeding. Angiodysplasias, age
older than 60 years, anticoagulants, and prior bleeding events were the main determinants
to predict bleeding relapses during follow-up (table 2). Capsule retention occurred in four
cases (1.36%) and surgical removal of the capsule was necessary in three cases (1.02%).
Conclusion: Age, anticoagulants, treatment, and diagnosis determine the occurrence of
bleeding relapses in obscure intestinal bleeding. Capsule endoscopy mainly contributes to
the diagnosis, and might therefore be regarded as the first line diagnostic method in intestinal
bleeding following negative bi-directional endoscopy.
Table 2. Influence on recurrent bleeding events and subsequent hospital admission (RR -
relative risk; n.s. - not statistically significant)
Table 1. Influence on therapeutic measures (RR - relative risk; n.s. - not statistically signi-
ficant).
T1109
Biochromoendoscopy: Molecular Imaging with Capsule Endoscopy for
Detection of Polypoid Lesions in the GI Tract
Howard Zhang, Douglas Morgan, Gerald Cecil, P. Kay Lund
BACKGROUND: Capsule endoscopy (CE) is a minimally invasive technology designed to
image the GI tract, primarily the small intestine. The ability of the current white-light CE
imaging to discriminate different types of polyps is limited. Molecular imaging utilizing
probes activated by neoplasm biomarkers, such as protease activated Near Infrared Fluores-
cent (NIRF) probes, is a potentially powerful tool to detect and distinguish premalignant
and malignant lesions. In this study, we tested whether CE could be integrated with NIRF
molecular probes to detect premalignant lesions. METHODS: A ProsenseTM680 (VisEN
Medical) probe activatable by proteases up regulated in polypoid lesions was used in the
ApcMin/+ mouse model of polyposis. ApcMin/+ mice (90 days of age) were injected intravenously
with ProsenseTM680 (2 nmol Cy 5.5 per animal). Animals were sacrificed 24 hours later
and the entire intestine was dissected. In a custom built light-tight chamber, the dissected
murine intestine was imaged to capture polypoid lesions with CE (Given Imaging, PillCam
SB) under white light and near infrared light. For NIRF imaging, a near-infrared filtering
device with excitation (680 nm) and emission (700 nm) filters was combined with CE.
Resulting CE images were captured, transmitted, and recorded in usual fashion. This molecu-
lar imaging of the polypoid lesions was further verified by the standard NIRF detecting
device, Xenogen (IVIS) Imaging System. In addition, positive and negative controls were
imaged with CE using ProsenseTM680 samples added to buffer with and without trypsin
on glass slides. RESULTS: NIRF images of polypoid lesions in the intestine of ApcMin/+ mice
were readily visualized by CE molecular imaging. White-light images obtained by CE through
the light-tight chamber were similar in quality to those from human applications. NIRF
images captured by CE revealed discrete light spots on the control slides only in solutions with
trypsin. CONCLUSION: Biochromoendoscopy proof of principle has been demonstrated.
Polypoid lesions were detected with CE under near infrared light using a molecular probe
specific for neoplastic intestinal lesions. Molecular imaging with capsule endoscopy may


















An Integrated Approach to Iron Deficiency Anemia: Role of Videocapsule
Endoscopy and CT-Enteroclysis
Angelo Milano, Chrysanthi Balatsinou, Francesco Laterza, Maria Pia Caldarella, Antonella
Filippone, Nicola Genovesi, Flora Sacco, Franco Cuccurullo, Matteo Neri
Background: Iron deficiency anemia (IDA) is frequently encountered in clinical practice.
Its main causes in developed countries is gynaecological in pre-menopausal women and
gastroenterological in men and post-menopausal women. However 30% to 40% of patients
usually remain undiagnosed even after extensive evaluation. Aims: i) to evaluate the efficacy
of a systematic approach to IDA with a standardised diagnostic algorithm including ileoscopy
and video capsule Endoscopy (VCE) in a large population of patients in whom extra-digestive
causes of anemia have been excluded, and ii) to compare the diagnostic yield of VCE versus
CT-enteroclysis. Materials and methods: Consecutive patients with IDA underwent upper
endoscopy and colonoscopy plus ileoscopy. Endoscopy negative patients were further evalu-
ated by small bowel follow- through and CT-enteroclysis and, if negative for stricture, by
VCE. Out of 189 patients evaluated 144 were diagnosed at upper endoscopy (40 peptic
ulcers, 20 erosive gastritis, 1 severe erosive esophagitis; 1 Cameron’s lesions, 5 atero-venous
malformations, 3 cancers, 5 celiac disease) and lower Endoscopy (4 diverticular disease, 12
angiodysplasia, 22 cancers, 4 IBD, 17 Haemorrhoids, 10 Bleeding polyps). In 45 patients
(26 M, 19 F; age 55, range 11-81) negative at gastrointestinal endoscopy, mean haemoglobin
levels were 9.2 gr/dl (range 6-12) and ESR, CPR, fibrinogen and orosomucoid were negative.
Overall the diagnostic rate by VCE was 77,8% versus 22,2% by X-ray techniques (p<0,001).
Interestingly, VCE was superior to entero-TC when mucosal lesions were found (angiodyspla-
sia: 100% vs 0%; small bowel Crohn’s disease: 88% vs 50% respectively), while a comparable
diagnostic accuracy was achieved on neoplastic diseases (both 85,7%). Overall this diagnostic
algorithm in 189 patients allowed a certain diagnosis in 96%. Conclusions: This integrated
diagnostic approach which includes endoscopy plus ileoscopy, VCE and CT-enteroclysis is
highly efficient in the evaluation of patients with IDA of digestive origin. VCE is superior
to CT-enteroclysis when angiodysplasia or Crohn’s disease occur.
T1111
Double Balloon Enteroscopy - A Useful Diagnostic Tool? Analysis of a Large,
Non-Selected Cohort of Patients Regarding Success and Complications of
Double Balloon Endoscopy
Christian Maaser, Hansjoerg Ullerich, Karin Menzel, D.R. Domagk, Andreas Luegering,
Wolfram Domschke, Torsten Kucharzik
Aim: Double balloon enteroscopy has become one of the most innovative diagnostic new
tool for the examination of the small bowel also allowing therapeutic interventions. The aim
of this analysis was the evaluation of the success on one hand and potential risks on the
other hand in a large cohort of non selected patients of one endoscopic center. Methods:
We evaluated all examinations performed in our center starting November 2004 until mid
November 2005, which resulted in a total of 215 examinations. Endoscopies were performed
with the double balloon enteroscope Fujinon EV EN-450F. The examinations were performed
by a team of 4 experienced endoscopists. Results: Indications for double balloon endoscopy
have been obscure/occult gastrointestinal bleeding in 94 patients, suspected Crohn s disease
in 18, strictures in 13 and suspected neoplasias in 14 patients. Overall we detected angiodys-
plasias in 32 cases, of which the most prominent ones were successfully treated with
argonplasma coagulation in 17 patients. In 9 out of 18 cases suspected Crohn s disease was
verified endoscopically and histologically. In 10 patients previously unknown neoplasias were
detected. These included a tubulo-villus adenoma, a carcinoid tumor, three gastrointestinal
stromal cell tumors (GIST), and intramural neurofibromatosis. Furthermore in 2 patients
Peutz-Jeghers polyps were successfully resected during double balloon enteroscopy. In
addition to the examination of the small bowel we used the double balloon technique to
reach the Papilla vateri successfully in 5 patients that presented with a Y-Roux anastomosis
and cholangitis. By using the double balloon technique we were able to successfully perform
papillotomies and dilatations leading to successful drainages of the bile ducts. Regarding
complications we recorded minor symptoms such as postinterventional abdominal pain or
mildly, temporarily elevated temperatures in about 10% of all patients. However non of the
double balloon enteroscopies led to any major complications, e.g. perforations, bleeding or
pancreatitis, Conclusion: Double balloon enteroscopy in this large, non-selected cohort
showed to be an effective and save procedure. The clear advantage of this new technique
is the possibility for therapeutic interventions, e.g. coagulation of angiodysplasias, polypec-
tomies and balloon dilatation of Crohn s disease strictures.
T1112
Clinical Outcome of Patients Submitted to Capsule Endoscopy for Suspect
Crohn’s Disease
Carlo M. Girelli, Paola Porta, Francesco Rocca
Capsule endoscopy (CE) has a diagnostic yield greater than radiology in the detection of
subtle inflammatory changes of the small bowel mucosa, but their clinical significance is
uncertain because of the lack of long term follow up studies. Aim of the study was to follow
a cohort of patients with suspect Crohn’s disease of the small bowel (SBCD) until a well
established diagnosis in order to detect the clinical meanings of CE findings. From April
2002 to March 2005, we submitted to CE twenty-seven patients (11 males, 40±18 yrs) with
abdominal pain and diarrhea lasting more than three months, and at least one of the following
features: anemia, weight loss, fever, extra-intestinal manifestation(s) of inflammatory bowel
disease. All subjects underwent an unremarkable pan-endoscopy, serology for celiac disease
and intestinal radiologic studies inconclusive for small bowel abnormalities. By CE findings,
patients were assigned to three groups; group A, severe stricturing lesions mandating surgery;
group B, moderate inflammatory lesions further investigated by invasive means; group C,
minimal inflammatory changes or normal findings (including lymphoid hyperplasia of the
terminal ileum (LH)), clinically observed every three months until a final diagnosis was
reached. Small bowel inflammatory lesions were found in 13 of 27 patients (diagnostic yield
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48%). Three patients underwent surgery (group A) and SBCD was confirmed in two; the
remainder had ileal adenocarcinoma, but was considered a true positive anyway. Group B
consisted of five patients and SBCD was histologically confirmed in 4 (one false positive;
ulcer and erythema of the terminal ileum not confirmed at ileoscopy and final diagnosis of
relapsing appendicitis). Finally, group C consisted of nineteen patients with a median follow
up of 21 months (range 15-27); within those with positive findings at CE, SBCD was
confirmed by clinical improvement to oral budesonide in seven of 8; the false positive one
had jejunal erythema and a final diagnosis of splenic lymphoma. Only one patient with LH
later developed overt ileal SBCD (one false negative). Sensitivity, specificity, positive and
negative likelihood ratio were 93%, 84%, 5.8 and 0.08, respectively. Assuming a pre-test
probability of disease of 40%, CE determined a post-test probability of 79%. In our selected
cohort, CE was a sensitive tool for the detection of small bowel abnormalities, doubling the
pre-test probability of having a structural small bowel disease. Focal erythema and luminal
debris may lower CE specificity. Patients with stricture are surgical candidates, whereas
those with LH may later develop SBCD and a careful follow up is warranted.
T1113
Wireless Capsule for Esophageal Endoscopy: Comparison with Upper GI
Conventional Endoscopy
Sylvie Sacher-Huvelin, Emmanuel Coron, Emmanuel Ben Soussan, Franck Cholet, Michel
Antonietti, Michel Robaszkiewicz, Herve Lamouliatte, Marc Le Rhun, Jean Paul Galmiche
Wireless videocapsule endoscopy is a new technology that has been successfully applied for
small bowel exploration. A new device (Pillcam ESO, Given Imaging) is currently in develop-
ment for the investigation of esophagus. We report our preliminary experience of Esophageal
Capsule Endoscopy (ECE) in patients referred for reflux symptoms or dyspepsia. The study
is conducted prospectively, with conventional upper GI endoscopy as the “gold standard”.
Patients : 27 patients recruited in 4 academic centers have been prospectively enrolled after
obtaining written informed consent. ECE was systematically swallowed before (from 30
minutes to 24 hours) upper GI endoscopy. Patients with severe dysphagia or symptoms
suspect of bowel obstruction were excluded. The data recorded by ECE were downloaded
on a computer and interpreted using a specific software (RAPID 3). Data were interpreted
blindly by the investigator who red ECE and the gastroenterologist who performed upper
GI endoscopy. The sensitivity analysis was done on an intention-to-diagnose basis (e.g
inability to swallow ECE considered as diagnostic failure). Results : 27 patients were enrolled.
Seventeen had reflux symptoms and 10 dyspepsia (13 men/ 14 women, mean age 53 years -
range 22-75). Only 50% of patients were on treatment, the remainders being “naïve” subjects
for endoscopy. All patients were able to swallow ECE, but in 3 cases imaging was incomplete
regarding distal esophagus. In one case, a technical failure was responsible for loss of signal.
Barrett’esophagus was detected by ECE in 6 out of 8 patients (comparison with upper GI
endoscopy). The 2 false negative cases were mainly short segments. All 6 mild/moderate
esophagitis were detected by ECE. In one patient with grade C esophagitis at upper GI
endoscopy, ECE did not reach the distal esophagus. In 2 other patients, ECE detected mild
erosions not confirmed by upper GI endoscopy. Hiatus hernia (present in 12 patients at
upper GI endoscopy) was only found in 6 subjects by ECE. Gastric erosions present in 3
patients at upper GI endoscopy were also seen by ECE in 2 cases. No neoplasia was detected
by both upper GI endoscopy and ECE. Conclusions : This preliminary study confirms the
feasibility and tolerability of this ECE. Provided these results could be confirmed on a larger
scale, ECE could represent a first-line investigation for the detection of Barrett’esophagus
and esophagitis. However, the technique probably lacks sensitivity for short segment Barrett’s
and does not accurately detect the presence or absence of Hiatus hernia. The study is ongoing
and results will be updated if abstract is selected for presentation.
T1114
Comparative Study of Capsule Endoscopy, Mesenteric Angiography and
Double Balloon Enteroscopy in Obscur Gastrointestinal Bleeding: Preliminary
Results
Begona Gonzalez-Suarez, Sara Galter, Jorge Carlos Espinos, Alfredo Mata, Carlos Castano,
Jordi Ortiz, Candid Villanueva, Jordi Villalba, Adolfo Gallego, Edgar Ayala, Joaquim
Balanzo
Introduction: Obscure gastrointestinal bleeding (OGIB) is cause of different studies, generat-
ing a high cost in the health system. That’s why it would be useful to find out which is the
most sensitive and efficacy test. Aims: 1. To compare the diagnostic yield of capsule endoscopy
(CE) with mesenteric angiography (MA) in the diagnosis of the OGIB. 2. To compare the
result of CE with double balloon enteroscopy (DBE). Patients and Methods: From March
2004 until November 2005, patients with OGIB (non-conclusive upper endoscopy and
colonoscopy) were included. These patients were submitted to an emergency mesenteric
angiography and a capsule endoscopy. Fron August 2005 until now mesenteric angiography
has been substituted for a DBE. Results: 33 patients were included (17 men, 16 women),
with a median of age of 70.8 +/- 12.1 years. In 4 patients capsule endoscopy remained in
the stomach and small bowel couldn’t be visualized. Emergency mesenteric angiography
wasn’t performed in 6 patients because of technical problems. CE was diagnostic in 25/33
patients (75%) observing small bowel lesions. 21 of the 27 mesenteric angiography done
were described as normal and only in 4 patients we found lesions responsible of the bleeding
(14.8%), that were intestinal angiodisplasias in all the cases. Until now we have included
11 patients in the study with double balloon enteroscopy (5 men, 6 women). CE was
diagnostic in 90% of patients (1 patient had CE retained in stomach during 8 hours). DBE
diagnosed also 90% of patients, coinciding with CE and we were able to perform endoscopic
therapy successfully in 81% of cases (9/11 patients). We have not had any complications
for the moment. Conclusions: 1. Capsule endoscopy is superior to mesenteric angiography
in the study of the OGIB (75% vs 14.8%, p < 0.001). 2. Double balloon enteroscopy is an
emergent procedure with a high sensibility detecting lesions in small bowel (90%) but we
need more prospective and randomized studies to evaluate these findings.
T1115
Minimally Invasive Measurement of Intestinal Edema Using An Impedance
Analyzer Circuit
Ravi S. Radhakrishnan, Kunal Shah, Hasen Xue, Frederick A. Moore, Norman W.
Weisbrodt, Brijesh S. Gill, Charles S. Cox
Acute intestinal edema has been shown to adversely affect intestinal transit, permeability,
and contractility. Current resuscitation modalities, while effective in reversing shock, are
associated with development of acute intestinal edema. Exact knowledge of levels of tissue
edema would allow clinicians to monitor intestinal tissue water and may help prevent the
detrimental effects of edema. While measurement of tissue edema is possible, there is no
minimally invasive method to measure intestinal tissue water. We sought to develop a tissue
impedance analyzer to quickly measure tissue edema without the need for invasive biopsy.
Methods: A BK Precision Function Generator provided the oscillating voltage input, which
was then fed into a voltage controlled current source (VCCS). Next, a Tektronix 2245 100
MHz oscilloscope measured the voltage output across any load supplied by the VCCS and
a resistor was added to the circuit to create a constant current. Rats (270g - 330g) were
randomized to three groups: sham, mild edema (ME, 80 cc/ kg of NS resuscitation), and
severe edema (SE, 80 cc/kg of NS resuscitation with mesenteric venous hypertension).
Intestinal edema was measured by wet to dry tissue weight ratio (W/D). Bowel impedance
was measured and converted to capacitance using a standard curve. Results: Acute intestinal
edema causes a significant increase in bowel capacitance. A linear correlation between tissue
water and capacitance was established indicating that bowel capacitance can be used to
predict tissue water concentration (Fig. 1). Conclusion: Using an impedance analyzer circuit,
it is possible to measure intestinal edema reliably, quickly, and minimally invasively. This
may prove to be a useful tool in the resuscitation of critically ill patients.
T1116
High-Resolution Sonography of the Bowel for Timely Diagnosis of Intestinal
Acute Graft Versus Host Disease After Allogenic Haematopoietic Stem Cell
Transplantation
Emma Calabrese, Massimiliano Postorino, Giovanna Del Vecchio Blanco, Luca
Franceschini, Raffaella Cerretti, Gottardo De Angelis, Carmelina Petruzziello, Micaela
Cretella, Livia Biancone, William Arcese, Francesco Pallone
Background. Acute Graft Versus Host Disease (aGVHD) is a major complication during the
first 100 days after Allogenic Haematopoietic Stem Cell Transplantation (AHSCT), with 30-
70% incidence. Target organs include the skin, the liver and the gastrointestinal (GI) tract.
Intestinal aGVHD shows a progressive worsening of the symptoms, but the prognosis may
be improved by an early diagnosis and timely treatment. Differential diagnoses include
intestinal infections and chemo/radiotherapy side-effects. Conventional diagnostic procedures
include the histologic assessment of the upper and lower GI tract, requiring invasive endos-
copic procedures in severely ill patients. Aim Aim of the present study was to determine
whether High Resolution Sonography (HRS) of the bowel may represent a useful non invasive
procedure for the diagnosis and assessment of aGVHD. We also aimed at explaining whether
HRS may be helpful for a timely treatment of aGVHD. Methods. From August 2004 to
October 2005, 15 patients (11M, 42 yrs, range 18-58) underwent AHSCT (patients received:
11/15 peripheral blood stem cell transplantation and 4/15 bone marrow transplantation).
Indication for AHSCT was: Acute Lymphocytic Leukemia in 2 patients, Acute Myeloid
Leukemia in 5 patients, Chronic Myeloid Leukemia in 2 patients, Non Hodgkin’s Lymphoma
in 3 patients, Hodgkin’s Lymphoma in 2 patients, Multiple Myeloma in 1 patient. GI
symptoms were observed in 11/15 patients, including anorexia, nausea, vomiting, watery
diarrhoea, intestinal bleeding. Symptoms onset began after a median of 48 days (range 7-
100) from AHSCT. Within 24 hours from the onset of GI symptoms, HRS was performed
by using a 7 MHz linear and a 3.5 MHz convex array transducers. Results. Among the 11
patients with GI symptoms, HRS detected changes suggesting aGVHD in 6 patients: aGVHD
was confirmed by clinical assessment in all 6 and by endoscopy in 3 patients. HRS changes
included: increased bowel wall thickness, small bowel and/or colon dilation, double-lined
inner echo. These 6 patients were treated with steroids and anti-TNFalpha MoAb. In the
remaining 5 patients, HRS showed increased colonic thickness with normal echo pattern of
the bowel layers. In 3/5 patients GI symptoms were related to chemo/radiotherapy toxicity,
while in 2/5 patients a Campylobacter jejuni and a CMV infection was detected and success-
fully treated. Conclusion. HRS is a feasible and non-invasive diagnostic tool which may
provide useful information for a prompt and appropriate treatment of patients with suspected
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aGVHD. The possible role of HRS for predicting the development of aGVHD and for grading
its severity warrants evaluation in prospective studies.
T1117
Assessment of a New Simple Capsule Endoscopy Crohn’s Disease Activity
Index (CECDAI)
Eyal Gal, Alex Geller, Gerald Frase, Zohar Levi, Yaron Niv
Introduction: Capsule endoscopy (CE) (PillCam SB, Yoqneam, Israel) is a relatively new
imaging tool for detection of small bowel pathology. It was found to be the most sensitive
procedure for detection of small bowel Crohn’s disease in several studies. Assessment of
endoscopic severity of Crohn’s disease by CE is not standardized and is limited by inter-
observer variation in interpreting findings and assessing their severity. Aim: To develop and
validate a new, simple CECDAI in order to grade the severity of small bowel CE findings.
Methods: The small bowel was divided into proximal and distal segments according to
transit time, and each segment was given a score according to the worst mucosal lesion,
extent of disease and presence of strictures (Table). The segmental score is calculated by
multiplying the inflammation score by the extent score and adding the stricture score (A x
B + C). The final score is the sum of the 2 segmental scores so CECDAI = (A1 x B1+ C1)
+ (A2 x B2+ C2). Four experienced endoscopists (2 with experience in CE interpretation)
reviewed 20 de identified, coded CE videos of Crohn’s disease patients, and graded them
according to CECDAI. Each examiner was blinded to the scores given by the others. The
scores were compared by Spearman’s correlation using SPSS for inter-observer variability.
Results: Total CECDAI score correlation was 0.867 (0.700-1.000 = strong degree association,
WHO classification, P<0.0001). CECDAI in 20 patients range was 0 to 26. All examiners
agreed that the score was simple to learn and apply, even for endoscopists with no specific
CE experience. Conclusions: The CECDAI score is a simple score for assessing small bowel
Crohn’s disease by CE, and shows a low inter-observer variability between examiners with
extensive endoscopic experience. Table - CECDAI A. Inflammation score 0=none 1= Mild
to moderate edema/hyperemia/denudation 2= Severe edema/hyperemia/denudation 3= bleed-
ing, exaudate, apthae, erosion, small ulcer (up to 0.5cm) 4= moderate ulcer (0.5-2cm),
pseudopolyp 5= large ulcer (>2cm) B. Extent score 0= none 1=Focal disease (single segment)
2=Patchy disease (multiple segments) 3= >Diffuse disease C. Narrowing score 0= none 1=
single, passed 2= multiple, passed 3= obstruction Segmental score Total score
T1118
A Novel Diagnostic Approach in Patients with Indeterminate Colitis: Wireless
Capsule Enteroscopy
Raffaele Bennato, Francesco Manguso, Agesilao D'Arienzo, Giovanni Lombardi,
Gianfranco De Dominicis, Francesco P. D'Armiento, Oscar Nappi, Antonio Balzano
BACKGROUND/AIMS: the term indeterminate colitis was indicative of inflammatory bowel
diseases in which there were difficulties in distinguishing between Crohn’s disease and
ulcerative colitis in colectomy specimens (10-15% of cases). Today the significance of the
term is more complex; it is linked not only to the histological findings but it is a clinic-
pathological definition with many aspects not yet well characterized. Wireless capsule enteros-
copy (WCE) is able to directly visualize the entire small bowel mucosa and identify superficial
lesions. The aim of our study was to evaluate small bowel mucosa by WCE in patients with
indeterminate colitis at the onset. MATERIALS: from October 2004 to November 2005, 11
patients (M/F:5/6; mean age 38.9 yrs, range 26-58) consecutively admitted to our two Units
with a first diagnosis of indeterminate colitis, were enrolled. The selection was made in a
population of patients with symptoms suggesting colonic inflammatory bowel disease by a
ileocolonoscopy. Mucosal biopsies were collected in terminal ileum and in all colonic seg-
ments (at least three specimens in the cecum, every 20 cm and in the mucosal areas judged
to be the most severely inflamed). Histological assessment was made by two pathologists
who were blinded to each other’s evaluation, according to guidelines of the British Society
of Gastroenterology. Discordances were resolved by consensus. A WCE was performed by
two blinded observers in all patients. Patients had not been using 5-ASA, salazopyrin,
NSAIDs and corticosteroids for at least one month before the WCE. RESULTS: complete
ileocolonoscopy was performed in all patients. In all cases there was not endoscopic and
histological involvement of terminal ileum. Every patient well tolerated WCE. Outcome
agreement between observers was 100%. In one case multiple small aphthous ulcers were
observed, in another patient two jejunal isolated aphthas were found, in two cases WCE
showed proximal segmental oedema and hyperemia. The overall percentage of ileal inflam-
matory findings was 36,4%. CONCLUSIONS: our study shows a small bowel inflammatory
involvement, in particular of the bowel proximal to terminal ileum, in a high percentage of
patients with indeterminate colitis, detected by wireless capsule enteroscopy. This novel safe
diagnostic method seems to be able to find also signs of very mild ileal inflammation and
could be used for a better classification of indeterminate colitis.
T1119
Role of Wireless Capsule Endoscopy (WCE) in Geriatric Gastroenterology
Adnan Muhammad, Yougandhar Akula, C.S. Pitchumoni
Introduction: The advent of WCE has provided a new diagnostic modality for diseases of
small bowel. Its impact on patient care and usefulness in clinical practice has steadily been
gaining ground. This new technology has been used in variety of clinical settings including
localization of obscure GI bleeding, IBD ( Crohn’s disease), suspected small bowel polyp
or tumor, chronic diarrhea, unexplained abdominal pain and Celiac disease. Aim: The aim
of this study is to identify WCE findings in patients who presented with different indications in
Geriatric population and compare it with other age groups. Material and Method: Consecutive
medical records of 333 patients presented for WCE at our Institution were recorded. Patients
were divided into three age groups as listed in the table. The most common indications and
findings were also recorded. Results: 1) The most common indication for WCE in Geriatric

















Erosion. Conclusion: WCE provides a valuable tool in the visualization of Small Bowel
pathalogy. WCE also plays a critical role in Geriatric population for the diagnosis of various
small bowel diseases.
Indications for WCE in different age groups.
Findings of WCE in different age groups
More than one WCE finding can be seen in one case.
T1120
Evaluating Mechanisms of Intestinal Intussusception
Kristin E. Killoran, Robia Pautler, Norman Weisbrodt, Margaret E. Conner
Obstructing intussusception occurs in approximately 1:1,000 children in the US with a 2:1
male to female bias. Intussusception rates vary among locales suggesting the importance of
genetics and/or environment. Intussusception is thought to be caused by dysregulated
intestinal motility. E.coli lipopolysaccharide (LPS) affects intestinal motility, is a potent
inducer of inflammation, and causes intussusception in a mouse model. In order to test our
hypothesis that intussusception is impacted by multiple host factors and is associated with
altered motility, adult mice are injected intraperitoneally with LPS and 6 hours later are
examined for intussusception following laparotomy or magnetic resonance imaging (MRI).
Intussusception rates differed significantly in male (38.5%) and female (55%) mice (p=
0.004) and among mouse strains (BALB/c 55%, CD-1 12%, C57Bl/6 0%) (p<0.001). These
data indicate a sexual and genetic dimorphism in the development of intussusception. In
vivo imaging by MRI is being pursued to define for the first time the longitudinal kinetics
of the development and resolution of intussusception and to assess intestinal contractile
activity post-LPS injection in BALB/c and C57Bl/6 mice. Using MRI, intussusceptions from
2 mm to 3 cm in length have been visualized in the small intestine and colon. Despite use
of anesthesia during MRI, motility of the intestine was observed. Examination of serial
UFLARE scans showed a contraction-relaxation sequence in an intussusception. Additionally,
we observed multiple intussusceptions that resolved during MRI. In one mouse that was
imaged multiple times for 20 minutes, an intussusception was observed that subsequently
resolved and then in a later series of scans a second intussusception formed in the same
area of the intestine. Because detailed determination of the kinetics of intussusception in
individual animals by MRI will require long-term anesthesia that may interfere with intestinal
motility, we evaluated intestinal transit of FITC-dextran in BALB/c mice anesthetized with
isoflurane for 0, 3, or 6 hours. In mice anesthetized for 3 and 6 hours, marker was transported
to the terminal ileum in 8/10 mice within 20 minutes. These data indicate that isoflurane
anesthetized mice retain substantial intestinal motility. Taken together, our data indicate
the feasibility of MRI for in vivo imaging of intussusceptions to obtain longitudinal acquisition
of anatomical and dynamic physiological information from individual animals that will allow
us to decipher the mechanisms of intussusception in vivo.
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T1121
Video Capsule Endoscopy Findings in Cirrhosis with Portal Hypertension: A
Prospective Study
Daniel Urbain, Danny de Looze, Pieter Hindryckx, Paul Ceulemans, Hendrik Reynaert,
Fazia Mana, Isabelle Colle
Background: Data concerning small bowel (SB) mucosal abnormalities in portal hypertension
are scarce. Video Capsule Endoscopy (VCE) is a good tool to study the SB mucosa in a
noninvasive way in these patients. Materials and methods: 24 patients with cirrhosis (mean
age: 62y, 16 males, 8 females) presenting endoscopic signs of portal hypertension (esophageal
varices > grade 2 and/or portal hypertensive gastropathy of mild or severe grade), but no
clinical signs of bleeding, were evaluated by VCE in two university centers. Patients with
former endoscopic therapy of the varices (mostly band ligation) were also included. Diagnosis
of cirrhosis was based on biopsy and/or clinical and imaging evidence. VCE was performed
within 1 month after oeso-gastro-duodenoscopy. Etiology of cirrhosis was: alcohol (16),
HCV (4), NASH (3), haemochromatosis (1). Results: Abnormalities of the SB mucosa were
observed in 87% of the patients (3 procedures were entirely normal). The lesions were
described as limited vascular lesions (erythematous spots, angiodysplasia-like lesions, angi-
oma) (62% of the patients), edematous aspect of the mucosa and mosaic pattern (33%),
varices (25%), ulcerations/erosions (25%). In 3 cases (12%), an active bleeding was seen
without identification of the underlying lesion. Atypical vascular lesions and edematous
aspect could be found as single lesions. Active bleeding and varices were always found in
association with other abnormalities.. Conclusions: Mucosal abnormalities are found in a
majority of patients with portal hypertension. The relevance of some findings (edema, limited
vascular lesions, ulcerations/erosions) can be questioned, but the detection of SB varices
and active bleeding in patients without clinical signs can be clinically important. A better
definition of the endoscopic findings remains mandatory to further define the place of VCE
in this field. Moreover, risk factors associated with the relevant findings like active bleeding
and SB varices are needed.
T1122
Usefulness of the Capsule Endoscopy in the Study of the Inflammatory Bowel
Disease: Preliminary Results
Sara Galter, Begona Gonzalez, David Monfort, Elena Ricart, Dolors Gonzalez, Edgar Ayala,
Carlos A. Guarner, Ingrid Ordas, Joaquim Balanzo
Introduction: Capsule endoscopy (CE) has been proved to be a new and useful tool in the
study of the inflammatory bowel disease, as Crohn’s Disease (CD) of the small bowel has
long presented diagnostic difficulties. Patients with colon CD or indeterminate colitis (IC)
are the best candidates, because intestinal lesions may lead to a change in the diagnosis or
the management of the patient. Aim: Assess the usefulness of the capsule endoscopy in
detecting small bowel disease in patients with Colon CD, IC or suspected CD, after a
normal small bowel follow through (SBFT). Patients and methods: Since January 2004 until
November 2005 we included 22 patients (8 males, 14 females) divided in differents groups:
established Colon CD (group 1, n=13), IC (group 2, n=7) and suspected CD (group 3, n=
2). 20 of the 22 patients had a previous normal SBFT. After an intestinal preparation and
8 hours of fasting, the exploration was performed. Results: CE was normal only in 6/22
patients (27.2%) and pathological in 16/22 (72.8%). In group 1, the capsule showed lesions
suggestive of CD in 7 patients (53%); in group 2, 5 patients had intestinal lesions, leading
to a diagnosis change (70%) and in group 3, CD was confirmed in 1 case (50%). The cecum
was reached in 90% of procedures and all capsules passed naturally. Conclusions: 1. Capsule
endoscopy is effective in the study of Indeterminate Colitis, leading to a diagnosis of Crohn’s
Disease in 70%. 2. The examination of the intestinal extent of Crohn’s Disease shows
lesions in 7 patients (53%), although the clinical relevance needs to be assessed. 3. Capsule
Endoscopy is superior to Small Bowel Follow Through in the detection of small bowel lesions.
T1123
Screening for Esophageal Varices with the PillCam ESO in Patients with
Cirrhosis and Massive Ascitis
Tonantzin Matheus, Girish Anand, Neha Wadhwa, Philip O. Katz, Kenneth Rothstein,
Santiago Munoz
Introduction: Esophageal varices are a major cause of morbidity and mortality in patients
with cirrhosis. The benefits of primary and secondary prophylaxis of variceal hemorrhage
have been established. The introduction of esophageal capsule endoscopy (ECE) for screening
and surveillance of esophageal varices is currently under active evaluation. The presence of
cirrhotic ascites is associated with increased intrabdominal pressure, esophageal vascular,
anatomical and functional changes, which may affect variceal visualization by ECE. Aim:
We evaluated the use of ECE using the PillCam ESO™ in patients with massive ascites due
to end stage cirrhosis. Methods: Ten patients with end stage cirrhosis of varied etiology
admitted for large volume paracentesis due to development of massive ascites. Patient
demographics were recorded. Informed consent was obtained and patients were instructed
about the procedure, which was performed prior to the paracentesis. The PillCam ESO
capsule acquired video images from both ends of the device. Results were then interpreted
using the following grading: F0: no varices present, F1: small varices encompassing <25%
circumference of esophagus, F2: medium or large varices, involving > 25% circumference
of esophagus. Results: All patients were male, mean age 52.8 yrs. Child Pugh class B: 6 pts,
class C: 4 pts. Mean MELD score was 22 (13-40). Ethnicity was diverse. Average capsule
transit time in esophagus was 3:58 min (range 20 sec-7:27 min). 30% patients had less
than 1 min. transit time, yet the ability to identify and grade the varices was not affected
by short transit time. Varices were identified in 6 patients and 83% had medium/large F2
varices. Half of the patients had an EGD available for comparison within 1 year of the
capsule and there was an 80% correlation between both tests. There were no severe adverse
effects associated with ECE. Conclusions: Esophageal capsule endoscopy of esophageal
varices appeared safe in advanced cirrhotics with massive ascites. The study demonstrated
a spectrum of sizes of esophageal varices, even in the presence of rapid capsule transit time
and severe ascites. 40% of patients had no esophageal varices in spite of having ESLD and
massive ascites, confirming the need for endoscopy to determine the presence/absence of
varices. These results indicate that further studies of ECE for esopagheal varices cirrhosis
are warranted.
T1124
Concomitant Immunosuppressive and Adalimumab Therapy in Patients with
Crohn’s Disease: 1-Year Results of the Classic II Study
R Panaccione, Stephen B. Hanauer, Richard Fedorak, Paul Rutgeerts, William J.
Sandborn, Paul Pollack
BACKGROUND Adalimumab, a fully human anti-TNF monoclonal antibody, is approved
for the treatment of rheumatoid arthritis and psoriatic arthritis. In CLASSIC I, a 4-week
randomized controlled study of adalimumab in the induction of remission in patients with
active Crohn’s disease (CD), immunosuppressant (IMM)—azathioprine, 6-MP, or methotrex-
ate—use was permitted if patients entered the study on a stable IMM dose for 12 weeks
prior to screening. IMM use did not influence the response to adalimumab in CLASSIC I.
PURPOSE To assess the effect of concomitant IMM on the efficacy of adalimumab over 1
year in CLASSIC II. METHODS All patients in CLASSIC II completed CLASSIC I and
received adalimumab 40 mg sc at Weeks 0 (Week 4 of CLASSIC I) and 2. Patients with
CDAI≥150 at Weeks 0 and/or 4 received open-label (OL) adalimumab 40 mg sc every
other week (eow), weekly dosing was permitted for flare or persistent non-response. Patients
with CDAI<150 at both Weeks 0 and 4 were randomized to receive adalimumab, 40 mg
sc eow or weekly, or placebo for up to 1 year. CDAI was assessed at each study visit.
Information on concomitant IMM use was collected at the start of the study through 56
weeks of treatment. The relationship of IMM and adalimumab on remission (CDAI<150)
and Δ100 CDAI response (decrease in CDAI score ≥100 points) and their potential interac-
tion was assessed. RESULTS Of 276 patients enrolled in CLASSIC II, 30% received concomit-
ant IMM (IMM+). In the OL cohort (N=221), 46% of IMM+ patients achieved CDAI<150
and 64% achieved Δ100 CDAI, versus 40% and 60% of those not receiving IMM (IMM-),
respectively. Results in the randomized cohort (N=55) are summarized in the table. IMM
status did not notably influence the efficacy of adalimumab. CONCLUSION Adalimumab
consistently improved CDAI outcomes with or without IMM use. Concomitant adalimumab
and IMM will be evaluated in larger, long-term CD studies.
Week 56 Remission and Response: CLASSIC II Randomized Cohort
LOCF
T1125
Adalimumab Maintains Improvement in Inflammatory Bowel Disease
Questionnaire (IBDQ) Scores Over 1 Year Following the Initial Attainment of
Remission in Patients with Moderately to Severely Active Crohn’s Disease:
Results of the Classic II Study
Paul J. Rutgeerts, Lisa E. Melilli, Ju Li, Paul F. Pollack
BACKGROUND Adalimumab, a fully human anti-TNF monoclonal antibody, is approved
for the treatment of rheumatoid arthritis and psoriatic arthritis. In CLASSIC I, a 4-week
randomized trial, the efficacy of adalimumab in the induction of remission in patients
with Crohn’s disease (CD) was demonstrated. OBJECTIVE Assess the maintenance of
improvement in physical function in subjects with active CD who achieved remission
(CDAI<150) when treated with adalimumab in CLASSIC I and maintained it at Week 4 of
CLASSIC II, an extension trial. METHODS All subjects in CLASSIC II completed CLASSIC
I and received adalimumab 40 mg sc at Weeks 0 (Week 4 of CLASSIC I) and 2. Patients
in remission at both Weeks 0 and 4 were randomized to receive adalimumab, 40 mg sc
every other week (eow) or weekly, or placebo for up to 1 year. CDAI and IBDQ were
assessed at each study visit. IBDQ measures disease-related functional changes in patients
with IBD. A Total IBDQ>170 score has been correlated to clinical remission (CDAI<150).1
RESULTS The mean baseline CLASSIC I IBDQ score of 55 patients randomized was 137,
consistent with active CD. The mean IBDQ score (186.4) at the start of CLASSIC II was
consistent with remission. Remission was maintained with adalimumab treatment through
Week 56 in 74% and 83% of patients treated with adalimumab 40 mg eow and weekly,
respectively, compared to 44% of placebo-treated patients (LOCF). IBDQ scores consistent
with clinical remission were maintained through Week 56 in patients treated with adalimu-
mab 40 mg eow or weekly (figure), while IBDQ scores declined rapidly in patients receiving
placebo. CONCLUSION In this randomized cohort, clinical remission and physical function
were maintained with adalimumab therapy. Larger, long-term studies of adalimumab in
patients with CD are ongoing. 1Irvine EJ, Feagon B, Rochon J et al. Gastroenterology
1994;106:287-96.
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T1126
Safety and Tolerability of Subcutaneous (SC) Certolizumab Pegol in Active
Crohn’s Disease (CD): Results from Two Phase III Studies (PRECiSE program)
Stefan Schreiber, Brian Feagan, Stephen B. Hanauer, Paul Rutgeerts, Juliet A. McColm,
William J. Sandborn
Background: Tolerability and safety of certolizumab pegol were examined in 2 parallel
Phase III trials (PRECiSE program) in active CD (CD Activity Index [CDAI] score 220-450)
involving more than 1300 patients (pts). Methods: In PRECiSE 1, pts received sc certolizumab
pegol 400mg (n=331) or placebo (PBO; n=329) at Weeks (Wks) 0, 2, 4, then 4-weekly up
to Wk 24. In PRECiSE 2, 668 pts received open-label sc certolizumab pegol 400mg at Wks
0, 2, 4. Pts who responded at Wk 6 received double-blind certolizumab pegol 400mg (n=
216) or PBO (n=212) 4-weekly from Wks 8-24. Adverse events (AEs) were monitored (n=
1328). Results: Most AEs in both trials were mild or moderate. In the double-blind phases,
the overall incidence of AEs was comparable for certolizumab pegol and PBO. For certoli-
zumab pegol, the most common AEs included headache and nasopharyngitis (both studies),
abdominal pain (PRECiSE 1), and cough (PRECiSE 2); the most frequently occurring infec-
tions included nasopharyngitis, urinary tract (UTI) and upper respiratory tract infections.
In PRECiSE 1, 10.3% of certolizumab pegol and 7.0% of PBO pts had serious AEs (SAEs).
Corresponding data for the double-blind phase of PRECiSE 2 were 5.6% and 6.6%, respect-
ively. Non-CD-related infection SAEs were infrequent in the PRECiSE 2 double-blind phase
(certolizumab pegol: 1 pulmonary tuberculosis [TB; responded well to anti-TB therapy], 1
pyelonephritis, 1 pneumonia; PBO: 1 bacteremia 6 days after the 1st PBO dose, 1 otitis
media) and in PRECiSE 1 (certolizumab pegol: 3 abscesses, 1 UTI; PBO: 1 abscess). Incidence
of reported malignancies in PRECiSE 1 was similar between certolizumab pegol (1 lung [10
months after withdrawal] and 1 rectal carcinoma) and PBO (1 non-Hodgkin’s lymphoma and
1 cervical carcinoma [linked with human papillomavirus]); none was reported in PRECiSE 2.
Injection reactions were less frequent for certolizumab pegol than PBO pts (PRECiSE 1 and
2: 11.8% vs 25.5% and 6.5% vs 19.8%, respectively). One certolizumab pegol-treated pt
in each study died (acute myocardial infarction/metastatic lung cancer (as noted above) and
Fentanyl overdose); neither death was considered related to study drug. Proportions of pts
negative for auto-antibodies at baseline, becoming positive at Wk 26/withdrawal were low
(anti-nuclear: ≤8.3%, and anti-double-stranded DNA: ≤1.4%). No cases of lupus were
reported. Conclusions: Experience in over 1300 pts with CD suggests that treatment with
sc certolizumab pegol 400mg is safe and well tolerated. The low incidence of auto-antibodies
observed following treatment with certolizumab pegol is strikingly different from that
reported for other anti-tumor necrosis factor-α agents.
T1127
Endoscopically Measured Mucosal Healing of Delayed-Release Oral
mesalamine 4.8 G/Day Versus 2.4 G/Day
Gary R. Lichtenstein, David Rubin, Gino Regalli, Rachelle Eusebio
Purpose: Determine the effect of delayed-release oral mesalamine 4.8 g/day (investigational
800mg tablet) vs 2.4 g/day (marketed 400mg tablet) on endoscopically measured mucosal
healing in patients with moderately active ulcerative colitis (UC). Methods: Data from two
Phase III, multi-center, randomized, double-blind, 6-week, controlled studies of similar
design (ASCEND I&II) were pooled and analyzed. Mucosal healing was defined as endoscopy
subscore of 0 or 1. Patients with moderately active UC (defined as a baseline Physician’s
Global Assessment score of 2) and baseline endoscopy subscore > 2 were included in this
analysis. Results: A total of 423 analyzable patients with moderate UC were randomized in
the two studies, of which 391 patients met criteria for this analysis. The two treatment
groups were balanced with regard to baseline and demographic characteristics, disease
history, and baseline disease state characteristics. In the population of patients with moder-
ately active UC and baseline endoscopy subscore > 2, the percentage of patients achieving
mucosal healing is shown in the table below: The 4.8g/day dose of mesalamine was well
tolerated, with adverse events comparable to 2.4g/day. Conclusion: Regardless of dose and
as early as 3 weeks, delayed-release oral mesalamine induces endoscopically measured
mucosal healing in >50% of patients. Compared to 2.4g/day, initiating therapy with 4.8g/
day significantly improves endoscopic measured mucosal healing in patients with moderately
active UC.


















Efficacy of Weekend 5-ASA (mesalazine) Enema As a Maintenance Therapy in
Patients with Ulcerative Colitis: A Randomized Controlled Study
Hiroshi Yokoyama, Sho Takagi, Shinichi Kuriyama, Shuichiro Takahashi, Hiroki
Takahashi, Masahiro Iwabuchi, Seiichi Takahashi, Yoshitaka Kinouchi, Ichiro Tsuji, Tooru
Shimosegawa
Background and aims: Oral aminosalicylates are well established in the maintenance treatment
of ulcerative colitis (UC). Mesalazine, both oral and topical (enemas and suppositories), has
been shown to be effective either alone or in combination with oral or rectal administration
for treating active UC. We report the results of a randomized controlled trial examining
efficacy of 1 g mesalazine enema treatment twice a week at weekend regimen with 3 g oral
mesalazine daily as a maintenance therapy for UC. This is the first randomized controlled
study on treatment using mesalazine enema in Japanese UC patients. Methods: We scheduled
a randomized controlled trial of weekend mesalazine enema as a maintenance treatment
with 200 patients with UC. Patients with UC were considered as eligible for the study who
had been just induced into a phase of clinical remission. They were randomly assigned to
weekend enema group or oral alone group; the former received 1g mesalazine enema twice
a week at weekend (Saturday and Sunday) with 3 g oral mesalazine daily, the later did not
use mesalazine enemas and received 3 g oral mesalazine daily. The clinical course was
followed at regular intervals after randomization. The relapse of UC was defined as the
primary endpoint of the study. We defined relapse as six and over of the clinical activity
index (CAI) score and over three of the endoscopic index (EI) score. Recruitment commenced
in January 2004 and is expected to be completed by January 2006 and follow-up will
continue until December 2008. However, we stopped the study after 24 patients had been
enrolled because an interim analysis showed the significant consequence. Results: Of 24
randomized patients, 11 were allocated to the weekend mesalazine enema group and 13 to
the oral alone group. In the group receiving weekend enema, 2 patients (18.2%) relapsed,
as compared with 10 (76.9%) in the group receiving oral mesalazine alone. The comparison
was statistically significant (P=0.037) and its hazard ratio was 0.19. During the course of
the study period, all patients did not have any adverse event related with the drugs. Conclu-
sions: This study has demonstrated the beneficial effects of adding 1 g mesalazine enema
twice a week at weekend with 3 g oral mesalazine for maintenance therapy of UC.
T1129
Comparison Between Intravenous Iron Gluconate Alone and Intravenous Iron
Gluconate Plus Levofolinic Acid for the Treatment of Iron Deficiency Anaemia
in Patients with Inflammatory Bowel Disease
Alfredo Papa, Silvio Danese, Simona Guglielmo, Italia Roberto, Marcello Covino,
Antonino Grillo, Riccardo Urgesi, Stefano Semeraro, Michele Bonizzi, Franco Tagliaferri,
Luisa Guidi, Italo de Vitis, Giuseppe Fedeli, Giovanni Gasbarrini, Antonio Gasbarrini
Background and aim: Anaemia is a common clinical feature in IBD patients, with rates
between 30% and 50%, leading to impaired quality of life. IBD-associated anaemia has a
multifactorial aetiology but iron deficiency is the leading cause. Aim of this prospective open
study was to compare the efficacy and safety of two different regimens for the treatment of
iron deficiency anaemia (IDA) in IBD patients. Patients and methods: We enrolled 30 IBD
patients (12 with Crohn’s disease and 18 with ulcerative colitis) with IDA, defined as
haemoglobin (Hb) value <10.5g/dl and hypochrome and microcytotic erythrocytes. None
of the patients had hemolysis, macrocytic anaemia, or renal insufficiency. Patients were
consecutively randomised in two groups comparable for disease type, activity and treatment.
Fifteen patients were included in group A, receiving 10 daily infusions of 5 ml of iron
gluconate (each corresponding to 62.5 mg of Fe+++) [Ferlixitâ, Aventis] and 15 patients
were included in group B, receiving daily the same infusion of iron gluconate followed by
the intravenous administration of 25 mg of levofolinic acid [Levofoleneâ, Schering]. Clinical
assessment of side effects and laboratory testing (blood cell counts, including iron, reticulo-
cytes, mean corpuscolar volume, transferrin, ferritin, and C-reactive protein) were made at
baseline and every five infusions. Results: At baseline, Hb levels, iron and ferritin concentra-
tions were comparable between the two groups. In particular, the mean Hb was 9.4±1.4 g/
dl in group A and 9.2±1.3 g/dl in group B. At the end of the scheduled therapy, Hb levels
increased to 10.2±1.5 g/dl in group A (P=0.142) and 11.1±1.8 g/dl in group B (P =0.025).
Side-effects were generally mild and transient (2 in group A and 3 in group B); no serious
adverse events were reported. Conclusions: The contemporary administration of intravenous
iron gluconate and levofolinic acid showed a more consistent increase of the Hb concentration
than iron gluconate alone in IBD patients with IDA. This results could be explained by the
frequent finding of low levels of folates in IBD patients also in absence of overt macro-
cytic anaemia.
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T1130
A Safety and Efficacy Study of a Novel Formulation of Prednisolone
Metasulfobenzoate (PREDOCOL) in the Induction of Remission and
Maintenance in Ulcerative Colitis
Jonathan M. Rhodes, Richard Robinson, Ian Beales, Stirling Pugh, Richard Dickinson,
Michael Dronfield, Steven Wilkinson
Background/Aims Prednisolone metasulfobenzoate is effective topically in ulcerative colitis
but is sparingly absorbed from the colon (McIntyre et al, Gut 1985). A modified-release
oral formulation has been developed (Predocol) comprising a Eudragit L-coated capsule
containing 200 controlled-release drug pellets. A pilot study showed very low systemic
absorption. This study compares the safety and efficacy of Predocol with prednisolone in
ulcerative colitis. Methods Patients were randomised to one of three treatment groups in a
double-blinded study. Group A (n=59) received Predocol 40 mgs /day for 6 months plus
placebo, Group B (n=61) received Predocol 60 mgs/day for 6 months plus placebo, and
group C (n=61) received Prednisolone 40 mg/day for 2 weeks which was then tapered to
30mg/day weeks 3 and 4, 20mg/day weeks 5 and 6, 10mg/day week 7, 5mg/day week 8
then placebo only until 6 months. All drugs were given in twice daily divided doses. Steroid-
related side effects and efficacy were assessed by patients using a visual analogue scale (VAS)
where 10cm = symptom-free and 0=worst possible. Efficacy was also assessed by Powell-
Tuck score, Physician global score and Baron endoscopic grading. The trial was designed
to assess non-inferiority. Results Predocol at 40mgs per day but not at 60mgs/day showed
non-inferiority compared to prednisolone at 2 months and 6 months (Table). Physician’s
global assessment confirmed non-inferiority for Predocol 40mg vs prednisolone at month
2 (remission 36% and 43% respectively) and month 6 (remission 65% and 43% respectively).
Similar efficacy was observed using Powell-Tuck and Baron grades. Patient’s global assessment
of steroid-related side-effects at 2 months was better for Predocol 40 mgs or 60 mgs (p=
0.001 and 0.002 respectively) compared with prednisolone. Predocol was also significantly
better than prednisolone on patient’s scoring for moon face, hirsutes, flushing, mood changes
and insomnia. Conclusion Predocol 40 mgs per day is non-inferior in efficacy compared
with a conventional tapering prednisolone regimen and is associated with fewer steroid-
related side effects.
T1131
Double-Blind, Double Dummy, Randomized, Multicentre, Comparative Study
On the Efficacy and Safety of Azathioprine (AZA) Versus mesalazine (5-ASA)
for Prevention of Postoperative Endoscopic Recurrence in Crohn’s Disease
Hans Herfarth, Florian Obermeier, Christin Tjaden, Milan Lukas, Zuzana Serclova, Axel
U. Dignass, Diether Ludwig, Ralph Mueller, And The Azt-1 Study Group Juergen
Schoelmerich
Background: Postoperative recurrence of Crohns disease represents a considerable clinical
problem. Two recently published studies addressing the therapy with 6-mercaptopurine (6-
MP) or azathioprine (AZA) postoperatively had several limitations (fixed low dose of 50 mg
6-MP, statistical problems due to missing data or lack of blinding) and further clarification
is needed. The aim of this study was to assess the efficacy of a postoperatively initiated
therapy with AZA or 5-ASA for the prevention of endoscopic and clinical recurrence 12
months after resective surgery in patients (pat.) with Crohns disease. Methods: In a prospect-
ive double-blind, double dummy, randomized, multicentre study 279 patients were screened
and 79 patients were randomized within 2 weeks postoperatively to 2.0-2.5 mg/kg body
weight/day AZA (42 pat.) or 4g 5-ASA/day (37 pat.). The study was stopped prematurely
after an interim-analysis due to a high therapy failure rate. 38 patients (AZA 18 pat.; 5-ASA
20 pat.) completed the study and could be evaluated regarding the primary endpoint therapy
failure. The other pat. terminated the trial prematurely due to the study stop, but were also
evaluated for adverse events (AE) and adverse drug reactions (ADR). Results: The overall
failure rate was 19/38 pat. (50%), equally distributed between both treatment groups (see
table 1). In the AZA and 5-ASA groups, respectively, in 69% and 70% of the patients an
AE and in 43% and 30% an ADR occurred. Overall the most frequent AE were headache
and abdominal pain. Conclusion: In this prematurely stopped trial a superiority of AZA
over 5-ASA could not be demonstrated due to a high percentage of therapy failures. No
specific reason for therapy failure could be defined. The high percentage of therapy failures
indicates the difficulties, which may arise in future clinical trials addressing the question of
postoperative immunosuppressive therapy in Crohns disease. Supported by Dr. Falk Pharma
GmbH, Freiburg, Germany
Table 1: Reasons for therapy failure in 19/38 patients
T1132
Clinical Trial On the Efficacy and Tolerability of a Novel Low-Volume
mesalamine Foam (2x1g 5-ASA/30ml) Vs mesalamine Foam (2x1g 5-ASA/
60ml) in Active Ulcerative Proctitis Or Proctosigmoiditis
Rami Eliakim, Zsolt Tulassay, Limas Kupcinskas, Kestutis Adamonis, Juris Pokrotnieks,
Simon Bar-Meir, Ralph Mueller, Roland Greinwald, On Behalf of the International Foam
Study Group Gross, Volker
AIM: To study the therapeutic efficacy and tolerability of a novel low-volume mesalamine
foam (2x1g 5-ASA/30ml) vs mesalamine foam (2x1g 5-ASA/60ml) in patients with active
ulcerative proctitis or proctosigmoiditis. METHODS: Patients with active ulcerative proctitis
or proctosigmoiditis (Clinical Activity Index [CAI] > 4, Endoscopic Index [EI] ≥ 4) where
elegible for this single-(investigator)-blinded, randomized, multicenter study. Patients
received 2x1g/30ml mesalamine foam (n=163) or 2x1g/60ml mesalamine foam (n=167) for
42 days. Primary endpoint was clinical remission (CAI ≤ 4) at the final/withdrawal visit
(per protocol [PP] population). RESULTS: 330 patients were randomized, 330 were evaluable
for safety and intention-to-treat (ITT), 290 for PP analysis. Efficacy See tables below. Safety
Both formulations were safe and no drug-related serious adverse events were observed. The
low-volume mesalamine foam was associated with a lower frequency of severe discomfort,
pain, and retention problems as compared to the high-volume foam. CONCLUSION: Low-
volume mesalamine foam (2x1g 5-ASA/30ml) is as effective as high-volume mesalamine
foam (2x1g 5-ASA/60ml) in the treatment of active ulcerative proctitis or proctosigmoiditis.
Both mesalamine foams are safe. Supported by Dr. Falk Pharma GmbH, Freiburg, Germany
Primary efficacy endpoint (final analysis):
*Non-inferiority margin: 20%; LOCF, Last observation carried forward
Secondary efficacy endpoints:
*At least marked improvement; ** At least slight improvement DAI, Disease Activity Index
(acc. to Sutherland); PGA, Physician’s Global Assessment (acc. to Hanauer)
T1133
Pharmacokinetics of Adalimumab in a Long-Term Investigation of the
Induction and Maintenance of Remission in Patients with Crohn’s Disease
(CLASSIC I and CLASSIC II)
Tushar S. Garimella, Joanna Z. Peng, Katrin Beck, Peter A. Noertersheuser, Kathleen G.
Lomax, Susan K. Paulson, Paul F. Pollack
BACKGROUND Adalimumab, a fully human anti-TNF monoclonal antibody, is approved
for the treatment of rheumatoid arthritis and psoriatic arthritis. In CLASSIC I, a 4-week
randomized controlled study of induction of remission in patients with Crohn’s disease
(CD), serum adalimumab concentrations were dose-proportional. Additionally, adalimumab
concentrations were sustained during the study period as a result of the initial loading
dose (Paulson et al, DDW 2005). PURPOSE To assess the pharmacokinetics (PK) and
immunogenicity of adalimumab following long-term administration in patients with CD.
METHODS In CLASSIC II, an extension study of CLASSIC I, all patients received adalimumab
40 mg subcutaneously (sc) at Week 0 (Week 4 of CLASSIC I) and Week 2. Patients in
remission (CDAI<150) at both Weeks 0 and 4 of CLASSIC II were randomized to receive
adalimumab, 40 mg sc every other week (eow) or weekly, or placebo for up to 1 year.
Patients not in remission at both Weeks 0 and 4 of CLASSIC II received open-label (OL)
adalimumab, 40 mg sc eow. Dose escalation to 40 mg/week was allowed for flare or persistent
non-response. Trough serum samples for adalimumab and anti-adalimumab antibody (AAA)
assays were obtained at Weeks 4, 24, and 56 to determine serum concentrations using
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validated ELISA methods. Population PK analyses were performed using the NONMEM
software to estimate adalimumab apparent clearance (CL/F) combining the data from both
CLASSIC I and II. A one-compartment model was used to describe adalimumab PK.
RESULTS Of 276 patients entering CLASSIC II, 55 were randomized to receive adalimumab,
40 mg sc eow (n=19) or weekly (n=18), or placebo (n=18). The remaining 221 patients
received OL adalimumab, 40 mg sc eow. The median CL/F (15.0 mL/hr) was consistent
with that using CLASSIC I data only (13.2 mL/hr), indicating relative time-independence.
Concomitant therapy with either the immunosuppressant 6 mercaptopurine (n=23) or azathi-
oprine (n=36) slightly lowered or had no impact on adalimumab CL/F. The effect of concomit-
ant methotrexate alone on adalimumab CL/F was inconclusive (n=6). The overall incidence
of positive AAA in CLASSIC II was 3.0% (8/269). Among 8 AAA+ patients, 3 (37.5%)
were in remission (CDAI<150) at Week 24 and 2 (25%) were in remission at Week 56.
CONCLUSIONS The pharmacokinetics of adalimumab in patients with CD remained con-
stant over time. The overall incidence of AAA was low and adalimumab was well-tolerated.
T1134
Intravenous Clodronate for Prevention of Steroid-Induced Bone Loss in
Patients Affected By Inflammatory Bowel Disease: A Prospective Randomized
Double-Blind Placebo-Controlled Trial (Clastos study)
Vered Abitbol, Gabriel Baron, Philippe Seksik, Antoine Charachon, Yoram Bouhnik,
Cecile Poupardin, Matthieu Allez, Dominique Lamarque, Christian Roux, Stanislas
Chaussade
Background : Osteoporosis is common in patients affected by inflammatory bowel disease
(IBD) with an increased risk of vertebral fractures (1). Corticosteroids induce a rapid and
important bone loss (2). Clinical trials have shown oral bisphosphonates to effectively prevent
steroid-induced bone loss. However, patients with IBD have been excluded from these
studies by fear of digestive adverse events. Clodronate is a non-amine bisphosphonate (BP)
available in intravenous form without expected digestive (oral BPs) or pro-inflammatory
(amine BPs) side effects. Aim : to assess the efficacy of intravenous clodronate in preventing
steroid-induced bone loss. Methods : 67 patients, 37 women, mean age 31 years, 52 Crohn’s
disease, 12 ulcerative colitis, 3 indeterminate colitis, at the start of a steroid therapy, were
included. In this prospective, multicentric, double blind parallel and placebo controlled
study, patients were randomized to receive during the steroid therapy, one infusion per 3
months of either intravenous clodronate (900 mg, n=33) or placebo. Calcium (1g/day) and
vitamin D (800 IU/day) were given to all of the patients during one year. Lumbar and
femoral bone mineral density (BMD) were measured by dual energy X-ray absorptiometry
at baseline, 6 and 12 months, with quality control procedures and analysis in a central
facility, blind to allocation of the treatment. BMD changes from 0 to 12 months were tested
to 0 (ΔBMD) in each group (clodronate or placebo) through a Wilcoxon test and compared
between the 2 groups. Results : Clinical and biochemical characteristics (age, gender, treat-
ments, steroid intake and initial BMD) were not different in the 2 groups. T scores at baseline
were -1.3 SD and -1.2 SD in the clodronate and placebo group, respectively. Tolerance to
the treatment was good. After 1 year, BMD remained unchanged with clodronate whereas
it decreased with placebo. There was a trend for a difference between groups at lumbar
spine level (P=0.06) (Table 1). Conclusion : Quarterly intravenous clodronate may be useful
for preventing vertebral bone loss when started early in a steroid therapy for IBD. (1) Abitbol
V et al. Gastroenterology 1995;108:417 (2) Roux C et al. Osteoporosis Int 1995; 5:156
Table 1. BMD changes after 1 year
T1135
Prospective Evaluation of Effects of NSAID Use On the Disease Course of the
Ileal Pouch-Anal Anastomosis (IPAA)
Bo Shen, Feza Remzi, Bret Lashner, Ana Bennett, Aaron Brzezinski, Jean-Paul Achkar,
Rocio Lopez, Ioannis Oikonomou, Kerry Sherman, Marlene Bambrick, Victor Fazio
The role of NSAID use in the exacerbation of IBD is controversial. There are no prospective
studies. We hypothesized that pouch diseases in a subset of patients were exacerbated by
chronic NSAID use and the cessation of NSAID use may help reducing disease activity and
inducing remission. AIM: To prosectively study the effect of cessation of NSAID use on
disease course of IPAA in patients with chronic daily use of the agents. METHODS: The 4-
wk study consisted of 2 consecutive cohorts of symptomatic patients seen in the Pouchitis
Clinic who had ulcerative colitis, had colectomy and IPAA, and had chronic (> 6 mo) daily
use of NSAID. The patients were treated either with avoiding NSAID (the Cessation Group,
N=17) or with avoiding NSAID plus being started with medical therapy with antibiotics,
mesalamines, or corticosteriods (The Cessation + Therapy Group, N=12). The Pouchitis
Disease Activity Index (PDAI) symptom scores, total PDAI scores, and Cleveland Global
Quality of Life (CGQL, range 0 - 1.0), Irritable Bowel Disease Quality of Life (IBS-QOL,
range 34-170), and short-form Inflammatory Bowel Disease Questionnaire (IBDQ, range 0-
70) scores were measured before and after the 4-wk trial. Compliance was assured. Appropri-
ate statistical analyses were used. RESULTS: Demographic and clinical data were similar
between the 2 groups. The Cessation Group consisted of 11 patients with chronic refractory
pouchitis (65%), 2 acute pouchitis (12%), 1 cuffitis (6%),1 cuffitis + chronic refractory
pouchitis (6%), 2 irritable pouch syndrome (12%); and the Cessation + Therapy Group had
7 chronic refractory pouchitis (58%), 2 acute pouchitis (17%), 1 cuffitis + chronic refractory
pouchitis (8%), and 2 irritable pouch syndrome (17%) (P > 0.05). The cessation of NSAID
use with or without concurrent medical therapy resulted in a significant reduction in symptom

















treatment outcome between the 2 groups (P > 0.05). CONCLUSIONS: Chronic daily NSAID
use was associated with diseases of IPAA, particularly chronic refractory pouchitis. The
majority of these patients benefited from complete cessation of NSAID use, suggesting that
NSAID use can play an important role in the pathogenesis of pouch diseases, particularly
chronic refractory pouchitis.
T1136
Different Definitions of Remission for Ulcerative Colitis Result in Large
Variations of Clinical Outcome Scores
Seymour Katz, Sunanda Kane, Peter Higgins, Rachelle Eusebio, Bruce Yacyshyn
Purpose: One of the treatment goals for ulcerative colitis (UC) is to induce remission.
Currently, there is no standard/accepted definition of remission for UC. Thus, the definition
of remission differs among clinical trials supporting various therapies for UC. The purpose
of this analysis was to estimate remission rates using several different definitions of remission.
Methods: Data from two Phase III, multicenter, randomized, double-blind, 6-week, controlled
studies of similar design (ASCEND I and II) were pooled and analyzed using different
definitions of remission. Definitions varied from complete resolution of clinical assessments
to still having mild UC signs and symptoms. Remission rates of delayed-release oral mesalam-
ine in patients with mildly to moderately active UC taking 2.4 g/day (marketed 400mg
tablet) were examined using several different definitions utilized by various UC therapies.
Results: A total of 687 patients with mildly to moderately active UC were included in the
study, of which 349 received 2.4g/day. Depending on the definition of remission used in
the analyses (see table below), the percentage of patients in remission varied from 22-50%.
Conclusion: Remission rates vary widely depending on the definition of remission used. As
there is no standard/accepted definition of remission for UC, physicians and other healthcare
professionals should pay attention and be aware of the definition of remission being utilized
when evaluating clinical efficacy.
T1137
Maintenance Therapy with Natalizumab Does Not Require Use of
Concomitant Immunosuppressants for Sustained Efficacy in Patients with
Active Crohn’s Disease: Results from the ENACT-2 Study
William Sandborn, Jean-Frederic Colombel, Robert Enns, Brian Feagan, Stephen Hanauer,
Ian Lawrance, Remo Panaccione, Paul Rutgeerts, Stefan Schreiber, Stephan Targan, Sander
van Deventer
Introduction: In the ENACT-2 study, natalizumab treatment was associated with a clinically
significant maintenance of sustained response and remission in patients who had previously
responded to natalizumab induction therapy in ENACT-1. Many of the ENACT-1 patients
had active Crohn’s disease (CD) despite receiving an adequate course of immunosuppressants
(IMM) at baseline of ENACT-1. Sustained response and remission rates in this subset of
patients were compared with those achieved in patients who were not receiving IMM at
ENACT-1 baseline. The protocol required that baseline IMM be continued as concomitant
therapy throughout both trials. Methods: A total of 339 adult patients with CD who achieved
response (>70-point reduction in baseline CD Activity Index [CDAI]) and/or remission
(CDAI score <150) and had a CDAI score <220 after receiving 3 infusions of natalizumab
in ENACT-1 were re-randomized in ENACT-2 to natalizumab 300 mg (n=168) or placebo
(n=171) and received up to 12 monthly infusions. The primary endpoint was the proportion
of patients that maintained response through 6 additional consecutive months of treatment
in ENACT-2. Results: A total of 122 natalizumab-treated patients who were receiving
concomitant IMM were in response and 94 were in remission at month 3 of ENACT-1, and
were re-randomized in ENACT-2, compared with 216 patients who were in response and
156 who were in remission and not receiving concomitant IMM. Sustained response and
remission rates following 12 monthly natalizumab infusions in ENACT-2 were similar
between the 2 groups, and significantly greater than placebo in both cases (Table). The
frequency and types of adverse events (AE) were also similar between the 2 groups. Persistent
anti-natalizumab antibodies (Abs) occurred in 0% of patients on concomitant IMM and
7.5% of patients not receiving concomitant IMM. Hypersensitivity reactions occurred infre-
quently and at the same rate in both groups. Conclusions: Natalizumab was significantly
better than placebo at maintaining sustained response and remission through 12 months,
and the benefit was similar regardless of concomitant IMM use. The AE profiles between
these subgroups were also similar. The rate of persistent anti-natalizumab Abs in patients
T : 89386$$CH2
05-04-06 23:18:29 Page 482Layout: 89386B : e
A-482AGA Abstracts
not receiving concomitant IMM was relatively low and did not appear to significantly impact
sustained efficacy at 1 year.
Proportion of Patients in Sustained Response or Remission Through 12 Months
T1138
A Meta-Analysis of the Placebo Effect for the Induction of Clinical Remission/
Response in Mild to Moderate Active Ulcerative Colitis
Volker Gross, Martina Elze, Ralph Mueller, Roland Greinwald
AIM: The present meta-analysis aimed to evaluate the placebo effect in the treatment of
mild to moderate active ulcerative colitis and to determine the effect of the route of drug
administration (oral/rectal) and of the year of the study (up to 2000/2001 to date). METHODS:
Published, randomised, controlled clinical trials, comparing the efficacy of active drugs
versus placebo in the treatment of active ulcerative colitis were considered. The primary
outcome measure was clinical remission. Secondary outcome measures were clinical improve-
ment, endoscopic and histologic remission and/or improvement. RESULTS: 63 studies fullf-
illed the criteria for analysis. In 29/63 studies the investigational products were administered
rectally, and in 27/63 studies orally. In 1/63, 4/63 and 2/63 studies intravenous, subcutane-
ous, or transdermal formulations were investigated, respectively. 51/63 studies were pub-
lished until 2000; 12/63 from 2001 to date. The pooled clinical placebo remission rate
across all studies was 13% (95% CI, 10% - 16%; N=38), across the studies with rectal
administration it was 15% (10% - 21%; N=18), across the studies with oral administration
it was 11% (8% - 14%; N=14). The pooled clinical placebo improvement rate across all
studies was 29% (95% CI, 25% - 33%, N=54). Pooled rates of 19% (14% - 24%; N=18),
30% (23% 38%; N=19), 9% (3% - 14%; N=9), and 23% (18% - 29%; N=13) were found
for endoscopic remission, endoscopic improvement, histologic remission, and histologic
improvement, respectively. The pooled rate of clinical remission in studies published up to
2000 was 12% (9% - 16%; N=29), and in studies published from 2001 to date 14% (8% -
20 %; N=9). CONCLUSION: The placebo remission rate of active ulcerative colitis is
13% (10% - 16%). Similar clinical placebo remission rates were found for oral or rectal
administration, as well as for studies published up to 2000 or from 2001 to date. Supported
bei Dr. Falk Pharma GmbH, Freiburg, Germany
T1139
SPD476, a Novel, High-Strength 5-ASA Formulation Induces Remission of
Active, Mild-to-Moderate Ulcerative Colitis in Subjects That Are Switched
from Low-Dose Oral 5-ASA Therapy Or Are 5-ASA NaïVe: An Analysis of
Pooled Data from Two Phase III Studies
William J. Sandborn, Michael A. Kamm, Gary R. Lichtenstein, Miguel Gassull, Stefan
Schreiber, Lechoslaw Jackowski, Prabhakar Boddu, Natalya Gubergrits
Background: Reasons for patients switching from one therapy to another within a drug
class may include improved convenience and/or clinical efficacy. During switching it is
essential to maintain or even improve disease control. Here we report an analysis of subjects
with ulcerative colitis (UC) who were switched from prior low-dose oral 5-ASA therapy to
moderate or high-dose SPD476, a novel, high-strength (1.2g/tablet) oral formulation of 5-
ASA that uniquely combines a gastro-resistant film to delay drug release until the terminal
ileum, with MMX Multi Matrix System™ technology to extend consistent release of the
active drug throughout the entire colon. Methods: Data from two phase III studies (SPD476-
301 and SPD476-302) of subjects with active, mild-to-moderate UC who received SPD476
2.4g/day (given once or twice daily), SPD476 4.8g/day (given once daily) or placebo (Pb)
were combined and further analyzed for subjects who were switched from prior low-dose
oral 5-ASA therapy (discontinued oral 5-ASA therapy [≤2g/day] ≤5 days prior to baseline)
and subjects who were 5-ASA naïve (no prior oral 5-ASA or had discontinued oral 5-ASA
therapy [≤2g/day] >5 days prior to baseline). Remission (UC-disease activity index score
of ≤1 with rectal bleeding and stool frequency scores of 0 and a ≥1 point reduction in
sigmoidoscopy score from baseline) rates at week 8 were analyzed. Results: No difference
in disease severity between treatment groups at baseline was observed. In the switched
group, significantly more subjects receiving SPD476 4.8g/day and numerically more subjects
receiving SPD476 2.4g/day achieved remission compared with Pb (Table 1). In the 5-ASA
naïve group, significantly more subjects achieved remission following either dose of SPD476
compared with Pb (Table 1). Conclusions: SPD476 was effective for the induction of
remission of active, mild-to-moderate UC in subjects switched from recent oral 5-ASA
therapies and subjects who were 5-ASA naïve. These data show that subjects with active
UC, despite prior oral 5-ASA therapy, can achieve remission following therapy with SPD476.
The 4.8g dose may give the best result in this setting. Switching to SPD476 may improve
patient compliance and treatment success.
Table 1. Summary of remission rates
*p<0.05; **p<0.01; ***p<0.001 vs Pb; CI = confidence interval
T1140
How Effective Is Anti-TNF-α Therapy? A RE-Analysis of the Precise 2
Maintenance Trial of Monthly Subcutaneous Certolizumab Pegol in Active
Crohn’s Disease Using Remission to Redefine All Efficacy Measures
Stefan Schreiber, Ian C. Lawrance, Juliet A. McColm, Ralph Bloomfield, William J.
Sandborn
Background: In most clinical studies of biologics in Crohn’s disease (CD), response —
defined as a drop of ≥70 or ≥100 points on the CD Activity Index (CDAI) — is used as
an endpoint. Maintenance trials (eg ACCENT I, PRECiSE 2), where patients (pts) responding
to open-label therapy are randomized to receive active agent or placebo (PBO) over 6−12
months, have evolved as a design which separates active treatment from PBO. However,
‘remission’ (CDAI ≤150) used as an efficacy measure throughout this clinical trial design
may better reflect clinical need. Certolizumab pegol is a PEGylated Fab’ fragment of a
humanized monoclonal antibody that neutralizes tumor necrosis factor α. In the PRECiSE
2 Phase III trial, 668 pts with active CD (CDAI 220−450) received open-label subcutaneous
(sc) certolizumab pegol 400 mg at Weeks (Wks) 0, 2, 4, followed by randomization of Wk
6 responding pts (≥100-point decrease from baseline in CDAI) to every 4 Wk certolizumab
pegol 400 mg (n=216) or PBO (n=212) up to Wk 26. Remission (CDAI ≤150) rates at Wk
26 were 47.9% for certolizumab pegol vs 28.6% for PBO (p<0.001) in the overall ITT
population (n=425). Methods: In a post-hoc analysis, remission after open-label induction
at Wk 6 was used to select randomized pts for analysis. Remission rates at Wks 8, 12, 16,
20, 24, and 26 were assessed in this population. In addition, absolute CDAI scores (last
observation carried forward) for the overall PRECiSE 2 ITT population were analyzed.
Results: At Wk 6, 278 pts (42%) were in remission following induction; 132 pts were
randomized to certolizumab pegol and 146 to PBO. At Wk 26, 80 pts (60.6%) in the
certolizumab pegol arm vs 50 PBO pts (34.2%) were in remission (p<0.001; Table). Median
CDAI scores in the overall ITT population remained close to remission levels with certoli-
zumab pegol (Wk 8: 142.0; Wk 26: 148.0), in contrast to PBO (Wk 8: 140.5; Wk 26:
195.4); p<0.001 at Wk 26. Conclusions: Using maintenance of remission as an efficacy
parameter demonstrates an efficacy signal for certolizumab pegol over PBO in a post-hoc
analysis that may better reflect clinical need. Almost two-thirds of pts receiving monthly
certolizumab pegol were in remission at Wk 26. Future induction/maintenance trials of
biologics using the ACCENT I/PRECiSE 2 trial design could use remission instead of response
as a clinically relevant endpoint.
*p≤0.05, **p≤0.01, ***p≤0.001 vs PBO
T1141
Moderate to Severe Crohn’s Disease Induces High Productivity Losses: Work
Productivity and Activity Impairment (WPAI) Baseline Data from the PRECiSE
program
Brian Feagan, Stefan Schreiber, Bernard Selke, Margaret C. Reilly, William J. Sandborn
Background: The direct costs associated with Crohn’s disease (CD) are substantial and are
driven by hospitalizations and surgical procedures. In addition, CD may lead to high indirect
costs — as measured by productivity losses — owing to its early onset during economically
productive years. However, limited information is available regarding work and activity
impairment in these patients. Methods: We described the burden of CD in terms of lost
productivity (at work and in unpaid activities) using baseline data from 2 Phase III multic-
enter, randomized, placebo-controlled clinical trials (PRECiSE 1 and 2) of certolizumab
pegol in moderate to severe CD (Crohn’s Disease Activity Index [CDAI] score 220-450
points, inclusive). The Work Productivity and Activity Impairment (WPAI) questionnaire
was used to collect data on impairment due to CD during the 7 days before the baseline
visit. Four mean scores were calculated: absenteeism (% of work time missed), presenteeism
(% of work time with impairment), overall work impairment (absenteeism plus presenteeism),
and activity impairment. Higher scores indicated greater impairment and lower productivity.
A univariate inferential analysis was used to identify possible factors associated with employ-
ment status. Results: At baseline, patients in the 2 studies of the PRECiSE program were
similar regarding sociodemographic status, clinical characteristics and WPAI scores. Data
from 1330 patients (mean duration of CD: 7.9 years) were analysed. In employed patients
(62.4% of the overall population), absenteeism was 19.5%, presenteeism was 42.0%, and
overall work impairment was 47.5%. Among all patients, the mean activity impairment was
53.3%. Female gender, older age, and presence of prior bowel resection were significantly
associated with being unemployed in patients with CD (Table). Conclusions: Moderate to
severe CD is associated with important loss of productivity. Assessments of the economic
impact of CD treatments should therefore include indirect costs as measured by productiv-
ity loss.
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**p<0.001; *p=0.006; χ2 test.
T1143
Maintenance Therapy with Tacrolimus in Patients with Crohn’s Disease
Refractory to Azathiopurine: 2 Years Trial
Hiroshi Nakase, Hiroyuki Tamaki, Minoru Matsuura, Satoko Inoue, Mitsunori Uza, Satoru
Ueno, Hiroshi Kitamura, Katsuhiro Kasahara, Tsutomu Chiba
Background&Aims: Azathiopurine (AZA) has been widely used in the treatment of inflam-
matory bowel disease (IBD), although many patients with IBD fail to respond to AZA or
suspend it because of its side effect. Tacrolimus has been shown to be effective in the
treatment of IBD. However, there are limited data about the effect of long-term use with
tacrolimus on patients with Crohn’s disease (CD) refractory to AZA. The aim of this trial
was to compare the role of tacrolimus in the induction and maintenance of remission in
CD patients with AZA. Patients and Methods: From 2003 to 2005, thirty seven patients
with moderate to severe CD (8 ileum, 23 ileum and colon, 6 colon) were enrolled in a 2
year prospective controlled study. CD patients who had been refractory to AZA received
tacrolimus therapy. 18 patients treated with tacrolimus were compared to 19 patients treated
with AZA. Tacrolimus was administered orally to aim for serum trough level of 10~15ng/
ml. After patients achieved their clinical remission, tacrolimus was tapered to the serum
trough level 5~10ng/ml. AZA dose used in our institution is adjusted to aim for WBC count
with less than 5000. Efficacy endopoints included clinical improvement (decrease in CDAI
>70), and remission (CDAI≦150). Patients were also monitered for IBDQ. Results: No
difference was present in mean CDAI, mean dose of prednisolone (PSL), and disease pheno-
type at study entry between the two groups. At 3months after treatment, a significant clinical
improvement was observed in both groups (tacrolimus vs AZA: complete remission 57%
vs 63 %, clinical improvement 78.5% vs79 %, p= n.s.). All patients in both treated groups
could completely taper off PSL. At 12months, a significant clinical improvement was observed
in both groups (tacrolimus vs AZA: complete remission 72.2% vs 84 %, p= n.s.). IBDQ
scores were also improved in both groups (tacrolimus vs AZA: 63% vs 53%). At 24months,
13 patients (72.2%) were in remission in tacrolimus group, compared with 14 patients
(73.6%) in AZA group. (p= n.s.). Patients had relapse in both groups, who were treated by
additional infliximab therapy. In tacrolimus group, two patients experienced the increase
of serum creatinine level, but this side effect was managed with dose reduction. No serious
infection was observed during 2 years. In AZA group, no serious side effect was observed.
Conclusion: Maintenance therapy with tacrolimus for 2 years resulted in complete with-
drawal of steroid and keeping remission in patients with CD similar to AZA. Tacrolimus is
a novel alternative option for patients with CD who are not successfully managed on AZA.
T1144
Treatment of Chronic Refractory Pouchitis - A Controlled Study
Bo Shen, Feza Remzi, Bret Lashner, Ana Bennett, Aaron Brzezinski, Rocio Lopez, Jean-
Paul Achkar, Ioannis Oikonomou, Kerry Sherman, Marlene Bambrick, Victor Fazio
Management of chronic refractory pouchitis, one of the most common causes of pouch
failure, is often challenging. AIM: to assess efficacy and safety of combined ciprofloxacin
and tinidazole therapy in patients with chronic refractory pouchitis as compared with
mesalamine therapy. METHODS: Two consecutive cohorts of ulcerative colitis patients with
chronic refractory pouchitis (disease > 4 wks and failure to respond to ≥ 4 wks of single-
antibiotic therapy) seen in the Pouchitis Clinic were assigned to receive a 4-wk course of
ciprofloxacin 1gm/d and tinidazole 15mg/kg/d (N = 16) or a 4-wk course of oral (4gm/d),
enema (8 gm/d) or suppository (1 gm/d) forms of mesalamines (N = 10). The Pouchitis
Disease Activity Index (PDAI, range 0-18) scores, clinical remission (PDAI < 7), clinical
response (reduction in PDAI ≥ 3), the Cleveland Global Quality of Life (CGQL, range 0-
1), Irritable Bowel Syndrome-Quality of Life (IBS-QOL, range 34-170), and Short-Form
Inflammatory Bowel Disease Questionnaires (SF-IBDQ, range 0-70) scores were calculated
pre- and post- therapy and compared between the 2 treatment groups. Adverse effects were
documented. RESULTS: The demographic and baseline clinical, baseline PDAI and QOL
scores were similar between the 2 groups. The 4-wk ciprofloxacin+tinidazole or mesalamine
therapy resulted in significant reduction in PDAI scores, and the antibiotic therapy also led
to a significant improvement in all QOL scores (Table). Patients in the antibiotic groups
had a greater reduction of the PDAI score and a greater improvement in IBS-QOL and IBDQ
scores than the mesalamine group (P < 0.03). The clinical remission and response rates
were 88% and 88% for the antibiotic group; 50% and 50% for the mesalamine group (P =
0.07). Two patients in the antibiotic group developed adverse effects (peripheral neuropathy
and dysgeusia)who were able to complete the trial, compared to none in the mesalamine
group had adverse effects(P = 0.51). CONCLUSIONS: A combined ciprofloxacin and tinida-
zole therapy was generally well tolerated, was effective in treating patients with chronic
refractory pouchitis by inducing remission, reducing disease activity scores and improving
QOL scores, and appeared to be more efficacious than mesalamine therapy. The results


















Efficacy of “Half Elemental Diet” As a Maintenance Therapy for Crohn’s
Disease: Crohn’s Disease Half Elemental Diet Study in Sendai (CHESS): A
Randomized Controlled Trial
Sho Takagi, Kyoko Utsunomiya, Shinichi Kuriyama, Hiroshi Yokoyama, Shuichiro
Takahashi, Masahiro Iwabuchi, Hiroki Takahashi, Seiichi Takahashi, Yoshitaka Kinouchi,
Nobuo Hiwatashi, Yuji Funayama, Iwao Sasaki, Ichiro Tsuji, Tooru Shimosegawa
[Background & aim] Crohn’s disease (CD) is a chronic inflammatory bowel disease which
is characterized by frequent relapses. In Japan, home enteral nutrition (HEN) has been used
preferably for a maintenance therapy, which includes a way that the patients take the half
of a daily consumption by elemental diet (ED) and the remaining half by food. We named
this type of HEN therapy as “half ED”. While there have been several reports on the efficacy
of HEN, it is also argued to deteriorate the quality of life (QOL) of patients. The aim of this
study was to investigate the efficacy of half ED as a maintenance therapy.[Methods] From
December 2002 to June 2005, patients were recruited from two clinical centers in Sendai,
Japan. Patients were eligible in the study, (1) when they had been diagnosed as CD clinically,
endoscopically, radiologically and/or histologically, (2) when they had been just induced to
remission stage and (3) when they had been guided properly in their eating by nutritionists
or medical doctors once or more. 51 patients were randomly assigned to either a half ED
group (n=26) or a free diet group (n=25). Participants belonging to the half ED group were
required to take the half daily calorie by ED and the remaining half by normal meal. The
dosage of half ED per day was set for 900-1200 kcal (3-4 packages) and was given through
a self-inserted feeding tube and/or oral intake. Participants belonging to the free diet group
were required to take all nutrition by normal unrestricted meal. The clinical course was
followed and the trial was stopped for significant efficacy after 51 patients had been random-
ized. The primary end point was the incidence of relapse and the secondary end points
included the QOL of participants and medical expenses. Remission and relapse were defined
as the Crohn’s disease activity index under 150 and over 200, respectively. [Results] A
relapse rate in the half ED group is significantly lower (34.6% vs 64.0%; hazard ratio 0.36
[95% CI 0.15-0.83], P =0.016) than that in the free diet group. The compliance of the 2
groups was similar. No adverse events had occurred in all patients through the study.
[Conclusion] This is the first randomized controlled trial showing the efficacy of half ED,
and the results indicated that half ED is one of valuable candidates as a maintenance therapy
for CD.
T1146
Long-Term Safety Analysis of Budesonide in Crohn’s Disease: A Pooled
Analysis of Five 1-Year Studies
Gary Lichtenstein, Louise Hapten-White, William J. Sandborn
Aim: To evaluate the overall long-term safety profile of oral budesonide (BUD) for mainten-
ance of remission in patients with mild to moderately active Crohn’s disease (CD) of the
ileum and/or ascending colon. Methods: Five 1-year, double-blind, placebo-controlled trials
evaluating BUD 6mg QD as maintenance therapy in mild to moderate CD with identical
protocols were analyzed. A total of 417 patients with CD in remission (CDAI ≤ 150) were
randomized to receive BUD 6mg (208 patients) or placebo (209 patients) QD for 12 months.
The primary endpoint of the study was to analyze safety of BUD and to compare this with
placebo. Results: Overall, reports of adverse events (AEs) by body system were similar
between the 2 groups. There were no significant differences (P ≥ 0.30) in reports of AEs
in patients treated with BUD or placebo in the following body systems: gastrointestinal (39%
vs 44%); general, whole body (21% vs 22%); respiratory (19% vs 18%); nervous system
(14% vs 11%); psychiatric (13% vs 11%); or skin and appendages (13% vs 13%). The only
significant differences in reported AEs by body system occurred in endocrine disorders (BUD
39%, placebo 25%; P = 0.0042) and resistance mechanism disorders (BUD 11%, placebo
5%; P = 0.042). The increased frequency in endocrine disorders was due to a higher, but
not statistically different, incidence of acne (BUD 15%, placebo 9%; P = 0.07) and moonface
(BUD 11%, placebo 6%; P = 0.075). There were no differences in other cutaneous corticos-
teroid (CS) symptoms such as swollen ankles (BUD 3%, placebo 3%; P = 1.00); bruising
(BUD 11%, placebo 7%; P = 0.23); hirsutism (BUD 6%, placebo 2%; P = 0.13); or skin
striae (BUD <0.5%, placebo 1%; P = 1.00). The majority of AEs were mild to moderate in
intensity. Thirty-five BUD and 41 placebo patients reported serious AEs (SAEs). Risk of
SAEs associated with CS use, such as adrenal insufficiency, cataracts, fractures, and osteopor-
osis were not increased with BUD treatment. The incidence of AEs was higher, although
not statistically different, in female versus male patients in both the BUD group (82% vs
73%, respectively; P = 0.21) and in the placebo group (82% vs 72%, respectively; P = 0.12).
The largest differences between female and male patients were seen in abdominal pain (17%
vs 10%, P = 0.20), vomiting (10% vs 2%, P = 0.052) and nausea (10% vs 3%, P = 0.12).
Finally, discontinuation due to AEs occurred in 8% and 10% of the BUD and placebo-
treated patients, respectively (P = 0.62). Conclusion: Long-term treatment with budesonide
capsules is well-tolerated, with a safety profile comparable to placebo and with rare occur-
rences of SAEs causally-related to its treatment.
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T1147
Once- and Twice-Daily Spd476, a Novel, High-Strength Formulation of 5-ASA,
Induces Remission of Both Mild and Moderate Ulcerative Colitis: A
Prespecified Analysis of Combined Data from Two Pivotal, Randomized,
Placebo-Controlled, Phase III Studies
Gary R. Lichtenstein, Michael A. Kamm, William J. Sandborn, Miguel Gassull, Stefan
Schreiber, Lechoslaw Jackowski, Prabhakar Boddu, Natalya Gubergrits
Background: Existing 5-ASA (mesalamine) formulations for the treatment of ulcerative colitis
(UC) require multiple-daily dosing, which may lead to patient non-compliance and thus
reduced treatment efficacy. SPD476 is a novel, high-strength (1.2g/tablet), once-daily formu-
lation of 5-ASA that uniquely combines a gastro-resistant polymer film, to delay release of
the active drug until the terminal ileum, and MMX Multi Matrix System™ (MMX) technology
to extend consistent delivery of 5-ASA throughout the entire colon. In two pivotal, random-
ized, placebo-controlled, phase III studies (SPD476-301 [Study 301] and SPD476-302 [Study
302]), SPD476 was well tolerated and effective for the induction of remission of mild-to-
moderate UC (a score of 4-10 on the UC disease activity index [UC-DAI]). To demonstrate
the efficacy of SPD476 in subjects that experienced either mild (UC-DAI score 4 to <6) or
moderate (UC-DAI score 6-10) disease, a prespecified analysis of combined data from these
studies was performed. Methods: Data from these two phase III studies were analyzed for
subjects with mild disease who received SPD476 2.4g/day (given once daily [QD; Study
302] or twice daily [BID; Study 301] combined n=67), SPD476 4.8g/day (given QD [Studies
301 and 302] combined n=70) or placebo (combined n=58). Similarly, data were analyzed
for subjects with moderate disease for each treatment regimen (combined n=104, 103 and
112, respectively). The proportion of subjects with either mild or moderate disease achieving
remission (primary endpoint: UC-DAI score of≤1, with a rectal bleeding and stool frequency
score of 0 and ≥1 point reduction in sigmoidoscopy score from baseline) after 8 weeks
treatment with SPD476 2.4g/day or 4.8g/day were compared with placebo. Results: At week
8, a significantly greater percentage of subjects with mild disease receiving SPD476 2.4g/
day achieved remission compared with placebo (44.8 vs 20.7%; p=0.004), while a numerically
greater proportion of subjects with mild disease receiving SPD476 4.8g/day achieved remis-
sion (35.7 vs 20.7%; p=0.061). Similarly, a significantly larger proportion of subjects with
moderate disease achieved remission following treatment with SPD476 2.4g/day or 4.8g/
day compared with placebo (32.7%; p=0.004 and 35.0%; p=0.001 vs 16.1%, respectively).
Disease severity was not a predictor of response to treatment. Conclusions: This unique 5-
ASA formulation, utilizing MMX technology, was effective for the induction of remission of
active, mild and moderate UC at doses of 2.4g/day and 4.8g/day. SPD476, by offering
treatment of mild and moderate disease with a simple dosing regimen, may improve overall
treatment success.
T1148
SPD476, a Novel Formulation of 5-ASA Given Once Or Twice Daily, Is
Effective for the Induction of Remission of Left-Sided and Extensive Ulcerative
Colitis: An Analysis of Combined Data from Two Pivotal, Randomized,
Placebo-Controlled Phase III Studies
Michael A. Kamm, Gary R. Lichtenstein, William J. Sandborn, Miguel Gassull, Stefan
Schreiber, Lechoslaw Jackowski, Prabhakar Boddu, Natalya Gubergrits
Background: Nearly 80% of patients diagnosed with ulcerative colitis (UC) have left-sided
disease, affecting the colon below the splenic flexure. 5-ASA treatment regimens, the standard
of care, often require inconvenient multiple-daily, oral dosing or enema administration in
order to induce remission. Such regimens can lead to patient compliance issues, which
may reduce drug efficacy. SPD476 is a novel, high-strength (1.2g/tablet), once-daily (QD)
formulation of 5-ASA that uniquely combines a gastro-resistant film, to delay initial drug
release until terminal ileum, and MMX Multi Matrix System™ (MMX) technology, designed
to extend consistent delivery of the active drug beyond the splenic flexure. Two phase III
studies (SPD476-301 and SPD476-302) have shown that SPD476 2.4g/day (administered
QD or twice daily [BID]) or 4.8g/day (administered QD) is effective and well tolerated for
the induction of remission of mild-to-moderate UC. Methods: In this analysis, data from
Studies SPD476-301 and SPD476-302 were combined to compare treatment responses for
subjects with left-sided disease and subjects with extensive UC (including pancolitis or
involvement of the transverse colon). Subjects with left-sided disease received SPD476 2.4g/
day (given QD [SPD476-302] or BID [SPD476-301]; n=137), SPD476 4.8g/day (given QD;
n=138) or placebo (n=129). Similarly, subjects with extensive disease received the same
treatment (n=35, 35 and 42 for each treatment group, respectively). Subjects with proctitis
only (inflammation ≤15cm from the anus) were excluded from the original studies. The
percentage of subjects with left-sided or extensive disease achieving remission (UC-disease
activity index of ≤1, with a rectal bleeding and stool frequency score of 0 and ≥1 point
reduction in sigmoidoscopy score from baseline) following 8 weeks treatment with SPD476
2.4g/day or 4.8g/day was compared with placebo. Results: At week 8, a statistically signific-
antly greater proportion of subjects with left-sided UC receiving SPD476 2.4g/day or 4.8g/
day achieved remission compared with placebo (37.2% [p<0.001] and 33.3% [p=0.006] vs
18.6%]). Similarly, statistically significantly more subjects with extensive UC receiving either
dose of SPD476 achieved remission by week 8, compared with placebo (37.1% [p=0.034]
and 42.9% [p=0.005] vs 14.3%). No correlation between disease location and treatment
activity was observed. Conclusions: SPD476, a unique, high-strength formulation of 5-ASA
utilizing MMX technology, is effective for the induction of remission of left-sided and more
extensive UC at doses of 2.4g/day and 4.8g/day. Additional benefit should accrue from high-
strength, once-daily dosing.
T1149
Maintenance Treatment with Natalizumab Improves the Health Related
Quality of Life (HRQOL) in Crohn’s Disease Patients
Brian Feagan, Jean-Frederic Colombel, Robert Enns, Stephen Hanauer, Ian Lawrance,
Remo Panaccione, Paul Rutgeerts, Stefan Schreiber, Stephan Targan, Sander van Deventer,
William Sandborn
Purpose: Crohn’s disease is associated with impaired HRQOL. This analysis investigated
HRQOL outcomes during maintenance therapy with natalizumab (a humanized monoclonal
IgG4 antibody to α4 integrin) in the ENACT-2 trial where higher rates of sustained response
and remission were observed compared with placebo. Methods: Patients who responded
to natalizumab induction therapy (n=339) were randomized to natalizumab 300 mg (n=
168) or placebo infusions (n=171) given monthly for up to 12 months. HRQOL was measured
by the Inflammatory Bowel Disease Questionnaire (IBDQ) and the Short Form-36 (SF-36)
at months 0, 3, 6, 9, and 12. Higher scores on each indicate better HRQOL. A Total IBDQ
score >170 has been identified as indicating clinical remission. The Physical Component
Summary (PCS) and the Mental Component Summary (MCS) of the SF-36 are computed
such that a mean score of 50 (SD=10) corresponds to the US general population. Results:
The mean total IBDQ scores of the natalizumab treated patients were significantly greater
than those of the placebo group at months 3 through 12 (p<0.01) and their scores remained
above 170 at each of these time points, while the placebo group fell below this threshold
by the month 3 assessment. Among patients who were in remission, those receiving
natalizumab had a higher quality of remission as measured by total IBDQ, with natalizumab
patients reporting significantly greater scores at months 3 through 12 (p<0.01). HRQOL
findings with the SF-36 paralleled those observed with the IBDQ, with natalizumab patient
PCS and MCS scores significantly greater than those of placebo patients at all measurements
post-randomization. With the exception of the MCS comparison at month 3 (p<0.011), all
PCS and MCS comparisons were significant at p<0.01. Mean month 12 scores of the two
arms on each of the 8 scales of the SF-36 were compared to established norms of the US
population. Natalizumab treated patients had significantly higher scores than the placebo
arm on all scales (p<0.01). While placebo patients scored significantly lower than US norms,
(p<0.011), natalizumab scores were not significantly different from US norms on 6 of the
8 scales (Physical Functioning, Role Physical, Bodily Pain, Social Functioning, Role Emotional,
Mental Health). Conclusions: Maintenance therapy with natalizumab resulted in significantly
improved HRQOL, as evidenced by both disease specific (IBDQ) and general (SF-36) meas-
ures. Patients receiving natalizumab were observed to achieve a higher quality of remission
than those receiving placebo and, across the majority of scales of the SF-36, their quality
of life was similar to that of the general US population.
T1150
Lysophosphatidic Acid (LPA) Stimulates Protein Kinase D2-Mediated Nf-κB
Dependent Interleukin-8 Secretion in Nontransformed, Human Colonic
Epithelial Cells- a Potential Signaling Pathway in Intestinal Repair
Wai Yin Leung, Mary Moyer, Robert M. Strieter, Enrique Rozengurt, Terence Chiu
Background/Aims: LPA, which is released at injured epithelial surface (2-20μM in serum),
stimulates intestinal epithelial cell migration, proliferation and interleukin-8 (IL-8) secretion.
We have shown that LPA stimulated Protein kinase D (PKD) activation in rat IEC-6 and
IEC-18 cells. PKD and the newly identified isoforms, PKD2 and PKD3, constitute a novel
family of serine kinases. Epithelial cell functions linked to PKD include migration, prolifera-
tion and polarized Golgi function. However, endogenous G-protein coupled receptor-medi-
ated regulation and function of PKD2 had not been examined. PKD2 is the only detectable
PKD isoform in nontransformed, human colonic epithelial NCM460 cells. We investigated
the signaling pathways mediating LPA-stimulated PKD2 activation and the potential contribu-
tion of PKD2 in regulating LPA-induced IL-8 secretion in NCM460 cells. Results: Treatment
of NCM460 cells with LPA (5μM) led to a rapid activation of PKD2, as measured by in
vitro kinase assay and phosphorylation at the activation loop (Ser706/710) and autophosphor-
ylation site (Ser876). Maximal effect was obtained after 1 min of LPA incubation. LPA-
induced PKD activation was abrogated by preincubation with PKC inhibitors, GF-I and
Ro 31-8220. Pertussis toxin partially inhibited LPA-induced PKD2 activation, suggesting
involvement of other G proteins in addition to Gi. RT-PCR yielded LPA receptor subtypes,
LPA2 and LPA3 in NCM460 cells. Both receptors couple to Gi and Gq in multiple cell types,
but LPA1 predominantly couples to Gi. To explore the significance of LPA-induced PKD2
activation, we tested whether LPA could stimulate IL-8 secretion. LPA induced a 20-fold
increase in IL-8 production at 6 hours. Given the importance of NF-κB in IL-8 expression
in human colonic epithelial cells, we examined whether PKD2 may mediate IL-8 production
via a NF-κB-dependent manner. LPA stimulated NF-κB activation as measured by NF-κB-
DNA binding, NF-κB driven luciferase reporter activity, and IκB-α phosphorylation. PKD2
gene silencing utilizing siRNAs targeting distinct PKD2 sequences dramatically reduced LPA-
stimulated IL-8 secretion as well as NF-κB promoter activity. Conclusion: PKC-dependent
PKD2 activation is a novel early event in the biological action of LPA and mediates LPA-
stimulated IL-8 secretion in NCM460 cells through a NF-κB-dependent pathway. We envisage
that at sites of intestinal epithelial injury, high local concentrations of LPA can stimulate
PKC/PKD2-mediated NF-κB activation, resulting in IL-8 secretion. This in turn may lead
to neutrophil recruitment to counter potential bacterial invasion and stimulation of myofibro-
blasts, engaged in repair process.
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Ginkgo Biloba Is a Potent Anti-Inflammatory Agent in Intestinal Epithelium:
Therapeutic Potential for Suppression of NF-kB Activation and I-kb
Degradation
Ali Banan, Lijuan Zhang, Philip Engen, Maliha Shaikh, Jeremy Z. Fields, Christopher B.
Forsyth, Ashkan Farhadi, Ali Keshavarzian
NF-κB activation is a crucial event in the development of inflammatory responses in a wide
variety of GI disorders, including inflammatory bowel disease (IBD). To date, in spite of
intensive investigation, an effective & safe means of attenuating NF-kB activation in GI tract
diseases is still lacking. Traditional Complementary & Alternative Medicine (CAM) systems
recommend putative anti-inflammatory herbs such as Ginkgo Biloba (GB). Despite claims,
it has not been established whether this herb has anti-inflammatory effects & is beneficial
against intestinal inflammation & its mechanism of action is not known. Aims: We sought
to determine whether NF-kB inactivation and cellular protection can be induced by GB
under conditions of oxidative stress. Methods: Intestinal cells were pretreated with GB &/
or NF-kB modulators prior to oxidants (H2O2 or HOCl). In other studies, cells were
transfected with an IkB mutant to inhibit NF-kB. We measured monolayer integrity (LIVE/
DEAD assay, fluorometry), NF-kB p50/p65 subunit activities (EMSA, ELISA), NF-kB modu-
lator, IkB-α levels/phosphorylation (PAGE), and structural protein integrity (laser confocal
microscopy, SDS-PAGE), n=6/grp. Results: {I} Pretreatment with GB dose-dependently
reduced IkB instability, decreased NF-kB nuclear translocation, and reduced NF-kB subunit
activities while protecting barrier protein cytoarchitecture & monolayer integrity. {II} IkB
stabilizers (MG-132, Lactacystin, etc) prevented oxidant-induced effects. Inhibitors of NF-
kB activation (e.g., PDTC) led to synergy induced protection in the presence of GB. Moreover,
selective potentiation of NF-kB activity by phosphoseryl/threonyl protein phosphatases [PAO,
PV] prevented GB protection during oxidative stress. {III} IkB stabilization by dominant
mutant transfection also led to protection. Similar to blunting effects of the above pharmacolo-
gical agents, mutant stabilization of IkB not only led to synergy induced protection with
GB, but also with growth factor (EGF), and abolished NF-kB alterations. Conclusions: Our
data indicate a unique anti-inflammatory affect for a traditional botanical dietary supplement,
Ginkgo Biloba. (1) Ginkgo Biloba appears to protect against oxidative injury through inactiva-
tion of the key proinflammatory factor, NF-kB. (2) The molecular mechanism underlying
this potent anti-inflammatory affect of Ginkgo Biloba appears to depend on the stabilization
of the endogenous inhibitor of NF-kB, namely IkB-α. Accordingly, this botanical dietary
supplement may be useful for development of novel therapies for a wide variety of inflammat-
ory gut disorders where NF-kB is activated.
T1152
Tacrolimus (FK506), An Immunosuppressive Agent, Prevents Indomethacin-
Induced Small Intestinal Ulceration in Rats: Inhibition of iNOS Expression
Through Suppressing Nf-Kappa B Activation
Shinichi Kato, Kazuhiro Fukushima, Yoko Aoi, Koji Takeuchi
Background/Aim: Tacrolimus (FK506), an immunosuppressive drug, is widely used for organ
transplantation and atopic dermatitis. Recent clinical studies have also demonstrated the
beneficial effect in the treatment of rheumatoid arthritis (RA) and inflammatory bowel
diseases. Nonsteroidal anti-inflammatory drugs (NSAIDs), which have been used for the
treatment with RA, are known to cause damages in the small intestine as well as the stomach.
Nitric oxide (NO) derived from inducible NO synthase (iNOS) plays a pivotal role in the
pathogenesis of NSAID-induced small intestinal ulceration. Since tacrolimus has been also
shown to suppress the expression of iNOS in various tissues and cells, this agent may have
a beneficial effect on indomethacin-induced intestinal ulceration. In the present study, we
examined the effect of tacrolimus on indomethacin-induced small intestinal ulceration in
rats. Methods: Male SD rats were used. Indomethacin (10 mg/kg) was administered SC,
killed 24 h later, and the area of lesions, myeloperoxidase (MPO) activity and thiobarbituric
acid reactants (TBARS) were evaluated. Tacrorimus (0.3~3 mg/kg) was administered PO
twice 30 min before and 6 h after indomethacin. The expression of iNOS mRNA was
determined by a quantitative real-time TaqMan RT-PCR, while the activity of NF-kappa
B DNA-binding was analyzed by electrophoresis mobility shift assays (EMSA) 6 h after
indomethacin. Results: Indomethacin provoked severe hemorrhagic lesions in the small
intestine, mainly the jejunum and ileum, accompanied with a marked increase in MPO
activity and TBARS. Oral administration of tacrolimus significantly prevented indomethacin-
induced intestinal lesions in a dose-dependent manner, a complete inhibition being observed
at 3 mg/kg. The increase in MPO activity and TBARS was also significantly attenuated by
tacrolimus. The expression of iNOS mRNA was apparently enhanced by indomethacin at
6 h after the administration, and this response was almost totally attenuated by tacrolimus.
Indomethacin also induced the NF-kappa B activation, in a tacrolimus-preventable manner.
Conclusion: Tacrolimus prevents indomethacin-induced small intestinal lesions. This effect
may be due to inhibition of iNOS induction through suppressing the activation of NF-kappa
B. It is thus assumed that tacrolimus is useful for not only the treatment of RA itself but
also for preventing the intestinal adverse effect of NSAIDs used in the treatment of RA.
T1153
Alterations of Expression and Function of the Na+/H+ Exchanger NHE3 During
Early Inflammation in IL-10 Knockout Murine Intestine
Tesfaye Tessema, Ayhan Cinar, Brigitte Riederer, Andre Bleich, Westendorf Astrid, Jan
Buer, Michael P. Manns, Ursula Seidler
Introduction: Acute flares of Crohn’s disease are often accompanied by watery diarrhea,
the pathophysiology of which is incompletely understood. In distal colon, inflammation
strongly downregulates both mRNA levels and surface expression of the epithe-lial sodium
channel ENaC, but this channel is not expressed in the proximal colon and ileum. In this
part of the intestine, electroneutral salt absorption predominantes, mediated by the Na+/
H+ exchanger NHE3 and the anion exchanger SLC26A3. Aim: We investigated NHE3 mRNA

















of IL-10 deficent mice, which develop a proximally predominant inflamma-tion. Methods:
IL-10 deficient mice on a C57/B6 backround were raised under SPF condi-tions, then in
part transferred to a normal environment. Age and sex-matched IL-10 +/+ mice raised in
identical environment were used as controls. mRNA expression levels of IF-gamma and IL-
1beta, as well as NHE3 in the ileal and proximal colonic tissue of IL-10 deficient mice in
the early stage of inflammation (8-12 weeks post exposure) were measured by quantitative
PCR. NHE3 protein localization was studied by immunohistochemistry. Sodium absorption
of isolated ileum and colon was measured in Ussing-chambers. To differentiate between
distur-bances of NHE3 transport function and leaky tight junctions, NHE3 transport rates
were as-sessed fluorometrically in the NHE3-expressing surface cells of BCECF-loaded IL-
10 +/+ and -/- colonic crypts. Total NHE exchange activity in the surface cell and cryptal
region was also measured, as well as NHE1 plus NHE2 activity in the crypts. Results: We
found that in IL-10 deficient mice in normal but not in SPF conditions developed mild
diarrhea and a virtual loss of active Na+ absorption in inflamed tissue. IF-gamma and IL-1beta
mRNA were strongly upregulated, as expected. Histology showed mild crypt hyperplasia and
leukocyte infiltration. Surprisingly, NHE3 mRNA was strongly upregulated, and the surface
cell area which stained apically for NHE3 were found to penetrate more into the openings
of the hyper-trophied crypts. On the other hand, NHE3 activity showed strongly decreased
acid-activated transport activity as well as impaired regulation. This reduction in transport
activity was seen only for NHE3, not for NHE in general. Conclusion: The data suggest
that in the early stage of immune-mediated intestinal inflammation, mRNA expression of
the Na+/H+ ex-changer NHE3 is strongly upregulated and NHE3 protein is correctly located
in the brush border membrane, but nevertheless transport activity is severely impaired due
to as yet un-known intracellular events.
T1154
Effect of Interleukin-1β (IL-1β) On Intestinal Epithelial Tight Junction
Permeability
Rana Al-Sadi, Thomas Y. Ma
IL-1β is a pro-inflammatory cytokine that plays a key role in intestinal inflammation. Recent
studies have shown that pro-inflammatory cytokines TNF-α and IFN-γ cause an increase
in intestinal tight junction (TJ) permeability. It has been proposed that the cytokine-induced
increase in intestinal TJ permeability is an important mechanism contributing to intestinal
inflammation. Despite its central role in promoting intestinal inflammation, the role of IL-
1β on intestinal TJ barrier remains unclear. The aims of this study were to determine the
role of IL-1β in the modulation of intestinal TJ barrier and to elucidate the intracellular
pathway involved in the IL-1β modulation of intestinal TJ barrier. Methods: Filter-grown
Caco-2 cells were used as an in vitro intestinal epithelial model system to study the TJ
permeability. Results: IL-1β caused a concentration and time-dependent decrease in Caco-
2 transepithelial resistance (TER). Conversely, IL-1β (10 ng/ml) caused a progressive time-
dependent increase in transepithelial permeability (20-fold increase) to paracellular marker
inulin. IL-1β induced increase in Caco-2 TJ permeability was accompanied by a decrease
in occludin expression and disruption in junctional localization. IL-1β treatment resulted
in a sequential degradation of IκB-α, cytoplasmic-to-nuclear translocation of NF-κB p65
and an increase in NF-κB binding to a known DNA binding site, indicating activation of
NF-κB pathway. NF-κB inhibitors, PDTC and SC-514, inhibited both the IL-1β induced
activation of NF-κB pathway and increase in Caco-2 TJ permeability. PDTC and SC-514
also prevented the IL-1β induced down-regulation of occludin protein expression and
disturbance in junctional localization. To further validate the requirement of NF-κB in the
IL-1β increase in Caco-2 TJ permeability, NF-κB p65 was depleted in filter-grown Caco-2
cells by siRNA transfection. NF-κB p65 siRNA transfection resulted in a marked knock-
down of NF-κB p65 protein expression (95% depletion). NF-κB p65 depletion completely
inhibited the IL-1β induced increase in TJ permeability and IL-1β induced down-regulation
of occludin protein expression. Conclusion: IL-1β caused an increase in Caco-2 TJ permeabil-
ity and disturbance in occludin expression and junctional localization. The IL-1β induced
increase in Caco-2 TJ permeability and alteration in occludin expression were mediated by
the activation of NF-κB pathway.
T1155
The Opioid Antagonist Naltrexone Alleviates Chemically-Induced Colitis
Gail L. Matters, John F. Harms, Leo R. Fitzpatrick, Anuj M. Parikh, Nicholas J. Nilo, Jill
P. Smith
Background and Aims: Endogenous opioids have been shown to influence inflammatory
responses through the modulation of cytokine production. Additionally, opioid antagonists
promote tissue growth and repair. It was hypothesized that the opioid antagonist naltrexone
could reduce inflammation and promote repair of the bowel in a chemically-induced mouse
model of inflammatory bowel disease. Methods: Forty-eight C57BL/6J mice were divided
into two groups: one received untreated drinking water and the other received 2% dextran
sodium sulfate (DSS) for 5 days. On the third day after DSS was introduced, 8 animals in
each group were injected subcutaneously with 0.1 ml saline (control) or naltrexone (NTX,
0.1 or 10 mg/kg) daily for 5 days. Disease activity index (DAI) scores, based on weight loss
and stool hemoccult, were calculated daily. Mice were necropsied on day 9 and inflammation
of the distal colons was analyzed histologically. Colonic RNA was evaluated by microarray
and real-time RT-PCR. Results: By day 4, DSS-treated animals had significant weight loss
(p = 0.006) and a higher DAI score (p < 0.001) compared to water controls. At necropsy,
DSS-treated mice that received NTX (10 mg/kg) had less weight loss (30.8%), lower DAI
scores (24.6%), and less inflammation (25.0%) compared to DSS mice that received only
saline. Real-time RT-PCR demonstrated an increased expression of the cytokines IL-6 and
IL-12 in DSS-treated mice. The increase in these pro-inflammatory cytokines was reversed
by NTX treatment to levels near or equal to the expression in mice without colitis. Further-
more, the expression of the transcription factors STAT3 and STAT4, downstream effectors
of cytokine signaling, was upregulated in the colons of DSS-treated mice and similarly
reversed by NTX. Conclusions: NTX treatment reverses the disease manifestations and histol-
ogic evidence of inflammation in DSS-induced colitis. The mechanism by which NTX acts
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to reverse colitis is related in part to the decreased expression of pro-inflammatory cytokines
(IL-6 and IL-12) and their downstream mediators (STAT3 and STAT4).
T1156
Stimulus Specific Role for Fer Tyrosine Kinase in Neutrophil Recruitment:
Role of P38 MAPK and PI3 Kinase
Maitham A. Khajah, Graciela Andonegui, Donna-Marie McCafferty
Neutrophil recruitment and directional movement towards chemotactic stimuli are important
processes in the innate immune response. This study examines if Fer PTK plays a role in
neutrophil recruitment and chemotaxis to various stimuli in vivo and in vitro. Mice targeted
with a kinase-inactivating mutation (ferDR/DR) or wild type mice (WT) were used. In vivo
time-lapse intravital microscopy was used to examine leukocyte recruitment and chemotaxis
in response to keratinocyte-derived cytokine (KC; 5.2 µM) or chemotactic peptide WKYMVm
(0.1 µM). In WT and ferDR/DR no difference in chemotaxis in response to KC was observed.
However, in response to WKYMVm a two fold increase in leukocyte emigration was noted
in ferDR/DR mice (p<0.05). Bone marrow chimeras, where ferDR/DR received WT bone marrow,
showed similar chemotaxis to WT in response to WKYMVm suggesting that endothelial Fer
kinase was not playing a role in chemotaxis. In vitro neutrophil chemotaxis was assessed
with bone marrow derived neutrophils using an under agarose gel assay. No difference in
chemotaxis was noted between WT and ferDR/DR mice in response to KC in vitro. However,
a two fold increase in chemotaxis was noted in ferDR/DR vs WT neutrophils in response to
WKYMVm. This chemotactic response was inhibited by two p38 MAPK inhibitors (SKF86002
and SB203580) in WT mice but not in ferDR/DR mice suggesting a regulatory role for Fer
kinase on the p38 MAPK pathway. Interestingly, in ferDR/DR mice a role for the PI3 kinase
pathway in chemotaxis was revealed using a PI3 kinase inhibitor (LY294002). In addition, in
ferDR/DR neutrophils superoxide anion production (O2-) started earlier than in WT neutrophils
which suggests that activation of the PI3kinase pathway is responsible for this observation.
These data suggest that Fer kinase regulates neutrophil chemotaxis in response to WKYMVm
through the regulation of p38 MAPK signaling pathway. This work was funded by a Canadian
Institutes of Health Research operating grant.
T1157
Proof of Gaps in Human Small and Large Intestinal Epithelium By in Vivo
Histology with Confocal Laser Endoscopy
Alastair J. Watson, Ralf Kiesslich, Elizabeth M. Angus, Peter R. Galle, Constantin
Schneider, Katharina Lammersdorf, Marshall H. Montrose, Markus F. Neurath
In vivo confocal microscopy has identified single-cell discontinuities in the small intestinal
epithelium of mice (Gastro 2005;129:902). These gaps lack cellular material but are the
diameter of epithelial cells and are created by the shedding of epithelial cells. Gaps are not
visualized well in standard histology. Aim: To evaluate the presence gaps in human small
and large intestinal epithelium using confocal laser endoscopy. Methods: Patients (n = 12)
designated for IBD screening were enrolled with informed consent and underwent total
colonoscopy with a confocal laser endomicroscope, enablingin vivo morphology of the
mucosal layer to be imaged in real time (Optiscan, Australia; Pentax, Japan; 488nm excitation
by argon ion laser; detection >515 nm) (Gastro 2004;127:706). Mucosal surface was analyzed
for the presence of epithelial gaps at 2 or more focal depths into tissue. A Gap was defined
as an area distinct from goblet cells which lacked nuclei and cytoplasm present in multiple
focal planes despite their presence in neighboring cells. Results: Gaps (arrows) are present
in both small and large intestine. At the colonic surface or villus tip their diameter varies
from 2 to 10 µm. This is consistent with gaps being transient structures after single cell
shedding. Gaps are not evenly distributed down the gut and appear to cluster on the colonic
table or near the villus tip. 30 ± 19% of analysable images contained gaps. Conclusion:
The presence of frequent discontinuities in normal human intestinal epithelium is a new
concept in gastrointestinal biology. The impact of these gaps on the pathogenesis of gastrointe-
stinal diseases such as IBD and celiac disease must now be evaluated.
T1158
Prohibitin (PHB) Expression Is Decreased During Intestinal Inflammation and
May Protect Against Inflammation-Induced Oxidative Damage
Arianne L. Theiss, Richard D. Idell, Lixin Wang, Dean P. Jones, Didier Merlin, Shanthi V.
Sitaraman
INTRODUCTION: Prohibitin (PHB) is an evolutionarily conserved and ubiquitously
expressed protein that is implicated in diverse cellular processes such as oxidative stress. The
expression and function of PHB in the normal intestine and during intestinal inflammation are
not known. Oxidative stress and its consequent effects on intestinal barrier dysfunction and
wound healing have been shown to play an important role in the pathogenesis of chronic
intestinal inflammation. We tested the hypotheses that the acute phase cytokine IL-6 increases
PHB expression and that PHB modulates oxidative stress associated with intestinal inflamma-
tion. METHODS: PHB protein expression was assessed in mucosal biopsies from Crohn’s
disease (CD) and normal patients and in colitic changes from mice treated with dextran
sodium sulfate (DSS) or from IL-10 knockout mice. PHB mRNA and protein expression
was measured in Caco2-BBE intestinal epithelial cells treated with IL-6 (100 ng/ml) for
various amounts of time. Localization of PHB was determined by confocal microscopy in
Caco2-BBE cells treated with IL-6 or transfected with a His-tagged PHB expression vector.
To determine the effect of oxidative stress on PHB expression, Caco2-BBE cells were treated
with 0.5 mM H2O2 for 1 hour to induce oxidative stress and assayed for PHB expression.
Caco2-BBE cells treated with IL-6, H2O2, or pretreated with IL-6 to induce PHB and then
treated with H2O2 were assayed for glutathione (GSH) levels, an established marker of
oxidative stress. RESULTS: PHB is down-regulated during active human CD, experimental
colitis in vivo, and during oxidant stress in vitro. IL-6 potently induces PHB expression in
Caco2-BBE cells. PHB is expressed in the cytoplasm and cell membrane of Caco2-BBE cells
during basal conditions and translocates to the nucleus upon IL-6 stimulation or when
overexpressed. Finally, IL-6 pretreatment inhibits H2O2-induced depletion of the antioxidant
GSH in Caco2-BBE cells. CONCLUSIONS: These results demonstrate that PHB expression
is decreased during oxidative stress and intestinal inflammation. Since IL-6-induced PHB
expression is associated with reduced oxidative stress stimulated by H2O2, perhaps PHB
protects against oxidative stress associated with intestinal inflammation.
T1159
Prerequisite of Bile Acids for Expression of COX-2 and iNOS As Well As
Lesion Formation in Rat Small Intestine Following Administration of
Indomethacin
Yuka Takahira, Nahoko Izumi, Akiko Tanaka, Koji Takeuchi
Background/Aim: Nonsteroidal antiinflammatory drugs (NSAIDs) such as dicrofenac and
indomethacin cause hemorrhagic lesions in the small intestine as the adverse reaction.
Numbers of elements such as a deficiency of prostaglandins, bile acids, enterobacteria and
inducible nitric oxide synthase (iNOS) are involved in the pathogenesis of NSAID-induced
intestinal lesions. A recent study demonstrated the up-regulation of cyclooxygenase (COX)-
2 expression in this tissue following the administration of NSAIDs and suggested that this
event is a key to NSAID-induced intestinal lesions. However, the role of bile acids in these
events remains unexplored. In the present study, we investigated the prerequisite of bile
acids in the intestinal ulcerogenic response to indomethacin and its relation to the up-
regulation of COX-2 and iNOS expression. Methods: Male SD rats were used. The animals
were given indomethacin (10 mg/kg) SC and killed various intervals after the administration.
Bile duct ligation or cholestyramine treatment (bile acid sequestrant, 300~1000 mg/kg, PO)
was performed 30 min before or 3 h after indomethacin. Enterobacterial count was deter-
mined 6 h after indomethacin treatment. The expression of COX-1, COX-2 and iNOS
mRNAs was examined by RT-PCR. Results: Indomethacin caused hemorrhagic lesions in
the small intestine 6 h later, and the severity increased with time up to 12 h later. Indomethacin
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increased bacterial count in the mucosa and up-regulated the expression of both COX-2
and iNOS in the small intestine without any change in COX-1 expression. Cholestyramine,
given 30 min before, significantly prevented the development of these lesions in a dose-
dependent manner, whereas this agent, given 3 h after indomethacin, failed to affect the
intestinal ulcerogenic response. Similar results were obtained by bile duct ligation; the
ligation 30 min before completely prevented the occurrence of intestinal lesions while the
ligation 3 h after indomethacin caused only a partial inhibition against these lesions. In
addition, cholestyramine given 30 min before indomethacin treatment significantly prevented
bacterial invasion in the mucosa and inhibited the up-regulation of COX-2 and iNOS
expression after the administration of indomethacin. Conclusion: These results suggest that
1) the presence of bile acids in the small intestine is essential for the occurrence of NSAID-
induced intestinal lesions, and 2) bile acids facilitate bacterial inversion in the mucosa and
contribute to the up-regulation of both COX-2 and iNOS expression, confirming that the
expression of these inducible enzymes is a key to NSAID-induced intestinal damage.
T1160
Roles of Endogenous Prostaglandins/Cyclooxygenases and EP4 Receptor
Subtype in Healing of Indomethacin-Induced Small Intestinal Lesions in Rats
Ryo Hatazawa, Ryoko Ohno, Mayu Tanigami, Akiko Tanaka, Koji Takeuchi
Background/Aim: Endogenous PGs play an important role in modulation of the mucosal
defense in the stomach as well as the healing aspect of gastric ulcers, and it is believed that
COX-1 or COX-2 is mainly involved in the former or the latter event, respectively. We
recently reported that PGs produced by both COX-1 and COX-2 are important in maintaining
the mucosal integrity of small intestine against NSAID-induced damage, yet the role of PGs
in the healing of these lesions remains unknown. In the present study, the role of PGs/COX
in the healing of indomethacin-induced intestinal lesions was examined in rats, using selective
COX-1 and COX-2 inhibitors. Methods: Male SD rats were used. Intestinal lesions were
induced by a single injection of indomethacin (10 mg/kg, SC), and the rats were killed 1,
4 and 7 days later. Indomethacin (2 mg/kg), SC-560 (COX-1 inhibitor: 3 mg/kg) and
rofecoxib (COX-2 inhibitor: 3 mg/kg) were given PO once daily for 6 days, during the first
3 or last 3 days of the experimental period. The effect of EP4 agonist and antagonist on the
healing was also examined in the presence or absence of indomethacin. Vascular content
was determined by the incorporation of Carmine. Expression of COX-2 mRNA in the mucosa
was examined by RT-PCR, while PGE2 content was measured by EIA. Results: All COX
inhibitors given for 6 days significantly impaired the healing of indomethacin-induced small
intestinal lesions. The healing was also impaired by rofecoxib given for the first 3 days or
by SC-560 given for the last 3 days. The expression of COX-2 mRNA in the intestine was
up-regulated after ulceration, persisting for 3 days and dissipating thereafter. Levels of
mucosal PGE2 markedly decreased within 3 hr after indomethacin was administered, reco-
vered 24 hr later, and increased above normal 1~3 days after ulceration. The PGE2 content
on 4 days after ulceration was decreased by rofecoxib but not SC-560 while that on 7 days
was suppressed by SC-560 but not rofecoxib. Vascular content in the ulcerated mucosa
significantly decreased when the healing was impaired by COX inhibitors. The deleterious
effect of indomethacin on the healing was mimicked by an EP4 antagonist and reversed by
co-administration of PGE2 as well as an EP4 agonist. Conclusion: These results suggest that
endogenous PGs play a role in the healing of intestinal ulcers, yet the COX isozyme responsible
for the production of PGs differs depending on the stage of healing, COX-2 in the early
stage and COX-1 in the late stage. In addition, the healing promoting action of PGE2 is
associated with stimulation of the angiogenic response and mediated by the activation of
EP4 receptors.
T1161
Bioactive Glass Stimulates Epithelial Wound Healing
Hussila Keshaw, Alastair Forbes, Richard Day
Ulcer healing is a complex process requiring proliferation and migration of epithelial cells
into the wound. A number of regulatory peptides mediate this process, many of which are
secreted from myofibroblasts, including basic fibroblast growth factor (bFGF) and vascular
endothelial growth factor (VEGF). 45S5 bioactive glass (BG) has previously been used to
facilitate hard tissue regeneration. More recently it has been shown to stimulate angiogenesis
and growth factor secretion from colonic myofibroblasts. Aim: To determine the effect of
BG-induced growth regulatory peptides on epithelial wound healing. Methods: Conditioned
culture medium (CM) was prepared by seeding CCD-18Co colonic myofibroblasts on surfaces
coated with various concentrations (0%, 0.01%, 0.1%, 1% w/v) of BG. CM was collected
after 72 h. The amount of bFGF and VEGF present in the CM was measured by ELISA.
Confluent monolayers of human colonic epithelial cell line CaCO-2 were wounded with a
razor blade and cultured in CM for 24 h. Triplicate plates containing four wounds were
used to quantitate the % (± SEM) changes in the area of cells across the wound border and
the average distance of the leading edge of the repairing monolayer from the wound border
using image analysis software. Results: CM collected from myofibroblasts cultured on BG
contained increased amounts of bFGF compared with 0% w/v BG. The amount of VEGF
in the CM was increased with 0.01% w/v and 0.1% w/v BG, but was reduced with 1% w/
v BG. Treatment of wounded monolayers with 0.01% w/v BG CM produced a significant
increase in the area of cells across the wound border (13% ± 6; p<0.05) compared with
0% w/v BG CM. The average distance of the leading edge was also significantly increased
(15% ± 7; p<0.05). Treatment of wounded monolayers with 0.1% w/v BG CM also increased
the area of cells across the wound border (10% ± 7; p>0.05) and average leading edge
distance (9% ± 8; p>0.05). Wounded monolayers treated with 1% w/v BG CM exhibited a
significant reduction in the area of cells across the wound border (54% ± 15; p<0.001) and
the average leading edge distance (54% ± 17; p<0.01) compared with 0% w/v BG. Conclusion:
This study demonstrates that myofibroblasts exposed to BG secrete regulatory peptides that
can stimulate epithelial wound healing. It is likely that other factors in addition to those
measured in the current study also contribute to the observed stimulatory effect. These
findings, together with the known ability of BG to stimulate angiogenesis, could offer a
novel therapeutic approach for ulcer healing and provide a rationale for further studies to


















Evidence of Monoclonality in Dysplasia in Ulcerative Colitis
Simon Leedham, Lara Maia, Sean Preston, Macdonald Stuart, Oliver Sieber, Ian
Tomlinson, Nicholas Wright
Aim: Ulcerative Colitis (UC) is a chronic inflammatory condition that increases the risk of
developing colorectal cancer (CRC). UC associated colorectal cancers (UCACRC) often
develop from areas of dysplasia, which can be widespread or multifocal. Loss of heterozygosity
(LOH) of important tumour suppressor genes such as Adenomatous polyposis coli (APC),
deleted in colon cancer (DCC) and SMAD4, can occur in UC associated dysplastic tissue.
LOH analysis can be used as a simple and reliable marker of clonality. The aim of this study
was to use LOH at the above 3 loci for the assessment of clonality within dysplastic and
inflamed tissue in UC to test the hypothesis that dysplastic lesions arise from a single mutated
clone. Methods: Paraffin embedded tissue from colectomy specimens was obtained from St
Marks Hospital pathology library. Tissue was categorised histologically into normal, acutely
or chronically inflamed or dysplastic, based on H&E slides. Laser capture microdissection
was used to isolate individual crypts. If no normal crypts were available from the tissue,
regions of lamina propria or muscularis mucosae were taken to allow LOH analysis compar-
ison. DNA was extracted and amplified for microsatellite markers close to the loci of APC
(5q21.1), DCC (18q21) and SMAD4 (18q21.1). PCR product was analysed with ABI 3100
sequencer and genotyper software and abnormal tissue allelic areas were compared with
normal tissue allelic areas as a ratio. Results: LOH for microsatellite markers was found in
chronic inflammation in 1 patient at a low frequency (1 marker, 50% of crypts). LOH of
the same microsatellite marker was seen in low grade dysplasia at a low frequency (44%)
but at a very high frequency across multiple high grade dysplastic patches in different
patients (up to 100%). LOH of multiple markers was seen in some patients. Conclusions:
Lower LOH frequency in inflamed and low grade dysplasia compared to high grade dysplasia
suggests which marker is lost first, and the earliest lost marker can be used a clonal marker.
‘Across the patch’ loss of the same allele in high grade dysplasia suggests monoclonal
derivation. Increased crypt fission is likely to be responsible for mutation spread, and further
work using mitochondrial DNA mutations to demonstrate shared mutations in neighbouring
crypts in UC is underway.
T1163
15-Deoxy-Δ 12,14-Prostaglandin J2 Ameliorates Dextran Sodium Sulfate-
Induced Colitis in Mice Via Induction of Heme Oxygenase-1
Tomohisa Takagi, Yuji Naito, Takahiro Suzuki, Hirokazu Kajikawa, Kouichi Terao, Hisato
Tsuboi, Takeshi Ishii, Kazuhiro Kamada, Toshimitsu Okuda, Osamu Handa, Satoshi
Kokura, Hiroshi Ichikawa, Norimasa Yoshida, Toshikazu Yoshikawa
Background: 15-deoxy-Δ12,14- Prostaglandin J2 (15d-PGJ2), a prostaglandin D2 metabolite,
exerts anti-inflammatory activity as a negative feedback mechanism. Both peroxisome pro-
liferator-activated receptor (PPAR)-dependent and -independent anti-inflammatory actions
of 15d-PGJ2 have been identified. However, a definitive mechanism for 15d-PGJ2-induced
reduction of intestinal inflammation has not been fully solved. In the present study, we
found that enema treatment with 15d-PGJ2 induced heme oxygenase-1 (HO-1) expression
and inhibited the development of murine colitis. Materials and methods: Acute colitis was
induced with dextran sodium sulfate (DSS) in male BALB/c mice. 15d-PGJ2 (5μM, 0.2ml)
was administrated everyday via rectal enema. Intestinal expression of HO-1 mRNA and
protein were evaluated by real-time PCR and western blotting, and the activity of HO-1
was determined by luminal carbon monoxide (CO) gas level. A disease activity index (DAI)
was determined on a daily basis for each animal, and consists of a calculated score based
on changes in body weight, stool consistency, and intestinal bleeding. Tissue-associated
myeloperoxidase (MPO) activity was measured in intestinal mucosa as an index neutrophil
infiltration. Moreover, we evaluated the effects by co-treatment of an HO-1 inhibitor, zinc
protoporphyrin IX (ZnPP 25mg/kg i.p., daily), or a specific PPAR-γ antagonist GW9662.
Results: Enema treatment with 15d-PGJ2 markedly induced HO-1 protein and mRNA
expression in the colonic mucosa, and increased luminal CO gas. The induction of HO-1
by 15d-PGJ2 was not affected by co-treatment with GW9662. Increase in luminal CO gas
level was significantly inhibited by the treatment with ZnPP. After DSS administration, DAI
score were increased in a time-dependent manner, in addition to decreased colonic length
and increased MPO activity. The treatment with 15d-PGJ2 ameliorated the increases in DAI
score and MPO activity after DSS administration. The inhibition by 15d-PGJ2 against intest-
inal inflammation was cancelled by the co-treatment with ZnPP, but not by GW9662.
Conclusion: These results demonstrate that 15d-PGJ2 down-regulates intestinal inflammation
in mice by PPAR-independent and HO-1-dependent actions.
T1164
Alterations of Matrix Metalloproteinase-9, Hepatocyte Growth Factor Receptor
and Insulin-Like Growth Factor Receptor-1 Expressions in Ulcerative Colitis
Laszlo Herszenyi, Ferenc Sipos, Orsolya Galamb, Balazs Gyorffy, Istvan Hritz, Istvan
Pregun, Bela Molnar, Zsolt Tulassay
Background: Epithelial cell growth regulation has been reported to be altered in inflammatory
bowel disease. Matrix metalloproteinases play an important part in extracellular matrix
remodelling. Hepatocyte growth factor receptor (c-met) and insulin-like growth factor recep-
tor-1 (IGFR-1) modulate intestinal epithelial cell proliferation and migration, play a role in
regenerative processes and intestinal wound healing. Aim: Determination of protein expres-
sion levels and mRNA of matrix metalloproteinase-9 (MMP-9), c-met and IGFR-1 in correla-
tion with the severitiy of inflammation in ulcerative colitis (UC). Materials and methods:
MMP-9, c-met and IGFR-1 expressions were analyzed in 40 paraffin-embedded tissue samples
by immunohistochemistry from patients with mild (n=10), moderate (n=10), severe (n=10)
UC and healthy control subjects (n=10). Immunostaining was determined semiquantitatively.
The RNA expression profile from biopsy samples was evaluated using TaqMan® assay Low-
Density Array to Gene Expression (Applied Biosystems). Statistical analysis with one-way
ANOVA and LSD tests were performed. Results: MMP-9 expression was significantly lower
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in each inflammatory group compared with normal (p<0.05). IGFR-1 and c-met expressions
were significantly higher in mild UC, but not in moderate and severe UC compared to
normal (p<0.005). MMP-9 and IGFR-1 mRNA expressions were significantly downregulated
in UC compared to the normal tissue (p<0.05), while c-met mRNA expression was slightly,
but not significantly higher only in mild UC compared to normal. The immunohistochemical
protein expression levels correlated to the mRNA expression array data. Conclusions: The
downregulation of MMP-9, IGFR-1 and c-met expression correlated with the severity of
inflammatory process in UC. The decrease of MMP-9 expression with the decreased IGFR-
1 and c-met expressions could contribute to the severity of epithelial damage in moderately
and severely active UC.
T1165
Aggravation of Indomethacin-Induced Intestinal Ulceration in Rats with
Adjuvant-Induced Chronic Arthritis: Involvement of Increased Expression of
Toll-Like Receptor (TLR)-4
Shinichi Kato, Kazuhiro Fukushima, Kikuko Amagase, Koji Takeuchi
Background/Aim: We previously reported that indomethacin-induced gastric lesions were
markedly aggravated in adjuvant-induced arthritic (AA) rats. This phenomenon is accounted
for by the overproduction of nitric oxide (NO) derived from inducible NO synthase (iNOS).
On the other hand, it has been shown that the increased expression of iNOS induced by
entrobacterial invasions in the intestinal mucosa plays a pathogenic role in the development
of indomethacin-induced intestinal lesions. In the present study, we examined the intestinal
ulcerogenic property of indomethacin in AA rats, in comparison with normal animals.
Methods: Arthritis was induced in male DA rats by injection of Freund’s complete adjuvant
(FCA) into the right hind paw. Two weeks later, the animals were given indomethacin (3~10
mg/kg, PO), and the intestinal mucosa was examined for lesions 6 and 24 h later. The
expression of iNOS and TLR-4, a receptor for bacterial lipopolysaccharide, was determined
by Western blotting. Results: Oral administration of indomethacin produced multiple
hemorrhagic lesions in the small intestine. The severity of these lesions was increased in
AA rats as compared with normal rats, and the lesions were observed even at 3 mg/kg, the
lesion score at 6 mg/kg being significantly greater than that observed at 10 mg/kg in normal
rats. NG-nitro-L-arginine methyl ester (L-NAME) and aminoguanidine when given once 6
h after indomethacin significantly prevented these lesions in normal rats, but failed to
suppress aggravation of these lesions in AA rats. However, aminoguanidine when given
twice 30 min before and 6 h after indomethacin significantly prevented the severity of lesions
in AA rats. Moreover, the onset of the lesions occurred much earlier in AA rats when
compared to normal rats, the severe lesions being observed even 6 h after indomethacin.
The development of these lesions in both normal and AA rats was potently prevented by
dexamethasone and the antibiotic, ampicilline. Although the expression of iNOS and TLR-
4 was only slightly detected in the small intestine of normal rats, both of these expressions
were clearly observed in the intestinal mucosa of AA rats without indomethacin treatment.
Conclusion: These findings suggest that the ulcerogenic response to indomethacin in the
small intestine is markedly aggravated in AA rats, similar to that in the stomach. Especially,
the onset of the lesion formation is much earlier in AA rats than that in normal rats,
and this may be partly due to the increased expression of TLR-4 in the small intestine
during arthritis.
T1166
The Anti-Inflammatory Effects of Cv-11974,AT1 Receptor Antagonist, On
Indomethacin-Induced Rat Enteritis
Toshimitsu Okuda, Norimasa Yoshida, Koichi Terao, Osamu Handa, Tomohisa Takagi,
Satoshi Kokura, Hiroshi Ichikawa, Yuji Naito, Takeshi Okanoue, Toshikazu Yoshikawa
Background and Aims: Angiotensin II (ATII) goes through angiotensin II type1 (AT1) and
type2 (AT2) receptor on various cells including vascular endothelial cells and activates
intracellular signal transduction mechanism. ATII plays an important role in blood pressure
regulation, blood vessel remodeling. Recently, it has been proposed that ATII is implicated
in the pathogenesis of oxidative stress-related vascular inflammation in various organs. The
aim of the present study was to examine the effect of ATII type1 receptor (AT1R) antagonist,
CV-11974, on indomethacin-induced rat enteritis. Methods: Male Wistar rats weighting
190-210 grams were given indomethacin (10mg/kg) subcutaneously and the intestinal
mucosal damage was estimated. CV-11974 was given to the rats by intravenous injection
3 h before indomethacin injection. The area (mm2) of macroscopic visible lesions, thiobarbit-
uric acid-reactive substances (TBARS) as an index of lipid peroxidation, myeloperoxidase
(MPO) activity as an index of neutrophils accumulation, and the content of cytokine-induced
neutrophil chemoattractant-1 (CINC-1) in the intestinal mucosa were estimated 24 h after
injection of indomethacin. AT1R in the intestinal mucosa was estimated using western
blotting and immunostaining. Results: Single administration of indomethacin at 10 mg/kg
provoked severe inflammatory lesions in the small intestine, mostly jejunum and ileum.
Microscopic findings revealed multiple hemorrhagic erosions and edema with numerous
inflammatory cells. The levels of TBARS, MPO activities and CINC-1 in the intestinal mucosa
significantly increased prior to the occurrence of macroscopic injuries in indomethacin-
treated group compared with the sham-operated group. In addition, AT1R-positive cells in
the mucosal layer increased in indomethacin-treated rats. The development of intestinal
lesions in response to indomethacin was prevented by CV-11974 together with significant
suppression of the increased level of TBARS, MPO activities and CINC-1 in the small
intestine. Conclusions: These results indicate that CV-11974 protected against the small
intestinal damage elicited by indomethacin, which suggesting that angiotensin II/AT1R
interaction is involved in the pathogenesis of intestinal inflammation associated with oxidat-
ive stress.
T1167
Evidence That a Novel Non-Chemical, Non-Electrical Intercellular Signaling
System Causes Oxidative-Induced Changes in Cell Protein Content and
Activation of Nf-κB in Distant Epithelial Cells
Ashkan Farhadi, Christopher Forsyth, Ali Banan, Maliha Shaikh, Phillip Engen, Jeremy Z.
Fields, Ali Keshavarzian
Background: Synchrony between physically separate biological units (e.g., synchronous
illumination of whole populations of fireflies) is well known. We determined whether cells
can induce synchronous behavior in physically separate neighboring cells and do so by a non-
chemical, non-electrical (NCNE) mechanism. To investigate synchrony, we took advantage of
the fact that cultured cells exposed to oxidants enter a state of emergency, decrease their
protein content by half in a matter of minutes, and activate NF-κB as the key regulation
point of cell stress signaling cascade. To determine whether information regarding this state
can be transmitted to distant cells, we used cultures of a gastrointestinal cell line. Method:
Caco-2 cell line cultures were divided into three groups: 1) Inducer cells were exposed to
oxidant (H2O2); 2) Detector cells were not exposed to oxidant and were placed in a
chemically isolated container in the proximity of inducer cells; 3) Control cells were also
not exposed to H2O2 and were kept in a separate room. Parts of the experiment were done
using a newly designed container (Farhadi’s cell container, patent pending) composed of
two isolated chambers for inducer and detector cells that are side-by-side and share a thin,
glass wall that precludes the passage of any chemical or electrical signals between the two
containers. Total protein contents of cell samples were measured using spectrophotometry
at 595 nm. NF-κB activation was assessed using a quantitative ELISA of the nuclear extracts
for the p65 sub unit. Results: Exposing inducer cells to hydrogen peroxide resulted in a
significant reduction in their total protein content (-50%) and increases in the level of nuclear
NF-κB p65 subunits (+38%). There were parallel and significant reductions in total protein
content (-48%) and increases in nuclear p65 subunit fractions of NF-κB (+35%) in detector
cells compared to controls (p<0.0001 and p=0.01, respectively). Conclusions: Our data
provide evidence for the existence of a NCNE signaling system among intestinal cells. This
novel signaling system can be activated by oxidative stress and result in decrease in cell
protein content and activation of NFκB pathway in distant cells. The mechanism underlying
this unique signaling phenomenon is unknown, although electromagnetic signaling due to
oscillating ions is a possible candidate. Intercellular NCNE signaling may play a pivotal role
in the pathogenesis and possible therapeutic intervention of gastrointestinal disorders related
to oxidative induced barrier injury such as IBD.
T1168
Role of Thromboxane in Flow-Mediated Vasoconstriction in Inflammatory
Bowel Disease (IBD)
Ossama A. Hatoum, David G. Binion, Hiroto Miura, Rebecca M. Selle, Shane A. Phillips,
Doron Kipelman, David D. Gutterman
Background and Aims: IBD (Crohn’s disease and ulcerative colitis) is characterized by areas
of refractory inflammatory ulceration and ischemic damage to the gut which correlates
with local microvascular dysfunction. Flow-induced vasodilation (FID) is a physiological
mechanism for regulating mucosal perfusion. The mechanisms underlying impaired mucosal
healing during IBD are not defined, therefore we hypothesize that flow-induced vasodilation
is impaired in chronically inflamed gut microvessels in IBD patients. Methods: The diameter
responses of freshly isolated intestinal submucosal arterioles (75-200μm), to flow were
determined from IBD and non-IBD patients undergoing intestinal surgery and bowel resec-
tion. Microvessels were cannulated with glass micropipettes and pressurized to 60 mmHg
in a heated chamber and perfused with physiological salt solution. Responses of vessels to
graded increases in flow (constant intraluminal pressure) were produced with intravascular
pressure gradients (0, 20, 40, 60, 80 and 100 cmH2O) between perfusion reservoirs.
Diameters were recorded intermittently after 5 minutes of each pressure gradient (steady-state
conditions) using videomicroscopy. Results: After constriction (30-50%) with endothelin-1,
FID was observed in non-IBD submucosal arterioles (max dilation (MD) 79.4 + 12%, n=
7). Inhibition of NO synthase (L-NAME) reduced MD to 40.5 ± 9.3%, P<0.05 n=5. Flow-
induced vasoconstriction was observed in chronically inflamed IBD arterioles (-57.5 + 6%,
n=7, p=<0.01 vs. controls). Cyclooxygenase blockade with indomethacin (INDO, 10-5M)
significantly attenuated the constriction (-55.7 ± 5% to 2.7 ± 4%). Treatment of IBD
microvessels with either the thromboxane receptor antagonist SQ-29548 (10-5M) or the
thromboxane synthase inhibitor dazoxiben (10-5M) converted the vasoconstriction to vasod-
ilation (MD: 81.9+8 and 46.1+2, respectively). Immunohistochemical studies demonstrated
a significant increase in the thromboxane staining in IBD arterioles when compared to vessels
from patient without IBD. All responses to flow in both non-IBD and IBD submucosal
arterioles were eliminated by endothelium denudation (-3 ± 5%; -4 ± 2.2%; respectively).
Conclusions: Flow-induced endothelium-dependent vasoconstriction of gut microvessels
during IBD may be related to increased synthesis of thromboxane. This microvascular
dysfunction may contribute to the progression of reduced tissue perfusion and ischemia
during IBD by limiting tissue perfusion, leading to ischemia and impaired mucosal healing
which could enhance inflammation.
T1169
Tegaserod Has No Potential for Vasoconstriction or Impairment of
Vasodilatation in Isolated Human and Non-Human Primate Mesenteric
Arteries
Eckhard Weber, Christian T. Hamel, Mario Bernhard, Hans-Juergen Pfannkuche
BACKGROUND. Tegaserod (Zelmac®/Zelnorm®), a potent 5-HT4 receptor agonist, is an
effective and safe treatment of chronic constipation and irritable bowel syndrome with
constipation. Since tegaserod has also affinity for human 5-HT1B receptors (5-HT1BR, Ki=
60nM) and agonists at 5-HT1BRs may cause mesenteric ischemia via local vasoconstriction,
we conducted studies addressing the potential of tegaserod to trigger 5-HT1BR-mediated
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visceral vasomotor effects in isolated mesenteric arteries from human and non-human prim-
ates. METHODS. Peripheral mesenteric arteries were obtained from patients undergoing
bowel resection for colon carcinoma (4m/4f, 44-92 years) and from cynomolgus monkeys
(8m/8f, 4-6 years). Artery rings (length: 3-5mm, diameter: 300-700µm) were mounted in
organ baths, contracted with KCl (100mM), washed and examined for functional integrity
of the epithelium. In a 1st study, cumulative concentration-response curves were established
for tegaserod (1nM-10µM) and the selective 5-HT1BR agonist, sumatriptan (1nM-10µM).
In a 2nd study, tegaserod (0.3µM) and the selective 5-HT1BR antagonist, GR55562 (0.1µM),
were investigated as to their inhibitory effects on sumatriptan-stimulated vasoconstriction.
A 3rd study was performed in monkey preparations only. Arteries were pre-constricted with
phenylephrine (10µM) and relaxed with the endothelial and non-endothelial mediators of
vasodilatation, acetylcholine, bradykinin and forskolin (0.1nM-10µM). These experiments
were done in absence or presence of tegaserod (1µM). RESULTS. Tegaserod did not induce
vasoconstriction in human (n=4) or monkey mesenteric arteries (n=6). In contrast, sumatrip-
tan concentration-dependently constricted both human (H) and monkey (M) artery prepara-
tions (EC50(H)=355±131nM, Emax(H)=16±12% of 100mM KCl, mean±SEM, n=4;
EC50(M)=214±137nM, Emax(M)=23±12%, n=8). Tegaserod (T) and GR55562 (G) competit-
ively inhibited sumatriptan-induced vasoconstriction (IC50(TH)=145±107nM, IC50(TM)=
59±280nM, n=4; IC50(GH)=8±30nM, IC50(GM)=36±77nM, n=8). Tegaserod (T), similar
to vehicle (V), had no effect on acetylcholine (A), bradykinin (B) and forskolin (F)-triggered
vasodilatation in phenylephrine-constricted monkey arteries (IC50(TA)=129±28nM,
IC50(VA)=143±71nM, n=5; IC50(TB)=1.2±0.4nM, IC50(VB)=1.1±0.2nM, n=6; IC50(TF)=
29±4nM, IC50(VF)=21±5nM, n=6). CONCLUSIONS. The present findings in mesenteric
arteries demonstrate that tegaserod can act as a 5-HT1BR antagonist and has no potential
to cause visceral vasoconstriction or impair vasodilatation. Our mechanistic studies provide
further evidence that tegaserod does not trigger visceral hemodynamic activities, which
might lead to mesenteric ischemia.
T1170
Kayexalate (Sodium Polystyrene Sulfonate) in Sorbitol Is a Common and
Frequently Unrecognized Cause of Intestinal Ischemia
Susan C. Abraham, Alyssa M. Krasinskas
Background: Kayexalate in sorbitol for management of hyperkalemia has been associated
both clinically and in animal studies with the development of bowel necrosis, potentially
as a result of mucosal ischemia from the hypertonic sorbitol solution. It is estimated that
gastrointestinal necrosis occurs in ~1% of patients receiving Kayexalate in sorbitol. However,
recognition of Kayexalate administration as an etiology of intestinal ischemia remains low,
and the characteristic crystalline resin of Kayexalate is easily overlooked in histologic sections
of intestinal biopsies or resections. Methods: We studied 115 surgical resections for acute
ischemic bowel (41 colonic, 40 small bowel, and 21 large and small bowel ischemia) among
102 patients. Clinicopathologic etiology of the ischemia was evaluated, along with histologic
evaluation for Kayexalate resin. Controls included 65 surgical resections for ileocolonic
adenocarcinoma and 36 surgical resections of non-cancerous, non-ischemic bowel. Results:
Kayexalate administration was associated with colonic (n=5) or ileocolonic (n=3) ischemia
in 8 of 102 (7.8%) patients and 10 of 115 (8.7%) surgical resection specimens. Patients
with necrosis due to Kayexalate in sorbitol included 5 males and 3 females with a mean
age of 59.4 years (range, 38-83 years). These demographics did not differ significantly from
those of the entire population with ischemic bowel (45 males:57 females, mean age 60.5
years, range 18-91 years). In 5 patients, Kayexalate in sorbitol was the only identifiable
etiology for bowel necrosis. The other 3 patients had alternative etiologies for ischemia that
could have initiated or exacerbated bowel necrosis, including 81- and 83-year-old men with
cholesterol emboli, and a 54-year-old woman who experienced necrosis of a rectosigmoid
anastomotic site after receiving Kayexalate 2 weeks following surgery for diverticular disease.
Kayexalate administration had not been recognized as the etiology of ischemia pre-operatively
in any of the 8 patients, and Kayexalate crystals were missed on initial histologic review of
the specimens in 7 of 10 resections. None of the 101 control specimens of non-ischemic
bowel contained Kayexalate crystals on histologic review. Conclusions: Administration of
Kayexalate in sorbitol predisposes to acute intestinal necrosis in a sizable minority (7.8%)
of patients requiring surgical intervention for ischemic bowel, and continuing ischemia in
some of these patients (3 of 8 in this series) necessitates additional bowel resection. Despite
this, clinical and histologic recognition of the role of Kayexalate in intestinal ischemia
remains low.
T1171
Enterocolic Lymphocytic Phlebitis: Its Prevalence and Role in Ischemic Bowel
Alyssa M. Krasinskas, Susan C. Abraham
Background: Enterocolic lymphocytic phlebitis (ELP) is a form of vasculitis limited to the
veins of the digestive tract. Histologically, ELP is characterized by mononuclear cell infiltrates
within and around walls of small to medium-sized veins; venous thrombi and granulomas
can be present. Since most cases of ELP reported in the literature are associated with intestinal
ischemia, it has been assumed that ELP is a cause of ischemic bowel by promoting thrombosis
on top of the phlebitic lesions. Although ELP appears to be uncommon, its prevalence is
not known. This study examines the prevalence of ELP and its role in intestinal ischemia.
Methods: We studied 115 consecutive cases of surgically resected acute ischemic bowel
(colon, n=46; small bowel, n=52; and both colon and small bowel, n=17) from 102 patients.
The control group included 101 surgical resection specimens (65 colonic adenocarcinomas
and 36 non-malignant, non-ischemic bowel). Tissue sections were evaluated histologically
for the presence and distribution of ELP. Results: Of the 115 cases of ischemic bowel, ELP
was present in 6 specimens (5.2%) from 6 patients (5.8%). Patients with ELP had a mean
age of 42 years (range 18-74 years), younger than the ischemic bowel patients without ELP
who had a mean age of 61 years (range 18-91 years); p=0.009. There were 4 males and 2
females. The colon was involved in 4 and the small bowel in 2. The ELP was mild, with
histologic evidence of perivenular lymphoplasmacytic inflammation within the submucosa
through to the subserosa and mesentery; one case had venous thrombi. In 3 cases, the ELP

















than ELP for their ischemia: nearby colon cancer, adhesions, incarcerated hernia, impacted
stool with perforation, recent surgery for pancreatic cancer and recent surgery for a gunshot
wound. Two of the cases had bowel resections 1 day and 10 days earlier and ELP was not
present in those specimens. Interestingly, ELP was present in four of the control cases (4%)
and all were associated with colon cancer; ELP extend away from the tumor in only 1 case.
Conclusions: ELP is uncommon, present in 5.2% of intestines resected for ischemia and
4% of non-ischemic resections. Although present in ischemic intestines, ELP does not appear
causative. Based on our results, including known etiologies for the ischemia in cases with
ELP, the presence of ELP in cancer and the absence of ELP in prior bowel resections in two
patients, ELP likely represents a secondary response to an altered mucosal barrier, rather
that a primary cause of ischemic enterocolitis.
T1172
The Chemokine Cxcl12 Regulates Intestinal Epithelial Restitution By
Increasing Actin Rearrangement and Activity of the Rho Signaling Pathway
Rebecca Moyer, Michael K. Wendt, Priscilla A. Johanesen, Michael B. Dwinell
The principal pathophysiologic features of inflammatory bowel disease and enterocolitis
include epithelial ulceration, leukocyte infiltration, and mucosal remodeling and repair.
Chemokines are essential regulatory factors that stimulate migration, proliferation and differ-
entiation in chemokine receptor expressing target cells. Mucosal barrier homeostasis is
dependent upon the tight physiologic balance between those processes suggesting chemok-
ines may regulate the competency of the epithelial barrier to withstand injury from luminal
stimuli and repair itself following damage. We have recently shown that binding of the
chemokine CXCL12 to its cognate receptor CXCR4 stimulates epithelial restitution. The aim
of the present study was to define the signaling mechanisms whereby chemokine receptors
mediate epithelial cell migration. Normal, non-transformed IEC6 epithelial cells or differenti-
ated polarized T84 epithelial monolayers were wounded and changes in F-actin assessed
using fluorescence microscopy and flow cytometry. Rho activity was defined using a rhotekin-
GST assay in conjunction with immunofluorescence microscopy. CXCL12 stimulated the
formation of F-actin, the accumulation of which was predominantly localized to the leading
edge of CXCL12-treated wounded epithelial monolayers and was greater than unstimulated
cells. In agreement with the increase in F-actin, CXCL12 binding to CXCR4 stimulated an
increase in the levels of active RhoGTP in both unwounded and wounded IEC6 epithelial
cells. Consistent with a role for Rho in chemokine mediated wound healing, inhibition of
the downstream Rho-kinase significantly blocked IEC6 migration. Similarly, blockade of the
myosin light chain kinase also prevented CXCL12 restitution. Our data demonstrate that
CXCR4 and CXCL12 function as an autocrine and paracrine mucosal signaling network
increasing activity of the canonical restitution mechanism. Our findings are consistent with
the notion that chemokines, ubiquitous immune mediators produced within the gut mucosa,
play a significant role in the restitutive repair processes of mucosal inflammation.
T1173
Increased Expression of Both Angiogenic VEGF, and Anti-Angiogenc
Endostatin and Angiostatin in Ulcerative Colitis in Rats, Mice and Humans:
An Explanation for Impaired and Delayed Healing
Xiaoming Deng, Zsuzsa Sandor, Tetyana Khomenko, Longchuan Chen, Ximing Xiong,
Andrzej Tarnawski, Sandor Szabo
Angiogenesis, which plays a key role in wound/ulcer repair, is governed by a balance between
pro- and anti-angiogenic factors. We, therefore, determined the levels of potent angiogenic
factor VEGF and angiogenesis inhibitors endostatin and angiostatin in colonic tissues of rats
and mice with experimental ulcerative colitis, and human ulcerative colitis. Methods: In rats
ulcerative colitis was induced by intracolonic administration of 6% iodoacetamide and the
animals were euthanized at 0.5, 1, 2, and 6 hr after iodoacetamide. The mouse colonic
tissues were obtained from an ulcerative colitis model induced by IL-10 knock-out, while the
colonic biopsy specimens of human ulcerative colitis were obtained from surgical pathology
archives. In the rat samples, levels of VEGF, endostatin and angiostatin were detected by
Western blotting with respective specific antibodies (Santa Cruz Biotechnology). In human
and mouse tissues, VEGF was detected by immunohistochemistry with a specific VEGF
antibody. Results: Western blotting showed that the levels of 23 kDa VEGF, 20 kDa endostatin
and 50 kDa angiostatin in the rats with colitis were 3- to 5-fold higher than controls at all
time points after iodoacetamide administration in rat colonic tissue. Immunohistochemistry
demonstrated that VEGF was strongly expressed in endothelial cells of blood vessels and
monocytes around the colonic lesion areas, while the control samples or the control negative
staining of mouse and human colonic tissues showed no staining. Conclusions: Our studies
demonstrated for the first time: 1) Both the angiogenic VEGF and anti-angiogenic endostatin
and angiostatin were increased in early stages of experimental ulcerative colitis. 2) Increased
VEGF was detected in endothelial cells of blood vessels and monocytes. 3) Active ulcerative
colitis may be due, in part, to inhibition of angiogenesis by increased angiostatin and
endostatin, even in the presence of markedly increased VEGF levels. 4) Thus, the enhanced
expression of anti-angiogenesis factors may be a new explanation for impaired and delayed
healing despite elevated VEGF.
T1174
PKC-β1 Activation Is Required for Epidermal Growth Factor (EGF) Induced
Cellular Migration and Cytoskeletal Remodeling in Enterocyte Monolayers: A
Unique Wound Healing Mechanism in GI Epithelium
Ali Banan, Lijuan Zhang, Maliha Shaikh, Christopher B. Forsyth, Ashkan Farhadi, Jeremy
Z. Fields, Ali Keshavarzian
Despite numerous studies of cell migration, the intracellular processes that orchestrate wound
healing are unclear. Using monolayers of gut epithelial cells as a model of repair, we reported
that oxidative stress injures monolayers by disrupting the cytoskeleton; EGF protects against
such injury. But, the molecular events are unclear. Since the β1 isoform of PKC is translocated
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to the cell membrane fraction by EGF in native gut cells, we hypothesized that PKC-β1
activation is required for EGF-induced cell migration & cytoskeletal remodeling in gut cells.
Methods: Intestinal cells were transfected to stably over-express or under-express PKC-β1.
These innovative clones were preincubated with EGF (1-100 ng/mL) or PKC activator (DAG
analog OAG, 0.01-1 uM) prior to exposure to oxidant (H2O2, 10-500 uM). Wild type (WT)
cells were treated similarly. We monitored cell migration/monolayer repair {2-D densitometry
cell count, fluorometry}, cytoskeletal integrity/oxidation {laser confocal microscopy, SDS-
PAGE fractionation}, PKC-β1 subcellular activity/distribution {in vitro kinase,
immunofluorescence}, oxidative stress (quenchable fluorescence), polymerized/monomeric
actin (43 kDa subunits of actin, SDS-PAGE), n=6/grp. Results: {I} Pretreatment of WT cells
with EGF or transfection of cells to overexpress (3.1 X) PKC-β1 enhanced repair as indicated
by native PKC-β1 activation, oxidative stress suppression, cell migration enhancement, stable
actin increases (F/G actin ratio) at the leading migration front, architectural remodeling of
actin filaments at the leading front, & increased monolayer barrier integrity. The transfected
clones exhibited enhanced cell migration & actin remodeling by low, previously non-
repair inducing doses of EGF or OAG. {II} Enhancement of migration induced by PKC-β1
overexpression was also potentiated by EGF or OAG. These effects were prevented by a
PKC inhibitor, bisindolylmalemide. {III} Most of the overexpressed PKC-β1 resided at the
leading edge membrane/cytoskeletal fractions. {IV} In both transfected clones & EGF treated
WT cells, PKC-β1 (78 kDa) was active & found with actin (43 kDa), forming endogenous
PKC-β1/actin complexes. {V} Stably inhibiting expression of native PKC-β1 substantially
prevented all measures of EGF-induced repair. Conclusions: We show for the first time that:
1) EGF-induced cell migration requires the activation of the PKC-β1 isoform in intestinal
cells; 2) PKC-β1 is perhaps a unique intracellular modulator of wound healing in epithelium;
3) The ability to promote normal dynamics of cell migration & cytoskeletal remodeling is
a newly discovered repair mechanism not previously attributed to this PKC isoform.
T1175
Development of a Collagen-Ceramic Composite for Fistula Repair
Hussila Keshaw, Paul Sibbons, Alastair Forbes, Richard Day
Tissue adhesives, such as fibrin sealant, continue to be used for treatment of complex anal
fistulae despite widely varying success rates. This is partly due to a lack of suitable alternatives
and the desire for a relatively simple procedure with low morbidity. Permacol™, cross-
linked porcine dermal collagen, has been used for treating small bowel fistulae and tissue
bulking and is currently being investigated for perianal fistula repair. Growth factors regulate
tissue healing and are likely to enhance fistula repair. Vascular endothelial growth factor
(VEGF) is a regulator of angiogenesis. Stimulation of angiogenesis with exogenous VEGF
dramatically accelerates healing of experimental ulcers. VEGF secretion from colonic
fibroblasts is significantly increased by 45S5 bioactive glass (BG). Aim: To modify Permacol™
with BG particles to enhance its bioactivity for use in fistula repair. Methods: 45S5 BG particles
(0% - 1% w/v) were added to cryogenically milled Permacol™ (Permacol™ Injection) to
produce a composite paste. Colonic myofibroblasts (CCD-18Co) were incorporated into the
composite and cultured. Conditioned culture medium was collected after 24, 48 and 72 h
and the amount of VEGF secreted was measured by ELISA. The amount of collagen-bound
VEGF was similarly measured at 72 h after dissolving the composite with collagenase type
1A. Viability of the incorporated cells was determined at 72 h using an MTT assay. Results:
At 48 h, the amount of VEGF secreted from the composites containing 0.1% w/v 45S5 BG
was significantly increased (2209 pg ± 26 (SEM); p<0.01) compared with 0% w/v 45S5 BG
(1822 pg ± 50). The amount of VEGF secreted at 72 h was significantly increased from
composites containing 0.01% (1720 pg ± 17; p<0.001) and 0.1% (1804 pg ± 53; p<0.01)
w/v 45S5 BG compared with 0% w/v 45S5 BG (1602 pg ± 17). At 72 h, the amount of
VEGF retained in Permacol™ containing 0.1% w/v 45S5 BG was significantly increased
(107 pg ± 18; p<0.01) compared with 0% w/v 45S5 BG (52 ± 2). At 72 h, there was no
significant difference in cell number between composites containing 0%, 0.01% and 0.1%
w/v 45S5 BG indicating increases in VEGF secretion were independent of an increase in
cell number. VEGF secretion was reduced with composites containing 1% w/v 45S5 BG
corresponding with a significant reduction in cell number at 72 h (72% ± 10; p<0.01).
Conclusion: The current study indicates that Permacol™-45S5 BG composites might provide
a safe filler material for repair of perianal fistulae. The increased secretion of VEGF from
cells in contact with or infiltrating the material may accelerate the healing of fistulae treated
with this composite.
T1176
PI3K-Dependent GSK3β Phosphorylation Is Implicated in the Intestinal
Epithelial Cell Wound-Healing Response
Thomas Karrasch, Brigitte Allard, Christian Jobin
Introduction: Improper gastrointestinal restitution following various intestinal injuries may
lead to acute and/or chronic inflammation through enhanced bacterial translocation and
immune cell activation. The molecular mechanism involved in the wound-healing response
in the intestine is poorly understood. The glycogen synthase kinase 3β (GSK3β) has been
implicated in various biological processes such as cellular motility and spreading. Aim: To
investigate the role of GSK3β in intestinal epithelial cell restitution. Methods: Rat IEC18
cells were serum-starved for 16-24h and wounded by multiple scraping. RelA(Ser536)-,
GSK3β(Ser9)-, β-catenin(Thr41,Ser45)-, Akt(Ser473)- and FAK(Tyr397)-phosphorylation
were determined by Western blot using specific phospho-antibodies. The specific inhibitors
AG1478 (1µM) and wortmannin (100nM) were used to block EGF-R autophosphorylation
and PI3K-activation, respectively. β-catenin/LEF/TCF dependent transcription was deter-
mined by reporter gene assay (TOP/FOP system). C-jun gene expression was evaluated by
reverse-transcriptase PCR. Results: Wounding induced focal adhesion kinase (FAK) , Akt,
GSK3β and β-catenin phosphorylation in IEC-18 cells. β-catenin phosphorylation/stabiliza-
tion led to enhanced (2 fold) LEF-TCF transcriptional activity and c-jun mRNA accumulation
in wounded cells. Blocking PI3K/Akt signaling with wortmannin prevented wound-induced
GSK3β phosphorylation and significantly attenuated restitution. Additionally, wounding
induced rapid and sustained NF-κB as well as FAK phosphorylation, which were inhibited
by AG1478, but not by wortmannin. Conclusion: We conclude that PI3K mediated GSK3β
activation is involved in the intestinal epithelial wound-healing response and operates inde-
pendently of NF-κB and FAK signaling. Activation of GSK3β may be important for intestinal
restitution by promoting cell motility, survival and proliferation.
T1177
Butyric Acid, a Physiologic Bacterial Fermentation Product, Represses
Epithelial Inflammatory Signaling Via Changes in Cul-1 Neddylation
Lauren S. Collier-Hyams, Shanthi Sitaraman, Andrew Neish
Background: The human enteric flora plays a significant role in intestinal health and disease,
and administration of exogenous probiotic bacteria may modulate inflammation. We have
shown that nonpathogenic enteric bacteria can inhibit the key proinflammatory NF-kappaB
pathway by blockade of IkappaB-alpha ubiquitination, a process catalyzed by the E3-SCFbeta-
TrCP ubiquitin ligase complex. This enzyme is itself regulated via covalent modification of
the Cullin-1 subunit by the ubiquitin-like protein NEDD8. We previously reported that
interaction of a variety of commensal bacteria with epithelial cells resulted in a rapid
deneddylation of Cullin-1 and resultant repression of the NF-kappaB pathway. How bacteria
mediate this process is not known, but conditioned media could recapitulate the inhibition.
HPLC analysis of conditioned media detected large quantities of organic acids. Purpose: As
short chain fatty acids have been previously shown to have immunomodulatory properties,
we sought to determine if these naturally occurring small molecules could have inhibitory
effects on IkappaB ubiquitination. Methods: T84, HeLa, and HT-29 epithelial cells, as well
as human colonic biopsy specimens were incubated with physiological quantities of butyric
acid [0.5-5.0 mM] and other short chain fatty acids. Cullin neddylation was assayed by
immunoprecipitation and immunoblot. NF-kappaB responses were evaluated by immuno-
fluorescence for p65 translocation and immunoblot analysis of IkappaB for phosphorylation,
ubiquitination and degradation events. The inflammatory gene response was evaluated by
ELISA for secreted chemokines. Results: We show that bacterial fermentation products
including butyric acid and other short chain fatty acids could deneddylate Cullin-1 in
cultured epithelial cells and intact human mucosa ex vivo in a dose dependent manner.
Deneddylation occurred within 30-60 min and was reversible. Short chain fatty acids were
able to inhibit IkappaB ubiquitination (but not phosphorylation), NF-kappaB translocation,
and IL-8 secretion as efficiently as live bacteria, and with similar kinetics. Conclusions: As
the normal flora produces significant quantities of organic acids, these observations may
explain the ability of the intestinal bacterial communities to influence inflammatory regulation
of the mammalian intestinal epithelia and may explain anti-inflammatory effects of probiotic
microbes. As SCF ubiquitin ligases control many aspects of epithelial cell biology, these
data also suggests how natural products of the normal intestinal flora could profoundly
influence many epithelial signaling pathways.
T1178
Remote Epithelial Dysfunction After Localized Intestinal Radiation Injury:
Possible Role of IL-1β?
Sandra Torres, Marc Benderitter, Jean-Pierre Caruelle, Agnes Francois
Motility disorders implicating unirradiated parts of the intestine have frequently been reported
in patients irradiated for pelvic tumors, as a consequence of localized radiation injury to
normal gut. However, less is known about intestinal transport capacity and epithelial barrier
properties outside the irradiation field. We investigated here how a localized radiation
exposure on the rat small intestine may induce intestinal dysfunction in shielded segments,
and particularly far from the site of injury (duodenum). A possible role of IL1β in this out-
of-field dysfunction was hypothesized. After laparotomy, 6 to 8 cm of rat small intestine
was exteriorized and exposed to a single dose of 19 Gy (X-rays). Two weeks post-exposure,
the functional capacity of the irradiated ileum (IR) and the non-irradiated segments (terminal
ileum, jejunum 20 (Jej20) and 40 cm (Jej40) proximal to the IR and duodenum) were
measured in Ussing Chambers. Basal parameters (short circuit current, potential difference,
tissue conductance), as well as epithelial response to 35Hz electrical field stimulation (EFS)
and exogenously-added carbachol were measured. The structural integrity of the segments
was studied by routine histology (morphometric measurements). Myeloperoxidase and
enteric innervation density was followed by immunostaining. All basal electrophysiological
parameters were diminished in IR as well as in shielded segments. Responses to a 35Hz
EFS were diminished in IR (-70%) and Jej20 (-48%). No difference was noticed in the
others segments. Conversely, responses to carbachol were severely diminished all along the
gut proximal to the injured area (IR: -70%, Jej20: -49%, Jej40: -66%), with the most
important decrease observed in the duodenum (-91%). The irradiated segments showed an
important inflammatory infiltrate with areas of severe mucosal ulceration, and a global
increase in both submucosal and myenteric ganglion numbers. Neither structural injury nor
change in enteric innervation density was observed in shielded segments. Conversely, a 4-
fold increase of IL1β mRNA (RT-PCR) was observed in the duodenum of irradiated rats
compared to those of control rats. Localized small intestinal irradiation in the rat induced
severe intestinal dysfunction in the injured segment, due to severe epithelial disruption. The
reason why intestinal transport capacity was impaired all along the small intestine, and more
particularly in the duodenum, is less clear, but a possible explanation may be an increase
in IL-1β expression. Ongoing studies investigate if this “remote effect” may be mediated by
either systemic circulation or by neurogenic inflammation (enteric nervous system).
T1179
Cytostatic Drug-Induced Mucositis in Mucin 2 Deficient Mice
Barbara de Koning, Maria Van der Sluis, Dicky Lindenbergh-Kortleve, Anna Velcich, Rob
Pieters, Hans Buller, Alexandra Einerhand, Ingrid Renes
The structural component of the mucus layer, mucin Muc2, is up-regulated after chemother-
apy. This suggests that Muc2 might be a potential target in mucositis prevention or reduction.
Our aim was to determine the role of Muc2 during chemotherapy-induced mucositis.
Mucositis was induced in Muc2 knockout (Muc2-/-) and wild type (Muc2+/+) mice by injecting
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methotrexate (MTX). Animals were weighed and sacrificed on day 2-6 after MTX treatment
and jejunal segments were analyzed. Before MTX treatment, the small intestine of Muc2+/+
and Muc2-/- mice were similar with respect to epithelial morphology and proliferation.
Moreover, sucrase-isomaltase and trefoil factor-3 protein expression levels were comparable
between Muc2+/+ and Muc2-/- mice. Up to day 3, there were no differences in percentage
weight-loss between Muc2+/+ and Muc2-/- mice. Thereafter, Muc2+/+ mice showed a trend
towards regaining weight, whereas Muc2-/- mice continued to lose weight. Surprisingly,
MTX-induced intestinal damage of Muc2-/- and Muc2+/+ mice was comparable. Prior to MTX
treatment, interleukin-10 mRNA was significantly up-regulated in Muc2-/- mice, but not in
Muc2+/+ mice, probably due to continuous exposure of the intestine to luminal antigens.
CONCLUSION: Our data do not provide evidence that Muc2 deficiency leads to an increase
in chemotherapy induced mucositis. This might be caused by the fact that Muc2 deficiency
triggers the immune system to up-regulate the anti-inflammatory cytokine interleukin-10
prior to MTX-treatment, which limits mucositis after MTX treatment.
T1180
Rabbit Enteropathogenic E.Coli Strains Expressing Shiga Toxins 1 (Stx1) Or 2
(Stx2) Induce Renal Lesions of Hemolytic Uremic Syndrome (HUS) in Dutch
Belted Rabbits
Edgar Boedeker, Chengru Zhu, Hernan Rios, Katherine Davis
Background: Shiga-toxin producing E. coli (STEC) strains, including those producing Stx1
and/or Stx2, induce hemorrhagic colitis and hemolytic uremic syndrome (HUS) in humans.
Although spontaneous occurrence of renal disease resembling HUS in Dutch Belted (DB)
rabbits infected with an O153 E.coli strain producing Stx1 has been reported, no reproducible
animal challenge model for the induction of HUS following ingestion of STEC strains has
been established. Aims: In order to develop orogastric challenge models for the induction
of HUS by both Stx1 and Stx2 strains, and to compare the virulence of the two toxins, we
challenged DB rabbits with rabbit enteropathogenic E.coli (REPEC) strains, observed their
clinical course and evaluated their kidneys histologically for lesions typical or characteristic
of HUS. Design: 1 kg specific pathogen free DB rabbits were orgogastrically inoculated with
saline(control),with the O153 Stx1 REPEC strain from the natural infection, or with REPEC
strains RDEC-H19A (O15 Stx1) and E22 Stx2 (O103 Stx2 which were selected in the
laboratory for acquisition of bacteriophage encoding Stx1 or Stx2. Animals were sacrificed
at 7-10 days following infection and H&E stained sections of their kidneys evaluated for
lesions typical or characteristic of HUS using a scoring system based on 4 quantifiable
parameters: glomerular congestion, glomerular heterophils, fibrin like vascular deposits in
medium vessels and cortical congestion. Results: no animals administered the WT O153
Stx1 strain developed wt. loss, diarrhea or renal lesions. All animals administered RDEC-
H19A-Stx1 or E22-Stx2 developed wt. loss and diarrhea. Results for renal histology for
REPEC strains selected for acquisition of Stx phages are tabulated below. Summary: WT
STEC isolates did not cause reproducible disease in DB rabbits. This may have been because
of previous exposure to the strain. REPEC strains which have laboratory-acquired Stx phages
produce consistent clinical disease and histological lesions which are quantifiable and suggest-
ive of HUS. Conclusions: Both Stx1- and STx2-producing REPEC strains induce reproducible
and quantifiable renal lesions in DB rabbits following orogastric challenge. These challenge
models should permit evaluation of therapies to prevent the onset of renal disease following
STEC infection
T1181
Tumor Suppressor Foxo3a Is Involved in Regulation of Inflammation Induced
By Enteric Pathogen Citrobacter Rodentium
Suzana Savkovic, Marinka Bulic, Amy Yang, Jameela Huq, Stanford L. Peng
Introduction: Enteric bacteria play an important role in initiating and maintaining chronic
intestinal inflammation, which is closely associated with colon cancer development. Infection
with Citrobacter rodentium (CR), a pathogen known to induce inflammation and promote
tumorigenesis in the mouse colon is an accepted model to study bacteria-triggered mechan-
isms that contribute to these processes. It has been shown that the NF-κB pathway that
controls intestinal inflammation is also involved in tumorigenesis. For example, the tumor
suppressor Foxo3a is inactivated by and also regulates the NF-κB pathway in tumor cells.
Aim: The aim of this study was to determine the mechanism of regulation of Foxo3a in
intestinal epithelial cells (IEC) and its contribution to CR-induced inflammation. Methods:
Mouse IEC, CMT-93, were infected with CR and examined for Foxo3a inactivation by
immunoblotting and immunofluorescent staining. IEC were transfected with retroviral vector
pMX-Foxo3a-IRS-GFP, allowing over-expression of Foxo3a. pMX-IRS-GFP was used as a
control vector, while independent expression of green fluorescent protein (GFP) was used
as a internal control to assess the efficiency of retroviral transfection. These cells were
analyzed for NF-κB activation by immunofluorescent staining of the p65 subunit of the NF-
κB complex and for expression of the cytokine macrophage inflammatory protein-2 (MIP-
2) by ELISA. Results: First we assessed whether infection with CR affects Foxo3a in mouse
IEC. During infection of mouse IEC with CR, Foxo3a is phosphorylated, translocated from
the nucleus into the cytosol, and degraded, suggesting its inactivation. Next, we examined
whether Foxo3a plays a role in CR-induced NF-κB activation in mouse IEC by assessing
the effect of over-expression of Foxo3a on CR-induced NF-κB translocation. CR-induced
translocation of p65 was attenuated by approximately 50% in the cells over-expressing the
Foxo3a as compared to the control. To assess the effect of Foxo3a on cytokine expression,

















from a CR culture known to induce expression of MIP-2 cytokine. Over-expression of
Foxo3a attenuated CR-induced MIP-2 expression (pMX untreated 2±1 pg/ml, CR-SN 4 h
97±8 pg/ml; pMX-Foxo3a untreated 2±1 pg/ml, CR-SN 4 h 60±7 pg/ml, n=6, p=0.007 for
SN treated pMX vs SN treated pMX-Foxo3a), suggests that Foxo3a plays a role in regulating
CR-induced MIP-2 expression in mouse IEC. Summary: i) Infection of mouse IEC with CR
induces phosphorylation, translocation, and degradation of Foxo3a; ii) Foxo3a regulates
CR-induced NF-κB activation and CR-induced MIP-2 expression.
T1182
Lactobacillus Casei Strain Shirota Prevent NSAID-Induced Small Intestinal
Injury By Suppressing Toll Like Receptor 4 Signaling Pathway
Hikaru Nishio, Toshio Watanabe, Tetsuya Tanigawa, E.J. Sasaki, Masatsugu Shiba,
Kazunari Tominaga, Yasuhiro Fujiwara, Nobuhide Oshitani, Kazuhide Higuchi, Kato
Shinichi, Tetsuo Arakawa, Koji Takeuchi
Background & Aims: Experimental studies have shown that enteric bacteria play crucial
roles in pathogenesis of NSAID-induced small intestinal injury. Probiotics have been used
to treat a variety of gastrointestinal disorders, including inflammatory bowel disease, but
effect on NSAID-induced small intestinal injury is unknown. In the present study, we
examined effect of a probiotic Lactobacillus Casei strain Shirota (LcS) on indomethcin (IM)-
induced small intestinal injury in rats and mice. Methods: Animals were administered IM
(10 mg/kg p.o.), and intestinal injury was evaluated 24 h later. Viable LcS (107-109 CFU
p.o.) was administered once or for a week, while heat-killed LcS (109 CFU p.o.) was
administered for a week. Ampicillin (active against both Gram-positive and Gram-negative
bacteria, 800 mg/kg), aztreonum (active against Gram-negative bacteria specific antibiotic,
250 mg/kg) or vancomycin (active against Gram-positive bacteria, 50 mg/kg) were given
p.o. twice 24 h and 1 h before IM treatment. Result: IM induced hemorrhagic lesions in
the small intestine of these animals. Both ampicillin and aztreonam suppressed the damage
in rats, while vancomycin had no effect. One-week treatment with LcS prevented IM-induced
intestinal injury with a 2.4-fold increase of the L-lactic acid (LA) concentration in small
intestinal luminal contents, and also inhibited increases in myeloperoxidase activity (a marker
for neutrophil infiltration) and expression of mRNA for tumor necrosis factor-α (TNF-α)
in small intestine by 24 h after administration of IM. Heat-killed LcS did not have the
preventive effect on IM-induced small intestinal injury. In Toll-like receptor (TLR) 4-deficient
mice, the intestinal damage was inhibited by 90% as compared with that in wild-type
littermates. TLR4 was mainly expressed on inflammatory cells in the rat small intestine. In
human monocytes cells (THP-1), both 10 mM LA and LcS culture supernatants containing
10 mM LA inhibited increases in TNF-α mRNA expression and TNF-α protein secresion
by lipopolysaccharide (LPS). Western blot analyses confirmed that LA and the LcS culture
supernatants suppressed phosphorylation of IκB. Conclusion: These results suggest that
TLR4 signaling pathway activated by LPS from Gram-negative bacteria plays a crucial role
in IM-induced small intestinal damage, and LcS has a potential prophylactic effect on NSAID-
induced damage by suppressing TLR4 signaling pathway, which is mediated by LA.
T1183
Metabolic Activity of Probiotics - Oxalate Degradation
Caroline Murphy, Sharon Murphy, Sinead Jacob, Maurice O'Donoghue, Thomas Boileau,
Gregory Sunvold, Gregory Reinhart, Barry Kiely, Fergus Shanahan, Liam O'Mahony
Background: Hyperoxaluria complicated by renal tract stones is an important clinical prob-
lem, particularly in patients with enteric hyperoxaluria secondary to conditions such as
Crohn’s disease. Aims: (a) To evaluate oxalate degradation by a range of lactic acid bacteria
(LAB) in vitro; (b) To determine the impact of LAB consumption on oxalate excretion in
vivo. Methods: Bacteria were grown in oxalate-containing media and their ability to degrade
oxalate in vitro was determined using reverse-phased HPLC. Selected LAB, or placebo, were
fed to rats (n=6/group) for 4 weeks. Urine was collected at weeks 0, 2 and 4 and oxalate
levels determined by HPLC. Results: In vitro oxalate degradation was detected for 11/18 of
the Lactobacillus strains. In contrast, 0/13 Bifidobacterium strains degraded oxalate. Lactobac-
illus (L.) animalis 223C, L. murinus 1222, L. murinus 5323 and L. murinus 3133 were selected
for investigation in the rat model. Urinary oxalate levels were significantly reduced (p<0.05)
in animals fed L. murinus 5323 (42% reduction) and L. animalis 223C (81% reduction) but
were unaltered when fed with L. murinus 1222, L. murinus 3133 or placebo. Conclusion:
Probiotic organisms vary widely in their capacity to degrade oxalate. In vitro degradation
does not uniformly translate to an impact in vivo. The results have therapeutic implications
and may influence the choice of probiotic, particularly in the setting of enteric hyperoxaluria.
T1184
Lactobacillus Farciminis Treatment Suppresses Stress-Induced Visceral
Hypersensitivity Through Inhibition of Colonic Epithelial Cells Myosin Light
Chain Kinase (MLCK)
Afifa Ait-Belgnaoui, Wei Han, Florence Lamine, Helene Eutamene, Jean Fioramonti,
Lionel Bueno, Vasillia Theodorou
Background. Increase in gut sensitivity and intestinal permeability have been reported in
irritable bowel syndrome. In rats, stress-induced increase in colonic paracellular permeability
through epithelial cell MLCK activation is responsible for stress-induced colorectal hypersens-
itivity. Treatment with the probiotic Lactobacillus farciminis has been shown to prevent stress-
induced increase in colonic paracellular permeability and colorectal sensitivity in rats, but
the mechanism involved remains unknown. This study aimed to evaluate in rats (i) acute
stress-induced changes in the levels of MLCK, myosin light chain (MLC) and its phosphoryl-
ated form (p-MLC) which is responsible for epithelial cells cytoskeleton contraction (ii) the
influence of L. farciminis treatment on these alterations. Materiel and Methods. In a first
series of experiments, 12 groups of 4 female Wistar rats were used for assessment of the
kinetics of MLCK, MLC and p-MLC protein levels after 15, 30, 45, 60, 75 and 90 min of
sham stress (groups 1-6) or partial restraint stress (PRS) (groups 7-12) proximal colonic
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mucosa was removed for determination of protein levels by Western immunoblotting. In a
second series of experiments, 4 groups of 4 rats received orally during 15 days either saline
(group 1, 2) or 1011 cfu/day of L. farciminis (groups 3, 4). At the end of treatments p-MLC
levels were determined after 45 min of sham stress (groups 1, 3) or PRS (groups 2, 4).
Results. Partial restraint stress did not modify MLCK levels. In contrast, p-MLC levels were
significantly (p<0.05) increased from 15 to 45 min of starting PRS (31.2 % of increase at
45 min compared with sham stress). MLC levels were significantly increased at 60 min after
the beginning of PRS. L. farciminis treatment significantly decreased p-MLC levels (- 26%
compared to saline, p<0.05) at 45 min of PRS. Conclusion. This study shows that a two-
week treatment by Lactobacillus farciminis reduces stress-induced MLC phosphorylation,
suggesting that this probiotic strain prevents stress-induced increase of colonic paracellular
permeability and colorectal sensitivity by inhibiting the contraction of colonic epithelial cells
cytoskeleton and, the subsequent tight junction opening.
T1185
Lactulose Breath Testing Detects Small Intestinal Bacterial Overgrowth in Rats
Justin H. Barad, Eileen O. Sullivan, Isella Nieto, Anna Hui, Henry C. Lin
Background: In rats, SIBO can be induced by feeding a diet containing raw red kidney
beans (RKB) or its constituent lectin phytohemagglutinin as shown by direct culture and
electron microscopy after euthanasia (Gastroenterology 1983;84:506). Recently, SIBO was
found in 84% of patients with IBS as demonstrated by an abnormal lactulose breath test.
The role of SIBO in IBS was supported by 75% improvement of symptoms with normalization
of lactulose breath test with an antibiotic. A rat with SIBO would then be an appropriate
animal model of IBS. Therapeutic strategies for IBS could be rapidly tested if lactulose breath
testing were to be used in an animal model of SIBO to follow treatment response. The aim
of this study was to test the hypothesis that hydrogen excretion following lactulose is greater
in red kidney bean fed rats. Methods: Lactulose breath test was compared at time 0, week
1 and week 2 in two groups of rats fed either standard rat chow (control) or chow supple-
mented with 24% powderized red kidney beans (RKB). To perform the lactulose breath
test, 0.5 ml lactulose was delivered into the stomach by gavage at time 0. The concentration
of hydrogen in the exhaled breath was then measured every 15 min for 180 min while the
rat was housed in a 3-L air-tight collection chamber that was equipped for timed air exchange.
Breath hydrogen concentration was plotted against time over the 180-minute monitoring
period. Data were analyzed by applying paired t-test against peak hydrogen concentration
(mean ± SE). Results: 1. At baseline, breath hydrogen profiles were similar between control
and RKB. 2. At week 1, while the peak concentration was 45 ± 16.6 ppm in the control
group, the value was 186 ± 123 ppm in the RKB (p < .17). At week 2, while there was a
peak concentration value of 35 ± 9.5 ppm for the control, there was a peak concentration
value of 107 ± 24 ppm for the RKB (p < .05). Conclusion: Higher hydrogen excretion was
detected in response to lactulose in the RKB fed rats to suggest SIBO after two weeks of
RKB feeding. Lactulose breath test may be used to detect SIBO in rats. This study was
supported (in part) by NIH P50 AA11999.
T1186
Proteomic Analysis of Potential Mechanisms Involved in the Lactobacillus
Paracasei -Mediated Restoration of Enteric Muscle Dysfunction Induced By
Trichinella Spiralis Infection
Gabriela E. Bergonzelli, Elena F. Verdu, Luisa V. Lopes, Andreas Fuerholz, Laure Marvin-
Guy, Irene Corthesy-Theulaz, Stephen M. Collins
Background & Aim: We have shown that L. paracasei NCC2461 or its spent culture medium
(SCM) improved post-T. spiralis (Tsp) neuromuscular dysfunction in part through modulation
of the immune response to infection. Here we investigate by proteomic analysis, other
potential targets involved in the restoration of post-infective (PI) muscle dysfunction mediated
by SCM. Methods: Tsp infected mice received 100 μl of growth media (MRS) or SCM from
day 10 to 21 post infection. Uninfected mice received 100 μl MRS. Protein extracts of
myenteric plexus longitudinal muscle from jejunum were analyzed by 2D gel electrophoresis.
Spots were quantified and excised for protein identification by MALDI-TOF-MS and NanoLC-
ESI-MS/MS. Results: Tsp infection altered the expression of 39 proteins. SCM treatment
resulted in total** or partial* normalization of 15/39 proteins involved in different pathways.
The table shows the most relevant functional clusters. SCM treatment restored Tsp-induced
alterations in NO-associated pathways (reflected by creatin kinase and arginase 1 normaliza-
tion), cytoskeleton organization, stress response and immune modulation but did not coun-
teract the parasite effect at the respiratory chain level. Conclusions: Proteomic analysis
suggests that the SCM-mediated normalization of PI muscle dysfunction is achieved through
the modulation of multiple proteins involved in filament organization and other components
of excitation-contraction coupling. This approach may be useful to identify novel therapeutic
targets in PI-IBS.
T1187
Safety and Tolerability of the Probiotic Organism Bifidobacterium Infantis
35624: Clinical Experience and Molecular Basis
Eamonn M. Quigley, Peter J. Whorwell, Fergus Shanahan, Douwe Vansinderen, Jun Xu,
Linda Altringer, Liam O'Mahony, Francisco Guarner, Progid Investigators
Background: Evidence for probiotic efficacy in a variety of gastrointestinal disorders accumu-
lates. While probiotics are generally regarded as safe, there have been few large-scale investi-
gations of short-term tolerance or long-term safety and theoretical concerns have been raised
regarding short-term tolerability in functional disorders and risk of systemic infections among
those with impaired barrier function. Aim: To evaluate the tolerability and safety of the
probiotic organism Bifidobacterium infantis 35624. Methods: Data from two randomised,
placebo-controlled, double-blind trials were used in this analysis. A four-week dose-ranging
study, (Bifidobacterium 106 vs. 108 vs. 1010) in subjects with irritable bowel syndrome (IBS)
and a one-year study among subjects with active Crohn’s disease and ulcerative colitis, were
reviewed for evidence of short-term tolerability and long-term safety, respectively. The
genome of the organism was also evaluated for evidence of genetic features of pathogenicity.
Results: In the IBS study, 270 subjects were randomised to one of the three doses of the
organism and 92 to placebo; 330 completed the study, including 243 on active treatment.
A total of 17 subjects withdrew due to adverse events (AE’s), 9 from the placebo group and
8 from the three treatment groups combined. The majority were occasioned by worsening
of IBS symptoms. The overall incidence of all AE’s was similar in the four groups at 48%,
37%, 52% and 43% for placebo, 106, 108, and 1010, respectively with the majority (29%,
37%, 28% and 24%) being IBS-type gastrointestinal symptoms. The incidence of severe
AE’s adjudged as treatment related was highest in the placebo group at 9%; rates for the
three treatment groups were 0%, 1% and 2%, respectively. In the inflammatory bowel
disease (IBD) study, 32 patients with Crohn’s disease and 50 with ulcerative colitis completed
the study. No instances of systemic or major organ sepsis were recorded. From genome
analysis it was apparent that Bifidobacterium infantis 35624 did not contain DNA that was
homologous to known pathogenicity islands or transferable antibiotic resistance markers.
Conclusions: Bifidobacterium infantis 35624 is well tolerated in the short term by patients
with IBS and is not associated, in long-term therapy, in a susceptible population (IBD),
with any evidence of risk for systemic sepsis. These clinical findings are supported by
genome analysis.
T1188
6 Months-Treatment of Symptomatic Uncomplicated Diverticular Disease
(SUDD) of the Colon with Lactobacillus Paracasei F19
Rosario Cuomo, Giovanni Maconi, Francesco De Giorgi, Edith Lahner, Giovanni Sarnelli,
Bruno Annibale
Background: Abdominal pain and bloating are frequent symptoms in SUDD, which are
generally accepted to be related to functional disorders. Albeit no specific standard treatment
for SUDD is accepted, guidelines of the American College of Gastroenterology suggest an
high-fibre diet in patients with SUDD. Some observations suggest a possible role of gut
microflora in determining symptoms related to SUDD, thus these patients may potentially
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benefit from probiotics treatment. Aim: to assess the efficacy of Lactobacillus paracasei F19
in patients with SUDD. Materials and Methods: Multicentric randomized controlled study
on 43 pts, aged 47-78 years (15 M, 28 F) with SUDD, diagnosed by double contrast
enema and biochemistry to exclude acute inflammation. SUDD was defined as: presence of
abdominal symptoms (pain <24h and bloating) for at least 6 months before enrollment. All
pts had a validated detailed questionnaire for abdominal symptoms and functional dyspepsia
(FD) including a visual analogic scale (VAS). Exclusion criteria were: complicated diverticular
disease, previous colon surgery, antibiotics or laxatives in the 30 days before enrollment,
use of NSAIDs. In all pts a daily intake of 30 g of dietary fibre (vegetables and fruit) was
recommended. Pts were randomly assigned to receive: 1 sachet b.i.d of L. paracasei F19
(containing 12.5x109 viable bacteria and 750 mg of gluco-oligosaccharides ) for 14 days/
month for 6 months (Group A, n=14), only fibre diet (Group B, n=13) or 1 sachet once
daily of L. paracasei F19 for 14 days/month for 6 months (Group C, n=16). Endpoint of
the study was to evaluate the decrease of abdominal pain and bloating after 6 months of
treatment by VAS. Results are expressed as mean±SD. Results: At baseline, 40 pts (93%)
had both abdominal pain and bloating, whereas 3 pts had only bloating. 34 patients (14
M, 20 F, 79%) completed the study: 1 patient (Group A) was withdrawn for diarrhea and
8 patients (3 from Group A, 4 from Group B, 1 from Group C) were lost at follow-up.
Symptoms related to FD were minimal and not affected by any treatment. Conclusion:
Patients with SUDD benefit of treatment with L. paracasei F19 since it significantly decreases
the intensity of abdominal pain and bloating. The efficacy of higher dosage of probiotics is
similar to that of lower dosage.
*p<0.05
T1189
The Probiotic Formulation Lacidofil®/ Entercine® Prevents Stress-Induced
Increase in Colonic Permeability and Sensitivity to Distension in Rats
Helene Eutamene, Chantal Chabo, Stephanie Guggisberg, Lionel Bueno, Jean Fioramonti,
Henri Durand, Bernard Fabre, Vassilia Theodorou
Background. Acute stress-induced increase in colonic paracellular permeability is responsible
for rectal hypersensitivity in rats (Pain 2005, 113: 141-7). In previous studies, the probiotic
formulation Lacidofil®/ Entercine® (Lactobacillus rhamnosus Rosell 11 and Lactobacillus
acidophilus Rosell 52) has been effective in preventing and/or alleviating the symptoms of
various gastrointestinal disorders. This study aims to evaluate the effect of the probiotic
formulation Lacidofil®/ Entercine® on hyperalgesia to rectal distension (RD) and increased
colonic paracellular permeability (CPP) induced by an acute stress. Methods. Four groups
of eight female Wistar rats received orally during 15 days either saline or the probiotic
formulation (8.4 109 CFU/day). In order to measure abdominal cramps reflecting visceral
pain, rats were chronically equipped with electrodes implanted in the abdominal striated
muscle. At the end of treatments, rats were submitted to a partial restraint stress (PRS)
during 2 h. Four hours before and 20 min after PRS, a RD was performed using a Fogarty
probe inflated from 0 to 1.2 ml. CPP was determined in rats fitted with an intracolonic (IC)
catheter. At day 0, 10 and 15 (20 min post PRS), rats received 51Cr-EDTA (250 µL; 0.7
µCi IC) and CPP was assessed by 51Cr-EDTA recovery in urines collected for 24 h. Results.
In basal conditions, RD significantly (p<0.05) increased the number of abdominal cramps
from 0.8 ml of RD. A similar nociceptive response was observed in Lacidofil®/ Entercine®
treated rats compared with vehicle. PRS significantly (p<0.05) increased the number of
abdominal cramps for all RD volumes applied reflecting colonic hypersensitivity. The probi-
otic formulation Lacidofil®/ Entercine® significantly (p<0.05) reduced the increase in the
number of abdominal cramps induced by PRS, up to basal level, for all RD volumes applied.
In absence of stress, at day 0 and day 10 similar values of CPP were observed in Lacidofil®/
Entercine® and vehicle group (0.85 ± 0.19 vs 0.91 ± 0.09; 0.96 ± 0.23 vs 0.87 ± 0.11 %
respectively). PRS significantly (p<0.001) increased CPP (2.95 ± 0.11 vs 0.91 ± 0.09 %).
Lacidofil®/ Entercine® treatment suppressed the PRS-induced increase of CPP (1.06 ±
0.05 vs 2.95 ± 0.11 %). Conclusion. A two-week treatment with Lacidofil®/ Entercine®
suppresses the stress-induced visceral hypersensitivity and increase of colonic paracellular
permeability in rats, suggesting a potential beneficial role of this probiotic formulation in
functional gastrointestinal diseases treatment.
T1190
Acute Metabolic Stress Activates Intermediate Conductance Potassium (IK)
Channels in the Basolateral Membrane of Human Colonic Crypt Cells
Arun Loganathan, John E. Linley, Jeremy P. Lodge, Malcolm Hunter, Geoffrey I. Sandle
Background: Intestinal ischaemia is associated with increased mucosal permeability, bacterial
translocation, and sepsis. Acute metabolic stress produced by 2,4dinitrophenol (DNP) and
deoxyglucose (DG) activates large conductance K+ channels in cardiovascular tissues, and
small conductance K+ channels in liver and biliary cell lines. A possible link between K+
channel activity and intestinal epithelial permeability has come from studies using cultured
monolayers of the T84 colonic adenocarcinoma cell line, which showed that an acute increase
in the basolateral membrane K+ conductance produced by mastoparan (an activator of G
protein-coupled K+ channels) caused a 4-fold increase in paracellular permeability. Aims:
To determine whether acute metabolic stress leads to activation of basolateral K+ channels
in human colonic crypts. Methods: With ethics committee approval and informed consent,

















of the investigation of altered bowel habit. In all cases, the colonic mucosa was normal
macroscopically and histologically. Intact crypts were isolated by Ca2+ chelation (Bowley KA
et al. Gut 52,854-860,2003). Cells were exposed to 100μM DNP + 5mM DG to produce
metabolic inhibition. Whole-cell K+ currents were measured using the perforated patch-
clamp technique (0.24mg/ml amphotericin in pipette), and single channel activity in the
basolateral membrane was studied in the cell-attached configuration. Results: 100μM DNP
+ 5mM DG activated whole-cell currents within 5 minutes. This response was associated
with an increase in whole-cell conductance from 1.28 ± 0.14nS to 2.60 ± 0.17nS (P<0.01;
n = 12), and hyperpolarization of the cell membrane voltage from -72 ± 3mV to -83 ± 3mV
(P<0.025), consistent with activation of a K+ current. In single channel recordings, 100μM
DNP + 5mM DG activated intermediate conductance (30pS, IK) K+ channels, channel activity
(expressed as N.Po, where N = number of channels in patch, and Po = single channel open
probability) increasing from 0.58 ± 0.2 to 0.81± 0.3 (P<0.05, n=10). There was no evidence
of activation of either large conductance (BK) or small conductance (SK) K+ channels,
both of which are normally present in the basolateral membrane of human colonic crypts.
Conclusion: Metabolic stress activates basolateral K+ (IK) channels in human colonic crypts. If
additional studies link increased K+ channel activity with changes in paracellular permeability,
specific K+ channel blocking drugs may provide a way of preventing the increase in paracellu-
lar permeability, thereby decreasing the risk of sepsis in patients with intestinal ischaemia.
T1191
The Lambda (λ) Isoform of PKC Is a Unique Modulator of Inducible NO
Synthase (iNOS) Signaling and Is Critical to Monolayer Disruption By
Oxidative Stress: A Novel Pro-Inflammatory Mechanism in Intestinal
Epithelium
Ali Banan, Lijuan Zhang, Maliha Shaikh, Jeremy Z. Fields, Ashkan Farhadi, Christopher
B. Forsyth, Ali Keshavarzian
iNOS upregulation & gut barrier disruption are key to the pathogenesis of inflammatory
GI disorders. Using monolayers of intestinal cells, we found that oxidants upregulate NO
production (by activating iNOS) & lead to disruption of cytoskeletal & barrier integrity.
But, the mechanisms are unclear. Since the atypical λ isoform of PKC is key to cell instability,
we investigated whether PKC-λ is crucial in oxidant-induced iNOS activation/NO overprod-
uction, and cytoskeletal oxidation & barrier disruption. Methods: We used innovative GI
clones stably transfected to overexpress PKC-λ or to inhibit its expression. Clones were
incubated ± oxidants (H2O2, HOCl, ONOO) or PKC activators or inhibitors. Wild type
(WT) cells were treated similarly. We monitored monolayer barrier integrity {fluorometry},
cytoskeletal integrity & oxidation {laser confocal microscopy, SDS-PAGE fractionation},
PKC-λ subcellular activity {immunoprecipitation, in vitro kinase}, iNOS activity & expression
{scintillation, PAGE}, NO levels {chemiluminescence}, oxidative stress (quenchable fluores-
cence[QF]), polymerized & monomeric actin (43 kDa subunits of actin, SDS-PAGE), n=6/
grp. Results: {I} Relative to WT cells exposed to vehicle, transfected cells overexpressing
(3.2 fold) PKC-λ or WT cells incubated with oxidant exhibited oxidative damage as indicated
by: PKC-λ activation, iNOS upregulation, NO over-production, oxidative stress (increased
QF), actin nitration & oxidation, actin disassembly (decreased polymerization, increased
disassembly), actin cytoarchitectural instability & monolayer barrier disruption. {II} All
measures of oxidative injury induced by PKC-λ overexpression were synergistic with oxidant
effects. Most of the overexpressed PKC-λ resided in membrane/cytoskeletal fractions (<8%
in cytosolic fractions), indicating constitutive activity. In both transfected clones & oxidant-
treated WT cells, PKC-λ (74 kDa) was active & found with iNOS (130 kDa), forming
endogenous PKC-λ/iNOS complexes. {III} Dominant mutant transfection to inhibit native
PKC-λ expression & activity (99.9%) prevented all measures of oxidation & inflammation
such as iNOS/NO & monolayer instability. Conclusions: We report for the first time that:
1) Activation of PKC-λ is necessary for cellular injury and oxidative stress of iNOS & NO
pathway activation; 2) PKC-λ is a unique intracellular modulator of iNOS signaling in
intestinal cells; 3) We have identified a novel proinflammatory mechanism - disruption of
barrier & cytoskeletal integrity through the upregulation of iNOS / NO signaling - among
the PKC family of isoforms. {Supported by NIDDK60511 & NCCAM01581; NIAAA13745}.
T1192
Role of Thrombin-Protease Activated Receptor 1 (PAR1) Pathway in Intestinal
Ischemia-Reperfusion in Rats
Hisato Tsuboi, Yuji Naito, Takahiro Suzuki, Kouichi Terao, Hirokazu Kajikawa,
Toshimitsu Okuda, Takeshi Hattori, Nami Nakabe, Tomohisa Takagi, Osamu Handa,
Satoshi Kokura, Hiroshi Ichikawa, Norimasa Yoshida, Toshikazu Yoshikawa
Background: CXC chemokines including human interleukin-8 (IL-8) and rat cytokine
induced neutrophil chemoattractant-1 (CINC-1) play a crucial role in the pathogenesis of
intestinal injury induced by ischemia-reperfusion(I/R). Thrombin and its specific receptor,
protease-activated receptor 1 (PAR1) act as important players in inflammation. However,
the association between thrombin activation and chemokine production during I/R is not
well studied. Aims: We investigated whether thrombin and PAR1 might be involved in the
pathophysiology of intestinal I/R, using in vitro and in vivo models. Materials and methods:
(in vitro model) Human umbilical vein endothelial cells (HUVEC) were subjected to hypoxia
in a Plexiglas chamber for 2 h. Reoxygenation was initiated in an environment of normoxia
for 8 h. IL-8 production was assayed by ELISA. The activation of nuclear factor-κB (NF-
κB) was determined by electrophoretic mobility shift assay. (in vivo model) Intestinal damage
was induced by clamping the superior mesenteric artery for 30 min followed by reperfusion
in male Wistar rats. ATIII was given to the rats intravenously just before the vascular
clamping. Thrombin-antithrombin complex (TAT) was measured as indicator of thrombin
activity. PAR1 was evaluated by real time-PCR and western blot. Tissue-associated myelop-
eroxidase (MPO) activity was measured in intestinal mucosa as index of neutrophil infiltration.
The intestinal protein concentrations and mRNA levels of CINC-1 were determined by ELISA
and real time-PCR. Results: Hypoxia-reoxygenation induced the production of IL-8 from
HUVEC. Treatment with thrombin markedly enhanced the IL-8 production after reoxygena-
tion, and ATIII blocked these enhancements by thrombin. Reperfusion after ischemia resulted
in increase in luminal protein and hemoglobin concentrations. Reperfusion significantly
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increased the serum levels of TAT and enhanced the expression of PAR1 in the intestinal
mucosa. Treatment with ATIII inhibited these increases after reperfusion in a dose-dependent
manner (1 - 30 U/kg). The increase in MPO activity after reperfusion was significantly
inhibited by treatment with ATIII. A profound expression of transcripts cording CINC-1
was detected in the course of reperfusion and ATIII significantly reduced protein and mRNA
levels. After I/R, DNA binding activities of NF-κB were markedly increased, whereas in ATIII
treated intestines these effects were significantly reduced. Conclusion: These results suggest
that thrombin-PAR1 pathway play an important role in the production of CINC-1 during
I/R, and that ATIII has potent anti-inflammatory effects on this injury via inhibition of pro-
inflammatory cytokines.
T1193
Novel Action of Ptca Compared with Cysteine/GSH Prodrugs Against Colitis
in Murine Model
Helieh S. Oz, Theresa Chen, Willem J. de Villiers, Jian Zhong, Herbert Nagasawa
Oxidant-mediated injury plays an important role in the pathophysiology of inflammatory
bowel disease. Recently, we showed that antioxidants modulated colitis in mice. In this
study, we further evaluated the protective effects of L-Cysteine and GSH prodrugs against
progression of colitis in a murine model. Methods: Male ICR mice were fed above compounds
incorporated into chow as follow: Group (A) received L-cysteine-glutathione mixed sulfide
(CySSG), a ubiquitous GSH derivative present in mammalian cells and suggested to be a
depot form of GSH. Group (B) was provided D-ribose-L-cysteine (RibCys) a cysteine prodrug
that releases in vivo L-cysteine. Group (C) was given (RS)-n-propylthiazolidine-4(R)-carb-
oxylic acid (PTCA) another cysteine prodrug involved in glutathione (GSH) biosynthesis.
Group (D) was fed chow supplemented with the vehicle. After 3 days, animals were further
provided with normal drinking water or water supplemented with 3.5% DSS, and the
progression of colitis was assessed in each group. Results: Mice administered with DSS
developed severe colitis with decreased hematocrit and weight loss. These parameters were
improved with prodrugs therapy, PTCA being superior to the others. Colonic lesions (scored
0-4) significantly improved in treated animals with PTCA and RibCyc and to a less extend
with CySSG therapy. Hepatic reduced GSH was depleted in colitis animals (control 6530+318
vs DSS 4814+298 nmol/g p<0.001) and normalized with prodrug therapies (control vs
treatments p>0.05). Protein expression of Serum amyloid A, inflammatory cytokines (TNF,
IL-6 and IL-12) were significantly increased in colitis animals and improved with therapies.
Immunohistochemistry showed significant upregulation of Cox-2, and CD68 expression
(macrophage specific marker) suggesting macrophage activation and infiltration in the colonic
lamina propria in colitis animals. These abnormalities were attenuated in prodrugs treated
mice. Conclusions: PTCA, RibCyc and to a lesser extend CySSG provided protection against
colitis in this murine model, further supporting a possible therapeutic application in IBD
patients. These data strongly support our previous report on the novel action of PTCA
against colitis.
T1194
Metabonomic Investigation to Study Gut and Systemic Responses to Stress
Doris M. Jacobs, Lionel Tornier, Ziad Ramadan, Sunil Kochhar, Carmen Alonso, Javier
Santos, Mar Guilarte, Maria Vicario, Maria Antolin, Esteban Saperas, Juanramon
Malagelada
Epidemiological, clinical and experimental evidence link life stress with the initiation, react-
ivation and perpetuation of gut mucosal inflammation although underlying biochemical
events are still poorly understood. Aim & Methods: To gain knowledge on the mechanisms
involved in stress-induced inflammation in the human intestine, we have investigated meta-
bolite changes in biofluids from 27 healthy volunteers (15 women and 12 men, average age
of 23.3±2.5) during intestinal jejunal perfusion, in basal conditions and after the exposure
to hand-cold pain stress for 15 minutes. Plasma and urine samples were collected at different
time-points (Figure 1). One-dimensional 1H NMR spectra were recorded on a Bruker DRX-
600 NMR spectrometer operating at a proton NMR frequency of 600.13 MHz and at a
temperature of 300 K. For plasma, Carr-Purcell-Meiboom-Gill (CPMG) spectra with the
spin echo sequence (D[-90°-(t-180°-t)n-FID) and the spin echo loop time of 128 ms were
additionally acquired. Results: Cold stress pain induced time-dependent metabolic changes
in plasma primarily in the glucose-alanine cycle and in anaerobic metabolism. The major
metabolite changes in urine were citrate, formate, acetate, lactate, alanine suggesting a
perturbed energy metabolism (Figure. 2). The accumulation of hypoxanthine in urine indic-
ates oxygen depletion, which may be associated to an imbalance between oxidative stress
and the defense mechanisms. Conclusion: Further in-depth analysis of the metabolite changes
using metabonomics approach is needed to understand the underlying mechanism of stress-
induced changes in gut functioning and its physiology.
Experimental design
Analysis of plasma and urine samples before and after stress. Left panel, Urine 1H NMR
fingerprints before and after stress from 2 randomly selected subjects. Right panel, pattern
recognition by principal component analysis (PCA) of the plasma 1H NMR data
T1195
Calcium-Dependent Activation of Signaling Kinases Mediates the Inhibitory
Effect of Hydrogen Peroxide On Colonic Epithelial Ion Transport
Kim E. Barrett, Linh Pham, Declan F. Mccole
Background: Hydrogen peroxide (H2O2) contributes to intestinal inflammation and dysfunc-
tion in inflammatory bowel disease (IBD). One feature of IBD is the decreased ability of the
intestinal epithelium to transport ions. We have previously shown that H2O2 inhibits carba-
chol (CCh) stimulated, Ca2+-dependent Cl- secretion across T84 colonic epithelial cells,
via a phosphatidylinositol-3 kinase (PI3-K) and extracellular signal-regulated kinase (ERK)
dependent mechanism. As H2O2 has been shown to activate intracellular Ca2+ release, this
study investigated the role of Ca2+ in the ability of H2O2 to activate signaling pathways that
negatively regulate ion transport. Methods: Protein phosphorylation was measured in T84
colonic epithelial cell monolayers by Western blot, and ion transport responses were measured
in Ussing chambers. Results: We have previously shown roles for ERK and the soluble
tyrosine kinase, Src, in the inhibitory effect of H2O2 on ion transport responses to CCh.
Pre-incubation of T84 cells with the intracellular Ca2+ chelator, BAPTA-AM (20 μM), com-
pletely blocked H2O2-induced phosphorylation of ERK and Src (p<0.001, p<0.05 respect-
ively; n=5). In addition, the Ca2+-dependent soluble kinase, Pyk-2, was also activated by
H2O2 in a time-dependent manner, similar to the timecourse of Src activation (p<0.01; n=
4). H2O2 activation of PI3-K signaling, as measured by phosphorylation of the downstream
target, Akt1, was also significantly blocked by BAPTA-AM (p<0.05, n=4). We previously
observed that p38 MAPK is activated by H2O2. The p38 inhibitor, SB203580 (10 μM),
reversed H2O2 inhibition of CCh (100 μM)-stimulated Cl- secretion (p<0.05, n=5), and
inhibited H2O2-induced Akt1 phosphorylation, indicating that p38 lies upstream of PI3-K
in the regulatory pathway (p<0.01; n=3). Moreover, H2O2-induced p38 phosphorylation
was partially reversed in the presence of BAPTA-AM (p<0.01; n=6), indicating a prominent
role for Ca2+ signaling in p38 activation by H2O2. Conclusions: Activation of Ca2+-dependent
regulatory kinases by H2O2 reduces the ability of colonic epithelial cells to secrete chloride.
These data increase our understanding of mechanisms involved in the suppression of colonic
epithelial ion transport by inflammatory mediators associated with IBD.
T1196
Redox Mechanisms in the Pathogenesis of Cysteamine-Induced Duodenal
Ulcers: Role of Iron in Organ-Specific Tissue Injury
Tetyana Khomenko, Joanna A. Bernstein, Xiaoming Deng, Klara Osapay, George Osapay,
Gordon D. McLaren, Hamid M. Said, Sandor Szabo
Cysteamine (C), a reducing aminothiol, reacts with transition metals to generate H2O2,
which can oxidize reduced metals and produce hydroxyl radicals (*OH) through the Fenton
reaction. C specifically induces ulcers in rat proximal duodenum where most dietary iron
absorption takes place. We hypothesized that iron may play a role in redox reactions involved
in the pathogenesis of C-induced duodenal ulcers. Methods: Non-fasting rats were given
either saline or C-HCl (25mg/100g) by gavage: once and euthanized 1, 2 hr later, twice
and euthanized after 6 hr, or three times at 4 hr intervals and euthanized 12, 24 hr later.
Duodenal mucosal oxygenation and redox status in rats at 2 and 12 hr after C were measured
using oxygen and redox electrodes. The production of hydroxyl radicals (*OH) in duodenal
mucosa was detected by fluorescence intensity of hydroxyphenyl fluorescein (HPF). The
amount of C in duodenal, gastric, jejunal, colonic mucosa or liver was determined by
HPLC. We also measured [C14]C uptake by isolated duodenal, gastric, jejunal and colonic
enterocytes, and by IEC-6 and Caco-2 cells. Results: C administration reduced pO2 (vs.
baseline) by 18-22% and significantly increased the redox status in the rat proximal duodenal
mucosa. The production of *OH in duodenal mucosa of rats treated with C was increased
from 9085±12 in controls to 10069± 68 (p=0.007) measured by fluorescence intensity. A
detectable level of C was found by HPLC assay 2 hr after C administration in duodenal
mucosa (0.018 ug/mg wet weight) and gastric mucosa (0.004 ug/mg), but not in jejunum,
colon or liver. A similar amount of C was detected in duodenal mucosa of rats given C by
gavage or subcutaneously. [C14]C uptake by isolated duodenal, gastric, jejunal and colonic
enterocytes, and by IEC-6 and Caco-2 cells increased linearly with time. [C14]C uptake by
all cells studied was pH dependent, with lower uptake at pH 5.0 and higher uptake in
more alkaline buffer. Unlabeled C (1 mM) markedly inhibited [C14]C uptake by all cells.
Overloading IEC-6 with iron (100 uM for 1 hr) accelerated uptake of [C14]C by 40%, but
incubation of cells with deferoxamine (100 or 200 uM for 24 hr) inhibited C uptake by
30% and 61%, respectively. Conclusions: 1) C induced local hypoxia, changed redox state
and generated the production of hydroxyl radicals in rat proximal duodenum. 2) Absorption
of C was mostly specific to the duodenal mucosa. 3) Absorption of C may be related to a
carrier-mediated system of C uptake with high uptake in alkaline pH and dependence on
iron. 4) Thus, iron-catalyzed redox reactions may play a key role in the pathogenesis of C-
induced organ-specific tissue injury.
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T1197
Alternative Method to Identify Susceptibility Genes for Crohn’s Disease
Through Transcriptome Analysis
Debby Laukens, Harald Peeters, Filip de Keyser, Eric Veys, Claude Cuvelier, D.R.
Elewaut, Erik Remaut, Martine de Vos, Pieter Rottiers
Objective Crohn’s Disease (CD) is a multifactorial disorder in which both genetic and
environmental factors are involved. In general, molecular genetic approaches currently used
to identify susceptibility factors for CD are hampered by variability in phenotype, genetic
heterogeneity across populations, uncontrolled environmental influences and limited statist-
ical power. Although the prospects for success have improved markedly, gene discovery in
CD might require additional evidence. We integrated the growing knowledge of susceptibility
loci to expression variation. Methods We compared basal gene expression levels in non-
inflamed colon biopsies from 16 CD and 11 control patients using a focus microarray chip,
and looked for variation in baseline expression level of genes that are located near one of
the known CD linkage markers. We focused on a cluster of highly related genes, called
metallothioneins (MT’s), located near the IBD1 locus. Quantitative real-time PCR (QPCR)
was used to specifically study the expression of different MT isoforms in an independent
population of CD and controls. The induction of MT1K in peripheral blood mononuclear
cells (PBMC’s) isolated from CD and controls was compared using Zn, oxidative stress and
several cytokines. The complete MT1K gene, and the promoter and coding regions of the
main transcriptional regulator of metallothioneins, MTF-1, were screened for mutations.
Results We identified 13 genes that differ in baseline expression and are located within CD
loci, of which 5 have so far been verified by QPCR. Three isoforms of MT specifically show
a decreased expression at basal level in colon biopsies of CD patients, as assessed by QPCR
(p<0.01). This lowered expression level was also seen in PBMC’s of CD patients, indicating
a genetic aberration. Interestingly, the expression level greatly depends on disease location:
the reduced MT expression observed in non-inflamed colon biopsies is more pronounced
in CD patients who have primarily a history of colitis. MT1K induction by Zn and cytokines
was not impaired in CD, but the response to oxidative stress was significantly higher
(p<0.005). No coding polymorphisms in MT1K were identified. Two missense mutations
in MTF-1 were found in 7 of 95 patients, and we are currently evaluating the occurrence
of a promoter polymorphism in CD. Conclusions Microarray screening can be useful in
identifying candidate susceptibility genes in CD. We provide evidence that MT expression
in CD is genetically determined, and we put forward potential candidate genes for muta-
tion screening.
T1198
The Role of Amino Acid-Rich Preservation Solution in Alleviating Intestinal
Ischemia-Reperfusion Injury in a Large Animal Model
Thomas Churchill, Payam Salehi, David Bigam
Introduction: Ischemia-reperfusion injury is a major determinant limiting the success of
small bowel (SB) transplantation. Over the past few years, our lab has clearly revealed the
effectiveness of an amino acid-based preservation solution (which is specifically tailored to
the metabolic requirement of SB) in alleviating mucosal ischemia-reperfusion injury in ex
vivo and in vivo rodent models. This study was designed to examine the role of this novel
solution in ameliorating SB ischemia-reperfusion injury in a large animal model to bridge
animal data to potential therapy protocols in the clinic. Methods: Under general anesthesia,
SB of Landrace-Yorkshire pigs (20-24 kg) (N=12) were randomly assigned for luminal
pretreatment with ~2 liter of the following solutions: Group 1 - none (control); Group 2 -
University of Wisconsin (UW) solution; Group 3 - an amino acid (AA) based solution. Total
warm ischemia (WI) was induced via superior mesenteric artery occlusion using a vascular
clamp, after 60 min the occlusive clamp was removed and reperfusion was monitored over
180 min. Energetics, oxidative stress and histology were assessed at 0, 15, 30, 60, 90, 120
and 180 min reperfusion. Results: ATP and ADP were markedly better preserved in Group
3 throughout the entire reperfusion period (p<0.05, compared to control and Group 2).
Group 3 also showed significantly greater ATP/AMP ratio compared to Groups 1 and 2 over
the first 60 min of reperfusion (p<0.05). After 60 min WI, Group 3 exhibited glutathione
levels ~40 % greater than Groups 1 and 2 (13.1 vs 8.4 and 8.4 µmol/g, respectively, p<0.05).
Group 3 glutathione (GSH) levels were up to 2.5-fold greater than corresponding values in
Groups 1 and 2 after 60, 120 and 180 min reperfusion (p<0.05). Malondialdehyde (index
of lipid peroxidation) in all groups were inversely correlated with GSH values at all time-
points. After 60 min WI, Groups 1 and 2 showed 30 % increase in tissue MDA contents;
levels in Group 3 remained unchanged compared to freshly isolated tissues. Histology
indicated superior preservation of mucosal architecture in amino acid treated tissues (Group
3) after ischemia and subsequent reperfusion. Conclusion: The strategy of administering a
luminal flush with the amino acid-rich preservation solution improves overall SB quality
when tested in a large animal model of ischemia-reperfusion. Applying an intra-luminal
flush of small bowel with AA solution on the ‘back table’ after a common intravascular flush
as part of multi-visceral procurement may be a practical way to minimize preservation injury.
T1199
Stable Gastric Pentadecapeptide Bpc 157 Studied for Inflammatory Bowel
Disease (PLD116, PL14736, Pliva) Inhibits Thromb Formation Following
Abdominal Aorta Anastomosis in Rat
Masa Jasprica, Predrag Sikiric, Sven Seiwerth, Lovorka Batelja, Alenka Boban Blagaic,
Miroslav Gjurasin, Leonardo Patrlj
Abdominal aorta surgery is regularly complicated by blood cloth obstructed the blood flow.
Stable gastric pentadecapeptide BPC 157 (now studied for inflammatory bowel disease
(PLD116, PL14736, Pliva)) protects endothelium, promotes angiogenesis and modulates
NO-synthesis (Life Sci 54:PL63-68, 1994, European J Pharmacol 332, 23-33, 1997, J Physiol
93, 479-485, 1999). Thereby, the focus was on injured abdominal aorta in rats, and we
show that BPC 157 affects thrombosis and other vascular changes presented after termino-

















(400-500 g), aortal segment between the renal and common iliac arteries was clamped and
cut, and a termino-terminal anastomosis performed using Prolene 9-0 sutures, and blood
flow restored, ascertained by palpable pulse on distal aorta. Then, at the site of anastomosis,
1 ml bath of gastric pentadecapeptide BPC 157 (dissolved in saline, 0/ml, 2 pg/ml, 2 ng/
ml, 2 µg/ml) was given, and the assessment micro-scopically (program SFORM, VAMSTECH-
Software Company, Croatia) was 24 hours thereafter, and compared with the values obtained
in corresponding healthy rats. Results. Regularly, following abdominal aorta anastomosis
controls present with thromb formed at the anastomotic site, and almost no blood flow in
blood vessel with apparently narrowed diameter. Contrasting with the findings in thrombotic
controls, gastric pentadecapeptide BPC 157 shows a dose dependent effect, with a clear
effectiveness in rats treated with µg-regimen. As shown in Fig. 1, these pentadecapeptide
BPC 157 rats present only a thrombotic ring at the site of the anastomosis, along with
preserved blood flow. Also, blood vessel diameter in gastric pentadecapeptide BPC 157 µg-
group being at the range of values noted in the healthy rats, is preserved, and much larger
than in thrombotic controls. Conclusion. Together, an inhibition of all events related to
abdominal aorta anastomosis is along with this pentadecapeptide BPC 157 as an agent
known to protect mucosa, endothelium, and to modulate NO-system. Likewise, with respect
to virtually no toxicity in clinical studies, these findings could be likely relevant for further
therapy applications.
T1200
Stable Gastric Pentadecapeptide BPC 157 (BPC157) in Trials for Inflammatory
Bowel Disease (PL-10, PLD-116, Pliva, Croatia). Heals Ileoileal-Anastomosis
and Counteracts Corticosteroid-Negative Effect in Rat
Tihomir Vuksic, Predrag Sikiric, Sven Seiwerth, Bozo Radic, Robert Klicek, Luka Brcic
Gastric pentadecapeptide BPC 157 (BPC157) is an anti-ulcer agent is one of the promising
agents in clinical trials for inflammatory bowel disease. More effective in ulcer and various
wounds both locally and systemically (perorally, parenterally), unlike other peptides it is
stable in human gastric juice, and used without carrier. Importantly, it competes corticos-
teroid-negative aspects. Thereby, it may be one of few pharmacological agents that could
be also effective in inflammatory bowel disease complications, that follow small bowel
resection and ileoileal anastomosis. Methods. Anastomotic healing was assessed in rats (at
1, 2, 3, 4, 5, 6, 7, 14 day after ileoileal anastomosis) by (i) ahddesions (0-7, (neighboring
loops, stomach, liver “packed”)), loop diameters (at 2cm orally and aborally), anastomosis
arcade vessels (between 10 cm orally and 10 cm aborally),(ii) the time (sec), the volume
(ml)(infunded through syringe-perfusion pump system (Argus 600,Argus Medical A6) 1ml /
10 sec) and the pressure (mmHg) to leak induction (catheter (BD Careflow 5Fr 200 mm,
Becton Dickinson, USA) connected with chamber (BD Gabarith PMSET 1DT-XX, Becton
Dickinson, USA) and monitor Sirecust 732 (Siemens, Germany) at 10 cm proximal to
anastomosis, and (iii) microscopically. Treatment was once daily (first after surgery, last at
24 h before sacrifice), saline, BPC 157 (10µg, 10ng, 10pg/kg i.p.)and/or 6-alpha-methyl-
prednisolone (1 mg/kg i.p.).Results. BPC 157 significantly improves the all parameters of
anastomotic wound healing. Besides, the low dose of pentadecapeptide BPC 157 that had
no effect on those parameters by itself, became effective confronted with corticosteroids
treatment that adversely affects healing of colonic anastomoses in the rat. Conclusion. the
pentadecapeptide BPC 157 effect could be quite specific considering the all aspects of
ongoing process in anastomosis healing.
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T1201
Hepatic and Mesenteric Steal Shown with Dynamic Angiography Relates to
Ischemia in Non-Corresponding, Unaffected, Bowel Regions in Patients with
Isolated CA or SMA Stenosis
Renzo Veenstra, Robert H. Geelkerken, Dick G. Gerrits, Ad B. Huisman, Jeroen J.
Kolkman
Introduction Gastric exercise tonometry (GET) is the only clinically available method to
detect GI ischemia. In patients with SMA stenoses, the GET may remain normal because of
isolated small bowel ischemia. Moreover, mesenteric steal syndromes have been described
which may lead to ischemia in the area of the unaffected vessel (f.e. gastric ischemia in SMA
stenosis). In our cohort of chronic splanchnic syndrome (CSS) pts in whom gastric and
jejunal tonometry was performed, we studied the relation between CA and SMA stenoses,
and ischemia in stomach and small bowel, as well as dynamic angiography. Methods 220
pts were studied with gastric and jejunal tonometry, using dynamic angiography. In contrast
to standard angiography, we studied the timing of appearance of contrast in the CA and
SMA, and its collateral filling patterns. Results In 47 pts (25 M, 22 F) a single vessel stenosis
was found, (43 CA, 4 SMA). Tonometry was false negative in 1 pt (2%). Ischemia in the
corresponding bowel region was seen in 83% (n=39), in 49% (n=23) in the corresponding
area alone, in 34% (n=16) in both areas. In 15% (n=7) ischemia was only seen in the non-
corresponding area. On angiography collaterals between CA and SMA were seen in 6/7
pts with non-corresponding ischemia and in 12/16 pts with combined ischemia. Non-
corresponding ischemia In all CA stenosis with small-bowel ischemia, an insufficient flow
in the SMA was seen corresponding with rapid retrograde filling of the hepatic artery,
suggesting ‘hepatic steal’. In 1 of 2 pts with SMA stenosis and gastric ischemia, a similar
defect in the CA was seen with rapid collateral filling of the SMA suggesting ‘mesenteric
steal’. Combined ischemia In 4 of 16 pts with combined ischemia, a pattern suggesting
hepatic steal was seen. Conclusions This study shows that a single stenosis of either CA or
SMA can lead to ischemia in non-corresponding bowel regions due to mesenteric and hepatic
steal mechanisms. The latter is rather common and can be demonstrated using dynamic
angiography with emphasis on the first phase of arterial filling and the distribution of
contrast over both vessels. Future studies are needed to quantify the parameters in dynamic
splanchnic angiography.
T1202
Survival Time of Hepatocellular Carcinoma Patients Stratified According to
the Time-to-Recurrence
Kohsaku Sakaguchi, Yoshiyuki Kobayashi, Shin-Ichi Nakamura, Yasushi Shiratori
[Aim] The intrahepatic recurrence of hepatocellular carcinoma (HCC) is inevitable even after
curative treatment. The period until recurrence is related to the prognosis of HCC patients.
However, in terms of the period until recurrence, the survival time of HCC patients has not
been fully evaluated. The aim of this study is to clarify the survival time of HCC patients
stratified according to the period until recurrence. [Patients and Methods] This study was
designed as the retrospective cohort study including 402 HCC patients who underwent
curative treatment (surgical resection, percutaneous ethanol injection therapy, or radio
frequency ablation) for primary tumor between January 1991 and December 2004, and
followed for tumor recurrence at our clinic. The time-to-recurrence is defined as the interval
between the initial treatment and either recurrence of HCC or latest follow-up visit. We
analyzed the survival time of HCC patients stratified according to the time-to-recurrence;
Group I, 247 patients with time-to-recurrence less than 2 years, Group II, 82 patients with
time-to-recurrence more than 2 and less than 4 years, and Group III, 46 patients with time-
to-recurrence of 4 years and more. [Results] The 5- and 7-year probability of survival was
33.9% and 15.3% in Group I, 71.0% and 46.8% in Group II, and 95.1% and 89.4% in
Group III, respectively. Median survival time was 3.8 (2.4-5.8) years in Group I, 6.8 (4.9-
9.2) years in Group II, and 11.7 (8.4--) years in Group III (P<0.001, by log-rank test). The
following analyses on the survival after the treatment for recurrent HCC were conducted
solely among patients who had recurrence of HCC during follow-up period. One hundred
fifty-nine patients in Group I, 60 patients in Group II, and 23 patients in Group III developed
recurrence of HCC. The cumulative survival rates at 3-years after the curative treatment for
recurrent HCC in Group I, Group II, and Group III were 76.8%, 67.5%, and 63.5%, and
median survival time were 4.4 (3.1-6.9), 5.3 (2.4-8.6), and 3.6 (2.6- ) years, respectively
(P=0.931, by log-rank test). On the other hand, the 3-year probability of survival of patients
who underwent non-curative treatment was 16.6% in Group I, 53.9% in group II, and
60.0% in group III. The median survival time after the non-curative treatment for recurrent
HCC was 1.8 (0.8-2.5) years in group I, 3.2 (2.0-5.1) years in group II, and 3.4 (2.1-4.8)
years in group III, respectively (P=0.036, by log-rank test). [Conclusion] The time-to-
recurrence significantly influences on the survival time of HCC patients, and the median
survival time of patients with time-to-recurrence more than 4 years is more than 10 years.
T1203
Prognostic Performance of the New Treatment Algorithm for Hepatocellular
Carcinoma (HCC) in Japan: Compared with Prognostic Staging Systems
Yoshiyuki Kobayashi, Shinichiro Nakamura, Yasuhiro Miyake, Kenji Miyoshi, Hirokazu
Miyatake, Kazuhiro Nouso, Yoshiaki Iwasaki, Kohsaku Sakaguchi, Yasushi Shiratori
(OBJECTVE) Several prognostic staging systems and treatment strategies for hepatocellular
carcinoma (HCC) that are linked with disease stage have been reported. Recently, a new
HCC treatment algorithm by the study group of Japan that is based on liver damage by
Liver Cancer Study Group of Japan and tumor factors (Japanese treatment algorithm) has
been proposed. The purpose of this study is to assess the stratification ability of Japanese
treatment algorithm compared with other prognostic staging systems. (SUBJECTS AND
METHODS) A retrospective analysis of 2256 consecutive patients with HCC diagnosed
between 1994 and 2004 was performed. Clinical characteristics of the patients was as follows;
the mean tumor size and number were 26 mm and 1.6; Child-Pugh classification A was
1578 (70%); tumor ablation, hepatic resection, and transarterial chemoembolization were
performed in 901 patients (40%), 425 patients (19%), and 738 patients (32%), respectively
. We stratified HCC patients according to each 2 treatment strategies (Japanese treatment
algorithm and BCLC staging classification) and 2 prognostic staging systems (CLIP score
and JIS score). The goodness of fit of each prognostic system were assessed by the likelihood
ratio (LR) test and Akaike information criterion (AIC) using Cox’s proportional hazards
model, and also the discriminatory ability was analyzed by linear trend test. (RESULTS)
The proportion of all the HCC patients classified according to each staging system, CLIP
score of 0, 1, 2, 3, 4, 5 and 6 was 33%, 34%, 17%, 9%, 5%, 2%, and 0%; JIS score of 0,
1, 2, 3, 4 and 5 was 18%, 31%, 25%, 16%, 7%, and 0%; BCLC staging of 0, A, B, C and
D was 6%, 62%, 16%, 10% and 6%; Japanese treatment algorithm of A,B,C,D,E,F and G
was 50%, 14%, 8%, 5%, 7%, 3%, and 12%, respectively. The cumulative 5-year survival
rates of the each best prognostic group, CLIP score 0, JIS score 0, BCLC stage 0 and
Japanese treatment algorithm A were 64%, 67%, 75% and 58%, respectively. In relation to
homogeneity of survival within each stage, CLIP score have found to be the most fitting model
for HCC prognosis (LR=62.6, AIC=13619, P=.0000), while Japanese treatment algorithm was
more fitting model (LR=35.8, AIC=13590, P=.0000) than BCLC staging classification (LR=
18.5, AIC=13577, P=.0009). Moreover, linear trend test showed that JIS score had the
highest discriminatory ability (χ2=984.9). (CONCLUSION) Prognostic staging systems have
higher stratification ability with regard to prognosis in patients with HCC than treatment
strategy, while Japanese treatment algorithm showed better prognostic performance than
BCLC staging classification.
T1204
Repeated Recurrence Profiles of Hepatocellular Carcinoma Within Milan
Criteria
Kenji Miyoshi, Yoshiyuki Kobayashi, Yoshiaki Iwasaki, Shinichirou Nakamura, Hironori
Tanaka, Hideki Onishi, Shouta Iwado, Kohsaku Sakaguchi, Yasushi Shiratori
BACKGROUND Milan criteria has been considered in judging transplantability in patients
with hepatocellular carcinoma (HCC). Most of HCC patients revealed tumor progression
beyond the Milan criteria during follow-up. The purpose of this study was to clarify clinical
profiles of HCC recurrence after treatment of HCC within Milan criteria. SUBJECTS AND
METHODS One hundred and ninety-three curative HCC patients within Milan criteria who
received hepatic resection (n=57) or tumor ablation (n=136) at Okayama University hospital
between January 1999 and December 2004 were prospectively enrolled. The first, second,
and third recurrence rate was analyzed by the Kaplan-Meier method. To identify risk factors
for the recurrence of HCC beyond Milan criteria, 20 variables were analyzed with logistic
regression model. RESULTS The group comprised 138 men and 55 women. Mean age was
68 years. Child-Pugh classification A was 149 (77 %). The mean tumor size and number
were 21.4 mm and 1.3. Of the 193 patients, 110 (57 %) presented the first recurrences of
HCC and 75 (68 %) of them met Milan criteria and 69 received further curative treatment.
Of the 69 patients, 53 (77 %) patients presented second HCC recurrences and 39 (73 %)
of them met Milan criteria and 18 received further curative therapy. Of the 18 patients, 9
(50%) patients presented third HCC recurrences. In HCC patient within Milan criteria, the
1st HCC recurrence rate at 1 and 2 years was 17% and 37%, and the 2nd HCC recurrence
rate at 1 and 2 years increased to 46% and 75%, respectively, and the 3rd recurrence rate
was 43% and 71% respectively ( log-rank test p=0.003). The logistic regression analysis
revealed that serumα-fetoprotein (AFP) level (P = 0.03, RR: 2.60, CI: 1.06-6.15 ) and
normalization of serum AFP level after the initial treatment (P = 0.024, RR: 0.36, CI: 0.15-
0.90 ) were related to the recurrence of HCC beyond milan criteria after initial cutative
treatment. CONCLUSIONS The recurrence of HCC beyond Milan criteria after initial curative
treatment is associated with the normalization of serum AFP level after the initial treatment,
and the cumulative recurrence rate increased along with repeated recurrence of HCC.
T1205
Effect of Previous Interferon Treatment On the Recurrence of Hepatocellular
Carcinoma in Patients with Hepatitis C
Hirokazu Miyatake, Yoshiyuki Kobayashi, Yoshiaki Iwasaki, Shinichirou Nakamura,
Hironori Tanaka, Yasuhiro Miyake, Ryo Terada, Kenji Miyoshi, Hideki Ohnishi, Shouta
Iwadou, Bon Shouji, Takeshi Kuwaki, Kohsaku Sakaguchi, Yasushi Shiratori
BACKGROUND; It has been reported that interferon (IFN) treatment for chronic hepatitis
C could prevent the development of hepatocellular carcinoma (HCC). HCC are liable to
recur frequently even after curative therapy mainly because of multicentric occurrence. The
purpose of this study was to clarify the effect of previous IFN treatment before the develop-
ment of HCC on the recurrence and survival of HCC patients. METHODS; One hundred
and five out of 897 patients with HCC diagnosed at Okayama University Hospital between
1995 and 2005, had received with IFN therapy for chronic hepatitis C before the development
of HCC. The first and second recurrence rate of HCC after curative treatment for HCC was
statistically analyzed. The potential risk factors for HCC recurrence, including 27 variables
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at HCC development and recurrence, were analyzed by Cox proportional hazards model.
RESULTS; The group comprised 62 men and 43 women, and mean age at IFN therapy and
development of HCC was 57 and 64 years old, respectively. Eighty nine out of 105 patients
(85 %) were classified into Child-Pugh classification A. The mean tumor size and number
were 21 mm and 1.4. Thirteen of them (12 %) showed a sustained virologic response (SVR)
in previous IFN treatment. Of 105 patients 71 (68 %) developed the recurrences of HCC
during mean follow-up period of 2.5 years. 44 (62 %) out of 71 patients with recurrence
were successfully treated for the recurrent HCC. Of these 44 patients, 25 (57 %) patients
developed 2nd HCC recurrences during mean follow-up period of 2.3 years. In univariate
analysis, the age at the time of interferon therapy (p=.038) was the only factor related to
1st HCC recurrence, while SVR (p=.014), tumor number (p=.021), serum AST levels (p=
.002), serum ALT levels (p=.0008), prothrombin time (p=.039), and serum albumin at 1st
recurrence (p=.045) were related to 2nd HCC recurrence. The multivariate analysis showed
no significant factors of 2nd HCC recurrence. The period to 1st HCC recurrence after the
curative treatment for primary tumor was not significantly different between SVR and non-
SVR patients. However, the period to the 2nd HCC recurrence after the curative treatment
for 1st HCC recurrence in SVR patients was significantly longer than that in non-SVR
patients. (1528 vs 667 days, (log-rank test; p=.026)). Overall survival rate of SVR patients
was higher than non-SVR patients (p=.007). CONCLUSIONS: Sustained virologic response
to previous interferon treatment in patients with hepatitis C may reduce the risk for the
second recurrence of HCC and improve survival.
T1206
Effects of Supplementation with a Branched-Chain Amino Acid-Enriched
Preparation On Event-Free Survival and Quality of Life in Cirrhotic Patients
with hepatocellular carcinoma: A Multicenter, Randomized Controlled Trial
Haruhiko Kobashi, Youichi Morimoto, Toshio Ito, Toshinari Shimoe, Yasuhiro Makino,
Yasuyuki Araki, Hiroshi Ikeda, Kouichi Takaguchi, Masaharu Ando, Masanobu Miyake,
Yoshiaki Iwasaki, Kohsaku Sakaguchi, Yasushi Shiratori
Background & Aims: Liver cirrhosis is often associated with protein energy malnutriotion
(PEM), and oral administration of branched-chain amino acids (BCAA) is known to correct
PEM and improve health-related quality of life (QOL). However, the effect of BCAA in
cirrhotic patients associated with hepatocellular carcinoma (HCC) is unclear. This study
aimed to elucidate the effects of long-term BCAA supplementation on event-free survival
and QOL in cirrhotic patients with HCC. Methods: A multicenter, randomized controlled
trial for 3 years was conducted in 233 cirrhotic patients with HCC (159 men and 74 women,
mean age of 69). The Child-Pugh stage was A/B/C/others in 58/162/10/3 patients, and the
TNM stage was 1/2/3/4A/4B/others in 56/65/94/4/2/12 patients. They were assigned randomly
to the BCAA group (n=123) and the control group (n=110). Patients in the BCAA group
were orally administered with 150g per day of BCAA-enriched preparation, containing 40.5
g of protein including 18.3 g of BCAA, and 630 kcal. Primary endpoint was event-free
survival, that is, survival without development or deterioration of hepatic failure (jaundice,
ascites, or encephalopathy), rupture of HCC, esophago-gastric bleeding, or liver-related
death. Secondary endpoints were QOL estimated by the Short Form-36 questionnaires, and
liver function tests such as serum albumin, serum ammonia, and BCAA/tyrosine ratio (BTR).
The study conformed to the Declaration of Helsinki and was approved by the institutional
ethical committee. All patients gave their informed consent. Results: (1) Before November
2005, when the mean observation time was 585 days, 107 patients died, 44 experienced
development or deterioration of hepatic failure, 2 experienced esophago-gastric bleeding,
and 80 experienced no events. The mean event-free survival was 535 days in the BCAA
group and 495 days in the control group (no significant difference by log-rank test). As for
the patients with hypoalubuminemia at baseline (3.7g/dl or less), comprising 90 patients
in the BCAA group and 68 in the control group, event-free survival was increased significantly
in the BCAA group (p=0.0374). (2) The “vitality”, “role-emotional”, and “social functioning”
domains in the Short Form-36 measures were significantly improved (p=0.0306, 0.0347,
and 0.0262, respectively) in the BCAA group. (3) Serum albumin increased significantly in
the BCAA group (p=0.024). There was no significant change in serum ammonia and BTR.
Conclusions: Long-term BCAA supplementation in cirrhotic patients with HCC improves
QOL and serum albumin level. It also improves event-free survival in cirrhotic patients with
HCC and hypoalbuminemia.
T1207
Efficacy of Long Acting Release Octreotide in Patients with Advanced
Hepatocellular Carcinoma: A Randomized Multicenter Phase III Study
Gontran Verset, Chris Verslype, Hendrik Reynaert, Ivan Borbath, Philippe Langlet, Ann
van den Brouck, Marc Peeters, Ghislain Houbiers, Peeter Michielsen, Marianna
Arvanitakis, Jean-Luc van Laethem
Background/Aim: The role of somatostatin analogues in hepatocellular carcinoma (HCC)
remains undetermined. We therefore designed a prospective randomized multicenter study
to assess the efficacy of long acting release (LAR) octreotide for the treatment of advanced
HCC. Primary study end point was patient survival. Patients and Methods: A total sample
size of 90 patients was required to demonstrate with a power of 80% that octreotide LAR
increases 1 year survival by 20% in patients with advanced HCC. 109 patients with HCC
who were not amenable to curative resection, liver transplantation nor to local treatment,
were included between March 2001 and March 2005 and were randomly assigned to the
octreotide group (n=56) or the control group (n=53). Patients in both groups were allowed
to receive best supportive care (BSC) and a daily dose of 20 mg of tamoxifen. An intramuscular
injection of 30 mg octreotide LAR was administrated once monthly in the octreotide group.
The clinical, biological and tumoral parameters were recorded every 3 months until death.
Groups were comparable with respect to age, gender, presence of cirrhosis, Child-Pugh
score, etiology of hepatopathy, Okuda classification, KPS, α-FP level, size of target lesion and
previous treatement of HCC. Uni- and multivariate analyses were performed for assessment of
specific prognostic factors. Results: On the last follow-up (median: 3 months, range: 0,1-
31 months), all but 2 patients had died and the treated patients in the octreotide group

















survival was 3 months (CI95%: 1,4-4,6) for the ocreotide group and 6 months (CI95%:2-
10) for the control group (p=0,609). There was no difference in terms of α-FP decrease,
tumor regression or improvement of quality of life between the two groups. Variables
associated with a better survival in the multivariable analysis were: presence of cirrhosis,
α-FP level< 400 ng/ml and Okuda stage I. Conclusion: In this study, octreotide LAR did
not provide any benefit in terms of survival, tumor response or quality of life compared
with BSC.
T1208
CT-Guided Brachytherapy of Hepatocellular Carcinoma in Liver Cirrhosis - A
Novel Therapeutic Approach
Alexandra Bergk, Gero Wieners, Viola Weich, Bertram Wiedenmann, Thomas Berg, J.N.
Ricke
Introduction: Unresectable hepatocellular carcinomas (HCCs) still are a major clinical chal-
lenge due to poor prognosis and limited therapeutic options. This includes mainly HCCs
exceeding a diameter of 5 cm or multifocal manifestations with more than 3 tumor nodes.
Study: We treated 48 consecutive patients with unresectable HCC with a total of 63 single
fraction, high dose rate brachytherapy procedures. A 192Iridium source was used to apply
a minimal median dose of 20Gy (15-25Gy) to the tumor tissue. Afterwards, patients were
followed up closely until now or to their death (4 weeks - 4 years, median 16 month). Liver
function was assessed by Child-Pugh criteria; 42 and 6 patients showing a Child A and B
stadium, respectivley. The number of lesions treated simultaneously ranged from 1 to 5
with a median tumor size of 3.8 cm (range 1 - 9 cm). Brachytherapy was generally well
tolerated. Only one acute intervention related complication was seen (arterial bleeding,
sufficiently treated by embolization), except for nausea (n=1) and chills until 4 hours p.i.
(n=1). Small perihepatic hematomas were seen in 4 patients 3 days after intervention, but
no postinterventional liver function impairment was found. Results: After 6 month, 1 year
and 2 year of follow up in 92%, 87% and 76%, respectively no local recurrence of HCC
could be detected by MRI in surviving patients. Nevertheless 8 patients (16%) had an
intrahepatic progression that could be treated with a second brachytherapy successfully.
Overall survival after six month, one year and 2 years was 92%, 77% and 62%, progression
free survival 73%, 61% and 48% respectively. Observed survival was compared to the life
expectancy according to the CLIP score by Kaplan-Meier analysis and showed a significant
advantage for brachytherapy-treated patients. Conclusion: Brachytherapy is safe and efficous
in the treatment of irresectable HCC. The direct comparison to other local ablative methods
like TACE, PEI or RFTA concerning progression free and overall long-term survival needs
to be examined.
T1209
Treatment Outcomes of Transcatheter Arterial Chemoinfusion (TACI) in
Patients with Unresectable Hepatocellular Carcinoma (HCC)
Bo Yoon Choi, Aijaz Ahmed, Mahmood Razavi, Daniel Sze, Joan Frisoli, Nicole Simpson,
Ruel T. Garcia, Emmet B. Keeffe, Mindie H. Nguyen
PURPOSE: A common treatment for unresectable HCC is transcatheter arterial chemoembol-
ization (TACE), which carries a 5-16% risk of serious complications. Compared to TACE,
TACI without embolization may have similar efficacy and less side effects, but few studies
have examined clinical outcomes of this modality. METHODS: We performed a retrospective
study of 345 consecutive TACI cases in 165 patients between 1/98 and 9/02 at single U.S
medical center. We searched the National Death Index for death records of all patients. We
examined tumor response (complete response [CR], partial response [PR], and no response/
progression of tumor [NR]) and survival rate (Kaplan-Meier curve). We used multivariate
Cox’s proportional hazards regression to identify independent predictors of survival function.
RESULTS: Patient mean age was 59 ±12 with most being male (79.4%) and white (29.7%)
or Asian (59.4%). Most had cirrhosis (75.8%), and either chronic hepatitis C (45.5%) or B
(35.2%). Mean MELD score was 9.2 ± 2.7 and mean CTP score was 6.0 ± 1.1. Tumor
staging at diagnosis was: TNM I=4.9%, II=31.5%, III=21.8% and IV=41.8%. Overall CR
was 32.6%, PR 33.3%, and NR 34.1%. There were statistically significant differences in
tumor response by TNM staging. Only 7 patients were hospitalized for >24 hours (hemoperi-
toneum due to HCC prior to TACI, hepatic artery injury, and persistent nausea or fever or
pain). Three patients (1.5%) had worsening of liver function within 30 days following TACI.
Overall survival rate is summarized in the Table. Survival was significantly poorer for patients
with TNMIV compared to those with TNMI, II, and III (median survival=16 versus 33
months, p=0.004). Following adjustment for age and etiology of liver disease, independent
predictors of poor survival were high CTP (HR=1.51, p<0.001) and TNMIV (HR=2.06, p=
0.002). Independent predictors for higher survival rate were female (HR=0.55, p=0.013)
and Asian (HR=0.55, p=0.01). CONCLUSION: TACI is an effective and safe treatment for
unresectable HCC with TNM stage I, II, and III. Rate of serious complications was only
2.7%. In addition, most of our patients (98%) required less than 24 hours of hospitalization,
while patients undergoing TACE generally require longer hospitalization. Overall survival
rates of TACI were comparable to those reported by Llovet et al and Lo et al in the only 2
individual RCT’s that show survival benefits with TACE (Table).
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T1210
Thermo-Chemoembolization for Malignant Hepatic Tumors Is Clinically
Useful
Mitsunori Yasuda, Motoharu Kondo, Satoshi Kokura, Yuji Naitoh, Norimasa Yoshida,
Toshikazu Yoshikawa
Although surgical resection, chemotherapy, radiation, topical therapy, etc., are available for
malignant hepatic tumors, treatment is often difficult in therapy-resistant cases or advanced
ones. We recently used a combination of transarterial chemoembolization with Degradable
Starch Microsphere (DSM) and hyperthermia (HT), i.e., thermo-chemoembolization (DSM/
HT), to treat such patients, and evaluated its clinical usefulness. Subjects and Methods: The
subjects were 68 cases who underwent either HT alone or DSM-HT at our hospital between
2003 and 2005. HT group had 10 cases (5 primary, 5 metastatic). DSM/HT group was
composed of 58 cases (20 primary, 38 metastatic liver cancers originating from the colorec-
tum, stomach, pancreas, biliary , esophagus, breast, lung, etc). Response rate, survival,
adverse reactions were compared between groups. DSM/HT was performed after a reservoir
for hepatic-arterial infusion was inserted percutaneously. Immediately before each HT session,
an appropriate amount of suspension containing DSM (an embolizing agent) and an anti-
cancer agent (primarily MMC) was infused intraarterially under fluoroscopy to achieve
temporary embolization of the entire liver. This was immediately followed by 50-minute
HT using a Thermotron RF-8 radiofrequency device (Yamamoto Vinita Co., Ltd.). Administra-
tion of DSM and anti-cancer agent just before HT was performed for the following reasons:
(1) chemical effects of the agent on hepatic tumors, (2) anti-tumor effect of tumor ischemia
induced by DSM, (3) anti-tumor efficacy by increase in temperature due to DSM-induced
tumor ischemia, and (4) repeatable this treatment because DSM is degraded in about 1 hour
by amylase, avoiding permanent damage of hepatic blood flow. This therapy was administered
once a week for as long as possible at OPC. Results: No noteworthy adverse reactions other
than temporary mild abdominal pain and nausea were noted in patients receiving DSM/HT
therapy. Response rate, as determined by findings of diagnostic imaging and tumor markers,
was about 40%. Survival was significantly longer in the DSM/HT than in the HT group. In
the DSM/HT group, survival period was positively correlated with frequency of treatment.
When patients receiving DSM/HT were divided by number of treatment sessions into three
groups (4 or less, 5 to 8, and 9 or more sessions), mean survival period differed significantly
between each groups, and increased with the frequency of treatment. Conclusion: Thermo-
chemoembolization is relatively noninvasive, could be performed repeatedly in the outpatient
clinic, and prolonged survival. It is thus a promising means of treating malignant hepatic
tumors.
T1211
Incidence of Acute Hepatic Failure and Related Risk Factors After
Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma
Kyungsik Park, Byoungkuk Jang, Woojin Chung, Kwangbum Cho, Jaeseok Hwang,
Sunghoon Ahn, Younghwan Kim, Jinsu Choi, Junyoung Hwang
Background/Aims : Although transcatheter arterial chemoembolization (TACE) is a major
modality in treatment of unresectable hepatocellular carcinoma (HCC), acute hepatic failure
after this procedure is not rare. But reports considering this important complication are not
enough and results are various. So the purpose of this study is to evaluate the incidence
and associated risk factors of acute hepatic failure after TACE. Methods : From year 2001
to 2004, 632 procedures were done at 377 patients (294 men and 83 women). Mean age
was 58.1 ± 10.1 years. Adriamycin mixed lipiodol solution and gelform were used for
TACE. Various clinical and radiological data before and after the procedure were reviewed
retrospectively. Univariate and multivariate analyses were done for evaluation of risk factors
associated with development of acute hepatic failure. Results : Acute hepatic failure occurred
in 76 (12.0 %) of the 632 sessions within 7 days. Univariate analysis revealed that Child-
Pugh class (p=0.005), history of previous TACE (p=0.004), total bilirubin level (p=0.005),
number of involved segments (p=0.004), total size of tumor (p=0.002), presence of right
portal vein thrombosis (PVT) (p=0.001) or main PVT (p<0.001), involvement of segment
1, 5, 6 , 7 (p < 0.05 at each segment) were significantly different between the patients with
or without hepatic failure after TACE. Of the variables, abscence of previous TACE (p=
0.010, E(β)=2.096), elevated total bilirubin (p=0.001, E(β)=1.334), large tumor size (p=
0.032, E(β)=1.149), presence of right (p=0.013, E(β)=2.421) or main (p=0.013, E(β)=
4.014) PVT were independently associated factors in multivariate analysis. Conclusions :
The incidence of acute hepatic failure after TACE was 12.0% and as predictive variables,
1st TACE, elevated bilirubin level, large tumor size, PVT can be considered.
T1212
Hepatic Hemodynamic Change After Percutaneous Radiofrequency Ablation of
Hepatocellular Carcinoma - Long Term Follow-Up Observation
Shinpei Sato, Hiroshi Miyakawa, Atsuko Takai, Eriko Kitazawa, Kentaro Kikuchi,
Takayuki Kawakami
OBJECTIVE: Radiofrequency thermal ablation(RFA) is a minimally invasive treatment widely
used for the treatment of liver neoplasms. The purpose of this study was to evaluate the
changes in hepatic hemodynamics with long term follow-up observation after percutaneous
RFA treatment of hepatocellular carcinoma using pulsed Doppler sonography. MATERIALS
AND METHODS: Between April 2004 and April 2005, 50 subjects with hepatocellular
carcinoma(1.2-4.3 cm in diameter,1-3 nodules) were treated by RFA. The RFA was performed
percutaneously using a monopolar cooled-tip electrode needle under US guidance with local
anesthesia. Hepatic hemodynamic change was examined in each patient two days before
and after the RFA. In addition, we examined hepatic hemodynamic change in the outpatients
in 3 and 6 months. The statistical analysis was performed on hemodynamic measurements
recorded in the fasting state by pulsed Doppler sonography. The time averaged velocity and
cross-sectional area of the portal vein, maximum velocity of hepatic artery were recorded.
Portal vein blood flow was calculated. Hepatic venous flow was classified into normal or
abnormal patterns. RESULTS: In the ablation zone, hepatic arterial velocity was significantly
elevated after RFA, compared to pre-treatment level (35.5cm/s vs 26.4cm/s),p<0.05. After
3 and 6 months, hepatic arterial velocity was reduced to pre-treatment level. while portal
vein flow and hepatic venous flow were not significantly altered. In the non-ablated zone,
there was no significant change in the hepatic hemodinamics before and after RFA. CONCLU-
SION: RFA treated zone had temporary elevated hepatic arterial velocity after RFA. But in
the non-ablated zone, no significant change was observed in hemodynamics of artery, portal
and hepatic veins, indicating that RFA is a safe and minimally invasive treatment, with no
untoward effect on hepatic hemodynamics outside the locoregional area.
T1213
Long-Term Outcome in Patients with Advanced Klatskin-Tumors Undergoing
Operative and/or Endoscopic Therapy
Andreas Weber, Sonja Landrock, Manfred Stangl, Roland Schmid, Christian Prinz
BACKGROUND: Tumors of the bile duct bifurcation (Klatskin tumors) are associated with
a high mortality. Bile duct tumors are classified into 4 stages according to the Bismuth
classification: stage I or II for tumors expanding up the hilus, type III A/B infiltrating left
or right hepatic duct, and stage IV with infiltration of both hepatic ducts and subsegments.
Because of the late presentation of symptoms, tumors are usually diagnosed in later stages
and most therapy concept can not be curative. Survival rates reported so far describe a very
limited life expectancy of <3 months if no treatment is offered. Possible treatment strategies
include endoscopic retrograde cholangiopancreatography including stent therapy (ERCP),
percutaneous transhepatic biliary drainage (PTBD) or surgery. METHOD: A long-term follow-
up of patients with Klatskin-tumor undergoing an endoscopic and/or surgical therapy was
performed by retrospective analysis. PATIENTS: 95 consecutive patients (57 male, 43 female;
mean age 68 years) underwent treatment for malignant hilar bile duct tumors of Bismuth
stages II-IV during a period of 8 years (1997-2004). RESULTS: 72/95 patients were treated
only by endoscopic procedures using ERCP (n =43) or PTBD (n =26). 23/95 patients could
be treated by surgery initially and had no contraindications or lymph node metastasis. 4 /
23 operated patients had R0 operation with complete tumor removal in histology. 19 had
recurrent obstruction and lateron required ERCP or PTBD. Overall mean survival was 372
days in the endoscopic group and 877 days in the group treated by surgery and subsequent
endoscopic procedures. In the surgery group, mean survival was 2612 days in patients with
BI/II stage (n=4), 721 days in B III (n=5), and 511 days in B IV (n=14) stages. In comparison,
Patients in the endoscopic group had survival rates of 617, 501 and 290 days in stage I/II
(n=7), III (n=20) and IV (n=42), respectively. CONCLUSIONS. Surgery of bile duct tumors
followed by endoscopic intervention significantly increases life expectancy; endoscopic stent-
ing or PTBD alone is useful in patients with advanced disease (B IV; LN pos., contraindications
towards surgery). Future therapies will aim at new strategies to improve the outcome.
T1214
Clinical Benefit of Radiation Therapy for Unresectable Extrahepatic Bile Duct
Cancer
Osamu Togawa, Hiroyuki Isayama, Yousuke Nakai, Takashi Sasaki, Hiroshi Kogure,
Natsuyo Yamamoto, Naoki Sasahira, Takeshi Tsujino, Minoru Tada, Yukiko Ito, Saburo
Matsubara, Kenji Hirano, Toshihiko Arizumi, Nobuo Toda, Haruhiko Yoshida, Takao
Kawabe, Masao Omata
Background: The patients with bile duct cancer presented obstructive jaundice. Both biliary
drainage and anti-tumor treatment were important for those unarectable cases. The efficacy
of self-expandable metallic stent (EMS) is being accepted. However, effective anti-tumor
treatment for those patients did not established. We estimated radiation therapy for the
patients with unrectable extrahepatic bile duct cancer. Methods: We treated 82 cases of
unresectable extrahepatic bile duct cancer and analyzed 59 locally advanced cases (26 in
Distal, 33 in Klatzkin tumor). Radiation strategies were total 60 Gy of external corporeal
radiation and 24 Gy of intra-bileduct radiation with remote after loading system (RALS).
We placed EMS for all cases, uncovered EMS (UMS) for hilar lesion (Klatzkin tumor) and
both UMS or covered EMS (CMS) for distal stricture cases. Results: There were 31 (14 in
distal, 17 in Klatzkin tumor) cases with both anti-tumor treatment and metallic stenting
(Combination group), remaining cases received metallic stenting alone (Stenting Group).
RALS was performed in 9 cases of Klatzkin tumor. Median survival period was 506 days
in Combination group and 251 days in Stenting group. The cumulative survival period of
Combinaton group was significantly longer than Stenting group (p=0.0014). In Combination
group, 1-year survival rate was 53 %, 2-year 28 % and 3-year 7 %. On the other hand, in
Stenting group, 1-year survival rate was 25 % but 2-year and more survival were 0 %. There
was no significant difference in cumulative stent patency between Combination and Stenting
groups. Conclusion: Radiation therapy was effective and contributes for prolongation of
survival period for the locally advanced unresectable extrahepatic bile duct cancer.
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T1215
Palliative Percutaneous Transhepatic Cholangiodrainage for
Cholangiocarcinoma: Complications and Outcome
Dorothee H. Dorlars, Peter Fleischmann, Jenny Gebhardt, Juergen Pausch
Background: The primary treatment goal in patients with nonresectable cholangiocarcinomas
(CC) and obstructive jaundice is to restore biliary flow via endostents. If ever, the placement
of a percutaneous transhepatic cholangiodrainage (PTCD) is recommended in cases where
the stenosis cannot be treated endoscopically. However, the PTCD treatment not only has
comparatively few complications, it also increases the patients’ survival time and quality of
life. Patients and methods: From 12/2002 to 10/2004, we treated 26 patients with CC using
PTCD (16 men, 10 women, mean age 71 [54-85] yrs; polyurethane PTCD, “Münchner
Drainage“, Pflugbeil & Co., Germany). In all cases, a curative resection of the tumor was
impossible, due either to the tumor itself or the patient’s general condition. The CC stages
(Bismuth classification) were as follows: Bismuth I n=3, Bismuth II n=7, and Bismuth IV
n=16. On average, 3.7 [2-7] sittings were required until the final PTCD was placed. The
PTCD was placed in the left (n=4), in the right (n=12), or in both hepatic ducts (n=10).
The average drain caliber was 11 (8-16) F for the right duct and 10 (8-12) F for the left.
Results: In 2 patients (7.7%), restoration of biliary drainage was not successful. In all of the
remaining cases, treatment was followed by a significant and sustained drop in elevated
serum AST, ALT, AP and GGT. Prior to treatment, AST and ALT were elevated two-fold
above the norm, AP and GGT even ten-fold. Bilirubin and inflammation parameters showed
a moderate decrease immediately after treatment, but increased again post-treatment. Of 47
procedures performed, 14.9% had mild acute complications (bleeding), 85.1% had none.
During follow-up we found 56.9% mild complications (dislocation/obstruction of drain,
leakage, cholangitis), and 3.8% severe complications (liver abscess). The average time the
drain remained in place was 185 days (min=30 d, max= 837 d). The median survival time
was 5.9 months. Conclusions: Compared to surgical intervention, PTCD is a safe and effective
palliative treatment for CC with relatively few complications (3.8% severe complications vs.
29% severe surgical complications; 0% 30d-mortality vs. 15% surgical 30d-mortality). The
average morbidity of our patient population was higher than is usual in surgical patients.
Yet, in spite of these inauspicious conditions, the median life expectancy of our patients
was 5.9 months, which compares favorably with the life expectancies reported in the literature
(median 3-6 mo. with PTCD, 2 mo. with surgery).
T1216
Efficacy of Radiofrequency Ablation in Patients with Colorectal Hepatic
Metastases
Kazuhiko Hosoda, Tomotaka Yasumura, Akiharu Yagawa, Ryota Sueki, Satoshi Kaji,
Takanori Maruyama, Toshifusa Ozawa, Ryuichi Iida
PURPOSE: Radiofrequency ablation (RFA) is a new minimally invasive method that has
been increasingly used in the treatment of hepatic metastases. The aim of this study was to
examine the therapeutic efficacy of RFA in patients with colorectal liver metastases. PATIENTS
AND METHODS: From April of 2000 until March 2005, 23 patients with colorectal liver
metastases who were not candidates for hepatic resection underwent RFA. They were 16
males and 7 females with a mean age of 65 years (34-79). The mean number of metastases
was 1.6 (1-4). The mean maximum diameter of tumor size was 1.96 cm (1.0-5.0). RFA was
performed percutaneously with ultrasound guidance. All procedures were performed with
a LeVeen needle electrode. Other 23 patients with colorectal liver metastases whose dominant
lesion was less than 3 cm underwent hepatic resection between June of 1991 and December
of 2004. The 5-year survival in the RFA group was compared with that in the hepatic
resection group. RESULTS: The mean number of RFA treatment was 1.1 (1-2). The average
hospital stay was 8 days. There was no treatment-related mortality. Major complications
occurred in only one patient ( peritoneal dissemination ). Local recurrence was occurred in
two patients (9.5%). The cumulative 5-year survival rates for all patients were 31.8% after
RFA. Patients with a carcinoembryonic antigen (CEA) less than 20 ng/ml had improved
survival compared with those with a CEA more than 20 ng/ml (P <0.05). Patients with the
dominant lesion less than 3 cm in diameter had improved survival compared with those
with the dominant lesion more than 3 cm (P<0.005). The cumulative 5-year survival rate
after RFA and resection for patients with the dominant lesion less than 3 cm in diameter
were 46.6% and 41.7%, respectively (nonsignificant). The presence of extrahepatic metastases
did not affect survival. CONCLUSION: RFA is a safe and effective treatment for colorectal
liver metastases. Especially, for patients with the dominant lesion less than 3 cm, survival
is comparable with hepatic resection. A randomized prospective study comparing RFA with
resection is necessary.
T1217
Colonic Complications After Liver Transplant, An Under Appreciated
Significant Problem?
Antonio Sanchez, Hugo Bonatti, Rolland C. Dickson, Justin H. Nguyen, Walter C.
Hellinger, Ronald A. Hinder, Heidi K. Chua, Jaime Aranda-Michel
BACKGROUND: Liver transplantation (LT) is the treatment of choice for end-stage liver
disease. Liver diseases can be associated with diseases of the intestinal tract and post LT
immunosuppressive agents might predispose to colonic complications. AIM: We retrospect-
ively analyzed the incidence and spectrum of colonic complications in a cohort of 402 LT
patients. PATIENTS AND METHODS: A total of 467 consecutive LTs in 402 individuals
were performed between 1998 and 2001 at the Mayo Clinic, Jacksonville, Florida. Standard
immunosuppression consisted of Tacrolimus, Mycophenolic acid and steroids. RESULTS:
During a mean follow up period of three years 81 colonic complications developed in the
467 LT events. 4/19 patients transplanted for PSC and inflammatory bowel disease (ulcerative
colitis n=16, Crohn’s disease n=3) had persistent colitis; 8/19 patients had colectomy prior
to LT and 7/19 had no colonic symptoms during the follow up period. Combined colonic
intervention and LT were performed simultaneously in 3 patients; one with colonic resection

















associated with acute liver failure and the last case a preexisting transverse colostomy that
had to be reinforced. Colonic polyps were endoscopically removed in seven patients and
three patients were diagnosed with colorectal cancer (one cecal, two rectal cancers), which
all were surgically treated. One patient developed a hemorrhage of the terminal ileum/cecal
region in the course of intra-abdominal sepsis, and was treated by endovascular embolization
of the ileocolic artery. Two patients developed hemorrhoids requiring surgical interventions,
and two patients had perianal fistulas. Two patients developed sigmoid diverticulitis and
one appendicitis requiring surgical intervention. There were 32 cases of Clostridium difficile
associated enterocolitis. Nine patients developed CMV gastrointestinal complications with
three cases of colitis, one leading to perforation, intra-abdominal sepsis and death. One
patient developed a herpetic rectal ulcer and two perianal HSV associated lesions. Chronic
diarrhea was seen in fifteen patients who had a negative evaluation that required withdrawal
of mycophenolic acid. CONCLUSION: The frequency of colonic disorders in our series
was higher than expected. Infection complications account for the majority of colonic
complications seen in LT patients. The high incidence of clostridium colitis warrants improve-
ment in screening and preventive measurements. Screening for polyps pre-transplant and
post-transplant is highly recommended.
T1218
Incidence, Endoscopic Findings and Treatment of Biliary Tract Complications
After Orthotopic Liver Transplantation - A Single Centre Experience
Nicolas Hoepffner, Yogesh Shastri, Bora Akoglu, Christina Zapletal, Wolf O. Bechstein,
Wolfgang Caspary, Dominik Faust
Background: Despite standardization for biliary reconstruction biliary complications after
orthotopic liver transplantation (OLTx) occur in 7 to 51% of cases and are an important
cause of early and late postoperative morbidity and mortality. The most common biliary
complications are bile leaks and bile duct strictures. Early diagnosis and prompt treatment
of biliary complications are necessary to reduce morbidity and mortality related to LTx.
Here we have evaluated the role of endoscopic retrograde Cholangio Pancreatography (ERCP)
in the diagnosis, treatment and outcome of post OLTx biliary complications. Patients and
methods: This retrospective study included 162 patients (109 male, age 52 ± 10 yrs; 53
female, age 49 ± 14 yrs) who underwent OLTx between 1984 and 2004 and were regularly
followed up at Frankfurt liver transplantation centre. The mean time since OLTx was 6 ±
4 years. Endoscopic therapy was performed with balloon dilation and or plastic endoprosth-
esis. 154 patients underwent biliary continuity by choledocho-choledochostomy (end to
side in 114 and side-to-side in 40) while 8 patients underwent Roux-en-Y choledocho-
jejunostomy. Results: 40 (24.6%) patients underwent ERCP for diagnosis and treatment of
biliary complications. The median time between OLTx and first suspicion of biliary complica-
tions was 12 month (range 1 to 94 months). Overall 70 different biliary tract complications
were identified. The most frequently diagnosed complication was isolated anastomotic stric-
tures in 28 (40%), followed by bile leakage in 17 (24%) and non anastomotic strictures in
6 (9%), whereas 19 patients (27%) experienced miscellaneous complications like choledocho-
lithiasis 7 (10%), abscess 5 (7%) or secondary cholangitis in 4 (6%). 50% of the patients
developed only 1 type of biliary complication after OLTx. Number of ERCPs performed per
patient ranged from 2 to 52. Sustained success was achieved in 26 (81%), while endoscopic
treatment failed in 6 (19%). Out of this, 3 patients were re-operated. Till date, none of
these were considered for re-transplantation. Conclusion: Biliary complications still remain
an important problem in liver transplant patients. Endoscopic management is usually effective
in majority of them but may require multiple procedures especially to treat strictures. Surgical
intervention is required only in a few selected cases.
T1219
Endoscopic Treatment for Biliary Complications in Donors After Living-Donor
Liver Transplantation
Seiji Shio, Shujiro Yazumi, Kazunori Hasegawa, Masaya Kida, Junichi Yamauchi, Shinsuke
Tada, Hiroto Egawa, Shinji Uemoto, Tsutomu Chiba
Background and Aims. With the increased number of living-donor liver transplantation
(LDLT), post-operative biliary complications of the donors have become one of the most
significant problems of the LDLT. The aims of this study were to characterize the features
of the biliary complications of the donors occurred after LDLT and to evaluate the feasibility
of treating biliary complication endoscopically. Patients and Methods. A database of 613
consecutive donors (360 right lobes and 253 left robes) of LDLT from July 1999 through
April 2005 in Kyoto University Hospital was reviewed. Biliary leakage and stricture were
treated by endoscopic naso-biliary drainage (ENBD) and endoscopic biliary drainage (EBD),
respectively. Results. The overall incidence of biliary complications was 4.1% (25/613); the
incidence in right-lobe donors [6.1% (22/360)] was significantly higher than that in left-
lobe donors [1.2% (3/253)] (p>0.001). The complications were 23 biliary leakages and 7
biliary strictures;5 of 7 biliary strictures occured after closure of biliary leakage. Out of 25
patients with biliary complications, 5 could not be treated endoscopically due to difficulty
of cannulation (n=2), and large sized biliary leakage (n=3). They were all converted to
surgical treatment. Biliary leakage (n=18) and stricture (n=7) were treated by ENBD and
EBD, respectively. Finally, 20 of 25 patients (80.0%) could be treated endoscopically. There
were no significant ERCP-related complications. Conclusion. The right-lobe donors for LDLT
have a significantly higher incidence of biliary complications than the left-lobe donors. The
endoscopic treatment is useful for biliary complications of donors for LDLT and should be
attempted before surgical conversion.
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T1220
Evaluation of Transabdominal Ultrasonography for Biliary Complications After
Liver Transplantation in Recipients with Choledochocholedochostomy
Without T-Tube
Chad J. Long, Scott Biggins, Ruth B. Goldstein, Eugene Yen, Karen Bagatelos, Sandy
Feng, James W. Ostroff
BACKGROUND: Biliary complications after liver transplantation (LT) are common, account
for significant morbidity, and can be difficult to distinguish from graft rejection or disease
recurrence. Transabdominal ultrasonography (TAUS) is a non-invasive initial diagnostic test
for biliary complications after LT. Prior studies have predominantly evaluated TAUS in LT
recipients with Roux-en Y biliary reconstruction or choledochocholedochostomy (CDCD)
with a T-tube. AIM: To evaluate the diagnostic characteristics of TAUS for biliary complica-
tions after LT in patients with CDCD without T-tube. METHODS: Records of patients who
had LT with CDCD anastomosis without T-tube at our institution between 4/30/1998 and
5/30/2003 were reviewed for evidence of post-transplant endoscopic retrograde cholangi-
opancreatography (ERCP), percutaneous transhepatic cholangiography (PTC), or biliary
surgery performed for the evaluation of a suspected biliary complication. Patients within
this group having TAUS within 4 weeks prior to ERCP, PTC, or surgery were included in
this study. TAUS reports were compared to ERCP, PTC, or surgical reports as the gold-
standard. Biliary dilation, perihepatic fluid collections, or intraductal stones were considered
positive sonographic findings. RESULTS: Of 459 LT recipients, 82 patients met inclusion
criteria for this study. Mean age was 51 years (range 18-72) and 58% were male. The most
common reason for transplantation was hepatitis C. 5/82 patients received living donor
transplants. The mean (range) time from TAUS to the gold-standard exam was 4.5 (0-28)
days. A biliary complication was confirmed in 71/82 (87%) patients based on gold standard
evaluation. The sensitivity of TAUS for detecting a biliary complication was 60/66 (91%)
with a specificity of 5/16 (31%). The sensitivity for detecting anastomotic stricture, non-
anastomotic stricture, and biliary leaks was 95%, 100%, and 100% respectively. The positive
predictive value and negative predictive value of TAUS in detecting any biliary complication
in this study was 60/71 (85%) and 5/11 (45%), respectively. CONCLUSION: In LT recipients
with CDCD biliary anastomosis, transabdominal ultrasonography is a sensitive screening
modality for the evaluation of biliary tract complications. Transabdominal ultrasonography
should be included in the initial evaluation of suspected post-tranplant biliary complications.
T1221
Predictive Factors for Graft and Patient Survival Following Liver
Transplantation for Hepatitis C
Speranta Iacob, Susanne Beckebaum, Razvan Iacob, Vito Cicinnati, Christian Klein, Liana
Gheorghe, Cristian Gheorghe, Irinel Popescu, Andrea Frilling, Massimo Malago, Guido
Gerken, Christoph Broelsch
INTRODUCTION: Hepatitis C virus (HCV) associated liver disease is the most common
indication for liver transplantation (LT). Short-term patient and graft survival for HCV-
infected recipients have been reported to be similar to that of most other indications, but
long-term survival rates are shorter. AIM & METHODS: To assess the impact of different
pre and post LT factors on graft survival. For this purpose we reviewed the records of 168
patients who underwent LT for HCV liver cirrhosis between January 1989 and October
2004. To identify potential predictors of graft and patient survival, univariate and multivariate
Cox’s proportional hazards regression model was used. RESULTS: One year overall graft
and patient survival rates were 72% and 85% respectively and 5 year survival rates were
51% and 73%. Median survival was 6.1 years for graft and 12 years for patient. In the
univariate survival analysis the following parameters were identified as predictors of both
graft failure and patient death: diagnosis of histologically proven recurrent hepatitis before
1 year after LT (p<0.0001 and 0.001), presence of early (within the first 6 months) biliary
complications (p=0.0007 and 0.002), administration of prednisone <180 days (p<0.0001
and 0.01) and mycophenolate mofetil (MMF) <180 days (p=0.0009 and 0.02), induction
without azathioprine (p=0.0002 and 0.003). Absence of post LT antiviral therapy was
associated with a poorer graft survival (p=0.003) and severity of pre LT liver disease illustrated
by Child-Pugh classification C (p=0.009), MELD score > 18 (p=0.01), presence of hepato-
renal syndrome (p=0.03) with patient mortality. Independent predictors of both graft failure
and patient death in the multivariate survival analysis were: presence of early biliary complica-
tions (p=0.0001 and p=0.004), administration of MMF<180 days (p<0.0001 and p=0.02)
and time to histologic recurrence less than 1 year (p<0.0001 and p=0.001). Graft loss was
independently influenced also by the recent year of LT after 2000 (p=0.0009), administration
of prednisone <180 days (p=0.0004) and induction without azathioprine (p=0.0005). A
higher MELD score>18 (p=0.01) had a independent negative prognostic value for post LT
patient survival. CONCLUSIONS: There are factors affecting both graft and patient survival,
among which certain immunosuppressive strategies, the presence of early bile duct complica-
tions and the identification of the histologic HCV recurrence in the first posttransplant year
seem to be of major importance.
T1222
Long-Term Outcome of Orthotopic Liver Transplantation in Cryptogenic
Cirrhosis
Herve Boucard, Rajat Parikh, Arun Samanta, Baburao Koneru, Dorian Wilson, Adrian
Fisher, Meelie Debroy, Andrew de la Torre, Kenneth Klein
Cryptogenic cirrhosis (CC) is one of the common indications for liver transplantation. Long
term outcome in CC is not clearly defined with previous studies revealing conflicting results.
It is being increasingly recognized that hepatitis following transplantation occurs in such
patients with varying frequency (0-50%). Aim: The present study compared the outcome
of liver transplantation in CC with that in hepatitis C virus related cirrhosis (HCVC) by
studying patient and graft survival. Method: This is a retrospective study involving 41
patients who underwent transplantation for CC between December 1994 and October 2003
at our transplant center. The diagnosis of CC was made by negative serology for auto-
immune liver diseases (ANA, Anti-smooth muscle Ab, AMA), negative viral hepatitis serology
(anti-HCV, HCV-RNA by PCR, HBsAg, HBsAb, HBcAb), normal ceruloplasmin, α-1 antitryp-
sin, transferrin saturation and confirmed by liver histology that was negative for viral or
known metabolic liver diseases. Results: Mean follow up for the CC group (mean +/- SE)
5.76 +/- 0.44 years and 4.14 +/- 0.31 years for HCVC patients. For patients with CC the
age, BMI and MELD score were 55.2 +/- 1.93 years, 30.9 +/- 3.82 m2/kg, and 19.45 +/-
1.06 respectively compared to 52.04 +/- 1.15 years, 27.58 +/- 0.68 m2/kg, 19.87 +/- 0.97
for HCVC patients. Diabetes mellitus was present in 55% of CC and 39% of HCVC (p=
0.17). Actuarial patient survival by Kaplan Meier analysis for CC was significantly better at
1 and 3 years being 90 +/- 7.5 % and 77.5 +/- 6.6 % compared to 84 +/- 4.6% and 62 +/-
6% for HCVC patients (p=0.0026). Actuarial graft survival for CC was also significantly
better at 1 and 3 years being 87.8 +/- 5.1 %, and 78 +/- 6.5% compared to 77 +/- 4.96 %
and 54 +/- 5.9 % for HCVC patients (p=0.0004). Conclusions: This study indicates that
OLT for CC is associated with a favorable outcome for patient and graft survival compared
to HCVC.
T1223
Frequency of Development of Hepatocellular Carcinoma and the Utility of
Surveillance Ultrasound Examination in Patients with END Stage Liver
Disease (ESLD) from Hepatitis C Cirrhosis On the Liver Transplantation
Waiting List
Anna Wieckowska, Nizar N. Zein
Background: Patients with hepatitis C virus (HCV) cirrhosis are at increased risk for the
development of hepatocellular carcinoma (HCC). Periodic surveillance ultrasound examina-
tion for early detection for HCC has been recommended. Aims: 1) to determine the frequency
of HCC in patients with ESLD due to HCV on the liver transplant (LT) waiting list, 2) to
define the utility of surveillance ultrasound in identifying HCC in this population. Methods:
Patients with HCV cirrhosis in the absence of HCC that were listed for LT at our institution
between 1997 and 2004 were identified. Histologically proven HCC (by biopsy, explanted
liver or on autopsy) was used to define HCC in this population. Patients who died prior to
LT and had no autopsy examination were excluded. Patients who were still on the waiting
list at the time of the analysis were excluded since histological examination was not available.
All patients had at least one ultrasound examination while waiting for LT. A total of 211
ultrasound examinations were performed in 98 patients during the waiting time (1 to 8
ultrasounds per patients). The mean time from listing to transplantation was 10.7 months.
Results: In total, 13 patients were found to have histologically proven HCC (13%). Of 98
patients, 18 (18.4 %) had at least one positive ultrasound examination identifying a liver
nodule during the waiting time on the list. Of these 18 patients, 9 were confirmed to have
HCC by histology, while 9 appeared to have a false positive ultrasounds for HCC. Of the
remaining 80 patients who had a negative ultrasound, 4 (5%) were found to have HCC on
histologic examination of explanted liver (2 of 4 HCC were greater than 2 cm). Overall,
surveillance US had a specificity of 89.4%, a sensitivity of 69.2% and a positive and negative
predictive value of 50% and 95%, respectively. Subjects with large nodules by ultrasound
examination (over 2 cm) were 60% more likely to have HCC than those with small nodules
(OR [95% CI]: 1.6 [0.2, 10.8]). Conclusion: 1) Patients with ESLD due to HCV cirrhosis
on the LT waiting list had a high frequency of HCC, supporting the need for surveillance
measures with high sensitivity for early detection. 2) The sensitivity of surveillance ultrasound
for early detection of HCC appears to be suboptimal, particularly in the current era where
patients with HCC may receive a higher priority score for LT.
T1224
Hepatitis B, Tumor Treatment and Immunosuppression Influence Recurrence
of Hepatocellular Carcinoma After Liver Transplantation
Sandra Ciesek, Thomas Becker, Tim Greten, Juergen Klempnauer, Michael P. Manns,
Christian P. Strassburg
Hepatocellular carcinoma (HCC) represents a considerable therapeutic challenge. Trans-
arterial chemoembolization (TACE) and percutaneous ethanol instillation (PEI) are employed
non-curing modalities. A potentially curative option is orthotopic liver transplantation (OLT).
Aim of this study was to identify factors associated with HCC recurrence. Eighty-five patients
with HCC transplanted between 1975-2004 at Hannover Medical School were analyzed
retrospectively. Follow-up ranged from 13 to 349 months (mean 88 months ±75.6). In 8/
85 (9.4%) HCC was established post OLT. Etiologies of chronic liver disease included HCV
(39%) and HBV (24%) infection, and alcoholic cirrhosis (15%). Cirrhosis was absent in 6/
85 (7%). Recurrent HCC occurred in 18.8% after a mean of 3.3 years following OLT. HCC
stages at OLT were T1 (18%), T2 (37%), T3 (13%) and T4 (12%). Recurrence was associated
with T4 (31% vs 7%, p=0.018, OR 5.82) but not with T1-3, with HBV (60% vs 40%, p=
0.02 OR 3.85), and with patients receiving tacrolimus (62.5% vs 37.5%, p<0.0001, OR 10)
and/or steroids (69% vs. 31%, p=0.0006, OR 7.69) compared to cyclosporine or mycophenol-
ate mofetil. After pre-operative TACE HCC recurrence (62.5%) was more frequent compared
to PEI (12.5%) (p<0.0001, OR 12.5), the PEI vs TACE group had 28%/0% Child C, 39%/
67% Child B, and 33%/33% Child A. Recurrence-free survival was achieved in 80% of
patients undergoing OLT. Tumor stage, TACE before OLT, HBV infection and immunosuppr-
ession with tacrolimus and steroids were identified as risk factors for HCC recurrence. Pre-
and post-operative management of HCC therefore influences the outcome in OLT in HCC.
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T1225
Effects of Tegaserod On Restraint Stress-Induced Visceral Hypersensitivity and
C-FOS Expression On Spinal Cord in Rats
Yan Sun, Gengqing Song, Fengling Liu, Wei Qian, Xiaohua Hou
Aims: The aim of this study was to investigate the effects of Tegaserod on restraint stress-
induced visceral hypersensitivity and c-fos expression on spinal cords in rats. Methods: The
study was performed in two experiments. In the first experiment, male Sprague-Dawley rats
were studied in control group without restraint stress, restraint stress groups with saline,
Tegaserod at different doses (0.3mg/kg, 0.6mg/kg, 1.2mg/kg, IP, respectively), or vehicle
(1-methyl-2-pyrrolidone 10%) at different doses (0.3ml/kg, 0.6ml/kg, 1.2ml/kg, IP, respect-
ively). The abdominal withdrawal reflex (AWR) score to colorectal distension (CRD) was
assessed. The second experiment included a control group without restraint stress and three
other groups with restraint stress. The experiment was conducted sequentially as follows:
restraint stress for 2h, administration of Tegaserod (1.2mg/kg, IP), vehicle (1.2ml/kg, IP),
or saline (1.2ml/kg, IP) respectively, and repetitive CRD for 2h. The expression of c-fos on
the thoraxlumbar (T13-L1) and lumbarsacral (L6-S1) spinal segments was detected by using
immunohistochemistry method. Results: (1) The AWR scores in restraint stress groups with
saline or vehicle were significantly higher than those in control group (Saline: 1.70±0.50
vs. 0.86±0.32, P<0.05; Vehicle: 1.45±0.35 vs. 0.86±0.32, P<0.05). (2) In comparison with
the restraint stress groups with saline or vehicle, the AWR scores in restraint stress group
with Tegaserod were significantly decreased in a dose-dependent manner at all distension
pressures (P<0.05). (3) In contrast to the control group, c-fos expression on L6-S1 and T13-
L1 spinal segments was significantly increased by repetitive CRD in restraint stress groups
with vehicle (45.5±3.9 vs. 3.2±0.1 and 40.1±5.6 vs. 3.5±1.0, P<0.05) or saline (35.5±3.5
vs. 3.5±1.0 and 28.8±2.63 vs.3.8±1.1, P<0.05). The c-fos immunoreactive positive neurons
were mainly localized in laminae I-II, V-VII and X. (4) The c-fos expression in the restraint
stress groups with Tegaserod was significantly lower than that in restraint stress groups with
vehicle or saline (19.6±1.3 and 15.7±1.8, P<0.05). Conclusions: Tegaserod dose-dependently
decreases restraint stress-induced visceral hypersensitivity and c-fos expression on L6-S1
and T13-L1 spinal segments. These findings suggest an antinociceptive property of Tegaserod
under stress condition.
T1226
Medical Consultation for Children’s Chronic Stomachaches Is Related to a
Belief That the Symptoms Have a Physical Cause But Is Not Related to
Anxiety About Serious Missed Diagnosis
Miranda Al. van Tilburg, Olafur S. Palsson, Denesh K. Chitkara, William E. Whitehead
Previous studies have shown that parental worries about their child’s abdominal pain predict
illness behaviors such as doctor visits and school absences (Gastroenterology 2004; 126(4),
A372). Contrary to expectations, however, fear of an overlooked serious illness did not
motivate consulting behavior. The aim of the present study was to confirm this observation
using a more detailed evaluation of disease conviction. METHODS: We recruited 183 parents
(97.8% mothers) of children ages 1-15 (M=8.1, 66.1% female) through the UNC Center
for Functional GI disorders website. All parents filled out the Illness Attitude Scale (IAS)
by Proxy. The IAS is a well validated measure of hypochondriac concerns with 2 subscales:
Health Anxiety (HA) and Illness Behaviors (IB). Illness behavior refers to the way people
perceive, evaluate and react to somatic symptoms and was measured by items such as
number of doctor visits, number of treatments, school absences, and concentration difficulties.
We revised the IAS to measure hypochondriacal concerns about one’s child. Factor analysis
yielded two similar scales for the IAS by proxy as for the original IAS, Cronbach α were
.88 for HA and .80 for IB. RESULTS: 140 families consulted a doctor for their child’s
stomach aches (76.5%). Consulting families (CF) reported increased IB compared to non-
consulting families (NCF; M=9.2 vs M=7.2, p < .01). There were no significant differences
in HA between CF and NCF. Additionally we tested 6 of the 11 HA items that focus on

















from a physical disease (M=.72 vs M=1.72 ;p<.01) but no significant differences were found
for worrying about child’s health, belief that pain is caused by a serious illness, or fear that
child suffers from cancer, heart disease or another serious illness. Parents who suffered from
chronic abdominal pain themselves (78.7%) did not report more HA or IB compared to
non-sufferers. Duration of symptoms significantly correlated with IB (r= .23; p < .01) but
not with HA. CONCLUSIONS: Medical consultation for children’s stomach aches is more
likely if parents believe that a physical illness is causing the symptoms regardless of whether
the illness is seen as serious or life threatening. Excluding major illnesses will most likely
not be reassuring nor change parental illness behavior. Offering coping mechanisms might
have more positive effects. [Supported by grant R24 DK67674]
T1227
Abdominal Pain and Co-Morbid Complaints from Childhood to Adulthood in
a Population Based Birth Cohort
Denesh K. Chitkara, Nicholas J. Talley, Amy L. Weaver, Miranda van Tilburg, Slauvica K.
Katusic, G. Richard Locke, Mary Jo Rucker, William E. Whitehead
Background: Abdominal pain (AP) of unknown origin is a common medical complaint
and is associated with comorbid complaints (headache, limb pain, back pain, anxiety and
depression). However, little is known about the medical presentation of AP with co-morbid
complaints throughout the lifespan. Aim: To examine the prevalence and patterns of co-
morbidity in individuals who present for AP from childhood to adulthood. Methods: A
birth cohort of all children born between 1976 and 1982 to mothers who were residents
of Rochester, MN, and who remained in the community after age 5 years, was considered
for this study. Medical visits for AP of unknown origin and co-morbid conditions (above)
were identified by HICDA codes. Subjects were followed based on their diagnoses accumu-
lated while <21 yo, and 80% of the population remained in the area until age 19. A group
of age and gender matched control individuals without a diagnosis of AP before age 21 was
used to compare co-morbid conditions. Results: Of the 5347 birth cohort members, 1358
(25%) individuals had an incident medical visit for AP of unknown origin from 5 to <21
yo (single visit only 61%, 2 visits 21%, 3 visits 9%, 4+ visits 9%). Individuals with a medical
visit for AP were more likely to present for headache (34% vs. 16%), back pain (18% vs.
8%), limb pain (29% vs. 18%), anxiety (34% vs 16%) and depression (24% vs. 11%)
compared to those who did not present for AP. Individuals with multiple visits for AP had
a progressively increased risk for presenting with a co-morbid diagnosis (Table; all p<0.001).
In individuals who had a visit for AP prior to being diagnosed with any of the co-morbid
conditions (47%), the average time between visits was 4.8 years (AP diagnosed at mean
10.4 years and co-morbid diagnoses at a mean of 15.2 years). For individuals with an AP
diagnosis occurring after the co-morbid diagnosis (46%) the average time between the
diagnoses was 4.6 years. Conclusion: Individuals who present with 1 or more medical visit
for AP are more likely to present with a co-morbid conditions throughout their lives. Co-
morbid diagnoses were no more likely to follow than to precede an AP visit. Supported by
R24 DK67674 and an unrestricted research grant to the Dyspepsia Center from Novartis.
The risk (O.R. 95% C.I.) for comorbid conditions with 1 or more visit for AP compared to
age/gender matched controls with no visit for AP
T1228
Hypervigilance in Irritable Bowel Syndrome (IBS) Compared with Other
Chronic Gastrointestinal Disorders
Iris Posserud, Jan Svedlund, Jenny Wallin, Magnus Simren
Background: Selective attention (hypervigilance) to gastrointestinal (GI) sensations has been
suggested as a contributing pathophysiological factor in IBS. IBS patients have previously
been shown to selectively recall words describing GI sensations compared with healthy
controls and patients with asthma (Gibbs-Gallagher et al Am J Gastroenterol 2001). However,
it remains unclear whether there are differences between IBS and other chronic GI disorders.
Aim: Evaluate the presence of hypervigilance towards the GI tract in IBS comparing these
patients with patients with other chronic GI diseases. Method: We included 20 IBS patients
(mean age 36 (22-55) years; 12 females) and 28 patients with organic GI disease (mean age
40 (20-60) years; 14 females) consisting of 15 patients with inflammatory bowel disease
(IBD) and 13 with celiac disease. Patients with IBD and celiac disease were in clinical
remission. They completed the Hospital Anxiety and Depression scale (HAD) and underwent
three tests: 1) Word association - freely write down as many words as possible representing
signs of disease during 60 seconds. 2) Word recall - memorize words representing 10 GI
symptoms, 10 positive affects, 10 negative affects presented randomly (each word displayed
for 3 seconds), then 15 minutes break before writing down remembered words. 3) Word
recognition (tachistoscope) - 3 sets of 4 categories of words (positive affect, symptom of
non-GI disease, GI symptom, negative affect) displayed (flashed) for increasing time (adding
5 milliseconds (msec) each step) until the subject identified the word. Results: For the word
association test IBS patients wrote down on average 8.0 symptoms including 1.8 GI symptoms
compared with 7.6 symptoms including 1.3 GI symptoms in the organic group (NS). For
the word recall test both groups remembered on average 10 words. The mean percentage
of GI words among remembered words was 44% in the IBS group and 40% in the organic
GI disease group. During the word recognition test the IBS patients were, compared with
the organic GI disease group, significantly faster in recognizing words representing GI
symptoms (21 vs. 28 msec; p=0.03) and negative affects (25 vs. 36 msec; p=0.04), but also
tended to be faster in recognizing positive affects (25 vs. 32 msec; p=0.06) and non-GI
symptoms (22 vs. 30 msec; p=0.09). There were no differences in HAD score between the
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groups. Conclusion: Our results suggest that there might be a hypervigilance regarding GI
sensations in IBS compared with patients with other chronic GI disorders. Despite no
differences in anxiety and depression, IBS patients also seem to be hypervigilant regarding
negative affects.
T1229
Effect of Autogenic Training in Patients with Irritable Bowel Syndrome: A
Randomized Controlled Trial
Masae Shinozaki, Motoyori Kanazawa, Michiko Kano, Yuka Endo, Michio Hongo, Shin
Fukudo
Background: Autogenic training (AT) is an useful and comprehensive relaxation technique.
However, there have been no studies that proved the effect of AT in irritable bowel syndrome
(IBS). With the randomized controlled trial, we test the hypothesis that AT is effective on
IBS symptoms. Subjects and Methods: Twenty-one IBS patients were randomly assigned to
AT (n=11, 5 male, 6 female, aged 33±3) or control therapy (n=10, 5 male, 5 female, aged
30±15). IBS was diagnosed with Rome II criteria. AT patients were trained intensively by
specialists eight sessions. The interval of each session was 2-4 weeks. Control therapy was
discussion about their life styles with same frequency and interval. At each session, all
patients completed to answer the adequate relief (AR) of IBS symptoms as a primary end-
point. Moreover, patients fulfilled the four questionnaires: Self-induced IBS Questionnaire
(SIBSQ) for IBS severity, Self-reported Depression Scale (SDS) for depressive state, State-
Trait Anxiety Inventory (STAI) for anxiety, and Medical Outcome Short Form 36 Health
Survey (SF-36) for quality of life (QOL). Results: The proportion of AR in AT group was
significantly higher than that in controls (ANOVA: group: p<0.0001, interaction: p=0.017,
Figure 1). The two subscales of SF-36, SF and Bodily Pain, were significantly improved in
AT group (p<0.05). Role Emotional (p=0.051) and General Health (p=0.068) showed trend
improvement in AT group. SIBSQ, SDS, or STAI did not show the significant difference
between AT group and controls. Conclusion: These results suggest that AT may be useful
for IBS treatment, probably via improving impaired self-control feeling in patients with IBS.
Because AT is simple and comprehensive psychotherapy, further studies in IBS are warranted.
T1230
Minimally Important Difference (MID) for Health Related Quality of Life
(HRQOL) Measures in Functional Bowel Disorders (FBD)
Douglas A. Drossman, Carolyn B. Morris, Yuming Hu, Brenda B. Toner, Nick Diamant,
William E. Whitehead, Christine B. Dalton, J.N. Leserman, Shrikant I. Bangdiwala,
Donald L. Patrick
Background. The study of HRQOL in FBD is of growing interest. What comprises a meaning-
ful change in HRQOL for FBD patients that would impact interpretation of treatment benefit
is unknown. Aim. To identify the MID using both anchor-based and statistical methods for
condition specific (IBS-QOL) and generic (Sickness Impact Profile-SIP) measures among
women with FBD undergoing a treatment trial. Methods. Females (n=402) with FBD entering
a 12-week treatment trial were studied at baseline and end of treatment with two HRQOL
measures: 1) IBS-QOL (condition-specific), 2) SIP (generic-daily function). Change scores
were compared using correlations and t-tests between the HRQOL measures and two more
frequently used clinical anchors: a) change in Visual Analog Scale (VAS) pain averaged over
2-week periods prior and at end of treatment, and b) Treatment Efficacy Questionnaire
(TEQ) obtained at end of treatment. Category definitions for pain and TEQ were defined
as worsening (<-25% drop in VAS; score <20 for TEQ), no change (<-25% to +50% for
VAS, score 20-28 for TEQ), and Improvement (>+50% for VAS and >28 for TEQ - the
definition of a responder). In addition, using the method of Norman (Medical Care, 2003).
we calculated a statistically based MID using ½ SD of the baseline values for the two HRQOL
measures. Significance was p < 0.05. Results. 1) IBS-QOL more than SIP were moderately
correlated with pain (r=-0.22. p<0.0001 for IBS-QOL; r=0.17 ; p=0.003 for SIP) and Satisfac-
tion (r=0.36; p<0.0001 for IBS-QOL; r=0.14; p=0.04 for SIP); 2) The HRQOL values for
clinical change categories are shown in Table 1, indicating MID for IBS-QOL and SIP of
approximately 14 (13.8 for pain and 14.3 for Satisfaction) and 3.5 (4.77 for pain and 2.43
for Satisfaction); 3) ½ SD at baseline for IBS-QOL was 10.2 and for SIP was 3.5. Conclusion.
We have estimated the MID in women with moderate to severe FBD is approximately 14




Somatization Trait and Somatization Disorder Have Different Impacts On IBS
Miranda Al. van Tilburg, Olafur S. Palsson, William E. Whitehead
The psychological trait of Somatization and Somatization Disorders (SD) are both increased
in Irritable Bowel Syndrome (IBS) and are related to symptom severity. However, somatization
and SD are not completely overlapping concepts. Somatization refers to the tendency to
report an excess of non-specific symptoms and is usually measured with questionnaires.
Somatization Disorder is a psychiatric diagnosis characterized by a history of many clinically
significant physical complaints that are not fully explained by a medical condition. It is
usually diagnosed by a clinician according to the Diagnostic and Statistical Manual IV (DSM-
IV) criteria. We explored how useful both concepts were in explaining well-being and
symptom status among IBS patients. METHODS: 156 IBS patients (age 18-73 M=35.2;
83.3% females) completed the Recent Physical Symptom Questionnaire (RPSQ; IBS specific
somatization), the Brief Symptom Inventory-18 (BSI-18; psychological distress), IBSS (IBS
Severity), IBS-QOL (Quality of Life) and the SD section of the Structural Clinical Interview
for DSM-IV (SCID; Somatization Disorder). RESULTS: 22 Patients (14.7%) met criteria for
SD or undifferentiated SD. T-tests revealed significant differences between SD and non-SD
patients in RPSQ (M= 13.9 vs 10.4; p<.01) and IBSS (M=314.6 vs 271.3; p <.05), but not
in BSI or IBS-QOL. Somatization as measured by the RPSQ correlated significantly with
IBSS (r=.26; p <.01), BSI-anxiety (r= .53, p < .001); BSI-depression (r= .53, p< .001) and
IBS-QOL (r= -.46, p < .001). In linear regression analyses with SD and RPSQ as independent
variables; SD was only a significant predictor of BSI Anxiety (β=-.16; p <.05). RPSQ explained
6% of IBSS (β=.18; p <.05) 20% of IBS-QOL (β=-.44; p< .001) 19% of BSI Depression (β=
.556; p <.001) and together with SD, 32% of BSI anxiety (β=.58; p < .001). CONCLUSIONS:
In this sample of IBS patients we found a high incidence of SD, similar to previous studies.
However, SD was a poor predictor of IBS outcomes. The data indicates that somatization
within the normal range affects IBS outcomes linearly. Somatization, as a psychological trait,
is therefore a more sensitive measure than SD in determining impacts on IBS outcomes. As
clinicians and researchers it is important to focus on the whole range of somatization rather
than SD alone. [Supported by grants R24 DK67674, R01 DK31369 and RR00046]
T1232
Parental Concerns in Childhood Functional Abdominal Pain: A Comparison
Study
Nader N. Youssef, Miranda van Tilburg, Annette Langseder, William E. Whitehead
BACKGROUND: Children with functional abdominal pain (FAP) have increased rates of
school absenteeism and decreased participation in social activities as compared to children
with abdominal pain of organic origin. One possible explanation is that FAP parents have
a different set of concerns than parents of children with organic gastrointestinal disorders
and may contribute to social withdrawl of these children. AIM: To compare concerns among
groups of parents whose children have FAP or organic causes for their abdominal pain
(ORG) to parents of healthy children without chronic abdominal pain (HC). SUBJECTS &
METHODS: From 04/ 2005 to 11/ 2005, 232 parents of children (mean age, 9.6 years,
range 4 to 18 years, 55% female) presenting to a tertiary pediatric gastroenterology office
completed a validated 25-item parent assessment instrument, Parental Worry of RAP Ques-
tionnaire (PWRQ), prior to their inital evaluation for abdominal pain. It consists of 4 subscales:
(1) Fear to ignore symptoms-worries surrounding the willingness to ignore symptoms (6
items), (2) Desire for care- frustration with doctors (7 items), (3) Worry about coping-
unable to cope with symptoms (7 items), and (4) Exacerbating factors- recognizing the role
of stress and family (5 items). Responses are scored on a 1 (not at all worried) to 5 (very
much worried) scale. Scores on items were added to create a subscale score. A clinical
diagnosis was assigned to each survey. A diagnosis of FAP was made utilizing the Pediatric
Rome Criteria. Parents of children diagnosed with FAP (N=135) were compared to those
with organic causes (gastroesophageal reflux, constipation, and inflammatory bowel, ORG
N= 65) and a group of age & gender matched children without abdominal pain served as
healthy controls (HC, N= 36). RESULTS: (Table) CONCLUSIONS: Parents of children with
chronic abdominal pain have significant concerns when compared to those of healthy
controls. There was no difference in specific parental worries between FAP and organic
causes of pain. Therefore, decisions to limit school attendance and social activities do not
arise from specific parental worries in FAP but may be a result of inappropriate parental
responses to FAP and subsequent parental worries. Therapeutic interventions targeted at
modifying parental response to FAP may serve as useful therapies for children with functional
abdominal pain. (Grant R24DK67674).
PWRQ Scores
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T1233
Increase in Global Symptom Reporting Does Not Explain Increased Prevalence
of Functional Bowel Disorders in First Degree Relatives of IBD Patients
Lisbeth A. Selby, Freddy Caldera, Houssam Mardini, Willem de Villiers
There is mounting evidence that inflammatory bowel disease (IBD) and irritable bowel
syndrome (IBS) may have a similar etiopathogenesis. In a recent study of 112 subjects we
found that first degree relatives of IBD patients (FDR-IBD) meet Rome II criteria for functional
bowel disorders (FBD) twice as often as general medical controls (GMC). Although this
finding suggests that FBD, such as IBS, are part of the same spectrum as IBD biologically, there
are numerous alternative explanations of these results. These include: increased symptom
reporting in general, increased bowel symptom awareness by FDR-IBD, learned illness
behavior, and response bias. Purpose: Evaluate the level of non-bowel symptom reporting
in this group. High levels of non-bowel symptom reporting would suggest that the bowel
symptoms endorsed by these FDR-IBD are part of a larger pattern of increased symptom
reporting and do not necessarily reflect a true increase in FBD. Methods: A self-administered,
mail-back survey contained 16 Rome II bowel questions and 27 other questions on physical
and psychological symptoms. Subjects were categorized as either FBD+ or FBD- based on
Rome II criteria. Chi-square and Mann-Whitney U tests were used to assess the associations,
estimate the odds ratios (OR) and the 95% confidence intervals of these associations. Results:
112 surveys were evaluated, 55 from FDR-IBD and 57 from GMC. The mean age of FDR-
IBD was 39. The mean age of GMC was 48. In FDR-IBD with FBD mean age was 31 v.
mean age of 46 in FDR-IBD without FBD (ns). FDR-IBD were 40% male; GMC were 32%
male (ns). Aggregate non-bowel symptom reporting was similar among FDR-IBD and GMC
(mean total no. symptoms = 5.88 v. 5.09, ns). Comparison of FDR-IBD who differed in
FBD status also showed no significant differences in non-bowel symptoms. IBD relatives
meeting FBD criteria did not have more non-bowel symptoms than GMC with FBD. Each
of the 27 non-bowel symptoms was also analyzed separately. FDR-IBD with FBD significantly
more often reported symptoms in only 3/27 categories: bruising - OR 5.5 (CI 1.3-23.8),
urinary frequency - OR 6.7 (CI 1.2-36.6), and anxiety - OR 4.6 (CI 1.0 - 20.2). Notably
musculoskeletal pain and fatigue, symptoms classically associated with FBD, were not more
prevalent in FDR-IBD with FBD. Conclusion: FDR-IBD do not have globally increased
somatic complaints compared to GMC. Therefore, our previous finding of an increased
prevalence of FBD in this group seems to reflect a relatively isolated increase in bowel
symptoms. The finding of increased anxiety in this group could suggest hypervigilance to
bowel symptoms. Further study with validated instruments is needed.
T1234
Influence of Experimentally Induced Anxiety On Rectal Sensorimotor
Function in Men
Brecht Geeraerts, Lukas van Oudenhove, Rita Vos, Jozef Janssens, Jan Tack
BACKGROUND: Various stressors, including emotions such as anxiety, may influence visceral
perception and motor function, thereby eliciting or aggravating gastrointestinal (GI) symp-
toms. Experimentally induced anxiety was shown to affect gastric sensorimotor function,
but it is unclear whether this also affects other parts of the GI tract. The AIM of the present
study was to investigate the effect of experimentally induced anxiety on rectal sensorimotor
function in health. METHODS: Eighteen healthy subjects (mean age 26.0±1.8 years) particip-
ated in a rectal barostat study. To assess sensitivity to rectal distension and rectal compliance,
stepwise isobaric distension (4 mmHg steps at 1.5 minute intervals, until discomfort or
pain) was performed during anxious and neutral emotional state. Both distension sequences
were separated by a 30-minute adaptation period. Rectal compliance was calculated as the
slope of the pressure-volume curve. Emotional context was altered using combined audio-
tape assisted recall of a neutral or anxious autobiographical experience and viewing of a set
of validated neutral or fearful facial expressions. Emotional context was modulated for 10
minutes at the start of each distension sequence. Anxiety levels were assessed using visual
analog scales (VAS) and the Spielberger State-Trait Anxiety Inventory (STAI). Lower abdom-
inal sensation was scored on 0-6 graded scales (0=no sensation, 6=maximal) at the end of
every distension step. RESULTS: Efficacy of anxiety induction was confirmed by VAS (AUC
0.6±0.3 vs. 9.1±1.3 mm*mmHg; p<0.00001) and STAI scores (36.1±2.1 vs. 45.6±2.5; p=
0.005). Emotional context did not alter rectal compliance (11.6±0.9 vs. 10.6±1.0 ml/mmHg;
NS). Pressure needed to induce first perception (score=1) (10.0±1.4 vs. 9.6±0.9 mmHg,
NS) or discomfort (score≥5) (29.3±1.4 vs. 29.8±1.5 mmHg, NS), and corresponding intra-
balloon volumes (respectively 50.5±12.9 vs. 40.6±5.4 ml, NS and 249.3±16.2 vs. 231.4±21.2
ml, NS) were not significantly altered. CONCLUSION: Contrary to its influence on gastric
sensorimotor function, experimentally induced anxiety does not affect rectal sensitivity or


















How Does Cognitive Behavioral Therapy for IBS Work? A Structural Equation
Modeling Analysis of Results from a Randomized Controlled Trial
Jeffrey M. Lackner, James Jaccard, Susan S. Krasner, Leonard A. Katz, Edward B.
Blanchard
While evidence supports the efficacy of cognitive-behavioral therapy (CBT) for treating IBS,
little is known about why it works or how to optimize CBT so that it is more potent,
streamlined, and cost efficient. One hypothesis is that CBT achieves its therapeutic effects
by reducing psychological distress (Aust NZ J Psychiatry, 39, 9, 807-815). Support for this
hypothesis requires ruling out the possibility that changes in distress are a consequence,
not cause, of symptom changes brought on by CBT. The relationship among symptom
improvement, distress, and the important endpoint of quality of life (QOL) was formally
evaluated using structural equation modeling (SEM) of data obtained prospectively from
the acute treatment phase of an NIH funded clinical trial. 147 Rome II diagnosed IBS patients
(81% female) were randomized to 1 of 3 10-wk conditions: (a) group-based CBT; (b) group-
based education (ED); or (c) wait list (WL). Primary endpoint was global ratings of IBS
symptom improvement (- 100 = substantially worse, 100 = substantially improved). Second-
ary endpoints were QOL (IBS-QOL) and psychological distress (BSI). SEM analyses yielded
3 major findings. First, CBT showed significantly greater symptom improvement than patients
assigned to WL (mean post treatment difference = 33.83 (95% CI = 16.26 to 50.04). A
comparison of CBT vs. ED (an active vs. passive control group) yielded statistically significant
(p < 0.01) relief of GI symptoms with CBT treated patients showing more symptom improve-
ment than the ED patients (mean difference = 25.82 (95% CI = 10.89 to 39.45). Second,
CBT reduced distress relative to WL (p < 0.05), but the effects were due to a complex chain
of mediation. Specifically, data were consistent with a model where CBT tended to improve
QOL and this, in turn, tended to lower distress (path coefficient = -0.36, 95% CI = -0.57
to -0.10, p < 0.01). Distress and QOL revealed a pattern consistent with a reciprocal causal
relationship. Not only did QOL changes produce distress changes, but changes in distress
produced changes in QOL (path coefficient = -0.13, 95% CI = -.21 to -.06, p < .01). Third,
3 paths consistent with a model that CBT works by reducing distress did not approach
statistical significance: (1) a direct path from global symptom improvement to posttest
distress, (2) a direct path from posttest distress to global improvement or (3) a reciprocal
influence between global improvement and posttest distress. Contrary to conventional wis-
dom, findings suggest that reducing psychological distress is not the primary mechanism
through which CBT achieves global improvement of IBS symptoms. Supported by NIDDK
grants 67878 & 54211.
T1236
Psychological Trait Dimensions in Functional Dyspepsia: Descriptive Data and
Relationship with Gastric Pathophysiology
Lukas van Oudenhove, Joris Vandenberghe, Brecht Geeraerts, Rita Vos, Phillippe
Persoons, Sebastien Kindt, Koen Demyttenaere, Jan Tack
Background: Psychological trait dimensions including alexithymia and trait anxiety are
believed to play a role in onset, course and outcome of functional dyspepsia (FD). This
study aims to describe the prevalence of alexithymia and trait anxiety and their relationship
with gastric pathophysiological mechanisms in FD. Methods: We studied gastric sensorimo-
tor function with a barostat (sensitivity, compliance & accommodation) and gastric emptying
test in 139 consecutive tertiary care FD patients (102 women, mean age 39.5±12). Patients
filled out the Toronto Alexithymia Scale (TAS-20) and the Spielberger State-Trait Anxiety
Inventory (STAI) as a part of a larger set of questionnaires. Results: Pathophysiological
mechanisms: 53 patients (38%) were hypersensitive to gastric distension, accommodation
was impaired in 52 patients (38%) and 17 patients of the 92 for whom standardized emptying
data were available (19%) had delayed gastric emptying. Psychosocial dimensions: 1)TAS-
20 The median total TAS-score was 56[19], which is significantly higher compared to healthy
subject samples (39-50,p<.0001) and medical patient samples (42-49) and significantly
higher than or similar to somatoform or psychiatric patient samples (49-55). Forty seven
patients (40%) scored low (<51) on alexithymia, 34 patients (29%) had an intermediate
score (51-61) and 36 patients (31%) scored high. The median scores on the TAS subscales
“Difficulty Identifying Feelings”, “Difficulty Describing Feelings” and “Externally Oriented
Thinking” were 17[10], 14[7] and 23[7], respectively. These scores are again higher compared
to healthy subjects and medical patients and higher than or similar to from somatoform or
psychiatric patients. No association was found between total or subscale TAS scores and
gastric sensitivity status or accommodation. There was a higher total alexithymia score in
the delayed emptying group (58 vs 51.7,p=.05). 2)Trait Anxiety The mean±SD STAI Trait
score was 41.8±10.8, which is significantly higher than the general population (38.3,p=
.0004), similar to a medical patients sample (40.6,p=.21) and significantly lower than a
psychiatric patients sample (51.8,p<.0001). Trait anxiety did not differ relative to gastric
sensitivity status, accommodation & gastric emptying. 3)Relationship alexithymia - trait anxiety
TAS-20 total score and STAI Trait score were moderately correlated (ρ=.35,p=.0002). Conclu-
sion: Alexithymia and, to a lesser extent, trait anxiety scores are high in tertiary care FD
patients. No association was found between psychological trait dimensions and gastric
pathophysiological mechanisms, except for alexithymia and gastric emptying.
T1237
Increased Pre-Pulse Startle Inhibition in Irritable Bowel Syndrome (IBS):
Evidence for Hypervigilance
Lisa A. Kilpatrick, Edward Ornitz, Hana Ibrahimovic, Mike Treanor, Michelle Craske,
Maria Nazarian, Emeran A. Mayer, Bruce D. Naliboff
Background: The eye blink acoustic startle response (ASR) is a simple reflex elicited by a
brief loud tone. Prepulse inhibition (PPI) of the ASR by an innocuous tone presented between
30-500 ms before the startle is a useful index for central inhibitory mechanisms regulating
sensorimotor processes and is decreased in schizophrenia but is increased with attention to
the prepulse or an increase in the threat value of the prepulse. Aims: To test IBS patients
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for either 1) decreased PPI and sensorimotor gating which would suggest deficient inhibition
of interoceptive signals or 2) enhanced PPI which would suggest increased saliency of the
pre-pulse and, therefore, general hypervigilance. Methods: ASRs were examined for 35
female ROME positive IBS patients (age = 35.2 ± 12) and 21 healthy female controls (age =
30.7 ± 8) during a series of startle stimuli trials, some of which were preceded by 25 ms
tones (75dB SPL, 1000 Hz, 4 ms rise and fall times). Startle stimuli consisted of a 50 ms
burst of white noise at 104 dB SPL with a 0 ms rise time presented binaurally through
earphones. ASRs were measured from the electromyographic response of the orbicularis
oculi muscle. Peak startle amplitude was defined as the highest point within a window from
20 ms to 105 ms following startle stimulus onset. The amplitude was log-transformed to
increase normality of the data. Results: Group and pre-pulse effects on ASR were examined
using mixed model analysis of variance. ASR amplitudes during trials in which no pre-pulse
stimulus was given did not significantly differ between IBS patients and healthy controls
(p = 0.239). However, there was a significant group by trial type interaction (p = 0.004).
This resulted from IBS patients showing smaller ASRs during the pre-pulse trails compared
to controls, indicating greater PPI in IBS patients. Conclusions: The results demonstrate
altered stimulus processing in IBS patients. Since the effect of the pre-pulse is dependent
in part on its saliency, the increased PPI seen in IBS patients may reflect increased general
vigilance. ASR responses may offer a simple and non-invasive approach to the study of
neurocognitive mechanisms in functional disorders. Supported by NIH grants P50 DK64539,
R24 AT002681, NR04881, and VA Medical Research.
T1238
Is a Structured Patient Educational Class An Efficient Tool in the Management
of Patients with Irritable Bowel Syndrome (IBS)?
Gisela Ringstrom, Stine Storsrud, Sara Lundkvist, Berndt Westman, Hasse Abrahamsson,
Magnus Simren
Background: IBS patients consume a lot of healthcare, but often feel that they are insufficiently
informed about their condition. Medical treatment options are still limited. This is a report
from a study evaluating the effect of a structured IBS patient educational class - an ‘IBS-
School’ - on symptom severity and the impact on daily life. Method: We included 62 patients
(mean age 39 (23-67) years; 51 women) with IBS according to the Rome II criteria. The
patients were referred from primary care physicians and gastroenterologists. The ‘IBS-school’
consisted of six two-hour lessons, once per week with eight to ten patients in each group.
Each lesson was held by one out of five professionals: a nurse specialized in functional
gastrointestinal (GI) disorders, a gastroenterologist, a dietician, a physiotherapist and a
psychologist. All patients completed validated questionnaires before and three months after
the start of the educational class to evaluate GI symptoms severity (Gastrointestinal Symptom
Rating Scale-IBS, GSRS-IBS and IBS Severity Scoring System, IBS-SSS), GI symptom-specific
anxiety (Visceral Sensitivity Index, VSI), quality of life (SF-36 and IBS Quality of Life,
IBSQOL), psychological symptoms (Hospital Anxiety and Depression scale, HAD) and coping
resources (Sense of Coherence index, SOC).The patients rated their perceived levels of IBS
knowledge and satisfaction with the knowledge using a visual analogue scale. Results: The
patients experienced increased knowledge about IBS at 3 months (42±23 vs. 76±13 mm
(mean ±SD); p= 0.0001), and were more satisfied with their knowledge (27±22 vs. 77±17;
p=0.0001). Overall GI symptoms severity was reduced according to IBS-SSS (322±87 vs.
289±109; p= 0.003). Of the individual GI symptoms abdominal pain was less severe after
the educational class (GSRS pain score 4.4±1.3 vs. 3.9±1.5; p= 0.005), whereas the bowel
habits were unchanged. GI symptom-specific anxiety was reduced, as measured by VSI
(50±18 vs. 56±16; p= 0.006). The QOL improved after the educational class, especially for
the mental component score on SF-36 (34±12 vs. 39±14; p= 0.01), and the patients showed
reduced levels of depression according to HAD (5.8±3.7 vs. 5.0±4.4 p= 0.03). Conclusion:
A structured IBS patient educational class enhances the knowledge about IBS, which helps
the patients to cope better with their symptoms. Patient education is efficient in order to
reduce the impact of GI symptoms on daily life in IBS-patients, with improvements in
quality of life. Performing patient education in a group setting probably enhances these
positive effects.
T1239
Gastroenterologist Ratings of Patient Anxiety: Perception Or Attribution?
Tiffany Havlicek, Michael P. Jones, Michael Williams, Robert Rahimi, Laurie Keefer
Introduction: Numerous studies have shown that MD assessment of pt anxiety (ANX) and
depression (DEP) is often poor. Further, studies suggest that MDs and other healthcare
providers often harbor negative attitudes towards pts with functional GI disorders (FGID).
This is problematic as accurate, unbiased assessments of psychosocial factors are needed to
optimize outcomes. We assessed gastroenterologist (GE) ratings of pt ANX and DEP with
respect to diagnosis. Methods: Subjs were pts making initial clinic visits at 2 university GI
clinics and their GE. Pts were grouped by post-visit diagnosis as FGID, organic disorder
(OrgDx; eg. IBD, PUD) or symptom-based diagnosis (SxDx; eg. abdominal pain, nausea).
Pts completed HADS and the Visceral Sensitivity Index (VSI: a measure GI symptom specific
ANX). GE rated ANX and DEP on 100mm VAS with anchors “not at all” and “severe.”
Results: 30 FGID, 29 OrgDx and 41 SxDx pts were evaluated by 26 GE. Groups did not
differ by age or sex. No differences existed btwn groups for HADS ANX or DEP(Table). VSI
scores were signif different btwn groups (F=4.254; p=0.019) with SxDx but not FGID signif
higher than OrgDx (p=0.03 and p=0.13 by Bonferroni). GE ratings of ANX in FGID were
higher than SxDx or OrgDx (p=0.11). GE ANX ratings correlated poorly with HADS-ANX
(r=0.11;p=0.26) and VSI. GE DEP ratings did not differ btwn groups (p=0.46). (r=0.17;p=
0.18). Conclusions: MD ANX and DEP ratings do not correlate with pt self-report. No signif
differences in DEP or generalized ANX exist btwn groups but VSI is higher in FGID and
signif higher in SxDx. GE rate FGID higher in ANX and DEP while SxDx is rated similar
to OrgDx, suggesting an attribution effect. Stigma assoc with FGID diagnosis may have
influenced this outcome and warrants futher study.
mean±SEM Bonferroni posttests comapred with OD: **(p=0.13) *(p=0.03)
T1240
What Patients with Irritable Bowel Syndrome (IBS) Expect from Their Health
Care Providers. National Survey On IBS Educational Needs and Expectations
Albena Halpert, Christine Dalton, Olafur Palsson, Yuming Hu, Carolyn Morris, Shrikant
Bangdiwala, Nancy Norton, Douglas Drossman
AIM: To identify patients’ expectations from the health care providers related to IBS.
METHODS: The study consisted of: 1) Questionnaire item generation using patient focus
groups to develop the IBS-Patient Education Questionnaire (IBS-PEQ); 2) Cognitive item
reduction of items considered important and relevant by IBS patients; and 3) Data acquisition.
The IBS-PEQ was administered to a national sample of IBS via mail and on line. Expectations
from the health care providers were assessed using a 7-point Likert scale questions. ANA-
LYSIS: We report the six most desirable qualities of the health care providers based on %
of subjects agreeing or strongly agreeing with that quality. RESULTS: We report the results
obtained from the first 495 subjects of a larger study. The mean age was 37.3 ± 11.7 years
with an educational attainment of 15.1± 2.6 years, and 84% were female, 85% have seen
an MD for IBS and 98% have previously used the web for health information. Illness duration
was 6.7 ± 4.0 years. 50% of all subjects stated they have received some helpful information
about IBS previously, but 100% wanted to know more about IBS. The most desired qualities
of the health care providers and respective prior experiences are summarized in Table 1.
Notably there is discrepancy between expectations and what patients report as their experi-
ence with the last MD they saw for IBS. CONCLUSION: 1) Patients with IBS feel they want
more information about IBS and expect their health care provider to provide more in depth
information, including additional learning sources and research options, to listen, and be
supportive. 2) There is a discrepancy between the above expectations and patients’ prior
experiences with physicians who they have seen for their IBS. Better understanding of
patients’ needs and expectations is needed in order to improve our ability to effectively
manage IBS. Supported by GIDH, Forest Laboratories and P&G.
Table 1
T1241
Family Physician Attitude Towards Irritable Bowel Syndrome
Alexandra Ilnyckyj, Lesley Graffe, Lawrence Elliott, Gina Sunderland
Background: IBS is primarily managed by family physicians (FP). This study explored FP
knowledge, clinical skill and personal satisfaction (attitude) in caring for patients with IBS
and explored factors contributing to personal satisfaction. As well, FP attitudes were compared
to those of other professionals. Aim: 1) Compare FP attitude towards IBS to other chronic
conditions 2) Compare FP attitude towards IBS to that of other professionals 3) Identify factors
contributing to FP satisfaction in managing IBS. Methods: Randomly selected FP,dieticians (D)
and psychologists (P) in a Canadian province were surveyed regarding their attitude with
respect to IBS, depression, anxiety, chronic musculoskeletal pain, fibromyalgia, and obesity
management. Comparison conditions were selected since education/ support is integral in
treatment. Independent and paired sample t tests were used, as appropriate, to compare FP
attitudes regarding IBS to those of other professions, and to other conditions. Multiple
regression analysis was used to explore the contribution of factors to FP satisfaction working
with IBS. Results: 100 surveys were sent to each professional group, with responses from
46 FP, 61 P, and 54 D. FP reported greater satisfaction treating the mental health conditions
compared to IBS (t=-3.12, p <.01), but lower satisfaction in treating those with chronic pain
conditions compared to IBS (t=3.32, p<.01). Similar results were found with respect to the
dimensions of self-reported knowledge and clinical skill across these conditions. In compar-
ison to other professionals, FP reported lower ratings than did D regarding their IBS know-
ledge (t=-2.06, p=.04) and clinical skills (t=-2.45, p=.02). There were no differences between
P and FP. Similarly, FP satisfaction in working with IBS patients was lower than D satisfaction
(t=-5.81, p<.001). There was no difference between P and FP. A regression analysis assessing
the effects of gender, knowledge, skills, time constraints and patient factors on FP satisfaction
in working with IBS patients found that level of clinical skills was the strongest predictor
(F=2.37, p=.05), explaining 29% of the variance. Conclusion: Family physicians report their
attitude to be greater towards the management of depression rather than IBS. However,
their attitude towards IBS is greater than towards chronic pain conditions. Dieticians reported
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greater attitude than did family physicians towards managing IBS. Strong clinical skills are
important in predicting family physician personal satisfaction in IBS management.
T1242
Interleukin-1β Stimulates Expression of NADPH Oxidases NOX1 and NOX4 in
Colonic Smooth Muscle: Mediation By Nf-κB and Differential Modulation By
C-Jun Kinase and ERK1/2
Wenhui Hu, Fang Li, Karnam S. Murthy
Brief exposure (< 3 h) of esophageal and colonic smooth muscle cells to IL-1β stimulates
H2O2 production and inhibits smooth muscle contraction. Direct exposure to exogenous
H2O2 also inhibits contraction raising the possibility that H2O2 is partly responsible for
inhibition of muscle contraction after brief exposure to IL-1β. The participation of H2O2 in
inhibition of contraction after prolonged exposure depends on continuous generation of
H2O2. An increase in NAPDH oxidase (NOX) expression or activity could provide a source
for superoxide that can be readily dismuted to H2O2. NOX1 and NOX4 are known to be
expressed in colonic tissues and smooth muscle cells. Aim. To determine the effect and
mechanism of action of IL-1β on NOX expression in colonic smooth muscle cells. Methods.
Cultured rabbit colonic smooth muscle cells in first passage were treated for 3 days with
IL-1β in the presence or absence of NF-κB and MAP kinase inhibitors. Expression levels of
NOX1 and NOX4 were determined by Western blot. Results. We have recently shown that
IL-1β activates NF-κB and various MAP kinases, including ERK1/2, p38 MAP kinase, and
c-Jun kinase (JNK). In this study, treatment of cultured muscle cells with IL-1β for 3 days
induced 3- to 4-fold increase in NOX1 and NOX4 protein expression. The increase in
expression of both NOX1 and NOX4 was strongly inhibited by an IKK2 inhibitor (IKK2-
IV, 10 µM), suggesting that the increase in expression was mediated via a canonical NF-kB
pathway (IKK2/IκBα/NF-κB). The increase in NOX1 expression was selectively inhibited
by the JNK inhibitor, SP600125 (10 µM), whereas the increase in NOX4 expression was
selectively inhibited by the MEK inhibitor, PD98059 (20 µM). Expression of either enzyme
was not affected by the p38 MAPK inhibitor, SB203580. Conclusion. IL-1β stimulates the
expression of NADPH oxidases NOX1 and NOX4 in colonic smooth muscle cells. The
increase in expression is mediated by NF-κB and differentially modulated by ERK1/2 and
JNK. The sustained increase in NOX expression provides a ready source for continuous
generation of superoxide that can be readily dismuted to H2O2.
T1243
Affect and Perceived Stress in Functional Dyspepsia: Descriptive Data and
Relationship with Gastric Pathophysiological Mechanisms
Lukas van Oudenhove, Joris Vandenberghe, Brecht Geeraerts, Rita Vos, Phillippe
Persoons, Sebastien Kindt, Koen Demyttenaere, Jan Tack
Background: Psychosocial factors including affect and stress are believed to play an important
role in the onset, course and outcome of functional dyspepsia (FD). The aim of this study
is 1) to provide descriptive data on positive and negative affect and perceived stress in FD and
2) to describe the relationship of these psychological factors with gastric pathophysiological
mechanisms. Methods: We studied gastric sensorimotor function with a barostat (sensitivity,
compliance and accommodation) and gastric emptying test in 139 consecutive FD patients
from a tertiary care centre (102 women, mean age 39.5±12). On the day of the barostat
investigation, patients filled out the Positive And Negative Affect Schedule (PANAS, 20
items) and the Perceived Stress Questionnaire (PSQ, 30 items), as a part of a larger set of
questionnaires. Results: Pathophysiological mechanisms: 53 patients (38.1%) were hyper-
sensitive to gastric distension, accommodation was impaired in 52 patients (37.7%) and 17
patients of the 92 for whom standardized emptying data were available (19%) had delayed
gastric emptying. Psychosocial dimensions 1) PANAS: Patients rated their affect over the
past two weeks. The mean±SD positive affect score was 28.1±7.4 and the median [IQR]
negative affect score was 17.8 [8]. The mean positive affect score was significantly lower
compared to the normal population (p<.0001). PANAS scores did not differ relative to
gastric sensitivity status, accommodation or gastric emptying. 2) PSQ: Patients rated their
level of perceived stress over the past month. The mean PSQ index score was 0.33±0.13,
which is significantly lower than in healthy subjects (0.37; p=.005) and in a sample of GI
out- and inpatients (0.44 & 0.49 respectively; p<.0001). The PSQ scores did not differ
relative to gastric sensitivity status, accommodation or gastric emptying. 3) Relationship
between affect and perceived stress: perceived stress correlated negatively with positive affect
(ρ=-.53, p<.0001) and positively with negative affect (ρ=.58, p<.0001). Conclusion: Tertiary
care FD patients have lower positive affect rather than higher negative affect compared to
healthy subjects. Surprisingly, perceived stress scores were lower than in both a sample of
healthy subjects and of GI out- and inpatients. Positive and negative affect scores and
perceived stress scores did not differ relative to gastric sensitivity, accommodation or emp-
tying.
T1244
What Determines the Compromised Quality of Life in Patients with Irritable
Bowel Syndrome (IBS)?
Magnus Simren, Gisela Ringstrom, Pia Agerforz, Per Jerndal, Martin Karpefors, Louis
Akkermans, Robert Spaziani, Karen Miranda, Stephen Collins, Markad Kamath, Alfred
Bayati
Background: Previous studies have demonstrated compromised quality of life (QOL) in
patients with IBS compared with the general population. Factors of importance for this are
incompletely known. Aim: To assess QOL in IBS and to evaluate the relative importance of
demographic factors, gastrointestinal and psychological symptom severity for QOL in a large
database study. Patients and methods: We included 88 healthy controls (58 females; mean
age 33 years) and 290 patients fulfilling the Rome II criteria for IBS (208 females; mean

















a structured interview. Patients completed two disease specific questionnaires, the Gastrointe-
stinal Symptom Rating Scale - IBS (GSRS-IBS) and the Visceral Sensitivity Inventory (VSI)
and two generic questionnaires, the Hospital Anxiety and Depression scale (HAD) and the
Short Form-36 (SF-36). As the main outcome QOL variables we used the two summary
scores on SF-36 - physical and mental component scores (PCS, MCS) Results: Compared
with the controls patients with IBS had lower scores on all SF-36 domains (=lower QOL),
including the two summary scores (PCS: 45±10 vs. 51±11 (mean±SD); p<0.0001; MCS:
43±13 vs. 55±7; p<0.0001). Using univariate analyses several domains on the questionnaires
as well as demographic factors were associated with PCS and MCS, but no association was
seen with IBS subgroup based on the predominant bowel pattern, duration of IBS, gender,
family history of IBS or marital status. Regression analyses demonstrated independent associ-
ations between PCS and the overall GI symptom severity (p<0.0001) and frequency
(p<0.0001), GSRS Satiety Score (p<0.0001), the presence of fibromyalgia (p=0.002) and
other functional GI than IBS (p=0.004), HAD depression score (p=0.01) and whether the
patient was working or not (p=0.003) (R2=0.34). MCS was independently associated with
HAD depression (p<0.0001) and anxiety scores (p<0.0001), age (p=0.003), recent psycholo-
gical consultation (p=0.006) and VSI total score (p=0.03) (R2=0.64). Conclusion: QOL is
severely compromised in patients with IBS. This is related to GI and psychological symptom
severity, but also to some extent to demographic and social factors. The subgroup of IBS
based on the predominant bowel habit does not seem to affect QOL. This study was supported
by AstraZeneca.
T1245
Is There An Association Between Gnβ3 C825t Genotype and Lower
Functional Gastrointestinal Disorders?
Viola Andresen, Michael Camilleri, H. Jae Kim, Debra A. Stephens, Paula J. Carlson,
Nicholas J. Talley, Yuri A. Saito Loftus, Raul Urrutia, Alan R. Zinsmeister
Background: GNβ3 influences G protein translation of a majority of ligand-receptor activa-
tions. It has been reported that functional dyspepsia (FD) is associated with homozygous
genotypes of the C825T polymorphism in the GNβ3 gene. In a small group of 19 patients
with FD overlapping with irritable bowel syndrome (IBS), borderline association with GNβ3
C825T was detected. It is unknown whether the GNβ3 genotype is associated with lower
functional gastrointestinal disorders (FGID). Aims: To compare the prevalence of the different
GNβ3 C825T genotypes in patients with lower FGID and healthy controls, and to test
associations of these genetic variations with subgroups of IBS grouped by bowel function,
functional abdominal pain (FAP), and high somatic symptom scores. Methods: GNβ3 C825T
polymorphism was analyzed in DNA from blood samples of 233 patients with lower FGID
and 152 healthy controls. Validated bowel and somatic symptom questionnaires characterized
the FGID phenotype: 82 IBS-constipation, 94 IBS-diarrhea, 38 IBS-alternating bowel function,
and 19 FAP. Logistic regression analyses assessed associations of the GNβ3 genotypes with
lower FGID as a group, subgroups of FGID and high somatic score. Results: GNβ3 C825T
genotype distributions were similar between the 2 groups: 50.7% CC, 40.8% TC, and 8.6%
TT in healthy controls and 51.5% CC, 40.8% TC and 7.7% TT in patients with lower FGID.
There were no significant associations of GNβ3 C825T polymorphism with lower FGID
overall or with the separate symptom subgroups including IBS and FAP (Fig 1), or with
high somatic symptom scores. Conclusion: In contrast to the reported association with
functional dyspepsia, GNβ3 C825T polymorphism is not significantly associated with lower
FGID or with different IBS or FAP phenotypes.
T1246
Subjective Bloating Is Not Correlated with Intestinal Gas Production But Is
Weakly Correlated with Abdominal Distention
Syed I. Thiwan, Olafur S. Palsson, Marsha J. Turner, William E. Whitehead
Background: Volume of intra abdominal contents, abdominal muscle activity and altered
perception are commonly proposed mechanisms to explain abdominal bloating. Bloating is
one of the main symptoms in patients with lactose malabsorption and bacterial overgrowth,
suggesting a possible role of intestinal gas production in bloating. Aims: To determine
whether subjective bloating is due to 1. volume of intestinal H2 and Ch4 produced by
bacteria in response to oral sugar load or 2. objective abdominal distension. Methods: 80
subjects (10 males, 70 females, including 25 Healthy controls (H), 25 IBS, 23 Lactose
Malabsorbers (LM) and 7 Slow Transit Constipation (C) underwent a hydrogen breath test
with 50g of lactose and 80g of sucrose on an empty stomach in the morning. Breath samples
for H2 and Ch4 were collected at baseline and every 15 min until 120 min and then every
30 min up to 180 min. Abdominal girth was measured at the level of the umbilicus at end-
expiration with subjects in a standing posture. Subjects marked the severity of bloating on
a visual analog scale. Breath H2 and Ch4 were analyzed using a Quintron Microlyzer model
SC. Analysis: Net gas production (H2CH4) was defined as area under the curve (AUC) of
combined H2+2*Ch4 - baseline H2+2*Ch4. Net abdominal distention (GM) was defined
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as AUC of girth measurement-baseline girth. Results: All 3 patient groups had significantly
higher AUC bloating scores than controls (p<0.05). LM patients had significantly higher H2
production and greater increases in GM, while constipated patients had significantly greater
increases in CH4 (see table). Net gas production (H2CH4) was significantly increased in
both LM and C. Regression analysis showed that H2Ch4 and GM together accounted for
3% of the variance in subjective bloating and 6% of the variance in peak bloating, but
only GM was significant (p<0.05). Conclusions: Increases in intra-intestinal gas volume in
response to oral sugar load did not contribute significantly to bloating, and the contribution
of abdominal distension to the bloating sensation is marginal. We speculate that altered
perception is the main mechanism of bloating. [Supported by Novartis Pharmaceuticals and
grants RO1 DK31369, R24 DK67674, and RR00046].
(a=vs. H, IBS, C; b=vs. IBS; c=vs. H, IBS; d= vs. H p<0.05 or better)
T1247
Initial Approach and Pharmacotherapy for Functional Dyspepsia - A Large
Clinical Trial in Japan
Michio Hongo
Though the functional dyspepsia (FD) is one of the common disorders in primary practice
of gastroenterology, there are many controversies for initial approach and pharmacotherapy
for FD. [AIM] This study has 3 main purposes; to clarify 1) the prevalence of organic
disorders among the subjects presumed to be FD, 2) the effect of early endoscopy to the
symptoms, and 3) the effect of mosapride in relieving the symptoms compared with teprenon
which is indicated for gastritis. [SUBJECTS & METHODS] Patients those who have dyspeptic
symptoms for more than 4 days during the preceding 2 weeks, presumed to be functional
origin, were asked to participate to the study after informed consent (IC). After IC, patients
had endoscopy for evaluation of gastric mucosa. Symptoms were evaluated one week after
endoscopy, and those who were still symptomatic were allocated to pharmacotherapy either
mosapride 15 mg tid or teprenon 150 mg tid following the computer-controlled randomiz-
ation. Symptom was evaluated in 2 domains, dysmotility-like symptom (feeling of stasis)
and ulcer-like symptom (epigastric pain), with their degree of severity and frequency (both
in 3 Likert scale). Sum of the scores were used as Symptom Score for both symptoms, at
1 and 2 weeks of medication. Patients’ preference and SF-36 (v2 J acute form) were also
obtained. [RESULTS] A total of 1,042 patients (57% are from GPs) gave informed consent,
and 1,025 patients had endoscopy. A total of 90 patients had organic lesions in their upper
GI tract which could be responsible for the symptoms. Lesions frequently found were, reflux
esophagitis (30%), erosive gastritis (22%), and gastric ulcer (22%). Gastric cancers were
found in 3% of patients. 935 patients (M:F=1:1.3) (mean age 46 y.o.) were diagnosed as
functional dyspepsia. One week after the endoscopy, dyspeptic symptoms were relieved in
30% of patients. 618 FDs were randomized to mosapride (n=311) or teprenon.(n=307).
Two weeks after medication, stasis-symptoms and pain-symptoms improved with mosapride
and stasis symptoms improved with teprenon. Improvement in symptom scores were higher
in mosapride group in both symptoms. Subcales of SF-36 in bodily pain, general health,
vigor and mental health were significantly higher in mosapride group. Proportion of patient’s
impression favoring medication was 91% with mosapride and 52% with teprenon. [CON-
CLUSION] Presumed diagnosis of FD was correct in 90% of patients. Reflux esophagitis
was the most common organic disorders among the presumed FDs. There were malignancies
in 3% of patients. Early endoscopy relieved symptoms in 30% of patients. Mosapride showed
better efficacy in relieving FD symptoms than teprenon.
T1248
Lactose Malabsorption, Small Bowel Bacterial Overgrowth and Celiac Disease
in IBS Patients
Syed I. Thiwan, Olafur S. Palsson, Marsha J. Turner, William E. Whitehead
Background: Symptoms of small bowel bacterial overgrowth (SBBO), lactose malabsorption
(LM) and Celiac disease (CD) are often similar to IBS and could be confused with IBS. LM
is found in 23- 40% of IBS patients. Recent reports indicate high prevalence of SBBO as
diagnosed by positive lactulose breath hydrogen test and Celiac disease in IBS patients, but
this needs replication. Aims: To determine the prevalence of SBBO, LM and celiac disease
in IBS patients. Methods: 197 subjects (158 IBS-mean age 35.2 yrs, 26 males, 132 females;
and 39 healthy controls-mean age 36.54yrs, 8 males, 31 females) underwent hydrogen
breath test with 50g of lactose and 80g of sucrose on an empty stomach in the morning.
Breath samples for H2 and Ch4 were collected at baseline and every 15 min until 120 min
and then every 30 min up to 180 min. Breath H2 and Ch4 were analyzed using a Quintron
Microlyzer model SC. Patients completed the Rome II Modular Questionnaire and additional
bowel habit questions. Anti-Gliadin and Anti-Endomysial antibodies were assayed using
ELISA and qualitative indirect immunofluorescence assay respectively. Analysis: LM was
defined as a rise of 20 ppm of H2 over baseline after 120 minutes or a combined rise of
15 ppm of H2 and Ch4 after 120 minutes. SBBO was defined as either a baseline H2 level
of >40 ppm or 10 ppm increase in H2 within 60 minutes of ingesting sucrose. Anti-Gliadin
antibodies were interpreted as positive if the titer was > to 50 EU. Results: The prevalence
of SBBO, LM, and positive antibody tests for celiac disease were similar in IBS patients and
healthy controls (see table). IBS patients with and with out SBBO did not differ in predominant
bowel symptoms nor in the frequency and severity of diarrhea or abdominal pain. There
was only one patient with celiac disease confirmed by presence of Anti Endomysial antibody
in the IBS group. Conclusions: Our findings do not support the previously reported increased
prevalence of SBBO, LM, and Celiac disease in IBS patients. Failure to replicate an increased
prevalence of SBBO in IBS may be due to our methodology: using sucrose is more accurate
and specific than lactulose, and a 10 ppm rise in H2 is a more sensitive. However, SBBO
in the distal small bowel may not have been detected with this method. [Supported by NIH
grants RO1 DK31369, R24 DK67674, and RR00046].
T1249
Optimizing Gastric Emptying Scintigraphy for the Detection of Gastroparesis
Henry P. Parkman, Alan Hutson, Alan H. Maurer, Linda C. Knight, Braden Kuo, William
L. Hasler, William D. Chey, Richard W. McCallum, John M. Wo, Kenneth L. Koch,
Michael Sitrin, Jeffrey M. Lackner, Jack Semler
Gastric emptying scintigraphy (GES) using a radiolabeled solid-phase meal is currently
considered the gold standard to detect gastroparesis. It is, however, performed in a variable
manner at different institutions. A method to standardize gastric emptying using a low fat
(EggBeaters) meal with imaging at 0, 1, 2 and 4 hours postprandially has been suggested
(Tougas et al, Am J Gastro 2000;95:1456). Extending GES from 2 to 4 hours has also been
advocated to detect more patients with gastroparesis (Guo et al, DDS 2001;46:24). The
optimal duration of GES to maximize sensitivity and specificity for detecting gastroparesis
has not been established. AIM: To determine the optimal duration of GES for detecting
gastroparesis. METHODS: In a multicenter study evaluating the emptying of a pH/pressure
recording capsule (SmartPill), GES was performed in 86 normal subjects and in 60 patients
with previously diagnosed gastroparesis (37 idiopathic, 23 diabetic) based on scintigraphy
within the past 2 years. GES was repeated in a standardized fashion with imaging at 0, 0.5,
1, 1.5, 2, 2.5, 3, 3.5, and 4 hours after ingestion of a 99mTc-sulfur colloid radiolabeled
meal (120 g EggBeaters, 2 pieces of bread with strawberry jam; 255 kcal, 2% fat) and 120
cc water. Receiver operating characteristic (ROC) curves were used to optimize sensitivity
and specificity for differentiating gastroparetic patients from normal subjects for the 50%
emptying time (T-50), 90% emptying time (T-90), and the percent retention (%R) at each
imaging time. The concordance statistic (c-statistic) denotes the area under the ROC curve
and is a global measure of diagnostic utility. RESULTS: The c-statistic was greater for %R
at 3 hours (c=0.843) than at 1 hour (0.670), 2 hours (0.792), or 4 hours (0.816). It was
also greater than that for T-50 (c=0.766) and similar to that for T-90 (c=0.849). The cutoff
point that maximizes both sensitivity and specificity for T-90, 182 min, gives a sensitivity
and specificity of 84.8% and 77.9%, respectively, whereas the cutoff point for %R at 3
hours, 9% retention, gives 85.0% and 75.6%, and the cutoff point for %R at 4 hours, 3%
retention, gives 70.0% and 73.2%. CONCLUSIONS: Using the previously validated EggBeat-
ers meal, T-90 is better than T-50 to differentiate patients with previously diagnosed gastro-
paresis from normal subjects. The percent retention at 3 hours provides diagnostic utility
similar to the 90% emptying time and avoids the need for data extrapolation. To optimally
detect gastroparesis, assessment of gastric emptying at times greater than 2 hours is needed
with the percent retention at 3 hours being the best individual time point.
T1250
Non-Diarrhea Irritable Bowel Syndrome Patients Exhibit Different Anorectal
Symptoms and Physiology to Functional Constipation Patients
Vid P. Suttor, Gillian Prott, Ross Hansen, John Kellow, Allison Malcolm
Background: Patients with functional constipation (FC) often manifest concomitant features
of pelvic floor dyssynergia (PFD). Patients with non-diarrhea predominant irritable bowel
syndrome (non-D IBS) can also present with symptoms of PFD similar to patients with FC
[Talley, Rev Gastroenterol Disord 2005]. Aim: To compare the anorectal symptoms and
sensorimotor function of patients with non-D IBS and PFD symptoms to FC with PFD
symptoms. Methods: We studied 30 consecutive female patients referred with constipation
and two or more features of PFD (straining, incomplete evacuation, blockage, digital evacu-
ation, or anal pain). These patients comprised two groups: IBS (n=17; mean age ±SD 48±15
yrs), and FC (n=13; 51±9 yrs), according to ROME II criteria. Assessments included the Bowel
Disease Questionnaire, the Hospital Anxiety and Depression score, a validated constipation
questionnaire [Knowles, Dis Colon Rectum 2000], 10 cm visual analogue scales for patient
satisfaction with bowel habit and impact on quality of life, as well as a comprehensive
anorectal physiology study (balloon expulsion, anal sphincter pressures, pelvic floor descent,
and rectal sensitivity). Results: Non-D IBS patients experienced a greater frequency of straining
to defecate (p<0.01) and of incomplete evacuation (p<0.01) than FC patients. However
there was no difference in the total number of PFD symptoms between the two groups.
Overall, the patients with non-D IBS scored lower on satisfaction with bowel habits than
the patients with FC (p=0.05). Physiologically, the non-D IBS patients more often displayed
impaired anorectal balloon expulsion (p=0.02). Non-D IBS patients however less often
manifested paradoxical anal contraction with straining (6/17 IBS vs 10/13 FC; p=0.03).
There was no difference in the anxiety and depression scores for the two groups, and no
difference in the impact of their symptoms on quality of life. Conclusion: While both FC
and non-D IBS patients exhibit features of PFD, these findings show that non-D IBS patients
with PFD can exhibit a different symptom profile (more straining and incomplete evacuation,
and a lower satisfaction with bowel movements), and a different anorectal physiological
profile (more abnormal bowel evacuation, and less paradoxical anal contraction with strain-
ing) compared to FC patients with PFD.
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T1251
Physical Activity Improves Quality of Life But Is Not Associated with
Decreased Prevalence of Bloating
Ashok Tuteja, Nicholas J. Talley, Sandra K. Joos, Tolman G. Keith, David H. Hickam
Background: Abdominal bloating is reported frequently by otherwise healthy individuals
and may be associated with prolonged intestinal transit. Because mild physical activity
accelerates intestinal transit, it may prevent or relieve bloating. However, the effect of physical
activity on the prevalence and severity of bloating has not been investigated. We conducted
a cross-sectional study evaluating the association among physical activity, bloating and
quality of life (QOL). Methods: 1069 employees (age range 24 to 77) of the Veterans Affairs
Health Care System were mailed validated questionnaires inquiring about their symptoms
including bloating (Bowel Disease Questionnaire), QOL (SF-36) and physical activity (modi-
fied Baecke questionnaire). Results: The questionnaire response rate was 72%. Bloating was
reported by 149 (21%) subjects. More women than men reported bloating (23.6% vs. 16.9%;
p= 0.03); but after controlling for age this difference was not significant. With increasing
age, fewer subjects reported bloating (OR= 0.98; 95% CI 0.96-1.00; p= 0.03). Subjects with
bloating reported lower QOL on all subscales of the SF 36 (all p< 0.05). There were no
differences in any domain of physical activity scores (household, occupational, leisure-time,
sports or total activity) between subjects with and without bloating (Table). Among subjects’
with bloating, higher levels of leisure-time, sports and total activity were associated with
higher scores of the physical functioning and health perception domains of QOL (r varied
from 0.30 to 0.42, all p≤ 0.01). Conclusions: The prevalence of bloating diminishes with
older age and is not different between men and women. Individuals who experience bloating
report significantly lower QOL. Levels of physical activity do not appear to reduce the risk
of bloating. However, among individuals who experience chronic bloating, higher levels of
physical activity are associated with better QOL. These results suggest that increased physical
activity may reduce the impact of bloating but not the symptom itself.
The Effect of Physical Activity Scores on Bloating
T1252
Effect of a Water Load Test On Gastric Myoelectrical Activity and Upper
Gastrointestinal Symptoms in Patients with Nausea and Vomiting of
Pregnancy
Kenneth L. Koch, T. Murphy Goodwin, Roberto J. Romero, Max E. Levine, Heather Tison
Nausea and vomiting of pregnancy (NVP) is a common syndrome in which symptoms
predominate in the first trimester of pregnancy. Symptoms range from mild to severe and
afflict up to 80% of pregnant women. The underlying mechanisms of NVP remain poorly
understood. Provocative gastric function testing has not been performed in these patients.
AIMS of this study were to determine the effects of the water load test on gastric myoelectrical
activity, nausea, and other upper gastrointestinal symptoms in pregnant women. METHOD.
A sample of 46 women with NVP, ages 18-44 yrs (mean age= 28.2 yrs), at an average of
11.5 weeks of pregnancy were studied prospectively. Gastric myoelectrical activity was
recorded throughout the study with electrogastrogram (EGG) methods. A 15 min baseline
period was followed by a water load test during which the women ingested water until full
over a 5 min period. After the water load, an additional 30 min of EGG was recorded. EGG
responses were categorized into four groups: normal (2.5-3.7 cycles/min), bradygastria
(1.0-2.5 cycles/min), tachygastria (3.7-10.0 cycles/min), and mixed gastric dysrhythmia
(combination of tachygastria and bradygastria). Nausea, bloating, stomach fullness, and
abdominal discomfort were recorded before, and 10, 20, and 30 minutes after ingestion of
water on 100 mm visual analog scales. RESULTS. In response to the water load test, 14%
of the women exhibited normal EGG responses, while significantly more (86%) exhibited
gastric dysrhythmias (p<.01). Of the dysrhythmic EGG responses, 57% were tachygastria,
11% were bradygastria, and 18% were mixed gastric dysrhythmia. Patients with tachygastria
ingested less water (338.0 ml) than patients with normal (370.8 ml), bradygastria (415.0 ml),
or mixed gastric dysrhythmia (393.8 ml) patterns, but the differences were not statistically
significant. 46% of the women reported nausea at baseline; significantly more women (72%)
reported nausea after the water load test (p<.05). At 20 min after the water load test, a
significant, direct relationship was observed between nausea severity and tachygastria (p<.05).
The other upper gastrointestinal symptoms were not significantly increased by the water
load test. CONCLUSIONS. (1) 86% of the pregnant women in this sample developed gastric
dysrhythmias in response to the water load test. (2) Tachygastria was the most common
dysrhythmia, and increased tachygastria was correlated with increased nausea. Gastric
dysrhythmias are evoked by the water load test in women with NVP, suggesting these



















Cumulative Incidence of Chronic Constipation: A Population-Based Study
1988-2003
Rok Son Choung, Giles R. Locke, Cathy D. Schleck, Alan R. Zinsmeister, Nicholas J.
Talley
Multiple studies have assessed the prevalence of chronic constipation (CC), but few have
addressed its incidence. Recognition of incident cases is required to understand pathophysiol-
ogy. Aim: To estimate the cumulative incidence of CC and evaluate potential risk factors.
Methods: In past cross sectional studies beginning in 1988, random samples of Olmsted
County, MN residents have been mailed valid GI symptoms surveys. A new, valid GI
symptom survey was mailed in 2003 to all the remaining eligible (e.g. still alive) subjects
that had been mailed to previously. CC was defined by at least 2 of 4 chronic symptoms
(straining, hard or lumpy stools, incomplete evacuation, infrequent stools). An incident case
of CC was defined as no constipation or IBS on the first survey but developed constipation on
the second survey. Risk factors for incident constipation were assessed by logistic regression.
Results: 5507 (79%) subjects responded to a first survey and 2300 (55%) subjects responded
to a second survey in which chronic constipation could be defined. The median time between
the two survey responses was 10.5 years. Those with new onset constipation had a mean
age of 59 (±12) years and 54% were female. The incidence of the new onset constipation
differed by gender in the young (under age 50) but not in the elderly (over 70 years) (see
table). Previous GI symptoms, abdominal surgical history, history of GI infection, smoking,
alcohol use, marital status and educational level were not significant predictors for new
onset constipation. The subjects with abdominal pain but not constipation at baseline
were at increased risk of developing CC. Conclusion: The cumulative incidence of chronic
constipation over a decade is more than one in 10 but does not rise significantly in the
elderly. Why young men have a low incidence remains unknown.
Cumulative Incidence of Chronic Constipation (%, 95% CI)
T1254
First Community-Based Study of Functional Gastrointestinal Disorders
(FGID) in Mexico Using the Rome II Modular Questionnaire
Aurelio Lopez-Colombo, Dalia Bravo-Gonzales, Araceli Corona-Lopez, Maria Elena Perez-
Lopez, Manuel Cervantes-Ocampo, Teresita Romero-Ogawa, Douglas Morgan, Max
Schmulson
Aims: The prevalence of FGID in Mexico is unknown. We recently found an unexpectedly
high frequency of IBS (35%) in volunteers in Mexico City using the Rome II modular
Questionnaire.(1) We sought to establish the prevalence of FGID in Mexico in a community-
based study. Methods: The State of Tlaxcala in central Mexico with a population of nearly
1 million inhabitants in 60 cities and villages, was chosen for the survey. We sampled 500
subjects (0.05%) from 500 households based on the registry of the National Institute of
Statistics and Geography (INEGI). Village population determined the number of households
recruited locally. Two physicians used the validated Spanish-Mexico Rome II Modular
Questionnaire with the first available adult of each sampled household. Additional question-
naire components included income, medical consultations, GI medications, and a depression
scale (CES-D). The CES-D is a short regionally validated self-rating scale designed to rate
depressive symptoms as absent, mild or severe. Results: Mean subject age was 40 years of
which 61% were females. Reported occupations: 44% Homemakers, 23% Office Employees,
20% Self Employed, 6% Students, 4% Laborers, 3% Others. The table summarizes FGID
prevalence. One or more FGID was found in 58%. The FGID group reported higher frequen-
cies of medical visits (35 vs. 17%) and GI medications (41 vs. 22%), both p<0.001. Also,
mild (9 vs. 3%) and severe (17 vs. 3%) depression was more frequent in FGID subjects,
p<0.001. Female predominance was more frequent in IBS (77 vs. 58%, p=0.001), IBS-C
(88 vs. 59%, p=0.001) and in Fxnl Bloating (76 vs. 59%, p=0.017), compared to those not
fulfilling criteria for these FGID. In IBS the F:M ratio was 3.4:1. Older age was found among
Fxnl Incontinence (48, p=0.005) and Levator Ani (55, p=0.016). Conclusions: This is the
first community-based study of the prevalence of FGID in Mexico by Rome II criteria,
showing similar frequencies to those reported in other global populations. These subjects
report higher frequency of medical consultations, GI medication use and depression as well.
Refs: 1. Schmulson M et al. Dig.Dis. in press.
FGID Prevalence in Mexico, Community-Based Survey. Expressed in percent (95% C.I.)
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The Bi Omnibus Study: An International Survey of Community Prevalence of
Constipation and Laxative Use in Adults
Arnold Wald, Michael Kamm, Stefan Mueller-Lissner, Carmelo Scarpignato, Wolfgang
Marx, Chris Schuijt
Reported prevalence of constipation range is 4-28%, depending on definitions and methods
used, making comparisons between countries difficult. To determine prevalence in a large
community, self definition of constipation is important and use of a standard questionnaire
is mandatory. AIM: To determine prevalence and demographics of constipation in 7 countries.
METHODS: Representative samples of approximately 2000 persons in each of US, UK,
Germany (GE), France (FR), Italy (IT), Brazil (BR), and South Korea (SK) were administered
a standard questionnaire. Questions concerned occurrence, duration and frequency of con-
stipation as well as treatment duration and frequency of laxative use by constipated persons.
RESULTS: Of 13,958 persons interviewed, 12.4% reported constipation in previous year.
This varied among countries, gender and age.
Table 1
In all countries, more women than men had constipation (OR2.43; CI 2.18-2.71) and except
for SK, age 60+ yr had more constipation than <30 yr (OR 1.5; CI 1.25-1.73). Over 70%
of constipated had constipation at least every 3 months; percentages of weekly constipation
were highest in BR, SK, IT (36-59%); those with daily constipation were highest in BR
(19%), lowest in US, SK, GE (5-7%).
Table 2
Laxative use (GE=1;) was highest in US (OR 1.69; CI 1.04-2.74), lowest in SK (OR 0.56;
CI 0.32-0.97); and similar in others. Use of laxatives increased with age (60+ vs <30 yrs =
OR 1.63; CI 1.14-1.64). CONCLUSIONS: Prevalence of self defined constipation varies
among countries and is related to gender and age in all but SK. Laxative use is highest in
US, lowest in SK and is influenced by age but not gender, duration and frequency of
constipation in all countries.
T1256
What Causes Functional Dyspepsia with Overlapping Symptoms?
Zhiqiang Song, Meiyun Ke, Zhifeng Wang, Xiaohong Xu
BACKGROUND: Overlapping of gastrointestinal symptoms is very common in patients with
functional dyspepsia (FD). It remains unknown what causes FD with overlapping symptoms
(OS). Exploring whether other differences exist between FD patients with and without OS
will facilitate us to understand the possible mechanisms. AIMS: To investigate the differences
between the functional dyspeptics with and without OS at the aspects of demographic
characteristics, symptomology, pathophysiology, quality of life, psychological and sleep
status. METHODS: Eighty-two patients with FD (24M, 58F, mean age 45yr) surveyed with
Rome II Modular Questionnaire are divided into two groups: the patients without OS (only
dyspeptic symptoms) and with OS (esophageal, intestinal or anorectal symptoms). The data
including demographic characteristics, dyspeptic symptoms subtypes (ulcer-like, dysmotility-
like, nonspecific) and severity scores (mild-1, moderate-2, severe-3), quality of life (SF-36),
psychological status and sleep status (4-Likert scale) were recorded. The tests including
liquid nutrient test (LNT), solid gastric emptying (GE, radiopaque makers and scintigraphic
evaluation), multi-channels electrogastrography (MEGG) and autonomic nerve system (ANS)
were performed. RESULTS: (1) The proportion of the patients with and without OS accounts
for 63% and 37%, respectively. (2) The two groups are matched in sex, age, BMI, occupation,
education, marital status, economical status, working and living stress (P>0.05). (3) No
statistical differences are found in two groups at the aspects of symptom subtypes distribution
and severity scores (P>0.05). (4) No statistical differences exist in any index related to the
tests of LNT, GE, MEGG and ANS (P>0.05). (5) However, the psychological status of the
patients with OS is much worse (disturbed mildly 10%, moderately 48%, severely 15%)
than that of the patients without OS (27%, 10%, 10%, respectively, P<0.05). The same
difference is also found in the sleep status (with OS: disturbed mildly 19%, moderately
35%, severely 29% vs. without OS: 30%, 17%, 13%, respectively, P<0.05). The quality of
life of the patients with OS is worse in the dimension of physical functioning, role limitations
due to physical health and general health (P<0.05). CONCLUSIONS: The same features exit
in demography, symptomology and pathophysiology between the functional dyspeptics with
and without OS. The worse psychological and sleep status and quality of life in the patients
with OS give us a hint that psychological factors are maybe involved in the mechanisms
underlying OS and the treatment of psychological support and improving sleep is necessary.
T1257
Elevated Breath Methane in Constipation
Syed I. Thiwan, Olafur S. Palsson, Marsha J. Turner, William E. Whitehead
Background: Increased methane production was reported in patients with constipation or
IBS-constipation. In animal studies, methane was shown to slow intestinal transit. Aims:
To compare breath Ch4 and H2 at baseline (fasting) and following a carbohydrate meal in
healthy controls, and patients with lactose malabsorption, IBS (without constipation) and
slow transit constipation. Methods: 80 subjects (10 males, 70 females, 25 Healthy, 25 IBS,
23 lactose malabsorbers and 7 constipated) underwent hydrogen breath test with 50g of
lactose and 80g of sucrose on an empty stomach in the morning. Breath samples for H2
and Ch4 were collected at baseline and every 15 min until 120 min and then every 30 min
up to 180 min. Breath H2 and Ch4 were analyzed using a Quintron Microlyzer model SC.
Patients with constipation underwent Sitzmark study for assessment of colonic transit time.
Analysis: One way ANOVA with Bonferreni correction was used to compare baseline as
well as area under the curve (AUC) of H2 and Ch4. Results: Baseline Ch4 levels were
significantly higher in constipation compared to IBS and was not significantly lower in IBS
compared to healthy controls (p<0.05). Constipated patients also had significantly elevated
Ch4 in response to the sugar load, compared to healthy controls and IBS (p<0.05). Mean
colonic transit time among constipated subjects was 97.4hrs (77-115hrs). The transit time
tended to correlate with AUC of Ch4 (r=0.48), but this was not statistically significant in
7 subjects. Baseline H2 was not statistically different between the different groups but as
expected, both H2 production and peak H2 level were significantly higher in subjects with
lactose malabsorption compared to other groups (p<0.001). Conclusions: Increased Methane
production is associated with constipation. Further experiments are needed to determine
whether this association is due to methane inhibiting intestinal motility or whether delayed
colonic transit facilitates the colonization of the colon with methanogenic bacteriae (i.e.
whether elevated methane is a cause or consequence of constipation). [Supported by Novartis
Pharmaceuticals and grants R24 DK67674 and RR00046.]
(a = vs. H, IBS, C p<0.05; b = vs. IBS p<0.05; c = vs. H, IBS p<0.001)
T1258
Possible Role of Intraluminal Gas Production On Functional Gastrointestinal
Disorders
Yoshihisa Urita, Susumu Ishihara, Kenichiro Arai, Jun Kondo, Tastuo Akimoto, Hiroto
Kato, Noriko Hara, Hideyuki Koshino, Yoshiko Honda, Yoko Nagai, Kazushige Nakanishi,
Nagato Shimada, Motonobu Sugimoto, Kazumasa Miki
Background: The presence of carbohydrates in the colonic lumen inhibits gastric and pancre-
atic secretions, and also influences lower esophageal sphincter function. Based on the fact
that 2-20% of carbohydrates escape small intestinal absorption, colonic fermentation is
considered to be present more frequency than expected and may result in various gastrointes-
tinal symptoms. It is still unclear whether patients with functional gastrointestinal disorders
have gastrointestinal fermentation more frequently. Because bacteria represent the sole source
of gut hydrogen (H2) and methane (CH4), fasting breath H2 and CH4 gases have been
used as markers of gastrointestinal fermentation. The aim of this study is to determine
whether fermentation in the digestive tract may associate with developing gastrointestinal
symptoms. Patients and Methods: A total of 53 patients (mean age 65 years, male/female=
9/44) diagnosed with functional dyspepsia according to the Rome II criteria were recruited
in the study. At endoscopy, intragastric and intraduodenal gas samples were taken for
measuring hydrogen and methane concentrations. Gastric emptying was measured with
13C-acetate breath test. After overnight fasting, the patient received a liquid test meal
(200kcak, 200ml), containing 100mg of 13C-acetate. Breath samples were collected at 10-
min intervals of 120min and gastric emptying were expressed as the time of peak 13CO2
excretion (Tmax). Results: Nineteen patients (36%) had delayed gastric emptying (Tmax>90-
min). Of these 19 patients, a high hydrogen level (more than 10ppm) of fasting breath,
intragastric and ntraduodenal samples, was detected in 3. 21. and 21%, respectively. A high
methane level (more than 10ppm) of three samples was found in 6, 15, and 6%, respectively.
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Among 34 patients with normal gastric emptying, 13 (25%) had high hydrogen and/or
methane levels of at least one sample. In 9 patients (17%) with FGID, Tmax in 13C-acetate
breath test and hydrogen and methane levels of all samples were normal. Conclusions:
Delayed gastric emptying was found in only 36% of patients with FGID, whereas enhanced
hydrogen or methane production in the digestive tract was detected in 42%. This suggests the
association between enhanced fermentation in the digestive tract and abdominal symptoms in
patients with FGID.
T1259
Familial Aggregation of IBS Is Specific to IBS
Yuri Saito, Jamshid S. Kalantar, G. R. Locke, Alan R. Zinsmeister, Nicholas J. Talley
Purpose: IBS has been observed to aggregate in families—17% in IBS relatives versus 7% of
spouse control relatives (Gut 2003;52:1703-7). Whether other functional and non-functional
gastrointestinal disorders cluster in families is unknown. Because of the overlap between
IBS and other disorders, we hypothesized that there would be an increased frequency of
other functional gastrointestinal disorders in first-degree relatives of IBS patients compared
with relatives of controls (the patient’s spouse). Methods: Patients attending an IBS educa-
tional program and residents of Olmsted County, Minnesota, who had been coded as IBS
on a database and their spouses were mailed a validated self-report Bowel Disease Question-
naire (BDQ) including a somatic symptom checklist and a family information form (FIF).
A BDQ was mailed to all first-degree relatives of subjects identified from the FIF. The
prevalence of Gastroesophageal Reflux Disease (GERD), Functional Dyspepsia (FD), Func-
tional Constipation (FC), Functional Diarrhea (Fdi), and Functional Bloating (FB), based
on standard criteria, were calculated in patient relatives and spouse control relatives. Results:
The BDQ was sent to a total of 303 eligible relatives, of which 73% responded. Relatives
were comparable in mean age, sex distribution, and somatization score. The prevalence of
the above disorders in IBS relatives and spouse control relatives are shown in the table
below. Except for FB and FC, the prevalence of GERD, FD, and FDi were similar between
the two relative groups. Conclusions: Familial aggregation of IBS had previously been shown
in this dataset. Except for constipation, aggregation of other gastrointestinal disorders was
not observed suggesting that aggregation of IBS symptoms is specific for IBS cases compared
with controls. This suggests that IBS (and FC) may be a distinct entity separate from other
functional disorders.
*LR = Logistic Regression model accounting for correlation within families †adjusting for
age, gender, and somatization
T1260
Anxiety and IBS: Influence On Severity of Symptoms, Consultation and
Quality of Life
Marta Moreno Ortega, Monica Garcia Alonso, Enrique Rey, Manuel Diaz-Rubio
Anxiety is associated with IBS, although it is unclear its actual role. Anxiety is considered
to be related to consultation behaviour. AIM: We aim to answer the following questions: is
severity of IBS symptoms related to anxiety level? Is anxiety associated to consultation
behaviour independently of severity of IBS symptoms? And how is the impact of anxiety
and severity of symptoms on HRQL? MATERIAL&METHODS. We targeted a population of
IBS subjects representative of the full spectrum of the disease. For this purpose, symptomatic
patients with the diagnosis of IBS were recruited from primary care and gastroenterologist
office, and non consulters IBS subjects were recruited from the general population. All
subjects (consulters and non consulters) must fulfil Rome II criteria for IBS to be included.
All subjects completed a clinical questionnaire, including health resources use. Severity of
IBS symptoms was evaluated using the functional disease severity index (FDSI); anxiety was
evaluated as state anxiety and trait anxiety using the STAI questionnaire. HRQL was assessed
with SF-36. Correlation was evaluated by Pearson coefficient. To evaluate factors associated
with consultation, a logistic regression model was constructed including state anxiety, trait
anxiety and FDSI as factors, adjusting by age and sex. Impact of anxiety (state and trait)
and severity of symptoms on each subscale of SF36 was evaluated using a multiple lineal
regression model, adjusting by age and sex RESULTS. We included 110 subjects, 52 IBS
non consulters and 60 IBS consulters (85 women, mean age 40; range 18-73) IBS consulters
suffered more severe symptoms (19 mild, 28 moderate and 13 severe symptoms) than non
consulters (41 mild 11 moderate symptoms). There were no correlation between FDSI
and state anxiety (r=0.07) or trait anxiety (r=0.15) even adjusting for consultation (partial
correlation coefficients -0.07 and 0.08, respectively). Consultation was independently associ-
ated with FDSI (adjusted OR 1.04 [1.02-1.06]) and state anxiety (1.03 [1.01-1.05]). In
multiple linear regression model Physical Subscale of SF36 was associated with FDSI (Beta=-
0.41; p<0.0001) and age (Beta=-0.28; p=0.001); Mental Subscale of SF36 was associated with
trait anxiety (Beta=-0.49; p<0.0001) and state anxiety (Beta=-0.28; p=0.002). CONCLUSION.
Severity of IBS symptoms are not related to the degree of anxiety. Both severity of symptoms
and anxiety are independently linked to consultation. Severity of symptoms and anxiety
affect different aspects of HRQL. Supported by a Grant from FIS: PI03521 (Carlos III


















Additive Effect of Pathophysiological Abnormalities On Gastrointestinal
Symptoms in Patients with Irritable Bowel Syndrome (IBS)
Magnus Simren, Hans Strid, Iris Posserud, Amanda Ersryd, Pia Agerforz, Anette Lindh,
Henrik Sjovall, Hasse Abrahamsson
Background: Both central and peripheral factors are thought to contribute to the symptoms
of IBS, including psychosocial factors, abnormal gastrointestinal (GI) motility and secretion,
and visceral hypersensitivity. The relative importance of these pathophysiological factors for
GI symptom pattern and severity is largely unknown. Methods: We included 79 IBS patients
fulfilling the Rome II criteria for IBS (56 females; mean age 36 (19-62) years). They all
underwent investigations to assess GI motility (stationary antroduodenojejunal manometry
and oroanal transit time, OATT), secretion (jejunal mucosal potential difference) and visceral
hypersensitivity (rectal sensitivity testing using an electronic barostat). Abnormal findings
were defined based on normal values obtained at our lab and internationally accepted criteria
(manometry).The patients also completed the Hospital Anxiety and Depression scale to
evaluate the presence of clinically significant anxiety and depression (score≥11). Gastrointes-
tinal Symptom Rating Scale (GSRS) was used to assess GI symptom severity. Results: All
patients but 8 had at least one pathophysiological alteration - small intestinal dysmotility
was seen in 51% of the patients (at least mild severity), abnormal jejunal secretion in 37%,
rectal hypersensitivity in 51%, anxiety and/or depression in 32%, accelerated OATT in 27%
and delayed OATT in 5%. Patients with rectal hypersensitivity vs. normal sensitivity had
more severe overall GI symptom severity (GSRS Total score: 3.6±0.8 vs. 2.9±0.6 (mean±SD);
p<0.0001), and more severe abdominal pain (p<0.0001), indigestion (p=0.001), reflux (p=
0.04) and satiety (p<0.0001). The presence of anxiety and/or depression was also related
to more severe overall GI symptom severity (3.7±0.8 vs. 3.1±0.8; p=0.006), as well as more
severe abdominal pain (p=0.04), constipation (p=0.01) and reflux (p=0.01). Patients with
abnormal jejunal secretion tended to have more severe overall GI symptom severity (p=
0.05) and more severe abdominal pain (p=0.04). Accelerated OATT was related to more
severe diarrhea (p=0.004) and delayed OATT with constipation (p=0.02). Small intestinal
dysmotility was unrelated to GI symptom severity and pattern. With increasing number of
pathophysiological alterations a gradual increase in the overall GI symptom severity was
found (p=0.009). Conclusion: Visceral hypersensitivity and psychological factors seem to
be the strongest predictors for GI symptom severity in IBS. The pathophysiological factors
in IBS seem to have an additive effect on GI symptom severity.
T1262
Idiopathic Bile Acid Malabsorption Is Prevalent in Patients with the Irritable
Bowel Syndrome (IBS)
Antal Bajor, Hans Strid, Jenny Wallin, Kjell-Arne Ung, Hasse Abrahamsson, Magnus
Simren
Background: Irritants within the gut may play a role in the pathophysiology of IBS. One
class of such irritants may be bile acids not being reabsorbed in the terminal ileum, but
leaking into the colon. In patients presenting with chronic diarrhea idiopathic bile acid
malabsorption (IBAM) is present in up to 40%, but the prevalence of IBAM in IBS is
unknown. The SeHCAT retention test is a reliable indirect method for the diagnosis of bile
acid malabsorption. Aims: To study the occurrence of IBAM in IBS patients and in the
different IBS subgroups based on the predominant bowel habit. The secondary aim was to
investigate whether symptoms are correlated to the SeHCAT values. Methods: IBS patients
fulfilling the ROME II criteria referred to our centre has been consecutively included in the
study, irrespective of the bowel habit of the patient. All patients completed the Bristol Stool
Form scale daily during a week for registration of stool frequency and consistency. They
also performed a SeHCAT test and a value of ≤10% on day 7 was considered abnormal.
Results: Forty-nine Rome II positive IBS patients were included (mean age 38 (20-72) years;
36 females). Of these, six patients had predominantly constipation (C-IBS), 22 diarrhea (D-
IBS) and 21 alternating bowel habits (A-IBS). A SeHCAT value ≤10% on day 7, compatible
with a diagnosis of IBAM, was found in13 patients (27%). In the IBS subgroups IBAM was
demonstrated in 8 patients with D-IBS (37%), in 5 patients with A-IBS (24%) and in
none the C-IBS group. The SeHCAT retention values differed significantly between the IBS
subgroups, p=0.02, with C-IBS patients having a median value of 54%, D-IBS 15% and A-
IBS 19%. There was no significant difference between the D- and A-IBS groups. Weak, but
statistically significant correlations between SeHCAT values and the stool frequency (R=
0,35, p=0.02) and consistency (R=0.34, p=0.02), respectively, were demonstrated. However,
no clear “cut-off” level regarding stool consistency and frequency predicting an abnormal
SeHCAT could be found. Conclusion: Idiopathic bile acid malabsorption is common in IBS
patients with diarrhea predominance, but also in patients with alternating bowel habits.
Stool consistency or frequency can not be used to reliably predict the presence of IBAM in
IBS. Ongoing studies using bile acid binding agents to treat IBS patients with IBAM will
further evaluate the clinical relevance of IBAM in IBS.
T1263
Performance Characteristics of a [13C]-Spirulina Platensis Gastric Emptying
Breath Test
Lawrence A. Szarka, Michael Camilleri, Duane D. Burton, Robert F. Martin
Background: Previous clinical trials of [13C]-Spirulina platensis gastric emptying breath test
(GEBT) utilizing variable meal compositions have demonstrated accuracy similar to scinti-
graphy. The validation of a [13C]-Spirulina platensis GEBT based upon a standardized meal
preparation consisting of only shelf-stable components would be greatly desirable. Aim: To
estimate the total variability of simultaneous scintigraphic and GEBT measurements in normal
human subjects in order to appraise performance characteristics of the GEBT. Methods:
Twenty healthy volunteers underwent assessment of gastric emptying in duplicate studies
using a dual-labeled test meal consisting of 100 mg [13C]-Spirulina platensis, 0.5 mCi 99mTc
sulfur colloid, 27 g freeze dried egg mix, 6 saltine crackers, and 6 oz water. The test meal
has a caloric content of 238 kcal. Breath samples and scintigraphic images were obtained
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at 45, 90, 120,150, 180, and 240 minutes after ingestion of the test meal. Tests were repeated
within a median interval of 10 days. The primary transit parameter for breath test is the
percent dose of carbon-13 excreted (PCD) multiplied by 1000 to produce kPCDt at any
time t. At respective times, the primary transit parameter for scintigraphy was percent
emptied from the stomach using decay corrected, geometric mean data from anterior and
posterior gamma-camera images. Coefficient of variation at each time point was calculated
within and between individual participants for the primary transit parameters for the two
tests. Results: The inter- and intra-subject coefficients of variation (%) of the breath test and
scintigraphy between 45 and 150 minutes were similar (table). At measurement times greater
than 150 minutes, scintigraphic coefficients of variation are reduced (truncated) as a greater
fraction of results reach the 100% emptied limit. Conclusions: The data suggest that gastric
emptying results for [13C]-Spirulina platensis breath test are generally as reproducible as
those for scintigraphy and that imprecision within and between individuals reflects normal
physiologic variation with both tests.
T1264
Impaired Drinking Capacity in Patients with Functional Dyspepsia:
Relationship with Intragastric Distribution
Bram D. Van den Elzen, Roel J. Bennink, Breg Braak, Guido N. Tytgat, Guy E.
Boeckxstaens
Introduction: We previously demonstrated that the impaired drinking capacity in patients
with functional dyspepsia (FD) could not be explained by altered proximal stomach function.
To what extent abnormal distal stomach function or an altered intragastric distribution could
explain the impaired drinking capacity in FD is unclear. Therefore, we determined gastric
volumes after a drink test using SPECT imaging. Methods: After a baseline scan 20 HV (13f)
and 18 FD (5f) underwent a drink test (100 ml/min) followed by SPECT scanning. A Mann-
Whitney U test (p<0.05) was used for statistical analyses. Results: Baseline gastric volumes
measured by SPECT were significantly higher in FD compared to HV for total (351 ± 18
ml vs. 225 ± 18 ml; p<0.001), proximal (264 ± 9 ml vs. 184 ± 12 ml; p<0.001) and distal
stomach (87 ± 12 ml vs. 41 ± 8 ml; p<0.001). FD ingested significantly less water compared
to HV (1148 ± 143 ml vs. 1818 ± 153 ml; p<0.001). The gastric volume increase induced
by the drink test was significantly different between HV and FD for total (2181 ± 149 ml
vs. 1500 ± 140 ml; p=0.006), proximal (1671 ± 115 ml vs. 1266 ± 119 ml; p=0.035) and
distal stomach (564 ± 48 ml vs. 234 ± 33 ml; p<0.001). There was a good correlation
between the ingested amount of water and the increase in gastric volumes measured by
SPECT (HV 0.61; p=0.004 and FD 0.88; p<0.001). The ingested water was differently
distributed with proportionally more ingested volume in the distal stomach of HV compared
to FD (fig. 1) and this resulted in a difference in proximal/distal stomach volume ratio for
FD compared to HV (6.4 ± 1.3 vs. 3.3 ± 0.4; p=0.001). Conclusion: These data suggest
that drinking capacity is mainly determined by antral volume, with a reduced antral filling
in FD compared to HV at maximal ingested volume. Whether this is due to an altered antral
compliance or an increased antral sensitivity for distension remains to be studied.
T1265
Distinguishing IBS Defined By the Manning Criteria from IBS Defined By the
Rome II: Does Manning in the Absence of Rome Really Identify a Different
Disorder?
Rok Son Choung, Nicholas J. Talley, Giles R. Locke, Yuri A. Saito, Cathy D. Schleck, Alan
R. Zinsmeister
Irritable bowel syndrome (IBS) diagnosis is based on positive symptom criteria; however,
more people meet the Manning criteria than the Rome criteria in population-based and
clinical studies. Some have argued that those fulfilling Manning but not Rome criteria still
have IBS, but the characteristics of this subpopulation have never been defined. Aim: To
determine if those with Manning but not Rome II criteria differ from those with Rome II for
IBS in the community. Methods: A population-based, cross-sectional survey was conducted by
mailing a valid and reliable questionnaire to an age- and gender- stratified random sample
of residents of Olmsted County, MN, aged 30 - 95 years (response rate 55%). Manning was
defined as abdominal pain plus 2 or more of 6 symptoms. IBS prevalence estimates were
calculated for Rome II and Manning criteria, and subjects were categorized as ‘Rome II (+)
or Manning (+)/Rome II (-) based on their symptom status. A logistic regression model was
used to estimate the odds ratios (OR [95%CI]) for Rome II (-) vs (+) in subjects that met
Manning criteria. Results: Among the 5119 subjects for which full data were available, 862
(17%) met Manning criteria, while 620 (12%) met Rome II criteria. Those subjects (N=242)
with Rome II (-) and Manning (+) had a mean age of 60 years; 67% were female. Demographic
characteristics were all similar in this group vs. Rome II subjects. Positive predictors for
subjects with Rome II (-) and Manning (+) compared to Rome II (+) were hard stools (OR
4.20 [3.06 - 5.76]), straining (OR 4.19 [3.01 - 5.83]), and less frequent stools (OR 2.06
[1.15 - 3.69]) (table). Negative predictors were loose or watery stools (OR 0.30 [0.21 -
0.44]) and urgency (OR 0.42 [0.30 - 0.58]). Severe and moderate pain severity were modest
negative predictors for Rome II (-) and Manning (+) subjects. Conclusions: Discordant
subjects with Rome II (-) but Manning (+) have similar demographic characteristics compared
to those fulfilling Rome II (+) IBS, but they were more likely to report constipation type
symptoms. Hence, Manning criteria may identify more people with the constipation subtype
of IBS missed by Rome II. Supported in part by an unrestricted grant from Novartis.
Individual symptoms that were independent predictors in different definitions of IBS
% is column percentage, OR calculated by row %
T1266
Exploring Epidemiology of Irritable Bowel Syndrome to the Middle Teen-Ager
Yuka Endo, Shin Fukudo, Yuko Kimura, Tomotaka Shoji, Kazuto Karahashi, Yasuhiro
Sagami, Joe Morishita, Michio Hongo
BACKGROUND & AIMS: Most of patients with irritable bowel syndrome (IBS) have IBS
symptoms since their middle teen ages. However, the prevalence and the features of adolescent
IBS were generally lacking. The objective of this research was to know the features of
adolescent IBS in Japan. SUBJECTS & METHODS: We randomly selected Junior high school
students in Miyagi prefecture, Japan according to population of each area. The response
rate was 76.9%, 833 boys and 888 girls (age: 15 y.o.) participated in this study. They
fulfilled self-reported questionnaires those include Rome-II Modular Questionnaire (RIIMQ),
Self-reported IBS Questionnaire (SIBSQ) based on Rome-II criteria, Generalized Self-Efficacy
Scale (GSES), SF-36 and other questions on their lives. RESULTS: One hundred and six boys
(12.7%) and 145 girls (16.3%) were diagnosed as IBS by Rome-II Modular Questionnaire. IBS
students had lower scores in GSES (p<0.0001) and every SF-36 subscales (p<0.0001,
respectively) than control students those have no abdominal symptoms (boys: n=214, girls:
n=148). No IBS students consulted hospital frequently because of IBS symptoms in the
present or in the past. Distribution of their resident area showed no significant difference
between IBS students and controls. IBS students complained sleep disturbance more often
than controls, especially initial insomnia (p=0.0007), difficulty in staying asleep (p=0.0005),
lack of satisfaction with sleep (p=0.0036) and short sleeping time (p<0.0001). IBS students
had more traumatic episodes and felt their lives more stressful than controls (p<0.0001,
respectively). IBS girls had more traumatic episodes (p=0.0332) and felt more stressful in
their lives (p=0.0407) than IBS boys. There were no significant differences in types of sleep
disturbances except initial insomnia between IBS boys and IBS girls. In IBS symptoms of
modular questionnaires, IBS girls had significantly severer symptoms in hard stool (p=
0.0004), strain (p=0.0312) and abdominal distension (p=0.0023) than IBS boys and IBS
boys had significantly severer symptoms in diarrhea (p=0.0116). Also, IBS girls showed
severer soft stool (p=0.033), abdominal distension (p=0.0012), stress (p=0.0007) and exag-
geration of symptoms under stress (p=0.0268) in a preceding week than IBS boys. In SF-
36, IBS girls had higher PF scores (p=0.0367) and lower MH scores (p=0.0239) than IBS
boys. CONCLUSION: Prevalence and some features of adolescent IBS have unique characters.
Further analysis of adolescent IBS may contribute to prophylaxis of functional gastrointesti-
nal disorders.
T1267
Functional Disorders (FD): One Or Many? A Longitudinal, Observational
Study of Patients (PTS) with FD in Binghamton, NY
Marcelo A. Barreiro, Gary D. James
Background: Functional Gastrointestinal Disorders (FGID) frequently coexist in pts with
other FD. Whether FGID are the gastrointestinal manifestations of a more generalized
syndrome that can produce symptoms referred to multiple organ systems, or whether
multiple FD are all separate clinical conditions which may occur as “comorbidities” is not
known. Objectives: To evaluate: 1) the characteristics of pts who present with multiple FD;
2) whether multiple FD present like a syndrome; and 3) whether there is a relationship
between the number of coexisting FD and psychological symptoms, health related quality
of life (HRQOL) and pain experience. Materials and Methods: The Disorders of Function
Clinic was created to address the needs of patients with any FD, trying to avoid subspecialty
bias. Pts were >18 years of age and without concurrent organic disease that could interfere
with their evaluation. All pts signed informed consent. Published symptom-based diagnostic
criteria were used to determine FD. Psychological symptoms were evaluated using the SCL-
90-R, and HRQOL was measured using the QOL Inventory (QOLI). Pain severity was
evaluated using a 10 cm Visual Analog Scale and was characterized as visceral or somatic.
Associations between the psychological symptom, QOL, pain and the number of FD were
evaluated using ANOVA and correlations. Results: A total of 183 patients were evaluated,
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167 of which presented with FD (mean age 47.0±13.0 years). Of these, 143 were female
(78 %) and 145 (87 %) presented with at least 3 FD (OR 6.57, CI 95 % 4.45-11.35,
p<.0001), far exceeding the possibility of association by chance. The most frequently observed
syndromes (Psychiatric Disorder 76 %, Chronic Fatigue Syndrome 74.3 %, Fibromyalgia
73.1% and Irritable Bowel Syndrome 63.5 %) tended to group together and formed a cluster
separate from other FD. In evaluating the SCL-90-R Global Severity Index, pts with 1-2 FD
had a significantly lower score than those with 3 or more FD (61.75 vs 67.17, p <.007).
They also had a higher QOLI Raw Score (2.07 vs 0.85, p<.013). Pain severity and type
were not related to type or number of coexisting FD. Conclusions: In pts seeking care in a
specialized clinic for FD: 1) The majority of pts are women. 2) Multiple FD coexist in the
same patient with a frequency that far exceeds chance, suggesting a common pathogenesis,
and 3) The more FD that coexist in a pt the more severe the psychological symptoms and
the poorer the QOL.
T1268
Is High-Frequency Gastric Electrical Stimulation Effective in Patients with
Chronic Functional Nausea and Vomiting and a Normal Gastric Emptying?
Richard W. McCallum, Zhiyue Lin, Irene Sarosiek, Jameson Forster
Previous reports have shown that long-term gastric electrical stimulation (GES) can improve
symptoms and quality of life in up to 70% of patients with refractory gastroparesis. The
aim of this study was to investigate the effectiveness of GES (Enterra™ Therapy) in patients
with symptoms suggestive of gastroparesis but who had a normal gastric emptying and were
given the diagnosis of functional nausea and vomiting not responding to standard approaches.
Methods: We studied 15 such patients (3M, 12F, median age: 41 years, 5 diabetic and 10
idiopathic) who had a documented normal baseline 4-hour gastric emptying test (GET)
(normal value at 4 hours <10% gastric retention) and received GES therapy for at least 1
year. The GET, total symptom score (TSS) derived from 7 upper GI symptom sub-scores
(0-4), quality of life (QOL) using SF-36 Health Status Survey questionnaire including physical
composite score (PCS) and mental composite score (MCS) and nutritional status were
evaluated at baseline and at 1 year of GES administrated according to our previous publica-
tions in gastroparesis (Am J Surgery 2001;182:676-81). Results: Of the 15 patients, 1 died
at 4 months from complications of misdiagnosed anorexia nervosa and 1 had her device
removed at 2 months due to infection in the pulse generator pocket. Results of 2- and 4
hour gastric retention, nausea, vomiting scores, TSS and weight at baseline and 1 year for
the remaining 13 patients are summarized in the table below. Overall there was no significant
change in GET and approximately 67% patients continued to have a normal GET after 1
year. However, one third of patients did develop a slowing of GET (>10% retention at 4
hours). Symptom severity of nausea, vomiting and TSS were significantly improved. 62%
of patients had ≧50% reduction in TSS and the median reduction of TSS was 51%. Median
PCS was significantly improved from 21.5 at baseline to 37.8 after 1 year but not MCS
(43.2 vs. 44.0). Weight remained stable. At implantation, 4 of the 13 patients required
enteral feeding tubes for nutritional support and only one continued after 1 year for infrequent
hydration needs. Conclusions: In patients with a normal GET and functional nausea and
vomiting high-frequency GES is effective in improving upper GI symptoms, QOL and
nutritional status with a good safety profile. These data extend the indications for GES
therapy in patients with chronic nausea and vomiting.
T1269
Autonomic Nervous System Function During Sleep in Women with Irritable
Bowel Syndrome
Monica E. Jarrett, Robert L. Burr, Kevin C. Cain, Anne P. Poppe, Margaret M. Heitkemper
Objective: Autonomic nervous system (ANS) functioning may be linked to predominant
bowel pattern in irritable bowel syndrome (IBS). In this study we examined the differences
in ANS function during sleep between IBS and Controls, as well as among predominant
stool patterns within the IBS group. Methods: 36 IBS and 40 Control participants slept for
3 nights in a research sleep laboratory. ECG-based R-R interval sequences were recorded
in synchrony with a standard polysomnographic montage. Time and frequency domain
HRV measures were computed to assess parasympathetic tone (lnRMSSD and lnHF) and
sympathetic/parasympathetic balance (SDratio and sqrtLF/HF). Sleep was broken down into 4
sleep periods of successive NREM (non-rapid eye movement) and REM (rapid eye movement)
across the night. The mean values across the 3 nights were computed. Rome II criteria were
used to differentiate predominant bowel pattern (diarrhea [n = 13], constipation [n = 9],
alternators [n = 14]). Results: There were no differences in parasympathetic tone or sympath-
etic/parasympathetic balance between the IBS and Control groups across the 4 sleep periods,
or during NREM and REM sleep. However, within the IBS group, those who were diarrhea
predominant had significantly higher levels of parasympathetic tone and lower levels of
sympathetic/parasympathetic balance than those who were constipation predominant or
alternators during both NREM and REM phases. Conclusions: These findings support a
relationship between ANS functioning and predominant bowel pattern in IBS during sleep.

















P* controlling for age.
T1270
Irritable Bowel Syndrome in South Korea: Prevalence, Symptom Patterns and
Risk Factors
Chang Hwan Choi, Sang Yon Hwang, Geun Jun Ko, Chang Woo Gham, Ki Joon Han,
Hyeon Geun Cho
BACKGROUND: Irritable bowel syndrome (IBS) is a common health problem affecting a
substantial proportion of the population. The aim of this study was to evaluate the prevalence
of IBS that satisfied ROME II criteria, and to determine the risk factors associated with this
prevalence and probable risk groups in South Korea. METHODS: A total of 2345 subjects
(1298 males and 1047 females) who have visited the Health Promotion Center of Kwandong
University College of Medicine, Myongji hospital in South Korea from March 2005 through
August 2005 were included in this study. They were interviewed by using a questionnaire
comprising demographic features and ROME II criteria for the diagnosis of IBS. The preval-
ence of IBS was analyzed according to various factors such as demographic characteristics,
body mass indexes (BMI), blood test, endoscopic and abdominal sonographic findings with
multivariate regression analysis. RESULTS: The prevalence of IBS was 8.3% (7.9% in male
and 8.8% in female) according to ROME II criteria in our region. Of the IBS patients, 30.8%
had characteristics of diarrhea-predominance, 23.6% constipation-predominance while
45.6% had alternating symptoms. The most frequent symptom was a sense of incomplete
evacuation (60.0%) followed by bloating or distention (54.9%), straining (36.9%), urgency
(29.7%), and mucus in stool (9.2%). In univariate analysis, the prevalence of IBS was
significantly higher in the younger age subjects (age<35) and in the under-weight subjects
(BMI<18.5). In multivariate regression analysis, the younger age (odds ratio, 2.04; 95% CI,
1.33 to 3.12) and the under-weight (odds ratio, 2.7; 95% CI, 1.37 to 5.35) were the factors
that independently affected the expression of IBS symptom. The IBS prevalence was not
different in terms of gender, resident area, occupation, smoking, alcohol intake, diabetes
and hypertension history, anemia, ABO blood groups, Helicobacter pylori infection, and
presence of peptic ulcer or fatty liver disease. CONCLUSIONS: The prevalence of IBS
according to ROME II criteria was 8.3% in general Korean population, and IBS with alternating
bowel habit is the most common subtypes based on predominant bowel habit. IBS was
more common in the younger age and in the under-weight people.
T1271
Determinants of Co-Existing Irritable Bowel Syndrome and Heartburn During
Long-Term Follow-Up of Functional Dyspepsia
Sebastien Kindt, Philippe Caenepeel, Joris Arts, Jozef Janssens, Jan Tack
Background: Considerable overlap exists among different functional gastrointestinal disorders
(FGID), especially between functional dyspepsia (FD), irritable bowel syndrome (IBS) and
heartburn (HB). However very little is known about possible factors underlying this overlap.
The aim of this study was to investigate the degree of overlap of IBS and HB with FD and
to assess variables promoting this overlap. Methods: 253 tertiary care patients with newly
diagnosed FD underwent a complete pathophysiological investigation with barostat, gastric
emptying for solids and liquids, 24-hour ambulatory pH-metry and H. pylori testing, and
were prospectively followed. After a follow-up of of 68±2 months, FD, IBS and heartburn
status were evaluated according to Rome II criteria by self-administered questionnaires.
Anxiety and depression were assessed with STAI and HADS questionnaires. Quality of life
was assessed with the Nepean Dyspepsia index (NDI). Differences between single and
overlapping FGID were evaluated with Chi-square. Factors promoting IBS or heartburn were
assessed with t-test, Wilcoxon test and logistic regression. Results: At follow-up, 24.9% were
asymptomatic, 66.0% still had FD, 36.5% had IBS and 26.5% had HB. FD and IBS overlap
were present in 29.5%, FD and HB overlap in 23.7%, and IBS and HB overlap in 14.9%.
Three overlapping FGID were present in 14.1%. There was a significant positive association
among the different FGID (all p<0.001). IBS overlap was associated with a greater weight
loss at presentation, a lower MDP, higher STAI-trait, NDI and HADS-depression scores,
female gender, use of FGID medication and diet. In logistic regression significant contributors
were MDP, female gender and the interaction term gender*STAI-trait score. HB overlap was
associated with a lower body length, a higher BMI, a greater weight loss at presentation,
more chronic fatigue complaints, more dietary restrictions and use of FGID medication, and
higher NDI, STAI and HADS scores. Body length was a significant contributor while STAI-
trait score and gastric emptying for solids showed a trend (p=0.058 and 0.051 resp.).
Conclusion: An important overlap among FGID is present in FD patients at follow-up.
Anxiety and female sex are risk factors for IBS, while anxiety, shorter body length and
delayed gastric emptying are risk factors for HB. FD patients with overlapping IBS or HB
have a lower quality of life, and use more dietary and medical treatments.
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T1272
Irritable Bowel Syndrome Aggregates Strongly in Families: A Family-Based
Case-Control Study
Yuri Saito, Nicholas J. Talley, Janice M. Zimmerman, William S. Harmsen, Mariza De
Andrade, Michael Camilleri, G. Richard Locke, Gloria M. Petersen
Background: Although environmental factors and learned illness behavior may contribute,
twin and pharmacogenetic studies suggest a potential genetic basis for Irritable bowel syn-
drome (IBS). Positive family history has been shown to be predictive of IBS, but no detailed
characterization of IBS pedigrees by direct data collection of entire families has been reported
to date. Study aims: 1) To quantitate familial aggregation of IBS, and 2) To assess the
accuracy of patient report of family history of IBS in cases and controls. Methods: The study
design was a case-control study of 50 cases with IBS seen in GI clinics and 53 age-, gender-
, and race-matched controls from General Medicine clinics at a major medical center in
2004-2005. Case and control probands completed a symptom questionnaire, and provided
symptom and contact information for their first-degree relatives (FDRs). Questionnaires
were then mailed to the FDRs for completion. Relatives were considered to have IBS if they
met Rome criteria, reported a physician diagnosis of IBS, or reported constipation and/or
diarrhea-type symptoms. Results: Case and control probands identified a total of 582 relatives
in their family structure--286 among cases, 296 among controls. 75(13%) were deceased,
48(8%) were minors, and 57(10%) were not allowed contact by the probands. 402(69%)
surveys were mailed with 203(50%) responding with consent and symptom data. When
comparing proband report with relative self-report data, case-probands reported 20% of
their FDRs had IBS; however, relatives’ self-reports showed 46% had IBS. Control-probands
reported 4% of their FDRs had IBS; in contrast, relatives’ self-reports showed 25% had IBS.
By chi-square analysis, both comparisons were statistically significant difference in % with
IBS (p<0.05). Kappa statistics for agreement between proband-report and FDRs’ self-report
were poor for both case-FDRs and control-FDRs(0.31 and 0.14, respectively). When including
proband information for non-participating relatives and unknowns were treated as a not
having IBS, 24% of case-relatives were still affected, compared to 11% of control-relatives
(p<0.001). Family comparisons showed that 70% of case-families have at least one affected
family member, compared to 43% of control-families (p=0.01). Conclusions: Cases and
controls typically underestimated the frequency of IBS-type symptoms in their relatives,
thus emphasizing the need for direct data collection from family members in any family
study of IBS. IBS was observed to aggregate strongly in this study sample, compared to control-
families. The environmental and genetic reasons for this clustering merit further study.
T1273
Interleukin 10 Genotypes in IBS-Rome II Subjects in Mexico
Gabriela Gutierrez-Reyes, Rosalinda Martinez-Garcia, Norma Morales-Rochlin, Marina
Gonzalez, Clarita Corona de Lau, Max Schmulson
Preliminary studies suggest that an inflammatory or genetic component may exist in some
cases of IBS with lower production of IL-10. (Gut 2003;52:91) Therefore we sought to
determine the frequencies of IL-10 and TNF genotype in a group of IBS subjects in Mexico.
Methods: 36 volunteers fulfilling Rome II criteria for IBS were recruited. They were matched
by age and gender with 73 non-IBS volunteers. Blood samples were obtained from each
subject. Genomic DNA was extracted from peripheral blood leucocytes and genotyping was
carried out by amplification refractory mutational system polymerase chain reaction methods
(Transl.Immunol.1999;7:127), using allele specific primers to identify the high and low
producer alleles of each biallelic polymorphic site of the IL-10 gene (-1082*G and -1082*A),
respectively and the TNF-a gene (-308*G and -308*A). Amplified DNA products were then
analyzed using electrophoresis on 2% agarose gel and viewed under UV light. Allele frequen-
cies were expressed in percentage. Genotypes for each subject were expressed as homozygous
for the high and low producer and heterozygous or intermediate producer frequencies and
compared by chi-sq. Results: 78% of IBS and 75% of controls were female. Age was similar
in both groups: 35+/-2 years. Allele frequency for IL-10 had a tendency to be lower for G
in IBS compared to controls: 32 vs. 42%, OR: 0.64 (95% CI: 0.334-1.195), p=0.088.
There was no difference in the overall genotype frequency in IBS vs. Controls (High, Low,
Intermediate %): 18, 33, 49 vs. 8, 45, 47 but according to gender, there was a tendency
to a lower proportion of the low producer among females with IBS.(Table) Allele frequency
for TNF-a was similar for the G and A in IBS: 83 and 17% vs. controls: 75 and 25%. Nor
was there any difference in the overall genotype frequency (High, Low, Intermediate %):
66, 0, 34 vs. 52, 1, 47 or according to gender. Conclusions: These preliminary results
suggest that in Mexico at least a subgroup of females may be genetically predisposed to
developing IBS because of a lower production of the protective anti-inflammatory effect of
IL-10. A larger study is warranted to determine if this hold true and if it is consistent
among males.
IL-10 Genotypes in IBS and Controls.
IBS: Female vs. Male, p=0.043 Controls: Female vs. Male, NS.
T1274
Short-Allele Serotonin Transporter Gene Polymorphism Is Associated with
Elevated Serotonin and Is Less Common in IBS with Constipation Compared
to Healthy Controls
William E. Whitehead, Olafur S. Palsson, Syed Im. Thiwan, Temitope O. Keku, Motoyori
Kanazawa, Shin Fukudo, Miranda Al. van Tilburg, Janie Peacock, Jeff Barnes, Marsha J.
Turner
Single or double short allele (s/l or s/s) polymorphisms of the gene encoding the serotonin
transporter protein (SERT) result in less effective serotonin reuptake at nerve synapses when
compared to the long-long (l/l) variant. This may affect bowel functioning. Association
between short alleles and diarrhea-predominant IBS were reported in 2 previous studies.
Short alleles were also associated with more severe psychological symptoms in some non-
IBS studies. Aims: Examine SERT genotypes in relation to IBS subtypes, bowel symptoms,
and psychological symptoms. Methods: 127 Rome II IBS patients and 27 healthy controls
provided 10 ml venous whole blood samples. DNA was extracted using a “Puregene” (Gentra
Systems, Minneapolis, MN) kit according to manufacturer’s protocol. After PCR amplification
of the DNA, the product was denatured with Hi-Di formamide and subjected to capillary
electrophoresis on the ABI 3100 Avant genetic analyzer. Alleles were determined with
GeneMapper software. Subjects also completed the Rome II Modular Questionnaire, IBS
Severity Scale, additional bowel habit questions and the Brief Symptom Inventory 18. Motility
index scores and thresholds for first sensation and moderate urge and pain (ascending
method of limits) were obtained with a balloon-tipped catheter placed in the sigmoid colon.
Results: IBS-C patients had more l/l and fewer l/s alleles than controls (X2=5.845, p=.054),
while IBS-D were similar to controls (table). IBS patients with short alleles had elevated
fasting whole blood serotonin (mean+SE: 186.9+ 7.0 ng/mL for s/l and s/s combined vs.
157.3+10.6 ng/mL for l/l; p=.02). IBS patients with l/l had significantly more straining with
defecation and tended to report more hard stools and fewer loose stools compared to s/l
and s/s. There were no differences in motility index, sensory thresholds, or psychological
symptoms. Conclusions: The SERT short allele was less common in IBS-C. It was associated
with lower fasting levels of whole blood serotonin, and this was reflected in less straining
and a tendency towards looser stools. However, we found no association between SERT
polymorphisms and psychological symptoms. These data support the hypothesized associ-
ation of SERT polymorphisms with IBS subtypes but require replication in larger samples.
[Supported by Novartis Pharmaceuticals and grants R24 DK67674, R01 DK31369 and
RR00046]
T1275
What Is the Correlation Between the Bloating Sensation and the Amount-
Distribution of Intestinal Gas in Patients with Functional Abdominal Bloating?
Fermin Mearin, Antonia Perello, Monica Perona, Agustin Balboa, Mario Pages, Diana
Hernandez, Antoni Castells
Many patients with functional abdominal bloating (FAB) relate their symptoms to excessive
intestinal gas. However, this relationship has not been clearly established. AIM: To evaluate
the amount and distribution of intestinal gas in patients with FAB in two different clinical
situations: 1. Without abdominal bloating sensation; 2. With abdominal bloating sensation.
METHODS: 9 patients diagnosed with FAB according to Rome II criteria were evaluated.
The amount and distribution of intestinal gas was analyzed by using a high-resolution CT
scan. Studies were conducted while patients experienced bloating sensation and while
experiencing no bloating. In addition, results were correlated to changes in abdominal girth,
measured multiple times using a diary. RESULTS: In “no bloating” conditions the mean
total gastrointestinal gas was 261 ± 44 ml (stomach: 36 ± 12 ml; colon: 182 ± 26 ml),
values being very scattered: total range from 66 to 507 ml, range in the stomach from 12
to 116 ml, and range in the colon from 42 to 312 ml. Volume change from “no bloating”
to “bloating” conditions were: 158 ± 129 ml for total intestinal gas, 16 ± 27 ml in the
stomach and 159 ± 128 ml in the colon, showing again scattered values: total range from -
45 to 1172 ml, range in the stomach from -67 to 215 ml, and range in the colon from -
58 to 1156 ml. No correlation was found between changes in abdominal girth during the
day (going from 2.2 to 9.2 cm; mean: 5.1 cm) and changes in total gas amount. CONCLU-
SION: While studying patients with functional abdominal bloating no correlation between
the bloating sensation experienced and the amount and distribution of intestinal gas was
found. Other pathogenic mechanisms deserve to be considered.
T1276
Development and Validation of a Concise Point-of-Care Severity Index in IBS:
The “B.E.S.T.” Questionnaire
Brennan M. Spiegel, Bruce Naliboff, Emeran Mayer, Roger Bolus, Lin Chang
Background: Severity is a multidimensional outcome in IBS that combines intestinal and
extraintestinal components. Although it is critical to accurately measure severity in IBS, data
suggest that it is often underestimated in everyday practice. We sought to develop a concise,
point-of-care index that accurately and rapidly measures IBS severity in the busy clinical
setting. Methods: Based on a conceptual model of IBS severity (Lembo et al Clin Gas Hep
2005), coupled with previously identified predictors of quality of life in IBS (Spiegel et al
Arc Int Med 2004), we identified 4 Likert-scaled items that balance brevity and scope. The
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resulting “B.E.S.T.” questionnaire included: 1) how Bad are your bowel symptoms?, 2) can
you still Enjoy the things you used to enjoy?, 3) do you feel like your bowel symptoms
mean there’s something Seriously wrong?, and 4) do your bowel symptoms make you feel
Tense? Scores were scaled on a 0-100 range (100=most severe). We prospectively measured
the cross-sectional correlation of BEST with 6 severity measures in Rome-II IBS patients,
including IBS-QOL, bowel symptom intensity [VAS] and duration, somatization [SCL-90],
anxiety/depression [HAD], and coping [Likert]. Results: The validation group included 56
patients (mean age=52; IBS-QOL=55; 33% women). Mean completion+scoring of BEST was
<3min. Figure 1 shows a striking correlation of BEST with IBS-QOL (r=-0.83). There
were moderate correlations between BEST and VAS (r=0.49), symptom duration (0.55),
somatization (0.55), HAD (0.54), and coping (r=-0.52). Conclusions: BEST is a concise,
rapidly completed, point-of-care IBS severity index that demonstrates moderate-to-large
correlations with disparate severity measures, and therefore has excellent cross-sectional
validity. Future work will measure the reliability and predictive ability of BEST, and evaluate
its impact on clinical decision-making.
BEST vs IBS-QOL
T1277
Gastrointestinal Functional Disorders Are Common in Women Regardless of
the Menstural Phase: A Rome II-Based Survey
Sun-Young Lee, Sang Kyun Yu, In-Kyung Sung, Hyung-Seok Park, Choon-Jo Jin, Won
Hyeok Choe, So Young Kwon, Chang Hong Lee, Kyoo Wan Choi
Background and Aims: It is known that functional gastrointestinal disorders are more common
in women in relation to the fluctuations of female sex hormones. We tried to detect the
gender-related differences in the prevalence of functional dyspepsia (FD) and irritable bowel
syndrome (IBS). In addition, we analyzed the symptoms according to their menstural phase
in women. Methods: A total of 505 subjects (253 women before menopause and 252 men
below age 50) who visited Digestive Disease Center of Konkuk University Hospital, from
October to November 2006, were included in this prospective study. Subjects were examined
by gastroenterologist after completing the questionnaire, and were diagnosed according to
Rome-II criteria. Further examinations including blood test, endoscopic procedures, and
imaging studies were done if needed. After the interview and examinations, subjects with
malignant disease or acute infection, or those who have chronic disease requiring medications
were excluded from the study. Women were subclassified into three groups according to
their menstruation; menstrual phase (day 0-6), proliferative phase (day 7-14), and secretory
phase (after day 15). Women under lactation or pregnancy, taking oral pills, or with irregular
menstrual period more than 36 days were excluded. Finally, 179 men and 193 women (60
menstrual phase, 41 proliferative phase, and 92 secretory phase) were analyzed. Results:
Women revealed higher prevalence of FD (P=0.03) and IBS (P=0.01) than men. In aspect
of FD subtypes, reflux-dominant type was common in men while mixed or unclassified
types were common in women (P=0.01). In aspect of IBD subtypes, diarrhea-dominant type
was common in men while constipation-dominant or mixed types were common in women
(P<0.001). Of 193 women, there was no significant difference in their gastrointestinal
symptoms according to their menstrual phase. Conclusions: Regardless of the menstrual
phase, functional gastrointestinal disorders are more frequent in women than in men.
Physicians should consider gender-based approach in clinical practice since higher prevalence
of FD and IBD in women may lead to reduced clinical reliability when accessing organic
disease. In addition, different symptomatic manifestations between men and women should
be considered when evaluating functional gastrointestinal disorders. Key Words: Functional
gastrointestinal disorder, Women, Dyspepsia, Irritable bowel syndrome, Menstruation
T1278
Functional Gastrointestinal Disorders: Overlapping Symptom Or a Single
Complex Syndrome? A Stratified Randomized Epidemiologic Study Using
Cluster Sampling in Northern China
Xiucai Fang, Meiyun Ke, Guo-Zong Pan, Shaomei Han, Jiaming Qian, Zhaolu Ding, Sucai
Lu
Functional gastrointestinal disorders (FGIDs) are commonly diagnosed in clinical practices
in most regions of the world. Recent reports for community populations in the USA suggest
that FIGD symptoms can occur in overlapping complexes. We analyzed stratified randomized
epidemiologic data, obtained by cluster sampling in Northern China, and obtained an
estimate of the prevalence of the major FGID symptoms and how they overlap in the general
population. The study was designed for stratified and randomized selection in a cluster
sampling of the inhabitant groups in the city of Beijing. A total of 2,486 subjectss (ages
18 - 70 years) were enrolled in the study. The subjects completed a questionnaire consisting
of 165 items with the assistance of trained physicians or medical students during visits to
their homes. Ten categories of symptoms were selected as representative of FGIDs. Chest

















than 6 times in the past year. Definitions for diarrhea, constipation and functional dyspepsia
(FD), chronic constipation (CC) and the irritable bowel syndrome (IBS) were according to
Rome II Criteria. Gastro-oesophageal reflux disease (GERD) was assesses by the intensity
and frequency of heartburn, acid reflux and regurgitation (>6 of 18). Acid reflux, heartburn,
abdominal fullness, and pain and discomfort in the upper abdomen ranged of 14 ~ 22%
in this general population. Chest pain, sensations of fullness and pain, constipation were
most common in the women (p<0.05). FGIDs were reported in 21.9% of the population,
and the prevalence of symptom complexes GERD, FD, CC and IBS were 10.2%, 12.2%,
6.3% and 1.0% respectively, with a higher prevalence of constipation in females than in
males (9.5% to 2.8%, p<0.001). Two-complex overlap was present in 6.2%, and three-
complex overlap was found for 1.1% of the population. Co-existence of upper FGIDs in
with CC ranged from 12.9 to 13.8% while the range for IBS was 3.6 to 4.3%. A complex
of upper FGID symptoms co-existed with CC in approximately one-fourth of this CC group
and in one-half of the IBS in the study. No significant relationship between the prevalence
of overlap and age, BMI, occupation, education, marital status, smoking, alcohol abuse or
emotional stress was found. The results suggest that FGIDs are present in the general
population of Northern China in numbers reminiscent of findings of similar studies elsewhere.
The significant overlap of symptoms between the upper and lower digestive tract suggests
that a common pathogenesis might be responsible for the overlap in a given patient.
T1279
Pain and Health-Related Quality of Life in Irritable Bowel Syndrome (IBS):
Clinicians’ Perspectives Differ from Those of Patients
Olivier Chassany, Martin Duracinsky, Marc Mathieu
Background. Although advances in psychometrics have enabled development of Health-
Related Quality of Life (QoL) questionnaires, from patient-to-GP information transmission
remains informal. We sought to measure the degree of agreement of pain and QoL as
reported by IBS patients, and that estimated by their general practitioners (GPs) during
consultation. Methods. 307 IBS patients [64% women; 58±16 yrs] and their 131 GPs were
included in a cross-sectional French study. Patients and GPs estimated patients’ pain on a VAS,
and QoL by the IBS-specific FDDQL questionnaire (patients) or 8 questions corresponding to
the label of the 8 FDDQL dimensions (GPs). Before analysis [weighted Kappa coefficients
(Kw), ANOVA (p), regression (r)], VAS and QoL values were transformed to give values
between 0 (no pain / bad QoL) and 100 (severe pain / good QoL). Results. Patient- and
GP-rated pain correlated moderately (Kw=0.31): the greater the pain according to the patient,
the greater according to the GP. GPs, however, underestimated pain (30.4±21.0 versus
39.0±24.9). Patient-assessed QoL decreased as patient-assessed pain increased (r=0.71).
However, patient-assessed QoL scores varied drastically for a given pain intensity, suggesting
that pain intensity only partially reflected QoL. Patients’ and GPs’ global QoL scores correlated
poorly (Kw=0.28). On all dimensions (excepted DA and AX), patients considered their QoL
more adversely affected than did their GP (Tab). On all dimensions (excepted DA and AX),
irrespective of GP ratings, patients’ mean QoL scores were similar from those of patients
rated 0 by their GP, suggesting that patients and GPs had discrepant perceptions of IBS
impact. Conclusions. Patients’ and GPs’ perspectives, although partly overlapping, differed.
Moreover, although patient-assessments of pain and QoL overlap to some extent, they
measure different concepts, i.e. QoL of IBS patients cannot be inferred from a pain score.
Reliable patient perception measurement is essential to take account of all the aspects of IBS.
Financial support: ALFIS (Association des Laboratoires et Firmes de Santé), Arcueil, France
T1280
Methane Gas Is Associated with Constipation Predominant Symptoms in IBS:
Results from a Double-Blind Controlled Study
Mark Pimentel, Sandy Park, Yuthana Kong, Kimberly Low, Soumya Chatterjee
Previous data suggests that methane gas on lactulose breath testing is associated with
constipation among subjects with irritable bowel syndrome (IBS). In this study, we re-
evaluate the relationship between methane and constipation in a new cohort of IBS patients
using both subjective and objective outcome measures. Methods: In a recent double-blind
randomized controlled study evaluating the use of rifaximin (a non-absorbable antibiotic)
for IBS, a nested study was conducted to evaluate the role of methane in constipation IBS.
After consent, subjects filled out a stool diary as well as a daily Bristol Stool Score for 7
days. Subjects then returned for a qualitative evaluation of their IBS symptoms including
diarrhea, constipation, bloating, urgency and abdominal pain on a VAS (0-100mm) after
which a lactulose breath test was conducted to determine the presence or absence of methane
based on having methane on all samples through 180 minutes of breath samples. Results:
87 patients were included in the analysis. Of these, 15 subjects (17%) were considered
methane producers. Methane production was associated with a constipation severity of
78.2±23.7 compared to 34.4±31.2 for non-methane (P<0.000001). On the contrary, the
diarrhea severity was lower in methane producers (9.3±24.7) compared to non methane
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(45.1±34.9) (P<0.001). Bloating (P<0.05) was more and urgency was less (P<0.0001) in
methane producers. Abdominal pain was not different. Based on objective scores, the stool
frequency was 0.92±0.79 per day among methane producers compared to 2.00±1.36 in
non-methane (P<0.01). The Bristol Stool Score was also lower in methane (P<0.05). Of
methane producing IBS subjects, 93% were considered constipation-predominant compared
to 31% for non-methane producers (OR=18.5, CI=2.91-114.6, P<0.001). Conclusions:
Among IBS subjects, methane is significantly associated with constipation symptoms in both
subjective and objective means of determining constipation.
T1281
Overlapping Functional Gastrointestinal Disorders in Irritable Bowel
Syndrome - Prevalence and Related Factors
Iris Posserud, Gunnar Midhagen, Hasse Abrahamsson, Magnus Simren
Background: Patients with irritable bowel syndrome (IBS) often complain of a wide range
of symptoms, including symptoms from other parts of the gastrointestinal (GI) tract than
the bowel. Overlap with other functional gastrointestinal disorders (FGIDs) has been reported
but the actual prevalence and influencing factors are largely unknown. Aim: Evaluate the
prevalence of other FGIDs and correlating factors in a large sample of IBS patients. Method:
We included 308 patients attending our referral centre fulfilling the Rome II criteria for IBS
(mean age 40 years, range 18-73; 226 females). Of these 117 had diarrhea predominant
IBS (IBS-D), 60 constipation predominant (IBS-C), and 131 alternating diarrhea and constipa-
tion (IBS-A). They completed the Rome II Modular Questionnaire, and the presence of
anxiety and depression was assessed with the Hospital Anxiety and Depression scale (HAD)
using validated cut-off levels. Demographic data was also collected. Results: Rome II criteria
for at least one additional FGID, was fulfilled in 76% of all IBS patients (mean number 1.3
FGID per patient, range 0-4). Functional anorectal disorders were most prevalent, and the
single most common FGID besides IBS was proctalgia fugax, which was present in 40%,
whereas levator ani syndrome was observed in 11%. Functional incontinence was found in
22%, of which soiling accounted for 14% and gross incontinence for 8%. The most frequent
symptom, beside IBS symptoms, was dyspepsia, defined as pain or discomfort centered in
the upper abdomen, reported by 48% (22% ulcer like and 26% dysmotility like). However,
only 6% fulfilled the Rome II criteria for functional dyspepsia since the majority reported
a relation with bowel function and/or presence of reflux symptoms. Esophageal symptoms
were also common, with 26% reporting reflux symptoms suggestive of functional heartburn
and 8% reporting symptoms of functional chest pain. The number of simultaneous FGIDs
in IBS patients was higher if the patients had anxiety (p=0.003 vs. no anxiety) or depression
(p=0.002 vs. no depression). Patients with IBS-A were more likely to have other FGIDs (p=
0.04 vs. IBS-D and IBS-C) and patients with additional FGIDs tended to be older (p=0.05).
There was no observed gender difference in the number of FGIDs. Conclusion: A majority
of IBS patients also report symptoms compatible with other functional gastrointestinal
disorders, implying a more widespread gastrointestinal disturbance. This is related to psycho-
logical factors, as well as subtype of IBS, but not with gender. Strict use of the present Rome II
criteria probably underestimates the presence of some FGIDs, especially functional dyspepsia.
T1282
Women with Irritable Bowel Syndrome (IBS) in Pre- and Post-Menopausal Age
Groups Report Similar Gastrointestinal (GI) Symptoms
Lin Chang, Claudia Alvarado, Emeran A. Mayer, Martijn G. van Oijen, Cathy Liu,
Brennan Mr Spiegel
Background: Sex differences in symptoms, and physiologic and treatment responses have
been reported in IBS (Gastro 2002;123:1686-1701). Animal and human studies support an
influential role of female sex hormones on GI function. While the effect of menstrual cycle
on IBS symptoms has been reported, the effect of menopause has not been well studied.
Aims: We sought to compare the prevalence and severity of IBS symptoms in pre- vs. post-
menopausal age groups in women with IBS, and to conduct similar comparisons in a control
group of men with IBS. Methods: We analyzed data from 1634 Rome+ IBS patients aged
18-88 yr recruited from clinic and advertisement at a university-based functional GI disorders
center. Subjects completed a bowel symptom questionnaire and validated psychological and
quality of life surveys. We stratified the data by gender and age group (≤35 vs. ≥50), and
compared key IBS symptoms between groups using univariate chi-squared and t-tests. We
then entered significant (p<0.05) variables into a series of regression analyses to determine
whether menopausal status independently predicted any specific IBS symptoms, and per-
formed similar analyses in the control group of men with IBS. Results: There were 459
women with IBS ≤35 and 296 ≥50 years old, and 296 and 172 men with IBS, respectively.
Univariate analyses in women revealed that only discomfort severity was significantly higher
in pre- vs. post-menopausal age groups (p<0.05), although the effect size of this difference
was not clinically significant (0.16 SD). There were no important differences in men between
age groups. In the regression analysis, the post-menopausal age group independently pre-
dicted a lower odds of having infrequent (<3/wk) bowel movements (OR 0.5, 95% CI=0.3,
0.8) and mucus in the stool (0.62; 0.4, 0.97) and higher odds of having visible abdominal
distension (3.5; 0.3, 0.8). These differences were not seen in men. There were no differences
in overall symptom severity, abdominal pain, bloating, or other bowel habit symptoms.
Conclusions: We found very few symptoms that were significantly different between pre-
vs. post-menopausal women with IBS. The decreased stool frequency more often reported
in younger women may be explained by the proposed inhibitory effect of female sex hormones
on GI transit. However, taken together with the lack of effect of oral contraceptive agents
and hormone replacement on IBS symptoms in past studies, these findings suggest that
cyclical, physiologic changes in female sex hormones have only a minor effect on IBS
symptoms. Future prospective studies are needed to confirm these findings. Supported by
NIH grant # P50 DK64539.
T1283
Evaluation of a Fast, Low-Caloric Versus a Slow, High-Caloric Drink Test in
Functional Dyspepsia
Trygve Hausken, Vernesa Dizdar, Ina Hjelland, Johan Lunding, Odd Helge Gilja, Arnold
Berstad
Background: Drinking capacity is often reduced in functional dyspepsia. Drink tests may
therefore have diagnostic potential. The aim was to find the best drink test in combination
with ultrasonography to diagnose patients with functional dyspepsia (FD). Material and
methods Sixteen patients with FD, age (median 33(18-57 yrs), BMI (mean (SD) 22 (4),
male/female 6/9, and 15 healthy controls, age (median 25 (20-30 yrs), BMI mean (SD) 25
(3.6), male/female10/6 were included. In randomized order the subjects drank either meat
soup (4 kcal/100 ml with a velocity of 100 ml/min) or Nutridrink (150kcal/100 ml with a
velocity of 15 ml/min) until maximal drinking capacity. Intragastric volume at maximal
drinking capacity was determined using 3-dimensional ultrasonography. Results: Drinking
capacity (p<0.003) and intragastric volume (p<0.003) were significantly lower in patients
than in the controls with the meat soup meal (696 (353) ml versus 1220(433) and 388
(190) ml versus 663 (230)ml, respectively) and for the Nutridrink (drinking capacity 196
(124) ml versus 558 (254) (p<0.0001), intragastric volume 164 (90) ml versus 386 (145)
(p<0.0002). Receiver operating characteristic (ROC) analysis indicated that optimal discrim-
ination between patients and controls was obtained by the combined test results of symptoms
per intragastric volume using Nutridrink 15 ml/min as the test meal. Area under the curve
0.94 with a sensitivity of 93% and a specificity of 75%. Conclusion Slow ingestion of a
high-caloric Nutridrink is preferable compared to the rapid ingestion of a low-caloric meat
soup to diagnose functional dyspepsia. Optimal discrimination between patients and controls
was obtained by the combination of the drink test with ultrasonography.
T1284
Prevalence and Burden of Irritable Bowel Syndrome and Chronic Constipation
in a Primary Care Sample of Healthcare Seekers
Michael Warren, Daniel Belletti, Christopher Zacker, Annamaria Cerulli
BACKGROUND: Irritable bowel syndrome (IBS) and chronic constipation (CC) are common
functional gastrointestinal (GI) disorders for which many patients never seek care or receive
a diagnosis from a healthcare provider. AIMS: To establish the prevalence of IBS and CC
in adult female patients among a primary care sample of healthcare seekers. The impact of
IBS and CC on work productivity, daily activities, and over-the-counter (OTC) medication
use was also evaluated. METHODS: Consecutive female patients >18 years, seeking care for
any reason, from 32 primary care providers throughout PA, NJ and WV participated in the
survey. A questionnaire including the Rome II criteria for IBS and CC, the Work Productivity
and Activity Impairment index and questions on OTC drug use and alternative therapy in
the past 4 weeks was used. Physicians completed a questionnaire for each patient assessing
prior GI diagnoses and drug use. Comparisons were made between 3 groups: patients with
IBS and patients with CC whose condition was confirmed by Rome II criteria or healthcare
provider, and patients with neither condition (NC) using Chi Square and T-tests for categor-
ical and continuous data, respectively. RESULTS: Out of 1,415 patients enrolled, 41.6%
met the Rome II criteria or had a healthcare provider diagnosis for either IBS or CC (29.5%,
IBS and 12.1%, CC). Of those patients meeting the Rome II criteria for IBS, only 100
(28.7%) had a healthcare provider diagnosis of IBS, and of those meeting the CC Rome II
criteria, only 35 (18.9%) had their condition diagnosed by a healthcare professional. A
total of 65.7% (174/265) of patients confirmed by Rome II criteria to have constipation-
predominant IBS or CC had ≥1 current GI-related symptom, and up to 42.6% (113/265)
had 2 symptoms or more. Patients in both groups reported current symptoms of constipation
(40.0%), bloating (37.4%), heartburn (26.0%), abdominal pain (22.6%), dyspepsia (18.9%),
and diarrhea (4.9%). IBS and CC patients reported greater impact of their symptoms on
overall work productivity compared to NE patients (19.3% for IBS and 10% for CC vs.
7.3% for NE; p<.05 IBS vs. NE). Daily activity impairment due to GI problems was 21.4%
for IBS, 13.6% for CC, and 5.5% for NE patients (p<0.05 for all). For patients taking OTC
medication (n=721/50.9%), the average number of medications taken was 2.1 (IBS) and 1.9
(CC) vs. 1.6 (NE; p<0.05). CONCLUSIONS: IBS and CC are common multiple symptom
disorders among female patients presenting to primary care providers; however, many
patients are never diagnosed despite the high symptom burden and adverse effect on patient
work productivity and daily activities.
T1285
Prevalence of Irritable Bowel Syndrome After Exclusion of Organic GI
Disorders: Is Symptom Based-Diagnosis of IBS Precise Enough?
Kyungsik Park, Byoungkuk Jang, Woojin Chung, Kwangbum Cho, Jaeseok Hwang,
Sunghoon Ahn, Yuna Kang, Junyoung Hwang
Backgrounds/Aims; Irritable bowel syndrome (IBS) is a kind of common functional GI
disorder. Recently, prevalence of this troublesome disease has been markedly increased in
Asia. Prevalence of IBS has been reported variously maybe due to use of different diagnostic
criteria . Because initial diagnosis of IBS is based on variable symptoms, the organic bowel
or other GI diseases may be passed over. Therefore the aims of this study are first to find
out precise prevalence of IBS by exclude organic components from patient group with IBS
symptoms . Second, to determine the degree of agreement between different diagnostic
criteria, and third, to analyze risk factors which were associated with presence of IBS.
Methods; Health examinees who had visited health promoting center in Keimyung university,
Dongsan medical center were requested to fill out questionnaire paper. Manning, Rome I,
and Rome II criteria were used in all examinees and prevalence was calculated by each
criteria. Degree of agreement between each criteria were analyzed by Cohen’s kappa value.
Risk factors were analyzed by comparing IBS and normal groups. Results; From January to
November 2005, 2,793(58.1%) out of 4,805 examinees, replied completely. Mean age was
45.4±10.3(16~82) years and male(59.5%) was predominant. Prevalence of IBS by Manning,
Rome I, and Rome II criteria were 22.4%, 14.9%, and 17.5%, respectively. Kappa value
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between Rome II and Manning criteria was 0.705 and between Rome II and Rome I was
0.474. Of 490 IBS patients by Rome II criteria, 8(1.6%) patients showed abnormal fecal
test. Colonoscopy was done at 390 persons and was abnormal at 34(8.7%). Thus accurate
prevalence by Rome II criteria was about 15.7%. Other GI disorders which were observed
at in IBS patients were peptic ulcer(1.2%), esophagitis(12.9%), GB stone(6.5%) etc. Punch
biopsy of intact-looking colonic mucosa was done at 71 informed IBS patients. Mucosal
hyperplasia, lymphoid aggregates, lymphoid follicle, and increased eosinophil count were
predominant pathologic finding. Gender(M:F=15.4%:20.7%, p<0.001)), occupation(no
occupation, p<0.001), young age(p<0.001) were independent risk factors for presence of
IBS in univariate and multivariate analysis. Conclusion; Exclusion of organic bowel problem
is necessary to find out precise prevalence of IBS. Overall prevalence of IBS by Rome II
criteria 1s 15.7% in Korea. Female gender, no occupation, and young age are independent
risk factor associated with presence of IBS.
T1286
Clinical, Topographic and Pathophysiological Characteristics of Funcional
Abdominal Bloating
Fermin Mearin, Antonia Perello, Monica Perona, Agustin Balboa, Diana Hernandez,
Antoni Castells, Mario Pages
Abdominal bloating without an organic cause (functional abdominal bloating: FAB) is one
of the most frequent digestive complaints but its clinical manifestations and causes are elusive.
AIM: To evaluate clinical characteristics, some putative pathophysiological mechanisms and
distribution of intestinal gas in FAB. METHODS: 34 patients with FAB (Rome II criteria)
were evaluated to ascertain factors favoring distention and increase in abdominal girth (as
recorded in a diary), presence of causative illnesses (celiac disease or hypothyroidism),
carbohydrate intolerance (lactose and fructose-sorbitol breath tests), bacterial overgrowth
(glucose breath test), visceral sensitivity (rectal barostat) as well as localization and amount
of intestinal gas (n=17; high resolution CT-scan with specific window). RESULTS: 85% of
patients showed an increase in bloating through the day and 88% after meals; 61% complained
of worsening with anxiety; 26% and 64% improved by belching or passing gas, respectively.
Range of abdominal girth increased was 0.1 to 9.2 (mean: 3.7 cm). Anti-tranglutaminase
antibodies were negative in every case and in one case the diagnosis of hypothyroidism was
made. Breath test for lactose, fructose-sorbitol and glucose were abnormal in 25%, 50%
and 5% of the cases, respectively. Visceral sensitivity was normal in 83% of the patients,
12% showing an increase and 5% a decrease. In most of the cases gas was mainly located
in the colon (63%) (colon: 191 ± 25 ml; stomach: 21 ± 3 ml) while the remaining (37%)
showed mixed distribution in the stomach and colon (colon: 167 ± 50 ml; stomach: 48 ±
17 ml). Three out of 11 patients with gas mainly located in the colon had some carbohydrate
malabsorption. In patients with mixed gas distribution some carbohydrate malabsorption
was found in 5 out of 6 patients, and 1 had bacterial overgrowth. CONCLUSION: FAB is
a homogeneous clinical syndrome but pathophysiologically heterogeneous with frequent
carbohydrate malabsorption and normal visceral sensitivity. No clear correlation between
pathogenic mechanisms and gas localization exists.
T1287
An Open Label Pilot Trial of High Dose Rifaximin in the Treatment of Patients
with Constipation Predominant Irritable Bowel Syndrome
James George, Michele Hunt, Asher Kornbluth, Peter Legnani
Introduction: A recent double-blind, placebo controlled trial (Pimentel M, et al ACG 2005)
demonstrated efficacy with rifaximin, a nonabsorbable broad spectrum antibiotic, effective
in the treatment of small intestinal bacterial overgrowth (SIBO) for patients with IBS.
Rifaximin was dosed at 200 mg. TID for 10 days and sustained improvement was noted in
patients for up to 10 weeks in global improvement, bloating and diarrhea. Although symptoms
of constipation were improved compared to placebo, this improvement did not reach statist-
ical significance. Objective: The aim of this open label pilot study was to determine if higher
doses of rifaximin would improve symptoms in patients with constipation-predominant IBS
(IBS-C) who tested positive for bacterial overgrowth. Methods; Patients with IBS-C underwent
lactulose breath testing for SIBO. Patients who had an elevation in H2 of at least 12 ppm
by 2 hours after ingesting 50 gm. lactulose were considered positive for SIBO. These patients
were then treated with rifaximin 800-1200 mg/d in divided doses for 10 days. Patients were
excluded if they had coexisting gastrointestinal diseases, recent antibiotic use or were on
tegaserod Patient outcomes were recorded by office visit follow-up or telephone interview.
Results: 14 patients with with IBS-C tested positive for SIBO with a mean increase of 37
ppm in H2 over 2 hours after oral ingestion of 50 gm lactulose.. Seven patients were treated
with rifaximin 400 mg BID and 7 patients were treated with rifaximin 400 mg TID. Six of
7 patients treated with rifaximin 800 mg/d had improvement in constipation and bloating
and 3 of 7 patients treated with rifaximin 1200 mg/d had improvement in constipation and
bloating. Symptomatic improvement occurred within the first week of treatment in all
patients. 6 patients relapsed within 2 weeks of discontinuation of therapy and all 6 improved
with reinstitution to rifaximin. The remaining patients remained in remission for at least 4
weeks after cessation of rifaximin. All patients tolerated rifaximin treatment without adverse
events. . Conclusion: Patients with IBS-C who test positive for SIBO have a 64% response
rate for symptoms of bloating and constipation with doses of rifaximin of 800-1200 mg/
day, and these doses were well tolerated in all patients. Prospective placebo controlled trials
of higher dose rifaximin with long term follow up are warranted to define its optimal dose


















Increased Risk of Ischemic Colitis Associated with Constipation and Irritable
Bowel Syndrome
Mark Cziraky, Kristijan H. Kahler, Ralph Quimbo, Jeffrey Kralstein
Background: Recent reports have suggested an increased risk of ischemic colitis (IC) among
patients with irritable bowel syndrome (IBS). More recently, it has been suggested that there
is an increased risk of IC in patients with chronic constipation (CC). In this study, we
attempt to evaluate the possibility that IBS and CC predispose patients to IC using a larger
database than used in previous studies. Methods: The source of data was the HealthCore
Managed Care Database which contains 12 million quality data lives, defined as those
members with complete eligibility, medical, and pharmacy data. From this data source we
identified two cohorts: patients newly diagnosed with IBS (ICD-9: 564.1) and patients newly
diagnosed with CC (564.0). The IBS and CC cohorts were matched 1:1 to control cohorts
using the propensity score method. Patients were identified from 1/1/2000 to 2/28/2005,
and had to have 6 months eligibility prior and at least 3 months post the first diagnosis
date. Patients were followed until the first occurrence of IC or the end of eligibility. Incidence
rates (IR) were assessed using a Kaplan-Meier estimator, and relative risks (RR) were calculated
using multivariate Cox proportional hazards models. Results: The IR for the development
of IC among the 100,143 newly diagnosed IBS patients was 90.37 cases per 100,000 patient-
years (167 cases) compared to 41.47 cases per 100,000 patient-years (77 cases) in the IBS
controls. We also identified 81,399 newly diagnosed CC patients where the IR for IC was
80.44 cases per 100,000 patient-years (119 cases) compared to 43.03 cases per 100,000
patient-years (64 cases) among the CC controls. IRs for those with IBS and ≥ 65 years old
(152/100,000 patient-years) were about two-fold higher than the rates among those with
IBS and < 65 (76/100,000 patient-years). The RR for IC was 8.16 (95% confidence interval
[CI]: 4.85- 13.75) and 2.60 (95% CI: 1.74-3.88) for IBS and CC, respectively. Conclusions:
We found that patients with a diagnosis of IBS had an eight times greater risk of developing
IC and patients with CC had a 2.6 fold increase in risk of IC relative to population controls.
Given prior research in this area, and results of this current research using a much larger
database than previous studies we conclude that IBS and CC are associated with the develop-
ment of IC, and studies evaluating IBS and CC therapies must control for the background
rate of IC among patients with these disorders.
T1289
Constipation-Predominant and Mixed/Alternating IBS Symptoms: Six-Month
Results from the Irritable Bowel Syndrome Longitudinal Outcomes Study -
ILOS
G. Richard Locke, Kristijan H. Kahler, Nadia Leskinova, Robert Balshaw
Background: The different effects of therapies suggest that irritable bowel syndrome with
diarrhea (IBS-D) and IBS with constipation (IBS-C) are not the same condition. The appropri-
ate classification of IBS patients with an alternating bowel habit remains uncertain. Aim: To
compare the outcomes of patients with IBS-C and mixed/alternating IBS (IBS-M/A) over
6 months in a community practice setting. Methods: ILOS was a 6-month, prospective,
observational study which enrolled 380 patients across the US who had a physician diagnosis
of IBS-C or IBS-M/A. Physician-reported clinical data were collected at baseline and patient-
reported symptom data were collected monthly for 6 months. Patients were classified as
having IBS-C or IBS-M/A based upon the physician’s assessment at baseline. Patients com-
pleted questionnaires to measure health-related quality of life (HRQOL), satisfaction with
relief of abdominal pain or constipation, and work and activity impairment (WPAI). A total
severity score (TSS) was calculated by summing the frequency, intensity and bothersomeness
of constipation, gas, abdominal pain/discomfort and bloating. Chi-square and Wilcoxon
rank sum tests were used for univariate comparisons between IBS-C and IBS-M/A subjects.
Results: At baseline, 93% of subjects were female with a mean age of 42 years. The physicians
characterized 224 (59%) patients as having IBS-C and 141 (37%) as having IBS-M/A. Six-
month questionnaires were submitted by 231 subjects (61%), with similar submission rates
for IBS-C and IBS-M/A subjects (58% vs. 64%, p=0.27). Among 175 subjects with TSS data
at baseline and 6 months, symptoms improved more for IBS-C subjects than IBS-M/A (change
in mean TSS: IBS-C -6.7 vs. IBS-M/A -2.8; p=0.02) with symptoms improving for 74% of IBS-
C subjects and 65% of IBS-M/A. Differences in symptom reduction were seen in constipation
(p<0.01) and bloating (p<0.01), though not in gas (0.48), abdominal pain (p=0.15), and
diarrhea (p=0.07). No significant differences were observed between IBS-C and IBS-M/A
subjects with respect to change in HRQOL overall score (p=0.611), or satisfaction with relief
of abdominal pain (p=0.607) or constipation (p=0.227). Changes in WPAI overall impairment
were similar for IBS-C and IBS-M/A subjects (p=0.179). Conclusion: In a community practice
setting, patients with IBS-C reported greater symptom improvement over a 6-month period
compared to patients with IBS-M/A. The availability of treatment for IBS-C and the lack of
proven treatment for IBS-M/A may be a possible explanation; however, further research
is necessary.
T1290
Efficacy of Oral Pancreatic Enzymes in Form of Enteric-Coated Mini-
Microspheres for the Treatment of Maldigestion Secondary to
Duodenopancreatectomy (DP)
Enrique Dominguez-Munoz, Maria Vilarino, Julio Iglesias-Garcia
Background: Maldigestion developing after gastroduodenal and pancreatic resection is a
major therapeutic challenge. Enteric-coated pancreatic enzymes in mini-microspheres are
the therapy of choice for maldigestion in chronic pancreatitis. The efficacy of this therapy
in patients after pancreatic surgery is unknown. Aim: To evaluate the efficacy of this oral
enzyme substitution therapy in patients with maldigestion after DP. Since the distal part of
the stomach is also surgically removed, it was also evaluated whether this therapy can be
improved by opening the enzyme capsules or by inhibiting gastric acid secretion. Methods:
A prospective, randomized, open, comparative, crossover study was carried out in 18 patients
(12 male, mean age 55 years, range 34-76 years) 32 months (range 3-164 months) after
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DP. Patients with maldigestion were randomized to receive four capsules containing 10,000
U lipase each in form of enteric-coated mini-microspheres (Kreon®, Solvay Pharma, Ger-
many) either closed or open during two consecutive 10-day periods. Esomeprazole 40 mg
od was added for further 10 days in patients with persisting maldigestion despite the enzyme
therapy. Fat digestion before (basal) and on the last day of each one of the three treatment
periods was evaluated by an optimized mixed 13C-triglycerides breath test. The cumulative
recovery rate of 13CO2 was considered as the result of the test. Data are shown as mean
[95%CI] and compared by the Student-t test for related samples. Results: 15 patients (83%)
suffered from fat maldigestion and were included in the study. One of them was finally
excluded because of protocol violation. Basal 13CO2 recovery rate was 35.9% [0-56.1%];
(normal >57.0%). Therapy with oral pancreatic enzymes markedly improved fat digestion
(13CO2 recovery 57.1% [15.8-84.9%]; p<0.01 vs basal), independently of whether capsules
were taken closed or open (13CO2 recovery 57.3% [0-94.1%] and 56.9% [31.7-95.2%],
respectively; n.s.). Eight patients (57%) normalized fat digestion under enzyme therapy.
The addition of esomeprazole in patients with persisting maldigestion increased significantly
the efficacy of oral pancreatic enzyme substitution therapy (13CO2 recovery from 40.0%
[15.8-55.0%] to 52.2% [22.3-63.3]; p<0.01), and 3 further patients were able to normalize
fat digestion. Conclusion: Maldigestion develops in most patients after DP. Treatment with
oral pancreatic enzymes in form of enteric-coated mini-microspheres is highly effective in
this setting. Despite partial gastrectomy, opening enzyme capsules is not required. Inhibition
of gastric acid secretion is of major help in patients with insufficient response to oral
enzyme therapy.
T1291
How to Optimize Oral Pancreatic Enzyme Substitution Therapy in Patients
with Chronic Pancreatitis to Assure a Normal Nutritional Status?
Enrique Dominguez-Munoz, Maria Vilarino, Marta Iglesias-Rey, Julio Iglesias-Garcia
Background: We have previously shown that malnutrition persists in most patients with
maldigestion secondary to chronic pancreatitis (CP) despite an adequate clinical response
to oral enzyme substitution therapy. As hypothesis, evaluation by objective methods of the
digestive ability under therapy may allow optimizing the treatment and assuring a normal
nutritional status in patients with CP. Aim: To evaluate the usefulness of the 13C-mixed
triglyceride breath test (13C-MTG-BT) as a tool for optimizing the therapy of maldigestion
related to CP, and to analyze the impact of this therapeutic optimization on the patients’
nutritional status. Methods: Prospective, interventionist, comparative and paired study. A
total of 20 consecutive patients (17 male, mean age 55 years, range 43-77 years) with fat
maldigestion secondary to alcoholic CP, who had abnormally low circulating levels of retinol-
binding protein (RBP) despite at least one year of adequate clinical control of maldigestion
(absence of weight loss and diarrhea) by enzyme substitution therapy were included. In all
of them, treatment of maldigestion was optimized by increasing the daily dose of oral
pancreatic enzymes (enteric-coated mini-microspheres) as much as needed to obtain a normal
13C-MTG-BT result (13CO2 recovery rate >57%). A proton pump inhibitor was associated
in case of insufficient response to oral enzymes. Serum levels of RBP (normal 3.0-6.0 mg/
dL) and prealbumin (normal 21.0-41.0 mg/dL) were measured before and one year after
optimization of the therapy. Results are shown as mean and 95% confidence interval, and
compared by the Student-t test for paired samples. Results: Before optimization, patients
were under treament with oral pancreatic enzymes at a median dose of 20,000 U lipase/
meal. A normal 13C-MTG-BT result was obtained in all patients by increasing the enzyme
dose up to 40,000 U (n=18) and 60,000 U (n=2) lipase/meal. In addition, three patients
(15%) required the association of esomeprazole 40mg od to normalize the breath test result.
By optimizing the therapy, serum levels of RBP increased from 2.4 mg/dL (2.1-2.7 mg/dL)
to 3.1 mg/dL (2.8-3.4 mg/dL) (p<0.001). Similarly, serum prealbumin levels increased from
20.7 mg/dL (18.8-22.6 mg/dL) to 25.2 mg/dL (23.8-26.6 mg/dL) (p<0.001). Serum RBP and
prealbumin levels reached normal values in 14 (70%) and 20 (100%) patients respectively.
Conclusion: Therapy of CP-related maldigestion may be optimized by the 13C-MTG-BT.
This therapeutic optimization allows assuring a normal nutritional status in patients with CP.
T1292
Development of a Breath Test with Stable Isotopes for the Evaluation of
Carbohydrate Digestion
Beatriz Cigarran, Maria Vilarino, Marta Iglesias-Rey, Enrique Dominguez-Munoz
Background: Diagnosis of carbohydrate digestion is becoming relevant in patients with
pancreatic diseases due to the development of new enzyme preparations including lipase
as the single enzyme. Carbohydrate maldigestion may also be an important aspect in diabetes
mellitus-related exocrine pancreatic insufficiency. At present, methods to evaluate carbohyd-
rate digestion are lacking. Aim: To develop a new breath test with stable isotopes for the
evaluation of carbohydrate digestion. Methods: A prospective, open, crossover comparative
study was performed. Eight healthy subjects (age rage 28-43 years, 6 male) were included.
A test meal consisting on a muffin (50g corn flour, 14 g fat) and 300 ml water was developed.
After overnight fast, metoclopramide 10mg were orally given 20-30min before test meal
ingestion. Breath samples were collected in Exeteiner tubes before and in 30min intervals
for 6 hours after test meal. The same test was repeated 7±2 days thereafter, when acarbose
100mg was orally given just at the beginning of the test meal ingestion. The quotient 13CO2/
12CO2 was measured by mass spectrometry. The area under the curve (AUC) of the global
13CO2 exhaled over the 6 hour time, expressed as delta over baseline (DOB)/6h, was
considered as the result of the test. Data are shown as median and range, and compared
by the Wilcoxon test for related samples. Results: Administration of a corn-based test meal
allowed us to obtain a 13CO2 exhalation curve concordant with the physiological process
of carbohydrate digestion. 13CO2 elimination peak occurred at 180-210 minutes in all
subjects and the AUC was 977 DOB/6h (range 632-1340 DOB/6h). Acarbose-mediated
inhibition of glucosidase activity led to a marked reduction of 13CO2 elimination in breath
(AUC 248 DOB/6h, range 72-503 DOB/6h) (p<0.01). Conclusion: A corn-based breath test
allows carbohydrate digestion to be evaluated. In this test, glucosidase activity is the main
factor determining the amount of 13CO2 exhaled.
T1293
Are Monolithic Enteric-Coated Enzyme Preparations Effective in Pancreatic
Exocrine Insufficiency? A Multicentre, Double Blind, Placebo Controlled
Cross-Over Trial
Jutta Keller, Peter Layer
Background: Due to dissociation between gastric emptying of meal nutrients and enzyme
supplements, monolithic enteric-coated pancreatic enzyme preparations are assumed to be
virtually ineffective in improving lipid digestion and absorption in severe pancreatic exocrine
insufficiency. Instead, enteric-coated microgranule preparations are recommended as stand-
ard treatment. However, the effects of monolithic preparations on digestion and absorption
have not been studied, yet. Aims: To test the effects of a monolithic enteric-coated pancreatin
preparation on lipid digestion in patients with severe pancreatic exocrine insufficiency.
Methods: 20 patients with documented chronic pancreatitis (19 males, 1 female, age: 52±2
yrs, BMI: 23.1±0.7 kg/m2, mean ± SEM) and fecal elastase-1 concentrations ranging between
15 and 105 µg/g (42.1±8.2 µg/g) were included in 3 study centres. On two study days
(separated by an interval of 3-14 days and each preceeded by at least 3 days without intake
of enzyme supplements) patients received a monolithic enteric-coated pancreatin preparation
containing 40,000 U of lipase or placebo together with a standardised test meal containing
250 mg of 13C-mixed triglycerides. Breath samples were collected at 30 min intervals for
8 h and analysed by isotope selective infrared spectrometry. The trial was performed according
to a randomised, double blind, placebo controlled, cross-over study design. Differences
between cumulative 13C-exhalation were evaluated as markers of lipid digestion during
treatment with verum and placebo. Results (mean ± SEM, statistics: ANOVA): One patient
had to be excluded because of major protocol violations. Moreover, intestinal lipolysis was
found to be normal during placebo treatment in 6 patients with decreased fecal elastase-1
concentrations. Thus, these patients were also excluded from the per protocol analysis. In
the remaining 13 patients, mean cumulative 13C-exhalation over 6 and 8 hours was markedly
higher following treatment with verum compared to placebo (6 h: 11±2% vs. 5±1% of dose,
p=0.035; 8 h: 18±3% vs. 9±1% of dose, p=0.015). No treatment related adverse events
occurred. Conclusions: In contrast to current belief, a monolithic enteric-coated pancreatic
enzyme preparation containing 40,000 U of lipase significantly improves lipid digestion and
absorption compared to placebo in patients with pancreatic exocrine insufficiency due to
chronic pancreatitis. Thus, current treatment recommendations should be reconsidered.
T1294
Effect of Proton Pump Inhibition and/or Cigarette Use On the Results of An
Endoscopic Secretin Stimulation Test
Neil Phelan, Wahid Wassef
Background: Recent data suggests that cigarette use may be an independent risk factor for
pancreatic insufficiency or the progression of chronic pancreatitis. Endogenous secretin
release is intimately linked to gastric acid production. A significant number of our patients
with chronic pancreatitis are current or previous cigarette users, and are currently taking a
proton pump inhibitor (PPI). Purpose: To determine the effect of cigarette use and/or PPI
use on the results of an endoscopic secretin stimulation test (SST). Methods: A total of 44
patients with suspected chronic pancreatitis have undergone the combination of endoscopic
ultrasound and an endoscopic SST at our institution. The SST involved measurement of
[HCO3-] with duodenal aspiration at 15 minutes and 30 minutes after the administration
of secretin. We retrospectively examined the effects of PPI use and tobacco use on the results
of the SST. Tobacco use was subdivided into remote use, mild use (≤ 1 PPD), and moderate
use (> 1 PPD). The relationship between peak [HCO3-] and PPI use was evaluated with a
T-test. The relationship between peak [HCO3-] and cigarette use was evaluated using linear
regression analysis. The combination of the two variables was evaluated using multiple linear
regression analysis. Cigarette use was also examined as a bivariate variable, using current
smoking versus none/previous smoking. Results: The mean peak [HCO3-]’s of PPI users
versus nonusers were 63.38 and 63.55, respectively (p=0.98). The mean peak [HCO3-]’s
of current cigarette users versus nonusers were 65.67 and 61.92, respectively (p=0.58).
There was not a statistically significant difference between any two groups when both
variables were analyzed in combination. Conclusion: In our study, neither PPI use nor
cigarette use, either alone or in combination, had a statistically significant effect on the
results of the endoscopic secretin stimulation test. The results may be secondary to beta
error, as the sample size within each group was small, but further study is ongoing to
clarify this.
T1295
Exocrine Pancreatic Function Testing in Pancreatic Sufficient Cystic Fibrosis
Patients: A Correlation Study
Michael Wilschanski, Amir Weintraub, Huda Mussaffi, Hannah Blau, Eli Picard, Lea
Bentur, Eitan Kerem
Background: Most patients with Cystic Fibrosis have pancreatic insufficiency (PI), however,
15% of the patients are pancreatic sufficient (PS). Many laboratory tests have been developed
in order to examine exocrine pancreatic function to distinguish between PI and PS. The
‘gold-standard’ to determine pancreatic function apart from direct pancreatic stimulation
test is the fecal fat excretion during 72 h, expressed as the coeffiecient of fat absorption
(CFA). Other tests include: fecal elastase and serum immuno-reactive trypsinogen (IRT).
Aim: To test the correlation between elastase and IRT as compared to fecal fat excretion,
thereby, to evaluate the best available test to determine exocrine pancreatic function in CF
patients. Methods: 21 CF PS patients performed the 3 tests of fecal fat excretion, elastase
and IRT. Correlation between the tests was evaluated by the kappa statistics test, sensitivity,
specificity, and positive and negative predictive values. Results: The correlation between
CFA and IRT was negative (kappa = -0.154), and between CFA and elastase was poor
(kappa = 0.213). The sensitivity, specificity, positive and negative predictive values of IRT
vs. CFA were: 0%, 88%, 0%, and 78%, respectively, and for elastase were: 40%, 81%, 40%,
and 81% respectively. Conclusion: Poor correlation was found between IRT, elastase and
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CFA, therefore, neither elastase in the stool nor IRT in the serum has the sensitivity or the
specificity to replace the ‘gold standard’ test of fecal fat excretion during 72 h. Thus, despite
the technical difficulties and the inconvenient of collecting stool, there is a need to evaluate
precisely the pancreatic function of the CF patients, at least at the time of diagnosis,
and non-infrequently during the follow-up period, especially, when changes in clinical
parameters occur.
T1296
Pancreatic Function Testing Is Best Determined By the One Hour Endoscopic
Tube Assisted Technique Rather Than the Rapid 15 Minute Direct Endoscopic
Aspiration Test
Picha Moolsintong, Frank R. Burton
BACKGROUND: Rapid 15 minute endoscopic secretin stimulated pancreatic function testing
(ESPFT) has been proposed as an alternative to standard secretin stimulated duodenal tube
pancreatic function testing. Various investigators have questioned the accuracy of ESPFT in
determining peak HCO3 concentrations (PHC). Expanded collection periods with an oral-
duodenal drainage tube allow for additional collections to capture PHC after the initial 15
minute period without extending the EGD procedure time. AIM: To evaluate whether the
one hour endoscopic secretin stimulated tube assisted technique is superior to the rapid 15
minute direct ESPFT in determining pancreatic exocrine function. METHODS: A retrospective
study was done of patients with chronic abdominal pain and normal pancreatic imaging,
whom had ESPFT testing with the following modified endoscopic collection system. ESPFT
testing as described by Conwell et al was conducted. Synthetic secretin (0.2mcg/kg) was
given IV 15 minutes before endoscopic duodenal aspiration. The first 15 minute collection
of duodenal secretions was obtained via direct endoscopic aspiration. A wire-guided Liguory
nasal-biliary drainage tube with a distal pigtail multiport aspiration tip was placed in the
3rd portion of the duodenum under direct endoscopic visualization. The endoscope was
withdrawn as the tube was brought out through the oropharynx and connected to continuous
aspiration. Two additional 10 min-period collections were obtained via the drainage tube
at 30 and 45 min after IV secretin. Patients were maintained in the left-lateral decubitus
position during the procedure to prevent any gastric fluid contamination. All fluid collections
were analyzed for bicarbonate (HCO3) concentration and those > 80 mEq/L were considered
normal. HCO3 concentrations at 15 minutes were compared to the 30 and 45 minute
collections. RESULTS: Of the 28 patients studied, 9 were male and 19 were female, with a
mean age of 47.9 years. PHC at 15 minutes occurred in 15 patients (54%) and after 15
minutes in 13 patients (46%). Normal concentrations of HCO3 were seen in 17 patients
(60.7%). Of the 17 patients with normal PHC, 9 had a PHC after 15 minutes. In 3 patients,
the 15 minute PHC would have been inadequate to diagnose normal exocrine function. In
the 11 patients who never achieved normal values, 4 required more than 15 minutes to
reach PHC. CONCLUSIONS: The one hour secretin stimulated endoscopic tube assisted
technique is superior to the rapid 15 minute direct ESPFT in pancreatic exocrine function
testing. It appears that 1 hour collections were necessary in 3 (18%) patients to determine
normal pancreatic exocrine function.
T1297
Long-Term Outcome of Oral Anti-Oxidant Therapy in Patients with Painful
Chronic Pancreatitis
Anil Bagul, Ajith K. Siriwardena
Introduction: The generation of short-lived oxygen free radicals(oxidative stress) has been
implicated in the pathogenesis of chronic pancreatitis (CP). Anti-oxidants are endogenous
inhibitors/scavengers of oxygen free radicals and their levels are depleted in patients with
CP. There is some evidence that supplementation with exogenous anti-oxidants modulates
symptoms in CP. This study reports long-term outcome in a cohort of patients with CP
given anti-oxidant therapy. Methods: Patients diagnosed as CP and having their index
presentation to a regional hepatobiliary service in the calendar year 1993 were identified
by computerised review of hospital discharge summaries using the search criterion of
Internaional Classification of Disease 9:577-1. 39 patients fulfilled these criteria. These
patients had undergone measurement of anti-oxidant levels and had then been commenced
on antox (Pharmanord, UK) an anti-oxidant preparation comprising selenium, methionine
and ascorbic acid. Their charts were retrieved and indepedently reviewed to confirm that
they had either CT and/or ERCP evience of chronic pancreatitis. Chart review was then
carried out with data recorded on baseline and subsequent annual levels of anti-oxidants,
opiate use (expressed as a percentage of the study population and taking documented
weekly prescription to signify “regular” opiate), endocrine and exocrine insufficiency, surgical
intervention and mortality over the subsequent 10 years. Data are presented as median
(range). Statistical comparisons are made using an assumption of non-parametric distribution
of data with significance accepted at the P<0.05 level. RESULTS: Serum ascorbic acid levels
at recruitment were 14.7(1.9-28.3)mg/l and at 10 years were 15 (1.9-27.1) [P=0.52;Mann-
Whitney U-test]. Serum selenium at recruitment was 85(28-214)microgm/l compared to
143(86-266)microgm/l at 10 years [P<0.001; Mann-Whitney U test]. The laboratory reference
range for ascorbic acid was 4-20 mg/l and for selenium 83-152 microgm/l. At recruitment,
2 patients (5%) were diabetic and by 10 years this had risen to 20 (51%). Twenty six
patients (78%) presented with pain - and 25 (75%) reported pain at 10 years. Eight (38%)
were on regular opiates at baseline compared to 21 (73%)at 10 years[P=0.01;Fisher’s 2-
sided]. CONCLUSION: Although long-term anti-oxidant therapy appears to sustain selenium
levels, there does not appear to be any sustained modulating effect on either the symptoms


















Reoperation in Chronic Pancreatitis
H Ramesh, Sadiq S. Sikora
Aim: This retrospective analysis of prospective data aims at analyzing a) indications for re-
operation, b) morbidity and mortality of late re-operation in chronic pancreatitis and c) to
study the long-term outcome in these patients. Patients and Methods: During 1987 to 2004,
623 patients underwent first surgery for chronic pancreatitis. During the same period, 57
patients underwent late re-operation (beyond 6 months of initial surgery). There were 3
groups: a) patients who had undergone other abdominal procedures for abdominal pain
prior to referral to this center (n=16), b) who had undergone pancreatic procedures elsewhere
(n=22) and c) patients who had undergone re-operation in this unit earlier (n=19). Results:
The data is summarised in Table 1: The Indications for re-operation is shown in Table 2:
Conclusions: Re-operation in chronic pancreatitis is often required when entire pancreatic
duct system is not drained or if inflammatory mass involving head is not dealt with during
the initial surgery. Re-operative surgery carries high morbidity and mortality even in a high
volume center. Those who underwent re-operative surgery have good pain relief and enjoy




Differential Effect of Opioids in Patients with Chronic Pancreatitis: An
Experimental Pain Study
Thomas R. Sorensen, Camilla Staahl, Lars Arendt-Nielsen, Asbjorn M. Drewes
Background and aims: Chronic gastrointestinal pain can be difficult to treat sufficiently with
classical opioids. This frequently results in a very poor quality of life for the patients. Animal
experiments and clinical observations have indicated a different working profile of oxycodone
compared to morphine, and we have previously shown that oxycodone attenuate visceral
(but not skin and muscle) pain better than morphine. This study aimed at testing oxycodone
and morphine on experimental pain in different tissues in patients with pain due to chronic
pancreatitis. Methods: In this blinded cross-over study we included 10 patients suffering
from painful chronic pancreatitis. Inclusion criteria were that the patients should fulfill the
Marseille-Rome/Cambridge diagnostic criteria for chronic pancreatitis. They should have
chronic abdominal pain typical for chronic pancreatitis despite the use of pain killers. The
patients should not suffer from any other kinds of chronic pain and they should have no
present alcohol abuse. The study was approved by The Ethics Committee of Northern
Jutland and the Danish Medicines Agency. The analgesic effect of morphine (30 mg),
oxycodone (15 mg) and placebo was tested against multi-modal (mechanical, thermal and
electrical) experimental pain in the skin, muscles and esophagus. Pain was assessed at
baseline and 30, 60 and 90 minutes after oral administration of the drugs. Results: In the
skin and muscles oxycodone had better effects than placebo and morphine on mechanically
(skin: F=12.4, P<0.001, muscle: F=11.0, P<0.001) and thermally (skin: F=8.5, P<0.001)
evoked pain. In the esophagus oxycodone attenuated heat pain better than both morphine
and placebo (F=9.5, P<0.001). Morphine was equal to placebo in the above pain tests.
Morphine and oxycodone both attenuated mechanical pain in the esophagus better than
placebo (F=8.6, P<0.001). After electrical stimulation no differences between the opioids
and placebo in any tissue studied could be demonstrated. Conclusions: The findings indicate
up-regulation of the opioid system in patients suffering from chronic pancreatitis. The model
supports the clinical impression that oxycodone works well after opioid rotation in patients
with persistent visceral pain.
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T1300
Is Pancreatic Insufficiency Significant in African American Patients with End
Stage Renal Disease On Hemodialysis?
Kapil Gupta, Chekai Tsao, Reuven Yakubov, Safak Reka, Moro Salifu, Scott Tenner,
Swaminath Iyer
BACKGROUND: Pancreatic exocrine insufficiency has been shown to be present in patients
with end stage renal disease (ESRD) on hemodialysis (HD). This finding is based on previous
autopsy studies, and evaluation of pancreatic exocrine function using standard tests like
fecal fat and chymotrypsin. Recently studies have shown fecal elastase 1 (FE1) as an effective
method to diagnose pancreatic insufficiency. The aim of this study was to determine the
prevalence of pancreatic exocrine dysfunction in patients with end stage renal disease (ESRD)
on hemodialysis using FE1. METHODS: This was a prospective cross-sectional study of 25
African Americans (14 women and 11 men), ranging in age from 29 to 71 years with mean
58 ± 2.26 (± SEM) with ESRD on HD 3 times a week. Patients with other causes of pancreatic
exocrine dysfunction were excluded from the study, including significant alcohol use, history
of acute or chronic pancreatitis, liver disease, HIV, and family history of pancreatic disease.
Fresh stool samples were collected from all the patients. Samples were stored at < - 20
degree C until analysis. FE1 was measured using an ELISA method (Joli Diagnostic, New
York: Reference values: 200 to> 500 ug/g of stool = normal; 100 to 200 ug/g of stool =
moderate to slight insufficiency; < 100 ug/g stool = severe exocrine insufficiency). RESULTS:
All patients had hypertension and the duration of hemodialysis varied from 1 yr to 20 yrs
with mean 4.7 ± 0.89. There were 12 subjects with and 13 without diabetes. Twenty four
of 25 patients (96%) had normal levels of FE1. Eighteen (72%) of the patients had levels
> 500 ug/g of stool. Only 1/24 (4%) patient had an FE1 level of < 200 (175.9) ug/g stool.
None of the patients had any clinical manifestation of pancreatic exocrine insufficiency.
Mean serum albumin level was 3.75 ± 0.11 and serum albumin levels did not correlate with
FE1 levels (p=0.08). There was no evidence of malnutrition in any patient. The mean BMI
was 27.95 ± 1.33. There was no correlation between BMI and FE1 levels (p=0.2). Using
the chi square test for independence there was no significant relationship between patients
with diabetes and levels of elastase (p=0.5). Using the linear regression analysis the duration
of dialysis also did not significantly affect FE1 (p=0.78). CONCLUSION: 1. In our pilot
study, stool FE1 levels did not indicate pancreatic .exocrine insufficiency in subjects with
ESRD on HD. 2. There was no clinical or laboratory evidence of pancreatic exocrine insuffi-
ciency in subjects with ESRD on HD. 3. There is no difference in presence of pancreatic
exocrine insufficiency in patients with and without diabetes.
T1301
Endoscopic Ultrasound (EUS)-Guided Fine Needle Biopsy (FNB) for the
Histological Evaluation of Chronic Pancreatitis
Julio Iglesias-Garcia, Ihab Abdulkader, Jose Larino-Noia, Jeronimo Forteza, Enrique
Dominguez-Munoz
Background: Histological diagnosis of chronic pancreatitis has been classically limited to
the study of surgical specimens. Since pancreatic biopsies are rarely done in the context of
chronic pancreatitis, histological characteristics at different stages of the disease are unknown.
Aim: To evaluate the histological characteristics of chronic pancreatitis in samples obtained
by pancreatic EUS-FNB, according to EUS findings. Methods: Twelve consecutive patients
(12 male, mean age 67 years, range 17-81 years) with known chronic pancreatitis, who
underwent EUS-FNB for the study of pancreatic masses were included. EUS-FNB was
performed under conscious sedation with a 22G needle guided by the lineal scanning
Pentax FG-38UX echoendoscope. EUS criteria for the diagnosis of chronic pancreatitis were
evaluated: parenchymal criteria included hyperechoic foci, hyperechoic strands, lobularity,
cysts and calcifications; and ductal criteria included dilation, duct irregularity, hyperechoic
duct margins, visible side-branches and intraductal calcifications. Following histological
features were evaluated: presence of acini, ductal epithelium, fibrotic tissue (collagen) and
inflammatory infiltration. Results: Adequate tissue sample for histological evaluation was
obtained in all cases. Infiltration by inflammatory cells was observed in all tissue specimens.
Samples included pancreatic acini in five cases (41.6%), in number of 2 to 13 acini each.
In the remaining 7 cases (58.4%) the presence of ductal epithelium together with fibrotic
tissue was observed. Biopsies including pancreatic acini were those obtained from patients
with mild to moderate EUS changes of chronic pancreatitis (up to 5 EUS criteria). On the
contrary, biopsy samples from more severe cases (8-10 EUS criteria) were those showing
only ductal ephitelium with fibrotic component. Conclusion: EUS-guided pancreatic biopsy
allows evaluating histological changes of all stages of chronic pancreatitis. This may be an
important advance for a better knowledge of the disease.
T1302
Timed Secretin-Enhanced Magnetic Resonance Cholangiopancreatography As a
New Non-Invasive Pancreatic Function Test - Results of a Pilot Study
Darwin L. Conwell, Mansour A. Parsi, Gregory Zuccaro, Joseph Veniero
Background & Aim: Secretin-enhanced magnetic resonance cholangiopancreatography (S-
MRCP) is a non-invasive imaging technique that allows the depiction of morphologic changes
in pancreatic ducts and a qualitative assessment of exocrine function by monitoring duodenal
filling after exocrine stimulation. In the present study we assessed the use of a timed S-
MRCP to assess pancreatic exocrine function during secretin stimulation and compared it
to the already validated endoscopic pancreatic function test using secretin (S-ePFT). Methods:
Sixteen patients with abdominal pain and suspicion of chronic pancreatitis underwent S-
MRCP and S-ePFT. After secretin stimulation during the MRCP, the timing of the duodenal
filling and the volume of the pancreatic excretion were assessed. Patients were deemed as
having pancreatic insufficiency if duodenal filling was not achieved or if the pancreatic
secretion was significantly delayed. The S-ePFT was performed after injection of 0.2 mcg/
kg synthetic porcine secretin. Duodenal fluid was collected with an upper endoscope during
endoscopy at 15, 30, 45 and 60 minutes after secretin injection and the peak bicarbonate
concentration of the collected juice was determined. The peak bicarbonate concentration less
than or equal to 80 mmol/l was defined as evidence of pancreatic insufficiency. Performance of
the S-MRCP was compared to the S-ePFT as the gold standard. Results: Eight patients had
a peak bicarbonate concentration of less than 80 mmol/l indicating presence of pancreatic
insufficiency. The sensitivity, specificity, positive predictive value and negative predictive
value of S-MRCP for detection of pancreatic insufficiency were all 63%. Conclusions: This
pilot study with a small number of patients suggests that S-MRCP may have clinical use as
a non-invasive pancreatic function test. Further studies with larger number of patients are
needed to determine the best cutt-off values for the time delay and volume of the pancreatic
secretion that would indicate presence of pancreatic insufficiency.
T1568
Synergy of Helicobacter Pylori Vacuolating Cytotoxin and IL-4 in Eotaxin
Expression in Human Gastric Epithelial Cells Through Stat6 Pathway
Jung Mogg Kim, Joo Sung Kim, Hyun Chae Jung, In Sung Song
Helicobacter pylori-infected gastric mucosa from patients with active chronic inflammation is
characterized by infiltration of various inflammatory cells such as neutrophils and eosinophils.
Although several mechanisms for neutrophil infiltration are well known, there has been
little known the role of eotaxin, which is a potent chemoattractant for eosinophils, on the
inflammatory process of H. pylori infection. The present study was to investigate the mechan-
isms of eotaxin expression in gastric epithelial cells stimulated with H. pylori vacuolating
cytotoxin (VacA). Stimulation with VacA purified from H. pylori slightly increased eotaxin
expression in MKN-45 gastric epithelial cell lines and primary human gastric epithelial cells.
In contrast, the combined stimulation with VacA and IL-4 synergistically increased the eotaxin
expression, as assessed by quantitative RT-PCR and ELISA. In MKN-45 cells transfected with
an eotaxin promoter-luciferase reporter plasmid, costimulation with VacA and IL-4 induced
more luciferase activity than either VacA or IL-4 alone did. However, such up-regulation
was significantly decreased in the cells transfected with luciferase reporter plasmid bearing
an eotaxin promoter which has a mutation at STAT6 binding site. Tyrosine phosphorylation
of STAT6 was definitely increased in both MKN-45 and primary gastric epithelial cells
stimulated with VacA and IL-4, compared with VacA or IL-4 alone. Furthermore, eotaxin
expression was significantly suppressed in MKN-45 cells transfected with STAT6 siRNA.
These results suggest that up-regulation of eotaxin in VacA-stimulated gastric epithelial cells
may be synergistically facilitated by IL-4 via a STAT6-dependent mechanism.
T1569
The Nikr Protein Mediates Nickel-Responsive Regulation of the Helicobacter
Pylori Iron-Uptake Genes FECA3 and FRPB3
Florian D. Ernst, Arnoud H. van Vliet, Wannie M. Horrevoets, Jeroen Stoof, Johannes G.
Kusters, Ernst J. Kuipers
Introduction: Intracellular homeostasis of iron is a necessity for most organisms, since both
iron-deficiency and iron-overload will result in cell death. The gastric pathogen Helicobacter
pylori has three copies of the fecA and frpB iron-uptake genes, of which the fecA1/2 and
frpB1/2 genes are regulated by the Fur protein. Surprisingly, fecA3 and frpB3 are not Fur-
regulated and thus were thought to be constitutively expressed. H. pylori expresses a second
metal-regulatory protein, NikR, and this was previously suggested to be involved in regulation
of the fecA3 and frpB3 genes, but the mechanims governing this regulation was not described.
Aim: We therefore investigated whether the fecA3 and frpB3 genes are regulated by NikR,
and characterized the molecular mechanism governing this regulation. Methods: H. pylori
reference strain 26695 and isogenic mutants were grown in Brucella broth supplemented
with NiCl2. Gene expression was monitored using Northern hybridization, primer extension
and SDS-PAGE. Results: Expression of the fecA3 and frpB3 genes was nickel-repressed in
wild-type H. pylori, but constitutively expressed in the nikR mutant. However, the genes
fecA1/2 and frpB1/2 did not display any nickel or NikR-dependent regulation. On the
translational level the nickel- and NikR-dependent regulation was confirmed for frpB3.
Mutation of frpB3 had no effect on growth in nickel-supplemented medium, possibly due
to the compensatory expression of the two other copies of the fecA and frpB genes. Direct
regulation of fecA3 and frpB3 by NikR was confirmed by the specific binding of recombinant
NikR to an operator sequence present in both the fecA3 and frpB3 promoters. Conclusion:
The NikR and Fur proteins each regulate the expression of a subset of iron-transporter
proteins, allowing differential expression of iron-uptake systems depending on the environ-
mental conditions. This may help H. pylori to survive the acidic conditions in the gastric
mucosa.
T1570
Iron-Responsive Repression of Urease Expression in Helicobacter Hepaticus Is
Mediated by the Transcriptional Regulator Fur
Clara Belzer, Ernst J. Kuipers, Bart A. van Schendel, Johannes G. Kusters, Arnoud H. van
Vliet
Introduction: The pathogen Helicobacter hepaticus colonizes the enteric and hepatobiliary
tract of rodents, and causes inflammatory bowel lesions, hepatitis, and hepatic malignancies.
Urease is an environmentally regulated key-virulence factor for gastric Helicobacter species,
but little is known about its role or regulation in non-gastric Helicobacter species. Low iron
is often used by pathogenic bacteria as a signal for entering the host. We have previously
shown that urease expression in H. hepaticus is not nickel-responsive, unlike the H. pylori
urease. In this study we have investigated the role of iron in regulation of H. hepaticus urease.
Methods: H. hepaticus strain ATCC51449 and its isogenic fur mutant were grown both
under low-iron and high-iron conditions. Gene expression was monitored by Northern
hybridization, and protein expression was monitored by SDS-PAGE. Urease activity was
measured via a colorimetric reaction representing production of ammonia. Results: Iron-
depletion of growth medium resulted in a three-fold increase in urease activity in wild type
H. hepaticus strain ATCC 51449. Using Northern hybridization it was demonstrated that
iron-repression of urease expression was mediated at the transcriptional level. Mutation of
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the fur gene abolished the effect of iron-depletion, suggesting a role for Fur in iron-repression
of urease expression. This was confirmed using a gel-shift assay, as recombinant Fur displayed
iron-dependent binding to the urease promoter region. Conclusion: Iron and Fur are likely
to contribute to H. hepaticus virulence as they are both involved in the repression of expression
of the urease virulence factor. This regulation strongly contrasts with the NikR- and nickel-
induction of urease expression in H. pylori. Iron-mediated urease regulation has not been
reported before and may be important in the colonization of the intestinal and hepatobilary
tract by H. hepaticus.
T1571
Cautions Regarding Relationships Between Expression of Helicobacter Pylori
Baba and Disease Outcome
Saori Fujimoto, Olabisi Ojo, Anna Arnqvist, Jeng Yih Wu, Stefan Odenbreit, Rainer Haas,
Rita Reddy, David Y. Graham, Yoshio Yamaoka
Background: Gastric mucosal ABO blood group antigens are recognized by the blood group
antigen binding adhesin BabA. The role of BabA in the outcome of H. pylori infections
remains unclear. Proposed relationships between BabA status and clinical outcome have
used PCR-based methods to distinguish functional babA2 genes from nonfunctional babA1
genes. These methods are based on detection of a 10 base pair deletion in the signal peptide
sequence of babA1. However, as expression of babA may also be regulated at the level of
transcription and by formation of chimeric babA-babB gene it is not clear whether the
PCR-based methods reflect BabA expression or whether the PCR-based methods provide
misleading estimates of babA expression. Aims: To investigate the accuracy of PCR-based
methods in providing an estimate of babA expression and to reassess the relation between
BabA status and clinical outcome. Methods: We compared 16 published PCR-based methods
for predicting BabA status with immunoblotting and Lewis b binding assays with Lewis B
binding assays being the gold standard. We then used immunoblotting to examine the
relationship between clinical presentation and BabA status. Results: Lewis binding assay
and BabA immunoblot yielded identical results. In contrast, PCR-based methods had low
sensitivity and specificity as the prevalence of the babA2-positive strains with different primer
pairs ranged from 30% to 98% among Western strains and from 55% to 100% among East
Asian strains. Sequence analyses showed among 137 strains deposited in GenBank and 18
strains examined here, only CCUG17875 carried the babA1 type of sequence. Of interest,
the primer regions targeted were not located in the conserved region of the babA gene. We
also examined 1,130 H. pylori isolates by immunoblot and found that BabA expression as
determined by immunoblot was weakly, but significantly, related to the presence of both
peptic ulcer and gastric cancer; peptic ulcer vs. gastritis (adjusted OR = 1.9; 95% CI = 1.1-
3.4), and gastric cancer vs. gastritis (OR = 1.9; 95% CI = 1.1-3.3). However, BabA was
expressed in the majority (74%) of strains isolated from patients with simple gastritis.
Conclusions: PCR-based methods correlate poorly with BabA expression status and can not
be used to reliably possible examine BabA associations. Immunoblot is currently the most
accurate and efficient method to assess BabA status. However, simple determination of BabA
status appears not to be clinically useful. Supported in part by the Gulf Coast Digestive
Disease Center.
T1572
Strain-Dependent and Independent Roles of the Alpab in Helicobacter Pylori
Infection: In Vitro and in Vivo Evidences
Hong Lu, Ellen J. Beswick, Victor E. Reyes, David Graham, Yoshio Yamaoka
Background: Two adjacent homologous genes encoding the outer membrane proteins;
adherence-associated lipoprotein (alpA and alpB) have been suggested to be associated with
adhesion. alpAB isogenic mutants were reported not to induce Interleukin-8 (IL-8) from
epithelial cells, but subsequent failed to confirm that finding. AlpAB were reported to be
involved in colonization of the guinea pig; however the studies using other animals had
never studied. Methods: We used 3 H. pylori cag pathogenicity island-positive strains
(TN2GF4, JK51 and ATCC43504) and their precise whole alpA-alpB deleted mutants (alpAB
KO). H. pylori were co-cultured with gastric epithelial cells (AGS, MKN28 or MKN45 cells).
Adherence was evaluated by flow cytometry and IL-8 levels by ELISA. Binding of nuclear
proteins to transcription factors was assessed by electrophoretic mobility shift assays and
protein/DNA array. Colonization ability was examined in C57BL/6 mice after 8 weeks.
Results: alpAB KO significantly decreased adherence (64-78% reduction) irrespective of cell
type or strain. However, the effect of alpAB KO on IL-8 induction from gastric epithelial
cells was strain-dependent (e.g., a 52-91% reduction compared to the parental strains with
strains TN2GF4 and JK51 but no reduction with ATCC43504). The effect of AlpAB in
activation of transcription factors located in IL-8 promoter (e.g., NF-κB, AP-1) mirrored its
effects on IL-8 induction. In contrast, the levels of the transcription factor cAMP response
element-binding protein (CREB) were decreased with all alpAB KO strains. High IL-8 produ-
cing alpAB KO infected mice equally well as their parental strain. In contrast, low IL-8
producing alpAB KO did not infect mice whereas the parental strain TN2GF4 did. Conclu-
sion: Overall, our results confirm that AlpAB is involved in adherence of H. pylori to
gastric epithelial cells. AlpAB’s effect on IL-8 induction was strain-dependent providing an
explanation for prior conflicting results. The role of AlpAB as a colonization factor was
independent of its effect on adherence but was related to the ability to induce IL-8. AlpAB
appears to pay a complex role in H. pylori pathogenesis only part of which is related to a


















Adherence, Internalization and Persistence of Helicobacter Pylori in Human
Hepatocytes
Kyoko Ito, Yoshio Yamaoka, Hala El-Zimaity, Hiroyoshi Ota, David Graham
Background: Helicobacter sp. including H. pylori have been identified in hepatocellular
carcinoma and other liver diseases suggesting a possible association between Helicobacter
infection and human liver disease. Aim: To explore the mechanisms of internalization and
persistence of Helicobacter pylori in hepatocytes. Methods: H. pylori NCTC11637 (CagA+,
VacA+) or 401C (CagA-, VacA-) were co-cultured with Huh7 cells, a human hepatocellular
carcinoma cell line. H. pylori adherence, internalization, and persistence were assessed by
quantitative bacterial culture and gentamicin invasion assay as well as by histology using
silver stains and electron microscopy. The mechanism for internalization was investigated
using anti-β1-integrin antibodies, chloroquine and cytochalasin D to assess the requirements
for attachment to β1-integrin, receptor-mediated internalization and actin polymerization,
respectively. Results: 1 hour after inoculation of 10(6) (to the 6th) CFU H. pylori, 5.2 ± 1
X 10(5) CFU (50% of the inoculum) adhered to hepatocytes (~7 CFU/cell) and 4.4 ± 0.4
X 10(3) CFU (1 CFU/ 10 cells) had invaded into the cells. By 6 hours the number of
adherent H. pylori had increased to 8.3 ± 0.5 X 10(5) CFU (P <0.05) whereas as the number
of intracellular H. pylori was essentially unchanged. After 48 hours the number of adherent
and internalized H. pylori decreased slightly (1.5 ± 0.2 X 10(5) CFU were adherent and
2.0 ± 0.9 X 10(3) CFU were internalized) (P <0.05). Adherence and internalization were
independent of the presence of CagA or VacA. Long term internalization assays revealed
that H. pylori persisted in hepatocytes (confirmed by electron microscopy after 5 passages)
for at least 13 passages (2 months). Cytochalasin D, chloroquine and anti-β1-integrin
antibody inhibited internalization of CagA/VacA-positive H. pylori. Internalization of CagA/
VacA-negative H. pylori was not inhibited by chloroquine, but was inhibited by cytochalasin
D and anti-β1-integrin antibody (P <0.05). Conclusion: H. pylori both adhered to and
invaded hepatocytes. Further, H. pylori persisted within hepatocytes during subculture.
Adherence and internalization were independent of H. pylori virulent factors. β1-integrin is
likely a receptor involved in internalization of H. pylori into hepatocytes and actin polymeriz-
ation was required for internalization of H. pylori. CagA/VacA-positive strains appeared to
utilize receptor mediated endocytosis. This is the first report of the adherence and internaliz-
ation of Helicobacter into hepatocytes as well as the long-term persistence of Helicobacter
inside human cells. Supported in part by the Gulf Coast Digestive Disease Center
T1574
Production of Reactive Oxygen Species in Peripheral Blood Is Increased in
Individuals with Helicobacter Pylori Infection and Decreased After Its
Eradication
Masayuki Mashimo, Manabu Nishikawa, Kazuhide Higuchi, E.J. Sasaki, Masatsugu Shiba,
Kazunari Tominaga, Toshio Watanabe, Yasuhiro Fujiwara, Tetsuo Arakawa, Masayasu
Inoue
Background: Helicobacter pylori (H. pylori) infection causes various diseases in the gastrointes-
tinal tract. Some reports have already been reported that reactive oxygen species (ROS)
production increased in local gastric mucosa. Recent studies have suggested that H. pylori
infection may also cause other systemic diseases, including hematological disorders, skin
and cardiovascular injury, by unknown mechanisms. We hypothesized that ROS contribute
to the etiology of these systemic diseases other than gastrointestinal disorders in H. pylori
infection. Methods: Production of ROS was determined in peripheral blood samples from
86 patients (34 H. pylori-negative and 52 H. pylori-positive subjects) using a highly sensitive
chemiluminescence probe [8-amino-5-chloro-7-phenylpyrido(3,4-d) pyridazine-1 and 4
(2H, 3H) dione] (L-012). Results: ROS production was significantly higher in individuals
with H. pylori infection than in those without such infection (non-H. pylori-infected: 1.76
± 1.26 kcpm; H. pylori-infected: 3.98 ± 3.21 kcpm; P<0.0005). Enhanced production of
ROS was decreased significantly after eradication of H. pylori (Paired t-test: P = 0.012). No
correlation was found between the extent of ROS production and sex, age, smoking status,
alcohol ingestion, use of medications, or serum level of C-reactive protein. Conclusion:
These findings suggest the possibility of involvement of enhanced ROS production in circulat-
ing blood in the etiology of various systemic diseases in patients with H. pylori infection.
Chemiluminescence analysis of blood samples using L-012 might permit evaluation of risk
of systemic diseases in patients with H. pylori infection.
T1575
Caga Positive Strains of H. Pylori in Patients with Stable and Unstable Angina
Pectoris
Francesco Franceschi, Antonio Gasbarrini, Giampaolo Niccoli, Alfonso Baldi, Marcello
Candelli, Florinda Feroce, Maria Assunta Zocco, Micaela Conte, Davide Roccarina,
Giovanni Gasbarrini, Filippo Crea, Nicolo Gentiloni Silveri
Background: Previous studies have reported an epidemiological association between CagA-
positive strains of H. pylori and ischemic heart disease (IHD). More recent studies, moreover,
have shown that antibodies anti-CagA recognize antigens of both normal and atherosclerotic
blood vessels, such as umbilical cord or atherosclerotic tibial arteries. In order to verify
those findings we have designed a study aimed at determining the prevalence of CagA-
positive strains and the antibody titre in patients with stable (SA) and unstable angina
pectoris (UA) and to verify whether anti-CagA antibodies cross-react with antigens of coronary
atherosclerotic plaques collected from the same patients. Methods: 38 (30 males, mean age
64±11 years) patients with angiographically documented UA, 25 patients with angiograph-
ically documented SA (21 males, mean age 62±10 years) and 50 healthy volunteers (38
males, mean age 62±10 years) were enrolled. The prevalence of H. pylori infection and
CagA-positive strains and the antibody titres were evaluated in all subjects through ELISA
(Radim, Italy). Fresh fragments of atherosclerotic plaques were obtained from all patients
through directional coronary atherectomy, and prepared for immunohistochemistry using
monoclonal antibodies anti-CagA (Austral Biologicals, USA). Results: Prevalence of H. pylori
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infection was significantly higher in patients with SA and UA compared to controls (60%
in SA, 61% in UA vs 38% of controls; p<0.04). Prevalence of CagA-positive strains was
significantly higher in patients with SA and UA compared to controls (44% in SA, 50% in
UA and 18% in controls; p<0.001). Moreover, the titre of anti-CagA antibodies was signific-
antly higher in patients with UA compared to those with SA (161±120 RU/ml vs 78.7±63.1
RU/ml; p<0.03). Interestingly, anti-CagA antibodies recognized antigens localized in the
cytoplasm of fibroblasts-like cells as well as lymphocyte-like cells inside atherosclerotic
plaques. Conclusions: Anti-CagA antibody titre is significantly higher in patients with UA
compared to those with SA. Interestingly, antibodies anti-CagA specifically recognize antigens
localized inside the atherosclerotic plaques of the same patients. The binding of anti-CagA
antibodies to those antigens could influence the progression of atherosclerosis. Antibody anti-
CagA titre may predict the destabilization of atherosclerotic lesions, in IHD infected patients.
T1576
Genotyping of the Cytotoxin Associated Gene Pathogenicity Island from
Helicobacter Pylori Isolates in Alaska
Karen Miernyk, Michael Bruce, Brian McMahon, Thomas Hennessey, Frank Sacco, Gerry
Sahagun, Paul Davis, Patrick Martinez, Michael Swenson, David Powers, Bane French,
Helen Peters, Debra Hurlburt, Alan Parkinson
Introduction: Several studies have shown a relationship between the severity of gastric disease
and the presence of the cag pathogenicity island (PAI). Presence or absence of the cag PAI
tends to differ by geographic region. Additionally, in strains with the cag PAI, there are
distinct differences in the 3’ region of the cagA gene when comparing Asian strains with
western strains. We studied Helicobacter pylori isolated from persons enrolled in a reinfection
study to determine how common cag positive H. pylori strains are in Alaska. Methods: We
enrolled American Indian (AI) and Alaska Native (AN) persons from three rural clinics in
western Alaska and one urban medical center in southcentral Alaska and non-Native persons
from two private urban clinics in southcentral Alaska. Study participants had an EGD and
H. pylori was cultured from their tissue biopsy. We used real time PCR to identify the strain
(either Asian or western) of cagA with primers amplifying portions of the cagA 3’ repeat
region. We used conventional PCR to identify the cag negative strains by amplifying the cag
PAI empty site. Strains that could not be identified with either the strain typing PCR or the
cag PAI empty site PCR were run with a second conventional PCR that detects the 5’ end
of the cagA PAI. Results: H. pylori was cultured and the isolate(s) genotyped from 257
persons. 201 (78%) persons were infected with a cag positive strain of whom 35 (17%)
were co-infected with a cag negative strain. Fifty-six (22%) persons were infected with a
cag negative strain only. AI/AN persons were more likely to have a cag positive strain of H.
pylori than non-Native persons (82% vs. 67%; p=0.01). Of persons infected with a cag
positive strain, 175 (87%) were infected with a western strain of the cagA gene, 7 (3%)
with an Asian strain, 5 (2%) with both western and Asian strains, and 14 (7%) with a strain
that could not be further identified. Conclusions: A high proportion of H. pylori strains
isolated from persons residing in western and southcentral Alaska contain the cag PAI.
Among cag positive strains, western cagA predominates. Further research is needed to
determine how cag positivity relates to clinical symptoms and disease etiology.
T1577
Dramatic Effect of Changes in Standards of Living On the Acquisition of
Helicobacter Pylori Infection in Childhood: A 10 Years Follow-Up Study in
Russia
Hoda M. Malaty, Michael Tkachenko, Zhannat Z. Nurgalieva, Elena L. Blashenkova,
Sergey V. Isachenko, David Y. Graham, Lev V. Erman
Background: The prevalence and rate of acquisition of H. pylori infection in children from
developing countries is higher than in developed countries. This phenomenon has been
related to differences in socioeconomic status, sanitation, and household hygiene. Russia is
in the process transformation from an underdeveloped to a developed country. Aim: We
examined the effect of recent improvement in standards of living on the prevalence of H.
pylori in Russian children. Methods: We conducted 2 cross-sectional studies among children
in St. Petersburg, Russia. The first study was conducted in 1995 and the second was
conducted a decade later. H. pylori status was evaluated the same ELISA method for anti-
H. pylori IgG (HM-CAP). Demographic data were obtained from each individual; socioecon-
omic class was assessed by the education level of the mother and family income. Results:
In 1995 the overall prevalence of H. pylori infection was 44% and decreased to 12% ten
years later. In both studies, the prevalence increased with age. In 1995 the prevalence was
30% among children younger than 5 years. A decade later the prevalence in the same age
group is zero. The age specific patterns of H. pylori infection is shown in the table. The
crude and the age-adjusted odds ratio risk of infection in children showed an inverse
correlation between the mother’s education level and H. pylori seropositivity (OR = 1.8, CI
95% 1 to 3.2), (p = 0.05). No associations were found between prevalence of H. pylori and
any factor tested including gender, type of dwelling, income or the number of persons living
in the home. Conclusions: Improvements in standards of living in Russia have resulted in
a marked reduction in H. pylori transmission. Different rates of acquisition H. pylori form
the basis for the differences in prevalence of infection between and among populations. The
changes in Russia are a dramatic example of how sensitive H. pylori acquisition is to
improvement in standards of living.
table
T1578
Fur and Perr Mediate Iron-Responsive Regulation of Peroxide Stress Defense
Genes in Helicobacter Hepaticus
Clara Belzer, Ernst J. Kuipers, Bart A. van Schendel, Theo Hoogenboezem, Peter W.
Hermans, Arnoud H. van Vliet, Johannes G. Kusters
Introduction: Murine infection with Helicobacter hepaticus is associated with an active cellular
immune response accompanied by the production of oxygen radicals. Iron also potentates
the formation of reactive oxygen species. Therefore, pathogens are forced to maintain
intracellular iron homeostasis and cope with oxidative stresses. The H. hepaticus genome
sequence contains genes encoding homologs of bacterial oxidative stress defense proteins,
and also homologs of the iron responsive regulatory proteins Fur and PerR, which mediates
regulation of peroxide stress defense in several other bacteria. However, to our knowledge
the function or of the regulation of expression of oxidative stress defense genes of H. hepaticus
has not been described to date. Aim: We therefore investigated the expression and regulation
of oxidative stress defense systems of H. hepaticus. Methods: H. hepaticus strain ATCC51449
and isogenic fur and perR mutants were grown both under low-iron and high-iron conditions.
Gene expression was monitored by Northern hybridization, and protein expression was
monitored by SDS-PAGE. Results: Growth of H. hepaticus in iron-restricted conditions
resulted in altered expression levels of six proteins. Three of these proteins displayed iron-
repressed expression, while three other proteins displayed iron-induced expression. Two of
the iron-repressed proteins were identified as AhpC (25 kDa) and KatA (55 kDa). Both
proteins are involved in the degradation of peroxide compounds, and are known to contribute
to the bacterial oxidative stress defense. Mutation of the fur and perR genes resulted in high-
level, iron-independent, expression of both AhpC and KatA. Conclusion: In H. hepaticus,
iron metabolism and oxidative stress defense are intimately connected via the Fur and PerR
regulatory proteins. This regulatory pattern resembles that seen in the enteric pathogen C.
jejuni, but contrasts with the regulatory patterns observed in the human gastric pathogen
H. pylori, where Fur regulates superoxide stress defense. Therefore, iron-dependent regulation
of peroxide stress defense may be an adaptation advantageous for enteric colonization.
T1579
Helicobacter Pylori Antigens Operating At Early Infection
Hee-Shang Youn, Eun-A Kim, Jin-Su Jun, Ji-Hoe Park, Min-Ji Koo, Jae-Hee Kim, Ji-Hyun
Seo, Gyung-Hyuk Ko, Hyung-Lyun Kang, Seung-Chul Baik, Woo-Kon Lee, Myung-Je
Cho, Kwang-Ho Rhee
OBJECTIVE: To identify the operating antigens of Helicobacter pylori during early infection,
H. pylori proteomics and western blot analysis with sera of the H. pylori infected young
infants were applied. METHODS: Two-dimensional large and small gel electrophoresis was
performed with the H. pylori strain 51. Two-dimensional IgG, IgA, IgM immunoblotting
using small gels were performed with the sera which were collected at the Gyeongsang
National University Hospital from the infants who were confirmed H. pylori infected by
urease test, histopathologic examination and pre-embedding immunoelectron microscopy.
Spots with strong IgM and weak IgA immuno reactivities were considered early infection
markers and those spots were compared to those of 2D large gel. Corresponding spots were
applied to MALDI-TOF-MS. Obtained peptide finger printings were applied to NCBI database.
RESULTS: Eight infant patients were confirmed to be H. pylori infected. One of 8 infants
showed distinctive 14 spots on IgM 2D immunoblot without IgA immunoreactivities. These
14 spots were bounded on the gels by the pI range 5.0-6.5 and molecular weight range
30-80 kDA. Total 10 proteins were identified. These were ATP-dependent protease binding
subunit, Elongation factor G, Putative hydantoin utilization, UreB subunit, Methyl-accepting
chemotaxis protein, Flagella hook protein, Pyruvate ferredoxin oxidoreductase, Elongation
factor TS, Putative proline peptidase, Fructose-1,6-bisphosphate aldolase. CONCLUSION:
A total of 10 proteins operating early during acute H. pylori infection were identified by
proteomics. These results might contribute to find the serological markers for the early H.
pylori infection in infants.
T1580
Characterisation of the Proteome of Helicobacter Pylori Outer Membrane
Vesicles
Erica M. Mullaney, Catherine H. Botting, Henry J. Windle, Ana M. Terres, Dermot P.
Kelleher
INTRODUCTION: The effects of H. pylori infection may be mediated by direct interaction
between the intact organism and the epithelium, and also, between released bacterial elements
know as outer membrane vesicles (OMVs) and the gastric epithelium. H. pylori OMVs are
small circular structures (Keenan et al, 2000) with an intact outer membrane that are
constitutively shed from the surface of the organism. The mechanisms of OMV action are
not clear but they may function as a vehicle for the delivery of virulence factors to the
gastric mucosa. It is presumed that contact between OMV and host cells is necessary. AIM: To
map the protein composition of H. pylori OMVs in an attempt to gain a better understanding of
their action in vivo. MATERIALS&METHODS: OMVs were harvested from H. pylori by
several rounds of ultracentrifugation. OMV samples were run on a 12.5% 1D mini gel,
transferred to a PVDF membrane and blotted for H. pylori proteins. OMVs electrophoretically
separated on a 1D mini gel were analysed by LC-MS/MS sequencing to determine the identity
of the protein complement of the OMVs. RESULTS: Electron Microscopy (EM) confirmed
the absence of whole cells and flagella in the OMV preparation and confirmatory Western
blot analysis detected Helicobacter proteins in the OMV samples. The samples of OMVs
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separated on a 1D SDS-PAGE gel were Coomassie and silver stained. Sequence analysis
following mass spectrometry indicates that H. pylori OMV proteins contain many known
outer membrane proteins including OMP 3, 5, 8, 11, 14, 15 and 20. Analysis has also
revealed the presence of several virulence factors, namely CagA, VacA. NapA and urease.
Interestingly, analysis also identified proteins from the ABC transporter system which is
involved in the production of a catalytically active urease. Many iron regulated outer mem-
brane proteins were also identified. CONCLUSIONS: This proteomic analysis of H. pylori
OMV has demonstrated the presence of multiple OMP, including adhesions, in addition to
recognised virulence factors. Given that OMV are constitutively shed by H. pylori in vivo,
the possibility that OMVs are involved in OMV - epithelial cell interactions, leading to
pathogenesis, both at the site of infection and at remote sites (e.g. duodenum) must now
be considered.
T1581
Two-Dimensional Blue Native / SDS Gel Electrophoresis of Multiprotein
Complexes from Helicobacter Pylori
Slovenie Pyndiah, Jean Paul Lasserre, Stephane Claverol, Armelle Menard, Valerie
Prouzet-Mauleon, Francis Megraud, Frank Zerbib, Marc Bonneu
The study of protein interactions constitutes an important domain to understand the physi-
ology and pathogenesis of microorganisms. A proteomic approach initially described for
eucaryotic cells, including protein separation by two dimensional blue native/sodium dodecyl
sulfate polyacrylamide gel electrophoresis (2D BN/SDS-PAGE) and protein identification by
mass spectrometry, was applied to strain J99 of the gastric pathogen Helicobacter pylori. It
was possible to identify 131 proteins grouped in 91 multiprotein complexes: 66 from the
cytoplasm, 22 from the membrane and 3 from both, including 43 complexes never reported
before, as well as 36 multi-homooligomeric complexes. Beside complexes involved in H.
pylori physiology, this method allowed to describe interactions involving known pathogenic
factors such as urease with GroEL, or IlvC, and CagA with BabA, or GyrA, as well as to
provide an insight on the partners of the adhesins. The 2D BN/SDS-PAGE combined with
mass spectrometry could be applied to the study of the differences in complexes isolated
in various situations and also to the study of the interactions between bacterial and eucaryotic
cell proteins.
T1582
Analysis of the SHP-2 Binding Site of Helicobacter Pylori Caga Protein in
Korean
Jun-Won Chung, Gin Hyug Lee, Hyung Joon Lee, Ja Young Kim, Kwi Sook Choi, Kee
Don Choi, Hwoon-Yong Jung, Weon-Seon Hong, Jin-Ho Kim, Jin-Yong Jeong
Background/Aims: The incidence of gastric cancer is very high in Korea. Recently the
pathological actions of CagA of H. pylori on gastric epithelial cells have been reported. There
are two major CagA subtypes according to the amino acid sequence in the 3' region of
CagA; i) the East Asian type (A-B-D of EPIYA motifs) and ii) the Western type (A-B-C of
EPIYA motifs). Repeated EPIYA motifs in the 3' region of CagA are involved in the interaction
with SHP-2. The East Asian type conferred stronger SHP-2 binding activity than the Western
type of CagA. Here we analyzed the amino acid sequences of the SHP-2 binding site of
cagA gene in H. pylori, and investigated whether there is any relationship between the
diversities of cagA and the disease outcome in Korea. We also examined the relationship
between cagA and vacA alleles. Methods: The 62 clinical isolates of H. pylori from 14 patients
with non-cardiac gastric cancer and 48 patients with chronic gastritis were studied. DNA
sequencing of CagA SHP-2 binding site was performed by use of the dideoxynucleotide
chain termination method. Then amino acid sequences were deduced from the results of
DNA sequencing. To confirm vacA genotype, parts of the vacA s- and m-regions were
amplified using appropriate primers. Results: Most of Korean H. pylori strains showed A-B-
D motifs (the East Asian type), and only one strain showed A-B-B-D motifs, which is also
the East Asian type. All strains contained s1 in the signal sequence region and m1 in the
middle region of vacA. The predominant vacA genotype in Korea was s1c/m1b (43/62,
69%). We also demonstrated that the predominant East Asia type CagA-positive strains had
vacA s1c/m1b genotype in Korea. Conclusions: In Korea, the incidence of atrophic gastritis
and gastric cancer is significantly high compared with Western countries. The high frequency
of the East Asian type CagA among Korean H. pylori strains would be involved in increasing
the risk of gastric cancer in Korean populations.
T1583
The Cause for the Birth-Cohort Phenomenon of Peptic Ulcer Disease
Amnon Sonnenberg
Background: The long-term time trends of gastric and duodenal ulcer have been shaped by
a birth-cohort phenomenon with a rise in susceptibility to develop peptic ulcer among
generations born during the 19th century and a subsequent decline among generations born
during the 20th century. Infection of the upper gastrointestinal tract with H. pylori is the
primary etiologic mechanism precipitating the occurrence of peptic ulcer. Since H. pylori
infection was endemic among all human populations for millennia until the turn of the
19th century, the cause of the rising ulcer epidemic during the second half of the 19th
century has remained an enigma. The aim of the present study is to present a mathematical
model of H. pylori epidemiology that explains the peculiar long-term trends of peptic ulcer
disease. Methods: The epidemiology model is based on two simple and straightforward
assumptions. First, the infection rate fell in the general population between 1800 and 2000.
Second, gastric ulcer was caused by H. pylori infection contracted between the ages 5 and
15 years and duodenal ulcer by infection contracted after the age of 15 years. The time-
dependent fall of H. pylori infection is modeled by a logistic equation. The age-dependent
rise in the fraction of subjects infected by H. pylori at increasingly older age is modeled by
an exponential equation. The actual time trends of ulcer mortality from England & Wales

















Results: The birth-cohort phenomenon of peptic ulcer could be explained by the interaction
of two opposing time trends, namely, declining infection rate and shifting of H. pylori
acquisition towards older age. The superimposition of a declining and a rising trend resulted
in a bell-shaped curve of ulcer occurrence among consecutive birth-cohorts. Similarly to
the real data, the modeled cohort pattern of gastric ulcer preceded that of duodenal ulcer
by 20 years. The time lag between the two curves of gastric and duodenal could be shortened
by changing time intervals of infection. The time constants of the mode shifted the peak of
ulcer occurrence along the time axis and determined the slopes of its rise and fall. Overall,
the outcome of the model remained robust to most changes underlying its assumptions,
and a very good resemblance was reached between the model and the actual epidemiologic
data. Conclusion: The unifying concept of a receding H. pylori infection accompanied by a
simultaneous shift in its age of acquisition secondary to increasing standards of hygiene
suffices to explain the historic birth-cohort phenomenon of peptic ulcer disease.
T1584
Cag-a Positive H. Pylori Strains Are Highly Prevalent in Ischemic
Cerebrovascular Disease: A Primary Care Multicenter Study
Rudy De Bastiani, Maurizio Gabrielli, Enzo Ubaldi, Edoardo Benedetto, Guido Sanna,
Carmelo Cottone, Maria Assunta Zocco, Nathalie Saulnier, Marcello Candelli, Giovanni
Gasbarrini, Antonio Gasbarrini
Background. Previous studies suggested an association between ischemic cerebrovascular
disease and H. pylori infection, in particular CagA-positive strains. Available data are con-
trasting and come from monocentric studies from referral tertiary centers. Moreover they
often assessed H. pylori infection by serology, that is less accurate and does not distinguish
between previous contact or active infection. Aim of the present study was to assess the
prevalence of active H. pylori infection and its CagA-positive strains in patients with ischemic
cerebrovascular infection with respect to controls without evidence of atherosclerotic-related
diseases. Methods. A total of 106 consecutive patients (age 76,4±8 years; males 50%) with
well documented history of ischemic cerebrovascular disease and 97 sex-age (age 76,4±8
years; males 45%) and social background-matched controls without relevant vascular dis-
eases. Subjects come from 5 different regions of Italy (1 in the North, 1 in the Center and
3 in the South). Data concerning CT scanning and/or brain magnetic resonance imaging,
duplex ultrasonography of the extracranial carotid arteries, history of atrial fibrillation were
recorded in all patients. Risk factors for ischemic cerebrovascular disease (familiar history,
arterial hypertension, smoke, diabetes mellitus, hypercholesterolemia, hypertrigliceridemia,
obesity) were assessed in all subjects. Active H. pylori infection was assessed by 13C-urea
breath test (Altana, Milano, Italy). In infected subjects, a serological assay for specific IgG
against CagA was also performed (Radim, Pomezia, Italy). Results. The prevalence of active
H. pylori infection higher in cases (63%) with respect to controls (54%), however without
reaching statistical significance (p=0.2, OR 1.21, 95%CI 0.85-2.61). On the other hand, a
significant association was found between patients and controls as concerning Cag-A positivity
(41.5% versus 17.5%; p<0.001, OR 1.65, 95%CI 1.74-6.40). Conclusions. This is the first
study assessing the prevalence of active H. pylori infection and CagA-positive strains in the
setting of the general population. Our findings suggest that CagA-positive more cytotoxic
strains of the bacterium are significantly associated to ischemic stroke. Future studies should
aim to assess the effects of selected eradication of CagA-positive strains in patients with
ischemic stroke to verify the causality of this epidemiological association.
T1585
H. Pylori Protease Activates Gastric Epithelial Cells to Produce IL-8 Through
Protease-Activated Receptor 2
Norimasa Yoshida, Hirokazu Kajikawa, Kazuhiro Katada, Fumihiro Hirayama, Osamu
Handa, Tomohisa Takagi, Satoshi Kokura, Hiroshi Ichikawa, Yuji Naito, Toshikazu
Yoshikawa, Takeshi Okanoue
Background and Aims: IL-8 production by gastric epithelial cells infected with H. pylori has
been implicated in the pathogenesis of gastric inflammation, however, its mechanism has
not been fully understood. Recently, it has been demonstrated that proteases such as trypsin
and thrombin activate many kinds of epithelial cells and endothelial cells to produce inflam-
matory mediators through protease-activated receptor (PAR). In the present study, we invest-
igated whether PAR2 is involved in the IL-8 production by H. pylori-infected gastric epithelial
cells. Materials and Methods: Expression of PAR-2 in human gastric epithelial cells, MKN-
45 cells, was assessed by reverse-transcriptase polymerase chain reaction (RT-PCR) method,
western blotting analysis and immunocytochemistry. MKN-45 cells were stimulated with
trypsin, agonist peptide (SLIGKV amide) for PAR-2 or H. pylori organism and expressions
of IL-8 mRNA and proteins were measured by RT-PCR and enzyme-linked immunosorbent
assay (ELISA). In addition, the effects of nafamostat mesilate and camostat msilate, serine
protease inhibitors, on IL-8 production from activated cells were determined. Finally, H.
pylori-induced IL-8 production was estimated using antibody to PAR-2 and cells transfected
with si RNA for PAR2. Results: PAR-2 mRNA and protein were constitutively expressed on
unstimulated MKN-45 cells. Treatment of cells with H. pylori resulted in mild increase in
PAR-2 expression. In addition, trypsin, agonist peptide for PAR-2 or H. pylori induced IL-
8 production from MKN-45 cells in a dose- and time-dependent manner. Nafamostat mesilate
and camostat mesilate protected against trypsin- and H. pylori-, but not agonist peptide-,
mediated cytokine production from MKN-45 cells. Finally, H. pylori-induced IL-8 production
was inhibited by antibody to PAR-2 and in PAR-2 deficient cells treated with siRNA Conclu-
sions: These results indicate that H. pylori-derived protease activates gastric epithelial cells
to produce inflammatory cytokines through PAR-2, suggesting an important role for PAR-
2 in the modulation of gastric inflammation associated with H. pylori.
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T1586
EGFR Inhibition Improves Helicobacter Pylori Induced Pathology and
Epithelial Cellular Kinetics in Vivo
Aht Jeremy, K Danjo, Mf Dixon, K Bransfield, Pa Robinson, Je Crabtree
Introduction: H. pylori has been shown to transactivate the EGF receptor (EGFR) in gastric
epithelial cells. H. pylori activation of the EGFR signalling pathway may be relevant to the
epithelial hyperproliferation and increased risk of gastric carcinogenesis associated with
infection. The aim of this study was to examine whether inhibition of the EGFR with the
specific inhibitor EKB-569 would alter H. pylori induced pathology in the Mongolian gerbil
model. Methods: Male Mongolian gerbils were infected with H. pylori (SS1 strain). 6 weeks
post-infection, infected and uninfected controls were fed on either, control, or EKB-569
(10mg/kg/gerbil/day) supplemented food. Gerbils were killed at 38 weeks post-infection.
Gastric pathology was assessed and epithelial proliferation and apoptosis quantified respect-
ively by anti-BrdU and activated caspase-3 histochemistry. Results: No difference in antral
pathology was observed in treated and untreated H. pylori infected gerbils. EKB-569 treatment
in H. pylori infected gerbils resulted in a significant reduction in corpus atrophy (p < 0.03)
and mucous metaplasia (p < 0.05) but chronic inflammation in the corpus was not signific-
antly different from untreated gerbils. There was significant (p < 0.05) reduction in submuco-
sal herniations in EKB-569 treated gerbils. Increased epithelial proliferation (p<0.001) was
observed in the antrum and corpus of both infected groups, whilst apoptosis was only
significantly increased (p<0.001) in the EKB-treated group compared to uninfected control
groups. There was a marked increase in apoptotic subepithelial mononuclear cells in the
EKB-569 treated infected gerbils. In infected gerbils, the proliferation/apoptosis ratio in the
untreated group was significantly greater (p<0.02) in both the antrum and corpus than in
the EKB-569 treated group, where the ratio was comparable to uninfected controls. Conclu-
sion: EGFR inhibition reduces H. pylori induced corpus pathology in vivo and promotes
apoptosis in both epithelial and subepithelial mononuclear cells. This study was funded by
Yorkshire Cancer Research
T1587
Restoration of RUNX3 Expression in H.pylori-Colonized Spasmolytic
Polypeptide-Expressing Metaplasia (SPEM) After H.pylori Eradication
Hidekazu Suzuki, Yuriko Minegishi, Kosei Ito, Toshihiro Nishizawa, Tatsuhiro Masaoka,
Eisuke Iwasaki, Yoshiaki Ito, Nicholas A. Wright, Toshifumi Hibi
Chronic H. pylori infection induces spasmolytic polypeptide-expressing metaplasia (SPEM),
which is positive for trefoil factor 2 (TFF2) (Gastroenterology 114:675, 1998). Recently,
SPEM was reported to be a precancerous lesion, which induces gastric cancer formation
with the recruitment of bone marrow-derived cells (Science 306:1568, 2004). RUNX3 (runt
domain transcription factor 3), a tumor-suppressor gene involved in gastric carcinogenesis,
has also been shown to be significantly downregulated in intestinal metaplasia (Cell 109:113,
2002). However, no studies have demonstrated RUNX3 expression in H. pylori-associated
SPEM lesions or alterations after H. pylori eradication. The present study investigates RUNX3
expression in H. pylori-colonized SPEM lesions in Mongolian gerbils before and after bacterial
eradication. Methods. Male Mongolian gerbils were inoculated with H. pylori (108 CFUs/
ml, ATCC43504) or with culture media alone and examined 12 or 24 weeks post-infection.
Other groups of H. pylori-inoculated gerbils in which infection was eradicated after 12 or
24 weeks of colonization, were examined 10 weeks after the eradication. RUNX3 mRNA
expression was determined by quantitative RT-PCR and in-situ hybridization. RUNX3 and
TFF2 protein expression was determined by immunohistochemistry. Results. Positive immu-
noreactivity for RUNX3 was observed in non-H. pylori-infected gerbils, predominantly in
chief cells and to some extent in mucous neck cells and surface epithelial cells of the gastric
fundic glands. RUNX3 mRNA expression was also detected in non-H. pylori-infected mice,
predominantly in the nuclei of the chief and mucous neck cells. In gerbils examined 12
weeks after H. pylori inoculation, although the pyloric side of the gastric fundus showed
the absence of RUNX3 immunoreactivity and mRNA expression and the presence of TFF2-
positive SPEM formation, RUNX3 expression was almost completely restored after eradication
of H. pylori. In the cohort examined 24 weeks after H.pylori inoculation, SPEM was encoun-
tered from the pylorus to the proximal end of gastric fundus, with significant reduction of
RUNX3 expression in these regions. In this cohort, RUNX3 expression was only partially
restored in the proximal fundic mucosa after the eradication. Conclusions. Reduction of
RUNX3 expression in regions showing SPEM in H. pylori-colonized stomach became more
pronounced with increasing duration of colonization. Although early eradication almost
completely restored the RUNX3 expression to normal levels with resolution of the SPEM
lesions, longer-term colonization of H.pylori reduced the mucosal reversibility in terms of
RUNX3 expression and SPEM formation.
T1588
Persistence of Hypermethylation of Cell Cycle and DNA Repair Genes in
Gastric Mucosa After H. Pylori Eradication
Yuan Yao, Gabriel Calilao, Dong Il Park, Jae J. Kim, David Y. Graham, Antonia R.
Sepulveda
Aims: To determine the methylation status of the gastric mucosa during Hp gastritis and
the effect of Hp eradication on methylation in the mucosa, and to determine whether Hp
organisms can induce CpG island methylation in epithelial cells in a co-culture system.
Methods: Methylation specific PCR (MSP) for CpG islands in the promoters of MLH1, MGMT
and p16INK4a was performed with DNA from antral biopsies of 37 patients with Hp gastritis
and at 6-8 weeks after Hp eradication (mean age=46 years, 9 women and 28 men) and 15
Hp-negative controls. Bisulfite sequence analysis was performed in MSP-positive cases.
Gastritis grade was determined with the updated Houston scale. Hp status was confirmed
histologically and by PCR for the Hp 16S rRNA and CagA gene. The methylation status of
gastric AGS cells after co-culture with Hp (strain 43504) was determined by MSP in cells
co-cultured with Hp bacteria or Hp water extracts. Results: P16 and MGMT CpG islands
were more frequently methylated in Hp-positive gastritis as compared to control Hp-negative
tissues. In contrast, MLH1 was not (Table). The number of samples demonstrating MLH1
and p16 CpG island methylation was not different in pre- and after Hp eradication samples,
while MGMT methylation was slightly reduced in the post-eradication group (Table). CagA
status was not associated with differences in frequency of CpG methylation. The gastritis
grades were not significantly different in methylated vs. unmethylated mucosal samples.
Co-cultures of Hp or Hp water extracts and AGS cells, showed that Hp was able to induce
methylation of the MLH1 and MGMT promoter, but not of p16. Conclusions: H. pylori
gastritis leads to increased CpG island methylation of DNA repair and cell cycle genes. In
vitro studies suggest that Hp bacteria may directly induce CpG island methylation. The
increased CpG island methylation induced by Hp infection in the gastric mucosa persists
after Hp eradication, suggesting that it is induced in progenitor cells with replicative potential.
T1589
Effect of Helicobacter Pylori On Leptin and Ghrelin Levels in Plasma and
Stomach
Jatin Roper, Fritz Francois, Michelle Mourad, Zhiheng Pei, Asalia Z. Olivares, Vivek M.
Shinde, Chi-Hong Tseng, Guillermo I. Perez-Perez, Martin J. Blaser
Background : Helicobacter pylori (HP) colonization may affect production of ghrelin and
leptin, possibly via the HP-induced inflammatory cytokine IL-1β. Our aims were to evaluate
circulating and gastric levels of leptin and ghrelin according to HP status and to correlate
these levels with gastric IL-1β. Methods: 217 patients referred for endoscopy were prospect-
ively enrolled. BMI was measured, fasting serum collected, and antral / fundic biopsies
obtained. Patients were categorized as HP+ if ≥ 2 tests (urease, histology, culture, HP
serology, and cagA serology) were positive, and HP- if all tests were negative. Levels of ghrelin,
leptin and IL-1β in plasma and gastric biopsy samples (pg/mg protein) were determined by
specific ELISAs, and results compared using non-parametric tests (Mann-Whitney U Test,
Spearman Rank). Results: 64 patients were HP- and 100 were HP+. 53 patients of indetermin-
ant status were not included in these analyses. Age and sex did not differ significantly
between groups. Mean BMI was lower in the HP+ than HP- group (27.5±4.7 vs. 29.0±5.2;
p=0.05). BMI was positively correlated with circulating, antral, and fundic leptin levels (R=
0.46, p<0.0001; R=0.19, p=0.02 ; R=0.29, p<0.001, respectively). After adjusting for BMI,
leptin levels were lower in the HP+ group than the HP- group for both circulating (median
2166 pg/ml, IQR (894-4057) vs. 4730 pg/ml (1831-9076); p< 0.001) and antral measure-
ments (median 58 pg/ml (25-157) vs. 94 pg/ml (58-178); p= 0.04); circulating and gastric
ghrelin levels did not significantly differ between HP groups. Regional gastric leptin and
ghrelin levels were positively correlated in the HP+ group (antral leptin and antral ghrelin,
R= 0.52 , p=0.0001; antral leptin and fundic ghrelin, R=0.38, p=0.005; fundic leptin and
fundic ghrelin, R= 0.47, p=0.0001), but not in the HP- group. Antral leptin levels were
correlated with antral and fundic IL1-β levels in the HP+ group (R= 0.34, p=0.007; R=0.26,
p=0.03, respectively), but not in the HP- group. Antral ghrelin and IL1-β levels were
positively correlated in the HP+ group (R=0.44, P=0.002), but not in the HP- group.
Conclusion: In this population, circulating and regional gastric leptin levels were lower in
those who were HP+ than HP- independent of BMI. The positive correlation between gastric
leptin and ghrelin in HP+ persons, associated with IL1-β levels, suggests that HP colonization
and induced inflammation affect gastric production of leptin and ghrelin.
T1590
Helicobacter Pylori CagA Induces Mitochondria-Dependent Production of
Reactive Oxygen Species in Gastric Epithelial Cell
Osamu Handa, Yuji Naito, Takeshi Ishii, Hisato Tsuboi, Satoko Adachi, Tomohisa Takagi,
Satoshi Kokura, Norimasa Yoshida, Hirofumi Matsui, Takeshi Azuma, Hai Ying Fu, Sunao
Kawano, Toshikazu Yoshikawa
Background: Helicobacter pylori (H. pylori) has been defined as a definite carcinogen by IARC/
WHO in 1994. One of the candidate protein by which H. pylori induce carcinogenesis is
cytotoxin associated gene product A (CagA) injected into host gastric epithelial cell by type
4 secretion system of H. pylori. Although CagA positive H. pylori infection has been reported
to produce excessive amount of reactive oxygen species (ROS) in human gastric mucosa,
the mechanism by which CagA itself induce ROS production in gastric epithelial cell is not
clear. Moreover, many in vitro studies have been done by using gastric “cancer” cell line.
Aim: In the present study, we investigated the effect of CagA on ROS production by rat
“normal” gastric mucosal epithelial cell (RGM-1). Materials and Methods: To this end, we
used cagA gene- and a Tet-off system- transfected RGM-1, in which CagA expression could
be controlled by tetracycline. CagA expression in the established cell line was detected by
western blotting and laser scanning confocal microscopy (LSCM) with CagA specific antibody.
ROS production in RGM-1 was assessed by redox sensitive fluorescent dye, RedoxSensor
and mitochondria selective fluorescent dye, MitoTracker under LSCM and a fluorometer.
Since nuclear factor kappa B (NFκB), a redox sensitive transcription factor, has been shown
to play a key role in the pathogenesis of H. pylori- associated disease through the production
of various cytokines, we also investigated the effect of CagA on NFκB nuclear translocation
and subsequent production of cytokine by RGM-1. Results: As a result, we found that
expressed CagA, after removal of tetracycline, induced significant ROS production by mito-
chondria, NFκB translocation into the nucleus and cytokine-induced neutrophil chemoat-
tractant-1 (CINC-1) production by RGM-1. Conclusion: Taken together, CagA itself might
have a pro-inflammatory effect on normal gastric epithelial cell through mitochondria-
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derived ROS-mediated mechanism and thus participate in the formation of vicious circle
of inflammation.
T1591
Close Surveillance Is Necessary to Detect Gastric Neoplastic Lesions After
Helicobacter Pylori Eradication in Japanese
Makoto Yonechi, Kazuhiko Ishida, Naotaka Fujita
Background The effect of H. pylori eradication on the prevention of gastric cancer develop-
ment in chronic carriers is still unknown. Also remaining unclear is how often esophagogas-
troduodenoscopy (EGD) should be done to detect gastric neoplastic lesions in an early stage
after successfulH. pylori eradication. The aim of this study was to determine whether frequent
procedures of EGD were required or not after H. pylori eradicaton to detect gastric neoplasia.
Patients and methods H. pylori was eradicated in a total of 1465 patients from December
1995 to September 2004. Of those patients, 929 (719 men and 210 women; mean age
55.9 years; range, 18-87 years) who achieved successful eradication and were kept under
surveillance with EGD for not less than 1 year, were included in this study. This group of
patients was comprised of 524 cases of gastric ulcer, 233 cases of duodenal ulcer, 61 cases
of gastroduodenal ulcer, 36 cases of early gastric carcinoma treated by endoscopic mucosal
resection (EMR), 15 cases of gastric polyps, 27 cases of chronic gastritis, 7 cases of acute
gastritis and 16 cases of MALT lymphoma. To detect neoplastic lesions in an early stage
after eradication, the patients underwent EGD at two months, six months and twelve months
after eradication. Thereafter, EGD was performed every 12 months. Results The mean
follow-up period was 30 months (2-112) and the mean number of EGD examination was
4.5. During the follow-up, gastric cancer was newly detected in 26 cases (2.8%). Background
diseases in these 26 patients were gastric cancer treated by EMR in 10 (38.5%) and gastric
ulcer in 16 (61.5%). Twenty-four cases (92.0%) were intestinal-type carcinoma and the
other two were diffuse type. All cancers but one were detected in an early stage. These early
stage cancers were completely resected by surgery or EMR. The only patient diagnosed as
gastric cancer of diffuse type in an advanced stage had undergone EGD until 24 months
after eradication, but had then dropped out from the surveillance. Conclusions The chance
of detecting gastric cancer increases after H. pylori eradication, probably due to facilitation
of recognition of local changes following improvement of mucosal inflammation. As those
patients who have had gastric ulcers or early cancer prior to H. pylori eradication have a
high prevalence of gastric cancer development, such patients should be kept under close
surveillance using EGD even after successful H. pylori eradication.
T1592
E-Cadherin Gene Promoter Hypermethylation in H.pylori-Induced Enlarged
Fold Gastritis
Tamana Miyazaki, Yoko Murayama, Kenji Watabe, Shuusaku Tsutsui, Tatsuya Kiyohara,
Shinji Tamura, Yasuhisa Shinomura, Norio Hayashi
Backgroud and Aim: We have previously reported that the odds ratio for gastric carcinoma
and the prevalence of diffuse-type early gastric carcinoma in H.pylori-enlarged-fold gastritis
increased with increasing fold width. However, the mechanism for the progression of gastric
carcinoma in H.pylori-associated enlarged fold gastritis is not clear. Recently, DNA methyl-
ation is reported as one of the regulatory mechanism associated with loss of function
of tumour suppressor genes. In diffuse-type gastric carcinomas, E-cadherin expression is
frequently reduced or lost. It is possible that hypermethylation of E-cadherin promoter is
associated with this event. Thus, we investigated E-cadherin methylation in both gastric
antral and body mucosa from H.pylori positive patients with enlarged fold gastritis, and
compared with those of H.pylori positive and negative patients without enlarged folds.
Methods: 19 H.pylori-positive patients with enlarged folds, 22 H.pylori-positive and seven
H.pylori-negative patients without enlarged folds were involved in the study. Genomic DNA
extracted from the gastric antrum and body biopsy samples of all patients were treated
with the sodium bisulfite. E-cadherin promoter methylation was studied using quantitative
methylation specific polymerase chain reaction (PCR) and the methylation index (%) was
defined as the percentage of the fluorescence emission intensity values for the E-cadherin
PCR products to those of the β- actin PCR products. E-cadherin expression was studied by
immunohistochemistry. Results: The average of the fold width were 8.0±0.27,
4.6±0.15,3.4±0.22mm in H.pylori-positive patients.with and without enlarged folds, H.pylori-
negative patients. E-cadherin methylation index of the gastric antral mucosa in H.pylori
positive patients with enlarged folds was much greater than that in both H.pylori positive
and negative patients without enlarged folds (20.2±2.0 ν11.9±1.4 ν1.4±0.48, p<0.01). E-
cadherin methylation index of the gastric body mucosa in H.pylori positive patients with
enlarged folds was much greater than that in both H.pylori positive and negative patients
without enlarged folds (15.6±2.8 ν 9.5±0.8 ν1.4±0.40, p<0.05 and p<0.01). After eradication
of H.pylori in the patients with enlarged folds, E-cadherin methylation index of the gastric
mucosa decreased significantly from 15.6±3.9 to 8.8±2.2 (p<0.05). Expression of E-cadherin
in H.pylori positive patients with enlarged folds was reduced. Conclusion: Our findings
suggest that hypermethylation of the E-cadherin promoter might be involved in the process
of gastric carcinomas in H.pylori-induced enlarged fold gastritis.
T1593
Effect of Caga Tyrosine Phosphorylation in Mmps Production By H. Pylori
Infected Gastric Epithelial Cells
Eunju Ryu, Yong Chan Lee, Inohk Lee, Young-Hee Nam, Seung-Taek Lee
Backgound/Aims: Recently, it has been shown that H. pylori infection induces expression
of matrix metalloproteases (MMPs), enzymes capable of degrading extracellular matrix com-
ponents. cagA positive H. pylori is known to induce greater amount of MMPs induction and
therefore, CagA, oncoprotein, could be implicated in a pivotal role in the release of MMPs
in gastric epithelial cells. The aims of this study was to identify the mechanism of expression

















Methods: MMP-9 and -7 production was measured by reverse transcription polymerase
chain reaction and gelatin zymography or western blot. Inducible CagA expression cell line,
W1804 (kind gift from Prof. Hatakeyama M. of Hokkaido Univ.) was used to evaluate the
role of tyrosine phosphorylation of CagA protein. Also, a pair of naturally occurring cagA
isogenic mutants 147C and 147A( different tyrosine phoshorylation activities) were used to
confirm the role of CagA protein tyrosine phosphorylation in MMP-9 production in vitro.
Results: CagA positive strains are able to induce greater magnitude of MMP-9 production.
And MMP-9 production was well correlated with the status of tyrosine phosphorylation
status of CagA protein. With the expression of CagA in AGS cells by inducible system,
transient transfection and H.pylori strains including positive (147C) and negative (147A)
EPIYA motif, gastric epithelial cells responded to H. pylori infection with the increased
production of MMP-9 in phosphorylation dependent manner. On the other hand, the
expression of MMP-7 is increased by H. pylori infection which is CagA dependent but
phosphorlation independent. Rather than phosphorylation of CagA, either presence of cagA
and cagE or pathogenicity island may be important in increased level of MMP-7 by H. pylori
infection. Conclusion: Taken together, these results suggest that tyrosine phosphorylation
of CagA may influence the production of MMP-9 in gastric epithelial cells, whereas the
phosphorylation status seems not to be important factor the expression of MMP-7 in gastric
epithelial cells.
T1594
Fas Blockage in Gastric Epithelial Cells Treated with H. Pylori: Role of
Reactive Oxygen Species and NFkB
Duane T. Smoot, Mohammad Daremipouran, Mamoon Elbedawi, Hassan Ashktorab
H. pylori (HP) infection is associated with an active chronic gastritis, peptic ulcer disease
and gastric cancer. Adherence of this bacterium to gastric cells activates signal transduction
pathways that lead to apoptosis. Studies have shown that H. pylori’s cytotoxicity is mediated
at least in part by the generation of reactive oxygen species (ROS) and inducing NFkB
activity within gastric epithelial cells. The following study was conducted to determine
whether H. pylori’s activation of Fas contributes to the generation of ROS within gastric
epithelial cells, and to determine whether or not this is associated with a reduction in active
NFkB. AGS cells (a human gastric adenocarcinoma cell line) were transfected with siFas
RNA and/or dominant negative-IKB (IkB-DN). The gastric cells were then exposed to a cag-
positive H. pylori strain and treated with a non-fluorescent probe DCFDA that fluoresces
after exposure to H2O2. ROS generation was measured using a flurometer. Cell death,
proliferation and NFkB promoter activity were measured using trypan blue exclusion, tetrazo-
lium assay and a luciferase reporter construct, respectively. SiFas reduced FAS levels by
more than 90% in gastric cells. There was a rapid increase in ROS in gastric cells within
15 minutes of exposure to H. pylori, and this peaked (at a 3-fold increase) after 3 hours.
siFas RNA resulted an increase in ROS generation in gastric cells exposed to H. pylori for
up to 3 hours. Blocking FAS stimulated ROS production in gastric cells, and the combination
of H. pylori and siFas RNA further increased both the ROS production and cell death in
gastric cells above that seen by H. pylori alone. Cell death did not increase in cells transfected
with both siFas and IkB-DN; therefore, inhibiting NFkB activation protected cells from H.
pylori induced cell death. In addition, down-regulation of FAS prevented H. pylori induced
increase in NFkB promoter activity gastric cells. In conclusion, inhibition of Fas induces
more ROS in gastric epithelial cells treated with H. pylori. Down-regulation of FAS does not
impair NFkB activation, which is important in H. pylori mediated cell death. The FAS signal
transduction pathway appears to be important in mediating cytotoxicity from this bacterium.
T1595
Altered Bone Morphogenetic Protein Signaling in the Helicobacter Pylori
Infected Stomach
Sylvia Pel-Bleuming, Ludmila L. Kodach, Maria J. Garcia Leon, Dick Richel, Maikel
Peppelenbosch, Pieter H. Reitsma, James C. Hardwick, Gijs R. van den Brink
Morphogens regulate epithelial cell fate decisions in the adult gastrointestinal tract. We
hypothesized that influx of inflammatory cells into the lamina propria may disturb the
normal expression gradients of morphogens (morphogenetic landscape) in gastrointestinal
epithelia. We therefore examined changes in the activity of the Bone Morphogenetic Protein
(BMP) pathway in the normal and Helicobacter (H.) pylori infected gastric mucosa. We
show that BMP receptors, the activated (phosphorylated) form of the intracellular BMP signal
transduction protein SMAD1 and BMP target ID2 all localize to gastric epithelial cells that
are at the end of the axis of epithelial renewal in the normal mucosa. Colonization of the
human gastric mucosa with H. pylori results in an increase of BMP2 expression caused by
influx of inflammatory cells that produce BMP2. Furthermore whereas no BMP4 is detected
in the normal antrum, Focal infiltrates of BMP4 expressing cells are found in the H.pylori
infected stomach. This influx of BMP expressing cells is associated with an increase in
epithelial BMP signaling. Interestingly, a shift of the activity of the BMP pathway is observed
towards the precursor cell compartment (isthmus) of the gastric units. Thus, H. pylori
infection results in an influx of inflammatory cells that disturb the normal activity gradient
of a morphogenetic pathway with an established role in epithelial cell fate regulation. Our
data suggest that morphological changes in epithelial histology may result from alterations
in the morphogenetic landscape secondary to changes in the cellular composition of the
lamina propria.
T1596
Secretory Leukocyte Protease Inhibitor (SLPI), a Target Gene of Helicobacter
Pylori Infection, Regulates NF-kB Signaling in Gastric Tumor Cells
Thomas Wex, Gerhard Treiber, Sabine Krueger, Michael Naumann, Peter Malfertheiner
Background: Recently, SLPI was identified as target gene in H.pylori (HP)infection. It is
expressed by the gastric epithelium and exerts antiproteolytic activity towards serine pro-
teases. In HP-infected patients, antral SLPI levels were strongly reduced independent of the
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associated disease (gastritis, ulcer disease or gastric cancer). Aim: To investigate functional
implications as well as mechanisms regulating SLPI expression in HP-infection. Methods:
Four gastric tumor cell lines (AGS, MKN-28, MKN-45, NCI-N87), co-incubated with HP
strain P1 and recombinant SLPI, were investigated by quantitative RT-PCR and ELISA
regarding their endogenous SLPI expression and NF-kB signaling. Furthermore, SLPI expres-
sion of antral biopsies was studied in context to the CagA status by immunoblot and
neutrophil-derived elastase, a target protease of SLPI, by ELISA. Results: The co-incubation
of all four cell lines with HP (MOI=50, up to 48 hours) resulted in a significant decrease
(-80%, P<0.001) of the SLPI protein in AGS and MKN-28 cells and a similar trend for
MKN-45 and NCI-N87, whereas corresponding transcript levels were induced up to 5-fold
in all cell lines (P<0.01). These data together with previous data from clinical samples suggest
a posttranslational mechanism like intracellular degradation as cause for reduced SLPI levels
in HP-infected subjects. The co-incubation of cell lines with HP strain P1 and recombinant
SLPI (0-5 µg/ml) for 24 hours lead to a dose-dependent inhibition of NF-kB signaling in
all cell lines except MKN-28 implying an additional anti-inflammatory effect of SLPI. Antral
biopsies of HP-infected subjects contained about 30-fold higher neutrophil-derived elastase
activity compared to HP-negative persons (P<0.01, ANOVA) proving the functional relevance
of SLPI for inhibiting proteases, which are capable to degrade mucosal components. The
presence of anti-CagA antibodies was strongly associated with a 50% down-regulation of
antral SLPI levels (1914 ± 455 pg/50 µg protein, P=0.01), whereas HP-infected without
anti-CagA antibodies and HP-negative subjects revealed similar SLPI levels of 3730 ± 402
and 3857 ± 129 pg/50 µg protein, respectively. Conclusions: The HP-induced reduction of
antral SLPI levels is primarily regulated at the posttranslational level. The association between
anti-CagA antibodies and reduced SLPI levels suggest a PAI-dependent mechanism for the
SLPI loss in HP-infection. The increased elastase-derived activity in gastric biopsies with
reduced SLPI levels and the inhibition of HP-induced NF-kB signaling by SLPI illustrate
the functional relevance of SLPI for gastric mucosa.
T1597
Acidic Conditions Synergistically Enhance the Induction of Helicobacter Pylori
Induced Gastric Mucosal Interleukin-8
Il-Ju Choi, Saori Fujimoto, Kazuyoshi Yamauchi, David Y. Graham, Yoshio Yamaoka
Background and Aims: Although acid and Helicobacter infection are two main causative
agents for development of peptic ulcers, their interaction remains largely unstudied. Interleu-
kin (IL)-8, a potent neutrophil chemotactic and activating peptide, is thought to play a
major role in the pathogenesis of H. pylori-associated diseases. We investigated the effect of
low pH on IL-8 induction in H. pylori infected gastric epithelial cells. Methods: H. pylori
(wild type strain TN2GF4 and its isogenic cag pathogenicity island [PAI] or oipA mutants)
were co-cultured with gastric epithelial cells (AGS cells) at pH’s ranging from 7.4 to 5.0.
IL-8 mRNA expression was evaluated by real time RT-PCR and IL-8 protein production by
ELISA. NF-κB binding activity was measured by electrophoretic mobility shift assay and
phosphorylation of IκB-α by immunoblot. The regulatory sites in the IL-8 promoter were
examined by luciferase reporter gene assay. Results: pH changes did not affect IL-8 levels
in uninfected control. Wild type H. pylori induced IL-8 mRNA in a pH dependent manner
with maximal levels at pH 5.5 (30-fold compared with uninfected control at pH 5.5, and
4.2-fold compared with infected cells at pH 7.4). Changes in IL-8 protein levels paralleled
mRNA levels (e.g., 2.9-fold increase at pH 5.5 compared with that at pH 7.4; 781 vs. 270
pg/mL, respectively). cag PAI or oipA mutants induced significantly lower amounts of IL-8
mRNA/protein than wild type strains; however both had similar pH dependent patterns.
Activation of NF-κB binding and phosphorylation of IκB-α was also pH dependent with
maximal levels at pH’s 6.4-5.5. Luciferase activity using wild type IL-8 promoter plasmid
also increased in lower pH and was abolished when AGS cells were transfected with NF-
κB mutated promoter plasmid. Conclusion: H. pylori and acidic conditions synergistically
induced IL-8 via activation of NF-κB. This provides a basis for reports that mucosal IL-8
levels are significantly higher in duodenal ulcer patients compared with gastritis only. The
interaction of H. pylori with acidic gastric contents appears to enhance inflammation through
increased IL-8 induction. Importantly, neither the cag PAI nor OipA were involved in pH
dependent IL-8 production. Supported in part by the Gulf Coast Digestive Disease Center.
T1598
Different Risk Factors for Atrophic Gastritis and Intestinal Metaplasia in
Korea
Nayoung Kim, Young Soo Park, Jin-Hyeok Hwang, Sook-Hyang Jung, Dong Ho Lee, Jung
Mogg Kim, In Wook Kim, Yoo-Deok Won, Joo Sung Kim, Hyun Chae Jung, In Sung
Song
Background/Aims: The prevalences of atrophic gastritis (AG) and intestinal metaplasia (IM)
are very high in Korea. The possible risk factors for these precancerous lesions were compre-
hensively evaluated. Methods: The study subjects consisted of 825, that is 119 of control
(87 Hp-positive), 234 patients of stomach cancer (202 Hp-positive), 253 of BGU (216 Hp-
positive), 162 of DU (155 Hp-positive) and 57 of dysplasia (52 Hp-positive). AG and IM
were scored histologically by using the Sydney system classification on biopsy specimens
taken from antrum and body of the stomach. Bacterial factors of H. pylori such as cagA,
anti-CagA antibody, vacA m1, m2, oipA were evaluated. Environmental factors such as
smoking, alcohol drinking, drinking water, high salt intake, diet pattern such as vegetable
and fruits, occupation, education and socioeconomic status were evaluated by questionnaires.
Host factors such as genetic polymorphisms for IL-1B-511, IL-1RN, TNF-A, IL-10-592, IL-
10-819, IL-10-1082, GSTP1, p53, and methylation state of MGMT, p16, GSTP1 were
evaluated. Risk factors were calculated by multiple logistic regression. Results: Risk factors
for AG and IM were different. That is, H. pylori infection was risk factor for IM (OR, 2.0;
95% CI, 1.3-3.1) but not for AG. In addition, the effect of remaining factors on the AG and
IM were different depending on H. pylori infected state. That is male gender, occupation
(farmer and blue color labor), daily salty soup, and sharing the room by at least three
children in the childhood were risk factors for AG and IM in the absence of H. pylori. In
contrast, smoking and low education such as elementary graduation were risk factors for
AG and IM in the presence of H. pylori. Low income was a common risk factor regardless
of H. pylori infection. Growing and living in the rural area was a risk factor for H. pylori-
positive IM. Among the several genetic polymorphism variables only IL-10-1082 G/A type
(OR, 5.2; 95% CI, 1.7-16.5) and p53 pro/pro type (OR, 1.7; 95% CI, 1.1-2.8) were risk
factors for H. pylori-negative IM but methylated GSTP1 was a risk factor for H. pylori-positive
AG (OR, 5.0; 95% CI, 1.1-22.9). Among bacterial factors only vac m1 strain was a risk
factor for both of AG (OR, 3.6; 95% CI, 2.1-6.2) and IM (OR, 3.0; 95% CI, 2.0-4.5).
Conclusions: These results that the risk factors are different for AG and IM, especially,
depending on H. pylori infection suggest that intestinal metaplasia and atrophic gastritis
might be caused by different mechanisms.
T1599
Regulation of Pathogenic Responses in Gastric Epithelial Cells By Helicobacter
Pylori Sphingomyelinase
Robert E. Williams, Ramakrishnan Sitaraman, Uma S. Krishna, Dawn A. Israel, Daniel P.
O'Brien, Seth R. Ogden, Aime T. Franco, Judith Romero-Gallo, Fang Yan, D. Brent Polk,
Richard M. Peek
Helicobacter pylori activation of extracellular signal-regulated kinase (ERK) induces epithelial
cell responses related to pathogenesis. ERK activation is dependent upon transactivation of
the epidermal growth factor receptor (EGFR) but can also occur in response to H. pylori
sphingomyelinase. Goals: To define the molecular pathways that mediate sphingomyelinase
activation of ERK in the context of H. pylori infection. Methods: ERK activation was deter-
mined by Western immunoblotting. Sphingomyelinase activity was quantified using a specific
sphingomyelin-N-ω-trinitrophenylaminolaurylsphingosylphosphorylcholine (TNPAL) assay.
EGFR activity was blocked using the EGFR kinase chemical inhibitors AG 1478 and
PD153035 (Compound 32). Results: H. pylori sphingomyelinase activity varied substantially
among a population of clinical isolates (n=9) and H. pylori strain J166 exhibited the highest
activity. Sphingomyelinase activity was significantly related to ERK activation in AGS gastric
epithelial cells co-cultured with these same clinical isolate strains. H. pylori strain J166
reproducibly activated ERK in AGS cells; however, EGFR inhibition had no effect on ERK
activation induced by this prototype isolate. Conclusion: The level of ERK activation in
AGS cells was related to the level of sphingomyelinase expression by H. pylori, and this was
not dependent upon transactivation of the EGFR. Implication: ERK activation by H. pylori
likely occurs via both EGFR-dependent and independent pathways, with potential implica-
tions for pathogenesis of injury and inflammatory responses leading to tumorigenesis.
T1600
Catalytically Active Adam17 Is Required for TNF-Stimulated Transactivation
of Erbb3
Stuart Hobbs, Robert Whitehead, Peter J. Dempsey, David-Brent Polk
Tumor Necrosis Factor (TNF) is a cytokine that regulates complex cellular responses during
injury and repair such as apoptosis and survival through signaling by Tumor Necrosis Factor
Receptor 1 (TNFR1) and Tumor Necrosis Factor Receptor 2 (TNFR2). As a result, deregulated
signaling by TNF plays an important role in the pathogenesis of gastrointestinal diseases
such as Inflammatory Bowel Disease (IBD) and Celiac disease in which there is an imbalance
between cell survival and apoptosis. A number of observations suggest that TNF-stimulated
signaling may additionally be important in the pathogenesis of gastritis and gastric cancer
induced by the gram-negative bacteria H. pylori. For example, we have observed that H.
pylori stimulates the expression of TNF in gastric epithelial cells. Furthermore, we have also
observed that TNF is able to stimulate transactivation of members of the ErbB family of
type I receptor tyrosine kinases. We have previously reported that H. pylori stimulates ErbB1
and ErbB3 transactivation in gastric epithelial cells. Therefore, we asked if TNF may play
a role in H. pylori transactivation of ErbB receptors. Our lab has observed that H. pylori
transactivation of the ErbB receptors ErbB1 and ErbB3 requires the cleavage of membrane-
bound ErbB ligands by the metalloprotease Tumor necrosis factor-α converting enzyme
(TACE/ADAM17). Therefore, we hypothesize that TNF transactivation of ErbB receptors
requires catalytically active ADAM17. Transactivation of ErbB receptors, such as ErbB3, that
strongly couple to anti-apoptotic pathways may be critical for any TNF-stimulated cell
survival and may contribute to the observed pathologies associated with gastric H. pylori
infections. As a result, we monitored TNF stimulation of ErbB3 tyrosine phosphorylation
in ADAM17 deficient Mouse Gastric Epithelial Cells (MGEC) in which wild-type ADAM17
(wt ADAM17) or a catalytically inactive E406A ADAM17 (E-A ADAM 17) mutant has been
ectopically expressed. Here we report that TNF stimulates ErbB3 tyrosine phosphorylation
in the ADAM17-/- MGEC wt ADAM17 cells. Moreover, TNF concentrations ranging from
0.1 ng/mL-100 ng/mL stimulate ErbB3 tyrosine phosphorylation. In contrast, TNF is unable
to stimulate ErbB3 tyrosine phosphorylation in the ADAM17-/- MGEC E-A ADAM17 cells.
In conclusion, TNF stimulates ErbB3 transactivation in gastric epithelial cells. Furthermore,
TNF-stimulated ErbB3 transactivation requires catalytically active ADAM17. This suggests
that TNF transactivation of ErbB3 may involve the cleavage of membrane-bound ErbB ligands
by ADAM17.
T1601
Interleukin-1b Gene Polymorphisms and Gastric Mucosal Interleukin-1β in
Benign Gastroduodenal Diseases with Helicobacter Pylori Infection
Young W. Chang, Hyoung C. Oh, Jae Y. Jang, Ji H. Jung, Myung J. Chae, Sang K. Lee,
Kwang R. Joo, Seok H. Dong, Hyo J. Kim, Byung H. Kim, Joung I. Lee, Rin Chang
Background & Aims: Host genetic factor is suggested to be an important determinant that
predispose to divergent clinical outcomes associated with Helicobacter pylori (H. pylori)
infection. The aims of this study were to examine Interleukin-1B (IL-1B) polymorphisms
in benign gastroduodenal diseases with H. pylori infection, and to analyze the correlation
between IL-1B genotypes and gastric mucosal inflammatory cytokines including IL-1β, matrix
metalloproteinase-3 (MMP-3), and IL-8. Methods: A total of 191 H. pylori-infected subjects
included 70 non-atrophic gastritis (NAG), 47 atrophic gastritis (AG), 28 gastric ulcer (GU),
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and 46 duodenal ulcer (DU) group. PCR-RFLP was performed to analyze the genetic poly-
morphisms of IL-1B-31 and IL-1B-511. IL-1β, MMP-3 and IL-8 level of gastric corpus
mucosa were determined by using an ELISA. Serum pepsinogen I and II levels were measured
by radioimmunoassay. Results: Since the alleles of IL-1B-511 were strongly linked with
those of IL-1B-31, we examined linkage disequilibrium between the IL-1B-31 and IL-1B-
511 alleles. Estimation of observed haplotype frequencies and comparison with those of
expected haplotype frequencies showed complete linkage disequilibrium coefficient in all
subjects (D'=1.0, P<0.0001). Therefore, we examined the effect of IL-1B-31/-511 haplotype
such as TT/CC, CT/CT, and CC/TT instead of IL-1B-31 or IL-1B-511 alleles each.on clinical
manifestations. There were no significant differences in IL-1B-31/-511 haplotypes frequencies
among the four groups. The haplotypes were not associated with the level of inflammatory
markers. AG showed significantly higher basal IL-1β and IL-8 level but, basal IL-1β and
MMP-3 were lower in DU compared to those of other groups. After H. pylori eradication,
IL-1β, MMP-3, and IL-8 levels were significantly decreased (P<0.001) but, pepsinogen I/II
ratio was significantly increased in all groups (P<0.001). Conclusions: Gastric mucosal levels
of inflammatory markers including IL-1βwere related to variable clinical outcomes associated
with H. pylori infection. The genotypes of IL-1B polymorphisms do not affect the mucosal
production of the inflammatory markers in benign gastroduodenal diseases.
T1602
Inhibitory Effect On Helicobacter Pylori and Anti-Oxidative Effect By Broccoli
Sprout Extract Containing Sulforaphane
Jae-Young Jang, Young-Woon Chang, Ji Heon Jung, Myung Jong Chae, Sang Kil Lee,
Kwang Ro Joo, Seok Ho Dong, Hyo Jong Kim, Byung-Ho Kim, Joung Il Lee, Rin Chang
Background/Aims: Isothiocyanate sulforaphane as the principal phase 2 inducer in broccoli
extracts was a dose-related inhibitor of carcinogen-induced mammary tumorigenesis in rats
and inhibited Helicobacter pylori (H. pylori) in vitro study. The aims of this study were to
investigate 1) whether sulforaphane has the inhibitory effect on H. pylori infection, 2) whether
sulforaphane has the preventive effect on lipid peroxidation and anti-oxidative effect on
gastric mucosal damage in patients with nonulcer dyspepsia. Subjects and Methods: We
designed a prospective, randomized controlled, single blind study. A total of 79 subjects
included in 55 H. pylori-positive subjects and 24 H. pylori negative subjects. Fifty-five H.
pylori-positive subjects randomly assigned to receive a capsule containing sulforaphane 300
μg or placebo twice per day for 4 weeks. Tweenty-four H. pylori-negative subjects were also
given sulforaphane twice per day for 4 weeks. All subjects were examined by C13-urea
breath test and upper gastrointestinal endoscopy before and after suforaphane or placebo
treatment. The concentration of ammonia was measured in gastric juice aspirate during
gastroscopic examination. Malondialdehyde (MDA) and reduced glutathione (GSH) concen-
trations in gastric corpus mucosa were measured by ELISA. Results: H. pylori-positive
sulforaphane group showed no significant changes in delta UBT values and gastric juice
ammonia concentration before and after treatment. The mucosal MDA concentrations
(149.8±131.5 nmol/g) were significantly reduced after sulforaphane treatment in H. pylori-
positive subjects (74.0±55.9 nmol/g, p<0.01). The mucosal MDA concentrations (120.3±62.0
nmol/g) were also significantly reduced after sulforaphane treatment in H. pylori-negative
subjects (72.3±49.0 nmol/g, p<0.001). Difference in MDA concentration between before
and after treatment was larger in sulforaphane groups irrespective of H. pylori infection than
that of placebo group (P<0.05). There were no significant differences in basal reduced GSH
concentrations in gastric mucosa between H. pylori-positive and negative subjects. Reduced
GSH concentrations between before and after treatment were not differ significantly between
sulforaphane group with or without H. pylori infection and placebo group. Conclusions:
Sulforaphane has no effect on eradication or inhibition of H. pylori infection in human
stomach. Sulforaphane may prevent lipid peroxidation in gastric mucosa and may play a
role in the cytoprotection in H. pylori-induced gastritis.
T1603
Low Serum Pepsinogen I/II Ratio Induces An Increase in Body Mass Index
After Eradication of H. Pylori
Hiroyuki Suto, Shinsuke Matsunaga, Ryuho Masaki, Tomoko Inagaki, Satoko Satomi,
Tomoyuki Okuda, Atsushi Muramatsu, Soshoku Lee, Yoshiyuki Ito, Yukinao Yamazaki,
Masaru Kuriyama, Takeshi Azuma
Background and aims: Recently some reported that the eradication of H. pylori induces an
increase in the body mass index (BMI). However the relationship between H. pylori infection
and the BMI is still controversial. Here we investigated the relationship between the change
in the BMI after the eradication of H. pylori and serum pepsinogen (PG) I/II ratio. Methods:
One hundred and ninety five H. pylori positive patients with atrophic gastritis were chosen
from subjects who visited multiphase health testing services and they underwent the eradica-
tion therapy for H. pylori. Cure of H. pylori infection was evaluated with 13C-urea breath
test 3 month after treatment. They were examined the relationship between the effect of
infection cure in terms of the BMI and the serum PG I/II ratio before treatment. All these
patients were investigated the BMI every year during 4 years after treatment. The BMI
changes were calculated each year by subtracting the BMI before treatment from that after
treatment. In addition, the serum leptin levels were also investigated before and one year
after treatment. Results: The serum PG I/II ratio was classified into three groups; group A
was PG I/II<2, group B was 2≦PG I/II<3 and group C was 3≦PG I/II. The BMI changes
(kg/m2) in 1 year after treatment in the groups A, B and C were 0.78±0.67, 0.16±0.66 and
0.04±0.71, respectively. The mean BMI change in the group A was significantly higher than
those in the groups B and C (p<0.01). The mean BMI changes in 2 and 3 years after
treatment in the group A were also significantly higher than those in the groups B and C
(p<0.01). The mean BMI change in 4 years after treatment in the group A was higher than
those in the groups B and C, although it was not significant. The infection cure had a great
effect on the BMI in the group A within 1 year after treatment and the influence of the
weight gain remained during at least 4 years. We found the negative correlations between
the serum PG I/II ratio and the BMI change in 1 and 2 years after treatment (p<0.01).

















and the serum PG I/II ratio. Conclusions: Low serum PG I/II ratio, especially PG I/II<2
induces an increase in body mass index after the eradication of H. pylori.
T1604
Helicobacter Pylori Itself and Interferon-γ Suppresses the Expression of a Hmg
Box Protein SOX2 Through Stat6-Mediated Interleukin-4 Signaling in Gastric
Epithelial Cells
Sho Asonuma, Akira Imatani, Naoki Asano, Tomoyuki Oikawa, Shuichi Ohara, Tooru
Shimosegawa
Background & Aim: Helicobacter pylori(Hp) is a major cause of the transdifferentiation to
gastric atrophy and intestinal metaplasia which are risk factors of gastric cancer development.
This progression is mediated by Th1-dominant host immune response to Hp infection. On
the other hand, a SRY-related HMG box protein Sox2 is a transcription factor of organ
development and differentiation in brain, lung and stomach. In stomach, Sox2 regulates
pepsinogen and MUC5AC, but there has been no report of the relationship between Hp
infection and Sox2. After evaluating Sox2 expression in Hp infected human gastric mucosa
including gastric atrophy and intestinal meteplasia, we investigated the molecular mechanism
responsible for the regulation of Sox2 by Hp itself and Hp-induced cytokines. Methods:
We evaluated twenty cases of Hp infected human gastric mucosa for Sox2 expression by
immunohistochemistry. Human gastric cell lines AGS and MKN45 were employed as an in
vitro model of human gastric epithelial cells. We stimulated them with CagA positive Hp
(ATCC#43504), IFN-γ, TNF-α, and IL-4 for 24hours independently, and also with IL-4
after the treatment with Hp or IFN-γ. We assessed the expression level of Sox2 stimulated
with Hp or those cytokines by western blotting respectively. RT-PCR analysis was performed
to determine the mRNA levels of MUC2, MUC5AC and MUC6. We also assessed phospho-
STAT6/STAT6 activity by immunoblotting. Results: Expression of Sox2 protein in human
oxyntic mucosa was observed in the nuclei of cells in the proliferative region, whereas in
atrophic mucosa and intestinal meteplasia with Hp infection it was decreased. In vitro the
expression level of Sox2 increased dose-dependently in both AGS and MKN45 after the
phosphorylation of STAT6 mediated by IL-4, a Th2-associated cytokine. MUC5AC, a gastric
specific mucin gene, was also up-regulated by IL-4 stimulation. Little changes of Sox2
expression were observed after the treatment with Hp, IFN-γ or TNF-α, independently, but
Hp itself and IFN-γ inhibited dose-dependently the expression of both Sox2 and MUC5AC
induced by IL-4, and abrogated phosphorylation of STAT6. Conclusion: These results sug-
gested that Hp itself and IFN-γ suppressed the expression of Sox2 through STAT-6 mediated
IL-4 signaling, and down-regulation of Sox2 may contribute to the progression of gastric
atrophy and intestinal metaplasia. Hp itself and Th1-dominant host immune response may
play an important role in the progression of them through the regulation of Sox2.
T1605
PCR for Immunoglobulin Gene Rearrangement Detects Residual MALT
Lymphoma in Histologically Negative Gastric Biopsies
William Ahrens, Jeffrey Sklar, Dhanpat Jain, Vytas Patriub, Sue Lagarde, Marie Robert
Background: Eradication of H. pylori will cause regression of gastric marginal zone B-cell
lymphoma (MALT) lymphoma in 60% to 90% of cases. However, monoclonal B cell popula-
tions can be detected by polymerase chain reaction (PCR) of immunoglobulin gene rearrang-
ments (IGRs) in histologically negative follow up biopsies. The clinical significance of persist-
ent clones in histologically negative biopsies is unclear. The value of surveillance, repeat
PCR analysis, and the criteria for determining complete remission in relation to such clones
has yet to be determined. Design: The pathology archives were searched for gastric biopsies
that were positive for MALT lymphoma. Subsequent gastric biopsies on these patients were
reviewed blindly by two pathologists and scored as being positive, negative or indefinite
for involvement by lymphoma. PCR results of clonal IGRs were correlated with H&E scores.
PCR performed on sequential specimens were compared when possible. Result: 37/90 gastric
lymphoma cases identified between 1992-2005 fit histologic/molecular criteria for low grade
MALT lymphoma. 16/37 were H. pylori positive, and those patients were treated with
antibiotic therapy. 15 patients had initial and at least one follow up PCR analysis to detect
B-cell clonality. The correlation of histology and PCR on the same biopsy material is shown
in Table 1. In 5 patients PCR positive on two biopsies, the clones detected were identical
on both biopsies, although an additional subclone was found in one patient. In another of
these five patients, PCR analysis on a third biopsy yielded products for IGRs different from
those in the previous two analyses, indicating either instability of the IGRs in a single clone,
or a new clone. 6/8 total patients with persistent IGRs were negative for lymphoma at last
follow up (range 4-89 months). Conclusion: Negative histology in follow up gastric mucosal
biopsies is insufficient to exclude low grade MALT lymphoma after therapy. The addition
of PCR for IGRs will detect small clonal populations that are frequently identical to the
original clones, but unapparent histologically. In addition, lymphoma detected after treatment
may have clonal IGRs that differ from those identified earlier. The clinical significance of
persistent clones or new clones in the face of minimal histologic infiltrates remains to
be determined.
Histology Score vs. PCR result
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T1606
Anti- Helicobacter Pylori Therapy Improves Iron Status and Gastric Acid
Output in Young Bangladeshi Women with Helicobacter Pylori Associated
Hypochlorhydria and Iron Deficiency Anemia
Shafiqul A. Sarker, Shamima Sultana, Shamima Sattar, Shafiqul Islam, George J. Fuchs,
Christoph Beglinger, Niklaus Gyr
Bacground: Hypochlorhydria is a risk factor for iron deficiency anemia (IDA), which affects
primarily infants and women of reproductive age. There are reports of H. pylori (Hp)
associated gastritis that may lead to hypochlorhydria. Aim: To determine if hypochlorhydria
contributes to IDA and to evaluate whether IDA and hypochlorhydria can be managed by
Hp eradication. Method: We studied 96 women, aged 20-40 years, infected with Hp based
on a positive urea breath test. We measured hemoglobin (Hb), serum ferritin (SF), and
soluble transferrin receptor (sTfR) to assess iron status. Gastric acid output (in mMol/h) was
measured during a 1-h basal period (BAO) and for an additional hour (1-hr stimulated
period =SAO) after stimulation with s.c. pentagastrin (6 mg/kg). Acid output and iron status
were reevaluated in women who had exhibited both IDA (Hb < 110 g/L, plus SF <12 µg/
L, and/or sTfR >8.3 mg/L) and hypochlorhydria (SAO <14.0 mMol/h), 60 days after comple-
tion of a supervised 2-weeks course of anti Hp therapy (amoxicillin, clarithromycin, and
omeprazole.Results: Of the 96 infected women, 57 (59%) had hypochlorhydria and 39
(41%) had normochlorhydria (SAO> 14.0 mmol/h). Compared to normochlorhydric women,
the prevalence of IDA was significantly higher in hypochlorhydric women (23% vs. 49%,
OR 0.31, 95% CI 0.16-0.6, χ2 =14.6, p=.0001). In women who exhibited both hypochlorhyd-
ria and IDA (n=28), anti-Hp therapy, which was 90% successful,improved both BAO (D-0
vs. D-60; 1.8 ± 1.6 vs. 2.7 ± 2.6, p=.024), and SAO (10.4 ±3.1 vs. 13.7 ± 4.4, p= <.0001)
and was accompanied by improvement of iron status; for Hb (mean ± SD, 10.5 ± 1.1 vs.10.8
± 1.13, p=0.13), for SF [(Geometric mean (-1SD,+1SD) 10.6 (4.5, 25.0) vs. 16.3 (4.4, 50.0,
p=.02], for sTfR [(Geometric mean (-1SD, +1SD) 10.2 (5.6,18.2) vs. 6.5 (3.9, 10.8), p=
<.0001]. In women with hypochlorhydria, 15 (54%) become normochlorhydric and 68%
became non-anemic following anti-Hp therapy. Conclusion : Our findings indicate that
hypochlorhydria and IDA is H-pylori associated in these women; both problems can be
managed by appropriate eradication therapy.
T1607
Lipopolysaccharides from Helicobacter Pylori Nctc11637 Up-Regulate IL-8 and
Vegf Via Toll-Like Receptor 2 in An Epithelial Cell System
Sinead Smith, Anthony P. Moran, Dermot P. Kelleher
Helicobacter pylori is the causative agent of chronic gastritis and a predisposing factor for
the development of both peptic ulcer disease and gastric cancer. Gastric epithelial cells
provide the first point of contact between H. pylori and the host, responding to H. pylori
infection by activating numerous signaling cascades. The best-characterised responses to
date are those leading to the expression and activation of the transcription factors NF-κB
and AP-1. One outcome of the activation of such transcription factors is the production of
the inflammatory cytokine IL-8. Toll-like receptors (TLRs) have recently been suggested to
mediate many of these cell signaling events. This study set out to investigate the role of
TLRs in the response of epithelial cells to lipopolysaccharides (LPS) from H. pylori
NCTC11637. Human embryonic kidney (HEK293) cells stably transfected with either TLR2
or TLR4 were treated with 10 μg/ml H. pylori LPS, and total RNA was isolated at intervals
over 48 hours. IL-8 mRNA expression was monitored using a real-time PCR-based assay.
It was observed that H. pylori LPS induced a transient up-regulation of IL-8 mRNA in
HEK293 cells stably transfected with TLR2 (HEK-TLR2), with a maximum induction of
approximately 18-fold following 4 hours of stimulation. This up-regulation was not observed
in HEK293 or HEK-TLR4 cells, suggesting that TLR2 was responsible for the LPS-mediated
increase in IL-8 mRNA. The HEK-TLR4 cells were found to express functional TLR4, since
treatment with the widely used TLR4 agonist, E. coli LPS, resulted in significant up-regulation
of IL-8. A number of genes have been shown to be induced in response to H. pylori infection
in vitro. The capacity of H. pylori LPS to stimulate a selection of these genes in HEK-TLR2
cells was next tested. VEGF was found to be significantly up-regulated by H. pylori LPS in
HEK-TLR2 cells, when compared with HEK293 or HEK-TLR4 cells. However, other genes
previously demonstrated to be induced by infection with live H. pylori, namely IL-1A, IL-
1B, ATF3 and C8FW, were not shown to be induced by H. pylori LPS in any of the HEK
cell lines. It is likely that other H. pylori-related virulence factors are involved in the induction
of these genes. In conclusion, IL-8 mRNA was shown to be induced by LPS from H. pylori
NCTC11637 via TLR2 in an epithelial cell system. In addition, VEGF was found to be up-
regulated during the TLR2-mediated response to LPS. Further studies are required to identify
genes whose expression is mediated by TLR2 in response to H. pylori LPS, and to elucidate
their role during H. pylori infection.
T1608
Effect of a Carcinogen On H. Pylori Infection: Expression of Cytokines and
TGFβ Receptor 2 in Rhesus Monkeys
Hui Liu, Cristina Semino-Mora, Steven Mog, Andre Dubois
Helicobacter pylori is recognized as a cause of gastric cancer, but only a fraction of infected
subjects develop gastric cancer. Transforming Growth Factor β (TGFβ) is a tumor suppressor
gene and mutations in TGFβ receptor II (TGFβR2) are present in human gastric cancer.
The present studies were undertaken to evaluate whether downregulation of TGFβR2 does
occur in rhesus monkeys infected with H. pylori and/or receiving the nitrosating carcinogen
ethyl-nitro-nitrosoguanidine (ENNG). We also investigated whether gastric precancerous
lesions and/or cancer emerge after ENNG administration, as reported in monkeys (J Natl
Cancer Inst, 1986). Gastroscopies were performed in 23 monkeys naturally infected with
H. pylori. Biopsies were fixed for histology, cultured, or flash frozen for gene expression
analysis. The mRNA expression of H. pylori 16S rRNA, IL-1β, IL-8, and TGFβR2 (copies/
100 ng RNA) were determined using an absolute real-time quantitative RT-PCR (TaqMan)
method, standard curves of cloned cRNA, and normalization with Rhesus monkey 18S
rRNA. After cure of the infection with quadruple therapy, H. pylori-negative monkeys were
assigned to one of four groups: controls (C, n =5); inoculation of a virulent H. pylori strain
isolated from a patient with gastric cancer (H, n =6); ENNG (E, 30 mg/day, n=6); and H.
pylori inoculation + ENNG (started 6 months post-inoculation; H+E, n =6). Follow-up
gastroscopies and biopsies were performed at regular intervals. Post inoculation, both H
and H+E groups had antral gastritis and H. pylori were present in the gastric lumen, attached
to, and inside, epithelial cells, and in the lamina propria. Starting at 21-month of ENNG
administration, gastric body biopsies of 3 H+E animals demonstrated atrophy, inflammation
with loss of parietal cells and conserved chief cells. At 31-month, gastric antrum biopsies
of one H+E animal showed intestinal metaplasia, small intestinal type, with marked epithelial
hyperplasia and regeneration. IL-1β and IL-8 cytokine expression increased in H. pylori
infected monkeys and TGFβR2 increased only transiently in H and H+E monkeys. Cytokine
mRNA expression was directly and significantly correlated with 16S rRNA expression both
in H and H+E (p <0.05). TGFβR2 expression was inversely correlated with H. pylori 16S
rRNA during natural H. pylori infection and after experimental inoculation (P <0.01). This
observation suggests that downregulation of TGFβR2 may play a role in gastric carcinogenesis.
Repeat endoscopies continue to be performed at 2-month intervals, the appearance of early
gastric carcinoma is investigated, and the relation between TGFβR2 and 16S rRNA expression
is explored.
T1609
The Prevalence of a-251t Polymorphism of IL-8 and G-308a of TNF in H.pylori
Positive and Negative Cases in Different Gastric Diseases
Dominika Szoke, Bela Molnar, Yvette Mandy, Zsolt Tulassay
Background: In vivo the H.pylori infection of the gastric mucosa induces the production of
various cytokines, like interleukin-1β, -6, -8 and TNFα. Presently available evidences suggest
that IL-8 may play a significant role in the pathogenesis of gastritis, which is closely associated
with H.pylori infection. The A-251T of IL-8 is a functional polymorphism reported to be
associated with the elevated expression level of IL8 and with pathogenesis of H.pylori related
diseases. The G-308A polymorphism in the regulatory region of TNFα gene has been
associated with susceptibility to a number of complex disorders, including infective diseases.
We aimed to examine the prevalence of these two polymorphisms in H.pylori positive and
negative cases in different gastric diseases. Materials and methods: Genomic DNA was
extracted from biopsy samples of 136 consecutive patients with gastritis (n=68), intestinal
metaplasia (IM) (n=28) and from histologically negative control patients (n=40). The IL-8
A-251T polymorphism was examined with using Amplification refractory mutation system
method, the G-308A polymorphism of TNFα was determined with PCR-RFLP method, with
NcoI restriction enzyme. H.pylori was determined in the samples by histology. The samples
were sorted also by the endoscopic findings to erosion and normal groups. Results: In the
case of the IL8 polymorphism the allele frequencies were significantly different with χ2-
probe between H.pylori positive erosion group and the normal group (p=0.0441) and between
H.pylori positive erosion and H.pylori negative erosion groups (p=0.0009). There were signific-
ant difference between the H.pylori negative and positive gastritis groups (p= 6.63E-16) and
significant difference were found between H.pylori positive IM and H.pylori positive gastritis
groups (p= 1.04E-09). In the case of the TNFα polymorphism the allele frequencies were
significantly different between the H.pylori positive IM and the negative control group (p=
0.0087) and between H.pylori positive erosion and the normal group (p=0.0049). There
were significant differences between the H.pylori negative and positive gastritis groups (p=
2.73E-11) and between H.pylori positive IM and H.pylori positive gastritis groups (p= 1.04E-
09). Discussion: Our findings suggest a relation between H.pylori infection and the presence
of the heterozygous state of A-251T polymorphism of IL-8, and the presence of the wild
type state of G-308A polymorphism of TNFα. The prevalence of these two polymorphisms
is significantly different between the different diseases groups independently from the H.py-
lori status.
T1610
The Role of Genetic Polymorphisms of Interleukin-1β, Interleukin-Receptor
Antagonist and Interleukin-6 in Helicobacter Pylori-Associated Diseases
Gyu Jeong, Jae G. Kim, Sill M. Park
Background: Interleukin-1beta (IL-1β), interleukin-1 receptor antagonist (IL-1RN) and
interleukin-6 (IL-6) genetic polymorphisms are known to be associated with pathogenesis
of the gastroduodenal disease infected with Helicobacter pylori. However, there has been
debate in real significance of these polymorphisms. The ethnic difference as well as genetic
heterogeneity should be taken into consideration to evaluate the significance of genetic
polymorphisms in these cytokines. We investigated IL-1β, IL-1RN and IL-6 genetic poly-
morphisms in Korean gastroduodenal disease patients to define their significance. Methods:
Gastric biopsy specimens were taken from H. pylori positive benign gastroduodenal disease
patients (chronic gastritis, n=23; benign gastric ulcer, n=59; duodenal ulcer, n=59: gastroduo-
denal ulcer, n=13), H. pylori positive gastric carcinoma patients (n=59) and H. pylori negative
gastric carcinoma patients (n=40). The DNA was extracted from gastric biopsy specimens.
The IL-1β polymorphisms at position -31, -511, +3954 and IL-6 polymorphisms at position -
174, -572, -597 were analyzed by PCR-restriction fragment length polymorphism. IL-1RN
variable number of tandem repeat (VNTR) polymorphism was analyzed by PCR. Results:
Among benign gastroduodenal diseases, the frequency of IL-1β-31T/T was significantly
higher in benign gastric ulcer (p=0.013) and duodenal ulcer (p=0.025) compared to chronic
gastritis. The frequency of IL-1β-511C/C was also significantly higher in benign gastric ulcer
(p=0.010) and duodenal ulcer (p=0.015) compared to chronic gastritis. H. pylori positive
gastric carcinoma patients had more IL-6-572*G allele compared to benign gastric ulcer
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and duodenal ulcer patients (p=0.041). Classifying of gastric carcinoma into intestinal and
diffuse type, there was no significant difference in genetic polymorphisms of these three
cytokines. Between H. pylori positive and H. pylori negative gastric carcinoma patients,
there was also no significant difference. Conclusions: IL-1β polymorphisms and IL-1RN
polymorphisms are not associated with gastric carcinogenesis in Korea. However, IL-6-
572*G allele may be contribute to pathogenesis of H. pylori positive gastric carcinoma. In
addition, IL-1β-31T/T and IL-1β-511C/C genotypes may be associated with pathogenesis
of peptic ulcer disease.
T1611
Use of Different Anti-Oxidant Strategies in Resisting Monochloramine-Induced
Accumulation of Intracellular Ca2+ in Gastric Glands of the Rabbit
Haley Naik, J. Matthew Dubach, David I. Soybel
AIM Monochloramine (NH2Cl), a thiol-directed oxidant which accumulates in H. pylori
gastritis, has been shown to induce Ca2+increase in the cytoplasm of the gastric parietal
cell due to intracellular store release and accelerated entry from extracellular spaces. This
study aims to determine whether these effects are prevented and reversed by different
antioxidant strategies, specifically thiol-reducing agent dithiothreitol (DTT) or oxidant scav-
enger Vitamin C (VitC). METHODS Glands were loaded with Ca2+-sensitive fluorescent
dyes, fura-2 (to monitor cytoplasm, [Ca2+]i) or mag-fura-2 (to monitor intracellular stores,
[Ca2+]S). Fura-2-loaded glands were perfused with standard Ringer’s solutions (Ca2+-free
+ 0.5mM EGTA or 1mM Ca2+). Mag-fura-2-loaded glands were permeabilized with 190nM
free-Ca2+ intracellular buffer and 10µM digitonin. Fluorescence excitation ratio (340nm/
380nm) was monitored in 6-8 parietal cells/gland. Heavy metal chelator, TPEN (20uM),
was used to screen out contaminating heavy metal cation contributions. Results are expressed
as mean +/- SEM and comparisons analyzed by t-test or ANOVA as appropriate. RESULTS
In the presence of extracellular Ca2+, exposure of glands loaded with fura-2 to NH2Cl
(200uM) led to sustained excitation ratio increases from 0.88+/-0.05 to 1.40+/- 0.09, corres-
ponding to [Ca2+]i increase of 300nM above baseline. In the absence of extracellular Ca2+,
NH2Cl exposure caused [Ca2+]i increases from 0.81+/-0.02 to 1.01+/-0.13, corresponding
to 100nM increase above baseline. These effects were prevented by pretreatment of glands
with DTT (100uM) or VitC (1mM). Vitamin C introduction during ongoing NH2Cl exposure
arrested but did not reverse [Ca2+]i accumulation. These disturbances were arrested and
partially reversed 1min after exposure to DTT (43.2%+/-6.5% decrease from max), compared
to a minimal reversal in the absence of DTT (9.1%+/-1.9% decrease from max, p<0.01).
In permeabilized glands loaded with mag-fura-2, NH2Cl exposure irreversibly depleted
intracellular stores. This was prevented by VitC, but not reversed by its addition during
ongoing NH2Cl exposure. DTT pretreatment prevented store-emptying, and its application
during ongoing NH2Cl exposure led to arrest of the depletion and partial refilling of
intracellular stores. CONCLUSION NH2Cl causes intracellular store Ca2+ release and extra-
cellular Ca2+ influx. NH2Cl-induced release of store Ca2+ is due to oxidation of intracellular
thiol groups, with inhibition and recovery in the presence of thiol-reducing agent DTT.
Oxidant scavengers such as VitC may prevent or arrest such disturbances, but should not
be expected to reverse ongoing injury due to NH2Cl.
T1612
Trichinella Spiralis Infection Alters Quality of Mucins in Previously H. Pylori
(HP) Infected Gerbils
Mohamed Sagar, Waliul Khan, Richard Hunt
BACKGROUND: Mucin hypersecretion is an important component of the immune response
to gastrointestinal nematode infection. Quantitative changes in mucus and qualitative changes
in the terminal sugars of goblet cell mucins have also been observed during nematode
infection. In contrast, H. pylori (HP) infection decreases gastric mucin synthesis via inhibition
of galactosyl transferase. This effect may impair the gastric mucosal barrier and contribute
to the mucosal injury induced by H. pylori infection. In this study we have investigated
whether infection with the nematode, Trichinella spiralis can alter the quality of mucins in
previously HP infected gerbils. METHODS: The gerbils were divided into 4 groups: control
group, group infected with HP-Sydney strain (HP-SS1), group infected with Trichinella
spiralis and group infected first with H. pylori and after 20 weeks with Trichinella spiralis.
Gerbils were sacrificed to investigate the expressions of terminal sugars of mucins by lectin
immunohistochemistry. Lectins used in this study were Griffonia Simplicifolia Lectin I (GSA
I), Griffonia Simplicifolia Lectin II (GSL II) and Elderberry Bark Lectin (EBL) which specifically
recognizes terminal N-acetylgalactosamine (GalNAc), N-acetylglucosamine (GlcNAc) and
sialic acid, respectively. RESULTS: Subsequent infection by T. spiralis altered the expression
of terminal sugars of mucins in HP infected gerbils. We observed a significant increase in
the number of GalNAc and GlcNAc expressing goblet cells in HP infected gerbils which
were also infected with T. spiralis (The number of GalNAc expressing cells/10 villi: 113 and
181 and the number of GlcNAc expressing cells/10 villi: 166 and 193 in HP infected and
HP+TSP infected gerbils; respectively. There was no significant difference in sialic acid
expressing goblet cells among the group. CONCLUSION: Our study demonstrated that T.
spiralis infection altered the quality of mucins in gerbils previously infected with HP and
suggests that helminth infection mediated changes in the composition of mucins may provide



















Helicobacter Pylori Lipopolysaccharide Enhances the Production of iNOS-
Derived NO in Cooperation with the Induction of Toll-Like Receptor (TLR) 2
Through TLR4 in Gastric Epithelial Cells
Uno Kaname, Kato Katsuaki, Ohara Shuichi, Shimosegawa Tooru
[Background and Aims] Cell-surface Toll-like receptors (TLRs) play essential roles in the first-
line of defense against virulent factors of Helicobacter pylori (HP). Microbial lipopolysaccharide
(LPS) is a strong inducer of iNOS and its action is mediated through TLR4. Recent studies
have suggested that HP-LPS may interact not only with TLR4 but also with TLR2. However,
little has been known about HP-LPS induced signal transduction in the gastric epithelial
cells. The present investigates the physiological roles of TLRs in HP-LPS induced iNOS in
gastric epithelial cells. [Materials and Methods] Changes in expression of iNOS, TLR2 and
TLR4 and downstream activation of MAPKs and NFκB were analyzed following stimulation
of normal mouse gastric mucosal GSM06 cells with HP-LPS and IFN-γ in the presence or
absence of inhibitors for MAPKs and NFkB, as well as siRNA for TLR2 or TLR4. Localization
of TLR2 in the human gastric mucosa was examined by immunohistochemistry. [Results]
Incubation of GSM06 cells with HP-LPS increased iNOS and also enhanced TLR2 expression,
but TLR4 expression remained. Increased expression of TLR2 in the human gastric mucosa
with Helicobacter pylori infection was also demonstrated immunohistochemically. HP-LPS-
initiated signal to induce iNOS and TLR2 expression was propagated through ERK phos-
phorylation and subsequent NFκB activation, independent on JNK and p38 pathways. The
decline in TLR4 expression caused by specific siRNA transfection showed less response to
TLR4-specific ligand, E.coli-LPS,i.e.; an increase in iNOS-induced NO production after
E.coli-LPS treatment was inhibited in TLR4-diminished cells. Similar inhibition of induction
of TLR2 and iNOS was observed in the cells treated with HP-LPS. TLR2-diminished cells
lost the response to TLR2-specific ligand PAM3CSK4. Although TLR2-diminished cells
retained iNOS induction following treatment with E.coli-LPS, the cells reduced the respons-
iveness to HP-LPS. These in vitro data indicated that HP-LPS might induce TLR2 mRNA
through TLR4 signaling and that enhanced TLR2 might participate in iNOS-derived NO
production by HP-LPS. In addition, HP-LPS may interact with TLR4 and inducible TLR2,
resulting in facilitating HP-LPS stimulated iNOS induction. [Conclusions] TLR4 signaling
initiated by HP-LPS and propagated by the activation of ERK and NFκB increased TLR2
expression and iNOS induction in gastric epithelial cells. This positive correlation between
TLR2 and TLR4 may constitute a mechanism for stimulating the innate immune response
against various bacterial components,including HP-LPS.
T1614
Proinflammatory Effects of Endothelial Nitric Oxide Synthase in Helicobacter
Pylori-Induced Gastritis
Toshio Watanabe, Kazuhide Higuchi, Tetsuya Tanigawa, E.J. Sasaki, Masatsugu Shiba,
Kazunari Tominaga, Yasuhiro Fujiwara, Nobuhide Oshitani, Tetsuo Arakawa
Background and Aim: Endothelial nitric oxide synthase (eNOS) is constitutively expressed
on endothelial cells. The contribution of eNOS to inflammatory response has received less
attention compared with inducible NOS, and the roles of eNOS in the pathogenesis of
gastrointestinal inflammation have been conflicting and inconclusive. Infection with Helicob-
acter pylori (H. pylori) is associated with neutrophil infiltration and over-expression of
inflammatory cytokines such as tumor necrosis factor-α (TNF-α). In this study, we assessed
the roles of eNOS in H. pylori-induced gastritis using eNOS-deficient mice. Methods: eNOS-
deficient and wild-type mice were inoculated with H. pylori, and were sacrificed 6 months
later. Expression of mRNAs for eNOS, TNF-α, and intercellular adhesion molecule-1 (ICAM-
1) in gastric tissue was determined by quantitative real-time RT-PCR. Measurement of
myeloperoxidase (MPO) activity in gastric tissue, a marker of neutrophil infiltration, was
assayed by the method of Bradley et al.. Expression of eNOS protein was evaluated by
Western blotting, while localization of eNOS protein was examined immunohistochemically.
Results: All mice inoculated with H. pylori were successfully infected, as assessed by bacterial
culture. In wild-type mice, H. pylori infection increased mRNAs for TNF-α and ICAM-1 by
22.6-fold and 6.9-fold, respectively, comparing to un-infected mice. The MPO activity was
also increased by 11.5-fold in wild-type mice infected with H. pylori. H. pylori infection did
not affect expression of both eNOS mRNA and eNOS protein. In wild-type mice, eNOS
staining was limited to endothelial cells, and localization of eNOS expression did not change
after induction of gastritis by H. pylori. Gastric inflammation induced by H. pylori was
significantly inhibited in eNOS-deficient mice, the inhibition of TNF-α mRNA expression,
ICAM-1 mRNA expression, and MPO activity being by 48%, 25%, and 45%, respectively.
Conclusion: These results suggest that eNOS has proinflammatory effects on gastric inflam-
matory response to H. pylori.
T1615
A Functional Role of Interleukin-21 (IL-21) in Promoting Matrix
Metalloproteinases Synthesis By Gastric Epithelial Cells During Helicobacter
Pylori Infection
Roberta Caruso, Claudio Tosti, Daniele Fina, Ilaria Peluso, Valentina Gioia, Carmine
Stolfi, Massimo C. Fantini, Thomas T. MacDonald, Francesco Pallone, Giovanni
Monteleone
Background and Aim. Helicobacter pylori (Hp) infection causes a Th1 cell-associated chronic
inflammation which can lead to gastric ulceration. How Th1 cell signalling promotes epithelial
damage in Hp-infected subjects remains unknown. However, studies in other systems suggest
that Th1 cell-derived cytokines stimulate the local production of matrix metalloproteinases
(MMPs), thereby promoting mucosal injury. Consistent with this, enhanced expression of
MMP, such as MMP-2 and -9, has been seen in the Hp-infected gastric epithelium. Here
we first examined whether in the Hp-infected gastric mucosa there is enhanced synthesis
of IL-21, a T cell-derived cytokine, which associates with Th1 cell response. Second, we
examined whether gastric epithelial cells express IL-21 receptor (IL-21R) and whether these
cells respond to IL-21 by increasing the production of MMPs. Methods. Gastric biopsies
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taken from patients with or without Hp infection were analysed for the content of IL-21
by Western blotting. IL-21R expression was examined in freshly isolated gastric epithelial
cells and gastric epithelial cell lines by Western blotting. Induction of MMPs by IL-21 in
gastric epithelial cells (AGS) was examined by Western blotting. To examine whether the
IL-21 effect on MMPs relies on MAP kinases and/or NF-KB activity, AGS were treated with
IL-21 for different time points and MAP kinase and NF-KB activation evaluated by Western
blotting and EMSA respectively. The effect of TPCK, an inhibitor of NF-kB activation, on
IL-21-mediated MMP production was also evaluated. Results. Constitutive production of
IL-21 was seen in the gastric mucosa of controls and Hp-infected patients. However, a more
pronounced expression of IL-21 was found in whole biopsies and isolated mucosal cells
from Hp-infected patients in comparison to normal controls and patients with Hp-negative
gastritis. Importantly, primary gastric epithelial cells and AGS expressed both the IL-21R
and the common γ-chain, which are necessary for IL-21-driven signalling. Consistently,
stimulation of AGS with IL-21 resulted in enhanced production of MMP-2 and MMP-9, but
not MMP-7, whereas tissue inhibitors of MMPs remained unchanged. Time-course analysis
also revealed that IL-21 enhanced NF-kB but not ERK1/2, p38 and JNK activation in AGS.
Consistently, inhibition of NF-kB by TPCK inhibited the IL-21-induced MMP production.
Conclusions. Data suggest that, in Hp-infected gastric mucosa, there is enhanced production
of IL-21, and that this cytokine can contribute to the Hp-associated epithelial injury by
promoting MMPs synthesis.
T1616
Ikk/Nf-κB Dependent Macrophage Activation Is Required for Helicobacter
Pylori-Induced Chronic Gastritis
Ayako Yanai, Shin Maeda, Youko Hikiba, Tomoya Ohmae, Wataru Shibata, Keiji Ogura,
Masao Omata
Innate immune system is the first line of host defense against pathogens, and macrophages,
main sources of pro-inflammatory cytokines, have been implicated. Helicobacter pylori (H.
pylori), one of the gram negative pathogens, induces chronic inflammation in stomach. To
investigate the relationship between macrophage activation and gastric inflammation, we
injected liposome-encapsulated clodronate for depletion of macrophages in H. pylori-infected
Mongolian gerbils, which showed similar gastritis as human stomach. We found that gerbils
treated with clodronate showed milder inflammation than ones without treatment. The NF-
κB family of transcription factors plays an important role in regulation of inflammation
through transcriptional regulation of pro-inflammatory cytokines in immune cells such as
macrophages. To clarify a role of NF-κB activation in H. pylori-mediated gastritis, an inhibitor
for IKK, which is a critical kinase for NF-κB activation, was administrated to H. pylori-
infected Mongolian gerbils every 24 h for two weeks. Inflammation levels were improved
after the treatment of the inhibitor. Correspondingly, IL-1β and IFN-γ levels of stomach of
the gerbils were suppressed by the treatment of IKK inhibitor. Macrophage cells (J774A.1)
were cultured with heat-killed H. pylori, it’s culture supernatant, or E. coli lipopolysaccharide
(LPS) for 24 h, and the concentration of IL-6 or TNF-α, which is tightly regulated by NF-
κB activation, was measured by ELISA. The culture supernatant, heat-killed H. pylori, or E.
coli LPS induced IL-6 production. Cells treated with IKK inhibitor inhibited H. pylori-
mediated IL-6 production compared to those without treatment. These results suggest that
IKK/NF-κB dependent macrophage activation is required for development of H. pylori-
mediated gastritis. This mechanism may be one of the important factors for progression
from chronic gastritis to gastric cancer.
T1617
The Neutrophil Activating Protein (HP-NAP) of Helicobacter Pylori Plays a
Role in Adherence to Gastric Epithelial Cells and to Mucin
Monique M. Gerrits, Ferry Namavar, Marion Sparrius, Arnoud H. van Vliet, Christina M.
Vandenbroucke-Grauls, Johannes G. Kusters, Ernst J. Kuipers
Introduction: Adherence of Helicobacter pylori to the gastric epithelium is believed to be an
important step in the induction of active inflammation of the mucosal layer. Several specific
adhesins, like SabA, BabA2, AlpA and AlpB have already been identified, but other factors
may well be involved. The H. pylori Neutrophil Activating Protein (HP-NAP) was previously
identified as a protein involved in immune modulation and is considered to be a candidate
for development of subunit vaccines against H. pylori. Aim: To assess the role of the Neutrophil
Activating Protein (HP-NAP) in adherence of H. pylori to epithelial cells. Methods: The napA
gene of H. pylori strain ATCC43504 was disrupted by insertion of a kanamycin cassette.
The wild-type ATCC43504 strain and its napA mutant were tested for their ability to adhere
to Hela cells and gastric tissue sections. In addition, the binding of recombinant HP-NAP
protein to mucin and sulfated oligosaccharides was studied by ELISA. Results: Wild-type
H. pylori ATCC43504 displayed strong binding to Hela cells, but mutation of the napA gene
resulted in a 10-fold reduction of this binding. The difference in adherence between the
wild-type strain and the napA mutant was also observed when using gastric tissue sections.
The wild-type strain primarily adhered to the mucus layer covering the epithelial cells.
When compared to the wild-type strain, the napA-mutant displayed strongly reduced binding
to purified mucin and sulfated oligosaccharides, suggesting that HP-NAP is indeed involved
in binding to sulfated mucins. Conclusions: HP-NAP is a multifunctional protein that plays
an important role in the persistence of H. pylori infection through binding to the gastric
epithelium. The cell surface receptor involved in the interaction with HP-NAP is still
unknown, but likely contains sulfated oligosaccharides.
T1618
Helicobacter Pylori Infection Induces Accumulation of Vδ1 T Cells Via CCR2
Upregulation
Seiji Futagami, Tetsuro Hiratsuka, Tomotaka Shindo, Tatsuhiko Hamamoto, Nobue Ueki,
Kenji Suzuki, Masafumi Kusunoki, Ken Wada, Kazumasa Miyake, Katya Gudis, Hidemi
Takahashi, Taku Tsukui, Choitsu Sakamoto
Background/Aims: Recent reports have shown that γδ T cells play an important role in
mucosal immunity and possess anti-tumor effects. It has yet to be elucidated whether the
response of the innate immune system, which includes γδ T cells, to antigenic stimulation
such as by H. pylori component might contribute to the gastric mucosal defense system.
Methods: Mucosal biopsies samples from 22 H. pylori-free and 75 H. pylori-infected patients
were classified into grades I-III gastritis groups according to mononuclear cell infiltration
based on the updated Sydney System. Phenotype analysis of peripheral T cells in H. pylori
grade III gastritis were evaluated by FACScan. The number of γδ, Vδ1, and Vδ2 T cells in
gastric tissues was evaluated by immunostaining and then compared with counts in 17
patients after H. pylori eradication (Triple therapy consisting of omeprazole (2 x 30mg/day),
clarithromycin (2 x 400mg/day), and amoxicillin (2 x 750mg/day) was prescribed for seven
day). TGF-β and IFN-γ levels of peripheral Vδ1 T cells stimulated by H. pylori component
(H. pylori urease, H. pylori-water extract protein (HPWEP) CagA+, HPWEP CagA-), IL-1β,
IL-7, and LPS were measured by ELISA method. CCR2 mRNA expression levels in stimulated-
Vδ1 T cells were also evaluated by real-time PCR. Results: γδ T cell count was significantly
higher in grade III gastritis patients, who exhibited strong IgA and IgG responses to H.
pylori urease, than in other groups. Vδ 1 T cells were dominantly resident in H. pylori-
infected gastric mucosa, whereas Vδ 2 T cells were mainly found in peripheral blood. Vδ1
T cell count was significantly reduced after H. pylori eradication therapy. In vitro studies,
H. pylori component stimulation significantly upregulated both TGF-β and IFN-γ production
in supernatant from stimulated peripheral Vδ1 T cells. Moreover, CCR2 mRNA expression
in Vδ1 T cells stimulated with H. pylori components was significantly increased. Conclusion:
Vδ 1 T cell accumulation of H. pylori-infected gastric mucosa might occur through the
upregulation of CCR2 expression.
T1619
Bone Morphogenetic Protein Signaling Regulates Fundic Gland Homeostasis
and Suppresses Tumorigenesis At Gastric Epithelial Transition Zones in Mice
Sylvia Pel-Bleuming, Xi He, Liudmilla Kodach, James Hardwick, Fiebo J. Ten Kate,
Sander J. van Deventer, Maikel Peppelenbosch, Johan G. Offerhaus, Linheng Li, Gijs R.
van den Brink
Background: Epithelial cells at the junction of two distinctive epithelial tissues are prone to
receive conflicting information from the two different epithelial environments. This may
make cells at epithelial junctions more vulnerable to tumorigenesis. Two important clinical
examples of tumors associated with epithelial transition zones in humans are carcinomas
that arise at the squamocolumnar junctions of the esophagogastric transition zone and the
uterine cervix. Background & aims: Morphogens regulate epithelial homeostasis in the
gastrointestinal tract. Bone Morphogenetic Protein (BMP) signaling stimulates apoptosis and
suppresses tumorigenesis in the small and large intestine. Here we examine the role of BMP
signaling in the murine stomach. Methods: We examined the expression of the BMP signaling
receptors Bmpr1a and Bmpr1b and the localization of the phosphorylated (active) form of
Smad1. We studied the role of the Bmpr1a in conditional Bmpr1a knock-out mouse. Results:
The BMP signaling receptors are differentially expressed in the gastric epithelium. Bmpr1a
is expressed in the gastric glands and by epithelial cells at the esophagogastric and gastrointes-
tinal transition zones. Bmpr1b is expressed by gastric pit (foveolar) cells and mesenchymal
cells. Upon conditional inactivation of Bmpr1a mice develop fundic gland hyperplasia.
Interestingly, these mice develop polyps that may develop intraepithelial neoplasia (dysplasia)
specifically in the esophagogastric and gastrointestinal transition zones. We show that these
transition zones are distinct areas of epithelium that lack some of the signals for differentiation
of the adjacent gastric epithelium and show increased proliferation. Conclusions: Here we
show that BMP signaling through Bmpr1a not only regulates fundic gland homeostasis but
also specifically suppresses tumorigenesis at gastric epithelial transition zones in the mouse.
This is the first example of a pathway that controls homeostasis at the junction between
different epithelial layers. Our data may have important implications for the understanding
of the genesis of esophagogastric tumors in humans.
T1620
Gastric Mucosal Fas Proliferative Signaling Requires Raf-1 Recruitment to the
Disc, Erk1/2 Activation and NF-kB Activity
Brian Moquin, Sharif Zubair, Hanchen Li, J.N. Carlson, Jeanmarie Houghton
Fas mediated apoptosis is increased in the stomach of both Helicobacter infected humans
and mice. This increase in Fas mediated apoptosis targets specialized cells within the oxyntic
mucosa preferentially, resulting in the loss of parietal and chief cells, with resultant atrophy
of the fundic mucosa. As cells become metaplastic and dysplastic however, they continue
to express Fas Ag receptor, but become resistant to apoptotic signaling. In addition to
apoptotic signaling, the Fas Ag/L cascade has been shown to signal for proliferation. Our
experiments suggest that Fas proliferative signaling may be important in driving gastric
cancer growth. The pathway for proliferative signaling has not been well worked out, and
the pathway used likely differs between cell types. Our experiments were designed to define
Fas apoptotic and proliferative signaling pathways within gastric mucosal cells. Using a
rat gastric mucosal cell line (RGM-1), we determined that gastric mucosal cells require a
mitochondrial amplification loop (Type II signaling) for apoptotic signaling, but not for
proliferative signaling. We manipulated the Fas Ag cascade at each known step of the Type
II apoptotic path using a combination of dominant negative proteins (FADD-DN), chemical
inhibitors (z-VAD-fmk, z-IEDT-fmk, UO126, ALLN) or naturally occurring inhibitory pro-
teins (IkB, FLIP). We found that proliferative and apoptotic signaling bifurcate at the death
inducing signal complex (DISC). Specifically, inhibition of FLICE with its known inhibitor-
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Flice Like Inhibitory Protein (FLIP) abrogates apoptotic signaling, but leaves proliferative
signaling intact. Increasing the strength of signal by increasing ligand availability or Fas Ag
receptor abundance in the presence of FLIP shunts Fas signaling toward proliferation. To
address the mechanism by which this switch occur, DISC complexes were immunoprecipit-
ated under conditions favoring either apoptosis or proliferation and recruitment of adaptor
proteins evaluated by Western blot. Raf-1 is recruited early after receptor ligation and
activates the MEK/Erk1/2 MAPK signal cascade. Erk1/2 activation of NF-kB has both pro-
proliferative and anti-apoptotic effects through upregulation of the anti-apoptotic protein
survivin. These studies demonstrate dual function for the Fas pathway within gastric mucosal
cells. The switch from apoptotic to proliferative signaling may contribute to gastric cancer.
T1621
High Expression of Metallopanstimulin-1 Reflects Tumor Progress and Stable
Suppression of Its Expression Inhibits Tumorigenicity of Gastric Cancer in
Vitro and in Vivo
Yunwei Wang, Ying Qu, Jianfang Li, Xuehua Chen, Bingya Liu, Qinlong Gu, Zhenggang
Zhu
Metallopanstimulin-1 (MPS-1) belongs to the S27E family of ribosomal proteins, whose
mRNA is highly expressed in a wide variety of actively proliferating cells. Convincing
evidences have also shown that MPS-1 is overexpressed in many types of malignant tumors
and maybe involved in progression toward malignancy. However, the expression of MPS-
1 in gastric cancer is still unknown and its potential role in cancer development and
progression has not been explored. In this study, we produced the anti-MPS-1 polyclonal
antibody and the expression pattern of MPS-1 was determined in 90 primary gastric cancer
specimens and 6 gastric cancer cell lines by immunohistochemistry and Western blot. To
investigate the functional significance of MPS-1 expression, three recombinant plasmids
producing hairpin small interfering RNA (siRNA) to target MPS-1 mRNA were constructed
and transfected into gastric cancer cell line SGC7901, an adherent, moderately differentiated,
human gastric cancer cell line, which we previously used to clone MPS-1 as a gastric cancer-
associated antigen gene. The stable cell lines transfected with the recombinant plasmids
containing the effective siRNA genes were selected and the biological features of the cells
were examined. We found that MPS-1 was overexpressed in 86% of the tumor samples and all
gastric cancer cell lines when compared with normal gastric mucosa tissues and immortalized
gastric mucosal epithelial cells. In addition, MPS-1 expression was even higher in tumors
with late TNM clinical stage than those with early clinical stage (p=0.007), which implied
that MPS-1 might also play an important role in malignant transformation of gastric cancer.
The MPS-1-specific siRNA recombinant plasmids pRNAT-133 could significantly reduced
the mRNA and protein expression levels of MPS-1 in pooled SGC7901/ pRNAT-133 cells.
Moreover, Hoechst33342 staining and flow cytometry showed an increased spontaneous
apoptosis rate of SGC7901/ pRNAT-133 transfectants. Furthermore, the stable transfectants
also exhibited significantly decreased proliferation and tumorigenicity in compared with
vector transfectants and parental cells in vitro and in vivo. These results provide the evidence
that MPS-1 may play an important role in the control of cell proliferation and tumor
development in gastric cancer and suggest MPS-1 is a promising target for gastric cancer treat-
ment.
T1622
5'-Untranslated RNA of the Human VEGF Transcript Facilitates Abnormal Cell
Growth of Human Colon Cancer Cells
Kiyoshi Masuda, Shigetada Teshima-Kondo, Kensei Nishida, Hideyuki Sasaki, Kumiko
Tominaga, Yuki Kuwano, Tomoko Kawai, Kyoko Morita, Atsuo Sekiyama, Keiya
Nakamura, Kazuhito Rokutan
Non protein-coding RNA (ncRNA) accounts for up to 98% of the total transcripts from
the human genome, and a large number of functional ncRNAs have been identified and
demonstrated to play crucial roles in RNA-directed gene expression regulation. To explore
a novel functional RNA, we have focused on the 5' untranslated region (UTR) of human
VEGF transcript. The 5' UTR is highly structured and unusually long (1,038 nucleotides)
and contains sequences that are important in regulating gene expression, including mRNA
stability and translational efficiency. During our investigation on specific roles of the 5' UTR
in cap-independent translational regulation (FASEB. J. 2004), we found that VEGF 5' UTR
could work as a trans-acting functional RNA molecule and regulate expression of distinct
genes. We established HCT116/VEGF 5' stable transfectants that expressed the full length
sequence of VEGF 5' UTR RNA. To identify genes specifically modulated by the 5' UTR,
we performed cDNA microarray analysis. The cDNA microarray analysis showed that over-
expression of VEGF 5' UTR specifically downregulated 7 genes including pro-apoptotic
genes and upregulated 18 genes including cell cycle-promoting genes. Moreover, we demon-
strated that HCT116/VEGF 5' cells showed an abnormal cell growth, which was demonstrated
by their higher proliferation rate and cell cycle progression in low-serum conditions, and a
higher degree of anchorage-independent growth. To identify the impact of VEGF 5' UTR
RNA on malignant tumorigenicity, we injected HCT116/VEGF 5' or parental control cells
subcutaneously into the flank fat pad of nude mice. At 28 days after injection, HCT116/
VEGF 5' cells formed larger tumors (2-fold increase) than parental control cells did. These
suggest that the 5' UTR of VEGF messenger can function as a modifier of tumor cell



















Influence of P21 and P53 On HDAC-Mediated Apoptosis in HCT116 Colon
Cancer Cells in Vitro and in Vivo
Matthias Ocker, Steffen Zopf, Daniel Neureiter, Marion Ganslmayer, Eckhart G. Hahn,
Christoph Herold
Background: Inhibitors of histone deacetylases (HDAC-I) have been shown to exert anti-
tumoral effects on different human cancers both in vitro and in vivo. We therefore investigated
the effect of a novel HDAC-I, A-422378.0, on wild-type HCT116 colon cancer cells as well
as derivatives lacking either p21 or p53. Methods: Cell lines were incubated with A-422378.0
at different concentrations (0.001 to 10 µM) for 3 to 120 h. Cell viability, proliferation and
apoptosis rates were determined quantitatively and verified qualitatively by western blotting,
detection of mitochondrial membrane potential breakdown, activation of caspases 3 and 8
and cytokeratin 18 cleavage.A subcutaneous xenograft model was established in NMRI mice.
Animals were treated with daily intraperitoneal injections of 10 mg/kg for 14 days. Tumor
size was measured, proliferation and apoptosis rate were determined immunohistochemically.
Results: All three HCT116 cell lines responded to A-422378.0 treatment with a time- and
dose-dependent induction of apoptosis with p21-/- cells being more sensitive than wild-
type or p53-/- cells. Apoptosis induction was induced by breakdown of ΔΨm. Caspase 3
was activated in wild-type cells only. Xenografts showed a pronounced growth inhibition
upon HDAC-I treatment, paralleled by down-regulation of PCNA and induction of apoptosis.
Conclusions: Treatment of wild-type or knock-out HCT116 cells with A-422378.0 exerts
potent anti-proliferative and pro-apoptotic effects in vitro and in vivo. Loss of p53 leads to
resistance to this treatment, while HCT116 cells deficient in p21 are sensitised to HDAC-
inhibitor mediated apoptosis. A-422378.0 might therefore be a potent new therapeutic
compound for the treatment of advanced colorectal cancers.
T1624
TGF-β Modulates Ubiquitination of Tumor Suppressor, ELF, and SMAD3, by
Praja, An E3 Ligase, That Control Hepatocellular Cancer
Tapas Saha, Katuri Varalakshmi, Hye Beak, Sang S. Kim, Yi Tang, Jogunoori Wilma, Volpe
A. Eugene, Bibhuti Mishra, Lopa Mishra
The TGF-β superfamily plays essential roles in cell differentiation and liver development,
as well as in both suppression and formation of hepatocellular carcinoma (HCC). TGF-β is
modulated through Smad activation and is dependent upon adaptor proteins such as ELF,
a β-spectrin as well as modifying E3 ligases such as PRAJA. Interestingly nearly two thirds
of elf+/- mutant mice develop hepatocellular carcinoma spontaneously at 12-15 months.
PRAJA is expressed in abundance in HCC and is an E3 ligase regulated by TGF-β and BMPs.
Aims: To analyze molecular interactions between ELF, Smad3 and PRAJA in TGF-β/BMP
signaling pathway in both normal liver formation and in HCC. Results: 1. PRAJA is expressed
in hepatocyte progenitor cells. Inhibition of PRAJA resulted in small livers, loss of liver
architecture with loss of hepatocytes growth and apoptosis with lineage alteration to cartilage
formation. 2. Confocal Microscopy and immunoprecipitation reactions demonstrate associ-
ation of PRAJA with ELF in a TGF β-dependent manner. 3. PRAJA manifests substantial
TGF-β regulated ubiquitination of ELF and Smad3 via its C-terminal RING-H2 domain.
Disruption of the RING finger domain of PRAJA (Delta-PRAJA) disrupts PRAJA ubiquitination
of ELF. 4. ELF and Smad3 interact with the N-terminal fragment of PRAJA (Delta-150-395)
in presence of TGF-beta. 5. PRAJA interacts with the Domain II of ELF (17 repeats region)
that contains both ankyrin binding domain and NLS under TGF-β stimulation. 6. All three
of the above interactions induce TGF-beta transcription through Luciferase reporter assays
using 3TPLux and (SBE)4Lux reporter plasmids. 7. Phosphorylation of PRAJA induces
association with ELF, however, this is not TGF-β dependent. 8. Conclusions: PRAJA associates
with ELF and PRAJA at independent sites from its RING finger domain. The RING finger
domain is required for ELF and Smad3 for ubiquitination. Phosphorylation of PRAJA is not
associated with the TGF-β activity, however it induces PRAJA to associate with ELF. These
studies reveal a mechanism for tumorigenesis in HCC whereby defects in adaptor proteins
for Smads, such as ELF as well as Smad3, can undergo degradation by PRAJA, through the
ubiquitin-mediated pathway and this RING E3 ligase serves as an important future therapeutic
target in HCC.
T1625
Inhibition of Colon Tumor Progression and Angiogenesis By P16ink4a
Amelie Boquoi, Tina Chen, Steven L. Gibson, Norman E. Sharpless, Colleen Brensinger,
Greg H. Enders
The Ink4a/Arf tumor suppressor locus is widely inactivated in cancer but little is known
about the tumor biology of its two products, p16Ink4a (p16) and Arf. Both the p16 and
Arf promoters are methylated in a significant fraction of human colon carcinomas, implying
a functional role for the locus in this tumor type. We have demonstrated previously that
Ink4a/Arf-null colon tumors display increased growth and vascularity in C57Bl6 mice carrying
the Min (multiple intestinal neoplasia) mutation. We present here an analysis of Min colon
tumors (N = 215) in mice with or without selective deficiencies in p16 or Arf, respectively.
Absence of Arf did not significantly alter tumor formation. In contrast, tumors in mice
lacking p16 were moderately larger and redder. Histological analysis demonstrated that
these tumors contained significantly more pockets of necrosis (P = 0.02), a marker of
carcinoma in situ; less apoptosis (P = 0.02); and higher red blood cell density (P = 0.02,
0.006 within vessels). Biochemical analyses demonstrated increased levels of vascular endo-
thelial cell growth factor (VEGF, P < 0.01). Exogenous p16 expression in human colon tumor
cells in vitro inhibited VEGF production. Microarray analyses of tumor mRNA expression have
identified additional candidate mediators of increased angiogenic signaling in the p16-null
tumors. These results suggest that p16 constrains colon tumor progression, in part through
inhibiting angiogenic signaling.
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T1626
Anoikis Induction By Galectin-1 in HCC Cells Requires Endocytosis of α5β1
Fibronectin Receptor
Hugo Sanchez Ruderisch, Martina Welzel, Katharina Detjen, Hans-Joachim Gabius,
Bertram Wiedenmann, Stefan Rosewicz
Background: We have previously shown that Galectin-1 (Gal-1) inhibits anchorage dependent
growth of various human carcinoma cell lines via G1 cell cycle inhibition. In contrast, Gal-
1 activates proapoptotic signaling pathways when applied under anoikis conditions, i.e. to
cells denied contact to an appropiate ECM. Gal-1 stimulated anoikis and cell cycle inhibition
required the presence of the α5β1 fibronectin receptor (FNR) and relied on binding and
functional interaction of Gal-1 with the FNR complex. Of the carcinoma cell lines studied,
hepatocellular carcinoma (HCC) cell lines were consistently susceptible to Gal-1 stimulated
anoikis, suggesting that Gal-1 activated proapoptotic pathways may be targeted for treatment
of HCC. Here we used HCC to elucidate the mechanisms that specify underlie Gal-1
stimulated anoikis. Methods: Interaction between Gal-1 and integrins was analyzed using
biotinylated Gal-1 and/or fluorescence labeled anti-integrin antibodies in flow cytometry
and immunofluorescence microscopy. Apoptosis induction was determined based on the
pre-G1 fraction in DNA-histograms using flow cytometry. Subcellular fractionation and
subsequent immunoblotting were carried out to determine integrin or Gal-1 complement
of the membrane compartment. Results: Gal-1 bound to the surface of Hep-G2 HCC cells
and co-localized with the α5β1 FNR. Under anoikis conditions, but not in adherent cultures,
Gal-1 binding was rapidly followed by a reduction of FNRs on the cell surface, as determined
by flow cytometry. This corresponded to a marked decrease of both α5 and β1 subunits
in membrane fractions of Gal-1 treated cells, confirming internalization of the FNR. Immuno-
fluorescence studies further revealed a concordant redistribution of Gal-1 from the cell
surface into the cytosol. In contrast to Gal-1, Galectin-3 was unable to stimulate internaliz-
ation. Moreover, the amount of α2, αV, β4 or β5 integrin subunits on the cell surface was
not influenced by Gal-1, suggesting that internalization was induced via a specific and
selective interaction between Gal-1 and the FNR. Preatreatment of cells with filipin, a
compound that inhibits endocytosis, prevented Gal-1 dependent internalization of the FNR
and protected Gal-1 treated cells from anoikis. A functional requirement for FNR internaliz-
ation was further supported by data from cell lines which despite Gal-1 binding failed to
internalize α5β1 integrin, and were found resistant to Gal-1 stimulation of anoikis. Conclu-
sions: Our data characterize the internalization of the FNR-Gal-1 complex as an integral
functional step in the signal transduction process leading to apoptosis induction under
anoikis conditions.
T1627
Fas AG Signaling in Colon Cancer: A Role in Proliferation and Metastasis
Sharif Zubair, Hanchen Li, Brian Moquin, J.N. Carlson, Jeanmarie Houghton
Mechanisms to overcome apoptosis are crucial for cancer cells to acquire if they are to
survive. The Fas Ag pathway of apoptosis is commonly dysregulated in cancer cells. Dysregul-
ation occurs at several sites along the cascade, however complete loss of receptor is unusual.
Thus retention of surface receptor suggests a pressure may exist to preserve the pathway
for functions other than apoptosis. Colon cancer cells express Fas Ag but appear resistant
to Fas mediated apoptosis. These cells also express Fas L on the surface which may function
in immune counter attack. We hypothesized that Fas Ag is retained in colon cancer cells
because it would give the cells a proliferative advantage. We also reasoned that Fas L
expression would increase liver metastasis. MC38 cells are a colon cancer cell line derived
from C57BL/6 mice. MC38 cells were transfected to express FLIP (FLICE -like inhibitory
protein) +/- Fas L. Cell growth characteristics were assessed in vitro by Annexin V staining
(apoptosis), cell counts, MIT assay and BrdU incorporation (proliferation). One million cells
were injected subcutaneously or intravenously into C57BL/6 mice, and the incidence, size
and invasive nature of local tumors, and the number of hepatic metastasis evaluated. MC38
cells and MC38 cells transfected with the empty vector express moderate amounts of Fas
Ag and no detectable Fas L. Cells grow poorly in culture and undergo Fas L induced
apoptosis. 30% of mice (n=10) injected with these cells developed subcutaneous tumors.
No hepatic tumors were identified (n=10) in mice receiving iv injections. Cells engineered
to express FLIP (MC38/FLIP) were resistant to Fas mediated apoptosis, and increased
proliferation with ligand. 100% of mice injected sq with MC38/FLIP cells developed tumors
(n=10), and 30% of mice receiving iv injections (n=10) developed hepatic tumors. Cells
expressing both FLIP and Fas L had high proliferation rates and were resistant to Fas L
mediated apoptosis. Subcutaneous tumors developed in 100% of mice. These tumors were
large, vascular and invasive. Mice receiving iv injections developed numerous hepatic tumors,
with 2 mice developing greater than 100 large lesions (n=10)within 2 weeks of injection.
The ability to avoid Fas mediated apoptosis may be an early event in colon cancer. Blocking
the apoptotic pathway while retaining proliferative signaling may offer cells a local growth
advantage while the expression of ligand increases both proliferation (by bypassing the need
for exogenous ligand for signaling) and metastasis. Agents targeted at this pathway may be
suitable for colon cancer therapy.
T1628
Differentiation Regulator Musashi-1 Enhances Malignant Potentials in AGS
Human Gastric Cancer Cells
Hiroaki Murata, Shingo Tsuji, Masahiko Tsujii, Masayo Matsuoka, Hiroshi Eguchi, Sunao
Kawano, Norio Hayashi
[Background & Aims] Musashi-1 (MSI-1) is an RNA-binding protein that regulates cell
differentiation. We reported that MSI-1 was expressed in the stomach, in particular, in
Helicobacter pylori-infected gastric mucosa. Previous reports showed that MSI-1 expression
correlated with grades and stages of brain tumors, but MSI-1 expression in gastric cancer
has poorly been investigated. Our preliminary investigation revealed that MSI-1 was expressed
in human gastric cancer tissue. Here we aimed to explore the involvement of MSI-1 in the
development of gastric cancer in vitro in terms of proliferation, apoptosis, and colony
formation. [Materials and Methods] AGS human gastric cancer cells were transfected with
Msi-1 cDNA (AGS-Msi-1 cells) and markers involved in proliferation and apoptosis were
examined by RT-PCR and Western blotting. Cell growth was evaluated by WST-8 assay.
After apoptosis was induced by actinomycin D (0, 0.01, 0.1, 1 µg/ml) and H2O2 (0, 0.001,
0.01, 0.1%), cell numbers were counted by WST-8 assay and apoptotic cells were visualized
by Hoechst 33342 staining and quantified by flow cytometry with propidium iodide (PI)
staining and double staining with annexin V. Cells were cultured in soft agar to examine
anchorage-independent growth capacity. [Results] Compared with wild-type and mock AGS
cells, AGS-Msi-1 cells grew significantly faster (p < 0.05), which was supported by ERK
activation. AGS-Msi-1 cells exhibited higher levels of anti-apoptotic Bcl-2 and lower levels
of pro-apoptotic Bax and Bad. While actinomycin D and H2O2 induced apoptosis in a dose-
dependent manner, AGS-Msi-1 cells circumvented apoptosis and significantly more cells
survived (p < 0.05). Flow cytometry with PI staining and double staining with annexin V
revealed a reduction in the sub-G1 cell population and the apoptotic cell fraction, respectively,
in AGS-Msi-1 cells. After induction of apoptosis, ERK was activated while JNK activation
was suppressed in AGS-Msi-1 cells. Soft agar assay revealed that AGS-Msi-1 cells formed
markedly larger colonies. [Conclusions] MSI-1 expression induces pro-proliferative and anti-
apoptotic properties as well as large colony formation in AGS cells. MSI-1 enhances malignant
potentials in gastric cancer cells.
T1629
Role of MAT and SAME in Colon Cancer Pathogenesis
Hui Chen, Mark Lin, Meng Xia, Xiaopeng Ou, Heinz Josef-Lenz, Shelly C. Lu
Methionine adenosyltransferase (MAT) is a critical cellular enzyme that catalyzes the forma-
tion of S-adenosylmethionine (SAMe). In mammals, two different genes, MAT1A and MAT2A,
encode for two homologous MAT catalytic subunits, a1 (forms either a dimer MAT III, or
tetramer MAT I) and a2 (MAT II); while a third gene MAT2b, encodes for a regulatory
subunit b that regulates MAT II. MAT1A is expressed mostly in liver whereas MAT2A is
widely distributed. In liver, increased MAT2A and MAT2b expression is associated with
lowering of cellular SAMe levels, increased growth and dedifferentiation. Interestingly, SAMe
can inhibit liver cell growth and induce apoptosis in liver cancer cells while protecting
normal hepatocytes against apoptosis. One small study found increased MAT II expression
in resected colon cancer specimens as compared to normal colon, which correlated with
stage of disease. The mechanism of MAT II up-regulation and whether this may play a role
in the pathogenesis of colon cancer is unknown. Furthermore, whether SAMe also regulates
growth and death response in colon cancer cells is also unknown. The current study examined
these questions using both resected colon cancer specimens and normal colon counterparts
from the same patients and colon cancer cell lines RKO and HT29. In six of seven randomly
selected patients, the MAT2A mRNA levels were elevated 2-fold in colon cancer specimens
as compared to normal colon controls. MAT2b mRNA levels were also higher (up to 5-
fold), particularly variant two (an alternatively spliced variant) in five of seven cancer
specimens as compared to normal colon controls. EGF, IGF1 and leptin, mitogens for colon
cancer cells that have been implicated in the pathogenesis of colon cancer, up-regulated
MAT2A (but not MAT2b) expression in RKO and HT29 cells. In RKO cells, transfection
with RNAi against MAT2A lowered MAT2A expression by 80%, inhibited cell growth by
15% and prevented the ability of these growth factors to induce MAT2A. Importantly, the
mitogenic effect of these growth factors is abolished if MAT2A induction is blocked by
RNAi. SAMe and its metabolite methylthioadenosine (MTA) lowered the baseline expression
of MAT2A and blocked the growth factor-mediated increase in MAT2A expression in colon
cancer cell lines. Furthermore, SAMe and MTA inhibited growth of colon cancer cells by
inducing apoptosis. Collectively, these data suggest similar to the liver, up-regulation of
MAT2A also provides a growth advantage and SAMe and its metabolite MTA regulate growth
and death in colon cancer cells.
T1630
Unique Accumulation of Ser45-Phosphorylated β-Catenin Across Different
Murine Models of Proliferation
Shahid Umar, Pomila Singh, Joseph H. Sellin
Background: Activation of β-catenin is recognized as a critical early factor in tumorigenesis.
Several pathways of β-catenin activation have been delineated, e.g. APC mutations, Wnt
signaling and gain-of-function mutations in β-catenin. We previously described a novel
mechanism of β-catenin activation in vivo using the transmissible murine colonic hyperplasia
(TMCH) model: GSK-3β inhibition with increases in Ser45-phosphorylated β-catenin (β-
cat45, DDW2005). It is unclear whether this is a unique pathway of β-catenin effects or
whether other models share a similar series of molecular events. Aim: Examine alterations
in the β-catenin pathway in independent animal models of proliferation. Methods: TMCH
in Swiss-Webster outbred mice was induced by Citrobacter rodentium inoculation. Trans-
genic mice overexpressing progastrin (hGAS), and mdr1a-deficient (-/-) mice that lack the
membrane efflux pump p-glycoprotein and develop spontaneous colitis were used as models
of proliferation. Crypt isolation and immunohistochemistry (IHC) studies were performed
via standard techniques. Results: During TMCH, an 8-fold increase in colonocyte proliferation
was accompanied by dramatic increases in abundance of cellular and nuclear β-cat45. IHC
studies also exhibited significant increases in cytoplasmic and nuclear β-cat45 immunoreactiv-
ity and correlated with biochemical data. Ser33,37/Thr41 residues in β-catenin however,
failed to show changes in phosphorylation despite in vivo blockade of proteasomal degrada-
tion via intra-peritoneal injections of proteasomal inhibitor PS-341. hGAS mice exhibited
hyperproliferation and an elevated BrdU-labeling index of crypts predominantly in the
proximal colon compared to wild type littermates. mdr1a-/- mice develop spontaneous colitis
at ~12 weeks of age when housed in a conventional mouse colony. At 8 and 10 weeks of age
however, these animals developed significant hyperplasia compared to wild type littermates,
without detectable colitis. IHC/biochemical studies performed in proximal and distal colons
of hGAS and mdr1a-/- mice respectively, exhibited dramatic accumulation of cytoplasmic
and nuclear β-cat45 without apparent increase in Ser33,37/Thr41-phosphorylated β-catenin.
Conclusions: A pattern of β-catenin related molecular changes found in TMCH is also found
in other animal models of colonic hyperproliferation, demonstrating a common final pathway
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in seemingly diverse initiating events. Defining the specific mechanisms involved in GSK-
3β inhibition and increased β-cat45 accumulation may provide insight into the regulation
of cell census in the colon and may help identify possible targets for early intervention/chemo-
prevention.
T1631
Reversal of Resistance to CPT-11 in Colorectal Cancer Following Inhibition of
PI3K
Farnaz Taghizadeh, Isabella T. Tai
Treatment for metastatic colorectal cancers (CRC) now includes irinotecan (CPT), with RR
of ~35% when used in combination with 5-fluorouracil (5-FU) compared to ~21% with 5-
FU alone. This still indicates that many patients have CPT refractory disease. To identify
potential mechanisms contributing to CPT resistance, microarray results revealed a 2-fold
increase in PI3K in MIP/C in comparison to sensitive MIP101 (MIP) cells. Confirmation by
RT-PCR led us to question whether PI3K can modulate therapy sensitivity in therapy
refractory CRC. AIM: To determine if modulation of PI3K mRNA and protein influences
the sensitivity of CRC cells to chemotherapy. METHODS: In-vitro studies to determine if
PI3K influences the sensitivity of cells to chemotherapy were performed by incubating
MIPand MIP/C with a specific inhibitors of PI3K, LY294002 (LY), followed by exposure to
200 µM CPT. To assess which subunit of PI3K was responsible for modulating chemotherapy
sensitivity, MIP and MIP/C cells were transfected with siRNA targeting PIK3CA (p110α
catalytic subunit) and PI3CG (p110γ subunit), followed by exposure to CPT. Cell viability
was determined by MTS assay, while the percentage of cells undergoing apoptosis were
analyzed by TUNEL and FACS analysis. RESULTS: In-vitro results indicated that following
inhibition of PI3K with LY, a significantly greater number of refractory MIP/C cells were
undergoing apoptosis, from 0 + 0.04 % in MIP/CPT cells exposed to CPT to 2.7 + 1.1 %
apoptotic cells when exposed to LY in combination with CPT. This increased sensitivity to
CPT in the resistant cells following inhibition with LY was associated with a decrease in P-
Akt and P-Bad, and increased PARP by immunoblot in comparison to MIP/C cells exposed
to CPT alone. Further evaluation revealed that inhibition of PIK3CA, and not PIKCG, by
siRNA, had the greatest influence on cell survival in MIP/C, resulting in a decrease in cell
viability from 5.9 + 3.9% with CPT alone to 36.8 + 6.1% following inhibition of PIK3CA
and exposure to CPT. Interestingly, DNA sequencing of exon 9 and 20 of PIK3CA revealed
a specific missense mutation in exon 20 (kinase domain) of MIP/C resistant cells that was
not present in either the sensitive MIP CRC or normal CCD-112 CoN colon cell lines.
CONCLUSIONS: In-vitro studies revealed that resistance to CPT in MIP/C cells was associated
with overexpression of PIK3CA, and that specific inhibition of the p110α catalytic subunit
re-sensitized therapy-refractory cells to undergo apoptosis following treatment with CPT.
Mutations in exon 20 that were specific to MIP/C may be responsible for enhancing PIK3CA
activity, and promote CPT resistance.
T1632
XAF1 Mediates Inhibition of Extracellular Signal-Regulated Kinase 1/2
Induced Apoptosis in Human Colon Cancer Cells
Lifen Yu, Jide Wang, Bing Zou, Yunlin Wu, Benjamin Cy Wong
Background/Aims: XIAP-associated factor 1 (XAF1) has been identified to negatively regulate
the function of X-linked inhibitor of apoptosis (XIAP) which is a potent member of IAP
family that exerts anti-apoptotic effects. Extracellular signal-regulated kinase (ERK) pathway
is thought to increase cell proliferation and protect cells against apoptosis. However, the
involvement of ERK in XAF1 expression in colon cancer cells is not clear. Methods: Four
human colon cancer cell lines were studied in present study, including HCT1116 and LoVo
(wide-type p53), DLD1 and SW1116 (mutant p53). Two LoVo stable transfectants, XAF1
sense and anti-sense were established. The effects of dominant-negative MEK1 (DN-MEK1)
and MEK-specific inhibitor U0126 on ERK signaling pathway were detected by Western
blotting, so did the expression of XAF1 and XIAP protein. The transcription activity of core
XAF1 promotor was assessed by dual luciferase assay. The levels of XAF1 and XIAP mRNA
expression were detected by RT-PCR. Cell proliferation was measured by MTT assay.
Apoptosis was determined by hoechest 33258 staining. Results: We found that U0126
(30uM) markedly induced XAF1 protein expression in HCT1116 and LoVo cells at 48h,
but XAF1 protein levels of DLD1 and SW1116 were still very low. U0126 induced XAF1
protein expression in a dose- and time-dependent manner in LoVo cells. DN-MEK1 also
induced XAF1 protein expression after transfection for 48h. Conversely, the XIAP protein
expression was down-regulation by these treatments. MEK1/2 phosphorylation was inhibited
similar to that of ERK1/2 inhibition. But expression of total ERK1/2 and MEK 1/2 protein
levels were not decreased in LoVo cells. The activities of XAF1 promotors were also signific-
antly increased by both U0126 treatment and DN-MEK1 transfection. The over-expression
of XAF1 mRNA induced by U0126 pretreatment was blocked by emetine. rhEGF-stimulated
phosphorylation of ERK had little or no effect on XAF1 expression, and was blocked by
pretreatment with U0126. LoVo cells with stable transfectants of XAF1 were more susceptible
to U0126-induced apoptosis in a time-dependent manner. LoVo cells with stable transfectants
of XAF1 anti-sense rendered less sensitive to U0126 treatment in cells proliferation and
lowered apoptotic cells levels compared with its parent cells. Conclusions: These findings
suggested that inhibition of ERK1/2 pathway could induce XAF1 expression which may
correlated with different status of p53 in human colon cancer cells. XAF1 is necessary for


















Comparative Promoter Analysis Suggests the Role of the NF Kappa B
Transcription Factor in the Transition Between Adenoma and Carcinoma
Balazs Gyorffy, Orsolya Galamb, Bela Molnar, Zsolt Tulassay
We have only scarce knowledge about the molecular mechanisms that cause the progression
from adenoma to colon cancer (CRC). In our recent micorarray study we set up a gene list
associated with the difference between adenoma and CRC. A major challenge in the genomic
era is to decipher the regulatory networks responsible for the expression changes in a set
of co-regulated transcripts. We aimed to identify transcription factors (TF) having overrepres-
ented binding sites (TFBS) in the promoter regions of genes associated with the adenoma-
cancer transition. We analyzed data obtained using Affymetrix HGU133A plus 2 gene chips.
The genome-wide gene expression patterns of 15 colon cancer specimens and 15 adenoma
specimens were compared. Using two independent normalization approaches, we identified
the top 37 differentiating genes. Using the EZ-Retrieve web service proximal promoter
sequences were available for 17 genes. The MotifScanner software, which searches the
TRANSFAC database, was used to detect TFBS in this set of sequences. We have identified
altogether 119 different TFBSs. The statistics tool of the Java program TOUCAN was applied
to the data in combination with the appropriate background model of human expected
frequencies (EPD - 0.1), thereby detecting over-represented TFBSs among the selected
genes. Only one binding site was significantly over-represented: NFKappaB65 (p=0.0339).
In summary, using an in silico comparative promoter analysis we identified the NF kappa
B65 transcription factor, which could represent a key element in a putative transcription
regulatory network responsible for the transition from adenoma to colon cancer.
T1634
TRF2 Promotes Multidrug Resistance in Gastric Cancer Cells By Inhibiting
DNA Damage Response
Zhiguo Liu, Hanbing Ning, Tingting Li, Lina Zhao, Daiming Fan
DNA double-strand breaks (DSBs) induced by anticancer drugs or irradiation increase TRF2
expression as an early response to DNA damage, which inhibits activation of the ATM-
dependent DNA damage response network. Therefore, TRF2 might probably be a general
DNA-repair factor rather than just a telomere-binding factor. In this study, the possible
involvement of TRF2 in anticancer drugs induced DNA damage response and drug resistance
was investigated. Adriamycin (ADR) and etoposide are clinically important anticancer drugs
which exert cytotoxic effect by inducing DSBs. Gastric cancer cell line SGC7901 and two
multidrug-resistant (MDR) variants were treated with various concentrations of ADR or
etoposide. It was found that telomerase activity and TRF2 were upregulated after treatment
in all three cell lines, but not TRF1. More dramatic upregulation of TRF2 was found in
MDR cells, which is accompanied by decreased ATM, H2AX, and p53 expression. Inhibition
of TRF2 expression by RNA interference in MDR cells partially reversed its MDR phenotype
and overexpression of TRF2 in SGC7901 promoted its MDR phenotype. Taken together,
current results indicate that TRF2 plays an important role in DNA damage response, and
is involved in drug resistance of cancer cell. Further study of the biological functions of
TRF2 might be helpful to dissect the molecular mechanism of MDR and generate novel
target to overcome MDR.
T1635
Involvement of P73 Protein in Gastrointestinal Tumorigenesis
Katarina Tomkova, Wael El-Rifai, Alexander Zaika
p73, a new member of the p53 tumor suppressor family, is a transcription factor that is
increasingly being recognized in cancer research as an important player in tumorigenesis,
as well as in chemotherapeutic drug sensitivity. Recently, we reported that that p73 isoforms
have oncogenic properties and are frequently overexpressed in more than 60% primary
adenocarcinomas of the stomach and esophagus. We have also demonstrated that this
overexpression can lead to the upregulation of β-catenin and TCF/LEF-dependent transcrip-
tion. Thus, despite substantial structural and functional similarities to p53, our results suggest
that p53 and p73 may differently regulate its transcriptional targets and may have distinct
roles in human tumorigenesis. Indeed, in contrast to p53, we found that p73 can upregulate
the gastrin gene transcription. Our results show that p73, when overexpressed, can bind
to the gastrin promoter in vivo. This leads to transcriptional upregulation of gastrin mRNA
and an increase in progastrin level. Moreover, for the first time, we found that NF-Y
transcription factor is a critical regulator of gastrin gene transcription can interact with p73
in promoter regulation. Taken together, our results demonstrate a novel mechanism for
regulation of gastrin gene transcription and support a concept that p53 and p73 may have
different biological roles in gastrointestinal tumorigenesis.
T1636
Capsaicin Induces Apoptosis in Gastric Cancer Cells - A Possible New “Hot”
Cancer Treatment?
Justine Chow, Manith Norng, Jianyuan Chai
Capsaicin (C18H27NO3) is an organic compound found in “hot” chili peppers belonging
to the genus Capsaicum. It causes insensitivity to painful stimuli through desensatation of
its receptor VR-1, after prolonged contact. Currently capsaicin is used in pepper spray and
pain medication. Studies have shown that capsaicin induces apoptosis in some cancer cells,
but its effect on gastric cancer is not clear. The aims of this study were to examine the effect
of capsaicin treatment on gastric cancer cells and mechanisms involved. METHODS: Human
gastric cancer cells AGS were treated with capsaicin at 10μM, 50μM, and 200μM for 2, 6
and 24 hours. Apoptosis was determined by Annexin V and TUNEL staining. Expression
of oncogene products was examined by cDNA array, Western blotting and Immunocytochem-
istry. Normal human gastric epithelial cells were used for comparison. RESULTS: 1) Capsaicin
treatment at 50μM increased apoptosis in AGS cells by 5.5, 12 and 4.5 fold (P < 0.001) at
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2, 6 and 24 hours, respectively, compared to vehicle-treated control. Capsaicin treatment
activated VR-1 expression and membrane localization at 2 and 6 hours, but the cellular
sensitivity to the treatment was reduced by 80% after 6 hours. Normal cells responded to
capsaicin treatment more slowly, compared to cancer cells. Apoptosis in normal cells came
after 6-hour capsaicin treatment, 1.5 and 5.5 fold (P < 0.005) at 6 and 24 hours, respectively.
2) After 6-hour treatment, the pro-apoptotic effect of capsaicin on AGS cells was increased
as concentration, 4, 12 and 14 fold (P < 0.01) at 10μM, 50μM, and 200μM, respectively.
In addition, 200μM capsaicin caused severe cell death in both types of cells, indicating its
toxicity. 3) In parallel to VR-1 activation, capsaicin increased Bax expression by 40% and
120% (P < 0.01) at 2 and 6 hours, respectively, compared to control, but did not alter
Bcl-2 expression significantly. Capsaicin also caused Bax translocation from cytoplasm to
mitochondria and increased mitochondrial permeability to allow cytochrome c release.
CONCLUSIONS: 1) Capsaicin induces apoptosis in both gastric cancer and normal cells,
but cancer cells to a much greater extent; 2) Capsaicin induces apoptosis in a dose-dependent
but not time-dependent manner, likely due to its desensatation property; and 3) Capsaicin
induces apoptosis in gastric cancer cells through the mitochondrial pathway.
T1637
Effects of Dietary Fatty Acid Composition On Rat Colon Carcionogenesis
Takehiro Fujise, Takashi Kakimoto, Ryosuke Shiraishi, Kanako Yamaguchi, Sadahiro
Amemori, Yasuhisa Sakata, Seiji Tsunada, Ryuichi Iwakiri, Kazuma Fujimoto
Background and Aim Resentry, there is an upward trend in age-adjusted mortality rates for
colon cancer in Japan. This upward trend in death rates due to colon cancer is mainly
attributable to Westernization of Japanese food habits. Many nutritional epidemiologic studies
have showed a positive association between dietary fat intake and colon cancer. Many studies
demonstrated that the colon tumor-promoting effect of a high fat diet depends not only on
the amount consumed but also on the fatty acid composition. Wnt signaling pathway and
Oxidative stress was integrally associated with colon carcinogenesis. The aim of this study
is to investigate an effect of different dietary fat on colon carcinogenesis in the rat pretreated
with azoxymethane (AOM). Materials and Methods Male SD rats were given intraperitonial
injections of AOM dissolved in 1 ml physiological saline once a week for 2 weeks at a dose
of 15mg/kg body wt or saline and fed on a basal diet or supplemented with 10% corn,
olive, beef, and fish oil for 44 weeks. Colonic aberrant crypt foci (ACF) were examined at
12 weeks and tumors, including adenomas and carcinomas, were examined at 44 weeks.
Colonic proliferation were evaluated by BrdU uptake, and COX-2, Beta-catenin, cyclinD1,
Wnt2 and Wnt5a were analyzed by Western blotting. Lipid peroxidation of colonic mucosa
was evaluated by TBARS, and 8-OHdG, which indicated DNA damage due to Oxidative
stress, were analyzed by immunohistochemistory. Results Long-term dietary olive and fish
oil decreased ACF, considered biological precursors of colon cancer in rodents and humans,
at 12 weeks and colon cancer incidence and multiplicity at 44 weeks even in AOM treated
rats. In contrast, both corn and beef oil increased ACF in AOM-treated rats at 12 weeks
and promoted colon cancer incidence and multiplicity. These two dietary oils increased
BrdU uptake and expression of cytosolic beta-catenin, cyclin D1 in the colon mucosa. Wnt2
and COX-2, in rats fed with dietary beef oil, and Wnt5a, in rats fed with dietary corn oil,
expression increased in both AOM-untreated and AOM-treated rats. In rats fed with both
dietary corn and beef oil, iNOS, expression and 8-OHdG positive cell in colon mucosa were
increased. Conclusion In the AOM-induced rat colon cancer model, Long term feeding of
dietary corn oil and beef oil increased cell proliferation via Wnt signaling pathway in the
colon mucosa, leading to promotion of colon cancer in the AOM treated rats. Furthermore,
increase of DNA damage due to oxidative stress and iNOS, COX-2 expression in the rat
colon mucosa were participate in the effect of colon carcinogenesis among different dietary
fatty acid composition.
T1638
Focal Adhesion Kinase (FAK) and C-SRC Protect Mammalian Cells from
Hyperosmotic Stress-Stimulated Apoptosis: Evidence That FAK Signaling Lies
Upstream of the Actin Cytoskeleton in IEC-18 Intestinal Epithelial Cells
Responses to This Apoptotic Stimulus
J. Adrian Lunn, Enrique Rozengurt
Background and significance: High salt diet has long been touted as a risk factor for gastric
cancer. Basic mechanisms underlying this phenomenon are lacking. Hyperosmotic stress(HS)
induces acute activation of MAP kinase signaling pathways, concomitant cell shrinkage and
F-actin rearrangement. Most studies show resultant apoptosis in response to chronic HS
exposure. Studies on anti-apoptotic responses of cells to HS are lacking. FAK is a cytoplasmic
tyrosine kinase critical to cell translocation as it regulates focal adhesion turnover. FAK also
promotes tumor invasion, and protects epithelial cells from anoikis. As such, FAK is poised
to play a central role in preventing HS-induced apoptosis. GPCR, RTK and integrin activation
of FAK, all suggest that F-actin re-organization is a central requirement. In epithelial cells
from rat intestinal IEC-18, human colorectal Caco2 and gastric NCI-N87 cancers, we exam-
ined specific FAK tyrosine residues phosphorylated in response to HS, and we tested the
hypothesis that F-actin organization is necessary for this FAK activation. Methods and Results:
Confluent, serum starved IEC-18/Caco2/NCI-N87 cells were exposed to media +/- 0.45M
sorbitol for various times. Western blots using phospho-specific (anti-FAKpTyr-397, pTyr-
576, pTyr-861, and anti-total FAK antibodies, of PAGE-resolved cell lysates were performed.
Basal levels of FAK pTyr-397 varied in the various cell lines, while levels of FAKpTyr-861
and FAKpTyr-576 were universally low. However, 15 min exposure to 0.45M sorbitol
stimulated increases in FAKpTyr-576, and dramatic increases in FAKpTyr-861 in all cell
lines. Using two distinct specific Src-family kinase inhibitors we demonstrated that HS-
stimulated increases in FAK pTyr-861 are Src-family-dependent. Pretreatment of confluent
IEC-18 cells with either 2μM cytochalasin D, or 3μM latrunculin A, significantly decreased
the high basal FAK pTyr-397 levels, but neither method of F-actin disruption inhibited HS-
induced FAKpTyr-397, 576, or 861 stimulation. Conclusions: Results presented here are
significant as they imply that FAK may be an important upstream regulator (rather than
downstream effector) of F-actin reorganization in response to hyperosmotic stress; and that
this FAK mediated reorganization of F-actin is critical to cell survival and anti-apoptosis
signaling in response to that stress. We propose that FAK phosphorylation on tyrosine 861
by Src, and subsequent reorganization of F-actin, initiate an important anti-apoptotic signaling
pathway. This FAK/c-Src anti-apoptotic signaling pathway may explain the tumor promoting
properties of high salt diet on gastric cancer.
T1639
Early Apoptosis and Cell Death By ATX-S10na(II)-Mediated Photodynamic
Therapy Are BAX- and P53-Dependent in Human Colon Cancer Cells
Makoto Mitsunaga, Akihito Tsubota, Kohichi Nariai, Makoto Sumi, Tetsuya Yoshikawa,
Akira Torii, Hisao Tajiri, Kiyotaka Fujise
Background & Aim: Photodynamic therapy (PDT) is a clinical approach that utilizes photo-
sensitizers for cancer therapy, including esophagus, stomach and colon. Various studies
showed that PDT kills tumor cells via apoptosis and/or necrosis in vivo and in vitro, that is
induced by various mechanisms, such as intracellular generation of reactive oxygen species.
Although the role of Bax and p53 in PDT has been investigated, it remains controversial.
So we aimed to determine whether or not Bax and p53 protein functions contribute to
photosensitivity of human colon cancer cells in PDT using a novel lysosomal photosensitizer
ATX-S10Na(II). Methods: Using the mismatch repair-deficient HCT116 human colorectal
cancer cell lines and Bax null or p53 null isogenic derivatives, we investigated contribution
of Bax and p53 to the cytotoxic and apoptotic effects of ATX-S10Na(II)-PDT. Photosensitivity
of these cells to ATX-S10Na(II)-PDT, irradiated with a diode laser using a wavelength of
670 nm, was determined by MTT assays, cell cycle analysis, annexin V apoptosis assays,
caspase activity assays and western blotting. Results: The extent of phototoxicity was intensity
of laser irradiation- and concentration of ATX-S10Na(II)-dependent manner. Occurrence of
cell death was significantly Bax- and p53-dependent in MTT assays. In Bax null and p53
null cells, induction of apoptosis was significantly inhibited as compared to wild-type
HCT116 cells in the sub-G1 population in cell cycle analysis or flow cytometry with annexin
V. While activation of caspases 2, 3 and 9 were significantly Bax- and p53-dependent,
caspase 8 was activated little. A level of cytochrome c release from mitochondria was reduced
but not absent in Bax null cells. Meanwhile, downregulation (photodamage) of anti-apoptotic
proteins Bcl-2 and Bcl-xl were Bax- and p53-independent. Conclusion: Induction of early
apoptosis and cell death by ATX-S10Na(II)-PDT are Bax- and p53-dependent in human
colon cancer cells. The intrinsic mitochondrial pathway of apoptosis through a p53-Bax
network in addition to photodamage of Bcl-2 and Bcl-xl play a central role in the early
apoptotic process by ATX-S10Na(II)-PDT.
T1640
Silencing of the Regenerating IV (Reg IV) Gene By Sirna Inhibits the Growth
and Proliferation of Human Colon Adenocarcinomas
Qizhi Luo, Kumar S. Bishnupuri, Courtney Houchen, Shrikant Anant, Brian K.
Dieckgraefe
The human Reg gene family encodes four small-secreted proteins expressed throughout the
gastrointestinal (GI) mucosa. Individual Reg genes have characteristic regional expression
profiles in the columnar epithelium of the GI mucosa. Ectopic or increased expression of
Reg proteins has been considered as a potential marker of colorectal mucosa at risk for
neoplasia. Reg IV is the dominant member of the Reg multigene family expressed in the
distal GI tract including cecal and colonic mucosa. Reg IV expression is significantly up-
regulated in malignancies of the GI tract including colon carcinoma, indicating its possible
role in the growth and development of human colon adenocarcinomas. The present study
tests the hypothesis that silencing of Reg IV by using siRNA in colon adenocarcinoma cells
may inhibit growth, proliferation and increase sensitivity to radiation-induced cell death. A
panel of 21-nucleotide siRNAs were designed to target Reg IV gene expression. The effects
were tested in HCT116 human colon adenocarcinoma cells. Reg IV protein levels were
assessed by western blot analysis. Several siRNA constructs were identified that led to
significant reductions in RegIV protein expression. Based on western blot analysis, the
addition of Reg IV-siRNAs (100nM) to the HCT 116 cells led to a ~65% reduction in Reg
IV protein expression 48 hours after transfection. Furthermore, transfection of cells with
Reg IV-siRNAs (50nM) led to a time dependent inhibition in cell proliferation when compared
to cells transfected with negative control-siRNA (Percentage reduction in cell number: 24hr
~8%, 48hr ~30%, 72hr ~46% and 96hr ~47%). Increasing concentrations of siRNA led to
increased inhibition of cell proliferation (100nM; 96hr ~ 64%). Next we determined the
effect of siRNA on radiation-induced cell death. Gamma-irradiation treatment demonstrated
a dose-dependent reduction in fractional cell survival. Furthermore, Reg IV-siRNA transfected
HCT 116 cells demonstrated a significantly greater reduction in cell survival. Conclusion:
Reduction in Reg IV protein expression by Reg IV-siRNA inhibits the growth and cell
proliferation of human colon adenocarcinomas and increases the effectiveness of cell killing
following radiation. Inhibition of endogenous Reg IV expression may be a new therapeutic
strategy for human colon adenocarcinomas.
T1641
Constitutive Activation of MEK1 Signaling Suppresses Chemotherapeutic
Agents Induced Apoptotic Cell Death in Rat Intestinal Epithelial Cells Via
COX-2 Activation
Youhei Horikawa, Michiro Otaka, Koga Komatsu, Sumio Watanabe
[BACKGROUND] We previously reported that the constitutive activation of MEK1 (CAMEK)
signaling results in transformation of rat intestinal epithelial cells (RIE and IEC-6). These
results may suggest that MEK-ERK signaling plays an important role in the development
and maintenance of intestinal cancers. Resistance to the chemotherapeutic agents is one of
the distinct features in cancer cells. Several reports have provided the evidence that MEK
inhibitors sensitize cancer cells to some chemotherapeutic agents. However, the exact role
and mechanism of MEK-ERK signaling in chemo-resistance has not been addressed. We
focus current study to evaluate the role of activated MEK-ERK signaling in the sensitivity
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to chemotherapeutic agents using CAMEK transfected rat intestinal epithelial cells.
[METHODS] To address the role of MEK-ERK signaling in chemo-sensitivity in intestinal
epithelial cells, two kinds of CAMEK permanently expressing rat IEC-6 cells(CAMEK1,
CAMEK2) were used in this the study. Cell viability was determined by WST assay following
treatment of various concentrations of chemotherapeutic agents (CDDP, 5-FU, VP-16, CPT-
11). Drug sensitivity was evaluated by calculation of inhibitory concentration of 50% (IC50).
To investigate the mechanisms of chemo-resistance in CAMEK cells, apoptosis induced by
CPT11 were analyzed by DAPI staining, DNA fragmentation and Western blot analysis of
the Bcl-2 homolog family. Also we examined the regulation of COX-2 protein expression
in CAMEK cells by Western blot analysis, and the effect of COX-2 selective inhibitor (NS398)
combination with CPT-11 in CAMEK cell viability by WST assay. [RESULTS]CAMEK cells
showed increased IC50 compared to each empty vector transfected cells. Apoptotic cells and
DNA fragmentation was remarkably suppressed in CAMEK cells. Expression of antiapoptotic
protein Bcl-2, Bcl-xL and Mcl-1 were increased in CAMEK cells. In contrast, expression of
proapoptotic protein Bak was increased in empty vector transfected cells. And expression
of COX-2 protein was markedly increased in CAMEK cells. CPT-11 combination with NS398
resulted in a significant dose dependent reduction in cell viability compared with either
drug-treated alone in CAMEK cells. [CONCLUSIONS]MEK activation led intestinal epithelial
cells to chemo-resistant variant. Therefore, the MEK-ERK signaling could be contributed to
chemo-resistance in transformed cells by anti-apoptotic effect via COX-2 activation. These
results also indicate that the MEK-ERK signaling pathway and inhibition of COX-2 may
provide an important target for developing new cancer drugs.
T1643
LPA Protection of CACO-2 Cells from Etoposide-Induced Apoptosis Is Erk1/2
MAP Kinase Dependent
Raluca Rusovici, Chris Yun
Lysophosphatidic acid (LPA) is an important regulator of cell proliferation, differentiation
and survival. The aim of this study was to decipher the signaling pathway involved in the
anti-apoptotic effect of LPA in Caco-2 cells. Apoptosis was induced by treating cells with
the chemotherapeutic drug etoposide. Apoptosis was determined by flow cytometry of cells
stained with annexin V-fluorescein isothiocyanate antibody. Treatment with 175μM etoposide
for 24 h resulted in a doubling of annexin V-positive cells compared to control. A significant
decrease in an annexin V-positive cell population was observed in the presence of etoposide
and 20μM LPA, suggesting that LPA has an anti-apoptotic effect in Caco-2 cells. Consistently,
etoposide doubled caspase-3/7 activity in Caco-2 cells compared with untreated control,
which was completely blocked by preincubation for 20 min with the general caspase inhibitor
zVAD-fmk. Co-incubation with LPA significantly blocked the increase in caspase activity
induced by etoposide. This was confirmed by an increase in the level of inactive procaspase
3 in cells treated with etoposide +LPA compared to etoposide alone. We have previously
shown that LPA activates Erk1/2 MAP kinase and Akt in Caco-2 cells. To determine a
potential contribution by Erk, cells were preincubated with the MAPK inhibitor U0126
(25μM) or the PLCβ blocker U73122 (5μM). In the presence of U0126 or U73122, LPA
did not protect the cells from etoposide-induced apoptosis indicating that the anti-apoptotic
effect of LPA is dependent on Erk1/2. In contrast, pretreatment of Caco-2 cells with the
PI3K inhibitor LY294002 (50μM) had a relatively smaller effect and LPA was able to protect
cells from apoptosis even in the presence of LY294002. To confirm involvement of MAP
kinase, phosphorylation of proapoptotic Bad was determined. Phosphorylation of Bad (p-
Bad) at Ser112 and Ser136 is an ERK- and Akt-dependent process, respectively. We deter-
mined levels of p-Bad after 13 h of treatment by western blot with antibodies against p-
Ser112 or p-Ser136 of Bad. The level of p-Ser112 was increased in LPA + etoposide treated
cells compared to etoposide alone, whereas the level of p-Ser136 was not changed. The
total amount of Bad remained constant. In summary, the anti-apoptotic effect of LPA in
Caco-2 cells is mediated by an inhibition of caspase activity and this protection involves
Erk1/2 MAP kinases.
T1644
Apoptosis and Cell Cycle Regulating Proteins in Gastroenteropancreatic
Neuroendocrine Tumors: Role of P27
Patricia Grabowski, Joerg Schrader, Dieter Hoersch, Rudolf Arnold, Christian N. Arnold,
Harald Stein, Martin Zeitz, Peter T. Daniel, Isrid Sturm
Background - Gastroenteropancreatic neuroendocrine tumors represent a heterogeneous
tumor entity. The growth pattern ranges from very slowly to fast growing, aggressive types
of tumors. In previous analysis, we established the prognostic relevance of alterations in
apoptosis- and cell cycle regulation in various malignancies. Little is known about the role
of apoptosis- and cell cycle regulating proteins in this tumor entity. Aim - Regulators of
apoptosis (p53/Bax) and the G1-restriction point (p16, p21, Cyclin E, p27) were evaluated.
Patients and Methods - Tumor specimens from 89 patients with a complete 5-year follow-
up were studied immunohistochemically for BAX, p16, p21, p27 and cyclin E expression
and for p53 mutations by SSCP-PCR. 29 patients with localized, well-differentiated gastroen-
teropancreatic neuroendocrine tumors (WDET, WHO class 1) had been curatively treated
by surgical or endoscopic tumor resection. 50 patients had well-differentiated endocrine
carcinomas (WDEC, WHO class 2), 10 patients were diagnosed with poorly differentiated
neuroendocrine carcinomas (PDEC, WHO class 3). The functional relevance of p27 was
evaluated in the human neuroendocrine cell line BON by the use of siRNA. Results - 26/
29 WDETs showed a high expression of p27, whereas all 10 PDECs displayed a low
expression of p27. In the 50 patients with metastatic WDECs, 20/50 (40%) tumors had a
low p27 expression. Those 20 patients had a statistically significant worse prognosis (median
survival of 68 versus 113 months, p=0.037). All other investigated proteins were not of
prognostic significance in this subgroup of patients. Downregulation of the p27 protein in
the human neuroendocrine cell line BON resulted in an increased phosphorylation of the
RB protein as well as an increase of cells in the S-Phase and G2/M Phase of the cell
cycle. Discussion - The loss of p27 seems to play a critical role in the progression of
gastroenteropancreatic neuroendocrine tumors. The analysis of p27 expression identifies

















underlying mechanism may be due to increased cell cycle progression in those tumors. We
propose that the determination of p27 expression could be used to individualize therapeutic
strategies in this tumor entity in the future.
T1645
FOXM1 Transcription Factor Is Essential for Proliferation and Growth of
Mouse Colorectal Cancer Induced by AOM/DSS Protocol
Yuichi Yoshida, Robert H. Costa
Colorectal cancer is one of the most common fatal malignancies in the world, with an
incidence second only to lung cancer. The Forkhead Box M1 (FoxM1) transcription factor
belongs to the Fox family proteins that share homology in the winged helix DNA binding
domain. FoxM1 is ubiquitously expressed in all proliferating mammalian cells and tumor
derived cell lines where it regulates expression of cell cycle genes critical for DNA replication
and mitosis. We previously showed that FoxM1 deficient (-/-) mouse hepatocytes are resistant
to developing carcinogen induced mouse hepatocelluar carcinoma. In this study, we demon-
strated that human and mouse colon cancer cell lines and human colon cancer specimens
express high levels of the FoxM1 transcription factor. To investigate the role of FoxM1 in
colorectal cancer, we induced colorectal cancer in Rosa26-FoxM1 transgenic (TG) mice that
ubiquitously expressed FoxM1 and mice conditionally deleted in the FoxM1 gene with the
Mx-Cre recombinase transgene using the carcinogen Azoxymethane (AOM) followed by
tumor promotion with Dextran Sodium Sulfate (DSS) administration. Rosa26-FoxM1 mice,
Mx-Cre FoxM1 -/- mice and wild type mice were subjected to a single IP injection of AOM
(10mg/kg body weight) followed by three cycles of one week of administrating 2.5% DSS
in the drinking water, each cycle separated by a two week period. We also examined
proliferation and transformation of human DLD1 and mouse CT26 colon cancer cell lines
depleted in FoxM1 levels by siRNA transfection. After 12 weeks of AOM/DSS exposure,
Rosa26-FoxM1 transgenic mice displayed an increase in the number and size of colorectal
tumors, suggesting that increased expression of FoxM1 promoted colon cancer growth.
Likewise, Mx-Cre FoxM1 -/- mice exhibited a significant reduction in the number and size
of colorectal tumors following AOM/DSS treatment, suggesting that FoxM1 is essential for
colon cancer progression. Moreover, transfection of siRNA against FoxM1 into these cell
lines caused a marked reduction of DNA replication and a significant inhibition of colony
formation on soft agar. In conclusion, these results suggest that suppression of FoxM1
function is a novel therapy to prevent proliferation and growth of colorectal cancer.
T1646
Histone Acetyltransferase P300 Regulates KLF4-Mediated Transactivation
Paul M. Evans, Chunming Liu
BACKGROUND/AIMS: Krüppel-like factor 4 (KLF4) is a transcription factor that controls
the expression of several genes that are known markers of the terminal differentiation of
colonic stem cells, such as intestinal alkaline phosphatase and mucin. Furthermore, KLF4
is a tumor suppressor in the gut, inhibiting the expression of genes controlling the cell
cycle, such as Cyclin E and Cyclin D1, and simultaneously induces expression of the cell
cycle inhibitor p21Cip1/WAF1. Since KLF4 interacts with p300 and recruitment of co-
activators to the transcriptional apparatus is a common method transcription factors use to
activate gene expression, we decided to study what effect KLF4/p300 interaction would
have upon expression of known KLF4 target genes. RESULTS: Via GST-labeled pull-down
assays, we confirmed that KLF4 and p300 do indeed interact. We then made several luciferase
reporter constructs containing the full-length reporter sequence of various KLF4 target genes
and tested the ability of p300 to synergize with KLF4 in transactivating these reporters. With
some of these reporter constructs, p300 further increased KLF4-mediated transactivation,
suggesting a synergistic interaction. To identify the KLF4 binding site, we made a panel of
deletion mutants for each promoter. These binding sites were then confirmed using chromatin
immunoprecipitation using a novel KLF4 antibody developed in our laboratory. Since KLF4
appears to recruit p300, a histone acetyltransferase, we decided to investigate the effect of
KLF4 binding to its binding element on chromatin remodeling. We tested this using chro-
matin immunoprecipitation against acetylated histones. CONCLUSIONS: We confirmed that
KLF4 and p300 interact and found that this interaction results in a synergistic activation of
several known KLF4 target genes. Furthermore, we were able to identify the binding element
for KLF4 on these target genes. Finally, we found that KLF4 plays a role in chromatin
remodeling via recruiting p300 to the promoter, suggesting that acetylation is important for
KLF4-mediated transactivation.
T1647
Characterization of a Human Neoplastic Enterochromaffin (EC) Cell Line,
KRJ-1 and the Anti-Proliferative Effects of Lanreotide and Rapamycin
Geeta N. Eick, Roswitha Pfragner, Mark Kidd, Manish C. Champaneria, John R. Murren,
Irvin M. Modlin
Small intestinal carcinoid (SIC) is the most prevalent GI carcinoid and has increased in
incidence by 740% over the last 3 decades (NCI SEER database, 2004). The proliferative
and secretory regulation of its cell of origin - the enterochromaffin (EC) cell - is unknown
and has hindered the development of rational therapeutic agents. The limited mechanistic
and biological knowledge of SIC reflects the absence of a human EC carcinoid cell line.
Other cell lines (BON, COLO320DM) are mixed cell (acinar-carcinoid/adenocarcinoid) and
not of EC cell origin, and cannot be used to assess SIC pathobiology. We have characterized a
neoplastic SIC cell line, KRJ-1, and evaluated its response to antisecretory and antiproliferative
agents using serotonin (5-HT) EIA for secretion and MTT for proliferation. The KRJ-1 cell
line was established from a malignant metastatic human SIC. Its doubling time is 1.8 days.
EM demonstrated oval or irregular lobulated nuclei and irregular pleomorphic secretory
granules that are Subst P and 5-HT-positive (immunohistochemistry (IHC)). Real time RT-
PCR detected transcripts for chromogranin A (CgA), VMAT1, tryptophan hydroxylase (TPH),
Subst P, guanylin and SERT (SLC6A4). All KRJ-1 cells were positive (using IHC) for CgA,
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SERT, VMAT1 and TPH, confirming a neuroendocrine, EC cell origin. Candidate secretory
and proliferative receptors identified by transcriptome analysis (Affymetrix U133 Plus chip)
included the somatostatin SSTR2/3, adrenergic α1C & β1, dopamine D2, nicotinic-type
cholinergic A5, A6, B1, muscarinic acetylcholine M4 and serotonin 2A receptors. Incubation
of KRJ-1 cells (45 min) with isoproterenol (a selective β-adrenergic receptor agonist) resulted
in a dose-dependent increase in intracellular cAMP (EC50=3.4x10-7M), paralleled by a
concentration-dependent increase in 5-HT (EC50=81nM) that was inhibited by the cAMP
antagonist 2’,5’-dideoxyadenosine (1mM) demonstrating that serotonin secretion in KRJ-1
cells is in part a cAMP-mediated event. Preincubation (10min) with the SST receptor agonist,
Lanreotide, inhibited isoproterenol-stimulated 5-HT secretion (IC50=4.3x10-7M). Secretory
granules (by EM) increased in cells preincubated with Lanreotide (100nM). Lanreotide
(10nM) and rapamycin (mTOR signaling, 50nM) maximally inhibited KRJ-1 proliferation
(20±12% and 35±5%), whereas Gefitinib (tyrosine kinase inhibitor, 1nM-10µM) had no
effect. These data confirm the KJR-1 cell line as a novel, neoplastic EC cell line and demon-
strate its utility as an in vitro model of SIC to study tumor secretion and proliferation.
Further transcriptome analysis will allow identification of novel therapeutic targets.
T1648
Regulation of Epithelial to Mesenchymal Transition By the Actin-Binding
Protein Villin
Leon Chatman, Alok Tomar, Sudeep George, Narendra Kumar, Seema Khurana
Epithelial-mesenchymal transition (EMT) is an important process during development by
which epithelial cells acquire mesenchymal properties and show reduced intercellular adhe-
sion and increased motility. The mechanisms that govern EMT are only now being unraveled
and many parallels have been found between these processes during embryonic development
and in adult tissue maintenance such as wound-healing, organ remodeling during fibrogenesis
as well as between mechanisms that propel invasive growth and metastases. Most recent
studies point to a critical role of EMT during tumor progression and malignant transformation,
bestowing the developing cancer cell with invasive and metastatic properties. EMT is always
associated with cell scattering, defined by the loss of intercellular junctions, massive actin
reorganization and acquisition of cell motility. In this study, we demonstrate the regulation of
EMT by villin. Villin is a tissue specific actin-binding protein that is expressed in differentiated
epithelial cells of the gastrointestinal tract and renal tubules including the absorptive cells
of the small and large intestines and in the pancreatic and biliary duct cells. In addition,
villin expression is maintained in tumor cells of intestinal origin. Previous studies from our
laboratory have demonstrated that villin regulates actin reorganization, cell morphology and
cell migration and that these functions of villin are regulated by tyrosine phosphorylation
of villin and the ligand-binding properties of phospho-villin (F-actin, PIP2, PLC-γ1). Using
Madin-Darby canine kidney (MDCK) Tet-Off cells expressing wild-type villin or various
phosphorylation site mutants of villin, we examined the role of villin in EMT during
hepatocyte growth factor (HGF)-induced tubulogenesis. In a three-dimensional culture, the
full-length villin, which was localized to the apical surface of MDCK cysts, enhanced HGF-
induced tubulogenesis. In contrast, ectopic expression of the phosphorylation site mutant
of villin, known to down-regulate PLC-γ1 signaling, actin reorganization, cell morphology
and cell migration, abolished the stimulatory effect on tubulogenesis. These findings, taken
together, suggest that villin plays a role in enhancing induction of EMT and that this function
of villin is regulated by its tyrosine phosphorylation and its ligand-binding properties.
T1649
AMP-Activated Protein Kinase Is a Positive Regulator of Poly(ADP-ribose)
Polymerase-1
John Walker, Humberto Jijon, Karen Madsen
Peutz-Jeghers syndrome (PJS) is a dominantly conferred genetic disorder typified by multiple
polyps in the intestine and the development of malignant intestinal tumours. Mutations of
the LKB1 gene on chromosome 19p13.3 have been identified in the majority of PJS patients.
The gene product (LKB1) has been identified as a serine-threonine kinase which functions
as an upstream regulator of AMPK. AMPK acts as a cellular fuel gauge, and responds to
decreased cellular energy status by inhibiting ATP-consuming pathways and increasing ATP-
synthesis. We have previously shown a functional relationship between AMPK and poly(ADP
ribose) polymerase (PARP), a nuclear enzyme involved in maintaining chromatin structure
and DNA repair. It can be hypothesized that a mutation involving AMPK may affect PARP
activity and contribute to tumorgenesis in PJS patients. Objective: The aim of this study
was to examine the role of AMPK in modulating PARP activity. Methods: Constitutively
active AMPK (Ad.CA-AMPK) was overexpressed in HT-29 epithelial cells and PARP activity
assessed using biotinylated NAD as substrate for ADP-ribosylation. To evaluate whether the
relationship between AMPK and PARP was mediated through direct interaction, HT-29 cells
were treated with H202 (5 mM) for 0-60 min. PARP was immunoprecipitated and samples
analyzed by Western Blot. Purified AMPK (0-10 mU/ml) was incubated with SAMS (synthetic
AMPK substrate) or purified PARP ± AMP (300 μM) and phosphorylation assessed. To
evalute the functional consequences of AMPK regulation, PARP was immobilized and the
incorporation of bioNAD measured ± AMPK and ATP (125 μM). Results: Cells infected
with Ad.CA-AMPK demonstrated a MOI-dependent increased PARP automodification and
a significant (≈ 2.8 fold) increase in bioNAD incorporation as compared with controls.
AMPK and PARP co-immunoprecipitated under basal conditions and in response to H202,
suggesting a physical interaction under both resting and stress-induced conditions. Incuba-
tion of PARP with purified AMPK resulted in the phosphorylation of PARP; further, the
inclusion of AMP as an AMPK activator potentiated PARP phosphorylation. Finally, using
immobilized PARP, the incorporation of bioNAD by PARP was dramatically increased follow-
ing the addition of AMPK. Conclusion: These data suggest a novel role for AMPK in
regulating PARP activity through a direct interaction involving phosphorylation. In the
physiological setting of the intestine where genotoxic stressors are abundant, a dysregulation
in LKB1 as seen in Peutz-Jeghers syndrome could be translated into a deficiency in DNA
repair through an inhibited AMPK signal to PARP.
T1650
Constitutive Matrix Metalloproteinase-Mediated Release of An Epidermal
Growth Factor (EGF) Receptor Ligand, HB-EGF, Regulates Basal Human Colon
Cancer Cell Proliferation
Kunrong Cheng, Jean-Pierre Raufman
Previously, we showed that muscarinic ligands and conjugated secondary bile acids stimulate
colon cancer cell proliferation by M3 muscarinic receptor-mediated transactivation of EGF
receptors (EGFR) (Cancer Res. 2003;63:6744 and Biochem. Pharmacol. 2005;70:1035). In
these studies, preliminary experiments with inhibitors of EGFR activation or EGFR-ligand
release indicated that the rate of basal cell proliferation was reduced. The aim of the present
study was to define the mechanism of basal EGFR-mediated cell proliferation in a well-
characterized human cecal adenocarcinoma cell line (H508) that abundantly expresses musca-
rinic M3 and EGF receptors. We measured cell proliferation with the validated sulforhodamine
B colorimetric assay and used several approaches to inactivate EGFR and block EGFR-ligand
release. Increasing concentrations of PD168393 (0.1 nM - 1 μM), an inhibitor of EGFR
activation, and LA1 (0.0001 - 5 μg/ml), an antibody to the ligand-binding domain of EGFR,
caused progressive reduction of H508 colon cancer cell proliferation. Maximal concentrations
of the agents reduced basal cell proliferation by 70% (p<0.005). Incubation with GM6001
(0.01 - 10 μM), a broad-spectrum matrix metalloproteinase (MMP) inhibitor, reduced basal
cell proliferation by 59% (p<0.005). Reduction of basal H508 cell proliferation was not
observed when the cells were incubated with NC-GM6001, an inactive control analogue of
GM6001. These results suggested that MMP-mediated release of an EGFR ligand is necessary
to maintain basal cell proliferation. To identify the responsible EGFR ligand, we examined
the effects of CRM197, a diphtheria toxin analogue that specifically blocks release of the
EGFR ligand, HB-EGF. By a magnitude similar to that observed with maximal concentrations
of PD168393, LA1 and GM6001, CRM197 (10-4 to 5x103 ng/ml) caused progressive reduc-
tion of basal H508 cell proliferation (p<0.005). Likewise, neutralizing antibody to HB-EGF
(0.1 to 20 μg/ml) reduced basal cell proliferation (p<0.05). To confirm that MMP-7-mediated
release of HB-EGF can stimulate H508 colon cancer cell proliferation, we examined the
actions of exogenous recombinant MMP-7 and HB-EGF. Increasing concentrations of both
MMP-7 (1-100 ng/ml) and HB-EGF (0.02 - 200 μg/ml) stimulated a progressive increase
in H508 cell proliferation (p<0.005). Collectively, these findings provide evidence that in
the human H508 colon cancer cell line, basal cell proliferation is dependent on MMP-
mediated release of an EGFR ligand, HB-EGF, and autocrine activation of EGFR. MMP-
mediated release of HB-EGF may provide a therapeutic target for reducing both basal and
stimulated colon cancer cell proliferation.
T1651
AKT-Dependent Mechanical Signaling Displays Isoform Specificity in Effector
Outcome
David H. Craig, Vijayalakshmi Thamilselvan, Hiroe Shiratsuchi, Marc D. Basson
Akt is a serine-threonine protein kinase implicated in a diverse range of cell functions
including cell migration, metabolism, growth and survival. Akt has three isoforms; Akt1
and Akt2 are ubiquitously expressed, whereas Akt3 is predominately restricted to the heart,
kidney, brain, lung, testes and skeletal muscle. Functional differences between Akt isoforms
in mechanical signaling have not been described. Increased extracellular pressure activates
colon cancer cell adhesion to matrix proteins, as well as stimulates phagocytosis by human
monocytes and macrophage-like THP-1 cells. These effects are regulated by Akt-dependent
signaling pathways and may both be prevented by global Akt inhibition. We hypothesized
that these distinct effects of pressure might be mediated by different Akt isoforms. To study
pressure-induced adhesion, human SW620 colon cancer cells were transfected with Akt1-
or Akt2-specific siRNA, subjected to 15 mmHg increased pressure and allowed to adhere
to collagen for 30 min. Non-adherent cells were washed away and adherent cells counted.
Akt1 and Akt2 expression were reduced by 50% and 60%, respectively. Silencing Akt1, but
not Akt2, completely prevented pressure-activated SW620 adhesion (P<0.001). Analysis of
isoform-specific gene silencing effects on total Akt protein showed that SW620 cells express
substantially more Akt1 than Akt2 (approximately 9:1). We performed parallel studies
in Caco-2 cells, which express more Akt2 (Akt1/Akt2 ratio approximately 3:7, similarly
determined). As in SW620 cells, reducing Akt1 by 80% blocked pressure-stimulated Caco-
2 adhesion. An 80% Akt2 reduction did not alter the pressure effect (P<0.001). Thus, the
isoform specificity of the pressure effect on adhesion is independent of the ratio of isoform
expression. The same siRNAs were transfected into human PMA-differentiated (macrophage-
like) THP-1 cells. Transfectants were incubated at 37°C with serum-opsonized fluorescence-
labeled latex beads under ambient or 20 mmHg increased pressure for 2 hrs, washed
and fixed. Phagocytosed beads were counted under a fluorescence microscope. Pressure-
stimulated phagocytosis exhibited opposite isoform specificity to pressure-stimulated adhe-
sion. Silencing of Akt1 by 40% significantly reduced basal phagocytosis (P=0.03) without
altering the pressure effect, but a 50% reduction of Akt2 inhibited pressure-stimulation of
phagocytosis (P<0.05) without significantly affecting basal phagocytosis. Thus, despite an
81% sequence homology, individual Akt isoforms, Akt1 and Akt2, perform distinct roles
in pressure-stimulated mechanotransduction with alternate effector outcomes.
T1652
FOXP3 Regulatory T Cells Regulate Cytolytic T Cell Function in Colorectal
Cancer Via the T-Box Transcription Factor Eomesodermin
Imke Atreya, Christoph Becker, Massimo Fantini, Christoph C. Schimanski, Martin R.
Berger, Heike Dornhoff, Maximilian Waldner, Dennis Strand, Peter R. Galle, Markus F.
Neurath
Introduction: An efficient cytolytic T cell function is essential for immune system mediated
cancer rejection, whereas regulatory T cells are supposed to suppress the activity of such
effector T cells. It has been shown, that the T-box transcription factor Eomesodermin is
critically involved in the regulation of CTL differentiation. Methods: Expression of Eomesod-
ermin and FoxP3 was analysed by RT-PCR and by Realtime PCR in colorectal tumors.
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Results were compared with clinical data. Regulatory T cells were co-incubated with CD8+
T cells and Eomesodermin expression was analysed in these cells. Results: The importance
of Eomesodermin in the differentiation of cytolytic T cells was emphasized by showing that
silencing of Eomesodermin in human CD8+ T cells by siRNA resulted in decreased perforin
and IFNγ levels, whereas Eomesodermin overexpressing cells showed increased expression
of cytolytic genes. By analysing the expression of Eomesodermin in 88 colorectal tumors,
we found a significant negative correlation between the expression of Eomesodermin in
these tumors and the infiltration of tumor cells into lymph nodes (p<0,02). This inverse
correlation was not dependent on varying numbers of tumor infiltrating CTLs. Furthermore
Eomesodermin expression in tumors correlated with improved prognosis based on the
UICC-classification (p<0,02). No significant correlation was found between Eomesodermin
expression and tumor grading, venous or lymph vessel invasion. Obviously, activation of
tumor infiltrating T cells was able to prevent infiltration of tumor cells into lymph nodes.
Looking for factors, responsible for the regulation of Eomesodermin in tumors, we assumed
that regulatory T cells might be critically involved. This hypothesis was underlined by a
reduced number of colorectal tumors in APCmin mice, depleteted for regulatory T cells.
Furthermore, regulatory T cells prevented Eomesodermin expression in co-cultured CD8+
T cells. To investigate the prognostic value of FoxP3 in colorectal cancer, the expression of
FoxP3 in human tumors was analysed. In line with our model, high FoxP3 levels in tumors
were associated with increased appearance of lymph node metastasis, implicating that high
numbers of Eomesodermin expressing effector T cells and low numbers of regulatory T cells
in tumors are beneficial for tumor patients. Conclusion: Based on our results, anti-tumor
immunity is negatively regulated by tumor infiltrating FoxP3 regulatory T cells, which are
able to suppress Eomesodermin induced activation of CTL mediated tumor defense.
T1653
Proteasome Inhibition and 5-FU Sensitises Hepatocellular and Colon
Carcinoma Cells But Not Primary Human Hepatocytes for Trail-Induced
Apoptosis By CFLIP Dependent and Independent Mechanisms At the Disc
Tom Ganten, Ronald Koschny, Tobias L. Haas, Jaromir Sykora, Min Li-Weber, Kerstin
Herzer, Wolfgang Stremmel, Henning Walczak
TNF-related apoptosis-inducing ligand (TRAIL) exhibits potent anti-tumor activity upon
systemic administration in mice. Due to its apparent non-toxicity and proven in vivo efficacy
TRAIL may serve as a novel antineoplastic drug for the treatment of human cancer. Pre-
treatment with the proteasome inhibitor MG132 or 5-FU rendered TRAIL-resistant hepatocel-
lular and colon carcinoma cells but not primary human hepatocytes sensitive for TRAIL-
induced apoptosis. To elucidate the different mechanisms of sensitisation of proteasome
inhibitiors and 5-FU for TRAIL-induced apoptosis, we investigated different levels of apop-
totic signal transduction. Both chemotherapeutics revealed an up-regulation of TRAIL-R1
and -R2, and substantially increased caspase-8 activation after sensitization. The increased
activation of caspase-8 could be explained by up-regulation of the death-inducing TRAIL
receptors and an increase of the ratio of caspase-8 to cFLIP within the DISC (Death inducing
signalling complex). Although hepatoma cells pretreated with the proteasome inhibitor up-
regulated TRAIL-R1 and -R2 less efficiently than 5-FU pretreated cells, they where signific-
antly more sensitive to TRAIL-induced apoptosis. Interestingly, at the same time cFLIPS was
markedly up-regulated in the TRAIL-DISC by proteasome inhibitor pretreatment and down-
regulated when pretreated with 5-FU. To test a recent hypothesis that cFLIP under certain
circumstance can reveal indeed a pro-apoptotic function we applied cFLIP siRNA in the
presence of 5-FU and the proteasome inhibitior. The results suggest that TRAIL-mediated
apoptosis in hepatocellular and colon carcinomas is controlled at the DISC level by a yet
unidentified factor and cFLIP.
T1654
Overexpression of Wild-Type PKD2 Leads to Increased Proliferation and
Invasion of BON Endocrine Cells
Lindsey N. Jackson, J.N. Li, L. Andy Chen, Courtney M. Townsend, B. Mark Evers
The BON endocrine cell line, established from a human pancreatic carcinoid tumor and
characterized in our laboratory, represents a unique in vitro and in vivo carcinoid tumor
model with production and secretion of serotonin, chromogranin A, and other peptides.
Protein kinase D (PKD), a novel serine/threonine protein kinase, has been implicated in the
regulation of transport processes in certain cell types. Recently, we have demonstrated an
important role for PKD in stimulated peptide secretion from BON cells; however, the role
of PKD isoforms, including PKD1 and PKD2, in the proliferation and invasion of carcinoid
tumors remains unclear. The purpose of our study was to determine the role of the PKD2
isoform on BON cell proliferation and invasion. METHODS. BON cells were stably trans-
fected with GST-tagged PKD2-wild type (WT), PKD2-kinase dead (KD), or empty vector
(control) and selected in medium containing G418 (800 µg/ml); transfection was confirmed
by assessment of GST expression. (i) To determine the effects of PKD2 on proliferation,
PKD2-WT, PKD2-KD, or control BON cell lines were plated in duplicate wells and MTT
assays performed. (ii) Invasion was determined by plating cells in triplicate on BD Matrigel
Invasion Chambers and counting cells invading the matrix after 24 h. RESULTS. (i) PKD2-
WT BON cells exhibited a greater than 2-fold increase (p<0.0001) in proliferation compared
to either PKD2-KD or control (empty vector) BON cell clones. There was no significant
difference in proliferation between PKD2-KD or control cells. (ii) PKD2-WT BON cells
demonstrated significantly increased invasion of Matrigel (40 ± 5.1 cells/chamber) when
compared with PKD2-KD BON cells (8 ± 1.5 cells/chamber) or control cells transfected
with empty vector (13.3 ± 1.2 cells/chamber). CONCLUSIONS. PKD2 overexpression
results in increased proliferation and invasion of the BON carcinoid cell line, suggesting an
important role for PKD2 in carcinoid tumor progression. Targeted inhibition of PKD2 may


















Gastrin-Induced CCN2/CTGF Over-Expression in Mastomys Gastric Carcinoid
May Be the Basis of ECL Transformation and Gastrin Autonomy
Mark Kidd, Irvin M. Modlin, Geeta N. Eick, Igor Latich, Michelle N. Zikusoka, Robert L.
Camp, Shrikant M. Mane
Connective tissue growth factor or CCN2 (particularly in concert with EGF) has been shown
to exert a mitogenic effect on a number of cell types including fibroblasts and stellate cells,
but its presence and effects have not been evaluated in gastric neuroendocrine cells. In
Mastomys, a rodent model of hypergastrinemia-induced gastric carcinoid neoplasia (enter-
ochromaffin-like cell [ECL]) dCHIP analysis of Affymetrix microarray data revealed up-
regulation of CCN2 transcript (+2.36-fold, p<0.01). This gene is also upregulated in a
transgenic mouse model (SV40 TAg under control of regulatory elements from the mouse
Atp4b gene: PNAS 2004; 101:4471-6) of neuroendocrine cell carcinoma. We confirmed
over-expression of CCN2 by Q RT-PCR in Mastomys tumor ECL cells, which exhibit elevated
levels of transcript (>20-fold; p<0.001) compared to an enriched (80%) elutriated population
of normal ECL cells. To validate this observation as an ECL cell specific event, we developed
a >96% pure naïve and tumor ECL cell fraction by FACS sorting histidine decarboxylase
(HDC) positive-ECL cells. CCN2 transcript was significantly increased in pure tumor ECL
cell fractions as opposed to normal ECL cells (41.3-fold±10.7, p<0.005). Immunostaining
of Mastomys gastric mucosa confirmed that while CCN2 protein was present in ECL tumors,
it was not expressed in normal ECL cells. TGFb1, the primary upstream regulator of CCN2,
elevated CCN2 transcript (3.5±0.6-fold, p<0.01) in normal short-term cultured ECL cells
(EC50 = 5 ng/ml), whereas gastrin (20 pg/ml) had no effect. TGFb1 had a similar effect on
CCN2 transcript expression in tumor ECL cells in short-term culture (2.8±0.3-fold, p<0.02).
Stimulation of tumor ECL cells with CCN2 induced proliferation (MTT assay) with an EC50
of ~0.01 ng/ml and an ECmax of 0.1 ng/ml, whereas normal ECL cells did not proliferate
in response to CCN2. Addition of EGF significantly augmented the CCN2-induced prolifera-
tion of tumor ECL cells with an EC50 of 6 pg/ml. No additive effect of CCN2 was noted
on EGF-stimulated naïve ECL cells suggesting that different downstream signaling pathways
are active in naïve and tumor ECL cells. In conclusion, CCN2 was absent in normal ECL
cells and is present only in ECL cell tumor cells. Its expression was upregulated by gastrin
and EGF, agents proven to induce ECL cell neoplastic transformation. Given its known
mitogenic role in other cell systems, CCN2 may represent a proliferative regulator that drives
ECL proliferation once cells become autonomous of gastrin regulation. Identification of
CCN2 in carcinoid biopsies may be useful as an indicator not only of ECL cell transformation
but also of gastrin-autonomy.
T1656
Functional Significance of Enhanced ETV4 and MYEOV Expression in
Colorectal Neoplasia Using Sirna-Mediated Gene Knockdown
Garrett Lowlor, Alan Moss, Donal Tighe, David W. Murray, Conor O'Keane, Peter Doran,
Padraic MacMathuna
Introduction Bioinformatic approaches have the advantage of generating novel disease gene
lists however; the functional significance of novel gene associations frequently remains
unclear. We have previously reported a computational study to identify ETV4 and Myeov
as novel genes with enhanced expression in colon cancer. However, the functional significance
remained to be determined. Aims To assess ETV4 and Myeov expression in normal, adenoma
and colon carcinoma tissue and to investigate the effect of gene knockdown on colon cancer
cell invasion and proliferation. Methods Digital differential display (DDD) was used to
identify differentially expressed colon cancer genes. Quantitative real time PCR was used to
assess expression levels in ex vivo human tissue. The effect of siRNA-mediated gene knock-
down on proliferation and invasion was evaluated in vitro using T84 cells. Results ETV4
expression was increased 4-fold in colon adenoma in comparison with normal, but unchanged
in carcinoma tissue. Cell proliferation was decreased by 90% with ETV4 knockdown by
48% with Myeov suppression (P<0.05). Cell invasion was decreased by 60%with ETV4
knockdown. Myeov suppression resulted in 40% decreased cell invasion. Conclusions We
have characterised two colon cancer related genes identified using DDD. ETV4 was shown
to have enhanced expression in colon adenoma and to promote cell proliferation and invasion.
Similarly, Myeov was shown to drive colon cancer cell proliferation and invasion. This data
supports the importance of bioinformatic approaches in disease gene identification as well
as the role of ETV4 and Myeov in colorectal neoplasia
T1657
Ying Yang 1 and NF-KappaB (p65) Are Markedly Increased in Metastatic
Colon Cancer: Roles of Iaps and Fas in Cytotoxic Resistance to Apoptosis and
Immune Privilege of Malignant Colon Cancer Cells, Respectively
Sergio Huerta, Emily J. Goulet, Sara Huerta-Yepez, Mario I. Vega, Berenice Sanchez-
Arellano, Benjamin Bonavida, Edward H. Livingston
Background/Objectives: Cell lines SW480 and SW620 were established from the same patient
at different stages of tumor progression: SW480 from a primary tumor (Duke’s stage B) and
SW620 from a lymph node metastasis. The SW620 cells are more resistant to apoptosis
when induced both by chemotherapeutic agents (i.e. cisplatin induced apoptosis) and by
treatment with anti-Fas monoclonal antibody, suggesting alteration of both the intrinsic and
extrinsic pathways of apoptosis in this aggressive cell line. However, caspases 3, 8 and 9
are unaffected in both cell lines. The following study was undertaken to elucidate the
mechanism rendering resistance to apoptosis in metastatic colon cancer cells. Methods: Cell
lines SW480 and SW620 were obtained from the ATCC and grown under standard condi-
tions. 1x105 cells were fixed in 4% paraformaldehyde. Immunohistochemistry was then
performed with the following antibodies: Fas (CD95), Bcl-xL, DR5, AIF, NFkappaB (p50
and P65), and YY1. Results: High levels of YY1 and p65 were noted in the nucleus of the
SW620 cell line and were almost undetectable in SW480 cells. Cytoplasmic p50 staining
was low in SW620 cells and moderate in SW480 cells. Bcl-xL staining was very high in the
cytoplasm of SW480 cells and moderate in SW620 cells. Fas levels were markedly high in
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SW480 cells and low in SW620 cells. DR5 was absent in both cell lines. While there was
a higher gradient of staining in the SW620 cells compared to the SW480 cells with AIF
antibody, this staining was limited to the cytoplasm. Conclusion: The high levels of p65 in
metastatic cells results in increased levels of survivin as well as TRAIL resistance to apoptosis
(as previously described). The high nuclear presence of NFkappaB in metastatic colon cancer
cells may explain the observed resistance to apoptosis by chemotherapeutic agents. The
ubiquitous anti-apoptotic YY-1 correlates with down regulation of Fas, which may provide
cancer cells immune privilege.
T1658
Side Populations of Human Gastrointestinal Cell Lines
Julia Burkert, William R. Otto, Derek Davies, Nicholas A. Wright
A distinct population of human tumour cells, defined by the ability to efflux the nucleic
acid staining dye Hoechst 33342, displays stem cell characteristics such as multipotential
differentiation and self-renewal. These cancer stem cells (CSC), as defined by the side
population (SP) phenotype, were first discovered in haematopoietic malignancies and have
more recently also been shown in solid tumours of the breast, brain and lung. We are
investigating the role of side populations in human tumour cell lines of the gastrointestinal
tract and their verification as CSCs. 7 of 7 tumour cell lines (6 colorectal and 1 gastric,
HGT101) show a distinct SP phenotype of between 0.3% and 10% of the whole population.
SP cells retained stem cell properties in vitro (clonal self-renewal and differentiation) and
their in vivo ability to generate tumours in NOD/SCID immunodeficient mice is under study.
SP cells were analysed by multicolour FACS analysis for the surface markers CD34, CD44
and CD133, and confirmed by semiquantitative RT-PCR and immunofluorescence staining.
SP cells from 4 lines showed two patterns of positivity: (Caco2: CD34- CD44+ CD133+;
HT29: CD34- CD44+ CD133+/-) compared to (SW620: CD34- CD44- CD133-; HGT101:
CD34- CD44- CD133-). Functional differences of the subpopulations with regards to stem
cell characteristics are being further investigated, including possible stem cell markers such
as musashi-1, c-kit, nanog. This may reveal useful information regarding the isolation and
therapeutic targeting of the CSC population.
T1659
Comprehensive Analysis of Prostaglandin E2 Production in Pancreatic Cancer
Cells
Hirozumi Sawai, Makoto Satake, Sascha Hasan, Howard A. Reber, Oscar J. Hines, Guido
Eibl
Background and Aim: There is substantial evidence that prostaglandin E2 (PGE2) contributes
to the malignant phenotype of several human cancers, including pancreatic cancer (PaCa).
Animal models have confirmed that PGE2 stimulates cancer cell growth, invasion, and tumor
angiogenesis. Conversely, inhibition of PGE2 synthesis decreases tumor growth. In the past,
studies focused almost exclusively on inhibition of the cyclooxygenase-2 (COX-2) isoform
in an attempt to reduce PGE2 formation. However, recent concerns of serious cardiovascular
side effects of selective COX-2 inhibitors necessitate a more comprehensive study of other
components of the prostaglandin production pathway in order to identify other therapeutic
targets. The aim of the present study therefore was to characterize PGE2 production in PaCa
cells. Methods and Results: Liquid chromatography-mass spectroscopy analysis revealed
comparable levels of the n-6 polyunsaturated fatty acid arachidonic acid (AA), the substrate
of cyclooxygenases yielding prostaglandin H2 (PGH2), in six human PaCa cells: AsPC-1 (A),
BxPC-3 (B), Capan-2 (C), HPAF-II (H), MIA PaCa-2 (M), and PANC-1 (P). Western blot
analysis demonstrated expression of cytosolic phospholipase A2 (PLA2), which releases AA
from membrane phospholipids, and COX-2 only in B, C, and H. COX-1 was expressed in
all six cell lines. The COX product PGH2 is converted to PGE2 by various PGE2 synthases
(PGES). While cytosolic PGES and microsomal PGES-2 were detected in all six cell lines,
microsomal PGES-1 expression was much more robust in B, C, and H. 15-deoxy-prosta-
glandin dehydrogenase (PGDH), which degrades PGE2, was similarly expressed in all six
cell lines. B, C, and H produced significant amounts of PGE2, while PGE2 levels were
virtually undetectable in A, M, and P, as determined by ELISA. Baseline PGE2 production
in B, C, and H was inhibited by selective COX-2, but not COX-1 inhibitors. Adding exogenous
AA time- and dose-dependently increased PGE2 production in B, C, and H, which was
inhibited by a selective COX-2 inhibitor. AA only slightly increased PGE2 levels in A, M,
and P, which was inhibited by a selective COX-1 inhibitor. Conclusions: Taken together,
our studies demonstrated for the first time that the components of the PGE2 production
pathway are variably expressed in PaCa cells. PGE2 production correlated with the robust
expression of cytoplasmic PLA2, COX-2, and microsomal PGES-1. These findings will help
to identify novel targets for inhibiting PGE2 production in pancreatic cancer.
T1660
Intestine-Specific Transcription Factors and Interferon-γ Cause Gastric Cancer-
Specific Expression of NADPH Oxidase 1 (NOX1)
Kazuhito Rokutan, Kumiko Tominaga, Yuki Kuwano, Kiyoshi Masuda, Kensei Nishida,
Hideyuki Sasaki, Atsuo Sekiyama, Shigatada Teshima-Kondo, Keiya Nakamura
Epidemiologic data show a clear association between chronic inflammatory conditions and
subsequent malignant transformation in the inflamed tissue. Gastric cancer is associated
with Helicobacter pylori infection and is histologically classified into the intestinal and diffuse
types. The carcinogenic pathway of intestinal-type gastric carcinomas involves well-character-
ized sequential stages; superficial gastritis, atrophic gastritis, intestinal metaplasia, and carcin-
omas. An intestine-specific CDX2 is one of the most likely candidates linked with the
induction of intestinal metaplasia, while the underlying mechanism for displasia is still
unkonwn. A novel NADPH oxidase 1 (Nox1) is implicated in the pathogenesis of inflamma-
tion and oxygen radical-dependent carcinogenesis. Northern hybridization and PCR of
human stomach cDNA libraries showed that the Nox1 mRNA was absent in the normal
human stomach, while they were specifically expressed in intestinal-type and diffuse-type
adenocarcinomas. Immunohistochemistry with use of polyclonal antiobody against human
Nox1 also demonstrated that Nox1 protein was expressed in intestinal (15/17 cases), diffuse-
type carcinomas (7/7), and signet-ring cell carcinomas (10/10 cases), while it was absent in
accompanying normal or chronic atrophic tissues with metaplasia. We cloned 5.0 kbp of
5'-frank of the human Nox1 gene. The 500 bp-proximal promoter of the Nox1 gene that
contains binding sites for GATA6, CDX1/2, and HNF-1α factors appeared to be essential
for the basal promoter activity. In fact, Nox1-expressing cancer cells possessed GATA6,
CDX1/2 and HNF-1α. Particularly, CDX1 and HNF-1α were specifically colocalized in
Nox1-expressing cancer cells. Furthermore, we found that a Th1 cytokine (IFN-γ) was a
potential activator for transcription of the Nox1 gene. In this case, STAT1 and GAS motif
located at -3960 to -3645 bp mediated the transcription stimulated by the Th1 cytokine. These
results suggest that inappropriate activation of specific developmental pathways (intestinal
metaplasia) plus enhanced Th1 cytokine production may cause dysregulated expression of
the Nox1, which may be associated with Helicobacter pylori-associated, oxygen radical-
dependent carcinogenesis in the stomach.
T1661
Establishment and Characterization of Hydroxycamptothecin-Resistant
SW1116/HCPT of Human Colon Cancer Cell Line and Reversal of HCPT
Resistant Phenotype
Zhi Hua Ran, Jian Zou, Shu Dong Xiao
Aims: To study multi-drug resistance mechanism of digestive tract tumor and reverse strategy.
Methods: Stepwise concentration-increasing method was used to develop SW1116/HCPT
which was hydroxycamptothecin-resistant cell line of human colon cancer. Cell growth
curve, drug sensitive test, cell cycle, telomerase activity and karyotype analysis were detected.
Human Cancer Drug Resistance & Metabolism Gene Array was used to determine the
expression profile of drug resistant genes. Expressions of 8 drug resistant genes were checked
by RT-PCR. BCRP siRNA were designed and transfected into drug resistant cells. HCPT
sensitiveness, cell cycle distribution and oncogenicity were detected in vitro. RT-PCR and
western blot were used to check the efficacy of BCRP gene knock-out. Results: Compared
with their parent cells, SW1116/HCPT was 120 times more resistant to cytotoxic action of
HCTP. The number of SW1116/HCPT cells in G0/G1 phase increased and that of S phase
decreased(P<0.01). Telomerase activity and karyotype of SW1116/HCPT cells had no appar-
ent change. Karyotype is aneuploid 54-69. There were 30 drug resistant genes whose
expression level were changed. Of them, 10 were down-regulated and 20 were up-regulated.
The result of RT-PCR was in accordant with that of gene array. 2 genes were down-regulated,
4 were up-regulated and another 2 had no apparent change. BCRP siRNA were designed
successfully, and the efficiency of liposome transfection was 42%. Compared with drug
resistant cells, sensitivity of HCPT was recovered and there was 62.5% decrease in IC50.
The number of SWt cells in G0/G1 phase decreased and that of S phase increased(P<0.05).
The oncogenicity of SWt cell were drop-down, and volum of clones were diminished. RT-
PCR and western blot shown that there was decrease in the expression of BRCP mRNA and
protein in SWt cells.Conclusion SW1116/HCPT is an ideal model for the study of multidrug
resistance in digestive tract tumor. Transfection of siRNA expressing plasmid is an effective
reverse strategy of HCPT resistant phenotype in human colon cancer cells.
T1662
Nf-κB Activation Is Linked to Proximal Colon Tumor Induction in UCP2
Deficient Mice
Zoltan Derdak, Edmond Sabo, Rose Tavares, Murray Resnick, Jack R. Wands, Gyorgy
Baffy
Background and aims. Uncoupling protein-2 (UCP2) has recently emerged as a negative
regulator of mitochondrial oxidant production. When overexpressed, UCP2 protects cells
from oxidative stress, while its absence may cause abundance of reactive oxygen species,
release of pro-inflammatory cytokines, and persistent activation of NF-κB, a pleiotropic
transcription factor with an increasingly recognized role in cancer. We have recently found
that mice deficient for UCP2 develop more aberrant crypt foci (ACF) and colon tumors
when treated with azoxymethane (AOM), a chemical carcinogen typically targeting the distal
colon (Gastroenterology 125(S1): A176, 2004). Surprisingly, increased susceptibility in
UCP2-/- mice to AOM primarily occurred in the proximal colon in association with a
disrupted balance between intestinal epithelial cell proliferation and apoptosis. To further
study these events, we analyzed their association with oxidative stress and NF-κB activation.
Methods. Proximal and distal colon tissue was obtained from 8-wk old male UCP2-/- mice
(n=12) and wild type littermates (n=8) treated with AOM at a dose of 10mg/kg/wk i.p.
for 6 wks and observed for an additional 24 wks. Oxidative stress was determined by
immunohistochemical staining for malondialdehyde (MDA) and inducible nitric oxide syn-
thase (iNOS). NF-κB activation was determined by Western blot analysis of phosphorylated
IκB (pIκB) and by immunohistochemical detection for the nuclear presence of p65 subunit.
Immunohistochemistry was evaluated by image analysis. Results. Increased MDA staining
was found in the distal colon (p<0.05) regardless of the genotype, supporting the importance
of regional differences. However, MDA staining was more intense in the proximal colon of
UCP2-/- mice (p<0.05). Staining for iNOS resulted in a similar pattern. In wild type mice,
less pIκB was found by Western blot analysis in the proximal colon, indicating diminished
activation of NF-κB in this region (p<0.05). However, pIκB was increasingly abundant in
UCP2-/- mice with a loss of regional differences (p<0.05). Moreover, nuclear p65 staining
was more intense in the proximal colon of UCP2-/- mice (p<0.01) indicating excessive NF-
κB translocation. Conclusion. Our findings indicate significant regional differences in mice
for the degree of oxidative stress and NF-κB activation between proximal and distal colon.
These differences are lost in UCP2 deficiency, suggesting a causal relationship to increased
tumorigenesis in the proximal colon of UCP2-/- mice. Additional studies are warranted to
assess the role of mitochondrial uncoupling in colon cancer development. Supported by
NIH grant RR-17695.
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T1663
Bone Marrow-Derived Stem Cells May Not Cause Fusion with Cancer Cells in
Vivo
Shuji Ishii, Shingo Tsuji, Toshiyuki Yoshio, Shinichirou Shinzaki, Satoshi Egawa,
Takanobu Irie, Tsutomu Nishida, Masakazu Yasumaru, Hideki Iijima, Hiroaki Murata,
Yoshiyuki Kanazawa, Sunao Kawano, Norio Hayashi
[Background and Aims] There are hematopoietic stem cells and storomal stem cells in the
bone marrow. On the other hand, a report suggests certain digestive cancers are bone
marrow-derived. It is also reported that stem cells cause fusion with tumor cells in vitro.
Another report suggests that the vascular endothelial cells in a tumor are a bone marrow-
derived. Therefore we investigated the fate of bone marrow-derived cells in colon cancer
allografts in mice. [Methods] Whole bone marrow cells were collected from the femurs and
tibias of GFP transgenic mice and were transplanted to C57BL/6 mice after whole body
irradiation (10Gy). MC38, a mouse-derived colon cancer cell line, were transplanted subcuta-
neously to the mice. MC38 cells were also injected to the spleen of the animals to make
metastatic liver tumors. After tumors formed, mice were sacrificed and perfused with 4%
paraformaldehyde/PBS. The tumors were removed immediately, and frozen in cryo-enbed-
ding compound. The frozen sections were immunohistologically analyzed for CD 45, CD
31, α -SMA, vimentine and GFP using confocal microscopy. MC38 were transfected with
pDsRed gene to label the cell with red fluorescence. The transfectant tumor cells
(MC38pDsRed cells) were also transplanted into the back of the mice harboring GFP+ bone
marrow. The tumor were also examined for the possible fusion of pDsRed+-tumor cells and
bone marrow-derived GFP+-stem cells. [Results] Both the subcutaneous tumors and the
metastatic liver tumors contained much GFP+ bone marrow-derived GFP+,CD45+ hemato-
poietic cells. Remaining several% are bone marrow-derived myofibrobrasts and fibrobrasts
(GFP+, α-SMA+ and GFP+ vimentine+. The cell which differentiated to a endotherial cell
with GFP + CD 31+ was not present. Furthermore, none of tumors did not contained GFP+,
pDsRed+ cells, suggesting that fusion of a tumor cell and a bone marrow-derived stem cell
may not occur in the tumor allografts. [Conclusions] Bone marrow is the source of tumor
myofibrobrasts and fibrobrasts. Bone marrow-derived cells were also mobilized toward the
tumor as hematopoietic cells. Fusion of bone marrow-derived stem cells and tumor cells
may hardly occur in mice in vivo.
T1664
Transient Receptor Potential Ion Channel TRPM8 Is Expressed and
Functionally Active in Neuroendocrine Tumor Cells
Stefan Mergler, Mathias Strowski, Simone Kaiser, Thomas Plath, Ursula Ploeckinger,
Bertram Wiedenmann, Carsten Groetzinger
BACKGROUND: TRPM8, a member of the melastatin-type transient receptor potential ion
channel family, is activated by cold temperatures. TRPM8 activation induces a rise in the
concentration of intracellular free calcium ([Ca2+]i). This increase in [Ca2+]i occurs as a
result of an influx of Ca2+ through the plasma mambrane via this non-selective cation
channel. To date, neither the identity nor the functional meaning of this channel in neuroen-
docrine tumor (NET) cells is known. AIM: This study was undertaken to investigate electro-
physiological properties of human NET primary cell cultures and permanent NET BON
cells combined with the analysis of intracellular Ca2+ responses mediated by extracellular
application of cooling compounds. METHODS: TRPM8 mRNA expression was detected
by RT-PCR and protein expression was confirmed by immunofluorescence staining and
microscopy. Ca2+ transients were measured by single cell fluorescence imaging. The whole-
cell patch-clamp technique was used to monitor icilin-mediated stimulation of TRPM8
activity. In addition, the effect of TRPM8 activation on neurotensin concentration was studied.
RESULTS: Extracellular application of iclin (300 nM) elicited non-selective cation channel
currents in BON cells. In addition, [Ca2+]i increased from 104 ± 8 nM to a peak level of
185 ± 14 nM followed by a recovery to 120 ± 7 nM (n = 3). These results were reproducible
if menthol (100 µM) was used as stumlus. In addition, in three primary NET cell cultures
icilin also led to an increase in [Ca2+]i (i.e from 104 ± 3 nM to 143 ± 9 nM; recovery
partially occurred to 130 ± 16 nM; n = 4). Furthermore, icilin increased neurotensin secretion
in BON cells. CONCLUSION: For the first time, we could demonstrate by several methods
that TRPM8 is expressed and functionally active in BON cells. Importantly, this TRPM
isoform is associated with neurotensin secretion.
T1665
Gene Expression Profiling Reveals Different Regulated Pathways for
Adenocarcinoma of the Esophagus and Cardia
Sjoerd M. Lagarde, Emiel E. Ver Loren van Themaat, Perry D. Moerland, Lisa A. Gilhuijs-
Pederson, Fiebo J. Ten Kate, Pieter H. Reitsma, Antouine H. van Kampen, Koos H.
Zwinderman, Frank Baas, Jan J. van Lanschot
Introduction: Adenocarcinomas of the distal esophagus and gastric cardia are two tumors
that have many features in common. However, the etiology is different with gastroesophageal
reflux disease playing a major role in adenocarcinoma of the distal esophagus, but not in
that of the gastric cardia. The molecular analysis of differences between these tumors has
mainly focused on single candidate genes. However, global gene expression profiling monitors
changes in tens of thousands of genes. Extracting biological insight from these data remains
a challenge. Gene Set Enrichment Analysis (GSEA) is used to detect modest but coordinate
expression changes of groups of (functionally) related genes. The aim of this study was to
identify differentially expressed genes and gene sets that are associated with tumor localization
(esophagus versus cardia). Methods: Resection specimens of either adenocarcinoma of the
esophagus (N=18) or cardia (N=16) were carefully selected. There was no difference in
stage, differentiation grade and lymph node ratio between the two tumor types. Whole
genome microarrays containing 44.000 probes were used to evaluate these 34 cancer speci-
mens. After quality control and normalisation, differentially expressed genes were identified

















microarray data using 1325 biologically defined gene sets and 100 permutation tests. Results:
SAM did not demonstrate differentially expressed genes between the two tumor types.
However, GSEA found coordinate expressed gene sets that were related to the cell-cycle
process and leptin pathway. Genes located on the chromosome loci 6p22 and 20q11 were
differentially regulated between the two tumor types. Both chromosome loci have several
interesting genes which are known to be associated with tumors in the digestive tract.
Furthermore, both chromosomes contain a member of the E2F-gene family. The E2F family
plays a crucial role in the control of the cell cycle, DNA replication and action of tumor
suppressor proteins. Conclusions: Adenocarcinomas of the distal esophagus and gastric
cardia have many features in common, but gene set enrichment reveals different regulated
pathways for the two tumors. This suggests that different pathways underlie the oncogenesis
of these tumor entities, which might necessitate distinct strategies for future targeted therapy.
T1666
Transcription Factor YY1 Is Overexpressed in Gastrointestinal Cancer Cells
Dharmaraj Chinnappan, Dongmei Xiao, Anita Ratnasari, Thomas King, Chris Andry,
Horst C. Weber
The zinc finger transcription factor Yin Yang 1 (YY1) is a negative regulator of tumor
suppressor gene p53, which is frequently mutated late in gastrointestinal (GI) carcinogenesis,
and has functions in the control of cell growth, tumor suppression and differentiation. We
recently identified YY1 as a transcriptional activator of the GRP-receptor in colo-rectal cancer
(CRC) cells, but the expression and regulation of YY1 in CRC has not been investigated.
Therefore, this study aimed to examine the expression of YY1 in normal human tissues,
CRC tissues and GI cancer cells in vitro. Methods: YY1-specific mRNA and protein expression
was examined in human cancer cells by Northern and Western blot using radioactively
labeled YY1 cDNA and a monoclonal anti-YY1 antibody, respectively. Immunohistochemistry
(IHC) was performed on CRC tissue arrays. Genomic DNA was used for Southern blot
analysis, and FISH was performed with a human YY1-specific probe in human cancer cells.
Results: Several distinct human YY1 mRNA isoforms (1.0, 2.6, 4.6, and 7.5 kb) were
ubiquitously expressed in normal tissues, most abundantly in skeletal and heart muscle,
but to a lesser extent also in colonic muscle and mucosa. In human GI cancer cells in vitro
(Lovo, Caco-2, HT-29), two major YY1 mRNA isoforms (7.5 and 2.6 kb) were significantly
over-expressed (2.6 kb: 3-6 fold; 7.5 kb: 2-20 fold) compared with normal skeletal muscle.
The YY1 mRNA half lives in Lovo and Caco-2 CRC cells were 2 and 8 hours, respectively,
and protein half lives were 6 hours (Lovo) and far exceeding 6 hours in Caco-2 cells. FISH
mapped the YY1 gene to chromosome 14q32 and showed various degree of aneuploidy in
cancer cells without increased signal intensity. Only 5% Lovo cells showed aneuploidy,
whereas in 95% of Caco-2 cells aneuploidy was noted (2n: 5%, 3n:36%, 4n:32%, 5n and
more: 27%). YY1 immunoreactivity of the colonic mucosa was confined to nuclear staining
of epithelial cells both in normal and cancer samples. Some neutrophils, lymphocytes and
muscle cells stained positive, whereas mitotic cells did not show YY1 staining. When analyzed
according to a standardized score (normalized intensity x % nuclei staining), we detected
a trend for increased score with increasing tumor grade. Conclusions: YY1 is significantly
over-expressed in cancer cells in vitro and some CRC tissue samples where it is confined
to nuclear localization. In cancer cells in vitro, over-expression occurs in the absence of
gene amplification and translocation and is regulated -at least in part- by mRNA and protein
stability. YY1 over-expression in CRC might be associated with cell dedifferentiation.
T1667
Novel Therapeutic Targets for Gastrointestinal Cancer
Eugene A. Volpe, Tapas Saha, Will J. Ferguson, Yi Tang, Varalakshmi Katuri, Wilma
Jogunoori, Tiffany M. Blake, Bubhuti Mishra, Lopa Mishra, Stephen Rt Evans
The TGF-β superfamily plays an important role in the formation of gastrointestinal carcinoma,
cell differentiation, tumor suppression and liver development. The TGF-β pathway is inactiv-
ated in most gastrointestinal cancers. TGF-β is modulated through Smad activation and is
dependent upon adaptor proteins such as ELF, a β-spectrin as well as modifying E3 ligases
such as PRAJA. We have shown that disruption of the Smad4 adaptor protein ELF, a β-
spectrin, disrupts TGF-β signaling. Elf-/- mice die in midgestation from gastrointestinal,
liver, neural and heart defects. Aim: To identify new therapeutic targets to control gastrointes-
tinal cancer when the TGF-β signaling pathway is inactivated. Methods and Results: 1. We
performed protein kinase assays and microarray analysis on ELF deficient mouse fibroblasts
as well as in control mouse fibroblasts to dissect new pathways that could be inactivated
when this key signaling pathway is inactivated. 2. We have identified a number of TGF-β
regulated proteins important in early gut progenitor cell homeostasis. ELF heterozygotes
develop gastrointestinal cancer. 3. Protein kinase assays demonstrate elevated expression of
Src and ERK1 in elf-/- fibroblasts when compare to elf+/+ when stimulated with TGF-β. 4.
Northern blot analysis and RTPCR confirms the above observations. 5. Microarray analysis
using 44K human array identified 77 genes that are up regulated and 65 genes that are
down-regulated in ELF deficient mice with significant probability (p value) when compared
to the normal control mice. 6. SWI/SNF related, matrix associated, actin dependent regulator
of chromatin (SMARCE1) protein has a 6 fold increase in expression in elf-/- mice. RING
finger protein 10 (RNF10) is also up-regulated by 1.8 fold in ELF deficient mice. Interestingly,
PRAJA, which is also a RING finger protein, is often found up regulated in gastric cancers
and has been shown to ubiquitinate ELF and destroy it through 26S proteasome pathway.
7. Furthermore, G protein coupled receptor (GPR64; 7.84 fold), origin recognition complex
subunit 6 (ORC6; 5.466 fold), transferrin (TF; 3.44 fold) and Jun B proto oncogene (JunB;
2.11 fold) are the most prominent proteins that are down-regulated in elf-/- mice. Conclu-
sions: These studies reveal a new therapeutic approach for tumorigenesis in gastrointestinal
cancers whereby defects in adaptor proteins for Smads, such as ELF, induce inactivation of
the TGF-β signaling pathway.
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T1668
Induction of Enteric Neurons from Embryonic Stem Cells in Vitro and in Vivo
Valentina Sasselli, Maria-Adelaide Micci, Pankaj Jay Pasricha
Introduction: In response to appropriate environmental signals, pluripotential embryonic
stem (ES) cells can differentiate into a variety of cell types including central and peripheral
neurons. However their potential for developing specifically into enteric neurons is unknown.
As part of an ongoing project on stem cell replacement therapy for enteric neuronal disorders,
this study examined the phenotypic response of ES cells to putative differentiating cues
derived from the enteric nervous system and related tissues. Methods: Mouse ES cells were
cultured as neurospheres for 7 days in serum free medium (NB27) supplemented with LIF,
EGF and FGF2. For in vitro experiments, neurospheres were co-cultured with a fresh
preparation of mouse longitudinal muscle-myenteric plexus (LM-MP) placed inside transwells
(no-contact) in NB27 medium without growth factors. After 10 days cells were processed
for immunofluorescence staining, Western blot and real time PCR to assess neuronal and
glial differentiation. For in vivo experiments, ES-derived neurospheres were transplanted at
a density of 50,000 cells/μl into the pylorus of C57BL/6J adult mice. Survival and differenti-
ation of grafted cells was assessed 7 days after transplantation. Results: As compared with
controls, exposure to LM-MP in vitro resulted in increased mRNA and protein expression
of nestin, as well as βIII-tubulin, MAP 2 and nNOS (protein expression data showed a fold
increase of 2.2 for nestin, 2.0 for βIII-tubulin, 1.9 for MAP2 and 1.9 for nNOS). Noticeably,
expression of the glial marker GFAP was not detected in either group. In vivo studies revealed
adequate survival of transplanted ES cells; however, these appeared undifferentiated and
did not express any of the above markers. Conclusions: Our results indicate that enteric
muscle and/or neurons secrete factors that can induce differentiation of ES cells to specific
neuronal fates including the expression of nNOS, a key molecule for regulation of gut
motility. On the other hand ES-derived neurospheres failed to adopt a neuronal phenotype
in vivo in normal tissue at least, suggesting the presence of local inhibitory influences. We
conclude that for an ES-based transplant strategy to successfully repopulate the ENS, the
cells will either need pre-transplantation “nudging” or further manipulation of the post-
transplant environment to acquire an enteric neuronal phenotype.
T1669
Turnover of Interstitial Cells of Cajal in the Murine Stomach: Regeneration
from Local Progenitors and Limited Survival After Loss of Electrical
Pacemaker Activity and Kit Expression
Doug Redelman, Andrea Lorincz, Viktor J. Horvath, Michael R. Bardsley, Hui Chen,
Tamas Ordog
We have recently shown that reduced insulin/insulin-like growth factor-I (IGF-I) signaling
and consequent decrease in stem cell factor (SCF) production by smooth muscle cells
may be responsible for the depletion of interstitial cells of Cajal (ICC) in murine diabetic
gastroparesis (Gastroenterology, in press). Preliminary results have also suggested a role for
cell turnover in the maintenance of ICC. The goal of this study was to identify ICC precursors
within the murine gastric tunica muscularis. We investigated the expression of CD34 and
CD44, putative markers for ICC precursors, and receptors for SCF (Kit, the standard ICC
marker), insulin, and IGF-I in gastric corpus+antrum muscles from adult and juvenile mice
by immunohistochemistry and flow cytometry. Effects of long-term (32-85-day) treatments
with SCF and IGF-I were studied in organotypic cultures. In freshly dissected tissues, CD34
was not detected in KitBright ICC. In contrast, a small population (≤0.6% of all cells) of
KitLow cells expressed high levels of CD34. These cells were oval-shaped, had no processes,
and occurred in small clusters on the serosal and submucosal surfaces of the gastric musculat-
ure and in the myenteric region. Unlike mature ICC, they also expressed insulin and IGF-
I receptors. All KitBright ICC and KitLow cells expressed CD44, a multifunctional glycoprotein
found in mesenchymal stem cells. Long-term treatment of cultured gastric muscles with
SCF caused the growth of the KitLowCD34+ cells into densely packed clusters in the myenteric
region or thick chords containing bipolar cells along the longitudinal axes of the nearby
smooth muscle fibers. SCF stimulated Kit expression but reduced CD34 levels. In contrast,
the IGF-I-treated cultures were dominated by normal, Kit+CD34- ICC networks that also
expressed CD44. The effects of IGF-I on ICC were blocked by inhibiting c-kit transcription
with interferon-γ. Kit+ ICC and electrical slow waves were lost in cultures maintained in
the absence of growth factors for up to 85 days. However, partially disrupted networks of
ICC-like cells could still be recognized by CD44 immunostaining. We conclude that mainten-
ance of gastric ICC probably involves their insulin/IGF-I-dependent regeneration from
KitLowCD34+ precursors. While the development of these cells into ICC can be initiated
with soluble SCF, their expansion and conversion into mature, CD34- ICC requires IGF-I
or insulin, which can stimulate both soluble and membrane-bound SCF. CD44 expression
is integral to the ICC phenotype and is maintained for some time after the loss of Kit
expression and physiological function. Supported by NIH Grants DK58185 and RR16464.
T1670
A Conditionally Immortalized Colonic Epithelial Cell Line from a Genetically
Engineered Mouse That Polarizes Spontaneously in Vitro
Robert H. Whitehead, Angela L. Tyner, Jeffrey L. Franklin
Background. The colonic epithelium is a polarized epithelium, however the study of the
mechanisms of polarization and transport has been limited by the lack of a normal epithelial
cell line that will polarize in vitro. Because of this, studies have depended on the use of
colon carcinoma cell lines that will polarize in vitro. Methods. Mice with disruption of the
gene encoding the Brk tyrosine kinase were mated with an “Immortomouse” and the progeny
carrying both genes mated to obtain homozygous knockout mice that carried the temperature
sensitive SV40 large T gene. At 12 weeks of age the colons were removed and the crypts
isolated using EDTA/DTT. These crypts were cultured in collagen-coated wells in LHC-9
medium. Results. A cell line was obtained that grew very slowly. The cells were sensitive
to trypsin and had to be passaged using EDTA/EGTA. The cells were cultured on transwells
that had been coated with Attachment Factor (Cell Systems Corporation). After 7 days
culture at 33oC the resistance of the monolayer was >400 milliOhms. Staining of the fixed
monolayer demonstrated the polarization of these cells. The polarization was confirmed by
fixing the filters with paraformaldehyde and staining with antibodies to E-cadherin, b-
catenin, occludin and ZO-1. In all cases a polarized staining pattern was seen. Discussion. This
is the first description of a polarizing conditionally immortalized murine colonic epithelial cell
line. It is not yet known whether disruption of the brk gene or the fact that these cells were
cultured in a serum-free medium was responsible for our success in deriving this cell line.
Studies are underway to reintroduce Brk into the cells to determine if absence of functional
Brk contributes to polarization
T1671
Gene Expression Profiles of Normal Proliferating and Differentiating Human
Intestinal Epithelial Cells: A Comparison with the Caco-2 Cell Model
Eric Tremblay, Joelle Auclair, Emile Levy, Daniel Menard, Nathalie Rivard, Ernest G.
Seidman, Pierre H. Vachon, Jean-Francois Beaulieu
Background/Aim: cDNA microarray technology enables detailed analysis of gene expression
throughout complex processes such as proliferation, differentiation and carcinogenesis. The
aim of this study was to analyze the gene expression profile of normal human intestinal
epithelial cells using cell models representing undifferentiated and mature intestinal epithelial
cells in comparison to the widely used Caco-2 cell model. Methods: Four independent RNA
preparations for each cell type were used on cDNA microarrays representing 19,200 human
cDNA clones (University Health Network, Ontario, Canada). A hierarchical clustering algo-
rithm was used to identify patterns of gene expression in the crypt-like proliferative HIEC
and tsFHI cells, and isolated villus epithelial cells as well as Caco-2 cells at two distinct
stages of differentiation (proliferative and twenty days postconfluence). Results: Unsupervised
hierarchical clustering analysis of global gene expression among the cell lines identified two
branches: one for the HIEC cells versus a second comprised of two sub-groups: a) the
proliferative Caco-2 cells and b) the differentiated Caco-2 cells and the closely related villus
epithelial cells. At the gene level, supervised hierarchical clustering with 272 differentially
expressed genes (one-way ANOVA with adjusted Bonferonni correction, p<0.05) revealed
distinct expression patterns specific to each cell phenotype. Among these expression patterns,
we observed a striking difference in up-regulated genes involved in proliferation between
the normal undifferentiated intestinal cells and proliferative Caco-2 cells suggesting a different
molecular regulation of cancer cells. Conclusions: We identified several up-regulated genes
that could lead to the identification of new regulatory pathways involved in cell differentiation
and carcinogenesis. The combined use of microarray analysis and human intestinal cell
models thus provides a powerful tool for establishing detailed gene expression profiles of
proliferative to terminally differentiated intestinal cells. Furthermore, the molecular differ-
ences between the normal human intestinal cell models and Caco-2 cells clearly point out
the strengths and limitations of this widely used experimental model for studying intestinal
cell proliferation and differentiation.
T1672
Basal Promoter Activation of Rat Nhe2 Gene in Intestinal Epithelial Cells
Ping Hua, Hua Xu, Jennifer K. Uno, Pawel R. Kiela, Fayez K. Ghishan
Introduction: Na+/H+ exchanger isoform-2 plays important roles in intracellular pH, cell
volume regulation and ion transport in the kidney and intestine. Our previous studies have
identified a minimal Sp1-driven promoter fragment (nt -36/+116) directing high expression
of NHE2 in mouse renal epithelial cells mIMCD-3. However, this minimal promoter region
was not sufficient to promote active transcription in intestinal epithelial cells, suggesting
the need for upstream regulatory elements to promote active transcription in the intestinal
epithelium. In this study, we used non-transformed rat intestinal cells (RIE) as a model to
identify the minimal promoter fragment and transcription factors necessary for the basal
transcription of NHE2 gene in intestinal epithelial cells. Methods: A series of 5’ deletion
constructs (-90, -85, -69, and -43 nt) were made by PCR and restriction enzyme digestion
and subcloned into pGL3 basic reporter vector. All constructs had the same 3’ end at nt
+116. These promoter constructs were transiently transfected into RIE cells, and assayed
for reporter gene activity. Nuclear protein was extracted from RIE cells by standard methods,
and electrophoretic mobility shift assay were performed to detect protein-DNA interactions.
Results: Reporter gene assays demonstrated that promoter constructs -90/+116, -85/+116,
and -69/+116 were all functional in RIE cells, with construct -69/+116 showing the highest
promoter activity. Compared to this construct, -43/+116 fragment had ~ 40% activity. EMSA
detected DNA-protein complexes within the minimal promoter region spanning -73/-23 bp
containing multiple and overlapping cis elements. Individual mutations at -56/-55 nt or -
52/-51 nt partially decreased protein binding affinity to a probe spanning -67/-43 nt of
NHE2 promoter, while in combination, these mutations completely abolished DNA-protein
interactions in this promoter region. Mutation at nt -56/-55 also reduced the NHE-2 promoter
activity by ~40%. Conclusion: The minimal promoter region for activating the rat NHE2
gene in intestine is located within -69/-36 nt upstream of transcription initiation site. The
cis elements involved are distinct from those identified in the renal epithelial cells. Reporter
gene assays indicated that -56/-55 region representing a predicted core binding site of
transcription factor MAZF is partially responsible for active transcription of NHE2 gene in
RIE cells. Future work will focus on identifying transcription factors, their functional and
physical interactions and their cognate cis elements participating in NHE2 gene transcription
in the intestinal epithelium.
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T1673
Monoclonal Conversion of Human Gastric Glands Gives Insights Into Stem
Cell and Clonal Architecture
Stuart A. McDonald, Laura C. Greaves, Simon J. Leedham, Maesha Deheragoda, Robert
W. Taylor, Sean L. Preston, Chung Yin-Lee, David Stoker, Marco R. Novelli, Janusz A.
Jankowski, Douglass M. Turnbull, Nicholas A. Wright
Studies on the intestine of animals and man have confirmed, beyond reasonable doubt, that
the structural units, the crypts, are clonally-derived . The unit found in the stomach, the
gastric gland, especially in the human, remains an enigma. Some animal reports show clonal-
derivation, whereas others show that a minority of glands remain polyclonal, suggesting the
possibility of multiple, possibly independent stem cells. In the human, results are also
mixed. We have used mutations in the mitochondrial cytochrome c oxidase subunit 1 gene
(COXsu1), as a clonal marker (J. Clin. Invest. 2003:112(9)), detecting COXsu1 in conjunction
with a nuclear-encoded oxidative enzyme, succinate dehydrogenase (SDH), by double enzyme
histochemistry. We have observed body-type gastric glands which are partially filled with
mutated cells, and others glands where all the cells in the gland are mutated (COXsu1-,
SDH+). These suggest that a stem cell bearing this mutation expands to fill the entire gastric
gland. Early observations suggest that all cell lineages in these mutated body-type glands
are involved in this process. Moreover, the mutated gland then appears to spread in the
mucosa by gland fission as shown by neighbouring glands having the same mitochondrial
mutations. Several conclusions are made possible by these observations: 1.Gastric glands
undergo a process of monoclonal conversion, where the gland becomes gradually replaced
by mutated cells; 2.Human gastric glands are maintained by a number of stem cells; 3.Each
body-type gland is derived ultimately from a single stem cell which gives rise to all the
contained lineages, and are therefore multi-potential; 4.These mutated glands then appear
to expand by gland fission, even in the adult stomach.
T1674
TGF-Beta Signaling Is Required for Ductal Progenitor Cell Differentiation and
the Disruption of TGF-Beta Signaling May Be Involved in Development of
Hepatocellular Carcinoma and Cholangiocarcinoma
Krit Kitisin, Natarajan Ganesan, Yi Tang, Varalakshmi Katuri, Jogunoori Wilma, Kirti
Shetty, Lynt Johnson, Lopa Mishra
Human hepatic progenitor cells can most likely give rise to hepatocellular carcinoma as well
as cholangiocarcinoma. In these models, a periportal population of small “primitive” oval
epithelial cells proliferate either in association with or before hepatocyte multiplication. In
mouse development, ventral floor of foregut endoderm produces cells destined to become
hepatoblasts, bipotential cells committed to fetal hepatocytes and biliary epithelial cells. In
adult human tissues, these hepatic progenitor cells (or mouse oval cells) are immature
epithelial cells found residing in the canals of Hering. TGF-beta is important in modulation
of biliary and liver epithelial cell morphogenesis. Both elf-/- and Smad2+/-/Smad3+/- mutant
embryos display hepatic hypoplasia. In addition, TGF-beta signaling proteins such as TBRII,
Smad4 and ELF are all implicated in suppressing HCC. Thus it is conceivable that cells
expressing these proteins are progenitors that are susceptible to bile duct malformation and
tumor development once tight TGF-beta control is lost. Aims: 1. To determine the role of
TGF-beta signaling in liver progenitor cell proliferation and differentiation utilizing a mouse
embryonic liver explant cultures. 2. To determine the localization of TGF-beta “progenitor
cells” to a specific region of portal tracts, we analyzed human regenerating liver after donor
transplant for TBRII, Smad4 and ELF expressions. Methods and Results: 1. Embryonic liver
tissues isolated from normal, elf-/- and Smad2+/-/3+/- mutants were cultured in TGF-beta
growth factor to determine their growth properties. Explant cultures from Smad2+/-/3+/-
mutants showed a lack of bile ductules 2. Addition of TGF-beta produced a rise in Smad2
and 3 activity, expression occurring at the rapid outgrowth of a limiting plate with bile duct
formation. 3. Immunohistochemical labeling revealed a tight region around portal tracts
where a 6-7 cell cluster specifically expressed TBRII, Smad4 and ELF. These clusters are
more prominent in regenerating liver and in low abundance (one per low power view).
Conclusion: Prominent expression of TGF-beta signaling proteins found in the periportal
cluster of cells indicates that these cells are under tight TGF-beta control. The cluster of
cells could represent the hepatic progenitor cell “niche” which is important in normal
intrahepatic bile duct formation and in regenerating liver. Disruption of TGF-beta signaling
has been implicated in numbers of human carcinogenesis. The exploration of these hepatic
progenitor cell “niche” and the loss of TGF-beta signaling control could provide insights to
the development of hepatocellular cancer and cholangiocarcinoma.
T1675
Failure of Vagal Sensory Axons to Innervate Aganglionic (Ret-deficient) Bowel:
Relationship to Enteric Expression of Netrin-1
Elyanne M. Ratcliffe, Lena Fan, Tandi J. Mohammed, Michael D. Gershon
Vagal sensory axons are concentrated in myenteric ganglia, intramuscular arrays, and the
lamina propria. This innervation develops during fetal life and results, in part, from the
attraction by enteric netrins of vagal fibers, which express the receptor, deleted in colorectal
cancer (DCC). We took advantage of the failure of crest-derived cells to form ganglia in the
subdiaphragmatic bowel of Ret -/- mice to study the role ganglia play in establishing vagal
sensory innervation. To label vagal sensory axons, DiI was applied bilaterally at E12 and
E16 to the nodose ganglia of Ret +/+, +/- and -/- mice. DiI-labeled vagal sensory axons were
identified in E12 Ret +/+ and +/- fetuses in fasciculated paraesophageal bundles; extensions
of these fibers were also seen in the gastric mesenchyme. In contrast, no labeled vagal axons
could be detected distal to the esophagus at E12 in Ret -/- animals. By E16, in Ret +/+ and
+/- mice, DiI-labeled vagal sensory fibers were well advanced into the small intestine;
however, in Ret -/- mice DiI-labeled vagal fibers could not be visualized distal to the
esophagus. Netrin-1 immunoreactivity was located in the developing gut of Ret +/+ (E12-
P2) and -/- (E12 and E16) to test the hypothesis that the failure of the vagal sensory

















netrin-1 expression. Nerves and ganglia were simultaneously located with antibodies to
PGP9.5. At E12 in Ret +/+ mice, netrin-1 immunoreactivity was concentrated in the outer
gut mesenchyme and the mucosal epithelium of the presumptive esophagus, stomach and
small intestine. Myenteric ganglia formed within the netrin-1 expressing mesenchyme and
were themselves netrin-1-immunoreactive. In Ret -/- mice, at E12 and E16, little netrin-1
immunoreactivity was detected in the outer gut mesenchyme or mucosa. We suggest that
the vagal sensory innervation of the gut depends on the formation of enteric neurons. The
decrease in netrin immunoreactivity in the aganglionic gut is consistent with the idea that
the vagal innervation fails in the Ret -/- bowel because these axons are not attracted by
netrins. Further studies are required to determine whether developing enteric neurons
acquire netrin immunoreactivity because they synthesize or take up netrins. Additional
studies of the interactions of developing ganglia with the enteric mesenchyme are also needed
to determine why the absence of enteric ganglia causes mesenchymal expression of netrin
to fail. Supported by K12-HD00850, AGA Research Scholar Award, NS12963 and NS15547.
T1676
Identification of Putative Transcriptional Regulatory Pathways Mediating the
Genomic Response to Iron-Deficiency in Rat Duodenum
James F. Collins, Zihua Hu
Introduction/Aims: Our previous microarray studies identified differentially expressed genes
(DEGs) in the duodenum of iron-deprived rats across different stages of postnatal develop-
ment (sucklings through older adults). We demonstrated that many known iron-responsive
genes were regulated in our rat model as expected, as well as many novel genes. We
hypothesized that small groups of identified genes would likely be regulated by similar
molecular mechanisms in response to iron-deprivation. Methods: To identify coordinately
regulated groups of genes, we performed 8 H Clustering Using Euclidean Distance and
Complete Linkage, which has allowed us to identify several clusters of genes that are similarly
regulated across the different age groups (and in the jejunum of adult iron-deficient rats).
One of the clusters of strongly induced genes (#7; containing 28 genes) was of the most
interest, as it contained several iron transport genes, in addition to several novel genes. In
order to identify transcriptional regulatory pathways that may coordinately control expression
of some of the genes in this cluster, we utilized the Genomatix Suite software (Release 3.4.1)
to extract promoter sequences of the 28 genes in this cluster and to search for complex
transcription factor binding frameworks. Results: Interestingly, we found that several genes
in cluster 7 including Divalent Metal Transporter 1 (DMT1), Transferrin Receptor 1, Menkes
Copper ATPase (ATP7A) and a novel intestinal zinc transporter, contained putative binding
sites for p53 and HOXF trans-acting factors (in close proximity to each other). We next
searched the Genomatix rat promoter database with our p53/HOXF framework and found
that the group of rat genes with similar binding sites was statistically enriched in iron
transport-related genes. Importantly, Hephaestin (a copper binding ferroxidase important
for intestinal iron transport) and some genes previously identified by the array studies were
also found to contain this framework. Discussion: We have thus identified a potentially
important regulatory pathway that may mediate the genomic response to iron-deficiency.
The possible involvement of p53 is intriguing as this protein is known to mitigate stress
responses and previous studies have demonstrated that p53 activity is increased by iron-
deprivation in various tissues and cell types. Moreover, iron-chelation is known to induce
apoptosis in many cell types, a response that is partially mediated by p53. The possibility
therefore exists that in addition to inducing apoptosis, p53 may play a role in iron homeostasis.
Supported by NIH Grant 1R21 DK068349.
T1677
Human Colonic Crypt Self-Renewal Ex Vivo
Alyson Parris, Amy Reynolds, Theodore Spahos, Andrew Trim, Andrea Munsterberg,
Richard Tighe, Michael Lewis, J.N. Cook, Alyson Prior, Chris Speakman, William
Stebbings, James Hernon, Khalid Ellamin, Ian Beales, Mark Williams
Following on from classical animal studies and work on adenocarcinoma cell lines, recent
gene targeted and transgenic mice studies have provided profound insights into the molecular
determinants of epithelial renewal in the intestine. However, there is an increasing call for
a complementary in vitro model of the intact human colonic epithelium that is amenable
to real-time imaging and functional genomic analysis of tissue renewal. AIMS: To apply bio-
imaging and functional genomic approaches to the study of intestinal tissue renewal in
cultured human colonic crypts. METHODS: Colonic crypts were isolated from tissue biopsies
obtained at sigmoidoscopy from healthy-subjects (Ethical approval). Isolated crypts were
attached to collagen-coated coverslips and cultured for 24 hours-7 days in serum-free DMEM
(5%CO2/37oC). Validatory expression experiments were performed on cryosections of biopsy
samples. Expression constructs and siRNA oligonucleotide duplexes were introduced to cells
by low-voltage square wave electroporation. Protein location was visualised by immunofluo-
rescence and confocal microscopy. A range of markers for cell polarity (e.g. NKCC1), cell
proliferation (e.g. BrdU incorporation and Ki67) and viability (e.g. propidium iodide, calcein-
am) were utilised. Cell migration was assessed by monitoring Hoechst 33342 or α tubulin-
GFP labelled cells. RESULTS: Colonic crypts maintained their gross morphological flask-
like appearance for at least 7 days in culture. Individual cells maintained the polarised
expression of proteins (e.g. basolateral NKCC1 and M3AChR) throughout the culture period.
Expression of these proteins predominated at the crypt base and this topological expression
gradient was preserved over the culture period. The proliferative hierarchy was also preserved
in culture: Ki67 positive cells were located at the crypt base, as were BrdU positive cells
(10 μM, 4 hour pulse). Accordingly, nuclear β-catenin labelled cells were confined to the
crypt-base. Pulse chase experiments (4 hour pulse, 48 hour chase) demonstrated that BrdU
labelled cells migrated to the upper crypt region (Ki67 negative). Tracking of Hoechst 33342
and GFP labelled cells confirmed a migration rate of approx. 5 μm/hour. Cell shedding was
visualised in real-time by propidium iodide/calcein status of detached cells. Cell viability
was compromised in lower crypt compartments by siRNA knockdown of β-catenin. CON-
CLUSIONS: Isolated human colonic crypts are amenable to real-time imaging and functional
genomic studies. We have demonstrated that many of the cellular processes associated with
rapid renewal of the colonic epithelium are recapitulated ex-vivo.
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T1678
Mapping Gene Expression Along the Anterior-Posterior Axis of the Adult
Human Colon
Lawrence C. Lapointe, Robert Dunne, Daniel Worthley, Peter Molloy, David Wattchow,
Graeme Young
Studies of colorectal adenocarcinomas suggest variable incidence, histopathology, and pro-
gnosis between proximal and distal tumors. While research has shown gene expression (GE)
differences between the proximal and distal colon, there have been no studies exploring the
nature of these expression gradients for such genes.AIM: To map individual gene variation
and patterns of multi-gene expression longitudinally along the colon. METHOD: The data
are from two sets of Affymetrix microarrays hybridized to mRNA isolated from non-diseased
colorectal tissue specimens with an anatomically-identifiable site of resection by segment as
one of cecum, ascending, transverse, descending, sigmoid or rectum. For discovery (hypo-
thesis generation) we used a large commercial database of 184 microarrays. To validate our
findings (hypothesis testing) we created a data set of 19 arrays from hospital tissue bank
specimens. We analyzed anterior-posterior (A/P) GE using three techniques: single gene
univariate diff. expression; linear models to compare a two-tier model of A/P GE change
vs. a gradual, multi-segment model of change; and multivariate techniques to explore general
GE patterns along the A/P axis. RESULTS: A total of 206 probesets, corresponding to
approx. 154 known genes, were differentially expressed between the proximal (n=74) and
distal (n=110) specimens (Bonferroni corrected p < 0.05). Of these, 31 (16.5 %) were also
differentially expressed in the validation data with a significant difference. (p<0.05). A subset
of 115 probesets that were differentially expressed between the cecum and rectum were
used for linear modeling. In 65 (57%) of these transcripts, there was a two-tier A/P expression.
The remaining 50 (43%) transcripts were best modeled by a gradual, multi-segment colon
model. Interestingly, 41 (82%) of the 50 multi-segment models show a gradual GE increase
along the colon. Multivariate methods, including principal components analysis (PCA) were
also used to explore GE patterns along the A/P axis. These results suggest that there are
two broad populations defined by the proximal vs. distal divide. CONCLUSION: We
observe two forms of gene expression change in the colon. The first corresponds to a two-
tier, or proximal-distal, expression roughly patterned on the midgut vs. hindgut embryonic
origins of the colon. A second set of genes exhibit a more gradual change from the cecum
to the rectum. These results are consistent with univariate and multivariate analysis.
T1679
Induced C-Myc Regulates P21 Transcription Through Proximal Region of Its
Promoter Following Increased Polyamines in Normal Intestinal Epithelial
Cells
Lan Liu, Xin Guo, Jaladanki N. Rao, Tongtong Zou, Bernard S. Marasa, Jie Chen, Jose
Greenspon, Robert A. Casero Jr, Jian-Ying Wang
Maintenance of intestinal mucosal epithelial integrity requires cellular polyamines that regu-
late expression of various genes involved in cell proliferation, growth arrest, and apoptosis.
Our previous studies have shown that polyamines are essential for expression of the c-myc
gene and that polyamine-induced c-Myc plays a critical role in stimulation of normal intestinal
epithelial cell proliferation, but the exact down-stream targets of induced c-Myc are still
unclear. The p21 is a major player in cell cycle control and it is primarily regulated at the
transcriptional level. The current study went further to determine whether induced c-
Myc stimulates normal intestinal epithelial cell (IEC-6 line) proliferation by repressing
p21 transcription following increased polyamines. Methods: c-Myc was increased by either
increased cellular polyamines by stable transfection of the ornithine decarboxylase (ODC)
gene (ODC-IEC cells) or transient infection with adenoviral expression vector containing c-
myc cDNA. Expression of the p21 gene was examined by measurements of its promoter,
mRNA, and protein. Deletion mutations and Sp-1 or Miz-1 point mutations were used to
map the c-Myc-responsive region within the p21-promoter. Results: Increased levels of
cellular polyamines by overexpression of the ODC gene induced c-Myc expression and
inhibited p21 transcription as indicated by decreases in p21-promoter activity and its protein.
Levels of c-Myc were increased by ~10-folds in stable ODC-IEC cells, whereas levels of p21-
promoter activity and its protein were inhibited by ~80%. In contrast, depletion of cellular
polyamines by inhibiting ODC enzyme activity with α-difluoromethylornithine decreased
c-Myc but increased p21 transcription. Expression of c-Myc was decreased by ~75% in
polyamine-deficient cells, while p21 transcription was >4 times the control level. Ectopic
expression of wild-type c-myc not only inhibited basal levels of p21 transcription in control
cells but also prevented increased p21 in polyamine-deficient cells. Studies using different
p21-promoter mutants showed that transcriptional repression of p21 by c-Myc was mediated
through Miz-1- and Sp1-binding sites within the proximal region of the p21-promoter in
normal intestinal epithelial cells. Conclusions: These results indicate that p21 is one of the
direct mediators of induced c-Myc following increased polyamines and that p21 repression
by c-Myc is implicated in stimulation of normal intestinal epithelial cell proliferation.
T1680
Cooperative Interactions Among Intestinal Gata Factors in Activating the Rat
Liver Fatty Acid Binding Protein Gene
Joyce K. Divine, Lora J. Staloch, Christopher W. Rowley, Hanna Haveri, Markku
Heikinheimo, Theodore Simon
GATA-4, GATA-5, and GATA-6 are endodermal zinc-finger transcription factors that activate
numerous enterocytic genes. GATA-4 but not GATA-5 or GATA-6 are present in enterocytes
of adult mice, and we now report the simultaneous presence of all three GATA factors in
enterocytes of mice before weaning age. An immunohistochemical survey detected enterocytic
GATA-4 and GATA-6 at birth and one week of age, and GATA-5 at one week but not birth.
Interactions among GATA factors were explored utilizing a transgene constructed from the
proximal promoter of the rat liver fatty acid binding protein gene (Fabp1). GATA-4 and
GATA-5 but not GATA-6 activate the Fabp1 transgene through a cognate binding site at -
128. A dose-response assay revealed a maximum in transgene activation by both factors,
where additional factor did not further increase transgene activity. At saturated levels of
GATA-4, however, additional transgene activation was achieved by adding GATA-5 expres-
sion construct, and vice versa. Similar cooperativity occurred with GATA-5 and GATA-6.
Identical interactions were observed with a synthetic target transgene consisting of a single
GATA site upstream of a minimal promoter. Furthermore, GATA-4 and GATA-5 or GATA-
5 and GATA-6 bound to each other in solution. These results are consistent with tethering
of one GATA factor to the Fabp1 promoter through interaction with a second GATA factor
to produce increased target gene activation. Cooperative target gene activation was specific
to an intestinal cell line and may represent a mechanism by which genes are activated in
the intestinal epithelium during the period before weaning.
T1681
CNS-Derived Neural Stem Cells Can Form Neurons, Glia Or Smooth Muscle
in Response to Putative Myogenic and/Or Neural Factors in the Enteric
Nervous System
Maria-Adelaide Micci, Rochelle R. Simmons, Kristen M. Kahrig, Pankaj Jay Pasricha
Introduction: Recent studies have explored the potential of multipotent neural stem cells
derived from the central nervous system (CNS-NSC) to repopulate the enteric nervous
system (ENS). However, the spectrum of plasticity of these cells in response to various
components of the ENS has not been characterized. The aim of this study was to investigate
the effect of putative differentiating factors secreted by the muscle and/or enteric neurons
on the differentiation of CNS-NSC in vitro. Methods: CNS-NSC were isolated from the
subventricular zone (SVZ) of embryonic mice and propagated in culture in NB27 medium
supplemented with EGF and FGF2. CNS-NSC were either (a) cultured for 10 days in the
presence of conditioned media collected from primary cultures of intestinal mouse smooth
muscle cells or (b) co-cultured with a fresh preparation of mouse longitudinal muscle-
myenteric plexus (LM-MP) placed inside transwells (no-contact) in NB27 medium without
growth factors. Control cultures were kept in standard differentiating conditions (NB27
medium alone). After 10 days cells were processed for immunofluorescence staining and
Western blotting to assess the expression of specific markers indicative of their phenotypical
fate. Results: A strong induction of α-smooth muscle actin was observed in CNS-NSC treated
with smooth muscle-conditioned media. Moreover, as compared to controls, expression of
the glial marker GFAP was increased (2.4 fold), while expression of the neuronal marker
βIII-tubulin was markedly reduced (100 fold reduction). By contrast, exposure of CNS-
NSC to LM-MP resulted in increased protein expression of βIII-tubulin (2.24 fold increase
compared with controls), as well as GFAP (2.04 fold increase). α-smooth muscle actin
expression, though more than controls (where it was undetectable), was markedly less than
in CNS-NSC exposed to smooth muscle-conditioned media. Conclusions: Our data show
that intestinal smooth muscle cells exert a strong myogenic and gliogenic effect on CNS-
NSC while inhibiting neuronal differentiation. In the presence of enteric neurons, however,
this myogenic influence is overcome and there is a marked shift towards a neuronal phenotype
at the expense of smooth muscle. Identification of these putative differentiating factors is
in progress. Our results also show that under the appropriate circumstances, CNS-NSC can
be induced to differentiate into muscle and thus suggest another potential therapeutic use
for these cells in gastrointestinal disorders.
T1682
Microarry Analysis of Rat Duodenal Mucosa: Expression of Iron Related
Genes Along the Crypt-Villus Axis
Kwo-Yih Yeh, Mary Yeh, Jonathan Glass
Iron homeostasis is regulated at the level of intestinal absorption with dysregulation, e.g.
in hemochromatosis, leading to iron excess with resultant tissue damage. The major proteins
involved in iron absorption are divalent metal transporter 1 (DMT1), ferroportin 1 (FPN1),
duodenal cytochrome b reductase (Dcytb) and hephaestin (Heph). How these proteins are
regulated remains unclear. The transcriptional regulation of iron related genes was examined
in rat duodenal villi by cryostat sectioning, isolating RNA from the top and bottom thirds
of the axis, and examining global gene expression in the two poles with Affymetrix Rat Gene
Chips comparing the iron deficient Belgrade (b/b) rats with wild-type (+/+) rats and b/b
rats fed iron for 3days (b/b+Fe). The location of the sections was confirmed by analysis of
sucrase-isomaltase, a marker of differentiated mucosa, and cryptdin 5, a marker of Paneth
cells in the crypts. Microarray data was sorted into genes that were either exclusively or
preferentially expressed in the villus bottoms or tops. The genes involved in dietary iron
absorption, Dcytb, Heph, DMT1 and FPN, were expressed in the villlus tops and genes
involved in systemic iron uptake, transferrin (Tf) and Tf receptor (Tfrc), were expressed in
the villus bottoms. Differential expression was confirmed by real time RT-PCR and Northern
and western blot analyses. In the b/b rats DMT1 and Dcytb expression increased markedly
and was reduced toward +/+ levels in the b/b+Fe. Groups of genes were defined in both
poles of the C-V axis that were iron responsive either increasing or decreasing in the b/b
rats and returning to normal in bb+Fe rats. This analysis allowed us to define genes involved
in iron transport because of differential spatial expression and changes in expression with
changes in iron status. However, other genes, e.g. the heme basolateral transporter Abcg2,
heme oxygenase 1, the Cu++ transporter ATP7a, solute carrier family 27 (fatty acid trans-
porter) and cytochrome P450, 4a10 (Cyp4a10) had expression that was also spatially related
on the C-V axis and whose expression was altered in the b/b rat, but not reversed with iron
feeding. These findings, especially the persistence of gene expression after iron feeding for
some genes and not others, strongly suggests that the b/b rat mutation has effects on gene
expression perhaps through epigenetic phenomena that occur as a result of iron deficiency.
Supported by NIH DK-65101 (KY) and DK-41279 (JG)
T : 89386$$CH2
05-04-06 23:18:30 Page 541Layout: 89386B : o
A-541 AGA Abstracts
T1683
Gata-6 and Hnf-4alpha Transcription Factors Regulate Murine Muc5ac Mucin
Gene Expression During Stomach Development
Ingrid B Renes, Nicolas Jonckheere, Anita M Korteland-van Male, Marie-Paule
Ducourouble, Isabelle van Seuningen
Introduction: During embryonic and foetal development of the gastrointestinal tract, the
MUC5AC mucin gene has a spatio-temporal pattern of expression restricted to the stomach
and the small intestine. In the adult, MUC5AC is only expressed in the surface epithelial
cells of the stomach. Aim: To gain insight into the molecular mechanisms responsible for
the restricted pattern of Muc5ac expression during mouse stomach development. Methods:
Expression of Muc5ac mucin and of transcription factors known to be involved in cell
differentiation programs during mouse gastric development was studied by immunohisto-
chemistry. The transcriptional regulation of Muc5ac by HNF and GATA factors was performed
in the murine CMT-93 cell line by co-transfection experiments. Cis-elements within the
promoter were identified by electrophoretic mobility shift assays and chromatin immunoprec-
ipitation. Results: Expression studies indicate that GATA-4, HNF-1alpha, and HNF-3beta
were already expressed in the pseudostratified epithelium of the hindstomach at embryonic
day (ED)14.5 and remained expressed at EDs 17.5/18.5, post natal day (PND)1.5 and in
adults. GATA-6 and HNF-4alpha started to be expressed in the stomach as of ED17.5,
concomitant with the outgrowth of the hindstomach into a glandular stomach. Their expres-
sion remained weak until ED18.5 but increased substantially after birth. As of ED17.5, all
the transcription factors studied were expressed in epithelial cells from the bottom to the
top of the glands. Interestingly, at PND1.5 we observed an increase in GATA-6 and HNF-
4alpha expression concomitant with the induction of Muc5ac. The implication of GATA-6
and HNF-4alpha in Muc5ac up-regulation during gastric development and differentiation
was confirmed by in vitro studies in which we showed up-regulation of promoter activity
by these two factors and binding of HNF-4alpha to two cis-elements in the promoter.
Conclusion: These results indicate that GATA-6 and HNF-4alpha play an important role in
mediating the spatio-temporal pattern of expression of Muc5ac mucin in the stomach and
may be responsible for its de novo ectopic expression in other tissues.
T1684
Colonic Stem Cells Are Unable to Selectively Segregate Their Genome At the
Time of Mitosis: Replication Errors May Persist
Sean L. Preston, Nikki Mandir, Toby Hunt, Robert A. Goodlad, Mairi Brittan, Simon J.
Leedham, Sabina Beg, Nicholas A. Wright, Malcolm R. Alison
Background: Compared to the large intestine, tumors of the small intestine (SI) are rare.
No satisfactory explanation for this discrepancy has been identified. SI stem cells appear
able to protect themselves from DNA replication errors by segregating their genome at the
time of cell division; always retaining the old (‘template’) strand and passing on the newly
synthesised DNA strand to their progeny (Potten et al. J Cell Sci 2002) - the Cairns hypothesis.
Does the same process take place in the colon when new stem cells and new ‘template’
strands are being produced following radiation? Could the higher rate of tumors in the
colon and the Min (APC +/-) be explained by an inability to selectively segregate their
genome at the time of division? Methods: 25 Min and 25 C57Bl/6J mice underwent whole
body irradiation at a dose of 8 Gy, followed by 6 hourly i.p. injections of tritiated thymidine
(3HTdR) over 48 hours - labelling the ‘template’ strand. The mice were then left for 8 days
and 5 mice from each group were killed at this time. The remaining mice were injected
with BrdU every 6 hours for 48 hours - labelling the newly synthesised strand, and killed
from 40 minutes to 25 days following the final injection. Sections were immunostained for
BrdU before autoradiography, and labelled cells mapped on a positional basis. Results: The
distribution of the two markers in the SI was consistent with the Cairns hypothesis. However,
in the colon the results were different: after 8 days 1.9% of colonic epithelial cells were
labelled with 3HTdR, with no labelled cells seen after 20 days. Labelled cells were distributed
equally throughout the length of the crypt and there were fewer labelled cells in the Min
mice. Most crypt cells were BrdU labelled at 1 day, but labelling declined sharply 3-5 days
after the last injection, with no labelled cells at 25 days. Cells containing both proliferative
markers were rare, distributed throughout the crypt, occurring only in the immediate 24
hrs following labelling. Conclusions: Since the stem cell cycle time is reduced by irradiation
the presence of 3HTdR labelling at 8 days is indicative of retention of part of the genome.
In the colon the disappearance of the label over the following 12 days and the dilution of
BrdU at the same rate suggests that the process is stochastic and there is no protective
mechanism in the colon selectively retaining the ‘template’ strand. This may contribute to
the higher incidence of tumors in the colon compared to the SI. The similarity in the
distribution of the labels between the Min and the C57Bl/6J mice, suggests APC does not
have a critical role in the process of segregation.
T1685
Differential Regulation of Intestinal Gene Expression By Hnf1α During the
Weaning Transition in Mice
Tjalling Bosse, John J. Fialkovich, Eva Beuling, Christina M. Piaseckyj, Robert K.
Montgomery, Stephen D. Krasinski
Lactase-phlorizin hydrolase (LPH) and liver fatty acid binding protein (Fabp1), both follow
a developmentally coordinated pattern in which their expression declines during the weaning
transition. Hepatocyte nuclear factor-1α (Hnf1α) is a transcription factor that is required
for the expression of LPH and Fabp1 in the adult jejunum as shown using hnf1α knockout
mice (Bosse et al, Am J Physiol, In Press), but its function during postnatal development is
currently unknown. Using this model, we investigated the importance of Hnf1α for the
regulation of LPH and Fabp1 during the weaning transition. Wild-type mice were analyzed
for Hnf1α mRNA and protein levels in the jejunum 7, 14, 21 and 28 days after birth by
real-time RT-PCR, Western analysis, and immunofluorescence. Although Hnf1α mRNA as
measured by real-time RT-PCR was relatively constant throughout postnatal development,

















of 7 day old mice and then increased incrementally to high levels in 28 day old mice, similar
to that in adults. At 7 days of age, Hnf1α was localized to the cytoplasm of the absorptive
enterocytes on villi, whereas at 28 days of age, Hnf1α was restricted to the nucleus, as
determined using co-immunofluorescent staining of Hnf1α with the DAPI nuclear stain.
Co-staining with lectin HPA revealed that Hnf1α in the cytoplasm of the 7 day old mice
was associated, in part, with the Golgi apparatus. Next, we investigated the function of
Hnf1α in the regulation of LPH and Fabp1 during postnatal development by comparing
jejunal mRNA levels between wild-type and Hnf1α null mice using real-time RT-PCR. LPH
and Fabp1 mRNA levels in the 7 day hnf1α-/- mice were reduced 50% as compared to
wild-type controls (P<0.05, n=4), whereas LPH and Fabp1 mRNA levels in 28 day old
hnf1α null mice was nearly undetectable (95% reduction). These data show that Hnf1α is
indispensable for LPH and Fabp1 gene expression in the intestine of 28 day old mice (similar
to adults), but is only partially required for the expression of these genes before weaning.
Conclusions: These data demonstrate (1) a previously unknown nuclear translocation process
for Hnf1α that is regulated during the weaning transition, and (b) a differential requirement
for Hnf1α before and after weaning for LPH and Fabp1 implicating differential regulatory
pathways for intestinal gene expression during postnatal development.
T1686
Specific Antigen Expression and Novel Gene Expression in the Cells At the
Bottom of the Colonic Crypt
Jeffrey L. Franklin, Paul Gregoli, Pamela S. Robinson, Walter Wakwe, Robert H.
Whitehead
Background. Although the stem cells of the colonic epithelium have been extensively studied
there are still no surface markers that would allow us to isolate these cells. The proliferative
cells can be identified by BrDU but this does not allow for viable isolation of the cells.
Methods. We initially bisected crypts and conducted comparative microarray studies using
a cDNA chip. This identified CD24 as a marker for the bottom 5% of the cells at the base
of the crypt. We have labeled avidin-linked Dynabeads and biotinylated CD24 antibody to
purify these cells and have undertaken further microarray studies using Affimetrix chips to
identify genes that are either upregulated or specifically expressed in this cell population.
We have repeated this study using CD44 antibody. Results. Both CD24 antibody and CD44
antibody have a very similar staining pattern on isolated crypts. Dynabead isolation with
CD24 antibody yielded 4% of the crypt cell population and CD44 yielded 6%. Microarray
studies showed that the CD24 + and CD44+ cell populations were more similar to each
other than to their negative cell populations. Of 32050 gene probes that had similar expression
in both CD24+ and CD44+ cells, 1650 were upregulated in the CD24 +/CD44+ cells relative
to CD24-/CD44- Cells. Discussion. CD24 and CD44 are the first 2 markers that allow for
the viable isolation of the cells at the bottom of the colonic crypt. Using these markers we
have been able to identify a panel of genes that are highly expressed in the 5% of cells at
the base of the crypt.
T1687
Imatinib Inhibits Kit Expression On Potential Interstitial Cells of Cajal in
Human Intestinal Smooth Muscle Culture Cells
Akiko Terauchi, Hiroshi Mashimo
Background/Aims: Imatinib inhibits KIT tyrosine kinase and can treat gastrointestinal stromal
tumors thought to originate from the neoplastic transformation of interstitial cells of Cajal
(ICC). Loss of ICC has been reported in various disorders of gastrointestinal motility. Efforts
to identify factors influencing the population of ICC have been hindered by the lack of cell
culture studies in humans. We reported that membrane-bound stem cell factor (mbSCF),
a natural ligand for KIT, increases expression of KIT in human intestinal smooth muscle
cells (HISM) and leads to unique morphological changes. In this study, we tested whether
imatinib decreases the appearance of ICC-like round and uniquely dendritic cells in cultures
of HISM when exposed to human mbSCF, and decreases the expression of KIT in HISM.
Methods: HISM were co-cultured for 1, 5, and 8 days with either untransfected murine Sl/
Sl4 fibroblasts (lacking murine SCF) or with Sl/Sl4 fibroblasts expressing transfected human
mbSCF (Sl/Sl4+mbSCF) in the presence or absence of imatinib (5μM). The HISM were
classified by shape (round, dendritic, spindle, or flat). HISM were distinguished from the
fibroblasts using anti-human MHC-I antibody and stained with anti-human KIT antibody
for detection of potential ICC-like cells. Results: Throughout the time span of culture, most
of the round cells (85.8 ± 2.8%) and the dendritic cells (94.6 ± 3.2%) were KIT-positive.
Compared to HISM co-cultured with Sl/Sl4 alone, in vitro exposure to mbSCF increased
ICC-like round cells (after 8 days, Table, p < 0.05). Uniquely dendritic cells also appeared
with SCF exposure, not immediately, but after 8 days of mbSCF exposure (Table). This
shift in the morphology of HISM correlated with increases in KIT expression from 1 day
to 8 days of culture (after 8 days, Table). However, these increases in round and dendritic
cells, as well as in KIT expression, were inhibited by imatinib (Table). Conclusions: KIT
expression and morphological changes in HISM appear dynamic and responsive to mem-
brane-bound SCF. Imatinib appears to block the effect of membrane-bound SCF, possibly
via the tyrosine kinase activity of KIT, leading to decrease in KIT expression in HISM.
This data allows further study of mechanisms of KIT expression, ICCs differentiation, and
morphological changes driven by the KIT receptor and mbSCF interaction.
Round, dendritic and KIT-positive cells after 8 days culture
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T1688
Expansion of Putative Colonic Stem Cells By Administration of Enteral
Antibiotics Is Associated with Colonic Adaptation Following Ileocecal
Resection in Mice
Christopher M. Dekaney, Susan J. Henning, Rachael J. Rigby, P. Kay Lund, Michael A.
Helmrath
Introduction: Surgical resection of the ileum and proximal colon is commonly performed
in patients with Crohn’s disease. Mechanisms of adaptive growth in large bowel after such
resections have not been well characterized. A murine model of ileocecal resection (ICR)
was developed and data from our laboratories using this model demonstrate enhanced
colonic adaptation in germ free mice. In addition, we have recently developed side population
(SP) flow cytometry methods to measure putative colonic stem cells. In this study, we
hypothesized that enteral antibiotics would expand the percentage of SP cells following ICR.
Methods: Ileocecal resection (ICR) or sham surgery (S) was performed on 8-12 week old
C57BL6 mice (n = 4-6 mice/group). Liquid diet with (AB) or without (CON) broad-spectrum
antibiotics was provided 3 days before and for the duration of the experiment. Colonic
tissue was harvested on postoperative day 3 and 7 for histology and fluorescent activated
cell sorting (FACS) to evaluate changes in the percentage of CD45-negative SP cells. Results:
ICR resulted in significant increases in colonic crypt depth in AB vs. CON mice at both 3
(78.8 ± 5.6 vs. 48.6 ± 2.2 μm) and 7 days (66.6 ± 8.2 vs. 52.9 ± 1.6 μm) post resection.
FACS analysis revealed that the addition of enteral antibiotics significantly increased the
percentage of CD45-negative SP in sham operated mice at both 3 (0.32 ± 0.23 vs. 0.79 ±
0.38) and 7 days (0.69 ± 0.17 vs. 0.58 ± 0.15), despite no differences in crypt depth between
groups. Significant increases in percent of SP following ICR in AB vs. CON were found at
3 days (1.16 ± 0.35 vs. 0.14 ± .07), but not 7 days. Conclusion: Administration of enteral
antibiotics increases the percentage of colonic CD45-negatvie SP cells. Following ICR, addi-
tion of enteral antibiotics results in early expansion of the percentage of SP cells and colonic
adaptation. These data suggest that commensal microflora inhibit expansion of putative stem
cells (SP) required for colonic adaptation following ICR. This work was supported by NIH
grants K08 DK 067395 and P30 DK 56338.
T1689
Direct Effects of Nitric Oxide On Histamine Release from Rat
Enterochromaffin-Like Cell
Naozumi Shibata, Hidetaka Matsui, Tomoyuki Yokota, Bunzo Matsuura, Kazutaka
Maeyama, Morikazu Onji
Backgrounds: Although there is evidence that nitric oxide (NO) inhibits secretion of gastric
acid, the contradictory results have also been reported. While enterochromaffin-like (ECL)
cells have a central role in the regulation of gastric acid secretion, the direct effects of NO
on these cells have not yet been demonstrated. In this study we investigated the direct
effects of NO donors on histamine release from rat ECL cells. Methods: ECL cells were
purified from the rats using an elutriator system, which can make the purity 80% or more.
After 48 h of cultivation, the cells were incubated with test substance for 1 h. Histamine
released from ECL cells was measured by a high-performance liquid chromatography (HPLC)-
fluorometry technique. Intracellular Ca2+ levels were assayed in Fura-2/acetoxymethylester
(AM) -loaded ECL cells. Intracellular cGMP content was measured by enzymeimmunoassay.
Intracellular histamine content and histidine decarboxylase activity were measured after
incubation with test substance for 8 h. Results: The NO donor, NOR3 (10 μM and 100 μM)
decreased gastrin-induced and PACAP (pituitary adenylate cyclase-activating polypeptide) -
induced histamine release significantly. In contrast, NOR3 over the concentration range 1
μM -100 μM did not augment basal histamine release. The inhibitory effect of the NO donor
appeared not to be caused by toxicity, as the cells were shown to be viable at the end
of the experiments as judged by trypan blue dye exclusion and also showed continued
responsiveness to gastrin after removal of the NO donor. 100 μM NOR3 increased cGMP
levels and reduced gastrin-induced calcium influx. ODQ, an inhibitor of guanylate cyclase,
completely blocked NOR3-induced inhibition of histamine release. NOR4, an NO donor,
did not affect intracellular histamine content and histidine decarboxylase activity. Conclu-
sions: These results suggested that NO inhibits gastric acid secretion via suppression of
gastrin-induced histamine release through a pathway in which NO activated soluble guanylate
cyclase, in addition to increasing cGMP levels and reducing gastrin-induced calcium influx.
The use of NO donor as a new type of gastric acid inhibitor that decreases histamine levels
in the stomach would be beneficial as histamine that is increased by using an H2 blocker
or proton pump inhibitor has various effects on tumors and immunological functions.
T1690
Down-Regulated Sonic Hedgehog Expression in the SPEM-Like Lesions in the
Stomach of H2 Receptor-Null Mice
Yuriko Minegishi, Hidekazu Suzuki, Mamoru Arakawa, Yasushi Fukushima, Takashi
Ishikawa, Nicholas A. Wright, Toshifumi Hibi
Spasmolytic polypeptide (trefoil factor family 2 ; TFF2)-expressing metaplasia (SPEM) has
been know to be associated with the development of oxyntic atrophy and metaplastic
cell lineages in response to H.felis infection (Lab. Invest. 79: 639, 1999; Gastroenterol.
127:582,2004), and mainly characterized as a loss of parietal cells. Sonic hedgehog (Shh)
is an important signal protein which is expressed in the stomach and involved in the
regulation of the homeostasis of fundic glands (Gut 51:28, 2002; Development 127:2763,
2000), and an in vitro study has showed that Shh expression is up-regulated under acidic
conditions (Lab. Invest. 83;1829, 2003). The present study was designed to clarify the
relation between gastric mucosal TFF2 and Shh under conditions of high pH in vivo, using
histamine H2 receptor-null (H2R-null) mice as a model of impaired parietal cell phenotype
and reduced gastric acid secretion. Methods. H2R-null mice and wild-type (WT) mice aged
10 and 63 weeks were examined. The surface gastric mucosal pH was measured. Gastric
Shh mRNA expression was examined by quantitative RT-PCR. In-situ hybridization (ISH) was
performed to detect the localization of Shh mRNA in gastric mucosa. Immunohistochemistry
against TFF2, Shh and gland-cell-specific markers was also performed. Results. Both the
10-week- and 63-week-old H2R-null mice exhibited higher gastric pH than WT mice of
corresponding age. The expression level of Shh mRNA was lower in the H2R-null mice than
in the WT mice (10 weeks: 0.8±0.06 in the WT mice vs. 0.5±0.06 in the H2R-null mice;
p<0.01; 63 weeks: 0.9±0.09 in the WT mice vs. 0.5±0.02 in the H2R-null mice; p<0.05).
ISH revealed strong Shh mRNA expression at the base of the fundic glands in the WT mice,
mainly in chief cells, while only faint staining was detected in the H2R-null mice. TFF2-
positive mucous cells were restricted to the mid-portion of the fundic glands in the WT
mice, while they were distributed throughout the fundic glands in the H2R-null mice. Mouse
pepsinogen-positive cells, which represent chief cells and were distributed at the base of
the fundic glands in WT mice, showed the shifted localization in the H2R -null mice.
Conclusion. The present study has shown for the first time that the gastric TFF2 expression
pattern also extends in parallel with SPEM lineage in H2R-null mice; while there is no loss
of parietal cells, impaired parietal cell phenotype is noted even in the absence of inflammation.
Taken together, down-regulation of Shh expression in vivo may lead the abnormal differenti-
ation of parietal as well as mucous neck-chief cell linage and TFF2-positive metaplastic
transformation in the gastric fundic gland.
T1691
The Antimicrobial Peptide Cathelicidin Promotes Gastric Ulcer Healing in
Rats
William K. Wu, Ying H. Yang, Emily K. Tai, Helen P. Wong, Emily K. Lam, Vivian Y.
Shin, Chi H. Cho
Cathelicidin, an antimicrobial peptide, has been shown to promote cutaneous wound repair
and reaches high levels in the gastric mucosa during infection and inflammation. We therefore
investigated whether this peptide contributes to gastric ulcer healing in rats. Ulcer induction
increased cathelicidin expression in the gastric mucosa. Further increase in expression of
this peptide by local injection of cathelicidin-encoding plasmid promoted ulcer healing by
enhancing cell proliferation and angiogenesis. Cathelicidin directly stimulated proliferation
of cultured rat gastric epithelial cells (RGM-1), which was abolished by inhibitors of matrix
metalloproteinase (MMP), epidermal growth factor (EGFR), or MAPK/ERK kinase (MEK).
Cathelicidin also increased EGFR and ERK1/2 phosphorylation via a MMP-dependent mech-
anism. Knockdown of transforming growth factor α (TGFα), which is a ligand of EGFR,
by small interfering RNA completely nullified the mitogenic signals evoked by cathelicidin
in RGM-1 cells. These findings suggest that cathelicidin exhibits pro-healing activity in
stomachs through TGFα-dependent transactivation of EGFR and its related signaling pathway
to induce proliferation of gastric epithelial cells.
T1692
Concomitant Activation of the Calcium-Sensing Receptor (CaSR) and the H2
Receptor Results in Inhibition of Acid Secretion in Isolated Rat Gastric
Glands
Stephanie M. Busque, John P. Geibel
INTRODUCTION: Acid secretion in parietal cells occurs via a histamine dependent pathway.
We have previously shown that an alternate acid secretory pathway exists in these cells by
allosteric modification of the CaSR by L-amino acids and extracellular Ca2+. The subsequent
increases in cAMP and intracellular Ca2+ during stimulation of these pathways results in acid
secretion via H+,K+-ATPase activation. To determine the effect of simultaneous stimulation of
both acid secretory pathways, we examined 1) the effect of L-phe or neomycin in the
presence of 2mM Ca2+ ± histamine while monitoring cytosolic pH in isolated rat gastric
glands; 2) the effect of the phosphodiesterase (PDE) inhibitor, IBMX, in histamine and CaSR
activated glands on cytosolic pH. METHODS: Male Sprague-Dawley rats were fasted for 18-
24 hours, anesthetized, and individual gastric glands were hand-dissected from the excised
stomach. Glands were loaded with the pH indicator dye BCECF (10μM), maintained at
37°C, and perfused. Intracellular alkalinization rates (ΔpHi/min) were used as an index of
H+ extrusion or H+,K+-ATPase activity. To induce an acid load, glands were exposed to a
20mM NH4Cl, 0mM Na+ perfusate. The glands were then exposed to 2mM Ca2+, 0mM Na+
solutions containing either 10mM L-phe or 400μM neomycin, both in the presence or
absence of 100μM IBMX and 100μM histamine. RESULTS: Exposure to 10mM L-phe +
2mM Ca2+ resulted in a mean H+ extrusion rate of 0.047±0.003 ΔpHi/min, while 400μM
neomycin + 2mM Ca2+ had a rate of 0.053±0.001 ΔpHi/min. When 100μM histamine was
added to both experimental protocols, the rates were reduced to 0.023±0.001 and
0.035±0.005 ΔpHi/min, respectively. In contrast, addition of 100μM IBMX in the continued
presence of histamine, 2mM Ca2+, and L-phe or neomycin led to enhanced H+ extrusion
rates of 0.036±0.007 and 0.05±0.005 ΔpHi/min, respectively. CONCLUSIONS: These data
suggest that: 1) the concomitant activation of the CaSR and histamine pathways result in a
down-regulation of acid secretion. 2) down-regulation of acid secretion occurs via PDE
activation. Our data demonstrate that activation of the CaSR in the continued presence of
histamine results in a reduction in cAMP-associated acid secretion due to PDE activation.
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T1693
Food Intake Dependent Expression of Mucosal Orexin Receptors Regulates
Small Intestinal Secretion in Rats
Magnus Bengtsson, Kari Makela, Markus Sjoblom, Sanna Uotila, Karl Akerman, Karl-
Heinz Herzig, Gunnar Flemstrom
BACKGROUND & AIM: The presence of orexins in intestinal enteroendocrine cells suggests
a role of these orexogenic peptides as regulators of small intestinal secretion, and recent
studies showed that low doses of orexin-A markedly increase mucosal electrolyte secretion.
However, short (overnight) fasting abolishes the secretory response and stimulation only
occurs in animals that have continuous access to food. Our aim was to further elucidate
the intestinal secretory action of orexin-A. METHODS: Lewis x Dark Agouti rats were
anesthetized and a 12-mm segment of proximal duodenum with intact blood supply was
cannulated in situ. Mucosal bicarbonate secretion (pH stat) was continuously recorded.
Orexin-A was infused intra-arterially to the duodenum, administered to the central nervous
system by intracerebroventricular infusion, or added to the luminal perfusate. Total RNA
was extracted from duodenal mucosa specimens of fasted and fed animals and reverse
transcripted to cDNA. Expression levels of prepro-orexin (PPO) and orexin receptors 1
(OX1) and 2 (OX2) were measured by quantitative real-time PCR. RESULTS: Intra-arterially
infused orexin-A (240-600 picomoles/kg,h) caused a dose-dependent increase in duodenal
bicarbonate secretion (p < 0.01). The OX1-receptor antagonist SB-33487 (600-6000 picom-
oles/kg,h) had no effect on basal bicarbonate secretion, but abolished the orexin-induced
secretory response. Intracerebroventricular infusion of orexin-A (2 - 20 nanomoles/kg,h)
did not affect the duodenal secretion, indicating a peripheral stimulatory action of the
peptide. Orexin-A added to the luminal perfusate (0.1-100 nmol/L) did not elicit a secretory
response, suggesting basolateral location of OX1. Fasting significantly reduced expression
levels of PPO (p < 0.05) as well as OX1 (p < 0.005) and OX2 (p < 0.005). CONCLUSION:
The secretory response to orexin-A is mediated by OX1-receptors located in the duodenal
mucosa and expression of these receptors is markedly related to food intake. Supported by
the Swedish Research Council and the Finnish Academy.
T1694
Hypophagia and Weight Loss Induced By Trichinella Spiralis Enteritis Are
TNFα-Independent
John Worthington, Richard K. Grencis, John McLaughlin
Background: Enteric inflammation is closely coupled to reduced food intake but the linking
molecular mechanisms are poorly understood, despite their potential clinical significance.
We have recently demonstrated that increased CCK production driven by CD4+ T-lympho-
cytes and IL4/13 contribute to the marked hypophagic response caused by Trichinella
spiralis, a nematode small intestinal infection (McDermott et al, Gut, in press). Food intake
reaches a minimum ~9 days post infection (p.i.), then normalises as the gut expels the
parasites. This model permits a mechanistic study of the mediators responsible for reduced
food intake during gut inflammation. Aim: Since TNFα is pivotal in many gastrointestinal
inflammatory responses, we explored its functional role in the hypophagic response in this
model. Methods: Wild type C57BL/6 (WT) or TNFα receptor knockout (p55/75) adult male
mice were infected by gavage with 300 T. spiralis larvae. Food intake and body weight were
monitored daily. The active role of TNFα in this process was assessed by quantifying worm
expulsion, counting residual intestinal parasites at 20 days p.i. Results: WT mice displayed
a significant fall in food intake: at day 9 p.i., infected mice consumed 1.77+/-0.24 g/mouse
vs naïve 2.94+/-0.04g/mouse (p<0.05). Body weight during infection fell to 90.3+/- 0.8%
of baseline, whilst rising to 108.5+/- 1.7% in naïve WT mice (p<0.001). However TNFα
activity played no role in these effects: infected p55/75 KO mice consumed 1.75+/-0.15 vs
naïve 3.46+/-0.15g/mouse (p<0.05). Body weight declined similarly in infected p55/75 KO
mice, falling to 87.6+/- 1.1% of baseline compared to 104.0+/-1.5% in naïve p55/75 KO
mice (p<0.001). Functional TNFα was however functionally important in the infection, as
demonstrated by the host response to clear parasites. At day 20, WT mice retained 1.5+/-
1.0 larvae, whilst p55/75 KOs retained 18.1+/- 4.5 larvae (p<0.05). Conclusion: although
TNFα contributes strongly to the host response to expel T.spiralis, this key cytokine is not
implicated in the profound hypophagic response and rapid weight loss observed during
small intestinal inflammation in this model.
T1695
Improvement of Anorexia By Rikkunshito Via Increased Ghrelin Secretion
Hiroshi Takeda, Kanji Kato, Takehiko Katsurada, Tatsuya Ohkawara, Tomohisa Hattori,
Masahiro Asaka
Abstract Body: Background/Aim : Rikkunshito (Chinese name Liu-Jun-Zi-Tang), one of the
traditional Japanese medicines, is widely prescribed for patients with chronic hypofunction
of the gastrointestinal tract, including gastric flatulence, anorexia, nausea, and vomiting.
However, the precise mechanism by which rikkunshito improves such dyspeptic symptoms
remains to be determined. To clarify this, we investigated the effect of rikkunshito on an
appetite-stimulating hormone, ghrelin,in CDDP-induced anorexic rats. Methods: To induce
anorexia, male SD rats were intraperitoneally given 2mg/kg of cisplatin(CDDP). Rikkunshito
(500 or 1000mg/kg) was orally given once a day for up to 3 days. Changes in food intake
and body weight were examined every day for 3 days. The plasma level of active ghrelin and
desacyl-ghrelin were measured by ELISA. Results: Treatment of rats with CDDP significantly
suppressed food intake from 17.3±0.9 g/day to 13.0±0.1 g/day (p<0.05). Oral administration
of rikkunshito (1000mg/kg) significantly improved the CDDP-induced reduction of food
intake (from 13.0±0.1 g/day to 15.7±0.6g/day, p<0.05). In the CDDP-treated anorexic rats,
plasma level of active and desacyl ghrelin was significantly decreased at 2 and 24 hours
after the administration of CDDP. The ratio of active to desacyl ghrelin (A/D ratio) was also
significantly reduced. After the oral administration of rikkunshito, the plasma level of active
ghrelin and A/D ratio significantly increased. On the other hand, plasma desacyl ghrelin
level did not changed. Conclusion:These results suggest that rikkunshito improve CDDP-

















#: P <0.05 vs normal by t-test, *:P < 0.05 vs control by Dunnett, The mean±S.E. of 10-
12rats, A/D ratio: plasma active /desacyl ghrelin ratio
T1696
GLP-1(7-36)Amid (GLP-1) Mediates the Ileal Brake in Human
Joerg Schirra, Samera Shakir, Mathias Nicolaus, Juergen Woerle, Burkhard Goeke
Nutrients appearing in the distal intestine induce a delay of upper gastrointestinal transit
and inhibit gastropancreatic secretion. This ‘ileal brake’ is the primary inhibitory feedback
mechanism which control transit and digestion of a meal. The factors mediating this response
are unknown. GLP-1 is a gut hormone postprandially released from intestinal L-cells. The
endocrine effects of GLP-1 are well described, it stimulates insulin and inhibits glucagon.
However, the importance of the predominant presence of L-cells within the lower gut is
not known. As GLP-1 is released by ileal nutrients, it is suggested as a candidate humoral
mediator of the ileal brake. Accordingly, we examined the effects of ileal nutrients on
pancreatic enzyme and gastric acid secretion with and without the specific GLP-1 receptor
antagonist exendin(9-39) (Ex-9). Methods: In 12 healthy volunteers, an amino acid solution
(3 ml/min, 0.6 kcal/min) was continously perfused into the duodenum stimulating pancreatic
enzyme and gastric acid secretion. After 40 min, a mixed liquid meal (90 ml, 44 kcal, starch,
maltose, sodium oleate, lipid) was perfused for 15 min into the ileum (150 cm from the
pylorus) approximating the amount of physiologically unabsorbed nutrients. Gastroduodenal
secretion was sampled in 10-min intervals until 240 min after ileal perfusion and quantified
using double-marker dilution technique. On 2 days in random order, Ex-9 (300 pmol/kg-
1/min-1) or saline were IV infused. The output of gastric acid, amylase and trypsin was
measured. Results: Duodenal amino acids significantly increased the output of gastric acid
and pancreatic enzymes on both study days (p<0.05). Ileal nutrient perfusion induced the
ileal brake by causing a pronounced reduction of endogenously stimulated gastropancreatic
secretion. The latter was markedly inhibited by IV Ex-9 (see table). Conclusions: : Physiolo-
gical amounts of nutrients within the ileum induce a prolonged inhibition of gastric acid
and pancreatic enzyme secretion. As this ‘ileal brake’ is largely prevented by the GLP-1
receptor antagonist, we suggest GLP-1 as mediator of this intestino-gastropancreatic reflex.
We conclude that beside its endocrine action, GLP-1 plays an important role as an enterogas-
trone. This may explain the very high densities of L-cells within the ileum and colon.
(supported by a grant of Deutsche Forschungsgemeinschaft DFG)
mean ± SEM. *:P<0.05 vs saline IV
T1697
Curcumin Inhibits Neurotensin-Mediated Interleukin-8 Production and
Migration in Hct116 Colon Cancer Cells
Xiaofu Wang, B. Mark Evers
Previously, we have shown that the GI hormone, neurotensin (NT), acting through its
native high-affinity receptor (NTR1) and multiple downstream signaling pathways, selectively
stimulates interleukin-8 (IL-8) gene expression and protein secretion in human colon cancer
cells. IL-8, a chemokine regulated by NF-κB and AP-1 transcription factors, is increasingly
recognized as an important factor in tumorigenesis. The purpose of this study was to
determine the effect of curcumin, a natural dietary product, on NT-induced IL-8 production
and cell migration in the human colon cancer cell line, HCT116, which possesses native
NTR1. Methods. HCT116 cells were pretreated with curcumin (5-25 μM) prior to NT (100
nM) treatment. To determine the role of NF-κB activation on NT-mediated IL-8 induction,
HCT116 cells were infected with an adenovirus encoding the super-repressor of IκBα (IκB-
AA) or the control vector encoding GFP; IL-8 mRNA expression and protein secretion were
determined by RNase protection assay and ELISA, respectively. The role of the MEK/ERK
pathway on IL-8 induction was assessed using the MEK/ERK inhibitors, PD98050 and
U0126. AP-1 and NF-κB binding activity was analyzed by gel shift assay. Intracellular
Ca2+ mobilization was measured by fura-2 spectrofluorometry. HCT116 cell migration was
assessed using collagen coated Costar Transwell plates. Results. (i) Curcumin significantly
inhibited NT-induced IL-8 mRNA expression and protein secretion in a dose-dependent
fashion. (ii) NT increased NF-κB and AP-1 DNA-binding activities, but not NFAT binding
activity (another transcription factor that binds to the IL-8 promoter). Overexpression of
the IκBα super-repressor significantly inhibited NT-mediated IL-8 mRNA induction. Both
PD98059 and U0126 blocked NT-stimulated AP-1 binding activity and significantly sup-
pressed IL-8 mRNA induction, but had no effect on NF-κB activation. Curcumin inhibited
both ERK-dependent AP-1 and ERK-independent NF-κB activation. (iii) Curcumin strongly
inhibited NT-activated Ca2+ mobilization in a dose-dependent fashion. (iv) A low dosage of
curcumin (10 μM) blocked NT-induced HCT116 cell migration. Conclusions. NT stimulates
growth of colon cancer cells with NTR1 and increases expression and secretion of IL-8.
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Curcumin inhibited NT-mediated IL-8 production through suppression of NT-induced AP-
1 and NF-κB activation as well as Ca2+ mobilization. Moreover, curcumin blocked NT-
induced HCT116 cell migration. The overall inhibitory effects of curcumin on hormone-
mediated IL-8 induction suggests that this agent may be useful therapy for the treatment
of certain colon cancers.
T1698
Different Expression of 5-Ht4 Receptor (5-HT4R) Transcripts Correlates with
the Functional Responses of Tegaserod On Chloride/Water Secretion in the
Human Ileum and Colon in Vitro
Moriko Ito, Eckhard Weber, Christian T. Hamel, Mario Bernhard, Stephan Marcaletti,
Ursula Mueller, Frederic Bassilana, Hans-Juergen Pfannkuche
BACKGROUND. Tegaserod, a 5-HT4R agonist, has been shown to stimulate chloride secre-
tion in the rat colon, suggesting a 5-HT4R-mediated modulation of intestinal fluid secretion
by the drug in men. Our investigations aimed (i) to determine the expression profile of 5-
HT4R transcripts and (ii) to demonstrate their function in 5-HT4R-mediated secretion in
human ileum and colon preparations. METHODS. Specimens of ileum (n=6) and colon (n=
5) were obtained from patients undergoing bowel resection for colon carcinoma (6m/5f,
47-83 years). Mucosa/submucosa sheets, obtained by micro-dissection, were examined in
parallel with respect to 5-HT4R mRNA expression and 5-HT4R-mediated secretion. Expres-
sion: RNA was extracted from tissues using standard methods and QRT-PCR was performed
for universal 5-HT4R mRNA and 5-HT4R splice variant mRNAs (a) (b) (c). In addition,
marker gene mRNAs specific for mucosa (CDX1) and muscle (desmin) were quantified.
House keeping genes, ubiquitin C (UBC) and β-2-microglobulin(β-2-MG) were used for
normalization. Secretion: Mucosa/submucosa sheets were mounted in Ussing chambers and
the effects of 5-HT4R agonists, tegaserod (1nM-10µM) and SDZ216-454 (0.1nM-1µM), on
chloride secretion were investigated. RESULTS. Expression: In ileum (I), universal 5-HT4R
mRNA was 3-fold more abundant than in colon (C) (I: 3.1±0.7, n=6; C: 0.9± 0.2, n=5,
relative to β-2-MG, mean±SEM, P=0.011, ANOVA). In both ileum and colon, splice variant
(b) was the predominant splice variant, higher (P<0.001) in ileum than in colon (I: (a) 0.01,
(b) 0.06, (c) 0.02, n=6; C: (a) 0.004, (b) 0.035, (c) 0.012, n=5, relative to UBC). The overall
expression ratios of splice variants (a), (b) and (c) were similar in ileum and colon (10:70:20).
Whereas CDX1 was expressed in mucosa/submucosa preparations, desmin was not. Secretion:
Tegaserod (T) and SDZ216-454 (S) stimulated chloride secretion in a concentration depend-
ent manner in ileum sheets reflected by increases in short-circuit currents (EC50(T)=
92±27nM, Emax(T)=41.1±5.8µA/cm2; EC50(S)=19±11nM, Emax(S)=85±31µA/cm2, n=6).
In contrast, both 5-HT4R agonists did not significantly alter baseline secretion in colon
sheets (Emax(T)=6.2±5.1µA/cm2, Emax(S)=2.0±1.1µA/cm2, n=5). CONCLUSIONS. The
study provides evidence for a higher 5-HT4R expression in the mucosa/submucosa of human
ileum than colon. The differential expression profile may be responsible for the differences
observed with respect to 5-HT4R-mediated chloride secretion. Our studies demonstrate that
tegaserod can act as a stimulus of intestinal fluid secretion in the human intestine.
T1699
Pharmacological Characterization of Human and Guinea Pig Opiate Receptors
M.C. O'Keefe, Elad Kaufman, Courtney Gee, Ngoc Mai, Jacqueline Smith, David Beattie,
Ross G. Vickery
Management of chronic pain with morphine and other opiates is associated with adverse
effects such as nausea, vomiting and debilitating bowel dysfunction (opioid-induced bowel
dysfunction, OBD) as a result of persistent activation of peripheral opioid receptors in
the gastrointestinal tract. The peripherally-restricted opioid antagonists, methylnaltrexone
(MNTX) and alvimopan, are currently undergoing clinical evaluation for the treatment of OBD
and post-operative ileus. In the present study, a detailed comparison of the pharmacological
properties of a panel of opioid antagonists, including MNTX, alvimopan and ADL 08-0011,
the active metabolite of alvimopan, at human and guinea pig recombinant opioid receptors
was undertaken using conventional [3H]-diprenorphine radioligand binding, guanine nucle-
otide exchange and adenylyl cyclase inhibition assays. The pKi values for MNTX for human
mu (hMOP), delta (hDOP) and guinea pig kappa (gpKOP) opioid receptors were 8.0±0.1,
6.2±0.1 and 7.5±0.1 (mean+sd; n>11), respectively. Alvimopan and ADL 08-0011 demon-
strated up to 100-fold higher affinity, with pKi values at hMOP, hDOP and gpKOP of
9.6±0.1, 8.6±0.2 and 8.3±0.1 for alvimopan and 9.6±0.2, 7.8±0.1 and 7.5±0.1 for ADL 08-
0011, respectively (n>6). To evaluate mu opioid receptor activation, binding of europium-
labeled GTP to membranes expressing the hMOP receptor was monitored. Relative to the
full agonist DAMGO, a range of intrinsic activity (IA) values were obtained for compounds
reported to be antagonists, including nalorphine (59±9%), naloxone (13±2%) and MNTX
(28±6%), whereas alvimopan and ADL 08-0011 demonstrated negative IA values under
these assay conditions (-7±9% and -8±2%, respectively) (mean+sd, n>12). Nalorphine,
naloxone and MNTX also behaved as partial agonists with respect to inhibition of forskolin
(3μM)-stimulated adenylyl cyclase, with IA values of 53%, 11% and 43%, respectively.
MNTX, alvimopan and ADL 08-0011 antagonized endomorphin-1-mediated reductions in
electrical field stimulation (EFS)-evoked ileal contractions (pA2 values of 7.7, 9.6, and 9.4,
respectively, n=3). For all compounds examined, there was good correlation between the
pKi values for the hMOP opioid receptor and native gp ileal receptors (r2=0.99). The clinical
significance of the distinct pharmacological profiles of MNTX and alvimopan remains to
be determined.
T1701
Tegaserod Stimulates 5-Ht4 Receptor (5-HT4R)-Mediated Epithelial Chloride/
Water Secretion Through cAMP/PKA Activation But Not Through cAMP/Epac
Or Ca2+-Dependent Signaling in the Rat Colon in Vitro
Eckhard Weber, Mario Bernhard, Hans-Juergen Pfannkuche
BACKGROUND. Tegaserod, a 5-HT4R agonist, has been demonstrated to stimulate intestinal
chloride/water secretion, presumably by coupling with Gs protein and thus activation of
adenylate cyclase. The present study aimed at the elucidation of downstream signaling
pathways potentially involved in epithelial electrolyte secretion, namely protein kinase A
(PKA), EPAC (exchange protein directly activated by cAMP) and Ca2+-dependent processes.
METHODS. Mucosa-submucosa preparations of rat colon (male Wistar rats, 230-470g) were
mounted in Ussing chambers. Following equilibration, epithelial chloride secretion was
triggered with tegaserod (10µM). Signaling pathways were studied by subsequent blockade
of PKA (H-89 or 8-Rp-cAMPS, 50µM) or cAMP/PKA-activated Cl- and K+ channels (NPPB,
100µM, and 293B, 1µM, respectively). Due to the lack of EPAC inhibitors, effects of the
EPAC ligand, 8-pCPT-2’-O-Me-cAMP (0.1-100µM), were studied in the presence and absence
of tegaserod (10µM), H-89 and 8-Rp-cAMPS (50µM). The potential involvement of Ca2+-
dependent pathways was investigated following blockade of PKC (bisindolylmaleimide -
BIM, 0.1µM) and large conductance Ca2+-activated K+-channels (charybdotoxin, 0.1µM).
RESULTS. Tegaserod induced sustained chloride secretion reflected by short-circuit currents
of 48.2±18.5µA/cm2 (mean±SEM, n=9). Inhibition of PKA using H-89 and 8-Rp-cAMPS
significantly reduced tegaserod-mediated secretion by 66.9±16.8% and 73.5±10.3%, respect-
ively (n=4-8, P<0.05, ANOVA). Blockade of cAMP/PKA-activated Cl- and K+ channels
virtually abolished secretory responses to tegaserod (NPPB: 95.4±4.6%; 293B: 91.0±5.3%
inhibition, n=6). The selective EPAC ligand, 8-pCPT-2’-O-Me-cAMP, concentration-depend-
ently increased chloride secretion (EC50=85±40µM, Emax=14.0±5.5µA/cm2, n=5). H-89
and 8-Rp-cAMPS alone or in combination with tegaserod did not alter, i.e. the latter did
not cause leftward-shifts of the 8-pCPT-2’-O-Me-cAMP concentration-response curves (mean
EC50=75±30µM, mean Emax=16.5±4.1µA/cm2, n=5). Blockade of PKC and Ca2+-dependent
K+-channels did not alter tegaserod-induced chloride secretion either (BIM: 3.8±10.9%;
charybdotoxin: 4.2±7.5% difference to control, n=4-6). CONCLUSIONS. The data suggest
that tegaserod stimulates intestinal chloride/water secretion via activation of cAMP/PKA
signaling in naive epithelium of the rat colon. EPAC does not seem to be involved in
tegaserod-mediated secretory effects. The complete blockade of tegaserod-induced secretion
by Cl- and K+ channel blockers, however, only partial inhibition by PKA blockers, suggests
that additional signaling pathways are involved in 5-HT4R-mediated intestinal electrolyte
secretion.
T1702
Tonic Inhibitory Influence of the Vagus in Chronic Experimental Colitis
Jean-Eric Ghia, Patricia Blennerhassett, Hari K. Ondiveeran, Elena F. Verdu, Stephen M.
Collins
Background/Aim: Previously we showed that the parasympathetic nervous system plays a
counter inflammatory role in acute DSS colitis. As parasympathetic dysfunction has been
identified in inflammatory bowel disease (IBD), we hypothesize that this may promote
inflammation in this disease. To address this, we have examined whether parasympathetic
nerves provide a tonic inhibitory influence in a chronic model of experimental colitis.
Methods: C57BL/6 mice received 3, 2, 2 % dextran sulfate sodium (DSS) in drinking water
for 3 cycles during 5 days with 11 days of rest between each cycle. Control mice received
normal drinking water. Bilateral truncal sub-diaphragmatic vagotomy plus pyloroplasty was
performed 10 days before colitis induction. Sham vagotomized mice served as controls.
After recovery, integrity of vagotomy was assessed by the sulfated cholecystokinin (CCK 8)
satiety test. Disease severity index was evaluated daily after induction of colitis. At sacrifice,
disease severity and inflammation were evaluated clinically and histologically. Myeloperoxid-
ase activity (MPO) and colonic cytokine levels were determined. Results: CCK8 decreased
food intake in sham operated but not in vagotomized mice, thus verifying the functional
integrity of the vagotomy. After the 1st DSS cycle (16 days), vagotomized mice exhibited
an accelerated onset and increased severity of clinical disease as assessed by loose stools,
weight loss and rectal bleeding. Vagotomy also increased the severity at the end of the 2nd
cycle (32 days). After the third cycle (62 days), no macroscopic deterioration was seen in
vagotomized mice. However, the histological score was significantly increased at 62 days
following DSS administration compared to controls (p<0.05). In addition, MPO activity
increased from 1.6±0.4 in DSS-sham operated to 3.9±0.7 U/mg/tissue in DSS-vagotomized
mice (p<0.05) and colonic tissue levels of IL-1b, IL-6, IL-18, INF-g and TNF-a,but not IL-
4, were significantly increased in vagotomized mice compared to sham mice that received
DSS. In control mice (without colitis) vagotomy per se did not affect any inflammatory
marker. Conclusions: These results support the hypothesis that the vagus nerve modulates
intestinal inflammation not only acutely but also in a chronic murine model of colitis.
Identification of the molecular mechanism underlying the tonic protective role of parasym-
pathetic nerves may lead to novel therapeutic targets in IBD.
T1703
Circulating Levels of Leptin, Adiponectin, Resistin and Ghrelin in
Inflammatory Bowel Diseases
Konstantinos Karmiris, Ioannis Koutroubakis, Costas Xidakis, Maria Polychronaki,
Theodora Voudouri, Elias A. Kouroumalis
Background: There is evidence that adipocytokines play an important role in metabolism
and in inflammation. Since human metabolism dramatically changes in inflammatory bowel
disease (IBD) and chronic inflammation is the hallmark of the disease, we studied serum
levels of leptin, adiponectin, resistin and ghrelin in patients with ulcerative colitis (UC) and
Crohn’s disease (CD) in comparison with healthy controls (HC). Methods: Leptin, adiponec-
tin, resistin and ghrelin serum levels were measured in 100 IBD patients (46 UC and 54
CD) and in 60-matched HC using commercially available enzyme-linked immunosorbent
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assays (ELISA). The ghrelin ELISA detected the active form of the hormone. Leptin, adiponec-
tin, resistin and ghrelin levels were correlated with disease activity, type, localization and
treatment. Results: Mean serum leptin levels were 10.6±2.0 ng/ml in UC patients, 12.5±2.6
ng/ml in CD patients and 15.0±1.8 ng/ml in HC (P=0.01). UC patients had significantly
lower leptin levels than HC (P<0.05). CD patients had lower but not significantly different
leptin levels compared with the HC. Mean serum adiponectin levels were 9514.8±787.8
ng/ml in UC patients, 7651.1±613ng/ml in CD patients and 7270.6±559.4 ng/ml in HC
(P=0.05). Only UC patients had significantly higher adiponectin levels than HC (P=0.02).
Mean serum resistin levels were 21.2±2.2 ng/ml in UC patients, 18.7±1.6ng/ml in CD
patients and 11.8±0.6 ng/ml in HC (P=0.0002). Βoth UC and CD patients had significantly
higher resistin levels than HC (P<0.01). Mean serum ghrelin levels were 48.2±4.2 pg/ml in
UC patients, 49.4±4.6pg/ml in CD patients and 14.8±3.0 pg/ml in HC (P<0.0001). Both
UC and CD patients had significantly higher ghrelin levels than HC (P<0.001). Mean serum
level of ghrelin was significantly higher in male (55.0 pg/ml) compared to female IBD patients
(40.3 pg/ml) (P=0.02). No significant correlation was found with CRP levels, clinical indices
of activity, disease localization, disease type (stenotic versus non stenotic), years of diagnosis
(early versus late disease), smoking habits and the current use of medications. Only serum
ghrelin was significantly higher in ileal compared to colonic CD (P=0.04). Patients with BMI
<25 had significantly lower serum leptin levels (6.8 ng/ml) compared to patients with BMI
≧25 (18.8 ng/ml) (P=0.004). Conclusions: Serum levels of adiponectin, resistin and ghrelin
are increased whereas serum levels of leptin are decreased in patients with IBD. This observed
dysregulation of protein secretion by adipose tissue may play an important role in the disease
pathogenesis. Further studies are needed to elucidate the role of adipocytokines in IBD.
T1704
Down-Regulation of Granulocyte Colony-Stimulating Factor Receptors By the
Condition of Iron Imbalance in Myelomonoblastic THP-1 Cells
Sang Wook Kim, In Hee Kim, Seong Hun Kim, Seung Ok Lee, Soo Teik Lee, Dae Ghon
Kim, Woo Sung Moon, Geom Seog Seo, Yong Sung Kim, Chang Soo Choi, Suck Chei
Choi, Eun Young Choi, Chang Duk Jun
Granulocyte colony-stimulating factor receptor (G-CSFR) is primarily expressed in immature
myeloid cells and mature neutrophils and transmits G-CSF signal for proliferation, differenti-
ation, and survival of macrophages, neutrophils, and their precursors. G-CSFR, as well as
G-CSF, expression is strictly controlled under steady-state and stress environments. In the
present study, we report that iron chelator selectively down-regulates G-CSFR in both human
myelomonoblastic THP-1 cells and peripheral blood mononuclear cells (PBMCs). Incubation
of THP-1 cells with deferoxamine (DFO), an iron chelator, significantly down-regulated
levels of G-CSFR mRNA and its protein and this was overcome by addition with ferric
citrate (FC). Interestingly, FC alone also induced decrease of G-CSFR at even low concentra-
tions, implying that conditions caused by either iron depletion or iron overload may influence
expression of G-CSFR in monocytic cells. Treatment with DFO significantly decreased
intracellular reduced glutathione (GSH) levels. However, restoration of GSH level by N-
acetyl-cysteine (NAC), a glutathione precursor, showed little effect on G-CSFR expression,
implying that down-regulation of G-CSFR expression by DFO is not likely due to oxidative
stress. The signal transduction studies showed activation of ERK1/2 and p38 MAP kinases
in response to DFO. Particularly, inhibition of ERK1/2 recovered the down-regulated G-
CSFR, suggesting that the DFO-activated ERK1/2 may contribute to the suppression of G-
CSFR expression. In conclusion, the present results demonstrate that conditions caused by
iron imbalance may act as a regulator of G-CSFR expression in myeloid cells, thereby altering
various cellular responses mediated by G-CSF.
T1705
PGE2 Stimulates Neurotensin Secretion and Gene Expression in the Human
Endocrine Cell Line Bon
J.N. Li, Kathleen O'Connor, Xiaofu Wang, Courtney M. Townsend, B. Mark Evers
Neurotensin (NT), a gut peptide localized predominantly to the small bowel, plays an
important role in gastrointestinal growth and colonic inflammation. Previously, we have
shown that forskolin (FSK), an agent that increases cAMP levels, stimulated NT secretion
in a novel human endocrine cell line BON, which produces and secretes NT peptide.
Prostaglandin E2 (PGE2), a product of arachidonate metabolism and a potent mediator of
inflammation, exerts its biological effects via cAMP/PKA and PLC/PKC pathways by binding
to its receptors, EP2/4 and EP1, respectively. The purpose of this study was to define the
role of PGE2 on NT secretion and gene expression. METHODS. (i) First, the presence of
PGE2 receptors in BON cells was determined by RT-PCR. To delineate the role of PGE2 on
NT secretion, cells were treated with varying doses of PGE2 for 1 h or PGE2 (1 μM) over
a time course. NT release was measured by a NT EIA kit; (ii) to determine involvement of
PKA or PKC, BON cells were pre-treated with PKA inhibitors, H89 and PKI, or transfected
with siRNA to PKC-α, -δ, -ε or -η; (iii) to determine if PGE2 regulates NT gene expression,
BON cells were treated with PGE2 for 24 h and NT mRNA analyzed by real time PCR. In
addition, human NT reporter plasmids containing varying lengths of the NT promoter or
the empty vector (pXP1) were transfected into BON cells and treated with PGE2 or vehicle
(control) for 24 h; luciferase activity was measured. RESULTS. (i) EP1, EP2 and EP4
receptors are expressed in BON cells, and their agonists induced NT release. Furthermore,
NT secretion from BON cells was significantly up-regulated by PGE2 in a dose- and time-
dependent fashion. (ii) PGE2-stimulated NT release was significantly suppressed by both
H89 and PKI, suggesting the involvement of cAMP/PKA pathway downstream of EP2/4. In
addition, PKC-ε siRNA significantly decreased NT secretion from BON cells treated with
PGE2, suggesting involvement of PLC/PKC pathway downstream of EP1. (iii) NT mRNA
expression was increased ~2-fold by PGE2. Moreover, transfection of NT promoter constructs
into BON cells, and treatment with PGE2 significantly induced NT promoter activity com-
pared with vehicle treatment. CONCLUSIONS. We demonstrate that PGE2 regulates NT
secretion and gene expression in BON cells. Furthermore, we showed that PGE2 regulates
NT secretion by both cAMP/PKA and PLC/PKC-dependent pathways. Since both PGE2 and

















expression and protein release may play an important role in gut inflammation and may
represent a target for the treatment of inflammatory diseases.
T1706
Prostaglandin E2 Induces IL-1α Via Both Transcriptional and
Posttranscriptional Mechanisms
Jinyi Shao, Hongmiao Sheng
Interleukin-1 (IL-1α and IL-1β) plays central roles in immune and inflammatory responses
through stimulating the expression of large number of genes that participate in immune
reactivity and inflammation. Cyclooxygenase-2 (COX-2) is an IL-1 target gene and can be
induced by IL-1 exposure. COX-2 derived prostaglandin E2 (PGE2) is thought to be an
important mediator of IL-1 pro-inflammatory actions. In the present study, we demonstrate
a positive feedback between the IL-1 signaling system and the PGE2 signaling pathway.
PGE2 has been shown to modulate a number of signaling pathways and gene expression.
Targeted microarray demonstrated that PGE2 specifically induced the expression of IL-1α.
Exposure to PGE2 rapidly increased the levels of IL-1α mRNA and the production of IL-
1α protein in colon cancer LS-174T cells. Transient transfection with the IL-1α promoter
construct showed that PGE2 treatment modestly increased IL-1α transcription. Therefore,
we further determined whether PGE2 altered the stability of IL-1α mRNA. LS-174T cells
were treated with PGE2 and new transcription was blocked by addition of DRB (5,6,-
dichlorobenzimidazole riboside). The decay rate of IL-1α mRNA was evaluated by real time
PCR. While the half-life of IL-1αmRNA in untreated LS-174T cells was ~2 h, PGE2 treatment
significantly stabilized IL-1α mRNA extending the half-life to ~4.5 h. To determine the role
of the 3’ untranslated region (3’UTR) of IL-1α mRNA in PGE2 stabilization of IL-1α mRNA,
we constructed a luciferase reporter vector (pCMV-Luc-3’UTR), in which luciferase cDNA
was under the control of a CMV promoter and followed by the 3’UTR of IL-1α mRNA
including class II AU-rich elements. pCMV-Luc-3’UTR was transiently introduced into LS-
174T cells, and the cells were treated with vehicle or PGE2. The presence of PGE2 increased
the luciferase activity ~3-fold compared to the cells treated with vehicle, suggesting that
PGE2 stabilized luciferase mRNA through the 3’UTR of IL-1α mRNA. Our results provide
additional insights to the understanding of intestinal inflammation and suggest that while
IL-1α exerts pro-inflammatory effects to the intestinal epithelium through induction of COX-
2, which derived PGE2 may, in turn, further increase the expression of IL-1α through
stabilizing IL-1α mRNA.
T1707
Gastrin Induces Leukocyte Adhesion to Human Endothelial Cells Through
CCK-B/Gastrin Receptors
Sales Ibiza, Angeles Alvarez, Maria D. Barrachina, Carlos Hernandez, Irene Diez, Juan V.
Esplugues, Sara Calatayud
Exogenous gastrin induces leukocyte / endothelial cell interactions in rat mesenteric venules
through the CCK-B/gastrin receptor (Gastroenterology, 128: A591), and a recent study
indicate that gastrin acts on human endotelial cells increasing the expression of leukocyte
adhesion molecules and inducing angiogenesis (Clin Cancer Res 2004, 10:8250). The aim
of the present study was to analyze whether gastrin acts on human endothelial cells to
induce leukocyte / endothelial cell adhesion. Methods: The interaction between gastrin and
human umbilical vein endothelial cells (HUVEC) was detected by measuring the binding
of a fluorescently labeled gastrin derivative (rhodamine green heptagastrin, RG-7P). HUVEC
were incubated with RG-7P (10-7M) for 30 min in the presence or absence of non-labeled
gastrin (10-8-10-5M) or the CCK-B/gastrin receptor antagonist L-365,260 (10-9-10-6M).
Adhesion of human monocytic cells (U-937) to HUVEC was analyzed in vitro in static
conditions. HUVEC were incubated with vehicle or different concentrations of gastrin for
1 h and washed afterwards. A suspension of calcein-labeled U-937 cells was then dropped
over these HUVEC monolayers and, 30 min later, the non-adherent cells were removed.
The proportion of U-937 cells adhered was calculated by measuring the fluorescence emitted
by these remaining cells. In some cases, HUVECs were pretreated with the CCK-B/gastrin
receptor antagonist L-365,260 (10-7M). Results: RG-7P interacted with HUVEC through
the CCK-B/gastrin receptors since the fluorescent signal emitted by the HUVEC-bound
compound was significantly reduced by co-treatment with either non-labeled gastrin or the
antagonist L-365,260 in a concentration-dependent manner. Treatment of HUVECs with
gastrin (10-11M, 10-10M and 10-9M) induced significant increases in the adhesion of U-
937 cells (113±3%; 125±3%*; and 126±5%* of control response, respectively. * P<0.05 vs
control). This pro-adhesive effect of gastrin was partially prevented by pretreatment with
L-365,260: 97±8%, 106±4%#, 108±5%# of control response, respectively. # P<0.05 vs
respective vehicle-treated group). Conclusions: Gastrin increases the adhesion of monocytic
leukocytes to human endothelial cells through the activation of endothelial CCK-B/gastrin
receptors. These results suggest that gastrin can exert a pro-inflammatory activity in humans.
T1708
Proliferative and Antiapoptotic Effects of Progastrin Peptides Are Attenuated
On Down-Regulation of Nf-κB Expression in AR42J Cells
William Rengifo-Cam, Sanjeev Choudhary, Shahid Umar, Pomila Singh
Background: Progastrin (PG) exerts proliferative and anti-apoptotic effects on pancreatic and
colon cancer cells. We previously reported that Src was required for mediating proliferative
effects while PI3K/Akt and p38/p44 MAP kinases were required for mediating anti-apoptotic
effects of PG (DDW 2005). Aim: To examine the role of NF-κB in mediating the growth
effects of PG on AR42J rat pancreatic cancer cells. Methods: Routine methods were used
for all the assays in these studies. Results: AR42J cells exposed to 0.1nM PG resulted in
IκBα phosphorylation and degradation followed by nuclear translocation of p65/Rel A.
EMSA revealed an inducible band in response to PG which increased significantly in a
biphasic manner peaking at 30 min and 6 hours. When super shift assays were performed
with antibodies against Rel A/p65, p50 and c-Rel both Rel A/p65 and p50 antibodies exhibited
T : 89386$$CH2
05-04-06 23:18:30 Page 546Layout: 89386B : e
A-546AGA Abstracts
super shifting of PG-inducible band while non-immune IgG and c-Rel antibodies failed to
do so suggesting presence of p50/p65 as predominant heterodimer after PG treatment.
Activation of NF-κB was further confirmed by an ELISA-based -reporter assay. Significant
inhibition of this activity in presence of NF-κB Essential Modulator (NEMO) peptide,
established the specificity of the response. Mechanistically, 0.1nM PG increased phosphoryl-
ation of p65 subunit at Ser 536 by ~5.0 fold (n=3). Thereafter, involvement of NF-κB
activation in mediating the biological effects of PG was elucidated through p65/Rel A siRNA.
Cells treated with randomly designed non-specific siRNA served as control. In control cells,
PG significantly reduced the activation of caspase 3 in response to the pro-apoptotic agent,
camptothecin; inhibition of NF-κB activation by p65 siRNA, resulted in the loss of anti-
apoptotic effects of PG and rescued the loss of activation of caspase 3 by 95%. Interestingly,
while the NEMO peptide decreased the proliferative effects of PG by only 20~30%, p65
siRNA expression decreased this effect by almost 90%, suggesting a possible involvement
of IKK β and IKK γ-independent pathways in PG-induced activation of NF-κB. Conclusions:
1. PG induces both phosphorylation/degradation of IκBα and phosphorylation of p65 subunit
which facilitates NF-κB’s nuclear import. 2. NF-κB activation is mediating both the survival
and proliferative effects of PG. 3. p65 siRNA significantly blocks PG-induced anti-apoptosis
and cellular proliferation and may be a useful tool for treating pancreatic and colon cancers
that are dependent on the growth effects of autocrine PG.
T1709
Morphogenic Protein Epimorphin Rescues Intestinal Epithelium from
Oxidative Stress By the Activation of EGF Receptor-ERK,-Akt Signals
Masahiro Iizuka, Kenji Sasaki, Yohei Hirai, Kenichi Shindo, Shiho Konno, Hiroaki Itou,
Shigetoshi Ohshima, Yasuo Horie, Sumio Watanabe
[Background and Aim] Epimorphin is a mesenchymal protein that regulates morphogenesis
of epithelial cells. Our preliminary study showed that epimorphin might modulate survival
of intestinal epithelial cells (IEC). We conducted this study to elucidate whether epimorphin
prolongs the life span of IEC and modulates cell survival and wound repair of IEC under
oxidative stress condition. [Methods] (1) Rat intestinal epithelial cell line, IEC-6, was cultured
in the absence or presence of epimorphin (10, 20 μg/ml), and the life span of IEC was
assessed. (2) Activation of the signaling proteins was assessed after treatment with epimorphin
using Western Blot. (3) We assessed the function of epimorphin for protecting IEC (IEC-
6 cells and Caco-2 cells) from severe oxidative stress conditions with hydrogen peroxide
by counting dead cells including necrotic and apoptotic cells stained with DAPI, Annexin-
V, Propidium iodide or by measuring lactate dehydrogenase (LDH) level in culture medium.
(4) Finally, we assessed the effect of epimorphin for wound repair of IEC under oxidative
stress condition using wound assays. [Results] (1) The mean life span of IEC-6 cells was
prolonged 1.9 times (p<0.0006) by treatment with epimorphin. (2) We discovered that
epimorphin phosphorylated EGF receptor, and activated both ERK1/2 MAPK and AKT
signaling pathways, and phosphorylated 90RSK and Bad, and induced Bcl-XL and survivin
protein. (4) Hydrogen peroxide (1mM) induced severe cell death (78%) in IEC, but epimor-
phin decreased 67.3% or 79.3 % of apoptosis or necrosis of IEC induced by hydrogen
peroxide (p<0.0001). LDH level in culture medium of IEC increased 17.9 times by treatment
with 100mM of hydrogen peroxide, but an increase in LDH level were dramatically (86.3%)
suppressed by treatment with 20μg/ml of epimorphin (p=0.0039). (4) We performed wound
assays and found that the number of migrated cells in wounded areas decreased 65% by
treatment with 30μM of hydrogen peroxide, but epimorphin 2.5 times increased the number
of migrated cells in wounded areas (p<0.0001). These functions of epimorphin were signific-
antly suppressed by treating IEC with EGF receptor-neutralizing antibody or MEK inhibitor.
[Conclusions] Our study indicates that morphogenic protein epimorphin also protects IEC
from oxidative stress by the activation of EGF receptor-ERK1/2 MAPK and AKT signals,
suggesting novel mesenchymal-epithelial relationship for protection of intestinal epithelia
cells.
T1710
In Human Colon Cancer Cells, Bile Acid-Induced Selective
Autophosphorylation of Epidermal Growth Factor Receptor (EGFR) Tyr992
Activates Post-Receptor Signaling
Kunrong Cheng, Jean-Pierre Raufman
In colon cancer cells conjugated secondary bile acids stimulate transactivation of EGFR,
p44/42 MAP kinase (MAPK) activation and cell proliferation (Biochem. Pharmacol.
2005;70:1035). In H508 human colon cancer cells, inhibition of EGFR kinase activation (2
μM PD168393) or of p44/42 MAPK activation with a MEK inhibitor (25 μM PD980959)
inhibited both bile acid-induced p44/42 MAPK phosphorylation and cell proliferation
(p<0.05). To determine the mechanism whereby bile acid-induced EGFR activation results
in p44/42 MAPK activation, we examined EGFR autophosphorylation. Immunoprecipitation
(IP) of H508 cell lysates with anti-EGFR antibodies was followed by immunoblotting (IB)
with specific antibodies to 5 C-terminal EGFR tyrosine (Y) autophosphorylation sites (Y845,
Y992, Y1045, Y1068, and Y1173). In H508 cells, incubation with deoxycholyltaurine (DCT;
100-300 μM) revealed selective phosphorylation of only Y992 whereas EGF (10 μg/ml)
caused phosphorylation of all 5 EGFR tyrosine residues examined. Adding the EGFR kinase
inhibitor (2 μM PD168393) abolished DCT- and EGF-induced Y992 autophosphorylation.
EGFR Y992 is a high-affinity binding site for SHP2, a phosphatase whose activation is critical
for sustained p44/42 MAPK phosphorylation, and phospholipase-Cγ (PLCγ), an enzyme that
catalyzes phosphoinositol hydrolysis and increases cell [Ca2+], thereby augmenting p44/42
MAPK activation. IB revealed that both DCT (300 μM) and EGF (10 ng/ml) markedly
increased phosphorylation of SHP2 Y542 (not SHP2 Y580). This provided evidence of bile
acid-induced SHP2 activation. Incubation with DCT (300 μM) followed by IP with anti-
EGFR antibodies and IB with antibodies to PLCγ1, revealed a marked increase in the
association of PLCγ with EGFR. This action was mimicked by HB-EGF (0.01 μg/ml), an
EGFR ligand, by matrix metalloproteinase-7 (0.1 μg/ml), an enzyme that releases HB-EGF,
but not with EGF. To determine the importance of bile acid-induced PLCγ activation and
propagation of downstream Ca2+ signaling, intracellular Ca2+ was reduced using two strat-
egies; chelation with BAPTA (25 μM), and incubation with thapsagargin (1 nM) to release
Ca2+ from intracellular stores in the presence of LaCl3 (25 μM) to prevent Ca2+ re-entry.
Both strategies inhibited bile acid-induced p44/42 MAPK activation. Collectively, these
findings provide evidence that bile acid-induced selective autophosphorylation of EGFR
Y992 activates SHP2 and PLCγ. In H508 human colon cancer cells, EGFR kinase-mediated
autophosphorylation of only Y992 in the C-terminal domain appears sufficient and necessary
to propagate downstream signaling and to stimulate maximal bile acid-induced cell prolifera-
tion.
T1711
Cloning and Characterization of Rabbit Rgs4 Full-Length cDNA and Rgs4
Promoter
Wenhui Hu, Fang Li, Karnam S. Murthy
We have recently shown that the pro-inflammatory cytokine, interleukin-1β (IL-1β) induces
up-regulation of RGS4 mRNA and protein expression in rabbit colonic smooth muscle cells
by activating NF-κB. The increase in RGS4 expression is responsible for IL-1β-induced
inhibition of initial Ca2+-dependent contraction. In order to examine the mechanism of up-
regulation of RGS4 expression, it is essential to characterize the gene sequence of rabbit
RGS4. Although the RGS4 cDNA sequence is available in other species, there are no reports
of the cloning of the RGS4 promoter. Aim. To clone the full-length rabbit RGS4 cDNA and
RGS4 promoter in rabbit colonic smooth muscle. Methods. Degenerative RT-PCR and
SMART cDNA 5’- and 3’-RACE were performed to obtain the full-length sequence of rabbit
RGS4. A 1.4 kb sequence including the promoter region and a 50 bp 5’-untranslated region
(UTR) was cloned into pMlu renila luciferase reporter vector by PCR using genomic DNA
from rabbit intestine as template. Results. Only one band of 5’-RACE PCR product was
present, consistent with a single transcript of 2.8 kb in Northern blot analysis of rabbit
colonic smooth muscle cells. There were 5 exons with long 3’-UTR. The 5’-UTR extended
120 bp nucleotides upstream of the RGS4 start codon with an in-frame stop codon, and
shared 93% homology with the 5’-UTR of the longest human RGS4 transcript. Analysis of
the assembled genome of rabbit and comparison with human RGS4 genome identified the
genomic organization of rabbit RGS4 gene. A putative promoter of 1.4 kb containing
consensus binding sites for several potential transcriptional factors important in inflammatory
responses was analyzed. Reporter gene assay showed that the cloned promoter region of RGS4
increased luciferase activity by 8-fold in rabbit smooth muscle cells, 50-fold in HEK293T cells,
and 12-fold in Hela cells. Further analysis by mutagenesis suggested that deletion of the
region containing NF-κB and AP-1 binding sites and core TATA box (P3: -1389 to -816)
eliminated promoter activity, whereas deletion of the distal regions beyond the NF-κB and
AP-1 sites (P2 and P4) enhanced promoter activity. Electrophoretic mobility shift assay
(EMSA) and chromatin immunoprecipitation (ChIP) assay confirmed the presence of NF-
κB and AP-1 binding sites within the proximal region (-247). Conclusion. We report the
first cloning of an RGS4 promoter and the cloning of RGS4 cDNA in the rabbit. The core
promoter region contains binding sites for various transcription factors including NF-κB
and AP-1, and possesses strong enhancer activity in regulating RGS4 transcription in rabbit
colonic smooth muscle cells.
T1712
Glucocorticoids Inhibit T Cell Receptor Signaling via LCK and FYN - A New
Mechanism for An Old Drug
Mark Lowenberg, Joyce Bilderbeek, Auke Verhaar, Jan van Marle, Frank Buttgereit, Maikel
Peppelenbosch, Sander van Deventer, Daan Hommes
BACKGROUND: Glucocorticoids (GCs) form the basis of current IBD treatment and mediate
well-defined genomic effects via the GC-receptor. There is increasing evidence for rapid
nongenomic GC-effects on cellular function which can not be explained by the traditional
mode of GC action. The aim of this study was to define rapid GC effects in CD4+ T
lymphocytes. METHODS: Cells were pretreated for 10 minutes with the synthetic GC
analogue dexamethasone and activated with anti-CD3 and anti-CD28 Abs for 15 minutes.
Cell lysates were used for peptide arrays containing 1176 different kinase consensus substrates
and results were validated with conventional techniques. RESULTS: Peptide array analysis
revealed marked early differences in phosphorylation patterns between GC-treated and non-
GC-treated cells. Suppressed phosphorylation of Lck/Fyn kinase consensus substrates was
seen in lysates prepared from GC treated cells, indicating reduced Lck/Fyn enzymatic
activities, and this was confirmed with in vitro kinase assays. Immunoprecipitation experi-
ments demonstrated GC-induced inhibition of Lck and Fyn recruitment to the T cell receptor
(TCR) complex, an essential step in Lck/Fyn-mediated TCR signaling. Western blot analysis
showed suppressed phosphorylation of a series of downstream Lck/Fyn signaling targets,
including PKB, PKC, ERK, JNK and p38 MAPKs due to short-term GC treatment. Experiments
with a pharmacological GC-receptor ligand (RU486) revealed a GC-receptor dependent
mechanism of reduced Lck/Fyn activity. Finally, parallel experiments conducted following
the application of GCs in healthy individuals confirmed suppression of Lck and Fyn in T
cells within 1 hr in vivo. CONCLUSIONS: This study identifies a nongenomic GC-receptor-
mediated inhibitory mechanism of Lck and Fyn, key-players in TCR signaling, providing a
cellular substrate for rapid GC-induced immunosuppression. We hypothesize that agents
selectively targeting Lck or Fyn could constitute a novel potent immunosuppressive therapy.
T1713
Evidence That Neither CCK1 Nor CCK2/Gastrin Receptors in the Duodenum/
Antrum Are Involved in the Physiological Regulation of the Exocrine Pancreas
in Pigs
Stefan Pierzynowski, Sofia Rengman, Bjorn Westrom
Our recent results - including those presented at actual meetings - indicate the importance
of CCK2 receptors, located in the duodenum and antrum after CCK-33 stimulation, to the
physiological regulation of the exocrine pancreas via short local reflexes in pigs. Since CCK2
receptors were originally identified as gastrin receptors, the question arises whether gastrin,
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might stimulate the pancreas in the same way. Thus the aim of the study was to highlight
and distinguish the role of gastrin from that of CCK in relation to the exocrine pancreas
via the duodenal/antral CCK2 receptors. Materials and methods: Experiments were performed
on 10 pigs (12 ± 3 kg b.wt.) that were surgically fitted with catheters for the administration
of CCK-33 and pentagastrin, in identical molar concentrations, to the local duodenal/antral
arterial circulation and to the general (peripheral) circulation via the jugular vein and for
pancreatic juice collection. During acute experiments in anaesthetised pigs after 2 x 10 min
baseline collections of juice, CCK-33 (n=5) or pentagastrin (n=5) was given as a bolus
injection via the gastric artery at 13 pmol/kg and pancreatic juice was collected at 2 x 5
and 2 x 10 min intervals. The pigs were then given a 30 minute rest period before the
procedure was repeated with injection of the hormones via the jugular vein to the general
circulation at 130 pmol/kg. The pancreatic juice collections were analysed for trypsin activity.
Results: Local injection of the low dose of CCK-33 stimulated the trypsin output from 1 to
20 U/kg/h while injection of low dose pentagastrin had no effect on the trypsin output.
Peripheral administration of the high doses of both hormones, stimulated both the trypsin
outputs from 1 to 25 U/kg/h. In conclusion: pentagastrin, in contrast to CCK-33, did not
stimulate the pancreas secretion via the local short reflex pathway originating in the duo-
denum/antrum. This indicates that the participation of CCK2 receptors sensitive to CCK-
33 in this reflex needs to be reconsidered. The existence of a third type of CCK receptor,
then CCK1 and CCK2/gastrin receptors in the duodenum/antrum, and its participation in
the physiological regulation of exocrine pancreatic regulation must be studied further.
T1714
Proteinase-Activated Receptor-2 (PAR-2) Increases Mucin Exocytosis Via
Multiple Signal Transduction Pathways in Dog Pancreatic Duct Epithelial
Cells (PDEC)
Mean-Hwan Kim, Bo-Hwa Choi, Kyong-Tai Kim, Thomas Sernka, Toan D. Nguyen, Duk-
Su Koh
INTRODUCTION: Proteinase-activated receptor-2 (PAR-2) is activated through cleavage of
its N-terminus by a protease (e.g. trypsin, tryptase) to expose a tethered ligand (activating
peptide, AP). We reported that PAR-2 activation on dog PDEC causes elevation of intracellular
Ca2+ ([Ca2+]i) to activate Cl- and K+ channels (JCI, 1999, 103: 261-269). We now describe
the effects of PAR-2 activation on exocytosis by PDEC and characterize the different signal
transduction pathways responsible for this action. METHODS: Exocytosis of a single PDEC
vesicle was monitored, using carbon fiber amperometry, as the exocytotic release of oxidizable
dopamine, preloaded into intracellular vesicles. [Ca2+]i was measured with single-cell photo-
metry using the Ca2+ sensitive dye, Indo-1, while mucin was measured as acetyl-D-[3H]gluco-
samine incorporated into TCA-precipitable protein. RESULTS: Trypsin (1 μM) and AP (10
µM) increased the average rate of exocytosis in PDEC ~ 6-fold in a biphasic manner: an
early transient peak followed by a steady and sustained increase. Trypsin and AP also
stimulated increases in [Ca2+]i with corresponding biphasic profiles. The early transient
[Ca2+]i increase was independent from extracellular Ca2+ (2 mM) and was resistant to 10
µM LaCl3, an inhibitor of the store-operated Ca2+ channels (SOC); this [Ca2+]i increase most
likely resulted from Ca2+ mobilization from internal stores. In contrast, the subsequent
sustained [Ca2+]i increase was dependent on extracellular Ca2+ and inhibited by LaCl3, it
likely reflected Ca2+ influx through SOC. When a Ca2+ chelator, BAPTA/AM (20 µM), was
used to abolish the [Ca2+]i increase, exocytosis was markedly, but not totally, inhibited.
This residual exocytosis was abolished with 100 nM bis-indolylmaleimide I and 10 µM
calphostin C, specific inhibitors of protein kinase C (PKC), but not with 500 nM bisindolylma-
leimide V, the inactive analogue, or 1 mM Rp-8-Br-cAMPS, an inhibitor of the cAMP-
activated protein kinase. Accordingly, both trypsin and AP stimulated the enzymatic activities
of the α and δ isoforms of PKC, as determined by histone H1 phosphorylation. AP (1 µM)
also stimulated mucin secretion. Consistent with previous localization of PAR-2 to the
basolateral membrane of dog PDEC, luminal application of trypsin to the cell monolayer
did not induce exocytosis. CONCLUSION: In PDEC, PAR-2 activation by trypsin and AP
induced a biphasic [Ca2+]i increase, through early mobilization of Ca2+ from intracellular
stores followed by a sustained influx of Ca2+ through SOC, to stimulate exocytosis. PAR-2
stimulated exocytosis is further partially mediated by PKC. Funded by NIH, VA, KRF,
and POSTECH.
T1715
Attenuation of Proteinase-Activated Receptor-2 (PAR2)-Mediated Inflammation
By Administration of Insulin
Eric Hyun, Steeve Houle, Nathalie Vergnolle
Trypsin, a serine protease, exerts various physiological roles in the body, including inflammat-
ory process, mainly via activation of the G-protein coupled receptor proteinase-activated
receptor-2 (PAR2). In the intestine, PAR2 activation has been reported to lead to inflammation.
Interestingly, trypsin has also been shown to regulate tissue functions, exerting “hormone-
like” activity. Cleavage of insulin receptor (IR) by trypsin results in enhanced tyrosine kinase
activity of the receptor that will no longer bind to insulin. On the other hand, activation
of IR has been shown to decrease the activity of various GPCR proteins. We postulated here
the existence of interaction between PAR2 and IR signaling pathways. To test this hypothesis,
we investigated whether or not administration of insulin would affect PAR2-mediated inflam-
mation in mouse paw and intestine. Basal paw thickness was measured using an electronic
caliper, before, and then every hour for 6 hours after intraplantar injection of saline, SLIGRL-
NH2 (selective PAR2 activating peptide) SLIGRL-NH2 + insulin, SLIGRL-NH2 + inactivated
insulin (boiled), LRGILS-NH2 (control peptide), LRGILS-NH2 + insulin, carrageenan alone
or carrageenan + insulin. The doses of compounds used for paw oedema experiments were
50 μg for SLIGRL-NH2/LRGILS-NH2, 150 pmol for insulin, and 200 μg for carrageenan.
Six hours after the intraplantar injections, mice were sacrificed and myeloperoxidase (MPO)
activity was measured in paw tissues. Additionally, vehicle, SLIGRL-NH2 (100 μg), SLIGRL-
NH2 + insulin (100 μg and 150 pmol, respectively), or LRGILS-NH2 (100 μg) were injected
intralumenally into mouse jejunum and intravital microscopy was performed to assess

















MPO activity in mice injected with SLIGRL-NH2 + insulin were significantly reduced com-
pared to mice injected with SLIGRL-NH2 alone. In contrast, insulin was not able to modulate
the effects of control peptide. Injection of insulin was not able to reduce carrageenan -
induced paw oedema indicating that insulin does not exert general anti-inflammatory proper-
ties. Injection of SLIGRL-NH2 + insulin resulted in significant reduction in both leukocyte
rolling and adhesion along the venule of jejunum compared to mice injected with SLIGRL-
NH2 alone. The insulin-dependent attenuation of PAR2-mediated inflammation was not
observed with inactivated insulin. Thus, this study shows for the first time in vivo that insulin
can modulate PAR2-induced inflammation both in the jejunum and in paw tissues.
T1716
A Novel Mechanism for Inhibition of RHOA By G13-Coupled PAR2 Receptors
in Smooth Muscle Involves PAR2-Mediated Activation of Nf-κB and Release of
the Catalytic Subunit of PKA from Its Scaffolding Protein IκBα
Wimolpak Sriwai, Sunila Mahavadi, Karnam S. Murthy
The protease-activated receptor PAR2 activates RhoA via G13 in smooth muscle. In other
cell types, PAR receptors activate the canonical IKK2/IκBα degradation/NF-κB pathway in
which the NF-κB inhibitor, IκBα, is phosphorylated by IKK2 leading to its degradation via
a proteasomal pathway and resulting in activation of NF-κB. Since IκBα acts as a scaffolding
protein for PKA, and proteasomal degradation of IκBα releases the catalytic subunit of PKA,
we postulated that PAR-activated RhoA could be inhibited via feedback phosphorylation of
Ser188 upon release of the catalytic subunits of PKA from its binding to IκBα. We have
previously shown that phosphorylation of Ser188 by PKA inhibits RhoA activity in smooth
muscle. Aim. To characterize the link between activation of NF-κB by PAR2 and inhibitory
phosphorylation of RhoA by cAMP-independent PKA. Methods. RhoA activation was deter-
mined from the increase in Rho kinase activity. The role of the IKK2/IκBα/NF-κB pathway
in feedback inhibition of RhoA was examined using the IKK2 inhibitor, IKKIV, and the
proteasomal degradation inhibitor MG132, and in cells expressing dominant negative mutants
of IKK2(K44A) or IκBα(S32A/S36A). The role of PKA in feedback inhibition of RhoA
was examined using the PKA inhibitor (myristoylated PKI) and in cells expressing PKA
phosphorylation-site deficient RhoA(S188A). Results. The PAR2 agonist, SLIGRL induced
degradation of IκBα and activation of NF-κB (determined by p65 phosphorylation); the
effects were abolished by the blockade of RhoA activity by Clostridium botulinum C3 exoen-
zyme suggesting that activation of NF-κB was downstream of RhoA. PAR2-stimulated Rho
kinase activity was significantly augmented by PKI, IKKIV or MG132, and in cells expressing
IKK(K44A), IκBα(S32A/S36A) or RhoA(S188A). The results imply that RhoA was inhibited
upon its phosphorylation by PKA at Ser188, and that the pathway involved activation of
the canonical IKK2/IκBα/NF-κB pathway. Conclusion. We have identified a novel pathway
for feedback inhibition of PAR2-stimulated RhoA. The pathway involves activation of the
canonical NF-κB pathway by PAR2 leading to release of the catalytic subunit of PKA from
its binding to IκBα and causing inhibitory phosphorylation of RhoA at Ser188.
T1717
Type-I-Interferon Mediates the Anti-Inflammatory Effects of Cpg Motifs On
Colitic CD4+CD62l+ T-Cells in the SCID-Transfer Model of Colitis
Florian Obermeier, Veit Philip, Ulrike G. Strauch, Nadja Dunger, Juergen Schoelmerich,
Gerhard Rogler, Werner Falk
Introduction: Recently, we and others demonstrated a prophylactic effect of CpG motifs in
experimental colitis. We could further demonstrate that CpG treatment of donor animals
reverses the colitiogenic potential of CD4+CD62L+ cells in the SCID model of colitis. A
very recent report suggests that the protective CpG-Oligodeoxynucleotide (ODN) effect in
an acute model of chemically induced colitis is mediated by CpG-induced Interferon-alpha.
We tested whether IFN-alpha effects are involved in the potent T-cell dependent, protective
effects of CpG-ODN in the SCID transfer model of colitis. Methods: Donor Balb/c mice were
either left untreated or were treated with CpG-ODN i.p. (10µg/d) for 5 days or CpG-
ODN (10µg/d) and rat IgG (100µg/d control) or CpG-ODN (10µg/d) and anti-IFN-alpha
monoclonal antibodies (mAb) (100µg/d). After treatment splenic CD4+CD62L+ cells were
isolated and transferred to SCID recipients which were sacrificed 8 weeks after transfer. The
body weight of the SCID recipients was monitored over 8 weeks and a standard histologic
score (HS) (0-4) considering epithelial damage and the extent of inflammatory infiltration
was used. Furthermore, cytokine secretion from isolated mesenteric lymph node cells (MLC)
was measured by ELISA. Results: At the end of the experiment, SCID recipients which were
not transferred increased their body weight averagely by 22%. Mice which received cells
from untreated donors showed no increase in body weight (untreated: average weight
change: -1%) and developed colitis (HS ± SEM: 3.3 ± 0.2) in contrast to recipients transferred
with cells from CpG-ODN (average weight change: +5%; HS ± sem: 0.7±0.2) or CpG-ODN
+ IgG (average weight change: + 6.5%; HS ± sem: 0.5 ± 0.3 control) treated donors. In
SCID recipients receiving cells from CpG-ODN + anti-IFN-alpha treated mice the CpG-
ODN induced attenuation of colitis was significantly reversed (average weight change: +1.8%;
HS ± sem: 1.7±0.3, p=0.03). This was accompanied by a complete loss of the CpG-ODN-
induced suppression of IL-6 (untreated: 800 ± 30 pg/ml, CpG-ODN + IgG: 66.0 ± 5 pg/
ml; CpG-ODN + anti-IFN-alpha: 934 ± 26 pg/ml) and IFN-g secretion (untreated: 28 ± 3.3
ng/ml, CpG-ODN + IgG: 0.7 ng ± 0.12 ng/ml; CpG-ODN + anti-IFN-alpha: 46 ± 8.5 ng/
ml) by MLCs isolated from SCID recipients. Conclusion: The prophylactic effect of CpG-
ODN in experimental colitis is mediated by CpG-ODN induced IFN-alpha production,
which effectively decreases the colitogenic potential of T-cells in the SCID transfer model
of colitis.
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T1718
Administration of TLR9L Modifies the Pro-Inflammatory Phenotype of Lp-Mdc
to Acquire Anti-Inflammatory Properties
Kazumichi Abe, Jongdae Lee, Carol J. Shen, Ji-Hun Mo, Jose M. Gonzalez-Navajas, Sean
Fine, Eyal Raz
The administration of TLR9L ameliorates DSS-induced colitis via the induction of type 1
IFN. Dendritic cells (DC) are the major source of this cytokine. In this study we investigated
how the administration of TLR9L modulates the composition and the properties of colonic
lamina propria (LP) DC. The administration of TLR9L increased myeloid (M) DC (CD11chigh
CD11b+), but not plasmacytoid DC (CD11clow B220+) population in LP up to 14 days
post-administration. This increase in MDC trafficking was not observed upon TLR2L, TLR3L,
TLR4L or TLR7L administration. The administration of TLR9L enhanced the expression of
CCL4 and CCL20 (DC chemoattractants) as well as GM-CSF (a growth factor of MDC) in
the colonic tissue. LP-MDC in TLR9L-injected mice isolated one week post-injection differed
from LP-MDC isolated one week post-DSS challenge. While TLR9L administration induced
LP-MDC to express high levels of CD40, B7RP-1 and OX40L, LP-MDC isolated from DSS-
challenged mice expressed low levels of CD80 and CD86. Administration of TLR9L to DSS
treated mice resulted in the normalization of the expression levels of CD40, CD80 and
CD86 but not of B7RP-1 and OX40L in LP MDC isolated from these mice. Finally, we
investigated the physiological role of LP-MDC in DSS-induced colitis using the diphtheria
toxin (DT) receptor (DTR)-tg mice. Injection of DT induced the depletion of MDC and
attenuated the severity of colitis in DSS-challenged DTR-tg mice. In contrast, the injection
of DT to TLR9L-treated, DSS challenged mice enhanced the severity of colitis. Collectively,
our results indicate that LP-MDC play an important role in the induction or the inhibition
of colonic inflammation and that the administration of TLR9L modifies the pro-inflammatory
phenotype of LP-MDC to acquire anti-inflammatory properties.
T1719
Expression of Receptor Activator of Nuclear Factor-κB Ligand (RANKL) and
Osteoprotegerin (OPG) in IL-10 -/- and Mdr1a -/- Mouse Models of Colitis
Silvia C. Resta-Lenert, Susan J. Lee
Background: Inflammatory bowel disease (IBD) is associated with osteoporosis and an
increased risk of spontaneous bone fractures. Bone homeostasis is characterized by continuous
remodeling through bone formation and resorption. The goal of the present study was to
determine whether dysregulated bone homeostasis in two mouse models of colitis is attribut-
able to alterations in bone formation, bone resorption, or both. Methods: 12 wk old colitic
IL-10 -/- and mdr1a -/- mice, and wild type (WT) counterparts matched for age and gender
(8-10 mice/group), were tested for femoral length and bone mineral density (BMD), for
serum OPG, RANKL and tartrate-resistant acid phosphatase (TRAP, a marker of osteoclast
activity) levels, and colonic tissue OPG mRNA and protein levels, by dual energy X-ray
densitometry, immunoassays, and Northern and Western blotting, respectively. Results:
Compared to the respective WT, both IL-10- and mdr1a-deficient mice had shorter femurs
(in mm: 12±2 vs 15±1 and 13±1 vs 16±2, respectively; p<0.05), and lower BMD (in mg/
cm2: 53.2±1.1 vs 61.3±0.8 and 49.8±1.5 vs 65.7±0.5, p<0.05 and p<0.01, respectively).
However, serum OPG levels were significantly elevated and RANKL levels decreased only
in mdr1a -/- mice compared to WT counterparts and IL-10 -/- mice (OPG/RANKL ratio:
3.7 vs 1.0 vs 1.2, respectively; p<0.05). OPG levels in supernatants from 24 h colonic tissue
cultures was significantly elevated in mdr1a -/-, but not in IL-10 -/- tissues compared to
the respective WT controls (in ng/ml: 65.7±2.2 vs 18.4±3.2, p<0.001, and 21.8±3.5 vs
18.1±2.1, respectively). OPG mRNA showed an increase only in mdr1a -/- colonic tissue
compared to WT (4.5-fold). Finally, serum TRAP levels were elevated significantly in
mdr1a -/- compared to WT and IL-10 -/- mice (in U/L: 10.5±1.1 vs 5.4±0.5 vs 6.5±1.0,
respectively; p<0.01 and p<0.05). Conclusions: Our data suggest that the mechanisms
underlying bone loss in colitis may correlate to disease pathogenesis, with prevalent alterations
in either bone formation or resorption processes depending on the model examined. Greater
insight into the mechanisms involved in bone homeostasis in the course of chronic inflamma-
tion may provide better guidelines for treatment and prevention of osteoporosis associated
with IBD and other chronic diseases.
T1720
Aquaporin 4 Is Highly Upregulated in Experimental Colitis
Jonathan J. Hansen, R Balfour Sartor
Inflammatory bowel diseases (IBD) are the result of dysregulated immune responses to
commensal enteric bacteria in genetically susceptible hosts. The aberrant responses include
up- or down-regulation of various effector and regulatory molecules on immune, epithelial,
endothelial and mesenchymal cells in the gastrointestinal tract. These phenomena occur in
both human IBD as well as the murine interleukin 10 knockout (IL10-/-) model of TH1-
mediated colitis. While expression levels of individual immunoregulatory molecules have
been studied in IL10-/- mice, no published data exist on genome-wide surveys of differentially
regulated inflammatory markers. Methods: Four wild-type (wt) and four IL10-/- mice born
in germ free conditions were transferred to specific pathogen free conditions for four weeks.
We isolated total RNA and protein from mesenteric lymph nodes (MLN) and various regions
of the intestinal tract and harvested adjacent sections for histologic analysis and explant
culture to measure interleukin 12 (IL-12) secretion. Total RNA from the ceca was analyzed
on microarray of 33,000 murine genes and results were validated using real-time quantitative
PCR, Western blotting, flow cytometry of MLN cells and/or immunofluorescence of frozen
sections. Results: As previously reported, greater histologic inflammation scores were
observed in ceca from the IL10-/- compared to wt mice (2.6±0.7 vs. 0.8 ±0.21, p=0.006).
Similarly, IL-12 secretion from intestinal explants was greater in IL10-/- mice (1424±331
vs. 82±18 pg/50mg tissue, p<0.005). Microarray analysis demonstrated greatest induction
of the following cell surface molecules in IL10-/- mice: aquaporin 4 (Aqp4), Sca-1, MHC
class II, CD7, and CD38 with 24, 14, 12, 9, and 5 fold increase, respectively. We also
observed down regulation of chloride calcium channel activated 3 and claudin 4 in IL10-/-
mice with 5.3 and 4.9 fold decrease, respectively. These findings were validated using
quantitative real-time PCR. In addition, we confirmed the mRNA results at the protein level
with Western blots for Aqp 4 as well as immunofluorescence of frozen intestinal sections
and flow cytometry of MLN cells for MHCII. Conclusion: While the majority of upregulated
cell-surface markers in animals with experimental colitis are immune-related, interestingly
Aqp 4, a membrane water channel gene not known to be associated with immune responses,
was most highly upregulated. This may have implications not only for further elucidating
the pathogenesis of chronic intestinal inflammation, but also for developing novel targeting
strategies to diagnose, manage, and treat IBD and its clinical symptoms.
T1721
Osteopontin-Deficiency Protects Mice from DSS-Induced Colitis
Jian Zhong, Erik R. Eckhardt, Helieh S. Oz, Dennis Bruemmer, Willem J. de Villiers
Background & Aims: Osteopontin (OPN), a secreted glycoprotein that promotes Th1 immune
responses, is involved in several inflammatory conditions. Recently, OPN plasma levels have
been demonstrated to be elevated in patients with Crohn’s disease (CD). Based on this
evidence we investigated in the present study whether OPN deficiency protects mice against
dextran sodium sulfate (DSS)-induced colitis. Methods: Colitis was induced in OPN -/- mice
and matched wildtype Black Swiss control mice by adding 3.5% DSS to their drinking water.
Disease progression was evaluated for 10 days by measuring body weight, stool consistency
and rectal bleeding, colon lengths, histology, and immuno-histochemistry. Levels of the
acute phase protein serum amyloid A (SAA), OPN, the pro-inflammatory cytokines IL-6
and IL-12, and the anti-inflammatory cytokine IL-10 were measured in the serum and, in
case of IL-10 and IL-12, also in supernatants from colonic explants at the end of treatment.
Results: Following DSS treatment, OPN -/- mice exhibited significantly decreased disease
activity compared to wildtype mice, as evidenced by reduced rectal bleeding, weight loss,
and histological intestinal injury (P<0.002). Furthermore, serum levels of SAA and IL-6
increased to a lesser extent (P<0.001), which was also the case for the release of IL-12 by
colonic explants (P<0.01). The release of IL-10 by colonic explants, on the other hand, was
increased (P<0.01). Serum levels of IL-10 and IL-12 were not affected by DSS treatment in
both wildtype and OPN -/- mice. Macrophage infiltration into inflamed colonic tissue was
also markedly attenuated in DSS-treated OPN -/- mice compared to wildtype mice. Conclu-
sion: This study shows that OPN-deficiency significantly protected mice from colitis, by
attenuating the Th1 response and macrophage chemotaxis. OPN may represent a novel
attractive target for pharmacological treatment of inflammatory bowel disease.
T1722
PECAM-1 Is a Key Mediator of Transendothelial Leukocyte Migration in
Experimental Colitis
Emile J. Rijcken, Rudolf Mennigen, Sebastian Schaefer, Mike G. Laukoetter, Christoph
Anthoni, Hans-Ullrich Spiegel, Norbert Senninger, Christian F. Krieglstein
Introduction: Recruitment of circulating leukocytes from the blood stream into the bowel
wall plays a key role for development of the inflammatory infiltrate in inflammatory bowel
disease. After initial adhesion to the vascular endothelium, transendothelial migration into
the submucosa occurs. The cell adhesion molecule PECAM-1 (CD31) is expressed in the
tight junction area of endothelial cells. The aim of this study was to determine the role of
PECAM-1 in leukocyte transmigration and to show whether therapeutic blockade of PECAM-
1 has anti-inflammatory effects in experimental colitis. Methods: Chronic colitis was induced
in female balb/c mice (20-22g) by cyclic oral administration of dextrane sodium sulfate
(DSS) 3% (wt/v). Three groups with each 10 animals were formed. The diseased control
group A received the carrier PBS. Group B served as healthy controls. The treatment group
C received 1 mg/kg anti-PECAM-1 (2H8) i.p. daily starting on day 26. On day 30 leukocyte
adhesion and transendothelial cell migration was measured in the distal colon by intravital
microscopy in N2O/isoflurane anaesthetised mice. Disease Activity Index (DAI) was scored
and degree of inflammation was studied by histology. Statistics: Kruskal-Wallis or Wilcoxon
test where appropriate (P<0.05). Results: Group A showed a marked increase in rolling
(112.9 ± 18.2 vs. 51.3 ± 7.8/mm2/30s), adherent (27.1 ± 11.2 vs. 4.2 ± 1.1/mm2/30s) and
transmigrated leukocytes (404 ± 40.8 vs. 38.8 ± 8.4/mm2/30s) as compared to group B.
The application of the 2H8 antibody reduced leukocyte transmigration (65.8 ± 6.8/mm2/
30s), rolling (112.9 ± 18.2/mm2/30s) and sticking (5.7 ± 0.6/mm2/30s) significantly. Treat-
ment with anti-PECAM-1 diminished DAI (2.8 ± 0.3 vs. 5 ± 0.4 pts.) and histological
inflammation score (15.4 ± 1.5 vs. 23.9 ± 1.2 pts) significantly compared to group A.
Conclusions: Our results demonstrate that PECAM-1 plays a significant role for leukocyte
extravasation through the endothelial barrier of colitic bowel. Blockade of PECAM-1 by
specific antibodies inhibited leukocyte transmigration and resulted in attenuation of inflam-
mation. Since 2H8 specifically inhibits leukocyte extravasation, the reduction of rolling and
sticking leukocytes may be a secondary effect to a reduced activation of inflammatory
cytokines. PECAM-1 should be considered as a novel target for anti-body based treatment
in IBD.
T1723
MUC2-IL-10 Knockout: Double Trouble
Maria Van der Sluis, Janneke Bouma, Anna Velcich, Hans Buller, Alexandra Einerhand,
Johannes van Goudoever, Isabelle van Seuningen, Ingrid Renes
Background & Aims: Expression of mucin MUC2, the structural component of the colonic
mucus layer, is lowered in inflammatory bowel disease. Furthermore, IL10 knockout
(IL10KO) mice, which are known to develop colitis, have reduced Muc2 levels long before
inflammatory infiltrates are present. Our aim was to obtain insight in the role of Muc2 and
IL10 in epithelial protection. Methods: Thereto, Muc2-IL10 double knockout (DKO) mice
were characterized and compared to Muc2 knockout (Muc2KO), IL10KO and their corres-
ponding wild type (WT) littermates. We monitored clinical symptoms, intestinal morphology
and differences in epithelial-specific protein and mRNA levels. Additionally, mRNA levels
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of the pro-inflammatory cytokine tumor necrosis factor-α (TNF-α) in the colonic tissue
were determined. Results: IL10KO mice were indistinguishable form WT mice throughout
this experiment and showed no signs of clinical or microscopical signs of colitis. Muc2-
IL10 DKO mice and Muc2KO mice showed significant growth retardation and clinical signs
of colitis as of 4 and 5 weeks of age, respectively. Furthermore, Muc2-IL10 DKO mice had
a high mortality rate [50% survival, 5 weeks of age] compared to all other types of mice,
of which none died during the experiment. Microscopic analysis of the colon of Muc2KO
showed mucosal thickening, increased proliferation and superficial erosions which was even
more pronounced in Muc2-IL10 DKO mice. Colonic goblet cells in both the Muc2 KO and
Muc2-IL10 DKO mice were negative for Muc2 but Tff3 was still detectable. Furthermore,
TNF-α mRNA was significantly up-regulated in the distal colon of Muc2KO and Muc2-
IL10 DKO mice compared to IL10KO and WT mice. Additionally, TNF-α mRNA levels
were the highest in the Muc2-IL10 DKO mice. Conclusions: Muc2KO mice develop severe
colitis indicating that Muc2 and most likely the mucus layer is essential for mucosal protection
and prevention of colonic inflammation. Muc2-IL10 DKO mice develop colitis which is
more severe in every aspect compared to Muc2KO and IL10KO mice, indicating that in
case of Muc2 deficiency, the anti-inflammatory cytokine IL10 can control epithelial damage,
though to a limited extend.
T1724
B6.129p2-IL10Tm1cgn (IL-10-/-) Mice Infected with Helicobacter Trogontum
Develop Peracute Ulcerative Typhlocolitis While Concurrent Infection with H.
Rodentium May Accelerate Preneoplasia of the Cecal-Colic Junction
Mark Whary, Stephen J. Danon, Yan Feng, Zhongming Ge, Nataliya Sundina, Arlin B.
Rogers, James G. Fox
Helicobacter trogontum is a urease-positive helicobacter first isolated from subclinically infected
rats and is related to H. hepaticus and the ‘H. rappini’ taxon by 16s rRNA analysis. H.
rodentium, a urease-negative murine helicobacter, has only been associated with disease in
SCID mice coinfected with H. bilis. In 3 experiments, H. trogontum infection was evaluated
in B6.129P2-Il10tm1Cgn mice (IL-10-/-) naturally infected with H. rodentium and in helicob-
acter-free IL10-/- and C57BL/6 (B6) mice. IL-10-/- mice naturally infected with H. rodentium
and then dosed by gavage with H. trogontum at 6-8 weeks of age developed morbidity and
severe typhlocolitis within 1 to 6 weeks post infection (PI). Dual infected IL-10-/- male mice
developed severe disease with 10 of 14 mice developing accelerated dysplasia with features
of gastrointestinal intraepithelial neoplasia (GIN) of the cecal-colic junction. Dual infected
female IL-10 -/- mice remained either clinically normal (12 of 16) or developed morbidity
at later time points (n=4) without as severe typhlocolitis or dysplasia. IL-10-/- mice infected
with H. rodentium alone (n=13) had subclinical disease with mild to moderate typhlocolitis.
In a 2nd experiment, male and female helicobacter-free IL10-/- and B6 mice (n=5 per group)
were dosed with H. trogontum and both genders of IL10-/- mice developed severe typhlocolitis
within 4 weeks but lesions did not develop to dysplasia consistent with GIN. B6 mice
colonized with H. trogontum were resistant to disease. IL10-/- male and female mice (n=10
per group) infected with H. trogontum in a subsequent experiment became severely debilitated
by 8 days PI. Clinical dehydration, weight loss and diarrhea were accompanied by severe
ulcerative typhlocolitis characterized by crypt necrosis, crypt abscesses, ulceration of epithe-
lium, submucosal edema and transmural inflammation progressing to serositis. A degenerative
left shift in the hemogram of infected mice suggests sepsis. These results demonstrate that
H. trogontum causes peracute ulcerative typhlocolitis in IL-10-/- mice while concurrent infec-
tion with H. rodentium promotes accelerated dysplasia of the cecal-colic junction, particularly
in male IL-10-/- mice. H. rodentium infection may delay the course of disease attributable to
H. trogontum sufficient to permit proliferation and dysregulation of intestinal epithelial cells
resulting in development of GIN. The accelerated development of dysplasia at the cecal-
colic junction in IL-10-/- mice coinfected with H. rodentium and H. trogontum provides a new
rapid onset model for evaluation of acute severe inflammation and lower bowel tumorigenesis
caused by bacterial pathogens.
T1725
VEGF-a Stimulation of Leukocyte Adhesion to Colonic Microvascular
Endothelium: Implications for Inflammatory Bowel Disease
Steven Goebel, William C. Davis, Marilyn Jennings, Teruna J. Siahaan, Steven Alexander,
Christopher G. Kevil
Inflammatory Bowel Disease (IBD) is a chronic inflammatory disorder characterized by
increased leukocyte recruitment and subsequent tissue damage. An increase in the density
of the microvasculature of the colon during IBD has been suggested, leading to the concept
that angiogenesis may play a pathological role in IBD. Increased tissue and serum levels of
the angiogenic cytokine VEGF-A have been reported in cases of active IBD. Here, we
examine the hypothesis that VEGF-A exerts a pro-inflammatory effect on colon microvascular
endothelium that contributes to colonic inflammation. Leukocyte adhesion to VEGF-A stimu-
lated colon microvascular endothelial cells was examined using a parallel plate hydrodynamic
flow chamber. ICAM-1 adhesion molecule expression on colonic microvascular endothelium
was also determined in response to VEGF-A stimulation, along with characterization of
leukocyte adhesion molecule expression. High dose VEGF-A (50 ng/ml) stimulation increased
neutrophil and T cell adhesion to and decreased rolling velocities on activated endothelium,
whereas low dose VEGF-A (10 ng/ml) was without effect. Colonic endothelium constitutively
expressed ICAM-1, which was significantly increased by treatment with 50 ng/ml VEGF-A
or 10 ng/ml of TNF-alpha but not 10 ng/ml VEGF-A. T cells expressed CD18 and CD11a,
with no expression of CD11b; whereas, neutrophils expressed CD18, CD11a, and CD11b.
Lastly, VEGF-A dependent leukocyte adhesion was found to occur in a CD18 dependent
manner. These results demonstrate that VEGF-A levels found in IBD exerts a pro-inflammat-
ory effect similar to other inflammatory agents and suggests that this cytokine may serve as


















Role of Adiponectin in DSS and TNBS Induced Colitis in Mice
Raja Fayad, Maria Pini, Joseph A. Sennello, Lawrence Chan, Giamila Fantuzzi
Role of adiponectin in DSS and TNBS induced colitis in mice Raja Fayad, Maria Pini, Joseph
A. Sennello, Lawrence Chan, Giamila Fantuzzi Department of Human Nutrition, University
of Illinois at Chicago, Chicago, IL; Department of Medicine, Baylor College of Medicine,
Houston, TX. Adiponectin is a protein produced by adipocytes and is best known for its
role in regulating insulin sensitivity. Adiponectin also displays prominent anti-inflammatory
activities, particularly in the context of atherosclerosis. In Crohn’s disease, adiponectin levels
are elevated in fat wrapping that surrounds inflamed areas of the intestine. Our hypothesis
is that adiponectin regulates intestinal inflammation and epithelial cell proliferation in models
of inflammatory bowel disease (IBD). Methods: Adiponectin KO mice and their WT littermates
in a C57BL6 background received 2% DSS in drinking water for 5 days and regular drinking
water for additional 5 days. A group of KO mice also received daily ip injection of 30
microgram of murine recombinant adiponectin. A clinical score including body weight, fecal
haemoccult and diarrhea was assessed daily for each mouse. To evaluate proliferation of
colonic epithelial cells, 1 mg of BrdU was injected ip 2 h prior to sacrifice and incorporation
analysed by immunohistochemistry. Colon cultures were performed to evaluate local cytokine
production by ELISA. For trinitrobenzene sulfonic acid (TNBS) experiments, mice received
2 mg of TNBS in 50% ethanol intrarectally on days 1 and 7. Parameters evaluated were the
same as reported for the DSS model. Results: Compared to WT mice, adiponectin KO mice
were protected from DSS-induced colitis, as evaluated by clinical and histologic findings.
Increased proliferation of colonic epithelial cells was observed in KO compared to WT mice
receiving DSS. Moreover, colonic MIP-2 and IL 6 levels were markedly reduced in KO
compared to WT mice. Administration of adiponectin to KO mice restored their response
to levels similar to those observed in WT mice, in terms of clinical score, histological findings,
epithelial proliferation and cytokine production. Similar results were obtained using the
TNBS model. Conclusions: Adiponectin KO mice were protected from DSS- and TNBS-
induced colitis, suggesting that adiponectin might play a pro-inflammatory and anti-prolifer-
ative role in IBD. To our best knowledge this is the first report of a pro-inflammatory role
for adiponectin. Supported by NIH grants DK61483 (to GF) and DK68037 and HL51586
(to LC).
T1727
Fty720 Suppresses CD4+CD44HighCD62l- Effector Memory T Cell-Mediated
Colitis
Takanori Kanai, Rei Fujii, Yasuhiro Nemoto, Shin Makita, Teruji Totsuka, Mamoru
Watanabe
Background: FTY720 (2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol hydrochloride),
a sphingosine-derived immunomodulator, causes immunosuppression via enhancement of
lymphocyte sequestration into secondary lymphoid organs, thereby prevents their Ag-activ-
ated T cell egress to sites of inflammation. It has been suggested that the egress-blocking
activity of FTY720 can be explained by its S1P1 down-modulating activity on lymphocytes.
Although FTY720 is highly effective in inhibiting autoimmunity in various animal models
in term of the prevention protocol, it is little known how FTY720 controls the migration
property of memory T cells. Methods: We evaluate the effect of FTY720 on two types of
colitis models, 1) our recently established memory T cell-mediated chronic colitis model
induced by the adoptive transfer of colitogenic lamina propria (LP) CD4+CD44highCD62L-
effector-memory T (TEM) cells into SCID mice, and 2) CD4+CD45RBhigh T-cell-trans. We
next evaluated expression pattern of S1P receptors in sorted normal splenic CD4+, CD4+
CD45RBhigh, and colitic LP CD4+ TEM cells, using quantitative PCR analysis. Results: We
demonstrate that FTY720 prevents the development of SCID colitis induced by the adoptive
transfer of LP colitogenic CD4+ TEM cells and suppresses IFN-γ , IL-2, and TNF-α production
by LP CD4+ T cells. The number of spleen, peripheral blood, mesenteric lymph nodes and
LP CD4+ T cells in FTY720-treated mice was significantly reduced as compared with the
control mice. Notably, LP CD4+ TEM cells as well as splenic CD4+CD45RBhigh T cells
expressed several S1P receptors that are targets for FTY720. Furthermore, FTY720 also
prevents the development of colitis induced by the adoptive transfer of splenic
CD4+CD45RBhigh T cells into SCID mice. Conclusions: Collectively, the present data indicate
that FTY720 treatment may control the colitogenic memory T-cell migration and suppress
the memory T cell-mediated autoimmune diseases including inflammatory bowel diseases
(IBDs). Although we have to pass many critical checkpoints, this study indicates that FTY720
offers a hope for the treatment, as well as the prevention, for human IBDs.
T1728
Impaired Production of Paneth Cell Defensin Precedes the Colonic
Inflammation in IL-10 Deficient Mice Model of IBD
Yuhei Inaba, Atsuo Maemoto, Toshifumi Ashida, Hiroki Tanabe, Jiro Watari, Tokiyoshi
Ayabe, Andre J. Ouellette, Yutaka Kohgo
Backgrounds/Aims: There has been accumulating evidence that the distorted immunological
response to intestinal bacteria is central for the pathogenesis of both human IBD and several
mouse model of IBD. In IL-10 KO mouse model of IBD, that develop the colonic inflammatory
response to the flora, abnormal Th-1 type cytokine productions of T cells were well-
investigated. However, the innate immune system is not fully understood in this model.
Diminished production of intestinal alfa defensin has been found in patients with human
Crohn’s disease by our previous studies. We herein investigated the production of Paneth
cell defensin in IL-10 KO mice, and revealed that the production of alpha defensin was
similarly impaired during the development of the colonic inflammation. Materials/Methods:
Five to 12-wk-old female wild type (WT) and IL-10 (-/-) C57BL/6 were used in this study.
They were moved from SPF condition to the usual environment at the age of 5-wk-old, and
given the normal chaw. Before and at 2, 4, and 6 weeks after settling to the contaminating
condition, inflammations of small intestines and colons were evaluated. mRNA and protein
expression of cryptdine-1 (cptd-1, mouse Paneth cell alpha defensin) expression in isolated
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intestinal crypts purified using the EDTA-disruption method, were examined by quantitative
RT-PCR and AU-PAGE. Results: Average colon lengths of IL-10 (-/-) measured were signific-
antly shorter, and the average tissue weight of colon of those were heavier than that of
WT at the fourth and sixth week. Histological examination revealed the mild increase of
inflammatory cells in lamina propria and the hyperplasia of colonic epithelia in IL-10 (-/-)
at sixth week, suggesting the spontaneous colonic inflammation might require for more than
a month of colonization period of intestinal flora from the environment. During in SPF
condition, cptd-1mRNA was equally expressed in isolated intestinal crypt of both IL-10 (-/-
) and WT animals. However, cptd-1mRNA expression in intestinal crypts of IL-10 (-/-) was
significantly suppressed during the observation period, to the average of 37% (at 2 week),
41.6% (at 4 week), and 42% (at 6 week) of the mRNA expression in WT animals. Protein
expression of cptd-1in IL-10 (-/-) crypts tested by AU-PAGE was also decreased. Conclusions:
These results suggest that the secretion of cptd-1, innate antimicrobial peptide from intestinal
Paneth cells in IL-10 (-/-) mice, is suppressed during the development, especially before
originating the histological changes of colonic inflammation. Th-1-skewed cytokine environ-
ment in this model might influence to the suppression of cptd-1 expression in Paneth cells.
T1729
Targeted Disruption of TGF-Beta/SMAD3 Signaling Confers Resistance to
Intestinal Fibrosis
Giovanni Latella, Giuliana Zanninelli, Antonella Vetuschi, Roberta Sferra, Angela
D'Angelo, Valentina Catitti, Maria Chiaramonte, Eugenio Gaudio, Renzo Caprilli
BACKGROUND & AIM. Transforming growth factor-beta(TGF-beta)/Smad3 signalling plays
an important regulatory role in the tissue fibrogenesis process acting as a potent stimulus
of extracellular matrix (ECM) proteins accumulation. Since loss of Smad3 confers resistance
to skin, kidney, lung and liver fibrosis, it could also be involved in intestinal fibrosis.The
potential role of Smad3 in the pathogenesis of intestinal fibrogenesis was investigated in
Smad3 knockout mice using a model of colonic fibrosis induced by intrarectal administration
of trinitrobenzene sulfonic acid (TNBS). METHODS. Colonies of Smad3 wild-type, heterozyg-
ous and null mice were developed in our laboratory using pairs of Smad3 heterozygous
mice kindly provided by A. Roberts (NCI, Bethesda, MD,USA).Genotype analysis was deter-
mined by the PCR method. Chronic colonic inflammation-associated fibrosis was induced
by weekly intrarectal administration of TNBS for 6 weeks in 15 healthy adult Smad3 null
and 13 wild-type mice. The colon was removed for macroscopic examination and histology
(Haematoxilin & eosin, Masson trichrome and silver staining), morphometry and immuno-
histochemistry (IHC) analysis. For IHC we used alpha-smooth muscle actin(alpha-SMA),vi-
mentin, desmin, TGF-beta1, connective tissue growth factor(CTGF), Smad3, Smad7, collagen
types I-III, and CD3 antibodies. RESULTS.At macroscopic examination the colon of Smad3
wild-type mice appeared significantly more indurated, thickened and shortened compared
to the colon of the Smad3 null mice. 50% of the wild-type mice showed strictures and
adhesions of the distal colon associated with dilatation of the proximal colon. Histological
and morphometric evaluation showed a significantly lower degree of colonic fibrosis and
accumulation of collagen in Smad3 null mice compared to wild-type, whereas the degree of
colonic inflammation did not differ between the two groups of mice. Immunohistochemistry
evaluation showed a significant decrease in alpha-SMA, CTGF, and collagen I-III staining
in the colon of Smad3 null mice compared to wild-type. TGF-beta1 and Smad7 staining
was significantly increased in Smad3 null mice as compared to wild-type. CONCLUSIONS.
The results indicate that Smad3 loss confers resistence to the development of TNBS-induced
colonic fibrosis. Reduced fibrosis appears to be due to deregulated ECM-producing cell
function, as the inflammatory response to TNBS was not significantly different between
Smad3 null and wild-type mice. Smad3 could be a novel target for potential therapeutic
treatment of intestinal fibrosis, especially in inflammatory bowel disease.
T1730
Α Critical Role for β7-Integrins But Not CCR9 or CCL25 in the Pathogenesis
of Experimental Ileitis
Maria Apostolaki, Konstantinos A. Papadakis, Menelaos Manoloukos, Marc-Andre Wurbel,
Armine Avanesyan, Masayuki Saruta, Dimitris L. Kontoyiannis, Bernard Malissen, George
Kollias
Background and Aims: The chemokine CCL25 and its receptor CCR9 have been reported
to play an important role in small bowel immunity. The upregulated expression of CCL25
and the increased frequency of activated peripheral blood CCR9+ T cells in SB Crohn’s
disease (CD) implicate CCL25/CCR9 in the pathogenesis of the disease. The aim of our
study was to determine the role of CCL25 and CCR9, as well as of the integrin β7, in the
pathogenesis of ileitis in the TNFΔARE model of Crohn’s-like disease. Methods: CCL25
mRNA and protein expression in the small bowel (SB) of TNFΔARE and wild-type mice
were assessed by real-time PCR and ELISA, respectively. The effect of CCR9 and β7 integrin
in the course of ileitis was evaluated by backcrossing the TNFΔARE mice with CCR9-/- and
β7 integrin-/- mice, whereas a neutralizing anti-CCL25 Ab was used to assess the effect of
CCL25 in the course of experimental ileitis. Results: CCL25 was upregulated early (1 month)
but not late (4 months) during the development of the disease in the TNFΔARE mice
compared to wild-type mice. Administration of anti-CCL25 Ab at 5 mg/kg twice per week
for 10 weeks, starting at 3 weeks of age, to TNFΔARE mice led to no significant improvement
of the ileitis compared to isotype control-treated mice. Backcrossing of TNFΔARE mice with
CCR9-/- mice led to similar ileitis development compared to CCR9-sufficient mice. In marked
contrast, backcrossing TNFΔARE mice with β7 integrin-/- mice led to significant amelioration
of the disease. Conclusion: β7 integrin is critically involved in the pathogenesis of experi-
mental ileitis, whereas CCL25 and CCR9 appear to play a dispensable role. CCL25 may be
involved in the early, but not late stages of the disease.
T1733
Modulation of Rat Colonic TNF-α, iNOS and Acute Colitis Through Down-
Regulation of NF-kB By Glycogen Synthase Kinase-3β Inhibition
Brendan J. Whittle, Csaba Varga, Aniko Berko, Aniko Posa, Andor Molnar, Marika Collin,
Christoph Thiemermann
Glycogen synthase kinase-3β (GSK-3β), a serine-threonine protein kinase, is now thought
to affect several biological processes including cell division and apoptosis. It can also promote
the the activity of the nuclear factor, NF-kB, a key transcription factor for the production
of pro-inflammatory mediators found in colitis such as tumour necrosis factor a (TNF-α)
and the expression of inducible nitric oxide synthase (iNOS). Since GSK-3β may thus be
involved in modulating the inflammatory process, the effects of two known selective inhibitors
of GSK-3β, TDZD-8 and SB 415286 have now been investigated in a 3 day colitis model
in the rat. Colitis was induced by the intracolonic instillation of trinitrobenzene sulfonic
acid (TNBS) and the extent of colonic inflammation assessed after 3 days in terms of
macroscopic injury and the colonic levels of the inflammatory biomarkers, myleoperoxidase
(MPO), TNF-α and iNOS. Administration of TDZD-8 or SB 415286 (0.1, 0.33 or 1.0 mg
kg-1, s.c, b.i.d., for 3 days) caused a dose-dependent reduction in the area of macroscopic
colonic injury (from 60 ± 2% to 44 ± 6% and 45 ± 4 % of the total area measured respectively,
at the highest doses, n=8; P<0.05) and also significantly reduced the macroscopic clinical
score. The increase in colonic MPO as an index of neutrophil infiltration was also dose-
dependently inhibited by both TDZD-8 and SB 415286 (by 48% and 59% respectively at
the highest doses, P<0.01). Moreover, the increase in the levels of TNF-α in the inflamed
colon was also significantly inhibited by either compound (by 46% and 51%, P<0.01) as
was iNOS protein, determined by Western Blot densitometry (by 43% and 33% respectively).
The elevated levels of the NF-kB subunit p65, also determined by Western blot densitometry,
in the nuclear extracts from the TNBS-provoked inflamed colonic tissue, were reduced by
TDZD-8 and SB 415286 treatment (by 56% and 66% respectively at the highest dose,
P<0.001). These ovservations demonstrate that two chemically distinct selective GSK-3β
inhibitors reduce the inflammatory biomarkers, iNOS, TNF-α and MPO and the tissue injury
in a rat model of acute colitis. The mechanisms underlying their anti-inflammatory action
is likely to be related to the observed down-regulation of NF-kB activity, involved in the
generation of TNF-α and other pro-inflammatory mediators.Thus, the findings suggest a
role for the protein kinase, GSK-3β, in the promotion of the inflammatory response in colitis.
T1734
Mutant Major Histocompatibility Complex II Lacking Interactions with CD4
Selects for Immunoregulatory T Cells That Prevent Colitis
Makoto Naganuma, Sanford H. Feldman, Peter B. Ernst
Background: Regulatory T cells suppress the ability of pathogenic T cells to induce autoim-
mune disease. Class II knock out (KO) mice lack Treg and develop colitis, although the
percentage of peripheral CD8+ CD25+ T cells from knock out mice is higher and these
cells exhibit regulatory activity. The purpose of this study was to examine how class II MHC
selects for regulartoy Th cells. Methods: Transgenic mice with a gene encoding mutant class
II MHC molecules that no longer bind CD4 were generated and back-crossed onto the class
II KO background (mutant mice). Mutant, class II KO and control mice were infected with
Helicobacter hepaticus and infection was confirmed by PCR. All strains were monitored for
colitis. The markers for Treg (CD25, CD45RBlo, CD62L, CD103, GITR and Foxp3) from
thymocytes and peripheral lymphoid tissues were assessed by flow cytometry and Foxp3
RNA levels were measured by PCR. Cytokine production by Th subsets and their ability to
inhibit Th cell proliferation in vitro was assessed. CD45RBhi T cells were transferred with
Treg from control and mutant mice into SCID mice to assess Treg function. Results: When
mice were infected with H. Hepaticus, 9 (5 severe, 4 mild) of 11 class II KO developed
colitis with mucosal prolapses, although no disease was observed in mutant and BL/6
mice. Histological analysis showed that goblet cells depletion, crypt abscess and transmural
inflammation was found in the colonic mucosa from class II KO mice. Total CD4+ Th cells
were decreased in thymocytes and the peripheral tissues of mutant mice but the relative
percentage of CD4+CD25+, CD45RBlo, GITR+, CD103+ T cells were increased from these
mice. However, neither CD4CD25+ nor CD8CD25+ T cells from class II KO expressed
Foxp3, while mutant CD4+CD25+, CD45RBlo, GITR+ cells constitutively express Foxp3,
suggesting that these Th subpopulation from mutant mice are Treg. IL-10 secretion and
RNA levels of both CD25+ and CD25- T cells from mutant mice were significantly higher
than those from control mice. In vitro, CD25+ cells from both control and mutant mice
suppressed proliferation of effector cells as a ratio of 1:2 and partially suppressed at a ratio
as low as 1:8. This inhibition was IL-10 independent but cell contact dependent. Co-transfer
of Treg cells from mutant mice with CD45RBhi T cells of BL/6 mice blocked wasting disease
and colitis in the SCID recipients. Conclusion: The expression of class II molecule is necessary
for development of Treg to prevent colitis. However, recognition of the class II MHC-peptide
complex can select for T reg that express FoxP3 in the thymus and peripheral tissues when
signaling through CD4 is impaired.
T1735
A Comparative Genomic Perspective On Murine Inflammatory Bowel Disease
Models
Trinidad Montero, Jose Maria Vieites, Xavier Llor, Olga Martinez, Fermin Sanchez de
Medina, Antonio Suarez
Disease heterogeneity in IBD, reflecting differences in underlying environmental and genetic
factors leading to the inflammatory mucosal phenotype, may be reflected in different intestinal
gene expression profiles. The ability to analyze gene expression data may provide a basis
for the knowledge of colitis development and for an improved classification and diagnosis
of IBD. Over the last years, the use of animal models has had a significant impact on the
understanding of the complex interplay of genes that ultimately result in mucosal inflamma-
tion. Although there is no a priori reason to assume the existence of common susceptibility
genes between species, it is highly likely that key pathways may be conserved. We have
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performed a DNA microarray analysis of the gene expression profile in three colitis models
(Dextran sulfate-induced colitis (DSS); Trinitrobenzene sulfonic acid-induced colitis (TNBS);
IL10-/- knockout mice) to provide previously unachievable information about the pathogen-
esis of colitis and to perform a comparative genomic study. Experiments were performed
as follows: DSS 5% was given orally to rats on days 1, 3, 5 and 7, continued with DSS 2%
on days 9, 11, 13 and 15, and, finally, no DSS on days 17, 19, 21, 23. TNBS was given to
rats and samples were collected in days 2, 5, 7 and 14. Samples from wild type C57BL/6
mice, germ-free and conventionally-grown IL10-/- mice were collected at 7, 9 and 12 weeks.
Colitis degree was assessed through biochemical, morphological and histological data. Total
RNA from 3 representative animals at each time point was independently reverse-transcribed
and hybridized on Affymetrix Rat Genome 230 2.0 arrays for DSS and TNBS experiments
and on Mouse Genome 430 2.0 array for IL10-/- knockout mice. Gen chip data was analyzed
and clustered with GeneSpring software. A set of comparisons for each individual experiment
was performed: healthy controls versus injured animals; early versus late colitis; colitis versus
recovery in DSS and TNBS experiments only. Probe set lists from each comparison were
analyzed with GoMiner, Gene Ontology, Panther and Ingenuity software packages. Genes
were associated with disease activity, and, categorized and grouped upon temporal expression
pattern (k-means analysis), molecular function, pharmacological information or cellular
marker. Results from these experiments are currently being cross-compared and show
interesting concordances in pathophysiological processes. Chromosomal localization of differ-
entially expressed genes partially matches with human chromosomal loci associated to IBD.
T1736
Cd30 Expression By Cd4 Cells At Inflammatory Sites in the Intestine
Shinichi Somada, Hiromi Muta, Eckhard R. Podack, Kazuhiko Nakamura, Kuniomi
Honda, Hajime Nawata, Kenzaburo Tani
Background: CD30 and its ligand (CD30L) are members of the tumor necrosis factor receptor
and tumor necrosis factor superfamily respectively. Although CD30 has long been recognized
as an important marker on many lymphomas of diverse origin and as activation molecule
on B and T cells, its primary function has remained obscure. We have shown previously
that CD30-Ligand deficienct (CD30LKO) mice have attenuated intestinal disease after anti
CD3 injection. Here we analyzed CD30 expressing cells in enteritis induced small intestine
in mice by immunohistochemistory and also determined the level of soluble CD30 (sCD30)
in the enteric mice and of patients with inflammatory bowel disease (IBD). Methods: 100μg
of anti-CD3 antibody was injected intraperitoneally into BALB/c mice to induce inflammation
of the small intestine. The CD30 positive cells were detected by immunohistochemistory in
the paraffin embedded intestinal specimens obtained from mice 24 hours after the injection.
CD30 positive cells were then analyzed by immunofluorescence staining to determine the
cell type expressing CD30. The levels of sCD30 were measured by ELISA on the sample
obtained from mie, IBD patients of ulcerative colitis (UC) and Crohn’s disease (CD), and
normal control Results: Anti-CD3 antibody injection induced small intestinal enteropathy.
CD30 positive cells in the small intestine obtained from anti-CD3 injected mice were detected
by immunohistochemistory mainly in mucosal lesions. (Normal small intestine was negative
for CD30 staining.) Immunofluorescence staining revealed CD30 expression by CD4+T cells.
The levels of sCD30 were increased in sera of the enteritis induced mice and patients with
UC and CD. The increased level of sCD30 in UC patients was correlated to the disease
activity. Conclusion: We detected CD30 positive cells in the intestines of mice damaged by
anti-CD3 antibody injection. Together with our previous report of CD30-Ligand knockout
mice, these results support the hypothesis that CD30/CD30L signals activate T cells at
inflammatory sites in the intestine. Although increased levels of sCD30 in UC patients has
been reported before, our study revealed that the levels of sCD30 were increased not only
in UC patients but also in CD patients. Furthermore, in UC patients, the level of sCD30
was correlated with the disease activity. As the level of serum sCD30 are thought to reflect
the total number of CD30 positive cells in the body, CD30/CD30L signals appear to be
augmented in IBD especially at the site of inflammation and may accelerate the disease
activity. Thus, regulation of the CD30/CD30 ligand pathway could be an effective method
for the treatment of IBD.
T1737
Both Experimental TH1 and TH2 Colitis and IBD Strongly Depend On IRF-4
Expression: Critical Role of IRF-4 in IL-6 Production and IL-6 Mediated
Apoptosis Resistance
Jonas Mudter, Lioubov Amoussina, Benno Weigmann, Hans A. Lehr, Stefan Rose-John,
Peter R. Galle, Michael Lohoff, Markus F. Neurath
Il-6 is known to be crucial in acute and chronic colitis in mice modulating T cell apoptosis
and transmural inflammation. The interferon regulating factor-4 (IRF-4) is a central player
in T cell regulation and differentiation. Its function in IBD is still unknown. The aim of
our work was to characterize the functional role of IRF-4 in the immunopathogenesis of
experimental colitis and IBD. In our studies, we analyzed cryo sections from human colon
specimen via immunofluorescence. Sections from both Crohn`s disease and ulcerative colitis
patients exhibited increased IRF-4 expression in the lamina propria (LP) compared to control
patients. The majority of these cells were also positive for CD3. To perform in vivo colitis
experiments, two murine models were evaluated in IRF-4 wild-type (WT) and knockout
mice (IRF-4 -/-). Colitis was induced by the application of either TNBS (Th1) or Oxazolone
(Th2). When exposed to TNBS, wild-type mice lost significantly more weight as compared
to IRF-4 -/- mice (-25% vs -11%) (n= 12 each group, three independent experiments). The
protective effect of IRF-4 -/- was also mirrored by endoscopical and histological scores (wild-
type+TNBS: 3.25+/-0.5; IRF-4 -/- +TNBS: 0.7+/-0.4). Interestingly, the rectal application of
oxazolone led also to significant weight loss in wild-type mice compared to IRF-4 -/- mice
(15% vs. 0%). This effect was also reflected by endoscopy and histology. Compared to TNBS
treated IRF4 -/- mice and untreated WT mice, TNBS and oxazolone treated WT mice exhibited
increased IL-6 m-RNA levels, whereas differences in the expression of the proinflammatory
cytokine IL-18 were less significant in the late state of colitis. IL-6 Immunofluorescence
staining of colon specimen showed similar results. In vivo, the protective effect of IRF-4 -/-

















exhibited enhanced apoptosis in splenic CD4+ T cells from IRF-4 -/- mice compared to
those from WT as measured by AnnexinV/PI staining and flow cytometry. The increased
rate of apoptosis was diminished by co-incubation with hyper-IL-6. Furthermore, TNBS
treated IRF-4 -/- mice exhibited an increased number of apoptotic LP cells (TUNEL assay)
compared to WT. Taken together, our data demonstrate a novel regulatory role for IRF-4
in experimental colitis and IBD. Both Th1 and Th2 mediated colitis forms are critically
dependent on IRF-4 that acts most likely as an upstream regulator of IL-6 production. IRF-
4, thus emerges as an attractive target for treatment of Th1 and Th2 dependent chronic
intestinal inflammation.
T1738
Feeding Specific Ag to Prevent CD45RBhi T Cell-Induced Colitis Is Associated
with Development of Foxp3 Expressing T Cells
Pengfei Zhou, Rajka Borojevic, Ken Croitoru
Antigen specific oral tolerance involves Ag induced T cell deletion or development of T cell
anergy. Regulatory T cells (Treg) are thought to be involved in this process. We have shown
that feeding OVA to SCID mice reconstituted with DO11.10 CD45RBhi T cells prevented
the development of colitis in part due to the emergence of regulatory T cells expressing
CD25. This was also associated with the development of tolerance of bacteria reactive T
cells. Although regulatory T cells are thought to be involved in oral tolerance, specific
induction of T cells expressing FoxP3 by oral Ag during the process of oral tolerance has
not been previously demonstrated. METHODS: SCID mice reconstituted with DO11.10
CD45RBhi naïve T cells were fed OVA (5 mg/day) or BSA (5 mg/day). Mice were sacrificed
after 10 weeks and intestinal tissues removed for histologic evaluation. Cells from spleen
and MLN were stained for surface CD4, CD25, KJ1-26 and for intracellular FoxP3 expression
and analyzed by flow cytometry. RESULTS: Less than 1% of DO11.01 CD45RBhi donor
cells transferred into the SCID mice expressed CD25+ or Foxp3+. OVA fed reconstituted
mice showed a significant increase in CD25 and FoxP3 expressing spleen and MLN cells
as compared to BSA fed controls. The percent of CD25+Foxp3+ cells increased from 0.83
to 5.21% in spleen and from 6.62 to 11.2% in MLN in OVA fed and BSA fed mice, respectively.
CONCLUSION: These findings indicate that OVA feeding led to the differentiation of
CD45RBhi naïve T cells into cells that expressed CD25 and FoxP3, makers of Treg cells.
Therefore, oral tolerance may well develop as a result of Ag specific induction of
CD25+Foxp3+ Treg cells. Defining this process may lead to new startegies of preventing or
treating intestinal inflammation. Funded by the CIHR and CCFC.
T1739
The Role of Mitogen-Activated Protein Kinase Phosphatase-1 in a Mouse
Model of Inflammatory Bowel Disease
Tom K. Lin, John A. Barnard, Yusen Liu
Background/Aims: Mitogen-activated protein (MAP) kinases are important mediators of the
innate immune response, integrally involved in the production of proinflammatory cytokines.
MAP kinase phosphatase (Mkp)-1 functions in a counterregulatory role in this inflammatory
pathway. Research in our laboratory has demonstrated that Mkp-1 knock-out (null) mice
have an augmented inflammatory response due to defective p38 and JNK inactivation in an
endotoxic shock model. In the current study, we sought to determine the susceptibility of
Mkp-1 null mice to inflammatory bowel disease (IBD) in the dextran sulfate sodium (DSS)
model of IBD. Methods: Wild-type (WT) and Mkp-1 null mice were provided 2.5% DSS
(weight/volume) in drinking water for 10 days. Colitis development was monitored daily
in a blinded fashion using a disease activity index scoring scale based on percentage weight
loss, stool consistency and stool blood. Blinded scoring of histologic colon damage was
performed using a modified, validated scoring scheme. Cytokine levels from colon homogen-
ates were determined by ELISA analysis. Results: Both WT and Mkp-1 null mice developed
weight loss and bloody diarrhea after DSS feeding. Surprisingly, WT mice developed more
severe colitis than Mkp-1 null mice. The disease activity index was higher in WT mice
versus Mkp-1 null mice (P=0.026, by principal component analysis of the three variables);
[percentage weight loss: WT 8.6%±7% vs. KO 1.7%±5% (P=0.020); stool consistency: WT
3.3±0.6 vs KO 2.6±0.7 (P=0.023); stool blood: WT 1.4±1.6 vs KO 0.6±1.3 (P=0.227)].
Histologically, colonic lesions in WT mice were also more severe [WT 6.2±2.8 vs. KO
3.0±1.8 (P=0.01)]. Tumor necrosis factor α (TNF-α) and interleukin (IL)-6 levels from
colonic homogenates were elevated in WT mice relative to Mkp-1 null mice [TNF-α: WT
338±263 pg/ml vs. KO 106±100 pg/ml (P=0.018); IL-6: WT 335±219 pg/ml vs. KO 142±148
pg/ml (P=0.033)], while levels of IL-10 and transforming growth factor (TGF)-β were
unchanged [IL-10: WT 40.9±9.4 pg/ml vs. KO 42.4±22.7 pg/ml (P=0.854); TGF-β: WT
3.10±1.23 pg/ml vs. KO 2.47±1.13 pg/ml (P=0.289)]. Conclusions: DSS colitis in Mkp-
1 null mice was significantly attenuated in clinical and histological severity and in the
proinflammatory cytokine response. This effect was independent of IL-10 and TGF-β secre-
tion. These findings suggest an integral role for Mkp-1 activity in the modulation of the
inflammation found in IBD.
T1740
Potential Role of Invariant Natural Killer T Cells On the Prevention of Acute
Intestinal Inflammation Induced By Dextran Sulfate Sodium-Induced Colitis in
Mice
Yoshitaka Ueno, Shinji Tanaka, Kyoko Yoshioka, Tsuyoshi Hatakeyama, Masaru
Shimamoto, Yoshihiro Miyanaka, Masamoto Kanno, Kazuaki Chayama
BACKGROUND &AIM: Invariant natural killer T (iNKT) cells recognize endogenous self-
and exogenous microbial-lipid antigens presented by CD1d on antigen presenting cells,
promptly secrete cytokines, and contribute an innate-type immune response to provide the
balance between tolerance and autoimmunity. However, the exact cellular mechanism of
iNKT cells on the anti-inflammatory effect remains unclear. The aim of the present study
was to investigate the role of iNKT cells in the early phase of intestinal inflammation by
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analyzing a murine colitis model induced by dextran sulfate sodium (DSS). METHODS:
Colitis was induced in C57BL/6 (B6) and Jα18 NKT cell-deficient (KO) mice by the adminis-
tration of various concentrations of DSS (1.5, 2.5, and 3.5%) in drinking water. The survival
rate, body weight loss, colon length, and histological score were investigated. Mononuclear
cells were isolated from the liver and labeled with α-galactosylceramide-loaded dimeric
CD1d:Ig fusion protein for the detection of iNKT cells. Activated CD4+T cells in the
mesenteric lymph nodes were detected by staining with FITC-conjugated anti-CD69 or PE-
conjugated anti-CD25 on day 0, 1, 3, and 7 after DSS administration. The populations of
these cells were all analyzed by flow cytometry. RESULTS: KO mice exhibited increased
susceptibility to DSS-induced colitis, as reflected by significantly higher lethality and higher
clinical and histological scores, and more severe colonic shortening compared to B6 mice.
Flow cytometric analysis revealed evidence of a significant increase in the percentage of
mesenteric CD69+CD4+ and CD25+CD4+T cells in DSS-fed KO mice compared to DSS-
fed B6 mice on day 1 and 3. Interestingly, intake of DSS increased the percentage of hepatic
iNKT cells from B6 mice. Moreover, the population of CD69+ iNKT cells but not CD69+
conventional T cells significantly increased in the B6 liver as early as day 1 after DSS
administration. CONCLUSION: The present study demonstrated that liver iNKT cells are
activated in the induction phase of intestinal inflammation and may exert an anti-inflammat-
ory effect by reducing the population of the activated CD4+ T cells in the intestinal draining
lymph nodes.
T1741
Influence of Carnitine On Butyrate Metabolism of Colonocytes in a Rat Model
of Experimental Colitis
Giuseppe D'argenio, Menotti Calvani, Orsolina Petillo, Sabrina Margarucci, Monica
Rienzo, Angela Torpedine, Giovanna Mazzone, Italo Sorrentini, Valeria Dargenio, Nicola
Caporaso, Gianfranco Peluso
Background &Aim.: It has been postulated that colitis may be the result of inability to
oxidize butyrate, the main source of energy for colonocytes. Since carnitine plays a pivotal
role in fatty acid metabolism, we evaluated carnitine transporter expression and carnitine
uptake as well as butyrate metabolism in colonocytes isolated from TNBS-treated and control
rats. Butyrate metabolism was analysed in cells before and after supplementation of liposome-
encapsuled carnitine. Methods. Total, free, and acyl-carnitine fractions were determined
by HPLC and tandem-mass-spectrometry. Butyrate metabolism was evaluated in isolated
colonocytes incubated by 1-14C-labelled butyrate. Expression of carnitine transporters was
analyzed by RT-PCR, real time RT-PCR and in-situ hybridization. Functional properties of
carnitine transporters were investigated on the basis of substrate specificity. The inhibitory
effect of several compaunds on L-carnitine transport was also determined. Results. The
functioning of high-affinity (Octn2) and low-affinity carnitine transporters (Atb0+) was
demonstrated in rat colonocytes. Expression of Octn2 and Atb0+ was also confirmed by
real-time RT-PCR and in-situ hybridization. Experimental colitis induced a decrease in
colonocyte carnitine uptake and a significant reduction of Octn2 and Atb0+ transcripts. The
concomitant decrease in carnitine cell content paralleled with a substantial decrease in
butyrate utilization by colonocytes. Carnitine supplementation in colonocytes by liposomes
proved capable of restoring butyrate metabolism, while secondary carnitine deficiency in
vivo increased colitis severity. Conclusions. In this study, we present evidence for the
complex interactions between carnitine, carnitine transporters and butyrate metabolism. The
altered colonocyte carnitine uptake in colitis leads to impaired butyrate oxidation and this,
in turn, results in energy failure. Thus, it is not a decreased butyrate uptake but rather an
altered utilization of this SCFA that produce toxic effects on the target cell. This may explain
the contradictory therapeutic efficacy of butyrate in inflammatory bowel diseases, as proved
by the last decades’ clinical trials. Our results suggest that colitis is characterised by an
energy deficiency, in which a lack of carnitine may lead to cell death and chronic inflammation
by perturbing butyrate metabolism.
T1742
Downmodulation of STAT4 Expression Can Control Experimental Intestinal
Inflammation Through Effects On Chemokine Expression and T Cell
Trafficking
Ivan J. Fuss, Atsushi Kitani, Warren Strober
Background: Stats are important molecules involved in cytokine synthesis. With respect to
Stat4, it has been shown that IL-12p70 signaling leads to phosphorylation of Stat4 and IFN-
g production. It is important to recognize, however, that Stat4 can be engaged in activities
other that IFN-g production. This is evident from micro-array analysis of Stat4-/- cells
showing that while upregulation of the IFN-g is the earliest function of Stat4, the activation
of other genes, such as chemokine receptors can be attributed to Stat4 activation. Methods:
Therefore, to further understand the function of Stat4 in Th1 development, we examined
the latter in the murine model of Th1 T cell-mediated inflammation, TNBS-colitis. In these
studies we analyzed the effects of downregulation of Stat4 in transgenic mice bearing a
doxcycline-regulatable anti-sense oligonucleotide to Stat4 under a CD2 promoter (AS-Stat4
Tg mice). This inducible effect upon STAT4 lended itself to study the separate effects of
Stat4 on IFN-g expression from that on chemokine receptor expression. Results: In these
studies, we demonstrate that during induction of TNBS-colitis whereas doxycline-induced
up-regulation of AS-Stat4 in T cells led to inability to induce gut inflammation, this effect
was not soley due to effects on IFN-g production at the local level. In further studies we
observed a significant effect on chemokine expression and cell trafficking. This was exempli-
fied by a negative influence on Th1 T cell-associated chemokine synthesis (involving CCR1,
CCR5 and CXCR3) in these Tg mice, which appeared to interfere with the trafficking of
Th1 cells to the site of inflammation. In this situation, Tg mice administered TNBS had Th1
cells accumulated in the spleen and could not traffic to the lamina propria and thus did
not cause TNBS-colitis in the latter site. In further studies, spleen CD4+ T cells obtained
from AS-STAT4 TG mice when transferred to naïve receipts (who receive TNBS re-challenge)
did not traffic to the gut and did not transfer colitis to the recipient. Furthermore, T cells
from the AS-STAT4 mice lacked migration responses in chemotaxis assays to MIP-1a, MIP1b
and RANTES. Finally, these findings correlated with the fact that in luciferase reporter gene
studies specific Stat4 binding sites were found within the CCR5 gene which are necessary
for activation. Conclusion: These studies indicate that Stat4 regulation is related to a range
of Th1-related functional activities, such as chemokine expression and effects on cell traffick-
ing, not just IFN-g production. The regulation of such may prove to be another useful
avenue in the treatment of intestinal inflammation.
T1743
Dose Dependent Transfer of CD4+CD25+ T Cells Attenuates Hfut1 Murine
Colitis
Gregory T. Moore, Steven J. Brown, Mark Lust, Sally J. Bell, P R. Elliott, William R.
Connell, Peter J. Cowan, Paul V. Desmond, Anthony J. D'Apice
Introduction: Human fucosyltransferase 1 (hFUT1) transgenic mice have thymic maturation
defects and Th1 colitis. Regulatory T cells (Treg) form in the thymus. hFUT1 mice may be
deficient in Tregs and transfer of normal Tregs may improve colitis. Methods: HFUT1 Balb/
c and Balb/c thymocytes were assessed for number and phenotype of Tregs via FACS. hFUT1+
mice received 10^5 (n=9) or 10^6 (n=8) Balb/c CD4+CD25+ T cells, 10^5 CD4+CD25- T
cells (n=8) or 10^5 naïve CD4+CD45RBhi T cells (n=4) at 4 weeks of age. Control hFUT1
mice (n=8) were similarly observed and euthanised eight weeks post transfer. Results: HFUT1
mice were deficient in mature CD4+ (1.92 vs 55.6 (x10^6)) and CD4+CD25+ thymocytes
(3.76 vs 49.6 (x10^4)). CD62L and GITR expression were reduced in hFUT1 Tregs. Foxp3
expression was similar. HFUT1 mice receiving 10^6 and 10^5 CD4+CD25+ and 10^5
CD4+CD25- T cells had greater weight gain with mean weights (+/-SEM) of 21.1g +/- 0.58,
(p<0.05), 20.4g +/- 0.80, (p=0.05) and 20.0g +/- 0.58 (p<0.05) versus hFUT1 controls
17.7g (+/- 0.98). (CD4+CD45RBhi group 16.3g +/- 0.81) Colitis improved in the 10^6
CD4+CD25+ group (1.17 +/-0.17, p<0.01) and 10^5 CD4+CD25- group (1.40 +/-0.50,
p<0.05) compared with the 10^5 CD4+CD25+ group (2.67 +/-0.41), CD4+CD45RBhi group
(3.75 +/- 0.25) and hFUT1 group (3.00 +/- 0.38). Conclusion: HFUT1 mice are deficient
in Treg number and transfer of normal CD4+CD25+ T cells improves hFUT1 colitis dose
dependently, along with CD4+CD25- T cells but not naïve CD4+CD45RBhi T cells. HFUT1
mice are deficient in CD4+CD25+ Treg and their colitis can be successfully treated with
normal mouse Tregs.
T1744
Changes of Intestinal Leukocyte Migration After Exposure to Long Chain
Fatty Acids: Interaction Between Platelets and Leukocytes
Masaaki Higashiyama, Ryota Hokari, Chikako Watanabe, Shunsuke Komoto, Yoshikiyo
Okada, Chie Kurihara, Atsushi Kawaguchi, Shigeaki Nagao, Kazuro Itoh, Soichiro Miura
Background: Dietary fatty acids could affect immune functions in small intestine. We previ-
ously reported that fatty acids modulate cytokine production from intestinal epithelial cells
and intraepithelial lymphocytes and enhance the migration of T lymphocytes to Peyer’s
patches. Recently it is reported that platelets contribute to the endothelial adherence of
leukocyte. However, there is no report whether activation of platelets could modulate the
leukocyte migration in the intestinal mucosa after fatty acid exposure through changes of
platelet migration. The aim of this study was to assess the influence of dietary long chain
fatty acid exposure on platelet adhesion to venular endothelium and interaction of leukocytes
and platelets. Methods: Splenic lymphocytes were isolated from C57B6 mice and monocytes
were isolated by MSP plate and labeled with rhodamine 6G. Blood of mice was collected
and anticoagulated with 0.1ml acid citrate dextrose buffer and centrifuged at 600g. The
platelet pellet was labeled with CFSE. Cell migration to intestinal microvessels was examined
under an intravital fluorescence microscope after injection of splenic lymphocytes, monocytes
and platelets labeled with CFSE. In some mice, platelets and leukocytes were simultaneously
observed using 3 CCD camera. Oleic acid (main ingredient of olive oil) and linoleic acid
were administered into the stomach 2 hours before examination. In addition, after treatment
with antibody against PSGL-1 or P-selectin, changes of monocytes and platelet migration
were also investigated. Changes of ICAM-1, VCAM-1 and MCP-1 expression were studied
by quantitative RT-PCR. Results: In control, some platelets directly interacted with venular
walls and a small number of leukocytes to which platelets are binding showed a rolling
behavior. Intraluminal unsaturated fatty acid administration significantly enhanced the rolling
and adhesion of both platelets and monocytes. Pretreatment with anti-P-selectin inhibited
the increased platelet adhesion to venular walls and also significantly attenuated the monocyte
adhesion or monocyte-platelet interaction induced by fatty acids. Pretreatment with anti
PSGL-1 ameliorated only monocytes adhesion induced by fatty acids. RT-PCR study did
not show significant changes in expression of ICAM-1, VCAM-1 and MCP-1. Conclusions:
We successfully observed interaction of platelets and monocytes and demonstrated enhanced
migration of platelets and monocytes by fatty acid exposure in intestinal microvessles. The
rapid increase in monocyte migration was mediated by P-selectin-PSGL-1 interaction which
may be largely influenced by platelet adhesion and leukocyte-platelet interactions.
T1745
Bone Marrow Transplantation Induces Remission in Crohn’s Disease: Where
Do the Cells Go?
Stefanie Schier, Natalie C. Direkze, Toby Hunt, Rosemary Jeffery, Thomas T. MacDonald,
Malcolm R. Alison, Richard Poulsom, Nicholas A. Wright, Mairi Brittan
Introduction:Recent studies show that bone marrow (BM) transplantation induces remission
in Crohn’s disease. We used a mouse model of Crohn’s colitis to elucidate the mechanism
of action of BM transplantation. BM forms myofibroblasts in inflamed colons, which we
now show can produce collagen. BM also forms multiple vascular lineages and contributes
to both angiogenesis and neovasculogenesis. Methods: Female mice were lethally irradiated
and rescued by a BM transplant from male donors. After 6 weeks, colitis was induced by
injection of trinitrobenzene sulphonic acid (TNBS), and colons analysed 1-14 days later. In
situ hybridisation for Y chromosome was combined with immunohistochemistry for specific
antigens to determine cell phenotype. A novel triple staining method combined in situ
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hybridisation and immunohistochemistry with autoradiography for collagen mRNA. Results:
Cells derived from BM (Y chromosome-expressing) were abundant in inflamed colons and
associated vasculature; vascular smooth muscle lining cells (VSMLCs) expressed alpha-
smooth muscle actin (SMA); endothelial cells expressed ICAM1 and vWF; myofibroblasts
expressed SMA and collagen mRNA. Inflammatory cell infiltration was ruled-out. BM contrib-
uted to 57% of myofibroblasts, which produced collagen. BM-derived endothelial cells,
pericytes and VSMLCs were frequent in blood vessels, with 27% of VSMLCs of BM origin
in inflamed colons. BM contributes to both angiogenesis and neovasculogenesis, confirmed
by vessels composed entirely of BM-derived cells. Discussion / Conclusion: This is the first
observation of BM-mediated neovasculogenesis in colitis. We provide an insight into the
regenerative function of BM by highlighting the capacity of BM to engraft within inflamed
colons and form multiple, functional lineages.
T1746
Genetic Inactivation of JNK1 and JNK2 Aggravates the DSS Induced Colitis in
Mice
Ansgar M. Chromik, Annette M. Muller, Julia Korner, Orlin Belyaev, Tim Holland-Letz,
Frank Schmitz, Thomas Herdegen, Waldemar Uhl, Ulrich Mittelkoetter
Background: The c-Jun N-terminal kinases (JNKs) are considered as novel targets for therapy
of IBD (inflammatory bowel diseases). However, the relevant isoforms have to be elucidated.
Here, we have analysed the individual contribution of the JNK1 and JNK2 isoforms in a
Dextran Sulfate Sodium (DSS) model of experimental colitis. Material and Methods: JNK1
and JNK2 knockout mice (JNK1 ko, JNK2 ko) and their wildtype controls (WT1, WT2)
received three cycles of DSS treatment, each consisting of 1.7% DSS for 5 days, followed
by 5 days with water. Animals were daily evaluated by a disease activity index (DAI)
comprising measurement of body weight, estimation of stool consistency and test for occult
blood/gross rectal bleeding. After 30 days all animals were sacrificed, and the inflamed
intestine was histologically evaluated by a crypt damage score. Results: Unexpectedly, neither
JNK1 ko nor JNK2 ko prevented mice from developing a chronic colitis when compared
to wildtype controls WT1 and WT2, respectively. In the very contrary, DAI and mortality
were aggravated in JNK2 ko compared to WT2. DAI and mortality did not differ between
JNK1 ko and WT1, but the histological crypt damage score was significantly enhanced in
the caecum of JNK1 ko mice. Conclusion: Genetic deletion of JNK2 deteriorates the clinical
outcome in an experimental model of murine colitis. We hypothesise that the functional
deletion of the otherwise pro-apoptotic JNK2 prolongs the activity of pro-inflammatory
immue cells with worsening of clinical course symptoms.
T1747
IL-12p35-Producing B Cells Regulate TH2-Mediated Chronic Colitis
Ken Sugimoto, Atsuhiro Ogawa, Yasuyo Shimomura, Atsushi Mizoguchi, Atul K. Bhan
BACKGROUND & AIMS: IL-10-porducing regulatory B cell subset appears in the mesen-
teric lymph mode (MLN) of T cell receptor knockout (αKO) mice after the development
of colitis and subsequently regulates the progression of this disease (Immunity 2002, 16:219).
However, it is unclear whether the IL-10 produced by regulatory B cells directly or indirectly
contributes to the regulation of this colitis. METHODS: Cytokine production by purified
MLN B cells was examined by flow cytometric, ELISA, Q-PCR and RPA analyses. To investigate
the functional role of p35 in the pathogenesis of colitis in αKO mice, IL-12p35-deficient
TCRα double knockout mice were generated. RESULTS: In the absence of B cells (B cell-
deficient TCRα double KO mice, αμDKO) or IL-10 (IL-10-deficient TCRα double KO mice,
αIL10DKO), IL-12p35 expression was significantly downregulated in the MLN of αKO
mice. Transfer of B cells from αKO but not αIL10DKO mice restored the IL-12p35 expression
in the recipient αμDKO mice. Unexpectedly, studies using purified several MLN cell types
(including B cells, T cells, macrophages, DCs, neutrophils, and NK cells) demonstrated that
B cells per se are responsible for the production of IL-12p35 in the presence of IL-10. Flow
cytometric and ELISA analyses revealed that the IL-12p35 production by purified MLN B
cell from αKO mice but not WT mice is further upregulated by the B cell receptor ligation
in the presence of TLR9 ligand, CpG. To test the functional role of p35 in the pathogenesis
of colitis, IL-12p35-deficient TCRα double knockout (αp35DKO) mice were generated. Of
note, the αp35DKO mice spontaneously developed much more severe colitis compared to
αKO mice. QPCR analysis showed that the deficiency of p35 enhances the IL-17 production
of CD4+ T cells. To further confirm whether IL-12p35-producing B cells are actually involved
in the regulation of colitis, B cells from aKO or αp35DKO mice were transferred into αμDKO
mice. Transfer of B cells from aKO mice but not αp35DKO mice efficiently inhibited the
progression of colitis in the recipient αμDKO mice. In addition, the transfer of αp35DKO
B cells enhanced the IL-17 production of CD4+ T cells. CONCLUSION: These results
indicate that IL-12p35-producing B cells are induced by IL-10-producing B cells and are
involved in the regulation of colitis. The deficiency of p35 is associated with an increase in
IL-17 producing CD4+ T cells (also called Th-17) in a model of Th2-mediated colitis.
T1748
Induction of Colitis in CDP/Cux Mutant Mice Is Associated with An Increase
of Disease Severity
Mathieu Darsigny, Francois Boudreau
INTRODUCTION: The CCAAT displacement protein (CDP/Cux) is a transcription factor
involved in the control of cell proliferation, differentiation and maintenance of the differenti-
ated state. We have recently demonstrated that CDP/Cux can repress the intestinal specific
gene sucrase-isomaltase. However, the intestinal physiological role of CDP/Cux remains to
be ascertained. Recent observations from the literature have linked CDP/Cux functions to
the development of the immune system as well as the regulation of inflammatory genes.
AIM: To determine whether CDP/Cux could be involved in the regulation of the intestinal
inflammatory response. METHODS AND RESULTS: The mouse knock-in model deficient

















transcription factor was involved in the maintenance of the mucosal intestinal immunity,
mice were challenged with a mild dextran sodium sulphate (DSS) induced-colitis protocol.
Three independent experiments were performed with groups of adult CDP/Cux mutant and
wild type mice treated or not with 2.5% of DSS in drinking water ad libitum. All animals
were sacrificed after 7 days and the disease severity was analysed among the individuals
according to a disease activity index (stools aspect, rectal bleeding and weight loss), histolog-
ical alterations, and cytokines profile in the distal intestine. CDP/Cux mutant mice showed
a severe colitis progression with the apparition of frequent fecal blood as well as rectal
bleeding as compared to the wild-type animals. Histological examination of the colon of
DSS-treated mutant mice with haematoxylin and eosin (H&E) stained sections revealed a
drastic destruction of the mucosa that was associated with an important recruitment of
inflammatory cells. DSS-treated wild type mice displayed minor alterations of the mucosa
with the formation of dispersed small inflammatory cells clusters. Proinflammatory cytokines
were generally stable between groups with some mutants showing upregulated mRNA levels
of TNF alpha and IL-1 beta as determined by a real-time PCR analysis. CONCLUSION:
Our results demonstrate that the loss of CDP/Cux transcription factor is associated with a
significant increased disease severity of the colonic mucosa when subjected to a mild DSS
treatment. Further investigations are ongoing to identify the molecular links between the
transcriptional regulator CDP/Cux and intestinal inflammatory processes. (This work was
supported by CIHR, NSERC, CRS, CFI and FRSQ).
T1749
The Role of the P110δ PI3-Kinase Isoform in Inflammatory Bowel Disease
Klaartje Kok, Wayne P. Pearce, Maikel P. Peppelenbosch, Bart Vanhaesebroeck, Daan W.
Hommes
Background IBD is thought to develop as a result of deregulated mucosal immune response
to normal luminal flora but the molecular mechanisms remain poorly defined. Toll-like
receptors (TLR) mediate innate immune responses and are present on immune cells such
as macrophages. Increased cytokine production through these receptors is thought to play
a role in the pathogenesis of IBD. Class IA PI3-kinases (PI3K) are lipid kinases that control
many cellular responses. The p110δ isoform of PI3K is mainly expressed in leukocytes.
Inactivation of p110δ (p110δD910A/D910A mice) leads to defects in B- and T-cell signaling
and chronic focal colitis. This implies a role for p110δ in the pathogenesis of IBD. Also the
human p110δ gene PIK3CD maps to the IBD7 locus. Previous studies have shown that
PI3K is a suppressor of cytokine production triggered by TLR signaling, preventing excessive
innate immune responses. Here we investigated the role of normal luminal flora in p110δ
related colitis and of p110δ in bone marrow derived macrophages (BMDM) TLR signaling.
Methods Colonic sections of p110δD910A/D910A mice derived from conventional and
specific pathogen-free (SPF) environments were stained with H&E for histological analysis.
Wild-type BMDM treated with or without D030 (p110δ inhibitor) or LY294002 (broad-
spectrum PI3K inhibitor) were stimulated with LPS 100ng/ml and protein phosphorylation
status was assessed. Results p110δD910A/D910A mice from a conventional environment
spontaneously develop colitis at 16 weeks of age. Histological examination reveals mucosal
hyperplasia, hyperplasic glands, elongated crypts, crypt abscesses, and leukocytic infiltration
of the lamina propria and focal erosion of the mucosa. In contrast, SPF p110δD910A/D910A
mice show no inflammation or other pathology in any layer of the bowel. LPS induced Akt
phosphorylation (indirect measure of PI3K activity) in BMDM is abrogated by LY294002
treatment and, to lesser extent, by D030 which is in contrast to phosphorylation of IκBα,
pIKKα/β, Erk and p38 which are unaffected by the inhibitors. Conclusion Mice lacking
p110δ spontaneously develop IBD only in the presence of normal luminal flora. This finding
emphasizes the role of p110δ in the pathogenesis of IBD. Stimulation of BMDM with LPS
leads to the activation of Akt/PI3K, MAP-kinase and NFκB pathways. PI3K inhibitors decrease
Akt/PI3K activity but fail to inhibit the other pathways. This suggests that PI3K does not
have a important role in LPS-induced cytokine production of BMDM and that other immune
cells are more responsible for this p110δ IBD phenotype. Candidates are regulatory T-cells
which are currently under investigation.
T1750
Role of Nitric Oxide (NO) and NO Synthases in Healing of Dextran Sulfate
Sodium-Induced Rat Colitis
Yoko Aoi, Shyun Terashima, Hikaru Nishio, Shinichi Kato, Koji Takeuchi
Background/Aim: NO synthase (NOS) exists in two isoforms, constitutively expressed NOS
(cNOS) and inducible NOS (iNOS). We previously reported that NO produced endogenously
plays a dual role in the development of rat colitis model induced by dextran sulfate sodium
(DSS), depending on the NOS isoform; a protective effect by constitutive cNOS/NO and a
proulcerogenic effect of iNOS/NO. However, the roles of NO and NOS isozymes in the
healing process of colitis remain unexplored. In the present study, we examined the effects
of various NO inhibitors on the healing of DSS-induced rat colitis. Methods: Male Wistar
rats were used. Experimental colitis was induced by feeding the rats for 6 days with 2.5%
DSS in drinking water. After DSS treatment, the animals were fed normally with tap water
thereafter and killed various days up to 7 days later. L-NAME (a nonselective NOS inhibitor,
5 mg/kg) or aminoguanidine (a relatively selective iNOS inhibitor, 20 mg/kg) was given PO
twice daily for 6 days starting from the termination of DSS treatment. The ulcerated area,
colon length, and myeloperoxidase (MPO) activity as well as thiobarbituric acid reactants
(TBARS) were measured on day 7 after DSS treatment. Mucosal NO content was measured
by Griess method. The expression of eNOS and iNOS mRNAs was examined by RT-PCR
while that of basic fibroblast growth factor (bFGF) was determined by Western blotting.
Results: DSS treatment caused severe lesions in the colon, accompanied by an increase in
MPO activity and TBARS as well as a decrease in body weight gain and colon length. The
lesions healed gradually after discontinuation of DSS treatment, with a histological restoration
and subsidence of inflammation. The healing of these lesions was significantly impaired
by daily administration of L-NAME or aminoguanidine when examined both macro- and
microscopically. The gene expression of eNOS was constantly observed in the mucosa while
the expression of iNOS mRNA was up-regulated by DSS treatment, reaching a peak on day
1, followed by a gradual decrease in later period, and these changes were associated with
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increase or decrease in NO content. The expression of bFGF was also up-regulated in the
colonic mucosa following DSS treatment. Both L-NAME and aminoguanidine significantly
suppressed the increase in NO content but had no effect on the expression of bFGF.
Conclusion: These results suggest that endogenous NO produced by iNOS plays an important
role in the healing of DSS-induced colonic lesions. Although the exact mechanism remains
unknown, it is assumed that the healing promoting effect of NO is accounted for by actions
other than modulation of the bFGF expression.
T1751
The PPARB Deficient Mice Are Highly Sensitive to the Oral Administration of
Dextran Sulfate Sodium
Dominique Velin, Frederic Varnat, Daniel Bachmann, Christian Felley, Walter Wahli,
Pierre Michetti, Beatrice Desvergne
Background: The peroxisome proliferator-activated receptors (PPARs) are members of the
nuclear receptor superfamily and are critical modulators of environmental and dietary stimuli.
Ubiquitously expressed, PPARb mRNA expression is highest in the brain, adipose tissue,
and epithelia. Aim: We studied the role of PPARb in the mouse model of distal colitis
induced by oral administration of dextran sulfate sodium (DSS). Methods: Wild type or
PPARb deficient mice received 2.5% DSS in drinking water for 7 days. Body weight, overall
wellness, colon histology, colon myeloperoxidase activity, and colon cytokine expression
were followed at different time points. Results: In comparison to wild type mice, PPARb
deficient mice lost significantly more body weight (-4.2±3.2% of the initial body weight for
PPARb deficient mice vs. +2.2%±2.8 of the initial body weight for wild type mice; p<0.0001;
n=14 per group, Day 3 values), developed rectal bleeding more frequently (35% vs 7%;
p<0.05; n=14 per group, Day 3 values) and died prematurely (2 out of 8 PPARb deficient
mice died before Day 7 vs. none of 8 wild type mice). Histological analysis at Day 5 showed
increased villi size in wild type mice, suggesting an ongoing regenerative process of the wild
type colon epithelium. In contrast, the intestinal villi of PPARb deficient mice were smaller
and a massive destruction of the colonic epithelium at Day 7 in PPARb deficient mice was
further observed. At Day 7 myeloperoxidase activities measured in the colon of wild type
mice (40± 10 unit MPO/mg protein) were higher compared to PPARb deficient mice (20±7.5
unit MPO/mg protein, n=7 mice, p=0.03). However, at Day 7, no statistical differences were
found in mRNA expression for TNFa, IFNg, MCP-1, IL-1b, IL-1Ra, and iNOS, in the colon
of wild type or PPARb deficient mice. Conclusion: PPARb deficient mice are extremely
sensitive to the DSS-induced colitis. The severe DSS-induced pathology in PPARb deficient
mice is not due to a predominant inflammatory process. We are currently exploring how
the lack of PPARb may interfere with the intestinal tissue repair capacity following DSS admin-
istration.
T1752
Sex Hormone Regulation of Colonic Macrophage Migration Inhibitory Factor
Expression in Basal and Inflammatory Conditions in the Female Rat
Eric Houdeau, Moriez Raphael, Leveque Mathilde, Waget Aurelie, Bueno Lionel,
Fioramonti Jean
Background and aims: Clinical data highlighted the influence of sex steroids on gastrointesti-
nal symptoms in female IBD patients. Macrophage migration inhibitory factor (MIF), a pro-
inflammatory cytokine that promotes the release of tumor necrosis factor-α (TNF-α) and
interleukin-1β (IL-1β), was shown as a target of sex steroids in inflammatory processes.
This study aimed to determine the influence of estradiol (E2) and progesterone (P) on MIF
expression and disease activity in a rat model of colitis. Methods: Basal concentrations of
MIF, TNF-α and IL-1β were determined by ELISA at all stages of the ovarian cycle in female
rats, or following ovariectomy (OVX) after a 8 day-treatment with subcutaneous capsules
containing either estradiol (E2), progesterone (P), or saline (controls). Colitis was induced
by intrarectal instillation of 80 mg/kg TNBS or vehicle in similar groups of rats. Twenty-
four hours later, rats were sacrificed and colons removed for evaluation of macroscopic
damage score (MDS), myeloperoxidase activity (MPO), and ELISA for MIF, TNF-α and IL-
1β. Results: In cyclic rats, only MIF levels fluctuated during the cycle, with lowest values
at estrus (endogenous E2 dominance) and highest in metestrus (endogenous P dominance)
(301±39 vs 781±135 ng/mg of protein, respectively; p<0,05). Similarly, E2 and P treatments
in OVX rats did not affect basal levels in TNF-α and IL-1β. In contrast, E2 decreased (-
64%) while P increased (+94%) MIF expression (32.5±2.6 and 173.1±11.5 ng/mg of protein,
respectively) when compared to controls (89.3±5.2 ng/mg of protein, p<0.001). In metestrus
rats with TNBS colitis, an increase in MDS (+78%, p<0.001) and MPO activity was observed
when compared with TNBS-induced colitis in estrus rats (1980±230 vs 882±100 U MPO/
g of protein, respectively; p<0.01). In TNBS-treated OVX rats, MIF levels were reduced by
E2 (-56%, p<0.001 vs controls+TNBS), and increased by P (+89%, p<0.001). In the same
animals, P also induced a rise in TNF-α levels (20.9±2.5 vs 10.9±1.4 pg/mg of protein in
controls), while E2 treatment was correlated to a diminution in IL-1β concentrations
(4154±404 vs 6381±495 pg/mg of protein in controls). Conclusions: Our data show that
E2 inhibits and P stimulates MIF expression in both normal and inflamed colon. The natural
shift from E2 to P dominance during the ovarian cycle may promote alternatively resistance
then susceptibility of the colon to inflammation, and modulates TNF-α and IL-1β production
in colitis. Thus steroid hormone regulation during the cycle could modulate disease activity
in women with IBD.
T1753
Constitutive Nitric Oxide Synthase Is Involved in Maintaining Colonic
Mucosal Blood Flow in DSS and TNBS Treated Rats
Olof Schreiber, Joel Petersson, Lena Holm
Background: The role of nitric oxide (NO) in inflammatory bowel disease is still controversial.
Furthermore, the very few in vivo measurements of colonic blood flow in colitis models
have not addressed the role of NO. The aim of this study was to investigate the involvement
of NO in regulating colonic mucosal blood flow in two different colitis models. Methods:
The rats were divided in four groups in respect to treatment: I/ saline and II/ trinitrobenzensul-
fonic acid (TNBS, 30mg/ml in 50% ethanol) intrarectally 7 days prior to the experiments,
III/ untreated and IV/ 5% dextran sulphate sodium (DSS) in the drinking water 9 days prior
to the experiments. On the experimental day the rats were anesthetized with Inactin® (120
mg.kg-1ip) and the colonic mucosa exteriorized. Blood flow, measured with laser-Doppler
flowmetry, and arterial blood pressure were continuously measured throughout the experi-
ments (100 min) and vascular resistance calculated. All four groups were given the NOS
inhibitor L-NNA (10 mg.kg-1 bolus followed by 3 mg.kg-1h-1 iv) 20 min after start of the
experiment. In a few experiments the iNOS inhibitor L-NIL was given in the same dose as
L-NNA. Results: TNBS induced a severe colitis with penetrating ulcers, reduced colon
length and thickening of the wall. DSS on the other hand induced a more diffuse mucosal
inflammation covering the entire colon and with greater fecal blood content than the TNBS
treated rats. Blood pressure before L-NNA was similar (≈100mmHg) in all groups and
increased to≈140 mmHg in all groups except the TNBS treated rats in which blood pressure
only increased to 121±7 mmHg. Colonic mucosal blood flow, calculated as perfusion units/
g tissue, was not significantly different in any of the four groups. The blood flow was not
altered in the control groups (I and III) during L-NNA but substantially reduced in the
TNBS and DSS treated rats (67±4% and 67±7% of basal, respectively). Vascular resistance
increased significantly more in the TNBS and DSS treated rats (202±10% and 218±10% of
basal, respectively) than in the control rats (169±15% group I 145±15% group III of basal).
L-NIL treatment did not significantly alter blood flow in any of the groups. Conclusions:
The results clearly indicate that constitutively expressed NOS, probably eNOS since L-NNA
most potently inhibits eNOS, is equally important in maintaining colonic mucosal blood
flow in the TNBS and DSS colitis models.
T1754
Pivotal Role in Colonic Protection for the Mucin MUC2 in Unchallenged and
Dextran Sulfate Sodium Challenged Mice
Maria Van der Sluis, Barbara de Koning, Adrianus De Bruijn, Anna Velcich, Johannes van
Goudoever, Hans Buller, Jan Dekker, Isabelle van Seuningen, Ingrid. Renes, Alexandra
Einerhand
Background & Aims: Expression of mucin MUC2, the structural component of the colonic
mucus layer, is lowered in inflammatory bowel disease. Our aim was to obtain insight in
the role of Muc2 in epithelial protection. Methods: Muc2 knockout (Muc2-/-) and Muc2
heterozygous (Muc2+/-) mice were characterized and challenged by a colitis-inducing agent,
dextran sulfate sodium (DSS). We monitored clinical symptoms, intestinal morphology and
differences in intestine-specific protein and mRNA levels. Results: The Muc2-/- mice showed
clinical signs of colitis (as of 5 weeks), aggravating as the mice aged. Microscopic analysis
of the colon of Muc2-/- showed mucosal thickening, increased proliferation and superficial
erosions. Colonic goblet cells in the Muc2-/- mice were negative for Muc2 and Gob-5, but
Tff3 was still detectable. In these mice, transient de novo expression of Muc6 mRNA was
observed at 5 weeks, but expression declined as the mice matured. On day 2 of DSS
treatment, the histological damage was more severe in Muc2+/- vs. Muc2+/+ mice, but the
disease activity index (DAI) was not yet different. By day 7, the DAI and histological score
were elevated in Muc2+/- vs. Muc2+/+ mice. The DAI of the Muc2-/- mice was higher (vs.
both Muc2+/+ and Muc2+/- mice) throughout DSS treatment. The histological damage in the
DSS-treated Muc2-/- mice was different vs. Muc2+/+ and Muc2+/- mice. Specifically, in Muc2-/-
mice many crypt abscesses were seen, instead of mucosal ulcerations. Conclusions: This
study shows that changes in the mucus composition (lack of Muc2) leads to inflammation
of the colon, and contributes to the onset and perpetuation of experimental colitis.
T1755
Characterization of Ileal Dendritic Cell Distribution in a Rat Model of Acute
and Chronic Inflammation
Manuel A. Silva-Munoz, Monica Porras, Jury Jennifer, Patri Vergara, Mary H. Perdue
Background: Crohn’s disease (CD) is an inflammatory bowel disease characterized by an
increased mucosal permeability and an imbalance in the distribution of dendritic cells (DC)
subtypes. Enhanced antigen uptake may affect the DC response and render the intestine
susceptible to immune activation and inflammation. Subcutaneous (sc) administration of
indomethacin in rats leads to intestinal inflammation (Porras et al. Am. J. Physiol. 2004),
with both acute and chronic stages having increased permeability (Porras et al. Neurogastro
Motility Meeting 2005, Toulouse, Fr). Here, our objective was to examine subpopulations
of DC to determine their location and migration patterns. Methods: Sprawley-Dawley rats
were treated with indomethacin (7.5 mg/kg sc, 2 injections 48h apart), and ileal segments
were obtained in the acute stage at day 4 (n=4) and in the chronic stages at day 15, and
30 after injection (n=6/group). Control rats (n=6) were injected with saline. Segments were
processed for light microscopy; sections were examined for inflammation (score 0-7) and
immunohistochemistry for CD103 and CD11b (rat DC markers), CD83 (DC marker of
maturation), CD163 (marker for macrophages), and double immune staining. Results: In
controls, both immature DC sub-populations, CD103+CD11b+CD163-CD83- and
CD103+CD11b-CD163-CD83-, were observed in the lamina propria (LP), and the CD11b-
population was also present in the sub-epithelial dome of the Peyer’s patches (PP). In the
acute stage, areas with or without ulcers were observed; both had an increased (p<0.05)
inflammation score compared to controls. CD103+ and CD11b+ (CD83-) DC were absent
from inflamed areas, reduced in non-inflamed tissue, but present in PP’s. In chronic stages
at day 15, CD103+ and CD11b+ cells were located in inflamed and non-inflamed areas,
and in PP. Also, CD83+ DC were detected in inflamed areas. At day 30, when we observed
a complete microscopic resolution of inflammation, CD103+ and CD11b+ DC were increased,
and at day 30 there were CD83+ DC beneath the epithelial cells layer. Conclusions: In this
model, at times of altered mucosal permeability, we documented changes in distribution of
DC in the ileum. Acute and chronic stages of inflammation had different morphological
patterns, DC distribution, and CD83 expression. Antigen uptake in acute stages may activate
the resident immature DC, inducing their migration to lymphoid tissue and maturation,
returning to the intestine in chronic stages to play a role in the local inflammatory response.
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T1756
Caveolin-1 Regulation of Experimental Colitis
James Joshua M. Greer, John H. Chidlow, Pascal N. Bernatchez, William C. Sessa, Deepti
Shukla, Christopher G. Kevil
Inflammatory bowel disease and experimental models of colitis display microvascular dys-
function which contributes to colon tissue pathology. Recent studies demonstrate that
caveolin-1 may be important in regulating microvascular function and inflammatory
responses. However, the pathological role of caveolin-1 in experimental colitis is unknown.
Here we subjected wild-type and caveolin-1-/- (Cav-1-/-) mice to the 3 % Dextran Sulfate
Sodium (DSS) model of experimental colitis. Analysis of weight change, stool consistency,
occult blood, and evidence of gross bleeding showed a significant decrease in disease activity
index (DAI) in Cav-1-/- mice compared to wild-type control mice. Moreover, examination
of tissue histopathology showed significant protection in Cav-1-/- colons. In wild type
colons, complete crypt dropout and transmural inflammation was observed with the infiltrate
consisting primarily of neutrophils and the degree of inflammation ranging from severe to mild
depending on disease severity. In contrast, DSS histopathology findings were significantly
diminished in Cav-1-/- colons. DSS induced colitis was also evaluated in wild type mice
treated with an AP-Cav-AB peptide (3 mg/kg) corresponding to the caveolin-1 scaffolding
domain. Interestingly, the AP-Cav-AB peptide significantly attenuated DSS DAI and histo-
pathology scores compared to the control peptide treated mice. These data identify a novel
pathway whereby caveolin-1 plays an important pathophysiological role during experi-
mental colitis.
T1757
Epithelial Contribution to Barrier Function and Carcinogenesis in the GIα2-
Deficient Mouse Model of Inflammatory Bowel Disease
Robert A. Edwards, Jennifer Davis
The Giα2-/- mouse model of inflammatory bowel disease spontaneously develops colitis
beginning at 6 weeks of age and is predisposed to developing non-polypoid, mucinous
colon cancers. Lymphocytes, dendritic cells, and myofibroblasts all appear to contribute to
disease in these mice, but the role of Giα2 signaling in the epithelium has not been
investigated. Histologic sections from more than 80 Giα2-/- mouse colons reveal pre-
neoplastic lesions present as early as 12 weeks of age, in the setting of mild colitis without
ulceration. This suggests a direct effect of the loss of epithelial Giα2 on carcinogenesis,
which occurs despite lower levels of mucosal PGE2. To test the hypothesis that Giα2
regulates the balance of colonic epithelial cell growth and apoptosis, we generated lines of
human T84 colon cancer cells stably overexpressing the dominant negative human Giα2
mutant, G203T-Giα2 by Amaxa nucleofection. These cells express 20-fold higher levels of
hGiα2 mRNA and overexpress Giα2 protein by western analysis. G203T-Giα2 cells show
enhanced basal proliferation rates in vitro, which correlate with increased BrdU incorporation
in the colons of 5 week old, non-colitic Giα2-/- mice. Like Giα2-/- myofibroblasts, G203T-
Giα2 T84 cells are defective in releasing arachidonic acid. Since arachidonate is an important
activator of sphingomyelinase that generates the pro-apoptotic factor ceramide, we tested
whether G203T-Giα2 cells were resistant to camptothecin induced apoptosis. In contrast
to WT and vector-transfected T84 cells, 6 hours’ treatment with 5 uM camptothecin induced
significantly less caspase 3 activity in G203T-Giα2 cells, suggesting a link between altered
arachidonate metabolism observed in multiple Giα2-/- cell types and the propensity towards
early neoplastic transformation in the colonic mucosa of Giα2-/- mice.
T1758
Course of Yersinia Enterocolitica Infection Is Dramatically Improved in CCR6
Deficient Mice - New in Vivo Model for M Cell Function?
Sabine Westphal, Andreas Luegering, Julia von Wedel, Ifor Williams, Christof von Eiff,
Wolfram Domschke, Alexander Schmidt, Gerhard Heusipp, Hermann Herbst, Torsten
Kucharzik
Introduction M cells are specialized cells within the follicle associated epithelium (FAE) of
Peyer’s patches (PP). We could recently demonstrate that CCR6-deficient mice lack M cells,
the “gatekeepers” of the mucosal immune system. Yersinia enterocolitica exploit M cells to
invade mucosal tissues and spread systemically. In our study, we therefore analyzed Y.
enterocolitica infection in CCR6 KO mice. Methods C57BL/6 wildtype mice (wt) and CCR6
deficient mice (KO) were orally infected with 2,5x108 CFU Y. enterocolitica. Intraperitoneal
(i.p.) injection was performed by 1x106 CFU. Invasion of PP by Y. enterocolitica was
determined by histology. To evaluate kinetic of infection, bacterial excretion in stool and
colonization in the PP and spleen was determined. Besides, we developed a scoring system
to grade severity of infection with Y. enterocolitica. Cytokine mRNA expression was analyzed
by real-time PCR. Results After oral application of Y. enterocolitica, CCR6-deficient mice
showed no clinical symptoms of infection, whereas wt mice suffered from septic infection.
Stomach and small intestine were extremely bloated by gas in wt mice. PP of wt mice were
conspicuously swollen and highly inflamed. 7 days post infection, Y. enterocolitica could
be found in stool and PP isolated from wt mice, whereas Y. enterocolitica was absent in PP
of KO mice. No bacterial invasion could be observed in spleens neither in wt nor in KO
mice. In addition, a significantly elevated level of TNF alpha RNA expression within PP of
wt mice 7 days post infection could be evaluated using real-time PCR, whereas no change
in TNF alpha level was assessed in KO mice. To bypass the routing of Y. enterocolitica
through PP, mice were infected intraperitoneally (i.p.). In contrast to oral infection, no
significant differences between wt and KO mice could be found in mice i.p. infected with
Y. enterocolitica. Both groups showed severe symptoms of infection and revealed equal
scores. Conclusions The interaction of CCR6 with its ligand Mip3 alpha is essential for the
development of PP and M cells. Deletion of CCR6 negatively influences the lympho-epithelial
interaction and causes inhibition of M cell differentiation within PP and consecutively
decreased infectious potential of Y. enterocolitica. The CCR6 knockout mouse model repres-


















Regulated Expression of Leukocyte Specific Transcript (LST)-1 in Human
Intestinal Microvascular Endothelial Cells (HIMEC) - Evidence for Multiple
Splice Variants
Jan Heidemann, Moritz Kebschull, Allon Canaan, Sherman M. Weissman, Kerstin
Klimmek, Andreas Lugering, Matthias Bruwer, Wolfram Domschke, Torsten F. Kucharzik,
Christian Maaser
Background: Leukocyte specific transcript (LST)-1, the human homologue of the murine
B144 gene is encoded by a gene located in the major histocompatibility complex III. Located
in close proximity of the TNF-α locus in humans and rodents, LST-1 is believed to possess
immunomodulatory functions in the inhibition of mitogen-induced T cell proliferation, as
well as functions required for dendritic cell differentiation and morphogenesis. The aim of
this study was to determine expression of LST-1 in human microvascular endothelial cells
(HIMEC). Material and Methods: Human intestinal microvascular endothelial cells were
purified and cultured from normal human colonic tissue specimens. For regulation experi-
ments, HIMEC were stimulated with TNF-α (20 ng/ml), LPS (1 μg/ml), IFN-γ (40 IU/ml),
or IL-1β (20 IU/ml). Expression of LST-1 in human endothelial cells was assessed by Gene
Array Analysis (Affymetrix HG-U 133), semi-quantitative RT-PCR, and sequence analysis of
obtained PCR fragments using a capillary DNA sequencing system (ABI PRISM 3100 Genetic
Analyzer). Protein expression in endothelial cells was assessed using polyclonal antisera by
immunoblot analysis. Results: Gene array analysis revealed a strong and exclusive up-
regulation of LST-1 in HIMEC, but not the human reference microvascular endothelial cell
line, HMEC-1, after stimulation with recombinant human TNF-α (20 ng/ml) after 4h and 24h,
respectively. Semi-quantitative RT-PCR analysis of HIMEC stimulated with proinflammatory
stimuli revealed a strong up-regulation of six LST-1 splice variants. Notably, of the stimuli
tested, only IFN-γ was unable to up-regulate LST-1 expression, which suggests that the
mRNA expression of LST-1 in HIMEC is likely dependent on activation of the transcription
factor, NF-κB. Sequencing analysis data obtained from purified RT-PCR fragments were
suggestive of soluble and transmembrane splice variants of LST-1. Immunoblot analysis of
whole cell lysates of HIMEC stimulated with TNF-α revealed multiple protein isoforms.
Conclusions: This is the first report indicating regulated expression of LST-1 in human
endothelial cells derived from human intestine. Given its potential functions in modulating
the immune system and antigen-presentation, further research is warranted to closely define
the role of soluble and membrane expressed LST-1 in the regulation of mucosal intestinal
immunity and inflammation.
T1760
Cytoplasmic Domain of Intercellular Adhesion Molecule-1 Is Required for T
Lymphocyte Adhesion and Migration: Implication for the Involvement of
Actinin Binding Motif
Suck Chei Choi, Hyun Mee Oh, Ki Jung Yun, Geom Seog Seo, Young Woo Sohn, Tae
Hyeon Kim, Yong Ho Nah, Chang Duk Jun
Intercellular adhesion molecule-1 (ICAM-1) has been known to enhance leukocyte adhesion,
thereby inducing migration through blood endothelial cells. However, the molecular event
during these processes is largely unknown. To identify whether ICAM-1 cytoplasmic domain
participates in T lymphocyte adhesion and migration, following ligand-receptor binding
event, we constructed several ICAM-1 cytoplasmic domain deletion mutants that were fused
with green fluorescence protein (GFP). COS-7 cells expressing ICAM-1_GFP mutant without
α-actinin binding motif (ICAM-1_ΔAT_GFP) revealed no association with the actin cytoskel-
eton, while wild-type ICAM-1_GFP showed clear association with the actin. In addition, in
contrast to the wild type ICAM-1_GFP, ICAM-1_ΔAT_GFP was not localized properly on
microvilli and revealed no punctuate forms on the cell surface, suggesting that α-actinin
binding motif is important for the proper localization of ICAM-1 on the cell membrane.
Membrane projection as well as T lymphocyte adhesion was decreased in the cells expressing
ICAM-1 without α-actinin motif or entire cytoplasmic domain. We also found that α-actinin
biding motif deficient ICAM-1 resulted in significant decrease of transmigration as determined
by transwell chamber assay. Collectively, these results suggest that α-actinin binding motif
in the cytoplasmic domain of ICAM-1 plays important role for T lymphocyte adhesion and
transmigration, presumably through the regulation of actin dynamics.
T1761
Novel Regulated Expression of Phosphatidylserine-Specific Phospholipase A1
(PS-PLA1) in Human Intestinal Microvascular Endothelial Cells (HIMEC)-
Evidence for Secreted Enzyme Activity
Jan Heidemann, Christoph Ruther, Moritz Kebschull, Matthias Lehr, Matthias Bruwer,
Wolfram Domschke, Torsten F. Kucharzik, Christian Maaser
Background: Phosphatidylserine (PS)-specific phospholipase A 1 (PS-PLA1) is a secreted
enzyme that efficiently hydrolyzes PS exposed on the surface of apoptotic cells and activated
platelets to produce 2-acyl-lysophosphatidylserine (lysoPS), which is a potent lipid mediator
for mast cells, neural cells, and T cells. Effects of lysoPS on T cells include the inhibition
of mitogen-induced proliferation, as well as activation of interleukin (IL)-2 production of
T cells. Gene arrays performed to assess intestine-specific gene expression patterns of human
endothelial cells after proinflammatory stimulation revealed a strong up-regulation of PS-
PLA1 mRNA. We therefore aimed to assess the expression and enzymatic activity of human
intestinal microvascular endothelial cells under proinflammatory conditions. Material and
Methods: Human intestinal microvascular endothelial cells were purified and cultured from
normal human colonic tissue specimens, and macrovascular endothelial cells from umbilical
veins (HUVEC) were obtained according to standard protocols. For regulation experiments,
endothelial cells were stimulated with TNF-α (20 ng/ml), LPS (1 μg/ml), IFN-γ (40 IU/ml),
or IL-1β (20 IU/ml). Expression of PS-PLA1 was assessed by semi-quantitative RT-PCR and
real time RT-PCR. Restriction fragment analysis was used to identify PS-PLA1 splice variants
in endothelial cells. A HPLC assay measuring oleic acid liberation from the PS-PLA1 substrate
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1-oleoyl-2-hydroxy-sn-glycero-3-[phospho-L-serine] was performed to detect PS-PLA1 activ-
ity in cell culture supernatants and endothelial cell lysates. MG-132, an inhibitor of NF-κB
activation was used in stimulation experiments. Results: Gene array analysis revealed a
marked up-regulation of PS-PLA1 in HIMEC after stimulation with recombinant human
TNF-α (20 ng/ml) after 4h and 24h. Likewise, endothelial PS-PLA1 expression was markedly
enhanced by proinflammatory stimuli utilizing the NF-κB pathway, including bacterial
lipopolysaccharide (LPS) and IL-1β. In turn, MG-132 inhibited the TNF-α induced stimula-
tion of PS-PLA1 expression in endothelial cells. Using RFLP analysis, HIMEC were shown
to concomitantly express an active splice variant, PS-PLA1ΔC. Moreover, HIMEC cellular
extracts and supernatants were shown to elicit regulated phospholipase A1 activity. Conclu-
sions: This is the first report describing the regulated expression of PS-PLA1 in human
endothelial cells. By secretion of PS-PLA1 activity, human microvascular endothelial cells
might mediate immediate and distant immune effects on T cells through generation of the
lipid mediator, lysoPS.
T1762
Human Intestinal Intraepithelial Lymphocytes (IELs) Carry Out Fas Ligand
(FL)-Mediated Spontaneous Cytotoxicity (sc) of Epithelial Cell (EC) Tumors
Through Nkg2d
Ellen C. Ebert
Introduction: Human IELs are TCRαβ+CD8+ T cells located between ECs. Their SC activity
specifically directed against EC tumors is likely to be an important host defense against
colon cancer. The binding of NKG2D on NK and CD8+ T cells with its ligands (ULBP1,
ULBP2, ULBP3, and MIC) on colon cancer is important for cytotoxicity. This study explores
the mechanism of SC activity by IELs, particularly the role of NKG2D. Methods: IELs were
co-cultured with 51Cr-labelled target cells, and the percentage lysis determined after 4- or
18-hrs. The involvement of NKG2D was studied using MIC-transfected CIR cells and chimeric
NKG2D and ULBP proteins. Results: After 4 or 18 hrs, fresh IELs had little perforin-mediated
cytotoxicity against anti-CD3-coated P815 cells. However, IELs carried out moderate TNFα-
and marked FL-mediated cytotoxicity against the WEHI cells and Jurkat cells, respectively,
target cells that are particularly susceptible to each mechanism of lysis. For killing of HT-
29 cells, however, IELs utilized a combination of TNFα- and FL-mediated mechanisms. For
this to occur, IELs needed 18 hrs of contact with HT-29 cells so that both TNFα and FL
were up-regulated on the surface of the IELs. This is necessary because TNF receptors and
Fas are minimally expressed on the surface of HT-29 cells. The involvement of the NKG2D
pathway was demonstrated by a 75% reduction in cytotoxicity of HT-29 cells when NKG2D
was blocked by specific antibodies or chimeric proteins. To determine whether the NKG2D
ligands on EC tumors were necessary for lysis, the LOVO colonic adenocarcinoma cells
were studied as they have low expression of the NKG2D ligands. The LOVO cells were as
susceptible to lysis as HT-29 cells although blocking NKG2D reduced cytotoxicity by only
20-30% and the lysis was mainly TNFα-mediated. This suggests that pathways not involving
NKG2D can trigger TNFα-induced lysis when NKG2D ligands are unavailable. Finally, IEL
killing of MIC-transfectants was inhibited by blocking MIC or FL, but not TNFα, suggesting
that the NKG2D pathway induces FL-mediated lysis. Conclusion: This study shows that
HT-29 cells are spontaneously lysed by IELs but only after an 18-hr co-culture during which
TNFα and FL are up-regulated on the surface of IELs. NKG2D induces mainly FL-mediated
cytotoxicity. When ligands to NKG2D are unavailable on the EC tumors, the lysis becomes
mainly TNFα-mediated.
T1763
A Murine Model of Appendicitis and Its Impact On the Lymphocyte
Constituents
Watson W. Ng, Andrew Llyod, Micheal C. Grimm
The appendix has long been regarded as an evolutionarily vestigial organ. Its role in gastrointe-
stinal mucosal immunity has been highlighted by the demonstration that appendicectomy
for appendicitis is protective against the development of ulcerative colitis. Although there
are well established murine models of colitis, no murine model of appendicitis has been
established. We therefore developed a murine model of appendicitis and examined its impact
on the lymphocyte constituents of the murine appendix. Methods: SPF Balb/c mice were
anaesthetised by intra-peritoneal injection of ketamine (100mg/kg) and xylazine (3.4mg/
kg). A 1cm left-sided laparotomy was performed. The caecum was mobilised. The caecal
patch (the murine equivalent of human appendix) was transformed into an appendix-like
pouch by standardised continuous suction and a ligation rubber band was loaded around
the neck of “appendiceal pouch”. The caecum with obstructed “appendiceal pouch” was
returned into the peritoneal cavity and sterile phosphate buffered saline was spread into the
abdominal cavity. The peritoneum and the skin were closed in layers. Mice were then
sacrificed at different time points and the “appendiceal pouches” were examined histologically
for features of appendicitis. Appendiceal lymphocytes were examined by flow cytometry in
particular for phenotypic markers of activiation and regulation. Results: All appendiceal
pouches developed histological features resembling human appendicitis with mucosal ulcera-
tion, transmural inflammation with neutrophilic and lymphocytic infiltrates, with occasional
eosinophils, and serositis. These changes were most evident between days 10 and 14 after
induction of appendicitis. No ischaemic necrosis, appendiceal abscesses, significant peritonitis
or perforations were observed. All mice remained well as determined by clinical scoring.
Compared with normal murine appendiceal lymphocytes, there is an increase in CD3 CD4
T cells (from 17.5% to 30.5%) and CD3 CD8 T cells (from 3.7% to 10.2%). In contrast,
there is a reciprocal reduction in B cells (from 68.8% to 42.2%). There is also an increase
in CD25 Foxp3 T cells (from 1.07% to 1.91%). Conclusion: This is the first description of
a murine model of appendicitis with features of mucosal ulceration, neutrophilic infiltration
and serositis resembling human appendicitis. Preliminary data showed that there is marked
shift of lymphocytes into a T cell predominant response associated with an increment in
regulatory T cells. Further experiments are ongoing to examine the full impact of appendicitis
on the lymphocyte constituents of the caecal patch and on the immunological outcome
of colitis.
T1764
PI3K Activates a Critical Step During Intestinal Inflammation-Induced
Activation of Intestinal Stem Cell
Ramanarao . Dirisina, Navdha Mittal, Jennet Manjali, Yueming Tang, Goo Lee, Radhika
Mutyala, Gery Grimm, Linheng Li, Xi C He, Gary Wu, Mei-Lun Wang, Samuel Ho, Xiao
De Tan, Yaqin Zhu, Hans Clevers, Harry Begthel, Terrence A. Barrett
In the current study we have investigated if PI3K regulates stem cell activation. Data from
human polyposis syndromes and gene knockout mouse models suggests that aberrant PI3K
signaling promotes intestinal neoplasia via activation of intestinal stem cell (ISC). To examine
regulation of ISC by local immune populations we utilized anti-CD3-induced T cell activation
model of intestinal inflammation. Following T cell stimulation we see an increase in activated
ISC as indicated by >150% increase in nuclear beta-catenin staining in crypts. Analysis of
isolated crypt cells revealed a rapid (3h) 125% increase in nuclear beta-catenin combined
with elevated (4-12 fold) mRNA for a range of Wnt/B-catenin target genes (cMyc, cyclin
D1, fra-1, MMP-7, cryptdin, Muc2, trefoil factor etc.). A robust proliferative response was
shown by marked expansion of cells that dual-stained for cMyc and incorporated BrdU.
Pluripotent effects on secretory lineage generation was determined by IHC, western blots
and real-time RT-PCR for cryptdin, MMP-7 and lysozyme (paneth), trefoil factor and Muc
2 (goblet), chromogranin A (enteroendocrine) and cryptdin and trefoil factor (intermediate).
Double staining of lineage marker with BrdU were used to determine accelerated generation
of enterocytes as well as secretory linages. Role of PI3K and its downstream targets was
assessed by western blot for pathway proteins (GSK3b, mTOR, BAD). Treatment of mice
with PI3K inhibitor LY294002 (30mg/kg X 4 doses) drastically reduced the numbers of T cell
induced activated ISC, cMyc+/BrdU+ progenitors while abrogating generation of multipotent
secretory progenitors. Taken together these data suggest that during T cell activation PI3K/
Akt signals led to nuclear beta-catenin accumulation and activation of ISC followed by
enhanced production of enterocytic as well as secretory lineages. Similarly these pathways
have increased production of goblet and Paneth cell factors to enhance barrier immunity
as well.
T1765
Mucosal Delivery of Ovalbumin By the Genetically Modified L.Lactis
Suppresses Systemic and Local Inflammatory T-Cell Responses in Do11.10
Mice
Inge L. Huibregtse, Henri Braat, Veerle Snoeck, Koen van Laer, Anje A. Te Velde, Pieter
Rottiers, Sander J. van Deventer
Background: Genetically modified Lactococcus lactis (Ll) can be used for local delivery of
immunomodulatory proteins to the intestinal mucosa. We adopted this strategy to study
the role of local and systemic immune responses after mucosal delivery of ovalbumin. For
this purpose we genetically engineered ovalbumin (OVA) secreting Ll and we evaluated the
immune response in OVA-TCR transgenic mice (DO11.10) after oral supplementation.
Methods: A PCR amplified OVA cDNA fragment was ligated in the erythromycin resistant
pT1NX vector. Bacteria were grown overnight at 37 C in erythromycin supplemented
medium, diluted 1:50 and grown for another three hours and harvested at exponential
growth phase (approximately 1x107 bacteria). Quantification of the secreted OVA was
evaluated by ELISA and western blot. Mice were fed for 10 consecutive days with low dose
OVA or 1x109 bacteria/day (Ll or LlOVA). Four days later mice were sensitized with 100ug
OVA s.c. in the base of the tail. Another 12 days later, mice ears were injected with 10ug
OVA, and ear thickness was measured after 24 hours. At day 27, the intestinal tract was
isolated for histology. Bulk spleen and bulk MLN cells were used for FACS analysis on T-
cell expression markers (CD4+OVATCR+ specific: CD25, foxp3, CD45RB, CD69, CD44
and CD62L) and restimulated with OVA (0.5mg/ml). Supernatants were used for cytokine
measurements. Results: Sequence analysis confirmed the cloning strategy of the vector. In
the exponential growth phase LlOVA produced 50 ng/ml OVA measured by ELISA. Daily
intragastric administration of LlOVA led to a significant decrease of ear thickness compared
to the sensitized Ll treated mice and the orally OVA fed mice (1x10-2mm vs 6.5x10-2mm
vs 16.2x10-2mm respectively). A decrease in IFN-g production in bulk spleen cells and an
increase in IL-10 production in MLN cells was seen in LlOVA compared to the Ll treated
mice (67.8 vs 278.9 pg/ml and 41.4 vs 9.25 pg/ml). Conclusion: The mucosal delivery of
OVA by genetically modified Llactis induces suppression of local and systemic inflammatory
OVA specific T-cell response in DO11.10 mice. These data strongly suggest that the mechan-
ism of action is the induction of regulatory T-cells and that the mode of mucosal delivery
of an antigen to the immune system critically determines immune activation.
T1766
Role of Trem-1 in PMN Transmigration
Titus A. Reaves, Lindsey M. Parent
Neutrophil (PMN) migration to sites of infection is the first line of defense serving as an
essential component of the innate inflammatory response. When dysregulated, PMN migra-
tion underlies the basis of a number of inflammatory diseases in the intestine. Microbial
products have been shown to have potent effects on the immune system and the intestinal
lumen contains considerable amounts of such products. A recently discovered protein, a
triggering receptor expressed on myeloid cells (TREM-1) has been implicated in PMN survival
when PMN are exposed to specific microbes and/or microbial products. TREM-1 has also
been shown to interact with toll-like receptors (TLR) and mediate the cell response to
microbial products. We set out to further characterize and investigate the role of TREM-1
in PMN migration by exposing PMN to gram-positive and gram-negative bacterial products
during fMLP directed migration across acellular filters. Following 120 minute incubation in
the absence of antibodies, 50% of the applied load of PMN migrated. In contrast, when
antibodies (mAb) to TREM-1 were used in transmigration ~25% of the applied load of PMN
migrated. Exposure of PMN to gram-positive bacterial products combined with mAb TREM-
1 produced a further reduction in migration. In particular, in the presence of lipoteichoic
acid (LTA) 38% of the applied load of PMN migrated. However, when LTA was combined
T : 89386$$CH2
05-04-06 23:18:30 Page 557Layout: 89386B : o
A-557 AGA Abstracts
with TREM-1, only 18% of the applied load of PMN migrated, representing a 65% decrease
in migration. A similar transmigration response was observed when PMN were exposed to
the gram-positive bacterial lipoprotein MALP-2. We also exposed PMN to gram-negative
bacterial products such as lipopolysaccharide (LPS) and PAM3CSK4 (bacterial lipoprotein).
Results show that PAM3CSK4 when combined with mAb TREM-1 reduced migration to
~21 % of the applied load of PMN. However, LPS when combined with mAb TREM-1 had
minimal effects on PMN transmigration. Migration assays using antibodies to TLR2 combined
with TREM-1 also had minimal effects on transmigration. Using Flow Cytometry, we con-
firmed that PMN expressed TREM-1 and that this expression is up regulated when PMN are
exposed to specific bacterial products. Furthermore, there appears to be immunofluorescence
differences in TREM-1 expression in PMN when PMN are exposed to gram-positive and
gram-negative bacterial products. Taken together this data suggests that TREM-1 expression
may affect PMN migration into the intestinal lumen and thus contributes to deregulated
PMN migration.
T1767
Pathophysiological Role of the Cholinergic Anti-Inflammatory and Immune
Pathway in a Murine Model of Food Allergy
Naho Utsunomiya, Takeshi Yamamoto, Toshihisa Kodama, Hirofumi Kuramoto, Makoto
Kadowaki
The enteric immune system which works as a bioprotection builds up the enteric intranet with
the enteric nervous system. It contributes to maintain enteric and whole body homeostasis as
they interact each other. Although the number of food allergy patients has been dramatically
increasing over the last several decades, the pathogenesis of food allergy has not been
elucidated. Therefore, regarding to the disturbance of the enteric intranet, we focused on the
cholinergic anti-inflammatory and immune pathway through vagus-nicotinic acetylcholine
receptors in a murine model of food allergy. METHODS: A murine model of food allergy
was developed using BALB/c mice. For induction of food allergy, a group of mice was primed
with ovalbumin (OVA) and aluminum hydroxide gel as adjuvant by intraperitoneal injection,
and the occurrence of diarrhea following repeated oral challenges with OVA in the primed
mice was recorded. Next, the colon of the food allergy mice was removed and used for
myeloperoxidase (MPO) activity analysis and for quantitative measurements of inflammatory
cytokine mRNA. RESULTS: Exposure of the primed mice to repeated oral OVA challenges
induced diarrhea [85.4 ± 8.5% (mean ± S.E.) after six OVA challenges] associated with 2.4-
fold increased MPO activities in the colon and with dramatically increased IgE levels in sera.
In addition, pretreatment with calcineurin inhibitor to suppress T helper cell type 1 (Th1)
responses deteriorated the allergic diarrhea. The treatment with anti-allergic drug, disodium
cromoglycate, failed to significantly suppress the allergic diarrhea. Notably, the central
stimulation of vagus nerves with 2-deoxy-d-glucose (200mg/kg i.p.) significantly improved
the allergic states (54.5% of the food allergy control, P<0.05). Furthermore, subcutaneous
administration of nicotine (3.2 mg/kg) suppressed allergic diarrhea (31.1% of the food
allergy control, P<0.01) and MPO in the colon (57.6% of the food allergy control, P<0.01),
whereas nicotine exerted no inhibitory effect on IgE levels in sera (121.2% of the food
allergy control). On cytokine mRNA expression, there was a significant increase in IL-4, IL-
5, and IL-10 (Th2 cytokines) in the food allergy mice, whereas IFN-γ (Th1 cytokine) was
not detected even in the food allergy mice, suggesting that immune response is skewed
toward Th2 in the food allergy mice. Those raised Th2 cytokines dropped back to the
normal state by the treatment with nicotine. CONCLUSION: Nicotinic acetylcholine receptors
work on the cholinergic anti-inflammatory and immune pathway to alleviate Th2-mediated
food allergy.
T1768
Intestinal Anaphylactic Response to Allergen Challenge Is Impaired in
Immunized Germ Free Mice
Robin M. Hopwood-Courville, Jody L. Gookin, Susan Tonkonogy, Bruce Hammerberg
The incidence and severity of food hypersensitivity is increasing. In sensitized individuals,
oral allergen challenge triggers a series of events termed intestinal anaphylaxis. Allergen-
bound IgE interacts with low affinity IgE receptors (CD23) on the surface of intestinal
epithelium and is transported transcellularly to the lamina propria. Subsequent recognition
of allergen by mast cell bound IgE results in release of pro-secretory mediators that induce
epithelial Cl- secretion. Intestinal microflora have been demonstrated to influence develop-
ment of tolerance to intestinal allergens and clinical studies demonstrate differences in
intestinal microflora between individuals that do or do not develop allergy. The objective
of this study was to determine the influence of normal intestinal microflora on immunization
and the intestinal anaphylactic response to allergen challenge. Specific pathogen free (SPF;
n=4) and germ free (GF; n=3) 129 S6/SvEv mice were immunized by intraperitoneal injection
of HRP (100 mg) in 0.2 ml alum and 50 ng pertussis toxin (days 0, 7 and 14). Age and
sex matched GF mice were immunized with adjuvant alone in PBS. On day 21-24 jejunal
mucosa was mounted in Ussing chambers, acclimated for 30-min, and challenged luminally
with HRP (2 mg/ml) or unrelated antigen (ovalbumin, 2 mg/ml) in the presence or absence
of blocking anti-CD23 antibody (0.1 mg/ml). Short-circuit current (Isc; reflects Cl- secretion
in this model) was recorded every 60-sec for 15-min. At 2-min after allergen challenge,
sections were removed, processed, and examined for transepithelial HRP transport by TEM.
Epithelial expression of CD23 was examined by immunofluorescence, mucosal mast cells
were enumerated, and HRP-specific serum IgE ELISA was performed. SPF mice demonstrated
a secretory response to luminal allergen challenge (μA/cm2 = 19 ± 3) while GF mice did
not. Epithelial CD23 expression did not differ between SPF and GF mice. HRP-challenged
GF mice demonstrated CD23-dependent transepithelial transport. Mast cell numbers did
not differ between SPF and GF mice and both groups demonstrated equivalent Isc responses
to the secretogogue aminophylline. HRP-specific IgE was significantly lower (p=0.03) in
sera of immunized GF mice (0.148 ± 0.067) as compared to immunized SPF mice (0.801
± 0.178). Results of the present study suggest that GF mice have impaired allergen signaling
post-transepithelial transport. In mice, elevated circulating IgE causes upregulation of high-
affinity IgE receptors on the surface of mast cells. A relative deficiency of IgE in GF mice


















Anti-TNF Agents Are Capable to Induce Apoptosis in Macrophages But Not in
Dendritic Cells - Potential Role of Mtnf
Pia Lebiedz, Sabine Westphal, Stefan Koch, Wolfram Domschke, Andreas Lugering,
Torsten Kucharzik
Introduction: Anti-TNF antibodies such as infliximab and adalimumab are established in
the treatment of chronic inflammatory bowel diseases. Previous studies demonstrated that
these antibodies may induce apoptosis in monocytes and T-lymphocytes. Furthermore,
infliximab has been shown to act through the transmembrane form of TNF (mTNF). We
herein investigated the effect of adalimumab and infliximab on human macrophages and
dendritic cells (DC). Material and Methods: Macrophages and dendritic cells were in vitro
differentiated from fresh human monocytes by stimulation with MCSF (25ng/ml) or GMCSF
(25ng/ml) plus IL-4 (10ng/ml), respectively. Cells were stimulated with 5 and 50µg/ml
adalimumab and infliximab. Apoptosis was determined by flow cytometric analysis of
annexin-V expression and immuno-blotting of cleaved PARP (poly [ADP-ribose] polymerase).
The proteasome inhibitor Mg132 was used as positive control for induction of apoptosis.
Expression of mTNF on cell surfaces was also determined by flow cytometry. MAPK activation
was analysed by immuno-blotting. Results: Infliximab and adalimumab were both able to
induce apoptosis in macrophages but not in dendritic cells as shown by annexin-V staining
and PARP cleavage. mTNF was found on the cell surface of human in vitro differentiated
macrophages whereas dendritic cells were mTNF negative. No difference in MAPK activation
could be determined between both cell populations. Discussion: We herein show that
infliximab and adalimumab both are able to induce apoptosis in human macrophages but
not in dendritic cells. As infliximab has been shown to induce apoptosis via reverse signalling
by binding to mTNF, the missing induction of apoptosis in DCs is probably due to a lack
of mTNF on this cell population. This observation further supposes the importance of mTNF
as a target for pro-apoptotic anti-TNF signalling.
T1770
The Expression of Ccr6 Identifies Lymphoid Tissue Inducer Cells Within
Cryptopatches
Andreas Luegering, Sabine Westphal, Christian Maaser, Jan Heidemann, Torsten
Kucharzik
Introduction: The murine gut contains small clusters of lymphocytes expressing the chemok-
ine receptor CCR6 known as cryptopatches (CP) that were recently identified as adult
lymphoid tissue inducer cells and represent precursors of isolated lymphoid follicles (ILF).
Although various studies documented the presence of ILF within the human intestine, CP
were not detectable. The aim of this study was to characterize the significance of CCR6
expression by adult LTi cells in CP and to identify similar structures within the human
intestine. Methods: Lymphoid tissue inducer cells were isolated from the lamina propria of
the murine small and large intestine, and c-kit+ lineage-marker negative cells (=LTi-cells)
analyzed by flow cytometry. Frozen tissue sections from the murine intestine were stained
for CCR6 in parallel. To identify human CP-like structures sections from colonic biopsies
of healthy controls as well as ulcerative colitis patients were stained with antibodies to c-
kit and CCR6. Results: Flow cytometric analysis of lin- c-kit+ cells isolated from the complete
lamina propria could demonstrate that 15-20% express CCR6 whereas 70-75% of CP cells
express CCR6 in tissue sections suggesting that LTi cells are present inside and outside CP.
The comparison of these two cell populations showed similar expression of IL-2R and IL-
7R, whereas other surface markers (CD4, CD8, CD45Rb) are differently expressed. In the
human intestine, staining for c-kit could identify a limited number of positive cells in small
lymphoid aggregates within crypts, whereas the majority of these cells express CCR6. A
significant increase of CCR6 positive lymphoid aggregates was found under inflammatory
conditions. Discussion: The chemokine receptor CCR6 is specifically expressed by LTi cells
within CP and might play a pivotal role in the progression of CP to ILF. The presence of
small lymphoid aggregates of CCR6 expressing cells within the human intestine suggests
that CP-like structures are also present in the human gut. As CCR6 is known to drive the
progression of CP to ILF this receptor may be a valuable target for intestinal inflammatory
conditions, e.g. inflammatory bowel disease.
T1771
Regulation of Intestinal Inflammation By Lamina Propria Cd4+ Cd25+/Bright T
Cells
Shin Makita, Takanori Kanai, Yasuhiro Nemoto, Yumi Ito, Michio Onizawa, Teruji
Totsuka, Mamoru Watanabe
Background & Aims: It is well known that immune responses in the intestine remain in a
state of controlled inflammation, suggesting that not only active suppression by regulatory
T cells plays an important role in the normal intestinal homeostasis, but also its dysregulation
leads to the development of inflammatory bowel disease. Here we assess the intestinal
CD4+CD25+T cells both in humans and mice. Methods: 1) Human normal mucosal samples
were obtained from unaffected areas in intestine resected from patients with colon cancer.
Informed consent was obtained from all patients prior to the study. We isolated human LP
CD4+ T cells and analyzed their surface molecules. We next sorted human LP CD4+ T cells
into CD4+ CD25- or CD4+CD25bright subsets using FACS Vantage, and both subsets were
examined expression of FOXP3. We further investigated whether LP CD4+CD25bright T cells
possess suppressive function in vitro. 2) For animal experiments, C.B-17 SCID mice were
injected i.p. with SP CD4+CD45RBhigh alone (2x105 per body), SP CD4+CD45RBhigh + SP
CD4+CD25+ (1x105 per body), or SP CD4+CD45RBhigh + LP CD4+CD25+ (1x105 per body)
to assess the role of LP CD4+CD25+ T cells in intestinal homeostasis. The recipient mice
after transfer were monitored the weight and clinical signs of illness. The histological score
of inflammation in the colon and the cytokine production by LP CD4+ T cells were also
examined. Results: 1) Human LP CD4+CD25bright T cells constitutively expressed CTLA-4,
GITR and FOXP3. LP CD4+CD25bright T cells suppressed the proliferation and various
cytokine productions of CD4+CD25- T cells. LP CD4+CD25bright T cells produced less
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amounts of IL-2, IFN-γ and IL-10 as compared with LP CD4+CD25- T cells. 2) The mice
transferred with the CD45RBhigh T cell population developed a wasting disease with severe
colitis. In contrast, the co-transfer of CD4+CD45RBhigh + SP or LP CD4+CD25+ cells prevented
a wasting disease and leukocyte infiltration in the colon, and suppressed IFN-γ and TNF-
α production by LP CD4+ T cells. Conclusion: These results suggest that LP is one of the
critical sites to control intestinal homeostasis by LP CD4+CD25+/bright regulatory T cells.
T1772
5asa Blocks Stem Cell Activation in Intestinal Epithelial Cells After T-Cell
Activation:a Possible Explanation for the Chemo Preventive Effects of 5asa
Therapy On Ulcerative Colitis Patients
Jennet J. Manjali, Goo Lee, Gery R. Grimm, Navdha Mittal, Terrence A. Barrett
Background and Aims: Recent data in humans suggest 5ASA therapy reduces the risk for
CRC in patients with IBD. We postulated that a potential mechanism for the chemopreventive
effects of 5ASA involves 5ASA acting as a scavenger for oxygen radicals that activate intestinal
stem cells thereby inhibiting proliferation during stages of intestinal inflammation. Methods
and Results: To address this hypothesis, mice (C57BL/6 (B6) and TNFR-/- ) were given
either low dose(LD,100mg/250g chow) or high dose(HD,300mg/250g chow) 5ASA(pellet
chow) regime for 5 days followed by T cell activation (anti CD3 mAb,0.2mg i.p) and the
epithelial response was studied. T cell activation increases proliferation of crypt progenitor
cells studied by BrdU incorporation(2h label). Mice (B6 and TNFR-/- ) were sacrificed 18h
after anti-CD3, the proliferative responses seen are summarized in Table 1. Intestinal stem
cell activation, as studied by immunohistogical staining of nuclear β-catenin increased on
induction (Xi et al,Nature Genetics2004).Table2 summarises the nuclear β-catenin in mice
sacrificed 3hours after induction with or without pretreatment with LD or HD 5ASA.
Apoptosis as studied by TUNEL showed an increase from 0.072 to 1.8 TUNEL positive
cells/colonic crypt in B6mice. HD 5ASA pretreatment showed a 16%decrease in the TUNEL
positive cells. Conclusion: Taken together these data suggest a)the chemopreventive effects
of 5ASA is dose dependent. b)5ASA acts is more effective in blocking the stem cell activation
in distal over the proximal colon. c)5ASA effects the stem cells via a TNF dependent pathway.
Grant supported by Proctor and Gamble
Table 1 Shows effects of 5ASA treatment on proliferation in T-cell activated Colon( Numbers
indicate BrdU positive cells/crypt)
*p value is less than or equals 0.05
Table 2 Shows the effects of 5ASA treatment on the expression of Nuclear Beta-Catenin in
T-cell activated colon (Numbers indicate Beta-Catenin positive nuclei/1000 epithelial cells)
T1773
Maternal Microchimerism in Crohn’s Disease
David Suskind, Melvin B. Heyman, Denice Kong, Baxter-Lowe Lee-Ann, Muench O.
Meunch
Crohn’s disease is a chronic disease characterized by inflammation of the gastrointestinal
tract. The etiology is unknown. Crohn’s disease shares many similarities with graft verses
host disease (GVHD) seen after bone marrow transplantation. Disease location, histology
and inflammatory responses are similar in both Crohn’s and GVHD. Adaptive transfer
models, using selective transfer of alloimmune cells, have been shown to cause transmural
inflammation within the intestines of immunodeficient mice. This suggests engraftment of
maternal cells during gestation could result in an immune response that leads to Crohn’s
disease. The aim of this study was to determine the presence and extent of maternal
microchimerism (MM) in the tissue of patients with Crohn’s disease. Methods: Eighteen
patients were recruited from the Division of Pediatric Gastroenterology at Children’s Hospital
in Seattle, Washington. Blood samples were obtained from mothers and patients for HLA
typing. Tissue samples from seven different regions of the gastrointestinal tract (stomach,
esophagus, rectosigmoid, descending colon, transverse colon, cecum and terminal ileum)
were obtained from patients during diagnostic endoscopy/colonoscopy. Using kinetic poly-
merase chain reaction (kPCR), patients’ tissues were evaluated for MM. Results: Of the
eighteen patients recruited, 7 were diagnosed with Crohn’s disease; 10 patients did not have
Crohn’s disease. Using kPCR, MM was observed in the tissues of 4 of the 7 (57%) patients
with Crohn’s disease and in 1 of the 11 (9%) patients without Crohn’s (p=0.05). In patients
with IBD, MM was identified in both inflamed and non-inflamed tissues (p=NS). There was
no association between MM and disease location, disease severity or granuloma formation.
In individuals with IBD, tissue microchimerism was found with a range of 0.4 to 2.8 copies
of maternal DNA per 25,000 copies of patients DNA. Conclusion: Maternal microchimerism
is present in the gastrointestinal tissues of patients with Crohn’s disease more frequently
than in those individuals without Crohn’s disease. Further investigation is required to help
elucidate the role of MM in Crohn’s disease.
T1774
Role of Appendix in Oral Tolerance Induction in Normal and Mice with
Dextran Sulfate Sodium Induced Colitis
Li Youming, Yu Chaohui, Yue Min, Liu Yulan
Aims: Oral tolerance is a state of specific immunologic hyporesponsiveness by feeding
antigens before challenging. Appendix, which was considered as a retrogressed organ, has
been postulated to be involved in mucosal immune responses and the pathogenesis of
dextran sulfate sodium induced colitis. We evaluated the presence of oral tolerance in
appendectomized or sham operated mice and those mice with dextran sulfate sodium induced
colitis. Materials and methods: Oral tolerance was induced via ingestion of ovalbumin with
either single dose of 20mg or 250μg every other day in 10 days after 7days of appendectomy
or sham operation(BSA as control). DTH reaction was detected at 7,14,21days after intraperi-
toneal injection of ovalbumin in CFA. Feeding 5% dextran sulfate sodium in water was
started 7 or 14 days after antigen challenging for 7 days to induce colitis. Clinical disease
activity was assessed daily and colonic injury was graded by histology 7 days after the
induction of colitis. Results: Feeding single dose of 20mg ovalbumin may cause oral tolerance
after 14 days in sham operated mice with alleviated DTH reaction while not in appendectom-
ized mice in 21 days after challenging. Repeated low dose of ovalbumin ingestion may
induce oral tolerance after 7days in sham operated mice but retarded to at least 14 days in
appendectomized mice. No significant alleviation of DTH reaction was detected in both
high dose ingested group in 21 days and repeated low dose ingested group in 14 days in
appendectomized mice with DSS induced cilitis, while decreased DTH reactions were
observed in both sham operated groups with colitis. No siginificant histological difference
was observed except in appendectomized mice ingested with lower dose of ovalbumin
repeatedly revealing significant lower damage scores in histology compared with BSA con-
trolled appendectomized ones. Conclusions: Appendix is essential to oral tolerance induction
and appendectomy may postpone the induction of oral tolerance. Oral tolerance still exits
during the procedure of DSS induced colitis in normal mice but has been distorted in
appendectomized mice with DSS induced colitis.
T1775
Absence of Cd1 Exaggerates Murine DSS-Induced Colitis: A Protective Role
for NK T Cells
Jacob Rullo, Christina Hirota, Alison E. Fox-Robichaud, Derek McKay
Ulcerative colitis (UC) is a multi-factorial disease with unknown aetiology. At the cellular
level, NK T cells have recently been illustrated as key immune regulators of mucosal
inflammatory processes. Our objective was to characterize both the role NK T cells and
dietary fat in murine dextran sodium sulphate (DSS) induced colitis which resembles human
ulcerative colitis. Male C57Bl/6 mice or B6/CD1-/- (NK T cell deficient) were given 4% (w/
v) DSS for 5 days followed by 3 days normal drinking water. Mice were grouped into either
a breeder (12% fat) or low fat (4%) diet. Mice were euthanized, a clinical score assigned
based on macroscopic observation, and portions of the mid-distal colon removed for electro-
physiological analysis in Ussing chambers and MPO activity. Normal mice on breeder diet,
exposed to DSS, displayed typical signs of colitis: diminished responses to pro-secretary
stimuli, namely electrical stimulation, carbachol and forskolin (all cause Cl- efflux from the
epithelium) when compared to age, time and diet matched control. B6/CD1-/- mice on
breeder diet responded to DSS with a 40% mortality rate, not seen in normal mice, in
addition to diminished short circuit current, both baseline and stimulated, as well as macro-
scopic scores (10.4±0.4 vs. 2.3±0.3) when compared to normal mice, given DSS, on a
breeder diet. It was also observed that a diet with reduced fat content increased the severity
of DSS-induced colitis and (7.3±0.5 vs. 2.3±0.3) decreased ion responses (Table). We have
demonstrated that mice exposed to DSS-induced colitis have a greater degree of inflammation
and altered ion-transport responsiveness when NK T cells are deficient. Diet also seems to
be mediating the response to DSS, as C57Bl/6 mice on low-fat diet display more severe
symptoms of colitis and comparatively diminished ion transport responses. This study may
help in determining the underlying environmental and immune mechanisms involved in
UC pathogenesis.
Ion Transport Responses and Inflammation Scores
*statistically significant, compared to age, time, diet matched control, P<0.03 †statistically
significant, compared to same strain, DSS treated, opposite diet, P<0.03 ‡statistically signific-
ant, compared to opposite strain, DSS treated, same diet, P<0.03
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T1776
The Transcription Factor Sox9 Contributes to the Defect in Ceacam1, 5, 6
Expression in CD
Giulia Roda, Stephanie Dahan, Ling Shao, Mee Sook Park, Franziska Roth-Walter,
Okebugwn Kamalu, Xianyang Yio, Lloyd Mayer
AIM: We have previously documented a transcriptional defect in the expression of three of
the CEA subfamily members expressed on intestinal epithelial cells (IECs), CEACAM6,
CEACAM5 and CEACAM1 in Crohn’s disease (CD) but not in ulcerative colitis (UC). The
consequence of the loss of expression is the lack of activation of CD8+ regulatory T cells.
SOX9 is a transcription factor that regulates IEC differentiation through the Wnt and ?-
catenin pathway. CEA expression has been shown to be down-regulated by SOX9. The aim
of this study was to define whether SOX9 was responsible for the defect in CEACAM
expression. METHODS: SOX9 mRNA and protein was assessed by RT-PCR and Western
Blot using a rabbit polyclonal antibody (Santa Cruz) in freshly isolated IECs from normal
controls (diverticulitis, cancer) and IBD patients (inflamed and uninflamed tissues). Differen-
tial expression from crypt to surface was ascertained following sequential dispase treatments.
Paraffin sections were stained with the same antibody and counterstained with hematoxylin.
Regulation of SOX9 was assessed in fresh IECs and 2 IEC lines (T84 and HT29Cl.16E)
using IL-6, TNF-? and IFN-? alone and in combination for 15 hours. RESULTS: SOX9
mRNA and protein expression was comparable in normal controls vs IBD IECs. Furthermore,
there was no differential expression from crypt to surface. However upon immunohistochem-
ical staining we noted that SOX9 protein was localized in the nucleus in CD IECs in contrast
to cytoplasmic localization in normal and UC IECs. ?-catenin expression paralleled SOX9
expression. SOX9 protein was decreased following treatment with IL-6, TNF-? and IFN-?
while CEA expression was enhanced. CONCLUSIONS: These findings suggest that SOX9
translocation to the nucleus in CD IECs suppresses transcription of CEA and that this is
not related to the presence of inflammatory cytokines.
T1777
Function of Intestinal Dendritic Cells Are Influenced By the Symphathetic
Nervous System in the Gut That Modulates Acute and Chronic Colitis
Ulrike G. Strauch, Florian Obermeier, Gisela Paul, Nicole Grunwald, Sonja Guerster,
Juergen Schoelmerich, Rainer Straub
Background: Within the intestinal lamina propria a dense network of symphathetic nerves
is found in close anatomical distance to intestinal immune cells such as lymphocytes and
dendritic cells. During acute intestinal inflammation a decrease in the density of symphathetic
nerves can be detected. The aim of our study was to investigate whether the sympathetic
nervous system within the gut influences the function of intestinal dendritic cells (DC) and
the course of colitis. Methods: Mice were sympathectomized by i.p. injection of 6-OHDA
and mesenterial lymph node DC (MLN-DC) were isolated. Additionally, acute colitis was
induced 5 days after sympathectomy by 3% DSS within the drinking water for 7 days.
Chronic DSS-colitis was induced by four cycles of 3% DSS feeding and mice were sympathec-
tomized directly after the last DSS-cycle. Weight loss was evaluated and colonic inflammation
was quantified by a histological score. Cytokine secretion was measured within the supernat-
ant of MLN-DC by ELISA. Immunohistochemistry for CD11c+ DC was performed on
frozen sections. Results: After induction of acute DSS-colitis weight loss was reduced in
sympathectomized animals (STX) as compared to control mice and colitis was significantly
ameliorated as shown by histological score (control 7.6±0.5, STX 4.2±1.1, p=0.0079).
Immunohistochemistry was able to demonstrate a reduction in the number of activated DC
within the lamina propria. On the other hand, in animals with established chronic colitis
and symphathectomy intestinal inflammation was more severe (control 1.5±0.4, STX 3.4±0.7,
p=0.0012). MLN-DC from symphathectomized mice expressed more costimulatory molec-
ules and higher levels of proinflammatory cytokines were secreted by these cells, representing
an activated phenotype of antigen-presenting cells. Conclusion: During acute colitis the
sympathetic nervous system plays a role within the induction and perpetuation of colitis as
it directs immune cells e.g. dendritic cells to the inflamed tissue, whereas in chronic colitis
it mediates protective effects as sympathetic stimuli inhibit activation of intestinal DC.
Therefore, the symphathetic nervous system influences gut inflammation by modulation of
activation status and migration pattern of intestinal DC and could play a major role in the
maintenance of tolerance within the healthy gut.
T1778
Iron Chelator-Induced IL-8 Production in Human Epithelial Cells Is
Independent from Nf-κB But Involves AP-1 and CREB Activation
Eun Young Choi, Geom Seog Seo, Chang Soo Choi, Eun Young Cho, Young Woo Sohn,
Ki Jung Yun, Tae Hyeon Kim, Suck Chei Choi, Yong Ho Nah, Chang Duk Jun
We have previously shown that a bacterial siderophore, deferoxamine (DFO), could trigger
inflammatory signals in human intestinal epithelial cells by ERK1/2 and p38 pathways.
In the present study, we determined transcription factors involved in DFO-induced IL-
8 production. DFO markedly up-regulated the mRNA levels of essential components of
transcription factor AP-1 in HT-29 cells. Although there was a slight expression of NF-κB
subunit, pharmacological inhibitors that affect NF-κB pathways showed little effect on the
DFO-induced IL-8 production as well as the NF-kB transcriptional activity. In contrast,
DFO significantly induced AP-1-dependent transcriptional activity and that transfection with
dominant-negative (DN) c-Jun mutant markedly inhibited DFO-induced IL-8 promoter
activity as well as AP-1-dependent transcriptional activity. Electrophoretic mobility shift
assays confirmed that DFO increases the specific binding of AP-1 but not NF-κB. Interestingly,
such AP-1 transcriptional and binding activities were blocked by pharmacological inhibitors
of ERK1/2 and p38 kinase pathways, suggesting that MAPKs lie upstream of AP-1-dependent
IL-8 production by iron chelator. DFO also induced phosphorylation of CREB and increased

















In summary, these results demonstrate that iron chelator-induced IL-8 production is inde-
pendent from transcription factor NF-κB but involves AP-1 and CREB activation in human
intestinal epithelial cells.
T1779
Membrane-Bound NAD(P)H Oxidase Repressess Cytotoxic Effects of Tumor
Necrosis Factor (TNF)-α in Pancreatic Stellate Cells (PSCs) Via NF-kB
Independent Mechanism
Eva C. Vaquero, Mariana Rickmann, Xavier Molero, Juan Ramon Malagelada
In many non-phagocytic cells NAD(P)H oxidase generates radical oxygen species (ROS) able
to activate critical survival signals such as NF-kB. PSCs, the main cell type responsible for
pancreatic fibrosis, are activated upon oxidative conditions. TNF-α is a redox-responsive
molecule able to activate both survival and death pathways. In PSCs TNF-α induces pro-
survival responses. AIM: To investigate the presence of a membrane-associated NAD(P)H
oxidase as ROS source induced by TNF-α and its role in precluding TNF-α pro-apoptotic
potential in PSCs. METHODS: Activated rat PSCs were preincubated for 30 min with the
NAD(P)H oxidase inhibitor dyphenilene iodonium (DPI) and then stimulated with TNF-α
for 30 min to 5h. Superoxide (O2.-) production by NAD(P)H oxidase was quantitated by
lucigenin-enhanced chemiluminescence on membrane fractions. Cell death analysis was
based on DNA fragmentation measured by ELISA; fluorescein diacetate (FDA)/propidium
iodide (PI) staining by FACS; caspase-8, -9 and -3 activities by fluorometry; and mitochondrial
membrane potential loss by FACS. mRNA expression of Nox subunits was analyzed by RT-
PCR. RESULTS: PSCs possess a functionally active NAD(P)H oxidase system as indicated
by a basal production of O2.- and expression of Nox 1, Nox 2, Nox 4, p22, p47phox, and
p67phox, key components of the enzymatic system. Exposure of cells to TNF-α for 30 min
induced a 3-fold increment in NAD(P)H oxidase activity. Both basal and TNF-α stimulated
NAD(P)H oxidase activities were abolished by DPI. TNF-α by itself did not elicit cell death.
However, when NAD(P)H oxidase activity was inhibited with DPI, TNF-α stimulated PSC
death, as shown by DNA fragmentation (TNF-α + DPI: 8.6 ± 2.2 vs DPI: 6.7 ± 2.5 relative
to control; p < 0.05), FDA-/PI- staining -apoptotic fraction- (TNF-α + DPI: 9.8 ± 3.4 vs
DPI: 6.4 ± 1.9; p < 0.05), FDA-/PI+ staining -aponecrotic fraction- (TNF-α + DPI: 18.5 ±
1 vs DPI: 13.3± 1.1; p < 0.05). The apoptotic effect of TNF-α upon NAD(P)H blockade
was preceded by mitochondrial membrane depolarization and associated to large activation
of caspase-8, -9 and -3. Upstream caspase-8 inhibition by IETD-fmk totally blocked DPI-
sensitization to TNF-α induced apoptosis, suggesting that DPI is uncovering the extrinsic
caspase pathway of TNF-α. TNF-α caused a rapid activation of NF-κB that was not prevented
by DPI. CONCLUSIONS: TNF-α stimulates ROS production in PSCs via NAD(P)H oxidase.
This pro-oxidative effect silences the cytotoxic actions of TNF-α by an NF-kB independent
mechanism. NAD(P)H oxidase can be a useful therapeutic target in the treatment of pancreatic
fibrosis by facilitating PSC elimination.
T1780
Natural Vitamin E Tocotrienols, But Not a-Tocopherol, Induce Apoptosis and
Autophagy in Pancreatic Stellate Cells (PSCs)
Mariana Rickmann, Eva C. Vaquero, Xavier Molero, Juan Ramon Malagelada
Natural vitamin E comprises two groups of compounds, tocotrienols and tocopherols.
Although a-tocopherol is widely used in clinical practice, tocotrienols exert stronger antioxid-
ant, cardioprotective, neuroprotective and tumor suppressive effects. Oxidative stress pro-
motes activation and expansion of PSCs in chronic pancreatitis. In these settings, induction
of PSC apoptosis might halt the progression of the disease. AIMS: To investigate the antioxid-
ant and death promoting effects of both a-tocopherol and a palm oil derived tocotrienol-
rich fraction (TRF) in PSCs. METHODS: Activated rat PSCs were treated with TRF or a-
tocopherol for 1 to 72 h. Intracellular radical oxygen species (ROS) were measured by FACS
using DCFH-DA; lipoperoxidation by fluorogenic assay in cells labeled with diphenyl-1-
pyrenylphosphine (DPPP); cell number by CyQUANT; apoptosis by DNA fragmentation,
changes in mitochondrial membrane potential, and caspase-8, -9 and -3 activities; autophagy
by detection of autophagic vacuoles stained with monodansyl cadaverine (MDC) and accumu-
lation of LC3-II protein by immunoblot. RESULTS: Both TRF and a-tocopherol caused a
mild decrease of ROS and a marked reduction (40% vs control) of lipoperoxidation. To
exclude cell toxicity interference on ROS assessment, only viable cells (PI-excluding) were
analyzed for DCFH-DA and DPPP labeling. Cell number decreased by 30% after 24 h
incubation with TRF but it was not affected by a-tocopherol treatment for up to 72 h. In
addition, TRF caused a significant increase in DNA fragmentation (5.7±1.5 fold vs untreated
cells; p < 0.0001), which was associated with a large activation of caspase-8, -9, and -3.
Apoptotic changes were heralded by a pronounced mitochondrial membrane depolarization
that was initiated during the first hour of TRF incubation. Interestingly, TRF did not induce
apoptosis in quiescent (oil red positive) PSCs plated on basement membrane-like substrate
(Matrigel). In contrast to TRF, a-tocopherol induced a weaker pro-apoptotic effect, shown
by a modest increase in DNA fragmentation (1.8±0.2 fold vs untreated cells; p<0.0001) and
by loss of mitochondrial membrane potential. Moreover, the apoptotic effect of a-tocopherol
did not involve caspase activity. Cells exposed to TRF developed cytoplasmic autophagic
vesicles as shown by MDC autofluorescence and accumulation of LC3-II. In contrast, a-
tocopherol was unable to induce the above autophagic changes. CONCLUSIONS: Tocotrien-
ols from palm oil, but not a-tocopherol, induce a robust cell death program (apoptosis and
autophagy) in activated PSCs. Tocotrienols should be strongly considered as a potential
therapeutic tool for chronic pancreatitis.
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T1781
Overexpression of Thioredoxin-1 Prevents Cerulein-Induced Pancreatic
Fibrosis in Mice
Shinya Ohashi, Akiyoshi Nishio, Hajime Nakamura, Junji Yodoi, Tsutomu Chiba
Background and Aims: Chronic pancreatitis (CP) is suggested to result from repetitive
pancreatic injury, so-called necrosis-fibrosis sequence hypothesis. Various cytokines, growth
factors, and chemokines released from injured tissues and inflammatory cells play an import-
ant role in the proliferation and activation of pancreatic stellate cells, which consequently
induce pancreatic fibrosis. Considering the production of these mediators, oxidative stress
is considered to play a crucial role. We previously reported thioredoxin-1 (TRX-1), an
endogenous redox-regulating protein with an anti-oxidant effect, prevents experimental acute
pancreatitis (AP) in mice. In this study, we aimed to clarify the protective role of TRX-1 on
pancreatic fibrosis using CP model in transgenic mice overexpressing TRX-1 (TRX-1-TG
mice). Methods: C57BL/6 wild type mice and TRX-1-TG mice of B6 origin were used for
the experiment. At first, experimental AP was induced by intraperitoneal administration of
cerulein and lipopolysaccharide injection. Histological changes and malondialdehyde levels
in the pancreas were examined. Next, experimental CP was induced by three episodes of
AP per week for 6 weeks. Pancreatic fibrosis was evaluated by histology and hydroxyproline
content. Activation of pancreatic stellate cells was assessed by immunostaining and Western
blotting for α-smooth muscle actin (α-SMA). Moreover, pancreatic gene expression of
transforming growth factor-β (TGF-β), platelet-derived growth factor (PDGF), and monocyte
chemoattractant protein-1 (MCP-1) was investigated using RT-PCR. Results: In AP model,
overexpression of TRX-1 suppressed oxidative stress as determined by malondialdehyde
levels, and attenuated acute pancreatic injury. In the pancreas of wild type mice in CP
model, the acinar units were atrophied and some acinar units redifferentiated into tubular
complexes. Moreover, thick bands of extracellular matrix accumulated around acinar units,
and increased numbers of inflammatory cells were infiltrated within the matrix. However,
pancreatic damages were obviously attenuated in TRX-1-TG mice. Pancreatic hydroxyproline
contents and α-SMA positive areas were significantly reduced in TRX-1-TG mice. Moreover,
a gene expression of TGF-β, PDGF, and MCP-1 in the pancreas was also significantly
decreased in TRX-1-TG mice. Conclusions: TRX-1 suppressed oxidative stress in AP, which
resulted in the attenuation of CP. These results support the necrosis-fibrosis theory and
oxidative stress is also supposed to be involved in the pathogenesis of CP.
T1782
Suppression of IFN-γ and Increase in IL-6 Is Associated with Ethanol-Induced
Chronic Pancreatitis Responses in the CsA Model of Alcoholic Chronic
Pancreatitis
Ilya Gukovsky, Mohammad Shahsahebi, Peggy P. Hong, Aurelia Lugea, Samuel W. French,
Stephen J. Pandol
Background & Aims: Alcohol abuse is a major cause of chronic pancreatitis; however, the
pathogenesis of alcoholic chronic pancreatitis (ACP) remains unknown. A critical obstacle
to understanding the mechanism of ACP is lack of animal models. We recently developed
a model of alcohol mediated pancreatitis, termed “the CsA model of ACP”, which for the first
time reproduces all 3 responses characteristic of chronic human disease: loss of parenchyma,
sustained inflammation, and fibrosis. These changes result from synergistic effect of ethanol
diet, an episode of acute pancreatitis, and cyclosporin A (CsA) treatment. Our goal is to
elucidate the mechanisms underlying these responses. Methods: Rats were pair-fed for 8
weeks Lieber-deCarli ethanol (E) or control (C) diet. For the last 2 weeks, they received
CsA or vehicle. After 1 week on CsA, rats were subjected to 1 episode of cerulein (CR)
pancreatitis, and killed at 3 h, 2, 4 or 7 d after CR treatment. Results: We found that ethanol
feeding greatly inhibited pancreatic expression of IFN-γ and up-regulated that of IL-6 in
our model. First, we compared the effect of all the treatments at 7 days after acute CR
pancreatitis. Expression of both cytokines was detected by RT-PCR only with the combined
treatment, i.e., C+CsA+CR and E+CsA+CR, but not in other groups. In E+CsA+CR rats,
IFN-γ mRNA expression was several fold lower while that of IL-6 was increased. These
changes were associated with a much more severe pancreatic injury in the ethanol-fed rats,
characterized by loss of up to 90% parenchyma, sustained inflammatory infiltration (9 times
greater than in C+CsA+CR group), and widespread fibrosis. In time-course experiments on
the two groups, IFN-γ expression in pancreas remained undetectable acutely (i.e., at 3 h)
and dramatically increased at 2 days after the episode of acute CR pancreatitis. IFN-γ mRNA
levels then subsided, but in E+CsA+CR group they were several-fold less than in C+CsA+CR
rats. By contrast, IL-6 mRNA expression was induced acutely, and it was significantly higher
in E+CsA+CR rats than in their control-fed counterparts. Conclusions: Ethanol-induced
suppression of IFN-γ, a key Th1 mediator, together with up-regulation of IL-6 (that can be
anti-inflammatory) may promote “immunoparalysis”-like condition, resulting in perpetuation
of pancreatic injury. Because IFN-γ is a major anti-fibrotic factor, its inhibition facilitates
fibrosis induced by ethanol feeding in our model. These findings have important implications
for the mechanism of ACP.
T1783
Sequence Variants of the CFTR Gene and Susceptibility to Idiopathic Chronic
Pancreatitis
Bernhard Steiner, Jonas Rosendahl, Heiko Witt, Nils Teich, Volker Keim, Marie-Pierre
Audrezet, Claude Ferec, Sabina Gallati, Macarena Gomez-Lira, Giorgio Cavallini, Kaspar
Truninger
INTRODUCTION Compound heterozygous mutations in the CFTR gene are associated with
idiopathic chronic pancreatitis (ICP), however, whether carriers of a single mutant CFTR
allele have an increased ICP risk is unknown. We evaluated the role of common CFTR
sequence variants, which we have recently shown to be associated with aberrantly spliced
CFTR transcripts. METHODS 132 ICP patients and 394 healthy controls were genotyped
for mutations and 5 sequence variants by SSCP-HD or dHPLC. We carried out a replication
study involving 304 ICP patients and 309 healthy controls. RESULTS Mutations were
identified in 43/132 (32.6%) patients and in 22/394 (5.6%) healthy controls (p < 0.001).
No control subject, but nine patients (7%) had a compound heterozygous genotype(OR
79.1, 95%CI 4.6-1371.4; p < 0.001). A single CFTR mutation increased ICP risk 5.6-fold
(95%CI 3.1-10.1; p < 0.001). None of the five sequence variants was associated with ICP,
except the p.M470V variant. The V allele was more common among controls than ICP
patients both in the first (53% vs 47%; p 0.08) and in the second population and ICP risk
was increased in carriers of two V alleles (1. Popul OR 0.63, 95%CI 0.36-1.08; p 0.09; 2.
Popul OR 0.62, 95%CI 0.39-0.99; p<0.05). The 5 sequence variants were used to infer
haplotypes, of which one was associated with increased ICP risk (OR 1.91, 95%CI 1.16-
3.15; p 0.02) and one with decreased ICP risk (OR 0.68, 95%CI 0.50-0.93; p 0.01). With
the use of the UPGMA clustering method, haplotypes were grouped. Statistical analysis
demonstrated one cluster to be associated with an almost 2-fold ICP risk increase (OR 1.92,
95%CI 1.20-3.07; p 0.008), whereas another cluster showed a protective effect(OR 0.36,
95%CI 0.13-1.03; p 0.05). Patients and controls were assigned a CFTR cluster group
combination depending on whether the haplotype group combination was associated with
an adverse or protective effect on ICP susceptibility. The frequency of the homozygous risk
genotype cluster was higher in patients (19%) than controls (10%)(OR 2.1, 95%CI 1.1-4.0;
p 0.02). Conversely, carriers of two protective genotype clusters were more common among
controls (42%) than patients (30%)(OR 0.4, 95%CI 0.2-0.7; p 0.002). These findings were
confirmed in the second population both for the risk (OR 2.0, 95%CI 1.2-3.2; p 0.005)
and the protective genotype cluster(OR 0.6, 95%CI 0.4-0.9; p 0.02). Finally, in carriers of
a single mutant CFTR allele, we found significantly more risk and protective clusters in
patients and controls, respevtively. CONCLUSION Common CFTR sequence variants and
their combinations modify ICP susceptibility, particularly in carriers of a single mutant allele.
T1784
Low-Dose Alcohol Redirects Postprandial Cholinergic-Stimulated Apical
Exocytosis in Pancreatic Acinar Cells to the Basal Membrane, the
Susceptibility Mechanism of Alcoholic Pancreatitis
Kai Yang, Patrick Lam, Herbert Y. Gaisano
BACKGROUND. We previously demonstrated that alcohol (ETOH) pretreatment of pancre-
atic acini caused the basal plasma membrane (BPM) to become receptive to aberrant BPM
exocytosis upon stimulation with submaximal CCK-8. These actions of alcohol on the acinar
cell were due to induction of PM-bound Munc18c to dissociate into the cytosol, rendering
the PM Syntaxin4 to interact with PM-SNAP-23 and granule-VAMP to form a complex
capable of mediating basolateral exocytosis into the interstitial space, which we had postulated
to be a mechanism of alcoholic pancreatitis. Human pancreas however lack CCK receptors
and instead responds to cholinergic stimulation. AIM: We therefore examined whether
postprandial ETOH concentration (20mM) is able to alter postprandial cholinergic stimula-
tion (1uM carbachol) of rat pancreatic acinar cells. METHODS: Rat pancreatic acini were
pretreated with non-stimulatory ETOH (20mM) followed by stimulation with postprandial
carbachol (1uM), a dose stimulating only half maximal amylase secretion. We then examined
the effects on secretion by: (1) determination of amylase release, (2) real-time epifluorescent
imaging of exocytosis using FM1-43; (3) confocal microscopy to examine the behavior of
basolateral SNARE complex proteins; (4) cell subfractionation to quantify the SNARE protein
levels on the PM. RESULTS: Whereas 20mM ETOH has no effect on amylase secretion,
preincubation of acini with 20mM ETOH inhibited 1uM carbachol stimulated secretion.
1uM carbachol evokes apical exocytosis, but pretreatment with 20mM ETOH redirected
exocytosis to the basal PM. While 20mM ETOH nor 1 uM carbachol affected BPM-bound
Munc18c, confocal microscopy and subcellular fractionation showed that 20mM ETOH
preincubation induced 1uM carbachol to displace Munc18c from the BPM into the cytosol.
CONCLUSION: We conclude that ETOH renders acini PM-Munc18c conducive for postpran-
dial cholinergic stimulation to displace into the cytosol, which would promote basolateral
exocytosis - which we propose to be the ‘susceptibility’ mechanism for human alcoholic
pancreatitis. (Funded by: ABMRF and NIH).
T1785
Activation of PAK2 By CCK in Rat Pancreatic Acinar Cells
Joo Weon Lim, John A. Williams
CCK activates small G proteins of the Rho family and both Rac and Rho play a role in
regulating secretion, cell morphology and the actin cytoskeleton. However, little is known
of their upstream regulators and downstream effectors. We used a GST-Rac1 fusion protein
loaded with GDP or GTPγS as an affinity reagent to pull out interacting proteins from
pancreatic lysate, which were then separated by 1D gel electrophoresis. Two protein bands
binding uniquely to Rac loaded with GTPγS were identified by MALDI TOF tandem mass
spectrophotometry as p21 activated kinase (PAK) 2 and βPIX. Both Western blotting and
RT-PCR identified PAK2 as the major form of PAK present in acini. Using Western blotting
and a pull-down assay with GST-PAK protein, we found two βPIX isoforms, β1PIX and
β2PIX were present and that β2PIX was able to bind to PAK2. When PAK2 was immunopreci-
pitated and used in a kinase assay with myelin basic protein as substrate, CCK activated
PAK activity, which was increased about 2 fold at 2 min and subsequently decreased but
remained elevated to 20 min. Using different concentrations of CCK, PAK activation showed
a maximal increase at 100 pM. Both time course and dose response for PAK2 paralleled the
activation of Rac as determined by a pull-down assay with GST-PAK-PBD domain. An
important role for βPIX was shown by use of a antisense oligonucleotide introduced into
acini with a cationic liposome DOTAP which reduced βPIX content by about 50% following
overnight incubation. The antisense but not the sense oligonucleotide led to a reduction in
activation of both PAK and Rac following stimulation with CCK. This result suggests that
βPIX is a regulator for both PAK and Rac activation and that Pak may mediate some of the
actions of Rac in rat pancreatic acinar cells.
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T1786
CCK-Induced Protein Kinase D Activation Is Regulated By Upstream PKC and
Plays a Role in Pancreatic Acinar Cell Secretion
L. Andy Chen, J.N. Li, Hiroaki Watanabe, B. Mark Evers
Protein kinase D1 (PKD1) is a novel serine-threonine kinase which has been implicated in
important intracellular functions such as cell survival and secretion. We have recently
demonstrated that the secretagogue cholecystokinin (CCK) induces rapid translocation,
phosphorylation, and activation of PKD1 in pancreatic acinar cells; however, the mechanism
and function of PKD1 activation in these cells is not known. The purpose of our study was
to delineate the signaling pathways upstream of PKD1 activation and to determine whether
PKD1 inhibition affects CCK-stimulated secretion. METHODS: Pancreatic acinar cells were
isolated from female Swiss Webster mice (2 to 3-mo-old) by collagenase digestion. (i) CCK-
induced PKD1 activation in acinar cells was determined by Ser744/748 phosphorylation,
kinase activity and translocation assays. A variety of pharmacological inhibitors were used
to test whether members of the PKC, MAPK, and PI3K family are involved in CCK-induced
PKD1 activation. (ii) Isolated acinar cells were treated with either Gö-6976 (which inhibits
PKCα and PKCβ1 as well as PKD) or Gö-6983 (which inhibits the α, β, γ, δ PKC isoforms
but not PKD). Inhibition of PKD was confirmed by kinase activity assay, and CCK-stimulated
secretion was assessed by amylase assay. RESULTS: (i) CCK-induced PKD1 phosphorylation
in acinar cells was inhibited > 70% by pre-treatment with GF109203X (5 µM), a broad-
spectrum PKC inhibitor and by rottlerin (2 µM), a PKC-δ inhibitor; neither the Akt inhibitor
(5 µM) nor the PI3K inhibitors, LY294002 (2 µM) or wortmannin (100 nM), significantly
affected PKD1 activation. (ii) CCK-induced amylase secretion was inhibited ~20% by Gö-
6976 (1 µM), a PKC inhibitor effective against PKD, but not by Gö-6983 (1 µM), a PKC
inhibitor ineffective against PKD. CONCLUSIONS: Our results demonstrate PKC-dependent
PKD1 activation in pancreatic acinar cells following CCK stimulation. Importantly, our
findings suggest a functional role for PKD1 in pancreatic acinar cell enzyme secretion.
T1787
Calcium-Regulated Phosphorylation of Crhsp-28 At Serine 136 Mediates Its
Translocation from a Perinuclear/Golgi Region to Plasma Membrane and
Induces Acute Changes in Cho-K1 Cell Plasma Membrane Morphology
Diana D. Thomas, Ning Weng, Christina L. Martin, Kala M. Kaspar, Megan D. Baumler,
Guy E. Groblewski
CRHSP-28 is member of the Tumor Protein D52 family that is under normal conditions
highly expressed in exocrine acinar cells, where it regulates Ca2+-dependent secretory activity.
CRHSP-28 is also overexpressed in cancers of the breast, colon, lung, and prostate. Stimula-
tion of acini induces a rapid translocation of CRHSP-28 from the trans-Golgi region to the
apical plasma membrane and an early endosomal compartment and directly coincides with
its acute serine phosphorylation. Ectopic expression of CRHSP-28 in CHO cells revealed
that elevation of cellular Ca2+ by ionophore treatment induced a marked translocation of
the protein from a perinuclear/Golgi region to the plasma membrane within 5 min and a
pronounced increase in its phosphorylation. Mutation of multiple serine sites to alanine on
CRHSP-28 revealed that ser136 is the major phosphoacceptor site in both basal and stimulated
conditions as indicated by immunoprecipitation following 32P-labeling and immunoblotting
following isoelectric focusing. Although CRHSP-28 was previously shown as phosphorylated
by CaM kinase II in vitro, ser136 is present within a casein kinase II consensus sequence.
Mutation of the single CaM kinase II consensus site (ser100) was without effect. Likewise,
mutation of two additional casein kinase II consensus sites alone or in combination with
ser136 did not further alter CRHSP-28 phosphorylation, confirming that ser136 is the
primary site of phosphorylation in intact cells. Strikingly, the ser136/ala mutation failed to
translocate to the plasma membrane following Ca2+-stimulation. Moreover, phosphomimetic
mutation of ser136 to aspartate or glutamate resulted in a pronounced accumulation of
CRHSP-28 along the plasma membrane. The CRHSP-28 ser136/asp and ser136/glut were
localized within distinct plasma membrane invaginations resembling endocytic vesicles that
appeared to be arrested during formation. Moreover, the plasma membrane of cells expressing
the phosphomimetic mutants displayed multiple cytoplasmic projections suggestive of cell
spreading/migration. These data demonstrate that CRHSP-28 Ca2+-mediated phosphorylation
occurs at ser136 and is the triggering mechanism for CRHSP-28 translocation to the plasma
membrane. Moreover, these data lend insight into the molecular nature of CRHSP-28’s
regulatory effects on acinar membrane trafficking and may have significant implications
regarding its overexpression in epithelial cell cancers.
T1788
The Large Gtpase Dynamin Localizes to and Is Involved in Zymogen Secretion
At the Pancreatic Acinar Cell Apical Membrane
Vijay Singh, Barbara Schroeder, Mark A. McNiven
Introduction: Dynamin is a large GTPase involved in membrane dynamics required for
endocytosis and secretion. In addition, dynamin provides a link between membranes and
the actin cytoskeleton through a direct interaction with the actin-binding protein cortactin.
The actin cytoskeleton is known to be involved in zymogen secretion and we have recently
shown that dynamin is involved in Golgi vesiculation in response to CCK in cultured
pancreatic acinar cells. However, the role of cortactin in these processes in conjunction with
dynamin is unknown. The GOAL of this study was to test the distribution and participation
of dynamin and cortactin in CCK-stimulated zymogen secretion from isolated pancreatic
acini. Materials and Methods: Male Sprague-Dawley rats weighing 100-150 grams were used.
For in vivo studies, rats received 0.05 mcg/kg of CCK in 0.2 ml saline or vehicle (0.2 ml
saline) intraperitoneally and were sacrificed 3 hours later. Harvested pancreas was embedded
in OCT and immunostained. For in vitro studies, acini were harvested in HEPES buffer and
either used fresh or cultured overnight in DMEM with 0.5% BSA. Fresh acini were stimulated
with CCK (0.1 nM) for up to 3 hours before immunostaining. For secretion studies, cultured
acini were transfected with 2 x 106/ml PFU adenovirus to induce expression of either GFP,

















Untransfected acini were used as a control. Results: Stimulation of acini with physiologic
doses of CCK resulted in a marked translocation of dynamin and cortactin to the apical
domain both in vivo and in vitro. Amylase secretion in response to 0.1 nM CCK from
cultured acini was not affected by expression of GFP or wild type dynamin compared to
controls (2.0+0.7% basal vs. 8.7+1.2% with 0.1 nM CCK). In contrast, expression of the
mutant dynamin, Dyn2K44A, resulted in a 70% reduction in stimulated secretion (2.5+0.3%
basal vs. 5.3+0.7% with 0.1 nM CCK). This reduced secretion was accompanied by a
reduction in cortical actin at the apical domain, which was rich in untransfected, GFP-
and wild type dynamin-transfected acini. Conclusions: Dynamin and cortactin translocate
apically, where they colocalize, in response to physiologic CCK stimulation. This apical
translocation may be related to zymogen granule secretion as disruption of dynamin function
resulted in the inhibition of CCK-stimulated secretion along with a loss in apical actin.
Thus, dynamin may translocate with cortactin to the apical membrane and together they
may aid in regulating CCK-stimulated zymogen secretion, possibly via a role in post-secretion
membrane retrieval.
T1789
Role of Protein Kinase C Delta (Pkcδ) in Cholecystokinin-8-Induced Amylase
Secretion and Nuclear Factor Kappa-B (Nf-κB) Activation in Pancreatic Acini
Jeffrey L. Wang, Akihiko Satoh, Lars S. Fischer, Stephen J. Pandol
Background and aims: Protein Kinase C represents a family of calcium and diacylglycerol
activated kinases. It has multiple roles in the regulation of both the physiology and pathophy-
siology of the pancreas. Four specific isoforms of PKC (α, δ, ε, and ζ) have been demonstrated
to be present in pancreatic acinar cells. Recent studies provide evidence for roles of PKCδ
in pancreatic enzyme secretion, and PKCδ and ε in activating inflammatory signal NF-κB.
Experiments with pharmacologic inhibitors suggest that PKCδ plays a key role in acinar
cells responses to cholecystokinin-8 (CCK). However, effects of genetic deletion of PKCδ
on acinar cells responses have not been studied. We investigated the role of PKCδ in both
amylase secretion and NF-κB activation induced by CCK in pancreatic acinar cells obtained
from PKCδ deficient and wild type mice. Methods: PKCδ-/- mice were generated in the
laboratory of Dr. Nakayama from Kyushu University, Japan. PKCδ deficiency was confirmed
by genotyping. Pancreatic acinar cells were isolated from PKCδ-/- and PKCδ+/+ and incubated
for 30 min with CCK concentrations ranging from 1ρM to 0.1 μM. CCK-induced amylase
secretion was measured using Phadebas kit; NF-κB activation was measured using electromo-
bility shift assay (EMSA). Results: CCK induced typical biphasic dose response curve for
secretion of amylase in acinar cells isolated from both PKCδ-/- and wild type mice with
stimulation up to approximately 0.1 nM and subsequent reduction of amylase release at
supra-maximal doses of CCK. At both physiologic and supra-physiologic doses, CCK-induced
amylase secretion was greater in acinar cells from PKCδ-/- versus that from wild type mice.
For example, 10 ρM CCK stimulated amylase secretion by ~ 20% more so in the acinar
cells from PKCδ-/- compared with the acinar cells from wild type mice. Our data suggest
that PKCδ is a negative regulator of CCK-induced amylase secretion in acinar cells. On the
other hand, CCK at supra-physiologic dose (0.1 μM) stimulated NF-κB activation in acini
isolated from both PKCδ-/- and wild type mice. There was a 25% inhibition of NF-κB
activation in the acini from PKCδ-/- mice, suggesting that PKCδ mediates CCK induced NF-
κB activation in pancreatic acinar cells. Conclusions: Experiments on pancreatic acinar cells
from PKCδ-/- mice indicate that PKCδ negatively regulates CCK-induced amylase secretion
and mediates CCK-induced NF-κB activation in pancreatic acinar cells. These effects of
PKCδ may play a role in dysregulation of amylase secretion and inflammatory infiltration
in pancreatitis.
T1790
Pancreatic Secretagogues But Not Growth Factors Activate Pkd1 in Rat
Pancreatic Acini By a Novel Mechanism
Marc J. Berna, Karl M. Hoffmann, Jose A. Tapia, Michelle Thill, Robert T. Jensen
Introduction: Protein kinase D (PKD) is a serine-threonine kinase that has been implicated
in cell survival, proliferation, migration, invasion and protein trafficking. PKD activation is
coupled to signaling by growth factors, G-protein coupled receptors and oxidative stress.
There are no studies of the ability of pancreatic acinar cell stimulants to activate PKD or
the possible processes involved. Methods: In dispersed rat pancreatic acini, PKD isoforms
were studied by using specific PKD total and phospho-antibodies after SDS-PAGE and
Western blotting. Immunocytochemistry was performed on cells after cytocentrifugation.
Results: In quiescent acini both PKD1 and PKD2 were detected. After stimulation with CCK,
a marked increase in serine-phosphorylated PKD1 (pPKD1) occurred both at the 916 and
the 744/748 site. CCK, carbachol, bombesin and TPA induced pronounced PKD1 phos-
phorylation, whereas stimulation with other secretagogues (VIP, secretin) and growth factors
(HGF, EGF, insulin, IGF1) had no effect. CCK-stimulated pPKD1 was studied in detail.
CCK-mediated PKD1 phosphorylation was detectable within 30 sec, reaching a maximum
after 10 min and lasting over 60 min. CCK caused a dose-dependent increase in pPKD1
(EC50=0.1 nM). Stimulation with the high-affinity CCKA-receptor agonist and low-affinity
antagonist JMV180 lead to a partial (20% of maximal CCK) PKD1 phosphorylation. Co-
stimulation with CCK and JMV180 resulted in a dose-dependent inhibition of CCK-mediated
PKD1 phosphorylation (IC50=600 nM JMV180). Inhibition of classical and novel PKC
isoforms with GF109203X induced a total suppression of TPA-mediated, but only a partial
(60%) suppression of CCK-induced PKD1 phosphorylation. Calcium depletion with thapsi-
gargin resulted in a nearly complete (90%) inhibition of CCK-induced but had no effect on
TPA-mediated PKD1 phosphorylation. The calcium ionophore A23187 did not induce PKD1
phosphorylation, nor did it potentiate TPA-mediated PKD1 activation. After stimulation
with CCK (10 nM), a rapid but temporary translocation of PKD1 from the cytosol to
the membrane could be observed both in Western blots and in immunocytochemistry.
Conclusions: A number of pancreatic secretagogues but not growth factors cause PKD1
activation in rat pancreatic acini. CCK-induced PKD1 activation is mediated by both the
high (20%) and low-affinity (80%) CCKA-receptor state. In contrast to other cells, CCK-
mediated PKD1 activation only partly relies on signaling through classical and novel PKC
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isoforms but is strongly dependent on calcium, suggesting pancreatic acini may possess
novel signaling mechanisms of PKD activation.
T1791
ATP Release from Pancreatic Duct Epithelial Cells (PDEC): Effects of Hypo-
Osmolarity and Ethanol
Toan D. Nguyen, Evelyn Tong, Thomas Sernka
INTRODUCTION: ATP may serve as an intercellular messenger by interacting with specific
P2 receptors on cell membranes; it may also be released from epithelial cells to act in an
autocrine fashion on the same cell, or in a paracrine fashion on neighboring cells. We
previously demonstrated the expression of different P2Y and P2X receptors on PDEC; we
now report the effect of hypo-osmolarity and ethanol on ATP release from these cells.
METHODS: Two human PDEC cell lines were studied, PANC-1 and CFPAC cells; of note,
CFPAC cells are derived from a patient with cystic fibrosis and do not express the CFTR
Cl- channels. ATP released from these cells was monitored by measuring the luminescence
generated when ATP reacts with luciferin through a reaction catalyzed by luciferase.
RESULTS: When exposed to a hypo-osmolar medium, both PANC-1 and CFPAC cells
release ATP. This release occurs at hypo-osmolar levels as low as 20% and increases with
increasing hypos-osmolar challenges, up to 60% (PANC-1: control: 12 ± 4; 20% hypo-
osmolar: 22 ± 5; 30%: 29 ± 4, 40%: 53 ± 17, 50%: 93 ± 17, 60%: 157 ± 7.6; CFPAC:
control: 16 ± 1, 20% hypo-osmolar: 57 ± 15, 30%: 162 ± 38, 40%: 247 ± 76, 50%: 352
± 42, 60%: 586 ± 96 [mean ± SEM, in arbitrary luminometric units]). Ethanol at concentra-
tions up to 1% did not cause ATP release. On the hand, when cells were preincubated with
1% ethanol, the response to a 50% hypo-omotic challenge was inhibited by 40% in PANC-
1 cells and 50% in CFPAC cells. This effect may be partially mediated by the osmotic
contribution of ethanol (1% = 172 mM) since cells pre-incubated with 172 mM mannitol
also showed a similar degree of inhibition. CONCLUSION: Hypo-osmolarity stimulates ATP
release from PDEC in a dose dependent manner. The ability of CFPAC cells to release ATP
suggests that the CFTR Cl- channel, previously postulated to also serve as ATP conductance,
does not mediate this release. If the released ATP interacts with P2 receptors to stimulate
secretion, this may constitute a possible protection mechanism, in this case against hypo-
osmolarity-induced cell swelling. As ethanol impairs this reaction, this may be a mechanism
whereby ethanol contributes to cellular injury. Funded by NIH RO-1 DK 55885 and VA
Merit Review.
T1792
JNK Activation Is Required for CCK Induced Pancreatic Acinar Cell Growth
in Culture
Lili Guo, Maria Dolors Sans, John A. Williams
Pancreatic growth occurs during fetal and early postnatal development and in the adult
animal can be regulated by diet and gut hormones such as cholecystokinin (CCK). Our
previous studies showed that endogenous CCK released by feeding trypsin inhibitor activated
JNKs and ERKs as well as inducing expression of a variety of early response genes such as
c-jun and c-fos. To more directly characterize the importance of the MAPK pathways and
early response genes in CCK induced pancreatic growth, we used an in vitro cell culture
model. Mouse pancreatic acinar cells were isolated with collagenase and cultured on type
I collagen with [3H] thymidine incorporation as a read out of DNA synthesis. CCK added
after 24h in culture enhanced DNA synthesis with a minimal effect at 30pM and a maximal
effect of 9.6±2.1 fold at 10nM. EGF and FGF, the most potent growth factors, induced a
maximal 7.8±1.2 and 3.6±0.4 fold increase of thymidine incorporation at 10nM; much smaller
effects on thymidine incorporation were seen with maximal concentrations of carbachol,
bombesin, insulin and IGF-1. BrdU incorporation visualized by immunohistochemistry
confirmed that stimulated DNA synthesis occurred in pancreatic acinar cells. JNK activity
was increased 30 min after adding 1nM CCK to the cultured acinar cells as shown by
western blot with an activity state dependent antibody. CCK also induced early response
genes expression at the mRNA level measured by quantitative RT-PCR including c-jun (17
fold), c-fos (44 fold) and ATF-3 (18 fold), while the expression of 18sRNA was not affected
by CCK and GAPDH was slightly decreased. These increases were maximal at 1-2 h and
decreased by 3 h. C-jun protein induction was also observed after CCK stimulation with a
maximal increase at 3 h; this induction was 70% blocked by the JNK inhibitor SP600125
at 30µM. Specific chemical inhibitors of the JNK and ERK pathways were used to initiate
studies of the importance of MAPKs to CCK induced acinar cell growth. SP600125 at 30µM
inhibited 80% of the thymidine incorporation. Two ERK pathway inhibitors U0126 and
PD98095 blocked more than 80% of thymidine incorporation at 1µM and 5µM respectively,
while the inactive analog U0124 had no effect. By contrast, Wortmanin, an inhibitor of PI-
3K had minimal inhibitory effect at 100nM. Our results suggest that MAPK cascades and early
response genes particularly c-jun participate in CCK induced pancreatic acinar cell growth.
T1863
The COX-2 -765c/-1195a Haplotype Predisposes for the Development of
Esophageal Adenocarcinoma
L.M.G. Moons, J. G. Kusters, A. M. Rygiel, Z.M.A. Groothuismink, W.A. Bode, H. Geldof,
K.K. Krishnadath, J.G.H.M. Bergman, A.H.M. van Vliet, P.D. Siersema, E.J. Kuipers
Introduction: The expression level of COX-2 is associated with an increased tendency for
neoplastic progression in the esophagus, since COX-2 expression increases the metaplasia-
dysplasia-adenocarcinoma sequence. High expression levels are also associated with poor
5-year survival rates of esophageal adenocarcinoma. COX-2 is the rate-limiting enzyme for
the production of prostaglandin E2 (PGE2), a compound associated with carcinogenesis in
many inflammatory diseases, and recently, it was suggested that PGE2 levels were COX-2
promotor haplotype dependent. Aim: To determine the association between COX-2 haplo-
types and the development of esophageal carcinogenesis. Methods: DNA was obtained from
140 Caucasian patients with an adenocarcinoma of the esophagus (mean age 63±11; 91%
male), 250 Caucasian patients with histologically confirmed Barrett’s esophagus (mean age
62±13; 68% male) with a mean Barrett-segment length of 4.2 ± 2.3 cm, and 247 Caucasian
patients with endoscopically confirmed reflux esophagitis (mean age 56±14; 53% male).
COX-2 haplotypes were determined by amplification of the promoter region by PCR, followed
by determination of the polymorphisms at -765C/G and -1195A/G by RFLP with restriction
enzymes AciI and PvuII respectively. COX-2 haplotype dependent PGE2 levels were deter-
mined by EIA. Results: The tested population contained 171 (14%) CA (-765C & -1195A),
817 (66%) GA, and 258 (20%)GG haplotypes , and none of the relatively rare GC-halotype.
The haploptype distribution in patients with reflux esophagitis and Barrett’s esophagus was
similar (CA 12%, GA, 68%, GG 21%), but differed significantly from patients with esophageal
adenocarcinoma (Ca 21%, GA 58%, GG 20%), in whom the CA-haplotype was significantly
more common (p<0.0001). Furthermore, homozygosity of CA was only found in patients
with Barrett’s esophagus patients (1.6%) and esophageal adenocarcinoma (5.0%) (p=0.002).
CA-carriership was associated with an increased risk for esophageal adenocarcinoma (OR
1.94; 95%CI 1.23-3.08; p=0.005), and homozygosity for the CA-allele was associated with
an even greater risk (OR 3.83; 95%CI 1.09- 13.84; p=0.036). Conclusion: The COX-2 CA-
haplotype is associated with an increased risk for the development of esophageal adenocarcin-
oma in Barrett’s esophagus and reflux esophagitis patients. As the COX-2 CA-haplotype is
associated with increased levels of PGE2, PGE2 seems to promote esophageal carcinogenesis
in patients with a Barrett’s esophagus and reflux esophagitis.
T1864
Expression of Tissue Inhibitors of Metalloproteinases and Target Proteases
During Barrett’s Carcinogenesis
Suhail Ahmed, A L Khan, L Pazmany, A Varro, K Bodger
INTRODUCTION A multi-step pathway for oesophageal adenocarcinoma (AdCa) proceeds
from squamous epithelium (SqEp) via Barrett’s metaplasia (BM) to dysplasia and cancer in
the setting of reflux disease. These processes involve remodelling of tissue architecture and
fundamental changes to extra-cellular matrix (ECM). Regulation of the ECM is under the
influence of the matrix metalloproteinases (MMPs) and their natural tissue inhibitors (TIMPs),
a system of molecules that have roles in ECM homeostasis, inflammation, angiogenesis and
metastasis. METHODS The aim of the present study was to define expression profile of
TIMPs (-1 to -4) and selected MMPs (-3 and -8) at different points in the cancer pathway.
Oesophageal biopsies were obtained for mRNA extraction, histopathology and immuno-
staining. Real time PCR was performed on cDNA generated by reverse transcription of RNA
extracts. Expression of transcripts was normalised for h-HPRT housekeeping gene. RESULTS
Compared to SqEp, BM was associated with a significant increase in mRNA abundance for
TIMPs -1, -2, -3 and -4 and MMP-8 (but not MMP-3), whereas AdCa was characterised by
increases in TIMP-4 (but not other TIMPs) and MMP-8 but a decrease in MMP-3. Compared to
BM, there was reduced TIMP-3 and MMP-3 but increased MMP-8 in AdCa. Immunostaining
confirmed cell-type specific changes in expression, with TIMP-4 in particular showing a
progressive increase in epithelial and basal layer immunostaining from non-dysplastic BM
through dysplastic BM to AdCa. CONCLUSION Neoplastic progression in the oesophagus
is associated with altered expression of specific TIMPs and MMPs. Levels of TIMPs -1 to -
3 mRNA are maximal at the stage of BM but decline at the stage of AdCa. In BM, enhanced
expression of protease inhibitors would reduce ECM degradation and favour fibrosis (eg.
peptic stricture), whereas in AdCa the finding of elevated MMP-8 but falling TIMPs would
suggest enhanced proteolyis favouring malignant infiltration and metastasis. TIMP-4 may
have potential as a biomarker of progression.
Mean mRNA abundance (relative to HPRT)
* p<0.05 versus SqEp
T1865
In Benign Barrett’s Epithelial Cells, Acid Increases Reactive Oxygen Species
That Activate the P38 MAPK Pathway
Linda A. Feagins, Lance S. Terada, Stuart J. Spechler, Rhonda F. Souza
Introduction: In extraesophageal tissues, reactive oxygen species (ROS) have been shown
to activate signal transduction cascades, like the mitogen-activated protein kinase (MAPK)
pathway, that regulate cell proliferation. In earlier studies, we showed that acid increases
ROS production in benign Barrett’s epithelial cells in vitro and that esophageal acid perfusion
activates the MAPK pathway in Barrett’s epithelium in vivo. Therefore, we sought to determine
whether acid-induced ROS production causes activation of the MAPK pathway in Barrett’s
epithelial cells. Methods: Equally seeded wells of telomerase-immortalized, non-neoplastic
Barrett’s epithelial cells were exposed to acidic media (pH 4.0) for 3-minutes, followed by
incubation in neutral pH media. The phosphorylation of ERK and p38 MAPKs (relative to
total ERK and p38) were determined by Western blotting of cell lysates collected during
and after the acid exposure in the presence and absence of TMPyP, a scavenger of ROS. To
determine whether acid-induced ROS production was unique to benign Barrett’s epithelial
cells, we incubated a normal esophageal squamous cell line and 3 esophageal adenocarcinoma
cell lines with H2DCF-DA, a fluorescent probe activated by ROS. The cell lines were then
exposed to acidic media at pH 4 for 3 minutes, followed by incubation in neutral pH media.
Fluorescent intensity of the cells was used for quantification of ROS production. Results:
Acid exposure increased the expression of phospho-p38 in Barrett’s cells to levels 4-6 times
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those of control cells that were not exposed to acid. In contrast, acid exposure had no
apparent effect on ERK phosphorylation. Incubation of Barrett’s cells with TMPyP abolished
the acid-induced p38 phosphorylation. In contrast to the benign Barrett’s cells, acid exposure
did not increase ROS production in the normal esophageal squamous cells or in any of the
3 esophageal adenocarcinoma cell lines. Conclusions: In benign, non-neoplastic Barrett’s
epithelial cells, acid induces the production of ROS which activate the p38, but not the
ERK, MAPK pathway. In contrast, acid exposure does not induce ROS production in normal
esophageal squamous cells or in esophageal adenocarcinoma cells. These findings highlight
differences between benign and malignant Barrett’s cells in their response to acid exposure,
and indicate that acid-induced ROS production affects a key proliferation pathway.
T1866
Rho Kinase and ERK2 MAP Kinase Contribute to Acid-Induced Expression of
NADPH Oxidase Nox5s (Short) in Barrett’s Adenocarcinoma Cells
Xiaoying Fu, Jose Behar, David Beer, Jack Wands, David Lambeth, Weibiao Cao
We have shown that NADPH oxidase NOX5S (short, i.e. without EF-hand motifs at its N-
terminal) is overexpressed in SEG1 esophageal adenocarcinoma cells associated with Barrett’s
esophagus (SEG1-EA). NOX5S mediates acid-induced hydrogen peroxide (H2O2) production
and contributes to increased cell proliferation and decreased apoptosis in SEG1-EA. In
addition, acid-induced NOX5S expression and H2O2 production are mediated by increased
intracellular calcium and activation of cyclic AMP response element binding (CREB) protein.
We now examine the role of Rho kinase and MAP kinases in acid-induced NOX5S expression
and H2O2 production in SEG1-EA. NOX5 was sequenced by RT-PCR and 5’-RACE in SEG1
EA cells. NOX5S was the only NOX5 isoform present in SEG1 cells and its sequence was
the same as in other tissues. SEG1-EA were exposed to pH 4.0 for one hour, then washed
and cultured at pH 7.2 for 24 hours. Acid increased NOX5S expression and H2O2 production,
that were significantly decreased by the MEK1 inhibitor PD98059 and by the Rho kinase
inhibitor Y27632, but not by the P38 MAP kinase inhibitor SB203580 nor by the protein
kinase C inhibitor chelerythrine. These data suggest acid-induced, Rho kinase and ERK1/
ERK2 MAP kinases-dependent NOX5S expression and H2O2 production. We have shown
that CREB is responsible for acid-induced NOX5S expression. To confirm the role of CREB
a reporter plasmid of NOX5S was generated by ligating a NOX5S promoter fragment (-
1396 to -6 from ATG) into the pGL3-basic vector. Overexpression of CREB caused 5.4-fold
increase in luciferase activity, indicating CREB induced activation of NOX5S promoter. Acid
treatment significantly increased CREB phosphorylation (serine 133), that was significantly
inhibited by PD98059 and Y27632, but not by SB203580 nor by chelerythrine, indicating
a role of ERK MAP kinases and of Rho kinase in acid-induced activation of CREB to
overexpress NOX5S. To confirm the role of these kinases in NOX5S expression we examined
the phosphorylation of the phosphatase catalytic subunit MYPT1 and of ERK MAP kinases.
Acid treatment significantly increased MYPT1 and ERK2 MAP kinase phosphorylation. Acid-
induced MYPT1 phosphorylation on threonine 696 was blocked by Y27632, but not by
PD98059. Conversely, acid-induced increase in ERK2 phosphorylation was blocked by
Y27632, indicating Rho-dependent phosphoryation/inhibition of the phosphatase mediates
ERK2 phosphorylation. We conclude that acid-induced NOX5S expression depends on
sequential phosphorylation/activation of Rho kinase, ERK2 MAP kinase and CREB, that are
potentiated by inactivation of phosphatases. Supported by NIH NCRR 1 P20 RR17695-01.
T1867
Bile Salt Augments Caudal-Related Homeobox Gene CDX1 Expression in
Esophageal Keratinocytes in Barrett’s Epithelium
Hideaki Kazumori, Shunji Ishihara, Mohammad A. Rumi, Yoshikazu Kinoshita
Background & Aims: The mechanism of transformation to intestinal metaplasia in Barrett’s
esophagus has not been clarified. Cdx1 is the homeobox gene which appears to play major
roles in the development of intestinal metaplasia in gastric epithelium. We investigated the
direct effects of bile salt on the expression of Cdx1 in cultured esophageal squamous epithelial
cells. Further, we studied morphological and histochemical changes of squamous cells to
intestinal epithelial cells in response to bile salt-induced expression of Cdx1. Methods: A
rat model of Barrett’s esophagus was produced by anastomosing the esophagus and jejunum,
and Cdx1 expression was investigated by immunohistochemistry. The response of bile salt
on Cdx1 gene expression was studied in human colon and esophageal adenocarcinoma cell
lines using a Cdx1 promoter luciferase assay. Further, Cdx1 gene expression was studied
in primary esophageal squamous epithelial cells in response to bile salt. Results: Esophago-
jejunal anastomoses formed intestinal goblet cell metaplasia in rat esophagus specimens.
Cdx1-positive cells with nuclear staining were mainly observed in the columnar cells in
these areas and the adjoining squamous cells. These findings suggest the possibility that
bile acid refluxate stimulates Cdx1 expression in esophageal squamous epithelium, followed
by the replacement with intestinal type columnar epithelium. When the effects of bile salt
mixture on the expression of Cdx1 were examined, bile salt mixture dose-dependently
increased Cdx1 promoter activity and Cdx1 protein production in cultured esophageal
keratinocytes. Conclusions: We showed that bile salt activates Cdx1 promoter, and stimulate
the production of Cdx1 protein in esophageal keratinocytes.
T1868
Methylation, and Its Role in Intestinal Metaplasia of the Esophagus
Xinyan Zhang, Xiaoxin L. Chen
Background & Aims: As an intestinal transcription factor, caudal-related homeobox 2 (Cdx2)
has been suggested as an early marker of intestinal metaplasia of the esophagus (Barrett’s
esophagus, BE). However, the mechanism of ectopic Cdx2 expression in the esophagus and
its role in the development of BE remained unclear. Methods: RT-PCR, pyrosequencing and
methylation-specific PCR were used to determine expression and promoter methylation of
Cdx2 in human esophageal epithelial cells (HET1A, SEG1) after treatment with 5-aza-2’-

















transfection of Cdx2 were characterized for morphology with light and transmission electron
microscopes, and gene expression profiles with Affymetrix array. Results: DAC induced
demethylation and expression of Cdx2 in HET1A and SEG1 cells, and treatment with a
DNA methylating agent counteracted the effect of DAC. Treatment of HET1A and SEG1
cells with acid, bile acids or both also resulted in promoter demethylation and expression
of Cdx2. HET1A cells with stable transfection of human Cdx2 formed crypt-like structures
in vitro, and undertook electromicroscopic changes reminiscent of human BE, such as
increased microvilli, tight junctions, and lateral interdigitations. Microarray analysis and
quantitative real-time PCR showed that stable transfection of Cdx2 up-regulated differenti-
ation markers of intestinalized columnar epithelial cells and goblet cells in HET1A cells.
Cdx2 might induce the goblet cell phenotype through the Notch signaling pathway. Conclu-
sions: This study demonstrated that gastroesophageal reflux activated Cdx2 expression in
human esophageal epithelial cells through promoter demethylation. Ectopic Cdx2 expression
in esophageal squamous epithelial cells played a causative role in intestinal metaplasia of
the esophagus.
T1869
Epithelial Cells Over-Express the Leptin Receptor During Malignant
Progression in Barrett’s Oesophagus
Suhail Ahmed, A L Khan, L Pazmany, K Bogder
INTRODUCTION Obesity is a recognised risk factor for oesophageal adenocarcinoma. The
reason for a link between excessive weight and cancer is unclear. We hypothesised that
leptin-receptor (OB-R) might be over-expressed in metaplastic or neoplastic oesophageal
epithelium during carcinogenesis. This would provide a mechanism whereby obesity-related
hyperleptinaemia might exert a direct growth-promoting effect on oesophageal mucosa,
potentially favouring malignant progression. Leptin has been shown to stimulate proliferation
of various epithelial cell lines expressing Ob-R. METHODS mRNA abundance of OB-Rb
(main functional Ob-R isoform) was determined by quantitative PCR performed on cDNA
generated by reverse transcription of RNA extracted from endoscopic biopsies. Values were
normalised relative to h-HPRT house-keeping gene. Product was confirmed by agarose gel.
Normal gastric fundus expresses Ob-Rb and was used as positive control. Immunohistochem-
istry for Ob-R was performed on formalin fixed biopsies and western blots on lysates of
oesophageal cancer cell line (OE33). RESULTS Ob-Rb is expressed at very low level in
the normal squamous oesophagus but exhibits progressive expression during malignant
progression at levels significantly in excess of the healthy stomach (See Table: Mean values
(SD), p<0.001 ANOVA). Epithelial cell staining was confirmed by immunohistochemistry
with marked upregulation of Ob-R in surface epithelial cells noted at the stages of dysplasia
and cancer. OE33 cells express Ob-R. CONCLUSION Over-expression of Ob-Rb occurs
during malignant progression. This is consistent with our leptin-hypothesis. The effects of
leptin on Barrett’s epithelial cells require further study. Therapeutic manipulation of leptin-
receptor signalling might provide a novel mechanism for the prevention or treatment of
oesophageal adenocarcinoma.
TABLE 1:Mean mRNA abundance(relative to HPRT)
T1870
Lymphoid Aggregates Precede the Development of Barrett’s Esophagus
V. Menke, L. M. Moons, R. R. Sital, E. J. Kuipers, J. G. Kusters, P. D. Siersema
Objective: Chronic inflammation of the alimentary tract predisposes to cancer. Isolated
lymph follicles that develop in this inflammatory process play a role in the perpetuation of
the inflammation. As a chronic inflammatory process is thought to play a role in the
pathogenesis of Barrett’s esophagus (BE), formation of lymph follicles may also develop in
the progression of BE. Aim: To understand the function of a chronic inflammatory process
in the induction of BE. Methods: Intestinal metaplasia (IM) was induced in 6 week old male
Wistar rats by gastrectomy with esophagojejunostomy. Rats were sacrificed at 0, 3 and 6
months. Mucosal thickness of the esophagus, area of lymphoid aggregates and distance to
the anastomosis was determined with Nikon EclipseNet software in H&E stained slides. In
addition, tissue was immunohistochemically stained with antibodies specific for proliferation
(Ki67), intestinal epithelium (CDX2), goblet cells (We9), B cells (OX33) and T cells (CD3).
Results: At baseline and in controls (n=30), no inflammation was found in the rat esophagus,
characterized by a mucosal thickness (MT) of 0.24±0.09, 0.14±0.04, 0.13±0.04, and
0.11±0.03mm, at respectively 0, 5, 10, and 20mm from the anastomosis, and in the absence
of lymphoid aggregates. At 3 months (n=3), chronic inflammation was observed in the
esophagus, which was associated with an increase of the MT to 0.78±0.17, 0.75±0.48,
0.52±0.10 and 0.45±0.11mm, at 0, 5, 10, and 20mm (p<0.001). Lymphoid aggregates were
determined, with a surface area that increased equally with the MT (r=0.67). At 6 months
(n=21), the chronic inflammatory reaction was even stronger with a MT of 1.25±0.59,
0.90±0.42, 0.75±0.43 and 0.59±0.30mm at 0, 5, 10, and 20mm ( p<0.001). IM, which
stained positive for CDX2 and We9, was observed in 21/21 rats with a mean length of
3.94±1.48mm. The surface area of the lymphoid aggregates again correlated with the MT
(r=0.68). Moreover, in 4/21 rats significantly larger lymphoid aggregates were detected
underneath the IM segment compared to the inflamed squamous epithelium (mean area
2.05±0.26 vs. 0.04±0.02mm2). The lymphoid aggregates in the IM tissue contained segreg-
ated B- and T cell areas and a high expression of Ki67 in the central B cell area, in contrast
to those in the squamous epithelium. Conclusion: Esophageal lymphoid aggregates develop
during the inflammatory process preceding BE. These lymphoid aggregates contain central
proliferation, suggesting an active local adaptive immune response. Local lymphoid aggregates
may thus play a key role in the determination and maintenance of the chronic inflammation
that is thought to be fundamental for the development of BE.
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T1871
Morphological Transformation in Esophageal Submucosa By Bone Marrow
Cells Esophageal Implantation Under External Esophageal Perfusion
Yan Li, John M. Wo, Ruifeng R Su, Susan Ellis, Mukunda B. Ray, Whitney Jones, Robert
C. Martin
Background: The bone marrow is an important resource of multipotential stem cells, and
evidences indicate that stem cells from the bone marrow have the capacity to engraft into
several organs including the esophagus in response to ongoing injury. Accumulating clinical
and experimental studies indicate that Barrett’s esophagus might arise through multipotential
stem cells under the stress of gastroesophageal reflux. We have presented a novel external
pump perfusion (EEP) rat model previously, and demonstrated that EEP with both acid
and bile can induce severe esophagitis in 1 week with a similarly pathological change seen
in humans. The aim of this study was to investigate the histological changes of esophagus
after bone marrow cell engraftment with bile and acid EEP. Methods: The EEP procedure
involved implantation of a micro-osmotic pump for esophageal perfusion. Bone marrow
cells were obtained by flushing of the femur marrow, and the cell suspension was injected
between the esophageal muscular and inner mucosa layer. Histological changes were deter-
mined after 4 weeks of perfusion. Proliferating cell nuclear antigen, 8-hydroxy-deoxyguanos-
ine, manganese superoxide dismutase and apoptosis were measured by immunohistochemical
staining and TUNEL assay, respectively. Results: Severe esophagitis were seen in both acid
and bile EEP. Suspicious glandular structure in submucosa was observed after bone marrow
esophageal implantation along with bile perfusion, but not with acid perfusion and controls.
Alcin blue-PAS staining showed positive staining within the glandular structure area, no
goblet cell was detected. Enhanced proliferation and apoptosis were observed, along with
increased oxidative damage and suppression of antioxidation. Conclusions: 1) bone marrow
implantation and EEP contribute the abnormal histological changes. 2) The engrafted bone
marrow cells in esophageal submucosa could transform under the circumstance with bile
perfusion. 3) Further studies are underway to explore the potential mechanism and induce
Barrett’s metaplasia.
T1872
Constitutive Nf-κB Activation in Barrett’s Epithelial Cells: Potential Role in
Carcinogenesis
Cathrine Demars, Malini Madhavan, Sarah Papenfuss, Marlys Anderson, Lori Lutzke,
Ganapathy Prasad, Louis Wong Kee Song, Kenneth Wang, Navtej Buttar
BACKGROUND: Acid and bile salts in the reflux can promote pro-survival signaling such
as activation of NF-κB and production of PGE2. Recent publications show that the clinical
outcome of esophageal cancer is worse in patients that have increased NF-κB activation.
Since many natural dietary products can inhibit NF-κB activation, the role of NF-κB activation
during carcinogenesis needs to be further explored. AIM: To determine the expression of
activated NF-κB during carcinogenesis in Barrett’s mucosa and to examine the functional
relevance of NF-κB activation on proliferation and apoptosis of premalignant Barrett’s epithe-
lial cells. METHOD: Endoscopic mucosal resections from 12 patients were stained using an
antibody that recognizes activated NF-κB. To determine the functional relevance of NF-κB
activation, Barrett’s epithelial cell cultures were treated with BAY 11-7082, which inhibits
NF-κB activation by preventing phosphorylation of I-κB. After a 48 hr treatment with BAY11,
cells were assessed for proliferation (Ki67) and apoptosis (TUNEL). Experiments were
repeated in presence or absence of PGE2, which is a downstream target of NF-κB to determine
if the effects of NF-κB on cell survival would be altered. RESULTS: Activated NF-κB was
localized to epithelial cells in dysplastic Barrett’s, cancer and the deeper, rapidly dividing
glandular cells. Normal squamous and non-dysplastic epithelium did not stain for activated
NF-κB. NF-κB inhibition resulted in decreased survival of Barrett’s epithelial cells. Compared
to vehicle only treated cells, 48 hour treatment with 1, 2.5, and 5 µM BAY11 decreased
proliferation rates by 51%, 60%, and 74%, respectively (p<0.05). The apoptosis rates of
cells treated for 48 hours with 1, 2.5, and 5 µM of BAY11 increased 2 fold, 2.4 fold, and
2.7 fold, respectively, compared to vehicle only treatment (p<0.05). The addition of exogen-
ous PGE2 reversed the effects of BAY11 on proliferation and apoptosis. In the presence of
2 ng/ml PGE2, BAY11 treatment had no significant effect on the proliferation or apoptosis
of Barrett’s cells. CONCLUSION: Constitutive NF-κB activation is noted in the epithelial
cells during the progression of neoplasia in Barrett’s esophagus. This activation appears to
be functionally relevant since the loss of NF-κB activation can decrease proliferation and
increase apoptosis in Barrett’s epithelial cells. Exogenous PGE2 can reverse the effects of
NF-κB inhibition on Barrett’s epithelial cell survival, which raises the possibility that PGE2
(a downstream target of NF-κB activation) may have a role in the effect of constitutive NF-
κB activation on the survival of Barrett’s epithelial cells.
T1873
Select Genomic Aberrations Occurring in Non-Dysplastic Barretts Esophagus
(BE) Mucosa from Patients with Carcinoma Do Not Occur in Patients with
Negative Long-Term Follow-Up: Array-Based Comparative Genomic
Hybridization (A-CGH) Study
Marek Skacel, Daniel P. Gaile, Xiaotong Zhang, Jeffrey Conroy, Norma Nowak, Graham
Casey, Thomas W. Rice, Mary P. Bronner, Gary W. Falk
Background: Genomic aberrations occur in long-standing inflammatory gastrointestinal dis-
orders including BE. It is not known if the genomic profile of intestinal metaplasia in BE
patients who have progressed to carcinoma is different from that encountered in patients
who have not progressed to dysplasia. Aim: To compare the genomic profile, using A-CGH,
of BE mucosa that is negative for dysplasia from patients who have progressed to esophageal
carcinoma to that in patients who have not developed dysplasia over years of follow-up.
Design: We studied 29 non-dysplastic biopsy- or esophagectomy-derived BE samples from
patients without evidence of dysplasia (n=12; in surveillance for a minimum of 3 years) and
with BE-associated adenocarcinoma (at least intramucosal; n=17). Whole genomic DNA
extracted from epithelial isolates from freshly frozen mucosa containing a minimum of 60%
goblet cells was labeled by random priming using Cy3 (sample DNA) and Cy5 (normal
human reference DNA). Labeled DNA was co-hybridized to microarrays containing triplicate
spots of approximately 19,000 genomic RPCI-11 bacterial artificial chromosome (BAC)
clones (Roswell Park Cancer Institute, Buffalo, NY). The fluorescence ratios and their log-
transformed values were analyzed using DNAcopy as well as customized software. Results:
The patients included 22 men and 7 women ages 53-74 years (mean: 62 years). Several
recurring aberrations were detected in a subset of patients who progressed to cancer but
never occurred in the nondysplastic epithelium of patients who had not progressed to
carcinoma. These included genomic gains at 8q24.21 (two different BAC clones in this
region), 3q24 and genomic loss at 12q31 (single clone in each of the latter two regions).
Due to the sample size and testing multiplicity, these results are significant only in the
context of an analysis with a liberal false discovery rate. Conclusion: Repetitive genomic
changes occur in non-dysplastic intestinalized BE mucosa in patients with carcinoma. These
changes were not detected in BE patients without dysplasia or cancer in this pilot cohort.
Further study by fluorescence in situ hybridization will more accurately assess the precise
distribution of these aberrations among BE patients.
T1874
Gene Promoter Methylation of ID4 and ARL4D in Barrett’s Esophagus and
Esophageal Adenocarcinoma
Eric Smith, Derek J. Nancarrow, Sandra Pavey, Nick K. Hayward, Neville J. de Young,
John J. Kelly, David C. Whiteman, B M. Smithers, David C. Gotley, Paul A. Drew
Introduction: DNA methylation has been reported in the promoter region of a number of
genes in oesophageal adenocarcinoma and its precursor lesion Barrett’s esophagus, and may
contribute to the progression to cancer. Analysis of gene methylation is important because
there is a need for biomarkers in non-dysplastic Barrett’s which might predict risk of
progression to cancer, and it may provide insights into the pathogenesis of the disease. Aim:
To determine the frequency of methylation in the promoter region of 10 genes in esophageal
tissues and cell lines. Results: Methylation in the promoter region of 10 genes was measured
in 3 oesophageal adenocarcinoma cell lines, single biopsies of Barrett’s associated adenocarci-
noma from 16 patients (AdCa), and multiple biopsies of metaplastic (BE) and single biopsies
of proximal squamous epithelium from 18 patients with Barrett’s esophagus. The percentage
of patients or cell lines with methylation in each of the genes tested is shown in the table.
In patients with Barrett’s esophagus from whom multiple biopsies of BE were available,
methylation often differed between the biopsies. Discussion: For the gene promoters exam-
ined there was less methylation in the squamous epithelium of the esophagus compared to
the metaplastic or adenocarcinoma tissues. There was no consistent relationship between
the methylation in the Barrett’s and adenocarcinoma tissue. Two genes are of particular
interest. ID4 is a member of the inhibitor of DNA-binding (ID) family, which inhibits DNA
binding of basic helix-loop-helix transcription factors, and has been suggested to suppress
tumour progression and metastasis. ARL4D is a member of the ARF family, and may play
a role in membrane-associated intracellular trafficking. This is the first report of methylation
of ID4 in Barrett’s esophagus and esophageal adenocarcinoma, and of ARL4D in any cancer.
This work is part of the Study of Digestive Health (Australia).
Percentage of patients or cell lines with methylation for each of the genes tested.
T1875
Hepatocyte Nuclear Factor-1-Alpha Is a Key Mediator of Muc4 Mucin Gene
Regulation By Bile Acids
Guillaume Piessen, Nicolas Jonckheere, Brigitte Hemon, Christophe Mariette, Isabelle van
Seuningen
Background: MUC4 is a membrane-bound mucin overexpressed in the early steps of eso-
phageal carcinogenesis and associated with Barrett metaplasia and gastro-esophageal reflux.
We previously showed that bile acids, a main component of reflux, upregulate MUC4
expression. Aim: To study the involvement of HNF1-alpha and HNF4-alpha, two transcrip-
tion factors that mediate bile acids effects, in the bile-acid mediated upregulation of MUC4
in esophageal cells and tissues. Methods: MUC4, HNF-1 and HNF-4 expression was evaluated
by immunohistochemistry in human esophageal tissues. MUC4 mRNA level, protein level
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and promoter regulation were studied in human esophageal adenocarcinomatous OE33 cells
by RT-PCR, western-blot and transient transfection assays, respectively. HNF1 and HNF4
cis-elements in the promoter of MUC4 were identified by electrophoretic mobility shift assay
and chromatin immunoprecipitation and their functionality was assessed by site-directed
mutagenesis. Results: MUC4 and HNF1-alpha are expressed by the same cells in esophageal
tissues during the whole carcinogenetic sequence whereas HNF4-alpha is only expressed in
adenocarcinomatous tissues. Studies on the promoter activity, at the mRNA level and at the
protein level indicate that HNF1-alpha is an important mediator of MUC4 activation. We
showed by gel retardation that HNF1-alpha mediates its effects by binding to two cognate
elements, respectively located at -3332/-3327 and -3040/-3028, in the distal promoter. We
confirmed their functionality by site-directed mutagenesis. Finally, we showed that HNF1-
alpha positively mediates taurodeoxycholic and taurochenodeoxycholic bile acid activation
of MUC4 transcription whereas HNF4-alpha has no effect. These effects are dose-dependent
and involve binding of HNF1-alpha to the -3332/-3327 and -3040/-3028 cis-elements
previously identified. Conclusion: These results describe a new mechanism of regulation of
MUC4 expression by bile acids that brings new insight in its up-regulation in oesophageal
carcinoma associated with bile reflux.
T1876
Cigarette Smoking and Barrett’s Esophagus: A Case-Control Study
Nicholas J. Shaheen, Melissa B. Spacek, Joseph A. Galanko, Paris Heidt-Davis
Background: Several studies have assessed the role of cigarette smoking as a risk factor for
adenocarcinoma of the esophagus. The association of cigarette smoking with the presence
of Barrett’s esophagus (BE) is less clear. Aim: To compare cigarette smoking habits between
subjects with BE and subjects with reflux symptoms but no BE. Methods: We performed a
case-control study comparing subjects with reflux symptoms who have BE to subjects with
reflux symptoms but no BE. Cases were subjects with BE, defined as endoscopically visible
tongues of any size in the tubular esophagus with histologic confirmation of specialized
intestinalized epithelium. Controls were those presenting to GI clinic with a complaint of
reflux symptoms, specifically heartburn or regurgitation. Cases and controls were between
the ages of 18 and 80. Subjects who had undergone endoscopic ablative therapy, those with
previous esophageal resection, and those with carcinoma on the index endoscopy were
excluded. All subjects underwent upper endoscopy to confirm their histology. They then
completed a series of questionnaires, assessing demographics, GERD severity, and quality
of life. Cigarette smoking was quantified both in magnitude and duration, as well as in
proximity of cigarette use to the survey date. A summary statistic of pack-years was generated
by multiplying the number of years smoked by the average number of packs smoked per
day. Bivariate analysis was performed using Chi square and Student’s t tests. Multivariate
logistic regression was performed with case/control status as the outcome variable, and age,
sex, and measures of cigarette use as predictor variables. Results: Four hundred and seventy-
one subjects were enrolled (169 controls, 302 cases). Sixty-nine percent of cases were male,
compared to 42% of controls (p<0.0001). The mean age of cases was 58.9 years (SD 11.9),
and of controls 51.2 years (SD 13.1) (p<0.0001). In bivariate analysis, a past history of
cigarette use was more common in subjects with BE than controls (58% vs. 47%, p=0.04).
There was also a trend toward more pack-years in subjects with BE than controls (15.9 p-
y vs. 13.4 p-y, p=0.09). However, after controlling for age and sex in multivariate logistic
regression, these differences disappeared (p=0.61). Conclusions: This large case-control
study demonstrates that, after controlling for potential confounders, subjects with BE appear
to be no more likely to have a history of cigarette smoking than subjects with reflux symptoms
but no BE. These data do not suggest that cigarette smoking is a risk factor for BE among
those with GERD symptoms.
T1877
P53 Mutation Does Not Predict Malignant Progression in Biopsies of Patients
with Barrett’s Metaplasia (BM)
Mamoun Younes, Baomin Liu, Jiang Wang, Juan Lechago, Atilla Ertan, Gulchin Ergun,
Margaret Bridges, Frank Meriano, Ray Verm, Karen Woods, Carl Schmulen, Craig
Johnson, Alberto Barroso, John McKechnie, Jim Schwartz, Cecilia Fenoglio-Preiser
p53 gene mutation has been implicated by many authors in malignant progression in Barrett’s
metaplasia (BM). The significance of p53 mutations in BM has not been adequately addressed
in prospective studies. We sequenced exons 2-10 of the p53 gene, utilizing microdissected
samples from formalin-fixed and paraffin-embedded biopsies from 190 consecutive cases
of BM. Morphological evaluation for dysplasia, was done by two gastrointestinal pathologists.
To date, 117 patients had one or more years of follow up (median 31 months), and these
are included in this study. Of the 117 biopsies only 20 had p53 mutations, and 4 of these
progressed to a higher grade of dysplasia (20%). Ninety-seven biopsies did not have any
p53 mutations, but 21 of these (22%) progressed to a higher grade of dysplasia. The
difference was not statistically significant (p=1.000). Additional studies and follow-up are
in progress to determine whether specific p53 mutations are associated with malignant
progression in BM. Supported by National Institutes of Health grant R01 CA81570-02, and
in part by PriCara, Unit of Ortho-McNeil, Inc. and by Eisai Inc.
T1878
The Effect of Oral Administration of Ursodeoxycholic Acid and Proton Pump
Inhibitors in Patients with Barrett’s Esophagus
Andreas Bozikas, Willem A. Marsman, Wilda D. Rosmolen, Jantine W. van Baal, Wim
Kulik, Fiebo J. Ten Kate, Sheila K. Krishnadath, Jacques J. Bergman
Background & Aims Bile acids may play a role in the pathogenesis of Barrett’s esophagus
(BE). Bile composition can be influenced by oral administration of ursodeoxycholic acid
(UDCA). We prospectively investigated the effect of proton pump inhibitors (PPI) supple-
mented with UDCA in vivo in patients with BE. Patients & Methods Pts with no or low-

















order to exclude the effects of acid reflux, all pts were initially treated with 40 mg esomeprazol
(ESO) BID for six mo and continued on this dose till the end of the study (t=12 mo). During
a period of six months (t=6 mo - t=12 mo) pts were treated with oral UDCA (600 mg BID).
Pts underwent endoscopy at t=0 mo, t=6 mo & t=12 mo with multiple biopsies of the distal
and proximal BE segment, normal squamous and gastric cardia. In addition, pH was measured
at t=0 mo & t=6 mo using a BRAVO wireless pH capsule and bile was sampled at the
beginning of the UDCA treatment and six mo later (t=6 mo & t=12 mo). All biopsies were
reviewed for the extent of metaplasia, dysplasia, and acute & chronic inflammation. In
addition proliferation (Ki67), differentiation (villin, cytokeratins 7 & 20) and inflammation
(COX-2) were investigated by immunohistochemistry (IHC). Results Nine pts (mean age
60 years, median BE length 7 cm) were included, of whom 3 had low-grade dysplasia. pH
measurements revealed a normalisation of the intraesophageal pH at t=6 mo. In addition,
bile composition analysis demonstrated the efficacy of UDCA. Combining the results of both
phases of the study, no significant changes were seen in any of the histological & IHC
parameters. In 5 patients the amount of metaplasia and dysplasia was marginally increased,
mostly pronounced distally. Differentiation and proliferation parameters showed no signific-
ant changes. Conclusion In this study, in BE pts who were clinically asymptomatic on PPI,
increasing the PPI dose to the maximum for six mo followed by the addition of UDCA for
six mo did not result in significant histological or IHC changes in their BE. This study was
financially supported by Zambon Netherlands.
T1879
Dual Roles for Nitric Oxide in the Development and Progression of Barrett’s
Adenocarcinoma
Nicholas Clemons, Ruwani Abeyratne, Rebecca C. Fitzgerald
Introduction: Oesophageal adenocarcinoma develops via a metaplsia-dyplasia sequence.
Luminal components such as acid and bile are thought to contribute to the neoplastic
progression. For example, pulsatile acid and bile exposure can alter proliferation and differen-
tiation status in ex vivo and in vitro models and low pH can induce DNA damage in vitro.
Recently, increased oesophageal concentrations of nitric oxide (NO) have been demonstrated
in Barrett’s oesophagus (BO) patients. NO and its derivates have been shown to induce
DNA damage in colorectal carcinogenesis. In addition, NO has been implicated in the
regulation of metastatic behaviours in cancer cell lines and in tissues. Aims: Using oesophageal
cell lines we investigated whether NO could induce DNA damage by studying the phosphoryl-
ation of histone H2AX (γH2AX), a specific and early marker of double strand breaks (DSBs).
The ability of NO to regulate metastatic behaviour was also investigated via in vitro invasion
and cellular aggregation assays. Methods: Adenocarcinoma cell lines BIC, SEG and FLO and
Barrett’s high-grade dysplasia cell lines ChTERT and GihTERT were used. Cells were treated
for 45min with 25-200μM of NO donor NOC-9 (Axxora) and γH2AX was assessed by flow
cytometry and confocal microscopy. Long-term survival following NO exposure was assessed
by clonogenic assay. For the in vitro invasion assay, FLO and GihTERT cells were added to
Matrigel (BD) coated trans-well inserts (BD Falcon) and treated with 5-100μM NO incubated
for 24hr. The effect of NO on adhesive behaviour was examined by a cellular aggregation
assay. NO-induced changes in the expression of genes implicated in metastasis were examined
by SYBR-green real-time PCR. Results: NO induced γH2AX in a dose dependent manner
(p<0.05 at all doses). The ability of NO to induce γH2AX appears to occur preferentially
in cells that are in S-phase. Long-term survival studies demonstrated that cells were able to
continue to grow following this initial insult. NO enhanced the ability of GihTERT and FLO
cells to invade through Matrigel (p<0.05 for 25μM and above). NO-induced metastatic
behaviour correlated with the induction of osteopontin, COX-2, MMP2 and MMP 9. Max-
imum gene expression was observed 1-3 hr after the addition of NO and had returned to
basal levels after 22hr. Conclusions: NO has the potential to generate DSBs in the oesophagus.
If not repaired correctly these lesions could lead to gross genetic and chromosomal abnormal-
ities that may aid in the progression of BE to adenocarcinoma. At later stages NO may
promote metastasis by increasing invasive potential and regulating expression of genes
involved in metastatic behaviour.
T1880
NADPH Oxidase Nox5s (short) Mediates Platelet-Activating Factor (PAF)-
Induced H2O2 Production in Barrett’s Adenocarcinoma Cells
Xiaoying Fu, Jose Behar, Ramy Eid, David Beer, Jack Wands, Weibiao Cao
A carcinogenic role of reactive oxygen species (ROS) has been demonstrated in several types
of human cancer. Elevated ROS levels have been reported in Barrett’s esophagus (BE) and
in esophageal adenocarcinoma. We have previously shown that NADPH oxidase NOX5S
(short, i.e. without EF-hand motifs at its N-terminal) is overexpressed in SEG1 esophageal
adenocarcinoma cells associated with Barrett’s esophagus (SEG1-EA) and mediates acid-
induced production of hydrogen peroxide (H2O2). It has been reported that PAF levels
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increase in esophagitis and that PAF causes production of H2O2 in other cell types. In the
present study we examined the role of PAF in H2O2 production in SEG1-EA. PAF dose-
dependently increased H2O2 in SEG1-EA cells. PAF (10-7M, 24 hours)-induced H2O2 produc-
tion was abolished by the NADPH oxidase inhibitor apocynin, suggesting a role of NADPH
oxidases in PAF-induced H2O2 production. The NADPH oxidase catalytic subunits NOX1
and NOX5S are highly expressed in SEG1-EA cells and PAF significantly increased expression
of NOX5S, but not of NOX1. Knockdown of NOX5S by NOX5S small interfering RNA
significantly decreased PAF-induced H2O2 production, suggesting a role of NOX5S in PAF
induced H2O2 production. PAF-induced H2O2 production was significantly reduced by
MEK1 inhibitor PD98059, the P38 MAP kinase inhibitor SB203580 and by the cytosolic
phopholipase A2 inhibitor AACOCF3, but not by the protein kinase C inhibitor chelerythrine,
suggesting that PAF-induced H2O2 production depends on activation of MAP kinases (ERK1/
2, p38) and cytosolic phospholipase A2. We conclude that PAF increases H2O2 production
in SEG1-EA cells through activation of MAP kinases (ERK1/2, p38), cytosolic phospholipase
A2 and NADPH oxidase NOX5S. Supported by NIH NCRR 1 P20 RR17695-01.
T1881
Oxidative Stress Is Induced By Bile Acids and Low pH in Barrett’s Esophagus
Biopsies and Esophageal Cell Lines
Katerina Dvorak, Melissa Chavarria, Lois Ramsey, Barbora Dvorakova, Ronnie Fass,
Richard Sampliner, Claire M. Payne, Harris Bernstein, Carol Bernstein, Sylvan Green,
Harinder Garewal
Background: Barrett’s esophagus (BE) appears to result from chronic irritation by gastric
acids and bile acids. Several studies implicate oxidative stress and induction of reactive
oxygen species (ROS) in the development of BE and esophageal cancer. Nevertheless, studies
evaluating the direct effect of low pH and bile acids on the production of ROS have been
lacking. Our aim was to evaluate whether brief exposure to bile acids and pH 4 induces
oxidative stress in esophageal cells and human biopsies. Methods: Esophageal cell lines
(normal squamous Het-1A cells, BE cells transfected with hTERT, Seg-1 adenocarcinoma
cells) were exposed to control medium, medium at pH 4 and/or a 0.1 mM bile acid
cocktail (BA) for 10 minutes. BA consisted of glycodeoxycholic, glycocholic, taurocholic,
glycochenodeoxycholic and deoxycholic acid. Oxidative stress was evaluated by staining
with 5μM MitoSOX Red, a compound that is oxidized by ROS to a fluorescent dye, using
fluorescent microscopy or flow cytometry. Oxidative stress was also evaluated in BE biopsies
with different grades of dysplasia (15 ND, 15 LGD, 15 HGD), duodenum and squamous
epithelium by immunohistochemical staining for 8-hydroxy-deoxyguanosine (8-OH-dG), a
marker of oxidative DNA damage. In addition, four separate biopsies from ten BE patients
were evaluated for 8-OH-dG expression after ex vivo incubation with control medium and
medium at pH 4 and/or 0.5 mM BA. Results: Exposure to pH 4 and BA resulted in an
increase in ROS in Het-1A, Seg-1 and BE cells, while no change in ROS was detected in
these cells after treatment with pH 4 alone or BA alone. Increased 8-OH-dG staining was
detected in BE biopsies compared to squamous and duodenal epithelia. The strongest staining
of 8-OH-dG was observed in the dysplastic glands, while a less intense signal was found
in nondysplastic tissue. Statistical evaluation indicated that dysplastic BE had significantly
greater 8-OH-dG levels than nondysplastic BE (p=0.003). In the ex vivo experiment, six
out of ten biopsies expressed elevated 8-OH-dG after pH 4 and BA exposure compared with
the biopsies exposed to control medium only. Interestingly, the majority of the biopsies (5/
6) with increased 8-OH-dG were nondysplastic. In contrast, two out of four cases that did
not show increased 8-OH-dG levels after pH 4 and BA exposure were dysplastic and a
strong 8-OH-dG signal was found in the biopsies exposed to control medium. Conclusion:
Our data indicate that oxidative stress is induced by short exposures to BA and low pH in
esophageal cell lines and human BE, especially in nondysplastic tissue. Such repetitive and
chronic stress may lead to DNA damage and cancer progression.
T1882
Chromosome 17 Hyperploidy and Her2/Neu Oncogene Amplification Are
Important Genetic Events in the Transformation of Barrett’s Esophagus Into
High-Grade Dysplasia
Agnieszka M. Rygiel, Franceska Milano, Jantine W. van Baal, Wilda D. Rosmolen, Paul
Fockens, Febo J. Ten Kate, Jacques J. Bergman, Maikel P. Peppelenbosch, Kausilia K.
Krishnadath
BACKGROUND: Barrett’s esophagus (BE) is associated with an increased risk for developing
esophageal adenocarcinoma (EAC). The progression of BE to cancer is a gradual process
that is characterized by increasing dysplasia and the accumulation of several genetic abnormal-
ities, for instance aneuploidy and amplification of the oncogene Her2/neu. The amplification
of Her2/neu is generally considered as a late event in cancer progression correlating with
poor survival. In BE however, studies examining the occurrence of this abnormality in
patients with different stages of dysplasia are lacking. AIM: The purpose of this study was
to investigate the frequency of Her2/neu (17q21) gene amplification and chromosome 17
aneusomy in a BE population with different stages of dysplasia. MATERIAL and METHODS:
Multi-color FISH using a centromeric probe for chromosome 17 and a locus-specific Her2/
neu probe was applied on brush cytology specimens of 100 BE patients. Brushes were taken
separately from the BE segment (n=100) and from the adjacent normal squamous epithelium
(n=20), the latter served as a controls. RESULTS: Of the 100 BE samples, 73 had BE without
dysplasia (ND), 8 had indefinite for dysplasia (IND), 10 had low grade dysplasia (LGD),
and 9 high grade dysplasia (HGD). We observed chromosome 17 trisomy in: 3 of 73 (4%)
of ND cases, 1 of 8 (13 %) of IND cases, and in 5 of 9 (56%) of the HGD cases. The Her2/
neu amplification was not seen in ND but was detected 1 of 10 (10%) of LGD, and in 8
of 9 (89%) of HGD cases. Interestingly, we observed that 5 out of 8 cases with HGD and
Her2/neu amplification also had a trisomy of chromosome 17. CONCLUSIONS: Our results
show that hyperploidy of chromosome 17 and/or Her2/neu gene amplification are important
genetic events contributing in the progression of BE with ND into HGD. We postulate
that this process starts with hyperploidy of chromosome 17, subsequently followed by
amplification of the Her2/neu gene. These genetic abnormalities are presently used as tumor
markers for the surveillance of a BE cohort.
T1883
Conversion of Stratified Squamous to Columnar Epithelium By Bone Marrow-
Derived Cells -three-dimensional Reconstruction Using a Primary Culture of
Epithelial Cells Isolated from Murine Esophagus and Forestomach -
Hidekazu Suzuki, Mamoru Arakawa, Yuriko Minegishi, Akifumi Ootani, Eisuke Iwasaki,
Toshifumi Hibi
Barrett’s esophagus is an acquired condition, in which squamous epithelium in the distal
esophagus is replaced by specialized (metaplastic) columnar epithelium. It is considered to
be mainly induced by chronic gastroesophageal reflux and to be a preneoplastic condition.
Despite the great interest in the pathogenesis of this condition, little is known regarding
the mechanism underlying the conversion of stratified squamous to columnar epithelium.
Recently, the importance of bone marrow-derived cells during the development of gastric
adenocarcinoma through the metaplastic and dysplastic stages was reported in a mouse
model of Helicobacter infection (Science 306:1568, 2004). The present study was designed
to investigate the involvement of bone marrow-derived cells in the conversion of stratified
squamous to columnar epithelium, by establishing a three-dimensional culture system for
highly differentiated murine esophageal epithelial cells. Methods. On postnatal day1, tissues
of the esophagus and forestomach of C57BL/6 mice were minced and digested in dispase
I solution. To reconstruct the esophageal mucosa, type I collagen gel solution was mixed
with fibroblasts isolated from the forestomach. As these fibroblast-containing collagen gel
layers have been shown to be comparable with the esophageal lamina propria in vivo, isolated
epithelial cells were cultured on the reconstructed lamina propria. Seven days later, the
cultured epithelial cells were fixed with Carnoy’s solution, vertically embedded in paraffin
and sections were stained with periodic acid-Schiff (PAS). Immunohistochemistry for cytoker-
atin 14 (CK14) was also performed to recognize cells of basal layers of stratified squamous
epithelium. Samples of bone marrow cells obtained from the same strain of mice were
incubated with the primary epithelial cell culture for 7 days. Results. A primary three-
dimensional culture system for epithelial cells isolated from the esophagus and forestomach
was established. The isolated epithelial cells developed PAS-negative and CK14-positive
stratified squamous cell layers, with keratinization of the surface layer. After the bone marrow-
derived cells were mixed into the culture, the isolated epithelial cells developed into a PAS-
positive and CK14-negative columnar monolayer epithelium. Conclusions. A primary three-
dimensional cell culture system for epithelial cells of the esophagus and forestomach was
established. Bone marrow-derived cells are considered to be involved in the genesis of
Barrett’s epithelium by promoting the transformation of stratified squamous epithelium into
columnar epithelium.
T1884
Y Chromosome Abnormalities in Barrett’s Esophagus: How Common Is It?
Kenneth K. Wang, Ganapathy Prasad, Navtej S. Buttar, Michel Wongkeesong, Kevin
Halling, Thomas Smyrk, Jason Lewis, Susan Abraham, Sheila Krishnadath, Marlys
Anderson, Lori Lutzke, Catherine Demars, Sarah Papenfuss, Lynn Borkenhagen, Dawn
Ferguson
Y chromosome abnormalities have been described to occur in 31-40 percent of Barrett’s
esophagus related cancer and dysplasia and has nearly always been reported to be loss of
Y. However, these reports have been in small cohorts of patients. Due to the male predomin-
ance of Barrett’s esophagus, there has been interest in delineating whether Y chromosome
alterations are more common than initially reported. Aim: To determine the frequency of
Y chromosome abnormalities in a cohort of patients with Barrett’s esophagus and associated
neoplasia. Methods: Patients were recruited from a specialized Barrett’s Esophagus Unit
where they underwent cytological brushing and four quadrant biopsies every centimeter of
Barrett’s esophagus. Y chromosome was assessed using fluorescent in situ hybridization
(FISH) using a centrometric probe (p11.1-q11.1, Vysis, Des Plaines, Il). All histological
interpretations were performed by two expert pathologists. FISH results were all interpreted
by an experienced cytopathologist. Results: 166 males with Barrett’s esophagus were entered
into this study. 42 patients had non-dysplastic Barrett’s mucosa, only 4 (10%) had y
chromosome abnormalities. 22 patients had low-grade dysplasia and only 5 or 23% had y
chromosome abnormalities all being losses. 81 patients had high-grade dysplasia, 36 (44%)
had y chromosome abnormalities with 32 of these being deletions. 21 patients had adenocarci-
noma with 13 (62%) having y chromosome abnormalities with loss of y in 12. . There was
a statistically significant difference in Y chromosome abnormalities between those with high-
grade dysplasia or cancer and those with low-grade dysplasia or no dysplasia (p<0.05).
Conclusions: Y chromosome abnormalities are frequent in Barrett’s esophagus and become
significantly more common with increasing degrees of dysplasia. Y chromosome loss is the
most frequent abnormality with gains found in <5% of patients. This suggests that the Y
chromosome loss may play an important role in the pathogenesis of Barrett’s esophagus.
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T1885
CDX2 Overexpression Is a Marker of Intestinalization in GERD - Metaplasia -
Adenocarcinoma Sequence
Leandro A. Streher, Luise Meurer, Marcelo Binato, Carlos Renato A. Melo, Richard R.
Gurski
Background: Barrett`s esophagus develops as a result of severe esophageal mucosa injury
from gastroesophageal reflux. It is a premalignant lesion and plays important role in the
development of esophageal adenocarcinoma. The histologic diagnosis of BE requires the
presence of globet cells, but this finding may not be the earliest indicator of intestinal
metaplasia (IM). The aim of the present study was to determine the expression of the Cdx2
in patients with GERD - metaplasia - adenocarcinoma sequence. Methods: We investigated
146 patients with gastroesophageal reflux disease assessing the imunoexpression of Cdx2 ,
in biopsy specimens obtained by endoscopy, from patients with normal esophageal mucosa,
esophagitis, columnar epithelium in distal esophagus and adenocarcinoma. The patients
were distributed into five groups according to the histological diagnosis : Group 1: normal
squamous epithelium (30), Group 2: chronic esophagitis (21), Group 3: columnar epithelium
in distal esophagus without IM (24) Group 4: columnar epithelium in distal esophagus with
IM (27), Group 4: adenocarcinoma (44). Results: Cdx2 immunoexpression was present in
0% in G1, 5% in G2, 0% in G3, 63% in G4 and 66% in G5 (p< 0,001). We observed that
Cdx2 is a highly sensitive marker of intestinal metaplasia and its expression was related
with presence of goblet cells. Conclusions: The Cdx2 protein expression may be one of the
useful biomarkers for assessing the intestinal metaplasia in patients with Barrett`s esophagus
. It could be capable of detecting intestinal differentiation in Barrett`s patients with missing
of goblet cells.
T1886
Early Markers of Esophageal Intestinal Differentiation After Mucosal Ablation
By Photodynamic Therapy
Gerda Spijkerboer, Leon M. Moons, Peter D. Siersema, Johannes G. Kusters, Jelle
Haringsma, Ernst J. Kuipers
Objective: Barrett’s esophagus (BE) is characterised by specialized intestinal metaplasia (SIM)
that expresses CDX2. The time course of CDX2 expression in SIM development is largely
unknown. Photodynamic therapy (PDT) results in ablation of the mucosal surface, followed
by rapid re-epithelialisation. The new epithelium is thought to derive from stem cells in the
esophagus. Aim: To determine the timing of CDX2 expression in the development of SIM
in the esophageal mucosa. Methods: Biopsies taken from the esophagus of 12 patients (75%
male, mean age 68 years) with high grade dysplasia and a mean BE-segment length of 6
cm (range 2-12) treated with PDT , were used to determine the expression of CDX2, intestinal
differentiation markers (Villin and MUC2), and proliferation (KI-67) by immunohistochem-
istry. Paired biopsies were taken after 3 weeks and 16 weeks post treatment. The presence
of SIM was determined in H&E stained sections and confirmed by an Alcian Blue stain.
Results: Although there were characteristics of tissue regeneration based on a more central
located nucleus, higher nucleus/cytoplasm ratio, and Ki-67 expression at 3 weeks, it was
possible to distinguish columnar epithelial from squamous epithelial differention by histology.
The columnar epithelial cells were not homogeneous and were all in various stages of
differentiation. At three weeks, well differentiated glandular epithelium could be detected,
which concerned SIM (CDX2+, MUC2+ and Villin+), as well as cardiac type epithelium
negative for these markers. In addition there was also epithelium with lacking clear signs
of differentiation; i.e. it was CDX2+, but showed only faint cytoplasmic MUC2 and Villin
expression. This epithelium also lacked the presence of goblet cells (H&E ). In 3 patients,
several glands could be detected with large strong Ki-67+ nuclei, a very high nucleus/
cytoplasm ratio, and absence of cytoplasmic organization. Although most of these glands
were not positive for CDX2, a few glands showed very weak nuclear CDX2 expression,
which was in 50% associated with perinuclear expression of MUC2. At 16 weeks only well
differentiated epithelium was detected with either squamous-, IM- or gastric type epithelium.
Conclusions: This study shows that the formation of glands in the esophagus precedes
differentiation into gastric- or intestinal type epithelium, and that CDX2 was already expressed
at very early stages of differentiation. Biopsies from early regenerating epithelium following
PDT provides a good opportunity to study the process of intestinal differentiation of the
human esophagus, and its underlying factors in a time dependent manner.
T1887
P63 Response to Bile and Acid Exposure in Esophageal Squamous Carcinoma
Cell Lines
Sabine Roman, Amelie Thepot, Agnes Hautefeuille, Jean-Yves Scoazec, Francois Mion,
Pierre Hainaut
Backgrounds and aim: The TP63 gene encodes for at least six different isoforms proteins
with homology to the tumor suppressor protein p53. These isoforms are produced from a
single gene using 2 promoters (TA and deltaN isoforms) and alternative splicing of the
primary RNA transcript (α,β and γ isoforms). TA and deltaN isoforms are involved in
keratinocyte stem cells differentiation and proliferation, respectively. P63 is present in
esophageal squamous epithelium but not in Barrett’s mucosa. Patients with Barrett’s mucosa
have an increased esophageal bile and acid exposure. Our hypothesis is that loss of deltaN
p63 expression induced by bile and acid is necessary to the development of Barrett’s
metaplasia. The aim of this study was to determine p63 expression after bile and acid
exposure in esophageal cell lines over expressing p63. Materials and methods: Two esophageal
squamous carcinoma cell lines, TE-1 and TE-13, were exposed to bile and/or acid (pH5).
Three bile salts, primary bile salt (chenodeoxycholate CDCA), secondary bile salt (deoxychol-
ate DCA) and conjugated primary bile salt (taurochenodeoxycholate TCDCA) were applied
at 200 µM concentration during 5, 10, 20, 40 and 80 minutes. P63 expression was studied
by western blot and RT-PCR at the end of bile and acid exposure. Actin was the reference
protein and gene. Results: When cell lines were exposed to DCA at pH5, p63 protein

















expression remained stable in all experimental conditions. No modification of p63 expression
was detected after cell exposure to DCA or acid alone. The same results were obtained with
CDCA whereas TCDCA exposure at acid or neutral pH had no effect on p63 expression.
Results were similar in both cell lines. Conclusion: A brief exposure to unconjugated bile
salt in acid medium induces a loss of p63 expression in esophageal squamous carcinoma
cell lines. This synergistic effect of bile and acid occurs very soon after exposure and is
probably linked to a post translation phenomenon. The potential role of bile and acid
induced p63 loss of expression in the initiation of Barrett’s metaplasia development will be
tested in primary esophageal cell cultures and in experimental models of bile and acid reflux.
T1888
Identification of Novel Genes Modulated By Acid and Bile Exposure in a
Barrett’s Esophagus Cell Line and Associated Differential Expression in
Esophagitis, Barrett’s Esophagus and Esophageal Adenocarcinoma
Clare Donnellan, Simon Everett, Chris Wild, Laura Hardie
Molecular changes linked to reflux exposure may serve as biomarkers to identify Barrett’s
esophagus (BE) patients at greatest risk of esophageal adenocarcinoma (EA) and improve
current surveillance programmes. To identify genes central to the molecular response to
reflux, we exposed the non-cancer BE cell line, qhTERT, to media containing acid, deoxych-
olic acid (DCA), or a mix of primary bile salts, all at pH 4.5, for 15 minutes. RNA was
extracted from treated and control cells, 2 and 6 hours later. Gene expression was assessed
by hybridising cDNA to Affymetrix U133 Plus 2.0 microarrays. Following ethical approval,
expression of selected genes was then assessed by Real Time (RT) PCR in matched biopsies
from the mid and lower esophagus of patients with non-erosive reflux disease (NERD) (N=
31), esophagitis (N=27), BE (N=20) and EA (N=32). Compared to other conditions, treatment
of the qhTERT cell line with DCA resulted in the greatest overall change in gene expression;
210 genes were up- and 65 down-regulated. Based on biological plausibility, 12 genes were
selected for further study. For 11 of the 12 genes, changes in expression were confirmed
by RT PCR in treated cells. Patient biopsy data revealed that none of the target genes were
changed in NERD but four (including Anterior Gradient 2 homolog and COX-2) were
increased in esophagitis tissue. In contrast, the levels of expression of 8 genes (including
Manic Fringe and DNA-damage-inducible transcript 3) were increased and 2 (Ras-related
associated with diabetes and heat shock protein-40) decreased in BE and EA compared to
matched normal tissue. This research highlights novel genes associated with acid and bile
exposure in BE and EA, which may have utility as biomarkers in the future.
T1889
Insulin Resistance in Barrett’s Esophagus Patients: Preliminary Results
Kayode Olowe, Jennifer Kimble, Jason Taylor, Amitabh Chak
Background: Obesity is independently associated with Barrett’s esophagus (BE) and eso-
phageal adenocarcinoma (EAC). Consistent with the hyperinsulinemia hypothesis of obesity
associated carcinogenesis, we propose that insulin resistance may contribute to the develop-
ment of BE and its progression to EAC. Aim: To determine the prevalence of insulin resistance
and measure body mass index (BMI) in subjects with BE. Methods: A fasting serum sample
was taken from subjects with BE who provided informed consent. Serum was assayed for
insulin and glucose levels. The lowest detectable insulin level was 3 μIU/ml. Levels below
this were treated as zero. Insulin resistance was calculated using the homeostasis model
assessment of insulin resistance (HOMA-IR) equation = [fasting serum insulin (μIU/ml) x
fasting glucose (mg/dl)]/405. Insulin resistance was deined as HOMA-IR ≥ 3.80. Measure-
ments of weight and height were taken to determine the BMI = kg/m2 with obesity defined
as BMI > 30kg/m2. Results: Fasting serum samples from 21 BE subjects were assayed. The
mean age of the BE subjects was 64.1 ± 11.7 years. Eighteen of 21 subjects (85.7%) were
men. The median HOMA-IR value was 2.62 with a range of zero to 16.81. Four of 21 (19%)
subjects had a HOMA-IR value > 3.80, indicative of insulin resistance. Eight of 20 (40%)
subjects were obese with BMI > 30kg/m2. All four subjects with HOMA-IR > 3.80 also had
BMI > 30kg/m2. Conclusion: Our preliminary data suggest that there is a significant degree
of insulin resistance in obese subjects with Barrett’s esophagus. This relationship between
obesity, insulin resistance, and Barrett’s esophagus needs to be further explored.
T1890
Antimicrobial Resistance for Primary and Secondary Helicobacter Pylori
Strains Isolated from Korean Patients
Jung Mogg Kim, Joo Sung Kim, Nayoung Kim, Sang Gyun Kim, Hyun Chae Jung, In
Sung Song
BACKGROUND and AIMS: The aim of this study was to assess MIC values and resistance
rates of several antibiotics in primary and secondary H. pylori isolates from Korean patients.
MATERIALS AND METHODS: Sixty-five strains of H. pylori were isolated from 65 patients
that had not received antibiotics, PPI or nonsteroidal anti-inflammatory drugs during the
preceding three months. Three hundred twenty-four strains of H. pylori were isolated from
67 patients who had taken PPI triple therapy consisting of amoxicillin and clarithromycin
for one week. The MIC values of H. pylori isolates to the antibiotics were determined
using the serial two-fold agar dilution method. The resistance breakpoints for amoxicillin,
metronidazole, and tetracycline were defined as >= 0.5, > 8, and > 4 μg/ml, respectively.
The breakpoint for clarithromycin was set at > 1.0 μg/ml, and those for azithromycin,
ciprofloxacin, levofloxacin, and moxifloxacin were provisionally defined as > 1.0 μg/ml. The
mutation of penicillin-binding protein 1A (pbp1A) was determined by PCR amplification
and nucleotide sequencing. RESULTS: The overall MIC values of secondary isolates showed
a shift to high concentrations compared with those of primary isolates. Primary resistances
to amoxicillin, clarithromycin, metronidazole, tetracycline, azithromycin, ciprofloxacin, levo-
floxacin and moxifloxacin were 18.5%, 13.8%, 66.2%, 12.8%, 32.3% 33.8%, 21.5% and
21.5%, respectively. Secondary resistances to amoxicillin, clarithromycin, metronidazole,
tetracycline, azithromycin, ciprofloxacin, levofloxacin and moxifloxacin were 31.3%, 85.1%,
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70.1%, 0%, 89.6% 35.8%, 32.8% and 32.8%, respectively. Sequence analysis of pbp1A in
H. pylori strains with more than 2 μg/ml of amoxicillin MIC revealed C206T (Asp69 to Val),
C1667G (Thr556 to Ser), A1684T (Asn562 to Tyr), A1777G (Thr593 to Ala), and C1798A
(Pro600 to Thr). In contrast, the activity of β-lactamase was detected in neither the amoxicil-
lin-resistant strains nor amoxicillin-susceptible strains. Eleven out of 67 treatment-failure
patients (16.4%) showed mixed infections with both antibiotic-susceptible and -resistant H.
pylori. The most common multidrug resistance was to clarithromycin, metronidazole and
azithromycin. CONCLUSIONS: These results indicate that MIC values of secondary isolates
were higher than those of primary isolates and that resistance to amoxicillin is likely mediated
through mutations in pbp1A.
T1891
Comparison Study On Effectiveness of Established Triple Therapy with Its
Modified Therapies for Helicobacter Pylori Eradication
Taewoon Park, Jae Eun Lee, Chang Woo Gham, Ja Sung Choi, Chang Hwan Choi, Ki
Joon Han, Hyeon Geun Cho
Background: The rate of Helicobactor pylori infection as well as related morbidity are
relatively high in Korea. H. pylori eradication is becoming an essential treatment not only
for peptic ulcer patients but also for functional dyspepsia patients. However, the eradication
rate by the established triple therapy (PPI + amoxicillin + clarithromycin, PAC) is still around
80%. In this study, we compared the efficacies of the established triple therapy with its
modified therapies for H. pylori eradication in order to obtain a better eradication rate.
Methods: This prospective study included a convenience sample of 355 H. pylori infected
patients (mean age 48.4+12.4 years) with functional dyspepsia (n=189) or peptic ulcer (n=
166)(table 1). From March 2003 to August 2005, the patients were randomly assigned to
PAC group (PPI: rabeprazole 10mg, bid + amoxicillin 1g, bid + clarithromycin 500mg, bid),
PACR group (PAC + roxatidine 75mg, bid at different timing from PPI), or DPAC group
(doubling PPI dose in PAC). The patients in three groups underwent each eradication
treatment for one week and the eradication was confirmed through follow-up endoscopy
or urea breath test at least four weeks after the completion of treatment. Results: Tests for
homogeneity demonstrated no significant differences between groups in age, gender, and
diagnosis. In per protocol analysis, the eradication rates were 83.2% in PAC group, 92.6%
in PACR group, and 81.6% in DPAC group. Significantly higher eradication rate was noted
in PACR group than the other two groups (p=0.034; p=0.019, respectively). Intent-to-treat
analysis also showed similar findings; 74.2% in PAC group, 84% in PACR group, and 69.0%
in DPAC group (p=0.043; p=0.003, respectively). In terms of drug tolerance, only seven
patients out of 355 patients failed to complete the treatment, but there were no differences
between groups. Conclusion: While doubling PPI dose in PAC did not change H. pylori
eradication rate, adding H2RA(roxatidine) to PAC did significantly increase the eradication
rate. Further studies with a large sample are recommended to support these results and
drug interaction between PPI and H2RA needs to be examined.
Tabel 1. Characteristics of Patients
P: proton pump inhibitor (rabeprazole), A: amoxicillin, C: clarithromycin, R: roxatitidine,
DP: double dose PPI PUD: peptic ulcer disease, FD: functional dyspepsia
T1892
Dose Atrophic Gastritis Affect the Accordance Between Stool Antigen Test and
Serology to Determine Helicobacter Pylori Infection in the Mass Survey?
Tadashi Shimoyama, Takao Oyama, Shinsaku Fukuda, Shigeyuki Nakaji, Akihiro
Munakata
Background: In Japan, infection of Helicobacter pylori is often tested in the mass screening
for gastric cancer along with the level of serum pepsinogen (PG) I and II. Although infection
of H. pylori is usually examined by serology, a stool antigen test (EIA) using monochronal
antibody to catalase is now available. We examined H. pylori infection by both serology and
this stool antigen test in a mass survey and studied whether age of subjects or atrophic
gastritis affect the results of the two tests. Methods: 994 healthy adults who received mass
survey in April 2005 were tested. There were 379 males and 615 females, and the mean
age was 57.7±13.9 years old. Stool samples were used to test the prevalence of H. pylori
antigen by EIA using monochronal antibody to H. pylori catalase. Serum samples were tested
for the prevalence of IgG antibody to H. pylori by ELISA. The level of PG I and II was also
measured and atrophic gastritis was considered significant if both PG I less than 70 μg/L
and PGI/II less than 3.0 were observed. Results: The prevalence of H. pylori infection was
defined as 60.7% by serology and 55.4% by stool antigen test. There were 22 subjects who
were positive only by stool antigen test and 75 subjects were positive only by serology. The
concordance of both tests was not affected by age of the subjects (91.7% in <50 years old,
88.1% in 50s, 92.1% in 60s, and 91.2% over 70 years old). The concordance of these tests
was not also different in subjects with atrophic gastritis (91.1%, n=418) and without atrophic
gastritis (90.1%, n=576). Conclusions: Both age and atrophic gastritis did not have significant
effect on the results of serology and stool antigen test. The discrepancy of the results seemed
to depend on the sensitivity and specificity of individual tests. Since stool antigen test have
been shown to have better sensitivity and specificity, it would be better non-invasive test
to determine H. pylori infection in the mass survey.
T1893
Significantly Different H.pylori Density and Genotypes in Erosive, Antral and
Corpus Routine Gastric Biopsy Specimen Detected By PCR
Bela Molnar, Dominika Szoke, Agnes Ruzsovics, Zsolt Tulassay
Background and aim: Determination of local intensity and genotypic variations in H.pylori
in gastric biopsy specimen could support the precise diagnosis and research of the H.pylori
infection. The aim of this study was the development of real-time PCR based new techniques
for this purpose and comparison with routine available techniques. Methods: Serial dilutions
of H.pylori (0.016-16 mikrog/μl) and control bacterial and human DNA samples were
prepared. From 53 patients who underwent routine gastroscopy, fresh frozen antral and
corpus gastric biopsy specimen were taken and DNA was isolated using a commercial assay.
UreaseA quantitative determination using hybridisation probes with parallel evaluation of
an internal human control gene (beta-globin) was performed on a real-time PCR system.
CagA and vacA genotypic characterisation was done using intercalating dye too. Comparison
of the data was made to UBT, histology, and Western blot analysis of human sera samples
for H.pylori and its antigens (UreaA, B, VacA, CagA). Results: The presence of H.pylori could
be detected by ureaseA-FRET(53%), UBT(46%) and Western blotting(43%), histology(41%)
as compared to the gold standard (44%). A significant correlation was found between the
quantitative real-time ureaseA/beta-globin ratio based H.pylori frequency and the UBT results
(p<0.01). Significantly increased bacterial density was found in the erosion as compared to
the healthy part of the antrum and corpus (p< 0.01). VacA genotyping was in significant
correlation (p<0.01) between the Western blot and real-time PCR, but CagA not. The
genomic profile (VAC/GAC) was different in 8,7% of the cases concerning three different
locations in the stomach surface. Conclusions: Real-time PCR based quantitative and geno-
typic determination of H.pylori in biopsy specimen can yield important data for routine
diagnosis and research. The density and genomic profile of gastric H. pylori infection shows
quantitative and qualitative differences between the place of erosion, antrum and stomach.
T1894
Clinical Practice Patterns for the Management of Helicobacter Pylori Infection,
Dyspepsia, and Gastroesophageal Reflux Disease
Steven W. Blume, Colin W. Howden, Gregory de Lissovoy
Background Since the recognition of Helicobacter pylori (H. pylori) as the major cause of
peptic ulcer, clinical guidelines for the testing and treatment of H. pylori infection have been
widely disseminated. One of the key recommendations has been that clinicians use non-
invasive testing for H. pylori infection, reserving prompt endoscopy for older patients or
those with alarm symptoms. Eradication therapy should be administered to all patients
testing positive. Little is known about adherence to these recommendations and actual
medical practice patterns. Methods Medical and pharmacy claims of a national sample of
two million non-elderly individuals continuously enrolled in managed care plans from 2002
to 2004 were the basis of a longitudinal cohort study. We selected patients with claims for
antisecretory medication, H. pylori tests, or endoscopies but having no disease-related claims
in the first six months of the study period and having at least six months of follow-up.
Patients were grouped by their initial clinical diagnosis: peptic ulcer disease (PUD) (n =
3456), non-ulcer dyspepsia (n = 14,593), or GERD (n = 36,233). The proportions of patients
treated contrary to guidelines, diagnostic procedures and medications received, and the
sequencing of key procedures and medications were examined by initial diagnosis, age, and
physician type. Results Two-thirds of the study population were enrolled in health mainten-
ance organizations and almost half were located in the Midwest census region. Several
practices contrary to guidelines were common. Twenty-five percent of suspected PUD patients
were not checked for H. pylori infection, and only 25% were treated with eradication therapy.
Of all patients aged 18-49, 15% had an endoscopy as their first clinical event. A third of
those receiving antibiotics for H. pylori infection had not been first tested for the infection.
Serology was used for 87% of pre-treatment tests in 2004 and was improperly used by
primary care practitioners for post-treatment testing. Nineteen percent of GERD patients
were tested for H. pylori. Patterns of care varied little by type of medical plan or geographic
region. Conclusions The study demonstrated substantial non-compliance with guidelines.
A better understanding by physicians of the indications for H. pylori testing and endoscopy
would improve patient care and resource use.
T1895
Seroprevalence of Helicobacter Pylori in Two Asymptomatic Dutch Populations
A. J. van Vuuren, R. A. de Man, H. F. van Driel, M. Ouwendijk, J. G. Kusters, E. J.
Kuipers, J. H. Richardus, P. D. Siersema, M. Blankenstein
Background: Helicobacter pylori (Hp) infection poses a potential risk for developing upper
gastrointestinal disorders ranging from peptic ulcers to gastric malignancies. The Hp preval-
ence is thought to be declining in Western countries, probably reflecting a birth cohort
effect resulting from improvements in hygiene. Aims: To examine the secular trends in the
Hp seroprevalence in a native Dutch population and in non-Western immigrants by determin-
ing the age specific Hp seroprevalence in representative groups from both populations.
Methods: Plasma samples were collected from 794 native Dutch blood donors living in the
South-Western Netherlands, which includes Rotterdam. Information concerning age, gender,
and geographic region was available, but no donor identity. Another 287 serum samples were
collected from asymptomatic volunteers from an urban district of Rotterdam, predominantly
populated by non-Western immigrants. All samples were tested for IgG antibodies against
Hp by a commercial ELISA (Orion Diagnostica), the results were divided into ten-year age
groups. Results: are summarized in the Table. Hp seroprevalence was overall 32% in the
native Dutch population: 34% in males, and 30% in females. Logistic regression within
donors reveals a higher age specific Hp prevalence compared to the younger age
groups(p<0,001): odds ratios (95% CI) are respectively 2,1 (1,22-3,57) group II, 2,4 (1,40-
4,03) group III, 2,4 (1,38-4,00) group IV, and 4,7 (2,79-7,86) group V. In contrast, in the
urban district Hp seroprevalence was far higher in all age groups, 72% in males, 66% in
females, 69% overall (p< 0.001 Chi-square test), without signs of an age specific increase.
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No gender differences were observed in either population. Conclusions: The secular trend
towards lower Hp infection rates was observed in the native Dutch population, but not
in volunteers of the urban district, with many non-Western immigrants. However, both
populations are living in the same region, Hp seroprevalence varies. These ethnical differences
are of obvious importance to public health authorities planning interventions to lighten the
burden of Hp associated disease.
T1896
Accuracy of Monoclonal Stool Antigen Test for the Diagnosis of H. Pylori
Infection: A Systematic Review and Meta-Analysis
Javier P. Gisbert, Felipe de la Morena, Victor Abraira
OBJECTIVE: To perform a systematic review and a meta-analysis of accuracy of monoclonal
stool antigen test for the diagnosis of H. pylori infection. METHODS: Selection of studies:
assessing the accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection.
Search strategy: electronic and manual bibliographical searches. Data extraction: independ-
ently done by two reviewers. Data synthesis: meta-analyses of the different tests were
performed combining the sensitivities, specificities, and likelihood ratios (LRs) of the indi-
vidual studies. RESULTS: Pre-treatment studies: Twenty-two studies, including a total of
2,499 patients, evaluated the monoclonal stool antigen test for the diagnosis of H. pylori
infection before therapy. Pooled sensitivity, specificity, LR+ and LR- were, respectively, 0.94
(95% CI, 0.93-0.95), 0.97 (0.96-0.98), 24 (15-41) and 0.07 (0.04-0.12). The accuracy of
both the monoclonal and the polyclonal stool antigen tests was evaluated together in 13 pre-
treatment studies, where a higher pooled sensitivity was demonstrated with the monoclonal
technique (0.95 vs. 0.83). Post-treatment studies: Twelve studies, including a total of 957
patients, assessed the monoclonal stool antigen test to confirm eradication after therapy.
Pooled sensitivity, specificity, LR+ and LR- were 0.93 (95% CI, 0.89-0.96), 0.96 (0.94-
0.97), 17 (12-23) and 0.1 (0.07-0.15). The accuracy of both the monoclonal and the
polyclonal stool antigen tests was evaluated together in 8 post-treatment studies, where,
again, a higher pooled sensitivity was demonstrated with the monoclonal technique (0.91
vs. 0.76). Although heterogeneity among studies was initially present, it disappeared when
a single outlier study was excluded. When subanalysis depending on the reference method
(gold standard based on only one diagnostic method vs. at least two reference methods) or
on the study population (adults vs. children) was performed, the results of the meta-analysis
were similar. CONCLUSION: Monoclonal stool antigen test is an accurate non-invasive
method both for the initial diagnosis of H. pylori infection and for the confirmation of its
eradication after treatment. The monoclonal technique has a higher sensitivity than the
polyclonal one, especially in the post-treatment setting.
T1897
H.pylori RE-Infection in Insulin Dependent Diabetes Mellitus Patients: A Five
Yaers Follow-Up
Veronica Ojetti, Dario Pitocco, Alessio Migneco, Michele Santoro, Ilir Leka, Giovanni
Gasbarrini, Giovanni Ghirlanda, Antonio Gasbarrini
Objective: Previous data show that diabetic patients (pts) have a low H.pylori eradication
and a high re-infection rate after 1 year of follow-up. The increased susceptibility of diabetics
to infections are based probably on many mechanisms (reduced lymphocyte activity, neutro-
phil dysfunction, failure of chemiotaxis, frequent hospitalization and dental plaque as H.pylori
reservoir). Aim of our study was to evaluate the H.pylori re-infection rate in insulin dependent
diabetes mellitus (IDDM) pts and in dyspeptic controls five years after successful eradication,
and the impact of H.pylori re-infection on glycaemic control. Methods: 40 pts (23males,17-
females; mean age 48+/-9) affected by IDDM and 50 dyspeptic control matched for sex and
age, previously treated for H. pylori infection and successfully eradicated, were submitted
to 13C urea breath test (UBT) after five years of follow-up. Daily insulin requirement,
glycosilated haemoglobin (HbA1c) expressions of glycaemic metabolic control and the devel-
opment of organ damage were evaluated. Results: We found a significantly higher incidence
of H. pylori re-infection in IDDM pts compared to controls. In particular, 11 of 40 (27%)
IDDM pts vs 2 of 50 (4%) controls resulted re-infected after 5 years (p < 0.001). Among
IDDM pts, re-infection occurrence was not affected by sex or age. At five years follow-up
in the re-infected diabetic pts an increased levels of HbA1c compared to values at enrolment
(8.26 vs 7.48, p<0.01) was observed, while no significant increase in HbA1c was found in
the negative group. Furthermore, the H.pylori positive group showed increased insulin
requirements compared to negative pts (0.69/Kg vs 0.61/Kg). These data reached not statistical
significance. Finally, we found statistical significant higher prevalence of diabetic organ
damages in the re-infected group compared to negative pts: neuropathies: 42 % vs 10 %
(p<0.01); nephropathies: 42 % vs 15 % (p<0.01); retinopathies: 28.6% vs 5 % (p<0.05),
respectively. Conclusions: IDDM pts show higher H.pylori re-infection rates compared to
dyspeptic controls. H.pylori re-infection in IDDM pts is associated with poorer glycaemic

















UBT as follow-up screening in successfully eradicated IDDM pts seems therefore a useful
tool in order to detect re-infected pts and optimize glycaemic control.
T1898
Lower Prevalence of Helicobacter Pylori Infection in Young Women: A 9-Year
Observational Study
Sun-Young Lee, Sang Kyun Yu, In-Kyung Sung, Hyung-Seok Park, Choon-Jo Jin, Won
Hyeok Choe, So Young Kwon, Chang Hong Lee, Kyoo Wan Choi
Background and Aim: Although many studies have reported on the trends of changes since
Helicobacter pylori was first discovered in 1982, detailed information is still lacking. We
surveyed the detailed information on the trends of changes in the prevalence of Helicobacter
pylori infection relative to age and gender. Methods: A total of 8646 subjects aged 16 years
or older (4099 men and 4547 women) who submitted to a rapid urease test during upper
gastrointestinal endoscopy, from January 1997 to July 2005, were included in this study.
We investigated how the prevalence of H. pylori infection varied with gender and age at the
date of examination. Results: H. pylori infection was noted in 3747 cases (43.3%) of all
cases. The infection rate was 50.0% in 1997, but declined gradually down to 40.6% in
2005 (P<0.001). In addition, the prevalence was higher in men (49.0%) than in women
(41.6%) before the age 50 years (P<0.001) in any of the years studied. In contrast, there
was no difference in the prevalence of H. pylori infection between the men (39.2%) and
women (41.1%) after the age 50 years (P=0.28). Conclusions: H. pylori infection has gradually
decreased over the past decade, and there is a lower rate of infection among young women
aged less than 50 years old when compared to men. Female sex hormone might be the
cause of this gender-related difference in the prevalence of H. pylori infection, which explains
indirectly the lower prevalence of intestinal-type gastric cancer among young women. Key
Words: Helicobacter pylori, Prevalence, Young, Women
T1899
The Diagnostic Yield of Various Tests for Helicobacter Pylori Infection in
Patients On Acid Reducing Drugs
Javed Yakoob, Wasim Jafri, Zaigham Abbas, Shahab Abid, Muhammad Islam, Saeed
Hamid, Hasnain Alishah, Zubair Ahmed
Aim: The aim of this study was to compare the diagnostic yield of various tests for Helicobacter
pylori (H. pylori) infection in patients on acid reducing drugs such as proton pump inhibitors
(PPI) and histamine-2 receptor blocker (H-2RB). Methods: Eighty consecutive patients with
dyspeptic symptoms on acid reducing drugs attending the endoscopy suite were enrolled.
Gastric biopsy specimens were collected at endoscopy for the rapid urease test (Pronto Dry,
Medical Instrument Corp, France), histopathology and polymerase chain reaction for H.
pylori 16S ribosomal DNA (PCR 16S rDNA). Results: These are the preliminary results of
an ongoing study. There were 57 % (35/80) males and 43 % (45/80) females with age range
17-80 years and mean age of 44 ± 14.8 years. Fifty-three (66%) patients were on PPI while
27 (34%) on H2RB. PCR for H. pylori 16S rDNA was positive in 65 (81%) and negative in
15 (19%). Of those positive 42 (65%) were on PPI and 23 (35%) on H2RB while those
negative 11 (73%) were on PPI and 4 (27%) on H2RB p=0.52. Pronto dry was positive in
23 (29%) and negative in 57 (71%). Of those positive, 10 (43%) were on PPI and 13 (57%)
on H2RB while those negative 43 (75%) were on PPI and 14 (25%) on H2RB p=0.009.
Histopathology showed H. pylori associated mild-moderate gastritis in 36 (45%) and H.
pylori negative mild non-specific gastritis in 44 (55%). Of those with H. pylori associated
gastritis 24 (67%) were on PPI and 12 (33%) on H2RB while of those with H. pylori negative
non-specific gastritis 29 (66%) were on PPI and 15 (34%) on H2RB p=0.63. Conclusion
This study shows that in patients on PPI with H. pylori infection, diagnostic yield of PCR
on gastric tissue is higher than rapid urease test and histopathology. These patients on acid
reducing drugs are likely to have a negative rapid urease test and a mild non-specific gastritis
on histopathology.
T1900
Rapid Stool Antigen Test for Diagnosis of H. Pylori Infection in Asymptomatic
Childre
Victor M. Cardenas, Delfina C. Dominguez, Flor Puentes, Corinne C. Aragaki, Karen J.
Goodman, David Y. Graham, Yoshihiro Fukuda
Background: Rapid immunochromatographic tests for H. pylori (HP) infection have been
developed to allow testing in clinics and in field epidemiologic studies. Aims: To determine
the diagnostic performance of the Testmate rapid H. pylori antigen detection test (Wakamoto
Pharmaceuticals) in diagnosing HP infection in asymptomatic children. Methods: We used
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data and fecal specimens collected from children participating in the ongoing Pasitos Cohort
Study that takes place in El Paso, Texas and Ciudad Juarez, Mexico on the US-Mexico
border. All children in the study had an HP stool antigen EIAs test (HPSA) status (HpSA
Premium, Meridian Bioscience) tested (positive = OD >=0.16). Children classified as Hp-
infected had a positive urea breath test (UBT) (urea hydrolysis rate =>10 based on adjusted
DOB readings from Wagner’s IRIS) and a positive HPSA. Children classified as uninfected
were negative on both tests and on serology (IgG concentration <2.2, HM-CAP IgG antibodies,
Enteric Products). Children were classified as status uncertain if they were positive on either
the UBT or HPSA test, but not both. For each subject, a dab of stored fecal specimen (frozen
at -70°C) was thawed and tested with the Testmate rapid H. pylori antigen kit following the
manufacturer’s instructions. Results: We tested specimens from 52 children. Twenty-four
were positive, 19 negative, and 9 had uncertain status. The sensitivity and specificity of the
Testmate rapid H. pylori antigen were 100% (24/24) (95% mid-P binomial CI: 88.3-100.0)
and 100% (19/19) (95% mid-P binomial CI: 85.4-100.0), respectively. There was 100%
concordance between HPSA and Testmate for those with uncertain Hp status. The observed
agreement between the EIA HPSA and this novel product was 96.1% with Kappa=92.4%
(95%CI=82.3-100.0). Discussion: This rapid stool antigen test should prove useful for point
of care testing and in epidemiologic field studies.
Results of Testmate rapid H. pylori testing in relation to H. pylori Infection Status of Asymptom-
atic Children in the US-Mexico Border
Hp infection positive status: EIA Stool Antigen Test positive and UBT positive. Hp infection
negative status: Negative to: 1) EIA Stool Antigen Test, 2) UBT and 3) HMCAP serology.
Table excludes 9 children of uncertain H. pylori infection status.
T1901
Long-Term Follow-Up of 13c-Urea Breath Test Result After Helicobacter Pylori
Eradication: Frequency and Significance of Borderline δ13co2 Values
Javier P. Gisbert, David Olivares, Isabel Jimenez, Jose-Maria Pajares
AIM: To quantify the 13C-urea breath test (UBT) result for several years following H. pylori
eradication, and to evaluate the frequency and the significance of borderline δ13CO2 values.
METHODS: Two-hundred H. pylori eradicated patients confirmed by 13C-UBT (100 mg of
urea, citric acid), and having had repeated this test yearly up to 5 years, were studied.
δ13CO2 values between 2 and 5‰ were considered as borderline results. RESULTS: Eight
H. pylori recurrences were observed during 406 patient-years of follow-up (1.97% yearly).
In 2/8 reinfected patients, the reinfection was preceded by a negative δ13CO2 value >2‰.
Borderline δ13CO2 values were detected in 4% of the 606 UBTs performed, and in 25%
when only patients in whom H. pylori recurrence was detected in subsequent UBTs were
included (p<0.05). The negative predictive value of a post-treatment δ13CO2 >2‰ for the
diagnosis of H. pylori recurrence was 99%. CONCLUSION: Positive and negative UBT results
tend to cluster outside of the range between 2 and 5‰. Nevertheless, a borderline UBT δ
value (e.g., very close to the selected cut-off point) should be cautiously interpreted, and
the result should probably be confirmed either by repeating the UBT or by other diagnostic
methods. On the contrary, a δ13CO2 value <2‰ very confidently confirms H. pylori eradica-
tion.
T1902
Helicobacter Pylori Infection As a Cause of Iron Deficiency Anaemia
Nikitas Papantoniou, Stylianos Karatapanis, Philip Lisgos, Emmanuel Spanos, Ypakoi
Papantoniou, Kostas Kladakis, Haridimos Tsibidakis, Kostas Komnianidis, Chrysostomos
Psellas, Stylianos Manolitsis, George Manolakas, Ioannis Stouraitis
Background: It is estimated that 30% of patients presented with iron deficiency anemia
remain undiagnosed despite complete upper and lower GI endoscopy and other tests.
Helicobacter pylori (H.pylori) infection is the main cause o chronic gastritis, peptic ulcer
disease and gastric cancer. H.pylori infection has a relation with iron metabolism but the
exact mechanism is unknown. Aim: To investigate the role of H.pylori infection in patients
with iron deficiency anemia of unknown aetiology. Patients and Methods : In the present
study we investigated 115 consecutive patients presented with iron deficiency anemia during
the period 2003-2004.We excluded patients with nutritional problems, with IBD, with a
history of upper GI surgery, patients receiving NSAIDS or aspirine, pregnant women and
patients with malignancy. Presence of H.pylori was assessed by histology (Giemsa), CLO-
test and/or UBT. Iron deficiency anemia was diagnosed in the presence of low plasma ferritin
and iron level and low transferrin saturation. Results : 54 out of the initial 115 patients
excluded from further evaluation (due to medication 33, due to malignancy 6, due to
pregnancy 2 and 13 due to recent episode of GI bleeding). From the remaining patients
38/61 (62.29%) had established Hp infection, while 23/61 (37.7%) were negative to H.pylori.
Mean haemoglobin levels were similar in both group of patients (8.9 gr% vs 8.7gr% ). On
the contrary the mean values of serum iron and ferritin levels and transferin saturation were
significantly lower in those patients harboured H.pylori infection as compared with those
negative to H.pylori testing. Conclusion : Chronic atrophic gastritis as a consequence of
chronic H.pylori infection correlates with iron deficiency anemia of unknown aetiology. The
interaction of H.pylori infection and iron metabolism remains obscure.
T1903
Applicability of a Helicobacter Pylori Stool Antigen Test to Determine the
Results of Eradication Therapy
Shinsaku Fukuda, Tadashi Shimoyama, Daisuke Nishiya, Akihiro Munakata
Background: 13C-urea breath test (UBT) is usually used to test the results of eradication
therapy of Helicobacter pylori. However, in most hospitals, results can not be obtained
immediately because this test requires particular equipments. H. pylori stool antigen tests
are non-invasive and results are obtained within 10 min. The aim of this study was to
examine whether stool antigen test is applicable to determine the results of eradication
therapy. Methods: 65 patients infected with H. pylori (35 males, 30 females, mean age 57.1)
received eradication therapy consisted of lansoprazole, amoxicillin and one of clarithromycin
or metronidazole. At least 5 weeks after finishing the treatment, results were evaluated by
13C-UBT. On the same day, Testmate rapid pylori antigen, which uses monochronal antibody
to H. pylori native catalase, was also performed and the results were compared with 13C-
UBT. Results: In all the 49 patients with negative 13C-UBT, Testmate rapid pylori antigen
was also negative. In 14 13C-UBT-positive patients, 12 were also positive by Testmate rapid
pylori antigen. One patient could not be tested because his stool was watery. Two patients
who had grey zone result by 13C-UBT was negative by Testmate rapid pylori antigen and
they were tested by 13C-UBT again one month later and the results were negative. Overall
accuracy of Testmate rapid pylori antigen to determine H. pylori eradication was 98.4%
when compared with 13C-UBT. Conclusions: Testmate rapid pylori antigen is an immediate
and accurate test to evaluate the results of H. pylori eradication therapy.
T1904
Detection of Helicobacter Pylori in Esophagus and Saliva in Humans
Luigina Cellini, Rossella Grande, Daniela Coraggio, Laurino Grossi, Leonardo Marzio
Introduction: Helicobacter pylori infection is the most common gastrointestinal bacterial
disease worldwide. The microorganism has established its niche in the human gastric mucosa,
but the presence of the germ has also been demonstrated in human dental plaque, in water
distributions and in feces supporting the oro-oral and/or fecal-oral transmission. In a previous
study we detected H.pylori in the esophagus of Balb/C mice 3 months after infection with
human H.pylori, suggesting for this location a possible role of reservoir for the infection and
transmission of the bacterium. Aim: to see if in humans the esophagus and saliva may be
reservoir of H.pylori. Methods: Saliva samples, and mucosal biopsy from esophagus, gastric
antrum and fundus were collected during upper g.i. endoscopy from 13 patients with
positive Urea Breath Test (UBT). Gastric biopsies were cultured to isolate H.pylori, whereas
saliva samples and esophagus biopsies were collected to investigate for H.pylori with a
Nested-PCR targeting the 16S rRNA gene using Hp1, Hp2 and Hp3 primers. Results :
H.pylori was isolated in gastric biopsies of 12 patients either in the antrum and/or in the
gastric fundus. The analysis in Nested-PCR gave positive results in all saliva and esophageal
samples studied. The amplified fragments of 109 bp were sequenced and were found in
accord with all the sequences present in the Data Base of the National Center for Biotechnology
Informations (NCBI), confirming the identity of the microorganism. Conclusion: These data
suggest that saliva and the esophagus may be considered reservoirs for H. pylori in humans.
Identification of the transmission route of H.pylori is crucial in developing an effective plan
of surveillance of the microorganism by finding new ways of managing the disease.
T1905
A Multiple-Step Polyclonal Versus a One-Step Monoclonal Enzyme
Immunoassay to Detect Helicobacter Pylori Antigen in the Stools in Children
Bruno Hauser, Ingrid Wybo, Gerard Tshibuabua, Denis Pierard, Yvan Vandenplas
Objective: Evaluation of a polyclonal and a monoclonal Helicobacter pylori stool antigen tests
(HpSAT) for the detection of a Helicobacter pylori (HP) infection in children. Methods: 43
children (mean age 8.9 years, range 3.5-17.5 years) underwent a 13C-urea breath test (13C-
UBT) and 2 HpSATs for the detection of HP: the “Premier Platinum HpSA“ test (PP-HpSAT)
(multiple-step polyclonal enzyme immunoassay) and the “ImmunoCard STAT! HpSA“ test
(ICS-HpSAT) (one-step monoclonal enzyme immunoassay). A child was considered as HP
positive if the 13C-UBT was positive. Results: Of the 43 children, 18 (41.9%) were HP
positive and 25 (58.1%) were HP negative. The sensitivity and specificity of the PP-HpSAT
was 94.4 % and 100.0 %, respectively. Results were equivocal with the ICS-HpSAT in 5/
42 (11.9%) of the tests due to visual interpretation difficulties of the change in colour of
the test-line. The sensitivity and specificity of the ICS-HpSAT was 100.0 % and 76.0 %,
respectively, when any change of colour of the test-line was considered as positive (according
to the guidelines of the manufacturer). However, sensitivity and specificity of the ICS-HpSAT
reached 100.0 % and 96.0 %, respectively, when the test was considered positive in case
a “significant change of colour” of the test-line occurred. Conclusions: Compared to the
13C UBT, the PP-HpSAT showed a comparable sensitivity and specificity and the ICS-
HpSAT had a comparable sensitivity but low specificity. However, sensitivity and specificity
of the ICS-HpSAT became comparable when a weakly positive test was considered as
negative. The ICS HpSAT is easy to perform with results available within 10 minutes, and
is therefore of particular interest in ambulatory medicine.
T1906
Prevalence of Helicobacter Pylori Infection in Gastric MALT Lymphoma: A
Systematic Review
Javier P. Gisbert, Laura Martin-Asenjo
Objective: To perform a systematic review of the studies evaluating H. pylori prevalence in
patients with gastric MALT lymphoma, and to analyze the factors influencing it. Methods:
Bibliographic searches were conducted in MedLine, selecting the articles that studied H.
pylori prevalence in patients with MALT lymphoma. Results: Thirty-eight studies were
identified, including 1844 patients. The mean prevalence of H. pylori infection was 79%.
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In patients diagnosed of H. pylori infection with 2 or more methods, the prevalence was
85%, whereas it was 77% when only one diagnostic method was performed (p<0.0001).
The H. pylori prevalence in patients diagnosed with histology was 75%, but this figure
increased up to 85% when serology was used (p<0.0001). The H. pylori prevalence in high-
grade lymphomas was 60%, and 79% in low-grade lymphomas (p<0.0001). H. pylori infection
was detected in 74% of MALT lymphomas confined to the mucosa or submucosa (EI1), but
in only 44% of those beyond submucosa (p<0.0001). Conclusions: The H. pylori prevalence in
patients with MALT lymphoma is variable, which seems to depend, at least partly, on the
number and the type of diagnostic methods used to detect the infection, on the histological
grade and on the stage of tumoral invasion. If the adequate diagnostic methods are performed,
and if only low-grade MALT lymphomas are considered, the H. pylori prevalence is remarkably
high, nearly 90%, which reinforces the role of this micro-organism in the pathogenesis of
gastric MALT lymphoma.
T1907
Efficacy of Helicobacter Pylori Erradication Treatment in Gastric MALT
Lymphoma: A Systematic Review
Javier P. Gisbert, Laura Martin-Asenjo
Objective: To perform a systematic review of studies evaluating the effect of H. pylori
eradication treatment on the histological regression of gastric MALT lymphoma. Methods:
Bibliographical searches were conducted in MedLine, and studies evaluating the effect of
H. pylori eradication treatment on the histological regression of gastric MALT lymphoma
were included. Results: Forty-one studies were identified, including a total of 1446 patients.
After H. pylori eradication, complete remission was achieved in 74% of the cases, partial
remission in 10%, and no response in 16%, during a mean follow-up of 23 months (range
12 to 35 months). After complete remission, tumoral relapse was detected in 6% of de
cases; of these, 25% were associated with H. pylori reinfection, and in 15% a high grade
MALT lymphoma component was identified. When only patients with MALT lymphoma
stage EI (confined to stomach) and with purely low-grade histological type were included,
complete remission was achieved in 80% (95% CI, 77-82%) of the cases. In stage EI1
(confined to mucosa or submucosa), the response to eradication treatment was higher than
in stage EI2 (beyond submucosa): 84% vs. 31%; p<0.0001. Conclusion: H. pylori eradication
in patients with gastric low-grade MALT lymphoma and stage EI achieves complete remission
in 80% of the cases. This figure increases up to 84% in EI1 lymphomas, but is of only 31%
in EI2 ones.
T1908
Levofloxacin-Based Rescue Regimens After Helicobacter Pylori Treatment
Failure: Systematic Review and Meta-Analysis
Javier P. Gisbert, Felipe de la Morena
OBJECTIVE: To systematically review the efficacy and tolerance of levofloxacin-based rescue
regimens, and to conduct a meta-analysis of studies comparing these regimens with the
quadruple therapy for H. pylori eradication failures. METHODS: Selection of studies: levoflox-
acin-based rescue regimens. For the meta-analysis, randomized controlled trials comparing
levofloxacin-based and quadruple regimens were included. Search strategy: electronic and
manual bibliographical searches. Assessment of study quality: independently by two
reviewers. Data synthesis: “intention-to-treat” eradication rate. Meta-analysis combining the
Odds Ratios (OR) of the individual studies. RESULTS: Mean eradication rate with levoflox-
acin-based regimens was 80%. 10-day regimens were more effective than 7-day combinations
(81% vs. 73%; p<0.01). The meta-analysis showed better results with levofloxacin than with
the quadruple combination (81% vs. 70%; OR=1.80; 95% CI=0.94-3.46). This difference
reached statistical significance and heterogeneity markedly decreased when a single outlier
study was excluded or when only high-quality studies were considered. Incidence of adverse
effects in general, and severe adverse effects in particular, in levofloxacin treated patients
was 18% and 3%. The meta-analysis showed less adverse effects with levofloxacin than with
quadruple regimen, both overall (19% vs. 44%; OR=0.27; 95% CI=0.16-0.46) and regarding
severe adverse effects (0.8% vs. 8.4%; OR=0.20; 95% CI=0.06-0.67). CONCLUSION: After
H. pylori eradication failure, levofloxacin-based rescue regimen is more effective and better
tolerated that the generally recommended quadruple therapy. A 10-day combination of
levofloxacin-amoxicillin-proton pump inhibitor constitutes an encouraging second-line
alternative.
T1909
Third-Line Rescue Therapy with Levofloxacin After Two H. Pylori Treatment
Failures
Javier P. Gisbert, Manuel Castro-Fernandez, Fernando Bermejo, Angeles Perez-Aisa, Julio
Ducons, Miguel Fernandez-Bermejo, Felipe Bory, Angel Cosme, Luis-Miguel Benito,
Laureano Lopez-Rivas, Eloisa Lamas, Manuel Pabon, David Olivares
AIM: Eradication therapy with proton pump inhibitor, clarithromycin and amoxicillin fails
in a considerable number of cases. A rescue therapy still fails in more that 20% of the cases.
Our aim was to evaluate the efficacy and tolerability of a third-line levofloxacin-based
regimen in patients with two consecutive H. pylori eradication failures. METHODS: Design:
Prospective multicenter study. Patients: in whom a first treatment with omeprazole-clarithro-
mycin-amoxicillin and a second with omeprazole-bismuth-tetracycline-metronidazole (or
ranitidine bismuth citrate with these antibiotics) had failed. Intervention: A third eradication
regimen with levofloxacin (500 mg b.i.d.), amoxicillin (1 g b.i.d.) and omeprazole (20 mg
b.i.d.) was prescribed for 10 days. Outcome: Eradication was confirmed with 13C-urea
breath test 4-8 weeks after therapy. RESULTS: One-hundred patients were initially included,
and 9 were lost for follow-up. All patients but 5 took all the medications correctly. Per-
protocol and intention-to-treat eradication rates were 66% (95% CI=56-75%) and 60% (50-
70%). Adverse effects were reported in 25% of the patients, mainly including metallic taste

















CONCLUSION: Levofloxacin-based rescue therapy constitutes an encouraging empirical
third-line strategy after multiple previous H. pylori eradication failures with key antibiotics
such as amoxicillin, clarithromycin, metronidazole and tetracycline.
T1910
Gatifloxacin Resistance and Mutations in Gyra Aftre Unsuccessful Helicobacter
Pylori Eradication in Japan
Toshihiro Nishizawa, Hidekazu Suzuki, Kumiko Kurabayashi, Tatsuhiro Masaoka, Hiroe
Muraoka, Eisuke Iwasaki, Intetsu Kobayashi, Tshifumi Hibi
Background/Aims: Gatifloxacin (GFLX) has been shown to have excellent activity against
H. pylori in vitro. Recently, higher eradication rates (92%) were reported with the administra-
tion of a 7-day regimen of GFLX, amoxicillin and rabeprazole (Helicobacter 9:255, 2004).
However, fluoroquinolones-resistant strains are more common in Japan than in Western
countries. The quinolone resistance-determining region of gyrA gene is reported to play a
critical role in ciprofloxacin resistance of H. pylori. The present study examines GFLX
susceptibility and mutation patterns of the gyrA and gyrB genes in H. pylori strains obtained
from Japanese patients after unsuccessful eradication therapy. Methods: H. pylori isolates
were obtained from the stomach of 48 patients. The MICs of GFLX, clarithromycin (CAM)
and metronidazole (MET) were determined by the agar dilution method. Twenty-three
GFLX-resistant strains (defined by MIC 1 μg/ml) and 25 GFLX-susceptible strains were
examined by PCR amplification and sequencing of the quinolones-resistance-determinant
regions of gyrA and gyrB. Four GFLX and CAM-susceptible strains were serially plated onto
GFLX-containing agar (0.12 μg/ml) or CAM-containing agar (0.015 μg/ml) of increasing
agar density. The GFLX and CAM susceptibility were examined by agar dilution method,
and the quinolones-resistance-determinant regions of gyrA gene were examined by PCR
amplification and sequencing. Results: The resistance rates to GFLX and CAM were 47.9%
and 79.2%. The GFLX resistance rate tended to be higher in the strains resistant to CAM
than in those susceptible to CAM (p=0.10). Twenty-two of the 23 (95.7%) GFLX-resistant
strains had point-mutations of gyrA at codon 87 Asn or 91 Asp. Only one of the 25 (4%)
susceptible strains had a mutation with substitution at amino acid 87. Neither the susceptible
nor the resistant strains showed mutations of gyrB. All four strains plated on GFLX- containing
agar developed GFLX resistance, and three of the four strains had mutations of gyrA. In
contrast, none of the strains plated on CAM-containing agar developed resistance, to either
CAM or GFLX, until the 10th generation of repeated culture. Conclusion: Mutation of gyrA
in H. pylori was significantly associated with higher MIC for GFLX. Although GFLX may
be one of the drugs of choice for the treatment of H. pylori infections, the selection of
antibiotics ideally should be based on the results of drug susceptibility testing or gyrA
gene analysis.
T1911
Mutations of 23s rRNA Gene of H. Pylori Determined By a Selmap (Self
Selective Multi Amplification Primers)-PCR Method
Takahisa Furuta, Naohito Shirai, Mitsushige Sugimoto, Akiko Nakamura, Mutsuhiro
Ikuma, Yoshihiro Soya, Masayoshi Kajimura, Akira Hishida
Backgrounds and Aims. Susceptibility to clarithromycin (CAM) is one of the determinants
of response to CAM-based therapy for H. pylori (Hp) infection. Bacterial resistance to CAM
is caused by single nucleotide polymorphisms (SNPs) of 23SrRNA gene. The SELMAP (Self
Selective Multi Amplification Primers)-PCR can measure couples of SNPs easily in the single
reaction tube within a short period by PCR amplification alone. Then, we intended to
develop the SELMAP-PCR assay for determining SNPs at positions 2142 and 2143 of 23S
rRNA gene of Hp. Methods. We designed the forward primer, FP3G, and the reverse primer,
RP2G, which specifically anneal with the 2143G and 2142G mutations, respectively. We
also designed the forward primer, FP-1, and reverse primer, RP-1, at the indicated sites in
Figure 1. When the strain is wt, neither of FP3G nor RP2G anneals with the template and
PCR amplification occurs between FP-1 and RP-1, resulting in the 320 bp amplicon. In the
case of 2143G mutation, PCR amplification occurs mainly between FP3G and RP-1 rather
than between FP-1 and RP-1, because PCR amplification preferentially occurs in the smaller
size of amplicon, resulting in the 118 bp amplicon. Similarly, in the case of 2142G mutation,
PCR amplification occurs mainly between FP-1 and RP2G, resulting in the 238 bp amplicon.
Then, the SNP can be distinguished by the PCR amplicon sizes. DNAs extracted from 64
gastric tissue samples were subjected to the SELMAP PCR analysis of 23S rRNA mutations.
The results were compared with minimum inhibitory concentrations (MIC) for CAM. Results:
29 of 64 samples were wt and others had 2143G mutation. The median of MIC values for
CAM in the wt strains was < 0.015 μg/ml. That of 2143G strains was 2.0 μg/ml. Conclusion:
The SELMAP-PCR assay for 23S rRNA mutation of Hp is a useful and easy method to detect
CAM-resistant strains of Hp, and could be a useful tool for the optimal antibiotic selection
in Hp eradication therapy.
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T1912
Recurrence of H. Pylori Infection After Eradication: 5-Year Follow-Up Study of
1,000 Patients
Javier P. Gisbert, Marta Luna, Blas Gomez, Juan-Manuel Herrerias, Joan Mones, Manuel
Castro-Fernandez, Pilar Sanchez-Pobre, Angel Cosme, David Olivares, Jose-Maria Pajares
AIM: To study the incidence of H. pylori recurrence, its chronological aspects, and the
variables that might influence it. METHODS: 1,000 patients in whom H. pylori had been
eradicated were prospectively studied. Therapies were classified as low and high efficacy
regimens. Four to eight weeks after completion of therapy, 13C-urea breath test was per-
formed, and it was repeated yearly up to 5 years. In some patients, endoscopy with biopsies
was also performed to confirm H. pylori eradication. RESULTS: 1,000 patients were included,
giving 2,744 patient-years of follow-up. Seventy-one H. pylori recurrences were observed
(2.6% per patient-year). Probability of being H. pylori-negative at 1 year was 94.7%, and at
5 years 90.7%. In the multivariate analysis, low age (OR: 1.84; 95% CI: 1.04-3.26) and low
efficacy therapies (OR: 2.5; 1.23-5.04) correlated with 1 year H. pylori recurrence. Differences
were observed when Kaplan-Meier curves were compared depending on age and therapy
regimen. CONCLUSION: Risk of post-eradication H. pylori recurrence is higher during the
first year, which suggests that most recurrences during this period are recrudescences and
not true reinfections. H. pylori recurrence is more frequent in younger patients and in those
treated with low efficacy therapies, but is exceptional if high efficacy therapies are used, in
which case post-therapy eradication can be safely confirmed at 4 weeks with 13C-urea
breath test.
T1913
Where Does the Antimicrobial Resistance of Helicobacter Pylori Come from,
Acquired After Birth Or Inherited from Parents? Different Mechanism Between
Clarithromycin and Levofloxacin
Naomi Torio, Mutsuko Konno, Ikuya Miki, Daisuke Shirasaka, Yoshinori Morita, Yuko
Matsumoto, Hideyuki Miyachi, Takao Tamura, Nobuo Aoyama
Background; Many reports revealed that most Helicobacter pylori (H. pylori ) infection might
be transmitted during childhood, mainly from their parents, and however, only a few reports
clarified the different acquisition mechanism of antimicrobial resistance of H. pylori in
childhood between antibiotics. Clarithromycin (CAM)-resistance is a major issue in standard
anti-H. pylori both in children and adults, in which situation levofloxacin (LVFX) is considered
one of alternative agents showing a good efficacy and tolerance. CAM can be used both for
children and adults for many infectious diseases, while LVFX cannot for children. Aim; We
revealed the mutation pattern and rate of H. pylori in the genes associated with CAM- and
LVFX-resistance in Japanese children, and focusing on the difference of antibiotics used
between children and adults, we clarified whether H. pylori antimicrobial resistance in
children might depend on their usage of antibiotics after birth or on the inheritance from
their parents. Methods; Forty H. pylori strains were isolated from 26 Japanese children and
14 parents using biopsy specimens obtained through endoscopy. In order to confirm CAM-
and LVFX-resistance, mutations were analyzed in the 23SrRNA gene (A2142G and A2143G)
and the gyrA gene performing amplification by PCR and direct sequencing, and mutation
patterns of H. pylori in children were compared to those in their parents. Results; Mutant
strains in the 23SrRNA gene were found in 7 children (26.9%), and none of their parents
harbored mutants in this gene. Mutants in the gyrA gene were found in 3 children (11.5%),
and 2 of their parents harbored the same type pf mutation point in this gene (Asn to Lys
at amino acid 87). Conclusion; CAM-resistance rate of H. pylori is very high in Japanese
children compared to that in Japanese adults previously reported, which may depend mainly
on its frequent use in childhood. In contrast, LVFX-resistance is often found although LVFX
cannot be used for children, which suggests that LVFX-resistance may be originated from
their parents. We have to realize the importance of proper usage of antibiotics in consideration
of not only acquired but also inherited antimicrobial resistance of H. pylori.
T1914
Increased Helicobacter Pylori Clarithromycin Resistance Rates in Patients with
Non-Ulcer Dyspepsia
Selahattin Unal, Meltem Yalinay Cirak, Sukru Dumlu, Tarkan Karakan, Doruk Engin,
Sevgi Turet, Mehmet Cindoruk
Background: Recent studies suggest that the Helicobacter pylori eradication rate in patients
with non-ulcer dyspepsia (NUD) is lower when compared to patients with peptic ulcer
diseases. Clarithromycin resistance was reported to be higher in NUD patients compared
to those with peptic ulcer. Aim: To determine and compare the clarithromycin resistance
profiles in patients with NUD, endoscopic esophagitis and peptic ulcer diseases. Methods:
A total of 120 consecutive patients referred for upper endoscopy were performed gastric
biopsies at four quadrants. Presence of HP was diagnosed by pathology, rapid urease test
and real time-PCR. Clarithromycin resistance was determined by real time-PCR. Endoscopic
diagnosis was classified as: NUD, esophagitis and peptic ulcer disease. Results: HP was
positive in 107 out of 120 patients (89.1%). Clarithromycin resistance was present in 20
patients (19%). Endoscopical diagnosis of patients was; 66.6% NUD, 15.8% esophagitis and
17.5% peptic ulcer disease. Clarithromycin resistance rate was higher in patients with NUD
than in patients with esophagitis and peptic ulcer disease; 21.7% vs. 16.6% vs. 10%,
respectively (p<0.05). In patients with NUD, endoscopical biopsies from corpus anterior and
posterior regions revealed significantly higher positive results for clarithromycin resistance.
Conclusions: Clarithromycin resistance rate is higher in patients with NUD and probably
this leads to sub-optimal treatment results in this patient population. The selective intragastric
distribution of clarithromycin resistance species of HP in gastric corpus, which is a secondary
finding in our study, might be related to the altered cell cycle kinetics of the bacteria. Further
studies are needed on this issue.
T1915
Antibacterial Effect of Mupirocin On Helicobacter Pylori in Vitro
Masaaki Minami, Takafumi Andoh, Osamu Maeda, Yasumasa Niwa, Naoki Ohmiya,
Michio Ohta, Hidemi Goto
[Background] Mupirocin (MUP) is an effective antibiotic against methicillin-resistant Staphylo-
coccus aureus.(MRSA). Its bactericidal effect is stable under acid condition and its mechanism
is unique. The present study was conducted to investigate the effect of MUP on clarithromycin
(CAM) or metronidazole (MNZ)-resistant and -susceptible strains of Helicobacter pylori (H.
pylori), and the post-antibiotic effect (PAE) of H. pylori.[Methods] The susceptibility to MUP
of 140 H. pylori including clinical strains, ATCC43504 (quality control strain), 26695 and
J99 (genome sequenced standard strains) and the susceptibility of CAM and MNZ-resistant
strains were measured by the agar dilution method. The clinical isolates were from lesion
biopsy specimens obtained by endoscopy at Nagoya University Hospital and a regional
health-care center. The time course of antibacterial effects was determined using strain
ATCC43504. Bacteria cultured for 4 days were diluted into a final inoculum of 105 CFU/
mL. Broth culture with MUP was incubated for 2 days at 37 °C. in a microaerophilic
atmosphere. At 0, 12, 24, 36 and 48 hours, samples were removed and the number of
colonies growing after 4 days’ incubation was counted. We preformed post-antibiotic effect
(PAE) test of MUP on ATCC43504. [Result] MIC90 and MBC of MUP on all 140 strains is
less than 0.064mg/l and 0.1mg/l, respectively. Ten of them were CAM-resistant strains and
3 were MNZ-resistant strains. There were no differences of MUP effect between susceptible
and resistant strains either for CAM or MNZ. By adding MUP, time-kill curve showed that
bacterial quantities decreased in dose and time-dependent manner and no viable colony
was found after 12 hour culture with 0.1mg/l MUP. The value of PAE is 12 and killing
effect on H. pylori remained after cessation of MUP exposure. [Conclusion] MUP is a potential
effective antibiotic for H. pylori even those for CAM/ MNZ-resistant strains.
T1916
The Effect of Mdr1 C3435t Polymorphism On the Eradication Rates of H.
Pylori By a Triple Therapy with Lansoprazole, Clarithromycin and Amoxicillin
Takahisa Furuta, Naohito Shirai, Mitsushige Sugimoto, Akiko Nakamura, Mutsuhiro
Ikuma, Masayoshi Kajimura, Akira Hishida
Backgrounds and Aims: Proton pump inhibitors (PPIs) are metabolized by CYP2C19 in the
liver. We have reported that eradication rates of H. pylori by a PPI-based therapy depend
on genotypic differences of CYP2C19. Recently, the polymorphism of MDR1 gene (from C
to T at the position 3435) has been made clear to be associated with the activity of the
ATP-dependent efflux transporter, P-glycoprotein (P-gp). Individuals who were homozygous
for 3435T (TT) had significantly decreased intestinal P-gp expression and increased bioavail-
ability of some drugs after oral administration, such as PPIs. Then, we intended to examine
whether eradication rates of a PPI-based therapy for H. pylori infection were associated with
the MDR1 polymorphism at the position 3435. Methods: Patients infected with H. pylori
underwent the triple therapy with lansoprazole 30 mg bid, clarithromycin 400 mg bid and
amoxicillin 750 mg bid for 1 week. DNA was extracted from the blood or tissue sample of
each patient. Polymorphisms of MDR1 at the position 3435 and CYP2C19 genotype status
wer measured by an Invader assay. The genotypes of MDR1 was classified into the three
groups: C/C, C/T, T/T. CYP2C19 genotype status was classified into rapid metabolizer (RM),
intermediate metabolizer (IM) and poor metabolizer (PM) as previously reported (Clin
Gastroenterol Hepatol 2005). Susceptibility of H. pylori to clarithromycin was also deter-
mined. Eradication of H. pylori was judged based on 13C-UBT. Results: Incidences of MDR1
genotypes were C/C: 35.0% (n = 41), C/T: 45.3% (n = 53) and T/T: 19.7% (n = 23). The
total eradication rate was 79.5%. The eradication rates in C/C, C/T and T/T groups were
79.5%, 88.7% and 69.6%, respectively (P = 0.0766). When patients were classified in the
three CYP2C19 genotype groups, eradication rates in C/C, C/T, and T/T groups of MDR1
were 70.6% (12/17), 90.0 % (9/10) and 66.7% (6/9)-(N.S.) in RMs of CYP2C19, those in
IMs of CYP2C19 were 76.1% (16/21), 83.3% (25/30) and 63.6% (7/11)-(N.S.), and those
in PMs were 66.7% (2/3), 100.0% (13/13), and 100.0% (3/3)-(P = 0.0599). In PMs of
CYP2C19 infected with clarithromycin-resistant strains of H. pylori, eradication rates in C/
C, C/T and T/T groups of MDR1 were 0.0% (0/1), 100.0% (5/5) and 100.0% (1/1)-(P =
0.0302). Conclusion: The impact of MDR1 polymorphism on the eradication rates of H.
pylori by a triple therapy with lansoprazole, clarithromycin and amoxicillin was generally
small but was significant in patients with PM genotype of CYP2C19 and infected with
clarithromycin resistant strains of H. pylori.
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T1917
A Cost-Effectiveness Analysis of Competing Strategies for Helicobacter Pylori
Eradication in Relation to Regional U.S. Antibiotic Resistance Patterns
Robert H. Harris, Miguel R. Arguedas
There are regional differences in Helicobacter pylori antibiotic resistance patterns in the United
States, which may alter the optimal choice for antimicrobial eradication therapies. Growing
antibiotic resistance to metronidazole and clarithromycin is often cited as a reason for the
increase in H. pylori treatment failures. As resistance grows, the economic impact of empiric
verses treatment guided by culture and antibiotic susceptibility testing will need to be
further explored. Methods: We conducted a cost-effectiveness analysis comparing competing
strategies for H. pylori eradication. The competing strategies were compared in each of four
U.S. regions (South East, North East, Mid West and West) in regards to recently published
regional antimicrobial resistance patterns. The strategies compared were: 1) quadruple ther-
apy followed by triple therapy and then third-line therapy for failures (quadruple-first
strategy) 2) triple therapy followed by quadruple therapy and then third-line therapy for
failures (triple-first strategy) 3) antibiotic susceptibility testing prior to initial treatment
followed by third-line therapy for failures (susceptibility testing-first strategy). A decision
analysis was created using Tree Age software. Probabilities and costs for the decision tree
were obtained from a Medline search of published medical literature and from hospital
pharmacy databases. Results: The cost per patient of using the quadruple-first strategy ranged
from $149.60-157.20 with 99-100% of patients achieving eradication. The cost per patient
of using the triple-first strategy ranged from $274.30-$287.10 with with 99-100% of patients
achieving eradication. The cost per patient of using the susceptibility testing-first strategy
ranged from $570.80-584.50 with 98-99% of patients achieving eradication. Even though
the cost of the quadruple-first strategy is increased in regions where metronidazole resistance
is higher it still dominated the other strategies tested. Conclusion: Based upon current
regional antimicrobial resistance patterns the quadruple-first strategy is the most cost-effective
method of H. pylori eradication across the U.S.
T1918
Could Frameshift Mutations in the Frxa and Rdxa Genes of Helicobacter Pylori
Be a Marker for Metronidazole Resistance?
Tatsuhiro Masaoka, Hidekazu Suzuki, Yohei Nomoto, Toshihiro Nishizawa, Toshifumi
Hibi
Background We had previously reported that in order to increase the accuracy of clarithromy-
cin-susceptibility testing and improve the eradication efficacy, dilution agar methods should
be combined with PCR-RFLP analysis before second-line eradication therapy (Aliment
Pharmacol Ther. Suppl 1:158, 2004). Although resistance of Helicobacter pylori (H.pylori)
to metronidazole (MET) had previously been reported to be associated with mutations in
the rdxA or frxA gene, several recent studies have indicated that they may, in fact, contribute
little to MET resistance. To clarify the roles of these two H.pylori genes in MET resistance,
we examined them in strains that were not eradicated by first-line eradication therapy.
Patients and Methods A total of 132 patients (92 males, 40 females, average age 53.8
years old)with H.pylori- positive peptic ulcer or chronic gastritis who underwent upper GI
endoscopy after unsuccessful first-line 7-day triple therapy with lansoprazole, amoxicillin
and clarithromycin were enrolled for this study. Endoscopically obtained biopsy specimens
were used for examining the susceptibility of the H.pylori strains to MET using the agar
dilution method. The H.pylori rdxA and frxA genes were then sequenced. The cutoff value
for resistance was 8 μg/ml. Results In the MET-resistant strains, the sensitivity and specificity
of detection of frameshift mutations in the rdxA gene were 44.4% and 98.4%, respectively.
A significant association between the presence of frameshift mutations in the rdxA gene and
resistance to MET was observed (p<0.001, odds ratio 48.4). Among the strains with frameshift
mutations in the rdxA gene, none was successfully eradicated by the metronidazole-containing
regimen. On the other hand, the sensitivity and specificity of detection of frameshift mutations
in the frxA gene in the MET-resistant strains were 22.2% and 91.1%, respectively and no
significant association between frameshift mutations in the frxA gene and resistance to MET
was observed. Among the strains with frameshift mutations in the frxA gene, 90.9% were
successfully eradicated by the metronidazole-containing regimen. Conclusion Mutation in
the rdxA gene was sufficient, but not necessary to confer resistance to MET in H.pylori.
Mutation in the frxA gene was not necessary for resistance to MET in H.pylori.
T1919
The Efficacy of Levofloxacin Based Triple Therapy for Helicobacter Pylori
Eradication
Sung Pyo Hong, Ji Hyun Lee, Chang Il Kwon, Lea Hyun Phyun, Byoung Sok Lee, Han
Ul Song, Kwang Hyun Ko, Seong Gyu Hwang, Pil Won Park, Kyu Sung Rim
Backgroud/Aims: In first and second line therapies, the failure rate of Helicobacter pylori
eradication therapy ranged from 15 to 20%. This study aimed to compare the efficacy and
safety of levofloxacin based triple therapy versus standard triple or quadruple therapy in
Korea. Method: We enrolled two hundred and sixty seven patients who were documented
Helicobacter pylori infection. One hundred and forty-one patients were treated with levoflox-
acin based triple therapy(LAP; levofloxacin, amoxicillin, PPI) to eradicate Helicobacter pylori,
and one hundred twenty-six patients were treated with standard triple therapy. Those who
failed in eradication were retreated with standard quadruple second-line therapy(MAPB;
metronidazole, amoxicillin, PPI, bismuth subcitrate) or levofloxacin based therapy(LAP or
LCP; levofloxacin, clarithromycin, PPI). Result: In first line therapy, the eradication rate
of levofloxacin based triple therapy and standard triple therapy were 69.8% and 74.0%
respectively(p=0.52). In second-line therapy, the eradication rate of levofloxacin based triple
therapy and standard quadruple therapy were 62.5% and 40.5% respectively(p=0.34). Con-
clusions: Levofloxacin based triple therapy was effective as standard regimen to eradicate
Helicobacter pylori and could be useful as an alternative rescue therapy.


















Successful Eradication Treatment of Ecabet Sodium Combined Salvage
Therapy for the Patients Who Had Previously Failed to Eradication of H.
Pylori with Peptic Ulcer
Wasaburo Koizumi, Satoshi Tanabe, Toru Sasaki, Katuhiko Higuchi, Katsunori Saigenji
BACKGROUND/AIMS: The recent increase in resistant strains of Helicobacter pylori has
become a serious problem. Ecabet is a novel anti-ulcer agent that acts directly on the gastric
mucosa, has bactericidal activity, and inhibits adhesion of Helicobacter pylori to the gastric
mucosa. We aimed to evaluate the efficacy of ecabet sodium combined salvage therapy for
eradication of H. pylori in patients who had previously failed to eradication of H. pylori with
peptic ulcer disease. METHODOLOGY: Forty-nine patients with peptic ulcer disease who
had failed eradication of H. pylori by proton-pomp inhibiter (PPI) + amoxicillin (AMPC)
+clarithromycin (CAM) therapy according to the Japanese guideline therapy were included
in this prospective study. The inclusion criteria included one or more failed attempts at
eradication and presence of H. pylori infection as evidenced by positivity of at least one of
three tests: rapid urease test (RUT), 14C urea breath test (UBT), and histology. The subjects
were treated with a 14-day regimen consisting of ecabet sodium 1000mg bid, OME 20mg
bid, AMPC 750mg bid, and metronidazole(MTZ) 500mg bid. Four weeks or more duration
after completion of therapy, H. pylori status was assessed by UBT. RESULTS: The study
subjects included 34 males and 14 females with a median age of 53 years (range: 31-71
years). Successful H. pylori eradication as defined by negativity of UBT, was achieved in
98% (48/49) of patients by intention-to-treat and 100% (48/48) of patients by per-protocol
analysis. Side effects were reported seven patients with diarrhea, 5; skin rash, 2; increased
serum transaminase, 2. There was no serious side effects were observed. DISCCUSION: We
already reported the eradication therapy for H. pylori using same regime of OME+AMPC+MTZ
without combined ecabet sodium as a first line therapy for the peptic ulcer patients previously
no eradication treatment for H. Pylori ( J Gastroenterol Hepatol. 1998 Mar;13(3):301-4).
The reported results of eradication ratio of H. pylori were 87% (20/23) by per-protocol
analysis. These results suggested that OME+AMPC+MTZ combined with ecabet sodium is
highly effective than without combined ecabet sodium. CONCLUSIONS: We conclude that
ecabet sodium combined salvage therapy was successful regimen for eradication of H. pylori
in patients who had failed to prior eradication of H. pylori by PPI+AMPC+CAM therapy.
T1921
Mutation Analysis in the Gyra Gene, Not the E Test, Can Be a Powerful
Predictor for Treatment Outcomes of Helicobacter Pylori Infection with
Levofloxacin-Based Therapy
Ikuya Miki, Daisuke Shirasaka, Hideyuki Miyachi, Yuko Matsumoto, Takao Tamura,
Yoshinori Morita, Masanori Toyoda, Toshifumi Mitani, Naomi Torio, Nobuo Aoyama
Background: Levofloxacin (LVFX) is one of the most attractive agents for refractory Helicob-
acter pylori (H. pylori) infection, but LVFX-based rescue therapy cannot show a high eradica-
tion rate in Japan compared to in other countries. Therefore, it is an urgent issue how to
predict treatment outcomes. Although antimicrobial susceptibility judged by culture method
such as the E test may be useful, recent studies have revealed the disagreement among the
results of susceptibility obtained by conventional culture method and molecular genetic
method in the case of clarithromycin (CAM)-based therapy. As for LVFX-based therapy, no
clinical studies are available concerning the clinical impact of molecular genetic approach
on treatment outcomes in comparison with the E test. Aim: In order to confirm whether
molecular genetic method can be a useful tool in LVFX-based rescue therapy, we evaluated
the clinical impact of gyrA mutations on treatment outcomes. Methods: Of 102 patients
who received 7-day-rescue therapy (lansoprazole, 30mg b.d., amoxicillin, 1000mg b.d., and
LVFX, 400mg or 600mg b.d.), 52 patients whose first-line treatment failure were judged
by positive culture were retrospectively analyzed. Susceptibility testing by the E test was
performed using two biopsy samples from the greater curvatures of the corpus and the
antrum after first-line therapy and before rescue therapy. Total DNA was extracted from
the recovered H.pylori isolates in the frozen state, and the quinolone resistance-determining
regions of H. pylori gyrA gene were amplified by PCR and directly sequenced. The association
between gyrA mutation and MIC values is analyzed according to treatment outcomes. Results:
Twenty (39%) of 52 strains had gyrA mutations. 11 and 8 strains respectively showed point
mutations in the gyrA gene at amino acid (aa) 87 (Asn to Lys or Ile) and at aa 91 (Asp to
Asn or Gly). Double mutations at aa 87 (Asn to Ile) and 91(Asp to Asn) were found in 1
strains. Nine out of 13 strains with MIC values to LVFX of ≧ 1ug/mL, and 10 out of 39
strains with those of <1ug/mL, were not successfully eradicated. Fourteen out of 19 refractory
strains to rescue therapy showed the gyrA mutations. Twenty-five out of 32 strains without
gyrA mutation were successfully eradicated. The existence of gyrA mutation showed a
tendency toward worse results regardless of the MIC values. Conclusion: In levofloxacin-
based rescue therapy for H.pylori infection, mutants in the gyrA gene is hardly eradicated
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regardless of the MIC values, suggesting that molecular genetic approach appears to be a
powerful indicator for treatment outcomes rather than the E test.
T1922
Levofloxacin- Versus Clarithromocyn-Based First Line Therapy for Helicobacter
Pylori Infection
Antonio Rispo, Elena Di Girolamo, Antonio Cozzolino, Hamma Lamine Ali Taleb, Luigi
Pasquale
line treatment of Helicobacter pylori (Hp) infection. Several reports have shown the efficacy
of levofloxacin for the rescue therapy of resistant Hp infection while its role as first line
treatment is poorly investigated. AIM: To evaluate the efficacy and safety of levofloxacin-
based triple therapy in the first line treatment of Hp infection when compared to the classical
clarithromicyn-based protocol. PATIENTS AND METHODS: 60 consecutive out-patients
with an histological diagnosis of Hp infection were prospectively randomised in two groups
of weekly treatment: Group A (# 30) levofloxacin 250 b.i.d, amoxicillin 1 gr b.i.d., esomepra-
zole 20 mg b.i.d.; Group B (# 30) clarithromycin 500 mg b.i.d., amoxicillin 1 gr b.i.d.,
esomeprazole 20 mg b.i.d. Cure of infection was determinated by urea breath-test. The cure
rate was expressed as intention-to-treat. Statistics was calculated by using MedCalc software
determining Pearson’s χ2. RESULTS: Hp eradication was achieved in 27 patients in Group
A and 26 patients in Group B (90% vs 87%; p= ns); 1 patient in Group B stopped therapy
because of diarrhoea and abdominal pain. CONCLUSIONS: Levofloxacin-based triple therapy
is effective and safe in first line treatment of Hp infection. Levofloxacin-based therapy could
be suggested in first line treatment of Helicobacter pylori infection in the areas with high
primary resistance to clarithromycin.
T1923
Effects of Red Ginseng Supplementary Treatment After Eradication Regimen
in Patients with Helicobacter Pylori-Associated Chronic Gastritis: A
Prospective Randomized Double-Blind Study
Kee Myung Lee, Marie Yeo, Soo Jin Park, Mi Sun Kwak, Jeong A Lee, Young Bae Kim,
Kwang Min Kim, Sung Won Cho, Ki Baik Hahm
The fact that mass eradication of Helicobacter pylori (H. pylori) can not be recommended as
a cost-effective means to prevent the development of gastric cancer, in spite definition as
class I carcinogen by IARC, drives us to search for better strategies for chemoprevention
including either attenuation of bacteria colonizations or lessening gastric inflammations.
Recent concept about the crossroads between inflammation and carcinogenesis stressed the
importance of the intervention of anti-inflammatory strategy. Based on our previous study
suggesting that red ginseng capsule could rescue gastric mucosa from H. pylori-associated
cytotoxicity, a randomized controlled trial was done to document the efficacy and advantages
of 10 weeks red ginseng capsules (2.7g/day) supplemented group compared with placebo
supplemented group after the eradication-regimen with PPI based triple therapy. Total 84
patients were enrolled and 70 patients completed the trial (83.3% per protocol analysis).
Statistically, the eradication rates were significantly augmented in red ginseng supplemented
group compared to placebo group (79.4% in placebo group and 91.7% in red ginseng
group, p<0.05). In respective analysis of gastritis based on Updated Sydney system, red
ginseng group showed statistically significant improvement in neutrophil infiltrations,
mononuclear cell infiltrations, gastric atrophy, and even intestinal metaplasia than placebo
group (p<0.05). H. pylori infection was associated with significant generation and nuclear
translocation of 8-OHdG, but red ginseng supplemented group was excellent in lessening
8-OHdG generations in parallel with attenuated apoptosis and single cell nuclear damages
(comet assay) than placebo group (p<0.05). Conclusively, red ginseng supplemented treat-
ment after H. pylori eradication could achieve either quantitative advantages or qualitative
improvement for H. pylori infection and the considerable gastroprotective properties or anti-
inflammatory activities of red ginseng might contribute to the improvement of H. pylori-
associated chronic gastritis including the scope of chemoprevention with long-term adminis-
tration.
T1924
Emergence of Ciprofloxacin Resistance in Helicobacter Pylori Isolated from
Korea: Mutational Changes in Gyra and Other Genetic Loci
Hyung Joon Lee, Gin Hyug Lee, Jun-Won Chung, Ja Young Kim, Kwi Sook Choi, Kee
Don Choi, Hwoon-Yong Jung, Weon-Seon Hong, Jin-Ho Kim, Jin-Yong Jeong
Background/Aims: Failures of proton pump inhibitor-based triple therapies for eradication
of H. pylori are frequently due to resistance to either clarithromycin or metronidazole. Thus,
other antibacterial drugs, such as quinolones, will be needed for H. pylori therapy in the
future. In this study, we selected ciprofloxacin-resistant H. pylori and studied the mechanisms
of ciprofloxacin resistance. Methods: H. pylori strains were obtained from gastric biopsy
specimens of 64 consecutive H. pylori-positive patients at Asan Medical Center (AMC) in
Seoul, Korea. Genomic DNA of ciprofloxacin-resistant strains was extracted and used for
PCR and DNA sequencing to determine the mutations in gyrA. To establish that the mutations
in gyrA and gyrB caused ciprofloxacin resistance, the PCR products were used to transform
a ciprofloxacin-susceptible strain of H. pylori to a resistant phenotype. Results: In one Korean
Hospital (AMC) the rate of resistance to ciprofloxacin (MICs, ≤1 ug/ml) in H. pylori was
10.9% (7 of 64 isolates) in 2004. High-level resistance (MICs,≤4 ug/ml) was mainly caused
by mutations in gyrA . The isolates showing low-level resistance (MICs=1-2 ug/ml) have no
mutation in gyrA and gyrB. There was a ciprofloxacin-resistant isolate (MIC=8 ug/ml)
having no mutation in gyrA but double mutations (Asp481Glu and Arg484Lys) in gyrB.
Transformation by the amplified fragment of gyrB of this isolate showed that the gyrB double
mutations are not associated with ciprofloxacin resistance, suggesting that the mechanisms
of ciprofloxacin resistance in H. pylori are not only mutational changes in gyrA but also in
other genetic loci. Conclusions: The rate of ciprofloxacin-resistant H. pylori was 10.9% at
AMC, Seoul, Korea. The mechanisms of ciprofloxacin resistance in H. pylori are not only
mutational changes in gyrA but also in other genetic loci, which is unknown so far.
T1925
Novel Action of Gastric Proton Pump Inhibitor On the Suppression of
Helicobacter Pylori-Induced Angiogenesis
Marie Yeo, Dong Kyu Kim, Sang Uk Han, Jong Eun Lee, Kee Myung Lee, Young Bae
Kim, Yong Kwan Cho, Kwang Jae Lee, Jin Hong Kim, Sung Won Cho, Ki Baik Hahm
Though the activations of mitogen activated protein kinases (MAPKs) by Helicobacter pylori
(H. pylori) infection, H. pylori infections are associated with induction of host angiogenesis,
which might contribute to H. pylori-associated gastric carcinogenesis. However, the strategy
for its prevention has not been identified yet. Since we previously reported a strong inhibitory
action of gastric proton pump inhibitor (PPI) on MAPK ERK1/2 phosphorylation, we investig-
ated whether PPI could suppress the H. pylori-induced angiogenesis via inhibiting MAPK
ERK1/2 and resultant angiogenic growth factors. To address the relationship between H.
pylori infection and angiogenesis, comparative analysis of density of CD 34+ blood vessel
was performed in tissues obtained from 20 H. pylori-positive gastritis and 18 H. pylori-
negative gastritis. Expression of HIF-1 and VEGF were tested by RT-PCR and secretion of
IL-8 and VEGF was measured with ELISA. To evaluate the direct effect of H. pylori infection
on the tubular formation of human endothelial HUVEC cells, in vitro angiogenesis assay
was employed. Activation of MAPK and NF-κB was detected by immunoblotting. H. pylori-
positive gastritis (40.9 ± 4.4) showed a higher density of CD34 blood vessel than H. pylori-
negative gastritis (7.2 ± 0.8), which was well correlated with the expression of HIF-1.
Conditioned media from H. pylori-infected gastric epithelial cells directly induced a tubular
formation of HUVEC cells and the increase of in vitro angiogenesis was suppressed by PPI
treatment. Infection of H. pylori significantly up-regulated expression of HIF-1 and VEGF
in gastric epithelial cells and the expression of proangiogenic factors was mediated by
MAPK activation and partially responsible for NF-kB activation. PPI effectively inhibited the
phosphorylation of MAPK ERK1/2 that is a principal signal for H. pylori-induced angiogenesis.
In conclusion, the fact that PPI could down regulate H. pylori-induced angiogenesis shed
light on that anti-angiogenic treatment using PPI could be a promising protective therapeutic
approach for H. pylori-associated carcinogenesis.
T1926
Prevalence of Eosinophilia and Eosinophilic Esophagitis in Adults in the
Community: A Random Population Based Study (Kalixanda)
Jukka Ronkainen, Nicholas J. Talley, Pertti Aro, Tom Storskrubb, Elisabeth Bolling-
Sternevald, Tore Lind, Michael Vieth, Manfred Stolte, Marjorie M. Walker, Lars Agreus
Background and aims: Eosinophilic esophagitis (EE) is thought to be a very rare inflammatory
condition in adults (estimated prevalence 1 in 10,000) but patient studies suggest the
incidence may be increasing. However, the prevalence and incidence in the general population
remain unknown, as endoscopy and biopsy are required in a random population sample.
EE can be associated with allergic disorders and presents with food impaction or dysphagia.
The aim of this study was to determine the presence of any eosinophilia in the distal
esophagus and the prevalence of EE in a random sample of a Swedish population. Methods:
A random sample (n= 3000) of the adult population (n= 21,610) in two Swedish municipalit-
ies was surveyed using a validated questionnaire assessing troublesome gastroesophageal
symptoms (response rate 74%). 1563 responders were randomly invited to an esophagogas-
troduodenoscopy (EGD). Esophageal biopsies were obtained 2 cm above the z-line and from
areas of structural abnormality. An infiltration of the esophageal epithelium was defined as
mild (< 15 eosinophils/hpf), moderate (eosinophils/hpf ≥15-< 20) or marked (≥ 20 eosino-
phils/hpf). Symptomatic gastroesophageal reflux disease (GERD) was defined as the presence
of heartburn and/or acid regurgitation during the last three months. Esophagitis was graded
according to the Los Angeles classification. Results: EGD with biopsy was performed in
1000 subjects (mean age 53.5 years, 51% female). Eosinophils in the esophageal biopsies
were found in 9 (0.9%, 95% CI 0.3-1.5): 5 with mild, 3 with moderate and one with
marked infiltration. Esophagitis (LA-grade A) was found in one individual with mild and
in one with moderate infiltration. No other endoscopic abnormalities were found in this
group. GERD was found in 2/3 with moderate and in the one with marked infiltration.
Dysphagia and asthma only occurred in the individual with marked infiltration. GERD and
esophagitis were not associated with eosinophilia but those with esophageal eosinophilia
had significantly less H.pylori on histology or culture in the stomach compared with those
without eosinophilia (0/9 vs. 323/942, p=0.032) and were less likely to ever having smoked
or used moist snuff (2/7 vs. 538/942, p=0.045). Conclusions: This is the first population-based
study to estimate the prevalence of eosinophilic esophagitis to our knowledge. Esophageal
eosinophilia was found in nearly 1% of the general Swedish population: four (0.4%) with
≥ 15 eosinophils/hpf and one (0.1%) with≥ 20 eosinophils/hpf. Asymptomatic eosinophilia
< 20/hpf is not apparently explained by GERD, and is more common than has been
appreciated in adults.
T1927
Psychological Factors Affect the Frequency of Belching in Patients with
Aerophagia
Albert J. Bredenoord, Bas L. Weusten, Robin Timmer, Andre J. Smout
Background and aim: In patients with excessive belching (aerophagia) an organic cause is
seldomly found and a psychogenic cause is often suspected. Aim of this study was to
investigate the effects of attention and distraction on the frequency of belching and to
investigate the mechanism of belching in these patients. Methods: In 10 patients with
aerophagia combined esophageal manometry, pH and impedance monitoring was performed
for 2 hours. These 2 hours consisted of 4 30-min recording periods. Period 1: patient under
the impression that recording had not yet commenced. Period 2: patient informed of recording
in progress. Period 3: patient being distracted by having him/her filling in questionnaires.
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Period 4: patient not being distracted. Data are presented as median (iqr). The study
was approved by the local IRB. Results: One patient stopped belching immediately after
introduction of the catheters and was excluded from further analysis. In the remaining 9
patients, a total of 1258 belches was measured, 51 of which were the result of air that
escaped from the stomach (gastric belches). The remaining 1207 belches (96%) were events
during which air was expelled in oral direction almost immediately after entering the
esophagus, before reaching the stomach (supragastric belches). Gastric belches were distrib-
uted equally over the first (1.5 (0.5-2.0)), second (1.5 (0.5-2.0)), third (1.0 (0-2.0)) and
fourth (1.0 (0-2.0)) recording period. In contrast, the incidence of supragastric belches
increased significantly (p<0.05) from 0 (0-32) in the first period to 30 (18-60) in the second
period, after patients were told that recording was started. During the questionnaires the
incidence of supragastric belches decreased (p<0.05) to 14 (4-30). In the fourth period the
incidence of supragastric belches increased (p<0.05) to 21 (10-49). Supragastric belches
were initiated either by sucking air into the esophagus by a negative thoracic pressure (8
patients) or by injecting air into the esophagus by a pharyngeal contraction (2 patients).
Conclusions: The vast majority of belches in patients with aerophagia is due to supragastric
belching. When patients are unaware that they are being studied or when they are distracted
the incidence of belching is significantly reduced. These findings confirm that a psychological
factor is important in this disorder, which supports treatments such as behavioral therapy.
The mechanisms the patients use to fill their esophagus with air during supragastric belching
are similar to the techniques described for facilitation of esophageal speech in laryngectomized
patients, which suggests that logopedic therapy might also be helpful.
T1928
Intra-Duodenal Capsaicin Infusion Induces Esophageal Hypersensitivity
Which Is Dose Dependent
Barbara J. Unsworth, Qasim Aziz, Peter Holzer, John McLaughlin, Anthony Hobson
Background: Capsaicin activates TRPV-1 receptors on spinal and vagal afferents. Its infusion
into the jejunum evokes burning and cramping sensations, the intensity of which are dose
dependent. Herein, we hypothesized that capsaicin infusion into the proximal duodenum
would result in increased excitability of spinal dorsal horn neurons (central sensitization)
and the development of sensitization in a visceral region with convergent spinal innervation.
Methods: We recruited 15 subjects (11 Female). A catheter was positioned in the proximal
duodenum with a 2nd in the distal esophagus. Pain thresholds (PT) to electrical stimulation
(ES) were assessed in the esophagus (500μsec duration, 0.3Hz frequency). Capsaicin was
then infused into the duodenum (2ml/min for 30-minutes). The concentrations of capsaicin
used were 100 and 200μg/ml, or saline control. Subjects were studied on 4 occasions
(1x100μg/ml, 2x200μg/ml, 1xSaline) in a double blind randomized order. Esophageal PT
were recorded at 15 and 45-minutes post infusion. Visual analogue scales (VAS) for pain,
unpleasantness, nausea and anxiety were recorded at 5-minute intervals during the infusion
and a short McGill pain questionnaire was used to describe the psychophysical properties
of the infusion. Results: Significant reductions in esophageal PT were seen on both occasions
at 200μg/ml (max group mean reduction in PT post infusion = -9.2mA and -11mA, p=
0.004) but this was not significant at 100μg/ml (-6.3mA, p=0.06) or with saline (-0.7mA,
p=0.77). Baseline Esophageal PT was reproducible within subjects when compared for the
2x200 μg/ml visits (Intra-class correlation coefficient (ICC) = 0.74). Whilst group data for
the magnitude of sensitization were similar for the 2x200 μg/ml visits (p=0.35), data within
subjects were less reproducible (ICC at 15mins post infusion = 0.431, 45mins = 0.421).
VAS scores for pain were higher than for other psychophysical measures and highest at the
200μg/ml concentration. The most common verbal descriptors used to describe the capsaicin
infusion were ‘cramping’, ‘hot-burning’ and ‘aching’. Conclusion: Capsaicin infusion into
the proximal duodenum induces sensitization in a visceral region known to have convergent
afferent input at the spinal cord level. The magnitude of sensitization increases with increasing
concentrations of capsaicin, as does the subjective awareness of the infusion. Whilst group
data provide reproducible findings, there is some variability seen within subjects with
regard to the development of sensitization. These data provide further evidence that central
sensitization plays an important role in the development of visceral hypersensitivity.
T1929
Expression of Eotaxin-2 and Chemokine Receptor 3 in Eosinophilic
Esophagitis Versus Reflux Esophagitis
James R. Carlsten, Murray B. Resnick, Patricia A. Meitner, Edmond Sabo, Adam Carter,
Sripathi Kethu, Baishali Bhattacharya
Background: Eosinophilic esophagitis (EE) is increasingly being recognized in biopsies from
the esophagus and distinguishing it from gastroesophgeal reflux disease (GERD) is important
given the differences in pathogenesis and treatment. Allergy is thought to play an important
role in the etiology of EE also supported by the fact that many of the EE patients suffer
from bronchial asthma and present with peripheral blood eosinophilia. Biopsies of EE cases
show markedly increased intraepithelial eosinophils >25/high power field (HPF) in the
esophageal squamous mucosa with luminal eosinophilic clusters and microabscesses.
Recently there has been much interest in the role of Eotaxins which act through their
receptor chemokine receptor 3 (CCR-3), in the recruitment and activation of eosinophils.
Much of the studies have been focused on bronchial asthma. But their role in EE has not
yet been elucidated. Design: This was a retrospective study using formalin-fixed paraffin
embedded blocks of biopsies taken from 12 cases of established EE, 22 cases of GERD
and 17 normal esophagus controls. Comparison was made between eosinophil count and
expression of Eotaxin-2 (CCL24)and Eotaxin receptor (chemokine receptor 3/CCR3) using
primers for mRNA. Result: All 12 EE cases were males, age 2-49 years, mean 17.25 years
with mean eosinophilic count of 62.45/HPF (range 34.5-140.75). The 22 cases of GERD
(13 males and 9 females)with a mean age 30.0 yrs had a mean eosinophil count of 3.6/
HPF. The 17 normal controls (8 males and 9 females)with a mean age 20.65 years had 0
eosinophil count. EE cases had symptoms of dysphagia (most common), food getting stuck,
abdominal pain etc. Endoscopic appearance consisted of friable mucosa, furrows, ridging,
cracking, white spots resembling candida etc. The mean expression of Eotaxin-2 among EE,

















ng, respectively. The differences were statistically significant between all groups
(p<0.0001,one way ANOVA followed by Bonferroni test). For the CCR-3 receptor, a signific-
ant difference was found between EE (1.80 +/- 1.05), and GERD (0.15 +/- 0.12),(p=0.016,
Kruskal Wallis ANOVA). A marginally significant difference was also found between EE and
the normal controls (p=0.057). Conclusion: Based on our study, Eotaxins and chemokine
receptor-3 appear to play a significant role in the pathogenesis of EE and therapeutic agents
targeting these molecules may have a promising role in the management and understanding
of this disease.
T1930
The Circular Smooth Muscle of the Distal Esophagus Is Oriented At An
Oblique Angle Leading to Axial Shortening of the Circular Smooth Muscle
During Peristaltic Contraction
Keng-Yu Chuang, Anil Vegesna, Rina Raju, Wassim Asfari, Zeeshan Ramzan, Parkman
Henry, Larry S. Miller
Background:The law of mass conservation implies that if the circular smooth muscle of the
esophagus (CSM) is oriented perpendicular to the longitudinal smooth muscle (LSM), only
the LSM should actively shorten in the axial (longitudinal) direction and any CSM shortening
in the axial direction is as a consequence of LSM drag during peristaltic contraction. Yet,
ultrasound studies demonstrate that the CSM actually shortens significantly more in the
axial direction than does the LSM, especially in the distal esophagus. Purpose:We hypothesize
that the CSM of the distal esophagus is oriented at an oblique angle to the perpendicular
and that this angulation accounts for an increase in CSM shortening over LSM shorting in
the axial direction. In addition we hypothesize that this angle is greatest in the distal
esophagus accounting for greater distal esophageal shortening. Methods:Nine cadaveric
esophagi underwent fine dissection to expose the LSM and CSM layers. The angles of the
muscle fibers between the two smooth muscle layers were measured at every cm, starting
at the gastroesophageal junction (GEJ)using digital imaging. Results:A significant difference
was found between the mean muscle angles of the CSM in the distal esophagus (at the GEJ)
and the muscle angles of the CSM above the GEJ (p<0.001). (see figure). Conclusions:A
significant difference was found between the muscle angles of the CSM at the GEJ and the
muscle angles above the GEJ. We believe that this oblique angulation along with drag from
the LSM leads to axial shortening of the CSM which is greater than the axial shortening
due to the LSM alone. Furthermore we believe that this oblique angulation is partially
responsible for the greater distal esophageal shortening of the esophagus during peri-
staltic contraction.
The angle of the muscle fibers is on the y axis. The distance from the GEJ is on the x axis.
T1931
The Tumor Suppressor Gene P53 As a Predictor for Development of
Esophageal Cancer in Patients with Achalasia
Ivonne Leeuwenburgh, Astrid Capello, Monique M. Gerrits, Johannes G. Kusters, Peter D.
Siersema, Ernst J. Kuipers
Introduction: Patients with longstanding achalasia, an esophageal motor disorder leading to
functional esophageal obstruction, have an up to 140x-increased risk of developing eso-
phageal cancer compared to the healthy population. Chronic food stasis (often present
despite LES-lowering therapy) may lead to chronic inflammation, epithelial hyperplasia,
multifocal dysplasia and squamous cell carcinoma (SCC). On the other hand, gastro-eso-
phageal reflux, a complication of LES-lowering therapy may lead to Barrett’s metaplasia and
adenocarcinoma (AC). Surveillance-endoscopies are advocated, however optimal sampling
and analysis methods as well as surveillance intervals remain to be determined. Aim: To
investigate whether p53- (tumor suppressor gene) and Ki 67 (proliferation) expression, and
changes in DNA-ploidy are early predictors for progression to malignancy. Methods: In our
cohort of 414 achalasia patients, 16 (4%) patients died of advanced esophageal cancer
despite bi-annual endoscopic surveillance. Out of those 16 cancer cases, we selected 8
patients (5 males, mean age 45.5 yrs (range 30-66) at the start of achalasia symptoms) who
developed esophageal cancer (6 SCC, 2 AC). Cancer cases had been under surveillance for
a mean of 8 yrs (range 2-20). All biopsy sets obtained during surveillance were studied for
p53 and Ki 67 expression using immunohistochemistry. Two independent researchers
counted the samples. Samples were considered positive for either marker if more than 15%
of nuclei stained positive. Five patients (3 males, mean age 50 (31-68) yrs at start disease)
with achalasia without esophageal cancer development during follow-up (mean 19 (18-20)
yrs) served as controls. Results: 28 biopsy sets were obtained during surveillance in the
cancer cases and compared with 25 sets from the controls. In 5/8 (62%) cancer patients (4
SCC, 1AC), p53 was expressed in previous surveillance biopsies at a mean time of 6 (1-
11) yrs prior to cancer development. In 1 SCC patient, p53 was negative, in 1 SCC patient
the expression was 10% and in 1 AC patient not enough material was available. In the
controls, no p53 expression was detected. Ki 67 was expressed in all surveillance biopsy
sets of all carcinoma and control patients. Flow cytometry of surveillance specimens did
not reveal aneuploidy. Conclusions: p53- expression, but not proliferation and changes in
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DNA-ploidy, appear useful to identify achalasia patients at increased risk of developing
esophageal carcinoma. A further prospective follow-up study is needed to determine the
effectiveness of intense surveillance of p53-positive patients for early detection of cancer.
T1932
Influence of Bolus Consistency and Position On Esophageal High Resolution
Manometry Findings
Anita Bernhard, Daniel Pohl, Oliver Goetze, Heiko Fruehauf, Werner Schwizer, Michael
Fried, Radu Tutuian
Background: Conventional manometry evaluating liquid swallows in recumbent position
has been criticized as it measures pressure changes only at limited number of sites in the
esophagus and it does not assess pressure changes during solid boluses in the physiologic
upright position. High resolution manometry (HRM) allows a more comprehensive evaluation
of the esophageal peristaltic and, using hydrostatic correction factors, allows evaluating
esophageal peristalsis during bread swallowing in upright and recumbent position. Aim: To
compare findings of esophageal motility abnormalities during water and bread swallows in
upright and recumbent position. Methods: Patients referred for evaluation of dysphagia,
chest pain and GERD symptoms (heartburn and regurgitation) underwent HRM testing
using a 32-channel low compliance water-perfused system. After transnasal placement of
the catheter patients received water swallows (10cc each) and bread swallows in upright
and left lateral decubitus position. Swallows were considered normal if in the isocontur plot
representation a peristaltic band >30mmHg spanned over at least 5cm in the distal esophagus,
ineffective if the pressure band in the distal esophagus was less than 5cm and simultaneous
if the onset velocity of the pressure band >30mmHg exceeded 8 cm/sec in the distal
esophagus. Abnormal esophageal manometry was defined as the presence of 30% or more
ineffective or 20% or more simultaneous swallows. Patients with achalasia were excluded
from the analysis. Results: From April 2003 to November 2005 data from 96 patients (64
F, mean age 50 years, range 19-79 years) who underwent HRM for dysphagia (56%), chest
pain (22%) and GERD symptoms (22%) were available for analysis. Change in position and
bolus consistency increased the percentage of patients with abnormal manometry findings
(Table). Conclusions: Manometry during bread swallows increases the sensitivity of finding
abnormal motility patterns in patients with esophageal symptoms.
Percentage of patients with abnormal manometry
T1933
Relationship Between Abnormal Bolus Transport and Dysphagia
Lilian R. Aprile, Ricardo B. de Oliveira, Roberto O. Dantas, Jiri Silny, Daniel Sifrim
The term dysphagia encompasses a number of sensations which are perceived as caused by
abnormal bolus transit from mouth to stomach. The mechanisms responsible for non-
obstructive dysphagia as well as its relations with altered esophageal motility and bolus
transit remain unclear. Aim: To investigate the relations between sensation of dysphagia
with esophageal motility and bolus tranport in normal volunteers whose esophagi were
rendered transiently hypocontractile. Methods: Concurrent esophageal manometry and
impedance were performed in 9 healthy volunteers. Subjects swallowed 10 (5ml) viscous
and 10 bread boluses in sitting position. Distal esophageal contractility was impaired with
sildenafil (50mg) ingested 10 min before the series of swallows. Perception of each swallow
was evaluated using a standardized 1-5 scoring system (1 fluid passage and 5 complete
blockade). Manometry was abnormal (A) if the amplitude of distal esophageal contractions
was < 30mmHg or if they were simultaneous; bolus transit by impedance was abnormal
(A) if bolus exit was not identified at one or more of the measuring sites or if total bolus
transit time was >12.5 min; and perception was increased (I) if score was >1. Agreements
between results were measured using Kappa statistic k. Results: Sildenafil provoked progress-
ive esophageal peristaltic failure starting at ± 20 min after ingestion. At least one enhanced
perception episode (I) was reported by eight of the nine subjects for bread swallows, and
by 5 of them for gel swallows; 30 of the 86 bread swallows (34.8 % ) and 15 of the 86 gel
swallows (17.4%) were perceived as (I). Agreement between manometry and impedance
occurred for 88% of bread swallows (k = 0.67; 95% CI: 0.48-0.87) and 86% of gel swallows
(k = 0.70; 95% CI: 0.54-0.85). In contrast, agreement between impedance and perception
occurred for only 52% of gel swallows (k = 0.12; 95% CI: 0.00-0.24) and 42% of bread
swallows (k = 0.04; 95% CI: -0.09-0.17). Agreement between perception and manometry
was even lower, observed in 36% of gel swallows (k = -0.04; 95% CI: -0.17-0.09) and 41%
of bread swallows (k = -0.02; 95% CI: -0.16-0.09). Conclusions: In sitting healthy subjects,
sildenafil-induced reduction of distal esophageal contractility is associated to impairment of
esophageal bolus transit but not with significant dysphagia. The hypocontractility-induced
abnormal bolus transport plays a minor role, if any, in the genesis of dysphagia. These
results suggest that in patients with non-obstructive dysphagia, factors other than hypocon-
tractility and abnormal bolus transport i.e hypersensitivity might be more relevant in dys-
phagia genesis. Support:CNPq,FAPESP
T1934
Intraluminal Impedance Detects Failure of Pharyngeal Bolus Clearance During
Swallowing: A Validation Study in Adult Dysphagia Patients
Taher Omari, Michal Szczesniak, Nathalie Rommel, Phil G. Dinning, Sergio Fuentealba,
Ian J. Cook
Introduction: Multichannel intraluminal impedance (MII) has been shown to detect bolus
flow through the pharynx and UES in healthy volunteers (1) . The aim of this study was
to determine if this technique can detect failure of pharyngeal bolus clearance in patients
with dysphagia. Methods: Patterns of pharyngo-esophageal pressure and impedance were
simultaneously recorded with videofluoroscopy (VF) in 5 adult patients (3M:2F, 57-78 yrs)
with dysphagia due to a range of causes; post-myotomy cricopharyngeal stenosis, post-
radiotherapy myopathy, motor neuron disease and medullary infarction. A combined MII-
manometry assembly with 6 impedance segments spaced at 1cm intervals was positioned
with 2-3 impedance segments located above the upper margin of the UES. Measurements
were performed during bolus swallows of 2-10ml liquid and semi-solid and MII values were
simultaneously recorded from bolus administration until bolus clearance. The VF determined
presence/absence of bolus/bolus residue was compared with the MII determined bolus
presence/absence (ie Ω ≦50% baseline = bolus present; Ω >50% of baseline = bolus absent)
at intervals of 0.4sec from the onset of pharyngeal swallow. Agreement between VF and
MII was then determined using Cohen’s Kappa statistics. Results: A total of 39 bolus swallows
were evaluated (15 liquid: 24 semisolid). Bolus residue following passage of the pharyngeal
stripping wave was present on VF for 19 swallows this was also detected by MII on 16
occasions (84%). The level of agreement between VF and MII in individual patients varied
from slight agreement (κ<2; 2 patients) to fair to moderate agreement (κ 2-6; 3 patients).
Agreement was better for semisolid (κ=0.47) than liquid boluses (κ=0.43) and agreement
improved with increasing bolus volume tested (κ= 0.41, 0.43 and 0.49 for 2ml, 5ml and
10ml respectively). Conclusion: These data indicate that pharyngeal impedance measurement
can detect failed bolus clearance in patients with dysphagia. Severe pharyngeal dysfunction
renders poorer agreement due to low baseline impedance values relative to nadir. 1. Omari
TI et al Assessment of Intraluminal Impedance for the Detection of Pharyngeal Bolus Flow
During Swallowing in Healthy Adults. Am J Physiol Gastrointest Liver Physiol. 2005
T1935
Topical Viscous Budesonide for Pediatric Eosinophilic Esophagitis
Seema Aceves, John Bastian, Robert Newbury, Ranjan Dohil
Background: Eosinophilic esophagitis (EE) is a disease of increasing incidence in both adult
and pediatric populations. Diagnosis depends on the presence of 20 eosinophils or more
per high power field (hpf) at 400x microscopy. Although treatment with topical fluticasone
appears to be effective, not all children can master the puff and swallow technique required
for pan-esophageal particle deposition. This may lead to treatment failure. Methods: Children
with upper gastrointestinal symptoms, including dysphagia and vomiting, who had endos-
copic and histologic evidence of EE were treated with topical budesonide mixed with
sucralose at doses of 1 to 2 mg per day. Some patients had previously received fluticasone
and/or elemental diet. All patients received concurrent acid-suppression therapy. At every
UGI endoscopy, 2-3 biopsies were taken each from the distal, mid and proximal esophagus.
Results: Fourteen children, 3 females and 11 males, with EE were treated with oral budeson-
ide. The mean patient age was 5.7 years (range 3-14 years). Three patients had previously
failed topical fluticasone therapy. Upper gastrointestinal endoscopy with biopsy following
3 to 4 months of therapy demonstrated disease improvement or resolution in 12 of 14
children following topical esophageal therapy with budesonide. The highest number of
eosinophils per hpf decreased from a mean of 78 (95% CI: 56.3-99.4) to 19 (95% CI: 4.9-33.4)
(p=0.0007). Among the responders, the highest number of eosinophils per hpf decreased from
a mean of 85 (95% CI 61.9-107.3) to 11.5 (95% CI 1.8-21.2) (p=0.00002) with 8 of 12
patients having less than 7 eosinophils per hpf following therapy. Histologic improvement
was pan-esophageal. In addition, 67% of responders had histologic resolution of basal zone
hyperplasia. None of the patients had a normal esophageal appearance on endoscopy prior
to budesonide therapy and 57% percent of the patients had a completely normal esophagus
at follow-up endoscopy. Of the responders 83% had improvement esophageal endoscopic
appearance. One patient developed Candidal esophagitis. Patients typically had symptomatic
improvement. None of the patients who were tested had suppression of their am cortisol
level. Conclusions: Topical viscous budesonide is a once daily, safe, palatable, and effective
therapy in children with EE and placebo controlled trials are warranted to evaluate the true
disease modifying effect of therapy.
T1936
Does Endoscopic Ultrasound Help Predict Clinical Outcome of Pneumatic
Dilation for Achalasia?
Woosuk Park, John J. Vargo, Edgar Achkar, Gary W. Falk, Michael F. Vaezi
INTRODUCTION: Pneumatic dilation (PD) is a widely accepted treatment option for idio-
pathic achalasia. Published studies on predictors of response to PD have not previously
addressed morphology of the lower esophageal sphincter (LES). AIMS: To assess LES morpho-
logy using endoscopic ultrasound (EUS) and to determine clinical and physiologic predictors
of PD outcome. METHODS: A prospective cohort study of all patients diagnosed with
achalasia undergoing initial Rigiflex pneumatic dilation at the Cleveland Clinic Foundation
between 2003 and 2005 was performed. Pre-dilation assessment included symptom score,
EGD, EUS, timed barium swallow (TBS) and esophageal manometry (ESMO). All patients
subsequently underwent Rigiflex pneumatic dilation using a 3.0 cm balloon. EUS of the
LES was performed immediately before and after PD using Olympus UM DP-12 25R 12
MHz echoprobe by a single endoscopist. Subjects were then followed at 1, 6, 12 and 18
months. At one month follow-up, all patients had repeat symptom score, TBS and ESMO.
Treatment failure was defined as recurrence of symptoms and/or abnormal TBS requiring
further therapy. RESULTS: 21 patients underwent 3.0 cm Rigiflex pneumatic dilation [Median
age (IQR): 51 years (37, 56), 52 % male]. The median (IQR) follow-up was 11 months (6,
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12). A total of 10 patients (48 %) failed therapy: 8 failed at one month and 2 failed at one
year. The treatment failure group (n=10) and treatment success group (n=11) showed no
significant difference in age, gender, pre- and post-therapy symptom score, TBS, LES pressure,
and LES inner circular muscle layer thickness. However, the treatment success group had
significantly thinner post-therapy outer longitudinal muscle measurements compared to the
treatment failure group [median thickness (IQR): 1.1 mm (1.0, 1.2) and 1.6 mm (1.5, 2.1)
respectively, p = 0.02]. ROC analysis showed that post-therapy outer longitudinal muscle
thickness≤ 1.5 mm was associated with 85.7 % sensitivity and 99 % specificity for treatment
success using a 3.0 cm dilator. CONCLUSIONS: 1) There are no demographic, clinical,
radiologic or manometric predictors of outcome with 3.0 cm PD for achalasia. 2) Post-
therapy EUS assessing thickness of the longitudinal muscle may be useful in predicting
clinical outcome in patients with achalasia undergoing PD.
T1937
Accuracy of Esophageal Impedance in the Evaluation of Esophageal Function
in Patients with Systemic Sclerosis
Lilian R. Aprile, Luciana A. Bento, Roberto O. Dantas, Daniel Sifrim, Jiry Silni, Ricardo B.
de Oliveira
Background: A number of studies show that esophageal impedance (EI), by allowing precise
assessment of movements of intraluminal contents, may be useful in the evaluation of the
esophageal function. Information about the accuracy of EI for detection of inneffective motor
activity in specific conditions is lacking. Systemic sclerosis (SS) is an important cause of
esophageal motor disorders. Aim: to determine the agreement between the data of conven-
tional manometry and EI in SS patients. Methods: twenty five informed patients meeting
the American College of Rheumatology criteria for SS (23 females, median age: 43 years,
range 20-72 years) were submitted to both perfusion esophageal manometry and EI recording
in separate days. During continuous EI recording, each subject was asked to give 6 swallows
of a 5 ml-saline bolus, 3 in the supine and 3 in the sitting position. EI was considered
abnormal if baseline impedance was lower than 1000 ohms or if deglutitions had impedance
nadir higher than 600 ohms or the post-deglutition impedance failed to reach the previous
baseline. Manometry was considered abnormal if severe distal esophageal body hypomotility,
namely contractions < 30mmHg and very low lower esophageal basal pressure was found.
Agreements between results were measured using Kappa statistic k. Results: fifteen of the
25 SS subjects (60%) had abnormal manometry. Agreement between manometry and basal
impedance occurred in 84% of the subjects in the sitting position (k= 0.67; 95% CI: 0.37-
0.96) and in 92% of them in the supine position (k= 0.83; 95% CI; 0.60-1.00). Agreement
between manometry and deglutitions data occured in 76% in the sitting position (k= 0.46;
95% CI: 0.12-0.81) and in 92% of them in the supine position (k= 0.83; 95% CI; 0.60-
1.00) .Taking manometry as “gold standard”, calculated sensitivity was 100% and specificity
was 80% for both supine EI parameters. Conclusions: the concordance between manometry
and EI data performed in the supine, but not in the upright position is high in SS patients.
The measurement of the baseline impedance is as accurate as the more complex analysis of
the deglutition profile for the detection of abnormal esophageal motility in SS patients. EI
may be a useful tool for detection of esophageal disorder in SS patients.
T1938
Impact of Age and Gender On Success of Pneumatic Dilation and Heller
Myotomy in Achalasia
Sandra El-Hachem, A Rocio Lopez, Marcelo Vela, Thomas Rice, Michael Vaezi
Background: The current recommendation in patients with achalasia advocates a graded
approach to pneumatic dilation (PD) starting with 3.0 cm balloon followed by 3.5 and 4.0
cm balloons in those who fail to respond. However, treatment response with this approach
has been disappointing in young males (Clin Gastroenterol Hepatol 2004; 2: 389-94). There
is controversy on whether Heller myotomy (HM) should be the initial treatment in this
group. The aim of this longitudinal study was to compare age and gender dependent success
of initial PD versus HM in previously untreated achalasia patients. Methods: Initial treatment
was PD with 3.0 cm balloon in 81 patients and HM (Heller Myotomy) in 53. Clinical
symptoms and timed barium swallow were recorded pre- and post PD and HM. Follow up
was 3 years and failure was defined as need for further treatment or a change in symptom
assessment <50%. A Cox proportional hazards model was used to study the effect of therapy,
age, and gender on outcome. Log-rank tests were used to compare success rates between
PD and HM in these subgroups: men under 50 and over 50, women under 50 and over
50 years. Results: Adjusting for age and gender, subjects who had PD with a 3.0 cm balloon
were 3.1 times more likely to fail than those who had HM (Figure, P = 0.01). Age and
gender were not significantly associated with treatment failure, but a subgroup analysis
showed higher success rates for HM compared to PD in men under 50 years (P = 0.01).
There was no age or gender difference in outcome for female patients. Conclusions: 1) Initial
therapy with Heller myotomy has a higher long term success rate in males under the age
of 50 than 3.0 cm PD 2) In this group graded approach to PD starting with 3.0 cm should
not be the standard of care. 3) Future studies should assess the differential response between



















Esophageal Testing and Diagnoses in Patients Discharged from the Hospital
with Non-Cardiac Chest Pain: A Missed Opportunity?
G R. Locke, Ross A. Dierkhising, Peter A. Smars, Guy S. Reeder, Alan R. Zinsmeister,
Nicholas J. Talley
Patients presenting to an emergency room (ER) with chest pain often do not have a cardiac
cause for their pain. Gastroenterologists will investigate for esophageal diseases, but the
degree to which esophageal diseases are considered in non-cardiac chest pain (NCCP)
patients in the community is not clear. Aim: To estimate the frequency of esophageal testing,
diagnoses and treatment in patients presenting to an ER and admitted with chest pain
who were discharged with a diagnosis of NCCP. Methods: The resources of the Rochester
Epidemiology Project were used to identify everyone who had presented to the ER in Olmsted
County, MN with chest pain, admitted to the hospital and then dismissed without a cardiac
diagnosis over an 8 year period. Their medical records were reviewed in detail to ascertain
GI testing, GI diagnoses and GI medication use. Results: 2058 residents presented to an ER
with CP; 1973 were admitted and 365 were not given a cardiac diagnosis (6 had to be
excluded because of research authorization). Of these, 94 (26%) received a digestive disease
diagnosis in the hospital (82 were GI and 12 were biliary); their mean age was 62 years
and 50% were male. 230 had no positive diagnosis given (NCCP group); there mean age
was 56 years and 53% were male. Median follow up was 5.3 years (range 0-13.5 yrs) for
the GI group and 5.8 yrs (0-12.9) in the NCCP group. 23 (24%) of the GI group died
during follow up, (median time to death 4.1 years) 8 died of cardiac causes. 31 (14%) of
the NCCP group died, (median time to death 3.6 years) of which 15 died of cardiac causes.
Among the 230 with an NCCP diagnosis, 22% had an EGD of which 65% were abnormal
and 31% had an UGI of which 20% were abnormal yet none had a ambulatory pH study
and just 5 had an esophageal manometry, of which 2 were abnormal. During follow up,
22% of the NCCP patients received a diagnosis of GERD. Conclusions: Although the GI
literature focuses on GERD or esophageal dysmotility in NCCP; very few people who have
sought care for NCCP get GI tests or a GI diagnosis. This highlights the referral bias in the
literature regarding pH and manometry for NCCP. In addition, a GI or NCCP diagnosis
does not protect a patient with chest pain from dying from cardiac disease. A better under-
standing of NCCP in the community is required. Supported by an unrestricted research
grant from Tap Pharmaceuticals
T1940
Gastric Atrophy: A Major Determinant Factor Differentiating Non-Erosive
Reflux Disease from Erosive Reflux Disease
Jin-Bae Kim, Yun-Jung Chang, Sung-Won Jung, Il-Hyun Baek, Myung-Seok Lee
BACKGROUND: It is still not known whether there are differences between erosive (ERD)
and nonerosive GERD (NERD). Some large epidemiologic study has shown that male gender,
overweight, and regular use of alcohol are independent predictors of ERD and Helicobacter
status (HP) is associated with a lower risk of ERD. On the contrary, the presence of HP,
HP gastritis, and female sex are reported to be more in relation with NERD. AIMS: The aim
of this study was to evaluate any differences in demographic and clinical characteristics and
in the degree of gastric atrophy between two forms of GERD. METHODS: We studied 114
consecutive patients with a clinical diagnosis of GERD (heartburn/acid regurgitation and
endoscopy). Reflux esophagitis was classified according to the modified LA classification.
HP status was determined with either rapid urease test or selology. Gastric atrophy was also
defined serologically as present when a pepsinogen I/II ratio is less than 3. The prevalence
of ERD and NERD were analyzed in relation to age, gender, BMI, presence of hiatal hernia,
HP status, alcohol intake, smoking, previous duodenal ulcer history or current showing
ulcer scar, and serological atrophic parameters. RESULTS: One hundred and fourteen patients
were diagnosed as having GERD based on either predominant symptoms of heart burn
and acid regurgitation and/or findings of reflux esophagitis. Patients with concomittent
gastrointestinal neoplasm (2), esophageal ulcer (1), clinical gastroduodenal ulcer (5), suspi-
cious functional dyspepsia (2), IBS (1), and underlying psychiatric disorders (5) were
excluded from the study. ERD was identified in 48 (49%) patients (mean age: 52.1±13.2
years) and NERD in 50 (51%) patients (mean age: 46.5±13.2), p=0.042. HP infection was
found in 30 (76.9%) ERD patients, and 30 (88.2%) NERD patients, p=0.208. Stepwise
regression analysis identified the following independent predictors of ERD: male gender
(OR, 11.6; p=0.008), older age (OR, 1.1; p=0.008). Serological atrophy were associated
with an increased risk of NERD (OR, 2.4; p=0.004). CONCLUSION: Female sex, younger
age, and gastric atrophy are associated with NERD. Chronic progressive gastritis may act as
an important factor in patient with NERD and contribute to the esophageal hypersensitivity
to acid. It remains to be seen whether HP eradication will be helpful or not in patient
with NERD.
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T1941
Characteristics of the Esophageal Pressure Trough in Patients with Esophageal
Symptoms. Studies Using High Resolution Manometry (HRM)
Daniel Pohl, Heiko Fruehauf, Oliver Goetze, Monika A. Kwiatek, Werner Schwizer,
Michael Fried, Radu Tutuian
Introduction: Human esophageal motility studies have described a physiologic pressure
trough in the transition zone from striated to smooth muscle. Combined fluoroscopy and
high resolution manometry (HRM) studies have been used to investigate bolus and pressure
dynamics in this region but there are limited data on the clinical relevance of the esophageal
low-pressure zone (LPZ). Aims: To investigate the relationship between esophageal symptoms
and the size of the LPZ, the hypothesis being that patients with esophageal symptoms may
have a larger LPZ. Methods: Esophageal symptoms (dysphagia, chest pain and heartburn/
regurgitation) were quantified using a validated questionnaire (Eraflux) and stratified accord-
ing to their main symptom. We analyzed 32-channel HRM data obtained during water
swallows in left lateral decubitus performed in patients with esophageal symptoms and
asymptomatic individuals. The analyzer was blinded to diagnosis and symptoms. Using a
two-dimensional spatiotemporal colour plot we identified the distal border of the upper
esophageal sphincter, the proximal border of the lower esophageal sphincter and the LPZ.
The LPZ was measured extending from the point where the amplitude of the proximal
contraction wave declined below 30 mmHg to the point where the amplitude of the distal
contraction wave first reached above 30 mmHg. Patients with achalasia were not included
in the analysis. Results: Data from 101 patients (53f, mean age 48, range 16-80) were
available for analysis. The average (±SEM) length of the LPZ measured 5.4±0.5 cm in
asymptomatic individuals (n=20) and did not differ (p>0.05) from the LPZ measured in
patients (n=44) with dysphagia (6.3±0.6 cm), in patients (n=17) with chest pain (6.7±0.9
cm) and patients (n=20) with heartburn/regurgitation (6.1±1.0 cm). These results did not
change even when the length of the LPZ was calculated as percentage of the total esophageal
length. The time gap between the proximal and distal contraction waves (i.e. “time-width”
of the LPZ) in asymptomatic individuals (2.0±0.2 sec) did not differ (p>0.05) from that
measured in patients with dysphagia (2.4±0.3 sec), chest pain (2.4±0.4 sec) or heartburn/
regurgitation (2.4±0.5 sec). Conclusion: Our study provides no evidence to support a
relationship between esophageal symptoms and the size of the physiologic esophageal low
pressure zone.
T1942
Esophageal Clearance Patterns in Normal Older Adults As Documented with
Videofluoroscopic Esophagram
Janice Jou, Jason Radowsky, Stephanie Kays, Jackie Hind, Eric Gaumnitz, Joanne Robbins
Objective: Normal esophageal bolus transport in asymptomatic older adults has not been
well defined. This study assesses the radiographic esophageal motility patterns seen in normal
older adults using videofluoroscopic recording. Esophageal clearance characteristics were
evaluated, including intraesophageal stasis (IES) and intraesophageal reflux (IER). IES was
operationally defined as any portion of the barium bolus failing to pass through the lower
esophageal sphincter after completion of the initial swallow. IER occurred when the barium
bolus traveled cephalad during the initial swallow before crossing the lower esophageal
sphincter without regard of the effect of subsequent dry swallows. Methods: Twenty-four
healthy asymptomatic adults, six males and six females in each of two age groups, 45-64
and older than 65 were enrolled. All subjects underwent videofluoroscopic esophagram
consisting of three 10mL thin liquid boluses, three 10mL semi-solid boluses, and one 13mm
pill. All bolus types were administered in the upright and prone positions except the pill,
which was administered upright only. Peristaltic bolus transport was noted for each patient.
Inefficiencies in esophageal clearance were quantified by a three-point numerical scale
signifying the degree of IES. The presence of IER was also recorded. Results: IES was more
frequent with semi-solid as compared with liquid regardless of position, which was statistically
significant (p<.0001). The rate of IES with liquid and semi-solid were 16% and 63-64%
respectively of all swallows. The rate of IER with liquid was 12-15% and with semi-solid
was 2-3% in all swallows. The prevalence of IER in males compared with females trended
toward significance, with males demonstrating a higher rate. Furthermore, older males
appeared to have an increased frequency of IER as compared to younger males. There were
no other differences revealed in reference to position, bolus consistency, age, or gender.
Conclusion: Semi-solid boluses elicit more stasis than liquid boluses, suggesting that a variety
of barium product consistencies simulating food-like viscosities need to be used in addition
to traditional fluids to fully evaluate esophageal transport with esophagram. Further studies
are required to confirm these findings with larger numbers of normals and elucidate the
observation of IER in older males. Our future efforts will provide a normative database for
comparison with dysphagic patients.
T1943
High Prevalence of Esophageal Involvement in Lichen Planus: A Study Using
Magnification Chromoendoscopy
Rutger Quispel, Ofke S. van Boxel, Marijke R. Canninga, Marguerite E. Schipper, Vigfus
Sigurdsson, Andre J. Smout, Melvin Samsom, Matthijs P. Schwartz
Lichen planus (LP) is a mucocutaneous disease which can also affect the esophagus. The
premalignant potential of oral LP has since long been established, but recently the first three
cases of squamous cancer in esophageal LP have been described. Aims of this study were:
1. to screen for the prevalence of esophageal involvement in a cohort of patients with
orocutaneous LP, 2. to assess the presence of esophageal dysplasia using magnification
chromoendoscopy (MCE). Methods: Twenty-two patients (8M/14F; mean age 56 years) with
a well-established history of LP were recruited from the dermatology outpatient clinic and
evaluated by upper endoscopy. Validated questionnaires were used to assess upper GI
symptoms. Mucosal abnormalities were described according to size, aspect and location.
MCE using indigo carmine focussed on mucosal surface irregularities and vascular pattern.
Biopsies were taken randomly at three levels in the esophagus and from all focal abnormalities.
Results: In 95% (21/22) of patients endoscopic findings compatible with, but not diagnostic
of, esophageal LP were found, including: a friable, coarse appearance of the proximal mucosa
in 41% (9/22), yellowish and whitish papules in 73% (16/22). In 9 of these 22 patients
(41%), histopathology confirmed the presence of lichen planus with characteristic features,
such as a lymphocytic infiltrate, subepithelial cleavage and Civatte bodies (i.e. necrotic
keratinocytes). Histopathology in the other patients showed no abnormalities in 27% (6/
22) and aspecific chronic inflammation in 32% (7/22). Endoscopy in the 9 patients with
biopsy-confirmed LP showed coarse mucosa in 5 and papules in 7. In the entire group
other endoscopic focal abnormalities were: linear mucosal breaks typical for reflux disease
in 55% (12/22), cylindric epithelium above the squamo-columnar junction in 14% (3/22)
and a proximal patch of cylindric epithelium in 4.5% (1/22). No lesions suspect for dysplasia
were detected by MCE. In concordance with MCE results, dysplasia was not found in any
of the biopsy samples. None of the 9 patients with documented esophageal LP reported
dysphagia, 1 had mild reflux symptoms. Conclusions: Screening endoscopy detects a high
prevalence of esophageal involvement in asymptomatic patients known with orocutaneous
lichen planus. True prevalence might even be higher than now described, because biopsy
sampling error cannot be ruled out. The potential benefit of surveillance endoscopy in
patients with lichen planus remains to be established, because in this cohort of patients
dysplasia was not found.
T1944
What Is the Prevalence of Motility Abnormalities in Patients with Non Acid
Reflux On High Dose Proton Pump Inhibitor Therapy?
Toan T. Nguyen, Matthew Gideon, Philip O. Katz
Background: The etiology of refractory GERD symptoms on antisecretory therapy is debated.
Multichannel intraluminal impedance/pH (MII-pH) has been advocated as a means of deter-
mining if reflux (acid or non acid) is temporally associated with these continued symptoms.
The prevalence of esophageal motility abnormalities in these patients and the potential
association with symptoms is not clear. Aim: To determine the prevalence of motility
abnormalities in GERD symptoms refractory to PPI and if these findings differ between
patients with positive and negative symptom indices (SI) to reflux episodes determined by
MII-pH. Patients and Methods: A retrospective analysis of patients referred for persistent
reflux symptoms despite high dose PPI therapy between 2003-2005. Inclusion criteria:
having had both ambulatory MII-pH and motility/manometry tests within a 1-week period.
MII-pH monitoring was performed with a 6-impedance electrode/2-pH electrode catheter
(Sleuth; Sandhill Scientific). Reflux episodes categorized as acid (pH<4) or non-acid (pH>4).
Positive SI defined as ≥ 50% positive correlation to reflux episode. Motility assessed using
a combined manometry/impedance catheter (Sandhill Scientific). Liquid and viscous bolus
transit was recorded. Motility abnormalities defined using standard manometric criteria.
Results: 64 patients met inclusion criteria. 42% patients had positive SI. 58% patients had
negative SI. The following manometric findings were noted in order of prevalence: 28%
Ineffective esophageal motility (IEM), 19% incomplete LES relaxation, 16% hypotensive
LES, 14% hypertensive UES, 9% nutcracker esophagus, 8% double high pressure zone, 5%
hypertensive LES, 3% incomplete UES relaxation, 3% distal esophageal spasm, and 2%
hypotensive UES. There was a trend towards more IEM and impaired liquid bolus transit
in patients with positive SI although statistical significance was not reached. See table.
Conclusion: The pathogenesis of symptoms in patients with non-acid reflux does not appear
related to abnormal motility or bolus transit. Further studies are needed in this population.
T1945
Measurement of Esophageal Bolus Transit Is Affected By Bolus Size and
Viscosity
Dawn Ferguson, Kenneth R. Devault, Ernest P. Bouras, Mark E. Stark, Sami R. Achem
Introduction: Multi-channel intraluminal impedance (MII) combined with esophageal mano-
metry (EM) allows for simultaneous evaluation of esophageal pressure and bolus transit.
Traditionally, 5 mL normal saline and viscous boluses have been used to assess transit.
Varying volumes and viscosities of boluses have not been examined in regards to their
performance in assessing esophageal dysfunction. Methods: We performed a chart review
of patients undergoing combined EM and MII testing in our laboratory. Routine clinical
procedure was followed for ten 5mL normal saline swallows. An additional ten swallows of
a viscous solution were given. The first five of these were 5mL boluses followed by five
10mL boluses. All swallows were given with the patient supine. The proportion of complete
esophageal bolus transit was compared between the saline and viscous swallows. Esophageal
bolus transit was considered abnormal if 30% or more of saline boluses had incomplete
transit or if 40% of viscous swallows were incomplete. The total bolus transit time (TBTT)
was compared between the saline boluses, the 5mL viscous boluses and the 10 mL viscous
boluses. The manometric findings were compared to the bolus transit results. Results: 40
patients underwent testing using this protocol. 93% of the normal saline swallows resulted
in complete transit compared to 83% of the viscous swallows (p<0.01). The 5mL viscous
bolus had the fastest mean transit time (7.7 sec) compared to the 5mL saline boluses (8.4
sec, p<0.05) and the 10mL viscous boluses (8.9 sec, p<0.01). Table 1 outlines the comparisons
of the EM and MII diagnoses. Conclusions: These results suggest that small volume (5mL)
viscous boluses transit the esophagus faster than similar volume saline boluses. The slowest
transit is seen with larger (10mL) viscous boluses. Abnormal viscous transit appears to be
more predictive of a manometry disorder than normal saline transit.
Association with Bolus Characteristic and Esophageal Manometry
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The viscous bolus transit was normal in all patients with abnormal saline bolus transit and
the saline bolus transit was normal in all patients with abnormal viscous transit.
T1946
Esophageal Pressurization: Clinical and Manometric Aspects
Brendan J. Boland, Christian G. Peyre, Cedric G. Bremner, Colleen B. Gaughan, Jeffrey A.
Hagen, Christian Rizzetto, Steven R. Demeester, John C. Lipham, Tom R. Demeester
Introduction: The baseline pressure of the intrathoracic esophagus is negative. In some
pathologic states this baseline pressure is increased. This phenomenon occurs in achalasia
and in other conditions and is thought to reflect outflow resistance. We measured esophageal
pressure and correlated the degree of pressurization with symptoms and other manometric
findings. Methods: A database of all motility studies from 2001 to 2005 was queried for
the finding of esophageal pressurization. Corresponding patient tracings were reviewed.
Esophageal pressurization was defined as a sustained elevation of esophageal pressure above
the gastric baseline not associated with vascular or other artifacts, or esophageal body
contractions. Esophageal pressure was measured by averaging the pressure in two channels
within the esophageal body relative to the gastric baseline at mid respiration. Clinical and
demographic information was collected. Results: There were 146 patients with esophageal
pressurization, 94 (64%) with achalasia and 52 (36%) with other abnormalities (hypertensive
lower esophageal sphincter 15, other motility disorders 13, and failed fundoplications 10).
The most common primary symptom was dysphagia 115 (79%) followed by chest pain 12
(8%). The mean esophageal pressure was 8.2 mm Hg and higher in achalasia than other
diagnoses [10.2 v 4.6 (p<0.0001)]. Esophageal pressure correlated directly with LES pressure
r = 0.5 [CI 0.36 to 0.61, (p < 0.0001)] and LES residual pressure r = 0.43 [CI 0.25 to 0.58,
(p < 0.0001)]. There was no association between esophageal pressure and findings on barium
esophagogram. Conclusion: Patients with esophageal pressurization have disorders associated
with outflow resistance such as achalasia, hypertensive LES, and failed fundoplication. This
observation is confirmed by the correlation between esophageal pressure, LES residual
pressure and LES pressure.
T1947
Distinct Allergic Predisposition of Children and Adults with Eosinophilic
Esophagitis
Nirmala Gonsalves, Thuy Anh, Qing Zhang, Amir Kagalwalla, Anne Ditto, Ikuo Hirano
Background: Eosinophilic Esophagitis (EE) is increasingly recognized as an important entity
in both children and adults. While the etiology of this illness is a topic of ongoing investigation,
previous studies have suggested an association with both food and environmental allergens.
The goal of this study was to compare allergic trends between children and adults with EE.
Methods: We conducted a retrospective chart review of pediatric and adult patients (pts)
with a confirmed histologic diagnosis of EE seen between 1999 and 2005. Demographic
and allergy testing data were recorded. Results are presented as the mean ± standard deviation.
Results: Charts from 234 patients with EE were reviewed including 114 adults (age 39 ±
13yrs) and 120 children (age 4.7 ± 4.5yrs). The duration of symptoms prior to the diagnosis
of EE was 6.7 ± 6.2yrs in adults and 1.2 ± 1.5yrs in children. There was a male predominance
of 75% in both groups. 101 patients including 83 children and 18 adults underwent formal
allergy testing with skin prick testing. Of those tested, 72% of children and 100% of adults
were found to have documented allergies. The most common food allergens were milk, egg,
wheat, soy, peanut, and seafood. Other allergens were recorded if positive. Children were
significantly more likely to have egg allergies (p<0.005) while adults were more likely to
have nut allergies (p<0.005). A significant difference was demonstrated in the following
allergens based on age: milk (p<0.005), egg (p<0.001), and wheat (p<0.005) with younger
patients more likely to have these allergens. Having an allergy to one food allergen increased
the likelihood of having additional food allergies. Environmental allergens were not routinely
tested in children. The most common environmental allergens in adults were ragweed (81%),
tree (75%), grass (81%) and mite (75%). Conclusions: (1) Allergies documented by skin
prick testing were present in 72% of children and 100% of adults in our EE cohort (2)
Younger patients were more likely to be allergic to milk, egg, and wheat, while adults were
more likely to be allergic to nuts. (3) Environmental allergens were found in 83% of adults
while food allergens were present in 61%. (4) The role of formal allergy testing for patients
with EE is still being defined.
T1948
Assessment of Esophageal Emptying in Achalasia Patients By Intraluminal
Impedance Monitoring
Jose M. Conchillo, Mohamed Selimah, Albert J. Bredenoord, Melvin Samsom, Andre J.
Smout
Background and aim: In achalasia patients, the timed barium esophagram is an objective
test for the assessment of esophageal emptying but its use implies exposure to ionizing
radiation. Intraluminal impedance monitoring can accurately determine the timing of eso-
phageal filling and emptying in healthy subjects without radiation. Aim of this study is to
evaluate the suitability of impedance monitoring for the assessment of esophageal emptying
in achalasia patients. Methods: 10 achalasia patients (6 men, mean age 44 years, range 20-
64) underwent simultaneous fluoroscopy and impedance recording during the esophageal

















a fluoroscopic image was recorded every 20 s. Fluoroscopic images were scored for bolus
clearance time (BCT), defined as the time when the barium column passed the impedance
channel at 1 cm above the LES. In addition, the height of the barium column level was
analyzed at 1, 5, 10 and 15 min. Impedance tracings were scored independently by 3
observers. Results: All patients showed a low baseline impedance level in the distal esophagus
suggesting stasis of fluids. Three patients had at least one period of regurgitation of fluids
and in 9 patients pathological air movement (air trapping) within the proximal esophagus
was detected. On fluoroscopy, 8 patients showed a BCT longer than 15 min. On impedance
monitoring, the percentage of patients having a BCT longer than 15 min as scored by the
3 observers was 50, 40 and 20%, respectively (mean 37%). Two observers scored BCT on
impedance monitoring similarly (±1 min) to the time on fluoroscopy in 70% of the patients
while the third observer found a similar BCT in 40% of the patients. Correlations between
height of barium on fluoroscopy and fluid level on impedance monitoring were poor at 1
and 5 min (r=0.53, p=0.11 and r=0.42, p=0.22) and moderate at 10 and 15 min (r=0.65,
p=0.04 and r=0.63, p=0.05). Kendall’s coefficient of concordance between the 3 observers
for assessment of fluid level on impedance monitoring was 0.31 (p=0.04) at 1 and 5 min,
0.26 (p=0.08) at 10 min and 0.44 (p=0.01) at 15 min. Conclusion: In achalasia patients,
pathological bolus transport patterns such as low baseline impedance and air entrapment
in the proximal esophagus make impedance monitoring unsuitable for the assessment of
esophageal emptying.
T1949
Validation of Platelet Count/ Spleen Diameter Ratio As a Noninvasive Method
to Screen for Prescence of Varices in Cirrhotic Patients
Trinh Meyer, Vidushi Golla, Helene N. Pena Sahdala, David J. Clain, Henry C.
Bodenheimer, Albert D. Min
Esophageal varices are a common complication of cirrhosis. Cirrhotic patients are routinely
screened for varices with upper endoscopy. A recent study reported 100% negative predictive
value (NPV) of platelet count/ spleen diameter (PC/SD) ratio using a cut-off value of 909
for presence of esophageal varices (Gut 2003;52:1200). The aim of our study was to validate
and asses PC/SD as a noninvasive predictor of varices in patients with cirrhosis. Method:
Records of all patients age ≥ 18 years with cirrhosis with and without esophageal and/or
gastric varices on upper endoscopy between January 2003 and October 2005 at Beth Israel
Medical Center, NY were reviewed. The data collected were age, gender, etiology of cirrhosis,
spleen diameter on CT/MRI scan, INR, total bilirubin, platelet count, albumin, Child-Pugh
score and endoscopic findings. Data were analyzed using t-test, chi-square and Fisher’s exact
test. Results: There were 137 patients, and 87 (63.5%) were men. Seventy-six (55%) patients
had esophageal and/or gastric varices. The mean age, gender and etiology of cirrhosis were
similar between the two groups (see Table). Patients with varices were more likely to have
lower platelet count, splenomegaly, ascites, lower albumin, and higher Child-Pugh score.
Using a PC/SD ratio with a cut-off value of 909, as previously reported, yielded a NPV of
only 53.7%. However, a PC/SD ratio with a cut-off of 200 yielded a NPV of 97%. In contrast,
using a platelet value of >50,000 alone, the NPV was 89%, although the positive predictive
value for presence of varices was only 11%. In addition, using a spleen diameter value of
> 14 cm alone, the NPV was 52% for presence of varices. Conclusions: Lower platelet count,
splenomegaly, ascites, lower albumin, and higher Child-Pugh score were positive predictors
of varices. In our study, a platelet count/ spleen diameter ratio with a cut-off value of 909
as an independent variable had poor NPV for varices. Upper endoscopy remains the best
method to screen for presence of varices in cirrhotic patients.
T1950
Endoscopic Findings in Eosinophilic Esophagitis (EE): A Morphologic
Clasification According to Manometric and Histopathologic Relationship
Alfredo J. Lucendo, Marta Navarro, Sonia Martin-Chavarri, Ramon Pajares, Juan Manuel
Pascual, Emilio Burgos, Pilar Castillo, Javier Larrauri
Background: EE is an inflamatory disease with increasing incidence and immunoallergic
etiology. It is defined by dense eosinophilic infiltration of the esophageal mucosa, descarting
infiltration of another sections of the alimentary tract. Eosinophilic infiltration produces
esophageal motility disturbances observed in manometry. Great variety of endoscopic findings
have been described in EE, judging by this as a polimorfic disease. Objective: To analize
endoscopic esophageal findings and to relate them with histopathologic and manometric
findings. Define a EE clasiffication in endoscopic patterns. Patients & Methods: Endoscopic
appearance of esophagus was described and recorded in a prospective cohort of 25 patients
with EE. Esophageal stationary manometry were achieved in all patients. Results: 8 patients
showed normal esophageal diameter, 6 concentric stenosis. 11 had simultaneous contraction
rings along the organ’s lumen. Main mucosal findings: 4 patients showed multiple papules
along the organ’s wall (granular aspect). 8 presented longitudinal mucosal furrows in all
the length of the organ. 2 patients showed undulated smooth mucosa and 5 had white
exudative lession of different size. 22 patients showed disturbances in esophageal manometry
affecting the 2 lower thirds: 14 of them had a severe non-especific motor disorder with
hypoperistalsis and low amplitude simultaneous waves. 8 presented great amplitude peri-
staltic waves. In 3 patients was normal. All histopathological exams showed the same type
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of lession characterized by epithelial edema with increasing of intercelular spaces, acanthosis,
papillomatosis and basal cell hyperplasia, with outstanding inflamatory infiltration by eosino-
phils. Severity of this changes was correlated with different endoscopic patterns. Discussion:
1) Endoscopic appearance of EE is defined by two tipes of independent finding: Alterations
in esophageal calibre, and lessions or disturbans in the organ’s mucosa. The first is manifested
like regular concentric estenosis preventting to observe distal lumen, or simultaneous contrac-
tion rings along the length of the organ. A normal esophageal diameter can also be observed,
with independence of mucosal apearance. This alterations are variable for a same patient
along the time in abscence of specific treatment, and don’t respond to organic lessions.
Mucosal lessions in our patients could be resumed in four well-deffined patterns: a) Granular
type mucosa. b) Longitudinal forrows along organ length. c) Circular undulated mucosa.
D) Exudative (white spots or exudates). 2) We describe a correlation beetwen endoscopic
mucosal pattern and severity of histopathologic changes.
T1951
An Essential Amino Acid, Isoleucine, Prevents Liver Metastases of Colon
Cancer By Antiangiogenesis
Kazumoto Murata, Masami Moriyama
Background: In spite of recent advances in the treatment of colon cancer, multiple liver
metastases are still difficult to treat. Antimicrobial peptides such as defensins play an import-
ant role in the innate immunity for all lives, including plants or insects that lack immune
systems. β-defensins are strong chemotactic factors for memory T cells and dendritic cells,
suggesting that they play an important role in the acquired immunity as well. On the
other hand, β-defensins are inducible by an essential aminoacid, isoleucine. Therefore, we
hypothesized that isoleucine may contribute to tumor immunity. Methods: Male BALB/c or
nude mice (8-10 w) were administered isoleucine, leucine (3 mg/day) or PBS 1 week before
implantation of colon 26 cells to the spleen until sacrifice on the 21st POD. After checking
liver metastasis, livers and spleens were taken for RT-PCR (VEGF: vascular endothelial growth
factor), western blot (β-defensin-3, p-4EBP-1, p-stat 3, HIF1-α) and immunohistochemistry.
Blood samples were taken for serum albumin. Colon 26 cells were cultured with isoleucine,
leucine or medium alone and subjected to RT-PCR or western blot and the culture medium
was subjected to ELISA for VEGF. These cells were also used for MTT assay to check
cytotoxicity by aminoacids. Results: Isoleucine (n=5) inhibited liver metastasis in a dose
dependent manner whereas no inhibition was observed by leucine (n=5) or PBS (n=5).
Serum albumin level was not impaired in the isoleucine-treated mice whereas significant
reduction was observed in the leucine- and the PBS-treated mice. However, β-defensin in
the liver was not induced even in the isoleucine-treated mice without any metastasis against
our hypothesis. Furthermore, isoleucine completely inhibited liver metastasis even in nude
mice (n=5), suggesting immune responses did not contribute to this mechanism. VEGF in
the culture medium of colon 26 cells was inhibited by isoleucine in a dose dependent
manner without affecting cell viability. Isoleucine inhibited VEGF mRNA expression in both
in vitro and in vivo experiment. In the liver of the isoleucine-treated mice, the expression
of p-4EBP-1 and p-stat 3 were mildly down-regulated in comparison with the leucine-treated
mice. The expression of HIF1-α was inversely correlated with expression levels of those.
Immunohistologic CD31 staining in the isoleucine-treated mice showed a marked decrease
in the number of blood vessels in comparison with the leucine-treated mice. Conclusion:
Isoleucine inhibits angiogenecity by impairment of VEGF expression partially through mTOR
pathway. Isoleucine could be a safe medicine for prophylactic use for liver metastasis of
colon cancer.
T1952
A Novel Synthetic Diphenyl, Difluoroketone (L-2395) Compound with Potent
in Vitro and in Vivo Anti-Cancer Activity
Dharmalingam Subramaniam, Sripathi M. Sureban, Robert George, Rama P. Ramanujam,
Hideg Kalman, Periannan Kuppusamy, Courtney W. Houchen, Brian K. Dieckgraefe,
Shrikant Anant
Curcumin is an anti cancer chemotherapeutic and chemopreventive agent. We have previ-
ously demonstrated that curcumin inhibits EGF mediated signaling and inhibits intestinal
adenomas in APCmin/+ Mice. Using the structure of curcumin, we have now developed a
new water-soluble molecule, diphenyl difluoroketone (L-2395, also known as EF24) and
tested it against cancer cells. L-2395 demonstrated a dose-dependent inhibition of prolifera-
tion and induction of apoptosis of a variety of adenocarconoma cells. This activity was
significantly higher and at lower doses than that observed with curcumin. In addition, L-
2395 induced G2/M cell cycle arrest, which was followed by the induction of apoptosis as
evidenced by caspase-3 activation and an increased number of cells with a sub-G1 DNA
fraction. Significant inhibition in the number and size of colonies were also observed. On
the other hand, the compound did not affect the proliferation of normal mouse embryo
fibroblasts. L-2395 significantly suppressed epidermal growth factor mediated induction of
AKT and ERK phosphorylation. Real Time PCR analyses were performed to determine
the effect of L-2395 on gene expression. L-2395 significantly inhibited the expression of
cyclooxygenase-2 (COX-2), interleukin-8 (IL-8) and vascular endothelial growth factor
(VEGF). Microarray analyses demonstrated increased expression of TNF-receptor II coupled
with induction of BAX, caspase-6 and -9 at 24 h, while inducing BAX, caspase-7 and -9 at
48 h. In addition, there was significant induction of p73, a p53-related nuclear transcription
factor within 24 h. The effect of L-2395 on growth of tumors in vivo was determined using
HCT-116 colon cancer tumor xenografts in nude mice. Xenograft tumors were established
by injecting a single-cell suspension of >95% viable HCT-116 cells implanted subcutaneously
into the backs of Balb/c athymic nude mice. Formation and size of the tumors were monitored
daily until day 30. L-2395 was injected intraperitoneally from day 7 onwards. L-2395
inhibited tumor growth in ectopic xenografts, with notably lower tumor volume and weight.
The microvessel density was also significantly lower in the tumors following L-2395 treatment
than in control tumors. Real Time PCR analyses demonstrated significant inhibition of COX-
2 and IL-8 mRNAs in the tumors. Our results indicate that the antitumor effect of L-2395
in colon cancer cells is shown at least in part through TNF-receptor II-mediated activation
of caspases and BAX genes, resulting in tumor growth inhibition with apoptosis induction.
T1953
Inhibition of the Nuclear Transcription Factor PPARγ Prevents Growth of
Colorectal Cancer By Directly Reducing Cellular Tubulin Concentration
Katherine Schaefer, Hirokazu Takahashi, Victor Morales, Atsushi Nakajima, Lawrence J.
Saubermann
Background: Colorectal cancer (CRC) is the third-most commonly diagnosed cancer
worldwide, and adjuvant therapies are urgently needed for advanced disease. The nuclear
transcription factor PPARγ has been explored as a potential therapeutic target for a variety
of cancers, and the thiazolidenedione PPARγ activating ligands have been shown to cause
growth arrest and apoptosis in a number of cancer cell lines. However, despite these
encouraging results, the effects of PPARγ activation in clinical trials have been extremely
modest, with no beneficial effect seen in metastatic CRC. More recent results in animal
models of CRC suggest that, although PPARγ activation is important in preventing the
development of CRC, it may in fact be harmful after CRC is established. We therefore
investigated the effects of PPARγ inhibition on CRC. Methods: The human CRC cell lines
HT-29, Caco-2, and LoVo were treated with the PPARγ inhibitors T0070907, GW9662,
and BADGE or PPARγ-specific siRNA. The effects on apoptosis, cell cycle and tubulin
function were investigated using flow cytometry, confocal microscopy, Western blot, and
in vitro tubulin polymerization assays. The ability of T0070907 to inhibit tumor formation
in a HT-29/SCID xenograft metastatic cancer model was also measured. Results: PPARγ
inhibitors induce dual G1 and M cell cycle arrest and apoptosis in CRC cell lines, with an
ED50 of 50 μM for T0070907 and GW9662 and 100 μM for BADGE. Before commitment
to apoptosis and independent of cell cycle, PPARγ inhibitors disrupt epithelial morphology
and microtubule networks. PPARγ-specific siRNA has the same effect on the cytoskeleton
as do the inhibitors. PPARγ inhibitors do not interfere with the polymerization of tubulin
monomer into microtubules, but instead directly reduce the cellular concentration of both
α and β tubulin monomer proteins. This regulation occurs post-transcriptionally, as tubulin
RNA levels are unaffected by PPARγ inhibitors. Consistent with these results, 1 and 5 mg/
kg/day T0070907 given daily starting the day after HT-29 cells were injected into the spleen
reduced both the number of metastatic colonies in the liver (to 37 and 29% of control,
respectively), and the total tumor volume (to 23 and 12% of control, respectively). Conclu-
sions: PPARγ inhibition can induce apoptosis of colorectal cancer cells through its effects
on cytoskeletal regulation and reduce the number and volume of metastases in an animal
model of CRC. These results suggest that PPARγ inhibition should be considered as a
therapeutic target in CRC.
T1954
Sulindac Independently Modulates ERK1/2 and PKG Pathways
Stevany Peters, D. Rayburn Moore, K. Scott Beard, Dennis Ahnen, Pamela Rice
Colorectal cancer (CRC) is the 2nd leading cause of cancer mortality in the US. Substantial
human and animal data support the ability of nonsteroidal anti-inflammatory drugs (NSAIDs)
to cause regression of existing colon tumors, and prevent new tumor formation. Despite
these chemoprotective effects, chronic use of NSAIDs is limited by GI toxicity. The mechanism
by which the NSAID sulindac exerts its growth inhibitory effects is poorly understood, as
sulindac modulates several growth-related pathways. We have described the ability of sulin-
dac to inhibit the ERK1/2 mitogen-activated protein kinase cascade at times and doses
consistent with the induction of apoptosis. Expression of a constitutively active MEK1 gene
prevents ERK1/2 inhibition and apoptosis induced by sulindac. Treatment with sulindac
also leads to activation of protein kinase G (PKG) and phosphorylation of JNK. Expression
of a dominant negative JNK1 gene prevents apoptosis and JNK activation by sulindac. The
purpose of this study was to determine if sulindac modulates ERK1/2 and PKG/JNK signaling
pathways independently in CRC cells. Parental HT29 CRC cells, or stable HT29 clones
expressing empty vector (pCEP) or constitutively active MEK1 (R4F) were treated with
sulindac metabolites, U0126 (MEK1/2 inhibitor), or YC-1 (activator of PKG). Sulindac
treatment resulted in 1) inhibition of EGFR, HER2, and ERK1/2 phosphorylation, 2) activation
of JNK and AKT phosphorylation, and 3) inhibition of beta-catenin protein expression.
HT29-R4F clones were resistant to ERK1/2 inhibition and apoptosis induced by sulindac.
However, inhibition of EGFR and HER2, activation of JNK and AKT, and inhibition of beta-
catenin expression occurred equivalently in drug treated HT29-pCEP and HT29-R4F clones.
Inhibition of ERK1/2 with U0126 induces apoptosis and G1 arrest of CRC cells, but does
not affect JNK activation. Activation of PKG with YC-1 leads to JNK phosphorylation,
increases apoptosis, and causes S-phase arrest of CRC cells without modulating ERK1/2.
Simultaneous treatment with U0126 and YC-1 produces synergistic apoptosis, and recapitu-
lates the biochemical effects of sulindac treatment - namely inhibition of ERK1/2, activation
of JNK and AKT, and decreased beta-catenin protein expression. These results indicate that
sulindac modulates ERK1/2 and PKG pathways independently in CRC cells. Co-treatment
with U0126 and YC-1 produces synergistic anti-tumor effects in vitro. Utilizing similar
approaches in vivo may provide more effective, less toxic chemotherapeutic strategies against
CRC. Such therapies could dramatically reduce the incidence and mortality from CRC.
T1955
Violacein Synergistically Increases 5-Fluorouracil Cytotoxicity, Induces
Apoptosis and Inhibits AKT-Mediated Signal Transduction in Human
Colorectal Cancer Cells
Liudmila L. Kodach, Carina L. Bos, Nelson Duran, Maikel P. Peppelenbosch, Carmen V.
Ferreira, James C. Hardwick
Despite recent additions to the armory of chemotherapeutic agents for colorectal cancer
treatment, the results of chemotherapy remain unsatisfactory. 5-fluorouracil (5-FU) still
represents the cornerstone of treatment and resistance to its actions is a major obstacle to
successful chemotherapy. Therefore new active agents in colorectal cancer and agents that
increase the chemosensitivity of cancer cells to 5-FU are still urgently required. Violacein,
a pigment isolated from Chromobacterium violaceum in the Amazon river, has a diverse
T : 89386$$CH2
05-04-06 23:18:30 Page 581Layout: 89386B : o
A-581 AGA Abstracts
spectrum of biological activities, and represents a novel cytotoxic drug with known antileu-
kemic properties. To assess the suitability of violacein as a chemotherapeutic agent in
colorectal cancer its cytotoxic effects were evaluated both as a single agent and in combination
with 5-FU. Its underlying mechanisms of action were further investigated by studying its
effects on the cell cycle, apoptosis and cell survival pathways (PI3 kinase/Akt, p44/42 MAP
kinase and nuclear factor kappa-B) in colon cancer cell lines. Violacein inhibits the growth
of all four colon cancer cell lines tested. It induces apoptosis, and potentiates the cytotoxic
effect of 5-FU in a poorly differentiated microsatellite unstable cell line (HCT116). Violacein
causes cell cycle block at G1, upregulates p53, p27 and p21 levels and decreases the
expression of cyclin-D1. Violacein leads to dephosphorylation of Rb and activation of caspases
and a pancaspase inhibitor abrogates its biological activity. Our data provide evidence that
violacein acts through the inhibition of Akt phosphorylation with subsequent activation of
the apoptotic pathway and downregulation of NFkB signaling. This leads to the increase of
chemosensitivity to 5-FU in HCT116 colon cancer cells. Taken together, our findings suggest
that violacein will be active in the treatment of colorectal tumors and offers new prospects
for overcoming 5-FU resistance.
T1956
Sulindac Inhibits Colon Tumor Cell Proliferation in Xenograft Mice
Matthew Quallick, Matthew Sericati, Nathan Susnow, Linda Driggers, Dennis Ahnen,
Pamela Rice
Regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) reduces the risk of colorectal
cancer (CRC) development. The NSAID, sulindac, prevents development of human aden-
omatous polyps and inhibits colon tumor formation in animal models. The mechanisms by
which sulindac prevents colon tumor growth in vivo are complex and poorly understood.
Inhibition of COX-1 and -2, the classical targets of NSAIDs, does not adequately explain
sulindac’s growth inhibitory effects in vitro or in vivo. Several COX-independent mechanisms
have been described for sulindac, including the extracellular signal-regulated kinase (ERK1/
2) pathway. Sulindac metabolites inhibit ERK1/2 activation, and this inhibition is both
necessary and sufficient for apoptosis of human colon cancer cells in vitro. The goal of this
study was to determine if sulindac treatment inhibits ERK1/2 activity and stimulates apoptotic
cell death in vivo, using the xenograft mouse model. Athymic mice were injected s.c. with
HT29 human CRC cells and tumors allowed to grow to a palpable size. Mice were then
placed on diets containing 0 or 320 ppm sulindac for 15 days. Tumors were measured
with calipers, harvested and prepared for immunohistochemistry using KI67 (a marker of
proliferation), cleaved caspase-3 (a marker of apoptosis) and phospho-ERK1/2 antibodies.
Sulindac treatment inhibited tumor growth, and this inhibition was associated with a signific-
ant decrease in Ki67 staining. Sulindac-induced growth inhibition was also associated with
increased cleaved caspase-3 staining and decreased phospho-ERK1/2 staining, however these
results were not statistically significant. Together these results suggest that inhibition of
tumor cell proliferation - and not induction of apoptosis - is the biological mechanism by
which sulindac prevents tumor formation in vivo.
T1957
Mechanism for Enhanced Anti-Tumor Effects of 5-Fluorouracil (5FU) By
Celecoxib in An Advanced Colon Cancer Model: Angiogenesis, Or 5FU
Metabolisms?
Takanobu Irie, Masahiko Tsujii, Shingo Tsuji, Shuji Ishii, Toshiyuki Yoshio, Shinichiro
Shinzaki, Satoshi Egawa, Tsutomu Nishida, Yoshimi Kakiuchi, Masakazu Yasumaru,
Hideki Iijima, Hiroaki Murata, Sunao Kawano, Norio Hayashi
Background & Aims: Many reports have suggested that COX-2 inhibitors are effective
chemopreventive agents against colorectal cancers. However, effect of COX-2 inhibitor
combined with chemotherapy for the treatment of advanced colon cancer remains obscure.
Therefore, we examined efficacy of combination therapy of COX-2 inhibitor and chemother-
apy for colon cancer cells, in vitro and in vivo, and whether COX-2 inhibitor influence
metabolism of 5FU. Methods: (1) in vivo assay: Male BALB/c mice were inoculated subcutane-
ously with 1x104 cells of colon 26 cells, a murine colon cancer cell line. When tumor
allografts reached more than 5 mm in diameter, mice were randomized and given daily
with either 5FU alone (20mg/kg, i.p.), celecoxib alone (3mg/kg, i.p.), or 5FU and celecoxib.
Tumor size was measured every 7 days. After 28 days, tumors were harvested and used for
analyzing angiogenesis (expression of CD31) by immunohistochemistry and for measuring
VEGF concentration by ELISA. (2) in vitro cytotoxicity: Colon 26, which is expressing COX-
2, was used. The cells were cultured for 3 days with or without 5-FU, celecoxib and/or SN-
38. Cell survival was evaluated by WST assay. (3) Influence on 5FU metabolism: Colon 26
cells were cultured for 24 hours with or without 5FU and/or celecoxib. Cells were harvested
and enzyme activity of thymidylate synthase (TS), intracellular 5FU and FdUMP (5-fluoro-
2’-deoxyuridine 5’-monophosphate ) concentration and 5FU incorporate into RNA were
measured. Expression of dihydropyrimidine dehydrogenase (DPD; catabolic enzyme of 5FU)
mRNA was analyzed by RT-PCR. Results: (1) 5FU (20mg/kg) and celecoxib (3mg/kg) treat-
ment significantly inhibited the growth of colon 26 allograft compared with control or other
groups. 5FU/celecoxib treatment significantly reduced VEGF production and suppressed
angiogenesis compared with 5FU alone. (2) Tumoricidal effect of 5FU (4μM) combined
with celecoxib (10μM) was significantly lower than 5FU alone, but it was recovered by
adding SN-38. (3) Intracellular concentration of 5FU and FdUMP and incorporation of 5FU
into RNA were lower, and TS activity and DPD mRNA expression were higher in 5FU/
celecoxib treatment group than 5FU alone. Conclusions: These results suggest that celecoxib
enhances antitumor effect of 5FU via suppressing angiogenesis, not via enhancing intracellular
metabolism of 5FU. Thus, COX-2 inhibitor, in combination with certain chemotherapeutic


















The Nucleoside Analog ARC Induces Apoptosis in GI Tumor Cells
Senthil K. Radhakrishnan, Andrei L. Gartel
Using a p21 promoter-lacZ reporter construct in LIM1215 colon cancer cells, we screened
a library of structurally diverse compounds obtained from the National Cancer Institute for
small molecule, transcriptional inhibitor of p21. We identified a nucleoside analog ARC (4-
amino-6-hydrazino-7 beta-D-ribofuranosyl-7H-Pyrrolo[2,3-d]-pyrimidine-5-carboxamide),
which has properties of a general transcriptional inhibitor. Specifically, ARC inhibits phos-
phorylation of RNA polymerase II by PTEF-b (positive transcription elongation factor b)
leading to a block in transcriptional elongation. ARC was able to potently repress p53
targets p21 and hdm2 protein levels, but dramatically increased p53 levels similar to other
transcriptional inhibitors, including flavopiridol. This increase in p53 corresponded to the
downregulation of short-lived protein hdm2, which is a negative regulator of p53. Further-
more, we found that ARC induces apoptosis in LIM1215 colon cancer, AGS gastric cancer
and HepG2 liver cancer cells, where we detected cleavage of caspase-3 after ARC treatment.
Interestingly, HepG2 cell line with stable knockdown of p53 (HepG2-p53si) also showed
cleavage of caspase-3 confirming that ARC-mediated apoptosis in these cells is p53-independ-
ent. Although ARC promoted accumulation of p53, ARC-induced apoptosis in tumor cells
was p53-independent, suggesting that it may be useful for treatment of tumors with function-
ally inactive p53. In order to evaluate if ARC induces apoptosis in colon cancer cells
comparable to that of the other known nucleoside analog DRB, we treated LIM1215 cells
with either ARC or DRB for 48 hrs. We found that 5 µM of ARC treatment resulted in
37.8% apoptosis, while a 50 µM of DRB treatment only showed 23.4% apoptosis suggesting
that ARC is much more efficient in eliciting apoptosis than DRB in LIM1215 colon cancer
cells. Furthermore, cell death induced by ARC had a strong correlation with downregulation
of anti-apoptotic gene survivin, which is often overexpressed in human tumors. To test how
ARC may affect angiogenesis we used cord formation assay using human umbilical vein
endothelial cells that were plated on a three dimensional layer of Matrigel, where they
formed cord-like structures. They were treated with different concentrations of ARC for 24
hrs and cord formation was quantitated as a function of cord junctions and cord length. A
dose dependent decrease was seen in response to ARC treatment in both junction and
length with respective IC50 values of 344.87 and 382.3 nM, suggesting that ARC has an
antiangiogenic activity. Taken together, our data suggest that ARC may be potentially useful
drug against GI cancers.
T1959
The Tyrosine Kinase SRC Regulates Adhesion to the Substrate of Pancreatic
Endocrine Cancer Cells
Alessia Di Florio, Gabriele Capurso, Massimo Milione, Francesco Panzuto, Raffaele
Geremia, Claudio Sette, Gianfranco Delle Fave
In a recent PETs microarray screen we identified overexpression of the Src-like tyrosine
kinase Lck. Src kinases belong to an oncogene family altered in several neoplastic cells and
involved in the control of cell adhesion, proliferation and motility. The present study is
aimed at testing the possibility that Src-like kinases are suitable therapeutic targets for PETs.
We have tested the PET cell lines (CLs) CM and QGP1, for the expression of the Src-like
kinases Lck, Fyn and Src by western blot (WB) and found Src to be the most aboundant
isoform. Further WB with a phospho-Src ab revealed Src activation. We confirmed expression
of Src in PETs in vivo by IHC on a series of 28 cases (18 primaries, 10 metastases) which
were all positive. To test the role of Src, CLs were cultured in the presence or absence of
the Src-kinase inhibitor PP2. Adhesion and initial spreading of cells on the culture plate
was severely inhibited. WB analysis confirmed that Src activity was selectively inhibited in
cells treated with PP2. Moreover, the effect of the inhibitor was specific for cell adhesion
and initial spreading, while prolonged incubation showed that PP2 exerted no effect on cell
cycle and/or apoptosis. In order to identify the molecular targets of Src in PET CLs, we
examined the pattern of tyrosine phosphorylation during adhesion. We observed a transient
increase of tyrosine phosphorylation in QGP1 cells adhering to the plate, with a peak at 75
min after seeding, when approximately 75% of cells are attached. Treatment of cells with PP2
caused a dramatic reduction in the number of attached cells and abolished phosphorylation of
candidate proteins with different molecular weight that we named p180, p130, p100, p70,
p55 and p40. To determine if these proteins could be isolated from the cell extracts, we
performed an immunoprecipitation experiment using an anti-phosphotyrosine antibody
followed by WB analysis with the same antibody and demonstrated that all the above
mentioned proteins could be immunoprecipitated from control but not from PP2-treated
cells, indicating their phosphorylation is Src-dependent. A pull-down assay using a purified
GST-SrcSH2 fusion protein showed that p180, p130, p70 and p55 can be specifically isolated
by the GST-SrcSH2 pull-down but not by a control GST pull-down, indicating that they
form a complex with Src upon phosphorylation. Identification of these Src substrates in
QGP1 cells by mass spectrometry and WB analysis of the immunoprecipitates is ongoing.
Our results suggest that Src plays a specific role during adhesion in PET CLs and may be
a therapeutic target able to limit their metastatic potential.
T1960
Final Results of a Randomized Comparison of Infusional 5-Fluorouracil/
Leucovorin Plus Oxaliplatin (FUFOX) Versus Capecitabine Plus Oxaliplatin
(CAPOX) in Metastatic Colorectal Carcinoma (MCRC)
Rainer Porschen, S Kubicka, A Grothey, U Graeven, A Kretzschmar, R Greil, W Freier, T
Seufferlein, Ht Arkenau, A Hinke, Hj Schmoll, W Schmiegel
Background: The combination of capecitabine and oxaliplatin has demonstrated good efficacy
results in phase II studies. Therefore, we initiated a phase III trial comparing FUFOX and
CAPOX as first line therapy in MCRC. Here, we present the final results of the efficacy and
toxicity analysis. Patients and methods: 462 pts. were required in order to exclude non-
inferiority of the CAPOX regimen (i.e. HR < 1,29). From 8/02 to 8/04 476 pts. (m:f =
299:177; median age 65 yrs) were randomized to receive either FUFOX (234 pts. arm A:
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5-FU 2000mg/m2 24h inf., leucovorin 500mg/m2, oxaliplatin 50mg/m2 d1,8,15,22; q5
wks) or CAPOX (242 pts. arm B: capecitabine 1000mg/m2 bid d1-14, oxaliplatin 70mg/
m2 d1 and 8; q3 wks). All pts. had measurable metastatic disease, ECOG performance
status 0-2, normal renal/hepatic/haematologic function. Results: To date 2635 treatment
cycles (1073 FUFOX, 1562 CAPOX) were administered (median number of cycles per
patient: FUFOX: 5, range 1-16; CAPOX: 6, range 1-24). Based on 371 events currently
observed, median time to tumor progression (primary study end point) was 8.0 months in
the FUFOX arm and 7.0 months in the CAPOX arm (HR: 1.19 (90% CI: 1.0 -1.41), p=
0.094). Median overall survival (OS) was 18.1 months in the FUFOX arm and 16.6 months
in the CAPOX arm, respectively (HR: 1.23 (90% C.I: 0.99-1.52), p=0.11). Response rates
(intention to treat, (ITT)) were similar in both arms (table 1). Conclusions: Treatment with
CAPOX and FUFOX induced similar response rates. There was no significant difference in
median PFS. Today median OS data are too immature as only 51% events occurred. Ongoing
studies will put our data into context and further define the role of the CAPOX regimen.
T1961
Antitumor Effect of Whole Body Hyperthermia Combined with
Immunotherapy in Subcutaneous Tumor Model of Colon Cancer
Takeshi Hattori, Satoshi Kokura, Tetsuya Okayama, Toshimitu Okuda, Satoko Adachi,
Naoyuki Sakamoto, Tomohisa Takagi, Osamu Handa, Yuji Naito, Norimasa Yoshida,
Toshikazu Yoshikawa
Aim: Whole body hyperthermia (WBH) has been applied as an adjunctive therapy with
various established cancer treatments such as radio-therapy and chemotherapy. Recently, it
has been reported that an activation of the immune system might contribute to the therapeutic
effect of WBH. On the other hand, it has been established that alpha-galactosylceramide
(alpha-GalCer), a glycolipid, is recognized by natural killer T (NKT) cells together with the
monomorphic MHC-like antigen, CD1d, in mice and humans. In this study, we investigated
the antitumor effect of WBH combined with alpha-GalCer in mouse subcutaneous tumor
model of colon cancer. Methods: Colon26 cells were inoculated subcutaneously in male
BALB/c mice to establish subcutaneous tumor. Colon26-bearing mice were treated with
WBH by using far infrared rays 3 times a week. Rectal temperature was maintained for 60
min at 41 degrees Celsius. In some experimental groups, alpha-GalCer was intraperitoneally
injected before WBH. We investigated the therapeutic effect of WBH, alpha-GalCer, and
the combined therapy. Furthermore, we also investigated the mechanism by which alpha-
GalCer enhanced the antitumor effects of WBH. We monitored the serum level of IFN-
gamma, and we measured both NK activity and CTL activity in each group. Results: (1)
Compared with control group, WBH alone showed a tendency to inhibit tumor growth and
to prolong survival rate. (2) Alpha-GalCer did not show the inhibitory effect to tumor
growth. (3) The combination of WBH and alpha-GalCer showed significant inhibitory effect
of tumor growth and prolongation of survival rate. (4) Serum IFN-gamma increased after
3 hours and returned to its basal level after 24hours of alpha-GalCer administration. (5)
Both NK activity and CTL activity were enhanced on the group of combination therapy
with whole body hyperthermia and alpha-GalCer. Conclusion: (1) Whole body hyperthermia
showed the antitumor effect on mouse subcutaneous tumor model of colon cancer. (2) The
combination with alpha-GalCer increased the efficacy of whole body hyperthermia probably
via the enhancement of both NK activity and CTL activity.
T1962
A Selective Cyclooxygenase-2 Inhibitor, Etodolac, Suppresses Stomach
Carcinogenesis in Helicobacter Pylori-Infected Mongolian Gerbils
Hirohito Magari, Yasuhito Shimizu, Ken-Ichi Inada, Izumi Inoue, Mkitaka Iguchi,
Hideyuki Tamai, Kimihiko Yanaoka, Kenji Arii, Masashi Oka, Masae Tatematsu, Masao
Ichinose
Purpose:Recent studies indicate that the selective cyclooxygenage-2 (COX-2) inhibitor
reduces the risk of colorectal cancer. Expression of COX-2 in chronic atrophic gastritis
(CAG) and intestinal metaplasia is reported recently. CAG including intestinal metaplasia
occurs in Helicobacter pylori (Hp)-infected Mongolian gerbils (MGs). Therefore, in the present
study, we investigated the effect of a selective COX-2 inhibitor, etodolac, on Hp-associated
stomach carcinogenesis in MGs. Methods:A total of 154 MGs were divided into five groups
(A-E). Animals were inoculated with Hp (3.0×108 CFU/ml, ATCC 43504) (groups A-D; n =
28, 35, 35, and 40, respectively) or vehicle alone (group E; n = 16). Groups A-D were given
MNU in the drinking water at a concentration of 10 ppm for 23 weeks. MNU was not
administered to group E. In groups B-D, the animals were given the stock Etodolac diet
from week 24 until week 53, whereas the animals in groups A and E received the control
diet. The daily administered dosage of etodolac in groups A-D were 0, 5, 10, 30 mg/kg/day
respectively. On the 53rd experimental week, all animals were sacrificed. Tissues sections
were stained with H&E and were also analyzed by immunohistochemistry for PCNA. Serum
levels of anti-Hp antibodies and 8-OHdG were measured using ELISA. COX-2 m-RNA level
in gastric mucosa was measured using RT-PCR. Results:In all the Hp-infected animals (groups
A-D), marked infiltration was observed in the lamina propria and submucosa. The mucosal
level of COX-2 mRNA tended to be dose-dependently reduced by etodolac treatment.
Infection with Hp remarkably elevated the serum level of 8-OHdG but it was not significantly
reduced by etodolac treatment. In contrast, the etodolac treatment dose-dependently reduced
the serum level of anti-Hp antibodies. Infection with Hp greatly enhanced mucosal cell
proliferation as revealed by immunohistochemistry using anti-PCNA antibodies. Etodolac
treatment resulted in a step-wise and significant reduction in the proliferation of Hp-infected
mucosal cells. In addition, etodolac repressed the development of intestinal metaplasia. As
a result of long-lasting infection with Hp, 14.8% of the animals in group A developed cancer.
The incidence of cancer decreased in a step-wise manner with the dose of etodolac, and
the development of the cancer was completely inhibited in group D Conclusion: Etodolac
treatment dose-dependently inhibited the development of gastric cancer. These results suggest
that COX-2 is a key molecule in inflammation-mediated stomach carcinogenesis and that
chemoprevention of stomach cancer should be possible by controlling COX-2 expression
or activity.
T1963
The Role of 99m-Technetium-Depreotide in the Management of
Neuroendocrine Tumours
Tahir H. Shah, Ilona Kulakiene, John Buscombe, Ann-Marie Quigley, Christos
Toumpanakis, Martyn E. Caplin
Background: Neuroendocrine tumours (NETs) express somatostatin receptors which can
be utilised for tumour imaging as well as for tumour targeted radiotherapy. 111Indium-
pentetreotide (OctreoScan®) is widely used for imaging and is associated with 67-95%
sensitivity. However, it mainly binds to somatostatin receptor subtype 2 (SSTR2) and will
miss neuroendocrine tumours (NETs) lacking SSTR2 or NETs which lose SSTR2 upon
alteration of tumour phenotype i.e. upon progression from low grade to high grade. Lack
of strongly positive imaging with agents targeting SSTR2 normally rules out SSTR-targeted
radiotherapy as an option. 99mTc-depreotide is a new somatostatin analogue that binds
SSTR2/3/5 with high affinity. Aim: To assess the diagnostic value of 99mTc-depreotide
scintigraphy in patients with negative or weakly positive 111In-pentetreotide scans (Krenning
scale ≤ 1 [range 0-4]) and to determine its role in guiding therapy. Methods: 39 patients,
with histologically proven NETs underwent paired 111In-pentetreotide and 99mTc-depreo-
tide scans. The results were compared with CT and/or MRI imaging. Outcomes in patients
subsequently receiving intravenously administered SSTR-targeted radiotherapy were ana-
lyzed. Results: Histologically 24%, 31%, and 45% of tumours were of low, intermediate,
and high grade respectively. The Krenning scores were: 0, 1, 2, and 3 in 36%, 32%, 25%,
and 7% of patients respectively when imaged with 111In-pentetreotide; and 29%, 21%
29%, and 21% respectively when imaged with 99mTc-depreotide. Scores were equal for
the 2 modalities in 29% of patients; 99mTc-depreotide > 111In-pentetreotide in 46%; 111In-
pentetreotid > 99mTc-depreotide in 14%; and separate tumour sites were highlighted by
the 2 agents in 11%. 4 patients received SSTR targeted radiotherapy: 1 patient currently
undergoing therapy; 2 patients had disease progression despite therapy; 1 patient had disease
stabilisation for 6 months followed by disease progression. Conclusion: 99mTc-depreotide
is a significant new imaging modality in NET patients with intermediate / high-grade tumours
which show complete absence or only limited uptake of 111In-pentetreotide. It identifies
patients amenable to radionucleotide therapy targeting SSTR subtypes 3 and 5 as well 2.
However initial results in patients identified for treatment using 99mTc-depreotide are
disappointing. This is due to the aggressive nature of NETs lacking SSTR2.
T1964
Inhibition of Nuclear Factor κB Inhibits Cancer Cell Implantation in Vivo
Brett W. Doxey, Phillip Gray, Scott K. Kuwada
The nuclear factor κB (NFκB) family of transcription factors is commonly over expressed
in malignant cells in which it promotes survival and angiogenesis. We previously showed
that NF-κB activity is transiently and strongly increased, and mediated cell survival, during
readhesion of colon cancer (CCa) cells in suspension (Scaife et al. Cancer Res 2002). AIMS:
To determine the vulnerability of digestive tract cancer cells to NF-κB inhibition during
readhesion in vitro and in vivo. METHODS: The apoptotic effect of BAY 11-7085 was
compared with vehicle on readhering human pancreatic cancer cells (Su.86, MIA PaCa-2)
and CCa cells (DLD-1, HT-29, HCT-116) using Annexin V-FITC or cleaved PARP detection.
Readhering HT-29, DLD-1, and HCT-116 cancer cells were treated with BAY 11-7085 with
or without anti-TNF antibodies or soluble RANK (receptor activator of NF-κB) protein
to determine the mechanism of NF-κB activation. 12 athymic mice were randomized to
intraperitoneal (i.p.) BAY 11-7085 (5mg/kg) or vehicle (DMSO). The mice were treated with
BAY 11-7085 or DMSO 24 hours prior to i.p. injection of 1 million Su.86 or MIA PaCa-2
cells, followed by i.p. treatment with BAY 11-7085 or DMSO every other day for 9 days.
RESULTS: Treatment of readhering pancreatic cancer and CCa cells with BAY 11-7085 for
8 hours caused a large induction of apoptosis versus controls. Anti-TNF antibodies or
soluble RANK inhibited readhesion-induced NF-κB activation in 0/3 and 3/3 CCa cell lines,
respectively. While 67-100% of vehicle-treated mice demonstrated intraabominal seeding,
only 33% of BAY 11-7085-treated mice did (p<0.05). There was a 2.5-11-fold reduction in
the mean number of peritoneal implants in the treatment groups versus the control groups
(p=0.045). CONCLUSIONS: Inhibition of NF-κB induced apoptosis and inhibited intraabdo-
minal implantation of readhering digestive tract cancer cells. CCa cells utilize RANK but
not TNF receptors to transiently activate NF-κB during readhesion. The strong dependence
of digestive tract cancer cells on NF-κB and RANK activity for survival during readhesion
provides a unique therapeutic opportunity to inhibit intraabdominal seeding and metastasis.
T1965
HSP70-Inducing Drug, Geranylgeranylacetone,, Enhances Anti-Tumor Effect of
Whole Body Hyperthermia in Mice Subcutaneous Tumor Models of Colon
Cancer
Satoko Adachi, Satoshi Kokura, Toshimitsu Okuda, Takeshi Hattori, Tomohisa Takagi,
Osamu Handa, Yuji Naito, Norimasa Yoshida, Toshikazu Yoshikawa
Background and Aim: The transcription factor NF-kB is constitutively activated in many
human cancers, and induces the expression of multiple genes including COX-2, VEGF, and
IAP. Therefore, the blocking of NF-kB activity may be associated with the suppression of
angiogenesis, and induction of apoptosis. Recently, we confirmed that heat pretreatment
inhibited activation of NF-kB through the expression of heat shock proteins in a human
colon cancer cell line. Thus, these facts raise a possible scenario that hyperthermia inhibits
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NF-kB activation of a cancer cell, resulting in the inhibition of cancer growth by the induction
of heat shock proteins. In this study, we investigated the effect of whole body hyperthermia
combined with a heat shock proteins-inducing drug, geranylgeranylacetone (GGA, Hsp70
inducer) in mice subcutaneous tumor models of colon cancer. Methods: Colon26 cells were
inoculated subcutaneously to establish subcutaneous tumor. Colon26-bearing mice were
treated with whole body hyperthermia by using far infrared rays 3 times a week. Rectal
temperature was maintained for 60 min at 41 degrees Celsius. In some experimental groups,
oral administration of GGA (250mg/kg) was performed 2 hr before whole body hyperthermia.
We investigated the therapeutic effects of whole body hyperthermia, single administration
of GGA, and the combined therapy. Moreover, Hsp70 of tumor tissue in each treatment
group was detected by Western bloting. The activity of NF-kB in tumor tissue after each
treatment was investigated by EMSA and ELISA. Results: 1) Whole body hyperthermia
significantly inhibited the growth of subcutaneous tumor. 2) A single administration of GGA
did not show the inhibitory effect of tumor growth. 3) The combination of whole body
hyperthermia and GGA made further inhibitory effect of tumor growth. 4) GGA or whole
body hyperthermia slightly induced Hsp70 in tumor tissue 24h after treatment. On the
other hand, whole body hyperthermia combined with GGA administration increased the
induction of Hsp70. 5) Whole body hyperthermia inhibited the NF-kB activation, which
was enhanced by the combination with GGA. Conclusions: The development of subcutaneous
tumor was inhibited by the treatment of whole body hyperthermia, and it might be suggested
that Hsp70 induced by whole body hyperthermia play the important role of the inhibition
of tumor growth because the effect of treatment was enhanced by using a Hsp70 inducer.
T1966
A Phase I/II Study of a Νew Radiolabeled Somatostatin Analogue 90yttrium-
Tyr3-Dota-Octreotate for the Treatment of Metastatic Neuroendocrine Tumours
Christos Toumpanakis, Tahir Shah, Nick Chong, Neil Davies, John Buscombe, Martyn E.
Caplin
Background: Radiolabeled somatostatin analogues can be used not only for tumor visualiza-
tion but also for treatment of metastatic neuroendocrine tumours. Aim: To estimate efficacy
and tolerability of a new radiolabeled somatostatin analogue 90Yttrium-Tyr3-DOTA-octreot-
ate in patients with metastatic progressive neuroendocrine tumours. Patients & Methods:
Sixteen patients (8m & 8f) with metastatic progressive neuroendocrine tumours were studied.
Mean age was 60.4 years (range:34-83years). Patients received 1-3 cycles of the radionuclide,
either intravenously (10/16) or intra-arterialy (6/16). In 4 patients of the latter group the
intrarterial administration was combined with particle embolization of hepatic metastases.
Intravenous aminoacids were also administered for protection of renal function. Clinical
and/or radiological response was assessed. Mean follow-up so far is 4.5 months (range: 2-
9 months). Results: In all patients the post treatment scintigraphic scans demonstrated
uptake and localization by the tumour. Clinical improvement was noted in 11/16 (68.75%
patients) after 1-3 treatments. Stabilization of tumor growth was achieved in all patients
who had already completed the 3 cycles of treatment. Bone marrow suppression was noted
in 4/16, persisting at 3 months in one patient with significant bone metastases. Despite
prophylactic aminoacids, one patient developed irreversible mild renal failure. Conclusion:
90Y-DOTA-octreotate seems to be a well-tolerated and safe treatment for patients with
progressive neuroendocrine tumors, despite a risk for bone marrow toxicity in patients with
large-volume bone metastases. Early results regarding efficacy are promising. Longer follow-
up and more patients are required for better evaluation of tumor response.
T1967
Astragalus Saponins Induce Inhibition of Cell Proliferation in Association with
COX-Independent Overexpression of NAG-1 in Colon Cancer Cells
Joshua K. Ko, Mandy M. Tin, Chi-Hin Cho, Kelvin K. Chan
Background & Aims: Active medicinal constituents of herbal origin may possess cytotoxic
and/or growth inhibitory effects in various cancers. Our recent findings have indicated that the
total saponin extract of radix Astragalus membranaceus causes significant growth inhibition in
colon cancer cells and tumor xenograft on nude mice. In the present study, we aimed to
examine the antineoplastic mechanism of extracted total astragalus saponins (AST) in HT-
29 colon adenocarcinoma cells and to identify the upstream molecular target. Methods: AST
at various concentrations was incubated in HT-29 cell culture for 48 or 72 h. Cytotoxicity
and cell proliferation were determined by MTT assay and BrdU ELISA, respectively. Flow
cytometry was then performed to determine cell cycle arrest and apoptosis. Modulation of
the apoptosis and growth-related proteins was assessed by Western analysis. The protein
and gene expression of the transcriptional factors cyclooxygenase (COX)-2 and NSAID-
activated gene (NAG)-1 were also evaluated. Results: Cell growth inhibition was observed
in HT-29 cells incubated with AST for 48 h (IC50=39.8 µg/ml) and 72 h (IC50=31.6 µg/
ml). The cytotoxic effect of AST after 48 h incubation was accompanied by a dose-dependent
reduction of cell proliferation (30-100 µg/ml). Data from flow cytometry had indicated that
AST (50 µg/ml) caused G2-M phase arrest, with a slight increase in the amount of apoptotic
cells (~10%) accumulated at the sub-G1 region of the DNA histogram. Western analysis
had demonstrated that AST induced cleavage of procaspase-3 and the caspase-3 substrate
PARP, markedly inhibited the expression of the anti-apoptotic protein Bcl-xL and the growth-
related protooncogene c-myc, and caused overexpression of the cyclin-dependent kinase
inhibitor p21 in HT-29 cells. In addition, a concurrent COX-independent NAG-1 protein
overexpression was also revealed. By using quantitative real-time PCR, we had shown a
time-dependent induction of NAG-1 mRNA by 3-6 h of AST incubation (50 µg/ml), of
which the gene expression returned to control level at 24 h. Conclusion: These findings
envisage the cytotoxic effect and inhibition of cell proliferation induced by AST in HT-29
colon cancer cells. The mechanism of action involves cell cycle arrest by modulation of the
growth-related proteins, with NAG-1 being identified as a vital molecular target. The upstream
transcriptional factors (e.g. an early growth response factor EGR-1) that could be triggered



















Gene-Wide Haplotypic Analysis Demonstrates Novel Association Between
ATP-Binding Cassete 3/Multidrug Resistance Protein 3 (ABCC3/MRP3) Gene
and Inflammatory Bowel Disease
Gwo-Tzer Ho, Nicole Soranzo, Elaine Nimmo, Albert Tenesa, David Goldstein, Jack
Satsangi
Background: Increasing evidence implicates the disruption of xenobiotic defence mechanisms
in the pathogenesis of inflammatory bowel disease (IBD)1,2. We have recently demonstrated
association between variations of the ABCB1/MDR1 gene and UC; microarray data now
implicates a series of other genetic determinants involved in the maintenance of intestinal
barrier function. Aim: We have analyzed the contribution of a panel of genes (derived from
recent microarray data by Langmann et al.) consisting of the Pregnane-X receptor (PXR),
ABCC2, ABCC3; and MEKK1 genes using a gene-wide haplotype tagging approach. Methods/
Results: We have assessed the linkage disequilibrium pattern in these candidate genes by
re-sequencing 24 CEPH Caucasian trios leading to the identification of 71 SNPs. A set of
22 haplotype tagging SNPs representing the common variations of these genes, both known
and unknown were then selected using the multiple marker criterion of haplotype r2 >0.8
for all genotyped SNPs. These SNPs were then genotyped in the Scottish cohort consisting
of 388 UC, 328 CD and 338 HC. Within the ABCC3 gene, 2 haplotype-tagging variants
demonstrated significant associations with CD (rs739921 C/G, p=0.005, OR 1.41, 95% CI
1.11-1.79) and UC (rs2277624 C/T SNP, p=0.003, OR 1.52, 95% CI 1.15-2.00) respectively.
In contrast, no associations were demonstrated at the allelic or haplotypic level (using log-
likelihood ratio tests, p=0.9-0.1) for the other genes studied. Conclusion: The present data
provides the first evidence of the involvement of the ABCC3 gene in determining susceptibility
to IBD. ABCC3 gene encodes for multidrug resistance protein 3 (MRP3) which is expressed
in the gut and liver. Further fine-mapping of associated interval of the implicated SNPs and
replication in other datasets are in progress, together with functional and expression data.
1. Langmann,T. et al. Gastroenterology 127, 26-40 (2004). 2. Ho,G.T. et al. Gastroenterology
128, 288-296 (2005).
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A Biological Pathway Approach to Disease Association Studies: Toll Receptor
Pathway Alleles and Susceptibility to Inflammatory Bowel Disease
Philip L. de Jager, Denis Franchimont, Alicja Waliszewska, Alain Bitton, Albert Cohen,
Diane Langelier, Jacques Belaiche, Lisa Farwell, An Goris, Cecile Libioulle, Niraj Jani,
Themistocles Dassopoulos, Gillian Bromfield, Benedicte Dubois, Judy H. Cho, Steven R.
Brant, Richard Duerr, Huiying Yang, Jerome I. Rotter, Mark S. Silverberg, A. Hillary
Steinhart, Mark J. Daly, Edouard Louis, David A. Hafler, John Rioux
The human gastrointestinal tract contains an abundant microbial flora that, along with
pathogens, has long been thought to play a role either in initiating or in exacerbating
inflammatory bowel disease (IBD). Host defenses such as the innate immune system are
critical to the host/pathogen interaction and have been implicated in the pathophysiology
of IBD. We therefore set out to characterize the role of genetic variation in a family of pattern
recognition receptors, the Toll-like receptors (TLRs), and their signaling molecules in IBD.
Our study implicates three of these molecules - IRAK2, TIRAP and TLR4 - in conferring
susceptibility to IBD. Specifically, we examined a total of 1919 subjects with IBD and describe
suggestive evidence that TIRAP (OR 1.16, 95% CI 1.04-1.30; P=0.007) and IRAK2 (OR
1.15, 95% CI 1.00-1.31; P=0.035) have modest effects on risk of IBD. In addition, our
genotyping of 1539 cases of IBD and meta-analysis of 4805 cases of IBD demonstrate that
one less common haplotype of the TLR4 gene is clearly associated with risk of IBD (OR
1.30, 95% CI 1.15-1.48; P=0.00017) and Crohn’s disease (OR 1.33, 95% CI 1.16-1.54; P=
0.000035), but not ulcerative colitis. This analysis of the TLR pathway in IBD is the first
attempt towards a comprehensive evaluation of innate immunity in a chronic inflammatory
disease and offers a road map for assessing other inflammatory diseases such as autoimmune
thyroiditis, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, and type
I diabetes that have been shown to share some susceptibility alleles.
T1970
The Nf-κB Regulator Card8/Tucan/Cardinal Is a Crohn’s Disease Modifying
Gene and Influeces Response to Microbial Antigens
Marie Pierik, Liesbet Henckaerts, Sofie Joossens, Isabelle Verstreken, Karolien Claes, Nele
van Schuerbeek, Marc Ferrante, Paul Rutgeerts, Severine Vermeire
INTRODUCTION & AIM Caspase recruitment domain (CARD) containing proteins are
involved in apoptosis and NF-kB activation. The association between CARD15 variants
and Crohn’s disease (CD) confirmed the role of a disturbed innate immune response in
inflammatory bowel disease (IBD). Recently an association between CD, especially ileal CD,
and CARD8 has been described. Given that patients with IBD show serum antibodies against
microbial antigens we hypothesized that a genetically determined altered innate immune
response may lead to an exaggerated adaptive immune response due to bacterial invasion.
We therefore studied the relation between CARD8 and CARD15 variants and ASCA (anti-
Saccharomyces cereviciae) and anti-Omp (anti-Escheria Coli outer membrane porin). MAT-
ERIALS & METHODS To study the association between CARD8 and IBD a cohort of 2016
individuals was genotyped for *10Cys with MALDITOFF mass spectrometry. CARD15
variants were genotyped with PCR RFLP. For 1190 subjects (760 CD, 193 UC and 237
controls) gASCA IgG and anti-Omp IgA were measured with ELISA (Glycominds and
Inova).The clinical charts of these patients were reviewed for disease location and behavior,
age at diagnosis, gender, disease duration, history of surgery and smoking at diagnosis.
RESULTS: There was no significant distortion of transmission of the CARD8 T allele in IBD,
CD or UC parent child trios. Multivariate analyses in CD patients showed an association
between the CARD8 T allele and stricturing disease (p=0.02 OR 1.73 95%CI{1.09-2.76})
and the prevalence of anti-OmpC (p=0.03 OR 1.51 95%CI{1.04-2.19}). The age at diagnosis
was significantly lower in CD patients with a CARD15 variant compared to CD patients
with no variants in CARD15 or CARD8 (24.59 and 27.64, p<0.01). However the mean age
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at diagnosis in patients with a concomitant CARD15 and CARD8 allele was not significantly
lower compared to CD patients without any of the studied variants (24.79 and 24.59). After
combining all subjects (IBD and controls) we found that Anti-Omp was more frequent and
the titer was higher in subjects with a CARD8 T allele (29.9% versus 24,1%, p<0.01
and p<0.01). gASCA antibodies were more often present and the gASCA serum level was
significantly higher in subject carrying at least one CARD15 variant (54.0% versus 31.8%,
p<0.01 and p<0.01). DISCUSSION Our results show a higher prevalence of antibodies
against microbial compounds (gASCA and anti-Omp) in patients carrying CARD15 and
CARD8 variants. These data therefore give further evidence that a genetically determined
altered immune response to microbial compounds plays a role in the molecular pathogenesis
of IBD.
T1971
Functional Polymorphisms of the Receptor for Advanced Glycation END
Products (RAGE G82S and -374T/A) in Chronic Inflammatory Bowel Disease
D.R. Foell, Frauke Friedrichs, Jochen Hampe, Torsten Kucharzik, Johannes Roth, Monika
Stoll, Stefan Schreiber
Background and aims - An imbalance between innate and adaptive immune mechanisms
may contribute to Crohn’s disease (CD) and ulcerative colitis (UC). The receptor for advanced
glycation end products (RAGE) is involved in innate immune mechanisms. Polymorphisms
of RAGE have been described as a factor amplifying inflammation in susceptible patients,
but the association of RAGE polymorphisms with inflammatory bowel disease (IBD) is not
known. Patients and Methods - The most relevant functional RAGE polymorphisms, namely
the promotor polymorphism -374T/A (rs1800624) and a coding polymorphism in exon 3
causing the amino acid exchange G→A (rs2070600), were studied in a German study
sample consisting of 421 CD patients, 211 UC patients and 549 controls. Results - Genetic
epidemiological studies using logistic regression models revealed that the A allele of the
RAGE promotor polymorphism at position -374 is negatively associated with CD (odds ratio
(OR)=0.71, 95% confidence interval (CI)=0.53-0.93, p=0.016, additive inheritance model).
This result was confirmed by a transmission disequilibrium test in the families of the CD
patients that are part of the association study (χ2=12.28, p < 0.001). The A allele was
significantly associated to CD when accounting for CARD15 and IBD5 risk variants (adjusted
OR=0.71, 95% CI=0.52-0.97, p=0.031). Genotype-phenotype analyses demonstrated that
carrying the A allele reduces the chance to develop a stenosis (OR = 0.627, 95% CI = 0.41-
0.98, p = 0.04). The -374T/A variant was not associated with UC (OR=0.99, 95% CI=0.71-
1.38, p=0.94). We were not able to demonstrate an association of rs2070600 to CD or UC.
However, the allele frequency of the rare variant is 3.3 % in CD patients, 1.1 % in UC
patients and 2.6 % in controls; thus larger study samples are needed to evaluate an association
with IBD. Conclusions - We conclude that 374T/A variant leading to facilitated RAGE gene
transcription may protect from developing CD by augmenting innate immune mechanisms
and increasing levels of soluble RAGE which neutralizes pro-inflammatory mediators. Further
studies will confirm this effect in a secondary sample and confirm the impact on RAGE
gene transcription in CD.
T1972
Novel Association Between the C3435t Polymorphism of the MDR1 Gene and
Crohn’s Disease
Simon Lal, Joanne M. Stempak, Elkadri A. Abdul, Law Christine, Thomas D. Walters,
Anne M. Griffiths, Gordon R. Greenberg, Hillary Steinhart, Mark S. Silverberg
Background: Bacteria-host interactions are important in the pathogenesis of Crohn’s disease
(CD) and genes that affect these interactions are likely to be important factors in the
susceptibility to developing disease. To further explore these pathways, we investigated
the influence of important candidate genes that affect microbe-host interaction on disease
susceptibility and phenotypic characteristics in a large Canadian cohort of patients with
inflammatory bowel disease (IBD). Methods: 358 CD and 164 ulcerative colitis (UC) affected
individuals and 809 unaffected family members from trio and tetrad families were evaluated.
Genotyping was performed for the following SNPs: NOD1/CARD4 (rs2075820), TLR4
(rs4986790) and MDR1 (rs1045642 and rs2032582). Medical records were reviewed for
all patients and phenotypic information compiled for disease type, behaviour and location
according to the Montreal classification. Association with disease susceptibility and genotype-
phenotype relationships were analyzed using the family-based association test (FBAT).
Results: Significant association between the C3435T (rs1045642) MDR1 polymorphism and
CD (p=0.02) was found. This result seemed to come primarily from Jewish CD patients (n=
86; p=0.01). The association was strongest among patients with both ileal and colonic
involvement (vs. small bowel only or large bowel only) (p=0.03). There was no association
between the C3435T polymorphism and UC, nor was there any association between the
MDR1 G2677T/A (rs2032582) polymorphism and either UC or CD.. The TLR4 Asp259Gly
(rs4986790) polymorphism was not associated with CD overall (p=0.06), however, there
was a significant association with Jewish CD patients (p=0.03), those with inflammatory
disease behaviour (p=0.02) as well as with ileocolonic location of disease (p=0.004). The
TLR4 Asp259Gly (rs4986790) polymorphism was not associated with UC. There was no
association between NOD1/CARD4 and either UC or CD. Conclusion: This is the first
demonstration of an association between the C3435T MDR1 variant and CD in a large
cohort; this association arises primarily from Jewish individuals with CD. We did not replicate
the previously described association between this polymorphism and UC. The association
of TLR4 (Asp259Gly) with CD primarily arose from Jewish individuals. These findings
reinforce the importance of ethnicity when classifying patients for genetic studies.
T1973
OCTN Variants Within Ibd5 Locus Contribute to Pediatric Crohn’s Disease
(CD) Susceptibility; Analysis of a Population-Based Pediatric Onset CD
Cohort
Umesh Babusukumar, Tao Wang, Erin McGuire, Ulrich Broeckel, Subra Kugathasan
Susceptibility to CD by the IBD5 locus is now confirmed in adults. Recently, two polymorph-
isms (SNPs) in the OCTN gene cluster within IBD5 have been associated with CD. Higher
LOD scores were associated with early age of onset CD (<16 yrs) by Rioux et al. We performed
a comprehensive analysis of OCTN variants in an independent, exclusively pediatric-onset
CD cohort and examined the genotype / phenotype correlations. We genotyped IBD5 variants
(OCTN1{SLC22A4} & 2 {SLC22A5} and 2 haplotype tagging SNPs (IGR2198, IGR2230)and
analyzed them using family-based associations (TDT) and case control designs. DNA was
genotyped from 264 Caucasian CD children (172 trios), 98 ulcerative colitis (UC) and from
527 Caucasian control children. Mean age of onset for CD was 12 years. A significant
association (TDT) was found with OCTN1 (Χ2 = 4.40, p = 0.036) and OCTN2 (X2 = 4.92,
p = 0.027) (table 1). All markers tested were in tight linkage disequilibrium with one
another. Case control analysis (logistic regression) showed TC homozygosity genotype TC/
TC (SLC22A4/SLC22A5) (table 2) was significant but modest for CD risk (OR 1.66, 95%
CI (1.06-2.61), p=0.041). No correlation is seen with regards to clinical phenotypes and
the SLC22A4 / SLC22A5 diplotype. There was a trend towards colonic disease (p=0.09).
There was no significant interaction between the SLC22A4 / SLC22A5 diplotype and the 3
CD-associated CARD15 SNPs. No associations were seen in UC. Conclusions: We confirm
the association of IBD5 locus in pediatric onset CD as seen in adult CD cohorts. However,
compared with adults, a relatively weak association of the OCTN variants was observed.
The contribution of OCTN1/2 variants is not independent of the IBD5 haplotype. The strong
linkage disequilibrium in the IBD5 locus requires extended linkage disequilibrium analyses
of OCTN variants before definitive conclusions can be drawn about these variants as causative
genes in pediatric CD.
Table 1
Table 2
(+/+) refers to genotype TC/TC, (-/-) refers to genotype CG/CG, (+/-) includes the genotypes
TC/TG, TC/CG or TC/CC, and other diplotypes refers to genotypes TG/CG, TG/CC or CC/CC
T1974
Mutations in Innate Immune Receptors Modulate the Serologic Response to
Microbial Antigens in Patients with Inflammatory Bowel Disease
Liesbet Henckaerts, Marie Pierik, Karolien Claes, Marc Ferrante, Nele Vanschuerbeek, Nir
Dotan, Gary Norman, Rom T. Altstock, Iris Dotan, Benjamin Schooler, Zakera Shums,
Paul Rutgeerts, Severine Vermeire
Introduction: The pathogenesis of inflammatory bowel diseases (IBD) remains unknown,
but a dysfunctional innate immune response in a genetic susceptible host seems important.
Patients with IBD show various antibodies directed against microbial epitopes. Antibodies
against Saccharomyces cerevisiae (ASCA) and the Outer Membrane Porin of bacteria (anti-
Omp) have been described in Crohn’s disease (CD), although their pathophysiological role
is unclear. Recently, three anti-glycan antibodies (Anti-Chitobioside-, Anti-Laminaribioside-
and Anti-Mannobioside Carbohydrate Antibodies or ACCA, ALCA and AMCA) have also
been associated with CD. Aims: We hypothesised that mutations in innate immune receptors
lead to altered serologic response in IBD. Methods: We genotyped a large cohort of 1225
patients with IBD (913 CD/272 UC/40 IC) for the main variants in CARD15 (R702W,
G908R, 1007fs), Toll Like Receptor-4 (TLR4 D299G), OCTN (OCTN1 C1672T, OCTN2 -
207) and DLG5 (R30Q and _e26). Serum samples were analysed for gASCA IgG, ALCA
IgG, ACCA IgA, AMCA IgG (Glycominds Ltd, Israel) and Omp IgA (Inova Diagnostics, San
Diego) antibodies, using commercially available Elisa assays. Results: Compared with wild
type, CD patients with 1 or more CARD15 variants were more gASCA positive (49.4% vs.
63.7%, p<0.0001), and had higher gASCA titres (61.9U vs. 83.7U, p<0.0001). A similar
finding was observed for ALCA (32.7% vs. 45.9%, p<0.0001; 41U vs. 46.8U, p=0.003,
respectively). Furthermore, the prevalence of gASCA and ALCA increased with the number
of variants, suggesting a gene dosage effect: gASCA prevalence increased from 49.6% to
61.2% and 71% (p<0.0001), and ALCA prevalence from 32.7% to 45.3% and 47.5% (p=
0.002), for 0, 1 and 2 CARD15 variants respectively. For TLR4 D299G, an opposite effect
was seen, as CD patients carrying a variant less frequently expressed ACCA (22.5%) compared
with wild type patients (37.2%, p=0.003). Similarly, UC patients with TLR4 variants were
less frequently Omp positive (3.1%) than UC patients without a variant (28.5%, p=0.001).
Here also a gene dosage effect was observed: ACCA prevalence in CD decreased from 37.2%
to 24.5% and 0% (p=0.001) and Omp prevalence in UC from 28.5% to 3.3% and 0% (p=
0.002) for 0, 1 and 2 variants respectively. Conclusion: We found a significant association
between variants in innate immunity genes and antibodies against microbial epitopes. Interest-
ingly, an opposite effect of CARD15 and TLR4 variants was observed with respect to
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the antibody response. This finding merits further exploration, and may contribute to
understanding the conflicting theories between loss-of-function and gain-of-function for the
genetic variants.
T1975
Dose Dependent Genetic Interaction Between CARD15 Variants and a
Promotor Polymorphism in Toll-Like Receptor (TLR)-9 in Crohn’s Disease
Helga P. Torok, Juergen Glas, Ilona Endres, Laurian Tonenchi, Peter Lohse, Thomas
Ochsenkuehn, Matthias Folwaczny, Christian Folwaczny
BACKGROUND: Recognition of bacterial DNA through Toll-like receptor (TLR)-9 seems to
be crucial for the maintenance of gut homeostasis and bowel inflammation. Recent data
suggest functional interactions e.g. synergism between CARD15 and TLR9, but it is yet
unknown whether this might be mirrored by genetic variations. We have previously described
an association of Crohn’s disease with the -1237 T/C promoter polymorphism in TLR9 (1),
located in a susceptibility locus for IBD. Herein we assessed the role of the two polymorphisms
in TLR9, which distinguish the four most common TLR9 haplotypes, in a second independent
IBD population and tested for potential genotype-phenotype correlations and genetic interac-
tions with Crohn’s disease (CD) associated mutations in CARD15. SUBJECTS AND
METHODS: The polymorphisms -1237 T/C and 2848 A/G in TLR9 and risk-associated
CARD15 variants were assessed in a total of 457 patients with CD, 247 patients with
ulcerative colitis (UC), and 792 healthy controls. Association with disease susceptibility,
clinical phenotypes defined by the Vienna classification, and possible genetic interactions
with CARD15 variants in CD were tested by case-control analysis. RESULTS: A significant
increase in the frequency of -1237C carriers was observed in patients with CD bearing at
least one disease associated variant in CARD15 [overall increase of 10%, p=0,008 vs. controls,
OR 1.62, 95 % CI (1.13-2.32)]. Notably, a dose-effect was observed: the risk associated
with -1237C carrier status increased in patients with double-dose mutations in CARD15
[p=0.004 vs. controls, OR 2.31 (1.28-4.16)]. In CD patients with wildtype CARD15 and
in UC no significant differences were observed. No significant associations with CD pheno-
types were noted and allele and genotype frequencies of the 2848 A/G polymorphism were
comparable in patients and controls. CONCLUSIONS: Our results provide novel evidence
for dose-dependent genetic interactions between CARD15 and TLR9 variants, increasing
susceptibility to CD. Similar to CARD15, TLR9 is expressed close to secretory granules in
Paneth cells, and is implicated in release of antimicrobial substances within mucosal crypts.
Genetic variants in CARD15 and TLR9 could result in impaired interactions between these
receptors and thus provide a first step in disturbance of mucosal homeostasis. Our observation
sustains the hypothesis of an impaired cross-talk between different receptors of the innate
immune system as a major first step in the pathogenesis of CD. 1. van Heel DA, et al. Gut
2005;54:1553-7. 2. Torok HP, et al. Gastroenterology 2004;127:365-6. 3. Rumio C, et al.
Am J Pathos 2004;165:373-381.
T1976
Case-Control Association Study of Tnfsf15 Polymorphisms in the Japanese
Patients with Crohn’s Disease and Ulcerative Colitis
Yoichi Kakuta, Yoshitaka Kinouchi, Kenichi Negoro, Masaki Matsuura, Hiroko Abe, Go
Imai, Atsuhiro Mochida, Masaki Tosa, Eiki Nomura, Sho Takagi, Seiichi Takahasi, Tooru
Shimosegawa
Background and Aims: Tumor necrosis factor superfamily (TNFSF) is considered to play
an important role in the pathogenesis of inflammatory bowel disease (IBD). TNFSF15 (TL1A,V-
EGI) is a novel member of TNFSF and its mRNA and protein expression is up-regulated in
IBD particularly in involved tissues of Crohn’s disease (CD). Recently, Yamazaki et al reported
that the polymorphisms in TNFSF15 conferred susceptibility to Japanese and European CD
(Human Molecular Genetics, 2005). To replicate the associations of TNFSF15 with CD and to
investigate the genetic susceptibility to ulcerative colitis (UC), we genotyped single nucleotide
polymorphisms (SNPs) of the TNFSF15 in the Japanese patients with CD, UC and healthy
controls (HCs). Subjects: A total of 826 Japanese individuals, 286 patients with CD, 263
patients with UC and 277 HCs, were analyzed in this study. Methods: We first confirmed
three SNPs, -640G/A (rs7848647) and -360C/T (rs6478109) in the 5'-flanking region and
+603G/A(V201V, rs3810936) in exon4, by direct sequencing of the whole gene using 24
CD patiens, but no other SNPs were found in 5'-flanking region and all exons. We then
performed a case-control analysis of a total of six SNPs including additional three SNPs
(TNFSF15_33, TNFSF15_31, TNFSF15_28 defined by Yamazaki) in introns which were
previously reported to be associated with CD. Genotyping for SNPs was performed by
polymerase chain reaction - restriction fragment length polymorphism analysis. We also
analyzed clinical phenotypic statuses of affected individuals and TNFSF15 genotypes. Results:
Minor allele frequencies of the -640G/A, -360C/T, +603G/A, TNFSF15_33, TNFSF15_31,
and TNFSF15_28 were 25.7%, 25.7%, 26.9%, 62.4%, 26.2%, 61.2% in CD, 36.3%, 36.3%,
36.3%, 47.7%, 36.5%, 47.7% in UC, and 39.0%, 39.0%, 40.0%, 48.0%, 39.2%, 47.1% in
HCs, respectively. There was strong linkage disequilibrium between -640G/A and -360C/
T, consisting of GC/AT haplotype. All of 6 SNPs showed significant associations with
susceptibility to CD (the highest odds value was found in -640A/G and -360C/T, p=1.84 x
10-6, odds ratio 1.85) but UC. No phenotypic statuses were related to CD or UC genotype
distribution. Conclusions: The association of CD with TNFSF15 previously reported was
replicated in our Japanese case-control, however, no evidence for association of TNFSF15


















Analysis of the Utah Population Database Demonstrates Elevated Risk of IBD
Among Family Members of IBD-Affected Individuals and Is a Source for Large
Pedigrees in Which IBD Is Aggregating
Stephen Guthery, Richard A. Kerber, Richard Pimentel, Geraldine Mineau
Background: The Utah Population Database (UPDB) contains computerized genealogical
records and family histories for over 6.4 million individuals dating back to the mid-18th
century. UPDB is probabilistically linked to the University of Utah Health Sciences Center’s
administrative healthcare database. This allows for the ascertainment of individuals with
diseases using ICD-9 codes and the aggregation of these diseases in UPDB pedigrees. We
calculated the familial risk of IBD, Crohn’s disease (CD), and Ulcerative colitis (UC) using
this resource and identify large pedigrees in which IBD is aggregating. Methods: ICD-9
codes were used to ascertain individuals with Crohn’s disease (555.x) and ulcerative colitis
(556.x) dating from 1991 to 2005. Cases consist of all UPDB subjects having at least one
of the indicated diagnoses who were also biologically related to at least one other UPDB
individual. The controls were selected from a pool of UPDB individuals who had at least
one hospital record and at least one relative in UPDB. Results: There were 1,093 cases of
CD and 896 cases of UC identified within multigenerational pedigrees. The familial risk for
first degree relatives of subjects with IBD is shown in the Table. The population attributable
risk percent for familial CD was 10.5%; for UC 5.3%; and for IBD 12.1%. Conclusions:
IBD, UC, and CD aggregate in families, and having a first degree relative with IBD is an
important risk factor for IBD. The risk to 1st degree relatives of probands with UC is higher
than previously reported, although we cannot exclude referral bias as an explanation for
this finding. Identification of specific Utah families in whom IBD aggregates is ongoing.
Extended pedigree studies in these families will likely complement other study designs
delineating the genetic contribution to IBD.
Relative Risks (95% CI) for first degree relatives.
T1978
CARD15 Mutations Decrease the Mucosal Bacterial Flora in Crohn’s Disease
Carsten Buening, Thomas Fiedler, Enno Gentz, Janine Buettner, Hartmut Schmidt,
Herbert Lochs, Alexander Swidsinski
Background and Aims: Crohn’s disease (CD) patients carrying mutations within the CARD15
gene suffer from a more aggressive disease behaviour, but the mechanisms explaining these
observations remain to be elucidated. CARD15 acts as an intracellular receptor in monocytes
repsonsible for the recognition of bacterial wall components. We therefore hypothesized
that CARD15 mutations have an impact on the composition of the mucosal bacterial flora
in CD patients. Methods: In total, 42 patients with CD (male: 17, female: 25; age: 21-57)
were included in this study. For analysis of the composition of the mucosal bacterial flora,
biopsy specimens were taken from the ileum, ascending and sigmoid colon and were analysed
by fluorescence in situ hybridization (FISH). For FISH analysis rRNA-targeted oligonucleotide
probes were synthesized and forty domain, group-, and species-specific probes were applied.
In addition, genotyping for the three common CARD15 mutations (Arg702Trp, Gly908Arg,
1007fins) was performed in all subjects. Furthermore, data were correlated to clinical
characteristics of all CD patients (including age, disease localisation and behaviour, standard
medical therapy). Results: Mucosal bacteria at concentrations greater than 109/ml were
overall found in 66.7% of CD patients. Genoytyping revealed that 45.2% of patients carried
at least one mutant allele within CARD15 (considered to be CARD15 positive, the remaining
54.8% considered to be CARD15 negative). We found that the presence of mucosal bacterial
concentrations less than 109/ml was significantly associated with CARD15 mutations (p=
0.03, Fishers exact test). We observed a similar composition of the mucosal flora. However,
Enterobacteriaceae were elevated in the CARD15 group. We have previously reported that
5-ASA therapy dramatically reduces mucosal bacteria resulting in a complete disappearance
of the mucosal flora in some CD patients. Interestingly, in this study we found that this
was more pronounced in patients with CARD15 mutations compared to CARD15 negative
patients (p=0.003). Conclusion: Mucosal bacteria are found in significantly lower concentra-
tions in CD patients with mutated CARD15 compared to patients without mutated CARD15.
5-ASA therapy was associated with a complete disappereance of the mucosal flora predomin-
antly in patients with CARD15 mutations. Further studies are warranted to investigate
whether genotyping for CARD15 mutations might be used to identify CD patients with a
more pronounced effect of 5-ASA therapy.
T1979
From Vienna to Montreal: The Impact of Changes in IBD Classification On
CARD15 Genotype-Phenotype Relationships in a Population-Based Cohort
Richard B. Gearry, Rebecca L. Roberts, Christopher M. Frampton, Michael J. Burt, Judith
A. Collett, Bruce A. Chapman, Melanie D. Allington, Martin A. Kennedy, Murray L.
Barclay
Introduction: The role of CARD15 mutations in the development of Crohn’s disease (CD)
at a population level is poorly understood. Recently, a new classification system aiming to
integrate clinical phenotype and laboratory markers was proposed. Aim: To compare IBD
phenotypes using the Vienna and Montreal systems, and to determine the CARD15 genotype-
phenotype relationship in a population-based IBD cohort. Methods: 1420 IBD cases (91%
of people with IBD) were recruited into the study from Canterbury, New Zealand (population
464,800). DNA and clinical information was obtained from the cases who were phenotyped
according to both the Vienna and Montreal classification systems. Population-based controls
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(201) and cases were genotyped for the three major CARD15 mutations associated with
(CD). Results: CD phenotype distribution was similar to other population-based cohorts
(Vienna system). The Montreal system led to fewer cases classified with penetrating disease.
The frequencies for having any one of the three CARD15 mutations were 0.132 (CD), 0.07
(UC) and 0.06 (controls). The R702W (p=0.002) and Cins1007fs (p=0.003) mutations, but
not the G908R (p=0.091) mutation, were significantly associated with CD. The presence of
a single mutation was associated with CD (odds ratio 2.3 [95% CI 1.4-4.8]) as was the
presence of two mutations (9.2 [1.2-68]). The following significant phenotype-genotype
associations were found using the Montreal system for carrying one or two mutations,
respectively: ileal location: (2.4 [1.6-3.6], 3.5 [1.7-7.4]), colonic disease (0.35 [0.22-0.54],
0.27 [0.10-0.72]), inflammatory disease (0.48 [0.33-0.71], 0.17 [0.04-0.42]), stricturing
disease (1.5 [0.98-2.2], 4.1 [1.9-8.8]) and penetrating disease (2.3 [1.3-3.9], 1.6 [0.61-
4.4]). Other associations with one or two CARD15 mutations were previous bowel resection
(2.3 [1.6-2.4], 3.2 [1.5-6.8]) extra-intestinal manifestations (0.47 [0.26-0.87], 1.3 [0.55-
3.2]) and first degree relative with IBD (2.8 [1.7-4.8], 4.8 [1.9-12]). Conclusions: Use of
the Montreal system leads to fewer CD cases classified with penetrating disease. In turn,
this strengthens the association between penetrating disease and carriage of one or two
CARD15 mutations. While the association between CD and CARD15 mutations remains, it
is weaker in this population-based cohort than in previous clinic-based cohorts.
T1980
Prognostic Significance of NOD2/CARD15 SNPs in Allogeneic Stem Cell
Transplantation (SCT) from Unrelated Donors: Evidence for An Important
Role of Macrophages
Julia Brenmoehl, Heike Bremm, Anne M. Dickinson, Hildegard Greinix, Gerard Socie,
Daniel Wolff, Graham Jackson, Gerhard Fischer, Vanderson Rocha, Beate Steiner-
Krammer, Joachim Hahn, Gerhard Hildebrandt, Guenther Eissner, Joerg Marienhagen,
Juergen Schoelmerich, Reinhard Andreesen, Ernst Holler, Gerhard Rogler
Introduction: NOD2/CARD15 has been associated with a significantly increased risk to
develop Crohn’s disease. Our previous studies demonstrated a major role of SNPs within
the NOD2/CARD15 gene in stem cell transplantation (SCT) in HLA-identical sibling trans-
plants. The presence of NOD2/CARD15 variants was followed by an increased risk to develop
Graft versus host disease (GvHD) and an increased mortality. Our pilot data in unrelated
donor (URD) transplantation were less clear, we now extended our analysis. Methods and
patients: TaqMan PCR analysis for major SNPs 8,12, and 13 of the NOD2/CARD15 gene
was performed in DNA samples from recipients (R) and their donors (D) of 341 URD
transplants performed in 5 European centres. Results were compared with other known
risk factors such as matching for class I and II, age, disease and stage at the time of HSCT,
use of T cell depletion and reduced intensity conditioning (RIC) as well as stem cell source,
and major outcome variables such as GvHD grade III/IV, 1 yr non-relapse related mortality
(NRM) and overall survival were analysed in relation to these risk factors. Results: GvHD
grade III/IV was 21% in transplants with wildtype NOD2 pairs or mutant NOD2 in R only,
but increased to 34% in transplants with D variants and to 43% in a small group (n=14)
of simultaneously occurring NOD2 variants in R & D. Further analysis revealed, if donors
had a SNP13 variant (n=23) there was a higher risk for GvHD and NRM. GvHD grade III/
IV of these patients rose from 22 to 48% (p 0.007) and 1 yr NRM from 27% to 59% (p
0.007). Multivariate cox regression analysis for 1 yr NRM revealed a strongly increased risk
of mortality in the presence of donor SNP13 variants (HR 3.7, 95% CI 1.77 -7.79, p 0.001)
whereas other risk factors such as age, stage at the time of SCT and more important, mismatch
at an allel- or even antigen-level did not reach significance. 1 yr NRM almost doubled in
this high-group, but did not reach significance. Conlusion: Our data suggest a different but
still relevant role of NOD2/CARD15 variants in URD transplants as compared to HLA
identical sibling SCT. As NOD2/CARD15 SNP13 variants result in a stronger suppression
of NOD2/CARD15 dependent function than other SNPs altered monocyte/macrophage func-
tions in unrelated donors may contribute to these specific effects. Our data furthermore
suggest for the first time that matching for a non-HLA gene could be more relevant than
differentiated HLA-matching in URD-SCT and strongly support a role of intestinal bac-
terial translocation.
T1981
Influence of Gender and DLG5 R30q On Susceptibility for Pediatric Onset
Crohn’s Disease
Vincent F. Biank, Umesh Babusukumar, Frauke Freidrichs, Monika Stoll, Tao Wang, Erin
McGuire, Ulrich Broechel, Subra Kugathasan
Using a positional cloning approach, a significant association has been found between the
DLG5 variant (R30Q) and inflammatory bowel disease (IBD), as well as, Crohn’s Disease
(CD). These findings have subsequently been confirmed by Daly et al. in several independent
adult IBD & CD cohorts, but have yet to be investigated in pediatric onset IBD. In addition,
there is growing evidence that gender significantly influences the effect of the DLG5 variant.
Furthermore, a 2:1 male to female ratio has been observed in pediatric onset IBD. We,
therefore, investigated the effect of gender and the association of the DLG5 variant in pediatric
onset IBD. 281 Caucasian CD cases (181 trios), and 479 Caucasian population-based controls
were genotyped for the DLG5 variant using Taqman assay. Logistic regression was performed
between cases and controls. Overall allele frequency for R30Q was 8.5 % in CD and 10.3
% in controls (Table 1 shows the allele frequencies separated by gender). While there was
no significant difference in males, a significant lower allele frequency for the R30Q mutations
was detected in females with CD (p=0.0048). Logistic regression analysis showed no signific-
ant effect combining both genders (OR 0.81; 95%CI 0.551-1.198, p=0.295). However, when
stratified by gender a significant effect was detected in females only (OR 0.392; 95%CI 0.2-
0.765; p=0.006). Furthermore, analysis investigating gender, R30Q and an interaction term
of gender and R30Q, also demonstrates a significant interaction between gender and R30Q
(OR 0.29, 95%CI 0.125-0.674, p= 0.004). Finally, adjusting for previously associated muta-
tions in the CARD15 gene (3020InsC) as well as a marker in the IBD5 locus (Igr2198), we
detect a significant effect of CARD 15 (OR 3.389, 95%CI 2.394-4.799; p<0.0001) as well
as significant interaction between R30Q and female gender (p<0.05). In conclusion, while
we did not find a significant association with R30Q in the overall cohort, when stratified
by gender, we show a significant negative association in females, therefore, suggesting DLG5
has a protective effect in female pediatric CD. Furthermore, we demonstrate a significant
interaction between the DLG5 variant and gender. Although, for males, the allele frequency
is higher in cases vs. controls, this did not reach statistical significance. Further studies are
therefore needed to address the complex effects of gender, mutation frequency, and age of
disease onset in pediatric IBD.
Table 1: Allele Frequency of DLG5 in CD and Controls Stratified by Gender
T1982
Array-Based Genetic Evaluation of Adenocarcinomas and Dysplastic Lesions
(DALM) in Ulcerative Colitis
Jolanda M. Van Dieren, Janneke van der Woude, Kees J. Vissers, Ruud Schouten, Hans J.
Tanke, Karoly Szuhai, Ernst J. Kuipers, Josiane C. Wink, Herman van Dekken
Background: Longstanding ulcerative colitis (UC) is associated with a high risk of developing
UC-related colonic adenocarcinoma (UCC). These carcinomas originate from dysplastic
regions referred to as Dysplasia Associated Lesion or Mass (DALM), whereas sporadic colon
carcinoma (SCC) develops from adenomatous polyps. Methods: We evaluated the genomic
spectra of 13 DALM/ UCC’s by array comparative genomic hybridization (aCGH) with a
3500-element BAC-PAC array. Seven tumors comprised early TNM stages (2 stage 0 [c.i.s.],
5 stage I), six neoplasms were late stages (5 stage III, 1 stage IV). Results: Frequent losses
of array clones (>20% of tumors) were detected at chromosome arms 4p, 5q, and 18q,
frequent gains of array clones (>20% of tumors) were found at 1q, 5p, 6p, 7p, 7q, 8p, 8q,
11p, 11q, 12q, 14q, 17q, 19q, 20p and 20q. The pattern of alterations is dominated by
gains on 5p and 20q with loss of 4p, all of which were already present in a patient with
carcinoma in situ. However, gain of BAC clone RP11-150P21 at 8q22.3 was found more
frequently in the late-stage sub-group (P= 0.02). The distribution of gains and losses in
DALM/ UCC is different from SCC, which is typically characterized by gains of whole
chromosomes 7 and 13, gain on 20q, and loss on 17p and 18q. Conclusions: UCC’s display
profound genomic instability with multiple genetic abnormalities. Furthermore, the genomic
changes underlying UCC differ from those seen in SCC supporting an alternative genetic
pathway in the carcinogenesis of DALM and UC-associated adenocarcinomas.
T1983
CARD8: A Novel Association with Childhood-Onset Ulcerative Colitis (UC)
Marla Dubinsky, Lirona Katzir, Iwona Wrobel, Antonio Quiros, Ling Mei, Yoana Picornell,
Xiaowen Su, Ghassan Wahbeh, Gary Silber, Ron Bahar, Bruce Grill, Eric Vasiliauskas,
Kent D. Taylor, Stephan R. Targan, Huiying Yang, Jerome R. Rotter
Background: CARD proteins play an important role in apoptosis and cytokine regulation,
including NFκB, processes which are important in the pathogenesis of IBD. CARD15/NOD2
was the first novel gene reported to confer Crohn’s disease (CD) susceptibility and influence
disease phenotype. CARD4 has not been found to be associated with CD. McGovern et al
reported a significant CD association with the CARD8/TUCAN/CARDINAL gene located at
19q13.3 in adult patients. Aim: The Western Regional Pediatric IBD Research Alliance
investigated the association of the CARD8-T10C polymorphism with susceptibility to UC
and CD in children. Methods: DNA was collected from 342 subjects (75 CD trios, 39 UC
trios). Both parents and the affected child were genotyped for 3 allelic variants of the CARD15
gene (R702W, G908R, 1007insC, also referred to as SNP 8, 12 and 13) as an association
control and 1 variant of the CARD8 gene (T10C) using Taqman technology. The transmission
disequilibrium test (TDT) was used to test association with either UC or CD using GENE-
HUNTER 2.0. Results: CARD8 allele T was present in 63% of CD patients and 77% of UC
patients. CARD15 frequency (any variant) was 25% and 11% in CD and in UC, respectively.
Similar frequencies were observed for parents for both genes. As expected, transmission
distortion was seen for all CARD15 variants in CD, but not in UC. No association was
observed between CARD 8 and CD, however, in contrast, TDT showed a highly significant
association with UC, with over transmission of the CARD8 common allele (Table). Conclu-
sions: This is the first report of a CARD8 association with childhood-onset UC. The over
transmission of the common allele in this analysis is similar to that which is seen with
PPARγ in type 2 diabetes and the insulin gene polymorphism in type 1 diabetes. These
findings are in contrast to the adult CD association suggesting different mechanisms for
pediatric IBD. Larger genotype-phenotype association studies are underway to further explore
this novel genetic association.
TDT analysis
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Only Relapse Rate in the Ulcerative Colitis Patients Differs Between Sporadic
and Familial Cases in a Prospective Population Based Norwegian Study
May-Bente Bengtson, Camilla Solberg, Morten Vatn
Background and aims: Does familial aggregation of IBD change the clinical phenotype compared
to sporadic cases? The aim of this study was to estimate the increasing prevalence of familial
cases over a ten years period. We also wanted to compare the clinical phenotype between
sporadic and familial cases both in Crohn (CD) disease and ulcerative colitis(UC) in a
Norwegian population based follow-up study from onset of disease. Methods: This incidence
study includes 415 patients with UC and 191 with CD enrolled 1990 to 1994, and followed
up at one, five and ten years. Disease distribution and behaviour were confirmed throughout
these years. At each follow up the patients were asked about 1. degree relatives with IBD,
which was later confirmed. Results: Affected first degree relatives were increased from 20
(10.5 %)at diagnosis to 33 (14.1 %)at ten years follow up in CD, and from 27 (8.2%) to
52 (12.5 %) in UC. Assuming a population prevalence of 150/100 000 for CD, and 400/
100 000 for UC, the relative risks in siblings and parents increased with 69 % and 17 %
in CD , and 28 % and 72 % in UC respectively through ten years. Concordance for disease
within families was 71,2 % for UC, and 70.4 % for CD patients. Cumulative relapse rate
during ten years follow-up was significantly greater in familial cases compare to sporadic
cases for UC (OR=3.6, 95 % CI: 1.09-12,01) There were no statistical differences between
the familial and sporadic cases regarding immune modulating therapy, bowel resection,
colectomy rate, disease behaviour, location of disease or age at diagnosis. However we found
a trend towards a lower age at diagnosis in familial cases in CD(p=0,06). Conclusion: The
prevalence of IBD increased in both parents and siblings with strong disease concordance.
The marked trend of increased number of affected siblings compared to parents in CD,
opposite to increased number in UC over ten year is a new observation. Only relapse rate
in UC patients was significantly increased in familial cases compare to sporadic cases.
T1985
Association Between Ancestry Proportion and Inflammatory Bowel Disease in
Puerto Ricans
Ling Mei, Yoana Picornell, Federico Gregory, Roberto Mera, Deb Dutridge, Jerome I.
Rotter, Esther A. Torres, Huiying Yang
Mapping by admixture linkage disequilibrium (MALD) in an admixed population has advant-
ages for mapping inflammatory bowel disease (IBD) genes compared to traditional LD
methods in terms of the number of markers required. This is due to the fact that LD in a
recently admixed population can extend over large chromosomal segments, so that substan-
tially fewer markers, termed ancestry informative, can cover the entire genome. However,
the success of MALD is proposed to depend on the existence of different disease prevalence
between ancestral populations. To investigate the potential feasibility of using a MALD
approach for mapping susceptibility genes for IBD in the Puerto Rican (PR) population, we
evaluated the association between ancestry and IBD in a PR IBD case-control sample.
Methods: 204 IBD cases (128 Crohn’s disease and 76 ulcerative colitis) and 110 controls
were ascertained from Puerto Rico. 44 ancestry informative markers identified from NCBI
SNP database and literature were genotyped. There were 31, 23, and 32 informative makers
with allele frequency difference > 0.3 between African and European ancestry, European
and Native American (NA) ancestry, and African and NA ancestry, respectively. The genotype
data from the HapMap Project, including 60 Yoruba, 60 European, and 45 Asian independent
individuals, were used to determine specific ancestral representation within PR subjects.
Individual and group admixture levels were calculated by using the program STRUCTURE.
Results: There was a wide range of genetic ancestry at an individual admixture level. On
average, IBD cases had a greater proportion of European ancestry (54% vs. 47%, p<0.0001),
and lower proportion of African ancestry (7% vs. 14%, p<0.0001) compared to controls.
There was no difference in NA proportion between cases and controls. Conclusions: The
results suggest that the risk of IBD in PR population may be influenced by genetic factors
that have different allele frequency in Europeans and Africans. Thus, for any candidate gene
studies, population stratification should be taken into consideration in the analysis. Most
important, MALD may be a viable approach to identify susceptibility genes for IBD in the
PR population.
T1986
Analysis of CCL20 Variants in Inflammatory Bowel Disease (IBD) Provides
Further Evidence for Genetic Heterogeneity in Disease Susceptibility
Charlie Lees, Elaine R. Nimmo, Richard K. Russell, Johan van Limbergen, Amanda Smith,
Hazel E. Drummond, Leif Torkvist, Nagamu Inoue, Toshifumi Hibi, Nobuhide Oshitani,
Ian D. Arnott, Jack Satsangi
Background. Expression of the chemokine CCL-20 is increased in colonic mucosa and
peripheral blood mononuclear cells in IBD. In a S Korean population, the 1706G→A
promoter polymorphism was strongly associated with susceptibility to UC (p<0.0001)1.
These data have yet to be replicated. The CCL20 gene is located on chromosome 2q36.3
in a short haplotype block containing no other genes. Aims. To assess the contribution of

















populations. Methods. The Scottish population, 100% white Caucasian, mean age at dia-
gnosis 28.1 years, comprised 523 cases of ulcerative colitis (UC), 442 of Crohn’s disease
(CD), & 351 healthy controls (HC). 292 Swedish UC cases & 254 HC; 105 Japanese UC
cases & 84 Japanese HC were also studied. Direct sequencing and Taqman analysis were
used for mutation screening of the CCL20 promoter and genotyping of variants. Results.
Only two common variants (1706G→A & rs6749704T→C) were identified in these popula-
tions. There was no difference in variant allelic frequencies in Scottish & Swedish HC (p=
0.20), or between Japanese & S Korean HC (p=0.53). However, 1706G→A allelic frequencies
were significantly different between N European (Scottish & Swedish) and Eastern (Japanese
& S Korean) HC (13.3% vs 38.5%, OR 4.09, p<0.0001). The 1706G→A variant was
significantly increased in Japanese UC (OR 1.59, p=0.035), but not in either N European
population (see Table). In the N European population there was a significant protective effect
with the rs6749704‘CC’ genotype in IBD & UC compared with HC (6.6% vs 10.6%, OR
0.60, p=0.0054). This variant was not associated with UC in the Japanese population, again
mirroring the S Korean data1. Conclusions. These observations provide further evidence
for genetic heterogeneity between Eastern and N European populations, paralleling the
experience of NOD2/CARD15 in CD2, and HLA-DRB1*1502 in UC. The weak effect of
1706G→A in the Scottish and Scandinavian populations contrasts strongly with the strong
effect in the S Korean and Japanese populations. The contribution of the rs6749704 variant
in both N European datasets suggests that 1706G→A may not be the causal variant. Further
detailed analysis of the CCL20 gene is warranted. References. 1.Choi SC et al Gastro
2005;128(4):A137. 2.Arnott ID et al. Genes Immun.2004 Aug;5(5):417-25.
T1987
NOD2/CARD15 Mutations in Crohn’s Disease Decreases Endogenous
Expression of Human Alpha 1 Defensin (DEFA1) After Salmonella
Typhimurium Infection in Colonic Epithelial Cells
Jesus K. Yamamoto-Furusho, Daniel K. Podolsky
Background: DEFA1 is an antimicrobial peptide that is expressed predominantly in Paneth’s
cells of the ileum. NOD2 mutations include Arg702Trp (tryptophan substituted for arginine
at codon 702), Gly908Arg (arginine substituted for glycine at codon 908), and leu1007fsinsC
(a frameshift mutation that truncates the 33 amino acids) may be involved in the defective
response of intestinal epithelial cell lines against to bacteria. Aim: To study the effect of
NOD2 mutants in the expression of DEFA1 after Salmonella typhimurium infection. Material
and Methods: SW480, HT-29, T84, Colo205, LS174 and HCT116 cells were obtained from
the ATCC and used for experiments after they had reached 90% to 100% confluence. Cells
were transfected with a cationic lipid (LipofectAMINE 2000, Invitrogen). An expression
plasmid-encoding GFP-tagged NOD2 mammalian expression vector was made. All NOD2
mutants were generated by PCR using the QuickChange Site-Directed Mutagenesis Kit
(Stratagene) and were sequenced. Real-time RT-PCR was performed in an ABI Prism 7000
Sequence Detector using SYBR Green JumpStartTM detection system. Total RNA of intestinal
epithelial cell lines was extracted by Trizol. For reverse transcription, 2μg of total RNA was
transcribed by SuperScript First-strand Synthesis System for reverse transcription polymerase
chain reaction. Immunoblotting: Proteins were blotted onto polyvinylidene difluorid mem-
branes and stained by affinity-purified biotinylated anti-DEFA1. Results: DEFA1 is expressed
in all the colonic epithelial cell lines studied. Expression of DEFA1 was increased after
infection with non-pathogenic bacteria (E.coli) and pathogenic (Salmonella typhimurium)
for at least two hours in colonic epithelial cell lines. Transfection of the three most common
NOD2-associated Crohn’s disease mutants Arg702Trp, Gly908Arg and leu1007fsinsC in
several epithelial cell lines with NOD2 endogenous expression showed a significantly
decreased of DEFA1 in mRNA and protein levels after exposition with Salmonella typhimur-
ium as compare to those cells without infection. Interestingly, DEFA1 endogenous expression
was not affected by NOD2 mutants after infection with Salmonella in cells which lack NOD2
endogenous expression. Conclusion: NOD2 Crohn’s disease mutations are associated with
decreased expression of DEFA1 after infection with bacteria.
T1988
Defective MDP Signaling in a Subset of Crohn’s Patients Not Explained By
Common NOD2 Mutations
Vinay K. Katukuri, Phyllissa Schmiedlin-Ren, Raj Jagirdar, Mark Naddaf, Peter D.
Higgins, Kate Kleaveland, Tahira Khan, Ellen M. Zimmermann, Gabriel Nunez
Certain variants of the NOD2/CARD15 gene (C2104T, G2722C, 3020insC) are strongly
associated with susceptibility to Crohn’s disease (CD) in Caucasian populations. Current
literature indicates that the major NOD2 mutations code for proteins that are unable to
induce NF-kB activation and increased transcription of inflammatory cytokines in response
to muramyl dipeptide (MurNAc-L-Ala-D-isoGln; MDP), a conserved structure of bacterial
peptidoglycan. The aim of this study was to determine if NOD2 mutations are accompanied
by differences in cytokine expression by peripheral white blood cells exposed to purified
bacterial products in vitro. Methods: Heparinized blood was obtained from patients with
CD and from healthy controls. White blood cells were exposed to MDP or Lipid A for 16
hours. Synthesis and release of IL-1, IL-6, IL-8, and TNF-ÿ was measured by ELISA. DNA
was isolated from another portion of the blood. Genotyping for the three common NOD2
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mutations was done by direct sequencing of PCR products. Results: Eleven CD patients
were enrolled in the study. CD patients had mildly active disease with mean CRP 0.6 and
mean ESR 12. Single NOD2 mutations were detected in 3 CD and 1 control subject. Two
mutations were detected in 2 of the CD patients. Notably, three patients were MDP non-
responders and did not have any of the three common NOD2 mutations. Viability and
responsiveness of the peripheral white blood cells was confirmed by their robust elaboration
of cytokines in response to Lipid A. IL-1, IL-6, IL-8, and TNF-ÿ production was lower in
the cells from CD patients as compared to controls (p<0.008, 0.019, 0.072, 0.015 for IL-
1, IL-6, IL-8, and TNF-ÿ , respectively); the difference was statistically significant for all but
IL-8 whether or not the presence of NOD2 mutations was considered. There was a trend
for all cytokines to be expressed at lower levels in response to MDP as the number of
mutations increased from 0 to 1 to 2, but statistical significance was not reached with our
small sample size. Conclusion: Patients with CD had decreased cytokine response of peri-
pheral white blood cells to MDP. MDP non responders without common NOD2 mutations
may have a novel defect in MDP signalling.
T1989
Analysis of Positional Candidate Gene HLA-B in Japanese Patients with
Ulcerative Colitis
Eiki Nomura, Yoshitaka Kinouchi, Go Imai, Yoichi Kakuta, Hiroko Abe, Masaki Tosa,
Atsuhiro Mochida, Kenichi Negoro, Sho Takagi, Seiichi Takahashi, Nobuo Hiwatashi,
Tooru Shimosegawa
Background & Aims: Evidence is accumulating that ulcerative colitis (UC) is a multifactorial
disorder, with both genetic and environmental factors. We have previously reported the
HLA region where a strong association was observed in UC, especially the centromeric region
of class I and the telomeric region of class III by fine mapping using microsatellite markers.
HLA-B gene is located in the center of this region. Previous study suggested the association
between UC and HLA-B52 using serotyping. Thus, HLA-B is one of positional candidate
genes for UC in Japan. The purpose of this study was to perform association study in HLA-
B by genotyping and also elucidate the association between HLA-B and disease phenotype
in Japanese patients with UC. Methods: A total of 310 patients with UC and 284 healthy
controls (HC) were included in this case-control study. All subjects were Japanese. Patients
were classified according to disease extent, age at diagnosis, need for intravenous intensive
steroid therapy and need for surgery. Genotyping of the HLA-B gene was performed by a
polymerase chain reaction sequence-specific primer that can classify the gene into 23 allele
groups. Allele frequencies were compared between UC and HC with chi-squared test using
a 2 x 2 contingency table. P values were corrected by the number of allele groups (n=23)
observed in the Japanese population or the number of clinical subgroups. Corrected P values
(Pc) of less than 0.05 were regarded as statistically significant. The strength of association
was estimated by the odds ratio (OR). The genotype relative risks (GRR) for homozygous
and heterozygous for the risk allele (B*52) and the population attributable risk (PAR) were
estimated. Results: HLA-B*52 and B*4002 allele were associated with UC compared with
HC, positively and negatively, respectively (28.5% of UC vs. 9.7% of HC, Pc=5.1 x 10-14,
OR= 3.73) (7.9% vs. 15.0%, Pc=0.0028, OR=0.49). In the subgroup analysis according to
phenotypes, none of the HLA-B alleles except B*52 showed any disease phenotype-genotype
associations. The allele frequency of B*52 in patients diagnosed before 39yo was significantly
higher than that in patients diagnosed after 40yo (Pc=0.0045, OR=2.04). The GRR for
homozygous and heterozygous for B*52 were 12.79 and 3.91, respectively. The PAR regarding
B*52 was 38.3%. Conclusions: High value of the PAR strongly suggest that HLA-B*52 itself
determines susceptibility to UC in Japan and may affect earlier onset of the disease. HLA-
B*4002 appears to be a disease resistance allele.
T1990
Age and Gender Dependent Distribution of the DLG5 R30q Variant in CD
Patients and Healthy Controls
Liesbet Henckaerts, Robert Vlietinck, Isabelle Verstreken, Karolien Claes, Nele
Vanschuerbeek, Steven Boonen, Paul Rutgeerts, Severine Vermeire
Introduction and aims: The inflammatory bowel diseases (IBD), Crohn’s disease (CD) and
ulcerative colitis (UC), are chronic gastrointestinal diseases of unknown etiology, but with
a important genetic background. Recently, the R30Q variant of the disc large homolog 5
(DLG5) gene on 10q23 has been reported to be associated with CD in European patients,
but we could not confirm these findings in a Flemish IBD population. Recent data suggest
that age and gender effects could be responsible for the lack of replication of this gene. We
therefore wanted to asses the influence of age and gender on the prevalence of the DLG5
R30Q variant in our cohort of CD patients, as well as in a large cohort of healthy controls.
Methods: A total of 730 CD patients (294 male; from 4 to 92 y) and 1101 healthy controls
(618 male; from 1 to 98 y) were genotyped for the DLG5 R30Q variant. Results: In the CD
group, no difference in allele frequency for DLG5 R30Q was observed between males (10.5%)
and females (10.3%). When adding age as a covariate, we noted a higher allele frequency
in men older than 40 years (p=0.028). Subsequently, we analysed the group of healthy
controls, in function of both gender and age. Here, a higher allele frequency of DLG5 R30Q
was observed in women (12.4%) when compared with men (9.6%, p=0.036). An age effect
was not seen in the healthy controls for either sex. Conclusion: There appears to be an age
and gender effect on the frequency of the DLG5 R30Q variant in a large cohort of healthy
controls. This may influence study results and might explain, in part, the divergent replication
findings for the DLG5 gene. These findings furthermore stress the importance, in studying
complex traits, of a large control cohort that is well matched, including for sex and age.
The observed difference in allele frequencies between males en females could be due to
gender dependent selection during development, but further research is needed in order to
determine the role of the DLG5 R30Q variant in healthy subjects. Investigating the effect
of the genetic variants on the function and expression of the gene might help to clarify its
possible role in the development of IBD.
T1991
Clinical and Molecular Characteristics of Isolated Colonic Crohn’s Disease
(CD)
Laura Hancock, Tariq Ahmad, John B. Beckly, Bryan F. Warren, Neil J. Mortensen, Derek
P. Jewell
Background: Clinical, serological and molecular data support the existence of discrete subsets
of CD defined by location of disease. Little is known about the epidemiology and natural
history of isolated Crohn’s disease of the colon (Montreal Classification L2) because most
studies have not accurately distinguished L2 from L3 disease (ileo-caecal). Aims:1. To
describe the clinical features and natural history of isolated colonic CD in a rigorously
characterised patient cohort. 2. To confirm the association with HLA-DRB1*0103, reported
in smaller cohorts, and to investigate its role in predicting disease course and need for
surgery. Methods: Patients with L2 disease were identified from a database of 1318 CD
patients. Only patients with a normal small bowel enema (70%), ileoscopy alone (30%) or
both (20%) were included. No patients had capsule endoscopy. HLA genotyping was per-
formed using PCR-SSP. Results: 136 (10.3%) patients were classified with L2 disease after
a median follow-up of 10.8 years (range 1.4-39.8). The mean age at diagnosis was 30.7
years. L2 disease was more common in women (74.3% vs. 61.0%; P=0.001;RR=1.7) and
in never smokers (52.2% vs. 41.3%; P=0.007;RR=1.5). 29.4% and 14.0% reported a family
history (1st or 2nd degree) of CD and UC respectively. Stricturing colonic disease was noted
in 10% of patients. 12% of the entire cohort received ≥ 1 Infliximab infusion and 19%
underwent colonic resection for severe disease (cumulative risk at 2yrs - 10.6%, 5yrs -
17.1%, 10 yrs - 32.8%). We confirmed the association with HLA-DRB1*0103 (14.7% cases
vs. 2.7% controls;P=5.5x10-9; RR=3.2) and report the novel association of this allele with
time to first surgical event (Log Rank P=0.002) and time to first ‘severity event’ (resection/
diversion ileostomy/Infliximab) (P=0.001). Conclusions: This study reports the clinical
manifestations of isolated colonic CD. We confirm the association with HLA-DRB1*0103
and further demonstrate that this allele may predict disease course.
T1992
CARD15 Susceptibility and Pediatric Onset Crohn’s Disease (CD): Increased
Risk in Male Gender
Subra Kugathasan, Umesh Babusukumar, Tao Wang, Manu Sood, Erin McGuire, Ulrich
Broeckel
Gender difference in disease presentation and outcome is complex and needs thorough
evaluation in CD. The overall incidence and prevalence of CD among females exceeds that
of males. The US, Canadian and UK studies involving children have reported nearly a 2:1
male-to-female ratio in the incidence of pediatric onset CD, but not in ulcerative colitis
(UC). Recent genetic progress documents that nearly 40% of Caucasian CD children have
CARD15 mutations. We investigated the influence of gender on CARD15 by family based
association and case control models in our population based, pediatric onset inception IBD
cohort. Only Caucasian IBD was studied. 273 CD (172 trios), 98 UC (72 trios)& 479
controls were genotyped for CARD15 variants (R702W, G908R, 3020InsC). There were
162 male and 111 female CD children. The mean age of onset for males were 12.1 and
females 12 yrs. The allele frequencies of CARD15 markers were not significantly different
between males and females. TDT performed after stratified by gender of the probands,
showed a significant association for all 3 CARD15 markers with male CD, but not in female
CD children (table 1). A significant association was seen in both male and female CD children
compared with controls for CARD15 markers by case control analysis. However, a significant
gender effect was seen for CD susceptibility in males when a logistic regression was performed
adjusting for gender (table 2). In addition, a much stronger male gender effect for association
was seen when all 3 CARD15 markers were combined (p<0.0001). Kaplan Meier analysis
showed gender has no effect on the age of onset in children with CARD15. No differences
in genotype-phenotype correlations were seen between males and females in CD. CARD15
was not associated in UC by TDT and case-control. Conclusions: A strong gender effect in
the association of CARD15 and CD suggest that CD susceptibility to CARD15 is increased
in male children. This novel finding is only seen in children and needs further investigation
since several CARD15 studies involving adults did not report gender differences in CD.
TDT Analysis of 172 Families stratified by gender of the proband
Gender effects on CARD15 mutation by logistic regression
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T1993
NOD2/CARD15 Variants Are a Risk Factor for Lung Complications After Stem
Cell Transplantation (SCT)
Julia Brenmoehl, Gerhard Hildebrandt, Daniel Wolff, Bernd Hertenstein, Hildegard T.
Greinix, Christian Schulz, Anne M. Dickinson, Juergen Schoelmerich, Reinhard
Andreesen, Gerhard Rogler, Ernst Holler
Introduction: Recently our group has shown that NOD2/CARD15 variants (SNPs) not only
are a risk factor to develop Crohn’s disease but also play a major role for the outcome after
SCT. As NOD2/CARD15 is involved in the recognition of bacterial translocation which also
takes place in the lung we supposed that it could also play a role for lung diseases. Bronchiolitis
obliterans syndrome (BOS) is a life-threatening complication after allogeneic SCT with high
mortality. Risk factors and pathophysiology have yet to be defined. NOD2/CARD15 is
expressed not only in monocytes/macrophages and intestinal epithelial cells IEC but also
in bronchial epithelial cells. Methods and patients: The association of NOD2/CARD15 SNPs
(SNP 8, 12, 13) with the occurrence of BOS was investigated 244 donor/recipient (D/R)
pairs of patients receiving allogeneic SCT. Follow-up was performed for a mean of 1243
172 days (range: 327-2149). BOS was diagnosed by pathology or by functional airway
obstruction (FEV1</= 80% of predicted). Results: 12 patients developed BOS with a mean
time point of diagnosis at 678 112 days after SCT (range: 186-1407). NOD2/CARD15
variants were observed at higher frequencies in D/R pairs developing BOS (donor: 60.0%
vs. 12.9%, p=0.001; recipient: 50.0% vs. 15.0%; p=0.007). 50% of patients with BOS died
between day +327 and day +1582 (mean: 844 195), whereas 6 patients are still alive (mean
follow-up: 1642 170 days). Incidence of BOS rose from 1.7% (3/174) in D/R pairs without
mutated SNPs to 10.0% (6/60) in pairs with mutated alleles in either donor or recipient
(p=0.01) and to 30.0% (3/10) in pairs with mutated alleles in both donor and recipient (p=
0.009). Survival did not differ between patients with BOS in relation to the presence/
absence of NOD2/CARD15 mutations. Finally, we analyzed whether other transplant-related
parameters contributed to the incidence of BOS. Conditioning regimen intensity, stem cell
source, donor type (matched unrelated donor vs. HLA-identical sibling), recipient age, donor
or recipient gender, and acute GVHD were not associated with BOS development, whereas
chronic GVHD was confirmed as a risk factor for BOS (p=0.01). Conclusion: Variations in
the NOD2/CARD15 gene are not only associated with an increased risk to develop Crohn’s
disease and GvHD after SCT but also with the development of lung disorders such as BOS.
This indicates that either NOD2/CARD15 directly plays a role in the bronchial epithelial
cells or bacterial translocation in the gut is relevant for lung disease.
T1994
The Single Nucleotide Polymorphism C3435t in the MDR1 Gene Predicts the
Efficacy of Steroid Tapering in Inflammatory Bowel Disease
Konstantinos Katsanos, Marc Ferrante, Liesbet Henckaerts, Marie Pierik, Karolien Claes,
Nele van Schuerbeek, Marie Joossens, Sofie Joossens, Gert van Assche, Epameinondas V.
Tsianos, Paul Rutgeerts, Severine Vermeire
BACKGROUND: Steroids are ‘pumped out‘ of target cells by means of the P-glycoprotein
pump (P-gp), the product of the multi-drug resistance (MDR) gene. A significant correlation
between single nucleotide polymorphisms (SNPs) in the MDR1 gene and P-gp expression
and function has been reported. There are no studies investigating the effect of MDR1
variants on the response to steroids in inflammatory bowel disease (IBD). AIM: To investigate
the relationship between MDR1 variants and the ability of systemic steroid tapering in IBD
patients. PATIENTS-METHODS: The prevalence of the MDR1 SNPs G2677T/A (Ala893Ser/
Thr), and C3435T(Ile1145Ile) was investigated using PCR-RFLP in 167 IBD patients (104
Crohn’s disease, 63 ulcerative colitis) who were initiated on systemic steroids (1 mg/kg)
together with azathioprine. IBD patients were grouped as unable to taper steroids (group
1), able of partial steroid tapering [steroids remaining >50% of the initial dose] (group 2),
able of significant steroid tapering [maintenance steroids decreased to <50% of the initial
dose (group 3) and able of complete steroid tapering (group 4). RESULTS: Seventy-seven
patients (45.9%) were unable to taper steroids (group 1) while partial, significant and
complete steroid tapering was recorded in 28 (17%), 18 (11.2%) and 44 (25.9%) of patients
respectively. The patients in groups 3 and 4 had a significantly lower prevalence of the
MDR1-3435T mutated allele [p=0.027, OR 0.58 (95%CI 0.35-0.94)] compared to patients
in groups 1 and 2 (table). No significant differences in steroid tapering among the different
groups were noticed for the G2677T/A SNP. CONCLUSIONS: In IBD patients the C3435T
SNP in the MDR1 gene correlates with steroid tapering. We found that patients carrying
the MDR1 3435T allele were more resistant to steroid tapering, further underscoring that


















NO Association of Polymorphisms in the Pparg Gene Encoding for Peroxisome
Proliferator-Activated Receptor-γ (Pparγ) with Inflammatory Bowel Disease
Juergen Glas, Helga P. Torok, Laurian Tonenchi, Christian Markus, Martin Wetzke,
Stephan Brand, Peter Lohse, Wolfram Klein, Joerg T. Epplen, Uwe Schiemann, Thomas
Mussack, Thomas Ochsenkuehn, Matthias Folwaczny, Christian Folwaczny
Background: PPARγ is a member of the peroxisome proliferator-activated receptors (PPARs),
a superfamily of nuclear hormone receptors. PPARγ is considered to be anti-inflammatory
limiting NF-κB activation similar to NOD2/CARD15. Recently Pparg was identified as a
susceptibility gene in Crohn’s disease (CD) in a mouse and in a cohort-based study investiga-
ting three polymorphisms in the human PPARG gene (SNPs 1-3) significantly associations
with CD were detected. The PPARG gene maps to a IBD linkage region on chromosome
3p25. Herein SNPs 1-3 were assessed in an inflammatory bowel disease population and
additionally tested for potential interactions with CD associated mutations in NOD2/CARD15.
Aim: The present study sought to investigate whether polymorphisms of the PPARG gene
are associated with inflammatory bowel disease. Methods: The study population comprised
620 patients with CD, 368 patients with ulcerative colitis (UC) and 791 healthy, unrelated
controls. Genotyping of the three SNPs was performed by PCR and RFLP analysis. Statistical
analysis was performed employing χ2-test. Results: The allele frequencies of all three poly-
morphisms showed no significant differences between Crohn’s disease or ulcerative colitis
when compared to the control group (table 1). Moreover, no significant associations could be
found concerning genotype and phenotype frequencies. Moreover, no significant associations
were detected with respect to NOD2/CARD15 status in CD. Conclusion: Herein, polymorph-
isms within the PPARG gene displayed no significant associations with inflammatory bowel
disease an could not confirm the predescribed association with Crohn’s disease. It has to
be considered that the previously found association was observed in a relatively small group
of 134 CD patients. In conclusion, the present study could not give evidence for a role of
the PPARG gene in inflammatory bowel disease and also no evidence for interactions between
PPARG and NOD2/CARD15.
Allele frequencies of PPARG polymorphisms in Crohn’s disease and ulcerative colitis
T1996
The 1059g/C Polymorphism in the Crp Gene Is Associated with Involvement
of the Terminal Ileum in Patients with Crohn’s Disease
Dominik Thalmaier, Julia Dambacher, Astrid Konrad, Veronika Schachinger, Simone
Pfennig, Fabian Schnitzler, Tanja Staudinger, Katrin Hofbauer, Jan-Michel Otte, Julia
Seiderer, Cornelia Tillack, Burkhard Goeke, Thomas Ochsenkuehn, Peter Lohse, Stephan
Brand
Background: The level of C-reactive protein (CRP) is used to evaluate inflammatory activity
in Crohn’s disease (CD). Recently, a single nucleotide polymorphism (SNP) in exon 2 of
the CRP gene (1059G/C) has been reported. Aims: Our aim was to analyze the influence
of this CRP polymorphism on CD phenotype. Methods: Using restriction fragment length
polymorphism analysis, genomic DNA from 223 patients with CD and from 199 unrelated
controls was analyzed for the 1059G/C substitution in the CRP gene. Disease phenotypes
were classified according to the Vienna classification of CD (Inflamm Bowel Dis 2000;6:8-
15). Results: No difference was observed in the genotype frequencies between CD patients
and the control group, although homozygous C/C carriers were detected only among CD
patients (p=0.13). In the CD group, 90.1% were wildtype G/G, 8.1% heterozygous G/C,
and 1.8% homozygous C/C. In the control population, no homozygous C/C carriers were
detected and 6.6% were G/C heterozygotes, while 93.4% had two wildtype alleles. However,
while only 117 of 201 patients with the wildtype G/G genotype (58.2%) had an involvement
of the terminal ileum, the terminal ileum was affected in 17 of 18 (94.4%) of the heterozygous
G/C carriers (p=0.002). Similar genotype frequencies were observed for the 1007fs CARD15
mutation, for which we demonstrated ileal involvement, in wildtype (17.6%) and heterozyg-
ous carriers (16.7%) suggesting that the observed association between the 1059 G/C poly-
morphism and ileal disease location is independent of the CARD15 1007fs mutant. Consistent
with this finding was the observation, that none of the G/C heterozygotes had disease
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involvement restricted to the colon only (L2 phenotype according to the Vienna classification),
while the L2 phenotype was found in 21.4% of patients with two G alleles (p=0.027).
Moreover, while only 2 of 22 heterozygous and homozygous carriers of the C allele (9.1%)
were diagnosed of a stricturing disease phenotype according to the Vienna classification,
68.2% of the hetero- and homozygotes had a penetrating phenotype as compared to 53.2%
patients with a penetrating phenotype and 27.9% with a stricturing phenotype in the
group with the G/G genotype (p=0.06). Conclusions: Heterozygosity for the CRP 1059G/C
polymorphism is associated with disease involvement of the terminal ileum and a tendency
to develop the more severe penetrating disease phenotype. Homozygous C/C carriers were
found only in the CD group. Given the overall low frequency of the homozygous C/C
genotype, larger trials are necessary to evaluate if homozygosity for the C allele is associated
with CD.
T1997
MDR1 As a Susceptibility Gene in Inflammatory Bowel Disease: Results of a
Large Case-Control and Family-Based Analysis
Korinne Bradley, Alissa Walsh, Beth Fowler, Susan Mason, Douglas Lincoln, Rebecca I.
Cooley, Graham L. Radford-Smith
Background: The MDR1 gene located at 7q22 has been implicated as a susceptibility gene
for ulcerative colitis (UC) and Crohn’s disease (CD). Results of 5 studies (5 case-control, 1
pedigree) are conflicting. The gene codes for P-glycoprotein 170, an efflux transporter pump
expressed on epithelial cells and lymphocytes. A murine knockout develops UC-like disease
while overexpression has been associated with treatment resistance in IBD patients1. At least
two functional SNPs have been identified, C3435T and G2677T/A. Aims: To establish
whether MDR1 C3435T and G2677T/A contribute to IBD susceptibility using both case-
control and family based approaches. To perform genotype-phenotype analysis if association
is demonstrated. Methods: A population-based cohort of 1044 IBD patients were recruited
for this study from the North Brisbane region. Population controls (405) were drawn from
the same geographical region and matched for sex and ethnicity. Phenotyping was based
upon original records of clinical history, histology, and radiology and confirmed by patients.
Genotyping was performed by PCR-RFLP and results confirmed by sequencing in 10% of
samples. Results: Analysis by genotype revealed significant differences in C3435T for UC
(P<0.001) and CD (P=0.04) compared to controls. An allele association analysis demonstrated
significance for CD (p=0.02) but not for UC. The results for G2677T/A were not significant.
A transmission disequilibrium test (TDT) using 89 UC trios and 120 CD trios for analysis
of the C3425T SNP did not reach significance either for UC (p=0.26) or for CD (p=0.62).
Phenotype-genotype analysis was based upon 398 UC patients and 450 CD patients. The
UC data demonstrated significant differences in C3435T genotype between patients suffering
acute severe colitis, strictly based on the Truelove-Witts criteria, and those with no history
of this complication (p=0.006). This was based on a higher CC and lower TT carriage rate
by those with severe disease. Colectomy for either acute, severe disease or chronic refractory
disease did not show significant association with genotype (p=0.13). There were no significant
findings for CD. Conclusions: This large case-control study supports association between
the C3435T MDR1 SNP and UC but this is not confirmed by our TDT analysis. This may
be due to lack of power in the latter. Phenotype-genotype analysis supports a possible role
for increased MDR1 expression in patients with severe disease. The issue of population
stratification may have been underestimated for this gene, and a larger consortium-based
investigation would be appropriate to address this. 1Farrell et al. Gastroenterol 2000
Feb;118(2):279-88.
T1998
Is There Any Difference in Phenotypes Between Familial and Sporadic Cases
of Inflammatory Bowel Disease? Results from a Population Based, Follow-Up
Study
Magne Henriksen, Jorgen Jahnsen, Idar Lygren, Morten H. Vatn, Bjorn Moum
Background: The risk of inflammatory bowel disease (IBD) in family members of patients
with ulcerative colitis (UC) and Crohn`s disease (CD) is increased. If phenotypes in familial
clustering differ from sporadic cases is not clear. However, there are few data from population
based, follow-up studies. Aim: To compare phenotypes in familial IBD with sporadic IBD
at diagnosis and after five years of follow-up. Methods: All patients (n = 843) diagnosed
with IBD in four different counties in southern Norway in the period 1990 - 94 were
followed prospectively (the IBSEN cohort). Diagnosis were re-evaluated after one and five
years of follow-up. CD patients were retrospectively classified according to the Vienna
classification at diagnosis and after five years. The extent of inflammation at diagnosis and
the maximal extent of disease during the follow-up period was recorded for UC patients.
Results: After five years of follow-up 454 patients with UC and 200 patients with CD were
alive and had data sufficient for analysis. At diagnosis 7,5 % of the patients had a first degree
relative with IBD increasing to 11,5 % after five years (10,1 % of UC patients and 14,5 %
of CD patients). CD patients with familial IBD were younger at diagnosis compared to
sporadic cases (mean age 26,9 vs 34,1 median age 25,0 vs 29,0 p = 0.03). This difference
in mean age was only seen in patients with colonic CD. No difference in age was observed
between UC patients with familial IBD compared to sporadic cases (mean age 41,4 vs 39,9
p = 0.6). In CD patients no difference in localisation or behaviour was observed at diagnosis
(p = 0.1 and p = 0.7) or after five years of follow-up (p = 0.3 and p = 0.4). In UC patients
no difference in extent was observed at diagnosis or after five years (p = 0.2 and p = 0.5).
Conclusions: CD patients with a family history of IBD and colonic involvement was younger
at diagnosis compared to sporadic cases. In CD patients no difference in localisation or
behaviour was observed between familial and sporadic cases. Furthermore, in UC patients
no difference in extent was observed between familial and sporadic IBD.
T1999
Na Transporters NHE3 and Na/K-ATPase, NHE3-Regulatory Factor1
(NHERF1) and the Intracellular Chloride Channel Clc5 Are Down Regulated
in IBD: Probable Contribution to IBD Diarrhea
Xuhang Li, Sean Sullivan, Mark Donowitz, Themos Dassopoulos, Steve Brant, Carmen
Cuffari, Yueping Chen
Diarrhea is one of most common symptoms in IBD. Decreases in Na absorption appear to
be the major electrolyte transport change in IBD based on mouse intestinal studies. To
increase understanding of intestinal Na absorption in IBD, we tested the hypothesis that
inhibition of Na absorption was due to changes in expression of intestinal Na transport
proteins. The expression of multiple intestinal Na transporters were examined, including
Na/H exchanger 3 (NHE3) and Na/K-ATPase, as well as the NHE3 regulatory protein
NHERF1 and an intracellular Cl channel important for trafficking, ClC5 . Studies examined
55 intestinal biopsies from 40 patients [43 sigmoid biopsies (12 normal, 13 UC active, 10
CD active, 5 UC and 3 CD inactive/unaffected) and 12 ileal biopsies (4 normal, 8 active
CD)]. Analysis was done by SDS-PAGE and Western blotting, using GAPDH as a loading
control. In 80% of biopsies from active UC and CD (sigmoid and ileal biopsies), NHE3 was
down regulated. In addition, NHE3 was down-regulated, although to a less extent in 50%
of sigmoid biopsies from inactive IBD. There was usually a coordinated down-regulation of
multiple ion transporters, including NHE3, Na-K-ATPase, and ClC5 in biopsies from active
CD or UC, although the change in Na-K-ATPase and ClC5 were less dramatic than that of
NHE3. NHERF1, an NHE3 regulatory factor, was also down regulated in mucosa of most
active CD or UC (>80%). In summary, (1) Na transport proteins, NHE3 and Na-K-ATPase
as well as proteins involved in regulation of trafficking, ClC5, and in regulation of NHE3
function, NHERF1, are usually down-regulated in IBD. (2) The down regulation occurs
more in the areas of active disease, but is also present in areas without active disease,
suggesting systemic mechanisms. We conclude (1) The diarrhea of IBD is due to decreased
Na absorption with the mechanisms including decreased expression of Na transport proteins,
including at least NHE3 and Na-K-ATPase, and of the proteins that are involved in NHE3
regulation (NHERF1 and ClC5). (2) In considering mechanisms for this coordinated regula-
tion, common transcriptional elements or mechanisms of message stability that respond to
inflammatory mediators of IBD should be considered.
T2000
Is There a Crosstalk Between DLG5 R30q and NOD2/CARD15 Or TLR4
Mutations in Hungarian Patients with Crohn’s Disease? Phenotype-Genotype
Correlations
Peter L. Lakatos, Karolien Claes, Tamas Molnar, Simon Fischer, Agota Kovacs, Istvan
Altorjay, Claudia Willheim-Polli, Zsolt Tulassay, Ferenc Szalay, Janos Papp, Hungarian
LBD Study Group, Paul Rutgeerts, Peter Ferenci, Severine Vermeire, Laszlo Lakatos
AIM: Mutations of NOD2/CARD15 gene predispose for Crohn disease (CD) and are associated
with fibrostenosing behavior and recent data from Germany have suggested that specific
haplotypic variants of the DLG5 gene on chromosome 10q23 may be associated with
susceptibility to inflammatory bowel disease (IBD). In this study, we investigated possible
associations between common NOD2/CARD15 mutations, D299G TLR4 polymorphism and
the carriage of DLG R30Q risk allele in Hungarian CD patients. METHODS: 475 unrelated
patients with CD (m/f: 265/262, age: 37.1±D12.6 years, duration: 8.4±7.0 years) and 150
healthy subjects were included. DNA was screened for possible NOD2/CARD15 mutations
(SNP8, SNP12 and SNP13) by denaturing-HPLC and if found mutations were confirmed
by direct sequencing. TLR4 D299G and DLG5 R30Q were tested by PCR-RFLP. Clinical
phenotypes - familial disease, age, age-at-onset, duration, location, disease behavior, perianal
involvement, extraintestinal manifestations (arthritis, PSC, ocular and cutaneous), need for
steroid or azathioprine, steroid resistance, need for surgery or multiple resections and
smoking habits - were determined by questionnaire. Comparisons between groups were
made by χ2 test using SPSS13.0 software. RESULTS: 20.8% of CD patients were carriers
of the 113A variant DLG5 allele compared to 28.0% of 150 healthy controls, associated
with a tendency with decreased frequency for the 113A allele (OR: 0.677, 95%CI: 0.44-
1.03, p=0.07). Similarly, TLR4 variant allele frequency was not different between patients
and controls (10.1% vs. 12.6%) and only carriage of variant NOD2 allele was identified to
confer risk (32.2% vs. 12.6%, OR: 3.3, 95%CI: 1.9-5.5). There were no associations between
DLG5, NOD2 and/or TLR4 in determining clinical phenotypes. In addition, solely carriage
of variant NOD2 allele but not variant DLG5 or TLR4 allele were associated with disease
location, behavior and increased risk for surgery in a logistic regression model. CONCLU-
SION: These results confirm in large cohorts of Hungarian CD patients the association of
variant NOD2 alleles with disease susceptibility, ileal disease, stricturing disease behavior
and risk for surgery. In contrast, presence of DLG5 R30Q or TLR4 D299G variant alleles
was not different from controls as well as no associations were found between the carriage
of these variants, NOD2 mutations and/or disease phenotype.
T2001
Mica and Micb Microsatellite Polymorphisms Are Associated with Ulcerative
Colitis in Chinese Patients
Bing Xia, Min Lv, Jin Li, Mei Ye, Zhengguo Hu
Aims The human MHC class I chain-related gene A and B (MICA and MICB) play a role
in regulating protective responses by intestinal epithelial Vδ1 γδ T cells and the polymorph-
isms of MICA and MICB have shown to be related to several autoimmune diseases. The
present study was aimed to investigate the association of the microsatellite polymorphisms
in the exon 5 of MICA and in the intron 1 of MICB with the susceptibility to ulcerative
colitis (UC) in Chinese population. Methods The microsatellite polymorphisms of the MICA
and MICB were genotyped in unrelated 127 Chinese patients with UC and 193 ethnically
matched healthy controls by a semiautomatic fluorenscently labeled PCR method. All the
subjects were the Chinese Han origins. Results The frequency of MICA-A5.1 allele (29.0%
vs. 17.4%, P=0.0010, Pc=0.0050, OR=1.936, 95%CI: 1.310-2.863), MICB-CA18 allele
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(14.0% vs. 5.8%, P=0.0016, Pc=0.024, OR=2.637, 95%CI: 1.443-4.820.) and MICA-A5.1/
A5.1 homozygous genotype (18.5% vs. 7.0%, P=0.0032, Pc=0.048, OR=3.036, 95%CI:
1.447-6.372) were significantly increased in UC patients compared with healthy controls.
And logistic regression analysis adjusted the effects of gender and age at onset confirmed
our results. Moreover MICB-CA18 allele was significantly increased in frequency in the
female UC patients compared with the female healthy controls (18.3% vs. 4.1%, P=0.0006,
Pc=0.0080, OR=5.224, 95%CI: 1.940~14.069). The comparison between MICA and MICB
alleles and the subgroups of UC according to the extent of disease and extraintestinal
manifestations were not shown any association. MICB-CA18 was significantly in linkage
disequilibrium with MICA-A5.1 although the MICA-A5.1/MICB-CA18 haplotype was not
associated with UC after Bonferroni multiple correction. No MICA-MICB haplotypes were
displayed significant differences between UC or UC subgroups and the healthy controls.
Conclusions The MICA-A5.1 allele, MICA-A5.1 homozygous genotype and MICB-CA18
allele were significantly associated with UC in Chinese population, but MICA and MICB
haplotypes have not shown these significant associations.
T2002
Mdr1, Runx3 and TGFβRii Pathways Implicated in Human IBD
Laura E. Harrell, Emily C. Baechler, Timothy W. Behrens, Sam M. Bracamonte, Betul
Yilmaz, Judy H. Cho
“Background:” There are numerous experimental mouse models where induced deficiencies
in host genes result in inflammatory bowel disease (IBD), but the relevance of corresponding
pathways in human IBD is incompletely defined. It would be anticipated that pathogenic
heterogeneity affecting different pathways would exist between individuals with IBD. Limited
numbers of expression microarray studies from intestine have been reported implicating
various impaired pathways in IBD, notably the pregnane X receptor (PXR) transcription
factor pathway involved in xenobiotic responses and MDR1 transcription. We sought to
define the most differentially regulated transcripts from peripheral blood leukocytes (PBL)
from individuals with active Crohn’s disease (CD) compared to controls in order to identify
transcripts also implicated in experimental mouse models. “Methods:” Nine patients with
a history of CD and a Harvey-Bradshaw CDAI score of ≥ 5 and 8 healthy controls were
examined. RNA was extracted from whole blood and hybridized to Affymetrix U133 2.0+
GeneChips. Microarray data files were processed using GeneData Expressionist Refiner 1.0
Pro. Patients and controls were compared using the following criteria: i) p-value < 0.001
from an unpaired student’s t-test, ii) fold change (FC) > 1.5 in expression between control-
mean and patient mean, and iii) absolute difference in expression > 100 between the means
of the two groups. “Results:” Comparing CD to controls, 299 differentially expressed genes
(200 down-regulated, 99 up-regulated) were identified. Among down-regulated transcripts,
three genes were identified for which targeted deficiency in mice result in IBD; RUNX3,
MDR1, TGFβRII transcripts demonstrated -3.1, -2.1 and -1.7 fold decreased expression,
respectively. Some heterogeneity in down-regulation of these transcripts was observed, but
overall, down-regulation of these transcripts was very consistently observed in all CD patients.
Down-regulation of PXR induced genes was not a general feature in CD, being observed
only with MDR1 and fatty acid synthase, among 14 expressed transcripts known to be
induced by PXR. RUNX3 is an integral downstream component of TGFβ signaling. “Conclu-
sion:” These data implicate the RUNX3, TGFβRII and MDR1 genes and pathways in the
pathogenesis of human IBD, corroborating findings from murine models. We observe a
TGFβ-RUNX3 signature in PBLs from patients with active CD. In addition, the present
differences in PXR pathway regulation from previously reported intestinal microarray studies
may reflect context-specific features, but further implicate MDR1 deficiency in human IBD.
T2003
Detection of Novel CARD15 Mutations in IBD Patients with a Severe Disease
Phenotype
Fabian Schnitzler, Stephan Brand, Tanja Staudinger, Simone Pfennig, Katrin Hofbauer,
Julia Seiderer, Cornelia Tillack, Burkhard Goeke, Thomas Ochsenkuehn, Peter Lohse
Background: CARD15/NOD2 encodes a protein involved in the intracellular recognition of
muramyldipeptide, a component of bacterial peptidoglycans. Three mutations in the CARD15
gene (c.2104C>T [p.R702W], c.2722G>C [p.G908R], and c.3019_3020insC [p.Le-
u1007fsX1008]) have been found to be associated with Crohn’s disease (CD). Aims: We
performed a limited DNA sequence analysis in patients with inflammatory bowel disease
(IBD) to identify additional mutations in the CARD15 gene. Methods: 89 patients with
Crohn’s disease (CD), 19 patients with ulcerative colitis (UC), and three patients with
indeterminate colitis (IC), who were heterozygous carriers of one of the common CARD15
mutations (c.2104C>T [p.R702W], c.2722G>C [p.G908R], or c.3019_3020insC [p.Le-
u1007fsX1008]), of a new amino acid substitution encoded by the 3'-end of exon 4, or of
the c.2462+10A>C variant in intron 4, were included in this study. In these patients, exons
4, 5, 6, 8, and 11 of the CARD15 gene were amplified by PCR and completely sequenced,
thereby theoretically covering 73.9% of the described CARD15 variants and 96.6% of the
mutated alleles. Results: Using this approach, eight novel amino acid substitutions
(c.1171C>T [p.R391C], c.1387C>G [p.P463A], c.2138G>A [p.R713H], c.2278C>T
[p.R760C], c.2368C>T [p.R790W], c.2371C>T [p.R791W], c.2475C>G [p.N825K], and
c.2546C>T [p.A849V]) were detected in six CD, two IC, and one UC patient. Five of these
amino acid replacements (p.R391C, p.R713H, p.R760C, p.R790W, and p.R791W) are most
likely true mutations considering Dayhoff’s calculations (Atlas Protein Seq Struct 1979;
5:345-52) and the observed disease phenotype, while the p.P463A variant appears to be a
polymorphism (frequency of exchange 29%). The two remaining variants p.N825K and
p.A849V with replacement frequencies of 14% and 10% have to be analyzed in functional
tests in order to determine whether these substitutions are polymorphisms or true mutations.
A severe disease phenotype was observed especially in those patients compound heterozygous
for a common and a novel CARD15 mutation. Conclusion: This study identified eight novel
CARD15 variants. Compound heterozygosity for one of these variants in combination with
one of the three common CARD15 mutations ([p.R702W],[p.G908R], and [p.Le-
u1007fsX1008]) was associated with a severe disease phenotype. Complete sequence analysis

















detect additional mutations in severely affected IBD patients with only one or none of the
common mutations.
T2004
Single Nucleotide Polymorphisms of the Mdr1 Gene in Inflammatory Bowel
Disease
Konstantinos Katsanos, Marc Ferrante, Karolien Claes, Nele van Schuerbeek, Marie Pierik,
Liesbet Henckaerts, Marie Joossens, Sofie Joossens, Gert van Assche, Epameinondas V.
Tsianos, Paul Rutgeerts, Severine Vermeire
BACKGROUND: There is conflicting data in the literature whether the multidrug resistance
1 (MDR1) gene by its product P-glycoprotein (P-gp) is implicated in susceptibility to inflam-
matory bowel disease (IBD). Current data suggest a role for the MDR1-C3435T variant in
the susceptibility to ulcerative colitis (UC). We studied functional variants in MDR1 in a
large cohort of IBD patients and healthy controls to look for association with the disease
and with disease-phenotypes. METHODS: In total 837 IBD patients (716 CD, 121 UC) and
383 healthy subjects from the same tertiary referral center were genotyped for MDR1-
G2677T/A (Ala893Ser/Thr) and C3435T (Ile1145Ile)] using PCR-RFLP. RESULTS: A signific-
antly lower prevalence of the MDR1-3435 T allele was found in CD patients (51%) comparing
to controls (58%) [p=0.004] while no association was observed in UC (54%). Multivariate
regression analysis in the CD patients showed that if the MDR1-3435T variant was present,
this was associated with fistulising Crohn’s disease (OR 1.84; 95% CI 0.98-3.5; p=0.058).
No significant differences between IBD, CD or UC patients and healthy subjects were noticed
for the G2677T/A SNPs. CONCLUSIONS: In this large IBD cohort, we show for the first
time an association of the MDR1-C3435T variant with susceptibility to CD. Although we
could not confirm an association with UC, a modest effect of MDR variants cannot be
excluded as our UC sample was relatively small. MDR1 mutations may be associated with
IBD susceptibility by disregulating the expression and functionality of the P-gp.
T2005
Multiple Genetic Testing to Explain Intolerance to Azathioprine
Orazio Palmieri, Anna Latiano, Fabrizio Bossa, Maria Rosa Valvano, Maurizio Vecchi,
Renata D'Inca', Renzo Caprilli, Francesco Tonelli, Salvatore Cucchiara, Angelo Andriulli,
Vito Annese
Background: Adverse drug reactions (ADRs) to azathioprine (AZA) may lead to therapy
interruption in up to one quarter of patients with inflammatory bowel disease (IBD). The
TPMT gene polymorphisms explain only the minority of cases of bone marrow toxicity
(BMT) and ADRs. Aim: The present study was undertaken to correlate the polymorphisms
of TMPT but also ITPA gene with AZA toxicity in Italian patients with Crohn’s disease (CD)
and ulcerative colitis (UC). Methods: 424 patients and 245 healthy controls were included
and genotyped for three polymorphisms (G460A/Ala154Thr and A719G/Tyr240Cys of the
TMPT gene, and C94A of the ITPA gene), by sequencing (ABI 310) or RFLP-PCR, respectively.
249 patients had CD (134 males, mean age 35 ± 14 yrs), while 175 had UC (94 males,
mean age 43.5 ± 15 yrs). 79 episodes of ADRs were reported in 69 patients: 20 cases of
BMT, 12 of abnormal liver transaminases, 16 of pancreatitis, 4 of skin reactions, 9 of nausea/
vomiting, 18 of fever/myalgias. Results: Main frequencies of risk haplotype (TPMT3*A, 3*B)
and genotype (ITPA CA) are given in the table. The frequency of the TPMT risk haplotype
(TPMT3*A,3*B) was similar in IBD patients (5.6%), and controls (3.2%). In contrast, the
risk haplotype was significantly increased in the whole group of patients with ADRs (13%,
p=0.001), and especially in patients with BMT (30%, p= 0.00001). More specifically the
risk haplotype was found in 9 out of 69 patients with ADRs and 6 out of 20 episodes of
BMT. No significant association of the allele and genotype frequencies of C94A polymorphism
of ITPA gene was found in the ADRs group (17.4%) compared to patients without ADRs
(13%), or healthy controls (12%). However, the ITPA risk genotype was found in 5 out of
20 episodes of BMT and 12 out of 69 patients with ADRs. Only one patient with severe
BMT had both TPMT risk haplotype and ITPA risk allele. Conclusions: The combined genetic
testing of TMPT and ITPA genes, enhanced the correlation between genotype and phenotype;
20/69 cases of ADRs, and more importantly 10/20 cases of BMT were explained. While the
positive predictive value was only 23%, the negative predictive value of both genetic tests
reached the 85%.
T2006
14 bp Deletion Polymorphism in the HLA-G Gene in Inflammatory Bowel
Disease
Juergen Glas, Helga P. Torok, Laurian Tonenchi, Molla Yirsaw Teshome, Martin Wetzke,
Wolfram Klein, Joerg T. Epplen, Uwe Schiemann, Thomas Mussack, Matthias Folwaczny,
Christian Folwaczny
Background: HLA-G is a non-classical major compatibility complex (HLA) class I molecule
highly expressed in cytotrophoblast. HLA-G supresses immune reactions mediated by T
cells, natural killer cells and dendritic cells. A recent study found an increased expression
of HLA-G in ulcerative colitis (UC), but not in Crohn’s disease (CD) (1). Thus, HLA-G
potentially is implicated in the pathogenesis of inflammatory bowel disease and is therefore
a functional and also a positional candidate gene for inflammatory bowel disease, as it is
localized in the linkage region IBD3. Within the HLA-G gene several polymorphisms have
been described, in exon 8 encoding for the 3' untranslated region a 14 bp deletion polymorph-
ism has been found (2). This polymorphism influences the mRNA stability und is of potential
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functional relevance (3). Herein, the 14 bp deletion polymorphism was assessed in a popula-
tion of inflammatory bowel disease patients and additionally tested for potential interactions
with CD associated mutations in NOD2/CARD15. Aim: The present study sought to investig-
ate whether the 14 bp deletion polymorphism within the HLA-G gene is associated with
inflammatory bowel disease. Methods: The study population comprised 359 patients with
CD, 253 patients with ulcerative colitis (UC) and 731 healthy, unrelated controls. Genotyping
was performed by PCR and agarose gel electrophoresis. Statistical analysis was performed
employing χ2-test. Results: The allele frequency of the 14 bp deletion polymorphism (Del
+) in the HLA-G gene displayed no significant differences between Crohn’s disease or
ulcerative colitis when compared to the control group. Moreover, no significant associations
were found concerning genotype and phenotype frequencies and also no significant associ-
ations were assessed with respect to NOD2/CARD15 status. Conclusion: Herein, the 14
bp deletion polymorphism within the gene encoding for HLA-G displayed no significant
associations with inflammatory bowel disease. The study could not give evidence for a role
of the HLA-G gene in inflammatory bowel disease and also no evidence for interactions
between HLA-G and NOD2/CARD15. However, as there are several partly functional poly-
morphisms within the promotor region potentially influencing expression of the HLA-G
gene and the differences of HLA-G expression between UC and CD could be influenced by
these polymorphisms.
Allele frequencies of the 14 bp deletion polymorphism in the HLA-G gene
T2007
Association of CARD15 Variants with Clinical Subtypes of Crohn’s Disease: A
Study of 630 Cases
Clive Onnie, Sheila Fisher, Alastair Forbes, Jeremy Sanderson, Cathryn Lewis,
Christopher Mathew
Introduction: The association of three common sequence variants in the CARD15 gene with
susceptibility to Crohn’s Disease (CD) is well established. Several studies have reported an
association of these variants with ileal disease location and complicated disease behaviour.
We have examined the relationship of the CARD15 variants with CD in one of the largest
cohorts of CD cases with detailed phenotype data collected to date. Methods: A total of 630
CD cases from two referral centers in London, UK were carefully phenotyped according
to the Vienna Classification with some modifications recently suggested by the World
Gastroenterology Congress. Details on drug history, histopathology, age at disease onset as
well as a detailed surgical history were recorded. CARD15 genotyping was performed by
TaqMan (ABI) (G908R) and pyrosequencing (R702W, L1007fs). Allele frequencies between
cases and 314 healthy controls were compared using chi-squared tests. Cases were analysed
using multinomial logistic regression, modeling CARD15 genotype on clinical factors of
disease. Results: All three CARD15 variants were significantly associated with CD with a
combined frequency of 21.3% in cases compared with 7.9% in controls (p=8x10-13); 33.8%
of cases carried at least one CARD15 variant. CARD15 genotype was significantly associated
with ileal disease (p=1.7x10-6) and stricturing disease behaviour (p=0.001). However, the
association with stricturing disease was not significant when adjusted for site of disease. A
significant association of CARD15 variants was also observed with age at diagnosis (p=0.001),
surgery (p=0.003), recurrent small bowel resection (p=0.03) and granulomas (p=0.0006),
which remained significant (p=0.003) when adjusted for presence of resectional bowel
surgery with full histopathology details. Conclusions: We have replicated the finding that
CARD15 variants predispose to ileal disease and have demonstrated a novel association of
CARD15 with the presence of granulomas. Carriage of CARD15 variants appears to predict
aggressive disease, with not only the need for surgery but also recurrent small bowel resection.
We propose that knowledge of CARD15 variant status in patients with small bowel CD
could be helpful in disease management and may lead to a more aggressive clinical approach.
T2008
Association Between NOD2/CARD15 Gene Variants and Response to
Antibiotics in Perianal Fistulizing Crohn’s Disease
Sieglinde Angelberger, Matthias Schwab, Clemens Dejaco, Thomas Waldhoer, Cornelia
Lichtenberger, Marieluise Harrer, Elke Schaeffeler, Harald Vogelsang, Walter Reinisch
Background: NOD2/CARD15 gene variants have been associated with susceptibility to
Crohn’s disease (CD). NOD2/CARD15 is involved in the immune system’s response to
bacteria by recognizing a specific peptidoglycan motif, muramyl dipeptide, and subsequent
activating NF-κB. Antibiotics are the first line strategy for perianal penetrating CD owing
to their antibacterial activity. Aim: This study aimed to explore an association of NOD2/
CARD15 gene variants and clinical response of perianal fistulas to antibiotic treatment.
Methods: 52 patients (f/m:24/28; median age:36) with draining perianal fistulas were treated
with ciprofloxacin (500-1000mg/day, n=49) or metronidazole (1000-2000mg/day, n=3) for
a median duration of 7 weeks. According to the Fistula Drainage Assessment complete
response was defined as fistula closure or the absence of any draining fistulas despite gentle
finger compression. Genotyping of the main coding mutations of CARD15/NOD2, denoted
SNP 8, 12 and 13, was conducted by TaqMan analysis (Applied Biosystems, Foster City,
CA, USA). Laboratory personnel were blinded to case status of the participants. Results:
Ciprofloxacin was discontinued in 1 patient due to diarrhea after 2 weeks.13 patients showed
complete response to antibiotic therapy, whereas 39 were rated as non- or partial-responders.
At least one mutation in NOD2/CARD15 gene was detectable in none of the responders,
but in 12/38 (31.6%) of non- or partial responders (p=0.01). Conclusion: Our preliminary
data suggest a pharmacogenetic significance of NOD2/CARD15 in the treatment of CD for
the first time. NOD2/CARD15 wildtype seems to be relevant for efficacy of antibiotic treatment
against bacterial flora in perianal fistulas.
NOD2/CARD15 Genotype and Frequency of NOD2/CARD15 Allelic Variants
Non-/partial responder vs. Responder *p=0.06, **p=0.006
T2009
Evaluation of Slc22a4 and Slc22a5 Ibd5 Locus Functional Variants in African
American IBD Patients and Controls
Toshihiko Okazaki, Howard A. Kader, Kim L. Isaacs, Duane T. Smoot, James D. Lewis,
Jerrold Canakis, Mary L. Harris, Themistocles Dassopoulos, Judy H. Cho, Yin Y. Shugart,
Steven Brant, Niddk IBD Genetics Consortium
BACKGROUND: Inflammatory bowel disease (IBD) is a complex genetic disorder. Genetic
associations have been observed for IBD, Crohn’s disease (CD) and/or ulcerative colitis (UC)
for CARD15 mutations (CD), HLA polymorphisms (CD and UC), and the chromosome 5q
IBD5 risk haplotype (CD) in white populations. Although African American IBD prevalence
is only modestly lower than white prevalence, IBD genetic research is only now being
initiated in African American cohorts. METHODS: In collaboration with the NIDDK IBD
Genetics Consortium, following informed consent, African American patients with confirmed
IBD and matched healthy controls (HC) were recruited for genetic investigations. Additional
similarly consented cases were previously recruited from University of Chicago and Duke
University. We genotyped the SLC22A4 (OCTN1) L503F and SLC22A5 (OCTN2) G-207C
polymorphisms (leading functional candidate variants for the IBD5 locus in white popula-
tions) by TaqMan for L503F and direct sequencing for G-207C. Allele and genotype frequen-
cies were compared by ChiSquare analysis (STATA version 8.0). RESULTS: 165 CD, 43 UC
and 56 HC were genotyped. Similar to that observed in white populations, the 503F and -
207C alleles were increased in CD cases as compared to controls (Table). UC showed similar
trends but was did not reach statistical significance. Carrier frequency of risk alleles in CD
vs. HC did not reach significance (503F 19.6% vs. 9.3%, p = 0.08; -207C 66.2% vs. 55.6%,
p = 0.16). Linkage disequilibrium between these two markers was markedly lower in African
Americans as compared to whites (r2 African American controls, 0.11; r2 NIDDK Consortium
white parental controls, 0.73). CONCLUSIONS: IBD5 functional variants of SLC22A4 and
A5 show borderline association with CD in African Americans. The greatly reduced linkage
disequilibrium in the African American population for these two markers suggests that
additional genotyping of the IBD5 locus in this population may allow separation of causative
risk variants from the background haplotype that is also associated. We are presently
expanding our African American cohort of IBD cases and controls and will pursue genotyping
of markers throughout the IBD5 candidate region.
T2010
Mthfr, Mtr, Mtrr and Tcn Polymorphisms and Homocysteine in a French
Population with Inflammatory Bowel Disease
Laurent Peyrin-Biroulet, Rosa-Maria Gueant-Rodriguez, Jean-Pierre Bronowicki, Marc-
Andre Bigard, Jean-Louis Gueant
Background: Mild hyperhomocysteinemia is commonly associated with inflammatory bowel
disease (IBD). However, the association of 5,10-methylenetetrahydrofolate reductase poly-
morphisms (MTHFR C677T and A1298C) with either homocysteine level or IBD remains
controversial. Furthermore, the influence of methionine synthase (MTR A2756G and MTRR
A66G) and transcobalamin (TCN C776G) polymorphisms has never been evaluated in IBD.
Methods: A study was carried out on a total of 121 IBD patients, including 111 cases of
Crohn’s disease and 10 cases of ulcerative colitis patients, compared to 100 healthy volunteers
from a Center of Preventive Medicine. Results: The mean age of IBD patients was 35.2 ±
14.8 years and the sex ratio 4:1 (F:M). Plasma homocysteine level (Hcys) was higher in IBD
patients than in controls (median 11.8 vs 10.4 µmol/L; p=0.0004). The folate and vitamin
B12 levels were significantly lower in IBD patients than in controls (8.6 vs 11.0 ng/mL; p =
0.0036, and 207 vs 255 pmol/L; p = 0.0082, respectively). In multiple linear regression
analysis, age (p=0.0337), folate (p=0.0101) and vitamin B12 (p=0.012) were independently
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associated with homocysteine in IBD patients. Hcys was higher in carriers of MTHFR 677TT
genotype than in CC and CT genotypes (p=0.0207) while a trend was observed when
comparing Hcys of MTR 2756AA with that of AG and GG (p=0.0759). The frequency of
MTRR 66 A allele was higher in IBD, compared with controls (0.54 [95%CI: 0.48-0.61]
and 0.39 [0.32-0.46], respectively, P=0.0009), with an odds ratio for IBD risk estimated at
4.0 [1.7-9.2] after adjustment for sex and age. Conclusions: MTHFR 677TT homozygous
genotype, folate and vitamin B12 levels are three determinants of homocysteinemia in IBD
cases from a French population of European origin. Furthermore, we found an association
of the MTRR A66G polymorphism with IBD which may be related to an increased cobalamin
reduction associated with oxidant stress.
T2011
Candidate Gene Analysis of Runx1 and Padi4 in Japanese Patients with
Inflammatory Bowel Disease
Masaki Tosa, Yoshitaka Kinouchi, Kenichi Negoro, Eiki Nomura, Yoichi Kakuta, Hiroko
Abe, Go Imai, Atsuhiro Mochida, Sho Takagi, Seiichi Takahashi, Tooru Shimosegawa
Backgrounds: A substantial genetic component of susceptibility to inflammatory bowel
disease has been demonstrated in epidemiological and linkage studies. It has been proposed
that genetic susceptibility loci for Crohn’s disease (CD) may be shared with other autoim-
mune/inflammatory diseases.Rheumatoid arthritis (RA) is also common chronic autoimmun-
opathy. CD and RA are characterized by chronic inflammation in which crucial roles for
Th1-cell, macrophage, and TNF have been demonstrated. In addition, Infliximab is effective
in the treatment of both CD and RA.Recently, three novel candidate genes associated with
RA, SLC22A4 on chromosome 5 known as IBD5 and PAdi4on chromosome 1 known as
IBD7 and RUNX1 on chromosome 21, were identified in Japan. We have already reported
IBD5 including SLC22A4 is not a major component of the susceptibility for IBD in Japanese,
while Padi4 and RUNX1 have not studied in Japanese patients with IBD. Thus the aim of
this study is to determine if the haplotype and SNP associated with RA in Japan were also
associated with IBD in Japan. We analyzed a genetic variant in Padi4 (Exon3 JST083451),
an intronic SNP in RUNX1 (intron6 JST022046G/C). Material and methods: A total of 758
Japanese individuals (241 patients with CD, 247 patients with ulcerative colitis (UC) and
270 healthy controls) were analyzed in this study. Genotyping for SNPs was determined by
polymerase chain reaction-restriction fragment length polymorphism analysis. Case-control
association analyses were performed using the chi-square test, and sub-stratification analyses
according to disease phenotype were also performed. Results: No significant differences
were observed between disease (CD, UC, CD + UC) and controls in the two SNPs located
in RUNX1 and Padi4. There were no significant association between clinical phenotype and
haplotypes of the Padi4. On the other hand, in RUNX1, the very weak relationship was
found in ileitis type of CD (p<0.05). Conclusion: We conclude that RUNX1, Padi4, does
not influence susceptibility to both UC and CD in the Japanese.
T2012
Polymorphisms with Possible Functional Relevance in the Genes for Octn1
and Octn2 in Ibd5 Locus in Inflammatory Bowel Disease
Helga P. Torok, Juergen Glas, Klaus Ott, Wolfram Klein, Peter Lohse, Thomas
Ochsenkuehn, Matthias Folwaczny, Christian Folwaczny
BACKGROUND: Recently, functional relevant polymorphisms in the genes for the organic
cation transporters OCTN1 and OCTN2 in IBD5 locus have been associated with Crohn’s
disease (CD). Based on statistical analysis and functional studies showing reduced function
in OCTN genes activity in vitro, a causative role for the described variants (C1672T in
SLC22A4 and -G207C in SLC22A5) has been suggested (1). However, due to the strong
linkage disequilibrium among the IBD5 locus it is possible that other unassayed polymorph-
isms in these or nearby genes are responsible for disease susceptibility (2). The aim of the
present study was to assess the frequencies of two other OCTN1 and OCTN2 polymorphisms,
which may have effects on gene function, in inflammatory bowel disease SUBJECTS AND
METHODS: The study population comprised 596 patients with CD, 355 patients with
ulcerative colitis (UC) and 790 healthy unrelated controls. All study participants were
Caucasians. The polymorphisms C917T resulting in the amino acid substitution T306I in
OCTN1 and C1721T in the 3’ untranslated region of the gene encoding for OCTN2 have
been assessed by restriction fragment length polymorphism analysis. CD patients were
stratified also with regard to presence or absence of major disease associated variants in
CARD15 (L1007fs, R702W, G908R). RESULTS: No significant differences in the allele and
genotype distributions between patients with CD, UC and controls have been observed. The
frequencies of the rarer 917T allele in OCTN1 were 0.373 in CD, 0.376 in UC and 0.378
in controls. The frequencies of the minor allele 1721T in OCTN2 were 0.116 in CD,
0.118 in UC and 0.135 in controls. A significant difference in the distribution of the two
polymorphisms was also not obtained after stratification of CD patients with regard to the
CARD15 genotype. 99.7 % of individuals carrying the 917T allele in OCTN1 and only 10.3
% of individuals carrying the 1721T allele in OCTN2 displayed the homozygous risk-
associated diplotype TT/CC concerning the polymorphisms OCTN1 C1672T and OCTN2 -
G207C (3). DISCUSSION: Herein two polymorphisms with possible functional relevance
in the genes encoding for OCTN1 and OCTN2 have been studied in IBD for the first time.
No independent association of these polymorphisms with CD or UC has been observed.
Due to the strong linkage disequilibrium in the IBD5 region, additional studies are required
before definitive conclusion regarding the causative role of polymorphisms within these
genes. 1. Peltekova VD, et al. Nat Genet 2004;36:471-5. 2. Urban TJ, et al. Inflamm Bowel


















The Functional Gene Polymorphisms for the Pathogenesis of Non-Alcoholic
Steatohepatitis
Akira Hirose, Toshiji Saibara, Chikako Namikawa, Yasuko Nozaki, Masafumi Ono, Akemi
Yoshioka, Masaya Takahashi, Naoaki Akisawa, Shinji Iwasaki, Saburo Onishi
BACKGROUND/AIMS: The pathogenesis of non-alcoholic steatohepatitis (NASH) is poorly
understood. The aim of this study was to examine genetic influences on NASH pathogenesis
in Japanese population. METHODS: Blood samples from 63 patients with biopsy-proven
NASH and 150 healthy controls were analyzed by the polymerase chain reaction (PCR) and
restriction fragment length polymorphism (RFLP). Four functional polymorphisms were
studied: the -493 G/T polymorphism in the promoter of microsomal triglyceride transfer
protein (MTP), the 190 T/A polymorphism in β3-adrenergic receptor, which results in
Trp64Arg (W64R) amino acid replacement, the 1183 T/C polymorphism in the mitochondrial
targeting sequence of manganese superoxide dismutase (MnSOD), and the -511 T/C poly-
morphisms in promoter sequence of the interleukin-1β. RESULTS: NASH patients had a
much higher incidence of the MTP gene G allele (P=0.001) and of the G/G genotype (P=
0.002) compared to the controls. Fat occupied more area in liver lobules and the stage of
NASH was advanced in patients with the G/G genotype than in patients with G/T genotype
(P=0.04). β3-adrenergic receptor R allele frequency (P=0.01) and the R/- (W/R and R/R)
genotype frequency (P=0.008) were significantly higher in NASH patients than those in
control subjects. Obesity, hypertriglyceridemia and hyperinsulinemia were associated with
NASH patients with the R/- genotype (P<0.001), whereas a decrease in insulinogenic index
was associated with NASH patients with the W/W genotype (P<0.01). NASH patients also
had a higher incidence of the MnSOD T/T genotype (P=0.016). Interleukin-1β -511 T allele
frequency (P=0.0001) and the T/T genotype frequency (P=0.00001) were significantly higher
in NASH patients than those in control subjects. CONCLUSION: The G allele in the MTP
promoter leads to decreased MTP transcription, less export of triglyceride from hepatocytes,
and greater intracellular triglyceride accumulation. The R allele in the β3-adrenergic receptor
leads to reduce energy expenditure. The T allele in MnSOD mitochondria targeting sequence
leads to less transport of MnSOD to the mitochondria. The T allele in the interleukin-1β
promoter leads to the development of inflammatory changes in the liver. Therefore, this
study confirmed that the contribution of hepatic steatosis, obesity, glucose intolerance,
hypertriglyceridemia and inflammation of the liver influenced by the functional gene poly-
morphisms for the development of NASH in the Japanese population.
T2014
The PPAR-α Agonist Wy-14643 Prevents Development of Nonalcoholic Fatty
Liver Disease in Mice Heterozygous for a Mitochohdrial Trifunctional Protein
Defect
Jamal A. Ibdah, Peter Perlegas, Hermina Borgerink, J. Mark Cline
Background and Aims: We reported previously that aging mice heterozygous for a mitochon-
drial trifunctional protein (MTP) defect develop insulin resistance and hepatic steatosis
(Gastroenterology 128:1381-90, 2005). MTP is the enzyme complex that catalyzes the last
3 steps of long chain mitochondrial β-oxidation. The peroxisomal proliferator activated
receptor (PPAR-α) regulates the gene expression of mitochondrial fatty acid oxidation
enzymes and is activated by the peroxisomal proliferator Wy-14643. We hypothesized that
treatment of the heterozygous (MTP+/-) mice with Wy-14643 enhances mitochondrial fatty
acid oxidation and prevents development of hepatic steatosis. Methods: A study group of
3-month old male mice (12 MTP+/- and 12 MTP +/+ mice) were fed a diet containing the
peroxisome proliferator Wy-14,643 (005% w/w diet) and a control group of 3-month old
male mice (12 MTP+/- and 12 MTP+/+ mice) were fed a control chow diet. All mice were
sacrificed after 12 months of dietary treatment and liver sections were evaluated using
routine histology and Oil Red O fat stain. Scores of 0 to 3 were assigned to hepatic steatosis.
Serum insulin levels were also measured. Results: On the chow diet, MTP+/- mice developed
mild but significant hepatic steatosis (score 1+ steatosis) while MTP+/+ had no or minimal
hepatic steatosis. There was no steatosis noted in the liver sections obtained from the MTP+/-
or MTP+/+ mice treated with the Wy-14,643 diet. However, the Wy-14643 diet caused
development of hepatic tumors in both MTP+/- and MTP+/+ mice, a known effect of Wy-
14643 use in mice. Gross and histological examination revealed that 75% and 25% of the
MTP+/- mice developed significant hepatic adenomatous and hepatocellular carcinomatous
lesions, respectively, compared to 33% and 17% in the MTP+/+ mice. The MTP+/- mice on
the control chow diet had hyperinsulinemia (2.31 +/- 0.45 ng/ml, mean +/- SD) compared
to MTP+/- on the Wy-14,643 diet (1.1 +/- 0.8 ng/ml, mean +/- SD, P<0.001), suggesting
that the Wy-14,643 diet prevents development of hyperinsulinemia in the MTP heterozygous
mice. Insulin levels in the MTP+/+ mice on the chow and Wy-14,643 diets were 0.95 +/-
0.63 and 1.3 +/- 0.6 ng/ml, respectively. Conclusion: The PPAR-α agonist Wy-14643 prevents
development of hepatic steatosis in the MTP+/- mice suggesting that enhancement of mito-
chondrial fatty acid oxidation prevents development of NAFLD.
T2015
Effects of N-Acetylcysteine On Change of Oxidative Stress and Histopathology
in Rats with Non-Alcoholic Steatohepatitis
Duangporn Thong-Ngam, Suchittra Samuhasaneeto, Onanong Kulaputana, Suthiluk
Pathumraj, Piyawat Komolmitr, Naruemon Wisedopas
Background: Prevalence of non-alcoholic steatohepatitis (NASH) appears to be increasing.
No therapy for NASH has been proven to be clearly effective. Aims: To determine the effects
of N-acetylcysteine (NAC) on change of oxidative stress and histopathology in rats with
NASH. Materials & Methods: Thirty-nine male Sprague-Dawley rats, 220-250 gram, were
divided into 4 groups. Group 1: control group, fed with 35% fat standard diet for 6 wks
(N=8). Group 2: NASH group, fed with 100% high-fat diet for 6 wks (N=8). Group 3:
NASH with diet treatment group, fed with 100% high-fat for 6 wks then 35% fat standard
diet for 4 wks (N=11). Group 4: NASH with NAC treatment group, fed with 100% high-
fat diet for 6 wks then NAC 20mg/kg for 4 weeks (N=12). Whole blood total glutathione,
T : 89386$$CH2
05-04-06 23:18:31 Page 594Layout: 89386B : e
A-594AGA Abstracts
hepatic malondialdehyde (MDA) concentration and liver histopathology were evaluated.
Results: In rats fed with 100% high-fat diet for 6 wks, all livers developed moderate to
severe macrovesicular steatosis and mild to moderate necro-inflammation. Whole blood
total glutathione and hepatic MDA concentration were significantly reduced in NASH+diet
and NASH+NAC group compared to NASH group. Less histopathologic evidence of steatosis
and necro-inflammation in NASH+diet and NASH+NAC group. More improvement of stea-
tohepatitis was found in NAC than in control diet alone. Conclusions: NAC and dietary
diet decreased oxidative stress via reducing total glutathione and hepatic MDA concentration
and attenuated steatohepatitis in rat fed with 100% high-fat diet model of NASH.
T2016
[1-13c]-Acetate Breath Test Reveals Impaired Acetate Metabolism in Patients
with Fatty Liver Diseases
Yoshihisa Urita, Susumu Ishihara, Kenichiro Arai, Jun Kondo, Tatsuo Akimoto, Hiroto
Kato, Noriko Hara, Hideyuki Koshino, Yoshiko Honda, Yoko Nagai, Kazushige Nakanishi,
Nagato Shimada, Motonobu Sugimoto, Kazumasa Miki
Background: [1-13C]-acetate breath test has been used to evaluate gastric emptying of liquid
test meals. Acetate is absorbed rapidly from the small intesrine and reaches the liver where
carbon dioxide (CO2) is produced and excretes in expired air. However, it has been unclear
whether the rate of production of 13CO2 directly reflects the rate of substrate oxidation or
gastric emptying. If acetate metabolism in the liver is changed, it is possible that 13CO2
excretion also changes regardless of gastric emptying. For example, it has been reported
that acetate metabolism is impaired in diabetics. We therefore conducted [1-13C]-acetate
breath test for the evaluation of acetate metabolism in patients with various liver diseases.
Patients and Methods: [1-13C]-acetate breath test.was performed in 23 chronic liver diseases
(mean age 67 years). The cause of liver disease was hepatitis C virus (HCV) in 8 patients,
hepatitis B virus (HBV) in 3, and primary biliary cirrhosis in 1, alcoholic liver disease in 4,
non-alcoholic fatty liver disease in 6. The patients received 100ml of water containing 100mg
of [1-13C]-acetate in the sitting position after an overnight fast. Breath samples were collected
at baseline and at 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, and 120min after
ingestion to analyze 13CO2. 13C was measured as the 13CO2/12CO2 isotope ratio and
was expressed as delta over baseline per mil (‰). Results: The 13CO2 concentrations
increased from the beginning, and peak enrichment values were reached after 20 min. A
peak value of 13CO2 excreted was lowest in patients with alcoholic fatty liver (mean 19.1+/-
8.6‰), followed by non-alcoholic fatty liver disease (mean 21.1+/-12.6‰), and viral hepatitis
(mean 48,9+/-5.6‰). There was a significant difference between alcoholic fatty liver group
and viral hepatitis group. Conclusions: In patients with chronic liver diseases, acetate metabol-
ism differs variously. Especially, [1-13C]-acetate breath test is a useful non-invasive tool for
distinguishing between patients with fatty liver diseases and those with viral hepatitis. When
[1-13C]-acetate breath test is used to evaluate gastric emptying in the subject with fatty
liver diseases, we should duly recognize the various metabolism of acetate.
T2017
Nonalcoholic Fatty Liver Disease in Japanese Patients with Type 2 Diabetes:
Clinical Features and Risk Factors
Nobuyuki Toshikuni, Koji Nakashima, Akiyoshi Omoto, Mikio Mitsunaga
Aims: Type 2 diabetes is commonly associated with nonalcoholic fatty liver disease (NAFLD).
An Italian study group has recently demonstrated that NAFLD is an independent risk factor
for cardiovascular events in type 2 diabetic patients. Furthermore, type 2 diabetic patients
with NAFLD have been reported to have a poor prognosis compared with nondiabetic
patients with NAFLD. Thus, type 2 diabetes with NAFLD is a serious health problem. To
date, there have been few studies investigating which factors play key roles in the development
of NAFLD in type 2 diabetic patients. The aim of this study was to analyze clinical features
of NAFLD and identify risk factors for NAFLD in Japanese patients with type 2 diabetes.
Methods: Drug-naïve patients with type 2 diabetes were enrolled. Exclusion criteria were
as follows: hepatitis B surface antigen, antibody to hepatitis C virus, alcohol consumption
(more than 20 g/d of ethanol). All patients underwent a clinical, anthropometric, and
laboratory investigation. The insulin resistance (IR) index was calculated by the homeostasis
model assessment (HOMA) method. The ratio of liver to spleen (L/S ratio) for computed
tomography numbers was used as an index of fatty infiltration of the liver; a L/S ratio < 1
was considered to represent fatty liver. Abdominal fat distribution was estimated by computed
tomography scans. Results: A total of 40 patients with type 2 diabetes (25 men, 15 women;
a mean age of 62 years) were enrolled. L/S ratio was strongly correlated with HOMA-IR
(r = -0.70, P < 0.0001). L/S ratio was also correlated with visceral fat area (r = -0.49, P =
0.001), but was not correlated with subcutaneous fat area (r = -0.24, P = 0.13). The 40
patients were divided into two groups: the group with NAFLD (group A; n=15 [11 men, 4
women]) and the group without NAFLD (group B; n=25 [14 men, 11 women]). HOMA-
IR in group A was significantly higher than that in group B (6.1 ± 4.3 vs 2.1± 0.8, P <
0.0001), although fasting plasma glucose and HbA1c did not significantly differ. Furthermore,
the incidence of the metabolic syndrome in group A (80% [12/15]) was higher than that
in group B (24% [6/25], P = 0.0008). Multiple logistic regression analysis with stepwise
variable selection showed that HOMA-IR (O.R. 10, 95% C.I. 1.2-91, P = 0.03) and alanine
aminotransferase (O.R. 22, 95% C.I. 1.0-486, P = 0.04) were independent risk factors for
NAFLD. Conclusions: This study suggests that insulin resistance may play a key role in the
development of NAFLD in Japanese patients with type 2 diabetes. HOMA-IR and alanine
aminotransferase may be serum markers of NAFLD in type 2 diabetes.
T2018
Correlation of Ultrasonography and Histology in Patients with Steatosis
Bashar M. Attar, Cory Halliburton, Erick Chinga-Alayo
Liver biopsy is currently the gold standard in the diagnosis of steatosis, particularly to
exclude other diseases and to assess inflammation and fibrosis. It is common practice to
assign a patient to a diagnosis of steatosis when it is positively identified on ultrasonography.
Prior studies correlating histologic steatosis with ultrasound findings were smaller and did
not reflect the actual clinical setting. Other studies used quantitative ultrasound attenuation
which is not commonly used in clinical practice. Methods: To assess correlation of ultrasonog-
raphy with biopsy proven cases of hepatic steatosis, we performed a retrospective study of
170 consecutive liver biopsies with complimentary ultrasound. Biopsies were performed for
evaluation of non-alcoholic fatty liver disease or to aid in decisions regarding hepatitis C
treatment. Cases were assessed for agreement between imaging and histology as the gold
standard. Steatosis was defined on histology as: not significant <5%, mild 5-30%, moderate
30-50%, marked 50-80% and severe >80%. An ultrasound study was considered positive
for steatosis if fatty liver was specified in the differential diagnosis. Results: Positive correlation
between steatosis on liver biopsy and ultrasound was poor. Our study found that ultrasound
had a sensitivity of 47%, specificity of 63%, positive predictive value of 11%, and accuracy
of 61% in diagnosing steatosis. However it does have good negative predictive value at 92%
for any grade of steatosis, and the specificity improves to 96% with steatosis of 50% or
greater. Interestingly the sensitivity, positive predictive value, or accuracy of ultrasound
imaging for detecting fat did not significantly improve with increasing degrees of steatosis.
Conclusion: Based on the very low positive predictive value of ultrasonography in identifying
hepatic steatosis, the detection of fat by this imaging technique does not accurately reflect
the presence of steatosis on histology. Our study demonstrates that ultrasonography should
not substitute for liver biopsy when fatty liver is found, although we understand our limitation
regarding the patchy distribution of fat in the liver. Ultrasonography is however a reasonable
test for ruling out steatosis when clinical hepatitis is present.
T2019
Alteration in Fatty Acid Composition in Liver Biopsies of Patients with Non-
Alcoholic Fatty Liver Disease (NAFLD) Compared to Those with Reported
Normal Liver Biopsy
Johane. P. Allard, Ellie Aghdassi, Ghazal Avand, Nita R. Prayitno, David W. Ma, Augustin
Nguyen, Maitreyi Raman, Maha Guindi, Morris Sherman, Jenny E. Heathcote
Background: Insulin resistance and abnormal lipid metabolism contribute to the pathogenesis
of NAFLD. In addition, alterations in the fatty acid (FA) composition in the liver may be
associated with lipogenesis, lipid mobilization, mitochondrial B-oxidation or lipid peroxida-
tion. Objectives: To compare the FA composition between liver biopsies of patients with
NAFLD and those with reported normal liver biopsy with no fat (NF). Method:This is a
prospective cohort study where 43 patients had liver biopsy for mildly elevated liver enzymes.
Alcohol intake was <20g/day and all other causes of liver diseases were excluded. Thirty-
three patients were diagnosed with NAFLD (14 steatosis,19 steatohepatitis) while10 had
normal biopsies. In addition to histology, total lipid FA composition was determined by gas
chromatography. Composition in % for total lipid (TL) is reported. Unpaired t-test was used
and P<0.05 is considered significant. Results: Patients with NAFLD had a significantly higher:
BMI (30.01± 0.85 vs 22.50 ± 1.28 kg/m2), ALT level (68.09±6.35 vs 47.85 ±6.61 u/L),
blood triglycerides (2.14 ±0.23 vs 1.13±0.20 mmol/l), and a trend towards a higher glucose
level (6.14±0.33 vs 5.10±0.40, p=0.08 mmol/l), total cholesterol (5.46±0.21 vs 4.27±0.34,
p=0.09 mmol/l) and a lower HDL(1.27±0.05 vs 1.56±0.12, p=0.058) compared to those
with NF. Other liver enzymes were similar. Compared to NF, NAFLD patients’ total polyun-
saturated FA (PUFA) (8.3±0.5 vs 17.8± 2.8) was significantly decreased due to significant
decreases in long chain n-6 and n-3 FA. In addition, there was a significant increase in n-
6 to n-3 ratio (7.3± 1.2 vs 3.2 ± 0.6) in NAFLD patients. Saturated fatty acids, palmitic
(30.1± 0.5vs 23.9±3.2) and stearic (23.3± 1.0 vs 18.4±2.7) were significantly higher in
patients with NAFLD whereas C20:0 (2.4±0.4 vs 5.4±1.3), C22:0 (0.7±0.1 vs 2.7±0.8) and
C24:0 (0.3±0.09 vs 1.1 ±0.3) were all significantly lower when compared to subjects with
NF. The monounsaturated FA, oleic (17.5±1.2 vs 11.2±1.9) and the elaidic (trans fat, 9.4±
0.7 vs 5.5±1.2) were significantly higher in patients with NAFLD. The conjugated linoleic
acids were significantly lower (1.6 ±0.3 vs 4.5±1.6) in patients with NAFLD when compared
to subjects with NF. Conclusion: patients with NAFLD have in their liver, a different fatty
acid composition compared to NF. This includes a decrease of the PUFA particularly from
the n-6 and n-3 series with a disproportionate increase in the n-6 to n-3 ratio. This pattern
of fatty acid composition may be the result of alteration in lipid metabolism favoring
hepatic steatosis.
T2020
Changes in Liver Histology After One Year of Treatment with Probucol in
Nonalcoholic Steatohepatitis
Shahin Merat, Mohsen Aduli, Rozana Kazemi, Masoud Sotoudeh, Reza Malekzadeh
Background and Aims: Nonalcoholic steatohepatitis (NASH) is rapidly becoming a major
health problem in many communities. No effective medical treatment has been yet approved
for this entity. It appears that oxidative damage is an important step in the pathology of
NASH. Probucol is a lipid lowering agent with significant antioxidant effects. We have
previously shown its effectiveness in normalizing liver enzymes in NASH patients. In the
current study, we report liver histology changes after using probucol for one year in 8
patients. Material and Methods: Eight cases of biopsy proven patients with NASH were
included. Viral and autoimmune hepatitis and other liver disorders were ruled out. None
of the patients used alcohol. The patients were given 500 mg probucol daily for 1 year.
Aminotransferases, lipid profile and weight changes were evaluated during the treatment.
Liver biopsies were performed before treatment and after one year. The biopsies were staged
using a modification of the system developed by Brunt et al. According to this modification,
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proposed by Sotoudeh et al. in DDW 2004, steatosis, hepatocyte ballooning, lobular Inflam-
mation and portal inflammation were scored from zero through three. Fibrosis was staged
from zero through four. The paired-samples T-test was used to compare variables before
and after treatment. Results: The patients completed one year of treatment and underwent
the second liver biopsy. At the end of therapy the mean alanine aminotransferase and alanine
aminotransferase levels decreased from 94 and 55 to 41 and 26 respectively (p=0.012 and
0.011 respectively). The mean weight of patients decreased by 2.9 kg and the mean body
mass index by 0.67 kg/m2, none reached statistical significance. The pathologic grade of
liver histology decreased from 7.4 to 5.6 (p=0.021), the stage changed from 1.13 to 1.25
(p=0.76), and the total score decreased from 8.5 to 6.9 (p=0.048). No adverse drug effects
were observed. Conclusion: Probucol is effective in normalizing aminotransferase levels in
patients with NASH. It also significantly reduces the histologic grade of steatohepatitis after
one year of treatment. We failed to demonstrate statistically significant improvement in
histologic stage.
T2021
Lovastatin Is Not Hepatotoxic to Patients with Pre-Existing Liver Disease
Andrew L. Avins, Michelle M. Manos, Theodore R. Levin, Lynn M. Ackerson, Wei K.
Zhao, Rosemary C. Murphy, Douglas J. Watson, Peggy May T. Hwang, Amy R. Replogle,
Jeffrey G. Levine
BACKGROUND: Data in the literature addressing the risk of adverse hepatic outcomes
associated with statin use among patients with pre-existing liver disease are limited. In
addition, the effect of statins on lipid metabolism may have beneficial effects among patients
with certain hepatic diseases. METHODS: This was a retrospective cohort study. Subjects
were adult members of the Northern California Kaiser Permanente Medical Care Program
from January 1994 through June 2004 who had at least two alanine aminotransferase (ALT)
elevations 6-18 months apart, a medical-record diagnosis of liver disease, or chronic hepatitis
B or hepatitis C infection. Patients were excluded if they used a statin medication within
one year of study entry. The primary endpoint was defined as concurrent serum ALT>3
times the upper limit of normal, total bilirubin>2 times the upper limit of normal, and
alkaline phosphatase <1.5 times the upper limit of normal (modified Hy’s Rule). Secondary
endpoints included any ALT>3 times the upper limit of normal, cirrhosis, and liver failure.
For univariate analyses, follow-up time was partitioned into lovastatin-exposed and unex-
posed time and rates of each endpoint were calculated and attributed to the appropriate
exposure time. Multivariate analyses were conducted with Cox proportional hazards models.
RESULTS: The study group consisted of 13,492 patients with lovastatin exposure and 79,628
patients without lovastatin exposure during the follow-up period. In univariate analyses,
exposure to lovastatin was associated with strong and significant reductions in all primary
and secondary endpoints, including Hy’s Rule (Relative Rate (RR)=0.29, 95% Confidence
Interval (CI): 0.14 to 0.60), elevated ALT (RR=0.55, 95% CI: 0.47 to 0.65), cirrhosis (RR=
0.25, 95% CI: 0.19 to 0.35), and liver failure (RR=0.21, 95% CI: 0.14 to 0.31). Results
were similar when adjusted for age and gender in multivariate analyses. Rates of statin
prescription were similar across subgroups defined by hierarchical categories of liver-disease
certainty, suggesting that confounding by contraindication was not a likely explanation for
these results. CONCLUSION: Exposure to lovastatin was associated with a large and signific-
ant decrease in adverse hepatic endpoints, possibly mediated through an effect on liver
disease by lovastatin’s alteration of lipid metabolism. These results are not consistent with
an increased risk of lovastatin hepatotoxicity in patients with pre-existing liver abnormalities.
T2022
The Role of ADH3 and CYP2E1 Gene Polymorphism in Alcohol Liver
Cirrhosis and Chronic Alcohol Pancreatitis
Halina Lach, Krzysztof Celinski, Jadwiga Partycka, Maria Slomka
Genetic polymorphism of enzymes involved in alcohol metabolism plays a relevant role in
etiopathogenesis of alcohol disease. The aim of the present study was to find in the Polish
population the ADH3 and CYP2E1 genotypes, which are likely to be responsible for higher
susceptibility to alcohol liver cirrhosis and chronic alcohol pancreatitis. The ADH3 and
CYP2E1 genotype and alleles frequencies were examined in 198 patients: 57 with alcoholic
liver cirrhosis, 44 with alcohol chronic pancreatitis, 43 abusing alcohol but without damage
to gastrointestinal organs -“healthy drinkers” and 54 nondrinkers as a control group. Genotyp-
ing of the ADH3 and CYP2E1 was performed using polymerase chain reaction -restriction
fragment length polymorphism methods on white cell DNA. The genotype ADH3*1/ADH3*1
was found to be significantly more frequent in alcohol abusers compared to non-drinkers.
The examinations of the group of alcohol abusers showed that the genotype ADH3*2/ADH3*2
occurred statistically significantly less frequently in patients with chronic pancreatitis than
those without alimentary lesions and patients with cirrhosis. In the examined population
the c2 allele was present only in 1.5% of patients. It was found only in patients abusing
alcohol. In the group of patients with alcoholic cirrhosis it was present in 3.5% of cases
while in patients with chronic alcoholic pancreatitis in 2.3%. The genotype c1/c2 was present
in 3% of subjects. The genotype c2/c2 was not found in any patient. Heterozygotes c1/c2
were present only in patients consuming excessive amounts of ethanol; in 7% of patients
with alcoholic cirrhosis and in 4.5% of those with chronic alcoholic pancreatitis. Our studies
suggest that allele ADH3*1 may be a risk factor for the developing alcoholic liver diseases
and allele ADH3*2 can protect against alcoholism and be the protective factor of chronic
alcohol pancreatitis. The frequency of alleles c2 in Polish population is low, but their presence


















Central Role of Srebp Lipogenic Pathways in Alcohol-Induced Hepatic
Steatosis
Cheng Ji, Christine Chan, Neil Kaplowitz
BACKGROUND: Alcohol induced fatty liver correlates with activation and induction of
SREBPs, transcription factors which regulate expression of genes which promote fatty acid
and triglyceride synthesis and inhibit β-oxidation. To determine the contribution of this
mechanism of steatosis, the aim of the present study was to compare the effects of intragastric
alcohol feeding on lipogenic pathways in wild type and SREBP1c null mice. METHODS:
Wild type and SREBP1c null mice were fed alcohol alone or with betaine (1% w/v) or
control diet for 4 weeks. Alcohol-induced liver damage was assessed with H&E and TUNEL
staining. Changes in gene expression were analyzed with Real Time PCR, RT-PCR and
immunoblotting. RESULTS: ALT, plasma homocysteine (Hcy), liver cholesterol (Chol), and
hepatic apoptosis were increased in alcohol-fed mice as compared to control in both genotypes
(Table 1). The alcohol induced liver cholesterol levels in SREBP1c null mice were higher
than in wild type. Liver triglycerides (TG) were increased 4 times in alcohol-fed wild type
but 1.8 times in alcohol-fed SREBP1c null as compared to the pair-fed controls. SREBP2
and HMG CoA reductase were increased slightly in wild type and significantly in knockouts
in response to alcohol. Selective genes related to triglyceride synthesis were increased in
wild type but not in SREBP1c null mice fed alcohol. Plasma adiponectin was reduced in
both genotypes fed alcohol but no significant changes were found in AMPKα or activated
AMPKα. In addition, neither Scap nor S1P was changed in response to alcohol in both
genotypes. Betaine reduced alcohol-induced changes in both genotypes. CONCLUSIONS:
SREBP1c knockout protects against alcohol induced triglyceride accumulation. SREBP2 may
provide compensatory pathways for lipid synthesis in the SREBP1c null mice fed alcohol and
thus a complete protection against alcohol-induced fatty liver seems to require inactivation of
both SREBP1 and 2 regulated lipogenic pathways (supported by NIAAA R01AA014428-03
& NIDDK P30DK048522-11 to NK and CJ. chengji@usc.edu).
Table 1 Pathological features of wild type and SREBP1c (-/-) mice fed ethanol
*P < 0.05; ** P <0.01 compared to control; a P < 0.05 compared to wild type.
T2024
N-Acetylcysteine and Ascorbic Acid Protect Against Oxidative Stress Related
Toxicity Caused By Ecstasy and Ethanol
Kristina Norman, Conni Mueller, Manuela Jackstadt, Herbert Lochs, Tilman Grune,
Matthias Pirlich
Introduction: Ecstasy (Methylendioxymethylamphetamine, MDMA) belongs to the most
commonly used designer drugs and is often consumed together with alcohol. Both MDMA
and ethanol are hepatotoxic and cause oxidative stress. They might be used as model to
test anti oxidative strategies. Aim: We investigated the impact of MDMA in combination
with ethanol on oxidative stress and cell viability in cultured hepatocytes and the effect of
a coincubation with the antioxidants N-Acetylcysteine (NAC) and ascorbic acid. Methods:
HepG2 cells were incubated with a) MDMA and b) MDMA and ethanol for 24 hours. Cell
viability was measured with trypan blue exclusion and protein carbonyls were assessed as
marker for protein oxidation. The tests were then repeated with a) NAC and b) ascorbic
acid coincubation. Results: 24 hours incubation with 0.5 mM MDMA increased protein
oxidation (+ 171%, after 24 h, p<0.01). When the HepG2 cells were incubated with MDMA
as well as 200 mM ethanol cell viability was further decreased (56.4%, p=0.048). However,
when NAC and ascorbic acid were simultaneously administered, cell viability was largely
preserved (72.9% with 0.05mM MDMA and 200mM ethanol with 3mM NAC; 63% 0.05mM
MDMA and 200mM ethanol with 0.2 mM ascorbic acid). Moreover protein oxidation (-
30% with 0.05mM MDMA and 200mM ethanol and 0.2 mM ascorbic acid) was also
significantly reduced. Conclusion: MDMA increases oxidative stress and reduces viability of
HepG2 cells. The effects on cell viability are accelerated when MDMA and ethanol are
coincubated. However administration of the antioxidants ascorbic acid and NAC partially
prevented these hepatotoxic effects. Studies should further evaluate these antioxidants in
the therapy of oxidative liver damage.
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T2025
Oxidative Stress and Lipid Peroxidation-Induced 1, N6-Ethenodeoxyadenosine
DNA Adducts in CYP2E1 Overexpressing HEPG2 Cells Upon Ethanol
Treatment
Jagadeesan Nair, Dan Zili, Felix Stickel, Bartsch Helmut, Helmut K. Seitz
Background and Aims: Alcohol abuse exerts detrimental oxidative stress and lipid peroxida-
tion (LPO) in humans which is now generally accepted as one of the mechanisms for the
induction of liver cancer in heavy drinkers. We have previously demonstrated that LPO-
induced 1, N6-ethenodeoxyadenosine (edA) levels were elevated in hepatic DNA of alcohol
liver disease patients (Frank et al., Carcinogenesis, 2004). We now investigated the role of
CYP2E1, the primary enzyme responsible for ethanol metabolism on edA formation. Methods:
HepG2 cell lines stably transfected with CYP2E1 (E47) and a vector mock transfected control
(C34) [kindly provided by N.N. and A.I. Cederbaum, New York, NY, USA] were used for
this study. εdA-adducts were detected by immunohistochemistry using MAb EM-1-A1.
Results: Ethanol treatment increased edA-staining in the nuclei of E47 compared to C34
cells. At 5, 10 and 25 mM ethanol concentration the number of positively stained nuclei
exhibited a dose response curve. Although all E47 cells were expected to show high CYP2E1
expression, an edA-increase was detected only in a fraction. Ethanol treatment reduced
glutathione in E47 cells measured by monobromobimane, again only in a fraction of cells.
It is likely that these cells are more prone to oxidative stress resulting in higher LPO-induced
DNA damage. Conclusion: Our results indicate that formation of miscoding etheno-DNA
adducts is an early response to CYP2E1 overexpression in ethanol-exposed liver cells. This
suggests that the ensuing mutations may play a role in the ethiopathogenesis of benign and
malignant alcohol liver diseases.
T2026
The Anti-Fibrogenic Effects of EGCG in Activated HSC in Vitro Are Mainly
Derived from Its Antioxidant Property By De Novo Synthesis of Cellular
Glutathione
Yumei Fu, Yajun Zhou, Shizhong Zheng, Anping Chen
BACKGROUND: Hepatic stellate cells (HSC) are the major players during hepatic fibrogen-
esis. Over-production of extracellular matrix (ECM) is a characteristic of activated HSC.
Transforming growth factor-beta (TGF-β) is the most potent fibrogenic cytokine while
connective tissue growth factor (CTGF) mediates TGF-β-induced ECM production. HSC
activation and hepatic fibrogenesis are stimulated by oxidative stress. Glutathione (GSH) is
the most important intracellular antioxidant. We recently reported that (-)-epigallocatechin-
3-gallate (EGCG), a major and the most active component in green tea extracts, inhibited
HSC activation by reducing cell growth and suppressing ECM gene expression [Chen at el.
Biochem J (2002) 368:695-704]. The underlying mechanisms remain largely to be elucidated.
AIM AND HYPOTHESIS: This study is to explore the mechanisms of EGCG in inhibition
of ECM gene expression in activated HSC in vitro. It is hypothesized that EGCG inhibits
ECM gene expression in activated HSC by interrupting TGF-β signaling through attenuating
oxidative stress. RESULTS: TGF-β signaling is interrupted by EGCG in activated HSC by
suppressing gene expression of type I & II TGF-β receptors. In addition, CTGF gene
expression is inhibited by EGCG, leading to the reduction in the expression of ECM genes,
including £\I(I)-procollagen. Exogenous CTGF dose-dependently eliminates the anti-
fibrogenic effect of EGCG. To elucidate the underlying mechanisms, EGCG is found to
attenuate oxidative stress in passaged HSC by scavenging basal cellular reactive oxygen
species and reducing lipid peroxidation mainly by the de novo synthesis of GSH. N-
acetylcysteine (NAC), a GSH analog, mimics the inhibitory effects of EGCG in passaged
HSC. L-buthionine-sulfoximine (BSO) is a specific inhibitor of glutamate-cysteine ligase
(GCL), a key rate-limiting enzyme in GSH synthesis. BSO eliminates the anti-fibrogenic
effects of EGCG. CONCLUSIONS: This study elucidates the underlying mechanisms of
EGCG in inhibition of ECM gene expression in activated HSC. The reduction of ECM
production by EGCG is mainly facilitated by interrupting TGF-β signaling and suppressing
gene expression of TGF-β receptors and CTGF. Our results, for the first time, demonstrate
that the antioxidant property of EGCG plays a critical role in its anti-fibrogenic effects and
is mainly derived from increasing intracellular GSH. These results provide novel insights
into the mechanisms of EGCG as a possible anti-fibrogenic candidate in prevention and
treatment of liver fibrosis. [The work was supported by the grant DK 47995 from NIH/
NIDDK to A. Chen, and by the Bridging Award to A. Chen from LSUHSC-S].
T2027
Tegaserod Enhances Gastric Accomodation By Antagonizing 5-HT2B Receptor
Activity in the Gastric Myenteric Plexus and Smooth Muscle
Ling Wang, Shi-Yi Zhou, Chung Owyang
Tegaserod (T) is a potent 5-HT4 receptor agonist with clinical efficacy in disorders associated
with reduced GI motility and transit. T has been shown to enhance gastric accommodation
in humans, but the underlying mechanism is unclear. In vitro studies indicate that T is not
strictly selective for the 5-HT4 receptor, as it has similar affinity for the 5-HT2B receptor.
We therefore investigated whether improved gastric accommodation evoked by T is mediated
by 5-HT4 or 5-HT2B receptors. In vivo gastric accommodation studies were performed in
anesthetized rats. A pressure transducer was inserted into the proximal stomach through
the pylorus along with a catheter to infuse saline for gastric distension. Intragastric distension
produced a stepwise increase in intragastric pressure (IGP). At 2 and 6 ml of gastric distension
IGP increased 7.25±0.8 and 5.4±0.2 mmHg respectively. T (1mg/kg iv) significantly reduced
this increase to 5.5±0.3 and 3.4±0.2 mmHg. T’s action was dose dependent and not affected
by a specific 5-HT4 antagonist (SDZ-205,557, 1mg/kg). Similarly, vagotomy did not affect
T’s action, suggesting T acts directly on 5-HT receptors other than 5-HT4 present in gastric
myenteric plexus or smooth muscle. To investigate the effects of activation of 5-HT2B
receptors on gastric motility, we showed that administration of a 5-HT2B agonist, α-methyl-
5HT (0.03 mg/kg) increased IGP to 7.1±0.5 mmHg, which was dose dependently antagonized
by T. Co-administration of SDZ-205,557 did not affect the antagonistic action of T suggesting
T is a potent 5-HT2B receptor antagonist. This action likely contributes to T’s ability to
enhance gastric compliance. High levels of both mRNA and protein for 5-HT2B receptor
were found in the gastric wall of rats by Rt-PCR and Western analysis. Immunocytochemistry
showed 5-HT2B receptors were present predominantly in the longitudinal and circular
smooth muscle layers and myenteric plexus. To investigate the mechanisms by which
activation of 5-HT2B receptor increases gastric contractions, we showed that electrical field
stimulation (1-20 Hz) of gastric muscle preparations resulted in a neuronally-mediated
contractile response significantly potentiated by application of α-methyl-5HT (10-6M) (30%
over control). Similarly α-methyl-5HT enhanced carbacol (10-9-10-6M) induced gastric
contractions by 50%. This potentiation effect could be blocked by T (10-6M). Conclusion:
T enhances gastric accommodation in rats. This action is not due to activation of 5-HT4
receptors but appears to be related to 5-HT2B receptor antagonist activity, which reduces
the release of acetylcholine from the myenteric plexus and/or its actions on gastric muscle.
T2028
Mitemcinal (GM-611), Motilin Receptor Agonist Accelerates Both Upper GI
Motility and Lower GI Motility in Dogs
Ken-Ichi Ozaki, Hirokazu Sudo, Hiroyasu Muramatsu, Tatsuo Yata, Kenshi Kamei, Reiko
Sekimori, Zen Ito, Satoshi Omura
INTRODUCTION Mitemcinal is an erythromycin-derived macrolide that is a motilin recep-
tor agonist to accelerate gastric emptying in dogs and humans. It remains unclear whether
motility of other alimentary tracts is accelerated by mitemcinal. In this study, therefore, we
investigated the actions of mitemcinal on lower gastrointestinal (GI) along with upper GI
in dogs. METHOD Lower esophageal sphincter (LES) pressure of the anesthetized dog was
measured by means of an infused catheter system. Proximal intragastric volume was measured
with a barostat during the constant pressure procedure and changes in gastric motility were
measured with force transducers sutured on the gastric antrum, simultaneously, in conscious
dogs. The effects of mitemcinal on colonic motility by force transducers and defecation were
examined in conscious dogs. RESULTS Mitemcinal (0.3-100 μg/kg, iv) increased the LES
pressure in a dose-dependent manner (see Figure) with a potency 30 times that of erythromy-
cin. This increase was inhibited in the presence of the motilin receptor antagonist GM-109
(1 and 10 mg/kg/h, iv infusion). Mitemcinal (3 and 10 μg/kg/h, iv infusion) decreased
intragastric volume in a dose-dependent manner and increased gastric motility at the same
time. The colonic motility was stimulated by mitemcinal (0.3-1 mg/kg, po) (see Figure) and
abolished in the presence of GM-109 (1 and 10 mg/kg/h, iv infusion). The latency period
of defecation was shortened without inducing diarrhea by mitemcinal (3 mg/kg, po). CON-
CLUSION Mitemcinal accelerated both upper and lower GI motility as well as gastric
emptying in dogs. Furthermore, it became clear that these actions by mitemcinal on upper
and lower GI were demonstrated with the same doses which accelerate gastric emptying.
This suggests that mitemcinal may be a promising agent for treatment of upper and lower
GI motility disorders.
T2029
Effects of a Novel 5-HT4 Agonist, ATI-7505, On Gastrointestinal and Colonic
Transit in Humans
Michael Camilleri, Duane Burton, Maria I. Vazquez-Roque, Thomas Ford, Sanna
McKinzie, Alan R. Zinsmeister
Background: ATI-7505 is a prokinetic 5-HT4 agonist shown to be devoid of QT prolongation
effects and not metabolized by CYP 450. This study assessed the effect of ATI-7505 on
gastrointestinal and colonic transit in healthy humans. Methods: This randomized, parallel-
group, double-blind, placebo-controlled study evaluated effects of ATI-7505, 3, 10 or 20
mg t.i.d., in healthy volunteers (12 per group). Validated scintigraphic methods were used
to measure gastrointestinal and colonic transit with 99mTc-egg meal and 111In-charcoal.
Primary endpoints were gastric emptying (GE) t1/2, colonic geometric center (GC) at 24
hours and ascending colon (AC) emptying t1/2. Stool diaries were kept during the 9-day
treatment period. An ANCOVA was used to assess overall treatment group differences,
and post-hoc unadjusted pairwise comparisons were also examined. Results: There were
borderline overall treatment effects (decrease) on GE t1/2 (p=0.154), with 20 mg t.i.d. ATI-
7505 accelerating GE vs. placebo (p=0.038). ATI-7505 increased colonic transit (GC24, p=
0.031, Fig.) with fastest transit at 10 mg t.i.d. vs. placebo (p=0.065). ATI-7505 accelerated
AC emptying t1/2 (overall p=0.075, Fig.) with 10 mg dose vs. placebo (p=0.042). There
were no changes in stool frequency or ease of passage, but there was somewhat looser stool
consistency (Bristol stool form scale, overall p=0.056) with the 10 and 20 mg t.i.d. doses.
No safety issues were identified. Conclusions: The 5-HT4 agonist, ATI-7505, accelerates
overall colonic transit, tends to accelerate GE and AC emptying and loosen stool consistency.
The optimal doses in health appear to be 20 mg and 10 mg t.i.d. to accelerate GE and
colonic transit, respectively.
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T2030
Dexloxiglumide, a CCK1-Antagonist, Improves Gas-Related Symptoms in
Healthy Subjects
Beatriz Lobo, Jordi Serra, Fernando Azpiroz, Massimo D'Amato, Juan R. Malagelada
Patients with irritable bowel syndrome and functional dyspepsia, often complain of gas-
related symptoms, particularly after meals. Duodenal lipids impair intestinal gas transit and
tolerance in healthy subjects, and this effect is exacerbated in patients with irritable bowel
syndrome. Our aim was to test whether dexloxiglumide, a CCK1-antagonist, blocks the
effect of lipids on intestinal gas transit and tolerance. METHODS. In 12 healthy subjects (6
female, 6 men) we used a validated model inducing gas retention in man (GE 2002; 123:700).
Briefly, a mixture of gases mimicking physiological venous gas was infused into the jejunum
at 12 ml/min for 3 h (total volume 2160 ml). Simultaneously, lipids were administered into
the duodenum (Intralipid, 1 kcal/min), and we quantified anal gas evacuation (via a barostat)
and abdominal symptoms (by a 0-6 scale). Paired double-blind studies with iv infusion of
either dexloxiglumide (2.5 mg/Kg bolus followed by 5 mg/Kg.h continuous infusion) or
saline (control) were performed on separate days in random order. RESULTS. As expected,
subjects developed significant abdominal symptoms (2.6±0.6 score) and intestinal gas reten-
tion (665±180 ml) in response to the gas plus lipids challenge test during i.v. saline. In
contrast, i.v. infusion of dexloxiglumide reduced abdominal symptoms (1.2±0.4 score;
p<0.05 vs saline) and evidenced a trend towards improving intestinal gas clearance (589±197
ml gas retention; NS vs saline). Interestingly, the effects of dexloxiglumide were much more
pronounced in the women subgroup (symptoms improved by 56±16% and gas retention
by 28±19%; p<0.05 vs saline for both). CONCLUSION. CCK1-antagonist dexloxiglumide
reduces gas-related symptoms and improves gas clearance, particularly in women.
T2031
Influence of Guanylate Cyclase C Binding Ligand Md-1100 On TNBS-Induced
Visceral Hypersensitivity in Wt vs Ko Guanylate Cyclase C Deficient Mice
Helene Eutamene, Vassilia Theodorou, Valerie Tondereau, Aurelie Waget, Jean Fioramonti,
Alexander P. Bryant, Lionel Bueno
Background. MD-1100 acetate (MD-1100) is a novel therapeutic agent in clinical develop-
ment for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic
constipation. MD-1100 is an agonist of the receptor guanylate cyclase-C (GC-C). Ligand
binding to GC-C stimulates cGMP production which initiates a signal transduction cascade
that culminates in activation of the cystic fibrosis transmembrane conductance regulator
(CFTR). In a previous study (DDW 2005) we showed that MD-1100 is active in a model
of trinitrobenzene sulfonate (TNBS) colitis induced hypersensitivity in rats. The aim of this
present study, using GC-C KO mice, was to elucidate the specific activity of MD1100 on
GC-C in inflammation-induced visceral hyperalgesia. Methods. Two groups of 12 mice
(C57Bl6), WT and GG-C KO (GCC, 22-25g) were used. To measure abdominal contractions
reflecting acute visceral pain, animals were equipped with NiCr electrodes implanted in the
abdominal striated muscle. Colorectal distension (CRD) was performed using a Fogarty
probe 4F inserted into the rectum at 1 cm from the anus. The balloon was gradually inflated
with water by steps of 0.02 mL from 0 to 0.12 mL each step lasting 10 sec at 5 min intervals.
The electromyographic (EMG) recording system was composed of 8 channel-differential
pre-amplifier associated with 4 amplifier analyser PowerLab/4SP connected to a computer.
Mice were submitted to control CRD performed before (basal condition) and 3 days after
intra-rectal administration of TNBS (20 mg/kg in 30% ethanol, 60 μL). Mice received MD-
1100 (0.01 and 0.3 μg/kg PO) or its vehicle (NaCl 0.9%), 1 hour before distension in basal
conditions and 3 days after colonic inflammation. Results. Under basal conditions, the
sensitivity was different in WT vs KO mice. The EMG response thresholds were significant
at 0.06 and 0.08 mL respectively and different between WT and KO mice. In these conditions,
MD-1100 was effective to reduce the basal sensitivity at a dose of 0.3 μg/kg in WT but not
in GC-C KO mice. TNBS instillation induced a similar hyperalgesia and allodynia in both
WT and KO mice. After TNBS-induced colonic inflammation, MD-1100 administered at a
dose of 0.01 μg/kg significantly reduced the hypersensitivity only in WT mice (48 ± 7 vs
20 ± 5 amplitude of contraction (mV/s) for 0.04 ml of CRD), whereas no changes were
observed in GC-C KO mice. Conclusion. In the basal condition, compared to WT, GC-C
KO mice are less sensitive to CRD, suggesting a key role of GC-C in the basal sensitivity
of the gut. Moreover, MD-1100 reduces inflammation-induced hyperalgesia through GC-C
binding, studies to elucidate the mechanism are underway.
T2032
Effect of Tegaserod On Meal-Related Symptoms Induced By the Nutrient
Drink Test in Man
George Karamanolis, Sebastien Kindt, Rita Vos, Josef Janssens, Jan Tack
In the majority of functional dyspepsia (FD) patients, symptoms are triggered or aggravated
by ingestion of a meal. Pathophysiological studies indicate that abnormalities of gastric

















5HT4 receptor agonist, enhances gastric emptying and gastric accommodation in man. The
aim of the present study was to investigate the effect of tegaserod on the maximum tolerated
volume of nutrient ingested and postprandial symptoms in man. Methods: Seventeen healthy
volunteers (7m, mean age 27±1) were studied on two separate occasions, after 3 days
pretreatment with placebo or tegaserod 6 mg b.i.d. They underwent a slow satiety drinking
test (1.5 kcal/ml; 13% proteins, 48% carbohydrates, 39% lipids) until maximum satiety. At
5-minute intervals, the intensity of 9 symptoms (satiety, fullness, bloating, nausea, belching,
pain, epigastric burning, heartburn, discomfort) was assessed on 10 cm visual analog (VAS)
scales. Nutrient tolerance, area under the curve (AUC) for symptom intensities and symptom
satiety scores were recorded and compared by paired t-test and ANOVA. Results: Pretreatment
with tegaserod had no influence on nutrient tolerance (maximum intake 670±57 vs. 671±65
ml, NS). After tegaserod, symptom intensity scores for fullness (AUC 1147±141 vs. 1568±141
mm*min, p<0.05), bloating (AUC 825±165 vs. 1352±227 mm*min, p<0.05), epigastric
pain (AUC 66±42 vs. 133±67 mm*min, p=0.05), and epigastric discomfort (AUC 701±50
vs. 1158±203 mm*min, p=0.05), were decreased (all ANOVA significant, p<0.05), while
scores for satiety, belching, heartburn, epigastric burning and nausea were not altered.
Conclusion: The 5-HT4 receptor agonist tegaserod does not affect meal-induced satiety and
nutrient volume tolerance, but tegaserod decreases the intensity of several meal-induced
symptoms. These data support a potential benefit of tegaserod in the treatment of meal-
induced FD symptoms.
T2033
Newer Antiepileptic Drugs for Adults with Cyclic Vomiting Syndrome (CVS):
A Novel Approach to Maintenance Therapy
Ray E. Clouse, Gregory S. Sayuk, Rajesh Shah, Patrick J. Lustman, Chandra Prakash
Management of CVS in adult patients is limited by the small number of effective agents
either for abortive treatment of episodes or maintenance of the episode-free interval. Tricyclic
antidepressants (TCAs) have been the most commonly used maintenance medications in
adults, but their use often is limited by high side effect profiles. Newer antiepileptic drugs
(AEDs), including zonisamide (Zonegran®, ZN) and levetiracetam (Keppra®, KP), are well
tolerated, are being used for off-label prophylaxis against migraine headache, but have not
been tested in CVS. Methods: 18 adult patients with CVS (mean age 38.6 ±3.3 yr; range
19-71; 7 female/11 male) were treated with maintenance open-label AEDs after TCA failure
(13 pts) or intolerance (5 pts). Each patient had typical Rome II features of CVS; 9 (50%)
also had a dominant abdominal pain component; and 5 subjects (28%) had a CVS picture
in face of diabetes mellitus without other satisfactory explanation for the stereotypical
vomiting episodes. 2 (22%) had personal or family history of migraine headache and 3 (9%)
had prodromal features. 4 subjects had used marijuana regularly but had no improvement
on withdrawal. Duration of CVS averaged 5.4 ±1.4 yr (range 0.2-21 yr), and episode rate
over the 1 year pre-AED averaged 1.1 ±0.3/month. Each subject was followed for≥3 months
on AEDs; response to treatment was evaluated on a 0-3 Likert scale (worse/no improvement
to near complete or complete response) with comparison to pre-treatment course. Results:
15 subjects (83%) were treated with ZN and 3 (17%) with KP; median final daily dose
(range) was 300 mg (100-600 mg) for ZN and 1000 mg (500-2000 mg) for KP. TCAs were
discontinued in 10 subjects (75%). Duration of follow-up on AEDs averaged 9.7 ±2.0 mo.
Response ≥2 on the Likert scale (at least moderate response) occurred in 13 (72%) of
subjects, while complete or near complete resolution of episodes was reported by 8 of these
(44% of total). Episode rate reduced to 0.5 ±0.2/mo (p<0.05 compared with pre-AED value)
for responders. Only 1 subject was intolerant (CNS side effects from ZN). Conclusions:
Newer AEDs, specifically ZN and KP, are beneficial in open-label, maintenance use for
reducing vomiting episodes in adults with CVS. Nearly three-fourths of subjects who were
unsatisfactorily managed with TCAs benefited over this short follow-up period. Further
investigation of these AEDs in CVS is indicated to better define efficacy, dosing and drug
superiority. Considering their high tolerance and lower side effect profiles, they may prove
superior to TCAs in primary maintenance strategies.
T2034
The Characterization of An Active Metabolite of MD-1100, a Therapeutic
Agent in Development for the Treatment of IBS-C and Chronic Constipation
Alexander P. Bryant, Robert W. Busby, Etchell A. Cordero, Marco M. Kessler, Christine M.
Pierce, Jenny V. Tobin, Angelika Fretzen, Caroline Kurtz, Mark G. Currie
MD-1100 acetate (MD-1100) is currently in clinical trials for the treatment of irritable
bowel syndrome with constipation (IBS-C), chronic idiopathic constipation and additional
gastrointestinal (GI) disorders. MM-419447 is an in vivo metabolite of MD-1100 that was
discovered in non-clinical pharmacokinetic studies. This metabolite was synthesized, charac-
terized and found to be a potent agonist of the receptor guanylate cyclase-C (GC-C) sharing
the pharmacological traits of the parent, MD-1100. Aim: To characterize the in vivo and in
vitro pharmacology of MM-419447 in rats through in vitro activity assays, competitive
radioligand binding assays, and in vivo efficacy experiments. Methods: MM-419447 was
characterized in vitro by measuring the concentration-dependent production of cyclic GMP
(cGMP) upon exposure to human T84 colon cancer cells. The binding of MM-419447 to
cell surface GC-C receptors on T84 cells was characterized using a competitive radioligand-
binding assay. The in vivo pharmacology was evaluated using widely accepted rodent models
of GI transit and intestinal secretion. Results: MM-419447 stimulated cGMP production in
vitro upon exposure to human T84 cells in a concentration-dependent manner over a range
of concentrations (0.03 to 1000 nM). Direct administration of MM-419447 into ligated
intestinal loops in the rat resulted in a statistically significant increase in lumenal fluid
secretion and cGMP production. Both high and low affinity GC-C binding sites were identified
for MM-419447. Finally, oral administration of MM-419447 resulted in a significant and
dose-dependent increase in GI transit in rats when compared with vehicle-dosed animals.
The lowest effective dose of MM-419447 in the GI transit study was 6.25 μg/kg compared
to 5.0 μg/kg for MD-1100. Conclusion: MM-419447 is an active metabolite of MD-1100.
Like the parent, this metabolite binds to the GC-C receptor, which results in elevated levels
of cGMP, and increased fluid and electrolyte secretion. When orally administered, this GC-
C agonist accelerates intestinal transit in rats, with comparable potency to MD-1100. The
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GC-C binding affinity of MM-419447 was similar to the parent compound and the in vitro
activity of MM-419447 is not statistically different from MD-1100.
T2035
Diabetic Gastroparesis: Effect of Mitemcinal By Subgroup Analysis in a 12-
Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Phase 2b
Study
Richard W. McCallum, Barry J. Goldstein
INTRODUCTION: Mitemcinal, a macrolide derived motilin-receptor agonist can accelerate
gastric emptying (GE) time in patients with idiopathic and diabetic gastroparesis. Obesity
and poor glycemic control are thought to be independent risk factors for upper GI symptoms.
We investigated how these factors affected placebo response and examined Mitemcinal
efficacy in the subgroup using an eligibility baseline cut-off of BMI<35kg/m2 and/or
HbA1c<10%. METHODS: 392 insulin-requiring pts with type 1 or 2 DM were stratified by
gastric emptying test results (solid meal scintigraphy, per site standard) and treated for 3
months with placebo (P), Mitemcinal 5mg or 10 mg BID. Complete Response (CR) required
positive monthly response (defined at least twice of “adequate symptom relief” in weekly
global assessments of a month) for all 3 months. Overall Response (OR) required at least
75% of the weekly global assessments to be positive for the whole treatment period. 145
of 392 pts were excluded for: lack of baseline data (36 total: 9 BMI, 23 HbA1c, 4 both),
BMI>=35 (89), HbA1c>=10% (18), both factors (7). Study subset (247 patients) included:
74% type 1: 26% type 2; 62% female: 38% male; and 52% delayed: 48% non-delayed.
RESULTS: Multivariate analysis in P demonstrated significant influences on placebo response
rate by BMI (Odds Ratio 3.08, 95% CI 1.00-9.46) and gender (2.73, 1.02-7.29). DM type,
GE status, age and HbA1c affected PR rate without achieving statistical significance; DM
history and symptom severity were not predictive. Multivariate analysis in ITT identified
BMI<35 subgroup for CR of Mitemcinal 10 mg vs. P (2.29 OR; 1.09-4.82, 95%CI). The
Weekly Response, CR and OR rates (%) for pts with baseline HbA1c<10% and BMI<35 are
reported. CONCLUSIONS: 1) A significantly higher response rate was seen in mitemicinal
treated patients; 2) BMI and gender were independent covariates for a greater placebo
response; 3) Insulin requiring diabetics with symptomatic gastroparesis who have a BMI<35
and HbA1c<10% may represent a subset of study patients more likely to accurately reflect
a clinically meaningful response with mitemcinal at 10 mg bid; 4) Tachyphylaxis to Mitemci-
nal was not observed over the 3-month double-blind study period. 5) Additional trials with
mitemcinal in diabetic gastroparesis and other gastropathies are warranted. [Research funded
by Chugai Pharma USA, LLC]
Mean ± SD (P value)
T2036
Long-Term Quality of Life in Patients with Irritable Bowel Syndrome with
Diarrhea Predominance (IBS-D) Receiving Cilansetron 2 Mg tid: Results from
a 52-Week Extension Trial
Philip Miner, James S. Novick
INTRODUCTION: Patients with IBS-D have impaired quality of life (QOL). In various
clinical trials, cilansetron, a 5HT3 antagonist has been shown to be effective in improving
symptoms of abdominal pain and altered bowel habits as well as QOL in patients with IBS-
D. The purpose of this analysis was to determine whether the QOL improvements observed
with cilansetron 2 mg TID during a double-blind, placebo-controlled 3-month efficacy and
safety study are maintained with long-term treatment. METHODS: Patients with Rome-
defined IBS-D who had completed the 3-month core efficacy study were eligible for
enrollment in a 52-week extension study. All patients in this study received open-label
cilansetron 2 mg TID. QOL was evaluated as a secondary endpoint in both studies and was
measured using the validated IBS QOL survey, a 34-item survey including 8 subscales.
Patients completed the survey at Baseline which was defined as the final study visit in the
core study, at Week 12, and at End of Treatment which was defined as the last post-baseline
assessment on study drug. Higher scores indicate better QOL (maximum score is 100).
RESULTS: In total, 543 subjects were enrolled in the extension study and 536 subjects
were included in the safety population. The overall mean cilansetron exposure was 351
days for subjects who received cilansetron in both studies (C/C group) and 254 days for
subjects who received placebo in the core study and cilansetron in the extension study (P/
C group). At the start of the extension study, the Baseline mean scores for all scales were
higher for C/C than for P/C subjects (Table). An improvement from Baseline to End of
Treatment was observed in all scales for the P/C group. At Endpoint, the mean IBS-QOL
Overall scores were 70.7 in C/C subjects and 70.9 in P/C subjects. The largest increases in
IBS-QOL were observed in those subscales with the lowest baseline levels. CONCLUSION:
The beneficial effect of cilansetron 2 mg TID on QOL in patients with IBS-D observed during
the 3-month core study was maintained over the 52-week extension study.
IBS-QOL overall and subscale scores
T2037
The Phytopharmacon STW5 (Iberogast®) Has Pro-Secretory Effects in the
Human Small and Large Intestine
Dagmar Kruger, Florian Zeller, Olaf Kelber, D Weiser, Thomas Frieling, Michael
Schemann
Phytotherapy is a promising alternative approach to treat functional gut disorders. The
hydroethananolic drug STW5 consisting of nine herbal extracts (bitter candy tuft, chamomile
flower, peppermint leaves, caraway fruit, liquorice root, lemon balm leaves, angelica root,
greater celandine herbs, and milk thistle fruit) is successfully used to treat functional dyspep-
sia. Clinical data would suggest that it may be of therapeutic value for treating patients with
irritable bowel syndrome (IBS). We therefore investigated the effect of STW5 on secretory
activity of mucosa/submucosa preparations from human ileum and colon using the Ussing
chamber technique. Experiments were performed on normal tissue from surgical specimen
(59 preparations from 29 patients, age:69.8±11.1). Serosal application of STW5 (256µg/ml-
1024µg/ml) concentration dependently increased the short circuit current. Mucosal applica-
tion had no effect. The response was similar in small and large intestine and the data were
therefore pooled. The increase was 9.7±2.9µA/cm2 for 256µg/ml, 22±7.9µA/cm2 for 512µg/
ml and 29±8.1µA/cm2 for 1024µg/ml (p<0.05 at all concentrations). The concentrations
used are well below the dose used to treat patients with functional dyspepsia which is 3x
51mg/ml daily. The STW5 evoked secretory effect was bumetanide (100µM) sensitive and
therefore due to increased chloride secretion. Nerve blockade by tetrodotoxin (1µM) had
no effect indicating a direct epithelial action of the drug. In addition the secretory response
after electrical field stimulation of nerves remained unchanged in the presence of STW5.
Our results indicate that STW5 has a powerful pro-secretory effect in the human intestine
in vitro. It does not interfere with neurally mediated secretion but appears to stimulate
chloride secretion at the level of the epithelial cell. Generally, patients with reduced secretion
may profit from this drug. STW5 (Iberogast®) may represent a novel treatment option for
IBS patients, in particular those with constipation predominant IBS.
T2038
Protein and Ginger for the Treatment of Chemotherapy-Induced Delayed
Nausea and Gastric Dysrhythmia
Max E. Levine, Marcum Gillis, Sara Yanchis, Anne C. Voss, Robert M. Stern, Kenneth L.
Koch
Background: Delayed nausea occurs in many cancer patients during the three days following
administration of a cytotoxic agent. Meals high in protein content decrease the nausea of
motion sickness and pregnancy, possibly by enhancing normal gastric myoelectrical activity
and/or by reducing gastric dysrhythmias. Ginger may also have anti-nausea properties. The
aim of this study was to explore the use of a nutritional intervention consisting of high protein
meals and ginger for the management of delayed nausea experienced by chemotherapy-naïve
cancer patients. Method: Twenty-eight cancer patients receiving emetogenic cytotoxic agents
were assigned to one of three groups. During the three day study period following their
first chemotherapy session, Control Group patients (n=9) continued with their normal diet,
Protein Group patients (n=9) were provided with a protein drink (ProSure®; 15g whey
protein) and 1 g of dried ginger root to consume twice daily, and High Protein Group
patients (n=10) were provided with a protein drink with additional protein powder (ProSure®
and ProMod®; 31 g whey protein) and 1 g of dried ginger root to consume twice daily.
All patients were asked to complete a symptom diary over the three days to assess the
severity, frequency, and bothersomeness of the nausea they experienced, as well as their use
of antiemetic medication. Gastric myoelectrical activity was assessed by electrogastrography as
five patients ingested a protein meal with ginger on the first morning of the study. Results:
Reports of nausea, of nausea being experienced often, and of nausea being bothersome were
significantly less frequent in the High Protein Group than in the Control and Protein Groups
(ps<.05); the Control and Protein Groups were not significantly different from each other.
Furthermore, significantly fewer patients in the High Protein Group elected to use antiemetic
medication than patients in the other two groups (p<.05). A significant increase in normal
gastric myoelectrical activity (3 cycles/min), and a significant decrease in gastric tachy-
arrhythmia (3.7-10 cycles/min), the gastric dysrhythmia that frequently accompanies nausea,
occurred with ingestion of the protein meals and ginger (ps<.05). Conclusions: (1) High
protein meals with ginger reduced the delayed nausea of chemotherapy, and reduced the
use of antiemetic medications. (2) Anti-nausea effects of high protein meals with ginger
were associated with enhancement of normal gastric myoelectrical activity and decreased
gastric dysrhythmias. High protein meals with ginger represent a novel, nutritionally-based
treatment for the delayed nausea of chemotherapy.
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T2039
Tegaserod Is Effective for Long-Term Use in Patients with Chronic
Constipation
Lin Chang, Marielle Cohard-Radice, Cornelia Dunger-Baldauf, Jeffrey Kralstein, Michael
A. Shetzline
BACKGROUND: Constipation is frequently chronic and presently only Tegaserod is approved
for the treatment of this disorder. Although constipation may be treated acutely for symptom
resolution, this approach does not address the underlying disease. In order to determine
the clinical benefit of tegaserod in patients with chronic constipation, we explored data
accumulated in a long term safety study to query the benefit of long-term (13 month)
tegaserod treatment in patients who respond to tegaserod 6 mg bid after a 4 week period.
METHODS: In this blinded extension study, symptoms of constipation were assessed monthly
for abdominal distension/bloating, abdominal pain/discomfort, bothersomeness of constipa-
tion and satisfaction with bowel habits (using a 5-point Likert scale). A responder in the
core efficacy treatment period (12 weeks prior to the 13 month extension) was defined as
having an average improvement of at least one complete spontaneous bowel movement per
week during the first 4 weeks of therapy. Response at 12 weeks was defined similarly.
Patients in the extension period continued on the same dose of tegaserod they were on at
the completion of the core trial. A responder in the extension period was defined as a patient
who had a reduction of the average symptom severity over month 1 to month 13 versus
baseline of at least 0.5 points for at least 50% of reported symptom scores. Responders to
tegaserod 6 mg bid in the core trial who took study drug in the extension were included
in this analysis. Average symptom scores were analyzed with paired t-tests against the within-
group baseline. RESULTS: 113 of the 278 patients who took 6 mg bid in the extension,
(41%) were 4-week responders. 100/113(88%) were responders at the end of the 12-week
core efficacy period and over the 13 months extension, 91/107 (85%) of the patients were
responders (6 excluded due to unavailable data). Average severity reductions (mean(SD))
were 0.93 (0.98) for abdominal distension/bloating, 0.88 (1.02) for abdominal pain/discom-
fort, 1.13 (1.04) for bothersomeness of constipation and 1.36 (0.93) for satisfaction with
bowel habits. All improvements were statistically significant (p<0.0001) and clinically mean-
ingful (at least 0.5 point improvement on a 5-point scale) CONCLUSION: 85% of patients
who initially respond to tegaserod will continue to respond and this clinical response averaged
one point improvement in a 5 point Likert scale over more than one year follow up. These
results clearly demonstrate that the vast majority of patients who respond to tegaserod after
4 weeks of therapy will manifest long-term improvement in the multiple symptoms of
chronic constipation.
T2040
Effect of a Novel Motilin Receptor Agonist, GSK326416, On Faecal Output in
the Rabbit
William Unsworth, Julia E. Smith, Colin A. Campbell, Simon T. Bate, Kim L. Matthews,
Alexander J. Stevens, Shaun McNulty, Kevin Lee, Susan M. Westaway, Sharon C. Stratton,
Celestine T. O'Shaughnessy
Background: Previously, we have shown that the known motilin receptor agonist erythromy-
cin (10mg/kg i.v.) increases faecal output in rabbits over a 2h period (20th International
Symposium on Neurogastroenterology and Motility, Toulouse, 2005:P096). In the present
study the effect of GSK326416, a novel small molecule motilin receptor agonist, on faecal
output in the rabbit was compared with that of erythromycin. The rabbit was chosen for
these studies due to the apparent absence of a functional motilin receptor in rodent species,
and the demonstrated expression of motilin receptors in the rabbit GI tract (Depoortere I
et al., 1991, Peptides 12:89-94). Methods: Male NZW rabbits (2.5-3.6kg; n=8) received
GSK326416 (1, 3mg/kg), erythromycin (10mg/kg) or vehicle (5% glucose, 10% HPB, 2%
DMSO) on 4 separate occasions via i.v. bolus injection. Due to the pattern of faecal output
in the rabbit following a clear circadian rhythm, dosing commenced at 4pm on each study
day to coincide with a return to hard faecal pellet production. Each study day was separated
by a period of at least 48h, with animals receiving treatments based on a randomised 4-
period cross-over design. Faecal output was assessed following a 2h period, during which
the animals were left undisturbed. Data were analysed using a linear mixed model approach
in SAS (Proc Mixed), with post hoc-planned comparisons between the predicted means.
Results: When administered erythromycin, rabbits produced more faecal pellets (67.9+/-
7.5 vs 35.9+/-8.0 pellets, p=0.0012) with an increased total faecal weight (28.3+/-3.8g vs
12.1+/-2.8g, p<0.0001) during the 2h period, compared to vehicle. No increase in faecal
output was observed when rabbits received 1mg/kg GSK326416 (37.9+/-10.2 pellets and
13.5+/-4.4g). However, significant increases in both faecal pellet number (61.5+/-7.8 pellets;
p=0.0065) and total faecal weight (23.8+/-4.0g, p=0.0014) were observed following dosing
of 3mg/kg GSK326416. Conclusion: We have demonstrated that the motilin receptor agonist
GSK326416 possesses in vivo efficacy similar to that of erythromycin in a model of faecal
output in the rabbit. GSK326416 therefore represents a novel class of motilin receptor
agonist, distinct from erythromycin derivatives or motilides, which may prove useful in the
treatment of gastrointestinal motility disorders including gastroparesis and functional dys-
pepsia.
T2041
Lactulose in the Treatment of Constipation in Pregnant Chinese Women: A
Double-Blind, Randomized, Placebo-Controlled, Multicenter Study
Daniel Becker, Daniele Compagnone, Lily Lu
Constipation is a common problem during pregnancy. The synthetic disaccharide lactulose
is effective and safe in the treatment of constipation and, as it is not absorbed in the small
intestine, presents no risk to the fetus. The aim of the study was to compare the efficacy,
safety and tolerability of lactulose versus placebo in the treatment of constipation in pregnant
Chinese women. Methods A randomized, double-blind, placebo-controlled, multicenter
study was carried out in 63 pregnant Chinese women with constipation (Type 1, 2 or 3 on

















run-in phase, with at least one Type 1 or 2 stool in each period). The study was conducted
according to ICH-GCP, and subjects provided written informed consent. After the run-in
period, subjects were allocated by prespecified, concealed randomization list to oral lactulose
solution (30 ml/day during breakfast, adjusted to 15 or 45 ml/day from day 3 if necessary)
or placebo for 14 days and were asked to record all stools in a diary. Efficacy was assessed
for the ITT sample in terms of stool consistency (BSFS), stool frequency and the subjects’
and physicians’ treatment satisfaction. The two primary efficacy variables, i.e. change in
mean stool consistency from baseline to endpoint and responder rate (mean stool consistency
of 3.5-5.5 or an increase of at least 1 in the last week), were tested using the Wilcoxon
Mann Whitney rank sum test and the Fisher’s exact test, respectively. Results A significantly
greater change in mean stool consistency (BSFS) from baseline to endpoint occurred with
lactulose than with placebo (1.3 vs. 0.7; p=0.0191). Other clinically significant benefits were
seen with lactulose versus placebo for the last week of treatment in terms of responder rate
(61.3% vs. 46.9%), proportion of subjects with a mean stool consistency of 3.5-5.5 (32.3%
vs. 18.8%), and the percentage of subjects who were ‘very satisfied’/‘fairly satisfied’ (61.3%
vs. 45.2%) and with ‘marked improvement’/‘improvement’ according to the investigator
(64.6% vs. 50%), although the differences were not statistically significant. Treatment-
emergent adverse events were more common with lactulose than with placebo (48.4% vs.
21.9% of subjects); all events in the lactulose group involved the gastrointestinal tract and
were categorized as mild by the investigator. Lactulose had no notable effects on vital signs,
physical findings or pregnancy outcome. Conclusion Lactulose was effective and safe in the
treatment of constipation in pregnant Chinese women in this study.
T2042
Interruption of Daily Activities in Cilansetron-Treated Patients with Irritable
Bowel Syndrome with Diarrhea Predominance (IBS-D): Results from a 16-
Week, Placebo-Controlled, Rerandomization Trial
Carlos F. Francisconi, Douglas A. Drossman, Emeran A. Mayer, Steven Caras
Background: Cilansetron is a 5HT3 antagonist currently under development for the treatment
of IBS-D. In various efficacy trials, cilansetron has been shown to improve IBS-D symptoms
(abdominal pain, bowel habits, and stool consistency) and IBS-related quality of life. AIM:
To review the impact of cilansetron treatment on the interruption of daily activities (IDA)
in patients with IBS-D. Methods: In a double-blind, placebo-controlled study, ROME-
defined IBS-D patients were randomized to cilansetron 2 mg TID or placebo for 12 weeks,
and then rerandomized to either treatment for an additional 4 weeks. IDA, a secondary
endpoint, was determined by asking patients the following question at pretreatment and
Months 1, 2, 3, and 4: Over the past 4 weeks, how have your IBS symptoms significantly
interfered with your ability to effectively perform your activities? 0 = not at all or rarely;
1 = occasionally (>10% of the time); 2 = often (>25% of the time); 3 = very often (>50%
of the time), 4 = almost always. IDA results were determined by intent-to-treat analysis.
Results: At baseline, >70% of all patients reported that their IBS symptoms “often,” “very
often,” or “almost always” resulted in IDA and ≤8% reported symptoms that “not at all or
rarely” resulted in IDA. By the 12-week endpoint, 46% in the cilansetron vs 32% in the
placebo group (p<0.001) claimed that their IBS symptoms “not at all or rarely” resulted in
IDA (Table 1). Results for the proportion of patients whose symptoms “not at all or rarely”
resulted in IDA during the rerandomization phase are presented in Table 2. Conclusions:
In patients with IBS-D, an increase in IDA was observed following blinded withdrawal of
cilansetron treatment while continued benefits were seen in patients maintained on cilanse-
tron. Patients rerandomized from placebo to cilansetron demonstrated improvement in IDA
while no relative changes were observed in patients maintained on placebo.
Proportion of patients reporting IDA at baseline and week-12 endpoint
Proportion of patients reporting IDA at rerandomization baseline and week-16 endpoint
C, Cilansetron; P, Placebo
T2043
Effects of Lactobacillus Plantarum 299v On Symptoms and Rectal Sensitivity
in Patients with Irritable Bowel Syndrome (IBS) - A Randomized, Double-
Blind Controlled Trial
Magnus Simren, Alma Syrous, Anette Lindh, Hasse Abrahamsson
The effects of probiotic bacteria on symptoms in IBS patients remain controversial. The
majority of studies published so far are small and the effects of the different bacteria tested
have varied. Lactobacillus Plantarum 299v (LP) has improved gastrointestinal (GI) symptoms
in IBS patients in some (Nobaek et al 2000; Niedzielin et al 2001) but not all studies (Sen
et al 2002). The mechanism of action is unclear, but recent animal studies have proposed
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a positive effect of probiotics on visceral sensitivity. The effects of probiotics on visceral
sensitivity in humans are unknown. METHODS: We included 76 IBS patients fulfilling the
Rome II criteria (48 females; mean age 40 years). After a screening period of two weeks
eligible patients were randomized to receive six weeks of treatment with either 400 ml per
day of a rose-hip drink containing 5 x 107 cfu/ml of LP or a plain rose-hip drink (control),
comparable in colour, texture, and taste. Symptoms were assessed before and after the
treatment period using the IBS severity scoring system (IBS-SSS) and the Gastrointestinal
Symptom Rating Scale-IBS (GSRS-IBS). Rectal sensitivity testing was performed before and
after the treatment period, both in the fasting state and after an 800kcal liquid meal.
RESULTS: Twenty-nine patients in each group completed the trial, 10 patients were screening
failures and 8 dropped out prematurely during the treatment phase, due to lack of effect
of the treatment or to factors unrelated to the study. The overall GI symptom severity
improved in both groups but the improvement did not differ statistically between the groups
(p=0.17). The improvement in the control group was statistically significant (IBS-SSS total
score: 305±73 vs. 245± 118 (mean± SD); p=0.0001) and a trend in the same direction was
seen in the LP group (295±95 vs. 279± 129; p=0.08). The majority of individual GI symptoms
assessed by the GSRS-IBS improved significantly in the control group, whereas only trends
in the same direction was seen for the LP group. The change in the severity of the individual
GI symptoms did not differ between the treatment groups. The rectal sensory thresholds
were not affected in any significant way by the treatments, except for trends towards reduced
pain thresholds after the treatment period in both groups, but with no difference between
the groups. CONCLUSION: We could not detect a positive effect of Lactobacillus Plantarum
299v on GI symptoms and rectal sensitivity in IBS patients. The effectiveness of probiotics
in IBS remains uncertain. This study was supported by an unrestricted grant from Probi AB.
T2044
Colonic Vascular Conductance Increased By Herbal Medicine Dai-Kenchu-to
Via Calcitonin Gene-Related Peptide
Takashi Koseki, Toru Kono, Jun Iwamoto, Shinichi Kasai
Background & Aims: Dai-Kencyu-To (DKT) is a traditional Chinese (Kampo) herbal medicine
and has been used as the treatment of paralytic ileus DKT may increment gastrointestinal
motility by an up-regulation of the calcitonin gene-related peptide (CGRP). CGRP is also
the most powerful vasoactive substance. In the present study, we investigated whether DKT
has any effect on the colonic blood flow (CBF) in rats. Methods: Experiments were performed
on 50 fasted anesthetized Wistar rats. Systemic mean arterial blood pressure (MAP) and
heart rate (HR) were recorded. Red blood cell flux in CBF was measured using laser Doppler
flowmetry, and colonic vascular conductance (CVC) was calculated as the ratio of flux to
MAP. We examined five key physiological mechanisms underlying the response using the
blocker drugs, CGRP receptor blocker (CGRP8-37), nitric oxide synthase inhibitor (L-
NAME), vasoactive intestinal polypeptide (VIP) receptor blocker ([4-Cl-DPhe6, Leu17]-VIP),
cyclooxygenase inhibitor (indomethacin), and substance P (SP) receptor blocker (spantide).
After laparotomy, a cannula was inserted into the proximal colon to administer the DKT.
Results: Intracolonal administration of DKT (100 and 300 mg/kg) increased CVC (% of
basal CVC, 170% and 220%, respectively) in a dose-dependent manner, whereas the MAP
and HR were not affected. CGRP8-37 completely abolished the DKT-induced hyperemia,
whereas [4-Cl-DPhe6, Leu17]-VIP, L-NAME and indomethacin partially attenuated the DKT-
induced hyperemia. Spantide did not affect the hyperemia. Conclusions: The present study
demonstrated that DKT increased CBF which was mainly mediated by CGRP. This suggests
that DKT may be useful in the treatment of intestinal ischemia-related disease.
T2045
The Effect of Lipase Supplementation On Upper Gastrointestinal Symptoms
and Gastric Myoelectrical Activity Induced By a High Fat Meal in Healthy
Volunteers
Max E. Levine, Vikram D. Gopal, Sara Yanchis, Kenneth L. Koch
Background/Aims: Dyspepsia symptoms of abdominal discomfort, fullness, early satiety,
and nausea occur after ingestion of meals in 20-30% of the population. Gastric dysrhythmias
are exhibited by approximately 55% of dyspepsia patients. Currently there are limited
therapies to reduce these symptoms. Gastric and pancreatic lipases are key enzymes in fat
digestion, and hydrolyze fat into fatty acids and monoglycerides. The aims of this study
were to characterize the effects of a high fat meal on upper gastrointestinal symptoms and
gastric myoelectrical activity, and to evaluate the effect of acid-resistant lipase supplementa-
tion on the same outcomes. Method: Sixteen healthy volunteers (12 males; mean age= 31
yrs) were enrolled in a double-blind, placebo controlled, cross-over trial. Volunteers were
given a high fat meal (Pulmocare®) that was 55% fat, 28% carbohydrates, and 17% protein
(237 ml; 355 Kcal). A capsule containing 280 mg of acid-resistant lipase (Amano Enzyme
USA) or placebo was administered immediately before ingestion of the meal. The order of
conditions was counterbalanced, and visits were separated by at least one week. At each
visit, individuals completed a Visual Analog Scale (VAS) concerning symptoms of nausea,
stomach fullness, hunger, bloating, and abdominal discomfort. The VAS was completed at
baseline, immediately after the meal, and at 10, 20, 30, 45, and 60 minutes after the meal.
Electrogastrograms (EGGs) were recorded throughout each visit to assess gastric myoelectrical
activity. Results: Nausea, bloating, and stomach fullness were significantly increased 10
min after ingestion of the meal (ps<.05), and hunger was significantly decreased (p<.001);
there was also a significant decrease in normal gastric myoelectrical activity (3 cycles/min),
and a significant increase in tachygastria (3.7-10 cycles/min) at 10 min after the meal
(ps<.05). By 45 min after the meal, dyspepsia symptoms and tachygastria had decreased
significantly from immediately after the meal, and normal gastric myoelectrical activity
had increased significantly (ps<.05). Stomach fullness was significantly lower with lipase
supplementation than with placebo condition at 20 and 30 min after the meal (p<.05); no
effect of lipase supplementation on gastric myoelectrical activity was detected. Conclusions:
1) The high fat meal induced dyspepsia symptoms and gastric dysrhythmias, suggesting the
meal may be a useful test for assessing gastric neuromuscular disorders; and 2) Acid-resistant
lipase supplementation decreased stomach fullness after ingestion of the meal, and warrants
further study in individuals with functional dyspepsia.
T2046
A Novel Model to Study the Effect of Infused Gastric Content On Gastric
Pressure and Content Distribution in Conscious Rats: Effect of Atropine,
Molsidomine and NG-Nitro-L-Arginine Methyl Ester
Pieter Janssen, Maria Astin Nielsen, Per-Goran Gillberg, Leif Hultin
Introduction The stomach accommodates food without major intragastric pressure (IGP)
increase. Impairment of gastric accommodation has been associated with abnormal gastric
food distribution (overloading the antrum) and causes symptoms in functional dyspeptic
patients. We present a novel model in which we can study the effect of increasing gastric
content on IGP and gastric distribution in conscious rats. Atropine (muscarinic receptor
antagonist; 1 mg/kg), NG-nitro-L-arginine methyl ester (L-NAME; nitric oxide synthase
inhibitor; 30 mg/kg) and molsidomine (MOL; nitric oxide donor; 20 mg/kg), known to
affect gastric muscle tone, were used to validate the model. Material & Methods Experiments,
performed in 5 female Wistar Kyoto rats, were run on a weekly basis alternating control
(no drug) and drug treatment. After an overnight fast, a test-meal infusion system and a
catheter to measure IGP were connected to a gastric fistula. Drugs were injected subcutane-
ously before start of the experiment. After a 20 min stabilisation period, the non-nutrient
test-meal (containing 0.5gr barium sulphate/ml in a 3% hydroxypropyl methylcellulose
solution) was infused at a preset speed of 0.25 ml/min for 2 min, thereafter 2 ml/min until
4 ml injected. Forestomach, corpus and antrum area, calculated as % of the total stomach
area, were evaluated from X-ray pictures continuously taken during the experiments. Results
(mean±SEM) were compared using a paired t-test (P<0.05 considered significant). Results
IGP increased linearly with test-meal infusion. Atropine and MOL significantly reduced the
maximum IGP from 13.3±0.4 and 13.4±0.7 to 12.0±0.3 and 5.9±0.4 mmHg respectively.
L-NAME significantly increased the maximum IGP from 13.4±0.6 to 15.9±1.3 mmHg.
Atropine and MOL significantly reduced the antrum area to respectively 6.7±1.8 and
4.0±1.6% compared to 13.9±1.6 and 14.8±4.3% in control experiments. Atropine increased
the forestomach area to 53.0±6.6% compared to 44.3±4.3% in control experiments whereas
MOL significantly increased the corpus area to 52.9±2.5% compared to 41.3±1.7 in control
experiments. L-NAME, however, had no significant effect on content distribution between
control and L-NAME treatment. IGP and content distribution did not significant differ
between the control groups. Discussion & Conclusion For same intragastric content,
atropine and molsidomine reduced IGP and the gastric content was more proximally distrib-
uted. L-NAME increased IGP but did not have any effect on intragastric distribution. This
novel rat model can be used to study the relationship between gastric content, gastric content
distribution and intragastric pressure in a reproducible way.
T2047
Tegaserod Is Proven Safe in IBS-C Patients and Those with Mixed/Alternating
Bowel Habits
Luis C. Sabbagh, William D. Chey, Gary Barton, Andrea Viegas, Gregory Ligozio, Michael
A. Shetzline
BACKGROUND: Tegaserod (T), a promotility agent, has been shown to be safe and effective
in the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic
constipation. Recently, studies in patients with a mixed/alternating bowel pattern (IBS-M)
have demonstrated efficacy for T. Since patients with a mixed/alternating bowel pattern are
more likely to have softer stool consistency and increased stool frequency when compared
with IBS-C patients, we studied safety and tolerability of T in this population. METHODS:
A randomized, double-blind, placebo-controlled, multicenter study (North American, Latin
American and United Kingdom centers) was performed in patients with IBS-C (Rome II)
and IBS-M (those without IBS-C or IBS-D by Rome). Safety assessments consisted of reporting
all adverse events, serious adverse events (SAEs), and pregnancies, as well as assessments
of laboratory studies, vital signs, physical condition and body weight. RESULTS: 661 women
were randomized; data were available for 329 T and 331 placebo (P) patients. Overall,
29.5% of patients experienced at least one adverse event during treatment with T and 25.7%
for P. The most frequent adverse events were diarrhea (T 9.4% and P 2.1%), headache (T
5.5% and P 6.6%), abdominal pain (T 3.0% and P 2.1%), and nausea (T 2.1% and P 3.3%).
Discontinuations due to adverse events were infrequent (T 1.8% vs P 3.0%). Diarrhea led
to study discontinuation in 1.5% receiving T vs 0.6% receiving P. Diarrhea was reported
more frequently in the IBS-M subset (T 12.1% and P 1.8%) compared with the IBS-C subset
(T 7.0% and P 2.4%). However discontinuations due to diarrhea were low in both subsets
(1.5% for IBS-M and 0.6% for IBS C). Diarrhea with T typically occurred soon after initiating
therapy and lasted 2-3 days without recurrence. There were no cases of diarrhea with
clinically significant consequences (i.e., hospitalization, need for IV fluids, abnormal lab
values). No deaths occurred during the study. One patient receiving P experienced a SAE
(appendicitis) and one T-receiving patient experienced chostochondritis. Neither SAE was
suspected to be related to treatment. There were no reports of ischemic colitis. CONCLU-
SION: Diarrhea is reported more frequently in the IBS-M population, however diarrhea is
well tolerated and infrequently results in discontinuation of medical therapy. T treatment
of patients with IBS, including the subset of patients experiencing a mixed/alternating bowel
pattern, is well tolerated and safe.
T2048
Quality of Life Improves in Both Male and Female Patients with Irritable
Bowel Syndrome with Diarrhea Predominance (IBS-D) Following 12 Weeks of
Cilansetron Treatment As Part of a Placebo-Controlled Rerandomization Trial
Lucinda A. Harris, Braden Kuo
BACKGROUND: Cilansetron, a selective 5-HT3 receptor antagonist, is being evaluated for
the treatment of irritable bowel syndrome with diarrhea predominance (IBS-D). In clinical
trials, cilansetron treatment provided significant relief from IBS symptoms in both men and
women. IBS has a negative impact on quality of life (QOL) in most patients and cilansetron
has been demonstrated to increase IBS-QOL scores in 2 previous phase III cilansetron trials.
AIM: To evaluate changes in QOL by gender in IBS-D patients treated with cilansetron.
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METHODS: In this double-blind, placebo-controlled trial, 770 Rome II-defined IBS-D
patients received either cilansetron 2 mg TID or placebo for 12 weeks and were then
rerandomized to either treatment for an additional 4 weeks. QOL data for the first 12 weeks
were analyzed by gender. QOL was measured using the validated IBS-QOL survey, a 34-
item survey comprising 8 domains: body image, dysphoria, food avoidance, health worry,
interference with activity, relationship, sexual, and social reaction. Patients completed the
survey at baseline and at Week 12 by responding to each of the 34 questions. Each response
was associated with a QOL score; the total score was transformed to a 0-100 scale with
higher scores reflecting better QOL. RESULTS: The IBS-QOL survey was completed by
744 patients (238 men; 506 women). There were no significant differences between treatment
groups in overall IBS-QOL score at baseline, although mean female scores (cilansetron: 49.6;
placebo: 50.6) were numerically lower than mean male scores (cilansetron: 59.0; placebo:
59.2). At the end of treatment, the improvement in overall IBS-QOL survey scores was
significantly larger in both men and women in the cilansetron group vs placebo (Table). In
both men and women, statistically significant improvements were found in the cilansetron
groups vs placebo for all 8 of the individual IBS-QOL subscales. CONCLUSION: Male and
female IBS-D patients demonstrated significant improvements in overall IBS-QOL after 12
weeks of cilansetron 2 mg TID treatment. Furthermore, significant improvements were
observed in male and female cilansetron-treated patients in all 8 individual IBS-QOL subs-
cales: body image, dysphoria, food avoidance, health worry, interference with activity,
relationship, sexual, and social reaction. These data are similar to IBS-QOL results reported
previously from 2 other placebo-controlled phase III trials of cilansetron.
Mean (SE) change from baseline to endpoint in QOL scores during the 12 week period
T2049
Clinical Hallmarks of Cyclic Vomiting Syndrome (CVS) in Adults and Role of
Long-Term Tricyclic Therapy
Farid Namin, Patel Jitan, Iman Joker, Zhiyue Lin, Reginald Dusing, Richard W. McCallum
Our goal was to prospectively investigate adult patients meeting Rome II criteria for CVS.
Methods: 24 patients (14M, 10F, mean age: 34 years, range 18-62) who were diagnosed
over an 18-month period completed a clinical questionnaire as well as a Hamilton Rating
Scale for Anxiety (HAM-A) and Zung Depression inventory. Gastric Emptying Time (GET)
by a 4-hour scintigraphy of a solid meal was assessed and electrogastrogram (EGG) recorded
between acute attacks. PET scan was performed in 5 patients during their attacks. 14 patients
who were taking Amitriptyline at 1mg/kg for minimum 6 months completed a follow up
questionnaire including global assessment of quality of life using 1 to 10 visual analog scales.
Results: The mean age of onset of CVS was 29, range 14-53 years. All subjects reported
that severe epigastric or diffuse abdominal pain accompanied the nausea and vomiting cycles.
A typical attack, ranged from 1 to 14 days, majority of 4-6 days. Average # of hospitalizations
or ER visits was 42 per year. The HAM-A revealed that 21 (88%) were suffering from anxiety
disorder. Results of Zung Depression inventory indicated that 19 (79%) suffered from mild
to moderate depression. No history of migraine was reported, but 11 (46%) had family
history of migraine. GET was delayed (>10% isotope remaining at 4 hrs) in 2 patients, while
18 (75%) had rapid GET (<30% retention at 2 hrs) and 4 were normal. The EGG revealed
tachygastria in 4 of 10 subjects. PET scans showed similar patterns with decreased metabolism
in the left inferior frontal cortex, thalamus and cingular gyrus in all. This was significant
with 2.4 SD on a “Neuro Q” Program based test. Marijuana was used to relieve symptoms
in 50% of patients and did not appear to explain cycles. For long-term prevention 14 were
treated with Amitriptyline with a target dose of 1 mg/kg for minimum of 6 months. The
average # of ER visits and hospitalizations were significantly diminished from 32 to 14 when
annually adjusted. Visual analog scale improved by average of 4 points. The major side
effect of amitriptyline was hypersomnia and dizziness that caused one subject to stop the
treatment. Conclusions: 1) Abdominal pain accompanies nausea and vomiting cycles; 2)
There is a high prevalence of anxiety and depression; 3) Rapid gastric emptying and tachy-
gastric EGG findings are present between cycles; 4) PET scan changes indicate central
mechanisms are present during acute cycles. 5) Successful suppression of attacks can be
achieved by long-term high dose amitriptyline therapy. This single center study extends the
spectrum of CVS from pediatrics and emphasizes its increasing recognition in adults.
T2050
Growth Hormone Favorably Affects Bone Turnover and Bone Mineral Density
in Patients with short Bowel Syndrome Undergoing Intestinal Rehabilitation
Vin Tangpricha, Menghua Luo, Concepcion Fernandez-Estivariz, Niloofar Bazargan,
Shanthi V. Sitaraman, Li H. Gu, Jan-Michael Klapproth, John R. Galloway, Lorraine M.
Leader, Thomas R. Ziegler
Background: Patients with short bowel syndrome (SBS) have a high prevalence of metabolic
bone disease due to nutrient malabsorption and other factors. Human growth hormone
(hGH) has been shown in some studies to have anabolic effects on bone, but hGH effects
on bone in patients with SBS are unknown. Methods: Adults with PN-dependent SBS
underwent a 7-day period of baseline studies while receiving usual oral diet and PN, then
were placed on modified diets designed to improve nutrient absorption and daily oral
calcium/vitamin D supplements (1500 mg elemental calcium and 600 IU vitamin D3,
respectively). Subjects received in a double-blind manner either sc hGH (0.1 mg/kg/day for
3 weeks, then on a 3X weekly basis for 8 weeks; n=14) or saline placebo (control; n=9).
Open-label hGH was given from weeks 13 to 24 in subjects who required PN at the end
of week 12. Markers of bone turnover [serum osteocalcin (bone formation) and urinary N-
telopeptide (NTX; bone resorption)], and vitamin D nutriture [serum calcium, 25-hydroxyvit-
amin D (25-OH D) and parathyroid hormone (PTH) concentrations] were obtained at

















to determine bone mineral density (BMD) at baseline and weeks 12 and 24. Results: The
control and hGH-treated groups were similar in gender, age, residual small bowel length,
% with residual colon in continuity, length of time on PN and daily PN requirements The
majority of subjects in each group exhibited evidence of vitamin D deficiency at baseline
(25-OH D levels <30 ng/mL; 78% of control subjects and 79% of hGH-treated subjects,
respectively; mean values were control 22±3 and hGH 27±3 ng/mL; NS). Serum 25-OH D
levels at weeks 4 and 12 remained unchanged from baseline in each group. Subjects treated
with hGH demonstrated a significant 62% increase from baseline in serum osteocalcin levels
at 12 weeks (baseline 6.3±1.7 vs week 12 10.2±2.5 pg/mL; p< 0.05) and a 71% increase
in urinary NTX levels at 4 weeks (baseline 51±20 vs week 4 87±30 nM/nM creatinine; p<
0.05); osteocalcin and NTX remained unchanged over time in control subjects. BMD of the
spine and total hip was unchanged from baseline in subjects treated with either placebo or
hGH at 12 and 24 weeks. However, femoral neck BMD was slightly, but significantly,
decreased in the placebo group at 24 weeks, but remained unchanged from baseline in the
hGH-treated subjects. Conclusion: hGH therapy significantly increased markers of bone
turnover during the initial 3 months of therapy and stabilized femoral neck bone mass over
a 6-month period in patients with severe SBS undergoing intestinal rehabilitation.
T2051
Colostrum Supplementation Causes Hypertrophy in An Intestinal Smooth
Muscle Cell Line (HISM) and in the Ileum of a Piglet Pre-Clinical Model of
short Bowl Syndrome
Prue M. Pereira, Sarah L. Vaughan, Russell G. Taylor, Peter J. Fuller, Magdy Sourial, Eva
S. Nagy, Julie E. Bines
Introduction:We have previously shown a trophic effect of colostrum protein concentrate
(CPC) on intestinal adaptation following massive small bowel resection (MSBR). However
no study has examined the effect of CPC on muscle following MSBR. Using a previously
developed preclinical model of SBS, together with a human intestinal smooth muscle (HISM)
cell line, the current study examines the impact of CPC supplementation on ileum muscle
morphology. Methods: (A)4-wk-old piglets underwent a 75% MSBR or sham operation.
Post-op, piglets received a polymeric infant formula diet (PIF; n=3-6) or PIF supplemented
with bovine CPC (PIF+CPC; n=6-9). At sacrifice (8 weeks post-op) serum IGF-1 levels were
measured, and the ileum removed for histological assessment. Circular and longitudinal
muscle area, and nuclei numbers were quantitated (5 random measurements/piglet). (B)50%
confluent HISM cells were treated with serum free media(SFM), 10% protein in SFM, or
10% CPC in SFM (n=3/treatment) for 6 hours. The cell area was determined (40 cells/
coverslip), the number of cells in 4 fields of view/coverslip counted, and protein and DNA
concentration calculated. Results: CPC supplementation resulted in increased circular and
longitudinal muscle area in sham-operated piglets (Table 1) and moderate increases in MSBR
piglets. Nuclei numbers were similar in all groups indicating a hypertrophic response. CPC
treatment of HISM cells increased cell area and protein concentration compared with media
alone treatment, but did not increase cell numbers (Table 2). Circulating unbound IGF-1
levels were significantly higher in CPC-fed, MSBR piglets compared with PIF alone MSBR
piglets. Conclusion: Supplementation of an infant formula diet with bovine colostrum resulted
in hypertrophy of ileum circular and longitudinal muscle. Hypertrophy was also observed
following colostrum treatment of a human intestinal smooth muscle cell line. We have
shown a significant increase in circulating levels of IGF-1 in CPC-fed, resected piglets and
are currently investigating the mechanism behind this hypertrophic response.
Table 2
Table 1
a sham vs sham, p<0.05, b sham vs sham, p=0.06, MSBR vs MSBR; d p<0.05, c p=0.09
T2052
Recombinant Human Growth Hormone (rhGH) Reduces Hpn Dependence
(HPNd) of short Bowel Syndrome (SBS) Adult Patients: A Randomized, Cross-
Over, Placebo Controlled Study
Francisca Joly, Claude Baudoin, Abdul Monem Badran, Pascal Crenn, Bernard Messing
Background: following a positive placebo controlled 3 arms study, 4 weeks rhGH (0.10 mg/
Kg/d), + a modified diet and glutamine continued 12 weeks, (Byrne TA, et al. JPEN
2003;27:S17) was recently FDA approved for HPN SBS patients weaning. This study was
to confirm lower rhGH (0.05 mg/Kg/d) alone efficacy. Methods: inclusion criteria were adult
SBS HPNd patients (> 2 PN cycle/week), on sufficient oral intake, with no neoplasia, other
organ failure, severe malnutrition, uncontrolled disease, steroids or octreotide. Patients
received A and B sc daily cross over treatment with 1 PN cycle / wk decrease every 3-wk
[for a maximum duration of 4(3-wk) treatment including no change in PN during run in
and a 3-wk wash out between A & B] until lean body mass (LBM) decline, evaluated on
DEXA, was more than 5%. It was expected at least 1 PN-decrease difference between A &
B with LBM change based on regression coefficient set up in each patient : a linear mixed
model was used for statistical analysis of the cross over design (Chapman and Hall, London
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1990). Results: 11 among 13 enrolled patients, completed the study (1 stop for personal
convenience after the run in and 1 convulsion before treatment) : 3F, 8M, 44(22-60) (median,
range) yr old, with a jejuno-colonic anastomosis, a small bowel remnant of 30(0-100)cm
and an initial PNd of 5(2-7) cycle / wk. PNd was -2(0-3) with A and -3(0-3) with B. LBM
changes (Kg/wk, mean±SD) were for AB sequence (n=6) -0.03±0.16 & +0.12±0.21, for BA
sequence (n=5) : +0.22±0.10 and -0.21±0.10 respectively. Difference between treatment A
and B was better for B : +0.29±0.08 (mean±SEM) (p=0.007) with neither carry over (p=
0.46) nor period effect (p=0.12). Conclusion : rhGH (treatment B) reduced PNd better than
placebo (treatmentA) with no LBM decline during rhGH treatment. The rhGH effect was
not sustained during the placebo period treatment.
T2053
The Effects of Glucagon-Like Peptide 2 (GLP-2) On Intestinal Mucosal Blood-
Flow Evaluated in the Stoma Nipple By Laser Doppler Flow in short Bowel
Patients
Peter Hoeyerup, Peter T. Schmidt, Per Hellstrom, Per B. Mortensen, Palle B. Jeppesen
Background: GLP-2 is a hormone secreted from the endocrine L-cells of the intestine in
response to enteral feeding. GLP-2 has been shown to be intestinotrophic in animal and
human studies. In animal studies it has also been described that GLP-2 acutely stimulates
proximal small intestinal blood-flow (Stephens-J et al. Am J Physiol Regul Comp Physiol
sept. 2005). Short bowel jejunostomy patients describe hyperemia and enlargement in stoma
nipple size in relation to GLP-2 treatment. Whether these observations are due to changes
in mucosal blod flow is unknown. The aim of this study was to evaluate the acute effect of
subcutaneous (s.c.) GLP-2 on stoma nipple mucosal blod flow (SNMBF) by Laser Doppler
Technique (LDT). Methods: In 5 fasting short bowel IBD patients (1F, 4M; 56±6 years;
small bowel 204±52 cm) a laser doppler flowmeter probe with 3 measure-points (site 1-3)
was inserted approximately 5 cm into the stoma and fixated. A control probe was fixed to
the skin in the maxillar region of the face (site 4) of the patients. SNMBF was measured
employing a Periflux PF 4001 Master (Perimed AB, Järfälla, Sweden) in 2 minutes intervals
at baseline and 14 and 59 minutes after injecting 800 microgram GLP-2 s.c. A wavelength
of 780 nm, a time constant of 0.2 sec, and a bandwidth of 20-25 kHZ with a sampling
frequency of 32 HZ were used. The SNMBF was expressed in units of relative perfusion
(perfusion units, PU). Results: The results are presented in the table. Conclusion: Although
a numerical increase in perfusion units was detected in SNMBF after an s.c. GLP-2 injection,
this did not reach statistical significance. Larger studies, more time intervals and possible
longer observation periods are needed to answer whether GLP-2 increase SNMBF or not.
Perfusion units (PU)
T2054
Increased Intestinal Absorption Rates By Segmental Reversal of the Small
Bowel in Patients with short Bowel Syndrome
Francisca Joly, Sophie Rousseau, Xavier Dray, Kouroche Vahedi, Nathalie Kapel, Patrice
Valleur, Yves Panis, Bernard Messing
Introduction : Segmental reversal of the distal remnant jejunum (SRJ) has been proposed
as rehabilitative surgery to decrease parenteral nutrition dependence in adult patients with
short bowel syndrome (SBS) type II (jejuno-colic anastomosis). However no solid data are
available concerning change in absorption. Aim: To compare the intestinal absorption rates
in SBS patients with and without SRJ. Methods: Intestinal absorption of total energy (bomb
calorimetry), nitrogen (nitrogen elemental analysis), fat (Van de Kamer method) and carbo-
hydrate (total - fat and protein) was analyzed during a 3-day period of (a) oral intake (no
TCM) measured by expert dietetic enquiry and (b) stool collection on ice. All causes of SBS
were included with the exclusion of SBS due to radiation enteritis. Seventeen SBS patients
with SRJ (median age 52 years, range 21-80) were matched to 17 control SBS patients
(median age 47 years, range 24-68) according to the post duodenal remnant small bowel
length and remaining colon. All patients presented with a jejuno-colic anastomosis. Wilcoxon
matched-pair signed-ranks test was used to compare continuous variables. Results: At the
absorption study period, the 17 patients of the SRJ group and 13 patients of the control
group were still on parenteral nutrition. The median remnant small bowel length was 35
cm (range 9-70) in the SRSB compared to 40 cm (range 0-80) in the control group (p=
0.86). The median (range) delay between the reestablishment of the jejunocolic anastomosis
and the absorption study was for SRJ 16(6-131) months and for SBS controls 47(5-227)
months (NS). The median (range) length of the reversal segment was 10 (8-15) cm. Oral
intake and stool output were similar in both groups (2572 kcal/d and 1577 ml/d in the SRJ
group, 2666 kcal/d and 1676ml/d in the control group, p=0.93 and p=0.90 respectively).
Net caloric absorption was higher in the SRJ group compared to the control group (1809
vs 1508 kcal/d, p=0.21), as well as mean relative absorption rates of total calories (69% vs
58%, p=0.03), nitrogen (63% vs 53%, p=0.06) and lipids (48% vs 33%, p=0.05), carbohyd-
rate absorption being similar (91% vs 85%, p=0.43). Conclusion: SBS Patients with SRJ
had a 10% to 15% improved intestinal caloric, fat and nitrogen absorption rates, which
corresponded to 21% of their mean resting energy expenditure (1442 kcal/j). These results
confirm SRJ as a tool to improve absorption in SBS.
T2055
Effect of LGG On Gut Barrier Function and Breath Hydrogen Testing in
Children with short Gut Syndrome: Results of a Randomized Placebo-
Controlled Clinical Trial
Timothy A. Sentongo, Xaiotan Zheng, Valeria Cohran, Simona Korff, Annie Xoomsai,
Christine Sullivan, Kishore Iyer
BACKGROUND: The disproportionately high incidence of bacteremia illnesses with gram
negative and enteric bacteria in children with short gut syndrome (SGS) is suspected from
translocation of gut bacteria. There are currently limited data about gut barrier function
(GBF) in patients with SGS. Lactobacillus casei (LGG) exerts an inhibitory effect on other
enteric bacteria and also enhances GBF in patients with atopy. Therefore we examined GBF
in children with SGS and explored the effects of probiotic therapy with LGG on GBF and
indicators of bacterial overgrowth (SBBO). METHODS: 11-week prospective double-blind,
placebo controlled cross-over study of LGG vs. placebo therapy in SGS. Children with SGS
and healthy controls had GBF measured at baseline using Lactulose:Mannitol ratio adjusted
for body surface area(LMR). Subjects with SGS then randomnly received either LGG or
placebo for 4-weeks, followed by 3-weeks of no therapy (washout) then therapy crossed-
over for another 4-weeks so that those initially treated with LGG now received placebo and
vice versa. LMR, hydrogen breath testing (HBT) for SBBO, and quantitative stool cultures
for LGG (cfu/g of stool) were measured during therapy with LGG and placebo. Comparisons
of LMR in SGS and controls at baseline and during therapy with LGG vs. placebo in SGS
were examined using Wilcoxon’s rank sum test. Associations between LMR and age were
examined using Spearman correlation. Rates of increased HBT (SBBO) during therapy with
LGG vs. placebo were examind using McNemar’s test. Signficiance was p < 0.05. RESULTS:
21 subjects enrolled; SGS (N = 9) median age 3.5 y (range 1.6 - 16.1 y) and controls (N =
12) median age 10.7 y (range 1.7 - 16.4 y). There was no difference in baseline LMR between
SGS and controls (mean±SD) 0.15±0.12 vs. 0.10±0.10 (p = 0.47). LMR was inversely
correlated with age (r = -0.82, p<0.0001) suggesting that permeability at tight junctions
decreased with advancing age in all subjects. Therapy with LGG vs. placebo had no effects
on LMR (0.33±0.35 vs. 0.23±0.23, p = 0.58). Stool colonization with lactobacillus during
therapy with LGG was (median)9.0x10(8) cfu/g, (range) 4.0 x10(5) to 4.0x10(9)cfu/g. The
prevalence of increased HBT (SBBO) was 67% and did not change during therapy with LGG
vs. placebo (p = 0.32). CONCLUSION: GBF in children with SGS and controls was similar
and mainly influenced by age. Emperic therapy with LGG and colonization with lactobacillus
had no measureable effects on GBF or prevalence of SBBO in this sample of children with
SGS. These findings are important for defining the role of probiotics in patients with SGS.
Supported by NIH Grant M01 RR-00048
T2056
Genetic Testing for Hypolactasia - Redefining Diagnostic Testing for Lactose
Intolerance?
Daniel Pohl, Radu Tutuian, Oliver Goetze, Martin Hersberger, Arnold von Eckardstein,
Bernadette Stutz, Michael Fried
Introduction: Lactase deficiency (LD) is the most common cause of lactose intolerance, a
highly prevalent condition and frequent cause of abdominal pain, bloating and diarrhea.
The standard test to diagnose lactase deficiency is the hydrogen breath test (H2-BT). Recently
the single-nucleotid-polymorphism C/T 13910 base pairs above the structural gene coding
for the enzyme lactase has been associated with lactase deficiency with a reported sensitivity
of 75% compared to lactose H2-BT. Aims: To evaluate the agreement between C/T13910
and lactose H2-BT as well as sensitivity, specificity and predictive values of gastrointestinal
symptoms in response to lactose ingestion. Methods: 41 patients (32f; mean age 36, range
11-76 years) with clinical suspicion of lactose intolerance underwent a 3-hour H2-BT after
intake of 50 g of lactose followed by genetic testing. During the H2-BT patients rated five
symptoms (abdominal pain, borborygmi, diarrhea, bloating, nausea) every 15 minutes on
a linear scale from 1-9. The H2-BT was considered positive with a rise of exhaled hydrogen
>20 ppm over baseline and the test considered symptomatic after an increment of >2 scale
units in at least two symptoms. Genotype CC13910 was considered indicative for lactase
deficiency. Results: All but one patient (genotype CC, H2-BT negative, symptomatic) had
concordant results in the genetic test and H2-BT indicating an almost perfect agreement
(kappa = 0.95). Sensitivity and specificity of the genetic test when compared to H2-BT as
gold standard were 100% and 96% respectively. All 17 patients with genotype CC were
classified as symptomatic as did 39%(7/18) of patients with genotype CT and 33% (2/6) of
patients with TT. Diarrhea had the highest positive predictive value (67%) and bloating the
highest negative predictive value (93%) to identify patients with LD. Abdominal pain had
the lowest diagnostic accuracy. Conclusions: Genetic testing has an excellent agreement
with the standard lactose hydrogen breath test and could replace breath testing for the
diagnosis of LD. Clinical evaluation of symptoms developed in response to the ingestion of
50 g lactose could be used as a simple screening test in patients suspected to have lactose
deficiency: No symptoms in particular absence of bloating and borborygmi make the diagnosis
of lactase deficiency unlikely.
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T2057
Functional Alterations Following Small Bowel Ischemia-Reperfusion Injury As
a Model of Infant Necrotizing Enterocolitis
Brian M. Chung, Fatima Ahmed, Kelly Tappenden
Infant necrotizing enterocolitis (NEC) presents both clinical and experimental challenges.
Clinicians are faced with the threat of bowel perforation, systemic multi-organ dysfunction
syndrome and failure to thrive, while researchers are challenged with few models of spontan-
eous NEC. One proposed initiator of NEC injury is bowel ischemia coupled with overfeeding.
We hypothesized that the presence of luminal nutrients in the face of ischemia-reperfusion
(I/R) injury would alter ileal nutrient transport to induce NEC-like symptoms. Two-day-
old neonatal piglets (n=20) were anesthetized and two 15-cm loops of distal ileum were
cannulated for the randomized luminal perfusion of saline or hydrolyzed infant formula
(20ml/hour) for the duration of the study. The small intestinal branch of the mesenteric
artery was then atraumatically clamped for 1 hour, followed by 1 hour of reperfusion injury.
Perfused tissues were harvested for electrophysiological analysis of nutrient transport in
modified Ussing chambers as well as gross morphology. Ileal tissues did not demonstrate
alterations in basal short circuit current, resistance, or transmural potential difference, glycyl-
sarcosine, proline, arginine or threonine transport, nor serotonin- or carbachol-induced
secretion, regardless of perfusate. However, tissues perfused with formula demonstrated
significantly (P<0.05) decreased glucose transport when compared to saline perfused loops
(formula 2.76±1.67 vs saline 9.66±1.67 uA/cm2), as well as decreased glutamine transport
(formula 4.65±2.14 vs saline 8.29±2.14, p<0.05). This was mirrored by fluid flux measure-
ments using the inert marker sodium ferrocyanide, where formula perfusion stimulated net
secretion (97±2.87), whereas saline perfusion stimulated net absorption (106.35±2.88%
stock perfusate p<0.05). Villus height, crypt depth and mucosal wet weight were not altered,
but a significant increase (p<0.05) in mucosal DNA in the formula perfused tissues (formula
1.87±.15 vs saline 1.32±.15 mg/mg mucosa) was observed. I/R in the presence of luminal
nutrients appears to be a viable model for initiation of NEC, as supported by: the decrease
in glucose and glutamine transport, coupled with net fluid secretion, and increase in mucosal
DNA, without change in the villus/crypt length, thus indicating imminent intestinal failure
associated with possible immune infiltration.
T2058
The Relationship Between Glucose Absorption and Gastric Emptying in
Critical Illness
Marianne Chapman, Robert Fraser, Laura Bryant, Carly Burgstad, Francis Bartholomeusz,
Stephanie Creed, Antonietta Russo, Karen Jones, Max Bellon, Barry Chatterton, Ross
Butler, Geoffrey Davidson, Michael Horowitz
Delayed gastric emptying is common in critical illness, resulting in reduced tolerance to
nasogastric feeding. In these patients, nutrient absorption is also impaired. As the small
intestine is the major site of absorption, gastric stasis may be a limiting factor. Absorption
may be further compromised by mucosal oedema, atrophy or reduced splanchnic blood
flow. There are limited data on the factors reducing nutrient absorption in critical illness.
Aim: To assess the relationship between glucose absorption and gastric emptying in critically
ill patients. Methods: Gastric emptying was measured (using scintigraphy) over 4 h in 15
mechanically ventilated, critically ill patients (12M; 60 ± 4 years; APACHE II score 18 (12-
30)) after the intragastric delivery of 100ml of Ensure labelled with 99mTc sulphur colloid.
Glucose absorption was assessed using 2g of 3-Ortho-Methyl-D-glucose (3-OMG) added to
the test meal. The % meal retention at 60, 120, 180 and 240 min was determined. Plasma
3-OMG concentrations were measured (using High Performance Exchange Chromatography)
at baseline, every 15 min during the first hour, and every 30 min thereafter for 3 h. The
area under the curve (AUC) was calculated for the 3-OMG concentrations over time. Patient
data were compared to 15 healthy subjects (8M; 35.2 ± 4.7 years) and are expressed as
mean ± SEM. Results: Meal retention at both 180 and 240 min was greater in critical illness
than in health (180min: 32.1 ± 9.2 v 3 ± 0.6 %, P<0.05; and 240min: 29.7 ± 9.2 v 1.7 ±
0.4 %, P<0.05). All healthy subjects and 8 critically ill patients (53%) had <10% meal
retention at 240 min. The mean area under the 3-OMG concentration curve was less in
critically ill patients than healthy subjects (AUC: 32.9 ± 4.8 v 65.9 ± 4.8, P<0.0001). There
was a negative correlation between the % meal retention (at all time-points) and 3-OMG
absorption in critically ill patients (r= -0.77 to -0.87; P<0.001), but not in healthy subjects.
Conclusion: Delayed gastric emptying has a negative effect on glucose absorption in critically
ill patients, but not in healthy subjects, suggesting this may be the rate limiting step in
patients. Prokinetic agents to stimulate gastric emptying should therefore enhance nutrient


















Development of a Simple Model of Orthotopic Small Bowel Transplantation in
the Mouse
Fatima Javairiah, Scott G. Houghton, Michael G. Sarr
BACKGROUND: Small bowel transplantation (SBT), though a promising treatment for
intestinal failure, is associated with multiple, still poorly understood functional problems of
the transplanted gut. Ability to study SBT models in mice is hindered by the extreme
technical difficulty of orthotopic SBT in the mouse. AIM: To develop an easily constructed
preparation of orthotopic, extrinsic denervation of the entire jejunoileum in mice as a model
of orthotopic SBT. HYPOTHESIS: This mouse model will allow more ready investigation
of physiologic changes in gut function after extrinsic denervation without confounding
factors of ischemia-reperfusion and/or immune phenomenon. METHODS: All neurolym-
phatic tissues accompanying the superior mesenteric artery and vein were transected at the
base of the small bowel mesentery just distal to the middle colic vessels. The superior
mesenteric artery and vein were stripped carefully of all adventitia, and the mesenteries up
to the proximal jejunum and proximal colon were transected in radial fashion. The proximal
jejunum and proximal colon were not transected and re-anastomosed. To confirm extrinsic
denervation, 4 weeks later, still innervated duodenum and extrinsically denervated jejunum
and ileum were harvested from 6 mice and stained for PGP9.5 (a non-specific neuronal
marker) and tyrosine hydroxylase (a marker of extrinsic innervation because the only catecho-
laminergic nerves in the gut are extrinsic sympathetic nerves). Neurally intact mice provided
control tissues. RESULTS: Immunohistochemistry showed complete lack of tyrosine
hydroxylase activity in jejunum and ileum in denervated mice but preservation of activity
in the duodenum. No obvious differences were noted in PGP9.5 staining. SUMMARY: This
technique in the mouse accomplishes complete extrinsic denervation of the jejunoileum.
CONCLUSIONS: This murine model of orthotopic SBT, by allowing the use of genetically
modified (knockout mice), will allow study of molecular and genetic effects of selective
extrinsic denervation on small bowel function.
T2060
Maltotriose, Product of α-Amylase Starch Hydrolysis, Suppresses Maltase-
Glucoamylase Activity and Slows Terminal Starch Digestion 44.5 Fold
Roberto Quezada-Calvillo, Claudia C. Robayo-Torres, Susan S. Baker, Bruce Hamaker,
Erwin E. Sterchi, Buford L. Nichols
Starches constitute the main caloric source in the average human diet. The digestion of
starches is far more complex than sugars and requires six different enzyme activities to
produce free glucose before absorption. Salivary and pancreatic α-amylase activities initially
hydrolyze internal 1-4 glucose bonds of starch to produce a limited pattern of soluble
glucose oligomers including maltotriose. Terminally, mucosal enzymes maltase-glucoamylase
(MGAM) and sucrase-isomaltase (SI) hydrolyze external linear bonds of starch oligosacchar-
ides to free glucose. Our aim was to determine the relative roles of the two mucosal enzymes
in terminal starch digestion. These experiments led to the novel discovery that rates of
integrated mucosal starch digestion to glucose are regulated by lumenal maltotriose substrate
inhibition, termed the maltotriose brake. Methods: Enterocytes were harvested from trans-
plant donor jejunum by scraping. The membranes were solubilized with 10% Nonidet P
40. MGAM and SI activities were immunoprecipitated (IP) with monoclonal antibodies and
incubated with dilutions of maltose, maltotriose and dextromaltose for 60 min, Dextromal-
tose, partially hydrolyzed amylopectin, substrate was analyzed by Mass Spectrometry. Glucose
production was measured by Sigma Infinity reagent. The protocol was approved by BCM
IRB as H-1320. Results: Dextromaltose has a median polymer length of 7 glucoses. Enzyme
IPs were shown pure and relative concentrations determined by Western blot. Concentration
of SI is 20 times MGAM. Under clinical assay conditions, SI accounted for all mucosal
maltotriase and 80% of IP maltase and dextromaltase activities. MGAM was inhibited (Ki
1.8 mM) by maltotriose. All activities followed Michaelian kinetics. Both enzymes hydrolyzed
dextromaltose but Km was 1.3 for MGAM and 58 for SI. Conclusion: MGAM and SI
accounted for 90% of all mucosal dextromaltase activity. MGAM is 44.5 times more active
than SI. MGAM is substrate inhibited by maltotriose but SI is not. SI is a low activity, high
capacity unregulated enzyme for terminal starch digestion. MGAM has higher activity (44.5
fold) and lower capacity (20 fold). MGAM provides rapid glucose production during early
and late starch feeding or snacking but its high activity is suppressed by the maltotriose
brake during heavy starch ingestion. MGAM matches Kms of amylase and the glucose
transporter but when the brake is applied, slower SI becomes rate limiting for the digestion
of starch to glucose. This work was supported in part by USDA/ARS/Children’s Nutrition
Research Center and Public Health Service grant DK56338, which funds the Texas Gulf
Coast Digestive Diseases Center.
T2062
Comparison of a Genetic Test for Lactase Polymorphism with Two Standard
Tests for Lactose Mal-Digestion in Adults
Andrew N. Szilagyi, Paula Malolepszy, Elise Hamard, Mary Ponniah, Xiaoqing Xue, Nir
Hilzenrat, Elizabeth MacNamara, George Chong
Introduction: The breath hydrogen test (BHT) is the most common indirect test of lactose
mal-digestion. A positive rise shows lactase non persistence (LNP). It agrees moderately
with an earlier blood glucose test (BGT) where a positive rise shows lactase persistence (LP).
The availability of a test for genetic polymorphism (GPT) in the LPH gene for LNP/LP status
allows head on comparison among these 3 tests. GPT correlates with intestinal lactase.
Participants: Previously established LNP/LP subjects, at a BH2 testing laboratory in a univer-
sity hospital setting. Their LNP/LP status was determined according to BHT and/or ethnic
background without IBS or other contraindications. Methods: Participants underwent a 50g
lactose challenge.The BHT (>10 or 20 ppm) with q30 min scored symptoms was measured
for 4.5 Hrs. by hand held electrochemical H2 sensor(Bedfont, UK). The BGT (>1.1 mmol/
L) was measured for 2/4.5 Hrs, by colorimeter (Roche Diagnostics). Blood drawn for GPT
was assessed by real-time PCR fluorescent resonance energy transfer (FRET) on the Light
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Cycler (Roche Diagnostics). Participants completed a validated lactose targeting 3 -day recall
questionnaire to assess average pre- test daily consumption. Analysis: Kappa statistics were
used to assess the agreement among the 3 tests. Wilcoxon signed rank test or chi-square
test were also used for other comparisons. Results: Thirty subjects (12 male, 18 female)
participated in the study. Among them, 17 are LNP and 13 are LP based on results from
BHT. However, the results by GPT showed 15 CC (LNP), 12 CT (LP) and 3TT (LP). Of 14
symptomatic subjects, 11/15 (73.3%) were LNP, and 3/15 (20%) were LP (p-value =0.01).
Symptomatic subjects including all Asians consumed significantly less lactose per day than
asymptomatic subjects. Conclusions: Either BHT or BGT reflects GPT substantially. All 3
tests agree well also but BGT only moderately agrees with BHT. LNP subjects were significantly
more symptomatic. Indirect tests like BHT or BGT may also reflect several physiological
effects. Studies on the impact of dairy consumption in adults probably should use both
GPT and another indirect test, i.e. BHT or BGT. Population prevalence studies could use
GPT alone.
Distribution of test outcomes
Kappa coefficients
T2063
High Prevalence of Vitamin D Deficiency in Patients with Inactive Crohn’s
Disease
Treasa Nic Suibhne, Colm O'Morain, Maria O'Sullivan
Vitamin D is essential for bone and muscle metabolism. Crohn’s disease (CD) patients are
at increased risk of vitamin D deficiency due to low dietary intake, malabsorption and low
exposure to sunlight, particularly during periods of high disease activity. AIM: To determine
the prevalence of vitamin D deficiency in inactive CD and to evaluate vitamin D and calcium
(Ca) intakes in CD patients compared to healthy controls. METHODS: Nutritional and
clinical assessments were conducted on 81 CD patients and 81 healthy controls matched
for age, sex and socio-economic status [CD patients, 60% (49/81) female, 36.43 ± 11.03
years v controls 60% (49/81) female, 37.03 ± 10.87 years]. Dietary vitamin D and Ca intakes
were assessed in all subjects using a validated food frequency questionnaire. Serum 1,25-
dihydroxy vitamin D3 was measured by radioimmunoassay in CD patients. The majority
of CD patients [68% (55/81)] were in clinical remission (defined by Crohn’s Disease Activity
Index (CDAI) <150; median 92.09 (0 - 371.67), had normal C-reactive protein (CRP) levels
[58% (47/78); median 3.85 (2.9 - 53.3)], and were on corticosteroid [51% (41/81)] or
infliximab therapy [15% (12/81)] during the previous 12 months. RESULTS: The majority
[63% (51/81)] of CD patients showed vitamin D deficiency (<20ng/ml). Of these, 46% (37/
81) had mild deficiency (10 - 20ng/ml) and 17% (14/81) had moderate deficiency (5 -
10ng/ml). Higher serum vitamin D was significantly associated with vitamin D intake from
supplements (r = 0.31, P = 0.00). There was no association with age (36.86 ± 10.91 v 35.70
± 11.38 years; NS), gender [57% (29/51) v 67% (20/30) female; NSχ2], CRP levels [63%
(30/48) v 57% (17/30) <5mg/L; NSχ2], serum tumour necrosis factor alpha (TNFα) levels
(6.03 ± 2.21 v 6.14 ± 1.88; NS), CDAI [69% (35/51) v 67% (20/30); NSχ2], seasonality
(P = 0.52χ2), disease site (P = 0.59χ2) or previous surgery (P = 0.43χ2). Dietary vitamin D
intakes were significantly lower in CD patients than controls (159.87 ± 13.96IU v 207.81
± 14.26IU, P = 0.01), and only 22% (21/78) of patients met the Recommended Daily
Allowance (RDA) of 200IU for vitamin D from diet alone. After addition of vitamin D intake
from supplements, 53% (41/78) of patients reached the RDA. Patients were more likely to
be prescribed vitamin D supplements if they had received steroids within the past year (r2 =
0.3, P = 0.01). Dietary Ca intakes were similar in both CD and controls (974.59 ± 51.22mg
v 1062.92 ± 57.16mg; NS). CONCLUSION: Vitamin D deficiency is prevalent in quiescent
CD, a group not typically considered at risk.
T2064
13c-Glucose Hydrogen Breath Test to Evaluate Glucose Oxidation and
Carbohydrate Malabsorption
Yoshihisa Urita, Susumu Ishihara, Kenichiro Arai, Jun Kondo, Tatsuo Akimoto, Hiroto
Kato, Noriko Hara, Hideyuki Koshino, Yoshiko Honda, Yoko Nagai, Kazushige Nakanishi,
Nagato Shimada, Motonobu Sugimoto, Kazumasa Miki
Background: Glucose is readily absorbed in the proximal small bowel. In patients with
gastorectomized patients, it was reported that 100% of the glucose ingested was absorbed
before reaching the colon. Therefore, the fact that any peak of breath hydrogen (H2) and
methane (CH4) excretion after ingestion of glucose is abnormal is the main advantage in
terms of the interpretation of H2 breath test using glucose. It has been unknown whether
carbohydrate malabsorption affect glucose metabolism. On the other hand, recent studies
have targeted prediabetic individuals for early therapeutic intervention in the hopes of
preventing progressikon to type 2 diabetes. Early intervention might be most appropriate
at the stage of disease progression when insulin resistance is present but before glucose
intolerance occurs. The aim of this study is to evaluate the association among glucose
oxidation, insulin resistance, and carbohydrate malabsorption. Patients and Methods: A
standard 75 g oral glucose tolerance test (GTT) was performed in 62 subjects, 32 women
and 30 men, aged 39-87 years. The patients received 75g (225 ml) of glucose solution in
the sitting position after an overnight fast. Breath samples were collected at baseline and at
5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, and 120min after ingestion to analyze
breath H2 and CH4 concentrations as well as 13CO2. An increase of at least 10 ppm within
a two-hour period is indicative of carbohydrate malabsorption. Venous blood samples were
obtained before ingestion and at 30, 60, 90, 120 min and blood glucose and serum insulin
concentrations were measured. Results: 13CO2 excretion rate in expired breath increased
up to 180 min. Recovery rate of 13CO2 in expired breath is 1.7% and 6.1% at 60 min and
120 min, respectively. Insulinogenic index (plasma insulin at 30 min-baseline/plasma glucose
at 30 min-baseline) significantly correlates with 13CO2 excretion at 60 min (R2=0.28).
Carbohydrate malabsorption was found in 16 patients (26%). These patients had slightly
increased insulin resistance, compared to diabetic patients without carbohydrate malabsorp-
tion. There was no significant difference in insulinogenic index and 13CO2 excretion at
any time point between two groups. Conclusions: It is concluded that carbohydrate malab-
sorption may have a role of keeping appropriate blood glucose concentration and progressing
insulin resistance. There was no significant correlation among carbohydrate absorption,
glucose oxidation, and insulin resistance.
T2065
Intestinal Absorption Capacity Is Normal in Recently Diagnosed Celiac
Disease, But Not in Refractory Celiac Disease
Nicolette Wierdsma, Job H. Peters, Chris J. Mulder, Marian A. van Bokhorst- de van der
Schueren, Adje A. van Bodegraven
Introduction Malnutrition due to malabsorption of nutrients is a common finding in celiac
disease (CD). It is not clear to what extent villous atrophy determines the level of malabsorp-
tion. To quantify intestinal absorption capacity may be helpful to distinguish patients that
may benefit from nutritional support. This study compared absorptiometry in patients with
de novo CD prior to a gluten free diet, in patients with refractory celiac disease (RCD) and
healthy controls (HC). Aims & Methods The objective was to determine a difference in
intestinal absorption capacity between the three groups. Absorptiometry was obtained by
recording oral caloric intake and the extent of fecal calorie loss by using the gold standard,
bomb calorimetry. A four days nutritional diary assessed oral intake and subsequent collection
of feces was performed from day two to four. Intestinal absorption capacity was calculated
as the difference in caloric intake and fecal loss expressed in percentage. Results A total of
nineteen patients was included. Nine patients (4M, 5F) in the de novo CD group had a
mean age of 50.1 ± 11.8 years, a BMI of 25.7 ± 4.9 kg/m2, a caloric intake of 2363 ± 533
kcal/day and a fecal caloric loss of 280 ± 124 kcal/day. Five patients (2M, 3F) in the RCD
group had a mean age of 62.8 ± 1.8 years (p=0.02 compared to CD, p=0.01 compared to
HC), a BMI of 20.9 ± 2.1 kg/m2, a caloric intake of 3020 ± 525 kcal/day (p=0.01 compared
to HC) and a fecal caloric loss of 772 ± 651 kcal/day. Five patients (5F) in the HC group
had a mean age of 42.5 ± 12.4 years, a BMI of 23.7 ± 3.3 kg/m2, a caloric intake of 2021
± 205 kcal/day and a fecal caloric loss of 224 ± 75 kcal/day. Mean intestinal absorption
capacity was 88.6 ± 3.7, 73.0 ± 24.7, 88.8 ± 3.8% in CD, RCD and HC, respectively.
Conclusion Intestinal absorption capacity in healthy controls is 90%. In patients with de
novo celiac disease, absorption capacity was equal to that of healthy controls. There was a
trend towards a decreased intestinal absorption capacity in RCD compared to both de novo
CD and HC, possibly due to individual variability in the RCD group. In these patients
nutritional support may be beneficial.
T2066
The Protein Absorption Capacity Is Intact in Human Neonates with An
Enterostomy
Maaike W. Schaart, Adrianus C. De Bruijn, Dick Tibboel, Johannes B. van Goudoever,
Ingrid B. Renes
Background: The intestine plays a key role in the maintenance of an effective protein
metabolism, which determines growth of human neonates. Bowel resection in the neonatal
period leads to a drastic loss of absorptive and protective surface and consequently to
malabsorption of nutrients. We therefore hypothesized that the net enteral protein absorption
of the small intestine is reduced in the postoperative period of human neonates following
bowel resection. Objective: To quantify the net absorption of dietary proteins in human
neonates with an enterostomy following bowel resection during a 4-week period after surgery.
Methods: Eighteen patients were included in the study [jejunostomy: n=3, ileostomy: n=
15]. After introducing enteral feeding, the outflow fluid at the stoma exit was collected
during 24-48 hours every week over a period of 4 weeks [wk 3 - wk 6] following bowel
resection. Protein levels in the outflow fluid were determined by Bicinchoninic Acid (BCA)
protein assay. The net absorption of dietary proteins was calculated by subtracting the
protein amount excreted in the outflow product from the protein amount ingested and was
expressed as the percentage of the total enteral protein intake. Results: The mean dietary
protein intake of all patients was 2.64 ± 1.28 gr/kg/d. The dietary protein absorptive capacity
was constant over the 4-week period for every individual patient. The mean net absorption
of dietary proteins was 86.7% ± 9.0% of the total enteral intake. The absorption capacity
of patients with a jejunostomy tended to be lower compared to patients with an ileostomy
[jejunum: 78.7% ± 2.1%, ileum: 88.3% ± 9.0%, p=0.066]. Conclusions: In contrast to our
hypothesis this study showed that the small intestine is capable to absorb dietary proteins
from 3 weeks following intestinal surgery. Thus, the protein absorption capacity is intact
in human neonates who underwent bowel resection in a very critical period of their life.
T2067
Determination of Residual Bowel Length Via Surgical, Radiological Or
Historical Data in Patients with short Bowel Syndrome and Intestinal Failure
Neha R. Parekh, Ezra Steiger, Douglas L. Seidner
Introduction: Treatment options for patients with short bowel syndrome (SBS) and intestinal
failure (IF) vary directly with the length and condition of the residual bowel. An accurate
assessment of remaining intestine is necessary to make optimal therapeutic decisions and
to efficiently track the progress of SBS and IF patients. The most reliable way to assess
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intestinal length is by measuring along the antimesenteric border from the Ligament of
Treitz at the time of surgery, although this is not often done. Radiologic techniques with
use of an opisometer may give a quantitative estimate, however the results have not been
entirely accurate. Our aim in this report is to describe the frequency with which surgical,
radiological and historical data is used to assess intestinal length in patients referred to a
tertiary center for intestinal rehabilitation. Methods: A total of 57 new patient referrals with
SBS and IF were seen in the Intestinal Rehabilitation Program (IRP) from March 1, 2005
to November 30, 2005. Remaining length of small bowel and colon was recorded in the
IRP database at the initial visit. Method of determination of bowel lengths (surgical reports,
radiology or patient history) and underlying diagnosis leading to SBS or IF were also recorded.
Results: One-third (33.3%) of new IRP patient referrals were diagnosed with Crohn’s disease.
This was closely followed by ulcerative colitis (21.1%), radiation enteritis (17.5%) and
mesenteric vascular infarction (12.3%). Despite the presence of significantly more known
vs. unknown anatomical information (p < 0.0001 for colon and small bowel lengths), only
26 (48.1%) of 54 known colonic measurements and 25 (53.2%) of 47 known small bowel
lengths were measured surgically. Conclusions: Although residual bowel length is important
in determining appropriate IRP therapy, surgical measurements were taken in only half of
SBS patients. The residual length of small bowel remains completely unknown in 15 to 20%
of patients referred for IRP intervention. Additional (non-surgical) means of accurately
assessing intestinal length or enterocyte mass, such as plasma citrulline levels, are needed.
T2068
Taste Receptor G-Protein α-Gustducin Does Not Colocalise with
Enteroendocrine Cell Markers in the Mouse Intestine
Kate Sutherland, Nicole J. Cooper, Michael Horowitz, Robert F. Margolskee, L Ashley
Blackshaw, Richard L. Young
A common complication of type 1 and type-2 diabetes is disordered gastrointestinal motility
which may reflect a hypersensitivity of the small intestine to nutrient-induced vagal reflexes.
The primary nutrient sensors of the intestinal tract are likely to be enterendocrine cells
capable of detecting luminal stimuli and releasing paracrine and/or endocrine mediators,
such as the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic peptide (GIP) or 5-hydroxytryptamine (5-HT), to activate vagal afferent end-
ings. However, the mechanism of intestinal glucose-sensing and signalling is currently
unknown. Alpha-gustducin (α-GD) a G-protein subunit involved in lingual sweet taste
transduction has recently been identified in the rat duodenum [1,2] and may be a key
signalling molecule of the intestinal glucose-sensor. The aim of this study was to map the
radial and longitudinal expression of α-GD in the mouse intestine and identify potential
enteroendocrine cells involved in signalling luminal glucose to vagal afferents. METHODS:
Immunohistochemistry for α-GD was performed in the tongue and intestine of 8 adult male
C57BL mice and combined with dual-label immunohistochemistry for 5-HT, GLP-1, GIP
and for nitric oxide synthase (NOS), a marker enriched in intestinal brush cells [1]. RESULTS:
We confirmed specific labelling of α-GD in circumvallate and fungiform taste cells of the
tongue. In the intestine a specific population of α-GD labelled epithelial cells was identified
showing strong immunoreactivity in cytoplasm and at the apical brush border membrane.
Individual α-GD cells were scattered throughout the epithelium and expressed in a regional-
specific manner; rare in duodenum, frequent in mid-jejunum (5-10-fold more than in ileum)
and less frequent toward the ileum. Radial α-GD expression was commonly seen in the
upper villus or villus tip, less frequently in the mid villus and was never seen in crypts.
Labelling for α-GD did not colocalise with 5-HT, GLP-1, GIP or NOS immunoreactivity in
any region of the gastrointestinal epithelium. CONCLUSIONS: Identification of the taste
molecule α-GD in specific populations of intestinal epithelial cells associated with upper
villi of the mid-jejunum suggests a potential role in chemosensory function. The transduction
pathways and identity of effector signalling molecules of the α-GD expressing cell type in
the small intestinal epithelium are the subject of ongoing studies in our laboratory. 1. Hofer
D et al Proc Nat Acad Sci USA 1996 93(13):6631-4 2. Gountounas N et al Gastroenterology
2005 128(4) suppl. 2:T1808 Supported by: University of Adelaide
T2069
Omega-3 Polyunsaturated Fatty Acids Change the Permeability Characteristics
of Intestinal Monolayers By Remodeling the Tight Junctions
Yasotha Duraisamy, Daniel Lambert, Catherine A. O'Neill, Philip Padfield
Aims: In this study we have examined the influence of eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), the two main omega-3 polyunsaturated fatty acids (PUFas)
found in fish oil, on the paracellular permeability characteristics of Caco-2 cell monolayers.
Methods: Confluent, fully differentiated, monolayers of Caco-2 cells grown on Transwell
filter inserts were treated with increasing concentrations of EPA and DHA for up to 8
days. Paracellular permeability was assessed by measuring transepithelial electrical resistance
(TEER) and the transepithelial flux of fluorescently labelled 4 kDa Dextran and Lucifer
yellow. In addition, the expression of tight junction proteins was determined by densitometric
analysis of Western Blots produced from extracts of control and treated Caco-2 cell mono-
layers. Results: EPA and DHA produced a time and concentration dependent decrease in

















70% to 80% decrease in TEER. In contrast over the same time period there was no detectable
increase in the paracellular permeability of either Dextran or Lucifer yellow. Next we examined
whether EPA and DHA were influencing TEER by altering the expression of the main protein
components of the tight junctions in Caco-2 cells, namely claudins 1, 3 and 4 and occludin.
The PUFAs produced a significant increase in both claudins 3 and 4, but a significant
decrease in claudin 1. Maximally (on day 8) EPA and DHA both produced a 30% to 35%
rise in claudin 3, whereas claudin 4 increased by 64% (EPA) and 123% (DHA). In contrast,
EPA and DHA produced a 39% and 61% decrease in claudin 1, respectively. The PUFAs
did produce a slight increase in occludin, however, the most profound influence was on
the phosphorylation status of the protein. Both PUFAs stimulated a dramatic increase in
the phosphorylation of occludin. These changes in the claudins and occludin were accompan-
ied by small but significant alterations in the ion selectivity of the paracellular pathway.
Specifically, EPA and DHA increased the relative permeability of divalent cations (Mg+) and
monovalent anions (Cl-) but had no effect on monovalent cations (K+). Conclusions: EPA
and DHA significantly changed the ionic but not the macromolecular permeability character-
istics of the paracellular pathway in Caco- 2 cell monolayers through altering the relative
protein composition and phosphorylation status of the tight junctions.
T2070
Expressions of TNF-α, TNFR-1 and TNFR-11 in the Intestinal Mucosa of LPS-
Injected Rats Maintained On Low-Protein and High-Fat Diets
Nilima Raina, Khursheed N. Jeejeebhoy
Background: Previously we showed that reduced energy and increased protein intake
decreased the expression of TNF-alpha and TNFRs in organs and muscle. The effects of
nutritional manipulations on TNF and TNFRs in intestinal mucosa are unknown. Objective:
To determine the effect of nutritional manipulations on TNF and TNFRs in intestinal mucosa
of endotoxic rats. Design: Thirty male wistar rats weighing 250 g were fed an isocaloric
liquid defined-formula diet and randomly allocated to 1)controls(C; n=6), receiving normal
protein/ CHO/fat energy density of 49.25/263.7/52.72 kJ/60 mL + normal saline (NS); 2)low-
protein(LP; n=3),receiving normal energy but a reduced protein energy density of 12.3 kJ/
60 mL + LPS; 3)high-fat (HF; N=3),receiving normal energy but increased fat energy density
of 145.6 kJ/60 mL + LPS; 4)refed(RF; n=6), initially fed on low-protein/high-fat diet(10 d)
and then repleted on normal protein/fat(10 d) + LPS; 5)Pair-fed (P-F; n=12)rats were
individually paired with LP, HF or RF rats + NS. After 10 d the rats were sacrificed and
mRNA expressions of TNF, TNFR-1 and TNFR-11 in the mucosa were measured by RT-
PCR. Results: LP rats showed no significant difference in the mRNA expressions of TNF,
TNFR-1 and TNFR-11, but HF rats (Fig 1) showed significant increase in the mRNA
expression of TNF and TNFR-11, compared with C and RF groups, respectively. Conclusions:
High-fat but not protein deficiency in mucosa of endotoxic rats increases the expression of
TNF and TNFR-11 which is suppressed by refeeding normal fat. This is clinically relevant
in IBD, since the data suggests that a low fat diet may reduce the inflammatory mediators’
expression in intestinal mucosa.
Fig 1: mRNA expression of TNF, TNFR-1 and TNFR-11. 281 bp=TNF-alpha, 301 bp=
TNFR-1, 264 bp =TNFR-11, 377 bp=GAPDH. Lanes 1 to 3- C, lanes 4 to 6- HF, lanes 7
to 9- P-F to HF, lanes 10 to 12- RF, lanes 13 to 15- P-F to RF.
T2071
Effect of Breakfasts with Different Glycemic Index and Glycemic Load On
Metabolic and Hormonal Responses to the Breakfast and to the Following
Meal
Luigi Benini, Fosca de Lorio, Laura Rigo, Anna Albiero, Furio Brighenti, Camilla
Melegari, Roberto Ciati, John Blundell, Naika Tacchella, Elisa Nesta, Donatella Ieluzzi,
Italo Vantini
BACKGROUND. Breakfast influences food intake; in the long term, subjects skipping break-
fast gain weight and present a reduced productivity. Breakfasts rich in protein and fat are
associated with an increase in BMI compared with carbohydrates rich ones. Aim of our
study was to compare the effects of isocaloric breakfasts (400 Kcal) with different glycemic
index (GI) and glycemic load (GL=GI x carbohydrate content). MATERIAL AND METHODS.
Sixteen healthy volunteers (13 females, aged 23-30 years) were studied in 3 different days
for 4 hours after 200 ml of tea and breakfasts with high GI-high GL (HGI-HGL; rich in
refined sugars: rusks 75 g, jam 30 g), high GI-low GL (HGI-LGL; higher fat content: rusks
45 g, jam 30 g, butter 22.5 g), or low GI-low GL (LGI-LGL, higher fiber content: cereals
biscuits 60 g, jam 60 g). On every occasion, they were studied also for 5 hours after the
following, standard main meal (mixed solid meal, 800 Kcal). The following parameters were
evaluated: gastric emptying and antral area (ultrasound), hunger, fullness and satiety (visual
analogue scales), biochemical parameters (glucose, triglycerides, NEFA), hormones (insulin,
CCK, ghrelin, leptin, PYY; Phoenix Pharmaceuticals). ANOVA for repeated measurements
and, when significant, the paired data Student’s t test were used for statistical analysis.
RESULTS. No differences were found in gastric emptying either of breakfasts or of the main
meals. The HGI-HGL breakfast produced a greater satiety and fullness compared with the
other ones after the breakfast, mirrored by a significantly greater antral distension during
the early postprandial period. On the contrary, no differences in sensations were found after
the following main meal. The HGI-HGL breakfast produced a higher peak both of glucose
and of insulin compared with the other breakfasts during the morning (p<0.001). On the
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contrary, after the main meal, higher insulin levels were observed the day with fat rich
breakfast (HGI- LGL; again, p<0.001). No clear differences were seen in triglycerids and
NEFA levels . No differences were observed in ghrelin, leptin or CCK levels. On the contrary,
PYY levels were slightly but significantly higher during the morning after the LGI-LGL
breakfast. This suggests that some of the metabolic effects of slowly digestible fibers are due
to their arrival to the distal intestinal tract and to PYY release. CONCLUSION. Isocaloric
breakfasts with different glycemic index and glycemic load produce different metabolic
responses in young, healthy volunteers, possibly mediated by PYY release. The effect of
these dietary manipulations in subjects at higher metabolic risk requires further studies.
T2072
Effect of Supplementing Different Macronutrients On Gastric Sensory and
Motor Functions and Appetite in Normal Weight, Overweight, Or Obese
Humans
Moo-In Park, Michael Camilleri, Helen O'Connor, Lavonne Oenning, Duane Burton,
Debra Stephens, Alan R. Zinsmeister
Background: The effects of supplementing different macronutrients on gastric sensory and
motor functions are unclear. Aim: To compare effects of 2 weeks’ supplementation of different
classes of macronutrients on gastric function, satiation, and appetite in health and obesity.
Methods: In a randomized, parallel-group, double-blind study, 52 healthy participants
[14M, 38F, aged 18-64y, body mass index (BMI) 19-47 kg/m2, n=13 per diet group] were
randomized to different isocaloric diets adjusted for BMI and activity level; standard diet
was 20% protein (P), 30% fat (F), and 50% carbohydrate (C). High P, F, or C diet contained
500 additional kcal in the respective nutrient class. On 3 separate days, we measured gastric
emptying of solids, gastric volumes, postprandial symptoms, appetite and food choice at a
buffet meal with validated methods. Age, gender, BMI and baseline satiation were covariates
in ANCOVA. Results: Fat supplementation was associated with increased maximum tolerated
volume (MTV) in people with high baseline MTV (P<0.05), irrespective of BMI (figure shows
MTV in each macronutrient-supplemented group). Gastric emptying and volumes, post-
Ensure® symptoms, total calories and food choices at a buffet meal were not significantly
different following each dietary preload. Fasting gastric volumes tended to be higher with
F-, than with C- or P-enriched diets (P≤0.1). Gastric emptying and volumes, and satiation
were not different in the BMI categories <30 and >30 kg/m2. Conclusion: Supplementing
500 kcal fat in excess of required calories for 2 weeks reduces satiation in normal weight
or obese healthy persons without significant change in gastric functions. This suggests that
calories from fat in excess of need may result in adaptation that leads to greater calorie
intake, and may lead to obesity.
T2073
Gastric Distension Does Not Affect the Inhibitiory Effect of Pyy3-36 On Food
Intake in Healthy Human Subjects
Lukas Degen, Philipp Cesena, Sibylle Oesch, Christoph Beglinger
Background: Intravenous (IV) administration of peptide YY (PYY3-36) dose-dependently
inhibits food and calorie intake in humans (Gastroenterology 129;1430f;2005), but a physiol-
ogic role has not been established for the peptide. Also, gastric distension induced by the
ingestion of a preload can alter food intake. The potential interaction between gastric
distension and IV PYY3-36 on food intake has not been studied before. The aim of the
present study was therefore to investigate whether a protein preload intensifies the inhibitory
effect of IV PYY3-36 on food intake in order to define a potential physiologic role for the
peptide. Methods: 16 healthy male subjects were studied in a randomized, double-blind,
4-period cross over design. On each study day, subjects ate a light breakfast before 8 a.m.,
but no food was allowed afterwards until 12 noon, when subjects underwent one of the
following treatments: a) water preload plus iv saline infusion; b) water preload plus iv PYY3-
36 infusion (0.4 pmol//kg/min); c) protein preload plus iv saline infusion c) protein preload
plus iv PYY3-36 infusion. The infusions were given throughout the experiments. A preload
(400 ml water or protein drink) was given orally 20 min before presenting a standard test
meal (ham sandwiches, orange juice, chocolate pudding, coffee). On each occasion, subjects
were free to eat and drink ad libitum. Volunteers scored feelings for hunger and fullness
on a standard visual analogue scale before and during food intake. The amount of food
eaten and of fluid drunk were measured. Total intake of calories was calculated and the
time to complete the meal was assessed. Plasma PYY and CCK were determined in regular
intervals. Results:(Mean ± SEM) Data were analysed using ANOVA followed by multiple
paired t-test with Bonferroni’s correction. Summary: 1) IV infusion of PYY3-36 at 0.4 pmol//
kg/min did reduce food and calorie intake, but the effect was not significant. Plasma PYY
levels were above the physiological range. 2) The protein preload did not modulate the
effects of PYY3-36. Conclusion: Whether PYY3-36 has a physiologic role in the regulation
of satiety in humans remains questionable.
Effect of PYY with and without a preload on food parameters
T2074
Peptide Yy (PYY) Release Is Increased in Critical Illness During Small
Intestinal Nutrient Stimulation
Nam Q. Nguyen, Richard Holloway, Robert Fraser, Laura Bryant, Marianne Chapman,
Carly Burgstad, Judith Wishart, Michael Horowitz
In critical illness, the entero-gastric feedback response to nutrient stimulation is enhanced
and may contribute to slow gastric emptying. PYY, an enterogastrone released in response
to small intestinal lipid, is known to slow gastric emptying. The potential role of PYY in
disordered gastric emptying of critical illness has not been assessed. Aim. To investigate
changes in PPY concentrations ([]) in response to duodenal nutrients in critically ill patients.
Methods. 19 critically ill patients (12M; 48±7 years) and 24 healthy volunteers (17M; 42±3
years) received a 60min duodenal infusion of Ensure, at either 1 Kcal/min (13 healthy vs.
9 patients) or 2 Kcal/min (11 healthy vs 10 patients). Blood samples for PYY and glucose
concentrations were collected during fasting, every 20 minutes during nutrient infusion and
2h after the infusion. [PYY] were analysed by radioimmunoassay. Results. Fasting [PYY]s
were similar in healthy subjects and patients prior both infusions. Both plasma and integrated
[PYY]s were higher in patients during duodenal nutrients stimulation(figure). There was a
dose-dependent increase in [PYY]s in healthy subjects but not in patients. A greater elevation
of [PYY]was observed in patients during 1kcal/min but not 2kcal/min infusion. In patients,
there was a positive correlation between the integrated changes in [PYY]s and changes in
blood glucose (r=0.6; P<0.001), fasting [PYY] (r=0.76, P<0.0001), body weight (r=0.45, P=
0.02) and length of ICU stay (r=0.6, P=0.03). Conclusion. Plasma PYY concentrations are
increased in critically ill patients. The greater elevation of PYY in response to 1kcal/min but
not to 2kcal/min duodenal infusion suggests an increased small intestinal sensitivity to
nutrients in triggering the “ileal brake” feedback. This abnormal response may contribute
to delay gastric emptying in these patients.
T2075
Protection Against Foodborne Bacterial Infections By Dietary Calcium: Role of
Duration of Calcium Supplementation and Gut Microflora Composition in
Rats
Ingeborg Bovee-Oudenhoven, Mischa Lettink-Wissink, Roelof van der Meer
Background: Even in industrialized countries >20% of the population contracts a foodborne
infection per year. We have shown earlier that calcium supplementation protects rats against
intestinal colonization and translocation of Salmonella enteritidis. Calcium also prevents
enterotoxigenic E. coli induced diarrhea in rats and humans. For now, the duration of
calcium supplementation necessary to achieve protection is unknown as well as the mechan-
ism involved. Aim: To determine the efficacy of acute versus continuous calcium supple-
mentation on resistance of rats to salmonella and to address the role of the gut flora. Methods:
SPF rats (n=8/group) were fed a Western diet with a low (LCa) or a high (HCa) calcium
content (20 vs 100 mmol Ca/kg). Two groups received LCa or HCa during the 20 study
days. The 3rd group was mostly fed LCa but HCa 1 day before and 1 day after infection only.
All rats were orally infected with 109 CFU S. enteritidis on day 10. Salmonella colonization, and
lactobacilli and enterobacteria were quantified by fecal culturing with time. Salmonella
translocation was determined by urinary excretion of nitric oxide metabolites. Specific IgG
was analyzed in sera obtained 10 days after infection. In a 2nd study the effect of sterilized
LCa and HCa (continuously supplied) was tested in SPF vs germfree (GF) rats housed in
isolators. Salmonella was supplied as mentioned above, except that 104 CFU were given to
GF rats. Gut mucosa, liver and spleen were isolated one day after infection for salmonella
culturing. Results: Continuous calcium supplementation is superior in reducing salmonella
colonization, but protection to a lesser extent was also observed in rats that received HCa
for only 2 days. Additionally, salmonella translocation was inhibited by calcium supplementa-
tion for 2 days or longer. This corresponded with lower serum IgG levels against S. enteritidis
in these groups. In contrast to the common thought that diet-induced changes in gut flora
composition require weeks, lactobacilli increased and enterobacteria decreased already after
2 days of extra calcium. So, an intermediate role of the protective microflora could not be
excluded. Therefore, the second infection experiment was performed. Calcium conferred
clear protection against ileal and colonic mucosal colonization and translocation of salmonella
to liver and spleen in SPF but not in GF rats, indicating that flora is involved in the protective
mechanism. Conclusion: Only 2 days of calcium supplementation are already effective in
reducing salmonella infection and this might be mediated by stimulation of lactobacilli and/
or inhibition of enterobacteria.
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T2076
Carnosine and Histidine Suppress the Induction of Inflammatory Cytokine in
Human Intestinal Epithelial CACO-2 and HT-29 Cells
Hideo Satsu, Dong Ok Son, Makoto Shimizu
Background/Aims: Carnosine, composed of beta-alanine and histidine, is one of antioxidative
dipeptides and is contained mainly in meat and poultry. The physiological function of
carnosine has been investigated in several tissues such as brain. However, little is known
about the function of carnosine in the intestine, especially intestinal-immune system. We
therefore investigated the effect of carnosine on the secretion of inflammatory cytokine,
especially interleukin-8 (IL-8), using human colon-derived Caco-2 and HT-29 cells as a
model of intestinal epithelial cells. The anti-inflammatory effect of histidine and beta-alanine
was also examined in this study. Methods: The amount of IL-8 secreted from Caco-2 and
HT-29 was assessed by sandwich-ELISA. The expression level of IL-8 mRNA was determined
by Real-time PCR analysis. The transcriptional activity of human IL-8 promoter was measured
by reporter gene assay. The carnosine uptake into Caco-2 cells was measured using [3H]-
carnosine. Results: In both human intestinal epithelial-like Caco-2 and HT-29 cells, the
hydrogen peroxide-induced IL-8 secretion was significantly reduced by the addition of
carnosine. Carnosine also suppressed TNF-alpha-induced IL-8 secretion in a dose-dependent
manner. Carnosine uptake into Caco-2 cells was also examined, suggesting that carnosine
was transported into the cells via proton-coupled peptide transporter (PepT1). Then in the
presence of Gly-Sar, typical substrate of PepT1, the intracellular content of carnosine was
decreased and the inhibitory effect of carnosine on the induction of IL-8 was also weakened,
suggesting that intracellular carnosine suppressed the IL-8 induction. The expression level
of IL-8 mRNA induced by hydrogen peroxide and TNF-alpha was not changed by carnosine,
suggesting that carnosine acts at the post-transcriptional level. The increase of IL-8 secretion
by hydrogen peroxide and TNF-alpha was also significantly suppressed by histidine, but
not beta-alanine. Interestingly, increased expression level of IL-8 mRNA and increased
transcriptional activity of IL-8 promoter by TNF-alpha were both significantly suppressed by
histidine treatment. Further histidine suppressed TNF-alpha-induced NF-kappaB-dependent
transcriptional activity, suggesting that histidine acts upstream of NF-kappaB pathway.
Conclusion: Both carnosine and histidine ameliorate the induction of IL-8 secretion in
intestinal Caco-2 and HT-29 cells, whereas their suppressive effect was likely to be regulated
in a different manner. Thus food-derived peptides and amino acids such as carnosine and
histidine may improve intestinal inflammation.
T2077
Relationship Between Blood Glucose Control and Feed Intolerance in Critical
Illness
Nam Q. Nguyen, Katrina Bland, Robert J. Fraser, Richard H. Holloway
Delayed gastric emptying and subsequent intolerance of naso-gastric feeding is common in
critically ill patients. Many of these patients have stress-related hyperglycemia and receive
insulin therapy. Hyperglycemia, even at physiological levels (8-10mmol/L), disrupts antro-
pyloro-duodenal motility and may slow gastric emptying. The contribution of physiological
hyperglycemia to the high incidence of feed intolerance in critical illness is unclear, as is
the role of tight glycemic control in preventing this complication. Aim. To assess the
relationship between blood glucose concentrations (BSL) and feed intolerance in critical
illness. Methods. Hourly BSLs and insulin requirements, over the first 10 admission days,
were assessed prospectively in 87 consecutive mechanically-ventilated, feed-intolerant (6-h
NG aspirate+250ml) patients (57M; 57+2yrs) and 48 age-matched, feed-tolerant patients
(32M; 56+2yrs). Only patients fed for at least 5 days were studied. Results. The mean BSLs
on admission, 24 hours prior to starting NG feeding and for the first 4 days of feeding, and
the use of insulin therapy were similar between the 2 groups (Table). In comparison with
feed-tolerant patients, feed-intolerant patients had slower rates of feeding (46+2ml/h vs
60+2ml, P=0.01), higher peak BSL and greater hourly variations in BSL both fasting and
during enteral feeds. The variation increased significantly during the 24hr up to the develop-
ment of feed intolerance. There was a weak but significantly negative correlation between
the admission BSL and the time taken to develop feed intolerance (r=0.2, P<0.0001).
Conclusions. Feed intolerance in critical illness is associated with significantly higher peak
and greater variation in BSL during both fasting and feeding. The contribution of these
findings to the development of delayed gastric emptying and feed intolerance is unclear,
but they suggest more intensive insulin therapy may be required to minimize the variability
in BSLs in feed intolerant patients.
T2078
Membrane Targeting and Intracellular Trafficking of the Human Thiamine
Transporter-2 (hTHTR-2) in Epithelial Cells
Veedamali S. Subramanian, Jonathan S. Marchant, Hamid M. Said
Background: The water-soluble vitamin thiamine (B1) is essential for normal growth and
development. Humans cannot synthesize the vitamin and thus must obtain it from exogenous
sources via absorption in the intestine. Studies from our laboratory have shown that thiamine
absorption involves both the hTHTR-1 and hTHTR-2 transporters. In contrast to hTHTR1,
nothing is currently known about targeting and intracellular trafficking of hTHTR-2 to the
apical membrane of polarized epithelial cells. The aim of this study was therefore to identify

















and also to study its intracellular trafficking. Methods: Live cell (Caco-2 and MDCK) confocal
imaging was used to resolve the localization and trafficking of full-length hTHTR2 and
truncated constructs fused to green fluorescent protein (GFP). Results: The fused full-length
hTHTR-2 protein was found to be only localized at the apical membrane of filter grown
polarized Caco-2 and MDCK cells and was functional. Complete or partial truncation of
the cytoplasmic tail of hTHTR2 failed to prevent its targeting to the apical cell surface,
although the level of expression of these COOH terminal truncations was reduced. In contrast,
deletion of specific sequences within the polypeptide backbone completely abrogated cell
surface expression of hTHTR2 and the truncated proteins were retained within the endo-
plasmic reticulum. Video-rate confocal imaging resolved rapid bi-directional movement of
intracellular vesicles containing hTHTR2-GFP. Treatment of cells with microtubule disrupting
agents lead to impairment in vesicles movement; disruption of the actin microfilament,
however, was without an effect. Similarly overexpression of the dynactin subunit, dynamitin
(p50) which inhibits cytoplasmic dynein led to impairment in apical expression of hTHTR2-
GFP. Conclusions: Our results shows for the first time that targeting of the hTHTR2 protein
is dependent on specific sequence located in the transmembrane backbone of the polypeptide.
In addition, apical delivery of hTHTR2 is depend on an intact microtubules and cytoplasmic
dynein. [Supported by grants from the DVA and the NIH (DK 56061, DK 58057(HMS)
and DK 63750 (VSS))].
T2079
Reduced Intestinal Cholesterol Absorption Lessens the Uptake of Long- and
Medium-Chain Saturated Fatty Acids in Mice
Eric Labonte, Ronald J. Jandacek, Joanna P. Davies, Yiannis A. Ioannou, David Y. Hui,
Philip N. Howles
Recent studies have documented the importance of Niemann Pick C1-like 1 protein
(NPC1L1), a putative physiological target of the drug ezetimibe, in mediating intestinal
cholesterol absorption. Mice deficient in NPC1L1 exhibit resistance to diet induced hypercho-
lesterolemia similar to that observed with ezetimibe treated wild type mice. However, the
effect of reduced cholesterol absorption and any direct or indirect role NPC1L1 in fat
absorption has yet to be delineated. In this study, we explored the impact of reduced
cholesterol absorption, by either ezetimibe treatment or NPC1L1 gene ablation, on fat
absorption efficiency in mice. Methods: Both NPC1L1+/+ and NPC1L1-/- mice in C57BL/
6 backgrounds, a strain utilized to study diet-induced obesity, were fed diabetogenic diets
(58 kcal% fat) consisted of a combination of soy bean oil and either or both lard and
hydrogenated coconut oil in the presence or absence of ezetimibe. Lipid extracted from
fecal pellets collected 24 hr after feeding were analyzed by gas chromatography to detect
dietary fat absorption utilizing the sucrose polybehenate method. Additionally, tissues were
collected during necropsy for lipid analysis. Results: Ezetimibe treatment and NPC1L1-
deficiency in mice both exhibited a similar reduction in the absorption of stearate (19%),
palmitate (10%), and myristate (9%). At the same time, the absorption of laurate, oleate,
and linoleate absorption was unchanged in these animals. NPC1L1-/- mice treated with
ezetimibe exhibited an exaggerated suppression of absorption for stearate (28%), palmitate
(13%), and myristate (13%). Gallbladder bile in NPC1L1+/+ and NPC1L1-/- mice in this
study were found to have similar concentrations of bile acids, cholesterol, and phospholipids.
Conclusion: Reducing intestinal cholesterol absorption in mice by NPC1L1 ablation or
ezetimibe treatment hindered the absorption of long and medium chain saturated fatty acids.
Simultaneously, the intestinal uptake of unsaturated fatty acids and of the shorter chain
laurate was unaffected. These results demonstrate a link between cholesterol and fatty acid
absorption in the gut and suggest that the metabolism of both types of lipids are linked in
the enterocytes of the small intestine. The additive effect of both ezetimibe treatment and
NPC1L1 ablation on medium chain saturated fatty acid absorption further suggests that
ezetimibe may have additional physiological targets.
T2080
Amino Acid Absorption in the Colon Is Evidenced By Means of a Colonic
Instillation Study Using 13C-Leucine
Karen Geboes, Anja Luypaerts, Vicky de Preter, Paul Rutgeerts, Kristin Verbeke
Introduction : The colon plays an important role in fluid and electrolyte conservation, but
presumably also in nutrient absorption, especially in pathological conditions. Under normal
conditions, the absorption of protein digestion products almost entirely occurs in the small
intestine. However, in patients with short bowel syndrome, functional adaptations such as
increased colonic absorption of nutrients have been observed. Recently, an amino acid
transporter capable of mediating the absorption of amino acids - including D-amino acids
derived from bacterial metabolism - has been characterized in human colonocytes. Methods
: Eleven healthy volunteers swallowed a narrow polyvinyl tube which progressed down the
intestine overnight. On the following morning, radiographic screening ensured the position
of the tube in the right colon. Baseline breath and serum samples were retrieved before
bolus administration of a 40-ml NaCl 0.9% solution containing 200 mg 13C-leucine. After
instillation, serum samples were obtained every 30 min during 6 hours. 13C-leucine serum
concentrations (µg/ml) were calculated from the 13C-leucine enrichment and the leucine
concentration which were both measured using gas-chromatography combustion isotope
ratio mass spectrometry (GC-C-IRMS, Delta Plus, Thermo Electron). Four hours after the
instillation, all volunteers received a sandwich with ham or cheese. Results : In all volunteers,
the evolution of 13C-leucine concentration over 6h was similar and characterized by two
peaks. Within 30 minutes after instillation, a sharp increase in 13C-leucine serum concentra-
tion was observed (0.39 +/- 0.16 µg/ml versus 0.21 +/- 0.04 µg/ml at baseline, means +/-
SD, p<0.01). This initial peak however, may be due to absorption in the ileum through
backwash. From 210 min after instillation on, a second peak in 13C-leucine concentrations
was observed, (0.22 +/- 0.06 µg/ml at 210 min, 0.32 +/- 0.08 µg/ml at 300 min (reaching
statistically significant difference as compared to baseline, p<0.01), means +/- SD) suggesting
absorption of 13C-leucine from the colon. This increase in 13C-leucine concentration could
not be explained by consumption of the sandwich, since the rise in 13C-leucine concentration
started before ingestion of the meal. Conclusion : Higher serum 13C-leucine levels were
observed after direct colonic instillation of this labeled amino acid, demonstrating the
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possibility of colonic absorption of dietary amino acid, which subsequently can be used for
human metabolism.
T2081
GIF 68a>G Genetic Polymorphism of Gastric Intrinsic Factor Is Not
Associated with Low Vitamin B12 Nor with High Homocysteine Plasma Level
in African and European Populations
Celine Chery, Cyrille Bessod, Rosa-Maria Gueant-Rodriguez, Emile Kousanta Amouzou,
Nicodeme Chabi, Ambaliou Sanni, Paolo Bosco, Guido Anello, Renee Debard, Marc
Andre Bigard, Jean-Louis Gueant
Background: Inherited GIF deficiency is a rare cause of pernicious anemia characterized by
gastric intrinsic factor (GIF) impaired secretion, normal acid secretion and absence of atrophic
gastritis and of anti-GIF auto-immunity. An association of a GIF 68A>G genetic polymorphism
with inherited gastric intrinsic factor (GIF) deficiency has been reported recently in 5 patients
(Yassin et al., Hum Mutation, 2004). Aim: to investigate the frequency of this polymorphism in
populations from 3 world area and its association with blood vitamin B12 and homocysteine, a
metabolic marker of B12 and folate deficiency. Methods: the GIF 68A>G was genotyped by
Q-PCR in 172 young healthy adults from Sub-Saharian Africa, 230 from France and 123
from Italy. Frequencies were compared by Fisher test. Genotype associations with vitamin
B12 and homocysteine were evaluated in univariate and multivariate analyses. Concentrations
were given as median and inter-quartiles and compared by Mann Whitney test. Results:
The frequency of allele GIF 68A was much higher in Africa than in France and Italy (0.192
[95%CI: 0.154-0.237], 0.026 [0.014-0.045], 0.017 [0.006-0.042], respectively, P<0.0001).
68GG homozygous genotype was reported in 5 cases from Africa but not in the population
samples from France and Italy. It was not associated with low vitamine B12 deficiency,
when compared with the 68AA+AG genotypes from the same African population ( 498
(452-529) vs 469 (321-687) pmol/L, P=0.8661), nor with homocysteine plasma level (9.9,
8.4-20.9 vs 12.7 (9.0-18.0) µmol/L, P=0.7052). There was no association of the GIF 68G
allele with vitamin B12 nor with homocysteine and hemoglobin level in any of the 3
populations. Conclusion: The difference in GIF 68A allele frequency between African and
Caucasian populations suggested either a founder effect and/or an environmental influence
that contrasted with a lack of phenotypic effect of this polymorphism with vitamin B12
status and anemia. The previously reported association of this polymorphism with inherited
GIF deficiency should be reconsidered in regard to our results.
T2082
The Small Intestine Used Dietary and Systemic Threonine Simultaneously for
Muc2 Synthesis in Human Neonates
Maaike W. Schaart, Adrianus C. De Bruijn, Henk Schierbeek, Johannes B. van Goudoever,
Ingrid B. Renes
Background: The intestine utilizes 60-90% of the dietary threonine intake in neonatal pigs.
Mucin 2 (MUC2), the predominant intestinal mucin, is a large glycoprotein, rich in threonine-
proline-serine tandem repeats. The high visceral need of the intestine for threonine might
reflect the high synthesis rate of MUC2. In this way threonine might be essential to maintain
the protective mucus layer. We hypothesized that dietary more than systemic threonine is
mainly incorporated into secreted proteins of the small intestine, especially MUC2. Objective:
To determine the dietary and systemic threonine incorporation into MUC2 and to quantify
the fractional synthetic rate (FSR) of MUC2 in human neonates with an enterostomy following
bowel resection. Methods: Intragastric (IG, n=8) and intravenous (IV, n=4) infusion of U-
13C labeled threonine was used to determine the incorporation of threonine into secreted
MUC2 in the outflow fluid at the enterostomy exit in human neonates. Small intestinal
MUC2 was purified by CsCl equilibrium ultracentrifugation. Mucin containing fractions
were identified by western-blot and Periodic Acid Schiff (PAS)-staining. Mucin containing
fractions were pooled and the isotopic enrichment of threonine in MUC2 was measured by
Gas Chromatography Isotopic Ratio Mass Spectrometry (GC-IRMS). Results: Dietary and
systemic threonine were incorporated into MUC2 of the small intestine, which was sub-
sequently secreted into the lumen of the small intestine. The FSR varied between 8% and
41% per day. The FSR tended to be higher during the intravenous threonine administration
[IG: 18.5 ± 9.9% vs. IV: 28.5 ± 10.1%, NS]. The maximal threonine enrichment of MUC2
during enteral threonine administration was not significantly different compared to the
maximal threonine enrichment of MUC2 during intravenous tracer infusion [IG: 0.770 ±
0.34 vs. IV: 0.714 ± 0.36 MPE]. Systemically derived threonine accounted for 58% of the
total amount of threonine used for MUC2 synthesis, whereas 42% was derived from the
luminal site. Conclusions: Both dietary and systemic threonine are utilized for small intestinal
MUC2 synthesis and secretion. The small intestine does not prefer dietary threonine above
systemic threonine for MUC2 synthesis in human neonates receiving (some) enteral nutrition.
T2083
Influence of the Mitochondrial Taurine Transporter Expression On Hepatic
Mitochondria Number in CCL4-Induced Liver Disease
Teruo Miyazaki, Yasushi Matsuzaki, Akira Honda, Tadashi Ikegami, Yining Zhang,
Bernard Bouscarel
Backgrounds/Aim Maintenance and enhancement of mitochondrial activity are key factors
in the improvement of liver diseases (LD). Taurine is one of the most abundant amino acids
and it is taken up by a specific transporter (TAUT). This cysteine derivative is suggested to
accumulate in the mitochondria and to play a role in the regulation of oxidative stress and
apoptosis. Therefore, the aim of the present study was to investigate the mitochondrial
TAUT expression level as its expression and alteration in LD is still unclear. Methods SD
rats were divided into four groups; normal, LD1, LD2 and LD treated with taurine (LDT)
groups. The LD1 and LDT groups received CCl4 for 5 weeks, and the LDT group was fed
a 2% taurine diet along with, as well as one week prior to the CCl4 treatment. The LD2
groups received CCl4 for 15 weeks. The expression levels of TAUT, porin and cytochrome
C (CytoC) were examined in the mitochondria, cytoplasm, and membrane fractions by
Western blotting. Furthermore, the respective hepatic lobular and intracellular TAUT expres-
sion levels were studied by immunohistochemistry. Results The taurine concentration in
hepatic tissue was significantly decreased in the LD1 and was even further decreased in the
LD2 group. Hepatic histological damage was observed mainly in the pericentral (PC) region,
and was significantly aggravated along with the duration of CCl4 administration. Furthermore,
the MitoTracker-positive mitochondrial numbers were markedly decreased in the liver of
CCl4 administered groups. The taurine supplement led to improvements of the hepatic
function, taurine concentration and histological parameters. The TAUT protein expression
in the hepatic lobule was markedly and predominantly expressed in cells of the PC region.
The TAUT was confirmed to be expressed in the mitochondria, cytoplasm and membrane
by both confocal laser microscopy and Western blotting. The mitochondrial and cytoplasmic
expressions of TAUT were significantly decreased in the LD1 and LD2 groups compared to
that in the normal group. The mitochondrial expressions of both CytoC and porin were
significantly reduced in the LD2 group, while these expression profiles were maintained in
the normal and LD1 groups. Taurine administration prevented the loss of TAUT in the
cytoplasm but not in the mitochondria. Conclusions The present results show that hepatic
damage with a reduction in mitochondria number in the CCl4-induced LD could be due
to a decreased hepatocellular TAUT expression level. Therefore, these findings support that
the maintenances of mitochondrial TAUT expression and taurine content are important
factors for mitochondria and cellular viability in LD.
T2084
A Novel Type Hypertriglyceridemia Observed in Spontaneous Hepatic
Steatosis Model FLS Mice
Masafumi Ono, Masaya Takahashi, Toshiji Saibara, Akira Hirose, Naoaki Akisawa, Shinji
Iwasaki, Saburo Onishi
BACKGROUND/AIMS: The unique inborn hypertriglyceridemia and hepatic steatosis seen
in FLS (fatty liver Shionogi) mice was relieved by the administration of purified apolipoprotein
(apo) C-II. Lipoprotein lipase (LPL) and its cofactor, apoC-II, play a pivotal role in VLDL
metabolism. Therefore, we investigated the genetic background involved in this hypertrigly-
ceridemia. METHODS: Plasma levels of TG and total cholesterol as well as LPL activity were
measured in male FLS mice and C57BL/6J mice. Agarose gel electrophoresis and fast protein
liquid chromatography were used to analyze the lipoprotein profile. Male FLS mice were
administered 0.1 ml of C57BL/6J mice plasma, saline, or saline with purified human apoC-
II. A cross experiment was done to determine the genetic background of hypertriglyceridemia
observed in FLS mice. cDNA sequences of apoC-II and apoC-III of FLS mice were determined.
RESULTS: Preα-lipoprotein was the predominant lipoprotein class in FLS mice plasma. LPL
activity remained in the range observed in C57BL/6J mice, and purified apoC-II transiently
relieved FLS mice from hypertriglyceridemia. Intravenous administration of either a small
amount of C57BL/6J plasma or purified human apoC-II restored LPL activity. Preα-lipoprotei-
nemia was inherited in an autosomal recessive manner. ApoC-III appeared to be a causal
factor for this unique hypertriglyceridemia. Microsatellite analysis, however, revealed that
the responsible chromosome was not 7; rather, apoC-III mapped onto chromosome 9.
CONCLUSION: We suggest apoC-III as a candidate causative factor for the hypertriglyceride-
mia observed in FLS mice because an excessive amount of apoC-III attenuates LPL activity
in vivo and in vitro. Therefore, the FLS mice may be the good model for study of the
abnormal hypertriglyceridemia such as apoC-II deficient patients.
T2085
Methionine Deficiency and Steatohepatitis in a Dietary Animal Model
Helieh S. Oz, Willem J. de Villiers, Craig McClain
Methionine is an essential sulfur amino acid involved in DNA methylation, biosynthesis of
cysteine and glutathione (GSH). Methionine (Meth) and choline deficient diets serve as
animal models for nonalcoholic steatohepatitis (NASH), but the mechanism of action is not
fully defined. We examined the effect of Meth on the development of steatohepatitis. Methods:
Young rats were fed (ad libitum) amino acid-based total Methionine and choline deficient
(MCD) or sufficient (MCS) diets. After 3 wks, MCD rats were daily gavaged with vehicle
(MCD), or Meth administration (Meth/MCD). One group of MCS rats was fed deficient diet
(MCS/MCD) for 2 additional wks. Result: Animals fed deficient diet for 2 wks (MCS/MCD)
had a normal hematocrit value but lost (29%) weight (MCS/MCD vs. MCS p<0.05). Rats
fed a deficient diet for 5 wks (MCD) weighed only 1/3 of those on sufficient diet (MCD vs
MCS p<0.001) and developed anemia (hematocrit: MCD vs. MCS p<0.01), but otherwise
appeared normal. Daily Meth administration (2 wks) normalized hematocrit and partially
(19%) improved weight (Meth/MCD vs MCD p<0.05). Liver transaminases elevated after
only 2 wks (MCS/MCD vs MCS p<0.01) and further increased (AST: 6-fold; ALT: 3-fold
MCD vs. MCS p<0.001) after 5 wks on deficient diet. Meth administration significantly
suppressed these abnormal enzyme activities (p<0.01). Rats fed deficient diet developed
severe liver lesions evidenced (2 wks) by fatty degeneration and inflammation (MCS/MCD
score: 2.8 +0.5) and progressed (5 wks) to necrosis (MCD score: 3.6+0.5 p<0.001). Liver
pathology was partially but significantly improved with Meth administration (2.4+0.2 Meth/
MCD vs. MCD p<0.01). Blood and liver reduced GSH and SAM were significantly affected
in rats fed deficient diet and improved with Meth administration. Deficient diet (2 wks)
significantly upregulated genes responsible for inflammation and those involved in tissue
remodeling and fibrosis; this upregulation was significantly ameliorated by Meth administra-
tion. Conclusion: Methionine deficiency resulted in markedly elevated liver enzymes, patho-
logy and expression of inflammatory/ fibrogenic genes after only 2 wks and advanced further
after 5 wks on a deficient diet. Meth administration partially but significantly improved
these abnormalities. These data support a pivotal role for Methionine in the pathogenesis
in this dietary model.
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T2086
Butyrate Up-Regulates the Bacterial Lipoprotein Stimulation of the NFkB
Inhibitory Protein,A20, in Intestinal Epithelial Cells
Meiqian Weng, W.allan Walker, Ian Sanderson
Butyrate are produced in the intestine by bacterial fermentation of carbohydrate. Studies
on the effect of butyrate on the expression of cytokines from intestinal epithelial cells have
given differing results. Both up-regulation and down-regulation of IL-8 have been reported.
Furthermore, butyrate enhances histone acetylation and render it more available to transcrip-
tion factors. However, it is difficult to understand how such an opening of DNA down-
regulates gene expression. We hypothesized that these lack of understanding could be
explained by butyrate up-regulating an inhibitor of NF-kB in a distinct time-dependent
manner. We therefore examined the effect of A20 on bacterial lipoprotein (BLP) stimulation
of IL-8, and how butyrate affected A20 -expression. Methods: Caco-2 cells were studied at
10 days after plating. A20-expression was inhibited by A20-specific SiRNA. Cells were
stimulated with BLP to produce IL-8. Butyrate or trichostatin A (TSA), a histone deacetylase
inhibitor, were given for 24 hours before stimulation with Toll-like receptor2 (TLR2) ligands.
Results: BLP induced IL-8 collected over 24 hours in normal Caco-2 cells and in those
transfected with non-specific RNA, but removing A20 -expression with specific SiRNA
increased IL-8 expression about 4-fold (Figure). BLP enhanced A20-expression and this was
increased by treating with butyrate or TSA. The effect of butyrate was dose dependent and
time dependent, with A20 increasing within 2 hours, and decreasing beyond 18hours.
Butyrate decreased BLP stimulated IL-8 expression at early time points, but greatly enhanced
it later. Conclusions: A20 inhibits the BLP stimulation of IL-8. Butyrate enhances IL-8
expression over 24 hours, but at early time points when A20 is increased butyrate inhibits
IL-8. Thus the effect of butyrate on NF-kB dependent genes depends on the relative expression
of the gene and its induced inhibition by A20.
T2087
Gene Expression Profile of Stomach in Response to Food Intake in Mice
Eli Helge, Chun-Mei Zhao, Turid Follestad, Paul van den Ijssel, Paul P. Eijk, Bauke Ylstra,
Duan Chen
Background/Aim: The physiological role of stomach is generally believed to serve as a
reservoir for ingested food and to secrete gastric juice containing HCl. The aim of the present
study was to reveal the gene expression profile of the stomach in response to food intake
in mice. Methods: Twenty mice (male, C57BL/6, 2-month old) were divided into fasted
group (6 mice) and re-fed group (14 mice). The re-fed mice were fasted for 24 h and then
given free access to the standard mouse food pellets for 4 h. The intact stomachs were
collected from each mouse and 6 stomachs in re-fed group were selected based on the
weight of gastric contents. RNA was isolated from each mouse stomach using Trizol method,
and the quality was checked by spectrophotometer and electrophoresis. The gene expression
profiling was performed by Affymetrix Mouse Gene Chips (39K), and verified by mouse
oligo expression microarray (21K), and qRT-PCR. Differentially expressed genes were annot-
ated using the gene ontology tool eGOn v. 2.0 (www.genetools.microarray.ntnu.no). Results:
Affymetrix analysis revealed a total of 1842 genes to be changed significantly. Oligo microarray
showed that 288 genes were changed significantly (false discovery rate < 0.05), in which
151 genes were up-regulated (> 2-fold) and 121 down-regulated (>50%), 4 h after starting
re-feeding. Annotation analysis revealed that these genes modulate mainly the expression
of transcripts that are involved in metabolism and catabolism (92+11 genes), cell growth
and/or maintenance (57), molecular transport (50), cell communication (31), and morpho-
genesis and organogenesis (14+12). Both expected and unexpected mRNA expressions were
observed, such as ATPase, intracellular chloride channel protein, and mast cell protease 9,
pre B-cell leukaemia transcription factor 1. Moreover, pancreatic polypeptide (PP) mRNA
expression was found in the stomach and was down-regulated by re-feeding after starvation.
Conclusions: In response to food intake, the stomach was almost entirely mobilized at the
level of transcription. Gastric PP might play a role in the regulation of food intake.
T2088
Analysis of Small Intestinal Gene Expression in C57bl/6 Mice Revealed a
Protective Effect of Calcium On Dietary Fat Induced Cell Proliferation
Nicole de Wit, Hanneke Vermeulen, Lydia Afman, Mechteld Grootte Bromhaar, Michael
Muller, Roelof van der Meer
Background and aim: Metabolic syndrome (MS) is characterized by obesity, insulin resistance
and hypertension and is induced by chronic metabolic stress that can result from a disturbed
balance between lipid metabolism and pro-inflammatory response. In this study, C57Bl/6
mice that develop characteristics of MS on a high fat diet were used to gain insight into
molecular mechanisms underlying the aetiology of MS. Methods and results: Changes in
gene expression were analyzed in small intestine of C57Bl/6 mice fed a high (45 kcal%) or

















10 and 16 weeks of diet intervention, the small intestine of mice (n=6 per diet) was collected
and divided in three equal parts. For microarray analysis, part I and II were pooled, while
part III was analyzed separately. Already after one week of diet intervention gene expression
changes could be detected. Moreover, a substantial number of genes showed a robust
differential expression throughout diet intervention. Pathway analysis revealed differential
expression of genes involved in biological processes, such as fatty acid metabolism and
immune response. Interestingly, in part III of small intestine, cell cycle genes showed an
increased expression on a high fat diet, especially in the first two weeks of diet intervention.
This indicates regeneration of small intestinal cells to compensate damage that is caused by
luminal free fatty acids and/or related metabolites. Additionally, this enterocyte damage
might trigger a pro-inflammatory response associated with onset of MS. It is known that
calcium precipitates luminal free fatty acids and can induce an antiproliferative effect in
colon. To determine the effect of calcium on small intestinal gene expression profiles induced
by a high fat diet, C57Bl/6 mice were fed a high fat diet with low (50 mmol/kg) or high
(150 mmol/kg) calcium content. After 10 weeks of diet intervention, microarray analysis of
part II and part III of small intestine showed a decreased expression of cell cycle genes on
the high calcium diet. Additionally, performing immunohistochemistry for Ki67, small
intestinal villi of mice fed the high calcium diet showed a lower labelling index compared
to mice fed the low calcium diet. This implies that also in small intestine calcium can provide
a cytoprotective and thus an antiproliferative effect. Conclusion: The results of the C57Bl/
6 mice studies indicate that enterocyte damage and the accompanying proliferation is an
early event in development of MS and that calcium can have a protective effect in this process.
T2089
The Enteroendocrine Fatty Acid Receptor GPR40 Retains Acyl Chain Length
Response Specificity When Heterologously Expressed in PC12 Cells
Andrew J. Higgins, Anthony D. Jackson, Craig P. Smith, John McLaughlin
BACKGROUND: Fatty acids (FA) cause secretion of cholecystokinin (CCK) from enteroen-
docrine cells (EEC), but the cellular mechanisms of FA detection remain unclear. The murine
enteroendocrine cell line, STC-1, secretes CCK in response to FA via a rise in [Ca2+]i, in
a chain length dependent manner. This requires a minimum of 12 carbons in the acyl chain,
matching that observed in vivo in humans. The molecular sensing mechanism is unknown.
The recent identification of the former orphan GPR40 as a FA receptor (expressed by
pancreatic β cells) has prompted this investigation into its potential role as a candidate lipid
sensor in EEC. AIMS: To express mouse GPR40 in a heterologous system, and study the
acyl chain length specificity of transferred fatty acid responsiveness. METHODS: mGPR40,
obtained by RT-PCR from the STC-1 cell line, was subcloned into the mammalian expression
vector pEYFP-N1 in C-terminal fusion with the fluorescent protein EYFP, and stably expressed
in the neuroendocrine cell line, PC12. Both wild type (WT) and mGPR40EYFP expressing
PC12 cells were loaded with Fura-2 to monitor [Ca2+]i by fluorescence microscopy and
analysis of the ratio of light emitted at 340 and 380nm. Cells were exposed to 500µM FA
of varying acyl chain lengths. RESULTS: FA of acyl chain length C4-C10 did not increase
[Ca2+]i in either PC12-WT or mGPR40EYFP+ cells. However, mGPR40EYFP+ PC12 cells
displayed significantly increased [Ca2+]i responsiveness to long chain FA compared to PC12-
WT cells. Dodecanoic acid (C12:0) produced no increase in [Ca2+]i in PC12-WT, but a
large response was elicited in mGPR40EYFP+ PC12 cells, with an average ratio increase of
0.5+/-0.05 units. Linoleic acid (C18:2) induced a small rise in [Ca2+]i in PC12-WT (0.1+/-
0.05 ratio units) which was amplified in mGPR40EYFP+ PC12 cells (0.4+/-0.1 ratio units;
p<0.05). For comparison, the maximal [Ca2+]i response induced by 70mM KCl was 0.7+/-
0.1 ratio units in PC12-WT and 0.6+/-0.1 in mGPR40EYFP+ PC12 cells. Responses were
reversible and reproducible, data representing a minimum of 5 independent experiments.
CONCLUSIONS: mGPR40 of EEC origin functions as a FA receptor when heterologously
expressed in the PC12 neuroendocrine cell line. The response to FA is chain length dependent,
and remains entirely concordant with previous studies in both the STC-1 cell line and in
humans, further supporting a functional role for GPR40 in FA-sensing by EEC. These data
justify further detailed study into the signalling pathways and detailed molecular physiology
of the GPR40 receptor in relation to EEC.
T2090
Expression of Metabolic and Signalling Genes Is Altered in Adipose Tissue of
Obese Children
Antonio Suarez, Concepcion Aguilera, Carolina Gomez-Llorente, Ines Tofe, Mercedes Gil,
Esther Farez, Jose Antonio Gomez-Capilla, Ramon Canete, Angel Gil
AIMS: To determine changes in gene expression profile of adipose tissue associated to obesity
in prepubertal children. METHODS: We selected 10 children, 5 obese (BMI adjusted for
age and sex z score > 2) and 6 control. During appendix surgery, about 400 mg of adipose
tissue was taken and immediately immersed in RNAlater solution; total mRNA was isolated
and cRNA was hybridizated on the Human Genome U133 Plus 2.0 Arrays (Affymetrix®).
To minimize array discrepancies all arrays were scaled up using the Affymetrix GCOS 1.1
software and the results of each array were compared with all the others. Expression
gene profiles were classified using the the GeneSpring software. Transcripts were classified
according to Gene Ontology and Panther softwares. RESULTS: 10976 sequences were
expressed in obese and 11014 in control children. Bidimensional cluster analysis allowed
to adequately separate samples by experimental condition (obese and control). 1588 genes
at P<0.05, 435 at P<0.01 and 57 genes at P<0.001 were found to be differentially expressed.
These transcripts were classified by biological process (30.5% metabolism, 17.7% cellular
physiological processes and 13,5% cell communication) molecular function (14.5% nucleic
acid binding, 10.4% protein binding and 8.5% metal ion binding), cellular components
(31% intracellular, 14.6% membrane and 2.7% cell fraction) and signalling pathways (2.3%
Cytokine signalling, 2.3% Wnt signalling and 2.2% angiogenesis). CONCLUSIONS: Obesity
in early childhood results in a marked alteration of gene expression. Metabolic genes are
the most affected ones followed by membrane and intracellular signalling proteins.
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T2091
Is Lys109lys in the Lepr Gene Associated with Protecting Obesity from
Hyperglycemia?
Chen Shaohua, Yu Chaohui, Jiang Lingling, Li Youming
Background and aim: The leptin receptor plays a critical role in regulation of body weight
by inhibiting food intake and stimulating energy expenditure. Mutations in LEPR gene
have been shown to cause obesity. Whether lys109arg in leptin gene affect obesity is still
unknown.The study analyse the association between lys109arg polymorphism in the lepr
gene and obesity. Materials and methods A total of 180 subjects (90 cases with BMI<25
and 90 cases with BMI≥25) who received physical examination were included in the study.
Genomic DNA samples were extracted from blood from subjects. Genotyping was performed
using oligonucleotide microarray. Blood were used to detect total protein, albumin, ALT,
triglyceride, cholesterol, HDL and fasting blood glucose. Results There are 144 (80%) subjects
with G/G genotype(arg109arg), 33(18.33%) with G/A genotype(lys109arg) and 3(1.67%)
with A/A genotype(lys109lys). All three cases (aged from 50 to 70 yrs) with lys109lys
polymorphism in the lepr gene were female, short (with height from 152 to 158cm),with
BMI26.31.The percentage of body fat and abdominal wall fat thickness is significantly higher
in lys109lys (37.73% & 4.07±0.40 cm) than that in arg109arg(28.80% & 2.72±0.74 cm)
and lys109arg (28.95% & 2.79±0.63 cm) (p<0.05). The level of triglyceride, cholesterol
and HDL of the three cases is normal. Conclusion Lys109lys polymorphism in the LEPR
gene may be involved in protecting obesity with high percentage of body fat and high
abdominal wall fat thickness from hyperglycemia. And the distinct mechanism is still not
known.
T2092
Identification of the Acute Effects of Lactobacillus Plantarum WCFS1 On
Transcriptional Responses in Human Intestinal Mucosa
Freddy Troost, Michiel Kleerebezem, Willem M. de Vos, Robert-Jan M. Brummer
The impact of probiotics on gut health parameters in health and disease has drawn a lot of
attention over the last years. However, the impact of probiotics on the regulation of human
intestinal mucosa is largely unknown. This study aimed to identify the acute response of
intestinal mucosa to Lactobacillus plantarum WCFS1 in vivo in healthy volunteers. Eight
healthy subjects without a history of GI symptoms were recruited to participate in this
randomized cross-over study. After an overnight fast, tissue samples from the horizontal
part of the duodenum were obtained during duodenoscopy. Subsequently, a perfusion
catheter was inserted into the proximal small intestine with an injection port located in the
proximal descending duodenum. A 1% glucose solution was infused for three h at 10 ml/min
and, after reaching steady state conditions, a solution containing either 10^11 Lactobacillus
plantarum WCFS1 in 1% glucose, or placebo (1% glucose) was infused for 60 min. A second
duodenoscopy was performed to obtain tissue samples after the perfusion experiments. Gene
expression profiles in the tissue samples were measured using Affymetrix U133A microarray
chips. A multivariate model was designed to correct the array data for interindividual day-
to-day variability and effects of the procedure. Only gene reporters that were consistently
regulated in all volunteers were considered for further analysis. A fold change ≥ 10% was
considered as a differentially expressed gene reporter. All gene intensities were loaded in
the Genmapp/Mappfinder public software programme (www.genmapp.org) to extrapolate
the gene results to functional biological processes. We observed significant changes in 689
gene reporters; 225 were upregulated, and 444 were downregulated. Twenty-three of the
upregulated gene reporters were associated with ribosomal proteins, 15 with immunoglobul-
ins, and many gene reporters could not clearly be allocated to a functional group of genes.
Genmapp analysis showed that ribosomes, and specific subgroups of ribosomes, were import-
antly mediated by Lactobacillus plantarum WCFS1. Other pathways that were regulated were
caveola, isomerase activity, translational initiation, ER to Golgi transport, GTPase activity,
fatty acid beta-oxidation, ubiquitin conjugating enzyme activity, chymotrypsin and trypsin
activity. This study shows that acute, 1-h exposure of intestinal mucosa to Lactobacillus
plantarum WCFS1 triggers a consistent transcriptional response in small intestinal epithelium
in vivo. Especially processes associated with protein synthesis, proteolysis, intracellular signal
transduction, fatty acid metabolism, and immune function seem to be regulated.
T2093
Prokinetic Therapy for Feed Intolerance in Critical Illness: One Drug Or Two?
Nam Q. Nguyen, Marianne Chapman, Robert Fraser J. Fraser, Laura Bryant, Richard H.
Holloway
In critical illness, enteral feeding is the preferred method of nutrition. Initial therapy for
intolerance of naso-gastric (NG) feeding is either IV metoclopramide (M) or erythromycin
(E). Persistent or recurrent intolerance is managed with combination therapy and, if drug
therapy fails, post-pyloric feeding. Data to support this practice are limited. Aims. (i) to
compare metoclopramide and erythromycin in the treatment of feed intolerance in critical
illness, and (ii) determine the success of ‘rescue’ combination treatment in patients who fail
monotherapy. Methods. 90 feed-intolerant (6hly NG aspirate>250ml) critically ill patients
received either M (n=45; 10mg IV QID) or E (n=45; 200mg IV BD) in a prospective, double-
blind randomized fashion. Age, sex and APACHE II scores were similar between the 2
groups. After the 1st dose of prokinetic therapy, NG feeding was recommenced and 6hly
aspirates were performed. If NG aspirate remained >250ml, combination therapy was given.
Patients were studied for 7 days. Results. The use of inotropes, opioids and sedations, and
BSLs were similar in the 2 groups. Both M and E significantly reduced gastric residual
volumes(GRV) and improved the % of patients with successful feeding (M: 62% and E:
87%) after 24h of therapy . Treatment with E was more effective than M (P<0.05, figure).
The % of patients who respond to either treatment on subsequent days declined rapidly.
‘Rescue’ combination therapy was highly effective and its effectiveness was maintained over
6d. Predictors of a poor response to single or combined prokinetic therapy were: older age,
high admission APACHE II score, multiple trauma, high pre-treatment GRV, and impaired
renal function. Conclusions. In critical illness, erythromycin is more effective than metoclop-
ramide in treating feed intolerance. Rapid tolerance to prokinetic agents renders both treat-
ments sub-optimal. Combination therapy in these patients is highly effective as ‘rescue’
therapy. Further study is required to examine the role of combined therapy as first line treat-
ment.
T2094
A Subjective Assessment of Skills and Social Support Required to Administer
Home Parenteral Nutrition and Presence of a Psychiatric Diagnosis Can
Predict the Development of Complications
Douglas Seidner, Lori Jeris de Burgoa, Cynthia Hamilton, Judy Stafford, Rocio Lopez,
Ezra Steiger
Aim: A prospective cohort study was performed to help define the risk factors associated
with complications of home parenteral nutrition (HPN). This report describes the impact
that psychosocial and training issues have on patient outcome. Methods: All adult patients
newly started on HPN and discharged to home from June 2003 through July 2005 were
included. Major complications were recorded for the first 90d after discharge. Data was
collected prospectively and included reason for HPN, psychosocial assessment, severity of
illness, and duration of training. A nurse and social worker skilled in assessing and training
patients for HPN gave each patient/caregiver a subjective score based on their likelihood of
success in performing the tasks of administering HPN. The grading was A>B>C>D>F.
Complications were categorized by type, severity, cause, and whether they were preventable.
Patients who had complications were compared with those who did not. Data is expressed
as median (Q25,Q75) and was analyzed using the Chi-square and Wilcoxon rank sum tests.
Results: 187 patients (age 51.4y (41.6, 61.5), 109F, 78M) were included in the study. The
median duration of HPN was 90d (41,90). 99 (52.9%) had a psychiatric diagnosis, usually
a mood disorder. There were 103 complications in 72 patients: 36 patients had one, 21
had two, and 5 had three complications. The analysis only included the first complication.
The distribution of complications was infectious 52 (50.5%), mechanical 24 (23.3%), and
metabolic 27 (26.2%). Twenty three (22.7%) of the complications may have been preventable.
There was an 81% agreement in success grade between the nurse and social worker. This
corresponds to a kappa value of 0.68 (95% CI, 0.55-0.81). For every 1 grade worsening in
the success score, the odds of having at least 1 complication increase 60% (OR [95%CI]:
1.60 [1.04, 2.4]). Subjects with a psychiatric diagnosis had an 88% higher odds of having at
least 1 complication than those with no psychiatric diagnosis (1.88 [1.03, 3.4]). Conclusions:
Patients with difficulty acquiring skills for HPN, a limited social support structure and an
underlying psychiatric diagnosis are at greater risk for developing a complication of HPN.
Identification of these factors is important and management may help decrease preventable
morbidity associated with this therapy.
T2095
Plasma Citrulline Concentration Is a Reliable Marker of Small Bowel
Absorptive Capacity in Crohn’s Disease and Is Independent of Intestinal
Inflammation
Cinzia Papadia, Ra Sherwood, Tommy Kalantzis, Katharina Wallis, U Volta, E Fiorini,
Alastair Forbes
Background & aims: Post-absorptive plasma citrulline concentration has been proposed as
a reliable marker of small bowel absorptive capacity in short bowel patients. Significant
correlation between reduced citrulline and abnormal histology has also been shown in patients
with intestinal damage, but the potentially confounding impact of intestinal inflammation has
not been addressed. The present study aims to evaluate plasma citrulline as a surrogate of
intestinal functional integrity in Crohn’s disease (CD) and whether concentrations are influ-
enced by inflammation. Methods: 55 patients were selected according to diagnosis, small
bowel length and degree of bowel inflammation, to constitute 8 groups: 1)CD with massive
small bowel resection: ≤ 50cm remaining (n=6); 2)resected CD with 50-150 cm remaining
small bowel (n=9); 3)CD with no resection but active inflammation (high CRP and Crohn’s
Disease Activity Index (CDAI) >220) (n=7); 4) CD with no resection and no active inflamma-
tion (normal CRP and CDAI<150) (n=6); 5) mesenteric infarction (MI) with massive small
bowel resection with≤50cm remaining (n=6); 6) mesenteric infarction with resection leaving
T : 89386$$CH2
05-04-06 23:18:31 Page 611Layout: 89386B : o
A-611 AGA Abstracts
50-150cm small bowel; 7) active celiac disease (n=6); 8) healthy volunteers (n=6). Post-
absorptive fasting plasma citrulline (in µmol/L) was measured using reverse-phase High
Performance Liquid Chromatography (HPLC). All patients had standard laboratory markers
performed and CD activity was scored according to the CDAI. Five hour urine collections
were then carried out on each patient following sugar mix ingestion (5g lactulose, 1g L-
rhamnose, 0.5g D-xylose and 0.2 g 3-O-methyl-D-glucose in 100 ml of demineralised water).
Results: The plasma citrulline concentration strongly correlated with small bowel length
(p<0.0001) and carbohydrate absorption (p<0.001). No correlation was found between
plasma citrulline concentration and small bowel permeability, and there was no correlation
with CRP, sedimentation rate, white cell count, platelets or albumin. Plasma citrulline was
significantly higher (p<0.0004) in CD and MI patients with a remnant small bowel length
of 50-150cm (mean value 21.0µmol/L) than in those with CD and MI patients with a small
bowel length ≤50cm (mean value 9.2µmol/L). No significant difference (p=0.734) was
found between groups of patients with CRP <10 compared to those CRP >10, nor between
active and inactive CD patients in whom the intestinal length remained intact. Conclusion:
Citrulline plasma concentration is a simple, sensitive and reliable surrogate for small bowel
absorptive capacity in Crohn’s disease patients and is not influenced by intestinal inflamma-
tion.
T2096
Reduced Muscle Function and Muscle Stores Are Common in Quiescent
Crohn’s Disease
Treasa Nic Suibhne, Colm O'Morain, Maria O'Sullivan
AIM: To define the nature and prevalence of undernutrition in quiescent Crohn’s Disease
(CD). METHODS: Nutritional and clinical assessments were conducted on 100 CD patients
and 100 healthy controls (mean age 35.73 ± 10.93 v 37.96 ± 11.02 yrs; NS) matched for age,
sex and socio-economic status. Protein stores were assessed by mid upper arm circumference
(MUAC, cm) and midarm muscle circumference (MAMC, cm), muscle function by grip
strength (GS, kPa) and fat stores by triceps skinfold thickness (TSF, mm). Muscle depletion
was defined as MUAC or MAMC <15th centile, reduced muscle function as GS < population
standard, and reduced fat stores by TSF <15th centile. Serum Tumour Necrosis Factor alpha
(TNFα) was measured by ELISA. RESULTS: Reduced muscle function was significantly more
common in CD patients than controls [72% (72/100) v 43% (43/100); P = 0.00χ2]. Patients
with reduced muscle function had significantly higher steroid usage in the past year [54%
(39/72) v 32% (9/28); P = 0.04χ2] compared to those with normal muscle function. Import-
antly, physical activity [44% (32/72) v 46% (13/28) <30mins per week; NSχ2] was similar
between groups. Other factors such as gender [61% (44/72) v 57% (16/28) female; NSχ2],
age [36.13 ± 10.62 v 34.67 ± 11.81 yrs; NS], Crohn’s Disease Activity Index (CDAI) [68%
(49/72) v 64% (18/28) <150; NSχ2], C-reactive protein (CRP) [59% (41/69) v 64% (18/28)
<5mg/L; NSχ2] and disease duration [8.55 ± 6.50 v 7.07 ± 6.39 yrs; NS] did not differ
between groups. Screening using standard nutritional and clinical parameters showed the
majority of patients with reduced muscle function were of normal BMI [88% (63/72); mean
25.29 ± 6.07 kg/m2], were in clinical remission [68% (49/72); median CDAI 95.24 (0 -
422.76)], had normal CRP levels [59% (41/69); median 3.90 (2.9 -38.6) mg/L], normal
plasma total protein [94% (66/70); mean 73.60 ± 4.89g/L], normal serum albumin [93%
(65/70); mean 42.62 ± 4.36 g/L] and normal fat stores [94% (68/72) with TSF >15th centile],
therefore, would remain undetected by standard measurements. Muscle depletion was similar
in CD and controls [42% (42/100) v 41% (41/100) <15th centile; NSχ2]. In CD, patients
with muscle depletion had significantly higher serum TNFα levels (6.85 ± 1.96 v 5.87 ±
2.05 pg/ml; P = 0.02) than those without . CDAI [62% (26/42) v 71% (41/58) <150; NSχ2],
CRP [(60% (24/40) v 61% (35/57) <5mg/L; NSχ2], steroid usage [52% (22/42) v 45% (26/
58); NSχ2] and physical activity [40% (17/42) v 48% (28/58) <30mins per week; NSχ2]
did not differ between groups. CONCLUSION: Reduced muscle function is prevalent in
CD patients with inactive disease and is associated with higher steroid usage.
T2097
The Effect of Distal Jejunal Feeding On in Vivo Trypsin Synthesis and
Turnover
Wen Zhou, Justin Kiswardy, Neeraj Kaushik, Marie Pietraszewski, Stephen J. O'Keefe
Recent studies of ours showed that bypass of the cephalic phase had no appreciable effect
on pancreatic secretion. However, converting the duodenal dietary infusion from polymeric
to elemental form decreased secretion by 50%, and delivery of the feed distal to 40cm
down the jejunum avoided pancreatic stimulation. In the present study, we extended our
investigations to assess the effect of distal jejunal feeding on the synthesis of trypsin. Pancreatic
trypsin synthesis and turnover was measured by the 6h IV infusion of 13C-labeled leucine
and collection and isolation of trypsin from duodenal secretions, as described previously
(AJPhysiol 2004), in 32 healthy volunteers studied during no nutrient (saline-placebo), IV,
duodenal or mid-distal jejunal nutrient infusion 20 or 120cm past ligament of Treitz (LOT)
given at 40 kcal/kg IBW/day and 1.5 g protein/kg IBW/day. Table summarizes group mean
(SE) results showing that duodenal feeding stimulated trypsin secretion and the rate of
appearance of newly synthesized trypsin, while mid-distal jejunal feeding did not. Secondly,
trypsin secretion and synthesis were significantly lower when the diet was changed from
duodenal to distal jejunal feeding site. Amylase and lipase secretion followed a similar
pattern. Although the response was exaggerated by infusion 60cm beyond the LOT, the
difference was not significant. Conclusion: Our results suggest that post-pyloric feeding with
an extended tube placed 40-120cm down the jejunum avoids the stimulation of pancreatic
enzyme synthesis resulting in lower secretion. Further studies are needed to see whether
ileal infusion can suppress basal enzyme synthesis for the management of pancreatic secret-
ory disorders.
















s Statistics: * p<0.05, ** p<0.001 Student’s t test vs. placebo or baseline, + p<0.05 vs. duodenal
T2098
Associations Between Growth and Dietary Intakes in Children After Liver
Transplant
Timothy A. Sentongo, Simona Korff Korff, Roopa Seshadri, Ann Quinn, Meena
Rammohan, Estella Alonso
BACKGROUND: Growth in children after liver transplant is improved but not normalized.
There are limited data about dietary patterns and their associations with growth after
transplant. Therefore this study examined relationships between dietary intakes and post-
transplant growth. METHODS: Prospective study of pediatric liver transplant recipients.
Weight (kg) and height (cm) were measured within three months (baseline) and at ~24
months (follow-up) post-transplant. Z-scores for weight (WAZ), height (HAZ), weight-for-
height (WHZ) and body mass index (BMIZ) were computed. Average daily energy intake
(EI, kcal/d) was determined from 3 randomn 24-hr diet recalls. EI was compared with
NHANES III data and expressed as a multiple of estimated basal metabolic rate (EI:BMR)
to assess level of intake above basal requirements. Calcium intake (mg/day) was expressed
as a percentage of Adequate Intake (%AI-Ca) and calcium-to-energy ratio (Ca:EI) to estimate
intake per 1000 kcal. Catch-up growth (significant change in z-score) was examined using
t-tests. Associations between growth and dietary intake were examined using correlations
and non-parametric tests. Significance was p < 0.05. RESULTS: 24 subjects (18 females)
enrolled. The median age at transplant was 1.65 y (range 0.40 - 14.8 y). The interval between
baseline and follow-up was (Mean±SD) 18.4±5.3 months. The baseline and follow-up growth
status was: WAZ -0.87±1.37 vs. -0.01±1.35; HAZ -0.89±1.37 vs. -0.58±1.03; WHZ 0.02±1.34
vs. 1.03±1.29; BMIZ -0.16±1.30 vs. 0.27±1.26. Catch-up growth occurred in weight (p =
0.021) and weight-for-height (p = 0.006). The mean EI was 1464±475 kcal/d and did not
differ from reference values (p = 0.21). The mean EI:BMR was 1.71±0.45 and not dependent
on age (p = 0.16). EI:BMR was inversely correlated with change in WHZ (r = -0.78, p =
0.002) suggesting that underweight children had relatively higher EI and also demonstrated
more growth. The Ca:EI and %AI-Ca were 646±268 mg/kcal/day and 137±65% respectively.
The Ca:EI and %AI-Ca were higher in children aged <3-y, p = 0.048 and p < 0.001
respectively. There was no correlation between %AI-Ca and total EI (r = -0.33, p = 0.16).
CONCLUSION: Growth in the first 2-y after liver transplant was characterized by more
rapid gains in weight than height. EI was influenced by nutritional status and correlated
with rates of post-transplant growth, whereas adequacy of Calcium intake varied by age and
was independent of total EI. Recognizing dietary trends and their association with age,
growth and likelihood of adequacy will lead to optimized nutritional support in transplant
recipients. Supported by NIH Grant: M01 RRR-00048
T2100
Dose Enteral Feeding Stimulate the Pancreas in Patients with Severe Acute
Pancreatitis?
Stephen J. O'Keefe, Marie Pietraszewski, Neeraj Kaushik
Recent studies have shown that enteral feeding is superior to TPN in the managment of
acute pancreatitis, despite tha fact that EN stimulates trypsin production and trypsin is the
initiating factor in the disease. Previously we have shown that secretion is lower in AP
patients than in healthy volunteers during enteral feeding, but we do not know whether
secretion is even lower during bowel rest. Consequently, we studied 8 patients with acute
severe necrotizing pancreatitis, first measuring secretion during bowel rest, and then again
during enteral feeding. Results demonstrated that secretion rates of typsin, amylase and
lipase were >90% lower in necrotizing pancreatitis than healthy controls, and that enteral
feeding had no significant effect on secretion (3 higher, 6 lower: Table) In conclusion, enteral
feding has no appreciable effect on luminal secretion of pancreatic enzymes in necrotizing
pancreatitis. However, further studies need to be performed to exclude the possibility that
EN increases trypsin synthesis but that the secretions are lost into the inflammatory mass.
Effect of Feeding on Secretion (mean(SE))
T2101
Survival Rate, Nutritional Independence, and Prognostic Factors in 100
Patients with Chronic Intestinal Failure
Italo Vantini, Silvia Montibeller, Luigi Benini, Giorgio Talamini, Elettra Marangoni, Fosca
de Lorio, Ulrich Thalheimer, Franco Capra, Franco Benini
Chronic intestinal failure (CIF) affects nutritional status and life expectance. Even though
recovery of nutritional independence is possible, about 50% of CIF need long-term artificial
nutrition. Aim of this study was aimed at assessing what factors influence the long-term
outcome of patients with CIF. PATIENTS AND METHODS. One hundred patients with CIF
(90 with short bowel syndrome (SBS) with or without colon in continuity, 10 with intestinal
pseudo-obstruction) were followed in our institution for a median of 36 months (range 6-
132). Twenty-two clinical and anatomical variables were considered. Statistical analysis was
carried-out with Mann-Whitney U-test, Pearson Chi square, Spearman correlation test,
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Kaplan-Meyer method and Cox’s proportion hazards regression analysis. RESULTS. Twenty
seven patients died, in 50% of the cases for catheter-related infections or for intestinal failure.
Survival rates were 94.8 and 79.4% at 1 and 5 years respectively. Survival was lower in
patients with permanent CIF and with long term dependence on parenteral nutrition (5
year survival 91 and 71% for patients on oral supplements and on artificial nutrition
respectively). Forty percent of CIF weaned from artificial nutrition, most of them within 3
months since hospital discharge. A 0.63 patient/year hospital readmisson rate was observed,
mainly because of catheter-related problems or malnutrition. In univariate analysis, the
variables which resulted associated with better outcomes were colon in continuity, length
of residual bowel > 100 cm, age <45 at onset and diagnosis of chronic idiopathic pseudo-
obstruction. Multivariate analysis showed that only the length of first hospital admission
was as a negative prognostic factor (OR 1.016, 95% CI 1.006-1.026). CONCLUSIONS.
Chronic intestinal failure represents a transient condition in about 40% of patients; nutritional
independence is achieved early in most cases, with a little gain thereafter. Age under 45,
colon in continuity, length of remnant bowel are associated with better outcome and higher
nutritional independence rate. The length of hospital stay as negative prognostic factor
probably mirrors the severity of CIF and a more difficult stabilization to be achieved
before discharging.
T2102
Efficacy of Home Pamidronate Infusion in Patients with Metabolic Bone
Disease On Home Total Parenteral Nutrition
Maitreyi Raman, Baun Mary, Ellie Aghdassi, Johane P. Allard
Background: Patients on long term home total parenteral nutrition (HTPN) are at increased
risk of developing metabolic bone disease (MBD). Pamidronate is a bisphosphonate, proven
to be effective at improving bone density in patients with osteoporosis. Pamidronate has
been poorly studied in patients with MBD on long term HTPN. Objective: This study
examined the change in bone density after receiving pamidronate in patients on long term
HTPN with MBD. Methods: This is a prospective cohort study with 11 patients receiving
intravenous pamidronate between 1998 and 2005. Bone mineral density (BMD) was per-
formed prior to receiving pamidronate and after at least 18 months of treatment. Pamidronate
was infused at home over 2 hours at a dose of 30 mg q 3 months Paired t-test was used
to compare t-score in the lumbar spine, femoral neck, and hip. Results are expressed as
mean + standard deviation. Results: Eleven patients (7 female; 4 male) receiving HTPN for
a mean of 10.6 + 6.3 years were studied. At baseline, mean age was 59.9+ 14.2 yr and
body mass index was 24.3 + 3.7 kg/m2. Indications for HTPN include: Short Bowel Syndrome
n=7, Crohn’s Disease n=1, malignancy n=1, radiation enteritis n=1, pseudo-obstruction n=
1. Two patients were receiving steroids. Mean duration of pamidronate treatment was 22.2
+ 5.4 months. There was a trend toward improvement in the mean t-score of the spine after
receiving pamidronate (pre pamidronate: -3.1 + 0.75 vs. post pamidronate: -2.9 + 0.69, p=
0.07). Additionally, a trend toward improvement was noted in the BMD of the hip (pre
pamidronate: 0.67 + 0.10 vs. post pamidronate: 0.73 + 0.09, p=0.05), and t-score of the
hip (pre pamidronate: -2.6 + 0.9 vs. post pamidronate: -2.3 + 0.84, p=0.09). No significant
change in bone density or t-score was noted in the femoral neck post pamidronate. After
excluding the 2 patients on corticosteroids, there was significant improvement in the mean
t-score of the spine (pre pamidronate: -3.4 + 0.57 vs. post pamidronate: -3.1+ 0.65, p=
0.036). Conclusions: In this small sample size, patients on HTPN receiving intravenous
pamidronate showed a trend toward improvement in BMD which became significant for
the spine when those receiving steroids were excluded. This suggests that home infusion
of pamidronate can be of benefit in this patient population. Further studies with longer
treatment period and larger sample sizes are needed to evaluate the true efficacy of pamid-
ronate.
T2103
Choline Deficiency Is Associated with Increased Risk for Venous Catheter
Thrombosis
Alan L. Buchman, Marvin E. Ament, Donald J. Jendon, Chul Ahn
Introduction Patients with intestinal failure that require long-term TPN develop catheter
thrombosis as a complication. This patient group may also develop choline deficiency because
of a defect in the hepatic transsulfuration pathway in the setting of malabsorption. This
study was undertaken to determine whether choline deficiency is a risk factor for development
of catheter thrombosis. Methods Plasma free and phospholipid-bound choline concentrations
were measured in a group of patients that required long-term TPN. 22 had short bowel
syndrome, 5 had pseudoobstruction, 3 unclassified sprue, and 11 had misc indications.
Episodes of catheter thrombosis from onset of TPN to the time of blood testing were recorded.
Results 41 subjects with 231 catheter years (one patient with a catheter for one year = one
catheter year) including 21 males (aged 34+/-26 yrs) that had received home TPN for 5.8+/-
5.0 yrs and 20 females (aged 55.1+/-18.1 yrs) that had received home TPN for 5.6+/-4.1
yrs were studied. 16 (39%) patients developed catheter thrombosis and 5 had recurrent
catheter thrombosis. Age, sex, TPN duration, and TPN indication were similar between
patients that developed catheter thrombosis and those that did not. Plasma free choline was
7.7 +/- 2.7 nmol/ml in patients with no history of catheter thrombosis and 6.2 +/- 1.7 nmol/
ml in patients with previous catheter thrombosis (p=0.076 by Wilcoxin rank-sum test). The
partial correlation between plasma free choline concentration and the frequency of clots
after controlling for catheter duration was r=-0.33, p=0.038. Plasma phospholipid-bound
choline concentration was 2191.7 +/- 679.0 nmol/ml in patients with previous catheter
thrombosis and 2103.3+/- 531.2 nmol/ml in patients without history of catheter thrombosis
(p=NS). Relative risk for catheter thrombosis in patients with a plasma free choline concentra-
tion <8nmol/ml (normal: 10-12nmol/ml)=10.00, 95% C.I.=(1.134, 88.167) Conclusion Cho-
line deficiency is a significant risk factor for development of catheter thrombosis in patients
with intestinal failure that require TPN.
T2104
Nasojejunal Feeding in Severe Acute Pancreatitis: Comparison of Endoscopic
and Self-Migration Tube Placement
Stephane Lecleire, Michel Antonietti, Eric Lerebours
Introduction. Nasojejunal feeding has become the first intention nutritional support in severe
acute pancreatitis. While it is recommended to start enteral nutrition early after the onset
of the disease, difficulties in tube placement in jejunum can delay the beginning of nasojejunal
feeding. The aim of the study was to compare the delay between nasojejunal tube placement
and the beginning of enteral nutrition regarding the feeding tube placement procedure,
using endoscopy or self-migration tube. Patients and Methods. Thirty patients presenting
with severe acute pancreatitis and enterally fed using nasojejunal tube were retrospectively
included in the study. Ranson’s score was > 3 with a C-reactive protein (CRP) > 150 m
and/or Balthazar CT scan assessment was scored D or E in the 72 first hours after the onset
of epigastric pain. Thirteen patients underwent endoscopic nasojejunal tube placement using
a nasofibroscope (group 1), and in 17 patients nasojejunal tube migration was stimulated
by the intravenous injection of a prokinetic twice a day during 48 hours (group 2). Control
of the jejunal site of the feeding tube was assessed by a plain radiograph at day 0 in patients
from group 1 and day 2 in patients from group 2. Nasojejunal feeding delay after tube
placement, duration of enteral feeding and length of stay were copared between the two
groups. Results. Patients from group 1 and 2 did not differ for mean age (53 (32-79) vs 48
(36-74); ns); mean Ranson’s score (3.6 (2-6) vs 3.4 (2-5); ns); mean Balthazar’s score; initial
CRP (243 (51-520) vs 262 (76-361); ns). Nasojejunal tube was placed in a median time of
5 days after admission in both groups (2-10 vs 2-12; ns). Nasojejunal tubes were all in
jejunum at day 0 in group1. In 18% of patients from group 2, the tube was not in jejunum
at day 2, leading to an endoscopic correction of the tube position. Enteral feeding was
started significantly earlier after admission in patients from group 1 as compared to patients
from group 2 (5.6 days (2-11) vs 8.9 days (4-15); p<0.01). Length of stay was significantly
shorter in patients from group 1 (17 days (12-41) vs 22 days (15-45); p<0.05). Conclusion.
Endoscopic placement of nasojejunal tube in patients with severe acute pancreatitis permits
to start enteral nutrition earlier and to significantly reduce the hospital length of stay. These
result should be confirmed by a large prospective study including a cost-analysis.
W1000
A Patient Navigator (PN) in An Open Access Endoscopy (OAE) Program
Facilitates Completion and Satisfaction with Screening Colonoscopy (SC)
Among Low-Income Underrepresented Minorities (URMs)
Stephanie A. Santos, Lina Jandorf, Steven Itzkowitz, Anabella G. Castillo, Jennifer Christie
BACKGROUND: African-Americans and Hispanics have lower screening rates for colorectal
cancer (CRC) than Caucasians. Organizational barriers such as lack of patient (pt) access
to timely referrals, adequate follow-up and reminder systems have an impact on successful
CRC screening. OAE is becoming more common in the United States. The advantages of
OAE include shorter waiting times, better control by referring physicians over pt preventive
services, and lower costs and inconvenience by eliminating an initial GI consultation. AIM:
To assess pt satisfaction with the SC process in an OAE program. METHODS: Average risk,
asymptomatic URMs from the primary care clinic at Mount Sinai Hospital were referred for
SC through OAE. The majority of pts reside in East Harlem, a medically underserved
community. The role of the PN included pt education, explanation of bowel preparation,
scheduling appointments, assisting with transportation/escorts, and providing counseling
and support to pts. After referral, the PN contacted each person to assess appropriateness
for OAE and discuss the procedure and bowel prep. Two weeks after SC, pts were contacted
by phone to conduct a 19-item patient satisfaction survey. RESULTS: From June-Oct 2005,
120 people completed their SC and 106 completed the pt satisfaction survey (response rate:
88%). 85% were female. 56% were Hispanic, 29% African-American and 11% Caucasian.
The mean age was 56.2 (SD= 5.2). 84.2% stated that their primary care provider (PCP)
adequately explained the reason for the SC. After contact with the PN, this rate increased
to 92.1% (p=.02). 34.9% of pts were extremely satisfied with their PCP’s explanation of the
bowel prep in comparison to 58.5% following the PN explanation (p=.00). 83% were
extremely satisfied or satisfied with PCP explanation of bowel prep versus 99.1% after PN
explanation (p=NS). 94% of pts were extremely satisfied/satisfied with the SC procedure
itself, and 89% were extremely satisfied/satisfied with the sedation during the procedure.
Only 2% of pts were dissatisfied with the quality of services received during the SC program.
10% of pts were extremely dissatisfied or dissatisfied with how the results were explained
after the procedure. Importantly, 64% of participants said they would not have completed
the SC without the assistance of the PN. CONCLUSIONS: PN, in an OAE program among
low-income URMs, helps pts overcome barriers to SC. Nearly two-thirds of pts would not
have undergone a SC without PN assistance. Overall, pts were highly satisfied with the SC
program. A PN program may help reduce racial disparities in CRC screening.
W1001
Yield of Initial Colonoscopy Screening in Patients < 50 Years of Age with a
Family History of Colorectal Cancer
Brooks D. Cash, Cecilia H. Kim, Dolores Y. Rhodes, Mark H. Johnston, Peter W. Soballe,
Philip S. Schoenfeld
Background: Current recommendations state that patients with a family history of colorectal
cancer (CRC) should undergo screening colonoscopy at age 40 or 10 years prior to the age
of the family member when diagnosed with CRC. These recommendations are largely based
on expert opinion. This study characterizes the prevalence and location of adenomas any
size and advanced neoplasia (adenomas > 10 mm, villous adenomas, adenomas with high-
grade dysplasia, or carcinoma) among 18-49 year-old patients with a family history of
CRC undergoing index colonoscopy. Methods: Prospectively collected data from endoscopic
databases at two tertiary medical centers was pooled. Inclusion criteria: asymptomatic men
and women < 50 years old with a family history of CRC in a first degree relative referred
for initial colonoscopy. Exclusion criteria: family history of HNPCC, FAP, IBD or other
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inherited CRC syndromes, recent history of hematochezia or abdominal discomfort, or
surveillance colonoscopy. Data was extracted on patient’s age, polyp histology, size and
location in the colon, prevalence of adenoma (any size) and advanced neoplasia. Results:
From 1998-2005, 380 patients aged 18-49 (mean age 41.9 years, 38.4% female) with a
family history of CRC underwent screening colonoscopy. 46/380 (12.1%) had at least one
adenoma identified at index colonoscopy, but only 2.1% (8/380) had advanced neoplasia.
When the distal colon is defined as colon distal to the splenic flexure (SF), 82.6% (38/46)
of patients with any adenomas and 50% (4/8) with advanced neoplasia had lesions proximal
to the SF without accompanying distal colonic neoplasia. Among patients < 40 years, 8.5%
(8/94) had adenomas (any size) and 0% (0/94) had advanced neoplasia. Among 40-49 year
old patients, 10.5% (30/286) had adenomas (any size) and 2.8% (8/286) had advanced
neoplasia. The prevalence of adenomas and advanced neoplasia was not significantly different
between these 2 age groups (p=0.694 and 0.208, Fisher’s exact test). Conclusions: Asymptom-
atic individuals < 50 years of age with a family history of CRC were usually found to have
proximal colonic neoplasia, confirming the appropriateness of screening with colonoscopy.
However, the prevalence of advanced neoplasia is relatively low. Additional data is needed
to evaluate the appropriateness of current screening recommendations for patients with a
family history of CRC.
W1002
Can Artificial Neural Networks Predict Need for Colonoscopy in Patients
Attending Colorectal Clinics?
Sushil K. Maslekar, Angela Gardiner, Graeme S. Duthie
Aims: Artificial neural networks (ANN) are computer programs used to identify complex
relations within data that cannot be detected with conventional linear-statistical analysis.
The routine clinical predictions of need for lower gastrointestinal endoscopy have been
based on population statistics with little meaning for individual patient. This results in large
number of unnecessary colonoscopies. We aimed to develop a neural network algorithm
which can accurately predict presence of pathology in patients attending routine outpatient
clinics. Methods: 300 patients undergoing lower gastrointestinal endoscopy prospectively
completed a specifically developed questionnaire which included 40 variables based on
clinical symptoms, signs, past and family history. Complete data sets of 50 percent of series
were used to train the artificial neural network; the remaining 50 percent were used for
internal validation. The primary output used was a positive finding on the colonoscopy,
including polyps, cancer, diverticular disease or colitis. Results: The outcome and pathology
reports of all the patients were obtained and assessed. Clear correlation between actual data
value and artificial neural network value were found (r = 0.931; P = 0.0001). The predictive
accuracy of neural network was 95% in the training group and was 89% (95% CI 84-96)
in the validation set. This accuracy was significantly higher than the clinical accuracy (69%).
Conclusions: We have shown that ANN is more accurate than standard statistics when
applied to prediction in individual patients of need for lower gastrointestinal endoscopy.
These results have obvious implications, with at least 20% resultant decrease in need for
unnecessary lower gastrointestinal endoscopy. The logistic and economic impact with this
development is tremendous.
W1003
Should We Suspect Hereditary Non Polyposis Colorectal Cancer (HNPCC) in
Patients with Colorectal Adenomas Before 40 ?
Driffa Moussata, Alexandra Glehen, Marie-Odile Joly, Beatrice Parmentier, Stephane
Nancey, Clermont-Carre Nathalie, Jean-Yves Scoazec, Jean-Christophe Saurin
Detection of a colonic adenoma before 40 years is part of the Bethesda’s criteria for suspicion
of HNPCC. The frequency of MSI adenomas and of clinical criteria of HNPCC in this
population is however poorly known. We aimed at evaluating the biological and genetic
status of these patients. Patients and methods: This was a retrospective study in 2 university
hospitals, based on pathological register. We identified 90 patients with at least one adenoma
diagnosed before the age of 40 between January 1999 and October 2004. Twenty-five cases
were excluded because of known HNPCC or PAF. Patients were interviewed by phone about
their familial history. The characteristics of the polyps were obtained from endoscopic
reports. Immunohistochemical studies were performed on available material (MSH2 and
MLH1, MSH6) and microsatellite instability (MSI) was tested. Results: Preliminary results
were obtained in 31 patients (12 women, mean age 39.3 ± 6.5 years (range 17-45)). The
mean age at diagnosis of adenoma was 36 ± 5.7 years (range 16-40 years). Colonoscopy
was scheduled because of family history of colorectal cancer or adenoma in 15 cases (48.5
%), of digestive symptoms in 16 cases (haemorrage (32.3 %), abnormal transit (9.6%), both
(9.6%)). The mean number of adenomas was 1.4 ± 0.73 (range 1-4) per patient, the mean
size was 10 ± 15.2 mm (range 3-70), there was 8 flat (31%), 14 sessile (36.8%) and 16
pedunculated adenomas (32.2%). The localisations were: left colon for 22 polyps (57.9 %),
rectal 8 (21 %), right colon for 8 polyps (21 %). Histology was of low grade dysplasia in
33 cases (86.4 %) and high grade dysplasia in 5 cases (13.6 %). Family history of colonic
neoplasia : at least one first- or second- degree relative with adenomatous polyp in 2 cases
(6.6 %), of colorectal cancer in 11 cases (35.5 %). Amsterdam criteria was observed in 1
case. Loss of MMR proteins expression was observed in 4/31 cases (12.9 %): 3 MSH6 and
1 MSH2; microsatellite instability was tested on available material of 28 pts, and on Bat 26
mononucleotide was present in 1/30 cases with loss of MSH6 protein expression and
MSI. He had a familial history of colorectal cancer, compatible with HNPCC. Conclusion:
Systematic biological testing of adenoma developed before 40 years reveals biological abnor-
malities in 13% cases. It was associated in 1 case with clinical criteria compatible with
Amsterdam criteria. That’s why we think that biological testing of adenomas in young
patients should be recommended for the identification of possible HNPCC patients. This


















Both Body Mass Index and Familial History of Cancer Are Risk Factors of
Colorectal Neoplasms
Takafumi Sugimoto, Yutaka Yamaji, Atsuo Yamada, Shintaro Kondo, Miki Ohta, Hirotsugu
Watabe, Keiji Ogura, Makoto Okamoto, Takao Kawabe, Masao Omata
(OBJECTIVE)In recent years, colorectal cancers have increased in Japan. It has been debated
that the westernized lifestyle of Japanese people is responsible for this increase. Indeed,
many studies have suggested that lifestyle is related to colorectal cancer. However, few data
are available about effects of lifestyle on colorectal polyps, that is considered precursor of
cancer. Thus, we conducted the present study to elucidate it. (METHODS)We investigated
the relationship between colorectal neoplasms and patient’s status taken by questionnaires,
including BMI(body mass index) as a parameter for lifestyle, and a familial history of cancer
as a heredity factor. We prospectively investigated 1735 patients (male:female 1042:693,
average age 61 yrs) who underwent total colonoscopy for their first examination of lower
intestine in the University of Tokyo hospital from January, 2003 to September, 2005. We
analysed the relationship of sex, age, BMI, and a familial history of cancer with the presence
of colorectal neoplasms (adenomata or cancers) by using chi-square test for univariate
analysis and logistic regression analysis for multivariate analysis. Age was classified by 10
years old interval, and BMI was classified to BMI <18.5, 18.5< BMI <25, 25< BMI <30s,
30< BMI according to a standard of Japanese obesity society. (RESULTS) We found colorectal
neoplasms in 890 (51.2%) of 1735 patients and invasive cancers in 24 (1.3%). By univariate
analysis, the presence of colorectal neoplasms was associated with familial history of cancer,
male gender, advanced age and high BMI. By multivariate analysis, it was significantly
associated with male (odd ratio [OR], 2.78; 95% confidence interval [CI], 2.26-3.41),
advanced age (OR, 1.42; 95%CI 1.30-1.55), familial history of cancer (OR, 1.24; 95%CI,
1.01-1.51) and BMI (OR, 1.24; 95%CI, 1.05-1.46). The presence of invasive cancer was
associated with only advanced age and familial history of cancer by univariate analysis. By
multivariate analysis, it was significantly associated with advanced age (OR, 1.47; 95%CI,
1.01-2.15) and familial history of cancer (OR, 2.37; 95%CI, 1.02-5.48), but not with male
(OR, 2.01; 95%CI, 0.79-5.14) and BMI (OR, 1.15; 95%CI, 0.59-2.26). (CONCLUSION)The
present study shows that colorectal neoplasms are associated with obesity and familial history
of cancer as well as with gender and age. As for invasive colorectal cancers, however, it is
suggested that the advanced age and familial history of cancer have greater association with
the diseases.
W1005
How Much Does Polypectomy Actually Reduce Colorectal Cancer (CRC) Risk?
Estimated Impact of Initial Colonoscopy/Polypectomy and Surveillance
Murtaza Parekh, Uri Ladabaum
BACKGROUND: Screening reduces CRC incidence and mortality, but the actual impact of
polypectomy is intensely debated. The National Polyp Study reported a post-polypectomy
CRC standardized incidence ratio (SIR) of 0.24 vs SEER (general population). In contrast,
data from 3 adenoma chemoprevention trials suggest a post-polypectomy CRC SIR of 0.98
vs SEER (Robertson Gastro 2005). Patients with adenomas are at elevated CRC risk. Thus,
even a post-polypectomy CRC risk similar to that of SEER may represent a substantial CRC
risk reduction. AIMS: To generate a quantitative estimate of the CRC risk reduction attribut-
able to polypectomy, and to compare the relative impact of initial screening/polypectomy
and post-polypectomy surveillance. METHODS: We constructed a Markov model of post-
polypectomy adenoma recurrence and CRC development, calibrated to data from placebo
arms of chemoprevention trials. We assumed that 90% of CRC arise from adenoma and
accounted for missed adenomas and CRC at colonoscopy. We used the derived rates of
adenoma formation, growth, and malignant transformation to project CRC incidence if 50
year-old patients with adenomas did not undergo screening/polypectomy (Natural History;
NH), and compared this with one-time colonoscopy/polypectomy at 50 (SCRN) or
screening+surveillance for age 50-80 (SCRN+SURV). RESULTS: While SCRN was calibrated
to trial data for only 4 yrs, SCRN continued to follow SEER CRC incidence closely through
age 80 (Figure). We estimated a CRC risk 2.9-fold higher without polypectomy (NH) than
with SCRN, representing a 66% CRC risk reduction attributable to initial polypectomy.
SCRN+SURV resulted in 92% risk reduction compared with NH. Approximately 71% of
the total risk reduction with SCRN+SURV was attributable to the initial polypectomy.
CONCLUSIONS: Initial polypectomy and post-polypectomy surveillance are both likely to
significantly reduce CRC risk. Even if post-polypectomy CRC risk is similar to that of the
general population, this may represent a dramatic 66% risk reduction compared with
no polypectomy.
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W1006
Age, Smoking Status and the ACE-27 Co-Morbidity Score Are Accurate and
Independent Predictors of Survival from Colorectal Cancer in the Elderly
Parita Patel, Muhammad Ayub, Samuel N. Forjuoh, Tushar Patel
Background: The incidence of colorectal cancer increases with age. There is a need for
accurate prediction of survival in the elderly who may have other competing causes of death.
Although aging is associated with an increased prevalence of co-morbid conditions, the
impact of these on survival from colorectal cancer are poorly understood. Thus, our aims
were to (1) identify factors that can predict survival, and (2) quantitate the impact of co-
morbidities on survival after a diagnosis of colorectal cancer in the elderly. Methods: Patients
aged 70 years or older diagnosed with colorectal cancer between 1997 and 1999 were
identified. The main outcome measures were the duration of survival. Follow-up was assessed
using a hospital-based cancer registry in which all patients were enrolled at the time of
diagnosis and prospectively followed-up. Chart reviews were performed to assess co-morbid-
ity which was described using the Adult Co-morbidity Evaluation 27 (ACE-27) Index.
Univariate and multivariate analysis were performed to determine the impact of several
clinical, demographic and laboratory variables on survival. Results: 243 patients were identi-
fied; age 70-74 yrs (n=77), 75-79 yrs (n=77), 80-84 yrs (n=42) and age 85 and above (n=
47). Follow-up data was available for all patients. The overall 1, 3 and 5-year survival rates
were 81.9%, 60.9% and 51.4% respectively. The overall ACE-27 co-morbidity index was
mild, moderate or severe for 28.4%, 27.6% and 30.5% of patients respectively. Survival at
one year was significantly associated with age group (p<0.0001), smoking status (p=.042),
presence of metastases (p=.001), use of an NSAID (p=.017), and the ACE-27 index (p<.0001).
Current smoking and the presence of a metastatic solid tumor were associated with lower
survival, whereas the use of an NSAID was associated with a higher survival. Multivariate
analysis showed that age group was a significant predictor of survival with an Odds ratio
(OR) of 16.0 (95%CI 4.0-64.0) for ages 80-84 and 5.6 (95%CI 1.4-22.0) for ages 85 and
over. The ACE-27 index and smoking status were also significant independent predictors
with an OR 3.8 (95%CI 1.3-11.3) for severe co-morbidity, and 3.7 (95%CI 1.3-12.8) for
active smoking status respectively. Summary and Conclusions: Elderly patients with severe
co-morbidity, active smoking and increased age have a worse survival after a diagnosis of
colorectal cancer. These parameters may be useful to develop a predictive model for survival
and may help facilitate clinical discussions regarding screening or management of colorectal
cancer in the elderly.
W1007
Evaluating Quality Improvement of Initial Colonoscopy and Polypectomy in
Patients with Precancerous Polyps and Cancers: A Three Year Followup Study
Harvey W. Olsen
Purpose: Prior studies of colonoscopy suggest a significant miss rate for advanced polyps
and colon cancer. In our private practice, we also have been concerned and are striving to
improve the effectiveness of the original colonoscopy and encourage compliance with follow-
up colonoscopies. This 30 year study identifies reasons for quality improvement in colonos-
copy and polypectomy by evaluating patient results from a three year follow-up period.
Method: All patients with polyps identified at colonoscopy since 1973 have been continuously
monitored. Four physicians in an urban private practice participated in this program. Informa-
tion is presented on all patients who underwent a follow-up colonoscopy from 6 to 42
months after an original colonoscopy and polypectomy. Demographic information and
findings from the original colonoscopy were used to stratify the risk for advanced polyps
and cancer in the follow-up period. The information was collected and compared at five
year intervals. Results: From 1973 to 2002, 2,090 patients had polyps or cancer identified
and removed at the time of an initial colonoscopy. Follow-up colonoscopy was performed
on 1,085 patients within three years of the original colonoscopy, a rate of 52 %. Overall
compliance with follow-up was 62% in patients with advanced polyps or cancer and improved
over the time of the study. Among the follow-up patients, 22 cancers were found, a rate of
1.8%. Only one missed cancer was identified during the last 10 years of the study, an
incidence of 0.3%. Advanced polyps were identified in10.8%. The incidence of advanced
polyps did not decrease dramatically over the 30 years of the study, but there was a decrease
in the number of missed polyps versus those that recurred. Conclusion: Compliance with
follow-up improved over the years of the study; specifically in patients with advanced polyps
and cancer on initial examination. This was important because these patients are at greatest
risk for missed or recurrent advanced lesions. A remarkable reduction of cancer during
follow-up was identified without a similar decrease in the rate of advanced lesions. Much
of the cancer prevention, we believe, was related to identifying the high risk patient and
encouraging earlier follow-up colonoscopy.
W1008
Prospective and Retrospective Study of the Effect of Oral Sodium Phosphate
Prior to Colonoscopy On Renal Function
Ramy D. Abaskharoun, Stephen Vanner, Depew William
Introduction: Oral sodium phosphate (NaP) for colon cleansing prior to colonoscopy is
better tolerated and is as good as or better than oral polyethylene glycol (PEG) solutions.
Isolated case reports of renal failure resulting from NaP use have been described. We tested
the hypothesis that NaP ingestion prior to colonoscopy is associated with renal insufficiency.
Methods: In a retrospective study serum creatinine and body weight were routinely measured
prior to colonoscopy from 1995-2004. We identified a cohort of consecutive patients who
had serum creatinine drawn prior to colonoscopy and at least 30 days after their procedure.
Development of renal insufficiency was defined by an abnormal serum creatinine at repeat
measurement. Renal insufficiency was also defined as an abnormal creatinine clearance as
measured by the Cockroft-Gault Equation. Medications and medical comorbid conditions
were recorded. In a prospective study, 24 hour urine collections were obtained prior to and
within one month post colonoscopy in a randomized trial comparing NaP and PEG to more
accurately measure development of RI. Results: In the retrospective study 767 patients
(51%F, 49%M; 81% NaP, 19% PEG) with normal baseline serum creatinine were identified
through our database. Of these, 55 (7%) developed renal insufficiency after colonoscopy. 42
patients (7%) receiving NaP vs. 13 patients (9%) receiving PEG developed renal insufficiency
(Fisher’s Exact test p=0.382). Using logistic regression analysis with the choice of preparation,
medications, and medical comorbid conditions as dependant variables; only age and blood
pressure were predictive of the development of renal insufficiency (p=0.014 and p=0.001
respectively). In the prospective study, 215 patients have been randomized and 25 have
completed their second urine collection. Their baseline creatinine clearance was similar. At
repeat measurement their creatinine clearance was 1.99ml/s vs 2.09ml/s in the NaP and
PEG group respectively (p=0.629). Conclusions: The prevalence of the development of renal
insufficiency between the NaP and PEG groups in this cohort of patients was similar (7%
vs 9% respectively) in our retrospective study. Predictors of renal insufficiency were age
and blood pressure independent of the preparation used. In our prospective study, prelimin-
ary data show that creatinine clearance is within the normal range and is similar between
both preparations at repeat measurement. Supported by an unrestricted educational grant
from C.B. Fleet Co.
W1009
Should Mixing of Sodium Phosphate with Sugared Drinks for Colonoscopy
Preparation Be Avoided?
Sherman Chamberlain, James C. Balart, Kostas Sideridis, Subbaramiah Sridhar, William
O. Thompson, Angelo Fernandez, Jeffrey Salek
We examined whether the addition of aspartame-containing liquids, as a dilution for oral
sodium phosphate(NaP), would provide better fluid and electrolyte balance, and provide
better colonoscopy prep than the accepted clear sucrose/corn-syrup-containing liquid dilu-
tion method. NaP preps are diluted in clear sucrose-based or corn syrup-based liquid diluents
for the improved patient acceptability. However, glucose-containing diluents, in combination
with the NaP preps, may activate the intestinal sodium-glucose co-transporter SGLT1 which
would facilitate Na and fluid absorption leading to intravascular fluid overload and con-
sequent poor colonoscopy prep quality. 49 in-patients undergoing colonoscopy in 2 different
hospitals were prospectively randomized into 2 groups to receive different NaP colonoscopy
preps. Both groups received standard pre-procedure diet instructions. Group A ingested
two 45mL doses of NaP diluted in two 720mL aliquots of sucrose-containing ginger ale
separated by 3 hours. Group B ingested two 45mL doses of NaP diluted in two 720mL
aliquots of aspartame-containing ginger ale separated by 3 hours. Serum electrolytes were
recorded on the morning prior to and day of colonoscopy. Primary endpoints were: quality
of colonoscopy preps as rated by blinded endoscopists and serum electrolytes on the morning
prior to and after preps. All patients completed the study with no adverse effects. No
significant difference in colonoscopy prep quality was seen between the two groups (Mantel-
Haenzel Chi-square=0.7954, p=0.4844) (see table). There were no significant differences in
mean electrolyte shifts of Na, K, or BUN/Cr ratio between the two groups (p = 0.116, 0.401,
and 0.473, respectively). Since no significant difference was seen between the two groups
with respect to quality of colonoscopy preparations or fluid and electrolyte balance, our
study suggests that passive fluid transport by aquaporins was the major mediator of fluid
and electrolyte shifts in the study subjects. This confirms the importance of aquaporins,
and minimizes the importance of SGLT-1, in fluid and electrolyte transport in the human
small intestine. Our study suggests that electrolyte-glucose fluid preparations may have little
benefit in enhancing hydration status.
Rating by Diluent
*One patient rated as inadequate and not included in table (5% of total aspartame group).
W1010
Comparison of Propofol and Midazolam On Psychomotor Performance
Akira Horiuchi, Yoshiko Nakayama
BACKGROUND: In many countries sedative medications are routinely used for endoscopic
procedures. Many patients express the desire to drive to work or home shortly after outpatient
EGD. Propofol is a sedative agent that provides rapid induction of sedation and has faster
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recovery than midazolam. We used driving ability as measured by a driving simulator (DS-
20, Mitsubishi Precision, Tokyo, Japan) as a sensitive indicator of drug effect after sedation.
We compared the residual effects of propofol and midazolam on driving ability and examined
the relationship between driving ability and the blood concentration of propofol. METHODS:
Sixty patients undergoing the diagnostic EGD were randomized to receive a bolus injection
of 40 mg of propofol (n = 30) or 4 mg of midazolam (n = 30). Administration of sedation
was performed by a registered nurse and supervised by the endoscopist. Patient satisfaction,
recovery time, and complications were evaluated. Driving ability was assessed using the
driving simulator. Drug levels were measured at before and at 30, 60, 120, and 180 after
drug administration. A control group of 20 patients who did not receive any sedative drugs
were compared for post procedure driving ability. RESULTS: No major complication occurred
in either group. Overall patient satisfaction on a 10-point visual scale was similar for propofol
and midazolam (8.3 vs. 8.6; p=0.68). On average, after the procedure, the propofol patients
could stand at the bedside sooner than midazolam (7.3 vs. 31min; p<0.01). Driving ability
recovered to baseline in all patients receiving propofol within 60 min of administration. In
contrast, 53% (16 patients) in the midazolam group had significantly impaired driving ability
at 180 min. Propofol concentrations ranged from 31 to 89 ng/ml (mean 67 ng/ml) at 60
min whereas midazolam ranged from 0.03 to 1.2 mg/L (mean 0.43 mg/L) at 180 min.
Driving ability recovered to the baseline when propofol levels were less than 100 ng/ml.
CONCLUSION: Diving ability as assessed using a driving simulator provides a sensitive
measure of a drug’s effect on psychomotor function. Driving or operating heavy machinery
appears safe 60 min after receiving 40 mg of propofol. However, driving a car should be
prohibited for the day the patient receives 4 mg of midazolam.
W1011
Trends in Colorectal Cancer, Obesity, Diet and Population Risk Factors in a
Multi-Ethnic Asian Population
Mark L. Fernandes, Yiong Huak Chan, Khay Guan Yeoh
Aim: To describe the time trends in the incidence of colorectal cancer, and potential risk
factors over the last 3 decades in Singapore. Methods: The incidence of cancers was obtained
from the Singapore Cancer Registry, a nation-wide population-based registry. Data on the
prevalence of smoking, obesity and diabetes mellitus were obtained from published national
population surveys. Data on per capita meat consumption was obtained from the Agri-food
and Veterinary Authority of Singapore. Results: Between 1968 and 2002, 22618 patients
with colorectal cancer were registered by the Singapore Cancer Registry. The age standardized
incidence (ASR) of colorectal cancer in the population rose by 107% between 1968-1972
to 1998-2002 from 19.3 to 39.9 per 100,000 men and by 90% from 15.3 to 19 per 100,000
women in the same period. Distal colorectal cancers increased more than proximal cancers
in this period. Amongst the three main ethnic groups, the age standardized incidence of
colorectal cancer was highest in Chinese (38 per 100,000 persons per year), followed by
Malays (20 per 100,000 person years) and Indians (14 per 100,000 persons per year). In
contrast, the ASR for esophageal cancer fell over the same period from 16.6 to 5.5 per
100,000 men and from 6.2 to 1.1 per 100,000 women, and the ASR for gastric cancer fell
from 37.3 to 18 per 100,000 men and from 17.3 to 9.9 per 100,000 women. From 1976
to 2004 the prevalence of smoking dropped by 10%. The prevalence of obesity increased
by 60% between 1982-85 to 2004 from 4.3% to 6.9%. The prevalence of diabetes mellitus
increased by 310% between 1975 to 2004 from 2% to 8.2% and the per capita consumption
of red meat fell by 6% between 1971 to 2000 from 6.3kg to 5.9kg. Conlusions: Colorectal
cancer incidence rates have increased dramatically in Singapore in contrast to other gastrointe-
stinal cancers such as esophagus and stomach. Distal colorectal cancers have increased more
than proximal cancer. The increase in colorectal cancers are concomitantly associated with
increase in the prevalence of obesity and diabetes mellitus, but were not associated with
trends in smoking and red meat consumption.
W1012
Proximal Shift in the Distribution of Adenomatous Colon Polyps and
Associated Factors Over the Past Ten Years
Sooyoung Park, Byung Chang Kim, Sung Jae Shin, Sang Kil Lee, Tae Il Kim, Won Ho
Kim
Background/Aims: In the recent reports, the incidence of right side colon cancer is increasing,
and adenomatous polyp is precancerous lesion of colorectal cancer. However, there were
not so many reports regarding chronologic changes in the distribution of adenomatous
polyps. We aimed to study changes in the distribution of adenomatous polyps over the past
ten years and to examine the factors associated with changes in the distribution of aden-
omatous polyps. Methods: We reviewed colonoscopic and pathologic reports of patients
who underwent colonoscopy at Yonsei University, Severance Hospital between January 1995
and December 2004. We enrolled the patients who had adenomatous polyp equal or larger
than 5 mm. Of these patients, the patients who had incomplete colonoscopic examination
or history of colon resection, polyp, colon cancer, polyposis syndrome, or inflammatory
bowel disease were excluded. Total of 2,498 patients were enrolled and analyzed in this
study. Proximal colon was defined as the colon proximal to the sigmoid-descending junction.
A large adenomatous polyp (≥10mm) or adenomatous polyp with villous component, high
grade dysplasia, or cancer transformation was defined as advanced polyp. Results: Over the
past 10 years, the proportion of patients who had adenomatous polyp at proximal colon
significantly increased from 48.5% to 66.3% (p<0.001), and that of patients with advanced
polyp at proximal colon, from 42.9% to 52.6% (p=0.003). The proportion of proximal
colon polyps significantly increased from 48.5% to 52.6% (p<0.001), and that of proximal
advanced polyp significantly increased from 40.4% to 50.6% (p=0.018). Male sex, old age
(≥60 years old), non-pedunculated polyps, small size (<10mm), tubular adenoma, low
grade dysplasia, non-advanced polyps, and the recent years (≥2000) were significantly
associated with proximal location of polyps. Conclusions: The proportion of patients who
had adenomatous polyps at proximal colon and the proportion of proximal colon polyps


















The Utilization of Colonoscopy As a Screening Method for Colorectal Cancer
in Two U. S. Metropolitan Teaching Hospitals
Mohammad A. Wehbi, Jae W. Nam, Charles G. Nesmith, Donald M. Pham, Kamil
Obideen, Vincent W. Yang
BACKGROUD: Colorectal cancer (CRC) is the second leading cause of cancer death in the
United States. Current guidelines advise the screening for CRC in asymptomatic individuals
with average risk to begin at age 50. Several screening modalities are available although
there has been no consensus on the most appropriate method with which to screen indi-
viduals. Moreover, no study has examined the utilization of various screening strategies in
detecting the ethnic or gender distribution of colorectal neoplasia. AIM: The current study
is designed to examine the utilization of colonoscopy as a screening tool in asymptomatic
individuals at average risk for CRC in two U.S. metropolitan teaching hospitals with different
demographics. METHODS: We conducted a retrospective review of all colonoscopies per-
formed between January 2000 and May 2005 in Emory University Hospital (EUH) and
Grady Memorial Hospital (GMH). The proximal colon was defined as the segment from the
cecum to splenic flexure. Advanced neoplasm was defined as tubular adenomas > 10 mm,
a polyp with tubulovillous or villous feature, a polyp with high-grade dysplasia or cancer.
Statistical analysis was performed using Fisher’s exact test. All confidence limits and p values
were two sided. RESULTS: A total of 9,737 colonoscopy records were reviewed. Among
these, 2,547 (26.2%) were performed to screen patients at average risk for CRC. The
percent of colonoscopies conducted for screening was 33.4% and 16.5% at EUH and GMH,
respectively. Among the 2,547 patients screened, 174 (7%) were found to have advanced
neoplasia, including 115 (66%) tubular adenoma > 10 mm, 36 (21%) tubulovillous adenoma,
7 (4%) high-grade dysplasia and 16 (9%) cancer. Ninety (53%) advanced neoplasm were
confined to the proximal colon. Caucasian patients had an increased risk for proximal
tubular adenoma > 10 mm with an odds ratio of 3.50 (95% CI 1.635 to 7.494). In contrast,
African American patients had a higher risk for proximal tubulovillous adenomas with an
odds ratio of 4.12 (95% CI = 1.67 to 22.76). There was a trend towards a higher prevalence
of proximal adenocarcinoma in African American patients (p value 0.0557). No differences
were detected in the pathology between genders or in the regional distribution of advanced
neoplasia between genders. CONCLUSION: (1) Colonoscopy as a screening tool could detect
a significant percentage (53%) of advanced colorectal neoplasia in the proximal colon, which
would have been missed by flexible sigmoidoscopy. (2) Our data shows that the pathology
of advanced neoplasia may differ between Caucasian and African American patients, with
AA having more pathologically advanced lesions.
W1014
The Rate of Polyp Recurrence in Patients Undergoing Colonoscopy in a U.S.
Metropolitan Teaching Hospital
Mohammad A. Wehbi, Jae W. Nam, Charles G. Nesmith, Donald M. Pham, Kamil
Obideen, Vincent W. Yang
BACKGROUND: The majority of colorectal polyps can be divided into two groups: neoplastic
(including adenomas and carcinomas) and non-neoplastic, primarily hyperplastic. It is well
recognized that adenomatous polyps are precursors to colorectal cancer but the role of
hyperplastic polyps is less clear. Thus, a better understanding of the natural history of the
distinct histologic categories of polyps could potentially lead to better management of
colorectal cancer. AIM: To examine the rate of polyp recurrence and their histological
distribution among patients undergoing colonoscopy in a U.S. metropolitan teaching hospital.
METHOD: We conducted a retrospective review of all colonoscopies performed between
January 2000 and May 2005 in Emory University Hospital. All patients with newly docu-
mented (incident) polyps were included. The polyps were classified by location, size and
histology. Recurrent polyps were defined as those detected upon a subsequent colonoscopy
performed beyond three years of the initial evaluation. RESULTS: A total of 5,557 colonoscopy
records were reviewed. Among these, 1,445(26%) had newly documented polyps, including
737 female (51%) and 708 (49%) male patients with an average age of 53 + 6.4 and 54 +
6.9, respectively. The majority (80%) of the patients were Caucasians. Three hundred sixty
one (25%) had recurrent polyps, including 97 hyperplastic polyps (27%), 246 tubular
adenomas (68%), and 18 tubulovillous adenomas (5%). Patients with an incident aden-
omatous polyp were more likely to have recurrent polyps of the same histology (p < 0.004;
95% CI = 1.08-4.66). Similarly, patients with an incident hyperplastic polyp were more
likely to have hyperplastic polyps at recurrence (p < 0.0004; 95% CI = 3.61-18.65). Incident
hyperplastic polyps > 8 mm had a statistically significant recurrence of adenomatous polyps
(p = 0.007). Patients with an age > 56 regardless of the histology of the incident polyp had
greater recurrence of adenomatous polyps (p = 0.003). Location of the incident polyps and
patient gender did not correlate significantly with recurrence. CONCLUSION: The results
of our study indicate that incident hyperplastic polyps > 8 mm, incident adenomatous
polyps and age > 56 are associated with recurrent adenomatous polyps. Identification of
these risk factors could help define surveillance strategies at follow up examinations and
could contribute to prevention of colorectal cancer.
W1015
Smoking As a Risk Factor for Colorectal Neoplasia (CRN) and Hyperplastic
Polyps (HP) in Japanese Patients
Fumio Omata, Fumiaki Ueno, Tetsuya Mine, Yang Chen
BACKGROUND: Smoking is a major public health issue in Japan and one of a few potentially
correctable putative risk factors for colorectal polyp. Although not directly involved in the
pathway to cancer, some studies suggest that HP may be a marker of a higher-risk colon.
The aim of this study was to determine the association between smoking and CRN or HP
among Japanese patients. METHODS: Smoking, together with other potential confounding
factors and effect modifiers were investigated by questionnaire in Japanese patients presenting
for colonoscopy at a single endoscopy unit in Japan. Patients with a personal history of
CRN, HP, inflammatory bowel disease, or non-steroidal anti-inflammatory drug use were
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excluded. 870 consecutive patients (mean age [sd] 52.2±14.5) had a complete colonoscopy
and were subsequently divided into 3 groups: CRN (N=194, mean age [sd] 60.8±10.4), HP
(N=132, mean age [sd] 55.3±13.2) and Control (N=586, mean age [sd] 49.2±14.6); 19
patients with colorectal cancer were included in the CRN group because the causal pathway
to cancer by smoking is assumed to be the same as in adenoma. The findings at colonoscopy
combined with histopathological findings served to measure the main outcome, i.e., the
presence or CRN or HP. Unconditional logistic regression was performed for both univariate
and multivariate analysis, using nine candidate predictors [smoking categorized in three
groups (Non, Moderate and Heavy smoker ), age, gender, drinking, body mass index (BMI),
history of cholecystectomy, history of appendectomy. RESULTS: In univariate analysis, the
increment of age by three categories of age divided by interquatile ranges (>=43, >=53, >=
63 yr), gender (male), moderate and heavy smoking, alcohol use, and BMI were significantly
associated with CRN, whereas, heavy smoking, gender, alcohol use and BMI were significantly
associated with HP. In the final model for CRN, the adjusted odds ratio for heavy smoking
was 1.720 (95%CI [1.127, 2.625]), the odds ratios for increment of age by 3 categories
(>43, >53, >63 yr) were 3.962 (95%CI [1.886, 8.326]), 8.931(95%CI [4.323, 18.45]), 12.5
(95%CI [6.09, 25.6]), respectively. For HP, the adjusted odds ratios for heavy smoking,
BMI, drinking were 1.787 (95%CI [1.109, 2.879]), 1.066 (95%CI [1.002, 1.134]), 1.751
(95%CI [1.14, 2.69]), respectively. Increase of BMI was associated only with HP. CONCLU-
SIONS: Among Japanese patients in Japan, heavy smoking (over 20 pack-year) is significantly
associated with both CRN and HP. Increment of age increases the risk of CRN but not of
HP. Increment of BMI increases the risk of HP but not of CRN. Drinking is significantly
associated with HP but not with CRN.
W1016
A Study of Relation Between Sigmoid Colon Polyps and Body Fatness in
Healthy Adults of Eastern Country
Young S. Park, Jeong Hoon Ji, Dong Ho Lee, Nayoung Kim, Ju Seong Kim, Hyun Chae
Jung, In Sung Song
Background and aims: Obesity has been thought as a social problem in western society, but
recently it is rising as a social problem in Asian people. Previous reports told us that colorectal
adenoma has a positive association with obesity. However there is a few report about the
relation between colorectal polyps and obesity in Asian society. Therefore we tried to find
out if body fatness is related to the presence of polyps, or adenomas in general Korean
populations. Method: A total of 6706 Korean patients (3564 men and 3142 women with a
mean age of 51.2 years), who visited to Seoul National University Bundang hospital for
screening of colorectal polyps between March 2002 and May 2005, were enrolled in this
study. A retrospective analysis was performed to investigate colonic findings such as size,
location, number, histopathological type by body mass index in general populations. Body
mass index (BMI) was used as indices of obesity. Results: Rectosigmoid polyps were present
in 29% (n=1949) of patients. In patients with polyps, Age, BMI, HbA1C, and triglyceride
level were significantly higher than patients without polyps. And in patients with polyps
HDL-cholesterol is significantly lower than the patients without polyps. In patients with
adenomatous polyps (16%, n=1073) age, BMI, HbA1C, and triglyceride level are significantly
higher than patients without adenomatous polyps. In multivariate analysis age, HbA1C,
HDL-cholesterol and LDL-cholesterol have relation with colorectal polyps. Conclusions: This
study shows that BMI and HDL-cholesterol, HbA1C, and LDL-cholesterol are associated
with colorectal adenomas in a Korean population. These findings suggest that obesity and
its metabolic parameters are associated with an increased risk of colon adenoma in Korea.
W1017
Quality Measures for Colorectal Cancer Diagnosis: A Systematic Review
Deborah A. Fisher, Christopher R. Mantyh, Michael A. Morse, Richard G. Prosnitz,
Gregory P. Samsa, Meenal B. Patwardhan
Objectives: Defining and measuring quality are critical to delivering best medical care.
Adherence to colorectal cancer (CRC) screening has been studied extensively, while the
quality of the subsequent evaluation of individuals with an abnormal screen test or who
present with symptoms has not. As part of a quality assessment study of CRC, we identified
and evaluated quality measures for the further evaluation of patients with positive CRC
screening tests or symptoms. Methods: The primary sources were MEDLINE and the
Cochrane Database. Databases were supplemented by hand searching references of included
articles and relevant reviews. Only US based articles published after 1990 were included.
Two investigators independently reviewed each abstract followed by full text review of
included abstracts. Finally, the included articles were rated for importance and usability,
scientific acceptability, and validation testing using standard methods. Results: Initially 3,429
abstracts were reviewed of which 843 articles underwent full text evaluation. Ultimately 73
articles were retained. Three measures were identified to assess the quality of CRC detection:
1. Percentage of patients with a positive fecal occult blood test (FOBT) who underwent full
colon evaluation 2.Time from symptom presentation to CRC diagnosis 3. Percentage of
patients with CRC who underwent colonoscopy as part of their evaluation. In addition, several
measures pertaining to the colonoscopy itself were identified including: cecal intubation rate,
complications rate, miss rate for significant neoplasia, performance by a provider with
specialized training. Conclusions: Few measures were found in the US-based literature for
CRC detection. The most widely used and well-developed measure was the percentage of
patients with a positive FOBT who underwent appropriate evaluation. This measure was
linked to mortality and validated in several populations. The other measures were intuitive
but not linked to outcomes. The quality measures of colonoscopy performance were well-
developed, but generally not validated. Notable gaps included the lack of measures for
follow-up of positive flexible sigmoidoscopy or barium enema and measures of appropriate
documentation. Future research should also include improvement of the existing measures
by more precise numerator and denominator definitions, linkage to an outcome of interest,
and additional testing for validity and reliability.
W1018
Usefulness of Detecting K-RAS Point Mutation in Stool of Patients with
Colorectal Cancer Compared to Measuring Hemoglobin and Lactoferrin in
Stool
Takashi Nishikawa, Shingo Yasumoto, Yosuke Abe, Takuya Inoue, Eijiro Morita, Naoko
Murano, Ken Toshina, Mitsuyuki Murano, Ryoichi Matsuse, Kazuo Uchida, Ken-Ichi
Katsu
BACKGROUND and AIMS: Colorectal cancer (CRC) is one of the most common cancers
in the world. The identification of high-risk individuals and the early diagnosis of CRC are
crucial since a large proportion can be prevented or usually be cured either by colonoscopic
resection or by surgery. In order to determine whether it could be used to screen for CRC,
we examined a technique for detecting point mutations of K-ras codon12 in stool samples
using one-step polymerase chain reaction/restriction fragment length polymorphism (PCR/
RFLP) analysis compared to measurement of fecal hemoglobin and lactoferrin. METHODS:
DNA was extracted from 200-mg stool specimens of 10 healthy controls and 31 CRC
patients. A 107-base-pair fragment of exon 1 of K-ras was amplified by PCR using mismatched
primers. PCR products were digested with Bst NI and analyzed by gel electrophoresis
followed by silver staining. Specificity of one-step PCR/RFLP was examined by using synthetic
oligonucleotides. The detection limit of K-ras codon 12 mutations was determined by using
SW480 and HT29 cells. Further, we also measured hemoglobin and lactoferrin simultan-
eously from stool specimens of patients with CRC. RESULTS: The K-ras gene was successfully
amplified from all healthy controls and CRC patients studied. Mutations of K-ras codon 12
were not detected in any of the healthy controls, but were identified in 41.9% of the patients
with CRC. Among patients who were positive for mutations in tumor tissue, the detection
rate in the stool was 84.6%. Mutations were detectable in all six synthetic mutant DNAs,
while none were detected among the wild type. The detection limit of this method was >
or = 0.1%. On the other hand, fecal hemoglobin and lactoferrin was detected 50% and
61.1% of patients with CRC respectively. CONCLUSIONS: One-step PCR/RFLP analysis to
detecting K-ras point mutation could be used in mass screening for CRC, because it is highly
specific, has a low detection limit, and is simpler than conventional methods for detecting
genetic abnormalities. Because K-ras point mutations are associated with 40-50% of CRC,
the detection sensitivity is low among cancers as a whole. However, our results suggests
that the technique should provide a more sensitive tool for colorectal cancer screening, if
used in combination with detection of fecal lactoferrin and hemoglobin.
W1019
Mail Return of Fecal Occult Blood Testing Is Low in a VA Population and
Strongly Related to Race: A Retrospective Study
Deborah A. Fisher, Marcus R. Johnson, Nicholas J. Shaheen
Objectives: Fecal occult blood testing (FOBT) is the primary screening modality for colorectal
cancer (CRC) in the VA system. One shortcoming of FOBT is that it requires the patient
to mail the completed stool cards. Our aim was to determine demographic predictors of
FOBT card return in the VA system. Methods: We examined records of 500 consecutive
patients at a single VA facility who had screening FOBT ordered in March 2004. All data
were abstracted by trained personnel onto a standardized data abstraction form. The primary
outcome variable was successful return of FOBT cards to the laboratory by 9 months after
the original order (yes/no). Co-variates collected included patient age, gender, race, post
office box (yes/no) and urban/rural status (by US census Metropolitan Statistical Area zip
codes). Logistic regression analysis was used to evaluate potential predictors of FOBT card
return. Results: The sample was 97% men; 62% Caucasian; 30% African American (AA);
6% race unknown <1% “other”. We excluded the 31 patients with unknown race and the
6 patients with “other” race from analysis (final N=463). The mean age was 64 years; 43%
<60; 26% 60-69; 23% 70-79; 7% >= 80. Only 46% of the patients had returned the FOBT
cards at 9 months. Fifty-one percent (51%) of Caucasians returned FOBT tests, compared
to 37% of AA patients. The adjusted odds (95% confidence intervals) of FOBT return were
1.8 (1.2-2.7) for Caucasian patients compared to AA patients. Logistic regression showed
no significant association with FOBT return and age, gender, urban/rural status or having
a post office box. Conclusions: Less than half of the primary care patients in this study
sample returned FOBT cards and therefore did not benefit from CRC screening. Caucasian
patients were almost twice as likely to return FOBT cards even as late as 9 months. No
other patient predictors were found, including factors directly related to convenience of
mail collection and delivery. Ordering an FOBT will inactivate the VA automatic CRC
screening reminder for 6 months even if test is not completed, and counts the patient as
successfully screened during that period. The poor return rate, particularly for AA patients,
therefore inflates estimates of CRC screening utilization in the VA system.
W1020
Factors Influencing Colorectal Cancer Screening Among African-American and
Caucasian Churchgoers
Christian S. Jackson, Colin W. Howden
Background: Colorectal cancer (CRC) is the second most common cause of cancer-related
death in the United States. It disproportionately affects African-Americans compared to other
racial and ethnic groups. One reason for this may be a lack of emphasis placed on screening
by primary care physicians (PCPs). Currently, however, there are only limited data available.
Methods: Several churches in the Chicago area were independently contacted. We provided
questionnaires to parishioners who attended a pre-scheduled seminar on cancer screening.
Parishioners did not have to complete the questionnaire to attend the seminar. All question-
naires were collected before the seminar; parishioners could not complete the questionnaire
during or after the seminar. The questionnaire asked for information on age, sex, income,
type of insurance, and knowledge of CRC and other cancers with high incidence and
prevalence in African-Americans. The questionnaire also inquired about primary care recom-
mendations in regards to CRC and other cancer-related screening. Results: 210 parishioners
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were given a questionnaire; all were collected. Of the 210 parishioners, 161 were African-
American and 49 were Caucasian. 117 (82 African-American and 35 Caucasian) parishioners
had a PCP and were deemed eligible to receive age-appropriate CRC screening. Of the
eligible African-Americans, 48% had annual income < $30,000; 69% of the eligible Caucasians
had annual income > $60,000. 68% of the eligible African-Americans and 97% of the eligible
Caucasians had health insurance. 59% of African-Americans and 91% of Caucasians had
been offered colonoscopy as a means of CRC screening by their PCPs. 72% of African-
Americans and 97% of Caucasians stated that they were interested in colonoscopy as means
of CRC screening. Of the parishioners who were not eligible for age-appropriate CRC
screening, 76% of African-Americans and 100% of Caucasians stated that they would interes-
ted in having colonoscopy for CRC screening. Conclusions: African-Americans were less
likely to have been offered screening colonoscopy than Caucasians. PCPs, who are in a
position to positively influence utilization of appropriate screening practices, need to be
more vigilant in offering CRC screening to African-Americans. There is high interest among
African-Americans concerning appropriate CRC screening.
W1021
Is Chronic Disease a Barrier to Colorectal Cancer Screening?
Maria Rosario Ferreira, Ahsan Arozullah, Marian L. Fitzgibbon, Nancy Dolan, Michael
Wolf, Alfred W. Rademaker, Charles Bennett
Objectives: Colorectal cancer (CRC) screening reduces CRC-related mortality and is recom-
mended for individuals >=50 years. It is not known if the presence of chronic disease affects
CRC screening use by patients or providers. This study evaluated whether recommendations
and adherence to CRC screening differ for veterans with chronic disease. Methods: Patients
were males, >=50 years, attending a general medicine clinic, at average risk for CRC, who
had not had CRC screening. After 6-18 months from enrollment medical records were
reviewed, for provider recommendations for CRC screening tests (fecal occult blood test,
flexible sigmoidoscopy, or colonoscopy), completion of tests, demographics and comorbid
illnesses (comorbidity index adapted from the Charlson index). Results: The mean age of
963 enrolled patients was 68, 45% were white and 50% African-American, and the average
number of clinic visits per year was 3. The Charlson index was 0 (no chronic disease) for
31% of patients, 1 for 27%, 2 for 21%, 3 for 12% and 4 or higher for 9% of patients.
Higher Charlson scores were associated with increasing age, and greater number of yearly
clinic visits, but there were no racial differences. Screening was recommended to 69.4% of
patients and 32.4% completed screening. Screening recommendations and completion were
lower for patients >= 75 years. Patients with higher Charlson scores had a non-significant
trend towards lower screening recommendation and completion rates. After adjustment for
age, race and yearly clinic visits, patients with one or more comorbid illnesses were signific-
antly less likely to receive a screening recommendation from their provider (p<0.01), com-
pared to patients with no chronic disease. However, there was no significant difference in
screening completion for patients with and without chronic illness. Implications: CRC
screening recommendations declined as comorbidity scores increased, but CRC screening
completion rates did not vary significantly. Based on these data it is not possible to determine
whether providers and patients are making CRC screening decisions appropriately with
regards to the presence of chronic illnesses.
W1022
Assessing Referral and Prioritisation Practices Using Standardised
Recommendations in An Open Access Colonoscopy Service
Dev S. Segarajasingam, Jacqueline M. Leber, Hooi C. Ee, Ian F. Yusoff
Introduction: Open access colonoscopy (OAC) has many potential advantages for service
provision in an era of unprecedented demand for colonoscopy however inappropriate proced-
ures and prioritisation remaining shortcomings. We aimed to i) Assess the adequacy of
information provided in referrals for OAC ii) Develop standardised evidence-based recom-
mendations for triaging patients referred for OAC iii) Validate this tool on a cohort of
patients and compare this tool with current clinical practice. Methods: We reviewed the
available literature and based on hospital policy we developed recommendations for i) the
minimum information required to appropriately triage OAC referrals and ii) desirable interval
to colonoscopy for common indications. Patients were classified into one of four categories
with recommended interval to colonoscopy for each (Category 1: <30d, 2: 30-90 d, 3:
>90d and 4: colonoscopy not indicated). Thereafter we used these recommendations to
prospectively assess referrals and findings at colonoscopy at our centre. Lastly we compared
the performance of the standardised recommendation with current clinical practice measuring
classification, interval to procedure and yield. Results: We studied 734 consecutive referrals.
In total, 67.6% (494/734) of referrals did not contain the minimum information to allow
appropriate prioritisation. The yield at colonoscopy by triage category is tabulated below.
The prioritisation interval given to the referral by the assessing clinician frequently varied
from the recommended interval. Comparisons of Clinician versus Recommended triage
categories and yield is presented below: (Insert table) Conclusions: A high proportion of
referrals for OAC have insufficient information to allow accurate clinical prioritisation. The
triage recommendation we have developed appears valid. Current clinical practice leads to
heterogeneity in prioritising urgency of OAC. A standardised system for prioritisation may

















*Significant pathology: CRC, colitis
W1023
Success Rates for Colorectal Cancer Screening Remain Disappointing Despite
Open Access Colonoscopy
Shibu Oommen, Vijay Jayaraman, Catherine Messina, Joseph C. Anderson, Robert D.
Shaw
Background: Colorectal cancer (CRC) is the second most frequent cause of cancer related
death in the United States. CRC screening has been proven to be effective yet less than half
of eligible patients are screened. A number of factors play a role in suboptimal screening
rates, including access to healthcare, poor patient acceptance, and failure of physicians to
refer patients. Our VA center promotes colonoscopy as the screening test of choice and has
open access for primary care referral of appropriate patients. The study was conducted in
an outpatient clinic in a suburban setting. Aim: To determine CRC screening rates in response
to institution of an open access program in which comprehensive screening modalities
including colonoscopy, sigmoidoscopy, and FOBT testing are available to all eligible veterans.
Methods: A review was performed of 1,373 patient visits to ten randomly selected primary
care practitioners that occurred between 9/1/2004 and 11/31/2004. Patients were eligible
for screening if they were between the ages of 50 and 80 and had no documented evidence
of endoscopic screening within an appropriate interval. Referral rates for endoscopic screening
and FOBT testing were recorded. Colonoscopy completion results were also recorded.
Results: 196 patients were deemed to be screening-eligible at the time of a primary care
visit (159 men, 37 women). All eligible veterans were given FOBT kits to return as part of
CRC screening. Of the 196 patients, 104 (53%) were not referred for endoscopic screening
and 58 (30%) refused. Thirty four patients were referred for endoscopic screening but
only 23 actually had colonoscopy completed. Of the 173 patients who were not screened
endoscopically, 49 had documentation of completion of home FOBT kits. Therefore 12%
of patients were screened endoscopically and 25% were screened by FOBT. Discussion: The
surprising result of our study was that screening rates for colorectal cancer remained low
despite open access to colonoscopy. It is likely that multiple factors are involved in the
physician/patient interaction at the time of referral that play a role in suboptimal screening
rates. Thus, dramatic improvements in colonoscopy screening rates will require a more
thorough understanding of the variables patients and doctors bring to the decision making
process. Exclusive emphasis on screening capacity without attention to the referral process
will likely result in only modest improvements in screening rates.
W1024
Significance of Abnormal Findings On Abdominal CT Scan As Compared to
Colonoscopy
Joseph Quagliata, Srikrishna Nagri, Krishna Kalakuntla, Anna Jagarlamudi, Laurel
Bastone, Yashpal Arya, Sury Anand
AIM: To evaluate the positive predictive value of abnormal findings in the colon as detected
by abdominal CT scan when compared to conventional colonoscopy. METHODS: We
retrospectively reviewed 49 consecutive colonoscopies performed in adult (>18 years of age)
patients where the indication was the evaluation of abnormal colon findings (Colonic Wall
Abnormality and Colonic Mass) during a period from April to September, 2005. RESULTS:
More than 800 abdominopelvic CT scans were performed at our community hospital for
various indications, 114 of which had positive findings (colonic wall abnormality or mass).
Of these patients, 49 underwent colonoscopy at our endoscopy unit for inpatient/outpatient
evaluation of same; 29 (59.2%) female and 20 (40.8%) male. The average age was 59.8
years (range, 22-88 years). The positive predictive value of the abdominopelvic CT scan
findings was 55% (95% CI=40.2-69.3). This was significantly lower than the accepted rate
of 80% (p=0.0001). The PPV was NOT significantly different when we compared the
anatomical location of the CT findings (right colon, left colon, diffuse). Biopsies of abnormal-
appearing colonic mucosa revealed the following: Non-specific inflammation (16), crypt
abscess formation (3), pseudomembranous colitis (2), tubular adenoma (2), hyperplastic
polyp (2), Invasive Adenocarcinoma (1), CMV Colitis (1). CONCLUSION: CT findings
correlated with colonoscopic findings in only approximately half of the cases. While reliance
on CT scan findings in planning patient management and colonoscopy may lead to unneces-
sary endoscopic work-ups in many patients, CT imaging is clearly a valuable tool in stratifying
at-risk patients for further evaluation. Clinical suspicion and careful history, along with
adjuvant and appropriate imaging, aid the clinician in determining pretest probability.
Positive Predictive Value (with 95% CI) for Abdominopelvic CT as Compared to Colonoscopy
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W1025
Colonoscopy Demand and Practice in a Regional Hospital Over 9 Years in
Hong Kong: Resource Implication for Cancer Screening
Annie On On Chan, Wai Mo Hui, Chi Kuen Chan, Kam Chuen Lai, Wayne Hc Hu, Man
Fung Yuen, Wai Man Wong, George Kk Lau, Chi Kin Hui, Shiu Kum Lam, Benjamin Cy
Wong
Background: The incidence of colorectal cancer (CRC) in Hong Kong is rising. The trend
of colonoscopy demand is uncertain. Aim: To investigate colonoscopy demand and practice
in a Hong Kong regional hospital over the past nine years. Methods: Colonoscopy data from
1st January 1997 to 31st August 2005 were retrieved and divided into two equal periods
for comparison. Colonoscopy practice and findings between the two periods were compared.
Results: There was no change in the number of endoscopists and colonoscopy sessions in
the two periods. The number of colonoscopy done in the two periods was 2681 and 2871,
respectively. The indications for screening of CRC (2.8% vs 9.7%, P<0.0001) and surveillance
of colonic adenomas (11.2% vs 25.9%, P<0.0001) were increased, but decreased for diarrhea
(18% vs 10.2%, P<0.0001) and per rectal bleeding (19% vs 8.1%, P<0.0001). The waiting
time was lengthened from 2 weeks to 4 weeks (P<0.0001). The percentage of colonic
adenomas (19.9% vs 27.2%, P<0.0001) was increased. A right-shift was observed in both
CRC (37% vs 50%, P=0.018) and adenoma (21.6% vs 38.1%, P<0.0001). Conclusion: The
number of colonoscopies performed was governed by capacity but not demand. Ways to
improve capacity for colonoscopies is needed.
W1026
Predictors of Failed Colonoscopy in Nonagenarians: A Single-Center
Experience
Eliahu Shemesh, Hemda Schmilovitz-Weiss
Goals and Background: Data on the benefits of advanced medical technologies in very old
patients remain limited. The aim of the study was to evaluate the success rate, safety
and outcome of colonoscopy in nonagenarian patients. Study: The success and safety of
colonoscopies performed during the last 5 years in our center were compared between 46
nonagenarians (group 1) and two control groups: 50 consecutive patients aged 70-79 years
(group 2) and 50 consecutive patients aged 50- 59 years (group 3). The medical records
were reviewed for background data, blood test results, co-morbidities, and mental and
functional status at the time of colonoscopy. Chi-square test was used to detect differences
in categorical variables by failure or age group. Failure was modeled using logistic regression
analysis, and odds ratios with 95% confidence intervals were calculated. All tests were two-
sided and considered significant at p<0.05. Results: Older age, anemia as the indication for
colonoscopy, poor functional and mental status, and low serum hemoglobin and albumin
levels were significantly associated with failure to complete colonoscopy. On logistic regres-
sion analysis, only serum albumin retained significance as a predictor of failed colonoscopy
(OR 0.13, 95% CI 0.02-0.6, p=0.009). Malignant findings were more frequently observed
in the oldest patients. Conclusions: Serum albumin is significantly associated with failed
colonoscopy in elderly frail patients. These patients should be offered other, less invasive
diagnostic modalities such as virtual colography, with conventional colonoscopy reserved
for therapeutic purposes. Larger, prospective, well-designed studies are needed to investigate
this issue.
W1027
Natural History of CRC in France: A Population-Based Study in Private
Practice
Pienkowski Patrice, Houcke Philippe, Lledo Gerard, Papazian Arsene, Richard-Mollard
Bruno, Rouillon Jean-Michel, Vaillant Eric
The aim of this study was to define the natural history of Colorectal carcinoma (CRC) and
its management in french population by private Gastroenterologists (PG). Material &
methods. All french PG were asked to participate the study and include all the patients seen
during one week (march 14-19th, 2005) for CRC whatever the circumstances (out-patients,
diagnosis, colonoscopy, follow-up) designed as “medical events”. 441 PG (22,4% of the
target) included 1250 patients. The PG sample was representative according to age, sex,
geographic area and medical practice; the patients sample was comparable to population-
based data from french cancer registries. Extrapolation of crude data of this 1250 patients
cohort was performed to the entire population of PG and for one year on the basis of 44.5
worked weeks. Results. 5363 « medical events » were recorded, that is to say 238654 per
year, including 29799 (12%) for diagnosis, 15001 (6,2%) for stagging, 31.645 (13,2%) for
treatment and 149044 (62,4%) for follow-up. 6288 new cases were diagnosed after screening
(21%) because of familial history of CRC or polyps (7.1%), positive Fecal Occult Blood Test
(8.3%), or mass population screening (1.5%). The total number of colonoscopies performed
each year to patients with CRC was 80058. Colonoscopy had been previously performed
in 7300 incident cases (24.5%) including 1250 cases within the year (6%) (mean-time : 19
months). Stagging was set on ultrasonography (85.5%), CT-scan (64.8%), CEA (82.4%%)
and chest X-ray (65.7%) ; 62% of the medical files were discussed in pluridisciplinary
sessions before treatment. Stagging was : Stage I : 34,3%, stage II : 27,6%, stage III : 24,8%
and stage IV : 13,2%. Surgery was performed in 95.4% of the patients ; adjuvant chemotherapy
(CT) was performed in 68.5% of the cases (Stage III : 57,4%, stage II : 30%) and palliative
CT in 55.2% (inc luding second l ine CT in 17.6%) ; cont inuous infusion of
fluorouracile(5Fu)+leucovorine was the most common regimen (41.3%) followed by
5Fu+Oxaliplatin 27.7%), 5Fu+Irinotecan (19.7%) and bolus 5Fu+leucovorin (16.4%) ; oral
5Fu was used in 5.8% of the patients and Cetuximab in 4.8% ; 4.2% of the patients
participated to randomized studies. Follow-up was managed by PG in 83.6% : 25.3% of
the patients were followed every 3 months and 41.2% every 6 months. Prevalence was
203.516 patients. Conclusion. PG in France are responsible for the diagnosis of 30.000 new
cases of CRC each year and for the management of 200.000 patients. These results emphasise
their position in health care system and give clinical data on natural history of CRC and
therapeutic strategies in a large non selected western population.
W1028
Cost-Effectiveness of mesalamine (5-aminosalicyclic acid, 5-ASA) Therapy for
Maintenance of Remission in Ulcerative Colitis (UC)
Eugene F. Yen, Sunanda V. Kane, Uri Ladabaum
BACKGROUND: 5-ASA is effective in the induction and maintenance of remission in UC.
The relative benefits and costs of maintenance 5-ASA therapy are uncertain. Sulfasalzine
has similar efficacy to 5-ASA, but may be less well tolerated. Our aim was to evaluate the
cost-effectiveness of maintenance 5-ASA therapy in UC. METHODS: We constructed a
Markov model of disease activity and treatments in patients with mild to moderate UC over
2 yrs. We examined 2 arms: 1) No maintenance 5-ASA, with 5-ASA 4.8 g/day used after a flare
to attempt to induce remission; 2) Maintenance 5-ASA 2.4 g/day, escalated and maintained at
4.8 g/day after first flare. In both arms, failure to induce remission led to other treatments
as needed: prednisone, parenteral corticosteroids, cyclosporine, colectomy. After 2 courses
of prednisone, 6-mercaptopurine was given . The model yielded flares/person, cost/person
and cost/flare prevented. To place this estimate in perspective, we assigned health state
utilities and calculated cost/quality-adjusted life-year (QALY) gained. Inputs included: risk
of flare without 5-ASA=25%/3mo; relative risk (RR) of flare on maintenance 5-ASA=0.7;
flares requiring immediate hospitalization=10%; remission rate with 5-ASA 4.8g/day=71%;
cost of 5-ASA 2.4g/day=$190/mo, outpatient flare=$60, inpatient flare=$5,500, colectomy=
$11,300; utility of no maintenance 5-ASA=0.972, maintenance 5-ASA=0.977, outpatient
flare=0.793, inpatient flare=0.608, status post colectomy=0.970. RESULTS: Without main-
tenance 5-ASA, mean flares/person were 1.77 and mean cost/person was $4,200 over 2 yrs.
With maintenance 5-ASA, flares/person decreased to 1.23 at a cost of $8,800/flare prevented.
Maintenance 5-ASA increased QALYs/person from 1.90 to 1.92 at a cost of $250,000/QALY
gained. SENSITIVITY ANALYSES: At the lower bound for RR of flare on 5-ASA (0.51),
maintenance 5-ASA cost $4,600/flare prevented. If the utility of outpatient flare fell to 0.608
(equal to inpatient flare) the cost of maintenance 5-ASA decreased to $155,000/QALY gained.
If sulfasalazine 2g (or 4g) could be tolerated instead of 5-ASA 2.4g (or 4.8g) at a cost of
$15 (or $30)/mo, it cost $670/flare prevented and $19,000/QALY gained. CONCLUSION:
Maintenance 5-ASA therapy decreases UC flares, but the cost/flare prevented may be signific-
ant, depending on society’s willingness to pay. The cost/QALY gained with maintenance 5-
ASA therapy may be substantial unless improvements in quality of life are more dramatic
than we assumed, or life expectancy is also improved. If a less costly alternative (sulfasalazine)
were tolerated and yielded the same benefits, maintenance therapy is likely to be considered
cost-effective.
W1029
Adverse Events Leading to Modification of Therapy in a Large Cohort of
Azathioprine-Treated Patients with Inflammatory Bowel Disease
Ulf Hindorf, Malin Lindqvist, Hans Hildebrand, Ulrika Fagerberg, Sven Almer
Background & aims: Adverse events (AE) leading to discontinuation or dose-reduction of
thiopurine therapy occur in 9-28% of patients with inflammatory bowel disease (IBD). The
aim of this retrospective study was to evaluate the influence of thiopurine methyltransferase
(TPMT) status and thiopurine metabolites in a large patient population for the risk of
developing AE. Methods: Three-hundred-and-sixty-four patients with IBD and present or
previous thiopurine therapy were identified from a local database. Results: The AE observed
in 124 patients (32%) were more common in adults than children (40% vs. 15%; p<0.001)
and in low to intermediate (≤9.0 U/ml RBC) than normal TPMT activity (p=0.02). Myelotox-
icity developed later than the other types of AE. Methylated thioinosine monophosphate
(meTIMP) were significantly higher in myelotoxicity [2650 vs. 1500 pmol/8x10^8 RBC; p=
0.03] and thioguanine nucleotide (TGN) in gastrointestinal intolerance [332 vs. 170 pmol/
8x10^8 RBC; p=0.02], when compared to patients without AE. An increased frequency of
AE was observed in patients with TGN above 400 or meTIMP above 11450 pmol/8x10^8
RBC. A shift to 6-MP was successful in 47% of AZA-intolerant patients and in all cases of
AZA-induced myalgia or arthralgia. Conclusions: A pre-treatment determination of TPMT
status might be validated as patients with low to intermediate TPMT activity are more prone
to develop AE, while determination of metabolite levels can be useful in selected cases as
myelotoxicity or gastrointestinal intolerance. 6-MP therapy should be considered in AZA-
intolerant patients.
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The Efficacy and Remission Time of Intravenous Cyclosporin in Patients with
Severe Ulcerative Colitis Are Increased When Given Immediately After An
Onset Or An Exacerbation
Naoki Yoshimura, Yasuo Suzuki, Masakazu Takazoe
BACKGROUND & OBJECTIVE: For decades patients with severe ulcerative colitis (UC)
have been treated with steroids followed by colectomy in many patients who failed. However,
in recent years cyclosporin (CsA) has been used as an alternative medical therapy in patients
with severe steroid refractory UC and is proved to be effective in reducing colectomy rate
in patients who may need surgery, but up to 66% patients who initially respond to CsA
relapsed within 9 months following start of CsA therapy. Therefore, a more sustainable CsA
induced remission time is desirable. The objective of this study was to explore strategies
which could increase the efficacy and the remission time of CsA in patients with severe UC.
METHODS: Between 1997 and 2005, 55 patients with UC, 24 female, 31 male, mean age
34.2 years, range 13 to 75 years received intravenous (iv) CsA (3-4mg/kg/day). These patients
were retrospectively evaluated. Nineteen patients had received iv CsA as monotherapy
(without iv steroids) or received CsA within 7 days of concomitant iv steroid, 20-40mg/day
(early CsA therapy group). Thirty-six patients who had failed to respond to at least 7 days
of iv steroid (40-60mg/day) received iv CsA with concomitant iv steroid (late CsA therapy
group). The mean age and initial clinical activity scores on admission were similar in both
groups. Patients whose condition did not improve after 14 days of CsA treatment underwent
colectomy. Patients who responded to CsA were discharged on a regimen of oral CsA or
oral CsA plus oral steroid (both were to be tapered) together with 5-aminosalicylate and
were followed up clinically and endoscopically for at least 18 months. Long-term outcome
was evaluated by Kaplan-Meier survival analysis. RESULTS: Overall, 36 of 55 patients
(65.5%) had a response within 14 days and avoided colectomy. Further, 17 of 19 patients
(89.5%) in the early CsA therapy group achieved remission compared with 19 of 36 patients
(52.8%) in the late CsA therapy group. Similarly, the mean remission time was 31.9 months
in the early CsA therapy group versus 13.8 months in the late CsA therapy group (P<0.01).
At 18 months, 11 of 17 patients (64.7%) in the early CsA therapy group had maintained
their remission versus 3 of 19 (15.7%) in the late CsA therapy group (P<0.01). CONCLU-
SIONS: The use of iv CsA in an early stage during severe UC has significantly better outcomes
compared with waiting until conventional intensive steroid therapy has failed.
W1031
Sargramostim Improves the Health-Related Quality of Life of Crohn’s Disease
Patients: Sf-36, IBDQ, and VAS Eq-5d Findings
Brian K. Dieckgraefe, Joshua R. Korzenik, Suzanne Laplante
INTRODUCTION: Quality of life (QOL) assessments are important for evaluating therapeutic
agents in Crohn’s disease (CD). Sargramostim (SRG) is an innate-immunity activator being
studied in clinical trials as a potential new CD therapy. Unlike current treatments that
suppress adaptive immunity, SRG enhances the innate immune system. We investigated the
effect of SRG on the QOL of CD patients (pts) using the Short-Form 36 Health Survey (SF-
36), the Inflammatory Bowel Disease Questionnaire (IBDQ) and the Visual Analogue Scale
of the EuroQoL (VAS EQ-5D). AIM: To quantify the effect of SRG on the QOL of pts with
moderately to severely active CD using the SF-36, IBDQ, and VAS EQ-5D. METHODS: A
placebo-controlled trial was conducted in pts with moderately to severely active CD. 124
pts were studied: 43 on placebo; 81 on SRG 6μg/kg/day. The SF-36, IBDQ, and VAS EQ-
5D were completed at baseline; at days 15, 29, 43, and 57 of treatment; and at 30 days
after treatment. Differences between responder/non-responder groups as well as remission/
non-remission groups were quantified using SF-36 and IBDQ scores (response=reduction
in CDAI≥100; remission=CDAI≤150). Differences between treatment groups were assessed
using the VAS EQ-5D. RESULTS: SRG treatment yielded significant improvements to the
QOL of CD pts. According to the SF-36, the physical & mental component summary scores
of responders improved by 34% (12±8 points) and 27% (10±11 points), respectively, vs
improvements of 4% (1±5 points) and -3% (-1±9 points) in non-responders. Responders
improved in all individual SF-36 domains (responders:30--300% vs non-responders:-11--
9%). According to the IBDQ, responders experienced an average improvement in total scores
of 42% (52±27 points) vs 6% in non-responders (7±21 points). The bowel, systemic,
emotional & social scores improved 36--56% in responders vs 3--10% in non responders.
Similar SF-36 and IBDQ findings were observed when comparing SRG vs placebo pts (results
described elsewhere) as well as remission and non-remission pts. VAS EQ-5D measurements
indicated that SRG induced significant QOL improvements observed soon after treatment
initiation. SRG pts reported significant improvements that varied 18--30% from baseline
while placebo pts reported improvements that varied 0--11%. CONCLUSION: SRG is an
innate immunity activator that, unlike current treatments that suppress the immune system,
enhances the function of the innate immune system. SF-36, IBDQ, and VAS EQ-5D measure-
ments indicated that CD pts treated with SRG experienced significant QOL improvements.
The improvements were seen early and were maintained throughout the treatment and
follow-up periods.
W1032
Crohn’s Disease Patients Treated with Sargramostim Are More Able to Attend
Work/School and Leisure/Sport Activities As Measured By Questions 4 and 12
of the IBDQ
Brian K. Dieckgraefe, Suzanne Laplante, Georg Groetzbach
INTRODUCTION: Sargramostim (SRG) is an innate-immunity activator under study as a
potential new therapy for Crohn’s disease (CD). Unlike current treatments that suppress
the immune system, SRG enhances the function of the innate immune system. In clinical
trials, SRG has been found to induce clinical response and remission of symptoms in patients
with moderately to severely active CD. We report on an investigation performed to assess
the effect that SRG has on two important aspects of the quality of life (QOL) of CD patients.

















work/school or to perform leisure/sport activities. METHODS: The effect of SRG treatment
on the QOL of patients with moderately to severely active CD was studied using a randomized
placebo-controlled trial involving 124 patients (43 received placebo (PBO); 81 received SRG
6μg/kg/day). The impact of treatment on the patients’ ability to attend work/school or
to carry out leisure/sport activities was estimated using the Inflammatory Bowel Disease
Questionnaire (IBDQ) social subscore questions 4 (work/school attendance) and 12 (leisure/
sport activities attendance). These questions were completed at baseline; at days 15, 29, 43,
and 57 of treatment; and at 30 days after treatment. RESULTS: SRG induced response (CDAI
reduction ≥ 100) in 48% of patients and remission (CDAI ≤ 150) in 40% of patients by
the end of the treatment period. These rates were significantly different from the rates
obtained with PBO (26% response [p=0.0134] and 19% remission [p=0.0135]). Changes
from baseline in total IBDQ score as well as in 3 of its 4 subscores were significantly greater
in the SRG group than in the PBO group (p=0.0001-0.0397). At baseline, question 4 revealed
that patients were not able to attend work/school a little or some of the time while question
12 revealed that patients had some to fair amount of difficulties doing leisure/sport activities.
The score to question 4 improved by up to 25% (1 point) in the SRG group compared to
0.6 points (13%) in the PBO group. Similarly, the score to question 12 improved by up to
42% (1.4 points) in the SRG group compared to 23% (0.8 points) in the PBO group. Overall,
the social score improved by 1.4 points (42%) in the SRG group compared to 0.9 points
(23%) in the PBO group (p=0.0288). CONCLUSIONS: SRG treatment significantly improved
the ability of CD patients to attend work/school and perform leisure/sport activities. SRG
is an innate-immunity activator that, unlike current treatments that suppress the immune
system, enhances the function of the innate immune system.
W1033
Quality of Life Indices Correlate with Clinical As Well As Endoscopic Activity
in Patients with Ulcerative Colitis
Alexandra Zahn, Ulf Hinz, Max Karner, Robert Ehehalt, Wolfgang Stremmel
Background & Aims: Inflammatory bowel disease (IBD) impairs health-related quality of
life (HRQOL). Our aim was to investigate if the improvement of the Clinical Activity
Index (CAI) and the Endoscopic Activity Index (EAI) is significantly correlated with the
advancement of the overall HRQOL and its dimensions and to assess in what way demo-
graphic and disease-related factors influence patients experience of HRQOL. This examination
was performed in the context of our recently published study of the anti-inflammatory effect
of retarded release oral phosphatidylcholine (PC) in chronic active ulcerative colitis (UC).
Methods: 60 patients with chronic active UC and with a CAI of > 4 were treated with
retarded release PC or placebo over three months. The patients had to fill in the Inflammatory
Bowel Disease Questionnaire-Deutschland (IBDQ-D) concerning HRQOL before and after
the study. The correlation between the CAI and EAI improvement and the quality of life
scores was calculated. Demographic factors and disease-related factors were obtained. Results:
A statistically significant lowering of CAI and EAI after treatment in the PC group led to a
statistically significant improvement of the HRQOL (r = -0.623, p = 0.0003 for the CAI and
r = -0.511, p = 0.005 for the EAI). Constant disease activity indices in the placebo group
came along with constant HRQOL (r = -0.747, p <0.0001 for the CAI and r = -0.634, p =
0.0002 for the EAI). Furthermore, besides a few exceptions, significant correlations between
CAI and EAI and the 4 dimensions of the IBDQ-D could be shown. In our study, demographic
parameters such as age, gender, disease duration and disease localization did not significantly
influence the IBDQ-D scores. Conclusion: This study points out the strong relationship
between clinical and endoscopic activity indices and all domains of HRQOL in patients with
UC. Therefore, the IBDQ-D is a valid and reliable assessment tool that reflects changes in
the health status of UC patients. It is a useful measure of therapeutic efficacy and should
be used in all clinical trials in IBD.
W1034
Sick Leave, Unemployment, Disability and HRQOL in Patients with
Inflammatory Bowel Disease
Tomm Bernklev, Magne Henriksen, Jorgen Jahnsen, Morten Vatn, Bjorn Moum
Background: Chronic diseases like IBD is connected with increased morbidity, like absence
from work and disability pension (DP). Information regarding these issues in Norwegian
IBD patients has not been available. Aim: To determine the rate of work disability, unemploy-
ment (UE) and sick leave (SL) in an unselected, Norwegian IBD-cohort and additionally to
measure the effect of working status and DP on the patient’s health-related quality of life.
Patients and Methods: Data regarding SL last six months was collected at the 5-year follow
up visit. Patients were also asked if they were unemployed or if they were receiving DP as
a consequence of their IBD. Data from the Norwegian background population regarding SL,
UE and DP were collected from Statistics Norway. HRQOL were determined with SF-36
and N-IBDQ. All together 495 patients were or had been in the work force during the 5-
year follow up period since diagnosis and were included in the analysis, mean age 41.2
(13.7), 49% females. Results: A total of 42 patients (8,5%) were on DP five years after
diagnosis, 18 (5,4%) with UC and 24 (14,9%) with CD. Females with CD had the highest
DP rate, 17 (24,6%). Disability rates from the background population were 8,8%. A total
of 58 patients (11,7%) reported to be unemployed at 5 years. This was equally distributed
between males and females, but more patients with UC were unemployed, 44/334 (13,2%)
compared to CD patients, 14/161 (8,7%). The unemployment rates in the Norwegian
population were 4,1%. SL for all causes was reported in 47% (143/306) with UC and 53%
(70/132) with CD. IBD-related SL was reported by 18% (54/306) with UC and 23% (31/
132) with CD. A majority of the patients were sick less than four weeks, while 25%
contributed to a large number of the total sick leave days. UE and DP reduced HRQOL
scores both in UC and CD patients. However, the most pronounced effect on HRQOL was
found in patients reporting IBD-related sick leave, measured with N-IBDQ and SF-36, with
reduction in scores from 9% to 40%. Conclusion: Unemployment or sick leave is more
common in IBD patients than in the Norwegian background population. The number of
patients receiving DP is significantly increased in females with CD, but not in the other
patient groups. Unemployment, sick leave and DP all affects the patients HRQOL in a
negative way, but this effect is most pronounced in patients reporting IBD-related sick leave.
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W1035
Quality of Life in Crohn’s Patients with Perianal Fistulas: Influence of Fecal
Diversion
Michael S. Kasparek, Joerg Glatzle, Tanja Temeltcheva, Mario H. Mueller, Alfred
Koenigsrainer, Martin E. Kreis
Perianal fistulas in Crohn’s disease are often refractory to medical and surgical treatment.
Fecal diversion may be necessary with the potential of impaired quality of life (QOL). Our
aim was to determine QOL in Crohn’s patients with perianal fistulas who live with or without
fecal diversion. We hypothesized that QOL is impaired in diverted patients. METHODS:
From 1996 through 2002, 116 Crohn’s patients were treated for perianal fistulas at our
institution. Four validated QOL instruments were sent to each patient, including the SF-
36, Gastrointestinal QOL Index (GIQLI), Cleveland Global QOL score (CGQL), Short Inflam-
matory Bowel Disease Questionnaire (SIBDQ). Additionally we sent our standardized ques-
tionnaire of alterations in everyday life. 77 questionnaires (66%) were returned. Patients’
age (median [range]) was 41 years [21-76 y]. RESULTS: At time of evaluation, 34 of the
77 patients were diverted, while 43 were not. Diverted patients had a longer duration of
Crohn’s disease (19 years [2-32 y] vs. 15 years [3-29 y]; p<0.05). Follow-up was similar
in both groups (diverted 49 months [18-97 mo] vs. no diversion 44 months [14-98 mo]).
No difference was observed in the SF-36 and CGQL as regards QOL in both groups. The
GIQLI demonstrated a better overall QOL (mean±SEM; 68±1% vs. 60±2%; p<0.05) and a
better QOL on the subscale “gastrointestinal symptoms” (81±1% vs. 67±2%; p<0.05) in the
diverted group. Similarly the SIBDQ also revealed a better QOL for diverted patients on the
subscale “bowel” (81±1% vs. 67±2%; p<0.05). Diverted patients were less likely to complain
of symptoms from their Crohn’s disease (44% vs. 79%; p<0.05). Concerning alterations of
everyday life, as evaluated by our standardized questionnaire, 10 of the 34 diverted patients
reported no restrictions secondary to their diversion, and 19 experienced no difference
compared to before diversion; only 5 patients reported deterioration of activities by the
diversion. CONCLUSION: Overall QOL does not deteriorate when fecal diversion is required
in Crohn’s patients with perianal fistulas and may even improve certain subscales of QOL.
W1036
A Systematic Review of the Quality of Patient Information On Medical
Treatment of Crohn’s Disease and Ulcerative Colitis On the World Wide Web
Morgan Langille, Chris Rodgers, Andre Bernard, Sander van Zanten
M Langille, C Rodgers, A Bernard, S Veldhuyzen van Zanten, Dalhousie University, Halifax
Background: Increasing numbers of patients with inflammatory bowel disease (IBD) use the
Internet to obtain health information on treatment of their disease. Study aim:to perform a
systematic review on the quality of educational information on treatment of IBD for patients
available on the web. Methods: medical treatments evaluated were:5-ASA, corticosteroids,
azathioprine/6-MP, infliximab and other immune suppressants. A Quality Evaluation Instru-
ment (QEI) was developed and pretested which covered indications, efficacy and common
or serious side-effects. The maximum possible QEI score was 101. A global overall quality
score (1-5) and reading grade level was also given. Each site was evaluated for integrity, that
is information about funding and ownership. Each website was scored by two independent
reviewers. Results: the top 50 sites retrieved by Google were evaluated by two independent
raters. 7 sites were excluded because they were web portals. The average global score was
2.1, 2 sites received a score of 5, and 2 sites a score of 4. The average QEI was 36 (range
0-96), 6 sites received a score of >70 and 13 sites received score >50. QEI scores were not
related to rank order in Google. Information on infliximab was lacking in 19 of 43 websites.
The average Flesch-Kincaid Grade Level was 11.4, ranging from 6.9 to 12.0. Only 24 sites
gave a date when the site was last updated. Only 23 sites did disclose the funding source.
Conclusion: the quality of information on treatment available for IBD patients on the Web
shows marked variation and only a small number of sites achieve high quality scores. There
is an urgent need for accreditation of websites that provide balanced information about
treatment for IBD
W1037
Calcium and Vitamin D Supplementation for Bone Loss in Children with IBD:
Does It Help?
Yoram Elitsur, Shaista Safder, Peter Chirico
Patients with inflammatory bowel disease (IBD) are at a high risk for bone fractures due to
increased bone loss. Osteopenia and osteoporosis have been reported in children prior to
and after steroid therapy. The current treatment protocol included calcium and Vit. D
supplementation. Unfortunately, the efficacy of this treatment in children has not been
established. Aim: To evaluate the efficacy of calcium and Vit. D supplementation for bone
loss in children with IBD, after more than 1 year of therapy. Methods: Children with IBD
were supplemented with Ca (1.5g/d) and Vit. D (800IU/d) for over 1 year. Bone mineral
density (BMD) and bone age were performed before and after >1 year of therapy. Bone age
was assessed radiographically, and BMD was assessed by Dual energy X-ray absorptiometry
(DEXA). Osteopenia was defined as BMD Z-score between -2.5 to -1.0, and osteoporosis
as Z-score below -2.5. Serum levels of calcium, urea, and creatinine were available at baseline
and at the end of the study in all patients. The BMD data was compared between baseline
and at 1 year treatment for each patient separately. Results: A total of 31 children with IBD
were retrospectively identified with a mean age of 15.4 years. 17 children had CD (12M/5F),
and 14 had UC (7M/7F). At baseline, among the 17 CD patients, 3 (17%) had osteoporosis, 8
(47%) osteopenia, and 6 (35%) patients had normal BMI; and of the 14 UC patients, 5
(36%) had osteopenia and 9 (64%) had normal BMI. Fourteen patients completed over 1
year of therapy (9CD/ 5UC), of whom 3 pts (2CD,1UC) had normal BMD at both measure-
ments. Of the 11 children with abnormal BMD, 8 (73%; 4 CD/ 4 UC) showed improved
BMD, 2 (18%; CD) worsened, and 1 (9%; CD) was unchanged. Serum calcium, urea, and
creatinine levels were normal in all patients throughout the study period. Conclusion: In
73% of our patients, calcium and Vit. D supplementations improved BMD in children with
IBD. No significant difference in bone loss was observed between CD and UC patients (65%
vs. 36% respectively, p=0.21). Larger studies will be needed to substantiate the efficacy of
Ca and Vit. D in reversing bone loss in children with IBD.
W1038
Genotype-Phenotype Analysis in a New Inception Cohort of Inflammatory
Bowel Disease in Copenhagen 2003-2004: A Study from the Danish Colitis
Crohn Database
Ida Vind, Cathrine Jespersgaard, Lene Riis, Paal S. Andersen, Pia Munkholm
Background: The Danish Colitis Crohn Database (DCCD) was established in the year 2000,
aiming to assure national quality of diagnosis, treatment and prognosis in patients with
inflammatory bowel disease (IBD). By now, the database is implemented at all departments
of gastroenterology and paediatrics in Copenhagen County and Community. Methods: All
residents from this region, who were diagnosed, in accordance to strict international criteria,
with Crohn’s disease (CD), ulcerative colitis (UC), or indeterminate colitis (IC) during the
period 1/1 2003 to 12/31 2004, were included in a prospective population based incidence
cohort. The background population counted 1.21 million inhabitants. Polymorphisms were
identified by single strand conformation (SSCP) analysis (CARD15 - SNP8, 12 and 13;
IGR2078a_1 - rs4705950); Taqman analysis (SLC22A4 - rs1050152; DLG5 - rs2289310)
or restriction fragment length polymorphism (RFLP) (SLC22A5 - rs2631367). Results: A
total of 562 patients (209 CD, 326 UC, 27 IC) were diagnosed with IBD during the two-
year period. The incidences increased significantly and were 8.6/105 for CD and 13.4/105
for UC. Three hundred and forty-seven Caucasian IBD patients (156 CD and 191 UC) were
available for the genetic analyses, 755 healthy persons served as controls. Fourteen percent
of CD patients were positive for at least one CARD15 mutation vs. 11% among controls
(NS). The risk associated with the TC haplotype (OCTN-TC) was only observed in homozy-
gotes, which were significantly more frequent among CD patients vs. controls (24% vs.
17%, p=0.03; OR 1.61 (95% CI: 1.06-2.43)). No differences were found between UC and
controls or between CD and UC. Neither did we find any differences between mutations
in the DLG5 gene in CD vs. controls or vs. UC patients. Extent of CD at diagnosis, according
to the Vienna Classification, was L1 (terminal ileum) in 31% of cases, L2 (colon) in 38%,
L3 (ileocolon) in 23%, and L4 (upper GI) in 8% of cases. In CD no particular disease
location was associated with mutations in CARD15 or OCTN haplotype. Conclusion: The
prevalence of at least one CARD15 mutation among CD patients from an unselected cohort
is not different compared to healthy controls or newly diagnosed UC patients. A difference
seems to exist between presence of the homozygous TC haplotype (OCTN-TC) in CD patients
vs. controls. Albeit no genotype- phenotype relation was found concerning localisation.
W1039
Environmental Factors Associated with Crohn’s Disease: A Population-Based
Case-Control Study
Richard B. Gearry, Ann Richardson, Christopher M. Frampton, Judith A. Collett, Andrew
Dodgshun, Bruce A. Chapman, Michael J. Burt, Murray L. Barclay
Introduction: The rapid increase in the incidence of Crohn’s disease (CD) in developed
countries is likely to be due to exposure to environmental factors in genetically susceptible
individuals. Aim:. To identify environmental factors associated with CD in a population-
based cohort. Methods: 1421 IBD patients (715 CD, 668 ulcerative colitis (UC)) were
recruited representing over 91% of people with inflammatory bowel disease in Canterbury,
New Zealand (population 464,800). This is part of the Canterbury IBD Project, a population-
based study of genetic and environmental factors associated with IBD. Sex and age frequency-
matched controls () were recruited at random from the electoral roll. Cases and controls
completed a self-administered questionnaire which was posted back to the investigators.
Univariate and multivariate analysis was performed. Results: Response rates were 94.4%,
95.2% and 84% for CD, UC and controls, respectively. Age, sex, current and childhood
socioeconomic status (SES) and smoking status were included in the multivariate model.
Statistically significant adjusted odds ratios with 95% confidence intervals included: one
relative with IBD 2.96 (2.15-4.08), two relatives with IBD 7.0 (3.27-14.99) smoking at
diagnosis 2.01 (1.51-2.68), appendicectomy 1.67 (1.20-1.95), tonsillectomy 1.48 (1.13-
1.95), breastfed as infant 0.55 (0.41-0.74), mother smoking in pregnancy 1.68 (1.21-2.34),
OCP use at diagnosis 1.843 (1.09-3.12), antibiotic use in adolescence 2.08 (1.30-3.31),
urban living in childhood 1.50 (1.09-2.07) and having a household vegetable garden in
childhood 0.52 (0.37-0.72). Furthermore, a duration-response effect was observed for breast-
feeding (p<0.001) and while high childhood SES was associated with later development of
CD (p=0.002), cases had lower current SES than controls (p=0.03). Over sixty additional
factors were not significantly-associated with CD. Conclusions: As well as recognised factors
associated with CD, some additional factors have been reported. The reduced risk associated
with breast-feeding, and the increased risk associated with antibiotic use and tonsillectomy
suggest an important role for faecal flora. High SES in childhood remains an important
factor in this population, although associations with low SES later in life may be due to
reverse causation. The association with having a vegetable garden suggests that diet early
in life may play an important role in CD aetiology.
W1040
Juvenile Onset of Crohn’s Disease: A Risk Factor for Reduced Lumbar Bone
Mass
David Armstrong, Marina Mauro
Background: Bone fragility is the result of both growth related and age-related factors
influencing skeletal size, its architecture and mass. Exposure to a chronic illness, such as
Crohn’s disease, during skeletal growth may compromise peak bone mass in early adulthood,
resulting in skeletal fragility later in life. Aim: To assess the effects of the onset of Crohn’s
disease during skeletal growth on lumbar bone mass in adulthood. Methods: A retrospective
chart review was performed to select CD adult patients who had a whole body and lumbar
densitometric evaluation (Hologic) between 2003 and 2005.Densitometric determinations
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included Bone Area, Bone Mineral Content (BMC), Bone Mineral Density (BMD), T, Z scores
in lumbar area and whole body BMC, Fat Mass (FM) and Lean Mass (LM). Age, gender,
weight, duration of CD and age at diagnosis were assessed. Standard t-tests, simple and
multiple stepwise correlation were analyzed as required. Results: Data from 39 patients (38+
15 years, M=15) were analyzed. Patients with a history of onset of CD before 16 years of
age (11.5+3 years old at diagnosis, n=9) had low lumbar T (mean -1.5) and Z (mean -1.4)
scores. They had a significantly lower weight, FM and BMC, BMD, T and Z scores in lumbar
area than those who were diagnosed after the age of 16. There was no difference in the
duration of CD between both groups (13.2 vs. 14.1 years) nor in total BMC and LM. There
was a significant correlation between age at diagnosis of CD, weight and LM and lumbar
BMC. After multiple regression analysis age at diagnosis and LM showed to be independently
associated with lumbar BMC. There was no correlation between age at diagnosis of CD and
total BMC. Summary: Patients who were diagnosed with CD before the age of 16 had a
reduced bone mass in lumbar area. The effect of the age of onset of CD on lumbar BMC
was independent of weight and LM. Conclusions: The onset of CD during axial skeletal
growth is a risk factor for reduced lumbar bone mass in adulthood.
W1041
Collagenous Colitis- a Ten Year Follow-Up Study
Ahmed Madisch, Stephan Miehlke, Franziska Lindner, Birgit Bethke, Manfred Stolte
Background: Collagenous colitis (CC) is a chronic disorder characterized by watery diarrhea.
Data about the long-term course and prognosis of this disease are sparse. Aim: to evaluate
the long-term outcome of patients with CC 10 years after the diagnosis. Patients and Methods:
In 1989/1990, 65 patients were diagnosed to have collagenous colitis. Initially and after an
interval of 10 years these patients were asked to complete a questionnaire on onset and
duration of diarrhea, stool frequency and consistency, other gastrointestinal symptoms
including weight loss, drug history, treatment success and other diseases. Diarrhea was
defined as three or more loose bowel movements. Improvement of diarrhea was defined as
reduction of frequency of diarrhea for at least 50 %. Results: After 10 years questionnaires
in 47 out of 65 patients (72.3 %) (female 40; mean age 68 years, range 41-95 years)
questionnaires were available for analysis. At baseline, duration of diarrhea was longer than
ten years and stool frequency was reported between 5 and 10 times per day in 24 patients
(51%). Acute onset of symptoms were reported by 27 patients (57 %). After a follow-up of
ten years 11 patients (23,4 %) had persistent diarrhea with no change of frequency and
consistency compared to baseline. Four patients (8,5 %) showed a reduction of diarrhea
frequency for at least 50 %. Diarrhea was resolved in 23 patients (48.9 %) during the follow-
up period. Of those, 20 patients received treatment such as corticosteroid, antibiotics,
bismuth or 5-aminosalicyclic. After a complete resolution of diarrhea during the long-term
follow-up, 9 patients (19.2 %) showed recurrence of symptoms. Conclusion: The long-term
outcome of CC is benign with resolution of diarrhea in up to 50 % of patients receiving
anti-inflammatory treatments. About 30 % of patients may experience persistent diarrhoe
even 10 years after diagnosis. Our data confirm that CC is a chronic disorder with a variable
course of symptoms during a long-term follow-up.
W1042
Risk Factors and Indications for First Surgery in Crohn’s Disease Patients:
Analysis of 289 Japanese Cases
Naofumi Morimoto, Jun Kato, Motoaki Kuriyama, Toru Nawa, Manabu Kurome, Koji
Takemoto, Sakiko Hiraoka, Yasushi Shiratori
(Aim) Despite appropriate medical treatment, a large fraction of Crohn’s disease (CD) patients
require surgical treatments during their clinical courses. Although many reports demonstrated
risk factors for recurrences after surgery in CD patients, risk factors for first surgery were
less frequently discussed. In this study, therefore, we aimed to identify risk factors and
indications for first surgery in CD patients. Moreover, which surgical indications were
associated with each risk factor was also investigated. (Methods) The clinical records of 289
consecutive Japanese CD patients treated at Okayama University hospital and 22 affiliated
hospitals between January 1981 and August 2003 were reviewed. Median follow-up period
was 7 years. Clinical factors including gender, age at onset, year at onset, disease extent at
diagnosis were examined, in order to identify the risk factors for first surgery. Indications
for first surgery were also investigated, and were stratified by presence or absence of each
risk factor. (Results) Of all patients, 113 (39%) patients underwent surgery. Female gender
(RR, 1.62; 95% CI, 1.09-2.41), and disease affecting ileum (RR, 2.06; 95% CI, 1.20-3.53)
were identified as the independent risk factors for surgery by multivariate analysis using
Cox proportional hazards regression model. Moreover, female patients were more likely to
receive first operation due to intestinal perforation than male patients (12% vs. 6%, p=
0.006). As for age at onset, Kaplan-Meier curves showed that patients with an onset more
than 20 years were likely to receive first operation within five years after onset, while patients
with onset less than 19 years were likely to receive first operation 10 years after onset.
(Conclusion) Our results suggested that risk factors and indications for first surgery in CD
patients varied according to patient clinical characteristics. Patients with disease affecting
ileum were more likely to receive surgical treatment. Moreover, female patients were more
susceptible to receiving operation, especially due to intestinal perforation. Therefore, CD
patients should be consulted carefully regarding individual clinical backgrounds with the


















Epidemiology of Inflammatory Bowel Disease in the Pediatric East Indian
Population of British Columbia
Vered Pinsk, Daniel A. Lemberg, Richard Schreiber, Collin Barker, David M. Israel, Kevan
Jacobson
Increasing incidence rates of ulcerative colitis (UC) and Crohn’s disease (CD) have been
linked to ethnicity and geography. Geographical differences, population migration and
changing epidemiology suggest an environmental role in prevalence and phenotypic expres-
sion of disease. Aim: To determine incidence and phenotypic expression of IBD in the
pediatric East Indian (EI) population of British Columbia (BC) diagnosed between 1985
and 2005 with comparison to the general pediatric IBD population in the same geographic
area. Methods: A retrospective and prospective medical chart review was undertaken in EI
pediatric patients≤16 of age diagnosed with IBD at BC Children’s Hospital between January
1985 and June 2005. Comparisons were made between EI pediatric patients (n=75) and
the rest of the pediatric IBD population (n=504). Age, gender, place of birth, family history
of IBD, type and extent of disease were included and analyzed. Provincial population statistics
were obtained from Statistics Canada. Diagnosis and classification of disease was based on
clinical, endoscopic, radiological and histological criteria. Results: EI patients represented
13.2% of IBD population, with 36 (48%) diagnosed with CD, 25 (33.3%) with UC and 14
(18.7%) indeterminate Colitis (IC), in contrast to 69.2%, 20.2% and 10.6% respectively in
the rest of the IBD population. The incidence rates for IBD between 1996 and 2001 for the
EI population was 14.06/105 (6.80/105 for CD, 5.44/105 for UC and 1.81/105 for IC)
compared to 5.5/105 for the rest of the IBD population (3.8/105 for CD, 0.91/105 for UC
and 0.79/105 for IC). The EI male/female ratio was significantly different from that observed
with the rest of the IBD population (2:1 vs. 1.12:1; OR 1.787 (95% CI, 1.07 to 2.97). Of
the EI patients with IBD, 92.6% were Canadian born. A family history of IBD was similar
in both groups (35% EI children compared to 36.6% rest of IBD population). No first degree
EI relatives had CD and only 22.3% of second degree relatives had CD. Irrespective of
disease type, pan colitis was more common in EI patients. No significant differences were
observed for age at diagnosis or duration of symptoms prior to diagnosis. Conclusions: This
data suggests a significantly higher incidence of IBD in the East Indian pediatric population
compared to the general pediatric population of BC, with a different pattern of phenotypic
expression and male predominance. Moreover, this data indicates a difference in phenotypic
expression from previously published East Indian adult IBD data. These results suggest an
effect of migration, environmental and life style change on incidence and phenotypic expres-
sion of IBD.
W1044
High Rate of Crohn’s Disease in Canterbury New Zealand - Results of a
Population-Based Study
Richard B. Gearry, Ann Richardson, Christopher M. Frampton, Bruce A. Chapman,
Michael J. Burt, Judith A. Collett, Murray L. Barclay
Introduction: Inflammatory bowel disease (IBD) has increased exponentially in industrialised
nations over the last fifty years. Previous New Zealand studies have shown that IBD is less
common than in other countries, however, clinical observations suggested a high incidence
and prevalence of IBD in Canterbury, particularly Crohn’s disease (CD). Aim: To determine
the descriptive epidemiology of IBD in Canterbury, Methods: Canterbury IBD patients,
recruited using multiple strategies, gave informed consent, permission for clinical record
review, completed a questionnaire and were bled for DNA extraction as part of the Canterbury
IBD Project. Cases were confirmed using standard criteria and completeness of recruitment
was validated using capture-recapture methods. Demographic and phenotypic data were
extracted from case notes. Results: 1420 patients (715 CD, 668 Ulcerative colitis (UC)) were
recruited (>91% of Canterbury IBD patients). In 2004, age-standardised (WHO World
Standard Population) IBD, CD and UC incidence rates were 25.2,16.5, and 7.6/100,000/
year respectively. The IBD, CD and UC point prevalences on 1 June, 2005 were 308.3,
155.2, and 145.0/100,000 respectively. CD patients were more likely than UC patients to
be female (61.4% v 47.1%) and to be younger (median age: 39.9 years v 43.7 years). 97.5%
of IBD patients were Caucasian. Conclusions: IBD is at least as common in Canterbury as
in other western regions. CD incidence and prevalence are amongst the highest ever reported
and are higher than for UC. IBD population characteristics are otherwise similar to other
countries. The Canterbury IBD Project will be a valuable tool for future population-based
IBD epidemiology and genetics research.
W1045
Risk Factors of Ulcerative Colitis in Chinese Population: An Age- and Sex-
Matched Case-Control Study
Bing Xia, Li Jiang, Jin Li, Mei Ye, Changsheng Deng
Background and aims The pathogenesis of inflammatory bowel disease (IBD) involves both
genetic and environmental factors. Cigarette smoking, alcohol use, appendectomy, oral
contraceptives and family history of IBD have all been shown to be associated with IBD,
but there were no reports of risk factors for IBD in Chinese population, in which the
incidence of IBD is increasing during the past decade. We conducted a case-control study
to examine associations between previously reported environmental risk factors and develop-
ment of ulcerative colitis (UC) in Wuhan city, central China. Methods A total of 177 patients
with UC and 177 age and sex matched controls were prospectively studied in Wuhan city
from January 2004 to December 2004. An age and sex matched case-control study was
conducted to assess the role of smoking, alcohol use, appendectomy, childhood and other
potential risk factors in the development of UC by a detailed questionnaire. The data were
analyzed by χ2 test with Yates correction and multiple logistic regressions. Results Smoking
was a protective factor and ex-smoking is a risk factor for UC (comparing with nonsmokers,
smokers: OR=0.28, 95%CI: 0.16~0.48, P=0,0001; ex-smokers: OR=4.36, 95%CI:
1.46~13.04, P=0.008). Familial history of IBD was a risk factor (OR=4.35, 95%CI:
1.21~15.71, P=0.025) whereas appendectomy was a protective factor (OR=0.24, 95%CI:
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0.07~0.86, P=0.028) for UC. There were no significant associations between UC and other
factors examined, including alcoholic drinking, tea consumption, capsicum consumption,
oral contraceptives, NSAIDs use, history of having been breast-fed in infancy, history of
measles, education status, present residence and childhood residence. Conclusions The same
as in western countries, smoking was a protective factor for development of UC and ex-
smoking and non-smoking were associated with an increase risk of UC in Chinese population.
Familial history of IBD was shown a risk for UC whereas appendectomy was associated
with a low risk for the disease.
W1046
Sexual Function in Men with IBD - A Survey with Controls
Antje Timmer, Alexandra Bauer, Beate Bokhof, Angela Takses, Axel Dignass, Gerhard
Rogler
Aims: We examined the relative frequency, type and determinants of impaired sexual func-
tions in patients with Crohn’s disease (CD) or ulcerative colitis (UC). Here, results are
presented for the subgroup of men aged 18 to 65. Methods: A random sample of members
of the local self-help group were surveyed using a standardized anonymous postal question-
naire (n=500). Age matched friends were used as controls; in addition, controls were selected
from a large health insurance cohort. Sexual function was evaluated using the International
Index of Erectile Function (IIEF); a low score was defined as a score < -1 on a z-transformed
scale (i.e. < normative mean minus 1 SD). Other psychometric instruments used included
the HADS and the SF36. Relative frequency and determinants of low function were calculated
as age adjusted OR (95% confidence intervals), using multiple logistic regression. Subgroup
analyses were performed to examine the effect of the type of control (friend / health insurance)
and disease activity (no or mild /moderate to high activity) on the strength of the associations.
Results: The response rate was 37% for cases. In 44% friend-controls were available. Overall,
153 case-control pairs were available for analysis (92 CD, 61 UC). Most patients were in
remission, there were only 26 cases with significant clinical activity. There were no differences
in the proportion of persons in stable relationships (overall, 86%, OR for cases 0.8 (0.4 to
1.6) or in having an active sex life (88%, OR 1.2, 0.5 to 2.7). In the sub analysis restricted
to patients with active disease, OR were consistently increased: low erectile function, OR
4.3 (1.0-18.5), orgasmic function 3.0 (0.7 - 13.2), sexual desire 6.3 (0.7 - 57.9), sexual
satisfaction 3.9 (0.9 - 16.6), overall satisfaction 5.4 (1.3 - 22.3) and total IIEF Score, 3.6
(0.8 - 15.7). IBD in remission or mild disease was not associated with any impairment of
sexual function, all OR were close to 1. There was no difference between UC and CD disease,
if controlled for disease activity. Depression and low physical quality of life score were the
most important determinants of impaired sexual function across subgroups and dimensions.
Conclusions: Active IBD is associated with impaired sexual function in all aspects examined.
However, most patients in this cohort had no or low disease activity and did not show
compromised sexual function.
W1047
Measurement of 6-Mercaptopurine Metabolites to Optimize Azathioprine
Therapy in Pediatric Inflammatory Bowel Disease Is a Clinically Useful and
Cost-Effective Management Strategy
Sanjoy Banerjee, Warren P. Bishop
BACKGROUND: Several studies have examined the utility of 6-mercaptopurine (6-MP)
metabolite assays for management of inflammatory bowel disease (IBD). One such study,
based on theoretical modeling, suggested an economic benefit (Dubinsky et al. Am J Gastroen-
terol 2005;100:2239). Since 2001, our group has routinely measured 6-MP metabolites in
pediatric IBD patients receiving azathioprine (AZA). We felt that this resulted in better
outcomes and reduced costs. We therefore chose to perform a retrospective analysis to
determine whether this has resulted in actual cost reduction. METHODS: We identified two
groups of patients. Group A received AZA without metabolite measurement (n=30) and
Group B had metabolites measured (n=71). These children were on a stable dose of AZA
for ≥4 months and had a follow-up of ≥6 months. Information gathered for each visit
included disease activity scores, lab results, 6-MP metabolite levels, and drug doses. We
also recorded surgeries and number and length of each hospitalization. The cost of care for
both groups of patients was calculated from a payer’s perspective, and was based on 2005
Iowa Medicare fees for relevant CPT codes, including laboratory tests and physician fees.
Hospitalization expense was based on standard costing data provided by the accounting
department. The total cost of care per 100 patient-years of follow-up was calculated for
each group. The total cost included cost of disease exacerbations, outpatient (OP) visits,
inpatient care, surgery, laboratory/pathology studies and 6-MP metabolite assays. We did
not quantify the cost associated with morbidity related to the disease or to increased corticos-
teroid use. RESULTS: Group B received less prednisone (p<.0001), had a lower Pediatric
Crohn’s Disease Activity Index or Simple Colitis Activity Index score (p<0.05), and received
a higher dose of AZA (median dose 2.4 vs. 1.7 mg/kg/day, p<.0001). The probability of
remission at each clinic visit was 0.81 ± 0.03 in Group B vs 0.67 ± 0.06 in Group A (p=
.009). The total cost of care per 100 patient-years for Group B was $192,122 compared to
a total cost of $345,476 in Group A. CONCLUSION: In our patient population with IBD,
we found a cost benefit of using the 6-MP metabolite assay for optimizing AZA dosing. The
majority of cost saving came from decreased inpatient utilization and reduced rate of disease
exacerbation. We speculate that the improved outcome in Group B resulted from higher
AZA dose used.
EVENTS PER 100 PATIENT-YEARS
W1048
Health Care Resource Utilization in IBD
Teresa Longobardi, Charles Bernstein
Background and Aims: To quantify temporal changes in health care utilization by a popula-
tion-based cohort of inflammatory bowel disease (IBD). Materials and Methods: Using the
University of Manitoba IBD Epidemiology Database we assessed utilization of outpatient
and hospital services, estimating the relative risk (RR) of utilization for IBD cases compared
to a matched cohort of non-IBD controls and for Crohn’s disease (CD) vs. ulcerative colitis
(UC). We tested differences in utilization between prevalence cohorts 1990/1 and 2000/1.
Also, utilization of the 1987/8 incidence cohort was followed forward 15 years from diagnosis.
The probability, intensity and volume of utilization were estimated. Results: In 2000/1, IBD
patients were more likely to have an outpatient visit (RRR=1.18; 95% CI, 1.17-1.19), and
an overnight hospital stay (RRR=2.32; 95% CI, 2.16-2.49). CD cases were more likely than
UC cases to be hospitalized (RRR=1.26; 95% CI, 1.11-1.43), and had a greater number of
outpatient visits. From 1990/1 to 2000/1, IBD cases experienced a significant drop in the
likelihood of an outpatient surgical visit relative to non-IBD controls (p<0.05), and for those
cases that were hospitalized, CD cases tended to be less likely than UC cases to experience
IBD-specific inpatient surgery (p<0.07). Of the 1987/8 cohort, 80% of the admissions that
occurred over the follow-up period were found in the first five years following diagnosis.
Conclusions: In 2000/1, health care utilization continued to be higher in IBD vs. controls
and CD vs. UC, however the gap in costly service utilization appeared to narrow between
the latter pair.
W1049
Use of Infliximab for Ulcerative Colitis in the Pre-Act I/II Era: An Analysis of
2000-2001 Commercial Insurance Claims
Patrick D. Meek, Marjorie Rosenberg, Nilay D. Shah, Bora Gumustop
BACKGROUND: Infliximab, a monoclonal antibody against tumor necrosis factor, has been
used successfully for patients with Crohn’s disease and rheumatoid arthritis since 1998.
Small clinical-trials published in 2001 and 2002 revealed the drug’s potential benefit in
ulcerative colitis patients (UC) for those with inadequate relief after standard therapy. At
the 2005 Digestive Disease Week meeting, data from two large controlled clinical trials
(ACT I and ACT II) Gastroenterology 2005;128(4):A-104,105) were released that appear
to confirm the benefit of the drug in UC. An evaluation of the patterns of infliximab use
during the early years of marketing, prior to the availability of ACT I/II, may provide
useful insight into the clinical decision making process during a pre-indication time period.
PURPOSE: In the post ACT I/II era, with increased infliximab use for UC, the impact of
the drug on subsequent health care utilization (inpatient, outpatient, concurrent prescription
drug use) by patients with UC remains unknown, and requires close evaluation. This study
describes the characteristics of patients and providers of infliximab use for UC during the
years of 2000-2001. METHODS: The study was a retrospective analysis of inpatient and
outpatient claims for persons with 12 months of continuous enrollment beyond the earliest
index claim coded for inflammatory bowel disease. The source of the data was the Medstat
MarketScan Commercial Claims and Encounters database. The study sample of interest
consists of 5,286 patients of any age who had at least 1 claim with a diagnosis for UC (ICD-
9 code of 556.xx) between January 1, 2000, and December 31, 2001. Infliximab use was
identified in outpatient service and prescription drug files using J1745 (J-code) and NDC
59784003001. RESULTS: (see Table) CONCLUSION: During the early pre-ACT I/II years
(2000, 2001), insurance claims for infliximab for patients with UC were rare. This study
provides information about the restricted nature of infliximab use in a privately insured
population. The encounter patterns seen in the analysis highlight the need for careful risk
adjustment by those evaluating resource use in UC.
Table. Characteristics of patients with ulcerative colitis by treatment group for 2000 and 2001
W1050
The Effect of Current Alcohol Consumption in Inactive Inflammatory Bowel
Disease
Garth Swanson, Laurie Keefer, Mary Kwasny, Sedghi Shahriar, Ali Keshavarzian
Background: Chronic heavy alcohol use has been known to increase inflammation in a wide
spectrum of disease. However, acutely alcohol has also been shown to decrease monocyte
activity and immune function. Currently there is a lack of literature and no guidelines for
IBD patients as to how alcohol may affect their symptoms. Our goals were to quantify
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alcohol intake in patients with IBD and to better characterize the possible relationship
between alcohol consumption and GI symptoms. Methods: We recruited 121 patients - 52
patients with biopsy proven inactive Crohn’s Disease (CD), 38 patients with biopsy proven
inactive Ulcerative Colitis (UC), and 31 patients with normal colonoscopies who met Rome
II criteria for IBS. All participants completed demographic data form, a validated questionnaire
to quantify alcohol consumption both by quantity and frequency per normal week, a validated
questionnaire on disease (CDAI, UCAI, or IBSS respectively), and a SF-12 quality of life
measure. Patients also completed a series of questions regarding the effect of alcohol on
their GI symptoms. Inactive disease in IBD was defined as a CDAI < 150 or UCAI < 4.
Current drinkers were defined as > 12 drinks of alcohol a year as defined by the NIAAA.
Pearson Chi square tests were used for analysis between the three groups. Results: Of the
121 patients surveyed, 75 were classified as current drinkers- 32 CD, 24 UC and 19 with
IBS. Patients that abstained from alcohol were 38% of CD, 42% of UC, and 65% of IBS.
Of current drinkers, 75% of CD (N=24), 75% of UC (N=18), and 37% of IBS (N=7)
reported a worsening of GI symptoms with alcohol [X2(2) =9.12, p-value .01]. Mean alcohol
consumption for each group was less than 1 drink per day, or light alcohol consumption
as defined by the NIAAA. Mean age in the CD, UC, and IBS groups were 42, 37, and 58
respectively. Patient gender, quality of life scores, and presence of binge drinking (> 5 drinks
on one occasion as defined by the NIAAA) were not statistically different between the three
groups. Conclusions: Current drinkers with inactive IBD are more likely to report GI symptom
exacerbation with alcohol than current drinkers with IBS. The mechanism of alcohol induced
symptoms in IBD is not clear, but may be one of many environmental triggers of the
inflammatory cascade in the gut lumen. Further prospective studies are needed to examine
the link between alcohol consumption and inflammation to establish dietary guidelines for
patients with IBD.
W1051
North American Inflammatory Bowel Disease (IBD) Experts and Community
GI Providers Differ Significantly in Prescribing 5-ASA Products in Crohn’s
Disease (CD)
Eric Esrailian, Brennan M. Spiegel, Laura E. Targownik, Marla C. Dubinsky, Stephan R.
Targan, Ian M. Gralnek
Background: Although the effectiveness of 5-ASA products is well established in ulcerative
colitis, their effectiveness in CD is unclear, and the appropriateness of using 5-ASA in CD
remains uncertain. We conducted a national survey of IBD experts and community GI
providers to measure beliefs about the appropriateness of prescribing 5-ASA products in
CD. Methods: We developed a survey consisting of 4 clinical vignettes: 1) patient with
newly diagnosed CD (CD Dx) 2) presentation of perianal fistula 3) patient with steroid
refractory CD and 4) patient status post ileocolonic (s/p IC) anastomosis for IC CD. The
survey elicited provider beliefs about the appropriateness of diagnostic tests and therapies
(including 5-ASA products). We measured appropriateness using the 9-point RAND Appro-
priateness Scale, where 1-3=inappropriate, 4-6=unsure, 7-9=appropriate and “endorsed.”
We calculated the RAND Disagreement Index (DI) for each set of ratings. The DI is a
validated measure of provider variation, where DI>1.0=extreme variation, and DI<1.0=
acceptable variation. We surveyed 55 recognized North American IBD experts and a random
sample of 91 AGA members. Results: Table 1 demonstrates a striking disconnect between
experts and community GI providers. For all vignettes, community providers were more
likely to endorse the use of 5-ASA products in CD. Moreover, both groups were internally
consistent in their ratings (all DIs<1.0 except for experts in s/p IC vignette). Among providers
endorsing 5-ASA, there were no significant differences in the ratings of Asacol®, Pentasa®,
or Colazal®, although Dipentum® was rated lower than the alternative formulations. In
multivariable regression analysis adjusting for key practice and provider characteristics,
only non-expert status independently predicted endorsement of 5-ASA products in CD.
Conclusions: Most community providers in this sample believe that 5-ASA products are
appropriate across a variety of CD presentations. In contrast, IBD experts are significantly
less likely to endorse 5-ASA products. Since intragroup beliefs are highly consistent, these
data demonstrate a marked disconnect between experts and community providers, and
suggest that further research and dialogue is critical to better understand the role of 5-ASA
products in CD.
Table 1. Endorsement of 5-ASA by Experts vs Community Providers Across Vignettes.
*DI≤1= “consensus.”
W1052
Evaluation of Densitometric Bone-Muscle Relationships in Crohn’s Disease
(CD)
David Armstrong, Marina Mauro
Background: Patients with CD are 1.4 to 2.5 times more likely than the normal population
to sustain a fracture but the factors involved in the pathogenesis are not clearly understood.
Osteopenia and osteoporosis are traditionally defined by Bone Mineral Density (BMD)
parameters, but this approach disregards the influence of bone size, a main determinant of
bone strength. Bone mineral content (BMC) may, therefore, provide a better measure of
bone strength. Bone mass is affected both by nutrition and by muscular activity. We hypothes-
ized that BMC would correlate better than BMD with lean mass (LM - a measure of muscular
mass) and that LM would correlate better than fat mass (FM) with BMC. Aim: To assess

















in CD patients, using LM and FM as markers of exercise and caloric intake status, respectively.
Methods: A retrospective chart review was performed to select CD patients who had a
whole body densitometric (Hologic) evaluation between 2003 and 2005. Densitometric
determinations included the BMC, Bone Area (BA), BMD, LM and FM of the whole body
and lower and upper limbs. Standard t-tests, simple and multiple stepwise correlations were
analyzed as required. Results: Data from 38 patients (38.8 +15.1 years, M=15) were analyzed.
Significant correlations were observed between whole body and regional BMC measurements
with BA (r>0.86), LM (r> 0.77) and body weight (r>0.55). In multiple regression analysis,
LM was the most significant independent factor correlated with BMC in whole body and
in all regions. There was no correlation between FM and BMC. LM (muscle mass) correlated
significantly with BMC (bone mass) (r > 0.77 in all regions) and BA (bone size)(r > 0.72
in all regions). In contrast, the observed correlations between LM and BMD were relatively
poor (r < 0.5 in all regions). Summary: These findings support the hypothesis that BMC
correlates better than BMD with LM and that there is a relatively poor correlation between
bone mass and FM. Conclusions: These results support the use of BMC in preference to
BMD as a marker of bone strength and they suggest that muscular mass and activity, rather
than overall body weight, are important determinants of bone strength in Crohn’s disease.
Thus, the management of bone loss in inflammatory bowel disease should address the effects
of both nutrition and exercise on muscle mass.
W1053
Magnifying Colonoscope Findings Are Predictive of Relapse in Patients with
Quiescent Ulcerative Colitis
Takafumi Ando, Yuji Nishio, Osamu Maeda, Kazuhiro Ishiguro, Osamu Watanabe, Naoki
Ohmiya, Yasumasa Niwa, Hidemi Goto
Background: Relapse of ulcerative colitis (UC) is difficult to predict by routine colonoscopy.
A high-resolution video-magnifying colonoscope with chromoscopy enables the observation
of colorectal mucosal pit patterns. Aims: We investigated the association between pit patterns
as assessed by magnifying colonoscopy with histological inflammation and mucosal chemok-
ine activity in patients with quiescent UC, and prospectively analyzed prognostic factors
that may predict exacerbations. Methods: Magnifying colonoscopy was performed in 113 UC
patients in remission. Pit patterns in the rectal mucosa were classified into four magnifying-
colonoscopy (MCS) grades on the basis of size, shape, and arrangement. Mucosal interleukin-
8 (IL-8) activity in biopsy specimens of rectal mucosa was measured and the specimens
were microscopically graded according to the system of Riley. The patients were then followed
until relapse or a maximum of 12 months. Multivariate survival analysis was performed to
determine independent predictors of clinical relapse. Results: A positive correlation was
identified among MCS grade, histological grade and mucosal IL-8 activity. Multivariate
proportional hazard model analysis showed that MCS grade was a significant predictor of
relapse. Kaplan-Meier estimate of relapse during 12 months’ follow-up was found to increase
with increasing MCS grade. Conclusion: MCS grading is associated with the degree of
histological inflammation and mucosal IL-8 activity in quiescent UC patients, and may
predict the probability of subsequent disease relapse in UC patients in remission.
W1054
Careful Patient Selection May Improve Response Rates to Infliximab in
Inflammatory Bowel Disease
Ian C. Lawrance, Callum B. Pearce
Introduction: Infliximab in the treatment of Crohn’s Disease (CD) is accepted and it also
appears to be effective in ulcerative colitis (UC). Careful patient selection, resulting in
infliximab use only for patients with active disease who are truly refractory to other treatments,
may improve its efficacy in inflammatory bowel disease (IBD). Methods: The aim of this
study was to determine whether careful patient selection improves infliximab efficacy in
IBD. Patients were recruited from a single tertiary institution with a particular interest in
the management of IBD. CD or UC/IBD unclassified patients (Montreal classification) were
considered for infliximab treatment only after failure of disease control with conventional
therapies and confirmation of ongoing active disease. Patients with purely inflammatory
disease received a single 5mg/kg infliximab dose. Patients with fistulising disease received
a course of 3 infusions of 5 mg/kg at weeks 0, 2 and 6. Changes to Harvey Bradshaw (HBI)
for inflammatory CD and Colitis Activity (CAI) for UC/IBDU were used to determine the
response and remission rates 2-4 weeks after treatment. In fistulising CD a remission was
sustained cessation of drainage and resolution of the fistula. Findings were correlated to
inflammatory marker levels. Adverse effects were analysed. Results: 70 IBD patients were
treated. In CD, 85.2% (46/54) had active luminal and 40.7% (22/54) fistulising disease.
Luminal CD responded in 91.3% (42/46) and remitted in 80.4% (37/46). Fistulising disease
responded in 77.2% (17/22) and remitted in 50% (11/22). Patients with isolated colonic
disease were more likely to remit 13/14 (92.9%) compared to those with ileal involvement
23/32 (71.9%). In UC/IBDU, 75% (12/16) responded and 43.8% (7/16) remitted. A total
of 11.4% (8/70) of all patients experienced an adverse event and 5.7% (4/70) a serious
adverse event. Conclusions: Infliximab therapy at our institution appeared to achieve a
higher remission rate in CD patients (80.4%) compared to the ACCENT 1 study (27%).
Efficacy was also found in the use of infliximab in UC/IBDU patients in line with the ACT
1 findings. These results suggest that strict patient selection may improve the observed
efficacy of infliximab.
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W1055
Risk Factors for Un-Investigated Dyspepsia and Non-Ulcer Dyspepsia (NUD)
in a Random Adult Population-Based Endoscopic Study (Kalixanda study)
Pertti Aro, Jukka Ronkainen, Tom Storskrubb, Elisabeth . Bolling-Sternevald, Nicholas J.
Talley, Lars Agreus
Background: Risk factors for non-ulcer dyspepsia (NUD) in a randomly selected adult
population are not well defined; smoking, H. pylori infection, use of aspirin, NSAIDs or
acetaminophen, alcohol and smoking may all be relevant in inducing dyspepsia. Aim: To
determine predictors for un-investigated dyspepsia (UID) and NUD in a random sample of
a Swedish adult population. Methods: A representative sample (n=2,860, mean age 50.4
years, 52.0 % male) of the adult population (n=21,610) in Northern Sweden was studied.
A third (n=1001, mean age 54.1 years, 48.8 % male) were then randomly selected for
esophagogastroduodenoscopy (EGD). They completed a validated Abdominal Symptom
Questionnaire (ASQ) and Hospital Anxiety and Depression scale (HADS). Dyspepsia was
defined according to Rome II criteria (excluding upper abdominal bloating which was not
asked in the ASQ). NUD was defined as dyspepsia excluding peptic ulcer disease, esophagitis
or cancer. UID without concomitant reporting of gastroesophageal reflux symptoms (GERS)
or irritable bowel syndrome (IBS) was also examined in the analyses (“UID only”). The data
were analyzed by multivariate logistic regression including smoking, use of alcohol, aspirin,
NSAIDs and acetaminophen, obesity (body mass index BMI≥30), education level, H. pylori,
depression and anxiety as exposure variables and adjusting for age, gender and acid reducing
drugs (proton pump inhibitors (PPI), histamine-2 receptor antagonists or antacids). Results:
Descriptive data of different dyspepsia groups are presented in table. Anxiety was independ-
ently associated with UID (OR=6.2, 95% CI: 2.4-16.1) and NUD (OR=3.2, 95% CI: 1.5-
7.0) but depression was only associated with UID (OR=6.0, 95% CI: 1.6-22.5) as was obesity
(OR=1.5, 95% CI: 1.05-2.3). Low education level was also a risk factor for NUD (OR=1.5,
95% CI: 1.01-2.1). Anxiety was an independent risk factor for “UID only” (OR=3.9, 95%
CI: 1.5-10.0); H. pylori was a negative predictor for “UID only” (OR=0.5, 95% CI: 0.3-0.99).
Conclusions: Anxiety and low education level are independent risk factors for NUD, but H.
pylori infection, smoking, alcohol and NSAID use appear to be unimportant in this disorder
in the community.
Descriptive data
significant differences; ^p=0.02, *p=0.02
W1056
Evaluation of Duodenal Acid Exposure in Healthy Subjects Using a
Radiotelemetry pH Monitoring System
Jason Bratten, Michael P. Jones
Introduction: Abnormal duodenal acid exposure is linked with both DU and NUD but our
understanding has been limited by cumbersome recording methods. Radiotelemetry pH
monitoring (RpHM) is a novel technology allowing minimally invasive study of pH through-
out the GI tract. The aim of this study was to determine the feasibility of duodenal RpHM
and to establish reference ranges in healthy subjs. Methods:Subjs underwent EGD to place
Bravo™ radiotelemetry capsules (RTC) in the distal duodenal bulb. RTC were secured with
endoclips. RTC retention was confirmed by US after EGD and at 48hrs. RpHM was performed
for 48hrs. Standardized test meals (1200 kcal/50gm fat/36 gm protein) were eaten twice
daily. Subjs were NPO other than sips of water between meals. Sleep periods were determined
from diaries. Meal periods were defined as the 3hr period following meal initiation. Results:
25 subjs were studied. Prolonged recordings obtained in 17/25. Reasons for incomplete
recordings were RTC dislodgement(5), procedural complication(1) and suspected gastric
prolapse of RTC(2). RTC dislodgements occurred early in the study and were corrected by
using additional endoclips to anchor the RTC. Avg EGD procedure length was 15 min. pH
(mean{95% CI}) did not differ signif btwn meal (5.67{5.42-5.93}), sleep (5.56{4.87-6.24})and
fasting(5.44{5.07-5.80})periods. This was also true when analyzed by [H+]. Frequency distri-
butions of pH values for the 3 periods did, however, differ signif (p<0.0001 for all pH
values)(Figure). pH mode was 6.5 during meal periods and 7.5 for sleep and fasting periods.
Fasting and sleep periods also had proportionately greater periods of time with pH <2.5.
Conclusions: Prolonged duodenal RpHM can be successfully performed using an RTC secured
with endoclips. Differing patterns of duodenal pH are seen during meals, fasting and sleep.
These data provide reference ranges in healthy subjs and will inform comparisons with NUD
pts currently being studied using this method.
W1057
The Link Between Meal Related Symptoms and Cytokine Release in Patients
with Functional Dyspepsia
Tobias Liebregts, Birgit Adam, Christoph Bredack, Alexander Roth, Susanne Heinzel, Eric
Smith, Paul Drew, Gerald Holtmann
Background: Immune responses are believed to play a critical role for the manifestation of
functional gastrointestinal disorders. In recent studies we have demonstrated (AJG
2004;99(4):703-10) differences in systemic cytokine levels after a meal. The current study
aimed to assess the link between baseline and lipopolysacharide (LPS) stimulated cytokine
levels and the symptom pattern in patients with functional dyspepsia. Methods: 22 (H.
pylori-negative) patients with functional dyspepsia according to ROME II (8 males, aged 21-
72 mean 46.3) were recruited after a standardized diagnostic work-up. Symptom pattern
and severity of symptoms were assessed utilizing the BDQ (Bowel Disease Questionnaire).
Peripheral blood mononuclear cells (PBMC) from 40 cc whole blood were freshly isolated
by density gradient centrifugation and cultured for 24 hours in RPMI 1640 supplemented
with 10% FCS. Basal and E. coli LPS (1-100ng/ml) stimulated pro-inflammatory cytokine
production (TNF-a, IL-1b, IL-6) of PBMC was measured by enzyme-linked immunosorbent
assay (ELISA). Results: Overall, intensity of abdominal pain or discomfort were significantly
associated with baseline TNF-α (r=0.70, p<0.001), IL-1β (r=0.54, p<0.001) and IL-6 (r=
0.51, p<0.002). The release of TNF-α, IL-1β and IL-6 were significantly higher in patients
reporting early satiety and meal related pain (TNF- α p<0.001; IL-1 β p<0.01; IL-6 p<0.05)
compared to patients without these symptoms. Cytokine release was not linked to nausea
or vomiting. Summary and Conclusion: In-vitro-release of cytokines from PBMC is linked
to severity of symptoms and in particular associated with meal related complaints. Based
upon these data we conclude that immune responses mediated by cytokine release are linked
to the symptom pattern in patients with functional dyspepsia.
W1058
Postprandial Hypersensitivity to Gastric Distension in Functional Dyspepsia
Correlates with the Presence of Headache
Michele Di Stefano, Ennio Pucci, Emanuela Miceli, Paola Tana, Samanta Mazzocchi,
Giorgio Sandrini, Giuseppe Nappi, Gino R. Corazza
Background and Aims: Several patients with functional dyspepsia very often present headache.
Up to now, no data are available on the putative pathophysiological mechanism responsible
for this association. Therefore, the aim of the present study was to assess whether headache
represents a symptom associated with a peculiar pathophysiological mechanism of functional
dyspepsia. Patients and Methods: Thirty-five HP-ve patients (22 F, mean age 33±9 yrs) with
functional dyspepsia, diagnosed according to Rome II criteria took part in the study. Eighteen
patients also suffered from migraine without aura depending on HIS criteria. As a control
group, ten age- and sex-matched healthy volunteers were also enrolled. In all patients
presence and severity of dyspeptic symptoms (epigastric discomfort, bloating, fullness, early
satiety, nausea, vomiting, belching, epigastric burning, epigastric pain) and headache was
evaluated by a 0-3 score where 0=absence of symptom, 1=mild, 2=relevant, and 3=severe.
All subjects underwent gastric barostat test according to previous studies in order to evaluate
whether an alteration of gastric accommodation (1) or hypersensitivity to gastric distention
(2) was present. Discomfort threshold was also determined postprandially to evaluate whether
postprandial sensitisation occurs, and a relevant reduction, according to results in healthy
volunteers, was defined as a threshold reduction higher than 4 mmHg. Finally, gastric
emptying for solids was evaluated by 13C-octanoic acid breath test. Results: The prevalence
of relevant (score=2 or 3) symptoms was not different between patients with impaired
accommodation (8/35; 22%) and patients with normal accommodation, between patients
with hypersensitivity (10/35; 28%) or normal sensitivity to gastric distention, and between
patients with delayed gastric emptying (25/35; 71%) and normal gastric emptying. On the
contrary, patients with postprandial reduction of discomfort threshold (15/35; 43%) showed
a significantly higher prevalence of headache (73% vs 35%; p=0.040). Stepwise multiple
logistic analysis confirmed the significant association (p=0.01) between relevant headache
and the risk of postprandial hypersensitivity to gastric distention. Conclusions: Among
patients with functional dyspepsia, the subgroup showing an association with migraine is
characterized by postprandial hypersensitivity to gastric distension.
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W1059
Risk Factors Associated with Uninvestigated Dyspepsia: A Population-Based
Study in Latin America
Jorge Olmos, Valeria Pogorelsky, Federico Tobal, Mariano Marcolongo, Graciela Salis,
Roberto Higa, Juan Carlos Chiocca
BACKGROUND: Dyspepsia is a frequent complaint in the general population. However,
population-based data on risk factors for uninvestigated dyspepsia are lacking in Latin
America. AIM: To assess uninvestigated dyspepsia association with potential risk factors in
a population-based study in Argentina. METHODS: We conducted a cross-sectional survey
of the adult population using a valid gastrointestinal symptom self-report questionnaire that
measured dyspepsia symptoms and potential risk factors. The questionnaires were submitted
to 1000 residents (aged 18-80 years) from 17 representative geographical areas of Argentina.
The samples were stratified according to age, gender, geographical areas and size of town
of residence. Dyspepsia was defined as pain or discomfort (fullness/satiety) centered in the
upper abdomen. Logistic regression was used to estimate the odds ratios (OR) with 95%
confidence intervals (CI) for dyspepsia symptoms associated with potential risk factors: age,
gender, body mass index, educational level, psychosomatic symptoms, lifestyle habits, use
of aspirin, NSAIDs, antiacids, sucralfate, prokinetics and antisecretory medication, physician
visits and the existence of diseases of the esophagus or stomach in any direct family member
(family history) or spouse (environment). RESULTS: 839 valid questionnaires were finally
evaluated (F/M 466/373, mean age 39.9 ±15.4 years). Uninvestigated dyspepsia was present
in 367 subjects (43.2%; 95%CI 39.8 - 46.6). A score >14 on the psychosomatic symptom
scale (OR, 2.52; 95%CI, 1.75 - 3.61), a family history (OR, 1.73; 95%CI, 1.19 - 2.52) and
an educational level >12 years (OR, 1.55; 95%CI, 1.05 - 2.29) were significantly and
independently associated with uninvestigated dyspepsia. CONCLUSIONS: A score >14 on
the psychosomatic symptom scale, a family history and educational level >12 years were
risk factors for uninvestigated dyspepsia. The association with a higher psychosomatic
symptom score suggests the role of psychological factors and somatization in this disorder.
W1060
Non-Dominant Heartburn Does Not Predict the Resolution of Symptoms in
Patients with Dyspeptic Symptoms (Uninvestigated and Endoscopy-Negative)
Nimish Vakil, Nicholas Talley, Johan Brun, Nigel Flook, Karsten Lauritsen, Sander
Veldhuyzen van Zanten, Elisabeth Bolling-Sternevald, Tore Persson, Ewa Bjorck, Lars-Erik
Svedberg
BACKGROUND: Non-dominant heartburn is common in dyspeptic patients and has led to
regulatory concerns that response to acid suppression for treatment of dyspeptic symptoms
is due to occult gastroesophageal reflux disease (GERD). We examine factors related to
symptomatic response to 8 weeks’ esomeprazole treatment in 2 clinical studies in patients
with dyspeptic symptoms. METHODS: In the STARS I study (SD-NED-0021), patients (18-
70 years) with non-ulcer dyspepsia (dyspeptic symptoms with a sum symptom score of ≥5
[scored daily: 0=mild to 3=severe] during the last 7 days of the run-in period; no predominant
GERD symptoms; no GERD symptoms >1 day/week) and normal findings at endoscopy
were randomized to either esomeprazole 40 mg once daily (qd), twice daily (bid) or placebo
for 1 week, followed by either esomeprazole 40 mg or placebo for 7 weeks (n=1589). In
the STARS II study (SD-NED-0022), Helicobacter pylori-negative primary care patients (18-
50 years) with dyspeptic symptoms (pain or burning centered in the upper abdomen) and
without endoscopy received 1-week’s esomeprazole 40 mg qd or bid, followed by 7-weeks’
treatment period with either esomeprazole 40 mg or placebo (n=1250). Symptoms were
scored daily (none to severe) and ‘response’ was defined as at most one day with mild
symptoms over last 7 days in the 8th week. Patients treated with esomeprazole during both
the 1-week and the 7-week period were included in this analysis. RESULTS: In STARS I
(non-ulcer dyspeptic patients) and STARS II (univestigated dyspeptic patients), 25.6% of
1589, and 38.7% of 1250 randomized patients had non-dominant heartburn at baseline.
Significant prognostic factors for treatment response are shown in Table 1. CONCLUSIONS:
When patients with predominant or frequent heartburn are excluded, the outcome of
treatment with acid inhibitors in dyspeptic patients (both in patients without significant
endoscopic findings and in those not investigated with endoscopy) is not affected by the
presence of background heartburn, regurgitation or burning centered in the upper abdomen.


















Meal Related Symptoms and Gastric Motor Function
Birgit Adam, Tobias Liebregts, Guru Iyngkaran, F Dylan Bartholomeusz, Max Bellon,
Jacob Bolwell, Gerald Holtmann
Introduction: The association of gastrointestinal symptoms during a test meal and the gastric
emptying pattern has not been systematically studied. Therfore we aimed to assess and
compare in healthy subjects and patients with functional dyspepsia the relation between
meal related symptoms and gastric motor function. Methods: We studied 16 patients with
functional dyspepsia (10 female, age 18 - 68) and 15 healthy subjects (8 males, aged 21-
45) without a history of relevant dyspeptic symptoms. After at least an 8 hrs fast, they
received every 5 minutes 200 ml of a standardized 99mTc-labelled enteral feeding solution
(EnsureR) up to a cumulative volume of 800mL. After each 200 mL drink, symptoms were
evaluated with a standardized instrument that assesses 7 key symptoms (fullness, abdominal
pain, retrosternal/abdominal burning, nausea, regurgitation, other) and determines peak and
cumulated symptom response. The gastric nutrient distribution and emptying were assessed
with a gamma camera. Data analysis: The cumulated symptom response during the 240
minute meal and post meal period was calculated separately for all symptoms. In addition,
the time from the start of nutrient ingestion until the peak of the various symptoms was
determined. Tlag, defined as the time at which activity was first seen in the proximal small
intestine, and gastric retention at 100 min were used to characterize gastric emptying. Non
parametric correlations were utilized to assess the association between symptoms and gastric
emptying parameters. Results: During the test meal, patients reported significantly more
severe abdominal symptoms than healthy controls (cumulated score 530 ±76 vs. 325 ±64,
p<0.05). The average time, between the start of the meal until the peak symptoms occurred,
were not different between patients and controls (p>0.05) while there were marked differences
for the various symptoms (i.e. nausea 12 min ±9 vs. pain 20 min ±23). Gastric emptying
(t1/2 and tlag) was not different for patient and controls. Interestingly, the cumulated fullness
and pain scores were inversely correlated with the tlag (r=0.50, p<0.02 and r=-0.42, p<0.05).
In contrast, t ½ or gastric nutrient retention at 100 min was not associated with any of the
symptoms. Conclusions: A rapid onset of delivery of nutrients into the duodenum is associated
with fullness and pain, while delayed gastric emptying was not associated with symptoms.
These data suggest that duodenal mechanisms (e.g. duodenal mechano- or chemosensory
afferents or nutrient clearance) play a crucial role for the manifestation of meal related symp-
toms.
W1062
Impact of the Rome II Criteria - Assessment of Related Comorbid Prevalence
and Costs of Patients with Functional Dyspepsia
Stephen George, Nathan L. Kleinman, Richard Brook, Jim . Smeeding
Background: The etiology of functional dyspepsia (FD) is debated, but according to the
ROME II Criteria, FD always presumes the absence of a structural or biochemical explanation
for the symptoms. No published data exist on the associated co-morbid prevalence or costs
for patients with FD. Objective: To assess the related co-morbid prevalence and costs
associated with FD. Methods: A retrospective database analysis was conducted of a person-
centric database derived from multiple large geographically diverse US based employers
with data from 2001 through 2004. Employees with FD (ICD-9 536.8) were compared to
employees without FD. Data were compared for a 12-month period beginning 3-months
prior to the first diagnosis of FD (the index date). The average index date from the FD
cohort was assigned for the control group. To control and adjust for differences in the
groups, we used multiple regression, Markov modeling techniques, and the Charlson Comor-
bidity Index. Prevalence comparisons were made using the 261 Agency of Healthcare Quality
in Research (AHQR) specific diagnostic categories. Results: A total of 275,857 patients were
identified, but only 1,669 patients (median age = 42 years, 54.1% female) met the inclusion
criteria for FD. Patients with FD had a higher prevalence rate of AHQR diagnostic categories
159 of 261 (p<0.05) and higher costs 141 of 261 (p<0.05). Excluding the FD diagnosis, 7
out of the top 15 most prevalent occurring AHRQ specific categories were greater in the
FD group (p<0.05) and included abdominal pain (46.5% vs 8.2%), other GI disorders
(28.1% vs 4.7%), screening suspected conditions (27.5% vs 20.3%), medical exam requiring
further evaluation (24.2% vs 15.9%), residual codes ill defined symptoms (21% vs 11.6%),
nonspecific chest pain (20% vs 7%), and unknown diagnosis (19.8% vs 11.3%). The top
costs differences between the two groups were for abdominal pain ($308), biliary tract disease
($299), coronary atherosclerosis ($228), stomach/duodenum disorders ($188), esophageal
disorders ($166), gastritis and duodenitis ($163), and nonspecific chest pain ($139). Global
health care cost comparisons for FD showed a difference of $3,421 (p<0.0001). Other cost
comparisons were statistically significant for prescription drugs ($780 vs. $415, p<0.0001)
and sick leave ($462 vs. $359, p<0.001). Of interest is that only 60% of FD patients were
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using drug therapy. Conclusion: This study shows that FD patients present with variety of
symptoms and their management is complex. There needs to be more education so that
practitioners can better understand the coexistence of associated conditions and apply the
ROME II criteria.
W1063
Endoscopic Findings in Patients with Dyspeptic Symptoms Who Fail Acid
Suppressive Therapy
Nimish Vakil, Sander Veldhuyzen van Zanten, Nigel Flook, Karsten Lauritsen, Tore
Persson, Ewa Bjorck, Johan Brun, Tore Lind, Nicholas J. Talley
BACKGROUND: The 2005 AGA guidelines on dyspepsia recommend that in low Helicobacter
pylori prevalence areas (<15%) patients should receive an empirical trial of proton pump
inhibitor (PPI) therapy, with endoscopy reserved for those who fail to respond. However,
there is little information on the abnormalities found in these patients. Our aim was to
determine the underlying endoscopic abnormalities in patients with uninvestigated dyspepsia
who fail to respond to acid suppressive therapy. METHODS: H. pylori-negative patients aged
18-50 years with intermittent or continuous epigastric pain or burning centered in the upper
abdomen for ≥3 months were recruited from primary care practices in 10 countries (Study
SD-NED-0022). Patients were excluded if they had: undergone endoscopy or radiographic
studies within the previous 6 months or on more than 2 occasions in the preceding 10
years, dominant symptoms of heartburn and acid regurgitation or alarm features (dysphagia,
weight loss, bleeding), or anti-H. pylori therapy in the previous 12 months. Patients received
esomeprazole for 1 week as a PPI trial, followed by esomeprazole 40 mg or placebo for 7
weeks. Data presented here relate to patients who prematurely discontinued from the study
or completed this study and had persistent symptoms. These patients underwent EGD.
RESULTS: Of 1250 patients who were included in the total study population and received
PPI therapy, 208 (16.7%) had an EGD because of persistent gastrointestinal symptoms.
Clinically significant abnormalities were found in 85 (41%) of patients. The most commonly
reported abnormalities are presented in the Table. No malignancies were reported in these
patients. CONCLUSIONS: Although erosive esophagitis is common in H. pylori-negative
uninvestigated dyspeptic patients with persistent symptoms after PPI therapy or placebo,
more serious abnormalities are rare. Peptic ulcer disease is very rare in these patients. These
data support the current AGA guidelines and demonstrate that serious abnormalities are
not found in patients with persistent dyspeptic symptoms despite PPI therapy.
Clinically significant abnormalities
W1064
Accelerate Reversal of Helicobacter Pylori-Induced Gastric Dysfunction By
Specific Probiotics Through An Anti-Inflammatory Effect
Premysl Bercik, Elena F. Verdu, Xian Xi Huang, Thomas Tompkins, Stephen M. Collins
Background/Aim: We have previously investigated the relationship between gastric dysfunc-
tion and Helicobacter pylori (Hp) eradication (E) in a murine model. Here we tested whether
specific probiotics accelerate the recovery of gastric inflammation and of impaired gastric
function after HpE. Methods: Uninfected control and Hp infected Balb/c mice were studied
before, at 2 weeks and 2 months after HpE. Immediately after antibacterial therapy, groups
of mice (n=8/group) were gavaged with a probiotic product, Lacidofil, containing Lactobacillus
helveticus R0052 and L. rhamnosus R0011 or, a maltodextrin placebo for 2 weeks. Gastric
emptying (GE) was assessed by videofluoroscopy image analysis. Frequency of eating bouts
and amount of food was recorded during 24 hours by a computer-assisted method. TNF-
α was detected by RT-PCR in gastric sections obtained 2 months after HpE. Results: Hp
infected mice had delayed gastric emptying by 42% compared to uninfected mice (p<0.05).
Uninfected mice had 13 ± 3.5 eating bouts/24 hours while Hp infected mice had 19.5 ±4.8
bouts/24 hours (p<0.05). Eradication therapy improved GE 2 weeks after HpE, and normal-
ized it at 2 months. In contrast, anti-H. pylori therapy had no effect on Hp-induced altered
eating patterns that remained abnormal 2 months after HpE. Altered eating patterns after
HpE were paralleled by a persistent 50% increase in TNF-α in gastric tissue when compared
to uninfected mice. Prompt probiotic therapy after HpE accelerated normalization of GE at
2 weeks, and normalized altered feeding behavior 2 months after HpE. Mice previously
infected but treated with probiotics had decreased levels of TNF-α in gastric tissue by 40%
vs previously infected mice treated with placebo (p=0.01). Conclusions: Persistent dyspeptic
behavior in mice, characterized by abnormal 24-hour feeding patterns after HpE, is normalized
by prompt treatment with L. helveticus R0052 and L. rhamnosus R0052. The underlying
mechanism may involve accelerated resolution of residual post-infective inflammation. Probi-
otics, given immediately after Hp eradication may be helpful in the management of accom-
panying dyspeptic symptoms.
W1065
Dyspeptic Symptoms Improvement in Patients with Non-Erosive Reflux
Disease Is Correlated with the Degree of Intragastric Acid Inhibition
Giovanni Sarnelli, Luigi Russo, Ida Esposito, Francesco De Giorgi, Maria Flavia Savarese,
Eleonora Efficie, Gabriele Budillon, Rosario Cuomo
Functional dyspepsia and non-erosive reflux disease (NERD) are highly prevalent functional
diseases. In both the diseases symptoms overlap can be expected by chance alone, but recent
data indicated that acid may be the common factor to explain symptoms generation. Indeed,
esophageal acid perfusion has been recently associated with the onset of dyspeptic symptoms
in healthy volunteers. Our aim was to study the effect of acid and its suppression, by PPI
therapy, on NERD patients with dyspeptic symptoms. Hundred-twenty consecutive patients
with reflux-associated symptoms were studied. Sixty-nine of them were selected because
they were found to have non-erosive reflux disease during upper GI endoscopy and fulfilled
the Rome criteria for functional dyspepsia. A standardized questionnaire, assessing the
severity (effect on daily activities, from 0 to 3) of belching, abdominal bloating, early
satiety, epigastric pain and burning, nausea, vomiting and postprandial fullness, and an
esophagogastric 24hr pHmetry were performed before and at 4th week therapy with esomep-
razole 20 mg bid. Intragastric acid inhibition was evaluated as the % of pH >3 and symptoms
improvement was considered effective if a reduction of dyspepsia severity score (at least
50%) respect to baseline was obtained. Esophageal basal acid exposure (pH<4 > 4%) was
pathological in 44 pts, whereas it was normal in 25. No significant difference was observed
in the prevalence and the severity of individual dyspeptic symptoms. At baseline the intra-
gastric % pH >3 was similar in subjects with normal and abnormal acid exposure (19±3.8
vs 18±4.5, p=NS). During esomeprazole therapy, reflux-associated symptoms improved in
the majority of patients, but 7/69 patients had persistent pathological esophageal acid
exposure. Overall PPI therapy significantly improved dyspeptic symptoms in 42/69 patients.
Dyspepsia improvement was present in a higher number of patients with abnormal than in
those with normal basal acid exposure (31/44 vs 11/25, respectively, p<0.05), with the
former having a longer intragastric acid suppression (78±2.6 vs. 65±5.4 %pH >3, p<0.05).
Our findings confirm that functional dyspepsia may coexist in patients with non-erosive
reflux disease. A four-week treatment with esomeprazole is effective in reducing dyspeptic
symptoms in 60% of subjects with NERD. Furthermore, a better improvement of dyspeptic
symptoms seems dependent on the extent of intragastric acid suppression.
W1066
Age and Alarm Symptoms As An Indication for Endoscopy in a Resource
Limited Environment
Dion A. Levin, Gillian A. Watermeyer, Sabelo J. Hlatswayo, David P. Epstein, Kd(chandu)
Bardhan, David C. Metz
Introduction: AGA guidelines suggest that in the absence of alarm symptoms, endoscopy
be reserved for dyspeptic patients over age 45. However, the yield of this approach may
not justify its use in a resource-limited environment such as South Africa. Aims: To compare
the endoscopic yield in dyspeptic patients with and without alarm symptoms (dysphagia,
anaemia, weight loss, vomiting, haematemesis or malaena) and to determine an age cut-off
for endoscopy dependent on the presence or absence of alarm symptoms. Methods: A
retrospective audit of 4129 upper endoscopic reports from a single tertiary-referral center
between February and December 2004 yielded 1081 eligible dyspeptics [32.9% males, mean
age 49.6± 15.1(range 13-92)]. Data validation was confirmed by review of 4% of reports.
Demographic data, presenting symptoms and endoscopic findings were recorded. Statistical
comparisons were made using Fischer’s exact test and Student t test where appropriate.
Results: Patients with alarm symptoms were older than those without; 53.2±16.9 yrs vs.
48.9±14.6 yrs (p= 0.0006), but the two groups did not differ in terms of gender or ethnicity.
Endoscopy was abnormal in 817 patients (75.6%), [143/172 (83.1%) of those with alarm
symptoms and 674/909 (74%) of those without alarm symptoms (p=NS)]. Abnormal endos-
copic findings included benign peptic ulcer disease in 186 patients (45 alarm, 141 no alarm,
p=NS), carcinoma in 16 (9 alarm, 7 no alarm, p=0.0003) and other findings (gastritis,
oesophagitis, etc) in 615 (89 alarm, 526 no alarm, p=NS). The yield for benign peptic ulcer
disease with or without alarm symptoms was unaffected by age. However, age did impact
on the yield for carcinoma according to the presence or absence of alarm symptoms (see
Table): Conclusion: Dyspeptic patients with alarm symptoms tend to be older with a higher
carcinoma yield. In our resource limited environment, our data support reserving endoscopy
for dyspeptics between the age of 45 and 60 years for those with alarm features only and
performing it in all dyspeptics 60 years or older. This strategy, in addition to missing 3
cancers below 45 years of age, misses 3 additional cancers between 45 and 60 years of age
(0.28% of all dyspeptics, 0.77% of all dyspeptics between 45 and 60 yrs).
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W1067
A Quality Study of Self-Care Use in Patients with Dyspepsia
Kerstin M. Stake-Nilsson, Maud Soderlund, Rolf Hultcrantz, Peter Unge
Background: Dyspepsia is a common condition and the lack of effective therapies may lead
to the use of self-care methods. This study was conducted to elucidate self-care methods
and their effects in Sandviken, a municipality in Sweden. Method: In this qualitative approach,
focus groups were used. Subjects with any dyspepsia according to the ROME 2 criteria and
actively seeking health care institutions were included. A total of thirty-two subjects were
invited. Thirteen women and twelve men gave their informed consent and were allocated
into five focus groups. The interviews were conducted during April until June 2005. Data
were studied systematically using thematic analyses of four self-care categories (1). The
effects were classified as preventive, partial and total symptomatic relief. Results: All subjects
had sometimes used self-care methods. The following self-care methods were identified to
each of the four categories; Nutritional: Banana, Milk products, Bicarbonate, Soda, Rosehip
soup, Whiskey, Butter, Hot water, Sweet almonds and Biscuits. All nutritional methods were
associated with partial or total symptom relief if initiated at an early stage. Three of these
methods were primarily used for prevention. Drug/Biologic: PPIs, H2RAs, Antacids, Silikol
(mineral mix of magnesium and silicon), Aloe Vera, Molkosan (whey product), Roots from
Roses, Dophilus capsules (lactobacillus) and Goat milk capsules. Drugs that achieved symp-
tom relief were PPIs, H2RAs and antacids. A lesser effect was experienced when the drug
was introduced at a late stage. PPIs and H2RAs were also regarded as preventive. Spiritual/
Psychological: relaxation. Physical forces/devices: exercise. The effect of the latter two category
methods was limited to partial symptom relief only. Conclusion: In this focus group, quality
study approach, a large number of self-care methods associated with various effects were
identified. All subjects had used at least one self-care method. The result from this study
will be further explored in a quantitative study of patients with dyspepsia. References:
1. Murray R, Rubel A. Physicians and healers: Unwitting partners in health care. NEJM
1992;326:61-64
W1068
Distinct Dyspepsia Subgroups Exist in the General Population
Rok S. Choung, Nicholas J. Talley, G R. Locke, Cathy D. Schleck, Alan R. Zinsmeister
Introduction: The heterogeneity of dyspepsia is well known. In selected tertiary referral
patients, subgroups appear to exist but community data are conflicting. We postulated that
dyspepsia comprises three distinct subsets, characterized by pain, early satiety or nausea.
We aimed to identify and characterize these subsets of dyspepsia: ‘frequent upper abdominal
pain (UAP)’, ‘early satiety (ES)’ and ‘nausea/vomiting (NV)’. Methods: A population-based,
cross-sectional survey study was conducted by mailing a valid questionnaire to an age- and
gender- stratified random sample of residents of Olmsted County, MN, aged 30-95 years
(response rate 55%). Dyspepsia and irritable bowel syndrome (IBS) prevalence were estimated
by Rome II; gastroesophageal reflux (GERD) by weekly or more frequent heartburn or acid
regurgitation. Dyspepsia subgroups were categorized based on a priori defined symptoms.
Results: The prevalence of dyspepsia was 15%. Of 343 dyspeptic subjects, 51% reported
UAP, 20% NV and 47% ES with limited overlap (figure). Among the three groups, the
subjects were similar in age, education level, IBS status and overall GI symptom severity.
Women were more likely to have ES than UAP; those with GERD were more likely to have
UAP than ES; subjects with childhood pain were more likely to have NV than UAP (table).
Conclusion: Distinct subgroups of dyspepsia do exist in the general population, suggesting
that separate evaluation and treatment strategies are needed. Supported in part by an
unrestricted grant from Novartis.


















Gastrointestinal Opportunistic Infection: Is It Associated with Dyspeptic
Symptoms in Immunodepressed HIV-Infected Patients Under Highly Active
Antiretroviral Therapy?
Ana Luiza Werneck-Silva, Ivete B. Prado
Background: Highly active antiretroviral therapy (HAART) has dramatically reduced the
incidence of opportunistic infections (OI) in HIV disease. However, gastrointestinal (GI) OI
still occur, mainly in patients with marked depressed immune function. It usually affects
the esophagus or intestine. Stomach is rarely involved, although many opportunistic agents
have been reported to cause gastritis. Nausea and vomiting are particularly common com-
plaints in HIV-infected patients, and may reflect a variety of different etiologies including
medications. On the other hand, clinically apparent GI OI are relatively infrequent. Whether
OI can cause dyspeptic symptoms is still unknown. Aim: We have done a prospective study
looking for gastrointestinal OI in a large cohort of adult HIV-infected patients under HAART
with and without dyspeptic symptoms, all of them with marked depressed immune function.
Patients and methods: 690 HIV-infected patients (508 men, 182 women; mean age 39.71
years old) underwent upper endoscopy with gastric and duodenal biopsies. All of them
were under HAART. The study conformed the principles of Declaration of Helsinki and
Brazilian requirements governing. Patients were classified in two groups. Group 1: 500
patients (161 women, 339 men; mean age 38.77 years old; mean CD4 count 154.3 cells/
mm3) with dyspeptic symptoms such epigastric pain, nausea, vomiting and fullness. Group
2: 190 patients (169 men, 21 women; mean age 40.66 years old; mean CD4 count 171.6
cell/mm3) without dyspepsia (in group 2 endoscopy was done to search for esophageal
varices or GI Kaposi sarcoma (SK) when indicated, or as part of weight loss, anemia or
halitosis investigation). Diagnosis of opportunistic infections was based on typical endoscopic
and histologic findings. Results: Group 1: OI was shown in 08 patients (1.6%): CMV (4 cases),
Cryptosporidium sp. (2 patients), Schistosoma mansoni sp. (1 patient) and Strongyloides
stercoralis (1 patient). In 3 of them OI was detected in normal appearance gastric or duodenal
mucosa. OI was diagnosed only in the stomach in 5 patients, just in the duodenum in 3
patients, and in both, stomach and duodenum, in 2 cases. Group 2: No GI OI was detected.
Although GI OI were detected only in Group 1, difference between groups was not significant
(p=0.07947). Conclusion: GI OI were shown in immunodepressed HIV-infected patients
under HAART in low numbers. Despite GI OI have been detected only in dyspeptic patients,
they could not be related to these symptoms, since numbers did not reach significance. To
correct diagnose GI OI, multiple biopsy specimens may be necessary, even from normal
appearance mucosa.
W1070
Correlation Between Electrogastrography (EGG) and Gastric Dysmotility,
Duodenal Dysmotility in Patients with Functional Dyspepsia
Weihong Sha, Nonko D Pehlivanov, P Jay Pasricha, Jiande Chen
Abnormalities in gastric slow waves and motility are frequently reported in patients with
functional dyspepsia. However, simultaneous assessment of the slow wave and motility
abnormalities has rarely been done. The aim of this study is to assess gastric slow waves
and antroduodenal motility simultaneous and determine the correlation among all measures
in patients with functional dyspepsia. Methods: 31 patients (8M, 23F, mean age 48.7,
Range (23-79) with functional dyspepsia were assessed for severity of upper gastrointestinal
symptoms, the electrogastrogram (EGG) and antroduodenal manometry. The EGG and
manometry was recorded for 3-4 hours in the fasting state and for two hours after a solid
meal. Computerized spectral analysis methods were utilized to compute the following EGG
parameters in the fasting and fed state. Dominant frequency, Dominant power and % of 2-
4 cycles/min slow waves. Common gastrointestinal symptoms of nausea, vomiting, upper
abdominal pain, bloating, early satiety and etc were assessed for symptom severity and
graded. Results: 1) The EGG was abnormal in 71.0% of patients. The abnormalities included
normal slow waves lower than 70% in fasting state (51.6% of patients) and in fed state
(48.4% of patients), a decrease in dominant power in 28.9% of patients. 2) Antral motility
was abnormal in 83.9% of patients and duodenal motility was abnormal in 74.2% of patients.
There was a significant correlation between these two abnormalities. 3) For the EGG and
antral motility, 19 of 31 patients had both abnormal EGG and abnormal antral motility; 2
of 31 patients had both normal EGG and normal antral motility. For the EGG and duodenal
motility, these values were 16/31 and 2/31 respectively. 4) The patients showed high symptom
scores particularly to upper abdominal pain, nausea and belch, with an average symptom
score of 2.5/4 for pain; 2.5/4 for nausea and 2.3/4 for belch, respectively. The mean total
score was 22/52 for all symptoms. 5) No significant correlation was noted between the
symptom scores and any of the EGG or motility parameters. Conclusions: More than 2
thirds of patients with functional dyspepsia have abnormalities in the EGG and antral
T : 89386$$CH2
05-04-06 23:18:31 Page 628Layout: 89386B : e
A-628AGA Abstracts
duodenal motility. The sensitivity of these two different methods is essentially the same.
Abnormalities in gastric motility and duodenal motility are correlated whereas the symptoms
are not correlated with any of the EGG or motility parameters.
W1071
The Effect of Helicobacter Pylori Eradication On Gastroesophageal Reflux,
Gastrointestinal Symptoms and Quality of Life in Patients with Functional
Dyspepsia
Irfan Soykan, Mehmet Bektas, Murat Toruner, Hulya Cetinkaya, Ali Ozden
Introduction: Although it has been postulated that reduced acid secretion related to Helicob-
acter pylori (H pylori) corpus gastritis might protect patients from gastroesophageal reflux
disease (GERD), the pathogenesis and possible relationship between H pylori and GERD
remains controversial. Aims & Methods: The aims of this study were to investigate the effect
of H pylori eradication on gastroesophageal reflux, gastrointestinal symptoms and quality of
life in patients with functional dyspepsia (FD). 20 H pylori positive patients (15 women,
mean age:44, range: 24-66 years) diagnosed as having FD according to Rome-II criteria
were enrolled into the study. H pylori status was evaluated by endoscopy before the study
and at least 4 months after the completion of the eradication therapy. In each patient 3
antral and 3 corpus biopsies were obtained and biopsy specimens were subjected to H pylori
culture, histologic examination and rapid urease testing. Esophageal motility testing and pH
recordings were obtained from each patient before and at the end of the study period. Each
patient’s gastrointestinal (GI) symptoms were recorded and graded according to Glasgow
dyspepsia score. 36-Item short-form health survey (SF-36) and EDQ5 health survey were
obtained form each patient in order to identify quality of life before and at least 4 months
after eradication therapy. Results: Helicobacter pylori eradication was accomplished in 13
patients (65%). Gastrointestinal symptoms improved in H pylori eradicated patients (10.3
vs 7.5, p<0.05) compared to baseline. Fasting lower esophageal sphincter pressures increased
(21.6 vs 24.4 mmHg) after H pylori eradication. Neither the amplitude of peristaltic contrac-
tions in the esophageal body (59.4 vs 57.7 mmHg) nor the velocity of peristaltic contractions
changed before and after eradication. The percent time of esophageal pH <4 (0.7 vs 2.6,
p<0.001), reflux events longer than 5 mins (0 vs 0.7, p<0.005) and total reflux number
(10.3 vs 19.3, p<0.005) significantly increased after eradication therapy. H pylori eradication
did not influence quality of life in patients with functional dyspepsia. Conclusion: Majority
of the patients experienced a significant change in esophageal acid exposure after H pylori
eradication. Development of GERD post H pylori eradication likely reflects an increase in the
acidity of the refluxate. H pylori eradication significantly decreases gastrointestinal symptoms,
however has no effect on quality of life in patients with functional dyspepsia.
W1072
Incident Dyspepsia in the Treatment of Peptic Ulcer Disease: A Meta-Analysis
Comparing H. Pylori (HP) Eradication Versus Proton Pump Inhibitor (PPI)
Therapy
Brennan M. Spiegel, Jennifer Tan, Brian Lim, Mary Farid, Inder Singh, Martijn G. van
Oijen
Background: Although guidelines recommend HP “test-and-treat” (T&T) for uninvestigated
dyspepsia, it remains uncertain whether T&T is preferable to empiric PPI therapy. Whereas
PPIs are modestly effective in functional dyspepsia and highly effective in GERD, T&T is
largely ineffective in these common etiologies of dyspepsia. T&T therefore rests on the
assumption that HP eradication is superior to PPI in symptomatic peptic ulcer disease
(PUD) - the remaining major etiology of dyspepsia. Yet it is unclear whether there is a
difference in dyspeptic symptoms (in contrast to ulcer healing) following T&T vs PPI in
PUD, and the answer to this question has cost-effectiveness implications when selecting
between strategies (Spiegel et al Gastro 2002). We performed a meta-analysis to compare
the incidence of dyspeptic symptoms in patients with PUD treated with HP eradication vs
PPI. Methods: We conducted a structured search of MEDLINE to identify English-language
clinical trials of HP eradication or PPI in PUD that provided data about incident foregut
dyspeptic symptoms, including “epigastric pain,” “acid reflux,” “nausea,” and “dyspepsia.”
Independent reviewers performed title and abstract selections using a priori criteria, and
subsequently abstracted data from each selected manuscript. We then calculated the sample
size-weighted pooled proportion of patients with incident dyspeptic symptoms in the HP
eradication and PPI arms of the included studies, and performed meta-analysis of head-to-
head comparisons. We calculated stratified weighted means to adjust for PPI dose and HP
eradication rates. Results: We identified 1497 titles, of which 122 (representing 260 arms)
were selected for final review. The weighted incidence of dyspepsia was 18.2% (95% CI=
13.7%, 23.2%) in the 148 PPI arms, and 22.8% (95% CI=19.4%, 26.2%) in the 112 HP
eradication arms (p<0.001 for difference). Meta-analysis of 5 head-to-head trials revealed a
higher incidence of dyspepsia with HP eradication vs PPI (RR=2.4; CI=1.6, 3.8), with a
“number needed to harm” of 10 (absolute risk increase=10%; CI=5%, 14%). There was less
dyspepsia with high vs low-dose PPI (p<0.001), and with high (>70%) vs low HP eradication
rates (p<0.001). Conclusions: The incidence of dyspeptic symptoms is higher in PUD
patients receiving HP eradication vs PPI therapy, and this difference is both statistically
significant (p<0.001) and clinically relevant (effect size=1.4 SD). Since previous data indicate
that T&T is inferior to PPI in functional dyspepsia and GERD, these data in PUD further
the argument that empiric PPI might be preferable to T&T in uninvestigated dyspepsia.
(this independent research is unfunded)
W1073
Acid and Weakly Acidic Reflux in 80 Patients with Unexplained Chronic
Cough: An Update
Kathleen Blondeau, Lieven Dupont, Jan Tack, Jozef Janssens, Daniel Sifrim
Acid gastroesophageal reflux has been recognized as a possible cause of chronic cough. We
have demonstrated that not only acid but also weakly acidic reflux can be temporally
associated with episodes of cough. We aimed to further characterize the relationship between
cough and both acid and weakly acidic reflux in our expanded series of 80 patients with
unexplained cough. Methods: Patients with chronic unexplained cough were studied with
ambulatory manometric-impedance-phmetry (Sandhill Sci). Out of these 63 [24 men, median
age 55 (22-77)] were studied “off” PPI and 17 were studied “on” PPI [5 men, median age
56 (39-73)]. Esophago-gastric manometry was used for precise recognition of cough, which
was defined as a rapid pressure increase occurring simultaneously in all channels. Reflux
was independently assessed with impedance-pH monitoring and defined as acid (pH < 4),
weakly acidic (pH 4-6.5) and weakly alkaline (impedance drops with pH >6.5). Cough was
considered “induced by” reflux, if it started in a 2 min period after a reflux event. A Symptom
Association Probability (SAP) was calculated for each type of reflux in every patient and
considered positive if > 95%. Results: In patients studied “off” PPI, a total number of 1970
cough bursts [25, (5-111)]/pat and 2782 reflux events [42, (7-89)]/pat were analyzed. Reflux
events were classified as acid (n=1637) [22(2-70)]/pat, weakly acidic (n=914) [13(1-44)]/
pat and weakly alkaline (n=285) [1(0-22)]/pat. Twenty-three patients had an increased
esophageal acid exposure. From the total number of cough, 250 (13%) were considered
“induced by” reflux (131 acid, 106 weakly acidic and 13 weakly alkaline). The per-individual
analysis showed a SAP+ for acid reflux in 7 patients, weakly acidic reflux in 13 patients
and for both acid and weakly acidic reflux in 3 patients. In patients studied “on” PPI, a
total number of 444 cough bursts [18(5-145)]/pat and 494 reflux episodes [36(7-68)]/pat
were recorded. Thirty-three reflux episodes involved acid reflux [1(1-18)]/pat, 317 weakly
acidic [22(0-46)]pat and 134 weakly alkaline [3(0-26)]/pat. All patients had a normal
esophageal acid exposure. In this group, 68 cough events (15.3%) were considered to be
“induced by” a reflux episode (3 acid, 46 weakly acidic and 11 weakly alkaline). The per-
individual analysis showed 5 patients with SAP+ for weakly acidic reflux. In total 21/80
patients had a SAP+ for weakly acidic reflux. Conclusion: A significant temporal relationship
between cough and weakly acidic reflux was found in 26% of the patients with chronic
unexplained cough. In those patients endoscopic or surgical anti-reflux procedures might
be considered.
W1074
Acid and Non-Acid Reflux After Lung Transplantation. Impedance-pH
Monitoring in Patients with and Without Post-Transplant Chronic Rejection
Kathleen Blondeau, Lieven Dupont, Jan Tack, Jozef Janssens, Daniel Sifrim
Pulmonary dysfunction due to Bronchiolitis Obliterans Syndrome (BOS) predisposes to a
poor long term survival after lung transplantation (Ltx). It has been suggested that acid
gastroesophageal reflux (GER) contributes to development of chronic rejection or BOS and
preventive antireflux surgery has been proposed. The role of less acidic reflux in the pathogen-
esis of BOS is unknown. Aim: to determine, in a cross-sectional study, the prevalence of
acid and non-acid reflux in a cohort of lung transplant recipients by means of combined
esophageal 24-hr impedance-pH testing. Methods: 54 patients [27 men,age 56 (19-75)]
underwent 24h impedance-pH recording (Sandill Sci) 3 years (1-9) after Ltx. Reflux episodes
were identified by impedance and characterized by pH as acid (pH < 4) and non-acid
(pH>4). Three different stages of BOS were defined: BOS”0”: normal pulmonary function
(n=25); BOS“p”: (FEV1 90% of baseline)(n=14) and BOS”1” :(FEV1 ≤ 80% of baseline)(n=
15). All patients were studied “on” weak acid suppression (omeprazole 20mg or ranitidine
300mg) and most patients with BOS”p” and BOS”1” were “on” azithromycin to improve
lung function. Azithromycin is a macrolide antibiotic with effect on gastrointestinal motility.
Results: The esophageal acid exposure was normal and similar in the 3 groups. Only 2
subjects (1 with BOS”0” and 1 with BOS”1”) had increased esophageal acid exposure. There
was no significant difference in the mean number of total, acid or nonacid reflux events
between patients with or without BOS. There was no correlation between FEV1 at the time
of impedance-pH testing and the esophageal acid exposure or the number of reflux events.
When examined separately, patients without adequate acid suppression (gastric pH < 4
more than 50%) (n=21), those with BOS”p” and BOS”1” showed a trend to decreased acid
reflux and bolus exposure. Conclusion: Our cohort of patients did not have increased acid
or non-acid reflux after lung transplantation. Unlike previous reports, our patients with BOS
had either similar or less reflux than those without BOS, perhaps due to an antireflux effect
of the macrolide antibiotic azythromycin (under current investigation).
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W1075
Baseline Analysis of Symptom Spectrum in GERD Clinical Trial Patients:
Results from the Request™ Database
Ronnie Fass, Vincenzo Stanghellini, Hubert Monnikes, Karna Dev Bardhan, Peter
Berghofer, Peter Sander, David Armstrong
PURPOSE: GERD patients suffer from a broad range of symptoms, not only heartburn and
acid eructation. Many of them often are not considered to be associated with the disease.
The validated reflux questionnaire ReQuest™ is a dimension-orientated tool assessing the
spectrum of GERD symptoms and general well-being. Here, we analyzed baseline data of
these dimensions (condensing 65 symptom descriptions) as collected from GERD clinical
trials that used ReQuest™. METHODS: The ReQuest™ database covers 12 erosive esophag-
itis (EE) as well as 2 non-erosive reflux disease (NERD) clinical trials. Baseline data of 6,810
per-protocol patients were analyzed without reference to subsequent treatment. Analyses of
the symptom spectrum were done using the ReQuest™ dimensions of acid complaints,
upper abdominal/stomach complaints, lower abdominal/digestive complaints, nausea, sleep
disturbances, and other (extraesophageal, atypical) complaints. Subdivided into EE and
NERD, mean scores of these ReQuest™ dimensions representing patients’ symptom burden
were calculated as weighted product of frequency x intensity. In addition, general well-
being was assessed and the percentage of patients reporting complaints was calculated for
each ReQuest™ dimension. RESULTS: 5,846 patients suffered from EE and 964 from
NERD. The percentage of patients experiencing complaints as well as their mean symptom
score was comparable in EE and NERD for each ReQuest™ symptom dimension. The
mean scores for general well-being were similar in both groups (EE: 2.1 vs. NERD: 1.9).
CONCLUSIONS: GERD is associated with other GI dysfunction since upper and lower
abdominal symptoms are also very common. Thus, the distinction between GERD and
functional disease may not be as clear as previously thought. EE and NERD have comparable
symptom and well-being profiles at baseline. ‘Acid complaints’ is not the only symptom
dimension associated with GERD. GERD therapeutic trials should evaluate the broad spec-
trum of GI symptoms and determine the extent to which these symptoms/dimensions respond
to treatment. The present analysis further reveals that NERD patients do not have more IBS-
like/functional symptoms than those with EE, suggesting that these patients have also
true GERD.
W1076
Distinct Pathophysiological Mechanisms and Clinical Characteristics of Non-
Erosive Reflux Disease (NERD) and GERD Related Noncardiac Chest Pain
(GCP)
Justin Wu, Carrian Cheung, Vincent Wong, Joseph Sung
BACKGROUND: GERD is a common cause of noncardiac chest pain. However, it is unclear
why many GCP patients do not have reflux symptoms despite abnormal esophageal pH
study and symptomatic response to acid suppressant. AIM: To compare the clinical character-
istics and esophageal functions of patients with GCP and non-erosive reflux disease (NERD).
METHODS: We prospectively recruited consecutive patients with NERD (defined as weekly
attacks of heartburn or acid regurgitation with symptom response to proton pump inhibitor
(PPI)) and GCP (defined as weekly attacks of noncardiac chest pain with absence of reflux
symptom but complete response to PPI). All patients completed a self-administered standard
questionnaire to evaluate symptom, underwent EGD to exclude erosive esophagitis, and
received esophageal function tests. The tests included stationary esophageal manometry
(EM), acid-perfusion and edrophonium provocation test, 2-hour postprandial EM and pH-
metry after a standard 400 kcal test meal; and ambulatory 24-hour pH metry. RESULTS:
48 NERD and 36 GCP patients were studied. Both groups were comparable in age (NERD
Vs GCP: 42.3+/-8.6 Vs 44.1+/-10.4, p=0.17), gender (male subjects, NERD Vs GCP: 22 Vs
15, p=0.7) and 24-hour esophageal acid exposure (Mean DeMeester score, NERD Vs GCP:
8.4+/-9.7 Vs 7.8+/-8.6, p=0.42). NERD patients had significantly higher prevalence of func-
tional dyspepsia (FD) and irritable bowel syndrome (IBS) than GCP patients (FD: 69% Vs
22%, p<0.001; IBS: 44% Vs 11%, p=0.001). For EM, GCP patients had higher prevalence

















sphincter (LES: pressure < 10 mmHg), whereas NERD patients had higher prevalence of
positive acid perfusion test. For 2-hour postprandial study, NERD patients had significantly
more transient LES relaxation (TLESR) with and without acidic reflux, whereas zero pressure
related acidic reflux predominated in GCP patients (Table). CONCLUSION: Despite similar
esophageal acid exposure and response to PPI, GCP and NERD have different pathophysiolog-
ical mechanisms and represent two distinct entities of GERD. The lower prevalence of
positive acid perfusion test and concomitant FD and IBS in GCP patients suggest that visceral
hypersensitivity plays a less important role in the pathogenesis of GCP as compared to NERD.
W1077
Increased Prevalence of Functional Dyspepsia and IBS in Proven GERD Has a
Negative Effect On Health-Related Quality of Life
D.R. de Vries, Margot van Herwaarden, Andre Smout, Melvin Samsom
Background: Previous studies reported overlap between GER symptoms, functional dyspepsia
(FD) and irritable bowel syndrome (IBS). To date this has not been shown among patients
with proven GERD. Furthermore, the effect of this overlap on the health-related quality of
life (HRQoL) has not been investigated. Aim: determine the prevalence of FD and IBS in
GERD patients and the impact of both on HRQoL. Method: GERD was diagnosed using
24-hour esophageal pH recording (total time pH<4≥6% and/or positive SAP) in 263 patients
(161 male; mean age 50.6; 48 patients recruited by advertisement, 215 referred because of
GERD). The patients completed a questionnaire which assessed the symptoms of FD and
IBS according to Rome II. The SF-36 was used to measure HRQoL in patients and 131 age-
and sex-matched healthy volunteers. Median scale scores were compared using Kruskall-
Wallis H and subsequently Mann-Whitney U tests. Results: FD criteria were met by 66
GERD patients (25%, prevalence in Dutch general population 13-14%). IBS criteria were
met by 93 patients (35%, prevalence in Dutch general population 2-6%). Thirteen GERD
patients had both FD and IBS (5%). When the group of referred patients was compared to
the group of patients recruited with an advertisement, FD and IBS prevalence were found
to be higher in the referred group (FD: 26% vs 21%; IBS: 39% vs 21%; FD and IBS: 5%
vs 4%). When GERD patients had no concomitant FD or IBS, they scored lower HRQoL
than healthy subjects on one scale only: physical functioning (P=0.001). GERD patients
with FD scored lower than healthy volunteers on the physical and social functioning scales,
the physical role limits scale, and the vitality and pain scales (all P≤0.001). GERD patients
with IBS scored lower than healthy volunteers on all these subscales and moreover on
emotional role limits and mental health (all P<0.001). GERD patients with both FD and
IBS scored lower on the same scales with the exception of mental health (all P≤0.001).
Patients with only GERD were compared to GERD patients who also had FD and/or IBS.
GERD+FD patients scored lower on physical and social functioning, pain, vitality and general
health experience (all P≤0.001). GERD+IBS patients scored lower on all scales (all P<0.001).
GERD+FD+IBS patients scored lower on physical functioning, emotional and physical role
limits, pain, vitality and general health experience (all P≤0.001). Conclusion: Compared
to the general population FD and IBS are more prevalent in patients with proven GERD.
In GERD patients who seek hospital care this prevalence is even higher. HRQoL is strikingly
lowered in GERD patients who have concomitant FD or/and IBS.
W1078
Symptom Type On PPI Bid Therapy Does Not Predict Reflux Identified By
Multichannel Intraluminal Impedance-pH
Inder Mainie, Radu Tutuian, Amine Hila, Amit Agrawal, Janice Freeman, Donald O.
Castell
Background: Combined Multichannel Intraluminal Impedance (MII) detects gastroesophageal
reflux (GER) at multiple levels of the esophagus independent of pH and is used in the
evaluation of patients with refactory symptoms despite PPI bid therapy. Aim: To clarify if
the type of symptom is a predictor of the type of reflux. Method: All patients with persistent
symptoms despite proton pump inhibitor (PPI) therapy referred to the esophageal laboratory
underwent combined MII-pH monitoring. Prior to the study, patients and/or the referring
physician were contacted to ensure that the patient had been on at least twice daily PPI for
at least a month or more prior to testing. The 2.1mm catheter monitors changes in intraluminal
impedance at 3, 5, 7, 9, 15 and 17cm above the LES with pH was at 5cm above and 10cm
below the LES. A positive SI (+SI) was declared if ≥ 50% (i.e. at least half of the symptoms
were associated with reflux). Typical GERD symptoms were heartburn, regurgitation or chest
pain. Atypical symptoms were cough, hoarseness, abdominal discomfort, nausea, dysphagia,
throat clearing, mucous, globus, belch, catarrh, hiccup and wheeze. Results: From a total
of 166 patients (Female: 119; mean age 52; range 16 to 85 years), 145 patients with
symptoms during test day. 265 GERD symptoms in total were recorded; typical (n=155)
and atypical (n=110). See graph below. Conclusion: MII-pH shows presence and type of
reflux related to persistent symptoms on PPI therapy. Individual symptoms, do not predict
whether the results will be positive or negative. Almost two-thirds of patients with regurgita-
tion have a positive study; however one-third of these patients did not show a temporal
relationship with reflux.
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Laryngo-Pharyngeal Reflux (LPR) and GERD: A Systematic Review and Meta-
Analysis of Medical and Surgical Therapies
Luigi Gatta, Nimish Vakil, Sara Zucchini, John Osborn, Giovanni Sorrenti, Dino Vaira
Aim: To evaluate the effectiveness of medical or surgical treatment for GERD in adult patients
with unexplained symptoms, and/or laryngoscopic signs of LPR. Methods: Data Sources:
Studies were identified by searching MEDLINE (1966-September 2005), EMBASE (1980-
September 2005), Cochrane Controlled Trials Register, and abstracts for the following
gastroenterological and ENT meetings: DDW (1975-2005), UEGW (1992-2005), AAO-
HNS meeting (1995-2005); Study Selection: RCTs (parallel group and crossover designs)
comparing GERD medical or surgical treatments with placebo;Data Extraction: Studies were
screened for inclusion by 2 authors who independently extracted the data;Data synthesis:
For the purpose of the primary analyses, we used the criteria for defining a “responder”
chosen by the authors of each paper, as these differed slightly across studies. The relative
risks of responding to therapy were pooled using a random-effects model, heterogeneity
was assessed using chi-square test, and publication bias using the Egger regression asymmetry
test. The analysis of treatment effect was performed on an intent to treat basis basis, and
the number needed to treat was calculated using the reciprocal of the pooled absolute risk
reduction. Results: Of the 113 paper retrieved, 6 studies (evaluating a total of 268 patients)
that used proton pump inhibitors (PPIs) as intervention met the inclusion criteria and were
included in the analysis. There were no controlled trials with surgical treatment as the
intervention. Two studies had relief of cough as the primary object whilst the remaining
four had resolution/improvement of laryngeal symptoms and/or signs as the principal end-
point. The pooled relative risk of responding to therapy was 1.20 (95%CI: 0.82 to 1.76;
Heterogeneity chi-squared = 4.36 [d.f. = 5], p = 0.49), and the NNT was 28 (95%CI: NNTH
7.4 to infinity to NNTB 14.5). All studies but one were small and there was evidence of
publication bias as the funnel plot showed statistically significant asymmetry (coefficient
1.66; 95%CI=0.38 to 2.94; p=0.023). Sensitivity analysis was performed evaluating Jadad
score, study design (parallel vs cross-over), type of symptoms assessed, type of PPI used,
duration of treatment,and it did not produce any significant change in the pooled RR.
Conclusions: PPIs were no more effective than placebo in resolving symptoms and/or signs
of LPR. Large and well-designed studies are needed in order to better define the population
of patients with LPR who respond to acid suppressive therapy.
W1080
Numerous Episodes of Atypical GERD Symptoms Are Unlikely to Be
Associated with Acid Or Non-Acid Reflux
Inder Mainie, Radu Tutuian, Amine Hila, Amit Agrawal, Donald O. Castell
Background: Combined Multichannel Intraluminal Impedance (MII) detects non-acid reflux
(NAR) and acid reflux at multiple levels of the esophagus. Aim: To detect whether the
frequency of typical or atypical GERD symptoms is associated with acid or non-acid reflux.
Methods:. All patients with persistent symptoms despite proton pump inhibitor (PPI) therapy
referred to the esophageal laboratory underwent combined MII-pH monitoring. Prior to the
study, patients and/or the referring physician were contacted to ensure that the patient had
been on at least twice daily PPI for at least a month or more prior to testing. Upon completion
of manometry a 2.1 mm MII-pH cathteter was passed transnasally with intraluminal imped-
ance sensors at 3, 5, 7, 9, 15 and 17cm above the LES and pH electrodes at 5cm above
and 10cm below the LES. A positive SI (+SI) was identified if ≥ 50% of symptoms were
associated with reflux. Typical GERD symptoms were heartburn, regurgitation or chest
pain. Atypical symptoms were cough, hoarseness, abdominal discomfort, nausea, dysphagia,
mucous, globus, wheeze and throat clearing. Results: One hundred patients (Female 67;
mean age 46; range 8 months to 84 years) with persistent GERD symptoms referred to our
laboratory underwent 24-hour combined MII-pH monitoring while taking at least twice
daily PPIs. Eighty-two patients recorded symptoms during the study. The graphs evaluate
the primary symptom. Conclusion: Patients with atypical GERD symptoms are more likely
to have numerous symptoms which are usually not associated with reflux.
W1081
In Children with Aspiration Syndrome the Lipid-Laden Macrophage Index Is
Strongly Correlated with Non-Acid Esophageal Reflux Type
Osvaldo Borrelli, Fabio Midulla, Letizia Cordischi, Valeria Tromba, Lelia Lo Russo, Felicia
Galos, Corrado Moretti, Salvatore Cucchiara
Background and aims. In children microaspiration of gastric contents has been suggested
as a trigger of lung disease, including acute and recurrent pneumonia, bronchiectasis,
interstitial disease, asthma and near-miss sudden infant death syndrome. The lipid-laden
macrophage index (LLMI) in the bronchoalveolar lavage (BAL) fluid, is thought to be a
sensitive marker for pulmonary microaspiration; however, its correlation with esophageal
acid reflux (AR), as measured by 24-hr pH-monitoring, remains controversial. Due to the
availability of multichannel intraluminal impedance and pH monitoring (MII-pH) in detecting
both acid (AR) and non-acid reflux (NAR) into the esophagus, we whished to measure
prospectively in children with suspected aspiration by esophageal reflux the LLMI and to
correlate it with all reflux types, as detected by MII-pH. Patients and Methods. 11 consecutive
children (median age 1 year; range 6 months-8 yr) underwent flexible fiberoptic bronchos-
copy and BAL, as well as 24-hour MII-pH. LLMI was determined by evaluating the amount
of lipid per single macrophage, assigning each cell a score from 0 to 4 according to the
amount of lipid in the cytoplasm. The number of cells graded 0-4 was calculated for each
patient, and the final LLMI was determined by evaluating 100 cells. In infants the pH sensor
was placed 2 cm above the lower esophageal sphincter (LES) with impedance sensors at 2,
3.5, 5, 6.5, 8 and 9.5 cm above the LES. In children (2-6 yrs) the pH sensor was placed
3 cm above the LES with impedance at 3, 5, 7, 9, 11 and 13 cm above the LES. The MII-
pH parameters evaluated were: total numbers of reflux episodes (TN), numbers of AR,
numbers of NAR, % of time with esophageal pH < 4 (ARI), numbers of long-lasting (> 5
min) acid reflux episodes (LAR). Results. (means±SD) In all children the studies were
successfully performed. LLMI was 60.73±38.53. The MII-pH of TN, AR, NAR, ARI and LAR
were 76.55±41.78, 41.27±21.97, 35.27±33.39, 6.92±5.77 and 2.9±2.25 respectively. A
significant correlation was found only between LLMI and TN (r: 0.70; p<0.05), as well as
between LLMI and NAR (r: 0.72, p<0.01), whereas no correlation was found between LLMI
and AR, ARI and LAR. Conclusion: In children with aspiration syndrome by esophageal
reflux, the LLMI is markedly correlated with gastroesophageal reflux of non acid type. The
latter may have a major role in causing pulmonary disease from aspiration of gastric content
refluxing into the esophagus. Our result account for the well known poor correlation between
acid reflux and LLMI and recommend the MII pH as principal tool when investigating
infants with suspected aspiration syndrome by esophageal reflux.
W1082
Gastroesophageal Reflux During Obstructive Sleep Apnea
Mari Urata, Hiroshi Fukuno, Masahiro Nomura, Tatsuro Ogata, Katuyoshi Tamaki,
Susumu Ito, Kimiko Nakayasu, Yutaka Nakaya
Purpose: Patients with obstructive sleep apnea syndrome (OSAS) are frequently complicated
by gastroesophageal reflux disease (GERD), because of the decreased pressure of pleural
cavity during sleep apnea. However, detailed relationship between OSAS and GERD have
been unclear. In the present study, gastric motility and autonomic nervous activity during
sleep apnea were studied. Method: Twenty subjects with OSAS who showed 10 times/hr
or more frequent sleep apnea events using a portable sleep polygraph were studied. Obese
individuals with a body mass index exceeding 25.0 and those with lordosis were excluded.
Percutaneous EGG was performed using an electrogastrograph (Nipro EG), and fast Fourier
transformation analysis was performed. The mean amplitude of EGG was compared by EGG
spectral analysis among brady-gastria (<2.4 cpm), normo-gastria (2.4-3.6 cpm), and tachy-
gastria (>3.6 cpm). Spectral analysis of heart rate variability was performed, and low frequency
(LF) power (0.04-0.15 Hz), high frequency (HF) power (0.15-0.40 Hz), and the LF/HF
ratio were measured. Upper gastrofiberscopy was performed in each subject, and presence
of GERD was diagnosed according to Los Angeles grade classification. Results: Normo-gastria
was significantly decreased, and brady- and/or tachy-gasatria were increased during sleep
apnea (p<0.01). Thirteen subjects (65.0%) were diagnosed as GERD, but there was no
significant relation between Los Angeles grade classification of GERD and severity of OSAS.
However, LF/HF ratio during sleep apnea was significantly increased than during non-sleep
apnea, which was opposite to the GERD without OSAS Decreased percutaneous arterial
oxygen saturation and normo-gastria were independent risk factors in severity of GERD.
Conclusions: The present study suggested that abnormal gastric motility, low oxygen, and
increased sympathetic nervous activity during sleep apnea might be related to the develop-
ment of GERD in addition to the decreased pressure of pleural cavity.
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Small Intestinal Bacterial Overgrowth (SIBO) in Patients with Non-Erosive
Reflux Esophagitis (NERD)
Alessia Cazzato, Emidio Scarpellini, Maurizio Gabrielli, Luca Santarelli, Ernesto Cristiano
Lauritano, Andrea Lupascu, Lucia Sparano, Giovanni Cammarota, Giovan Battista
Gasbarrini, Antonio Gasbarrini
Background and Aim: Up to 70% of patients with typical symptoms of gastro-esophageal
reflux disease are affected by non-erosive esophagitis reflux disease (NERD). Possible patho-
physiological causes of functional heartburn include non-acid reflux (liquid, gas, mixed),
minute changes in the esophageal acidity above a pH of 4, motility disorders such as sustained
contractions of the longitudinal musculature, visceral hypersensitivity, and emotional and
psychological abnormalities, but no definitive data are available. Moreover, overlap of reflux
symptoms and irritable bowel syndrome (IBS) has been widely investigated. SIBO, a clinical
condition characterized by abnormally high bacterial population level in the small intestine,
exceeding 106 organisms/mL, associated with the chronic presence of symptoms such pain,
bloating, diarrhoea and/or signs of malabsorption, shows a strong epidemiological association
with IBS. Aim of this study is to investigate the possible pathophysiological contribution of
SIBO in NERD symptoms development. Patients and Methods: Thirty consecutive patients
with NERD were enrolled. NERD diagnosis was based on the concordance between a
symptomatologic pattern suggestive of reflux disease, evaluated using the reflux disease
questionnaire (RDQ), and the absence of oesophagel mucosal breaks at upper endoscopic
examination. Besides, 40 healthy volunteers were used as control group. All subjects enrolled
underwent glucose breath test (GBT) to detect SIBO under standard conditions. The presence
of SIBO was based on the occurrence of a peak of H2 values more than 12 ppm above the
basal value after 50 gr glucose ingestion. NERD patients with positive GBT were treated
with 1-week course of rifaximin (1200 mg/day); GBT test was reassessed 1 month after the
end of the therapy. Results: SIBO prevalence resulted higher in NERD patients (19/30;
63.33%) when compared to control subjects (2/35; 5.71%); the difference between groups
was statistically significant (p<0.05). One month after the end of the eradication treatment
73.68% (14/19) of NERD-SIBO positive patients, showed a negative GBT; complete heartburn
relief was significantly higher in the eradicated group (9/14; 64.24%) compared to non
eradicated patients (1/6; 16.66%) (p=0.05). Conclusion: In this study NERD patients show
an higher prevalence of SIBO compared to healthy subjects. Eradication of SIBO seems
reducing the occurrence of heartburn in NERD patients. The overlap of SIBO and NERD
could be associated to a commom dismotility pathogenic mechanism. However, whether
this is a causal or casual association has to be investigated.
W1084
Nocturnal Reflux Is Not Predominant in Children and Adolescents with
Persistent Asthma and Gastroesophageal Reflux
Lucas Dalle Molle, Helena A. Goldani, Simone F. Canani, Vera G. Vieira, Sergio G. Barros,
Themis R. Silveira
Introduction: The gastroesophageal reflux (GER) causal role in asthma is not well established.
Some studies have shown a higher frequency of nocturnal (supine) GER in patients with
respiratory symptoms. This study in children and adolescents with persistent asthma aimed
to evaluate prevalence of GER (supine and upright) by prolonged intraesophageal pH study
and compare to GER symptoms and spirometry in children with and without GER. Patients
and Methods: Thirty-eight patients were studied. All had diagnosis of asthma (NIH guidelines,
1991) and were chronically using medications for asthma control such as inhalated corticos-
teroids or leukotriene antagonists. Gastrointestinal symptoms suggestive of GER were consid-
ered as regurgitation, heartburn, and abdominal pain. Prolonged intraesophageal pH study
(Digitrapper MKIII, Synetics, Sweden) and spirometry (Jaeger Flow Pro, Erich Jaeger GmbH,
Germany) were obtained in all patients. GER was considered positive when reflux index
(RI) was higher than 5%. Pulmonary function was evaluated by measuring FVC (forced
vital capacity), FEV1 (forced expiratory volume in 1st second of FVC) and FEF 25-75%
(midexpiratory flow rate). Results: Median (range) age was 10 (5-15) years and 23 (59%)
patients were male and 16 female. GER prevalence was 47.3%. The patients were divided
in 2 groups: asthma and GER (group 1, n=18); asthma without GER (group 2, n=20).
Median (range) of reflux index during supine and upright periods from group 1 were 8.7%
(3.2 - 23.6) and 10.5% (5.2 - 15.0), without significant difference (p=0.913) There was no
significant difference of symptoms frequency between groups 1 and 2 (p=0.48). Nine patients
(50%) from group 1 did not have any symptom of GER. Regarding spirometry results, only
FEF 25-75% was <80% of expected value (66.8% and 56.8% in groups 1 and 2 respectively,
without significant difference, p=0.34). There was no significant correlation between RI and
FVC (r:-0.17, p=0.28); RI and FEV1 (r: -0.17, p=0.29) and RI and FEF 25-75% (r:-0.10,
p=0.54). Conclusion: A high prevalence of GER in children and adolescents with persistent
asthma was found, without a predominance of nocturnal or upright GER. There was no
significant correlation between results of pH study and spirometry.
W1085
Prevalence of Gastroesophageal Reflux Symptoms in Adults with Cystic
Fibrosis
Arash A. Sabati, Robert R. Kempainen, Carlos E. Milla, Marjorie Ireland, Malcolm N.
Blumenthal, Sarah J. Schwarzenberg, Jordan M. Dunitz, Khalid M. Khan
OBJECTIVE: To evaluate the frequency of gastroesophageal reflux (GER) symptoms in adults
with Cystic Fibrosis (CF), identify any risk factors and impact on severity of pulmonary
disease. BACKGROUND: Several studies have reported increased frequency of GER in CF.
The reported prevalence of symptoms in adults and children with CF has varied between
25 - 81%. METHODS: We performed a cross-sectional survey of adult CF patients at the
University of Minnesota from outpatient pulmonology clinic using two validated survey
instruments, the Mayo and Gastroesophageal reflux Symptom Assessment Scale (GSAS)

















actively followed at our center were invited to participate in the study. 31 declined participa-
tion and of the 243 who received survey materials 204 (84%) were returned. Incomplete
surveys (n=3,1.5%) were excluded from analysis leaving 201 completed surveys. The most
common symptoms over the last year were heartburn (n=106,53%), acid regurgitation (n=
67,33%) and dysphagia (n=36,18%) with 63% (n=127) reporting at least one of these
symptoms. Gastric acid suppression was common with 122 (61%) taking medications over
the past 12 months. Sub-group analysis showed females to report worse mean GSAS symptom
(4.93 vs. 4.05,p=0.025) and GSAS distress scores (5.63 vs. 3.75,p=0.005) compared to
males. Patients who reported weight loss over the last year (n=51) had worse mean GSAS
symptom scores (5.29 vs.4.24,p=0.041), worse mean GSAS distress scores (6.75 vs. 3.99,p=
0.012), lower mean FEV1 (62% vs. 71%,p=0.045) and lower mean FVC (82% vs. 91%,p=
0.019). Dividing patients into subgroups based on FEV1 (>90%, 70-89%, 40-69% and
<40%) yielded no significant differences in GSAS scores or report of heartburn or acid
regurgitation between the groups. Patients with the worst GSAS symptom scores (top quartile,
GSAS symptom ≥7,n=49) had significantly better FEV1 (79.4% vs. 65.7,p=0.014) than
those reporting fewer symptoms. Similarly patients with the worst GSAS distress scores (top
quartile, GSAS distress ≥7,n=48) also had a better mean FEV1 (77.4 vs. 66.2,p=0.033)
than those with fewer symptoms. CONCLUSIONS: Over the past year 63% of patients
reported at least one major GER symptom, the most common being heartburn (53%). The
relationship between severity of GER symptoms and severity of lung disease remains unclear.
We cannot comment on the relationship between GER symptoms and the rate of decline
in lung function. Females and patients reporting weight loss also report more symptoms.
This finding requires further investigation because of the increased mortality in these
patient groups.
W1086
A Realistic Mechanical Simulation of the Human Swallow in a 3D Virtual
Model
Rita Yassi, Leo K. Cheng, Vijay Rajagopal, Martyn P. Nash, John A. Windsor, Andrew J.
Pullan
Introduction The understanding of the role of the gastro-esophageal junction (GEJ) in normal
swallowing and GERD has been limited by the inability to integrate anatomy and physiology
into a unified model. The aim of this study is to reproduce a realistic propagation of a
normal peristaltic wave using an anatomically-based model of the human esophagus and
GEJ. Method An initial 3D computer model of the human esophagus has been constructed
based on [1,2]. The outer and inner diameters of the model defined to be 18 mm and 10
mm respectively (wall thickness 4 mm), and the length was set to 220 mm. The model
consisted of 60 nodes, 480 total degrees of freedom, and the tissue was assumed to be
homogenous, isotropic and incompressible. A peristaltic wave was simulated by applying a
realistic range of pressures (60-140 mmHg; see [3]) to the inner surface of the model at
different locations along the esophagus. The outer and inner wall displacements and the
change in esophageal length were calculated at 5 locations in the model, during the propaga-
tion of a peristaltic wave, by solving the laws of mechanics that govern finite deformation
elasticity and results were compared to experimental recordings [1,4]. Results The outer
and inner wall circumferences during maximum distention were 64 ± 3 mm, and 43 ± 5
mm respectively (experimental; outer 84 mm, inner 70 mm). The mean circumferences of
the outer and inner walls during maximum contraction were 49 ± 2 mm and 19 ± 5 mm
respectively (experimental; outer 49 mm, inner 15 mm). The length of the esophageal
model was reduced by 6.2% (experimental; 7%). Conclusions The initial model successfully
represented a qualitatively realistic swallow. Future model developments will include the
addition of different muscle layers. It is envisaged that the model will help provide a better
understanding of the mechanical behavior of the regions during swallowing. This work is
supported by a Royal Society of New Zealand Marsden Grant and by NIH grant (RO1
DK64775). A. J. Pullan is supported by James Cook Research Fellowship, which is gratefully
acknowledged. 1. Gregersen, Biomechanics of the gastrointestinal tract: New perspectives
in motility research and diagnostics, UK: Springer-Verlag London Ltd., 2003. 2. Meyer,
Austin, Brady, Castell, “Muscle Anatomy of the Human Esophagus”, J Clin Gastroenterol,
8(2) 1986. 3. Tytgat, Gastro-Oesophageal Reflux and Gastric Stasis: Pathophysiology, Dia-
gnosis, and Therapy, UK: Adis International Ltd., 1991. 4. Edmundowciz, Clouse,
“Shortening of the esophagus in response to swallowing”, Am J Physiol 260 (Gastrointest
Liver Physiol 23), 1991.
W1087
Upper Esophageal Sphincter Dysfunction: An Alternative Explanation for
Symptoms and Signs Attributed to Laryyngopharyngeal Reflux
David A. Knuff, Reza Shaker, Walter J. Hogan, Benson T. Massey
BACKGROUND: Supraesophageal symptoms are increasingly being ascribed to laryngophary-
geal reflux (LPR), based on laryngoscopic exam. Many patients diagnosed with LPR fail to
respond to treatment, suggesting acid reflux is not the cause and that an alternative diagnosis
should be sought. We hypothesized that some patients may have upper esophageal sphincter
(UES) dysfunction accounting for symptoms attributed to refractory LPR. METHODS: The
motility lab database was reviewed to identify patients with abnormal UES manometry
(Dentsleeve), referred for further evaluation following a prior diagnosis of LPR. All diagnoses
of LPR were made by otolaryngologists, based on patient symptoms and laryngoscopic
findings. Charts of these patients were reviewed and the following clinical findings and test
results recorded: 1) presenting symptoms 2) typical heartburn symptoms 3) esophagram 4)
ambulatory pH monitoring 5) swallow study 6) EGD 7) esophageal body manometry 8)
cricopharyngeal (CP) electromyography (EMG)/laryngeal nerve conduction (NCV) 9) CP
pathology 10) treatment and response. RESULTS: We identified 16 patients (age 41-77 yr,
13 F) with UES dysfunction (absent, incomplete, and/or short-duration deglutitive relaxation)
and a prior diagnosis of LPR. They presented with the following cervical symptoms: globus
9, hoarseness 6, throat clearing 6, chronic cough 5, and/or dysphagia 4. Eleven had no or
rare heartburn and another 5 patients responded to treatment. However, cervical symptoms
in all patients failed to respond to PPI therapy. While esophagram in 4 of 14 patients
suggested gastroesophageal reflux, the esophagus on EGD (performed in 9) was completely
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normal, and ambulatory pH monitoring in 10 patients (6 with 3-site probe and 4 with 2-
site probe) showed normal acid exposure. Swallow study was done in 12 patients and 5
suggested abnormal pharyngeal transit while 7 were read as normal. Esophageal body
manometry in 9 of 15 patients was normal. The remainder had nutcracker, nonspecific
motor disorder, hypertensive lower sphincter, and/or tight wrap. CP EMG/laryngeal NCV
was done in 8 patients and 5 suggested neuropathy, 2 myopathy, and 1 borderline laryngeal
sensory abnormality. In one patient CP pathology showed neurogenic myopathy. Four of
8 patients responded at least temporarily to one of several treatments directed towards UES
dysfunction (swallowing exercises, dilation, botulinum toxin, CP myotomy). CONCLU-
SIONS: Patients with supraesophageal symptoms and a laryngoscopic diagnosis of LPR, who
do not respond to PPI, may have UES dysfunction. Such patients should have appropriate
manometric evaluation before pursuing invasive anti-reflux therapy.
W1088
Prevalence and the Degree of GERD Symptoms in Japanese General
Population
Hatsushi Yamagishi, Shuichi Ohara, Tomoyuki Koike, Ken Ariizumi, Yoshifumi Inomata,
Katsunori Iijima, Akira Imatani, Tooru Shimosegawa, Shigemitsu Aida, Ktsuaki Kato,
Daisuke Shibuya
Background and Aim: Gastroesophageal reflux disease (GERD) is a common disease in the
West, which now appears to be increasing in the prevalence in Japan. However, few studies
have reported the prevalence of GERD in Japanese general population. The aim of this study
was to examine the prevalence of GERD symptoms in more than 100,000 unselected subjects
in Japan. Subjects and Methods: A total of 145,367 Japanese (male: female, 52,694: 92,672,
mean age 61.9) who underwent a group check-up on the stomach at the Miyagi cancer society
between January and December 2003 were enrolled in this study. An X-ray examination was
performed on all the enrolled subjects as well. Also, among these subjects ,we randomly
selected a total of 67,246(male : female, 26,173 : 41,073 , mean age 62.4)for evaluating
the prevalence of abdominal pain. The respective subjects were prospectively asked to
complete the questionnaires concerning the symptoms of heartburn, dysphagia, and abdom-
inal pain within one month. The subjects were requested to simply answer “ yes” or “ no”
and if “ yes”, they were further questioned the frequency of symptoms (“ usually” or “
sometimes”). In addition, we evaluated a disease classification by X-ray examination. The
values are expressed as frequency, and categorical variables were compared using theχ2
test. P-values<0.05 were considered significant. Results: The prevalences of the respective
symptoms in male and female were; 16.6%(sometimes 16.1%, usually 0.5%) vs. 21.6%(some-
times 21.0%, usually0.6%)in heartburn, 5.4%(sometimes 5.0%, usually0.4%) vs.
7.9%(sometimes 7.4%, usually 0.5%)in dysphagia, and 6.6%(sometimes 6.5%, usually
0.1%)vs. 9.7%(sometimes 9.6%, usually 0.1%)in abdominal pain, respectively. All symptoms
were significantly more common in female than in male. (p=0.001) Among these symptoms,
heartburn was particularly high comparing to other symptoms (p=0.001), and its prevalence
showed a significant age and gender related difference in the patients aged 60-89 years, that
is a significant increase in the prevalence with age in females, while a decrease over 60 years
old in males. Heartburn was relatively frequent in male with age 30-49 years and in female
with age 50-89 years. Dysphagia was also significantly more frequently seen in female, and
abdominal pain was significantly more prevalent in younger age group of 30-49 years than
the elderly. GERD symptoms were more common in the subjects with hiatal hernia than
those without it. Conclusions: The prevalence of GERD symptoms (heartburn) was high,
approximately 20%, in Japanese general population, and the frequency was especially high
in female with age 60-89 years old.
W1089
Premature Central Apnea and Its Relationship with Gastroesophageal Reflux
Edgardo Suarez, Ivonne Cedillo-Ley, Nuria Perez y Lopez, Jesus Alejandro Insunza,
Cinthia Hernandez, Moises Gerardo del Hoyo, Armando Tello, Eduardo Cardenas-Lailson
INTRODUCTION The gastroesophageal reflux and the apnea frequently occur in the prema-
ture newborns. The refluxed gastric content may reach the larynx and cause central apnea
as well as airway obstruction; nevertheless, the previous studies have not been able to
establish a cause-effect relationship. The aim of this study is to establish if there is a cause-
effect relationship between gastroesophageal reflux and prematurity; to evaluate if the severity
of reflux is associated to earlier birth. MATERIAL AND METHODS This is a retrospective,
observational, comparative and longitudinal study. 32 files from premature and full term
newborns from the intensive care unit at the Hospital Español de México were evaluated.
They were diagnosed with central or mixed apnea. Every patient underwent polisomnography
to determine the type of apnea and pHmetry for the diagnosis of GERD. Genders, gestational
age, extrauterine days of life and weight were registered. RESULTS 17 (53%) were males
and 15 (47%) were females. Twenty three were premature (72%). Polisomnography showed
central apnea in 59% and pHmetry showed pathological reflux in 32%. Premature newborns
have 8 times more risk of having central apnea (Odds ratio 9.92, confidence interval 95%-
1.27-97.1, x2 Mantel-Haenszel=6.49, p=0-008). Patients with central apnea had lower weight
(2002.89 gr) than the patients with out apnea (mean 2757.23 gr). T-Student -3.176 with
30 degrees of freedom, p=0.003. We did not find any relationship between gestational age
and reflux severity (p=0.670). We found that newborns with reflux had twice the risk of
developing central apnea by odds ratio, but the confidence interval was too wide as to affirm
this. CONCLUSSION The premature and low weight newborns have higher risk of developing
central apnea. Immaturity may favor gastroesophageal reflux and the physiological reflux
may give rise to it. We only measured acid reflux with the 24 hour pHmetry, but the non-
acid reflux could also unchain the problem.
W1090
The Effect of Gastroesophageal Reflux (GER) On Upper Airway Obstruction
in Patients with Mild Obstructive Sleep Apnea (OSA)
William C. Orr, Jennifer J. Robert, John R. Houck, Cheryl Giddens
Obesity is a risk factor for both OSA and GER, and heartburn is a common symptom noted
in patients with OSA. Heartburn has been shown to be more common in patients with more
severe OSA. It has been speculated that GER may alter the upper airway in a way which
would facilitate the occurrence of OSA. In this investigation we have tested the hypothesis
that significant acid suppression and reduction of GER would significantly reduce the rate
of OSA in patients with mild OSA. METHODS: Prospective subjects were recruited from
the community at large, as well as from our database of patients. All subjects underwent a
sleep evaluation as well as a 24-hour esophageal pH evaluation. To qualify subjects had to
have an apnea hypopnea index (AHI) of 15 or less, and esophageal acid contact time in the
supine position of greater than 6% total or 3% supine. Qualifying subjects underwent 8
weeks of treatment with 20mg bid of rabeprazole. The Epworth Sleepiness Scale was com-
pleted before and after treatment. At the end of 8 weeks all subjects repeated the sleep and
24-hour esophageal pH evaluations. RESULTS: Subjects had significantly (p<.05) less reflux
events in both upright and supine positions and significantly less (p<.05) % acid contact
time after the 8-week treatment compared to baseline. Subjects also had significantly shorter
events after the 8-week treatment compared to baseline. Sleep onset latency and REM onset
latency were significantly (p<.05) shorter after the 8-week treatment period compared to
baseline. There was no difference in the apnea hypopnea index at baseline compared to the
8-week rabeprazole treatment. Subjects reported significantly (p=.02) more daytime sleepi-
ness at baseline (12) compared to the post-treatment condition (10). CONCLUSIONS: 1.
Rabeprazole improved heartburn symptoms and subjective reports of daytime sleepiness in
patients with mild OSA. 2. Significant acid suppression and reduction of GER did not
significantly reduce the rate of OSA in patients with mild OSA.
W1091
Discriminating Non-Cardiac Chest Pain from Chest Pain with Positive
Coronary Angiography: The Utility of Reflux Symptoms
Guy D. Eslick, Nicholas J. Talley
BACKGROUND: Non-cardiac chest pain (NCCP) is common and costly; discriminating this
non-lethal entity from cardiac chest pain (CCP) in practice remains a major clinical issue.
NCCP is most commonly caused by gastroesophageal reflux disease (GERD); whether reflux
symptoms help to distinguish NCCP from cardiac pain is unknown. We aimed to determine
the characteristics and predictors of a positive angiographic study among patients being
investigated for chest pain. METHODS: A consecutive sample of 176 chest pain patients
(cardiac and non-cardiac) aged 18 years and over who underwent coronary angiography at
Nepean Hospital were enrolled in the study. A detailed history and physical examination
were included in these initial procedures. Coronary artery disease was judged ‘significant’
at coronary angiography if there is at least a 70 percent diameter stenosis of one or more
major epicardial coronary segments or at least a 50 percent diameter stenosis of the left
main coronary artery. All patients completed the valid Chest Pain Questionnaire (CPQ).
RESULTS: The sample consisted of 117 males and 59 females. The mean age was 63 years
(SD=10 years, range: 37-86 years). There were 44 (25%) CP patients who had a positive
coronary angiogram result. Univariately, the following variables were associated with a
positive coronary angiogram amongst CP patients: advancing age (OR=1.04, 95% CI: 1.01-
1.09); male gender (OR=0.35, 95% CI: 0.15-0.80); worse chest pain on cough (OR=0.06,
95% CI: 0.01-0.44); less frequent acid regurgitation (OR=0.59, 95% CI: 0.35-0.98); less
frequent dysphagia (OR=0.66, 95% CI: 0.44-0.99). In multiple logistic regression models
independent predictors of a positive coronary angiogram amongst the patients were: increased
chest pain severity (OR=2.61, 95% CI: 1.16-5.85); shorter chest pain duration (OR=0.63,
95% CI: 0.43-0.93); worse chest pain on cough (OR=0.06, 95% CI: 0.01-0.48); and less
severe heartburn (OR=0.22, 95% CI: 0.06-0.71). The model explained 10% of the variance
(R 2=0.10). CONCLUSIONS: Chest pain patients with a positive coronary angiogram are
more likely to have severe chest pain and have chest pain of shorter duration. These patients
are less likely to have severe heartburn suggesting reflux symptoms do have some limited
predictive value in identifying NCCP in this population.
W1092
Prevalence, Risk and Recurrence Risk of Esophageal Stricture in the United
States
Kenneth J. Rothman, Charles E. Wentworth, Mari-Ann Wallander, Saga Johansson, Stefan
Eklund
Little is known about prevalence or risk of esophageal stricture, or risk for recurrence. Using
the Pharmetrics database, a large US health claims data source with over 7 million records,
we identified nearly 40,000 patients who had an initial claim for repair of an esophageal
stricture (procedure codes 43450 - dilate esophagus unguided, 43453 - dilate esophagus
guidewire, 43455 - dilate esophagus, 43456 - dilate esophagus balloon/dilator, 43458 -
dilate esophagus w/large balloon, 43330 - repair esophagus (Heller type), 43331 - repair
of esophagus). From these numbers we estimated the prevalence of serious esophageal
stricture and the risk for a first stricture serious enough to warrant repair, by age and sex.
Among the approximately 10,000 patients who had a new claim for stricture repair and no
history of esophageal cancer, and for whom there was prior enrollment data for at least one
year, we estimated the risk of a recurrent stricture using life-table methods. The prevalence
of esophageal stricture was slightly greater among males at all ages, and increased steadily
by age, reaching about 3/1000 among those 60-79 years of age; the 1-yr risk of stricture
among those with no stricture history was about 1/2000 for both men and women age 60-
79, and less for younger ages (table). The risk of recurrence was approximately 11% during
the two years following the initial claim. Because the estimates of prevalence, risk and
recurrence presented here are based on claims data, they are less reliable than estimates
that could be derived from study populations in which the diagnoses have been validated.
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On the other hand, in the absence of such validated information, estimates such as these
from claims data can provide a reasonable first assessment for basic epidemiologic measures.
By restricting cases to those with a procedure code for stricture repair, we increased the
specificity of our disease classification and thus focused on more serious strictures. Sensitivity
and specificity are far from perfect when using claims databases to define disease prevalence
and risk, but no classification is perfect, and the estimates obtained here are a useful start
toward describing the epidemiology of esophageal stricture.
Prevalence and Risk of Stricture
W1093
Prevalence of GERD and Its Effect On Quality of Life in a Large Cohort of
Patient with Obstructive Sleep Apnea
Bryan Green, Michael Thorn, John F. Oconnor
Purpose: Determine the prevalence of GERD and its effect on quality of life in a large cohort
of patients with obstructive sleep apnea. Methods: Consecutive patients presenting for
nocturnal polysomnography completed self-administered GERD questionnaires and SF-36.
Results: 168 patients were analyzed. Daytime and nighttime reflux symptoms were experi-
enced an average of 1.8 days (26%) and 1.6 nights (23%) respectively during the previous
week. Daytime and nighttime reflux severity was moderate or severe in 24% and 31%
respectively during the previous week. Obstructive sleep apnea patients had a much lower
quality of life score in all subscales of the SF-36 (except mental health) than the U.S. general
population. Concomitant moderate or severe nighttime reflux further worsened the quality
of life. Conclusion: Reflux symptoms are common and frequently severe in patients with
obstructive sleep apnea. Quality of life is severely impaired in obstructive sleep apnea and
coexistent moderate/severe nighttime reflux is associated with an even worse quality of life.
This study was supported by AstraZeneca.
Quality of life as measured by the SF-36 in patients with no or mild nocturnal GERD (0-
1 on scale) compared to patients with moderate to severe nocturnal GERD (2-5 on scale).
A lower score indicates worse quality of life. U.S. population normal values for Physical and
Mental Component Scores = 50.
Quality of life as measured by the SF-36 in patients with obstructive sleep apnea compared
to normal values for the U.S. population.


















Esophageal Strictures in Primary Care: Incidence, Treatment Patterns and
Recurrence Rate
Ana Ruigomez, Luis A. Garcia Rodriguez, Mari-Ann Wallander, Saga Johansson, Stefan
Eklund
Background and Purpose: Epidemiological data on esophageal strictures are scarce. Our
study aimed to determine the incidence of esophageal strictures, and to establish its natural
history in newly diagnosed primary care patients. Methods: A population-based, case-control
study was conducted using the UK General Practice Research Database (GPRD). To determine
the incidence rate of esophageal strictures, we identified patients aged 20-79 years who had
an esophageal stricture diagnosis during the study period (1994-2000); diagnoses were
confirmed by a physician-completed questionnaire. We used unconditional logistic regression
analysis to compute odds ratios (OR) and 95% confidence intervals (CI). Cox proportional
hazards regression was used to estimate the mortality rate and risk of recurrence of strictures
between first diagnosis and December 2001. Results: From the GPRD, we identified 596
patients with a first diagnosis of an esophageal stricture. The overall incidence rate of
esophageal strictures was 1.1 per 10000 person-years and increased with age to 3.5 per
10000 person-years in the 60-79 year age group. Dysphagia was present in 83% of cases
and was the strongest predictor of an esophageal stricture. Most cases of stricture (68%)
were peptic strictures linked to gastroesophageal reflux disease (GERD) or esophagitis; peptic
strictures had an incidence rate of 0.8 per 10000 person-years. As well as GERD (OR: 8.4;
95% CI: 6.2-11.2), peptic ulcer disease and prior alcohol use were also associated with an
increased risk of an esophageal stricture. Proton pump inhibitors (PPIs) and H2-receptor
antagonists were prescribed in 64% and 6% of patients, respectively, after an esophageal
stricture diagnosis. More than half of esophageal stricture patients had at least one esophageal
dilatation, and patients needing more than two dilatations in the year after diagnosis had
an increased likelihood of a further stricture recurrence. The recurrence rate after one year
among patients with peptic strictures was 6.1 per 100 person-years. The risk of esophageal
stricture recurrence decreased among long-term users of PPIs (RR: 0.6; 95% CI: 0.3-1.3).
The mortality rate in patients with peptic strictures was similar to that in the general
population. Conclusion. Esophageal strictures are rare, and most cases found in primary
care were peptic strictures. Our data suggest that long-term PPI treatment could protect
against recurrence of esophageal stricture.
W1095
Characteristics of Acid and Weakly Acidic Reflux Temporally Related to
Cough
Kathleen Blondeau, Veerle Mertens, Lieven Dupont, Jan Tack, Richard H. Holloway,
Daniel Sifrim
Both acid and weakly acidic reflux can be temporally related to episodes of cough. In patients
with heartburn, lower nadir pH and increased proximal extent of reflux are determinants
of symptom perception. In patients with cough, such determinants remain unclear. Aim:
To identify reflux characteristics underlying the reflux-cough association. Methods: 49
patients [24 M, age 55 yr] with chronic unexplained cough, with at least 1 symptomatic
reflux event during ambulatory impedance-pH-manometry monitoring (Sandhill Sci.) were
selected for analysis. Manometry was used for precise and objective cough recognition.
Reflux was detected by impedance and defined by pH as acid (pH < 4) or weakly acidic
(pH 4-6.5). Reflux episodes were considered symptomatic if cough occurred in a 2-min
time window starting at the onset of the reflux event. Asymptomatic reflux episodes that
occurred from 1h before to 1h after a symptomatic episode served as controls. We compared
“symptomatic” vs. “asymptomatic” reflux events in 3 subsequent steps: 1) Determination of
the number of reflux related cough episodes occurring during esophageal acid (pHmetry)
and/or volume exposure (impedance) during the 24hs 2) Comparison of acid and volume
burden, defined as total area over the curve of acid and volume exposure during 120min
before each reflux episode. 3) Comparison of characteristics of individual reflux events:
nadir pH, acid clearance, volume clearance, and proximal extent. Results: 250 symptomatic
reflux episodes (131 acid, 119 weakly acidic) were detected. Only 6.8% of reflux-associated
cough episodes occurred during esophageal acid exposure, 6.4% during volume exposure
and 9.6% during both. The majority (76.8%) of reflux related cough events occurred
when esophageal acid or volume was already cleared. The volume burden was similar for
symptomatic (28000) and asymptomatic episodes (33000) whereas the acid burden was
lower for symptomatic episodes (506 vs. 2800, p=0.07). Acid clearance (30.05s vs. 31.01s),
volume clearance (37.1s vs. 27.9s) and proximal extent (9.3cm vs. 9.4cm) did not differ
significantly in symptomatic events and controls. However, the nadir pH was significantly
higher (pH 4.4 vs. pH 3.4, p=0.007) in the symptomatic events. Thirty-five percent of the
symptomatic events occurred during the first postprandial hour. Conclusion: Unlike in
patients with heartburn, reflux episodes preceding cough were less acidic and probably had
similar volume than asymptomatic reflux events. Cough within 2 min after reflux occurred
outside the period of acid or volume exposure suggesting either a slow triggering mechanism
or a non-acidic component.
W1096
Pepsin, a Marker of Gastric Content Is Increased in Tracheal Aspirates from
Premature Infants Developing Bronchopulmonary Dysplasia
Sabeena Farhath, Zubair H. Aghai, Judy Saslow, Tarek Nakhla, Zhaoping He, Dev Mehta
Background: Gastroesophageal reflux (GER) is very common in premature neonates. Chronic
aspiration of gastric contents is likely to be important in the pathophysiology of bronchopul-
monary dysplasia (BPD). Detection of pepsin in tracheal aspirate (TA) is a new reliable
marker of gastric content and micro-aspiration. Objective: To study the association between
pepsin in TA and development of BPD in premature infants. Design/Methods: Serial TA
samples were collected during the first 28 days from 45 mechanically ventilated premature
neonates (gestational age <30 weeks, birth weight <1250 grams). BPD was defined as oxygen
requirement at 36 weeks postconception age (PCA). Moderate BPD was defined as < 30%
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oxygen requirement and severe BPD as > 30 % oxygen requirement at 36 weeks PCA. An
enzymatic assay with a fluorescent substrate was used to detect pepsin. Pepsin was also
measured in 10 serum samples from 8 neonates collected at the same time of TA collection.
Results: Eleven infants had no BPD (gestational age 26.4± 1.4 weeks, birth weight 927±185
grams), 23 infants developed BPD (GA 25.4±1.6 W, BW 696±107 G) and 11 infants died
before 36 weeks PCA (GA 24.7±1.1 W, BW 737±146 G).A total of 227 TA samples were
collected from 45 premature neonates (birth weight 762±166 grams, gestational age 25.5±1.5
weeks). Thirty seven samples were collected from infants with no BPD (average 3.3 samples
per infant), 140 from infants who developed BPD (average 6 samples) and 50 samples from
infants who died (average 4.5). Pepsin was detectable in 205/227(90.3%) of TA samples
and none from the serum samples. Mean pepsin level was significantly lower in infants with
no BPD (222±243 ng/ml) compared to those who developed BPD (364±320 ng/ml, P=0.014)
or died (429±502 ng/ml, P=0.03). Moreover, there was a trend towards higher pepsin levels
in infants with severe BPD (404±433 ng/ml) compared to moderate BPD (305±283 ng/ml,
P=0.07) Conclusions: Pepsin, a marker of gastric content was detectable in TA from all
premature ventilated neonates and none from serum samples. The level of pepsin is increased
in TA from premature infants developing BPD. Chronic aspiration of gastric contents is
likely to be important in the pathophysiology of BPD.
W1097
The Esophagus and Beyond: Nondigestive Symptoms in Nonerosive Reflux
Disease: Nature, Prevalence and Relation to Acid Reflux
Hershcovici Tiberiu, Zimmerman Joseph
Background: Some half of the patients with nonerosive gastroesophageal reflux disease
(NERD) meet the criteria for irritable bowel syndrome (IBS) (1). Since nondigestive symptoms
are common in IBS, it is expected that NERD patients should also experience such symptoms.
The aim of the present study was to test this hypothesis. Methods: All patients referred for
esophageal pH monitoring during 1977-2004 were included in this study. Nondigestive
symptoms and IBS status (according to the Rome I criteria) were assessed in patients
diagnosed with NERD (esophageal pH <4 for ≥5% of the time on 24-h pH monitoring and
normal upper endoscopy; n=326) in relation to non-patient controls (n=174). Symptoms
were scored using a validated, self-administered inventory including the following scales:
musculoskeletal pain, urinary, sleep and neurasthenia (NA) (2). Reflux symptoms were
scored on a validated scale (3). Results: The mean age was 43 and 41 in NERD and controls.
The male/female ratio was similar in both groups (1:1.6), as was the proportion of smokers
(17%). NERD patients scored significantly higher than controls on all scales (p<0.001). After
adjustment for age, gender and smoking the scores on the scales of pain, sleep and NA
were significantly associated with NERD. ROC curve analysis yielded cutoff scores on these
scales that were highly specific (89, 91 and 89% respectively) in the discrimination of NERD
patients from controls.Within the group of NERD patients, nondigestive symptoms were
independently associated with age, reflux symptoms score and IBS status (p<0.001), but
not with gender, smoking or acid exposure. The score on the reflux scale correlated with
the scores on all the nondigestive scales (r=0.36, 0.32, 0.38 and 0.19 for NA, pain, sleep
and urinary symptoms; p<0.001, adjusted for age, gender and smoking). 49% of the NERD
patients and 18% of the controls were classified as IBS nonpatients (IBS(+)NERD)
(p<0.001).IBS(+)NERD patients scored significantly higher than those not meeting the IBS
criteria (IBS(-)NERD) on all the nondigestive scales (p<0.001). Nevertheless, IBS(-)NERD
patients did score significantly higher than controls on all these scales (p≤0.005). Conclu-
sions: In NERD patients, nondigestive symptoms were:1:scored significantly higher with
respect to controls, and were highly specific in the differentiation between these two groups.
2: correlated with the reflux symptoms score, but not with esophageal acid exposure.3.
predicted by IBS status, being more severe in the IBS(+)NERD patients. References: 1.
Aliment Pharmacol Ther 2004; 20:1297-1303; 2: Dig Dis Sci, 2003; 48:743-749 3: Scand
J Gastroenterol, 2004; 39:212-216.
W1098
Relationship Between Laryngopharyngeal Reflux and Symptoms and Signs
Won Moon, Moo In Park, Gyung Mi Kim, Jeong Hoon Seo, Yoon Jung Kim, Ji Hun Roh,
Dae Gwan Im, Kyu Jong Kim, Seun Ja Park, Hyo Sung Mun, Kang Dae Lee
Background/Aim:Laryngopharyngeal reflux is of great interest to gastroenterologists. How-
ever, its correlation with symptoms and signs is yet incompletely understood, especially in
the Asians. This investigation was done to evaluate the relationship between reflux severity
and symptoms and signs in Koreans. Methods:Twenty-nine, nonsmoking patients with one
or more laryngeal symptoms of unknown cause, who completed a symptoms questionnaire,
videostrobolaryngoscopy, esophagoscopy, 24-hour pharyngeal pH testing and esophageal
manometry were identified retrospectively. Components of symptoms index, scored as 0-5
at every item were the following: problem with voice, cleaning throat, excess throat mucus,
difficulty swallowing, coughing after eating or lying down, breathing difficulties, troublesome
cough, lump in throat, stomach acid coming up. Components of reflux finding, scored as
0-4 were the following: subglottic edema, ventricular obliteration, erythema, vocal cord
edema, diffuse laryngeal edema, posterior commissure hypertrophy, granuloma, thick endola-
ryngeal mucus. Twelve patients (reflux group, RG) had one or more reflux episode, defined
as positive reflux at 24-hour pharyngeal pH testing and remainders were 17 (non-reflux
group, NRG). Results:Between RG and NRG, there was no difference in mean age (44 vs.
52) and sex (male:female, 5:7 vs. 3:14). The most predominant symptom with the highest
mean score (2.4 vs. 2.7) was a problem with voice in each group. There was no difference
in total scores (10 vs. 12) of symptoms questionnaire and mean duration (17 months vs.
30 months) of symptoms. Posterior commissure hypertrophy, the most predominant sign
in each group was worse in RG compared to NRG (2.3 vs. 1.6, p=0.027), but no difference
in total scores (3.6 vs. 3.1) of signs. There was no difference in the rate of reflux esophagitis
(50% vs. 31%) on esophagoscopy, basal pressures of upper and lower esophageal sphincters
(PUES, 68 mmHg vs. 73 mmHg and PLES, 31 mmHg vs. 35 mmHg) and rate of normal
peristalsis on 24-hour esophageal manometry. In RG, the mean number and percent time
per 24 hours of pharyngeal acid reflux with pharyngeal pH<4 were 12 and 2% respectively.
None of symptoms and signs did not correlate with reflux severity. However, the time
percent correlated significantly with duration of symptoms (coefficient=0.509, p=0.032) and
negatively with PLES (coefficient=-0.547, p=0.022) Conclusion:Laryngeal symptoms, signs
and findings of esophagoscopy and esophageal manometry did not seem to predict pharyngeal
reflux. However, PLES might be related with severity of pharyngeal reflux in Korean patients.
Keywords:laryngopharyngeal reflux, pH testing
W1099
Pepsin Is Detectable in Tracheal Aspirates from Premature Neonates:
Relatioship with Feeding and Steroid Therapy
Sabeena Farhath, Zubair H. Aghai, Zhaoping He, Tarek Nakhla, Judy Saslow, Dev Mehta
Introduction Gastroesophageal reflux (GER) is very common in premature neonates. Aspira-
tion of gastric contents due to GER can worsen lung disease in ventilated neonates. Aspiration
of gastric contents has been shown in infants with bronchopulmonary dysplasia (BPD).
Detection of pepsin in tracheal aspirate (TA) is a new reliable marker of gastric content and
micro-aspiration. Objective To determine the frequency with which pepsin is detectable in
TA of mechanically ventilated premature neonates and its association with feedings and
steroid therapy. Material and Methods Serial TA samples (days 1,3,5,7,14,21 and 28) were
collected from premature neonates on ventilator for respiratory distress syndrome. Samples
were also collected before and 72 hours after starting steroids. An enzymatic assay with a
fluorescent substrate was used to detect pepsin. Pepsin was also measured in 10 serum
samples from 8 neonates collected at the same time of TA collection. Results A total of 227
TA samples were collected from 45 premature neonates (birth weight 762±166 grams,
gestational age25.5±1.5 weeks). Pepsin was detectable in 205/227(90.3%) of TA samples
and none of the serum samples. Median pepsin level of all aspirates was 248 ng/ml (range
0-2102). Pepsin was significantly lower on day 1 (mean ±SD, 149±174 ng/ml) compared
to all other time points (days 3,5,7,14,21 and 28, all P<0.01). There was no significant
difference in pepsin level amongst other time points. Mean concentration of pepsin was
significantly lower when infants were unfed (273±278 ng/ml) compared to during feeding
(392±398 ng/ml, P=0.007). 18 infants received 20 courses of steroids. The mean level of
pepsin significantly increased after dexamethasone therapy (584±485 ng/ml) compared to
before steroids (228±221 ng/ml, P=0.006). Conclusion Pepsin, a marker of gastric content
is detectable in TA from all premature ventilated neonates. The levels are increased in fed
compared to unfed infants. Steroid therapy increased pepsin in TA. Chronic aspiration of
gastric contents is likely to be important in the pathophysiology of BPD in premature infants.
W1100
A Sham-Controlled Study of the Influence of Radiofrequency Delivery (The
Stretta Procedure) On Symptoms, Acid Exposure and Distensibility of the
Gastro-Oesophageal Junction in Gord Patients
Joris Arts, Philippe Caenepeel, Rita Devos, Lieselot Holvoet, Daniel Sifrim, Toni Lerut,
Paul Rutgeerts, Jozef Janssens, Jan Tack
Several studies, including one sham-controlled study, have reported symptom relief in gastro-
oesophageal reflux disease (GORD) patients treated with radiofrequency delivery (Stretta
procedure) at the gastro-oesophageal junction (GOJ). The mechanism underlying this
improvement is unclear as changes in pH monitoring are often inconsistent. Recently, it
was proposed that decreased distensibility of the GOJ is involved in the symptomatic
improvement observed after the Stretta procedure (Arts DDW 2005). The aim of the present
study was to investigate the effect of Stretta on symptoms, acid exposure and GOJ distensibility
in a double-blind randomised cross-over design. Methods: Consecutive GORD patients
underwent two upper gastrointestinal endoscopies with 3 months interval, during which
active or sham Stretta treatment was performed in a randomised double-blind fashion. The
endoscopic procedure was performed by a team which was otherwise not involved in the
follow-up of these patients. Before the start of the study and 3 months after the first
treatment, they underwent symptom assessment, endoscopy, manometry, 24h esophageal
pH monitoring and a barostat distensibility test of the GOJ before and after administration
of 25 mg of sildenafil. Symptom scores, acid exposure, lower esophageal sphincter (LES)
pressure and GOJ compliance data (mean±SEM) were compared using Student’s t test.
Results: 22 GORD patients (17 females, mean age 47±12) participated in the study; 11
received Stretta first and 11 sham first. Three months after initial sham treatment, symptom
score (16.8±2.6 vs. 17.7±2.3, NS), acid exposure (9.0±1.3 vs. 7.5±1.8 % time, NS), LES
pressure (15±2 vs. 13±1 mmHg, NS) and GOJ compliance (14.1±4.5 vs. 12.8±3.0 ml/
mmHg, NS) were not significantly altered. Three months after initial Stretta procedure, no
changes were observed in esophageal acid exposure (16.3±4.8 vs. 16.5±2.7% time, NS) and
LES pressure (11.9±1.1 vs. 13.0±2.2 mmHg, NS). In contrast, symptom score was signific-
antly improved (12.6±1.1 vs. 7.5±1.8, p<0.05) and GOJ compliance was significantly
decreased (15.8±2.5 vs. 8.3±2.5 ml/mm Hg, p<0.05). After administration of sildenafil, an
esophageal smooth muscle relaxant, GOJ compliance after Stretta was normalised to pre-
Stretta level (13.2±1.4 vs. 13.2±2.8 ml/mmHg, NS), which rules out GOJ fibrosis as an
underlying mechanism. Conclusion: In this sham-controlled study, Stretta was associated
with improvement of GERD symptoms, decreased GOJ compliance and unchanged acid
exposure or LES pressure. Decreased GOJ compliance, which reflects altered LES neuromus-
cular function, may contribute to symptomatic benefit by decreasing refluxate volume.
W1101
Predictive Factors of Long-Term Outcome After Antireflux Surgery (ARS): A
Community Practice Experience
Ronan Thibault, Sylvie Sacher-Huvelin, Veronique Sebille, Stanislas Bruley des Varannes,
Jean-Paul Galmiche
Background: Data about predictive factors of clinical outcome after ARS are scarce. Most
studies were performed in tertiary referral centers. Quality of life (QOL) is considered as
the main end-point for ARS assessment. We aimed to determine the factors predicting
outcome after ARS in GERD patients managed in community practice. We choose QOL as
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the primary end-point for long-term assessment. Methods: We selected all consecutive
patients referred to our laboratory between the 1st January 1995 and 31 December 2002
for 24-hour pH monitoring before ARS. Patients were referred by 33 surgeons, most working
in district hospitals or private surgical centers. Patients were included only if there was clear
evidence that acid reflux was responsible for symptoms, i.e. symptom index (SI)≥50% and
symptom-association probability (SAP)≥95%. Esophageal acid exposure (EAE) could be
normal or abnormal (≥4.2%). We included 121 patients (49 women, mean age 47±13 yr,
61 with erosive disease and 60 with non-erosive GERD). The laparoscopic approach was
chosen in 96% and Nissen procedure in 85%. After ARS, QOL was measured with the
French validated GERD-specific questionnaire, REFLUX-QUAL. QOL was considered good
or excellent when REFLUX-QUAL global score was above 80. After univariate statistical
analysis, variables independently associated with a score >80 were determined by a stepwise
logistic regression. Results: After an average 43±19 month follow-up, 58% of patients reported
a good or excellent post-operative QOL. Male gender (72% with score >80 vs 28% with
score≤80, P<0.001), abnormal EAE (62% vs 38%,P=0.02), preoperative regurgitation (54%
vs 46%,P=0.04), absence of preoperative dysphagia (63% vs 37%,P=0.02), PPI-dependence
(68% vs 32%,P=0.007), SI ≥75% (68% vs 32%,P=0.02) and history of GERD symptoms
≥4 yr (67% vs 33%,P=0.04) were significantly associated with a postoperative QOL score
>80. Only two factors were significantly and independently associated with an excellent
post-operative QOL, namely male gender (OR=4.4; 95%CI [2.00-9.80],P<0.001) and abnor-
mal EAE (OR=3.0; 95%CI [1.03-8.69],P=0.04). Conclusion: In community practice, good
or excellent surgical results are reported in less than 2/3 of patients. These results are
consistent with a similar study conducted in US*. Although only 2 variables were independ-
ently predictive of long-term outcome, our results strongly support the recommendation of
preoperative pH-monitoring assessment. 3) Patients with hypersensitive esophagus (normal
EAE but positive SAP) are not good candidates for surgery especially those of the female
gender (the most frequent situation in this case). *Vakil N et al. Am J Med 2003;114:1-5.
W1102
Quantification of Esophagogastric Junction Emptying Mechanics After
Fundoplication with High-Resolution Manometry (HRM)
Eric T. Volckmann, John E. Pandolfino, Qing Zhang, Sudip K. Ghosh, Nathaniel J. Soper,
Peter J. Kahrilas
AIM: Impaired esophageal emptying post-fundoplication is complex, related to both increased
outflow resistance and a diminished esophageal propulsive mechanism after surgery (Ghosh
SK, et al. Am J Physiol 2005; 289: G21-35). However, the manometric evaluation of post-
fundoplication patients has been subjective unless coupled with concurrent fluoroscopy and
intense analysis. This study leveraged the enhanced spatial resolution of HRM along with
recently developed automated analysis paradigms to quantify the mechanical effects of
fundoplication. METHODS: 74 normal subjects (NLs) and 46 post-fundoplication patients
(FPs) were studied with a solid-state 36-sensor (1 cm spacing) HRM assembly (Sierra
Scientific Instruments Inc, Los Angeles, CA). Ten 5 ml water swallows were analyzed for
EGJ relaxation and peristaltic integrity. FP patients were subdivided into those with normal
peristalsis (FP-NP) and those with ineffective motility (FP-IEM) using the criteria of ≥ 30%
failed peristalsis. HRM data during EGJ relaxation were analyzed in custom written MATLAB
programs (Pandolfino JE et al. Am J Physiol 2006; In Press) to derive: 1) the duration of
time that pressure gradient from 2 cm above the EGJ relative to a 6 - 10 cm E-sleeve-type
measure spanning the EGJ favored esophageal emptying [antegrade flow permissive (AFP)
time] 2) the median pressure gradient during AFP time, and 3) integrated relaxation resistance
(IRR) which is the median E-sleeve relaxation pressure divided by the duration of relaxation.
Comparisons were made among NLs, FP-NP, and FP-IEM. RESULTS: Both groups of FP
patients exhibited significantly decreased AFP time, an HRM demonstration of outflow
obstruction (Table). The complaint of dysphagia was similar in both FP groups (10/29 FP-
NP; 5/17 FP-IEM). AFP gradient and IRR were increased only in the FP-NP group as both
of these indices are influenced by peristaltic function; the genesis of the intrabolus pressure
in the case of AFP gradient and of the intra-sphincteric pressure during flow in the case of
IRR. CONCLUSION: HRM allows for an automated quantitative assessment of deglutitive
EGJ relaxation that can identify and quantify the outflow resistance associated with FP. The
symptom of dysphagia was not unique to FP-IEM patients but occurred with equal frequency
in the FP-NP group suggesting a multifactorial etiology.
All values are mean (SE); * p<0.05 vs. NL; # p<0.05 vs. FP-NP
W1103
Effect of Endoscopic Gastroplication On Acid and Weakly Acidic Gastro-
Esophageal Reflux: A Study Using Impedance Monitoring
Jose M. Conchillo, Matthijs P. Schwartz, Mohamed Selimah, Albert J. Bredenoord, Melvin
Samsom, Andre J. Smout
Background and aim: In the evaluation of several endoscopic antireflux procedures a discrep-
ancy in the degree of improvement between symptoms and objective reflux parameters has
been reported. We aimed to perform an in-depth analysis of the effect of endoscopic
gastroplication on esophageal reflux using combined pH-impedance recording. Methods:
10 patients with GERD (9 men, mean age 48 years, range 36-58) and no hiatal hernia were
included. They were treated with 3 endoscopic gastroplications (Endocinch™ suturing
system) and underwent 24hr pH-impedance monitoring before and 3 months after treatment.
Acid inhibitory drugs were discontinued 1 week before recordings. Analysis of the pH-
impedance signals included total reflux time, number of reflux episodes according to reflux

















extent of the refluxate. Results: Impedance and pH-metry data before and after endoscopic
gastroplication are shown in the table. Total and upright reflux times assessed by impedance
were significantly decreased after treatment, but not when assessed by pH-metry. The total
number of reflux episodes was significantly reduced after treatment as measured by both
impedance and pH monitoring. Comparable reductions in acid and weakly acidic reflux
episodes were observed. Mean acid and volume clearance times as well as proximal extent
of the refluxate were unaffected by the procedure. Conclusions: Endoscopic gastroplication
leads to a reduction in gastro-esophageal reflux of all types (acid/weakly acidic, liquid/
gaseous, upright/supine). The proximal extent of reflux is not affected by the procedure.
W1104
The Impact of Laproscopic Fundoplication On Esophageal Bolus Clearance
Determined By Combined Manometry and Multi-Channel Intraluminal
Impedance (man-MII)
Nam Q. Nguyen, Katrina Bland, Jenny Myers, Marcus Tippett, Glyn G. Jamieson, Richard
H. Holloway
Dysphagia is a significant sequela of fundoplication and is related to impaired esophageal
clearance. Assessment of clearance by manometry and/or fluoroscopy is suboptimal. MII
measures esophageal clearance directly. Aim. To assess the impact of laparoscopic fundoplic-
ation on esophageal clearance using combined man-MII. Methods. 11 patients with proven
reflux disease (6M:5F; 54+4yrs) underwent combined man-MII before and 3-6 months after
laparoscopic fundoplication (4- 360 degree, 7 - 90 degree). Esophageal body motility and
impedance were measured concurrently at 4 sites 5-cm apart starting 2cm above the lower
esophageal sphincter (LES). LES pressure was recorded with a sleeve sensor. Ten, 5-ml
liquid (L) boluses and 10 x 5-ml viscous (V) boluses were tested in each subject. Impaired
clearance was defined by either prolonged bolus presence time (BPT) and/or total bolus
transit time (TBTT). An individual was judged to have abnormal esophageal clearance
function if there were > 2 liquid or > 3 viscous responses with impaired clearance. Results.
Fundoplication increased nadir LES pressure, distal esophageal wave amplitude, and distal
and total propagation time (Table). Fundoplication increased the proportion of responses
with impaired clearance (liquid: 60/110 vs 32/110, P=0.001; viscous: 46/110 vs. 17/110,
P<0.001), and increased BPT in the mid and distal esophagus and TBTT. After fundoplication,
more patients had abnormal bolus clearance (9/11 vs 4/11) and the median number of
impaired responses per patient increased (L: 5(2.5-8) vs. 2(0.5-3.5), P=0.07; V: 4(2-6) vs.
1(0-2.5), P=0.03). No patient had improved bolus clearance post-operatively. There was a
positive correlation between the nadir LOSP and both BPT at the most distal segment
(L: r=0.4, P<0.001; V: r=0.2, P=0.01) and TBTT (L: r=0.3, P<0.003; V: r=0.4, P<0.001).
Conclusions. Fundoplication impairs oesophageal clearance, predominantly at the distal
2cm of the esophagus. This is related to increased resistance to flow at the gastroesophageal
junction caused by the fundoplication wrap.
W1105
Long-Term 5-Year Follow-Up of The Stretta Procedure for Treatment of Reflux
Disease
Rebecca J. Ryan, Suresh Sivanesan, William C. Tam, Mark N. Schoeman, John Dent,
Richard H. Holloway
We have shown previously that radiofrequency (RFe) treatment of reflux disease (Stretta)
reduces reflux symptoms, medication use and esophageal acid exposure over a 12-month
follow-up (Gastroenterology 2002;122:A47). However, data on long-term efficacy are limited.
Aims: To assess whether improvement in symptoms, medication usage, and esophageal acid
exposure is sustained over a 5 year follow up period. Methods: Twenty patients (10M, 10F)
with GERD (heartburn, %pH<4 >4%, ± h/o erosive esophagitis within 6 mths) underwent
endoscopy, 24h ambulatory pH monitoring and symptom assessment (SF-36, GERD-HRQoL,
dysphagia score) before and 6 months after RFe treatment. All patients were dependent on
acid suppressant therapy before RFe; therapy was stopped after RFe and restarted only if
symptoms relapsed. Thirteen patients (6M, 7F) were available for follow-up at 5 years
(56-63 mo) after treatment. These patients underwent re-evaluation with endoscopy, 24h
ambulatory pH monitoring and symptom assessment (SF-36, GERD-HRQoL, dysphagia
score). Results: At 5 years, 9 of the 13 patients required ongoing acid suppression: 8 at or
above the pre-treatment level; 1 had also undergone fundoplication. Only 4 patients were
off therapy but all had mild symptoms. Two patients had mild (LA-A or B) erosive esophagitis
but more severe than at entry; the remainder were endoscopy-negative. Esophageal acid
exposure and scores for reflux symptoms and quality of life at 5 years were not statistically
different from those pre-treatment or at 6 months post-treatment (Table, median (IQR)).
Conclusions: The beneficial effects of the Stretta procedure that are apparent at short-term
follow up are not sustained over 5 years. The role of the Stretta procedure in the management
of reflux disease requires re-evaluation.
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W1106
Laparoscopic Nissen Fundoplication in Children with Severe Gastroesophageal
Reflux Disease: A Five Year Follow-Up of Esophageal Function
Osvaldo Borrelli, Valentina Mancini, Letizia Cordischi, Felicia Galos, Marina Aloi,
Manuela Cirulli, Valeria Labalestra, Ciro Esposito, Salvatore Cucchiara
Background and Aim. Despite laparoscopic surgery has become the most common operative
procedure for refractory gastroesophageal reflux (GER) disease (GERD), there are few data
on the esophageal functional outcome in patients with severe GERD treated with this
technique. We studied esophageal function through esophageal manometry and intraluminal
pH recording in a group of children with severe GERD who underwent laparoscopic antireflux
fundoplication. Subjects and Methods. From September 1995 to October 2004 40 patients
(median age: 8.3 years, range: 3-15) were studied. Neurologic and systemic diseases had
been excluded in all. Clinical assessment (symptomatic score), esophageal manometry and
24-hour esophageal pH test were performed in each patient before and 3, 6, 12, 24, 36,
48 and 60 months after surgery. Esophageal manometry was performed with a low compliance
system to evaluate lower esophageal sphincter (LES) pressure (LESP)(mmHg), % of deglutitive
LES relaxation (PLESR), amplitude (Amp)(mmHg) and % of peristaltic waves (PPW). Intraeso-
phageal pH was considered abnormal when the 24-hour % of GER was >5. Statistical analysis
was done by Anova. Results. (mean±SD). Surgery resulted in a marked reduction in the
symptomatic score from a baseline value of 9.7±2.1 to 4.2±0.9, 4.1±1.2, 3.51±1.4, 4.12±1.4,
3.8±1.9, 4.2±06 and 3.7±1.0 at 3, 6, 12, 24, 36, 48 and 60 months, respectively (p<0.01
vs baseline). A significant reduction in the intraesophageal acid exposure was detected at
all the follow up study months (3: 4.58±1.4; 6: 4.78±1.56; 12: 4.8±1.17; 24: 4.95±1.53;
36: 4.86±1.86; 48: 4.7±1.4; 60: 4.6±1.7) as compared to baseline (10.01±6.17, p<0.01).
Baseline values of LESP, PLESR, Amp and PPW were 8.1±2.78, 89.05±7.7, 38.8±15.8,
82.0±12.24, respectively. LESP, Amp and PPW were significantly increased at all the post-
operative follow up studies (3, 6, 12, 24, 36, 48, 60 months) as compared to baseline:
LESP: 16.5±3.41, 16.6±3.07, 16.54±3.18, 17.0±2.8, 16.9±2.5, 17.2±3.0, 16.8±2.9 (p<0.01);
Amp: 51.25±14.5, 51.35±14.1, 50.8±14.46, 55.9±15.03, 57.81±14.7, 56.8±16.0, 58.5±16.8
(p<0.01); PPW: 87.0±10.9, 87.5±10.06, 87.05±9.8, 88.2±9.02, 88.7±8.82, 88.0±9.2,
87.5±8.8 (p<0.05). The PLESR did not statistically change at the follow up evaluation.
Conclusions: After 5 years of follow-up, in children with severe GERD laparoscopic Nissen
fundoplication provides excellent and sustained functional results consisting in reduced
esophageal acid exposure and improved esophageal motor activity.
W1107
Long-Term Results of Radio Frequency Energy Delivery for the Treatment of
Gastroesophageal Reflux Disease Sustained Improvements in Symptoms,
Quality of Life and Drug Use At 4-Year Follow-Up
Alvaro Reymunde, Nilda Santiago
The aim of this study was to evaluate the efficacy of the Stretta procedure for GERD patients
based on symptom control, quality of life and medication use. All patients underwent careful
evaluation to document the diagnosis of GERD. Also,the patients symptoms were assessed
using standardized validated tools complemented by patient diaries and symptom logs with
use of visual analog scale including GERD Symptom Score. A Quality of Life in Reflux and
Dyspepsia scale was used to assess patients quality of life related to reflux disease on a scale
of 0-5 with higher numbers indicating better disease control. Medication use assessment
was performed, patients were specifically queried about the use of all acid reflux medications
including proton pump inhibitors, H2 receptor antagonists, antacids and promotility agents.
This testing was repeated 12, 36 and 48 months following the Stretta procedure. Results:
83 consecutive patients; 65men (78%) and 17 women (22%)have reached follow-up of 48
months. Complete, matched data sets for 80 patients (96.4%) are reported with assessments
at baseline and 12, 36 and 48 month follow-up; three patients were lost to follow-up. No
serious complications were associated with the Stretta procedure.All results were statistically
significant at all timepoints. GERD symptom scores improved from a mean score of 2.7 at
baseline to 0.3 at 36 months and 0.6 at 48 months. 68.67% of patients showed complete
resolution of symptoms with scores of 0 (p<0.001). The mean quality of life scores improved
from 2.4 at baseline to 4.6 at 36 months, 4.3 at 48 months (p<0.001). Use of anti-
secretory medications in patients following Stretta was reduced from 100% of patients using
prescription anti-secretory medication at baseline to 29.4% of patients at 12 months and
12.1% of patients at 36 months and 13.75% of patients at 48 months (p<0.001).No patient
who was previously on PPI BID returned to this requirement following the Stretta procedure.
90.2% of patients on PPI or H2RA levels pre-procedure had reduced their medication to
none at all. 88.75% of patients had complete elimination of the need for anti-secretory
medications or a reduction in their medication usage and significant improvement in both
symptom score and QOL measures. Our study demonstrates the Stretta represents a durable
modality that can be offered to patients suffering from persistent GERD as a clinically viable
treatment for the relief of symptoms and requirement for ongoing medical management or
the potential need for an invasive surgical procedure.
W1108
Long-Term Results of Laparoscopic Antireflux Surgery
Jeroen Maljaars, Avinash D. Roopram, Jan Ringers, Ad A. Masclee
Laparoscopic (partial) fundoplication is the preferred surgical treatment for therapy resistant
reflux disease. High success rates have been reported after short-term follow up of 6-12
months. In our patient population complete symptom relief occurred in 85% and normaliza-
tion of 24 hr pH metry in 80% of patients. Little is known however on long-term results
and symptom relief after laparoscopic antireflux surgery. Our aim was to evaluate the long-
term results of 130 patients operated at our institution between 1991 and 2001 for therapy
resistant reflux disease. From 1991 to 1995 complete fundoplication was performed, there-
after partial fundoplication. We evaluated symptoms (severity score 0-3, frequency score 0-
3, combined score 0-9), use of anti-reflux medication, patient satisfaction and quality of life
(SF-36) by questionnaires. Response rate was over 70%. Results: Mean age of patients was
54 ± 1.4 yr (women 53%). The mean follow up time after surgery was 7.8 ± 0.5 yrs.
Indication for surgery was therapy resistant reflux disease or unwillingness to maintenance
therapy. Reflux was documented by endoscopy (esophagitis) or 24 hr pH metry. Eight
patients underwent reoperation because of recurrent reflux or dysphagia. These data were
also included. Heartburn scores decreased sign. (p<0.0001) from 6.6 ± 0.3 (pre-op) to 1.6
± 0.3 (long term post-op), retrosternal pain from 5.0 ± 0.4 to 1.8 ± 0.3 (p<0.0001) and
dysphagia from 4.0 ± 0.4 to 2.2 ± 0.3 (p<0.0001). Concerning antireflux medication: 60
% had no need for medication, while 31% still needed acid reducing medication on a daily
basis and 9 % on a weekly basis. Patient satisfaction with surgical result: 25% was not
satisfied with the procedure, 15 % moderately satisfied and 60 % fully satisfied. When
compared to age matched controls, quality of life by SF-36 was significantly (p<0.05) reduced
for all domains in the patients post fundoplication. In the patients with follow up of 10-15
yrs and of 5-10 yrs, quality of life was significantly (p<0.008) higher versus patients with
0-5 yrs follow up. These results were not affected by the type of surgery, nor by age or
gender. In conclusion: long term follow up of patients after laparoscopic surgery shows a
much less favorable outcome compared to short term follow up. One third of the patients
still needs acid reducing drugs to control symptoms and 25% is not satisfied with the
procedure. Nevertheless, quality of life increases with duration of post-operative follow-up.
W1109
Effect of Diaphragm Biofeedback Training On Esophageal Acid Exposure and
Proximal Gastric Volume in Patients with Gastroesophageal Reflux Disease
Zhaolu Ding, Meiyun Ke, Xiaohong Sun, Zhifeng Wang, Dabo Xu
Background & aims: Our recent study showed that diaphragm biofeedback in the fasting
state could enhance EGJ pressure and reduce intake of acid inhibiting agent in patients with
GERD. Since more gastroesophageal reflux occurred after a meal, which might be related
with proximal gastric function impairment. The aim of our study was to investigate whether
postprandial diaphragm biofeedback could reduce esophageal acid exposure and improve
the proximal gastric emptying. Methods: 19 patients with GERD and 6 HS with matched
demographic characteristics were enrolled. Esophageal manometry including EGJ pressure
and transdiaphragmatic pressure(PDP) was performed with simultaneous esophageal pH
recorded in a 30 min fasting period and a 120 min postprandial period. Patients were
divided into three groups: 7 patients received diaphragm biofeedback training during 1st
hour after meal (The 500 kcal/500ml liquid nutrient test meal) (group BA) and 6 patients
received diaphragm biofeedback training during 2nd hour after meal (group AB), whereas
6 patients received no diaphragm biofeedback training after meal (group AA). Proximal
gastric emptying was measured by ultrasonography at 0 min and every 30 min after meal.
Results: (1) Compared with group AA, the percentage time with pH<4 in group BA was
reduced in 120 min postprandial period [1.4%(0.1%-3.0%) vs. 8.4% (2.0%-17.5%), p<0.05]
and there was no significant difference of esophageal acid exposure between group AB and
AA. (2) At the 60min and 120min after the test meal, the group BA, AB and AA showed
similar volume of proximal stomach (p>0.05), but significant difference was found between
HS and GERD groups(p<0.05). (3) The crural diaphragm pressure and EGJ pressure were
significantly increased from 11.8±2.8 and 17.1±3.5 mmHg at baseline to 35.3±1.7 and
42.4±8.0 mmHg during biofeedback training (p<0.01), but no alteration of LES pressure
was present. (4)The increase of EGJ pressure during biofeedback training was higher than
that of PDP (42.4 vs. 22.4 mmHg, p<0.05). Conclusions: The diaphragm biofeedback training
during the 1st hour after test meal could reduce esophageal acid exposure. The reduction
in esophageal acid exposure may be due to enhanced anti-reflux barrier of the EGJ function.
Therefore, diaphragm biofeedback training may provide a potential approach to conservative
treatment of GERD. The effect of diaphragm biofeedback training on the proximal stomach
function and transient lower esophageal sphincter relaxations (tLESRs) should be further
investigated.
W1110
Mdm2 Promoter Polymorphism Associated with Susceptibility to Gastric
Carcinoma and Its Prognosis
Naoki Ohmiya, Ayumu Taguchi, Nobuyuki Mabuchi, Akihiro Itoh, Yoshiki Hirooka,
Osamu Maeda, Takafumi Ando, Yasumasa Niwa, Hidemi Goto
Background & Aims:Recently, a single nucleotide polymorphism in the MDM2 promoter
(SNP309) has been found to lower the age of onset of tumors and increase the occurrence
of multiple primary tumors in Li-Fraumeni syndrome and accelerate the development of
even sporadic adult soft-tissue sarcoma. The aim of this study was to determine whether
SNP 309 associates with susceptibility to gastric carcinoma and its prognosis. Methods: In
a case-control study including 438 controls and 410 patients with sporadic gastric carcinoma,
MDM2 SNP309 was genotyped. Serum pepsinogens (PGs) I and II were measured in 438
controls and 253 cases selected from 410 patients. Tumor tissue was immunostained with
p53 and examined for mutations in exons 5-8 of p53 using polymerase chain reaction-based
single strand conformational polymorphism analysis and direct sequencing. Results: The
risk of overall gastric carcinoma for SNP309 (G/G) was significantly increased when compared
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to T carriers (P=0.009), especially carcinoma with extragastric tumors (P=0.004), carcinoma
with severe atrophic gastritis positive for PG assay (PG I level < 70 ng/ml and PG I/II < 3.0)
(P=0.004), antral carcinoma (P=0.01), intestinal-type carcinoma (P=0.004), p53-immunopo-
sitive carcinoma (P=0.004), and carcinoma with p53 mutations (P=0.002). No significant
difference in age at diagnosis was observed among genotypes. SNP309 (G/G) was an inde-
pendent marker of poor overall survival (hazard ratio, 2.08; 95% CI, 1.01-4.28). Conclusions:
This study provides evidence supporting the association of SNP 309 with gastric carcinogen-
esis via p53 tumor suppressor pathway, extragastric tumorigenesis, and poor prognosis.
W1111
Increased Tumor Multiplicity in BALB/C Mice Congenic for Both the Min
(ApcMin/+) and RAG2 Knockout (Rag2tm1Fwa) Mutations
Claude Nagamine, J.N. Sohn, Elizabeth Groff, Katie Schlieper, Prashant R. Nambiar,
James G. Fox, David B. Schauer
The C57BL/6-ApcMin/+ (B6-Min) mouse harbors a point mutation in its adenomatous polyposis
coli gene, the same gene that is mutated in hereditary and many sporadic forms of human
colorectal cancer. Therefore, the B6-Min mouse is a clinically relevant model for human
colorectal cancer and can be used to dissect the molecular and genetic mechanisms underlying
colorectal carcinogenesis and progression. B6-Min mice have a reduced (≤ 6 months) life
span due, in part, to complications from intestinal polyposis-induced hemorrhage. This
reduced life span complicates long-term studies of tumorigenesis. To circumvent this prob-
lem, we placed the ApcMin mutation on the BALB/c genetic background to generate the
BALB-Min (C.B6-ApcMin/+) congenic strain. BALB-Min mice had a lower tumor multiplicity
and a concomitant increase in life span. In our colony, B6-Min mice developed an average
of 100 small intestinal (SI) adenomas (n=17 mice, age = 3.2-6.1 months). In contrast, BALB-
Min mice developed an average of 18 SI tumors (n = 15 mice, age = 2.9-14.6 months).
Moreover, BALB-Min mice had a longer life span with some mice surviving >1 year. Recomb-
ination activating gene 2 (Rag2 ) is required for the normal development of T and B cells.
To investigate the interplay of the adaptive immune system and tumorigenesis, the Rag2
knockout allele from the BALB/c congenic strain C.129S6(B6)-Rag2tm1Fwa was introduced
into BALB-Min to generate the compound mutant strain BALB-RagMin (C.Cg-ApcMin/+,
Rag2tm1Fwa). Interestingly, BALB-RagMin mice showed an increase in SI tumor multiplicity
relative to the parental BALB-Min strain, developing an average of 44 SI adenomas (n = 58
mice, age = 3.1-8.4 months). Thus, in contrast to previous studies, we found a putative
dependence of SI tumor multiplicity on the adaptive immune system. We are currently
characterizing the differences between B6-Min, BALB-Min, and BALB-RagMin tumors and
the mechanism by which tumor multiplicity is increased in BALB-RagMin mice.
W1112
Colorectal Adenomatous Polyposis Linked to MYH Gene Mutations: Genotype
and Phenotype Characteristics in a French Series of 56 Patients
Guillaume Bouguen, Sylvain Manfredi, Martine Blayau, Catherine Dugast, Bruno Buecher,
Dominique Bonneau, Laurent Siproudhis, Veronique David, Jean-Francois Bretagne
Aim: Recent literature reports that a subgroup of patients with attenuated and classic polyposis
as well as with young-onset colorectal cancer (CCR) is associated with mutations in the base
excision repair gene MYH. The aim of this study was to establish the prevalence of germ-
line MYH mutations in a French series of 56 consecutive patients with no detectable APC
mutation and to describe the phenotype of those with MYH mutations. Methods: MYH
mutations were screened by DNA sequencing after PCR amplification of each exon. Clinical
and endoscopic characteristics (age, sex, family history, extra-colonic manifestations, number
and types of polyps, associated cancer) and surgical data have been collected for tested
patients. Results: MYH germ-line mutations were identified in 11 (19.6%) of the 56 tested
patients. The prevalence of MYH mutations was 34.4% in the subgroup of 32 patients having
10 or more adenomatous polyps. No mutation was found among patients with mixed
polyposis (n=2) and with CCR (n=13). Among 10 patients with biallelic MYH mutations,
2 proved to be homozygotes and the other 8 were compound heterozygotes. Only one
patient had a monoallelic mutation. At least one of the two mutational hot spots (Y165C
and G382D) was identified in all cases, except one patient. There were 9 males and two
females aged of 47 years old (ranged 36-57). Three patients presented a family history of
adenomatous polyposis in siblings, but no vertical transmission was noted. The median
number of colorectal adenomatous polyps was 53 (11-100) without preferential localization.
A CCR was associated to polyposis in 7 of the 11 patients (63.6%); 2 cancers were stage I,
3 stage II and 2 stage III. Gastric and duodenal adenomas with high grade dysplasia were
diagnosed in one case. Ten of the 11 patients were operated on: restorative proctocolectomy
was performed in 4 cases, a subtotal colectomy with rectal preservation in 5 cases and a
left colectomy in 1 case. In the latter case, polyposis was diagnosed two years after the left
colectomy and total colectomy is planned at this time. Rectal adenomas were diagnosed
during the follow-up in 3 patients with preserved rectum. Conclusions: 1) MYH mutations,
mainly corresponding to biallelic mutations have been observed in one third of French
patients who had more than 10 colorectal adenomatous polyps without APC mutation. 2)
The phenotype of the disease is similar to attenuated FAP, but its transmission shows
evidence on recessive or more complex inheritance. 3) The high risk of CCR suggests that
prophylactic colectomy is recommended. 4) Upper GI endoscopy should be also recom-
mended.
W1113
Role of Ultrasound for Thyroid Cancer Screening in the Familial Adenomatous
Polyposis Syndrome
Maite Herraiz, Giuseppe Barbesino, Gilbert Daniels, Daniel C. Chung
Background: Thyroid carcinoma (TC) is an extraintestinal manifestation of the Familial
Adenomatous Polyposis (FAP) syndrome. Screening with thyroid ultrasound (TU) has been

















to determine the role of TU in patients with FAP. Methods: We performed a retrospective
chart review of patients with a proven diagnosis of FAP at a single institution. Clinical
parameters including family history, Adenomatous Polyposis Coli (APC) gene testing, and
TU were analyzed. Results: 50 patients were diagnosed with FAP by clinical and/or genetic
criteria. Papillary TC was diagnosed in 6 female patients (12%). The mean ages of diagnosis
for FAP and TC in these 6 patients were 28 years (range 19-48 years) and 33 years (range
18-51 years), respectively. No genotype-phenotype correlations between APC mutations and
risk of TC were identified. APC germ-line mutations in those with TC were located at codon
302 (exon 8), codon 564 (exon 13), codon 1935 (exon 15), and in segment 2 (between
codons 686-1217, exon 15). All 6 patients had multifocal tumors and 4 had bilateral disease.
On pathologic examination, some of the additional malignant foci were small (1-5 mm).
None of these small foci had suspicious features of malignancy on TU. After a median
follow-up of 34 months (range 13-186), all patients were alive and disease-free. Of 24 FAP
patients who had at least one screening TU, 19 (79%) had thyroid nodules; the disease was
multinodular in 73%. The median age of patients with nodules was 41 years (21-66); 68%
were women. The largest nodule was ≥ 9 mm in half of the patients. Fine-needle aspiration
(FNA) was performed in 10 patients who had screening ultrasound. Two out of the 6 TC
cases were discovered in this manner. Follow-up ultrasound in 10 patients after a mean of
15 months (range 12-20 months) revealed no changes in either the number or size of
nodules. Conclusion: The prevalence of TC in this series of patients with FAP is 12%, which
is higher than previous reports of 1-2%. Screening for TC with ultrasound can detect
asymptomatic tumors, and the tumors are often multifocal. Nodular thyroid disease is very
common among FAP patients. Because nodules < 5 mm may be malignant, close follow-
up with thyroid ultrasound and FNA as needed is warranted. However, the impact of
screening for TC on survival cannot be predicted at this time.
W1114
The Use of Genetic Testing in Hereditary Non-Polyposis Colorectal Cancer
Families
Dewkoemar Ramsoekh, Anja Wagner, Monique van Leerdam, Dennis Dooijes, Carli Tops,
Hanne Meijers-Heijboer, Ernst Kuipers
Background: Hereditary non-polyposis colorectal cancer is an autosomal dominantly inherit-
ing cancer susceptibility syndrome. Genetic testing in subjects from known HNPCC families
is of considerable medical and psychological significance. Subjects with a mutation can
benefit from a medical surveillance program, i.e. surveillance endoscopy, while subjects
without a mutation are relieved from anxiety and can be dismissed from further surveillance.
The aim of the present study was to determine the use of genetic testing in clinical ascertained
HNPCC families with a known mutation in MSH2, MLH1 or MSH6. Methods: Data were
collected from medical records and family pedigrees of patients originating from HNPCC
families, who visited the department of Clinical Genetics of the Erasmus Medical Center
between 1995 and August 2005. Pre-test genetic risk was defined as 100% (diagnosed with
an HNPCC related tumor), 50% (first degree relative with an HNPCC related tumor or with
a mutation) and 25% (parent with a 50% risk). Results: Thirty-four HNPCC families with
a known mutation in MSH2 (n=10), MLH1 (n=12) and MSH6 (n=12) were included in the
study. At the time of clinical ascertainment 27 of the 34 families fulfilled the Amsterdam
II criteria. The 34 families consisted out of 970 living subjects (50% male) with a 100%
(n=108), 50% (n=533) or 25% (n=329) pre-test genetic risk of carrying the family specific
mutation. Genetic testing was used by 418 (43%) subjects, a family-specific mutation was
detected in 203 (49%) of them. Of the subjects with a pre-test genetic risk of 100%, 50%
or 25% for carrying the mutation, respectively 76%, 53% and 16% used genetic testing (p
< 0.0001 for 100% vs. 50% risk; p < 0.0001 for 100% vs. 25% risk; p < 0.0001 for 50%
vs. 25% risk). In the 970 subjects there was a significant difference in the test rate between
men (36%) and women (50%), p < 0.0001. This significant difference between sexes was
found in the 50% pre-test genetic risk group (46% vs. 60%, p = 0.001), but not in the
100% ( 70% vs. 81%, p = 0.2) and 25% pre-test genetic risk group (13% vs. 20%, p =
0.07). Conclusions: There is interest in genetic testing in subjects from HNPCC families
with a known mutation. Genetic testing is used more frequently by women, and by subjects
with a higher pre-test genetic risk. However, acceptance of testing is far from complete, a
considerable number of subjects refrains from genetic testing. This has implications for
surveillance in order to prevent cancer. Methods for improved implementation of genetic
testing should be studied and optimal testing should be used as a part of the standard
medical care for subjects at risk for HNPCC.
W1115
Polygenic Familial Colorectal Cancers Are Associated with the E-Cadherin
Polymorphism -160a/C
Frank Gruenhage, Matthias Jungck, Christine Berg, Christoph Lamberti, Ursula Becker,
Constanze Pagenstecher, Michaela Mathiak, Tilman Sauerbruch, Frank Lammert
Although up to 20% of colorectal cancer (CRC) patients show some kind of familiarity, the
genetic factors underlying polygenic familial CRCs have yet to be defined. However, many
CRC association studies did not differentiate between sporadic and familial cancers, and
controls were not evaluated for CRC precursor lesions, i.e. colorectal adenomas. Thus, our
aim now was to test a group of patients with strong evidence for CRC familiarity (but exclusion
of monogenic CRC syndromes) for association with polymorphisms of CRC candidate genes
in comparison to patients with sporadic CRCs and healthy controls. Methods: We recruited
98 patients with familial CRC, as defined by two of the following criteria: (1) three affected
relatives, one of them a first-degree relative of the others; (2) one member diagnosed with
CRC before age 50; (3) two affected generations. All tumors showed regular expression of
hMLH1 and hMSH2, and microsatellite instability was excluded. For comparison, we studied
95 CRC patients without inherited CRC syndromes and a negative family history as well
as 220 ‘hyper-normal’ controls who displayed no adenomatous polyps on colonoscopy.
Polymorphisms in the genes encoding E-cadherin (-160A/C), cyclin D1 (870A/G), p53
(R72P), the vitamin D receptor (-8C/T) and the ileal bile acid transporter (169C/T, A171S)
were genotyped using PCR-based assays. Results: Familial cases (56 ± 12 yrs) were signific-
antly (p<0.001) younger than sporadic CRC cases (65 ± 9 yrs) and hyper-normal controls
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(63 ± 8 yrs). Hyper-normal controls were not significantly younger than sporadic CRC cases.
Gender distributions did not differ. The frequency of the minor allele of the E-cadherin
SNP -160A/C was significantly higher in hyper-normal controls compared to familial CRC
cases (p=0.042), but no such difference was detected in comparison to sporadic cases. The -
160A/C allele distribution did not differ significantly between familial and sporadic CRCs.
Overall, carriers of the -160C allele were significantly more common among hyper-normal
controls, indicating a protective effect of this variant (χ2=4.77, CI 0.35-0.95, OR 0.58). No
differences in allele frequencies were detected for the other polymorphisms. Conclusions:
In our study, the presence of the minor allele of the E-cadherin polymorphism -160A/C
might be protective for the development of familial CRCs. Our findings complement the
observation of a similar association in patients with sporadic CRCs, indicating that common
pathways affect carcinogenesis in familial and sporadic CRCs.
W1116
Somatic Mutation As a Possible ‘Second Hit’ in Hereditary Diffuse Gastric
Cancer Patients with E-Cadherin Germ-Line Mutations
Miriam Barber, Sarah Hyland, Nicola Grehan, Cristina Bordin, Carlos Caldas, Rebecca
Fitzgerald
Introduction: Germ-line mutations of the E-cadherin gene (CDH1) are causative in 30% of
Hereditary Diffuse Gastric Cancer (HDGC) cases. Although this is not a large percentage,
the penetrance of the mutation is 70% and CDH1 mutations are associated with a five-year
survival rate of only 10% at the time of diagnosis. Therefore the consequences for families
affected with the mutation are profound. Similar to other autosomal dominant cancer
predisposing syndromes, only one of the E-cadherin alleles is mutated in the germ-line and
the second allele is inactivated within the gastric tissue. Hence, E-cadherin acts as a recessive
tumour suppressor and both alleles have to be inactivated to result in loss of E-cadherin
function and for cancer to occur. Aim: To determine if somatic mutation could act as the
possible ‘second hit’ in patients with known germ-line mutations of CDH1. Methods: Five
individuals (4 male, 1 female) from 4 mutation carrying HDGC families were analysed. The
germ-line CDH1 mutations found in these individuals are spaced throughout the gene (from
exon 1 to exon 10) and there is no mutation ‘hotspot’ associated with HDGC. Therefore
exon specific primers were used to amplify each of the 16 exons of the E-cadherin gene
individually and sequencing was carried out for each exon. Any sequences alterations
identified were further analysed using the TA Cloning Kit with One Shot TOP10 Chemically
Competent E. coli (Invitrogen) and M13 primer sequences. Protein expression was investig-
ated using immunohistochemistry. Two E-cadherin specific antibodies were used for this
analysis; one that recognises an epitope in the extracellular domain (BD Transduction
Laboratories) and one that recognises an epitope in the cytoplasmic domain (Neomarkers).
Results: Two novel gene alterations were identified in addition to the germ-line mutations
previously found. Both novel mutations are located in splice site regions and may therefore
affect splicing. Immunohistochemical analysis showed that E-cadherin protein expression
was still present in these individuals with somatic mutation, although in one case localisation
of the protein had altered, with reduced, patchy membranous staining and increased cyto-
plasmic staining in the tumour tissue compared to strong membranous staining in the
surrounding normal glands. Conclusion: Somatic mutations have been identified as the
possible ‘second hit’ in two HDGC patients with E-cadherin germ-line mutations. Loss of
heterozygosity and hypermethylation analyses are required to investigate alternative mechan-
isms for E-cadherin down-regulation in patients without somatic mutations.
W1117
Reproductive Decision-Making in Familial Adenomatous Polyposis: Attitudes
Towards Prenatal Testing
Fay Kastrinos, Elena M. Stoffel, Judith Balmana, Sapna Syngal
BACKGROUND: Familial Adenomatous Polyposis (FAP) is an autosomal dominant syndrome
associated with a >95% risk of colorectal cancer in the absence of prophylactic colectomy.
Classic FAP is most commonly associated with underlying mutations in the Adenomatous
Polyposis Coli (APC) gene. In cases of FAP where there is an identifiable APC gene mutation,
prenatal testing can be performed to determine whether an embryo or fetus carries the
gene mutation. However, the willingness of FAP patients to undergo prenatal testing for
reproductive decision-making has not been studied. We conducted a pilot study to assess
attitudes towards prenatal diagnosis among individuals with FAP. METHODS: Individuals
affected with FAP completed a self-administered survey containing questions on demo-
graphics, personal and family history related to FAP, and attitudes towards prenatal testing,
including amniocentesis, chorionic villous sampling (CVS), and preimplantation genetic
diagnosis (PGD). RESULTS: A total of 17 subjects (10 females and 7 males) completed the
40-item survey. The mean age of participants was 43.3 +/- 14.2 years (range: 28-73 years).
Of the 10 subjects who had children, 5 had children affected with FAP and 5 had children
whose disease status is unknown. Four of 5 subjects with affected children had at least one
child diagnosed with cancer or desmoid tumors. Sixteen of 17 (94%) subjects stated that
they would consider undergoing PGD and 77% would consider amniocentesis or CVS .
Early reassurance of having an unaffected child was cited as the most important advantage
of PGD. Eleven respondents favored PGD over amniocentesis or CVS because it provides
an opportunity to avoid a pregnancy termination. No participants felt that it was unethical
to provide any form of prenatal testing for FAP and all four subjects reporting a “strong”
religious background said they would consider PGD over other forms of prenatal testing
for FAP. Lack of medical insurance reimbursement and the expensive cost of PGD was an
important concern and possible deterrent for 64% of this sample. CONCLUSION: Patients
with FAP are willing to consider prenatal testing approaches to prevent transmission of
disease to their children. Further studies are warranted in larger study populations to evaluate
optimal methods of providing information regarding prenatal testing and to evaluate ways
to facilitate prenatal counseling referrals for affected patients.
W1118
Genetic Testing Is Associated with Appropriate Colorectal Cancer Screening
Among Individuals At Risk for Hereditary Nonpolyposis Colorectal Cancer
(HNPCC)
Elena M. Stoffel, Rowena Mercado, Shilpa Grover, Beth Ford, Wendy Kohlmann, Kristen
Shannon, Peggy Conrad, Jonathan Terdiman, Stephen Gruber, Daniel Chung, Sapna
Syngal
Background: Individuals at risk for HNPCC require colonoscopy starting at age 25 at intervals
of every 1-2 years for prevention of colorectal cancer (CRC). Clinical experience suggests
many patients at highest risk for CRC undergo inadequate screening. Objective: To assess
the prevalence of appropriate CRC screening among individuals with HNPCC and identify
clinical factors associated with appropriate screening. Methods: 261 subjects who met Beth-
esda criteria for HNPCC recruited through 4 U.S. cancer genetics clinics completed a written
questionnaire. Subjects provided information on personal and family medical history, genetic
testing, and frequency of cancer screening tests. Subjects were considered to have had
appropriate CRC screening if they reported undergoing colonoscopy at least every 2 years.
Results: Overall, 241/261 (92%) subjects had had at least 1 colonoscopy and 163 (62%)
reported undergoing colonoscopy at least every 2 years. Among the 105 subjects who had
either an identifiable mismatch repair gene mutation or had inconclusive genetic test results
but fulfilled Amsterdam Criteria, 90 (86%) had CRC screening at the appropriate interval.
In contrast, only 13/38 (34%) who did not undergo genetic testing but fulfilled Amsterdam
Criteria reported CRC screening that was appropriate for HNPCC (p<0.0001). Half (20/
40) of those with inadequate CRC screening practices indicated that their physician had
recommended colonoscopy every 3-5 years or less frequently. In multivariable analysis
controlling for subjects’ age and prior history of CRC, history of genetic testing (OR = 11.6,
95% CI = 3.4 - 40.0) and history of a first degree relative with CRC at age <50 (OR = 4.8,
95% CI = 1.3 - 18.0) were independent predictors of appropriate screening. Conclusions:
Genetic testing is associated with appropriate CRC screening among individuals at risk for
HNPCC. Patients with personal and/or family history suspicious for HNPCC should be
referred for genetic evaluation so they and their physicians can be informed about the
specialized screening required for cancer prevention.
W1119
Patients with Diabetes More Than 15 Years Have Increased Odds of Colorectal
Cancer
Donald Garrow, Brenda Hoffman, Leonard Egede
OBJECTIVE: To assess the effect of duration of diabetes mellitus on the odds of colorectal
cancer within a nationally representative population. BACKGROUND: Previous studies have
yielded evidence that diabetes mellitus may be a risk factor for colon cancer. Both hyperinsuli-
nemia and hyperglycemia have been noted in vitro to be promoters of colon cancer growth.
Furthermore, insulin and insulin-like growth factor-1 (IGF-1) receptors have been found
on colon cancer tissue. Also, high levels of circulating IGF-1 are associated with an elevated
risk of colorectal adenomas and cancer. This study seeks to assess the effect of duration of
diabetes on the risk of colorectal cancer. METHODS: Data collected by the 1997-2003
National Health Interview Survey (NHIS) was analyzed to assess the risk of colorectal cancer
among individuals with diabetes. The NHIS is a comprehensive nationally representative
survey weighted to represent the U.S. adult population. There were 226,953 subjects repres-
ented in the combined seven years of the NHIS. Duration of diabetes was divided into four
groups; 0-5 years, 5-10 years, 10-15 years, and > 15 years. Multiple logistic regression was
performed probing the relationship between duration of diabetes and colorectal cancer while
adjusting for age, race, gender, obesity, alcohol use, tobacco use, and treatment for diabetes
(insulin, pill, both, or diet only). NHIS data from 1997 - 2003 was merged with SAS v.
9.1.3. Analyses performed with STATA v. 8.0, which accounted for the complex survey
design of the NHIS and generated population estimates. Multiple logistic regression was used
to determine independent correlates of colorectal cancer among individuals with diabetes.
RESULTS: Among the 226.953 subjects in this study, 13,399 (5.9%) revealed a history of
diabetes mellitus. Adjusted for potential confounders, individuals with diabetes > 15 years
were significantly more likely to have colorectal cancer than persons without diabetes (Odds
Ratio (OR) = 1.76, 95% Confidence Interval (CI) = 1.03 to 3.00). Other independent
correlates with significant findings included age > 50, history of tobacco use, and history
of alcohol use. CONCLUSIONS: Individuals with diabetes more than 15 years were noted
to have an increased likelihood of colorectal cancer. If this association remains positive in
prospective trials, people with diabetes may require earlier and more aggressive screening
for colorectal cancer than the general population. Research should be directed at understand-
ing the pathophysiologic reasons why duration of diabetes is associated with increased odds
of colorectal cancer.
W1120
Colorectal Cancer Risk Perception Is Inappropriately Low in Individuals At
Risk for HNPCC with Indeterminate Genetic Test Results
Shilpa Grover, Elena M. Stoffel, Rowena C. Mercado, Beth M. Ford, Kohlmann K. Wendy,
Kristen M. Shannon, Amie M. Blanco, Jonathan P. Terdiman, Stephen B. Gruber, Daniel
C. Chung, Sapna Syngal
Background: Hereditary nonpolyposis colorectal cancer (HNPCC) is associated with inherited
germline mutations in mismatch repair genes. When there is an identifiable mutation in a
family, mutation carriers have up to an 80% lifetime risk of developing colorectal cancer
(CRC), whereas individuals who do not inherit the mutation are at average population risk
(true negative). A subset of individuals fulfilling clinical criteria have indeterminate genetic
test results (no gene mutation found, or a mutation of unclear pathogenic significance) and
should still be considered to be at high risk. There are limited data regarding patients’
understanding of the complexities of genetic test results. Objectives: To examine CRC risk
perception in individuals tested for HNPCC gene mutations and to identify the factors
associated with an accurate cancer risk perception. Methods: 261 subjects who met the
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Bethesda criteria for HNPCC were recruited through 4 U.S. cancer genetics clinics and
completed a self-administered questionnaire eliciting demographic data, individual and
family genetic test results, as well as personal and family cancer history. Subjects were also
asked to estimate their CRC risk on a 5-point scale, comparing their risk to that of other
individuals their age. Results: Of 165 individuals who underwent genetic testing, 98 (59%)
were found to carry an HNPCC mutation and 89/98 (91%) correctly estimated their CRC
risk as being “high” or “very high” compared to other individuals their age. Seventeen of
23 (74%) individuals with true negative test results correctly estimated their CRC risk with
respect to their personal history of CRC and polyps. However, only 27/44 (61%) individuals
with an indeterminate genetic test, correctly stated that their CRC risk was increased.
Approximately half (8/17) of those who underestimated their cancer risk believed their risk
of CRC was “below average” and 9/17 reported their cancer risk as “the same as the average
population.” The presence of a pathogenic germline HNPCC mutation (OR 2.7, 95% CI
1.5-4.9) and history of a family member with a known mutation (OR 2.8, 95% CI 1.1-7.4)
were strong independent predictors of accurate CRC risk perception. Conclusions: Patients
at risk for HNPCC with an indeterminate genetic test may be falsely reassured. As underes-
timation of cancer risk may adversely affect compliance with appropriate cancer screening
recommendations, additional post-test counseling is needed to help patients interpret their
genetic test results and the implications for their clinical care.
W1121
Are Colorectal Cancer (CRC) Patients with Clinical Diagnosis of Hereditary
Non Polyposis Colorectal Cancer (HNPCC) Receiving Optimal Surgical
Treatment?
Zohar Levi, Rachel Hazazi, Paul Rozen, Yaron Niv
Introduction: Patients with Lynch syndrome have a lifetime risk of 80 % for CRC and a
high incidence of synchronous or metachronous neoplasia. Therefore, once a diagnosis of
CRC is made subtotal colectomy should be considered rather than segmental resection. Aim:
We reviewed the surgical procedures performed on our CRC bearing patients having a
clinical diagnosis of HNPCC. Methods: 20 patients having CRC and fulfilling either the
Amsterdam II criteria (group A, n=9) or revised Bethesda/incomplete Amsterdam II criteria
(group B, n=11) were identified in our Familial Cancer Clinic. The type of surgery and
subsequent follow-up were evaluated. Results: Table. Conclusion: Only 10% of the patients
with CRC and clinical (Amsterdam II) or suspected (Bethesda) criteria of HNPCC underwent
primary subtotal colectomy. This requires better understanding of the syndrome by the
surgeons, communication with the Familial Cancer Clinic, and more definitive surgical guide-
lines.
W1122
Higher Gastric Mucin Secretion and Lower Gastric Acid Output in First-
Degree Relatives of Gastric Cancer Patients
Alexander Vilkin, Zohar Levi, Sara Morgenstern, Haim Shmueli, Eyal Gal, Bracha Hadad,
Britta Hardi, Yaron Niv
Background: Patients infected by Helicobacter pylori who have first-degree relatives with
gastric cancer have an 8-fold increased risk of developing gastric cancer themselves. Mucins
are high-molecular-weight glycoproteins that play a cardinal role in the protective mechanism
of the gastric epithelium. Aim: To study gastric acid and mucin secretion in dyspeptic
patients with and without a family history of gastric cancer and Helicobacter pylori infection.
Materials and Methods: Twenty-six dyspeptic patients underwent esophago-gastro-duodeno-
scopy, gastric biopsies, and acid and mucin secretory tests. The sample was divided by
family history of gastric cancer and Helicobacter pylori status. Results: Patients who were
infected by Helicobacter pylori had a significantly higher degree of inflammation than those
who were not. Helicobacter pylori-positive patients with a positive family history had a lower
basal and maximal gastric acid output than infected patients with no family history and
non-infected controls, and a higher basal and maximal mucin output than infected patients
with no family history. MUC5AC was the major mucin species expressed in gastric juice.
Conclusions: In patients with relatives with gastric cancer, Helicobacter pylori infection is
associated with a more severe inflammatory reaction consisting of decreased gastric acid


















Characteristics of Adult Children in Families Where Both Parents Have
Pancreatic Cancer
Emmy Ludwig, Jennifer Simon, Sara Olson, Robert C. Kurtz
Familial pancreatic cancer (FPC) is thought to represent about 10% of pancreatic cancers
(PC). The search for predisposing genes has been centered on registries of patients and
family members in loosely-defined high-risk FPC pedigrees. A goal of such registries is the
identification of genetic, environmental and lifestyle factors which may play a role in the
genesis of pancreatic cancer. Our FPC registry identified a small group (n=11) of families
where both parents died of pancreatic cancer. This report describes the characteristics of
this unusual cohort. Methods: We began our FPC registry for patients and their at risk
relatives in December, 2002. The Registry also is tied to an epidemiologic case-control study
of environmental risk, including both familial and sporadic PC cases, a surveillance program
of at-risk relatives with cross-sectional imaging and endoscopy, and banking of serum for
future genetic evaluation. All enrolled participants complete an extensive questionnaire
detailing factors related to known and potential PC risk factors and family history. In
addition, pedigree review for other associated syndromes such as HNPCC, and BRCA1 and
2, leads to formal genetic counseling. Results: We compared the 11 registry participants
where both parents had PC to a control group made up of other unaffected relatives of PC
patients who joined our registry based on their family history of PC (n=82). The 11 individuals
in our cohort are similar in age to controls (64% are less than 50 years vs 54% in controls;
mean age 50.3 years vs 49.3 years), show no difference in proportion exposed to second-
hand tobacco smoke as a child (55% vs. 57% in controls); had similar BMI at age 25 (91%
with normal BMI vs 78% in controls); and are similar in race (100% vs. 90% white non-
Hispanic). However, they are less likely to be Catholic (18% vs 45%). In addition, in all of
the two-parent PC families, parents were concordant for family ancestry compared to only
52% of the controls (exact p=0.0022). Conclusions: We describe a cohort of healthy indi-
viduals where both parents had PC. To our knowledge, this is the first analysis of such a
group. We demonstrate that they are no more likely to have been exposed to second-hand
smoke growing up than relatives of PC patients in the control group. The finding of uniform
concordance for family ancestry suggests a common genetic factor yet to be identified.
Planned enrollment of additional family members belonging to this cohort and gene analysis
of their banked specimens may help elucidate mechanisms that lead to the development of
pancreatic cancer in the parents of this unique group of individuals.
W1124
Cryoablation of Barrett’s Esophagus (BE)
Mark H. Johnston, Brooks D. Cash, John D. Horwhat, Lavonne R. Johnston, Cathy A.
Dykes, Halisha S. Mays
Background: The aim of this study was to explore the safety and efficacy of circumferential
relative to hemi-circumferential cryoablation using an endoscopic low pressure liquid N2
device (CryMed Tech. Inc, Baltimore, MD) in BE. Methods: Twenty patients with BE were
enrolled. The first 10 (group I) were treated hemi-circumferentially. The next 10 patients
(group II) were treated circumferentially. In both groups 4 cm segments were treated at a
time. Each area was frozen for 20 seconds, followed by thaw and then re-frozen for 20
seconds. Results: The mean age for both groups was 58. The mean BE length, pre-cryo, for
group I was 4.5 cm, and for group II 2.7 cm. Post cryo the mean BE length for group I
was 0.3 cm and for group II was 0 cm. The mean number of treatments for group I was
4.8 versus 2.1 in group II. There was no sub-squamous specialized intestinal metaplasia
(SIM) for either group at 6 months follow-up for whom there was data. There were no
serious complications. Group II experienced more transient chest discomfort and dysphagia
(see table). Both patient discomfort and dysphagia completely resolved. No patient developed
an esophageal stricture. Conclusion: Preliminary results indicate that circumferential cryoabl-
ation compared to hemi-circumferential is similarly efficacious with respect to reversal of
BE and absence of subsquamous SIM. It requires less than half the treatments of hemi-
circumferential treatment but at the cost of increased patient discomfort.
Table I
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H=hemi-circumferential; C=circumferential; p=pending; mo=months
W1125
Safety of Fine Needle Aspiration (FNA) During Endoscopic Ultrasound (EUS):
A Prospective Study
Mohammad Al-Haddad, Catherine M. Hodgens, Robin D. Toton, Seth A. Gross, Kyung
W. Noh, Surakit Pungpapong, Timothy A. Woodward, Michael B. Wallace, Massimo
Raimondo
Background: FNA is commonly performed in conjunction with EUS procedures. There is
limited prospective data on complication rates. Hypothesis: In prospective assessment, FNA
is a safe procedure with limited complications in a high volume EUS referral center. Methods:
Approximately 1200 patients undergo EUS at Mayo Clinic Jacksonville on annual basis for
different indications. Of those, about 40% will undergo FNA. Between April and October
2005, 230 patients who underwent EUS- FNA were included in this study. These patients
were screened for post-procedural complications including abdominal pain, nausea, vomit-
ing, fever, gastrointestinal bleeding and dysphagia. Complications were assessed on day 0
by direct examination and at day 30 by a telephone call. Inquiries were made about emergency
room visits or hospitalizations during the same period of time. Results: Table 1 demonstrates
location of FNA for all patients (n=230). Complete follow up information was obtained on
207 patients (90%). -Day 0: Three patients were admitted to the hospital for observation.
Two patients had abdominal pain after pancreatic cyst FNA and one was observed after
mediastinal lymph nodes FNA for chest pain. All three patients were discharged within 24
hours of admission. There was no requirement of blood transfusion and no evidence of
pancreatitis or infection in any of the hospitalized patients. One patient reported to the ER
after EUS-FNA and was sent home on oral analgesics after appropriate evaluation. -Day 30:
Four patients expired during the first month after EUS from primary disease process (3 had
pancreatic cancer and one had lung cancer). Five patients were hospitalized for planned
elective surgeries during the same period of time. There was no unplanned morbidity or
mortality attributable to EUS-FNA. Conclusion: FNA is a safe intervention in patients under-




Confocal Microscopy: A Novel Method to Assess Aberrant Crypt Foci in APC
Min+/- and APC Min+/- (PPARα-/-)Mice
Anthony Shonde, Krish Ragunath, George Anagnostopoulos, David R. Bell, Andrew J.
Bennett, Christopher J. Hawkey
Background: Peroxisome proliferator-activated receptorα (PPARα) is expressed at low levels
in murine and human colon tumours. Apc min+/- mice fed with methylclofenapate (a PPARα
ligand) have 50% less tumour burden in the small intestine and colon than control1. Recent
studies showed that aberrant crypt foci (ACF) are the earliest morphological lesion detectable
in colorectal epithelium that may lead to cancer. However it is unclear whether PPARα has
a role in suppressing the formation of ACF or the progression of tumour development.
Dissection microscopy is the most common method used for quantifying ACF. However it
is time consuming and requires a great deal of skill to obtain a good preparation. Aims: (1)
To assess whether Confocal Microscopy is a viable method for identifying ACF in scientific
practice. (2) Examine the role of PPARα in colon carcinogenesis using APCmin+/- and
APCmin+/-(PPARα-/-) mice. Method: Once weaned APCmin+/- mice and APCmin+/-
(PPARα-/-) mice were fed standard chow throughout the study. Mice were weighed weekly,
until mice showed signs of anaemia or lost >20% of weight at which time they were sacrificed.
ACF were assessed using Cell~vizio Confocal Microscopy probe (Mauna Kea technologies,
Paris) made of 30,000 optical fibers following colonic staining with acryflavine. Result: High
definition images with 2.5 µm lateral resolution of normal crypts and ACF were clearly
identified using Confocal Microscopy. APCmin+/-(PPARα-/-) mice have more ACF than
APCmin+/-mice in the colon, but this failed to reach significance (n=9). The mean number
of ACF was 5.0/ 10 fields (CI 2.10- 7.90) in APCmin+/-(PPARα-/-) mice and 2.75/ 10 fields
(CI 1.22- 4.27) in APCmin+/- mice. Conclusions: Confocal Microscopy using the Cell~vizio
probe is a simple and quick method of accessing ACF, with the potential of refining
experiments so that mice can be studied serially. PPARα role in colon carcinogenesis may
be to inhibit the formation of ACF rather than their progression. Greater understanding of
PPARα dependant genes may enable the pathogenesis of colon cancer to be further under-
stood. 1. Potential role for peroxisome proliferator activated receptor (PPAR) in preventing
colon cancer. Jackson L, et al Gut. 2003 Sep;52(9):1317-22.
W1127
The Usefulness of Endoscopic Submucosal Dissection (ESD) for the Treatment
of Premalignant and Malignant Gastric Neoplasm
Sun-Taek Choi, Tae-Nyeun Kim, Jung-Hoon Lee, Jong-Ryul Eun, Jun-Hwan Kim, Byung-
Ik Jang, Heon-Ju Lee
Background/Aims; Minimally invasive treatment such as endoscopic mucosal resection (EMR)
is widely used as a treatment for gastric neoplasm. But, it is difficult to obtain en bloc
resection in case of large lesion with a conventional EMR techniques. Recently, ESD is
reported to be a promising method to resect the lesion as an en bloc. The purose of this
study was to evaluate the efficacy and safety of ESD. Methods; 78 patients referred for
ESD between September 2004 and November 2005 were studied prospectively. ESD was
performed using IT-knife or needle knife after submucosal injection of saline-epinephrine
solution. The en bloc resection rate, complete resection rate and associated complications
were recorded. Results; 83 lesions were removed by ESD in 78 patients. Indications were
adenoma 56.6%, dysplasia 9.6%, adenocarcinoma 33.7%. 3 cases of scar like mucosal lesion
were resected (two cases; adenocarcinoma, one case; adenoma). The median size of the
lesion and the resected specimen was 15.0 mm, 24.8 x 18.0 mm, respectively. The en bloc
resection rate and complete resection rate were 95.2%, 91.6%, respectively. Complication
rate for bleeding after ESD was 18%. 11 cases(73%) of bleeding were notified during early
second look endoscopy within the first 24 hours. Hemostasis was achieved in all cases in
response to endoscopic therapy. One case of perforation underwent an operation because
the specimen spilt on the peritoneal cavity. The mean length of procedure time and hospital-
ization were 40 minutes, 5.5 days, respectively. Post-ESD histopathology was adenoma 47%,
dysplasia 12%, adenocarcinoma 41%. ESD resulted in upgrading of pathologic staging to
adenocarcinoma or dysplasia in 22%. Conclusions; ESD has high en bloc and complete
resection rate in gastric neoplasm. ESD is associated with perforation and a high risk of
bleeding, sufficient experience and endoscopic treatment technique are essential. Early second
look endoscopy within 24 hours may be helpful to prevent bleeding from ESD. ESD changes
pathologic diagnosis in a significant number of patients. Long-term follow up results of ESD
are needed.
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Comparision of Ultrahigh and Standard Resolution Optical Coherence
Tomography (OCT) for Endoscopic Imaging of the Esophagus
Hiroshi Mashimo, Saleem Desai, Yu Chen, Aaron D. Aguirre, Pei-Lin Hsiung, Shu-Wei
Huang, Joseph M. Schmitt, James G. Fujimoto
BACKGROUND/AIMS: Endoscopic optical coherence tomography (EOCT) is an emerging
medical imaging technology which generates high resolution, cross-sectional images in situ,
without tissue removal. Previous clinical studies using EOCT with 10-15 um axial resolution
have demonstrated its capability in diagnosing Barrett’s Esophagus (BE). Quantitative EOCT
image analysis was promising for detecting high grade dysplasia in BE patients. We recently
developed an EOCT with improved axial resolution (5 um). The goal was to compare
standard and ultrahigh resolution OCT (UHR-OCT) for image quality and algorithmic
detection of BE. METHODS: Images of the esophagus were obtained in vivo using UHR-OCT
(5 um) and standard OCT (12 um). Image quality was compared and assessed quantitatively
(speckle size). Image features of 50 endoscopic OCT images from normal and Barrett’s
esophagus were extracted through computational metrics including the intensity histogram
(mean and standard deviation), spatial frequency analysis (2D FFT), and statistical texture
analysis (center symmetric auto-correlation). These features were analyzed using principle
component analysis (PCA) to reduce the vector dimension and increase the discriminative
power. RESULTS: UHR-OCT images of both in vivo and ex vivo GI tissues showed improved
visualization of fine architectural features over standard resolution. In addition, the quantitat-
ive image feature analysis showed reduced speckle size and enhanced discrimination of
normal (o) and Barrett’s (+) esophagus with UHR-OCT. The variance of the first 2 principle
components are further separated for texture features in the UHR-OCT images (Fig. 1).
CONCLUSIONS: The ability of UHR-OCT to image tissue morphology at an improved
resolution could help in discerning the fine features in OCT images, which could be useful
in diseases diagnosis. The enhanced classification abilities of image features using UHR-
OCT would help in the computer aided diagnosis of GI diseases. This work demonstrates
enhanced discrimination of BE from normal esophagus, but these results may also prove
important in the discrimination of dysplasia from Barrett’s tissues.
W1129
Endoscopic Optical Coherence Tomography (EOCT) with Balloon Based
Catheter Probe ---for the Screening of Barrett’s Esophagus (BE)
Zhilin Hu, Michael V. Sivak, Andrew M. Rollins
The presentation will report a device based on endoscopic optical coherence tomography
(EOCT) imaging that can accurately and safely screen patients with Barrett’s esophagus (BE)
for changes in the esophagus that anticipate the development of cancer of the esophagus.
Barrett’s esophagus (BE) is a premalignant condition that occurs in a large proportion of
individuals with reflex of gastric acid into the esophagus. Once established, BE confers a
10% life-risk of esophageal cancer. Management of patients with BE is by surveillance for
precancerous changes (known as dysplasia). Surveillance consists of examination of the
esophagus by endoscopy at intervals of 1-2 years with procurement of biopsies from the
involved segment of the esophagus. Biopsies are taken because the precancerous changes
are usually microscopic and not visible at endoscopy. Thus, biopsies are taken according
to a specific sampling protocol. However, it is well established that even the best sampling
protocol can overlook the presence of precancerous changes (dysplasia). Moreover, surveil-
lance based on biopsies is time consuming and expensive. Endoscopic OCT (EOCT) was
developed as an imaging modality for use at endoscopy. EOCT imaging is performed using
a catheter probe inserted through the endoscope. By virtue of its high resolution and other
properties, EOCT demonstrates the microscopic structure and tissues of the wall of the
esophagus. In a series of clinical trials, our group has shown that EOCT has an accuracy
of 70% for the detection of dysplasia in BE. If importance, the negative predictive value of
EOCT for the presence of dysplasia is greater than 90%. Additionally, preliminary work
suggests that the accuracy can be increase by computer aided diagnosis (CAD). Unfortunately,
the EOCT probe images relatively small volumes of tissue. Thus, it is unsuitable for a
surveillance examination of a large surface area of tissue, which in a patient with well
developed BE could be as much as 20 square centimeters or more. What is needed, therefore,
is a device that can provide OCT imaging data for the entire area of the esophagus involved
by BE. At the presentation, we will describe the detail of our device, EOCT and a prototype
of catheter probe equipped with an inflatable centering balloon that can be inserted through


















Endoscopic Tri-Modal Imaging (ETMI) for the Detection of Dysplastic Lesions
in Barrett’s Esophagus
Wouter L. Curvers, Louis M. Wong Kee Song, Kenneth K. Wang, Christopher J. Gostout,
Micheal B. Wallace, Herbert C. Wolfson, Krish Ragunath, Paul Fockens, Fiebo J. Ten
Kate, Kausilia K. Krishnadath, Jacques J. Bergman
Background The ETMI system (Olympus, Tokyo, Japan) incorporates high-resolution endos-
copy (HRE), autofluorescence imaging (AFI) and narrow band imaging (NBI) in a single
device. The system uses an endoscope with 2 CCD chips; one for HRE and NBI (with an
optical zoom function) and one for AFI. In the AFI mode, real-time images are constructed
using a new algorithm based on total tissue autofluorescence and green reflectance. The
aim of this multi-center feasibility study was to investigate the diagnostic potential of ETMI
and the relative contribution of each modality for the detection of dysplasia in Barrett’s
esophagus (BE). Methods Pts with known BE with or without a prior diagnosis of dysplasia
were recruited in the study. The esophagus was first inspected with HRE followed by AFI
for the detection of additional suspicious lesions. All lesions detected with HRE or AFI were
subsequently inspected by NBI using the zoom mode to evaluate the presence of abnormal
mucosal and microvascular patterns followed by biopsies for blinded histopathological
assessment. Standard surveillance biopsies were also performed. Results Twenty-three pts
have been assessed with the ETMI system to date, including 9 pts referred for inconspicuous
dysplasia and 14 pts participating in a standard surveillance program. Per patient assessment:
6 pts were diagnosed as having high-grade dysplasia (HGD), and 4 of them had lesions
detected with HRE and AFI. In one of these pts, AFI detected an additional lesion with
HGD that was missed under HRE. In 2 pts, no abnormalities were seen with HRE and HGD
was solely diagnosed with AFI. In total, 9 pts were diagnosed with low-grade dysplasia
(LGD) or HGD. In 5 pts, dysplastic lesions were detected with HRE and AFI. In 4 pts, LGD
or HGD was detected only with AFI. Per lesion assessment: 30 suspicious lesions were
identified with AFI; 7 of these contained HGD, the remaining 23 (77%) were found to be
false-positives for HGD. With detailed characterization of these lesions using NBI, 5 of the
7 lesions containing HGD were classified as suspicious. Seven of the 23 false-positive lesions
were also classified as suspicious thereby reducing the overall false positive rate to 23%.
Conclusion AFI appears to enhance the detection of dysplastic lesions relative to HRE.
However, AFI seems to be associated with a high false-positive rate, which may be reduced
with the addition of NBI. The potential of ETMI for enhancing lesion detection in BE is
promising but a more accurate assessment of its diagnostic performance will be obtained
as more patients are enrolled in this ongoing multi-center study.
W1131
Comparison Between Multislice CT and Endoscopic Ultrasound (EUS) in the
Diagnosis and Staging of Pancreatic and Periampullary Malignancy
Mansfield Stephen, John Scott, Kofi W. Oppong, David Richardson, G Sen, Bryon C.
Jaques, C O'Suilleabhain, Derek Manas, Richard M. Charnley
Introduction Multislice CT, which offers improved scanning speed and resolution compared
to conventional CT, was compared with EUS in patients with pancreatic and periampullary
malignancy. Methods Prospective data collection on all suspected pancreatic and periampul-
lary cancers between June 2002 and June 2004. Dynamic triple phase multislice CT and
EUS were performed where clinically indicated. For quality reasons only in-house CTs were
accepted for the analysis. Presence of malignancy, portal vein invasion and resectability were
compared using McNemar’s test of paired proportions (Table 1). Results Of 345 patients,
134 underwent in-house multislice CT, 188 EUS and 84 both. Of these, 35 underwent
laparotomy. The use of EUS guided fine needle aspiration was not assessed. No significant
difference was demonstrated between the modalities either in the whole cohort or when
small tumours (≤20mm) were analysed separately. When the clinical impact was assessed
EUS had most impact in the following groups of patients: Benign on CT - 5/21, 23.8%;
Portal vein invasion on CT - 18/37, 49%; Uninterpretable CT findings - 9/9, 100%. Conclu-
sion Multislice CT is the primary imaging modality in assessing these tumours. EUS is not
indicated in those patients in whom CT confidently demonstrates a resectable tumour. In
those patients in whom CT suggests benign disease or borderline vascular invasion, however,
EUS has an important role in determining resectability.
W1132
Patients with Celiac Sprue Appear to Have An Increased Incidence of White
Matter Brain Lesions On Cerebral Magnetic Resonance Imaging (MRI)
Friedemann Paul, J.N. Wurfel, Bertram Wiedenmann, Axel U. Dignass, Daniel C.
Baumgart
BACKGROUND: Celiac sprue causes neurological symptoms in 10% of patients. Clinical
presentation can be subtle and may even occur in the absence of gastrointestinal symptoms.
Common neurological manifestations of celiac disease include ataxia and polyneuropathy.
White matter lesions (WML) occur in a variety of inflammatory conditions and can be
detected with cerebral magnetic resonance imaging (cMRI). Their prevalence in patients
with elevated gliadin serum antibody levels or celiac sprue is not known. METHODS: In
this prospective, comparison study 41 adult patients with either WML of unknown etiology
(group 1) despite an extensive work-up including spinal tap and serologic screening for
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infectious, autoimmune, metabolic, genetic diseases, and imaging studies to rule our cardiova-
scular conditions or small intestinal biopsy proven celiac sprue with no apparent neurolo-
gically symptoms (group 2) were evaluated. RESULTS: In group 1, 11% of patients were
positive for gliadin or transglutaminase antibodies. Two of these patients presented with
atypical optical neuritis. In group 2, none of the patients had any abnormal electrophysiolo-
gical findings, but there was an increased incidence (25%) of WML on cMRI (Fig. 1).
Recruitment is still ongoing. CONCLUSION: Based on the data analyzed to date, the preval-
ence of gliadin antibodies in patients with WML of unknown etiology appears to be similar
to what has been reported for the normal population (12 to 15%). In patients with celiac
disease though, there seems to be an increased incidence of WML even in the absence of
neurological symptoms. cMRI may be helpful to detect neurological abnormalities in celiac
sprue patients early on.
Fig. 1
W1133
Sonoct® - A New and Promising Imaging Technique That Improves On
Conventional Ultrasound in the Visualisation of Pancreatic Duct
Steffen Rickes, Janett Boehm, Klaus Moenkemueller, Peter Malfertheiner
Background and aims: In sonographic diagnostic investigation, evaluation of the pancreatic
duct plays an important role. Evaluation frequently relates to changes to the duct, as might
result from chronic pancreatitis or pancreatic carcinoma. This prospective study aimed to
establish whether the new SonoCT® can improve on conventional ultrasound technique in
the visualisation of the pancreatic duct. The study specifically focused on the role of the
examiner in achieving good results. Patients and methods: The pancreatic duct of 14 healthy
volunteers were assessed by an experienced and an inexperienced examiner, respectively,
using both traditional B-mode sonography and SonoCT® (dynamic 2-5 MHz sector scanner,
HDI 5000, Philips Ultrasound, Bothel, WA, USA). Assessment was based on a pre-determined
set of criteria. Chi-square test was used to detect significant differences between both
ultrasound methods. Results: In none of the probands, conventional B-mode sonography
was able to clearly delineate the pancreatic duct. This is in marked contrast to 100% of
probands using SonoCT® (p<0.05). Both examiners fully concurred on this (100%) in
their respective assessments. SonoCT® also achieved significantly better results in terms of
visualising borders. Whilst in conventional B-mode sonography, partial fine focusing of the
Wirsungs duct could only be achieved in 4 out of 14 cases (29%), fine focusing of the
pancreatic duct was successful in all cases using SonoCT® (p<0.05). Again, both examiners
entirely concurred on this. Regarding clarity of representation, both examiners again agreed
on significant advantages offered by SonoCT®. Using SonoCT®, the experienced examiner
in particular judged the Wirsungs duct to be completely anechoic in 12 out of 14 cases
(86%), compared to no such rating for conventional B-mode sonography (p<0.05). Conclu-
sion: SonoCT® yields markedly better results than conventional B-mode sonography in
terms of delineation, visualisation of borders and artefact-free representation of the pancreatic
duct. Future studies will be needed to determine whether certain diseases can be diagnosed
more readily using SonoCT® rather than conventional sonographic technique.
W1134
Qualitative and Quantitative Analysis of Contrast-Enhanced Extracorporeal
Ultrasonography (US) in the Diagnosis of Gallbladder Diseases
Yukinari Matsumoto, Yoshiki Hirooka, Akihiro Itoh, Hiroki Kawashima, Kazuo Hara,
Akira Kanamori, Hiroki Uchida, Jun Goto, Koji Nonogaki, Naoki Ohmiya, Yasumasa
Niwa, Hidemi Goto
Recently, contrast-enhanced US(CE-US) has been developed in digestive organs, but there
are few reports of quantitative analysis. In this study, we evaluated the diagnostic usefulness
of CE-US in gallbladder disorders both qualitatively and quantitatively. (Subjects and
methods) The subjects consisted of 16 gallbladder disorders (8 carcinoma - 3 papillary
adenoca., 3 tubular adenoca. and 2 adenosquamous ca.-, 1 cholesterol polyp(CP), 6 chronic
cholecystitis(CC), 1 adenomyomatosis(AM)). The agent (Levobist, Nihon Schering, Japan)
was adjusted to 300mg/ml in concentration, and was injected intravenously inserted into
the right median antecubital vein, at a rate of 1ml/sec (8 ml in total volume). The observation
procedure was as follows: 1) The target lesions were observed by pulse inversion harmonic
mode with low mechanical index (M.I.) value (0.4) for 60 seconds after injection - early
phase. 2) After three minute suspension of scanning, the lesions were observed by the same
mode with high M.I. value (1.3) by a sweeping scan around the lesion- late phase. In all
cases, we evaluated enhancement effect between plain images and enhanced images both
qualitatively and quantitatively. For the quantitative analysis, a region of interest (ROI) was
established by a circle (diameter, 5 mm) in the target lesion. The intensity (dB) in the circle
was measured using QLAB (Philips, USA). QLAB was provided by Philips and this software
tools rapidly quantify image characteristics within ROI. In the early phase, the percentage
change (max intensity / pre-enhancement intensity) was measured. The apparatus used was
HDI-5000 (ATL, Philips, USA). (Result) The enhancement patterns of carcinoma were
classified into three patterns: arborizing enhancement in 2 cases, dotted-rich enhancement
in 2 cases and dotted-poor enhancement in 2 cases and no enhancement in 2 cases. As to
papillary adenoca., two cases showed arborizing enhancement and one case was dotted-rich
enhancement. As to tubular adenoca., one case showed dotted-rich enhancement and dotted-
poor enhancement was seen in 2 cases. There were no enhancement effects in 2 cases of
adenosquamous ca.. In 8 cases of CP, CC and AM, the enhancement effect was poor and
could not classified into any pattern. As for quantitative analysis, the percentage change
(max intensity / pre-enhancement intensity), gallbladder carcinoma (2.28) showed the higher
value than that of another gallbladder diseases (1.63). (Conclusion) Although further analysis
using other parameters for more lesions is needed, quantitative analysis in addition to
qualitative evaluation may be helpful in the diagnosis of the gallbladder diseases.
W1135
Chromoscopic Magnifying Colonoscopy for Colorectal Cancer Screening: Is It
a Better Tool?
Hulya Cetinkaya, Ali Tuzun, Mehmet Bektas, Murat Toruner, Arzu Ensari, Irfan Soykan,
Ali Ozden
Background: Conventional colonoscopic examination has been reported to be one of the
most commonly used techniques in colorectal cancer screening. In recent years, it has been
shown that chromoscopic magnifying colonoscopy combined with chromoscopic agents
permits early detection of neoplastic colorectal lesions, especially flat and depressed types
which are known to be somehow difficult to detect with convensional colonoscopy. We
therefore conducted a study to examine the role of chromoscopic magnifying colonoscopy
in colorectal cancer screening. Subjects and Methods: 75 asymptomatic subjects over 50 years
old who were admitted to Ankara University Medical School, Gastroenterology department for
colorectal cancer screening were recruited into this study. Following an appropriate sedation
with either propofol or midozolam, “back to back colonoscopy” was performed to each
subject. Conventional pan-colonoscopy with targetted biopsy was performed initially fol-
lowed by magnifying colonoscopy for chromoscopic evaluation of recto-sigmoid area. Addi-
tional biopsies were obtained as well during magnifying colonoscopy from additional suspi-
cious lesions. Results: Thirty patients were male and forty-five subjects were female with a
median age of 58 years (range: 50-60 years). Mean colonoscopy time (both first phase
“conventional” and second phase “back to back” was 35.3±13.3 minutes. Mean volume of
0.4% Indigo Carmine was 9.9±5.3 mililiters. Overall, forty-one suspicious lesions were
detected in 23 subjects (30.1%), following indigo carmine dye spraying and 62 additional
abnormalities were detected in 48 subjects (64%). Thirteen of the additional abnormalities
were serrated adenomas, while thirty lesions were flat elevated lesions, eighteen lesions
were polipoid lesions and one of them was a depressed lesion. Conclusion: Chromoscopic
magnifying colonoscopy might be a better technique than conventional colonoscopy in
detecting colorectal malignant and/or pre-malignant lesions. However, studies sould be
performed to evaluate cost effectiveness of this technique in colorectal cancer screening
before using it in population screening.
W1136
Assessment of Methods to Quantify Autofluorescence Intensity in
Adenomatous Polyps
Audrey L. McCallum, John T. Jenkins, Derek Gillen, Richard G. Molloy
Introduction The technology of autofluorescence (AF) endoscopy is based on tissue fluores-
cence of endogenous molecules and has been developed to improve detection of GI lesions.
It produces a colour image with an autofluorescence intensity (AI) reading which indicates
the strength of green autofluorescence and red reflectance present within the tissue. A wide
variation in AI readings in colonic polyps was noticed when assessing with AF colonoscopy.
Our aim was Aim To better quantify AI readings in relation to presence and degree of
dysplasia of adenomatous polyps. Methods 51 patients were assessed with AF colonoscopy
(Xillix LIFE-GI) with AI readings recorded of polyps, surrounding area to polyps and rectum.
Biopsies of all polyps were taken. A total of 38 polyps were identified of which 20 were
confirmed histologically to be adenomatous. Five different methods were used to quantify
AI reading with degree of dysplasia. The first used AI polyp alone (P), the second used AI
polyp minus AI surrounding tissue (P-ST), the third being AI polyp minus AI rectum (P-
R), the fourth AI polyp/AI surrounding tissue ratio (P/ST) and finally AI polyp/AI rectum
ratio (P/R). The five methods were tested statistically to determine if there was a significant
difference for degree of dysplasia for any method. Results A significant statistical difference
for degree of dysplasia, using Kruskal-Wallis test, was found with P/R method (p value of
0.02). The other methods did not produce a stastically significant difference with p values
of 0.43 for P, 0.49 for P-ST, 0.34 for P-R and 0.89 for P/ST. Conclusion AI readings can
be better quantified in relation to degree of dysplasia within adenomatous polyps when a
ratio is used of AI polyp/AI rectum. This new AI measurement may allow autofluorescence
colonoscopy to determine the degree of dysplasia within adenomatous polyps.
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W1137
Evaluation of Autofluorescence Colonoscopy for the Detection and Diagnosis
of Colonic Polyps
Audrey L. McCallum, John T. Jenkins, Derek Gillen, Richard G. Molloy
Introduction: Autofluorescence (AF) has been developed to enhance conventional white
light (WL) endoscopy in the diagnosis of neoplastic lesions of the GI tract. It is based on
the stimulation of endogenous fluorophores and produces a pseudo-colour image of tissue.
Metaplastic polyps are common and do not need to be treated, whereas adenomatous polyps
carry a neoplastic potential. It would therefore be helpful to be able to distinguish between
adenomatous polyps and metaplastic polyps when performing colonoscopy. Aim: To evaluate
AF for the endoscopic detection and differentiation of colorectal polyps. Methods: Patients
were invited to attend for colonic assessment with both AF (Xillix LIFE-GI) and WL colonos-
copy. The intensity of autofluorescence (AI) is quantified automatically and readings, pictures
and biopsies were recorded of any visible pathology or areas of high AF. The biopsy results
were analysed and an AI reading for each biopsy site obtained by subtracting the actual AI
reading from the background reading for the rectum of each patient. Results: A total of 47
patients were assessed with AF and WL colonoscopy. A total of 33 polyps were detected
(19 adenomatous and 14 metaplastic polyps). It was found that adenomatous polyps had
higher AI readings (median 0.53, IQR 0.15-1.05), than metaplastic polyps (median 0.09,
IQR 0.06-0.10). [Mann Whitney U-test: p=0.00003] Conclusion: These early data suggest
that autofluorescence colonoscopy has the potential to differentiate between metaplastic and
adenomatous polyps and may have a role as a new diagnostic technique for the improved
detection of colonic dysplasia and early malignancy.
W1138
Randomised Prospective Study On Accuracy, Acceptability, Feasibility and
Safety of Transnasal Gastroscopy Without Sedation in Comparison to
Transoral Gastroscopy Under Sedation
Italo Stroppa, Claudio Tosti, Cinzia Razzini, Sabrina Mazzocchi, Enrico Grasso, Omero
Alessandro Paoluzi, Livia Biancone, Francesco Pallone
Background and aims - Conscious sedation is frequently required during transoral gastroscopy
(TO). Transnasal gastroscopy (TN) has proven to be less invasive than TO, suggesting
feasibility with no sedation. Aim of the study was to evaluate diagnostic accuracy, acceptabil-
ity, feasibility and safety of TN without sedation compared to TO under sedation in a series
of pts undergoing gastroscopy. Patients and methods - Thirty pts (16 male, mean age 48.47
± 13.37 years) candidate to upper GI endoscopy were randomised to undergo TN and TO,
on two consecutive days, by two different gastroenterologists. Pts underwent TO under
conscious sedation (i.v. midazolam) and TN under local anesthesia (lidocaine). Before endos-
copy, all pts were assessed for anxiety using Hamilton A scale. Diagnostic accuracy was
judged comparing endoscopic findings by TN and TO. In order to assess the concordance
of endoscopic patterns (inter-observer) a third endoscopist reviewed tape recordings of both
examinations. Reliable histology of gastric biopsy specimens collected both during TN and
TO was also considered. Acceptability was assessed on the basis of discomfort at insertion
and during endoscopy and preference between TN or TO under conscious sedation. Endosco-
pists and nurses also gave their opinion on feasibility of TN and TO. Safety of TN and TO
was evaluated comparing cardio-respiratory parameters (oxygen saturation, one-lead ECG,
blood pressure) monitored during endoscopy. Results - All pts underwent both TN and TO
but one who did not tolerate TO, which had to be stopped. All TN and TO, performed
until the second portion of duodenum was reached, showed similar findings, the concordance
between endoscopic patterns being complete. All biopsy specimens were adequate for histol-
ogical assessment. Anxiety was absent in 18 pts, mild in 9, moderate in 1 and requiring
treatment in 2. Mean scores of discomfort were similar in both groups, but 26/30 pts (87%)
preferred TN. Of 12 pts with anxiety, only 2 preferred TO with sedation. Feasibility was
good both for TN and TO. No severe cardiac or respiratory adverse event occurred during
TN and TO. Concusions - The present study demonstrates that TN without sedation is well
tolerated and better accepted than TO under sedation. The high levels of diagnostic accuracy
and safety suggest that TN should be taken into account as a valid alternative to TO in
routine diagnostic gastroscopy.
W1139
A Retrospective Analysis of Abnormal Findings On Virtual Colonoscopy
Compared with Optical Colonoscopy
Courtney Barancin, Brent Roeder, Daniel Cornett, Terrence Frick, Patrick Pfau, Andrew
Taylor, David Kim, Perry Pickhardt, Mark Reichelderfer
Background: Virtual colonoscopy (VC) is a new minimally invasive method for colon polyp
and cancer screening. At our institution, patients (pts) with abnormal findings on VC are
often referred for optical colonoscopy (OC) which allows analysis of the accuracy of VC for
detecting polyps. The aim of this study was to compare abnormal findings on VC with those
on OC. Methods: We retrospectively reviewed all OCs performed from April 2004 to October
2005 in pts referred to OC following VC. VC was performed by primary 3D read with 2D
resolution, as we have previously reported. Pts were uniformly referred for OC if they had
findings on VC of a polyp or mass greater than 10 mm. Pts with polyps between 6-9 mm
were offered OC or follow up VC under an IRB-approved protocol. Patients were also refered
to OC if a significant portion of their colon was not adequately visualized on VC. Potential
lesions under 6 mm were not reported. The number, size, and characteristics of the polyps
as well as pathology findings (if available) were recorded. Results: A total of 119 pts had
OC, with 41 pts having polyps on OC that were not seen on VC. A total of 90 polyps were
found with the following sizes: 46 were < 6 mm; 13 were from 6-9 mm; 9 were at least
10 mm; 22 insufficient information. By pathology, the number of polyps identified on OC
but not on VC that were adenomas were 4/46 (< 6 mm); 1/13 (6-9 mm); 3/9 (at least 10
mm). We found a total miss rate of polyps greater than 6 mm to be 8.4% (10/119 pts).
The total miss rate of adenomas greater than 6 mm was 3.4% (4/119 pts). The false positive

















not seen or found to be a non-polypoid lesion on OC. Conclusions: 1) The majority of
missed polyps found at OC were less than 6 mm and are not reported on VC per protocol.
2) The adenoma-miss rate of polyps greater than 6 mm on VC was very low in our study.
3) VC with our method is a highly accurate method for colon cancer and polyp screening.
W1140
Life Events and Inflammatory Bowel Disease Relapse: A Prospective Study of
Patients Enrolled in Remission
Angela Vidal, Esther Gomez Gil, Miquel Sans, Portella J. Maria, Salamero M, Pique M.
Josep, Julian Panes
The impact of life events in recurrence of inflammatory bowel disease (IBD) is unclear. We
sought to determine whether stressful life events are associated with IBD exacerbations,
hypothesizing that the exposure of life events among patients with inactive disease will
increase the risk of subsequent relapses. METHODS: In this prospective study 163 patients
with inactive IBD, who had had at least one relapse in a 2-year period before entry into the
study, were enrolled. The Social Readjustment Rating Scale (measuring life events), a measure
of the emotional impact of these life events, and an IBD activity index were completed
monthly up to the end of the study (maximum eleven months) or up to a relapse. Potential
biological factors associated with an increased risk of relapse were identified in patients who
relapsed. RESULTS: Fifty-one patients relapsed (32.9%), 104 remained in remission and
eight dropped out. Multivariate Cox regression analysis with time dependent variables
showed that a high number of life events was not associated with an increased exacerbation
rate after adjustment for significant covariates on the subsequent month (hazard ratio=0.87,
95% CI= 0.67-1.11, p=0.27) or in the time-lagged analysis (subsequent two or three month
periods). Subgroup analysis of UC and CD patients also showed a lack of association between
the number of life events and risk of relapse for all lag periods studied. The emotional
impact of stressful events was also not associated with the risk of relapse (hazard ratio=
0.99, 95% CI= 0.99-1.00, p=0.60). When patients who suffered a biological risk factor for
relapsing were excluded in subsequent statistical analyses, similar results were obtained
when analyzing the risk of relapse associated with the number of life events (hazard ratio=
0.91, 95% CI= 0.68-1.22, p=0.54) or the emotional impact of these events (hazard ratio=
0.99, 95% CI= 0.99-1.00, p=0.75).. CONCLUSIONS: Our results suggest that stressful life
events do not trigger exacerbations in patients suffering from IBD.
W1141
Role of Variant Interleukin-10 Receptor 1 (IL-10R1) Signaling in Ulcerative
Colitis (UC) and Cytomegalovirus (CMV) Infection
Paul Grundtner, Manuela Nemeth, Neeraja Kambham, Teri A. Longacre, Christoph
Gasche
Background: Animal models link the IL-10 pathway to human inflammatory bowel disease,
indicating that IL-10 regulates gut homeostasis. The IL-10 family of proteins consists of
several human and viral homologs that also share receptors. One of the viral IL-10 homolog
genes belongs to CMV and is thought to alter the host’s response to viral infection or
reactivation. Previously we have identified two variants on the IL-10R1 (SNP3 and 4) that
were associated with Crohn’s colitis but protected from UC in Caucasian populations.
Computer modeling predicted that SNP3 alters IL-10 or IL-10 homolog binding to the
extracellular receptor domain (J Immunol 170:5578). SNP3 is in linkage disequilibrium
with SNP4 building the SNP3+4 haplotype. In this study we asked whether these IL-10R1
variants alter the likelihood of CMV reactivation in patients with colitis and thereby predispose
certain populations. Methods: Genomic DNA from 78 colitis patients and 100 ethnicity
matched controls (mainly normal tissue from cancer patients) was isolated from paraffin
embedded tissue (colonic biopsies or colectomy samples) and small fragments (80-150bps)
spanning the IL-10R1-SNP3 and IL-10R1-SNP4 were amplified by PCR, purified, and
sequenced. CMV positive cases were identified from histological slides by H&E and immuno-
histochemistry against CMV immediate early antigen (Am J Surg Pathol 28:365). Results:
In the colitis population, the allele frequencies of IL-10R1 SNP3 and SNP4 were significantly
higher than in controls (SNP3 p<0.05, SNP4 p<0.001, by chi square). No difference was
seen between refractory and non-refractory cases, however, the CMV positive population
showed the highest allele frequency of the SNP3+4 haplotype (table). Within this group, 50%
of patients were heterozygous for this allele. Conclusions: The unexpected high frequency of
IL-10R1 variants in this colitis population may reflect ethnic or diagnostic differences to
previous studies. The enrichment of SNP3 alleles in the CMV-positive population, however,
points to the presence of genetic predisposition in this cohort. These findings fit with
computer modeling of SNP3 and justify further studies to elucidate the role of variant IL-
10 signaling in CMV reactivation.
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W1142
Nonsteroidal Anti-Inflammatory Drug Use and Inflammatory Bowel Disease
Relapse: Individual and Disease-Specific Susceptibility Factors
Mireia Penalva, Javier P Gisbert, Olga Merino, Marta Lucia Luna, Miquel Sans, Nuria
Massuet, Josep Maria Pique, Julian Panes
The effect of nonsteroidal anti-inflammatory drugs (NSAIDs) on inflammatory bowel disease
(IBD) remains controversial. AIMS: To determine the relationship between NSAIDs use and
IBD relapse. To explore the possible existence of disease or individual susceptibility factors.
PATIENTS AND METHODS: Consecutive outpatients with established diagnosis of ulcerative
colitis (UC; n=198) or Crohn’s disease (CD; n=216) were included. Patients under medical
treatment for achieving remission were excluded. Patients with active IBD as determined
by the corresponding index (Harvey- Bradshaw or Truelove) were considered cases. Patients
in remission were considered controls. Data about NSAIDs consumption during the last 6
months before the visit and previous history of relapse related to NSAIDs use were collected.
RESULTS: 414 patients were included; 108 were cases and 306 controls. Overall, 30% had
used NSAIDs within the previous 6 months. The case-control study showed an association
between NSAIDs use within the previous 30 days and IBD relapse (28% cases, 16% controls;
p=0.0054), which remained significant for the period of the previous 14 days (22% cases,
12% controls, p=0.008), but not for the period of -15 to - 30 days. There was no association
between NSAIDs consumption within the 6 previous months and IBD activity. When examin-
ing separately UC and CD, statistic significance was found only for UC patients (27% cases,
10% controls, p=0.004) but not for CD (18% cases, 14% controls, p=0.40). Logistic regression
analysis confirmed that NSAIDs use is an independent risk factor for disease relapse in UC
(OR 3.93, CI 95% 1.65-9.37, p=0.002), but not in CD (OR 1.48, CI 95% 0.65-3.35, p=
0.34). In the subgroup of patients having consumed NSAIDs during the previous 14 days,
a significant relationship was detected between disease activity at time of evaluation and a
previous individual history of relapse related to NSAIDs (15% cases, none controls; p=
0.017;PPV=0.9). CONCLUSIONS: In IBD patients, NSAIDs use within the two previous
weeks is related to an increased risk of relapse. This association is observed in UC. The risk
of relapse related to NSAIDs remains constant in individual patients and can be used to
identify susceptible and tolerant patients.
W1143
Radiological Sacroiliitis in Crohn’s Disease: A Multicenter Association Study
Harald Peeters, Bert Vander Cruyssen, Herman Mielants, Kurt de Vlam, Severine
Vermeire, Edouard Louis, Paul Rutgeerts, Jacques Belaiche, Martine de Vos
Background: Radiological sacroiliitis (SI), a hallmark of spondylitis, is considered to be the
most frequent objective extra-intestinal manifestation (EIM) of Crohn’s disease (CD). SI in
CD can be asymmetrical and is often asymptomatic. Data on the association of SI with other
clinical features of CD are scarce. A possible association with the presence of CARD15
polymorphisms has been suggested. Aim: To investigate in a cross-sectional, multicentric
study the association of SI in CD patients with clinical phenotypes of the disease, other EIM
and the presence of CARD15 polymorphisms. Methods: Radiographs of the sacroiliac joints
were taken in a total of 236 CD patients from 3 Belgian university hospitals (Gent, Leuven,
Liège) and scored by 2 rheumatologists. Sacroiliitis was defined as the presence of at least
grade 2 unilateral or bilateral changes. We recorded sex, age, age at onset of CD, disease
duration, familial history, smoking habit, the history of ileal resections, fistulas and EIM
including axial disease (inflammatory back pain or ankylosing spondylitis), peripheral arth-
ritis, uveitis, erythema nodosum, pyoderma gangrenosum and primary sclerosing cholangitis
and the CARD15 genotype (R702W, G908R and/or 1007fs). X2 and Mann-Whitney U tests
were used for univariate analysis. Multivariate analysis was performed using logistic regression
(SI as dependent variable), including all clinical features and CARD15 polymorphisms.
Results: In 7 patients the quality of the radiographs did not allow an adequate scoring of
the sacroiliac joints. Sacroiliitis was diagnosed in 63 of the remaining 229 patients (27.5%)
of whom 23 had unilateral SI grade 2 and 40 patients had bilateral changes or a higher
grading. Thirty-six of the 63 patients with SI (57.1%) had no known history of inflammatory
back pain. Compared to patients with normal sacroiliac joints, patients with radiological SI
had more peripheral arthritis (42.9% vs 24.7% P=0.007, OR 2.3, 95% CI 1.2-4.2) and
uveitis (15.9% vs 6.6%, P=0.03, OR 2.7, 95% CI 1.1-6.6) in their history. No associations
with the other recorded clinical features or with CARD15 polymorphisms were found. Only
the association with peripheral arthritis was confirmed in a multivariate analysis (peripheral
arthritis P=0.023; uveitis P=0.073). Conclusions: Our study confirms the high prevalence
of (often asymptomatic) radiological sacroiliitis in a multicenter CD cohort. Patients with
SI are more prone to develop peripheral arthritis during their disease course, suggesting a
similar pathogenetic mechanism. We could not confirm the previously reported association
between SI and the presence of CARD15 polymorphisms.
W1144
Most Frequent Forms of Patient’s Non-Adherence to the Treatment of
Inflammatory Bowel Disease
Petr Cerveny, Martin Bortlik, Milan Lukas, Milan Nobilis, Jiri Vlcek
Objective: Non-adherence to the treatment of inflammatory bowel disease (IBD) is reported
to be a quite often event and such patients are exposed to higher risk of relapse. We assessed
the overall non-adherence to the treatment among patients with Crohn’s disease (CD) and
Ulcerative colitis (UC) and quantified it’s most frequent forms. Patients and methods: 177
IBD patients were enrolled in our prospective study (84 male, 93 female, mean age 36,9,
range 16 - 78, 117 CD, 60 UC). Patients were interviewed about their non-adherent behavior
during the treatment. Medication, disease type and activity were completed from the docu-
mentation. Of these 177 patients, urine sample was taken from 47 patients treated by
mesalamine (27 male, 20 female, mean age 38,7, range 22 - 65, 32 CD, 15 UC) for HPLC
analysis. All the data were processed with factor analysis. Results: 1.Overall voluntary non-
adherence (treatment breaking, dose reducing or medication non-refilling) was reported by
36 % of patients. These patients are likely to be chronically active or in relapse (τ =0,212,
p=0,002). A 18 % of patients reported they minimally once in their life broke the treatment.
Treatment breaking was more often among patients who ever noticed any drug adverse
effect (p=0,04). Reporting of adverse drug effects escalates with knowledge about disease
and pharmacotherapy (p< 0,01). Voluntary dose reducing was reported also by 18 % of
patients. Dose reducing was more often among patients taking themselves to be well informed
about the disease (p=0,01). A 14 % of patients occasionally non-refill the medication in
time. In voluntary non-adherence, there were no differences between male and female,
disease type, undergone bowel surgery, singles or married and smokers and non-smokers.
A 38 % of patients reported unintentional non-adherence. Forgetting of taking daily doses
paradoxically negatively correlates with number of prescribed medicines (τ = -0,217, p=
0,001). 2.In the group of 47 patients of which the urine was taken, in 6 cases (12 %)
mesalamine was undetectable, suggesting drug holiday or non-refilling of medication in
time. Of these 6 patients, 4 of them reported non-adherence in the interview. There were
no statistically significant relationships among interview data on non-adherence and results
of urine analysis. Conclusions: 1.Overall non-adherence was reported or analytically proved
among 40 % of patients. 2. Adherence to the treatment in our cohort seems to be strongly
influenced by knowledge related to disease and pharmacotherapy. Our results can stimulate
discussion how to improve education of patients.
W1145
Voluntary Childlessness in IBD
Sheetal Marri, Chul Ahn, Alan L. Buchman
Introduction: Issues surrounding childbearing have received relatively little attention even
though IBD predominantly affects women during their childbearing years. To date, only
two studies have investigated this topic, but they provided limited/conflicting data about
issues concerning childlessness. The aim of this study was to better understand patients’
considerations in decision making about pregnancy. Methods: Data were obtained from
specific questions in 3147 surveys mailed anonymously to all members of the statewide
CCFA Illinois Carol Fisher chapter. Subjects were provided a pre-addressed, pre-stamped
return envelope and instructed to return completed surveys with no identifying information.
Results: The survey response rate was 20% (637); 63% female, 34% male. A majority
(67%)indicated the state of their illness did not change previously held opinions on having
their own children. Of the 33% whose opinion changed, 59%) stated they decided to have
children despite their illness. Of the 27% of patients that decided against having their own
children the major reasons were: concern for of genetically transmission of disease to their
children (63%), concern of being unable to care for their child (59%),concern of added
stress of raising a child (55%), and concerns of worsening/recurrent IBD or their partner’s
IBD (46% and 41% respectively). In women who had undergone previous pregnancy, the
course of those pregnancies did not change opinions of 75% of the respondents regarding
future pregnancies. Of the 25% that did change their opinion,(53%) decided to have a
second pregnancy. Conclusion: This study is the largest survey to date on this issue, and
contradicts previous limited data about factors contributing the pregnancy decision making
process. Contrary to previous data(1), physician counseling against having children or for
terminating pregnancies was not a major factor in the decision making process. Our data
also indicate women with IBD do not have an increased rate of voluntary childlessness as
previously thought(2. Our data suggests a positive effect of pregnancyt in patients with IBD
on desire for future pregnancy. References: 1. Baird DD, Narendranathan M, Sandler RS.
Increased risk of preterm birth for women with inflammatory bowel disease. Gastroenterology
1990;99:987-94 2. Mayberry JF, Weterman IT. European Survey of Fertility and Pregnancy
in Women with Crohn’s Diseases: A Case-Control Study by European Collaborative Group.
Gut 1986 Jul;27(7):821-5.
W1146
Prothrombotic Mutations and Inflammatory Bowel Disease
Charles N. Bernstein, Michael Sargent, Frits R. Rosendaal
Background and Aims: Patients with Crohn’s disease (CD) and ulcerative colitis (UC) have
a 3-4-fold increased risk of venous thrombosis compared with the general population. We
aimed to determine if patients with CD and UC had increased likelihood of mutations in
genes that increase clotting risk, in a population-based case control study. Methods: Subjects
were drawn from the University of Manitoba IBD Research Registry and controls were drawn
from Manitoba Health’s administrative database. Cases (CD, n=327, UC, n=165) and controls
(n=412) underwent venipuncture and DNA was purified from whole blood. Genotypes
for common mutations were determined for factor II (prothrombin, G20210A), Factor V
(G1691A), methylenetetrahydrofolate reductase (MTHFR, C677T), and Factor XIII (val34-
leu). Results: Of all participants, 1.5% were heterozygous for Factor II G20210A and 6.1%
for Factor V, without differences between cases and controls. Only 1 subject was homozygous
for Factor V mutation (and none were homozygous for Factor II mutation). UC patients
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were less likely than controls to have a mutation in MTHFR (50.3% vs 59.4%), with odds
ratio (OR) for carrying at least one copy of the mutated C377T allele of 0.7, (95% CI, 0.47-
1.01). CD patients were more likely to be homozygous for the FXIII val34leu mutation than
controls (8.7 vs 4.3%) (OR=2.0, 95% CI 1.04-4.27). Age, sex, or disease phenotype did
not modify these associations. Conclusions Although we found an increase in homozygosity
for FXIII val34leu mutation for CD vs controls, we could not explain the increased risk of
venous thrombosis in CD and UC by these 4 common genotype mutations. However, this
increase in mutated Factor XIII in CD should be further explored.
W1147
The Manitoba IBD Cohort Study: A Comparison of Participants’ Perceptions
Regarding Psychological Health, Disability, Social Supports, and Access to
Health Care with a Population-Based Control
Linda Rogala, Norine Miller, Ian Clara, Patricia Rawsthorne, Lesley A. Graff, Cory
McPhail, John R. Walker, Charles N. Bernstein
The Manitoba IBD Cohort Study is a longitudinal, population-based study of multiple
determinants of health outcomes in IBD in those diagnosed within 7 years at enrollment.
In this substudy we aimed to determine participants’ perceptions of their physical and
psychological health, social supports, and access to health care. Methods: Interview questions
were directly drawn from the Canadian Community Health Surveys 1.1 and 1.2 (CCHS)
which allowed us to compare the IBD cohort to a community sample matched on age,
gender, and region. All comparisons reported as significantly different were at p<0.01.
Results: IBD participants (n=388)reported significantly higher levels of personal disability,
with more days spent in bed and decreased activity levels at home and work. IBD subjects
had higher levels of daily stress, and lower levels of general well-being. IBD participants
reported significantly increased barriers to health care, including difficulties with transporta-
tion to health services, availability of health services, waiting time to see a doctor, and cost
of health care. However, availability of social support (including someone who helps with
household chores, someone to confide in, someone who provides love, someone who helps
with worries or gives suggestions, someone who makes them feel wanted and frequency of
affective support in the prior year) as well as employment levels and levels of work stress
were not different between IBD and controls. Furthermore, despite significantly increased
daily stress, lower well-being and less access to health care, IBD participants were not
different in terms of alcohol intake and were less likely to use alternative or complementary
medicines. Conclusions; The finding that IBD participants reported increased barriers to
health care is surprising as this region is served by a universal health care system with no
charge for physician visits or hospital services. It may be that individuals with a serious
disease requiring specialized services find it difficult to obtain prompt access to the services
they need relative to individuals who are more likely to be healthy and require fewer services.
While IBD participants experienced more stress and disability, they are as likely to be
employed as controls (although may be missing more work) and on balance have similar
levels of social support. Their degree of perceived stress and general well-being may require
professional intervention. Several studies have reported on complementary medicine use in
IBD, but this is the first controlled study to show that this use is less than in general population.
W1148
TNF-α Neutralizing Antibody Improves Endothelial Dysfunction in Patients
with Crohn’s Disease
Alessandro Armuzzi, Francesca Schinzari, Barbara de Pascalis, Nadia Mores, Giovanni
Gasbarrini, Domenico Melina, Carmine Cardillo
Background: Persistent systemic inflammation due to dysregulated cytokine activity may
predispose patients with inflammatory bowel disease (IBD) to increased risk of premature
atherosclerosis. Activation of the proinflammatory cytokine tumor necrosis factor-α (TNF-
α) observed in patients with IDB could be involved in the pathogenesis of endothelial
dysfunction. Methods: Endothelium-dependent and -independent vasodilator responses to
intraarterial infusion of increasing doses of acetylcholine (ACh) and sodium nitroprusside
(SNP), respectively, were assessed by strain-gauge plethysmography in patients with Crohn’s
disease (CD; n=12) or ulcerative colitis (UC; n=12) and in a group of matched controls (n=
12). In patients with CD, vasodilator function was reassessed following intraarterial infusion
of infliximab, a TNF-α neutralizing antibody (200 µg/min, 60 min). Results: Both patients
with CD and UC had elevated circulating levels of inflammatory mediators (C-reactive
protein and interleukin-6; both P<0.05 vs. controls), without differences between the 2
disease groups (both P>0.05). Circulating levels of TNF-α and soluble TNF receptor type
1 and 2, in contrast, were similar among the 3 groups (all P>0.05). Endothelium-dependent

















with UC (P=0.46 vs. controls). By contrast, endothelium-independent vasodilation was not
different among the 3 groups (P=0.69). In patients with CD, TNF-α neutralizing antibody
markedly enhanced the responsiveness to ACh (P=0.005 vs. saline), but did not affect the
response to SNP (P=0.53). Conclusions: Despite comparable degrees of systemic inflammation
in patients with CD and UC, endothelial dysfunction is present only in patients with CD.
In these patients, even in the absence of increased circulating TNF-α activity, intravascular
administration of TNF-α neutralizing antibody beneficially affects endothelial function. These
findings suggest a predominance of disease-specific factors over inflammation per se in the
pathophysiology of the atherogenic process and underscore the mechanistic role of selective
cytokines activated within the vessel wall.
W1149
Post-Operative Complications Related to Surgical Approach and Medical
Therapy for Inflammatory Bowel Disease
Lori A. Coburn, Brad E. Maltz, Paul E. Wise, Alan J. Herline, Roberta L. Muldoon,
Tatsuki Koyama, David A. Schwartz
Introduction: Advances in medical and surgical treatment of inflammatory bowel disease
(IBD) in the last decade has led to the increasing utilization of immunosuppressive agents,
biologic medications, and laparoscopy (LAP). Steroids have been shown to increase the risk
of post-operative complications, but the affect of other commonly used agents such as
azathioprine (AZA), 6-mercaptopurine (6-MP), methotrexate (MTX), and infliximab (IFX)
on post-operative complications has not been fully defined. Methods: Charts of patients
(pts) with IBD who underwent surgery at an academic medical center from 2001-2005 were
reviewed. Pts with follow-up <4 mos were excluded, therefore 124 pts were identified. Pts
were categorized by IBD type [Crohn’s (CD) / ulcerative colitis (UC)], meds at the time of
surgery [IFX (within 8 wks), prednisone low (≤ 20mg daily) or high (>20mg daily) dose,
AZA/ 6-MP, MTX], and type of surgery (open or LAP). Results were controlled for age,
gender, smoking, timing of surgery (emergent vs. elective), disease location, and preoperative
albumin level. Complications were divided into early (≤ 30 days) and late (>30 days).
Wound infection, wound dehiscence, recurrent disease, and pneumonia were considered
minor complications. Major complications included anastomotic leak, abscess/fistula, sepsis,
bacteremia, small bowel obstruction, thromboembolism, or death. Results: Of the 124
surgeries, 69 were LAP (56%) and 87 had CD (70%). Overall complication rate was 50%
(2/3 were major complications). 72 (58%) pts were on steroids (33 low dose), 74 (60%)
were on AZA/6-MP, 7 (6%) were on MTX, and 44 (35%) were on IFX. After controlling
for confounding, there was no increase risk of complications associated with the use of any
of these agents except IFX. 64% of pts who received IFX within 8 weeks of surgery had a
complication vs. 43% of pts not on IFX (p=0.012), with an odds ratio of 3.7 [95%CI (1.3-
10.3)]. Further analysis of the IFX group revealed a trend toward a higher number of minor
complications. There was no difference in complication rates based on approach (open vs.
LAP) or IBD type. Conclusions: There is a significant increase in post-operative complications
associated with IFX within 8 weeks of surgery, but not with steroids, AZA/6-MP, or MTX.
Laparoscopy and type of IBD is not associated with an increased risk of post-operative
complications. Prospective evaluation of complications associated with IFX is warranted.
W1150
Azathioprine Intolerant Crohn’s Disease Patients: A Clinical Subgroup with
Significantly Worse Disease Complications, Severity and Disability
Ramesh Ashwathnarayan, Lydia R. Weber, Mazen Issa, Josh F. Knox, Sue Skaros, Ossama
A. Hatoum, Jeanne Emmons, Mary F. Otterson, David G. Binion
Introduction: Azathioprine (AZA) is a mainstay of longterm therapy for Crohn’s disease
(CD) pts with moderate to severe disease. However, a subgroup of CD pts do not tolerate
AZA, and face fewer treatment options. The natural history of AZA tolerant (TOL) and AZA
intolerant (INTOL) CD pts has not been defined. We utilized a referral center database to
characterize objective markers of disease complications and severity to define the natural
history of pts able to receive AZA treatment vs those who were intolerant. Methods: All
AZA treated CD pts followed at a referral center over a 7-year period were reviewed, including
pts referred because of drug intolerance history. Pts who discontinued or were ineligible
for AZA due to side effects formed the INTOL group, while those continuing AZA comprised
the TOL group. Demographic information, smoking history, CD duration, treatments, drug
allergy/intolerance, surgeries, hospitalizations and permanent disability were recorded.
Results: Among 505 CD pts who were candidates for AZA, 335 (66.3%) were TOL and 170
(33.7%) were INTOL. Mean age in TOL was 39±14y (SD) and in INTOL was 43±14y (SD;
p<0.05). There were 56% female in TOL and 61% in the INTOL (p=NS). History of any
tobacco use was significantly higher in the INTOL vs TOL group (38% vs 26%; p≤0.01),
as was active smoking (INTOL 24% vs TOL 16%; p≤0.03). Hospitalizations were significantly
higher in the AZA INTOL group (mean 2.9±2.7 (SD)) compared with TOL (mean 2 ± 1.8
(SD); p<0.001) as was permanent disability (INTOL 12.9% vs TOL 4.5%; p<0.001). Mean
surgeries in INTOL was 2±3.7 (SD) compared with TOL 1.4±1.5 ((SD); p=NS). Maintenance
infliximab use was similar between the 2 groups (INTOL 27% vs TOL 26%) however, a
higher percentage of INTOL pts had received biologic therapy (58% vs 49%; p<0.05). The
percentage of INTOL pts who experienced complications with infliximab immunogenicity
was higher than the TOL group (27% vs 14%; p<0.01). The percentage of AZA INTOL CD
pts receiving maintenance methotrexate was 31%, with a mean duration of 1.9 ± 1.3y (SD)
which was significantly shorter that the mean duration of AZA use in the TOL group (4.5
± 3.1y (SD); range 0 - 27 y; p <0.0001). Conclusions: AZA INTOL CD pts are a clinical
subgroup challenged by more severe disease related complications compared with pts who
may benefit from long-term purine analog treatment. Although mechanism for AZA intoler-
ance is not clear, history of smoking appears to correlate. MTX appears to be underutilized
in AZA INTOL pts. The comparison of AZA TOL vs INTOL pt subgroups suggests that
long-term AZA treatment modifies the natural history of moderate to severe CD.
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Vitamin D Deficiency Is Associated with Deficits in Trabecular and Cortical
Bone in Incident Pediatric Crohn’s Disease
Meena Thayu, Robert N. Baldassano, Babette S. Zemel, Bruce W. Hollis, Mary B. Leonard
Crohn disease (CD) is characterized by inflammation of the gastrointestinal tract leading to
malabsorption, micronutrient deficiencies, and decreased bone mass. The relationships
between vitamin D deficiency and musculoskeletal deficits have not been addressed in
incident pediatric Crohn disease. The objectives of this prospective study were to determine
the prevalence of vitamin D deficiency, and to identify the relationship between serum
vitamin 25-hydroxy D [25(OH)D] levels and muscle and bone deficits in children with CD
prior to the initiation of therapy, compared to healthy controls. Serum 25(OH)D levels were
determined by I125 RIA in 72 CD subjects (57% male, 11% black) and 160 healthy controls
(50% male, 21% black), ages 5-21. 25(OH)D insufficiency was defined as < 30 ng/mL and
deficiency as < 10 ng/mL. Peripheral quantitative computed tomography (pQCT, Stratec
XCT 2000) scans were used to measure trabecular volumetric bone mineral density (vBMD)
at the 3% distal site, cortical bone cross-sectional area (CSA) at the 38% site, and muscle
CSA at the 66% site. Height and BMI are expressed as age and sex-specific standard deviation
scores (Z-scores). Bone and muscle measures are expressed as gender and race-specific Z-
scores derived from linear regression models in the controls. Multivariable linear regression
models were used to assess relations between CD, vitamin D levels and pQCT Z-scores.
Among non-black CD subjects, 80% were 25(OH)D insufficient and 5% were deficient.
Among black CD subjects, 100% were 25(OH)D insufficient and 63% were deficient.
25(OH)D levels were significantly lower in CD compared with controls (p < 0.05) adjusted
for season and race. CD subjects had significant height, BMI, bone and muscle deficits,
compared to controls (all p < 0.001) (Table). Within the CD subjects, trabecular vBMD Z-
score was significantly associated with 25(OH)D levels (p = 0.008), adjusted for race; each
10 ng/mL decrease in 25(OH)D was associated with a 0.43 decrease in vBMD Z-score.
Cortical CSA Z-score was significantly associated with 25(OH)D levels (p < 0.05), adjusted
for race; each 10 ng/mL decrease in 25(OH)D was associated with a 0.34 decrease in cortical
CSA z-score. Muscle CSA Z-scores were not significantly associated with 25(OH)D levels.
25(OH)D levels, bone, and muscle deficits were not associated with Pediatric Crohn Disease
Activity Index or symptom duration. A longitudinal study of vitamin D status and changes
in bone and muscle in CD is underway.
Crohn Disease Subject Z-scores
*Adjusted for age **Adjusted for tibia length
W1152
Factors Predicting Postoperative Recurrence with Placebo Therapy in Patients
with Crohn’s Disease: A Meta-Analysis of Clinical Trials Evaluating
Postsurgical Maintenance Therapy
Chinyu Su, James D. Lewis, Monina F. Pascua, Colleen Brensinger, Gary R. Lichtenstein
Background: Placebo-controlled RCTs (PC-RCTs) are the gold standard for evaluating drug
efficacy for preventing postoperative recurrence (Rec) in patients with Crohn’s disease (CD).
Knowledge of the relapse rate on placebo (Plac) therapy and factors influencing this rate is
important for designing future trials and may provide valuable information for management
of postoperative CD. Aim: To estimate the Plac relapse rate from prior CD PC-RCTs for
postoperative maintenance therapy and to identify factors influencing this rate. Methods:
PC-RCTs evaluating therapies for CD with surgically-induced remission (Rem) were identified
from MEDLINE through Sept 2005. Outcomes were dichotomized into Rem v. Rec. Pooled
estimates of the Plac clinical (Clin) and endoscopic (End) Rec rates were calculated using
logistic regression after applying sample weights based on Plac size. Univariate logistic
regression models were used to estimate the influence of design features on this rate. Results:
8 studies met the inclusion criteria. The pooled estimate of Plac End Rec rate was 0.56
(95%CI=0.48-0.64; p for study heterogeneity=0.003). This rate was 0.56 (95%CI=0.46-
0.65) limiting analysis to 5 studies using Rutgeerts score ≥2 as definition. Of the 7 studies
reporting Clin outcome, the pooled estimate of Plac Clin Rem rate was 0.59 (95%CI=0.48-
0.69, p for heterogeneity<0.001). The table shows factors associated with the Plac outcomes.
Both Clin and End outcomes were independent of study visit #/frequency, disease duration
and smoking status of Plac groups. The Clin but not End outcome was independent of disease
distribution and phenotype. Conclusions: In PC-RCTs for CD postoperative prophylaxis, the
Plac rates of End and Clin Rec were 56% & 41%, respectively. Prior surgery and study
duration were associated with higher cumulative relapse rates. While disease distribution
and phenotype appeared to influence the Plac End Rec rates, they were not associated with
Plac Clin outcome. These factors may be considered when predicting the likelihood of
postoperative recurrence in patients without active intervention.
*OR>1 indicates that the factor was associated with a higher cumulative rate of Clin Rem
or End Rec in Plac-treated patients
W1153
A Large Number of Siblings Is Protective for Crohn’s Disease- An Israeli
Population Based Study
Eyal Klement, Joseph Lysy, Eran Goldin, Tsippy Shochat, Eran Israeli
Background: It was previously shown that subjects with a large number of siblings have
lower risk for the development of asthma and atopic dermatitis. Similar case control studies
for patients with Crohn’s disease (CD) have failed to show conclusive results. Methods: We
performed a large population based cohort study based on the computerized medical database
of the Israeli Defense Forces. The association of CD with number of siblings was stratified
by gender, place of birth and origin. For each gender 4 groups were analyzed: (1) Israel
born Asian/African origin; (2) Israel born European/North American origin; (3) Israel born
Israeli origin; and (4) European/North American born. Results: A population of 296,684
males and 214,942 females was included in the study. The prevalence of CD was 237 per
100,000 population. Relative Risk (RR) for the first three groups of males for families of 1-
4 siblings vs. families of 5 or more, were 1.09 (CI95%= 0.81-1.46), 1.67 (0.71-3.92) and
2.07 (1.41-3.07) while for European/North American born males, a smaller number of
siblings seemed to have a protective effect as RR was 0.49 (0.26-0.91). RR in African/Asian
and in European/North American Israeli born females were 1.54 (0.94-2.52) and 2.63 (1.08-
6.38) respectively, while for females included in groups 3 and 4 RR could not be calculated
since there were no females with CD, in families with 5 or more siblings. Conclusions: A
high number of siblings is protective for CD, primarily among Ashkenazi Israeli born males
and females. We suggest that this association is due to the lower socioeconomic status in
large Israeli families, a hypothesis that coincides with the hygiene theory.
W1155
Determinants of Progression of Indefinite Or Low-Grade Dysplasia to
Advanced Dysplasia in Ulcerative Colitis
Salma Akram, Loftus V. Edward, William J. Tremaine, William A. Faubion, Darrell S.
Pardi, Debra A. Jewell, William J. Sandborn
BACKGROUND: Patients (pts) with ulcerative colitis (UC) are at increased risk of colorectal
cancer (CRC) and dysplasia. Recent preliminary work suggests that 5-ASA use might reduce
the progression of indefinite dysplasia (ID). AIMS: To determine the risk of progression of
dysplasia in UC pts evaluated at our institution over a ten-year period and to determine
the influence of 5-ASA use on the clinical course of dysplasia. METHODS: We retrospectively
identified 32 UC pts with either ID or low-grade (LGD) flat dysplasia diagnosed between
1994 and 2003. 5-ASA use data was obtained from the medical records. Pts who underwent
colectomy within 2 months of the diagnosis (dx) of ID/LGD were excluded. RESULTS: There
were 23 (72%) males with median age of 53 years (yrs) (range, 29-75 yrs) at ID/LGD dx.
Median duration of UC at the time of ID/LGD dx was 11 yrs (1-34 yrs). Nine pts had ID
and 23 had LGD. Median follow-up from ID/LGD dx was 6.9 yrs (0.3-10.4 yrs). Progression
from ID to LGD was noted in 3/9 (33%) and from LGD to high-grade dysplasia (HGD) in
5/23 (22%). Persistent dysplasia in 10 (31%) and regression of dysplasia noted in 14 (44%).
Median age at UC dx was 33 yrs in progressive/persistent pts versus 37 yrs in regressors
(p=0.04). Median duration of UC at ID/LGD dx was 12 yrs for progressive/persistent pts
versus 8 yrs for regressors (p= 0.01). Sixteen pts (50%) had colectomy with median time
to surgery of 1 yr (0.3-5 yr). Reasons for surgery included persistent LGD/ID in 9 (56%),
progression from LGD to HGD in 4 (25%) and progression from ID to LGD in 3 (19%).
During the study period, 4 pts (13%) died but none were from CRC. There was no difference
in the average daily dose of 5-ASA prior to ID/LGD dx between progressive/persistent pts
and regressors. In the post-ID/LGD period, average daily dose of 5-ASA was higher in the
regressors (2.3 gm) compared to the progressive/persistent group (1.5 gm) (p=0.01). In the
post-ID/LGD period, 5 progressive/persistent pts (27%) used >2.4 gm/day of 5-ASA versus
7 regressors (50%) (p=0.04). Ten progressive/persistent pts (56%) had a history of PSC
versus 4 regressors (29%) (p=0.01). Nine progressive/persistent pts (50%) had moderately
severe pancolitis vs. 7 regressors (50%). CONCLUSION: Pts with progressive/persistent ID/
LGD were younger at UC dx, had longer UC duration and were more likely to have PSC.
Extent and severity of UC were not significant predictors of progression. Post-dysplasia 5-
ASA dose was significantly higher in regressors compared to those with progressive/persistent
dysplasia. A higher percentage of regressors were on >2.4 gm/d of 5-ASA. Supported by
Procter & Gamble Pharmaceuticals.
W1156
Potential Contribution of Endothelin-Converting Enzyme, and ETA and ETB
Receptors to Inflammatory Processes of Crohn’s Disease in Humans
Takehisa Suekane, Junko Arimoto, Yoshihiro Ikura, Masahiko Ohsawa, Kenji Watanabe,
Yasuhiro Fujiwara, Nobuhide Oshitani, Kazuhide Higuchi, Tetsuo Arakawa, Makiko Ueda
BACKGLOUND AND AIMS: Endothelin-1 (ET-1) is a powerful vasoconstrictor and smooth
muscle cell (SMC) mitogen. ET-1 can be generated locally by endothelin-converting enzyme
(ECE), and the actions of ET-1 are mediated by the specific receptors, ETA and ETB. It had
been recognized that the vasoconstrictive and mitogenic properties of ET-1 are mediated
mainly by binding to ETA receptors, whereas ETB receptors mediate vasodilatation. However,
accumulating evidence has recently shown that ETB receptors also contribute to vasoconstric-
tive and mitogenic reactions. Moreover, these components of the ET system are considered
to participate in inflammatory and wound healing processes. Previous reports have suggested
a role for the ET-1 in the pathological mechanism of Crohn’s disease (CD). However, the
expression of ECE in affected intestinal tissues of CD has not been studied, and precise
roles of ETA and ETB receptors in the inflammatory and fibrogenic process of CD remain
to be elucidated. In the present study, we immunohistochemically investigated the expression
of ECE and ETA and ETB receptors in affected human intestinal tissues of CD. METHODS:
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Eighteen intestinal tissue specimens were sampled from patients with CD by surgery. Reasons
for the surgical resections were mostly intestinal strictures. Normal colonic tissues as controls
were obtained from 11 patients having surgery for colonic tumors. Frozen tissue sections
cut from the samples were analyzed using immunohistochemical single and double staining
techniques. For the analysis of the ET system, we used anti-ECE and anti-ETA and ETB
receptors antibodies as primary antibodies. In addition, SMCs, macrophages, and endothelial
cells were stained using their specific antibodies. RESULTS: In diseased intestinal tissues of
CD, proliferation of SMCs and new vessels was frequently seen in association with inflammat-
ory infiltration and fibrotic tissue reactions. In addition to the original SMC components
such as the muscular layer and vascular SMCs, the proliferated SMCs were distinctly positive
for these ET system components, ECE and ETA and ETB receptors. Vascular endothelial
cells in the lesions had immunoreactivity for ECE and ETA receptor. Moreover, accumulated
macrophages in the lesions also showed the expression of ECE, ETA receptors, and ETB
receptors. CONCLUSION: These results strongly suggest that ECE and ETA and ETB recep-
tors collectively play an important role in inflammatory and fibrogenic processes of CD.
The upregulation of the ECE/ETA and ETB receptor system may contribute to SMC prolifera-
tion and enhance constrictive functions, which could lead to the development of intestinal
strictures in CD.
W1157
Cancer in Infliximab-Treated Or Untreated Crohn’s Disease Patients: A 1 Year
Longer Follow Up from a Multicenter Matched-Pair Study
Livia Biancone, Ambrogio Orlando, Anna Kohn, Elisabetta Colombo, Roberto Sostegni,
Erika Angelucci, Fabiana Castiglione, Davide Checchin, Claudio Papi, Andrea Cocco,
Gianmichele Meucci, Gabriele Riegler, Carmelina Petruzziello, Federico Mocciaro,
Alessandra Geremia, Emma Calabrese, Mario Cottone, Francesco Pallone
Background and Aims. The widespread use of Infliximab (IFX) in Crohn’s Disease (CD)
rises concerns about cancer risk in the long term. We previously reported, in a cohort of
matched-pair CD patients (pts.) followed up from April 1999 to October 2004, no differences
between IFX-treated and untreated pts. in terms of new diagnoses of cancer. However, the
frequency of cancer in a longer follow up needs to be assessed in this cohort of pts. Aim
of the present study was therefore to assess, in a 1 year longer follow up, the frequency of
new diagnoses of cancer in the same cohort of IFX-treated or untreated CD pts. Methods.
In a multicenter matched-pair study, the same cohort of 404 CD pts. treated with IFX (CD-
IFX) matched with 404 CD never receiving IFX (CD-C) included in the previous study,
was followed up for 1 more year. Cases and controls were matched for sex, age (±5 yrs),
CD site, age at diagnosis (±5 yrs), immunosuppressants (ISS) use and follow up. CD-IFX
pts. were matched with CD-C showing the same follow up length (±5 yrs), not necessarily
requiring that CD-C were in follow up on October 2004. Therefore, CD-C and their matched
CD-IFX pts. not in follow up on October 2004 were excluded from the present study. A
lower proportion of CD-IFX pts. were lost to follow up on October 2005, thus reducing
the number of pts. included in the present study. The following events from October 2004-
October 2005 were recorded: new diagnoses of cancer, outcome of previously diagnosed
cancer, new IFX or ISS use. Results. Matched-pair CD-IFX and CD-C still in follow up on
October 2005 include 458 pts (229 CD-IFX and 229 matched-pair CD-C). Among these
458 pts, the frequency of newly diagnosed cancer from April 1999 to October 2004 was
comparable in the CD-IFX (8/229 pts. 3.49%) and in the CD-C (7/229, 3.05%; p=1.00)
group. Among the whole group of 458 pts., new diagnoses of cancer from October 2004
to October 2005 was observed in 3 pts., including: 1 breast cancer (F, age 57, no ISS use)
in the CD-IFX group; 1 cutaneous T cell lymphoma (F, age 43, on AZA for 5 yrs), 1 duodenal
adenocarcinoma (M, age 48, no ISS use) in the CD-C group. All these 3 pts. are currently
in follow up. Conclusion. Present findings from a multicenter matched-pair study in a cohort
of CD pts. matched for clinical variables, support previous observations from a shorter
follow up period, suggesting that the frequency newly diagnosed cancer is comparable in
pts. treated or untreated with IFX. However, the finding of new cases of cancer during the
last year recommend the need of a longer follow up to appropriately assess the risk of cancer
in this cohort of CD pts.
W1158
Does Infliximab Influence Surgical Morbidity Or Long-Term Outcome of Ileal
Pouch-Anal Anastomosis in Patients with Ulcerative Colitis?
Stefanie J. Schluender, Eric A. Vasiliaukas, Marla Dubinsky, Konstantinos A. Papadakis,
Andrew Ippoliti, Stephan Targan, Phillip Fleshner
PURPOSE: As infliximab has recently been approved for the treatment of patients with
refractory ulcerative colitis (UC), physicians will be increasingly faced with operating on
patients who have failed therapy with this potent immunosuppressant medication. The
effects of infliximab on short-term and long-term outcomes after colectomy are unknown.
The aim of this study was to compare the incidence of postoperative complications and
pouchitis in UC patients treated with and without infliximab prior to surgical resection.
METHODS: A retrospective review of patients undergoing ileal pouch-anal anastamosis
(IPAA) for medically-refractory UC over the 12-year period ending October 2005 was
performed. Two patient groups were identified. Group A patients (n=17) had failed infliximab
treatment. Group B patients (n=134) were never treated with infliximab. Postoperative
medical complications, surgical morbidity, and length of hospital stay (LOS) were compared
between patient groups using chi-square analysis or Wilcoxon nonparametric tests. Long-
term outcome was assessed prospectively and included acute pouchitis (AP) and chronic
pouchitis (CP). Pouchitis was diagnosed using clinical symptoms and confirmed in all
patients with pouchoscopy. RESULTS: A two-stage IPAA was initially performed in 112
patients (74%) and an initial subtotal colectomy (STC) with ileostomy (three-stage IPAA)
was used in 39 patients (26%). Procedures performed in Group A included 15 (88%) IPAA
and 2 (12%) initial STC, and in Group B included 97 (72%) IPAA and 37 (28%) initial
STC. There was no mortality in either patient group. Postoperative complications were
observed in 43 patients (28%), with no significant difference observed between Group A
patients (n=6, 37%) and Group B patients (n=37, 27%). Overall median LOS did not differ

















range, 3 to 53 days). The incidence of either AP or CP was also not significantly different
between Group A (12%,7%) and Group B (19%,10%) patients. CONCLUSION: These
results suggest that preoperative treatment with infliximab does not significantly increase
the incidence of postoperative complications or change the incidence of pouchitis in patients
undergoing surgical treatment for medically-refractory UC.
W1159
High Incidence of IBD in Multiple Affected Families: Results from a
Prospective Study and Association with Known Environmental and Genetic
Risk Factors
Marie G. Joossens, Julien Branche, Delphine Allorge, Boualem Sendid, Herbert J. van
Kruiningen, Sofie Joossens, Karolien Claes, Nele van Schuerbeek, Paul Rutgeerts, Peggy
Vandewalle, Annie Standaert-Vitse, Corinne Gower, Daniel Poulain, Franck Broly, Jean-
Frederic Colombel, Mathias Chamaillard, Severine Vermeire
INTRODUCTION An exceptionally high frequency of familial Crohn’s disease (CD) has
been reported in Northern France and Belgium. We previously performed a study on
environmental risk factors in 45 families with at least three members affected with CD.
AIMS & METHODS We hypothesized that environmental and genetic risk factors cluster
in these multiple affected families and therefore prospectively followed up on the health
status of the unaffected family members of these families. Four years after the original study,
a telephone and a questionnaire survey were performed to identify if new diagnoses of IBD
had arisen in the multiple affected families (including 166 CD patients and 261 unaffected
relatives) as well as in 15 matched healthy control families without IBD and 27 matched
sporadic IBD families (only one case affected) who also took part in the initial study. Known
genetic risk factors (CARD4, CARD8, CARD15, TLR4, DLG5) and multiple anti-microbial
antibodies, anti-Saccharomyces Cerevisiae (ASCA), anti-Candida albicans (ACAA), anti-chito-
bioside and anti-laminaribioside carbohydrate (ACCA and ALCA) and anti-porin (OMP),
were determined on blood samples of the initial visit four years ago. RESULTS All families
returned our survey. Unlike sporadic and healthy control families, eight new diagnoses of
IBD (6 CD and 1 UC first degree relatives and 1 CD in a fourth degree female) were made
in seven multiple affected families. The age at diagnosis in these newly-diagnosed relatives
varied between 12 and 44 years. Of the newly diagnosed CD patients for whom full data
were available, 3 patients carried a CARD15 variant (patient A Arg702Trp and patients B
and C a 1007fs mutation) as well as NOD1 mutations (A: C27606T and C45343T; B
homozygote and C heterozygote for C32656TTindel). Two CD patients (C, D) and the new
UC patient carried a CARD8 Cys10* mutation. CD patients A and B expressed positive
ASCA and ALCA, A in combination with OMP antibodies, B with ACAA and ACCA. The
UC patient also carried ASCA. Two of the CD patients (B, D) were ex-smokers, one (C)
was a current smoker. CONCLUSION Over a period of four years, we identified eight new
cases of IBD in 45 multiple affected families and none in 27 simplex CD families nor in 15
healthy control families. Compared to the reported incidence of IBD of 10-15/100.000/year
in our region, these findings show a 30-fold increase in incidence. Unaffected relatives in
multiple affected families are therefore at much higher risk to develop IBD. We observed a
high prevalence of genetic, environmental and serological markers but the interplay between
these factors in the pathogenesis of the disease remains unknown.
W1160
Familial Distribution of Serological and Genetic Markers in Crohn’s Disease
Patients and Their Healthy Relatives
Marie G. Joossens, Julien Branche, Boualem Sendid, Delphine Allorge, Sofie Joossens,
Nele van Schuerbeek, Karolien Claes, Paul Rutgeerts, Peggy Vandewalle, Annie Standaert-
Vitse, Corinne Gower, Franck Broly, Daniel Poulain, Jean-Frederic Colombel, Severine
Vermeire, Mathias Chamaillard
BACKGROUND Crohn’s disease (CD) is a chronic inflammatory disease of the gastrointestinal
tract. Both genetic (e.g. CARD15) and serological (e.g. ASCA for Anti-Saccharomyces cerevis-
iae Antibody) markers have been associated with Crohn’s disease. However the genetic
determinants of the serological markers associated with CD remain poorly understood. AIM
& METHODS In multiple affected families a high prevalence of CD patients and serological
markers is observed. We hypothesized that genetic variants might influence familial expres-
sion of these markers and therefore investigated 45 multiple affected families (with at least
three members with CD), 27 matched sporadic IBD families and 15 matched healthy control
families. Four novel serological tests were used to determine anti-outer membrane porin
(OMP; INOVA, USA), anti-mannan (gASCA), anti-chitobioside and anti-laminaribioside
carbohydrate (ACCA IgA, ALCA IgG) (IBDXtm line, Glycominds Ltd., Israel) antibodies in
the sera of patients and healthy individuals. The serotypes for the ASCA IgG/A/M (Sendid
B et al Clin Diagn Lab Immunol, 1996) and the new tests, and genotypes for CARD4
(complex In/del), CARD8 (C10X), CARD15 (R702W, G908R and 1007fs), TLR4 (A299G)
and DLG5 (R30Q) were determined. We compared data of 166 CD patients (143 and 23
CD patients from multiplex and simplex families respectively), 247 healthy relatives (181
and 66 healthy relatives from multiplex and simplex families respectively) and 83 healthy
controls. RESULTS The seroprevalence of ASCA IgG/A/M (71%;38%;4%), gASCA
(60%;12%;6%) and ALCA IgG (44%;13%;13%), but not of ACCA IgA (40%;32%;24%) and
OMP IgG (36%;27%;14%) was significantly higher in CD patients compared to their first-
degree healthy relatives (HR) and to healthy controls (HC). Whereas healthy relatives of
CD patients showed a higher seroprevalence of ASCA IgG/A/M compared to healthy controls
(p=1.10-3), no significant difference was found between HR and HC for gASCA and ALCA
IgG. Using intraclass analysis the clustering of serum levels for the different tests was higher
in multiple (0.82) compared to sporadic families (0.55). Interestingly, in multiple affected
families the difference in magnitude of serological response in gASCA and ALCA IgG titres
between CD patients and their HR (p=1.10-10; p=1.10-18; and p=4.10-6 respectively)
was much higher compared to single affected families (p=5.10-2; p=5.10-3; and p=5.10-2
respectively). CONCLUSION Taken together these results indicate that, among the serological
markers, gASCA and ALCA IgG are the most specific markers for disease in familial CD.
Correlations with genetic determinants and/or phenotypes are currently investigated.
T : 89386$$CH2
05-04-06 23:18:31 Page 648Layout: 89386B : e
A-648AGA Abstracts
W1161
Are Non-Inflammatory (adenomatous or metaplastic) Polyps Rare in Ulcerative
Colitis?
Venkataraman Subramanian, Ashwini Banerjee, Richard Pollok
Introduction: Risk of cancer in patients with ulcerative colitis (UC) is higher than the general
population. The importance of adenomatous polyps in contributing to this increased cancer
risk is unclear. Recent evidence suggests that the prevalence of adenomatous polyps are less
common in this patient population. We aimed to ascertain the prevalence of adenomatous
and metaplastic polyps in patients with ulcerative colitis and compare it with a control
population. Methods: We performed a retrospective review of endoscopic and histological
records of patients with a confirmed diagnosis of UC. A control group of patients undergoing
colonoscopy for altered bowel habit or abdominal pain were used as a control group. All
the data was obtained from the electronic patient data records of St George’s hospital.
Significance was calculated using standard T-tests of proportions for independent samples.
Results: 20 (5.03%) of 397 patients with UC had adenomatous polyps. 3 of these polyps
were located outside the histological extent of the disease. In contrast 77(9.3%) of 828
controls had at least one adenomatous polyp. Adenomatous polyps were significantly less
common in patients with UC (p=0.004). 9(2.27%) of patients with UC and 43(5.2%) of
controls had a metaplastic polyp (p=0.002). Inflammatory polyps on the other hand were
significantly more common in patients with UC. Conclusions: Both adenomatous and meta-
plastic polyps occur less frequently in patients with UC. Adenomatous polyps therefore
seem unlikely to contribute to the increased risk of colorectal cancer noted in patients with
UC. The reduced incidence could be related to 5-ASA use, genetic factors or related to the
disease process itself and further studies are warranted to evaluate these factors.
W1162
Nodular Regenerative Hyperplasia with Portal Hypertension in Patients with
Inflammatory Bowel Disease Treated with Azathioprine
Gwenola Vernier-Massouille, Jacques Cosnes, Marc Lemann, Philippe Marteau, David
Laharie, Guillaume Cadiot, Yoram Bouhnik, Martine de Vos, Arnaud Bourreille, Walter
Reinisch, Jean F. Colombel
Azathioprine (AZA) and 6-mercaptopurine are commonly used to treat inflammatory bowel
disease (IBD). Treatment of IBD with a closely related compound 6-thioguanine (6-TG)
resulted in the frequent occurrence of a serious adverse event, nodular regenerative hyperpla-
sia (NRH) of the liver that could lead to portal hypertension (PHTN). This observation
raised the level of concern for the potential hepatotoxic effects of AZA. Aims: This retrospective
study was performed to assess the characteristics, clinical course and potential risk factors
of NRH in IBD patients treated with AZA in our centers. Results: Thirty cases of NRH (24
M, 6F) were identified between 1994 and 2005 in 8 centers. Twenty-seven patients had
Crohn’s disease (CD) and 3 had ulcerative colitis. CD location was the small bowel in 15,
the colon in 8 and both the small bowel and colon in 4. IBD mean duration was 14.8 yrs
(1-39). Seventeen patients had one (n=5) or multiple (n=12) surgical resections. The median
time between the start of AZA and diagnosis of NRH was 47 mos (6-187). Prothrombotic
disorders were present in 10/14 explored patients including hyperhomocysteinemia in 6
(with 2 patients homozygous for C677T variant of MTFHR gene) and protein C or S
deficiency in 5. The median dose of AZA was 2 mg/kg/d (1.5-3). In 6 patients in whom it
was available, median 6-thioguanine nucleotide concentration was 215 pmol/8.108 erythro-
cytes (68-352). NRH was suspected on clinical and/or morphological evidence of PHTN in
16, abnormal liver function tests in 9 and/or a thrombocytopenia in 11 and confirmed by
a liver biopsy in all patients. PHTN was then found in all but 3 patients. AZA was stopped
in all patients. After a median follow-up of 16 mos (1-138), 13 patients developed complica-
tions of PHTN with variceal haemorrhage in 9. This required insertion of a transjugular
intra-hepatic porto-sytemic shunt in 2 patients and a liver transplantation in one. The three
patients with no evidence of PHTN at diagnosis had no clinical complications at follow up
(15, 28 and 45 mos). Conclusion: NRH can be seen in patients treated with AZA for
IBD and cause severe PHTN. Male gender, small bowel resection and/or involvement, and
prothrombotic conditions seem to be risk factors. Clinicians should be aware of this serious
complication, closely monitor liver function tests and platelet counts, and have a low
threshold to perform MRI and/or liver biopsy in their patients with IBD treated with AZA.
W1163
The Use of Immunomodulators and Biologics in Inflammatory Bowel Diseases
(IBD): A Cross-Sectional French Nationwide Cohort 2004-2005
Laurent Beaugerie, Fabrice Carrat, Bouvier Anne-Marie, Nicole Brousse, Franck
Carbonnel, Jean-Frederic Colombel, Jean Faivre, Jean-Francois Flejou, Marc Maynadie,
Jean-Louis Dupas, Jean-Pierre Gendre, Philippe Godeberge, Jean-Pierre Hugot, Marc
Lemann, Stephane Nahon, Jean-Marc Sabate, Gilbert Tucat
Introduction: The use of immunomodulators and biologics in IBD was initially restricted
to patients with refractory Crohn’s disease (CD). Immunomodulators are now regarded as
the reference maintenance treatment of CD and an alternative to surgery in patients with
ulcerative colitis (UC). Few data are currently available on the use of these agents in
gastroenterological practice. Patients and Methods: This cross-sectional nationwide French
cohort CESAME was originally designed to prospectively assess the risk of cancers associated
with the use of immunomodulators in IBD. All French gastroenterologists were invited to
participate in the study. Among them, 819 (322 and 497 with hospital and private practice,
respectively) included in the cohort all consecutive IBD patients seen in their practice between
May 2004 and May 2005. At the end of the inclusion period, 20,919 patients were enrolled
in the cohort (12,463 with CD, 7,679 with UC and 777 with indeterminate colitis). The
male/female ratio was 0.8 and 1.0 for CD and UC, respectively. The mean age of the patients
was 40+16 yrs (m+SD). The mean time from diagnosis to the entry into the cohort was 8+8
yrs. Results: Among patients with CD, 56% ever received thiopurines (38% and 18% for
current and former use, respectively), 10% ever received methotrexate (MTX) (5% and 5%),
and 15% ever received anti-TNFα therapy (7% and 8%). Among patients with UC, 26%
ever received thiopurines (18% and 8%), 2% and 1% ever received MTX and anti-TNFα
therapy, respectively. The proportion of IBD patients who ever received thiopurines according
to the time between diagnosis and inclusion in the cohort increased from 11 to 50% for
intervals from 1 to 5 years, then ranged between 50 and 55% for longer intervals. Conclu-
sions: These data show that currently in France: more than half of the CD patients ever
received thiopurines whereas 10 and 15% of them were ever treated by MTX and anti-
TNFα, respectively; one quarter of the UC patients ever received thiopurines. In both CD
and UC, the proportion of patients treated by thiopurines according to time from diagnosis
increases progressively during the 5 first years of the disease, but does not significantly vary
thereafter. The cancer incidence study on progress in the CESAME cohort should allow us
to establish the relative risks of cancers associated with the current use of immunodulators
and biologics.
W1164
Proton Pump Inhibitor Use and the Risk of Flare of Inflammatory Bowel
Disease
Faten Aberra, James D. Lewis, Gary R. Lichtenstein, Yu-Xiao Yang
Background: Gastric acid suppression by proton pump inhibitors (PPI) and histamine recep-
tor antagonists (h2ra) is associated with increased small bowel bacterial colonization and
enhanced intestinal viability of pathogenic bacteria. Published data suggest intestinal micro-
organisms may play a role in the pathogenesis and course of inflammatory bowel disease
(IBD). We hypothesized that hypochlorhydria may increase risk for flare of IBD by altering
the intestinal bacterial flora. Our objective is to determine if gastric acid suppression by
PPIs increases the risk of flare of IBD. Methods: Subjects with IBD were identified from the
United Kingdom General Practice Research Database, a clinical outpatient database,
from1988-2002. A case-crossover design was used. Onset of a flare was identified by a new
prescription for corticosteroids (CS) or 5-aminosalicylate (5-ASA) following a remission
period, validated in a prior study. A remission period started when there had been no
prescription for CS or 5-ASA for >=122 days. We assessed exposure to a PPI within 90 days
of a randomly chosen index date within each remission and the date of flare. To address
potential confounding by indication we also assessed chronic PPI exposure (defined by PPI
use within a 90 day window before index date, of >=28 days in duration, last use within
7 days before index date and >=1 prescription for PPI between 60-90 days before index
date) and PPI dose. Conditional logistic regression was used to assess the association between
PPIs and flare of disease. Potential confounders assessed were exposure to h2ra, azathioprine,
NSAIDs, aspirin, antibiotics and calendar year of flare and remission. Results: There were
1134 flares/1144 remission periods among 782 Crohn’s disease (CD) subjects and 1928
flares/1943 remission periods among 1235 ulcerative colitis (UC) subjects. The adjusted OR
for CD flare associated with h2ra was 0.58(95% CI:0.32-1.08). The adjusted OR for UC
flare associated with h2ra was 1.55(95%CI:0.93-2.59). Any PPI exposure was associated
with an adjusted OR of 1.45(95%CI:0.81-2.59) for CD flare and adjusted OR of
2.30(95%CI:1.16-4.55) for UC flare. Chronic PPI exposure was associated with an adjusted
OR 1.11(95%CI:0.44-2.76) for CD flare and 3.23(95%CI:1.12-9.34) for UC flare. Increased
risk of flare was also appreciated with higher doses of PPI for UC (test for trend p=0.02)
and not for CD (test for trend p=0.12). Conclusions: PPI exposure was associated with
increased risk of flare in UC, but not in CD. Further exploration is suggested to validate
these initial findings and explore the mechanism by which PPIs may increase risk of flare
of disease.
W1165
Leukopenia As a Marker for Susceptibility of Infection in IBD Patients On
Immunosuppressive Therapy
Scott O. Levin, Amy E. Barto, Faten N. Aberra, Chinyu Su, Gary R. Lichtenstein
Background: Leukopenia (WBC<4x103) has long been a marker for immunosuppression
and a predictive value of one’s susceptibility to infection. Leukopenia has not been investigated
as an independent risk factor for IBD patients on immunomodulator therapy. We hypothesize
that in the presence of leukopenia, patients taking immunomodulators (IMMs) alone or in
combination with corticosteroids (CS), and infliximab have an increased risk of infectious
complications. Methods: A computer generated list using ICD 9 codes for ulcerative colitis
(UC) and Crohn’s disease (CD) patients seen at our institution between 2000-2005 was
compiled. Patients were divided into the following five groups: IMMs alone, IMM and CS,
IMM, CS, and infliximab, IMM and infliximab, CS and infliximab, and infliximab alone.
Leukopenic patients in each group were then compared to non-leukopenic patients. WBC
values were recorded along with infectious complications that were acquired during the
same timeline. (Severity of infection, hospitalization, duration of leukopenia, smoking and
other co-morbidities were included as other possible contributing/risk factors.) Leukopenia
was defined as a WBC<4x103. Infection was defined as bacterial and viral based on clinical
features documented. Results: Data was collected on 248 patients (50 UC/198 CD; 142male/
116female). Average age was 41 years (range: 19-90 years). Average duration of disease was
14.8 years (range: 1-59 years). 30% of UC patients and 42% of CD patients developed
infections over an average follow-up time of 18 months (range: 1-70 months). Infection
risk was compared for leukopenic and non-leukopenic patients within the different medica-
tion groups. The incidence rate ratio (IRR) for infections was 1.36 (p= 0.52) for IMM alone,
3.70 (p =0.24) for both CS and IMMs, 2.51 (p= 0.23) for CS, IMMs and infliximab, and
1.19 (p=0.80) for IMMs and infliximab. The CS and infliximab group and infliximab alone
group could not be analyzed due to small sample sizes. Conclusion: Comparison of infectious
risk between leukopenic and non-leukopenic patients in all medication groups showed no
significant difference. A future study using severe leukopenia as a variable (WBC < 2 x 103)
may demonstrate differences between medication groups.
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W1166
Ulcerative Colitis: Annual Costs of Care from a Payer Perspective
Songkai Yan, Clark Paramore, Steven W. Blume, Kathy Fraeman, Mohan Bala
Objective: To assess the annual cost of care for patients with ulcerative colitis (UC) from a
medical claims database. Methods: Using the PharMetrics claims database, patients with a
diagnosis of UC (ICD-9 code 556.x) in the year 2001 (between 1/1/2001 and 12/31/2001)
were included in this analysis. Claims in 2002 (between 1/1/2002 and 12/31/2002) were
used to categorize these patients into three mutually exclusive disease severity groups and
conduct cost analysis. These groups were: Group 1, required hospitalization for UC; Group
2, required chronic aggressive pharmacotherapy (i.e. corticosteroids or immnunosuppres-
sants) for ≧ 4 months; Group 3, all remaining patients. Patients were matched (1:4) to
controls (those without UC) based on age, gender, region, and previous time-in-plan. Direct
costs based on reimbursement amount by place of service were reported. Results: 7174
patients were analyzed: 323 (4.5%) in Group 1, 578 (8.1%) in Group 2, and 6273 (87.4%)
in Group 3. Average age of patients was 47.3 years and 46.7% were men. Mean annual
total cost for all patients were $7820, compared with $3,661 for controls. Group 1 patients
incurred the highest mean cost ($39782), while Groups 2 and 3 incurred $12496 and
$5744, respectively (Table 1). Inpatient hospitalization costs constituted the largest compon-
ent ($2860, 36.6%) of the mean annual total cost for all patients. The next highest cost
components were prescription medications ($1718, 22.0%), outpatient visits ($1219,
15.6%), and physician office visits ($1134, 14.5%). Conclusions: UC is associated with a
high cost of care that is more than twice of the cost for those without UC. Patients requiring
hospitalization incurred the highest cost. New therapies that can reduce hospitalizations
have the potential to decrease overall cost of care for UC.
Table 1. Mean 2002 total costs for patients with a UC diagnosis in 2001
W1167
The Manitoba IBD Cohort Study: Assessing the Nature of Medication
Adherence
Charles N. Bernstein, Jason P. Ediger, Lesley A. Graff, Patricia Rawsthorne, Linda Rogala,
Norine Miller, Kathleen Deering, Cory McPhail, John R. Walker
This study reports medication adherence data from the Manitoba IBD Cohort Study, a
longitudinal, population-based study of multiple determinants of health outcomes in IBD
in those diagnosed within 7 years at enrollment. Methods: Data were available from 334
subjects. Adherence was measured with a validated multi-item self-report assessment. Differ-
ences in adherence were tested across levels of disease activity (defined by Harvey Bradshaw
and the Powell Tuck activity indices) and diagnosis. Further testing also explored potential
correlates such as age, gender, beliefs about medication, memory strategies, obstacles to
compliance and psychological factors. Results: The most commonly reported forms of non-
adherence were taking less than instructed (12% often/very often), altering the dose (10%),
using it only when feeling unwell (10%), and forgetting to take it when scheduled (9%).
The most commonly reported obstacles to taking medication regularly were cost (often/very
often a problem) (25%), a sense that taking medicine is a reminder that one has a health
problem (13%), unpleasant side effects (12%), and uncertainty about whether the medicine is
helpful (11%). Participants reporting more obstacles to medication compliance demonstrated
significantly poorer adherence (r = 0.371, p < 0.001). Participants with active disease reported
more difficulty with adherence than those with inactive disease (F (1, 327) = 4.30, p <
0.05). There were no significant differences in adherence between genders or IBD subtypes.
Poor adherence was moderately associated with higher levels of stress (r =0.228, p < 0.001),
lower levels of psychological well-being (r = -0.247, p < 0.001), and younger age (r = -
0.195, p <0.001). While 62% of respondents agreed that the medication prevented them
from getting worse, 62% expressed concerns about long term effects, 30% expressed concern
about becoming dependent, and 39% reported that they worried about having to take
medication. Many thought doctors used too many medicines (40%) and placed too much
trust in those medicines (27%). The most common strategies reported to facilitate taking
the medication were daily routine cues like meals or bedtime (78%) and dispensers with
daily compartments (17%). Conclusions: Adherence to medication treatment is a problem
in the treatment of IBD as in other disorders. It is helpful for the physician to ask specifically
about problems with adherence in a non-judgmental way, in order to address specific
concerns related to less than optimal adherence, and subsequently improve treatment out-
come.
W1168
Increasing Impact of Clostridium Difficile On Inflammatory Bowel Disease: A
Tertiary Referral Center Experience
Mazen Issa, Sue Skaros, Dawn B. Beaulieu, Lydia R. Weber, Aravind S. Vijayapal, Mary
Beth Graham, Joshua F. Knox, Jeanne Emmons, Ossama A. Hatoum, Mary F. Otterson,
David G. Binion
Introduction: Diarrhea and pseudomembranous colitis due to the anaerobic spore-forming
bacillus Clostridum difficile (C. diff) is a major health problem, and recent reports suggest

















idsociety.org). C. diff infection can impact clinical course in pts with inflammatory bowel
disease (IBD: Crohn’s disease (CD); ulcerative colitis (UC)). We reviewed a tertiary referral
center database regarding the detection of C. diff and clinical outcome in patients with IBD.
Methods: This was a retrospective observational study of all consecutive IBD pts followed
at a single center. History of a positive stool analysis for C. diff toxin A and B (2004 - 2005)
was used to identify subjects. Demographic information, diagnosis and anatomic location
of disease, concomitant IBD therapy, hospitalizations and surgeries were recorded. Results:
C. diff was detected in 3% (23/766) of the IBD pts evaluated in 2004 and 10% (98/958)
of pts evaluated in 2005 (p<0.001). Among the 40 new C.diff diagnoses in 2005, there
were 11 UC and 29 CD, mean age 38.9±14y (SD). C. diff positive IBD patients were also
more likely to be female (26 vs. 14). Although the number and rate of IBD hospitalizations
related to C.diff remained unchanged between 2004 (n=14) to 2005 (n=27; p=NS) the
number of colectomies in C.diff positive IBD pts decreased from 5/8 (63%) in 2004 to 4/
40 (10%) in 2005 (p<0.001). Colonic involvement was found in 79% of the CD pts, and
85% of the total IBD cohort with C.diff. Maintenance immunomodulators (azathioprine,
methotrexate and/or infliximab) were used by 88% of the pts who contracted C.diff co-
infection. Thirteen of the pts were in remission on stable regimens of immunomodulators
(10 pts) or infliximab (3 pts) when they experienced disease flare at the time of C.diff
diagnosis. The rate of C.diff ELISA stool detection was: 1 sample (54%), 2 samples (75%),
3 samples (78%), 4 samples (92%). Conclusions: Co-infection with C. diff in IBD pts has
increased 3 fold from 2004 to the present. C.diff was associated with flare activity in pts
who were previously on stable maintenance regimens, including infliximab and immunomod-
ulators. The decreased rate of colectomy noted in IBD pts infected with C.diff may reflect
increased awareness and rapid detection and treatment of pts with appropriate antibiotics.
C.diff appears to preferentially affect pts with prior histories of chronic inflammation in the
colonic mucosa. Increased awareness of the potential for C. diff to impact clinical course
in IBD patients is warranted and aggressive diagnostic evaluation is recommended.
W1169
Increased Protein Catabolism Correlates with Increased Disease Activity in
Children with Crohn’s Disease
Ashish Patel, John M. Andersen, Dana Hardin
Introduction: Crohn’s disease is a condition of chronic relapsing and remitting inflammation
involving the gastrointestinal tract with a propensity for the ileocecal region. Growth failure
is a major symptom of Crohn’s disease in children. Previous studies have documented that
in other chronic inflammatory diseases with impaired growth, such as cystic fibrosis, whole
body protein turnover is catabolic and this increased catabolism correlates with worsened
clinical status. No pediatric studies have correlated the protein turnover status of steroid
naïve prepubertal Crohn’s disease patients with the clinical perception of disease as scored
by an activity index such as the pediatric Crohn’s disease activity index (PCDAI). Hypothesis:
Crohn’s disease negatively impacts whole body protein turnover resulting in catabolism
which correlates with the clinical perception of disease activity as measured by the PCDAI.
Methods: Steroid naïve prepubescent (Tanner I or II) patients diagnosed with Crohn’s disease,
without any co-morbid conditions, were eligible for this study. Measurements of whole body
protein turnover were estimated using [1-13C] leucine, a previously described and validated
methodology (Hardin et al, J of Clinical Endocrinology & Metabolism 2001). The PCDAI
has been validated in the pediatric Crohn’s population as a reliable index of disease activity.
The scoring system uses patient reported data (frequency of stools, abdominal pain, general
well-being), objective data (hematocrit, erythrocyte sedimentation rate, albumin), and clini-
cian reported data (weight, height, abdominal exam, perirectal disease, extra-intestinal mani-
festations). The PCDAI was calculated at the time of the study. The PCDAI score and the
rate of protein turnover were correlated using Pearson’s correlation. Results: All five patients
studied so far displayed a marked increase in the rate of total body protein catabolism, an
average rate of 321.7 µmol/kg/hr (range 171.4-540.3 µmol/kg/hr), when compared with
age and Tanner matched children (80-85 µmol/kg/hr). The correlation coefficient for PCDAI
scores and protein turnover was 0.623. Conclusion: Protein catabolism in children with
Crohn’s disease is markedly increased in active disease and correlates with disease activity
as scored by the PCDAI. We speculate that increased protein catabolism in children with
Crohn’s disease contributes to growth failure.
W1170
Familial Occurrence of Inflammatory Bowel Disease: A Korean Study
Suk-Kyun Yang, Jong Beom Park, Jeong-Sik Byeon, Eui-Ryun Park, Gyoo Moon, Seung
Jae Myung, Won Kap Park, Seo Goo Yoon, Hyun Sik Kim, Jong Gyun Lee, Jin Ho Kim,
Young Il Min, Kwang Yeon Kim
Background and Aims: Few data are available about familial aggregation of inflammatory
bowel disease (IBD) in Asia. The aim of our study was to determine the risk of familial
aggregation of IBD among first-degree relatives of patients with ulcerative colitis (UC) or
Crohn’s disease (CD) in an ethnically distinct Korean population. Methods: A total of 1440
unrelated patients with UC (n=1043) or CD (n=397) were enrolled in the present study.
All patients were interviewed and answered to a detailed questionnaire for the evaluation
of the family pedigrees and the occurrence of IBD in their first-degree relatives. Familial
aggregation of IBD was evaluated in several different ways including family history, preval-
ence, population relative risk, and lifetime risk of IBD in first-degree relatives. Results: The
male to female ratio was 0.99 : 1 among the probands with UC, whereas it was 2.13 : 1
among those with CD. The age at diagnosis was significantly younger in the probands with
CD (24.0±8.3 years) than those with UC (37.5±13.1 years). A positive first-degree family
history of IBD could be confirmed in 27 probands (1.88%): 21 (2.01%) of 1043 with UC
and 6 (1.51%) of 397 with CD. Twenty-five probands had only one affected first-degree
relative, and 2 had 2, resulting in 29 first-degree relatives with IBD. The overall concordance
for type of IBD among first-degree relatives was 82.8%. The crude prevalence of IBD in
first-degree relatives of probands with IBD was 0.31%: 0.10% in parents, 0.31% in offspring,
and 0.45% in siblings. There was no difference in the prevalence of IBD between first-degree
relatives of UC probands and those of CD probands (0.31% vs. 0.35%). Also, the prevalence
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of UC among first-degree relatives of UC probands was similar to that of CD among first-
degree relatives of CD probands (0.27% vs. 0.23%). The age- and sex-adjusted population
relative risk of IBD was 13.8 in first-degree relatives of probands with IBD. The age-adjusted
empirical risk (i.e., lifetime risk) of developing IBD was 0.52% for all first-degree relatives
of UC probands, and 0.67% for those of CD probands. The lifetime risk of IBD in first-
degree relatives of probands with IBD was 0.54%: 0.12% in parents, 0.79% in siblings, and
1.43% in offspring. Conclusions: Although a positive family history, prevalence, and lifetime
risk of IBD among first-degree relatives of Korean patients are much lower than those of
Western patients, the population relative risk in first-degree relatives is about the same
between Koreans and Westerners. This means that a positive family history is an important
risk factor for IBD in Koreans as well as in Westerners.
W1171
Preoperative Steroid Use in Patients with Inflammatory Bowel Disease and
Risk of Postoperative Complications: Meta-Analysis of Observational Studies
Venkataraman Subramanian, Sonia Saxena, Richard Pollok
Introduction: Patients with inflammatory bowel disease (IBD) are frequently treated with
steroids. Almost a third of them will require surgery within a year of treatment with steroids.
Studies examining postoperative complication risk associated with use of steroids in patients
with IBD have yielded conflicting results. The purpose of this meta-analysis was to estimate
the risk of postoperative infectious complications following abdominal surgery in patients
with IBD on steroids at the time of surgery. Methods: We searched electronic databases
Pubmed, EMBASE, CINAHL, Ovid, Zetoc and Ingenta, and hand searched citations from
the reference lists in all the articles identified. Studies were included if patients had been
on steroids in the month preceding surgery, compared with a control group. Studies that
evaluated infectious postoperative complications in the two groups with duration of post-
operative follow up of a maximum of 30 days or the hospitalization period were included
in the analysis. Data for calculation of odds ratios (OR) had to be provided or could be
calculated from the tables or figures for the study to be included. We used the random
effects model to calculate pooled odds ratio and 95% confidence intervals. Results: All 6
studies that met the inclusion criteria were observational studies. Pooled analysis showed
an increased risk of infectious postoperative complications among patients on steroids (OR
1.60, 95% confidence interval 1.17-2.20). Conclusions: This is the first meta-analysis on
risk of post-operative infectious complication in patients with IBD taking steroids. Our data
indicates that there is an increased risk of infectious complications following the pre-operative
use of steroids. This is consistent with data on pre-operative steroid use and risk of post-
operative complications in other general medical patients.
W1172
Remission in Ulcerative Colitis Patients Is Associated with Improved
Employment and Disability Status, Work Hours, and Productivity
William J. Sandborn, Songkai Yan, Brian G. Feagan, Walter Reinisch, Paul Rutgeerts,
Graham Radford-Smith, Stephen Xu, Debra Eisenberg, Allan Olson, Jean-Frederic
Colombel
Purpose: To examine the impact of remission on employment and disability status,hours
per week actually worked (HPWAW),and productivity,in 2 controlled clinical trials in patients
(pts) with ulcerative colitis (UC). Methods: 728 pts with moderately to severely active UC
were enrolled in ACT 1 and ACT 2.Pts were randomized to placebo, infliximab 5, or 10mg/
kg. Treatment was administered at baseline, wks 2, 6, and then q8 wks.Pts answered a
questionnaire regarding employment and disability status, and work hours in the past 8
wks,at baseline and wk 30. In ACT 1,pts completed a scale ranging from 0(not at all
productive)to 100(fully productive) to assess their productivity at work or school in the 2
wks prior to the visits.Employment and disability status was compared for pts in remission
and those not in remission at wk 30 using Fisher’s exact test; the mean change of HPWAW
and mean change of productivity were compared using analysis of variance on van der
Waerden scores. Remission was defined as a Mayo score ≤ 2 points, with no individual
subscore >1.Analyses were performed on ACT 1 and ACT 2 combined data except for
productivity.No treatment failure rules or other imputations were applied. Results: At base-
line, 35.4%(257/727) of pts were not employed, and 7.0%(51/728) were receiving disability
compensation. The mean baseline HPWAW was only slightly more than half-time,and the
mean baseline productivity was only about 2/3 of fully productive(Table 1). Among pts who
were not employed at baseline,more patients in remission at wk 30 were employed,vs those
not in remission (20.6%[14/68] vs. 8.3%[9/108],p<0.001). Among pts who were receiving
disability compensation at baseline, a greater percentage of those who were in remission at
wk 30 were not receiving disability compensation,vs those not in remission (58.8%[10/17]
vs. 20.0%[3/15],p=0.060). Pts in remission at wk 30 had significantly greater increases in
HPWAW (p<0.001)and productivity (p<0.05) vs those not in remission (Table 1). Conclu-
sion:In UC pts,remission is associated with improved employment and disability status,hours
per week actually worked,and productivity at work or school.Achieving remission has
important indirect cost implications in UC.
Table 1. HPWAW and productivity by remission status at week 30: Mean baseline and
change from baseline at week 30
*Set to 0 for patients who were not employed
W1173
Crohn’s Disease, Fatigue, and Infliximab: Is There a Role for Pro-Inflammatory
Cytokines in the Pathogenesis of Fatigue?
Itta M. Minderhoud, Melvin Samsom, Bas Oldenburg
Background: Fatigue is an important feature in Crohn’s disease (CD). In daily practice,
treatment with infliximab often seems to result in a reduction of fatigue. We studied the
effect of infliximab in CD patients in order to elucidate the involvement of pro-inflammatory
cytokines in the pathogenesis of fatigue. Methods: Fourteen patients with proven CD were
enrolled and blinded for treatment. All patients received placebo at baseline, followed by
infliximab after two weeks with a follow up of 4 weeks after the last infliximab infusion.
Patients completed questionnaires on fatigue, depression, quality of life, and clinical disease
activity at baseline and during follow up. Blood samples were drawn every two weeks.
Results: After placebo infusion, fatigue scores decreased after a few days (p≦0.01), but
returned to baseline values within 14 days after this infusion. In contrast, the drop of fatigue
scores following infliximab infusion was sustained until the end of the study (p≦0.05). The
quality of life was increased at the end of the study compared to baseline values (p≦0.005),
whereas depression scores were significantly decreased (p≦0.01). We did not find a correla-
tion between fatigue and the levels of cytokines. Conclusions: The reported rapid reduction
of fatigue after treatment with infliximab in daily practice is subjective to a placebo effect.
The effect of infliximab on fatigue, however, persists while the placebo effect disappears
after a short period of time, suggesting involvement of inflammation-related processes. A
clear role of pro-inflammatory cytokines could not be substantiated.
W1174
Combination Therapy of Infliximab & Azathioprine Prevents Disease
Progression in Crohn’s Disease
Shahida Din, Claire J. Cochrane, Colin L. Noble, Jack Satsangi, Ian D. Arnott
Introduction: The Vienna classification of CD categorised disease behaviour into a hierarchy
of inflammatory, structuring & penetrating types. 92% of patients have been shown to
progress over a 20 year period. Infliximab induces mucosal healing & clinical remission; it
is unknown whether this drug reduces the progression of disease type. We aimed to examine
the impact of episodic infliximab treatment on the progression of disease behaviour in CD.
Methods: 73 CD (38F) patients who received episodic infliximab were assessed, together
with an age and sex matched control group comprising 73 patients who had received
azathioprine for at least 4 months. Both groups had 2 years follow-up during which disease
progression events were identified. Demographic details, disease characteristics and treatment
history were collected. Kaplan-Meier survival curve analysis, the log rank test & multiple
logistic regression were used to test for differences and identify independent variables
associated with disease progression. Results: Twice as many patients experienced progression
of disease type in the control (azathioprine) group (10/50) compared with the infliximab
group (5/42), p=0.165, log rank test. Patients on both azathioprine and infliximab (n=17)
had less disease progression compared to those on azathioprine alone (0/17 v 10/50, c2,
p=0.045). Surgical rates did not differ. Disease progression was also associated with signific-
antly more disease flares (p=0.017) and higher surgical rates (p=0.000). Multivariate analysis
identified smoking at treatment induction & concomitant usage of corticosteroids as inde-
pendent predictors of disease progression. Conclusion: Combination therapy with episodic
infliximab and azathioprine retards the progression of disease in CD and therefore may alter
the “natural” history of this disease. Smoking at treatment induction and concomitant
corticosteroid therapy are independent predictors of disease progression.
W1175
Differences in Medical Treatments Between African Americans and Caucasians
with Inflammatory Bowel Disease: A Retrospoective Cohort Study
Mark Flasar, Sandra Quezada, Priti Bijpuria, Grishma Joshi, Sharmeel Wasan, Raymond
K. Cross
Introduction: Racial disparities between African Americans (AA) and Caucasians have been
reported in several diseases. There has been limited study in Inflammatory Bowel Disease
(IBD), where the incidence in AA is approaching that of Caucasians. This may be due to
an underestimated prevalence of Ulcerative Colitis (UC) in AA as opposed to that in Crohn’s
Disease (CD). Our objectives were to assess the differences between AA and Caucasians
with respect to medical therapies used to treat IBD as well as response to treatment. Methods:
We identified outpatients with UC and CD evaluated at the University of Maryland from
1997 to 2005. We assessed the history of medications used and corresponding disease
responsiveness by race. Results: We identified 413 patients; 102 were AA (25%). The only
significant difference in demographic variables was that AA were more likely to have been
evaluated at the VA compared to Caucasians; 45% vs. 32% (p=.0062). There was also a
trend towards a higher proportion of males in the AA cohort as compared to Caucasians;
44% vs. 33% (p=.055). AA patients were less likely to receive steroids; 55% compared with
68% (p=0.0207). However, there was no difference between AA and Caucasians in rates of
response to treatment with steroids or rates of steroid dependant disease. No difference was
found in the use of or response to oral 5-ASA preparations by race. Conversely, AA were
less likely than Caucasians to be treated with 6-MP; 28% vs. 40% (p=0.031). Further, AA
were less likely than Caucasians to be treated with Infliximab; 10% vs. 20% (p=0.029).
Despite this, there was no significant difference in rates of response to treatment with either
6-MP or Infliximab by race. After adjustment for multiple variables, only age at diagnosis
<40 (OR 2.51, 95% CI 1.59-3.97) and evaluation at the VA (OR 0.36, 95% CI 0.23-0.57)
were associated with use of steroids. Age at diagnosis <40 (OR 2.99, 95% CI 1.83-4.86)
and a diagnosis of UC (OR 0.43, 95% CI 0.28-0.67) were associated with use of 6-MP,
while there was a trend towards an association with AA (OR 0.61, 95% CI 0.36-1.03).
However, AA (OR 0.45, 95% CI 0.21-0.95), having UC (OR 0.15, 95% CI 0.07-0.30), and
age at diagnosis <40 (OR 3.25, 95% CI 1.56-6.77) were all significantly associated with the
use of Infliximab therapy. Discussion: After adjustment for multiple factors, being AA was
significantly associated with a decreased rate of Infliximab use in an IBD cohort. Further,
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there was a trend to a decreased rate of 6-MP therapy in AA as compared with Caucasians.
Prospective studies are needed to further examine these findings.
W1176
Characterization of Clinical Phenotypes of Crohn’s Disease of the Ileal Pouch
Bo Shen, Victor Fazio, Feza Remzi, Ana Bennett, Rocio Lopez, Aaron Brzezinski, Jean-
Paul Achkar, Ioannis Oikonomou, Kerry Sherman, Marlene Bambrick, Bret Lashner
Crohn’s disease (CD) of the pouch can occur in patients with restorative procolectomy and
ileal pouch-anal anastomosis (IPAA) originally performed for a pre-operative diagnosis of
ulcerative colitis or indeterminate colitis. The clinical phenotypes of CD of the pouch have
not been described and characterized. AIM: To characterize clinical, endoscopic, histologic
features, quality of life (QOL), and treatment in patients with inflammatory, fibrostenotic,
and fistulizing CD of the pouch. METHODS: The study was IRB approved. 60 consecutive
patients with CD of the pouch seen in the Pouchitis Clinic were enrolled, including 22
inflammatory CD, 16 fibrostenotic CD, and 22 fistulizing CD. The clinical phenotypes of
CD and concurrent cuffitis or afferent limb disease were diagnosed based on a combined
assessment of clinical, endoscopic, radiographic, and histologic features. Demographic, clin-
ical, endoscopic, histologic, QOL (Cleveland Global QOL, Irritable Bowel Syndrome-QOL,
and Short-Form Inflammatory Bowel Disease Questionnaires), and treatment variables were
prosectively studied. A multivariable logistic regression analysis with stepwise selection was
performed. Three separate analyses were performed; and for each analysis, the outcome of
interest was having one of the phenotypes versus not having it. RESULTS: There were no
statistical differences in QOL scores between the 3 clinical phenotypes of CD. The results
of multivariable analyses were shown in Table. CONCLUSION: As time went on after IPAA,
the risk for inflammatory CD decreased while the risk for fibrostenotic CD increased. Diarrhea
was a predominant symptom in inflammatory CD, whereas obstructive symptoms were more
common in fibrostenotic CD. Females and maybe patients with a pre-op diagnosis of
indeterminate colitis were prone to fistulizing disease. Concurrent cuffitis was more common
in fibrostenotic and fistulizing CD; and the afferent limb were more often involved by
inflammatory and fibrostenotic CD. IMPLICATION: Natural history, etiopathogenesis, and
clinical features of the 3 phenotypes of CD are different.
W1177
Long-Term Follow-Up of Patients Hospitalized with Ulcerative Colitis Failing
Outpatient Steroid Therapy
Eric K. Ganguly, Richard Zubarik, James A. Vecchio
Aim: To describe the one, three, and five-year colectomy rates for hospitalized patients with
ulcerative colitis who have failed outpatient steroid therapy. To identify clinical predictors
of colectomy. Methods: Records of patients admitted with ulcerative colitis to a single,
university hospital from 1990 to 2003 were reviewed. Patients 18 years or older were
included if they had been taking the equivalent of at least 30 mg of prednisone for at least
3 days prior to hospitalization. Patients were excluded if they lacked a proven diagnosis of
UC, were transferred from another hospital, or were admitted directly for surgery. Clinical
and laboratory data were collected from hospital and clinic charts, as well as follow-up
telephone interviews. Results: 40 patients were included (24 Male, 16 Female). The average
age was 35; the average duration of UC was 2.5 years. The mean outpatient steroid dose
was 51 mg of prednisone/day, and the mean duration of oral steroid therapy was 14 days.
All patients had moderate to severe UC by Truelove and Witts criteria. The mean dose
of IV steroids (in equivalent prednisone dosing) during hospitalization was 89 mg/day
(hydrocortisone or methylprednisolone). 8 patients were C. difficile toxin positive on admis-
sion, 33% received antibiotics, and 35% were given TPN. In total, 26 of 40 patients (65%)
had a colectomy. The 1, 3 and 5 year colectomy rates after hospitalization were 60%, 60%
and 63% respectively. One patient had a colectomy 6 years after hospitalization. Of patients
undergoing colectomy, 24 of 26 (92%) had surgery within 1 year of hospitalization. There
was no significant difference between patients undergoing colectomy or not with respect to
age, gender, disease duration, c. difficile toxin detection on admission, inpatient steroid
dose, or inpatient use of antibiotics or TPN. Patients undergoing colectomy had a significantly
higher dose of outpatient oral steroids (52.3 mg/d vs 44.5 mg/d, p=.027), shorter outpatient
steroid course (10.8 days vs 17.5 days, p=.038), and a higher admission platelet count (450
vs 365, p=.036). Conclusions: Patients admitted for ulcerative colitis treatment after failing
outpatient steroid have a 5 year colectomy rate of 63%, with over half needing surgery
within 1 year of admission. Higher platelet count, higher outpatient steroid dose, and shorter


















Preterm Birth Is Associated with, But Not An Independent Risk Factor for
Developing Crohn’s Disease Later in Life
Barbara Sonntag, Birgit Stolze, Andreas Luegering, Jan Heidemann, Pia Lebiedz, Emilie
Rijcken, A Heinecke, Wolfram Domschke, Torsten Kucharzik, Christian Maaser
Background: IBD is a heterogeneous condition the exact cause of which is still unknown.
Exposure to bacterial antigens of the intestinal flora is one of the potential trigger mechanisms.
Vaginal delivery is the earliest time point in life when the intestine is exposed to a microbial
flora. In an initial detailed analysis of the perinatal circumstances looking at a local cohort
of IBD patients we recently found a significant association of preterm delivery and the
development of Crohns disease later in life. The aim of this study now was to extend our
findings to a larger national cohort. Methods: A self-administered questionnaire concerning
the circumstances at birth was mailed to patient members of the German Crohns and Colitis
foundation (DCCV). Their partners having no IBD served as controls. Statistical analysis
was performed using the Statistical Package for Social Sciences (SPSS). Comparisons of
categorical and continuous variables were conducted using the Chi-Square- and t-test or
analysis of variance, respectively. Odds ratios (OR) together with 95 % confidence intervals
(CI) were calculated to estimate the relative risk of disease status associated with various
exposures. Multivariate analysis using logistic regression was performed to identify independ-
ent risk factors. Results: Information was obtained from a total of 2737 persons (763
ulcerative colitis (UC), 1096 Crohns disease (CD), 878 controls (C)). Female sex (CD: OR
3.703, CI 3.067-4.484; UC: OR 1.879, CI 1.540-2.293), smoking (CD: OR 1.229, CI 1.009-
1.497; UC: 0.792, CI 0.638-0.984), appendectomy (CD: OR 2.934, CI 2.334-3.689; UC:
OR 0.614, CI 0.460-0.819) and maternal IBD (CD: OR 4.521, CI 1.578-12.949; UC: OR
3.705, CI 1.232-11.140) were significantly associated with disease status. In addition, preterm
birth, but not caesarean section and breastfeeding was significantly associated with CD (OR
1.522, CI 1.122-2.066), but not with UC (OR 1.377, CI 0.987-1.923). Accordingly, birth
weight was significantly lower in the UC and CD group (3341 vs. 3354 vs. 3438 g, p =
0.017). Multivariate analysis confirmed all but preterm birth as independent risk factors.
Discussion: Our results confirm a significant association of preterm birth with the develop-
ment of CD later in life, which may be due to alterations in the vaginal microbial flora.
However, it does not prove as an independent risk factor in the multivariate analysis.
W1179
Population Based Cost Analysis of Screening for Dysplasia in Primary
Sclerosing Cholangitis
Gilaad G. Kaplan, Steven J. Heitman, Robert J. Hilsden, Stefan Urbanski, Sam S. Lee, Rob
P. Myers, Kelly W. Burak, Mark Swain, Remo Panaccione
Background: Patients with primary sclerosing cholangitis (PSC) and either ulcerative colitis
(UC) or Crohn’s disease (CD) are at risk of developing colorectal cancer (CRC). Recommenda-
tions suggest annual screening colonoscopy to detect dysplasia in patients with PSC and
colitis. For a 90% confidence to detect dysplasia 33 colonic biopsies are required. Costs
associated with screening PSC patients are unknown. Aims: 1) to determine the rate of
dysplasia or cancer in PSC patients and 2) to assess the costs associated with screening.
Methods: A population-based study was conducted between 2000 and 2004 to identify all
patients with a diagnosis of PSC. PSC patients were identified using regional databases and
were confirmed by chart review. Colonic histopathology was reviewed in PSC patients with
colitis for: 1) the number of biopsies taken during screening colonoscopy, 2) frequency of
colonoscopies conducted between 2000 and 2005, and 3) the presence of CRC, dysplasia
or a dysplasia associated lesion or mass (DALM). The direct cost of a screening colonoscopy
and the pathology costs incurred were determined locally. Predicted costs for the recom-
mended annual screening colonoscopy with 33 random biopsies were compared to the
actual costs accrued in our cohort using the Wilcoxon signed-rank test. All costs are reported
in US dollars. Results: During the study period 45 eligible PSC patients with UC or CD
were identified. Five patients (11.1%) were diagnosed with low grade dysplasia (n=2), DALM
(n=2) or CRC (n=1) in the 5 year period. Two of these lesions were detected through screening
and 3 because of symptomatic presentation. Of an expected 131 screening colonoscopies for
dysplasia, only 56 were actually conducted. The median number of biopsies collected was
27 (IQR: 19-33). The incidence rate for detecting a lesion through screening was 3.6 events
per 100 annual colonoscopies. The actual cost of screening over the 5-year study period
was $42,608.71 compared to a predicted cost of $107,108.24 (p<0.001). The annual pre-
dicted cost of screening one PSC patient would have been $850.04. Based on a detection
rate of 3.6 lesions per 100 annual colonoscopies, $23,801.25 would be spent to detect one
case of dysplasia, DALM or cancer. Conclusion: PSC patients have a high rate of colorectal
dysplasia or cancer. We have shown that screening in these patients is underperformed
compared to current practice guidelines. Overall, the cost to identify one case of dysplasia,
DALM or cancer in PSC patients would be $24,000 with annual screening. This is an
acceptable value given the morbidity and mortality associated with the development of
colorectal neoplasia.
W1180
Thrombocytosis in IBD-Associated Anemia Is Regulated By Iron
Stefanie Kulnigg, Christoph Gasche
Introduction: Thrombocytosis is a common finding in IBD, specifically when associated with
iron deficiency anemia. We previously reported that iron sucrose (a semi-labile iron complex)
causes an erythropoietin-independent normalization of elevated platelet counts in IBD-
associated anemia. We hypothesized that this observation is caused by a direct regulatory
effect of iron on megakaryopoiesis. This is specifically relevant because of the increased risk
of thromboembolic complications in IBD patients. Methods: We studied the effect of a
different iron compound (Vit-45, a novel, non-toxic, stable iron complex; Vifor Int., St.
Gallen, Switzerland) in a cohort of 8 anemic IBD patients (mean hemoglobin 9.1g/dl, ferritin
11.3µg/l, transferrin saturation 3.5%) and measured platelet counts as well as the number
of circulating megakaryocytic progenitor cells (CFU-Mk). PBMC were isolated prior to iron
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therapy and after 4 weeks by Ficoll and cultured for 12 to 14 days using the MegaCult
medium (StemCell Technologies, Vancouver, BC). CFU-Mk were stained with anti-CD41
and counted microscopically. Growth experiments were further conducted by MTT assay
using two megakaryocytic cell lines (Meg-01, Dami). Iron-depleted conditions were accomp-
lished with various iron chelators (deferoxamine [DFO]; deferiprone [L1]), FCS-dilution
and addition of holo- (iron loaded) or apo- (iron free) transferrin. Results: Upon therapy
with Vit-45, patients receiving a hemoglobin-adjusted mean iron dose of 1538mg, platelet
levels decreased from 421 G/l to 342 G/l (week 4, p=0.0719) and 300 G/l (week 8, p=
0.0095). Small and medium sized CFU-Mk increased from 0.12 to 0.42 (p=0.065) and 0.19
to 0.43 (p=0.036), respectively. The proliferation of Meg-01 and Dami was unchanged with
low concentrations of iron chelators but significantly dropped at higher doses (>1µM for
DFO and >50µM for L1). Both cell lines showed unchanged growth characteristics down
to 1% FCS. Low concentrations of holo-transferrin (0.4 - 50µg/ml) induced significantly
better growth than higher concentrations >50µg/ml. Conclusion: Vit-45, a novel, non-toxic
intravenous iron complex, causes a normalization of elevated platelet counts in patients with
IBD-associated anemia similar to what has been observed with iron sucrose. These findings
support the hypothesis that the observed effect is related to ferric iron rather than the sugar
complex. Circulating CFU-Mk changed inversely to platelet counts indicating that iron
deficiency might inhibit megakaryocytic proliferation. Thus, thrombocytosis through iron
deficiency may rather be due to an increase in megakaryocytic ploidy rather than number.
W1181
Variation in Initial 6-Mercaptopurine Dosage in Pediatric Crohn’s Disease
Richard B. Colletti, Robert N. Baldassano, David E. Milov, Peter A. Margolis, Pibdnet
Pediatric IBD network for research and improvement
Background Variation in care can be due to overuse, underuse or misuse of diagnostic and
therapeutic interventions. 6-mercaptopuprine (6MP) and its prodrug azathioprine (AZA)
have efficacy in Crohn’s disease (CD). Measurement of thiopurine methyltransferase (TPMT)
prior to starting treatment can identify normal genotype or phenotype patients to whom
the recommended dose (6MP 1.0-1.5mg/kg/d) can be administered. Aim To determine the
variation in care by pediatric gastroenterologists in administering 6MP and the effect on
dosage of measuring TPMT. Methods In a prospective cohort of CD patients by PIBDNet,
pediatric gastroenterologists enrolled patients who were starting treatment with 6MP or
AZA. They provided care as usual and completed patient encounter forms via the PIBDNet
Data Collection web site. Patients Preliminary data from 37 sites are presented on 93 patients
(5-17 yr, 57% male, 90% Caucasian, 12% Jewish). 19% had involvement of the esophagus,
74% ileum, 60% colon, 25% perineum, and 3% extraintestinal. 56% were underweight,
60% were taking daily prednisone, and the CRP was elevated in 61%. By the Physician
Global Assessment CD was inactive in 8%, mild in 35%, moderate in 48% and severe in
9%. The Harvey Bradshaw Index was >4 in 39%. The most common indication for 6MP/
AZA treatment was early or induction therapy. Results 24 patients (26%) were treated with
AZA and 69 patients (74%) with 6MP. Of the 69 patients treated with 6MP, TPMT was
measured in 49 (71%); in 41 the TPMT was normal. Of patients in whom the TPMT was
normal, the dose was between 1.0 and 1.5 mg/kg/d in 51%, and 23% received a dose <1.0
mg/kg/d (mean starting dose 1.17 mg/kg/day; range 0.68-1.89). In contrast, of patients
without TPMT measurement, the dose was between 1.0 and 1.5 mg/kg/d in 45%, and 55%
received a dose <1.0 mg/kg/d (mean starting dose 0.95 mg/kg/day; range 0.36-1.44) (p=
0.009). Conclusion There is considerable variation in the selection of drug, measurement
of TPMT and dosage prescribed. Patients in whom TPMT had not been measured were
more likely to receive a dose of 6MP lower than recommended. (Supported by a grant from
NASPGHAN with funds from the American Board of Pediatrics.)
W1182
Crohn’s Disease Involving the Jejunum Or Proximal Ileum
Greta S. Lee, Dian Templeton, Rebecca I. Cooley, Elizabeth Fowler, Douglas Lincoln,
Timothy Florin, Graham L. Radford-Smith
Background: Crohn’s disease (CD) affecting the jejunum or proximal ileum (JPI) is less
common than classical CD involving the terminal ileum and/or colon. Reports of its prevalence
range from 3.3% to 9.5% in adults. This area of the gut, until recently, has been difficult
to image and investigate. Patients with JPI disease have not been well characterized - small
case series predominantly reflect patients with symptomatic clinically significant disease.
Aims: To determine the prevalence and major clinical associations of patients with JPI disease
in a prospectively collected cohort of adult patients with CD from the population of Brisbane.
Methods: Patients were recruited from the Brisbane IBD database. Information was collected
prospectively by interview and questionnaire. All specific investigations for small bowel
involvement were reviewed as well endoscopic, surgical, radiological and pathological reports
to determine method of diagnosis of JPI disease, number/types of confirmatory investigations,
extent of small bowel disease, surgical resection for small bowel disease and presence of
granulomas. The cohort with JPI disease was compared with the rest of this population-
based CD cohort. Univariate analysis used chi-square or t-test, followed by multivariate
analysis. Results are expressed as ratios, means ± standard deviations or odds ratio (OR)
with 95% confidence intervals (CI). A significant p-value was defined as <0.05. Results:
Patients with JPI disease represented 9.9% of the CD population. There was a highly
significant male predominance in this subgroup (OR=3.1; 95% CI: 1.8-6.4). This gender
difference was not related to age at diagnosis, smoking history or any other clinical feature.
The rate of surgical recurrence was significantly higher in the JPI group (P=0.018). Granul-
omas were significantly more prevalent in this group on multivariate analysis when corrected
for age, gender, immunosuppression and bowel resection (OR=1.8; 95% CI: 0.9-3.6). Conclu-
sion: Symptomatic CD involving the jejunum or proximal ileum, leading to investigation of
this region, occurred in 10% of our patients. There was a strong male predominance in
patients with JPI Crohn’s disease, not explained by other potential confounders such as sex,
age or smoking. Proximal small bowel CD should be considered early, especially with the
number of emerging imaging modalities available. Surgical recurrence rates were almost
double in patients with JPI involvement, despite high rates of immunosuppression use. This
has important implications for future approaches to treatment.
W1183
Are There Other Factors Explaining Why UC-Patients with Normal
Colonoscopy Still Reports IBD-Related Symptoms?
Tomm Bernklev, Magne Henriksen, Oivind Palm, Jorgen Jahnsen, Morten Vatn, Bjorn
Moum
Background: It is well known from clinical practice that IBD patients with inactive disease,
judged by colonoscopy and histology, may well complain of disease-related symptoms. The
lack of objective findings makes it difficult to explain this, but other, non-IBD related factors
may contribute to their symptoms. Aim: To identify possible factors explaining the presence
of symptoms in UC-patients with inactive disease at the time of investigation. Material and
Method: All UC patients in the IBSEN cohort were offered a colonoscopy with biopsies in
connection with the five-year follow-up visit. Disease symptoms were classified as none,
mild, moderate/severe by the patient, judged on the last 14 days before the visit. Health-
related quality of life was investigated with N-IBDQ and SF-36. All patients underwent a
clinical examination and interview. In addition, the frequencies of fibromyalgia (FM), chronic
widespread pain (CWP) and non-inflammatory joint pain (NIJP) were determined by an
experienced rheumatologist. Results: All together 164 UC patients (50%) accepted and
underwent a colonoscopy, mean age 45.3yrs (15.4), 47% female. Of these, 28 patients
(17%) complained of IBD-related symptoms but had a normale colonoscopy; mean age
47.4(14.3), 46% female. HRQOL was significantly reduced for the dimensions stool consist-
ency/frequency, bowel pain and worries, compared to UC patients without symptoms. Of
all patients with FM/CWP in the IBSEN study, 25% were found in this subgroup, compared
to 2.7% in symptom-free UC patients. Smoking was also more frequent in this subgroup,
as well as a lower educational level, compared to symptom-free UC patients,18% vs. 8%
and 36% vs. 24%, respectively. Conclusion: UC patients with normal colonoscopy and
symptoms are more frequently smokers, have a lower education, have an increased risk for
having FM/CWP and have more bowel complains, bowel pain and worries than symptom-
free UC patients.
W1184
Outcome of Surgical Versus Percutaneous Drainage of Abdominal and Pelvic
Abscesses in Crohn’s Disease
Alexandra Gutierrez, Hang Lee, Bruce E. Sands
Objective: Abdominal and pelvic abscesses (APA) are a common problem in the management
of Crohn’s disease (CD). The criteria used for selection of operative and radiographic-guided
percutaneous drainage have become increasingly controversial. We studied the effect of the
initial choice of therapy (surgery or percutaneous drainage (PD)) for APA on time to resolu-
tion. Methods: We recorded clinical, laboratory, and radiographic data on all adult patients
with CD and APA treated at Massachusetts General Hospital between 1991 and 2001 and
then followed for at least one year. Baseline characteristics were individually tested using
univariate analysis to identify factors or variables associated with choice of initial modality.
Statistically significant and clinically significant variables were included in a multivariate
Cox’s proportional hazards model to identify factors independently associated with time to
resolution. Results: Of 66 episodes identified, surgery was the initial modality in 29 and
PD in 37. Median time to resolution was 22 days (95% CI 13-43), with no significant
difference between those treated with surgery (25 days, 95% CI 12-47) or PD (21.5 days,
95% CI 12-58). Older patients, those with longer duration of APA symptoms prior to
drainage, no fistula identified radiographically, on immunomodulators and admitted to the
medical service were more likely to have PD as initial modality. These factors, when incorpor-
ated in a Cox regression model, did not significantly affect the time to resolution. Days from
onset of APA symptoms to radiographic diagnosis or drainage were independently associated
with time to resolution of the abscess. Conclusion: Time to resolution of APA in CD is
similar regardless of whether PD or surgery is performed. Earlier intervention for APA is
associated with shorter time to resolution.
W1185
Mesalamine Reduces the Rate of Colorectal Dysplasia in Patients with
Inflammatory Bowel Disease and Primary Sclerosing Cholangitis Who Are On
Urosdeoxycholic Acid
Timothy Smith, Prabhakar Swaroop
BACKGROUND: Ursodeoxycholic acid (UDCA) has been known to reduce the risk of colonic
neoplasia in patients with primary sclerosing cholangitis (PSC) and ulcerative colitis (UC).
PSC-UC patients are at higher risk of developing colorectal cancer (CRC) and dysplasia
compared to UC alone. This study aims to investigate the effect of mesalamine and folate
supplementation on dysplasia in patients with PSC and inflammatory bowel disease (IBD)
who are already on UDCA. METHODS: All patients with both PSC and IBD evaluated at
St. Louis University between 1995 and 2005 were identified through a retrospective review
of the medical record. Cases were required to have PSC diagnosed by cholangiography
(ERCP and/or MRCP) and at least one prior colonoscopy with biopsies at our institution.
Medication history was reviewed and patients who were not on UDCA were excluded. For
the remaining patients, medication history and histologic data from prior colon biopsies
was reviewed for dysplasia, pathology indefinite for dysplasia, or absence of dysplasia. Rates
of usage of mesalamine and folic acid were compared. RESULTS: Twenty-four patients were
identified (80% of IBD was UC). Of the 24 patients, 2 (8%) had biopsies revealing dysplasia,
5 (21%) had biopsies indefinite for dysplasia, and 17 (71%) had no dysplasia. Nineteen
patients had been on mesalamine and 5 had not. Among patients who had received mesalam-
ine, 1/19 (5%) had dysplasia, 3/19 (16%) were indefinite for dysplasia, and 15/19 (79%)
had no dysplasia. Among patients who did not receive mesalamine, 1/5 (20%) had dysplasia,
2/5 (40%) were indefinite for dysplasia, and 2/5 (40%) had no dysplasia. All five patients
on folate supplementation had no dysplasia. Among the patients who did not receive folate,
2/19 (11%) developed dysplasia, 5/19 (26%) were indefinite for dysplasia, and 12/19 (63%)
had no dysplasia. These results are summarized in the table below. The relative risk of
developing dysplasia in patients who were not on mesalamine was 1.9 (95 % CI = 0.6 to
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5.9). There was a trend toward a protective effect of folate as well. CONCLUSIONS: Mesalam-
ine appears to provide an additional chemoprotective effect on the risk of colonic neoplasia
in PSC-IBD patients on UDCA. Folate may also have an additive chemoprotective effect. In
PSC-IBD patients taking UDCA, addition of both mesalamine and folate should be considered.
Effect of mesalamine and folate on rate of dysplasia in patients with PSC-IBD who are
on UDCA
W1186
Comparison of Clinical Outcomes Between Intestinal Simple Ulcer and
Intestinal Behcet’s Disease
Yun Jin Chung, Chang-Min Cho, Young Dae Park, Won Young Tak, Seong Woo Jeon
Background/Aims: Intestinal simple ulcer, which does not meet the criteria of Behcet’s
disease, is not uncommon in clinics. However, its clinical courses and outcomes are not
well understood. This study was performed to compare intestinal simple ulcer with intestinal
Behcet’s disease in clinical outcomes. Methods: We retrospectively reviewed the medical
records of 52 patients who were suspected as intestinal Behcet’s disease according to the
patient’s symptoms, colonoscopic, laboratory and pathologic characteristics. Of them, 27
patients (Group 1) met both the criteria of the International Study Group for Behcet’s Disease
and the Behcet’s Disease Research Committee of Japan. Thirteen patients (Group 2) met
only the latter and the remainder (Group 3) didn’t meet any critieria. The efficacy of medical
treatment was assessed by the gastrointestinal symptoms and follow-up colonoscopic or
radiologic findings. Results: Mean age of the onset of gastrointestinal symptoms was 36.4±12.8
years. Sex ratio was 1.08:1 (M:F) and mean follow-up duration was 35.2±39.5 months.
Forty-six patients had gastrointestinal symptoms and abdominal pain was the most common
symptom. Single, smaller than 5mm, round and shallow ulcer with erythematous margin,
which located at ileocecal area, was the most typical colonoscopic feature. No significant
differences were found in clinical manifestations and colonoscopic findings among three
groups. Mean duration of medical treatment was 19.6±24.4 months. The overall complete
or partial remission was observed in 36 patients (83.7%) and mean time to achieve remission
was 12.1±25.3 months. There were no differences among groups in the rate (20 (90.9%)
vs. 9 (75.0%) vs. 7 (77.8%), group 1, 2, 3, respectively, p=0.47) and mean time (7.1±9.2
months vs. 26.2±46.7 months vs. 8.0±7.5 months, group 1, 2, 3, respectively, p=0.15) to
achieve medical remission. The overall cumulative rate of first operation and second operation
was 40.5% and 71.9% in 10 years. No statistical relationship was found in the cumulative
rate of operation among groups (p=0.54). Conclusions: Clinical courses and outcomes of
the intestinal simple ulcer are not different from that of intestinal Behcet’s disease. The
differences of pathophysiologic mechanism between intestinal simple ulcer and intestinal
Behcet’s disease have not been established. However, it is desirable to regard and treat
intestinal simple ulcer as intestinal Behcet’s disease.
W1187
Exercise and Bone Mineral Density in Crohn’s Disease
Reshma C. Rakshit, Len Almond, Farook Al-Azzawi, Keith Abrams, John F. Mayberry,
Richard J. Robinson
Introduction: Bone loss is a common complication of Crohn’s disease with a prevalence of
30-50%. It is multifactorial in causation. The beneficial effects of a year long low-impact
exercise programme were shown in a previous randomized controlled study. (1) Aim: 1.To
evaluate the long-term effects of exercise on bone mineral density (bmd) in Crohn’s disease
2.To compare the exercise activity indices of patients with Crohns’ disease over a period of
8 years. Methods: A cohort of patients with Crohn’s disease randomized to one year of
low-impact exercise versus controls was followed up after 8 years. Demographic details and
exercise activity levels (based on the Allied Dunbar National Fitness Survey)were collected.
DEXA (Dual Energy X-Ray Absorptiometry) scans of the spine and the hip were performed
at baseline and repeated after 8 years to assess bmd. Results: Data was available for 55
patients (30 males, 37 female patients) with a mean age of 51.9 years (sd=11.95 years). Of
these, 26 were originally randomized to exercise and 29 were controls. Independent T-test
showed no statistical difference in the change in the bmd at the spine or hip over 8 years
between the exercise and control groups. Chi-square testing revealed no difference between
the current exercise levels of the exercise and control groups. (p=0.21). There is a significant
difference in percentage change in bmd at the spine and hip (p=0.015; p=0.027) between
the different groups according to current activity level further strenghthened by post hoc
analyses. A Wilcoxon test shows no significant difference in the exercise habits of patients
over 8 years (p=0.81). No statistical difference was demonstrated in activity levels when
comparing patients randomized to exercise or control groups. (p=0.21). Conclusions: 1.
Short term effects of exercise on bmd do not extend over a longer time frame in patients
with Crohn’s disease. 2. Patients with higher levels of current activity have higher bmd at
both hip and spine compared to those who are least active. 3. Short term increases in activity
levels were not maintained over the 8 year period. We know that bone mineral density
change in Crohn’s disease is multifactorial. The effect of exercise/activity in isolation is small.
Therefore, prospective studies with larger number of patients will be required to assess the
overall beneficial effects of exercise on bmd in future. Reference: 1.Robinson RJ, Krzywicki
T, Almond L et al. Effect of a Low-Impact Exercise Program on Bone Mineral Density in


















Can Clinical ‘Red Flags’ At the Time of Presentation with Ulcerative Colitis
Predict Which Patients Will Subsequently Undergo a Change in Diagnosis to
Crohn’s Disease?
Gil Y. Melmed, Andrew F. Ippoliti, Gary C. Chen, Igor Nastaskin, Eric A. Vasiliauskas,
Konstantinos A. Papadakis, Carol J. Landers, Robert M. Elashoff, Stephan R. Targan
Background: The diagnosis of inflammatory bowel disease often involves combining evidence
from many sources in order to correctly diagnose ulcerative colitis (UC) or Crohn’s disease
(CD). Some patients initially diagnosed with UC are subsequently diagnosed with CD.
Established criteria for the differentiation of UC from CD require at least a colonoscopy
with biopsies (Lennard Jones, 1989), although additional diagnostic testing may be helpful.
Methods: Nested case-control study of subjects with inflammatory bowel disease entered
into longitudinal database. Cases were defined as patients initially diagnosed with UC via
full colonoscopy at presentation and who subsequently met Lennard-Jones criteria for CD.
Cases were age and sex-matched with controls (‘pure’ UC and CD) in an approximate 1:2:2
ratio. Using modified RAND expert panel methods, clinical predictors (red flags) for CD
were determined by 4 IBD experts: non-bloody diarrhea, upper GI symptoms, >10% weight
loss, active smoking, history of transfusions, family history of CD, oral ulceration, anal skin
tags, thrombocytosis, hypoalbuminemia, and elevated C-reactive protein (CRP). In addition,
CD-specific serologies (ASCA IgA/IgG, OmpC, I2, CBir1) and pANCA were run in a blinded
fashion from stored sera collected at the time of entry into the database. Significance threshold
was adjusted for multiple testing. Results: Of 162 patients with a reported change in
diagnosis, 143 had either insufficient documentation of CD criteria or only a sigmoidoscopy
at presentation and were excluded. 21 subjects with change in diagnosis, 50 UC controls,
and 56 CD controls underwent chart review to corroborate diagnosis and assess for clinical
parameters at initial presentation. Those with a change in diagnosis were more likely than
UC controls to have had nonbloody diarrhea (p<0.001) and weight loss (p<0.01); other
parameters were not significantly different. Family history of CD trended highest in those
with CD, lowest in those with UC, and in-between among those with a change in diagnosis
(p=0.06). Those with a change were more likely to have at least 2(p=0.05), 3 (p=0.05) or
4 (p<0.01) clinical ‘red flags’ than patients with UC. Quantitative levels of ASCA IgA, ASCA
IgG, and CBir1 were highest in CD controls, lowest in UC controls, and in-between among
those with a change in diagnosis (p<0.001 for linear trend for each serology). Conclusions:
Most patients with UC subsequently diagnosed with CD had insufficient workup at the time
of initial diagnosis. Further diagnostics for CD may be warranted in UC patients who present
with nonbloody diarrhea, weight loss, or at least 2 red flags. Prospective studies are needed.
W1189
Phenotypic Classification of Crohn’s Disease (CD) and Ulcerative Colitis (UC)
in Olmsted County Minnesota: Assessment of Temporal Changes
Emelie F. Helou, E V. Loftus, W J. Tremaine, W S. Harmsen, A R. Zinsmeister, D A.
Jewell, W J. Sandborn
Background: A simple, reliable classification system is desirable to stratify inflammatory
bowel disease patients (pts) for prognosis and genetic associations. The Vienna system for
CD categorized by age of onset, location, and behavior. Limitations include no recognition
of early-onset pts, and instability in behavior over time from disease progression. A formal
system for UC does not exist. The Montreal classification includes new age categories for
CD and a system for UC. Purpose: To assess for associations among age, gender, maximal
extent of disease, and time period of diagnosis in population-based cohorts of CD and UC.
Methods: Medical records of all 308 CD and 372 UC pts diagnosed while residing in Olmsted
County, MN between 1940 and 2000 were reviewed. The Montreal system was used to
reclassify age of onset and maximal disease extent. Pearson Chi-square tests were used to
assess associations among age of onset, gender, disease extent, and calendar period. Results:
Median age of onset was 29 years (range 4-91) for CD and 33 years (1-88) for UC. The
classification is shown in Table 1 for CD and Table 2 for UC. For CD, age of onset changed
significantly over time, with more late-onset cases recently. Ileocolonic involvement was
more common in recent years. Early-onset pts were more likely to have ileal (32%) or
ileocolonic disease (64%), while late-onset pts had more colonic involvement (42%)
(p<0.001). There were no significant associations between gender and extent, gender and
age of onset, or gender and time period. For UC, left-sided disease and extensive involvement
was more common in recent years. Early-onset pts were more likely to have extensive disease
(59%) than late-onset patients (39%, p=0.01). Early-onset pts were more likely to be males
(88%) than late-onset pts (59%, p=0.01). No significant associations were seen between
gender and extent, or gender and time period. Conclusions: In these population-based
cohorts of IBD pts, involvement was more extensive in recent years. Early-onset pts are
more likely to have extensive disease.
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W1190
Characteristics of Crohn’s Disease Patients with History of Bowel Resection
Who Had Lactulose Breath Test for Evaluation of Small Bowel Bacterial
Overgrowth
Tom Mathew, Faten Aberra, Chinyu Su, Yu-Xiao Yang, Gary R. Lichtenstein
Background: Patients with Crohn’s disease may have gastrointestinal symptoms that are not
attributable to active disease. Small bowel bacterial overgrowth may occur in patients with
Crohn’s disease, particularly those with prior intestinal resections. There has been no study
examining factors that predict a positive lactulose breath test (LBT) in patients with Crohn’s
disease who have undergone intestinal resection. Our objective was to determine the charac-
teristics predictive of a positive LBT in this patient population. Methods: We performed a
retrospective chart review of successive Crohn’s disease patients with history of intestinal
resection who underwent LBT over the past 2 years at a tertiary care institution. All patients
had a negative colonoscopic and /or radiographic evaluation for disease recurrence. Patients
underwent LBT for 3 hours with breath hydrogen monitoring in a standard fashion. Basal
hydrogen levels and patterns after lactulose administration were critically analyzed. We
compared patients with positive LBT to those with negative LBT based on the following
characteristics: smoking, type of surgery, diseases causing hypomotility (diabetes and hypo-
thyroidism) , drugs causing hypomotility (narcotics, anticholinergics, and calcium channel
blockers), specific GI symptoms or signs (abdominal pain, bloating, diarrhea, abdominal
mass and general well being), Harvey-Bradshaw index and presence of a stricture. Two sided
Fisher’s exact test was used to compare clinical characteristics between patients with positive
LBD and those with negative LBT. Results: 18 patients (8 men /10 women; mean age 19
years, range 25-69) with CD and prior bowel resection underwent LBT during the study
period. Six of the 18 patients (33%) had a positive LBT. Most subjects had ileocolonic
resection ( 88% vs 6% ileal vs 6% colonic resection). All six patients with positive LBT had
ileocolonic anastomosis, while only 6/16 patients with ileocolonic anastomosis had positive
LBT. Smokers were significantly more likely to have a positive LBT compared to nonsmokers
(80% vs, 16%, p=0.02). Conclusions: In our study, bacterial overgrowth was documented
in one-third of CD patients with prior intestinal resection who underwent LBT for active
GI symptoms despite negative workup for disease recurrence. Smoking appeared to be a
positive predictor of positive LBT in these patients.
W1191
Etiology of Anemia in Patients with Ileal Pouch-Anal Anastomosis (IPAA)
Ioannis Oikonomou, Victor W. Fazio, Feza Remzi, Rocio Lopez, Sandra El-Hachem, Bret
A. Lashner, Bo Shen
Background and Aim: Restorative proctocolectomy is the surgical treatment of choice in
patients with medically refractory Ulcerative Colitis (UC) and Familial Adenomatous
Polyposis (FAP). Even though anemia is frequently observed in patients with IPAA it has
not been studied. The identification of the underlying cause is often challenging. Our aim
was to define the prevalence and to identify etiologic factors for anemia in this patient
population. Methods: Prospectively maintained database and medical records of all patients
who had restorative proctocolectomy between 1983 and 2005 were reviewed. All patients
with at least one hemoglobin value more than 6 months after IPAA between 10/1998 and
10/2005 were studied. The last reported Hb served as the index value. All patients with
anemia (Hb<13.5g/dL males, <12g/dL females) were identified. A second group of randomly
selected patients with normal Hb served as control. A thorough chart review in regards to
etiologic factors included bleeding, chronic inflammation (pouchitis or other), malignancy,
chronic renal insufficiency, and medications. Results: 389 patients (M:F, 214:175) had
documented CBC values. 67 patients (17%) had anemia. The prevalence of anemia was
19% and 15% in males and females, respectively. Anemia prevalence was 17% in UC patients
vs. 26% in FAP patients (P=0.27). Mean Hb in the anemia group was 11.4 (median 11.7);
1 patient (2%) had severe (<7), 11 (16%) moderate (7-9.9), and 55 (82%) mild anemia
(≥10); 1 patient (2%) had macrocytic, 16 (24%) microcytic, and 49 (74%) normocytic
anemia. The etiology of anemia in the disease group was unclear in 16 patients (24%).
Clinical characteristics were similar in the anemia and the control group, except of GI
bleeding and bone-marrow suppressive medications which were more common in the anemia
group, each affecting one fifth of the patients (P<0.05). Conclusion: Persistent anemia is
common in patients with IPAA. Even though GI bleeding and bone-marrow suppressive
agents were at least partially accountable, one fourth of the patients had unclear etiology.
Other etiopathologic pathways should be explored.
W1192
Clinical Remission Prior to Initiation of Immonusuppression with
Azathioprine Positively Impacts Responsiveness in Crohn’s Disease But Not in
Ulcerative Colitis - Results from a Multicenter Study in 1176 Patients with
IBD
Martin H. Holtmann, Frank Krummenauer, Christina Claas, Kristina Kremeyer, D.R.
Lorenz, Iris Vogel, Olivia Rainer, Norbert Luegering, Guido Gerken, Wolfgang Kruis,
Stephan Boehm, Juergen Stein, Ulrich Boecker, Jan Schmidt, Hans Herfarth, Carsten
Buening, Rainer Duchmann, Andreas Sturm, Max Reinshagen, Andreas Stallmach, Daan
Hommes, Geert D'Haens, Peter Galle, Markus Neurath
Introduction: Azathioprine (AZA) is the goldstandard for maintenance therapy in IBD. In a
multicenter study on 818 patients with Crohn’s disease (CD) and 358 patients with ulcerative
colitis (UC) from 14 european centers we were able to show contrary to preexisting data,
that AZA possesses efficacy in maintenance of remission beyond 4 years in both CD and
UC and to give a quantitative assessment of the significant steroid sparing effect of AZA. In
a subsequent analysis we investigated the impact of the remission status for responsiveness
to AZA. Infections are a feared complication of long term immunosuppression. Additionally,
we therefore analysed the rates of hospitalization due to infections under AZA treatment.
Methods: Endpoints were intrainddividual changes in flare frequency and steroid need
between the time periods prior to and under AZA intake. Changes of flares/year or predniso-
lone equivalent/month were indicated as medians with quartils in brackets. P<0.05 in the
T-test indicated statistic significance. For determining the hospitalization rates, the total
number of hospitalizations were refered to the cumulative number of treatment years. Results:
In CD patients who were put on AZA, while in remission, subsequent numbers of flares/
year and steroid consumption where significantly lower than in those patients who had
disease activity at the beginning of AZA treatment. Flare incidences were 0.0/y (0-3.43)
versus 0.0/y (0 - 6.492) (p<0.001) and steroid consumption was 10.17mg/month (0-148)
versus 79.11mg/month (0-235.59) (p<0.001). This was not due to selection bias, because
in UC there was no difference between those patients in remission and those with still active
disease. Flare incidences in UC were 0/y (0 - 0.818) versus 0/y (0 - 0.572) (p=0.488). The
corresponding number for median intake of prednisolone equivalent were 65.41mg/month
(0 - 236.66) and 69.17mg/month (0 - 250) (p=0.455). In CD the number of hospitalizations
because of infections under AZA were 23 during 2495 cumulative treatment years (0.009/
y); in UC there were 10 cases during 987 treatment years (0.01/y). Discussion: The divergent
results regarding the role of the remission status for responsiveness to AZA in CD and UC
emphasize the pathogenetic differences between these entities and might support a hit hard
and early strategy in CD. Severe infectious complications requiring hospitalization are rare
and seem to be an overestimated risk of long term immunosuppression.
W1193
The Effect of Acute Treatment with Budesonide On Body Mineral Density in
Greek Patients with Newly Diagnosed Mild-to-Moderate Crohn’s Disease
Gerassimos J. Mantzaris, Christoforos N. Kalantzis, Evangelos Kokkinakis, Anastassios
Roussos, Stavroula Koilakou, Efstratios Grivas, Demetrius Tsounis, Nickolaos Raptis,
Nikolaos Kalantzis, George Triantafyllou, John Kalafatas
Aim: To investigate the effect of short-term treatment with budesonide controlled ileal release
(B-CIR) on Body Mineral Density (BMD) of patients with active Crohn’s disease (CD).
Methods: Forty-five patients [27 female, mean age 25 (17-49) y] with newly diagnosed
mild-to-moderate Crohn’s ileitis or ileocolitis as defined by a Crohn’s Disease Activity Index
(CDAI) between 200 and 400 were included in a prospective study. CD was diagnosed by
ileocolonoscopy, EGD, histology, and enteroclysis. Patients were treated with B-CIR 9 mg/
day for 8 weeks followed by 6 mg/day for another 8 weeks. Routine hematology, biochemistry,
and CDAI measurements were performed at baseline, and after 8 and 16 weeks of treatment.
Body weight and height were recorded, and the body mass index (BMI, kg/m2) was calculated.
Gender, age, hormonal status (women), smoking status, time with symptoms prior to
diagnosis, profession, family history of osteoporosis, and sedentary lifestyle were also evalu-
ated at baseline. Menopaused women, patients with prior hormonal replacement therapy,
or treatment with calcium, vit D, or biphosphonates were excluded. Dual energy X-ray
absorptiometry scans (DXA) were performed to measure BMDs of the lumbar spine (LS,
L2-L4) and the left proximal femoral neck and trochanter (FNT) at baseline and within 1
week after stopping B-CIR. LS and FNT T-scores (number of SD from a mean of normal
ethnic controls) were used to evaluate the effect of treatment on BMDs. Results: All patients
completed the study. The mean (SD) CDAIs at baseline were 267(58). Nine patients (20%)
worsened during treatment, 9 (20%) did not improve and 27 (60%) were improved (CDAI
≤70 over baseline) or achieved remission (CDAI<150). The mean (±SD) T-scores at baseline
T : 89386$$CH2
05-04-06 23:18:31 Page 655Layout: 89386B : o
A-655 AGA Abstracts
were -0.3 (±0.8). Sixteen patients (35.5%) had mild osteopenia (-1<T score) but none had
osteoporosis (T-scores>-2.5). Low BMIs, female gender, longstanding symptoms prior to
diagnosis, and heavy smoking were associated with lower T-scores. Treatment with B-CIR
for 16 weeks did not result in significant changes in LS/FNT T-scores. Nine patients whose
disease worsened during treatment showed a not significant decrease in LS/FNT T-scores.
T-scores were improved in 18 patients and remained unchanged in 18 patients compared
with baseline. Conclusion: The majority of Greek patients in reproductive age with newly
diagnosed mild-to-moderate CD had BMDs not significantly deviating from healthy controls
which did not deteriorate after short-term treatment with B-CIR. This may be due to the
effect of sunshine on vit D turnover and, consequently, to BMD. The effect of chronic B-
CIR treatment in these patients is under investigation.
W1194
Long Term Follow Up of Crohn’s Disease Patients Treated with Infliximab
Using An Episodic Strategy
Vincent Pacault, Fathia Ben Hriz, Jean-Marc Gornet, Matthieu Allez, Maria Nachury,
Ravzan Iacob, Jean-Frederic Colombel, Marc Lemann
Background. Infliximab (IFX) is a treatment for luminal and fistulizing Crohn’s disease (CD).
Episodic (“on demand”) treatment has been initially used but this strategy has been recently
challenged as it could facilitate immunisation leading to more intolerance reaction and/or
loss of efficacy than a scheduled strategy. Long term data in patients treated with IFX using
an episodic strategy are still scarce. Patients and methods. All records of patients treated
with IFX for CD in our center between January 1999 and July 2004 were retrospectively
reviewed; data were updated until June 2005. In patients responder to IFX and initially
treated using an episodic strategy, we estimated the probability of the following events: relapse
after the induction regimen, switch to a scheduled IFX treatment and IFX discontinuation due
to intolerance and/or loss of response (Kaplan-Meier method). Results. 137 patients were
treated with IFX for luminal (n=88) or fistulizing (n=49) CD; median follow up was 35
months. 125 patients (91%) responded to the induction regimen (1-3 infusions); among
them, 110 (88%) were treated using an episodic strategy (on demand re-treatment). Probabil-
ities of sustained remission after the induction regimen were 33%, 24% and 15% at 1, 2
and 4 years, respectively. Young age (RR: 1.6; 95CI: 1.1-2.4), prior use of immunosuppres-
sants (IS) (RR: 1.9; 95CI 1.2-3.0) and smoking (RR: 1.6; 95CI: 1.1-2.5) were associated
with an increased risk of relapse (multivariate analysis). Probabilities of switching to a
scheduled strategy due to frequent relapses were 10%, 23% and 41% at 1, 2 and 4 years,
respectively. Probabilities of discontinuation due to intolerance and/or loss of efficacy were
5% (intolerance 1% and loss of efficacy 4%) at 1 year, 18 % (8% and 13%) at 2 years, and
44% (26% and 24%) at 4 years. Absence of continuous treatment with IS after the IFX
induction regimen was the only factor associated with an increase risk of IFX discontinuation
due to intolerance and/or loss of efficacy (RR: 2.2; 95CI: 1.1-4.8). Nine severe adverse events
were observed: tuberculosis (n=1), severe pneumonia (n=1), severe skin infection (n=2),
intra-abdominal abscess (n=1), myocardial infarction (n=2), anaphylactic shock (n=1) and
cancer (n=2, uterus and thyroid).Two patients died of a cause unrelated to IFX. Conclusion.
IFX episodic strategy is associated with a high rate of relapse and of re-treatment even when
combined with IS. The rate of IFX discontinuation due to intolerance and/or loss of response
was 44 % at 4 years, despite a switch to a scheduled IFX treatment in 41%. Continuous
treatment with IS significantly reduced the rate of discontinuation.
W1195
Infliximab for Hospitalized Ulcerative Colitis Patients Failing Intravenous
Corticosteroids
Miguel Regueiro, Jennifer Curtis, Scott Plevy
Aims: To evaluate the efficacy of infliximab in hospitalized ulcerative colitis (UC) pts refractory
to iv corticosteroids. Background: Treatment options for corticosteroid refractory UC pts
are limited and include cyclosporine and colectomy. Although two recent studies (ACT I/
II) demonstrate a benefit from infliximab in outpts with moderate to severely active UC,
the utility of infliximab in hospitalized UC pts refractory to iv corticosteroids is less clear.
Study: We report our open label experience with infliximab for hospitalized UC pts at the
University of Pittsburgh Medical Center. Response to infliximab was defined as avoidance
of colectomy and cessation of corticosteroids. A Disease Activity Index (DAI) which accounts
for stool frequency, rectal bleeding, and the physician’s rating was also used to track
improvement; DAI range 0-9 with 0 denoting normal and 9 severe UC. Results: There were
12 UC inpts refractory to iv corticosteroids and subsequently treated with infliximab. None
of the pts had longstanding UC (median duration of UC = 5.5 mos, range 1 mos-4yrs) and
none had received prior immunomodulators. All of the pts had severe UC (DAI=9) and had
failed to respond to outpt oral prednisone (median dose 30 mg). None of the pts had toxic
megacolon. Nine of the 12 pts (75%) failed to respond to infliximab and required a colectomy;
median time to colectomy 3 mos. Three pts received only 1 dose (week 0) prior to colectomy,
2 pts received 2 doses (0,2, weeks), 1 pt 3 doses (0,2,6 weeks) and 3 pts 4 doses (0,2,6,14
weeks); none of the nonresponders had a significant drop in CAI (median CAI=8.5) after
infliximab. Three of the 12 pts (25%) did respond to infliximab (median DAI=1, range 0-
3) and were able to avoid colectomy and discontinue corticosteroids. The DAI’s began to
drop two weeks after the first infusion of infliximab with scores of 5,7, and 8. Unlike the
nonresponders, there was continued improvement after the second dose of infliximab and
by 4 wks the median DAI was 3. Conclusions: In this open label analysis, infliximab was
not effective for the majority of hospitalized UC pts refractory to iv corticosteroids. Those
few pts who did improve, had a response after 2 doses of infliximab; unlike the nonresponders.
Whether earlier use of infliximab will alter the natural course of UC and prevent the need


















Corticosteroid Dose Influences Colectomy Rate in Hoospitalized IBD pts with
Clostridium Difficile
Mazen Issa, Sue Skaros, Mary F. Otterson, Sarah Lundeen, Lydia R. Weber, Dawn B.
Beaulieu, Josh F. Knox, David G. Binion
Background: Recent reports suggest that Clostridum difficile (C. diff) has increased in the
U.S and diminished effectiveness of metronidazole has led to the increased use of vancomycin.
(DM Musher Clin Infect Dis. 2005;40:1586-90). Previous reports described increasing rates
of C.diff in inflammatory bowel disease (IBD) pts, noting that colectomy was needed in a high
percentage of these cases. Since C.diff affect preferentially immunosuppressed individuals and
treatment for severe colitis emphasizes high-dose intravenous corticosteroids, we examined
the impact of decreased intravenous steroid dose on clinical outcome in IBD pts with C.diff.
Methods: This was a retrospective observational study of consecutive IBD pts infected with
C.diff from a tertiary referral center between 2004-05. In addition, we focused on hospitalized
pts between 3/2003-11/2005 with colitis and C.diff confirmed by positive stool ELISA
toxin A/B assay. Outcome measures included colectomy and successful medical treatment.
Corticosteroid dosing was examined and pts were classified into 2 groups: low dose corticos-
teroid (LDC; ≤ 150mg/day of hydrocortisone) and high dose corticosteroid (HDC; >150
mg/day hydrocortisone). Demographic data, smoking status, surgical outcome and use of
infliximab during hospitalization were recorded. Results: Colectomies occurred in 5/8 (63%)
C.diff infected IBD pts diagnosed in 2004 and decreased to 4/40 pts (10%) in 2005 (p<0.001).
We then focused on specific data from 25 consecutive admissions of IBD pts (9 UC ; 15
CD) with C.diff (9 male, 15 female). Colectomies occurred in 32% of the IBD pts (5/9 UC;
3/15 CD). Active smokers with C.diff who underwent colectomy included 2 pts with UC
and 1 with CD. There were 11 pts classified as HDC and 13 in the LDC group. Seven pts
in the HDC required colectomy (7/11 (64%); p<0.01) and 1 pt in the LDC group underwent
colectomy (1/13, 8%). Oral vancomycin was used in all pts with successful medical treatment
and only 4/8 (50%) of the pts needing colectomy had received vancomycin. Infliximab was
used at the time of hospitalization in 5/8 of the pts who required colectomy and in 7/16
with successful medical treatment. Conclusion: C.diff infection is associated with poor clinical
outcome in IBD colitis pts who require hospitalization. Past treatment regimens which
emphasize high dose intravenous corticosteroids correlated with increased rate of colectomy.
Use of lower dose corticosteroids in conjunction with oral vancomycin appears to offer the
best strategy for successful medical management of C.diff in the setting of IBD colitis.
W1197
Efficacy and Safety of 4 Weeks of Adalimumab Treatment in Subjects with
Active Luminal Crohn’s Disease Who Lost Response Or Showed Intolerance to
Infliximab
Joaquin Hinojosa, Santiago Garcia, Guillermo Bastida, Cristina Saro, Jose L. Cabriada,
Miguel A. Gassull
PURPOSE To assess the efficacy and safety of adalimumab, a fully human monoclonal
antibody that targets TNF-α, in inducing clinical remission, clinical response, and fistula
closure in patients with moderately to severely active Crohn’s disease (CD) who have lost
response or showed intolerance to infliximab. METHODS In this open-label, multi-center
study, subjects with moderately to severely active CD (CDAI>220) and intolerance or lost
response to infliximab were treated with subcutaneous adalimumab: 160 mg at Week 0, 80
mg at Week 2, then 40 mg every other week (eow) for 52 weeks. Subjects were assessed
after 4 weeks for clinical remission (CDAI<150), clinical response of Δ70 or Δ100 (decrease
in CDAI of more than 70 or 100 points compared to baseline), fistula closure, and adverse
events (AE). RESULTS Of 36 subjects with mean baseline CDAI 268.3±100.6 enrolled,
28% had fistulas (3.8±5.5, mean) at baseline; 42% (n=15) had previously lost responsiveness
to infliximab and 58% (n=21) had developed intolerance to infliximab. Week 4 results are
given in the table. Treatment-related AE were mild to moderate in severity and similar to
those observed in studies of adalimumab in patients with rheumatoid arthritis. The most
common AE were nausea/dizziness, vomiting, weakness, and myalgia. One patient dropped
out due to self-limited fever resolved after adalimumab discontinuation. No serious AE were
reported. CONCLUSIONS Adalimumab was effective and well-tolerated in inducing clinical
remission and response in subjects with moderately-to-severely active luminal CD who had
lost response or developed intolerance to infliximab. No new safety concerns were found
in patients with CD compared to other adalimumab-treated populations.
Remission and Clinical Response to Adalimumab at 4 Weeks
Intention to treat analysis
W1198
Infliximab Is Effective As Rescue Therapy for Acute Severe Ulcerative Colitis -
The Initial Edinburgh Experience
Charlie Lees, Alan G. Shand, Ian D. Penman, Ian D. Arnott, Jack Satsangi
Introduction. As many as 40% of patients with acute severe ulcerative colitis (UC) will fail
to respond to medical therapy. Treatment of these patients has been limited to surgery or
second-line medical therapy (cyclosporine). Doubts remain about the efficacy of cyclosporine
and concerns over its toxicity(1). Infliximab therapy is well established for Crohn’s disease,
but its role in UC remains contentious(2). Most recently, Jarnerot et al demonstrated in a
randomised controlled trial that infliximab as “rescue” therapy for severe UC was effective
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with emergency colectomy rates of 29% vs 67% for placebo (p=0.017, NNT<3)(3). For the
first time, this trial provided evidence to support the clinical use of infliximab as rescue
therapy for UC. Methods. Data were retrospectively collected from all patients treated with
infliximab for acute severe UC requiring hospitalisation for intensive medical therapy between
May 2005 & September 2005. Results. 9 patients (6 male, 3 female, mean age 41) treated
with infliximab for acute severe UC were identified. They were characterised by either lack
of response to initial intravenous steroid therapy (6/9) or by deterioration following conver-
sion from iv to oral steroids (3/9). Infliximab (5mg/kg) was given an average of 7.8 days
(range 4-16) after admission. 6/9 (67%) acutely treated patients demonstrated a good clinical
response to infliximab within 48 hours, were commenced on azathioprine/6-MP therapy
whilst in hospital & discharged on reducing courses of oral steroids. The median duration
from infliximab to discharge was 6.5 days. All avoided colectomy to the most recent point
of follow-up (median 122 days, range 73-192). One patient developed uncomplicated herpes
zoster and another asymptomatic transaminitis following infliximab therapy. The other 3
patients (33%) underwent emergency colectomy (median 5 days post-treatment). Baseline
clinical data (stool frequency, CRP, albumin, calprotectin) did not predict response. Addi-
tional follow-up and steroid withdrawal data will be presented. Conclusions. These data
provide further evidence that infliximab may successfully rescue acute severe UC. The
treatment can function as a bridge to long-term immune-suppression and immediate colec-
tomy can be avoided. References: 1. Shibolet O et al. The Cochrane Database of Systematic
Reviews 2005, Issue 1. Art. No.: CD004277.pub2. 2. D’Haens G. Gastroenterology
2005;128(7):1805-11. 3. Jarnerot et al. Gastroenterology 2005;125:1805-11.
W1199
Open Label Experience with Adalimumab in Pediatric Crohn’s Disease
Patients Who Lost Response Or Were Intolerant to Infliximab
Colette Deslandres, Christophe Faure, Martha H. Dirks, France Gervais, Ernest G.
Seidman
Adalimumab(Admab)was reported to be effective in adult Crohn’s disease (CD). Aim: Test
the efficacy & safety of Admab in pediatric CD. Patients & Methods: 9 pediatric CD patients
(7 M, 2F) who had lost their responsiveness (n=5, after mean of 8.6 infusions, range 4-12,
last @ 10/kg) or developed intolerance to infliximab (n= 4, 4.2 infusions, 2-9) were treated
with Admab. In the acute phase for induction of remission (Harvey Bradshaw index, HBI
>5) we used 80 or 160 mg/1.73m2 s.c,, followed by 40 or 80 mg/1.73m2 2 wk later (n =
5 & 3 respectively). Outcome measures: tolerance to Admab and response (@1 mo), defined
as responders (HBI < 4; decrease >50%), partial(HBI >4, decrease >50%), or non-responders.
As maintenance, responders received Admab 40 mg/1.73m2 q2wk. The primary outcome
measures were maintenance of remission, reduction in steroids, and tolerance. Secondary
outcomes included changes in hgb, serum albumin & CRP or ESR. Concomitant immunosup-
pressors were maintained(5 MTX, 3 on 6-MP). Results: Mean age at time of 1st treatment
was 10 (range 3.1-18) years. Acute phase: Among the 8 cases, 4 responded completely
(50%), 1 partially (12.5%) and 3 failed (37.5%). Patients with loss of response to infliximab
were less likely to respond to Admab (2 of 5), vs those intolerant as indication(3/3). Mean
HBI scores decreased from 13.9 (range 8-24) to 5.3(0-24). 1 non-responder had serious
adverse effects, including fever and a flu-like illness after each Admab. 2 complained of
local pain or erythema. Maintenance phase: In 7, remission was induced with Admab, and
with prednisone in 1 other. Mean follow up was 3.6 months (range 1.5-8.5). Remission
was maintained (HBI < 4)in 6 patients (75%). 2 failed to respond after 2 & 4 doses (HBI
16). Among 6 responders, the mean baseline prednisone was 1.03 mg/kg/d (range 0.6-1.6).
At the time of the last visit, it was substantially reduced in all 6, to 0.14 mg/kg/d; p< 0.05).
The maintenance dose of Admab had to be increased to 40 mg/1.73m2 weekly in 1 case
to taper steroids. That patient had an adverse event (pneumonia + pleural effusion), requiring
temporary cessation of Admab. CRP and/or ESR normalized in 5/6 responders, not in 2
non-responders. Among responders, mean hgb increased by 20 gm/L in 2 and was stable
in the other 4. Mean serum albumin increased from 34 (range 23-42 g/L) to 36.8 (28-47),
& normalized in 2/6 responders. Conclusions: Our preliminary data suggest that Admab
can be effective in pediatric CD with adverse events or lost response to infliximab. Although
generally well tolerated, adverse events occur, and controlled trials are needed to determine
efficacy and dose response.
W1200
Crohn’s Disease Patients’ Willingness to Accept the Risks of Serious Adverse
Events in Exchange for Clinical Benefits
Bruce Sands, Corey Siegel, Hass Steve, David Miller, Jeff White, Reed Johnson, Semra
Ozdemir
OBJECTIVE: To evaluate the willingness of Crohn’s disease (CD) patients to accept treatment
related serious adverse event (SAE) risks in exchange for improvements in their daily symptom
experience. BACKGROUND: All medical interventions carry risks of adverse outcomes that
must be evaluated against their clinical benefits. Information from patients regarding their
benefit vs. risk trade-offs can aid clinicians and regulatory agencies in their decision-making.
METHODS: An on-line panel of self-identified CD patients who were US residents > 18
years old completed a questionnaire containing stated preference benefit-risk trade-off items.
The questionnaire required patients to select between treatment alternatives with different
levels of the benefit and risk attributes. The treatment attributes included the severity of
daily symptoms and activity limitations, the rate of serious complications (fistulas, abscesses,
bowel obstructions), the time between flare-ups, oral steroid use and varying levels of SAE
risks (progressive multifocal encephalopathy [PML] death or disability, death from serious
infection or lymphoma). The questionnaire also contained the short form of the Inflammatory
Bowel Disease Questionnaire (SIBDQ), and items regarding patient demographics and disease
and treatment history. The maximum acceptable 10-year risk (MAR) for SAE development
was calculated for various levels of clinical benefit. RESULTS: A total of 357 patients
completed the survey. The mean (SD) age was 45 (13) and 73% of respondents were female.
There was approximately equal representation of patients in each of four categories of SIBDQ
generated Total IBDQ score (<119, 120-144, 145-169, >170). Treatment decisions were
primarily driven by the desire for improvements in daily symptom severity. Higher MAR,
indicating greater risk acceptance, was observed for trade-off tasks involving higher levels
of clinical benefit, among patients with lower current SIBDQ scores and among patients
reporting a low level of worry about the potential adverse events. For the PML SAE, the
mean (SE) MAR for an improvement from severe daily symptoms to remission and moderate
daily symptoms to remission were 7.2% (0.26) and 4.7% (0.18), respectively. The lowest
observed MAR for any of the three studied SAEs is significantly above the observed rates
of SAE occurrence with natalizumab or any commonly used CD medications. CONCLU-
SIONS: CD patients indicated they are willing to accept a defined risk of death or disability
in exchange for clinical efficacy. The patient perspective on the balance between potential
benefits and risks can assist in making treatment and regulatory decisions.
W1201
Relationship of Phenotype and Function of Blood T Lymphocytes to Disease
Severity in Ulcerative Colitis Patients
Jacky Woo, Samuel M. Siegel, Jia Shi, Yajun Mu, Zhilan Zheng, Jianmin Li, Tanny Tsao,
Lyubov Efros, James Sheridan, Jim Lowder, Uma Mahadevan, Vladimir Vexler
Background: Ulcerative colitis (UC) is an inflammatory disease of the bowel that affects the
large intestine. Since dysregulated immune reactivity contributes to the disease pathogenesis,
conventional treatment strategies for UC rely on reducing inflammation. However, as the
disease progresses, immunosuppressive drug regimens are used. Both the disease severity
and treatment can alter immune cell function. To assess immune cell function as related to
disease status and therapy, the immunophenotype and in vitro function of blood T lympho-
cytes from healthy subjects and UC patients were evaluated. Methods: Samples from 99 UC
patients, 10 in clinical remission (3 on 6-MP), 16 with mild-to-moderate disease (4 5-ASA
or no meds, 10 steroids, 5 6-MP+steroids) and 73 inpatients with severe-fulminant disease
(intravenous steroid refractory) were evaluated. Absolute blood counts of T, B, and NK cells,
naïve, memory and activated CD4 cells, and putative virus-controlling CD8 cell subsets
were measured by flow cytometry. Functional T cell status was assessed by staphylococcus
enterotoxin B (SEB)-induced expression of intracellular IFN-g and IL-2 by T cells. Cell-
mediated immunity (CMI) was assessed with ImmuKnowTM assay (Cylex®), which reflects
the immunocompetence of peripheral CD4+ cells. Results: Reduced CD4 counts (<400 cells/
uL) were observed in 5% of healthy subjects, 10% of remission, 25% of mild-to-moderate,
and 48% of severe-fulminant UC patients. Similar trends were observed for CD8+ T cells,
NK cells and B cells. 38% of severe-fulminant UC patients demonstrated low CMI activity.
In contrast, none of the mild-to-moderate UC subjects or healthy volunteers demonstrated
a low CMI response. Steroids and 6-MP administration were also associated with reduced
lymphocyte counts. Conclusion: Increasing impairment of immune cell function was observed
with increasing disease severity (and by inference increasingly stringent treatment regimens).
UC patients refractory to steroid and 6-MP therapy are significantly immunosuppressed yet
still have active disease. These data suggest that treatment strategies for this patient population
should avoid general immunosuppression and rather focus on therapeutics that promote
mucosal-healing and restoration of the mucosal immune balance.
W1202
Open-Label Pilot Study of Sequential Treatment with Metronidazole and E.
Coli Nissle 1917 for Severe, Postoperative, Endoscopic Recurrence of Crohn’s
Disease
Karin C. Schweiger, Mina Meshkat, Gottfried Novacek, Clemens Dejaco, Harald
Vogelsang, Walter Reinisch
Background: Patients with severe endoscopic recurrence of Crohn`s disease (CD) one year
after ileocecal resection are at high risk of suffering from a clinical relapse within the following
year. Metronidazole is effective in the postoperative prevention of CD relapses. For Escherichia
coli strain Nissle 1917 (EcN) anti-inflammatory activities in IBD have been demonstrated.
We hypothesized that sequential treatment with metronidazole and EcN may enhance
mucosal healing in patients with postoperative endoscopic recurrence of CD. Patients and
Methods: In an open-label pilot study we included 23 patients with severe endoscopic
recurrence of CD as defined by a Rutgeerts’ score of i3 or i4 after ileocecal resection, intolerant
or refractory to azathioprine. The study was designed to apply metronidazole at a daily dose
of 20-30 mg per kg for 12 weeks followed by two capsules of EcN daily (each capsule
containing 2,5-25 x 10 9 viable bacteria) for 40 weeks. Concomitant medication had to be
stable throughout the study. Ileocolonoscopies were performed before and after the treatment
and the endoscopic score was determined by a single investigator who was unaware of any
other patient-related study data. Response was defined as a Rutgeerts’ score of i2 or less,
remission was defined as mucosal healing matching i0. Results: At the time of inclusion 17
of 23 patients (74%) were rated as i4 and 6 of 23 patients (26%) as i3. In per intention-
to-treat analysis response was observed in 7 patients (30%) and complete remission in one
patient (4%). Three patients refused follow-up ileocolonoscopy, 9 patients discontinued or
changed dose of study medication mostly due to gastrointestinal adverse events. The per-
protocol analysis of 11 patients revealed 3 responders (27%) and one patient with mucosal
healing (9%). One patient experienced a clinical flare of CD during the study period.
Conclusion: Our results suggest that sequential treatment with metronidazole and E. coli
Nissle 1917 may improve the endoscopic picture of patients with severe postoperative
endoscopic recurrence of CD in a subset of patients. However, clinical relapse in patients
at high risk of disease flare-up was rarely observed.
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W1203
Extractible Polyurethane-Covered Expandable Nitinol Stent (PCENS) in the
Treatment of Intestinal Strictures in Crohn’s Disease: Preliminary Report of
Seven Cases
Yoram Bouhnik, Philippe Bulois, Kouroche Vahedi, Jean F. Colombel, Marc Lemann
Background : Intestinal strictures are a common problem in patients with Crohn’s disease.
Endoscopic management with hydrostatic balloon dilation is an effective alternative to surgery
in patients with endoscopically accessible lesions that are shorter than 4-6 cm. However,
recurrences are noted in about 2/3 of cases and need further dilations or surgery. Extractible
polyurethane-covered expandable nitinol stent (PCENS) has been proposed in the treatment
of benign intestinal stenosis. Purpose : To investigate the technical feasibility and clinical
effectiveness of PCENS in the treatment of Crohn’s intestinal strictures. Methods : Seven
patients (M-4, F-3, mean age 41 years) with CD who presented with obstructive symptoms
were treated with PCENS. All patients were under immunosuppressive therapy (azathioprine
n=6, methotrexate n=1). They had strictures from recurrent disease at the site of an ileocolonic
anastomosis. All of them except one have been successfully treated with balloon dilation
but relapse occurred within 4 months. The mean length of the strictures evaluated radiolo-
gically was 31 mm (range 10 - 60). The procedures were performed under intravenous
sedation. Extractible PCENS was introduced from the operator channel of the colonoscope
(diametre 4.2 mm) under fluoroscopic control in all but one patient. Informed consent was
obtained in all patients before procedure. Results : Stent placement was successful in 6
patients, but failed in one patient who had a 60 mm length stricture. After stent placement,
symptoms improved in 5 of the 6 patients. Stent migration occurred in four patients 1-3
days after the procedure. One stent was systematically extracted at W3, and one patient
had to be operated on at W5 for occlusion due to incarceration of the stent. In the 5 other
patients, one patient was operated on for occlusion at W2 (after stent migration), one patient
relapsed at M12 (in relation with multiple small intestinal stenosis) and three patients
remained symptom free at 10 -17 month follow-up. Conclusion : Treatment of CD intestinal
strictures with PCENS is feasible and may represent an alternative to dilatation and surgery.
Further studies are needed to evaluate the long term benefit of this new treatment.
W1204
Adacolumn Selective Leukocytapheresis in Patients with Active Ulcerative
Colitis: Clinical Efficacy, Effects On Plasma Interleukin-8 and the Expression
of Toll Like Receptors On Granulocytes
Yasuo Suzuki, Hiroshi Aoki, Kentaro Nakamura, Yasushi Yoshimatu, Yukiko Tuda, Masaki
Irie, Katuyuki Fukuda, Nobuo Hosoe, Nobuo Takada, Koji Shirai
Background: Active ulcerative colitis (UC) is often associated with elevated peripheral blood
granulocytes, monocytes/macrophages (GM) which show activation behaviour, increased
survival time and are found in vast numbers within the intestinal mucosa. This is widely
believed to contribute to the perpetuation and exacerbation of UC. Accordingly, recently
we have been able to induce remission of active UC by selective GM apheresis (GMA) with
the Adacolumn. Our view has been that the efficacy of GMA might not be fully attributed
to the depletion of GM per se. In this study, we additionally investigated the effects of
Adacolumn on plasma interleukin-8 (IL-8) and the expression of toll-like receptors (TLR).
TLR are transmembrane proteins expressed predominantly on myelocytic cells, with essential
role in innate and adaptive immune responses, but also inappropriate TLR signaling can
lead to strong inflammatory response. TLR promote overexpression of proinflammatory
cytokines including IL-1beta and IL-8. Methods: Twenty-two patients with clinical activity
index (CAI) 5-17 were included. Fifteen had total colitis and 7 had left-sided colitis. Twenty-
one patients were on aminosalicylates, 1.5-2.25g/day for over 8 weeks prior to entry and
13 were on prednisolone, 5-40mg/day for at least 2 weeks prior to entry, but no additional
drug was given. Each patient could receive up to 10 Adacolumn sessions at 1 or 2 sessions/
week. Efficacy was assessed during the course of GMA up to 2 weeks after the last Adacolumn
session. Remission was defined as CAI≤4. Further, at entry and pre-Adacolumn time points,
blood samples were taken for determining full blood count, the expression of TLR on
leukocytes by flow cytometry and plasma IL-8. Results: An 87.5% of patients achieved
remission after the 10th session (P<0.001); the majority after 5 sessions. C-reactive protein
fell to <1mg/dL in all patients (P<0.001) and there was a very marked fall in plasma IL-8
(P<0.05). Also, there was a fall in circulating granulocytes (P<0.05), but an increase in
lymphocytes (P<0.05). The expression of TLR2 on granulocytes was significantly down-
modulated by GMA (P<0.05). A similar down-modulation of TLR2 was observed when
human blood was exposed to the Adacolumn leukocytapheresis carriers in vitro. Conclusions:
It appears that Adacolumn leukocytapheresis is an effective adjunct therapy to induce
remission in the majority of patients who are then spared from excess drug therapy. The
procedure, in addition to depleting excess activated peripheral blood granulocytes and
monocytes/macrophages is associated with interesting immunomodulation. Control studies
should strengthen these findings.
W1205
Hyperhomocysteinemia Is Associated with Osteoporosis in Patients with
Crohn’s Disease
Xavier Roblin, Jean Marc Phelip, Veronique Ducros, Bruno Bonaz
Background: a high prevalence of osteopenia and osteoporosis is observed in Crohn’s disease
(CD) (40% and 15% respectively). Risk factors are usually age, low weight, corticosteroid
treatment, inflammation, malabsorption, and malnourishment. According to recent data,
homocysteine concentration, which depends on diet intake, is an important risk factor in
demineralization and bone fracture. Aim: The authors had for aim to screen for an association
between homocysteine concentration and low bone mineralization (LBM) in CD patients.
Patients and methods: CD patients were prospectively included between September 2003
and September 2005. Bone densitometry was performed on inclusion. LBM was defined by
a T-score < -1 and osteoporosis by a T-score < -2.5 at the femoral neck and/or lumbar spine

















vitamin D levels, or taking drugs able to interfere with homocysteine metabolism (folates,
vitamin B12, methotrexate). Postmenopausal women, men over 50, and patients previous
given anti-TNF infusions were also excluded. The following parameters were analyzed:
age, sex, clinical activity indexes (CDAI), duration and impact- of CD, smoking status,
corticosteroid treatment, immunosuppressive drugs, plasma homocysteine, folates, and B12
concentration. Results: 92 patients (sex ratio M/F 0.87; mean age: 36.6+/- 13.2 years) were
prospectively included. The prevalence of a high homocysteine concentration (>15 µmol/l)
was 59.7%. In multivariate analysis, a low level of folates was the only risk factor for a high
homocysteine concentration: RR: 3.59 [1.27 - 10.17]. Osteoporosis and LBM was observed
in 26 (28.2%), and 60 (65.2%) patients respectively. In the multivariate analysis after an
adjustment to the other parameters, associated factors for osteoporosis were hyperhomocyste-
inemia (OR: 61.4; IC95:23-250; P<0.001), and ileal CD [OR: 13.8; IC95:2.5-150; P: 0.036].
In the multivariate analysis, the associated factors with bone demineralization were: hyperho-
mocysteinemia [OR: 63.7; IC95:8.5-250; P<0.001] and a duration of disease of at least 5
years [OR: 11.4; IC95: 1.31-99; P: 0.039]. These results were comparable whatever the
location of osteoporosis or LBM (femoral neck or lumbar vertebral). Conclusion: hyperhomo-
cysteinemia was observed in 59.7% of our CD patients and strongly associated with LBM
and osteoporosis (OR: 61.4). High hyperhomocysteinemia (> 15µmol/l) was equally associ-
ated with bone demineralization in the hip and in the spine.The effect of folate supplementa-
tion on bone mineralization in CD should be of interest.
W1206
Safety and Effectiveness of Endoscopic Pneumatic Dilatation (EPD)+Infliximab
Combined Therapy in Stenosing Crohn’s Disease
Fausto Barberani, Sandro Boschetto, Alessandro Gigliozzi, Maurizio Giovannone, Mauro
Tosoni
BACKGROUND: biological anti-TNF treatment(Infliximab-IFX)is routinely indicated in
patients with fistulazing CD and in those refractory to other medical treatment.No definite
data are currently available about IFX in stenotic patients and its modulation role in fibrogentic
cytochine pathway is still controversial (Van Assch.Inflamm. Bowel. Dis. 2004; Di Sabatino
Aliment. Pharmacol. Ther. 2004). EPD avoids surgery only in about 50% of these patients
and frequently with relapses of stenosis and/or no complete symptoms release. AIM: to
evaluate safety and effectiveness of EPD+IFX combined therapy in pts with stenotic CD
refractory to other medical treatment. METHODS:between 2002 and 2005,25 pts(M:F-
17:8;age range 22-50)were diagnosed affected by stenosing CD.4/25 underwent to ileocolic
surgery for severe stenosing disease;11/25 presented mild stenosing disease and continued
‘conventional’ medical therapy after successfully EPD;10/25 of these pts(moderate/severe
disease-CDAI>250)with unique and<8 cm length ileal/ileocolic stenosis,underwent to EPD
followed by IFX therapy 5mg/kg scheduled with conventional induction timing.Endoscopic
and small bowel ultrasonography (US)follow up were scheduled after 6 and 12 months and
then each year,while clinical data were monitored every 8 weeks.4 pts had associated perianal
fistulas and 1 psoriasys.5/10 had anamnestic report of previous ileocolic surgical treatment
for stenosis CD. RESULTS:all EPD were successfully performed with no complications;3 pts
have a follow up between 12 and 24 months,4 between 24 and 36 months and 3>36
months.No side effetcs or sensibilization were recordered during IFX infusion.All 10 treated
pts had optimal clinical response with no significant symptoms at follow up and interrupted
all other medical treatment in next 6 months.8/10 pts had no stenosis at each endoscopic
and US follow up while only 2/10 pts presented mild and asymptomatic stenosis at 6 months
endoscopy and underwent to second EPD.8/10 pts had complete mucosal healing at each
endoscopic follow up while only 2 pts presented mild flogistic activity.Only 1 pts underwent
surgery for bowel sub-occlusion surgically related to fibrotic adhesion with pre-operatory
endoscopy negative for stenosis or mucosal inflammation CONCLUSION:lack of obstructive
complications during 2 years medium follow up of all our patients provides first evidence
of safety of anti-TNF therapy in patient with stenotic CD after EPD.Optimal clinical and
endoscopic response to EPD+IFX in all our treated patients confirm effectiveness of each
therapy and suggest this combination as new therapeutical option avoiding surgery in severe
stenosing CD
W1207
Effect of Infliximab in Patients with Stricturing Crohn’s Disease
Frederic Marrache, Jean Marc Gornet, Vincent Pacault, Fathia Ben Hriz, Matthieu Allez,
Maria Nachury, Marc Lemann
Background: Acute bowel obstruction has been reported in patients treated with Infliximab
(IFX) for stricturing Crohn’s disease (CD). For this reason IFX is not recommended in such
patients. However, data concerning the potential risk or benefit of IFX in this setting are
still scarce. The aim of this study is to report our experience with IFX in a series of patients
with CD strictures. Patients and methods: Among 141 patients treated between January
1999 and December 2004, 22 had 33 intestinal strictures (range 1-4) at the time of IFX
infusion. Stricture-related symptoms were graded according to the following scale: 0: no
symptom; 1: abdominal pain suggestive of intestinal stricture; 2: incomplete obstruction
defined by nausea or vomiting, frequent abdominal pain or dyschesia; 3; complete obstruc-
tion. Location of strictures was duodenum (n=1), jejunum (n=4), ileum (n=8), colon, (n=
5), anorectum (n=8) and anastomosis (n=7). Evolution of stricture-related symptoms was
recorded as well as the need for dilatation or surgery. Results: Median follow up was 16
months (range 0.5-53.9). Median number of IFX perfusion was 5 (range 1-18). Eight patients
underwent a dilatation of stricture before IFX treatment (anus: n=5, anastomosis: n=3).
Evolution of stricture-related symptoms is reported in the table. Complete obstruction
occurred in three patients (14%), 1, 7, and 11 months after the first IFX infusion, requiring
surgical treatment (n=2) or dilatation of an ileorectal anastomosis (n=1). In addition, anorectal
(n=3) and anastomotic (n=1) dilatations were performed due to the persistence of stricture-
related symptoms during IFX treatment in 4 patients. Conclusion: In this series of patients
with stricturing Crohn’s disease treated with IFX: 1) complete obstruction occurred in
14%; 2) conversely, improvement of stricture-related symptoms was observed in 45% of
symptomatic patients. The effect of IFX in stricturing Crohn’s disease remains unclear and
should be assessed in further studies.
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W1208
An Open Label Pilot Trial of Rifaximin in the Treatment of Patients with
Refractory Pouchitis
Asher Kornbluth, Michele Hunt, James George, Peter Legnani
Introduction: Patients who undergo the ileoanal anastamosis procedure for ulcerative colitis
are at risk for the development of idiopathic inflammation of the pouch, termed pouchitis.
This complication occurs in at least 50% of patients followed long-term. Although there is
limited randomized controlled trial data for the use of the antibiotics metronidazole and
ciprofloxacin, they are the mainstay of therapy for patients with pouchitis, with approximately
80-90% success rates .However about 5-10% of patients are either refractory to these
medications or require chronic suppressive antibiotic therapy. Rifaximin is a nonabsorbable
antibiotic with a broad range of coverage against small bowel intestinal flora. Objective: The
aim of this study was to determine the safety and efficacy of rifaximin in the treatment of
patients with refractory pouchitis. Methods: 16 patients who were refractory to all therapies
including metronidazole, ciprofloxacin, and probiotic therapy with VSL-3, Lactobacillus, or
Saccaromyces boullardi were treated with rifaximin; 6 of these patients had also failed
treatment with budesonide 9 mg/day prior to rifaximin. Patients were treated with the
addition of rifaximin in doses of 600-800 mg daily. The diagnosis of pouchitis was confirmed
in all patients prior to starting rifaximin treatment with pouchoscopy, and severity was
defined as moderate-severe using the Pouchitis Disease Activity Index. Results: 11 patients
were treated with rifaximin 400 mg BID, and 5 patients were treated with 200 TID. 9 of
11 patients (82%) treated with 400 mg BID demonstrated significant clinical improvement
and 4 of 5 patients (80%) treated with 200 mg TID demonstrated clinically significant
improvement. There were no adverse effects of treatment, and all patients with clinical
response improved within 3 weeks. All patients with previously medically refractory pouchitis
who responded to rifaximin continued maintenance therapy with a mean dose of 400 mg/
day and sustained clinical improvement during a mean follow up of 16 weeks. Conclusions:
In this open-label series of 16 patients with medically refractory pouchitis, rifaximin in doses
of 600-800 mg/day was effective in 81%, without toxicity, and was effective for maintenance
for a mean of 4 months, with ongoing follow-up. Prospective randomized controlled trials
are warranted to define the role of rifaximin in the management of patients with pouchitis.
W1209
Short-Term Response to Infliximab in Ulcerative Colitis and Pouchitis: Results
from a Single-Center Experience
Marc Ferrante, Severine Vermeire, Maja Noman, Godelieve Godefridis, Gert van Assche,
Ilse Hoffman, Xavier Bossuyt, Paul Rutgeerts
BACKGROUND & AIMS: Infliximab (IFX) is an efficacious drug for treatment of moderate
to severe ulcerative colitis (UC) as shown by the recent ACT1 and ACT2 randomised
controlled trials. We studied the outcome of IFX treatment in UC patients in a single-center
and investigated if predictors of early response or failure could be identified. METHODS:
103 patients (mean age 40 yrs (range 9-82 yr) and 50% female) with mild to moderate UC
(n=95) or indeterminate colitis (n=8) were treated with IFX. Eighty-seven patients (84.4%)
received 5 mg and 15.6% received 10 mg IFX per kg body weight. Clinical response was
defined as complete if there was absence of diarrhea and blood loss, partial if there was
marked improvement but still with presence of some blood. In 53 (51.5%) patients, sig-
moidoscopy (Mayo score) was performed before infusion as well as at week 4 (in case of
single infusion) or week 10 (in case of three-dose induction IFX at weeks 0-2-6). Two thirds
(67.0%) of patients were on concomitant immunosuppressive therapy at the start of IFX
(55 on azathioprine, 14 on methotrexate). Eleven patients (10.7%) had a previous colectomy
and were treated for refractory pouchitis. Multivariate analysis was done to identify variables
influencing response. RESULTS: Overall 69 (67.0%) of patients showed clinical response
(45 complete and 24 partial) and 34 (33.0%) had no response. Mucosal healing (Mayo
score 0 or 1) was observed in 3/14 (21.4%) non-responders versus 31/39 (79.5%) responders
(p=0.0001). Clinical response was not different in the 40 patients receiving 0-2-6 induction
therapy (67.5%) compared to the 63 patients not given the three-dose induction (66.7%).
Although more mucosal healing was observed with the induction scheme (69.7% versus
55.0%), this lacked significance (p=0.28). Gender, age, extent of disease, smoking, baseline
CRP, concomitant immunosuppressive therapy and the presence of perinuclear antineutro-
phil cytoplasmic antibodies (pANCA) did not influence the short-term outcome of IFX.
DISCUSSION: In this large single-center cohort of UC patients treated with infliximab, the
short term response was 67.0% and mucosal healing was observed in 64.2% of patients.
We could not identify clinical or serological predictors of early response or failure. Other
serological and genetic markers are under investigation. Infliximab is an effective drug for
the treatment of UC.
W1210
Ciclosporin in Severe Ulcerative Colitis: Predictors of Response
Garret Cullen, Denise Keegan, Hugh E. Mulcahy, Diarmuid P. O'Donoghue
Introduction: Ciclosporin (CsA) will induce a remission in severe steroid resistant ulcerative
colitis (UC) in 65% of patients. Opponents of CsA argue that this merely delays surgery
and does not justify the risk of adverse drug reactions. Aim: To examine the long-term
outcome for patients treated with CsA in a single unit and evaluate factors associated with
response. Methods: 107 consecutive UC patients were treated at this unit since 1994.
Data were retrieved from a prospectively maintained database, chart review and telephone
interview. All subjects had failed at least 5 days of intravenous corticosteroids. A standard
regimen of ciclosporin 4mg/Kg IV daily in 2 divided doses for 1week was used. Responders
were then treated with oral CsA for a further 3 months. Treatment failure was defined as
the requirement for colectomy within 6 months of commencing CsA and this was used in
the primary analysis. A secondary analysis was performed using colectomy (either before
or after 6 months) as the endpoint. Results: 62 patients achieved clinical remission more
than 6 months in duration. The use of immunomodulatory drugs (p = 0.004) was associated
with this response as was male gender (p = 0.009). Regression analysis showed that both
of these variables were independently associated with a sustained response. 38 of these 62
patients remain in long-term remission. Immunomodulatory drug use was also associated
with a favourable long-term outcome (p < 0.001) as was previous or current cigarette
smoking (p = 0.03). Adverse reactions to CsA were unusual and reversible. Conclusion:
Only one third of patients with severe UC rescued by CsA avoid surgery. Concomitant
immunomodulatory drug use has a significant beneficial impact on initial response and
long-term remission in clinical practice.
W1211
The Use of Tacrolimus in Children with Ulcerative Colitis: A 5 Year
Experience
David A. Ziring, William Mow, Marvin E. Ament
Aim: To review our experience in treating children with both steroid-dependent and steroid-
resistant ulcerative colitis with tacrolimus, and determine those factors that contributed to
successful outcomes. Methods: We evaluated eighteen consecutive patients (13 with pancol-
itis) who were treated with oral tacrolimus at UCLA Mattel Children’s Hospital, from May
1999 to October 2005, in our retrospective review. Ten patients had the diagnosis of steroid-
resistant UC, defined as continued symptoms of bloody diarrhea despite five days of IV
steroids at a dosage of 1-2 mg/kg (up to 60 mg/d), and eight patients were steroid-dependent,
defined as inability to wean from steroids secondary to recurrence of symptoms of diarrhea,
urgency, and/or bloody stools. We started patients initially on tacrolimus 0.2mg/kg divided
twice daily into equal dosage, with a goal of plasma trough level of 10-15 ng/ml for the
first two weeks, and then titrated doses to achieve plasma levels between 7-12 ng/ml following
induction. All patients received prophylaxis for Pneumocystis carinii pneumonia and magnes-
ium supplementation if necessary. We monitored our patients with daily measurements of
serum electrolytes, blood urea nitrogen, creatinine, magnesium, and tacrolimus trough levels
on all inpatients until their lab values and plasma drug levels were stable. Results: Of the
18 patients in this study, seventeen responded positively to tacrolimus therapy, and one
was a non-responder. Four patients achieved a prolonged response to tacrolimus while ten
required colectomy. Three patients had only an abbreviated response (less than three months)
before they required surgery. The mean time in days from initiating tacrolimus therapy until
a response was noted (cessation of diarrhea) was 8.5 days. The mean duration of response
was 260 days (representing those patients that had to discontinue tacrolimus and those who
continue to receive tacrolimus as of the last follow-up date.) The mean time from initiation
of tacrolimus therapy until colectomy was 392 days. Steroid-dependent patients have a
higher likelihood of prolonged remission with tacrolimus. Conclusions: We found that using
tacrolimus in pediatric patients with steroid-resistant UC was unlikely to provide a positive
prolonged clinical response, and in fact, all of these patients either underwent curative
colectomy or are now considering colectomy in the short term. Although we have treated
only six patients with steroid-dependent UC with tacrolimus, it is possible that this therapy
may be of benefit in those who have problems tolerating traditional maintenance therapy
with 6MP or azathioprine.
W1212
Treatment of Steroid Refractory and Steroid Dependent Crohn’s Disease (CD)
with Leflunomide (LEF) - An Open Label, Controlled Phase I Study On
Efficacy and Tolerability
Martin H. Holtmann, Anna-Lena Gerts, Arndt Weinmann, Peter R. Galle, Markus F.
Neurath
Introduction: Azathioprine is the gold standard for maintenance of remission in CD. However,
in a relevant proportion of patients, azathioprine is not effective or not tolerated. Equally
effective treatment options are not available. Since 1999, Leflunomide is approved as disease
modifying agent in rheumatoid arthritis (RA). Because of immunopathogenetic similarities
between CD and RA, we studied LEF as second line therapy for maintenance of remission
in CD. Methods: 24 patients with AZA refractoriness or intolerability were included. Treat-
ment was started with 100mg/d over 3d, followed by 10-20mg/d. Primary end points were
reduction of CDAi and steroid requirement, given as medians with quartils as well as adverse
side effects over a period of 12 months. T-testing with p<0.05 indicated statistical significance.
Results: Of 24 patients included, 8 patients completed the trial. The CDAi decreased signific-
antly from a median of 219 (160-264) to 87 (20-127) (p=0.018). The steroid sparing effect
was significant, too, with a decrease from 25mg/d (12-50) to 3mg/d (0-20) (p=0.033). All
9 patients with predominant arthralgias reaches partial or complete remission after 3 months.
The predominant adverse side effects were skin rashes (37%) and headaches (31%). 20-
25% of the patients reported mostly selflimiting alopecia, nausea, high blood pressure. Less
than 10% developed anemia, tachycardia, tremor, insomnia, constipation, diarrhea and
others. 13 out of 24 patients developed > 4 adverse side effects. These led to discontinuation
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of the treatment in 15 patients. Discussion: LEF is probably effective in CD, in particular
in the treatment of CD associated arthralgias. However, the rate of adverse side effects was
much higher than in the studies published for RA. The may in part be explained by the highly
pre-selected group of patients characterised by sometimes multiple drug intolerabilities.
Interestingly, a recent post marketing study reported a 70% discontinuation rate in RA
because of lack of efficacy (38%) and intolerability (32%). Further studies are warranted to
define the potential role of LEF in CD.
W1213
Oral Glycine Improves Symptoms in Mild to Moderate Ulcerative Colitis: An
Open-Label Pilot Study
Shih-Kuang S. Hong, Christian D. Stone
PURPOSE: L-glycine is a nonessential amino acid with cytoprotective properties. In mice,
dietary supplementation with glycine has been shown to effectively treat and prevent develop-
ment of chemically induced colitis. This study sought to 1) determine whether oral glycine
has a therapeutic benefit in subjects with mild to moderately active ulcerative colitis (UC)
and 2) establish its safety in UC patients. METHODS: Seven subjects with mild to moderately
active UC, defined by the Simple Clinical Colitis Activity Index (SCCAI), were treated with
open-label L-glycine orally at a dose of 12 g three times daily for 8 weeks. An SCCAI score
≤ 4 is defined as clinical remission; 5-8 as mild disease; 9-12 as moderate disease; and ≥
13 as severe disease. All subjects were maintained on stable doses of concomitant medications
and additional therapy for UC was not allowed during the study period. A complete clinical
response is defined as a decrease of ≥ 4 points. Patients with SCCAI score 5-12 and aged
18 to 65 were included. Patients on daily prednisone dose > 20 mg, or with history of
chronic renal or hepatic disease were excluded. Subjects requiring additional therapy for
UC during the treatment period were dropped from the study. The primary endpoint was
change in SCCAI score at week 8. Secondary endpoints included change in IBD Questionnaire
(IBDQ) and visual assessment scale (VAS) scores at week 8. Comparisons were made using
a paired Student’s t-test. RESULTS: Mean age was 39 (range 26-58). Five of 7 subjects
completed 8 weeks of therapy. One subject was lost to follow-up and another required an
increase in prednisone dose. Mean SCCAI scores at weeks 0 and 8 were 7.0 and 4.2,
respectively (p = 0.045). Three of 5 subjects achieved complete response and 2 achieved
remission. Mean SCCAI scores at weeks 0 and 4 were 7.1 and 5.6, respectively (p = 0.1).
At 4 weeks, 3 of 7 subjects achieved complete response. Mean IBDQ scores at 0 and 8
weeks were 131 and 159, respectively (p = 0.01). Mean VAS scores at 0 and 8 weeks were
60 and 75, respectively (p = 0.02). Glycine was well tolerated by all subjects. One subject
on concomitant mesalamine developed self-limited interstitial nephritis. CONCLUSIONS:
Oral glycine improved symptoms and quality of life in patients with mild to moderately
active UC in this open label study. Three of 5 patients achieved complete response. Oral
glycine was safe and well-tolerated. These results support further study of oral glycine in
UC in a controlled trial.
W1214
Infliximab Therapy and LFT Abnormalities in Patients with Crohn’s Disease
Eric Blum, Jeffry Katz
Background: Infliximab has been associated with elevations in ALT and AST in Phase III
trials for Crohn’s disease (CD). In post-marketing studies, infliximab has also been associated
with significant hepatotoxicity, including acute liver failure, jaundice, hepatitis, and cholest-
asis. However, significant hepatotoxicity has not been evident in patients receiving infliximab
for CD at our institution. Aims: The aims of this study were 1) to evaluate the change in
LFTs associated with infliximab infusion and 2) to identify subgroups of infliximab-treated
patients at increased risk for LFT abnormalities. Methods: 79 patients who received at least
one dose of infliximab were evaluated. Pre- and post-infusion LFTs for each patient were
collected along with data on age, sex, race, use of concomitant immunomodulators, and
smoking status at the time of the infusions. Analyses were done using paired sample Wilcoxon
rank sum tests and multivariate linear regression models. Results: Table 1 shows the overall
distribution of normal and abnormal values for each of the four LFTs. Infliximab was
associated with an above normal elevation of AST in 3.8% of patients and of ALT, alkaline
phosphatase, and total bilirubin in 6.3% of patients. Table 2 shows the median for each
pre and post-infusion LFT along with the associated 95% CI and p-value for the comparison.
In multivariate linear regression models, only the pre-infusion LFT was a consistent predictor
of the post-infusion LFT. No patient sub-groups could be identified with an increased risk
of elevated LFTs, including patients on immunomodulators. Conclusions: Although there
is a statistically significant difference in AST, ALT, and total bilirubin after infliximab infusion,
the absolute differences are not clinically important. In routine clinical practice, infliximab
does not appear to be associated with significant liver function abnormalities.
Table 1



















Endoscopic Polypectomy for Dysplastic Polyps in Chronic Ulcerative Colitis
Rabi Kundu, Wojciech Blonski, Franz Fogt, Chinyu Su, James D. Lewis, Julius J. Deren,
Gary R. Lichtenstein
Background: Malignancy in Chronic Ulcerative colitis (CUC) is believed to develop by
adenoma carcinoma sequence. The management of dysplastic polyps is evolving. At least 2
small retrospective studies have suggested endoscopic polypectomy is safe for management
of dysplastic polyps in CUC (Rubin, Gastro 1999;117:1295. n=30; Odze, Clin Gastro Hep
2004;2:534. n=24). This study reports outcomes of 30 pts with CUC and dysplastic polyps
following colonoscopic polypectomy. Methods: Institution / pathology database searches for
words dysplasia, low grade dysplasia (LGD), high grade dysplasia (HGD), ulcerative colitis,
and inflammatory bowel disease from 1997-2004. All pathology reports were screened for
dysplastic polyps.Patients with dysplastic polyps were evaluated in this study. Outpatients,
inpatients and endoscopic data were reviewed for outcomes. Results: 87 pts had dysplastic
lesions of whom 30 CUC pts had dysplastic polyps removed and are in the study. Mean
age was 55 yrs (17-80 yrs). 24 pts were male. The total no of polyps resected were 54.Mean
no of dysplastic polyp per patient is 1.8.Mean size of polyps 4 mm (2-13 mm). 6(11%)
polyps occurred outside the area of active colitis. The index polyps were distributed 6 in
rectum, 5 in sigmoid colon, 3 in descending colon, 7 in transverse colon, 10 in ascending
colon and 6 in cecum. Of the 30 pts, the most advanced polyp histology was HGD in 9
and LGD in 21. Mean followup of the whole group was 38.4 mos (1-101 mos), during
which 87 colonoscopies were done, mean 2.9 per pt (range: 1-11). One pt progressed from
LGD to HGD and regressed to LGD (in an area outside of colitis) and one from HGD to
cancer in 4 months. During surveillance 4 pts with LGD polyps formed new polyps which
were removed. 7 pts (23%) had colectomy, 6 for flat LGD and 1 for cancer. The diagnosis
of cancer in one patient following removal of polyp with HGD is concerning, but the
diagnosis was made in 5 months after the initial colonoscopy and was detected in early
stage(well differentiated, Duke A). No complications occurred after colonoscopy or colec-
tomy. Conclusion: In our experience polypectomy and stringent colonoscopic surveillance
is an acceptable modality of treatment for dysplastic polyps in CUC, although the diagnosis
of cancer in one patient following removal of a polyp with HGD is concerning.This confirms
earlier observation by Odze and Rubin et al. Longer follow up is needed to clarify the safety
of this strategy.
W1216
Tacrolimus (FK506) Is Safe and Effective in Patients with Refractory
Extraintestinal Manifestations of Inflammatory Bowel Disease
Daniel C. Baumgart, Barbara T. Tanczos, Andreas Sturm, Bertram Wiedenmann, Axel U.
Dignass
BACKGROUND: Between five to twenty percent of inflammatory bowel disease patients
develop extraintestinal disease manifestations (EIM), which do not always respond to conven-
tional medical or topical therapy. Tacrolimus, a macrolide immunosuppressant inhibiting
T cell activation, is currently approved for the prophylaxis of organ rejection in patients
receiving allogeneic liver or kidney transplants. We have recently published the successful
use of oral low dose tacrolimus in refractory inflammatory bowel disease (IBD). Here we
report our experience in managing refractory EIM in patients with IBD. METHODS: In this
retrospective, observational single center study the charts of 29 (16 female, 13 male) adult
(mean age: 41.6±11.6 SD years) IBD patients with steroid-dependent (n=15) or steroid-
refractory (n=14) inflammatory bowel disease (Crohn’s disease, n=7; ulcerative colitis, n=10;
pouchitis, n=2) and extraintestinal disease manifestations (reactive arthritis n=14, sclerosing
cholangitis = 5, pyoderma gangrenosum n= 7, erythema nodosum n=1, autoimmune hemo-
lytic anemia n=1, autoimmune hepatitis n=1) were reviewed. Tacrolimus (0.1 mg/kg body
weight per day) was administered orally in all patients, aiming for serum trough levels of
4-8 ng/mL. No PCP prophylaxis was administered. The mean treatment duration was 33±7.6
SD months (range, 2.8-164.4 months). Patients were followed-up for a mean of 46±7.3 SD
months (range, 12-164.4 months). Response was evaluated using a disease activity score
(M-CAI), laboratory data, and or repeated skin inspection plus photo documentation.
RESULTS: 21 patients (72.4%) experienced a clinical and laboratory response, usually
between 3 and 5 days. Tacrolimus was particularly effective in skin, blood and hepatic EIM.
Mean M-CAI values dropped from 12.2 at initiation to 2.5 at 36 months follow-up. Side-
effects included a temporary rise of creatinine (n=2, 6.9%), hyperkalemia (n=1, 3.45%),
and opportunistic infections (n=1 3.45%). CONCLUSION: Oral low dose tacrolimus appears
to be safe and effective in refractory EIM of inflammatory bowel disease.
W1217
Dilation of Colonic Strictures By Intralesional Injection of Infliximab in
Patients with Crohn’s Colitis
Simon Lichtiger
Intestinal stenosis is a frequent complication of Crohn’s disease, often leading to repeated
bowel obstruction and surgery. The prevalence of small bowel strictures has ranged from
20-40%,and 7-18% in colonic disease. Although balloon dilation is an initial approach,
many patients end up with surgical resection or stricturoplasty. Infliximab, a monoclonal
antibody against TNF, has been effective in the treatment of enteric as well as fistulous
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disease. In patients with active disease, tissue levels of TNF are elevated and may mirror
activity of disease. Repeated systemic administration has been successful for active inflammat-
ory disease, yet has been reported to be ineffective for stricturing disease.This report describes
three patients with obstructive disease who had failed all medical therapy,in whom successful
dilation was accomplished by injection of Infliximab intrastricturally. Methods: Two patients
with colonic strictures and a patient with a rectal stricture were studied. 100 mg. of Infliximab
was injected circumferentially in sclerotherapy technique into the distal end of short strictures.
None of these strictures admitted a pediatric colonoscope. .Results: Within three weeks,
each of the strictures were dilated leading to easy passage of the colonoscope in all three
patients. Each of these patients represented with obstructive symptoms at approximately
three months, and responded to reinjection. Conclusion: Intrastrictural injection of 100 mg.
of Infiximab was effective in dilating short strictures which had not responded to all medical
therapy. Similar to patients who respond to systemic Infliximab, these patients recurred
with symptoms at approximately three month intervals, and responded to reinjection. This
technique requires further investigation, and may hold some promise in the treatment of
inflammatory strictures.
W1218
Allopurinol Favorably Affects AZA/6mp Metabolism By Lowering 6-Mmp
Levels in Patients with Hepatoxicity from AZA/6mp Without Affecting Red
Blood Cell Thiopurine Methyltransferase (TMPT) Activity
Purvi C. Panchal, Charles J. Zielman, Cynthia Schuhmacher, John F. Valentine
Background: 6-Mercaptopurine (6MP) and azathioprine (Aza) are metabolized to 6-thioguan-
ine (6TGN), the putative therapeutic metabolite for the treatment of inflammatory bowel
disease. However, many patients are unable to tolerate this class of medication secondary
to high levels of the hepatotoxic metabolite, 6-methyl-mercaptopurine (6-MMP). 6MP is
metabolized to 6MMP by TPMT and the activity of TPMT is genetically determined. We
examined the effect of allopurinol on 6MMP levels and TPMT activity in patients who had
hepatotoxicity on Aza or 6MP. Methods: 12 patients (9 with Crohn’s disease, 3 with ulcerative
colitis) who had elevated transaminases and toxic levels of 6-MMP while on 6-MP or AZA
were treated with allopurinol 100mg per day and 6-MP (11) or Aza (1) at 25-30% of their
hepatotoxic doses. Weekly liver function tests and complete blood counts were monitored
for potential side effects such as hepatotoxicity, leukopenia, anemia, or thrombocytopenia.
At four weeks from the initiation of allopurinol, 6-TGN and 6-MMP metabolite levels, and
TPMT enzyme activity levels were determined (Prometheus Labs). Results: Complete data
is available of 8 subjects and one additional pt is missing TPMT data. With concomitant
use of allopurinol and a lower dose of 6-MP or Aza, the mean 6-TGN levels changed from
194 to 283 pM/8x10^8 RBCs (p< 0.04). The mean 6-MMP levels decreased from 21,143
to 598 pM/8x10^8 RBCs (P< 0.0002). There was no statistically significant change found
in red cell TPMT activity. The mean TPMT activity prior to allopurinol was 30.42 EU and
activity while on allopurinol was 32.39 EU (P=0.3). All patients liver profiles remained
normal. Conclusions: In patients with demonstrated hepatoxicity from 6MP or Aza, institution
of low dose 6-MP or Aza along with allopurinol 100 mg/d was able to achieve therapeutic
levels of the active metabolite, 6-TGN, while significantly decreasing 6-MMP, the hepatotoxic
metabolite, to low or undetectable levels. All patients maintained normal liver profiles. These
data confirm that IBD patients who have been unable to tolerate 6-MP or AZA secondary
to hepatoxicity, may now be able to resume 6MP or Aza at lower doses with allopurinol
and effectively avoid the hepatotoxic side effects. Furthermore, the addition of allopurinol
did not affect TPMT enzyme activity suggesting an alternative mechanism for allopurinol
that remains to be determined.
W1219
Efficacy and Safety of Leflunomide Therapy in IBD Patients. An Uncontrolled
Observational Study
Milan Lukas, Robert Donoval, Martin Bortlik
Introduction: The optimal immunosuppressive therapy in inflammatory bowel disease (IBD)
patients who are unresponsive or intolerant to thiopurines is still missing. The pyrimidine
analogue leflunomide has been shown to be effective in rheumatoid arthritis in patients who
had been previously intolerant to thiopurine analogues. Aims of the study: 1. to evaluate
efficacy of leflunomide therapy in IBD patients unresponsive to thiopurine analogues; 2. to
assess a tolerability and side effects of leflunomide therapy in IBD patients. Methods: This
was an uncontrolled, observational study, performed in a tertiary referral center during years
2004-2005. Twelve IBD patients (7 female), who had been unresponsive or intolerant to
standard immunosuppressive treatment (AZA/6-MP), were managed by leflunomide 20 mg
p.o. daily. There were 5 pts with Crohn’s disease (CD), and 7 pts with ulcerative colitis
(UC), mean age 40.5 years. All patients were treated by corticosteroids (mean dose 25 mg
prednisone per day) for chronic active course of UC (mean UC-DAI=8.8 ), or CD (mean
CDAI = 277) prior to leflunomide initiation. Demographic information, concomitant therapy,
disease activity, and adverse events were evaluated. Results: The mean time of leflunomide
treatment was 22 weeks. Positive response, i.e. decline of disease activity index (UC-DAI>2,
CDAI>70), or reduction or withdrawal of corticosteroids, was observed in 5 pts (42%).
Nevertheless, no patient went to the complete clinical remission during treatment period.
Adverse events due to leflunomide therapy developed in 7 pts (58%). In 6 of them frequent
liquid stool appeared within 2-8 weeks after leflunomide initiation. For three patients, the
diarrhea was disqualifying to continue in the treatment with leflunomide. The skin rash in
one patient and mild elevation of functional liver tests in two other cases were observed.
Conclusions: 1. The positive therapeutical response of leflunomide therapy was observed
in 42% of IBD patients with previously unsatisfactory course of the disease. However, no
clinical remission during the mean time of 22 weeks of leflunomide treatment was achieved.
2. The adverse events were quite frequent (7/12 pts). Diarrhea, the most often disqualifying
side effect, might be the major limitation for widespreading this drug in clinical practice.
Futher trials with leflunomide on IBD patients unresponsive or intolerant to standard immun-
omodulators are needed.
W1220
Increased IL-10 Production By Peripheral Blood Memory T Cells Accompanies
Crohn’s Disease (CD) Remission and Clinical Response Induced By G-CSF
Treatment
Peter Mannon, Francisco Leon, Ivan Fuss, Catherine Groden, Zhiqiong Yang, Chuli Yi,
Julia Friend, Ronald Hornung, Margaret Brown, Shakuntala Gurprasad, Brian Kelsall,
Warren Strober
BACKGROUND: CD is associated with excess Th1 cytokine activity. G-CSF has several
properties that could modulate Th1 activity including inhibition of IL-12Rβ2 expression to
reduce IL-12 signals and enhancing plasmacytoid dendritic cells (PDCs) to induce Th2 and
T regulatory cell responses. We studied whether G-CSF effects on peripheral blood dendritic
cells and memory T cell cytokine production were associated with responses to G-CSF
treatment. METHODS: 9 patients with active CD (CDAI of 220-450) received G-CSF 5 µg/
kg SC QD for 29 days with follow-up (F/U) for 24 weeks after the final dose. Outcomes
included changes in CDAI scores, blood DC populations (lin-DR+CD11c+ for myeloid DCs,
lin-DR+BDCA-2+ for PDCs), and CD4/CD45RO cytokine production by ELISA. RESULTS:
6 of 9 patients (baseline CDAI 313±18, mean±SEM) had a clinical response (drop≥100CDAI
points) including 2 remissions (CDAI<150). Responses occurred by 2 weeks and were
durable for 8 to 24 weeks after the last dose. CD4/CD45RO cells from responders produced
significantly more IL-10 at the end of treatment vs nonresponders (NRs) (14690±2808 pg/
ml vs 4574±290, mean±SEM, p=0.04), with a trend of increased IL-4 production (9042±3774
pg/ml vs 1987±983, p>0.05) and no differences in INFγ or TNFα production. Responders
showed a significantly decreased myeloid (MDC) to PDC ratio at pretreatment vs the end
of treatment (2.1±0.2 vs1.1±0.2, mean±SEM MDC/PDC, p=.003) and kept a low ratio after
4 weeks of F/U (1.1±0.4, p=0.05). NRs showed a trend of lower MDC/PDC ratio at the end
of treatment (3.5±1.7 vs 0.9±0.3 p>.2) rebounding after 4 weeks of F/U (2.3±0.4 p>0.6).
There were no significant differences in increases of PDCs between groups (responders:
19±4 pretreatment, 29±8 at and of treatment and 24±7 4 weeks after treatment mean±SEM
%PDC/PBMC(x102); NRs: 16±8 to 28±8 and 5.2±0), NRs showing a trend of nonsustained
PDCs. Corticosteroid use significantly inhibited the effect of G-CSF on the MDC/PDC ratio:
steroid group (n=4) 3.1±1.3 to 1.4±0.1 at the end of treatment, p>0.2 vs the steroid-free group
(n=5) 2.2±0.3 to 0.7±0.1 p=0.001. Steroid use also inhibited increased IL-10 production by
peripheral CD4/CD45RO cells. CONCLUSIONS: Clinical responses to G-CSF therapy of
CD are accompanied by increased production of IL-10 by blood CD4/CD45RO cells. Clinical
responses were also accompanied by durable decreases in blood MPC/PDC ratios. Corticos-
teroid use blocked the effect on DC ratio changes and inhibited induction of IL-10-producing
cells, due perhaps to reported PDC enhanced sensitivity to steroids. G-CSF may be a valuable
agent in CD by exerting unique immunomodulatory effects.
W1221
Subcutaneous Methotrexate: A Safe and Effective Therapy in IBD
Peter Gibson, Debbie Nathan, Iser John
Increased understanding of the chronically active nature of Crohn’s disease in the majority
of patients has led to the widespread use of long-term maintenance therapy with immunosup-
pressive agents. Purine analogues have been the mainstay, but more than one in three
patients experience intolerance or lack of efficacy. Methotrexate (MTX) has high level evidence
for efficacy but its application has been limited in part due to the impracticality of intramuscu-
lar administration and the perception of poor efficacy when used orally. Aim: To assess the
response to and safety of MTX when used predominantly by the subcutaneous route in
patients with IBD in a single IBD Clinic. Methods: The medical records of patients treated
with MTX were evaluated with regard to the dose, duration, tolerance of and response to
MTX. Response was defined as improvement in bowel symptoms and/or ability to reduce
the dose of steroids. Remission was defined as improvement in symptoms with no requirement
for steroids for three months, or ability to wean off steroids. Results: 65 patients, 45 Crohn’s
disease (CD) and 20 ulcerative colitis (UC), were identified. The median (range) age was
46 (19-79) years. 46% were men. MTX was initiated because of intolerance or resistance
to azathioprine/6MP in 45 (69%) and 9 (17%), respectively. 8 patients were considered
steroid-dependent. The initial weekly dose was 25 mg in 29 patients, 20 mg in 16, 15 mg
in 7 or 10mg in 3. 84% were treated subcutaneously, the remainder refused injections
(11%) or were initiated elsewhere (4%). All received folate supplementation and blood test
monitoring. Remission was achieved in 23 of 45 (51%) with CD and 12 of 19 (63%) with
UC. An additional 7 (15%) and 1 (5%) showed a response. The median duration of treatment
was 11 (3-36) months in responders and 6 (1.5-10) months in non-responders. Dose
reduction was used in maintenance for 4 patients and was necessary due to asymptomatic
elevation of ALT in 5 or other side effects in 4. The drug was tolerated well with no apparent
side effects in 85%. 7 (11%) ceased therapy due to intolerance. The use of subcutaneous
administration was well accepted. 11% changed to oral therapy after >6 months in remission.
Conclusions: Subcutaneously administered MTX exhibits apparent efficacy, acceptance, toler-
ance and safety in patients with CD or UC who are steroid-dependent and where purine
analogues have been ineffective or intolerable. Such results in this more challenging group
of patients suggest that MTX should be promoted from the reserve’s bench to the starting
line-up in immunosuppressive therapy in both CD and UC.
W1222
Mobilization of Mucosa Lymphocytes By Leukocytapheresis
Joerg Emmrich, Brock Peter, Gisela Sparmann, Stefan Liebe, Reinhard Klingel, Wolfgang
Ramlow
Introduction: Recently published studies have suggested that leukocytapheresis (LCAP) is
an useful therapy of inflammatory bowel disease after failure of conventional treatments.
The mechanisms of this immunomodulatory strategy are poorly understood. Especially, the
relation between the removal of blood cells through the apheresis procedure and lymphocytes
localized in the gut tissue is not known. Methods: Ten patients suffering from active steroid-
dependent ulcerative colitis (CAI according to Rachmilewitz: 6 - 10) were included in our
T : 89386$$CH2
05-04-06 23:18:31 Page 661Layout: 89386B : o
A-661 AGA Abstracts
study. All patients had not responded to azathioprin therapy given in a dosage of 2mg/kg
body weight during 6 months. The patients received leukocytapheresis therapy weekly for
five weeks using the Cellsorba FX® column system (Asahi Medical, Tokyo, Japan). Blood
samples were obtained before and after each LCAP session followed by flowcytometric
analysis with mouse anti-human specific monoclonal antibodies (Becton Dickinson, Oxford,
England) detecting CD3, CD4, CD8, CD19, activated T cells (HLA DR), NK cells (CD16,
CD56), and mucosa-derived lymphocytes (CD103). Results: Remission of the disease
(defined by CAI ≤ 4) has been achieved in 6 of 10 patients by means of the LCAP
strategy. LCAP-related side effects were not observed. Due to the adsorption on the Cellsorba
membrane, the apheresis procedure reduced lymphocyte counts in the blood by 25% to
32%. In contrast, the number of 103+ mucosa-derived lymphocytes increased significantly
in the peripheral blood after two as well as after five apheresis sessions. Moreover, there
was a tendency to a positive correlation between higher numbers of CD103+ cells provoked
by the apheresis sessions and the clinical improvement of the disease in response to the
LCAP treatment. The other investigated species did not show significant changes comparing
the composition of the lymphocyte subpopulations before and after LCAP. Conclusion: The
LCAP technique can be considered as an alternative therapeutic approach inducing remission
in patients suffering from steroid dependent and azathioprin refractory UC. The LCAP- caused
increase of CD103+ lymphocytes suggests the mobilization of mucosa-derived lymphocytes as
an immunomodulatory mechanism of the leukocytapheresis technique.
W1223
An Open-Labeled Trial of Granulocyte and Monocyte Adsorption Apheresis for
Pouchitis
Atsushi Sakuraba, Toshiro Sato, Yuko Iwakami, Yasuhiro Takada, Nagamu Inoue,
Masahiro Takaishi, Haruhiko Ogata, Yasushi Iwao, Toshifumi Hibi
[Background] Pouchitis is a chronic inflammatory disorder that occurs after ileal-pouch
anastomosis. Antibiotics and probiotics are the most common treatments. However, some
patients are resistant to conventional therapy and require pouch-excision. We have recently
reported that granulocyte and monocyte adsorption apheresis (GCAP) is efficacious for active
ulcerative colitis. The efficacy of GCAP for acute pouchitis has not been elucidated yet. In
this pilot study the efficacy of GCAP for pouchitis was analyzed in an open-labeled uncon-
trolled trial. [Patients & methods] Six patients with acute pouchitis confirmed by the Pouchitis
Disease Activity Index (PDAI) were treated with GCAP for 10 sessions. The efficacy and
tolerability of GCAP was assessed. [Results] Four out of 6 patients improved and had a
decrease in the PDAI score. No severe side effects were observed, but 1 patient had difficulty
of venous access. [Conclusion] In this pilot study GCAP was effective and safe for acute
pouchitis. It may be an alternative for patients who are resistant to antibiotics and probiotics.
W1224
Appropriateness of Initial Treatment for Mild-to-Moderate Luminal Crohn’s
Disease: Application of EPACT Criteria to the EC-IBD European Cohort
Pascal Juillerat, Valerie Pittet, Christian Mottet, Christian Felley, Vincent Wietlisbach,
Jean-Jacques Gonvers, Robert W. Dubois, John-Paul Vader, Bernard Burnand, Florian
Froehlich, Frank Wolters, Reinhold Stockbruegger, Pierre Michetti
Background: The appropriate use of therapy for mild-to-moderate luminal Crohn’s Disease
has never been formally assessed. The European Panel on the Appropriateness of Crohn’s
Disease Therapy (EPACT) convened in Lausanne, Switzerland to develop appropriateness
criteria. We have applied these criteria, retrospectively, to the EC-IBD prospectively-
assembled, uniformly-diagnosed European population-based inception cohort of inflammat-
ory bowel disease (IBD) patients diagnosed between 1991 and 1993. Methods: 426 Crohn’s
Disease (CD) patients from 13 European participating centers (10 countries) were included
at the time of diagnosis (first flare, naive patients, no maintenance treatment, not steroid-
dependent or -refractory). We used the EPACT definition of mild-to-moderate luminal CD
(acute flare in an ambulatory patient, no documented fistula or stenosis, no surgery required)
and disease location to classify patients. We analyzed the initial drug prescription of this
cohort, according to the EPACT criteria ([C]: colonic location only, [IL] : ileal location +/-
colonic): Appropriate (A): prednisone alone or combined with sulfasalazine [C], budesonide
[IL]. Uncertain (U): 5-ASA compounds, sulfasalazine [IL]. Inappropriate (I) : antibiotics,
methotrexate, budesonide [C]. Results: 163 (38%) of the cohort patients initially suffered
from mild-to-moderate luminal CD. The disease location was ileal or ileocolonic for 92
patients (56%) and colonic only for 71 (44%). A single treatment was given in 89 cases
(55%) and 74 patients received >1 drug simultaneously or successively during the acute
episode. 96 patients (60%) received at least an appropriate treatment, while for 66 patients
(40%) the treatment was uncertain and in 1 case (<1%) inappropriate. The number and
percentage of patients with the various combinations of treatments are presented in detail
in the table below. Conclusion: The EPACT panel criteria (www.epact.ch) were applied,
retrospectively, for the first time to a European population-based (EC-IBD) IBD patient
cohort. An appropriate treatment was given in the majority of cases for the initial treatment
of mild-to-moderate luminal CD, but was associated with an uncertain treatment for two-



















An Open Label Study of Adalimumab in Crohn’s Disease Patients with a Loss
of Response to Infliximab
Malik Anwar, Maria O'Sullivan, Barbara Ryan, Niall Breslin, Humphrey O'Connor, Colm
O'Morain
Introduction: Chimeric tumour necrosis factor (TNF) alpha antibody, infliximab, is an
effective therapy for active Crohn’s disease (CD). Patients, however, may become unrespons-
ive to this therapy over time. The aim of this study was to determine the efficacy of
adalimumab, a fully humanised anti-TNF-alpha antibody, in CD patients who become
unresponsive to infliximab therapy. Methods: A total of 107 CD patients were treated with
infliximab of which 64% had a clinical response. Consecutive patients (n=13) who lost
response to long-term infliximab management (3.2±0.7 years since first infliximab infusion)
were assigned to adalimumab. Study protocol comprised a loading dose of 80mg of adalimu-
mab subcutaneously and 40mg every 2 weeks. Clinical response was defined as a drop in
Crohn’s disease activity index (CDAI) of 70 points or more and remission as CDAI < 150.
Results: In this group, 69% (9/13) responded to adalimumab therapy: 62% (8/13) had a
clinical response and 1 patient (8%) went into complete remission. On follow up, at a
median of 5.0 months, 62% (8/13) of patients maintained a clinical response. No significant
adverse events were documented, apart from a localised reaction at the site of infusion in
one patient. Conclusion: This study suggests that adalimumab is an effective option for the
management of CD in patients who become unresponsive to infliximab therapy.
W1226
Successful Infliximab RE-Initiation in a Previously Allergic Crohn’s Disease
Patient Following Hematopoietic Stem Cell Transplantation (HSCT)
Lydia R. Weber, Dawn B. Beaulieu, Jeanne Emmons, Josh F. Knox, Mary F. Otterson,
Mazen Iss, Sue Skaros, David G. Binion
Introduction: Allergic reaction to infliximab in severely ill Crohn’s Disease (CD) patients
intolerant to standard immunomodulators leaves limited treatment options. HSCT has been
used as a rescue strategy for CD patients refractory to all forms of therapy (Oyama Y et
al.Gastroenterology. 2005;128:552-63). HSCT is believed to ablate acquired immunity which
may underlie its therapeutic success in CD. We report a 30 y/o female CD pt allergic to
infliximab who required long term TPN for treatment of SB/LB fistulizing CD with remission
induced with HSCT. CD relapsed 18 months following HSCT and maintenance infliximab
treatment was re-initiated with no associated anaphylactic reaction. Case history: CD was
diagnosed at the age of 21 with stricturing terminal ileal and perirectal fistulizing lesions
which required multiple surgical drainage procedures over the next 6 years. No response
to 5-ASA agents, severe headaches with systemic corticosteroids and intolerance to purine
analogues led to infliximab use. She responded to episodic infliximab infusions but was
discontinued following anaphylactic reaction during dose #7. Two unsuccessful attempts at
infliximab desensitization left the drug unavailable. Failed additional therapies included 6TG
(resulted in ascites), parenteral methotrexate, mycophenolate mofetil and leflunomide (no
response). She became TPN dependent over a 16 month period, and required 17 hospitaliza-
tions for refractory CD as well as 2 SB resections and a temporary diverting ileostomy.
Experimental treatment with HSCT induced remission off all drugs for 18 months. CD
symptoms recurred with fever, abdominal pain, diarrhea and weight loss with no response
to budesonide. Given that HSCT ablates prior acquired immunity, and presumably drug
allergies, infliximab was re-attempted. The patient tolerated the infusion and subsequent
maintenance treatment over the next 15 months. She is currently stable with no active
disease, receiving 5 mg/kg infusions every 7 weeks with no further hospitalizations or
surgeries. Discussion: HSCT can induce remission in patients with refractory CD, and the
mechanism is believed to involve reconstitution of acquired immunity with ablation of prior
immune responses, including allergies. We report a patient with severe CD whose allergy
to anti-TNF alpha therapy was eradicated with HSCT allowing successful treatment with
infliximab following relapse of her condition.
W1227
Safety and Efficacy of Oral, Colonic-Release, Low Molecular Weight Heparin-
Mmx™ for the Treatment of Mild to Moderate Left-Sided Ulcerative Colitis:
Preliminary Report of a Pilot Study
Simone Saibeni, Luisa Spina, Clementina Signorelli, Luca Pastorelli, Roberto De Franchis,
Luigi Moro, Roberta Villa, Roberta Bozzella, Giuseppe Celasco, Maurizio Vecchi
Background: efficacy of subcutaneous heparin and low molecular weight heparins (LMWHs)
has been suggested in the treatment of ulcerative colitis (UC). The multimatrix oral formula-
tion MMX™ (Cosmo Technologies Ltd, Ireland) allows the release of active drugs to the
left colon. Thus, the LMWH Parnaparin in the colon-release MMX™ formulation should
be able to exert its therapeutic effect at the site of disease, avoiding systemic absorption and
side effects. Aim: to assess the safety and efficacy of 3 oral dosages (70,140,210 mg once
daily) of Parnaparin-MMX™ in mild to moderate left-sided UC. Materials and Methods: 4
UC patients (pts) were planned to be enrolled for each group. We report the results in the
8 pts enrolled so far. All pts (6 men, mean age 48.5 yrs) had relapsed during maintenance
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mesalazine therapy and had Disease Activity Index(DAI) ≧ 4 and ≦ 10 and Endoscopic
Activity Index(EAI) ≧ 2. The study was approved by the local ethical committee.All pts,
after informed consent, received the study drug while continuing mesalazine treatment at
a stable dose for 8 weeks. Clinical Activity Index (CAI) was assessed at time 0 and at 1,2,4,6
and 8 weeks. EAI and DAI were assessed at time 0 and week 8. Clinical and laboratory
follow-up,including clotting parameters and anti-factor Xa activity,was performed throughout
the study. Statistical analysis was performed by means of Student’s paired “t” test. Results:1
patient of low-dose group (VM) retired from the study for clinical deterioration. No relevant
side effects were observed. Slight and transient increases in CK and ALT were observed in
two patients. There were no interference with hemocoagulative parameters and no increased
rectal bleeding. One patient (GL) was concurrently treated for a few days with antibiotics
and steroids due to an acute bacterial sinusitis. Mean(± SD) final CAI and DAI are significantly
lower than basal CAI (5.0±1.6 vs. 1.7±1.5;p<0.007) and DAI (7.5±1.5 vs. 4.7±2.6;p<0.03).
Basal and final EAI do not show significant difference (8.0±1.8 vs. 6.7±3.9). Conclusions:
oral parnaparin-MMX™ appears to be a safe and effective treatment option in mild to
moderate UC. Controlled studies are warranted to confirm its therapeutic effect.
W1228
Lymphocytic Enteritis (LESION TYPE MARSH I): Response to Gluten-Free
Diet (GFD)
Merce Rosinach, Fernando Fernandez-Banares, Maria Esteve, Montse Alsina, Carme Farre,
Jaume Casalots, Rebeca Santaolalla, Montse Forne, Jorge Espinos, Antonio Salas, Josep
Maria Viver
Lymphocytic enteritis (LE) is the first stage of the spectrum of the gluten sensitive enteropathy
(GSE). Based on the ESPGAN criteria a diagnosis of celiac disease (CD) is performed when
there is villous atrophy, and only then a GFD is started. There are scarce data in the literature
suggesting that LE may cause clinical symptoms similar to CD, which may improve with a
GFD. Aim: To assess clinical, serologic and histological response to a GFD in patients with
LE. Methods: 50 consecutive patients (50±1.9 years; 15M, 35W) with LE were included.
Diagnostic criteria were: 1- To belong to a risk group of CD; 2- To have more than 25%
intra-epithelial lymphocytes (IEL) in the mucosa from distal duodenum; and 3- To have
positive HLA-DQ2/DQ8. Clinical symptoms, associated autoimmune diseases, routine blood
analysis, and bone mineral density (BMD) were prospectively recorded. Serum IgA antiendo-
misial (AEA) and anti-transglutaminase (TGA) antibodies, and TGA in the supernatant of
the duodenal mucosa culture were assessed. A clinical and histological follow-up was per-
formed at least 7 months after starting GFD (mean: 17.3±1 months). McNemar and Student
t for paired data tests were used in the statistical analysis. Results: The main form of
presentation was 54% intestinal, 8% extra-intestinal and 38% asymptomatic or with minor
symptoms. A 4% had type I diabetes, and a 8% thyroid disease. Clinical and biological
manifestations were: 50% diarrhea, 46% abdominal pain, 8% weight loss, 8% fecal incontin-
ence, 68% gas-related symptoms, 58% abdominal distension, 32% BMD abnormalities, 30%
iron deficient anemia and 12% hypertransaminassemia. Positive AEA/TGA was observed in
12%, and TGA in the supernatant in 10% of cases. 11 patients did not accept to start GFD
(9 asymptomatic and 2 with diarrhea). Response to GFD (36 patients with symptoms) was
(%before vs after GFD): diarrhea (63.9% vs 11.1%; p<0.0005), abdominal pain (61.1% vs
8.3%; p<0.0005), gas-related symptoms (80.6% vs 30.6%; p<0.0005), abdominal distension
(77.8% vs 33.3%; p<0.0005) and anemia (41.7% vs 14.3%; p=0.004). Overall, clinical
improvement was observed in 31/36 patients (86%; 95% CI, 71-94%). At present, histological
response after GFD has been evaluated in 28 patients showing improvement in 18 (64.3%),
with a decrease in IEL number (42±2.5 vs 28.9±2.9%; p=0.003). In 6 patients with clinical
improvement, persisted a similar intestinal lesion. Conclusions: LE is a frequent form of
GSE which causes clinical symptoms in a high percentage of patients, is often associated
with a negative celiac serology, and shows in a high percentage of patients a good response
to a GFD. Funded by Fundació Banc Sabadell.
W1229
Antibodies to Synthetic Gliadin-Related Peptides for Detecting Celiac Disease
in a Population with High Pre-Test Probability
Sonia Niveloni, Emilia Sugai, Maria L. Moreno, Horacio Vazquez, Zulema Kogan, Ana
Cabanne, Edgardo Smecuol, Roberto Mazure, Silvia Pedreira, Juan C. Gomez, Gisella S.
Selvaggio, Eduardo Maurino, Julio C. Bai
Introduction: A novel antibody assays based on synthetic gliadin-related peptides (AGA II)
has shown very high diagnostic yield for identification of celiac disease (CD) in selected
populations. Aim: to determine the value of these antibodies for detecting CD in individuals
with high pre-test probability undergoing intestinal biopsy due to clinical suspicion of
small bowel disorder. Materials: From October 2004 to September 2005, 122 unselected
consecutive patients attending the Malabsorption Clinic of our institution were prospectively
enrolled in the study. We excluded patients with prior CD-related serology, intestinal
histology or diagnosis of CD or dermatitis herpetiformis. At the time of endoscopy and
biopsy, serum samples were obtained for CD-related serology which includes: AGA II IgA,
AGA II IgG (QUANTA Lite Gliadin IgA and IgG II- INOVA Diagnostic Inc.; San Diego, CA),
anti-tissue transglutaminase antibodies (a-tTG) type IgA. Diagnosis of CD and characterization
of patients were based on histological criteria (Marsh’s type II lesion or greater) and was
supported by a-tTG and the response to a gluten-free diet in discordant patients. Results:
While 57 patients (47%) were finally diagnosed as having CD, 65 had no evidence of the
disorder. Compared with controls, CD patients had very significantly higher mean absolute
values of both AGA II antibodies (p<0.0000). Sensitivity (Sen), specificity (Spe), diagnostic
accuracy (Acc), positive and negative predictive values (PPV and NPV, respectively), and
positive and negative likelihood ratios (+LR and −LR, respectively) are reported in the table
1. Although all assays exhibited outstanding results, the AGA II IgG assay had the best
statistical value, even better than the well-recognized a-tTG. Conclusions: Our study based
on a population of individuals with high pre-test probability has shown that the new gliadin-
related peptide antibody assays are observer-independent tests having the highest diagnostic
accuracy for detecting CD that should be employed in the setting of high pre-test probabil-
ity populations.
W1230
Celiac Disease IGA Class Autoantibodies Disturb Normal Capillary Formation
in Angiogenesis
Katri Lindfors, Essi Myrsky, Mari Syrjanen, Ilma Korponay-Szabo, Markku Maki, Katri
Kaukinen
INTRODUCTION: A characteristic feature for celiac disease (CD) are specific IgA class
autoantibodies targeted against transglutaminase 2 (TG2). These antibodies are produced
locally in the small bowel and are typically deposited in the intestinal mucosa below basement
membrane and around small capillaries. We have previously shown that these antibodies
inhibit the mesenchymally-induced differentiation of small intestinal epithelial cells. Because
of the presence of IgA in the small bowel capillaries, our aim is to study whether the
angiogenic differentiation of mesenchymal cells is disturbed in CD small bowel mucosa and
if CD-specific IgA class autoantibodies are responsible for abnormal angiogenesis. METHODS:
The expression level of vascular mesenchymal α-smooth muscle actin, recarded as a marker
for smooth muscle cell differentiation, was evaluated in CD biopsy samples from 10 patient
during active disease and on gluten free diet (GFD) by immunofluorescence stainings. The
effects of CD IgA on angiogenesis “” in vitro “” were studied both in HUVEC endothelial
cells cultures and in co-cultures of HUVECs and mouse mesenchymal 10T1/2 cells. The
length of the tubes, the motility of the cells as well as the expression level and intracellular
localisation of α-smooth muscle actin were recorded RESULTS: Semiquantitative measure-
ment of vascular mesenchymal cell α-smooth muscle actin from immunostained biopsy
samples showed reduced expression in the active phase of CD which was normalized during
GFD. In cell culture, the length of the capillary tubes in CD-IgA treated cultures was
approximately half of that measured in non CD IgA treated cultures. This phenomenon
caused by CD IgA was apparently due to inhibited cell motility as indicated by the conven-
tional wound closure assay. CD IgA decreased the overall expression level of α-smooth
muscle actin, as in biopsy samples, but more importantly caused a clear deorganisation of
the actin cytoskeleton essential for cell migration. CONCLUSIONS: CD-associated IgA class
autoantibodies disturb mesenchymal-endothelial cell crosstalk during angiogenesis leading
to the inhibition of mesenchymal cell differentiation, also seen in CD patient biopsy samples,
as well as migration of both mesenchymal and endothelial cells due to deorganisation of
the actin cytoskeleton necessary for proper cellular movement.
W1231
Splenic Hypofunction and the Spectrum of Autoimmune and Malignant
Complications in Celiac Disease
Antonio Di Sabatino, Maria M. Rosado, Paolo Cazzola, Raffaele Morera, Rosanna Riboni,
Federico Biagi, Rita Carsetti, Gino R. Corazza
“Background & Aims”: We investigated the prevalence of functional hyposplenism in autoim-
mune disorder (AID)-associated and complicated celiac disease (CD). Additionally, since
the association between hyposplenism and overwhelming infections due to “Streptococcus
pneumoniae” in CD is well known, we investigated whether IgM memory B cells, which are
responsible for the protection against infections by encapsulated bacteria and require the
spleen for their generation and/or survival, mirror the reduced splenic function in CD.
“Methods”: Peripheral blood samples were collected from 78 adult CD patients (32 with
AID, 36 without AID and 10 with CD-related complications, including enteropathy-associated
T cell lymphoma, refractory sprue and ulcerative jejunoileitis, tested for T cell receptor g
chain clonality). Thirty-four non-CD patients with AID, 35 healthy volunteers and 29
splenectomised patients were also studied. Counting of erythrocytes with membrane abnor-
malities (pitted red cells) was used as an indicator of splenic function, and flow cytometry
was performed to analyse peripheral blood B cells. “Results”: A significantly higher risk for
hyposplenism was found in AID-associated CD (59%) and complicated CD (80%) that in
uncomplicated CD without AID (19%). In AID-associated CD, the degree of splenic function
did not correlate to the duration of gluten-free diet. In AID-associated and complicated CD,
the frequency of circulating IgM memory B cells was significantly lower than in CD patients
without AID or healthy subjects. A significant inverse correlation between IgM memory B
cells and pitted red cells was found in all 78 CD patients. “Conclusions”: The prevalence of
splenic hypofunction is increased in CD with AID and in complicated CD, and is not related
to the duration of gluten-free diet. IgM memory B cells are reduced in AID-associated and
complicated CD. This defect, which is related to the impairment of splenic function, might
predispose hyposplenic CD patients to infections by encapsulated bacteria. Polysaccharide
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protein conjugate vaccines, that bypass the immunological impairment due to the lack of
IgM memory B cells by eliciting a T cell-dependent response, may be more appropriate than
traditional 23-valent polysaccharide vaccine in reducing the risk of systemic infections in
hyposplenic CD patients.
W1232
Evaluation of a New Simple and Fast Assay for HLA Typing of the Celiac
Disease-Associated Alleles
Saverio Teresi, Sandro Drago, Eleonora Gucciardino, Mariarosaria Di Pierro, Donatella
Sangiorgi, Giuseppe Stampone, Calogero Scalici, Antonio Carroccio, Giuseppe Iacono
Background: Celiac disease (CD) is an autoimmune disease, with a prevalence of 1:100 in
the general population, triggered by the ingestion of gluten in genetically predisposed
individuals. It has been demonstrated that all celiacs carry HLA II DQA1*05-*0201/DQB1*02
(that codify for DQ2 haplotype) and/or DQA1*03/DQB1*03 (haplotype DQ8) alleles. The
subjects who have not the DQ2 or DQ8 haplotype cannot develop CD. The association
between HLA DQ2/DQ8 and CD can be used to exclude the diagnosis in debate cases.
However, at present, the HLA typing test commercially available are cumbersome and time-
consuming. Aims: To evaluate a new simpler and faster system for the CD-associated HLA
typing (BioDQ Screen and BioDQ Typing; DiaGene S.r.l, Italy). Subjects and Methods: 23
biopsy-proven CD patients and 79 their first degree relatives were enrolled. All the subjects
in a first step, BioDQ Screen detects in one reaction DQB1*02, DQB1*03 alleles to exclude
all the subjects who are not DQ2 or DQ8. In a second step, BioDQ Typing reveals in 8
reactions the DQA1*0201, DQA1*03, DQA1*05, DQB1*02, DQB1*03, DRB1*03,
DRB1*04, DRB1*07 alleles encoding for DQ2/DR3-DR7 and DQ8-DR4 haplotypes. Both
kits required a rapid DNA extraction from whole blood (5 min), DNA amplification (2
hours) and electrophoresis (15 min). All reactions contain primer for internal control and
all reagents are provided and ready to use. In order to check the concordance of the results
obtained with BioDQ system, the same samples were also typed for DQB alleles (Histo type/
DNA-SSP kit, Germany). Results: According to DQ Screen results, 23/102 subjects were not
DQ2 and/or DQ8 and 79/102 DQ2 or DQ8-positives. According to the DQTyping we found
38/102 DQ2/DR3, 18/102 DQ2/DR7, 20/102 DQ8/DR4, 1/102 DQ2-DQ8/DR3-DR4, 2/102
DQ2-DQ8/DR7-DR4. All subjected resulted not DQ2 or DQ8 with BioDQ Screen were
confirmed not DQ2 or DQ8 with BioDQ Typing. Moreover, the concordance of the results
with those obtained with the reference test (Histo Type BAG) was 100%. The cost of the
102 assays with the new system was € 2.800,00 in comparison with a cost of € 5.800,00
of the traditional system. The time needs was 3 hours for 12 samples with the new method
and 18 hours for 12 samples with the traditional method. Conclusions: BioDQ system is a
simple and rapid system for HLA class II typing specific for Celiac Disease and it has high
sensitivity and specificity. Due to the results obtained (DQScreen false negative rate 0%)
we suggest to use BioDQScreen as first step in order to identify in 1 reaction DQ2 or DQ8
subjects, and successively only the positive samples (DQ2 or DQ8) with BioDQ will be
assayed by BioDQ Typing.
W1233
Gliadin Induces Epidermal Growth Factor Receptor (EGFR) Dependent
Proliferation in Cultured Biopsies from Celiac Disease (CD) Patients Through
a Delay of Endocytosis
Maria Vittoria Barone, Franco Paparo, Maria Maglio, Ribecco Maria Teresa, Giuliana
Lania, Merlin Nanayakkara, Virginia Vitale, Erasmo Miele, Riccardo Troncone, Salvatore
Auricchio
Background Peptic-tryptic digests of gliadin (PTG) and P31-43 gliadin peptide mimic EGFR
(Epidermal Growth Factor) signaling inducing actin rearrangements and proliferation in
several cell lines through a delay of the EGFR endocytosis. Here we show that gliadin effects
on EGFR pathway can be reproduced in cultured biopsies from CD patients. Alexa 488
traffiking into endocytic vesicles in presence of PTG and P31-43 in biopsies from florid
patients is investigated. PTG and P31-43 ability to exert EGF proliferative effects on biopsies
from florid CD patients in colture cells was also tested. Comparison of gliadin proliferative
and apoptotic effects is provided. Aim Characterization of the role of EGF signaling and
traffiking in the proliferative effects of gliadin peptides on jejunal culturered biopsies from
CD untreated patients. Methods Biopsies from untreated CD patients were cultured over-
night in an organ culture system in the presence of peptic-triptic digest of gliadin (PTG) or
of ovalbumin (PTO). In other experiments gliadin peptides P31-43 or P56-68 were used.
To test the EGFR involvement in PTG and P31-43 effects on cell proliferation the bloking
antibody anti EGFR 528 was employed. Bromodeoxiuridine was added to the medium to
detect cells in to the S-fase of the cell cycle. Pulse and chase experiments described the
endocytic alterations of the EGF-Alexa488 traffiking Results Incubation of untreated celiac
biopsies in presence of PTG or P31-43 induces a delayed uptake of the EGF labelled with
Alexa 488 fluorocrome: it is still visible in endocytic vesicles after 6 hours chase in treated
samples, but not in prsence of media alone or P56-68 treated sample. An increase of both
apoptotic and proliferating epithelial cells is detectable: with BrdU incorporation rising to
38% (-/+ 8%) versus 15% (-/+ 5%) of the control, and Tunel positive cells rising to 28%
(-/+ 10%) versus 8% (-/+ 4%) of the control. EGFR inhibitor anti-EGFR 528 is able to
prevent the increase of BrdU incorporation obtained in presence of PTG and P31-43. In
contrast PTG and P31-43 induced apoptosis was not greatly altered in presence of the
EGFR inhibitors. Conclusion PTG and gliadin peptide P31-43 induce EGF accumulation in
endocytic vesicles and induce EGFR activation dependent proliferation, but not apoptosis


















Antiendomysial and Tissuetransglutaminase Autoantibodies Detection in Oral
Culture Media of Untreated Coeliac Disease (CD)
S. Vetrano, M.C. Anania, C. Maffia, F. Lettieri, M. Di Tola, L. Sabbatella, S. Lanci, P. Lista,
V. Libanori, O. de Pita, M.G. Sanjusto, P. Ruatti, U. Zampaletta, A. Picarelli
Aims: CD is an autoimmune disorder characterised by high levels of antiendomysial (EMA)
and anti-tissuetransglutaminase (anti-tTG) autoantibodies (Ab) in sera. EMA and anti-tTG
Ab can be detected in culture supernatants of intestinal biopy from untreated CD patients.
But it is not known whether they can be released also from other mucosal surfaces within
the gut -associated lymphoid tissue (GALT) . The major site of gut involvement in CD is
in the jejunal mucosa, but immunological changes have been observed also in oral and
rectal mucosa after local gliadin challenge. In this study we investigated whether EMA and
anti-tTG Ab can also be detected in culture media from oral mucosa specimens and if the
mouth could be used as an area of immunological testing for CD. Patients & Methods: 26
adults with clinical suspicion of CD were enrolled . All were submitted to serological
screening (EMA and anti-tTG Ab) and to (EGDS) to diagnose CD. 15/26 patients (pts) have
been diagnosed to have CD, whilst in the other 11 pts was excluded, and there enrolled as
controls. Cheek mucosal and duodenal biopsies (organ cultures), from 15 pts with active
CD and 11 from controls, were cultured in vitro for 48 h at 37°C in medium culture. EMA
and anti-tTG Ab were detected in sera and in the supernatants of organ cultures by indirect
immunofluorescence and ELISA .Mann-Whitney test was used to compare anti-tTG values
of CD pts vs. controls. Results: EMA and anti-tTG were positive in sera of all CD patients
and in media culture from intestinal samples of 14/15 CD pts, whereas they were positive
in mediaculture from oral samples of 15 out of the 15 patients. No EMA and anti-tTG Ab
were detected in sera and in the culture supernatants from 11 controls. The linear correlation
test between oral and duodenal mucosa showed values for p>0.05 and r=0.49.Conclusions:
Our data confirm that oral mucosa as well as intestinal mucosa is involved in CD and
demonstrate that oral mucosa releases EMA and anti-tTG Ab in untreated CD patients. The
correlation of values of tTG Ab between oral and duodenal mucosa seems to promote mouth
mucosa like immunological site to detect the pathognomonic Ab of CD.
W1235
Gliadin-Induced Apoptosis of Human Intestinal Epithelial Cells Is Potentiated
By Enteric E. Coli/ K1
Michelle M. Pietzak, Eliza Chakraborty
Aim: An increase in DNA fragmentation is seen in the areas of villous atrophy in the biopsies
of patients with untreated celiac disease. This apoptotic profile is restored to normal after
the withdrawal of gluten from the diet. E. coli K1 RS218 (O18:K1:H7) has been shown in
our lab to induce apoptosis in both human and rat intestinal epithelial cells. Bacterial flora,
in the presence of gluten, may be a potential environmental trigger for celiac disease. We
hypothesized that bacteria, in addition to gliadin, can synergistically cause apoptosis in
intestinal epithelial cells. Methods: Apoptosis in T84 cells was quantified by Annexin V-
FITC (AV) expression and loss of propidium iodide (PI) exclusion after incubation with E.
coli K1, gliadin (Sigma, from wheat gluten), or both for 24 hours. Cells were tracked from
AV- PI- (viable), to AV+ PI- (early apoptosis with membrane integrity), to AV+ PI+ (end
stage apoptosis and cell death). Cells underwent FACS analysis with a Becton-Dickinson
FACSCalibur flow cytometer and CellQuest Software. Results: Intestinal epithelial cells at
baseline showed 27% AV+PI- and 30% AV+PI+. After incubation with bacteria, AV+PI- cells
increased to 51% and AV+PI+ to 54%. After incubation with 5ug, 50ug, 100ug, 500ug, and
1000ug gliadin, AV+PI- increased to 35%, 32%, 41%, 55% and 70%, and AV+PI+ to 43%,
40%, 51%, 62%, and 65% of cells, respectively. The addition of bacteria to 50ug, 500ug
and 1000ug gliadin increased AV+PI- to 39%, 99% and 96%, and AV+PI+ to 54%, 94%
and 76% of cells, respectively. Only 0.3 to 1.6% of cells remained viable after incubation
with bacteria and 500 to 1000ug of gliadin. Conclusions: Our results suggest that enteric
bacteria E. coli K1 and gliadin can synergistically induce rapid, dramatic apoptosis in
intestinal epithelial cells. Understanding the dietary and microbial triggers of mucosal damage
and tissue remodelling in celiac disease may lead to novel therapeutics for this condition.
W1236
Positive and Negative Predictive Values of a Combination of Celiac Disease
Serology Tests As Compared to Intestinal Histology Damage
Sonia Niveloni, Deborath Kryszak, Maria L. Moreno, Valeria Familiari, Anna Sapone,
Emilia Sugai, Ana Cabanne, Zulema Kogan, Horacio Vazquez, Eduardo Maurino, Carlo
Catassi, Alessio Fasano, Julio C. Bai
Background: Currently, the gold standard for the diagnosis of celiac disease (CD) is an
upper GI endoscopy (EGD) with an intestinal biopsy. During the past few years, several
non-invasive serological screening tools for CD have been developed. To establish the true
sensitivity and specificity of these serological tests, either alone or in combination, and to
develop possible non-invasive CD diagnostic algorithms alternative to EGD, a study design
in which an intestinal biopsy is the entry criterion is necessary. Aims: To establish the
positive predicted value (PPV) and negative predicted value (NPV) of a combination of
serological tests for CD using an intestinal biopsy as a gold standard. Methods: Sixty-eight
consecutive patients (average age 38 yrs, range 18-80) referred by the Small Bowel disorders
clinic to EGD and intestinal biopsy because of suspicion of intestinal disorders (chronic
diarrhea, weight loss, abdominal distention, recurrent abdominal pain, and/or anemia) were
enrolled between August 2004 and July 2005 (Group A). During the same period, a random
sample of patients (n=98, average age 47 yrs, range 23-73) undergoing to an EGD for
symptoms or disorders not related to CD was also enrolled (Group B). All duodenal biopsies
were blindly scored using the modified Marsh criteria by pathologists (AC and ZK). At the
time of the procedure, a serum sample was also obtained to check for serum anti-actin
antibodies (AAA), anti-tissue transglutaminase antibodies (TTG), and zonulin levels. Results:
Thirty-three of the 68 patients from group A (48%) and 1/98 (1%) from group B showed
histological findings compatible with CD (Marsh IIIa-IIIc). Of the 34 CD patients identified,
T : 89386$$CH2
05-04-06 23:18:31 Page 664Layout: 89386B : e
A-664AGA Abstracts
27 tested positive to all three tests, 4 tested positive to TTG and zonulin, and 3 tested
positive to zonulin alone. The combination of AAA, TTG, and zonulin tests showed a
sensitivity of 79%, a PPV of 100%, and a NPV of 100%. Conclusions: In subject experiencing
malabsorptive symptoms, the combination of positive AAA, TTG, and zonulin can be used
to rule in CD without the necessity to perform an EGD. This approach would have allowed
avoiding an invasive procedure in 38% of the cases of malabsorption enrolled in this
study, an approach that could translate in cost saving and better patient’s acceptance. The
combination of negative AAA, TTG, and zonulin rules out CD without the necessity of any
additional study. In these cases, an EGD could be still necessary to rule out other causes
of malabsorption.
W1237
Endoscopic and Histological Findings of the Small Bowel in Patients with
Celiac Disease: The Additional Value of Double-Balloon Endoscopy
Muhammed Hadithi, Dimitri G. Heine, Abdulbaqi Al Toma, Adriaan van Bodegraven,
Maarten A. Jacobs, Chris J. Mulder
Background and aims: The relative risk to develop enteropathy-associated T-cell lymphoma
is markedly increased in patients with refractory celiac disease. Double-balloon endoscopy
is an innovative endoscopy technique that allows examination of the small bowel with
capabilities to take biopsy samples. We investigated the value of DBE in patients with
refractory celiac disease. Methods: A total of 20 consecutive symptomatic patients with
refractory celiac disease were prospectively examined by Double-balloon endoscopy to detect
enteropathy-associated T-cell lymphoma that has been treated before by surgery and chemo-
therapy in seven of them. Another five symptomatic patients with celiac disease and without
villous atrophy in duodenal histology participated in the study as controls. The small bowel
was assessed for loss of folds, scalloping, nodularity of mucosa, and ulcerations. Biopsy
specimens were taken from the small bowel to be evaluated according to the modified Marsh
criteria and for EATL. Results: Twenty-eight double-balloon endoscopy procedures were
successfully performed without complications in 25 patients. Enteropathy-associated T-cell
lymphoma was found in four patients (25%; 95% CI 6 to 44) as circumferential, discrete,
or confluent ulcerations. Two patients had ulcerative jejunitis in absence of histological
evidence of enteropathy-associated T-cell lymphoma, and only loss of folds, scalloping and
nodularity were found in the other patients with refractory celiac disease. The small bowel
appeared normal in control patients. Marsh III was found in two patients with enteropathy-
associated T-cell lymphoma and Marsh I in another two. In patients with past history of
EATL, Marsh III was found in three, Marsh I in one, and normal histology was found in
one patient. Marsh III was found in all other patients with refractory celiac disease including
two patients with ulcerative jejunitis. In control patients, histology was normal in three and
showed changes of Marsh I in two patients. Conclusions: Small bowel examination and
obtaining histology during double-balloon endoscopy in symptomatic patients with celiac
disease could detect efficiently complications like ulcerative jejunitis or enteropathy-associ-
ated T-cell lymphoma. This technique should be reserved for patients with refractory celiac
disease or patients with past history of enteropathy-associated T-cell lymphoma.
W1238
A Third Celiac Disease: Genotyping Reveals a Functionally Distinct Subtype
Jason A. Tye-Din, Tim Beissbarth, Robert P. Anderson
Celiac disease (CD) is an enteropathy mediated by HLA-DQ2 and DQ8-restricted T cells
specific for gluten peptides. Although 90% of CD is associated with the “classical” HLA-
DQ2 heterodimer (HLA-DQA1*05 + DQB1*02, “DQ2.5”) about 5% is associated with the
“lower risk” HLA-DQA1*02 + DQB1*02 (“DQ2.2”) combination. Does the subtle difference
in HLA-DQ genotype translate to a different immunological phenotype? AIM: To compare
gluten peptides recognized by T cells in DQ2.2 and DQ2.5 CD. METHODS: Amongst 250
individuals with biopsy proven CD on strict gluten free diet, DQ2.5 was present in 232,
and DQ2.2 in only 6. Subjects ate wheat bread (200 g/d) (DQ2.2 n=2, DQ2 n=16) or barley
grain (150g/d) (DQ2.2 n=1, DQ2 n=17) for three days. Interferon-γ ELISPOT assays were
performed on peripheral blood mononuclear cells (PBMC) collected on the 6th day after
commencing gluten challenge to screen a comprehensive wheat gluten or hordein peptide
library. Both wild-type and transglutaminase-pretreated peptides were assessed. RESULTS:
PBMC from all subjects responded to gliadin with activity enhanced by deamidation. Follow-
ing wheat ingestion, the most immunoreactive peptide in DQ2.2 subjects was an omega-
gliadin (DQ2-ω-I; QPEQPFPQPEQPFPWQP) with strong responses to closely related poly-
morphisms. Neither subject responded (no different to medium alone) to the “immunodomin-
ant” A-gliadin peptide (p57-73 QE65; QLQPFPQPELPYPQPQS). In comparison, 13/16
DQ2.5 subjects had a dominant response to p57-73, and 10/16 responded to DQ2-ω-I.
Following barley challenge, DQ2-ω-I was immunodominant in both DQ2.2 and DQ2.5 CD
subjects, and responses to p57-73 were absent or weak. CONCLUSIONS: The hierarchy of
gluten T cell epitopes in DQ2.2 CD is distinct from classic DQ2.5 CD, implicating a role
for HLA-DQA1*05 in determining the immuno-dominance of p57-73. Although DQ2.2 CD
is rare and the numbers of subjects available is small, the immuno-phenotype of DQ2.2 CD
appears distinct from DQ2.5 CD. Future studies should involve more subjects and determine
whether the clinical phenotype of DQ2.2 differs from DQ2.5 CD.
W1239
Flow Cytometry Patterns Specifying Celiac Disease in Lymphocytic Enteritis
(MARSH I ENTEROPATHY): A Pilot Study
Anton Vrij, Alexander Martens
INTRODUCTION In celiac disease, cytology changes seem to precede more structural damage
in duodenal biopsy specimens. In an early phase of celiac disease, a cytological classification
could be of help in its diagnostic process. AIMS & METHODS To study the lymphocytic
characteristics of colour flowcytometry of duodenal biopsies in patients with signs of maldig-
estion and a disturbed sugar absorption test, suspected for celiac disease, in comparison with
biopsies from patients with dysmotility like dyspepsia (DLD, non-inflammatory controls), and
ulcerative duodenitis due to peptic ulcer disease or Crohn’s disease (inflammatory controls).
Parallel to histology, flow cytometry patterns were studied to characterize T cell subsets in
clinically active disease in 26 patients with Marsh II-III seropositive celiac disease, 13 patients
with seronegative but HLA DQ2/8 positive Marsh I enteropathy, 11 patients with seronegative
as well as HLA DQ2/8 negative lymphocytic enteritis, 25 patients with DLD, as well as in
7 patients with ulcerative duodenitis. In Marsh I enteropathy. Patients with Marsh I enteropa-
thy and Helicobacter pylori gastritis (n=5) were excluded from the analysis. RESULTS In
newly diagnosed and untreated patients with Marsh I, as well as Marsh II-III celiac disease,
the % of lymphocytes expressing a CD3+ profile (CD103+, CD3+CD16/56+ ) was significantly
higher, and a CD3- profile (CD3-CD16/56+, CD3-/CD7+) significantly lower, as compared
to patients with idiopathic (HLA DQ2/8 negative) lymphocytic enteritis, ulcerative duodenitis
or patients without duodenal inflammation (DLD). Both seronegative and seropositive celiacs
had a significantly higher % γδT cells as compared to patients with idiopathic (HLA DQ2/
8 negative) lymphocytic enteritis, ulcerative duodenitis or patients without duodenal inflam-
mation (DLD). CONCLUSION In Marsh I celiacs, a higher % of γδT and lower % of CD3-/
CD7+ was found as compared to HLA DQ2/8 negative lymphocytic enteritis, ulcerative
duodenitis or DLD. The combination of a high % of γδT and CD103+ cells, as well as a
low % of CD3-CD16/56+ and CD3-/CD7+ lymphocytes seems characteristic for celiac disease.
W1240
A Practical Method for Counting Intraepithelial Lymphocytes in Duodenal
Biopsies: Data from a Population-Based Endoscopic Study
Marjorie M. Walker, Robert D. Goldin, Michael Vieth, Manfred Stolte, Jukka Ronkainen,
Pertti Aro, Tom Storskrubb, Joseph A. Murray, Nicholas J. Talley, Lars Agreus
Background: A raised intraepithelial lymphocyte (IEL) count in the duodenum is an important
feature for the early diagnosis of celiac disease. A robust and simple method to estimate
these IELs would be useful and diminish diagnostic confusion. The aims of this study were
to establish the optimal site of duodenal biopsies and the number of enterocytes required
to accurately count IELs to assess pathological intraepithelial lymphocytosis in the duodenum.
Method: Paired duodenal (D,) biopsies from both D1 and D2 were obtained from an
unselected representative sample (n=1000) of an adult general population in two Swedish
municipalities, Kalix and Haparanda. To establish a time efficient method to count IELs 5
samples were subjected to detailed counts as follows: in each biopsy, 4 villi with epithelial
nuclei aligned to the basement membrane were selected and marked. Three observers each
performed IEL counts, in groups of 10 enterocytes, starting at the base of a crypt and
continuing until the next base in the same 4 villi. The IEL count/100 enterocytes was
extrapolated for cumulative groups of 10 enterocytes and plotted on a graph to establish at
which point the counts became stable. A repeat examination of one villus per biopsy was
performed to assess intraobserver variation in IEL count. CD3 immunostained duodenal
biopsies from patients with known high counts of IELs were compared with H&E counting.
Results: In 200 paired D1 and D2 biopsies, 98.5% had comparable IEL counts. In 2 of the
3 subjects where D1 counts were >D2, 2 had H. pylori pangastritis and one had raised IELs
with no gastric pathology. Extrapolation of IEL counts/group of 10 enterocytes showed that
when 50 enterocytes have been counted there is a consistent count/100, with minor variation
per villus. Importantly, both intraobserver and interobserver variation was minimal (with
70% agreement to within 5 IELs/ 100 enterocytes) and made no difference to the diagnosis.
CD3 counts demonstrated more lymphocytes than H&E generally (4/5 biopsies) but only
by 3-4 IELs/100 enterocytes. Conclusions: D1 and D2 IEL counts are comparable. Counts
to give a quantitative meaningful value for clinicians can be performed by counting IELs/
50 enterocytes. There is minor intervillus variation in IEL counts so selection of two villi
per biopsy is prudent. Interobserver variation is minimal in IEL counts and does not affect
a diagnostic cut off value of 25 IELs/100 enterocytes. Immunostaining for CD3 counts
demonstrated slightly more lymphocytes than H&E, but is costly for everyday practice and
was of no practical value.
W1242
The Prevalence of Celiac Disease Is Increasing in Process of Time
Sini Lohi, Kirsi Mustalahti, Katri Kaukinen, Kaija Laurila, Pekka Collin, Harri Rissanen,
Olli Lohi, Enzo Bravi, Antti Reunanen, Markku Maki
BACKGROUND Celiac disease is a gluten triggered autoimmune-mediated disease with both
intestinal and extraintestinal manifestations. The prevalence of celiac disease has increased
substantially during the last decades reaching 1 % in the United States and many European
countries. The aim of this study was to investigate whether the increase reflects a true rise
of incidence in recent years or whether it is only due to a better detection rate. METHODS
The prevalence of celiac disease was determined in two cross-sectional studies representing
Finnish adult population in 1978-80 and 2000-01 with cohorts’ sizes 8,000 and 8,028,
respectively. The total prevalence of celiac disease was defined by adding together clinically
diagnosed celiac disease patients and previously unrecognized celiac disease cases, which
were found by tissue transglutaminase and endomysial antibody screening. RESULTS Only
two (0.04 %) clinically diagnosed celiac disease cases were found in 1978-80 compared to
32 (0.5 %) in 2000-01. The prevalence of previously unrecognized screen-detected cases
was high in the both cohorts being 1.1% and 1.4%, respectively. Most importantly, the
total prevalence of celiac disease increased significantly from 1.1 % (CI 0.8-1.3) in 1978-
80 to 1.9 % (CI 1.6-2.2) in 2000-01. CONCLUSIONS The total prevalence of celiac disease
nearly doubled in Finland during the last two decades and it cannot be explained by the
better detection rate. The substantial rise in the frequency of celiac disease is in agreement
with the increasing rate of other autoimmune diseases such as type 1 diabetes. The environ-
mental factors responsible for the increasing prevalence of celiac disease in process of time
are still unclear.
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Baboons Affected By Hereditary Chronic Diarrhea As a Possible Non-Human
Primate Model of Celiac Disease
Alessio Fasano, Debby Kryszak, Michelle Leland, Henry McGill
Background: Celiac disease (CD) represents a unique model of autoimmunity in which, in
contrast to most other autoimmune diseases, a close genetic association with HLA genes
(DQ2 and/or DQ8), a highly specific humoral autoimmune response (autoantibodies to
tissue transglutaminase, (TTG)), and, most importantly, the triggering environmental factor
(gluten), are known. Given the undisputable role of gluten in causing inflammation and
immune-mediated tissue damage, CD could provide unique opportunities to tackle the
pathogenic basis of autoimmune processes. However, the lack of an animal model of the
disease represents a major limitation in reaching goals. Methods: Baboons from the pedigreed
colony at the Southwest Foundation for Biomedical Research (SFBR) in San Antonio, Texas
were reviewed. Those animals with chronic diarrhea (≥21 days) and more than two clinical
admissions between January 1998 and December 2003 were selected. This search yielded
163 baboons. An infective cause of the diarrhea was ruled out. CD serology and intestinal
histological analysis were performed on a selected number of animals. Results: The onset
of diarrhea occurred at all ages (few months-15 years) and was analyzed for distribution
among the 4,200 offspring of 57 sires of the pedigreed colony. Fifty-one of the 163 cases
(31%) of chronic diarrhea occurred among the offspring of 4 sires. Of the 15 cases studied,
9 (60%) tested TTG IgA and/or IgG antibodies positive, compared to 2/14 (14.3%) in healthy
control baboons. Zonulin, a modulator of intestinal permeability that is up regulated in CD,
resulted elevated in 9/15 (60%) baboons with chronic diarrhea and 0/14 controls. There
was 100% correlation between positive TTG IgG and elevated zonulin. Duodenal samples
obtained after the baboons were euthanized showed increased intraepithelial lymphocytes
and, occasionally, marked lymphocytic mucosal infiltration and villi distortion and blunting.
Four baboons with chronic diarrhea, weight loss, anemia, and histological findings of
intestinal damage compatible with CD were individually caged and fed a gluten-free diet
(GFD). After 6 weeks of diet the diarrhea persisted, however the animals began to gain weight.
Conclusions: These preliminary observations suggest that a gluten-dependent enteropathy is
present in the pedigreed baboon colony studied, and that it is clustered among the progeny
of a few sires. This sire effect is presumptive evidence that the condition is hereditary. The
clinical, serological, and histological features suggest a similarity to human CD and, therefore,
that the progeny of this sire can be potentially used as a primate non-human model of CD.
W1244
Evidence of Neuroautonomic Dysfunction in Celiac Disease
Roberto Zulli, Franco Nicosia, Stefania Bertolazzi, Alessandra Mora, Francesco Daminelli,
Massimiliano de Vecchi, Paolo Donati, Francesco Lanzarotto, Vittorio Grassi, Alberto
Lanzini
Neuroautonomic function has been reported to be altered in many inflammatory conditions.
Celiac disease (CD) is a chronic inflammatory disease with highly heterogeneous clinical
presentation, but little information is available on involvement of the neuroautonomic system.
The aim of our study was to assess the neuroautonomic function in CD by using prolonged
electrocardiographic recording and analysis of the cardiac cycle variability (heart rate variabil-
ity analysis, HRV) both by time and frequency domain analysis. We also evaluated the
potential relationships between HRV and inflammatory parameters reflecting the severity of
the disease. We enrolled 52 consecutive untreated CD patients (9 male, 43 female, mean
age 34 years) with positive antiendomysial-ab and CD compatible duodenal histology, and
52 sex and age matched healthy controls with no clinical conditions potentially interfering
with HRV analysis. The proportion of the numbers of the R to R successive intervals differing
more than 50 milliseconds (pNN50) was significantly lower in CD than in controls (14.8±9.8
vs 22.1±11.7, p<0.01, respectively), and the root mean square of successive NN intervals
(rMSSD) was also significantly lower in CD than in controls (37.3±12.5 vs 42.3±9.4 p<0.05,
respectively). The Low Frequency power spectral band (LF, an index of sympathetic modula-
tion) and the High Frequency power spectral band (HF, and index of parasympathetic
modulation) values were significantly reduced in CD (LF 586.8± 520.3 msec2 vs
815.3±499.3, p<0.05, HF 453.5±687.3 msec2 vs 681.4±555.7, p<0.05). LF/HF ratio was
higher in CD though the difference was not statistically significant. There was a significant
relationship in CD between HRV parameters and biochemical inflammatory indexes (pNN50,
rMSSD, LF, HF vs ESR, neutrophils count and fibrinogen with r values ranging from -0.30
to -0.47 at Pearson’s analysis). Our study suggests that neuroautonomic function is altered in
CD as indicated by reduced HRV parameters, particularly those related to the parasympathetic
modulation. This phenomenon is independent of the severity of gastrointestinal symptoms,
and it is likely to be related to inflammatory changes in CD, as reported for other inflammatory
conditions and to the severity of the disease.
W1245
Anti-Yeast Antibodies Correlate with Serological Markers in Celiac Disease
Sebastien Ratajczyk, Annie Standaert, Peggy Vandewalle, Boualem Sendid, Sylvain
Dubucquoi, Daniel Poulain, Jean F. Colombel
Background: Antibodies against the oligomannosidic epitopes of the yeast Saccharomyces
cerevisiae (ASCA) are a serological marker for Crohn’s disease. Studies from our group have
shown that Candida albicans is an immunogen for ASCA (1). High prevalence of ASCA has
also been reported in celiac disease. It has recently been suggested that C.albicans could be
a trigger in the onset of celiac disease through its virulence factor hyphal wall protein 1
(Hwp1) which is a transglutaminase substrate (2). Aim of the study: To look at the correlation
between two yeast antibodies anti- C.albicans antibodies (ACAA) and ASCA and serological
markers of celiac disease. Patients and methods: This cross-sectional study involved 81 celiac
adults (55F, 26M) with an average age of 34 yrs at diagnosis and of 43 yrs at the time of
the study. IgG antibodies against gliadin (IgG-AGA), tissue transglutaminase antibodies
(TTG-IgA), ASCA, ACAA and C.albicans antigenemia were determined by usual techniques.

















Results: The prevalence of serological markers was 49% for IgG-AGA, 26% for TTG-IgA
52% for ASCA and 22% for ACAA No patient had a positive C.albicans antigenemia. There
was a correlation between the presence of ASCA and TTG-IgA (p= 0.037) and between the
presence of ACAA and TTG-IgA (p=0.008). Presence of ASCA and ACAA was also correlated
(p=0.049). TTG-IgA titers were correlated with ASCA titers (p<0.01). Presence of TTG-IgA
was correlated with adherence to GFD but no correlation was found for both anti-yeast
antibodies. Conclusion: Celiac disease is frequently associated with anti-yeast antibodies.
The correlations established between ASCA/ACAA and TTG-IgA presence and levels support
the hypothesis that C.albicans could play a role in the pathophysiology of the disease. 1 :
Standaert A et al. Gastroenterology 2005; 128 (suppl 2: A508 ; 2 : Nieuwenhuize WF et
al. Lancet 2003;361:2152-4
W1246
The Role of Indoleamine 2,3 Dioxygenase (IDO) in Celiac Disease
Ram P. Janardhanam, Sherman Chamberlain, Jeffrey Lee, David Munn, Robert Schade
Purpose: IDO is the first enzyme catalyzing tryptophan degradation along the kynrenine
pathway. IDO has proved to be an important immunosuppressive and tolerogenic mechanism
in the immune system (Science 297: 1867, 2002). The current study addresses the hypothesis
that IDO is an anti-inflammatory mechanism expressed by cells of the gut to control T-cell
proliferation that results in the injury and inflammation seen in celiac disease. Methods:
Archival biopsy samples obtained during upper endoscopy were retrieved. The samples
selected were from biopsy-proven celiac disease and obtained at a time of histologically-
proven active disease. Overall samples were obtained from 4 patients. These included 2
patients with untreated active disease and 2 patients that included samples before and after
8 weeks of gluten free diet. Replicate sections and appropriate controls were deparaffinization
and immunohistochemistry was performed using the standard avidin-biotin complex method.
Affinity-purified polyclonal rabbit antibody was used for IDO staining. The samples were
graded for IDO activity in lamina propria inflammatory cells and in small bowel epithelial
glands in a blind fashion on a scale of 0-4+, with 4+ showing the highest expression of
IDO. Results: IDO expression was seen in the lamina propria inflammatory cells (granulocytes,
macrophages, eosinophils, and dendritic cells) and crypt epithelial cells. Three areas of the
biopsy samples were scored for IDO expression: epithelial cells, inflammatory cells and
dendritic cells. The epithelial cell IDO mean score was 1.75, the inflammatory cell IDO
mean score was 1.75 and dendritic cell IDO mean score was 1.5. When comparing the sets
of samples that received treatment with gluten free diet, the epithelial cell IDO mean scores
pre and post-treatment were 1.5, but the inflammatory cell IDO mean scores pre and post
were 1.5 and 0.0, and dendritic cells IDO mean scores pre and post were 1.5 and 0.0.
Conclusions: IDO is expressed by glandular epithelial cells and lamina propria inflammatory
cells of the gastrointestinal tract in patients with celiac disease. T cell proliferation can be
regulated by IDO, thus we hypothesize that IDO’s presence serves as a counter-regulatory
or anti-inflammtory role in these cells. The difference observed in IDO expression of inflam-
matory and dendritic cells by pre and post treated patients suggests that the upregulation
of IDO maybe a protective response in active celiac disease.
W1247
Screening for Celiac Disease in Family Members: Is Follow-Up Testing
Necessary?
David S. Goldberg, Debbie Kryszak, Alessio Fasano, Peter H. Green
Background: Celiac disease (CD) occurs at an increased rate among first- and second-degree
relatives of individuals with CD. They are advised to be screened. The role of subsequent
testing after an initial negative screening serologic test is unclear. The aim of our study was
to determine (1) if one-time screening is sufficient and (2) the frequency of subsequent
testing. Methods: The University of Maryland Celiac Research database for the previously
published study of serologic screening for CD (Arch Intern Med. 2003; 163: 286-292.) was
analyzed. The initial serologic testing of subjects included antigliadin antibodies (IgA,IgG)
and endomysial antibodies (EMA). As the study progressed, transglutaminase antibodies
(tTG) were measured. We identified those subjects who were tested on >1 occasion. Results:
Of the 13,423 subjects in the database, 288 were tested more than once. Of these, 171
were family members who had an initial negative EMA; 3.5% (six subjects) developed a
positive EMA on repeat testing (4 female, 2 male, ages 11-63). The average time to seroconver-
sion was 1.7 ± 1.2 years (6 months-3 years, 2 months); statistically equivalent to the time
interval between testing for those that remained EMA negative (1.5 ± 1.0 years). Of the six,
one had classical CD symptoms of diarrhea, three had atypical symptoms (joint pain,
heartburn, gaseousness, and abdominal pain), and two were asymptomatic. None of the
patients had any change in symptoms at the time of EMA seroconversion. At initial testing,
one of the six had an elevated IgA AGA, but at repeat testing, four had elevated IgA AGA
levels. Of the four that had IgA tTG measured at the time of seroconversion, all had
elevated levels. Four of the subjects were first-degree relatives, two second-degree. The six
seroconverters and the 165 non-seroconverters were statistically equivalent in terms of age,
gender, genetic relatedness to CD patients, and symptoms. The only statistical difference
between the groups was that a higher percentage of seroconverters had abnormal levels of
IgA AGA at repeat testing. None of the other groups in the database, either those at
risk because of symptoms or CD-associated diseases, seroconverted on follow-up testing.
Conclusions: We found that 3.5% of family members who underwent repeat serologic testing
subsequently developed a positive EMA. One-time testing of family members of those with
CD is insufficient. A reasonable recommendation is that all first- and second-degree relatives
be screened a second time, at 4 years after the initial testing, regardless of age or symptoms.
Further studies are needed to determine the role of subsequent testing after that time period.
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Alemtuzumab Treatment of Refractory Celiac Disease Type II
Knut E. Lundin, Inger Nina Farstad, Melinda Raki, Yngve Benestad, Ole Hoie, Geir
Tjonnfjord
Introduction: Celiac disease is usually a benign disorder. However, some patients fail to
improve or develop villous atrophy in spite of a strict gluten free diet. This is termed celiac
disease which again is divided into two categories. Type I does not, whereas Type II has a
monoclonal population of premalignant intraepithelial T-lymphocytes. Type II will often
develop into enteropathy-assosiated T-cell lymphoma, a condition with a poor prognosis.
Patients with type II do also have a poor prognosis with a 5-year survival of well below 50
%. No effective cure has so far been described. We have used the monoclonal antibody
alemtuzumab for treatment of one such patient. Alemtuzumab is directed against the surface
marker CD52 on T-and B-cells. Alemtuzumab is effective in treatment of various malignant
disorders, including chronic lymphatic leukaemia and pro-T-cell leukemia. Patient: A now
63 year old man presented in 2003 with total villous atrophy and positive IgA-TG2. He had
an initial good effect of gluten free diet but then developed weight loss, hypoalbuminaemia,
diarrhoea and enlarged abdominal lymph nodes. A lymphoma was suspected and he was
operated. No tumor was found. Gastroduodenoscopy, capsule endoscopy and enteroscopy
showed ulcerative jejunitis. In the resected material and in small intestinal biopsies we found
a monoclonal and oligoclonal population, respectively. The intraepithelial lymphocytes were
phenotypically abnormal as they lacked CD8. S.c. treatment with alemtuzumab was started
after careful consideration and full information of the patient. The first dose gave mild
general symptoms with fever and discomfort. He had later no symptoms of the treatment
that lasted for 12 weeks with 30 mg alemtuzumab 3 times/week, total dose 1200 mg. The
treatment gave full clinical remission. Profylaxis with valciklovir and Trimetoprim-Sulfa was
given. Duodenal and jejunal biopsies after the treatment showed a phenotype compatible
with regular celiac disease. Capsule enteroscopy and a double balloon enteroscopy showed
some erosions in the ileum. Biopsies suggested persistence of the malignant monoclonal
population. The patient is in these days being treated with high dose chemotherapy and
total body irradiation with autologous stem cell rescue. Discussion: Refractory celiac disease
type II (cryptic T-cell lymphoma) is a serious disease with a poor survival. Previously tested
treatment options have not proved effective. Treatment with alemtuzumab gave clinical,
histopathological and partly molecular biological remission. The treatment is promising but
must be tested in larger patient series.
W1249
The Raffinose/Mannitol Sugar Absorption Test Is Related to the Severity of
Celiac Histopathological Small Bowel Changes
Ivar M. Harkema, Jeroen J. Kolkman, Joop J. Vanbaarlen, Cees J. Doelman
Introduction In celiac disease, defined as partial to total villous atrophy in the duodenal
biopsy, the sugar absorption test (SAT) has proven to be a reliable tool for assessment of
the small bowel permeability. This test consists of ingestion of a sugar solution containing
monomer (mannitol), dimer (lactose) and trimer (raffinose) saccharides. Ratio’s of this
saccharides are determined in the urine 5 hours after ingestion. Normal mucosa will only
allow a small amount of resorption via a paracellular route. . Loss of villous architecture
and “mucosal leakage”, in villous atrophy increases mall bowel permeability, and therefore
increased large-small sugar ratio. Several studies suggested a relation between the ratio and
the severity of villous disruption, mostly comparing villous atrophy to normal mucosa. Aim
To establish the relation between SAT and mucosal histopathology in patients biopsied for -
suspected - celiac disease, stratified according to the Marsh criteria. Method We retrospect-
ively studied patients in whom duodenal biopsies were taken and the SAT determined. The
biopsies were stained with using haematoxylin/eosin staining and immunohistochemical IEL
counting (CD3), and graded according to Marsh: M-I: intraepithelial lymphocytes (IEL) >30/
100, M-II: increased IEL plus crypt hyperplasia, M-IIIa: partial, IIIb: subtotal and IIIc: total
villous atrophy . For the SAT we used 150 ml sugar solution, with 7 g raffinose, 20 g lactose,
2 g mannitol and 20 g saccharose. Urine was collected from 0-5 hours after ingestion. The
raffinose/ mannitol ratio was calculated. The previously established normal cut-off for SAT
was > 18. Results From 1997-2005 we performed 30.564 gastroscopies, and took 3454
duodenal biopsies. In 575 patients time-matched duodenal biopsies and SAT was available.
M-0 M-I M-II M-IIIa M-IIIb M-IIIc No 288 205 44 24 12 3 Abnormal SAT 46 38 15 12
10 3 Mean SAT 14 12 20 37 83 212 Using the Spearman rank correlation we found a
significant correlation between the Marsh classification and the SAT test, r=0,20, p<0,0001.
SAT as diagnostic test for villous atrophy showed a sensitivity of 64%, specificity of 82%
with a likelihood ratio of 3,47 (p<0,001). Conclusion SAT is a reliable predictor of mucosal
permeability and is related to the presence and severity of villous atrophy. The diagnostic
accuracy seems insufficient to use it as screening tool.
W1250
High Prevalence of Intraepithelial Lymphocytosis Found in Duodenal Biopsies
in a Large Cohort of Patients Referred for Routine Gastroduodenoscopy
Ivar M. Harkema, Joop J. van Baarlen, Jeroen J. Kolkman
Introduction The histological diagnosis of celiac disease is based on the triad of villous
atrophy, crypt hyperplasia and intra-epithelial lymphocytosis according to the Marsh classi-
fication. In recent years, the required histopathological abnormalities have changed from
required total villous atrophy to more subtle villous abnormalities. In this latter group several
authors have shown development of overt villous atrophy with gluten challenge or resolution
of symptoms with gluten free diet; thus suggesting that some of these patients have mild
celiac disease. It is currently unclear what the prevalence of intra-epithelial lymphocytosis
is among patients referred for gastroduodenoscopy. Methods From 1997 we routinely took
3-4 duodenal biopsies in patients referred for either suspected celiac disease, or patients
with diarrhea, anemia, weight loss or severe dyspepsia. The duodenal biopsies were stained
with haematoxylin/eosin (HE) and scored for the presence of villous atrophy, crypt hyperpla-
sia and intra-epithelial lymphocytes (IEL’s). If elevated IEL’s were found on standard HE
staining, immunohistochemical staining of CD-3 positive lymphocytes was performed with
morphometric measurement of IEL infiltration (expressed as lymphocyte count per 100
epithelial cells). A normal cut-off point of 30 IEL / 100 was chosen. The biopsies were
classified according to Marsh. Results From January 1997 until september 2005 a total of
30.564 gastroduodenoscopies were performed. In 3454 patient (11%) duodenal biopsies
were taken. 2396 (69,4%) patients showed normal mucosa, 792 patients (22,9%) had a
Marsh I lesion, 116 patients (3,4%) Marsh II, and 150 (4,4%) patients had villous atrophy
(Marsh IIIa-c). Thus, intra-epithelial lymphocytosis without villous atrophy was seen in
26,3% of patients, villous atrophy was seen in 4,4%. Conclusions In patients presenting
with diarrhea, anemia, weight loss and severe dyspepsia undergoing gastroduodenoscopy,
intra-epithelial lymphocytosis is a common finding when immunohistochemic staining is
used.
W1251
Psychiatric Alterations, Depression and Symptomatic Dimensions in Patients
with Celiac Disease At Diagnosis: The Impact On Quality of Life
Cristina Sfoggia, Fabio Nachman, Eduardo Maurino, Horacio Vazquez, Edgardo Smecuol,
Silvia Pedreira, Sonia Niveloni, Emilia Sugai, Roberto Mazure, Maria L. Moreno, Julio C.
Bai
Background/aims: Celiac disease (CD) is a chronic inflammatory enteropathy characterized
by a wide clinical variability. Depression and other psychiatric symptoms have been reported
as common clinical features of CD occurring in about 30% of patients. In this context, little
is known about how patients perceive their health state and how depression impacts in it.
Our aim was to determine the prevalence of depression and its impact on the quality of life
(QoL) of patients with CD assessed at diagnosis. Methods: We prospectively enrolled a series
of 134 consecutive newly diagnosed adult CD patients (117 females). At diagnosis, 100
patients evidenced classical symptoms and 34 were categorized as subclinical/silent cases.
At diagnosis, all patients underwent a battery of self-administered questionnaires including
the Short Form 36 Health Survey (SF-36), the Beck Depression Inventory (BDI) and the
Symptom Checklist 90 Revised performed (SCL 90R). These tests allow define three levels
of psychiatric morbidity. Results: At diagnosis, the CD population exhibited a profound
alteration of the 8 items of the SF-36. The BDI showed that 50% of the overall population
had evidence of depression, this finding was significantly more prevalent in patients with
classical symptoms (55%) than in those subclinical/silent cases (21%; p<0.04). There was
an inverse correlation between BDI and the eight items of SF-36 (r: -0.50, p<0.0000). The
SCL 90 R analyses evidenced that 35 (27%) of patients had no morbidity, 36 (28%) had a
minor psychiatric compromise and 57 (45%) had major psychiatric morbidity. Of the nine
assessed dimensions somatization (n=25) and hostility (n=25) were the most prevalents.
Conclusions: According to the present findings, CD patients have a profound alteration of
the subjective perception of QoL. Depression was present in 50 % of patients being greater
in those expressing classical symptom and impacts inversely on the QoL. Finally, the use
of two different tests for psychiatric assessment emphasizes two still unrecognized features
in adult patients such as somatization and hostility. The frequency of psychiatric alterations
makes necessary a specialized support of these patients.
W1252
Is a Control Biopsy in Pediatric Celiac Disease Necessary?
Anna Killander, Arnell Henrik, Hildebrand Hans, Yigael Finkel
The criteria for paediatric celiac disease (CD) rely on histopathological examination (HPath)
of small bowel biopsies (SBB) and serology before and on glutenfree diet (GFD) (1). There
is still controversy about the need for control SBB on GFD. Aim: To investigate the use of
pre-GFD biopsies and IgA-transglutaminase antibodies (IgA-TGA) in diagnosis of pediatric
CD. Method: Retrospective review of work-up for CD in children older than 18 months
after one-year GFD. Children with positive IgA-TGA and pre-GFD biopsy were included,
children with IgA deficiency were excluded. 71 children , median age 5 (1,5-16 years)
underwent gastroscopy with biopsies from bulb and distal duodenum pre-GFD (2). In 56/
71 children, (34 girls), median age 5 years (1,5-16 years) data on HPath pre-GFD, IgA-
TGA before and on GFD and Z-score for weight and height on GFD were analysed (group
1). 15/71 children (11 girls) median age 7 (1,6 -11 years) underwent a second SBB on GFD
(group 2). Results: HPath of SBB pre GFD showed partial, subtotal or total villous atrophy
in all children. In group 1, IgA-TGA was normal after one-year GFD in 53/56, borderline
in 3. Z-score for weight (W) and height(H) increased in 34/44 (2 missing data) young and
prepubertal children aged 1,5-12 years on GFD for one-year. Median Z scores for children
1,5-2years; W +0,74, H+0,46, 2-7 years; W +0,35, H + 0,16, 8-11 years; W +0,32 and H
+0,08. In group 2 after one-year GFD 14/15 had normal TGA (1 missing),and HPath of
SBB was normal in 13/15, while 2 children had considerably less HPath changes compared
to pre-GFD SBB. A complete remission of symptoms related to CD on one-year GFD was
reported in most children in both groups. Conclusion: We are confident to diagnose celiac
disease in children 1,5 - 11 years on a combination of pre-GFD SBB and TGA and remission
of symptoms, normalised IgA- TGA and catch-up growth on GFD. 1.Revised criteria for
diagnosis of coeliac disease.Arch Dis Child. 1990;65(8):909-911. 2.Kappinen K. Arnell H,
Finkel Y, Hildebrand H, Lindholm J. Villous atrophy in pediatric celiac disease may be
confined to the proximal part of duodenum. J Pediatr Gastroenterol Nutr. 2005;39 Suppl
1:s202-203
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W1253
Usefulness of the Assesment of Celiac Disease Serological Markers in Healthy
Working People for the Detection of Silent Disease Among General Population
Meritxell Marine, Maria Esteve, Montserrat Alsina, Carme Farre, Montserrat Cortijo,
Antonio Salas, Margarita Tomas, Elias Abugattas, Merce Rosinach, Fernando Fernandez-
Banares, Rebeca Santaolalla, Clarisa Gonzalez, Josep Maria Viver
INTRODUCTION: Several epidemiologic studies have demonstrated that the total prevalence
of CD is about 1:250. Most of these cases still remain undiagnosed. Despite celiac disease
(CD) has most of the WHO criteria for early disease detection (Wilson & Jungner), mass
screening of the general population is nowadays controversial. AIMS: 1- To asses the use-
fulness of including CD specific antibodies -antitransglutaminase antibodies (tTGA) and
antiendomisium antibodies (EMA)- in healthy working population blood tests for the detec-
tion of the disease. 2- To reevaluate the cut off for positive values of tTGA (recommended
cut-off by the supplier >8 U/ml). METHODS: 1781 individuals were included [1308 males,
age: 36.9±0.32 years; 473 females, age: 36.6±0.5 years]. Blood tests were performed to all
participants, including CD markers: tTGA (ELISA: Pharmacia Diagnostics) and EMA (IFI:
BMD Biomedical Diagnostics). tTGA were considered positive when values >2U/ml were
found, confirmed twice in the same sample. Duodenal biopsy and HLA DQ2/DQ8 genotyping
were performed to all individuals with EMA positive values and/or tTGA. Histological damage
was established using Marsh criteria. Results were expressed as % and x±SEM. RESULTS:
Positive antibodies were detected in 20 individuals (1.1%): 5 with EMA+/tTGA+, 14 with
tTGA+/EMA- and 1 EMA+/tTGA. Two subjects did not accept further evaluations, and 1
has not yet been evaluated (1 EMA+/tTGA+, 2 EMA-/tTGA+). We detected four Marsh III
[all of them EMA and tTGA+ (values between 8.5 and 63.4 U/ml); 3 DQ2+, 1 DQ2/DQ8-
], 8 Marsh I [7 EMA-/tTGA+ (values between 2 and 5 U/ml); 1 EMA+/tTGA-; 5 DQ2+, 2
with one positive allele of the DQ2 , 1 in course)], 5 Marsh 0, two of them with 16% and
20% intraepithelial lymphocytes [EMA-/tTGA+ (values between 2 and 3.4); 5 DQ2+]. The
percentage of CD (Marsh I-III) detected by histopathology was 0.67%. CONCLUSIONS: 1-
The percentage of CD found in this study (higher than other diseases where population
screening is recommended) justifies the inclusion of CD serologic markers in healthy working
population blood tests. 2- To establish the tTGA cut off in 2 U/ml allows diagnosing more
number of CD type Marsh I, which can be as much symptomatic as Marsh III. 3- tTGA is
more sensitive than EMA in this situation. This study has received financial support from
“Banc de Sabadell” of Catalonia (Spain).
W1254
Endoscopic and Pathological Response of Ulcerative Jejunitis to Infliximab
Therapy
Neil Rajoriya, Mattew Priest, Galloway Aileen, Robert Jackson, John MacKenzie, John
Morris
Aim: To assess endoscopic and histological response of patients with Ulcerative Jejunitis to
Infliximab infusion(monoclonal anti-TNF-alpha) therapy. Methods: Patients with Ulcerative
Jejunitis complicating Coeliac disease were identified. All patients had: clinical status and
Coeliac antibody status, push enteroscopy, histology and immunophenotyping studies carried
out preceding and within 6 weeks post-Infliximab therapy (5mg/kg). Results: 4 patients (3
male and 1 female) with Ulcerative Jejunitis were treated with Infliximab. The median age
was 42.3 years (Range: 18-62 years). The time between diagnosis of Coeliac disease and
Infliximab therapy was median 6 years (Range 20 months-17 years). All 4 patients had
received oral corticosteroid treatment pre-Infliximab therapy. 3 were started on Azathioprine
(2mg/kg) in the peri-infusion period, and 1 patient had been on it for 7 years (disease onset
at 16 months of age). Pre-treatment 3 were negative and 1 positive for Coeliac disease
antibodies. All 4 had enteroscopic evidence of ulcerative jejunitis complicating Coeliac
disease which was confirmed by histology. 3 patients were intra-epithelial lymphocyte T-
cell receptor CD3 +ve/CD8 -ve (one was CD8 +ve). 2 patients were T-cell receptor CD30
+ve. PCR of intra-epithelial lymphocytes showed 3 of 4 patients were monoclonal and 1
patient oligoclonal for TCR-gamma gene rearrangement. Post-Infliximab treatment, all 4
patients had clinical improvement at 6 weeks. Repeat enteroscopies were done within 6
weeks of Infliximab therapy all showing macroscopic and histological improvement with
complete healing of ulcers in 2 patients. In 2 patients there was a marked reduction in
CD30+ve cells, one of whom became CD30-ve. The follow up times since Infliximab have
been: 3 months, 6 months, 30 months and 50 months. 2 patients had a relapse of symptoms
at 6 months, one of whom died secondary to a perforated High grade T-cell Lymphoma.
The 3 remaining patients are on low dose corticosteroid therapy. Conclusion: Infliximab
therapy leads to short-term enteroscopic, histological
W1255
Risk Factors for Osteoporosis and Effect of Gluten Free Diet On Bone Density
in Patients with Celiac Disease
Donald Duerksen, Carrie Wilhelm-Boyles, David Parry
Celiac disease (CD) is associated with osteoporosis and decreased bone density. The preval-
ence of decreased bone density may vary according to the population studied. The objectives
of this study were to determine i) the prevalence of decreased bone density (BD) in patients
with newly diagnosed CD and in patients on a gluten free diet for greater than 6 months
ii) the effect of clinical presentation at diagnosis on the development of osteoporosis. iii)
the effect of a gluten free diet (GFD) on bone density. Methods: Adult patients with CD
Group 1 (BD < 6 mo. after diagnosis (dx) of CD) and Group 2 (BD > 6 mo. after dx of
CD) underwent testing with BD. Group 1 patients were divided into 3 categories based in
clinical presentation at diagnosis: P1-GI symptoms and wt loss, P2-GI symptoms, P3-Silent/
Atypical Results: The following are the patient characteristics: Grp 1 N=51 M:F 5/46 Mean
age at dx 42.6. Grp 2 N=61 M:F 13/48 Mean age at dx 44.3, mean duration GFD 9.42y.
see Table 1 There were 42 patients who had follow-up bone density tests a mean of 2 years
from the initial test. There was a 5.8 % mean increase in BD in the spine and 6.3 % mean

















73% (spine) and 79% (femur), significant numbers of patients had osteoporosis or osteopenia
(48% spine and 50% femur). The effect of clinical presentation on diagnosis is summarized
in Table 2 Conclusions: 1) Low bone density is common in newly diagnosed celiac patients
and in those who have been on a GFD for a prolonged period of time. 2) The majority of
patients have an improved bone density after 2 years of GFD with a significant increase in
bone density of ~ 6%. 3) Even after a GFD of 2 years, ~ 50% of patients are osteopenic/
osteoporosis. These patients required long-term monitoring to evaluate their risk for fractures
4) Weight loss at presentation is a significant risk factor for low bone density at diagnosis.





Seroprevalence of Anti-Gliadin and Anti-Endomysium Antibodies in Mexican
Adults
Nahum Mendez-Sanchez, Daniel Zamora-Valdes, Francisco Sanchez-Giron, Maria A.
Montano-Reyes, Lizet Lopez, Martha H. Ramos, Misael Uribe
Background: Diseases associated with a pathological immune response, such as Crohn’s and
celiac disease, are considered to be less prevalent in developing than in developed countries.
Our concept of celiac disease have changed during the last decade, as more asymptomatic
or oligosymptomatic cases are identified. There is no information concerning the prevalence
of celiac disease in our country. Aim: Determine the seroprevalence of anti-gliadin and anti-
endomysium antibodies in a check-up unit in Mexico City. Methods: We carried out an
observational study in a check-up unit of a University Hospital in Mexico City. Anthropomet-
ric, metabolic and biochemical variables were measured in subjects between 20 and 70
years. The diagnostic conclusions of the check-up were recorded. Serum was tested for
total IgA (Immage, Beckman-Coulter); for gliadin IgA antibodies by micro ELISA; and for
endomysium and gliadin IgA by indirect immunofluorescence (IIF) with anti-human IgA
FITC-labelled and slides containing primate intestine and Gliadine Biochips. Gliadin IgA
ELISA was positive if result was >25 U/L. For IIF screening dilution was 1:10, positivity
was assessed at 100x magnification, all positives were diluted 1:100, as well as IgA anti-
gliadin and anti-endomysium antibodies using ELISA. Results: We studied 400 subjects,
71% male and 29% female. The median age was 45 ± 11 years, body mass index 25.9 ±
3.7, waist-to-hip ratio 0.86 ± 0.08, body fat 28.3 ± 5.7 %. Four patients exhibited IgA <
70 mg/dL and one had a below range level. We identified twelve positive cases, eleven
positive for IgA anti-gliadin and two for IgA anti-endomysium. One patient had 1:100
positivity to both antibodies and four had a 1:100 positivity for anti-gliadin and 1:10 for
anti-endomysium. The seropositive group were 75% male and 25% female, its median age
of 47 ± 9 years, body mass index 25.8 ± 4.5, waist-to-hip ratio 0.88 ± 0.09 and body fat
27.5 ± 5.4%. Four patients positive to anti-gliadin antibodies were symptomatic, two pre-
sented diarrhea and two had a previous diagnosis of irritable bowel syndrome. Conclusions:
We found a seroprevalence of 2.7% for anti-gliadin and 0.5% for anti-endomysium antibodies.
These results are comparable to countries such as Italy and lower than countries like Sweden
or the United States.
W1258
Economic Burden of a Gluten-Free Diet
Anne R. Lee, Dianna Ng, Peter H. Green
Introduction: Individuals with celiac disease must consume a gluten free diet. Gluten free
foods are available at general and specialty food stores as well as via the Internet. A cost
survey was conducted to evaluate the economic burden of adhering to a gluten free diet.
Method: A standardized product list (regular wheat based and their gluten-free substitutes)
was used to evaluate the cost differences. The differences in price between purchase venues,
both type of store (general grocery store, an upscale grocery store and a health food store
and four internet based grocery sites) and region was also analyzed. The stores were surveyed
in the New York (New York City and Westchester County), Portland Oregon, Atlanta Georgia,
Rapid City South Dakota, and Chicago Illinois. The prices comparisons are reported in price
per ounce for comparative purposes. Results: In all geographical regions the gluten-free
products were more expensive (240%) than their wheat-based counterparts. The increase
in cost varied for the different food types (between 140 to 350%). The health food stores
were more expensive than the regular grocery store or the upscale markets for both the
gluten-free and wheat based products (by 123%). The Internet was more expensive for the
gluten free foods by 1.1 to 1.6 times the cost. Geographic location did not affect the cost
comparisons as much as did choice of shopping venue. Availability varied between the
regular grocery store, the health food store, the upscale market, and on line shopping. The
on line sites and the health food stores carried the largest selection of gluten-free products.
The variability was only 25 to 75% of the gluten-free food items on the list were carried at
either the general grocery store or the upscale market compared to 100% on the Internet
sites Conclusions: To date there have not been any studies in the United States evaluating
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the cost of gluten free foods. Our study demonstrated firstly, that the availability of gluten-
free foods is limited. Not all regular grocery stores carry gluten-free products. This forces
patients to purchase gluten-free products at either specialty stores or via the Internet. In
addition we determined that overall gluten-free products are far more expensive than their
regular wheat based gluten containing products. As more research is done on the impact
of the gluten free diet on an individuals’ quality of life attention should also focus on the
economic burden of adhering to the diet. Additional investigation is needed to determine
if the economic burden of the diet is an issue of noncompliance to the gluten-free diet regime.
W1259
High Resolution SSOP Typing of Celiac Disease-Associated HLA DQ
Haplotypes
Esther Oh, Mary Barry
BACKGROUND: The involvement of HLA DQ alleles in celiac is well established. About
95% of celiacs express the DQ2 heterodimer DQA1*05 and DQB1*02, while the majority
of non-DQ2 carry DQ8 (DQA1*0301/DQB1*0302). DQA1*0201/DQB1*02 has also been
implicated in a small number of celiacs. The majority of the remaining patients without
DQ2 or DQ8, carry at least half of the DQ2 heterodimer. The literature reports a hierarchy
in the relative risk of the DQ haplotypes, with individuals homozygous for DQB1*02 at a
higher risk. AIM: To evaluate and validate a high-resolution sequence-specific oligonucleotide
probe (SSOP) method for determining the celiac-associated DQ haplotypes. METHOD: DNA
from reference cells with known HLA DQ haplotypes was obtained from IHW and ECACC.
DNA was isolated from whole blood with commercial reagents. PCR amplification was with
biotinylated nucleotides in two multiplex reactions for the DQA1 and DQB1 locus. Amplified
product was hybridized with 35 DQA1- and 37 DQB1-specific probes immobilized on
membrane strips, and detected with enzyme-conjugated streptavidin in an automated con-
trolled water bath environment (LiPA, Innogenetics). Probe reactivity patterns were inter-
preted in LiRAS to determine the alleles. RESULTS: Among the 30 reference DNA tested,
13 unique DQA1 and 13 DQB1 alleles were detected. Three DQA1 and two DQB1 alleles
differed from their known typing; sequencing results confirmed the SSOP typing, all of
which were more recent alleles (Table). 25 samples previously typed as DQ2 and/or DQ8
(defined above) by SSP were also correctly identified. DQB1*0302 in the presence of certain
other DQB1 alleles may result in ambiguities. All three of the potential ambiguous haplotypes
include alleles that are very rare (HLA Dictionary, 2004). The DQB1*0302-030101 ambiguity
with DQB1*030302-0304 was further investigated by re-amplifying the DNA bound to a
probe specific for DQB1*0302, followed by hybridization to DQB1 probes; this confirmed
the presence of the DQB1*0302 allele in all 20 cases tested. Conclusion: High-resolution
SSOP typing of HLA DQ alleles is accurate and specific, and provides detailed haplotype
information (i.e. both DQA1 and DQB1 alleles, and the number of copies of the alleles)
that may be clinically useful for assessing the risk levels, or for eliminating patients from
consideration for celiac disease.
W1260
Proinflammatory Cytokynes IL-1b and Tnfa Gene Polymorphisms in Celiac
Disease
Alejandra Chernavsky, P A. Correa, Natalia Periolo, Sonia I. Niveloni, Eduardo Maurino,
Julio C. Bai, J M. Anaya
Background/aim: Celiac Disease (CD) is a well-characterized intestinal disorder with a strong
genetic predisposition in the HLA-DQ region. It is also thought that non-HLA genes are
determinants of CD susceptibility. Our aim was to establish the influence of TNFA and IL1B
genes polymorphisms as risk factors for developing CD. Materials and methods: We enrolled
114 patients with well-established CD and 122 healthy controls with similar gender distribu-
tion and ethnicity. Genomic DNA was extracted from anti-coagulated PBMC by standard
methods. Genotyping of single nucleotide polymorphisms (SNP) of TNFA -308(G/A) and -
238(G/A), and IL1B -511(C/T) and +3953(C/T) was performed by PCR-RFLP. Hardy-Wein-
berg (H-W) equilibrium and linkage disequilibrium testing were performed using Arlequin
software. Results: IL1B but not TNFA markers met H-W equilibrium genotype proportions.
There was linkage disequilibrium between TNFA and IL1B loci but there were no significant
differences in any inferred haplotype in both controls and CD patients. Compared with
controls, CD patients had a significant increased prevalence both of the allele TNFA -308A
(OR: 1.47, 95% CI: 1.01-2.13) and the TNFA -308AA homozygosis (OR: 3.28, 95% CI:
1.64-6.53). Furthermore, TNFA -308GA heterozygosis constitutes a protective factor (OR:
0.38, 95% CI 0.21-0.70). While the IL1B -511T allele resulted a protective factor for
CD (OR: 0.66, 95%CI: 0.45-0.96), no association was found at IL1B +3953 position.
CONCLUSIONS: Our findings show that a gene polymorphism at TNFA at position -308
is a genetic marker of CD susceptibility in the Argentinean population. Conversely, our data
on the contribution of IL1B -511 suggest a protective role for the T allele.
W1261
Impact of Age On Outcomes of Acute Variceal Hemorrhage in Patients with
Cirrhosis
William Sanchez, Jayant A. Talwalkar, Mark V. Larson, Theresa A. Nolte, Stephanie M.
Johnson, Louis M. Wong Kee Song, Vijay H. Shah, W R. Kim, Patrick S. Kamath
BACKGROUND: Despite major advances in the management of gastrointestinal (GI) bleeding,
older patients are often excluded from clinical trials. Few studies examine the impact of age
on acute variceal hemorrhage (AVH). AIMS: 1) Determine the frequency, clinical features,
and outcomes of AVH in cirrhotic patients ≥ 65 years of age. 2) Compare short and long-
term survival rates following AVH in patients ≥ 65 years of age with younger patients.
METHODS: The study cohort was identified from a prospectively collected database for all
emergent endoscopies from 1/1/1989-12/31/2004. Patients with upper GI hemorrhage from
varices (esophageal, gastric) were selected. Liver disease severity was defined by the MELD
score. Baveno III criteria were used for defining the acute bleeding episode, control of bleed,
and rebleeding. Patients were censored at the date of death, transplantation, or last follow-
up. Vital status was ascertained using the Social Security Death Index. RESULTS: 490 patients
with at least one episode of AVH comprised the study cohort. 100 patients (20.4%) ≥ 65
yrs of age were identified. Mean age was 57 yrs (18-92 yrs) with 66% men. The etiology
of the cirrhosis was alcohol (29%), viral hepatitis (14%), and cholestatic (15%). Mean MELD
score was 19 (12-25). Endoscopic and vasoactive therapies were used in 78% and 53% of
patients, respectively. Median time to follow-up was 323 days (20-1688 days). There was
no significant difference in time to recurrent AVH (p=0.66) or transplant-free survival
(p=0.23) between older and younger patients. Average MELD score, use of endoscopic/
pharmacologic therapy, and ICU days were similar between subgroups (p>0.05 for all). The
mean # of blood transfusions was less in older patients (5.9 vs 8.2, p=0.02). Frequency of
comorbid illness was significantly higher in the older cohort (p<0.01). In patients ≥ 65 yrs
of age, the presence of recurrent AVH was not associated with lower transplant-free survival
(p>0.05). Patients ≥ 75 yrs of age (n=53) had an increased mortality rate (p=0.016) without
excess recurrent AVH (p=0.06) compared to patients less than 75 yrs old. Frequency of
comorbid illness (p=0.004) was the only variable associated with increased mortality risk
in this subgroup. CONCLUSIONS: 1) In patients with AVH, an estimated 20% of individuals
are ≥ 65 years of age. 2) Transplant-free survival and frequency of recurrent bleeding is
similar to younger patients regardless of MELD score or severity of bleeding. 3) Management
strategies for the treatment of AVH are as effective for older patients as younger patients,
and older patients should no longer be excluded from important clinical trials.
W1262
Intrahepatic Hyperphosphorylation of the Rho-Kinase-Substrate Moesin in
Experimental and Human Cirrhosis
Martin Hennenberg, Jonel Trebicka, Ludger Leifeld, Michael Schepke, Erwin Biecker,
Tilman Sauerbruch, Joerg Heller
Background: In cirrhosis, increased vascular intrahepatic resistance contributes to portal
hypertension. The elevated intrahepatic resistance is associated with an increased susceptibil-
ity to vasoconstrictors. We have previously shown, that this is due to an upregulation of
RhoA and Rho-kinase (Hepatology 2004;40(4)S1:483A). The RhoA/Rho-kinase-pathway
mediates vasocontraction and is coupled to vasoconstrictor-receptors. However, Rho-kinase-
activity has not been studied at protein or molecular level in cirrhotic livers so far. Therefore,
we studied the phosphorylation of the Rho-kinase-substrate, moesin, in cirrhotic livers of
rats with secondary biliary cirrhosis and patients with liver cirrhosis. Methods: In rats,
cirrhosis was induced by bile-duct-ligation (BDL). Sham-operated rats served as controls.
Human liver samples were obtained from biopsies and transplantations. Phosphorylation of
moesin at the Rho-kinase-specific phosphorylation-site (Thr-558) was investigated by West-
ern-blot-analysis with densitometric quantification and immunohistochemically using a site-
and phosphospecific antibody. Results: Western-blot-analysis of whole liver homogenates
revealed an increased phosphorylation of the Rho-kinase-substrate moesin (Thr-558) in
livers from BDL-rats compared to sham-operated rats (BDL: 217+/-25% of sham, p<0.04).
Total moesin was similar between both groups (BDL: 105+/-22%, p=0.88). As shown by
immunohistochemistry, moesin-phosphorylation is elevated in the intrahepatic branches of
portal veins in cirrhotic livers from BDL-rats (stained cells/vessel wall: sham 37+/-9.3%,
BDL 88+/-6.4%, p<0.0001). The same trend to an increased moesin-phosphorylation was
observed in whole liver homogenates from patients with alcohol-induced liver cirrhosis
compared to non-cirrhotic patients (cirrhosis: 128+/-12% of non-cirrhotic controls). Discus-
sion: The increased moesin-phosphorylation reflects an increased Rho-kinase activity, which
presumably contributes to the increased intrahepatic resistance of cirrhotic livers, both in
rat and man.
W1263
Liver Regeneration Factors After Extended Hepatic Resection with Or Without
Portosystemic Shunt in a Large Animal Model
Ruth Ladurner, Martin Schenk, Alfred Koenigsrainer
Background: The necessary liver volume after extended hepatic resection still remains to be
clarified. In the literature, the most important limiting factor seems to be portal hyperperfusion
in a small liver remnant. The aim of this study was the immunohistochemical analysis of
liver regeneration factors after extended hepatic resection with or without portosystemic
shunt. Methods: An extended left hemihepatectomy (approximately 75% of liver volume)
was performed in 25 6 to 8 weeks old domestic pigs (body weight 25 - 35 kg). In 15 cases
liver resection was carried out after construction of a portosystemic H-shunt between portal
vein and infrahepatic vena cava. After surgery the animals were weaned from anesthesia
and resumed oral feeding ad libidum after recovery. Liver biopsies were taken immediately
postoperatively in the follow up until death and the factors Ki-67 and CK-7 were analysed
immunhistochemically in paraffin embedded tissue sections. RESULTS: Extended left
hemihepatectomy was technically feasable in all animal and hypertrophy of the remnant
right lateral segment reached 250% in both groups at the end of the first postoperative
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week. In the animals with H-shunt, portal blood flow decreased significantly, whereas arterial
perfusion increased. The number of Ki-67 positive cells showed no substantial change in
the H-shunt group, but increased significantly in the group without shunt. With 19 versus
4 cells / 10 Glisson fields, nevertheless, Ki-67 was significantly higher in the H-shunt group
within the first postoperative day. Expression of CK-7 was significantly higher in the group
without shunt immediately postoperative and also in the first postoperative week. Conclu-
sions: The expression of Ki-67 in the H-shunt group was exclusively increased within the
first postoperative day, although portal hyperperfusion after extended liver resection was
reduced and arterial perfusion increased. However, in the first postoperative week the
regeneration of hepatocytes (level of Ki-67) and biliary regeneration (CK-7 expression) was
more increased in the group without shunt.
W1264
Is Sedation Or Analgesia Necessary for Transjugular Liver Biopsy? A
Randomized Placebo Controlled Trial
Sylvie Evrard, Micheal Adler, Axel Hittelet, Jacques Deviere, Olivier Le Moine
Background: Transjugular access to the liver is increasingly used in clinical settings either
for the measurement of hepatic venous pressure gradient (HVPG) or to obtain liver tissue
samples in the case of contra-indications to the percutaneous route. HVPG is an important
prognostic variable in cirrhotic patients and it might help stratifying patients to specific
treatments or follow up the efficiency of medical treatments. Aim: To randomly assess
patient’s tolerance to transjugular liver biopsy with or without sedation/analgesia. Methods:
One hundred eighty patients were included after signing informed consent. They were asked
to state their level of anxiety on a scale from 1 to 10 before the procedure. Afterwards, they
were randomized either to receive placebo (group 1, n=60), 0.02 mg/kg midazolam (group
2, n=60), or 0.02 mg/kg midazolam+1mg/kg pethidine (group 3, n=60) intravenously over
2 minutes before cervical local anesthesia. After the procedure (HVPG measurement +
biopsy), patients were asked to scale from 1 to 10 their level of anxiety, pain, memory (very
good or good) and willingness (yes or no) to repeat the procedure. The Mann Witney test
was used to compare the groups. Results: Clinical (sex, age, etiology of liver disease, usual
medication), biological (Child-Pugh scoring, creatinin) and procedure related parameters
(HVPG and biopsies: length of the procedure, need to use a guidewire, number of punctures
per examination, total length of samplings) were not different in the 3 groups. No significant
complication occurred during or after the procedure. Overall, no significant difference was
observed between the 3 groups regarding anxiety before and after the procedure, pain,
memory, and willingness to repeat the procedure (Table). However, patient’s tolerance
reflected by pain (p=0.022), post examination anxiety (p=0.001) as well as the duration of
the procedure and the number of liver puncture per examination (p=0.0001 and 0.001,
respectively) were operator- dependent, although the evaluation of the technical difficulties
assessed by the operators were not statistically different. Conclusions: Intravenous sedation
or analgesia does not improve the patient’s tolerance and willingness to undergo repeated
transjugular liver biopsy or HVPG measurement as compared to placebo. This underscores
the need for referral in highly trained centers.
W1265
Endoscopic Treatment of Esophagogastric Variceal Bleeding in Patients with
Non-Cirrhotic Extrahepatic Portal Vein Thrombosis: A Long-Term Cohort
Study
Vmcw Spaander, S Darwish Murad, Hr van Buuren, Be Hansen, Ej Kuipers, Hla Janssen
Background: Esophagogastric variceal bleeding is the most important complication of extra-
hepatic portal vein thrombosis (EPVT), and is usually treated endoscopically. Little is known
on the prognosis of these patients. In the current cohort study, we investigated the clinical
outcome and efficacy of endoscopic treatment in patients with variceal bleeding secondary
to EPVT. Methods: Consecutive patients with variceal bleeding secondary to non-cirrhotic,
non-malignant EPVT, who underwent endoscopic treatment at our hospital between 1982
and 2005, were enrolled in this study. Data on diagnosis, endoscopic procedures and
outcome were collected by systematic chart review. Overall and re-bleeding-free survival
was calculated by the Kaplan Meier method. Multivariate Cox regression, stratified for
number of re-bleedings, was used to determine predictors of re-bleeding. Results: Thirty-
one patients (29% males; median age 45.6 years (range 3.5-87.5)) were followed after their
first bleeding episode for a median follow-up of 8.3 years, range 0-22.4). Underlying diseases
were protein S deficiency (n=5), infections (n=3), IBD (n=1) and other forms of hypercoagul-
ability (n=10). A total of 164 endoscopic procedures were performed, including variceal
ligation (n=36), sclerotherapy (n=125) or both (n=3). Of these, 30 interventions were done
for active bleeding, and 134 for follow-up treatment. In all patients, initial control of bleeding
was obtained. Re-bleeding occurred in 13/31 (42%) patients; in 10 (77%) after sclerotherapy,
in 1 (8%) after band ligation and in 2 (15%) after both modalities. Overall re-bleeding risk
was 19% (95% CI 9-30) at 1- and 43% (95% CI 29-59) at 5-years. Extension of thrombosis
appeared the only independent predictor of re-bleeding, with a nearly 3-fold risk for EPVT
patients with concomitant splenic and/or mesenteric vein thrombosis (RR=2.93;P=0.03).
Two complications, both sclerotherapy-induced, were noted: esophageal stenosis needing
dilatation, and ulcer bleeding leading to death. A porto-systemic shunt procedure was

















patients died, 6 due to the underlying disease causing EPVT and 1 after bleeding. Overall
5- and 10-year survival was 100% and 65 % (95% CI 42%-91%), respectively. Conclusion:
In patients with variceal bleeding from EPVT, endoscopic procedures, in particular band
ligation, appear safe and effective with low re-bleeding risk. Bleeding related mortality is
rare; survival appears primarily determined by the underlying disease causing EPVT.
W1266
Role of NOS Isoforms in the Development of Vascular Hypo-Response
Following Portal Hypertension
Nicholas J. Skill, Nicholas G. Theodorakis, Janice L. Theodorakis, James V. Sitzmann
Aim: Portal hypertension (PHT) is a major complication of liver cirrhosis and accounts for
the deaths of thousands of Americans annually. Predominantly there are two principle
underlying causations of elevated pressure within the portal vasculature. Initially the develop-
ment of cirrhosis and related increase in resistance to portal blood flow elevates portal
pressure and precipitates a subsequent and secondary development of vascular dysfunction.
This secondary vasculopathy manifests through an elevation of vasodilators and a reduced
vascular response to vasoconstrictors, resulting in increased forward flow to the portal system
and elevated portal pressure. To date the enzyme nitric oxide synthase (NOS) has been
implicated in the development of vascular complications of PHT. However, the precise
mechanism and the roles of individual NOS isoforms are not clear. To address this deficiency
we investigated the development of vascular hypo-responsiveness to vasoconstrictors in NOS
isoform gene deficient mice. Methods: Pre-hepatic PHT was generated by the partial ligation
of the portal vein in wild type, endothelial (eNOS) or inducible (iNOS) gene deficient mice.
Sham operated mice were used as controls. 7 day following PVL or sham surgery aortic
response to vasoconstrictors was determined in-vivo and ex-vivo. In-vivo response to vaso-
constrictors was determined by monitoring the abdominal aortic flow prior to and following
a bolus injection (IV) of 2μg/g body weight of the α1 adrenoceptor agonist methoxamine.
Ex-vivo response to vasoconstrictors was determined by quantitating the contractile response
of abdominal aortic rings in 10nM-1μM methoxamine. Results: Abdominal aortic flow was
significantly reduced following administration of methoxamine in wild type and NOS gene
deficient sham operated mice. However, in PVL operated mice reduced flow in response to
methoxamine was blunted in all three mouse groups. In a similar manner, aortic ring
contractility was significantly reduced 7d following PVL surgery. Discussion: The develop-
ment of vascular hypo-responsiveness following PHT is not NOS isoform specific. Therefore,
neither iNOS nor eNOS individually are important to the development of PHT dependant
vascular hypo-responsiveness and additional studies are required to better understand
PHT vasculopathy.
W1267
Therapeutic Efficacy of Balloon-Occluded Retrograde Transvenous Obliteration
in Patients with Gastric Variceal Bleeding
Kyungsik Park, Byoungkuk Jang, Woojin Chung, Kwangbum Cho, Jaeseok Hwang,
Sunghoon Ahn, Younghwan Kim, Jinsu Choi, Junyoung Hwang
Backgroud/Aims: Gastric variceal bleeding is fatal complication of portal hypertension caused
by end stage liver disease which is common in east Asia. But endoscopic treatment of the
condition is sometimes very difficult as its hemodynamics and accessability are different
with those of esophageal varix. Though transjugular intrahepatic portosystemic shunt is
another important therapheutic option in gastric varix, it also has some limitations such as
aggravation of hepatic encephalopathy or deterioration of hepatic function. Recently balloon-
occluded retrograde transvenous obliteration(BRTO) has been used as a new procedure for
gastric variceal bleeding with minimal invasiveness but reports about the results of this
procedure are not enough. So we analyzed the results of our cases which we have experienced
for recent 39 months. Methods: Twenty eight patients who were recevied BRTO for the
purpose of primary hemostasis or secondary prevention from December 2001 to March 2005
were analyzed retrospectively. Size of gastric and esophageal varix, clinical presentations,
laboratory findings were compared before and after procedure. Cumulative rebleeding and
survival rate were also analyzed with Kaplan-Meier curve. Results: Twenty three men and
five women were involved and mean age was 53.7 ± 9.6 years. Technical and clinical success
rates were 89.3% and 85.7%, respectively. Follows up were continued for 17.5 ± 12.5
months in 23 patients. Gastric varices were disappeared in 78.3% and decreased in size
more than 50% in 21.7%. Relapse was occurred in a(4.3%) patient. Preexisting hepatic
encephalopathy was improved in all patients. Aggravation or development of ascites, eso-
phageal varices, portal hypertensive gastropathy were observed in 45.8%, 30.4%, 56.5%,
respectively. Temporary decreased albumin concentration(p=0.002), increased bilirubin con-
centration(p<0.001) and Child-Pugh score(p<0.001)was observed at 3 days after procedure
but resolved at 7 days after procedure. Increased albumin concentration and decreased
Child-Pugh score were maintained thereafter. Rebleeding was occurred in 3 patients and
all cases were esophageal variceal bleeding. There were no factors related with rebleeding.
Two-year survival rate was 54.6%. Presence of hepatocellular carcinoma(HCC)(p=0.001)
and Child-Pugh grade B(p=0.036) and C(p=0.012) affected survival in univariate analysis
and presence of HCC was independent risk factor(p=0.010, OR=15.837) in multivariate
analysis. Conclusions: BRTO is effective therapheutic procedure for primary hemostasis,
secondary prevention, and improvement of survival in gastric variceal bleeding patients.
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W1502
Proteome-Based Identification of a Novel Interacting Protein with GLI,
Transcription Factor of Hedgehog Signal
Yoshinari Asaoka, Keisuke Tateishi, Yasuo Tanaka, Motoko Seto, Bayasi Guleng,
Amarsanaa Jazag, Miki Ohta, Motohisa Tada, Fumihiko Kanai, Takao Kawabe, Masao
Omata
(Background and aim) The Hedgehog (Hh) family of signaling proteins play central roles
driving many developmental programs from fly to humans, whereas deregulated Hh signaling
results in a variety of congenital malformations and cancers. Although it is becoming increas-
ingly clear that this pathway is also critical to gastrointestinal development and tumorigenesis,
it is not unraveled which molecule in this pathway is involved. In vertebrates, three Gli
proteins, Gli1, Gli2, and Gli3, function in transcriptional control of Hh target genes. Each
Gli protein has unique roles. Gli3 is well investigated to behave as Ci, the Gli transcription
factor of Drosophila, which is phosphorylated and processed in the absence of Hh and is
transferred to the nucleus without cleavage responding to Hh. However it is still not well
defined how Hh signals regulate Gli1 and Gli2 transcriptional activity.Here, we identify a
novel interactor with Gli transcription factor by conducting a tandem affinity purification
method and mass spectrometry. (Methods) We conducted a tandem affinity purification
approach coupled with MS-based proteomics technology to identify cellular proteins associ-
ated with the Gli1. The purification strategy employed an N-terminal affinity tag (termed
MEF) composed of two independent epitope tags, myc and FLAG, that were fused in tandem
and separated by a spacer sequence containing a TEV protease cleavage site. The MEF
cassette was fused to the N terminus of the Gli1, and 293T cells were transfected to express
the MEF-fused version of the Gli1 and were lysed. The expressed MEF-Gli1 was recovered
with its binding proteins by the immunoprecipitation using agarose beads conjugated with
anti-myc and anti-FLAG antibodies. The recovered proteins were analyzed by a direct
nanoflow LC-MS/MS system. (Results) We identified the 14-3-3 protein as a novel Gli1
binding protein. We further showed that this interaction was phosphorylation- dependent
as well as other 14-3-3 interactors and identified the binding site of Gli1. This site is
conserved in Gli2 and Gli3, so we examined their interaction with 14-3-3. Gli2 and Gli3
also bound to the 14-3-3 in a phosphorylation-dependent manner. This interaction was
revealed by reporter assay to downregulate the transcriptional activity of Gli2, neither Gli1
nor Gli3. (Conclusion) Through a tandem affinity purification approach coupled with MS-
based proteomics technology, we identified 14-3-3 as a Gli interactor. This interaction,
dependent on phosphorylation by a specific kinase, downregulates the transcriptional activity
of Gli. So, this reseach reveals a novel mechanism of Hh signal transduction.
W1503
EGFR Signaling Is Up-Regulated in Hyperproliferative Human Aberrant Crypt
Foci: Roles of Activated ERBB2 Receptors, Activated ERK and Increased
Cyclin D1
Reba Mustafi, Jeff Nathanson, Anusara Chumsangsri, Greg Cohen, Nathaniel Little, Sonia
Cerda, Loren Joseph, Sharad Khare, John Hart, Maria Tretiakova, Robert Carroll,
Alessandro Fichera, Marc Bissonnette
Introduction: Aberrant crypt foci (ACF) are putative precursors of human colon cancer and
the earliest detectable lesions in experimental colon cancer models. We recently examined
EGFR signaling in human ACF isolated by chromoendoscopy and demonstrated that hyper-
proliferative ACF (PCNA mRNA ≥ 2-fold of control) possessed upregulated transcripts for
EGFR, TGF-α, and cyclin D1 (Gastroenterology, 128: A-121, 2005). In preliminary studies
we also reported that some ACF had increased PCNA protein, elevated EGFR levels, activated
wild type Ras, and increased pERK or cyclin D1 by Western blotting. Since each of these
proteins was not assessed within the same ACF, our conclusion that EGFR signaling is
activated in hyperproliferative ACF remained inferential. Our goal in this study was to
optimize our assay conditions for multiplex Western blotting to directly quantify expression
and/or activation of several EGFR signal transduction components within the same ACF.
Methods: Using magnification chromoendoscopy in 11 patients, we collected 67 additional
large ACF (≥ 50 crypts/focus), as well as adjacent mucosa (>5 cm from ACF). The ACF
had endoscopic features of dysplasia. We employed 4-20% gradient gels, and combinations
of monoclonal and polyclonal primary antibodies, to assess expression levels of PCNA (36
kDa), EGFR (170 kDa), pErbB2 (185 kDa), pERK (42, 44 kDa), and cyclin D1 (37 kDa).
Patient-matched normal biopsies and individual ACF were examined on the same blot
by multiplex quantitative Western blotting, circumventing the need for stripping. Protein
expression levels in ACF were expressed as fold-control and ACF classified as hyperprolifer-
ative for PCNA levels ≥2-fold-control. Comparisons were made by paired Student’s t-test.
Results: Among large ACF, 46% were hyperproliferative (PCNA = 4.5 ± 0.4-fold), 72% had
increased total EGFR and 40% had activated ERK. In the hyperproliferative group, 44%
possessed simultaneous up-regulations or activations in all four EGFR signaling components:
EGFR (9.5 ± 1.3-fold, p<0.05), phospho-(active) ErbB2 (2.2 ± 0.3-fold, p<0.05), phospho-
(active) ERK (3.7 ± 0.6-fold, p<0.05) and cyclin D1 (3.4 ± 0.4, p<0.05). Hyperproliferative
ACF with increased EGFR but lacking pERK, may be driven by other EGFR pathways. Non-
hyperproliferative ACF with increased EGFR presumably lack other components, reflecting
the heterogeneity of ACF. Conclusion: Thus, in the first quantitative study of EGFR signaling
components within the same human ACF, we demonstrated that dysregulated EGFR signaling
contributes to the increased proliferative state of dysplastic appearing ACF, the earliest visible
stage of colonic malignant transformation.
W1504
Essential Roles of AP-1 and Transcriptional Coactivator P300/CBP in the
Synergistic Induction of COX-2 By Gastrin and EGF in Intestinal Epithelial
Cells
Yan-Shi Guo, Ji-Zhong Cheng, Mark R. Hellmich, Courtney M. Townsend, Jr.
Cyclooxygenase (COX)-2 plays an important role during early stage of colorectal carcinogen-
esis. The molecular mechanisms that lead to COX-2 activation in the gut are not well defined.
EGF is an inducer of COX-2 expression. We reported that gastrin stimulates expression of
COX-2 mRNA, protein and its promoter activity in intestinal epithelial cells (J Biol Chem
2002; 277:48755). The purposes of this study were to determine whether gastrin and EGF
synergistically upregulate COX-2 gene expression in gut cells, and if so, what mechanisms
are involved. Methods: A non-tumorigenic rat intestinal cell line (RIE/CCK2R) was used
that stably transfected with CCK-2 receptor and possesses EGF receptor. Cells were treated
with gastrin (100 nM) and EGF (50 ng/ml) in serum-free conditions. COX-2 mRNA, protein
and promoter activity were examined by Northern blot, Western blotting, and luciferase
assay, respectively. AP-1 transcription factor binding activity was determined by electrophor-
etic mobility shift assay. Results: Gastrin and EGF alone induced a time-dependent increase
of COX-2 protein levels (3- to 5-fold) in RIE/CCK2R cells. The combination of both peptides
synergistically stimulated the COX-2 protein expression (10- to 30- fold), COX-2 mRNA
abundance and promoter activity level, as well as induced a synergistic increase of transcrip-
tion factor ELK-1-dependent luciferase activity and the AP-1 binding activity. The increased
COX-2 promoter activity induced by costimulation of gastrin and EGF was blocked by c-
fos siRNA and by cotransfection with EIA expression vector, which serves as a p300/CBP
antagonist. The synergistic induction of COX-2 protein levels was abolished by p300/CBP
selective inhibitor Roscovitine. Conclusions: Gastrin collaborates with EGF to synergistically
induce COX-2 gene expression in intestinal epithelial cells. This effect appears to result
from the synergistic induction of AP-1 transcriptional activity and the recruitment of coactiv-
ator p300/CBP. These findings provide new insight into the regulating mechanisms of COX-
2 in intestinal epithelial cells.
W1505
Interferon-β-Induced Expression of XAF1 Requires Phosphorylation of STAT1
and a Sequential Activation of Protein Kinase C and JNK in Colon Cancer
Yunwei Sun, Jide Wang, Harry.H.X. Xia, Bing Zou, Marie Cm. Lin, Hsiang Fu Kung,
Benjamin C. Wong
Background:XIAP associated factor 1 (XAF1) induced apoptosis and cell differentiation
through antagonizing XIAP. The expression of XAF1 is increased in response to IFN, but
the precise mechanisms remain unclear. In this study, we investigated the regulation of
XAF1 expression by IFN β through JAK-STAT pathway. Methods: Lovo and HCT1116 were
treated with IFN β(500 U/ml). Cells were transfected with encoding constructs of ShRNA-
STAT1, DN-JNK1; and pretreated with or without protein kinase C delta (PKCδ)-specific
inhibitor Rottlerin (20 μM) and JNK inhibitor SP600125 (2.5 μM) for 1 hour, followed by
IFN β for several time points. Expressions of XAF1 and STAT1 were detected by RT-PCR
and Western blot. Dual luciferase assay was used to detect the involvement of STAT1. EMSA
was used to detect the activity of STAT1 in ISGF complex. Results: Low and medium level
of XAF1 was detected in HCT116 and LOVO cells, respectively. Treatment of cells with
ShRNA-STAT1 and Rottlerin significantly antagonized IFN β-induced XAF1 expression.
The influence of PKCδ on IFN β-mediated induction of XAF1 is dependent upon the
phosphorylation of STAT1 at serine 727. Furthermore, PKCδ-mediated activation of STAT1
requires the activation of JNK, as the inhibition of JNK activity by its specific inhibitor or
transfection of its dominant negative mutant suppresses both serine phosphorylation of
STAT1 and XAF1 expression but not the activation of PKCδ. It implied that JAK-STAT1
signaling was involved in IFN β-induced XAF1 expression in colon cancer cells. Conclusion:
Our results suggest that the induction of XAF1 transcription by IFN β through STAT1
depends upon sequential activation of PKCδ and JNK.
W1506
Protein Kinase C-ζ Is Down-Regulated in Human Adenomas and Pkc-ζ
Expression Levels Inversely Correlate with CACO-2 Colon Cancer Cell
Proliferation
Reba Mustafi, Sonia R. Cerda, Anusara Chumsangsri, Marc Bissonnette
Background: Protein kinase C-zeta (PKC-ζ) is an atypical PKC isoform involved in the
regulation of cell growth, differentiation and apoptosis. PKC-ζ is downregulated in human
and experimental colon cancers. To elucidate the growth regulatory role of this isoform in
human colon cancer cells, we established stable Caco-2 transfectants expressing PKC-ζ
under an inducible promoter. We found that PKC-ζ up-regulation significantly inhibited
proliferation, enhanced differentiation and accelerated apoptosis of Caco-2 cells grown on
collagen-1. We have now extended these studies by inhibiting PKC-ζ expression or activity
and assessed their consequences on Caco-2 cell growth. We also assessed PKC-ζ expression
in colonic adenomatous polyps. Methods: We used Caco-2 cells transfected with human
PKC-ζ under a ponasterone-inducible eukaryotic vector. In addition, we prepared Caco-2
transfectants, stably expressing wild type or kinase dead PKC-ζ under a constitutive CMV
promoter. Cells were grown on collagen-1 or in soft agar. Proliferation was measured by
Coulter counter, WST-1 assay, or colony counts (soft agar). PKC-ζ expression was inhibited
by PKC-ζ specific siRNA and kinase activity was blocked with a PKC-ζ pseudosubstrate.
PKC-ζ expression and biochemical activity were assessed by Western blotting and immunop-
recipitation kinase assay, respectively. Results: In this study, we established that PKC-ζ up-
regulation was accompanied by a 50% increase in insulin-stimulated kinase activity compared
to EV cells (p<0.05). Compared to EV cells, we also demonstrated that constitutively up-
regulated wild type PKC-ζ inhibited Caco-2 cell growth in soft agar (82%inhibition), whereas
kinase dead PKC-ζ increased growth in soft agar(3.7-fold,p<0.05). Consistent with our
previous findings that PKC-ζ upregulation inhibited proliferation, PKC-ζ knock-down with
siRNA (>70% inhibition), or kinase inhibition with the specific inhibitor, PKC-ζmyristoylated
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pseudosubstrate, significantly and dose-dependently increased Caco-2 cell growth on colla-
gen-1 (p<0.05). In human colon, PKC-ζ was significantly decreased by more than 70% in
adenomatous polyps, compared to adjacent mucosa (n=4, p<0.05). Conclusions: Inhibition
of PKC-ζ expression or activity increased Caco-2 cell proliferation on either collagen-1 or
soft agar. We postulate that PKC-ζ regulates cell proliferation by integrin-dependent and
independent pathways. Since PKC-ζ loss occurs early in colonic tumorigenesis, and the
expression of this isoform correlates inversely with cell proliferation, PKC-ζ down-regulation
appears to contribute to colonic malignant transformation.
W1507
Deoxycholic Acid Transactivates C-MET
Sharad Khare, Cory Holgren
Background: Bile salts have been suggested to be involved in the pathogenesis of colon
cancer. Hydrophobic bile acids such as deoxycholic acid (DCA) have been shown to induce
apoptosis and Cox-2 expression whereas hydrophilic ursodeoxycholic acid (UDCA) inhibits
proliferation. We have shown previously that UDCA inhibits cyclooxygenase-2 (Cox-2)
expression and suppresses colon cancer in rat azoxymethane (AOM) model [Cancer Research
63, 3517-3523, 2003]. Further, bile acid transporters have not been identified in the colon
and labeled bile acids are not taken up, in vitro, by colon cancer cells. It is presumed that
these amphipathic molecules exert their effects by perturbing plasma membrane structure
and function. However, the precise role of DCA in tumor promotion remains unclear. Here
we demonstrate, for the first time, that DCA transactivates hepatocyte growth factor receptor
(c-Met-R), a prognostic marker of colorectal cancer. Methods: HCA-7 cells were grown
McCoy’s 5A media containing 10% fetal calf serum. Phosphorylation status of c-Met-R, EGF-
R, IGF-1R and EphA2 was assesed by immunoprecipitation and Western blotting. c-Met-R
autophosphorylation and in vitro kinase activity towards an exogenous substrate was assayed
with [γ32P] ATP. Immunoprecipitation and Western blotting assessed co-association of β-
catenin with c-Met-R. Colony formation or cell growth in matrigel was also determined.
Cell proliferation was measured by MTT analyses. Cox-2 expression was assesed by Western
blotting. Results: Treatment of HCA-7 cells with DCA significantly increased c-Met-R phos-
phorylation in a time and concentration dependent manner. To determine the specificity of
this activation, we also investigated other growth factor receptors EGF-R, IGF-1R and EphA2.
DCA treatment had no effect on tyrosine phosphorylation status of these receptors. DCA
significantly increased c-Met-R association with β-catenin. Increased association with c-Met-
R with β-catenin was accompanied by a marked increase in tyrosine phosphorylation of β-
catenin. Correlating with the induction in c-Met kinase activity, HCA-7 cells had significantly
increased in vitro growth rates and soft-agar colony-forming abilities in the presence of
DCA. Further, k252a, a c-Met inhibitor completely abolished Cox-2 induction by DCA.
Summary: Clinical studies have shown that patients with colorectal cancer have higher levels
of secondary bile acids in colonic lumen. We demonstrate, for the first time, that tumor
promoter DCA activates c-Met receptor and downstream signaling. The characterization of
this pathway has implications for diverse disease processes including colon cancer progression
and metastasis.
W1508
Intestinal Cell Kinase (ICK) Is Detected in a Subset of Crypt Cells in
Intestinal Epithelium Following Radiation Injury and in the Colorectal Cancer
Cell Line Colo 205
Zheng Fu, Alda Vidrich, Steven Cohn, Thomas Sturgill
Intestinal Cell Kinase (ICK) shares sequence and structure homology to both ERK2 and
CDK2 at the catalytic domain. This similarity suggests that ICK may have MAPK- and CDK-
like regulation and potential functions in regulation of the cell cycle, lineage specification,
and/or cell fate decisions. ICK was originally cloned from an intestinal crypt cDNA library
by Dr. Anil Rustgi’s laboratory. The ICK mRNA localizes specifically to the crypt compartment
of small intestine suggesting that ICK may play a role in lineage specification and cell fate
determination in crypt epithelium. Our preliminary data indicated that ICK mRNA expression
increases over 10 fold with maximal levels observed at 72 hours after irradiation correspond-
ing to the initial appearance of regenerating crypts. When we examined small intestine and
colon for ICK protein expression at this time point, we observed a high level of immunoreac-
tive ICK in a restricted cell population more consistent with stem or progenitor cells
than the more numerous transit amplifying cell population in early regenerating crypts.
Additionally, our preliminary studies demonstrated that ICK is a transcriptional target for
b-catenin and other regulatory proteins that control stem cell fate and differentiation in
the gut. Given the surprising restricted localization of ICK protein to a small subset of
undifferentiated crypt epithelial cells, our working hypothesis is that ICK regulates cell fate,
replication, or function of the more restricted stem cell or progenitor cell population within
the crypts. Although the common CDKs and MAPKs may regulate most of the cell cycle
events in the crypts and at the crypt-villus junction during normal epithelial homeostasis
under basal conditions, our preliminary data suggest that ICK may be a key component for
regulating events in the crypt during epithelial regeneration following injury or during initial
morphogenesis of the crypt epithelium. ICK mRNA expression is strikingly increased in
human colon cancer cell line COLO 205 as compared to other cancer cell lines in the NCI60
panel (http://symatlas.gnf.org/SymAtlas/, Gene symbol ICK). Human COLO 205 colon cancer
cells are highly proliferative but poorly differentiated and lack epithelial cellular polarity
and columnar morphology. We used ICK antibody to analyze the protein level of ICK in

















up-regulated in COLO 205 cells, suggesting that ICK may play a role in the regulation of
cellular proliferation, differentiation and/or polarization of this colorectal cancer cell line.
W1509
Constitutive Activation of Erk1b/MAP Kinase Induces Transformation of
Intestinal Epithelial Crypt Cells Independently of Phosphatidylinositol 3-
Kinase/AKT, COX-2 and EGF Receptor Activation
Veronique Durand, Etienne Lemieux, Nathalie Rivard
Strong evidences exist for the critical involvement of Ras/Raf/MEK/ERK cascade in the
regulation of intestinal epithelial cell proliferation. K-rasV12G is the most frequently mutated
oncogene in colorectal cancer and targeted expression of K-rasV12G in the intestinal epithe-
lium causes activation of the MEK/ERK pathway and tumorigenesis in mice. Moreover,
blockade of the MEK/ERK pathway suppresses growth of colon tumors in vivo. However,
the mechanisms by which the MEK/ERK cascade induces intestinal epithelial cell tumorigen-
esis remain to be clarified. Methods. Retrovirus encoding the HA-tagged MEK1 wild type
(wtMEK) or a constitutive active mutant of MEK1 (MEK1-S218D/S222D, caMEK) were used
to infect normal intestinal epithelial crypt cells IEC-6. The effects of pharmacological inhib-
itors of MEK1/2 (UO126, 10 uM), PI-3Kinase (LY294002, 10 uM), COX-2 (NS-398, 10
uM) and EGF receptor (PD153035, 10 uM) were examined on cell growth and morphology.
Activation profiles of ERKs and Akt as well as COX-1/2 protein expression were also examined
by western blotting. Results. 1) Stable expression of caMEK, but not wtMEK, in IEC-6 cells
induced growth factor relaxation for DNA synthesis, enhanced migration (Boyden chambers),
induced deregulation of contact inhibition cell growth, promoted morphological transforma-
tion and growth in soft agar. In addition, we found a significant up-regulation of c-myc,
phosphorylated (T58,S62) c-myc and cyclin D1 expression levels. 2) Intriguingly, expression
and activity of ERK1/2 and Akt remained comparable in wtMEK- and caMEK-expressing
IEC-6 cells; however, the alternatively spliced isoform of ERK1, ERK1b, is constitutively
and markedly activated in caMEK-expressing IEC-6 cells. 3) Interestingly, protein expression
levels of COX1/2 were not enhanced in caMEK- versus wtMEK-expressing IEC-6 cells. 4)
Pharmacological inhibition of PI-3Kinase, COX-2 or EGF receptor tyrosine kinase did not
influence the transformed phenotype of caMEK-expressing IEC-6 cells. 5) By contrast,
treatment of caMEK-expressing IEC-6 cells with UO126 inhibitor reduced ERK1/2 phos-
phorylation levels, abolished ERK1b phosphorylation levels and resulted in the reversion of
the transformed phenotype of these cells. Conclusion. Our results suggest that ERK1b, an
alternatively spliced isoform of ERK1, contributes to the induction of transformation of
intestinal epithelial cells by MEK, independently of PI-3Kinase/Akt, COX-2 and EGF recep-
tor activation.
W1510
Aspirin Inhibits Deoxycholate-Induced NfκB, Caspase and Protein Kinase C
Signaling During Programmed Cell Death of Human Gastric Epithelial Cells
Maria Redlak, Jacinda Power, Thomas Miller
We have previously shown that apoptosis is one of the major mechanisms of gastric cell
death induced by deoxycholate (DC) and aspirin (ASA), and in this process the caspase
cascade, mitochondria and PKC signaling play key roles. The transcription factor NFκB has
been shown to modulate apoptosis by regulating the transcription of numerous pro- and
anti-apoptotic genes. The aim of the present study was to examine the NFκB signaling
pathway in DC- and ASA-induced apoptosis in a gastric carcinoma cell line (AGS). Methods:
AGS cells were incubated with DC (300 µM) or ASA (40 mM) for varying time periods. In
separate experiments cells were treated with DC with or without preincubation with aspirin
(ASA, 40 mM) or proteasome inhibitors. NFκB (p65) activation was measured in nuclear
fractions by ELISA. pIκB, caspases, PKCs, PARP and Lamin A expressions were analyzed
by Western blots from cytosol fractions. Apoptotic DNA fragmentation was detected by
agarose gel analysis. Results: We observed that DC activated the NFκB pathway, resulting
in a time-dependent translocation of NFκB (p65) into the nuclear compartment. Cytosolic
pIκB expression showed a transient increase with the maximum at 30 min and decreases
thereafter with longer exposure to DC. Aspirin exposure, in contrast, did not affect NFκB
activation; however, pre-incubation with ASA reduced DC-induced NFκB (p65) translocation
into the nucleus and IκB phosphorylation in the cytosol. DC-induced NFκB (p65) transloca-
tion was dependent upon proteasome activation, since proteasome inhibitors (Proteasome
Inhibitor I, Lactacystin and MG-132) significantly inhibited this process. We also observed
that DC-induced IκB phosphorylation was potentiated in cells pre-treated with proteasome
inhibitors. In addition, we found that aspirin (but not proteasome inhibitors) prevented DC-
induced caspase-3,-6, and -9 activation, PARP, PKC (ε), PKC (β1) and Lamin A processing, as
well as DNA degradation. Conclusion: Our results indicate that DC induces the NFκB
signaling pathway in gastric epithelial cells and that aspirin modulates this effect, most likely,
by inhibition of IKK β. Our findings also indicate that aspirin inhibition of DC-induced
apoptosis was associated with attenuation of caspase activation, PARP deactivation, PKC (ε)
and (β1) isoform expression, and Lamin A processing, and DNA degradation. Inhibition of
the proteasome which completely inhibited DC-induced NFκB signaling, however, had no
effect on other DC apoptotic targets such as caspases, PKCs, PARP, Lamin A and DNA
fragmentation. (Supported by NIH Grant DK 25838).
W1511
Prostaglandin E2 Dependent Proliferation of K-RAS V12 Transduced IEC-18
Cells
Hung Pham, Benny Chong, Lee W. Slice
Background: Elevated prostaglandin E2 (PGE2) and K-Ras mutations have been observed
in colorectal cancers. Transduction of Ras signaling proceeds through multiple pathways
but the Ras/Raf/MEK/ERK pathway appears critical in the proliferation and transformation
of cells. Aim: The aim of this study was to determine whether K-Ras signaling through MEK/
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ERK increases the expression of cyclooxygenase-2 (COX-2) and microsomal prostaglandin
E synthase-1 (mPGES-1) resulting in increased PGE2 and proliferation. Methods: Transduced
rat ileum epithelial cell line (IEC-18) with the lentivirus containing K-RasV12-GFP (18.K-
Ras) or GFP (18.GFP) were propagated. Real time PCR, Western blot analysis and EIA was
used to measure mRNA, protein levels and PGE2, respectively. Proliferation was determined
by MTT and [3H]-thymidine uptake and colony formation was determined by soft agar
assay. Results: 18.K-Ras colonized in soft agar and exhibited double growth rate and higher
density growth. PGE2 levels were increased and inducible by AngII and EGF in 18.K-Ras.
Serum-starved 18.K-Ras showed higher levels of COX-2 and mPGES-1 mRNA whereas
serum-starved 18.GFP cells produced lower levels of PGE2 as well as COX-2 and mPGES-
1 mRNA. Stimulation with AngII, EGF or AngII/EGF resulted in elevated PGE2 production
with increased COX-2 and mPGES-1 expression. The MEK inhibitor U0126 inhibited COX-
2 and mPGES-1 mRNA expression in 18.K-Ras cells. The COX-2 specific inhibitor NS-398
abolished PGE2 production as well as the proliferation of 18.K-Ras cells without affecting
the proliferation of 18.GFP cells. Conclusion: These findings demonstrate that active Ras/Raf/
MEK/ERK signaling leads to elevated COX-2 and mPGES-1 expression and PGE2 production,
resulting in the proliferation of 18.K-Ras.
W1512
TGF[Beta] Reverses the Phosphatidylinositol 3 Kinase /PTEN Axis in SMAD4-
Null Colon Cancer Cells
Jennifer Cabral, Jimmy Y.C. Chow, John M. Carethers
BACKGROUND: TGF[beta] functions as a tumor suppressor in early stages of colonic
turmorigenesis, but promotes tumor growth during later tumor stages and metastasis.
TGF[beta]-induced tumor suppression is thought to be mediated by the SMAD-dependent
signaling pathways, but little is known about SMAD-independent regulation. Here we exam-
ined the mitogenic phosphatidylinositol 3 kinase (PI3K) and its opposing regulation by the
tumor suppressor PTEN and its influence by TGF[beta]. METHODS: We used SMAD4-null
SW480 colon cancer cells, which express TGF[beta] surface receptors. Cells were treated
with 10 ng/mL TGF[beta] for time points up to 48 hours. Cells were then lysed for protein
extraction and Western blotting. Antibodies against PTEN, p85 (a subunit of PI3K), phospho-
tyrosine, and SMAD2/3 were used. Total RNA was also extracted to determine PTEN mRNA
expression using RT-PCR. Cell counting was performed over a 72-hour time period after
TGF[beta] treatment with or without PD98059 (a MEK inhibitor) or LY298002 (a PI3K
inhibitor). Luciferase assays with the p3TP plasmid were conducted to measure TGF[beta]-
induced SMAD-dependent promoter activity. RESULTS: TGF[beta] reduced PTEN mRNA
expression maximally at 24 hours by 80%, but reappeared at 48 hours, without having any
effect on PTEN protein levels. TGF[beta] also induced tyrosine phosphorylation of p85, 24
and 48 hours after treatment. TGF[beta] promoted cell growth in the first 24 hrs, which
was suppressed by LY294002 but not by PD98059. Despite the absence of SMAD4, TGF[beta]
induced p3TP activity. CONCLUSIONS: In SMAD4-null cancer cells, TGF[beta] treatment
induces activation of PI3K while simultaneously reduces PTEN mRNA, events that favor
cellular proliferation. The mechanisms for reversing the PI3K/PTEN axis from tumor suppres-
sion towards favoring tumor growth likely involves SMAD-dependent (but SMAD4-indepen-
ent) pathways as evidenced by our luciferase assay, as well as SMAD-independent pathways
(through PI3K activation as revealed by p85 tyrosine phosphorylation). These findings could
explain signaling mechanisms by which TGF[beta] uses to become a tumor promoter in
cancer cells.
W1513
FOXO3A Mediates Trail Down-Regulation in HT29 Cells
Salil Bose, Qingding Wang, B. Mark Evers
Phosphatidylinositol 3-kinase (PI3K) and its downstream effector protein, Akt, play a major
role in intestinal cell proliferation and survival. Previously, we have shown that PI3K inhibi-
tion induces expression of TRAIL (TNF-related apoptosis inducing ligand) which plays a role
in intestinal differentiation The apoptosis-inducer forkhead (FOXO) family of transcription
factors, a downstream target of Akt, modulates cell apoptosis by affecting PI3K-dependent
signaling. The aim of the present study was to determination whether the two FOXO
isoforms, FOXO1 and FOXO3a, regulate TRAIL expression in the intestine. METHODS.
(i) HT29 human colon cancer cells were treated with FOXO1 and FOXO3a siRNA or non-
targeting control and protein extracted for determination of TRAIL expression and expression
of the Cdk inhibitor proteins p27kip1 and p21waf1. Additionally, RNA was extracted and real
time (RT)-PCR performed to assess TRAIL mRNA levels after FOXO inhibition and treatment
with sodium butyrate (5 mM), a known differentiation inducer in transformed colon cancer
cells. (ii) To further confirm a role for FOXO regulation of TRAIL, wild-type and mutant
FOXO3a promoter plasmids were co-transfected with a construct containing the TRAIL
promoter (-1523/+23) linked to luciferase; luciferase activity was measured by dual reporter
assay with transfection efficiency controlled by Renilla luciferase. RESULTS. (i) FOXO1
inhibition by siRNA treatment decreased TRAIL and p27kip1 protein expression. FOXO3a
siRNA also decreased TRAIL mRNA levels. (ii) Additionally, co-transfection of wild-type
FOXO3a plasmids with the TRAIL promoter plasmid increased relative luciferase activity
compared with a FOXO3a mutant plasmid. CONCLUSIONS. FOXO3a inhibition decreased
TRAIL protein and mRNA levels in HT29 cells suggesting FOXO3a regulation of TRAIL in
intestinal cells. The regulation of TRAIL by FOXO3a was further confirmed by an increase
in the relative TRAIL promoter activity in HT29 cells. Importantly, alterations in TRAIL
protein and mRNA levels, mediated by the PI3K/Akt/FOXO3a pathway, may be a critical
component in the regulation of intestinal cell differentiation and survival.
W1514
Novel Isoform of PKC May Be Involved in the Rapid Translocation of Tight
Junction Proteins to the Cell −Cell Contact By EGF in TMK-1 Gastric Cancer
Cells
Kenichi Yoshida, Shigeru Kanaoka, Tetsunari Takai, Mutsuhiro Ikuma, Masayoshi
Kajimura, Naoyuki Miura, Haruhiko Sugimura, Akira Hishida
Background: Tight junction (TJ) is disrupted in a number of tumor types, including stomach.
Expression level of TJ proteins is involved in differentiation of gastric cancer (Am J Pathol
151: 45-54, 1997). Recently, an increasing number of growth factors have been shown to
modulate TJ proteins and function. However, little is known about the effects of growth
factors on TJ proteins in gastric cancer. TMK-1 cells, which are diffuse type of gastric cancer,
loosely contact to adjacent cells and weekly express ZO-1 and occludin proteins on the cell-
cell contact. We found that exposure of fresh fetal bovine serum (FBS) to TMK-1 cells led
to rapid translocation of ZO-1 and occludin from the cytosol to the cell-cell contact. In the
present study, we examined the effects of FBS or EGF on TJ proteins of TMK-1 cells.
Methods: TMK-1cells were cultured 60-80% density. Cells were exposed to fresh medium
containing 10% FBS or 1-1000 ng/ml EGF. The effects on ZO-1 and occludin were observed
by immunofluorescence (IF) and Western blot (WB) analyses. Finally, we examined
intracellular signaling associating with the effects using various inhibitors. Results: IF demon-
strated that ZO-1 and occludin were some weak expression at the cell-cell contact and were
predominantly localized to the cytoplasm. When the medium was replaced with fresh
medium containing 10% FBS or EGF, the cells formed close contacts with the adjacent cells
and ZO-1 and occludin were translocated from the cytosol to the cell-cell contact within
30 minutes. These effects were observed dose-dependently at the range of concentration of
1 to 100 ng/ml and sustained for 2 hours after the treatment of EGF without significant
increasing numbers of cells. Adversely, 1,000ng/ml EGF showed weaker effects than those
of 100 ng/ml. WB revealed that NP-40 soluble fractions of ZO-1 and occludin were decreased
after 100 ng/ml EGF treatment. And also the ratio of NP-40 insoluble to soluble fraction
of ZO-1 and occludin with 100 ng/ml EGF treatment were approximately 2.0-fold higher
than those in the absence of EGF. Levels of ZO-1 and occludin protein in total cell extract
were not changed. EGF-induced effects were inhibited PKC inhibitors, calphostin C and
bisindolylmaleimide I (more specific for novel type of PKC), but not another PKC inhibitor
Go6976, PD98059 (MAP kinase inhibitor), LY294002 (PI3 kinase inhibitor) and KT5720
(PKA inhibitor). Conclusion: EGF induced the rapid translocation of ZO-1 and occludin
from the cytosol to the cell-cell contact through the activation of PKC in diffuse type of
gastric cancer cell, which is accompanied with change of cell shape similar to that of intestinal
type of gastric cancer.
W1515
Modulation of Bone Morphogenetic Protein (BMP)-Induced Growth
Suppression By Activated K-RAS
Stayce Beck, Barbara Jung, Eunice Del Rosario, Jessica Gomez, John M. Carethers
BACKGROUND. BMPs, part of the transforming growth factor [beta] superfamily, regulate
cell differentiation, proliferation, and apoptosis through a canonical SMAD signaling cascade
in mesenchymal cells. Recent evidence indicates BMPs also regulate intestinal epithelial
growth in a murine model, additionally; lack of BMP signaling contributes to the formation
of intestinal juvenile polyps in humans with colon cancer prone familial juvenile polyposis.
As sporadic colorectal cancers appear to have intact BMP signaling, we evaluated if K-RAS,
a mitogenic pathway commonly activated in colon cancer, negatively affects BMP-SMAD
signaling. METHODS. We treated non-tumorigenic FET cells, which have activated K-RAS,
with BMP2 (100 ng/ml) and the MEK inhibitor PD98059 and the PI3Kinase inhibitor
LY294002 to inhibit potential downstream effects of K-RAS, as well as transiently transfected
cells with DN-RAS to directly inhibit K-RAS. We assessed BMP-induced transcriptional
activity using a SMAD-dependent BRE-luciferase construct, measured cell growth by direct
cell counting and MTT metabolic assays, and measured p21 by RT-PCR, pWWP-luciferase
activity, and p21 stability after cyclohexamide. RESULTS. While BMP2 treatment of FET
cells increased BMP transcriptional activity 2-fold over control and modestly decreased cell
growth, inhibition of K-RAS, MEK1, and PI3Kinase with BMP2 treatment further enhanced
transcriptional activity by an additional 1.5 to 2 fold and improved growth suppression by
20%. BMP2 did not increase the transcription of the cell cycle inhibitor p21, but instead
increased the stability of existing p21 protein over controls. CONCLUSIONS. BMP2 is
directly growth suppressive in FET colon cancer cells, which occurs simultaneously with
BMP2-SMAD-specific transcriptional activity, and increases p21 protein stability. K-RAS
and its potential downstream effectors MEK1 and PI3Kinase interfere with BMP2-induced
transcriptional activity and growth suppression. These mitogenic pathways may slow SMAD
cytoplasmic to nuclear translocation due to phosphorylation of the SMAD linker region as
suggested in the literature. BMP2-induced transcription in colon cancer cells is modulated
by activated K-RAS to reduce the growth suppression directed by this pathway.
W1516
Activin Induces Non-Transcriptional P21 Protein Stability in Colon Cancer
Cells and Modulated By Mitogenic Pathways
Barbara Jung, Stayce Beck, Jessica Gomez, John M. Carethers
BACKGROUND: Activin is a growth suppressive ligand of the TGF[beta] superfamily and
its signaling pathway is targeted for disruption in colon cancers. The receptor encoded by
ACVR2 is frameshift mutated in more than 80% of microsatellite unstable and a subset of
microsatellite stable colon cancers, causing loss of ACVR2 protein expression. Activin binds
to ACVR2, triggering phosphorylation of intracellular SMAD proteins that translocate to the
nucleus to affect transcription of target genes to slow cellular growth. Here, we dissect the
mechanism of p21 protein increase by activin as well as its modulation by mitogenic
pathways. METHODS: Synchronized, activin-sensitive FET colon cancer cells were treated
with activin (25ng/ml) in conjunction with inhibitors of the RAS/MAPK and PI3kinase
pathways. P21 RNA expression was assessed with RT-PCR, and protein expression by
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Western blotting. Transcriptional activation was assessed using the p21-specific pWWP-Luc
reporter. P21 protein degradation was monitored after inhibiting translation with cyclohexa-
mide. RESULTS: Activin decreases cellular growth in FET colon cancer cells in association
with an increase in p21 protein. Activin-induced growth suppression and p21 protein
increase are further augmented with concomitant inhibition of PI3kinase or MAPK/ERK.
While neither p21-specific transactivation nor p21 mRNA are increased following activin
treatment; activin leads to stabilization of p21 protein levels. CONCLUSIONS: Activin
signaling is growth suppressive in colon cancer cells and is associated with p21 protein
stabilization. This effect is augmented with inhibition of mitogenic pathways, indicating
their interference with activin growth suppressive signaling. The p21 increase is due to
reduced protein degradation, a novel mechanism mediating activin growth suppression in
colon cancer.
W1517
Insulin-Like Growth Factor-1 Activates R-Type (CAV2.3) Channels and
Chromogranin a Secreton in the Neuroendocrine Tumor Cell Line Bon
Stefan Mergler, Mathias Strowski, Javier Prada, Carsten Groetzinger, Bertram
Wiedenmann, Ursula Ploeckinger
BACKGROUND: Blocking voltage-operated Ca2+ channels (VOCCs) of the R-type (CaV2.3)
with the tarantula toxin SNX-482 led to a decrease in intracellular calcium ([Ca2+]i) as well
as chromogranin A (CgA) secretion in the human neuroendocrine tumor (NET) cell line
BON (J. Membr. Biol. 2003, 194, 177-186). Insulin-like growth factor 1 (IGF-1) is a potent
mitogenic and secretory factor and acts on Ca2+ permeable channels. It is not known,
whether VOCCs play a role in the IGF-1-dependent regulation of CgA secretion in NET
cells. AIM: We therefore investigated the effect of IGF-1 on individual VOCC subtypes and
their role in mediating IGF-1-dependent regulation of CgA secretion in NET cells. METHODS:
Patch-clamp techniques as well as single cell fluorescence imaging methods were used. In
addition, the IGF-1 induced effect on CgA secretion was studied in BON cells. RESULTS:
Using specific modulators of VOCC subtypes, we identified the functional activity of L-, N-
, P/Q- and R-type channels in BON cells. IGF-1 (10 ng/ml) significantly increased the
maximal VOCC inward currents (control = 2.59 ± 0.23 pA/pF vs. IGF-1 = 3.41 ± 0.11 pA/
pF, n = 5) resulting in a significant increase in [Ca2+]i to 128 ± 6% of its control (base
level was set to 100%, n = 10). This effect was reduced by the specific R-type channel
blocker SNX-482 (10 nM). IGF-1 potently induced CgA secretion, which was reduced by
inhibition of R-type channel activity. CONCLUSION: R-type Ca2+ channels are expressed
in NET cells and mediate both, IGF-1 receptor signalling as well as CgA secretion. Thus,
pharmacological interference with R-type channels reducing Ca2+ signalling and IGF-1-
dependent hypersecretion may represent a new therapeutic option in NET disease.
W1518
Protein Kinase D Stimulates Mitogenic Response and Cell Proliferation in
Human Pancreatic Cancer Cells
Krisztina Kisfalvi, Cliff Hurd, Enrique Rozengurt
Ductal adenocarcinoma of the pancreas, which comprises 90% of all human pancreatic
cancers, is a devastating disease with overall 5-year survival rate of only 3-5%. The major
challenge is to identify novel targets and develop strategies for its treatment. These new
approaches will most likely arise from a detailed understanding of the molecular signaling
pathways that stimulate the unrestrained proliferation of these cells. Consequently, the
elucidation of the signaling pathways that mediate DNA synthesis and anchorage-independent
growth in pancreatic cancer cells is of fundamental importance in the identification of novel
targets for therapy. Protein kinase D (PKD) is implicated in the transduction of specific PKC
signals, which are shown to increase growth in multiple cell types. Aim: Our hypothesis
was that PKD pathway plays a role in promoting the proliferation of pancreatic cancer cells.
Methods: To determine the effect of PKD on the growth of these cells we derived PANC-
1 cells that stably and inducibly express high levels of PKD (wild-type and kinase-dead
[K618N] forms of PKD), and examined the cell proliferation in these derived cell lines. We
utilized a model system in which the wild type or mutant (constitutively active or kinase
dead mutants) of PKD were expressed under the control of a modified ecdysone receptor
enhancer/promoter. To determine whether overexpression of PKD stimulates growth in
PANC-1 cells, we measured DNA synthesis ([3H]-thymidine incorporation) and anchorage
independent growth (cell number after 7-9 days in cultures growing on PolyHEMA-coated
dishes) of cells treated in the absence or presence of ecdystone to induce PKD. Result: Cells
overexpressing wild type PKD showed a two-fold increase in [3H]-thymidine incorporation
(dose-dependent of inducer). The inactive PKD mutant had no effect on DNA synthesis.
On PolyHEMA-coated cultures we observed similar results, the number of cells overexpress-
ing active PKD was significantly increased (dose-dependent of inducer) but the inactive
mutant had no effect on cell proliferation. Our results demonstrate that expression of wild
type but not kinase-dead mutant PKD stimulated a significant increase (p<0.005) in both
DNA synthesis and anchorage independent growth. Conclusion: PKD overexpression leads
to a mitogenic response and cell proliferation in pancreatic cancer cells. Our data suggest
that PKD plays an important role in signaling proliferation of pancreatic cancer cells and thus
can be a potential target for new and effective therapeutic intervention in this deadly cancer.
W1519
Gastric and Esophageal Stromal Tumors (GIST): Does Size Matter?
Alan Weiss
Background: It is not clear how frequently submucosal esophagogastric stromal tumors
(GIST) less than 3 cm in size are malignant and whether such lesions can be safely followed
with endoscopy. Objective: To determine the presentation and the outcome of GIST involving

















presence of malignancy and clinical outcome was correlated. Methods: Patients with esophag-
ogastric GIST seen at the British Columbia Cancer Agency during a ten-year period (1995-
2004) were reviewed. Patient demographics, the presence or absence of symptoms, and the
nature of the symptoms were assessed. The size and the determination of malignancy were
based on pathological findings. The patient’s clinical outcome was determined. Results: 54
patients were reviewed (25 men, 29 women). Mean age of the total population was 60.33
years (range 21-81). 45 patients were symptomatic, 6 were asymptomatic, and in 3 cases
symptomatology was not recorded. 52 tumors were located in the stomach and 2 in the
esophagus. Mean size of symptomatic lesions was 9.7cm and mean size of incidentally found
lesions was 9 cm (ns). Three lesions were smaller then 3cm: two were symptomatic and
one was found incidentally. Range of symptomatic tumors > 3cm was 3.2 -25cm and the
range of those found incidentally was 5.0-14.5cm. Overall, there were 40 histologically
malignant tumors and 14 benign lesions. In the lesions >3cms, 38 were histologically
malignant (76%) and 11benign (24%): out of this group 10 patients died and 11 had
recurrences or metastases (total 47%). In lesions < 3cm, 2 out of 3 had a malignant clinical
course and one patient died. Conclusion: In this series, small GISTs were uncommon;
however, 2/3 of the tumors were malignant and one death occurred. This experience strongly
suggests that once a submucosal lesion is detected on endoscopy, it should be examined
with endoscopic ultrasound and, if it is determined to be consistent with a GIST, excision
rather then follow up should be considered.
W1520
The Tetraspanin Cd9 Is a Negative Regulator of EGF Receptor Signaling in
Cancer Cells
Yoko Murayama, Yasuhisa Shinomura, Shinji Tamura, Norio Hayashi
Background & Aims: CD9 is a member of the tetraspanins, and has been shown to be
involved in a variety of cellular activities such as migration, proliferation and adhesion. In
addition, it has been known that CD9 can associate with other proteins. Here we investigated
the physical and functional association of CD9 with epidermal growth factor receptor (EGFR).
Methods: The cell surface expression of CD9, β1 integrin, EGFR was analyzed by flow
cytometry. The association of CD9 with EGFR and/or β1 integrin was examined by double-
immunostaining and immunoprecipitation. Tyrosine phosphorylation of Shc was determined
by immnoprecipitation and immunoblot. Shc and Grb2 were determined by immunoblot.
Clones overexpressing CD9 was established by stable transfection with CD9/pEFBOS into
a hepatocellular carcinoma cell line (HepG2) or a chinese hamster ovary cancer cell line
expressing human EGFR (CHO-HER). Results: In a human gastric cancer cell line MKN-
28, double-immunofluorescent staining and immunoprecipitation demonstrated that CD9
and EGFR as well as CD9 and β1 integrin form complexes and that they co-localized on
the cell surface, especially at the cell-cell contact sites. Treatment of MKN-28 cells with
anti-CD9 antibody ALB6 induced a dotted or patch-like aggregation pattern of both CD9-
EGFR and CD9-β1 integrin complexes, and the ALB6-treatment strengthened the association
of CD9 with EGFR. It is noteworthy that the internalization of EGFR after EGF-stimulation
was significantly enhanced by the treatment with ALB6. Moreover, overexpression of CD9
specifically down-regulated the surface expression of EGFR, leading to the attenuation of
EGF/EGFR-signaling such as Shc tyrosine phosphorylation and Grb2 recruitment. Conclu-
sions: These results suggest that CD9 might have an important role that attenuates EGFR
signaling. Therefore, CD9 not only associates EGFR but also a new regulator, which may
affect EGF-induced signaling in cancer cells.
W1521
Immunohistochemical Expression of Leptin in Colorectal Adenocarcinoma and
Clinicopathological Characteristics
Dae Won Jun, Oh Young Lee, Won Sohn, Ki Seok Jang, Seung Sam Paik, Tae Wha Kim,
Sun Young Yang, Sung Hee Han, Hang Lak Lee, Byung Chul Yoon, Ho Soon Choi, Joon
Soo Hahm, Dong Hoo Lee, Min Ho Lee, Choon Suhk Kee
Background: Leptin, the adipocytes-derived hormone, has an important role for obesity and
acts as a growth factor in several cancers including gastrointestinal malignancies. Leptin can
stimulate mitogen-activated protein kinase activity in vitro and short-term infusion has been
reported to have a proliferative action on the colon in vivo. First, We immunohistochemically
analyzed the expression of the leptin in colon adenoma-carcinoma sequence from surgical
resection at the same person, same surgical specimen (normal, adenoma and adenocarcinoma
tissue respectively). Second, We investigate whether leptin expression was correlated with
clinicopathological characteristics or disease outcome in colon cancer patients. Methods:
This was a retrospective study of 24 colorectal adenocarcinoma patient who was taken
total or hemicolectomy and adenomoatous polyp was seen in the same surgical specimen
simultaneously. leptin expression was assessed using immunohistochemical methods and
was evaluated by grading both staining intensity (0, +1, +2, +3) and staining pattern (diffuse,
focal, apical). The relationships between leptin expression and clinicopathological features
of the patients was also evaluated. Results: Basic characteristics of 24 patients were as follow;
age: 60.8 years (41-77), gender: 18 male, 6 female, Dukes’ stages: 3 (12.5%) at A, 8 (33.3%)
at B, 8 (33.3%) at C, 5 (20.8%) at D. Leptin expression was observed in 4.2% (1/24)
of normal colon mucosa, 33.3% (8/24) of adenomatous polyps and in 50% (12/24) of
adenocarcinomas respectively (p <0.05). And average of immunohistochemical intensity
score was also higher in adenocarcinoma (+1.50) than in adenoma (+1.25) and normal
tissue (+1.00). There was no relationships between leptin expression and tumor size (tm <
3 cm or tm > or = 3 cm), number of metastatic lymph nodes (< 4 or 3 > or = 4), localization
of the tumor (colon or rectum), distant metastasis, and vascular invasion of the tumor.
However, poorly differentiated cell type was much more in leptin positive adenocarcinoma
patient (poorly differentiated or moderately + well differentiated) (p < 0.05), but it was not
associated with stage and patient survival. Conclusion: Positive rate of leptin expression and
intensity have increased according to normal-adenoma-adenocarcinoma sequence in same
colon cancer patient, and leptin expression correlated with histological differentiation. These
results suggest leptin might play a role in colon adenoma-adenocarcinoma sequence, and
tumor differentiation.
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W1522
Neurotensin Receptor-1 (NTR-1) mRNA Expression in Colorectal
Adenocarcinoma: An in-Situ Hybridization Study
Xianyong Gui, Paul R. Dobner, Grace Guzman, Shrihari S. Kadkol
BACKGROUND & AIM - Neurotensin (NT), a 13-AA peptide, is expressed in early fetal,
but not adult colonic mucosa. However, it is re-expressed in colonic adenocarcinomas. NT
was found to stimulate the in vitro growth of a few types of carcinoma cells, including colon
cancer, through NT receptors (NTR). Therefore NT may be involved in the development
and/or progression of colon cancer, and NTR expression patterns between normal and
malignant colonic epithelium may be different. In this study we specifically characterized
NTR-1 mRNA expression in normal, precancerous and carcinomatous colonic mucosa.
MATERIALS & METHODS: NTR-1 mRNA expression was determined by in-situ hybridiza-
tion on formalin-fixed and paraffin-embedded tissue sections. Tissue blocks of 21 cases of
colorectal adenocarcinoma (male 13, female 8, mean age 63.4 yo) were selected. A 322-bp
KspI/PstI fragment of hNTR-1 cDNA was subcloned into pBluescript II KS+ vector. Digoxig-
enin-labeled antisense and sense riboprobes were generated. Anti-DIG-AP conjugate and
BCIP/NBT were used in chromogenic detection for hybridization signals. Negative controls
included sections hybridized with sense riboprobe or with hybridization solution without
probe. Representative sections treated with RNase A prior to hybridization with antisense
probe were also employed to ensure specificity. Within the same tissue section, the signals
were assessed in adenocarcinoma and in adjacent normal mucosa and areas of hyperplasia,
dysplasia and adenoma. The signal intensity was classified as negative, weak, moderate and
strong. RESULTS - In normal colonic mucosa adjacent to tumors, NTR-1 expression was
absent in 74% (14/19) and weak in 26% (5/19) of the cases. In areas of hyperplasia,
expression was absent in 45% (4/9) and weak in 55% (5/9) of the cases. In areas of dysplasia,
weak expression was observed in 74% (14/19) and moderate expression in 26% (5/19) of
the cases. In 9 cases with adenomas from which adenocarcinomas arose, the adenomatous
components showed weak expression in 78% (7/9) and moderate expression in 22% (2/9)
of the cases. A heterogenous pattern was observed in adenocarcinomas. 24% (5/21) showed
weak, 71% (15/21) showed moderate and 5% (1/21) showed strong expression. The infiltrat-
ing margins and the foci of lymphovascular invasion of tumors showed a higher intensity
of expression compared with the rest of the tumor. CONCLUSION - This study suggests
that enhanced expression of NTR-1 mRNA are associated with tumor progression and
aggressive behavior in colonic adenocarcinoma. NTR-1 seems to play a role in the growth
of human colorectal adenocarcinoma.
W1523
Activation of Survival Kinases and NF-KappaB Delays Anoikis in Primary
Human Colonic Epithelial Cells
Claudia Hofmann, Monika Artinger, Johannes Grossmann, Werner Falk, Juergen
Schoelmerich, Gerhard Rogler, Florian Obermeier
Background: Apoptosis induced by loss of cell anchorage - “anoikis” - plays an important
role in the life cycle of colonic epithelial cells. Loss of anchorage dependency is believed to
be a critical step in metastatic transformation. Recent studies with the IEC-18 cell line from
normal rat intestinal epithelium showed that epithelial cells can activate a set of important
kinases as well as NF-κB, which transiently protects them from apoptosis. Therefore, we
investigated the regulation of NF-κB as well as distinct kinases known to play a role for cell
survival in primary human colonic epithelial cell (CEC) anoikis. Methods: CEC were isolated
as intact crypts from the mucosa of surgical specimens. Induction of anoikis was achieved
by incubation of crypts in suspension for up to four hours. Reconstitution of cell-cell contacts
was obtained by “pelleting” of CEC. Induction of anoikis was demonstrated by caspase-3
activation (Western Blot, DEVD-pNA). Cell lysates were analyzed for phosphorylation of
Src, EGFR, Erk1/2, p38-MAPK, JNK and c-Jun by Western Blot or ELISA. Cell culture
supernatants were assessed for their content of EGF and TGF-α by ELISA. NF-κB activation
was quantified by ELISA. Results: Immediately after detachment of CEC from the basal
membrane a rapid increase in phosphorylation for all tested kinases was detected. Phosphoryl-
ation of EGFR, Erk1/2 and JNK reached peak levels after 60 min, while phosphorylation
of Src and p38 MAPK was still increasing thereafter. The initial activation of these kinases
was observed before active caspase-3 could be detected. CEC undergoing anoikis deliberated
high amounts EGF and TGF-α. A time-dependent activation of NF-κB also was detected
after detachment of CEC. Interestingly, progress of anoikis could effectively be blocked
when CEC, incubated up to 60 min in suspension, were “rescued” by reconstitution of their
cell-cell contacts, as caspase-3 activity was reduced by up to 50 % (p=0.04). Phosphorylation
of Src and p38 MAPK also decreased when cell-cell contacts were reconstituted. Conclusions:
Detachment of primary human CEC triggers a transient increase in the activity of anti-
apoptotic kinases, as well as a strong increase in growth factor secretion and NF-κB activity.
By these mechanisms, CEC achieve to be transiently protected from anoikis immediately
after detachment and can be “rescued” from anoikis by reconstitution of physiological
cell contacts.
W1524
Chenodeoxycholic Acid Stimulates P38 MAPK Protein Expression and
Activation Through Activation of PKC Alpha
Bernard Bouscarel, Jianping Ming
Background and Aim: We and other have previously reported that dihydroxy bile acids and
chenodeoxycholic acid (CDCA) in particular stimulate PKCalpha isoform activation not only
in hepatocytes but also in non-hepatic cells, while other have reported activation of p38
MAPK by bile acids. The aim of the present study was to determine whether the increase
expression and activity of p38 was PKCalpha-dependent. Methods: Human dermal fibroblasts
were cultured under standard conditions. mRNA and protein expression levels were measured
by RT-PCR and Western Blotting, respectively. PKCalpha translocation and activation was
determine both by Western blotting and fluorescent microscopy. Results: CDCA stimulated
PKCapha translocation and activation in a time-and dose-dependent manner. The maximum
translocation to the plasma membrane was observed in around 60 min with 50 microM
CDCA. Furthermore, CDCA stimulated both PKCalpha and p38 MAPK phosphorylation
with a maximum observed at 60 to 150 min. Furthermore, CDCA stimulate p38 MAPK
protein expression by around 4-5 fold with 100 microM. Both PKCalpha DN mutant and
Gö6976 reduced the basal by ~20% and the CDCA-induced p38 MAPK protein expression
by over 80%. PKCalpha WT over expression increased basal p38 MAPK expression by over
5 fold and that induced by CDCA by another 1.5-2 fold. Conclusion: The results of the
present study underline a CDCA-induced PKCalpha-dependent increased protein expression
and activation of p38 MAPK. Since the skin is one of the major non-hepatic organs that
accumulate bile acids in cholestatic liver diseases and that both PKCalpha and p38 MAPK
are involved in cell proliferation and apoptosis, this study highlights the possible association
of bile acids and skin cancer under pathological conditions that lead to the accumulation
of bile acid in the skin.
W1525
High Expression of the EGFR and Phosphorylation of STAT3 On Tyrosine 705
in a Series of Colorectal Carcinoma, a Possible Link with Activated P60c-SRC
Gaetan Des Guetz, Christine Lagorce, Ali Tadlaoui Hbibi, Jean-Francois Morere, Jean-Luc
Breau, Philippe Wind, Antoine Martin, Bakthiar Bejou, Remi Fagard, Robert Benamouzig
Introduction The cellular kinase p60c-src belongs to the family of non receptor tyrosine
kinases. Src synergises with the EGF receptor (EGFR) and is required for the activation of
STAT transcription factors. We previously observed in a series of colorectal cancers that the
EGFR is overexpressed and phosphorylated on tyrosines, and that STAT3 is phosphorylated
on tyrosine 705, both parameters being correlated. This work was undertaken to determine
the relationship between active (tyrosine 416-phosphorylated) p60c-src,the expression of
EGFR, the phosphorylation of STAT3 and the clinicohistological parameters in a series of
115 colorectal cancers. Materials and Methods Inclusion blocks from 115 colorectal cancers
were used. For each tumor, four cores, 0.6 mm in diameter, were punched in donor
blocks and arrayed into the recipient paraffin block using a tissue arrayer device (Beecher
Instruments). Tissue arrays were then labeled with the anti- phosphotyrosine 416-Src -
antibody (Cell Signaling, USA). The labeling was then graded as follows: 0, no positive cells;
1, 1-25% labeled cells; 2, 25-50% labeled cells; 3, > 50% labeled cells. A composite score,
ranging from 0 to 9, was obtained by multiplying the grade by the intensity. Univariate
analysis was conducted to determine the associations between the levels of P-STAT3, EGF-
R and P-EGF-R and the clinicohistological parameters. Results An high level of activation
of Src (P-tyr-416) was observed in 86 % of the cases of colorectal cancer. Labeling was
cytoplasmic from moderate to high intensity in 61% of the cases. There was no significant
relationship between the tyr-416 phosphorylation of Src, the clinicohistological parameters
and the survival of patients. There was a significant correlation between the activated form
of Src, the expression of EGFR (p = 0.008) and the tyrosine 705 phosphorylation of STAT3
(p = 0.002). Conclusion Our observation of a frequent detection of activated Src in colorectal
cancer and its correlation with the elevated expression of EGFR and the phosphorylation
of STAT3 on tyrosine 705 is in line with the synergy between Src and the EGFR and their
activation of STAT3 in tumor cell lines. This correlation confirms the implication of Src in
human colorectal cancer and suggests possible mechanisms involving the EGFR and STAT3.
The consequences of Src activation may affect the proliferation or other aspects of cell
behavior such as adhesion and migration ultimately regulating metastasis.
W1526
The Combinatorial Biological Effects of EGFR Overexpression, hTERT
Activation and P53 Mutation Result in Malignant Transformation with the
Induction of MMP-9 in a Novel Organotypic Culture Model
Takaomi Okawa, Claudia Andl, Carmen Michaylira, Hiroshi Nakagawa, Munenori
Takaoka, Cameron Johnstone, Therese Deramaudt, Yuting Chen, Ben Rhoades, Wafik S.
El-Deiry, Anil K. Rustgi
Introduction: The molecular basis for malignant transformation in different types of epithelia
is dependent upon the cellular and tissue microenvironment context. The stratified squamous
epithelium is the most common type of epithelium in the human, and cancers that arise in
this epithelium are common. Indeed, tumor cell migration and invasion is influenced by
the cross talk between the epithelium and mesenchymal compartment. Methods: Primary
human esophageal cells were retrovirally transduced individually and in combination with
EGFR, hTERT and/or a dominant-negative p53R175H, reflecting common genetic alterations
in esophageal cancer. These cells were subjected to migration (Boyden chamber) and Matrigel
invasion assays. In order to mimic the tissue or tumor microenvironment, the genetically
altered epithelial cells were grown on a matrix comprising type I collagen and Matrigel.
Exposure to a liquid-air interface induces epithelialization (hence, organotypic culture) and
phenotypes can be assessed by histopathology and immunohistochemistry. In addition, the
conditioned media was analyzed by gelatin and casein zymography in order to determine
matrix metalloproteinase (MMP) activity. Results: The specific combination of EGFR over-
expression, telomerase activation and mutant p53 resulted in a statistically significant increase
in cell migration and invasion, compared to controls or with 1 or 2 genetic alterations.
Organotypic culture revealed a dramatic phenotype that precisely recapitulated malignant
human esophageal squamous cell cancer with a severely dysplastic epithelium, invasive
malignant cells into the matrix, and “pearl” formation (a marker of well-differentiated tumors).
Given there was evidence of proteolytic activity of mesenchymal fibroblasts and invading
cancer cells, gelatin zymography revealed induction of active MMP-9, but not MMP-2.
Importantly, the invasive esophageal cancer cells were abolished with an MMP-9 inhibitor.
Conclusions: In aggregate, we have established a model in which important genetic alterations
(EGFR overexpression, telomerase activation and p53 mutation) conspire to recapitulate
faithfully the cardinal features of invasive, malignant esophageal squamous cell cancer.
Invasion through the extracellular matrix is facilitated by the induction of MMP-9, and
which can be reversed with an MMP-9 inhibitor. Apart from the mechanistic insights gained,
such a model permits the testing of therapeutic drugs that exert their actions on specific
targets of molecular pathways critical in malignant transformation and invasion in the local
tumor microenvironment.
T : 89386$$CH2
05-04-06 23:18:32 Page 675Layout: 89386B : o
A-675 AGA Abstracts
W1527
Inhibiting Trefoil Factor Family-3 (TFF3) Expression Decreases Colon Cancer
Cell Invasiveness
Christina Twyman, Yio Xianyang, Yan Zheng, Jie-Yu Zhang, Matthew Diamond, Mark
Babyatsky, Lawrence Werther, Steven Itzkowitz
Background: Trefoil factor family-3 (TFF3) is a small peptide expressed by intestinal epithelial
cells which contributes to mucosal healing by promoting epithelial cell migration and
inhibiting apoptosis. We previously demonstrated that rat colon cancer cells that natively
express TFF3 (LN cells) have a more aggressive phenotype in vivo and in vitro compared
to their TFF3-negative counterpart (LP cells) (Clin Exp Metastasis 22:157, 2005). Stable
transfection of the non-aggressive LP cells with TFF3 caused them to become more aggressive.
Inhibiting TFF3 expression would provide more direct evidence of the role of TFF3 in
cancer cell behavior. Aim: To determine the effect of inhibiting TFF3 expression on colon
cancer cell invasion, a hallmark of cancer cells. Methods: Two rat TFF3-specific siRNA oligos
(si365 and si78) and a scrambled siRNA oligo (negative control) were generated. LN (native
TFF3 expression) and LP-CRI cells (stably expressing TFF3) were transfected with the siRNA
oligos. Expression of TFF3 was analyzed by RT-PCR. Cell invasion assays were performed
using modified Boyden chambers with reconstituted basement membrane (Matrigel) barriers.
Results: Introducing either TFF3-specific siRNA into LN cells decreased expression of TFF3
RNA by RT-PCR. In LN cells, compared to scrambled siRNA controls, si365 resulted in a
44% decrease in invasion (p=0.01), and si78 reduced invasion by 53% (p=0.01) (Table).
In LP-CRI cells, there was a decrease in invasion of 50% (p=0.03) and 74% (p=0.01),
respectively. Conclusions: The decreased invasion caused by inhibiting TFF3 suggests that
TFF3 contributes to the malignant behavior of colon cancer cells. Future studies will confirm
this effect using an in vivo animal model and determine the signal transduction pathways
involved.
Number (Standard Deviation) of Invading Cells
*p=0.01 vs. scrambled control **p=0.03 vs. scrambled control
W1528
Cross-Talk Between ELF and HFE Is Important in Suppression of
Hepatocellular Carcinoma
Yi Tang, Varalakshmi Katuri, Ruihong Wang, Wilma Jogunoori, Tapas Saha, Chu-Xia
Deng, David J. Brandhagen, Anton Sidawy, Bibhuti Mishra, Lopa Mishra
Hereditary hemochromatosis is associated with an increased risk for hepatocellular carcinoma
(HCC). The risk had been estimated to be as high as 200-fold increased. The Biological
signals for transforming growth factor beta (TGF-β) play diverse and essential roles in cell
proliferation and liver development. Precise modulation of TGF-β is through Smad activation
by the type I receptors, and is dependent upon adaptor proteins such as ELF, a β-spectrin.
Recently, we uncovered a novel role of TGF-β/Smad4 in regulating intestinal iron transport
and iron homeostasis. Interestingly, we also found an increased incidence of hepatocellular
cancers in elf+/- mutant mice. Aims: To determine the role of ELF and HFE in cell proliferation
and HCC suppression. Methods and Results: 1. Prussian Blue staining results showed
slightly increased level (+) of iron in elf+/- mutant muse HCC tissues when compared to the
wildtype normal liver tissues. 2. Microarray results demonstrated Transferrin (TF) transcrip-
tion is downregulated by two and half fold (p=0.05) in elf-/- mouse embryonic fibroblasts
(MEF) when compared to the normal MEFs. Incontrast, Ferritin transcription is increased
one and half fold (p=0.04) in elf-/- mutants. Other genes involved in iron transport and
metabolism such as Hfe, Hepcidin, Ferroportin, TFR2, TFRC, Ireg, Dcytb, Dmt, Nramp and
Mtp did not show a significant change in transcription in elf-/- mutants. 3. Realtime RT-PCR
showed a decreased expression of elf and Hfe in fifty percent of hereditary hemochromatosis
patient samples, which carry HFE point mutations at C282Y. 4. Co-immunoprecipitation
results demonstrated endogenous association of ELF with HFE upon TGF-β treatment.
Confocal microscopy studies further confirmed colocalization of ELF and HFE. 5. Further-
more, we found p21 expression is dramatically decreased in the hereditary hemochromatosis
patient samples that demonstrated decreased ELF and HFE expression. Conclusions: Our
results show that the HFE interacts with ELF potentially regulating hepatocyte proliferation.
The disruption of ELF by HFE regulates p21 expression through the TGF-β/ELF signaling
and thus inhibits cell cycle progression and cell proliferation. Loss of TGF-β/ELF function
could result in the increased risk of HCC in the hereditary hemochromatosis patient carrying
Hfe mutations.
W1529
Missense Mutation of the P53 Gene in Lugol-Unstained Esophageal Lesions
with Non-Dysplastic Epithelium in Esophageal Cancer-Free Patients
Kazuhiro Kaneko, Atsushi Katagiri, Toshinori Kurahashi, Hiroaki Ito, Taikan Yamamoto,
Yosuke Kumekawa, Meiko Kuwahara, Takashi Muramoto, Yutaro Kubota, Michio Imawari
Background & Aims: Mutations of the p53 gene are detected frequently in the early stages of
esophageal cancer. It is unclear whether Lugol-unstained lesions (LULs) with non-dysplastic
epithelium (NDE) are precursors of esophageal squamous cell carcinoma (ESCC). Character-
ization of human esophageal precancerous lesions at the molecular level is of critical import-
ance to our understanding of the etiology of this disease and to the identification of useful
biomarkers for prevention studies. To investigate whether Lugol-unstained lesions (LULs)
with non-dysplastic epithelium (NDE) were related to the carcinogenesis of esophageal
squamous epithelium or not, the p53 mutational status in LULs-NDE was analyzed prospect-
ively. Methods: Videoendoscopy with Lugol staining was performed prospectively in 542

















ml of 2.0% glycerin-free Lugol’s iodine solution was sprayed from the gastroesophageal
junction to the upper esophagus using a plastic spray catheter passed through the biopsy
channel of the endoscope. Lugol-unstained lesions were detected in 103 patients (19%). A
total of 255 samples, including 152 Lugol-unstained lesions (NDE, 137; dysplasia, 15) and
103 paired normal-samples of normal staining epithelium, were obtained for biopsy from
103 patients. DNA was extracted from 20-µm thick sections obtained from archival blocks
of formalin fixed and paraffin embedded tissue. After polymerase chain reaction analysis,
direct sequencing was used to detect p53 gene mutations in exon 5 to 8. Results: All samples
of LULs-NDE had esophagitis, while 78% of the 103 normal Lugol-staining epithelium
samples had esophagitis and 22% had normal epithelium. A mutation in the p53 gene was
detected in 5 of 137 samples with LUL-NDE (4%) and 5 of 15 samples with dysplasia
(33%). A “hotspot” mutation was found in 20% of LULs-NDE with p53 mutation and in
40% of dysplasia with p53 mutation. The hotspot mutations of LULs-NDE and samples
with dysplasia were found at codon 273 and codon 175, respectively. In contrast, no p53
mutations were found in NDE samples with normal Lugol-staining, although approximately
80% of the normal Lugol-staining epithelium samples had esophagitis. Conclusions: In
biopsy samples from esophageal cancer-free individuals, a hotspot mutation in the p53 gene
was found in non-dysplastic epithelium that was identified as a Lugol-unstained lesion. The
findings suggest that some Lugol-unstained lesions with non-dysplastic epithelium may
represent the earliest initial lesions in the carcinogenesis of esophageal squamous epithelium
in our Japanese individuals.
W1530
Increased Susceptibility to Gastric Cancer Formation in Mice with Transgenic
Cyclooxygenase-2 Overexpression
Wai K. Leung, Kai-Chun Wu, Christine Y. Wong, Arthur Ching, Anthony W. Chan,
Minnie Y. Go, Jun Yu, Xin Wang, Yl Chui, Dm Fan, Joseph J. Sung
Background: Cyclooxygenase-2 (COX-2) overexpression is frequently detected in gastric
cancer. We have previously shown that inhibition of COX-2 suppresses gastric cancer
formation in animals [Hu, Gut 2004]. However, the effects of forced COX-2 overexpression
on gastric carcinogenesis remain unknown. Methods & Results: COX-2 transgenic mice
were developed in C57/BL6 strain using the full length cloned human cox-2 cDNA construct.
Integration of transgene was verified by PCR of tail genomic DNA. The transgenic mice line
with high COX-2 expression in gastric epithelium was selected for subsequent experiments.
To study the effects of COX-2 overexpression in gastric cancer formation, mice were exposed
to gastric carcinogen N-methyl-N-nitrosourea (MNU). Six-week-old COX-2 transgenic or
wild type (WT) mice were divided into four groups to receive MNU or vehicle alone. MNU
(240 μg/L) were given to mice ad libitum as drinking water in five alternating cycles of 1-
week MNU and 1-week normal distilled water. All mice were sacrificed at the end of 50-
week. Stomach was harvested and examined macroscopically and microscopically for the
presence of invasive cancer. Whilst COX-2 was expressed in very low level in the stomach
of WT mice, high level of COX-2 expression in gastric epithelium was confirmed in the
stomach of transgenic mice by both western blot and immunohistochemistry. Gastric cancer
was found in 17/29 (58.6%) transgenic mice and 4/33 (12.1%) WT mice at the end of 50-
week (RR = 4.84, 95% CI 1.84 to 12.74, P = 0.0001). None of the WT and transgenic mice
treated with water alone developed gastric cancer. There was no premalignant gastric lesion
noted in all animals. In normal gastric mucosa, we found no significant difference in the
apoptotic and proliferation index between WT and transgenic mice. However, there was a
marked increase in expression of angiogenic factor VEGF in the normal gastric mucosa of
transgenic mice which is sparsely detected in WT mice, suggesting induction of angiogenic
factors may play an important role on the cancer susceptibility of COX-2 transgenic mice.
Conclusion: Our results suggest that COX-2 overexpression alone is insufficient for gastric
tumor induction, but rather increase the susceptibility to gastric cancer formation induced
by carcinogen.
W1531
In Vivo and in Vitro Evidence for Epithelial to Mesenchymal Transition (EMT)
in Oesophageal Adenocarcinoma
Jonathan R. Rees, Benjamin A. Onwuegbusi, Vicki E. Save, Derek Alderson, Rebecca C.
Fitzgerald
Background: Local invasion and metastasis occur early in the pathogenesis of oesophageal
adenocarcinoma (AC) and result in poor long term outcome even with radical therapy.
Epithelial to mesenchymal transition (EMT) has been shown to play a role in the aggressive
behaviour of cancer, however data is lacking for AC. EMT is driven by a number of
mechanisms and TGFβ1, a cytokine family member has been implicated in this process.
Aims: 1. Determine whether there is in vivo evidence for EMT in AC. 2. Develop an in vitro
model system for EMT in AC in order to elucidate the signalling pathways involved, deduce
whether EMT can be reversed and identify the functional significance of these changes.
Methods: 167 tumours were screened, and sections with both an invasive component and
a central tumour area were identified n=10. Immunohistochemical characteristics of epithelial
(E-cadherin, cytokeratin 18) and mesenchymal (vimentin, α-smooth muscle actin) markers
were compared at the invasion front and within the tumour in 10 tumours. Following
TGFβ1 (0-5ng/ml) treatment of TE7 oesophageal adenocarcinoma cells, phenotypic and
molecular changes were assessed using phase contrast microscopy, immunofluorescence and
real-time RT-PCR. The activation of cell-signalling pathways (AKT, MAPK, SMAD2, SMAD3,
SIP1, snail) were assessed by real-time RT-PCR and western blotting. Functional treatment-
effects were assessed using wound healing, invasion, slow aggregation and time-lapse motility
assays. We further assessed whether BMP-7 a recognised antagonist of TGFBβ1 signalling
and SMAD4 RNAinterference could reverse EMT. Results: At the invasive margin there was
down-regulation of epithelial markers and up-regulation of mesenchymal markers, with
evidence of increased TGFβ1 expression at the invasive margin. TGFβ1 induced similar
molecular expression changes in vitro (p<0.05) and these changes were accompanied by a
change from an epithelial to a mesenchymal morphology. BMP7 treatment reversed these
changes, causing re-expression of epithelial markers (p<0.05) and return to an epithelial
morphology. These changes were mediated via canonical TGFβ1 signalling with concomitant
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up-regulation of SIP1 (P<0.05). Alterations in wound healing, invasion, aggregation and
cell motility parameters following TGFβ1 were consistent with a more invasive phenotype
(p<0.005) and these changes were reversed by both BMP7 treatment and SMAD4 RNAi.
Conclusions: EMT may be relevant in oesophageal carcinogenesis and targeting TGFβ1 signal-
ling pathways may offer potential therapeutic opportunities and require further investigation.
W1532
Colorectal Cancer (CRC) Chemoprevention By Polyethylene Glycol (PEG)
Involves Inhibition of Mucosal Hyperproliferation Via Modulation of Snail/β-
Catenin Signaling
Ramesh K. Wali, Dhananjay P. Kunte, Jennifer L. Koetsier, Hemant K. Roy
Experimental and epidemiological studies indicate that PEG is one of the best chemopreven-
tive agents against CRC. [Can Epi Bio & Prev, 2003]. However; its precise molecular mechanism
is unclear. Previously we have shown that E-cadherin induction, with concomitant suppres-
sion of β-catenin activity by membrane sequestration [Can Let, 2005], are important molecular
events of chemoprevention. While the mechanism of E-cadherin induction has not been
well explored, we have demonstrated that the transcriptional repressor SNAIL is increased
in most CRCs [Dig Dis & Sci, 2005] resulting in diffuse mucosal hyperproliferation [Mol Can
Ther, 2004]. In this study, we assess the role of SNAIL/E-cadherin/β-catenin axis in the
chemopreventive activity of PEG. Methods: 75 Fisher rats were randomized into 3 groups.
Group 1 was injected saline and 2&3 AOM (20 mg /kg/ week x 2). Two wks later, group
3 was switched to PEG-8000 (5 mg/100g) supplemented diet. After 30 weeks colons were
removed, ACF and uninvolved crypts biopsied and protein profile analyzed by IHC and
Western blot. Results: PEG blocked the AOM-induced increase in the number of larger
ACFs (by 64%; p< 0.001), BrDu labeling (by 78%; p< 0.001) and Cyclin D1 expression (by
53%; p<0.001). While total β-catenin was unchanged, PEG reduced its nuclear localization in
ACF (50%; p< 0.05). PEG blocked AOM-induced loss of E-cadherin (p< 0.01) by inhibiting
SNAIL (p< 0.05). Similarly, in HT-29 cells treated with 5% PEG, there was a 50% decrease
in PCNA (proliferation marker), 43% decrease in β-catenin/Tcf activity (TOPflash luciferase
activity; p< 0.05), 70% increase in E-Cadherin expression and 52% decrease in SNAIL
mRNA level. In conclusion, these studies demonstrates that PEG-mediated antiproliferative
activity involves induction of E-cadherin and decrease in β-catenin activity, Snail and Cyclin
D1 expressions.
Effect of PEG on SNAIL/β-Catenin Pathway
W1533
Proteomic Dissection of the Molecular Mechanisms Underlying Hepatic
Metastasis in Colorectal Cancer
Fensong Wang, Xia Ding, Fang Wu, Zhiyou Fang, Zhihong Yang, Yong Chen, Helen Kim,
Xuebiao Yao
Colorectal cancer currently accounts for 11% of all cancers in the United States with 135,000
new cases each year and is the second leading cause of cancer-related death, with the majority
of deaths attributable to hepatic metastases. While surgical resection offers the best chance
for long-term survival and potential for cure, few patients are deemed candidates for resection
due to late-stage diagnosis. A better understanding of the molecular events of colorectal
hepatic metastasis may lead to improved screening and treatment options for these patients.
To delineate the molecular mechanisms underlying liver metastasis, we carried out proteomic
analyses of a primary colon cancer cell line paired with liver metastatic cell lines. The protein
expression patterns of these paired cell lines were analyzed in same gel using DIGE system.
Proteins differentially displayed in the region of molecular masses of 21-200 kDa with
isoelectric point of 3-10 were isolated, proteolyzed and finger-printed using MALDI-TOF
and LC-MS/MS mass spectrometries. Ninety-seven spots corresponding to 63 different pro-
teins served as “landmarks” for hepatic metastasis. The potential modification sites were
pinpointed using LC-MS/MS, which revealed potential phospho-regulation of 13 proteins.
The identified proteins included cytoskeletal proteins (i.e., ezrin; IQGAP1; Arp2/3), proteins
involved in signal transduction (i.e., mTOR, S6K1, WWOX), cell proliferation and differenti-
ation (i.e., numatrin, beta-catenin, UPLC), and metabolism (i.e., FOXO). Using a combination
of siRNA-mediated protein knock-down with invasion assay, we confirmed that overexpres-
sion of 37 proteins among the list promotes the invasive activity. Currently, we are evaluating
the role of these proteins in hepatic metastasis in immunodeficient mice using biolumines-
cence imaging.
W1534
HMG A1 Gene: A Novel Therapeutic Target for Pancreatic Adenocarcinoma
Siong-Seng Liau, Stanley W. Ashley, Edward E. Whang
Background: Pancreatic adenocarcinoma has an overtly malignant phenotype. The high
mobility group A1 (HMGA1) proteins are architectural nuclear proteins which play important
roles in regulating gene expression. We hypothesize that HMG A1 is a determinant of
malignant phenotype of pancreatic adenocarcinoma. Methods: We studied highly invasive
pancreatic adenocarcinoma cell lines, MiaPaCa2 (low expression of HMGA1), BxPC3 and
PANC1 (overexpression of HMGA1). Two independent RNA interference (RNAi) methods
were used: short interfering RNA (siHMGA1) and short-hairpin RNA (shHMGA1) expression
plasmids targeting HMGA1 gene. Stable shRNA expressing cell lines were developed.
HMGA1-overexpressing MiaCaPa2 clones were developed following stable transfection with
HMGA1 cDNA vector. Effect of silencing HMGA1 on cellular expression of carcinoembryonic-
antigen related cell adhesion molecule 6 (CEACAM6), a determinant of pancreatic adenocarci-
noma invasiveness, was determined using Western analysis. Cellular invasiveness was assayed
using modified Boyden chambers. Matrix metalloproteinase 9 activity assay was used. Akt
kinase activity assay was performed using GSK-3 phosphorylation assay. Anchorage-inde-
pendent growth in soft agar was assessed. Stable transfectants of shRNA were subcutaneously
xenografted into nude mice and tumor growth was monitored weekly. Results: Using both
RNAi techniques, we achieved 55-90% silencing of HMGA1 protein expression when com-
pared to controls (scramble siRNA or shRNA) (p<0.05, based on densitometry). Both
siHMGA1 and shHMGA1 transfected MiaPaCa2 and PANC1 cells showed significantly lower
invasive capacity compared to controls (60-84% reduction vs. controls, p<0.05). MiaPaCa2
and PANC1 cell lines stably expressing shHMGA1 have significantly reduced MMP9 activity
(p<0.05). In both MiaPaCa2 and PANC1 cell lines, there was a significant reduction in Akt
kinase activity in shHMGA1 stable transfectants (p<0.05). Silencing of HMGA1 significantly
attenuated the ability of MiaPaCa2 and PANC1 cells to form soft agar colonies (p<0.05).
Cellular expression of CEACAM6 was reduced in MiaPaCa2 and BxPC3 with silencing of
HMGA1. Forced overexpression of HMGA1 in MiaPaCa2 resulted in significantly elevated
levels of CEACAM6 and MMP9 expression (p<0.05, based on densitometry). In nude mouse
xenograft models, silencing HMGA1 significantly inhibited the growth of subcutaneous
tumors (p<0.05). Conclusions: HMG A1 plays a role in inducing tumor invasion and growth.
This is in part modulated by CEACAM6 expression, Akt and MMP9 activity. HMGA1
represents a novel therapeutic target for pancreatic cancer, warranting further investigation.
W1535
Overexpression of Angiopoietin-2 Enhances Angiogenesis and Lymphatic
Spread in Pancreatic Neuroendocrine Tumors
Svenja Rieke, Annett Rexin, Petra Schulz, Sandra Rudloff, Sonja Vollmer, Peter Hauff,
Michael Schirner, Bertram Wiedenmann, Stefan Rosewicz, Arne Scholz
Introduction: Angiopoietin-(Ang)-2 acting through the endothelial tyrosine kinase Tie-2 has
been implicated in the regulation of tumor associated angiogenesis. To date, no data are
available about the expression and biological significance of Ang-2 in well vascularized
human pancreatic neuroendocrine tumors (NET). We addressed this question by analyzing
human NET specimens and by experimental overexpression of Ang-2 in a novel orthotopic
xenograft mouse model. Methods: 10 surgical specimens of human pancreatic NET and 8
benign pancreatic specimens were analyzed for Ang-2- and Tie-2 expression by in situ
hybridization and immunohistochemistry, respectively. The human pancreatic NET cell line
BON was stably transfected with Ang-2 cDNA or empty expression vector (mock control).
3 Ang-2 expressing clones and 3 mock clones with comparable growth characteristics (Alamar
blue assay) were selected for orthotopic injection into the pancreas of immunodeficient mice
(9-11 mice per clone). Evaluation of the biological effects in vivo was based on tumor
weight, metastatic spread (macroscopically suspect lesions, human cytokeratin staining, PCR
for human chromosome 17 DNA), serum human Ang-2 levels (ELISA) and microvessel
density (CD34 staining). Results: Endothelial cells of malignant as well as benign human
pancreatic tissues expressed both, the Tie-2 receptor and small amounts of Ang-2 mRNA.
In sharp contrast, expression of Ang-2 mRNA in epithelial cells was found exclusively in
the NET tumor samples. When overexpressed in Bon cells, Ang-2 neither affected the
proliferation of tumor cells in vitro nor the weight of orthotopic Bon tumors in vivo. However,
animals bearing Ang-2 clones exhibited significantly higher serum Ang-2 levels, confirming
successful expression in vivo. Analysis of metastatic spread in these mice based on visual
detection of macroscopically suspect lesion and subsequent confirmation via the presence
of human cytokeratin revealed metastases in 25% of the Ang-2 tumor mice versus 8 % of
animals bearing mock transfected clones. In good agreement, Ang-2 enhanced the lymphatic
spread of tumor cells into abdominal lymph nodes as evidenced by more frequent PCR
amplification of human microsatellite DNA. The increased metastatic potential of Ang-2
overexpressing tumors was associated with a significant induction of the microvessel density.
Conclusion: De novo expression of Ang-2 in human pancreatic NET promotes angiogenesis
and lymphatic spread and thus defines a novel clinically relevant pathomechanism. Interfer-
ence with the Ang-2 /Tie-2 pathway may represent an attractive therapeutic strategy in this
well vascularized tumor entity.
W1536
SRC-Dependent PI 3-Kinase Activation in Response to Extracellular Pressure
Is Required for AKT and FAK Activation and FAK Translocation to the Cell
Membrane: A Mechanism for Pressure-Stimulated Cell Adhesion
Vijayalakshmi Thamilselvan, David H. Craig, Marc D. Basson
BACKGROUND: Physical force induced inside-out signals may regulate tumor cell adhesion
and metastasis. In particular, increased extracellular pressure stimulates integrin-mediated
adhesion via FAK and Src, but how such signals modulate adhesion is not known. Since
the PI 3-kinase/Akt signal pathway has been implicated in tumorigenesis, invasion and
metastasis, we sought to evaluate the effect of pressure on PI 3-kinase and Akt and the
interaction of these signal proteins with FAK and Src. METHODS: We subjected suspended
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SW620 colon cancer cells to 15mm Hg increased pressure for 30 minutes. We studied
adhesion to collagen I, PI 3-kinase activity, tyrosine phosphorylation of the PI 3-kinase p85
subunit, Akt phosphorylation at Ser473, and Akt membrane translocation. In some studies,
we inhibited PI 3-kinase by LY294002, Akt by Akt inhibitor IV or siRNA to Akt1, Src
kinases by PP2 or FAK by siRNA, with appropriate vehicle controls or non-targeting siRNA.
We also evaluated the interaction of the p85 subunit of PI 3-kinase with FAK and Src
by coimmunoprecipitation, and FAK distribution by subcellular fractionation. RESULTS:
Increased pressure (15mm Hg) for 30 minutes stimulated colon cancer cell adhesion and
this effect was completely blocked by PI 3-kinase or Akt inhibition or 50% Akt1 reduction
by specific siRNA (n>3; P<0.05 for all). Pressure significantly increased PI 3-kinase activity,
tyrosine phosphorylation of the p85 subunit, Akt phosphorylation at Serine 473 and Akt
translocation to the membrane fraction (n>3, P<0.05 all). Pressure-induced PI 3-kinase
activity and Akt phosphorylation were completely blocked by the Src inhibitor PP2 or by
the PI 3-kinase inhibitor LY294002. Reducing FAK protein using specific siRNA did not
affect pressure-induced PI 3-kinase activity but completely blocked Akt phosphorylation.
Interaction of the p85 subunit with Src and FAK was significantly increased by pressure,
based upon coprecipitation studies. Extracellular pressure also stimulated FAK translocation
(32.0±1.0%; n>3; P<0.05) to the membrane and this effect was blocked by Akt inhibitor
IV and by PP2. CONCLUSIONS: These results suggest that pressure-induced FAK and Src
are important cofactors for PI 3-kinase dependent Akt phosphorylation. Src acts as an
upstream regulator of PI 3-kinase in this pathway. PI 3-kinase associates with Src and FAK,
activating FAK and Akt, and eventually inducing translocation of cytosolic FAK and Akt to
the membrane, where the translocated FAK may upregulate integrin binding affinity or
facilitate integrin clustering. This novel pathway may play a significant role in integrin-
mediated colon cancer metastasis.
W1537
Biphasic Alteration of Caveolins and Its Implication in the Malignant
Progression of Human Gastric Carcinoma
Hyo Jong Kim, Sung-Gil Chi, Jae Young Jang, Kwang Ro Joo, Seok Ho Dong, Byung-Ho
Kim, Young Woon Chang, Il Joung Lee, Rin Chang
Background & Aims: Reduced expression of caveolin-1 (Cav-1)has been observed in many
types of human malignancies. However, elevated expression of Cav-1 was also identified to
correlate with increased metastatic progression of some cancers. We investigate caveolin
alteration in human gastric tumorigenesis. Methods:We characterized the expression and
mutational status of Cav-1 and Cav-2 in a series of gastric cancer cell lines and tissue specimens
using quantitative RT-PCR, Western blot, and PCR-SSCP analysis. Results: Expression of
Cav-1 and Cav-2 transcripts was detectable in all normal and benign tissues. In contrast,
absence or extremely low levels of Cav-1 and Cav-2 transcript were detected in 40% (6 of
15) of cancer cell lines while high levels of expression were found in 47% of cell lines. All
of the 4 cell lines originated from primary cancers exhibited loss or reduction of Cav-1 and
Cav-2 expression whereas 7 of 11 (64%) cell lines derived from metastasized lesions showed
elevated expression, raising the possibility that high level of caveolin expression provides
tumor cells with a advantage for metastatic progression of gastric cancer. Consistent with
cell lines, 43% (36 of 84) of primary carcinomas showed downregulation of Cav-1 and Cav-
2 expression while 14% of tumors exhibited strong expression of both genes. Mutational
analysis revealed that genomic deletion of caveolin genes is infrequent but some tumor cells
harbor missense mutations in Cav-1 or Cav-2. Expression of Cav-1 and Cav-2 was reactivated
in nonexpressor cells by 5-aza-dC treament, and bisulfite DNA sequencing analysis revealed
that hypermethylation of the promoter CpG islands is associated with altered expression of
Cav-1. Whereas proliferation and colony forming ability of Cav-1-negative tumor cells was
suppressed by restoration of wild-type Cav-1. Likewise, blockade of Cav-1 function in
Cav-1-overexpressing cells by DN-Cav-1 (P132L) or siRNA-mediated knockdown of Cav-
1 expression led to a significant inhibition of tumor cell adhesion to endothelium. Conclusion:
Our data suggest that caveolin expression might suppress early stage tumor growth but its
increased expression can enhance invasive or metastatic progression of the cells.
W1538
Tumor Cells Induce MMP-9 Synthesis in Rat Pancreatic Stellate Cells -
Potential Role of Emmprin
Martin Mehrlaender, Gisela Sparmann, Robert Jaster, Heike Weber, Stefan Liebe, Joerg
Emmrich
Background & aims: It is generally accepted that pancreatic stellate cells (PSC) are decisively
involved in extracellular matrix (ECM) turnover. In addition to ECM components, PSC
synthesize matrix metalloproteinases (MMP). The extracellular matrix metalloproteinase inducer
(EMMPRIN), a transmembrane glycoprotein preferentially expressed on tumor cells, has
been reported to be a candidate in stimulating the expression of MMP in adjacent fibroblastic
cells. The aim of the present study was to investigate the expression of MMP-2 and -9 in
PSC in response to pancreatic cancer cells and the potential role of EMMPRIN. Methods:
Primary PSC were obtained by collagenase digestion of rat pancreata and subsequent density
gradient centrifugation. Cultured PSC were incubated with tumor cell membrane vesicles
(TCMV) obtained by homogenization and subsequent differential centrifugation from the
rat pancreatic tumor cell lines DSL-6A and AR42J. After co-incubation with TCMV, the
expression of MMP-2 and -9 in PSC was analyzed on RNA- as well as protein level by
competitive RT-PCR and zymography, respectively. Membrane vesicles were used to prevent
contamination of PSC samples with RNA and/or proteins released from metabolically active
tumor cells. EMMPRIN expression was investigated by immunocytochemistry and Western
blotting. To abolish EMMPRIN glycosylation, vesicles were prepared from tunicamycin-
treated tumor cell lines. Studies on signal transduction pathways were performed using
Western blot analysis and specific inhibitors. Results: Western blot analysis of tumor cell
lysates as well as of TCMV showed heterogeneous EMMPRIN patterns indicating a differential
glycosylation of the molecule. Co-incubation with TCMV resulted in a clear induction of
MMP-9 in PSC on RNA- as well as on protein level. In contrast, MMP-2 expression remained
unchanged. The intracellular signal cascade in response to TCMV incubation included the

















cells. Deglycosylation of EMMPRIN resulted in an inactive protein conformation with respect
to MMP regulation and consequently, TCMV-mediated effects on PSC were reduced. Conclu-
sion: Our results suggest that glycosylated transmembrane EMMPRIN of pancreatic cancer
cells regulated the expression of MMP-9 in stellate cells. This mechanism may be substantially
involved in the crosstalk between malignant cells and PSC facilitating tumor cell invasion
and metastasis.
W1539
Prostaglandin E2-EP4 Receptor Signalling Promotes Tumorigenic Behaviour of
HT-29 Human Colorectal Cancer Cells Via cAMP and ERK Signalling
Gillian Hawcroft, Stanley C. Ko, Mark A. Hull
Background & Aims: Prostaglandin (PG) E2 is the predominant pro-tumorigenic product
of the cyclooxygenase (COX) pathway in the human colon. Signalling by PGE2 occurs via
four G protein-coupled receptors termed EP1-4. Preliminary in vitro evidence has implicated
the EP4 receptor in the pro-tumorigenic activity of PGE2 on human colorectal cancer (CRC)
cells. The objective of this study was to further investigate the role of the EP4 receptor in
PGE2 signalling in human CRC cells. Methods: A model of stable human EP4 receptor
over-expression in HT-29 human CRC cells (HT-29-EP4) was used to investigate the role
of the EP4 receptor in diverse effects of PGE2 on HT-29 cell behaviour such as resistance
to apoptosis and anchorage-independent growth. The role of the EP4 receptor was confirmed
using the EP4 receptor antagonist ONO-AE3-208 (EP4A). Results: PGE2 (1 μM) induced
resistance to spontaneous apoptosis and increased anchorage-independent growth in HT-
29-EP4 cells but not control transfected (HT-29-con) cells. In addition, EP4A increased
apoptosis of HT-29-con cells which express low levels of endogenous EP4 receptors. PGE2
(1 μM) increased intracellular cAMP levels in HT-29-EP4 cells but not in HT-29-con cells.
This was associated with phosphorylation of cAMP-response element binding protein (CREB),
and PKA-dependent extracellular signal-related kinase (ERK) activity, but not epidermal
growth factor receptor (EGFR) trans-activation. Conclusion: PGE2-EP4 receptor signalling
promotes tumorigenic behaviour of HT-29 human CRC cells. EP4 receptor activation by
PGE2 in this cell line is coupled to an increase in cAMP levels, leading to phosphorylation
of CREB and PKA-dependent ERK activation. Therefore, the EP4 receptor is a candidate
novel target for chemoprevention of CRC. Comparision with existing literature suggests that
cell type-specific differences occur in EP4 receptor coupling to downstream signalling path-
ways.
W1540
Association of Carcinogenesis and Emergence of Spasmolytic Polypeptide-
Expressing Metaplasia (SPEM) in Helicobacter Pylori-Infected Mongolian
Gerbils with Carcinogen
Nao Yoshizawa, Hirokazu Yamaguchi, Yoshiharu Takenaka, Sachiyo Nomura, James R.
Goldenring, Jeffrey R. Lee, Michio Kaminishi
Background: In previous studies, We have reported that Spasmolytic polypeptide (TFF2)-
expressing metaplasia (SPEM) is observed in adjacent mucosa to human gastric cancer and
at the base of fundic glands showing oxyntic atrophy in rodent models such as Helicobacter
felis infected mice, MT-TGFα transgenic mice, rats with remnant gastric cancer, and mice with
DMP-777 treatment. Oxyntic atrophy is well known as a background of gastric carcinogenesis,
therefore those results can set up a hypothesis that SPEM is a precursor of gastric cancer.
Aim: To explore the time course changes in fundic glands and the relationships between
SPEM and gastric carcinogenesis using H. pylori(Hp)-infected and carcinogen-treated Mon-
golian gerbils. Materials and methods: Mongolian gerbils were assigned into four groups:
Group A; with Hp infection and treatment of N-Methyl-N-Nitrosourea (MNU), Group B;
with treatment of MNU, Group C; with Hp infection, Group D; control. MNU was given
at 30 ppm in drinking water at experimental week 1, 3, 5, 7, 9. At week 11, Hp colony
samples were inoculated. The animals were sacrificed at 11, 14, 20, 25, 35, 50 weeks. The
removed stomachs were fixed in 4% formaldehyde for 24 hours, embedded in paraffin, and
cut into 4-μm sections. Replicate sections were stained with hematoxylin and eosin (H&E).
Immunohistochemistry using anti-Human TFF2 antibody and anti-human Intrinsic Factor
(IF) antibody were also performed. Furthermore immunofluorescence for TFF2 and IF
was performed. Results: In Group B, no SPEM and carcinoma were observed. Group C
demonstrated SPEM but no neoplasm. Only Group A showed both. SPEM emerged earlier
in Group C than Group A. The incidence of SPEM in Group C kept about 60% all along,
however, in Group A it increased gradually up to 80%. In the earlier stage, SPEM demon-
strated TFF2 and IF double staining. Although number of animals with SPEM increased,
SPEM showing double staining rather decreased and SPEM showing single staining by anti-
TFF2 was observed in the later stages. SPEM changed also morphologically. In the earlier
stage SPEM organized slender and straight glands, however, in the later stage SPEM became
small and distorted. Many heterotopic proliferations and adenomata were TFF2 positive.
Around dysplasia SPEM was seen, however most of them are IF negative and they were
small and distorted. Conclusion: SPEM was observed in the animals infected with Hp. With
carcinogen and Hp, SPEM was gradually changed morphologically and immunohistochem-
ically, and that was seen around dysplasia. These results support the hypothesis that SPEM
is a candidate for a precursor of gastric cancer.
W1541
X-Ray Irradiation Promotes the Occurrence and the Multiplicity of Invasive
Carcinoma in Intestinal Tract of APCMin/+ Mouse
Toshiyuki Nakayama, Kazuyuki Yamazumi, Takashi Uemura, Ayumi Yoshizaki, Yuichi
Yakata, Ichiro Sekine
BACKGROUNDS & AIM: X-ray is well known to cause genetic damage and induce many
types of carcinomas in human. Mouse model for human familial adenomatous polyposis
(FAP), APCmin/+ mouse, contains a truncating mutation in APC gene and spontaneously
developes intestinal adenomas. To elucidate the role of X-ray in the intestinal tumor, we
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examined the promotion of carcinogenesis in X-ray irradiated APCmin/+ mouse. METHODS:
APCmin/+ mice and wild-type, C57BL/6J mice, were irradiated with a single whole body of
5 Gy X-rays at 8 weeks of age. After 20 weeks, all animals were sacrificed. RESULTS: Total
51.9% cases (40 of 77) of X-ray irradiated APCmin/+ mice were highly observed invasive
carcinoma in small intestine. 54.5% (24 of 44) in male and 48.5% (16 of 33) in female
were showed adenocarcinoma with invasion to proprial muscle layer of small intestine. The
other side, only 20.3% cases (13 of 64) of non-irradiated APCmin/+ mice were observed
invasive carcinoma. 28.1% (9 of 32) of male and 12.5% (4 of 32) of female in non-irradiated
APCmin/+ mice were showed invasive carcinoma in small intestine. There was statistical
difference of the occurrence of invasive intestinal carcinoma between X-irradiated and non-
irradiated Apcmin/+ male or female mice (p=0.019, p=0.0017, respectively). Wild-type mice
with or without X-irradiation were not occurred any invasive carcinoma. X-irradiated Apcmin/
+ mouse showed higher number of invasive carcinoma than non-irradiated mouse in male
(p=0.041). APCmin/+ mice presented many polyps in small and large intestine with or wthout
X-ray irradiation. The number of polyps did not show any difference between X-irradiated
and non-irradiated Apcmin/+ mice. CONCLUSIONS: X-ray irradiated Apcmin/+ mice were
highly observed intestinal invasive carcinoma and showed the multiplicity of invasive carcin-
oma. Our results suggested that X-ray irradiation promotes the invasive activity of intestinal
tumor in Apcmin/+ mouse.
W1542
Positive Correlation Between mRNA Expression and Protein Array Results in
Colorectal Cancer
Sandor Spisak, Balazs Gyorffy, Tamas Zagoni, Mark Juhasz, Zsolt Tulassay
Backgrounds and aims: The relevence of the results’ of mRNA expression studies on protein
levels is not proven yet. Recently new whole genome mRNA expression arrays became
available. Protein chips with several hundred of proteins was used to confirm mRNA results
from colorectal cancer patients. Patients and methods : in 5 Dukes B and 5 Dukes stage D
colorectal cancer patient malignant and normal specimen were collected and fresh frozen
immediately after surgery. mRNA and proteins were isolated using Trisole reagent. mRNA
expression was evaluated using a whole gebnome array ( Affymetrix U133 plus 2.0) and
compared to the results of a commercial protein chip analysis containing 576 proteins
(Clontech, Atlay Arrays, USA) from the same specimen. Significantlly differently expressed
genes were identified by T test using the MAS (Affymetrix, USA) programpackage and
the R programpackage. Statistical analysis was performed concerning the coexpression of
corresponding mRNA and the proteins using Spearmann’s R method. Results: All the protein
arrays were applicable for the expression study. The mRNa profile was in 86,5 % in correlation
with the protein expression array results. However in a relatively high number significant
negative correlation was found (14.5 %). Between the Dukes Stage B and D cancer patients
the top 5 discriminator genes were HLA-DQA1, DnaJ (Hsp40) homolog, subfamily C,
member 10, cetrin 3, acetyl-Coenzyme A acetyltransferase 2, solute carrier family 39, member
8. Dukes Stage B, C and D group could classified by cluster analysis of the top 100 gene.
Conlusions: Protein arrays can utilised for the verification of whole genome mRNA expression
studies. Dukes stage B and D disease demonstrates a different genomics entity as it was
shown in the mRNA expression profile. The difference between the protein and mRNA
expresssion results could be justified by the possible mRNA splicing alternatives and protein
or mRNA digestion in the sample preparation process.
W1543
Molecular Characteristics of Small Bowel Carcinomas Vary with Location
Marloes Berkhout, Leonie J. Mekenkamp, Fred J. van de Molengraft, Wilbert H. Peters,
Fokko M. Nagengast, Han J. van Krieken, Iris D. Nagtegaal
Background: Primary carcinomas of the small intestine are rare and their carcinogenesis
remains poorly understood. The most frequent site of development is the duodenum (± 50
%), followed by the jejunum (± 25%) and the ileum (± 13%). It is not known whether the
process of carcinogenesis differs in the different parts of the small intestine. Aim: The aim
of this study is to elucidate the genetic pathways leading to the development of small
intestinal carcinomas by immunohistochemical comparison of several candidate proteins in
tumors of the duodenum, jejunum and ileum. Methods: The duodenal carcinomas (n = 20),
jejunal carcinomas (n = 14) and ileal carcinomas (n = 6) were compared on Tissue Microarrays
by immunohistochemical staining for the cytokeratins (CK7, CK20), DNA mismatch repair
proteins (MLH1, MSH2, MSH6, PMS2), cell cycle proteins (P16, P53, cyclin D1), cell
adhesion proteins (beta-catenin, E-cadherin, Ep-CAM) and SMAD4, CO-TL1, CEA. Results:
In the majority of carcinomas (more than 90%) invasion through the bowel wall was
present (T3/T4). Most tumors were adenocarcinomas, the exceptions being 1 signet ring
cell carcinoma in the duodenum, 1 mucinous carcinoma and 1 adenosquamous carcinoma
in the jejunum and 1 mucinous carcinoma in the ileum. Approximately 50% of these tumors
were poorly/undifferentiated. Both CK7 and CK20 were differentially expressed along the
small bowel; with CK7 positivity in 63%, 28% and 0% and CK20 negativity in 35%, 15%
and 0% of the carcinomas of the duodenum, jejunum and ileum respectively (p = 0.01, p =
0.06). P53 was overexpressed in 32%, 79% and 100% of the duodenal, jejunal and ileal
carcinomas respectively (p = 0.002). Moderate to high loss of extracellular E-cadherin was
seen in 75% and 92% of the carcinomas of duodenum and jejunum respectively in comparison
to 33% of the ileal carcinomas (p = 0.02). Conclusions: Overexpression of P53 is less
frequent in the duodenal carcinomas compared with more distal small bowel carcinomas.
Differential expression of both CK7 and CK 20 reflects preexisting differences between the
upper gastrointestinal tract and the colon. We propose that in the proximal small bowel
carcinogenesis reflects gastric carcinogenesis, while in distal small bowel carcinogenesis
resembles colonic carcinogenesis.
W1544
Epigenetic Silencing of the Chemokine CXCL12 in Colorectal Carcinoma
Enhances Metastasis
Michael K. Wendt, Priscilla A. Johanesen, Ningling Kang-Decker, Vijay H. Shah, Michael
B. Dwinell
The chemokine CXCL12 and its receptor CXCR4 are co-expressed in several tissues and
cell types throughout the body and play essential roles in development, where disruption
of either gene leads to embryonic lethality. Not only is this signaling axis a key regulator
of hematopoietic stem cell, leukocyte, and lymphocyte migration but it has also been shown
to play a critical role in carcinoma cell metastasis. We have previously defined constitutive
functional expression of CXCL12 and CXCR4 in the human colonic epithelium, an expression
pattern absent in several colorectal carcinoma cell lines due to CXCL12 silencing by promoter
hypermethylation. We hypothesized that silencing of CXCL12 in CXCR4 expressing carcin-
oma cells contributes to in vivo disease progression. Consistent with our hypothesis, we
show aberrant methylation of the CXCL12 promoter in several primary colorectal carcinomas,
a dysregulation not observed in normal colonic epithelial isolates. CXCL12 and CXCR4, in
agreement with our prior reports, were co-expressed in normal colonic epithelium, while
in adjacent transformed epithelium CXCL12 expression was notably absent. Importantly,
CXCR4 expression in tumor tissues was maintained. Re-expression of functional, endogenous
CXCL12 in colorectal carcinoma cells by stable transfection resulted in smaller tumor cell
foci in soft agar. Similar results were observed in vivo, as colonic carcinoma cells re-expressing
CXCL12 injected into the hepatic portal vein formed dramatically smaller liver metastases
in Scid mice as compared to CXCL12 silenced control cells. These data likely reflect an
increase in apoptosis in CXCL12 expressing carcinoma cells as defined using a caspase assay.
Taken together, our data constitute the unique observation that silencing of CXCL12 within
human colonic carcinoma cells greatly enhances their survival, contributing to increased
metastasis, exacerbating disease progression.
W1545
Rho-Like Proteins in Human Colon Cancers Are Uniquely Expressed As a
Function of Differentiation and Tumor Invasion
Jameela Huq, Grace Guzman, Bassem Elgohary, Lubna Shakir, Sarah C. Glover
Background: Rho-like proteins i.e. Rho A, B, and C have been identified as playing distinct
roles in post neoplastic transformation and metastasis in breast, bladder, hepatocellular,
ovarian, lung, and prostate cancers. Specifically, Rho A promotes proliferation and neoplastic
transformation while Rho C increases with tumor de-differentiation where it promotes
invasion and metastasis. Rho B behaves in an exact opposite manner by enhancing apoptosis
of tumor cells. Action of these proteins on their downstream effector, ROCK (Rho Associated
Kinase), has been associated with cancer progression through its action on the actin cytoskel-
eton. Specific inhibition of ROCK suppresses cancer growth and spread (Nat Med 1999;
5(2): 221). While Rho has been shown to be increased in both expression and activity in
colon cancer cell lysates, little is known about expression of individual Rho-like proteins
or ROCK in colon cancer. Since each of these proteins may have a different impact on colon
cancer cell behavior, we set out to determine the presence and location of individual Rho-
like proteins as well as that of their downstream effector, ROCK, in human colon cancer
specimens. Methods: Ten colon cancers containing of distinct differentiation were obtained
from the UIC department of pathology under an exempt IRB. All specimens were immunohis-
tochemically probed using antibodies directed against Rho A, B, C, ROCK 1, and ROCK II.
Antibody-specific chromogen was determined by quantitative immunohistochemistry (J.
Histochem. Cytochem. 2003, 51:1041) for each cellular region. Results: Both Rho A and B
were expressed in normal and dysplastic tissue adjacent to the colon cancer as well as at
the leading edge of the colon cancer suggesting that they may play a role in neoplastic
transformation as well as post neoplastic transformation. Rho C and ROCK II expression
was dramatically increased in the cytoplasm of cells at the leading edge of the tumor and
in poorly differentiated cells. The expression pattern of Rho C and ROCK II correlated with
expression data from other solid tumors where overexpression of these proteins was directly
linked with an increase in cancer related death due to metastatic disease (Clin Cancer Res
2003; 9(7): 2632). ROCK I expression was minimal in this same tumor specimen suggesting
that it plays a lesser role. Conclusions: We show for the first time that colon cancers
overexpress Rho-like family members as well as their downstream effector, ROCK II, in a
unique manner and that their expression changes not only in relationship with cell differenti-
ation but also with level of invasion.
W1546
Antitumor Effect of Whole Body Hyperthermia Combined with
Geranylgeranylacetone in Mice Pulmonary Metastasis Models of Colon Cancer
Tetsuya Okayama, Satoshi Kokura, Toshimitsu Okuda, Satoko Adachi, Takeshi Hattori,
Nami Nakabe, Naoyuki Sakamoto, Tomohisa Takagi, Osamu Handa, Yuji Naito, Norimasa
Yoshida, Toshikazu Yoshikawa
Aim: It is reported that the inhibition of NF-kB activation leads to inhibition of cancer
metastasis and growth. On the other hand, heat treatment is known to initiate a wide variety
of reaction through the expression of heat shock proteins (HSPs). We confirmed that heat
pretreatment inhibited activation of NF-kB through the expression of heat shock proteins
in a human colon cancer cell line and human endothelial cell line. Therefore, it is expected
that hyperthermia inhibits NF-kB activation of a cancer cell and a vascular endothelial cell,
resulting in the inhibition of cancer metastasis and cancer growth by the induction of heat
shock proteins. In this study, we investigated the effect of whole body hyperthermia and a
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heat shock proteins-inducing drug, geranylgeranylacetone (GGA, Hsp70 inducer) in mice
pulmonary metastasis models of colon cancer. Methods: Colon26 cells, a mouse colon
adenocarcinoma cell line, were injected via the tail vein of male BALB/c mice and numbers
of pulmonary metastases were assessed 18 days later. Colon26-bearing mice were treated
with whole body hyperthermia by using far infrared rays 3 times a week. Rectal temperature
was maintained for 60 min at 41 degrees Celsius. In some experimental groups, oral
administration of GGA (250mg/kg) was performed 2 hr before whole body hyperthermia.
We investigated the therapeutic effect of whole body hyperthermia, single administration
of GGA, and the combined therapy. Moreover, Hsp70 of lung tissue in each treatment group
was detected by Western bloting. The activity of NF-kB in lung tissue after cancer cells in
oculation was investigated by EMSA and ELISA. Results: 1) Whole body hyperthermia
decreased the number of the lung metastases. 2) A single administration of GGA did not
show the inhibitory effect to lung metastases. 3) The combination of whole body hyperthermia
and GGA made further inhibitory effect to lung metastases. 4) GGA or whole body hyperther-
mia slightly induced Hsp70 in lung tissue 24h after treatment. On the other hand, whole
body hyperthermia combined with GGA administration increased the induction of Hsp70,
and inhibited the activation of NF-kB in lung tissue. Conclusions: The incidence of lung
metastasis was reduced by the treatment of whole body hyperthermia, and it might be
suggested that heat shock proteins induced by whole body hyperthermia attenuated lung
metastases because the effect of treatment is enhanced by using a Hsp70 inducer together.
W1547
Association of TGF-β1 Overexpression in Barrett’s Cancer with Advanced
Tumor Stage and Worse Prognosis
Burkhard H. A. Von Rahden, Mario Sarbia, Marcus Feith, Joerg Theisen, J. Ruediger.
Siewert, Hubert Stein
Objective. Expression of TGF-β1, a major member of the TGF-β superfamily and important
promoter of tumor growth, was investigated in a series of primary resected Barrett’s adenocar-
cinomas to establish its potential clinical significance and prognostic relevance in this entity.
Methods. A series of 123 primary resected adenocarcinomas of the distal esophagus (Barrett’s
cancer), and corresponding normal squamous epithelium (n=12) and non-malignant Barrett’s
mucosa (n=11), were investigated by means of quantitative RT-PCR for expression of TGF-
β1, using paraffin embedded tissue samples. Gene expression levels were correlated with
clinical parameters and overall survival. Results. TGF-β1 mRNA was expressed in all tumors,
but relative gene expression levels varied largely among different tumors. The relative gene
expression was significantly higher in tumor tissue compared to squamous epithelium (p=
0.005) and Barrett’s mucosa (p=0.002), expressing only low amounts of TGF-β1. Relative
overexpression of the TGF-β1 gene was associated with advanced UICC stage (III/ IV vs. I/
II; p=0.009), depth of tumor infiltration (pT3 vs. pT1/2; p<0.001), nodal involvement (pN1
vs. pN0; p=0.006) and lymphatic vessel invasion (L1 vs. L0; p=0.011). On univariate survival
analysis, TGF-β1 overexpression had a significant negative impact on survival (log rank test;
p=0.0255). However, the prognostic impact was not independent from other strong pre-
dictors of survival (pT, pN) on multivariate survival analysis. Conclusion. Our data show
that TGF-β1 overexpression is associated with advanced stage of Barrett’s cancer and implies
a negative impact on survival. The TGF-β pathway may be a potential target for molecular
therapies of advanced tumors of this entity.
W1548
Atorvastatin Reduces the Attachment of Colorectal Cancer Cells to
Endothelial Cells in Vitro By Down-Regulating the Endothelial Cell Surface
Expression of Adhesion Molecules
Cary Aarons, Karen L. Reed, Olga Bajenova, Peter Thomas, James M. Becker, Arthur F.
Stucchi
Background: Colorectal cancer (CRC) is the second most common cause of cancer mortality
in the United States. Although the liver is the main organ affected by metastasis from CRC
only a small percentage of patients with liver metastases are candidates for curative surgical
resection. Therefore, a better understanding of the mechanisms regulating metastasis will
improve the overall outcome for the metastatic cancer patient. Recent studies have shown
that statins inhibit the growth of CRC cells and reduce the relative risk of colorectal cancer;
however, little is known about whether statins can affect metastasis. The aim of this study
was to examine the role of statins in modulating two key steps in the metastasis of CRC
cells: 1) endothelial cell (EC) surface expression of adhesion molecules, and 2) the attachment
of CRC cells to endothelial cells. Methods: Using an in vitro model of CRC metastasis,
human umbilical vein endothelial cells (HUVECs) were pretreated for 12-16 hrs with atorvas-
tatin (10μM) and then stimulated for up to 24 hours with either TNF-α (10ng/ml) or
conditioned media from differentiated THP-1 (D-THP) macrophages incubated for 24 hours
with carcinoembryonic antigen (CEA) (2μg/ml). As we have shown, D-THPs possess func-
tional CEA receptors and when stimulated with CEA express a pattern of proinflammatory
cytokines similar to that expressed by liver macrophages, Kupffer cells. The EC surface
expression of the adhesion molecules, ICAM-1 and E-selectin was quantified by a modified
ELISA. Using the same conditions as above, the attachment of HT-29 CRC cells to HUVECs
was measured by a fluorescent assay. Results: Atorvastatin pretreatment reduced the TNF-
α induced upregulation of ICAM-1 and E-selectin protein expression in HUVECs by 46%
(p<0.05) and 36%, respectively, compared with controls. Atorvastatin also reduced the CEA-
conditioned media induced rise in E-selectin by 47% (p<0.05) compared with controls.
While the incubation of HUVECs with TNF-α and CEA-conditioned media significantly
increased the attachment of HT-29 cells to EC by 141% and 235% (p<0.05), respectively,
a 60 minutes pretreatment with atorvastatin significantly inhibited this attachment by up
to 132% (p<0.05). Conclusion: These data demonstrate that statins may modulate one of
the early pathophysiological steps in metastasis of CRC from the colon to the liver and suggest


















CD24 Is a Novel Oncogene in Colorectal Cancer, Detected By Microarray
Profiling of Cell Transformation, and Is a Target for Immunotherapy of Cancer
Eayl Sagiv, Lorenzo Memeo, Dana Yona, Adi Karin, Diana Kazanov, Jasmin Jacob, Gidi
Rechavi, Hanina Hibshoosh, Nadir Arber
Aims: To identify genes that play a role in colorectal cancer (CRC) carcinogenesis by analysis
of differential gene expression of normal and transformed CRC cell lines. Methods: Gene
expression array analysis, (RG-U34) Genechip®, was performed in normal and transformed
rat intestinal epithelial cells before and after exposure to celecoxib, a CRC prevention agent
(Pfizer, New York, NY, USA). In particular, we were looking for: a. altered gene expression
in the transformed cells that reverts to normal following exposure to a selective COX2
inhibitor. b. Novel genes. c. Genes encoding membrane receptors or ligands. The CD24
gene fulfilled all these criteria. As a validation of the results and for human patients,
immunohistochemistry was performed on 398 biological samples from the entire GI tract
(normal, polyps and adenocarcinomas). Human cancer cell lines were tested for their response
to anti-CD24 monoclonal antibodies. Three different antibodies were added separately to
the medium at different concentrations or durations; viability was measured by Methylene
blue assay. CD24 cellular levels in HT29 CRC cell line were stably down regulated using
siRNA technology and changes in their proliferation capacities were examined. Results:
1081 genes were differently expressed following malignant transformation; 71 genes showed
alter expression that reverted to normal following treatment with celecoxib; among them
was the gene to CD24. Immunohistochemistry confirmed that increased expression of CD24
is an early event in CRC carcinogenesis. It was expressed in 90.7% of adenomas and 86.3%
of CRC. Very low expression was seen in normal epithelium (16.6%). Human cancer cell
lines showed growth inhibition in response to the antibodies, according to their expression
levels of CD24 and in dose and time dependent manners. These results were repetitive for
three different antibodies. The derivatives of HT29 that showed reduced levels of CD24
following transfections with two siRNA expression vectors that differ in their binding sites,
showed a significant reduction in growth rate when compared to parental HT29 and HT29
with a control-siRNA. Conclusions: CD24 is a new gene that is overexpressed in the colonic
mucosa, already at an early stage of carcinogenesis and might play a role in tumor progression.
Therefore, it is likely to be a useful biomarker for early detection and might be of use as a
new target in CRC therapy.
W1550
Nuclear MDM2 Accumulation: A Novel Mechanism of TP53 Inactivation in
Anal Squamous Cell Carcinoma?
Heena S. Patel, John M. Northover, Andrew R. Silver
Background MDM2 is an important negative regulator of TP53 that binds and inhibits TP53
transactivation and/or results in TP53 degradation. MDM2 is overexpressed in several human
tumours including cervical cancer (a human papillomavirus-associated tumour) but has not
been investigated in anal squamous cell carcinoma (ASCC); cervical cancer and ASCC share
similar disease aetiology. The primary mechanism of MDM2 overexpression is amplification
of the gene in breast and soft tissue tumours and consequent abrogation of the pro-apoptotic
functions of TP53. Interestingly, nuclear TP53 accumulation has been observed in ASCC,
indicating a potential role for MDM2 in ASCC tumorigenesis. This possibility is now investig-
ated. Methods Anal squamous carcinomas (n=29) were analysed for: TP53 and MDM2
somatic mutations by direct DNA sequencing of TP53 exons 5 - 8 and the MDM2 nuclear
export signal (aa 90-102) and critical residues glutamine 58, cysteine 438 and 464, TP53
and MDM2 accumulation by immunohistochemistry; and MDM2 amplification by quantitat-
ive PCR. HPV status was also examined. Results One somatic TP53 mutation (frameshift
resulting from 14bp deletion, exon 5,codon 176, 779-792) was detected (3%, 1/29). 83%
(24/29) of anal SCC were positive for TP53 and 48% (14/29) of anal SCC were positive for
MDM2 by immunohistochemistry. Normal anal epithelium controls were all negative for
TP53 and MDM2 immunostaining. Nuclear accumulation of TP53 and MDM2 in this group
of ASCC are independent variables (p=0.33, Fisher’s exact test). MDM2 was not amplified
in our samples and no mutations were detected. A high frequency (83%) of samples was
HPV positive (24/29) of which 67% (16/24) contained HPV 16 DNA. Nuclear MDM2
accumulation and HPV status were independent variables (p= 0.65, Fisher’s exact test).
Conclusions Nuclear MDM2 accumulation was observed at high frequency in ASCC in the
absence of MDM2 gene amplification or somatic mutation. This may be a feature of a novel
pathway of TP53 abrogation in this tumour and adds to the known mechanisms of TP53
transcriptional inactivation and proteosomal degradation by HPV E6 and E7. Somatic TP53
mutation was rare in this study and probably has limited contribution to tumorigenesis
in ASCC.
W1551
Novel Interaction Between Xiap-Associated Factor 1 (XAF1) and Nuclear
Coactivator Cbp in Colon Cancer
Yunwei Sun, Harry.H.X. Xia, Senlin Zhu, Bing Zou, Marie Cm Lin, Hsiang Fu Kung,
Benjamin C. Wong
Background: XAF1 (XIAP-Associated Factor 1) is a nuclear protein that directly interacts
with endogenous XIAP and results in XIAP sequestration in nuclear inclusions. cAMP
response element binding protein (CREB)-binding protein (CBP) play an important role as
multifunctional transcriptional coactivators. In this study, we examined the association
between XAF1 and CBP in colon cancer cell. Methods: Expressions of XAF1 and CBP were
detected by Western blot in colon cancer cells. The association of XAF1 with CBP was
confirmed in vitro by glutathione S-transferase (GST) pull-down assay and in vivo by
coimmunoprecipitation. Co-localization of XAF1 and CBP was demonstrated by immunofluo-
rescence microscopy. An AP1 reporter assay was used to determine the functional interaction
between XAF1 and CBP in the presence or absence of PMA. Results: Low level of XAF1
and CBP was detected in SW1116 cells. Using GST-CBP (1-1099,1098-1758,1098-1858
and 1620-1877) bound to sepharose beads and in vitro expressed 35S-labeled XAF1, we
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found the XAF1 binding sites on CBP are located in the cysteine-histidine-rich C/H1 domains
(residues 1-1098). Plasmids encoding XAF1 and HA-tagged CBP were transfected into
SW1116 cells alone or in combination. Immunoprecipitation of over-expressed CBP protein
with anti-CBP polyclonal antibody co-precipitated XAF1 was mainly located in the nucleus.
CBP was located exclusively in the nucleus. XAF1-RFP and CBP-HA co-localization were
seen in the nucleus after immunofluorescence staining. Reporter assays demonstrated that
co-transfection with pCDNA3-XAF1 and pRc/RSV-CBP led to one fold reduction of AP1
luciferase activity stimulated by PMA, which was further enhanced by co-transfection of
CBP’s homolog pCMV-P300. Conclusions: Our results identified CBP as a novel binding
partner for XAF1 and indicated that CBP, as a coactivator, cooperated with XAF1-mediated
inhibition of AP1 transcription.
W1552
Significance of Eras Expression in Gastric Cancer: Resistance to Anti-Cancer
Agents
E.J. Kubota, Hiromi Kataoka, Makoto Sasaki, Satoshi Tanida, Tadayuki Oshima, Naotaka
Ogasawara, Tomonori Yamada, Tsuneya Wada, Yoshinori Mori, Takaya Shimura, Fumitake
Fujita, Kiyofumi Asai, Takashi Joh
Background and aims: Embryonic stem (ES) cells are pluripotent, immortalized cells with
a rapid growth rate that makes them attractive sources for stem cell therapies. However,
when ES cells are transplanted, they produce tumors (teratomas). ERas, a novel member of
the ras family, was found to be expressed in ES cells only. ERas is constitutively active
without any mutations and plays a crucial role when transplanted in the transformation of
ES cells to teratomas and the expression level of ERas gradually decreases when ES cells
are induced to differentiate. The aim of the current study is to investigate the expression
and the roles of ERas, especially resistance to chemotherapeutic agents in human gastric
cancer cells. Material and Method: 1. We assessed expression of ERas in human gastric
cancer and gastric cancer cell lines, including MKN28, MKN45, MKN78, KATOIII, GCIY,
AGS, HGC-27, NUGC-4 and ISt-1 by western blot. 2. To analyze the functions of ERas in
gastric cancer, we established stable transfectans of GCIY overexpressing ERas with pCAG-
Myc-human ERas-IP vector, the expression plasmid for ERas. Activation of PI3k/Akt and
MAPK pathway was analyzed. 3. To assess the cytotoxicity, cells were exposed to four anti-
cancer agents commonly used for treatment of gastric cancer: CPT-11, 5-Fluorouracil,
Cisplatin and Paclitaxel and cell survival was measured by MTS assay. To evaluate apoptosis
induced by anti-cancer agents, we measured caspase-3 activity using Caspase-Glo3/7 assay.
4. We investigated the effect of Rapamycin, inhibitor of mTOR which is downstream of
PI3k/Akt pathway, to the cell survival. Results: 1. ERas was expressed in human gastric
cancer and all gastric cancer cell lines except for AGS. 2. Overexpression of ERas did not
induce the phosphorylation of MEK. However, overexpression of ERas induced phosphoryl-
ation of Akt. 3. The ERas transfectants were significantly more resistant to CPT-11 than the
parent lines (survival rate: control 23.0%, the ERas transfectants 67.4%, p <0.001), but not
to 5-Fluorouracil, Cisplatin, and Paclitaxel. Overexpression of ERas significantly reduced
CPT-11-induced apoptosis (p <0.01). 4. Administration of Rapamycin significantly induced
cytotoxicity to the ERas transfectants (survival rate: control 93.9%, ERas transfectant 68.5%,
p <0.01). Conclusion: ERas was expressed in human gastric cancer and gastric cell lines,
and plays crucial roles for anti-apoptosis via phosphorylation of Akt. Gastric cancer cells
which express high level of ERas might be susceptible to Rapamycin and resistant to CPT-11.
W1553
Loss of Cooperative Function of Elf, a β-Spectrin, with SMAD3 Leads to
Abnormal Localization and Transcriptional Activation Upon TGF-β Response,
Which Is Essential for Gastrointestinal Tumor Suppression
Sang Soo Kim, Hye Jung Baek, Varalakshmi Katuri, Tapas Saha, M. Blair Marshall, Anton
Sidawy, Bibhuti Mishra, Lopa Mishra
TGF-β/Smads regulate a wide variety of biological responses through transcriptional regula-
tion of target genes. ELF, a β-spectrin, plays a key role in the transmission of TGF-β-
mediated transcriptional response through interactions with Smad3 and Smad4. ELF was
originally identified as a key protein involved in endodermal stem/progenitor cells committed
to foregut lineage. Also, as a major dynamic adaptor and scaffolding protein, ELF is important
for the generation of functionally distinct membranes, protein sorting and the development
of polarized differentiated epithelial cells. Disruption of elf results in the loss of Smad3/
Smad4 activation and, therefore, a disruption of the TGF-β pathway. If heterozygous, the
elf mice display dramatic tumors of the digestive tract with an exacerbated phenotope on
a Smad4 heterozygous background. Aim: These observations led us to pursue the interactions
between ELF and Smads especially Smad3 which is directly activated by TGF-β. Utilizing
deletion fragments, confocal microscopy, and luciferase assays for TGF-β transactivation,
we mapped the regions of ELF responsible for interaction, localization, and transactivation
upon TGF-β stimulation. Methods and Results: First, we found that Smad3 but not Smad2
is a major interacting partner of ELF in COS-7 cells. Our further detailed analyses showed
that N-terminal MAD1 domain of ELF displays a strongest interaction with of Smad3. The
mid-portion of ELF containing consensus repeats and nuclear localization signal (NLS)
domains also shows a moderate interaction but C-terminal MAD2 region does not. Smad3
MH1 and MH2 domains, but not the linker region, are responsible for ELF interactions.
However, one mid-portion of ELF displays a dramatic nuclear translocation and transactiv-
ation upon TGF-β stimulation. Conclusions: Taken together, these findings show ELF is
finely modulated upon TGF-β response and through its N-terminal associates with Smad3,
utilizing the middle fragment for nuclear translocation, TGF-β targets gene activation through
Smad3 interaction, localization, and transactivation. Therefore, loss of ELF, frequently found
in human gastric and colon cancer, prevents the proper function of TGF-β signaling pathway
which is responsible for suppression of tumorigenesis.
W1554
T-Darpp Suppresses Apoptosis Through Up-Regulation of BCL2 in
Gastroesophageal Adenocarcinomas
Abbes Belkhiri, Altaf Dar, Wael El-Rifai
We have recently shown mRNA and protein overexpression of both 32-kilodalton dopamine
and cyclic adenosine 3',5'-monophosphate-regulated phosphoprotein (DARPP-32) and its
novel truncated form t-DARPP in majority of gastroesophageal carcinomas (GECs). In addi-
tion, we have shown that these proteins provide anti-apoptotic role, which may explain the
poor response of GECs to therapy. To further study the anti-apoptotic function of t-DARPP,
AGS cells stably expressing t-DARPP or control cells expressing pcDNA3 empty vector were
treated with acetyl ceramide (10 µM, 20 µM) for 24 h. Immunoblot analysis on protein
extracts showed that processing of caspase 9 did not occur in t-DARPP-expressing cells
following treatment with 20 µM ceramide. Under the same conditions, caspase 9 was almost
fully processed in control cells, indicating initiation of apoptosis. Treatment of t-DARPP
cells and control cells with 10 µM ceramide was not sufficient to induce apoptosis as
indicated by lack of caspase 9 activation. In addition, Bcl2 protein expression was confirmed
in ceramide-treated and -untreated t-DARPP-expressing cells, whereas Bcl2 protein was not
detected in control cells. Quantitative real time RT-PCR analysis indicated that mRNA level
of Bcl2 was 3-fold higher in t-DARPP-expressing cells than control cells. The use of siRNA-
DARPP-32/t-DARPP significantly abolished the expression of Bcl2 at mRNA and protein
levels. As Bcl2 promoter contains a CREB response element (CRE), we investigated CREB/
ATF-1 protein levels and found significantly higher in t-DARPP-expressing cells compared
with control cells. Thus, we proceeded with electrophoretic mobility shift assay (EMSA)
using a CREB specific probe, and detected a stronger ATF-1/CREB/CRE binding in t-DARPP-
expressing cells than control cells. Binding specificity was confirmed by supershift using
ATF-1 antibody. Taken together, these results show that t-DARPP suppresses apoptosis as
indicated by caspase 9, through up-regulation of Bcl2 as shown by EMSA, mRNA and
protein levels. These results indicate that t-DARPP may be a novel gene with potential
oncogenic properties. To verify this hypothesis, transformation studies are underway.
W1555
Inhibition of Biliary Duct Cancer Cell Growth By RUNX3 Induction
Kazunori Hasegawa, Shujiro Yazumi, Toshiharu Sakurai, Masaya Kida, Junichi Yamauchi,
Chouhei Sakakura, Hiroshi Ida, Yoshiaki Ito, Tsutomu Chiba
Background and Aim: RUNX3, a Runt domain transcription factor involved in TGF-β
signaling, is a candidate tumor-suppressor gene localized in 1p36, a region commonly
inactivated by deletion and methylation in a wide variety of human tumors. The aim of this
study was to elucidate the function of RUNX3 in biliary tract cancer cell line. Materials and
Methods: A biliary tract cancer cell line, Mz-ChA-2, which does not express RUNX3 but
has intact TGF-β receptorII and SMAD4, was stably transfected with RUNX3 expressing
plasmid (pcDNA3.0/RUNX3). Mz-ChA-2 cells stably transfected with pcDNA3.0 were used
as control. RUNX3 expression was confirmed by RT-PCR and western blotting. Results:
Four Mz-ChA-2/RUNX3 clones and control cells (mock) were obtained. The expression
levels of RUNX3 in clones 1, 2, and 3 were 3.5, 2.4, 1.1 times as much as that in clone 4.
To better characterize the biological features of RUNX3, both cells were assessed for TGF-
β-induced growth inhibition assay. Although TGF-β slightly inhibited growth of control
cells, the growth inhibition by TGF-βwas significantly enhanced in clones 1 and 2 transfected
with RUNX3. Moreover, we analyzed the DNA contents of the clone 1 by flow cytometry.
Flow cytometry demonstrated that TGF-β-induced G1 arrest was significantly enhanced in
clone 1. In contrast, TGF-β-induced apoptosis was not demonstrated in both RUNX3-
transfected and control cells by flow cytometry or TUNEL assay. Western blotting analysis
demonstrated that although TGF-β slightly increased p21 expression even in control cells,
it was strongly enhanced in clone 1 with simultaneous decrease of cyclins D1 and E
expressions. Nude mice zenograft models disclosed that tumorigenecity was significantly
decreased in the Mz-ChA-2/RUNX3 clones with inverse proportion to the expression levels
of RUNX3 as compared to control cells (mock). Conclusions: Our results showed that forced
RUNX3 expression enhanced TGF-β-induced G1 arrest by up-regulation of p21 in biliary
tract cancer cell line. Moreover, RUNX3 might not be always necessary for TGF-β signaling.
W1556
EGFR Reactivates Telomerase in Immortalized Squamous Epithelial Cells
Through PI3K/AKT-Mediated Phosphorylation and Transcriptional Regulation
Via Hif-1alpha
Steffen Heeg, Michael Quante, Erdmann Scheffer, Alexander von Werder, Gitta Goessel,
Michaela Doebele, Christine Fulda, Heike Kunert, Hiroshi Nakagawa, Roderick L.
Beijersbergen, Hubert E. Blum, Oliver G. Opitz
Introduction: In our cellular model of oral-esophageal carcinogenesis immortalization was
induced independent of the activation of telomerase but through the recombination based
alternative lengthening of telomeres (ALT). In this stepwise model additional overexpression
of EGFR in immortalized cyclin D1 overexpressing/p53 inactivated cells (OKF6 D1/del.p53)
led to in vitro transformation and reactivation of telomerase. Therefore, we sought to identify
the cellular pathways involved in the reactivation of telomerase and the in vitro transformation
induced by EGFR. Methods: We overexpressed EGFR in immortalized OKF6 D1/del.p53
cells by retroviral mediated gene transfer. Expression levels and phosphorylation status of
the PI3K/AKT and MAPK/ERK pathways as well as respective downstream targets were
analyzed by western blot and RT-PCR. Protein-protein-interactions were demonstrated by
co-immunoprecipitation. Cells were additionally treated with respective inhibitors and ana-
lyzed for growth characteristics and telomere biology. Furthermore, analysis of the hTert
promoter including site-directed-mutagenesis was performed. Results: EGFR overexpression
induced a robust telomerase activity in immortalized squamous epithelial cells. The level of
AKT expression was unchanged compared to OKF6 D1/del.p53 cells. Nevertheless, AKT
was phosphorylated at Ser 473 and Thr 308 indicating the activation of the PI3K/AKT
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pathway. In contrast, ERK 1/2 levels and phosphorylation status remained unchanged. IP-
western blot analysis showed a direct phosphorylation of hTert as well as Hif-1alpha by
AKT. Analysis of the hTert promoter indicated an additional transcriptional regulation of
telomerase reactivation depending on the presence of a Hif-1alpha binding site at the hTert
core promoter. Corresponding to these findings, protein levels of Hif-1alpha were increased
in EGFR overexpressing cells. In addition, p21 is also a target of phosphorylation by
AKT. Conclusion: We were able to show that EGFR reactivates telomerase in immortalized
squamous epithelial cells mediated through the PI3K/AKT pathway. This reactivation is
effected by two different mechanisms, namely direct phosphorylation of hTert by AKT as
well as transcriptional regulation by Hif-1alpha as key transcription factor. Surprisingly, Hif-
1alpha is also phosphorylated by AKT and thereby stabilized. Phosphorylated p21 is known
to be translocated to the cytosol and thus it is not able to accomplish its nuclear function.
Whereas immortalization is induced by ALT, in vitro transformation is dependent on telomer-
ase reactivation, indicating an additional role of telomerase in tumor progression besides
elongating telomeres.
W1557
CDX2 Expression Is Increased in Gastric Cancers with Less Invasiveness and
Intestinal Mucin Phenotype
Gwang Ha Kim, Geun Am Song, Tae Oh Kim, Jeong Heo, Dae Hwan Kang Kang, Mong
Cho, Seung Keun Park, Chul Soo Song, Hee Ug Park, Sang Hyun Kim
Objective. CDX2 is an intestinal transcription factor that might be involved in the regulation
of proliferation and differentiation of intestinal epithelial cells. It is well known that both
gastric and intestinal phenotypic cell markers are expressed in gastric cancers. The aims of
this study were to analyze the CDX2 expression and its relationship with the patients’
clinicopathological characteristics and the mucin phenotypes and by performing immuno-
histochemistry. Material and methods. A total of 259 gastric cancers (122 early and 137
advanced cancers) were evaluated histologically and phenotypically. The CDX2 expression
was assessed by immunohistochemistry. Results. Increased CDX2 expression correlated with
a higher proportion of intestinal-type cancers of Lauren and early gastric cancers (p<0.001
and p<0.001, respectively) and a lower proportion of perineural invasion and lymph node
metastasis (p<0.001 and p=0.003, respectively). Increased intestinal mucin (MUC-2, CD10)
expression and decreased gastric mucin (MUC5AC) expression was associated with an
increased CDX2 expression (p<0.001, p=0.045 and p=0.004, respectively). MUC6 expression
was not associated with the CDX2 expression. There was a significantly increased CDX2
expression in the intestinal phenotype than the other phenotypes (p<0.001). Conclusions.
These results suggest that CDX2 might be a useful marker to predict the clinical outcome
for patients with gastric cancers.
Correlations between the expression of CDX2 and the phenotype classification in the 259
gastric cancers
Correlations between the expression of CDX2 and the expression of MUC2, CD10, MUC5AC
and MUC6 in the 259 gastric cancers
W1558
Simultaneous Silencing of Key Oncogenic Pathways - A Promising Novel
Approach to Colon Cancer Treatment
Johannes Fruehauf, Shuanglin Xiang, Youxin Yang, Chiang J. Li
Background Carcinogenesis of colon cancer is a multistep process involving alterations in
several defined oncogenes. Gains of function and losses of function result in the acquisition
of a super-phenotypical cell -the colon cancer cell- which has clear environmental advantages
over normal epithelial cells, including, among others, increased proliferation, reduced

















hypothesized that colon cancer cells require the activity of these oncogenes not only to
develop into malignant cells in the first place, but also to be able to maintain their malignant
phenotype. If this is true, knocking down some of these oncogenes would result in the loss
of one or more of the super-abilities and might create a means of killing cells and treating
colon cancer. Methods RNA-Interference (RNAi) was used to silence oncogenic k-Ras (codon
12 GGT/GTT) and activated beta-catenin in human colon cancer cells (SW 480) in vitro
and in vivo. Hairpin-RNA expressing plasmids were used to obtain gene silencing. Silencing
of either oncogenic pathway resulted in marked decrease of target mRNA and protein. k-
Ras down-regulation alone resulted in 46% reduction in cell number, while beta-catenin
knockdown caused 40% reduction. Simultaneous silencing of both pathways resulted in
59% inhibition. In nude mice (n=24) carrying SW 480 human colon cancer xenografts,
simultaneous silencing of both k-Ras and beta-catenin over 4 weeks lead to a significant
reduction in growth speed and final tumor sizes (p<0.05). Tumors in treated animals were
found to have lowered k-Ras as well as beta-catenin expression on both mRNA and protein
levels. The fraction of proliferating cells was significantly decreased (PCNA stain). Conclusion
We conclude that cancer cells require the continued activity of diverse oncogenes to be able
to maintain their super-phenotype, at least regarding the aspect of increased proliferation.
Both oncogenic (mutated) k-Ras as well as activated beta-catenin are promising treatment
targets for RNAi based therapy and can be successfully silenced in vitro and in vivo.
Simultaneous combination treatment of key oncogenic pathways increases the efficiency of
oncogenic targeting and is likely to circumvent the possible development of resitance to
this type of treatment.
W1559
The Expression of P53, BCL-2, MGMT, P16, BAX, GSTP, KI-67 Protein in
Neoadjuvant Chemoradiotherapy Responsiveness for Rectal Cancer
Jung Hoon Lee, Jong Ryul Eun, Tae Nyeun Kim, Byeong Ik Jang, Jun Hwan Kim, Sun
Taek Choi, Heon Ju Lee
<Introduction> Neoadjuvant chemoradiotherapy for rectal cancer has been shown to reduce
viable tumor size, to lower local recurrence rate, to increase disease-free survival. But some
case does not responed to this therapy. Therefore selection of patient is more important
because neoadjuvant chemoradiotherapy for non-responder make sometimes result in pro-
gression of disease. We aimed to identified the molecular predict factors in responder patients
to neoadjuvant chemoradiotherapy in rectal cancer and to apply clinical usefulness of it.
<Methods> Between January 2000 and july 2003, 70 patients with rectal cancer underwent
neoadjuvant chemoradiotherapy and operation were selected. Colonoscopic findings and
pathologic findings pre- and post- neoadjuvant chemoradiotherapy were reviewed, and we
analyzed the expression of p53, bcl-2, MGMT (O6-methylguanine-DNA methyltransferase),
p16, Bax, GSTP (Glutathione S -transferase pi), Ki-67 protein by immunohistochemistry.
Responsiveness of therapy was divided into non-responder and responder group, the former
is less than half of tumor cell necrosis or disappearence and the latter is more than half of
tumor cell necrosis or disappearence, or no viable tumor cell. <Results> Mean age of total
70 Patients (male 45, female 25) was 58.9 (range 32 to 78). Non-responsive group was
17(24.3%) and responsive group was 53(75.7%) and there was no relationship between
protein expression of p53, bcl-2, MGMT, Bax, GSTP, Ki-67 and responsiveness to neoadjuvant
chemoradiotherapy. But non-responsive group had higher p16 positive stain rate than
responsive group, 9(56.3%) and 14(28.6%), respectively (p=0.018). <Conclusions> In neoad-
juvant chemoradiotherapy for rectal cancer, testing of p16 protein expression may help to
predict the responsiveness of the therapy and further more clinical study is needed.
W1560
Mutational Analysis of Braf Gene in Colorectal Mucinous Carcinoma in
Associated with Histological Configuration
Naoto Yoshitake, Shigehiko Fujii, Keiichi Tominaga, Kenichiro Mukawa, Kouichi Fukui,
Hideyuki Hiraishi, Akira Terano, Takahiro Fujimori
Aim: Activation of MAP kinase cascade by K-ras mutation is associated with tumor progression
in colorectal carcinoma. Furthermore, because K-ras mutation has been found frequently
in colorectal carcinoma with polypoid growth, a relationship between K-ras mutation and
histological configuration has been clarified. Whereas, the BRAF gene, one of raf family that
is a intermediate element of the MAP kinase cascade, has been recently reported to be
mutated in a variety of tumors, including colorectal carcinoma. However, nothing is known
about the frequency of BRAF mutation in colorectal mucinous carcinoma (MUC). In our
study, we examined the incidence of the BRAF mutation, and reviewed its relationship to
K-ras mutation and histological configuration. material and method: Mutations of BRAF and
K-ras were evaluated in 43 colorectal MUC by direct DNA sequencing analysis. To determine
the extent of microsatellite instability (MSI), five microsatellite markers were examined.
Mismatch repair deficiency was assessed by immunohistochemistry for hMLH1. Tumors
were classified into two different sub types as polypoid if the tumor was elevated above the
level of the adjacent normal mucosa, but nonpolypod if the tumor was at the level or below
the adjacent normal mucosa. Result: Seventeen of 43 (39.5%) MUC studied had either BRAF
or K-ras codon 12 and codon 13 mutations. BRAF mutation was detected in 4 (9.3%) MUC
and was all located exon 15. K-ras mutation was detected in 13 (30.2%) MUC, which was
located 10 (76.9%) of codon 12 and 3 (23.1%) of codon 13. No BRAF and K-ras mutations
were identified simultaneously in the same tumor. MSI was detected in 5 (11.4%) MUC. A
higher incidence (50%) of MSI in BRAF mutated tumors was found, compared with non
BRAF mutated tumors (p = 0.075).As well, a higher incidence (50%) of mismatch repair
deficiency in BRAF mutated tumors was found (p = 0.039). Consequently, a significant
lower incidence of MSI and mismatch repair deficiency in K-ras mutated tumors was found
(p<0.001). Of the classifiable tumors, 20 of 43 (46.5%) were polypoid, and 18 of 43 (41.9%)
were nonpolypoid. All of 4 MUC with BRAF mutation and 9 of 13 K-ras mutation were
classified as polypoid type. B-RAF or K-ras mutated tumors were higher incidence of polypoid
(p = 0.023), compared with non BRAF and K-ras mutated tumors Conclusion: Our results
show that BRAF gene are associated with mismatch repair deficiency and that activation of
MAP kinase cascade plays a significant role in tumor progression of colorectal MUC. Further-
more, similar K-ras mutation, BRAF mutation would associate to the polypoid growth pattern.
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W1561
Suppression for Colon Cancer Cell (HT-29) Proliferation By Dominant
Negative Gene Transfer of Apoptosis Signal-Regulating Kinase (ASK)-1
Hikaru Kuwamura, Kazunari Tominaga, Masayuki Siota, Reiko Ashida, Takafumi Nakao,
E.J. Sasaki, Toshio Watanabe, Yasuhiro Fujiwara, Nobuhide Oshitani, Kazuhide Higuchi,
Hidenori Ichijo, Hiroshi Iwao, Tetsuo Arakawa
Background: Apoptosis signal-regulating kinase (ASK)-1 is identified as a molecule which
mediates pro-apoptotic signaling thereby inducing apoptosis for many types of cells. On
the other hand, some reports indicated that ASK-1 induced the cellular differentiation and
survival. These results suggest that ASK-1 had a broad range of biological activities depending
on cell types and cellular context. In the present study, we investigated the role of ASK-1
in colorectal cancer cells. Materials & Methods: We used the well-characterized colorectal
cancer cell line: HT-29 in this study. Adenovirus vector carrying dominant-negative form
of ASK-1 (AD-DN-ASK-1) was produced by PCR as previously reported method. Phosphoryl-
ation of ASK-1, c-Jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase
(MAPK) was analyzed by Western blot analysis. On day 5 after the transfection of AD-DN-
ASK-1 or AD-LacZ, a control vector, the viable cell number was counted by the hemocyto-
meter using a lightmicroscope. On day 2 after the transfection of AD-DN-ASK-1 or AD-
LacZ, Hoechst staining was performed to evaluate the apoptotic cell number. Results: Selective
phosphorylation of ASK-1 at Thr-845, a kinase domain cite, but not Ser 83 nor 967 cites
was induced in HT-29 cells by the serum stimulation in a time-dependent fashion. Its
phosphorylated levels reached to the maximum levels (about 3 fold) compared to the control
levels by 30 min. Using AD-LacZ, the accuracy of the transfection techniques into HT-29
cells was confirmed by the immunostaining. Gene transfer of AD-DN-ASK-1 inhibited the
serum-induced phosphorylation of JNK and p38MAPK which are downstream molecules
of ASK-1. Gene transfer of AD-DN-ASK-1 at a multiplicity of infection (MOI) of 30, 50 or
100 diminished the serum-induced proliferation in a dose-dependent fashion. The number
of positive cells for Hoechst staining after the AD-DN-ASK-1 transfection was significantly
higher than that of AD-LacZ-transfected cells. Conclusion: These results indicated that
inactivation of ASK-1 may inhibit colorectal cancer cell proliferation mediated by the apop-
totic induction. DN-ASK-1 gene transfer seems to be a new strategy for the treatment of
colorectal cancer.
W1562
Allelic Alterations in Ileal Well-Differentiated Neuroendocrine Tumors
(Carcinoid Tumors) By Genome-Wide Single Nucleotide Polymorphism
Analysis
Do H. Kim, Yasuhiko Nagano, Li Zhang, James C. Yao, Jill A. White, Asif Rashid
Background: Ileal well-differentiated neuroendocrine tumors (carcinoid tumors) are uncom-
mon indolent neoplasms. The genetic alterations of these tumors are not well characterized.
Chromosomal deletions and amplifications contribute to cancer pathogenesis. We used high-
density single nucleotide polymorphism (SNP) arrays to detect copy number alterations in
thirteen ileal carcinoid tumors. Methods: Frozen tumor and non-neoplastic tissue were
obtained from surgical specimens of patients undergoing resections for well-differentiated
neuroendocrine tumors in the frozen section laboratory of the Department of Pathology,
MD Anderson Cancer Center. In this study Xba1 GeneChip Mapping 50K Assay Kit (Affyme-
trix, Inc., Santa Clara, CA) was used. Locus-specific hybridization intensity of genomic DNA
from non-neoplastic and neoplastic tissue were compared. Results: The average genotyping
call rate for the normal and tumor samples were over 90% ( normal 90.4%, tumor 91.6%).
Alleleic imbalances were identified by copy number variation from the reference set and
from the copy number of the matched non-neoplastic samples. The average copy numbers
for all the non-neoplastic samples was 2.0 ± 0.05. In contrast, tumor samples with deletions
of chromosome or chromosomal loci had average copy number of 1.5 or less, and with
amplifications of chromosome or chromosomal loci had average copy number of 2.5 or
more. We found both known and novel genomic amplifications and deletions. This was
further confirmed by comparing the SNP allelotyping status and by loss of heterozygosity
status of chromosomes 9p, 11q, 16q, and 18 reported previously. Loss of chromosome 18
was the most common aberration and present in 69% (9/13) of tumors, of chromosome 9p
and 16q in 23% (3/13) each, and chromosome 2q in 15% (2/13). Gain of chromosomes 4
and 17q was the most common amplification and present in 23% (3/13) of tumors each,
of chromosomes 5, 14 and 20 in 15% (2/13) of tumors each. Conclusions: Our study show
that genome-wide allelotyping using SNP array is a powerful new tool for the analysis of
allelic imbalance in ileal well-differentiated neuroendocrine tumors and should strengthen
our ability to discover cancer-causing genes.
W1563
Progression of Barrett’s Metaplasia to Adenocarcinoma Is Associated with the
Expression of Unphosphorylated Retinoblastoma Gene Product (pRB)
Alexander Braun, Dietmar Stueker, Thomas Kratt, Alfred Koenigsrainer
Background: Barrett’s esophagus (BE) is a premalignant lesion characterized by replacement
of normal squamous epithelium with columnar epithelium. Derangements in cell cycle
control and apoptosis regulation might be responsible for the progression from metaplasia
to intraepithelial neoplasia and adenocarcinoma. This study was undertaken to examine the
expression of retinoblastoma gene product (pRB) in the carcinogenesis of Barett adenocarcin-
oma. Methods: A total of 30 patients with adenocarcinoma (n = 20) and intraepithelial
neoplasia (n = 10) in BE were included. Finally, as control group, we selected 10 patients
without intraepithelial neoplasia. Samples of invasive adenocarcinoma derived from 20
oesophagectomy specimens. Endoscopic mucosal resection (EMR) was used in 20 patients
(82 samples) with (42 samples) and without (40 samples) intraepithelial neoplasia. Expression
of the phosphorylated / un(der)phosphorylated retinoblastoma gene product (pRB) were
measured by flow cytometry. Results: 85% (17/20) of Barrett adenocarcinoma and 60% (6/
10) of intraepithelial neoplasia showed an expression of un(der)phosphorylated pRB whilst
20% (4/20) of Barrett adenocarcinoma and 10% (1/10) of intraepithelial neoplasia showed
the phosphorylated pRB. The un(der)phosphylated pRB was found in 5% (2/40) in BE
without intraepithelial neoplasia whilst 65% (26/40) expression of phosphorylated pRB was
detected. Conclusions: Expression of un(der)phosphorylated pRB are common events in
Barrett adenocarcinoma. These data adress that un(der)phosphorylated pRB may be a novel
biomarker for BE and that its expression may help to predict the prognosis of this pathology.
In the future, the use of this procedure could play an important role in the evaluation of
patients with BE.
W1564
Intestinal Epithelial Cell Migration Is Regulated By SMAD5 in Mice Impaired
for BMP Signaling
Jean-Francois Schmouth, Yannick D. Benoit, Benoit A. Auclair, Lieve Umans, An Zwijsen,
Deborah L. Gumucio, Nathalie Perreault
BACKGROUND: Bone morphogenetic proteins (BMPs) are members of the TGF-Beta super-
family that play crucial roles in embryogenesis, organogenesis and homeostasis in adult
tissues. The interaction of BMP proteins with their receptors triggers a signalization cascade
that is driven by R-Smad transcription factors (Smad 1, 5 and 8). Smad5 null mice die at
mid-gestation due to multiple embryonic defects including a vestigial gut. Despite an increas-
ing interest in BMP signaling in the biological processes and pathologies of the gut, very
little is known of the specific roles played by individual Smads in gut morphogenesis and
intestinal epithelial cell homeostasis. AIM: To investigate the specific function of Smad5
within BMP signaling during intestinal organogenesis and cellular function. METHODS AND
RESULTS: With the use of the Cre/loxP system we have generated two distinct mouse lines
having either Bmpr1a or Smad5 exclusively deleted in the gut epithelium. These deletions
were generated by crossing floxed Bmpr1a or floxed Smad5 mice with the Villin-Cre line.
Histological analysis, with H&E staining, revealed multiplication and elongation of the crypt
compartment as well as an important lengthening of the villi in the Villin-Cre;Bmpr1a
loxP/loxP line. However, only an increase in the length of the villi was observed in the
VillinCre;Smad5 loxP/loxP mice when compared to control littermates. Proliferation assays
with a 90-minute BrdU pulse showed a significant increase in the number of proliferating
cells in the Bmpr1a conditional KO mice. No significant modifications in the number or
localization of proliferating cells were noticed in the Smad5 conditional KO mice when
compared to control littermates. Migration assays with a 48-hour BrdU pulse showed an
increase in the epithelial cell migration rate along the crypt/villus axis in both mutant mouse
models. Immunostaining with an E-cadherin specific antibody revealed a relocalization of
E-cadherin mainly to the basal membrane in both Bmpr1a and Smad5 mutant mice whereas in
control littermates E-cadherin was found at the Zonula Adherens. CONCLUSION: Altogether,
these results demonstrate that Smad5 plays an important role in intestinal epithelial cell
migration possibly due to its implication in E-cadherin localization. Because of some differ-
ences in the phenotype of the conditional KO of the upstream receptor Bmpr1a and the
downstream signal mediator Smad5, this study suggests that the various R-Smads associated
with BMP signaling might have distinct functions in the gut epithelium. Further analysis will
allow us to delineate the differences between the BMP related R-Smads in the gut epithelium.
W1565
Regulation of β-Catenin/TCF Complex Transcriptional Activity By Tyrosine
Phosphorylation/Dephosphorylation of β-Catenin in Intestinal Epithelial Cells:
Role of SRC Tyrosine Kinase and SHP-1 Tyrosine Phosphatase
Melanie Simoneau, Nathalie Rivard
β-catenin plays a dual role as a key effector in the regulation of adherens junctions and as
a transcriptional coactivator of the Wnt pathway in intestinal epithelial cells. We have
demonstrated that the phosphatase SHP-1 negatively regulates the nuclear transcriptional
function of β-catenin (Duchesne et al. J.Biol.Chem. 2003). In addition, it has been demon-
strated that phosphorylation of tyrosine-654 decreases its binding to E-cadherin but stimu-
lates the association of β-catenin to the basal transcription factor TATA-binding protein.
Herein, we have further investigated the role of tyrosine phosphorylation in the regulation
of β-catenin stability and transcriptional activity in intestinal epithelial cells. Methods. Trans-
fection and Western blotting were performed in human intestinal epithelial crypt cells HIEC,
Caco-2/15 colon carcinoma and HEK293 cells. We constructed specific mutants of putative
tyrosine phosphorylation sites (Y86F, Y654F) and transactivation potential on the TOPFLASH
reporter and on c-myc and cyclin D1 promoters was assessed. The effects of the tyrosine
phosphatase inhibitor, pervanadate (0.1 mM), and ectopic expression of a constitutive active
mutant of src (Y529F,caSrc) and SHP-1 were also analyzed on phosphorylation, stability
and transcriptional activity of β-catenin. Results. 1) SHP-1 expression significantly decreased
by 40-50% the transactivation potential of β-catenin on the TOPFLASH reporter and on c-
myc and cyclin D1 gene expression in HIEC cells; by contrast, expression of caSrc enhanced
by 10-fold the transactivation potential of β-catenin on the TOPFLASH reporter in HIEC
and Caco-2/15 cells and this effect was markedly reduced by co-expression of SHP-1. 2)
Overexpression of SHP-1, but not the inactive form of SHP-1 (C453S), resulted in a strong
decrease in tyrosine phosphorylation of β-catenin; by contrast expression of caSRC or
treatment with pervanadate strongly increased tyrosine phosphorylation levels of β-catenin.
3) Ectopic expression of caSRC significantly enhanced β-catenin stability, increasing β-
catenin protein levels, an effect abolished by co-expression of SHP-1. 4) Mutations of
tyrosine-86 (Y86F) and tyrosine-654 (Y654F), two putative phosphorylation sites for c-src,
significantly decreased by 50% the transactivation potential of β-catenin on the TOPFLASH
reporter and on target gene expression (cyclin D and c-myc) in HIEC and Caco-2/15 cells.
Conclusion. Taken together, our results indicate that the transcriptional activity of β-catenin/
TCF complex is controlled by tyrosine phosphorylation of β-catenin which in turn, may be
determined by Src tyrosine kinase and SHP-1 tyrosine phosphatase activities.
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W1566
Stabilization of the Cytoskeleton By Transfection of Phospho-Hsp27 Restores
Caveolin-Mediated Physiological Signaling Cascade Responsible for
Contraction in Aged Internal Anal Sphincter
Sita Somara, Jeffrey R. Martens, Khalil N. Bitar
Background: Aging-related decline in signal transduction results in decreased contraction.
Decline in signal transduction may be due to an age-related deficiency in the docking of
signaling molecules on the membrane. Objective: Is restoration of cytoskeletal stability and
caveolae formation able to reinstate smooth muscle contraction in aged smooth muscle cells
(SMC)? Methods: SMC were isolated from the Internal Anal Sphincter (IAS) of adult rats
(12-18 mos) and aged rats (33 mos). Aged rats SMC were transfected with either phospho-
HSP27 mutant or wild type cav1 cDNA. Results: 1) Whole cell lysate of IAS SMC showed
the presence of all three caveolin isoforms; cav1, cav2 and cav3; 2) Significant reduction in
the levels of cav1 was observed in the particulate fraction of aged IAS SMC (48.24 ± 0.06%)
as compared to adult IAS SMC (100 ± 0.03%); 3) Immunoblotting of cav1 immunoprecipitates
showed reduced acetylcholine-induced association of cav1 with PKCα and with HSP27 in
aged IAS SMC (PKCα: 107.40 ± 1.09% at 30sec and 111.75 ± 1.03% at 4min and
HSP27:109.87 ± 2.33% at 30sec and 114.47 ± 2.46% at 4min) as compared to adult IAS
SMC (PKCα:177.22 ± 0.27% at 30sec and 179.74 ± 0.81% at 4min and HSP27: 161.67 ±
1.48% at 30sec and 170.30 ± 5.91% at 4min); 4) Transfection of aged IAS SMC with
phospho-HSP27 restored: a) cav1 levels in the particulate fraction of aged IAS SMC (74.27
± 0.02%); b) acetylcholine-induced association of cav1 with PKCα (157.68 ± 4.23% at
30sec and 159.46 ± 4.12% at 4min) and c) acetylcholine-induced association of cav1 with
HSP27 (154.39 ± 1.12% at 30sec and 164.37 ± 5.93% at 4min). 5) Transfection of aged
IAS SMC with cav-1 restored: a) acetylcholine-induced association of cav1 with PKCα
(143.57 ± 4.62% at 30sec and 148.07 ± 4.72% at 4min) and b) acetylcholine-induced
association of cav1 with HSP27 (136.69 ± 0.96% at 30sec and 146.77 ± 0.99% at 4min).
Summary: Aged IAS SMC showed reduced cav1 levels resulting in reduced acetylcholine-
induced association of cav1 with PKCα and with HSP27 in the particulate fraction. Transfec-
tion of aged IAS SMC with either phospho-HSP27 or with wild type cav1 restored acetylchol-
ine-induced association of cav1 with PKCα and with HSP27 in the particulate fraction.
Conclusions: Introduction of phospho-HSP27 into aged IAS SMC may restore cytoskeletal
stability. A stable cytoskeleton or introduction of wild type cav1 into aged IAS SMC may
restore caveolae formation by maintaining cav1 on the membrane, thus reinstating the
physiological signaling cascade responsible for contraction in aged IAS SMC.
W1567
Differential Regulation of Pyk2 Phosphorylation At Tyr-402 and Tyr-580 in
Intestinal Epithelial Cells: Roles of Calcium, SRC, Rho Kinase, and the
Cytoskeleton
Steven S. Wu, Enrique Rozengurt
The calcium-dependent proline-rich tyrosine kinase Pyk2 is activated by tyrosine phosphoryl-
ation, associable with focal adhesions, and has been linked to proliferative and migratory
responses in gastrointestinal and other cell types. Pyk2 phosphorylation occurs at functionally
distinct sites: Tyrosine 402 (Tyr-402) is the target for autophosphorylation, the initial event
in activation, while phosphorylation of Tyr-580 within the kinase domain further enhances
enzymatic activity. These activation events are thought to be tightly coupled in a sequential
manner, as in the closely homologous focal adhesion kinase (FAK), though the mechanisms
involved are unclear. The aim of this study was to examine the pathways mediating Pyk2
auto- and transphosphorylation in intestinal epithelial cells. Methods: Pyk2 phosphorylation
at specific tyrosine sites was measured by immunoprecipitation and Western blotting with
phosphospecific antibodies. IEC-18 cells were stimulated with the G protein-coupled receptor
(GPCR) agonists angiotensin II (Ang II) or lysophosphatidic acid (LPA), or with the Ca2+
ionophore ionomycin; selected cells were also preincubated with inhibitors of PKC, Src,
Rho kinase, actin stress fibers, or Ca2+ signaling. Results: Both Tyr-402 and Tyr-580 were
rapidly and transiently phosphorylated following cell stimulation by Ang II or LPA, mirroring
the rapid peak (1 min) of total Pyk2 tyrosine phosphorylation. However, at Tyr-402 these
agonists also induced a delayed (30-60 min) secondary phosphorylation peak, with no
corresponding rise at Tyr-580. Other evidence showed differential phosphorylation of these
two sites: Only Tyr-580 was affected by either Ca2+ inhibition (with thapsigargin+EGTA)
or by Ca2+ release (via ionomycin). Conversely, Tyr-402 phosphorylation was primarily
sensitive to inhibition of actin stress fibers (by cytochalasin D) or of Rho kinase, an upstream
regulator of stress fiber assembly. Neither Tyr-402 nor Tyr-580 was sensitive to the Src
inhibitor PP2. Conclusion: These results suggest that Pyk2 autophosphorylation is stress
fiber-dependent, while transphosphorylation within the kinase domain requires Ca2+, and
is Src-independent in intestinal epithelial cells. This better defines the mechanisms involved
in Pyk2 activation, and contrasts with the sequentially coupled model of phosphorylation
that occurs in FAK, further underlining the differences between these closely related kinases
in the intestinal epithelium.
W1568
Sensitization of Human Intestinal Microvascular Endothelial Cells (HIMEC) to
Ionizing Radiation By Curcumin
Aaron Rogaczewski, Pamela J. Kexel, Monica E. Theriot, Victoria M. Nelson, Mary F.
Otterson, David G. Binion, Parvaneh Rafiee
INTRODUCTION: Advanced colorectal adenocarcinoma is frequently treated with radiation
therapy. Research into the anti-neoplastic mechanisms of external beam ionizing radiation
has focused primarily on direct effects against tumor cells. Recent investigation suggests that
the therapeutic effect of radiation may also involve the destruction of microvessels supplying
blood and O2 to tumors. This possibility has prompted new investigation into the effects
of ionizing radiation on endothelial cells. The aim of this study is to investigate the radio-
sensitizing effects of curcumin, a promising anti-inflammatory agent, on primary cultures

















exhibits growth inhibitory effects on a broad range of tumors. METHODS: Serum-deprived
HIMEC cultures (passage 8 - 12) with and without curcumin were exposed to 2-10 Gy
ionizing radiation and incubated for 1-48h. We tested the effect of a combination of curcumin
and radiation on cell survival, PI3K/Akt proteins, MAPK, NFκB activation, induction of
apoptosis and COX-2 expression. Analyses were performed using RT-PCR, Western blotting,
in vitro Kinase activity, and Tunnel assay. RESULTS: Curcumin in combination with radiation
significantly abolished PI3k/Akt activities and enhanced HIMEC apoptosis. Ionizing radiation
alone induced HIMEC growth which was associated with PI3K/Akt activation and JNK
activity. Ionizing radiation also induced NFκB transcription factor activation in HIMEC,
resulting in increased expression of bcl-2 protein. Curcumin treatment of HIMEC combined
with radiation abolished JNK activity and inhibited NFκB activity, resulting in down-regula-
tion of bcl-2 protein and enhanced radio-sensitization. COX-2 mRNA and protein were up-
regulated in irradiated HIMEC in a dose and time-dependent manner. Curcumin treatment
of HIMEC abolished COX-2 mRNA and protein expressions in irradiated HIMEC. CONCLU-
SIONS: The combination of radiation and curcumin abolished PI3k/Akt activities and
enhanced apoptosis in HIMEC. This data suggests that curcumin sensitizes HIMEC by
causing the radiation-induced pro-survival gene expression. Curcumin inhibited COX-2 via
suppression of JNK and NFκB in irradiated HIMEC. We concluded that curcumin sensitizes
HIMEC by modulating the mitogenic, anti-proliferative and apoptotic pathways. Thus curcu-
min may have potential as a new radiosensitizing strategies in radiation therapy.
W1569
Increased Arginase II and Decreased NO Synthesis in Human Microvascular
Endothelial Cells (HIMEC) of IBD Patients
Scott Horowitz, Aaron Rogaczewski, Victoria Nelson, Zelmira Lazarova, Christopher
Andrekopouis, Balaraman Kalyanaraman, Mary F. Otterson, David G. Binion, Parvaneh
Rafiee
Introduction: Inflammatory bowel disease (IBD) is characterized by microvascular dysfunc-
tion in areas of chronically inflamed bowel. IBD microvascular dysfunction is linked to
impaired endothelial generation of nitric oxide (NO), normally a homeostatic mechanism
in vascular physiology. Mechanisms underlying diminished microvascular endothelial genera-
tion of NO in IBD are not fully defined. The arginase enzymes (ARI, ARII) deplete L-arginine
levels in the intracellular environment, preventing NOS isoforms from accessing the essential
substrate for NO generation. We hypothesized that arginase expression is increased in
chronically inflamed IBD microvessels and their endothelial lining, which contributes to
decreased NO production in the chronically inflamed gut microvasculature. Methods: Freshly
resected human gut tissues and HIMEC cultures (passage 8 - 12) from control and IBD pts
were used for all studies. L-arginine (L-Arg) acted as substrate for both NO synthase (NOS
isoforms) and arginase (ARI, ARII), producing either NO or urea respectively. AR and NOS
was assessed in both HIMEC and gut tissues by immunostaining, RT-PCR, western blotting
and enzymatic assays. Results: TNF-α/LPS increased ARII mRNA and protein in HIMEC.
The arginase inhibitor L-Val (30 mM) decreased urea and increased NO production in both
control and TNF-α/LPS activated HIMEC, while addition of excess substrate (10 mM L-
Arg) increased both urea and NO production. Combination of both excess substrate (L-
Arg) and AR inhibitor (L-Val) decreased urea production compared with L-Arg alone and
increased NO production compared with L-Val alone. These data suggest that competition
for intracellular L-Arg by AR may be involved in the regulation of NOS activity in control
HIMEC and in response to TNF-α/LPS treatment. Finally, immunostaining of freshly resected
control and IBD tissues revealed marked increase in perivascular arginase protein expression
in IBD tissues. Discussion: Loss of NO production in IBD microvessels is linked to enhanced
levels of AR in endothelial cells exposed to chronic inflammation in vivo. The enhanced
expression of AR in passaged HIMEC, which are removed from the chronic inflammatory
environment suggests acquired pattern of arginase overexpression in response to TNF-α/
LPS. These data suggest that increased arginase expression is an epigenetic alteration in
endothelial gene expression in human endothelial cells exposed to chronic inflammation
in IBD.
W1570
Comparison of Kinase Profiles in Barrett’s Esophagus, Normal Squamous
Esophagus and Normal Gastric Cardia Proves That Barrett’s Esophagus Has a
High Glycolytic Activity
Jantine van Baal, Sander H. Diks, Agnieszka M. Rygiel, Francesca Milano, Jacques J.
Bergman, Ronald J. Wanders, Maikel P. Peppelenbosch, Kausilia K. Krishnadath
BACKGROUND: Barrett’s esophagus (BE) is the metaplastic process in which the normal
squamous epithelium (SQ) is replaced by columnar lined epithelium. To gain more insight
into the cellular mechanisms in the development of BE, the aim of this study was to create
a comprehensive description of cellular kinase activity occurring in BE, SQ and gastric
cardia (GC). MATERIAL AND METHODS: Peptide arrays exhibiting 1176 specific consensus
sequences for protein kinases were used to produce a global analysis and comparison of
cellular kinase activity of BE, SQ and GC. Differences in kinase activity were validated by
conventional technology in tissue samples of 27 BE patients. RESULTS: Three unique kinome
profiles were compared. Validation by immunoblotting showed that in BE the MAPK signaling
is decreased probably due to increased inhibition of c-Raf through Rab. One of the most
prominent differences between BE and SQ was the significant decreased phosphorylation
of Src consensus substrates. Furthermore, we found that EGF receptor activity is decreased
in BE compared to SQ, but its activity is increased compared to GC. In addition kinome
analysis demonstrated that glycolysis is an important process in BE as validated by pyruvate
kinase activity confirming that this activity is significantly up-regulated in BE compared to
SQ and GC (see Figure below). CONCLUSIONS: Using a peptide array we demonstrated
that BE has several specific kinase activities when compared to the kinome profiles of SQ
and GC. This study contributes to a better understanding of kinase activities, and several
signal transduction pathways and cellular functions that are associated with BE. Future
manipulations of these pathways will help us to treat BE and prevent the associated eso-
phageal adenocarcinoma.
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W1571
Myosin Vi Regulates Surface Expression of CFTR and Its Endocytosis from
the Apical Plasma Membrane in the Intestine in Vivo
Nadia Ameen, Franca G. Bisello, Hannes Kohnke, Gerard Apodaca
The cystic fibrosis transmembrane conductance regulator (CFTR) is present in organelles that
participate in clathrin-mediated endocytosis in the intestine, but the physiologic mechanisms
regulating its endocytosis are not understood. Myosin VI is a unique inwardly directed actin
motor that regulates apical endocytosis in polarized cells and its distribution overlaps that
of CFTR in the small intestine. We hypothesized that Myosin VI would regulate surface
expression of CFTR, its endocytosis from the apical plasma membrane and function in the
small intestine Methods: Intestinal tissues from Myosin VI -/- mice were examined by electron
microscopy. CFTR distribution in the intestine was examined by immunofluorescence con-
focal microscopy and surface biotinylation. CFTR endocytosis was determined following
surface biotinylation in vivo Results: Scanning and transmission electron microscopy revealed
disordered and shorter microvilli in Myosin VI -/- mice compared to littermate controls
(.82µm vs. 1.18µm, n= 14 cells, p<0.005). Quantification of CFTR fluorescence in immunola-
beled sections revealed a two-fold increase in apical CFTR. Surface biotinylation confirmed
a 3-fold increase of CFTR cell surface expression in Myosin VI-/- intestine and endocytosis
of CFTR was reduced by 50% in Myosin VI -/- mice. Conclusions: Myosin VI regulates
surface expression of CFTR and its endocytosis from the plasma membrane in the native
small intestine. Functional studies of CFTR anion transport in Myosin VI-/- intestine will
determine the physiologic relevance of these novel observations.
W1572
Involvement of the Apelin-Apj System in Intestinal Epithelial Proliferation
During Development
Guiyun Wang, Song Han, Xiang Qi, Ella W. Englander, George H. Greeley
Apelin is the endogenous ligand for the APJ receptor. Apelin and APJ are expressed in the
GI tract and mammary gland. In the rat, breast apelin expression increases ~7- to 20-fold
during pregnancy and lactation. In breast milk and stomach lumen of nursing rats, apelin
peptide levels are exceptionally high (300-600 ng/ml) suggesting that luminal apelin plays
a role in regulation of GI development. The aim of these studies was to define expression
levels of apelin and APJ receptor in the developing rodent gut. Additionally, the effect of
exogenous apelin on GI epithelial proliferation was tested. Methods. Apelin and APJ mRNA
levels in the developing mouse and rat GI tracts were measured by real time RT-PCR. Enteric
apelin peptide levels were examined by immunohistochemistry (IHC). The effect of apelin
(50 µg, 3x/day for 3 days, SC) on stomach, duodenal and colonic epithelial proliferation
was assessed in mice by giving BrdU (290 mg/kg) 90 min before sacrifice. BrdU incorporation
was examined by IHC. Results. Apelin mRNA levels in the rat and mouse stomach, duodenum
and colon were highest at birth and declined after weaning into adulthood (see Table, mouse
colon values shown only). IHC showed that enteric apelin peptide levels were low perinatally
and increased only after weaning. APJ mRNA levels in the gut were highest at birth and
decreased dramatically before weaning into adulthood. Apelin administration decreased the
colonic proliferation rate by 50% (control BrdU cells: 149 ± 23 vs apelin treated BrdU cells:
67 ± 16/field; N=5 mice/group, P<0.05); the stomach and duodenum were unaffected.
Discussion and Conclusions. Ingestion of apelin in breast milk suggests a role for lumenal
apelin in regulation of the GI tract during development. Despite high enteric apelin expression
during development, marginal amounts of apelin peptide are produced in the perinatal gut
indicating a dependence upon milk-borne apelin. The importance of luminal apelin and the
GI apelin-APJ system is reinforced by the high APJ expression levels in the gut at birth and
the perinatal period. The finding that apelin treatment lowers colonic, but not small intestine
and stomach epithelial proliferation indicates apelin exerts a selective modulatory role on
colonic epithelial proliferation during development.
* = P<0.05 vs fetal, † = P<0.05 vs fetal, 6 d pup 1 = mean ± SEM, N=5 mice/group
W1573
Novel Mechanisms of Beta-Catenin Regulation By Tumor Suppressor APC
Jun Yang, Wen Zhang, Paul M. Evans, Chunming Liu
Background: The majority of colorectal cancers have mutations of the APC (adenomatous
polyposis coli) gene or beta-catenin gene. These mutations result in abnormal beta-catenin
accumulation and activation of beta-catenin target genes which leads ultimately to cancer.
In normal cells, beta-catenin degradation is initiated by serine/threonine phosphorylation
at its amino terminal region. Our previous studies have shown that, without Wnt signaling,
glycogen synthase kinase-3 (GSK-3), casein kinase I alpha (CKIalpha) in complex with the
scaffold protein Axin, carries out beta-catenin phosphorylation. Moreover, we have shown
that ubiquitin ligase beta-Trcp recruits the phosphorylated beta-catenin for ubiquitin/pro-
teasome degradation. beta-catenin with serine/threonine mutations escapes CKIalpha or
GSK-3 phosphorylation and beta-Trcp recognition, resulting in constitutive beta-catenin
activation that leads to cancer. APC is required for beta-catenin degradation, however, the
molecular mechanisms regulating APC mediated beta-catenin degradation are not known.
Method: Colon cancer cell lines, HT29, SW480, DLD-1 and HCT116 were used for this
study. beta-catenin phosphorylation was analyzed with phospho-specific antibodies that
recognize GSK3 or CK1alpha phosphorylation sites of beta-catenin. beta-catenin ubiquitin/
degradation was analyzed by treating the cell with proteasome inhibitor, MG132. APC
fragments were delivered to cells by adenovirus. Results: APC has two types of beta-catenin
binding domains, 15aa repeats and 20aa repeats. APC also has Axin binding domains.
It was suggested that APC is involved in the Axin complex and regulates beta-catenin
phosphorylation. Surprisingly, we found that the APC mutations do not prevent beta-catenin
phosphorylation in colon cancer cells. We also found that, in the colon cancer cell line
SW480, APC truncations block beta-catenin ubiquitination regardless of beta-catenin phos-
phorylation. After introducing functional APC by adenovirus, we found that the beta-catenin
ubiquitin/degradation was rescued in SW480 cells, suggesting that APC regulates beta-
catenin ubiquitin/degradation in addition beta-catenin phosphorylation. The functions of
different APC domains were analyzed in this study. We found that at least three 20aa repeats
of APC were required for beta-catenin ubiquitin/degradation. The effects of APC on beta-
catenin subcellular localization were also analyzed. We hypothesize that APC regulates beta-
catenin phosphorylation and ubiquitination by distinct domains and by separate molecu-
lar mechanisms.
W1574
Induction of Trail Expression By the PKCθ/PKD/NFAT Pathway in Human
Intestinal Cells
Qingding Wang, Yuning Zhou, Suimin Qiu, B. Mark Evers
TNF-related apoptosis-inducing ligand (TRAIL; Apo2) has been shown to promote intestinal
cell differentiation. Recently, we found that PKCθ (a novel PKC isoform), PKD (serine/
threonine kinase structurally distinct from the PKC proteins), and the nuclear factor of
activated T cells (NFAT) are involved in the regulation of intestinal cell differentiation. The
purpose of this study was to determine the upstream regulation of TRAIL associated with
intestinal differentiation. METHODS. (i) The human colon cancer cell lines HT29, SW480
and Caco-2 were used. Cells were treated with interferon-γ (IFN-γ), which induces TRAIL
expression, in the presence or absence of cyclosporine A (CsA), which inhibits NFAT signaling
through inhibition of calcineurin; TRAIL expression was assayed by Western blotting. To
further determine the role of NFAT, cells were transfected with the NFAT reporter construct,
NFAT siRNA or constructs overexpressing NFAT. (ii) To determine the possible role of
PKCθ or PKD, cells were co-transfected with the control vector or the plasmid overexpressing
the active form of PKCθ or PKD, in combination with a 1.3 kb TRAIL promoter construct.
TRAIL promoter activity was determined by luciferase assays using a dual reporter assay
system; transfection efficiency was controlled by Renilla luciferase. (iii) Expression of PKD
(total and phosphorylated) and TRAIL was analyzed in human colon mucosa by immuno-
histochemistry. RESULTS. (i) Inhibition of NFAT by CsA or transfection with NFAT siRNA
attenuated IFNγ-induced TRAIL expression in HT29 and SW480 cells, whereas overexpres-
sion of NFAT increased TRAIL promoter activity in Caco-2 cells. Consistent with these
results, five putative NFAT binding sites were identified in the proximal TRAIL promoter.
(ii) Overexpression of active PKCθ increased TRAIL promoter activity as well as NFAT
reporter activity. Activation of PKD by PKCθ was noted by increased PKD phosphorylation
in cells overexpressing PKCθ. Moreover, overexpression of active PKD increased NFAT
reporter activity as well as TRAIL promoter activity and protein expression. (iii) TRAIL, total
PKD and phospho-PKD demonstrated similar expression patterns with localization to the
upper crypts (ie, most differentiated region) of the colonic mucosa. CONCLUSIONS. Our
results are the first to identify TRAIL as a downstream target of the PKCθ/PKD/NFAT
pathway. Importantly, the PKCθ/PKD/NFAT signaling pathway may regulate intestinal cell
differentiation through the regulation of TRAIL expression.
W1575
Transforming Growth Factor-Beta Signaling May Play a Protective in
Preventing Liver from Insulin Induced Steatosis By Regulating Insulin Driven
AKT Inactivation of Forkhead Transcriptional Factor Proteins
Krit Kitisin, Tang Yi, Varalakshmi Katuri, Nady Golestneh, Wilma Jogunoori, Kirti Shetty,
Lopa Mishra, Lynt B. Johnson
Non-alcoholic fatty liver disease (NAFLD) represents a progression of liver fibrosis, liver
injury, and possibly development of hepatocellular carcinoma. Disruption of the transforming
growth factor-beta (TGF-beta) signaling cascade, which plays a critical role in hepatic
homeostasis and normal liver development, might also contribute to initiation of hepatic
steatosis. Precise modulation of TGF-beta through Smad activation by the type I receptors
is dependent upon adaptor proteins such as ELF, a beta-spectrin. Normal biliary epithelial
development is absent in the elf-/-and in the Smad2+/-/3+/- mutant embryos. Both elf-/-
and Smad2+/-/3+/- mice die at mid-gestation from defective liver development. Mice with
elf+/- mutant are viable but as many as 35% (7/20) develop hepatocellular carcinoma (HCC)
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with significant centrilobular steatosis. Aside from the TGF-beta signaling pathway, forkhead
transcriptional proteins, particularly FOXA2 and FOXO1, are essential in gluconeogenesis
and fatty acid oxidation during starvation. Mice with either FOXA2 or FOXO1 knockout
develop insulin-resistance and diabetes. Aims: 1. To investigate a possible cross-talk between
TGF-beta signaling and forkhead protein regulation under PI3 kinase signaling. Methods
and Results: Embryonic liver tissues isolated from normal (wt), elf-/- and Smad2+/-/3+/-
mutants were isolated and cultured in a large range of growth factor combinations and
conditions to determine their growth properties. 1. Explants from Smad2+/-/3+/- mutant
embryo treated with insulin demonstrated a dramatic increase in steatosis. 2. Western blot
analysis of cell lines derived from elf+/- and elf+/-/Smad4+/- mutants revealed significant
increases in p-AKT level compared to the wild type cell line. 3. p-AKT levels in these mutant
cell lines decrease with restoration of ELF protein. 4. Immunohistochemical labeling of
hepatocellular cancer taken from elf+/- mice revealed increased cytoplasmic labeling of
FOXO protein. Conclusions: In Smad2+/-/3+/- and elf+/- mutant embryo explants, the
addition of insulin resulted in severe steatosis. The mechanisms of these findings could be
secondary to the alteration in forkhead protein transcriptional factors level whereby forkhead
proteins are sequestered by Insulin driven Akt, and are unable to partner with Smads and
ELF to modulate expression of forkhead target genes. More importantly, in adult tissues
these derangements may promote fibrosis, steatosis and hepatocarcinogenesis.
W1576
Histamine Stimulates EGF Receptor Ligand Production from Gastric Parietal
Cells
E.J. Nakamura, Ryo Hatazawa, Takuya Endo, Kikuko Amagase, Hideki Taniguchi,
Susumu Okabe, Koji Takeuchi
Background & Aims: We previously reported that both H2 receptor-knockout (H2R-KO)
mice and histidine decarboxylase-knockout (HDC-KO) mice exhibit marked gastric mucosal
hyperplasia due to hypergastrinemia. However, the degree of hyperplastic changes in HDC-
KO mice was much less than that of H2R-KO mice, and there was an apparent difference
in the levels of gastric mucosal histamine contents between these two groups. In the process
to clarify the mechanisms underlying such different phenotypes between H2R-KO and HDC-
KO mice, we found that the marked gastric hyperplastic changes were induced by not only
histamine overexpressed by hypergastrinemia but also chronically administered histamine
mediated via EGF receptor pathway in vivo. Thus, in the present study, we further performed
the more detailed analyses to characterize the source cells of EGF receptor ligand(s) stimulated
by histamine in the gastric mucosa. Methods: Immunohistochemical analyses to detect TGF-
α, amphiregulin and HB-EGF as well as betacellulin were performed in the gastric mucosa
of C57/BL6J mice treated with histamine (10 mg/kg, subcutaneously) or vehicle (saline). In
addition, to exclude the involvement of the systemic factor, the isolated gastric mucosae
incubated with or without histamine was also examined immunohistochemically. Cell charac-
terization was performed for parietal cells (anti-H+, K+-ATPase), enterochromaffin-like cells
(ECL; anti-HDC), chief cells (anti-pepsinogen), G cells (anti-gastrin) and D cells (anti-
somatostatin). Western blotting was used for the quantitative analysis for TGF-α and amphire-
gulin expression. Results: The expression of amphiregulin and TGF-α proteins was observed
relatively potently in the parietal cells and weak in the surface cells in vehicle-treated mice.
Exogenous histamine increased the expression of amphiregulin in a time-dependent manner.
Famotidine, an histamine H2-receptor antagonist, had no effect on the stimulatory effect of
histamine on the expression of amphiregulin in the parietal cells. Conclusion: These results
indicate that histamine stimulates the expression of EGF receptor ligand in the parietal cells
and this action may be independent of the activation of histamine H2-receptors.
W1577
The BRK Tyrosine Kinase Confers Resistance to Dextran Sodium Sulfate
Induced Colitis
Katherine Jelinek, Wenjun Bie, Andrea Haegebarth, Angela L. Tyner
Brk (also called Sik or Ptk6) is an intracellular epithelial specific tyrosine kinase expressed
in normal epithelial linings of the gastrointestinal tract. Previously it was reported that Brk
expression is increased in colon tumors. Since chronic inflammation and cancer are often
linked in the colon, we investigated functions of Brk in a murine colitis model. We subjected
wild-type and Brk-/- mice to 3% dextran sodium sulfate (DSS) in drinking water ad libitum
for 5 days, followed by a recovery period with water for 3 days. Mice were closely monitored
for weight loss and rectal bleeding. At 5 or 8 days post initiation of DSS treatment, mice
were sacrificed and colons were isolated. Colon sections were stained with hematoxylin and
eosin and evaluated by light microscopy. Brk-deficient colons had more severe and extensive
denudation of the surface epithelium and goblet cell depletion than wild-type control mice.
Furthermore, Brk-deficient mice had a greater amount of inflammatory infiltrate in the
submucosa and lamina propria and more crypt distortion. Although Brk-/- mice had more
localized inflammation in their distal colons following DSS administration, this did not have
an impact on their immediate survival. Total RNA was isolated from untreated and DSS
treated colons of wild-type and Brk-/- mice and pro-inflammatory cytokine gene expression
was analyzed by multiprobe RNase protection assays. After DSS treatment, expression of
RNAs encoding several pro-inflammatory cytokines was detected in both wild-type and Brk
knockout mice. However, a significantly greater increase in induction of IL-1 alpha/beta,
and IL-6 mRNA expression was observed in Brk-deficient mice when compared with wild-
type control mice. In contrast, the severe denudation of the epithelium in the Brk-/- colon
led to decreased epithelial IL-18 mRNA expression. Our results demonstrate that Brk-
deficient mice develop more severe acute colitis in response to DSS, and suggest that Brk


















KLF5 Transcriptionally Upregulates Integrin β1 and Ilk and Activates the Mek/
ERK Pathway in Non-Transformed Primary Esophageal Cells
Yizeng Yang, Bree G. Goldstein, Yuliya Yermolina, Jonathan P. Katz
Background and aims: Klf5 (IKLF; BTEB2), a member of the Krüppel-like factor (KLF)
family, is expressed in epithelia of the gastrointestinal tract as well as several other organs.
Klf5 is found in regions of active cell proliferation and promotes proliferation, mediates the
transforming activity of oncogenic H-ras, and negatively regulates Klf4 (GKLF). Klf5 is
expressed in the basal layer of the esophagus, where interactions with the extracellular
matrix (ECM) are critical. Integrins, heterodimeric transmembrane receptors, and integrin-
linked kinase (ILK) are also expressed mainly in basal cells. Integrins and ILK transduce
signals from the ECM to downstream pathways and are crucial for numerous cellular
processes, including proliferation, migration, and survival. We hypothesized that Klf5 pro-
motes proliferation and migration in esophageal epithelial cells by upregulating integrin
signaling. Methods: We stably infected primary mouse esophageal keratinocytes with retro-
virus overexpressing Klf5 or siRNA directed against Klf5. Control cells and those with
overexpression or suppression of Klf5 were infected with adenovirus to express wild-type
or dominant negative ILK. Cells were examined for growth characteristics, and migration
was assessed by transwell assays. Immunohistochemistry, including staining for markers of
proliferation, differentiation, and apoptosis, was performed, and DNA, RNA, and protein
were isolated for real-time PCR, Western blots, protein kinase assays, and chromatin immuno-
precitation (ChIP). Results: Overexpression of Klf5 in primary esophageal cells increased
proliferation and migration, while suppression of Klf5 inhibited proliferation and migration.
Klf5 upregulated mRNA and protein levels of integrin β1 and ILK and increased ILK kinase
activity. ChIP assay demonstrated Klf5 binding directly to the integrin β1 and ILK promoters.
Overexpression of Klf5 increased phosphorylation of MEK and ERK. In contrast, total MEK
and ERK, as well as total and phosphorylated Akt and GSK3β were not altered. As Akt and
GSK3β are ILK targets in other tissues, these data suggest that ILK may act specifically
on MEK/ERK signaling in esophageal epithelia. Conclusions: Klf5 is crucial for normal
proliferation and migration in esophageal epithelial cells. Klf5 transcriptionally upregulates
integrin β1 and ILK and increases ILK activity, leading to specific activation of the MEK/
ERK pathway. These data provide evidence of a critical link between Klf5 and integrin
signaling in non-transformed primary esophageal cells, providing a new paradigm for the
regulation of proliferation and migration by Klf5 in esophageal basal cells.
W1579
Glucagon-Like Peptide-2 Intracellularly Stimulates eNOS Phosphorylation and
Specifically Induces Submucosal Arteriole Vasodilation Via a Sheer Stress-
Independent, Local Neural Mechanism
Xinfu Guan, Keying Zhang, Heidi Karpen, John Bukowski, Xiaochun Bian, James
Galligan, Douglas Burrin
Glucagon-like peptide-2 (GLP-2) is a nutrient-responsive neuropeptide that exerts diverse
actions in the gastrointestinal tract, including enhancing mucosal cell survival and prolifera-
tion, mucosal blood flow, luminal nutrient uptake, and suppressing gastric motility and
secretion. We have shown that GLP-2-stimulated mucosal blood flow is associated in vivo
with increased activation of endothelial nitric oxide synthase (eNOS), but not neuronal nitric
oxide synthase (nNOS), in the neonatal pig intestine. We have also shown that the GLP-2
receptor (GLP-2R) is co-localized with eNOS in enteric neurons. However, it is well estab-
lished that blood flow-induced sheer stress is a key stimulator of endothelial eNOS activity.
Thus, the GLP-2-induced increase in blood flow may indirectly activate endothelial eNOS.
We hypothesized that GLP-2R activation intracellularly stimulates eNOS phosphorylation
in enteric neurons and is independent of blood flow-mediated sheer stress. Our aim was
to establish whether the GLP-2-mediated activation of eNOS occurs intracellularly via a
neural-dependent mechanism, independent of blood flow-induced sheer stress. We first
studied an ex vivo submucosal preparation from the young guinea-pig jejunum to quantify
individual submucosal arteriole diameter with a computer-aided, real-time videomicroscopy
system. Under pre-constriction with KCl (60 mM), super-perfusion of human GLP-2 (at
100 nM) immediately increased the submucosal arteriole dilation by approximately 30%,
but did not alter mesenteric artery dilation. However, GLP-2-induced vasodilation was
completely blocked with co-superfusion of either a NOS inhibitor (NG-nitro-L-arginine at
300 μM) or a neuronal Na channel blocker (tetrodotoxin at 300 nM), implying that the
GLP-2-mediated vascular action was localized specifically on the submucosal arteriole (the
final and major resistance vessel in the gut) via a nitric oxide-dependent local neural
mechanism. We next defined whether GLP-2R activation activates eNOS intracellularly in
HEK 293T cells transiently transfected with full-length cDNA clones of human GLP-2R and
eNOS. GLP-2 treatment dose-dependently induced eNOS phosphorylation on Ser1177 in
the double transfected HEK 293T cells and this was maximal within 15 min at 20 nM GLP-
2. Thus, we concluded that GLP-2-induced submucosal arteriole dilation is locally mediated
via a neural-dependent mechanism, independent of blood flow-mediated sheer stress. More-
over, GLP-2R activation intracellularly leads to stimulation of eNOS phosphorylation, inde-
pendently from sheer stress. (Supported by NIH HD33920 and USDA/ARS 2533703361).
W1580
Transcriptional Regulation of Acidic pH Induced Interleukin-6 Expression and
Secretion in Human Esophageal Epithelial Cells (HET-1) Via Mapks
Parvaneh Rafiee, Aaron Rogaczewski, Victoria M. Nelson, Irshad Ali, David G. Binion,
Reza Shaker
INTRODUCTION: Inflammation is a complex biologic process involving a highly orches-
trated interaction among several cells of different origin and function. Human esophageal
epithelial cells contribute to esophageal inflammation by expressing and secreting a variety
of cytokines and chemokines in response to various stressors. IL-6 is a pleiotropic cytokine,
which regulates immune defense and inhibits apoptosis. Involvement of IL-6 in various
diseases including carcinogenesis has been established. We have recently demonstrated that
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acidic exposure stimulates IL-6 production in HET-1 cells via COX-2. However, mechanisms
underlying IL-6 expression and secretion in response to acidic pH exposure are complex,
involving multiple protein kinases and transcriptional factors. The aim of present study is
to investigate MAPK signaling pathways in transcriptional regulation of IL-6 expression and
secretion in HET-1 cells following acidic pH stimulation. METHODS: HET-1 cells monolyer
were exposed to acidic pH 4.5 for 1h, then incubated in regular culture media for 1, 3, 6,
12 and 24. To determine the role of MAPKs family member the cells were pretreated with
PD98059 (ERK), SP600125 (JNK) and SB203580 (p38 MAPK) inhibitors 30 min prior to
acidic exposure. IL-6 mRNA expression was done by RT-PCR. ELISA and Western blotting
were utilized to analyze IL-6 protein secretion and expression respectively. NFκB activity
was measured by ELISA based DNA binding nuclear protein assay and Western blotting.
RESULTS: Exposure of HET-1 to acidic pH 4.5 enhanced IL-6 secretion, mRNA and protein
expression as measured by ELISA, RT-PCR and Western blotting respectively. Acidic pH
also resulted in phosphorylation and activation of ERK, p38 MAPK and JNK in HET-1 cells.
The IL-6 expression was blocked by the ERK inhibitor PD98059, and by the JNK inhibitor
SP600125, but not by the p38 MAPK inhibitor, SB203580. Acidic pH enhanced the transcrip-
tional activity of the IL-6 gene by activation of the transcriptional factors NF-κB, which was
attenuated by PD98059. JNK phosphorylation was inhibited by SP600125 without blocking
either p38 MAPK or ERK. CONCLUSIONS: These results demonstrates an independent role
for ERK and JNK in acidic pH induced IL-6 expression and secretion via NF-κB in HET-1
cells. Our data suggests that acidic pH induction of the IL-6 in esophageal epithelial may
contribute to pathophysiologic mechanisms in GERD.
W1581
Increased Human Intestinal Microvascular Endothelial Arginase Activity
Mediated By RHOA Pathway: Mechanisms Underlying IBD Endothelial
Dysfunction
Parvaneh Rafiee, Scott Horowitz, Aaron Rogaczewski, Victoria Nelson, Balaraman
Kalyanaraman, Mary F. Otterson, David G. Binion
BACKGROUND: Arginase competes with endothelial nitric oxide synthase (eNOS) for the
substrate L-arginine and decreases nitric oxide (NO) production. NO plays a critical role
in vascular physiology, and production is decreased in blood vessels from chronically inflamed
bowel in human inflammatory bowel disease (IBD). Mechanisms underlying the decreased
production of NO in IBD microvascular endothelial dysfunction are not fully defined. We
sought to define the signaling pathways involved in the microvascular endothelial expression
of arginanse. Previously we have demonstrated that MAPK activation occurs during TNF-
α and LPS-induced endothelial activation in human intestinal microvascular endothelial
cells (HIMEC). Because GTP-binding proteins have been implicated in MAPK activation we
hypothesized that Rho a GTP-binding protein is a mediator of TNF-α/LPS induced arginase
activity in HIMEC and IBD tissues. METHODS: HIMEC monolayers passage 8-14 stimulated
with TNF-α and LPS, were used to examine arginase expression by western blotting and
fluoresence microscopy. MAPK activity was assessed using a phospho-specific in vitro kinase
assay. p38 MAPK inhibitor (SB203580), p44/42 MAPK inhibitor (PD098059), RhoA inhibitor
(Clostridium botulinum C3 exoenzyme) and Rho-associated coiled-coil kinase (ROCK) inhib-
itor Y-27632 were used to demonstrate the involvement of these signaling pathways in TNF-
α/LPS induced arginase expression and activity. Control and IBD tissues were also analyzed
using Western blot analysis. RESULTS: Arginase enzymatic activity was increased in a
concentration and time dependent fashion in response to 100 U/ml of TNF-α and 1μg/ml
of LPS for 24 hours, peaking at a 2 fold increase. TNF-α/LPS activation of HIMEC resulted
in a rapid, sustained increase in endothelial p38 MAPK and p44/42 MAPK activity. Inhibition
of p38 MAPK and p44/42 MAPK with SB203580 and PD098059, respectively, decreased
TNF-α/LPS induced arginase in HIMEC. C3 exoenzyme RhoA inhibitor and Y-27632 ROCK
inhibitor both attenuated TNF-α/LPS induced MAPK activation and blocked arginase expres-
sion in HIMEC. Moreover, a significantly higher arginase II activity and increased RhoA
protein level were observed in IBD tissues surrounding microvessels as compared with
normal control tissue. CONCLUSIONS: TNF-α/LPS enhances arginase activity via RhoA/
ROCK in HIMEC. Rho acts upstream of MAPKs in mediating TNF-α/LPS induced arginase
activity. Higher arginase expression and enzymatic activity appears to play a key role in
IBD endothelial dysfunction. Targeting vascular arginase may represent a novel therapeutic
strategy for inflammatory bowel disease.
W1582
Role of Mapk in Activation of Signal Transducers and Activators of
Transcription (STATs) Proteins in VEGF Stimulated Human Intestinal
Microvascular Endothelial Cells (HIMEC)
Parvaneh Rafiee, Monica Theriot, Mary F. Otterson, David G. Binion
INTRODUCTION: VEGF effects on endothelial cells, preventing apoptosis as well as inducing
migration, growth, proliferation and differentiation. VEGF activates various signaling cascades
(i.e. MAPKs, PI3K/Akt) in HIMEC. STAT proteins modulate cell growth responses, and play
a role in endothelial proliferation, but have not been characterized in human intestinal
microvascular angiogenesis. We investigated the contribution of STATs signaling pathway
in tissues from control and IBD pts as well as control and disease specific HIMEC following
VEGF activation. METHODS: Mucosa from control and IBD (UC and Crohn’s disease(CD))
pts were homogenized in hypotonic buffer and nuclear proteins were prepared. Control
and IBD HIMEC monolayers were treated with VEGF, and nuclear translocation of STAT
proteins was detected by immunofluorescence staining. An ELISA-based oligonucleotide
binding assay containing an immobilized STAT consensus binding site was used to demon-
strate the DNA binding in nuclear protein extracts. Phospho-STAT proteins were detected
by Western bloting using specific phospho-antibodies. Inhibitors of p38 MAPK and p44/
42 MAPK were used to identify the signaling pathways. The specific VEGFR2 antibody was
used to determine whether STATs activation in HIMEC were mediated through VEGFR2/
KDR receptor. RESULTS: Western bloting revealed phosphorylated STAT1 and STAT3 in
both UC and CD intestinal tissues but not the control and uninvolved mucosal specimens.
Similarly DNA-nuclear proteins assay demonstrated increased level of STAT1 and STAT3
but not STAT5A and 5B. VEGF induced tyrosine phosphorylation and nuclear translocation
of STAT1α, STAT3, STAT5A and STAT 5B in HIMEC. VEGF activated IBD HIMEC (n=4)
demonstrated enhanced STAT1 and STAT3 compared with control HIMEC (n=3). Pre-
treatment of HIMEC with VEGFR2 antibody suppressed STATs phosphorylation and nuclear
translocation. The p38 MAPK inhibitor SB203580 decreased STAT1α activation, whereas
PD098059 (MEK/p44/42 MAPK inhibitor) suppressed both STAT1α and STAT3 in HIMEC.
CONCLUSIONS: Differential STAT activation characterizes intestinal inflammation in IBD
tissues and HIMEC.VEGF activates STATs in HIMEC through the VEGFR2/KDR receptor.
MAPK family members play a differential role in STATs activation. These findings suggest
a role for the STATs in the regulation of gene expression associated with chronic inflammation
and the angiogenic effects of VEGF in gut specific microvascular endothelial cells.
W1583
Identification of Ser58 in C-Jun As a Novel Phosphorylation Site Targeted By
Protein Kinase D
Richard T. Waldron, Julian P. Whitelegge, Enrique Rozengurt
Background: The protooncogenic transcription factor c-Jun, a major component of AP-1
complexes, regulates gene expression critical for development, inflammation, growth and
proliferation. Furthermore, c-Jun has been recently found to participate in colorectal carcin-
oma via interaction with the Wnt signaling pathway. Protein kinase D (PKD), a target of
GI peptides, attenuates c-Jun N-terminal kinase (JNK)-c-Jun signaling and forms complexes
with JNK. We previously demonstrated that PKD directly phosphorylates the c-Jun N-
terminus in vitro at Ser/Thr sites distinct from JNK, but did not identify the site(s). Methods:
Here, we have used isolated PKD in kinase assays with glutathione S-transferase (GST)-c-
Jun fusion proteins as substrates to identify novel PKD-mediated phosphorylation sites within
c-Jun. Results: PKD was incubated with GST-c-Jun (1-89) and tryptic fragments derived
from the phosphorylated protein were analyzed using LC-MS/MS. Using this approach, we
obtained a phosphopeptide containing phospho-Ser58. PKD-mediated phosphorylation of
a protein comprising GST fused to the first 135 amino acids of c-Jun was diminished by
approximately 40% in a S58A point mutant. In contrast, PKD phosphorylation of a S63A
mutant was equal to that of wild type GST-c-Jun(1-135). Interestingly, PKD also robustly
phosphorylated a GST-c-Jun(1-72) fusion protein, to levels comparable to GST-c-Jun(1-
135), and this was again reduced by approximately 40% in a S58A mutant but not a S63A
mutant. These results substantiate the specificity of Ser58 phosphorylation and suggest the
presence of at least one additional PKD phosphorylation site within the c-Jun amino terminal
(aa1-72). Notably, incubation with activated PKD in an in vitro kinase assay did not prevent
subsequent binding of GST-c-Jun(1-72) to JNK2. Accordingly, phosphorylation by PKD was
not appreciably altered by S37A, a mutation within the JNK-docking motif of GST-c-Jun(1-
72). In COS-7 cells, myc-tagged, full-length, wild-type c-Jun was transfected either alone
or together with PKD to examine its effect on c-Jun phosphorylation in vivo. Using metabolic
labeling with 32P, we found that cotransfection with PKD significantly increases both basal
and serum-stimulated total c-Jun phosphorylation, suggesting that PKD can phosphorylate
c-Jun in vivo. Luciferase reporter gene assays indicate that c-Jun-myc promotes the expression
of AP-1-containing genes in HEK-293 cells. Conclusions: PKD-mediated phosphorylation
of c-Jun at distinct and novel sites in vivo including Ser58 may affect gene expression either
directly, or by regulating the binding of c-Jun to its upstream regulators/transcriptional coac-
tivators.
W1584
N-Acetyl-L-Cysteine Is a Potent Secretagogue for Intestinal Cholecystokinin
Release
George H. Greeley, Feng Qin, Jason Reed, Ella W. Englander
Administration of N-acetyl-L-cysteine (NAC), an antioxidant and substrate for endogenous
glutathione (GSH) synthesis, to diabetic animals improves hyperglycemia, glucose intolerance
and defective insulin secretion. The notion that NAC increases secretion of gut hormones
that stimulate insulin secretion and glucose disposal (ie, incretins) has not been tested. Our
aim was to define influence of NAC on secretion of intestinal cholecystokinin (CCK), an
incretin. Methods. For in vivo experiments, adult male SD rats were given NAC acutely
either into the stomach (5 ml, 100 mg/ml) or duodenal (1 ml, 100 mg) lumen by gastric
lavage or direct duodenal administration. Plasma was collected 15 min later for measurement
of CCK levels by immunoassay. For in vitro experiments, intestinal STC-1 cells were exposed
to NAC (10 mM) for different periods (4, 7, 24 h), media were then replaced with fresh
media alone or media containing bombesin (10-9 M), a CCK secretagogue. Media and cells
were harvested 30 min later for CCK measurements. Cell density was monitored. Results.
Administration of NAC into the gastric or duodenal lumen caused a significant elevation in
plasma CCK levels (CCK level [pg/ml]: basal: 1 ± 1 vs stomach: 35 ± 6 or duodenal: 36 ±
14, P<0.05, N=6 rats/group). In vitro exposure of STC-1 cells to NAC, for 4-24 h, enhanced
basal and bombesin-stimulated CCK secretion significantly (1.3- to 4-fold, P<0.05) (see
Table, 24 h NAC exposure). NAC exposure for 24 h also increased cellular CCK content
~4-fold (control: 2823 ± 151 vs NAC treated: 9143 ± 275 pg/ml, P<0.05). Conclusions
and Discussion. NAC is a potent secretagogue for CCK secretion. In vitro findings show
that NAC can act directly on enteroendocrine cells to cause CCK release and synthesis. The
finding that NAC exposure for 24 h enhanced basal CCK release to a greater magnitude
(~4-fold) when compared to acute (3, 7 h) exposure (1.3- to 1.5-fold) suggests involvement
of increased GSH levels in stimulation of CCK secretion and synthesis. These findings suggest
that beneficial effects of NAC on insulin secretion and glucose levels are mediated partly
by increased CCK secretion.
1 = mean SEM, N=6 dishes/group. * = P<0.05 vs vehicle.
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W1585
Interruption of Transforming Growth Factor-Beta Signaling By Curcumin
Negatively Regulates Gene Expression of Peroxisome Proliferator-Activated
Receptor-Gamma in Rat Hepatic Stellate Cells
Anping Chen, Shizhong Zheng
BACKGROUND: Activation of hepatic stellate cells (HSC), the major effectors of hepatic
fibrogenesis, is coupled with sequential alterations in gene expression, including an increase
in receptors for transforming growth factor-β (TGF-β) and a dramatic reduction in the
peroxisome proliferator-activated receptor-gamma (PPARγ). The casual relationship remains
obscure. We previously demonstrated that curcumin induced gene expression of PPARγ in
activated HSC, leading to reducing cell proliferation, inducing apoptosis and suppressing
the expression of ECM genes. The underlying molecular mechanisms are largely unknown.
We recently observed that stimulation of PPARγ activation by curcumin suppressed gene
expression of TGF-β receptors in activated HSC, leading to the interruption of TGF-β
signaling. [Zheng and Chen Am J Physiol Gastrointest Liver Physiol (November 23, 2005).
doi:10.1152/ajpgi.00450.2005]. This observation partially supported our assumption of the
existence of an antagonistic relationship between PPARγ activation and TGF-β signaling in
HSC. AIM AND HYPOTHESIS: The current study is to further elucidate the mechanisms
of curcumin in induction of PPARγ gene expression and to evaluate the effect of TGF-β
signaling on regulating PPARγ gene expression in activated HSC. We hypothesize that TGF-
β signaling might negatively regulate gene expression and activation of PPARγ in activated
HSC. RESULTS: The present report demonstrates that exogenous TGF-β1 inhibits gene
expression of PPARγ in activated HSC. Pretreatment of cells with curcumin eliminates the
inhibitory effect likely by interrupting TGF-β signaling. Transfectection assays further indic-
ates that blocking TGF-β signaling by dominant negative type II TGF-β receptor increases
the promoter activity of PPARγ gene. Promoter deletion assays, site-directed mutageneses
and gel shift assays reveal two Smad binding sites (SBS) within -1522 to -1492bp of the
PPARγ gene promoter. The two SBS act as the curcumin response elements and negatively
regulate the promoter activity of PPARγ in passaged HSC. CONCLUSION: Results in this
study demonstrate that interruption of TGF-β signaling by curcumin induces gene expression
of PPARγ in activated HSC in vitro. Our studies provide novel insights into the molecular
mechanisms of curcumin in induction of PPARγ gene expression and in inhibition of HSC
activation. [The work was supported by the grant RO1 DK047995 from NIH/NIDDK and
the Bridging Award from LSUHSC-S to A. Chen].
W1586
Magi-3 Negatively Regulates Signaling By the Lpa2 Receptor
Huanchun Zhang, Randy A. Hall, Chris Yun
Lysophosphatidic acid (LPA) mediates multiple cellular responses by activating G protein-
coupled receptors, LPA1-4. We and others have shown that LPA2 is overexpressed in several
types of cancers, including ovary, colon, and testis. LPA2 receptor has been shown to interact
with PDZ domain-containing proteins, NHERF2 and rhoGEF. To further identify other PDZ
proteins that interact with LPA2, we screened a PDZ domain proteomic array that contains
96 distinct PDZ domains expressed and purified as His-tagged proteins. This blot was
overlaid with C-terminal (45 amino acids) GST fusion proteins of LPA2 receptor. In contrast
to GST alone, the C-terminus of LPA2 interacted with several of the PDZ domains on the
array, including NHERF2, NHERF1, MAGI-2, MAGI-3, and neurabin. In the current work,
we report the findings on the role of MAGI-3 in LPA2-mediated signaling. The interaction
between LPA2 and MAGI-3 was confirmed by far-Western blot where individual PDZ
domains of MAGI-3 were overlaid with GST-LPA2 or GST as a control. The strongest binding
of GST-LPA2 was observed with the 5th PDZ domain. This binding was confirmed by co-
purification of LPA2 and MAGI-3 from transiently transfected SW480 cells. To determine
a role of MAGI-3 in LPA-mediated signaling, we stably over-expressed V5-tagged human
MAGI-3 in SW480 cells. SW480 transfected with V5-MAGI-3 or pcDNA vector were treated
with 10 μM LPA for up to 24 h. The activation of Erk1/2, as determined by Western blot
using anti-phospho-Erk1/2 antibodies, was not significantly affected by over-expression of
MAGI-3. Because MAGI-3 has previously shown to affect the JNK pathway of Frizzled, we
next determined whether MAGI-3 affected LPA-mediated JNK pathway. In control SW480/
pcDNA cells, LPA maximally activated JNKs at 2 h without any appreciable change in the
total amount of JNKs. In contrast, LPA-mediated JNK activation was drastically attenuated
in SW480/MAGI-3 cells. This down-regulation of the JNK pathway by MAGI-3 was confirmed
by similar attenuation in phosphorylation of c-Jun, a known target of JNKs, in SW480/
MAGI-3 compared with SW480/pcDNA. In addition to c-Jun phosphorylation, LPA greatly
increased the amount of c-Jun protein in SW480/pcDNA, whereas this stimulation in c-Jun
expression was significantly inhibited in SW480/MAGI-3 cells. Our results demonstrate that
MAGI-3 specifically interacts with LPA2 receptor and down-regulates activation of the JNK
pathway by the LPA2 receptor.
W1587
Intracellular Activation of Epidermal Growth Factor Receptor and
Phosphatidylinositol 3-Kinase Regulate Human Gastric Epithelial Cell
Migration
Marie-Pier Tetreault, Nathalie Rivard, Daniel Menard
The integrity of the gastric epithelium is maintained through its highly-dynamic renewal
capacity. Following stem cell division in the isthmus, cell migrating upward will differentiate
into surface mucous cells (mucine-5) while those migrating downward will differentiate into
mucous neck cells (mucine-6), chief cells (human gastric lipase, pepsinogen) and parietal
cells (HCl). Our previous studies established that growth factors (EGF/TGFa,HGF) differently
regulate the migration of human gastric epithelial cells (Exp Cell Res.306(1):285-297, 2005).
However, the intracellular signaling pathways that transmit extracellular cues and that
regulate basic and stimulated gastric epithelial cell migration are still unclear. Aim: To

















signalling pathways in the regulation of human gastric epithelial migration. Methods: Conflu-
ent HGE-17 cell monolayers were wounded with a razor blade and the migration was
quantified by counting the number of cells across the wound margin. The effects of pharmaco-
logic inhibitors LY294002 (PI3K), PD153035 (EGFR), PP2 (Src) and of a neutralizing
antibody against EGFR were examined. Wounded cultures were lyzed at different time
intervals and the activation profiles of Akt, Src and EGFR were analyzed. Results: The kinase
Akt was stimulated in a PI3K-dependent manner by wounding and TGFa treatment. Moreover
the addition of LY294002 strongly inhibited (40-60%) basal and TGFa-induced responses
and this inhibition was already significant after only 60 min exposure. Accordingly, treatments
with phosphatidylinositol(3,4,5)-triphosphate greatly accelerated cell migration by 230%.
Pharmacological inhibition of EGFR tyrosine kinase activity decreased basal migration by
73% while the prevention of EGF binding with an EGFR neutralizing antibody had no
effect on basal migration. Furthermore, treatment of wounded monolayers with the EGFR
neutralizing antibody has no effect on the Akt activation whereas treatment with the EGFR
inhibitor completely inhibited Akt activation. Wounding also stimulated the Src activity and
the Src inhibitor PP2 significantly diminished (72%) the number of cells across wound
margin. Pre-treatment of cells with PP2 completely blocked the phosphorylation levels of
Akt. Conclusion: Activation of PI3K signalling pathway is a central event in the modulation
of gastric epithelial migration. Moreover, a ligand-independent intracellular mechanism
mediated by Src/EGFR inhibits the basal migration, this transactivation being responsible
for the PI3K/Akt signaling pathway activation in human gastric epithelial cell migration.
W1588
Down-Regulation of Soluble Guanylyl Cyclase (sGC) Expression and Activity
By Interleukin-1β in Colonic Smooth Muscle Cells Is Mediated By PKG-
Dependent Activation of JNK
Jiean Huang, Wenhui Hu, Sunila Mahavadi, Karnam S. Murthy
Pro-inflammatory cytokines such as interleukin-1β (IL-1β) and tumor necrosis factor-α
induce expression of iNOS in immune cells, endothelial cells, and smooth muscle cells. NO
generated from iNOS activates soluble guanylyl cyclase (sGC) to generate cGMP. Despite
the sustained increase in NO resulting from iNOS activity, the initial increase in cGMP
reverts to basal levels; in addition, the cGMP response to nitrovasodilators is attenuated.
We postulated that the decrease in cGMP response reflected down-regulation of soluble GC.
Aim. The aim of the study was to identify the mechanism by which IL-1β inhibits sGC
expression and activity in smooth muscle. Methods. Colonic circular muscle strips were
incubated in DMEM in the absence or presence of IL-1β (10 ng/ml) for 48 h. Muscle cells
isolated from these strips were used for measurement of sGC activity and expression.
Expression of iNOS and sGC was determined by immunoblot analysis, and sGC activity
was measured by cGMP formation in response to Na nitroprusside (SNP) in the presence
of a PDE5 inhibitor. JNK phosphorylation (activation) was determined using phospho-
specific antibody in the presence or absence of a PKG inhibitor. Results. In muscle cells
isolated from cultured smooth muscle strips in the absence of IL-1β, sGC expression and
sGC activity were similar to those of freshly dispersed muscle cells. In cells isolated from
strips pretreated with IL-1β, iNOS expression was induced, whereas sGC expression and
SNP-induced sGC activity were decreased by 65% and 72%, respectively, and JNK activity
was increased. Treatment of the tissue with the PKG activator, pCPT-cGMP in the absence
of IL-1β, also decreased SNP-stimulated sGC activity and increased JNK activity. Addition
of the NOS inhibitor, L-NNA, the PKG inhibitor, 8-pCPT-cGMP[S], or the JNK inhibitor
SP600125 restored SNP-stimulated sGC activity (cGMP levels). Conversely, JNK activity
induced by treatment with IL-1β was inhibited by L-NNA and the PKG inhibitor, 8-pCPT-
cGMP[S]. The results implied that inhibition of sGC expression and activity were mediated
by PKG-activated JNK. Conclusion. IL-1β augmented iNOS expression, but the sustained
formation of NO and activation of sGC and PKG were abrogated by PKG-mediated activation
of JNK, which triggered a feedback mechanism that resulted in inhibition of sGC expression
and activity.
W1589
Effect of High Cholesterol (Ch) Levels On the Genomic Effects Induced By
Progesterone (PG) in Muscle Cells from Human Gallbladder (GB)
Cong Ping, Piero Biancani, Jose Behar
The incidence of gallbladder complications is increased during pregnancy due to higher Ch
concentrations in bile and GB stasis. It has been suggested that they are caused by lithogenic
bile with Ch worsened by rising levels of estrogens in the first two trimesters and to impaired
muscle contraction induced by PG in the last two trimesters. PG impairs muscle contraction
induced by agonists that are receptor (CCK-8) or G protein (GTPγS) dependent due to
down regulation of G proteins that mediate contraction (Gi3) and up regulation of G proteins
that mediate relaxation (Gs). In contrast high levels of caveolar Ch impairs the contraction
induced by receptor dependent agonists (CCK-8) and by KCl without affecting G protein
patterns. These studies therefore were aimed at examining the effect of high caveolar Ch
on those PG actions that is the actual setting in human pregnancy. The PG genomic effects
were examined in enzymatically dissociated muscle cells from GB with high caveolar Ch
(specimens with Ch stones) and normal caveolar Ch (specimens with pigment stones). The
cells were pre-treated with buffer, Ch-rich liposomes or Ch-free liposomes for 90 min and
then treated with PG (10-5 M) for 6 h. The Ch-rich liposomes increased Ch levels and the
Ch-free liposomes removed the excess Ch from caveolae. High levels of caveolar Ch in
muscle cells from GB with ChS or incubated with Ch-rich liposomes blocked the actions
of PG. The contraction patterns in muscle cells incubated with Ch-rich liposomes followed
by treatment with PG were similar to that observed in muscle cells incubated with Ch-rich
liposomes alone. Antibodies against caveolin-3 protein (CAV3) also blocked PG genomic
effects. Similar results were obtained in muscle cells transfected with CAV3 siRNA in tissue
culture for 24 h. CAV3 siRNA decreased CAV3 expression by 60%. High Ch levels, caveolin
3 protein antibodies or CAV3 siRNA significantly reduced the incorporation of 3H-PG into
the caveolae at 10, 30 and 60 min. It is concluded that PG is internalized through caveolar
domains with CAV3 facilitating its transport; and, that high levels of caveolar Ch inhibits
PG induced genomic effects by blocking its incorporation into the caveolae These results
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suggest that PG is unlikely to contribute to the high incidence of GB complications during
pregnancy, which may instead be due to abnormal Ch incorporation into gallbladder
muscle cells
W1590
Gastrointestinal Hormones Cause C-Met Receptor Downregulation Via a
Clathrin-Mediated Endocytosis and Lysosome Dependent Mechanism
Karl M. Hoffmann, Jose A. Tapia, Marc Berna, Michelle Thill, Till Braunschweig, Samuel
Mantey, Terry Moody, Robert T. Jensen
The receptor tyrosine kinase c-Met when activated by hepatocyte growth factor (HGF) has
potent growth effects on many normal tissues and tumors. C-Met expression is regulated
by HGF exposure, but it is unknown if it can be regulated by gastrointestinal (GI) hormones.
This question is important because c-Met is found in many GI tissues/tumors that possess
GI hormone receptors. To investigate this question we studied rat pancreatic acinar cells
that possess c-Met as well as numerous GI hormone receptors using Western blotting and
immunofluorescence-histochemistry (IF-IHC). Incubation of rat pancreatic acini with CCK-
8, carbachol and bombesin caused a time-dependent decrease in c-Met which at 45 min
decreased by 85±5, 32±9 and 26±10% of control, respectively. Secretin or VIP had no effect.
Since CCK-8 caused the largest decrease its effect was studied in detail. Maximal c-Met
downregulation occurred with 100 nM CCK-8 (IC50 5 nM) and at 45 min (t0.5 17.5 min).
CCK-JMV (1 µM) had no effect. CCK-8 (100 nM) treatment for up to 90 min did not
decrease cell viability or the ability of EGF to cause tyrosine (Y) phosphorylation of Y1068
of the EGF receptor in pancreatic acini. GF109203X (PKC inhibitor), thapsigargin (Ca++
inhibitor) or a combination of both partially reversed the effect of CCK-8 (31±3, 40±9,
60±5% of control, respectively). CCK-8 abolished HGF induced Y1234/1235c-Met phos-
phorylation and that of Y627Gab1, which is crucial for c-Met signaling. In situ IF-IHC
studies showed a decrease in c-Met receptor staining with CCK-8 treatment. Prolonged HGF
exposure (>3h) caused a 46% decrease in c-Met, a process that was sensitive to the proteasome
inhibitor lactacystin and the lysosome inhibitor concanamycin A. CCK-8’s effect was pre-
vented by concanamycin A and by inhibitors of clathrin-mediated endocytosis (sucrose,
phenylarsine oxide, concanavalin A), but not by lactacystin. CCK-8 induced pancreatic c-
Met downregulation also occurred in-vivo in rats injected intraperitoneally with CCK-8. In
conclusion we describe for the first time that GI hormones down-regulate c-Met and that
this regulation can occur in vitro and in vivo. CCK-8 differed from HGF’s downregulation
of c-Met in that it had a greater effect (85% vs 46% decrease), was more rapid, was
insensitive to proteasome inhibition and was dependent on clathrin-mediated endocytosis
and degradation through the lysosome. These results indicate a new mechanism of influencing
c-Met expression and signaling which could be important for its regulation in normal as
well as in neoplastic tissue in the GI tract.
W1591
Cholecystokinin-2 Receptor Splice Variant Stimulates Hif-1α and VEGF
Expression and Promotes Tumor Growth in Vivo
Celia Chao, Elizabeth Goluszko, Courtney M. Townsend, Jr., Mark R. Hellmich
Introduction: Colorectal, pancreatic, and esophageal cancers express a variant of the CCK2
receptor (CCK2R), called the CCK2i4svR. Unlike CCK2R, CCK2i4svR can constitutively activate
the proto-oncogene Src, which regulates receptor subcellular distribution and increases its
rate of resensitization. We have shown that expression of CCK2i4svR, unlike CCK2R, enhances
HEK tumor growth in vivo, in part, through a Src-dependent mechanism in the absence of
exogenous gastrin. The aim of this study was to determine the role of constitutive receptor
activity and the molecular mechanism of CCK2i4svR-stimulated tumor growth in vivo.
Methods: To assess tumor growth in vivo, nu/nu mice were injected subcutaneously with
4x106 cells transfected with CCK2R, CCK2i4svR, or vector, randomized into 4 groups (n=
6) for each receptor, and treated with NaCl, CR2945 (CR) antagonist, pentagastrin (PG),
or both PG and CR, at 30 mg/kg/day. On day 21, tumors were weighed. To determine in
vitro cell proliferation, growth assays were performed in triplicate over 8 days. Levels of
hypoxia-inducible factor-1 (HIF-1α) expression were assessed by Western blot. Vascular
endothelial growth factor (VEGF) upregulation was demonstrated by Northern blot. Results:
There was a 16.5-fold increase in the mass of CCK2i4svR (297±118 mg) compared with the
CCK2R tumors (18±10) injected with NaCl. PG induced greater (2-3x) tumor mass for both
receptor variants (660±245 and 62±30 mg, respectively). CR blocked the stimulatory effects
of PG on both receptor-expressing tumors, but had no effect on basal growth when used
alone. Thus, CCK2i4svR expression promotes tumor growth in both a constitutive and agonist-
dependent manner, whereas, CCK2R-mediated tumor growth requires agonist. Since in vitro
growth studies revealed no statistical differences between the doubling times for CCK2i4svR-
and CCK2R-expressing cells (47±5 h vs. 38±4 h, respectively), we reasoned that the increased
growth of CCK2i4svR-expressing tumors in vivo may result from angiogenesis. In support of
this hypothesis, basal HIF-1α protein levels were elevated in both CCK2i4svR-expressing
cells in vitro and in tumor tissue when compared with CCK2R. Concomitant with the
increased HIF-1α was an increase in the mRNA levels of VEGF. Conclusions: Previously,
we have shown that expression of CCK2i4svR promotes tumor growth in vivo, in part, via
the constitutive activation of Src. Overexpression or activation of Src is known to promote
tumor growth/survival by induction of HIF-1α target genes such as VEGF. Since CCK2i4svR
does not increase cell growth in vitro, we suggest that the mechanism in vivo may be the
upregulation of proangiogenic factors.
W1592
Pacap Activation of Secretory and Proliferative Signaling Pathways in Bon
Cells Is Mediated Through PKA, Calmodulin and RAS
Sandy N. Lieu, David S. Oh, Nils Lambrecht, Iskandar Yakubov, George Sachs, Joseph R.
Pisegna, Patrizia M. Germano
Introduction: BON is an established human neuroendocrine tumor cell line, in which we
have shown the expression of the receptor for PACAP, PAC1, and that PACAP induces
intracellular Ca2+, and cAMP increase, serotonin release, and growth. However, the signaling
cascades mediating these events in BON are unclear. Aims: To characterize the intracellular
pathways mediating PACAP’s effects in BON by microarray analysis. Methods: Total RNA
was isolated from BON cells, unstimulated, or activated by PACAP for 24h. The RNA was
assessed for purity and stability, fluorescently labeled with Cy3- or Cy5-CTP and then
amplified. Labeled cRNA from unstimulated BON cells and BON cells stimulated with PACAP
were combined and hybridized to a 44K human oligonucleotide expression array. The
microarray was then scanned and the intensities normalized. Results: Microarray gene expres-
sion specific to G protein-coupled signaling pathways were examined in response to PACAP.
The gene expression of Gaq pathway regulators, revealed down regulation of Gaq subunits
and PLC (0.55+0.35, 0.49+0.33, respectively). Furthermore, DAG (1.07+0.04), PKC isoforms
(1.34+0.28), and MAPK (1.04+0.38) displayed generally neutral responses to PACAP activa-
tion, further suggesting that PACAP does not strongly activate the PKC pathway in BON
cells. However we found highly significant increased expression of calmodulin (2.56), which
is consistent with our previous finding of PACAP eliciting a Ca2+ response in BON cells.
Subsequently, rRAS gene expression was also significantly enhanced (2.14+0.05). We next
examined regulators pertinent to the GaS pathway and found a three-fold activation of
adenylyl cyclase (AC) 7 in BON cells, and a significant activation of PKA. These results
and our previous biochemical studies indicate that PACAP, acting at the PAC1 receptor,
predominantly activates the GaS pathway, but may also activate Gaq and Ca2+ signaling.
These data further establishes that PACAP and PAC1 induced signaling pathways are coupled
to proliferation in neuroendocrine tumoral BON cells. Conclusion: PACAP and PAC1 trig-
gering leads to the activation of calmodulin, rRAS, AC, and PKA genes in BON cells, as
determined by our microarray analysis studies. This methodology provides a useful tool for
further defining signaling pathways that can be integrated with secretion and proliferation
in BON cells to permit a greater understanding of the role of PACAP in the regulation of
neuroendocrine tumors.
W1594
PKC Mediates Constitutive CCK2i4svR Internalization and the Steady-State
Phosphorylation of the 3il Domain
Jeseong Park, Kirk L. Ives, Courtney M. Townsend, Jr., Mark R. Hellmich
Introduction: Cancers of the colon, pancreas, and esophagus express a splice variant of the
CCK2 receptor (CCK2R), called CCK2i4svR. Compared to CCK2R, CCK2i4svR has 69 additional
amino acid residues in its 3rd intracellular loop (3il) domain, and shows distinct signaling
properties, including stimulation of tumor growth in nude mice, agonist-independent activa-
tion of Src kinase, constitutive internalization, and an accelerated rate of resensitization.
Since phosphorylation of the 3il domain of G protein-coupled receptors plays a critical role
their regulation, the aims of this study were to determine the phosphorylation state of
the 3il domain of CCK2i4svR and to identify both the protein kinase(s) and the specific
phosphorylation site(s) involved. Methods: Phosphorylation of the 3il domain was assessed
by labeling cells with [32P]ortho-phosphate followed by immunoprecipitation of EGFP-
tagged 3il protein with an anti-EGFP antibody. To identify the protein kinases involved in
3il phosphorylation, cells were treated with either the PKC inhibitor, GF109203X, the Src
kinase inhibitors, SU6656 or PP2, the EGF receptor inhibitor, AG1478, or the mitogen-
activated kinase kinase inhibitor, PD98059. Specific phosphorylation sites within the 3il
domains of CCK2i4svR and CCK2R were identified by Matrix-Assisted Laser Desorption
Ionization Time-of-Flight/Time-of-Flight Mass Spectrometry (MALDI-TOF/TOF MS) ana-
lyses. To assess the effect of receptor phosphorylation on subcellular distribution, EGFP-
tagged receptor-expressing cells were analyzed using Laser Scanning Confocal Microscopy
(LSCM). Results: There was an increased level of basal (steady-state) phosphorylation of
the 3il domain of CCK2i4svR compared to CCK2R. Inhibiting PKC with either GF109203X
or overnight treatment with PMA (1 μM) blocked the steady-state phosphorylation of
CCK2i4svR, whereas, treatment with 100 nM PMA for 30 min (a condition that activates
PKC) further increased (2-fold) the level of 3il phosphorylation. Treatment with SU6656,
PP2, AG1478, or PD98059 did not affect the steady-state levels of 3il domain phosphorylation
of either receptor variant. MALDI-TOF/TOF MS analyses identified two peptide fragments
with the same sequence (KLEMELS312WER), but which differed in their mass by approxim-
ately 30 Daltons, suggesting phosphorylation of S312. S312 is located within the 69 amino
acid insertion unique to CCK2i4svR. Treatment of cells expressing CCK2i4svR for 24 h with PMA
caused a 2.5-fold increase in the level of plasma membrane-associated receptor. Conclusions:
Constitutive CCK2i4svR phosphorylation and internalization is regulated, in part, by a PMA-
sensitive PKC isozyme.
W1595
CGRP and SP Differentially Modulate Epithelial Cell Restitutioin Via
Expression of TGFβ in Fibroblasts and Mastcells in Vitro
Kerem Bulut, Peter Felderbauer, Karoline Hoeck, Susanne Deters, Wolfgang E. Schmidt,
Peter Hoffmann
Background: Substance P (SP) and calcitonin gene related peptide (CGRP) are neurotransmit-
ters of the afferent sensory nervous system. In experimental models of colitis in rats and
rabbits, a protective role of SP and CGRP on intestinal mucosa was presumed. The mucosal
protection in part depends on a SP and CGRP mediated modulation of mucosal blood flow
after injury. We demonstrate a mastcell and fibroblast mediated effect of SP and CGRP on
epithelial cell restitution in vitro. Methods: Mastcell and rat kidney fibroblast (NRK-49F)
cell- lines were exposed to CGRP or SP in various concentrations. After incubation, the cell
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culture supernatants were taken from the mastcell of fibroblast cultures and were directly
applied to IEC-18 or Caco-2 monolayers, which were wounded with a razor blade as
described previously 24h prior to the experiments. Epithelial cell migration was assessed
by counting cells across the wound edge and epithelial cell proliferation was assessed using
the MTT- test. Results: CGRP significantly induced epithelial cell migration and proliferation
in vitro via stimulation of mastcells but had no effect on epithelial cells via stimulation of
fibroblasts or when applied directly to epithelial cells. SP significantly induced epithelial
cell migration and inhibited epithelial cell proliferation via stimulation of fibroblasts but
had no effects via stimulation of mastcells or when applied directly to epithelial cells in
vitro. The effects on epithelial cell migration were abolished after neutralizing anti-TGFβ
was added to the cell cultures. Conclusion: CGRP and SP modulate epithelial cell restitution
in vitro mediated either by mastcells or by fibroblasts. The epithelial cell migration depends
on a TGFβ release from CGRP stimulated mastcells or SP stimulated fibroblasts. This
observation underlines an important role for the afferent sensory nervous system in mucosal
defence and repair and in keeping the mucosal homeostasis.
W1596
Myd88-Dependent Phosphatidylinositol 3-Kinase (PI-3K) Activation in
Flagellin/Toll-Like Receptor 5-Mediated Signaling
Sang Hoon Rhee, Kristopher S. Strach, Charalabos Pothoulakis
Background & Objectives: PI-3K activation is essential for intestinal epithelial cell prolifera-
tion in vitro and in vivo. Bacterial flagellin, released from commensal and enteroinvasive
microbes in the human gut, stimulates Toll-like receptor 5 (TLR5) leading to proinflammatory
responses and activation of PI-3K in colonic epithelial cells. However, the molecular mechan-
isms by which TLR5 activates PI-3K have not been well investigated. Here we determined
the signaling pathways involved in flagellin/TLR5-induced PI-3K activation in human
colonocytes. Methods: C3H/HeJ mice received water or dextran sulfate sodium (DSS)(2.5%)
followed by intracolonic administration of flagellin-containing enema (0.8mg/day). After 7
days total colonic protein extracts were analyzed by immunoblot analysis to evaluate flagellin-
induced PI-3K activation. To determine PI-3K activation in vitro, expression of TLR5 or its
adaptor molecule MyD88 was silenced by stable transfection of TLR5 or MyD88 siRNA
constructs, respectively in non-transformed NCM460 human colonocytes. Several TLR5
mutants harboring point-mutated tyrosine residues, including SH-2-domain binding motif
‘YXXM’ in the cytoplasmic TIR domain of TLR5, were generated by site-directed mutagenesis.
Co-immunoprecipitation assays were performed to determine the association between TLR5
and MyD88 or PI-3K. Results: Flagellin administration in DSS-disrupted colon resulted in
PI-3K activation, while intact colon did not respond to flagellin. Flagellin exposure to
NCM460 cells transiently activated PI-3K within 10-30 min, while blocking PI-3K reduced
IL-8 production in colonocytes. TLR5 silencing blocked PI-3K activation by flagellin, indicat-
ing that TLR5 specifically mediates PI-3K activation in colonocytes. Immunoprecipitation
studies showed that TLR5 recruits the p85 regulatory subunit of PI-3K to its cytoplasmic
TIR domain following flagellin stimulation. Moreover, following flagellin stimulation, MyD88
interacted with TLR5 in a time-dependent manner. Immunoprecipitation studies with TLR5
mutant constructs demonstrated that the SH-2 binding ‘YXXM’ motif in the TIR domain of
TLR5 is not involved in p85 recruitment, implying that p85 is indirectly recruited to TLR5.
Moreover, silencing MyD88 expression in colonocytes disrupted PI-3K activation and blocked
the association between TLR5 and the p85 regulatory subunit. Lastly, co-immunoprecipit-
ation experiments showed that MyD88 binds directly to p85 in response to flagellin. Conclu-
sions: PI-3K activation in TLR5-associated signaling in human colonocytes is MyD88-depend-
ent. Supported by a Senior Research Award (CP) and a Research Fellowship Award (SHR)
from the CCFA
W1597
Histamine H4 Receptor Antagonism Attenuates Toll-Like Receptor Signaling
and Inhibits Experimental Colitis in the Rat
Paul J. Dunford, Csaba Varga, Robin L. Thurmond, Brendan J. Whittle
The histamine H4 Receptor (H4R) is a newly described G-protein coupled receptor with
little homology to the pro-inflammatory histamine H1 receptor or the H2 receptor. Expression
appears limited to immune cells of hematopoietic lineage such as mast cells, dendritic cells,
T cells and eosinophils. We have previously demonstrated the involvement of H4R in toll-
like receptor (TLR)-mediated acute inflammation (JPET.2004;309:404-13) and here describe
the activity of a novel H4R antagonist both in vitro, against bacterial derived TLR ligand
mediated events and in vivo, in a hapten-mediated colitis model in the rat. Hapten-mediated
IBD models share a similar proposed enteric bacteria (and possibly TLR) mediated etiology
and pathology with human IBD. Daily oral dosing of rats with the highly selective H4R
antagonist, JNJ 10191584 (10-100mg/kg bi.d) commencing 1 day prior to intra-colonic
trinitrobenzene sulfonic acid (TNBS) challenge caused a dose dependent inhibition of macro-
scopic damage, inhibition of TNBS-elevated myeloperoxidase (MPO) and a reduction in
histologically assessed neutrophil influx by 40 ± 8, 79 ± 6 and 70 ± 9%, respectively, n=
10; P<0.001 at the highest dose) as well as attenuation of the mucosal/sub-mucosal thickening,
determined after 3 days. Analysis of cytokine levels in TNBS diseased tissues indicated
elevations in TNF-α and IL-6 that were significantly inhibited by administration of JNJ
10191584 (by 67 ± 6 and 75 ± 5% at the highest dose respectively, n=10, P<0.01). As
dendritic cells are intimately associated with the recognition and signaling of TLR ligands
we investigated the role of H4R in TLR signaling on in vitro cultures of CD11+ dendritic
cells. Pre-treatment of these cultures with 10μM H4R antagonist markedly attenuated the
production of pro-inflammatory cytokines in response to stimulation with Pam3Cys (1 ng/
ml) and lipopolysaccharide (LPS, 1 ng/ml ), ligands of TLR2 and TLR4, respectively. Most
notably, TLR2-mediated TNF-α and IL-6 release was reduced by 59% and 50%, respectively.
Irregular expression and/or signaling of TLRs has been genetically and clinically implicated
in the pathogenesis of human IBD. From the present findings in vitro and in vivo, we
conclude that H4R antagonists may have a potential therapeutic role in the treatment of


















Efficacy of An Estrogen Receptor-β(ER-β)Agonist, But Not An ER-α Agonist Or
ER Antagonist, in the Mdr1a-/- Murine Colitis Model
Silvia C. Resta-Lenert, Kim E. Barrett
Background: We have shown that estrogens have important roles in the physiology and
pathophysiology of the gut and that an ER-β agonist modulated ion transport and barrier
function in colitic mdr1a-/- mice. We hypothesized that ER agonists may also have a role
in preventing mucosal injury in this model of intestinal barrier dysfunction. Methods: 4 and
12 wk old mdr1a-/- (KO) mice (8-10 mice/group, M=F), were treated with an ER-β agonist,
diarylpropionitrile (DPN), an ER-α agonist, propylpyrazole triol (PPT), 17β-estradiol (E),
the ER antagonist, tamoxifen (TMX), or placebo for 4 weeks. Basal and stimulated ion
transport and transepithelial resistance (TER), histopathology and inflammation markers
(iNOS, COX-2, MPO, TNFα) were examined in harvested colonic tissues by Ussing chamber
methodology, microscopy, Western blotting, or immunoassays, respectively. Results: 4 wk
old KO mice were clinically normal whereas 12 wk old KO mice showed evidence of severe
colitis, as expected. 4 wk old KO mice treated with placebo developed colitis over the 4
wk treatment period. Colitis in all animals was associated with increase in basal ion transport,
diminished ion transport responses to forskolin, and impaired barrier function. E- and DPN-
treated 4 wk old KO mice showed improved basal (50.0±16.5 and 30.3±3.5 vs 84.0±3.3;
p<0.01, respectively), and forskolin-stimulated (155.5±6.0 and 165.7±5.0 vs 77.7±4.0,
p<0.01, respectively) colonic ion transport, measured as change in short circuit current in μA/
cm2, and increased TER (68.5±5.0 and 69.8±3.0 vs 55.3±3.0 Ω.cm2; p<0.05, respectively)
compared to placebo-treated KO mice. Colonic tissues from 4 wk old E- and DPN-treated KO
mice maintained their census of goblet cells, and showed decreased neutrophilic infiltration
compared with controls. DPN and E also significantly reduced iNOS, COX-2, MPO and
TNFα in 4 wk old mice, effectively abrogating the onset of colitis. In 12 wk old KO mice,
colitis is already established. While E and DPN did not reverse this colitis completely,
electrophysiological, histological and inflammatory parameters were all significantly
improved. In contrast, PPT and TMX were without effects on colitis in either age group,
despite evidence of bioavailability. Conclusions: Activation of ER-β prevented the onset of
colitis in 4 wk old KO mice and improved colitis in older mice with established disease.
Our data support the hypothesis that estrogen may play important roles in the physiology and
pathophysiology of the gut, and that selective ER agonists devoid of effects on reproductive
physiology may represent therapeutic alternatives in inflammatory bowel diseases.
W1600
Up-Regulation of Rgs4 Expression Induced By Interleukin-1β in Colonic
Smooth Muscle Cells Is Mediated By Nf-κB
Wenhui Hu, Fang Li, Jiean Huang, Karnam S. Murthy
Initial Ca2+-dependent contraction of intestinal smooth muscle mediated by Gq-coupled
receptors is attenuated by the intrinsic GTPase activity of Gαq. GTPase activity is accelerated
by a protein regulator of G-protein signaling (RGS4), resulting in rapid inactivation of
Gαq. Our recent studies have shown that treatment of colonic muscle cells with the pro-
inflammatory cytokine, interleukin-1β (IL-1β) inhibits initial acetylcholine-stimulated con-
traction by increasing the expression of RGS4. The signaling pathways involved in transcrip-
tional regulation of RGS4 are not known. Aim. To determine whether up-regulation of
RGS4 expression by IL-1β is mediated by transcription factor NF-κB. Methods. Rabbit
colonic smooth muscle cells were cultured in DMEM and experiments were performed in
first passage. RGS4 mRNA levels were determined by quantitative RT-PCR. IL-1β-induced
NF-κB activity was measured by electrophoretic mobility shift assay (EMSA), luciferase
reporter gene assay, and by immunoblot using phospho-specific antibody to IKK (Ser178/
180) or p65 (Ser536). The involvement of NF-κB pathway in RGS4 expression was analyzed
using kinase-inactive IKK2 mutant (K44A), phosphorylation-deficient IκBα mutant (S32A/
S36A) and by the use of selective inhibitors for IKK2 (IKKIV) and NF-κB (NF-κB activation
inhibitor). Results. Exposure of smooth muscle cells to IL-1β induced activation of NF-κB
as demonstrated by EMSA, reporter gene assay, IκBα degradation, and by phosphorylation
of IKK2 at Ser178/180 and p65 at Ser536. IL-1β induced both rapid (1 h) and sustained
15-fold increase in RGS4 mRNA expression after 3 days. RGS4 expression was blocked by
selective inhibitors of IKK2 or NF-κB and in cells expressing dominant negative mutants
of IKK2(K44A) or IκBα(S32A/S36A). The results imply that the increase in RGS4 expression
caused by IL-1β is mediated by the canonical NF-κB pathway, which involves phosphoryl-
ation of IκBα by IKK2 and its degradation via a proteasomal pathway resulting in activation
of NF-κB. Conclusion. Up-regulation of RGS4 expression in response to IL-1β is mediated
by transcription factor NF-κB. The increase in RGS4 expression accelerates deactivation of
Gαq and results in inhibition of Ca2+-dependent muscle contraction.
W1601
Sepsis Upregulates Enteric Apelin Expression Through An ERK Pathway
Guiyun Wang, Ella W. Englander, George H. Greeley
Apelin, the endogenous ligand for the APJ receptor, shows a widespread distribution in the
body. Apelin is expressed in the vasculature, brain, kidney, adipose tissue, heart, lung and
GI tract. Apelin signaling can influence the cardiovascular system, water and food intake.
These effects of apelin may play a role in the pathophysiology of sepsis. The aim of these
studies was to investigate the influence of sepsis on apelin expression in GI tract, the role
of increased apelin transcriptional activity in the elevated apelin expression during sepsis,
and to identify the signaling pathway behind LPS-increased apelin transcriptional activity.
Methods. Sepsis was induced by lipopolysaccharide (LPS, 100 µg/kg, IP) administration to
rats. Gut tissues were harvested for measurement of apelin mRNA levels by Northern blotting.
The effect of LPS on apelin transcriptional activity was tested in transient transfection assays
using a mouse macrophage cells (RAW264.7) transfected with either rat or human apelin
5’-upstream fragment-luciferase reporter gene constructs. Involvement of p38, JNK, ERK or
NFκB signaling in LPS-induced activation of apelin promoter activity was tested by means
of pharmacologic inhibitors: (SB203580 [20 µM], JNK inhibitor II [20 µM], PD98059 [40
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µM], and SN-50 NFκB [10 µM]). EMSAs were done to define the extent to which LPS alters
binding of a consensus AP1 oligonucleotide for a nuclear protein extract of RAW264.7 cells.
A putative AP1 binding site occurs in the rat and human apelin core promoters. Results.
Apelin expression increased 2 to 3-fold in the rat stomach, duodenum and ileum 8 and 24
h after LPS treatment (stomach-control: 0.5 ± .05 vs LPS: 1.2 ± 0.2; duodenum-control:
0.3 ± .03 vs LPS: 1.1 ± .01; ileum-control: 0.3 ± .03 vs LPS: 1.3 ± 0.3; P<0.05). Transient
transfection experiments showed LPS (100 ng/ml) stimulated rat and human apelin promoter
activity ~3-fold maximally 24 h after LPS. Apelin promoter activity was increased in a dose-
and time-dependent manner. Blockade of ERK activity but not p38, JNK and NFκB signaling
lowered LPS activation of apelin promoter activity. EMSAs showed that LPS exposure
increased AP1 binding activity. Conclusions and Discussion. LPS treatment increased
apelin expression in the GI tract significantly. Enhanced apelin expression may be due to
increased apelin transcriptional activity. LPS may stimulate apelin transcription via an ERK
pathway since inhibition of ERK activity blocked LPS induced apelin promoter activity and
LPS increased AP1 binding activity. These changes in GI apelin expression may have a role
in the pathophysiology of the wasting syndrome during sepsis.
W1602
H. Pylori Caga Protein Down-Regulates TGF-β Signal Pathway and Attenuates
TGF-β-Induced Rgm1 Cell Growth Inhibition
Hai Ying Fu, Kayoko Asahi, Yujiro Hayashi, Tsutomu Nishida, Hiroaki Murata, Hiroshi
Eguchi, Takeshi Azuma, Sunao Kawano
Background and Aim: CagA, a toxic protein of H.pylori, is injected into host cells via a type
IV secretion system of bacteria and undergoes tyrosine phosphorylation forming complex
with SHP-2 in the cells, thereby modifying cellular signal transduction. We have reported
that CagA protein increased cell growth via MAPK pathway. On the other hand, TGF-β is
reported to inhibit the cell growth of normal gastric epithelial cells and negatively to regulate
Th1 cell development. Here, we investigated the effect of CagA expression on TGF-β and
Smad signal pathway. Materials and Methods: We transfected a cagA gene into rat gastric
mucosal (RGM1) cells and established cell lines, in which CagA expression can be controlled
under the Tet-off system. Smad7 expression induced by CagA protein was analyzed by RT-
PCR. The expression of CagA, Smad7, Smad2/3 and the phosphorylation of Smad2/3 were
investigated by Western blot analysis. EMSA was used to examine the nuclear import of
Smad 2/3/4 complex. The effect of CagA expression on TGF-β-induced cell growth inhibition
was investigated with WST-8 reagent. Results: In cagA gene-transfected RGM1 cells, the
increased Smad7 expression and decreased Smad2/3 phosphorylation were found after CagA
expression. Moreover, the nuclear import of Smad2/3/4 complex was inhibited in CagA
expressing cells, compared with those in CagA unexpressing cells and mock cells. Further-
more, the addition of TGF-β into cell culture medium showed inhibition of RGM1 cell
growth. Conclusion: CagA from H.pylori, expressed in RGM1 cells, increased Smad7 expres-
sion, decreased Smad2/3 phosphorylation and inhibited the nuclear import of Smad2/3/4
complex. Moreover, TGF-β-induced RGM1 cell growth inhibition was blocked by CagA
expression. The results indicate that CagA protein down-regulates TGF-β and Smad signal
pathway, attenuating TGF-β-induced cell growth inhibition.
W1603
Secretory Responses to Substance P (SP) Are Mediated Via Several Neurokinin
(NK) Receptor Subtypes in the Mucosa of the Chronically Inflamed Rat Colon
Caroline B. Appleyard, Marangelie Morales, Cariluz Santiago
We have previously shown that SP-induced mucosal responses of the normal healthy rat
colon are region-specific, with NK1 receptors contributing proportionately more in all
regions. Changes in SP and its receptors have been documented in colitis representing a
possible therapeutic target. AIM: To systematically characterize the contributions of NK
receptor subtypes to the responses induced by SP in chronically inflamed mucosa along the
length of the rat colon. METHODS: Chronic colitis was induced in Sprague-Dawley rats
by intracolonic administration of TNBS, reactivated 6 weeks later. Following euthanasia
segments of proximal, mid and distal colon (4-5 cm) were stripped of muscularis propria
and mounted in Ussing chambers for the measurement of short circuit current. Data were
expressed as a percentage of each tissue’s maximum response to acetylcholine (Ach). The
effects of selective agonists and antagonists were assessed. RESULTS: Visible colonic macro-
scopic damage was found in all animals, with ~35% having diarrhea at the time of sacrifice.
Each region of the rat colon mucosa exhibited a concentration-dependent secretory response
to Ach (10-9-10-3M) and SP (3.3x10-10-3.3x10-6M). The largest SP responses occurred in
the proximal region (50.2±10.5%, n=8), and this could be attenuated by pre-treatment with
TTX (10µM, p<0.01). Indomethacin pretreatment had no effects. In all regions the selective
NK1 agonist Pro9SP (7.2x10-10-7.2x10-6M) elicited concentration-response curves that were
more potent than for SP. The NK2 agonist [Nle10]-Neurokinin A (1.3x10-10-1.3x10-6M)
produced less potent responses reaching a significantly smaller maximum in both the prox-
imal and distal colon (15.9±5.8% and 13.3±7.3% respectively, n=5 p<0.05). The NK3
agonist [MePhe7]-Neurokinin B (7.8x10-10-7.8x10-6M) produced little response in any region
until the highest concentration. The selective NK1, NK2 and NK3 antagonists (SR140333,
SR48968 and SR142801 respectively) each significantly attenuated SP-induced responses of
the distal colonic mucosa (10µM; p<0.01). SR142801 also significantly reduced the proximal
mucosal responses to SP (10µM; p<0.05). CONCLUSIONS: In the chronically inflamed
rat colon NK1 receptors play a greater role in the mucosal response than either NK2 or
NK3. These neurokinin-mediated secretory responses appear to be region specific, and to
be mediated via both direct and indirect mechanisms. The use of selective agonists revealed
the presence of all three NK receptor subtypes, and selective antagonism confirmed that
each appears to mediate responses to endogenous SP in the chronically inflamed distal rat
colon. Supported in part by SO6GM08239 and RR03050.
W1604
Nitric Oxide Derived from Neuronal Nitric Oxide Synthase Regulates Relation
of Ghrelin and Insulin
Tatsuhiro Masaoka, Hidekazu Suzuki, Yohei Nomoto, Hiroshi Hosoda, Toshihro
Nishizawa, Eisuke Iwasaki, Makoto Suematsu, Kenji Kangawa, Toshifumi Hibi
Background Ghrelin is a gastrointestinal peptide with physiological roles, including stimula-
tion of growth hormone release, food intake and gastric motility. We previously reported
increased plasma ghrelin levels in rats with streptozotocin-induced diabetes (FEBS Lett.
541:64,2003),H.pylori-infected Mongolian gerbils (Gut 53:187, 2004) and rats with cysrtea-
mine-induced duodenal ulcers (Am J Physiol. 289:G138. 2005). Although in normal obese
individuals, decreased plasma ghrelin levels have been reported, in patients with Prader-
Willi syndrome (PWS) characterized by hyperphagia and obesity, increased plasma and
gastric ghrelin levels have been reported (J Clin Endocrinol Metab. 90:5441, 2005). This
could be attributable to the lower level of insulin resistance in these patients as compared
with that in patients with simple obesity. Since nitric oxide (NO) induces adaptive relaxation
of the lower esophageal sphincter or gastric fundus, NO is considered to be an conditioning
factor for meal ingestion. Thus, a relationship between NO and ghrelin is suggested. Using
neuronal nitric-oxide-synthase-deficient (nNOS-/-) mice, we evaluated whether NO derived
from nNOS contributed to the mechanism of ghrelin production and secretion. Method
Twelve-week old male nNOS-/- mice (n=10) and wild-type (WT) mice (n=10) were examined
after eighteen hours fasting. The plasma and gastric ghrelin levels were measured by radio-
immunoassay, and the preproghrelin mRNA expression level was measured by quantitative
RT-PCR. Ghrelin-immunoreactive cells in the stomach were evaluated by immunohistochem-
istry. Serum leptin and insulin levels were measured by ELISA. Results In the nNOS-/- mice,
the body weight, food intake, plasma levels of active and total ghrelin, gastric levels of active
and total ghrelin, gastric preproghrelin mRNA expression levels and numbers of ghrelin-
immunoreactive cells in the gastric fundus were significantly increased as compared with
the corresponding values in the WT mice. Furthermore, while the serum levels of leptin,
which reflect the amount of adipose tissue, tended to be higher in the nNOS-/-mice as
compared with those in the WT mice (WT mice: 647.3 ± 157.9 ng/ml vs nNOS-/- mice:
1480.7 ± 370.6 ng/ml, p=0.06), there were no significant differences between the two groups
of mice in the serum levels of insulin. Conclusion The production and secretion of ghrelin
from the stomach were significantly increased in nNOS-/- mice, which manifest significant
body weight increase and lower levels of insulin resistance, as reported for patients with
PWS. The results suggest that NO derived from nNOS may regulate the relation between
ghrelin and insulin.
W1605
Teduglutide (ALX-0600), a Glucagon-Like Peptide-2 (GLP-2) Analogue Inhibits
Contractility in the Colon Ex Vivo
Hong Wang, Lidia L. Demchyshyn
BACKGROUND: Administration of teduglutide, a dipeptidyl peptidase IV resistant peptide
analogue of human GLP-2, increases intestinal mass, promotes nutrient transport activity
and enhances barrier function in the gastrointestinal epithelium. Numerous studies have
demonstrated that teduglutide reduces epithelial damage and mortality in animal models of
intestinal injury. The physiological effects of GLP-2 and teduglutide are mediated by the
GLP-2 receptor (GLP-2R). OBJECTIVE: The following study examined the effects of teduglu-
tide and GLP-2 on the contractility of rodent colon ex vivo. METHODS & RESULTS:
Segments of colon from Sprague Dawley rats were suspended in organ bath chambers
containing Krebs’ solution and maintained at 37°C with 95% O2 and 5% CO2. Basal tone,
contractility rate and peak height were used to measure the properties of spontaneous and
ligand-mediated colonic contractions. Segments were initially loaded to a tension of 2 g and
allowed to equilibrate for 60 minutes. During this period, segments were repeatedly washed
every 10 minutes. GLP-2 analogues were subsequently incubated with each tissue segment
for 5 to 10 minutes. The tissues were allowed to re-equilibrate with repeated washes following
each experiment. Teduglutide and GLP-2 inhibited muscle contractility in a concentration-
dependent manner with an estimated IC50 of 4.9 ± 1.9 nM (n=6) and 13.5 ± 5.4 nM (n=
9), respectively. Contractions did not recover to the original amplitude following wash-out
and teduglutide re-challenge suggesting GLP-2R desensitization. While having no effect
alone, GLP 2(3-33), the primary breakdown product of GLP-2, blocked the inhibitory effects
of teduglutide and GLP-2. In the presence of 10 μM GLP-2(3-33), teduglutide and GLP-2
inhibited colon contractility with an IC50 of 59.9 ± 11.9 nM (n=6) and 142.7 ± 55.9 nM
(n=5) respectively. The rank orders of potency of GLP-2 peptide analogues were similar to that
previously reported for peptide-induced increases in cAMP levels in cell lines recombinantly
expressing the rGLP-2R. CONCLUSIONS: Teduglutide reproducibly and significantly
reduced the contractility of rat colon in a concentration-dependent manner. GLP-2(3-33)
exhibited no inhibition on contractility alone, however blocked the effects of teduglutide
and GLP-2, acting as a GLP-2R antagonist. The rank order of potency of GLP-2 analogues
on the inhibition of colon contractility was comparable to the rank order of increased cAMP
accumulation in heterologous cells expressing GLP-2R. This study demonstrates the ability of
teduglutide and GLP-2 to directly affect native GLP-2R-mediated contractility in colon tissue.
W1606
Dual Mechanism for Inhibition of cAMP By Interleukin-1β in Smooth Muscle:
Inhibitory S-Nitrosylation of Adenylyl Cyclase V/Vi Via iNOS-Derived NO and
Stimulation of Pde4 Expression and Activity
Jiean Huang, Sunila Mahavadi, Karnam S. Murthy
Exposure of smooth muscle to the pro-inflammatory cytokine, IL-1β induces iNOS expression
leading to sustained release of nitric oxide (NO) that triggers feedback inhibition of soluble
guanylyl cyclase (sGC) expression and activity and a decrease in cGMP formation. IL-1β
also causes a decrease in cAMP levels, but the mechanism(s) for this decrease is/are unknown.
The decrease in cAMP levels could reflect down-regulation of adenylyl cyclase V/VI (AC V/
VI) and/or up-regulation of cAMP-specific phosphodiesterase, PDE4D5, both of which are
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specifically expressed in smooth muscle. Aim. To characterize the expression and activities
of AC V/VI and PDE4D5 in smooth muscle treated with IL-1β. Methods. Colonic circular
muscle strips were incubated for 48 h in DMEM with or without IL-1β (10 ng/ml). Muscle
cells were then isolated from these strips and used for determination of AC V/VI and PDE4D5
expression and activity. S-nitrosylation of AC V/VI was determined by the biotin-switch
method. Results. IL-1β induced iNOS expression, and increased AC V/VI expression deter-
mined by immunoblot and RT-PCR. However, isoproterenol- and forskolin-stimulated cAMP
formation (measured in the presence of IBMX to eliminate the effect of PDEs) was decreased,
suggesting that IL-1β inhibited AC V/VI activity. Addition of NOS inhibitor (L-NNA), but
not the sGC inhibitor (ODQ) or the PKG inhibitor (R-pCPT-cGMP[S]), reversed the effect
of IL-1β on cAMP formation, implying that the effect was mediated directly via iNOS-
derived NO. Treatment of muscle tissue with the NO donor S-nitroglutathione (GSNO),
but not with a cGMP analog (8-Br-cGMP) or a PKG activator (CPT-cGMP), also inhibited
isoproterenol- or forskolin-stimulated cAMP formation, providing further support for a direct
inhibitory effect of NO. IL-1β or GSNO induced inhibitory S-nitrosylation of AC V/VI: a
thiol reducing agent, DTT, blocked S-nitrosylation and reversed the inhibition of cAMP
formation. In addition to its effect on cAMP formation, IL-1β increased cAMP degradation
by stimulating PDE4D5 expression (determined by immunoblot) and activity (determined
by degradation of 3H-cAMP). These effects were also evident by the decrease of cAMP levels
in response to isoproterenol or forskolin (measured in the presence of L-NNA to eliminate
the inhibitory effect of NO on AC V/VI and in the absence of IBMX). Conclusion. IL-1β
inhibits cAMP formation via S-nitrosylation of adenylyl cyclase V/VI by iNOS-derived NO,
and augments cAMP degradation by stimulating the expression and activity of cAMP-
specific PDE4D5.
W1607
Gastric Secretory Response to a Meal and Modulation of Somatostatin and
Gastrin Immunoreactive Cells During Fasting and Feeding in Somatostatin
Receptor Type 2 (SSTR2) Knockout Mice
Lixin Wang, Laura Piqueras, Yvette Tache, Vicente Martinez
The prandial state differentially regulates somatostatin and gastrin gene expression in the rat
stomach. We previously established the role of SSTR2 in mediating somatostatin antisecretory
effects using SSTR2 knockout (KO) mice (N-S Arch Pharmacol 370:510, 2004). AIM: To
examine the distribution and regulation of gastric somatostatin- and gastrin-immunoreactive
(IR) cells by the prandial status and the acid response to a meal in conscious SSTR2 KO
mice. METHODS: Gastrin- and somatostatin-IR cells were quantified, after staining with
anti-gastrin (CURE 05109.1) and anti-somatostatin (CURE S.6) antibodies, in the fundic
and antral mucosa in adult SSTR2 KO and wild-type (WT) mice fasted for 18-20 h or fed
ad libitum. Microscopic gastric morphology was also assessed in H-E stained sections.
Gastric secretory responses (intragastric pH and acid content) to a standard meal were also
determined. RESULTS: Fasting increased the number of fundic, but not antral, somatostatin-
IR cells by 2- and 7-fold in STTR2 KO and WT respectively (Table). In SSTR2 KO mice
the number of antral somatostatin-IR cells was decreased by 53% and 58% in fed and fasted
state, respectively, compared with WT (Table). Gastrin-IR cells were present in the antral
but not fundic mucosal glands. Their density was similar in KO and WT mice and not
altered by fasting (Table). Stomach weight (WT: 186±8 mg; KO: 201±5 mg, each n=20)
and morphometric analysis of the antral and fundic mucosa, submucosa or muscular revealed
no differences between KO and WT mice. Basal intragastric pH and acid content were similar
in fasted WT (3.5±0.2 and 6.9±0.4 µmol, n=5) and KO mice (3.1±0.1; 8.4±1.2 µmol, n=
5). The acid response to re-feeding for 1 h was similar in both groups (WT: 4.6±0.1; 8.6±1.1
µmol; KO: 4.8±0.3; 9.8±1.0 µmol; each n=5). CONCLUSIONS: SSTR2 KO mice had a 2-
fold reduction in the number of antral somatostatin-IR cells vs WT, while gastrin-IR was
not altered. The unchanged acid response to feeding in KO mice indicates that functional
somatostin-SSTR2 pathways do not modulate normal postprandial secretory responses.
Compensatory changes to the absence of SSTR2-dependent inhibitory pathways at functional
and/or ultrastructural levels might explain the apparent normal gastric morphology and
functionality of SSTR2 KO mice.
Data are mean±SEM and represent IR cells/field. *:P<0.05 vs cell density in fasted mice; #:
P<0.05 vs corresponding value in WT mice
W1608
Effect of Female Sex Hormone Supplementation and Withdrawal On
Gastrointestinal and Colonic Transit in Postmenopausal Women
Jonathan Gonenne, Tuba Esfandyari, Michael Camilleri, Lorraine Fitzpatrick, Duane D.
Burton, Debra Stephens, Kari Baxter, Alan R. Zinsmeister
Females are disproportionately affected by constipation, which is often aggravated during
pregnancy and the luteal phase of the menstrual cycle. Aims: To evaluate effects of acute
administration of 400 mg/day micronized progesterone, 0.2 mg/day estradiol, combination
of the same doses of progesterone and estradiol, or placebo on gastric emptying (GE), small
bowel transit, and colonic transit (CT) in healthy postmenopausal subjects; and to determine
whether withdrawal of the hormones was associated with a change in transit. Methods: 48
postmenopausal females were randomized (12 per group) and underwent scintigraphy
using a 99mTc-egg meal and 111In-charcoal. All kept daily stool diaries. After withdrawal of
medications, transit measurement was repeated. Treatment assignment was double-blinded;

















t1/2 (hr) and colonic geometric center (GC) at 24 hours. Secondary variables were colon
GC at 4 and 48 hours, GE at 4 hours, colonic filling at 6 hours, and stool frequency,
consistency (Bristol stool form scale) and ease of passage. Results: A statistically significant
effect of progesterone on colonic transit was evident by shorter ascending colon emptying
t1/2 (Fig.) and significantly accelerated overall transit shown by colonic geometric center
at 48 hours. Other transit endpoints were not significantly altered by progesterone. No
transit endpoints were altered by estradiol or combined hormonal treatment relative to
placebo. Withdrawal of the hormone supplement was not associated with any significant
alteration in transit. Progesterone (p=0.024) and estradiol (p=0.04) were associated with
looser stool consistency. Conclusion: Micronized progesterone accelerates colonic transit in
postmenopausal females. This has implications for the pathophysiology and management
of slow transit constipation in postmenopausal females.
W1610
Intracerebroventricular, But Not Intravenous, Stresscopin Acts By CRF Type 2
Receptor to Inhibit Pengastrin-Induced Stimulation of Gastric Acid Secretion
in Rats
Chih-Yen Chen, Full-Young Chang, Shou-Dong Lee
Background & Aims: Stresscopin, a novel 40-amino acid peptide, was recently identified
and characterized. Stresscopin represents endogenous CRF2 receptor ligand for maintaining
homeostasis after stress. Although stresscopin has been shown to suppress food intake,
delay gastric emptying and decrease heat-induced edema in mice, no previous studies have
examined the effects of this novel stress-related peptide on pentagastrin-induced stimulation
gastric acid output (GAO) in rats. Methods: We first examined the effects of intracerebroven-
tricular (ICV) or intravenous (IV) administration of stresscopin on pentagastrin-stimulated
GAO in urethane-anesthetized rats. The novel selective CRF2 receptor antagonist, astressin2-
B, was either ICV or IV injected before stresscopin given. The responsible receptor sites in
the brain as well as periphery were investigated. IV injection of omeprazole served as the well-
known inhibitory control group of GAO under pentagastrin-induced stimulation. Results: IV
injected stresscopin, even at the very high dose (4.58 nmol), failed to suppress pentagastrin-
stimulated (16 ug/kg/hr, IV) GAO, whereas IV injected omeprazole (345 ug) significantly
inhibited pentagastrin-induced stimulation. In contrary, ICV injected stresscopin (0.3, 1 and
3 nmol) dose-dependently inhibited pentagastrin-stimulated GAO. Pre-treatment with ICV
injection of the selective CRF2 receptor antagonist, astressin2-B, completely blocked ICV
injected stresscopin-induced inhibition of pentagastrin-stimulated GAO. However, pre-treat-
ment with IV injection of astressin2-B did not have effects on ICV injected stresscopin-
induced inhibition on pentagastrin-stimulated GAO. Conclusions: The results suggest that
ICV but not IV injection of stresscopin inhibits pentagastrin-induced stimulation of GAO
in rats. In the brain, CRF receptor subtype 2, is involved in this acid inhibitory mechanism.
W1611
Gastric Emptying in CRF-Overexpressing and CRF Receptor 2 Knockout Mice
Lixin Wang, Million Mulugeta, Vincent S. Wu, Pu-Qing Yuan, Honghui Liang, Mary P.
Stenzel-Poore, Pauline M. Jamison, Yvette Tache
Background: Previously we showed in rodents that CRF and related peptides inhibit gastric
emptying (GE) through CRF receptor type 2 (CRF2) while post-operative gastric ileus does
not occur in CRF1 knockout mice or is prevented by CRF1 unlikely by IP CRF2 antagonist
(Peptides 2004, 25:1733; Gastroenterology 2003, 125:654). The CRF1-medaited action may
involve the central sympathetic pathways. Aim: To characterize GE in transgenic mice with
altered CRF signaling system: CRF-overexpressing (OE) and CRF2 deficient (-/-). Methods:
Female adult CRF-OE and CRF2-/- mice or their wide type littermates (WT or CRF2+/+)
fasted for 16-18 h were anesthetized for 10 min and underwent abdominal surgery (celiotomy
and 30 s cecum palpation), or no surgery (sham). The 20 min GE was determined by
gavaging the mice with a non-nutrient liquid at 100 min after the surgery. Brains from CRF-
OE mice were processed 2 h after surgery for Fos immunoreactivity (IR) and the stomach
for expression of CRF receptors and urocortin 2 using RT-PCR. Results: CRF-OE mice had
higher basal GE than WT mice and developed delayed GE after abdominal surgery that had
similar magnitude of decrease from respective basal values (Δ changes: 33.4% in CRF-OE
v 30.7% in WT) (Table). Abdominal surgery induced expression of Fos-IR in selective brain
areas such as the paraventricular nucleus of the hypothalamus (PVN), central nucleus of
the amygdale, lateral parabrachial nucleus, ventrolateral medulla and nucleus of the solitary
tract. However, there was no significant difference between CRF-OE and WT mice. Expression
of transcripts of CRF2β (the functional subtype) and urocortin 2 (CRF2 ligand) in the gastric
corpus did not show differences among groups. No CRF or CRF1 transcript was detected
in the stomach of both CRF-OE and WT mice in this study. Abdominal surgery inhibited
significantly GE in both CRF2-/- and CRF2+/+ compared to sham (Table), while interleukin-
1β (10 µg/kg, IP) did not inhibit GE in CRF2+/+ as it did in CRF2-/-. Conclusions: Peripheral
CRF2 is not involved in post-operative gastric ileus but may contribute to impaired GE
induced by cytokines. The negative feedback of glucocorticoid on CRF containing neurons
in the PVN in CRF-OE mice (Peptides 2001, 22:733) and metabolic changes may override
the CRF signaling system, resulting higher GE.
Table. Gastric emptying rate (%) of a non-nutrient liquid meal in CRF-OE and CRF2-/- mice
after abdominal surgery.
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*: P<0.05 vs the same genotype sham; #: P<0.05 vs WT sham.
W1612
PI3K/Akt Signaling Regulates Stem Cell Activation in Colitis-Induced Cancer
Goo Lee, Ramanarao Dirisina, Navdha Mittal, Jennet Manjali, Gery Grimm, Yueming
Tang, Xi C. He, Linheng Li, Terrence A. Barrett
Data in human colitis-induced cancer(CIC) indicate that neoplastic transformation occurs
via distinct mechanism from sporadic colorectal cancer. To examine the mechanisms involved
CIC, we utilized piroxicam model of colitis in IL10-/- mice which induces severe transmural
colitis followed by indolent period of chronic inflammation associated with elevation in pro-
inflammatory cytokine and chomokine mRNA. Current study is focused on epithelial stem
cell response to chronic inflammation. Using BrdU incorporation as an indicator for epithelial
proliferation, we found that crypt proliferation increased by 2 fold during early period of
colitis but areas of high grade dysplasia seen on D35-42, BrdU index increased by 6 fold
with levels as high as 10 folds above normal in invasive cancer observed on D70. Staining
for nuclear (activated) beta catenin (Bcat-N) was used to enumerate activated stem cells in
tissue(He et al Nat genet 2004). Real time PCR analyses were performed to detect induction
of Bcat target genes (cmyc, cox2, mmp7, fra-1, enc-1). This study indicated that number
of stem cells increased by 4 fold in colitis and 12 fold in area of dysplasia with areas of
invasive cancer with 15 fold. Activate stem cells in areas of dysplasia and carcinoma were
remarkably identified outside basally located stem cell zone. Western blot analysis revealed
that PI3K signaling was induced with 20-50% higher levels of P-Akt and P-GSk3 beta seen
in colitis and 100% elevated levels of phosphrylated intermediates in dysplasia and tumor
nodules. To examine the effect of PI3K inhibition on stem cell activation in colitis and
cancer, mice were treated 3d with systemic LY294002 (30mg/Kg/day). Data revealed that
numbers of activated stem cells were reduced significantly with the greatest effect(90%
reduction) detected in cancer nodules without significant change of pro-inflammatory cyto-
kine mRNA level. Western blot analysis of Bcat-N levels in isolated epithelial cells revealed
that PI3k inhibition reduced Bcat-N levels by 30-50% in colitis and dysplasia whereas levels
were reduced by 90% in areas of carcinoma. These data correlated well with reduction of
proliferation in these tissues as well as dramatic amelioration of cMyc expression in LY294002-
treated mice. Taken together these findings suggest that stem cell activation is a critical step
for induction of CIC. Furthermore, aberrant activation of PI3K/Akt pathway was required
for persistent stem cell activation in colitis and during neoplastic transformation. Most
notably, inhibition of this pathway showed most pronounced effect in areas of carcinoma
suggesting that this may be a target for future therapeutic intervention.
W1613
IL-7 Overexpression: Role for Intestinal EC-Derived IL-7 in Formation of
Intraepithelial and Lamina Propria Lymphocyte Populations
Hua Yang, Deborah L. Gumucio, Blair Madison, Daniel H. Teitelbaum
Background: We have previously shown that loss of IL-7 results in significant derangements
in intestinal lymphocyte phenotypes including a decline in intestinal lymphocyte numbers.
Because IL-7 plays a crucial role in controlling T-cell development and homeostasis, we
investigated the effect of intestinal specific over-expression of IL-7 on intestinal mucosal
lymphocytes. Meathod: We generated an intestinal epithelial cell specific over-expressing
IL-7 transgenic mouse model (IL-7vill), by cloning mouse IL-7 cDNA behind an intestine-
specific villin promoter (P12.4 KVill). IL-7 vill mice were sacrificed at 8 weeks of age. Wild-
type C57BL/6J (WT) mice were used as control. Intestinal derived IL-7 expression was
detected using RT-PCR and Western blot. Serum IL-7 levels were detected by ELISA. To
further confirm the transgenic IL-7 specific expression was only from intestinal mucosa,
thymocytes and splenocytes, as well as hepatic and kidney tissue were also harvested.
Phenotype changes of intraepithelial lymphocytes (IEL) and lamina propria lymphocytes
(LPL) were studied with flow cytometry. Results: RT-PCR showed IL-7 expression to be
expanded exclusively in the small and large intestine. Intestinal mucosal IL-7 protein expres-
sion in IL-7vill mice increased 3-fold compared to WT mice. No serum IL-7 was detectable
in either WT and IL-7vill mouse. Numbers of IEL and LPL in IL-7vill mice were significantly
(P<0.05) higher than WT mice (Table). CD8αβ+, presumably thymic-dependent, increased
5.6-fold in IEL, CD4+CD8- IEL increased 6.5-fold, whereas CD4+CD8- LPL increased 2-
fold. TCR-αβ+ IEL increased 2.5-fold, mature CD4+ IEL (denoted by CD44+) increased
1.5-fold, mature CD4+ LPL increased 2-fold; and activated CD4+ IEL (CD4+,CD69+)
increased 7.6-fold compared to WT mice, activated CD4+ LPL increased 3.7-fold. Systemic
lymphoid populations did not change in IL-7vill mice. Conclusions: IL-7 over-expression
by intestinal epithelial cells significantly affected both IEL and LPL populations, resulting
in over-expansion of the CD4+ and CD8αβ+ IEL subtypes, as well as an increase in IEL
and LPL maturation and activation. These results offer further insight into the role of epithelial
cell-derived IL-7 in IEL and LPL development.
Results are mean±SD. *P<0.05 using t test
W1614
Quercetin Inhibits TNF-Induced IRF-1 But Not NF-κB Recruitment to the IP-
10 Gene Promoter in Intestinal Epithelial Cells Through the Modulation of
Histone Acetyl Transferase Activity
Pedro A. Ruiz, Annett Braune, D.R. Haller
Background & Aim. The molecular understanding of nutritional factors in the process of
host factor-mediated activation of the intestinal epithelium may play an important role for
assessing adjunct nutritional therapy of chronic intestinal inflammation. In this study, we
characterized the molecular mechanisms of the polyphenolic compound quercetin and its
enteric bacterial metabolites taxifolin, alphitonin and 3, 4-dihydroxy-phenylacetic acid to
inhibit TNF-induced pro-inflammatory gene expression in the murine small intestinal epithe-
lial cell (IEC) line Mode-K. Methods. Mode-K cells were stimulated with TNF (5 pg/ml) for
various times in the presence and absence of 100 μM of the polypehenolic compounds
followed by the analysis of IP-10 protein secretion, NF-κB reporter gene activity, Akt and
IκB/NF-κB phosphorylation/degradation, caspase 3 activation, IP-10 gene promoter binding
activity. Oral application of quercetin (10 mg/day/kg body weight) were applied to heterozyg-
ous TNFΔARE mice. Results. Quercetin inhibits TNF-induced IP-10 gene expression with
an effective inhibitory concentration of 39 μM. Interestingly, taxifolin, alphitonin and 3, 4-
dihydroxy-phenylacetic acid completely failed to inhibit TNF responses in IEC, suggesting
that the colonic microbial transformation of quercetin completely abolished its anti-inflam-
matory effect. Interestingly and in contrast to 3’-hydroxy-flavone, quercetin completely failed
to inhibit TNF-induced NF-κB/I-κB phosphorylation and IκB degradation as well as TNF-
induced NF-κB transcriptional activity, suggesting NF-κB independent inhibitory mechan-
isms. Chromatin immunoprecipitation (ChIP) revealed inhibitory effects of quercetin on the
recruitment of the transcriptional co-activator interferon regulated factor (IRF)-1 but not
NF-κB to the IP-10 gene promoter. Most important for the molecular understanding of this
inhibitory mechanism, quercetin inhibited histone acetyl transferase (HAT) activity and the
phosphorylation/acetylation of histone 3 at the IP-10 gene promoter. In addition, quercetin
inhibited TNF-induced survival pathways by blocking Akt phosphorylation associated with
the late induction of pro-apoptotic mechanisms in IEC. The physiological role of quercetin
in modulating experimental ileitis is currently evaluated in heterozygous TNFΔARE mice.
Conclusion. These studies support an anti-inflammatory effect of quercetin on the small
intestinal epithelium through mechanisms that inhibit co-factor recruitment at the chromatin
level by modulating the histone acetyl transferase activity.
W1615
PI3-Kinase Regulates T Cell Activation-Induced SDF-1/CXCR4 mRNA
Expression in Intestinal Epithelial Cells
Yueming Tang, Gery Grimm, Goo Lee, Terrence Barrett
Background and Aims: The intestinal stem cell differentiates into 4 main lineages of epithelial
cells, namely, enterocytes, goblet cells, enteroendocine cells, and Paneth cells. Our recent
studies show that Wnt/β-catenin signaling pathway plays an important role in intestinal
stem cell activation in T cell activation and colitis-induced cancer model. Intestinal stem
cells were activated by T cell or colitis to proliferate into terminally differentiated cells or
cancer cells through PI3-Kinase/β-catenin signaling. Stromal cell-derived factor-1 (SDF-1)
and its receptor (CXCR4) are important regulators of stem cell homeostasis in different
physiology or pathology conditions such as inflammation and cancer. Recent research has
indicated that SDF-1 is up-regulated in malignant tissues and CXCR4 is involved in increasing
the metastatic potential of colon cancer. Therefore, inhibition of SDF-1/CXCR4 axis could
be a strategy for the prevention of colon caner. In current study, we use T cell activation
model to study the effects of T cell activation on SDF-1/CXCR4 expression and the role of
PI3kinase in the mechanisms. Methods and Results: To activate T cells, 6-8 week-old C57BL/
6 mice were injected intraperitoneally with 200μg anti-CD3. Mice were sacrificed for tissue
harvest at 3 hours after anti-CD3 injection. Intestinal epithelial cell were isolated using a
modification of a previously published method. SDF-1/CXCR4 mRNA expression were
assessed by quantitative real time PCR. The data show that T cell activation induced SDF-
1 mRNA increased 1.9±0.20 folds, CXCR4 mRNA increased 2.75±0.32 folds. Pretreatment
with the PI3kinase inhibitor LY-294002, the T cell activation-induced SDF-1/CXCR4 mRNA
expression were inhibited 64% and 76%. Conclusions: Our data show that SDF-1/CXCR4
is up-regulated by T cell induced PI3kinase signaling. Since T cell-induced PI3kinase/β-
catenin signaling plays an important role in the mechanisms of IBD and colon cancer, our
results suggest that SDF-1/CXCR4 might be a general target for inhibition of intestinal
epithelial cell proliferation. SDF-1/CXCR4 inhibitors have potential as anticancer agents to
suppress outgrowth of micrometastases.
W1616
Carcinoembryonic Antigen Expressing Cells Preferentially Activate CD8+ T
Cells
Xianyang Yio, Caroline Korsten, Constantin Friedman, Mee Sook Park, Jiang Yio,
Franziska Roth-Walter, Lilani Perera, Oke Kamalu, Lloyd Mayer
Background: Previous studies in our lab have demonstrated that the intestinal epithelial cell
(IEC) is able to activate CD8+ regulatory T cells, termed TrE. Evidence suggests that the
induction of TrE cells results from interactions of the gp180/CD1d complex and CD8/T cell
receptor. Protein sequencing data concluded that gp180 belongs to the carcimoembryonic
antigen (CEA) family. This finding raises the spectre of immune suppression by tumor cells
expressing CEA. Aim: To study whether CEA/gp180 affects CD8+ and CD4+ T cell prolifera-
tion in antigen non-specific and alloantigen stimulated T cell proliferation systems. Methods:
1) PHA was used to stimulate peripheral blood T cells, CD8+ T cells, and CD4+ T cells, in
the presence or absence of gp180 or CEA. 3H-thymidine incorporation measured cell
proliferation. 2) T cells were co-cultured with a human melanoma cell line transfected with
either human CD1d cDNA (FO1.D5), the CD1d and CEA (FO1.D5-CEA), or FO1.D5 pulsed
with CEA. T cell proliferation was assessed by 3H-thymidine incorporation. 3) PARP western
blot was performed to assess the induction of apoptosis. Results: gp180/CEA suppressed
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total T cell proliferation in PHA stimulated T cell in a dose dependent fashion. Apoptosis
was absent by PARP western blot. This suppression was specifically inhibited by addition
of monoclonal antibody to gp180 (mAb B9), suggesting gp180/CEA exerts an inhibitory
effect on T cell proliferation. Addition of gp180 enhanced the proliferation of CD8+ T cells
but suppressed CD4+ T cell proliferation. Interestingly, FO1.D5 cells were able to induce
CD4+ T cell proliferation while CEA expressing FO1.D5-CEA failed to induce such prolifera-
tion, suggesting an inhibitory effect of CEA on CD4+ T cells. In contrast, the CEA expressing
FO1.D5-CEA cell resulted in better CD8+ T cell proliferation as compared to FO1.D5 cells
alone. These results suggest that CEA/gp180, either in soluble or membrane bound form,
stimulates CD8+ T cell proliferation. These results are consistent with our previous findings
that gp180 is involved in the induction of CD8+ suppressor T cells. Conclusions: It appears
that cells expressing CEA/gp180 stimulate CD8+ T cell proliferation while inhibiting CD4+
T cells. Further studies are required to characterize and compare the proliferating CD8+ T
cells stimulated by the soluble or membrane form of CEA/gp180 in the presence or absence
of CD1d. (Supported by the AGA Centocor Excellence in IBD Clinical Research Fellowship
and CCFA grant).
W1617
Dose-Dependent Inhibition of Stem Cell Activation 5 ASA: A Possible
Explanation for the Chemo Preventative Effect of 5 ASA Therapy in Colitis-
Induced Cancer
Gery Grimm, Goo Lee, Ramanarao Dirisina, Navdha Mittal, Elizabeth Managlia, Jennet
Manjali, Yueming Tang, Jeffrey Brown, Terrence Barrett
Intro/Aims:Data suggest that 5ASA medications reduce the risk of colitis-induced can-
cer(CIC). The AOM/DSS mouse model of CIC was utilized to examine whether 5ASA reduces
the risk for CIC in colitic mice by impairing epithelial stem cell activation. Methods: C57BL/
6J mice were given azoxymethane (AOM-8mg/kg ip), fed 2% dextran sulfate sodium(DSS)
x7d followed by H2O x14d for 2 cycles. 5ASA dosages 100mg/250g chow (low dose-LD)
or 300mg/250g chow (high dose-HD) were chosen based on their partial (~25%,LD) and
moderate (~75%,HD) inhibition of T cell-induced mucosal iNOS, CXCL-10 and COX-2
mRNA. 2 treatment groups were used to assess the ability of 5ASA to prevent CIC. Initially,
we confirmed reports that long term 5ASA reduces dysplasia by giving mice 5ASA from
day 1 of the protocol for 50d. Mice were given 5ASA after the initial bout of colitis to study
the treatment effects of 5ASA(d21-42). Colitis (grade 0-4), levels of low grade dysplasia
(LGD) and high grade dysplasia (HGD), and cancer (Ca) were measured (Cooper et al, Lab
Invest, 1993) at sacrifice. Epithelial stem cell activation was assessed by IHC of nuclear
beta-catenin (Xi et al, Nature Genetics, 2004). RESULTS: Long term LD and HD 5ASA
reduced levels of dysplasia by 50-60% (LD 5ASA) and by >90% (HD 5ASA). To determine
effects of 5ASA used as a treatment for active colitis, mice were examined after 5ASA was
given to mice with severe colitis (Fig.1). Summary: 1) A dose-dependent drop in rates of
HGD was seen in mice given 5ASA x 3wk after the onset of severe colitis. 2) LD and HD
5ASA blocked the progression of CIC. 3) Severe colitis dramatically increased rates of stem
cell activation and crypt cell proliferation. 4) 5ASA treatment reduced stem cell activation
and proliferation in a dose-dependent manner. Conclusions: These data suggest that 5ASA
inhibition of aberrant stem cell activation explains its chemopreventative effect in CIC.
W1618
The Differentiation of Intestinal Epithelial Cells (IECs) Is Regulated By the
Crosstalk Between IECs and Lamina Propria Lymphocytes
Stephanie Dahan, Giulia Roda, Franziska Roth-Walter, Lloyd Mayer
The interactions between luminal contents, epithelial cells and mucosal T cells likely play
a significant role in maintaining intestinal homeostasis. Data from many systems support
crosstalk between IECs and T cells. In this study, we asked whether Normal or Crohn’s
Disease (CD) lamina propria lymphocytes (LPL) could provide signals to IECs promoting
their growth and differentiation. METHODS: T84, Caco-2 and HT29 subclone 16E cells
were grown polarized or non-polarized and co-cultured with freshly isolated LPL for varying
periods. After removal of LPL, IECs were lysed and subjected to i) Western blot analysis
for MAPK and Akt activation; ii) quantification of alkaline phosphatase (AP) activity; iii)
RT-PCR for MUC2 and TFF3 gene expression. In vitro findings were corroborated in vivo
using immunohistochemistry (MAPK and Akt activation) on human colonic tissue sections.
RESULTS: Phospho-MAPK (ERK1/2, p38, and JNK) and phospho-Akt were seen as early
as 30 min after co-culture persisting for at least 3 hours. Interestingly, the level of the MAPK
activation was greater in T84 and Caco-2 cells co-cultured with CD LPL than with Normal
LPL. There was an increase in epithelial P-ERK1/2 and P-JNK staining of the surface colonic
mucosa in active CD vs inactive CD or normal mucosa. In contrast, P-Akt had a different
localization pattern, ie in the basolateral aspect of the upper 2/3 of the surface IEC in normal
mucosa, which extended into the crypt in inactive CD, but not in active CD mucosa. AP
activity was slightly increased in T84 cells (and slightly decreased in HT29 16E cells ) co-
cultured for 8 days with Normal LPL (82±54 in T84 alone vs 219±194 nmol pNP/mg prot).
In contrast, AP activity was significantly increased in both T84 and HT29 16E cells co-
cultured with CD LPL (86±84 in T84 alone vs 686±18 nmol pNP/mg prot; and 249±24 in
HT29 16E alone vs 337±8 nmol pNP/mg prot). Despite this, the co-culture of either Normal
or CD LPL with HT29 16E for 4 days shut down the MUC2 mRNA expression. CONCLU-
SION: The MAPK and PI-3K signaling pathways are involved in cell survival, growth,
and differentiation. LPL provide signals to IECs, which tend to favor IEC differentiation.



















Curcumin Modulates Neutrophil Migration At Multiple Levels
Claire Billerey-Larmonier, Monica T. Midura-Kiela, Anna J. Midura, Fayez K. Ghishan,
Pawel R. Kiela
Polymorphonuclear neutrophils (PMN) are the first cells recruited at the inflammation site.
These cells play a key role in the innate immune response by recognizing, ingesting and
destroying many pathogens without the support of the adaptive immune response. However,
transepithelial migration of neutrophils in intestinal inflammation results also in reduction
of epithelial barrier function, perpetuation of inflammatory processes, and tissue destruction
via oxidative damage and the release of proteases. Curcumin (diferulolylmethane) has been
shown to display a protective role in mouse models of IBD, a phenomenon accompanied
by a dramatic reduction of neutrophilic infiltration in the colon. We therefore hypothesized
that this molecule may modulate PMN recruitment and function. The effects of dietary
curcumin-mediated attenuation of colonic inflammation in BALB/c mouse model of TNBS-
induced colitis were measured via microarray and real-time PCR analysis, with a particular
focus on expression of genes involved in neutrophil chemotaxis. These analyses identified
a list of genes intimately involved in this process which were normalized by dietary curcumin.
This list included CXCL-2 (MIP-2; mouse IL-8 homologue), CXCL-13, CCL-9, IL1β, formyl
peptide receptor-like 1 (Fprl1), colony stimulating factor 2 receptor (Csf2rβ1), C3
complement, calgranulins A and B, and SSP1 (osteopontin). Curcumin-mediated attenuation
of LPS-stimulated transcription and secretion of MIP-2 and IL1β was further confirmed in
YAMC colonic epithelial cells and macrophages (RAW264.7 and resting peritoneal macro-
phages). In vitro chemotaxis assays with calcein-stained bone marrow-derived mouse PMN
demonstrated profound effects of curcumin when conditioned medium from control, LPS,
or LPS/curcumin treated peritoneal macrophages, RAW264.7 or YAMC cells was used as
chemoattractants. This inhibition corresponded with the dramatically decreased concentra-
tion of MIP-2 in the medium. Although curcumin had only a moderate effect on PMN
chemotaxis toward recombinant MIP-2, it markedly inhibited random migration of PMN in
the absence of chemoattractants, suggesting an effect on neutrophil motility and chemokin-
esis. This finding was further confirmed with PMN pre-treated with increasing concentrations
of curcumin, which had dramatically reduced random and MIP-2 directed translocation in
vitro, with a maximal effect at 10 μM of curcumin. In summary our results indicate that
curcumin could interfere with the early phase of colonic inflammation partly through
inhibition of neutrophil chemotaxis, both directly as well as indirectly via inhibition of
expression of chemotactic molecules and their receptors.
W1620
Differential Regulation of the IL-18/IL-18bp System in Human Intestinal
Epithelial Cells
Stephan Haas, Melanie Gruber, Darko Gosenca, Peter Feick, Manfred V. Singer, Ulrich
Boecker
Background: An imbalance of cytokines on the mucosal level is believed to contribute
to the immunopathogenesis of chronic inflammatory bowel diseases. Biological effects of
interleukin-18 may promote intestinal inflammation if insufficiently counterbalanced by
their natural antagonists, the IL-18 binding proteins. Aim: To determine whether expression
and release of IL-18 and IL-18bp are differentially regulated in intestinal epithelial cells.
Methods: Cultivated intestinal epithelial cell lines HT-29 and Caco-2 were exposed to
different stimuli in vitro in the presence or absence of specific inhibitors of signal transduction.
Expression of IL-18, IL-18bp and Caspase-1 mRNA and protein was determined by PCR,
Western blot analysis and ELISA. Caspase-1 activity was assessed by a functional assay.
Presence of IL-18, IL-18bp and caspase-1 in primary human intestinal epithelial cells was
analyzed by immunohistochemistry on mucosal biopsies from Crohn’s disease patients and
controls. Results: Both IL-18 and Il-18bp mRNA were constitutively expressed in intestinal
epithelial cells. Only the 24kDa proform of the IL-18 protein was detectable in unstimulated
cells. Butyrate enhanced the expression of IL-18, while the basal level of IL-18bp remained
unchanged. By contrast, up-regulation of IL-18bp was achieved by exposure to IFN-γ and
augmented by co-incubation with TNF-α, but abrogated in the presence of butyrate. Dose-
dependent induction of IL-18bp by IFN-γ was completely suppressed when protein kinase
C activity was inhibited by RO 31-8220. As opposed to the differential effects of IFN-γ,
exposure to gram-positive Staphylococcus aureus (SAC) increased both the protein content
of IL-18 and IL-18bp in the intracellular compartment; only IL-18bp was synergistically
enhanced by SAC and IFN-γ. Expression and functional activity of caspase-1 was markedly
augmented by IFN-γ and SAC, respectively. In the presence of chronic inflammation expres-
sion of IL-18, IL-18bp and caspase-1 was up-regulated in the epithelium of mucosal biopsies.
Conclusions: Expression of IL-18 and IL-18bp is differentially regulated by IFN-γ, TNF-α
and SAC in human intestinal epithelial cells. A better understanding of the signal transduction
processes involved may enable a selective shift of the IL-18/IL-18bp ratio in chronic inflam-
matory bowel disease.
W1621
Crosstalk Between Intraepithelial Lymphocytes (IELs) and Epithelial Cells
(ECS) Increases IL-8 Production Through the CD2-CD58 Interaction with
Regulation By Interferon (IFN)γ
Asit Panja, Ellen Ebert
Introduction: IL-8 is produced in large quantities by intestinal ECs. Since IELs have potent
chemotactic activity with IL-8, they are drawn into the epithelium. We hypothesize that IL-
8 production by ECs and IELs is modulated by interactions between the two cell types.
Methods: IELs were isolated from jejunal mucosa of patients undergoing gastric bypass
operations for morbid obesity. HT-29 cells were used as a model of ECs. IELs and ECs were
co-cultured without a stimulus at a 5:1 ratio for 18 hrs. IL-8 was measured by ELISA.
Results: Both IELs and HT-29 cells produced IL-8. There was a 1.6-fold synergistic increase
in IL-8 when these two cell types were cocultured. When IELs were cultured in an insert
overlying a monolayer of HT-29 cells, IL-8 still synergistically increased but not to the same
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extent as when the cells were cultured together. This suggests the involvement of cell contact
as well as a soluble factor. Antibody blocking experiments revealed that the synergistic
increase in IL-8 with coculture of IELs and HT-29 cells was dependent on the CD2-CD58
rather than the TCR-MHC class I interaction. When neutralizing various cytokines with
specific antibody, the most marked change in IL-8 production was a 1.7-fold increase with
anti-IFNγ. When cells were cultured separately, IFNγ surprisingly reduced while anti-IFNγ
increased IL-8 production by IELs but not by HT-29 cells. In addition, IFNγ increased CD58
expression on HT-29 cells, potentially up-regulating IFNγ release by IELs through the CD2
pathway. Conclusion: This study shows a synergistic increase in IL-8 production when IELs
and HT-29 cells were cultured together. This increase depended on the CD2-CD58 interac-
tion, a potent stimulus for IFNγ. IFNγ, in turn, up-regulated CD58 expression on HT-29
cells, potentially stimulating further IFNγ release through the CD2 pathway in IELs. Finally,
IFNγ suppressed IL-8 production, not by HT-29 cells, but by IELs. IFNγ as an inhibitor of
IEL function is a novel, and surprising, finding that serves to control IL-8 production.
W1622
Regulation of Matrix Metalloproteinases Synthesis By Interleukin-21 (IL-21) in
Human Intestinal Fibroblasts
Ilaria Peluso, Daniele Fina, Roberta Caruso, Carmine Stolfi, Valentina Gioia, Massimo C.
Fantini, Thomas T. MacDonald, Francesco Pallone, Giovanni Monteleone
Background and Aim: Activated lamina propria T cells play a central role in the pathogenesis
of tissue damage in Inflammatory Bowel Disease (IBD). Although, the exact mechanism by
which T cells mediate mucosal injury during chronic intestinal inflammation remains
unknown, there is evidence that T cell derived-cytokines stimulate stromal cells to synthesize
matrix metalloproteinases (MMPs), thereby promoting mucosal degradation. We have previ-
ously shown that, in IBD, mucosal inflammation associates with high production of interleu-
kin (IL)-21, a T cell-derived cytokine. In this study we have extended our analysis of IL-
21 biological activity in the gut, and first examined whether intestinal fibroblasts express
IL-21 receptor (IL-21R), and second investigated the effect of IL-21 on MMP production.
Methods: IL-21R was evaluated in normal and IBD fibroblasts cultured in the presence or
absence of inflammatory cytokines by RT-PCR and Western blotting. To examine the effect
of IL-21 on MMPs, IBD fibroblasts were either left untreated or treated with graded doses
of IL-21 in the presence or absence of TNF-α, and then MMPs synthesis evaluated by RT-
PCR, Western blotting and zymography. Finally, we evaluated the effect of a neutralizing
IL-21R fusion protein (IL-21R/Fc) on the induction of MMPs in fibroblasts stimulated with
Crohn’s disease (CD) lamina propria mononuclear cell (LPMC) supernatants. Results. A
constitutive expression of both IL-21 receptor (IL-21R) and common gamma-cytokine chain,
which are necessary for IL-21-driven signaling, was seen in intestinal fibroblasts isolated from
normal and IBD mucosa. Importantly, TNF-α but not IFN-γ enhanced IL-21R expression.
Stimulation of both normal and IBD fibroblasts with IL-21 resulted in enhanced synthesis
of interstitial collagenase, stromelisyn-1, gelatinases A and B, whereas expression of tissue
inhibitors of MMP-1 and -2 remained unchanged. Importantly, the effect of IL-21 on MMPs
secretion was dose-dependent and enhanced by TNF-α. Finally, we showed that CD LPMC
supernatants stimulate MMP secretion by intestinal fibroblasts, and that this effect is partly
inhibited by IL-21R/Fc, clearly indicating that CD LPMC-derived IL-21 is functionally capable
of regulating MMP production. Conclusions: These results suggest that fibroblasts are a
potential target of IL-21 in the gut and that, in IBD, IL-21 can contribute to the tissue
damaging immune response by driving MMPs production.
W1623
IL-7 Is Essential for the Development and Persistence of Chronic Colitis
Teruji Totsuka, Takanori Kanai, Yasuhiro Nemoto, Motomi Yamazaki, Shin Makita,
Mamoru Watanabe
Background: IL-7 has recently emerged as a key cytokine involved in controlling the survival
of peripheral resting memory CD4+ T cells and their homeostatic turnover. We have previ-
ously demonstrated that mucosal CD4+ T cells expressing high levels of IL-7 receptor (IL-
7Rhigh) are pathogenic cells responsible for chronic colitis. Methods & Results: To investigate
the role of IL-7 in the development and the persistence of chronic colitis, we transferred
normal CD4+CD45RBhigh T cells or colitogenic lamina propria (LP) CD4+ memory T cells into
IL-7+/+ × RAG-1-/- and IL-7-/- × RAG-1-/- mice. After the adoptive transfer of CD4+CD45RBhigh
splenocytes into syngeneic IL-7+/+ × RAG-1-/- mice, the recipients develop massive inflamma-
tion of the large intestinal mucosa concurrent with massive expansion of Th1 cells. In
contrast, clinical and histological signs of disease are completely absent in IL-7-/- × RAG-
1-/- mice transferred with normal CD4+CD45RBhigh splenocytes. Furthermore, IL-7+/+ × RAG-
1- / - , but not IL-7 - / - × RAG-1- / - , mice re-t rans ferred wi th the col i togenic LP
CD4+CD44highCD62L- effector-memory T (TEM) cells obtained from colitic CD4+CD45RBhigh
transferred RAG-1-/- mice, developed colitis. Surprisingly, rapid proliferation of donor colitic
LP CD4+ memory TEM cells was observed in the in IL-7-/- × RAG-1-/- LP to a similar extent
of those in IL-7+/+ × RAG-1-/- LP CD4+ memory TEM cells 7 days after the transfer into RAG-
1 -/- mice using CFSE dilution method. In contrast, a massive LP CD4+ T-cell apoptosis was
observed in IL-7-/- × RAG-1-/-, but not in IL-7+/+ × RAG-1-/-, mice. Conclusions: Taken
together, IL-7 is essential for the development and persistence of chronic colitis as a critical
survival factor rather than growth factor for colitogenic LP CD4+ memory CD4+ T cells,
suggesting that therapeutic approaches targeting IL-7/IL-7R signal pathway may be feasible
in the treatment of inflammatory bowel disease.
W1624
Mechanism of Interferon-Gamma (IFN-γ) Induced Increase in Intestinal
Epithelial Tight Junction Permeability: Cross-Talk Between PI-3 Kinase and
NF-κB Pathways
Praveen K. Roy, Michel Boivin, Angela Bradley, John C. Kennedy, Thomas Y. Ma
Background: Interferon gamma (IFN-γ) induced increase in intestinal epithelial tight junction
(TJ) permeability has been proposed as an important pathogenic mechanism contributing
to intestinal inflammation. However, the intracellular pathways that mediate the IFN-γ
induced increase in intestinal TJ permeability remain poorly understood. Previous studies
have shown that IFN-γ may activate PI-3 kinase or NF-κB in various cell types. Thus, the
purpose of this study was to investigate the possible role of the PI-3 kinase pathway and
the intracellular mechanism involved in mediating the IFN-γ induced increase in intestinal
tight junction permeability using filter-grown T84 intestinal epithelial cells. Methods: T84
TJ permeability was assessed by measuring the trans-epithelial electrical resistance (TER)
and paracellular permeability. PI-3 kinase activation was assessed by translocation of PI-3
kinase (p85) subunit from the cytoplasm (soluble) to the membrane (insoluble) fraction by
western blot. NF-κB activation was assessed by DNA binding ELISA assay and NF-κB
responsive SEAP promoter assay. Results: IFN-γ produced a concentration and time-depend-
ent decrease in T84 TER (80% decrease at 72 hours). The drop in TER correlated with a
three-fold increase in paracellular permeability to inulin. IFN-γ induced drop in T84 TER
was also associated with a decrease in occludin protein expression and disruption in junctional
localization. IFN-γ treatment resulted in rapid activation of PI-3 kinase (within 5 minutes);
and inhibition of PI-3 kinase activation by selected inhibitors, LY 294002 and Wortmanin,
prevented the IFN-γ induced drop in T84 TER and decrease in occludin expression, suggesting
that PI-3 kinase activation was required for the IFN-γ induced increase in T84 TJ permeability.
IFN-γ caused a delayed activation of NF-κB pathway (8 h after treatment); and inhibition
of NF-κB activation with NF-κB inhibitor PDTC prevented the IFN-γ drop in TER and
down-regulation of occludin expression. Moreover, PI-3 kinase inhibition also prevented
NF-κB activation. Conclusion: Our results suggest for the first time that the IFN-γ induced
increase in intestinal TJ permeability and disturbance in occludin protein were mediated by
the activation of PI-3 kinase pathway. Our findings indicate that IFN-γ leads to upstream
activation of PI-3 kinase, which in turn leads to a step-wise activation of NF-κB pathway,
down-regulation of occludin protein expression and a functional opening of the T84 TJ bar-
rier.
W1625
Histidine Inhibits LPS-Induced Pro-Inflammatory Cytokine Secretion from
Macrophages Via Suppression of NF-κB Activation
Ayatoshi Andou, Tadakazu Hisamatsu, Susumu Okamoto, Hiroshi Chinen, Nobuhiko
Kamada, Masaki Hashimoto, Hideaki Kihara, Toshifumi Hibi
BACKGROUND: Elemental diet (ED) therapy for Crohn’s disease is efficacious in the
induction and maintenance of remission. Although some of its therapeutic effects are postu-
lated due to its low antigenic load and low fat content, the mechanisms remain unclear.
ED contains a high amount of free amino acids, some of which were recently reported to
contribute to the modulation of gut inflammation in a colitis model. In an IL-10 knock-out
(KO) transfer model, dietary histidine significantly reduced local inflammation. AIM: To
investigate the mechanism of the ameliorating effect of histidine on experimental colitis.
METHODS: In the IL-10 KO transfer model (Ikenoue et al. Int Immunopharmacol. 2005),
the severity of colitis was evaluated pathologically, the wet colon was weighed. Colonic
mRNA expression of TNF-α was detected by quantitative RT-PCR. The localization of
macrophages in the colon was confirmed by frozen section immunohistochemistry. In vitro,
thioglycolate-induced mouse peritoneal exudate cells (TG-PEC) or human peripheral blood
derived CD14+ monocytes were incubated with LPS and amino acids. The concentration of
cytokines in the supernatant was determined by enzyme-linked immuno-sorbent assay. Cell
viability was determined using a colorimetric assay (WST-8). Degradation of IκB-α was
comfirmed by immunoblotting analysis. RESULTS: In the IL-10 KO transfer model, dietary
5% histidine, but not 5% alanine, reduced histological damage, colonic weight (38% inhibi-
tion, p < 0.05), and colonic mRNA expression of TNF-α. Since immunohistochemical
analysis revealed a significant increase of F4/80+ macrophages in the inflamed lamina propria
in this model, we hypothesized that histidine directly inhibits TNF-α secretion from the
intestinal macrophage. In vitro, histidine inhibited LPS-induced TNF-α and IL-6 secretion
from mouse macrophages (TG-PEC) in a dose-dependent manner and the inhibition rate
reached 80% at a concentration of 5mM (basal medium; 0.2mM histidine), whereas alanine
had no such effect. Neither amino acid was toxic to the cells at concentrations up to 25mM.
Furthermore, histidine reduced the ability of LPS to activate NF-κB as assessed by IκB-α
proteolysis. Finally, histidine also suppressed TNF-α production in human monocytes.
CONCLUSIONS: These results suggested that histidine reduced NF-κB activation, and this
effect was attributable to its down-regulatory action on pro-inflammatory cytokine production
in macrophages. The anti-inflammatory effects of amino acids might reveal a new aspect of
the action mechanism of ED therapy for Crohn’s disease.
W1626
A New Transcription Factor That Regulates TNF-α Gene Expression, LITAF
(Lipopolysaccharide Induced TNF-α Factor) Is Increased in Ileal and Colonic
Tissues from Patients with Crohn’s Disease and Ulcerative Colitis
Karen L. Reed, Arthur F. Stucchi, Michael J. O'Brien, Sandra R. Cerda, Charles Andrews,
Adam C. Gower, Kristen N. Bushell, Susan E. Leeman, Salomon Amar, James M. Becker
Background: The proinflammatory cytokine TNF-α plays a key role in the pathogenesis of
Crohn’s disease (CD) and ulcerative colitis (UC). Recently, a new transcription factor, LITAF,
was shown to mediate TNF-α gene transcription in human macrophages by binding directly
to the TNF-α promoter. Since the initial studies implicating LITAF in TNF-α gene expression
were performed in a macrophage cell line, the aim of this study was to determine LITAF
expression in vivo in ileal and colonic tissues resected from patients with CD and UC. We
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also sought to determine the relative levels of LITAF message and protein in inflamed
compared to non-inflamed areas of these tissues. Methods: Human ileal and colonic tissues
from patients with CD and UC were collected at the time of surgery. LITAF protein was
localized by immunohistochemistry and quantified by Western blot analysis, while LITAF
mRNA was measured by real time PCR. Results: COLON: LITAF immunostaining was
localized to lamina propria macrophages and was markedly increased in UC and CD tissues
compared to non-IBD controls. Non-inflamed CD tissues expressed 5-times more LITAF
mRNA compared with non-IBD controls (p<0.05). A further 60% increase in LITAF mRNA
was observed in inflamed CD tissues vs. to non-inflamed areas (p<0.08). In UC, LITAF
mRNA levels from non-inflamed areas of the colon were elevated 15-fold (p<0.05) above
non-IBD controls. However a further increase was not observed in tissues resected from
inflamed areas. Similar to PCR results, Western blot analysis showed a marked increase in
LITAF protein in inflamed areas compared with non-inflamed areas of the colon (p<0.05)
from patients with CD. In tissues obtained from patients with UC, LITAF protein levels
were similar in non-inflamed and inflamed areas. The relative levels of TNF-α mRNA and
protein in these tissues paralleled those of LITAF. ILEUM: Similarly, in inflamed ileal tissues
from CD patients, LITAF was localized to lamina propria macrophages, and LITAF mRNA
and protein levels were significantly increased in inflamed ileal tissues compared with non-
inflamed areas. Conclusions: This is the first demonstration of LITAF expression in colonic
and ileal tissues from patients with either CD or UC. LITAF is readily detectable in these
tissues and is significantly elevated above controls. It is localized to macrophages, a major
source of TNF-α. These data provide strong evidence for a role for LITAF in the pathophysiol-
ogic regulation of the TNF-α gene and underscore the potential value of anti-LITAF strategies
in the clinical management of these diseases.
W1627
A STAT3 Dependent Transcriptome Is Up-Regulated in Pediatric Crohn’s
Colitis At Diagnosis
Rebecca Carey, Xiaonan Han, Lee Denson
The IL-6 dependent transcription factor STAT3 has been implicated in the pathogenesis of
IBD. We have reported that growth hormone (GH) down regulates STAT3 activation in
Crohn’s disease (CD)and reduces STAT3 activation and mucosal inflammation in IL-10
deficient murine colitis. However, a global assessment of STAT3 target genes which may
promote chronic colitis has not been reported. We hypothesized that STAT3 target genes
regulating leukocyte recruitment, cell proliferation and survival, and tissue remodeling would
be up-regulated in CD at diagnosis, and that GH would exert an anti-inflammatory effect
in murine colitis via down regulation of these genes. Methods: Colon biopsies and serum
were obtained from eight children with CD at diagnosis and eight healthy controls. RNA
was prepared from colon biopsies and gene expression was determined using the Affymetrix
Human Genome U133 array and analyzed with GeneSpring™ software. Serum cytokine
and chemokine levels were measured using the Bioplex™ assay. CD colon biopsies were
exposed to GH in short term culture and localization of activated STAT3 was determined.
IL-10 deficient mice with colitis were treated with GH and colon chemokine expression
were determined. Results: Bioplex analysis of serum cytokines and chemokines showed
consistent up regulation of IL-6. Moreover, multiple IL-6/STAT3 target genes were up
regulated in affected CD colon. These included chemokines regulating neutrophil (CXCL2,
3, 5, and 6) and T cell (CXCL11) recruitment, several collagen (COL1A1 and COL4A1)
and matrix metalloproteinase (MMP1, 3, and 10) subtypes, and transcription factors regulat-
ing cell proliferation and survival including C-FOS, JUNB, and C/EBPD. The degree of up
regulation of these genes was proportional to the degree of histological injury, as measured
by the Crohn’s Disease Histological Index of Severity (CDHIS). Short term exposure to GH
in tissue culture reduced STAT3 activation in CD colon biopsies in both CEC and LP
mononuclear cells. mRNA expression of the murine homologues of the T cell chemokines
CXCL9 and CXCL11 was increased in IL-10 deficient mice and localized primarily to CEC
by immunohistochemistry. Chronic GH administration partially reduced expression of these
chemokines, in association with reduced STAT3 activation and mucosal inflammation. Con-
clusions: A pro-inflammatory IL-6/STAT3 dependent transcriptome which regulates leuko-
cyte recruitment, cell proliferation and survival, and tissue remodeling is activated at diagnosis
in pediatric Crohn’s colitis. Therapeutic approaches which reduce STAT3 activation are
likely to promote mucosal healing in Crohn’s colitis.
W1628
Pro-Inflammatory Cytokines IL-1β and TNF-α Repress Transcriptional
Activation of the Enterocyte Differentiation Marker Intestinal Alkaline
Phosphatase Gene
Madhu S. Malo, Shaluk Biswas, Mario A. Abedrapo, Lisa Yeh, Alexander Chen, Richard
A. Hodin
INTRODUCTION: Gut inflammatory diseases such as IBD are associated with an alteration
in the phenotype of the intestinal epithelial cells, most notably a loss in expression of the brush
border marker, intestinal alkaline phosphatase (IAP). In the present study we investigated the
molecular mechanisms responsible for this IAP gene silencing. METHODS: HT-29 cells were
treated with 5 mM sodium butyrate (NaBu) to induce villus-like differentiation. The cells
were exposed to the cytokines IL-1β and TNF-α prior to the differentiation stimulus in
order to simulate the inflammatory conditions seen in vivo. Northern analysis, IAP-luciferase
reporter assays, western blotting, and chromatin immunoprecipitation (ChIP) were performed
to examine the mechanism of the effects of cytokines on NaBu-induced IAP gene activation.
RESULTS: Northern blot analyses confirmed the marked induction in IAP expression after
24 h of NaBu treatment, whereas pre-treatment (6 h or 18 h) with cytokines showed a
dose-dependant decrease in IAP mRNA levels (approximately 35% for IL-1β, 25% for TNF-
α at 10 ng/ml of cytokines). The transfection studies revealed that IAP-Luc activity was
markedly induced by NaBu (approximately 5-fold), but the cells pre-treated with cytokines
showed significant inhibition of IAP activation (90% and 60 % with IL-1β and TNF-α,
respectively). Western analyses on purified histones showed that NaBu induced a dramatic
H4 and H3 acetylation, consistent with its known activity as a histone deacetylase inhibitor.

















or TNF-α. ChIP assays showed that NaBu induced both H4 and H3 acetylation in the IAP
proximal promoter region (H4 > H3). This local H4 and H3 acetylation was selectively
reduced by pre-treatment with IL-1β, but not by TNF-α. CONCLUSION: We conclude that
the cytokine inhibition of IAP gene expression is not due to a blockade of global histone
hyperacetylation, but in the case of IL-1β, it may be due to a specific inhibition of acetylation
within the proximal promoter region. It is likely that the altered enterocyte phenotype
associated with the inflammatory cytokines results from distinct inhibitory pathways.
W1629
Blockade of Interleukin (IL)-21 Enhances Lamina Propria T Lymphocytes
Apoptosis in Patients with Inflammatory Bowel Disease (IBD)
Daniele Fina, Ilaria Peluso, Roberta Caruso, Valentina Gioia, Carmine Stolfi, Massimo C.
Fantini, Fabio Andrei, Gian C. Naccari, Salvatore Bellinvia, Francesco Pallone, Giovanni
Monteleone
Background & Aim. In IBD, lamina propria T lymphocytes (T-LPL) are resistant to apoptosis,
but the mechanism underlying such a defect is not fully understood. We have recently
shown that IL-21 is produced in excess in IBD. As IL-21 signals through the γ-chain receptor,
and γ-chain-mediated signals inhibit T cell apoptosis, we evaluated whether blockade of IL-
21 enhances IBD T-LPL death. Materials & Methods. IBD CD3+ and CD4+ LPL were cultured
with a neutralizing IL-21 antiserum or control serum (1:500-4000 final dilution), and the
number of Annexin V (AV) and/or propidium iodide (PI) cells was evaluated by flow
cytometry. Loss of mitochondrial potential was assessed by DIOC6 staining. Total extracts
were prepared from either untreated or treated LPL and analyzed for caspase-3 by Western
blotting. Results. After 20 hours culture, the anti-IL-21 dramatically reduced the survival
of CD3+ LPL. Flow cytometry analysis revealed that the anti-IL-21 significantly enhanced
the percentages of AV+ (28,5±8), PI+ (7±1,4) and AV+PI+ (41±7,6) in comparison to
unstimulated (AV: 11±1; PI: 1,5 ±0,16; AV-PI:20,8±5,7) or control serum-treated (AV:
11,6±0,69; PI: 2 ±0,7; AV-PI:21±5,77) cells (P<0.01). The anti-IL-21 also enhanced the
percentage of AV and PI in CD4+LPL, thus excluding the possibility that its effect occurred
via an antibody-mediated cytotoxicity. These effects were associated with a time- and dose-
dependent loss of mitochondrial potential and caspase-3 activation. Conclusions: Data indic-
ate that neutralization of IL-21 activity dramatically reduces the survival of IBD LPL thus
suggesting a role for this cytokine in maintaining the ongoing T cell-mediated inflammation
in IBD.
W1630
Differential Interaction of Cmvil-10 with Variants of the IL-10 Receptor Chain
1 (IL-10R1)
Sabine G. Gruber, Paul Grundtner, Gloria Luciani, Christoph Gasche
Background: CMV reactivation in UC is commonly associated with therapy refractory disease,
which might be caused by virus-host interactions such as cmvIL-10 (a viral IL-10 homolog).
Affinity measurements had shown a similar affinity of human IL-10 and cmvIL-10 to the
IL-10R1 (PNAS 99:9404). Genetic variations of the IL-10R1 (SNP3 and 4) are associated
with Crohn’s colitis but protect from ulcerative colitis (UC) in Caucasian populations.
Computer modeling predicted that IL-10R1 SNP3 changes IL-10 or IL-10 homolog binding
to the extracellular receptor domain (J Immunol 170:5578). Together with the high frequency
of the IL-10R1-SNP3+4 haplotype in a CMV-positive colitis population, these findings
indicate that SNP3 may differentially alter human and viral IL-10 signaling and thereby
influence virus-host interactions. We therefore studied cmvIL-10 signaling through the
variant IL-10R1 receptors. Methods: HeLa cells were transfected with pIRESpuro constructs
of various IL-10R1 alleles (wt, SNP3, SNP4, or SNP3+4) or the empty vector. Stably trans-
fected single cell clones expressing the various IL-10R1 were chosen based upon receptor
density (as measured by flow cytometry and Western blot) and IL-10-dependent STAT3
phosphorylation. Cells were incubated with various concentrations of cmvIL-10 or human
IL-10 (0.01 to 10ng/ml; both R&D). After 30 min, cells were harvested and protein extracts
were analyzed for STAT3 and pSTAT3 (Y705) phosphorylation by Western blotting. Blots
were quantified by densitometry (ImageJ; http://rsb.info.nih.gov/ij), ratios between pSTAT3
and STAT expression levels were calculated, and the results of cmvIL-10 stimulation were
normalized to human IL-10 for each variant clone. Results: From a large number of clones,
one clone of each IL-10R1 variant was selected based on moderate IL-10R1 expression and
similar (human) IL-10-induced STAT3 phosphorylation. In the IL-10R1-wt clone, cmvIL-
10 was about 100-fold more active than human IL-10. In the IL-10R1-SNP3 and IL-10R1-
SNP4 clones, cmvIL-10-induced STAT3 phosphorylation was slightly reduced (IL-10R1-
SNP3: 75-83%, IL-10R1-SNP4: 81-87% of IL-10R1-wt), while the IL-10R1-SNP3+4 clone
showed significant reductions (42-49% of IL-10R1-wt). Minimal STAT3 phosphorylation
(6-10%) was observed in the mock-transfected HeLa. Conclusion: The IL-10R1-SNP3+4
displays a loss of cmvIL-10 signaling in relation to human IL-10. This functional change
might explain why patients that carry this allele are at higher risk to reactivate CMV in UC
and why they may become refractory to anti-inflammatory therapy.
W1631
The Novel IL-10 Related Cytokine IL-26 Is Increased in Active Inflammatory
Bowel Disease and Intestinal Epithelial Cells Express the Functional IL-26
Receptor Complex
Julia Dambacher, Florian Beigel, Rosa Golluscio, Torsten Olszak, Kathrin Zitzmann,
Soeren T. Eichhorst, Jan-Michel Otte, Julia Seiderer, Helmut Diepolder, Christoph J.
Auernhammer, Thomas Ochsenkuehn, Burkhard Goeke, Stephan Brand
Background: Human interleukin-26 (IL-26) signals through a receptor complex consisting
of IL-20R1 and IL-10R2. Preliminary studies suggest T lymphocytes as primary source of
this cytokine. Aim: The purpose of this study was to analyze IL-26 receptor expression,
signal transduction and specific biological functions of this cytokine system in intestinal
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epithelial cells (IEC). Methods: Expression studies were performed by RT-PCR and quantitat-
ive PCR. Signal transduction was analyzed by Western blot experiments and ELISA. Cell
proliferation was measured by MTS assay and Fas induced apoptosis by flow cytometry.
Results: The IEC lines Caco-2, SW480, HCT116 and HT-29 express both IL-26 receptor
subunits IL-20R1 and IL-10R2. IL-26 binding to its receptor complex activates ERK-1/2
and SAPK/JNK MAP kinases, and Akt. IL-26 also induced phosphorylation of STAT1 and
STAT3. IL-26 slightly decreased cell proliferation while it had no effect on Fas-ligand induced
apoptosis. Moreover, IL-26 stimulation increased IL-8 protein expression levels in ELISA
assays up to 3.7-fold. IL-26 mRNA expression was increased in inflamed colonic lesions
compared to non-inflamed tissue in 8 out of 12 patients with Crohn’s disease (CD; average
5.0-fold increase) and in 7 out of 10 patients with ulcerative colitis (UC; average 3.4-fold
increase) and correlated highly with the IL-8 expression in these lesions (r=0.659 for CD
patients; r=0.788 for UC patients). Conclusion: IEC express the functional IL-26 receptor
complex. Binding of IL-26 to its receptor results in phosphorylation of MAP kinases and
STAT proteins and an increased expression of proinflammatory cytokines. Moreover, our
data indicate a role for this cytokine system in intestinal inflammation as seen in patients
with inflammatory bowel disease.
W1632
Anti-TNF Antibody Induced Stimulated T Lymphocyte Apoptosis Depends On
the Concentration of the Antibody and Etanercept Induces Apoptosis At Rates
Equivalent to Infliximab and Adalimumab At 10 Micrograms Per Ml
Concentration
Rakesh Chaudhary, Matt Butler, Raymond J. Playford, Subrata Ghosh
Background: Infliximab, but not etanercept, has been reported to cause apoptosis in stimu-
lated peripheral blood and lamina propria T lymphocytes in healthy controls and Crohn’s
disease patients. We aim to investigate whether higher concentrations of etanercept might
induce lymphocyte apoptosis similar to infliximab and adalimumab. Methods: Peripheral
CD4 T lymphocytes were isolated from healthy subjects (n=6). Medium with or without
anti-TNF antibody (Ab) was added at the time of antibody stimulation. Infliximab, adalimu-
mab and etanercept were added at concentrations of 0.1, 1 and 10ug per ml. Human Ig G
1 antibody was used as a negative control. Apoptosis was detected using annexin following
7 days of stimulation by flow cytometry. Topro3 was used as dead cell discriminator. Baseline
apoptosis was taken as the rate of apoptosis of stimulated lymphocytes with medium alone.
Results: All 3 anti-TNF Abs were found to cause an increase in CD4 lymphocyte apoptosis.
The mean increase in lymphocyte apoptosis rates compared to baseline with 0.1ug/ml, 1ug/
ml and 10ug/ml for infliximab was 50%, 99% and 132%. For adalimumab the rates were
42%, 102% and 109% for 0.1ug/ml, 1ug/ml and 10ug/ml doses. Corresponding apoptosis
rates with etanercept were 30%, 40% and 77%. Infliximab and adalimumab were significantly
better than etanercept at 1ug/ml (p≤0.05) at inducing lymphocyte apoptosis but not so at
10ug/ml (p=NS). Conclusion: In our in-vitro model not only infliximab and adalimumab
but also etanercept causes apoptosis of stimulated lymphocytes. Anti-TNF antibody induced
apoptosis was found to be concentration dependant, and at higher concentrations the
difference between etanercept and infliximab / adalimumab tends to diminish. These in-
vitro observations bring into question whether lack of apoptosis by etanercept is an integral
property of the molecule. If apoptosis is an important mechanism of action then the possibility
that a higher dose of etanercept might be clinically effective cannot be excluded.
W1633
A New Transcription Factor That Regulates TNF-α Gene Expression, Litaf
(Lipopolysaccharide Induced TNF-α Factor) Is Increased in Lamina Propria
Macrophages After Trinitrobenzene Sulfonic Acid (TNBS)-Induced Colitis in
Mice
Kristen N. Bushell, Susan E. Leeman, Salomon Amar, Karen L. Reed, Adam C. Gower,
Arthur F. Stucchi, James M. Becker
Background: Crohn’s Disease (CD) is a chronic inflammatory bowel disease known to
involve the dysregulation of proinflammatory cytokines, primarily TNF-α. The chronic
exposure of the GI tract to bacterial endotoxins, such as lipopolysaccharide (LPS), leads to
the upregulation of cytokines in inflammatory cells which exacerbate the inflammation and
destroy tissue structure. LITAF is a newly discovered transcription factor that binds to the
TNF-α promoter and has been shown to regulate TNF-α gene expression in a cell line of
differentiated human THP-1 macrophages. Since the initial studies implicating LITAF in the
regulation of TNF-α gene expression were performed in a macrophage cell line, the aim of
this study was to determine the relative levels of LITAF message and protein in lamina
propria macrophage cells (LPMC) isolated from colonic tissues in a murine model of CD.
Methods: C57BL/6 mice were rectally administered TNBS (1.5 mg in 50% EtOH vehicle)
and were monitored for up to 7 days. Body weights were measured daily. Myeloperoxidase
(MPO) levels were measured in isolated colon tissue extracts. LITAF protein was measured
by Western blot analysis and LITAF mRNA quantified by real-time-PCR (RT-PCR) in whole
cell extracts of LPMC. Results: Body weights fell significantly on days one and two in TNBS
treated mice compared with controls. By day 4, MPO levels were increased 3-fold in colon
tissue extracts from TNBS treated mice compared to controls (p<0.05). LITAF protein levels
in LPMC extracts were increased by 75% following TNBS administration compared to
controls. RT-PCR analyses of colon tissue at day 7 showed a two-fold increase (P<0.05) in
LITAF message in TNBS treated mice compared to controls. Conclusions: These data provide
evidence that this transcription factor, LITAF, which is associated with an increase in the
expression of several other proinflammatory cytokines in addition to TNF-α, responds to
the induction of CD in this murine model and underscores the potential value of anti-LITAF
strategies in the therapeutic management of this disease.
W1634
Neutralization of Soluble and Membrane Tumor Necrosis Factor-α (TNF-α) By
Infliximab, Adalimumab, Or Certolizumab Pegol Using P55 Or P75 TNF-α
Receptor-Specific Bioassays
Amie Gramlick, Gianluca Fossati, Andrew M. Nesbitt
Background: The pro-inflammatory cytokine tumor necrosis factor-α (TNF-α) plays a key
role in Crohn’s disease and rheumatoid arthritis. Biologic agents that neutralize TNF-α have
been developed for these inflammatory conditions. The two TNF-α receptors — p55 and
p75 — are both widely expressed on many cell types, and most bioassays do not differentiate
between signaling via each of the receptors. To address this limitation, we aimed to engineer
two cell lines that could be activated following specific binding of TNF-α to either the p55
or the p75 receptor, respectively. These cell lines could be used to assess the ability of the
anti-TNF-α agents infliximab, adalimumab and certolizumab pegol (CDP870) to neutralize
signaling instigated by the binding of soluble or membrane TNF-α to either the p55 or p75
receptor. Methods: The A549 human lung carcinoma cell line was transfected with a
luciferase reporter system that allowed the measurement of TNF-α signaling via the p55
receptor only. Similarly, a chimeric p75 receptor construct was transfected into the Jurkat
human T cell line to allow the measurement of p75-specific signaling, again using a luciferase
reporter gene. The ability of infliximab, adalimumab, or certolizumab pegol to neutralize
human recombinant soluble TNF-α and membrane TNF-α signaling via p55 or p75 receptor-
specific pathways was assessed in vitro using these cell lines. In addition, an NSO cell
line transfected with non-cleavable human membrane TNF-α was used to measure the
neutralization of membrane TNF-α by the anti-TNF agents. Results: All three anti-TNF
agents were equally potent at neutralizing membrane TNF-α signaling via either the p55
or the p75 receptor. However, certolizumab pegol was at least 2-fold more potent than
adalimumab or infliximab at neutralizing soluble TNF-α signaling via either receptor. Conclu-
sion: Certolizumab pegol, infliximab, and adalimumab were equally potent at neutralizing
membrane TNF-α signaling via either the p55 or the p75 receptor. However, certolizumab
pegol was more potent than infliximab or adalimumab at neutralizing the signaling induced
by soluble TNF-α through each receptor.
W1635
Induction of in-Vitro Apoptosis of Stimulated Cd4 T Lymphocytes Can Be
Demonstrated with Not Only Infliximab and Adalimumab But Also Etanercept
If Anti-TNF Antibodies Are Added Simultaneously with Anti-CD3 and Anti-
CD28 Antibodies
Rakesh Chaudhary, Matt Butler, Raymond J. Playford, Subrata Ghosh
Background: Apoptosis is considered an important mechanism of action of anti-TNF therapy
in Crohn’s disease. Infliximab, but not etanercept, has been reported to cause apoptosis in
stimulated peripheral blood and lamina propria T lymphocytes in healthy controls and
Crohn’s disease patients. We report on the induction of stimulated peripheral T lymphocyte
apoptosis by infliximab, adalimumab and etanercept in relation to the timing of addition
of anti-TNF antibody (Ab) in-vitro. Methods: Peripheral CD4 T lymphocytes were isolated
from healthy subjects and stimulated with anti-CD3 & anti-CD28 antibodies. Medium with
or without anti-TNF Ab was added either simultaneously (n=7) or after stimulation for 72
hours (n=5). Control antibody was used as a negative control and cisplatin as a positive
control. Apoptosis was detected after 7 days of stimulation using annexin V and topro-3
by flow cytometry. Three anti-TNF Abs- infliximab, adalimumab and etanercept- were used
at a concentration of 10ug/ml. Apoptosis was expressed as a percentage (± SEM) of the
background apoptosis of stimulated lymphocytes i.e. rate of apoptosis of stimulated lympho-
cytes following the addition of medium alone. Results: Following anti-TNF Ab addition to
lymphocytes stimulated for 72 hours the apoptosis rates compared to background apoptosis
were 92% (±5%) for infliximab, 93% (±8%) for adalimumab and 91% (±8%) for etanercept
(p=NS). With simultaneous lymphocyte stimulation and anti-TNF Ab addition lymphocyte
apoptosis compared to background was 232% (±18%), 203% (±16%) and 172% (±11%)
with infliximab, adalimumab and etanercept respectively. This increase in apoptosis following
synchronous anti-TNF Ab addition and stimulation was significant for all 3 anti-TNF Abs
compared with control Ab (p<0.0001) but the difference between the 3 anti-TNF Abs was
not significant (p=0.08). Conclusion: The manner of lymphocyte stimulation determines the
apoptosis read out. When anti-TNF Abs is added simultaneously at the time of stimulation
all anti-TNF Abs including etanercept cause a significant increase in lymphocyte apoptosis.
The difference between the 3 anti-TNF Abs did not reach statistical significance. In contrast,
if drug is added following 72 hours of stimulation then there is no detectable increase in
apoptosis. We conclude that under appropriate conditions all 3 anti-TNF Abs may induce
apoptosis of stimulated T lymphocytes though there is a trend towards slightly lower rates
with etanercept (not reaching statistical significance).
W1636
Antigenic Soluble Factors (ASF) in Patients with Crohn’s Disease According to
Their Pathological Behaviour
Id Pousa, J Mate, X Salcedo, R Moreno-Otero, Javier P. Gisbert
INTRODUCTION: CD can be classified according to their behaviour in the Vienna’s classifica-
tion into three subgroups: inflammatory, fistulizing and fibrostenotic. The angiogenic process
is closely related to the inflammation and to the fibrosis, and therefore it could be assumed
that the expression of some angiogenic soluble factors (ASF) could be altered in the inflammat-
ory or fibrostenotic subgroups of these patients. AIMS: To evaluate the differences in ASF
concentrations according to the disease’s behaviour of patients with CD in remission.
METHODS: Thirty patients with CD in remission classified according to their behaviour:
inflammatory (mean age 48 ± 14 yr), fistulizing (49 ± 17), fibrostenotic (41 ± 11); and 10
healthy controls (41 ± 12) were studied. Serum levels of vascular endothelial growth factor
(VEGF) and its receptors (Flt-1 y KDR), placental growth factor (PlGF), basic fibroblast
growth factor (bFGF), angiopoietin 2 (Ang-2) and its receptor (Tie-2) were determined by
ELISA. Statistical analysis: ANOVA one-way. RESULTS: Overall, significantly increased VEGF,
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Flt-1, PlGF, Ang-2 and Tie-2 serum levels were observed in patients with CD in remission,
when compared with healthy controls (table 1). A tendency to increased VEGF, FGFb
and Ang-2 levels was observed in patients with fibrostenotic CD compared to those with
inflammatory or fistulising behaviour. In patients with inflammatory CD, an increase of
PlGF and Tie-2 levels was demonstrated in comparison with those with another disease’s
behaviour. However, these tendencies did not reach statistical significance, probably due to
the limited sample size. CONCLUSIONS: 1) Patients according to their disease’s pathological
behaviour showed differences in the levels of several ASFs. 2) In the patients with fibrostenotic
CD, an increase of VEGF, FGFb and Ang-2 levels was observed, whereas those with inflam-
matory CD showed a higher expression of PlGF and Tie-2. 3) Further and more extensive
studies are necessary to determine if these ASFs could be useful to predict the evolution of
patients with CD.
Means ± SD of ASF concentracions [pg/mL]. *p<0.05. **p<0.01. ‡< 0.001. Controls vs.
CD’s subgroup.
W1637
Generation of Ceramide in Tight Junctions Increases Transepithelial
Permeability
Juergen A. Bock, Gerhard Liebisch, Joachim Schweimer, Gerd Schmitz, Juergen
Schoelmerich, Gerhard Rogler
Background: The sphingolipid ceramide, generated by the action of acid sphingomyelinase
(ASM), has emerged as a second messenger of stimuli as diverse as ionizing radiation,
chemotherapy, ligation of various receptors or infection with some bacteria and viruses.
Many signaling molecules involved in intestinal inflammation (e.g. TNF, INF-γ, PAF), also
activate the ASM. Recently we had shown that hydrolysis of sphingomyelin to ceramide by
exogenous sphingomyelinase (Smase) contributes to an increased permeability of intestinal
epithelial cells. Therefore, we now aimed to characterize the occurring lipid modifications
and localize the underlying mechanism. Methods: Sphingolipid-rich membrane microdo-
mains were isolated by discontinuous sucrose gradients and characterized for their association
with TJ-proteins by western-blot. The contents of ceramide, sphingomyelin and cholesterol
were analysed by tandem mass spectrometry. Localization of ceramide was determined
by immunofluorescent staining. Permeability of Caco-2 monolayers was determined by
measurement of transepithelial flux and transepithelial resistance (TEER). Results: Incubation
of Caco-2 cell monolayers with Smase induced a rapid accumulation of ceramide in sphingoli-
pid-enriched microdomains with concomitant decrease of sphingomyelin and cholesterol.
Using 0.25 U/ml Smase, ceramide increased from 1 % to 6 % of analysed lipids within 10
min. In comparison the increase of ceramide was only 0.75 % in the total cell lysate.
Accumulation of ceramide occurred in the same membrane fractions containing occludin and
claudin-4, which represent TJ-proteins. Immunofluorescent staining of ceramide confirmed
clustering of ceramide at the sites of cell-cell contact. Investigation of transepithelial flux
after incubation with 0,25 U/ml Smase led to an increase of permeability by more than 50
% after 6 h with moderate decrease of TEER, indicating an increase of TJ-permeability.
Neutralization of surface ceramide completely prevented the permeability-increase induced
by platelet-activating factor. Conclusion: These findings indicate that the geometry of tight-
junctional ceramide, sphingomyelin and cholesterol regulate transepithelial permeability
which might be responsible for loss of barrier integrity upon various cellular stimuli.
W1638
Downregulation of the Ubiquitin-Proteasome Machinery in Normal Colonic
Lamina Propria Macrophages and RE-Induction in Inflammatory Bowel
Disease Mucosa
Andrea M. Brandl, Monika Seidl, Katrin Menzel, Juergen Schoelmerich, Hans Herfarth,
Gerhard Rogler, Martin Hausmann
Background: The ubiquitin-proteasome machinery is a large multiprotein complex that
degrades cellular proteins. Ubiquitin is required for ATP-dependent, nonlysosomal intracellu-
lar degradation of proteins with a rapid turnover. Intestinal lamina propria macrophages
(IMACs) in normal mucosa are anergic and have a tolerance inducing and tolerance preserving
function. Inhibition of the ubiquitin-proteasome system can suppress the activation of
transcription factor nuclear factor-kappa B (NF-κB) by stabilizing the inhibitory protein IκB.
Regulating the ubiquitin system has important functions in the immune and inflammatory
response. Methods: IMACs were isolated and purified from intestinal mucosa of surgical
specimens with the help of immunomagnetic beads armed with a CD33 antibody. mRNA
from in vitro differentiated macrophages and IMACs from normal mucosa and IBD mucosa
was isolated and Affymetrix© oligonucleotide array analysis was applied. Quantitative Taq-
man-PCR for five proteasomal and five ubiquitinylation genes was performed. Ubiquitin B
in the intestinal mucosa was analyzed by immunohistochemistry. Results: Affymetrix analysis
showed a downregulation of all represented 25 proteasomal and 22 ubiquination mRNAs
in IMACs compared to in vitro differentiated macrophages and monocytes. By Taqman-PCR
up to ten fold higher mRNA expression of 5 ubiquitination-associated genes (ubiquitin-

















in vitro differentiated macrophages compared to IMACs was demonstrated. Immunohisto-
chemistry confirmed lack of ubiquitin B in intestinal mucosa of control patients and patients
suffering from diverticulitis. In contrast, a significant increase in ubiquitin B protein was
revealed in the intestinal mucosa of patients with Crohn’s disease and ulcerative colitis.
Using double labelling technique CD68 positive cells in those specimens showed co-staining
with ubiquitin B. Upregulation (re-induction) of ubiquitin B mRNA in patients with inflam-
matory bowel disease was confirmed by Taqman-PCR. Conclusion: Reduced expression of
subunits of the ubiquitin-proteasome machinery in IMACs from control patients supports
the concept of a non-reactive, anergic macrophage phenotype present in the gut under
normal conditions. Re-induction in IMCAs from IBD mucosa reflects activated IMACs that
present antigenic peptides and support inflammation.
W1639
Beneficial Effect of Mesalamine on Microvascular Dysfunction in Ulcerative
Colitis
Ossama A. Hatoum, Hiroto Miura, Rebecca M. Selle, Brandon T. Larsen, Doron
Kopelman, Mary F. Otterson, David D. Gutterman, David G. Binion
Introduction: Treatment with mesalamine derivatives has formed the mainstay of therapy
for uncomplicated mild to moderate inflammatory bowel diseases (IBD). Although precise
mechanism of action is not known, the beneficial effects of mesalamine in IBD have been
attributed to its anti-inflammatory and antioxidant properties. We have previously demon-
strated microvascular dysfunction in vessels isolated from chronically inflamed IBD intestine,
which is characterized by sustained increase in oxyradical species. The aim of this study
was to investigate the effect of mesalamine on microvascular dysfunction found in ulcerative
colitis (UC) and Crohn’s disease (CD) patients. Methods: Freshly isolated arterioles (140 ±
32 μm) were dissected from IBD (UC + CD) human bowel specimens collected at the time
of intestinal surgery. The vessels were cannulated with glass micropipettes and pressurized
at 60 mmHg in a vessel chamber and perfused with physiological salt solution. Changes in
the internal diameter were recorded using videomicroscopy. Reactive oxygen species (ROS)
production was assessed using dihydroethidine and DCF-DA staining. Results: After constric-
tion (30-50%) with endothelin-1, graded doses of Ach (10-9-10-4M) were administered to
UC and CD vessels with and without mesalamine (dose equivalent to 4.8g/day). Improvement
in Ach dilation was observed in UC vessels with mesalamine (max dilation (MD) = 70.4±5.7%,
compared to UC vessels without mesalamine 23.5±6.7%, n=6, p=<0.01). However, mesalam-
ine did not improve dilation of CD vessels to Ach, as vasorelaxation remained at the low
levels typically seen in CD (MD 25.4±5.8%, n=4, N.S). Furthermore, clinically relevant
concentrations of mesalamine (equivalent to 0.6, 1.2, 2.4, 3.6, 4.8, and 6 g/day) caused a
significant dose-dependent enhancement of dilation in response to Ach in vitro (17.72±3.2,
21.25±2.77, 33.25±2.8, 50.26±6.1, 70.4±5.7 and 78.51±4.5, respectively, n=4, p<0.05).
Using dihydroethidine and DCF-DA staining to assess ROS production, we observed a
significant reduction in superoxide production (322.56±19.4343 vs. 206.6±14.7, n=5,
p<0.05), but not in hydrogen peroxide production in mesalamine-treated microvessels from
UC patients compared to non-treated vessels. Conclusions: IBD is associated with acquired
microvascular endothelial dysfunction in the human gut. Mesalamine promotes the rapid
re-establishment of dilation to Ach in vitro in UC but not in CD patients, by reducing
superoxide generation. These results suggest that, in addition to its anti-inflammatory proper-
ties, mesalamine may also improve microvascular function in UC patients through its antiox-
idant effects.
W1640
Lipopolysaccharide Activates Innate Immune Responses in Murine Intestinal
Myofibroblasts Through Multiple Signaling Pathways
Kristen L. Walton, Leisha Collins, R Balfour Sartor
Background: Myofibroblasts (MF) play an important role in wound healing in the intestine.
A compromised epithelial barrier exposes intestinal subepithelial MF to luminal bacterial
products. However, the responses of murine intestinal MF to bacterial adjuvants are not
well defined. We investigated the responsiveness of primary murine MF to lipopolysaccharide
(LPS) and the signaling pathways activated by this bacterial adjuvant. Methods: Multiple
primary murine MF lines were established from the ileum or colon of 129 SvEv mice
following collagenase digestion and mechanical disruption. Expression of toll-like receptors
(TLR) -2, -4, -5, and -9 were detected by RT-PCR. Intracellular responses to 20 ng/ml LPS
were assessed by western blotting for the phosphorylated p65 subunit of NFκB, IκBα,
phosphorylated Akt, ERK1/2, p38 MAP kinase, and cyclooxygenase-2 (COX-2). Secretion
of prostaglandin E2 (PGE2), interleukin (IL)-6, IL-10, and the neutrophil chemoattractant
KC/CXCL1 after stimulation with E. coli LPS or E. coli lysate was measured by ELISA.
Results: All intestinal MF lines tested expressed TLR-2, TLR-4, TLR-5, and TLR-9 mRNA.
LPS caused rapid phosphorylation of NFκB p65 and degradation of IκBα. Phosphorylation
of Akt, p38 MAPK, and ERK 1/2 were also detected after LPS stimulation. Maximal phos-
phorylation of Akt was detectable by 15 min of LPS stimulation, while phosphorylation of
p38 MAPK and ERK 1/2 were maximal at 30-60 minutes. COX-2 protein was increased in
MF after 8 or 24 hr of LPS treatment. Inhibition of the PI3-kinase pathway by wortmannin
reduced LPS-induced COX-2 protein expression in MF. A similar attenuation of COX-2
expression occurred when cells were co-incubated with LPS and SB203580, an inhibitor of
the p38 MAPK pathway. Both LPS and E. coli lysate induced secretion of PGE2 (1.8±0.2
fold above unstimulated cells, n=5, p<0.05), IL-6 (3.5±0.8 fold induction, p<0.05), and KC
(3.25±0.5 fold induction, p<0.01), but not IL-10. Conclusions: Primary murine intestinal
MF respond to a bacterial adjuvant, evidenced by LPS- stimulated activation of NFκB, PI3-
kinase and MAPK signaling pathways and secretion of the proinflammatory molecules KC,
IL-6, and PGE2. Inhibition of the PI3-kinase and p38 MAPK pathways attenuated LPS-
dependent COX-2 expression, indicating that multiple signaling pathways are involved in
activation of MF by LPS. These data support the hypothesis that MF are a component of
the innate immune system that may regulate adjacent epithelial and immune cell responses
in a paracrine fashion by responding to luminal bacterial adjuvants.
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W1641
The Thrombomodulin-Activated Protein C-Endothelial Protein C Receptor
Pathway: A Novel Anti-Inflammatory System in Inflammatory Bowel Disease
Silvio Danese, Franco Scaldaferri, Cristina Graziani, Alessandro Sgambato, Bruce Gerlitz,
Alfredo Papa, Riccardo Ricci, Miquel Sans, Brian Grinnell, Giuseppe Fedeli, Achille
Cittadini, Antonio Gasbarrini
Coagulation and inflammation are intimately interdependent processes. Endothelial protein
C receptor (EPCR) and thrombomodulin (TM) are expressed at high levels selectively in
the microvasculature, and convert protein C (PC) to its activated form (APC), which is a
potent anti-coagulant and anti-inflammatory molecule. In several chronic inflammatory
conditions, the protein C pathway is down regulated, leading to an impaired generation of
APC. The aim of this study was to explore the protein C pathway in inflammatory bowel
disease (IBD), and to assess the therapeutic implication of manipulating this system in
experimental colitis. The levels of TM and EPCR expression was evaluated by immunohisto-
chemistry in colonic sections from controls, Crohn’s disease (CD) and ulcerative (UC)
subjects, and by flow cytometry in human intestinal microvasculature endothelial cells
(HIMEC), at baseline and after treatment with TNF-α, TGF-β and IL-10. The capacity to
generate APC by HIMEC was measured by colorimetric assay at baseline and after treatment
with TNF-α. The anti-inflammatory effect of recombinant APC was studied on TNF-α
stimulated HIMEC, and expression of VCAM-1 and ICAM-1 assessed by flow cytometry,
and ENA-78 and IL-8 measured by ELISA. Adhesion assays were used to evaluate the
capacity of APC to inhibit T-cell adhesion to HIMEC. In vivo, the anti-inflammatory effect
of APC was tested in the 2.5 % dextran sodium sulphate (DSS) model of colitis in mice.
Both CD and UC patients expressed lower levels of TM and EPCR in intestinal microvasculat-
ure than controls. In cell culture, TNF-α significantly (p<0.001) down regulated HIMEC
expression of EPCR and TM, leading to impaired capacity (p<0.05) to generate APC. Recom-
binant APC had a potent anti-inflammatory effect, being able to significantly (p<0.01) down-
regulate TNF-α-dependent VCAM-1 and ICAM-1 expression, as well as ENA-78 (p<0.01)
and IL-8 (p<0.001) production. APC was able to significantly (p<0.01) inhibit T-cell adhesion
to HIMEC. Finally, APC was very effective in preventing experimental colitis in the DSS
model, as assessed by weight loss (p<0.05), disease activity index (p<0.01) and histological
colitis (p<0.05). The protein C pathway is strongly down regulated in the inflamed intestine
in IBD and represents a new system involved in microvascular inflammation in the gut.
Restoring APC conversion may represent a new therapeutic approach to down play intestinal
inflammation by inhibiting endothelial cell adhesion molecule expression and chemokine
production in intestinal microvasculature, thus avoiding leukocyte recruitment into the
inflamed gut.
W1642
Induction of Resistin-Like Molecule Beta (Relm-β/Fizz2) Expression During
Initiation of Ileitis in Samp1/FC Mice Does Not Depend On Th2 Cytokines Or
Luminal Flora
Sean L. Barnes, Alda Vidrich, Giorgos Bamias, Fabio Cominelli, Steven M. Cohn
RELM-β is a goblet-cell-secreted, cysteine-rich-peptide with immunomodulatory function
that is normally expressed in the colon. SAMP1/Fc mice develop ileitis similar to human
Crohn’s disease beginning at about age 6 wks. We previously found that RELM-β is highly
expressed in the ileum of adult SAMP1/Fc mice with ileitis. Previous studies (W. He et al
2003; Gastroenterology 125:1388) have shown that RELM-β expression in the colon is
dependent on bacterial colonization and is induced by Th2 cytokines. AIM: To determine
whether luminal bacteria and/or Th2 cytokines expressed in the inflammatory milieu mediate
the induction of RELM-β in the ileum of SAMP1/Fc mice. METHODS: RNA was isolated
from the ileum of specific pathogen free (SPF), germ free (GF) SAMP1/Fc mice and SPF
AKR controls. Some SPF SAMP1/Fc mice received weekly injections of anti-mouse IL4 MAb
starting at age 3 wks. Levels of RELM-β, IL4, IL5, and IL13 mRNA were determined by
quantitative real-time RT-PCR. Histologic assessment of ileitis was performed. RESULTS:
RELM-β is highly induced in the ileum of the SAMP1/Fc mice beginning at age 5-6 wks
coincident with the initial histologic appearance of ileitis. In contrast, IL5 and IL13 mRNA
levels began to increase between age 8 and 10 wks, well after the observed induction of
RELM-β and reached peak levels (179 fold and 1420 fold, respectively) during the chronic
phase of inflammation. A modest increase (3.9 fold) in ileal IL4 mRNA was seen at age 4
wks compared to AKR controls, suggesting this cytokine might drive the induction of RELM-
β. However, RELM-β mRNA levels and inflammatory scores were not altered by treatment
with anti-mouse IL4 MAb. GF SAMP1/Fc mice had a modest degree of ileitis relative to SPF
mice (6±0.1 vs 18±0, p< 0.0001). RELM-β mRNA levels were increased in the ileum of
80% of GF SAMP1/Fc mice examined relative to SPF AKR mice of similar age. Although
levels of ileal RELM-β mRNA in GF mice were modestly decreased compared to those of
SPF SAMP1/Fc mice, these levels were still 13 to 154-fold higher compared to SPF AKR
controls. CONCLUSIONS: Neither induction of RELM-β expression nor ileal inflammation
requires the presence of viable intestinal flora. However, intestinal flora may modulate the
level of RELM-β once inflammation is established. Th2 cytokines do not appear to mediate
the induction of RELM-β in the ileum of SAMP1/Fc mice. The regulation of RELM-β
expression in the intestine is complex, likely involving both Th2-dependent and independent
mechanisms. We speculate that early induction of RELM-β in the ileum may be involved
in the initiation of inflammation in SAMP1/Fc mice.
W1643
Poly a Element Is Involved in TNFα Mediated Decreases in Phex Gene
Transcription
Jennifer K. Uno, Helayne R. Feferman, Olga I. Kolek, Hua Xu, Pawel R. Kiela, Fayez K.
Ghishan
Reduced bone mass is a common complication of IBD; however the mechanisms contributing
to osteopenia are not fully understood. TNFα is a major target in the successful treatment
of IBD and has been shown to inhibit bone mineralization. Disruption of Phex gene, expressed
primarily in osteoblasts, results in defective bone mineralization. Phex is thought to be
down-regulated by a variety of factors including vitamin D3, PTH, and TNFα. Recent work
on Phex transcriptional regulation implicates the involvement of a polyadenine element in
the proximal Phex promoter. Studies suggest that this poly A region (nt -117/-100) plays
a significant role in the basal regulation of Phex gene transcription. The aim of this study
was to determine if the mechanism involved in TNFα-mediated down-regulation of Phex
gene transcription. Methods: Chimeric promoter constructs were made in the pTAL-Luc
vector which is designed for assaying enhancer sequences cloned upstream of a TATA-like
promoter region form the Herpes simplex virus thymidine kinase promoter. These constructs
were transfected into UMR106 osteoblast-like cells treated with PBS or TNFα. Electromobility
shift assays (EMSA) were performed with nuclear protein from UMR106 cells treated with
PBS or 10 ng/ul TNFα for 72 hrs using probes from predicted putative binding sites. Mutated
oligos were also used to specify the site of protein-DNA interactions. Results: Reporter gene
assay with a series of 5’ deletion constructs (-133/-2, -98/-2, -74/-2) showed the -133/-2
construct was functional in UMR106 cells and was down-regulated by TNFα. Conversely,
the -98/-2 and -74/-2 constructs, which lack the poly A region of the Phex promoter,
inhibited luciferase activity below basal levels suggesting the presence of a repressive element.
Luciferase activity with these two constructs was not altered by TNFα. EMSAs performed
with a probe spanning -134/-84 confirmed a protein-DNA complex which was diminished
in TNFα treated cells. Further, unlabeled poly A probe, but not its mutated form, successfully
competed for binding with the radio-labeled wild-type probe. Competition with unlabeled -
134/-84 probe with mutated poly A region did not affect the decreased binding in response
to TNFα. Conclusions: The poly A region of the Phex promoter plays an important role in
TNFα-mediated down regulation of the murine Phex gene transcription. Identification of
the putative trans-factor binding to the poly A region and its complex interactions within
the Phex promoter will provide better insight into the mechanisms of Phex gene transcription
and how its down-regulation contributes to the metabolic bone disease associated with IBD.
W1644
Chitinase 3-Like-1 (CHI3L1) Elicits the Production of Proinflammatory
Cytokines and Chemokines in Colonic Epithelial Cells and Exacerbates TNBS-
Induced Colitis
Mayumi Kawada, Yuriko Hachiya, Emiko Mizoguchi
Background & Aims: Many complicated factors are actively involved in the development of
IBD. Our group recently demonstrated that a Chitinase 3-like-1 (CHI3L1/YKL40/HC-gp39)
molecule, which is expressed by colonic epithelial cells (CEC) and lamina proprial macro-
phages, is involved in the development of acute and chronic colitis. However, the pathogenic
mechanisms of CHI3L1 have not been fully defined. Methods: SW480 and HT29 colonic
epithelial cell lines were stimulated with purified human CHI3L1 protein at different concen-
tration. The effect was evaluated by NF-κB lucifease reporter assay, ELISA, and RT-PCR.
To examine the functional role of CHI3L1, anti-CHI3L1 Ab was administrated into TNBS-
induced colitis model. Results: CHI3L1, a mammalian chitinase, shows high sequential
homology with human Chitinase 3-like -3 (also known as eosinophil chemotactic factor-L:
ECF-L) and acidic mammalian chitinase (AMCase), both of which possess strong stimulatory
effect on chemokine production. To examine the pro-inflammatory effect of CHI3L1, SW480
and HT29 (transfected with 10 ng PIV-NF-κB-luciferase and 1 ng renilla plasmids) were
stimulated with or without purified human CHI3L1 (Quidel, San Diego, CA) at the concentra-
tion of 5-80 ng/ml for 5 hours. NF-κB luciferase assay showed that CHI3L1 stimulation
significantly activates the NF-κB transcription in SW480 (3.2 fold) and HT29 (9.2 fold)
cells compared to these cells without CHI3L1 stimulation at the dose of 80 ng/ml. CHI3L1
also significantly stimulated IL-8 (CXCL8) production in the cell lines. In addition, CHI3L1
significantly enhanced the production of TNFα, RANTES, and exotaxin in SW480 and HT29
cells with a dose-dependent manner. IκBα-phosphorylation has been detected by western
blot as well as immunofuorescence analyses after stimulated with 80 ng/ml of CHI3L1 in
SW480 cells. In vivo administration of anti-CHI3L1 Ab (on days -1, 0, and 1) significantly
enhanced the recovery from TNBS induced colitis as indicated by the improvement of body
weight loss, clinical and histological score, and colonic epithelial damage (evaluated by
BrdU-incorporation). One time injection of the Ab on day -1 was not significantly effective
compared to three times injection. Of note, anti-CHI3L1 Ab treated mice showed significantly
less inflammatory infiltration (T cells, macrophages, and neutrophils) and chemokine produc-
tion in colonic mucosa. Conclusions: CHI3L1 plays a crucial role in the pathogenesis of
colitis by enhancing the production of proinflammatory cytokines and chemokine of CEC.
Inhibition of CHI3L1 activity would provide a rationale to develop new therapeutic strategy
for human IBD.
W1645
Concordant Expression of Secretory Leukocyte Protease Inhibitor (SLPI) in
Colonic Tissue of IBD and Animal Models of Colitis
Stephen M. Prouty, John R. Mabus, Cynthia Smith, Edward S. Kimball, Craig R.
Schneider, Nathaniel H. Wallace, Paul R. Wade, Meghan Towers, Sergey Ilyin, Michael
D'Andrea, Anton Bittner, Andrew Carmen, Dhammika Amaratunga, Oscar Go, Pamela J.
Hornby
Background: Successful drug development for IBD relies on animal models that are predictive
of the pathophysiology in IBD patients. Comparison of changes in mRNA expression in
animal models and humans can identify genes on conserved signaling pathways that could
be used for drug targets and/or biomarkers. Therefore, patterns of gene expression were
compared between murine colitis induced by 1) dextran sulfate sodium (DSS), 2) oil of
mustard (OM), and in human ulcerative colitis (UC) and Crohn’s colitis (CC). One example
of conserved gene expression revealed by these studies is that of Secretory Leukocyte Protease
Inhibitor (SLPI), a serine protease inhibitor with antibacterial activity, and is of interest
given the role of proteinase-activated receptors in infectious colitis. Methods: For DSS-
induced colitis, mice were treated with 5% DSS in drinking water for 7 days, whereas
controls received normal drinking water. For OM-induced colitis, 0.5% OM was applied
intracolonically, and colitis allowed to develop for 2, 6, 24, or 72 hours. Human colonic
biopsies (diseased and adjacent “normal”) were obtained by informed consent from patients
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diagnosed with UC (n=6) or CC (n=2). Total RNA, isolated from murine full-thickness distal
colon and from human biopsies, was analyzed by microarray and quantitative (q) RT-PCR.
Cell-type expression was determined with immunohistochemistry (IHC). Results: Microarray
analysis of DSS-treated mice and human UC/CC revealed increased SLPI mRNA with colitis
(9.6 fold, P<2.9x10-8 and 3.4 fold, P<4.0x10-6, respectively). qRT-PCR validated these
elevations (DSS: 19.4 fold increase, P<0.0001; UC/CC: 3.16 fold increase, P<0.0001). There
was a correlation between SLPI mRNA levels and macroscopic damage scores in OM colitis.
SLPI mRNA began to rise at 6 hours (2.1 fold) and peaked at 24 hours (4.38 fold increase,
P<0.001), correlating with time-dependent increases in macroscopic damage scores. In
normal mouse and human colon, by IHC, SLPI protein expression occurs in the upper half
of glandular epithelia, as well as in cells in the lamina propria. In human colon, SLPI was
expressed in a subset of enteroendocrine (EE) cells. In colitis tissues, epithelial expression
increased in the lower half of the glands. Conclusions: Increased SLPI expression is a
component of a fundamental signaling pathway in experimental colitis and in human IBD,
which likely functions to limit serine proteolytic activity and/or bacterial invasion, both of
which are events associated with IBD. SLPI expression in EE cells suggests a protective role
in the human colon and its potential for use as a biomarker in human and experimental colitis.
W1646
AP-1 and PPAR-γ Are Involved in Peptidoglycan-Mediated Immune Activation
of Enteric Glial Cells (EGC)
Eike Hollenbach, Shyam Kavuri, Manfred Neumann, Peter Malfertheiner, Anne Ruhl
NF-κB and activator protein-1 (AP-1) are major transcription factors inducing mainly pro-
inflammatory responses. Our previous work has suggested a role for EGC in intestinal
immune responses via NOD and NF-κB. Here, we have investigated if bacterial peptidoglycan
(PGN) challenge induces activation of AP-1 and if PPAR-γ receptor is involved in NF-κB
activation in EGC. Rat EGC were incubated with H. pylori to model intracellular translocation
of PGN. A radioactive in-vitro kinase assay for c-Jun N-terminal kinase (JNK) activity using
immunoprecipitated JNK and GST-coupled c-jun as substrates demonstrated a marked up-
regulation with a peak of JNK activity at 30-60 min after exposure of EGC to an H. pylori
strain with an intact type IV secretion system. In contrast, only weak JNK activation could
be detected after EGC infection with a mutant H. pylori strain that is unable to convey PGN
translocation. JNK activation was completely blocked by pre-treatment with SP600125 (5µM
for 30 min). Results of the in-vitro kinase assay were confirmed by AP-1 electrophoretic
mobility shift assay (EMSA). Supershift analysis revealed that the activated AP-1 complex
consists mainly of c-jun and only to a minor extent of c-fos. We further investigated the
role of PPAR-γ in glial NF-κB activation. Expression of PPAR-γ in EGC was determined by
FACS analysis using intracellular staining of the intracellular receptor. The expression of
PPAR-γ was significantly upregulated 8 hours after infection with the PGN secretion-compet-
ent H. pylori strain, whereas the mutant H. pylori strain did only induce a weak PPAR-γ up-
regulation. 30-60 min after exposure of EGC to the wild-type H. pylori strain, immunoblot
analysis revealed a strong peak of IκBα-degradation and nuclear translocation of p65 as a
measure of NF-κB activation, which was significantly attenuated by a 30 min pre-incubation
period of EGC with the PPAR-γ agonist Ciglitazone (15µM) or the endogenous ligand 15d-
PGJ2 (20µM). These findings were confirmed by EMSA, revealing a reduction of NF-κB
activation by the PPAR-γ agonists. In contrast, RICK (a downstream kinase of the NOD
receptor) activity - which is dramatically upregulated 60 min after infection - was unaffected
by PPAR-γ agonist treatment. These results provide further evidence for an immunoregulatory
role of EGC in the intestine. Glial stimulation by bacterial products like PGN results in a
PGN-dependent activation of AP-1 and NF-κB. Glial NF-κB, but not RICK activation, is
attenuated by PPAR-γ agonists, indicating a contribution of IκBα stabilization, probably via
IKK inhibition. Supported by Broad Medical Research Program IBD-0105R.
W1647
Expression of the IGF-I Splice Variants, IGF-IEC and IGF-IEB, Encoding
Mechano Growth Factor By Smooth Muscle Cells Is Upregulated in Crohn’s
Disease and TNBS Colitis
John F. Kuemmerle, Jennifer G. Bowers
Endogenous Insulin-like Growth Factor-I (IGF-I) regulates the growth of intestinal smooth
muscle cells. IGF-I expression in muscle is upregulated in Crohn’s Disease and TNBS colitis,
and regulates muscle hyperplasia. The IGF-I gene is alternatively spliced with the main
isoform, IGF-I, encoded by the IGF-IEa splice variant. An IGF-I splice variant, IGF-IEc in
human (IGF-IEb in rat), has been identified that encodes a distinct protein, Mechano Growth
Factor (MGF) which mediates skeletal and cardiac muscle hypertrophy post injury. Aim:
To identify the effect of inflammation on expression of the IGF-IEc in humans, and IGF-
IEb splice variants, in rats. Methods: Intestinal smooth muscle cells were isolated from
regions of active Crohn’s Disease or normal resection margins and from TNBS or vehicle
treated rat colons 7 days post TNBS instillation. Isolated muscle cells were used to prepare
total RNA or placed into primary culture. Expression of IGF-I splice variants was quantified
with real time PCR using primers specific for IGF-IEa, IGF-IEc and IGF-IEb. Changes in
expression were determined using β-actin as control. IGF-I receptor activation by IGF-I and
MGF was measured by phosphotyrosine immunoblotting and growth by [3H]thymidine
incorporation. Results: The IGF-IEa and IGF-IEc splice variants were expressed in human
intestinal muscle cells. IGF-IEa expression increased 2.4 ± 0.2 fold and IGF-IEc expression
increased 4.2 ± 0.3 fold in the inflamed muscle of Crohn’s Disease. IGF-IEa and IGF-IEb
splice variants were expressed in rat smooth muscle cells. IGF-IEa expression increased 1.9
± 0.2 fold and IGF-IEb expression increased 5.8 ± 0.4 fold in the TNBS treated rats compared
to control. IGF-I (100 nM) increased IGF-I receptor phosphorylation by 210 ± 12% and
360 ± 30% in normal human and rat intestinal smooth muscle cells, respectively, and
increased [3H]thymidine incorporation by 280 ± 15% and 209 ± 14%, respectively. The
effects of IGF-I on receptor phosphorylation and [3H]thymidine incorporation were inhibited
by 70-95% by the of IGF-I receptor blocking antibody, 1H7 (10 μg/ml). MGF (100 nM)
had no effect on IGF-I receptor phosphorylation or [3H]thymidine incorporation in either
species. Conclusions: Expression of IGF-IEc (human) and IGF-IEb (rat) splice variants that

















concomitantly with expression of IGF-IEa that encodes IGF-I. Increased MGF expression
may mediate smooth muscle cell hypertrophy, and jointly with increased IGF-I expression,
which mediates smooth muscle hyperplasia, contribute to stricture formation in the chronic-
ally inflamed intestine.
W1648
Phosphatidylcholine Can Therapeutically Be Used in IBD. It Modulates
Membrane Dependent Reactions and Inhibits TNFα Induced NFκB Activation
Robert Ehehalt, Irina Treede, Mark Kuehnel, Thomas Giese, Annika Braun, Alexandra
Zahn, Joachim Fuellekrug, Gareth Griffiths, Wolfgang Stremmel
Introduction: Intestinal mucosal cells are protected against injurious contents of the gastrointe-
stinal lumen by a surface barrier, which consists in part of a continuous, hydrophobic and
adherent mucus layer. A major lipid of this mucus layer is phosphatidylcholine (PC). We
could recently show that mucus from patients with ulcerative colitis (UC) is characterized
by an abnormally low level of the lipid PC while clinical studies reveal that therapeutic
addition of PC to the colonic mucus using slow release preparations is beneficial to UC
patients (Scand J Gastroenterol (2004) 39: 737-742; Gut (2005) 54: 966-971). The positive
role of PC in this disease is completely elusive. However, we now could show that PC is
involved in signaling networks that inhibit pro-inflammatory signaling in membranes.
Methods: Different phospholipids with various fatty acid side chains (including PC with
saturated, monounsaturated, polyunsaturated, short chain, long chain and combinations
thereof) were tested on isolated phagosomal membranes in vitro and at the cellular level
using intestinal epithelial cells. The main experimental read outs were actin assembly from
phagosomal membranes as well as NFκB activation and pro-inflammatory gene transcription.
Results: All PC species inhibited actin assembly in vitro. Most effective were PCs with very
long fatty acid side chains with exception of those with arachidonic acid side chains. The
in vitro results were consistent with the findings for a cellular system. Experiments on the
intestinal cell line CaCo-2 revealed that application of a low concentration of PC (< 50 µM)
could inhibit TNFα induced translocation of NFκB from the cytoplasm into the nucleus
(dose dependent effect) and thus prevents pro-inflammatory gene transcription. Conclusion:
PC can inhibit cell signaling responses induced by inflammation at the level of cell membranes.
These effects are upstream of NFκB induced gene transcription. This is a potential mechanism
how PC can diminish inflammation in ulcerative colitis. Further studies are needed to better
characterize the membrane networks involved in this process.
W1649
Intestinal Epithelial Inflammatory Challenge Modulates Chemokines
Expression in Neurons: Induction of Neuronal Chemotactic Properties
Emmanuelle Tixier, Jean-Paul Galmiche, Michel Neunlist
INTRODUCTION: Although recent evidences suggest that enteric neurons can secrete
chemokines during intestinal inflammation, the cellular mechanisms and functional con-
sequences of this phenomenon remain unknown. Therefore, the aims of the study were (1)
to investigate the role of neuro-epithelial interactions in the modulation of chemokines
production by neurons and (2) to determine the ability of neurons to induce the chemotaxis
of immune cells. METHODS: (1) Neuro-epithelial interactions were studied using a coculture
model composed of human Caco-2 intestinal epithelial cells, and human NT2-N neuronal
cells. Before being placed in coculture with NT2-N, Caco-2 were inflamed or not with
TNFalpha and IFNgamma. Pharmacological studies were performed using IL-1receptor
antagonist (IL-1ra) and direct effect of IL-1beta upon neuronal chemokines expression was
studied in NT2-N cells and human specimens of submucosa. IL-8 or MIP-1beta expression
was measured by real time RT-PCR, ELISA or immunohistochemistry. (2) Neuronally-
induced chemotaxis was studied using a coculture model of NT2-N neurons and human
peripheral blood mononuclear cells (PBMC). Before being placed in coculture with PBMC,
neurons were inflamed or not with IL-1beta. RESULTS: (1) The coculture of inflamed Caco-
2 with NT2-N induced a 4.6-fold increase in IL-8 mRNA expression (n=12, p<0.001) and
a 6.9-fold increase in MIP-1beta mRNA expression (n=10, p<0.005) in NT2-N compared
to control. Neuronal induction of IL-8 and MIP-1beta mRNA expression was blocked by
IL-1ra (n=4, p<0.05). In addition, IL-1beta induced IL-8 and MIP-1beta expression both in
NT2-N and human submucosal neurons. (2) Following IL-1beta treatment, NT2-N induced
a 2-fold increase in the chemotactic response of PBMC compared to control (n=10, p<0.05).
Neuronally-induced chemotaxis was reduced by a specific neutralizing anti-IL-8 antibody
(n=7, p<0.05) but not by a specific neutralizing anti-MIP-1beta antibody. CONCLUSION:
Direct neuro-epithelial interactions can modulate chemokines production in neurons via an
IL-1beta-dependent pathway. Furthermore neurons can induce the chemotaxis of immune
cells via IL-8 neuronal secretion. This study could set new basis for the development of
novel pharmacological approaches in enteric inflammatory neuropathies.
W1650
Inflammatory Bowel Disease Induces Heparanase (HP) Expression By Colonic
Epithelial Cells
Matti Waterman, Neta Ilan, Gabriel Groisman, Rami Eliakim, Israel Vlodavsky, Ofer Ben-
Izhak
Background: Hp is an endoglycosidase that specifically cleaves heparan sulfate (HS) side
chains of HS proteoglycans (HSPG), yielding HS fragments of still appreciable size (~5-7
kDa) and biological potency. HSPG consist of a protein core to which HS side chains are
covalently attached. These complex macromolecules are highly abundant in the extracellular
matrix (ECM) and are thought to play an important structural role, contributing to ECM
integrity and insolubility. Hp activity has been traditionally correlated with cellular invasion
associated with cancer metastasis, as is now also supported by compelling clinical studies.
Similarly, Hp activity was implicated in dissemination of immune cells during the course
of inflammation. Aim: To study Hp expression in patients with inflammatory bowel disease.
Methods: We applied immunohistochemistry on archived paraffin-embedded colon sections
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obtained from patients with Crohn’s disease (CD, n=17), ulcerative colitis (UC, n=17),
infectious colitis (n=8) and normal-looking mucosa distant from the tumor margins, collected
from 17 patients who underwent colon resection for colorectal carcinoma. Immunostaining
was performed with anti-heparanase polyclonal antibodies that preferentially recognize the
50 kDa (#733), and 8 kDa (#810) subunits of the active Hp heterodimer vs. the latent 65
kDa pro-enzyme, thus closely reflecting Hp activity. Immunostaining was assessed by an
expert pathologist in a blind manner, and staining intensity was classified as (0): no staining;
(2): weak; (4): moderate; and (6): strong staining. Results: Hp expression was barely detected
in normal-looking colon specimens (mean score=0.65). In contrast, expression was markedly
induced in tissue specimens obtained from patients with UC and CD (mean score=3.47,
2.82, respectively, p<0.001). Surprisingly, the colonic epithelial cells, rather than inflammat-
ory cells, were strongly stained with both anti-heparanase antibodies, and staining intensities
correlated with inflammation severity. Additionally, significantly low enhancement of Hp
expression was observed in specimens of infectious colitis patients (mean score=0.88,
p<0.008). Conclusions: Our results suggest, for the first time, that chronic, rather than acute
inflammatory conditions, induce Hp expression by epithelial cells and may contribute to
inflammation severity. This possibility is supported by studies demonstrating that unfraction-
ated heparin, as well as low molecular weight heparin, which inhibit Hp activity, are
therapeutically effective in the treatment of IBD patients.
W1651
Inhibition of the PI3kinase Pathway Abrogates Poly I:C-Stimulated
Hyaluronan-Mediated Human Mucosal Smooth Muscle Cell Binding of U937
Monocytic Cells
Sudip K. Bandyopadhyay, Carol A. de la Motte, Scott A. Strong
Background: The origin of inflammatory bowel disease (IBD) is unknown and likely multifac-
torial. Our laboratory has established that cellular stress induced by virus or viral mimic
double stranded RNA (poly I:C) in human mucosal smooth muscle cells (M-SMCs) increases
cell surface hyaluronan (HA) deposition and formation of long cable-like structures of HA
that are important for leukocyte attachment. Since hyperplasia of M-SMCs and accumulation
of mononuclear leukocytes are characteristic pathological changes observed in the intestinal
mucosa of IBD patients, and the PI3Kinase/Akt signaling pathway has an established role
in cell survival, we investigated whether this pathway is involved in this unique HA-mediated
leukocyte attachment. Methods: Colonic M-SMC cultures were derived from human surgical
specimens and all experiments were performed within the first three passages. M-SMCs
were either untreated or treated with poly I:C for 22h in presence or absence of PI3Kinase
inhibitor (Ly294002) and leukocyte binding of M-SMCs was assayed using 51Cr-labeled
U937 cells. Cellular extracts were prepared by standard method for Western blot analysis
using specific antibody and immunohistochemical analyses were performed for HA staining.
Results: Poly I:C-stimulated M-SMCs monolayers bound substantially more U937 cells than
unstimulated cells and this response was inhibited in a dose-dependent manner by treatment
with the PI3Kinase inhibitor, LY294002. Treatment of M-SMCs with LY294002 alone had
no effect on U937 cells binding. Since Akt is a critical downstream regulator of PI3Kinase,
we investigated the response of Akt in M-SMCs after treatment with poly I:C for 1h followed
by Western blot analysis using an antibody specific to the phosphorylated 473-serine residue
of Akt. A phosphorylated Akt band was observed under these conditions and, as expected,
the phosphorylated-Akt band was undetectable in LY 294002- plus poly I:C-treated extracts.
Confocal microscopy of M-SMCs stained for HA revealed HA cable formation after poly I:C
treatment that was abrogated by LY 294002. Conclusions: Poly I:C-stimulated M-SMC
cultures express phosphorylated Akt, demonstrate HA cable formation, and promote leuko-
cyte adhesion through a PI3Kinase-dependent manner.
W1652
Serotonin Synthesis Is Increased in Crohn’s Disease Patients in Remission
with Irritable Bowel Syndrome-Like Symptoms
Itta M. Minderhoud, Bas Oldenburg, Marguerite E. Schipper, Jose J. Ter Linde, Melvin
Samsom
Background: Symptoms suggestive of irritable bowel syndrome (IBS) are frequently reported
in Crohn’s disease (CD) patients in remission. Studies of the mucosal content of serotonin,
which is a pivotal neurotransmitter in the gut, suggest that serotonin availability is altered
in IBS patients. We aimed to study the role of serotonin in IBS-like symptom generation in
CD patients in remission. Material and methods: Ileal- and colonic biopsies were obtained
from 20 CD patients in remission, 10 with and 10 without IBS-like symptoms, and 11
healthy controls. Enterochromaffin (EC) cells were counted, and mRNA expression levels
of tryptophan hydroxylase (TpH)-1 and the serotonin reuptake transporter (SERT) were
determined. Results: The levels of mucosal SERT expression were significantly higher in the
ileum than in the colon, in all groups studied (p < 0.02). Analyzing ileum and colon
separately, TpH-1 expression in the colon of CD patients with IBS-like symptoms was found
to be significantly higher compared to the two other studied groups (controls: p< 0.005;
CD patients without IBS-like symptoms: p< 0.01). The number of EC cells per gland was
comparable for the patient groups in ileum and colon. Discussion: CD patients in remission
with IBS-like symptoms have elevated mucosal TpH-1 levels in the colon, suggesting that
increased serotonin biosynthesis in the colon plays a role in the generation of IBS-like
symptoms. As it is known that inflammation affects the serotonergic pathway, our data
implicate that these changes persist in the subset of CD patients in remission with IBS-
like symptoms.
W1653
Effect of Immunosuppressing Drugs On the Migration of Human Primary
Colonic Lamina Propria Fibroblasts (CLPFs)
Julia Brenmoehl, Carmen Epp, Sandra N. Leeb, Werner Falk, Juergen Schoelmerich,
Gerhard Rogler
BACKGROUND: A central event during wound repair is the migration of activated myofibrob-
lasts (colonic lamina propria fibroblasts, CLPFs) to the wound area. Recently, we have shown
that Crohn’s disease(CD)-CLPFs have a reduced migratory potential compared to control
CLPFs. A permanent reduction of the migratory potential of CLPF from control mucosa
could be induced by 3 day incubation with IFN-γ and TNF. Most immuno-suppressants
used in the therapy of CD cause a reduction of the secretion of TNF, IFN-γ, IFN-α and
other interleukins. We therefore investigated whether drugs typically used in IBD therapy
modulate the migration and wound contracting ability of CLPFs. METHODS: Primary
CLPF were isolated from patients with CD and from healthy controls. The influence of 5-
aminosalicylic acid (0.01-1 mg/mL), azathioprine (0.001-1 µg/mL), budesonide (0.001-10
µg/mL), cyclosporine A (0.1-50 µg/mL), infliximab (0.001-3 µg/mL), methotrexate (0.001-
10 µg/mL), prednisolone (0.001-100 µg/mL) and tacrolimus (0.1-50 ng/mL) on the migration
of CLPFs was determined in migration assays in the modified 48-well Boyden chamber.
CLPF-mediated contraction was tested in collagen matrices with control-CLPFs. The CLPFs
were incubated for 14 h with tacrolimus, cyclosporine, and azathioprine. Matrix diameters
were measured every 24 h for 7 days. RESULTS: 5-aminosalicylacid, azathioprine, budeson-
ide, prednisolone, and methotrexate had no effect on the migration of control- and CD-CLPFs.
Cyclosporine A reduced the migratory potential of CD- and control-CLPFs significantly. 50
µg/mL cyclosporine reduced the migration of CD- and control-CLPFs to 5% of untreated
CLPFs. Infliximab reduced only the migration of control-CLPFs significantly at a concentra-
tion of 100 ng/mL and 1µg/mL to 72% and 69%, respectively. The migration of CD- and
control-CLPFs was significantly decreased by 50 ng/mL and 100 ng/mL tacrolimus to 36
and 38 %, respectively. After 7 days the matrix diameters of azathioprine incubated CLPFs
were 34% lower than of untreated control-CLPFs indicating higher contracting activity.
Cyclosporin A treated CLPFs contracted 33% more and tacrolimus incubated CLPFs con-
tracted 58% more compared to control-CLPFs. CONCLUSION: Cyclosporine, tacrolimus,
and infliximab reduced the migration of control- and CD-CLPF at pharmacological concentra-
tions. Azathioprine as well as cyclosporine A and tacrolimus increased matrix contraction
by CLPFs. These results may provide a first explanation for the mechanism of fistulae closure
by these drugs.
W1654
S100-β Secretion and Enteric Glial Cells Alterations During Inflammatory
Bowel Disease (IBD)
Arnaud Bourreille, Emmanuel Coron, Claudine Azoulay, Tanguy Chaumette, Julien
Chevalier, Claude Masliah, Jean-Paul Galmiche, Michel Neunlist
Introduction : Enteric Glial Cells (EGCs) represent an important component of the enteric
neurons system which exerts major physiological functions. They express several proteins
among which S100-β is secreted into the extra-cellular compartment and therefore in the
serum. In animal models, glial alteration results in severe intestinal damage. The aims of
our study were to assess modifications in S100-β secretion according to the severity of the
disease and to characterize EGCs phenotype in colonic mucosa of IBD patients. Methods:
43 IBD patients (23 Crohn’s disease (CD), 20 ulcerative colitis (UC)) were studied at different
phases of their disease. Serum concentrations of S100-β and C-Reactive Protein (CRP) were
measured by electro-chemoluminescence and nephelemetry respectively. Biopsy samples
were obtained in inflammatory and non-inflammatory areas in 6 patients with active disease
and the EGCs network was characterized by immunohistochemistry using an anti-S100-β
monoclonal antibody. In seven active CD patients, S100-β concentrations were measured
after infliximab therapy after achieving clinical remission. Results: 1) S100-β serum concen-
trations were significantly lower during active phase of IBD irrespectively of the type of IBD
(i.e. CD or UC). 2) After anti-TNF-α therapy induced remission, S100-β significantly
increased (0.058±0.016 vs 0.071±0.017; p=0.005; t test). 3) S100-β protein concentrations
were inversely correlated to CRP concentrations(r=-0.256; p=0.03; Spearman’s test). 4) At
immunohistochemistry, EGCs showed important alterations with a reduced expression of
S100-β staining in inflammatory segments compared to non-inflammatory segments. Conclu-
sions: S100-β protein changes are detected in the colonic mucosa and in peripheral blood
of IBD patients during an active phase of their disease. These changes are reversible after
treatment and non-specific for CD or UC. Although these data are not in favor of a primary
deficiency of S100-β, they support an important role of EGCs in human IBD.
W1655
Modulation of the Migration of Colonic Lamina Propria Fibroblasts By
Elevation of Intracellular Cyclic AMP
Florian Rieder, Julia Brenmoehl, Monika Artinger, Anita Zuegner, Katrin Menzel, Martina
Georgieva, Juergen Schoelmerich, Werner Falk, Gerhard Rogler
Introduction: Regulation of the migration of colonic lamina propria fibroblasts (CLPF) and
their synthesis of extracellular matrix (ECM) is an important mechanism during wound
healing and fistula formation in Crohn`s disease (CD). Prostaglandin E2 (PGE2) leads to an
elevation of intracellular cyclic AMP (cAMP) by ligation of its EP2-receptor and is elevated
in CD. However its role on CLPF migration has not been investigated so far. Methods:
Primary cultures of CLPF were isolated from the mucosa of surgical specimens of patients
with active CD (CD-CLPF), CD fistulas (FI-CLPF) and control persons (CO-CLPF). Migration
assays were perfomed in the 48-well Boyden chamber (number of migrated CLPF counted
per four high power fields at a magnification of 400x) and PGE2, EP2-receptor and cAMP
were determined by ELISA, immunohistochemistry and Western Blot. Results: PGE2 and
the EP2-receptor agonist butaprost significantly and dose-dependently reduced the migration
of CO-CLPF, CD-CLPF and FI-CLPF starting at a dose of 10nM PGE2 and 5µM butaprost
(*p<0,05). The effect of PGE2 on migration could be partly reversed by treatment with the
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EP2-receptor antagonist AH6809. The EP2-receptor was present on all CLPF tested with
an increase after stimulation with IL-1β. Initial experiments indicate a higher expression in
CD-CLPF compared to controls with maximum levels in FI-CLPF. In addition to this the
EP2-receptor was stronger expressed in the submosa of CD-patients and patients with fistulas
compared to controls as detected by immunohistochemistry. Forskolin, a direct activator
of adenylatecyclase, dose dependently reduced migration in CO-CLPF (*p<0,05). PGE2,
butaprost and forskolin led to an increase in intracellular cAMP in CLPF. In addition to
this CLPF spontaneously secreted PGE2 (430 pg/ml) with a dramatic increase after stimulation
with IL-1β (20100 pg/ml). The EP1/EP3-receptor agonist sulprostone did not alter CLPF
migration. Conclusion: Elevation of intracellular cAMP reduced the migration of CO-CLPF,
CD-CLPF and FI-CLPF. This effect is partly mediated by the EP2-receptor. As CLPF secrete
significant amounts of PGE2 in colonic inflammation this might be one possible mechanism
for the impairment of intestinal wound closure and fistula formation in CD.
W1656
Galectin-3 Differentially Induces Migration of Intestinal Fibroblasts
Elisabeth Lippert, Julia Brenmoehl, Werner Falk, Juergen Schoelmerich, Gerhard Rogler
Background: Recently we identified galectin-3 (gal-3) as the most potent activator of intestinal
(myo)fibroblasts secreted or deliberated by colonic epithelial cells (CEC). In addition, we
showed that gal-3 is strongly expressed in normal and inflamed mucosa, however gal-3
protein was demonstrated to be reduced in Crohn`s disease (CD) fistula and strictures. As
fibroblast migration plays a central role in wound closure and is believed to be relevant for
fistulae and stricture formation, we investigated the influence of gal-3 on the migration on
mucosa-fibroblasts Material and Methods: Colonic lamina propria fibroblasts (CLPFs) were
isolated from surgical specimens. CEC were isolated from specimens without inflammation.
CEC-conditioned medium containing gal-3 was used after incubation for 24 h. Recombinant
gal-3 was applied in concentrations between 1, 5 and 10 µg/ml. Migration assays of CLPFs
were performed in a modified 48-well Boyden chamber (with or without addition of fibronec-
tin) with CEC-conditioned media, fibronectin as positive control and unconditioned media
as negative control for 6 h. Migration was determined as cells/microscopic field. Each
experiment was repeated 8 to 12 times per patient. Results: In cultures of control and CD
fibroblasts from inflamed mucosa gal-3 induced significant less migration compared to
fibronectin (control CLPF: gal-3: 8.4 +/- 4.5 vs fibronectin: 29.8 +/- 11.5 cells/hpf). In
fibroblasts derived from ulcerative colitis mucosa gal-3 incubation was followed by a higher
migration, which was not significantly different to fibronectin (29.8 +/- 5.9 vs 38.0 +/- 5.9
cells/hpf). In CPLF derived from CD fistula gal-3 induced a strong migration comparable
to that induced by fibronectin (51.1 +/- 9.9 vs 64.1 +/- 13.3 cells/hpf). Discussion: Besides
induction of cytokine secretion gal-3 mediated an induction of fibroblast migration compar-
able to fibronectin, which so far was regarded as strongest activator of migration. However,
the extent of migration-induction was strongly dependent on the source of CLPF (fistula or
UC versus control or inflammation).
W1657
The Angiogenic Chemokine Granulocyte Chemoattractant Protein-2 (GCP-2)
Is Selectively Expressed By Endothelial Cells in Ulcer Beds in Chronic
Inflammatory Bowel Diseases (IBD)
Klara Gijsbers, Gert De Hertogh, Gert van Assche, Paul Rutgeerts, Jo van Damme, Karel
Geboes
Background Chemokines are small proteins released by many cell types upon stimulation
with inflammatory mediators. By attracting and activating immune cells, chemokines play
a crucial role in the onset and perpetuation of inflammatory reactions. Overexpression of
chemokines causes an uncontrolled immune response that leads to chronic inflammation.
IBD is characterized by a constant, proinflammatory cytokine and chemokine-mediated
influx of leukocytes in diseased tissues. Aim GCP-2 is an angiogenic chemokine that selectively
attracts neutrophils. Because these are abundantly present in zones of active inflammation,
the expression of GCP-2 was investigated in intestinal tissue sections of IBD subjects. Methods
Transmural bowel biopsies from 29 Crohn’s disease (CD) patients and 31 ulcerative colitis
(UC) patients were stained immunohistochemically for GCP-2. Fourteen biopsies from
macroscopically normal bowel in colorectal cancer patients and 6 normal conjunctiva samples
were used as non-inflammatory controls. Two inflamed appendices and 13 biopsies from
vernal keratoconjunctivitis served as intestinal and extra-intestinal inflammatory controls,
respectively. Results Microscopic analysis of non-involved tissues from IBD patients showed
only a small number of GCP-2 positive mucosal leukocytes. The number of GCP-2 positive
leukocytes in the lamina propria was increased in pathological areas in IBD and correlated
with the disease activity observed in the biopsy samples. In addition, pronounced GCP-2
positive staining was observed in endothelial cells (Factor VIII+, CD34+) of blood vessels
located in ulcer beds in IBD patients. No GCP-2 positive endothelial cells were observed
in inflamed areas without epithelial or mucosal defects. There was also no endothelial
GCP-2 staining in inflammatory and non-inflammatory controls. Conclusion The selective
expression of GCP-2 by endothelial cells at sites of ulceration in IBD is probably important
for the attraction of neutrophils into inflamed ulcer beds. This may be an essential defense



















Subclinical Inflammation Causes Alterations in Serum Antioxidant and Fatty
Acid Levels in Quiescent Inflammatory Bowel Disease (IBD)
Thomas Koernicke, Lennart Schaper, Luzia Valentini, Susanne Hengstermann, Ralph-
Joachim Schulz, Sabine Buehner, Brigitte M. Winklhofer-Roob, Carsten Buening, Herbert
Lochs
Aim: The aim of this project was to assess the nutritional and inflammatory status in IBD
patients in clinical remission and compare the results to those of healthy controls. Methods:
Inflammatory status (C-reactive protein (CRP), Orosomucoid and faecal calprotectin, a non-
invasive marker of intestinal inflammation) was assessed in 52 IBD patients (37 ± 10yrs.;
22,3 ± 2,1 kg/m2) and 52 healthy controls pair-matched for sex-, age- and BMI. All IBD
patients were in clinical remission (32 Crohn disease (CD), CDAI 65 ± 41; 20 ulcerative
colitis (UC), CAI 3,3 ± 1,8). Furthermore, plasma levels of protein, fatty acid patterns (FA),
antioxidants (lutein/zeaxanthin, retinol, β-cryptoxanthin, α-and γ-tocopherol, lycopene, α-
and β-carotene) were compared. None of the patients was steroid-dependent. Results are
expressed as median and interquartile range. Results: In total, 88 % of IBD patients were
well nourished according to subjective global assessment, body mass index and serum
albumin > 40 g/l. However, we observed differences in the inflammatory status with respect
to CRP, orosomucoid and faecal calprotectin of CD patients (see table). In addition, ω-3,
ω-6 and total FA levels were significantly higher in CD patients, especially α-linolenic,
arachidonic, docosatetranoic and docosapentanoic acid (see table). We also found increased
protein values (77 [73;81] vs 74 [72;77] g/l, p=0.013). Plasma antioxidant concentrations
were comparable to healthy controls except for decreases in carotene levels (see table). UC
patients only showed higher calprotectin levels (17.4 mg/l vs. 0.0 mg/l, p=0.05) but no
significant changes with respect to all other values compared to controls. Conclusion: CD
patients even when they are in disease remission show clear signs of systemic and intestinal
inflammation which is associated by increases in serum polyunsaturated FA levels and higher
oxidative stress. Further studies are warranted to investigate the potential impact of our
findings on disease relapse.
W1659
Novel Effects of Pkc-Lambda (Pkc-λ) Isoform Activation On Intestinal
Monolayers: Carbonylation and Nitration of Cytoskeletal Proteins and
Cytoskeletal and Barrier Disruption Following NO Generation in Intestinal
Epithelium
Ali Banan, Lijuan Zhang, Jeremy Z. Fields, Ashkan Farhadi, Maliha Shaikh, Christopher
B. Forsyth, Ali Keshavarzian
Despite a decade of attempts at unraveling the role of PKC isoform signaling in the GI tract,
the structures &/or targets of PKC isoforms are unclear. Using monolayers of intestinal cells,
we reported that the λ isoform of PKC (a member of the atypical PKC subfamily) is required
for barrier instability, but the mechanisms underlying this unique phenomenon are unknown.
Since inducible NO Synthase (iNOS) is key to cell injury, we hypothesized that PKC-λ
activation induces iNOS upregulation and NO overproduction, leading to cytoskeletal oxida-
tion / disarray & barrier disruption. Methods: Intestinal cells were transfected to create new
clones over- or under-expressing PKC-λ. These innovative cells were incubated ± oxidants
or PKC activators/inhibitors. Wild type (WT) cells were treated similarly. We assessed
cytoskeletal integrity {confocal microscopy}, cytoskeletal oxidation / nitration {carbonylation /
nitrotyrosination of actin, PAGE fractionation}, cytoskeletal assembly / disassembly {F-actin /
G-actin ratio, SDS-PAGE}, barrier permeability {fluorometry}, PKC-λ subcellular activity /
distribution {immunoprecipitation, in vitro kinase}, iNOS / NO levels {scintillation counting,
PAGE, chemiluminescence}, n=6/grp. Results: Exposure of WT cells to oxidant stress or
transfection of cells to overexpress PKC-λ disrupted the cytoskeleton & increased oxidative
injury as indicated by native PKC-λ activation, iNOS pathway upregulation [iNOS activity/
protein levels, NO levels, oxidative stress/quenchable fluorescence, actin oxidation/nitration],
actin pool instability (reduced F-actin, increased G-actin), structural disruption of the actin
cytoskeleton, & monolayer barrier dysfunction. Disruption induced by PKC-λ synergized
with disruption by oxidants. In oxidant-treated transfected or WT cells, PKC-λ was active
& complexed with actin. Dominant mutant inactivation of endogenous PKC-λ prevented
all measures of iNOS upregulation & its injurious consequences to the cytoskeleton. Conclu-
sions: We have discovered a new pathophysiological process in gut epithelium. 1) PKC-λ
is required for oxidant-induced iNOS upregulation & the consequent nitration & oxidation
of cytoskeletal proteins. 2) PKC-λ activation causes cytoskeletal injury following upregulation
of NO driven processes. 3) Molecular events underlying the destabilizing effects of PKC-λ
are increases in carbonylation & nitration of the subunit components of the cytoskeleton.
The ability to promote NO overproduction & cytoskeletal nitration / oxidation is a novel
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pathophysiological mechanism not previously attributed to the atypical subfamily of PKC
isoforms. {Supported by NIDDK60511 & NCCAM01581; NIAAA13745}.
W1660
IFNγ and TNFα Synergize to Induce Maximal Nf-κB Activation, Nf-κB-
Mediated Trail Expression and Apoptosis of Colonic Epithelial Cells
Kenneth Nally, Darren O'Brien, John MacSharry, Emer Bairead, Gerald C. O'Sullivan, Joe
O'Connell, Fergus Shanahan
Background and Aims: IFNγ and TNFα are potent cytokines with pleiotropic activities
such as induction of inflammation, cell cycle arrest and apoptosis. While both are pro-
inflammatory, they have opposing roles in tumorigenesis, with IFNγ being primarily a tumor
suppressor and TNFα a tumor promoter. TNFα mediates its effects through activation of
the transcription factor NF-κB. As inappropriate activation of NF-κB promotes both chronic
inflammation and tumor progression, modulation of its function is seen as a potential strategy
for both diseases. Because inhibition of NF-κB function is known to sensitize cells to TNFα-
triggered cell death, we investigated the involvement of NF-κB in IFNγ-mediated sensitization
of colonic epithelial cells to TNFα-triggered apoptosis. Methods and Results: IFNγ+TNFα
synergized to induce apoptosis of HT29, WIDR, SW480 and Colo-205 cell lines. In the
HT29 cell line, IFNγ treatment did not block TNFα-induced phosphorylation or degradation
of the NF-κB inhibitory protein, IκBα. In contrast to other published studies, IFNγ treatment
did not inhibit the nuclear translocation, DNA binding or transactivation function of NF-
κB/RelA. In fact, compared to TNFα treatment alone, IFNγ+TNFα significantly increased
DNA binding of RelA between 4 and 16 hours. Quantitation of the NF-κB target genes
RelA, p50, RIP2K, SOD2, cIAP2 and IL-8, demonstrated that IFNγ+TNFα synergized to
induce maximal expression of all these genes. In addition, compared to IFNγ or TNFα
treatment alone, IFNγ+TNFα synergized to induce massive expression of TRAIL, as quantit-
ated by PCR and ELISA. However, siRNA-mediated knockdown of TRAIL receptor - DR5
but not DR4 - expression only provided modest protection from IFNγ+TNFα-triggered
apoptosis. Interestingly, siRNA-mediated knockdown of RelA in HT29 cells did not sensitize
them to TNFα-triggered apoptosis. It did, however, increase the degree of apoptosis induced
by IFNγ+TNFα. Finally, quantitative PCR analysis of cDNA from HT29 cells — transfected
with siRNA to knockdown RelA expression — demonstrated, that RelA is absolutely required
for the synergistic increase in expression of cIAP2, SOD2, IL-8 and TRAIL by IFNγ+TNFα.
Conclusions: These data show that IFNγ and TNFα synergize to induce maximal NF-
κB activity, NF-κB-mediated TRAIL expression and apoptosis of colonic epithelial cells.
Surprisingly, they also demonstrate that inhibition of NF-κB/RelA expression does not
sensitize these cells to TNFα-triggered apoptosis. Finally, they show that NF-κB is required
for the synergistic induction of both anti-apoptotic and pro-apoptotic genes by IFNγ+TNFα
in colonic epithelial cells.
W1661
Characterization of a Novel TNF-Alpha Signalling Cascade Involving
Autocrine EGF Receptor Trans-Activation in Human Intestinal Epithelial Cells
Hb Jijon, A Buret, K Fines, S Mokashi, H Parsons, Paul Beck
Background: Tumor Necrosis Factor-alpha (TNF-α) is a key inflammatory mediator in the
pathogenesis of Inflammatory Bowel Diseases. Intestinal epithelial cells are in a key position
to interact with the intestinal lumen and communicate with the intestinal immune system,
thus it is important to understand how TNF-α signaling in enterocytes elicits changes in
enterocyte function. We have previously demonstrated that TNF-α activates multiple mitogen
activated protein kinase (MAPK) cascades in intestinal epithelial cells. As the EGFR is a
potent activator of MAPKs, we hypothesized that the EGFR may participate in TNF-dependent
MAPK activation. Aims: In this study we examined the possible interaction between the
TNF and EGFR’s in HT-29 cells. Methods and Results: Immunoprecipitation of the EGFR
and subsequent immunoblotting revealed that the EGF receptor is phosphorylated on tyrosine
following a 15 minute treatment of intestinal epithelial cells (HT-29) with 10 ng/ml TNF-
α. This event is dependent on the intrinsic kinase activity of the EGFR as tyrosine phosphoryl-
ation of the EGFR was blocked by the EGFR kinase inhibitor AG1478 (200nM-1μM) but
not by the platelet-derived growth factor (PDGF) receptor kinase inhibitor AG1298 (10
μM). Autophosphorylation of the EGFR was also inhibited by both the Src-kinase inhibitor
PP2 (10 μM) and the tyrosine kinase inhibitor genistein (100 μM), suggesting a role for a
Src-family kinase in EGFR phosphorylation. In addition, EGFR autophosphorylation was
inhibited by the matrix metalloproteinase (MMP) inhibitor BB94 (10 μM). Conclusions:
These results suggest that activation of the TNF receptor leads to the activation of a Src-
related kinase, leading to the activation of an MMP, potentially the release of a membrane
bound EGF receptor ligand ultimately resulting in the activation of the EGFR tyrosine kinase
in a manner similar to what has been described for G protein-coupled receptor-mediated
transactivation of the EGFR. These results reveal a previously unrecognized interaction
between the TNF receptor and the EGFR and suggest that the latter may act to relay signals
emanating from TNF receptors.
W1662
SRC Kinase and Rac1 Gtpase Signals Mediate the Mitogenic Downstream
Activation of Focal Adhesion Kinase and Mitogen-Activated Protein Kinases
ERK1/2 By Repetitive Deformation in Human CACO-2 Intestinal Epithelial
Cells
Lakshmi S. Chaturvedi, H. Michael Marsh, Marc D. Basson
Intestinal epithelial cells are subject to repetitive deformation during normal gut peristalsis
and villous motility, while the mucosa atrophies during sepsis or ileus when such stimuli
are absent. We have previously shown that rhythmic mechanical strain stimulates intestinal
epithelial cell proliferation and promotes differentiation. Activation of focal adhesion kinase
(pp125FAK) and mitogen-activated protein kinases ERK1/2 appears required for the strain
effect in human Caco-2 intestinal epithelial cells. However, the upstream mediators of these
effects are unknown. We investigated whether c-Src and the small GTPase Rac1 mediate
stretch-induced FAK phosphorylation and proliferation in Caco-2 cells. Cells were cultured
on collagen I-precoated membranes and subjected to an average 10% repetitive deformation
at 10 cycles/minute, consistent with the deformation which the mucosa experiences in vivo.
Cells were harvested for Western blot analysis, in vitro kinase assay, subcellular fractionation,
crystal violet staining, or cell counting. Mechanical strain activated c-Src within 2 minutes
and caused translocation of Rac1 GTPase from cytosol to membrane within 5 minutes after
the initiation of strain in a time-dependent manner. (n=4, p<0.05). Furthermore, strain
induced both rapid and sustained (up to 1 h) increases in phosphorylation of c-Src tyrosine
kinase at Tyr416, Rac1-cdc42 at Ser71, FAK at Tyr576 and Tyr397, and ERK1/2 at Thr202/
Tyr204 (n=5, p<0.05). Twenty four hours of cyclic strain increased cell numbers compared
with static conditions (n=5, p<0.005). The Src kinase inhibitor PP2 (10 µmol/l) or the Rac1
specific inhibitor NSC23766 (50 µmol/l) blocked strain-induced mitogenicity. The c-Src
kinase or Rac1 inhibition also prevented strain-induced FAK576 and ERK1/2 phosphoryl-
ation, but not FAK397 phosphorylation (n=4, p<0.05). Reducing total FAK by 70% using
specific siRNA attenuated stretch-induced ERK1/2 phosphorylation but not c-Src tyrosine
kinase or Rac1-cdc42 phosphorylation (n=6, p<0.05). The Src kinase inhibitor PP2 blocked
strain-induced pRac1-cdc42 phosphorylation (n=5, p<0.05). In contrast, the Rac1 specific
inhibitor NSC23766 did not inhibit c-Src phosphorylation (n=4, p<0.05). In conclusion,
these data suggest that repetitive deformation induced by peristalsis or villus motility may
support the gut mucosa by a pathway involving c-Src kinase, the small GTPases Rac1 and
cdc42, FAK, and ERK1/2. Aberrations in this signal pathway during ileus or fasting may
contribute to mucosal atrophy despite adequate parenteral nutrition and may represent an
important target for therapeutic intervention designed to support the mucosa.
W1663
PIAS-1 Promotes GATA4 Sumoylation and Potentiates Gata4 Mediated
Transcriptional Activation of Intestinal Promoters
Narasimhaswamy S. Belaguli, Mao Zhang, Muhammad Aftab, David H. Berger
Introduction: Expression of several gut epithelial differentiation marker genes is regulated
by the gut epithelium-enriched GATA factor, GATA4. Tissue-specificity and promoter-
specificity of GATA4 appears to be due to its ability to interact with various ubiquitously
expressed and gut epithelium-restricted cofactors. We have used the yeast two hybrid system
to identify gut tissue-expressed GATA4 cofactors. Methods: Zinc finger and the C-terminal
domains of GATA4 fused in frame with the GAL4 DNA binding domain was used as bait.
The bait and the GAL4 activation domain-fused human small intestinal cDNA library were
cotransformed into yeast Y187 strain and selected for growth on ade/his/leu/trp quadruple
dropout media. For coimmunoprecipitation experiments, lysates prepared from HCT116
cells transiently transfected with HA epitope tagged GATA4 and FLAG epitope tagged PIAS-
1, were used. For GST pulldown experiments, bacterially expressed, GST fused GATA4 and
PIAS-1 proteins and 35 [S] methionine labeled in vitro translated mutants of GATA4 and
PIAS-1 were used. Site directed mutagenesis of GATA4 and PIAS-1 were performed using
QuickChange II XL kit (Stratagene). Transient transfection experiments were performed by
cotransfecting subconfluent HCT116 cells with 0.2 ug of IAP and IFABP promoter-luciferase
vectors with 0.2 ug to 0.4 ug of GATA4 and PIAS-1 expression vectors. Results: Protein
inhibitor of activated STAT-1 (PIAS-1) was identified as a GATA4 cofactor by yeast two
hybrid analysis. Coimmunoprecipitation experiments were used to demonstrate that GATA4
and PIAS-1 interact in vivo in mammalian cells. Using GST protein pulldown experiments,
the second zinc finger domain and the immediately C-terminal basic region of GATA4 were
identified as regions mediating the physical interaction between GATA4 with PIAS-1. PIAS-
1 stimulated sumoylation of GATA4 and mutation of SUMO acceptor site (K365) of GATA4
or mutation within the RING finger region of PIAS-1 (C350) affected GATA4 sumoylation.
In transient cotransfection assays GATA4 synergistically activated IAP and IFABP promoters
in the presence of wild type PIAS-1 but not the SUMO ligase activity deficient mutant of
PIAS-1 (C350A). Conclusions: PIAS-1 is a GATA4 cofactor that promotes GATA4 sumoylation
and synergizes with GATA4 in transcriptional activation of IAP and IFABP promoters.
W1664
Induced PDK1 Kinase Activity Suppresses Apoptosis in Intestinal Epithelial
Cells By Activating AKT Signaling Following Polyamine Depletion
Kaspar M. Keledjian, Jaladanki N. Rao, Tongtong Zou, Lan Liu, Bernard S. Marasa,
Aihong Zhang, Eric D. Strauch, Jian-Ying Wang
Apoptosis plays a critical role in maintenance of gut mucosal homeostasis and is highly
regulated by numerous factors including polyamines. Our previous studies have demon-
strated that decreasing cellular polyamines promotes the resistance of intestinal epithelial
cells (IECs) to apoptosis by increasing Akt kinase activity, but the exact mechanisms by
which polyamine depletion activates Akt remain unknown. The 3-phosphoinositide-depend-
ent protein kinase-1 (PDK1), a kinase functioning downstream of PI3K and upstream of
Akt, serves as a major regulatory point in Akt signaling and regulates various cellular
functions. The current study tests the hypothesis that polyamine depletion induces PDK1
kinase activity resulting in Akt activation in IECs. Methods: Studies were conducted in IEC-
6 cells, derived from rat small intestinal crypts. Apoptosis was induced by exposure to tumor
necrosis factor-α (TNFα) plus cycloheximide (CHX). PDK1 activation was examined by
measuring levels of phosphorylated PDK1 (pPDK1) and its kinase activity. Functions of
PDK1 were investigated by using small interfering RNA targeting PDK1 (siPDK1). Results:
Depletion of cellular polyamines by α-difluoromethyl-ornithine (DFMO) (specific inhibitor
of polyamine synthesis) induced phosphorylation of PDK1 and increased PDK1 kinase
activity, which were completely prevented by exogenous polyamine spermidine. Levels of
pPDK1 and its kinase activity were increased by ~3 times the control values 6 days after
treatment with DFMO. Induced PDK1 activation following polyamine depletion was associ-
ated with a significant increase in phosphorylated Akt (pAkt) and Akt kinase activity. Levels
of pAkt in polyamine-deficient cells were ~6 times the control value, while Akt kinase
activity was increased by ~10 times. This activated PDK1/Akt was also associated with
decreased caspase-3 activation and increased resistance to TNFα/CHX-induced apoptosis.
In contrast, polyamine depletion did not alter levels of total PDK1, total Akt, PTEN, p85,
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and p110 (subtypes of PI3K) proteins. Inactivation of PDK1 in polyamine-deficient cells by
either treatment with PI3K inhibitor LY294002 or transfection with siPDK1 not only pre-
vented the induced Akt activation but also blocked the increased resistance to TNFα/CHX-
induced apoptosis. Conclusions: These results indicate that induced PDK1 activation mediates
Akt phosphorylation and is crucial for the increased resistance to apoptosis following polyam-
ine depletion.
W1665
Keratins Modulate Mitochondrial HMG-CoA Synthase in the Colon
Diana M. Toivola, Aida Habtezion, Jian Liao, Qin Zhou, Eugene C. Butcher, M B. Omary
Background: Keratin 8 (K8) was the first intermediate filament (IF) protein targeted for
deletion in transgenic mice. In addition to a liver injury susceptibility phenotype, K8-null
mice develop, within 2-3 weeks of birth, colonic hyperproliferation and colitis with diarrhea
that respond to antibiotic therapy, and enterocyte mistargeting of ion transporters. Aim: We
hypothesized that a proteomic analysis will provide molecular insight regarding the function
of keratins in the colon, and the colitis that is induced by keratin absence. Methods: Wild-
type (WT) and K8-null colons were removed followed by isolation of colonic crypts using
calcium-free conditions. Protein homogenates were prepared and equal fractions were labeled
with Cy3 (WT) and Cy5 (K8-null). Labeled fractions were analyzed using 2-Dimensional
Differential In Gel Electrophoresis (2-D DIGE) coupled with mass spectrometry to identify
differentially regulated proteins. Results: In K8-null enterocytes, eleven major non-keratin
proteins were down-regulated which include selenium binding protein, 3-hydroxy-3-methyl-
glutaryl Coenzyme A (HMG-CoA) synthase and carbonic anhydrase I. Fourteen major
proteins were up-regulated including dimethylglycine dehydrogenase, and argininosuccinate
synthase 1. We focused on HMG-CoA synthase, an important mitochondrial regulator of
ketogenesis, whose four isoforms were downregulated 3-6 fold in K8-null colonic crypts.
The decreased expression of HMG-CoA synthase was confirmed at the protein (by immunob-
lotting and immunofluorescence staining) and RNA levels. Changes in colonic HMG-CoA
synthase were specific to the colon in that they were not found in the liver. Peroxisome
proliferator-activated receptor gamma (PPAR gamma), an HMG-CoA synthase transcriptional
activator was also down-regulated in K8-null colon. Conclusion: Our results suggest that
colonic keratins may be involved in lipid and ketone body metabolism, which is likely
relevant to the colitis phenotype since bacteria are the major source of colonic butyrate.
W1666
Norepinephrine Enhances Radiosensitivity in Rat Ileal Epithelial Cells
Mutsumi Matsuu-Matsuyama, Kazuko Shichijo, Kumio Okaichi, Toshiyuki Nakayama,
Masahiro Nakashima, Ichiro Sekine
BACKGROUND: We previously reported that after X-irradiation the apoptosis index in
jejunal crypt cells in spontaneously hypertensive rats, a well-known model for essential
hypertension in humans, was significantly greater than in control Wistar-Kyoto rats. Also,
the administration of reserpine to induce sympathetic dysfunction of spontaneously hyper-
tensive rats or Wistar-Kyoto rats resulted in a significant suppression of apoptosis. (J. Radiat.
Res, 41, 55-65, 2000). We hypothesized that hyperfunction of the sympathetic nervous
system is involved in the high susceptibility of the jejunal crypt cells to radiation-induced
apoptosis. To test this hypothesis, the effect of norepinephrine (NE) on cell survival was
examined using the clonogenic assay and on apoptosis after X-ray irradiation in rat ileal
epithelial cells (IEC-18) in vitro. METHODS: Rat ileal epithelial cells (IEC-18) in serum-
free medium were treated for 2 h with 1μΜ NE or without NE, then exposed to 8 Gy X-
ray irradiation, and followed by the colony formation assay. Apoptotic fragments were
confirmed by TUNEL staining at 6 h after 8 Gy irradiation. In another series of experiments,
cells were incubated with prazosin (5μΜ), yohimbine (5μΜ) and propranolol (5μΜ), which
are alpha1, alpha2, and beta-adrenergic receptor antagonists respectively, for 30 min before
NE treatment, and colony formation assays were examined after 8 Gy irradiation. Cleaved
caspase-3 expression was examined by western blot analysis at 3 h after irradiation. RESULTS:
NE treatment in rat ileal epithelial cells resulted in the decrease of cell survival in a dose
dependent manner. A combination of NE and radiation significantly decreased the surviving
fraction at 8 Gy from 24.1% to 6.4 % (p<0.05). NE concentration of 1μM resulted in
significantly increasing the apoptotic rate from 3.5 % to 6.0 % 6 h after 8 Gy irradiation
(p<0.05). The survival fraction of prazosin (130%) and yohimbine (141%) treated IEC-18
cells increased compared to non-treated cells after 8 Gy irradiation. Enhanced cell sensitivity
to radiation by NE was attenuated by alpha1-adrenergic antagonist (prazosin) but was
not affected by beta-adrenergic antagonist (propranolol). Cleaved caspase-3 (active form)
expression in NE treated cells was increased compared to non-treated cells 3 h after 8 Gy
irradiation, but was reduced by prazosin treatment. CONCLUSIONS: The results of this
study suggest that norepinephrine enhanced the radiosensitivity including radiation-induced
apoptosis of rat ileal epithelial cells and that the alpha1- adrenergic receptor may be involved
in the process.
W1667
Differential Promoter Usage and Activity May Regulate Function of RNA
Binding Protein CUGBP2 in Intestinal Epithelial Cells
Satish Ramalingam, Courtney W. Houchen, Brian K. Dieckgraefe, Shrikant Anant
RNA binding protein CUGBP2 is a ubiquitously expressed protein that is located in the
nucleus under physiological conditions. When subjected to physiological stress, such as
exposure to radiation, CUGBP2 expression is significantly induced. Furthermore, the protein
translocates to the cytoplasm, where it is found bound to AU-rich sequences in the 3'untrans-
lated region of cyclooxygenase-2 (COX-2) mRNA. Following binding to 3'UTR, the protein
stabilizes COX-2 mRNA but inhibits its translation. CUGBP2 contains two N-terminal RNA
recognition motif (RRM) domains, one C-terminal RRM domain, and alanine and glutamine-
rich region between the second and third RRM domains. SAGE analyses for ten normal

















by the total number of tags in libraries derived from that tissue and subsequently then
normalized by multiplying by 1.2M demonstrated highest levels of expression in the brain
and spinal cord, but high levels were also seen in liver, kidney and lungs. We have also
observed expression of CUGBP2 in the intestine, but the expression is significantly suppressed
in cancer tissues. Alternative promoter usage, and alternative splicing results in three tran-
script variants encoding slightly different CUGBP2 isoforms. Isoform 1 encodes the smallest
protein of 490 amino acids, while the isoforms 2 and 3 include additional 24 and 19 amino
acids in the N-terminus of the protein, respectively. Based on RT-PCR analyses, we have
determined that isoform 1 is the dominant form of CUGBP2 mRNA that is expressed in
human colon cancer cell lines, HT-29, HCT-116 and SW480. Furthermore, the protein
encoded by isoform 1 is localized in the nucleus. We have previously shown that CUGBP2
expression is significantly induced in HT-29 cells following radiation, while its expression
is lost following treatment with prostaglandin E2 (PGE2). We have now determined that
isoform 1 is significantly induced in the cells following radiation exposure. Furthermore,
expression of isoform 1 is suppressed following treatment of the cells with either PGE2 or
epidermal growth factor (EGF). In contrast, expression of isoforms 2 and 3 were lost following
treatment of cells with either radiation, PGE2 or EGF. Ectopic overexpression on isoform 1
induces cells to undergo apoptosis. Together these data suggest that radiation treatment
results in expression of an isoform that is involved in apoptosis.
W1668
Juvenile Polyps Express Muc5ac Which May Be Related to Reduced SMAD4
and Cdx2 Expression
Raquel Almeida, Rita Barros, Jose Almeida, Nuno Mendes, Isabelle van Seuningen, Celso
Reis, Filipe Santos-Silva, Carme De Bolos, Leonor David
Mucin core proteins are used as cell differentiation markers. MUC5AC is a marker of gastric
foveolar differentiation, MUC6 is a marker of gastric glandular differentiation and MUC2 is
a marker of intestinal goblet cells. Aberrant expression of mucins occurs in cancer and in
lesions that are benign or pre-neoplastic: MUC2 is expressed in gastric intestinal metaplasia
(IM), whereas MUC5AC is expressed in the colon in hyperplastic and serrated polyps. Cdx2
is the master gene responsible for intestinal differentiation and is involved in the transcription
of several intestinal genes including MUC2. Transgenic mice with Cdx2 ectopic expression
in the gastric mucosa develop IM and conversely Cdx2+/- mice develop hamartomatous
polyps in the colon with gastric differentiation. Interestingly, Smad4+/- mice also develop
hamartomatous lesions in the colon. Based on these observations we hypothesized that loss
of CDX2 and/or Smad4 might contribute to generate hamartomatous lesions of the colon,
with a switch from colonic to gastric phenotype, including juvenile polyps that in familial
and sporadic cases can occur in the presence of Smad4 mutations. Based on the same line
of thought we hypothesized that Smad4 might regulate Cdx2 expression. We characterized
18 juvenile polyps by immunohistochemistry for gastric mucins expression, MUC5AC (MoAb
CLH2) and MUC6 (MoAb CLH5), intestinal mucin expression, MUC2 (MoAb PMH1) and
expression of Cdx2 (Biogenex) and Smad4 (B8, SantaCruz Biotechnology). MUC2 expression
was also assessed by In Situ Hibridization. Transactivation of Cdx2 by Smad4 was assessed
using Luciferase reporter assays. We observed that 83% of the polyps express de novo
MUC5AC, none of the cases express MUC6 and all the cases express MUC2 with a “patchy”,
heterogeneous pattern, with areas of absence of immunostaining and negativity by ISH. Both
Cdx2 and Smad4 expression were observed in all cases, with a “patchy” pattern including
negative areas. Luciferase reporter assays showed that Smad4 transactivates Cdx2 promoter.
In conclusion, acquisition of a foveolar gastric differentiation, indicated by the presence of
MUC5AC, is a common feature of juvenile polyps, as previously demonstrated for hyperplastic
and serrated colon polyps. This aberrant gastric differentiation is associated with loss of
colonic differentiation, namely MUC2, and with reduced Cdx2 and Smad4 expression. The
observed transactivation of Cdx2 by Smad4 may contribute to explain, in the absence of a
functional Smad4 pathway in juvenile polyposis, the onset of a gastric phenotype.
W1669
Functional Characterization and Transcriptome Analysis of Mastomys
Enterochromaffin Cells
Mark Kidd, Irvin M. Modlin, Geeta N. Eick, Manish C. Champaneria
Although the enterochromaffin (EC) cell is one of the primary neuroendocrine (NE) regulatory
cells of the small intestine, the lack of a purified cell system has precluded its characterization.
We have developed methodology to produce a pure population of Mastomys ileal EC cells
utilizing density gradient centrifugation and FACS sorting, and have investigated its functional
regulation and transcriptome. Mastomys ilea (n=10) were everted, end-ligated, digested with
pronase/collagenase, Nycodenz gradient centrifuged, and EC cells collected by FACS sorting
of acridine orange-labeled cells. Enrichment was confirmed by immunostaining of specific
EC cell markers, serotonin content, EC cell marker gene expression and electron microscopy.
PACAP, somatostatin, and gastrin receptor expression was determined by real-time RT-PCR.
FACS sorted EC cells were cultured and the effects of forskolin, isoproterenol, acetylcholine,
GABAA, PACAP-38 and gastrin on serotonin secretion (ELISA) assessed. The EC cell tran-
scriptome was derived from GeneChip Affymetrix profiling of FACS-sorted cells. FACS
sorting produced a >70-fold enrichment of EC cells with a serotonin content of 240+22ng/
mg protein. Preparations were 99+0.7% pure by immunostaining for tryptophan hydroxylase
(TPH). The contaminating cell type was NE (CgA/neurotensin-positive). Somatostatin cells
were absent in FACS preparations. VPAC1 and SSTR2 receptors were present but PAC1
and CCK2 receptors were undetectable. Forskolin, isoproterenol and PACAP-38 stimulated
serotonin secretion at EC50 values of 5x10-10M, 4.5x10-10M and 1.2x10-9M, respectively.
Octreotide, acetylcholine and GABAA inhibited serotonin secretion with IC50 values of
3x10-11M, 3x10-10M, 2.9x10-10M, respectively. Gastrin had no effect on serotonin secre-
tion. Analysis of the EC cell transcriptome revealed highly expressed (>22.6-fold) EC cell
marker genes (TPH, substance P and guanylin), the absence of marker genes for other small
intestinal cell types (villin, mucins, defensins, CD4, inflammatory gene complexes), and
a receptor profile that included cholinergic (M4), adrenergic (b1), dopaminergic (D2),
serotoninergic (5-HT2C), GABAergic (A a2 & b), and prostaglandin receptors (E1,4 &
F). The isolation of a homogeneous preparation (>99%) of live EC cells for regulatory
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characterization and transcriptome assessment indicates that functional characterization of
the human ileal EC cell is feasible. This will enable physiologic assessment of the role of
the EC cell in conditions such as inflammatory/irritable bowel disease and investigation of
its role in the development of carcinoid tumors.
W1670
The Glycine Transporter GLYT1 Is Required for Glycine-Mediated Protection
of Intestinal Cells and Is Up-Regulated in Response to Stress
Alison Howard, Imran Tahir, Sarah M. Waring, Barry H. Hirst
In the intestine glycine attenuates cell damage caused by ischemia/reperfusion (IR), prevents
or reverses colitis induced by 2,4,6-trinitro-benzene sulphonic acid (TNBS) and dextran
sulphate, and inhibits apoptosis during IR. The aim of this study was to investigate the
mechanism of glycine cytoprotection in the intestinal cell lines, HCT-8 and Caco-2. In both
cell lines, glycine uptake at the basal membrane was approximately five fold greater than
at the apical membrane and the specific glycine transporter GLYT1 accounted for 30-40%
of this. Monolayers of cells were subjected to oxidative stress by incubation for 24h in
medium containing 150µM tert-butylhydroperoxide (t-BOOH). This induced approximately
50% cell death (cell viability controls, 100 ± 1.98%; t-BOOH treated, 53.5 ± 4.9%, n=8;
p<0.05). Pre-incubation of the cells in medium containing 1 or 5mM glycine protected the
cells from injury and reduced cell death to ~20-30% (cell viability, 72.5 ± 4.9 and 81.2 ± 8.1%
of control respectively, n=8; p<0.05 compared to t-BOOH treated cells both concentrations).
Glycine added into the medium during t-BOOH treatment had no effect on the decrease in
cell viability. Including the GLYT1 inhibitor N-[3-(4’-fluorophenyl)-3-(4’-phenylphenoxy)-
propyl] sarcosine (ALX-5407) in the pre-incubation medium completely blocked the protect-
ive effects of glycine (cell viability, 48.5 ± 2.0 %, n=8). Glycine pre-treatment preserved
cellular glutathione concentration during exposure to t-BOOH (glutathione concentration
in control cells, 1.94 ± 0.45 µg/mg protein, n=9; t-BOOH treated, 0.32 ± 0.20, n=9; 5 mM
glycine + t-BOOH treated; 1.36 ± 0.22, n=9). To study the effect of stress on GLYT1 mRNA
levels, cells were incubated in medium lacking amino acids or supplemented with diethyl
maleate, to deplete glutathione, or tunicamycin, to invoke ER stress and the unfolded protein
response. Abundance of mRNA relative to 18S rRNA was measured by real-time RT-PCR.
GLYT1 mRNA levels were increased significantly by all treatments (relative mRNA level:
controls, 1.00 ± 0.85 arbitrary units; amino acid starved, 3.18 ± 1.09; tunicamycin, 2.39 ±
0.62; DEM 2.46 ± 0.12. n=9, p<0.05 for all). Similar increases were seen in mRNA encoding
the cystine-glutamate exchanger xCT. Expression of the peptide transporter, PepT1, was
unchanged. These results indicate that GLYT1 activity is required for glycine protection of
intestinal cells and that abundance of its mRNA is increased during intestinal cell response
to stress. Corresponding increases in GLYT1 and xCT mRNA levels suggest that this response
may lead to increased supply of amino acids leading into glutathione synthesis.
W1671
The Transcriptome and Function of Normal and Neoplastic Human EC Cells
Irvin M. Modlin, Mark Kidd, Geeta N. Eick, Manish C. Champaneria, Roswitha Pfragner
The neuroendocrine (NE) regulation of small intestinal (SI) function is ill-understood since
pure NE cells are unavailable. Similarly, the biological basis of SI carcinoid tumors—of
enterochromaffin (EC) cell origin— is unknown since neoplastic human EC cells are unavail-
able. We purified EC cells from ilea and characterized a malignant EC cell carcinoid cell
line (KRJ-1) to define the functional regulation and transcriptome of naïve and neoplastic
EC cells. Human ilea (n=12) from R. hemicolectomies were pronase/collagenase digested,
Nycodenz gradient centrifuged, and EC cells FACS sorted after acridine orange-labeling.
Enrichment was defined by immunostaining, gene expression, serotonin (5-HT) content and
real-time RT-PCR. Naïve FACS-sorted EC and KRJ-1 cells were cultured and 5-HT secretion
was measured after stimulation with forskolin, isoproterenol (Iso), acetylcholine (ACh),
GABAA, PACAP-38 and gastrin. The normal and neoplastic EC cell transcriptome was
acquired by Affymetrix profiling (U133A). FACS produced 100±0.3% (CgA staining) and
99+0.7% pure (TPH) EC cells with >67-fold enrichment and a 5-HT content of 180+18ng/
mg protein (mucosa=3.5+0.9). The <1% contamination was neurotensin-positive cells. NE/
EC-specific (CgA, VMAT1, TPH ~14-21-fold >than mucosa), as well as subst P, guanylin
and SERT transcripts were detected. VPAC1 and SSTR2 receptors were present on both cell
types but PAC1 and CCK2 were undetectable. Forskolin and Iso-stimulated 5-HT secretion
was 10-100x >potent for naïve (EC50=1.8x10-9M; 5.1x10-9M) vs neoplastic cells (EC50=
2.1x10-7M; 8.1x10-8M) but PACAP-38 was similar (EC50=1x10-7M). Iso stimulated cAMP
levels 1.6±0.1-fold vs basal (EC50=2.7x10-9M). ACh inhibited normal EC cell 5-HT secretion
more than neoplastic (IC50=3.2x10-9M vs 1.6x10-7M), while GABAA was more potent in
neoplastic cells (IC50=3.9x10-10M vs 4.4 x 10-9M). Octreotide inhibited normal but not
neoplastic basal 5-HT secretion; its inhibitory effect on Iso-stimulated secretion (IC50=
1.3x10-8M and 5.3x10-9M) was not significantly different. Gastrin had no effect on 5-HT
secretion in normal or KRJ-1 cells confirming the absence of a CCK2 receptor. Comparison
of transcriptomes revealed shared NE (CgA, VMAT1) and EC cell specific (TPH, subst P,
guanylin) marker genes. Neoplastic cells expressed somatostatin SSTR2/3, serotonin 5-HT2A,
adrenergic a1C/b1, glutaminergic Ag3 receptors vs SSTR2/5, 5-HT1A and B/2C, b1, and
Aa6/b2 receptors in naïve cells. The putative carcinoid malignancy genes (MTA1, MAGE-
D2) are unique to the EC cell neoplastic transcriptome. Further delineation will allow
identification of novel targets to control secretion and proliferation of carcinoids.
W1672
Specific Upregulation of Pancreatic Enzymes in Rat Duodenal Mucosa By
Duodenal Ulcerogens: Gene Expression Indicates New Elements in
Pathogenesis
Longchuan Chen, Xiaoming Deng, Klara Osapay, Tetyana Khomenko, Sandor Szabo
Chemically induced duodenal ulcers in animal models have been widely used to study the
pathogenesis and healing of duodenal ulcers. Our previous structure-activity studies have
identified the functional groups of potent ulcerogenic chemicals (PNAS, 1991, 88:6298-
6302 ), e.g., cysteamine (HS-CH2-CH2-NH2) is a potent ulcerogen while its close analog
ethanolamine (HO-CH2-CH2-NH2) fails to induce duodenal ulcers in rats. Propionitrile
and mepirizole are also potent duodenal ulcerogens. Using these chemicals, we have per-
formed DNA microarray analysis of gene expression in rat duodenal mucosa to identify
gene expression changes specifically associated with duodenal ulceration. Goals: to identify
common and distinct molecular pathways leading to duodenal ulcer formation induced by
various ulcerogens. Methods and Results: Groups of unfasted Sprague-Dawley female rats
(180-200g) were given cysteamine (25mg/100g, once or x3, every 4 hr) or equimolar amount
of ethanolamine (21.47mg/100g, once or x3, every 4 hr) by gavage, or propionitrile (5mg/
100g, x3) injected subcutaneously. Rats were euthanized by CO2 inhalation at 2 hr or 12
hr after first dose of chemicals. Proximal duodenal mucosa was scraped after pancreatic
tissue was carefully removed. Total RNA was extracted from mucosal samples and further
processed for DNA microarray analysis using Affymetrix Rat 230 2.0 chip (30,000 transcripts).
Results from two independent experiments were analyzed. Real-time PCR was performed
to confirm candidate genes that were upregulated. A cluster of pancreatic enzymes such as
chymotrypsinogen B, carboxypeptidase A2, chymotrypsin-like protein, pancreatic colipase,
pancreatic trypsin 1, phospholipase A2, and a secretory granule protein syncollin were
among the genes that were upregulated (4-100 fold) by cysteamine (at both 2 hr and 12
hr) and propionitrile but not affected by ethanolamine (at either 2 hr or 12 hr). Conclusions:
1) We have identified a group of genes upregulated by duodenal ulcerogens but not by
nonulcerogenic analog in the duodenal mucosa. 2) The unconventional upregulation of
these genes especially proteases and lipases in the duodenal mucosa may point to a new
mechanism of ulcer formation and organ-specific tissue injury. 3) Thus, gene and protein
expression studies may help to identify new pathways in the pathogenesis of duodenal ulcera-
tion.
W1673
The Molecular Mechanism of Tumor Necrosis Factor-α (TNF-α) Modulation of
Intestinal Tight Junction (TJ) Permeability: Regulation of Myosin Light Chain
Kinase (MLCK) Promoter Activity
Dongmei Ye, Thomas Y. Ma
TNF-α induced increase in intestinal epithelial TJ permeability has been proposed as an
important mechanism contributing to intestinal inflammation. Our previous studies have
indicated that the TNF-α increase in Caco-2 TJ permeability was mediated by an increase
in MLCK promoter activity, leading to a step-wise increase in MLCK expression and activity,
and an increase in Caco-2 TJ permeability. TNF-α increase in Caco-2 TJ permeability also
required NF-κB activation.(AJP 2004; 286:G367-76) The aim of this study was to delineate
the regulatory mechanisms that mediated the TNF-αmodulation of MLCK promoter activity.
Methods: A 2091 bp MLCK promoter was cloned (Gene ID DQ 090939). Various molecular
and biochemical methods were used. Results: A series of 5’ deletion constructs of MLCK
promoter were generated and the minimal MLCK promoter region identified (-448 to -18).
Two functionally active NF-κB binding sites were identified on the promoter region (-84/-
75 and -456/-447). The κB motif at -84/-75 was located within the minimal promoter region
(cis-element) and the κB motif at -456/-447 was located outside the minimal promoter
region (trans-element). MLCK promoter deletion constructs encoding only cis- or trans-κB
site were generated. TNF-α caused an increase in the promoter activity of the DNA construct
encoding the cis-κB site (but lacking the trans-κB site). In contrast, TNF-α caused a small
decrease in the promoter activity of the DNA construct encoding only the trans-κB site.
These results indicated that the two κB sites on the MLCK promoter have opposite regulatory
actions. Electrophoretic mobility shift assay indicated that NF-κB p50/p65 heterodimer binds
to the cis-κB site, while p50/p50 homodimer binds to the trans-κB site, suggesting that the
binding of p50/p65 to cis-κB site induces an up-regulation while binding of p50/p50 to
trans-κB site induces a down-regulation of the promoter activity. Lastly, the depletion of
NF-κB p65 expression in Caco-2 cells by siRNA prevented the TNF-α induced up-regulation
of promoter activity caused by the cis-κB site (binds to p50/p65), but did not affect the
down-regulation by the trans-κB site (binds to p50/p50). Conclusions: Our results indicate
that the TNF-α induced activation of MLCK promoter is selectively regulated by binding
of specific NF-κB dimer type to the cis and trans-κB motifs on the MLCK promoter. These
studies provide important new insight into the molecular mechanism of TNF-α regulation
of MLCK promoter activity and Caco-2 TJ barrier function.
W1674
Glycogen Synthase Kinase 3 Regulates Cytokine and Lipopolysaccharide-
Induced Gene Expression in Intestinal Epithelia
Eleana M. Harmel, Kris A. Steinbrecher
Background: While glycogen synthase kinase 3α (GSK-3α) and GSK-3β control numerous
signaling pathways, little is known about the role of these potential therapeutic targets in
intestinal inflammatory diseases. Initial studies suggest that GSK-3 is able to regulate the
activity of specific nuclear factor κB (NF-κB) and activator protein 1 (AP-1) subunits that
are integral to both cytokine and Toll-like receptor (TLR)-mediated intestinal epithelial cell
(IEC) gene expression. We hypothesize that blockade of GSK-3 activity in IECs results in
deregulated gene expression following tumor necrosis factor-α (TNFα) or lipopolysaccharide
(LPS) stimulation. Methods: We used the pharmacological inhibitor SB216763 or stable
integration of short hairpin-expressing RNAi constructs to decrease GSK-3 activity in a
nontransformed intestinal epithelial cell line (IEC-18). Kinase assays and/or western blotting
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were used to evaluate the status of relevant signal transduction molecules including NF-κB
activation pathway intermediates and mitogen-activated protein kinases following TNFα or
LPS stimulation. Gene expression studies were performed using realtime RT-PCR. Results:
Inhibition of GSK-3 in IEC-18 cells greatly decreased GSK-3-mediated phosphorylation of
β-catenin without increasing β-catenin levels. The ability of IEC-18 cells to use alternative
β-catenin regulation pathways provides a system to investigate the function of GSK-3 without
the potentially confounding high levels of β-catenin found in many transformed IEC lines.
Similar to that seen in TNFα-signaling, decreased GSK-3 activity in IEC-18 cells did not
effect the initial steps in LPS-induced activation of NF-κB. Western blotting and kinase
assays suggested that TNFα- or LPS-mediated activation of JNK and phosphorylation of c-
Jun were sustained in cells lacking full GSK-3 activity. This effect on JNK regulation was
specific as we saw no change in ERK1/2 activity in GSK-3-blocked IECs. Regulation of
numerous NF-κB and AP-1 target genes was altered in cells lacking GSK-3 activity. While
IκBα mRNA levels were unaffected, interleukin 6 expression was greatly diminished. Con-
versely, TNFα or LPS stimulation resulted in increased CXCL1 and MCP-1 expression after
loss of GSK-3 activity. Conclusions: Based on these data, we suggest that GSK-3 proteins
regulate cytokine and TLR-mediated gene expression in IECs. Furthermore, transcriptional
control of these genes appears to be highly promoter specific. These data and our previous
work support the concept of an important function of GSK-3 in modulating NF-κB and
AP-1 function that may be especially relevant to intestinal inflammatory diseases.
W1675
Transcriptional Regulation of Adenosine 2b Receptor By IL-6
Vasantha L. Kolachala, Tracy S. Obertone, Brittani Kridler, Adel Driss, Lixin Wang, Didier
Merlin, Shanthi V. Sitaraman
Background and Significance: We have previously shown that adenosine, generated during
intestinal inflammation through neutrophil-epithelial cross-talk, induces transcriptionally-
mediated synthesis of IL-6 by intestinal epithelial cells. We also demonstrated that IL-6
receptors are present basolaterally in intestinal epithelial cells and IL-6 induces the activation
of NF-kB and STAT signaling in epithelial cells. In this study we addressed the effects of
IL-6 on the regulation of epithelial adenosine 2b receptor (A2bR). Methods: Model colonic
epithelial cells, T84, were stimulated with IL-6 (100 ng/ml, basolateral). Homo sapiens
chromosome 17S was obtained from a PAC library (P1 derived artificial chromosome) clone
and PCR was performed to obtain a 1.4-kb fragment upstream of A2bR coding region which
was subsequently cloned into a pGL3 luciferase vector. The luciferase vector containing
insert was transfected into COS7 cells. 72 hours after transfection the luciferase activity was
measured. The transcription start site was determined using rapid amplification of cDNA
ends (RACE). The potential regulatory elements within the promoter region were identified
by sequence analysis and by transcriptional element search system. Results: Pretreatment of
intestinal epithelial cells with IL-6 increased A2b receptor mRNA (two-fold) and protein
expression (66% increase). The increase in IL-6-induced A2bR mRNA was seen starting at
2 hours and protein levels were increased after 12 hours of pretreatment with IL-6. In
order to further understand the transcriptional regulation of A2bR by IL-6, we cloned and
characterized the 1.4kb 5’ flanking region of the human A2bR gene. The transcriptional
start site was seen at 119 bp upstream of the translational start site. There were multiple
IL-6 response element binding sites (IL-6 RE-BP) as well as STAT binding site in the A2bR
promoter. Transfection of COS-7 with the A2bR promoter resulted in 6-fold increase in
activity. Deletion and mutation studies are ongoing in the laboratory. Conclusions: We
demonstrate that IL-6 induces a transcriptionally regulated synthesis of A2bR, likely through
activation of IL-6RE-BP/STAT sites in the A2bR promoter. Along with our previous observa-
tion that IL-6 is induced by adenosine in epithelial cells, these data suggest autocrine
regulation of A2b receptor by the epithelial-derived IL-6.
W1676
SP1 and SP3 Mediate the Effects of Histone Deacetylase Inhibitor, TSA, On
the Induction of the Human NHE3 Promoter Activity in C2BBE1 Cells
Jaleh Malakooti, Leda Ghannad, Ricardo Sandoval, Pradeep K. Dudeja, Krishnamurthy
Ramaswamy
NHE3 is the major Na+/H+ exchanger isoform in the ileum where it plays a critical role in
Na+ and water absorption. Previous reports indicate that sodium butyrate and trichostatin
A (TSA), two histone deacetylase inhibitors, enhance the NHE3 mRNA expression and
transport activity both in vivo and in vitro. However, the mediators of these effects are poorly
understood. To examine the molecular events involved in these processes, we investigated the
effect of TSA, a specific histone deacetylase, on the transcriptional regulation of the human
NHE3 promoter. Transient transfection of a series of 5’-deletion NHE3 promoter-luciferase
constructs in C2BBe1 cells revealed that the TSA-responsive element is located in a GC-
rich region ~85 bp upstream from transcription initiation site. The promoter construct
containing the TSA-response element showed a 4-fold increase in reporter gene activity,
subsequent to exposure to TSA (100 ng/ml and 24 h). In gel mobility shift assays, transcription
factors Sp1, Sp3 and AP-2α bind to the GC-rich sequence and co-transfection with the Sp1
and Sp3 expression vectors elevate the NHE3 promoter activity in SL2 cells. However,
neither the protein expression level nor DNA binding affinity of Sp1 and Sp3 were affected
by TSA treatment as judged by Western blot analysis and GMSA. Mutational analyses
confirmed that the TSA response element coincides with the GC-box in the core promoter
region, as deletions or point mutations of the Sp1/Sp3 and AP-2 binding sites reduced the
basal and TSA-stimulated NHE3 promoter activity. P300, an acetyltransferase, has been
shown to function with both Sp1 and Sp3 in GC-box-dependent transcription. Therefore,
we examined the transactivation property of a P300 expression vector on the NHE3 core
promoter containing the GC-box in C2BBe1 cells. These results showed that transfection
of P300 expression vector enhanced the NHE3 promoter activity in a dose-dependent
manner, with maximum activity of ~4-fold in the highest concentration of the P300 expression
construct. Thus the TSA-responsive GC-box is also involved in mediating the functional
effect of P300. In conclusion, induction of NHE3 expression by TSA appears to be mediated



















Sodium Butyrate Increases Human NHE3 Gene Expression Via Sp1/Sp3
Transcription Factors and Blocks the Repressive Effects of IFN-γ and TNF-α in
C2BBE1 Cells
Md Ruhul Amin, Jaleh Malakooti, Pradeep K. Dudeja, Krishnamurthy Ramaswamy
Diarrhea associated with inflammatory bowel disease has been attributed to stimulated
secretion of pro-inflammatory cytokines like IFN-γ and TNF-α, which have been shown to
down-regulate the expression of the sodium hydrogen exchanger3 (NHE3) gene. NHE3
isoform is localized to the apical pole of the intestinal epithelial cells where it plays a major
role in regulating water and sodium ion absorption. Previously, we have shown that IFN-
γ and TNF-α down-regulate the expression of the human NHE3 gene by phosphorylating
Sp1 and Sp3 transcription factors in C2BBe1 cells. It is known that sodium butyrate (NaB)
stimulates NHE3 gene expression in intestinal cells, and this stimulation is mediated by PKA.
However, further details of the mechanisms how NaB up-regulates NHE3 gene expression are
not known. In this study, we have investigated the mechanisms involved in up-regulation
of NHE3 gene expression by NaB and its effect on the down-regulation of NHE3 gene by
combined IFN-γ (30 ng/ml) and TNF-α (20 ng/ml) treatment. In transient transfection
studies, NaB (5 mM) led to ~ 10-fold stimulation of NHE3 promoter activity after incubation
for 24 hours. Using 5′-deletion constructs, the NaB responsive region was mapped to the
NHE3 core promoter region (-95 to + 5), which contains a number of cis-elements including
Sp1 binding sites and mediates the repressive effects of IFN-γ and TNF-α on the NHE3
promoter. The stimulatory effect of NaB on the NHE3 promoter was reduced by 60% in
the presence of these cytokines. Gel mobility shift assays with nuclear proteins from NaB
or cytokine-treated cells showed enhanced and diminished binding of Sp1 and Sp3 to the
NHE3 promoter, respectively, compared to control. The stimulatory effect of NaB on the
NHE3 promoter was partially blocked by phosphatase inhibitors, Fostriecin (100 nM) and
Okadaic acid (200 nM) in transient transfection assays. NaB or cytokine treatment showed
no effect on Sp1 and Sp3 mRNA and protein expression as assessed by RT-PCR and
Western blot analyses. In conclusion, our data suggest that NaB treatment may result in
dephosphorylation of Sp1 and Sp3 proteins leading to their increased affinity for binding
to the NHE3 promoter in C2BBe1 cells and resulting in increased transcription of NHE3.
W1678
Human Gene Transcriptional Activation By Vitamin D Studied in Small
Intestinal Endoscopic Biopsies in short Term Culture
Sonia Sangha, Sara Balesaria, Julian R. Walters
Background: Knowledge of the regulation of gene expression in the human small intestine
has been impaired by the lack of a suitable differentiated cell-line. Differences may exist
when compared with animal model systems. Consequently we aimed to develop a human
small intestinal explant system which could be used to determine transcriptional regulation
of gene expression. Changes in expression of calcium transport genes were studied in
response to the active hormonal form of vitamin D, 1,25(OH)2D3. Methods: Volunteers
undergoing diagnostic upper endoscopy were recruited after giving informed consent for
studies, approved by the local research ethics committee. Subjects with various specific
disorders were not included. After diagnostic biopsies had been obtained, 8-10 additional
duodenal mucosal biopsies were taken and placed in pre-oxygenated tissue culture medium.
Biopsies in groups of 2-4 were placed on microporous membrane inserts and incubated in
tissue culture medium with either hormone or vehicle control. After culture, biopsies were
placed in RNAlater and then stored frozen. RNA and cDNA were prepared using standard
methodology. Real-time quantitative RT-PCR (Taqman) was used to assay gene expression,
which was standardized to expression of the housekeeping gene, GAPDH. Results: Experi-
ments were performed after 6h exposure to 1,25(OH)2D3 (10-9M), or control. The expression
of transcripts for the brush-border membrane calcium channel, TRPV6, increased significantly
(p<0.001, Wilcoxon signed rank test; TRPV6/GAPDH ratios 1.50±0.21 (mean ±SEM) in
controls, and 5.38±1.00 in the treated group). 29 out of 30 subjects showed an increase;
the median change in expression ratios was 3.10. Similar changes occurred in men and
women and were not related to age. Transcripts for the basolateral calcium-pumping ATPase,
PMCA1, increased significantly (p<0.02, median change 1.34) but the cytoplasmic calcium
binding protein, calbindin-D9k, did not change significantly. Sucrase transcripts were also
unaffected. Conclusion: A robust human small intestinal explant system has been developed.
This was able to show a marked increase by 6h in expression of transcripts for the TRPV6
calcium transporter and PMCA1 with physiological doses of 1,25(OH)2D3. It has the potential
to study other agents that may regulate gene expression including other hormones and drugs.
W1679
MDP-Mediated Activation of NALP3/NOD2 Cooperates with Tlr2 in Secretion
of IL-8 in Intestinal Epithelial Cells
Tatjana Eigenbrod, Johann Federhofer, Christian Huy, Manuela Gunckel, Julia Brenmoehl,
Werner Falk, Juergen Schoelmerich, Gerhard Rogler
Background: The NODs and the NALPs are members of the NLR family of cytoplasmic
pattern recognition receptors (PRRs) which are involved in activation of the innate immune
system. Mutations of NALPs and NODs are associated with inflammatory diseases. To date,
14 different NALPs have been identified. Activation of NALP1 and NALP2/3 finally results
in assembly of the ‘inflammasome’, a multiprotein platform which mediates the autocatalytic
cleavage of the inflammatory caspases-1 and -5. Subsequently, the active caspases induce
proteolytic cleavage and maturation of IL-1b and IL-18. While most NALP ligands are still
unknown, Muramyldipeptid (MDP) has only recently been identified as a ligand for NALP3.
MDP is also known to activate NOD2, resulting in NF-kB mediated production of IL-8 and
pro-IL-1b. Therefore, NOD2 and NALP3 might be coworkers for the induction of innate
immune responses. Furthermore, a synergistic as well as an antagonistic cross-talk of MDP-
mediated signalling and TLR2-signalling has been reported in monocytic cells but has not
yet been investigated in intestinal epithelial cells (IEC). Methods: Expression patterns of
NALP 2-14 were assessed in different epithelial cell lines (Caco-2, HT29, SW480, T84) and
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in primary IEC from inflamed and noninflamed mucosa by quantitative Taqman PCR.
Primary IEC isolated from noninflamed mucosa were stimulated with varying concentrations
of MDP and/or Pam3Cys, a synthetic TLR2 ligand, and IL-8 was measured in the supernatant.
Results: NALP7 was not detected in any cell type and NALP5 was not expressed in Caco-
2 and HT29. NALP12 was only expressed in SW480 and in T84. The other investigated
NALPs were detected in all tested cell types. The highest expression of NALP2 was observed
in Caco-2 (4- to 64-fold higher than in the other tested cells), whereas all other NALPs
were in average 4- to 32-fold higher expressed in primary IEC than in the investigated cell
lines. Primary IEC isolated from inflamed mucosa did not show an upregulation of NALP
mRNA. Stimulation of primary IEC with MDP or Pam3Cys resulted in a dose-dependent
secretion of IL-8. In order to investigate a potential cross-talk of NALP3/NOD2- and TLR2-
signalling, cells were simultaneously stimulated with MDP and Pam3Cys in varying concen-
trations. In these co-stimulation experiments, a synergistic effect of MDP- and Pam3Cys-
Signalling on IL-8 secretion could be detected. Conclusions: NALPs show different expression
patterns in epithelial cell lines and in primary IEC. Activation of the NALP3/NOD2 signalling
pathway by MDP cooperates with TLR2-mediated induction of proinflammatory cytokine
IL-8 in primary IEC.
W1680
Monocyte Chemotactic Protein-1 Polymorphism Is Associated with Acute
Recurrent Pancreatitis
Giulia M. Cavestro, Simone Bertolini, Stefano Okolicsanyi, Giuliana Sereni, Luca Frulloni,
Lucas Cavallaro, Elena Masselli, Alessandra Protti, Paolo Del Rio, Paola Zanelli, Mario
Sianesi, Giorgio Cavallini, Angelo Franze, Francesco Di Mario
Pancreatitis is associated with an intense inflammatory response. Monocyte chemotactic
protein-1 (MCP-1) is a chemokine that plays a central role establishing and maintainig the
inflammatory process. Polymorphism -2518 G of the regulatory region of monocyte MCP1
affects the level of expression of this chemokine increasing the inflammatory response. Aim:
To determine wether: 1)MCP1 2518 G allele is associated with the severity of acute pancreat-
itis (AP) 2)MCP1 2518 G polymorphism is associated to acute recurrent pancreatitis (ARP)
Patients amd Methods: Determination of MCP1 2518 G polymorphism was achieved by
PCR/RFLP in 93 patients affected from a single episode of biliary AP (61.3% M); 63 patients
affected from ARP (58.7% M) and 73 healthy controls of the same ethnical group (56.3%
M). The severity of AP and ARP was based upon the Atlanta criteria: 119 patients had mild
pancreatitis (76.3%), 37 had severe pancreatitis (25.7%). MCP1 2518 G polymorphism is
associated with ARP (Fisher’s exact test,p=0.005,OR=2.97,CI=[1.38-5.21]). Table 1 shows the
heterozygous polymorphism of MCP1 (A/G) was found in 32 ARPs (50.8%); the homozygous
polyomorphism (G/G) was found in 6 ARPs (9.5%) and 25 ARPs did not present the G
allele (A/A; 39.7%). 45 APs (48.4%) were found A/G positive; 1 AP (1.1%) was G/G positive
and 43 APs did not present the G allele (50.5%). In control group, 21 subjects (28.8%)
were positive for A/G genotype; G/G genotype was found in 5 controls (6.8%) and 47
subjects did not present the G allele (64.4%). No association was observed between MCP1
G polymorphism and AP (p=0.27). No association between MCP1 G polymorphism and
severity of AP was detected (p=0.9): table 2 shows A/G genotype was found in 60 mild APs
(50.4%); G/G was found in 5 mild APs (4.2%) and 54 mild APs did not present the G allele
(45.4%). A/G genotype was found in 17 severe APs (45.9%); G/G was found in 2 severe
APs (5.4%) and 18 severe APs did not present the G allele (48.6%). MCP-1 polymorphism
is associated with ARP. This polymorphism could increase the inflammatory response leading
to a recurrence of the disease and possibly to chronic pancreatitis.
Table 1: MCP genotype in Acute Pancreatitis (AP) and Acute Recurrent Pancreatitis (ARP)
MCP genotype in Mild Acute Pancreatitis (AP) and Severe Acute Pancreatitis (ARP)
W1681
Activated Protein C Up-Regulates TM and EPCR Expression to Attenuates the
Severity of Severe Acute Pancreatitis in Rats
Ping Chen, Yaozong Yuan, Yongping Zhang, Mingming Qiao
Aim & backgroud: The protein C pathways were recognized for their role in regulating
thrombin activity and generation, but they were increasingly understood to have diverse
regulatory functions in inflammation. However, the exact of mechanisms of which remained
unclear in severe acute pancreatitis (SAP). The aim of our studies was the investigation of
the effect of pre-treatment activated protein C (APC) on endothelial protein C receptor
(EPCR) and thrombomodulin (TM) expressions to expose the mechanisms of attenuating
the severity of SAP in rats. Methods: Sixty SD rats were randomly allocated four groups as
follows: In SAP group, rats were retrograde infused with 5% sodium taurocholate (1.5 ml/
kg) into the pancreatic duct to stimulate severe acute pancreatitis (n = 20); In treatment
groups, rats were received different dose of APC just before the induction of SAP (50 ug/
kg, 10 ug/kg, n = 15, i. v., respectively); In control group, rats only given sham operation
(n = 10). Blood sample and pancreatic tissue were harvested at 16 hours after the onset of
induction. The severity of pancreatitis was evaluated by histological scoring, serum amylase
level and pancreatic dry/wet weight ratio. RT-PCR was performed to quantify the intrapancre-
atic EPCR, TM and matrix metalloproteinase 9 (MMP-9) mRNA levels. The protein expression
of EPCR, TM and MMP-9 were investigated by the method of western blotting. Meanwhile,
immunohistochemistry located pancreatic EPCR and TM expression and was performed
semi-quantitive analysis. Serum TNF-α and IL-8 levels were determined by ELISA Results:
The expression of pancreatic tissue MMP-9 at mRNA and protein levels were significantly
reduced in high-dose and low-dose groups compared to SAP group (p < 0.01 or < 0.05,
respectively). Meanwhile, serum TNF-α and IL-8 levels showed significant decrease in the
treatment groups (p < 0.01). On the other hand, the expression of intrapancreatitic EPCR
or TM at mRNA and protein levels were significantly up-regulated in treatment groups
compared with those in SAP group and control group (p < 0.01 or < 0.05, respectively).
Histological scoring, serum amylase level and pancreatic dry/wet weight ratio in treatment
groups were also decreased in comparison with SAP group (p < 0.01). Conclusion: The
finding suggested that APC up-regulated EPCR and TM expression by suppressed the
expression of MMP-9 and decreased the release of TNF-α and IL-8. We speculate that the
administration of exogenous APC in induction of SAP could augment the anti-coagulation
and anti-inflammatory activity of the protein C pathways, and could attenuate the following
pancreatitic damage.
W1682
Involvement of Endogenous Growth Hormone and Insulin-Like Growth Factor-
1 in the Protective Effect of Ghrelin in Necrotizing Acute Pancreatitis
Zygmunt Warzecha, Artur Dembinski, Piotr Ceranowicz, Wieslaw W. Pawlik, Ryszard
Sendur, Romana Tomaszewska, Beata Kusnierz-Cabala, Jerzy Naskalski, Peter C.
Konturek, Atsukazu Kuwahara, Ikuo Kato
Background: Ghrelin, an endogenous ligand for the growth hormone secretagogue receptor,
was primary isolated from the human and rat stomach. It stimulates growth hormone
secretion, food intake and exhibits gastroprotective properties. In the previous study, we
have shown the protective effect of ghrelin against edematous caerulein-induced pancreatitis.
This study has been undertaken to check whether ghrelin administration protects the pancreas
against ischemia/reperfusion-induced necrotizing pancreatitis and, if so, what is the role of
growth hormone (GH) and insulin-like growth factor-1 (IGF-1) in this effect. Methods: Two
weeks after sham-operation or hypophysectomy, acute pancreatitis was induced in Wistar
rats by clamping of inferior splenic artery for 30 min followed by reperfusion. Ghrelin was
administered twice (30 min prior to start of ischemia and after next 3 h) at the doses: 4, 8
or 16 nmol/kg/dose. After 6-h reperfusion animals were sacrificed. Results: In rats with
intact pituitary, treatment with ghrelin increased serum level of ghrelin and attenuated
the development of ischemia/reperfusion-induced pancreatitis, what was demonstrated in
histological examination as the reduction in pancreatic edema, inflammatory infiltration,
necrosis, hemorrhages and the decrease in vacuolization of pancreatic acinar cells. Also,
ghrelin administration decreased the activity of lipase and poly-C ribonuclease, and concen-
tration of pro-inflammatory IL-1 in the serum, whereas the pancreatitis-evoked fall in
pancreatic DNA synthesis was partly reversed. Treatment with ghrelin was without effect
on serum level of anti-inflammatory IL-10 and the pancreatitis-related fall of pancreatic
blood flow. Ischemia/reperfusion-induced pancreatitis strongly reduced serum concentration
of GH and IGF-1, and ghrelin administration reversed this effect. Ghrelin at the dose 8
nmol/kg exhibited maximal beneficial effect. Hypophysectomy lowered serum concentration
of growth hormone under the detection limit and reduced serum level of IGF-1 by 90%,
but increased serum level of ghrelin. These effects were associated with augmentation of
pancreatic damage after induction of acute pancreatitis. Administration of ghrelin was without
significant effect on the pancreatic damage evoked by ischemia/reperfusion-induced pancreat-
itis in hypophysectomized rats. Conclusions: (1) Administration of ghrelin attenuates pancre-
atic damage evoked by ischemia/reperfusion-induced pancreatitis; (2) Protective effect of
ghrelin administration on the pancreas is related to its action on the pituitary and the release
of GH and IGF-1.
W1683
Protective Effects of Vascular Endothelial Growth Factor On Intestinal
Epithelial Cell Apoptosis and Endotoxin/Bacterial Translocation in
Experimental Severe Acute Pancreatitis
Takahiro Nakajima, Takashi Ueda, Yoshifumi Takeyama, Takeo Yasuda, Hidehiro Sawa,
Yoshikazu Kuroda
Background and Aim: Endotoxin/bacterial translocation (E/BT) plays an important role for
systemic complications in severe acute pancreatitis (SAP). Breakdown of intestinal integrity
is considered to be implicated in E/BT. We recently demonstrated that accelerated apoptosis
of intestinal mucosa may be participated in E/BT. On the other hand, vascular endothelial
growth factor (VEGF) is a glycoprotein with potent angiogenic, mitogenic and vascular
permeability-enhancing activities specific for endothelial cells. We recently reported that
serum VEGF levels are significantly elevated in patients with SAP, and that VEGF functions
as a protective factor via an antiapoptotic effect against the renal and liver injuries in rat
experimental SAP. This study aimed to investigate effects of VEGF on intestinal epithelial
cell apoptosis and E/BT in experimental SAP. Methods: Male Wistar rats weighing 250-300
g were used. Only laparotomy was performed in sham-operated rats (Sham group). Severe
hemorrhagic necrotizing pancreatitis was induced by retrograde injection of 3% sodium
deoxycholate into the biliopancreatic duct (SAP group). Recombinant rat VEGF (2 μg/ml,
1ml) was injected from jugular vein, and immediately SAP was induced as described above
(VEGF+SAP group). Eight hours after induction of SAP, serum amylase and lipase levels
were measured, and apoptosis of ileal mucosa was evaluated biochemically by DNA frag-
mentation ELISA and histochemically by TUNEL staining. After 18 hours, histological
examination of the terminal ileum was conducted by HE staining, and villous height and
crypt depth were measured. Furthermore, blood endotoxin level was determined, and
bacterial culture of the mesenteric lymph nodes was examined. Results: Eight hours after
induction of SAP, serum amylase and lipase levels were significantly elevated in SAP group
than those in Sham group. VEGF did not affect them. Apoptosis of ileal mucosa was
accelerated in SAP group compared with Sham group. VEGF significantly improved the
increasing apoptosis. Eighteen hours after induction of SAP, villous height and crypt depth
were significantly lower in SAP group than that in Sham group. VEGF significantly improved
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them. Blood endotoxin levels were significantly elevated and bacterial translocation occurred
in SAP group. VEGF significantly improved the elevation of blood endotoxin and prevented
the bacterial translocation. Conclusion: These results suggest that breakdown of intestinal
mucosa via accelerated apoptosis causes E/BT in SAP, and that VEGF inhibits intestinal
epithelial cell apoptosis and following E/BT.
W1684
Galanin Antagonism Reduces Hyperenzymemia Associated with Acute
Pancreatitis (AP) in a Possum Model
Mayank Bhandari, Anthony C. Thomas, Colin J. Carati, Masahiko Kawamoto, Mark
Brook-Smith, James Toouli, Gino Saccone
Background/Aim: Severe AP is associated with significant morbidity and mortality, and is
characterized by microcirculatory and secretory disturbances, leading to pancreatic necrosis
and plasma hyperenzymemia. To date, there is no specific treatment for AP. We have shown
that the neurotransmitter galanin (GAL) is abundant in the pancreas of the Australian possum,
and affects pancreatic vascular perfusion. In this study, we investigated the effect of GAL,
and its antagonist galantide (GT) on plasma enzymes, in an AP possum model. Methods:
AP was induced in anaesthetized possums by pancreatic duct ligation and simultaneous
hyperstimulation with i.v. cholecystokinin and secretin for 6h. In separate experimental
groups (n=5-10), GAL (1-10nmol/h) or GT (3-30nmol/h) was administered as bolus injections
15min prior to duct ligation followed by a continuous i.v. infusion for the duration of
experiment (prophylactic dose). In order to simulate a clinical situation, GT was also adminis-
tered 2h post AP onset (therapeutic dose) in separate animals. Blood was collected hourly
for 8h and analyzed for plasma lipase and amylase activity. The pancreas was harvested at
the end of the experiment (8h) for histological assessment. Statistical analysis used ANOVA.
Results: AP was associated with significantly increased plasma lipase which reached a plateau
at 3h (Figure). This change was exacerbated by prophylactic GAL and significantly amelior-
ated by prophylactic GT. At 8h therapeutic GT also significantly reduced the plasma lipase
activity (mean±SE, 589±54 IU) compared with the AP group (mean±SE, 942±71 IU). Statistic-
ally significant similar effects were noted for plasma amylase levels (P<0.05). Conclusion:
Prophylactic and therapeutic administration of GT significantly decreased the plasma lipase
and amylase levels, perhaps by ameliorating the severity of AP. Ongoing histological studies
are assessing the effect of GT on pancreatic necrosis in AP.
W1685
Pseudorabies Virus Infection Stimulates Pancreatic Ductal HCO3- Secretion
Viktoria Venglovecz, Zoltan Rakonczay, Balazs Ordogh, Tamas Takacs, Janos Lonovics,
Annamaria Szabolcs, Andras Varro, Andras Toth, Gyula J. Papp, Mike A. Gray, Barry E.
Argent, Zsolt Boldogkoi, Peter Hegyi
Background. We have previously shown that hypersecretion can be observed during the
early phase of experimental oedematic and necrotizing pancreatitis. However, the source
and the role of hypersecretion are unknown. Several viruses have been reported to cause
acute pancreatitis, but we have no information concerning the effect of viral infection on
pancreatic secretion. Our aim in this study was to examine the effect of acute infection
caused by a herpesvirus (pseudorabies virus; PRV) on pancreatic ductal secretion. Methods.
Ba-DupGreen (BDG), a genetically modified replicating strain of PRV was used in this study.
The green fluorescent protein (GFP) gene was inserted into the PRV antisense promoter
region located in the inverted repeat segment of the virus. Small intra/interlobular ducts
were isolated from the pancreas of guinea pigs. Ducts were incubated in McCoy’s based
culture medium containing BDG virus (107 plaque forming units/ml) for 6 hours, while
the control ducts were incubated only with the culture media. The ducts were then cultured
for further 18 hours. The rate of HCO3- secretion was determined as described earlier
(Hegyi et al. Am J Physiol Cell Physiol 285:C268-C276, 2003). All the experiments were
performed in HCO3--buffered Ringer solution at 37oC. Viral structural proteins were visual-
ized by immunohistochemistry. Native GFP expression and immunofluorescence signals
were recorded by a confocal laser scanning microscope. Results and Conclusions. The virus
infected all accessible epithelial cells of the duct as judged by the appearance of GFP and
viral antigens in the ductal cells. PRV infection stimulated ductal HCO3- secretion about
4-5-fold after 24h. We suggest that this response of pancreatic ducts to PRV infection could
represent a defence mechanism against invasive pathogens to avoid pancreatic injury. This


















Arginine Induced Oxidative Stress Is Required for the Initiation of
Endoplasmic Reticulum Stress Signaling and Acute Pancreatitis in Rats
Constanze H. Kubisch, Thiruvengadam Arumugam, Craig D. Logsdon
Background: We previously found that all major ER stress signalling pathways are activated
early in arginine induced acute pancreatitis. In the current study, we investigated the
mechanisms involved in this response and the relationship between the extent of ER stress
and disease severity. Methods: Pancreatitis was induced in rats by ip injection of 4.0g/kg
bw arginine. Pancreatitis severity was assessed by analysis of serum amylase, pancreatic
trypsin activity, water content and histology. ER stress related molecules PERK, XBP-1 were
analyzed. We examined the influence of the NADPH oxidase inhibitor diphenylene iodonium
(DPI) on ER stress and acute pancreatitis. Results: Arginine treatment induced pancreatitis,
as indicated by increased serum amylase, pancreatic edema, and acinar cell damage within
4h. Arginine treatment also activated ER stress, as shown by phosphorylation of PERK (268%
increase after 4h) and XBP-1 splicing (152% increase after 24h). Inhibition of NADPH
oxidase by DPI profoundly inhibited the activation of ER stress mechanisms. PERK phos-
phorylation was inhibited by 60% at 4h and 55% at the 24h. XBP-1 splicing which occurred
later was reduced by 49% at 24h. The development of acute pancreatitis was also significantly
reduced by NADPH inhibitor treatment. Serum amylase levels were reduced by 54% and
66% and tissue water content was reduced by 9% and 14% after 4 and 24h, respectively.
Moreover, treatment with NADPH inhibitor dramatically reduced pancreatic histological
damage. Conclusions: These results indicate that inhibition of the oxidative stress mechanisms
involving NADPH oxidase prevent arginine induced ER stress and acute pancreatitis. These
data are consistent with a model in which arginine causes oxidative stress leading to ER
stress and subsequent acute pancreatitis.
W1687
Effect of SiRNA Mediated Gene Knockdown of Pancreatitis-Associated Protein
(PAP) in Experimental Pancreatitis
Yin Yao Lin, Martin Bluth, Albert Stanek, Hazal Drew, Tamar A. Smith-Norowitz,
Domenico Viterbo, Cathy M. Mueller, Michael E. Zenilman
Background: The pancreatitis-associated protein (PAP) family of genes is induced in acute
pancreatitis. We have previously demonstrated that antisense mediated gene knockdown of
PAP in vivo decreased PAP gene expression and worsened pancreatitis. Here we investigated
the effect of a more specific inhibition of PAP using siRNA gene knockdown using in vitro
and in vivo models of experimental pancreatitis Methods: In vitro, pancreatic acinar cell
line, AR42J, was cultured with IL6 and dexamethasone (IL6/dex) to induce expression of
PAP. Following transfection of siRNA into stimulated AR42J cells, culture supernatants were
analyzed for amylase and lipase levels at 12, 24, and 48 hr. In vivo, acute pancreatitis was
induced in Sprague Dawley rats by retrograde infusion of 4% sodium taurocholate (NaT)
into the pancreatic duct with subsequent subcapsular administration of PAP specific siRNA.
Controls included administration of scrambled siRNA (scRNA) or vehicle alone. After 24hr,
pancreata were harvested and assessed for worsening pancreatitis by histopathology; serum
was analyzed for PAP (ELISA), amylase and lipase protein levels. In both models endogenous
PAP (PAPI, PAPII, PAPIII) gene expression was assessed at 24 hrs using real time RT-PCR.
Data are presented as mean +SEM, p<0.05, Student’s t-test. Results: In vitro, PAP isoform
(PAPI, PAPII, PAPIII) mRNA expression was reduced (PAPI: 76%, PAPII: 8%, PAPIII: 24%)
in cells treated with PAP siRNA when compared with controls. Amylase and lipase levels
were also reduced at all time points (23%+7, 36%+8, respectively) in cells treated with PAP
siRNA when compared with controls. In vivo, induction of pancreatitis was confirmed by
histopathology, serum amylase and lipase levels. PAP isoforms expression was reduced (PAPI:
36%, PAPII: 49%, PAPIII: 66%) in siRNA treated rats, compared with controls. However,
serum PAP protein levels were similar between siRNA and control groups. Serum amylase
levels decreased after administration of PAP siRNA compared with vehicle control (3013+317
U/L vs. 1583 +312.U/L) (p<0.05). In addition, serum lipase levels decreased after administra-
tion of PAP siRNA compared with vehicle control (478+125 U/L vs. 162 +42 U/L; p=0.08).
There was a trend of less tissue damage (histopathology) with siRNA administration compared
with controls (p=0.06). Conclusions: siRNA mediated gene knockdown of PAP appeared to
improve pancreatitis severity and demonstrated an opposite effect of antisense gene knock-
down. This observed difference may be due to increased specificity, transfection stability,
and/or different mechanisms of action for siRNA gene knockdown compared with anti-
sense technology.
W1688
Role of MCP-1 On the Blood Brain Barrier Permeability Increase in Rats with
Pancreatitis
Zhen Ding, Rong Lin, Wei Qian, Xiaohua Hou
Background & Aims: Monocyte chemotactic protein-1(MCP-1) is known as a kind of Chemo-
kine which can attract leukocytes especially monocyte and T cell. Our aim was to value the
relationship between the expression of MCP-1 and the increase of blood brain barrier (BBB)
permeability in the rats which had been induced experimental pancreatitis. Methods: Male
Wistar rats were divided 8 groups in terms of sampling time and the grade of acute
pancreatitis, including control group, mild acute pancreatitis (MAP, 2- and 6-h group),
severe acute pancreatitis (SAP, 2-, 6-, 12-, 24- and 48-hour group). Each group had 6 rats.
Acute pancreatitis was induced by intrapancreatic ductal injection of choleate sodium, which
concentration was 0.5% and 5% in inducing MAP and SAP respectively. Immunohistochem-
istry straining was used to detect the expression of MCP-1 in rats’ pancreas and brain. Evans’
blue was a matter to detect the permeability of BBB. Result: (1) There were no significant
increases in BBB permeability in rats with MAP than in control rats (MAP 2h 1.67±0.13
mg/dl vs. 1.54±0.25 mg/dl p=0.389; MAP 6h 1.71±0.13 mg/dl vs. 1.54±0.25 mg/dl p=
0.205). (2) BBB permeability was increased in all of SAP rats (SAP2h 1.97±0.17; SAP6h
2.75±0.15; SAP12h 2.95±0.45; SAP24 3.24±0.23; SAP48h 1.86±0.09). However, in the
comparison of group SAP2h and SAP48h, it was much higher in groups SAP6h, SAP12h,
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and SAP24. (3) MCP-1 expressed in all SAP groups in brains, but there was no MCP-1
expression in controls and MAP rats. Conclusion: BBB permeability is significantly increased
in SAP rats and this change is time dependent, but no change in MAP rats. At the same
time, MCP-1 expressed in the brain only in SAP group. Therefore, MCP-1 expression may
be an early event in the pathogenesis of pancreatic encephalopathy and play an important
role in the increasing of BBB permeability because of its ability of attracting leukocytes.
W1689
Oral Administration of a Pancreatic- and Neutrophil- Elastase Inhibitor
(ZD0892) Ameliorates Caerulein Induced Pancreatitis
Julia Mayerle, Manuel Ruthenbuerger, Frank-Ulrich Weiss, Walther Halangk, Markus M.
Lerch
Introduction: Circulating serum levels of neutrophil-elastase (PMN-elastase) are known to
correlate with the severity of clinical pancreatitis and are closely associated with the extent
of leukocyte transmigration into inflamed tissue. We tested whether prophylactic administra-
tion of a novel, orally available peptidyl trifluoromethyl ketone inhibitor of PMN-elastase (ZD-
0892), with cross-specificity for pancreatic elastase, can ameliorate experimental pancreatitis.
Methods: Male Wistar rats (250-300gr) received gavage tube feeding of ZD-0892 (at a dose
of 240 mg/kg per day) at 3h and 1h before the induction of acute caerulein pancreatitis for
4 and 12 hrs. Pancreatic and lung tissue as well as serum were collected for further analysis
of clinical and morphological severity markers. Isolated pancreatic acini were incubated with
ZD-0892 and protease activity after supramaximal caerulein stimulation was monitored
employing specific fluorogenic substrates for trypsin, elastase, cathepsin B and cathepsin L.
Results: Oral administration of the elastase inhibitor ZD-0892 significantly reduced the
serum level of amylase, the extent of pancreatic edema, as well as leukocyte infiltration in
the pancreas and lungs during caerulein-induced pancreatitis. Incubation of isolated pancre-
atic acini with ZD-0892 and subsequent supramaximal CCK stimulation reduced pancreatic
elastase activity to below 20%, whereas neither trypsin, nor cathepsin B nor cathepsin L
activity were affected. Conclusion: Prophylactic administration of a novel, orally available
PMN-elastase inhibitor with cross-specificity for pancreatic elastase improves the severity of
acute experimental pancreatitis. ZD-0892 therefore represents the first orally active drug
with treatment potential for patients at risk of developing pancreatitis such as those before
ERCP, those with exogenous risk factors (e.g. ethanol abuse) and those with inherited predis-
positions.
W1690
Description and Characterization of An Experimental Model of Severe Acute
Pancreatitis in Mice Induced By Infusing Na-Taurocholate Into the Pancreatic
Duct
Gijs J. Van Acker, Eric R. Weiss, Michael L. Steer, George Perides
Background/Aim: The availability of genetically modified mouse strains makes that species
an ideal candidate for mechanistic pancreatitis studies but, unfortunately, clinically relevant
models of pancreatitis in mice have not been described. Rather, the current mouse models
depend upon supramaximal secretagogue stimulation with caerulein, exposure to toxic doses
of arginine, or administration of a choline-deficient ethionine-supplemented diet. Since
clinical pancreatitis is not triggered by these events, the clinical relevance of each of these
models has been questioned. We now describe techniques which have enabled us to adapt
the well-described rat model of bile salt-induced biliary pancreatitis for studies involving
mice. Methods: Following hilar occlusion of the bile duct, the pancreatico-biliary duct was
cannulated with a 30G needle passed trans-duodenally. A 0-5% Na-taurocholate/saline
solution (10-50µl) was infused into the duct at a rate of 1-5µl/min. The needle was removed
and, in some animals, the duct was ligated. The animals were returned to their cages, given
water ad libitum, and sacrificed at intervals of up to 24 hours. Pancreatitis severity was
evaluated histologically. Results: Infusion of saline alone did not cause histologic changes
of pancreatitis but it did cause mild, transient pancreatic edema. In contrast, infusion of
saline followed by duct ligation for 24 h resulted in mild pancreatic injury and inflammation.
Infusion of Na-taurocholate in the absence of duct ligation caused extensive pancreatic
necrosis and inflammation and the severity of that pancreatitis was directly related to the
volume of the infusion as well as the concentration of Na-taurocholate being infused. Ligation
of the pancreatic duct for 24 h after Na-taurocholate infusion markedly worsened the severity
of Na-taurocholate induced pancreatitis. None of the animals died within 24 hours of duct
infusion, with or without duct ligation. Conclusion: We have developed a highly reproducable
mouse model of biliary acute pancreatitis which is induced by retrogradely infusing the
pancreatic duct with Na-taurocholate. The severity of this pancreatitis can be manipulated
by altering the amount of the infusion and the concentration of Na-taurocholate or by
ligating the pancreatic duct. This model will be of great value for studies using genetically
altered mouse strains to probe mechanistic questions regarding pancreatitis. Supported by
NIH grant R01-31396. THIS PRESENTATION, IF GIVEN IN ORAL FORM, WILL BE
ACCOMPANIED BY A VIDEO THAT DEMONSTRATES THE ANATOMICAL LANDMARKS
AND SURGICAL PROCEDURES THAT ARE INVOLVED IN CREATING THIS MODEL.
W1691
Application of Caerulein-Induced Pancreatitis in the Recessive Yellow (e/e)
Mouse Strain Reveals a New Role of Melanocortin 1-Receptor in the
Development of An Acute Inflammation
Tobias Meister, D.R. Wennmann, Thomas Brzoska, Wolfram Domschke, Juergen
Schnekenburger
Introduction: Melanocortin-1-receptors (MC1R) are mainly expressed on melanocytes but
also on the surface of dendritic cells, granulocytes, monocytes and endothelial cells. The
main ligand of MC1R is alpha-melanocyte-stimulating-peptide (a-MSH). It has been shown,
that a-MSH exerts anti-inflammatory properties and that a dysfunction of MC1R increases
the lethal outcome in mice with an experimentally induced colitis. In the present study we
analyzed the course of a caerulein-induced pancreatitis in a mouse strain defective for a
functional MC1R. Materials and methods: Experimental pancreatitis was induced with 7
intraperitoneal injections of caerulein (50µg/kgBW) in wildtype mice and e/e-mice, who
express a truncated MC1R without any biological activity. After this procedure mice were
sacrified. Pancreas, lung and blood serum were taken and standard parameters of pancreatitis
were measured. The severity of pancreatitis was determined by measuring amylase and
trypsin activity in serum and pancreas homogenates by means of fluorometry. Paraffin-
embedded sections of pancreatic tissue were stained with hematoxylin/eosin. The localization
of MC1R was detected by immunofluorescence microscopy using MC1R specific antibodies.
Additionally RNA was purified from pancreas homogenates and isolated acinar cells for
mRNA-expression studies. All animal experiments were in accordance with the guiding
principles of the American Physiological Society. Results: Supramaximal stimulation with
cerulein caused a significant slower increase in serum-amylase activity in e/e-mice compared
to wildtype mice. Trypsin activity in pancreas homogenates was not significantly altered in
cerulein-treated e/e-mice compared to wildtype mice. The analysis of hematoxylin/eosin
stained sections of caerulein-treated wildtype mice showed clear signs of pancreatitis with
typical zymogen-granula, infiltration of macrophages and edematous tissue while caerulein-
treated e/e-animals had only mild signs of pancreatitis. MC1R expression was only detected
in infiltrating leukocytes after supramaximal caerulein stimulation. Conclusions: In contrast
to comparable animal models of acute gastric inflammations the dysfunction of MC1R in
e/e-mice reduced the severity of a caerulein-induced pancreatitis. The fact that a-MSH does
not induce a signalling cascade once bound on MC1R in e/e mice suggests that either a-MSH
has no anti inflammatory function during an acute pancreatitis or that the anti inflammatory
properties must be mediated through other receptors, possibly the MC3R.
W1692
The Systemic Cytokine Response During Experimental Acute Pancreatitis:
Impact of Enteral Probiotics
Harro M. Timmerman, L. Paul van Minnen, Wilco de Jager, Sergey R. Konstantinov,
Femke Lutgendorff, Andre Verheem, Wil Harmsen, Maarten R. Visser, Hauke Smidt, Hein
G. Gooszen, Louis M. Akkermans, Ger T. Rijkers
Background: In the course of severe acute pancreatitis, mortality usually occurs early ( <
1 week) or late ( > 2 weeks). Early mortality is often a consequence of the severe systemic
inflammatory response syndrome (SIRS), whereas late mortality can be attributed to secondary
infection of pancreatic necrosis. Translocation of intestinal microorganisms is primarily held
responsible for infection of pancreatic necrosis during the late phase, but may also contribute
to SIRS in the early phase. Selected probiotic bacteria are able to modulate intestinal flora
and prevent bacterial translocation. Aims of this study were: 1) to correlate plasma levels
of various cytokines and chemokines during early and late phase of pancreatitis with clinical
outcome, and 2) assess the effect of probiotics on cytokine profiles. Materials and methods:
Acute pancreatitis was induced in male Sprague-Dawley rats by intraductal bile salt infusion
(glycodeoxycholate, 15 mM) followed by pancreatic hyperstimulation (intravenous cerulein,
5μg/kg/hr, for 6 hours). Probiotics or placebo were administered daily via a permanent
gastric cannula, from five days prior to until seven days after induction of pancreatitis.
Plasma cytokine levels were determined before, and 6 hrs, 24 hrs and 7 days after induction
of pancreatitis. Bacteraemia was assessed by blood cultures, performed on day 7 after
induction of pancreatitis. Cox regression analysis was used to correlate plasma cytokine
levels and probiotic treatment with mortality and bacteraemia. Results: In the course of
severe acute pancreatitis specific ‘cytokine signatures’ could be detected which were associated
with differential clinical outcome: 1) Early mortality (< 24h) was preceded by significantly
higher plasma levels of IL-6, IL-10 and CXCL1, 2) Elevated levels of TNF-α and IL-1β were
predictive for the onset of bacteraemia potentially causing late mortality, 3) an early and
self-resolving IL-10 response was found in animals protected from early mortality, whereas
sustained elevated IL-10 levels (24h) were associated with bacteraemia. Clinical outcome,
being mortality or bacteraemia at day 7, was improved by probiotic treatment (Hazard ratio
0.37, P = 0.039). Probiotic treatment resulted in a modest reduction of plasma levels
of pro-inflammatory cytokines and significantly reduced CXCL1 levels (24h), preventing
unfavourable neutrophil activation and associated remote organ damage. Conclusions:
Specific pro-inflammatory and regulatory cytokine combinations are predictive for mortality
and bacteraemia during severe acute pancreatitis. Prophylactic treatment with probiotics
reduced pro-inflammatory cytokine overexpression.
W1693
Pancreatic Secretory Trypsin Inhibitor Is a Target Antigen in Experimental
Autoimmune Pancreatitis in Mice
Masanori Asada, Akiyoshi Nishio, Keiichi Kiriya, Kazuyuki Saga, Jyunya Tanaka,
Katsuhiro Kasahara, Masahiro Kido, Satoru Ueno, Norimitsu Uza, Satoko Inoue, Hiroshi
Kitamura, Shinya Ohashi, Toshiro Fukui, Minoru Matsuura, Norihiko Watanabe, Hiroshi
Nakase, Kazuichi Okazaki, Tsutomu Chiba
Background & Aim: Autoimmune pancreatitis (AIP) is a unique type of chronic pancreatitis.
Hypergammaglobulinemia, increased serum levels of total IgG or IgG4, and various autoanti-
bodies are often observed in patients with AIP. However, the autoimmune mechanisms
leading to AIP still remains unclear. We previously reported that autoantibodies against
pancreatic secretory trypsin inhibitor (PSTI) are specifically detected in patients with AIP.
(DDW 2004, New Orleans) In this study, we aimed to investigate the role of PSTI as an
autoantigen in the pathogenesis of murine experimental model of AIP. Materials & Methods:
Six-week old female MRL/+ mice were injected with polyinosinic polycytidylic acid (poly
I:C) intraperitoneally at a dose of 5 mg/kg of body weight twice a week up to 12 weeks.
Control mice were injected with phosphate-buffered saline (PBS). Mice were serially sacrificed
and the severity of the pancreas was graded based on the histological scoring system (0 to 4).
Immunohistochemical examinations were also performed. The serum levels of autoantibodies
including anti-PSTI antibody, were measured by ELISA method. Results: All mice developed
pancreatitis 12 weeks with poly I:C treatment, but controls did not. Histological examinations
demonstrated destruction of the pancreatic acini and fatty degeneration accompanied by
intense infiltration of inflammatory cells. Histological score of the pancreatitis increased
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according to the treatment period. (6wk; 1.8 ± 0.4, 12wk; 3.3 ± 0.6) Immunohistochemistry
revealed that B220+ B cells were diffusely infiltrated into the pancreatic parenchyma but
CD4+ T cells and CD8+ T cells were mainly observed around the pancreatic ducts. Poly
I:C administered mice highly produced anti-PSTI antibody (91.7%) in contrast with the
relative low frequency of anti-lactoferrin antibody (45.8%) or anti-carbonic anhydrase-II
antibody (33.3%). Conclusions: Anti-human PSTI antibody is highly detected in poly I:C
administered MRL/+ mice. PSTI may be involved in the pathogenesis of experimental autoim-
mune pancreatitis model in mice.
W1694
Overexpression of SMAD6 Enhances Pancreatic Fibrosis in Transgenic Mice
Tamao Miyamoto, Hayato Nakamura, Hiroshi Asaumi, Yoko Nomiyama, Shiro Watanabe,
Yoshikuni Nagashio, Mituo Tashiro, Makoto Ostuki
Introduction: We have developed transgenic (Tg) mice overexpressing Smad6 in the pancreas
and demonstrated that acute pancreatitis induced in these mice by repeated intraperitoneal
injections of cerulean (Cn) or by feeding choline-deficient, ethionine-supplemented diet was
severer than that in control C57BL/6N (Wt) (Kaku M, et al. Gastroenterology 2005;128:A-
379). In the present study, we examined whether overexpression of Smad6 has any influences
on pancreatic fibrosis after chronic pancreatic injury. Method: Chronic pancreatic injury
was induced in Tg and Wt mice by six hourly intraperitoneal injections of 50μg/kg body
weight Cn, three times a wk for 4 wks. Pancreatic wet weight and body weight were measured
at wk 0, 1, 2, 3, and 4. Serum amylase activity and amylase and trypsinogen contents in
the pancreas were determined. Pancreatic fibrosis was evaluated by histological examination
after H&E and Azan staining and image analysis, and by measuring hydroxyproline contents
in the pancreas. Results: There were no significant differences in body weight, pancreatic
wet weight, and amylase activity in serum and the pancreas between the two groups through-
out the observation periods. Pancreatic trypsinogen contents in Tg mice at baseline were
similar to those in Wt mice, but significantly increased in Tg mice after induction of pancreatic
injury compared with those in Wt mice (Fig 1). Histological grade of fibrosis and fibrotic area
by image analysis in Tg mice were significantly higher than those in Wt mice. Hydroxyproline
contents in the pancreas in Tg mice were significantly higher than those in Wt mice at wk
1 and 2 (Fig 2). Conclusion: Our present results demonstrate that overexpression of Smad6
in the pancreas enhances the development of pancreatic fibrosis induced by chronic pancreatic
injury, probably due to decreased exocytosis of trypsinogen.
W1695
Autophagic Cell Death of Pancreatic Acinar Cells in Serine Protease Inhibitor
Kazal Type 3 Deficient Mice
Masaki Ohmuraya, Masahiko Hirota, Hideo Baba, Ken-Ichi Yamamura
Background & aims: Acute pancreatitis is a severe inflammatory disorder of the pancreas,
which is believed to be caused by an autodigestion of the pancreas by its own digestive
enzymes. Digestive enzymes, however, are secreted from the pancreas as inactive precursor
zymogens and are normally activated only in the duodenum. Thus, premature protease
activation should occur in the pancreas to trigger pancreatitis. Because the main trigger is
conversion of trypsinogen to trypsin, it is important to know how trypsin activation is
inhibited not to develop pancreatitis. Serine protease inhibitor Kazal Type 1 (SPINK1),
which is structurally similar to epidermal growth factor, can bind to trypsin to inhibit its
activity. Point mutations in the SPINK1 gene seem to predispose to human pancreatitis;
however, the clinical significance of SPINK1 mutations remains unclear. This study aimed
to elucidate the role of SPINK1. Methods: We generated Spink3-deficient (Spink3-/-) mice
by gene targeting in mouse embryonic stem cells. Embryonic and neonatal pancreases were
analyzed morphologically and molecularly. Specific probes were used to examine the typical
autophagy occurring during acinar cell death. Results: In Spink3-/- mice, the pancreas
developed normally up to embryonic day (E) 15.5. However, autophagic degeneration of
acinar cells started from E16.5; and rapid onset of cell death, but not of necrosis and
apoptosis, in the pancreas and duodenum within a few days after birth, resulting in death
by 14.5 days. Although the trypsin activation in the pancreas of Spink3-/- mice was observed
when examined by very sensitive method, it seems to be too low to induce autophagy.
There was no sing of acinar cell regeneration despite the fact that residual duct-like cells
strongly expressed pancreatic duodenal homeodomain containing protein at 7.5 days after
birth, Conclusions: Inactive trypsinogen can be activated to trypsin in the absence of Spink3,
suggesting that the mutation of SPINK1 gene may result in pancreatitis due to trypsin
activation or due to potentiation of the harmful effect of other genetic and environmental
insults. In addition, Spink3 may have direct roles in autophagosome formation and acinar
cell regeneration, and hence the lack of Spink3 may result in the progressive disappearance
of acinar cells. Taken together, Spink3 has essential roles for maintenance of integrity and


















Hydrogen Peroxide and Nicotine Induces P-ERK 1/2 and P-Akt Activation,
Increases Lipid Peroxidation and Decreases Stimulated Cell Function in
AR42J Cells
Parimal Chowdhury, Azida Walker, Kodetthoor Udupa
One of the hallmarks of pathophysiological basis of pancreatic injury is the oxidative stress.
The current study was conducted in AR42J cells to evaluate the direct effect of an oxidative
marker on pancreatic acinar cell. In earlier studies we have established nicotine dose and
time of 100 μM and 3 min incubation at which p-ERK 1/2 and p-Akt were activated. In
this study we have established dose and time response curve for hydrogen peroxide of 20
μM and 15 min of incubation at which significant induction of these signals occurred.
Methods: AR42J cells were grown in F-12 nutrient medium at 370C and 5% CO2. At log
phase, they were separated, sub cultured for 3 days at specified dose and time with hydrogen
peroxide, nicotine and the combination of both. The cells were lysed and cellular extracts
were subjected to Western blotting employing antibodies to ERK 1/2, and Akt. Lipid peroxida-
tion assay was conducted employing malondialdehyde (MDA) as a standard biomarker of
lipid peroxidation. For functional assay, AR42J cells were incubated with either 20 μM of
hydrogen peroxide for 15 min, or with 100 μM of nicotine for 3 min or the combination
of both for the same time and concentration in serum free medium. At the end of the
incubation period, the cells were washed, re-suspended and then incubated with CCK-8
(10-10 M) for 30 min at 370C. Cell function was assessed by the amount of amylase released
in the media with procion yellow starch as substrate Results: Incubation of AR42J cells for
15 min with hydrogen peroxide (20 μM) or with nicotine (100 μM ) induced 3-4 fold
activation of phospho-ERK 1/2 and p-Akt when compared to untreated cells (p<0.05). This
response was associated with significant increase in MDA levels in the cell lysate (p<0.05).
Incubation of cells with hydrogen peroxide (20 μM), CCK-stimulated release of amylase
was not different from that of control cells, however, the cells treated with 100 μM of
nicotine showed a significant increase in stimulated cell function as compared to control
and hydrogen peroxide treated cells. Incubation of cells with combination of both hydrogen
peroxide and nicotine decreased stimulated cell function by (25 %) when compared to the
stimulated amylase release by nicotine-treated cells. Conclusion: These data suggest that in
AR42J cells, mitogen activated protein kinase (MAPK) signaling is induced by hydrogen
peroxide in concert with nicotine treatment as reported earlier with an increase in lipid
peroxidation and subsequent decrease in cell function. The data implies a plausible mechan-
ism by which oxidative stress may implicate cell injury leading to its compromised function.
W1697
Existence of Autocrine Loop Between Interleukin-6 and TGF-β1 in Activated
Rat Pancreatic Stellate Cells
Hiroyoshi Aoki, Hirohide Ohnishi, Kouji Hama, Satoshi Shinozaki, Kentaro Sugano
Background and Aims: Pancreatic stellate cells (PSCs) are activated in chronic pancreatitis
and promote pancreatic fibrosis by producing and secreting extracellular matrix. Interleukin-
6 (IL-6) is a pro-inflammatory cytokine assumed to participate in the progression of pancreatic
fibrosis by stimulating pancreatic stellate cells. Although activated PSCs secrete multiple
cytokines, it is still unclear whether activated PSCs secrete IL-6. In this study, we examined
IL-6 secretion from culture-activated rat PSCs and its regulatory mechanism. Methods: PSCs
isolated from rat pancreata using Nycodenz gradient centrifugation were culture-activated
during 2-3 passages. The mRNA expression and peptide secretion of IL-6 and TGF-β1 was
determined with RT-PCR and ELISA, respectively. TGF-β1/Smad signaling was investigated
with adenovirus(AdDNSmad2/3)-mediated expression of dominant-negative Smad2/3. Extra-
cellular signal-regulated kinase (ERK) dependent signaling pathway was examined using
MEK1 inhibitor PD98059. Results: Activated PSCs express IL-6 mRNA and secrete IL-6
peptide. Since autocrine TGF-β1 plays central roles in the functional regulation of PSCs, we
examined the effect of autocrine TGF-β1 on the IL-6 expression and secretion by activated
PSCs. TGF-β intracellular signaling is mainly mediated by Smad2/3-dependent pathways.
The infection with AdDNSmad2/3 expressing dominant-negative Smad2/3 did not alter TGF-
β1 mRNA expression or peptide secretion of activated PSCs. However, when autocrine TGF-β1 signaling was blocked by the infection with AdDNSmad2/3, IL-6 expression and secretion
of activated PSCs was inhibited. Furthermore, exogenous TGF-β1 added in the culture
medium enhanced IL-6 expression and secretion of PSCs. In contrast, exogenous TGF-β1
could not increase IL-6 expression or secretion of PSCs infected with AdDNSmad2/3. These
data suggest that autocrine TGF-β1 enhances IL-6 expression and secretion of PSCs through
Smad2/3-dependent pathway. We also examined the reciprocal effect of PSC-secreted IL-6
on the TGF-β1 secretion from PSCs. Anti-IL-6 neutralizing antibody added in the culture
medium inhibited TGF-β1 secretion from PSCs in a dose dependent manner. In addition,
exogenous IL-6 enhanced TGF-β1 expression and secretion of PSCs. Preincubation of cells
with 10 nM PD98059, an ERK-dependent pathway inhibitor, attenuated basal and IL-6-
stimulated TGF-β1 expression and secretion of PSCs. Conclusion: These data indicates the
existence of autocrine loop between IL-6 and TGF-β1 through ERK- and Smad2/3-dependent
pathways in activated PSCs.
W1698
Pancreatic Stellate Cells Express Toll-Like Receptors
Atsushi Masamune, Kazuhiro Kikuta, Noriaki Suzuki, Tooru Shimosegawa
Background & Aims: Activated pancreatic stellate cells (PSCs) play a pivotal role in the
pathogenesis of pancreatic fibrosis. Upon activation, PSCs acquire proinflammatory as well
as profibrogenic properties. Toll-like receptors (TLRs) are proteins involved in the recognition
of foreign pathogen-associated molecular patterns and activation of processes leading to
innate immune recognition. This study aimed to clarify whether PSCs expressed TLRs and
responded to foreign pathogen-associated molecular patterns. Methods: PSC were isolated
from rat pancreas tissue and used in their culture-activated, myofibroblast-like phenotype.
Expression of TLRs was examined by reverse transcription-PCR and Western blotting. PSCs
were treated with lipoteichoic acid (LTA from Staphylococcus aureus, a ligand for TLR2),
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polyinosinic-polycytidylic acid (poly I:C; a ligand for TLR3), lipopolysaccharides (LPS from
E. coli; a ligand for TLR 4), or flagellin (from Salmonella munchen, a ligand for TLR5).
Activation of mitogen-activated protein (MAP) kinases was assessed by Western blotting
using antiphosphospecific antibodies. Activation of transcription factors was examined by
electrophoretic mobility shift assay. Chemokine production was examined by enzyme-linked
immunosorbent assay. Expression of inducible NO synthase (iNOS) was examined by West-
ern blotting. Fluid-phase and mannose receptor-mediated endocytosis was assessed by uptake
of fluorescein isothiocynate-labeled low-molecular weight (10 kDa) and high-molecular
weight (70 kDa) dextran. Results: PSCs expressed TLR2, 3, 4, and 5 as well as CD14 and
MD2. Ligands of TLRs activated activator protein-1, nuclear factor-κB, and MAP kinases
(extracellular signal-regulated kinase, c-Jun N-terminal kinase, and p38 MAP kinase). TLR
ligands induced the expression of monocyte chemoattractant protein-1 and iNOS. TLR
ligands-induced monocyte chemoattractant protein-1 production was abolished in the pres-
ence of an inhibitor of nuclear factor-κB. PSCs could internalize both low- and high-molecular
weight dextran, indicating the ability of PSCs to perform fluid-phase and mannose receptor-
mediated endocytosis. Conclusion: Activated PSCs expressed a variety of TLRs, and
responded to foreign pathogen-associated molecular patterns followed by the induction of
chemokines and iNOS. In addition, activated PSCs had a powerful endocytic activity, sug-
gesting that PSCs might participate in the immune functions of the pancreas.
W1699
Smad7-Dependent TGF-β1 Negative-Feedback Is Constitutively Attenuated
Through Nf-κB in Activated Pancreatic Stellate Cells
Kouji Hama, Hirohide Ohnishi, Hiroyoshi Aoki, Satoshi Shinozaki, Kentaro Sugano
Background and Aim: During chronic pancreatitis, pancreatic stellate cells (PSCs) are activated
and transformed to myofibroblast-like cells, and play central roles in pancreatic fibrogenesis
by producing and secreting extracellular matrix such as collagen and fibronectin. Autocirne
TGF-β1 accelerates the activated PSC functions promoting pancreatic fibrosis. Smad7 is an
inducible antagonist of TGF-β1 signaling that physiologically acts as TGF-β1 negative-feed-
back regulator. However, activated PSCs are continuously stimulated by autocrine TGF-β1
and promote fibrogenesis in chronic pancreatitis tissue. Therefore, we conducted this study
to examine whether Smad7-operated TGF-β1 negative-feedback machinery exists in activated
PSCs. Methods: PSCs were isolated from rat pancreas using Nycodenz gradient centrifugation
and activated during passages 2-3. Smad proteins function was examined with their aden-
ovirus-mediated overexpression. Smad7 transcription activity and mRNA expression was
determined by Smad7-Luciferase assay and RT-PCR, respectively. NF-κB-dependent pathway
was examined by blocking NF-κB activity using N-tosyl-L-phenylalanine chloromethyl ketone
or using an adenovirus expressing an IκB super-repressor (Ad5IκB). Results: Exogenous
TGF-β1 added in the culture medium increased Smad7 transcription and mRNA expression
in activated PSCs in a dose-dependent manner concomitantly with increasing α-smooth
muscle actin (α-SMA) expression, a parameter of PSC transformation. Although adenovirus-
mediated overexpression of Smad proteins did not alter the amount of autocrine TGF-β1,
overexpression of the combination of Smad3 and Smad4 enhanced Smad7 transcription and
mRNA expression in activated PSCs. These data indicate that excess TGF-β1 stimulation
can induce Smad7 expression through Smad3- and Smad4-dependent pathway in activated
PSCs. Moreover, overexpression of Smad7 inhibited basal and TGF-β1-stimulated α-SMA
expression of PSCs, indicating that excess Smad7 expression can attenuate TGF-β1 stimulation
in activated PSCs. On the other hand, when NF-κB activity in activated PSCs was blocked
by the preincubation with N-tosyl-L-phenylalanine chloromethyl ketone or by the infection
with Ad5IκB enhanced basal and TGF-β1-stimulated Smad7 transcription and mRNA expres-
sion. These results indicate that Smad7 transcription is constitutively attenuated via NF-κB
dependent pathway. Conclusion: Smad7-dependent TGF-β1 negative-feedback machinery
exists in activated PSCs but is constitutively inhibited through NF-κB dependent pathway.
W1700
Isolation of Pancreatic Sensory Neurons: 1,1'-Dioctadecyl-3,3,3',3'-
Tetramethylindocarbocyanine Perchlorate (DiI) Retrograde Tracing and
Immunohistochemisty in Rat Dorsal Root Ganglia (DRG)
Sarah Grahn, Helge Eilers, Elizabeth Wick, Mark Schumacher, Kimberly S. Kirkwood
Experimental pancreatitis induces inflammatory hyperalgesia as evidenced by an increase
in fos protein expression at the T9-T10 levels in the spinal cord. Recent studies suggest that
the vanilloid receptor TRPV1 may be activated by inflammatory mediators resulting in
pancreatic hyperalgesia. Our understanding of pancreatic nociception is limited by our
inability to study sensory neurons from the pancreas. The purpose of the present study was
to use a vital dye to isolate pancreatic afferent neurons, quantify the distribution of these
neurons within DRGs at different levels and identify these pancreatic neurons in cultured
DRGs. The vital dye DiI was injected into pancreatic parenchyma of anesthetized rats as a
retrograde nerve tracer. After 10 days the rats were killed and the DRGs removed for either
cell counting, immunohistochemical staining or culture. Injection of DiI into the pancreas
resulted in labeling of small to medium diameter neurons in the T7-L2 DRGs. The greatest
number of labeled neurons were in the T9-Tll DRGs (Figure 1). Among pancreatic (DiI+)
neurons 75% were TRPV1 positive by immunohistochemical staining (Figure 2). Pancreatic
afferents labeled with DiI were easily identified among DRG neurons in short term culture.
Thus we have developed a technique by which we identified and quantified specific pancreatic
afferent neurons in rat DRGs using a vital dye and these neurons have been isolated in short
term culture. These small-medium fiber neurons are TRPV1 positive and therefore represent
potential pancreatic nociceptors which may be activated during acute pancreatitis leading
to pancreatic hyperalgesia.
Co-localization of DiI and TRPV1 in a T11 DRG neuron showing cell body with central
nucleus and cytoplasmic staining (40X).
W1701
Pioglitazone Restores CCK Stimulated Pancreatic Secretion & Normalizes
Insulin Resistance in eNOS (-/-) Mice
Yibai Hao, Raj Reddy, Sae-Hong Lee, Owyang Chung, Matthew J. Dimagno
BACKGROUND: We recently showed that eNOS isoform modulates pancreatic secretion;
NOS inhibition or eNOS gene deletion reduced in vivo murine pancreatic secretion by 40-
45% in response to carbachol and CCK-8. eNOS also modulates organ perfusion, and eNOS
(-/-) mice exhibit insulin resistance. Thus, our aims were to detemine if exocrine pancreatic
secretion is linked to pancreatic blood flow (PBF) in WT mice and to determine if pioglitazone
(an insulin sensitizer) reduces insulin resistence and improves exocrine pancreatic secretion.
METHODS: We used microspheres to measure PBF in WT mice in response to graded CCK-
8 doses. WT & eNOS (-/-) mice were gavaged with pioglitazone (20 or 50 mg/kg/d) or
vehicle x 5 days. Then mice were anesthetized and either the bile-pancreatic duct cannulated
to study in vivo pancreatic secretion in response to maximal stimulatory CCK-8 (160 pmol/
kg/h) or we measured pancreatic digestive enzyme mRNA content, hepatic insulin receptor
protein expression & serum insulin concentration (by RIA). RESULTS: In WT mice, baseline
PBF was unaffected by physiologic CCK-8 (40-160 pmol/kg/h). Supramaximal CCK-8 (400
& 1600 pmol/kg/h) increased PBF 1.6 and 2.4 fold respectively (p<0.05). Pioglitazone
augmented CCK-8 (160 pmol/kg/h) stimulated protein output in eNOS (-/-) (p<0.05) but
not in WT mice; in response to vehicle, 20 & 50 mg/kg pioglitazaone increased CCK-8
stimulated output in eNOS (-/-) mice by 195+/-29%, 266+/-39% and 357+/-47%, repectively
and in WT mice by 328+/-35%, 336+/-46% and 284+/-48%, respectively. Also, during
physiologic CCK stimulation, pioglitazone (50 mg/kg) normalized the 2-fold greater serum
insulin values observed in eNOS (-/-) mice receiving vehicle (p<0.05) vs WT groups and
secondly, augmented cytosolic and membrane hepatic insulin receptor expression by 35+/-
10% and 26+/-5% respectively. Although insulin increases protein synthesis, pancreatic
mRNA expression of multiple digestive enzymes was unaffected by eNOS genotype. CON-
CLUSION: Physiologic CCK-8 evoked pancreatic secretion in WT mice is not coupled to
increased PBF. Pioglitazone restores pancreatic secretion in CCK-8 stimulated eNOS (-/-
) mice without affecting these parameters in WT mice. Secondly Pioglitazone reverses
hyperinsulinemia in CCK-8 stimulated eNOS (-/-) mice, and increases hepatic insulin receptor
expression, which might reduce hyperinsulinemia by increasing receptor dependent hepatic
insulin uptake and clearance. Insulin resistance may reduce pancreatic secretion in eNOS
(-/-) as well as in humans with diabetes mellitus, and be reversible by pioglitazone.
W1702
Regulatory Interaction Between Apical Na+-H+ Exchange and Cystic Fibrosis
Transmembrane Conductance Regulator in Mouse Pancreatic Duct Cells
Akiko Yamamoto, Hiroshi Ishiguro, Takaharu Kondo, Satoru Naruse
Background and Aim: Na+-H+ exchangers (NHE) are localized in both basolateral and apical
membranes of various epithelia and 8 isoforms have been identified. NHE3 is localized in
the apical membrane and mediates HCO3- absorption in kidney proximal tubule and H+-
coupled dipeptide absorption in the small intestine. In the present study, to investigate the
role of apical NHE in HCO3- secretion from pancreatic duct cells, we examined the activity
of apical NHE in interlobular pancreatic duct segments isolated from normal and ΔF mice,
a cystic fibrosis mouse model in which the ΔF508 mutation was introduced in the mouse
CFTR (cystic fibrosis transmembrane conductance regulator) and pancreatic HCO3- secretion
is impaired. Methods: Interlobular duct segments (diameter: ~100 μm) were isolated by
collagenase digestion and microdissection. The ducts were superfused with HCO3--free
Hepes-buffered solutions at 37oC and the lumen was microperfused separately. Intracellular
pH (pHi) was measured by microfluorometry in ducts loaded with pH-sensitive fluoroprobe
BCECF. The duct cells were acid-loaded with a 2-min pulse of 20 mM NH4+, which was
followed by a Na+-free solution in both the bath and lumen. The rate of pHi recovery after
re-addition of Na+ to the luminal solution was calculated as a measure of the activity of
apical Na+-H+ exchange. Results: The rate of pHi recovery (dpH/dt) (dependent on luminal
Na+, independent of HCO3-) was 0.12 ± 0.01 pH unit/min (mean ± SD, n = 8) in wild
type (WT/WT) ducts, which was completely inhibited by 100 μM HOE642, an inhibitor
of NHE. Forskolin (1 μM), an activator of adenylate cyclase, reduced the apical NHE activity
to 0.05 ± 0.01 pH unit/min (n = 9, p < 0.01). The apical NHE activity in cystic fibrosis
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(ΔF/ΔF) ducts was 0.20 ± 0.01 pH unit/min (n = 6), which was significantly (p < 0.01)
higher than that in wild type ducts and was accelerated to 0.66 ± 0.11 pH unit/min (n =
6, p < 0.01) by application of forskolin. Conclusions: In mice pancreatic duct cells, the
activity of apical NHE was suppressed by functional CFTR and it was stimulated by cAMP
in the absence of functional CFTR. These data suggest that the inhibitory regulation of apical
NHE by CFTR does not work in cystic fibrosis pancreatic duct, which may lead to acidification
of pancreatic juice.
W1703
Lack of in Vivo Evidence for a Constitutive Secretory Pathway for Pancreatic
Trypsinogen in Fasted Healthy Human Subjects
Stephen J. O'Keefe, Justin M. Kiswardy, Wen Zhou
Experimental evidence, based on in vitro animal studies, suggested that there are 2 primary
mechanisms for the acinar cell secretion of newly synthesized enzymes, the ‘constitutive’
pathway where enzymes are discharged from the acinar cell after the trans Golgi network,
and the ‘regulated’ pathway which becomes operational only during food-stimulation where
newly synthesized enzymes are only secreted following equilibration with the stored zymogen
pool. The finding of the early release of low quantities of highly labeled enzymes during
fasting lead investigators to conclude that secretion during fasting was chiefly supported by
the constitutive pathway. To test this hypothesis in human physiology, we studied healthy
volunteers during fasting (n=5) and feeding (n=7) by in vivo labeling of pancreatic trypsinogen
with prime, continuous 6-h IV infusions of 13C-leucine and isolation of trypsin form duodenal
secretions (AJPhysiol 1994). To determine whether trafficking was disrupted during acute
pancreatitis, 9 patients with severe necrotizing disease were studied in the same manner.
Results: Figure shows that the isotope enrichment of secreted trypsin followed a similar
pattern during fasting and feeding, but that the time of first appearance of labeled enzyme
was significantly faster during feeding (75(7) vs. 94(11) minutes, p=0.044, Mann-Whitney
NP test). Measurements in pancreatitis patients showed the early release of labeled enzymes
with disturbance of the isotope enrichment curve. In conclusion, our results fail to support
the presence of a constitutive pathway in healthy fasted humans as the isotope enrichment
curves fitted the ‘regulated’ model described by Jameson & Palade (1967), only the process
is accelerated during feeding. In patients with acute pancreatitis, the capacity to synthesize
enzymes is conserved, but post-Golgi trafficking is disrupted.
W1704
High Glucose Inhibits Fluid Secretion and Na+-Hco3- Cotransport in Rat
Pancreatic Duct Cells
Sachiko Futakuchi, Hiroshi Ishiguro, Satoru Naruse, Shigeru Ko, Miyuki Nakakuki,
Toshiyuki Yoshikawa, Akiko Yamamoto, Takaharu Kondo, Hidemi Goto
Pancreatic exocrine dysfunction is commonly found in diabetic patients, in whom not only
enzyme secretion (acinar function) but also fluid and HCO3- secretion (ductal function) is
impaired. To clarify the mechanisms by which ductal secretion decreases in diabetes, we
examined (1) effects of glucose concentration on fluid secretion and Na+-HCO3- cotransport
in pancreatic ducts isolated from normal and streptozotocin-induced diabetic rats, and (2)
mRNA expression of glucose transporters in pancreatic ducts. Interlobular ducts (diameter
~150 µm) were isolated from the pancreas obtained from normal and diabetic rats. The
ducts were cultured overnight in either a normal-glucose (10mM) or high-glucose (44 mM)
solution, during which time both ends of the ducts sealed spontaneously. Fluid secretion
into the closed luminal space was measured by videomicroscopy and expressed as secretory
rate per unit area of epithelium. Intracellular pH (pHi) was measured by microfluorometry
using BCECF to estimate Na+-HCO3- cotransport activities. The mRNA expression of Na+-
dependent and -independent glucose transporters (SGLT1, 2 and GLUT1, 2, 3, 4, 8) in
isolated ducts was examined by RT-PCR. Isolated ducts were superfused with HCO3--
buffered solution (glucose 10 mM) at 37oC and stimulated with secretin (1 nM). The fluid
secretory rate in ducts from normal rats was 1.74 ± 0.14 nl min-1 mm-2, n = 8, mean ±
SE). When glucose in the perfusate was raised to 44 mM, the secretory rate decreased by
41.4 % (p < 0.05). The addition of mannitol (34 mM) did not affect fluid secretion. Isolated
ducts from diabetic rats kept in the high-glucose condition secreted fluid at a significantly
(p < 0.05) lower rate (0.70 ± 0.07, n = 8) than those in the normal condition. When the
diabetic ducts were kept in the normal-glucose condition, the secretory rate recovered by
37.4 % (p < 0.05). The rate of pHi recovery after acid-loading with NH4+-pulse was
significantly (p < 0.05) reduced in diabetic ducts and in normal ducts under the high-
glucose condition. SGLT1, GLUT1, GLUT2, GLUT3, and GLUT8 mRNAs were abundantly
expressed in pancreatic ducts. High glucose reversively inhibits fluid secretion from rat
pancreatic duct cells probably by inhibiting HCO3- uptake via Na+-HCO3- cotransport.
Under a high-glucose condition, the entry of Na+ via SGLT may reduce the transmembrane


















Phosphatidylinositol 3-Kinase Facilitates Bile Acid-Induced Ca2+ Responses in
Pancreatic Acinar Cells
Lars Fischer, Anna S. Gukovskaya, Josef M. Penninger, Helmut Friess, Ilya Gukovsky,
Stephen J. Pandol
Background & Aims: Bile acids induce Ca2+ responses in the pancreatic acinar cell; however,
the underlying mechanisms are poorly understood. These responses may play a role in bile
acid-induced experimental acute pancreatitis. We have recently shown that phosphatidylinos-
itol 3-kinase (PI3K), and in particular its gamma isoform, regulates changes in free cytosolic
Ca2+ ([Ca2+]i) elicited in pancreatic acinar cells by neurohormones such as cholecystokinin
(CCK). We showed that PI3K negatively regulates CCK-induced Ca2+ reloading into endo-
plasmic reticulum (ER) stores by inhibiting sarco/endoplasmic reticulum Ca2+-ATPase
(SERCA). The present study sought to determine whether PI3K regulates bile acid-induced
[Ca2+]i responses in the pancreatic acinar cell. Results: In isolated pancreatic acini, pharmaco-
logic inhibition of PI3K with LY294002 or wortmannin markedly inhibited [Ca2+]i responses
(measured with Fura-2) induced by taurolithocholic acid 3-sulfate (TLC-S) and taurochenod-
eoxycholate (TCDC). Furthermore, genetic deletion of PI3K gamma isoform also decreased
[Ca2+]i responses to bile acids. Depletion of CCK-sensitive intracellular Ca2+ pools or
application of caffeine, a blocker of inositol 1,4,5-trisphosphate (IP3) receptor, inhibited
bile acid-induced [Ca2+]i signals, indicating that bile acids release Ca2+ from agonist-
sensitive ER stores via IP3-dependent mechanism. The PI3K inhibitors increased the amount
of Ca2+ releasable from the intracellular stores during exposure of acinar cells to bile acids.
This suggests that PI3K negatively regulates the SERCA-dependent Ca2+ reloading into ER
during bile acid stimulation. Further, in permeabilized acinar cells bile acids inhibited
Ca2+ reloading into the ER, and this effect was augmented by phosphatidylinositol 3,4,5-
trisphosphate (PIP3), a major product of PI3K. These results indicate that both bile acids
and PI3K act synergistically to inhibit SERCA. Conclusions: Our results indicate that PI3K
and its product, PIP3, facilitate bile acid-induced [Ca2+]i responses in pancreatic acinar
cells through inhibition of SERCA-dependent Ca2+ reloading into the ER. The findings have
important implications for the mechanism of acute pancreatitis since [Ca2+]i increases
mediate key pathologic processes in this disorder.
W1706
Development of An Efficient Inducible Acinar Cell Specific Transgenic Model
(BAC-Elastase-Cre-Er)
Baoan Ji, Jian Song, Craig D. Logsdon
Background: Pancreatic acinar cells play critical roles in gastrointestinal physiology as the
primary source of digestive enzymes.These cells are also central to the initiation of pancreatitis
and may also be involved in pancreatic cancer.Acinar cell specific gene promoters have been
widely utilized to control acinar cell specific transgene expression with the rat pancreatic
elastase promoter being the most widely utilized.However,the partial sequence(531bp) typic-
ally utilized for this purpose is not highly efficient nor is its expression restricted to fully
differentiated acinar cells.Aim: In order to develop an improved system for pancreatic acinar
cell specific transgene expression we utilized a full-length pancreatic elastase promoter using
bacterial artificial chromosome(BAC) technology. Furthermore, for maximum flexibility and
utility in studies of pancreatic biology, we developed a mouse line in which this BAC elastase
promoter is used to express a tamoxifen regulated Cre (BAC-El-Cre-Er).This allows acinar
cell specific and tamoxifen regulated Cre recombination that when used in conjunction with
a gene controlled by a loxp-flanked stop sequence allows highly efficient and specific regulated
expression in acinar cells.Method: We used an E. coli-based chromosome engineering system
developed by Dr. Copeland (NCI). A BAC carrying the intact elastase I gene was modified
to express Cre-Er. An IRES-Cre-Er-frt-Kan-frt PCR fragment was produced by replacing the
EGFP-Cre with Cre-Er in plasmid pICGN21. To either side of this expression cassette was
added ~50 bp DNA fragments homologous to the sequence of elastase I gene between the
last exon and the polyA signal. Using homologous recombination, the IRES-Cre-Er-frt-Kan-
frt cassette was inserted into the elastase I gene. The Kan selection marker was then removed
by flp-mediated recombination and the insert site and orientation were verified by sequencing.
Transgenic mice were produced by pronuclear microinjection. Results:Founders were identi-
fied by PCR using Cre primers and crossed with Rosa26 reporter mice. Double transgenic
mice were injected with tamoxifen 3mg/40g/d for three days before the pancreas was removed
for X-gal staining. We found that nearly 100% of acini from double transgenic mouse
expressed β-gal after, but not before, tamoxifen treatment, indicating highly efficient regulated
recombination. Initial analysis indicates that the expression was completely specific for acinar
cells.Conclusion: A BAC-El-Cre-Er transgenic mouse has been developed. This model of
pancreatic acinar specific conditional gene expression will be a powerful tool for future
transgenic, knockout and cell linage studies.
W1707
RHOA Directly Interacts with TRPC1 and Regulates Capacitative Ca2+ Entry
During Intestinal Epithelial Restitution After Wounding
Rao N. Jaladanki, Tongtong Zou, Lan Liu, Bernard S. Marasa, Kaspar M. Keledjian, Ai-
Hong Zhang, Lan Xiao, Jie Chen, Jian-Ying Wang
Early mucosal restitution occurs as a consequence of epithelial cell migration to resealing
of superficial wounds after injury. An increase in cytosolic Ca2+ concentration ([Ca2+]cyt) is
crucial for initiating cellular response and consists of an initial phase that reflects Ca2+ release
from intracellular stores and a second phase that results from Ca2+ influx through Ca2+
permeable ion channels. We have recently reported that TRPC1 (canonical transient receptor
potential-1) functions as a store-operated Ca2+ channel mediating capacitative Ca2+ entry
(CCE) in intestinal epithelial cells (IECs) and that increasing Ca2+ influx through CCE plays
an important role in early epithelial restitution. However, the exact mechanisms by which
TRPC1 channels are activated after Ca2+ store depletion in IECs remain unclear. This study
determined if RhoA, a small GTP-binding protein, interacts with and regulates TRPC1 during
epithelial restitution. Methods: Studies were conducted in the IEC-6 cells, derived from rat
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intestinal crypts. Association of RhoA with TRPC1 was measured by immunoprecipitation
(IP), while [Ca2+]cyt was measured by fluorescence digital imaging analysis. Functions of
RhoA were investigated by using its specific inhibitor exoenzyme C3 transferase (C3) and
transfection with dominant negative mutant RhoA (DNMRhoA) or wild-type RhoA (WT-
RhoA). Cell migration was measured in a model that mimics cell division-independent
epithelial restitution. Results: Stable TRPC1-transfected IEC-6 cells (IEC-TRPC1) exhibited
increased TRPC1 expression, and levels of TRPC1 protein were ~5-folds the value of parental
IEC-6 cells. Consistently, sustained Ca2+ influx through CCE induced by store depletion
was increased by ~2-folds in IEC-TRPC1 cells. RhoA interacted with TRPC1 and formed
the RhoA/TRPC1 complexes. RhoA/TRPC1 complexes in IEC-TRPC1 cells were increased
by ~30% compared with those observed in parental IEC-6 cells. Inactivation of endogenous
RhoA by either exposure to C3 or ectopic expression of DNMRhoA not only reduced RhoA/
TRPC1 complexes but also inhibited Ca2+ influx through CCE. RhoA/TRPC1 complexes
were decreased by ~40% in IEC-TRPC1 cells treated with C3 or transfected with DNMRhoA,
while Ca2+ influx through CCE was decreased by ~50%. Cell migration was also inhibited
by ~40% after C3 treatment or DNMRhoA transfection. In contrast, ectopic expression of
WT-RhoA induced RhoA/TRPC1 complexes, increased Ca2+ influx through CCE, and pro-
moted cell migration after wounding. Conclusions: These findings indicate that RhoA directly
interacts with and regulates TRPC1, thus stimulating cell migration as a result of increase
in Ca2+ influx.
W1708
Expression and Glucocorticoid Regulation of Multiple Corticotropin-Releasing
Factor (CRF) Receptor Type 2 Variants in the Rat Esophagus
Shuping V. Wu, Pu-Qing Yuan, Lixin Wang, Yenlin Peng, Yvette Tache
Background: Corticotropin-releasing factor (CRF) and three related urocortin (Ucn) peptides
act on two distinct G protein-coupled receptors: CRF1 and CRF2 to exert stress-inducing
and coping effects. Both CRF receptor subtypes are expressed in multiple isoforms in the
central and peripheral tissues. In the gastrointestinal tract, the involvement of CRF receptors
in gastric emptying and colonic motility has been well documented. However, the presence
of CRF ligands and receptors, and their functional roles in the esophagus are not yet
determined. Aims: This study was designed to determine: 1) whether functional CRF receptors
and their ligands are present in rat esophagus, 2) which CRF receptor isoforms are expressed
in specific esophageal cell types that can be regulated by corticosterone treatment, and 3)
the effects of CRF and Ucn on cultured esophageal cell signaling. Methods: The upper,
middle and lower esophagus including lower esophageal sphincter (LES) from naïve, vehicle-
and corticosterone-treated rats were collected. Mucosal and muscle sections were obtained
by laser capture microdissection and cells were isolated by enzyme/EDTA dispersion and
cultured in serum-containing medium. RT-PCR and DNA sequencing were performed to
detect and confirm the presence of transcripts of CRF receptors and ligands in the whole
tissues, laser-captured sections and cultured cells. Activation of ERK1/2 was assessed by
Western blot in cultured esophageal cells. Results: In rat esophagus, CRF1 was detectable
but present at very low levels, while multiple CRF2 variants were abundantly expressed.
CRF2β was predominantly found in the epithelial and circular muscle layer while CRF2α
was present throughout the esophagus. In addition to wild type CRF2α, two novel CRF2α
variants were identified: the first variant CRF2α-desQ106, encodes a functional membrane-
bound receptor, the second variant CRF2α-I3 containing unspliced intron 3, is a truncated
soluble receptor. All three urocortins, but not CRF, were detected in both mucosa and
muscle sections. Acute injections of corticosterone decreased the esophageal expression of
CRF2α-I3 variant but caused no significant changes in wild type CRF2α and CRF2β levels
after 6 h. Exogenous Ucn stimulated dose-dependent activation of ERK1/2 in cultured
esophageal cells. Conclusion: These data demonstrate that multiple and functional CRF2
receptor isoforms and their cognate ligand urocortins are expressed in the esophagus and
LES, suggesting that CRF2 system may play important roles in regulating mucosal blood
flow, muscle contraction and relaxation, and maintenance of epithelium and muscle integrity
in the esophagus.
W1709
The Roles of Prostaglandin EP2 Receptors, cAMP, P-CREB, VEGF and
Angiogenesis in Esophageal Ulcer Healing: Signaling Pathways and Effect of
PGE1 Analog
Andrzej S. Tarnawski, Dolgor Baatar, Zsuzsanna Sandor, Rama Pai
Previous studies demonstrated that esophageal ulceration induces Cox2 expression in the
ulcer margin and clinical studies indicate that prostaglandins E (PGEs) may facilitate healing
of tissue injury and ulcers. The roles of PGEs, their EP receptors, signaling pathways and
their relation to VEGF and angiogenesis during esophageal ulcer healing remain unknown.
We examined in rats: whether esophageal ulceration alters EP1-4 receptors expression
and cAMP response element-binding protein (CREB) activity; and whether PGE1 analog,
misoprostol (MIS), agonist of EP receptors, affects cAMP concentration, CREB activity, VEGF
expression, angiogenesis in granulation tissue and ulcer healing. METHODS: Esophageal
ulcers were induced in rats by focal application of 100% acetic acid. Rats were treated with
either placebo or MIS i.g. 50 µg/kg b.i.d. STUDIES at 3, 6 and 9 days after ulcer induction:
1) ulcer size; 2) quantitative histology; 3) cell proliferation; 4) microvessel density; 5) VEGF
mRNA and 6) EP1-4, CREB, P-CREB and VEGF protein expression by Western blotting. In
cultured human esophageal epithelial HET-1A cells (derived from normal human esophageal
epithelium), we examined expression of EP1-4 receptors and the effects of MIS, Rp-cAMP
(PKA inhibitor) and Sp-cAMP (PKA activator) on cAMP levels, P-CREB and VEGF expression.
RESULTS: Esophageal ulceration triggered EP2 (but not EP1, 3 or 4) receptor overexpression
at day 3 (>200% p<0.01), increases in cAMP, CREB phosphorylation (4.5-fold increase; p
<0.01) and VEGF mRNA and protein by ~ 2- and 6-fold, respectively, at day 3 (both p <
0.01). MIS treatment further enhanced in ulcerated esophageal mucosa CREB activation and
VEGF expression (in squamous epithelium) and angiogenesis in granulation tissue (by 50%
and 60%, respectively, at day 6 and 9) and accelerated ulcer healing. In cultured human
HET-1A cells, MIS increased intracellular cAMP levels (by 163-fold; p<0.001), significantly
increased P-CREB and VEGF expression. PKA inhibitor inhibited all these MIS actions, while
PKA activator had similar to MIS action. CONCLUSIONS: 1) Esophageal ulceration triggers
overexpression of EP2 (but not EP1, 3 or 4) receptors, CREB phosphorylation and VEGF
upregulation in squamous epithelium bordering ulcer; 2) EP2/cAMP/protein kinase A path-
way mediates stimulatory effects of MIS on CREB activity and VEGF expression in ulcerated
esophageal mucosa, which in turn activates angiogenesis and ulcer healing; 3) Increased
VEGF production by epithelial cells activates VEGF receptors in endothelial cells and thus
angiogenesis, reflecting local epithelial-mesenchymal interactions and paracrine regulation.
W1710
Downregulation of Tff1 (pS2) Expression By SOX2 in Gastric Epithelial Cells
Tadahito Shimada, Takero Koike, Kyoko Tabei, Takashi Namatame, Akihiro Tajima,
Masashi Yoneda, Hideyuki Hiraishi
Background and Aim: SOX2, a SRY-related HMG box protein, is a transcription factor
expressed in a wide variety of tissues. SOX2 is considered to be critically involved in organ
development and cell differentiation. In the gastrointestinal tract, previous studies showed
the expression of SOX2 in gastric epithelial cells. However, little is known about the function
and the target genes of SOX2 in gastric epithelial cells. Trefoil factor family is a group of
small peptides that play important roles in the mucosal defense of the gastrointestinal tract.
Among TFF subtypes (TFF1, TFF2, and TFF3), TFF1 and TFF2 are expressed at high levels
in the gastric mucosa. In this study, we examined the expression of SOX2 in gastric cell
lines and investigated whether SOX2 affects the expression of TFF. Methods: MKN45, Kato3,
and AGS, cell lines derived from human gastric cancers, were used. COS-7 cells were also
used in some experiments. TFF1, TFF2, TFF3, and SOX2 mRNA expression levels were
examined by real-time RT-PCR. Beta-actin mRNA measurement was also performed for
standardization. SOX2 protein expression was examined by Western blot analysis. TFF
reporter genes were made by inserting PCR-amplified human TFF1 gene promoter sequence
(-956 to +36), TFF2 gene promoter sequence (-912 to +24), and TFF3 gene promoter
sequence (-956 to +12) into the pGL3-basic vector. SOX2 expression vector was made by
inserting the cording sequence of human SOX2 gene into pcDNA3.1 vector. Results: (1)
SOX2 mRNA and proteins were expressed in MKN45, Kato3, and AGS cells at a significant
level. (2) In COS-7 cells, the overexpression of SOX2 slightly upregulated the transcription
of TFF1, TFF2, and TFF3 reporter genes. (3) In contrast, in gastric cell lines, the overexpres-
sion of SOX2 significantly downregulated the transcription of TFF1 reporter gene. (4) The
transcription of TFF2 reporter gene was slightly suppressed by SOX2 overexpression and
that of TFF3 reporter gene was not significantly affected by SOX2 overexpression in gastric
cell lines. (5) Consistent with this, endogenous TFF1 mRNA expression was found to be
downregulated by the overexpression of SOX2 in gastric cell lines. (6) In a series of reporter
gene experiments, SOX2 responsive element was mapped between -456 and -326 from the
transcription start site of the human TFF1 gene. Conclusions: These results suggest that
SOX2 negatively regulates TFF1 expression in gastric epithelial cells. Since SOX2 overexpres-
sion caused opposite effect on the transcription of TFF1 reporter gene in COS-7 cells,
other gastric cell specific factors might also be involved in the action of SOX2 in gastric
epithelial cells.
W1711
Involvement of the Pineal Gland in Gastroprotection and Ulcer Healing By
Endogenous Melatonin and Its Precursor, L-Tryptophan
Iwona Brzozowska, Danuta Drozdowicz, Peter C. Konturek, Krystyna Zwirska-Korczala,
Tomasz Brzozowski, Michal Pawlik, Stanislaw J. Konturek, Wieslaw W. Pawlik, Eckhart
G. Hahn
Melatonin, a major hormone of pineal gland, exhibits gastroprotective and ulcer healing
actions, but the mechanism of anti-ulcerogenic beneficial activity of this indole has been
little studied. In this study, using rats without or with removed pineal gland (pinealectomy),
we compared the effects of i.g. or i.c.v. treatment of melatonin and its precursor, L-tryptophan,
with or without concurrent treatment with luzindole, a selective antagonist of melatonin
MT2 receptors, indomethacin or rofecoxib to suppress cyclooxygenase (COX-1) and COX-
2 activity, respectively on gastric lesions induced by water immersion restraint stress (WRS)
and healing of preexisting gastric ulcers (acetic acid method; ulcer area=28 mm2). At 3.5 h
after the end of WRS or 9 days after ulcer induction, gastric lesions and ulcers were measured
by planimetry, gastric blood flow (GBF) was determined by H2-gas clearance technique,
plasma melatonin and gastrin levels and mucosal PGE2 generation were traced by specific
RIA and expression of mRNA for COX-1 and COX-2 was assessed by RT-PCR. Melatonin
(1.25-10 mg/kg i.g.) or (1.25-10 μg/rat i.c.v.) dose-dependently attenuated the WRS-induced
gastric damage and accelerated ulcer healing while raising GBF, plasma melatonin and gastrin
levels and mucosal generation of PGE2. Pinealectomy, which suppressed plasma melatonin
levels, aggravated the gastric lesions induced by WRS and significantly delayed ulcer healing
and these effects were counteracted by treatment of pinealectomized rats with exogenous
melatonin or L-tryptophan. Luzindole abolished the gastroprotective ulcer healing effects
of melatonin and L-tryptophan and attenuated significantly the rise in GBF evoked by the
indole and its precursor. Indomethacin and rofecoxib which diminished PGE2 biosynthesis
by ~90% and 75%, respectively, significantly attenuated melatonin- and L-tryptophan-
induced protection , ulcer healing and the rise in the GBF. COX-1 mRNA was detected by
RT-PCR in the intact and melatonin-treated gastric mucosa, while COX-2 mRNA, which
was undetectable in the intact gastric mucosa, appeared as a strong signal in melatonin-
treated animals. We conclude that 1) exogenous melatonin and its precursor, L-tryptophan,
attenuate WRS-induced gastric lesions via interaction with melatonin MT2 receptors and an
enhancement of gastric microcirculation, probably mediated by PGE2 derived from COX-2
overexpression and activity, and 2) the pineal gland plays an important role in the limitation
of WRS-induced gastric lesions and acceleration of ulcer healing via releasing melatonin,
which exerts gastroprotective and ulcer healing actions.
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Title Role of Reg I for Regeneration After Gastric Mucosal Injury: A Lesson
from Transgenic Mice
Hiroyuki Fukuhara, Yasunori Kadowaki, Takayuki Ose, Syunji Ishihara, Yoshikazu
Kinoshita
Background and Aim Reg I (regenerating gene product I) was originally identified as a
growth factor involved in pancreatic regeneration, and was suggested also to be a controller
of gastric mucosal regeneration, based on its temporal and spatial expression pattern around
the gastric ulcers. Recently, we created RegI-transgenic (Tg) mice to demonstrate that RegI
has an activity to stimulate the growth of the gastric stem cells, as well as an activity to
direct the proper differentiation(Oncogene 2004;23:3572). In the current study, we utilized
the RegI-transgenic mice as a model system to provide the direct in vivo evidence that Reg
I is involved in the regeneration process after gastric mucosal injury. Method Gastric mucosal
injury was experimentally induced in large array of littermate pairs (86 pairs of Wild type
(Wt) and Tg) by administration of HCl/ethanol. Each animal was sacrificed 6hr (injury
phase), 12hr, 18hr or 24hr (recovery phase) after the administration, and the ulcer index
was measured and statistically processed. The gastric specimen from each time point was
subjected to northern blot analysis or immunohistochemistry to examine the expression
levels of several proliferation markers. Results There was no difference in the ulcer index
between Wt and Tg in the injury phase (6hr: Wt 32mm +/- 5mm, Tg 39mm +/- 8mm;
N.S). However, in the recovery phase, level of gastric injury of Tg-mice was significantly
decreased compared with that of wild-mice. (12hr: Wt 36mm +/- 5mm, Tg 23mm +/- 2mm;
p=0.0044)(18hr: Wt 19mm +/- 3mm, Tg 9mm +/- 3mm; p=0.0207)(24hr: Wt 12mm +/-
3mm, Tg 5mm +/- 1mm; p=0.0178). Expression levels of c-myc and c-fos, which were
employed as proliferation markers, in Tg became significantly higher than those in wild-
type mice in the recovery phase. Conclusion Reg I-Tg mice were less susceptible to HCl/
ethanol-induced gastric mucosal injury than Wt mice. Based on the data from the time course
study, we concluded that the overexpressed Reg I protein contributed to the phenotype, not
by enhancing mucosal defense, but rather by enhancing the cell growth required in regenera-
tion process of the mucosal architecture.
W1713
Simultaneous Effects of Nitric Oxide and Growth Factors On Wound Healing
in Cultured Gastric Mucosal Epithelium
Outi Nylander-Koski, Harri Mustonen, Tuula Kiviluoto, Pauli Puolakkainen, Eero
Kivilaakso
High levels of nitric oxide can be produced by inducible nitric oxide synthase during infection
and inflammation. For example, during chronic Helicobacter pylori infection a constant nitric
oxide production is likely to occur, which may lead to cell and tissue, and even DNA
damage, thus increasing the risk of cancer development. Helicobacter infection also promotes
apoptosis, possibly via induction of iNOS. Since Helicobacter infection occurs commonly
in the stomach we have here investigated the simultaneous effects of growth factors and
nitric oxide on cell migration and apoptosis, with an attempt to simulate the conditions of
epithelial repair in inflamed gastric mucosa. METHODS: Isolated primary cultured rabbit
gastric epithelial cells were cultured to confluency in appropriate media (5% CO2, 37oC).
The cells were treated by hepatocyte growth factor (HGF), transforming growth factor alpha
(TGFα) and keratinocyte growth factor (KGF), with or without sodium nitroprusside (SNP,
NO donor). Caspase-3 (promoter of apoptosis) enzyme activity was measured with time
resolved fluorescence based assay and cell viability was measured with tetrazolium salt
based assay. Migration rate after wounding was calculated from the decreasing wound
area. RESULTS: HGF was the most potent growth factor to stimulate migration, increasing
migration speed from 15.6±0.2 to 27.6±1.1 μm/h (p=<0.001, N=21, 10ng/ml), which was
significantly faster than the TGFα (10ng/ml) stimulated migration speed (20.2±0.4 μm/h,
p<0.001) or KGF (10ng/ml) stimulated migration speed (16.1±0.7 μm/h, p<0.001). SNP
dose dependently decreased the migration speed from 17.6±0.3 to 11.8±0.3 μm/h (p<0.001,
N=144, 1mM SNP). The SNP retarded migration (12.6±0.5 μm/h) was returned to normal
values by HGF (22.8±1.3 μm/h, p<0.001, N= 15) and TGFα (16.1±0.8 μm/h, p<0.001, N=
12), whereas KGF had no effect. SNP also induced caspase-3 activity (1.50±0.08 fold control,
p<0.001, N=12), which was inhibited by HGF (0.98±0.05 fold control, p<0.001, N=12)
and TGFα (1.10±0.03-fold control, p<0.001, N=12). CONCLUSION: Our findings indicate
that growth factors inhibit apoptosis signaling and that they can also overcome the nitric
oxide induced retardation of migration. This inhibition of apoptosis might also contribute
to the observed stimulatory effect of growth factors on SNP retarded wound healing, since
as the number of surviving cells is increased, they can cover the wound faster.
W1714
Cyclooxygenase-2/Prostaglandins Accelerate Healing of Gastric Ulcers Through
Up-Regulation of VEGF Via EP4 Receptors
Ryo Hatazawa, Akiko Tanaka, Yuka Takahira, Mayu Tanigami, Koji Takeuchi
Background/Aim: It is known that selective cyclooxygenase (COX)-2 inhibitors impair the
healing of pre-existing gastric ulcers and that endogenous prostaglandin E2 (PGE2) derived
from COX-2 play a pivotal role in the mechanism of ulcer healing. However, it remains still
unexplored which type of EP receptor subtypes is responsible for the healing promoting
action of PGE2, and how PGE2 contributes to ulcer healing. In the present study, we
investigated the effects of subtype selective EP agonists and antagonists on the healing of
gastric ulcers and investigated the possible mechanism involved in this action. Methods:
Male SD rats were used. Gastric ulcers were produced by thermocauterization (70°C, 20
sec) under ether anesthesia, and the animals were killed 3, 7 and 14 days later. Indomethacin,
rofecoxib or SC-560 was given PO once daily for 10 days starting 3 days after ulceration.
Various EP agonists were given SC together with or without indomethacin. Gastric fibroblasts
were isolated from rat stomachs. The stomachs were minced and incubated in collagenase/

















with 10% fetal calf serum. Results: Ulcer healing was significantly delayed by daily administra-
tion of indomethacin and rofecoxib but not by SC-560. Mucosal PGE2 content was markedly
increased after ulceration, and this response was significantly suppressed by administration
of rofecoxib but not SC-560. The delayed healing caused by indomethacin was significantly
reversed by co-administration of 11-deoxy PGE1, the EP3/EP4 agonist, but not by others
including EP1, EP2 and EP3 agonists. Daily administration of the EP4 antagonist also
significantly impaired the healing of gastric ulcers, as effectively as rofecoxib did. The
expression of VEGF protein was markedly up-regulated in the ulcerated mucosa. The intensity
of the VEGF expression was further enhanced by the EP4 agonist while the intensity was
apparently suppressed by indomethacin and rofocoxib as well as the EP4 antagonist, but
not SC-560. On the other hand, the expression of VEGF protein in gastric fibroblasts in
vitro was also increased by the pre-incubation with PGE2 as well as the EP4 agonist, and
these changes were inhibited by the co-incubation with the EP4 antagonist. Conclusion:
These results demonstrated that COX-2/PGE2 plays an important role in the healing process
of gastric ulcers, and further suggested that this action of PGE2 is associated with the
stimulation of VEGF expression in the gastric fibroblasts mediated by the activation of
EP4 receptors.
W1715
Methylnicotinamide Counteracts the Augmentation of Aspirin- and Stress-
Induced Gastric Lesions Under Diabetic Conditions in Rats
Tomasz Brzozowski, Peter C. Konturek, Slawomir Kwiecien, Urszula Szczyrk, Stefan
Chlopicki, Jakub Cieszkowski, Stanislaw J. Konturek, Wieslaw W. Pawlik
Gastric mucosa of diabetic rats is highly vulnerable to the damage induced by variety of
damaging agents but the influence of methylnicotinamide (MNA), an amide derivative of
witamin B1, that has been shown to exhibit anti-inflammatory properties in gastrointestinal
tract, on aspirin (ASA)- and stress-induced gastric lesions under diabetic conditions has not
been elucidated. In this study, streptozocin (70 mg/kg injected intraperitoneally) was used
to induce diabetes mellitus and non-diabetic and diabetic rats were pretreated 30 min prior
to exposure to ASA (150 mg/kg in 0.1 N HCl i.g.) or 3.5 h of water immersion and restraint
stress (WRS) with 1) vehicle (saline) or 2) MNA (2.5 - 50 mg/kg i.g.). The area and number
of gastric lesions was determined by planimetry, gastric blood flow (GBF) was examined
by H2-gas clearance technique and mieloperoxidase (MPO) activity and activity of superoxide
dismutase (SOD) and the malonyldialdehyde (MDA) concentration as an index of lipid
peroxidation were determined in gastric mucosa using ELISA. The gene expression IL-1β
and TNF-α in the gastric mucosa and their plasma levels were evaluated by RT-PCR and
ELISA, respectively. ASA and WRS caused typical gastric lesions and reduced significantly
GBF (by 35% and 28% from basal) and increased MPO activity (by 2-3 folds) and gastric
mucosal MDA content and these effects were significantly augmented in diabetic rats (plasma
glucose ≤400 mg/dL). The ulcerogenic effects of ASA or WRS were accompanied by the
fall in the GBF and the overexpression of mRNAs for TNF-α and IL-1β and the marked
increase in their plasma levels. MNA dose-dependently attenuated ASA- and WRS-induced
gastric erosions in diabetic and non-diabetic animals while raising GBF in intact and injured
gastric mucosa by about 22% and 33%, respectively, and caused downnregulation of IL-
1β and TNF-α. The mucosal SOD activity was significantly decreased while the MDA activity
was significantly increased in ASA- and WRS-exposed animals without or with diabetes and
these effects were markedly attenuated by MNA. We conclude that 1) diabetes enhances
the susceptibility of gastric mucosa to the damage induced by ASA and WRS via mechanism
involving fall in GBF, suppression of SOD activity, an increase in lipid peroxidation and
overexpression of proinflammatory cytokines IL-1β and TNF-α, and 2) MNA affords protec-
tion against ASA- and WRS-induced damage under diabetic conditions, possibly due to
enhancement in the GBF mediated by attenuation of both, the oxidative stress and proinflam-
matory cytokine expression and release.
W1716
Intracellular pH and Ca++ Measurements in the Mouse Esophagus
Solange M. Abdulnour-Nakhoul, Stephanie M. Busque, John P. Geibel
Introduction: Mouse esophagus is lined by keratinized squamous epithelium which has a
stratum germinativum layer and two to three layers of cells in the stratum spinosum and
corneum. The availability of transgenic mice makes this tissue a very good model for the
elucidation of ion transport mechanisms in different genotypes and disease models caused
by specific mutations aimed at ion transport proteins. We examined the effect of Ca-sensing
receptor (CaSR) activation on intracellular pH (pHi) regulation and intracellular Ca++ (Cai++)
in the mouse esophagus. Immunofluorescence methods using an antibody to CaSR were
used to localize the protein in cryosections of esophageal tissue. Methods: Wild type (CaSR+/
+/GCM2+/+) mice were anesthetized and the esophagus was dissected out and stripped
from its muscularis propria in cold HEPES-buffered Ringer. Thin sections (~200 µm) were
transversely cut, mounted on cover slips and loaded with BCECF (10µM) for pHi measure-
ments or Fluo-4 (5µM) for Cai++ measurements. Changes in Cai++ were estimated from
changes in fluorescence signal measured in arbitrary units (AFU). Results: Immunofluoresc-
ence showed the presence of CaSR on the basolateral membrane of the basal cells. Reduction
of extracellular Ca++ to 0.5 mM reduced AFU by 3±0.8% while increasing Ca++ to 5 mM
caused an increase in AFU of 5±0.9%. When extracellular Ca++ was removed (+EDTA)
there was a 20±5.2% decrease in arbitrary fluorescence units (AFU). Mean pHi in 17 different
tissues was 7.34±0.05. When the cells were acid-loaded by pre-treatment with NH4+ in
nominally HCO3- free Ringer pHi measurements showed a pHi recovery (rate 0.22±0.03
pH/min) that was totally dependent on the presence of extracellular Na. Activation of the
CaSR with neomycin and/or increases in extracellular Ca++ did not significantly affect the
rate of pHi recovery from an acid load. Conclusion: The mouse esophagus expresses a
basolateral Na-H (NHE) exchanger whose activity appears to be independent of both extracel-
lular and intracellular Ca++. Furthermore this protein is not modulated by activation of the
CaSR. We postulate that the mouse esophageal NHE plays a role in cell pH homeostasis.
CaSR expressed in this tissue may be less involved in regulation of pHi or ion transport
than in other cell functions such as growth and differentiation. Supported in part by a VA
Merit grant.
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Role of Monocarboxylate Transporter 1 in the Recovery of Wounds Induced in
the Gastric Epithelial Cells
Shusaku Hayashi, E.J. Nakamura, Yoshikazu Kubo, Susan J. Hagen, Koji Takeuchi
Background/Aim: During the early healing process of gastric mucosal lesions, the intact
epithelial cells migrate to promptly reseal the wounded area. It has been suggested that the
regulation of cell volume and intracellular pH through ion transporters plays a role in cell
migration. However, the role of ion transporters in cell migration after injury in the gastric
mucosa remains still unclear. We have previously reported that DIDS, a stilbene compound,
reportedly known to block Cl-/HCO3- exchangers (AE), Na+/HCO3- co-transporters (NBC)
and monocarboxylate transporter (MCT), completely abolished the recovery of injury both
in the rat gastric epithelial cell line RGM1 monolayers and the isolated guinea pig gastric
mucosa. In the present study, we determine which ion transporters are involved in the
repair process of epithelial cells after injury. Methods: After RGM1 cell monolayer being
confluent, a round artificial wound with constant size was induced in the center of the cell
monolayer using a pencil-type mixer with a rotating silicon tip. The restoration process was
monitored 0, 4 and 8 h after the induction of wound. In the guinea-pig gastric mucosa
mounted in Ussing chamber, injury was produced by mucosal application of 0.5% Triton-
X for 5 min, and the restitution was evaluated by recovery of the electrical resistance (R)
and morphology. We also examined the messenger RNA and protein expression of various
ion transporters in RGM1 cells. Results: In the vehicle-treated group, the size of cell-free
areas was decreased with time after induction of the wound. Phloretin, an inhibitor of
MCT, significantly suppressed the repair of wound in a concentration-dependent manner.
Replacement of the physiological buffered solution with Na+, Cl- or HCO3--free buffer
significantly suppressed the recovery of wound. Addition of phloretin to ion-free buffer
potentiated the suppression of wound recovery observed in each ion-free buffered solution.
Concerning the MCT subtypes, RGM1 cells potently expressed MCT1 mRNA and protein.
In addition, RGM1 cells also expressed both AE2a and NBC1. Conclusion: These results
suggest that MCT1, in addition to AE2a and NBC1, plays an important role in the recovery
of the gastric mucosa by regulating the migration of epithelial cells after injury.
W1718
Lipopolysaccharide Injury to the Stomach May Promote Remote Organ
Pathogenesis
Michelle Lopez-Storey, Lenard Lichtenberger, Elizabeth Dial
Background: Previously we reported that systemically administered bacterial lipopolysacchar-
ide (LPS, E. coli 0111:B4) induced a reflux of intestinal bile acid into the stomach, a reduction
of gastric surface hydrophobicity, and the appearance of bleeding into the stomach (Shock
17:77, 2002). While the presence of blood in the gastric lumen suggested there was local
injury to the mucosa, the status of the gastric mucosal barrier was not fully known. Therefore,
we decided to directly investigate the effect of LPS on the permeability of the stomach to
sucrose, as an indice of the integrity of the barrier. We also assessed a role for another potential
luminal damaging agent, that of intestinal protease activity. Methods: Fasted Sprague-Dawley
rats were administered LPS (0, 5, and 20 mg/kg, ip) four hours before gastric contents were
collected for analysis of bile acid, protease activity, and hemoglobin levels. In a separate
study, rats were similarly dosed with LPS and then were administered sucrose orally (1 g/
1.5 ml/rat) 3.5 hours later. The absorption of intact sucrose has been shown to reflect
damage to the gastric mucosal barrier (Gastroenterology 104:1619, 1993). After an overnight
collection of urine from these animals, sucrose was analyzed by a precise colorimetric method
(Analytical Biochemistry 244:103, 1997). Results: As shown in the table below, LPS treatment
induced a dose-dependent increase in bile acid, protease activity and hemoglobin in the
stomach. LPS also caused a significant increase in gastric permeability to sucrose. Conclusion:
LPS-induced injury to the gastric mucosa may involve the reflux of multiple intestinal factors,
including bile acid and proteolytic enzymes. The accompanying attenuation in the barrier
property of the stomach, to both small (HCl) and potentially large (toxins) molecules, may
contribute to further pathogenesis of the mucosa or to that of remote organs. (Supported
by NIGMS P50 GM38529).
W1719
DSKB-2, a Newly Synthesized NF-KappaB Inhibitor, Ameliorates Gastric
Mucosal Damage Induced By Ischemia and Reperfusion in Rats
Hiroshi Ichikawa, Norimasa Yoshida, Tomohisa Takagi, Osamu Handa, Satoshi Kokura,
Yuji Naito, Takeshi Okanoue, Youichi Nunokawa, Toshikazu Yoshikawa
Objective: Nuclear factor kappa B (NF-kappaB) is activated by several factors, which increase
the inflammatory response, and this activation leads to the expression of several genes such
as cytokines, and may play an important role in ischemia-reperfusion injury. DSKB-2, a
new NF-kappaB inhibitor, is an indan derivative with inhibition of NF-kappaB transcriptional
activation, and it has been reported that this compound suppressed the production of TNF-
alpha and of nitric oxide in RAW 264.7 cells stimulated with LPS. Furthermore DSKB2 also
ameliorated carrageenan-induced rat paw edema formation in vivo. Aim: The aim of the
present study is to evaluate the anti-inflammatory effect of DSKB-2 on reperfusion-induced
gastric mucosal injury in rats. Methods: Gastric ischemia was induced for 30 min by applying
a small clamp to the celiac artery in male Sprague-Dawley (SD) rats weighing 190 - 210
grams. Reoxygenation was produced by removal of the clamp. Just before removal of the
vascular clamp, DSKB-2 at a dose of 0.1-1 mg/kg was injected intraperitonealy. Sixty minutes
after reperfusion, the rats were killed by exsanguinations, and stomachs were removed.
Results: The area of gastric mucosal erosion or ulcerative lesion (erosion index) significantly
increased from mean basal levels after 60 min of reperfusion. This erosion index was
significantly inhibited by pretreatment with DSKB-2 dose-dependently. The concentration
of thiobarbituric acid-reactive substances (TBA-RS) in the gastric mucosa, an index of lipid
peroxidation, was also significantly higher than basal level after 60 min of reperfusion. This
increase in TBA-RS in the gastric mucosa after ischemia-reperfusion was inhibited by the
pretreatment with DSKB-2. Furthermore, myeloperoxidase (MPO) activity in the gastric
mucosa, an index of neutrophil infiltration, significantly increased by ischemia reperfusion,
and pretreatment of DSKB-2 significantly reduced this increase of MPO activity in gastric
mucosa. The content of both mucosal TNF-alpha and CINC-1 in the control group was
significantly increased compared with the levels of those in the normal group. These increases
of the levels of TNF-alpha and CINC-1 were significantly inhibited by the treatment with
DSKB-2. Conclusion: These findings suggest that the activation of NF-kappaB plays an
important role in the pathogenesis of ischemia-reperfusion injury, and that the NF-kappaB
inhibitor, DSKB-2, may become a new therapeutic agent for reperfusion injury.
W1720
Taurocholate Potentiates Ethanol Induced NfκB Activation and Inhibits
Caspase-3 Activity in Cultured Rat Gastric Epithelium
Harri Mustonen, Tuula Kiviluoto, Pauli Puolakkainen, Eero Kivilaakso
We have previously shown that ethanol induces NFκB activation and apoptosis in rat gastric
epithelium. However, it is not known how concomitant exposure to other ulcerogenic agents
modulates these actions. This study investigates NFκB activation and apoptosis in cultured
gastric epithelium following concomitant exposure to ethanol and taurocholate. METHODS:
Rat gastric mucosal cells (RGM-1) were grown in cell culture flasks to confluent monolayers
at 37oC in humidified atmosphere containing 5% CO2 in air. The cells were exposed apically
for different time periods to ethanol and taurocholate. For assessment of NFκB activation
nuclear protein extracts were analyzed with ELISA based transcription factor assay. Caspase-
3 (promoter of apoptosis) enzyme activity was measured with time resolved fluorescence
based assay. Cell viability was measured with tetrazolium salt based assay and cell membrane
integrity with lactate dehydrogenase based assay. RESULTS. 2% and 5% ethanol induced
NFκB activation dose dependently 1.6±0.2 (p<0.01, N=8) fold and 3.7±0.4 (p<0.01, N=8)
fold as compared to control. Exposure to 5% ethanol with simultaneous exposure to 5mM
or 10 mM taurocholate increased NFκB activation from 3.4±0.4 to 7.9±0.9 fold control
(p<0.01, N=8) and from 3.4±0.4 to 8.5±1.7 fold control (p=0.01, N=8), respectively. Tauro-
cholate exposure alone had no effect on NFκB activation. Exposure to taurocholate (10
mM) decreased caspase-3 activity from 1.0±0.1 to 0.43±0.1 fold control (p<0.01, N=12).
Taurocholate (10 mM) decreased the ethanol (5%) induced caspase-3 activity from 2.0±0.3
to 0.88±0.2 fold control (p=0.02, N=16). Also the ethanol (5%) induced decrease in cell
viability was opposed by simultaneous exposure to taurocholate (10 mM) from 93±2% to
105±2% (p<0.01, N=20, control cells=100%, lysed cells=0%). The ethanol induced cell
membrane damage was also opposed by low concentrations (10 mM) of taurocholate from
7.7±0.3% to 0.6±0.3% (p<0.01, N=24, intact membrane=0%, totally damaged membrane=
100%). Larger concentrations than 10 mM of taurocholate with ethanol resulted gradually
in severe cell membrane damage and decrease in cell viability. CONCLUSIONS. Although
taurocholate itself does not induce NFκB activation at low concentrations, it potentiates
ethanol induced NFκB activation, inhibits ethanol induced apoptosis and increases cell
viability lowered by ethanol. Larger concentrations of taurocholate result in cell membrane
damage with ensuing loss of cell viability.
W1721
Mechanism Underlying Impaired Healing By Alendronate of Gastric Ulcers in
Rats
Kikuko Amagase, Shusaku Hayashi, Eitaro Aihara, Kaoru Nishikawa, Koji Takeuchi
Background/Aim: Bisphosphonates (BPPs) such as alendronate have been developed as anti-
resorptive agents capable of treating diseases related to bone remodeling. These drugs have
untoward effects on the upper gastrointestinal tract in humans such as gastroesophageal
inflammation and ulceration. However, the influence of these drugs on the healing of the
pre-existing gastric ulcers has not been much studied. In the present study, we examined
the effect of alendronate on the healing of acetic acid-induced gastric ulcers in rats and
investigated the mechanism involved in this action. We also examined the effect of alendronate
on the epithelial restitution after injury, using the rat gastric epithelial cell line (RGM1).
Methods: 1) Male SD rats and RGM1 cells were used. Gastric ulcers were induced in rats
by serosal application of acetic acid (99%, 100 μl) for 60 sec, using a small cup. Alendronate
(60 mg/kg, PO) or indomethacin (2 mg/kg, SC) was given once daily for 7 days, starting 3
days after acid application. Prostaglandin (PG) E2 content was measured by EIA. Expression
of growth factor protein was determined by western blotting. 2) After RGM1 cell monolayer
being confluent, a round artificial wound was induced in the center of the cell monolayer
using a pencil-type mixer with a rotating silicon tip, and the restitution process was monitored
up to 8 h thereafter. Results: Gastric ulcers induced by acetic acid healed spontaneously
with up-regulation of COX-2 expression and PGE2 production as well as the expression of
VEGF and bFGF in the ulcerated mucosa. The healing of the ulcers was significantly impaired
by the repeated administration of indomethacin or alendronate. Indomethacin significantly
inhibited the production of PGE2 in the mucosa while aledronate did not. However, alendron-
ate decreased the protein expression of both VEGF and bFGF in the ulcerated mucosa,
similar to indomethacin. On the other hand, the size of cell-free areas in RGM1 cells in vitro
decreased with time after the wound induction, the process being due to a migration of
intact cells, and this healing was significantly promoted by EGF (10 ng/ml). Co-incubation
with alendronate (1 mM) did not affect the spontaneous healing but significantly suppressed
the accelerated wound healing caused by EGF. Conclusion: These results suggest that 1)
alendronate delays the healing of acetic acid gastric ulcers in rats, and 2) the healing
impairment effect may be related to the down-regulation of growth factors such as VEGF
and bFGF, important for the vascularization/granulation, and the suppression of the stimula-
tory action of EGF on the epithelial proliferation/migration.
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Dietary Nitrate and Luminal Nitrite Decrease Taurocholate and Diclofenac
Induced Gastric Mucosal Damage
Joel Petersson, Mia Phillipson, Emmelie A. Jansson, Jon O. Lundberg, Lena Holm
Background: Most of the dietary nitrate originates from green leafy vegetables. Bacteria in
the oral cavity reduce nitrate to nitrite. In the acidic stomach nitrite is further reduced to
nitric oxide (NO). We have earlier shown that acidified nitrite increases gastric mucosal
blood flow (GMBF) in both rats and mice, and that this is a direct effect of luminal NO.
We wanted to investigate the gastro-protective role of acidified nitrite administrated luminally
as well as dietary intake of nitrate, by measuring the mucosal permeability and GMBF,
before, during and after a provoked damage caused by diclofenac and taurocholate. Methods:
Rats were anesthetized with inactin (120mg×kg-1ip) and the gastric mucosa was exteriorized
for intravital microscopy. Mucosal permeability was measured as blood to lumen clearance
of 51Cr-EDTA. During the experiments (130 min), the gastric mucosa was covered with 10
mM HCl. Diclofenac (5 mg×kg-1iv) was given 20 min after start and 30 min later 20 mM
taurocholate was applied luminally for 40 min. The luminal solution was replaced every 10
min for analyses of 51Cr-EDTA. One group of animals received 2.0 mM NaNO2 luminally
10 min after start and then throughout the entire experiment. A second group was pretreated
with NaNO3 (0.1 mg×kg-1 daily) in the drinking water for 7 days before the experiment.
A third group served as controls. GMBF (Laser-Doppler flowmetry) and blood pressure were
measured during the experiments and vascular resistance was calculated. Luminal NO
was measured with chemiluminescence. Results: Animals given nitrite and nitrate had
significantly higher GMBF and lower vascular resistance than the control group. Permeability
did not significantly differ between the groups before taurocholate and diclofenac administra-
tion, but was significantly less increased during the provocation in the nitrite and nitrate
treated animals (Table 1). Animals pretreated with nitrate had greatly increased luminal NO
levels (6280±1995ppb), compared to control animals (127±40ppb). Conclusions: Nitrite
and nitrate pretreatment decreases taurocholate and diclofenac induced mucosal damage.
The gastro-protective effect might depend on a higher basal mucosal blood flow due to
NO production.
Table 1
*p<0,05 vs Control, Clearence (ml/min 100g tissue) Resistance (mmHg/PFU) Values are
mean ± SEM
W1723
Da-9601, a Standardized Extract of Artemisia Asiatica, Blocks TNF-α-Induced
Mip-3α/Ccl20 Production By Inhibiting P38 Kinase and Nf-κB Pathways in
Human Gastric Epithelial Cells
Tae Young Oh, Chang-Duk Jun, Chang Yell Shin, Suck-Chei Choi, Eun-Ju Choi, Hyun-
Mee Oh, Eun-Young Choi, Myeung-Su Lee, Yong-Il Shin, Suck-Jun Choi, Won-Jung Lee,
Jae-Sik Park
CCL20 appears to link innate and acquired immunity by attracting immature dendritic cells,
effector memory T cells and B cells via its unique receptor CCR6. Artemisia asiatica has
been used in traditional Asian medicine for the treatment of inflammatory and other disorders.
The formulated ethanol extract (DA-9601) of A. asiatica have pronounced anti-oxidative
and anti-inflammatory activities and exhibit cytoprotective effect againsts gastrointestinal
damages. Here we have investigated whether or how DA-9601 inhibits TNF-α-induced
CCL20 production in gastric epithelial AGS cells. Treatment of AGS cells with DA-9601
reduced TNF-α-induced CCL20 promoter activity as well as the gene expression and protein
release. Although all three MAP kinase family members were phosphorylated in response
to TNF-α, only SB203580, a selective inhibitor of P38 kinase, could inhibit both NF-κB-
dependent transcriptional activity and CCL20 production, suggesting that p38 kinase is
functionally linked to NF-κB-dependent pathways in regulating CCL20 induction. Interest-
ingly, DA-9601 also selectively inhibited p38 kinase phosphorylation induced by TNF-α.
Moreover, DA-9601 blocked NF-κB-dependent transcriptional activity, NF-κB p65 nuclear
translocation, and I-κB degradation in TNF-α-treated AGS cells or HEK293T cells. Collect-
ively, we conclude that DA-9601 potently inhibits TNF-α-mediated CCL20 production by
blocking p38 kinase pathway and/or a signal leading to NF-κB-dependent pathways.
W1724
Epigenetic Inactivation of Wnt Inhibitory Factor-1 Is Frequently Observed in
Human Gastrointestinal Cancers
Hiroyuki Yamamoto, Hiroaki Taniguchi, Katsuhiko Nosho, Yasushi Adachi, Takao Endo,
Kohzoh Imai, Yasuhisa Shinomura
Aberrant activation and upregulation of the Wnt pathway is a key feature of many cancers.
Wnt antagonists have recently attracted wide attention. Wnt inhibitory factor-1 (WIF-1) is
a secreted antagonist that can bind to Wnt proteins directly and inhibit Wnt signaling
pathway. It has been reported that WIF-1 expression is down regulated in several solid
tumors and that WIF-1 is silenced by promoter hypermethylation in lung and colorectal

















analyzed expression and methylation of WIF-1 in cancer cell lines and freshly resected
cancer tissues of the esophagus, stomach, colorectum, and pancreas. Downregulation of
WIF-1 mRNA expression was observed in 61 (91.0%) of 67 cancer cell lines, 16 (80.0%)
of 20 esophageal, 23 (74.2%) of 31 gastric, 41 (82.0%) of 50 colorectal, and six (75.0%)
of eight pancreatic cancer tissues. Downregulation of WIF-1 expression was also observed
at protein level. No significant association between WIF-1 downregulation and clinicopathol-
ogical characteristics was found, suggesting that downregulation of WIF-1 expression is an
early event in carcinogenesis of these cancers. Indeed, downregulation of WIF-1 expression
was observed in 32 (72.7%) of 44 colorectal adenoma tissues and 18 (78.2%) of 23 early
mucosal or submucosal colorectal carcinoma tissues. CpG island hypermethylation in the
WIF-1 promoter region correlated with downregulation of WIF-1 expression in cancer cell
lines and tissues. Treatment with demethylating agent, 5-aza-2’-deoxycytidine (5-aza-dC),
restored WIF-1 expression in cancer cell lines. A combined treatment of 5-aza-dC and
a histone deacetylase inhibitor, trichostatinA, restored WIF-1 expression synergistically,
indicating the role of cytosine methylation and histone deacetylation in the silencing of the
WIF-1 gene. Transfection of the WIF-1 gene construct into TE-1 esophageal cancer cell
lines or SW48 colon cancer cell lines lacking WIF-1 expression resulted in a significant
inhibition on colony formation, cell proliferation, anchorage-independent growth in soft
agar. TOPflash assay showed WIF-1 inhibits Wnt canonical signaling in these cell lines.
These results suggest tumor suppressive function of WIF-1, due to its ability to inhibit Wnt
signaling. Our results suggest that WIF-1 silencing due to promoter hypermethylation is
an important mechanism underlying aberrant activation of the Wnt signaling pathway in
carcinogenesis of the digestive organs. Modulation of the Wnt pathway, through reversal of
WIF-1 silencing by demethylating agents, is a potential target for treatment and/or prevention
of gastrointestinal cancers.
W1725
Epigenetic Silencing of Axin2 in Colorectal Carcinoma with Microsatellite
Instability
Koji Koinuma, Hideo Nagai, Hiroyuki Mano
Mutation or epigenetic silencing of mismatch repair genes, such as MLH1 and MSH2, results
in microsatellite instability (MSI) in the genome of a subset of colorectal carcinomas (CRCs).
However, little is yet known of genes that directly contribute to tumor formation in such
cancers. To characterize MSI-dependent changes in gene expression, we have now compared
transcriptomes between fresh CRC specimens positive or negative for MSI (n=10 for each)
with the use of high-density oligonucleotide microarrays harboring >44 000 probe sets.
Correspondence analysis of the expression patterns of isolated MSI-associated genes revealed
that the transcriptome of MSI(+) CRCs is clearly distinct from that of MSI(-) CRCs. Such
MSI-associated genes included that for AXIN2, an important component of the WNT signaling
pathway. AXIN2 was silenced, apparently as a result of extensive methylation of its promoter
region, specifically in MSI(+) CRC specimens. Forced expression of AXIN2, either by treat-
ment with 5'-azacytidine or by transfection with AXIN2 cDNA, resulted in rapid cell death
in an MSI(+) CRC cell line. These data indicate that epigenetic silencing of AXIN2 is
specifically associated with carcinogenesis in MSI(+) CRCs.
W1726
A Cpg Island Within the P-Cadherin Promoter Is Hypomethylated Early
During Colorectal Tumourigenesis: Biological Consequences
Stuart McDonald, Paul A. Atherfold, Jolanta Obszynska, Robert G. Hardy, Scott Sanders,
Rebecca Harrison, Andrew Rowan, Ian P. Tomlinson, Nicholas A. Wright, Janusz A.
Jankowski
Cadherins mediate cell-cell adhesion in tissues of higher organisms. Our group and others
have shown that in colorectal tumourigenesis, altered patterns of cadherin expression are
associated with neoplastic progression. Specifically, P-cadherin, normally expressed only in
stratified epithelia (and not normal colon), is intimately associated with early Aberrant Crypt
Foci (ACFs) and subsequent colorectal carcinoma development. Neither mutation within
nor chromosomal amplification of the P-cadherin gene accounts for such ectopic expression,
and this study therefore assessed whether changes in P-cadherin promoter methylation
correlate with changes in expression and what the functional implications might be. Using
methylation-specific PCR (MSP), the methylation status of the P-cadherin promoter was
analysed in 19 samples of normal colorectal mucosa, 20 samples of normal colorectal mucosa
adjacent to carcinoma, 15 ACFs and 15 carcinomas. P-cadherin mRNA and protein expression
was confirmed by RT-PCR and immunohistochemistry. In DNA from 4 of 39 ‘histologically
normal’ colon samples, the P-cadherin promoter was fully unmethylated, but only these
cases, which were derived from tissue adjacent to colorectal cancer, had detectable P-cadherin
mRNA expression. In the remaining samples, both methylated and unmethylated DNA was
detected. Microisolation of enterocytes from non-expressing normal colonic mucosa showed
that these cells were fully methylated. All ACFs and carcinomas analysed possessed a fully
unmethylated promoter, and expressed P-cadherin mRNA, indicating demethylation during
or prior to tumourigenesis. Forced P-cadherin mRNA expression in non-constitutively
expressing cells increased S-phase cell cycle fractions. siRNA experiments, in colorectal
cancers cell lines without promoter methylation demonstrated that down regulation of P-
cadherin expression increased G0/G1 cell cycle fractions and decreased total cell counts.
These results demonstrate that demethylation of the P-cadherin promoter can occur at very
early stages of tumourigenesis. Our data suggest that this mechanism can lead to the P-
cadherin gene being ectopically expressed, increasing entry into the cell cycle and contributing
to hyperplasia, in ACFs and neoplasia.
T : 89386$$CH2
05-04-06 23:18:32 Page 716Layout: 89386B : e
A-716AGA Abstracts
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Laterally Spreading Type of Colorectal Adenoma Exhibits a Unique
Methylation Phenotype and K-RAS Mutations
Sakiko Hiraoka, Jun Kato, Joichiro Horii, Keita Harada, Hideyuki Fujita, Tamiya
Morikawa, Hidenori Shiraha, Yasushi Shiratori
Background and aims: Laterally spreading tumors (LST) of the colon, which are characterized
by lateral extension along the luminal wall with a low vertical axis, were initially reported
by Kudo et al. (World J Surg 1997). A previous report indicated that LST were found in
approximately 6% of early stage colorectal cancers. LST were further classified into granular
type LST (G-LST) and flat type LST (F-LST) according to the morphology of the surface
(Hurlstone DP. et al. Gut 2004). G-LST were composed of superficially spreading aggregates
of nodules forming a flat based lesion with a granulonodular and uneven surface, while F-
LST have a flat smooth surface, with an absence of granulonodular formation. Although
these types of tumors were initially recognized only in Japan, they have also been detected
and accepted in Western countries in recent years. However, genetic and epigenetic character-
istics of these tumors were scarcely reported. The aim of this study is to determine methylation
phenotypes and K-ras mutations of LST in comparison with those of conventional protruded
adenomas. Methods: A total of 108 sporadic colorectal adenomas larger than 1 cm were
collected. These tumors were classified into conventional protruded-type (73 lesions, 68%),
G-LST (23 lesions, 21%), and F-LST (12 lesions, 11%) according to the macroscopic
appearance of adenomas, based on colonoscopy observations. CpG island methylator pheno-
type (CIMP) was determined by examination of methylation status at p16, MINT 1, 2, 12,
and 31 loci. CIMP-high was defined as adenomas with concordant methylation of two or
more sites out of five regions examined. K-ras codon 12 and 13 point mutations were also
examined. The relationship between macroscopic appearance and CIMP status or K-ras
mutations was analyzed. Results: CpG island methylation involving two or more loci (CIMP-
high) was more likely to be observed in G-LST (14/23; 61%) than in conventional protruded-
type adenomas (18/73; 25%) (p = 0.002). The prevalence of K-ras mutations in G-LST (18/
23; 78%) was significantly higher than that in protruded-type adenomas (18/73; 25%) (p
< 0.0001). Moreover, the prevalence of CIMP-high and K-ras mutations in G-LST located
in the proximal colon was much higher (11/13; 85%, and 12/13; 92%, respectively). In
contrast, F-LST exhibited low prevalence of CIMP-high (1/12; 8%) and K-ras mutations (2/
12; 16%). Conclusions: High prevalence of CIMP-high and K-ras mutations in G-LST,
especially in the proximal colon, could strongly suggest that G-LST appearance is associated
with a unique genetic and epigenetic carcinogenic pathway.
W1728
Genome-Wide Analysis of Allelic Imbalance By Using High-Density Single
Nucleotide Polymorphism (SNP) Array in Colorectal Cancer
Motohisa Tada, Fumihiko Kanai, Yasuo Tanaka, Lian-Jie Lin, Keisuke Tateishi, Osamu
Yokosuka, Masashi Sanada, Yasuhito Nannya, Seishi Ogawa, Masao Omata
(Background and Aim) Most human cancers are characterized by genetic instabilities. These
genetic instabilities in colorectal cancer can be divided into two distinct types, with over
85 % of tumors showing chromosomal aberrations, and 10 % of tumors demonstrating
microsatellite instability. Though comparative genomic hybridization (CGH) was initially
used to detect chromosomal copy number changes, it was difficult to identify key molecule
for carcinogenesis because of low resolution (about 20 Mbp).In this study, we sought to
identify the key molecule in colorectal cancer pathogenesis by using high-density SNP array.
(Materials and Methods) We analyzed 35 colorectal cancer cell lines and 20 primary colorectal
cancer for areas of DNA copy number changes and loss of heterozygosity (LOH) through
genome-wide analysis of 116, 204 SNPs distributed across all human chromosomes with
Affymetrix GeneChip Human Mapping 1OO K Set (mean intermarker distance 23.6 Kbp).
Copy Number Analyzer for GeneChip (CNAG), our original analysis tool that automates
the detection of copy number and regions of LOH, was used for data analysis. The results
from the array analysis were verified by PCR, quantitative real-time PCR and Fluorescent
In Situ Hybridization. (Results)Over all, in both cell lines and primary tumors, gain of 8q,
13q, 20p and 20q, loss of 8p and 18q and LOH of 5q, 14q, 17p and 18q were detected
with high frequency. Moreover, allelic homozygosity was detected at 5q, 14q, 17p and 18q
frequently in both cell lines and primary tumors. In detail, narrow (less than 1 Mbp) 22
regions of high grade amplification (n ≧ 5) were found in at least two cell lines. The
size of minimal common amplified region was 42 Kbp. Thirty-two regions of high grade
amplification (n ≧ 4) were detected in at least one primary tumor. Twenty-four regions of
homozygous deletion were detected in at least one cell line and the size of minimal deletion
was 11 Kbp. Homozygous and hemizygous deletions were detected in 6 and 29 regions in at
least one primary tumor, respectively. In addition to known genetic abnormality, homozygous
deletion of Chr.4q22.1 region was newly identified. (Conclusion) Affymetrix GeneChip
Human Mapping 100 K Set and CNAG revealed that allelic homozygosity may be one of
the mechanisms of colorectal carciniogenesis and by using these methods, we could detect
minimal region of copy number alteration, which had never been able to detect by other
methods because of its limitation of resolution. The novel amplified and deleted regions
discovered in this study may be significant and useful for early diagnosis and novel therapy
based on molecular targeting in colorectal cancer.
W1729
Mgmt Promoter Hypermethylation in Barrett’s Adenocarcinomas and Its
Premalignant Lesions
Regine Schneider-Stock, Doerthe Kuester, Dar Altaf, Michael Vieth, Ulrich Peitz, Brigitte
Peters, Christopher C. Moskaluk, Frank Meyer, Manfred Stolte, Peter Malfertheiner, Hans
Lippert, Albert Roessner, Wael El-Rifai
Transcriptional silencing of tumor suppressor genes by promoter CpG island hypermethyl-
ation plays a role in the multistep-carcinogenesis of many tumors of the gastrointestinal
tract. Reports on methylation status of the premalignant lesions of Barrett’s adenocarcinoma
(BA) are limited. The DNA-repair gene O6-methylguanine-DNA methyltransferase (MGMT)
transfers alkyl groups at the O6-position of guanine to a cysteine residue avoiding specific
mutagenic effects of DNA damage. Thus, MGMT inactivation is associated with G:C to A:T
mutations in the p53 gene. It was reported that p53 mutations and p53-LOH are highly
frequent events in BA even in the absence of dysplasia and adenocarcinomas. Therefore, we
studied the MGMT promoter methylation status as well as MGMT mRNA and protein
expression in a group of 61 BA and their corresponding preneoplastic lesions and normal
esophageal mucosae (NT). Separation of the different histological stages of Barrett’s carcino-
genesis was done on hematoxylin-eosin slices of formalin-fixed, paraffin-embedded tissue
and partly performed by laser microdissection. Furthermore, we studied the immunohistoch-
emical MGMT protein expression using tissue microarrays of additional 66 BA and correlated
these findings with clinicopathological data. Using methylation-specific PCR we revealed
MGMT hypermethylation (low/high) in 21.4%/0% of NT, 22.2%/66.7% of Barrett’s mucosa
(BM), 6.7%/93.3% of intraepithelial neoplasia, and 17.9%/59% of BA. MGMT promoter
methylation correlated significantly with a decrease in MGMT mRNA expression (p=0.048)
and with a decrease in MGMT immunohistochemical protein expression (p<0.01). There
was a tendency for BA with progressed GERD status to have MGMT promoter methylation
more frequently. We noted a frequent loss of MGMT protein expression with advanced
depth of tumor invasion and tumor stages (p=0.04). There was no correlation between
MGMT inactivation and sex, age, tumor grading and gastric Helicobacter pylori status. We
report an increased frequency of MGMT hypermethylation with tumor progression of BA
and consider MGMT promoter hypermethylation an early event in Barrett’s carcinogenesis.
W1730
Helicobacter Pylori Infection, Interleukin 1 Beta Polymorphism and
Predisposition to Gastric Cancer Through the Cpg Island Methylation
Pathway
Annie On On Chan, Kent Man Chu, Suet Yi Leung, Camy Huang, Yun Wei Sun, Samuel
Ko, Man Fung Yuen, Harry Xia, Chi Hin Cho, Wai Mo Hui, Shiu Kum Lam, Asif Rashid,
Benjamin Cy Wong
Background: The association of HP infection and IL-1β polymorphism increases the risk of
developing gastric cancer. Gastric mucosa of patients with Helicobacter pylori (HP) infection
have CpG island methylation at tumor suppressor genes. Interleukin 1beta (IL-1β) increases
gene methylation at CpG islands. We postulate that HP infection and IL-1β polymorphism
predispose to gastric cancer through CpG island methylation pathway. Aim: To investigate
if an association exists between IL-1β polymorphism, HP infection and methylation and in
patients with gastric cancer. Methods: We determined IL-1B-511/-31 and IL-1RN genotypes
in 98 patients with gastric cancer. Methylation of MGMT, E-cadherin, DAPK and p16 were
assessed in these patients using methylation-specific PCR and confirmed by sequencing. HP
status was confirmed by histology and serology. Results: HP infection was present in 65.3%
(64) patients. The T and C alleles at the -511 locus of the IL-1B gene were in near total
linkage disequilibrium with the C and T alleles at the -31 locus. Hence only -511 locus was
assessed. The allele frequencies at IL-1B-511 were 16% (16), 59% (58), and 25% (24) for
C/C, C/T, and T/T genotypes, respectively. Allele 2 of the IL-1RN locus was not detected
in any patients. Methylation of MGMT, E-cadherin, DAPK and p16 were present in 30%
(29), 59% (58), 43% (42) and 45% (44) of patients, respectively. Methylation of two or
more genes was present in 84% (20) of patients with the IL-1B-511 T/T genotype, 44% (7)
with C/C genotype, and 74% (43) with T/C genotype (p = 0.02). This association was
present in patients with HP infection: 88% (15) with T/T genotype, 38% (3) with C/C
genotype, and 77% (30) with T/C genotype (p = 0.02), but not present in patients without
HP infection (p = 0.6). Conclusion: We postulate that the patients with HP infection and
IL-1B-511 T/T genotype may be predisposed to gastric cancer through the CpG island
methylation pathway.
W1731
A Negative Correlation Between IL-6 and DNA Methylation in Patients with
Gastric Cancer
Li Ping Tang, Chi Hin Cho, Wai Mo Hui, Camy Huang, Ching Lung Lai, Harry Hx Xia,
Shiu Kum Lam, Asif Rashid, Benjamin Cy Wong, Annie On On Chan
Background: Serum IL-6 levels have been shown to have prognostic significance in gastric
cancer. CpG island methylation is an important mechanism for gene silencing and has been
demonstrated in gastric cancer. It has been shown that DNA methylation is a non-redundant
repressor of the Th2 effector system. Aim: To investigate the association between serum IL-
6 levels and CpG island methylation at p16, DAPK, MGMT and E-cadherin in patients
with gastric cancer. Methods: Methylation status was studied using methylation specific
polymerase chain reaction (MSP) in surgical specimens of 75 patients with gastric adenocarci-
noma. CpG island methylator phenotype (CIMP) was defined as positive if methylation was
present in more than one marker. IL-6 serum levels were measured by chemiluminescent
enzyme immunoassay (CLEIA) in sera of these patients. Concentration of IL-6 was expressed
in median (range). The comparison of IL-6 in relation to methylation and clinical data was
assessed by Mann Whitney test. Results: Methylation of p16, DAPK, MGMT, and E-cadherin
were present in 53%, 48%, 32%, and 59% of patients. Patients with tumors methylated at
p16 and DAPK had lower serum levels of IL-6 compared to patients with unmethylated
tumors (1.8 pg/ml (range: 0.6-15.6 pg/ml) vs 4.8 pg/ml (range: 0.3-206.3 pg/ml), p=0.01
for p16, and 1.5 pg/ml (range: 0.6-100.8 pg/ml) vs 6.2 pg/ml (range: 0.3-206.3 pg/ml), p=
0.0001 for DAPK), but there was no difference with MGMT and E-cadherin methylation
status. Lower concentration of IL-6 was also observed in patients with CIMP+ tumors: 2.2
pg/ml (range: 0.3-206.3 pg/ml) vs 7.0 pg/ml (range: 1.2-34.7 pg/ml) (p=0.016). Serum IL-
6 levels were also associated with TNM stage (p=0.001), depth of tumor invasion (p=0.002),
lymphatic invasion (p=0.01), vascular invasion (p=0.008), metastasis (p=0.002) and signet
cell histology (p=0.001). Conclusion: Low serum IL-6 levels were associated with tumor
methylation in patients with gastric cancer, which may be due to simultaneous methylation
at the IL-6 gene, or that inflammatory cytokines can modulate tumor methylation.
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Is Risk for Sporadic Colorectal Adenoma with Higher Calcium and Vitamin D
Intakes Modulated By XRCC1 Base Excision Repair Genotype?
Aasma Shaukat, Woody J. Coker, Roberd M. Bostick
BACKGROUND: Despite a strong rationale and support from basic science and animal
models, findings in humans for an association between calcium and vitamin D intake and
risk for colorectal neoplasms have been inconsistent, and the underlying reasons for this
inconsistency are unclear. The XRCC1 gene is involved in DNA base excision repair. Calcium
and vitamin D intake may protect colonocytes from DNA damage by reducing free bile acids
in the gut. However, an interaction of calcium and vitamin D with XRCC1 genotype on
risk for colorectal neoplasms has not been investigated. AIMS: To investigate whether the
capacity for calcium and vitamin D intake to reduce risk for incident sporadic colorectal
adenomas depends upon XRCC1 base excision DNA repair genotypes. METHODS: We
analyzed data from a community/colonoscopy-based case-control study of incident sporadic
colorectal adenomatous polyps. Average risk patients 30 - 74 years of age were scheduled
for elective, outpatient usual care colonoscopies and completed questionnaires, including a
food frequency questionnaire, prior to colonoscopy. To determine XRCC1 genotypes, 167
pathology-confirmed cases and 214 adenoma-free controls underwent PCR-RFLP analyses
for C194T (exon 6), G280A (exon 9), and G399A (exon 10) polymorphisms of the XRCC1
gene. Calcium and vitamin D intake was categorized above and below the median intake
in controls. RESULTS: Overall, risk for adenomas was lower with higher intakes of calcium
(OR 0.58, 95% CI 0.36-0.93), but not vitamin D (OR 0.71, 95% CI 0.71-1.12). In analyses
stratified by XRCC1 genotypes risk for adenomas with higher calcium intake was more
pronounced among those with one or more variant alleles at exons 9 (OR 0.23, 95% CI
0.04-1.43) and 10 (OR 0.30, 95% CI 0.15-0.60), but it was statistically significant only
with exon 10 (p = 0.001). In fact, any combination of exon 9 and 10 genotypes that
contained even one allele with a GA or AA genotype was associated with lower risk for
adenoma with higher calcium intake (OR 0.34, 95% CI 0.18-0.64). The results for vitamin
D were similar but less pronounced and not statistically significant. CONCLUSION: These
results suggest that possible preventive effects of calcium and perhaps vitamin D may depend
on XRCC1 genotype, and provide a possible explanation for inconsistent associations between
calcium and vitamin D intake and risk for colorectal adenomas.
W1733
Inactivation of Differential Tumor Suppressor Genes in Neuroendocrine
Tumors of the Gastrointestinal Tract
Christian Arnold, Andrea Sosnowski, Rudolf Arnold, Hubert E. Blum
Introduction: Little is known about the molecular mechanisms leading to neuroendocrine
tumors (NET) of the gastrointestinal system. We have recently demonstrated the role of
promoter methylation of tumor suppressor genes (TSG) in NET. In this study we investigated
the differential inactivation of TSG and the functional significance of genes silenced by
promoter methylation which are believed to be frequently inactivated in NET. METHODS:
In this study 118 well differentiated fore- and midgut NET from 71 patients were investigated.
The methylation status of hMLH1, p16, APC, O6-MGMT, PTEN, HIC1, e-cadherin, RASSF1a,
TIMP3 and MEN1 was examined by methylation specific PCR. The expression profiles of
p16-, APC- and MENIN were investigated by immunohistochemistry. TSG expression and
methylation status was correlated with the ki-67 proliferation index. RESULTS: Promoter
hypermethylation was a prominent feature. Apart from a difference in promoter hypermethyl-
ation of the runx3-gene in functional vs. non-functional NET (p = 0,023), no differences
in the promoter methylation profile of the tumors were evident. Tumors with high ki-67
index (> 10%) were significantly more often methylated than NET with low ki-67 index (<
2%) (p = 0,034). We observed a significant loss of p16-expression (p≤ 0,05) in insulinomas
vs. pancreatic non-functional and non-functional NET. p16-expression in functional vs.
non-functional NET was also significantly decreased (p≤ 0,01). APC was expressed signific-
antly less in gastrinomas (p ≤ 0,01) and functional NET (p ≤ 0,05) vs. non-functional
tumors. APC-expression was strongly decreased in insulinomas vs. pancreatic non-functional
tumors (p = 0,017). NET with the carcinoid syndrome (p = 0,029) and non-functional NET
(p = 0,019) expressed MENIN significantly less than insulinomas. In general, NET with the
carcinoid syndrome had a decreased MENIN-expression than pancreatic NET (p = 0,033).
Discussion: This is the first study demonstrating differential expression of p16, APC and
MENIN in NET. In general, functional NET of the pancreas showed a decreased expression
of p16 and APC, while MENIN was expressed less in NET with the carcinoid syndrome.
Promoter methylation was a common feature in all tumor types from various origins with
only few differences. Tumor with a high proliferation index demonstrated a high promoter
methylation status compared with tumors with a low ki-67 index indicating a prognostic
significance for promoter methylation in NET.
W1734
Microsatellite Instability in Human Colorectal Cancer (CRC): Effect of EGFR
Overexpression
Nijez Aloulou, Marie-Therese Chaumette, Amel Sekour, Karen Leroy, Mohammad
Abolhassani, Iradj Sobhani
EGFR is expressed in colorectal tumours. In the experimental models, EGF like peptides
exert either trophic effect and control anti tumoral immune response in CRC. The most
immunogenic tumours have high frequency of MSI-H. The aim of this work was to analyze
EGFR expression in colon tumours with respect to the mismatch repair (MMR) status.
Patients-methods. Data of 130 consecutive patients [57 W, 73 M; median age 70 (29 to
100) yrs] were collected. MSI-H was determined using Fluorescent PCR Pentaplex and
Immunohistochemistry (IHC) on the basis of at least 3 instable sequences out of 5 mono-
morphic microsatellite markers, and lack of hMLH1 or hMSH2, respectively, when tumoral
tissue was compared to the normal homologous mucosa. EGFR expression was similarly
determined via IHC. Membrane expression of EGFR was evaluated semi quantitatively as E

















very strong). The “E x I” score (0 to 16) was used to define two classes with weak (Wk<9)
or high (ST>or=9) EGFR expression with MaxE x I being =9 in normal tissues. The statistical
analyses were carried out by X2 or Anova and multiple regression logistic tests and survival
KM curve. Results. Tumours were of stage I (4), II (54), III (49) and IV (23) in pTNM
classification with 55 tumours displaying high EGFR expression (ST). There was no difference
on ST status concerning the type of surgery, pTNM, and tumour size at baseline, the number
and the type of adjuvant or palliative chemotherapy afterward. Among the 24 tumours with
MSI-H, 2 did not express hMSH2 and 21 hMLH1 on IHC with 16 of them (66%) being
ST (vs 36% in MSS; p=0.01) and 6 MSI-H tumours displaying a score of 16. The univariate
analysis showed a significant relationship between ST of EGFR, and age<60 (48+/-38 vs
62+/-26; P=0.01), right-sided (58% vs 32% left and 34% rectum; P=0.017), characteristics
of tumours (66% vs 45% ulcerated or 26% perforated; P=0.009), the presence of mucoid
component (54% vs 34%; P=0.03), and a more important lymphoid infiltration (49% vs
30%; P=0.04) whereas the number of lymph node, vascular or nervous infiltrations were
not significantly related. There was no difference in term of survival according to the EGFR
expression although the time to relapse was longer (21 month) in patients with tumours
(of stage II) with strong expression than for the tumours with weak EGFR expression (19
month; P=0.05). In multivariate analysis only MSI-H status appeared as independent factor
(Odds Ratio = 2.7, 95% IC 1.1-7.2; P=0.04). Conclusion: The high EGFR expression in
colorectal tumours may be linked to the mismatch repair alteration.
W1735
Aberrant Promoter Methylation Pattern in Ulcerative Colitis-Associated
Carcinomas
Doerthe Kuester, Wael El-Rifai, Thomas Guenther, Arndt Hartmann, Andrea Tannapfel,
Frank Meyer, Ulrich Bohr, Matthias Pross, Michaela Guenther, Frauke Bataille, Petra
Ruemmele, Andrew Silver, Peter Malfertheiner, Hans Lippert, Albert Roessner, Regine
Schneider-Stock
Ulcerative colitis (UC) is a disease that is characterized by chronic inflammation, rapid cell
turnover, and a substantial risk of colorectal cancer. Little is known about the significance
of promoter hypermethylation in inflammatory bowel disease. It is not known if the promoter
methylation pattern can serve as a criterion for differentiating UC-associated colorectal cancer
from sporadic colorectal cancer. Thus, we compared a group of 37 UC-associated with 80
sporadic colorectal cancers, investigating a panel of genes from different signal cascades.
These markers included CHFR1 (check point with FHA and ring finger), GpX3 (glutathione
peroxidase 3), GSTP1 (glutathione S-transferase 1), DAPK (death-associated protein kinase),
and p16. CHFR1 is a stress-related mitotic checkpoint regulation gene. GpX3 and GSTP1
are major scavengers of ROS and play an important role in protecting the gastrointestinal
epithelium from cytotoxic and carcinogenic agents. DAPK is a serin-threonine kinase involved
in apoptotic cell death. P16 is a cyclin-dependent kinase inhibitor regulating the G1/S
checkpoint of the cell cycle. Methylation-specific PCR from formalin-fixed, paraffin-embed-
ded carcinoma tissue revealed the following methylation pattern of the UC-associated/
sporadic colorectal carcinoma: CHFR1 (71.4%/41.2%), GpX3 (40%/50%), GSTP1 (13.5%/
6%), DAPK (17.6%/56%), and p16 (15.8%/29.4%). Immunohistochemical protein expres-
sion of all markes were investigated by tissue microarray analysis. Here, promotor methylation
status correlated significantly with a decrease or loss of protein expression. In UC-associated
colorectal cancer, 40% of cases did not show any hypermethylation, whereas more than
30% of cases showed simultaneous methylation in 2 or more genes investigated. In sporadic
colorectal cancer, only 10% of the cases did not show methylation in any of the genes
investigated. In more than 60% of the cases 2 or more genes were methylated simultaneously.
Whereas CHFR1 and GpX3 seem to be important markers, GSTP1 is only weakly involved
in the carcinogenesis of both carcinoma types. Furthermore, there is a different methylation
pattern for both carcinoma types, with high methylation (more than 40%) for CHFR1/GpX3
in UC-associated colorectal cancer and CHFR1/GpX3/DAPK in sporadic colorectal cancer.
Transcriptional silencing by promoter hypermethylation seems to be critical in the inflamma-
tion-associated development of carcinomas in UC. Furthermore, we suggest that differences
in the frequency and the pattern of hypermethylation reflect multiple pathways for the
development of UC-associated and sporadic colorectal cancer.
W1736
What Is a Crucial Factor Related to CPG Islands Hypermethylation of Tumor-
Related Genes in H.pylori-Infected Gastric Mucosa?
Mitsuru Kaise, Jin Yonezawa, Takuji Yamasaki, Jun Miwa, J.N. Tashiro, Takashige Tomita,
Yasuo Matsubara, Hisao Tajiri
Background and aim: CpG islands hypermethylation (CIHM) of tumor-suppressor genes
involves gastric carcinogenesis. We have demonstrated that H.pylori eradication significantly
reduces CIHM, and the organism may act as a carcinogen via inducing CIHM (Gastroenterol-
ogy. 128 suppl2;A134, 2005). However, the levels of CIHM may be different among H.pylori-
infected individuals because H.pylori can elicit diverse clinical disorders. The aim of our
study is to elucidate crucial factors related to CIHM in H.pylori-infected gastric mucosa.
Methods: Two samples from non-cancerous corpus mucosa were obtained in H.pylori-
infected patients with duodenal ulcer (DU, n=22), gastric ulcer (GU, n=20), and gastric cancer
(GCA, n=25). One sample was pathologically examined, and morphological parameters such
as polymorphoneutrophil infiltration (PMN), mononuclear cell infiltration (Mono), atrophy,
intestinal metaplasia (IM) and H.pylori density were scored according to the updated Sydney
system (score 0 to 3 equating to normal, mild, moderate and marked). Genomic DNA
retrieved from the other sample was subjected to bisulfite modiciation. We examined CIHM
status of p16, E-cadherin (Ecad) and death-associated protein kinase (DAPK) gene promoters
by and methylation-specific PCR. Levels of CIHM were compared between diseases, and
between morphological parameters. Results: (1) Methylation rates of DAPK, Ecad and p16
promoters were significantly (p<0.001) higher in GCA (96%, 96%, 83%) than in GU (55%,
50%, 15%) and in DU (74%, 30%, 9%). (2) Methylation rates of DAPK, Ecad and p16
promoters were significantly (p<0.01) higher in PMN-positive samples (90%, 76%, 47%)
than in PMN-negative ones (39%, 17%, 11%). Those were neither different between IM-
positive and IM-negative samples, and nor between atrophy-positive and atrophy-negative
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samples. Methylation rates of DAPK were significantly higher in H.pylori-abundant samples
(score>1) than in H.pylori-scanty ones (score=1 or <1), but those of Ecad and p16 were not
different. Those of DAPK were significantly higher in Mono-abundant samples (score>1)
than in Mono-scanty ones (score=1 or <1), but those of Ecad and p16 were not different.
Conclusions: H.pylori significantly induces CIHM of tumor-related genes in non-cancerous
gastric mucosa bearing GCA as compared to mucosa bearing DU or GU. PMN in H.pylori-
positive mucosa was a crucial factor linked with CIHM, suggesting that PMN-induced events
or factors such as superoxide may elicit CIHM.
W1737
Aberrant DNA Methylation Associates with the Initiation and Progression of
Colon Adenomas and Is Maintained in Colon Adenocarcinomas
Young-Ho Kim, Slavomir Dzieciatkowski, Joseph Willis, M. Kay Washington, Steven C.
Stain, Will Chapman, William M. Grady
Background: The aberrant methylation of the 5’ promoter regions of genes is a recently
appreciated epigenetic mechanism for silencing tumor suppressor genes in colon cancer.
Aberrant DNA methylation has been observed as early as the aberrant crypt focus step of
the adenoma-carcinoma sequence, but its role in affecting genes that mediate initiation and
progression events in the colon cancer formation process is not well defined, particularly
regarding the metastatic spread of colon cancer. Aim: To clarify the role of epigenetic
silencing by promoter hypermethylation in the full range of the adenoma-carcinoma progres-
sion sequence through the assessment eight genes implicated in cancer formation and
progression, MGMT, HLTF, hMLH1, p14ARF, p16/CDKN2A, TIMP3, THBS1, and CDH1.
Methods: DNA, extracted from formalin-fixed, paraffin-embedded tissues obtained from
individuals with colon adenomas (n=41), adenocarcinomas (n=80) and metastases (n=28),
was subjected to treatment using sodium bisulfite and then methylation specific PCR using
primers that assess the methylation status of the genes listed above. Among 28 cases of
hepatic metastasis, 14 cases could be matched with primary colorectal cancer. Results: The
average number of methylated genes per case in the primary cancers was significantly higher
than in the adenomas (2.04±1.35 vs 1.59±1.70, p=0.04), but there was no significant
difference between primary cancers and metastatic cancers (2.04±1.35 vs 1.75±1.20, p>0.05).
In the adenomas, the average number of methylated genes in the advanced adenomas was
higher than in the non-advanced adenomas (2.25±1.73 vs 0.70±1.22, p=0.03). There were
differences in the frequency of hypermethylation between individual genes between the
adenomas, primary cancers, and metastatic cancers. Statistical analysis of these differences
is ongoing to determine if these trends are statistically significant. Finally, the methylation
pattern of metastatic cancer was similar, but not identical to that of matched primary cancer.
Conclusions: Epigenetic silencing by promoter hypermethylation of the genes assessed in
this study is associated with the progression of adenomas to adenocarcinomas but not of
early adenocarcinomas to late adenocarcinomas. The frequency of gene methylation in the
different stages of the adenomas and adenocarcinomas varied between genes suggesting
that there are unique gene-specific selective pressures that influence the frequency of the
methylation of the genes in these histological steps of colon cancer formation.
W1738
Evidence for BRAF Mutation and Variable Levels of MSI in a Sporadic
Colorectal Cancer (CRC) in African Americans (AA)
Hassan Ashktorab, Hassan Brim, Serwat Siddiqi, Francis Giardiello, Ed Lee, Duane T.
Smoot
Background: An alternative pathway of tumorigenesis has been identified in the CRC associ-
ated with serrated precursor lesions, variable levels of microsatellite instability (MSI), and
driven in part by activating mutations in the BRAF proto-oncogene (V600E). We have
assumed that BRAF mutations might be associated with hMLH1 methylation status rather
than MSI status. Therefore, we studied the sporadic CRC on the status of the methylation
of mismatch repair genes hMLH1, hMSH2, MSI, BRAF (V600E mutation) and explored the
molecular profiles of CRC in AA that are known to be at higher risk of CRC. Methods: We
used five different sets of primers (BAT25, BAT26, NR21, NR22 and NR24) for MSI in CRC
samples from 94 patients (55 females/39 males). HMLH1 and hMSH2 gene expression was
checked using an immunohistochemical (IHC) and MSP technique. BRAF V600E mutation
was determined using Mutector technique. The mean age for carcinoma diagnosis was 65.7
years (69.4 years for female patients and 60.1 years for male patients). Results: Of the 94
patients, 28 (30%) were MSI-H 8 (8.5%) were MSI-L and 58 (61.5%) were MSS. Of the
28 MSI-H, 19 (67.8%) were in the right colon while 7 (25%) were in the left colon (2 were
unknown). V600E was observed in 7 of 94 (7.4%) cancers. Of the 26 MSI-H, 6 were BRAF
V600E (23%) and 1 of 8 MSI-L (12.5%). Of five with BRAF V600E mutation, four (80%)
were expressing (by IHC) hMLH1 while one didn’t (20%). All of BRAF V600E mutation
except one was located in the right side of colon. In addition, of five of BRAF V600E
mutation, four (80%) were methylated for hMLH1 while one was not (20%). The MSI-H
tumors were of three different tumor stages with 10 tumors at stage II, 13 tumors at stage
III and one tumor at stage IV. Most tumors were moderately differentiated (19 of 28 MSI-
H and 6 of 8 MSI-L). Eight MSI-H and one MSI-L were poorly differentiated while only
one MSI-H was well differentiated. Mucin production was noted in 13 MSI-H and 2 MSI-
L tumors. HMLH1 promoter was methylated in 30 of 34 (88%) tumors of which 13 (87%)
CRCs demonstrated MSI-H. In total, 56% and 42% of tumors assayed by IHC showed loss
of staining for hMLH1 and hMSH2, respectively. In addition, loss of hMLH1 and hMSH2
staining was observed in 66% and 38% of MSI-H tumors, respectively. These findings suggest
that BRAF activation may participate in the carcinogenesis of sporadic CRCs with hMLH1
hypermethylation in the proximal colon, and it may be dependent on the MSI status.
Conclusion: Overall, the prevalence of MSI-H colorectal tumors was 2 fold higher and the
defect in the MMR genes (hMLH1 and hMSH2) and BRAF in AA patients may play important
role in CRC.
W1739
Promoter Methylation of Helicase-Like Transcription Factor Is Associated with
the Early Stages of Gastric Cancer with Family History
Jae J. Kim, Seung Won Chung, Jung Hwan Kim, Sung Kim, Sang Yong Song, Joobae
Park, Duk-Hwan Kim
Background: The aberrant methylation of the CpG island at the promoter region of the
helicase-like transcription factor (HLTF) gene has been detected in approximately 20-50%
of primary gastric cancers, suggesting that HLTF methylation is a frequently-encountered
feature of tumorigenesis in the stomach. The aim of this study is to investigate the clinicopa-
thological significance of promoter methylation of HLTF in primary gastric cancer. Methods:
Two-hundred fifty six patients participated in this study. Methylation status of HLTF gene
was evaluated in fresh-frozen tissues by methylation-specific polymerase chain reaction. All
statistical analysis were two-sided, with a 5% type I error rate. Results: Aberrant methylation
of HLTF was found in 98 (38%) of 256 gastric cancer patients. HLTF methylation was
significantly associated with family history in the early stages of gastric cancer, regardless
of histologic types. In the intestinal-type cases, HLTF methylation occurred in 15 (56%) of
27 patients with family history, and in 26 (31%) of 85 patients without family history (P =
0.02). In the diffuse-type cases, patients with family history were also found to exhibit a
higher prevalence of HLTF methylation than those without family history (61% vs. 34%;
P = 0.009). HLTF methylation in both of the histologic types occurred in about 70-90% of
the early stage cases in which the patient had a family history and in 15-30% of cases in
which the patient did not have a family history. In the multivariate logistic regression
analysis, the stage I, II cases with family history were determined to carry a higher risk of
HLTF methylation than did the stage III, IV cases without family histories in both the
intestinal-type (OR = 6.01, 95% CI = 1.20-30.01, P = 0.02) and the diffuse-type cancers
(OR = 8.25, 95% CI = 1.67-40.86, P = 0.009). Conclusions: These results suggest that
HLTF methylation may play a crucial role in the early stages of gastric carcinogenesis in
patients with family history and may prove to be a valuable susceptible marker for the risk
of gastric cancer in individuals with family history.
W1740
Genomwide Methylation of CPG Sites in Patients with Gastric Cancer and in
Patients with Increased Risk to Develop Gastric Cancer
Andreas Leodolter, Sergio Alonso, Matthias Ebert, C Roecken, Thomas Wex, Ulrich Peitz,
Peter Malfertheiner, Manuel Perucho
Hypomethylation of genome wide CpG sites is observed in tumor tissues from cancer
patients. The Correa model of development of gastric cancer (GC) assumed a cascade of
changes in gastric mucosa mainly caused by H. pylori infection. The aim of this study was
to evaluate the methylation level of CpG sites in patients with GC and compare these levels
with those of patients with advanced stages of gastritis before and after H. pylori eradication
therapy, first degree relatives and controls. Methods: Gastric DNA was analyzed from patients
with GC (n=95 adenocarcinomas, diffuse/intestinal type, tumor and non-tumor tissues),
high risk gastritis (corpus-predominant/pangastritis w or w/o intestinal metaplasia (n=14)
with H. pylori infection, previous high risk gastritis after eradication therapy (n=24), first
degree relatives of gastric cancer patients (n=16) and controls (n=17) without H. pylori
infection. In all patients a M.SssI enzyme assay for methylation of CpG sites with s-adenosyl-
L-[methyl-3H]methionine as methyl donor was performed using 100ng of genomic DNA
at a time. For standardization of DNA amount and to calculate the percentage of methylated
CpG sites a dam enzyme assay (methylates A in GATC sites) was performed using equal
test conditions. All experiments were repeated three times. Results: The mean value of
methylation of CpG sites differed significantly in patients with GC compared to all other
investigated groups. The non-tumor tissue revealed a significant lower amount of methylated
CpG sites compared to tissue of patients without tumor. By establishing a cut-off for severe
hypomethylation based on the results of the healthy controls, 39 cases (41%) with gastric
adenocarcinoma had a severe hypomethylation and even in 22 cases (23%) this was detectable
in the non-tumor tissue. In the groups with high risk gastritis 36% had severe hypomethyl-
ation and 33% in the groups with previous H. pylori eradication therapy and high risk
gastritis (ns). The portion of patients with severe hypomethylation in the group of 1st degree
relatives was lower (13%). Conclusions: The decreased methylation level of non-tumor tissue
in GC patients compared to healthy controls suggests an early occurrence of the tumor
associated epigenetic alterations. Severe genomewide hypomethylation is already detectable
in patients with high risk gastritis and might be not reversible by H. pylori eradication
therapy. For parts of the epigenetic alterations the point of no return might be already
reached for those patients with severe H. pylori associated gastritis.
W1741
Epigenetic Regulation of the 11p15 Mucin Genes (MUC2, MUC5AC, MUC5B,
MUC6) in Epithelial Cancer Cell Lines and Tissue Patients
Audrey Vincent, Jean-Luc Desseyn, Christophe Mariette, Marie-Christine Copin, Pascal
Pigny, Isabelle van Seuningen
Introduction: The human mucin genes MUC2, MUC5AC, MUC5B and MUC6 are clustered
on the p15.5 arm of chromosome 11 in a GC-rich area known to be a hot spot of methylation
in cancer. These four genes encode large secreted gel-forming mucins that participate in
protection of underlying epithelia. Alteration in their expression in cancers will have con-
sequences for epithelium homeostasis and maintenance of an efficient barrier to various
aggressions. Aim: The organization as a cluster in a hot spot of methylation and the structure
of their promoters led us to evaluate the influence of DNA methylation and histone acetylation
on their expression in epithelial cancer cell lines and tissue patients. Methods: Influence of
methylation and histone acetylation was evaluated by treating pre- and post-confluent cells
with the demethylating agent 5-aza-2’-deoxycytidine (5 µM, 72h) or with the histone
deacetylase inhibitor, trichostatin A (0.3 µM, 24 h), respectively. Level of mucin mRNA and
protein expression were measured by RT-PCR and immunochemistry, respectively. Mapping
of the methylated cytosines in the promoters was performed by MS-PCR and bisulfite-treated
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DNA sequencing both in cell lines and tissue patients. Results: MUC2 and MUC5B are highly
submitted to epigenetic regulation in epithelial cancers cells and their level of methylation is
directly correlated to the state of differentiation of the cells. The promoter of MUC2 is
characterized by site-specific methylation of a few CpG sites whereas MUC5B is silenced
by extensive hypermethylation throughout its promoter. Compared to MUC2 and MUC5B,
the promoter of MUC5AC is not very rich in CpG sites and was shown to be rarely regulated
by methylation. We showed that the MUC6 promoter possesses a highly methylated distal
region that does not interfere with its expression. Moreover, the proximal CpG island located
upstream of the transcription start site was not submitted to methylation. Correlation between
the methylation of mucin gene promoters and repression of their expression in bronchial
tumors from patients with lung cancers confirmed our in vitro data. Conclusion: This first
wide study about the influence of methylation and acetylation on the expression of the four
mucin genes belonging to the 11p15 cluster points out an important role for epigenetics in
regulating the 11p15 mucin genes in epithelial cancers. Evaluation of methylation status of
mucin genes may thus become a promising tool as a diagnostic and/or prognostic marker
in epithelial cancers.
W1742
Microsatellite Instability Is Associated with Reduced Proliferative Indices in
Human Colorectal Cancers
Frank A. Sinicrope, Rafaela L. Rego, Kevin C. Halling, Nathan Foster, Daniel J. Sargent,
Amy French, Megan Garrity, Richard M. Goldberg, John A. Laurie, Lawrence J. Burgart,
Stephen N. Thibodeau, Thomas E. Witzig
BACKGROUND. Colorectal cancers with microsatellite instability (MSI) are reported to have
a favorable clinical outcome, yet prognostic factors underlying this observation are poorly
understood. We studied differences in biomarkers between MSI-H and MSS/MSI-L tumors
including DNA ploidy and proliferative indices (PI), chromosome 17p allelic imbalance (AI),
p53 expression, and patient survival. MATERIALS/METHODS. We examined Dukes’ stage
B2 and C primary colon (n=305)and rectal (n=25) carcinomas from patients enrolled in five
5-fluorouracil-based adjuvant trials conducted by the North Central Cancer Treatment Group.
MSI and AI were determined using 11 microsatellite markers. hMLH1, hMSH2 and p53
proteins were evaluated by immunostaining. DNA ploidy and PI (S phase + G2M) were
analyzed by flow cytometry. Correlations between markers and associations with overall
survival (OS) were determined. RESULTS. MSI-H (n=61) vs. MSS/MSI-L tumors were more
frequently Dukes’ B than C (p=0.0008) and had fewer metastatic lymph nodes (p=0.005).
MSI-H tumors were more frequent in female patients (vs. MSS/MSI-L; p=0.0003), and
were highly correlated with proximal site, high grade histology, diploidy and reduced p53
expression (vs. MSS/MSI-L; all p<0.0001). Median overall PI (15.8; mean 16.2±7.6) was
lower in MSI-H compared to MSS/MSI-L tumors (11.7 versus 16.8, p=0.001). Lower PI was
associated with diploid DNA content, reduced p53 expression, and intact 17p (Table 1).
Of 44 MSI-H cases tested, 41 showed loss of hMLH1 (n=39) or hMSH2 (n=2) proteins.
Overall survival was related to tumor stage (p=0.002), DNA ploidy (p=0.03), histologic
grade (p=0.0003), loss of mismatch repair proteins (p=0.02), and number of lymph nodes
(p<0.0001). MSI status (p=0.07), and PI (p=0.07), were of borderline significance whereas
17p AI and p53 were not related to patient survival. CONCLUSIONS. Reduced proliferative
indices are a component of the MSI-H phenotype in human colorectal cancers. Lower
proliferative indices, indicative of reduced tumor growth rates, may contribute to the earlier
stage at presentation of MSI-H tumors.
W1743
Molecular Subtyping of Colorectal Cancers with Microsatellite Instability
Luigi Laghi, Paolo Bianchi, Massimo Roncalli, Alberto Malesci
Background. Colorectal cancers (CRC) with mismatch repair (MMR) defects and microsatell-
ite instability (MSI) are heterogeneous as to hereditary (HNPCC) or sporadic features and
promoter methylation. Aim. To find correlations between molecular and phenotypic features
of MSI CRC. Materials and methods. In a cohort of 88 (M/F, 50/38) MSI CRC staged by
AJCC criteria (stage 1-2/3-4, 59/29), comprising HNPCC (n=25) and sporadic (n=63) cases,
we determined MMR defects, hMLH1 and P16 methylation, BRAF mutations and frameshift
mutations in target genes (FMT). Results. Out of 88 MSI CRC, 59 (67%) had methylation
of hMLH1 (M/F, 28/31; p=0.01), and 45 (51%) of P16 (M/F, 29/16). hMLH1 methylation
only occurred in 21 (24%) CRC (M/F, 6/15; p=0.003) and of P16 only in 7 (8%; M/F, 7/

















ones (70.6±12.1 vs 60.1±15.7 yr, respectively; p=0.001), a difference not observed for P16.
The age of patients with hMLH1-methylated CRC did not differ as to gender, but as to BRAF
status (mutated, n=33, 76.1±7.1 yr vs wild-type 63.5±13.5 yr; p<0.001). In MSI CRC, the
median FMT was 4, the only 5 MSI CRC with no frameshifts lacked hMSH6 or PMS2.
hMLH1-methylated MSI CRC had higher FMT (median=4) than un-methylated (median=2,
p=0.03) ones. Stage 3-4 CRC were more frequent in males than females (M/F 21/8; p=
0.03), in proximal than distal tumors (27/69, vs 2/19; p=0.02), in P16-methylated than un-
methylated CRC (21/45, vs 8/43; p=0.005) and in MSI CRC with FMT≤3 than in CRC
with FMT≥4 (p=0.037). P16 status was associated with advanced stages even in sporadic
CRC (4/26 in un-methylated vs 19/37 in methylated CRC; p=0.003). Upon multivariate
analysis, proximal site, FMT≤3and P16 methylation were independently associated with
advanced tumor stage in all cases, but only P16 in sporadic disease (p=0.016; OR 3.8,
95%CL 1.4-10). In females we observed 7 stage 3-4 cancers out of 16 with P16 and hMLH1
methylation, but only 1 (7%) in 15 with hMLH1 methylation only (p=0.03). Conclusions.
hMLH1-methylated MSI CRC are frequent in females and in old patients, P16 is more
frequently methylated in stage 3-4 than in stage 1-2 MSI CRC. The combination of female
gender and hMLH1-only methylation can identify a sub-set of patients with a profuse mutator
phenotype and less advanced MSI CRC. In contrast, P16 methylation is associated with
advanced disease, and tumors with MMR defects other than hMLH1 and hMSH2 do not
require alterations of the mutator pathway.
W1744
Microsatellite Instability Accounts for Tumor Site-Related Differences in
Prognostic Markers in Human Colon Cancers
Frank A. Sinicrope, Rafaela L. Rego, Nathan Foster, Daniel J. Sargent, Amy French,
Megan Garrity, Richard M. Goldberg, John A. Laurie, Lawrence J. Burgart, Thomas E.
Witzig, Stephen N. Thibodeau
BACKGROUND. Evidence indicates that proximal and distal sporadic colon cancers have
a different pathogenesis and prognosis. We compared cellular and molecular marker expres-
sion in relation to tumor site, microsatellite instability (MSI), DNA mismatch repair proteins,
DNA ploidy and p53 expression. MATERIALS & METHODS. Dukes’ stage B2 (n= 158) and
C (n= 370) primary colon adenocarcinomas were analyzed from patients enrolled in six 5-
fluorouracil-based adjuvant therapy trials conducted by the North Central Cancer Treatment
Group. Tumors were analyzed for MSI using 11 microsatellite markers and MSI was classified
as instability at > or equal 30% (MSI-H) or <30% of loci (MSS/MSI-L). Immunostaining for
hMLH1 / hMSH2 (n= 329), and p53 proteins was also performed. DNA ploidy was analyzed
by flow cytometry and categorized as diploid versus aneuploid/tetraploid. RESULTS. Patients
with proximal cancers were older (≥ 65 years) and proximal tumors were more likely to
be MSI-H, diploid, and to have high histologic grade compared to distal tumors (Table 1).
Nuclear p53 staining was more frequent in distal tumors (p= 0.001) that were generally
aneuploid/tetraploid (p= 0.008). Patients with MSI-H tumors (n=95) were more likely to
be female (vs. MSS/MSI-L; p=0.0002), and were also more frequently proximal, diploid,
and more likely to have a high grade histology (vs MSS/MSI-L; all p< 0.0001). When MSI-
H tumors were excluded, no differences were found for any of the variables between proximal
versus distal MSS/MSI-L tumors, except for p53 expression which remained significant
(p= 0.039). CONCLUSIONS. MSI-H tumors account for differences in prognostic markers
between proximal and distal colon cancers, and to a lesser extent for p53. Therefore,
previously described differences in the pathogenesis and prognosis of colon cancers based
upon tumor site appear to be predominantly explained by the inclusion of MSI-H cases.
W1745
Posttraumatic Sclerosing Cholangitis (PTSC): A Novel Biliary Disease
Dorothee H. Dorlars, Jenny Gebhardt, Juergen Pausch
Background: To date, we have increasingly observed a new entity of severe progressive
cholestasis syndromes mimicking post-traumatic sclerosing cholangitis (PTSC). These
patients usually have healthy livers prior to trauma or ICU treatment. PTSC is different from
non-alcoholic fatty liver disease following total parenteral nutrition and can, however, rapidly
progress to the point of requiring transplantation. Patients and methods: From 5/2001 to
11/2005, we observed 13 patients presenting with post-traumatic cholestasis syndrome. All
were men, aged 21 to 66 yrs (mean 48). All had required long-term mechanical ventilation
(10- 74 days, n=8 for more than 4 weeks) and a longer stay at the ICU (13-164 days, mean
48). 2 patients had a 2nd degree craniocerebral injury. 11 patients suffered polytrauma:
one had multiple fractures followed by ARDS, 10 cases suffered fractures and a primary
thoracic trauma (lung contusion, hematopneumothorax), 4 of them in combination with a
craniocerebral injury. We analyzed common clinical findings, risk factors and the natural
history of PTSC. Results: Upon admission to hospital, the liver function tests (LFTs) were
normal in all patients. Overall, the cholestasis parameters in 12/13 patients increased between
day 4 and 10 of their ICU stay. The AP values peaked at 695 - 5073 U/l (mean 3193), the
GGT values at 360 - 2509 U/l (mean 1181), bilirubin values at 0.8 - 28 mg% (mean 10).
AST and ALT were only slightly elevated. The ERC showed the typical signs of sclerosing
cholangitis or vanishing bile duct syndrome. 6 of 13 patients were treated endoscopically
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(removal of sludge etc.). The histological evaluations showed sclerosing cholangitis and
varying degrees of liver fibrosis and inflammation. Follow-up: All patients are being treated
with UDCA 20-25 mg/kg. To date, 1 patient has received a liver transplant, and 2 patients
are currently listed for transplant. In 6 patients the disease is progressively worsening, 3 of
these are ineligible for transplant. Finally, 4 patients are clinically and histologically stable.
Conclusions: PTSC is a not entirely rare, but usually unrecognized disease with a poor
prognosis. Risk factors are male gender, polytrauma with thoracic trauma, craniocerebral
injury, extended ventilation and (acc. to literature) burns. Laboratory findings include early
elevated AP more than GGT. The ERC findings also suggest an etiological role for ITBL
(ischemic-type biliary lesions). Recommended modes of treatment include regular endoscopic
interventions, high-dose UDCA therapy and early assessment for liver transplant. Future
research must aim to identify high risk patients and possible prophylactic treatments.
W1746
Low Dietary Cholic Acid Administration to ABCB4-/- Mice Is Sufficient to
Unravel Critical Phenotypic Features Mimicking the Severe Consequences of
ABCB4 Mutations in Humans
Majorie Martel, Veronique St-Hilaire, Beatriz Tuchweber, Marie-Eve Bourbonnais,
Guylaine Bouchard
Mutations in the canalicular phospholipid translocator ABCB4 contribute to a large array
of liver diseases. In humans, the most severe complications of ABCB4 genetic variants result
in progressive familial intrahepatic cholestasis type 3 (PFIC-3), with affected children often
exhibiting growth failure and progression of liver disease necessitating transplantation. Albeit
Abcb4-/- mice develop spontaneous cholangiopathy and hepatic liver disease, they do not
suffer from growth failure or highly premature death rate. In search of a more valuable
experimental model that could mimic these severe complications, we here tested the response
of Abcb4-/- mice to long-term low cholic acid (CA) feeding. Methodology: Post-weaning
Abcb4-/- mice and wild-type controls (FVB/J) were fed a semi-synthetic diet supplemented
or not with 0.025% w/w CA. Body weight was followed weekly for the first month and
then monthly. A small saphene vein puncture enabled to follow serum liver enzymes monthly.
Mice were sacrificed after 4 months of treatment and liver histology (HPS, Masson Trichrome)
was performed and scored in a blind fashion. Results: Body weight gain in Abcb4-/- and +/
+ mice not fed CA was undistinguishable despite a specific and progressive elevation in
serum liver enzymes in -/- mice. At sacrifice, -/- mice exhibited significant ductular prolifera-
tion, moderate portal inflammation and fibrosis, with a clear progression of all these features
compared to -/- mice sacrificed at the post-weaning stage. In contrast to +/+ mice where
no significant influence was observed on all parameters assessed, addition of low dietary
CA to -/- mice markedly changed the severity of the phenotype as exposed by lack of body
weight gain as well as more rapid and sustained elevations of serum ALT, AST, ALP, GGT,
bilirubin and total bile salts. After 3-4 months of CA treatment, Abcb4-/- mice started to
exhibit severe signs of physical distress, culminating in a 40% death rate. In the surviving -/-
mice, gross appearance of the liver was drastically changed and severe bridging portal fibrosis
and ductular proliferation were now observed, with portal inflammation level however
remaining similar to -/- mice not receiving CA. Conclusion/Speculation: Although Abcb4-/-
mice spontaneously develop cholangiopathy, they do not fully express the severe phenotypic
consequences of ABCB4 defects observed in human. However, a pathologic profile mimicking
severe cases of human ABCB4 deficiency can be recreated by very low supplementation
with CA. Further studies using this strategy shall now enable a better comprehension of
the severe mechanistic consequences of ABCB4 malfunction.
W1747
Hepatic Aquaporin-8 (AQP8) Water Channels and Oxidative Stress Are Early
Affected During Extrahepatic Cholestasis in Bile Duct Ligated (BDL) Rats
Piero Portincasa, Ignazio Grattagliano, Mario Testini, Nicola Marinelli, Michele Persichella,
Antonio Moschetta, Giuseppe Palasciano, Maria Svelto, Giuseppe Calamita
Background: Interruption of bile flow during extrahepatic cholestasis may result in liver
failure. Here we investigate for the first time if both AQP8-mediated osmotic water movement
and oxidative stress might be early affected in an animal model of cholestasis. Materials and
methods: Wistar rats underwent proximal BDL or sham operation; at days 1, 3, and 7 we
measured liver histology, AQP8 (expression, subcellular localization), oxidative stress as total,
oxidized glutathione (GSH, GSSG), and protein sulphydril (PSH, cytosolic/mitochondrial
fractions). Results: BDL livers showed progressive intrahepatic bile duct dilatation, bile
aggregates, inflammatory changes, cell degeneration, mitochondrial swelling. At day 3,
intracellular but not plasma membrane AQP8 was decreased by 75% (P< 0.001). At day 7,
AQP8 was decreased both intracellularly (-67%) and in plasma membranes (-56%) (P<
0.05), suggesting defective translocation or membrane insertion of AQP8. Cytosolic GSH
and PSH gradually decreased while GSSG increased (P<0.01, ANOVA) after BDL. Specifically,
GSH and P-SH levels declined and GSSG increased earlier in mitochondria than cytosol.
Conclusions: Water transport is greatly affected by BDL; here we observed an early down-
regulation of hepatocyte AQP8 protein expression which could contribute to bile secretory
dysfunction of cholestatic hepatocytes. Also, early cholestatic liver shows associated remark-
able changes of GSH content and redox status, especially in hepatocyte mitochondria.
W1748
Enhanced Expression of Caveolin-2 of the Proliferating Bile Ductules At
Protein and Gene Levels in Primary Biliary Cirrhosis
Hiroaki Yokomori, Masaya Oda, Toshifumi Hibi
BACKGROUND AND AIMS: An increase in bile ductular structures is observed in diverse
human liver diseases, especially in primary biliary cirrhosis (PBC). These structures harbor
the progenitor cell compartment of the liver. Caveolins (CAV) are cholesterol-binding proteins
involved in regulating of several intracellular process, including cholesterol transport. In
this study, immunohistochemistry, Western blotting and in situ hybridization were performed
on human liver specimens from patients with primary biliary cirrhosis (PBC) and normal
liver specimens. MATERIALS AND METHODS: Ten wedged liver biopsies of PBC (10 cases
each of stage 2 and stage 3) were studied. As controls, wedge biopsy specimens from normal
portions of the liver were obtained from 10 patients (8 males and 2 female; aged from 44
to 73 years with a mean of 57.3 years) who underwent surgical resection for metastatic liver
carcinoma (4 colonic carcinoma and 1 gastric carcinoma). Immunostaining was performed
on serial sections. Four-micrometer sections were cut from paraffin blocks of formalin-fixed
tissue, deparaffinized with xylene, and rehydrated by graded ethanol The expression of
CAV-1 and -2 was determined using specific antibodies. Western blotting was conducted
using fresh control and PBC liver tissues. In situ hybridization was done to examine the
messenger RNA expression of CAV-1 and -2 on formalin-fixed, paraffin-embedded sections
using peptide nucleic acid probes and the catalyzed signal amplification technique. RESULTS:
In normal liver samples, there was scarce staining for CAV-1 and 2 on bile ducts. In
PBC liver samples, CAV-2 expression was strongly increased on proliferative bile ductules,
especially in stage 2-3 specimens. Especially, regenerating bile ductules at the interface of
portal tracts and necrotic areas stained intensely for CAV 2. While CAV-2 was stained
intensely in the cytoplasm, CAV-1 was stained mainly on the plasma membrane. CAV-1
and 2 protein expression was confirmed by Western blot. In situ hybridization demonstrated
CAV-1 and 2 mRNA expression in bile ductules. CAV-2 mRNA was especially strongly
expressed on infiltrating bile ductules. CONCLUSION: The present results demonstrate
increased expression of caveolin-2, and to a less extent caveolin-1, in proliferating bile
ductules in primary biliary cirrhosis, which may be related to the homeostasis of cholesterol
transport in the regenerating bile ductules in PBC liver.
W1749
Is Helicobacter Pylori Associated with Primary Sclerosing Cholangitis?
Alyssa M. Krasinskas, Yuan Yao, Parmjeet Randhawa, Antonia R. Sepulveda
Helicobacter pylori (Hp) DNA has been identified in human livers and has been implicated
in chronic liver disease and liver cancer. Hp DNA can be isolated from the blood of patients
infected with the organism; hence it is not clear whether Hp DNA detection in the liver
represents a “contaminant” from the circulation in hepatic blood vessels or in Kupffer cells,
or whether bacteria or bacterial products reach the biliary epithelium through bile reflux
from the duodenum and cause a chronic inflammatory response similar to that seen in
gastritis. Data from different populations and different countries are conflicting. To better
understand the potential role of Hp in primary sclerosing cholangitis (PSC), an idiopathic
inflammatory disease with unknown etiology, Hp infection status was studied in a group
of patients with PSC from the US. Methods: Explanted livers from 25 patients with end-
stage PSC and 33 age-matched controls with nonbiliary tract disease were studied. Hilar
hepatic ducts and limited adjacent liver parenchyma was microdissected from formalin-
fixed, paraffin-embedded tissue sections. Genomic DNA was extracted and a 398 bp fragment
was amplified with primers for the Hp 16S rDNA. The PCR products were resolved by gel
electrophoresis. Serum was available on 14 patients and was tested for Hp anti-IgG by
ELISA. Immunohistochemical (IHC) staining for Hp was performed on all specimens in step
sections of the slides used for microdissection. Results: Hp was detected in 9 of the 58
(16%) patients in this study; Hp was detected by PCR in 8 cases and by ELISA in 2 cases
(1 case was also PCR positive); 6 of the 25 (24%) patients with PSC and 3 of the 33 (9%)
controls (nonalcoholic steatohepatitis, n=2 and acetaminophen toxicity, n=1) were positive
for Hp (p=0.15). No Hp organisms were identified in the livers by IHC. Conclusion: Hp
was detected in 16% of explanted livers from patients with biliary and nonbiliary liver
disease. A higher percentage of patients with PSC had evidence of Hp infection (24%)
compared to the controls (9%). In all but one Hp-positive case, Hp was detected in microdis-
sected hilar biliary epithelium, supporting the hypothesis that the organisms or bacterial
products might reach the biliary tract through bile reflux from the duodenum, in addition
to circulating through the blood. Our findings support a possible contributory role of Hp
in some PSC patients.
W1750
Response to Steroid Therapy in Patients with Sclerosing Cholangitis
Associated with Elevated IgG4 Level
Ryo Terada, Hirofumi Kawamoto, Yasuhiro Miyake, Kohsaku Sakaguchi, Yoshiaki Iwasaki,
Akinobu Takaki, Haruhiko Kobashi, Yoshiaki Kobayashi, Shin-Ichiro Nakamura, Kazuhide
Yamamoto, Yasushi Shiratori
Background and Aims: Multiple fibrosing inflammatory strictures of the biliary tree can be
caused by both primary and secondary screlosing cholangitis. Recently, it is reported that
bile duct lesions were associated with autoimmune pancreatitis or immunoglobulin(Ig) G4-
related cholangitis. We investigated the clinical course of patients who demonstrated bile duct
lesions resembling primary sclerosing cholangitis(PSC) by cholangiography and evaluated the
effect of steroid administration. Patients and Method: The subjects were 33 patients (21
male, 12 female) who demonstrated PSC-like bile duct stricture by endoscopic retrograde
cholangiography or magnetic resonance cholangiopancreatography at our university or its
affiliated hospitals between December 1988 and June 2005. The median age at the diagnosis
was 47 years (range 14-70) and the median observation period was 37 months (range 4-
163). Results: Out or 33 cases, 28 patients had PSC, one patient had cholangiocellular
carcinoma, 3 patients had autoimmune pancreatitis with biliary duct lesions and one patient
had sclerosing cholangitis associated with marked eosinophoilia (WBC 20450/mm3, Eo
70%). Since this patient with eosinophilia had no apparent pancreatic lesions and elevated
serum IgG4 level (218 mg/dl, normal range 4.8-105), he was considered as IgG4-related
cholangitis. Five of 28 PSC patients were treated with steroid therapy. However, no patients
showed the improvement of the bile duct lesions. On the other hand, three patients with
autoimmune pancreatitis and one patient with IgG4-related cholangitis were responded to
steroid therapy and showed prompt amelioration of liver-function tests and improvement
of bile duct lesions. The serum IgG4 level of these four patients were relatively high (Mean
± S.D. 300 ± 224 mg/dl), as compared with 38.3 ± 25.1 mg/dl in patients with PSC and
cholangiocellular carcinoma. Conclusion: Patients with autoimmune pancreatitis and IgG4-
related cholantitis need to be distinguished from PSC, as they can be treated with steroid
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therapy. The serum IgG4 concentrations and eosinophilia may be a useful marker for
diagnosis of these “steroid-responsive” sclerosing cholangitis.
W1751
The Incidence of Cholangiocarcinoma in Primary Sclerosing Cholangitis
During Longtime Treatment with Ursodeoxycholic Acid
Adolf Stiehl, Petra Kloeters-Plachky, Gerda Rudolph
Introduction. Cholangiocarcinoma (CCA) represents a serious complication of primary
sclerosing cholangitis (PSC). In two recent studies with 604 and 161 patients followed over
a median time of 5.7 and 11.5 years the reported incidence rate of CCA was 13.3 and 6.8
% (A Bergquist et al., J Hepatol 2002;36:321-327; K Burak et al., Am J Hepatol 2004;99:523-
526). Ursodeoxycholic acid (UDCA) possibly may influnce the incidence of CCA in man
(B Brandsaeter et al. J Hepatol 2004;40:815-822). Aim of study. The aim of the present
study was to evaluate the incidence rate of CCA in PSC patients treated with ursodeoxycholic
acid. Patients and methods. The present study was started in May 1987 and data up to May
2005 were considered in the evaluation. A total of 150 patients (105 men and 45 women)
with PSC but without evidence of CCA at entry were included in the study. Of the patients
included 101 had inflammatory bowel disease (93 ulcerative colitis and 6 Crohn’s disease).
Altogether 120 patients were treated for 1 year, 107 for 2 years, 97 for 3 years, 83 for 4
years, 72 for 5 years, 62 for 6 years and 57 for 7-18 years. Up to 1995 the patients were
treated with UDCA in a dose of 750 mg/d (8.8-15.3 mg/kg), starting from 1997 with 13.8-
17.4 mg/kg and starting from 2001 with 18-20 mg/kg. A minority of 63 patients who were
included in a study of UDCA absorption intermittently received higher doses of up to 30
mg/kg for up to 3 months. All 72 patients with dominant stenoses were treated by repeated
endoscopic dilatation. Diagnosis of CCA was established in each case by histologic examina-
tion of tissue obtained at laparotomy or in the explanted liver at the time of liver transplanta-
tion. Results. The median treatment time of the 150 patients was 6.4 years. Altogether 5
patients developed a CCA during UDCA treatment yielding an incidence rate of 3.3 %. The
calculation of CCA per patient years revealed 0.58 CCA per 100 patient years in years 0-
2.5, 0.49 CCA in years 2.5-8.5, and no CCA thereafter up to 18 years after entry into the
study. The Kaplan Meier estimate of CCA incidence during UDCA treatment reached a
plateau after 8.3 years. All 5 patients with CCA belonged to the subgroup of patients with
colitis and in addition to the subgroup of patients with dominant stenosis. Summary and
conclusion. The annual incidence rate of CCA in PSC treated with UDCA is low and decreases
with time of treatment. Compared with the CCA incidence rates reported in studies on
the natural course of the disease, the CCA incidence after UDCA treatment was lower
than expected.
W1752
Does Maternal Immunization Using Rotavirus Virus-Like Particles Prevent
Rotavirus-Associated Biliary Atresia in Neonatal Mouse Pups?
Paula M. Hertel, Sue E. Crawford, Finegold J. Milton, Estes K. Mary
BACKGROUND: Biliary atresia (BA) is a progressive, irreversible obliterating disease of bile
ducts that results in severe childhood liver disease and is the indication for more than 50%
of pediatric liver transplants. Rotavirus infection in the very early neonatal period is suspected
to be the cause of some cases of BA. We hypothesized that: a) inoculation of neonatal mice
with live rotavirus will cause biliary atresia, but inoculation with inactivated virus will not;
and b) maternal immunization using recombinant VP 2/6/7 rotavirus virus-like particles
(VLPs), which contain immunogenic rotavirus capsid proteins but are noninfectious, will
prevent rotavirus-associated biliary atresia in pups. METHODS: To assess if live virus is
required to cause biliary atresia, Balb/c mouse pups were inoculated intraperitoneally (ip)
with 4x107 pfu live, purified rhesus rotavirus (RRV), with comparable doses of inactivated
RRV, or with saline on day of life 2. Stool color was assessed daily using a graded color
scale. Cholestasis (blockage of bile flow into the small intestine) was defined as pale stools.
Mice were euthanized at 1, 2, or 3 weeks post-inoculation (pi). To assess maternal immuniza-
tion as a preventive measure against BA, serum rotavirus antibody titers were determined
in Balb/c dams with varying rotavirus exposure histories. Dams were then given intramuscular
injections with either 20μg rotavirus VLPs plus adjuvant or adjuvant alone before mating.
When litters were born, maternal serum antibody titers were repeated. Pups were inoculated
with 107 pfu live RRV ip on the 2nd day of life, and assessed 5-11 dpi for cholestasis. All
were euthanized at 11 dpi. RESULTS: 0% of pups inoculated with saline or with inactivated
virus developed cholestasis, whereas 100% of live-RRV-infected pups born to unexposed,
unimmunized mothers developed cholestasis. Pups born to previously unexposed dams
immunized with rotavirus VLPs + adjuvant did not develop cholestasis following rotavirus
infection, whereas pups born to dams immunized only with adjuvant developed cholestasis.
Pups born to dams with high rotavirus antibody titers prior to immunization were protected
whether dams were immunized with VLPs + adjuvant or with adjuvant alone. CONCLU-
SIONS: Infection of neonates with live virus is required to cause biliary atresia; inactivated
virus is insufficient. High maternal rotavirus antibody titers can protect offspring against
biliary atresia following rotavirus infection in the neonatal period. Maternal immunization
of previously nonimmune mothers confers protection to offspring against biliary atresia
following neonatal rotavirus infection.
W1753
Paclitaxel Inhibits LPS-Induced Collagen Formation By Rat Bile Duct
Fibroblasts By Preventing PDGF-BB Synthesis in Rat Cholangiocytes
Jong Ho Moon, Christopher E. Savard, Ho Soon Choi, Tae Hyun Kim, Igino Rigato,
Rahul Kuver, Sum Lee
Background/Aim: The pathogenesis of proliferative cholangitis in chronic biliary disease is
unknown. Platelet-derived growth factor (PDGF)-BB is an important signal in the process
of hepatic fibrosis. Paclitaxel (Taxol) is a demonstrated anti-fibrotic agent. The present study

















on this process. Methods: Rat cholangiocytes and bile duct fibroblasts were isolated and
cultured. Cells in serum-free medium were treated with E. coli lipopolysaccharide (LPS),
with or without addition of paclitaxel (1nM) one hour earlier. Collagen content in cells and
medium was assessed by colorimetric assay and gel electrophoresis. mRNA of PDGF-BB,
and TGF-β1 was measured by relative quantitative real-time PCR. Results: Fibroblasts treated
with LPS increased collagen in cells by 76.6% and in medium by 41.1% compared to
controls; paclitaxel reversed this process. mRNA of PDGF-BB was expressed by cholangiocytes
and fibroblasts, but its receptor (PDGFR-β) mRNA was only expressed by fibroblasts. LPS
increased mRNA of PDGF-BB levels 20X in cholangiocytes and fibroblasts. In cholangiocytes,
but not in fibroblasts, this response was almost completely suppressed by paclitaxel. mRNA
of TGF-β1 was not increased significantly with LPS. Conclusions: Our data suggest that
PDGF-BB is involved in biliary fibrosis. Binding of PDGF-BB to PDGFR-β on subepithelial
fibroblasts may cause collagen deposition leading to fibrosis. Inhibition by paclitaxel of
PDGF-BB formation by cholangiocytes might provide a new approach to limiting collagen
synthesis and fibrosis in the biliary tract.
W1754
Usefulness of Contrast-Enhanced Ultrasonography in Differential Diagnosis of
Gallbladder Diseases
Kazuo Inui, Junji Yoshino, Hironao Miyoshi, Masashi Hattori, Kazumu Okushima, Yuta
Nakamura, Toshihiko Chikaishi
We investigated usefulness of contrast-enhanced ultrasonography for differential diagnosis of
gallbladder diseases in 71patients, comparing contrast-enhancement patterns with pathologic
findings. Surgical pathologic diagnosis (n=30) or clinical diagnosis (n=41) patients included
gallbladder carcinoma in 27, adenoma in 2, benign polyp in 33, and adenomyomatosis in
9. We used two ultrasonographic instruments developed by TOSHIBA (Tokyo, Japan, SSA-
370A and SSA-770A). A galactose-based contrast agent (Levovist, Nippon Schering, Japan)
was resolbilized to represent a dose of 300 mg/ml. Seven milliliters of solution was injected
intravenously as a bolus at a rate of 1 ml/sec. We monitored vascular flow with Advanced
Dynamic Flow for 60 sec, constructing a time/intensity curve (TIC) with flash-echo imaging
(FEI) after administration of an additional 7 ml of Levovist. We investigated the diagnostic
capability for gallbladder diseases of contrast-enhanced patterns and TIC. We also compared
number of vessels, degree of inflammation, and vessel diameter determined by contrast-
enhancement patterns and by pathologic examination using CD31 immunohistochemistry
and hematoxylin and eosin staining in five fields at ×400. Contrast-enhancement patterns
were classified as linear (type L), scattered (type S), diffuse (type D), or branched (type B).
Among carcinomas type B was seen in 4 and type D in 15; among adenomas type S in 1
and type D in 1; among case of adenomyomatosis, type S in 8 and type D in 1; and among
benign polyps, type L in 12, type S in 14, and type D in 7. When type D and type B were
considered indication of cancer, accuracy was 84.5%; sensitivity 100%; and specificity 76.9%.
When only type B was so considered, accuracy was 100%. In gallbladder carcinoma, the
TIC rose from no contrast to early-phase contrast sooner than in adenoma or adenomyom-
atosis. The TIC in benign gallbladder polyps rose gradually from the early to the late phase.
In adenocarcinoma, high-intensity values persisted at 120 sec after injection, which was
unusual in other diseases. With an intensity of 90 or greater at 120 sec taken as an indication
of cancer, accuracy was 89.7%; sensitivity 89.5%; and specificity 89.7%. Vessels were
significantly more numerous in type D cases than in those with other pattern. Type D and
type B included the greatest number of cases with advanced inflammation. Vessel diameter
was greatest in type D and type B patterns, both differing significantly from type L. In
conclusions, ultrasonographic contrast-enhancement patterns show characteristic associ-
ations with pathologic findings and serve as valuable adjunct in diagnosis of gallbladder dis-
eases.
W1755
Modified Criteria of Fatty Meal Hepatobiliary (HIDA) Scan for Diagnosis of
Biliary Dyskinesia
Abdullah Rashdan, Kusai Al-Muqbel, Mohammad Bani-Hani
Background: The utilization of fatty meal HIDA scan for evaluating acalculus right upper
quadrant (RUQ) abdominal pain of suspected biliary origin is not well recognized. We
conducted a study with modefication of diagnostic criteria of fatty meal HIDA scan for
diagnosis of biliary dyskinesia. Methods: Patients with chronic acalculus RUQ pain were
investigated with 40 gm fatty meal HIDA scan. Biliary dyskinesia was considered if the
gallbladder ejection fraction (GBEF) was ≤ 50% [compared to the standard criteria of GBEF
≤ 35%] or delayed biliary-bowel transit time beyond 60 minutes of the filling phase. Subjects
with abnormal study were offered laparoscopic cholecystectomy versus medical management
of functional pain. Symptomatic improvement were recorded prospectively and correlated
with the degree of dyskinesia and histologic findings. Results: 117 patients enrolled, 68
(59%) had abnormal HIDA scan. 52 subjects underwent cholecystectomy 48 patients (92%)
had complete or partial relief of symptoms on long-term follow up (mean of 3 years).
Chronic cholecystitis was found in 50 (96 %) of the cases. No correlation was between
degree of dyskinesia and symptomatic relief. The current criteria has 90% sensitivity with
specificity of 86% and overall accuracy of 88%. Conclusion: Modified criteria using fatty
meal HIDA scan appears to be an accurate diagnostic tool in patients with suspected
biliary dyskinesia
W1756
Clinical Features of Patients with Choledocholithiasis Showing High Levels of
Aminotransferases
Won Joong Jeon, Joung Ho Han, Seon Mee Park, Hee Bok Chae, Sei Jin Youn
Aims: We aimed to determine the clinical features of patients with common bile duct (CBD)
stones who showed very high serum levels of AST or ALT. Methods: A retrospective review
of 93 patients with CBD stones was completed. Clinical characteristics, CBD diameters,
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and pre-endoscopic retrograde cholangiopancreatography (ERCP) diagnoses were assessed
between the two groups with ≥400 IU/L (group 1) or ≤l00 IU/L (group 2) of serum AST
or ALT levels. Results: The numbers of patients were 19 and 17 in group 1 and group 2,
respectively. The most common symptom was abdominal pain in both groups. Group 1
was about 14 years younger than group 2 (p=0.003). The duration of symptoms in group
1 and group 2 were 4.1 and 36.8 days, respectively(p=0.005). The CBD diameter was smaller
in group 1 (11.4 mm) than that of group 2 (16.3 mm)(p=0.001). Most patients were
diagnosed to have CBD stones by abdominal ultrasound or computed tomography before
ERCP, except two patients in group 1 who diagnosed as hepatitis initially. All recovered by
stone removal during ERCP and antibiotics treatment. There were inverse correlations
between CBD diameters and AST or ALT levels (r=-0.517, p=0.002/r=-0.504, p=0.002).
Conclusion: The common bile duct stones with high AST or ALT levels are frequently
observed in the younger patients with shorter duration of symptoms and smaller CBD
diameter. In these patients, it is possible to misdianose as acute hepatitis. Therefore, special
caution is needed in diagnosis of the patients with CBD stones who show very high AST
or ALT level.
Clinical Features between the Groups
WBC, white blood cell; CBD, common bile duct. All data represent mean±standard deviation.
W1757
Role of Endoscopic Ultrasound in Prevention of Unnecessary ERCP: A
Prospective Follow-Up Study of 150 Patients
Rasoul Sotoudehmanesh, Shadi Kolahdoozan, Morteza Khatibian, Ali Ali Asgari, Sanaz
Ainechi, Reza Malekzadeh
Background & Aims: The aim of this study was to determine the impact of substituting
endoscopic ultrasonography for endoscopic retrograde cholangiography in cases of low to
intermediate risk for choledocholithiasis. Methods: During 16 months patients who referred
for suspected choledocholithiasis, biliary colic or acute biliary pancreatitis on the basis of
slight alteration in liver enzymes with or without gallbladder stone seen in transabdominal
ultrasound were included. Patients with common bile duct stone on endoscopic ultrasonogra-
phy were subjected to endoscopic retrograde cholangiography and those with cholecystolithi-
asis sent for cholecystectomy. Other cases underwent EUS and were followed up to one
year post-procedure by phone. Results: During 16 months, a total of 150 patients (55 male,
95 female with a mean age of 49.6 ± 17.5) were included. Thirty three cases (22%) were
diagnosed as choledocholithiasis by endoscopic ultrasonography. Of these, 31 underwent
endoscopic retrograde cholangiography and the diagnosis was confirmed in 24 patients
(77.4 %). Fifty one cases had normal common bile duct and follow up for one year showed
no abnormality. No complications were encountered by endoscopic ultrasound. Endoscopic
retrograde cholangiography was avoided by this approach in 111 cases (74%). Conclusion:
When the pretest probability for choledocholithiasis is low, EUS before ERCP can preclude
the need for endoscopic retrograde cholangiography in most cases.
W1758
Carbon Dioxide Mdct Cholangio-Pancreatography Providing Synchronous
Virtual Angiography
Maki Sugimoto, Hideki Yasuda
PURPOSE: The authors investigated the feasibility of a new software system employing 3-
dimensional (3D) virtual anatomic reconstruction using MDCT with carbon dioxide (CO2)
gas as a negative contrast agent, and intra and extra luminal virtual exploration for detection
of preoperative visualization of the cholangio-pancreatic (CP) anatomy. MATERIALS AND
METHODS: Total of 70 patients who were thought to have CP disease underwent therapeutic
endoscopic drainage were included in this study. 16-slice MDCT was performed with the
infusion of 5-50 cc CO2 via endoscopic naso-pancreaticobiliary drainage (ENBD, EPS). Three-
dimensional MDCT CP images (CO2 MDCT-CP) were produced using volume rendering for
virtual CP endoscopy . Capability of CO2 to pass the obstruction and delineate distal parts
of the CP duct was evaluated. 1. CO2 MDCT-CP All procedures had 100% technical success;
complication had a 0% morbidity rate. The correct diagnosis was made on CO2 MDCT-CP
for cholelithiasis, adenomyomatosis of the gallbladder, xantogranuromatous cholecystitis,
bile duct malignancies, over 2mm cystic lesions in IPMN, and invasive pancreatic cancer.
CO2 could go through the narrowing cystic duct and obstructed bilio-pancreatic duct,
additional distal segments of the occluded bile duct induced the impact stone and bile duct
cancer occlusion. 2. CO2 Virtual endocopy Virtual CP endoscopy using CO2 MDCT revealed
excellent and moderate endoluminal visualization to detect stenosis, obstruction, and detailed
protruding lesions over 2mm . 3. Syncro CO2 MDCTA-CP Generally MDCT angiography
(MDCTA) with CP imaging has to be needed multiphase fusion scanning. Our CO2 MDCT-
CP can provide the entire synchronous CP imaging by CO2 with virtual angiography initiated
after the IV infusion of contrast agent (CO2 MDCTA-CP) because of the high contrast
interface between soft tissue and gas. This provides valuable information for planning surgery,
including the location of the obstruction and its relationship to the surrounding vessels.
CONCLUSION: Our preliminary results emphasize that synchronous CO2 MDCTA-CP is
a newer safe tecnique providing visualization of CP disorder and detailed preoperative
reconstruction of CP anatomy. Because of its low viscosity, CO2 is a useful contrast medium
to visualise the extrahepatic biliary system before performing percutaneous drainage in
biliary obstruction. Unnecessary intraductal manipulations may be reduced. Newer software
developments may further enhance its accuracy, so that CO2 MDCTA-CP might challenge
or replace more invasive diagnostic measures in the near future.
W1759
The Clinical Outcome of Palliative Drainage Methods (Percutaneous T-Stent
Internal Drainage versus Endoscopic Retrograde Biliary Drainage) in Klatskin
Tumors
Dae Han Kang, Gwang Ha Kim, Tae Oh Kim, Joo Ho Lee, Jeong Heo, Geun Am Song,
Mong Cho, Chang Won Kim, Jeong Ho Heo, Jae Seung Lee
Background/Aims : Curative surgery is not possible in majority of Klatskin tumors. Palliation
with endoscopic or percutaneous internal drainage is a well-established procedure in such
a irresectable biliary tumor. We evaluated the clinical efficacy of bilateral internal drainage
by means of a newly designed T -configured dual stent placement. We compared the
clinical outcome of percutaneous T-stent with that of endoscopic retrograde unilateral biliary
drainage. Methods : From 2001 to 2004, 36 patients with Klatskin tumors were treated
with percutaneous transhepatic placement of two self-expandable metallic endoprostheses
in a T configuration through a single transhepatic access. We undertook a retrospective
chart review of all 29 Klatskin tumors which drained by unilateral ERBD during the period
same as the above. Results : The patients’ characteristics are outlined in Table 1. Klatskin
tumor grades according to the Bismuth classification differ among both study groups (T
stent group: 8 type II, 23 type III, and 5 type IV versus ERBD group: 11 type I, 14 type
II, and 4 type III). To compensate the differences, we corrected the obtained clinical outcome
data (Table 2) according to the covariance analysis. The frequency of cholangitis in T stent
group was lower than that in ERBD group, but the difference was not statistically significant.
Also there were no significant differences in survival and stent patency among both T-stent
and ERBD groups. Conclusions : T stent placement can be used effectively and safely to
achieve bilateral internal drainage in biliary bifurcation tumors and is technically simple. In
the more advanced hilar tumors, it can be considered as the first palliative drainage method.
But, in the not advnced hilar tumors unilateral drainage by ERBD can achieve sufficient
palliation as bilateral drainage.
Table 1. Clinical characteristics of the patients who have Klatskin tumors which drained by
T-stent or ERBD.
Table 2. Clinical outcome data of the Klatskin tumors in both study groups.
W1760
Percutaneous Biliary Drainage: Influence of Microbiology On Antibiotic
Strategy and Therapeutic Management
Olivier Corcos, Frederique Maire, Oana Zamfir, Annie Sibert, Magaly Zappa, Philippe
Levy, Valerie Vilgrain, Marie-Helene Nicolas-Chanoine, Dermot O'Toole, Philippe
Ruszniewski
Percutaneous biliary drainage has proven to be efficacious in symptomatic hilar or intrahepatic
biliary stenosis. However, drainage is often complicated by biliary super-infection (the latter
which is complicated by bilio-digestive drains and/or stents and their lavage; indeed digestive
flora contamination appears frequent) and antibiotic treatment is therefore difficult. Here
we describe the type of germs and antibiotic strategies employed in a large cohort of patients
treated in a single centre. Patients/method: 64 consecutive patients (mean age 64 years)
underwent percutaneous biliary drainage between July 2004 and March 2005. The cause
of biliary stenosis was cholangiocarcinoma (n=27), pancreatic adenocarcinoma (n=7), benign
disease of the CBD (n=5), biliodigestive anastomosis (n=7), post liver transplantation (n=8)
compression from metastases (n=5). Indications of drainage were: ascending cholangitis (n=
21), pruritus (n=13), jaundice (n=17), obstruction of pre-existing biliary stent (n=5) or
prior to surgery (n=10). Microbiologic analysis of bile was performed during drainage and
subsequent follow-up. Results: In 35 patients (55%) the 1st bile aspirate was sterile (20
patients were on antibiotics, 11 for ascending cholangitis). In 29 patients with a positive
culture of 1st bile aspiration antibiotic treatment prior to drainage had administered in
17 (58%), 10 for ascending cholangitis: the aspiration showed a single bacteria species
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(Enterococcus, E. coli, Proteus mirabilis and other species of Enterobacteria, naturally resist-
ant to amoxicillin and clavulanic acid namely Enterobacter, Citrobacter and Morganella
species). Bile which was subsequently analysed in the internal/external drains (n=56) was
positive in 99% of cases with a multitude of digestive micro-organisms including bacteria
and fungi. Such colonisation was clinically symptomatic in 18 cases (33%). Conclusion: 1)
The initial bile aspirate during percutaneous drainage is sterile in the over half of patients
whether pre-treated or not with antibiotics; 2) The bile sample is contaminated in a majority
of patients with ascending cholangitis treated by antibiotics (59%); 3) subsequent bile
samples are frequently contaminated by digestive micro-organisms but a minority have a
clinical infection; 4) Antibiotic prophylaxis using amoxicillin and clavulanic acid, frequently
employed in these patients, does not treat most of the Enterobacter species encountered.
W1761
Clonorchiasis Is Associated with Cholangiocarcinoma, Not with Biliary Stone
or Hepatocellular Carcinoma: Nation-Wide Multicenter Survey in Korea
Ho Gak Kim, Myung-Hwan Kim, Seung-Ok Lee, Sung-Jae Park, Chan-Guk Park, Young-
Eun Joo, Gwang Ha Kim, Chang-Hun Yang, Jin Bong Kim, Kyu Taek Lee, Dongki Lee,
Taehyo Kim, Hyun Soo Kim, Jae Seon Kim, Young-Soo Moon, Chang-Min Cho, Woo Jin
Lee, Kyo-Sang Yoo, Gabjin Cheon, Jong Ho Moon, Tae Nyeun Kim, Yong Woo Choi,
Byeong Moo Yoo, Ji Kon Ryu, Yong Bum Yoon
Background/Aim: Clonorchiasis has been recognized as one of the most important endemic
diseases in Korea. Infection rate of Clonorchis sinensis(CS) was not reduced despite of
Praziquantel because of the custom of eating raw freshwater fish. We investigated nation-
wide infection rate of CS in patients with gastrointestinal(GI) symptoms, and the relation
of CS with hapato-biliary diseases prospectively in 26 secondary and tertiary hospitals in
Korea. Patients and Methods: Consecutive patients who were admitted in Gastrointestinal
Department with GI symptoms were enrolled from March to April 2005 in 26 nation-wide
hospitals. Present and past CS infection was diagnosed by one of stool direct smear, serologic
test for IgG clonorchis circulating antibody(CAb), intradermal test for CS, bile cytology, and
typical radiological findings. Epidemiology, correlation between CS infection and hepato-
biliary diseases were surveyed. Results: Among the 3081 patients with GI diseases,
396(12.9%) were infected with CS at present or in the past. 1131 patients had history of
eating raw freshwater fish and 235(20.8%) patients infected with CS. 161(8.4%) of 1925
patients who had no history of eating raw freshwater fish also infected with CS. Cholangiocar-
cinoma(CCa) was more prevalent in CS infected patients than CS not-infected patients {27/
396(6.8%), 102/2685(3.8%) respectively, p=0.038}. CS infected patients were more common
in the patients who ate raw fish in the basins of 5 rivers in southern part of Korea than
those who ate raw fish in the basins of 5 rivers in middle part of Korea {182/578(31.5%),
38/464(8.2%) respectively, p=0.000}. CCa was more prevalent in the patients who ate raw
fish in the basins of rivers in southern Korea than the patients who ate raw fish in the basins
of rivers in middle Korea {28/353(7.9%), 8/232(3.4%) respectively, p=0.027}. CCa and CS
infection have significant positive cross-relation each other(p=0.008). Alcoholic pancreatitis
was more common in CS infected patients than CS not-infected patients {19(4.8%), 71(2.6%)
respectively, p=0.018}. It is explained by that Korean people have a custom of eating raw fish
at drinking parties. Choledocholithiasis, cholecystolithiasis, cholangitis, and hepatocellular
carcinoma were not related with CS infection. Intradermal test for CS has the highest
sensitivity(75.1%) compared with serologic CAb test(42.9%) and stool direct smear(17.1%).
Conclusions: Infection rate of CS is high in patients with GI diseases in Korea, and is not
reduced for recent two decades. CCa is related with CS infection and is more common in
the areas of CS prevalent rivers, so CS can be the possible etiology of CCa.
W1762
Management Strategies of the Gallbladder Polyps
Joo Kyung Park, Yong Bum Yoon, Yong Tae Kim, Ji Kon Ryu, Won Jae Yoon, Jun Kyu
Lee, Sang Hyub Lee, Min Jung Park
Introduction Polypoid lesions of the gallbladder(GB) encompass a wide variety of pathologies.
Although most the lesions are benign, problems remain in selecting patients for surgery or
regular follow up. Aims and Methods The aim of this study is to describe the natural course
of GB polyps and to propose reasonable factors for making a decision in favor of surgery
or regular follow-up. We studied the epidemiology of GB polyps in Health Care Center of
Seoul National University Hospital from Oct. 2003 to July 2005. In 24,617 healthy individuals
who underwent abdominal ultrasonography (USG), the prevalence of GB polyps was 7.1%
and 4.8% for men and women, respectively. The 740 patients with GB polyps documented
by abdominal USG from January 1988 to December 2004 at Seoul National University
Hospital were randomly enrolled, but 69 patients were excluded due to such comorbidities
: congestive heart failure, chronic renal failure, coronary heart disease, liver cirrhosis or
malignancy. Results There were 399 men and 272 women in the total of 671 patients. The
median age was 47 years old, and the median follow up duration was 51 months. The mean
diameter of initially diagnosed polyp was 6mm (range from 2 to 30mm). Two hundred
thirty six patients (35 %) had polyps below 5mm, 312 patients (47 %) from 5 to 9mm,
and 123 patients (18 %) above 10mm. Four hundred patients (60%) had single polyp and
271 (40%) patients had two or more polyps (range from 2 to 10). There were 57 patients
with accompanying gallstones. The majority of patients experienced no change in the GB
polyp (496; 74%) or decreased GB polyp size by more than 3mm (69; 10%). Pathologic
reports were obtained on the 163 patients who underwent surgery. There were 7 patients
(1%) who had adenocarcinomas of GB, and all of them had polyps with size of more than
10mm (range from 10.0mm to 24mm). There were 44 patients (7%) who had adenomas
of GB, and the size of polyps was variable (range from 3 to 20mm). We performed χ2 test
to find risk factors of precancerous lesions (adenoma) and cancer: sex, age, symptoms,
associated stones, size, shape and multiplicity of polyps. Among them, size of the
polyp(≧10mm) was the only statistically significant risk factors of cancer and adenoma (p =
0.007, 0.04). Conclusion The GB polyp is fairly common finding in clinical practice, and

















clinical factors, the size of the polyp(≧10mm) was the most important risk factor of precancer-
ous lesion (adenoma) and cancer, and such a polyp should be carefully observed. Also,
more investigations should be performed to look for indications of surgery.
W1763
Role of Pro-Hepcidin in PSC Patients with Bacterial Infections of Bile Ducts
Hasan Kulaksiz, Adolf Stiehl
Background & Aims: Primary sclerosing cholangitis (PSC) is characterized by progressive
fibrotic inflammation and strictures of the biliary system. Recently, we have shown that
bacterial infections are a frequent finding in PSC patients with dominant stenoses of the
bile ducts (Pohl et al. Eur J GastroenterolHepatol 2005). Since the newly discovered hepatic
peptide hormone hepcidin has antibacterial and antifungal effects, we have analyzed pro-
hepcidin in bile of PSC patients with infections of the bile ducts. Methods: Bile probes were
obtained during endoscopic retrograde cholangiographie (ERC) in 42 PSC patients (26
patients with dominant stenosis and bacterial infections of the bile ducts; 16 controls with
dominant stenosis but no infections). Immunoblot analysis with specific antibodies were
performed to detect pro-hepcidin in bile fluids. A sensitive ELISA assay was developed for
determination of pro-hepcidin in bile probes. Results: The antibacterial and antifungal peptide
pro-hepcidin is present in bile. In PSC patients with dominant stenoses but no infections
of the bile ducts the mean pro-hepcidin level was 22.2 ng /ml. Enhanced levels of pro-
hepcidin (mean 67.9 ng/ml) were found in PSC patients with dominant stenoses and
infections of the bile ducts. High levels of pro-hepcidin were associated with elevated serum
bilirubin. A significant correlation was also found between pro-hepcidin and serum C-
reactive protein and leucocytes. Conclusion: Detection of pro-hepcidin in the bile and its
association with bacterial infections of bile ducts implicates a possible local antibacterial
activity of this peptide in PSC patients with dominant stenosis. This finding underlines the
major impact of dominant stenoses in inflammatory processes of the bile ducts.
W1764
Sacral Extracorporeal Magnetic Stmulation Is the Same Effective Treatment for
Pelvic Floor Dyssynergia As Biofeedback Therapy
Joon Seong Lee, Hee Hyuk Im, Hyun Ku Jung, Young Dae Kim, In Seop Jeong, Su Jin
Hong, Jin Oh Kim, Joo Young Cho, Moon Sung Lee, Chan Sup Shim, Boo Sung Kim
Background: Recent development of extracorporeal magnetic stimulation (ECMS) which
uses current-changing magnetic fields allows the induction of electrical stimulation in the
desired deep tissue. Preliminary study shows that ECMS of sacral nerve can modify pelvic
floor function and expel rectal balloon in patients with pelvic floor dyssynergia (PFD). Aim:
To evaluate the effect of ECMS compared with biofeedback therapy(BF) in patients with
PFD. Methods: Thirty-eight patients who fulfilled Rome II criteria for PFD by colon transit
time and anorectal function tests, were randomly treated with 8 sessions of ECMS (2/weeks;
n=19) or BF (2/weeks; n=19). Stimulation parameters were set at 50-80% of maximum
intensity, 10 and 50 Hz frequency, 3 s burst length with 3 and 6 s off using arm-typed
stimulator (BioCom-1000, Mcube Co., Korea). Symptom scores for constipation, anorectal
function test were repeatedly measured after each treatment. Response was defined as 50%
or more decreased symptom score after treatment (partial response: 30-50%, poor: <30%).
Results: Fifteen patients (age 49.1±13.4 yr, mean±SD; 4 men) completed 8 session of BF
and 14 patients (54.5±17.6 yr, 3 men) completed 8 session of ECMS. Total symptom scores
were significantly decreased after treatment in both treatment group (13.4± 6.6 vs. 4.3±4.0
for BF, p=0.009; 14.9±5.6 vs. 3.4±4.0 for ECMS, p<0.001). Thirteen out of 15 patients
showed response in BF group and 12 out of 14 showed good response in ECMS group.
Conclusion: ECMS is as effective as BF for the treatment of PFD. Long-term effect of ECMS
need to be evaluated. Key words: magnetic stimulation, pelvic floor dyssynergia, biofeedback
W1765
Role of Rho Kinase in the Basal Tone in the Internal Anal Sphincter (IAS)
Smooth Muscle
Chirag A. Patel, Marcio A. De Godoy, Satish Rattan
Background & Aims: Increase in Rho kinase (ROK) activity has been associated with the
agonist-induced sustained contraction of the smooth muscle. However the role of ROK in
the truly tonic smooth muscle in the basal state is not known. Methods: The present studies
examined the effects of ROK inhibitor Y27632 in the tonic smooth muscle of the IAS vs.
in the flanking phasic smooth muscle of the rectum (RSM) using computerized recording
of force measurements. The studies were performed in the tissues from rat, an appropriate
animal model for human anorectal studies. In addition, studies were performed to determine
the relationship between the changes in the basal IAS tone following Y 27632 vs. ROK and
protein kinase C (PKC) activities. We also determined changes in free intracellular Ca2+]<
([Ca2+]i). The levels of RhoA/ROK in these diverse smooth muscles were determined using
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Western Blots and reverse transcriptase-polymerase chain reaction (RT-PCR). In order to
investigate the cellular distribution of RhoA/ROK in the IAS vs. the RSM, we performed
confocal microscopy studies in the isolated smooth muscle cells (SMC). Results: The ROK
inhibitor caused several-fold and significantly more potent relaxation of the IAS as compared
with the RSM. In this regard, 27632 (1 μM) causing 50% inhibition (IC50) in the basal IAS
tone had minimal effect on the RSM phasic activity (p < 0.05; n = 7). The relaxant effect
of Y 27632 was directly at the SMC because different neurohumoral antagonists (including
NOS inhibitor L-NNA (0.3 mM) and tetrodotoxin (1 μM)) did not modify this effect. In
addition, a similar relaxation was observed in the IAS SMC. The IAS relaxation by Y 27632
correlated directly with the decrease in ROK activity without significant changes in the levels
of [Ca2+]i and PKC activity. ROK activity assays, Western Blot and RT-PCR studies revealed
that in the basal state, the IAS had distinctly higher levels of RhoA/ROK as compared to
the RSM. Confocal microscopy studies verified relatively higher distribution of RhoA/ROK
towards the periphery of the SMC of the IAS in contrast to the RSM. In in vivo studies, the
lower doses of Y 27632 caused potent and selective fall in the IAS pressures (IASP) without
any adverse systemic effects. 5 nmoles/kg of Y 27632 caused maximal fall in the IASP while
25 μmoles/kg (5,000 times) of the ROK inhibitor was required to produce a similar fall in
the mean systolic blood pressure. Conclusions: 1). Rho kinase plays an important role in
the maintenance of the basal tone in the IAS; and 2). ROK inhibitors have a therapeutic
potential in the IAS dysfunction especially characterized by the hypertensive IAS.
W1766
Fecal Incontinence: Doctors Don’t Ask and Patients Don’t Tell
Sara K. Hawes, Afkhamossadat Merikhi, Ayaz Matin, Elango Vinjirayer, James C.
Reynolds, Asyia Ahmad
Fecal incontinence (FI) is a severely debilitating and embarrassing disorder rarely reported
by patients. Previous studies have only elicited a history of FI by mailed surveys or question-
naires given to patients upon arrival at their doctor’s office. The value of a direct patient-
doctor interview to identify the prevalence of patients with FI has never been evaluated.
Our aim was to determine the prevalence of FI in patients presenting to a gastroenterology
(GI) office by including FI questions in a thorough gastroenterology review of systems.
METHODS: Two hundred random outpatient charts were retrospectively reviewed for any
documentation pertaining to fecal incontinence during the initial doctor-patient interview.
We then prospectively asked 150 patients in our GI office a thorough review of systems
including if s/he experienced the escape of flatus or soiling with liquid or formed stool.
Patients that answered yes were entered into our study and administered a questionnaire
regarding their demographic and medical history as well as the validated Rockwood FIQOL
(quality of life) and FISI (fecal incontinence severity index). Patients were also asked if the
topic of FI had ever been addressed by their health care provider. RESULTS: Retrospective
chart review revealed that only 2 out of 200 (1%) outpatient GI patients had documentation
of any discussion regarding FI. In the prospective arm of our study 29 (19%) of patients
interviewed had a history of FI and 80% of these patients had never been questioned about
FI by any doctor. Only one of these patients had ever been asked by a primary care doctor
about FI, yet 86% of our FI patients had a medical history significant for well known risk
factors for FI. Of the 29 patients with FI, only 2 of them specifically came to our office for
that reason, yet 55% had >1 episode of FI per day and 67% had symptoms for >1 year.
Furthermore 38% percent of patients had poor QOL and 66% of patients had high FISI.
Regression analysis revealed a direct correlation between FISI and QOL (R=0.77) in women.
Surprisingly there was no correlation between FISI and QOL in men. Our study differs from
previous studies in that 65% of our patients were women. Interestingly, 50% of our patients
had an education level beyond high school. CONCLUSIONS: Nineteen percent of patients
seen in gastroenterology offices with FI will be missed unless specifically questioned. Unfortu-
nately, despite greatly diminished QOL, high SI scores and advanced education level, patients
rarely bring up FI with their doctor. To elicit a history of FI it is imperative for gastroenterolog-
ists to specifically and routinely question their patients about FI.
W1767
Mode of Delivery Affects Anal Sphincter Innervation
Heiko Franz, Heidemarie Hinninghofen, Axel Kowalski, Roberto Merletti, Paul Enck
Introduction: Surface-EMG (S-EMG) of external anal sphincter (EAS) by multi-electrode
arrays (MEA) was used for a large series of gynecologic patients for the first time. We wished
to determine the degree of asymmetry of sphincter innervation, its determinants, and the
relationship to fecal incontinence. Material and Methods: In 129 continent women following
childbirth and in 40 patients with fecal incontinence recruited in a gynecological hospital,
S-EMG of the EAS was performed by 16-channel MEA during maximal voluntary contraction,
and generation and propagation of individual motor unit actions potentials (MUAP) were
recorded in the anal circumference at 3 levels within the anal canal. Innervation zones (IZ)
of MUAP, their circular distribution in the quadrants as measure of symmetry, as well as
the statistical characteristics of amplitude (average rectified values,ARV; root mean square,
RMS) and mean frequency (MNF) of MUAP firing were compared between and across
subgroups (age, continence status, number and mode of deliveries) by ANOVAs. Results:
All S-EMG characteristics were best identified in the proximal and distal anal canal, but IZ
and ARV were overall lower in incontinence, and differences between the three levels were
less pronounced in incontinent patients. Age reduced independently the number of IZ (p=
.017) and the amplitude (ARV, p=0.046). In incontinent subjects, lower amplitudes (RMS)
(p=.084) and higher firing frequency (MNF) (p<0.001) of EMG were found. Significant
asymmetry of innervation was found for dorsal versus ventral, but not for left versus right
comparison of amplitudes (RMS, p=.004) and frequency (MNF, p=.001), and was more
pronounced in the distal anal canal for IZ distribution (p=.007) and in the proximal canal
for EMG amplitude (ARV, p=.007). The asymmetry of firing frequency (MNF) was increased
with more deliveries, especially in incontinent women (p=.026). Episiotomy was asociated
with significant left/right asymmetry of IZ distribution (p=.075), as was vacuum extraction
(p=.04) and forceps delivery (p=.04), but not cesarian section (n.s.). Conclusions: Asymmetry
of innervation of the EAS seems to play a role in incontinence, with independent contribution
of age, number of childbirth, and the mode of delivery. (Supported by grants from the EU
and the Fresenius Foundation, Germany)
W1768
Length Tension Relationship of the Puborectalis Muscle in Women
Bikram S. Padda, Sung-Ae Jung, Delores Pretorius, Jianmin Liu, Debbie Denboer,
Ravinder K. Mittal
Aims and Hypothesis: Role of puborectalis muscle (PRM) in fecal continence remains unclear
because of the lack of an adequate recording technique to monitor PRM function. Recent
study suggests that the vaginal high-pressure zone (VHPZ) may be related to PRM contraction.
If that were true, increasing PRM length should increase pressure in the vaginal HPZ (length
tension function) Methods: 15 nullipara females were studied. Effect of vaginal distension,
using a 30 mm bag, on PRM length was determined using 3D-transperineal ultrasound
imaging. VHPZ was recorded using probes of diameters 5, 10, 15, 10, 25, & 30 mm. Probes
of diameter >10 mm had a linear groove to accommodate a 5 mm diameter sleeve sensor
for pressure measurement. Pressures were recorded with the sleeve sensor facing the anterior
and posterior position, at rest and maximal voluntary squeeze. Results: 3D US images show
the entire loop of the PRM from which PRM length were determined using a computer and
software. Increase in bag diameter increased the PRM length. VHPZ shows a resting pressure,
which increases with voluntary squeeze. A linear increase in the resting, squeeze and delta
(difference between rest and squeeze pressures) pressure in the VHPZ was recorded with
the increase in the probe size. There is a wide variability in the maximal pressures recorded
among different subjects (max squeeze pressure of 250-800 mmHg). Anterior VHPZ pressures
are 2-4 times greater than posterior pressures. Conclusions: Pressure increase in the VHPZ
with the increase in PRM length further proves that the VHPZ is related to PRM contraction.
Future studies should determine the role of PRM length-tension function in fecal continence.
Effect of PRM Distension on Vaginal Pressure Recording
W1769
Rectocele and Intrarectal/Anal Intussusception Are Not Related with Impaired
Rectal Transit and Emptying, in Functional Constipation
Federico Alghisi, Danilo Badiali, Roberto Cappuccio, Fiorella Anzini, Enrico Corazziari,
Fortunee Irene Habib
Rectocele and intra-rectal/anal intussusception are frequent findings in chronic constipation,
and their surgical repair has been proposed for the treatment of obstructed defecation
syndrome. However, it is not established whether rectocele and intra-rectal/anal intussuscep-
tion, per se, affect rectal transit and/or emptying. Aim of this study was to assess the
relationship between rectocele and intra-rectal/anal intussusception with rectal transit and/
or emptying. Materials and methods: 146 consecutive patients (F 130, mean age 45.8±13.6
yrs), affected by functional chronic constipation according to ROME II criteria, were submit-
ted to defecography and measurement of rectal transit time by means of radio-opaque
markers assessed at 72-hrs intervals on abdominal antero-posterior x-ray. To identify the
rectum, a latero-lateral radiogram, including sacrum and coccyx, was added when markers
reached the pelvis. At defecography the presence of significant rectocele (>3.5 cm), intra-
rectal/anal intussusception, post-evacuative residue were assessed. Results: Rectal transit was
delayed in 45 pts (30.8%). The following defecographic findings were found: rectocele
32.2%, intra-rectal/anal intussusception 41.8%. The frequency of prolonged rectal transit
did not differ in patients with, and without, rectocele (χ2=0.12, n.s.) and intra-rectal/anal
intussusception (χ2=0.01,n.s.). A moderate/severe post-evacuative residue was observed in
66.4% of the patients, with no statistical difference between patients with and without
defecographic changes or delayed rectal transit. Conclusions. The results of this study suggest
that both rectocele and intra-rectal/anal intussusception, per se, scarcely affect rectal emptying
and do not delay transit through the rectum.
W1770
Comparison of Water-Perfused (WPM) and Manoscan™ High Resolution
(HRM) Anorectal Manometry (ARM)
Jennifer Post, Sarah Wessinger, Michael P. Jones
Introduction: ARM is used to evaluate fecal incontinence and dysynergic defecation. It is
poorly standardized and agreement btwn ARM and other tests of anorectal function is
often poor. HRM is a new stationary recording technique using closely spaced solid state
transducers. In esophageal studies, HRM provides superior resolution of motility compared
with WPM. We compared WPM and HRM in patients undergoing ARM. Methods: Consecut-
ive pts referred for ARM underwent simultaneous WPM and ARM. WPM was performed
using a 6cm sleeve assembly with sideholes spaced at 3cm intervals. HRM was performed
using the ManoScan™ system consisting of a 4.2mm, 36-channel catheter with sensors
spaced at 1cm intervals. Space-time pressure data were displayed in topographic form using
ManoView™ analysis software that is part of the ManoScan™ system. Balloon distension
was performed using a random distension protocol with volumes between 20-100ml. Results:
18 pts were studied. Indications were constipation in 13 and incontinence/urgency in 5.
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Good correlation existed between the two methods for anal sphincter (AS) pressure at rest,
with voluntary contraction and during 40ml rectal balloon distension (table). Correlation
of AS/intrarectal(IR) pressure ratios during pseudodefecation were also good. HRM provided
greater resolution of AS. The figure demonstrates paradoxical puborectalis contraction during
pseudodefecation seen with HRM but not WPM. Conclusions: HRM and WPM were highly
correlated. HRM provides greater anatomic detail allowing superior discrimination of anorec-
tal function. HRM may be of particular value in the evaluation of suspected dysynergic defeca-
tion.
AS=anal sphincter EAS=external anal sphincter IAS-internal anal sphincter
W1771
Rectosigmoid Compliance and Visceral Perception in Spinal Cord Injury
Patients
Beatrice Salvioli, Roberto De Giorgio, Vincenzo Stanghellini, Giovanni Barbara, Mauro
Menarini, Roberto Corinaldesi, Gabriele Bazzocchi
Background and Aim: In studies assessing anorectal motor function in traumatic complete
or incomplete spinal cord injury (SCI), various continence mechanisms have been shown
to be disturbed, resulting in either constipation or incontinence. Rectal or colonic compliance
may be normal or reduced in SCI patients compared to controls. Data indicate that the
colonic response to food is preserved in patients with higher T6 SCI. Theoretically, patients
with cervical lesions, classified as having a complete injury according to clinical criteria
(American Spinal Injury Association, ASIA), do not experience pelvic sensation. Nevertheless,
some evidence reports a preservation of sensory functions in these patients. The origin of
this sensation has not been determined yet and data on physiological features of recto-
sigmoid compliance and perception in SCI patients are lacking. The scope of this study was
to investigate recto-sigmoid compliance and perception in chronic SCI patients. Methods:
We evaluated recto-sigmoid responses to fixed tension distensions applied by means of a
tensostat in 6 patients (6M, 42±4 yrs) with complete transsection of the spinal cord (high-
SCI; 5 tetraplegic C5-C7 and 1 paraplegic T4-T6) classified as ASIA-A and impaired evacu-
ation (i.e., constipation). Results were compared to those obtained in 10 healthy subjects
(6M, 25±1 yrs). Results: SCI patients had higher rectosigmoid compliance at the highest
distension level than controls (10.3±2.4 mL/mmHg vs. 5.1±0.8 mL/mmHg; P<0.05) and
reduced maximal tension tested (54±14 g vs 85±4 g; P<0.05). Perception scores at first
sensation were higher in patients (2.3±0.7 vs. 1.1±0.1; P<0.05), but were not different at
the highest distension levels (3.7±0.8 vs. 3±1; NS). In 2 patients, rectosigmoid distension
induced autonomic dysreflexia. Compared to controls, the most commonly reported sensation
by patients was distension/bloating (70% vs. 54%, respectively; NS). Patients reported
sensations less commonly to the hypogastrium (the sub-umbelical region) compared to
controls (29% and 88%; NS). Conclusion: Patients with ASIA-A SCI have: 1) increased
recto-sigmoid compliance; 2) maintenance of visceral perception, which appears differently
referred from that defined by controls. These data indicate that increased compliance is an
underlying mechanism of abnormal evacuation in these patients. The preservation of visceral
sensations, although abnormally referred, implies the occurrence of sensory input remodelling
at spinal level.
W1772
Effects and Mechanisms of Vaginal Electrical Stimulation On Rectal Tone and
Anal Sphincter Pressure: Therapeutic Potentials for Fecal Incontinence
Gengqing Song, Hongbing Zhu, Jiande Chen
Aims: The aims of this study were: 1) to evaluate the effect of vaginal electrical stimulation
(VES) on rectal tone and compliance and anal sphincter pressure (APS); 2) to explore possible
mechanisms involved in the effects of VES on the rectal tone in conscious dogs. Methods:
8 female hound dogs inserted with a VES polyacetal probe with two rings electrodes were
studied. The study included two experiments. The first experiment was composed of 2
separate sessions: rectal tone and compliance; and ASP. Each session included three sub
sessions: VES with long pulses (500ms, 6mA, 12cpm), VES with trains of short pulses (0.3
ms, 6mA, and 40 Hz with 2s on, 3s Off), and VES with trains of long pulses (4 ms, 6mA,
and 40 Hz with 2s on, 3s Off). The second experiment was performed in two sessions
(long-pulse or long-pulse train VES with guanethidine). In each session, rectal tone was

















guanethidine (3 mg/kg for 5-min), 20 min during VES and 20 min after the termination of
VES. Results: 1) VES with long pulses or trains of long pulses but not trains of short pulses
was able to significantly decrease rectal tone (P<0.05, ANOVA). VES significantly increased
the intra-balloon volume from 27.6±5.3 ml at baseline to 38.2±6.6 ml with long pulses (P=
0.0077) or 35.6±5.9 ml with trains of long pulses (P=0.023), respectively. 2) VES with long
pulses or trains of long pulses but not trains of short pulses was capable of significantly
increasing ASP (P<0.05, ANOVA). In comparison with ASP at baseline (57.7 ±8.2), VES
significantly increased ASP with long pulses (79.3±10.1, P=0.014) or with trains of long
pulses (71.5±9.6, P=0.027). 3) Neither method of VES altered rectal compliance (P>0.05).
4) The inhibitory effect of VES with trains of long pulses but not long pulses on rectal tone
was abolished by guanethidine. After the infusion of guanethidine, the intra-balloon volume
with long-pulse VES was significantly increased in contrast to that without VES (36.5±5.4
ml vs. 30.4±6.2 ml, P=0.041). Conclusion: VES with long pulses or trains of long pulses
but not trains of short pulses reduces rectal tone and increases ASP. The inhibitory effect
of VES with trains of long pulses is mediated by the sympathetic pathway. These findings
suggest that VES may be a potential treatment for fecal incontinence.
W1773
Anorectal Dysfunction Persists and Adversely Impacts Daily Activities 5 Years
After Radiation Treatment for Prostate Carcinoma
Addolorata C. Di Matteo, Rochelle J. Botten, Richard H. Holloway, Robert J. Fraser, Eric
Yeoh
Data on the late sequelae of radiation proctitis in patients following external beam radiation
therapy (RT) for prostate carcinoma (CaP) are limited, despite its major impact on QOL1.
We have shown that symptoms such as urgency of defecation and fecal incontinence persist
at least 2 years following RT despite the introduction of newer techniques of treatment such
as 3-D conformal RT2. However, the long term effects of RT on anorectal function are
unknown. Aim: To determine the symptomatology and pathophysiology of anorectal dys-
function and the effect on daily activities 5 years after completion of RT. Methods: Anorectal
symptoms and function were prospectively evaluated in 20 patients (59-76 years) with
localized CaP (T1 and T2, N0, M0 on TNM classification). Studies were performed pre-
treatment and annually up to 5 years after its completion. The following parameters were
evaluated (i) symptoms including impact on daily activities (validated questionnaire), (ii)
anorectal motility (perfused sleeve sidehole manometry), (iii) sensory function (response to
graded balloon distension) and (iv) anal sphincter morphology (endoanal ultrasound). Data
are mean±SEM, analysed using two way repeated measures ANOVA. Results: The increase
in frequency and urgency of defecation after RT was still present 5 years after treatment,
although increases in fecal incontinence and rectal bleeding seen 1 and 2 years after RT
were not sustained. The decrease in anal sphincter pressures and increase in rectal sensation
seen at 1 and 2 years after RT were still present at 5 years. There was a progressive reduction
in rectal compliance at 5 years (see Table: *p<0.05, **p<0.01, #p<0.001, ##p<0.0001) External
but not internal anal sphincter thickness (mm) was also reduced after RT. Altered anorectal
function had an adverse impact on the daily activities of 45% of patients. Conclusion:
Anorectal dysfunction persists for up to 5 years after RT for CaP even in the absence of
rectal bleeding. The resultant symptoms have significant impact on the daily activities of
patients. This information needs to be provided to patients with CaP when considering their
treatment options. 1 Yeoh et al, Am J Gastro , 2004, 99920:361-369, 2 AC Di Matteo et al,
Gastroenterology 2005, 128(4) A:265
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The Cytokinesis Blocked Micronucleus Assay Correlates with Acute Anorectal
Dysfunction After Radiation Therapy (RT) for Carcinoma of the Prostate and
May Predict Individual Radiosensitivity
Addolorata C. Di Matteo, Rochelle J. Botten, Julie F. Butters, Michael Fenech, Ian Olver,
Eric Yeoh
RT for carcinoma of the prostate (CaP) is associated with anorectal dysfunction which persists
and impairs the daily activities of patients 2 years later1. Patients receive the same radiation
dose despite wide variations in individual susceptibility to normal tissue damage2. The
Cytokinesis Blocked Micronucleus (CBMN) assay, which quantifies radiosensitivity based
on ex-vivo irradiation of peripheral blood lymphocytes (PBL), has been correlated with
symptoms of anorectal damage after RT for CaP2. However, there has been no prospective
study to examine the relationship between the CBMN index and anorectal dysfunction after
RT. Aim: To determine whether the CBMN assay predicts individual susceptibility to anorectal
dysfunction after standard dose (70 Gy/ 35 fractions/ 7 weeks) 3D conformal RT for localized
CaP. Methods: Each patient had fasting venous blood taken before RT and the CBMN index
of PBL determined at baseline and after 3Gy ex-vivo irradiation3. GI symptom scores (LENT-
SOMA based questionnaire4), anorectal motor and sensory function (perfused sleeve anorectal
manometry and graded rectal balloon distension1) and anal sphincteric morphology
(endoanal ultrasound) were evaluated before RT and after its completion. GI symptom scores
and motor and sensory function variables of 12 patients (55-78 years) who have completed
evaluation at 1 month were analysed using paired t-test. Linear regression was used to
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examine the relationships among the baseline and irradiated CBMN index data and (i) LENT-
SOMA symptom scores, (ii) motor and sensory function and (iii) the total volume of rectum
irradiated. All statistical analyses were 2 tailed and a p value of≤ 0.05 considered significant.
Results: LENT-SOMA GI symptom scores but not anorectal motor and sensory function
variables increased 1 month after RT. Baseline CBMN index was directly related to (i) urgency
of defecation (r=0.66, p<0.05) and (ii) diarrhea (r=0.62, p<0.05) scores at 1 month. Ex-
vivo irradiated CBMN index was inversely related to rectal compliance (ml/mmHg) in the
patients 1 month after RT (r=-0.63, p<0.05). Conclusions: Mis-repair of spontaneous and
radiation-induced genomic damage are likely to be important underlying pathogenetic mech-
anisms of acute anorectal dysfunction after RT for carcinoma of the prostate. Baseline and
ex-vivo irradiated CBMN index may form the basis for individualizing patient RT. 1Yeoh et
al Amer J Gastrointerol 2004, 2: 361-369 2Lee et al Int J Radiat Oncol Biol Phys 2003, 57:
222-229 3Fenech Mutation Research 2000, 455: 81-95 4Yeoh et al Int J Radiat Oncol Biol
Phys 2003, 55: 943-955
W1775
Antegrade Continent Enema for Chronic Constipation in Adults: Long Term
Results
Sushil K. Maslekar, Jill Marshall, Graeme S. Duthie
Introduction: Slow transit chronic constipation in adults can be very difficult to treat and
defaecation can be often painful. Total colectomy with ileorectal anastomosis is offered
conventionally but is associated with persisting constipation in 10-30% patients. Ileostomy
brings relief but is not universally acceptable. Antegrade continent enema (ACE) procedure
has previously been shown to be effective in approximately half of these patients in the
short term, but longer-term results are unknown. The aim of this study was to evaluate the
long-term results of the ACE procedure in chronic constipation and faecal leakage, including
its impact on quality of life. Methods: All patients undergoing ACE procedure from 1996
to 2000 were included in the study. Telephonic interview was conducted following which
questionnaires were sent to all the patients. These questionnaires included SF-36 type
questions, faecal incontinence quality of life, Wexner score type and general questions about
the procedure. Retrospective review of the case notes was done to obtain clinical, demographic
and anorectal physiology data. Results: 24 patients (22 females) with a mean age of 37.9
years underwent the ACE procedure, out of which 17 were done laparoscopically. 18 patients
had chronic refractory constipation, 3 patients had faecal leakage and 3 patients had mixed
symptoms preoperatively. At a median follow up of 72 months (minimum 5 years follow
up), 14 patients (60%) were still successfully irrigating. 8 of the 24 patients needed revision
of their conduits. After ACE reversal in the remaining 10 patients, 5 patients (50%) underwent
ileostomy. No serious complications occurred in any patient. 75% patients had demonstrated
initial improvement in symptoms and 52% showed satisfactory improvement in bowel
function at 72 months follow up. Quality of life showed significant improvement in the
mean mental score on theSF-36 form from 34.6 preoperatively to 51 (p=0.04; Mann-Whitney
U test) and an improvement in mean physical component score from 38.3 to 44.3 (p=0.08).
The type of symptoms or type of conduit did not influence the outcomes. Conclusion This
is the longest follow up of adults undergoing ACE procedures. The procedure is technically
simple and effective, and affords an improvement in the quality of life in patients with
chronic constipation and faecal leakage.
W1776
Is There Any Correlation Between Viscero-Motor Response and Sensation in
Man?
Alfred Bayati, Martin Karpefors, Per Jerndal, Kristina Jordo, Louis M. Akkermans
Viscero motor response (VMR) to colorectal distension has been used in animals for some
time as a marker for noxious stimuli. This response is believed to represent discomfort and
pain which otherwise can not be measured in animals. In order to see if this hypothesis
can be tested in man we sought to test firstly if this response can be measured in man,
secondly if this response is indeed related to discomfort/pain and thirdly if there is any
difference between healthy volunteers and IBS patients in this respect. A total of 69 healthy
volunteers (43 females) and 97 IBS patients (66 females) were included in these studies
with ramp tonic distension. In a smaller group of 10 healthy volunteers and 9 IBS patients
an ascending method of limit paradigm (AML) was performed using a barostat. Abdominal
muscle EMG was measured using surface electrodes and VMR was calculated as the area
under the curve of the rectified EMG signal. Discomfort and pain was measured continuously
using a newly developed electronic analogue scale (EAS). It is shown that during AML, VMR
could be measured in all subjects. The VMR increased by increasing pressure showing a
good linear correlation to the distension pressure. Discomfort felt by the subjects measured
by EAS was completely related to the pressure and VMR changes. During ramp tonic
distension, VMR could be measured in 54% and 44% of healthy volunteers and IBS patients
respectively. The threshold was calculated to 34±2 and 40±2 mmHg (p=0.1) and the
maximum AUC to 0.97±0.09 and 0.6±0.07 V*s (p=0.009) in healthy volunteers and IBS
patients respectively. In the rest of the subjects VMR response was, probably, blocked by
cortical control soon after its start. It is concluded that VMR can be measured in man in
the same way as it is measured in animals and it is very well correlated to the sensation felt
by the subjects and differed between healthy volunteers and IBS patients.
W1777
Influence of Naloxone On Rectal Sensitivity and Accommodation of the
Rectum After Consecutive Distensions in Health
Brecht Geeraerts, Lukas van Oudenhove, Rita Vos, Georgios Karamanolis, Jan Tack
Background: Failure of descending anti-nociceptive pathways (with opioids as the main
candidate neurotransmitters) has been suggested to contribute to the pathogenesis of irritable
bowel syndrome (IBS). Rectal balloon distention studies in IBS patients have revealed hyper-
sensitivity to rectal balloon distention (Whitehead 1990) and impaired rectal accommodation
to repeat balloon distention (Kwan 2004). The aim of this study is to investigate the effect
of suppression of endogenous opioids by naloxone on rectal sensorimotor function in health.
Methods: Thirteen healthy subjects (age 26±1 years) participated in a randomized, placebo-
controlled, double blind rectal barostat study. Sensorimotor function was evaluated during
2 consecutive stepwise distensions (4 mmHg steps at 1.5 minute intervals, until discomfort
or pain) separated by 30 minutes of basal volume recording. Continuous infusion of saline
or naloxone (20 µg/kg/h after 0.4 mg bolus) was started 15 minutes before the 2nd distension.
VAS scales were used to register relevant symptoms. Upper abdominal sensation was scored
on a 0-6 graded scale (0=no sensation, 6=maximal) at the end of every distension step.
Results: Naloxone did not alter the pressure-perception curve compared to saline or to
baseline. Consequently, the pressure needed to induce first perception (12.9±1.3 vs. 12.9±1.8
mmHg, NS) or discomfort (34.0±1.4 vs. 34.6±1.6 mmHg, NS) and corresponding intra-
balloon volumes (respectively 108±21 vs. 93±19 ml, and 248±16 vs. 258±17 ml, both NS)
did not differ between saline and naloxone. Comparison of VAS scores between naloxone
and saline did not reveal altered intensities of pain (AUC 17.3±8.8 vs. 19.4±9.1 mm*mmHg,
NS) or discomfort (AUC 35.9±12.2 vs. 33.1±16.2 mm*mmHg, NS). During the second
distention, the pressure-volume curve was shifted to the left in the placebo condition but
not in the naloxone condition: compared to the baseline distension, a significant adaptive
increase in compliance occurred during the second distension after saline (7.3±0.8 vs.
10.0±0.6 ml/mmHg, p=0.008), as previously reported (Kwan 2004). This adaptive increase
in rectal compliance did not occur after naloxone (8.7±0.8 vs 9.2±0.9 ml/mmHg, NS), and
the increase in compliance between both distentions was significantly suppressed after
naloxone (Δcompliance 2.6±0.8 vs. 0.5±0.7 ml/mmHg, p=0.003), thereby mimicking previ-
ous findings in IBS (Kwan 2004). Conclusion: Naloxone does not alter rectal sensitivity
but it abolishes rectal accommodation in response to repeat balloon distention. These
observations suggest that the endogenous opioid system is involved in control of rectal tone
rather than rectal sensitivity.
W1778
Anorectal Inhibitory Reflex (RAIR) Can Be Assessed When Children Are
Sedated with Etomidate
Reinaldo Garcia, Michael Reed, Lia Lowrie, Gisela Chelimsky
Background: The manometric evaluation of the anorectal area is a noninvasive, inexpensive
and simple test that is often used as a diagnostic tool in Hirschsprung’s disease. In non-
sedated patients the rectoanal inhibitory reflex may be masked by patients’ lack of cooperation.
To avoid this technical obstacle, effective sedation of the younger or uncooperative child
undergoing anorectal manometry is essential. We have been using etomidate at our institution
to sedate children undergoing anal manometry. Etomidate is an imidazole sedative-hypnotic
agent with a very rapid onset of action (5-20 seconds) and rapid recovery time following
single dose administration. Methods: Age, sex, etomidate dose, number of doses, total amount
administered, length of the procedure, drug-associated complications, other medications
used, and the presence of RAIR were obtained from the procedural records of children who
underwent sedated anal manometry at Rainbow Babies and Children’s Hospital from 1/00
to 12/02. Results: Twenty-four children, ages 3 months to 8.8 years (mean 2.99 years, SD
+/- 2.26) underwent an etomidate-sedated anorectal manometry. All but 2 were effectively
sedated with etomidate. Individual etomidate doses ranged from 0.06 to 0.6 mg/kg/dose
with the total amount of etomidate per procedure ranging from 0.4 to 1.4 mg/kg. All
but one child tolerated etomidate without difficulty (one subject with Down’s syndrome
experienced airway obstruction, resolved with repositioning). No other significant complica-
tions were observed. One subject had inconsistent RAIR, but had ganglion cells present on
rectal biopsy. In 4 patients we were unable to immediately determine their rectoanal inhibitory
reflex since they were too deeply sedated. Despite their level of sedation the total amount
of medication given in mg/kg did not differ from the other subjects. Successful determination
of the rectoanal reflex was later obtained in this subset of subjects as the sedation was
wearing off. Average sedation time: 29 minutes (range from 13 to 68 minutes (> 50 min
when other medications were added). Two patients had oral midazolam (0.33mg/kg) prior to
the procedure; two subjects had inadequate sedation with etomidate and required additional
medications to be given (propofol, pentothal). All of these subjects demonstrated RAIR.
Conclusion: Anal manometry is an integral component of a patient’s evaluation for Hirschs-
prung’s disease. Our data supports that etomidate can be safely and effectively used in
the setting of anal manometry without inhibiting the ability to assess for the rectoanal
inhibitory reflex.
W1779
Validation of a Novel Surface EMG Probe for Assessing Anal Sphincter
Innervation
Juila Traue, Jasper Daube, William Litchy, Nima Mowzoon, Paul Enck, Adil Bharucha
Background-Needle electromyography (nEMG) is the only technique that can accurately
evaluate for neural injury affecting the anal sphincter. Because nEMG examination requires
considerable technical expertise, a novel surface EMG (sEMG) probe with 16 circumferential
electrodes to characterize anal sphincter innervation was developed (Digestion 2004;69:112).
Aims-The aims of this study were to validate the sEMG probe against nEMG exam for
assessing anal sphincter innervation. Methods-Anal sphincter innervation was assessed simul-
taneously in a 2 channel recording of nEMG and sEMG in 18 healthy, nulliparous women
[mean age 40 years (range 19-75 years)] without a functional GI disorder and 6 women
with fecal incontinence (FI). Sphincter activity was recorded by nEMG in each of 4 quadrants
at rest (60 seconds) and during squeeze (2 repetitions, 15 seconds each). SEMG tracings
were reviewed to characterize the site of onset and propagation of surface motor unit
potentials (SMUP). Because the sEMG signal represents a composite of several SMUP,
individual SMUP were identified by spike triggered averaging (STA) off-line. MUP were
isolated from the needle recording by both manual isolation with trigger windows (Bromberg)
on a Nicolet Viking EMG machine and by decomposition quantitative EMG (DQEMG)
(Doherty & Stashuk) on a Neuroscan Comperio EMG machine. Needle MUP triggered an
average of the surface signal to identify the SMUP. Propagation of individual STA SMUP
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around the sphincter was confirmed. Data Analysis-For validation, we assessed the propor-
tion of total and propagated SMUP also identified by the needle electrode. Data were averaged
across both squeeze maneuvers. A 2-sided Wilcoxon signed rank test was used to assess if
these proportions differed from that anticipated due to chance alone (i.e., 0.5). Results-At
least 1 sMUP was recorded in 15 women at rest and in all women during squeeze. 50% of
sMUPs at rest and 78% of sMUPs during squeeze were propagated. The proportion of sMUPs
that were also recorded by the needle was greater than expected by chance alone (Table).
Conclusions-Propagated and non-propagated MUAPs in the anal sphincter generally corre-
spond to identical motor units recorded by needle EMG in controls and FI. Less well-defined
propagation can be due to superimposition of more than one needle MUP in generating the
SMUP. These findings validate the use of sEMG for investigating anal sphincter innervation
in health and disease.
Values are mean number (SE) or mean % (SE); * p<0.01
W1780
Effect of Hysterectomy On Anorectal Functions - A Prospective Study
Barbara M. Seide, Christopher J. Klingele, John B. Gebhart, Alan R. Zinsmeister, Adil
Bharucha
Background - Hysterectomy ranks as the second commonest surgical procedure among
women in the USA with over > 600,000 procedures performed annually. One in three
women will have a hysterectomy by the age of 60 years. Dissection of the rectovaginal
septum can also damage the extensive network of nerve fibers surrounding the rectum,
cervix, and lateral vaginal surfaces during a hysterectomy. While a radical hysterectomy is
known to impair anorectal functions, the effects of a “simple” (i.e., vaginal or abdominal)
hysterectomy on anorectal functions are poorly understood. Aims - To prospectively assess
the effects of a simple hysterectomy on anorectal sensori-motor functions. Methods - In
this ongoing study, anorectal functions are assessed before and 2 months after a hysterectomy
[vaginal (14) or abdominal (2)] in 16 women [(age 47 ± 3 years (Mean ± SEM)] without
significant GI symptoms. Assessments include: (i) anal resting and squeeze pressures and
the traction required to expel a latex balloon filled with 60 ml of water; (ii) rectal compliance
(balloon volume response to 4 mmHg stepwise increments from 0-44 mmHg); (iii) rectal
sensation, measured by thresholds for first sensation, desire to defecate (DD), and urgency
during the staircase distention and a 100-mm VAS scale for gas, urgency and pain during
phasic colonic balloon distentions of 8,16, and 24 mmHg above operating pressure delivered
in random order; and (iv) rectal evacuation assessed by the external traction (gm) required
to expel a balloon filled with 60 ml water. Analyses - Staircase distentions were summarized
as Pr½ (the pressure at ½ max volume) and rectal capacity (i.e., volume at 32 mmHg).
Anorectal functions were compared before and after a hysterectomy by 2-tailed paired,
parameteric or nonparametric tests. Results - Table shows mean (SEM) for parameters before
vs after hysterectomy. Also, rectal volumes, but not VAS scores tended to be lower during
phasic distentions (data not shown). Conclusions - These preliminary observations suggest
that rectal evacuation and capacity decline 2 months after a hysterectomy. Long term
assessments, currently in progress, are necessary to identify the risk factors for anorectal
dysfunctions after a hysterectomy.
Effect of Hysterectomy on Anorectal Functions
* p = 0.02, # p = 0.1 by paired analysis
W1781
Sacral Nerve Stimulation in Fecal Incontinence: Are There Factors Associated
with Failures?
Syrine Gallas, Guillaume Gourcerol, Francis Michot, Philippe Denis, Anne-Marie Leroi
Background: Sacral nerve stimulation has been used successful in treating faecal incontinence.
The effectiveness of the procedure has been tested by temporary nerve stimulation. Neverthe-
less, some patients show deterioration in primary outcome measures. Our aim was to
determine parameters associated with these failures. Methods: A total of 29 patients (26
women) (median age 56.5 years old, range 33-77) with refractory faecal incontinence,
underwent permanent sacral nerve stimulation for a median of 12 months (range 6-72).
The results of sacral nerve stimulation were evaluated based on daily bowel-habits diaries
over a 3-weeks period. More than 50% improvement of faecal incontinence and/or urgency
episodes was considered successful sacral nerve stimulation. The factors compared between
the two groups (success and failures) were patients’ age and sex, diagnosis and characteristics
of faecal incontinence, previous surgery, quality of life scores, anorectal manometry, endoanal
ultrasound, electrophysiological test performed before implantation and rate of success of
temporary nerve stimulation. Results: After permanent implantation, 31% of patients did
not achieve the effect of the screening phase in the number of episodes of faecal incontinence
or urgency (failures). It appeared that the left bulbo(clitorido)-cavernosus reflex was more
frequently delayed in the success group than in the others (60.5+21.4 msec versus 44.3+12.1

















results observed on faecal urgency (r=0.48; p=0.02). Conclusion: Diarrhoea and electro-
physiological results evaluated before implantation could be factors of prognosis for the
treatment by sacral nerve stimulation.
W1782
Sacral Nerve Neuromodulation As Primary Treatment for Faecal Incontinence
with Disrupted Anal Sphincters: Medium and Long-Term Results
Sushil K. Maslekar, Angela B. Gardiner, Graeme S. Duthie
Introduction The standard treatment for faecal incontinence secondary to obstetric sphincter
damage is anal sphincter repair. However, the results of this procedure deteriorate with
time. Sacral nerve stimulation (SNS) has become an established therapy for faecal incontinence
in patients with intact sphincter muscles, with good medium term results. We assess the
medium and long-term results of SNS as first line treatment in patients with obstetric-related
faecal incontinence. Methods: All patients with obstetric-related faecal incontinence and
demonstrated external and internal sphincter disruption on anal endosonography were
included in the study. These patients would have normally undergone anterior anal sphincter
repair. Patients underwent temporary stimulation followed by assessment at 2 weeks. Perman-
ent stimulator was then implanted in patients with significant improvement. Post implantation
patients were followed up 1, 3, 6, 12, 36, and 48 months. Demographic, clinical, operative
and anorectal physiology data was collected prospectively. Results: 20 consecutive women
with a median age of 42 (35-62) years completed temporary screening and 19 went on to
permanent implantation. Faecal incontinence improved in all patients from Wexner scores
of median 16 (10-20) preoperatively to median 5 (1-11) at 2 weeks. There was further
improvement in faecal incontinence with median Wexner scores of 3, 3.5, 4, 4, 3.5 & 3 at
1,3,6,12,36 & 48 months respectively (p<0.0001). The remaining patient was followed
up at 2 weeks post temporary SNS and demonstrated significant improvement in faecal
incontinence (Wexner score 19 pre-procedure to 3 post-procedure), but was lost to follow
up thereafter. There was significant improvement in general and mental health, emotional
role, social function and vitality in all patients. There were no major complications and no
implants were removed. Conclusion: This is the first study showing long-term results of
SNS for primary treatment of faecal incontinence with damaged anal sphincter. We have
shown that sacral nerve neuromodulation is a safe and effective minimally invasive first line
treatment for such patients. The improvement in faecal incontinence achieved in short term
is sustained over a follow up of 4 years.
W1783
Effect of Acute Fasting Hyperglycemia and Duodenal Glucose On Rectal
Perception and Compliance in Healthy
Hermann Harder, Ana C. Hernando-Harder, Heinz-Juergen Krammer, Manfred V. Singer
Background: Acute changes in blood glucose concentration have major reversible effects on
gastrointestinal motor and sensory function. Aims: To test influences of intravenous glucose
(hyperglycemic hyperinsulinemia) duodenal glucose (euglycemic hyperinsulinemia) and
duodenal saline (as control) on rectal perception and compliance. Methods: In 8 healthy
subjects, responses to fixed tension rectal distension applied by means of an electronic
tensostat were compared on 3 separate days in randomized order during a marked hypergly-
cemic clamp (~13 mmol/l), duodenal glucose at 2 Kcal/min, or duodenal saline as control.
Results: At perception of normal urge to defecate (score 3) on the 0 - 5 rectal scale, perception
of rectal distension was significantly lower during hyperglycaemia (83 ± 4 g tolerance)
whereas perception of rectal distension was significantly higher during duodenal glucose
(45 ± g tolerance), both reaching significance as compared to control (64 ± 6 g tolerance;
p<0.05). At the former perception level, no relevant variations of rectal compliance were
seen, which were 9.5 ± 1 ml / mmHg for the group with hyperglycemia, 10.3 ± 1 ml /
mmHg during duodenal glucose (p>0.05 vs. control for both) and 9.7 ± 2 ml / mmHg in
the control studies. Overall rectal compliance ranged between 8.3 ± 2 ml / mmHg and 11
± 1 ml / mmHg (p>0.05 for all). Conclusion: Acute hyperglycemia contributes to rectal
hyposensitivity whereas duodenal glucose provokes rectal hypersensitivity. Despite different
rectal tensosensitivity, compliance remains unchanged.
W1784
Morphologic and Mechano-Sensitive Characteristics of the Rectum After
Prostate Carcinoma Treatment with High-Precision Radiotherapy
Agustin Balboa, Meritxell Molla, Antonio Salas, Antonia Perello, Monica Perona, Raimond
Miralbell, Fermin Mearin
Radiotherapy is very effective in the treatment of prostate carcinoma but it may cause late
complications in the rectum, both inflammatory and mechano-sensitive (chronic radiation
proctitis). OBJECTIVE: To investigate whether new high-precision radiotherapy with modu-
lated intensity and extracranial stereotactic positioning system lead on not to late rectal
alterations, both morphologic (endoscopic or histologic) and mechano-sentive (rectal compli-
ance and sensitivity). METHODS: In 29 patients that had received radiotherapy for prostate
carcinoma at least 15 months prior to procedure, we evaluated endoscopic lesions (mucosal
edema, telangiectasis, ulcers, stenosis and necrosis), histologic abnormalities (epithelial
lesions, crypts distortion, vascular edema, lamina propria fibrosis, and inflammatory activity)
and mechano-sensitive characteristics with a rectal barostat (rectal compliance and sensitivity
thresholds) RESULTS: Both, endoscopic and histologic scores were low (1.3±0.2 over 5 and
2.5±0.3 over 15, respectively), with a good correlation between both scores (r = 0.63; 95%
IC: 0.34-0.81; p<0.05). We didn’t find any correlation between morphological scores and
total radiation doses. Rectal compliance was normal (5.3±0.4 ml/mmHg) whereas rectal
sensitivity was low compared to healthy control values: first perception threshold: 12.0±1.7 vs
6.2±0.8 mmHg, p<0.05; tenesmus threshold: 23.5±1.6 vs 20.4±3.0 mmHg; p=NS; discomfort
threshold: 36.0±2.9 vs 20.7±2.1 mmHg; p<0.05. No correlation was found among sensitivity
thresholds and histologic or endoscopic scores. CONCLUSION: Minimal morphological
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alterations of the rectum are observed after prostate carcinoma treatment with high-precision
radiotherapy; rectal compliance does not change whereas rectal sensitivity is decreased.
W1785
Comparison of Rectal Contractile Responses During Inflation, Sustained
Distention, and Deflation in Health and Fecal Incontinence
Christopher N. Andrews, Barbara M. Seide, Alan R. Zinsmeister, Adil Bharucha
Background-Rectal distention paradigms focus on perception thresholds during rectal infla-
tion. An exaggerated contractile response to distention may partly explain increased rectal
perception in IBS (Corsetti, CGH 2004). Current concepts suggest that the rectum generally
accommodates to sustained distention in health. However, patients often complain of persist-
ent rectal urgency, perhaps due to a persistent contractile response to sustained distention.
It is also unknown if rectal deflation can induce a contractile response, akin to the off
response described in esophageal smooth muscle (Goyal, AJP 1984). Aim-To compare the
contractile response and perception during inflation, sustained distention, and deflation in
health and fecal incontinence (FI). Methods-Rectal balloon pressure and volume were
recorded during barostat-driven rectal distention in 51 FI patients (60 ± 2 years; mean ±
SEM) and 20 healthy controls (age 61 ± 2 years). Three ramp distentions (25, 50, 100mL/
min from 0-200mL) were performed in random order. Each distention was comprised of
inflation, sustained distention (at 200 mL for 1 min) and deflation. Contractions were
identified by a ≥ 2 mmHg change in baseline pressure for at least 5 seconds. The number
of contractions during inflation (I), sustained distention (SD) and deflation (D) in controls
and FI were analyzed by a repeated measures analysis of variance assessing for effects of
group (i.e., control or FI) and rate. Results-Modulation of rectal volume evoked rectal
contractions not only during I, but also during SD and during D (Table). The contractile
response during SD and D was more prominent (p ≤ 0.01) during faster distention in FI
and controls. During I, a rate effect was observed in controls, but not FI (p for group*rate
interaction < 0.05). Group effects were not significant. Conclusions-Rectal distention
induced a contractile response not only during I, but also during SD and to a lesser degree
during D in controls and FI. This contractile response may increase rectal pressures and
contribute to rectal urgency.
Effect of Rectal Distention on Rectal Contractions
All values are mean (SEM) for contractions/minute
W1786
Baroreceptor Sensitivity in Irritable Bowel Syndrome Patients and Healthy
Volunteers During Colorectal Distension
Robert Spaziani, Keith Redmond, Harjeet S. Bajaj, Alfred Bayati, Karen Miranda, Hakan
Larsson, Subhas Ganguli, Steven Collins, Markad Kamath
Background: Arterial baroreflex provides an immediate adjustment of blood pressure follow-
ing a perturbation. Baroreceptor sensitivity (BRS) analysis (ΔR-R/ΔBP) using systolic blood
pressure (SBP) provides an index of baroreceptor control of heart rate (HR) by autonomic
mechanisms. Aim: To examine the BRS response to colorectal distension (CRD) in Irritable
Bowel Syndrome patients (IBS) compared with healthy controls (HC). Materials and Methods:
After a 20-min. baseline, a barostat-controlled rectal balloon (max. volume 863 mL) was
distended (0.3 mmHg/s), to a max. pressure of 70 mmHg, or 50% tolerable discomfort
(whichever came first), and maintained in this tonic state for 3 mins. A 20-min. recovery
period was recorded. Forty-six HC (19 females; 30±10 yrs.) and 32 patients (28 females;
40±11 yrs.) with IBS were studied. BRS was computed during baseline, ramp, tonic, and
post-distension periods using 3 or more increasing sequences within continuous HR and
systolic BP time series. Group means were compared using Student’s t-test. Results: IBS
patients and HC reached similar CRD pressures (51±15 mmHg vs. 52±14 mmHg); patients
experienced more discomfort (69±20% vs. 58±11%, p=0.01). With tonic distension, both
HR (HC: 65±8 to 70±10 BPM, p=0.01 vs. IBS: 64±9 to 71±11 BPM, p=0.007), and SBP
(HC: 124±15 to 144±19mmHg, p<0.001 vs. IBS: 129±20 to 157±23mmHg, p<0.001)
increased significantly. IBS patients had a larger SBP response to CRD compared to HC (p =
0.006). HR (HC: 65±8 BPM; IBS: 63±9 BPM) and SBP (HC: 131±16 mmHg; IBS: 138±20
mmHg) decreased in the post-distension phase. Table 1 compares BRS in IBS vs HC.
Conclusions: BRS was consistently diminished in IBS patients compared with HC at rest
and throughout the CRD paradigm. CRD induced a sympathetic response in both HC
and IBS patients with increased HR and SBP. IBS patients demonstrated the greatest SBP
perturbation, suggesting insufficient baroreceptor control. Attenuated baroreceptor respons-
iveness suggests an underlying autonomic abnormality in patients with IBS. Funded by:
AstraZeneca, NSERC and DeGroote Foundation.
Table 1: BRS (msec./mmHg) in IBS vs. Healthy Controls with CRD
* p<0.05 when compared to controls ** p<0.05 when compared to baseline † p<0.05 when
compared to post
W1787
Development of a Validated Questionnaire to Identify Idiopathic Fecal
Incontinence
Alexandra Ilnyckyj, Jennifer Laforce, Sandra Allford
Background: The epidemiology of fecal incontinence(FI) remains incompletely understood;
prevalence studies have not found consensus. This may stem from a lack of validated
measures and poor discrimination of idiopathic FI from FI ocurring within a known GI
condition such as irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD). Aim:
Develop and validate a brief self-report questionnaire to assess the prevalence of idiopathic
FI. Methods: A 10 item FI measure, including validated and not validated questions used
in previous prevalence studies were administered to 95 participants, who were recruited
from GI and Internal Medicine ambulatory clinic. All participants were assessed by one
gastroenterolgist and/or GI nurse clinician to define status of bowel function and GI diagnosis.
Participants were classifed into one of 6 groups 1)idiopathic FI (no IBS, IBD or other known
organic disease to explain FI) 2)IBS with FI 3)IBD with FI 4)Normal bowel function 5)IBS
no FI 6) IBD no FI. Results: Six items were found to accurately identify participants with
FI and 2 items were found which discriminated those with idiopathic FI from those with
FI due to a known cause. Thus, from the 10 items, 2 scales emerged; 1) FI scale: a 6 item
scale measuring FI and 2)abdominal distress scale: a 2 item scale discrinating FI secondary
to IBS/IBD. The use of these two scales was supported by a Maxiumum Likelihood factor
analysis with Oblique Rotation in which the two factor solution accounted for 55% of the
scale variance. Both scales are internally consistant, Cronbach’s alpha = .83 and .84 for scale
1 and 2 respectively. Participants with FI scored higher on the FI scale (M=6.52,SD 1.53)
than did those with GI conditions but no FI (M=3.76,SD=1.79). Both groups scored higher
than healthy participants (M= 2.13,SD=0.79), F(2,93)= 66.26, p<.001. Within the sample
of participants with FI, the abdominal distress scale was able to discriminate those with FI
due to a known cause vs idiopathic FI. The group with idiopathic FI (M=4.34, SD=2.37)
scored lower on this scale than the groups with FI with a known cause (M=7.23, SD=2.54,
t (36)= -3.55, p=.001. Conclusion: The FI scale and abdominal distress scale are robust
instruments to measure FI and differentiate those with FI secondary to known conditions.
The items are brief making them suitable for application in a prevalence study.
W1788
Influence of Sildenafil On Rectal Sensorimotor Function in Irritable Bowel
Syndrome (IBS) Patients
Maria Teresa G. Medeiros, Armenio A. Santos, Ricardo B. Oliveira, Monica Colares O.
Lima, Geraldo M. Macedo, Ana Paula M. Maia, Miguel Angelo N. Souza
Rectal hypersensitivity is frequently found in IBS. Pharmacologically-induced reduction of
rectal tone may change both the mechanical and the sensitivity patterns of the rectum. The
aim of the present study was to evaluate the effects of sildenafil, a phosphodiesterase type-
5 inhibitor, on the sensorimotor function of the rectum in IBS patients. METHODS: Twelve
informed IBS patients, (Rome II criteria), aged 27-60 yr, 4 males, took part in the study.
Four presented constipation, 3 diarrhea, and 5 had both diarrhea and constipation. Anxiety
and depression were assessed by means of Hamilton′s scores. Fourty minutes before experi-
ments, each patient received either sildenafil (50 mg tablet diluted in standardized orange
juice) or, 15 days apart, placebo (standardized orange juice) in a single dose, double-blind
design, crossover, randomized order. Rectal ramp distension (Synectics), were performed
in each experiment using a 600mL PVC bag (12-cm cross-sectional radius) attached to a
single lumen 16F catheter. The rectal pressure (mmHg), volume (mL) and wall tension
(g×cm-1) thresholds for the first sensation, first desire to defecate, pain, and maximum
tolerated distension were determined. A perfect spherical bag shape was assumed for wall
tension calculation. Data (mean±SEM) were analyzed by Student′s t test and Pearson correla-
tion. RESULTS: In the sildenafil study day, rectal wall tensions at 8, 12, 16, 20 mmHg
distending pressures were higher than in the placebo study day (19.7±2.3 vs 22.3±2.4, p=
0.01; 40.5±3.6 vs 44.5±3, p<0.001; 65.5±2.8 vs 69.5±1.6, p<0.001; 89.9±2.4 vs 92.3±1.6,
p<0.001; respectively), denoting a higher rectal cross-sectional radius and relaxation. The
thresholds for the first desire to defecate were higher after sildenafil (15.8±1.3 vs 26.1±3.8
mmHg, p=0.01; 127.6±15.9 vs 185.4±14.9 mL, p=0.004; 66.3±7.4 vs 126.9±20.4 g×cm-1,
p=0.008); higher at nonsignificant levels for the first sensation (13.8±1.5 vs 17.6±1.9 mmHg,
p=0.11; 111.8±19.9 vs 144.8±12.7 mL, p=0.12; 55.3±8.9 vs 76.9±8.9 g×cm-1, p=0.12); and
similar to placebo for pain and maximum tolerated volume. Sildenafil and placebo minimal
distending pressures were similar (3.7±0.7 vs 3.6±0.7 mmHg). Pressure, volume, and wall
tension thresholds for pain correlated inversely to anxiety score after sildenafil (r=-0.69, p=
0.03; r=-0.71, p=0.02; r=-0.68, p=0.03; respectively) but not after placebo (r=-0.01, p=
0.98; r=-0.42, p=0.23; r=-0.14, p=0.7; respectively). CONCLUSION: In IBS, rectal relaxation
by sildenafil diminished the perception to defecate and possibly the first rectal sensation.
Remarkably, it also unfolded anxiety trait associated pain threshold lowering.
W1789
Effect of Atropine On the Esophago-Gastric Junction Opening Function:
Assessed Using Intraluminal Ultrasound Imaging
Valmik Bhargava, Ibrahim Dogan, Torahiko Takeda, Jianmin Liu, Ravinder K. Mittal
Relaxation and opening of the esophago-gastric junction (EGJ) are two distinct and crucial
functions for esophageal transport across EGJ. It is well known that atropine causes a
significant reduction (relaxation) in the lower esophageal sphincter pressure but there is
limited information on its effect on the EGJ opening. Methods: Eight healthy subjects were
studied before and after atropine (15 μgm/kg I.V.) to assess its effect on the EGJ opening
function using a novel ultrasound (US) methodology. A high frequency intraluminal US
probe, a solid-state pressure transducer and an infusion tube were placed inside a 20 mm
diameter cylindrical bag, which was placed across the EGJ. Bag was incrementally inflated
with pressures between 10 and 60 mmHg and at each bag pressure US transducer was
pulled across the bag, inside its sheath, using a motorized puller at a constant speed. B-
mode US images were digitized and converted into M-mode images to display the entire
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region of the esophagus, EGJ and stomach. From these M-mode images, the narrowest
region of the EGJ was identified and its corresponding cross-sectional area (CSA) determined
from B-mode image. Results: Our study shows that at low bag-pressures (<20 mmHg) EGJ
but not esophagus and stomach, is collapsed around the bag. With an increase in the bag
pressure, there is a gradual opening of EGJ, starting from its distal end. The region of the
EGJ surrounded by crural diaphragm is least distensible. Mean bag pressure for the EGJ
opening was 18 mmHg. We observed a linear relationship between bag-pressure and EGJ-
CSA. Bag pressures to open 50% and 80% of the maximal bag diameter were 37±4 and
56±6 mmHg respectively. Atropine reduced opening bag pressure and shifted the EGJ
pressure-CSA curve upward slightly without affecting the slope of the line. Conclusion: EGJ
opening curve shows two distinct components, the first component (initial EGJ opening),
which is likely to be related to the tonic EGJ contraction and a second component, related
to its viscoelastic properties. Atropine has minimal effects on the EGJ opening function.
W1790
Effect of Phonation On the Intraluminal Pressures of the Esophagus and Its
Sphincters
Lilani Perera, Krisna Chai, Candy Hofmann, Tanya Rittmann, Mark Kern, Einat
Liebenthal, Reza Shaker
Recent studies have documented the existence of a reciprocal influence between the upper
GI and the aerodigestive tracts. Phonation is known to be accompanied by a significant
increase in subglottal tracheal pressure that is believed to be generated by contraction
of the diaphragm, simultaneously causing an increase in intra-abdominal pressure. This
phenomenon, especially during high intensity vocalization such as seen with professional
singers, can predispose to gastroesophageal reflux, a recognized clinical problem in this
group. The mechanisms of protection against esophageal or pharyngeal reflux of gastric
content during this function have not been systematically studied. AIM: To determine and
characterize the effect of phonation on the luminal pressures of the esophagus and its
sphincters. METHODS: We studied 7 healthy volunteers (3M, 4F) by concurrent high
resolution manometry (Manoscan, Sierra Scientific) and voice analysis (Praat, University of
Amsterdam). We tested high and low pitch vowels for durations of 10 seconds. Findings
were verified in 2 subjects by UES manometry using a sleeve device. RESULTS: High and
low pitch vowels had significantly different frequencies (Hz) (ΔP<0.05) (Table). UES pressures
during phonation were significantly higher compared to the resting baseline for all of the
studied pitches (69 ± 6 vs 140 ± 26, 92 ± 9, 185 ± 31, 104 ± 11 mmHg, respectively).
Pressure changes during phonation compared to those immediately prior to phonation
showed similar patterns and are shown in the table. Findings were similar for studies
using a sleeve device (214 ± 22, 297 ± 15 mmHg, high pitches A and E, respectively).
CONCLUSIONS: Phonation affects UES intraluminal pressure differently from the esophageal
body and LES, in that, UES pressure change due to phonation is pitch-dependent. During
high pitch phonation UES pressure increase is significantly higher than that of esophageal
and gastric pressures, providing a barrier against potential pharyngeal reflux of gastric
content. Supported in part by NIH grants T32 DK61923 and RO1 DK25731.
* p<0.05 UES vs gastric, esophagus
W1791
Mast Cells Recruit Eosinophils in the Guinea Pig Esophagus After Antigen
Inhalation Challenge Via a Histamine Pathway
Shaoyong Yu, Edward Stahl, Qing Li, Ann Ouyang
Introduction: Mast cells (MC) play an important role in the inflammatory responses in the
esophagus. We have previously shown that antigen challenge induces mast cell degranulation
and histamine release in the esophagus. Eosinophils (Eos) have been observed to increase
in the esophagus after allergen inhalation in a mouse model (J Clin Invest 2001; 107:83-
90). Aims: To test the hypothesis that antigen inhalation induces esophageal mast cell
activation resulting in the recruitment of eosinophils in the esophagus, via a histamine-

















of ovalbumin (10 mg/kg). Three weeks after the third injection, groups of animals received
either inhalation of 0.1% ovalbumin for 2-10 minutes or repeated inhalation challenge daily
for three days. After 1 and 24 hours with one inhalation challenge (C-1 and C-24) or 1
hour after the three repeated inhalations (C-72 (x3C)), esophageal tissues were removed,
processed and sectioned for immunofluorescent-staining of mast cell tryptase (Tryp-LI)
and eosinophil major basic protein (MBP-LI). An additional group of animals received
thioperamide (histamine H3/H4 receptor antagonist, 5 mg/kg, i.p.), 30 mins prior to, and
were sacrificed 24 hours after challenge (C-24 (T)). Total Tryp-LI and MBP-LI cells were
counted as well as the percent of positive cells in the epithelial layer of the mucosa. Results:
Esophageal MC and Eos are mainly located in the sub-epithelial layer of the mucosa. Total
number of Tryp-LI cells did not change in challenged groups, but the % of mast cells in
the epithelium increased significantly in C-1 and C-72(x3C) groups. MBP-LI cells increased
in C-1 and C-72 (x3C) (p=0.07) groups, and the percentage of Eos migrating to the epithelium
increased in the C-24 and C-72 (x3C). Thioperamide inhibited Eos migration into the
epithelium. Conclusion: Inhalation with antigen induces mast cell and Eos to migrate towards
and into the esophageal epithelium via a pathway involving either (or both) the H3 or H4
histamine receptor.
Antigen inhalation induced mast cells and eosinophils responses in the guinea pig esophagus
W1792
Vanilloid Receptor TRPV1-Induced PAF Production Mediates Acid-Induced
Esophageal Inflammation
Ling Cheng, Karen M. Harnett, Weibiao Cao, Jose Behar, Piero Biancani
The transient receptor potential channel, vanilloid subfamily member-1 (TRPV1), was origin-
ally described in primary sensory neurons as a receptor for capsaicin and related natural
irritants (also called vanilloids). TRPV1 is believed to function as a molecular integrator of
noxious stimuli, including heat, acids, and endogenous pro-inflammatory substances. To
test whether this acid-sensitive receptor may be a candidate as the initial mediator of acid-
induced inflammation in the esophagus, a tubular segment of normal mucosa was removed
from the esophagus, tied at both ends, forming a mucosal sac. The sac was filled with 0.01N
HCl (or normal Krebs’ for control) and kept in oxygenated Krebs’ solution at 37 C. The
supernatant outside the HCl-filled mucosal sac was collected after 3 hr incubation and
applied to circular muscle strips. The supernatant of the HCl-filled sac almost abolished
contraction of normal muscle strips in response to electric field (i.e. neural) stimulation
(EFS). This supernatant-induced inhibition was reversed by application of the TRPV1 antag-
onist IRTX inside the mucosal sac, confirming presence of TRPV1 receptors in the mucosal
wall. Similarly, EFS-induced contraction of esophageal circular muscle was almost abolished
by supernatant of capsaicin (1 μM) - filled mucosal sac. The reduction induced by supernatant
of capsaicin- filled sac was reversed by application of the selective TRPV1 antagonist IRTX
inside the mucosal sac, confirming presence of capsaicin-sensitive TRPV1 receptors in the
mucosal wall. The reduction in contraction caused by supernatant of capsaicin- filled sac
was also abolished by pre-exposure of the muscle to the PAF receptor antagonist CV9388.
This is consistent with release of PAF by mucosa in response to activation of TRPV1 by
capsaicin. Measurements of PAF in mucosa tissue and in mucosa supernatant indicate that
PAF levels increase 4-5 times in the HCl-filled mucosal sac and in its supernatant when
compared to control (Kreb’s filled mucosal sac at pH7.4). The HCl-induced increase in PAF
was abolished by the TRPV1 receptor antagonist IRTX The data indicate that acid-induced
activation of TRPV1 receptors in the mucosa, induces production and release of the pro-
inflammatory mediator PAF that affects contraction of circular muscle in response to electrical
field stimulation.
W1793
Manometry in the 21st Centry: A Novel Fibre Optic Based Technology for
Multi-Channel Intraluminal Manometry
Taher Omari, John Arkwright, Simon Doe, Michal Szczesniak, Nathalie Rommel, Philip
Dinning, Ian Cook
INTRODUCTION: Mutichannel intraluminal pressure measurement is routinely used for
the measurement of gut motility and diagnosing motility disorders. Perfused manometric
assemblies are inexpensive, but technically demanding, require luminal infusion of water,
are subject to movement artefact, baseline drift and hydraulic dampening of the pressure
signal. Solid state manometric assemblies are expensive, fragile and require low temperature
chemical sterilisation. Neither of these technologies are amenable to single use. We have
developed a novel fibre optic technology that offers the potential for low cost, high fidelity,
multi-channel intraluminal manometric recordings from a large number of pressure sensing
elements based on a single optical fibre. The number of sensing elements is limited only
by the available optical hardware and can theoretically exceed 50 discrete elements. We
report our initial results from a pilot study of single and multiple sensor assemblies (OD
3.5mm). METHODS: Multiple pressure sensing elements were fabricated on a single optical
fibre using multiple fibre Bragg gratings (FBG) designed to reflect a unique optical wavelength.
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Each FBG was encased in a pressure sensitive diaphragm such that distortion of the membrane
resulted in a proportionate change in the pitch of the FBG and therefore a change in reflected
optical wavelength. Wavelength division multiplexing (WDM) allows simultaneous tracking
of changes at each wavelength and therefore any variation in pressure along an array of
sensors can be monitored in real time. In healthy adult volunteers, we recorded esophageal
pressure waves initiated during bolus swallows using FBG assemblies and compared these
with simultaneous side-by-side recordings made using a solid state transducer assembly
(GaelTech Ltd). RESULTS: A total of 20 x 10ml and 20 x 20ml bolus swallows were analysed.
The peak amplitudes of esophageal pressure waves recorded by the FBG assemblies and
solid state assembly were similar (85.2 ± 24.9 mmHg vs 84.5 ± 24.2 mmHg) and there was
a significant agreement between the two devices (r2 = 0.95, p > 0.0001, using Pearson
correlation). CONCLUSIONS: Fibre optic manometric assemblies incorporating FBG sensor
elements are capable of high fidelity manometric recordings of intraluminal pressure. This
technology offers the potential of single use manometric assesmblies with large pressure
sensor arrays using a single optical fibre and therefore without the need to increase the
external dimension of the catheter or the complexity of the recording system as the sensor
count increases.
W1794
Patients with Successfully Treated GERD Are Persistently Hypersensitive to
Esophageal Balloon Distension
Joel H. Rubenstein, Borko Nojkov, Sheryl Korsnes, Beth Weinman, John M. Inadomi,
William D. Chey
Background & Aims: Patients with erosive esophagitis are hypersensitive to esophageal
acid perfusion. Some evidence suggests that patients who have undergone a healing course
of proton pump inhibitors (PPIs) have resolution of their chemosensitivity to acid perfusion.
Less evidence is available regarding mechanosensation to balloon distension. We aimed to
compare esophageal sensation to acid perfusion and balloon distension in patients with
typical gastroesophageal reflux disease (GERD) that has responded to PPI therapy to healthy
volunteers without GERD. Methods: 19 healthy volunteers (heartburn less than 3 times a
month), and 16 subjects with a history of heartburn at least 3 times a week prior to PPI
and no heartburn after at least 8 weeks of PPI, underwent esophageal perfusion with 0.1
normal HCl at 10mL/min for 10 minutes and stepwise intraesophageal balloon distension
in random order. Subjects rated their sensation and unpleasantness on validated 20cm scales.
Acid sensation scores, and acid unpleasantness scores were calculated (cm x time of sensation /
100). Subjects also underwent ambulatory esophageal pH monitoring. Results: GERD
patients after PPI treatment had lower threshold pressure for weak sensation with balloon
distension than controls (12.8 vs. 17.3 mmHg, p=0.01), and tended to have lower threshold
pressure for discomfort (18.3 vs. 23.8 mmHg, p=0.08). In mixed models of sensation over
various pressures of balloon distension, male gender and increasing age tended toward lower
sensation. Similar associations were found for unpleasantness. Controlling for gender and
age, GERD patients had higher sensation (+ 3.8cm, p=0.01) and higher unpleasantness (+
3.2cm, p=0.02) at any given pressure than controls. GERD patients tended to have higher
sensitivity to acid (34.6 vs. 27.5 cm-s, p=0.89), and unpleasantness with acid perfusion
(29.2 vs. 23.3 cm-s, p=0.96), but neither was statistically significant. Neither the results of
ambulatory pH monitoring, nor the order of testing affected the results. Conclusions:
Despite resolution of symptoms with PPI therapy, patients with GERD have persistent
hypersensitivity to balloon distension. This could be due to allodynia induced by prior
GERD. This study was supported by an unrestricted grant from Janssen Pharmaceutica, a unit of Ortho-McNeil and Esai
Inc., and a greant from the Univ. of Michigan General Clinical Research Center. JHR was funded by NIH Training Grants
T32 DK07367 and DK062708, and GlaxoSmithKline Digestive Health Clinical Research Award.
W1795
The Role of Esophageal Mast Cells in Patients with Symptoms of Heartburn
Shaoyong Yu, Deborah M. Bethards, Allen C. Myers, Ann Ouyang
Introduction: The mast cell is known to be an important inflammatory cell in the GI tract.
Our previous pre-clinical animal studies show that mast cell activation results in the release
of inflammatory mediators in the esophagus with resulting stimulation of nociceptors. Our
hypothesis is that heartburn may be a symptom similarly generated by the effect of mast
cell activation on esophageal nociceptors in humans. Aims: To identify mast cells in the
esophagus and review their correlation with symptoms of heartburn. Method: Sixteen patients
were recruited from all patients who were referred for upper endoscopy. Exclusion criteria
included asthma, atopic skin disease, chronic inflammatory conditions (RA, SLE), food
allergies, known celiac disease, recent steroid treatment, ischemic heart disease or esophageal
varices. During upper endoscopy biopsies were obtained from the lower esophagus and the
mucosal appearance of the esophagus was noted and graded by the endoscopist. Mast
cell tryptase staining was performed using a standard immunofluorescence method by an
investigator blinded to the clinical information and the number of mast cells per mm2 was
calculated. The sections were also stained with antibodies to TRPV1 (capsaicin receptor)
and PGP9.5. The patients’ symptoms of heartburn were categorized using a scale from 1-5
for severity, duration and frequency (giving a maximal score of 15); this information was
obtained by questionnaire completed prior to the procedure. Five patients had a symptom
score of 0-4, one had a score between 5-9 and ten had a score between 10-15. The esophageal
mast cell count was compared between patients with symptoms scores of 0-4 and those
with scores of 10-15. Results: In the majority of patients no significant macroscopic esophageal
mucosal change was noted on endoscopy. The number of mast cells was found to be
significantly elevated in those patients with a heartburn score of 10-15 compared to those
with a score of 0-4 (119.4 ± 37.8 vs 42.8 ± 19.1 cells/mm2, mean ± SEM, p<0.03). The
TRPV1 positive nerve fibers were identified in the esophageal mucosa in proximity to mast
cells. Conclusion: In a patient population in which allergic and inflammatory conditions
have been excluded there is a significant correlation between heartburn symptom score and
number of mast cells in lower esophageal biopsies. We propose that mast cells release
inflammatory mediators that are responsible for the development of heartburn symptoms
in these patients without macroscopic esophagitis.
W1796
PAF Induced Activation of NADPH Oxidase Is Mediated By Arachidonic Acid
and the Myeloid-Related Proteins S100a8/A9
Ling Cheng, Karen M. Harnett, Weibiao Cao, Jose Behar, Piero Biancani
In a cat model on in vivo-induced esophagitis by acid perfusion repeated over three days
and in a human esophageal specimen with histologically confirmed erosive esophagitis, we
have shown that PAF is produced and released by esophageal mucosa and present in
esophageal circular muscle, where PAF induces production of H2O2 and reduces contraction
in response to electrical field stimulation (EFS). We therefore examined mechanisms of PAF-
induced production of H2O2. In esophageal circular muscle PAF(10-5 M, 2 hour) increased
H2O2 level 2.8 times over that of control. PAF-induced production of H2O2 was confirmed
by examining esophageal muscle contraction in response to electrical field stimulation (EFS).
EFS-induced contraction was reduced by PAF, and the reduction was reversed by the H2O2
scavenger catalase, indicating that the reduction was mediated through production of H2O2.
The PAF-induced reduction was reversed by the NADPH oxidase inhibitor apocynin, by
the p38 MAK kinase inhibitor SB203589, and by the cPLA2 inhibitor AACOCF3, indicating
that formation of H2O2 depends on activation of the p38 MAK kinase and of the cytosolic
PLA2, with formation of arachidonic acid, and activation of NADPH oxidase. This conclusion
was confirmed by direct measurements of H2O2 in response to PAF. The PAF-induced
increase in H2O2was inhibited by apocynin, by the p38 MAK kinase inhibitor SB203589,
and by the cPLA2 inhibitor AACOCF3, indicating that activation of the p38 MAK kinase
and of the cytosolic PLA2, with formation of arachidonic acid, may be required steps for
activation of NADPH oxidase and formation of H2O2. It has been shown that arachidonic
acid promotes activation of NADPH oxidase by binding to the myeloid-related proteins
S100A8/A9 which then interact with the p47-p67 NADPH components promoting interac-
tions between the oxidase subunits and enabling oxidase activation. We therefore examined
a possible role of S100A8 in PAF induced production of H2O2 in cat esophageal circular
muscle. Enzymatically isolated smooth muscle cells in primary culture were electroporated
in the presence of S100A8 small interfering RNA (siRNA) or scrambled siRNA. With
scrambled siRNA, PAF increased H2O2 2.5 times, and arachidonic acid increased H2O2 3.2
times, when compared to control. When the electroporated cells were incubated with S100A8
siRNA, S100A8 protein expression decreased by more than half, as measured by Western
blot analysis and the increase in H2O2 in response to PAF and arachidonic acid was reduced
by more than half. The data indicate that PAF-induced production of H2O2 is mediated
through arachidonic acid interaction with S100A8 to activate NADPH oxidase.
W1797
Novel, Automated High-Resolution Manometry (HRM) Paradigms for
Quantifying EGJ Relaxation: Integrated Relaxation Resistance (IRR) and
Median Flow Permissive Pressure (mFPP)
John E. Pandolfino, John Rice, Sudip K. Ghosh, Qing Zhang, John P. Norvell, Peter J.
Kahrilas
Aim: Post-deglutitive esophageal emptying depends on the balance between EGJ resistance
and intrabolus pressure proximal to the EGJ, making these ideal measures of EGJ function.
The enhanced spatial resolution of HRM make it possible to quantify both in an automated
fashion. This study aimed to establish normal values for IRR, mFPP, and E-sleeve pressure
during post-deglutitive EGJ relaxation and compare their performance in assessing 400
consecutive patients. Methods: 75 controls were studied with a 36-channel solid state HRM
assembly (1 cm spacing) to establish normal values for: 1) the lowest 3 s mean residual
pressure after swallow (E-sleeve), 2) mFPP, and 3) IRR. mFPP was the median pressure it
would take to overcome post-deglutitive EGJ resistance (10 s or until the arrival of the
contractile complex). IRR was the mFPP divided by the interval between the swallow and
the arrival of the contractile complex (if present). Data from 400 consecutive patients who
underwent HRM were then analyzed to compare the performance of the E-sleeve and IRR
in assessing EGJ relaxation with the mFPP being the final adjudicator of abnormal function.
All measurements were made by computer analysis, either in ManoScan or custom written
Matlab programs. Results: The 95th percentile of normal for EGJ relaxation parameters
amongst the 75 controls were: 15 mmHg for the E-sleeve; 18mmHg for mFPP; and 3.0
mmHg/s for the IRR. 90 patients were abnormal by E-sleeve. Of these, 69 were also abnormal
by IRR confirming EGJ dysfunction. Of the remaining 21, the mFPP was abnormal in
12 patients most of whom were aperistaltic (mFPP 18.0-27.2 mmHg) also verifying EGJ
dysfunction. However, in an additional 8 patients, the E-sleeve value was deceptively abnor-
mal because of interference with either the crural diaphragm or the heart, neither of which
led to spurious mFPP or IRR calculations. Only one patient (with aperistalsis) exhibited
normal values of IRR (1.9 mmHg/s) and mFPP (10.6 mmHg) with an abnormal E-sleeve
(19.7 mmHg). 310 patients were normal by E-sleeve criteria. Of these 13 had abnormal
IRR or mFPP. Further scrutiny of these patients showed that all 13 patients had EGJ pathology
(variant achalasia or post-fundoplication dysphagia) suggesting that the E-sleeve misclassified
them. Conclusion: IRR and mFPP are novel HRM parameters for assessing deglutitive EGJ
relaxation demonstrating superior clinical performance to E-sleeve relaxation pressure.
W1798
The Effect of a Novel 5-HT3 Receptor Partial Agonist (DDP733) On Feline
Esophageal Peristalsis and Lower Esophageal Sphincter Pressure
Kalina Venkova, Anthony C. Johnson, Matthew O. Fraser, Karl B. Thor, Beverley
Greenwood-van Meerveld
The present study investigated whether DDP733, a new 5-HT3 receptor partial agonist, affects
lower esophageal sphincter pressure (LESP), esophageal peristalsis and distal esophageal pH
in a feline model. We hypothesized that activation of 5-HT3 receptors, known to cause
excitation of mucosal vagal afferents and local enteric neurons, may increase LESP and present
a novel approach to the treatment of gastroesophageal reflux disease (GERD). Methods: In
anesthetized cats, esophageal contractility and LESP were recorded manometrically via a
water-perfused catheter assembly system. Changes in pH in the distal esophagus were
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monitored continuously throughout the experiment using a computerized Orion II system.
Mean LESP, the number of spontaneous dry swallows (SDS) and the SDS-induced LES
relaxation were monitored. Each cat received the vehicle or DDP733 (0.1-10 mg/kg) adminis-
tered intravenously (i.v.) or intragastrically (i.g.) in separate recording sessions performed
7 days apart. Results: Preliminary studies revealed that following i.v. dosing DDP733
induced an immediate and dose-dependent increase in LESP. To simulate oral dosing in
our anesthetized cat model, DDP733 (at single doses of 0.1, 1 or 10 mg/kg) or the vehicle
were administered i.g. DDP733 induced a dose-dependent increase in LESP (Table 1). The
increase in LESP reached a maximum within 20-45 min of treatment and remained elevated
60-min after drug administration. There was no significant difference between the number
of SDS recorded during the 1-h following treatment with DDP733. Despite the increase in
LESP induced by DDP733, each SDS was associated with a normal esophageal peristalsis
through the striated and smooth muscle portion of the esophagus. DDP733 did not alter
the ability of the LES to relax in response to SDS. Esophageal pH data recorded simultaneously
with the esophageal pressure suggested a trend of DDP733 to decrease the duration of lower
esophageal exposure to harmful pH levels (pH<4) during LES relaxation. Conclusion: Our
results demonstrate that activation of 5-HT3 receptors promotes an increase in LESP without
altering the ability of the LES to relax in response to a swallow. Overall, the findings suggest
that oral administration of DDP733 may be useful in the treatment of GERD.
Table 1
Mean values from 5-6 experiment in different animals. * p<0.05 compared to vehicle.
W1799
Apnea-Associated Inhibition of Esophageal Body Motility and Lower
Esophageal Sphincter Tone in Premature Infants
Taher Omari
INTRODUCTION: The association of gastroesophageal reflux (GER) and apnea is controver-
sial. A large number of studies have investigated this association and have demonstrated
both a relationship and no relationship. Esophageal motility studies in premature infants
indicate that the lower esophageal sphincter (LES) is a competent anti-reflux barrier and
that GER episodes require LES relaxation, usually transient LES relaxation. LES pressure
during apnoea has not been described in infants. The aim of this study was to characterise
pharyngo-esophageal motility during episodes of significant (life threatening) apnea in prema-
ture infants. METHODS: A retrospective review was undertaken of all combined manometric
and physiological monitoring studies performed in premature infants at the WCH between
1994-2002. Significant apnoea was defined as a respiratory pause of >20sec, which was
associated with bradycardia to a HR of <100 beat/min and desaturation to a SaO2 <90%.
For each apneic event identified, pharyngeal swallowing, oesophageal motility and LES
pressure was assessed before, during and after apnea. RESULTS: Twelve episodes of significant
apnea (mean duration 44sec, HR 64 beats/min, SaO2 72%) were identified in 7 of 156
infants who had undergone esophageal motility studies. All were predominantly central
apneic events incorporating short periods of obstructed breaths at the onset and/or offset
of apnea and therefore were defined as ‘mixed’ apnea episodes. A sequence of swallows was
observed during the period of apnea with the first swallow occurring within 2sec before to
6sec after apnea onset (mean 1.3±0.7sec after). The median [IQR] number of swallows
occurring before, during and after apnea was 0[0, 0], 4[2, 7](p<0.05) and 1[0, 1] swallows
respectively. The esophageal body was refractory during apnea. Only 19% of swallows
triggered during apnea initiated normal antegrade and complete oesophageal peristalsis,
compared while 82% of swallows after apnoea. LES pressure dropped during apnea from
a basal pressure of 15.6±2.7mmHg at apnea onset to a nadir of 4.1±0.8mmHg (p<0.0005)
an average of 6.0±1.1sec after apnea onset. Inhibition of LES tone was maintained for the
duration of apnea. CONCLUSION: Rare episodes of significant apnea are associated with
an increase in pharyngeal swallowing coupled with a refractory esophageal body and a
decrease in LES tone. These observations suggest that a reduction in vagal drive at the onset
of apnea also impacts upon the motility of the upper GI tract. LES inhibition coupled
with esophageal inhibition during apnea may make triggering of GER more likely during
apnea episodes.
W1800
Effects of Electroacupuncture On Esophageal Motility and Serum Hormones in
Cats with Esophagitis
Xiaowei Shuai, Pengyan Xie, Jianxiang Liu, Yanshu Xiang, Jiang Li
AIM: To investigate effects of electroacupuncture (EA) applied to the Zusanli point (36S)
on esophageal motility, and compare the effect of EA on serum gastrin (GAS), motilin (MTL),
and vasoactive intestinal peptide (VIP). METHODS: Thirty-two cats were randomly divided
into 4 equal groups. All animals underwent a Heller myotomy. 6-8 weeks after the operation,
endoscopy confirmed if reflux esophagitis had been developed. Two frequencies (2-15 Hz/
2-100 Hz) of EA (2-4 mA) were delivered in two different groups through acupuncture
needles inserted bilaterally into Zusanli acupoints on hind limb (low-frequency EA group,
high frequency EA group). Animals submitted to EA (2-15Hz/2-100Hz) on a non-point
region (EANP) were used as controls respectively in the other two groups (low-frequency
EANP group, high-frequency EANP group). Thirty minutes of electric stimulation was applied
in each group. Esophageal motility was continuously monitored using water-perfusion mano-

















were also measured. RESULTS: The LESP decreased significantly after Heller myotomy
compared with that before the operation (19.4±4.66 v.s. 35.8±5.12mmHg, P<0.01), and
there were no significant differences among groups. Mild to moderate esophagitis developed
following Heller myotomy in all the cats. The LESP decreased in both low-frequency EA
cats and low-frequency EANP cats, and in EA cats the pressure decreased more (12.1±5.06
v.s. 15.1±5.99mmHg). On the contrary, the LESP increased in high-frequency EA group
(30.0±10.36mmHg), which was signif icantly higher than that in EANP group
(24.6±15.86mmHg, P<0.05). EA had no effect on contraction duration. Although high-
frequency EA significantly increased the peak amplitude in esophageal peristalsis, low-
frequency EA did not decreased it. There was a decrease in serum GAS and MTL in low-
frequency EA cats compared with low-frequency EANP cats (GAS 14.5±3.51 v.s. 26.6±4.55
pg/ml, MTL 53.5±17.38 v.s. 95.2±13.26 pg/ml, both P<0.01). GAS and MTL were signific-
antly higher in high-frequency EA group than in high-frequency EANP group (GAS 51.0±5.18
v.s. 30.7±8.79 pg/ml, MTL 162.7±14.87 v.s. 113.4±23.86 pg/ml, both P<0.01). Serum VIP
decreased in high-frequency EA group (14.0±4.83 v.s. 50.0±8.49 pg/ml, P<0.05), while
increased in low frequency EA group (82.6±8.11 v.s. 43.6±8.74 pg/ml, P<0.05), compared
with EANP groups respectively. CONCLUSION: EA with a high frequency at Zusanli might
enhance the esophageal motility, while EA with a low frequency might weaken it. The effect
of acupuncture is acu-point-specific, and this effect appears to be mediated through GAS,
MTL, and VIP.
W1801
Effect of Atropine and L-NAME On LESP in Rats By Electro-Acupuncture At
Zusanli Acupoint
Xiangdong Mu, Pengyan Xie, Jianxiang Liu, Huhong Wang
AIM: To observe the effect of atropine and N-nitro-L-arginine methyl ester (L-NAME) on
the pressure of lower esophageal sphincter (LESP) by electro-acupuncturing (EA) at Zusanli
acupoint (He-Sea, st 36) of stomach meridian and the neural mechanism of EA. METHODS:
Forty-eight rats were divided into six groups: control group, EA group, atropine group,
atropine+EA group, L-NAME group and L-NAME+EA group. LESP was observed and
recorded by using three-channel perfusion manometric measurement system. RESULTS: (1)
The basic LESP of EA group was 10.7+/-2.1mmHg; LESP increased significantly under EA
or 0-20, 21-40min after EA (P<0.01), the variation degrees were respectively 62.77+/-
27.02%, 131.01+/-36.42% and 122.6+/-25.9%. (2) LESP of atropine+EA group significantly
decreased 16.0+/-7.7% (P<0.01) after atropine intraperitoneal injection; LESP under or after
EA contrast to those before EA (after atropine i.p.) increased respectively 28.5+/-19.7%
(P<0.01) and 31.2+/-28.5% (P<0.05), which were significantly lower than those of EA group;
no significances were observed between the LESP under EA or after EA (P1=0.155, P2=
0.252) contrast to basic LESP. (3) LESP of L-NAME+EA group significantly increased 30.5+/-
17.4% (P<0.01) after L-NAME intraperitoneal injection; LESP under or after EA contrast to
those before EA (after L-NAME i.p.) increased respectively 39.4+/-28.6% and 48.6+/-41.4%,
which were significantly lower than those of EA group (P<0.01); LESP under or after EA
contrast to basic LESP increased respectively 82.0+/-45.0% and 93.0+/-58.0% (P<0.01), no
significances were observed between L-NAME+EA group and EA group. CONCLUSIONS:
(1) LESP increases significantly under or after EA at Zusanli acupoint. (2) Cholinergic M
receptor blocker partly abolishes the influence of EA on LESP, but EA can restore the
decreased pressure of cholinergic M receptor blocked rats. (3) Nitric oxide synthase (NOS)
inhibitor increases LESP, and EA can make it higher. (4) The main efferent pathway of
regulating effect of EA at Zusanli acupoint on LESP is possibly via the cholinergic vagus nerve.
W1802
Prevalence of Increased Esophageal Muscle Thickness in Patients with
Esophageal Motor Disorders
Ibrahim Dogan, James L. Puckett, Bikram S. Padda, Ravinder K. Mittal
Background and aims: Patients with achalasia, diffuse esophageal spasm and nutcracker
esophagus have a thicker muscularis propria than normal subjects. The goal of our study
was to determine the prevalence of increased muscle thickness (MT) in a group of unselected
patients referred to the esophageal functions laboratory for esophageal symptoms. Methods:
We studied 40 normal subjects (mean age 41.8±14.4 yr; 25 males, range 21-75 yr) and 94
consecutive patients with esophageal symptoms (mean age 53.6±15.3 yr; 46 males, range
20-81 yr). Manometry and ultrasound images of the esophagus were recorded concurrently,
using a special custom-built catheter. Esophageal MT and muscle cross sectional area (MCSA)
were measured at 2 and 10 cm above the lower esophageal sphincter (LES). Patients were
assigned manometric diagnosis and determination was made if they had increased MT and
MCSA. Results: Esophageal baseline MT (1.45±0.31 mm) and MCSA (65.08±9.51 mm2) in
normal subjects, at 2 cm was greater than MT (1.24±0.23 mm) and MCSA (54.49±8.61
mm2) at 10 cm above the LES (p<0.05). Based on mean+2SD value in normal subjects,
baseline MT of greater than 2.08 mm and 1.71 mm, at 2 and 10 cm sites respectively were
considered to be abnormal. Corresponding normal values for MCSA at 2 and 10 cm sites
were 84.11 mm2 and 71.72 mm2 respectively. All patients with achalasia, 7/8 subjects with
diffuse esophageal spasm and 2/2 patients with nutcracker esophagus showed an increase
in the MCSA at 2 cm site. Nearly all patients with well-defined spastic motor disorders, i.e.,
achalasia, diffuse esophageal spasm and nutcracker esophagus revealed an increase in MT
or MCSA, 2; increase in esophageal MT/MCSA was seen, albeit at a lower prevalence rate,
in patients with less well-characterized manometric abnormalities, i.e., hypertensive LES (1/
1), impaired LES relaxation (1/1), ineffective esophageal motility (7/11) and hypotensive
LES (5/9), 3; 24% of patients with esophageal symptoms but normal manometry were also
found to have an increase in MCSA. Dysphagia was more likely, and heartburn less likely
in patients with increased MT/MCSA, but there were no differences in chest pain and
regurgitation symptoms between the groups. Conclusion: An increase in esophageal MT/
MCSA is sensitive but not specific marker of manometrically defined esophageal motor
disorders. Further studies are needed to determine the cause of increase in esophageal MT/
MCSA in patients with esophageal symptoms.
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W1803
The Effect of Lower Esophageal Sphincter (LES) Electrical Stimulation On
LES Pressure
Claudia P. Sanmiguel, Masanobu Hagiike, Martin P. Mintchev, Ryan B. Dela Cruz, Edward
H. Phillips, Scott A. Cunneen, Jeffrey L. Conklin, Edy E. Soffer
Background: Electrical stimulation (ES) of the stomach has been shown to modulate LESP.
Electrical stimulation, using neural high frequency stimulation (NGES) can induce contrac-
tions of the smooth muscle of the gut. The purpose of this study was to determine if electrical
stimulation of the LES can affect LESP. Methods: Four female hound dogs, weight: 20-25
kg, underwent an esophagostomy that allowed the introduction of a sleeve manometry
catheter into the esophagus. They were also implanted with a pair of electrodes along the
longitudinal axis of the LES. After 3 weeks of recovery, they underwent esophageal manometry
recording during control and ES, performed randomly on separate days, using 4 different
stimulations: 1-Low frequency: freq: 6 cycles/min, pulse: 350 milisec, amp: 5 mAmp; 2 High-
frequency: freq: 50Hz, pulse: 1 milisec, amp: 5 mAmp; 3- NGES: freq: 50Hz, pulse:20milisec,
amp:10 volts; 4- High-frequency, circular: freq: 20Hz, pulse:1milisec, amp:5 mAmp. All
recordings were performed 1 hour after consumption of 3 ounces of canned dog food, to
prevent fluctuations in LESP and under mild sedation (acepromazine 0.5m/kg). Tests con-
sisted, during ES days, of 3 periods of 20 minutes each: control , stimulation and post
stimulation. The effect of NGES was also tested under anesthesia and following administration
of L-NAME 50 mg/kg IV. and also atropine 0.05mg/kg IV. Analysis: area under the curve
(AUC) and pressure were compared among the 3 periods. Data shown as mean±SD, ANOVA
and t-test, p<0.05. Results: Sustained increase in LESP was observed during low frequency
stimulation, 32.1±12.8 vs. 42.4±18.0 vs. 50.1±23.6, control vs. stimulation vs. post stimula-
tion respectively, p=0.013. AUC also significantly increased during and after stimulation,
39,320±15,722 vs. 51,294±21,826 vs. 59,823±28,198 mmHgxsec, control vs. stimulation
vs. post stimulation respectively, p=0.01. There was no significant change with other types
of ES. NGES induced an initial rise in LESP followed within few seconds by relaxation with
slow resumption of pressure over a 1 minute period. L-NAME increased LESP and augmented
the initial rise in LESP following NGES but markedly diminished or abolished the relaxation
phase. Atropine lowered LESP and abolished the initial rise in LESP induced by NGES.
Conclusions: Low frequency ES of the LES increases LESP in conscious dogs. NGES has
dual effect on LESP: an initial stimulation, cholinergically mediated, followed by relaxation
mediated by nitric oxide.
W1804
Protection Against Pharyngeal Reflux of Gastric Content During Coughing:
Another Role for the Upper Esophageal Sphincter (UES)
Lilani Perera, Krisna Chai, Candy Hofmann, Tanya Rittmann, Mark Kern, Reza Shaker
Respiratory functions such as coughing induces significant increase in intra-abdominal
pressure causing a circumstance conducive to development of gastroesophageal reflux. Indeed
this phenomenon is documented frequently during pH monitoring studies. However, these
reflux events do not occur during every cough event and not in every individual suggesting
the existence of anti-reflux mechanism(s). The nature of this mechanism preventing gastroeso-
phageal/pharyngeal reflux events, however, has not been systematically studied. Our aim
was to determine and characterize the gastroesophageal, UES and LES pressure phenomena
during high and low amplitude cough in healthy individuals. METHODS: We studied 7
healthy volunteers (3M, 4F) by a concurrent manometric (Manoscan, Sierra Scientific) and
voice analysis technique (Praat, University of Amsterdam) and quantified and correlated
upper GI pressures during low and high intensity coughing. Each event was studied x3.
RESULTS: Amplitudes of tested coughs were 42 ± 3 dB for weak and 59 ± 2 dB for
strong cough. Intragastric, Intraesophageal, LES and UES pressures during coughing were
significantly higher than pre-cough pressures (p<0.001). UES pressure increases for both
cough intensities were significantly higher than those of the esophagus, LES, and stomach
(*p<0.001). There was a direct relationship between intensity of the cough and intragastric
LES, intraesophageal and UES pressure increases (#p<0.05). CONCLUSION: Different cough
intensities induce different changes in pressures of the esophagus and its sphincters. Cough-
induced LES and intraesophageal pressures are similar to that of intragastric pressure and
as such may not be effective in preventing GE reflux. Cough-induced UES pressure, on the
other hand, is significantly higher than intragastric, LES and intraesophageal pressure,
providing a strong barrier against pharyngeal reflux of gastric content. Supported in part
by NIH grants T32 DK61923 and RO1 DK25731.
LESP: lower esophageal sphincter pressure; UESP: upper esophageal sphincter pressure
W1805
The Upper Esophageal Sphincter Contractile Response to Reflux Events Is Not
Acid Sensitive
David A. Knuff, Tanya Rittman, Reza Shaker
BACKGROUND Prior studies have shown that the upper esophageal sphincter (UES) con-
tracts in response to reflux events. However, the effect of reflux acidity on the UES contractile
response (UESCR) is unknown. Our aim was to compare the UESCR to acid (ARE) and
non acid (NARE) reflux events. METOHDS: Five subjects with gastroesophageal reflux (GER)
were studied. In order to avoid the stimulatory effect of perfused manometry a Manoscan
(Sierra Scientific Instr. Los Angeles) catheter was placed transnasally such that the pressure
sensors covered the entire length of the UES and esophagus. In addition a two site pH probe
was placed transnsally. After confirming intragastric pH the pH sensors were positioned
5cm and 15cm above the manometrically determined lower esophageal sphincter. Subjects
then ingested a standard 1000kcal meal and were placed in the supine position. Simultaneous
data were then continuously recorded with the Manoscan system and pH probe for 90
minutes. Each subject was studied off of acid suppressive therapy for at least 24 hours and
again on acid suppressive therapy for at least 72 hours. We determined the occurrence of
common cavities and their characteristics, UES pressure prior to and during common cavities,
presence of secondary peristalsis response, as well as corresponding esophageal pH. RESULTS:
36 ARE (pH<4.0) and 45 NARE (pH>4.0) were identified. All events, irrespective of pH,
were associated with a UESCR. The common cavity characteristics and UES parameters were
not significantly different between ARE and NARE. Table (mean±SE). Frequency occurrence
of UESCR was significantly more than that of secondary peristalsis response *(P<0.05).
CONCLUSION: The UESCR to gastroesophageal events is mediated by esophageal distension
and is insensitive to refluxate pH. The UESCR, but not secondary peristalsis response, to
GER events is all or none.
W1806
Oesophageal Solid Bolus Transit: Studies Using Concurrent Videofluoroscopy
and High-Resolution Manometry
Mark Fox, Michael Fried, Werner Schwizer
INTRODUCTION: Esophageal solid bolus transit is less efficient than that of liquids in
health and disease. Esophageal function is complex and current investigations do not collect
data that fully addresses the relationship between motor function and bolus transport. A
recent study has shown that high-resolution manometry (HRM) resolves the segmental
anatomy of the esophagus and predicts the success of liquid bolus transport more accurately
than conventional techniques. AIM: Concurrent HRM and videofluoroscopy (VF) were
performed to study esophageal solid bolus transport. METHOD: 18 healthy subjects were
studied on swallowing 10ml liquid barium and 10mm barium marshmallow bolus in a
supine posture. HRM and VF were analyzed separately and in a blinded fashion. The
characteristics of esophageal peristalsis on HRM were assessed and related to the success of
solid bolus transport by covariant analysis. RESULTS: Data was available for 75 swallows
(median 4/subject). Esophageal clearance was complete for 88% liquid and 65% solid bolus
swallows (p<0.01). For successful swallows, peristalsis and bolus transport from pharynx
to stomach took more time for solid than liquid bolus (8.7s vs. 8.2s; p<0.05) mainly due
to slower peristaltic velocity in the proximal esophagus (2.9 vs. 3.4 cm/s; p<0.05); velocity
in the mid- (4.7 vs. 4.8 cm/s; p=ns) and lower- (2.7 vs. 2.8 cm/s; p=ns) esophagus was not
affected. Contraction pressures were higher during solid than liquid bolus transport in the
proximal (75 vs. 67 mmHg; p<0.05), mid- (90 vs. 70mmHg; p<0.01) and lower- (119 vs.
102mmHg; p<0.01) esophagus. The pressure gradient across the gastro-esophageal junction
was greater during solid bolus transit (p<0.01). Failures of solid bolus transport usually
(86%) occurred at the pressure trough between the proximal- and mid- segments of the
esophagus. This ‘transition zone’ was wider when bolus escape occurred (2.9 vs. 1.7cm,
p<0.01). Contraction pressure in the proximal esophagus (68 vs. 70mmHg, p=0.62) and
nadir pressure in the ‘transition zone’ (21 vs. 25mmHg, p=0.18) were not affected. Below
the level of bolus escape in the distal esophagus contraction pressure was reduced (90mmHg
vs. 107mmHg, p<0.04). Only ‘transition zone’ width was independently associated with
failure of solid bolus transport (i.e. other effects were the result rather than the cause of
bolus escape). CONCLUSION: The physical properties of the bolus alter esophageal function.
When bolus escape occurs in healthy subjects it is usually in the ‘proximal transition zone’.
Coordination between segmental contractions is more important than contraction pressure
to the success of solid bolus transport.
W1807
High Resolution Manometry (HRM) of the Upper Esophageal Sphincter (UES):
An Accurate Automated Method for Quantifying Deglutitive Function
Sudip K. Ghosh, Qing Zhang, John E. Pandolfino, Jennifer M. Post, Peter J. Kahrilas
Aim: Pathophysiological studies of the UES suggest that sphincter pathology is clinically
manifest by increased intrabolus pressure (IBP) during trans-sphincteric flow (Williams et
al., AJP, 281:1290, 2001). Those studies utilized concomitant manometry and fluoroscopy
to track sphincter movement and localize intra-sphincteric pressure. Though possible, such
studies are cumbersome and we sought to determine whether the enhanced spatial resolution
and interpolation techniques of HRM allow for an accurate assessment of these clinically
relevant attributes of UES function in an automated fashion and without fluoroscopy.
Methods: 75 asymptomatic controls (40 male, ages 19-48) were studied. A solid-state
manometric assembly with 36 circumferential sensors spaced 1 cm apart was positioned to
record from the hypopharynx to the stomach (Sierra Scientific Instruments Inc., Los Angeles,
CA). All subjects performed 10 5 ml water swallows and 1 each of 1, 10, and 20 ml. Pressure
profiles across the UES were displayed in isobaric contour format and analyzed using an
automated computational algorithm written in Matlab (The Mathworks Inc, Natick, MA)
that measured: 1) the relaxation interval (RI) defined as the onset of maximal relaxation to
the instant that the sphincter recovered to 50 mmHg, 2) the median intrabolus pressure
(mIBP) during the RI, and 3) the integrated relaxation resistance (IRR) defined as mIBP/RI.
Mean values were compared using ANOVA. Results: Mean ± SD RI for the 1, 5, 10 and
20 ml swallows were 0.30 ± 0.09 s, 0.40 ± 0.09 s, 0.46 ± 0.09 s and 0.52 ± 0.12 s respectively
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(p<0.01). Mean ± SD mIBP for the 1, 5, 10 and 20 ml swallows were 5.99 ± 3.42 mmHg,
6.42 ± 2.18 mmHg, 8.99 ± 3.40 mmHg and 11.13 ± 3.01 mmHg respectively (p<0.01).
The IRR across volumes were 22.4 mmHg/sec, 21.3 mmHg/sec, 21.0 mmHg/sec and 22.7
mmHg/sec for increasing swallow volumes; none of these differences were significant. Peak
pharyngeal contraction during the return to the resting state post-swallow was 265.42
mmHg, 284.75 mmHg, 291.97 mmHg and 297.43 mmHg for 1, 5, 10 and 20 ml respectively;
none of these differences were significant. Conclusions: 1) The enhanced spatial resolution
of HRM allows for the accurate, automated assessment of UES relaxation and intrabolus
pressure characteristics, in both cases confirming the volume-dependent effects and absolute
values of these parameters demonstrated by detailed analysis of concurrent manometry/
fluoroscopy data in previous studies. 2) A new HRM parameter, the IRR, was developed
that normalized the volume-dependent variability of the mIBP and RI, potentially providing
an index to quantify functional obstruction at the UES.
W1808
Effects of Positive Modulation of Gabab Receptors On Gastro-Esophageal
Reflux (GER), Basal Lower Esophageal Sphincter Pressure (BLESP) and
Esophageal Motility in Conscious Dogs
Marie-Laure Rouzade-Dominguez, Ludovic Perrot, Elisabeth Braun, Hans-Juergen
Pfannkuche
Introduction: GABAB receptor agonists, such as baclofen reduce the incidence of Transient
Lower Esophageal Sphincter Relaxations (TLESRs) in men and dogs and decrease swallows.
Positive modulators of GABAB receptors act synergistically with an agonist by enhancing
the activation of the receptor, but have no or only little intrinsic agonistic activity. Aim: To
investigate the role of GABA tone on GER, BLESP, swallows and esophageal motility using
a positive modulator of GABAB receptors (CGP7930) alone or in combination with a threshold
dose of baclofen. Method: In Beagle dogs (n = 6) with chronic esophagostomies, TLESRs
were triggered by gastric infusion of a liquid caloric meal (pH 3, 100ml/min, 30 ml/kg)
followed by air infusion (50ml/min, 20 min). CGP7930 (3 mg/kg, i.v.) or vehicle were tested
with and without a threshold dose of baclofen (1.2 µmol/kg, s.c.). TLESRs and acid reflux
were counted during food and air infusion in the stomach. BLESP was averaged every 2
min (excluding swallows and TLESRs), the number of swallows were counted and esophageal
motility (contraction duration and amplitude, propagation speed) was evaluated in baseline
conditions, following compounds administration and during gastric distension. Data were
represented as mean ± SEM. Results: The control number of TLESRs (6.2 ± 0.5) was
significantly (p<0.05) reduced by baclofen (4.3 ± 0.6), but not by CGP7930 (6.2 ± 0.7).
With the combination of CGP7930 and baclofen, TLESRs were significantly (p<0.05) reduced
vs control but not vs baclofen (4.2 ± 0.4). Control acid reflux (2.2 ± 0.4) was not changed
by baclofen (2.5 ± 0.6) or CGP7930 alone (2.2 ± 0.8) but was significantly (p<0.05) reduced
by the combination (1.0 ± 0.3). BLESP was not modified by any compound administered.
The control number of swallows/10 min during distension in the vehicle experiment (8.6
± 0.6) was not changed by baclofen (7.0 ± 1.2) or CGP7930 (8.2 ± 0.7) but was significantly
(p<0.05) reduced with the combination (4.7 ± 1.7). No major effect on esophageal motility
were found for any treatment. Doses of CGP7930 higher than 3 mg/kg were not tolerated.
Conclusion: In our dog model, at the dose tested, CGP7930 did not reduce TLESRs and
did not potentiate the effects of a threshold dose of baclofen. However, the reduction of
acid reflux and swallows with the combination of baclofen and CGP7930 are suggestive of a
positive modulation of GABAB receptors. Swallowing pathways seems to be under GABAergic
control. The apparent discrepancy between effects on TLESRs and on acid reflux might
suggest a dual regulation of gastro-esophageal reflux mechanisms.
W1809
Effect of Tegaserod On the Topography of Esophageal Motility in Subjects
Receiving OMEPRAZOLE: A Study Using High-Resolution Manometry (HRM)
Ray E. Clouse, Laura Haroian, Mikhail Rojavin, David L. Earnest
Tegaserod has gastric and intestinal prokinetic effects, but its impact on esophageal motility
is less understood. Preliminary findings suggest tegaserod can favorably influence transit by
an unknown mechanism. The mid esophagus (2nd topographic segment in the peristaltic
chain as defined by HRM) is under dominant cholinergic control with potential susceptibility
to a 5HT4 agonist. This segment also may be important in the peristaltic pump. Subjects:
8 asymptomatic volunteers (age 38.4±10.9 yr, age range 35-47 yr, 5 female) who had taken
omeprazole 20 mg BID for 1 week underwent HRM to see if an effect of tegaserod could
be detected, particularly in this region of interest. Methods: Following overnight fast, subjects
were studied with a 21-lumen water-perfused system (1-cm recording port spacing) designed
for use in HRM and for display of topographic 3-dimensional (isocontour) pressure data
(MMS, Enschede, Holland). The catheter was anchored distally so that the majority of the
esophageal body including both smooth-muscle peristaltic segments (segments 2 & 3) and
LES after contraction (segment 4) was present. 10 baseline 5-ml water-bolus swallows were
taken followed by a 12 mg PO dosage of tegaserod. Swallows were repeated at 30 min, 60
min, and 90 minutes following the dose, and all data were analyzed without knowledge of
the sequence or subject. The primary outcome measure was segment 2 pressure volume
(mmHg.cm.s) at 60 min, measured using a previously described on-screen assessment tool.
Additional measures (segment length, peak segment amplitude) also were extracted from
the topographic isocontour maps. Results: Tegaserod increased segment 2 volume at each
time point and to a significant degree by 60 min (1171±997 vs 1364±965 mmHg.cm.s, p=
0.032), whereas volumes of segments 3 and 4 were unaffected. Tegaserod lengthened segment
2 at each time point (6.3±1.1 vs 7.3±1.4 cm at 60 min, p=0.036) and increased peak
amplitude within the segment (89±53 vs 99±51 mm Hg at 60 min, p=0.007). Segment 3
decreased in length (8.3±2.8 vs 7.6±2.9 cm at 60 min; p=0.06) in response to lengthening
of segment 2, but there were no other changes with tegaserod on the topographic analyses.
Conclusions: As demonstrated by HRM, a single 12 mg PO dose of tegaserod selectively
increases contractile strength in the mid esophagus in subjects who had been taking omepra-


















The Manometric Common Cavity Phenomenon Is An Unreliable Indicator of
Gastroesophageal Reflux
Marissa C. Aanen, Albert J. Bredenoord, Melvin Samsom, Andre J. Smout
Introduction The manometric common cavity phenomenon is characterized by a simultan-
eous intra-esophageal pressure rise to gastric pressure level and is considered indicative of
gastroesophageal reflux. There are differences in opinions on the sensitivity and the specificity
of the common cavity phenomenon as reflux detector, as well as on the nature of reflux
events that are associated with a common cavity. Therefore we tested the value of reflux
detection by means of common cavity analysis using combined impedance and pH recording
as the gold standard. Methods Ten healthy male subjects (mean age 28 year range 20-46)
underwent combined stationary pressure, pH and impedance recording for 4.5 hours. After
75 minutes of recording, a reflux-eliciting meal was consumed (McDonald’s Quarter Pounder
hamburger, onions 20 grams, chips 44 grams, and orange juice 475 ml; total of 967 kCal).
A common cavity was defined as a pressure increase in at least two esophageal tracings to
gastric level within 1s and remaining at that level for >0.5s. Reflux episodes were classified
as liquid, mixed or gaseous reflux and the acidity of liquid and mixed reflux episodes was
determined. The chi-square test was used for statistical analysis. Results A common cavity
was found in 96 (43%) of the 223 reflux events detected by impedance, while 7 common
cavities were unrelated to a reflux episode. In 54% of the reflux events detection of a
common cavity was obscured by either contractile activity or artifacts caused by posture
changes. The type of reflux associated with a common cavity (liquid 60%, mixed 31%, gas
9%) and without a common cavity (liquid 59%, mixed 29%, gas12%) did not differ, nor
did the acidity of the reflux episodes (with common cavity: pH<4 67%, pH>4 33%; without
common cavity pH<4 58%, pH >4 42%). Discussion The manometric common cavity
phenomenon is specific but not sensitive as marker of gastroesophageal reflux. Furthermore,
a common cavity is not specific for a particular type of reflux.
W1811
A Practical in-Vitro Model for Physiological and Pharmacological Studies of
Esophageal Muscle Function
Samuel K. Arthur, Yousif Al-Serkal, David F. Evans
We describe a model for studying separately, the contraction of esophageal muscles without
anatomically separating them. Preloaded, whole esophageal segments from rats (N=36) were
mounted in organ baths with Krebs-Ringer solution (KRS) at 37 Celsius gassed with 95%
oxygen and 5% CO2. Maximal carbachol-induced longitudinal contraction of the segments
was achieved with a dose of 10μM carbachol. This was followed by tetanic electric field
stimulation (EFS) with stimulus parameters 40V, 0.2ms, 25Hz for 2s. The resulting lonitudi-
nal isometric force of contraction was superimposed on the carbachol stimulated contraction.
In the presence of calcium-free KRS, ouabain, dantrolene or barium chloride, esophageal
segments were also stimulated by EFS. Carbachol stimulated contraction was abolished
completely by 1μM atropine and by 100μM hexamethonium. EFS resulted in a biphasic
isometric contraction. The second phase of contraction was abolished completely by 1μM
atropine and by 100μM hexamethonium but the first phase was not. Ouabain did not affect
either phase of EFS induced contraction. However, BaCl2 abolished the second phase with
topographical differences in the dose of BaCl2 required. The first phase was also abolished
by BaCl2 but at a higher dose than required for the second phase. BaCl2 inhibition of the
second phase was greater in low-potassium (1mM) KRS than in normal potassium (4.16mM)
KRS. The second phase EFS induced contraction disappeared in calcium- free KRS and was
restored by adding 2.5 mM calcium. The first phase contraction was not affected by calcium-
free KRS. However, dantrolene significantly reduced the first phase contraction without
affecting the second phase. We have shown that the physiology of esophageal smooth and
skeletal muscles can be studied separately without disrupting the anatomical integrity of
the esophagus. It is evident that postganglionic nicotinic receptor activation, activation of
acetylcholine gated ion channels and calcium entry into the smooth muscle cell are involved
in the initiation of rat esophageal smooth muscle contraction. This model has potential for
use in the study of the dynamics of calcium signalling in esophageal muscle contraction. It
can also be used to study topographical differences in anatomy and function. Because
anatomical integrity is preserved it is a good model for studying enteric neural transmission.
Tissue viability can be maintained for up to 4h with this model. Finally, this model is
promising for the development of new prokinetic drugs.
W1812
Upper Esophageal Sphincter (UES) Responsiveness to Esophageal Stimulation
in Infants with Chronic Lung Disease of Infancy
Sudarshan R. Jadcherla, Alankar Gupta, Soledad Fernandez, Reza Shaker
BACKGROUND: Chronic lung disease of infancy (CLDI) is defined as oxygen requirement
beyond 36 wks corrected gestational age(GA). UES is an important barrier that confers
airway protection. UES function with esophageal provocation in CLDI is not understood.
OBJECTIVE: To identify the characteristics of Esophago UES Contractile Reflex (EUCR)
responses with esophageal stimulation with air and water infusions in CLDI and compare
with control infants. HYPOTHESIS: EUCR is impaired in infants with CLDI. METHODS:
We recorded pharyngo-esophageal motility using a micromanometric pneumohydraulic
water perfusion system, a specially designed pharyngo-esophageal catheter assembly with
5-sideports, UES sleeve, concurrent with submental EMG to document swallow, with MMS
motility system, in 6 healthy neonates (36±2 wk, GA) and 6 infants with CLDI (28±5 wk
GA) at a corrected GA of 39±2 wks and 52±11 wks respectively. Graded volumes (0.1-
2.0ml)of air and water infusions were given thrice via the mid-esophageal infusion port.
Sensory and motor characteristics of UES responses were evaluated upon stimulation with
268 esophageal infusions. All values are stated as mean ± SD or %. ANOVA and t-test were
performed. RESULTS: In contrast to controls, subjects with CLDI required longer (*P <
0.01) respiratory support (4 ± 5 vs 200 ± 170 days*), gavage feeds (27 ± 37 vs 188 ± 174
days*) and length of stay (29 ± 26 vs 197 ± 171 days*). Threshold volumes of air (1.6 ±
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1.8 vs 1.3 ± 0.6 ml) and water (0.7 ± 0.3 vs 0.8 ± 0.3 ml) were similar. Frequency of EUCR
was 68% vs 26 % with air and 49% vs 18 % with water (both, P< 0.001). Response time
to EUCR with air was 1.6±0.6 vs 3.2±2.2 sec and with water 1.4±0.9 vs 4.7 ± 2.1 sec (both,
P<0.05). EUCR response was volume dependent (table) with air in controls and CLDI (both,
P<0.05); and with water in controls only (P<0.05) but not in CLDI. Comparison between
the groups was significant with both air and water (P<0.05). CONCLUSIONS: Threshold
volumes to evoke EUCR with air and water were similar. Response time was longer in CLDI
with both media. Volume dependent recruitment of EUCR was significantly different between
the groups. The proximal aerodigestive tract sensory-motor functions are impaired in response
to esophageal stimuli in CLDI and may contribute to increased resource utilization.
% EUCR, stimulus response relationship: Controls vs CLDI
* P<0.05, † P<0.05 between groups
W1813
Influence of Sleep Stages On Glottal Function: Implications for Nighttime
Airway Safety
Jasmohan Bajaj, Tanya Rittmann, David Knuff, Kulwinder Dua, Reza Shaker
BACKGROUND: Airway inlet is controlled by the striated adductor/abductor glottal muscles.
Deeper sleep stages, particularly REM sleep, are associated with varying degrees of muscular
hypotonia of striated muscles; however, the effect of various sleep stages (ST) on glottal
function has not been systematically evaluated. AIM: To quantify and compare respiration-
induced movements of the vocal cords during various sleep stages. METHODS: Six healthy
volunteers (31±5 yrs, 4M) were studied during awake state and for at least 4 hours during
various stages of sleep in a sleep laboratory. Glottal function was assessed by direct video
recording of the vocal cords through a transnasal (3mm OD) video-endoscope(Pentax FNL
OAP) and sleep parameters were measured by concurrent polysomnography (REMbrandt,
Amsterdam), electromyography (EMG) and pulse oximetry (SpO2). Glottal function during
inspiration (in) and expiration (ex) was studied by measuring its intra-luminal lateral (LA),
antero-posterior (AP) diameters and glottal inlet area (Area). Findings were compared to
those measurements in the awake state. RESULTS: Glottal function was studied in all subjects
during ST 1 & 2, three subjets during delta sleep and 2 during REM sleep. There was no
significant difference in the respiratory rate or O2 saturation between conditions (15±2,
96±1%, respectively). Vocal cord movements were maintained during REM sleep despite
generalized muscle hypotonia. However, LA, AP & Area were affected by deeper sleep stages
in that area of glottal inlet was reduced in delta sleep and increased in ST 1, 2 & REM
compared to awake state (Table). Area(in) Delta sleep was significantly reduced compared
to ST 1(p=0.003)and trended towards significance compared to Stage 2(p=0.06)and during
expiration. CONCLUSION: Generalized hypotonia during REM sleep does not prevent vocal
cord inspiratory/expiratory movements. Sleep stages affect glottal function differently; while
Delta sleep seems to reduce the size of the glottal inlet, other stages are accompanied by
an increase in laryngeal inlet compared to the awake state.
%Δ: percent change compared to awake state
W1814
Manometric and Endoscopic Findings in the Symptomatic Post-Fundoplication
and Post-Redo-Fundoplication Patients: Do They Differ Significantly?
Moises Garcia, Benson Massey, Reza Shaker, Walter Hogan
Fundoplication is associated with postoperative morbidity in a significant minority of
patients.Redo fundoplication does not assure a successful outcome either. Aim of study:
Define the differences in symptoms,manometric and endoscopic findings in post-fundoplica-
tion(Post-F)and post-redo fundoplication(Post-redo)patients from a single referral center.
Methods:94 patients(64F;30M;age 47.7 ± 12.8 yrs)were referred to the MCW Dysphagia
Institute from January 2000 to July 2005 for evaluation of post-operative symptoms.There
were 57 Post-F patients and 37 post-redo patients.All Post-F patients had manometry(abnor-
mal criteria: wrap pressure elevated(>25 mmHg)or low(<7 mmHg);ramp pressure >25 mmHg
or peristalsis frequency <60% of swallows).48 of 57 Post-F patients (84%) had endoscopy(ab-
normal criteria:inflammation,slipped,improperly placed,disrupted or too tight wrap).All 37
Post-Redo patients had manometry study; 32(86%)had endoscopy.Symptoms were recorded
by an experienced investigator prior to manometry study. Results:Dysphagia was the primary
symptom in both groups, with a frequency in the Post-redo(24/37;65%) versus Post-F
patients(26/57;46%)(p=0.106).Heartburn was the major symptom in 17 Post-F(30%) versus
7 Post-redo patients (19%)(p=0.346). Manometry abnormalities were detected in 53% Post-
F(decreased peristalsis 35%) compared to 59% Post-redo patients.A too-tight wrap(elevated
wrap or ramp pressures)was found on 10/57 post-F;13/37 post-redo patients.Endoscopy
detected abnormalities in 60% of Post-F(wrap abnormalities 45%)and 69% of Post-redo
patients(31% deformed wrap)(p=0.284).Intubation of the wrap was considered snug in 10/
32 post-redo and 3/48 Post-F patients(p<0.008),but this did not correlate manometricaly.
Esophagitis was more frequent on endoscopy in Post-F(35%)versus Post-redo
patients(19%)(p=0.737)Conclusions:manometry and endoscopy findings in symptomatic
post-F and post-redo patients were not significantly different.Dysphagia was the major post-
op symptom in both groups.Heartburn was more common in Post-F patients reflecting
the higher incidence of inflammation seen on endoscopy.Manometry and endoscopy are
complimentary in assessing Post-Fundoplication and Post-redo-fundoplication symptoms.
When one or both diagnostic modalities are abnormal,a plausible explanation is present in
greater that 80% of these patients.
Diagnostic results post-F(n=57) vs. post-redo(n=37)
Not significant difference.
W1815
Different Ca2+ Stores Mediate Acetylcholine (ACh)-Induced Contraction of Cat
LES and Esophageal Circular Smooth Muscle
Weibiao Cao, Karen M. Harnett, Ling Cheng, Jose Behar, Piero Biancani
We have previously shown that in smooth muscle cells from the circular layer of cat esophagus
(ESO) ACh-induced contraction is IP3 and calmodulin-independent and mediated through
a protein kinase C (PKC)-dependent pathway, involving a calcium insensitive PKCε. We
have also shown that in ESO calcium is needed to activate phospholipases and produce
second messengers. In contrast, in the lower esophageal sphincter (LES) contraction in
response to a maximally effective dose of acetylcholine (Emax ACh) is mediated through
IP3-induced Ca2+ release from intracellular stores, and activation of a calmodulin-dependent
pathway. In LES fura 2-loaded cells, Emax ACh caused a cytosolic Ca2+ increase from
93±8nM to 537±54nM in normal Ca2+ buffer and from 59±7nM to 483±57nM in Ca2+-free
medium with 200μM BAPTA (0 Ca2+), causing the same Ca2+ change in normal Ca2+ buffer
(444±47nM) and in 0 Ca2+ (424±50nM). These data confirm that the ACh induced Ca2+
signal in LES is mainly caused by Ca2+ release from intracellular stores. This Ca2+ signal
was significantly reduced by the IP3 receptor antagonist xestospongia C (1μM) and by the
PIP2-specific phospholipase C inhibitor U73122 (1μM), but not by ruthenium red (5μM),
an inhibitor of ryanodine sensitive Ca2+ channels, or by the phosphatidylcholine-specific
phospholipase inhbitor D609 (10μM), confirming that in LES ACh causes Ca2+ release from
IP3-sensitive stores. In ESO fura 2-loaded cells Emax ACh increased intracellular Ca2+ from
100±10nM to 547±84nM in normal Ca2+ buffer and from 56±7nM to 190±69nM in 0 Ca2+,
thus the ACh-induced Ca2+ change was significantly higher (p<0.05, ANOVA) in normal
Ca2+ buffer (447±87nM) than in 0 Ca2+ (134±65nM), suggesting that both Ca2+ influx and
Ca2+ release contribute to the ACh induced Ca2+ signal in ESO. In 0 Ca2+ the KCl induced
Ca2+ signal was abolished, confirming that incubation in this medium (0 Ca2+) abolishes
influx of extracellular Ca2+ . ACh induced Ca2+ signal in normal Ca2+ buffer was significantly
reduced by ruthenium red, and by D609, but not by xestospongia C, or by 10μM AACOCF3
(cPLA2 inhibitor), or 10 μM NPPB (a chloride channel blocker), suggesting that in ESO
ACh causes Ca2+ release from ryanodine sensitive stores. This Ca2+ release is not mediated
by arachidonic acid or by chloride channel activation, and is different from intestinal muscle
cells as reported by others. The data suggest that the ACh-induced calcium signal in ESO
depends in part on ryanodine-sensitive Ca2+ stores, and in LES on IP3-sensitive Ca2+ stores.
W1816
NADPH Oxidase-Derived H2O2 Contributes to Maintenance of Human Lower
Esophageal Sphincter (LES) Tone
Weibiao Cao, Karen M. Harnett, Ling Cheng, Jose Behar, Piero Biancani
We have previously shown that a low molecular weight group I PLA2 mediates cat and
human in vitro LES tone by producing arachidonic acid, which is metabolized to PGF2α
and thromboxane A2. These arachidonic acid metabolites act on receptors linked to Gi3 and
Gq proteins to activate phospholipases, producing second messengers, and maintaining
LES tone. In cat the non-selective cyclooxygenase inhibitor indomethacin abolishes tone,
confirming a role of arachidonic acid metabolites in tone maintenance. Indomethacin, how-
ever, was less effective in reducing tone of vitro human LES circular muscle, causing
approximately a 50% reduction, and suggesting that other mechanisms may also contribute
to maintenance of tone. We have previously shown that high levels of H2O2 are present in
esophagitis and reduce LES tone through several pathways, including release of calcium
from intracellular stores, resulting in depletion of releasable calcium. In the present study
we examined a possible role of low levels H2O2 in maintenance of human LES tone. H2O2
in low doses (10-8 - 10-6 M) increased spontaneous tone of in vitro human LES circular muscle
strips, and the membrane-permeable hydrogen peroxide scavenger tiron dose-dependently
decreased LES tone, suggesting that low levels of H2O2 may contribute to maintenance of
human LES tone. The NADPH oxidase inhibitor apocynin dose-dependently decreased LES
tone, indicating that NADPH oxidase-derived reactive oxygen species may play a role in
maintenance of tone. The apocynin-induced reduction in LES tone was not affected by the
nitric oxide synthase inhibitor L-NNA, indicating that inhibition of NADPH oxidase and
reduction in basal levels of H2O2 relaxes LES muscle through an NO-independent mechanism,
which is different from the role of NADPH oxidase in maintenance of vascular tone. The
sustained contraction induced by H2O2 was abolished by the Rho kinase inhibitor Y27632
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and was significantly decreased by the MEK1 inhibitor PD98059 and by the P38 MAP kinase
inhibitor SB203580 in LES muscle strips and in isolated muscle cells. These data are consistent
with a role of low levels H2O2 in mediating sustained contraction of human LES circular
muscle, in contrast to high levels of H2O2, that reduce LES tone through multiple pathways.
W1817
Assessment of Dietary Nutrients That Influence Cortical Perception of Intra-
Esophageal Acid Reflux Events
Michael Shapiro, Colleen N. Green, Jimmy M. Bautista, Roy Dekel, Sara Risner-Adler,
Robin Whitacre, Ellen Graver, Ronnie Fass
Background: Gastroesophageal reflux disease (GERD) symptoms are most commonly
reported postprandially, suggesting that some diet components are likely to induce symptoms
more than others. Aims: To determine which of the various dietary nutrients is a strong
predictive factor for symptom generation in association with a sensed acid reflux event
(reflux event that is associated with GERD-related symptom). Methods: Subjects with typical
heartburn symptoms were evaluated by the GERD Symptom Checklist and a demographics
questionnaire. Thereafter, all patients underwent an upper endoscopy to assess for the
presence of esophageal inflammation. Subsequently, ambulatory 24-hour esophageal pH
monitoring was carried out using a four-sensor pH probe. During the pH study, patients
completed a detailed 24-hour dietary intake record using the University of Minnesota
Nutrition Data System Research (NDS-R) version. This is a micro-computer based system
for collection and analysis of dietary data that prompts the user to describe detailed food
intake. Results: Fifty GERD patients (22 with erosive esophagitis, M/F 37/13, mean age
51.5, mean BMI 27.9) were enrolled into the study. A total of 112 (78%) symptoms were
considered as sensed reflux event. BMI did not correlate with having sensed reflux event
through all regressions (R2 = 0.005, β = 0 .05, t-value = 0.55). Patients who consumed
more cholesterol, saturated fatty acids and had more percentage calories from fat were
significantly more likely to experience a sensed reflux event (r = 0.22, 0.16, 0.18, respectively,
p <0.01). Regression analysis and beta coefficient were specifically significant for cholesterol
(R2 = 0.03, F-change = 3.3, β = 0.0004, t-value = 2.5, p <0.01). Alcohol consumption
demonstrated negative correlation with having a sensed reflux event (r = -0.2, p <0.01). All
other dietary nutrients, including monounsaturated fatty acids, polyunsaturated fatty acids,
caffeine, vegetable protein, animal protein, total protein, total carbohydrates and total fat
did not correlate with a sensed reflux event. Also, % calories from fat, carbohydrates or
protein were not correlated with a sensed reflux event. Conclusions: Of all dietary nutrients
and components, cholesterol enhances the most the perception of intra-esophageal acid
reflux event in patients with GERD.
W1818
Does Esophageal Acid Infusion in Healthy Subjects Cause Esophageal
Thermal Sensitivity?
Philip J. Matthews, Lowri Gwyn, Qasim Aziz
Background A proportion of gastroesophageal reflux disease sufferers have heartburn symp-
toms which may be due to esophageal hypersensitivity (EH) to acid. An experimental model
of EH has been developed in which distal esophagus acid infusion induces hypersensitivity to
electrical stimuli in the proximal (non-acid exposed) esophagus [1]due to central sensitisation.
However electrical stimulation activates all sensory afferent esophageal nerves. We chose to
test whether esophageal thermoreceptors are specifically sensitised by esophageal acid infu-
sion in the model. Aims To determine whether the distal esophageal acid infusion (DEAI)
could induce hypersensitivity to thermal stimuli (a specific receptor mediated sensation) in
the proximal esophagus and chest wall of healthy volunteers. Method 7 healthy subjects
were studied. After esophageal intubation, thermal stimuli were delivered in the proximal
esophagus using a specially designed solid state thermal stimulating catheter. Subjects
recorded their response on a modified Visual Analogue Scale. Chest wall thermal stimuli
were delivered using a somatic thermode. After baseline readings the subject were randomised
to an esophageal infusion of either 0.15 M HCL or N saline(control) which was delivered
into the distal esophagus. Readings were taken periodically for 2 hours thereafter. Results
DEAI caused significant proximal oesophageal thermosensitivity compared to control. Mean
AUC for saline was 21.6 (95% C.I. -19 to 62) compared with 364.7 for acid (95% C.I. 172
to 556 (p<0.007)). Chest wall thermosensitivity remained unchanged after acid infusion in
comparison to saline infusion. Conclusion This study shows that esophageal thermosensitivity
is increased by esophageal acid exposure and this may be relevant to the development of
esophageal hypersensitivity in susceptible individuals. We have previously demonstrated
the presence of the acid / thermosensitive receptor TRPV1 in esophageal mucosal biopsies
of normal subjects and patients with esophagitis (in whom it is increased)[2]. With the
advent of specific antagonists to TRPV1 receptors; esophageal hypersensitivity to acid might
be usefully explored using this model in future drug trials. 1. Sarkar, S., et al., Contribution
of central sensitisation to the development of non-cardiac chest pain. Lancet, 2000.
356(9236): p. 1154-9. 2. Matthews, P.J., et al., Increased capsaicin receptor TRPV1 nerve
fibres in the inflamed human oesophagus. Eur J Gastroenterol Hepatol, 2004. 16(9): p.
897-902.
W1819
Outstanding Change in Esophageal Muscle Thickness and Cross Sectional
Area Using High-Frequency Intraluminal Ultrasound 6 Months Later After
Pneumatic Dilation in Patients with Achalasia
Jeong Hwan Kim, Poong-Lyul Rhee, Yong Sung Choi, Hee Jung Son, Jae J. Kim, Jong
Chul Rhee
Background: All forms of treatment for achalasia focus on reducing the pressure gradient
across lower esophageal sphincter (LES). LES pressure can be reduced by forceful pneumatic
dilation of the gastroesophageal junction, which is considered the main procedures for

















activity of the denervated esophagus. Recently, it has been reported that an increase in
esophageal muscle thickness using a high-frequency intraluminal ultrasound (HFIUS) is an
important feature of patients with primary esophageal motility disorder such as achalasia.
We aimed to compare the clinical features, the radiological and manometric findings, and
the esophageal mean muscle thickness and cross sectional area (CSA) between pre and post
pneumatic dilation states in patients with achalasia. Methods: Fifteen patients (8 men and
7 women, mean age 39 ± 15 years) with achalasia treated by pneumatic dilation were
enrolled in this study. The assessment of the clinical features, the maximal diameter of
esophageal body on barium esophagogram, the LES resting pressure on manometry, and
the esophageal mean muscle thickness and CSA at 3 cm above LES on HFIUS was performed
before pneumatic dilation for baseline assessment. And these were repeated 6 months later
after pneumatic dilation. Results: In post pneumatic dilation state, enrolled patients exhibited
distinctly different features from pre pneumatic dilation state; an improvement of dysphagia
symptom, a recovery of weight, a reduction of maximal diameter of the esophageal body,
and a decrease of LES resting pressure. These differences between the two states were
statistically significant. Esophageal muscle thickness and CSA were observed to be signific-
antly lesser in post pneumatic dilation state than in pre pneumatic dilation state at 3 cm
above LES (mean muscle thickness (mm); pre vs. post = 2.04 ± 1.02 vs. 1.67 ± 0.54, CSA
(mm2); pre vs. post = 138 ± 44 vs. 90 ± 45, P < 0.05, respectively). Conclusions: Esophageal
muscle thickness and CSA was recoveried after pneumatic dilation as was the clinical,
radiological, and manometric findings in patients with achalasia in this study. This result
may be aided to understand the functional motor disturbance of achalasia.
W1820
Acid Induced Symptom Generation (Heartburn) May Not Be Mediated By
Esophageal Muscle Contraction
Toshihiko Tomita, Chizuko Hayashi, Yongmin Kim, Kazuhiko Nakajima, Noriyasu
Yamamoto, Takashi Sakagami, Takayuki Matsumoto, Hiroto Miwa
(Background and Aim)Heartburn and regurgitation is considered as typical symptom of acid
reflux, yet the symptom resolution is not always achieved by acid inhibition treatment,
suggesting acid itself does not cause the symptoms directly. However the mechanisms of
the symptom generation remain unknown. Accordingly we observed esophageal muscle
contraction in esophageal acid perfusion test, by which we can monitor the physiological
changes of the esophagus during heartburn symptom generation. (Subjects and Methods)
Eight healthy subjects (6 males, mean age 26+3.5yrs, ranged 23 to 34) underwent acid
perfusion test. Briefly, a double rumen gastric tube was inserted via nasal route and placed
at the middle portion of the esophagus (15cm above LES) where the acid (0.1M) was applied
in the rate of 8ml per min for 12 minutes (after two minutes application of saline). The
ultrasonographic transducer was put and placed from the other rumen at 5cm above LES,
by which the thickness of the esophageal muscle was monitored every 5 seconds and video
recorded. The esophageal muscle thickness was measured on the image analyzing system.
The intensity of the heartburn was evaluated real-timely using visual analogue scale. The
mean baseline thickness (that of first two minutes during saline perfusion) and that of 10
to 12 minutes (last two minutes) was measured both in subjects with none or mild and
moderate or severe heartburn. (Results) Of eight subjects, four had moderate to severe
heartburn while the rest of four subjects had no or mild symptoms. The relative esophageal
muscle thickness at last two minutes compared to the initial two minutes was1.14+0.25
and 0.98+0.0 (mean+SD) in the subjects with and without heartburn, respectively (p=0.231).
Contraction amplitude as well as contraction duration was not significantly altered during
acid perfusion both in the subjects with and without symptoms. (Conclusion) Our results
indicate that acid induced symptom generation (heartburn) may not be mediated by eso-
phageal muscle contraction.
W1821
The Virtual Esophagus: An Interactive Model of Esophageal Physiology,
Pathophysiology, and Simulation of Esophageal Motility Disorders
George Fantry, Marjorie McShane, Stephen Beale, Joshua Forman, John Raczek, Sergei
Nirenburg, Bruce Jarrell
Background: A computer model simulating esophageal physiology and demonstrating the
symptoms and test results of motility disorders would enhance trainee understanding of
esophageal diseases and allow rehearsal of medical decision-making prior to patient care.
Aim: To develop an interactive virtual esophagus that demonstrates automatic behavior
reflective of underlying normal and diseased physiological functions and models motility
and clinical management strategies. Methods: Knowledge engineers and subject matter
experts collaborated to elicit knowledge rich in normal esophageal physiology, pathophysiol-
ogy and clinical management. This included modeling normal esophageal concepts: anatomy,
physiology and neuromuscular function, and abnormal concepts: acid reflux, inflammation,
LES dysfunction, esophageal dysmotility and associated symptoms. The knowledge was
encoded into machine tractable language using existing techniques developed by the collabor-
ators. Computational methods were developed to reason with the encoded knowledge to
achieve a virtual esophagus that functions in a realistic manner. Results: The knowledge
and reasoning capacity successfully created an esophagus with automatic behavior capable
of generating multiple qualities: (1) Intrinsic normal organ function such as basal lower
esophageal sphincter pressure and lower esophageal sphincter relaxation and peristalsis in
response to swallowing, (2) Symptoms of esophageal diseases such as heartburn and dys-
phagia, (3) Associated diagnostic test results on barium swallow, endoscopy, manometry,
and 24 hr pH monitoring such as bird’s beak, stricture, aperistalsis, and DeMeester score,
(4) Natural disease progression such as progressive dysphagia as the esophageal lumen
narrows, (5) Disease response to various treatments such as resolution of heartburn with a
proton pump inhibitor or improvement of dysphagia with dilation of a stricture. The
accumulation of these qualities provides a functioning virtual esophagus capable of demon-
strating the normal esophagus, achalasia, gastroesophageal reflux disease (GERD), GERD
with erosive esophagitis, Barrett’s metaplasia, or adenocarcinoma. Conclusions: We have
designed the backbone of an interactive virtual esophagus that models esophageal physiology,
pathophysiology, and clinical management for common esophageal diseases. Use of the
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virtual esophagus may provide a novel and optimal teaching opportunity to allow a trainee
to query the esophagus, diagnose esophageal diseases, perform treatments, and observe the
results of treatments. This model will be further refined with addition of other esophageal
pathology and expanded to include other organs.
W1822
Vigorous Achalasia and Classic Achalasia: Two Similar But Separate Entities?
Amit Agrawal, Amine Hila, Radu Tutuian, Marcelo Vela, Donald O. Castell
BACKGROUND: Achalasia is primarily defined manometrically by an aperistaltic esophagus.
Traditionally, hypertensive LES, and incomplete lower esophageal sphincter (LES) relaxation
are considered part of the manometric definition. Vigorous achalasia is identified in a subset
of patients having distal esophageal amplitude (DEA) greater than 37 mmHg, while still
having total absence of peristalsis. Combined multichannel intraluminal impedance and
manometry (MII-EM) allows both a functional and a manometric evaluation of esophageal
motility and also identifies chronic fluid retention. AIM: To compare manometric and MII
characteristics in patients with achalasia and vigorous achalasia. METHODS: Review of 73
MII-EM tracings (38 females; mean age 53.5; range 14 - 95 years) from patients with
achalasia and 73 patients with normal motility (49 females; mean age 54; 22-82 years).
Manometric and MII characteristics were compared during 10 liquid and 10 viscous swallows.
Patients were divided into 3 groups: classic achalasia, vigorous achalasia, and normal.
RESULTS: There were 59 (81%) patients with classic achalasia and 14 (19%) patients with
vigorous achalasia. EM and MII details are shown in Tables 1 and 2 respectively. In 73
patients with normal motility, the mean baseline MII was 1955 + 229 ohms, 1985 + 232
ohms after 10 liquid swallows and 2102 + 246 ohms after 10 viscous swallows. There was
also a significant difference (p<0.05) between the baseline MII in patients with both classic
and vigorous achalasia and normals. CONCLUSION: Patients with vigorous achalasia are
likely to have a hypertensive LES, higher number of swallows with complete bolus transit
for liquid and viscous swallows, and higher impedance suggesting less fluid retention than
those with classic achalasia. Classic and vigorous achalasia are similar but have distinct
features. Combined MII-EM helps confirm the diagnosis.
Table1: Manometric data
Table 2: Impedance data
CBT = complete bolus transit; MII measured at baseline, post 10 liquid and viscous swallows.
W1823
Novel MII-pH Methods in the Evaluation of Physico-Chemical and
Spatiotemporal Characteristics and Peristaltic Clearance Mechanisms with
Reflux Events (RE) in Infants with Chronic Lung Disease of Infancy
Sudarshan R. Jadcherla, Alankar Gupta, Soledad Fernandez, Carlo Dilorenzo
BACKGROUND The role of physico-chemical properties of GER in prematurely born infants
with CLDI (oxygen need at >36 wk corrected gestation age, GA ) is not well understood.
OBJECTIVES To characterize the association between the physical (gas, mixed, liquid),
chemical (acid, minor-acid, non-acid) and spatiotemporal (height of refluxate and duration)
characteristics of RE with aerodigestive symptoms and clearance mechanisms (primary peri-
stalsis, PP and secondary peristalsis, SP). METHODS Six neonates (27±1 wk GA) with CLDI
associated with dysphagia were studied. First, esophageal manometry was performed to
determine the segmental lengths of the aerodigestive tract. Next, a 24-hr concurrent MII-
pH recording was performed following manometry. Clinical symptoms were documented
in real time. The physical and chemical nature and the extent of the refluxate were determined
for each RE. Symptoms were considered associated if they occurred during, before and after
1-min of RE. Clearance mechanism (PP, SP, and none) with each RE was recorded based
on the proximal extent of the refluxate and aboral propagation. Proportions were compared
between the RE characteristics, and symptom sensitivity index (SSI = # of RE with symptoms/
total RE * 100). RESULTS A total of 318 RE (gas 36%, mixed 19%, liquid 45%) were
analyzed. Of these, 23 % were acid pH < 4.0, 10% minor acid as pH-decrease by 1 unit,
and 67% non-acid events. Proximal extent of all RE was up to pharynx (PX, 76%), proximal
esophagus (PE, 17%), mid esophagus (ME, 7%), and distal esophagus (DE, 1%). The bolus
clearance time for mixed events was 17± 18 sec, liquids 19 ± 29 sec (P=NS). Response time
for peristaltic reflex for gas RE was 3.6 ± 5.6 sec, mixed RE 32± 18 sec, and liquid 16 ±
13 sec ( ANOVA P<0.001). 134 symptoms were noted with 318 RE; of which 20% with
gas, 28% with mixed, 52% with liquid. CONCLUSIONS The symptoms associated with RE
and the clearance mechanisms are dependent on the physical properties and proximal extent
of the refluxate. The gas and mixed RE constitute the majority of the RE with symptoms.
Response times for clearance reflex responses were dependent on the physical property of
refluxate. Occurrence of PP (esophago-deglutition response) with refluxate stimulating DE,
ME, and PE are noted.
Peristaltic clearance reflexes and SSI based on physical and spatiotemporal parameters
Chi Square and ANOVA, * P<0.05, All values in %
W1824
Syntaxin 1A Paradoxically Increases Esophageal Smooth Muscle Kv1.2
Membrane Trafficking to the Plasma Membrane
Leila Neshatian, Yuk M. Leung, Xiaodong Gao, Robert G. Tsushima, Herbert Y. Gaisano,
Nicholas E. Diamant
Background: Kv1.2 is an important delayed rectifier potassium channel in esophageal smooth
muscle (ESM) and is involved in setting the resting membrane potential. In secretory cells,
Syntaxin1A (Syn1A), a t-SNARE protein, regulates Kv2.1 current density, in part by reducing
the trafficking of these channels to the plasma membrane. During exocytosis, Syn1A
undergoes a conformational change from the ‘inactive’ closed form to an ‘activated’ open
configuration capable of binding and activating Syn1A-binding proteins to effect their actions.
Remarkably, we have found that in ESM, wild-type Syn1A paradoxically decreased Kv1.2
current density more effectively than the open-form mutant. Hypothesis: Syn1A-induced
inhibition of Kv1.2 current density is in part by inhibition of trafficking of Kv1.2 to the
ESM plasma membrane surface. Methods: Using streptavidin resin, cell-surface biotinylation
was performed on Kv1.2- expressing HEK293 cells cotransfected with Syn1A wild-type or
open-form. Results: Wild type Syn1A coexpression caused plasma membrane Kv1.2 protein
levels to increase by 72%, whereas open-form Syn1A co-expression had no effect. Total
Kv1.2 protein content in the total lysates did not change, indicating that neither Syn1A
proteins had any effect on Kv1.2 protein synthesis. Conclusion: Wild-type Syn1A paradoxic-
ally promotes Kv1.2 ESM plasma-membrane surface expression, while open-form Syn1A
has no effect. That is, wild-type Syn1A, presumably in its closed conformation, facilitates
trafficking of Kv1.2 to the ESM cell membrane despite its strong and direct inhibition of
the channel. These results indicate that reduced Kv1.2 current amplitude by wild-type Syn1A
must be due entirely to a primary and specific effect of the wild-type Syn1A protein on the
channel. These effects of Syn1A on the non-secretory ESM are opposite to those transduced
by Syn1A in secretory cells, and may indicate that Syn1A modulation of Kv1.2 current
differs depending on the functional role involved, e.g. setting resting membrane potential
vs. exocytosis.
W1825
Evidence for Extrinsic Autonomic Dysregulation in the Spastic Esophageal
Motility Disorders (SMDs)
Gregory S. Sayuk, Clinton T. Snedegar, Laura R. Haroian, Phyllis K. Stein, Robert M.
Carney, Patrick J. Lustman, Ray E. Clouse
SMDs, including diffuse esophageal spasm (DES) and nonspecific SMDs, are esophageal
motor disorders commonly detected in symptomatic subjects, but their pathogenesis is
poorly understood. Imbalance between cholinergic and non-adrenergic, non-cholinergic
intramural mechanisms is likely; whether this results from an intrinsic esophageal process
or extrinsic autonomic dysregulation is unknown. Heart rate variability (HRV) was measured
concurrently with esophageal manometric testing to determine if specific spectral patterns
could predict SMDs and support a component of extrinsic autonomic dysregulation in their
pathogenesis. Methods: Consecutive patients referred for clinical esophageal manometry
without confounding conditions or contraindications underwent HRV testing during mano-
metry. Manometric patterns were analyzed independently of HRV and categorized using an
established classification scheme. HRV, including high-frequency (HF, parasympathetic) and
low-frequency (LF, sympathetic) spectra, in addition to the LF:HF ratio, was examined in
relation to both motility pattern and individual manometric features representing the SMDs.
Results: 57 non-achalasic subjects (48±14 yr; 39 F) with either normal manometry (NORM,
n=14), hypomotility (HYPO, n=23) or SMDs (DES, n=1; nonspecific SMDs, n=19) were
evaluated. HF was reduced in SMDs compared with HYPO (184±28 vs. 422±74, p<0.01)
and in SMDs compared with NORM (184±28 vs. 430±104, p=0.01), whereas HYPO and
NORM did not differ (p=0.99). LF did not differ across groups. LF:HF ratios were increased
in SMDs compared with both NORM (8.5±1.3 vs. 3.6±0.7, p<0.01) and HYPO (8.5±1.3
vs. 4.4±0.6, p<0.01), whereas HYPO and NORM again did not differ (p=0.18). Logistic
regression analyses controlling for intergroup differences in age and sex confirmed that
decreased HF predicted the presence of an SMD (OR 2.7, 95%CI: 1.3-5.9; p=0.02) over
other manometric patterns and that an elevated LF:HF ratio portended a nearly five-fold
increased odds of SMDs over other motility patterns (OR 4.6, 95%CI: 1.4-15.6; p<0.01).
Correlations of HF and LF:HF ratio with individual parameters that collectively represent
the SMDs were nonsignificant. Conclusions: Reduced parasympathetic tone and increased
sympathetic-to-parasympathetic ratio using HRV testing predicted the presence of SMDs
over other manometric patterns. These findings support the presence of extrinsic autonomic
dysregulation in the production of the SMDs. SMDs may share a pathophysiological basis
with other conditions, e.g., irritable bowel syndrome, that demonstrate a similar HRV pattern.
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W1826
Presence of Acid Reduces the Threshold for Elicitation of Esophago-UES
Contractile Reflex and Secondary Peristalsis During Sleep But Not in Awake
State
Jasmohan Bajaj, David Knuff, Tanya Rittmann, Kulwinder Dua, Reza Shaker
Background: Earlier studies have shown the activation of esophago-upper esophageal sphinc-
ter contractile reflex (EUCR) and secondary peristalsis (2P) by minute infusion of water in
the proximal esophagus. It is not however, known whether presence of acid results in
sensitization of these reflexes. Aim: To compare the threshold volume (Tvol) for elicitation
of EUCR and 2P by proximal esophageal infusion of 0.1 N Hcl and water during awake
and stage II sleep states. Methods: Four healthy volunteers (32±4 yrs;3 M) were studied in
supine position during awake and sleep stage II using polysomnography (REMbrandt)
and electromyography (EMG) in the sleep laboratory. Esophageal manometry was assessed
concurrently by a pneumohydraulic manometry apparatus(Dentsleeve,Arndorfer Specialit-
ies)passed transnasally with a posteriorly-directed injection port below the upper esophageal
sphincter (UES). Infusion of water and 0.1 N Hcl were carried out at a rate of 2.7ml/min
until swallow, cough or elicitation of EUCR and 2P occurred.A 10 minute water washout
water was performed after each Hcl infusion. Subjects were blinded to the nature of the
infusions and a visual analog scale was used 1 minute after each injection to evaluate chest
discomfort in awake state. Tvol for EUCR and 2P elicitation were recorded. Results: All
subjects were monitored for at least 4 hours during sleep and none reported chest discomfort
during the study. EUCR and 2P were successfully elicited in all during awake state and
Stage II sleep. Acid perfusion resulted in a significant reduction in Tvol for both EUCR and
2P during stage II sleep but not the awake state (Figure/Table). Conclusion: Presence of
acid influences the elicitation of EUCR and 2P differently in awake and sleep states. While
in stage II sleep, presence of acid reduces the Tvol for triggering of EUCR and 2p, in awake
state its influence is not significant.
*significant compared to StII water; St:Stage
W1827
High Viscous Liquid Manometry Unmasks Esophageal Dysmotility in Patients
with Early Chagas’ Disease
Lucilene R. Westmore, Roberto Dantas, George Triadafilopoulos, Clovis Kuwahara, Pedro
Leite, Miriam Zebian
Introduction: Patients with early esophageal Chagas’ disease may present with dysphagia
without megaesophagus. After demonstration that changes in bolus viscosity may alter
esophageal contractility, highly viscous substances have been used during esophageal mano-
metry (EM) to unmask defects not otherwise revealed by dry and water swallows. Aims:
To evaluate the esophageal motility in symptomatic patients with early Chagas’ disease by
dry swallows and by liquids of different viscosities (water and sugar cane syrup) swallows.
Methods: Fifteen healthy volunteers (9 male, 6 female; median age: 42 years, range: 26-
60) and 10 patients with Chagas’ disease, with dysphagia but without megaesophagus (5
male, 5 female; median age: 43 years, range: 36-63), were submitted to perfusion EM. Basal
lower esophageal sphincter (LES) pressure was measured by the rapid pull-through. With
the catheter positioned with 1 lumen opening in the LES, and the others at 5, 10 and 15
cm above the LES, 10 dry swallows, 10 swallows of 5 mL of water, and 10 swallows of 5
mL of sugar cane syrup were performed. Amplitude, duration and velocity of contractions
and the LES relaxation duration were measured. Morphology, peristalsis and failed contractile
waves were also studied. Results: There was no difference (p>0.05) between patients and
controls in LES pressure and duration of contractions for dry, water as well as sugar cane
syrup swallows. Patients had shorter LES relaxation duration than controls only after dry (p=
0.0005) and sugar cane syrup (p=0.04) swallows. They also had more synchronus contractions
than controls only for dry (p=0.01) and sugar cane syrup (p=0.04) swallows. Patients had
lower amplitude of contractions only after sugar cane syrup swallows at 10 cm (p=0.05) and
5 cm above LES (p=0.04). They also had more multipeaked contractions than controls only
for sugar cane syrup swallows (p=0.0002). Patients had tendency to present higher velocity
of contractions only after sugar cane syrup swallows from 15 to 10 cm above LES (p=0.09)
as well as 10 to 5 cm above LES (p=0.08). Failed contractions were more frequent in patients
than controls for dry (p=0.003), water (p=0.02), and sugar cane syrup (p=0.05) swallows.
Conclusion: Patients with symptomatic early esophageal Chagas’ disease may exhibit eso-
phageal dysmotility, more likely following high viscous substance swallows than after water
and dry swallows. High viscous liquid manometry may be the preferred approach in patients


















Evaluation of Transit in the Transition Zone On Multichannel Intraluminal
Impedance (MII) Allows Detection of Transit Abnormalities in More Patients
with Abnormal Motility
Amine Hila, Amit Agrawal, Wojciech Blonski, Inder Mainie, Janice Freeman, Donald O.
Castell
BACKGROUND: Combined MII and esophageal manometry (MII-EM) allows both functional
and manometric evaluation of esophagus. MII-EM catheter has 4 impedance segments
(5,10,15,20cm above LES) and 5 pressure sites (at LES and 5,10,15,20cm above LES).
Manometric diagnoses are based on data provided by sites in distal 10cm of esophagus; i.e.
smooth muscle. Site at 15cm above the LES is not included as it may contain smooth and
striated muscle (transition area). Evaluation of swallows with MII is assessed for complete
or incomplete transit, defined by bolus entry at 20cm and bolus exit in 15, 10 and 5cm
segments. Does inclusion of the 15cm segment, which is in the transition zone, overly
detects abnormalities in patients with normal manometry? AIM: To assess the effect of using
impedance data from the transition zone on accuracy of MII-EM interpretation. METHODS:
200 consecutive MII-EM studies (65% females; mean age=54yrs). All patients given 10 saline
and 10 viscous swallows while recumbent. All tracings initially read defining complete transit
for each swallow based on bolus entry at 20cm and bolus exit at 15, 10 and 5cm. Then,
all tracings read a 2nd time with complete transit defined by bolus entry at 20cm and bolus
exit at 10 and 5 cm, thus excluding transition zone. Manometric and transit diagnoses from
these 2 different reading methods were compared. RESULTS: Excluding transition zone
from impedance analysis changed transit diagnosis from incomplete to complete transit in
33 patients (17%): 16 changed in liquid transit, 16 in viscous transit and 1 in both. 1st
table summarizes prevalence of manometric diagnoses in all patients (group A), and in the
33 where transit diagnosis changed (group B). In patients where transit diagnosis changes
from normal to abnormal with addition of transition zone, a higher percentage of patients
have abnormal manometric finding. In all studies, there were 3962 swallows (group C), of
which 226 swallows (group D) changed diagnosis. 2nd table summarizes prevalence of
manometric diagnoses by swallows. In swallows where transit diagnosis changes from normal
to abnormal with addition of transition zone, a higher percentage have abnormal manometry.
CONCLUSION: Using findings from the transition zone in the transit diagnosis detects
transit abnormalities in more patients with abnormal manometry than in patients with
normal manometry.
W1829
Manometric and Impedance Characteristics of Achalasia: Facts and Myths
Amit Agrawal, Amine Hila, Wojciech Blonski, Radu Tutuian, Inder Mainie, Marcelo Vela,
Donald O. Castell
BACKGROUND: Achalasia is defined manometrically by an aperistaltic esophagus. Variations
in the manometric findings occur in achalasia suggesting that all manometric features should
not be required to diagnose achalasia. Combined multichannel intraluminal impedance and
EM (MII-EM) allows both a functional and a manometric evaluation of esophageal motility
and identifies chronic fluid retention. AIM: To compare manometric and MII characteristics
in patients with achalasia. METHODS: Review of 73 MII-EM tracings (38 females; mean
age 53.5; range 14 - 95 years) from patients with achalasia were compared with 73 patients
with normal manometry (49 females; mean age 54; 22-82 years). Manometric and MII
characteristics were compared during 10 liquid and 10 viscous swallows. RESULTS: In 2/
73 (2.7%) achalasia patients, the catheter would not pass the lower esophageal sphincter
(LES). 23/71 (32%) of the achalasia patients had hypertensive LES. Mean LES pressure for
the 71 patients with achalasia was 37.9 + 4.5 mm Hg compared to 27.3 + 3.2 mm Hg
(p<0.05) in patients with normal motility. Elevated intraesophageal pressure (IEP) was noted
in 45/73 (61.6%). Mean LES pressure with elevated IEP was 41.1 + 6.1 mm Hg compared
to 32.5 + 6.1 mm Hg (p<0.05) with normal IEP. Mean LES residual pressure in this group
was 11.9 + 1.5 (p<0.05) compared to 8.5 + .6 mm Hg with normal IEP. Mean baseline MII
was 801 + 94 ohms compared (p <0.05) to 523 + 61 ohms after 10 liquid swallows and
417 + 48 ohms after 10 viscous swallows. In 73 patients with normal motility, mean baseline
MII was 1955 + 229 ohms, 1984 + 232.4 ohms after 10 liquid swallows and 2102+ 246
ohms after 10 viscous swallows. There was a significant difference (p<0.05) between the
MII (p<0.05) in patients with achalasia and normals. CONCLUSION: Most patients with
achalasia have elevated IEP, elevated LES residual pressure, normal LES pressure, and low
baseline impedance. All manometric features should not be required to diagnose achalasia.
Patients with an elevated IEP are likely to have an elevated LES pressure and LES residual
pressure. Low MII values identify chronic fluid retention and helps confirm the diagnosis.
Table 1 summarizes the manometric findings
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W1830
Esopahgeal Function Test (EFT) in the Evaluation of the Effectiveness of
Peristalsis: Viscous Vs. Liquid Swallows
Pernilla Lundgren, Gisela Ringstrom, Hasse Abrahamsson, Magnus Simren
The term ineffective peristalsis (IP) is based on videomanometry recordings, where peristaltic
waves with amplitude <30mmHg in the distal esophagus often failed to move a barium
swallow normally. In previous studies the number of swallows studied was limited by the use
of radiation. With combined manometry and intraluminal impedance (EFT) this limitation is
overcome. Moreover, recent investigations have added viscous swallows to the test of eso-
phageal function. The additional value of this in the assessment of the effectiveness of
peristalsis needs to be further evaluated. Methods: EFT was performed in 35 asymptomatic
volunteers (16 M; mean age 37 (21-63) years) and 31 patients with dysphagia without a
specific esophageal motility disorder (12 M; mean age 47 (18-71) years). Pressure sensors
were located in the lower esophageal sphincter (LES) and 20, 15, 10 and 5cm above the
LES, and impedance segments centered 20, 15, 10 and 5cm above LES. Subjects were
investigated in supine position: 20 swallows (5ml), 10 liquid (saline) and 10 viscous material.
IP was defined as contraction amplitude <30mmHg in at least one of the two most distal
recordings in the esophageal body. Results: With liquid swallows IP was found in 102/676
swallows, compared with 101/638 swallows with viscous material (NS). Incomplete bolus
transit was more prevalent with viscous than with liquid swallows (19% vs. 10%; p<0.0001).
Swallows with incomplete bolus transit had lower contraction amplitudes at all recording
sites in the esophageal body, both with viscous and liquid swallows (p<0.0001 for all
comparisons). Also the propagation velocity (onset) of the contractions waves were faster
in swallows with incomplete bolus transit, both with liquid (5.7±5.4 vs. 4.8±2.9; p=0.04)
and viscous swallows (5.7±5.3 vs. 4.5±3.5; p=0.007), whereas the LES pressure was similar.
The mean pressure in swallows with incomplete bolus transit tended to be higher at all
levels in the esophageal body with viscous vs. liquid swallows. Conclusion: The effectiveness
of peristalsis should be determined with impedance rather than with manometry alone. The
use of viscous as compared with liquid swallows increases the proportion of incomplete
bolus transit without affecting the proportion of ineffective peristalsis based on characteristics
of the pressure waves. By combining manometry and impedance additional valuable informa-
tion regarding esophageal function is obtained, and the addition of viscous material seems
to be a greater challenge for the esophagus.
W1831
An Automated Measurement and Diagnostic System for Esophageal Motility
Disorders
Hongbing Zhu, Zhijun Weng, Jiande Chen
Esophageal motility disorders are common among patients ranging from gastroesophageal
reflux diseases (GERD) to dysphagia. Measurement and diagnosis of various esophageal
motility disorders, however, require extensive knowledge and expertise. The aim of the
study was to develop a fully automated measurement and diagnostic system for esophageal
manometry. Methods: The novel automated measurement and diagnostic system was com-
posed of 1) man-machine interface modular for interactive performance of the esophageal
motility procedure. This modular automatic determines the location of each channel and
provides step-by-step guidelines for the measurement procedure. 2) automated identification
of all esophageal motility parameters, including lower esophageal sphincter (LES) pressure at
resting and relaxation during wet swallows, amplitude and propagation patterns of esophageal
contractions during wet swallows as well as profile of upper esophageal sphincter. 3)
automated diagnosis of various esophageal motility disorders. A rule-based algorithm has
been developed. Based on the esophageal motility profile and patient’s symptoms, the final
diagnosis is provided by the system including one of the followings: normal, achalasia,
hypotensive or hypertensive LES, diffuse esophageal spasma, ineffective esophageal motility
disorder and non-specific esophageal motility disorders. 4) database. All patient information
and their motility profiles are stored in a database. The database can be searched based on
patient symptoms or diseases, or procedures or any specific esophageal motility disorders.
Results: 1) The interactive navigating measurement system was tested in 10 patients and
accurate guidelines were provided regarding the detection of the LES location. Each time
when the catheter was passed through the LES, the tracings were accurately highlighted
enabling users to identify LES. It was found extremely useful in patients with hypotensive
LES pressure. 2) Automated identification of motility profiles was confirmed by simultaneous
visual examination of tracings in 20 patients. The identification accuracy was higher than
90%. 3) Comparing with experts’ diagnosis, the automated system provided 94% matched
diagnosis in 50 patients with various esophageal motility disorders. Conclusions: The newly
developed automated system provides interactive guidelines during the procedure, which
is extremely useful for new users or users with little experience. The automated analysis of
motility parameters is accurate and does rarely need users’ interventions, suggesting the
feasibility of complete automated quantitative analysis and diagnosis.
W1832
Altered Counts of Small Bowel Bacteria in Patients with Irritable Bowel
Syndrome (IBS)
Iris Posserud, Per-Ove Stotzer, Einar S. Bjornsson, Hasse Abrahamsson, Magnus Simren
Background: Small intestinal bacterial overgrowth (SIBO), diagnosed using the lactulose
hydrogen breath test (LHBT), has been proposed to be common in IBS. This has not been
confirmed using culture of jejunal aspirate with a standard definition of SIBO (≥100,000
colony forming units (cfu)/ml). However, the presence of minor alterations in small bowel
bacterial flora in IBS remains unclear. Aim: To further investigate alterations in the jejunal
bacterial flora in IBS and correlation with symptom profile, results on LHBT, and altered
small bowel motility. Method: We included 165 IBS patients (mean age 38 years, range 19-
68; 122 females) and 26 healthy controls (mean age 40 years, range 20-79; 15 females).
The bacterial flora in the small bowel was evaluated by cultures from jejunal aspirate obtained
from all subjects during an antroduodenojejunal manometry. Presence of small intestinal
dysmotility was assessed by an experienced investigator based on internationally accepted
criteria and normal values obtained in healthy volunteers at our lab. Forty-three patients
also underwent a LHBT. Patients were divided into subgroups based on ROME II criteria
resulting in 51 patients with diarrhea predominant IBS, 37 constipation predominant, and
77 with alternating diarrhea and constipation. Results: There were no significant differences
in the prevalence of ≥100,000 cfu/ml between IBS patients and healthy controls (6% vs.
4%). However, mildly elevated counts of small bowel bacteria (respiratory flora excluded)
were more common in patients compared with controls. Cultures with ≥10,000 cfu/ml
were found in 24% of patients compared with 4% in controls (p=0.02), and cultures with
≥5,000 cfu/ml were observed in 43% vs. 12% (p=0.002). Signs of small intestinal dysmotility
were found in 41% of all patients and were more frequently observed in patients with
≥50,000 cfu/ml of colonic type bacteria (p=0.02). Bacterial counts did not differ between
the different subgroups based on predominant bowel habit. LHBT was positive in 16% of
the patients, but the results from the LHBT did not reflect the results from the jejunal
cultures, since there was no difference in bacterial counts between patients with positive
and negative LHBT. Conclusion: A substantial number of IBS patients have mildly elevated
counts of small intestinal bacteria compared with controls. Signs of small intestinal dysmotility
are found in some patients but there is no association with a specific bowel habit and the
clinical relevance remains unclear. The LHBT does not seem to reflect altered counts of
bacteria in the upper part of the small bowel in IBS.
W1833
A New Non-Scintigraphic Method for Measuring Gastrointestinal Transit in
Gastroparetic Patients
Irene Sarosiek, Kenneth Koch, Kathy Selover, Braden Kuo, Henry Parkman, William
Halser, Wo M. John, Sitrin Michael, William D. Chey, Jeffrey Lackner, David D'Andrea,
Richard W. McCallum
Background: Clinical diagnosis and therapy of motility disorders could be enhanced by
better methodology for assessing Gastric Residence Time (GRT) as well as GI Total Transit
Time (TTT) providing opportunity to improve correlation of symptoms with transit tests.
The aim of the study: The aims of this study were to compare TTT and its major components
GRT and small/large bowel transit time (SLBTT), measured with a new diagnostic capsule
(SmartPill) in asymptomatic volunteers (Controls, C) and compare with corresponding values
recorded in patients with gastroparesis (GP). Methods: 60 patients with GP: 23 diabetics
(DM), 37 idiopathic (ID); 50 F & 10 M, mean age of 42 (range 19-66) mean BMI 26.3
(range 16.8-41.8) and 87 asymptomatic controls (C) 32F & 55M, mean age of 31 (range
19-57 years), with mean BMI 25.8 (range 17.9-41.1) participated in this multicenter study.
After an overnight fast all subjects swallowed a wireless GI monitoring capsule (SmartPill)
equipped with sensors that measured pressure, pH, and temperature. After initial data
gathering at the study site, subjects returned to their normal ambulatory environment with
parameters being captured by a portable recording device. Gastric Residence Time (GRT)
was defined as the time from ingestion to an abrupt sustained rise in pH to >4 and at least
a rise of 3 pH units from the baseline. GRT <30 was excluded from calculations. The TTT
was measured from the time of ingestion of the wireless capsule until a drop in temperature
or abrupt loss of signal associated with a bowel movement confirmed by patients’ diary. By
subtracting GRT from TTT, SLBTT was calculated. Mann-Whitney Rank Sum Test was used
to address statistical data. Results: In GP the median TTT was significantly longer than in
controls (48.3 h vs 26.9 h, P<0.001), as was GRT (10.2 vs 3.7 h, P<0.001) as well as SLBTT
(29.5 vs 22.2 h, P<0.001). Additionally, the TTT in patients with GP of diabetic etiology
was significantly prolonged compared to patients with ID GP (60.1 vs 32.1 h, P=0.036).
As was the SLBTT in DM GP compared to ID GP (53.1 vs 28.2 h, P=0.014). TTT, GRT,
and SLBTT were similar for both genders among gastroparetics. Conclusions: 1. Significant
differences in GRT, TTT, and SLBTT were observed between GP and controls by utilizing
non-scintigraphic capsule technology. 2. Diabetic GP patients exhibit a prolonged SLBTT
consistent with contributions from neuropathy, hyperglycemia, and other factors. 3. SmartPill
has research and diagnostic potential for assessment of GI tract function in health and disease
including physiologic and pharmacologic studies.
W1834
Modulation of µ-Opioid Agonist-Induced Inhibition of Gastrointestinal Transit
By δ-Opioid Receptor Antagonism
Beverley A. Moore, Rachel King, Sandra L. McKenney, Pamela J. Hornby, Paul R. Wade
Opioid analgesics are used to manage severe acute or chronic pain and produce analgesia
by acting as full agonists at μ opioid receptors (ORs) and as partial agonists at δORs in the CNS.
Activation of ORs in the enteric nervous system (ENS) inhibits propulsive gastrointestinal (GI)
motility, resulting in constipation - a common side effect of opioid analgesics. Selective
inhibition of δORs has been shown to accelerate colonic transit in vitro (Foxx-Orenstein
AJP 275:38,G979, 1998). We tested the hypothesis that combination of an µOR agonist
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with an δOR antagonist will ameliorate the inhibitory effects of µOR agonists on ENS-
mediated GI smooth muscle contraction in vitro and on GI transit in vivo. Methods: Segments
of guinea pig ileum were mounted in a myobath apparatus to record longitudinal contractions
evoked by electrical field stimulation (EFS), normalized as % of contraction to 1µM acetylchol-
ine (ACh). Selective µOR agonists or δOR antagonists were applied to the bath and their
effects on the EFS-evoked twitch recorded. GI transit was determined in vivo in CD-1
mice by calculating the geometric center (GC) of a FITC-labeled dextran (70kD; in 0.5%
methylcellulose) marker, 45 min after oral (p.o.) administration. Results: The effects of the
µOR agonist [D-Ala2, N-Me-Phe4, Gly5-ol] enkephalin (DAMGO) and the δOR antagonist
naltrindole (Naltr) on the ileal twitch were concentration-dependent: DAMGO inhibited (61
± 4.2%; EC50 = 1.8 nM) and Naltr enhanced (145 ± 5.5%; EC50 = 18.4 nM) ileal twitch.
Combination of the ligands at their EC50s restored the twitch to 94 ± 5% of ACh control
(P<0.001 vs DAMGO alone; N = 4). GI transit was dose-dependently (1 - 10 mg/kg, p.o.)
inhibited by morphine or loperamide (Lop; a peripherally restricted, selective µOR agonist);
GC at 10 mg/kg: morphine = 4.5 ± 0.27; Lop = 3.7 ± 0.3; vehicle treated controls = 8.3 ±
0.22; n=5, P<0.0001 vs controls). Naltr alone (3 - 100 mg/kg, s.c.) did not alter GI transit;
however, when given 1 hr prior to Lop, Naltr dose-dependently attenuated the inhibitory
effect of Lop. This effect of Naltr was also observed when given p.o. (30 mg/kg) in combination
with either Lop or morphine (3 mg/kg) 1 hr prior to measuring GI transit (GC: Lop, 4.3 ±
0.23 vs Lop+Naltr 5.7 ± 0.30, P<0.01; morphine, 5.1± 0.13 vs morphine+Naltr 7.2± 0.04,
P<0.01; N=6,). Conclusions: These data show that selective antagonism of δOR reduces the
inhibitory effects of µOR agonists on GI contractility; moreover these same actions have
now been demonstrated on propulsive motility in vivo, and suggest that δOR antagonism
may attenuate constipation associated with opioid analgesics.
W1835
Proteinase-Activated Receptor 2 Agonist Prevents Mesenteric Ischemia/
Reperfusion Injury in Rats: Partial Involvement of Substance P (SP) and
Calcitonin-Gene Related Peptide (CGRP)
Fiore Cattaruzza, Elisabetta Barocelli, Mariannina Impicciatore, Vigilio Ballabeni, Paola
Ghizzardi, Nathalie Vergnolle, Catia Sternini
Background and Aims: In an experimental model of rat intestinal ischemia/reperfusion (I/
R) we previously observed that the exogenous stimulation of Proteinase-Activated Receptor
2 by the PAR2-activating peptide (AP), SLIGRL-NH2, prevented motility and inflammatory
disorders in part through the involvement of mast cells and extrinsic visceral afferents. A
role for PAR-2 as signalling system in the neuro-immune communication in intestinal
ischemic injuries was proposed, but the mechanism remained to be clarified. Hence the aim
of the study was to investigate the effects of blockade of receptors for CGRP and SP,
neuropeptides colocalized in visceral afferents, on PAR2-AP induced gastrointestinal transit
(GIT) acceleration and anti-inflammatory response in I/R rats. Methods: Mesenteric ischemia
(1h), induced by occlusion of the superior mesenteric artery, was followed by 6 hr reperfusion
(I/R) in Wistar rats. Sham operated (SO) animals served as controls. CGRP receptor antagonist,
CGRP (8-37) (150 μg/kg, i.v. repeated 4 times every 2 hours) or, RP 67580 (1 mg/kg i.v.
followed by 0.5 mg/kg after 3 hours) antagonist of NK1, the preferred receptor for SP, was
administered in different groups of rats starting from 15 min before I/R or SO. The PAR2-
AP, SLIGRL-NH2 (3.5 mg/kg) or saline was intraduodenally administered at the beginning
of reperfusion. GIT was measured by charcoal gavage and expressed as % of the distance
travelled by the charcoal in the small bowel. Leukocytes infiltration, as index of tissue
inflammation, was evaluated by measuring myeloperoxidase activity (MPO) of jejunal tissue
and expressed as mU/mg proteins. Results: PAR2-AP stimulatory effect on GIT in I/R
(76.99±3.09% vs. saline I/R 42.69±3.63%; P<0.001) was reversed by CGRP receptor antagon-
ist (38.37±8.9% vs. 76.99±3.09%; P<0.001) and by NK1 antagonist (43.06±5.96% vs.
76.99±3.09%; P<0.001). The increase of MPO activity induced by I/R was prevented by the
administration of SLIGRL-NH2 (1.82±1.00 vs. 8.46±1.78 mU/mg). This PAR2-AP protective
effect was not altered by CGRP receptor antagonist- (1.73±0.42 vs. 1.82±1.00 mU/mg), nor
by NK1 antagonist-pretreatment (3.26±0.74 vs. 1.82±1.00 mU/mg P=NS). Conclusions:
This study supports the hypothesis that CGRP and SP mediate GIT acceleration induced
by PAR2-AP in I/R rats while the apparent anti-inflammatory effect of PAR-2 pharmacological
activation might involve different mechanisms. Supported by PRIN (MIUR2004) grants, NIH
grants DK51455, 57037 & 41301, & Crohn’s & Colitis Foundation of Canada.
W1836
Sodium Channel Mutations and Polymorphisms in People with IBS-Potential
Role for An Ion Channelopathy
G. Richard Locke, David Tester, Yuri Saito, Smita Halder, Nicholas Talley, Michael
Ackerman, Gianrico Farrugia
Background: The SCN5A-encoded NaV1.5 sodium channel is expressed in human intestinal
circular muscle layer interstitial cells of Cajal and smooth muscle cells. Mutations in SCN5A
result in distinct cardiac channelopathies. Recently, we reported that patients with mutations
in SCN5A predisposing to either SCN5A-precipitated long QT syndrome or Brugada syndrome
were more likely to report GI symptoms, especially abdominal pain. This led to the hypothesis
that a possible pathogenic mechanism for abdominal pain associated with irritable bowel
syndrome (IBS) may be defective sodium channels. Aim: To evaluate SCN5A as a candidate
gene involved in the pathogenesis of IBS. Methods: Comprehensive mutational analysis of
the 27 translated exons of SCN5A was performed on genomic DNA obtained from 47 subjects
who were seen in an academic practice for IBS and who reported chronic (more than two
years), and at least moderately severe abdominal pain. Mutation/polymorphism data derived
from over 800 healthy controls served as the reference group. Results: In the 47 cases, the
distribution of genotypes for the H558R-SCN5A common polymorphism was HH = 55%,
HR = 34% and RR = 11% as compared to 60%, 35% and 5% in controls, respectively.
Although the frequency of the R allele was numerically greater than control this was not
statistically significant (p value = 0.18). However, one patient hosted a loss-of-function,
missense mutation, G298S. This mutation has been previously published in one patient
with cardiac conduction disease and has not been observed in over 3000 reference alleles

















EKG showed normal sinus rhythm, with a QT of 376 ms and a QTc of 439 ms. Conclusions:
This pilot data provides molecular and functional evidence that perturbations in SCN5A
may confer susceptibility to the development of IBS. While further studies are necessary, the
concept of an IBS-predisposing channelopathy in the GI tract deserves ongoing exploration.
Supported by a grant from the Miles and Shirley Fiterman Foundation and NIH DK52766
W1837
Effects of Intestinal Electrical Stimulation On Postprandial Small Bowel
Motility and Transit in Fed Dogs
Huibin Qi, Jiande Chen
Background and aims: Intestinal electrical stimulation (IES) with long pulses has been
reported to inhibit small intestinal motility yet accelerate intestinal transit of continuous
perfusion. However, it is unknown whether there is a correlation between the IES-induced
alterations in motility and transit and unknown whether the effect of IES on the transit of
a bolus is different from that of continuous perfusion. The aims of this study were therefore
to investigate the effects of IES on small bowel motility and transit and their correlations
in dogs. Methods: The study was performed in 2 postprandial sessions (control and stimula-
tion) in 5 hound dogs with 1 pair of electrodes chronically implanted on the serosal surface
of the proximal jejunum and with 2 intestinal cannulas, one 20 cm from the pylorus and
the other 150 cm distance from the first cannula. IES was performed using repetitive long
pulses (pulse width: 200 ms, amplitude: 6mA, frequency: 20 pulses/min). Intestinal motility
was recorded manometrically via a water-perfused catheter inserted via the proximal intestinal
cannula. A bolus of phenol red was injected into the intestine via the proximal cannula and
collected through the distal cannula. Small bowel transit time was expressed as the time
from the phenol red injection to the complete clearance of phenol red assessed from the
distal cannula. Results: 1. In comparison with the control session, IES significantly decreased
the motility index (14.3±1.0 vs. 6.7±0.9, P<0.01). 2. IES significantly increased small bowel
transit time compared with the control (170.0±27.3 min vs. 38.0±12.1 min, P <0.001). 3.
A significant negative correlation (Pearson correlation r= -0.89, p < 0.001) was found between
motility index and small bowel transit time. Conclusion: IES with long pulses inhibits small
bowel motor activity and delays small bowel transit of a bolus. A significant negative
correlation exists between motility index and small bowel transit time during IES. It seems
IES has different effects on the transit of a bolus and that of continuous perfusion.
W1838
Excitatory Effects of Synchronized Intestinal Electrical Stimulation On Small
Intestinal Motility in Dogs
Jieyun Yin, Jiande Chen
Our previous studies showed that synchronized gastric electrical stimulation enhanced antral
contractions, accelerated gastric emptying in dogs. It has never been reported whether
synchronized electrical stimulation could improve small intestinal motility. The aim of this
study was to investigate the effects of synchronized intestinal electrical stimulation (SIES)
on small bowel motility in both fasting and fed states in dogs. Methods: Five healthy female
dogs (18-24Kg) were equipped with a duodenal cannula for the measurement of small bowel
motility using manometry. Two pairs of bipolar electrodes were implanted on the small
intestinal serosa with an interval of 25cm; the first one was 10 cm beyond the pylorus and
used for stimulation. The experiment was consisted of four sessions in each dog with a
randomized order. In the fasting state, 20min after occurrence of phase III, SIES was initiated
and maintained for 45min, small bowel motility was recorded during the entire experiment,
and no stimulation was performed in the control session. In other two sessions, dogs were
fed with solid meal at the beginning of the experiment; glucagon (0.1mg/kg) was injected
20min after feeding, SIES was initiated at the same time for 20min followed by 20 min
recovery period. The stimulus was composed of train of pulses with on-time of 0.5s, frequency
of 20Hz, pulse width of 2ms and amplitude of 4mA. Results: 1). In the fasting state, SIES
induced small intestinal contractions during phase I. The motility index was 5.2 ± 0.6 in
the control session and significantly increased to 10.3 ± 0.7 with SIES (P = 0.003). 2). In
the fed state, glucagon substantially and significantly inhibited small intestinal motility. The
motility index was 11.3 ± 0.7 after feeding and reduced to 3.4 ± 0.5 with glucagon injection
(P < 0.001). SIES significantly enhanced glucagon-induced small intestinal postprandial
hypomotility. The motility index was 3.4 ± 0.5 in the control session and increased to 6.0
± 0.3 with the presence of SIES (P = 0.03). Conclusions: Intestinal electrical stimulation
synchronized with intestinal slow waves induces intestinal contractions during phase I and
enhanced small intestinal postprandial hypomotility induced by glucagon. SIES may have
the therapeutic potential for treating small intestinal motility disorders. (Supported by a
grant from American Diabetes Association)
W1839
Large Propagating Contractions in Pig Ileum Are Myogenic and Inhibited By
Intrinsic Nerves: Evidence from Spatio-Temporal Mapping
Bridget R. Southwell, Julie E. Bines, Kathleen B. Neal, Joel C. Bornstein
Studies in mice have shown that Interstitial cells of Cajal (ICC) act as pacemaker cells
producing electrical slow waves and act as intermediates in transmission from nerves to
muscle. Previous studies also suggest that nerves inhibit and modulate slow wave activity.
This study used computer analysis of video recordings to determine the relative roles of
ICC and intrinsic nerves in producing and controlling propagating waves of contraction in
pig ileum. Methods: Computer analysis of video images of contracting intestine was used
to investigate motor patterns in intact segments of juvenile pig intestine. Ten cm segments
of ileum from 5 landrace pigs (8-wk old) were cannulated, placed in horizontal water bath,
and perfused and superfused with Krebs physiological saline. Mesenteric arteries were
cannulated and perfused to help preserve mucosal integrity. A video camera was mounted
30 cm above the segment, images recorded (10 frames/sec) onto a computer and software
used to analyse intestinal motor activity. The intestinal diameter was converted to greyscale
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then plotted against distance along the segment and elapsed time to create spatio-temporal
maps of intestinal motility. These reveal motor patterns that are difficult to detect with other
techniques. Decanoic acid and alanine were perfused lumenally, carbachol via the mesenteric
artery and tetrodotoxin (TTX) was added to the bath (serosal surface). Results: Ileum infused
with Krebs solution, decanoic acid or alanine was largely quiescent and small localised
constrictions (diameter 20mm, amplitude 2mm). Addition of 10-5M carbachol (cholinergic
agonist) via the mesenteric artery caused constriction (diameter reduced from 20 to 10mm)
followed by oscillating contractions/relaxations at the narrower diameter. Addition of 10-6
M TTX to block all neural activity produced large rhythmic oscillations (amplitude 10 mm,
frequency of 9.6 /min) that propagated orally or anally for the length of the preparation.
Carbachol added in the presence of TTX reduced the diameter, reduced the amplitude of
oscillations and eliminated orally propagating constrictions leaving only anally propagating
constrictions. Conclusions: Blocking neural activity in intact segments of pig ileum revealed
large rhythmic propagating oscillations (constrictions and relaxations) that occur at the
frequency reported for slow waves in the pig. The oscillations are suppressed by activity
within the enteric neural circuitry and hence are myogenic, presumably arising from activity
of interstitial cells of Cajal. Neural activity altered the diameter of the intestine, and the
amplitude, frequency and direction of propagating constrictions.
W1840
Serotonin Transporter Expression Is Reduced in Celiac Disease
Stephen Foley, Nicholas Coleman, Geoffrey Holmes, Eugene Campbell, Andrew Bennett,
Robin Spiller
Background We have previously shown that T-cell inflammation in celiac disease is associated
with increased mucosal 5-HT content, and enhanced 5-HT release. The sodium dependant
serotonin transporter (scl6a4) is primarily expressed in gut epithelial cells and is downregul-
ated in inflammatory states including experimental colitis, and ulcerative colitis. We examined
expression of serotonin transporter in duodenal mucosa in patients with celiac disease (Marsh
Grade III-IV) and healthy controls. Methods Duodenal (D2) biopsies were taken from 14
patients with celiac disease and 11 controls. Biopsies were snap frozen in liquid nitrogen and
stored at -80C. The biopsies were homogenised and RNA purified by Guanidine thiocyanate/
phenol extraction. RNA was reversed transcribed using Superscript II reverse transcriptase
(Invitrogen). Quantitative real time PCR was performed using Platinum Mastermix kits
(Invitrogen) and an ABI Prism 7700 PCR machine. Primers and probes for Cytokeratin 20
(CK20) (as an epithelial cell-specific control) and Serotonin transporter(SERT) were designed
using Primer3 software. The primer and probe sequences were as follows CK20 Forward
TGCTCAACTGCAAAATGCTC Reverse, CCTTGGAGATCAGCTTCCAC, Probe
CTGGCTGCTGAGGACTTCAGACTGAA SERT Forward TAGATGCAGCCGCTCAGAT
Reverse GATGACAAATCCCGAAACG Probe GGGTCCTGCTGGCTTTTGCTAGCT. 18s RNA
was measured using the eukaryotic 18s endogenous control kit (Applied Biosystems).Relative
quantification was calculated using the standard curve method. Conclusions Cytokeratin 20
expression is reduced in celiac disease, presumably reflecting the loss of epithelial cells.
Serotonin transporter expression was reduced in celiacs relative to controls when normalised
with either 18s or CK20. Thus SERT expression is lower in celiac patients than in control
even when reduction in epithelial cell number is taken into account. These findings add
further evidence that SERT is downregulated in inflammatory states. This reduction in SERT
expression may contribute to the 5-HT excess in celiac disease that plays a role in the




Impaired Intestinal Gas Clearance During Marked Hyperglycemia in Patients
with Functional Abdominal Bloating
Hermann Harder, Ana C. Hernando-Harder, Frank Riddinger, Heinz-Juergen Krammer,
Manfred V. Singer
BACKGROUND: We have previously demonstrated an acceleration of intestinal gas clearance
in healthy by acute fasting hyperglycaemia (Digestion 2005 Jun 2;71(3):179-186) and this
physiological mechanism may fail in patients with functional abdominal bloating and disten-
sion. METHODS: In 14 healthy subjects and 14 patients with functional abdominal bloating
we compared, by paired studies, effects of acute fasting hyperglycemia during intravenous
glucose infusion (hyperglycemic clamp; ~12mmol/l) and euglycemia during intravenous
saline infusion (control studies; 2 ml/min) on intestinal gas dynamics and tolerance. Gas
was infused into the jejunum (12 ml/min) for 120 minutes while rectal gas evacuation was
continuously measured; perception and abdominal girth changes were separately evaluated.
RESULTS: In healthy, rectal gas expulsion after 1 hour jejunal gas infusion was significantly
accelerated during acute fasting hyperglycemia. No relevant change in abdominal perception
or of abdominal perimeter was observed. In contrast, acute hyperglycemia failed to increase
1 hour gas expulsion and significant gas retention developed during hyperglycemia and
euglycemia, being maintained until the end of the 120-minute study period. Gas retention
was accompanied by an increase in abdominal perception and perimeter (Table 1). CONCLU-
SION: In patients with abdominal bloating, retention of intestinal gas and missing acceleration
of intestinal gas clearance by acute hyperglycemia contribute to abdominal complaints.
Table 1: 1-hour intestinal gas retention, abdominal perception and girth increment during
jejunal gas infusion (12 ml/min) and hyperglycemia (~12mmol/l) or normoglycemia (control
studies) in 14 healthy subjects and 14 patients with functional abdominal bloating (* p<
0.05 vs. control; ** p< 0.05 vs. healthy).
W1842
Alterations of Neuropeptid Expression in Human Gut Myenteric Neurons
During Sepsis
Petra Jacob, Jutta Jahn, Udo Nagele, Joerg Hennenlotter, Arnulf Stenzl, Alfred
Konigsrainer, Jorg Glatzle
Background: It is well recognized that gastrointestinal motility is significantly reduced during
sepsis. However the pathomechanism is poorly understood. We therefore investigated the
expression of pro- and anti-kinetic neuropeptides in the neurons of the myenteric plexus
during sepsis in human gut tissue. Aims: To investigate the expression of SP and VIP in
human small intestinal myenteric plexus neurons during sepsis. Methods: Tissue samples
of human ileum were gathered from either healthy patients undergoing ileum conduit
operation or patients with severe peritonitis. In fixed, whole mount sections of ileum
immunohistochemistry for myeloperoxidase (MPO), and the neuropeptides substance-P (SP)
and vasoactive intestinal peptide (VIP) was performed using commercial antibodies (Dianova,
Biotrend and Fitzgerald). To determine the inflammation of the gut, MPO positive cells
were counted in intestinal muscularis whole-mounts. SP and VIP immunoreactivity was
analyzed in myenteric plexus of whole mount sections, using the Leica Quantimed system
at a magnification of 20x. A threshold for the immunostaining of either neuropeptide was
set in contrast to the background staining. The area of the immunostaining within a myenteric
plexus was analyzed in relation to the total area of the plexus. In the following immunoreactiv-
ity is expressed as a percentage independently of the size or shape of a myenteric plexus.
Results: During sepsis inflammatory MPO positive cells were significantly increased it the
intestinal musculature compared to healthy control tissue (MPO positive cells per optical
section, control vs. sepsis: 18±6.5 vs. 66±23; p<0.01). Further the immunoreactivity for SP
was significantly reduced by approximately 80% in myenteric plexus neurons during sepsis
(SP immunoreactivity, control vs. sepsis: 32.3±5.8% vs. 6.5±1.4%; p<0.05). In contrast the
immunoreactivity for VIP was significantly increased by more than 2-fold in myenteric
plexus neurons during sepsis (VIP immunoreactivity, control vs. sepsis: 5.1±1% vs.
11.1±0.8%; p<0.05). Conclusions: We have shown in human small intestinal tissue that
under control conditions about 30% of myenteric plexus nerve fibers are immunoreactive
for SP, known as a pro-kinetic neuropeptide and only 5% of the fibers express VIP, known
to inhibit small intestinal motility. During sepsis the neuropeptide expression changes
dramatically; only about 7% of the fibers express SP and 11% of the fibers express the anti-
kinetic neuropeptide VIP; this may contribute to the hypomotility during sepsis. Supported
by DFG GL 311/3-1.
W1843
Use of High Resolution Manometry to Characterize the Human PYLORIC
Sphincter
Joshua Desipio, Annapurna Korimilli, Henry P. Parkman, Joel E. Richter, Robert S. Fisher,
Benjamin Krevsky, Frank K. Friedenberg
Background: Measurement of pyloric pressure has been elusive due to difficulty in securing
manometric assemblies across the channel for prolonged periods. There are inherent limita-
tions to established techniques using either station pull through or sleeve devices. Our
purpose was to demonstrate the feasibility of prolonged pyloric measurement using a solid
state catheter system. Methods: 5 healthy subjects (3 male, age 24-40) were recruited.
A catheter (4.2 mm OD) with 36 circumferential manometric leads spaced 1 cm apart
(ManosScan360,Sierra Scientific)was placed transnasally and advanced to the duodenum.
Endoscopic and fluoroscopic confirmation of position was performed. After 30 min recovery,
subjects underwent 180 min of recording followed by 250 cc of Ensure® and another 60
min of recording. The catheter was thermally calibrated upon removal. Recordings were
analyzed using Sierra’s ManoView Analysis software after zeroing to atmospheric pressure.
The pylorus was identified using all of the following criteria: 1.Fluoroscopic position 2.Pres-
sure wave form spatially located between antral and small bowel pressure tracings during
Phase III MMC 3.Manometric morphology representing a hybrid of antral and duodenal
morphology 4.Persistence as a high pressure zone throughout study as identified using the
color contour feature of ManoView. Results: The catheter’s distal sensor was placed a mean
of 9.4±2.1 cm beyond the pylorus (range 6.0 - 13.0). Mean pyloric axial length was 2.5±0.4
cm (2.2 to 3.0). Table 1 shows data for resting pressures in the fasting and fed states
during Phase I. Mean pyloric pressure increased in the fed state (12.5±8.4 to 19.8±7.7;P=
0.043,Wilcoxon ranks). In 3 subjects complete pyloric relaxation was observed during antral
contractile events of Phase III MMC’s. Conclusion: With high-resolution manometry we
were able to identify and record pyloric pressures. We found remarkable consistency in
pyloric channel axial length. Resting pyloric pressure was consistently increased relative to
gastric and duodenal pressures, and pressures within all three regions increased after a liquid
nutrient meal. Pyloric relaxation during antral contractile events of Phase III MMC’s was
easily identified.
Table 1. Phase I MMC Pressure Data
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W1844
Smartpill As a Novel Non-Scintigraphic, Ambulatory Method for Assessing GI
Transit: Results in Normal Subjects
Irene Sarosiek, Richard W. McCallum, Michael Sitrin, John Wo, Henry Parkman, Braden
Kuo, William Hasler, William D. Chey, Judy Hooker, Beverly Landrigan, Kenneth Koch
Background: Although the clinical tests for gastric residence time (GRT) have been evolving,
estimation of the small/large bowel transit time (SLBTT) and gastrointestinal total transit
time (TTT) poses more of a challenge for imaging technology. The aim of the study: To
evaluate a new methodology for assessing the GRT, SLBTT, and TTT based on a diagnostic
capsule (SmartPill) in asymptomatic volunteers. Methods: Eighty seven asymptomatic sub-
jects (32F & 55M), mean age of 31 (range 19-57 years); mean BMI of 25.8 (range 17.9-
41.1); after an overnight fast swallowed a wireless GI monitoring capsule (SmartPill ACT-
I) equipped with sensors that measured pressure, pH, and temperature. After initial data
gathering at the study site asymptomatic subjects returned to their usual daily environment,
with parameters being captured by a portable recording device. Gastric residence time (GRT)
was defined as the time from ingestion to a sudden rise in pH to >4 of at least 3 pH units
from the baseline. GRT <30 min was excluded from calculations. The TTT was measured
from the time of ingestion of the wireless capsule until there was a drop in temperature or
abrupt loss of signal associated with a bowel movement confirmed by patients’ diary. By
subtracting GRT from TTT we calculated SLBTT. T-test compared TTT female vs males;
Mann-Whitney Rank Sum Test calculated GRT and SLBTT in regard to gender and Pearson
PMC test addressed correlations between BMI and TTT. Data are presented as mean ±1SD
or median. Results: All normal subjects had a mean GRT of 4.67 ±4.47 hours, mean SLBTT
of 25.1 ±14.1 hours and mean TTT of 29.4 ±14.3 hours. Mean TTT among females was
longer 34.8 ±17.7 hours, compared to males 26.3 ±11.0 hours (P=0.020). Median GRT for
females and males was similar, 3.8 vs 3.67 hours. SLBTT of 25.3 hours in females was
prolonged compared to 21.4 hours in males (P=0.05). There were correlations between BMI
and TTT (r=-0.323; p=0.0086), BMI and SLBTT (r=-0.26; p=0.035), but not for BMI and
GRT (r=-0.092; p=0.42). Conclusions: 1. The SmartPill capsule represents a novel, non-
scintigraphic advance for assessing not only gastric residence, but also small bowel and
colon transit times. 2. In normal subjects small/large bowel transit time was longer in females
than males. 3. Longer small/large bowel transit time correlates with higher BMI in both
genders. 4. This technology has potential for clinical and research applications in neuromus-
cular gut disorders.
W1845
Diagnosis of Intestinal Motor Abnormalities By Endoluminal Image and
Displacement Analysis: A Novel Approach
Carolina Malagelada, Fosca de Lorio, Fernando Azpiroz, Panagiota Spyridonos, Petia
Radeva, Juan R. Malagelada
Gold standard diagnosis of intestinal motor disorders is based on intestinal manometry and
full thickness intestinal histopathology. Our aim was to apply a non-invasive diagnostic
method to the evaluation of these patients, based on an original technological approach.
METHODS. In 11 patients with small bowel dysmotility diagnosed by manometric criteria
(n = 10) and / or abnormal full thickness biopsy ( n = 5) and 14 healthy subjects, the
Pillcam capsule (Given Imaging) was administered. When the capsule reached the jejunum,
a test meal ( Ensure HN, 300 ml, 1 kcal/ml) was ingested. Endoluminal images of the gut
were analysed using a semisupervised computer program. Contractions were defined as
partial or total luminal occlusion. Intercontractile phenomena included tunnel pattern,
defined as static, large blob area by La Placian filtering, and secretory component defined
by color histogram analysis based on self organizing maps using a support vector machine.
The program also analyses and correlates data on displacement (velocity) of the capsule
within the abdomen. RESULTS. Endoluminal image and displacement analysis identified
several abnormalities in patients as compared to healthy subjects. Patients exhibited: 1)
Reduced contractility (1.7±4 contractions/ min vs 4.0±0.2 in health; p<0.01); 2) Slower
velocity (16% lower displacement over time than healthy subjects; p<0.05), whereas total
displacement covered by the capsule was similar; 3) Frequent endoluminal images of static
tunnel reflecting quiescence (17±5 % of the recording time vs 5±2 % in health; p <0.05);
4) More frequent secretory component (44±10% of the time vs 18±3% in health; p<0.05);
5) Impaired postprandial response with blunted postprandial increment in contractility and
propulsion, as opposed to healthy subjects. Based on the above criteria, only 2/14 healthy
subjects exhibited one parameter out of the normal range, while all patients exhibited one
or more abnormalities (mean 2.2). CONCLUSION. Endoluminal image and displacement
analysis identifies abnormal parameters of motor function, establishing an objective, non-
invasive, positive diagnosis in patients with small bowel motility disorders. (Supported in


















The Prevalence of Small Bacterial Overgrowth in Type 1 Diabetic Patients
Veronica Ojetti, Dario Pitocco, Emidio Scarpellini, Franco Scaldaferri, Alessio Migneco,
Francesco Zaccardi, Giovanni Gasbarrini, Giovanni Ghirlanda, Antonio Gasbarrini
Objective: Gastrointestinal motility disorders are often present in diabetic patients (pts).
Impaired intestinal motility is often followed by small-bowel bacterial overgrowth (SBBO),
but only few studies evaluated the relationship between autonomic neuropathy, impaired
intestinal motility and SBBO in diabetic pts. Intestinal motility dysfunction in diabetes has
been attributed to autonomic neuropathy even though the pathophysiological mechanisms
are not completely defined. Autonomic neuropathy in diabetic pts is normally evaluated
through cardiovascular autonomic tests (score< 2). Aim of our study was to compare the
prevalence of small-intestine bacterial overgrowth and oro-cecal transit time between type
1 diabetic pts showing autonomic cardiovascular dysfunction and type 1 diabetic pts without
autonomic dysfunction. None of these pts had previously known diabetes-related gastrointes-
tinal disorders. Methods: 25 pts (13males,12females; mean age 44.2+/-7 duration of diabetes
22.3 ± 1.3 years, HbA1c 7.06 ± 0.3%) affected by IDDM with normal cardiovascular
autonomic test (group A)and 25 IDDM pts matched for sex and age, with abnormal cardiovas-
cular autonomic test (group B) were submitted to H2-lactulose breath test. Exclusion criteria
were gastric or pancreatic surgery, celiac disease, inflammatory bowel disease, lactose intoler-
ance, scleroderma, hypothyroidism. Pts took only insulin, but no other drugs. They did not
use laxatives or antibiotics eight weeks before the test. Results: 2 out of 25 (8%) showed
bacterial overgrowth among group A pts, while 11 out of 25 (44%) showed bacterial
overgrowth among group B pts (p< 0.01). 16 of 25 (64%) pts of group A and 19/25 (76%)
pts of group B showed delayed transit time. Conclusions: All diabetic pts showed a high
prevalence of delayed transit time, but only pts with altered cardiovascular autonomic tests
showed high prevalence of SBBO. This is probably due to the fact that delayed transit time
may be considered a risk factor for the development of secondary SBBO. Our study shows
a significant association between SBBO and autonomic neuropathy diagnosed by pathological
cardiovascular reflex tests, probably because these pts suffer from a more severe degree of
intestinal motility disturbance.
W1847
Voltage-Dependent Changes in Cholinergic Component of Nerve-Stimulated
Contractions in Diabetic Guinea Pigs
Kathy J. Lepard, Joseph Cellini, Ryan Pommier
Diabetes mellitus can result in neuropathy of autonomic neurons, including enteric neurons,
resulting in abnormal gut motility. These studies investigated contractions due to pharmacol-
ogic activation of muscarinic and tachykinin receptors and nerve-stimulated neurotransmitter
release. Contractions were recorded using whole ileal strips from control guinea pigs and
animals made diabetic by streptozotocin. Drugs were added to the tissue bath or nerves
were stimulated to release endogenous substances. (*p<0.05). Activation of muscarinic
receptors by an agonist (bethanechol, 1-1000 μM) or by inhibiting acetylcholine (Ach)
breakdown (neostigmine, 0.05-1.0 μM) produced stronger contractions in diabetic tissues
[Bethanechol (g contraction, n=40): 1 μM: Control, 0.46±0.07; Diabetic, 0.86±0.1*; 10 μM:
Control, 1.30±.0.07; Diabetic, 1.57±0.09*] [Neostigmine (% increase): 0.3 μM (n=16):
Control, 69±7%; Diabetic, 119±16%*]. Substance P (1-1000 nM)-induced maximal contrac-
tions were increased in ileum from diabetic animals at the lowest dose only [g contraction
(n=16-24): 1 nM: Control, 0.76±0.04; Diabetic, 0.96±0.09*]. In contrast, electrical field-
stimulated contractions (6V) were decreased in diabetic tissues [g contraction (n=60): Control,
2.11±0.04; Diabetic, 1.84±0.07*]. At 6V, contractions were more noncholinergic as peak
amplitudes were reduced only 29±5% (diabetic, n=21), as compared to 42±4% (control,
n=21, p=0.06), by the M3 receptor antagonist 4-DAMP (1 μM). For 6V, the concentration
of Ach in the tissue bath was similar (nM Ach/100 μl/mg tissue wt: Control, 0.33±0.06;
Diabetic, 0.42±0.08). At 4V, contractions were similar in amplitude [g contraction (n=40):
Control, 1.69±0.05; Diabetic, 1.64±0.08], but were more cholinergic in diabetic tissues.
Peak amplitude was reduced 63±8%* (diabetic, n=21) and 39±7% (control, n=21) by 4-
DAMP (1 μM). Again Ach was not different (nM Ach/100 μl/mg tissue wt: Control 0.44±0.07;
Diabetic, 0.60±0.13). Even though Ach remained the same, in diabetic tissues contractions
were more cholinergic at 4V (63±8%) as compared to 6V (29±5%). The role of substance
P in mediating nerve-stimulated, noncholinergic contractions was investigated using CP-
96,345, a neurokinin receptor antagonist. CP-96,345 (30 μM) equally reduced the peak
amplitude of nerve-stimulated contractions [% decrease (n=24): 4V: Control, 26±7%; Dia-
betic, 40±8%; 6V: Control, 38±5%; Diabetic, 48±6%]. In diabetic, but not control, tissues,
the proportion of the total contraction due to Ach varied depending on the voltage. Substance
P may mediate the 4-DAMP-resistant portion of the total contraction. Supported by College
of Health Sciences and NS047106.
W1848
Electrogastrography Differentiates Enteric Neuropathy from Myopathy in
Adults with Severe Motility Disorders of the Gut
Shahab Abid, Greger Lindberg
Chronic intestinal pseudo-obstruction, enteric dysmotility and slow transit constipation are
severe motility disorders of the gut that usually are associated with an underlying enteric
neuropathy or myopahty. Electrogastrography is a non-invasive technique that records gastric
myoelectric activity. Aim of the study. To determine whether EGG can differentiate enteric
neuropathy from myopathy as the primary pathology in patients with severe motility disorders
of the gut. Material and methods. This is a retrospective analysis of patients with various
motility disorders of the gut that underwent full thickness small bowel biopsy. A single
bipolar channel measured the EGG. The ability of EGG to differentiate between neuropathy
and myopahty was tested by comparing EGG parameters between the groups. EGG para-
meters analysed were; (i) Percentage of time with a dominant frequency (DF) in normogastric
(2-4 cpm), tachygastric (4-10 cpm) and bradygastric (0.5 - 2 cpm) frequency bands, (ii)
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EGG power attributed to the three frequency bands (normogastria, tachygastria and bradygas-
tria), (iii) the ratio of postprandial to fasting power of the DF, (iv) the overall DF in fasting
and postprandial periods, (v) variability of the dominant frequency (DFIC) for the fasting
and postprandial periods, and (vi) variability of the dominant power (DPIC) in the fasting
period and postprandial periods. Results. A total of 38 patients, 35 (92%) females, mean
age 42±13 years, were analysed. Twenty patients had enteric dysmotility (19 with neuropathy
and 1 with myopathy), 12 had slow transit constipation (10 with neuropathy and 2 with
myopathy), and 6 had chronic intestinal pseudo-obstruction (3 with neuropathy and 3 with
myopathy). Patients with myopathy showed higher percentages of fasting time with DF in
bradygastric and tachygastric frequency bands and a higher postprandial DF (Table) than did
patients with neuropathic motility disorders. Conclusions. Patients with visceral myopathy
exhibited more arrythmia during fasting and a higher DF following the test meal and this
indicates that myopathies are associated with more electrical disturbances than neuropathies.
EGG may be considered for differentiating between these two disease entities.
Comparison of EGG parameters in visceral neuropathy and myopathy
DF = dominant frequency; † = median and range
W1849
Effects of Itopride Hydrochloride On Ileal and Colonic Motility of Guinea Pig
in Vitro
Hyojin Park, Lim Jung Hyun, Young Gyun Kim
Backgrounds: Itopride has antiacetylcholinesterase activity as well as dopamine D2 receptor
antagonist activity and is used for the treatment of functional dyspepsia. However, there
are limited data showing the stimulatory action on small bowel and colonic motility. Aim:
Therefore, we investigated the effects of itopride on ileal peristalsis and colonic trnasit in
the guinea pig. Methods: A specially designed peristaltic bath was used to investigate the
effect of itopride on peristaltic waves induced by intraluminal perfusion. The mechanical
activity of the circular muscle was measured with a clip attached, via the three sites of
serosal surface, to the underlying circular muscle of ileum in the peristaltic chamber. For
the measurement of colonic transit time study, artificial feces were inserted into the oral
side of lumen, and moved toward the anal side by intraluminal perfusion via a peristaltic
pump. Total 10 CM was observed and the time taken for moving about each 2 CM was
measured. Results: Itopride (10-9~10-7M) increased the amplitude of contraction and area
under curve at anal side, and it increased the peristaltic velocity in a concentration dependent
manner. Itopride also shortened the transit time of colon. Neostigmine significantly decreased
the colonic transit time than control. Dopamine decreased the peristaltic velocity of ileum,
but dopamine plus itopride significantly increased the velocity. Dopamine increased the
colonic transit time than control, and dopamine plus itopride significantly decreased the
colonic transit time. Conclusions: We concluded that itopride exerted prokinetic effect on
the ileum and colon of guinea pig by both dopamine receptor antagonistic activity and anti-
acetyl cholinesterase activity. We suggest the potential use of itopride for functional bowel
disorders, such as constipation or postoperative ileus, in human.
W1850
What Is the Relevance of Small Intestinal Motor Abnormalities in Patients
with Irritable Bowel Syndrome (IBS)?
Magnus Simren, Amanda Ersryd, Pia Agerforz, Gisela Ringstrom, Iris Posserud, Hans
Strid, Hasse Abrahamsson
Background: Altered gastrointestinal motility is considered to be important in IBS, but its
relevance for specific symptoms remains unclear. Some studies have proposed a link between
small bowel motor abnormalities and symptoms (Kellow et al Gastroenterology 1987),
whereas others have failed to confirm these findings (Gorard et al Gut 1994). However, the
majority of previous studies have been performed in small groups of patients, potentially
limiting their usefulness. Methods: We included 95 patients with IBS according to the
Rome II criteria (68 females; mean age 36 (19-68) years). They underwent a stationary
antroduodenojejunal manometry with fasting recording for 3 hours and recording for 1
additional hour after intake of a standard 500kcal meal. The presence of dysmotility was
assessed by an experienced investigator (blinded to patient characteristics) based on interna-
tionally accepted criteria and normal values obtained in healthy control subjects at our lab.
All patients completed the Gastrointestinal Symptom Rating Scale (GSRS) to assess severity of
GI symptoms and the Hospital Anxiety and Depression scale (HAD) to evaluate psychological
symptom severity. Results: Small intestinal dysmotility was observed in 53% of the subjects,
with moderate to severe alterations in 16%, the rest having mild abnormalities. The most
common abnormalities found were isolated bursts (24%), postprandial discrete clustered
contractions (DCCs) lasting more than 30 min (13%) and frequent long clusters outside the
normal range in healthy controls (19%). Less commonly seen abnormalities were abnormal
appearance or propagation pattern of phase III (7%), generalized hypocontractility (ampli-
tude<20mmHg) (3%) and late postprandial phase III-like activity (2%). The GI and psycholo-
gical symptom severity assessed with GSRS and HAD did not differ between IBS patients
with or without small intestinal dysmotility. The presence of small intestinal dysmotility
was similar in IBS subgroups based on the predominant bowel pattern. DCCs in the fasting
state was common (32%), but not regarded as abnormal if it was the only alteration
demonstrated. Patients with DCCs had more severe abdominal pain (4.0±1.1 vs. 3.3± 1.0;
p=0.01) and satiety (3.0±1.5 vs. 2.2±1.4; p=0.05) as compared with patients without DCCs.
Conclusion: Small intestinal dysmotility of mild to moderate severity is commonly seen in
patients with irritable bowel syndrome. However, its direct relevance for the symptoms in
these patients remains questionable. Discrete clustered contractions may have some relevance
for pain in IBS.
W1851
Effect of Tegaserod On Antroduodenal and Jejunal Motility
Issam Nasr, Ashok Attaluri, Robert Summers, Satish Rao, Syed Hashmi
BACKGROUND & AIM: Tegaserod, a 5-HT4 agonist, has been shown to accelerate gastric
and small bowel transit in healthy males. However, there is little information on the effects
of Tegaserod on antral and small bowel activity in humans. In an open- labeled study, we
investigated the effects of Tegaserod on antral, duodenal and jejunal motor activity in subjects
with suspected upper GI dysmotility. METHODS: 24 patients (M/F = 4/20; mean age =
37) with symptoms of upper gut dysmotility underwent prolonged Antro-Duodeno-Jejunal
manometry by placement of a 6 sensor solid state probe, with 2 sensors located in each
segment. 18 hrs after probe placement, in the fasted state, baseline motor activity was
recorded for 30 min. Subsequently, 12 mg of Tegaserod was administered orally and motility
recordings were continued for 3 hours. The Area Under the Curve (AUC) of pressure waves
was calculated as an index of overall motility. RESULTS: When compared to the baseline
period, Tegaserod significantly (p<0.05) increased pressure wave activity in the antrum,
duodenum and jejunum (table). Following Tegaserod administration, a ‘fed- response’ like
pattern was seen, with intermittent, phase II- like waves at 2-3 cycles/min in the antrum
and 10-14 cycles/min in the small bowel. The highest activity (p<0.05) occurred in the
jejunum and in the 3rd hour (p<0.05, table). Post drug, phase III MMCs were seen in 10
patients (41%). During the study, 6 patients reported nausea (27%). Prior to the procedure,
patients reported the following symptoms on a questionnaire: fullness (91%), bloating (91%),
nausea (79%), abdominal pain (79%), vomiting (70%), diarrhea (63%), indigestion (58%)
and weight loss≥10 lbs (62%). CONCLUSIONS: Tegaserod induces a gradual but sustained
increase in upper gut motility, starting within 60 minutes. This effect is more pronounced
in the jejunum than the antrum. These findings suggest that Tegaserod has a prokinetic
effect in the upper gut, is well tolerated and may be useful in the treatment of patients with
upper gut dysmotility. Supported in part by NIH R01 DK5700-03.
W1852
In Search for New Parameters of Intestinal Motor Activity in Humans
Fosca de Lorio, Carolina Malagelada, Fernando Azpiroz, Fernando Vilarino, Jordi Vitria,
Anna Accarino, Juan R. Malagelada
Current evaluation of intestinal motility relays on manometric detection of occlusive contrac-
tions, but these phasic events account only for a minor fraction of recording time, and
quiescence is assumed by exclusion. Our aim was to explore the potential use of other
parameters, related to intercontractile phenomena, and hence, manometrically silent events.
METHODS. Twenty six healthy subjects were studied modelling two experimental conditions:
prokinetic stimulation was induced by ingestion of a meal ( Ensure HN, 300 ml, 1 kcal/
ml; n = 13) and motor inhibition was induced by glucagon administration (4.8 μg/kg bolus
plus 9.6 μg/kg h infusion for 1 h; n = 5). Pos-treatment events were compared to basal
conditions (fasting; n = 8). Intestinal motor activity was evaluated through analysis of images
emitted by the Pillcam capsule (Given Imaging) and recorded by external detectors fixed
to the abdominal wall. Endoluminal images of the gut were analysed using a semisupervised
computer program. Contractions were defined as partial or total luminal occlusion. Intercon-
tractile phenomena included tunnel pattern, defined as static, large blob area by La Placian
filtering, and secretory component defined by color histogram analysis based on self organiz-
ing maps using a support vector machine. The program also correlates data on displacement
(propulsion) of the capsule within the abdomen. RESULTS. The meal stimulus increased
the number of contractions (5.1±0.4 contraction/min), while motor inhibition suppressed
contractile activity (0 contractions/ min) as compared to basal conditions (2.5±0.5 contrac-
tions/min; p<0.05 for both). Key parameters reflecting motor activity were also significantly
affected by the experimental manipulation: 1) Propulsion of the capsule increased by 118%
during prokinetic stimulation, and decreased by 73% during inhibition. 2) During motor
inhibition the percentage of time when the capsule was completely still was much longer
than during basal conditions (65±6 % of the time vs 6 ±2 %, respectively; p <0.05). 3)
Conversely, prokinetic stimulation reduced the time during which the gut presented a static
tunnel appearance (3±1% of the time vs 14±8 % during basal conditions), and the this was
not due to reduced visibility by intraluminal contents (secretion), which were only detected
during 7±2% of the time (vs 23±7 % during basal conditions; p <0.05). CONCLUSION.
Intestinal motility can be non-invasively evaluated by endoluminal image computer analysis,
that quantifies parameters of the dynamic and static components that determine gut motor
function. (Supported in part by a Research Grant from Given Imaging Ltd).
W1853
Bran-Induced Small Bowel Secretion: Assessment By Novel Non-Invasive MRI
Technique
Luca Marciani, John J. Totman, Caroline L. Hoad, Steve Evans, Amisha Mistry, Penny A.
Gowland, Robin C. Spiller
Background: Bloating, abdominal distension and pain are frequent symptoms in Irritable
Bowel Syndrome (IBS) which can often be aggravated by bran, but the underlying mechanisms
are currently unknown. We have previously shown using scintigraphy that both bran and
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plastic pellets accelerated small bowel transit. However it was not feasible to use the then
available perfusion techniques to demonstrate the hypothesised increase in small bowel
secretions. Recent developments in magnetic resonance imaging (MRI) allow high resolution,
non-invasive, monitoring of small bowel water content. Aims: To test the hypothesis that
bran acts by stimulating gastrointestinal secretion using MRI. Methods: 9 healthy volunteers
attended on 2 separate days, having fasted overnight. They ate a standard 331 kcal rice
pudding with or without added 15 g of coarse wheat bran. Serial MRI imaging was performed
at 45 min intervals for 8 hours. A pasta and dessert meal (1007 kcal) with 250 ml water
was consumed at t=7 hours. The volume of fluid in the small bowel at each time point after
the meal was calculated by integrating all image pixels containing water signal above a given
threshold. Results: (mean±SEM) Bran increased the small bowel water content which was
significantly higher at time t=225 min after the bran meal (202±48 ml) than after the control
meal (135±54 ml), n=9, paired Student’s p<0.05. The figure below shows 5 contiguous
coronal slices acquired across the abdomen of a volunteer at time t=225 min for both meals.
The images were thresholded to blank out all pixels with intensity below water. Conclusion:
We have shown for the first time that bran markedly increases small intestinal water content
probably by stimulating intestinal secretion.
W1854
Small Bowel Motility and Quality of Life in Patients with Severe Irritable
Bowel Syndrome Compared with Chronic Intestinal Pseudo-Obstruction
Jutta Keller, Kai Kobarg, Christiane Fibbe, Peter Layer
Background: Intrinsic neuropathies disturbing small bowel motility have not only been
demonstrated in chronic intestinal pseudo-obstruction (CIPO) but also in severe irritable
bowel syndrom (IBS). Moreover, both diseases are known to markedly impair quality of life
(QoL). However, neither small bowel motility nor QoL of patients with severe IBS or
CIPO have been compared directly, so far. Methods: Small bowel motility, gastrointestinal
symptoms and QoL were prospectively evaluated in 12 healthy subjects and 54 patients
with severe abdominal symptoms using manometry and standardised questionnaires (SF-
36 for QoL). Eight-channel antro-duodeno-jejunal manometry was performed using a water-
perfused system for 3 to 4 h during fasting and for 2 h following a 450 kcal meal. Manometry
was classified as pathological if at least two parameters (motility index (MI), phase III-
characteristics, preterm postprandial phase III, number of clusters, bursts and giant contrac-
tions) were found to be abnormal. Nine patients were classified as having severe IBS (constipa-
tion-predominant in 7 subjects) and 6 as having CIPO without taking manometric findings
into account. Data from patients with other diagnoses (e.g. slow transit constipation, func-
tional dyspepsia, mechanical subocclusion and known neurological diseases including known
extrinsic neuropathies) were not analysed in this study. Results: Overall, IBS patients tended
to have a lower duodenal MI than healthy subjects (p=0.04), but, compared with IBS,
duodenal MI was even more decreased in CIPO (p=0.02). Absence of phase III during up
to 4 h of fasting or pathological propagation was less frequent in IBS than CIPO. According
to manometric criteria, 5 CIPO patients had neuropathic disease. QoL was markedly and
similarly decreased in IBS and CIPO compared with healthy subjects (tab.). Conclusions:
Patients with severe IBS show similar but less marked alterations of small bowel motility
compared with CIPO. In particular, signs of intrinsic neuropathy are less frequent. Thus,
our findings may support the hypothesis that certain cases of severe IBS might be a mitigated
form of CIPO. However, other mechanisms appear to contribute to the decrease in QoL in
severe IBS which is as marked as in CIPO patients.
(1) at > 1 recording site (2) absence or pathological propagation * p=0.078 vs. CIPO **
p<0.01 vs. healthy subjects
W1855
A Physiological Rate of Butyrate (B) Entry Into the Cecum of Piglets Causes
Increased Cell Proliferation (CP) in Cecum, Distal Colon, and Jejunum
Without Affecting Cecal pH Or Inducing Injury, But the Prebiotic, Inulin (IN),
Inhibits This Effect
C. Lawrence Kien, Ruth Blauwiekel, Wendy Frankel, Rhonda Maple, Karen Everingham
Increased colonic CP may be detrimental to the risk of cancer, but increased gut CP may
be beneficial in patients post gut resection. Previously, we showed that lactulose feeding
caused decreased cecal CP and increased cecal B synthesis. Thus, we hypothesized that cecal
infusion of B at a rate equal to the abnormal increment in B production (during lactulose
feeding) also would cause decreased CP in cecum, colon (distal colon), and perhaps jejunum.
Since pre- and/or co-feeding IN seemed to attenuate the decreased cecal CP during lactulose
feeding, we also hypothesized that the same effect would be seen when B was exogenously
“produced”. Piglets (N=24, 11-13 d age) were all fed sow milk replacement formula and
randomized into 4 equal groups: (I) cecal phosphate buffered saline infusion (PBS); (II)

















of oral feeding (± IN), a cecal catheter was inserted, and B or PBS was infused for 4d. On
d 4 post-op, cecal, colon, and jejunal CP (fractional proliferative index, entire crypt or villus)
was assessed using BrdU, and injury/inflammation was scored. Data were analyzed by two
way analysis of variance. Cecal wet/dry weight ratio was affected by the IN treatment (P =
.018, no interaction): I (8.7 ± 0.7); II (7.6 ± 0.8); III (5.9 ± 0.4); IV (6.7 ± 1.0), but there
was only a borderline IN effect on the frequency of loose stools (P = 0.08). Cecal pH also
was affected by IN (P = 0.007) but not B (no interaction): I (7.04 ± 0.11); II (7.01 ± 0.17);
III (6.61 ± 0.19); IV (6.51 ± 0.13). There were no group effects on weight gain, breath
concentration of H2 or CH4, cecal or colon crypt depth, jejunal villus height, or injury
score for cecum, colon, or jejunum. IN per se did not affect CP in cecum, colon, or jejunum.
B caused increased CP in the cecum, colon, and jejunum but only in group I: Cecum: P =
0.003, interaction, P = 0.003, I (0.19 ± 0.02), II (0.42 ± 0.02), III (0.26 ± 0.05), IV (0.27
± 0.03); Colon: P = 0.024, interaction, P = 0.018, I (0.09 ± 0.01), II (0.18 ± 0.02), III (0.14
± 0.02), IV (0.14 ± 0.02); Jejunum: P = 0.013, interaction, P = 0.002, I (0.10 ± 0. 01), II
(0.22 ± 0.01), III (0.17 ± 0.02), IV (0.16 ± 0.03). Thus, in contrast to the association,
during lactulose feeding, of increased synthesis of B with decreased CP, increased exogenous
B in the cecum causes increased CP, both locally and distally/systemically(distal colon and
jejunum), but IN blocks this effect in an analogous but opposite effect to how it attenuates
decreased CP during lactulose feeding. (Support: DK61775).
W1856
Butyrate Increased the Growth Activity and Showed An Anti-Inflammatory
Effect in An Intestinal Epithelial Cell Line
Osamu Kanauchi, Keiichi Mitsuyama, Akira Andoh, Yoshiaki Matsumoto
Background: There is increasing evidence that intestinal microflora play an important role
in the pathogenesis of inflammatory bowel disease. In our previous study, a prebiotic,
germinated barley foodstuff, significantly increased the number of Eubacterium limosum
and production of its major metabolite butyrate in experimental colitis and patients with
ulcerative colitis. This study was carried out to examine the effects of certain organic acids
that are metabolites of Eucabterium limosum on a colonic epithelial cell line in vitro.
Methods: HT-29 (ATCC No. HTB-38) was cultured in modified Eagle medium with butyrate,
propionate, acetate, lactate, and succinate (0, 0.1, 0.5, 1.0, and 2.0 mM). Cell growth activity
was determined by the activity of succinate dehydrogenase (SUDH) using a commercial
kit. For evaluation of the anti-inflammatory effects of organic acids, IL-8 production with
stimulation of TNF-alpha (50 ng/ml) was determined by ELISA. The expression of toll-like
receptor 4 (TLR4) mRNA was determined in T-84 (ATCC No. CCL-248) as well as in HT-
29. These two expressions were treated with TNF-alpha (25 ng/ml) with sodium butyrate
(0, 0.5, 1.0, and 2.0 mM), then the total RNA was extracted and RT-PCR was performed.
Results: Butyrate (at 0.1 and 0.5 mM), propionate (at 2.0 and 5.0 mM), acetate (at 2.0 mM),
and lactate (at 0.1 mM) significantly increased the SUDH activity. In IL-8 production,
butyrate (at 0.5, 1.0, and 2.0 mM), propionate (at 0.5, 1.0, and 2.0 mM) and lactate (at
2.0 mM) showed significant decreases. Succinate had no significant change in both SUDH
activity and IL-8 production. Interestingly, the expressions of TLR4 mRNA in both HT-29
and T-84 were increased by TNF alpha stimulation, and this increase was significantly
attenuated by butyrate (at 1.0 and 2.0 mM) in both cell lines. Conclusion: The major
metabolite of Eubacterium limosum, butyrate, is considered to have multifunctional roles
that accelerate growth activity, decrease inflammatory cytokine (IL-8) production, and modu-
late the mucosal barrier function via TLR4. The new mechanism of the expression of TLR4
may contribute to new treatments for inflammatory bowel disease in view of the interaction
between epithelium and bacteria in the intestinal tract.
W1857
Experimental Examination About the Usefulness of the Water-Soluble Dietary
Fiber On Metabolic Syndrome
Satomi Akagiri, Hiroshi Ichikawa, Yuji Naito, Osamu Handa, Tomohisa Takagi, Satoshi
Kokura, Norimasa Yoshida, Toshikazu Yoshikawa
Aim: The change of the lifestyle in Japanese eating habits caused the rapid increase in the
metabolic syndrome which makes obesity an underlying disease. Lifestyle habit is also exert
a deep influence on digestive diseases including fatty liver, nonalcoholic steatohepatitis, and
irritable bowel syndrome. Furthermore these diseases are closely related to obesity or meta-
bolic syndrome. The aim of this study is to evaluate the influence of the water-soluble
dietary fiber using metabolic syndrome animal models. Methods: We used the male Otsuka
Long-Evans Tokushima Fatty (OLETF) rat which is a model of human non-insulin-dependent
diabetes mellitus (NIDDM). OLETF rats are characterized by late onset of hyperglycemia at
18 weeks of age, followed by insulin-dependent diabetes mellitus at 65 weeks of age. In
this study, at 5 weeks of age, OLETF rats were fed a control diet (CRF-1) or a high-fiber
diet (5% of the Guar gum origin water-soluble dietary fiber) for 30 weeks. This dietary fiber
was prepared by selectively cleaving the mannan backbone-chain of guar gum by using
endo-β-D-mannanase and is composed of galactomannan with a molecular weight of about
20,000 Da. Body weight, food intake, oral carbohydrate tolerance test, plasma insulin levels,
urine glucose and urine protein were measured every week. As an indicator of insulin
resistance, the homeostasis model assessment for insulin resistance (HOMA-R) was applied.
Histological search of liver was carried out after the end of the study. Results: There was
no significant difference between 2 groups in the increase in body weight and in daily food
intake. All OLETF rats in control diet group have developed glucose tolerance or diabetes
within 30 weeks of age. The insulin resistance evaluated by the HOMA-R index was signific-
antly improved by the water-soluble dietary fiber ingestion. The levels of urine glucose and
of urine protein were significantly lower in high-fiber diet group than in control diet group.
Histological findings of the liver showed that the severe fatty infiltration at the periphery
of central vein was found in control diet group but not in high-fiber diet group. Conclusion:
This indicates conclusively that ingestion of water-soluble dietary fiber prevents development
of symptoms of metabolic syndrome and insulin resistance. Furthermore, it has been demon-
strated that dietary fiber intake prevent the onset of fatty liver.
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W1858
Dose-Response Effect of Arabinoxylanoligosacharides On the Colonic Nh3-
Metabolism Using Lactose-(15N, 15N’)-Ureide in Healthy Volunteers
Lieselotte Cloetens, Paul Rutgeerts, Katrien Swennen, Christophe M. Courtin, Jan A.
Delcour, Kristin Verbeke
Introduction: Arabinoxylanoligosacharides (AXOS), with a variable degree of substitution
(DS) and polymerisation (DP) can be obtained by enzymatic treatment of arabinoxylans
from cereals. AXOS are non-digestible in the upper gastrointestinal tract and may exert
prebiotic effects in the colon. Lactose-(15N, 15N’)-ureide (15N-LUR) has previously been
evaluated as a biomarker to quantify the effectiveness of prebiotics by measuring their
influence on the colonic NH3-metabolism.1 Upon stimulation of bacterial growth and/or
metabolic activity, a shift from urinary 15N-excretion towards faecal 15N-excretion is expected.
The influence of different doses AXOS (DP of 15, DS of 0.27) has been investigated. Materials
and methods: Twelve healthy volunteers (age 25±5.; BMI 21.8±1.6) consumed five times a
standard test meal (pancake) containing different doses of AXOS (0g (baseline), 0.25g, 0.75g,
2.25g and 5g) in random order with an interval of at least one week. Each test meal contained
75mg 15N-LUR to measure the influence of AXOS on the NH3-metabolism in the colon and
185kBq 3H-PEG as an inert marker to measure total transit. After each test meal, a 48-h
urine collection and a 72-h faeces collection were performed. The 15N enrichment in the
samples was measured by combustion-IRMS. All results were expressed as % of administered
dose. Faecal data were corrected for total transit. Results: The 15N-excretion in the 48-h
urine collection was 42.53±8.84 at baseline. Upon addition of 0.25g or 0.75g AXOS,
no differences were observed in the urinary 15N-excretion (respectively 40.15±9.89 and
42.92±10.09). On the contrary, administration of 2.25g (34.08±6.16) or 5g (35.50±6.76)
AXOS resulted in a significantly decreased urinary 15N-excretion (respectively p=0.008
and p=0.035). Faecal 15N-excretion was significantly increased after the intake of 2.25g
(23.89±6.42; p=0.034) and 5g (23.90±7.13; p=0.019) AXOS as compared to baseline values
(15.38±6.43) whereas lower doses of AXOS, 0.25g (20.54±17.34) and 0.75g (17.61±3.98),
did not influence the faecal 15N-excretion significantly. The shift from urinary to faecal 15N-
excretion after addition of 2.25g and 5g AXOS suggests a lower generation of ammonia in
the colon and/or a higher uptake of 15N due to an increased bacterial metabolism and
growth and provides an indication for prebiotic properties of AXOS. Conclusion: AXOS
administered at a dose of minimally 2.25g significantly influences the colonic ammonia
metabolism in human volunteers, providing (preliminary) evidence for AXOS prebiotic
properties. 1De Preter et al., Br J Nutr 2004; 92,439-446
W1859
Differential Effect of Long-Term Dietary Intake of Lactulose and Oligofructose-
Enriched Inulin On the Nh3-Metabolism and Predominant Microbiota in the
Colon of Healthy Volunteers
Vicky de Preter, Tom Vanhoutte, Geert Huys, Jean Swings, Paul Rutgeerts, Kristin Verbeke
Introduction: Dietary intervention with prebiotics can cause changes in the ecological balance
of intestinal microbiota and hence influence the microbial metabolic activities in the colon.
In the present study, the influence of lactulose and oligofructose-enriched inulin (OF-IN)
on the relative composition of the predominant faecal microbiota was studied. Changes in
metabolic activity, especially the metabolic fate of NH3, were investigated by means of
lactose-[15N, 15N]-ureide (LU). Methods: The effect of lactulose and OF-IN was evaluated
in a randomized study. At the start of the study and at the end of the 4-week treatment
period, healthy volunteers consumed a test meal containing 75 mg LU. During the study
period, they received 10g lactulose (b.i.d.) group 1 (n=29) or 10g OF-IN (b.i.d.) group 2
(n=19). Urine and faeces were collected during 48-h and 72-h, respectively. Samples were
analysed for 15N-content by combustion-IRMS and results were expressed as % of adminis-
tered dose. A culture-independent approach using PCR-DGGE population fingerprinting
was applied to determine the composition of the predominant faecal microbiota, using a
universal primer targeting the V3 region of the 16S rRNA gene. Results: In group 1, a
significant decrease in the urinary 15N content was found after lactulose intake, as compared
to the baseline values (from 44.12±13.13 to 36.52±12.81; p=0.011).This decrease was
compensated by an increase of the faecal 15N excretion (from 19.94±6.48 to 26.29±8.01;
p=0.032). Concurrently, comparison of DGGE banding patterns indicated the appearance
or intensification of a specific DGGE band after lactulose intake in 75% of the subjects,
which was assigned to bifidobacterial organisms. In group 2, OF-IN significantly reduced
the urinary 15N-excretion from 41.72±8.76 to 24.59±12.27 (p<0.001), whereas the faecal
excretion of the label remained unchanged (19.03±6.43 vs. 22.18±5.21; p=NS). As a con-
sequence, long-term administration of OF-IN resulted in a decreased total 15N-excretion
(from 60.30±9.50 to 46.34±13.92, p=0.001), suggesting that a higher fraction of 15N is
retained within the human body. In DGGE profiling, no universal changes were observed
after OF-IN intake. Possibly, the observed retention of the marker in the colon may be
linked to the fact that OF-IN primarily stimulates mucosa-associated microbiota rather than
the microbiota in the lumen of the colon. Conclusions: Administration of lactulose has a
favourable effect on the colonic NH3-metabolism and was accompanied by an overall stimula-
tion of the bifidobacterial population. In contrast, administration of OF-IN only resulted in
a reduction of the urinary 15N-excretion.
W1860
Enteropathogenic Infection in a Human Enterocyte Zinc Deficiency Model Is
Modulated By Probiotic Factor(S)
Ilse J. Broekaert, N Nanda Nanthakumar, W Allan Walker
Background: In developing countries infectious diarrhea is frequently associated with malnu-
trition and an impaired immune status. Previous observations have shown that infants with
infectious diarrhea become zinc (Zn)-deficient causing altered intestinal epithelial functions.
Both probiotic bacteria and Zn-supplementation have been shown to improve diarrhea.
However, there are no studies addressing the effect of probiotic bacteria on enteropathogenic
infection in Zn-deficiency. Aim: The aim is to investigate the probiotic effect of different
Lactobacilli species and Bifidobacterium bifidum on enteropathogenic invasion (Salmonella
typhimurium and Listeria monocytogenes) and the epithelial response in a Zn-deficiency
model. Methods: Human intestinal cell lines (Caco-2 and T84) were grown either in Zn-
sufficient or deficient growth media for 1 week. Then they were infected with Gram-negative
S. typhimurium or Gram-positive L. monocytogenes in the presence or absence of the
supernatant of several lactobacilli or B. bifidum or purified probiotic bacteria. Pathogenic
invasion in enterocytes grown in Zn-deficient versus sufficient media was quantified by
standard gentamycin assay and IL-8 response was measured by ELISA. To characterize the
putative probiotic factor(s) the supernatant was treated with acids, proteases, DNAses, and
RNAses and exposed to heat. Results: Probiotic supernatants but not purified probiotic
bacteria reduce both pathogenic invasion and IL-8 production of intestinal epithelial cells
grown in Zn-sufficient and deficient media. Zn-deficiency allows greater pathogenic invasion
and enhanced IL-8 secretion of intestinal epithelial cells. The properties of the probiotic
factor(s) are resistant to acid, proteases, DNAses, RNAses and to heat. Conclusions: Pathogenic
invasion and IL-8 production is significantly enhanced in enterocytes grown in Zn-deficient
media. Probiotic supernatants of several lactobacilli and of B. bifidum significantly reduce
the increased invasion with S. typhimurium and L. monocytogenes and the enhanced IL-8
response in enterocytes grown in Zn-deficient media, suggesting that the effect of Zn and
probiotics may be synergistic. The inhibiting factor(s) is neither a protein nor a nucleic acid
and is stable with acid, pH and heat changes. Ongoing studies will definitively characterize
the nature of the probiotic factor(s). Our observations suggest that probiotics may reduce
the duration and severity of infectious diarrhea found in Zn-deficiency by enhancing the
innate immune response of the intestinal epithelium. Therefore, probiotics and Zn might
be inexpensive tools in the prevention and treatment of infectious diarrhea.
W1861
The Effects of the Water-Soluble Dietary Fiber On Gene Expression in
Intestinal Cells in Otsuka Long Evans Tokushima Fatty Rats Using a High-
Density Oligonucleotide Array
Hiroshi Ichikawa, Yuji Naito, Satomi Akagiri, Ktsura Mizushima, Osamu Handa,
Tomohisa Takagi, Satoshi Kokura, Norimasa Yoshida, Toshikazu Yoshikawa
Aim: Although the gene expression patterns during the development of diabetes have been
studied in both rodent models and humans, only a small portion of the mRNAs expressed
in the intestinal cells has been characterized. The purpose of the present study is to evaluate
the biological effects of the water-soluble dietary fiber on gene expression in intestinal cells
by using cDNA microarray analysis in experimental rat models of type 2 diabetes in vivo.
Methods: We used 5-week-old male Otsuka Long-Evans Tokushima Fatty (OLETF) rat
which is a model of human non-insulin-dependent diabetes mellitus. At 5 weeks of age,
OLETF rats were fed a control diet (CRF-1) or a high-fiber diet (5% of the Guar gum origin
water-soluble dietary fiber) for 30 weeks. As an indicator of insulin resistance, the homeostasis
model assessment for insulin resistance (HOMA-R) and oral carbohydrate tolerance test
were applied every week. Intestinal cells were obtained from the terminal ileum of OLETF
rats by laser capture microdissection. Preparation of cRNA and target hybridization were
performed according to the Affymetrix Gene Chip Eukaryotic Small Sample Target Labeling
Assay Protocol (version II). The gene expression profile was determined by the Rat Genome
230-2.0 GeneChip (Affymetrix). Results: All OLETF rats in control diet group have developed
glucose tolerance or diabetes within 30 weeks of age. The insulin resistance evaluated by
the HOMA-R index was significantly improved by the water-soluble dietary fiber ingestion.
Microarray analysis revealed that by comparison between control diet group and high-fiber
diet group, 1747 probes that increased in expression with ingestion of dietary fiber and
1182 probes that decreased in intestinal cells were identified. It was found that the decreased
gene expression for enzymes involved in lipid or bile metabolism, such as FABP6, solute
carrier family 10 and bile acid-Coenzyme A in intestinal cells by ingestion of water-soluble
dietary fiber. Furthermore, the increased expression of genes for enzymes, such as PPAR-
gamma (coactivator 1alpha) and PPARalpha were recognized in intestinal cells. As for
gastrointestinal hormone related genes, we could see the decreased expression of PYY
precursor and secretin, and also see the enhanced expression of ghrelin precursor, ACE1
and VIP. Additionally, the upregulated expression of genes involved in anti-inflammation,
such as caspase 6, MIF and estrogen-related receptor alpha, were found. Conclusion: We
suggest that the preventive effect of water-soluble dietary fiber on diabetes was involved in
the gene expression for lipid metabolism, gastrointestinal hormone and anti-inflammation.
W1862
Comparison of the Effect of Long-Term Administration of Of-in Ingested in
Combination with Lactobacillus Casei Shirota with of-in Alone On the Colonic
Fate of Protein Fermentation Metabolites NH3 and Phenols
Vicky de Preter, Tamara Coopmans, Paul Rutgeerts, Kristin Verbeke
Introduction: Dietary intervention with probiotics or prebiotics may cause changes in the
relative populations of colonic bacteria and hence in microbial metabolic activities. Their
synbiotic combination could stimulate not only the growth of the endogenous bacterial
strains, but also the growth of the exogenous ones and perhaps favour their implantation.
In the present study the influence of long-term administration of the synbiotic combination
of Lactobacillus casei Shirota cells with oligofructose-enriched inulin (OF-IN) on the colonic
fate of NH3 and phenolic compounds (phenol and p-cresol) was compared with the adminis-
tration of OF-IN alone. Methods: A randomized, cross-over study was performed in 9 healthy
volunteers. The lactose-[15N, 15N]-ureide biomarker was used to study the fate of NH3 (1).
At the start of the study and at the end of each 4-week treatment period, urine was collected
during 48-h. Each treatment period was separated by a 14-day wash-out period. In the
prebiotic test period, the volunteers received 10g OF-IN (b.i.d.) and in the synbiotic test
period they received 6.5x109 L. casei Shirota cells + 10g OF-IN (b.i.d.). The urinary p-cresol
and phenol content was determined by means of GC-MS (mg phenols/24-h). The 15N-
content was analysed by combustion-IRMS (% of administered dose). Results: Long-term
administration of OF-IN resulted in a statistically significant reduction of the urinary 15N
content compared to baseline (from 39.47 (IQR 33.83-49.39) to 24.60 (IQR 10.81-31.74)
(p<0.001). Also after synbiotic intake the 15N-excretion significantly decreased from 39.47
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(IQR 33.83-49.39) to 15.43 (IQR 5.95-27.67) (p<0.001). The urinary p-cresol content
decreased from 24.43 (IQR 15.28-39.72) at baseline to 14.70 (IQR 7.07-31.34) after OF-
IN intake (p=0.015), respectively to 9.79 (IQR 4.56-27.03) after synbiotic administration
(p=0.021). No significant effect on the urinary phenol content was observed after long-term
administration of the substrates. Conclusions: The results of this study demonstrate that
OF-IN and the synbiotic combination of L. casei Shirota cells with OF-IN are able to modulate
the colonic environment and the metabolic activity of the intestinal flora, with a favourable
effect on the colonic protein metabolites NH3 and phenols. A tendency to more pronounced
effects was observed after synbiotic intake compared to OF-IN alone. (1)De Preter V et al.
Br J Nutr (2003)
W1863
Amino Acid Fermentation in the Colon Is Impaired Upon Simultaneous
Administration of Fermentable Carbohydrates: Results of a Direct Instillation
Study Using 13C-Leucine
Karen Geboes, Anja Luypaerts, Vicky de Preter, Paul Rutgeerts, Kristin Verbeke
Introduction : Stimulation of carbohydrate fermentation is believed to prevent accumulation
of toxic products from amino acid metabolism. In this study, the influence of inulin on the
colonic fermentation of 13C-leucine has been evaluated using direct instillation. Methods :
Eleven healthy volunteers swallowed a narrow polyvinyl tube which progressed down the
intestine overnight. On the following morning, radiographic screening ensured the position
of the tube in the right colon. Baseline breath and serum samples were retrieved before
bolus administration of a 40-ml NaCl 0.9% solution containing 200 mg 13C-leucine in the
first experiment and 200 mg 13C-leucine with 2g of inulin (Raftilin HP®) in the second.
After instillation, breath samples for analysis of 13C-enrichment were obtained every 15
min and serum samples were obtained every 30 min during 6 hours. 13C-leucine serum
concentrations (µg/ml) were calculated from the 13C-leucine enrichment and the leucine
concentratrion which were both measured using gas-chromatography combustion isotope
ratio mass spectrometry (GC-C-IRMS, Delta Plus, Thermo Electron). 13C-breath content was
analyzed using a stable isotope ratio mass spectrometer (IRMS, PDZ). Four hours after the
instillation, all volunteers received a sandwich with ham or cheese. Results : The 13CO2
excreted in breath is a measure for the total oxidation of 13C-leucine and originates from
colonic bacterial metabolism of 13C-leucine with subsequent diffusion of 13CO2 through the
colonic wall or from oxidation of absorbed 13C-leucine in the liver. In the presence of inulin,
a clear, although statistically not significant decrease in 13CO2-excretion in breath was seen
(cum% 13CO2/6h : 36 +/- 12% versus 29 +/- 9%, mean +/- SD, n=11, p=0.14). The absence
of an effect on serum 13C-leucine concentration favours the hypothesis that the lower 13CO2-
excretion in breath is due to a lower 13CO2-generation in the colon and hence, a lower
degree of fermentation of 13C-leucine in the presence of inulin. Therefore, the results of
this study are in agreement with the generally accepted idea that stimulation of carbohydrate
fermentation through administration of inulin impairs amino acid fermentation. The absence
of a clear change in amino acid absorption, suggests another fate for the remaining 13C-
leucine. Presumably, more of the amino acid is incorporated by bacteria and used for
microbial growth. Conclusion : We demonstrated in a direct instillation study that stimulation
of carbohydrate fermentation through administration of inulin decreases fermentation of
13C-leucine in the colon.
W1864
The Modest Addition of Prebiotics to An Elemental Liquid Diet Alleviates the
Intestinal Compromise Associated with Weaning Syndrome in Piglets
Kristin L. Reifsteck, Brian M. Chung, Kristy L. Powell, Kelly Tappenden
A prebiotic is a non-digestible food ingredient that beneficially affects the host by selectively
stimulating the growth and/or activity of one or a limited number of bacteria in the colon,
thus improving host health. Using a preclinical model for intestinal compromise in human
infants, this study tested the hypothesis that intestinal injury caused by weaning syndrome
is reduced by the consumption of enteral formula containing prebiotics. Forty-eight 17-
day-old piglets were randomized into one of three experimental groups: 1) sow-fed negative
control (SOW); 2) early weaned, onto a low-residue complete whey-based, peptide liquid
diet (WEAN-), or; 3) early weaned, onto an identical peptide diet containing 3.6 g prebiotics/
L (WEAN+). Piglets were further randomized to be euthanized at experimental day (D) 2
or D4. While initial body weight (BW) did not differ between groups, SOW BW was increased
(p<0.0001) compared to WEAN- and WEAN+ on D1-D4, consistent with weaning syndrome.
Daily formula intake (mL/kg BW) did not differ between WEAN- and WEAN+ over the
course of the study. Structural and functional attributes of the duodenum, jejunum, ileum,
and colon were measured on D2 and D4. Jejunoileal length (cm/kg BW) was lower (p=
0.0007) in WEAN- than either SOW or WEAN+ on D2, but both WEAN groups were
higher (p=0.0007) than SOW on D4. Duodenal (p=0.0131) and colonic (p=0.0167) length
did not differ between groups at D2, but were higher than SOW in both WEAN groups on
D4. At D2 and D4, intestinal weight (g/kg BW) was greatest in SOW compared to either
WEAN group. Consistent with weaning syndrome, transmural resistance in the duodenum
(p<0.0001), jejunum (p<0.0001) and ileum (p<0.0001) were lower in both WEAN groups
than SOW. However, transmural resistance in the colon did not differ between SOW and
WEAN+, but was lower (p=0.0062) in WEAN-. Sodium-dependent glucose transport did
not differ between either WEAN group in any intestinal segment studied, but was higher
than SOW in the jejunum (p=0.0005) and ileum (p=0.013). Duodenal (p=0.005), jejunal
(p=0.020), and colonic (p=0.024) glutamine transport on D4 was higher in WEAN-, whereas
WEAN+ did not differ from SOW. In summary, the data obtained in this study indicate
that the modest addition of prebiotics to a whey-based, peptide liquid diet can alleviate
some complications associated with weaning syndrome in piglets. These beneficial effects
impact both structural and functional attributes of the intestine and occur throughout the
entire gastrointestinal (GI) tract. Further research examining the potential benefits of prebiotic


















Effect of short- and Long-Term Administration of Lactobacillus Casei Shirota
and Bifidobacterium Breve On the Colonic Fate of Protein Fermentation
Metabolites Phenol and P-Cresol
Vicky de Preter, Tamara Coopmans, Paul Rutgeerts, Kristin Verbeke
Introduction: The presence of saccharolytic species such as lactobacilli and bifidobacteria
in the colon has been reported to be benefial to health. Dietary intervention with those
species may cause changes in the relative populations of colonic bacteria and hence in
microbial metabolic activities. The aim of present study was to investigate in vivo whether
short- and long-term intervention with Lactobacillus casei Shirota (LacS) and Bifidobacterium
breve would reduce the concentration of p-cresol and phenol in the colon. p-Cresol and
phenol are unique bacterial metabolites of aromatic amino acid-containing proteins, which
are either excreted in the faeces or absorbed through the colonic wall and, after sulphate-
or glucuronide-conjugation in the mucosa or liver, urinary excreted. Phenols have been
implicated in the pathogenesis of bladder and bowel cancers. Methods: To evaluate the
immediate influence of administration of L. casei Shirota or B. breve on the excretion of
phenol and p-cresol, the volunteers received a pancake test meal to which in the first test
no substrate and in the second test respectively 6.5x109 LacS (n=19) or 109 B. breve cells
(n=10) were added. To study the influence of long-term administration of the substrates,
the same volunteers received either 2x/d 6.5x109 LacS or 2x/d 109 B. breve cells during 1-
month and consumed a pancake test meal at the end of the intake period. For each test,
the volunteers performed a 48-h urine collection. The urinary p-cresol and phenol content
was determined by means of GC-MS. The results were expressed as mean p-cresol/phenol
content excreted in urine (mg/24h). Results: Simultaneous administration of LacS or B. breve
cells with the test meal resulted in a decreased excretion of p-cresol, respectively p=0.013
for LacS and p=0.028 for B. breve. Also long-term dietary intervention with LacS or B. breve
cells resulted in a significant decrease in p-cresol excretion compared to baseline values (p=
0.005 (LacS) and p=0.001 (B. breve)). No changes in the excretion of phenol were observed
after short- or long-term probiotic intake. Conclusions: The results of this study demonstrate
that Lactobacillus casei Shirota and Bifidobacterium breve are able to modulate the metabolic
activity of the intestinal flora, with a favourable effect on the colonic p-cresol and phenol meta-
bolism.
* Significantly different from baseline
W1866
Quantitative Analysis of hTERT mRNA in Pancreatic Juice Is More Useful for
Differentiating Pancreatic Cancer from IPMN Than from Chronic Pancreatitis
Kenoki Ohuchida, Kazuhiro Mizumoto, Eishi Nagai, Hiroyuki Konomi, Koji Yamaguchi,
Masao Tanaka
Backgrounds. Although telomerase activity is a promising diagnostic marker for pancreatic
cancer, clinical introduction of this marker for cancer diagnosis is still problematic due to
the lack of means of evaluating sample quality. hTERT, one of the subunits of telomerase,
is also a promising diagnostic marker. Aim To determine the feasibility of quantitative
analysis of hTERT mRNA for diagnosis of pancreatic cancer. Methods. hTERT expression
was determined in 88 pancreatic juice samples and carcinoma cells, intraductal papillary
mucinous neoplasm (IPMN) cells, and chronic pancreatitis-affected cells obtained by microd-
issection. Results. Quantitative analyses of hTERT mRNAs in pancreatic juice were more
useful in discriminating carcinoma from IPMN than from chronic pancreatitis. When the
specificity was set at 100%, the sensitivity for differentiation between carcinoma and IPMN
was 43.5%, whereas the sensitivity of cytologic examination was 22.0%. There were significant
differences in hTERT expression between carcinoma cells, IPMN cells, and normal ductal
cells isolated from pancreatic tissues by microdissection. Lymphocytes and hyperplastic
epithelial cells isolated from tissues with the histologic appearance of pancreatitis showed
various expression levels of hTERT. Conclusion. Our results suggest that quantitative analysis
of hTERT mRNA in pancreatic juice is advantageous over cytologic analysis for differentiation
between carcinoma and IPMN but probably not for differentiation between carcinoma and
chronic pancreatitis.
W1867
Endoscopic Biliary Stenting for Pancreatic Cancer and Biliary Obstruction:
Predictive Factors of Stent Patency and Patient Survival
Cristina Gomez, Carlos Guarner, Candid Villanueva, Xavi Cusso, Antonio Farre, Joaquin
Balanzo
Endoscopic biliary stenting is a well established palliation treatment for patients with biliary
stricture caused by nonresecable pancreatic cancer. Stent clogging is the predominant late
complication, ocurring more frequently with plastic stents. The use of self-expanding metallic
stent (SEMS) however is not current practice due to their high cost. It would be important
to select patients in our area with a better predicted survival, who could benefit from a SEMS,
in order to be more cost-effective. OBJECTIVES: To evaluate the efficacy and complications of
palliative endoscopic treatment for biliary obstruction caused by pancreatic cancer, and to
investigate predictive factors of stent patency and patient survival. PATIENTS AND
METHODS: Prospective, non-randomized trial in patients with nonresectable pancreatic
cancer and biliary obstruction treated with endoscopic plastic or SEMS between January
2000 and May 2005. RESULTS: One hundred and twenty-six patients with nonresectable
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pancreatic cancer and biliary obstruction were treated with 151 endoscopic stents (plastic=
111, SEMS= 40). Technical success was 90%. Early complications were observed in 17%
of cases (cholangitis 6%, early stent obstruction 6.5%, haemorraghe 2.5% and migration
2.7%). The most common late complication was stent clogging (25.7%). Median stent
patency (period between stent placement insertion and obstruction or death) was 4 months.
The type of stent (plastic vs. SEMS) was identified in a multivariate analysis as the only
independent predictive factor of patency. Comparing plastic versus SEMS, the actuarial
probability of patency at 6 months was the 12% and 50.1% (p<0.05) respectively. In a
multivariate analysis, the absence of metastases (median survival=6.2 months versus 4 months
with metastasic disease) and coadjuvant chemotherapy (median survival= 13 months versus
4 months without chemotherapy) were independent predictive factors of better prognosis
for survival (>4 months). CONCLUSION: Patients with nonresecable pancreatic cancer and
biliary obstruction without metastases are the ideal candidates for self-expanding metallic
biliary stent insertion.
W1868
Nationwide Survey of the Contemporary Management of Pancreatic Cancer
Kolitha Goonetilleke, Ajith K. Siriwardena
Introduction: Outcome after pancreatic cancer surgery is better in specialist, high-volume
units. In the United Kingdom this has led to concentration of pancreatic surgery in specialist
units. However, there remains no consensus on many aspects of management including
optimal staging and pre-operative biliary drainage. This questionnaire-based survey addresses
aspects of practice volume, resection volume and outcome, technical aspects of pancreaticod-
uodenectomy and terminology for post-operative complications. Methods: A postal question-
naire survey was undertaken in 2005 of the 517 members of the Association of Upper
Gastrointestinal Surgeons of Great Britain (AUGIS). Of 162 respondents, 57 surgeons stated
that they undertook pancreatic resection. This figure was cross-checked with the UK Pancre-
atic Society (a pancreatic specialists forum) which estimated 64 pancreatic surgeons. A
further cross-check was carried out by comparing numbers of PD stated as being carried
out by respondents with Government Data. A total of 734 PD were reported by respondents
compared to 822 PD for financial year 2003/2004 for UK NHS hospitals. Results: The modal
case volume per annum was 6-10. Thirteen (23%) undertook more than 15 procedures
each and 1 more than 25. There were 24 in-hospital deaths in 732 resections (3%) mortality.
For individual respondents the modal percentage mortality was 5% (0 to 16%). All clinicians
with mortality in excess of 10% did less than 10 resections per annum. In terms of staging:
contrast CT is used by all. Endoscopic ultrasound by 27(47%) and laparoscopy by 27(40%).
Laparoscopic ultrasonography was used by 11 (19%). Positron emission tomography (PET)
was used by 2 (4%). No respondents utilised mesenteric angiography. Pre-operative biliary
drainage was undertaken by 29 (51%). In terms of operative detail, 60% undertook intra-
operative frozen section, 96% reconstructed by pancreaticojejunostomy and 36% used a
post-operative feeding jejunostomy. A range of descriptors was made available for definition
of post-pancreaticoduodenectomy pancreatic fistula and 96% favoured the following term:
amylase rich discharge (>3x serum amylase) beyond 7th post-operative day Conclusion:
Bearing in mind that survey results can be affected by biased or idealized responses, this
major survey captures the majority of pancreatic resectional activity in the UK for 2004. It
is clear that there remain volume-related effects on mortality and important variations in
staging and biliary drainage practice. For the first time, there is evidence of a national
consensus on the choice of terminology for definition of post-resection pancreatic fistula.
W1869
Malignancies Associated with Intraductal Papillary Mucinous Neoplasm of the
Pancreas
Terumi Kamisawa, Naoto Egawa, Hitoshi Nakajima, Kouji Tsuruta, Atsutake Okamoto
Background and Aim: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is
a distinct entity characterized by intraductal papillary growth and thick mucus secretion.
IPMN is a slow-growing tumor and many cases of branch duct type IPMN have been followed.
As IPMN has a favorable prognosis, associated malignancies have potential significance in
these patients. We examined the incidence and characteristics of preexisting, coexisting and
subsequent malignancies in patients with IPMN. Patients and Methods: Seventy-nine cases
(54 males and 25 females, average age 68.5) of IPMN were diagnosed by detection of mucus
in the pancreatic duct during endoscopic retrograde pancreatography. Twenty-three patients
underwent surgical resection. Histological diagnosis was confirmed in 30 cases (adenoma
(n=19) and adenocarcinoma (n=11)). Other primary malignancies associated with IPMN,
occurring in the prediagnostic or postdiagnostic period, were investigated. Average postdia-
gnostic follow-up period was 3.3 years (range, 0.2-20). Results: Other 40 malignancies
occurred in 28 (35%) of 79 patients with IPMN. They were found before (n=15), at (n=
19) and after (n=6) the diagnosis of IPMN. Major associated malignancies were gastric
cancer (n=12), colonic cancer (n=7), esophageal cancer (n=4), pulmonary cancer (n=4), and
independent pancreatic cancer (n=3). Three other organs were involved in 3 patients, and
two organs were in 4. All of 15 other malignancies occurring 1-10 years before the diagnosis of
IPMN were resected surgically or endoscopically. Fifteen of 19 other malignancies diagnosed
simultaneously with IPMN were resected surgically or endoscopically. Only 1 other malig-
nancy diagnosed after IPMN was surgically resected. Fourteen patients died of associated
malignancies. Three IPMNs associated with independent pancreatic cancer were of branch
type located in the pancreatic head and ranged from 1.5 to 3 cm, and the lesion of IPMN
was proximal to pancreatic cancer in 2 patients and distal in the other. Two patients had
the two lesions synchronously, and pancreatic cancer occurred 3 years after diagnosis of
IPMN in one patient Development of other malignancies was related to age (71.9 vs. 66.8,
p<0.05), but not to gender, follow-up period, site of IPMN, or resection of IPMN. Conclusion:
IPMN is associated with a high incidence of other malignancies, particularly gastric and
colonic cancers. Common genetic mechanisms between IPMN and other associated malig-
nancies might be present. Clinicians should pay attention to the possibility of associated
malignancies in preoperative screening and follow-up of patients with IPMN.
W1870
Predicting Success of Endoscopic Aspiration for Suspected Pancreatic Cystic
Neoplasms
Richard M. Walsh, Gregory Zuccaro, John Vargo, John Dumot, Nancy Brown
The analysis of cyst fluid contents can play a valuable role in the management of patients
with suspected pancreatic cystic neoplasms. It has an increasing role in evaluating small
incidental cysts when observation is being considered. We reviewed our experience with
cyst aspiration of suspected pancreatic cystic neoplasms to determine the size and location
of cysts which resulted in a successful cyst fluid analysis. Over a five-year period ending
December 2004, 235 patients enrolled in a prospective protocol for evaluation of suspected
pancreatic cystic neoplasms. The route for all cyst aspirations was by endoscopic ultrasound
(EUS). A successful aspiration analysis was defined by the ability to determine up to three
variables: cytology including qualitative assessment of extracellular mucin, CEA and amylase.
The distribution of cystic lesions was: 87 (37%) in the head, 77 (33%) tail, 42 (18%) body,
22 (9%) uncinate, and 7 patients with multiple cysts. EUS was performed in 210 patients
(89%) for cysts with a mean size of 3.4 cm. An aspirate was obtained in 194 patients (92%)
with a mean volume of 10 cc. There was a significant correlation between cyst size and
volume aspirated (Spearman correlation of 0.60, p<0.0001). The ability to achieve a complete
aspirate analysis (all three variables) significantly correlated with cyst size (Spearman correla-
tion of 0.31, p<0.0001). All three variables were successfully obtained in 67 patients (35%)
with a mean cyst size of 4.3 cm, two or more variables in 81 patients (42%) with a mean
size of 4.3 cm, and one or more variables in 149 patients (77%) with a mean size of 3.8cm.
Logistic regression curves predict the likelihood of success based on cyst size, e.g. aspiration
of a 2 cm cyst will be successful in 73% to determine one variable, 33% for two variables,
and 26% for three variables. There was no significant difference between location of a cyst
and successful aspiration (p= 0.14), although there was a trend towards an unsuccessful
aspiration and fewer cysts with a complete aspirate analysis for uncinate cysts when compared
to all other locations (44% versus 20% and 18% versus 37%, respectively). Twenty-five
patients did not undergo EUS and their cysts averaged 1.9 cm, and 16 (8%) had an
unsuccessful attempt at EUS aspiration with cysts that averaged 2.4 cm. There was one EUS
complication of a duodenal perforation in a patient with a serous cystadenoma who survived
emergent surgical repair. In summary, there are a predictable number of variables that can
be obtained from an EUS aspiration from a pancreatic cyst based on cyst size which is
independent of location.
W1871
Incidence of Other Malignancies and Overall Prognosis in the Patients with
Intraductal Papillary Mucinous Neoplasms (IPMN) of the Pancreas
Manabu Osanai, Hiroyuki Maguchi, Akio Katanuma, Kuniyuki Takahashi, Satoshi Tanno,
Yutaka Kohgo
Background/Aims: The intraductal papillary-mucinous neoplasms (IPMN) of the pancreas
is a relatively new and increasingly reported entity. An IPMN is characterized a low potential
for malignancy, and a slow-growing tumor with a better prognosis than other pancreatic
malignancies. In addition, IPMN often found in elderly people, so their prognosis would
be sometimes affected by other disease. However, little is known about pancreatic cancer
and extrapancreatic malignancies in patients with IPMN. We evaluated the incidence of
other malignancies and overall prognosis in IPMN patients. Methods: 307 patients with
IPMN were diagnosed in our two hospitals. There were 181 males and 126 females, with
a mean age of 68.3 years (35-87). Fifteen patients were main duct type and 292 patients
were branch duct type. Eighty-three patients who had underwent surgery (hyperplasia 7,
adenoma 41, non-invasive adenocarcinoma 26, invasive adenocarcinoma 8) and 224 patients
were follow up cases. Result: Seventy-one patients (23.1%) had extrapancreatic malignancies
and 10 patients (3.3%) had both IPMN and independent pancreatic cancer before (n=31),
at (n=28), and after (n=22) the diagnosis of IPMT. These 71 cases included colon cancer
(n=19), gastric cancer (n=18), lung cancer (n=10), Esophagial cancer (n=5), and others.
Fifty-three IPMN patients died. Among them, 6 patients (11.3%) died of invasive malignant
IPMN, 11 patients (20.8%) died of extrapancreatic malignancies, 10 patients (18.9%) died
of pancreatic cancer, 26 patients (49.0%) died of others. Conclusions: IPMN is highly
associated with other malignancies, especially during follow-up period. Cause of death from
other malignancies accounted for 39.7% of all deaths, which was higher than the death rate
of 11.3% from the IPMN. In IPMN patients, even in follow up cases, systemic surveillance
is necessary for detection of the other malignancies.
W1872
Predictors of Malignancy in Branch Duct Intraductal Papillary Mucinous
Neoplasms (IPMN-Br): A Study of 62 Resected IPMN-Br
Mario Pelaez-Luna, Thomas C. Smyrk, Jonathan E. Clain, Michael J. Levy, Randall K.
Pearson, Bret T. Petersen, Mark D. Topazian, Santhi Swaroop Vege, Michael B. Farnell,
Suresh T. Chari
Background/Aims: The prevalence of carcinoma at diagnosis in main duct IPMN (IPMN-M)
is high (57% to 92%). This has led to recommendation that all mucin-producing neoplasms
need resection, a view tempered by rapidly increasing frequency of diagnosis of IPMN-Br
and its uncertain natural history. The aim of our study was to describe clinical, imaging
and histological characteristics of a large cohort of resected IPMN-Br and determine pre-
operative characteristics that distinguish benign from malignant IPMN-Br. Methods: Demo-
graphic, clinical, imaging and histological data were collected from medical records of 62
patients identified from the surgical pathology database who underwent surgical resection
for IPMN-Br between 2000 and 2004 at our institution. On imaging, all patients had ≥1
cystic lesion of the pancreas without main duct dilation (<6 mm). Cysts with ovarian-type
stroma were not included in the study. Results: The mean age at surgery for IPMN-Br was
64±11 yr and 55% were women. Only 56 % of patients had symptoms definitely or possibly
related to the cysts (abdominal pain, acute pancreatitis, weight loss) and the remaining were
asymptomatic or had non-specific symptoms. Over half (55%) the cysts were in the uncinate
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process and head of pancreas. Twenty eight (45%) patients had multiple IPMN-Br and they
tended to be older than those with single lesions (66 ±11 vs 62 ± 11 years, p=0.06). On
pathology, 54 (87%) were benign (adenoma [n=39] or borderline [n=15]) and 8 (13%)
were malignant (carcinoma in situ [n=3] or invasive carcinoma [n=5]). Patients with benign
and malignant IPMN-Br did not differ in age, gender, size of lesions (28 ± 16 mm vs 28 ±
25mm), presence of multiple IPMN-Br, cyst fluid CEA levels or presence of symptoms.
Presence of one or more of the following identified all patients with malignancy: cyst related
symptoms, solid mass lesion on CT, suspicious cytology in cyst fluid or intra-mural nodules
on endoscopic ultrasound. However 71% of benign IPMN-Br also met one or more of these
criteria. Conclusions: Compared to reported prevalence of malignancy in main duct IPMN,
prevalence of malignancy in resected IPMN-Br is much lower (<15%). Clinical symptoms,
imaging (CT and endosonography) characteristics and analyses of cyst aspirate can help
identify malignancy in IPMN-Br; however, these criteria have low specificity.
W1873
Pancreatic Cyst: Depiction On Magnetic Resonance Cholangiopancreatography
and Relationship to Pancreatic Cancer
Saburou Matsubara, Minoru Tada, Hiroyuki Isayama, Masaaki Akahane, Kuni Otomo,
Takashi Sasaki, Toshihiko Arizumi, Osamu Togawa, Natsuyo Yamamoto, Yousuke Nakai,
Naoki Sasahira, Kenji Hirano, Takeshi Tsujino, Nobuo Toda, Haruhiko Yoshida, Takao
Kawabe, Masao Omata
Background & AIM: Widespread use of magnetic resonance cholangiopancreatography
(MRCP) has led to the identification of increasing numbers of patients with asymptomatic
pancreatic cysts. The purpose of our study was to examine whether pancreatic cyst could
be a risk factor for pancreatic cancer by checking incidence of pancreatic cyst detected by
MRCP. Patients & Methods: Frequency of pancreatic cyst and divisum by MRCP was
compared between patients with and without pancreatic cancer. MRCP was obtained in 85
patients with pancreatic cancer and 532 controls between 1998 and 2005. Controls were
consisted of patients with biliary diseases or suspicion of biliary symptoms. All the images
were reviewed for the presence of pancreatic cysts and pancreatic divisum. Pancreatic cysts
smaller than 5mm in diameter were excluded in this study. Result: Pancreatic cysts were
detected in 41 (48.2%) patients in cancer group, and in 41 (7.7%) in controls, respectively
(OR=11.1, p<0.01). In cancer group, median size of cysts was 18mm. Proportion of single
number of cyst and simple cyst was 27/41 (65.9%) and 16 /41(39.0%), respectively. In 17
of 41 (41%) patients, these cysts were occupying the pancreas proximal to the carcinoma,
which suggested that these cysts had existed prior to the development of cancer. In the
control group, median size of cysts was 8mm. Proportion of single number of cyst and
simple cyst was 27/41 (65.9%) and 14 /41(34.1%), respectively. Pancreatic divisum was
observed in one (1.4%) patient with cancer, and 11 (2.1%) in controls, respectively (p=
n.s.). Conclusion: High incidence of pancreatic cyst in patients with pancreas cancer suggested
that pancreatic cyst could be a risk factor for the carcinoma. Picking up and follow-up of
patients with asymptomatic pancreatic cysts may lead to early diagnosis of pancreatic cancer.
In contrast, panceatic divisum was not associated with pancreatic cancer.
W1874
Twist, a Novel Oncogene, Is Up-Regulated in Pancreatic Cancer; Clinical
Implication of Twist Expression in Pancreatic Juice
Kenoki Ohuchida, Kazuhiro Mizumoto, Eishi Nagai, Hiroyuki Konomi, Koji Yamaguchi,
Masao Tanaka
Backgrounds. Despite accumulation of evidences that Twist, a highly conserved basic helix-
loop-helix transcription factor, is a novel oncogene, there is no report on Twist expression
in pancreatic cancer. Intraductal papillary mucinous neoplasm (IPMN) is the representative
cystic neoplasm of the pancreas, which is being detected with increasing frequency due to
application of diagnostic imaging technologies, such as computed tomography and magnetic
resonance. Aim. To investigate Twist mRNA expression levels in pancreatic cancer, IPMN
and normal or pancreatitis-affected pancreas. Method. We performed quantitative analysis
of Twist mRNA in bulk tissues, microdissected cells, and pancreatic juice samples. Results.
We found significant differences in Twist expression between bulk pancreatic cancer and
IPMN tissues, but did not between bulk pancreatic cancer and normal pancreatic tissues.
There were significant differences in Twist expression between cancer cells, IPMN cells, and
pancreatitis-affected cells isolated by microdissection. In pancreatic juice analysis, we found
a significant difference in Twist expression between cancer- and IPMN- juice samples, but
not between cancer- and chronic pancreatitis-juice samples. ROC curve analysis showed
that quantitative analyses of Twist mRNA are more useful in discriminating cancer from
IPMN than from chronic pancreatitis. Conclusion. Our results suggest that Twist is a novel
oncogene of pancreatic cancer and that quantitative analysis of Twist mRNA in pancreatic
juice may be useful for differentiation of pancreatic cancer from IPMN.
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